id|nct_id|allocation|intervention_model|observational_model|primary_purpose|time_perspective|masking|masking_description|intervention_model_description|subject_masked|caregiver_masked|investigator_masked|outcomes_assessor_masked
33840774|NCT02474862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840775|NCT02306551|||CASE_CONTROL||PROSPECTIVE|||||||
33840776|NCT00022581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840777|NCT05504252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840778|NCT04211597|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Given the distinctive nature between types of scar treatments (spray vs gel, or no treatment at all), care provider and patients will not be blind to the group assignment. However, outcomes assessors are trained nurse practitioners and research associates, who do not have access to participants' group assignment records.|Upon enrollment, full medical history of the participants was obtained, including history of hypertrophic scar or keloid. Scars from previous injuries or surgical incisions were evaluated and recorded. Each patient was randomized to one of the three treatment arms: Group 1 (receiving no scar treatment), Group 2 (silicone gel only), and Group 3 (silicone gel plus Me-EGF).|f|f|t|t
33840779|NCT05834062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blind, placebo-controlled clinical trial|t|t|t|t
33840780|NCT04413305|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33840781|NCT01167491|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33840782|NCT03026075|NA|SINGLE_GROUP||SCREENING||NONE||||||
33840783|NCT05249647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840784|NCT04557553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840785|NCT04677218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840786|NCT03270410|||COHORT||PROSPECTIVE|||||||
33840787|NCT04020315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840788|NCT04606901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Medications will be provided by Merck, Sharp \& Dohme Corp and will be delivered to the inpatient pharmacy in such a way as to blind the pharmacist. Patients will also not know which medication they are receiving|Study groups will be treated equally except for delivery of the neuromuscular blockade reversal medication|t|f|t|f
33840789|NCT04070404|||OTHER||PROSPECTIVE|||||||
33840790|NCT01621776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840791|NCT03287895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840792|NCT05891808|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33840793|NCT02919215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840794|NCT00021424||||TREATMENT||||||||
33840795|NCT02635893|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33840796|NCT02946853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840797|NCT03149549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840798|NCT05616676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840799|NCT03820297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840800|NCT00873028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33840801|NCT06609655|||OTHER||RETROSPECTIVE|||||||
33840802|NCT05140226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840803|NCT01006252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840804|NCT01065142|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33840805|NCT02294903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048728|NCT01134679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152694|NCT06000605|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participant will not be blinded because they must consciously adhere to study requirements, i.e., fasting for 3 days. The investigators will be blinded to the fasting and fed conditions.|Participants will complete both arms: 1) fasted and 2) fed.|f|f|t|f
34152695|NCT03610009|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Women (patients), clinician performing oocyte retrieval and clinical embryologist will be blinded to the method used for monitoring follicle development|Follicle development in women undergoing IVF will be monitored either by conventional 2D ultrasound or SonoAVC.|t|t|f|t
34152696|NCT05485324|||COHORT||OTHER|||||||
34152697|NCT02916251|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34152698|NCT02454062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152699|NCT05413148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152700|NCT03678168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be unaware of the type of packaging used port rhinology surgery to control pain and bleeding.||t|f|f|f
33737515|NCT01340339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840806|NCT02527824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840807|NCT05994131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840808|NCT04822779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization of patients will be performed before the intervention in the R software package and the results of the randomization will be known only to the therapist who will be involved in the treatment.|The research will be a double-blind randomized control prospective study.|t|f|t|f
33840809|NCT01539369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33840810|NCT00722280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048729|NCT05361902|NA|SINGLE_GROUP||OTHER||NONE||||||
34048730|NCT01612689|NA|SINGLE_GROUP||||NONE||||||
33840811|NCT05662189|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Obese people with normal glucose regulation , patients with long standing or newly diagnosed type 1 diabetes, patients with long standing or newly diagnosed type 2 diabetes, subjects with pre-diabetes, and lean healthy age- and gender-matched controls will participate in two study sessions on two separate days:~* Session A (Endocrinology and Metabolic Diseases Unit) - Quantitation of beta cell functional mass (BCFxM) by mixed-meal test~* Session B (Nuclear Medicine Unit) - Quantitation of beta cell mass (BCM) by PET-CT scan."||||
33840812|NCT04627610|||OTHER||RETROSPECTIVE|||||||
33840813|NCT02468362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840814|NCT00211068|||CASE_CONTROL||RETROSPECTIVE|||||||
33840815|NCT02710227|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048731|NCT04312867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048732|NCT04255680|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048733|NCT01250873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048734|NCT02990936|||COHORT||PROSPECTIVE|||||||
34048735|NCT05720130|NA|SEQUENTIAL||TREATMENT||NONE||||||
34048736|NCT06191003|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34152701|NCT05807685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34152702|NCT02032407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152703|NCT06371976|||COHORT||PROSPECTIVE|||||||
33840816|NCT03433677|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33944717|NCT01162031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944718|NCT01951833|||CASE_CONTROL||PROSPECTIVE|||||||
33944719|NCT05158127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737516|NCT01563250|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33737517|NCT06288867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944720|NCT02104232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33840817|NCT03245047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study is double-blinded, i.e., during the study, neither the investigator(s), study and appropriate Abbott Nutrition staff, nor participants will be informed of the identity of any of the study products. Study center personnel will not analyze the contents of the study products or in any way seek to learn the identity of the study products. The investigator should ensure that if it becomes necessary, blinding is broken only in accordance with the protocol.|This is a prospective, randomized, placebo controlled, double-blind, parallel design, multi-center study. Eligible participants will be randomly allocated to one of two groups: oral nutritional supplement with dietary counseling group or placebo supplement with dietary counseling group. Randomization will be stratified by MUST malnutrition status (medium risk or high risk) and site of recruitment. All participants, including both recently discharged patients from the hospital or elderly recruited from the polyclinics.|t|f|t|t
33840818|NCT00666900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737518|NCT02039427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33840819|NCT03750786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840820|NCT02631577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944721|NCT02115568|||COHORT||PROSPECTIVE|||||||
33840821|NCT01739439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048737|NCT00037947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048738|NCT06681935|||COHORT||PROSPECTIVE|||||||
34048739|NCT00811330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048740|NCT00876655|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34048741|NCT02694354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34048742|NCT02040857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048743|NCT03477201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be randomized into two groups either laparoscopic or robotic assisted arm.|The investigators plan to conduct a prospective, randomized controlled trial of patients undergoing elective laparoscopic or robotic unilateral inguinal hernia repair. Patients will be randomized into two groups, with one group undergoing laparoscopic transabdominal preperitoneal (TAPP) technique and a second group undergoing robotic inguinal hernia repair (TAPP technique) with the Xi DaVinci System (Intuitive, Sunnyvale, CA). The monopolar instrument will deliver via standard instruments on 30W coagulation mode (ForceTriad electrosurgical generator, Covidien, Boulder, CO). At the completion of the procedure, skin biopsies will be taken at each of the three port incisions. These samples will be examined for visual and histologic evidence of thermal injury by a blinded pathologist.|t|f|f|f
34048744|NCT05005585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor isnt involved in the intervension|VST with immediate implant placement versus contour augmentation with early implant placement in fresh extraction sockets in esthetic zone.|f|f|f|t
33944722|NCT00777439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048745|NCT05400499|||COHORT||PROSPECTIVE|||||||
34048746|NCT02348801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048747|NCT04357665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This prospective study included 120 consecutive patients with bilateral primary inguinal hernia managed by simultaneous bilateral repair. Patients were randomized by sealed opaque envelopes containing computer generated random numbers into 3 groups, each includes 40 patients. Group I treated by laparoscopic transabdominal preperitoneal repair using 2 separate meshes (Lap TAPP), Group II treated by open preperitoneal mesh repair with mesh fixation (Open PP), while Group III treated by standard bilateral Lichtenstein repair (LICHT group).|t|t|f|t
34048748|NCT01355016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048749|NCT03928899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944723|NCT01551043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048750|NCT04386824|||CASE_CONTROL||RETROSPECTIVE|||||||
34048751|NCT02337439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048752|NCT04542421|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34048753|NCT00601172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34048754|NCT03628339|NA|SEQUENTIAL||OTHER||NONE||This is a single sequence cross-over trial.||||
33944724|NCT00409565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944725|NCT06111755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944726|NCT02746276|NA|SINGLE_GROUP||TREATMENT||NONE||Sparse sample pharmacokinetics study||||
33944727|NCT03608124|||OTHER||CROSS_SECTIONAL|||||||
33944728|NCT04533932|||COHORT||PROSPECTIVE|||||||
33944729|NCT03152643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944730|NCT03329053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944731|NCT02933333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944732|NCT01496391|||CASE_CONTROL||PROSPECTIVE|||||||
33944733|NCT01716299|||||PROSPECTIVE|||||||
33944734|NCT02079077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944735|NCT02626078|||COHORT||PROSPECTIVE|||||||
33944736|NCT06207708|||COHORT||PROSPECTIVE|||||||
33944737|NCT00960323|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944738|NCT03303144|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944739|NCT04146259|||COHORT||PROSPECTIVE|||||||
33737519|NCT04747938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840822|NCT02700542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33840823|NCT00034788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840824|NCT03327272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33840825|NCT00002622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840826|NCT00852176|||COHORT||RETROSPECTIVE|||||||
33840827|NCT00422812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840828|NCT02650713|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840829|NCT00146367|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840830|NCT00552929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944740|NCT05637827|||COHORT||PROSPECTIVE|||||||
34048755|NCT06131684|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944741|NCT04853368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944742|NCT01467531|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34048756|NCT03489018|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, parents of participants and all of the study team apart from the vaccinator will be masked with respect to the infant's allocation to a trial arm between A-F. If randomly allocated to trial arm G, parents and study personnel will be unmasked due to the necessity for trial arm G to receive a different vaccine schedule compared to trial arms A-F. It is thought that this unmasking will have minimal impact on retention, follow up and outcome assessment across the trial arms for primary and secondary outcomes.|"Participants will be randomised to one of seven groups for the duration of the study:~A. Full dose PCV13 vaccination in a 2p+1 schedule; B. 40% fractional dose PCV13 vaccination in a 2p+1 schedule; C. 20% fractional dose PCV13 vaccination in a 2p+1 schedule; D. Full dose PCV10 vaccination in a 2p+1 schedule; E. 40% fractional dose PCV10 vaccination in a 2p+1 schedule; F. 20% fractional dose PCV10 vaccination in a 2p+1 schedule; G. Full dose PCV10 vaccination in a 3p+0 schedule."|t|f|t|t
34048757|NCT02507557|||||RETROSPECTIVE|||||||
34048758|NCT06655142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with site specific controls. 60 with ONCObind procedure and 60 Controlled||||
34048759|NCT03005327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048760|NCT03659175|||COHORT||PROSPECTIVE|||||||
34048761|NCT02355964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048762|NCT06683937|||CASE_ONLY||RETROSPECTIVE|||||||
34048763|NCT06682910|NA|SINGLE_GROUP||OTHER||NONE||||||
34048764|NCT04731090|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048765|NCT00741429|||COHORT||PROSPECTIVE|||||||
34048766|NCT05432154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048767|NCT04062162|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048768|NCT01655966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048769|NCT04896398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation of the patients will be made by an evaluator who has no knowledge of group distribution.|After the patients are numbered according to the order of application, they will be divided into 2 groups as study and control groups according to randomization made with the computer program (block randomization). A total of 5 sessions of ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the study group (1st group) for 2 weeks. Median nerve and tendon shifting exercises will be taught to the patients and they will be asked to do it regularly. Patients in the control group (Group 2) will be asked to perform median nerve and tendon shifting exercises only for the wrist. Patients will be evaluated before treatment and at 4 and 12 weeks after treatment.|f|f|t|f
34048770|NCT04019613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients undergoing a clinically indicated invasive cardiac hemodynamic exercise test will be eligible for enrollment into the study.||||
34048771|NCT03207464|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048772|NCT04490603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective randomized open-label clinical trial||||
34048773|NCT04868656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel cluster-randomized trial (parallel-CRT): used in pragmatic evaluations of health program or policy interventions, where half the clusters (in this case, VA hospitals) are randomly assigned to two interventions: Foundational support (active comparator) vs. Enhanced support (experimental).||||
33840831|NCT04821297|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33840832|NCT03388268|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Placebo|Double-blinded randomized controlled trial of CDI treatment with oral vancomycin vs. placebo|t|t|t|t
33840833|NCT04839822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded with respect to the study arm and will unlikely determine if they are part of the intervention or active control.||t|f|f|f
33840834|NCT02517814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840835|NCT05114343|RANDOMIZED|PARALLEL||OTHER||SINGLE|Primary outcome (i.e., endothelial function) will be assessed by a blinded investigator.||f|f|f|t
33944743|NCT00518167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944744|NCT00948896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944745|NCT01005966|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33840836|NCT01675453|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33840837|NCT03658759|||COHORT||PROSPECTIVE|||||||
33944746|NCT03570658|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33944747|NCT01478542|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33944748|NCT03104270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944749|NCT02800096|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33944750|NCT03260699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34048774|NCT04633538|||COHORT||PROSPECTIVE|||||||
34048775|NCT01609647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048776|NCT06031610|||COHORT||PROSPECTIVE|||||||
34048777|NCT03580941|||COHORT||RETROSPECTIVE|||||||
34075663|NCT01492777|||||PROSPECTIVE|||||||
34075664|NCT00174200|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34075665|NCT06167785|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34075666|NCT00941304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075667|NCT05625724|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33840838|NCT03482089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840839|NCT06395051|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Study participants will receive in random order acutely 395 mg/kg body weight ketone monoesters or placebo, seperated by a wash-out period of at least 1 week.|t|f|t|t
33840840|NCT04617340|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33840841|NCT06450847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840842|NCT00902746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840843|NCT04356053|||COHORT||RETROSPECTIVE|||||||
33840844|NCT04616729|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized before start of ovarian stimulation to either DEPOT group (group A) or control group (group B), only after patient eligibility has been established and patient consent has been obtained.~Group A will receive the GnRH agonist Depot form for final oocyte maturation followed by daily GnRH antagonist injections for 1 week.~Group B will receive the GnRH agonist daily form for final oocyte maturation. After one week the Depot form combined with daily GnRH antagonist injections for 7 days, will be administered in view of ovarian protection during chemotherapy.~Blood analysis and ultrasounds will be organised on day 3, 5 and 7 after oocyte pick-up in both groups."||||
33840845|NCT00603525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840846|NCT03867695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33840847|NCT00241046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840848|NCT05471284|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33840849|NCT05045651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840850|NCT05512351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840851|NCT04672408|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized crossover double-blind|t|f|t|f
33840852|NCT02954198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840853|NCT01035567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840854|NCT00483990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840855|NCT01840410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840856|NCT04176731|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, multi-center, prospective clinical study.||||
33840857|NCT01293253|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33840858|NCT00872209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840859|NCT01820520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840860|NCT05766527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840861|NCT04907019|NA|SEQUENTIAL||TREATMENT||NONE||||||
33840862|NCT04713969|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention with PPI (Pantoprazole 40mg twice daily) in 30 FD patients. Baseline procedures in 30 healthy controls.||||
33840863|NCT00941967|RANDOMIZED|PARALLEL||TREATMENT||||||||
33840864|NCT04796077|RANDOMIZED|PARALLEL||OTHER||SINGLE|An observer-rated behavioral anxiety outcome was masked (raters were blinded to patient group assignments). Other measures were patient self-report (unmasked).|Patients were allocated via a block-randomized list to either the intervention arm (the educational pop-up book) or the control arm (standard care).|f|f|f|t
33840865|NCT04735068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840866|NCT01279018|||COHORT||CROSS_SECTIONAL|||||||
33840867|NCT05997628|||COHORT||OTHER|||||||
33840868|NCT01810458|||COHORT||PROSPECTIVE|||||||
33840869|NCT03664102|||COHORT||RETROSPECTIVE|||||||
33944751|NCT00911508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944752|NCT03560791|||CASE_ONLY||RETROSPECTIVE|||||||
33944753|NCT05597852|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Patients with local recurrence of prostate cancer with previous irradiation will have a hydrogel spacer, SpaceOAR™ inserted.||||
34075668|NCT02213315|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34075669|NCT03857698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34075670|NCT01000987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075671|NCT00242411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075672|NCT05221970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34075673|NCT02526485|||COHORT||CROSS_SECTIONAL|||||||
34075674|NCT03058354|||OTHER||RETROSPECTIVE|||||||
34075675|NCT01795794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075676|NCT03613714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33840870|NCT00721201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840871|NCT05717491|||OTHER||CROSS_SECTIONAL|||||||
33840872|NCT02993185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840873|NCT06250959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840874|NCT00077831|||CASE_CONTROL||PROSPECTIVE|||||||
33840875|NCT01014611|||COHORT||PROSPECTIVE|||||||
33840876|NCT03378453|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33944754|NCT01866280|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33944755|NCT05633394|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944756|NCT00964470|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944757|NCT01080157|||COHORT||PROSPECTIVE|||||||
33944758|NCT00631228|||COHORT||PROSPECTIVE|||||||
33944759|NCT06076174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944760|NCT03688841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Due to the obvious differences between the intervention and comparator, it is impossible to blind the participants or the care providers.~However, the investigator, the outcomes assessor and statistician are blinded to treatment received."|This is a randomised, parallel group, active-control trial, with patients randomised in a 1:1 ratio to one of two treatment arms.|f|f|t|t
33944761|NCT04282811|||COHORT||PROSPECTIVE|||||||
33944762|NCT04652609|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33944763|NCT01583608|||COHORT||PROSPECTIVE|||||||
33944764|NCT03584412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to the ACT OPEN treatment condition immediately or following a 5 month wait using a 2:1 randomisation ratio (2: immediately; 1: waiting list control).|f|f|f|t
33944765|NCT00984958|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1 will get treatment and Group 2 will have no treatment for 2 month||||
34075677|NCT01583413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075678|NCT03213847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective cohort study||||
34075679|NCT00734266|||CASE_CONTROL||PROSPECTIVE|||||||
33840877|NCT05419622|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Early study to evaluate the diagnostic and diagnostic performances of an imaging sequence, non-randomized, observational, prospective and bicentric.||||
33840878|NCT01670253|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
33840879|NCT05520853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840880|NCT03921502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient and the physician responsible for the follow-up will be blinded as to the procedure performed (it will not be specified if transmural drainage was performed in the endoscopic report, nor will images of the drainage be included in the discharge report available in the electronic medical record until after the completion of the study or if complications are suspected).|Multicentric double-blind randomized trial|t|t|f|t
33840881|NCT05136053|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33840882|NCT01640405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840883|NCT01875029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840884|NCT00236379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840885|NCT01013038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840886|NCT01346813|||COHORT||PROSPECTIVE|||||||
33840887|NCT01661764|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33840888|NCT02086890|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33840889|NCT00527462|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33840890|NCT02145338|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33840891|NCT00767429|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33840892|NCT00484484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840893|NCT04167423|||OTHER||CROSS_SECTIONAL|||||||
33840894|NCT04665726|||COHORT||PROSPECTIVE|||||||
33840895|NCT01079351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840896|NCT01770847|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33840897|NCT03240653|||COHORT||RETROSPECTIVE|||||||
33840898|NCT02833324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840899|NCT03435913|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840900|NCT04756102|||COHORT||RETROSPECTIVE|||||||
33840901|NCT03894072|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||HFHO-CPAP CPAP-HFHO|f|f|f|t
33840902|NCT05509049|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This study is designed as a prospective, parallel, large simple superiority randomized controlled trial using simple randomization (no blocking, no stratification).|t|t|t|f
33840903|NCT02812940|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33840904|NCT04224402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840905|NCT02397668|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, prospective, single-arm, Pivotal study of subjects receiving the Cor TRICUSPID ECM Valve or Cor PEDIATRIC Tricuspid ECM Valve||||
33840906|NCT00111995|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33840907|NCT01809860|NA|SINGLE_GROUP||||NONE||||||
34075680|NCT01185470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075681|NCT06204770|NA|SINGLE_GROUP||OTHER||NONE||Participants will be asked to use NR Pepti as part their management of mild to moderate Cow's milk protein allergy||||
34075682|NCT05966116|||COHORT||PROSPECTIVE|||||||
34075683|NCT03358823|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075684|NCT03513679|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34075685|NCT04999943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075686|NCT01000974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34075687|NCT03628859|||COHORT||PROSPECTIVE|||||||
34075688|NCT02610517|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33840908|NCT02653612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840909|NCT03231358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We will randomize adolescents (with parents) to an intervention arm (testing Our Family Our Future, n=440) or a control arm (n=440) of usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care). We will randomize based on permuted blocked randomization.|f|f|f|t
33840910|NCT04819061|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This is a sham-controlled, double-blind randomized multicentric clinical trial that will analyze patients with a confirmed diagnosis of Parkinson disease who were subjected to tDCS associated with dual-task motor training. Whe aim to predict response to tDCS treatment using electroencephalographic biomarkers and machine learning approach.|t|t|t|f
33840911|NCT03582800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840912|NCT04489290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840913|NCT02865512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840914|NCT00547014|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33840915|NCT02990988|||OTHER||PROSPECTIVE|||||||
33840916|NCT00119457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33944766|NCT04959162|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944767|NCT05461404|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the visible nature of the intervention, it is not possible to completely mask allocation; thus, the trial will be open-label. However, study physicians will not have access to patient randomization lists.|Infants will be enrolled after informed consent, stratified by birthweight (700- \<1000 g, 1000-1500 g) and randomly allocated 1:1 to the two arms of the trial which will be run in parallel.||||
33944768|NCT02298790|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34075689|NCT02404610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075690|NCT06218446|||COHORT||PROSPECTIVE|||||||
34075691|NCT04069884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840917|NCT01371292|RANDOMIZED|PARALLEL||||NONE||||||
33840918|NCT02091206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840919|NCT04682860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840920|NCT05172050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Appearance, including packaging and labelling, of the investigational medicinal product (IMP, capsules, packaging) will not allow to recognize actual treatment (either raloxifene or placebo).|"Multicenter, adaptive, double-blind, randomized, placebo controlled, double blind, parallelgroup, to study efficacy and safety, with the following adaptive components:~* Parallel multi-arms (2 interventional arms and 1 placebo control arm);~* A 2-stage sequential design (1 interim analysis + 1 final analysis);~* Sample size re-calculation at interim stage;~* Stopping rule for efficacy or futility at interim stage."|t|f|t|f
33840921|NCT05824000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944769|NCT05526599|||COHORT||RETROSPECTIVE|||||||
33944770|NCT01622842|||CASE_ONLY||CROSS_SECTIONAL|||||||
34048778|NCT05218343|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and care providers will be unaware of the intervention. However, prescribers will be able to prescribe all available doses, without any restrictions|"This cluster randomized crossover (CRXO) trial involves 10 sites in an urban health system: five clinics will start the trial under the intervention/control during a first time period (T1) then will switch to intervention/control status (T2). The primary outcome is prescription rate of a lower default dose for 8 high-risk drugs.~Other inputs used for trial design were: baseline rate of prescriptions meeting the geriatric standard (sources: local data, Geriatrics At Your Fingertips), within-period intraclass correlation coefficient (ICC, correlation between two randomly chosen observations in the same cluster), cluster autocorrelation (ratio of between-period ICC to within-period ICC), and coefficient of variation of cluster sizes (required when unequal sample size per cluster is expected). The aim is for ≥80% power to detect a ≥50% increase in prescriptions meeting the geriatric standard; this is based on previous studies and on the researchers' preliminary data on Trazodone."|t|t|f|f
34048779|NCT06667622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152704|NCT04322825|NA|SINGLE_GROUP||TREATMENT||NONE||prospective cohort study||||
34152705|NCT00752726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152706|NCT04379778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152707|NCT01205477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152708|NCT00418977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152709|NCT05204433|||CASE_CONTROL||PROSPECTIVE|||||||
34152710|NCT04770636|||COHORT||CROSS_SECTIONAL|||||||
34152711|NCT02014779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048780|NCT03694847|||CASE_CONTROL||RETROSPECTIVE|||||||
33737520|NCT01484470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048781|NCT06684860|||COHORT||PROSPECTIVE|||||||
34048782|NCT00910208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048783|NCT02228733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048784|NCT02119793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048785|NCT02497443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking was specified as Opel Label study in old format||f|f|t|f
34048786|NCT03718520|||COHORT||PROSPECTIVE|||||||
34048787|NCT00671528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048788|NCT03468166|||CASE_ONLY||CROSS_SECTIONAL|||||||
34048789|NCT03619239|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048790|NCT03008863|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048791|NCT02980419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34048792|NCT02898571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34048793|NCT05790512|||OTHER||CROSS_SECTIONAL|||||||
34048794|NCT00713791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34048795|NCT06685055|||COHORT||PROSPECTIVE|||||||
34048796|NCT03316053|||CASE_ONLY||PROSPECTIVE|||||||
34048797|NCT02107859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048798|NCT02960035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048799|NCT04768101|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There is no masking in this protocol.|There is no masking in this protocol.||||
33737521|NCT04657159|||COHORT||PROSPECTIVE|||||||
33737522|NCT05897216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944771|NCT01347515|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33944772|NCT01136759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33944773|NCT06471686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944774|NCT03612635|||COHORT||PROSPECTIVE|||||||
33944775|NCT05588622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048800|NCT02794792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048801|NCT06675435|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In a prospective single center clinical study, participants with acute hypoxemic respiratory failure will receive inhaled nitric oxide for 15 minutes. Study outcomes will compare cardiopulmonary responses to inhaled nitric oxide (vs. no inhaled nitric oxide).||||
34048802|NCT02342197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048803|NCT06676475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048804|NCT01949844|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34048805|NCT00006471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048806|NCT05954585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The person conducting follow-up assessments will be masked as to the intervention assignments.||f|f|f|t
34048807|NCT03025139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048808|NCT00931437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048809|NCT03329183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34048810|NCT02858999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048811|NCT06057662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048812|NCT00325156|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34048813|NCT02511964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048814|NCT06654076|||COHORT||RETROSPECTIVE|||||||
34048815|NCT06149364|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34075692|NCT01255072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152712|NCT03841760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152713|NCT05781321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The MRI scan indicating progressive disease will be fused with our treatment planning scan and the region of progression will be contoured by an investigator blinded to the GTV_MRI, T2_FLAIR_NCET, GTV_PET, PTV_high, and isodose lines.||f|f|f|t
34152714|NCT04457492|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34152715|NCT05282420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients were randomized into two groups, twenty patients (20 eyes) each. The first group received 0.5 mg\\0.1 ml ranibizumab intravitreal injections and the second group received 2.0 mg\\0.1 ml aflibercept intravitreal injections. all patients were followed up for at least 12 months.~Patients were given the planned treatment throughout the study and no switching was done between anti-VEGF drugs"|t|f|f|f
34152716|NCT03120377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152717|NCT05406609|||COHORT||RETROSPECTIVE|||||||
34152718|NCT00973245|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840922|NCT02915419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840923|NCT00770887|||||PROSPECTIVE|||||||
33840924|NCT05630534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33840925|NCT00479882|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33840926|NCT04300465|RANDOMIZED|PARALLEL||OTHER||NONE||"Randomised parallel design. 2 study groups and within each group there are 2 arms.~Patients with stable rheumatoid arthritis (RA) and their partners~* 16 RA patients + 16 partners~* each pairing is randomised into 1 of 2 groups~  1. With partner: The RA patients + their partners partake in the the intervention (8 RA patients and 8 partners)~ 2. Without partner: the RA patients partake in the intervention alone (8 patients) The partner does not partake in the intervention (8 partners).~Patients with stable stage 3 or 4 chronic kidney disease (CKD) and their partners~* 16 CKD patients + 16 partners~* each pairing is randomised into 1 of 2 groups~  1. With partner: The CKD patients and their partners partake in the the intervention (8 CKD patients and 8 partners)~ 2. Without partner: the CKD patients partake in the intervention alone (8 patients). The partner does not partake in the intervention (8 partners)"||||
33840927|NCT02440425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840928|NCT04515290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840929|NCT00201877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840930|NCT03461770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840931|NCT01254552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840932|NCT03296670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840933|NCT00613743|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33840934|NCT02736240|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33840935|NCT03514277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33840936|NCT05060341|||COHORT||OTHER|||||||
33840937|NCT05364567|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants were randomly assigned to two groups: the control group and the study group. Both groups were treated with phototherapy including 308-nm excimer laser or narrowband ultraviolet B. Study group additionally had vitamin D supplementation through the injection of cholecalciferol.||||
33840938|NCT02804997|||CASE_CROSSOVER||PROSPECTIVE|||||||
34048816|NCT03716557|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Single-blind crossover design|t|f|f|f
34048817|NCT01068886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048818|NCT05425641|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||The study uses a factorial design to randomize participants to all combinations of 4 behavior change techniques (BCTs). There will also be a control group which will receive no BCT intervention.||||
34048819|NCT03592667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048820|NCT03732352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048821|NCT06451419|||COHORT||PROSPECTIVE|||||||
34048822|NCT01788189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048823|NCT06130189|||OTHER||CROSS_SECTIONAL|||||||
34048824|NCT03573557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048825|NCT06576115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048826|NCT05758610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048827|NCT02048826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840939|NCT02814981|||COHORT||PROSPECTIVE|||||||
33840940|NCT03526653|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
33840941|NCT04691791|||COHORT||PROSPECTIVE|||||||
33840942|NCT01060839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840943|NCT04857424|||COHORT||PROSPECTIVE|||||||
33840944|NCT03156972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944776|NCT02405273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048828|NCT00952796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048829|NCT04105803|||CASE_CONTROL||PROSPECTIVE|||||||
34048830|NCT05932589|||CASE_CONTROL||PROSPECTIVE|||||||
34048831|NCT02322658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048832|NCT06665451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048833|NCT03979053|||COHORT||PROSPECTIVE|||||||
34048834|NCT00741676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152719|NCT00265031|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34152720|NCT01229449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152721|NCT04040621|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Non-randomized, single arm||||
33840945|NCT06533085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was designed as blinded, randomized and controlled.the person who evaluates the patients before and after the treatment is blind.In other words,the person evaluating the patients and the person giving the treatment are different.|randomized controlled study|t|f|f|t
33840946|NCT04056988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893335|NCT06201143|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33893336|NCT04725656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944777|NCT03449342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944778|NCT03740724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944779|NCT01072175|NON_RANDOMIZED|||TREATMENT||NONE||||||
33944780|NCT00491062||PARALLEL||||||||||
34048835|NCT04524819|||CASE_CROSSOVER||PROSPECTIVE|||||||
34048836|NCT02821741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34048837|NCT03507322|||COHORT||PROSPECTIVE|||||||
34048838|NCT00113854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34048839|NCT04255810|||COHORT||PROSPECTIVE|||||||
34152722|NCT01915862|||COHORT||PROSPECTIVE|||||||
34152723|NCT01620528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152724|NCT03474783|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34152725|NCT03291392|||OTHER||OTHER|||||||
34152726|NCT04900285|NA|SINGLE_GROUP||PREVENTION||NONE||Subject serve as their own control sleeping without the device for five days and recording snoring on the SnoreLab app and filling out the Snore Outcomes Survey. The lower dental device is used for five days while recording snoring. The subject will then complete the Comfort and Difficulties Form and the bed partner completes the Snore Outcomes Survey. The process is repeated with the upper device for those who tolerate the lower device. use.||||
34152727|NCT01093066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152728|NCT02667470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840947|NCT04151836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A statistician who did not participate in the study randomly assigned patients to the experimental or control group according to the list generated by the computer software.|Both groups were tested by demographic characteristics, dietary behavior measurement, SF-36 Questionnaire and body composition analyzer for the same project. The experimental group needs to cooperate with the moderate-intensity walking exercise training prescription for 3 times a week ; Control group no exercise intervention.|f|f|f|t
33840948|NCT02084758|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33840949|NCT05155670|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single Group Assignment||||
33840950|NCT02773004|NA|SINGLE_GROUP||OTHER||NONE||||||
33840951|NCT03912051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840952|NCT04756076|||COHORT||PROSPECTIVE|||||||
34048840|NCT05689190|||CASE_ONLY||PROSPECTIVE|||||||
34048841|NCT06685315|||OTHER||CROSS_SECTIONAL|||||||
33840953|NCT06173453|||CASE_ONLY||RETROSPECTIVE|||||||
34048842|NCT04750265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, parallel-group, open label pilot trial||||
34048843|NCT05497479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||All eligible subjects will be enrolled and randomized (1:1) to one of two treatment groups: active (0.003% AR-15512) or control (AR-15512 vehicle). Following enrollment, subjects in the two treatment groups will each be randomized 1:1 to which Visit (Visit 1 or 2) anesthetic will be used with the Schirmer test.|t|t|t|t
33840954|NCT05358041|||COHORT||PROSPECTIVE|||||||
33840955|NCT01310231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048844|NCT00515775|||CASE_CROSSOVER||PROSPECTIVE|||||||
33840956|NCT04483180|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|Double blind study. Neither the participant nor the investigator will be aware of the coding of beverages used in the study.|Multi-centre crossover study with 4 conditions using balanced block randomisation. The three centres will follow different randomisation sequences but will all test the same 4 conditions (University of Navarra, University of Copenhagen, University of Liverpool).|t|f|t|f
34048845|NCT00563641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048846|NCT04099511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind raters will be used to collect all outcomes measures|A single-blind, parallel, randomized clinical trial design will be used in this study. Randomization will be conducted using stratified randomization. Randomization will be stratified by age (50-68 v 69-85) and stroke severity (NIHSS total score 1-16 v \>16). Within each strata randomization will be blocked to help ensure an equal number of participants have been assigned to each intervention group.|f|f|f|t
34048847|NCT04610112|||COHORT||PROSPECTIVE|||||||
33840957|NCT02985840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840958|NCT04709289|NA|SINGLE_GROUP||TREATMENT||NONE|Evaluator assesses photographs without prior knowledge of intervention|||||
34048848|NCT06280144|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33840959|NCT05645601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048849|NCT01217476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893337|NCT02354950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048850|NCT06663540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34048851|NCT05347667|RANDOMIZED|PARALLEL||OTHER||NONE||In a randomized fashion, participants will have one leg undergo unilateral resistance exercise training to assess the muscle protein synthetic response in each menstrual cycle phase.||||
34048852|NCT02258373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048853|NCT06685666|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34048854|NCT03960489|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34048855|NCT00617890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048856|NCT05650645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048857|NCT06446115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a two-arm, randomized 1:1, pilot study.||||
34048858|NCT00527033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048859|NCT00301301|||||RETROSPECTIVE|||||||
34048860|NCT05681325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34048861|NCT06304285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048862|NCT06682585|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34048863|NCT03912090|||OTHER||RETROSPECTIVE|||||||
34048864|NCT05376371|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34048865|NCT02658955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048866|NCT02049905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048867|NCT01547143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893338|NCT02065661|||CASE_ONLY||PROSPECTIVE|||||||
33893339|NCT00125333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33893340|NCT06061445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944781|NCT05008627|||CASE_ONLY||PROSPECTIVE|||||||
33944782|NCT04919889|||COHORT||PROSPECTIVE|||||||
33944783|NCT00001961||||TREATMENT||||||||
34048868|NCT03024762|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The intervention assessed is the targeted Provider-Initiated Testing and Counselling (tPITC) whereby HIV positive parents receiving HIV services in the hospital are invited to have their children of unknown HIV status tested for HIV. The control arm is the blanket Provider-Initiated Testing and Counselling (bPITC) whereby all children consulting in the hospital (and with unknown HIV status) are invited to test for HIV and this irrespective of the presenting complaint. The study is assessing in the same hospital the effectiveness of tPITC vs bPITC.||||
34048869|NCT06683495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34048870|NCT03892174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048871|NCT06138873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34048872|NCT04305691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048873|NCT04679311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The laboratory that performs the assays and the assessor of the angioedema will be blinded to the treatment the subject received.||f|f|f|t
34048874|NCT01797861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048875|NCT06682325|||COHORT||PROSPECTIVE|||||||
34048876|NCT01333904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048877|NCT04379531|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34048878|NCT00012519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048879|NCT03427099|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34048880|NCT05411094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048881|NCT00661609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048882|NCT00396773|||DEFINED_POPULATION||PROSPECTIVE|||||||
34048883|NCT03269721|||COHORT||PROSPECTIVE|||||||
34048884|NCT00711568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34048885|NCT04761198|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Basket study||||
34048886|NCT02040636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048887|NCT01209585|||COHORT||PROSPECTIVE|||||||
34048888|NCT06398496|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants randomized to either a control (usual care only) or exercise (usual care + aerobic exercise) intervention group. 'Usual care' is whatever the participant's current treatment plan is, including pharmacological and psychological treatment.||||
34048889|NCT00544115|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048890|NCT02727777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048891|NCT05199571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048892|NCT03524235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048893|NCT05032066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048894|NCT05976269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048895|NCT02218099|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34048896|NCT06318988|||COHORT||PROSPECTIVE|||||||
34048897|NCT06048562|NA|SEQUENTIAL||DIAGNOSTIC||NONE||To evaluate all full term infants of diabetic mother for the presence of hypertrophic cardiomyopathy who admitted in NICU at Assiut University Children Hospital and to follow up of these cases after 6 months for recovery.||||
34048898|NCT03408509|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34048899|NCT04237753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial with adaptive trial design. Randomization will first involve treatment with one of two delivery methods: (1) a web-based mobile health application or (2) a single video session. For women who do not improve (SMART design), they will receive a first or second video session.|f|f|f|t
34048900|NCT01644292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048901|NCT04441528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048902|NCT02511067|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34048903|NCT05175885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors and compare it by means of retrospective matching with static cold storage.||||
34048904|NCT01794182|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048905|NCT01609543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048906|NCT06667349|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||1727||||
34048907|NCT05334485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34048908|NCT04828213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|2-arm parallel trial|t|f|f|t
34048909|NCT05635435|||COHORT||PROSPECTIVE|||||||
34152729|NCT01072253|||COHORT||RETROSPECTIVE|||||||
34152730|NCT03301467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo|Placebo crossover to active|t|t|t|t
34152731|NCT05749952|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34152732|NCT00630773|||CASE_ONLY||PROSPECTIVE|||||||
33737523|NCT03797027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737524|NCT00927927|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33944784|NCT03751462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944785|NCT03845426|||COHORT||PROSPECTIVE|||||||
34048910|NCT03937440|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34048911|NCT00154232|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34048912|NCT04431908|||COHORT||PROSPECTIVE|||||||
34048913|NCT00986921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048914|NCT02526979|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34048915|NCT04392375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients are enrolled and randomly selected to receive Nifedipine or placebo through delivery of her infant.|t|t|t|f
34048916|NCT05806398|||OTHER||CROSS_SECTIONAL|||||||
33764392|NCT01592149|||COHORT||CROSS_SECTIONAL|||||||
33944786|NCT03563807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A blinded rater will perform the Mini-BESTest of balance before and after the intervention||f|f|f|t
34048917|NCT03109353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048918|NCT06682416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34048919|NCT06018298|||COHORT||PROSPECTIVE|||||||
34048920|NCT06045455|||CASE_ONLY||PROSPECTIVE|||||||
34048921|NCT06598592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34048922|NCT04647799|||COHORT||PROSPECTIVE|||||||
34048923|NCT05849883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, single blind, single dose, 2-treatment, 3-sequence, 3-period partial replicate design study with one week washout period in 36 healthy subjects under fasting condition.|t|f|t|f
34048924|NCT06371495|||CASE_CONTROL||PROSPECTIVE|||||||
34048925|NCT01353690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048926|NCT04176419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34048927|NCT01850147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048928|NCT05045781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944787|NCT01025739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944788|NCT00006382||||SCREENING||||||||
34048929|NCT04206813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The control group will have 120 subjects will receive a 3-dose regimen as recommended by Center for Disease Control (CDC) given at 0, 2 and 6 months. The intervention group will have 240 subjects who will receive a modified 3-dose regimen given at 0, 6, and 12 months. Both groups will have HPV titers drawn at Visit 1 (pre-vaccination) and Visit 7 (after three doses for the Control group and 2 doses for the Intervention group).||||
34048930|NCT03233529|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34048931|NCT05000684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048932|NCT06519357|NA|SINGLE_GROUP||TREATMENT||NONE||Self-controlled, prospective case series pilot study||||
34048933|NCT04269304|||COHORT||PROSPECTIVE|||||||
34048934|NCT06471569|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048935|NCT05837845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized study. Participants will be 1:1 randomized to receive either MDMA or CPT.|f|f|f|t
34048936|NCT00078975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048937|NCT05387473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048938|NCT00600561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048939|NCT06470022|RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient and operator cannot be blinded to allocated treatment. Most outcomes are registry based and randomization is not anticipated to impact outcome assessment.|Randomized 1:1||||
34048940|NCT01356303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048941|NCT04325022|||OTHER||PROSPECTIVE|||||||
34048942|NCT00200174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048943|NCT06588868|||COHORT||RETROSPECTIVE|||||||
34048944|NCT05063357|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, multi-center clinical trial||||
34048945|NCT06028802|||CASE_ONLY||PROSPECTIVE|||||||
34048946|NCT00507728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048947|NCT06458335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34048948|NCT06665893|NA|SINGLE_GROUP||TREATMENT||NONE||Children aged 6-15.9 years of age will be asked for participation. Participants included in the study will perform daily weighings at home and parents will be able to follow treatment closely in an application on their phone. Through a communication function in the application, families will be able to communicate in a fast and easy way with healthcare professionals at the clinic. The study duration is 6 months.||||
34048949|NCT01188980|||CASE_ONLY||PROSPECTIVE|||||||
34048950|NCT01768442|||CASE_CONTROL||PROSPECTIVE|||||||
34152733|NCT05042973|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel Assignment|t|t|t|t
34048951|NCT05206253|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34152734|NCT02733289|||COHORT||PROSPECTIVE|||||||
34048952|NCT01563614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152735|NCT05117177|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm 1: sequential dose escalation Arm 2: randomized crossover Arm 3: single treatment assignment||||
33840960|NCT03451019|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective randomized open-label study included 34 patients with CKD. Single oral dose of one of phosphate binders (sevelamer or lanthanum) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal. Serum calcium, phosphate and parathormone were measured at 0, 3, 6, 12, 24 hours after each medication. Bone alkaline phosphatase (BAP), sclerostin, calcitriol and FGF-23 were measured at 0, 12 and 24 hours after dose. Calcium and phosphate were measured in 24h urine collections after each drug.||||
33840961|NCT02801695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840962|NCT04536129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048953|NCT04161638|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Due to the nature of the experimental manipulation in this study and to maintain validity, mild deception was necessary. Participants were told that the study was examining BP, HR, mood, and behavioral responses to various forms of media and were not informed specifically of the purpose until after they completed the study. In order to verify that the participants were unaware that their cardiovascular reactivity to a weight stigma exposure was being measured, a manipulation check was implemented wherein participants were asked to report what they believed the study purpose to be. No participants reported the true purpose of the study during the manipulation check. At the conclusion of the study, participants were debriefed about the true purpose of the study.|Participants were randomized using www.randomization.com to either STIGMA at Visit 2 and NEUTRAL at Visit 3, or NEUTRAL at Visit 2 and STIGMA at Visit 3.|t|f|f|f
34152736|NCT04922905|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is an observational, prospective, cross-sectional and monocentric cohort study||||
34152737|NCT05574465|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Subjects who meet the inclusion and exclusion criteria will be eligible for participation in this study. It is anticipated that the largest number of subjects will come from patients undergoing extubation in an intensive care unit (ICU).||||
34152738|NCT05307809|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152739|NCT06041633|||CASE_CONTROL||RETROSPECTIVE|||||||
34152740|NCT01500304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152741|NCT00332891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152742|NCT05675228|||CASE_ONLY||CROSS_SECTIONAL|||||||
34152743|NCT05216471|||COHORT||RETROSPECTIVE|||||||
34152744|NCT06020755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152745|NCT01343732|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34152746|NCT04940884|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33840963|NCT04922229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840964|NCT00819702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33840965|NCT03874689|||COHORT||CROSS_SECTIONAL|||||||
33840966|NCT04243746|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840967|NCT00807339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840968|NCT01555177|||CASE_CONTROL||PROSPECTIVE|||||||
33840969|NCT04098562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840970|NCT00147589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840971|NCT02212353|||COHORT||PROSPECTIVE|||||||
33840972|NCT03338296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840973|NCT04445740|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|key personnel will be masked||f|f|t|f
33840974|NCT01052610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944789|NCT03088995|||CASE_ONLY||PROSPECTIVE|||||||
33944790|NCT05433116|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840975|NCT05926453|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33840976|NCT01430468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840977|NCT00383539|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33840978|NCT05183529|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33840979|NCT00250549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34048954|NCT05811676|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048955|NCT00943150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048956|NCT03554148|||COHORT||PROSPECTIVE|||||||
34048957|NCT00296946|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34048958|NCT06681987|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34048959|NCT04687046|||COHORT||OTHER|||||||
34048960|NCT05390242|||CASE_CONTROL||RETROSPECTIVE|||||||
34048961|NCT04505072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome assessed by blinded rater|Randomized Controlled Trial|f|f|f|t
34048962|NCT01940887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048963|NCT00250874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048964|NCT05337306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34048965|NCT06574789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048966|NCT00747370|NON_RANDOMIZED|PARALLEL||||NONE||||||
34048967|NCT06320717|||COHORT||CROSS_SECTIONAL|||||||
34048968|NCT01366703|||COHORT||PROSPECTIVE|||||||
34048969|NCT04197336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All procedure images and reports, regardless of the randomization arm, will be kept with the unblinded member of the study team, and will not be housed centrally. All participants will adhere to the same follow-up schedule, meeting with blinded members of the study team only. The procedural team will not have further contact with the participant, the participant will only be followed by the blinded study team. Once the study is closed, all reports and images will be entered into the clinical record.|prospective, double-blinded, randomized, sham-controlled study|t|t|t|t
34048970|NCT06091917|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33764393|NCT01833312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764394|NCT03114202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840980|NCT03235752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, Double-blind, Placebo-controlled|Randomized, Double-blind, Placebo-controlled|t|t|t|t
33840981|NCT02571595|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33840982|NCT00599443|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33840983|NCT03361605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33840984|NCT04083820|||COHORT||PROSPECTIVE|||||||
33840985|NCT01135303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840986|NCT04948177|||OTHER||RETROSPECTIVE|||||||
33840987|NCT00570284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840988|NCT05082168|||COHORT||PROSPECTIVE|||||||
33840989|NCT03582787|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33840990|NCT00085787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840991|NCT01696045||PARALLEL||TREATMENT||NONE||||||
33840992|NCT01038375|||CASE_CONTROL||PROSPECTIVE|||||||
33840993|NCT00691587|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33840994|NCT00573846|||CASE_CONTROL||RETROSPECTIVE|||||||
33840995|NCT00248352|RANDOMIZED|CROSSOVER||||NONE||||||
33840996|NCT04267705|RANDOMIZED|PARALLEL||OTHER||SINGLE||The proposed study is a randomized, 3-arm, parallel, placebo-controlled design|t|f|f|f
33840997|NCT04679805|||COHORT||PROSPECTIVE|||||||
33840998|NCT01770977|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33840999|NCT00047697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841000|NCT03918369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter prospective, non-randomized, controlled study of the intracorporeal mechanical side-to-side isoperistaltic anastomosis versus extracorporeal anastomosis in laparoscopic right hemicolectomy. TREND-study||||
33841001|NCT04411329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841002|NCT03821103|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33841003|NCT00074477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841004|NCT05902325|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with severe recurrent CRSwNP will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital.||||
33841005|NCT06292949|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841006|NCT03434444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841007|NCT05936723|RANDOMIZED|PARALLEL||OTHER||NONE||parallel group-randomized trial||||
33841008|NCT06185231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841009|NCT02954978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841010|NCT01023958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841011|NCT03530748|||COHORT||PROSPECTIVE|||||||
33841012|NCT04743609|||COHORT||PROSPECTIVE|||||||
33841013|NCT02517762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841014|NCT00508053|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33841015|NCT06138652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893341|NCT06037876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation concealment will be warranted using sequential, opaque, sealed envelopes. Outcome assessors in the lab will be blinded.|Parallel open-label randomized controlled superiority trial|f|f|f|t
33893342|NCT04435340|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||retro- and prospective arm|t|f|f|f
33893343|NCT00994617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893344|NCT01784887|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33893345|NCT01819792|NA|SINGLE_GROUP||OTHER||NONE||||||
33893346|NCT02698410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893347|NCT03150940|||COHORT||PROSPECTIVE|||||||
33841016|NCT05105334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical assessments and grading of severity of acne scarring will be performed by blinded-investigator assessment at each visit and at the post-treatment 3-month visit using live evaluations and photographs. At the 3-month follow up, three additional blinded dermatologists will clinically assess the severity of acne scarring.|Prospective, randomized, split-face, evaluator-blinded study|f|f|f|t
33841017|NCT01200342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841018|NCT04341467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841019|NCT01730950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841020|NCT05287490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841021|NCT05692700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||- Having pain, having smell problems, having systolic blood pressure below 100 mm Hg, having lung cancer, asthma and chronic obstructive pulmonary disease, allergic to known plants, flowers and related essential oils, using any medication for anxiety and sleep problems Lavender and bergamot oil were not administered to the patients by inhalation.||||
33841022|NCT00513305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841023|NCT01468181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841024|NCT00949000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841025|NCT02311647|||CASE_CONTROL||PROSPECTIVE|||||||
33841026|NCT02893839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841027|NCT02758067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841028|NCT00003705||||TREATMENT||||||||
33841029|NCT03987971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33841030|NCT04815980|RANDOMIZED|PARALLEL||SCREENING||NONE||Two groups randomized; no-exercise control vs. Pilates exercise group.||||
33841031|NCT00933790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841032|NCT05169697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841033|NCT02611453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841034|NCT00732862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841035|NCT05915949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841036|NCT02338453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841037|NCT06135740|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33841038|NCT04662229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841039|NCT05110690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841040|NCT05116826|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33841041|NCT02305277|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841042|NCT01824745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33841043|NCT02181153|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33841044|NCT03711292|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge cluster randomized trial||||
33841045|NCT06132542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841046|NCT04148651|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33841047|NCT04957147|||COHORT||PROSPECTIVE|||||||
33841048|NCT05637099|||COHORT||PROSPECTIVE|||||||
33841049|NCT05689892|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841050|NCT01301040|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841051|NCT04353505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841052|NCT04993105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||study will evaluate the effects of Graston assisted soft tissue mobilization on the patients with plantar fasciitis .Study will include two groups , one will be treated with graston and one will be treated without graston in the time period of two weeks.|t|f|f|f
33944791|NCT04675034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All participants will be centrally assigned to randomised IP using an IRT/RTSM system. Before the study is initiated, the telephone number and call-in directions for the IRT and/or the log in information and directions for the RTSM will be provided to each site.~The IRT/RTSM will provide the investigator(s) or appropriate study personnel with the kit identification number to be allocated to the participant at the IP dosing visit.~Details for this will be described in the IRT/RTSM user manual that will be provided to each centre.~All participants, investigators, and study personnel involved in the conduct of the study will be blinded to treatment assignment. The unblinded study personnel (eg, site pharmacist) will not participate in study procedures or data analysis prior to unblinding of the study data to all study-related personnel. Unblinded AstraZeneca personnel who are not otherwise involved in the study will prepare data for review and interim analyses."|"This is a Phase IIb, multinational, multicentre, randomised, double-blind, placebo-controlled, dose-response study of MEDI7352 in participants 18 to 80 years of age (inclusive) with moderate-to-severe chronic pain of the knee. The study consists of a screening period of up to 45 days, a 12-week treatment period, and a 24-week follow-up (FU) period.~Daily pain scores (as measured on an 11-point numerical rating scale \[NRS\]) recorded at the first screening visit and from Day -7 to Day -1 will be used be used to determine eligibility.~Participants will be randomised to one of 4 doses of MEDI7352 or placebo. Each participant will receive 6 doses of MEDI7352 or placebo during the treatment period.~After the end-of-treatment (EOT) visit at Week 12, participants will enter the FU period, which comprises 3 clinic visits (Weeks 18, 32, and 36) and 4 FU phone calls (Weeks 15, 21, 24, and 28). All participants who receive IP are expected to complete the FU period."|t|t|t|t
33944792|NCT01385917|||COHORT||PROSPECTIVE|||||||
33944793|NCT01928758|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33841053|NCT01745692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841054|NCT04681157|||CASE_ONLY||RETROSPECTIVE|||||||
33841055|NCT04725916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841056|NCT05591261|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841057|NCT02476175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841058|NCT04904198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841059|NCT00760253|||CASE_CONTROL||PROSPECTIVE|||||||
33841060|NCT06480292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be a comparison between two groups; experimental and control group.|f|f|f|t
33841061|NCT03583775|||OTHER||PROSPECTIVE|||||||
33841062|NCT00657735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841063|NCT02677870|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33841064|NCT03581903|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841065|NCT02905448|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841066|NCT04721613|||CASE_CONTROL||PROSPECTIVE|||||||
33841067|NCT05461833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841068|NCT05154331|||COHORT||PROSPECTIVE|||||||
33841069|NCT03864198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841070|NCT03253445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33841071|NCT03563326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841072|NCT01766115|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841073|NCT01681121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841074|NCT01427777|||CASE_ONLY||PROSPECTIVE|||||||
33841075|NCT03357419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"A randomized, 1:1, double-blind, placebo controlled trial designed to evaluate the effect of prophylactic antibiotic on patients presenting for skin excision from lower limbs.~Before the surgery patient's demographics, medical history, skin lesion's site, properties and size will be documented. During the surgery the size of the wound and the sutures used will be documented. Afterwards, the wound will be assed for signs of infection (criteria adapted from the Centre for Disease Control and Prevention definition for superficial SSI \[42\]) and other complications during the follow-up period as needed until sutures will be removed at our clinic."|t|t|t|t
33841076|NCT03178370|||COHORT||PROSPECTIVE|||||||
33841077|NCT06011434|||COHORT||PROSPECTIVE|||||||
33841078|NCT04161053|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841079|NCT01796626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841080|NCT05183776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841081|NCT02461953|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33841082|NCT02031653|||COHORT||PROSPECTIVE|||||||
33841083|NCT02731079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841084|NCT03586908|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841085|NCT03432455|||COHORT||OTHER|||||||
33841086|NCT00509249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841087|NCT03683823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841088|NCT05538026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841089|NCT06378684|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33841090|NCT03711422|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841091|NCT06391762|||COHORT||CROSS_SECTIONAL|||||||
33841092|NCT06117670|NA|SINGLE_GROUP||TREATMENT||NONE||patients will undergo posterior colporrhaphy using gamma-irradiated amniotic membrane as a graft||||
33841093|NCT03232580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841094|NCT06408701|||COHORT||PROSPECTIVE|||||||
33841095|NCT04487678|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|There will be two intervention arms that will take place in a randomised, single blinded fashion so that participants are not aware of which dose of ketone esters they receive|Single-centre, randomised, single blinded, crossover study in 6 individuals with type 1 diabetes (see inclusion/exclusion criteria)|t|f|f|f
33841096|NCT03042923|||CASE_CONTROL||PROSPECTIVE|||||||
33841097|NCT04953598|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33841098|NCT03242967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841099|NCT01213537|||COHORT||PROSPECTIVE|||||||
33841100|NCT00213460|||||PROSPECTIVE|||||||
33841101|NCT01576380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841102|NCT02235311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841103|NCT01005082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152747|NCT04228432|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34152748|NCT02942654|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34152749|NCT01137253|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34152750|NCT04029571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152751|NCT02427503|||COHORT||PROSPECTIVE|||||||
34152752|NCT03595488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152753|NCT05327764|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized counterbalanced study||||
34152754|NCT03584243|NA|SINGLE_GROUP||TREATMENT||NONE||"This experimental study is a prospective, one-center city and non-comparative study.~Patient with progressive keratoconus will be included after providing their consent. The intervention of the study is to perform transepithelial crosslinking with oxygen Outcomes will be evaluated from pretreatment baseline of the patient."||||
33841104|NCT03934151|||COHORT||PROSPECTIVE|||||||
33841105|NCT04515433|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33841106|NCT05104203|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33841107|NCT01969851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841108|NCT05240326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841109|NCT02881593|||COHORT||PROSPECTIVE|||||||
33841110|NCT05910905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841111|NCT00573859|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33841112|NCT03599752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841113|NCT00709228|||COHORT||PROSPECTIVE|||||||
33841114|NCT00528619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841115|NCT01307683|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841116|NCT04846777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841117|NCT05034159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Following a baseline assessment, participants are initially randomized to either CBT-I or waitlist. Those in the waitlist condition will repeat their baseline assessment after 8 weeks, then will start CBT-I.||||
33841118|NCT03657602|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant will be blinded to group assignment|Participants will be randomly allocated one to one to the Kyleena or Mirena group and assessment will occur in parallel|t|f|f|f
34152755|NCT03149029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152756|NCT03040115|||COHORT||CROSS_SECTIONAL|||||||
34152757|NCT04588181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841119|NCT01224977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841120|NCT01937377|||COHORT||PROSPECTIVE|||||||
33841121|NCT04110925|NA|SINGLE_GROUP||SCREENING||NONE||||||
33841122|NCT01365481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841123|NCT05852977|||COHORT||RETROSPECTIVE|||||||
33841124|NCT05315570|RANDOMIZED|PARALLEL||OTHER||NONE||Multicenter, international, randomized (2:1 ratio), open-label, superiority trial||||
34152758|NCT00463554|||COHORT||PROSPECTIVE|||||||
34152759|NCT00791596|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34152760|NCT03903939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both patient, investigator and outcome assessor will be blinded||t|t|t|t
34152761|NCT05515289|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study is a single-center, open, single-dose, self-controlled clinical trial.||||
33841125|NCT04200638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, investigator and assessor.The trial design of this study will be a prospective, parallel.|The trial design of this study will be a prospective, parallel, Randomized clinical trial (RCT).|t|f|t|t
33841126|NCT01632540|||COHORT||PROSPECTIVE|||||||
33841127|NCT04287010|||COHORT||PROSPECTIVE|||||||
33841128|NCT00843505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841129|NCT00313092|||CASE_ONLY||PROSPECTIVE|||||||
33841130|NCT03011567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841131|NCT00504673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841132|NCT02548286|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841133|NCT01376453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841134|NCT00508313|||CASE_CONTROL||PROSPECTIVE|||||||
33841135|NCT06169462|||COHORT||RETROSPECTIVE|||||||
33841136|NCT00943852|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33841137|NCT00690664|||CASE_CONTROL||PROSPECTIVE|||||||
33841138|NCT02470780|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Participants randomized to the drug ended their study participation at 3 months without switching over to a placebo. Those randomized to placebo were switched to the drug after 3 months and followed for another 3 months (6 months total).|t|f|t|f
33841139|NCT02162004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841140|NCT04545333|||COHORT||PROSPECTIVE|||||||
33841141|NCT00967902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841142|NCT02456519|||COHORT||PROSPECTIVE|||||||
33841143|NCT01741805|||COHORT||PROSPECTIVE|||||||
33841144|NCT04260178|RANDOMIZED|PARALLEL||OTHER||SINGLE|Double blinding is not considered possible for EBIP interventions, where participants and researcher can recognize group assignment. However, giving and scoring the assessments were masked wherever feasible. The assistant researcher who administered and scored the questionnaires and the nurse that carried out PFT measurement and assessments were blind to experimental groups. Coded answer sheets were analyzed only after the study's completion|randomized controlled trial|f|f|f|t
33841145|NCT03724253|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study design included a dosimetry and non-dosimetry groups and with the following tumor types:~* Breast Cancer: dosimetry and non-dosimetry groups~* Prostate Cancer: dosimetry and non-dosimetry groups~* Colorectal cancer: non-dosimetry group~* Non-Small Cell Lung Cancer (NSCLC): non-dosimetry group~* Small-Cell Lung Cancer (SCLC): non-dosimetry group All data presentations were to be presented primarily by the overall population but were also to be repeated split by tumor type where relevant. Some presentations were also to be repeated split by whether or not the patient was found to have tumors bearing GRPR expression according to cytology and/or histopathology findings."||||
33841146|NCT02954744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841147|NCT04223804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841148|NCT01409551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841149|NCT01869023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841150|NCT03699891|||COHORT||RETROSPECTIVE|||||||
33841151|NCT03015129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841152|NCT00461981|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841153|NCT06233890|||COHORT||PROSPECTIVE|||||||
33841154|NCT03211117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152762|NCT05849519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841155|NCT04252274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841156|NCT02656719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841157|NCT00557908|||COHORT||OTHER|||||||
33841158|NCT00876824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841159|NCT00485277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841160|NCT02035618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841161|NCT00355290|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841162|NCT02779114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841163|NCT04079634|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will not be informed if they were randomized to control or treatment until Month 2 follow-up visit.||t|f|f|f
33841164|NCT00279136|||DEFINED_POPULATION||OTHER|||||||
33841165|NCT06181539|||COHORT||PROSPECTIVE|||||||
33841166|NCT00002745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841167|NCT03377478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841168|NCT03461159|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152763|NCT01826734|||CASE_ONLY||PROSPECTIVE|||||||
33841169|NCT02777892|||CASE_ONLY||RETROSPECTIVE|||||||
33841170|NCT00213889|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841171|NCT05049057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841172|NCT03005353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841173|NCT02179177|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33841174|NCT06274931|||OTHER||PROSPECTIVE|||||||
33841175|NCT03417570|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33841176|NCT02457377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841177|NCT00406692|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841178|NCT05369559|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The fluid challenge is given intravenously via a specific venous line.~Patients are assigned in a random chronological order to:~* receive a mini-bolus :50 ml of crystalloid solution, regularly infused over 30 seconds~* and passive leg raising.~Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes."||||
33841179|NCT03297177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841180|NCT04118608|||COHORT||CROSS_SECTIONAL|||||||
33841181|NCT00523640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893348|NCT06656182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152764|NCT04803955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764395|NCT04241692|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||To allow for this type of comparison, each enrolled research subject will wear both systems simultaneously||||
33893349|NCT00005705|||||RETROSPECTIVE|||||||
33893350|NCT04927312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944794|NCT00883896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841182|NCT05017090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple (Participant, Care Provider, Investigator) Blocks will be administered after induction of general Anesthesia so participants will be blinded to which intervention they have had.~Study investigators will not be aware of what group the participant belongs to when assessing the patient at post-operative period"|Allocation: Randomized Intervention Model: Parallel Assignment|t|t|t|f
33841183|NCT00045773|||CASE_ONLY||PROSPECTIVE|||||||
33841184|NCT04635969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33841185|NCT02815943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841186|NCT05574283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33841187|NCT02182050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841188|NCT03517943|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34152765|NCT05293925|||COHORT||PROSPECTIVE|||||||
33841189|NCT01228318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841190|NCT00002950||||TREATMENT||||||||
33841191|NCT04488523|NA|SINGLE_GROUP||TREATMENT||NONE||This study is designed to iteratively adapt a family-based intervention with feedback from youth and caregiver participants and stakeholder partners, as well as to evaluate the feasibility, acceptability, and preliminary effectiveness of the intervention.||||
34152766|NCT01654809|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33841192|NCT04148664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a multi-center prospective single-blinded randomized controlled trial. Enrollment of 60 subjects undergoing clinically-indicated AF ablation is planned with 1:1 block randomization (standard 'low power' RF settings n=30, HPSD n=30 and allowing for 10 drop-outs / consent withdrawals). Follow-up will be over 12 months.|t|f|f|f
34152767|NCT00718770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841193|NCT04808076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||INPH patients and Healthy Individuals.||||
33841194|NCT04684823|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm device pilot study||||
33841195|NCT03776123|||COHORT||PROSPECTIVE|||||||
33841196|NCT02352519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33841197|NCT03637218|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low altitude and High altitude||||
33841198|NCT04348253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Scares are identical. Patient and examiner are blinded|randomized trial|t|f|f|t
33841199|NCT02164903|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33841200|NCT05396651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841201|NCT00353041|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
33841202|NCT06029023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33841203|NCT05177887|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841204|NCT01506440|||CASE_ONLY||PROSPECTIVE|||||||
33841205|NCT03822975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841206|NCT02374723|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841207|NCT05932901|||COHORT||RETROSPECTIVE|||||||
33841208|NCT05844059|||COHORT||PROSPECTIVE|||||||
33841209|NCT02291939|||CASE_ONLY||PROSPECTIVE|||||||
33841210|NCT06457282|||CASE_CONTROL||RETROSPECTIVE|||||||
33841211|NCT03834324|NA|SINGLE_GROUP||TREATMENT||NONE||Technology development and Observational study||||
33841212|NCT04091035|||COHORT||RETROSPECTIVE|||||||
33841213|NCT00172523|||DEFINED_POPULATION||OTHER|||||||
33841214|NCT02703259|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33737525|NCT06191679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Family Units (AYA and caregiver participants) are randomized to one of three arms: (1) Usual Care \[no intervention\], (2) DECIDES \[access to web-based decision aid\], or (3) DECIDES + Coach \[access to web-based decision aid with coach-assisted support\].~Oncology health care providers of participating AYA are not enrolled in an intervention arm."||||
33737526|NCT03181516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33737527|NCT03927157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Participants will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.|t|t|t|f
33841215|NCT06090188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33841216|NCT05431218|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study suggests dividing patients, depending on the initial vitamin D level, into 4 groups: normal level, deficiency, deficiency and severe deficiency. Also, the division into groups according to the severity of chronic obstructive pulmonary disease: mild, moderate, severe and extremely severe||||
33841217|NCT04061876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841218|NCT04415320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841219|NCT02252770|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33841220|NCT04684017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841221|NCT06019559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841222|NCT00002385||||TREATMENT||DOUBLE||||||
33737528|NCT06664333|||CASE_ONLY||PROSPECTIVE|||||||
33841223|NCT00667225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841224|NCT06340477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841225|NCT04706897|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33841226|NCT03232918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The labor room nurse will be aware of the patient group assignment and will adjust the dose of the drug based on group assignment. The Investigator, Physician Provider and Outcome Assessor will be blinded.||t|f|t|t
33841227|NCT00924742|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34152768|NCT03125694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152769|NCT05896813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737529|NCT06664710|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33841228|NCT02839889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841229|NCT00071461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152770|NCT02248636|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33841230|NCT00343070|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841231|NCT06479213|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33841232|NCT02849444|||COHORT||PROSPECTIVE|||||||
33841233|NCT00198770|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33841234|NCT04525794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841235|NCT01223547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152771|NCT05730972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152772|NCT00439036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841236|NCT02735928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841237|NCT06261632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33841238|NCT03414177|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will receive asthma follow up care via telemedicine at a remote clinical sites. The second group will receive in-person asthma follow-up care at a specialty clinic.||||
33841239|NCT04496245|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will be randomised to the wait list group (Group 1) or the initial intervention group (Group 2) using a one-to-one ratio, stratified by hospital and department \[High risk, lower risk\].|Participants will be randomized to either Group 1 (waitlist control, delayed treatment group) or Group 2 (initial treatment) for treatment for a period of 3 months with 3 months follow-up off treatment||||
34152773|NCT05379452|||COHORT||PROSPECTIVE|||||||
33841240|NCT00443170|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33841241|NCT00710905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152774|NCT02986113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33841242|NCT02886039|NA|SINGLE_GROUP||||NONE||||||
33841243|NCT01899898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841244|NCT06503692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841245|NCT02595775|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33841246|NCT06373562|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Wrestlers in H group were living in hypoxic rooms for 8-14h/d and between that they were participating in sports training. C group was participating in the same training protocol.||||
34152775|NCT01727414|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Every participant receives placebo and three different dose of MPH for one week each in a triple blinded fashion|t|t|t|t
33841247|NCT00449605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841248|NCT02531555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841249|NCT03174431|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel group design with participants randomized to either DICD or CP (active treatment concurrent control) in a 1:1 allocation ratio for a 4-week treatment period followed by a six-month phone call follow-up to assess continued use and other treatment utilization after the initial study treatment phase.||||
34152776|NCT01508845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841250|NCT01071343|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33841251|NCT00259623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841252|NCT01868425|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33841253|NCT04523428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152777|NCT03892135|||OTHER||RETROSPECTIVE|||||||
33841254|NCT02086877|||COHORT||PROSPECTIVE|||||||
33841255|NCT03049553|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33944795|NCT02063802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152778|NCT00480389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152779|NCT03459365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152780|NCT02591459|NA|SINGLE_GROUP||||NONE||||||
34152781|NCT01286571|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152782|NCT04495725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152783|NCT01867138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152784|NCT06033872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34152785|NCT04891107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152786|NCT04448353|||COHORT||RETROSPECTIVE|||||||
34152787|NCT01262664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152788|NCT00013169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152789|NCT00036257|NON_RANDOMIZED|||TREATMENT||NONE||||||
34152790|NCT00599508|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33944796|NCT00711009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944797|NCT02101216|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34152791|NCT04622813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152792|NCT02788058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152793|NCT02951429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152794|NCT02368821|||CASE_CONTROL|||||||||
34152795|NCT02423980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152796|NCT01345682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152797|NCT03429543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152798|NCT05387057|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study will be conducted as a single-blinded study: the outcome evaluator of the pre- and post-measurements will be blinded to group allocation. Blinding of participants will not be possible since usual care will be used as a control intervention.|Allocation ratio = 1 (Intervention) : 1 (Control) stratified by gender and per institute (study site)|f|f|f|t
34152799|NCT05899582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152800|NCT01959243|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34152801|NCT01392612|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152802|NCT03441698|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34152803|NCT01068080|||COHORT||PROSPECTIVE|||||||
34152804|NCT05136261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Emollients will be dispensed in identical, unmarked containers||t|t|t|t
34152805|NCT01656694|||COHORT||OTHER|||||||
34152806|NCT01694108|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33841256|NCT00133809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944798|NCT04387396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944799|NCT05929872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Prospective, double-blind, randomized controlled study|t|f|t|f
33944800|NCT01233284|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33944801|NCT05596864|||OTHER||PROSPECTIVE|||||||
33944802|NCT04166721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944803|NCT03914131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944804|NCT02996981|||COHORT||RETROSPECTIVE|||||||
34152807|NCT02315482|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34152808|NCT06544031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study employs a Solomon Four Group Design, which includes parallel groups for evaluating the impact of the Healthy Nutrition education program on nutritional knowledge and attitudes among elderly individuals."||||
34152809|NCT04927572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152810|NCT06106763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Mandala and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
34152811|NCT00875342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152812|NCT02934737|||COHORT||RETROSPECTIVE|||||||
33737530|NCT03610490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944805|NCT06186154|NA|CROSSOVER||DIAGNOSTIC||NONE||Pilot single group study where each study subject acts as their own control||||
34048971|NCT01167673|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34048972|NCT04166344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistical analyses will be performed by one researcher unaware of patient allocation||f|f|t|f
34152813|NCT04556318|||COHORT||PROSPECTIVE|||||||
33737531|NCT06570018|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737532|NCT00216294|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33737533|NCT05568394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A single-blinded design|f|f|t|t
33737534|NCT04454385|||COHORT||PROSPECTIVE|||||||
33737535|NCT06383624|||CASE_CROSSOVER||PROSPECTIVE|||||||
33737536|NCT03465696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737537|NCT03980847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841257|NCT05691751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants were randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups, and the allocation was put into concealed envelopes independent of the surgeon and the author, and the randomization was performed by a research fellow who was not involved in patient care, the patients were blinded to the intervention during the whole period of the study, while the surgeon and the author were unblinded by opening the envelope by a research member just before initiating anesthesia, the data was collected by the author's assistant who was blinded of the intervention during the whole period of the study||t|t|t|t
33841258|NCT00642408|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841259|NCT01410305|||CASE_CONTROL||PROSPECTIVE|||||||
33841260|NCT01021618|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841261|NCT01453400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841262|NCT00783276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33841263|NCT05031949|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase 1b, Open-Label, Single-Arm Study to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.||||
33841264|NCT03260777|||CASE_ONLY||CROSS_SECTIONAL|||||||
33841265|NCT02385240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841266|NCT03925805|||OTHER||CROSS_SECTIONAL|||||||
33841267|NCT03241459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841268|NCT02790827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841269|NCT04449380|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an interventional, monocentric, phase 2, randomized (2:1), open label, controlled clinical study||||
33841270|NCT04855162|||COHORT||PROSPECTIVE|||||||
33841271|NCT06504160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841272|NCT00278447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841273|NCT05923853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Respiratory therapists and study coordinators will be unblinded. Study investigators, medical monitor and statistician will be blinded.||f|f|t|t
33841274|NCT04188873|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Daily smokers will be recruited from primary care to participate in a fully crossed, 2x2x2x2 factorial experiment (N=608) that evaluates 4 different factors: 1) Medication Type (Varenicline vs. Combination NRT \[C-NRT\]), 2) Preparation Medication (4 Weeks vs. Standard), 3) Medication Duration (Extended \[24 weeks\] vs. Standard \[12 weeks\]); and 4) Counseling (Intensive vs. Minimal).||||
33841275|NCT04633525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841276|NCT06412354|NA|SINGLE_GROUP||OTHER||NONE||"The VIVHEART EasyCross™ fist-in human (VIV-FIH) study is a singlecenter, prospective, open-label, non-randomized, single-group assignment, first-in-human feasibility trial of the VIVHEART EasyCross™ catheter used according to the indication of use. The experimental part of the trial which differs from the traditional TAVR procedure is the use of the self-centering catheter from its insertion in an artery and up to its removal from the patient body (henceforth investigational procedure)."||||
33944806|NCT05702840|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Members of the research team that perform measurements are blinded to group allocation.|Randomised controlled pilot trial with two groups, resistance exercise + weight loss group and weight loss only group.|f|f|f|t
33944807|NCT04390620|||COHORT||PROSPECTIVE|||||||
33944808|NCT05515887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737538|NCT04132349|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33737539|NCT01529645|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33737540|NCT02336984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737541|NCT03993418|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2-group parallel 12-week intervention study with control group||||
33737542|NCT04379011|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33737543|NCT04989257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ticagrelor-based dual-antiplatelet therapy vs. Clopidogrel-based dual-antiplatelet therapy||||
33737544|NCT02899897|||COHORT||PROSPECTIVE|||||||
33737545|NCT03120624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737546|NCT03074734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737547|NCT01222481|||COHORT||PROSPECTIVE|||||||
33737548|NCT04077034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33737549|NCT01590641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737550|NCT02453451|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737551|NCT01623440|||COHORT||CROSS_SECTIONAL|||||||
33737552|NCT02586701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841277|NCT05204797|RANDOMIZED|PARALLEL||SCREENING||SINGLE|"At the research office of health professions at IRCCS Istituto Ortopedico Rizzoli in Bologna, Italy (coordinating centre), a block of 5 randomisation list using the site www.randomisation.com will be generated. A sequence of opaque envelopes will be set up with a sequential number on the outside. A label will be placed iside the envelope that will contain the words CORI or STANDARD, according to the sequence indicated by the generated list. Envelopes will be always sealed at the Research Centre and the list kept under lock. The envelopes will be placed in a dedicated box and delivered to the studio manager."|Two blinded groups operated via robotic-assisted surgery (1st arm) or conventional technique (2nd arm).|t|f|f|f
33841278|NCT00002320||||TREATMENT||DOUBLE||||||
33841279|NCT04752553|||COHORT||CROSS_SECTIONAL|||||||
33841280|NCT04520503|||COHORT||PROSPECTIVE|||||||
33841281|NCT05483413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled||||
33841282|NCT03796377|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33841283|NCT00003124||||TREATMENT||||||||
33841284|NCT04548284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841285|NCT04393194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm,Randomized, Double- Blind, Placebo Controlled, Clinical Trial|t|f|t|f
33841286|NCT04611945|||COHORT||PROSPECTIVE|||||||
33841287|NCT05909826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841288|NCT02089568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841289|NCT04302688|||OTHER||RETROSPECTIVE|||||||
33841290|NCT02406677|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33841291|NCT04827472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841292|NCT04993482|||CASE_CONTROL||PROSPECTIVE|||||||
33841293|NCT01259089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841294|NCT05512689|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||We aimed to avoid classical randomization due to a possible learning and habituation effect from the feedback when using the RFM. We started with a phase of routine ventilation, in which the healthcare professional ventilated the infants using the RFM but did not receive any feedback about the ventilation. This represents the normal clinical setting. In the second phase, the healthcare professional then received visual feedback from the RFM during ventilations. The healthcare professional could then adjust his ventilation technique in real time.||||
33841295|NCT06186921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841296|NCT01345864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33841297|NCT06465225|||COHORT||PROSPECTIVE|||||||
33841298|NCT00712972|||COHORT||PROSPECTIVE|||||||
33841299|NCT02490033|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048973|NCT03064815|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841300|NCT02038387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841301|NCT03004001|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33841302|NCT03520738|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33841303|NCT04797052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective observational study||||
33841304|NCT01173965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841305|NCT03524196|NA|SINGLE_GROUP||OTHER||NONE||||||
33841306|NCT05568953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Arms B1 and B2 will be double-blinded. Arm B3 will be open label.|"58 subjects will be randomised into 1 of 2 arms (Arm B1 and Arm B2) in a 1:1 ratio, in a double-blind fashion. Randomization will be performed via a web-based randomization system: http://www.randomization.com by an independent person who has no direct contact with the subjects. Randomization opaque envelopes will be prepared by an independent team in accordance to the Master Randomization List generated. The randomization envelopes are to be opened sequentially for each enrollment by the study team and will determine the subject's allocation to one of the three groups.~Arm B3 will be conducted as a separate single-arm open label design in 14 subjects.~Enrolled subjects will be randomised into 1 of 3 arms (Arm B1, Arm B2 and Arm B3) in a 2:2:1 ratio. The study will be double-blinded."|t|f|t|t
33841307|NCT03514329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048974|NCT02504853|||CASE_CONTROL||PROSPECTIVE|||||||
33841308|NCT06151028|||COHORT||PROSPECTIVE|||||||
33841309|NCT04498364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944809|NCT02457130|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048975|NCT04240626|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients agreeing to participate in the study will be assigned one of two treatment arms. Neither the care team nor the patient will be masked.|Patients will receive Gabapentin and Ofirmev post surgery (dosage based on patients pre-operative weight) with on-call medications as needed including narcotic analgesia for breakthrough pain control||||
34048976|NCT04676451|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center, single-arm, interventional clinical trial. Subjects that meet inclusion and exclusion criteria are invited to participate.||||
34048977|NCT02571842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048978|NCT04644926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048979|NCT03660774|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34152814|NCT00759525|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34048980|NCT03688178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assignment to Groups 1 and 2 is blinded, and neither the study team nor the subject knows which pre-conditioning regimen is given. Assignment to Group 3 is not blinded, and the subject and study team know that Td preconditioning and Varlilumab is given.||t|t|t|f
34152815|NCT02924909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152816|NCT04637399|||COHORT||PROSPECTIVE|||||||
34152817|NCT01107223|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152818|NCT06321939|||COHORT||PROSPECTIVE|||||||
34152819|NCT02578329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152820|NCT01098526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152821|NCT04349956|||COHORT||PROSPECTIVE|||||||
34152822|NCT00003691|RANDOMIZED|||TREATMENT||||||||
34152823|NCT02567994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152824|NCT00001009||||TREATMENT||NONE||||||
34152825|NCT01976260|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33944810|NCT04643158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944811|NCT00490828|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34152826|NCT04867460|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
34048981|NCT01280032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048982|NCT05929768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048983|NCT06685627|||COHORT||PROSPECTIVE|||||||
34048984|NCT06684665|||CASE_CONTROL||OTHER|||||||
34048985|NCT04653246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048986|NCT02065375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152827|NCT03930407|||CASE_CONTROL||RETROSPECTIVE|||||||
34048987|NCT03025815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34152828|NCT03249103|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects are masked to the sequence in which they are taking placebo QD, NYX-2925 20 mg QD, NYX-2925 200 mg QD.|All subjects will receive placebo, NYX-2925 20 mg QD, NYX-2925 200 mg QD for sequential 2 week treatment periods, then go into Follow-up for 1 week.||||
34048988|NCT05182112|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I rolling 6 design dose escalation study.||||
34048989|NCT05239000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study design is a randomized pilot clinical trial with two arms. Enrolled patients are those aged ≥70 years with newly diagnosed or post-operative head and neck squamous cell carcinoma. Patients will be undergoing radiation with concurrent chemotherapy.||||
34048990|NCT01964196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048991|NCT03438149|||CASE_ONLY||PROSPECTIVE|||||||
34048992|NCT03127735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048993|NCT04758364|||COHORT||PROSPECTIVE|||||||
34048994|NCT05076032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocyst transfer resulting from donor oocyte IVF/ICSI.|t|t|t|t
34048995|NCT06513143|||COHORT||CROSS_SECTIONAL|||||||
34048996|NCT05269173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048997|NCT06160895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048998|NCT01017770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048999|NCT03185754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152829|NCT03522727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34152830|NCT00504894|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34152831|NCT05934331|NA|SEQUENTIAL||TREATMENT||NONE||||||
34152832|NCT05314959|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The control group will have usual care, meaning that the physician will NOT see the patient's survey results. The patient is blinded to randomization and will not know whether or not the physician is aware of their preferred level of shared decision making.|Women will be randomly assigned to physician awareness or treatment as usual (control) using a 1:1 allocation|t|f|f|f
34152833|NCT02929212|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152834|NCT02134678|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737553|NCT04891549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the surgical nature of the study the surgeon can not be blinded. The outcome assessor, patients and care providers will be blinded with regards to the two treatment groups.|This study is a multicenter pragmatic, prospective, assessor-blinded, randomized independent clinical trial|t|t|f|t
33737554|NCT01812044|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33737555|NCT01766375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737556|NCT03487367|||COHORT||PROSPECTIVE|||||||
33737557|NCT06434207|||COHORT||PROSPECTIVE|||||||
33841310|NCT03934177|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants, investigators, and statistician will blinded to treatment.|This 14-week crossover study includes 4 weeks for each of the two supplementation periods (blueberries and placebo), with a 4-week wash out between.|t|f|t|t
33841311|NCT01495598|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944812|NCT00734916|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33944813|NCT01087944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049000|NCT05920902|||COHORT||PROSPECTIVE|||||||
34049001|NCT04719052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study, the participants cannot be blinded to the intervention, although the investigators who will perform the sample and data analysis will be blinded.|A multicentre, blind, single-randomized, parallel, clinical trial|f|f|t|f
34049002|NCT02231138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049003|NCT05025800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049004|NCT05840224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049005|NCT06493032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||enrolling 20 participants who are being referred for G-POEM procedure into this study for a baseline alimetry and then again at 3-6 months.||||
34049006|NCT01442311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049007|NCT06327087|||OTHER||PROSPECTIVE|||||||
34049008|NCT02109770|||COHORT||PROSPECTIVE|||||||
34049009|NCT02094976|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049010|NCT01131143|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34049011|NCT03759015|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049012|NCT06299384|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34049013|NCT06638879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049014|NCT06205628|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Masking Description|Model Description|t|t|t|t
34049015|NCT06628765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049016|NCT02649244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34049017|NCT01546129|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34049018|NCT03505125|||OTHER||RETROSPECTIVE|||||||
34049019|NCT05019027|NA|SINGLE_GROUP||OTHER||NONE||||||
34049020|NCT03069196|||COHORT||PROSPECTIVE|||||||
34152835|NCT03902119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34152836|NCT05907837|||COHORT||PROSPECTIVE|||||||
34152837|NCT03337009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34049021|NCT05040204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34049022|NCT02125942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34049023|NCT04927832|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049024|NCT01847339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34049025|NCT01694329|||COHORT||RETROSPECTIVE|||||||
34049026|NCT02387957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841312|NCT03609892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841313|NCT00350597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841314|NCT01593787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841315|NCT03859063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single-blinded. The investigator and outcomes assessor will be blinded to group allocation.|A two armed parallel group randomized controlled trial|f|f|t|t
33841316|NCT04400487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841317|NCT06267144|||COHORT||PROSPECTIVE|||||||
33841318|NCT04109781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841319|NCT00644163|RANDOMIZED|PARALLEL||PREVENTION||||||||
33841320|NCT03981848|||COHORT||RETROSPECTIVE|||||||
33841321|NCT02037477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841322|NCT01406470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841323|NCT03969680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841324|NCT00658905|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33841325|NCT01383655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841326|NCT00490152|||COHORT||PROSPECTIVE|||||||
33841327|NCT03420248|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841328|NCT04697940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841329|NCT03913572|||COHORT||RETROSPECTIVE|||||||
33841330|NCT05050825|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Control (routine practice) vs Intervention (CDSA strategy)"||||
33841331|NCT03020459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841332|NCT03599102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841333|NCT00176150|||DEFINED_POPULATION||OTHER|||||||
33841334|NCT01122303|||||CROSS_SECTIONAL|||||||
33841335|NCT02018653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841336|NCT01390597|||OTHER||RETROSPECTIVE|||||||
33841337|NCT05104489|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33841338|NCT04239131|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841339|NCT02259023|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33841340|NCT00599573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841341|NCT03553108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition||||
33841342|NCT05432336|||COHORT||PROSPECTIVE|||||||
33841343|NCT05106777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841344|NCT03560024|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomized, double-blind placebo-controlled design in healthy volunteers.|18 healthy volunteers will receive PACAP27 or placebo. All Data will also be analyses blinded.|t|f|t|f
33841345|NCT04655027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841346|NCT05624905|||COHORT||PROSPECTIVE|||||||
33841347|NCT05867277|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant blinding was performed in this study. Students did not interact with each other while practicing the PIVC placement in different laboratory rooms on the same day. Thus, students were prevented from knowing their group allocation. In addition, when the students received information about the study, they did not know which group they belonged to because they were not informed about the groups. Investigators could not be blinded, as they knew the group allocation of each student group.|Single-blinded study with parallel groups.|t|f|f|f
33841348|NCT00370864|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33841349|NCT04628156|||COHORT||CROSS_SECTIONAL|||||||
33841350|NCT04678505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841351|NCT01214642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841352|NCT04854876|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an open-label, two arm interventional exploratory study, in which one arm will consist of 100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) and those will be treated with 150mg 5-ALA Phosphate/SFC for 28 days. The second arm will consist of 100 subjects that were vaccinated with the first dose of a COVID-19 Vaccine (any brand approved in Bahrain is permitted) only (Control). This is to determine the safety and evaluate the efficacy of 5-ALA-Phosphate-SFC during the vaccination of subjects against SARS-CoV-2 (COVID-19) virus infection and to activate the immune system during SARS-CoV-2 vaccination.||||
33841353|NCT00744562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841354|NCT04174001|||CASE_CONTROL||PROSPECTIVE|||||||
33841355|NCT04287699|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study was planned as randomized controlled. Pregnant women and their accompanying persons assigned to the study group will be informed about working in the tram room where the pregnant woman is before the active phase begins 'Using the Birth Dance Practice Guide (Annex 3) and cervical dilatation 4 cm. they will be asked to practice in accordance with this guide. Details of the application (such as dance time, rest time) will be recorded in the 'Birth Dance Control Guide' (Annex 4) by the researcher. Pregnant women will be followed by the doctor and midwife responsible for the pregnancy during the tram, and the researcher will not be involved in tram follow-up of the pregnant woman (cervical dilation, pediatric heart sound, contraction follow-up, vital signs of the pregnant woman).||||
33841356|NCT00878826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841357|NCT00968825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841358|NCT04853446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial medication was produced by Glostrup Pharmacy. The trial medication is produced as identically appearing opaque capsules containing either dexamethasone or placebo. The trial medication is stored in sequentially numbered containers that will be allocated to each participant as they enter the trial. All involved in the trial will be masked to treatment allocation until the final statistical analysis has been agreed upon by the steering committee.||t|t|t|t
33841359|NCT03808142|||COHORT||OTHER|||||||
33841360|NCT03448770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049027|NCT06665503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomly assigned to three groups of equal size, exclusively receiving the standard antibiotic regimen or the zinc and probiotics groups|t|f|f|f
33737558|NCT02415816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737559|NCT03569722|||CASE_ONLY||PROSPECTIVE|||||||
33737560|NCT06301165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737561|NCT04816357|||CASE_CONTROL||OTHER|||||||
33841361|NCT05977608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33841362|NCT05985226|NA|SINGLE_GROUP||OTHER||NONE||||||
34049028|NCT02587585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients wear identical watches; one gives no feedback on activity levels and one gives feedback on a two-hourly basis, with progress against a target derived from activity 24 hours earlier.|A randomised, parallel group, single-blinded, attention and feedback controlled study|f|f|t|t
33841363|NCT06052709|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33841364|NCT01020877|RANDOMIZED|CROSSOVER||||NONE||||||
33841365|NCT03364075|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33841366|NCT00430729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841367|NCT03505164|||COHORT||PROSPECTIVE|||||||
33841368|NCT01841268|||CASE_CONTROL||PROSPECTIVE|||||||
33737562|NCT02460198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737563|NCT03439826|||CASE_ONLY||PROSPECTIVE|||||||
33841369|NCT03664440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737564|NCT01612546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049029|NCT05217641|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33841370|NCT05675254|||COHORT||RETROSPECTIVE|||||||
33841371|NCT03235700|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33841372|NCT01312259|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33841373|NCT05002335|||COHORT||PROSPECTIVE|||||||
34049030|NCT04161456|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be treated with Apremilast||||
33841374|NCT02292862|||CASE_CONTROL||PROSPECTIVE|||||||
33841375|NCT03917862|RANDOMIZED|PARALLEL||TREATMENT||NONE||SASH Trial is a multicenter, prospective, open and randomized 1:1 study. Will be included 200 consecutive patients randomized to receive TDM-621 or regular procedure. It will be performed in 5 different centers.||||
33841376|NCT02583529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841377|NCT01152814|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049031|NCT00006103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049032|NCT02310425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33841378|NCT04406506|||COHORT||PROSPECTIVE|||||||
34049033|NCT05865899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049034|NCT00811811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34049035|NCT03850340|||COHORT||RETROSPECTIVE|||||||
34049036|NCT04254198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
34075693|NCT06379373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||According to the order of enrollment, the random number table method was used to divide the massage spinal manipulation+ placebo group (oral placebo, each dose: 50mg/time for 4-7 years old, 75mg/time for 7-12 years old, 100mg/time for 10-18 years old, 2 times/d), relaxation manipulation+ western medicine group (oral Typride tablets, each dose: 50mg/time for 4-7 years old, 75mg/time for 7-12 years old, 100mg/time for 10-18 years old, 2 times/d) for 2 consecutive weeks. Both groups were intervened for 2 courses. The observation time points were 2 weeks, 4 weeks, and 3 months before treatment and after treatment.|t|f|f|t
34075694|NCT03362762|||CASE_ONLY||PROSPECTIVE|||||||
34075695|NCT02864407|||OTHER||PROSPECTIVE|||||||
33737565|NCT00885872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737566|NCT05089539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737567|NCT06662851|||COHORT||PROSPECTIVE|||||||
33737568|NCT02617147|||COHORT||PROSPECTIVE|||||||
33737569|NCT05115994|||COHORT||PROSPECTIVE|||||||
33737570|NCT05174767|NA|SINGLE_GROUP||TREATMENT||NONE||Primary Cohort (n=93) and Continued Access (n=40)||||
33737571|NCT02124291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737572|NCT01048138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737573|NCT01344057|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33737574|NCT02279641|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737575|NCT01313572|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33737576|NCT03977324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841379|NCT00004853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841380|NCT00311389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737577|NCT06151327|||OTHER||RETROSPECTIVE|||||||
33737578|NCT03275727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737579|NCT04928742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator, outcome assessors and data analysts will be blinded to participant allocation.|Participants will be randomly assigned in a 1:1 ratio to the treatment group (online PHN-delivered group CBT) or the control group (treatment as usual).|f|f|t|t
33737580|NCT04317612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel assignment|t|t|t|t
33737581|NCT03952039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841381|NCT04944745|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participants will have knowledge of the two different intensity treatments they will receive. However, the researchers will be blinded as to which treatment intensity the participant received at which session.|Single blind between subjects repeated measures crossover design|f|f|t|t
33841382|NCT01343758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977896|NCT05511597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants receive training in both arms and will be blinded to the exercise group differences.~Outcomes assessor will be blinded to the group allocation and will carry out all assessments in a standardized manner irrespective Investigator will perform blinded analyses of the data"|Randomised single-blind parallel-group study|t|f|t|t
33737582|NCT04619693|||COHORT||PROSPECTIVE|||||||
33764396|NCT01897701|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33764397|NCT04042116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841383|NCT01791998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841384|NCT04855409|||COHORT||CROSS_SECTIONAL|||||||
34075696|NCT04235426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075697|NCT04472897|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind study.|This is a double-blind, randomized, sequential, parallel dose cohort study.|t|f|t|f
34075698|NCT05136677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075699|NCT00667992|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34075700|NCT00292552|||COHORT||PROSPECTIVE|||||||
34075701|NCT06380920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841385|NCT05724927|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The study was planned as an experimental study, which was planned to be carried out in a single group pretest-posttest research design in order to evaluate the effect of animal-supported activities applied to elderly individuals living in nursing homes on the depression and loneliness levels of individuals. Masking was not planned as it was a single group.|quasi-experimental in a single group pretest-posttest research design||||
33841386|NCT05732753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For the assignment to the groups, a random sampling will be carried out using the Epidat program. This classification will be hidden, therefore, those responsible for admitting the patients to the intervention phase will not know to which group each one has been assigned. Said assignment will be made previously by a researcher who will not intervene in the subsequent phases of evaluation, data recording intervention and database preparation. The assignment will be communicated using fully opaque sealed envelopes. The analysis of the results will be carried out by a researcher unrelated to the group assignment and the intervention.||f|t|t|t
33841387|NCT01562353|||CASE_CONTROL||RETROSPECTIVE|||||||
33841388|NCT02797522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841389|NCT00274105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841390|NCT02481570|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33841391|NCT04301895|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Each subject is his/her own control.||||
34152838|NCT05016843|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33841392|NCT01593605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152839|NCT05834348|||OTHER||RETROSPECTIVE|||||||
33841393|NCT04145700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841394|NCT02859090|NA|SINGLE_GROUP||||NONE||||||
33841395|NCT03722225|NA|SINGLE_GROUP||OTHER||NONE||This is a descriptive, single arm, non-randomized interventional study. The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control.||||
33841396|NCT06143592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841397|NCT02032589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841398|NCT02748889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841399|NCT00655018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841400|NCT01862380|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841401|NCT05092126|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||All subjects will be asked to complete the exercise test and the fitness questionnaire||||
33841402|NCT01146600|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33841403|NCT06195930|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a multi-center, single arm, open label study of vericiguat initiation at 5 mg in HFrEF patients with EF \<45%. The total study duration is approximately 4 weeks, including a 2-week screening period and a 2-week treatment period .~Screening: Approximately 120 participants will be screened to achieve at least 100 participants who are assigned to study intervention and complete the treatment period of up to 2 weeks. Participants will undergo a screening visit to assess eligibility. Eligible participants must wait a mandatory 2 weeks before returning for Visit 1 in order to be clinically and hemodynamically stable.~Treatment: At Visit 1, participants will receive vericiguat 5 mg (on top of standard of care) with directions to take once daily for 2 weeks. Participants will return for a study visit (Visit 2) after 2 weeks of treatment.~Unscheduled visits may be utilized between Visits 1 and 2 at the discretion of the investigator for AE review and reporting."||||
33841404|NCT04605289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||-Cymbopogon citratus oil gel /-Placebo gel. will be intrapocket application as an adjunctive treatment to conventional therapy|t|f|f|f
33841405|NCT06020183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33841406|NCT00082875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841407|NCT03151070|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33841408|NCT02865239|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33841409|NCT05703906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841410|NCT01049451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841411|NCT04542213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Physicians who will be providing health support will not be aware of the treatment that patients will be receiving regarding this protocol, also the principal investigator and the personal who will be measuring glucose levels and prognosis, will not be aware of the group of treatment, since all the patients will be receiving the same protocol of insulin administration|The study will include two parallel groups of intervention|f|t|t|t
33737583|NCT03646344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There will be an unblinded member of the research team (the individual administering the intervention) but otherwise the participant, the other members of the research team, the clinical team and blinded assessors will be blinded to the intervention.|Multi-centre, parallel group 1:1 randomised placebo controlled trial|t|t|t|t
33841412|NCT00571181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841413|NCT04735848|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The participants will take all three different doses of iron and will serve as there own control||||
33841414|NCT03215940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841415|NCT00167752|||||PROSPECTIVE|||||||
33841416|NCT02782143|||COHORT||PROSPECTIVE|||||||
33841417|NCT05461170|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33977897|NCT04884893|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33977898|NCT01208012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152840|NCT02161926|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152841|NCT03299283|||COHORT||PROSPECTIVE|||||||
34152842|NCT05453045|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34152843|NCT03009968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152844|NCT02512211|||COHORT||PROSPECTIVE|||||||
34152845|NCT01939366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152846|NCT03420404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The rheumatologist will be blinded for the first 6 weeks.||f|t|t|f
34152847|NCT02064790|||COHORT||PROSPECTIVE|||||||
34152848|NCT06027021|||COHORT||PROSPECTIVE|||||||
34152849|NCT06158113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152850|NCT04563013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152851|NCT04285489|||COHORT||RETROSPECTIVE|||||||
34152852|NCT02424045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841418|NCT04243551|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The PI, CRA and study biostatistician will be masked until database lock.|A two-period crossover design will be used where the two possible treatment sequences will be assigned at random.|t|f|t|f
34152853|NCT01181258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841419|NCT03430180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind|"Treatment Group A: Naloxone hydrochloride 40mg/ml nasal spray Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.~One spray of naloxone hydrochloride 40mg/ml nasal spray contains 4 mg naloxone hydrochloride in a formulation of benzalkonium chloride, sodium edetate, sodium chloride, hydrochloric acid and purified water.~Treatment Group B: Placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.~One spray of placebo nasal spray contains benzalkonium chloride, sodium edetate, sodium chloride, hydrochloric acid and purified water"|t|f|t|t
34152854|NCT04028466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized, Single Blind Study. Only primary investigators are blinded. the primary investigator also are the outcome assessors|Pragmatic, Randomized, Single Blind Study|f|f|t|t
34152855|NCT01124955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152856|NCT02136147|||COHORT||PROSPECTIVE|||||||
34152857|NCT03412253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841420|NCT03248882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind|C1171002 is a randomized, double blind, placebo controlled, 5 arm (placebo, plus 4 active doses of PF 05221304), parallel group study.|t|f|t|f
34152858|NCT06249906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152859|NCT01893918|||COHORT||PROSPECTIVE|||||||
34152860|NCT02277119|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33841421|NCT02944201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152861|NCT00017290|RANDOMIZED|||TREATMENT||DOUBLE||||||
33841422|NCT04792619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152862|NCT00958932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33841423|NCT00036127||||TREATMENT||||||||
34152863|NCT04506801|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A randomization list will be generated by the permutated block method (variable size 4-6) and will be kept in a sealed envelope by a person not included in the study.|randomised double-blind study|f|t|f|f
34152864|NCT00166231|||COHORT||PROSPECTIVE|||||||
33737584|NCT06663748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841424|NCT01355861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737585|NCT03447327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841425|NCT04676061|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33841426|NCT01923467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152865|NCT05102253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841427|NCT04659330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841428|NCT06393725|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to one of two interventions.||||
33841429|NCT04263168|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Bariatric surgery candidates for two types of bariatric surgery, i.e. sleeve gastrectomy (n=80) and Roux-en-Y gastric bypass (RYGB, n=80) will be recruited to the study from the bariatric surgery clinic in the Sheba medical center and will be followed pre- and postoperatively. A control group of candidates for another non-bariatric upper-GI surgery, i.e. cholecystectomy (n=80), will be recruited as well. All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').||||
33841430|NCT03729375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152866|NCT01105598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841431|NCT00573053|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841432|NCT06466278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841433|NCT01755572|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33841434|NCT03937518|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841435|NCT04059640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841436|NCT02390453|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34152867|NCT02954666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152868|NCT01174173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152869|NCT06229054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34152870|NCT03539991|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34152871|NCT01183754|||COHORT||PROSPECTIVE|||||||
34152872|NCT01587235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152873|NCT02033239|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34152874|NCT02238834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152875|NCT02068417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152876|NCT06303245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152877|NCT03147989|||CASE_ONLY||RETROSPECTIVE|||||||
34152878|NCT01577472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152879|NCT03525132|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152880|NCT05679063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will not know in which treatment group they are, and the investigator in charge of carrying out the evaluation will not know to which group the subjects he evaluates belong to.|Trough a randomization program, participants will be assigned to the treatment group or the control group.|t|f|f|t
34152881|NCT03926988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152882|NCT04320368|||COHORT||PROSPECTIVE|||||||
34152883|NCT04678791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152884|NCT02343718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152885|NCT01816724|||CASE_ONLY||PROSPECTIVE|||||||
34152886|NCT00235911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152887|NCT00644111|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34152888|NCT00660985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841437|NCT02574845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841438|NCT00625651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841439|NCT00237731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841440|NCT06256081|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Single arm study of children trialling an app|Teal of an app||||
33737586|NCT05771519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841441|NCT03061422|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33841442|NCT03106753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841443|NCT04808752|NA|SINGLE_GROUP||TREATMENT||NONE||This is a open-label, multi-center, prospective, single-arm clinical trial||||
33841444|NCT03491891|||COHORT||PROSPECTIVE|||||||
33841445|NCT02721992|||COHORT||CROSS_SECTIONAL|||||||
33841446|NCT04931368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841447|NCT01148329|||COHORT||PROSPECTIVE|||||||
33841448|NCT00001005||||TREATMENT||NONE||||||
33841449|NCT01448629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841450|NCT05331690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841451|NCT00354757|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841452|NCT02927197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841453|NCT03506074|||COHORT||CROSS_SECTIONAL|||||||
33841454|NCT01006980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841455|NCT00472849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841456|NCT06213038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841457|NCT05343169|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two arm, parallel randomized control trial||||
33841458|NCT04745169|NA|SINGLE_GROUP||PREVENTION||NONE||This is a pilot study to be conducted at Baylor College of Medicine in Houston, TX examining the feasibility, safety, acceptability, and preliminary efficacy of home-based exercise on frailty parameters and SPPB score in patients with varying levels of kidney function. The effects of exercise on HRQOL, physical activity, and adverse outcomes including hospitalizations, will also be explored.||||
34049037|NCT03086031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Due to the nature of the study, it is not possible to blind neither the participants nor the rehabilitation team, but they will be asked not to disclose any details about the allocation, or the content of the VR. The two independent research assistants will be trained to administer the assessments and will be blinded to the allocation when entering data into the database. The researchers and the statistician performing the data analysis are blind to the treatment arm in which the participants are allocated. The rehabilitation team and the research assistants will only be involved in the data collection and will therefore not participate in the data analyses.|In order to avoid confounding between the VR intervention and the control group due to random probability, the number of cases and controls within each of the four municipalities is fixed to be the same (+1/-1). Due to the prospective nature of the inclusion, which practically means that the number of patients included within each municipality is not a priori known, the randomization is performed by randomly assigning the first patient within each municipality to either the VR intervention or the conventional VR program. The following patient (within each municipality) is then assigned consecutive to the other group and so forth. This randomization scheme ensures equal distribution of cases and controls both within each municipality as well as in time avoiding confounding by these two factors.|f|f|t|t
34049038|NCT05821634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049039|NCT03008265|||COHORT||RETROSPECTIVE|||||||
34049040|NCT04512534|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's optimal two-stage design||||
34049041|NCT02959099|||CASE_CONTROL||RETROSPECTIVE|||||||
34049042|NCT05525858|||COHORT||PROSPECTIVE|||||||
34049043|NCT04434092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049044|NCT00785616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049045|NCT06113965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049046|NCT05066711|||COHORT||PROSPECTIVE|||||||
34049047|NCT00172601|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33737587|NCT01126541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841459|NCT03228628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinding. Gaz bottles are in undistinguishable boxes. Neither the patients nor the person doing the LP and the evaluation of pain and anxiety will know the treatment used|1:1 randomization to receive experimental treatment (50% N2O - 50% O2) or placebo (Medical Air: 22% O2 - 78% N2)|t|f|f|t
33841460|NCT04590157|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group received pelvic floor muscle training ,and the study group received the same program in addition to laser acupuncture on neurogenic acupoints||||
33841461|NCT05234723|||CASE_CONTROL||RETROSPECTIVE|||||||
33841462|NCT03739853|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Blinded assessor will perform clinical evaluations.||f|f|f|t
33841463|NCT06055504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841464|NCT05637359|||CASE_ONLY||PROSPECTIVE|||||||
33841465|NCT04081129|||CASE_ONLY||PROSPECTIVE|||||||
33841466|NCT04617275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841467|NCT02810145|||COHORT||PROSPECTIVE|||||||
33841468|NCT00436605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841469|NCT05293977|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33841470|NCT02200653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841471|NCT04530097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049048|NCT03444064|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737588|NCT03171636|||COHORT||PROSPECTIVE|||||||
33737589|NCT03603964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737590|NCT02505516|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
33737591|NCT05690958|||OTHER||CROSS_SECTIONAL|||||||
33737592|NCT04174677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841472|NCT04798170|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33841473|NCT04032184|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33841474|NCT00211224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841475|NCT05195346|||COHORT||CROSS_SECTIONAL|||||||
33841476|NCT06043258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33841477|NCT02075281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049049|NCT02026791|RANDOMIZED|PARALLEL||||NONE||||||
34049050|NCT00943553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049051|NCT04348864|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Subject with or without symptoms consistent with COVID-19 and have been tested at the point of care (POC) with a molecular diagnostic test (e.g. PCR or isothermal LAMP) or clinical diagnosis, and have been determined to be positive or negative will undergo testing for antibodies or antigen or viral RNA. Roughly three times more subjects testing negative for SARS-CoV-2 compared to positive subjects are expected to be tested from NP samples gathered at the POC by POC staff or self-swab.||||
33841478|NCT03780361|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34049052|NCT04808700|NA|SINGLE_GROUP||OTHER||NONE||||||
34049053|NCT05128955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049054|NCT02177916|NON_RANDOMIZED|PARALLEL||||NONE||||||
33841479|NCT04449419|||COHORT||PROSPECTIVE|||||||
33841480|NCT02881346|||COHORT||PROSPECTIVE|||||||
33841481|NCT03300505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049055|NCT02226640|||COHORT||PROSPECTIVE|||||||
33841482|NCT01978951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841483|NCT03117998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841484|NCT01828905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841485|NCT04115657|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33841486|NCT00565487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841487|NCT04684667|NA|SINGLE_GROUP||TREATMENT||NONE||This study will involve patients with infantile hemangiomas who will be admitted at the Assiut University Children Hospital between January 2021 and December 2021.||||
33841488|NCT05629312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841489|NCT03072524|||CASE_ONLY||PROSPECTIVE|||||||
33841490|NCT05709301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049056|NCT06325839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Pregnant women included in the study were randomly divided into two groups using the sealed envelope method.|The research is an experimental study with a randomized control group.|t|f|f|f
33841491|NCT00284440|||CASE_ONLY||PROSPECTIVE|||||||
33841492|NCT01457898|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33841493|NCT01258257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049057|NCT03909334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049058|NCT03063086|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33841494|NCT05319912|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33841495|NCT05611827|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152889|NCT03196531|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34152890|NCT03322670|||COHORT||PROSPECTIVE|||||||
34152891|NCT03613363|NA|SINGLE_GROUP||OTHER||NONE||This trial is an engineering study is to verify the overall performance and controls of the Helix Ventilator as compared to the participant's current therapy device.||||
33841496|NCT03479775|||COHORT||PROSPECTIVE|||||||
33841497|NCT00465075|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33841498|NCT00643292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841499|NCT02538952|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33841500|NCT05842499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The double-blind status will be established for the patient and the person responsible for the follow-up and clinical evaluation, who will never know the arm to which the patient has been randomized.~Logically, this randomization will be known to the operator who will carry out the intervention, which will be performed on the basis of two treatment schemes."||t|f|t|f
33841501|NCT00201903|||||PROSPECTIVE|||||||
33841502|NCT02526966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841503|NCT00328289|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841504|NCT03908151|||OTHER||CROSS_SECTIONAL|||||||
33841505|NCT00781105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841506|NCT01956604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841507|NCT05820399|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, Double-Blind, Placebo Controlled, Parallel Arm Trial|t|f|t|t
33841508|NCT02398669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152892|NCT03207802|||COHORT||RETROSPECTIVE|||||||
34152893|NCT00002921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152894|NCT02668913|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152895|NCT02666677|||OTHER||PROSPECTIVE|||||||
33841509|NCT02445053|||COHORT||PROSPECTIVE|||||||
33841510|NCT05937867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841511|NCT05753436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841512|NCT04031443|||OTHER||CROSS_SECTIONAL|||||||
33841513|NCT06409234|||CASE_CONTROL||PROSPECTIVE|||||||
33841514|NCT00040651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841515|NCT00713986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841516|NCT06013553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841517|NCT00158197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841518|NCT03251729|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial of cerclage versus no cerclage in singleton pregnancies without prior spontaneous preterm birth and with a short transvaginal ultrasound cervical length||||
33841519|NCT02169570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33841520|NCT02897050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841521|NCT00384774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841522|NCT01409577|||COHORT||PROSPECTIVE|||||||
33841523|NCT01818531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841524|NCT01390870|||OTHER||CROSS_SECTIONAL|||||||
33841525|NCT05249738|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33841526|NCT02224703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049059|NCT06667830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841527|NCT01940432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841528|NCT03560752|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841529|NCT03129126|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33841530|NCT03416322|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization of participants will be done in a 1:1 ratio, with the random sequence in blocks 2, 4 and 6. The sequence of treatments within the blocks and the block sequence will be randomized. For this randomization, the REDCap platform will be used.|"Clinical, prospective and comparative, randomized study. Patients referred to the Endoscopy Department of the Barretos Cancer Hospital from August 2017 to August 2018 will be invited to participate in the study, with an indication of performing a diagnostic colonoscopy for high-risk CCR screening (Lynch and Li Fraumeni Syndrome) or who are in post-polypectomy follow-up.~After agreeing and signing the Informed Consent Term (ICF), the included patients will be divided into two groups. The first group will be submitted to the technique of second right frontal view of the right colon (SEVF), which consists in reexamining the right colon after reaching the hepatic angle on colonoscope withdrawal. The second group will be submitted to the Underwater technique, which consists in evaluating the right colon after this segment has been cleaned with water, injected water and aspirated after. During aspiration of water, the colon will be examined."|t|f|f|f
34049060|NCT00589381|NON_RANDOMIZED|||TREATMENT||NONE||||||
34049061|NCT06664931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Model Description|t|f|t|t
34049062|NCT03220295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind safety study. The pharmacist is unblinded.||t|t|t|f
33841531|NCT04855006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are aware if they are allocated as donors or recipients. If the participants are allocated as recipients, they are blinded towards receiving experimental treatment or placebo treatment.||t|t|t|f
33841532|NCT02597712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841533|NCT05794490|||COHORT||PROSPECTIVE|||||||
34049063|NCT00430417|||COHORT||PROSPECTIVE|||||||
33841534|NCT03705598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049064|NCT02589990|NA|SINGLE_GROUP||SCREENING||NONE||||||
34049065|NCT06685003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will know what group they are in. When data is sent to the statistician for analysis it will be coded in the groups (e.g., 123) without informing which is which. This masks (or blinds) him to the condition.|Conduct a fully randomized controlled trial of 3 levels of digital training (Level 1 - Digital tutorial only \[T\]; Level 2 - Tutorial \& digital training materials for self-study \[TM\]; Level 3 - Tutorial, digital materials, feedback and coaching \[TMC\]) to examine the effects of training on CRAFT knowledge, fidelity, and treatment entry and retention.|f|f|f|t
34049066|NCT02918474|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33841535|NCT03984981|||COHORT||RETROSPECTIVE|||||||
34049067|NCT06302452|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"The trial uses a unidirectional crossover stepped wedge design with a sequential roll-out of the intervention, ACTFAST, RE-AIM implementation framework, over several discrete time points or steps. Each of the three trauma centers will be randomly assigned to one step that will determine when they crossover from control to implementation.~Data are collected over multiple wedges, each 4-6 months in length. During the first wedge, none of the participating trauma centers will receive ACTFAST. During the second wedge, the first trauma center completes the Adoption and Implementation period. Over the third wedge, the first center shifts to the Maintenance period, the second trauma center enters the Adoption and Implementation period, and the remaining cohort stays in the control condition. This pattern continues until all trauma centers have progressed from control condition through the active implementation period."||||
34049068|NCT04061512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049069|NCT00520611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049070|NCT01090362|||COHORT||PROSPECTIVE|||||||
34049071|NCT02710812|||COHORT||PROSPECTIVE|||||||
34049072|NCT06177535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34049073|NCT06171204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049074|NCT00800592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049075|NCT05708443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049076|NCT06062238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049077|NCT06570824|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will receive sham rTMS by flipping the coil upside down. This will still provide similar sensory experience as an active stimulation that the patients will not distinguish between. Dyskinesia assessment is filmed during the visit and an experienced rater is unaware of a treatment condition of the patient.|The study has a double-blinded crossover design. The research participants will, in two separate stimulation sessions, receive either real rTMS treatment or a sham-TMS stimulation. The session order (real rTMS first or sham first) will be randomised between research participants. The research participant will be blinded to which treatment (real or sham) they receive at any session. There will be two sequential groups of patients. First group will receive gamma burst rTMS stimulation and sham and the other group will receive beta burst rTMS and sham.|t|f|f|t
34049078|NCT04362696|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34049079|NCT04445714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049080|NCT02469688|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049081|NCT05567744|||COHORT||OTHER|||||||
34049082|NCT06664996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049083|NCT04384042|||CASE_CONTROL||RETROSPECTIVE|||||||
34152896|NCT03052023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|this is a randomized trial where the participants are selected randomly to each of the previous three groups , and the post operative assessment of complication and pain done by different surgical residents whom are not informed about the groups of study.|comparative study between three procedures of inguinal hernioplasty; open (LICHTENSTEIN), TAPP, and laparoscopic DUAL APPROACH (modified TAPP)|t|f|f|t
34152897|NCT03148015|||COHORT||RETROSPECTIVE|||||||
34152898|NCT04841109|||COHORT||PROSPECTIVE|||||||
34152899|NCT06455748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152900|NCT03380767|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomized controlled trial||||
34152901|NCT04412447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Training of paralysed musculature of the lower limb by using electrical stimulation.||||
33737593|NCT04408443|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple (Participant, Care Provider, Investigator)||t|t|t|f
33737594|NCT01886794|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33737595|NCT00788866|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|t|t|f
33944814|NCT05618769|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Quasi-experimental design based on a non-randomized cluster trial, in which moderate-late preterm born infants will be allocated to the intervention or control group based on location of neonatal care. This design was chosen based on the limited amount of participating clusters and feasibility. As a quasi-experimental design can result in confounding by cluster and to increase internal validity, subjects of the control and intervention groups will be demographically matched at baseline||||
33944815|NCT00800189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944816|NCT01883362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944817|NCT01599091|||OTHER||OTHER|||||||
33944818|NCT05961124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944819|NCT02493829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944820|NCT05457712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, full blinding will not be possible. However, the statistical analysis team will be blinded.|Randomized clinical trial, pragmatic, with blind evaluation of outcomes.|f|f|f|t
33944821|NCT04622059|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34049084|NCT04644705|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|This three part study has double-blinded (placebo-controlled) and open-label parts.|"Part A is a randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study with 3 planned cohorts.~Part B consists of two randomized, open-label, two-sequence, two-period crossover cohorts comparing the new niclosamide solution with the marketed chewing tablets.~Part C is a randomized, double-blinded, placebo-controlled multiple dose study investigating the safety and pharmacokinetics of the combination of niclosamide solution and camostat over a treatment period of 7 days."|t|f|t|f
33944822|NCT01658527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944823|NCT01115205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944824|NCT04084210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Participants will be randomly assigned to Juul, Very Low Nicotine Cigarette, or No Product with no masking of product type. However, participants will be randomly assigned to receive either placebo or active nicotine patch with masking regarding placebo vs active patch.|"For this mixed design study, 180 daily adult smokers who are not planning to quit smoking will be randomly assigned to one of three levels of the between-subjects factor: 1) VLNCs; 2) Juul e-cigarettes; or 3) no alternative product. During two different weeks, participants will be asked to switch from their usual cigarettes and use only study products. They will also be asked to use either an active nicotine or placebo patch (the within-subjects factor), provided in double-blind fashion and counterbalanced order.~It should be noted that there were no significant within-subject effects (i.e. comparing Juul + Active Patch in Wk 1 and Placebo Patch in Wk 2 vs. JUUL + Placebo Patch in Wk 1 then Active Patch in Wk 2 yielded no significant differences) therefore results are presented as a 3-group parallel design (i.e. Juul + Active vs. Placebo Patch, VLNC + Active vs. Placebo Patch, No Product + Active vs. Placebo Patch)."|t|t|t|t
33944825|NCT00003824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944826|NCT04419220|||OTHER||PROSPECTIVE|||||||
33944827|NCT02978300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944828|NCT02318082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944829|NCT06245850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33944830|NCT05259124|||OTHER||PROSPECTIVE|||||||
33944831|NCT05870358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944832|NCT05649020|NA|SEQUENTIAL||OTHER||NONE|The nurse blinded to the dose, was absent during the procedure and assessed each block. Furthermore, all patients were unaware of the injected dose of HP.|To evaluate the ED50 and ED90 of intrathecal HP for patients undergoing undergoing ambulatory MRI/ultrasound fusión prostate biopsy.||||
33944833|NCT03110172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All patients will be randomly divided into two groups. The control group is going to be given celecoxib 200mg/24h to 2 weeks after operation. On the basis of the above scheme, the The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation.|t|f|f|t
33944834|NCT04382066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944835|NCT04536142|||CASE_CONTROL||PROSPECTIVE|||||||
33944836|NCT03301168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049085|NCT01726725|||CASE_CONTROL||PROSPECTIVE|||||||
34049086|NCT03846830|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The investigators will randomize placement in two groups of gaze stability exercises (IVE or traditional VPT). Each of the three Aims will recruit active duty service members with mTBI and dizziness from the Intrepid Spirit Center at Fort Belvoir Community Hospital (FBCH) and civilians with unilateral vestibular hypofunction from Johns Hopkins University (JHU). Inclusion criteria for the FBCH site are active duty service member with mTBI and 'vestibular' symptoms (dizziness, oscillopsia, motion sensitivity, imbalance). Inclusion criteria for the JHU site are civilians with unilateral vestibular hypofunction.|t|t|t|t
34049087|NCT02985424|||COHORT||PROSPECTIVE|||||||
34049088|NCT06377631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049089|NCT06656000|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34049090|NCT05755711|||CASE_ONLY||PROSPECTIVE|||||||
34152902|NCT00973492|||CASE_ONLY||PROSPECTIVE|||||||
34152903|NCT01340599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152904|NCT00084149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152905|NCT01274520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152906|NCT00383162|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34152907|NCT05717023|NA|SINGLE_GROUP||TREATMENT||NONE||Single case experimental design||||
34152908|NCT06083818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind masking||t|f|f|t
34152909|NCT01417364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152910|NCT03867942|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737596|NCT01177501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841536|NCT01387191|||OTHER||PROSPECTIVE|||||||
33841537|NCT01205789|||COHORT||PROSPECTIVE|||||||
33841538|NCT01220245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152911|NCT00552604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152912|NCT02707796|NA|SINGLE_GROUP||SCREENING||NONE||||||
34152913|NCT01672411|||CASE_ONLY||PROSPECTIVE|||||||
34152914|NCT03032549|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34152915|NCT00730678|||CASE_CONTROL||PROSPECTIVE|||||||
34152916|NCT01154751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944837|NCT06018402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, Single Blinded Study|t|f|f|t
33737597|NCT04626674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737598|NCT06569342|||COHORT||RETROSPECTIVE|||||||
33944838|NCT02605720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737599|NCT02334748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764398|NCT00899561|||COHORT||PROSPECTIVE|||||||
33944839|NCT03014700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33944840|NCT03400202|||CASE_CONTROL||PROSPECTIVE|||||||
33764399|NCT02430701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33944841|NCT06401902|||COHORT||PROSPECTIVE|||||||
33944842|NCT04696601|NA|SINGLE_GROUP||SCREENING||NONE||||||
33944843|NCT00412555|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33944844|NCT03955068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944845|NCT05894187|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE||prospective, randomized, single-blind controlled superiority|f|t|t|t
33944846|NCT03581708|||COHORT||PROSPECTIVE|||||||
33944847|NCT05853835|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The investigational drug blind will be maintained through a randomization schedule held by the dispensing pharmacist. The investigational drug blind shall not be broken by the site Investigator unless information concerning the investigational drug is necessary for the medical treatment of the subject. All study assessments and causality will be performed, if possible, prior to unblinding.||t|f|t|t
33944848|NCT06021028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Triple (Investigator, Outcomes Assessor)|Randomized Parallel Controlled Trial. Trial type: Two, Parallel arm design. Trial framework: Equivalence frame Allocation ratio: 1:1.|f|f|t|t
33944849|NCT03133702|||COHORT||RETROSPECTIVE|||||||
33944850|NCT00854776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944851|NCT02808299|||COHORT||PROSPECTIVE|||||||
33944852|NCT02434666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944853|NCT05384756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944854|NCT00300989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944855|NCT05177861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944856|NCT04491591|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33944857|NCT01756846|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||this is a stepped wedge cluster randomized trial, meaning it is both parallel and cross-over. During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period).|f|f|f|t
33944858|NCT02505945|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944859|NCT02061020|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33944860|NCT00579059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944861|NCT04391894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-masked||t|t|t|f
33944862|NCT03860870|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|First phase - open label Second phase - double-blinded|"Two phases:~First phase sequential Second phase crossover"|t|t|t|t
33944863|NCT01347359|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33944864|NCT04997512|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unable to mask participants and trailists due to study design.|Randomised controlled trial (not blinded due to study design)||||
33944865|NCT04210141|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized adaptive design||||
33944866|NCT06254794|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Delfi PTS device for BFR allows for a systematic and customized approach to BFR training in the clinic. This instrument provides a digital display of pressure, inflation time, and provides the user with an interface to control the tourniquet system. Pressure is monitored and regulated continuously to compensate for changing levels in the cuff during movement. Each cuff is specifically designed for the tapered contour of a body limb (arm or leg) and sized appropriately based on body region. These cuffs only work with the Delfi PTS device and allow for comfortable pressure application. Exercise will be performed with the cuff placed around the proximal limb and inflated through the duration of activity (\~5 minutes), then immediately deflated.||||
33944867|NCT02052180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33944868|NCT03846856|||CASE_ONLY||PROSPECTIVE|||||||
33944869|NCT02874755|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33944870|NCT00584428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944871|NCT00440362|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33944872|NCT01432470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944873|NCT04369443|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33944874|NCT03573921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Clustered study, where each centre will select which of the two study arms (Gastrografin or Saline solution) they will offer at their centre.||||
33944875|NCT05852002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944876|NCT00749866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944877|NCT04033718|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944878|NCT03606265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944879|NCT02487524|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33944880|NCT02503956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764400|NCT03884504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764401|NCT02235883|||CASE_ONLY||PROSPECTIVE|||||||
33764402|NCT01254201|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33841539|NCT00645268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841540|NCT03982251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841541|NCT00825539|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33841542|NCT04680767|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841543|NCT01423591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841544|NCT03752970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764403|NCT00553501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841545|NCT04362943|||OTHER||RETROSPECTIVE|||||||
33841546|NCT03202953|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|participants, investicator, outcome assessors will be blinded for group allocation.|"1. 1:1 I:E ratio VCV group~2. autoflow VCV group"|t|f|t|t
33944881|NCT06177925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944882|NCT01189201|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944883|NCT00573352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944884|NCT05210959|||OTHER||PROSPECTIVE|||||||
33944885|NCT00697242|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33944886|NCT04337463|NA|SEQUENTIAL||TREATMENT||NONE||||||
33944887|NCT05577572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||200 patients are divided into two groups: one group receive probiotic for treatment period and the other group receive placebo. The treatment period is designed for 56 days: Bismuth containing quadruple therapy is performed from day 1\~10 and probiotic (or placebo) is taken from day 1\~56.|t|t|t|t
33944888|NCT05941494|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants and outcomes assessors will be blinded to the combination of anesthetic maintenance agents (propofol or sevoflurane) and vasopressors (phenylephrine or ephedrine) that were used during surgery.|This is a prospective, 2x2 factorial design, blinded, randomized controlled study. Written informed consent will be obtained from all participants. We will recruit 80 adult patients (age \>18 years old), who are ASA I-III and are scheduled for surgery under general anesthesia. We will randomize these patients into one of the four groups in 1:1:1:1 ratio for one of two choices of anesthetic maintenance agents and vasopressors.|t|f|f|t
33944889|NCT00745004|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33944890|NCT04476641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944891|NCT05658133|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single survey, one version for student athletes survey and another version for Influencers of student athletes||||
33944892|NCT00861575|||COHORT||PROSPECTIVE|||||||
33944893|NCT02443558|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944894|NCT03575741|||COHORT||PROSPECTIVE|||||||
33944895|NCT05132751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||ventilator decision system|t|f|t|t
33944896|NCT04185766|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944897|NCT00918502|||CASE_ONLY||PROSPECTIVE|||||||
33944898|NCT01728870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944899|NCT02404792|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944900|NCT04424758|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|See protocol|See protocol|f|f|t|t
33944901|NCT06035341|NA|SINGLE_GROUP||TREATMENT||NONE||There are one study group. A single session of orofacial manual therapy will be applied to all participants.||||
33944902|NCT02303470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944903|NCT02382419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944904|NCT03244280|NA|SINGLE_GROUP||OTHER||NONE||||||
33944905|NCT03521089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Randomized 1:1 to active or sham transcranial direct current stimulation (tDCS) intervention|t|f|t|f
33944906|NCT04235673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33944907|NCT01990417|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33944908|NCT03715127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|quadruple-blind|placebo-controlled, quadruple-blind, randomized, mono-centric|t|t|t|t
33944909|NCT05600842|||COHORT||PROSPECTIVE|||||||
33944910|NCT00579514|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33944911|NCT00972309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944912|NCT05637086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded.||t|t|t|f
34049091|NCT00809471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049092|NCT06595303|||COHORT||PROSPECTIVE|||||||
33944913|NCT04563845|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33944914|NCT02114736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944915|NCT03375866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944916|NCT01103661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944917|NCT00821886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944918|NCT02581657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944919|NCT01905839|||||PROSPECTIVE|||||||
33944920|NCT01610752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944921|NCT00944762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944922|NCT01425268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944923|NCT02259452|||COHORT||PROSPECTIVE|||||||
33944924|NCT00526760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944925|NCT06347146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944926|NCT03366649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944927|NCT01031784|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944928|NCT05288764|||COHORT||PROSPECTIVE|||||||
33944929|NCT04409574|||CASE_ONLY||CROSS_SECTIONAL|||||||
33944930|NCT01000233|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944931|NCT04645225|||CASE_CONTROL||PROSPECTIVE|||||||
33944932|NCT00727662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944933|NCT04513249|||COHORT||PROSPECTIVE|||||||
33944934|NCT03528811|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33944935|NCT05447299|||OTHER||PROSPECTIVE|||||||
33944936|NCT02445768|NA|SINGLE_GROUP||TREATMENT||SINGLE||||||
33944937|NCT04278846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944938|NCT04129736|NA|SINGLE_GROUP||TREATMENT||NONE||Pharmacokinetic||||
33944939|NCT03924960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33944940|NCT04135300|NA|SINGLE_GROUP||TREATMENT||NONE||Hemophilia B patients||||
34049093|NCT06541158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049094|NCT03884699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152917|NCT00996060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152918|NCT00756782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944941|NCT05734534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33944942|NCT01379599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944943|NCT02291068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944944|NCT03797781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33944945|NCT01205399|||COHORT||CROSS_SECTIONAL|||||||
33944946|NCT05223764|||COHORT||RETROSPECTIVE|||||||
33944947|NCT05727696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944948|NCT03154424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients were randomized by drawing lots currency (Face = A - treatment with fixation non-bridging; Crown = B - Treatment with the method bridging), which were printed and placed in sealed envelopes before the study started."||t|t|t|f
33944949|NCT05029102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944950|NCT03243318|||COHORT||PROSPECTIVE|||||||
33944951|NCT03970330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double Blind, Placebo Controlled Trial|t|t|t|t
33944952|NCT00389909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33944953|NCT06046937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944954|NCT03726840|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33944955|NCT05497570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049095|NCT04705363|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants will be blind to condition. Investigators will be blind to which participants will be assigned to which interventions.|3:2 randomization with a control group|t|f|t|f
34049096|NCT05064878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049097|NCT06529614|||OTHER||OTHER|||||||
34049098|NCT01510795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049099|NCT05546905|||COHORT||OTHER|||||||
34049100|NCT03039621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049101|NCT06495138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be block-randomized to one of two treatment groups. These groups will be stratified based on the region(s) of central nervous system involvement as determined by participants' Functional System Scores. During the six-week intervention phase, StableEyes will deliver either D-IVA-GSE or I-VA-GSE to participants based on their randomization results.|f|f|t|f
34049102|NCT01868438|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049103|NCT05087303|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049104|NCT00005502|||COHORT||PROSPECTIVE|||||||
34049105|NCT03374696|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomized controlled trial with parallel assignment||||
34049106|NCT06521554|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049107|NCT02989246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049108|NCT01913938|||CASE_ONLY||PROSPECTIVE|||||||
34049109|NCT01248052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34049110|NCT01065896|||CASE_CONTROL||PROSPECTIVE|||||||
34049111|NCT05662332|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor will be blinded throughout the study.|||||
34049112|NCT06085326|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34049113|NCT05702801|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049114|NCT01168102|||CASE_ONLY||CROSS_SECTIONAL|||||||
34049115|NCT01263236|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34049116|NCT04647396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34049117|NCT03781362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 + 3 dose escalation study design||||
34049118|NCT05193071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049119|NCT05223647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049120|NCT02478866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944956|NCT02756182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049121|NCT05853861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049122|NCT05194436|||COHORT||PROSPECTIVE|||||||
34049123|NCT05581303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049124|NCT01765348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841547|NCT02137317|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33841548|NCT06186297|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33841549|NCT04295967|||OTHER||CROSS_SECTIONAL|||||||
33841550|NCT03330626|RANDOMIZED|PARALLEL||TREATMENT||NONE||One is control for the patients under conventional methods (I/O based fluid monitoring). The other is case for the patients under Inbody S10 methods.||||
33841551|NCT00002477||||TREATMENT||||||||
33944957|NCT00971100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33944958|NCT04632316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944959|NCT05503758|||COHORT||RETROSPECTIVE|||||||
33944960|NCT03734601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049125|NCT02745613|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34049126|NCT05786040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049127|NCT01793961|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049128|NCT02952092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049129|NCT05127616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34049130|NCT06030232|||COHORT||RETROSPECTIVE|||||||
34049131|NCT01941745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049132|NCT05784584|||COHORT||PROSPECTIVE|||||||
34049133|NCT06666413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049134|NCT00381732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049135|NCT05092022|NA|SINGLE_GROUP||SCREENING||NONE||||||
34075702|NCT05807971|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The study will be double-blinded. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (ATH-063 or placebo).|"Cohorts (4 each) within the SAD and MAD part will be dosed sequentially in an ascending fashion.~MAD cohorts and FE cohort will be dosed in parallel after the completion of the SAD Cohorts."|t|t|t|t
34075703|NCT03714477|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial||||
34075704|NCT04241198|||OTHER||PROSPECTIVE|||||||
34049136|NCT06030622|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The treatment plan is as follows: The first 3 patients enrolled in the study, will receive metformin (850 mg twice a day), digoxin (0.25 mg once a day), and simvastatin (20 mg once a day) for 28 days. If no toxic effects, the remaining 22 patients will be enrolled. Patients will be provided C3 medications every 28 days and will continue on the C3 medication for at least 2 years, or until death or recurrence/advancement of the disease. If more than one patient develops a toxic event, the dose will be reduced to metformin 850 mg/day, simvastatin 5 mg/day, and digoxin 0.0625 mg/day. If no further toxicities, then the remaining patients will receive the lower dose. If however, more than two patients develop a toxic event, then study discontinuation will be considered. If patients decline first line therapy (Gemcitabine), they will be offered the choice of C3 medications only.||||
34049137|NCT03728426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049138|NCT06555393|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blind randomized cross-over study.|t|f|t|f
34049139|NCT05021679|NA|SINGLE_GROUP||TREATMENT||NONE||Step-wedge clinical trial||||
34049140|NCT01914471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049141|NCT06592261|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34049142|NCT05327829|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are blinded to stimulation versus no stimulation.|Block design|t|f|f|f
34049143|NCT00035867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049144|NCT03045510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049145|NCT02622334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049146|NCT06478017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049147|NCT06665373|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34049148|NCT05093634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049149|NCT05941962|||COHORT||PROSPECTIVE|||||||
34049150|NCT02280746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049151|NCT00857064|||CASE_ONLY||CROSS_SECTIONAL|||||||
34049152|NCT03391570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049153|NCT06244550|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
34049154|NCT00001177|||COHORT||PROSPECTIVE|||||||
34049155|NCT03983278|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Cluster-randomised, investigator-masked trial. Investigators assessing the components of the main study outcome will be masked to the study group assignment of the school.~Staff assessing data for the main outcome will be masked to a child's group assignment."|"This is a cluster randomized trial, with eligible children allocated to the intervention that their school (N=141) was randomized to receive. This will be one of the following three:~School Model: Vision screening will be carried out by the vision screeners; refraction will be done at the schools by refractionists, and children who need them will be given free spectacles at the school within two weeks.~Referral Model: Vision screening carried out by the vision screeners, and children are referred to nearby Vision Center/ secondary center for refraction and delivery of free spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance.~Referral Model + Cost Recovery: Vision screening carried out by the vision screeners; children referred to Vision Center for refraction and delivery of spectacles with an option to purchase upgrade spectacles. Teachers will contact families not presenting for follow-up care and for spectacle compliance."|f|f|t|f
34049156|NCT06005285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interviewers, assessors and video coders will be naive to group status (ESDM or TAU).|The primary aim of the proposed study is to test the effectiveness of ESDM using a hybrid type 1 (effectiveness/implementation) randomized controlled trial in which community based agency (CBA) regions will be randomized to receive training in the Early Start Denver Model (ESDM) or continue treatment as usual (TAU). The investigators decided to randomize by region to address potential contamination across providers and children.|f|f|f|t
34049157|NCT06236607|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial will have a four-arm, parallel group design, with 9-month intervention phase. Adults with T1D on MDI therapy will be randomized in a 1:1:1:1 ratio to receive either: 1) BetaBionics iLet HCL system; 2) Insulet OP 5 HCL system; 3) Tandem Control IQ HCL system, or 4) Continued MDI. All trial participants will use CGM, Block randomization, within strata defined by A1c (\> vs ≤ 9%), using blocks of sizes 4 and 6, randomly permuted will be done. The groups are expected to have \>20% participants screening A1c \>9%.||||
34049158|NCT06665191|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34049159|NCT03927261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049160|NCT01335048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049161|NCT05761184|||COHORT||PROSPECTIVE|||||||
34049162|NCT02985645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075705|NCT02959216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34075706|NCT00931632|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34075707|NCT03812900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152919|NCT00624754|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34152920|NCT04454944|RANDOMIZED|FACTORIAL||OTHER||NONE|Prices and locations were public information.|Participants were randomized to 5 price levels and to 5 LPG cylinder exchange depots, for a total of 25 possible location/price combinations. Additionally, participants were enrolled into 4 arms (see arms description).||||
34152921|NCT00376766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841552|NCT06003322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33841553|NCT04680195|NA|SINGLE_GROUP||TREATMENT||NONE||Thalidomide Group||||
33841554|NCT05294653|||COHORT||PROSPECTIVE|||||||
33841555|NCT02860689|||||CROSS_SECTIONAL|||||||
33841556|NCT01431495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841557|NCT04809324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patient and the treating clinician will not be aware of the randomisation allocation(gross examination or frozen section) prior to resection of the tumour specimen||t|t|f|f
33841558|NCT06116747|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention study with one control group and one intervention group||||
34152922|NCT05600582|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Study participants eligible to participate will be enrolled in each of 4 escalating-dose cohorts and administered intratumoral CodaLytic in the injected lesion during the dosing period as follows: Three (3) doses 4 weeks apart at the low dose, five (5) doses 2 weeks apart at the low dose, three (3) doses 4 weeks apart at the high dose and five (5) doses 2 weeks apart at the high dose.||||
34152923|NCT01520025|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049163|NCT03118362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the crystalloid infusion solutions will be introduce in Opabag|"Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L) which may overcome overwhelm the potential risks associated with hyperchloremic solutions. Plasmalyte® also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.~Ringer Lactate® is also a balanced solution containing a low chloride concentration (i.e. 111 mmol/L)"|t|f|f|f
34152924|NCT05014568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator, study center staff, subject, and sponsor will be blinded to treatment assignment.|Following a 30-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily treatment with tapinarof cream, 1% or vehicle cream.|t|t|t|t
34152925|NCT01896245|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34152926|NCT05158790|||COHORT||RETROSPECTIVE|||||||
34049164|NCT02959021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049165|NCT06683521|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34152927|NCT00550901||||TREATMENT||||||||
34152928|NCT05460156|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34049166|NCT02562469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049167|NCT06525805|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will be blinded to the intervention. In the cover letter, participants will be informed that the study aims to examine the characteristics of an abstract. However, they will not be informed that the primary focus of this study is the influence of the abstract´s length. Furthermore, the participants will be not aware of the number of different abstracts that were randomly allocated.|This will be a two-arm, single-blinded, superiority, parallel-group randomized controlled trial (RCT) with 1:1 allocation of intervention and control groups.|t|f|f|f
34049168|NCT06683326|RANDOMIZED|PARALLEL||OTHER||NONE||Two randomized groups of trainees.||||
34049169|NCT01054092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049170|NCT05816798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant: The participant will be blind to the group they will be participating in. The device display will be hidden so the patient cannot see if it is on or off. The device activation noise will be recorded and used to mimic the irradiation.~Principal Investigator: only the auxiliary investigator who will apply the laser will know the group of participants. The principal investigator performing the initial and final (post-treatment) assessments will be blinded to the treatment/placebo groups"||t|t|t|t
34049171|NCT03050853|RANDOMIZED|PARALLEL||OTHER||SINGLE|All follow-up assessments will be conducted by the masked outcome assessor with the exception of the tobacco use and e-cigarette use self report and the satisfaction with e-cigarettes scale administered to the intervention group.|This is a study to learn about the appeal and health impacts of using e-cigarettes in people with serious mental illness who are not currently thinking about qutting smoking. Reduction of craving or quitting are not targets|f|f|f|t
34049172|NCT04940286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049173|NCT05540912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049174|NCT05027477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049175|NCT03843463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049176|NCT06335797|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34049177|NCT06683625|||COHORT||PROSPECTIVE|||||||
34049178|NCT00438607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049179|NCT05790837|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Randomized parallel-group trial. The groups will be recruited from higher education institutions. The length of this study will be six months. Measurements shall be made for both groups at baseline, 3rd, and 6th months.~The intervention group will receive the computer prompt Stand up for your Health® and information about sedentary behaviour. The computer prompt appears when the workers accumulate one hour the work front to screen. The break is two minutes, and one video with exercises starts with instructions for workers during this time.~The control group will receive only information through the leaflet."|f|f|f|t
34152929|NCT01882868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944961|NCT03436212|NA|SINGLE_GROUP||OTHER||NONE||||||
33944962|NCT06452680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33944963|NCT01273012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33944964|NCT02114346|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944965|NCT02961153|||CASE_ONLY||PROSPECTIVE|||||||
33944966|NCT06417658|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study employs a structured protocol involving random allocation to groups, preoperative assessments, surgery, postoperative follow-ups, and statistical analysis. It aims to evaluate differences in scar appearance, spread, erythema, suture marks, hypertrophy/atrophy, and overall impression between the two surgical approaches using the Scar Cosmesis Assessment Rating (SCAR) scale. Additionally, patient-reported outcomes such as itch and pain will be examined. This model ensures comprehensive evaluation of cosmetic outcomes and patient satisfaction, providing valuable insights to inform treatment regimens.||||
33977899|NCT02116712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977900|NCT01113268|NA|SINGLE_GROUP||OTHER||NONE||||||
33977901|NCT05137678|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label, result blind method|Patients in the case group were treated with glibenclamide within 10 hours after onset, orally or through nasogastric tube, 1.25 mg each time, once every 8 hours, for 7 consecutive days. The control group was blank control.||||
34049180|NCT06257017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152930|NCT01653236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152931|NCT02929940|||COHORT||PROSPECTIVE|||||||
34152932|NCT06221891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34152933|NCT03005808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152934|NCT03467672|||CASE_CONTROL||PROSPECTIVE|||||||
33841559|NCT06336018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841560|NCT00115908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841561|NCT01217177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944967|NCT04954560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study was designed as a randomized, crossover, head-to-head comparative study. Randomization was carried out using MS Excel random number generator. After qualification each patient was randomly assigned to receive either losartan (Lorista, KRKA, Slovenia) or eprosartan (Teveten, Solvay Pharmaceuticals, Austral-ia). The patients were taking all other previously prescribed drugs in unmodified dos-es during the whole course of the study. Each study drug was given in a random or-der as a single morning dose (50 mg of losartan or 600 mg of eprosartan) for two periods each lasting 3 months separated by 2-week wash-out time.||||
33944968|NCT00051246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944969|NCT03534089|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33944970|NCT00917917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944971|NCT04784559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients Will be randomised in 1:1:1 to: Plitidepsin 1.5 mg arm, Plitidepsin 2.5 mg arm and Control arm||||
33944972|NCT06437223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase 2 randomized, masked, placebo-controlled clinical trial||t|t|t|t
33944973|NCT02112396|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944974|NCT04667611|||COHORT||PROSPECTIVE|||||||
34049181|NCT06667011|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944975|NCT02557269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944976|NCT03609775|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Double-dummy, four-way crossover study design|t|t|t|t
33944977|NCT03809260|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944978|NCT01920165|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34049182|NCT06682689|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33944979|NCT01148108|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944980|NCT04203082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944981|NCT06090461|||COHORT||RETROSPECTIVE|||||||
33944982|NCT05038007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33944983|NCT03993002|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34049183|NCT01828983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049184|NCT05830136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049185|NCT04017351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049186|NCT00598351|||COHORT||PROSPECTIVE|||||||
34049187|NCT05652699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049188|NCT05286255|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single group, Phase 1 study||||
34049189|NCT05969964|||CASE_CONTROL||PROSPECTIVE|||||||
34049190|NCT06355258|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||According to the inclusion criteria, participants will be randomly divided into mild patients and severe patients, and then patients with severe disease were randomly assigned to placebo + low molecular weight heparin group or troxerutin + low molecular weight heparin group, and patients with mild disease were randomly assigned to placebo group or troxerutin group|t|t|t|f
34049191|NCT00327769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049192|NCT04905602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049193|NCT03088124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049194|NCT06656312|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34049195|NCT05875025|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34049196|NCT06225570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049197|NCT06668662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049198|NCT01172496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049199|NCT00991471|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049200|NCT04019340|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34049201|NCT06100263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049202|NCT01718795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049203|NCT03566914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049204|NCT05950737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049205|NCT05669131|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to either the motor imagery training group or the control group.||||
34049206|NCT04980378|||COHORT||PROSPECTIVE|||||||
34152935|NCT01571856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944984|NCT04264949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944985|NCT03767309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944986|NCT06381024|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients initiating either oral or intravenous chemotherapy for cancer will be randomly allocated in a 1:1 ratio to either:~* In-person care alone (Standard of care group).~* In-person care with telemonitoring (Standard of care with Cureety group).~The randomization will be stratified by:~• Oral versus intravenous cancer treatment. The number of patients initiating oral treatment at randomization will be restricted to 20 patients."||||
33944987|NCT03229512|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049207|NCT03773172|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34049208|NCT05449301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049209|NCT03741751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will be masked to the TMS versus sham treatment. Sham treatment will be very similar to active TMS without the active magnetic stimulation|randomized controlled trial|t|f|f|f
34049210|NCT06615557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049211|NCT01540214|||COHORT||PROSPECTIVE|||||||
34049212|NCT04421222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152936|NCT04512508|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A randomized and consecutive number will be assigned. If it is a non-number, the self-test will be performed first, followed by liquid cytology and then anoscopy. If it is a even number, first the liquid cytology will be performed, then the autotoma and the anoscopy||||
34152937|NCT03976999|NA|SINGLE_GROUP||OTHER||NONE||||||
34049213|NCT06449404|||CASE_CONTROL||PROSPECTIVE|||||||
34049214|NCT05989828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049215|NCT05230004|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34049216|NCT01536925|||CASE_ONLY||PROSPECTIVE|||||||
34075708|NCT05617807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized Controlled Trial|t|f|f|t
34049217|NCT04237103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The study was performed double blind. MTX will be repackaged in capsules and will look the same as placebo capsules. These capsules are packaged in vials whose labeling allows the maintenance of the blind.~The flasks are numbered in a corresponding list established by biostatistician study which specifies processing to be put in each bottle according to the number.~At each visit (inclusion and monitoring), the patient will be assigned as many lots of numbers needed to reach the next visit (2 or 4).~Only Methods Center (USMR) and Pharmacy of Bordeaux University Hospital have the correspondence between the number of treatment and nature. At no time during the study, the investigator (s) and patients will not have access to this list."|Methotrexate taken orraly once a weekcombination with UVB TL01 in a population of adult patients with progressive vitiligo|t|t|t|f
34049218|NCT02283996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049219|NCT03260244|||COHORT||PROSPECTIVE|||||||
34049220|NCT02919423|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34049221|NCT03000426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049222|NCT05017311|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
34152938|NCT04079881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants are randomly assigned receive intervention A then intervention B or to receive intervention B than intervention A||||
34152939|NCT04690244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152940|NCT01150968|NA|SINGLE_GROUP||||NONE||||||
34152941|NCT01073917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34152942|NCT03173768|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152943|NCT06061029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841562|NCT03535831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single arm study to assess the contribution of 18F-DCFPyL PET imaging (PET/MR or PET/CT) to the management of patients with prostate cancer (PCa).||||
33841563|NCT01609426|||CASE_ONLY||OTHER|||||||
33841564|NCT02234505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841565|NCT01498887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841566|NCT06341777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841567|NCT06415110|||COHORT||PROSPECTIVE|||||||
33841568|NCT02576119|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33841569|NCT03766477|||COHORT||PROSPECTIVE|||||||
33841570|NCT00399464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841571|NCT02957032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841572|NCT04292704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841573|NCT05332964|||CASE_CONTROL||PROSPECTIVE|||||||
33841574|NCT04327297|||COHORT||PROSPECTIVE|||||||
33841575|NCT02092597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841576|NCT04776642|||COHORT||PROSPECTIVE|||||||
33841577|NCT04546425|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841578|NCT04206202|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33841579|NCT00696189|||COHORT||PROSPECTIVE|||||||
33841580|NCT02893384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841581|NCT06306170|||COHORT||RETROSPECTIVE|||||||
33841582|NCT04383626|||OTHER||CROSS_SECTIONAL|||||||
33841583|NCT00413205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841584|NCT02378038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049223|NCT01088672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049224|NCT04241250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Exoskeletal assisted walking and spinal cord epidural stimulation (EAW+SCES) Exoskeletal assisted walking and Transspinal stimulation (EAW+TS)||||
34152944|NCT01304589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152945|NCT03536026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152946|NCT03775564|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||RemedRugby program Vs TAU + TouchRugby||||
34152947|NCT03240159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152948|NCT00122655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152949|NCT05729984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152950|NCT00898391|||CASE_ONLY||RETROSPECTIVE|||||||
34152951|NCT00488904|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34152952|NCT02467842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34152953|NCT04426136|||COHORT||PROSPECTIVE|||||||
34152954|NCT05850923|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||At first, all the participants will be randomized into a speech competition experimental group and a placebo control group, after 2 weeks the two interventions for two arms will be switch.|f|f|f|t
34152955|NCT06583421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152956|NCT03110575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841585|NCT01615289|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33841586|NCT01538641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944988|NCT03954054|||OTHER||PROSPECTIVE|||||||
33944989|NCT02627157|||CASE_ONLY||PROSPECTIVE|||||||
33841587|NCT02895204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33841588|NCT05337098|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33841589|NCT06142110|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A controlled trial was conducted by including all professional football players in the city and an equivalent number of sedentary individuals|t|f|f|t
33841590|NCT02088957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841591|NCT01908504|NA|SINGLE_GROUP||OTHER||NONE||||||
33841592|NCT02795364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33841593|NCT01169922|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33841594|NCT05679089|||CASE_CONTROL||PROSPECTIVE|||||||
33841595|NCT00443924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33841596|NCT01124383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841597|NCT01891019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841598|NCT01282853|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841599|NCT06104553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open, multicenter, dose-finding and dose expansion investigational Phase Ib/II clinical trial||||
33841600|NCT00956176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841601|NCT00078351||||TREATMENT||||||||
34049225|NCT01372488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34049226|NCT00986128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049227|NCT00006483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049228|NCT06101641|NA|SINGLE_GROUP||OTHER||NONE||This study is a prospective, self-controlled clinical trial||||
34049229|NCT06513403|||COHORT||CROSS_SECTIONAL|||||||
34049230|NCT06280807|||COHORT||PROSPECTIVE|||||||
34049231|NCT05245149|||COHORT||PROSPECTIVE|||||||
34049232|NCT02216656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049233|NCT00436475|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34049234|NCT05768230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized to treatment group A: intravenously injected levosimendan 12.5mg with 5% glucose injection 50ml configuration at 2ml/h for 24h, or treatment group B: control group with 5% glucose injection 2ml/h for 24h.|t|t|t|f
33944990|NCT04867668|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The actual recruitment rate is 2106.||f|f|t|f
34049235|NCT00417456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049236|NCT06253637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049237|NCT00976976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049238|NCT02282631|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049239|NCT02830113|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049240|NCT02308072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049241|NCT06355310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind placebo control|1:1 randomization|t|t|t|t
34049242|NCT03991962|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single group design||||
34049243|NCT06683378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049244|NCT03209622|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants hospitalized for acute coronary syndrome were randomly assigned to either group A, initiating Nicotine replacement therapy (NRT) in intra-hospitalization or a control group B that received NRT after hospital discharge."||||
34049245|NCT05772377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049246|NCT03894020|||CASE_ONLY||PROSPECTIVE|||||||
34049247|NCT02309411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049248|NCT05917834|||COHORT||PROSPECTIVE|||||||
34049249|NCT04859283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049250|NCT03841058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo will be used that will be identical to active drug in appearance (PM women)|Randomized controlled trial (PM women) Open-label treatment study (Men)|t|t|t|t
34049251|NCT03753919|NA|SINGLE_GROUP||TREATMENT||NONE||"* Cohort 1: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle. Cell and poorly-differentiated thyroid carcinoma (DTC).~* Cohort 2: Advanced medullary thyroid carcinoma (MTC).~* Cohort 3: Advanced anaplastic thyroid cancer (ATC)."||||
34049252|NCT06666673|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34049253|NCT04414969|NA|SINGLE_GROUP||TREATMENT||NONE||An Open-label, multicenter, single group, phase II trial,||||
34049254|NCT01008371|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049255|NCT05907538|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049256|NCT03550872|RANDOMIZED|PARALLEL||OTHER||NONE|Open Label|To evaluate the physical effect of physical training in patients with heart failure and permanent atrial fibrillation||||
34049257|NCT00436124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049258|NCT06398067|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A 2-arm, parallel, single-blind randomized controlled trial (RCT).|t|f|f|f
34049259|NCT02679391|||COHORT||RETROSPECTIVE|||||||
34049260|NCT00434174|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049261|NCT04903353|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomly assigned to either Risperidone or Aripiprazole after a clinician has chosen to start the patient on an atypical antipsychotic||||
34152957|NCT05327504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to randomization status.|Randomized clinical trial within a Substance Use Disorder (SUD) clinic to evaluate whether treatment as usual (TAU) plus Written Exposure Therapy (WET) is superior to TAU augmented by a neutral topic writing on both PTSD and addiction outcomes for Veterans who present to SUD treatment with comorbid SUD/PTSD.|f|f|f|t
34152958|NCT05709639|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34152959|NCT06152549|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34152960|NCT01877577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152961|NCT04591236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152962|NCT01501123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944991|NCT00639600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944992|NCT04628364|||COHORT||PROSPECTIVE|||||||
34049262|NCT04354012|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
34152963|NCT00291421|||||PROSPECTIVE|||||||
34152964|NCT04485884|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841602|NCT04630704|||CASE_CONTROL||PROSPECTIVE|||||||
34049263|NCT04560985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34049264|NCT06684340|||COHORT||RETROSPECTIVE|||||||
34049265|NCT02135185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049266|NCT04536012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34049267|NCT06389305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a prospective cohort study|t|f|t|f
34049268|NCT03502070|NA|SINGLE_GROUP||OTHER||NONE||||||
34049269|NCT03606928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049270|NCT03522714|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 allocation ratio||||
34049271|NCT05942417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistical analysis investigator will be masked.||f|f|f|t
34049272|NCT02585128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049273|NCT05838443|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049274|NCT02587507|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34152965|NCT01092663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152966|NCT05606341|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Subjects will be randomly allocated in a blinded fashion to receive s.c. injection of either CpG ODN (dose level 1, 0.1 mg/kg) or placebo (saline). Dose escalation will occur after 10 weeks after the last injection in a new subject cohort, and will be based on the safety data and immunostimulatory assessments at previous dose level cohorts.|t|f|t|f
34152967|NCT02773654|||COHORT||CROSS_SECTIONAL|||||||
34049275|NCT05514405|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34049276|NCT04387019|||CASE_CONTROL||PROSPECTIVE|||||||
34049277|NCT05283902|||CASE_CROSSOVER||PROSPECTIVE|||||||
34049278|NCT02782949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34049279|NCT05367973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049280|NCT01273129|||COHORT||PROSPECTIVE|||||||
34049281|NCT03374917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049282|NCT04723628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Randomized Controlled Trial||||
34049283|NCT05126030|NA|SINGLE_GROUP||TREATMENT||NONE||Topaz TTVR System||||
34049284|NCT03207919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049285|NCT02626130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049286|NCT02566382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049287|NCT05152966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049288|NCT00105768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34049289|NCT03092297|||COHORT||PROSPECTIVE|||||||
34049290|NCT05660421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049291|NCT06684067|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34049292|NCT00356356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049293|NCT05478135|NA|SINGLE_GROUP||OTHER||NONE||||||
34049294|NCT01003314|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049295|NCT06539624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049296|NCT00860197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049297|NCT05871944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be single blind randomized control clinical trail in which just participant will be unware about which group he/she is included|Two groups will be formed. one group will receive joint mobilization technique and other will get post facilitation stretch technique|t|f|f|f
34049298|NCT04111250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Where possible, outcomes assessor was blinded.|Split mouth design|f|f|f|t
34049299|NCT05909878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049300|NCT04094987|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, cohort||||
34049301|NCT04579523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049302|NCT06144125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients are randomly divided into two groups (experimental vs control groups).|t|f|f|t
34049303|NCT06683703|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34049304|NCT00116155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049305|NCT01232686|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049306|NCT01376661|||CASE_ONLY||PROSPECTIVE|||||||
34049307|NCT06659705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049308|NCT03024684|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34049309|NCT05087810|||COHORT||PROSPECTIVE|||||||
34049310|NCT05457218|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|A randomized double-blind crossover design with neither the subjects nor the investigators knowing who is on which treatment. The interventions will be coded using a blinded alphabetical letter code (A, B, C). A delegate researcher (independent party not further involved in the study) will randomize all interventions using a computer-generated randomization list. The delegate will hand in the code-breaker to the principal investigator in a sealed envelope. The envelope will be stored in a locked filing cabinet in the principal investigator's office, which will also be locked when unoccupied. The envelope will be opened by the principal investigator after completing the analysis of blood samples.|"Participants will consume a supplemental dose (0.25 g/kg body weight) of either IPC80, Whole Buffalo Powder or whey protein.~The type of consumed supplementation will be randomized where neither the participant nor investigator will know which supplement is being consumed. Each participant will repeat the protocol three times."|t|f|t|t
34049311|NCT06049966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049312|NCT04121065|||COHORT||PROSPECTIVE|||||||
34049313|NCT06682767|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As diet requires volitional activity, the study participants cannot be blinded. To minimize bias, the investigators evaluating cognitive, research labs, and MRI outcomes will be blinded to group assignments.||f|f|f|t
34049314|NCT06167733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study personnel, including the investigator and raters and study subjects will be blinded to the treatment assignment (active vs. sham)|Active vs. Sham|t|f|t|t
34049315|NCT06388642|NA|SINGLE_GROUP||OTHER||NONE||||||
34049316|NCT06667401|||COHORT||PROSPECTIVE|||||||
34049317|NCT04229095|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Parallel Assignment, Double-Blind, Randomized Stratified at randomization based on sex and Pittsburgh Sleep Quality Index Total Score (PSQI) greater than or equal to 5 versus less than 5.|t|t|t|t
34049318|NCT03840759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049319|NCT06668714|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34049320|NCT00282399|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152968|NCT03481140|||CASE_CONTROL||RETROSPECTIVE|||||||
34049321|NCT00730730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049322|NCT06083961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center study, Registry based, Pragmatic, Prospective trial||||
34049323|NCT06665399|||COHORT||PROSPECTIVE|||||||
34049324|NCT03901833|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049325|NCT02125786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049326|NCT02059499|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34049327|NCT02521142|||COHORT||PROSPECTIVE|||||||
34049328|NCT04194320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049329|NCT05284799|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind|"Randomized assignment (1:1:1) into 3 groups of 60 subjects to receive:~* First group: OVX836 480µg and Quadrivalent Inactivated Influenza Vaccine at commercial dose administered~* Second group: Quadrivalent Inactivated Influenza Vaccine at commercial dose, concomitantly administered with placebo~* Third group: OVX836 480µg, concomitantly administered with placebo"|t|f|t|f
34049330|NCT00712543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049331|NCT04821609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049332|NCT06526143|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants collecting follow-up data will be blind to site's randomization group.|Sites will be assigned to receive (1) training-as-usual or (2) training plus implementation facilitation.|f|f|f|t
34049333|NCT04830111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049334|NCT05747898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor was blinded to the treatment applied to each half of the scar.|Each scar was split into two equal halves; the upper right half were treated using a cannula- based subcision approach, while the lower left half was treated using a common needle-based procedure|f|f|f|t
34049335|NCT01019395|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34049336|NCT04116658|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049337|NCT04409808|NA|SINGLE_GROUP||OTHER||NONE||||||
34049338|NCT06019845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049339|NCT05510128|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049340|NCT04903496|||OTHER||CROSS_SECTIONAL|||||||
34049341|NCT02089308|RANDOMIZED|CROSSOVER||||NONE||||||
34049342|NCT01549561|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34049343|NCT01938430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049344|NCT01282372|||||PROSPECTIVE|||||||
34049345|NCT03770962|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician who performs the statistical analysis will be blinded.||f|f|t|f
34049346|NCT01477996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049347|NCT01559350|||CASE_CONTROL||PROSPECTIVE|||||||
34049348|NCT04544488|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34049349|NCT01648725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049350|NCT06140355|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049351|NCT04276116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049352|NCT02219113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049353|NCT05034198|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34049354|NCT04450277|||COHORT||PROSPECTIVE|||||||
34049355|NCT05121714|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a Phase 1, 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine) and a known CYP1A2 inhibitor (fluvoxamine). Sixty (60) healthy adult male and female subjects 18 to 55 years of age are planned to participate in the study. Separate cohorts of subjects will be enrolled for Part A (24 subjects) and Part B (36 subjects).||||
34049356|NCT06149585|||COHORT||PROSPECTIVE|||||||
34049357|NCT00671359|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34049358|NCT04641325|NA|SINGLE_GROUP||TREATMENT||NONE|The primary investigator and the co-PI (physical therapist) will know whether testing is at baseline or follow-up, but will not know the cardiovascular outcome measures. The cardiovascular outcomes assessor will be fully blinded.|"The first part of trial was a Randomized Controlled Step-Wedge Pilot Trial as below 2 groups (Exercise Intervention Group and Current Care Group) The first phase of the study will maintain the Current Care Group as the control. At the end of the first phase, the Current Care Group will crossover and receive the Exercise Intervention as the second phase of the trial.~With the COVID-19 pandemic causing delays in the study, and decreased enrollment and decreased access to MRI, the study was altered to a single group. comparing the same outcomes at baseline and after the intervention. This eliminates the blinding of the PI, but those interpreting the tests are still blinded."||||
33737600|NCT04355416|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|care provider not involved in the study|Twenty five systemically healthy patients either male or female with chronic periodontitis aged between 30 and 45 years with pocket depth of 5-7 mm affecting at least two nonadjacent sites will be included. A split mouth design will be followed Selected sites will be randomized into control and experimental sites. In the experimental site scaling and root planing to be performed, followed by placement of the curcumin gel and periodontal pack application. In the control site, sub gingival scaling and root planing alone will be performed followed by periodontal pack application. collecting of GCF from the pocket to determine the level of IL_8 by ELISA and measurement of the clinical Parameters to be included: PLI (plaque index), BOP (bleeding on probing), PPD (probing pocket depth) and RAL (relative attachment level). These parameters will be recorded on day 0 and 30 days.|f|t|f|f
33737601|NCT02048462|||COHORT||PROSPECTIVE|||||||
33737602|NCT05081661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33841603|NCT05169840|||OTHER||PROSPECTIVE|||||||
33841604|NCT03076073|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841605|NCT05276908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049359|NCT06683313|||CASE_CONTROL||PROSPECTIVE|||||||
34049360|NCT04875728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841606|NCT05758948|||CASE_ONLY||OTHER|||||||
33841607|NCT03183505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841608|NCT01877148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841609|NCT04193787|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841610|NCT00002305||||TREATMENT||||||||
33841611|NCT03582527|||COHORT||PROSPECTIVE|||||||
33841612|NCT00677105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049361|NCT06441838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049362|NCT06685614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075709|NCT04257396|RANDOMIZED|PARALLEL||OTHER||SINGLE|Skin assessments carried out by blinded observers||f|f|f|t
33841613|NCT05290753|NA|SINGLE_GROUP||OTHER||NONE||||||
33841614|NCT02932540|||CASE_CONTROL||PROSPECTIVE|||||||
33841615|NCT01092429|||COHORT||PROSPECTIVE|||||||
33841616|NCT05769556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33841617|NCT06381180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841618|NCT03349619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841619|NCT03362385|||COHORT||PROSPECTIVE|||||||
33944993|NCT03131856|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients were randomized to either the intervention group or control group.||||
34049363|NCT04067726|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Stratified permuted block randomized design will be used to generate the randomization table where permuted block randomization will be used for each stratum by age, with a varying block size of 4 and 6.|t|t|t|f
34049364|NCT02940418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049365|NCT04297514|||COHORT||RETROSPECTIVE|||||||
34049366|NCT05454761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049367|NCT05021874|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34049368|NCT01137929|||CASE_CONTROL||PROSPECTIVE|||||||
34049369|NCT04838457|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The interventional model takes place in two parts. Part 1 is a successive cohort design in which a small cohort of participants complete the treatment, and provide qualitative and quantitative feedback on the treatment. The treatment process is then revised accordingly. A second and third cohort of participants complete treatment, followed by the same revision process. Part 2 involves a single-arm pilot trial of acceptability and feasibility of recruiting methods, treatment, and measurement of outcomes for participants.||||
34049370|NCT06682455|||COHORT||PROSPECTIVE|||||||
34049371|NCT04637581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049372|NCT02582450|||COHORT||PROSPECTIVE|||||||
34049373|NCT04559438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049374|NCT01415817|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049375|NCT06642142|||CASE_ONLY||PROSPECTIVE|||||||
34049376|NCT01490073|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049377|NCT05184283|||CASE_CONTROL||PROSPECTIVE|||||||
34049378|NCT03972657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049379|NCT06684522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049380|NCT06239194|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049381|NCT01042119|||CASE_ONLY||RETROSPECTIVE|||||||
34049382|NCT05882305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049383|NCT06476912|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34049384|NCT04623034|RANDOMIZED|CROSSOVER||OTHER||NONE||Stage 1 - single ascending dose, Stage 2 - crossover and food effect study||||
34049385|NCT00166543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049386|NCT05078866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049387|NCT04590911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Semi-randomized, controlled, before-after study with follow-up at six-months with blinded outcome measurement|f|f|f|t
34049388|NCT04349059|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Outcomes assessor will be blinded to randomization group and order of testing.|Randomized crossover design|f|f|f|t
34049389|NCT02610335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737603|NCT02752048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737604|NCT00180739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737605|NCT04992949|NA|SINGLE_GROUP||TREATMENT||NONE||Open label multicenter phase II non-randomized study||||
33737606|NCT06458049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737607|NCT00961259|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33737608|NCT04243824|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737609|NCT05673694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737610|NCT05105269|||COHORT||PROSPECTIVE|||||||
34049390|NCT03554395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
34049391|NCT06685458|||CASE_CONTROL||RETROSPECTIVE|||||||
34049392|NCT05274854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the treatment groups.|An Effectiveness-Implementation Hybrid Design with a two stage randomisation will be used to determine and compare efficacy and cost-effectiveness of different management approaches/interventions. Patients will initially receive standardised assessment of symptoms and wheat intolerance. Those patients that continue to experience symptoms will then be randomised to one of four pre-consultation interventions followed by randomisation to one of two consultation interventions conditional on their response to the initial intervention.|f|f|f|t
34049393|NCT01031836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049394|NCT04767997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049395|NCT04373395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049396|NCT02149758|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34049397|NCT05590416|||COHORT||PROSPECTIVE|||||||
34049398|NCT05131464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049399|NCT06664905|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34049400|NCT06136208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049401|NCT00695292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049402|NCT01681680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049403|NCT01316211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049404|NCT00003113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049405|NCT05732779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049406|NCT00522106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049407|NCT06068218|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049408|NCT06682247|||COHORT||RETROSPECTIVE|||||||
34049409|NCT05175326|||COHORT||PROSPECTIVE|||||||
34049410|NCT04623216|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049411|NCT04102176|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel arm study randomised 1:2||||
34049412|NCT04826965|RANDOMIZED|PARALLEL||OTHER||NONE||Screen 60 subjects in hopes to enroll 40. There will be 20 subjects per arm. All subjects will have a wound vac applied. The randomization will be whether or not irrigation is included.||||
34049413|NCT06275620|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049414|NCT06075446|||CASE_CONTROL||PROSPECTIVE|||||||
34049415|NCT04036435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049416|NCT03821714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152969|NCT04401878|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Care Providor, Outcome Assessor)|This study is carried out in the Orthopedic unit and included 120 patients divided into two groups: the treatment group (A) and the control group (B). Group A recruit 60 patients with a past history of epidural anesthesia who suffered from of PDPH within five days after the dural puncture. Group B included 60 patients with a history of epidural anesthesia with no PDPH.|f|t|f|t
33944994|NCT01723527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152970|NCT05382611|||CASE_CONTROL||PROSPECTIVE|||||||
34152971|NCT01331291|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152972|NCT06195189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944995|NCT05257876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open-labelled parallel pilot RCT||||
33944996|NCT01247467|||COHORT||RETROSPECTIVE|||||||
33944997|NCT03999203|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34049417|NCT06214936|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33944998|NCT06412471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944999|NCT06195033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945000|NCT01265719|||COHORT||PROSPECTIVE|||||||
33945001|NCT00081276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945002|NCT03462628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
33945003|NCT05047549|||COHORT||PROSPECTIVE|||||||
34049418|NCT03945747|||CASE_CONTROL||PROSPECTIVE|||||||
34049419|NCT01957436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049420|NCT03462394|||COHORT||PROSPECTIVE|||||||
34049421|NCT01961154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049422|NCT02419014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049423|NCT06314646|||COHORT||PROSPECTIVE|||||||
34049424|NCT06408610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"1. Patients will receive moderate intensity continuous training (MICT)~2. Patients will receive high intensity interval training (HIIT)~3. Patients will be instructed to follow low fermentable short chain carbohydrates diet (low FODMAP)"||||
34049425|NCT00628238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049426|NCT06581523|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The SKY Breath and Meditation intervention will be for both the individuals with Parkinson's Disease and their care partners.||||
34049427|NCT04418128|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is an open-labelled, randomized clinical trial to evaluate the efficacy of nafamostate in patients with COVID-19 pneumonia.||||
34049428|NCT04149782|||COHORT||PROSPECTIVE|||||||
34049429|NCT05897710|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152973|NCT00982202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152974|NCT04084821|||COHORT||RETROSPECTIVE|||||||
34152975|NCT05047848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945004|NCT02551900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152976|NCT00005875||||TREATMENT||||||||
34152977|NCT01093872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152978|NCT01026740|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152979|NCT01761695|||COHORT||PROSPECTIVE|||||||
34152980|NCT02326233|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34152981|NCT01599741|NON_RANDOMIZED|||TREATMENT||NONE||||||
33945005|NCT01743781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945006|NCT03834857|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Insertion of Stentrode TM device||||
33945007|NCT01446835|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33945008|NCT06241131|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33945009|NCT01180452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945010|NCT00843128|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33945011|NCT00553319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945012|NCT01539616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049430|NCT05911048|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34049431|NCT05943561|||COHORT||PROSPECTIVE|||||||
34049432|NCT01981954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049433|NCT00897702|||CASE_ONLY||PROSPECTIVE|||||||
34049434|NCT05787561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152982|NCT01973504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945013|NCT00472628|||||PROSPECTIVE|||||||
33945014|NCT02136719|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33977902|NCT02473211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977903|NCT02527096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977904|NCT02068040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977905|NCT05333523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977906|NCT05481307|NA|SEQUENTIAL||TREATMENT||NONE||||||
33977907|NCT04182971|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Cross-over||||
33977908|NCT04585321|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34049435|NCT06128044|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049436|NCT04523272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049437|NCT06012890|||COHORT||PROSPECTIVE|||||||
34049438|NCT03441802|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049439|NCT04214262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049440|NCT04065971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075710|NCT03066830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075711|NCT00004268||||TREATMENT||||||||
34152983|NCT01571232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152984|NCT00889772|||COHORT|||||||||
34152985|NCT06496334|||CASE_ONLY||PROSPECTIVE|||||||
34152986|NCT04408911|||COHORT||RETROSPECTIVE|||||||
34152987|NCT05943782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152988|NCT00908466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152989|NCT06351722|||CASE_CONTROL||PROSPECTIVE|||||||
34152990|NCT05262283|||CASE_ONLY||CROSS_SECTIONAL|||||||
34152991|NCT01377870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152992|NCT04197388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152993|NCT00588094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152994|NCT04117698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945015|NCT03938857|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Phase 1b randomized, double-blind, placebo-controlled dose escalation trial. The study will randomize participants to receive placebo (fentanyl standard of care) titrated to sedation+saline placebo (bolus+infusion) or one of the following 3 Dexmedetomidine treatment arms in a sequential cohort fashion: Cohort 1: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2 mcg/kg/hr infusion); Cohort 2: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion); Cohort 3: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion).|t|t|t|f
33945016|NCT06510023|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||2X3 non-randomized, within-participant design.||||
33945017|NCT05401708|||COHORT||PROSPECTIVE|||||||
33945018|NCT05277805|||OTHER||CROSS_SECTIONAL|||||||
33945019|NCT00759499|||OTHER||PROSPECTIVE|||||||
33945020|NCT02098291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945021|NCT00764465|RANDOMIZED|FACTORIAL||||NONE||||||
33945022|NCT05578664|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are assigned to one of two groups (ARM A vs ARM B) in parallel for the duration of the study.~Eligible patients will be randomized 2:1 to receive:~* ARM A: pembrolizumab at flat dose of 400 mg every six weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1; OR~* ARM B: local therapy alone within 42 days."||||
33945023|NCT01974427|||COHORT||PROSPECTIVE|||||||
33945024|NCT05712343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049441|NCT06604624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.|This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.|t|f|f|f
34049442|NCT00004647|RANDOMIZED|||TREATMENT||DOUBLE||||||
34049443|NCT01638312|||CASE_CONTROL||PROSPECTIVE|||||||
34049444|NCT05475366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049445|NCT04614038|||COHORT||PROSPECTIVE|||||||
34049446|NCT00170625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049447|NCT05748847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049448|NCT06685575|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Comparative Outcomes of Conventional Transforaminal Lumbar Interbody Fusion With Posterior Decompression Surgery Versus Endoscopic Foraminotomy Surgery in Stable Lumbar Foraminal Stenosis An Ambi-directional Cohort Study||||
34049449|NCT01990131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049450|NCT05062733|||CASE_ONLY||PROSPECTIVE|||||||
33945025|NCT03231059|||COHORT||RETROSPECTIVE|||||||
33945026|NCT02607904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977909|NCT05857839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049451|NCT01011530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049452|NCT04216290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049453|NCT01098760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049454|NCT06667375|||COHORT||RETROSPECTIVE|||||||
34049455|NCT01459029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049456|NCT03033602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049457|NCT06111885|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Indapamide, hydrochlorothiazide and chlorthalidone will be provided in identically looking bottles containing identically looking capsules. All trial personnel that is involved in recruitment and care of patients, trial assessment, monitoring and statistical analyses will be blinded to the assigned trial arm.|Eligible individuals will be randomly allocated to one of six treatment sequences with indapamide 2.5 mg, chlorthalidone 25 mg or hydrochlorothiazide 50 mg once daily per os in the morning. Active treatment phases will be 28 days each, separated by wash out periods of 28 days. Active treatment periods can be extended by a maximum of one week, wash out periods can be extended to a maximum of eight weeks.|t|t|t|t
34049458|NCT02713360|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34049459|NCT03406585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049460|NCT05038592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049461|NCT04999436|NA|SINGLE_GROUP||SCREENING||NONE||We will collect observational data to assess the impact of the training program on clinical practice. We will collect pre-test data before the intervention, and post-test data after the intervention.||||
34049462|NCT02294396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049463|NCT03625765|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34049464|NCT01139424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049465|NCT00730795|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049466|NCT05754762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049467|NCT04954001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049468|NCT06249737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There will be 3 intervention groups where they will train the movement of different DoF of the affected upper extremity (the DoF target and other DoF of the shoulder or wrist) or the DoF target and other DoF of the contralateral lower extremity (to maintain the practice dose among all groups)||||
34049469|NCT04834505|||CASE_ONLY||OTHER|||||||
34049470|NCT02166736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049471|NCT01971775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049472|NCT06667765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075712|NCT03852823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075713|NCT06386380|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34075714|NCT01063309|||COHORT||CROSS_SECTIONAL|||||||
34152995|NCT03068208|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152996|NCT00184756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152997|NCT02504307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152998|NCT02161107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152999|NCT04716920|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34153000|NCT00934908|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34153001|NCT06318065|||COHORT||RETROSPECTIVE|||||||
34153002|NCT04345094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153003|NCT05697796|||COHORT||RETROSPECTIVE|||||||
34049473|NCT03906032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Simple randomization technique using an online random number generator will be utilized. Sequential sealed envelopes with group allocation will be opened at the time of the daily trauma meeting and the appropriate plan made for the patient. Patients are randomized according to 3 mobility groups - independent, walking stick/crutch or walking frame.|Gait speed (mean velocity): Sample size calculations are based on a two-sample, two-sided t-test for a difference in means with 80% power, a 5% type 1 error rate. The minimal clinically important difference (MCID) in gait speed is stated in the literature as between 0.10 - 0.20 m/s. We considered treatment effect of 0.2 m/s (while assuming a SD of 0.3). The resulting total sample sizes for this effect is 74 patients at the 6 months post-operative timeframe. A significant attrition rate (50%) for this population will be allowed for by additional recruitment of \>150 participants|t|f|t|t
34049474|NCT00199238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049475|NCT05477901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Post-baseline Procedure -- Random Assignment to Intervention After baseline, families will be randomized in a 1:1 ratio to receive either a high ($40/month) or low ($2/month) supplemental transfer for 2 years and remains in their study arm throughout the study after randomization||||
34049476|NCT06685081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34049477|NCT06333808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized in parallel in one of two treatment groups during the Blinded Phase. Participants in both treatment groups will be given the option to continue BIC/LEN FDC treatment during the Open-Label Phase.|t|f|t|f
34049478|NCT06010693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049479|NCT03048318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Subsequent patients undergoing living donor liver transplant with right lobe grafts will be randomised|t|f|f|f
34049480|NCT03913416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049481|NCT05498155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"There will be 2 cohorts:~Cohort A will consist of a lower-risk population Cohort B will consist of a higher-risk population Participants will be allocated to receive 300 mg oral olaparib twice daily as monotherapy or in combination with durvalumab 1500 mg via intravenous infusion every 4 weeks for a minimum of 4 and a maximum of six 28-day cycles before undergoing definitive surgery. Each participant will undergo definitive surgery, preferably within 6 weeks after receiving the final dose of neoadjuvant olaparib therapy, followed by standard treatment (radiation therapy, systemic therapy per institutional standards). Participants who achieve pCR at surgery, will be allowed to continue on treatment with olaparib in the adjuvant setting in lieu of standard adjuvant systemic therapy, per physician's choice. If the physician chooses adjuvant olaparib, then the total duration of olaparib therapy in the neoadjuvant and adjuvant setting should be 12 cycles."||||
34049482|NCT02208362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049483|NCT04216199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049484|NCT03380078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Coders assessing provider outcomes are masked from study condition and aims.|"We will use a randomized factorial dismantling design to examine the independent and combined effectiveness of the TEAMS modules. MH programs (AIM HI study) and School districts (CPRT study) from San Diego, Sacramento, and LA Counties will be randomized to one of four conditions (STANDARD EBI-specific training only (control condition); TIPS (Motivational Module); TLI (LOCI Implementation Leadership Module).~The Extension Study will use a scale-out open pilot design to examine the impact of a team enhanced TLI on provider and child outcomes."|f|f|f|t
34049485|NCT00120562|||||PROSPECTIVE|||||||
34049486|NCT03169881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Primary providers and bedside caregivers will be blinded to randomization group. If the dose will be administered IV, the study drug will be administered slow IV push by the bedside nurse. If the dose will be administered subcutaneously, the study drug will be brought to the bedside in a closed container, and injections will be shielded behind screens and out of earshot from caregivers and parents. An adhesive bandage (or 2x2 gauze) will be placed over the true and sham injection sites and either taped or held in place until no evidence of the injection is visible. The parents, medical providers, data collection staff and neurodevelopmental follow up personnel will be masked to the treatment arm.|Randomized, masked, placebo-controlled trial|t|t|t|t
34049487|NCT01546337|||CASE_ONLY||PROSPECTIVE|||||||
34049488|NCT04541953|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049489|NCT04236661|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty subjects with self-reporting sleep disturbance will use the Chilipad cooling mattress for 5 weeks. The subjects will be given a Diary to complete tracking sleep quality during the 5 weeks. Subjects will also be given questionnaires before and after the sleep study part of the study to measure changes||||
34049490|NCT00863148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049491|NCT02731651|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34049492|NCT06063148|NA|SINGLE_GROUP||OTHER||NONE||||||
34049493|NCT03131973|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34049494|NCT03691311|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel two arms trial randomized in 2:1 proportions to intervention group vs control group. . At least 24 patients with hormone receptor negative breast cancer and 24 premenopausal patients will be included in the study so allocation of patients without any of these two characteristics will be restricted depending on the overall characteristics of the included population||||
34049495|NCT04713722|||CASE_CONTROL||PROSPECTIVE|||||||
34049496|NCT06682936|NA|SINGLE_GROUP||OTHER||NONE||Feasibility of outpatient intervention||||
34049497|NCT01644799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049498|NCT00297180|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34049499|NCT04881227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049500|NCT01340027|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34049501|NCT05720715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945027|NCT05066906|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Randomization into two groups A and B. Group Intervention or group A will comprise of participants who will be given usual referrals to pre-employment training, and will not use Identifor or Companion app. Intervention or group B will comprise of participants who were randomly selected to use Identifor and Companion app, in addition to referrals to pre-employment training.||||
33945028|NCT03039699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945029|NCT06278181|||COHORT||PROSPECTIVE|||||||
33764404|NCT04005534|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Each step of the study will be performed by anesthesiologist who will not participate in any other step. All of them, and the patient will be blinded to groups.|This is a prospective, double-blind and randomized clinical trial.|t|t|t|t
33945030|NCT04650932|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
34049502|NCT02805660|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049503|NCT06104072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients participated will be masked about the type of intervention, where (GA) patients will receive PT program + sham computer based cognitive training, while patients in (GB) will receive computer -based REHACOM cognitive training in addition to the same PT program as (GA).|Randomized Controlled Clinical trial, where the recruited patients will be randomly assigned into 2 equal groups ( GA \& GB) using sealed envelopes. control group (GA) and study group (GB). Patients in (GA) will be treated by a designed physiotherapy program consisted of aerobic exercise on treadmill, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Graduated active exercises, gait training, Reciprocal and weight shifting exercises in addition to sham computerized cognitive training. Patients in (GB) will be treated by computer-based cognitive training in addition to the same physiotherapy program as GA.|t|f|f|t
34049504|NCT00690261|||CASE_CONTROL||PROSPECTIVE|||||||
34049505|NCT05204927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomized on a 2:1 basis to receive Lu177-PSMA (Investigational Arm) or standard of care hormone therapy (Control Arm). The Control Arm will consist of treatment with either abiraterone with prednisone or enzalutamide depending on the clinical judgement of the investigator. Participants who are randomized to the control arm who demonstrate radiographic progression may be eligible to crossover to receive Lu177-PSMA.||||
34049506|NCT03862131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will be classified based on baseline segmental MyoStrain Fast-SENC strain testing, into lower and higher risk groups. The higher risk group will be randomized with half blinded and half unblinded to intramyocardial strain in terms of assessing cardiotoxicity incidence and management. Physicians will have knowledge of MyoStrain intramyocardial strain and cardiac MRI information in the unblinded group to augment standard of care in detecting and managing cardiotoxicity. Physicians will not have access to or knowledge of intramyocardial strain and cardiac MRI data, except 4 standard cardiac measures, for patients in the blinded group.||t|t|f|f
34049507|NCT04720911|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34049508|NCT04339985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Approx. 210 subjects randomized and 16 subjects will be in an open-label sub-study|Subjects will be randomly assigned by using Interactive Web Response System (IWRS) to one of three treatment groups|t|f|t|f
34049509|NCT02390102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049510|NCT03485495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049511|NCT05419180|NA|SINGLE_GROUP||TREATMENT||NONE||retrospective part and prospective part||||
34049512|NCT04562441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049513|NCT05978544|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049514|NCT06307860|||COHORT||OTHER|||||||
34049515|NCT04687943|||CASE_CONTROL||PROSPECTIVE|||||||
34049516|NCT02660281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049517|NCT06571838|||COHORT||PROSPECTIVE|||||||
34049518|NCT01204814|||OTHER||CROSS_SECTIONAL|||||||
34049519|NCT05986578|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34049520|NCT06642506|||COHORT||RETROSPECTIVE|||||||
34049521|NCT00904761|NON_RANDOMIZED|PARALLEL||||NONE||||||
34049522|NCT04665037|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049523|NCT02572076|NA|SINGLE_GROUP||SCREENING||NONE||||||
34049524|NCT02611271|||COHORT||PROSPECTIVE|||||||
34049525|NCT01177293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34049526|NCT05448963|NA|SINGLE_GROUP||TREATMENT||NONE||single arm surgical intervention||||
34049527|NCT02360150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049528|NCT05726838|||COHORT||OTHER|||||||
34049529|NCT05796466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will only know the name of the parenting program they are taking part of, but the name of the other program will not be disclosed. All research assistants who will conduct evaluations (i.e., observational tasks) or code parent-child interactions will be blind to experimental assignment.||f|f|f|t
34049530|NCT01475851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075715|NCT01618786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34075716|NCT03717779|||CASE_ONLY||PROSPECTIVE|||||||
34153004|NCT03086902|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group sample sizes of 44 in Group 1 and 44 in Group 2 achieve 80% power to detect a difference between the group proportions of -0.2000. The proportion in Group 1 (the treatment group) is assumed to be 0.2500 under the null hypothesis and 0.0500 under the alternative hypothesis. The proportion in Group 2 (the control group) is 0.2500. The test statistic used is the two-sided Z test with pooled variance. The significance level of the test was targeted at 0.0500. The significance level actually achieved by this design is 0.0531.||||
34153005|NCT03033199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153006|NCT00257972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945031|NCT00400504|||DEFINED_POPULATION||PROSPECTIVE|||||||
33945032|NCT03792230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Because of only one investigator, there is no blinding|prospective randomised controlled study|f|f|t|f
33945033|NCT03478631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and study coordinators will be blinded to the nature of the treatment allocation. Stratified randomization lists by baseline sex and age will be created.|The study will be a randomized, double-blind, controlled parallel study. There will be two experimental arms of 16-week duration, in which participants are assigned to test or control arms under free living conditions in an outpatient setting.|t|t|t|t
34075717|NCT03521882|||OTHER||PROSPECTIVE|||||||
33764405|NCT01368822|||COHORT||CROSS_SECTIONAL|||||||
33764406|NCT01678014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945034|NCT02206776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049531|NCT06666842|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two conditions in a parallel design with assessments occurring before randomization (Baseline) and at 16, 29, 42, and 68 weeks.||||
34049532|NCT02312466|||OTHER||CROSS_SECTIONAL|||||||
34049533|NCT02881320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049534|NCT05965180|||OTHER||PROSPECTIVE|||||||
34049535|NCT06193356|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A survey containing 15 High Definition - White Light (HD-WL) and Narrow Band Imaging (NBI) images, a learning intervention on detection of RRA (LT), then another set of 15 images was circulated to a mailing list of the GIEQs (Gastrointestinal Endoscopy Quality and Safety) foundation. Each image contained the same questions: Is this a resection scar? Is there RRA? What is your level of confidence? Information on the participant was obtained: number of EMRs performed, grade (consultant vs trainee) and years of experience. Comparisons were made to expert opinion derived at a consensus meeting of the senior authors regarding the appearances of the scars using the approach set out in Desomer et al. 2017.||||
34049536|NCT04896346|||OTHER||PROSPECTIVE|||||||
34049537|NCT05879523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HRS-1893 compared with placebo|t|t|t|t
34049538|NCT02070016|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34049539|NCT04298905|RANDOMIZED|PARALLEL||OTHER||NONE||Study design overview: LEAP-TB-SA is a pilot randomized controlled trial. There are two arms: mHealth intervention (100) and health education control (100).||||
34049540|NCT02591901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049541|NCT06660381|NA|SINGLE_GROUP||TREATMENT||NONE|No masking, open-label study.|Each participant will undergo two open-label psilocybin dosing sessions (25 mg followed by 25mg or 35 mg).||||
34049542|NCT03378219|||COHORT||PROSPECTIVE|||||||
34049543|NCT06684808|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049544|NCT00003101||||TREATMENT||||||||
34049545|NCT06615401|||COHORT||RETROSPECTIVE|||||||
34049546|NCT02693171|||COHORT||PROSPECTIVE|||||||
34153007|NCT00472966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153008|NCT01420822|||||PROSPECTIVE|||||||
34153009|NCT01181674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153010|NCT05454878|||COHORT||PROSPECTIVE|||||||
34153011|NCT05702086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153012|NCT05293678|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34153013|NCT01816802|||COHORT||PROSPECTIVE|||||||
34153014|NCT03256253|NA|SINGLE_GROUP||TREATMENT||NONE||open label pilot study||||
34153015|NCT00164411|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34153016|NCT03194360|||CASE_CONTROL||RETROSPECTIVE|||||||
34153017|NCT02093338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153018|NCT00450073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153019|NCT04806802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153020|NCT01075737|||CASE_CONTROL||PROSPECTIVE|||||||
34153021|NCT00541853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153022|NCT02349750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153023|NCT02795091|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34153024|NCT04424927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153025|NCT00304863|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34153026|NCT05686642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153027|NCT04156594|||COHORT||PROSPECTIVE|||||||
34153028|NCT05931991|||CASE_ONLY||PROSPECTIVE|||||||
34153029|NCT06220019|||COHORT||PROSPECTIVE|||||||
34153030|NCT03057080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153031|NCT02800265|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764407|NCT06613529|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33764408|NCT05536843|||OTHER||PROSPECTIVE|||||||
33764409|NCT01602757|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764410|NCT00212901|RANDOMIZED|CROSSOVER||||NONE||||||
33945035|NCT04020042|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945036|NCT02904317|||CASE_CONTROL|||||||||
33945037|NCT00372073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945038|NCT04748731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049547|NCT06681857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049548|NCT06569173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049549|NCT05631093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049550|NCT05730959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049551|NCT04666259|RANDOMIZED|PARALLEL||TREATMENT||NONE|Cohort A and B will be randomized but not C|||||
34153032|NCT04409093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153033|NCT03341455|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Allocation of interventions cannot be concealed from either training staff or study participants once implementation occurs.~All data collectors will be blinded to the intervention status of preschools.~The study will be presented as a project related to family health and wellbeing, no specific study hypotheses will be presented to participants, and data collectors will not be involved in delivering the intervention. However, parents at preschools receiving the intervention will be aware of the training activities, and may still link the intervention to survey activities."|The study will be implemented using a randomised controlled trial design. Parents with children attending government-managed preschools in two study areas will be recruited to participate. Preschools will be randomly assigned to an intervention or control group. Preschool teachers in the intervention group will also be recruited to participate.|t|f|f|f
34153034|NCT01635803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153035|NCT06508229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153036|NCT02825212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153037|NCT02562807|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34153038|NCT03706300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153039|NCT00737633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049552|NCT02355938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049553|NCT05557643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2-arm, randomized, open-label trial for 24 participants.|f|f|f|t
34049554|NCT02355821|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34049555|NCT03328871|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34049556|NCT04859400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049557|NCT06675526|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A two-armed RCT (Detour vs digital self-help material to quit smoking as the control group) will be conducted to test the efficacy of Detour.~All participants fill out Qualtrics questionnaires comprising self-report measures at screening, pre-test, post-test, 3-month follow-up, and 6-month follow-up. In addition, participants in the game group answer some questions in the mobile application, participant in-game behaviour (such as time spent playing) is measured, and text-data from the player chat room and social shell will be used."||||
34049558|NCT06230861|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34049559|NCT03179020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In the present study ICUs will be randomized to manage potential organ donors through the use of a evidence-based checklist or to manage potential organ donors according usual care.||||
34049560|NCT03575793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049561|NCT02180139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049562|NCT00957268|NON_RANDOMIZED|PARALLEL||||NONE||||||
34049563|NCT06240702|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a randomized controlled clinical trial with 2 groups, experimental and control. The experimental group will be treated with telerehabilitation while the control group will not.||||
34049564|NCT05459402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be done to prevent biasing participants or staff about the suspected group assignments. Blinded medication doses will be over-encapsulated by the research pharmacy, which will manage all randomization and blinding. Participants will be informed as part of their enrollment that no increases in methadone dosing will be permitted during the active intervention period; dose decreases will be permitted if determined necessary for safety purposes by medical providers and any changes will be implemented in a double-blinded manner by the study pharmacist.|Participants will be enrolled for a 14-week Phase II between-group intervention period followed by a 6-month follow-up period with once monthly visits. All participants will be transitioned from liquid to tablet methadone within a 1 to 2-week period before being randomized to treatment as usual versus split daily methadone dosing for a 12-week period. Participants will complete monthly follow-up visits during months 4 - 9.|t|t|t|t
34049565|NCT01054274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049566|NCT05265442|||COHORT||PROSPECTIVE|||||||
34049567|NCT04921592|NA|SINGLE_GROUP||OTHER||NONE||Randomized into 1 of 3 groups||||
34049568|NCT01553604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34049569|NCT04448457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049570|NCT00966004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049571|NCT02471352|||COHORT||PROSPECTIVE|||||||
34049572|NCT03909061|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Subjects will be choose to be in one of three groups: one group will receive maintenance training immediately with no follow up, one group will receive the maintenance training immediate with a 1 month \& 6 month follow up, and one group that will be randomized to either receive the maintenance training immediately or to receive the maintenance training after a 6 month wait (with follow ups).|This is a randomized single blind study.||||
34049573|NCT01713010|||CASE_ONLY||PROSPECTIVE|||||||
34049574|NCT02555787|||COHORT||PROSPECTIVE|||||||
34049575|NCT03123835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049576|NCT03174873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049577|NCT05902026|||OTHER||CROSS_SECTIONAL|||||||
34049578|NCT04169048|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial with intervention group and waiting group (treatment as usual)||||
34049579|NCT06663189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049580|NCT04879121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049581|NCT00230854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049582|NCT00003416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049583|NCT06098729|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34049584|NCT00741533|||CASE_ONLY||PROSPECTIVE|||||||
34049585|NCT05929677|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34049586|NCT05521698|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participants and the study team will be blinded.||t|t|t|t
34049587|NCT06060158|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot feasibility study looking at delivering small group therapy online.||||
34049588|NCT01703806|||COHORT||PROSPECTIVE|||||||
34153040|NCT05652153|NA|SINGLE_GROUP||OTHER||NONE||Two cohorts of adolescents (40 with current depression and prior suicidal ideation, but no prior suicidal behavior, Dep/SI group; 40 with depression and prior suicidal behavior \[an interrupted or aborted attempt, or suicide attempt\], Dep/SB group) will be followed longitudinally for 12 months. Measurement of clinical scales, negative urgency, and neurophysiology (TMS-EEG measurement of cortical inhibition) will be collected at baseline, 6 months, and 12 months. There is no allocation to an intervention.||||
34153041|NCT00209300|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34153042|NCT00357825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153043|NCT05648565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153044|NCT02193412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153045|NCT02816229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153046|NCT04456374|||COHORT||CROSS_SECTIONAL|||||||
33945039|NCT00983125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34049589|NCT01352949|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049590|NCT00179777|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049591|NCT06682897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049592|NCT01985191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049593|NCT00067301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34049594|NCT00981214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049595|NCT00849511|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34049596|NCT06684834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A randomised, three-arm parallel-group study||||
33945040|NCT02944058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33945041|NCT01006785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049597|NCT06066996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34153047|NCT04708509|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label, multi-center interventional Phase 1 study to implement and evaluate perceptions of Extubation Advisor in consenting patients in the intensive care unit.||||
34153048|NCT04836247|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049598|NCT00761280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049599|NCT01856478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153049|NCT05049187|||COHORT||PROSPECTIVE|||||||
34153050|NCT01854424|||CASE_ONLY||PROSPECTIVE|||||||
34153051|NCT03544307|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel design with treatment group and control||||
34153052|NCT04680819|||COHORT||PROSPECTIVE|||||||
34153053|NCT00094107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153054|NCT05047432|||OTHER||CROSS_SECTIONAL|||||||
34153055|NCT03550235|||CASE_ONLY||PROSPECTIVE|||||||
34049600|NCT05147402|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No masking; open label|Participants who are enrolled in the study will be randomized to 1 of 2 dosing regimens, both of which receive the same intervention in opposite order. Group 1 receives a Fasted Treatment followed by a Fed Treatment, while Group 2 receives a Fed Treatment followed by a Fasted Treatment.||||
34049601|NCT06682741|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049602|NCT04689854|||COHORT||PROSPECTIVE|||||||
34049603|NCT06669884|||COHORT||PROSPECTIVE|||||||
34049604|NCT06683079|||COHORT||PROSPECTIVE|||||||
34049605|NCT03827330|||COHORT||RETROSPECTIVE|||||||
34049606|NCT05636215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049607|NCT06684145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34049608|NCT04523103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049609|NCT04900753|||COHORT||PROSPECTIVE|||||||
34049610|NCT06601634|||COHORT||PROSPECTIVE|||||||
34049611|NCT02788396|||COHORT||PROSPECTIVE|||||||
34049612|NCT06600087|||COHORT||PROSPECTIVE|||||||
34049613|NCT02288845|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34153056|NCT05265897|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||"Alternating intervention controlled trial where treatment assignment was alternated weekly.~Participants who underwent baseline or annual lung cancer screening were assigned to receive a mailing within one week of their scan, either: 1) usual care: a brief form letter with screening results; or 2) usual care plus Commonly Asked Questions informational document (intervention)."|t|t|f|t
34153057|NCT01868334|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34153058|NCT01099436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153059|NCT05207683|||COHORT||CROSS_SECTIONAL|||||||
34153060|NCT03076723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153061|NCT00025246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153062|NCT04253587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|After recruitment, participants are randomly assigned to treatment arms. Participants and experimenters with whom they interact during the experiments are blind to the purpose of the randomly-assigned arm. First-level analysis performed blind to participant's treatment arm.||t|f|f|t
33764411|NCT00635765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764412|NCT06284317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764413|NCT00799695|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33945042|NCT03898882|||COHORT||PROSPECTIVE|||||||
33945043|NCT03728647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study used a randomized repeated-measures experimental design. The experimental group received a multimedia health education program and the control group received a regular health education program.|f|f|f|t
33945044|NCT04391192|NA|SINGLE_GROUP||OTHER||NONE||Feasibility of using a phone line to provide overdose response.||||
33945045|NCT04384120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33945046|NCT00758576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945047|NCT01291420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945048|NCT02383966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945049|NCT05492552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945050|NCT06241495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33945051|NCT03260543|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33945052|NCT00490815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764414|NCT04072341|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective, open-label, proof-of-concept, single-center. Each patient served as their own control.||||
34049614|NCT01625819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34049615|NCT03778918|||COHORT||PROSPECTIVE|||||||
34049616|NCT00277303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049617|NCT05831644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34049618|NCT04864886|||CASE_CONTROL||PROSPECTIVE|||||||
34049619|NCT06667362|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34049620|NCT05076669|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomised, comparative, controlled, national and multi-centre study with minimal risks and constraints to routine care.||||
34049621|NCT05039684|||COHORT||CROSS_SECTIONAL|||||||
34049622|NCT03602235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049623|NCT01527695|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34049624|NCT02737969|||COHORT||PROSPECTIVE|||||||
34049625|NCT06302153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049626|NCT05195255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34049627|NCT05214183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049628|NCT02410785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049629|NCT02043769|||COHORT||PROSPECTIVE|||||||
34049630|NCT04971850|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049631|NCT04455191|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34049632|NCT01640379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34049633|NCT03557931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049634|NCT04732546|||COHORT||RETROSPECTIVE|||||||
34049635|NCT03961061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The control group will receive standard Brenner FIT care. The intervention group will receive standard Brenner FIT care in additional to mobile health components in the hopes of maximizing the benefits that are already seen with pediatric weight management programs like Brenner FIT.|f|f|f|t
33945053|NCT02967393|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049636|NCT06395506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study plans to enroll 30 breast cancer patients who have completed chemotherapy within 6 months prior to consenting for this study. Each arm will have 15 participants. One arm will receive creatine and the other will serve as the control group with no creatine.||||
34049637|NCT02669836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049638|NCT04124341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049639|NCT00224328|||DEFINED_POPULATION||PROSPECTIVE|||||||
34049640|NCT06458582|NA|SINGLE_GROUP||OTHER||NONE||||||
34049641|NCT01339637|||COHORT||CROSS_SECTIONAL|||||||
34049642|NCT06610578|||COHORT||PROSPECTIVE|||||||
34049643|NCT03835624|||CASE_CONTROL||PROSPECTIVE|||||||
34049644|NCT05621746|||COHORT||PROSPECTIVE|||||||
34049645|NCT02261948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049646|NCT06458036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049647|NCT02228798|||COHORT||PROSPECTIVE|||||||
34049648|NCT06683027|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"There are two conditions.~1: Experimental group receives access to the online intervention immediately. 2. Treatment as Usual (TAU) group receives delayed (10 weeks) access to the intervention."||||
34049649|NCT03275974|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049650|NCT06545669|RANDOMIZED|PARALLEL||TREATMENT||NONE|The statistical analyst will not be made aware of which treatment group received the intervention.|Eligible participants are randomly assigned to intervention or no intervention. Outcomes for those who receive the intervention will be compared to outcomes for those who do not receive the intervention. Those who do not receive the intervention during the initial study period will receive it at the end, to ensure access to treatment for all participants.||||
34049651|NCT05817539|RANDOMIZED|PARALLEL||OTHER||SINGLE|"For this protocol, the double blind is impossible to set up. Clinicians in charge of patients and implementing the depletion strategy cannot be blinded.~The patients will be blinded, they will not be aware of strategy applied. The medical staff will ensure that no information about the intervention is given to the patient."||t|f|f|f
34049652|NCT06263855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049653|NCT01187680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049654|NCT05974488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34075718|NCT03216707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075719|NCT01216878|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153063|NCT03951116|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Phase 1 Dose escalation study||||
34153064|NCT04896593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153065|NCT02579681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153066|NCT05504005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945054|NCT00324519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153067|NCT03872791|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34153068|NCT04693351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153069|NCT02913495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153070|NCT02975726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153071|NCT02836431|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945055|NCT03063515|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34153072|NCT04794023|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I~* Successful unilateral treatment of the dominant eye according to standard of care prior to investigational treatment~* Unilateral investigational treatment on an amblyopic eye or a post-cataract eye~* 4 eyes \& 4 participants~* Staged patient enrolment, to allow assessment and evaluation of safety parameters before investigational treatment is applied to the next participant~* Interim analysis I - Verification of correction factor when all participants have reached 7 days follow-up~Phase II~* Initiated after Interim analysis I~* Successful unilateral treatment of the dominant eye according to standard of care prior to investigational treatment~* Unilateral investigational treatment on the non-dominant eye~* 10 eyes \& 10 participants~* Interim analysis II - Confirmation of correction factor when all participants have reached 7 days follow-up~Phase III~* Initiated after Interim analysis II~* Bilateral investigational treatment~* 26 eyes \& 13 participants"||||
34153073|NCT05831605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153074|NCT06086483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, placebo-controlled|t|t|t|f
34153075|NCT05754593|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153076|NCT00230503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153077|NCT00124410|||CASE_ONLY||PROSPECTIVE|||||||
34153078|NCT05417191|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34153079|NCT02092311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153080|NCT02163421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153081|NCT06228898|||COHORT||PROSPECTIVE|||||||
34153082|NCT05021575|||COHORT||RETROSPECTIVE|||||||
34153083|NCT06392269|||CASE_ONLY||PROSPECTIVE|||||||
33945056|NCT03856242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945057|NCT04460495|NA|SINGLE_GROUP||OTHER||NONE||oxygen-enhanced molecular MRI in healthy volunteers.||||
33945058|NCT01012765|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33945059|NCT06493617|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33945060|NCT03887143|||COHORT||RETROSPECTIVE|||||||
33945061|NCT04226209|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33945062|NCT05689645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153084|NCT04859374|RANDOMIZED|PARALLEL||OTHER||SINGLE|None (Open Label)||t|f|f|f
33945063|NCT02074527|||OTHER||CROSS_SECTIONAL|||||||
34075720|NCT04072250|||CASE_CONTROL||RETROSPECTIVE|||||||
34153085|NCT03950310|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open -but assessors are blinded|||||
34153086|NCT02905487|||COHORT||CROSS_SECTIONAL|||||||
33945064|NCT05416086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153087|NCT03612908|||CASE_CONTROL||PROSPECTIVE|||||||
34049655|NCT05088603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The neurologist will wear the mask type assigned by randomization for the duration of involvement in the surgery. At the conclusion of the neurologist's interaction with the participant, the participant will be asked a series of questions to evaluate the communication experience. This step will be performed by another member of the study team (not the participating neurologist) who will read from the questionnaire and record the participant's responses. During questioning, the neurologist will step out of the operating room to reduce potential bias from the participants answering subjective questions in front of the neurologist.||||
34049656|NCT01783028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049657|NCT05323240|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34049658|NCT06682780|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049659|NCT06001333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049660|NCT03751735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049661|NCT02776267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049662|NCT06684730|||OTHER||PROSPECTIVE|||||||
34049663|NCT03148860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Methotrexate tablets will be encapsulated equal to Placebo to ensure blinding. Ustekinumab will be open-label|randomised, placebo-controlled, double-blind, multicenter study|t|t|t|f
34049664|NCT01694290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049665|NCT06305598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049666|NCT06325566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049667|NCT02798549|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34049668|NCT03649490|||COHORT||PROSPECTIVE|||||||
34049669|NCT04439227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049670|NCT03840395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34049671|NCT01279759|||||PROSPECTIVE|||||||
34049672|NCT04117620|||CASE_CONTROL||PROSPECTIVE|||||||
34049673|NCT01489215|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34049674|NCT03116581|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34153088|NCT02272166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34049675|NCT02819752|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049676|NCT05906563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blinded study||t|t|t|f
34049677|NCT06667778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049678|NCT06062121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049679|NCT05143229|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Standard 3+3 dose escalation||||
34049680|NCT06154980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049681|NCT06271772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049682|NCT00812981|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34049683|NCT05819086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049684|NCT05934604|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Phase 2 is not blinded.|||||
34049685|NCT03961958|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"In phase 1, target-controlled infusion propofol anesthesia was adjusted to maintain BIS 40 to 60.~In phase 2, there were 2 planned reductions in propofol target concentration: (1) immediately after loss of consciousness - reduction calculated using a predefined formula, and (2) before positioning - reduction equal to the average percentage decrease in CO after knee-chest position in phase 1."||||
34049686|NCT01665950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049687|NCT06682156|||COHORT||PROSPECTIVE|||||||
34049688|NCT05902273|||CASE_ONLY||PROSPECTIVE|||||||
34049689|NCT03428113|||CASE_ONLY||OTHER|||||||
34049690|NCT06113328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049691|NCT02685358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The CAPS-5 will be administered via phone by a central assessor, blind to condition, at baseline and post-treatment and will be the primary measure of change in PTSD symptom severity.|Clinician-Supported PTSD Coach (CS PTSD Coach) consists of four 20-30 minute sessions focused on instructions for using the PTSD Coach app, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for completion between sessions. PC-MHI providers deliver CS PTSD Coach using a treatment manual, which was developed and piloted by the PIs. Session 1 will be face-to-face and sessions 2-4 may be face-to-face or by phone, depending on patient preference. To help participants overcome treatment barriers psycho-education about treatment options are provided and active problems solving is encouraged. Specific next steps for treatment or self-management are developed collaboratively, typically in session 4. After session 4, Participants are encouraged to continue using PTSD Coach and have access to the research version of the app until the 24-week follow-up.|f|f|f|t
34049692|NCT05197530|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34049693|NCT03784482|||COHORT||RETROSPECTIVE|||||||
34049694|NCT06023446|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049695|NCT05251831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The 40 patients with alopecia areata will be divided into 2 groups:~Group A: 20 patients will be treated by activated PRP with Calcium chloride (CaCl2). Those patients will be treated with an intradermal injection.~Group B: 20 patients will be treated by non-activated PRP through intradermal injection"|t|t|f|t
34049696|NCT06682806|NA|SEQUENTIAL||TREATMENT||NONE||||||
34049697|NCT05170529|||OTHER||CROSS_SECTIONAL|||||||
34049698|NCT05202353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049699|NCT04290910|NA|SINGLE_GROUP||OTHER||NONE||||||
34049700|NCT01167114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049701|NCT01075035|||CASE_CONTROL||PROSPECTIVE|||||||
34049702|NCT06684210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34049703|NCT05887258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049704|NCT04094038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049705|NCT03523364|||COHORT||RETROSPECTIVE|||||||
34049706|NCT02981082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049707|NCT03108768|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Phonak Virto V and the successor of Phonak Virto V will be fitted to the participants individual hearing loss.|t|f|f|f
34049708|NCT06366516|NA|SINGLE_GROUP||SCREENING||NONE||Women who aged 25 to 65 years are screened for cervical cancer and they are all positive of high-risk HPV.||||
34049709|NCT06220175|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34049710|NCT03618173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049711|NCT00151190|RANDOMIZED|PARALLEL||||NONE||||||
34049712|NCT04996160|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049713|NCT03196466|||COHORT||RETROSPECTIVE|||||||
34049714|NCT00449358|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049715|NCT02229175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34049716|NCT06366464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049717|NCT00915876|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34049718|NCT05069025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049719|NCT01590121|||OTHER||RETROSPECTIVE|||||||
34049720|NCT02828046|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34049721|NCT02698332|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34049722|NCT02578121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049723|NCT00347464|||CASE_ONLY||PROSPECTIVE|||||||
34049724|NCT03171038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, multi-center randomized controlled trial|f|f|t|t
34049725|NCT03261674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel: participants are assigned to one of two or more groups in parallel for the duration of the study.|f|f|f|t
34049726|NCT06384911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049727|NCT05397535|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34049728|NCT02379377|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cohorts A and B are Parallel. Cohorts C and D are Single Group. Cohorts E and F Single Group||||
34049729|NCT04448834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049730|NCT05824520|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34049731|NCT00594100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049732|NCT03604679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049733|NCT05854667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All participants will receive identical capsules (i.e., smell, taste, and colour), reducing bias by blinding participants, providers, and research staff to the study drug.~To maintain the blinding of the study medication, dose adjustments will be known by Qualified Investigators and the Pharmacy team according to the Induction Phase schedule and at the Investigator's discretion, without unblinding the study medication (i.e., LDX-01 versus placebo) except for some limited safety related reasons. Access to the randomization code will be strictly controlled by the Data Management Centre. Each participant's assignment will be kept so that an individual code may be broken without unblinding the randomization allocation of other participants."|"Participants will be randomized to one of four arms:~1. Treatment as Usual with Placebo~2. Treatment as Usual with Placebo and Contingency Management~3. Treatment as Usual with Lisdexamfetamine (LDX-01)~4. Treatment as usual with Lisdexamfetamine (LDX-01) and Contingency Management"|t|t|t|f
34049734|NCT04212884|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049735|NCT04991077|||CASE_CONTROL||PROSPECTIVE|||||||
34049736|NCT00967785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049737|NCT02890485|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34049738|NCT04164043|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will enter a 14 week baseline data collection period followed by a 12-week Wellness Recovery Program||||
34049739|NCT04767594|||COHORT||PROSPECTIVE|||||||
34049740|NCT05946317|NA|SINGLE_GROUP||TREATMENT||NONE||The research sample included 20 patients from the Faculty of Dentistry in Tishreen University and maxillofacial surgery department in Tishreen Hospital who had have an impacted mandibular third molar indicated for extraction and their age under 25 years.||||
34049741|NCT06150716|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33945065|NCT06070246|||CASE_CROSSOVER||PROSPECTIVE|||||||
34049742|NCT00575783|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049743|NCT05657197|RANDOMIZED|PARALLEL||TREATMENT||NONE|Multicentre parallel randomised controlled trial|||||
34049744|NCT01080118|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34049745|NCT05814016|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34049746|NCT04081220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049747|NCT02655991|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049748|NCT04533646|NA|SINGLE_GROUP||TREATMENT||NONE||This study design involves a within-subjects comparison using a sequential cross over that occurs over a 2-week time frame. During the first seven days of wear, the participants will be asked to dose their mealtime rapid-acting insulin by fixed-dose, and the next seven days, participants will be asked to dose their mealtime rapid-acting insulin by carbohydrate counting. After the 14 days, participants will return their continuous glucose monitor (CGM) devices for analysis and interpretation.||||
34049749|NCT06457191|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34049750|NCT00650325|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34049751|NCT04052386|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were randomized into one of two conditions (BASICCS intervention and control \[assessment-only\]).|Participants will be randomly assigned to one of two conditions (BASICCS and assessment-only control group).|t|f|f|f
33945066|NCT02221804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945067|NCT02337816|||CASE_CONTROL||PROSPECTIVE|||||||
33945068|NCT04781127|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33945069|NCT00837720|||||PROSPECTIVE|||||||
33945070|NCT04673760|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Patients with a new medical indication for specialized palliative home care are assigned to intervention arm.~Patients without a new indication for specialized palliative home care are controls ."|t|f|f|f
34049752|NCT04084561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049753|NCT01756794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049754|NCT05364021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049755|NCT05170152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33945071|NCT06157970|||CASE_CONTROL||RETROSPECTIVE|||||||
34049756|NCT04199000|||CASE_ONLY||OTHER|||||||
34049757|NCT00565877|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34049758|NCT06178523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Clinical investigator; the Radiologist, and Biostatistician; data analyst).|Couples with unexplained infertility (n=900) were divided into three equal groups. Group-A received Sildenafil Citrate (Viagra®) and Clomiphene Citrate (Clomid®). Group-B received Clomiphene Citrate (Clomid®) and subjected to intra-uterine insemination (IUI). Group-C received Clomiphen Citrate (Clomid®) alone (Control group).|f|f|t|t
34049759|NCT06006247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049760|NCT05237102|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34049761|NCT05239403|||COHORT||PROSPECTIVE|||||||
34049762|NCT01567345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049763|NCT04117646|||CASE_CONTROL||PROSPECTIVE|||||||
34049764|NCT02069912|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34049765|NCT06342401|||CASE_CONTROL||RETROSPECTIVE|||||||
34049766|NCT05746416|||CASE_CONTROL||PROSPECTIVE|||||||
34049767|NCT04946994|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will first be randomized to continuous moderate intensity or high-intensity interval training for 16 weeks.||||
34049768|NCT06682923|||COHORT||PROSPECTIVE|||||||
34049769|NCT03492762|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2 groups: Healthy Volunteers and Volunteers with Documented ILD Diagnosis||||
34049770|NCT06684795|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A total of 40 patients are planned for enrolment. The study will include two arms, where one arm will consist of patients with presumed low-grade gliomas (pLGG) and one with meningiomas.~Initially, 20 patients (pLGG=10 and meningioma=10) will be enrolled in the trial followed by an interim analysis. Here, further modifications in the trial with respect to dose administration time and administered dose is possible before enrolment of the last 20 patients (pLGG=10 and meningioma=10)."||||
34049771|NCT01623635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153089|NCT06486415|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"In participants with clinically suspected ectopic pregnancy who come to the Gynecology clinic with menstrual delay and high Beta Human Chorionic Gonadotropin (BHCG) levels, serum BHCG values will be checked 5 times with 2-hour intervals on the same day. 10 ectopic pregnancy and 10 normal pregnancy patients will be included in the study. The serum BHCG increase trend of patients whose normal pregnancy was clinically detected by ultrasound despite the suspicion of ectopic pregnancy, and the change trend in serum BHCG of patients whose diagnosis of ectopic pregnancy is confirmed will be analyzed and compared. Diagnostic criteria for BHCG change in ectopic pregnancy will be established according to the differences in the serum BHCG increase trend.~This is an interventional study. Taking 5 blood samples of the ectopic pregnancy patients in the same day are the interventions of the study."||||
34049772|NCT04726072|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomly assigned to one of two groups for the duration of the study. One group was a Kundalini Yoga intervention while the other was a psychoeducation control group.||||
34049773|NCT00737295|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049774|NCT03374501|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34049775|NCT00556010|||COHORT||PROSPECTIVE|||||||
34049776|NCT06532812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049777|NCT00061867||||TREATMENT||NONE||||||
34049778|NCT01694069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049779|NCT06530680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049780|NCT01105078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049781|NCT06160115|||CASE_CONTROL||PROSPECTIVE|||||||
34049782|NCT00800774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049783|NCT06257927|NA|SINGLE_GROUP||TREATMENT||NONE||The study will follow a single case (N of 1) series design. Pre-post changes will be measured, and repeated measures will be administered before, during, and following the intervention to track change over time. The timing of entry into the study and the numbers of repeated measures data points are randomized across families. Data analysis will aim to (a) identify patterns of change over the course of the intervention and (b) relate change trajectories to theorized mechanisms of action.||||
34049784|NCT05280366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049785|NCT06109246|||CASE_ONLY||PROSPECTIVE|||||||
34153090|NCT03530501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34153091|NCT01353911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153092|NCT04100941|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34153093|NCT06070909|||COHORT||CROSS_SECTIONAL|||||||
34153094|NCT06531317|||COHORT||PROSPECTIVE|||||||
34153095|NCT06502847|||CASE_CONTROL||PROSPECTIVE|||||||
34153096|NCT02727491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153097|NCT05234203|NA|SINGLE_GROUP||OTHER||NONE||Prospective, interventional, single-arm, open-label pilot study||||
34153098|NCT02175368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049786|NCT04831827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Investigators will be blinded to study arm; research coordinators will not be blinded because it is not practical to do so, but steps will be taken to minimize their awareness about study hypotheses.||f|f|t|f
34049787|NCT03258658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049788|NCT06665360|||OTHER||OTHER|||||||
34049789|NCT02291601|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34049790|NCT03005743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049791|NCT06388616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Three cohorts (two hepatic impairment cohorts and controls with normal hepatic function) will be enrolled into this study.~All subjects will receive the study intervention:~* Cohort 1 will enroll 8 participants with mild hepatic impairment~* Cohort 2 will enroll 8 participants with moderate hepatic impairment~* Cohort 3 will enroll 8-12 healthy participants matched on a group level regarding age, BMI and sex"||||
34049792|NCT00323401|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34049793|NCT05202158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049794|NCT01953601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34049795|NCT03745690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049796|NCT04693832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049797|NCT05833113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049798|NCT06152185|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The research associates who interact with participants following randomization will be blind to condition. The study coordinator and investigators will not be blind to condition; they will be responsible for interacting with participants during the intervention but will not be involved in post-randomization data collection.|Participants will be randomly assigned to the Mindfulness intervention (n = 90) or Enhanced Usual Care (n = 60) using a 3:2 randomization sequence.|f|f|f|t
34049799|NCT05444725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Self administered questionnaire||||
34049800|NCT06681259|||COHORT||PROSPECTIVE|||||||
34049801|NCT04801147|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, 2-stage Simon design (Simon et al., 1997), single-centre, uncontrolled, open label, non-randomized study.||||
34049802|NCT06089109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049803|NCT04974281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049804|NCT06136598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049805|NCT05692830|||OTHER||OTHER|||||||
34049806|NCT03418584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049807|NCT05108350|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be two independent cohorts of subjects who will each receive two treatments (high dose strength and low dose strength), and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability. In each cohort approximately 40 healthy subjects will be randomized to receive treatment with IP to complete at least 36 evaluable subjects.||||
33945072|NCT04143815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049808|NCT06514430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049809|NCT01337492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049810|NCT06683144|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34049811|NCT02000700|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049812|NCT05292989|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Deidentified data|Prospective randomized controlled trial design|f|f|f|t
34049813|NCT02799667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34049814|NCT06632184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No additional parties beyond participants, care providers, investigators, and outcomes assessors are masked in this study.|This study employs a parallel assignment model, in which participants are randomly assigned to one of two groups. One group will receive ondansetron combined with bicarbonate for intraperitoneal administration, while the other group will receive ondansetron in saline solution. Each group will receive their respective treatment throughout the study period, and outcomes such as postoperative pain intensity, need for rescue analgesia, and occurrence of nausea or vomiting will be measured and compared between the groups. No crossover of treatments between groups will occur.|t|t|f|t
34049815|NCT04697420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34049816|NCT05338502|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34049817|NCT02683928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049818|NCT05846490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049819|NCT01512446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34049820|NCT02717416|RANDOMIZED|PARALLEL||TREATMENT||NONE||After randomization, patients in both group will undergo endoscopic hemostasis with epinephrine injection therapy. In the study group, Endo-clot will be applied after epinephrine injection therapy. In the control group, hemoclip will be applied after epinephrine injection therapy. The efficacy of Endo-Clot and hemoclip will be compared.||||
34049821|NCT06503783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049822|NCT05588973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The present study is a double-blinded pilot randomized controlled trial with skin cosmetic products aimed at breast and head and neck cancer patients who will undergo radiation therapy. For the study, individuals will be sought from the German Oncology Center of Limassol. The study will include 80 patients of the German Oncology Center who will be diagnosed with breast cancer and will undergo radiotherapy and 20 patients with head and neck cancer who will also undergo radiotherapy. Individuals included in the study will be over 18 years of age and will have signed written consent to participate in the program. This study will involve 100 patients. Patients will be randomized, (giving a number to each patient) into 2 homogeneous groups of 50 people, either to the control group using panthenol (placebo), or to the intervention group using MEDISKIN.|t|t|f|t
34049823|NCT06682364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049824|NCT00494052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34049825|NCT01522001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049826|NCT03464370|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This pilot study is prospective, monocentric, epidemiologic, case control||||
34049827|NCT00890708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34049828|NCT05284708|NA|SINGLE_GROUP||OTHER||NONE||Single Group Usability Observational Study, Operators||||
34049829|NCT01639404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049830|NCT03681678|||COHORT||PROSPECTIVE|||||||
34049831|NCT04617834|||COHORT||PROSPECTIVE|||||||
34049832|NCT06685419|||OTHER||PROSPECTIVE|||||||
34049833|NCT04540159|||CASE_CONTROL||PROSPECTIVE|||||||
34049834|NCT00068367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049835|NCT05278546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049836|NCT03297606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153099|NCT02501525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153100|NCT05271851|||OTHER||CROSS_SECTIONAL|||||||
34153101|NCT01065831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153102|NCT05364320|||COHORT||PROSPECTIVE|||||||
33945073|NCT02195531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945074|NCT04584827|||OTHER||PROSPECTIVE|||||||
33945075|NCT05131139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049837|NCT01068210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049838|NCT06453928|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial.||||
34049839|NCT05608460|||COHORT||PROSPECTIVE|||||||
34049840|NCT06462352|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34153103|NCT04919096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153104|NCT03856203|||COHORT||PROSPECTIVE|||||||
34153105|NCT01362387|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34153106|NCT03161574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049841|NCT03951064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the obvious treatment differences between the two groups, blinding of treatment group will be impossible. However, the investigators will have one outcome assessor who will have access only to the data necessary to determine the primary outcome (Ventilator-Free Days at 28-days), and this assessor will be blinded to treatment group using built-in REDCap tools.||f|f|f|t
34049842|NCT03258541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049843|NCT06557122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049844|NCT03395080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049845|NCT02776891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049846|NCT01103258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049847|NCT06484348|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A total of 20 NT1 patients, 20 IH patients and 20 Healthy Controls (HC) matched for age and gender will be prospectively included. The NT1 patients and HC groups will also matched for and be split into 2 subgroups of 10 participants according to BMI (\<25 kg/m2 and ≥ 25 kg/m2). IH will be matched to NT1 for wake-promoting drugs dosage.||||
34049848|NCT03706430|NA|SEQUENTIAL||OTHER||NONE||||||
34049849|NCT05717049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049850|NCT06667934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049851|NCT03282721|||CASE_CONTROL||RETROSPECTIVE|||||||
34049852|NCT03551769|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34049853|NCT04505267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049854|NCT03105479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor masking in Part B only (no masking in Part A)||f|f|f|t
34049855|NCT06122012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049856|NCT04331977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049857|NCT04439968|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Assessors of neurodevelopmental outcome are blinded to targeted vs non-targeted monitoring|randomized to 2 groups: Targeted NIRS monitoring vs Non-targeted, blinded NIRS monitoring|f|f|f|t
34049858|NCT05558982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049859|NCT02549287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049860|NCT06630364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049861|NCT06665542|||COHORT||OTHER|||||||
34049862|NCT04428476|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Extension of the HOPE-2 Trial||||
34049863|NCT06683404|||COHORT||PROSPECTIVE|||||||
34049864|NCT04020692|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization"||||
34049865|NCT04914884|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049866|NCT03246308|||OTHER||PROSPECTIVE|||||||
34049867|NCT03072589||SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34049868|NCT00535717|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049869|NCT05364593|||COHORT||PROSPECTIVE|||||||
34049870|NCT03804424|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Images will be assessed by independent observers (nuclear medicine expert in evaluating PET images using novel radiotracers, and MR radiologist expert in evaluating MR images), who will initially be blinded to all clinical information available (such as tumor size and location), which will be followed by un-blinded combined reading of the PET and MR images||f|f|t|f
34049871|NCT06205498|||OTHER||RETROSPECTIVE|||||||
34049872|NCT03927521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049873|NCT06204471|RANDOMIZED|CROSSOVER||OTHER||NONE||Pilot study of two months, then crossed over to the other for two months||||
34049874|NCT05761886|RANDOMIZED|PARALLEL||TREATMENT||NONE||the target sample size in our pilot study is 72 in the intervention group. The target for the control group is 168.||||
34049875|NCT05975034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Computerised randomisation by a researcher in a separate department, probiotic/placebo packaged in identical bottles (label indicates group A or B). Probiotic/placebo delivered directly from supplier to participants (without involvement of the investigators).|Double-blinded randomised trial|t|t|t|t
34049876|NCT04754412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33764415|NCT01933971|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33764416|NCT02139657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764417|NCT02955121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33764418|NCT02027480|||||PROSPECTIVE|||||||
33764419|NCT00063102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049877|NCT06582784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049878|NCT06066619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 126 healthy participants will be recruited. Inclusion criteria includes body weight ≥110 pounds, age 30-55, BMI 18.9-29.9 kg/m\^2, and education level high school and above. A stratified block randomization will be applied to separate participants into three different beverage groups. Three-digit codes will be assigned to different beverages. This coding process should be conducted by an individual who is not involved in the study. Maintain blinding by using the coded treatment labels during the study can help to eliminate potential biases in the assessment of outcomes.|t|f|t|f
34153107|NCT03772171|||COHORT||PROSPECTIVE|||||||
34153108|NCT05832749|||COHORT||PROSPECTIVE|||||||
34049879|NCT06053203|||COHORT||CROSS_SECTIONAL|||||||
34049880|NCT05821959|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049881|NCT05032495|||CASE_CONTROL||PROSPECTIVE|||||||
34049882|NCT01983943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34049883|NCT04833894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049884|NCT05110846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049885|NCT05973058|||COHORT||PROSPECTIVE|||||||
34153109|NCT06010134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double (Participant, Investigator) Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group 1 (control group) and Group 2 (Whole Body Vibration group).|G 1 (control) received traditional physical therapy program for 30 min. G 2 (study) received traditional physical therapy program for 15 min. and Whole Body Vibration for 15 min|t|f|f|f
34153110|NCT00375167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153111|NCT03973762|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Investigator responsible for CAD system operation is masked to the expert panel grading result.|This trial aims to evaluate the diagnostic performance of a CAD system for retinal images； And DR grading by clinicians is used as the golden standard.|f|f|t|f
34153112|NCT03870425|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized controlled|f|t|t|t
34153113|NCT03111953|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34153114|NCT01020084|||||CROSS_SECTIONAL|||||||
34153115|NCT01967615|||COHORT||RETROSPECTIVE|||||||
34153116|NCT03422536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153117|NCT06136611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||PORTRAIT is a cohort study including: 14 prospective patients for the experimental arm which assumes a TRUE toxicity rate of 20% (the study needs 13 patients and we allow 1 patient for replacement). This means that there is less than 10% chance that 4 or more patients will experience a toxicity defined as a complication. For the non-experimental arm, 28 prospective patients will be recruited.||||
34153118|NCT03564002|||CASE_CONTROL||PROSPECTIVE|||||||
34153119|NCT00093821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153120|NCT00372541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153121|NCT00610389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153122|NCT00310622|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153123|NCT01303198|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34049886|NCT04768972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049887|NCT02708537|||CASE_ONLY||PROSPECTIVE|||||||
34049888|NCT06685510|||COHORT||PROSPECTIVE|||||||
34153124|NCT04797871|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Single (Investigator)||f|f|t|f
34153125|NCT04241263|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE|This is a feasibility study but there are two arms and the babies, parents and staff will all be considered participants -it will be approximately 20 families recruited|||||
34153126|NCT03117179|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34153127|NCT06342973|NA|SINGLE_GROUP||TREATMENT||NONE||Single group||||
34153128|NCT04841772|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34153129|NCT00100594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153130|NCT01920737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153131|NCT00439374|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and care providers are masked to treatment assignment.|Treatment with 17 alpha-hydroxyprogesterone caproate via weekly injections of 250 mg of 17p until 37 weeks gestation or delivery vs. weekly injections of placebo oil until 37 weeks gestation or delivery.|t|t|f|f
34153132|NCT04022655|||COHORT||RETROSPECTIVE|||||||
33945076|NCT02784665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153133|NCT01812512|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34153134|NCT02404428|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34153135|NCT00850083|||COHORT||PROSPECTIVE|||||||
34153136|NCT05420649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153137|NCT00005834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153138|NCT03931694|||OTHER||PROSPECTIVE|||||||
34153139|NCT05399290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153140|NCT02807688|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153141|NCT00000382|RANDOMIZED|||PREVENTION||||||||
34153142|NCT03080636|RANDOMIZED|CROSSOVER||PREVENTION||NONE||20 healthy adults, public servants (9W and 11M), randomly underwent three experimental sessions in early morning prior to their work routine: a circuit resistance session at 40% of 1RM, a treadmill exercise session at 60-70% of heart rate reserve and a resting control session.||||
34153143|NCT01517386|||COHORT||CROSS_SECTIONAL|||||||
34153144|NCT04223414|||CASE_ONLY||PROSPECTIVE|||||||
33945077|NCT05946837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153145|NCT03753139|||CASE_CONTROL||PROSPECTIVE|||||||
34153146|NCT05095857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153147|NCT05944627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Phase 1 clinical trial was an open-label. Phase 2a clinical trial was conducted in a single-blind.||t|f|f|f
34153148|NCT04071678|||COHORT||PROSPECTIVE|||||||
34153149|NCT02823379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153150|NCT00995995|||OTHER||RETROSPECTIVE|||||||
34153151|NCT03485040|||COHORT||PROSPECTIVE|||||||
34153152|NCT04645589|||COHORT||PROSPECTIVE|||||||
34153153|NCT04771676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153154|NCT05874622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153155|NCT03599479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153156|NCT01371045|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34153157|NCT00595816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34153158|NCT04397419|RANDOMIZED|PARALLEL||TREATMENT||NONE||1 intervention group, 1 placebo group||||
34153159|NCT05417308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34049889|NCT05304793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049890|NCT06462820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will receive either active or sham stimulation to the DLPFC. Patients will be randomized to either condition with a 50:50 chance.|t|t|t|t
34049891|NCT01950351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049892|NCT06685133|||COHORT||PROSPECTIVE|||||||
34049893|NCT05432622|||COHORT||RETROSPECTIVE|||||||
34153160|NCT03286283|NA|SINGLE_GROUP||TREATMENT||NONE|This is a single-arm study in which investigators are not blinded. However, blinded Independent Photographic Reviewers (IPR) will be utilized to review all images (baseline and all follow-up time points) and assign FWS scores.|This is a multi-center, single arm, evaluator-blind prospective study of 55 study subjects who are seeking a procedure to reduce the appearance of wrinkles and rhytides. Enrolled study subjects will receive one procedure with J-Plasma at enrollment. Wrinkle severity will be assessed using the Fitzpatrick Wrinkle and Elastosis Scale (FWS) at baseline and at each follow-up time point. Scores at each follow-up time point will be compared to the scores at baseline for each enrolled subject.||||
34153161|NCT05490004|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Research Assistant will be blinded to group allocation. The RA will be responsible for following-up with participants to make sure they've completed quantitative assessments (online survey) or, if participants choose to complete the surveys over the phone, the RA will complete them over the phone with the participant.|To determine the feasibility of evaluating the effectiveness of both of VEGA's educational approaches, as well as to generate preliminary estimates of effect for sampling and effect size calculations, a two-arm pilot randomized controlled trial (RCT) will be used (Eldridge et al., 2016). Eligible participants will be randomly assigned to receive either self-directed (i.e., experimental) or facilitator-led (i.e., active control (AC)) VEGA.|f|f|f|t
34153162|NCT01041287|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34153163|NCT02726022|||COHORT||PROSPECTIVE|||||||
34153164|NCT00806143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153165|NCT00146380|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34153166|NCT03899051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153167|NCT05722223|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All the participants will receive trimodal prehabilitation. Only one arm||||
34153168|NCT03865784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34153169|NCT00172341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153170|NCT01735942|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34153171|NCT00877396|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34049894|NCT00665860|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34049895|NCT06665620|NA|SINGLE_GROUP||PREVENTION||NONE||At each decision point (once per day), participants will be randomized to receive a n nudge encouraging them to access the ViraBrite app and utilize suicide safety planning skills vs. no nudge. At each decision point, participants will have a seventy-five percent chance of receiving a nudge. Given that they are randomized to receive a nudge, participants have a 33.3% chance of receiving a notification at one of three time points: morning, midday or evening.||||
34049896|NCT04061616|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34049897|NCT03817008|||COHORT||RETROSPECTIVE|||||||
34049898|NCT03861702|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, single-arm, open-label, clinical study.||||
34049899|NCT06515236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Teens and their parents will not know what condition their clinician is randomly assigned to, but clinicians will be aware as will the site.|Strategic Treatment Assessment for Youth (STAY) is a theoretically-driven, culturally-tailored measurement-based care (MBC) approach for racial and ethnic minoritized youth with depressive symptoms and/or suicidal thoughts and behaviors.|t|f|f|f
34049900|NCT05805722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049901|NCT05523011|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Single-center, single-arm, open-label study||||
34049902|NCT06683183|||COHORT||PROSPECTIVE|||||||
34153172|NCT06583785|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A randomized, open-label, crossover design with a week wash-out period for investigating the acute and short-term effects of black rice consumption on the cognitive function, inflammation and microvascular function in older adults.||||
34153173|NCT02242383|||COHORT||PROSPECTIVE|||||||
34049903|NCT01252563|||CASE_ONLY||PROSPECTIVE|||||||
34049904|NCT04412343|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|No experimenter or investigator expectancy effects as all assessment occurs online (i.e., online questionnaire). Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group.||f|f|f|t
34153174|NCT04576897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is an open label study in that all participants will receive the same study procedures. Participants only receive this Velacur intervention if they are enrolled in this trial.|All participants will undergo quantitative ultrasound with Velacur by Sonic Incytes by a certified technician.||||
33945078|NCT03554798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation of each subject to a given group will be described in a computer-generated randomization schedule. Based on this randomization code, the study vaccine will be packaged and labeled. Medication code numbers will be preprinted on the study vaccine labels and assigned as subjects qualify for the study and are randomly assigned to dosing schedule.||t|f|t|f
34049905|NCT06002451|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33945079|NCT03691831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded vehicle solution is packaged to match the active study drug and will be stored under the same conditions.|Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study|t|t|t|t
33945080|NCT01939015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049906|NCT00090220|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34153175|NCT06012110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945081|NCT01205568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34049907|NCT06348030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34049908|NCT02529449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049909|NCT00971607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049910|NCT00052130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34049911|NCT04604444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049912|NCT03431844|||COHORT||PROSPECTIVE|||||||
34049913|NCT00384748|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34049914|NCT01940900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049915|NCT02423343|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049916|NCT02782065|||COHORT||PROSPECTIVE|||||||
34049917|NCT01341340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049918|NCT05410405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|implant stability assessment was blinded|split mouth|f|f|t|f
34049919|NCT03761030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34049920|NCT06684197|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049921|NCT04950075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||INBRX-109 and placebo arms are in parallel. Patients on placebo are allowed to cross-over to open-label INBRX-109 at time of disease progression.|t|t|t|t
34049922|NCT02255305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049923|NCT04096638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049924|NCT06674655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049925|NCT06180278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049926|NCT01177631|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34049927|NCT06682988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049928|NCT03511040|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, open-label, single-arm trial||||
34049929|NCT03137940|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The medical device randomly assigns, to each subject, the sequence of the type of sessions, so no one knows the kind of session performed.|Each subject receives, randomly, a real session of tDCS and a sham session with BrainStim Stimulator.|t|t|t|t
34049930|NCT06666270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049931|NCT01482065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049932|NCT02759172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049933|NCT02683395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049934|NCT05368272|||COHORT||PROSPECTIVE|||||||
34049935|NCT00858533|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34049936|NCT05273190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049937|NCT03970681|||CASE_CONTROL||RETROSPECTIVE|||||||
34049938|NCT03044223|||COHORT||PROSPECTIVE|||||||
34049939|NCT02179658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049940|NCT01062113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049941|NCT02156908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049942|NCT05727761|NA|SINGLE_GROUP||PREVENTION||NONE||Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks in 36 total high risk oral leukoplakia patients.||||
34049943|NCT04852068|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Similar vaccine control|t|t|t|t
34049944|NCT05969769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049945|NCT06532474|||CASE_ONLY||PROSPECTIVE|||||||
34049946|NCT06261983|||COHORT||PROSPECTIVE|||||||
34049947|NCT06667063|||COHORT||PROSPECTIVE|||||||
34049948|NCT00168272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34049949|NCT06571734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049950|NCT04063293|NA|SINGLE_GROUP||TREATMENT||NONE||The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. In case a perfect relaxation will not be achieved, then the patient will be intubated. The patient will be positioned as gynecological position. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound. The final condition of the sphincters will be pictured with the device. The same surgeon (MCH) will perform all procedures. No antibiotics will be used. Local anesthetics will not be injected. If the patient will feel pain after the operation, he/she will be free to use oral painkillers. The patient will be discharged from the hospital on the same night or the day after according to the patient's desire. Patients will be questioned for possible PRP complications during the hospitalization period, and they will be asked to report anytime during the study period.||||
34049951|NCT06497894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049952|NCT06666985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34153176|NCT01136109|||COHORT||PROSPECTIVE|||||||
34153177|NCT06503380|||COHORT||OTHER|||||||
34153178|NCT04979494|||CASE_ONLY||PROSPECTIVE|||||||
34153179|NCT04169074|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label Phase II single-arm window trial.||||
34153180|NCT01010152|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153181|NCT03117413|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Subjects with asymmetric hearing loss treated with a cochlear implant and a control group of normal hearing subjects||||
34153182|NCT05320393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153183|NCT06165263|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34153184|NCT03865485|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|The implementing partners in each country site will notify the participating families of their allocation status (based on clusters) after baseline data collection is completed in each cluster to assure that participants are blind to allocation during the initial assessment. Research assistants conducting data assessments and conducting analysis will be blind to allocation to minimize assessment bias. Because of facilitators' involvement in the program implementation, blinding will not be possible for service providers. Similarly, participants will not be blind to their own treatment condition.|Factorial Assignment For the study, a factorial design will be used testing 3 components. With these three components, there will be a total of eight conditions. The purpose of this factorial experiment is to estimate the main effects of the three intervention components and interactions between the components, not to compare the 8 experimental conditions to each other. Each main effect and interaction estimate is based on all of the experimental conditions.|t|f|t|f
34153185|NCT02670668|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764420|NCT04197011|||COHORT||CROSS_SECTIONAL|||||||
33945082|NCT00416299|||||PROSPECTIVE|||||||
34049953|NCT05743595|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049954|NCT00355147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34049955|NCT05799612|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34049956|NCT05171036|NA|SINGLE_GROUP||SCREENING||NONE||||||
34049957|NCT04446455|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Pilot Study|t|f|t|f
34049958|NCT06664385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|The masking consists of the investigator not performing the physical evaluations.|non controlled clinical trial||||
33945083|NCT01613209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049959|NCT01094301|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34049960|NCT02778685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153186|NCT01032031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34153187|NCT04528056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153188|NCT02300181|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34153189|NCT00546091|||||PROSPECTIVE|||||||
34153190|NCT04797546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153191|NCT06130111|||COHORT||RETROSPECTIVE|||||||
34153192|NCT02072369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34153193|NCT00895544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945084|NCT05868629|||OTHER||PROSPECTIVE|||||||
34049961|NCT02129413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049962|NCT06033807|||OTHER||CROSS_SECTIONAL|||||||
34049963|NCT04176315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049964|NCT04375072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34049965|NCT06194370|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34049966|NCT05423535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It concerns a surgical intervention. Hence, the treating surgeon cannot be masked. As each patient receives both the control and test treatment at the same moment, the patient is masked. The investigators and outcome assessors are masked.|Intra-subject RCT with 2 treatment arms (control group: collagen matrix; test group: hemostatic gelatine sponge). In every patient two teeth are extracted. Coincidence (coin flip) will determine which site is treated with the gelatine sponge and which with the collagen matrix.|t|f|t|t
33945085|NCT02973399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049967|NCT04150211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each pill bottle was assigned a five characters numeric code and a letter (A or B). Then, the codes were randomly distributed to the participants. Once the study finished, an external person to the study revealed the placebo and controlled group for each letter.|Single dose, Randomized, triple Blinded, Placebo-controlled Study|t|f|t|t
34049968|NCT04594369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049969|NCT01925131|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049970|NCT05995860|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049971|NCT04284397|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Two groups of subjects (young, older) participate in twelve experiments; experimental conditions consist of six different combinations of temperature and humidity and are performed at two different exercise intensities. The experiments are conducted in randomized order and are separated by a minimum of three days. A subgroup of older adults will be asked to complete all trials after taking daily low-dose aspirin for seven days, and aspirin will be continued until all trials are complete.||||
34049972|NCT06665802|||COHORT||PROSPECTIVE|||||||
34049973|NCT06683612|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049974|NCT02527252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34049975|NCT06684938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049976|NCT05325281|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34049977|NCT06569602|||COHORT||PROSPECTIVE|||||||
34049978|NCT03745729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34049979|NCT03526536|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34049980|NCT06331260|||COHORT||PROSPECTIVE|||||||
34049981|NCT06175325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049982|NCT03647579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34049983|NCT06684184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049984|NCT03614468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants.|Formula feed infants will be randomized to receive either a new infant formula formulated for healthy term infants (Formula A) or a commercially available infant formula for healthy term infants (Formula B). Infants will consume the formula for a total of 52-weeks.|t|t|t|t
33945086|NCT02577107|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945087|NCT06138912|||COHORT||CROSS_SECTIONAL|||||||
34049985|NCT06684990|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will conduct POC testing for HbA1c and cystain C in outpatients with diabetes, and present the results to their providers. Follow up data on fasting glucose, HbA1c, serum creatinine, urine albumin to creatinine ratio (UACR), lipids profile, ...etc will be collected every 6 months for 3 years. Patients who decline to POC testing but provide consent to observational follow up will serve as the controls. The investigators will examine the effects of POC testing on changes in glycemic control and renal function in study participants.||||
34049986|NCT05263271|NA|SINGLE_GROUP||TREATMENT||NONE||Part one, priming dose exploration: 5 dose levels (0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg) Part two, therapeutic dose exploration: 3 dose levels (10 mg/kg,30 mg/kg,45 mg/kg)||||
34049987|NCT02751346|||OTHER||OTHER|||||||
34153194|NCT00609739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153195|NCT00784537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153196|NCT00473408|||COHORT||PROSPECTIVE|||||||
34153197|NCT00774683|||COHORT||PROSPECTIVE|||||||
34153198|NCT03029507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153199|NCT00953940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945088|NCT02311660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945089|NCT01363999|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34049988|NCT05579392|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants will be randomly assigned to receive Bright light therapy or placebo (wearing a similar device but will not receive the therapy) for 4 weeks, then they will do a washout period. After the washout period, the same participants will crossover to the opposite group for the remaining 4 weeks of the study, i.e. placebo or bright light therapy.|t|f|f|f
34049989|NCT05971498|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34049990|NCT05837663|||COHORT||PROSPECTIVE|||||||
34153200|NCT02588209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153201|NCT03782441|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34153202|NCT05387668|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34049991|NCT00186966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34049992|NCT02573415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049993|NCT06666244|||CASE_ONLY||CROSS_SECTIONAL|||||||
34049994|NCT03836950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized control trial. Participants will receive either active or sham rTMS|t|t|t|t
34049995|NCT06666946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician||t|f|f|t
34049996|NCT00528489|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34049997|NCT06389877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153203|NCT04268173|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants were enrolled in a 2-arm, non-randomized intervention trial based on the location where they received harm reduction services. Harm reduction clients receiving services at offices in 3 selected Wisconsin counties (La Crosse, Brown, and Marathon) were assigned to work with a Prevention Navigator at the office location, while clients receiving services in other counties (Douglas, Eau Claire, and Outagamie) received usual services.||||
33945090|NCT04797364|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34049998|NCT01872065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153204|NCT03730415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945091|NCT03222869|||COHORT||PROSPECTIVE|||||||
33945092|NCT04151654|NA|SINGLE_GROUP||OTHER||NONE||The demographic information of the individuals (age, gender, height, body weight, body mass index (BMI), educational status) were recorded. Footwear suitability was evaluated with the Footwear Assessment Score. Subjects were assessed using the Sharpened Romberg test and Single Leg Stance test for static balance, Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals. The wearing duration of footwear and accompanying disease was also recorded, and crossover methods were used for assessing balance and functional tests, with and without footwear.||||
33945093|NCT00374920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945094|NCT04335929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34049999|NCT05581940|||CASE_CONTROL||PROSPECTIVE|||||||
34050000|NCT05362396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050001|NCT01382472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153205|NCT01997671|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34050002|NCT05405309|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050003|NCT03477253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||62 patients with acute calcular cholecystitis are divided into 2 study groups by the time of laparoscopic cholecystectomy comparing to onset of symptoms||||
34050004|NCT00186979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153206|NCT03052816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050005|NCT03411980|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050006|NCT01710371|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050007|NCT04590170|||COHORT||RETROSPECTIVE|||||||
34050008|NCT02448537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050009|NCT04871204|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallell design with Control arm receiving standard treatment and Experimental arm receiving Octreotide treatment||||
34050010|NCT01235026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34050011|NCT03724903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050012|NCT05843383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants were anesthetized and were unaware of the grouping. Care providers did not know the grouping. Specific investigators who did the intervention were aware of the grouping. The outcome assessors and the data analyzers did not know the grouping.||t|f|t|t
34050013|NCT01399463||PARALLEL||||SINGLE||||||
33945095|NCT05107557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050014|NCT03636971|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34050015|NCT00111319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050016|NCT02727790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050017|NCT03037346|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050018|NCT00623740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050019|NCT03866083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050020|NCT01310088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050021|NCT04523038|||CASE_CONTROL||PROSPECTIVE|||||||
34050022|NCT03453099|||COHORT||PROSPECTIVE|||||||
34050023|NCT02470065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050024|NCT05397912|||COHORT||PROSPECTIVE|||||||
34050025|NCT02836574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050026|NCT06666062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050027|NCT05945264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34050028|NCT06584448|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050029|NCT05756777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050030|NCT06078774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050031|NCT04353544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050032|NCT06684444|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34050033|NCT06665490|||COHORT||PROSPECTIVE|||||||
34050034|NCT00034424|||FAMILY_BASED||OTHER|||||||
34050035|NCT02586610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050036|NCT03360851|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel cluster-randomised trial with historical control period||||
33945096|NCT03831581|NA|SINGLE_GROUP||TREATMENT||NONE||Assignment interventional||||
33945097|NCT03290274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945098|NCT03747497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945099|NCT02530580|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945100|NCT02240394|||COHORT||PROSPECTIVE|||||||
33945101|NCT01044095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34153207|NCT06368934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study employed a single-blind approach whereby the participants were unaware of the kind of surgical resection they were receiving.|"Type of study: randomized parallel controlled, open-label, multicenter clinical trial.~Interventions: the intervention group was to receive frontal, temporal, parietal, and occipital sub-lobotomies that met anatomical criteria, and the control group was to receive imaging total resection (T1-enhanced borders) that met the Response Assessment in Neuro-Oncology (RANO) criteria.~Randomization The control group and intervention group were equal in size. Following intraoperative pathological diagnosis, participants were randomly assigned using a centralized randomization system known as the Interactive Web Response System (IWRS). Stratification factors included preoperative age brackets of \[18-65\] and (65-80), gender (male or female), and tumor site in the frontal, temporal, parietal, and occipital lobes."|t|f|f|f
34153208|NCT00585572|||OTHER||OTHER|||||||
34050037|NCT06366269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group allocation will be masked to the care provider and investigators only while participants undergo the initial 6 weeks of treatment. Due to the nature of the intervention (acupuncture) participants are not able to be blinded.||f|t|t|f
34153209|NCT05870683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153210|NCT02861482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153211|NCT00225784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153212|NCT00865319|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153213|NCT01771445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34153214|NCT00844558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153215|NCT05318911|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34050038|NCT02181582|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050039|NCT06051838|||COHORT||RETROSPECTIVE|||||||
34050040|NCT05815511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Clinical trial randomized, double-blind, and placebo-controlled|t|f|t|f
34050041|NCT06627309|||COHORT||PROSPECTIVE|||||||
34050042|NCT03319342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050043|NCT03359109|||CASE_CONTROL||PROSPECTIVE|||||||
34050044|NCT02802761|||CASE_ONLY||PROSPECTIVE|||||||
34050045|NCT04289376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||There is no intervention or treatment in this study||||
34153216|NCT00683839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153217|NCT05557305|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot, randomized, controlled, longitudinal trial||||
34153218|NCT00582569|||CASE_ONLY||PROSPECTIVE|||||||
34050046|NCT02453334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153219|NCT04787562|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34153220|NCT03187808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153221|NCT00057408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153222|NCT00454181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153223|NCT00678834|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34153224|NCT03133923|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34153225|NCT00788710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153226|NCT01476631|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153227|NCT06108830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153228|NCT01020253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153229|NCT01005927|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34050047|NCT03206541|||CASE_CONTROL||PROSPECTIVE|||||||
34050048|NCT00518245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050049|NCT05133089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050050|NCT04967495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050051|NCT03341143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050052|NCT06665711|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will employ a randomized controlled trial (RCT) design, which is considered the gold standard for evaluating the efficacy of interventions. The primary aim is to compare the effectiveness of 3% hypertonic saline against Salbutamol (Ventolin) in treating bronchiolitis in children.||||
34050053|NCT02149446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050054|NCT03869840|||COHORT||PROSPECTIVE|||||||
34050055|NCT04566003|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34050056|NCT05031416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050057|NCT04362072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050058|NCT04742712|||COHORT||PROSPECTIVE|||||||
34050059|NCT03755414|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34153230|NCT02248363|||COHORT||PROSPECTIVE|||||||
34153231|NCT01292915|||COHORT||PROSPECTIVE|||||||
34153232|NCT01961648|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34153233|NCT00379054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153234|NCT03673020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153235|NCT05987436|||COHORT||PROSPECTIVE|||||||
34153236|NCT00708695|||COHORT||RETROSPECTIVE|||||||
34153237|NCT05602077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"The two modalities to be compared (POCUS and XR) and the reference standard (CBCT) will be applied in a consecutive series of 130 patients with a suspicion of an indirect elbow fracture at the emergency department of a single center. All investigations will be part of the initial, single visit of the patient at the emergency department.~The modalities will be evaluated blinded for each other. The design is well known as a comparative, paired accuracy study. The design allows to estimate the accuracy of the two diagnostic modalities and the corresponding difference as well as the agreement between the two modalities."|Prospective single centre comparative diagnostic accuracy study||||
34153238|NCT03527524|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34153239|NCT05201950|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants: it is not feasible to mask participants from their educational intervention Investigator: Two investigators (JCL and LZY) will not be masked as they will be scheduling and delivering interventions. The remaining investigators will be masked, including those assisting participants as standardised assistants during outcome assessment simulation.~Outcome assessors: They will be masked from participants' group assignment."|Participants are assigned to learning through either virtual simulation, or team based in situ simulation, and are not planned to cross over during the study period.|f|f|t|t
34153240|NCT03570320|RANDOMIZED|PARALLEL||OTHER||NONE||Control arm versus interventional arm||||
34153241|NCT01276223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153242|NCT05900973|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153243|NCT05792527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153244|NCT03532139|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized to Arm Enoxaparin and Arm Enoxaparin + Rosuvastatin, and those requesting no randomization willl be directly assigned to Arm Standard-of-care Thromboprophylaxis||||
34153245|NCT05013788|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34153246|NCT05500430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)||t|f|f|t
34153247|NCT01489657|||CASE_ONLY||PROSPECTIVE|||||||
34153248|NCT05393024|||OTHER||OTHER|||||||
34153249|NCT01671631|||COHORT||PROSPECTIVE|||||||
34153250|NCT04654455|||COHORT||PROSPECTIVE|||||||
34153251|NCT05301309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34153252|NCT02999633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153253|NCT01683578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153254|NCT00700505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153255|NCT03033264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153256|NCT01195493|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34153257|NCT05070806|||OTHER||OTHER|||||||
34153258|NCT03802773|||CASE_ONLY||PROSPECTIVE|||||||
34153259|NCT04784624|||COHORT||PROSPECTIVE|||||||
34153260|NCT03888209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The device is preprogrammed by a third party non participating in any element in the study. They then chose (using opaque envelopes) the treatment code for each participant.|randomized, triple blind, sham controlled|t|t|t|t
34153261|NCT00671606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153262|NCT01686282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153263|NCT06543342|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-group trial in which one group serves as intervention recipients and one as assessment-only controls.||||
34153264|NCT06245538|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The outcomes assessors are blinded as to the group allocation (stress or control group) and study arm when analysing the collected data.|Matched-pair (individuals with stress-related symptoms versus matched healthy controls) randomized-order crossover experimental trial with three experimental conditions separated by a wash-out period of 7 days: 20-min leg cycling exercise at moderate intensity, 20-min leg cycling exercise at vigorous intensity, and 20-min seated rest (passive control condition)||||
34153265|NCT02837042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153266|NCT05040360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153267|NCT06358144|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will complete a 15-minute online survey, where they will be randomized to one of five conditions: four intervention conditions with a different image on the package and one without any imagery.|t|f|f|f
34153268|NCT00852241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153269|NCT05367323|||COHORT||RETROSPECTIVE|||||||
34153270|NCT06234787|||COHORT||PROSPECTIVE|||||||
34153271|NCT00517569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153272|NCT05522595|NA|SINGLE_GROUP||OTHER||NONE||||||
34153273|NCT02524418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153274|NCT01232348|||COHORT||PROSPECTIVE|||||||
34153275|NCT06583928|||COHORT||PROSPECTIVE|||||||
34153276|NCT04266756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153277|NCT05052294|||COHORT||PROSPECTIVE|||||||
34153278|NCT01204762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153279|NCT01915979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153280|NCT05496556|NA|SINGLE_GROUP||OTHER||NONE||||||
34153281|NCT01263145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153282|NCT00908037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153283|NCT04766554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be masked concerning the allocation group. The anesthesiologist responsible for conducting the case will not be involved in the application of the neurocognitive tests, nor will he be aware of the test results. Investigators who apply the tests will be covered up by the patient allocation group.|Patients will be monitored with cerebral oximetry using INVOS 5100 monitor (Covidien, Boulder, CO), with electrodes applied bilaterally in the frontal region. Following the placement of the electrodes, the baseline records HR, blood pressure, rSO2, and peripheral O2 saturation (SPO2) will be recorded following 1 minute of electrode placement and the proper verification of the signal on the monitor. Later, during the surgery, if the rSO2 reaches levels below 15% of the baseline values or below 50% in absolute value for over 30 seconds, protocol-based interventions will be performed in the intervention group to return the oximeter to baseline values. The alarm on the equipment should be programmed to signal values below 15% of the baseline values.|t|f|t|t
34153284|NCT00465140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34153285|NCT05638243|||COHORT||PROSPECTIVE|||||||
34153286|NCT06216548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention participants will complete the Enhanced Primary Care via Telehealth (E-PRIME) intervention for 12 months while Comparison participants will receive usual care for 6 months then complete the E-PRIME intervention for 12 months.||||
34153287|NCT03866564|||COHORT||CROSS_SECTIONAL|||||||
34153288|NCT06415773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153289|NCT03222947|||COHORT||RETROSPECTIVE|||||||
34153290|NCT01936415|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153291|NCT00555737|||COHORT||PROSPECTIVE|||||||
34153292|NCT02973516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153293|NCT06525233|||CASE_CROSSOVER||PROSPECTIVE|||||||
34153294|NCT02328027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153295|NCT01392209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153296|NCT00875290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153297|NCT05187871|||CASE_ONLY||PROSPECTIVE|||||||
34153298|NCT05698953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research consists of 3 groups. These groups are Reiki group, Placebo group, control group.|The study are conducted based on randomized controlled experimental design with double-blind, pre-test-post-test to determine. The research consists of 3 groups. These groups are Reiki group, Placebo group, control group.|t|f|f|f
34153299|NCT03292276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34050060|NCT06431841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153300|NCT02086422||||TREATMENT||||||||
34153301|NCT05375214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153302|NCT01659099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153303|NCT03326622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single blinded||f|f|f|t
34153304|NCT05892640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153305|NCT02113358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153306|NCT01656070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153307|NCT03675984|NA|SINGLE_GROUP||TREATMENT||NONE||Annual evaluation after educating asymmetrical stabilization exercise. Cohort study.||||
34153308|NCT03222024|||COHORT||PROSPECTIVE|||||||
34153309|NCT04338737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34153310|NCT01553643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153311|NCT05551507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153312|NCT00001644||||TREATMENT||||||||
34153313|NCT05137977|||CASE_CONTROL||OTHER|||||||
34153314|NCT04166539|||COHORT||PROSPECTIVE|||||||
34153315|NCT05750550|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34153316|NCT01656668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153317|NCT02854254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153318|NCT05691010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153319|NCT03335280|||COHORT||PROSPECTIVE|||||||
34153320|NCT03511456|||CASE_ONLY||RETROSPECTIVE|||||||
34153321|NCT01243827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050061|NCT02718989|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34153322|NCT00809653|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34153323|NCT03485170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153324|NCT02643537|||COHORT||RETROSPECTIVE|||||||
34153325|NCT06527534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153326|NCT04758923|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34153327|NCT04189029|||COHORT||PROSPECTIVE|||||||
34153328|NCT03720002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participant/care provider/investigator blinded|After an initial open-label run-in (if successful) the patients will be randomized to receive HF2 or placebo (2:1 allocation)|t|t|t|f
34153329|NCT03180970|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34153330|NCT05954429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153331|NCT03746041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153332|NCT01640262|||CASE_ONLY||PROSPECTIVE|||||||
34153333|NCT04473664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153334|NCT02335424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153335|NCT04051502|||COHORT||PROSPECTIVE|||||||
34153336|NCT04217213|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33764421|NCT05324930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomized, all boxes of dressings were opened and healthcare professional applying the dressing and assessing the wound was unaware of what treatment is being given.|Double blinded, randomized control trial|t|t|f|t
33764422|NCT05960370|||COHORT||PROSPECTIVE|||||||
33945102|NCT00759993|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33945103|NCT02119728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945104|NCT02440191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945105|NCT03693846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945106|NCT05102734|||COHORT||PROSPECTIVE|||||||
33945107|NCT03558230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A double-blinded stratified randomized controlled trial||t|t|t|t
33945108|NCT00471666|||||PROSPECTIVE|||||||
34050062|NCT06084949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assessor won't know the allocation of participants.|Participants are randomly allocated into intervention group or controlled group.|f|f|t|t
34050063|NCT03356080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050064|NCT06289478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34050065|NCT05173831|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study examining safety and effects of two sessions of MDMA-assisted therapy each followed by four integrative therapy sessions||||
34153337|NCT02476292|||||PROSPECTIVE|||||||
34153338|NCT04779983|||COHORT||PROSPECTIVE|||||||
34153339|NCT06236490|||CASE_ONLY||RETROSPECTIVE|||||||
34153340|NCT01839136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153341|NCT02002520|||CASE_CONTROL||PROSPECTIVE|||||||
34153342|NCT00435084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153343|NCT04577482|||COHORT||PROSPECTIVE|||||||
34153344|NCT00545103|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153345|NCT01574885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153346|NCT04161170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group A: no intervention Interventional group B: digital integrated healthcare platform Interventional group C: digital integrated healthcare platform + CGMS apply + medical team monitoring + educational intervation||||
34153347|NCT02146027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34153348|NCT04651829|||CASE_ONLY||PROSPECTIVE|||||||
34153349|NCT06092775|||COHORT||PROSPECTIVE|||||||
34153350|NCT00441805|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153351|NCT02619032|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34153352|NCT00861471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153353|NCT00498355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153354|NCT05138887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153355|NCT05067751|||COHORT||PROSPECTIVE|||||||
34153356|NCT01452919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153357|NCT00020878|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34153358|NCT00828750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153359|NCT06085313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153360|NCT04110080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153361|NCT06505486|||COHORT||RETROSPECTIVE|||||||
34153362|NCT02891382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153363|NCT06564896|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153364|NCT05726747|||COHORT||PROSPECTIVE|||||||
34153365|NCT04519580|||COHORT||PROSPECTIVE|||||||
34153366|NCT01887847|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153367|NCT05713435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and outcome assessor are blinded|3 parallel arms of equal size, participants can cross over after 3 initial treatments|t|f|f|t
34153368|NCT02018744|||COHORT||PROSPECTIVE|||||||
34153369|NCT00666965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153370|NCT03589755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical providers in the epilepsy clinic are blinded||f|f|t|f
34153371|NCT00620113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153372|NCT00000802||PARALLEL||TREATMENT||||||||
34153373|NCT02728362|||COHORT||PROSPECTIVE|||||||
34153374|NCT04411745|||COHORT||PROSPECTIVE|||||||
34153375|NCT01211340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153376|NCT04792827|||CASE_CONTROL||RETROSPECTIVE|||||||
34153377|NCT00615641|||COHORT||PROSPECTIVE|||||||
34153378|NCT04443166|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34153379|NCT01571453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153380|NCT04224506|||CASE_ONLY||PROSPECTIVE|||||||
34153381|NCT02678455|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153382|NCT00808548|||CASE_ONLY||RETROSPECTIVE|||||||
34153383|NCT04161001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153384|NCT00334711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153385|NCT05401318|||COHORT||PROSPECTIVE|||||||
34153386|NCT01090063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153387|NCT01772576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153388|NCT02217917|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34153389|NCT00395850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153390|NCT03310385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|multicentre, dose-finding,double-blind, randomized placebo-controlled trial|t|f|t|t
34153391|NCT04918355|||OTHER||PROSPECTIVE|||||||
34153392|NCT00661947|||||PROSPECTIVE|||||||
34153393|NCT05842681|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34153394|NCT03151941|||OTHER||PROSPECTIVE|||||||
34153395|NCT05583019|||COHORT||PROSPECTIVE|||||||
34153396|NCT06199362|||COHORT||PROSPECTIVE|||||||
34153397|NCT03891758|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153398|NCT02653547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153399|NCT03355677|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||All patient identified by an electronic algorithm as at risk of having possible COPD were invited to attend a case finding clinic at their local GP practice for lung function testing. The algorithm was applied to control group practices and the number of new cases of COPD in the records was compared. 'At risk' patients with existing asthma and COPD were also invited to attend, and have their health status reviewed. We were unable to complete control group comparisons on this group of patients.|f|f|f|t
34153400|NCT04368793|||COHORT||PROSPECTIVE|||||||
34153401|NCT00871962|||COHORT||PROSPECTIVE|||||||
34153402|NCT02339792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153403|NCT00000466|RANDOMIZED|||PREVENTION||DOUBLE||||||
34153404|NCT01321593|||COHORT||PROSPECTIVE|||||||
34153405|NCT02692378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153406|NCT01402648|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153407|NCT01608841|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34153408|NCT01623739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153409|NCT01734759|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34153410|NCT00258934|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153411|NCT05997706|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34153412|NCT00317382|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34153413|NCT00378261|RANDOMIZED|PARALLEL||||NONE||||||
34153414|NCT04190277|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34153415|NCT02259894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153416|NCT02286557|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34153417|NCT02035319|||CASE_ONLY||PROSPECTIVE|||||||
34153418|NCT02180958|||COHORT||PROSPECTIVE|||||||
34153419|NCT06497296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed and ordered envelope will be opened by assistant and the allocation was written on it. After then, lidocaine spray will be administered. The operator will be informed to prepare 30 seconds before the EGD initiation.|Both group accepted 6 puff of lidocaine spray. EGD will be inserted one minute after the lidocaine spray in 1-minute group and 3 minutes waiting in 3-minute group|t|f|t|f
34153420|NCT01780753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153421|NCT02060643|||COHORT||CROSS_SECTIONAL|||||||
34153422|NCT02677857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded||f|f|t|t
34153423|NCT06233097|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34153424|NCT01555125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153425|NCT04809259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153426|NCT06398717|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34153427|NCT00230542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153428|NCT04969692|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34153429|NCT03666221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153430|NCT00599638|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34153431|NCT04684953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153432|NCT05291663|||CASE_CONTROL||RETROSPECTIVE|||||||
34153433|NCT03468894|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot RCT||||
34153434|NCT04203420|||COHORT||CROSS_SECTIONAL|||||||
34153435|NCT03157037|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Single Arm study||||
34153436|NCT06515262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153437|NCT02678299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153438|NCT03879304|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Twelve participants were randomized to follow a multimodal physiotherapy program for 6 weeks. At the end of this period the participants will be crossed to another intervention without virtual reality glasses. The results will be measured before and after each intervention during the study.|f|f|f|t
34050066|NCT05535075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and legal representatives are blinded for the allocation to the intervention or standard-of-care arm until the end of study. The statistician is kept blinded until after data analysis.||t|f|f|t
34153439|NCT03715946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153440|NCT01587365|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34153441|NCT03757377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
34153442|NCT02346513|||CASE_CONTROL||PROSPECTIVE|||||||
34153443|NCT03219411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34153444|NCT00738218|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34153445|NCT03091764|||COHORT||PROSPECTIVE|||||||
34153446|NCT02258087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153447|NCT02678923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153448|NCT02178696|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34153449|NCT05115916|RANDOMIZED|PARALLEL||SCREENING||NONE||3880 patients 51-75 years old, within the UCLA Health Managed Care group overdue for average risk CRC screening without prior history of documented FIT or colonoscopy will be randomized into 2 groups, in a 1:1 ratio. The 2 groups represent standard of care, and then the MyChart Message group||||
34153450|NCT02343198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34153451|NCT01828411|||CASE_ONLY||CROSS_SECTIONAL|||||||
34153452|NCT01008904|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34153453|NCT05120141|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34153454|NCT00116116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153455|NCT00225095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153456|NCT00559676|NON_RANDOMIZED|||TREATMENT||||||||
34153457|NCT01504204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153458|NCT05903261|||COHORT||PROSPECTIVE|||||||
34153459|NCT05018026|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34153460|NCT04629027|||CASE_ONLY||RETROSPECTIVE|||||||
34153461|NCT03846557|||OTHER||PROSPECTIVE|||||||
34153462|NCT05573841|||COHORT||PROSPECTIVE|||||||
34153463|NCT00705887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34153464|NCT01281319|||CASE_CONTROL||PROSPECTIVE|||||||
34153465|NCT04518683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Free randomization via a pre-established listing including a coding system (0-intervention group and 1-control group) will be set up. A set of 30 opaque envelopes including a coding will be drawn for each participant by a person other than the principal investigator.|study pilot mixte by a quantitative part corresponding to a randomized controlled intervention study and a phenomenological qualitative aspect|t|t|t|t
34153466|NCT00488826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153467|NCT05747534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind: Participant and Investigator blinded. Pharmacy unblinded.|"Drug arm Placebo arm~Subjects \<25.0 kg will receive 250 µg of AT1001 or placebo, and subjects ≥25.0 kg will receive 500 µg of AT1001 or placebo"|t|t|t|t
34153468|NCT02640495|||CASE_ONLY||PROSPECTIVE|||||||
34153469|NCT01257607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153470|NCT06141759|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153471|NCT02037217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153472|NCT02081872|||COHORT|||||||||
34153473|NCT00997360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153474|NCT01636349|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153475|NCT03204669|||COHORT||RETROSPECTIVE|||||||
34153476|NCT04058886|NA|SINGLE_GROUP||OTHER||NONE||||||
34153477|NCT02553408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153478|NCT01177566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153479|NCT03750643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153480|NCT00682318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153481|NCT04274556|||OTHER||PROSPECTIVE|||||||
34153482|NCT05094141|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Cross over study will be performed. Subjects will be randomized (1 to 1 randomization) at their initial encounter to either VR or Non-VR. During their second visit patients will be given the alternative mode of care (i.e. patients who initially received VR distraction will be given Non-VR distraction, and patients who initially received Non- VR distraction will receive VR distraction)|t|f|f|f
34153483|NCT02738424|||COHORT||PROSPECTIVE|||||||
34153484|NCT04928560|||COHORT||PROSPECTIVE|||||||
34153485|NCT02828332|NA|SINGLE_GROUP||||NONE||||||
34153486|NCT01371305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153487|NCT00952900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945109|NCT04435951|||OTHER||CROSS_SECTIONAL|||||||
33945110|NCT00303602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945111|NCT02493712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945112|NCT03506165|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050067|NCT04164108|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050068|NCT02156297|||COHORT||PROSPECTIVE|||||||
34050069|NCT04563741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not know the treatment assignment. Because this is a behavioral intervention, with supervision provided by the lead investigator, the participants, care providers, and investigators will not be blinded.|This is a hybrid type 1 trial with Veterans with PTSD who are classified as overweight or with obesity, and who are currently enrolled in PTSD care. Participants will be randomized to usual care enhanced with MOVE! (control) or usual care enhanced with MOVE!+UP (intervention).|f|f|f|t
34050070|NCT02195622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050071|NCT03910452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153488|NCT06262243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|In this randomized controlled study, 78 mothers, 39 in each group, will be included in the intervention and control groups that meet the criteria for participation in the study. The researcher will give general information about the research to the mothers in the intervention and control groups during hospitalization and nurse admission, and their written informed consent will be obtained.|The research is a randomized controlled experimental design.|t|f|f|f
34153489|NCT03194438|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort of sample with repeated measure assessment of symptoms.||||
34153490|NCT04147806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153491|NCT05967949|||COHORT||RETROSPECTIVE|||||||
34153492|NCT03012867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153493|NCT05328752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Site will have masked and unmasked investigators. An unmasked investigator will prepare and administer dose while a masked investigator will perform all assessments.|randomized, placebo-controlled safety study of XXB750|t|t|f|f
34153494|NCT03983863|||COHORT||PROSPECTIVE|||||||
34153495|NCT02540993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153496|NCT00922714|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34153497|NCT06536556|||COHORT||PROSPECTIVE|||||||
34153498|NCT00890682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153499|NCT02641067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153500|NCT04420403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were randomly assigned to manual therapy plus cervical stabilization exercise group (intervention group) and only the manual therapy group (control group).|f|f|f|t
34153501|NCT00695864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34153502|NCT05945303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153503|NCT04556019|||COHORT||OTHER|||||||
34153504|NCT00003775||||TREATMENT||||||||
34153505|NCT02408263|||COHORT||PROSPECTIVE|||||||
34153506|NCT06035848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The diagnosis, application of randomization to each group and blood sampling were performed by the neonatology staff, both the patients and the surgical team that provided care were blinded.|"The aim of this study was to determine an indication for early surgery in preterm neonates with necrotizing enterocolitis by using paracentesis in combination with the components of metabolic derangement compared to using the Bell´s criteria.~Two groups of patients were formed (Control and Intervention). Control group: determination of surgery in a conventional manner according to Bell's criteria (absolute indication: pneumoperitoneum), with radiographic surveillance every 6 hours.~Intervention Group: components of metabolic derangement measurement every 3rd day, it was considered positive when 3 or more points were present. These patients underwent paracentesis and if it was positive (faecal aspiration, serous fluid with Gram + staining, or serohematic fluid) the decision for surgery was made."|t|f|t|f
34153507|NCT03981068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153508|NCT03637517|RANDOMIZED|PARALLEL||OTHER||NONE||Phase 1, single-dose, open-label, randomized, parallel group design in healthy adults (males, females of non child bearing potential) in 3 groups of 14 subjects each.||||
34153509|NCT06379282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Recruited participants will be randomised to either exercise only, exercise + nutritional guidance, or control for 12 weeks||||
34153510|NCT04183608|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34153511|NCT03154749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153512|NCT02218944|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34153513|NCT00133224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153514|NCT00266682|NON_RANDOMIZED|||TREATMENT||NONE||||||
34153515|NCT01141491|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153516|NCT02387489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34153517|NCT01555489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153518|NCT06068465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764423|NCT04195880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Intervention implemented in providers assigned to experimental condition, so all knew they were in a study. Control facilities did not know there was a study underway.|Pair matched cluster randomized trial; randomization at the provider level.||||
33764424|NCT06481852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33764425|NCT05869682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, only the designated study team member knows the participant's allocation. Oncologists or clinical research associates collecting data are not informed of patient allocation.||f|f|f|t
34153519|NCT04379076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|randomized controlled of treatment vs placebo|t|t|t|t
34153520|NCT02462993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153521|NCT05819944|||CASE_CONTROL||PROSPECTIVE|||||||
34153522|NCT04967261|||COHORT||RETROSPECTIVE|||||||
34153523|NCT02280447|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34153524|NCT03309930|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||During Study 1 participants will be exposed to three different conditions: (a) written text only, (b) auditory synthetic speech output only and (c) a combined condition (written and auditory output). During Study 2 participants will be provided repeated exposure to synthetic speech. Participants can participate in 1 or both studies with 1 study results not being dependent on the other study. .||||
34153525|NCT00269633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34153526|NCT04135014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153527|NCT06583551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were informed only about the type of treatment they received. The results were measured and recorded by another researcher other than the operator.|Group 1: Botulinum toxin (BTX-A) injection (n=20) Group 2: Dry needling (DN) (n=20) Group 3: Pharmacological therapy (PT) (n=20) Group 4: Manual therapy (MT) (n=20)|t|f|f|t
34153528|NCT00995748|||COHORT||PROSPECTIVE|||||||
34153529|NCT03442660|NA|SINGLE_GROUP||OTHER||NONE||||||
34153530|NCT06389110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a study to demonstrate superiority, double-blind, randomized, controlled, comparative, and multicenter phase III clinical trial.|t|t|t|t
33764426|NCT02276066|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945113|NCT02131974|||CASE_ONLY||PROSPECTIVE|||||||
33945114|NCT01892046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153531|NCT02337634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153532|NCT06377709|NA|SINGLE_GROUP||OTHER||NONE||||||
34153533|NCT05769049|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blinded|Totally 48 eligible participants, 24 for each age group, will be enrolled in the study with a 2:1 randomization ratio to receive REC610 (50 μg) or Shingrix® (50 μg) respectively.|t|t|t|t
34153534|NCT00342953|||COHORT||RETROSPECTIVE|||||||
34153535|NCT02919514|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34153536|NCT02048488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153537|NCT02381873|||COHORT||PROSPECTIVE|||||||
34153538|NCT03320590|||COHORT||PROSPECTIVE|||||||
34153539|NCT03683745|||OTHER||CROSS_SECTIONAL|||||||
34153540|NCT05379101|||CASE_CONTROL||PROSPECTIVE|||||||
34153541|NCT04507971|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two parallel treatment arms. Responders to either treatment will continue with their assigned treatment through to the end of the study. Non-responders will cross-over to the other treatment at week 4 of the study.||||
34153542|NCT03565835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153543|NCT02215304|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34153544|NCT03076294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153545|NCT00296153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153546|NCT03158181|||COHORT||PROSPECTIVE|||||||
34153547|NCT05215730|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized multisite two arms study: one arm will be treated with Negative Pressure Wound Therapy (NPWT) known also as Vacuum-assisted closure (VAC) treatment (VAC Arm). The second arm with MedCu wound dressings with copper oxide (COD) (Copper Arm)."||||
34153548|NCT00835341|||COHORT||PROSPECTIVE|||||||
34153549|NCT01106235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153550|NCT03450265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153551|NCT04725487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153552|NCT02682797|||COHORT||PROSPECTIVE|||||||
34153553|NCT05908201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153554|NCT04913740|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34153555|NCT04122131|||CASE_ONLY||PROSPECTIVE|||||||
34153556|NCT04597840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The type of incisional hernia repair (simple suture or mesh reinforcement) will be masked to the primary outcome assessor.||f|f|f|t
34153557|NCT05354193|||COHORT||RETROSPECTIVE|||||||
34153558|NCT00162812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153559|NCT06019377|RANDOMIZED|PARALLEL||PREVENTION||NONE||10-module group psychoeducational curriculum model||||
34153560|NCT03450733|||COHORT||CROSS_SECTIONAL|||||||
34153561|NCT03913494|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34153562|NCT05368168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Assignment to one group or the other will be randomized by a simple 1:1 randomization method through the CRF automatically and after hospital discharge.~Double-blind masking will be performed (patients will not know to which group they belong and the investigator will not know to which group each patient is assigned). The only person aware of the outcome of the randomization will be the functional tests nurse, who will apply the PTNS treatment.~Patients in both groups will be appointed in the same way in the functional testing office, although patients in group 2 will not receive PTNS, the tibial nerve puncture will be applied, they will be stimulated until they perceive the corresponding current and then the neurostimulator will be turned off so that they do not receive the treatment."||t|f|t|t
34153563|NCT00968877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153564|NCT05458323|RANDOMIZED|PARALLEL||TREATMENT||NONE||CLEVER is a single centre, open label, 2-arm, parallel group, stratified, interventional randomised trial, with allocation ratio of 1:1 powered to test superiority of the impact of providing spectacles on rates of cognitive decline among older adults.||||
34153565|NCT00730548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153566|NCT02607111|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34153567|NCT01091441|||COHORT||PROSPECTIVE|||||||
34153568|NCT03679026|||COHORT||RETROSPECTIVE|||||||
34153569|NCT02849015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153570|NCT02927938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153571|NCT03605498|||COHORT||PROSPECTIVE|||||||
34153572|NCT03729245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153573|NCT05733078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Randomization of patients:~The patient will be randomized into control(placebo) and test (Vit C tablet) groups using the randomization code. The patients in treatment group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks. In the control group the patients will be given oral rehydration effervescent tablet as placebo with their usual dose of Levothyroxine for 12 weeks.~The patient in test group will be provided vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The patients who wish to continue at the end of 12 weeks will be provided another 12 weeks supply of vitamin C effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for with thyroid function tests and clinical score assessed at the end of week 24."|t|f|f|f
34153574|NCT00164515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153575|NCT02694887|||COHORT||PROSPECTIVE|||||||
34153576|NCT01720238|||COHORT||PROSPECTIVE|||||||
34153577|NCT06487728|||COHORT||PROSPECTIVE|||||||
34153578|NCT00567411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34153579|NCT02832024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153580|NCT03689855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153581|NCT01700712|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34153582|NCT05597332|NA|SEQUENTIAL||PREVENTION||NONE||Before and after study||||
34153583|NCT06421922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153584|NCT06014099|RANDOMIZED|PARALLEL||OTHER||SINGLE|Not possible because of the material and characteristics of the catheter||f|f|f|t
34153585|NCT05169060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Following recruitment and eligibility confirmation the study subjects will be randomized to take either 2g or 4g (in the form of capsules) of fish oil and either 1.5g or 3g of salsalate in addition to the fish oil in the final 2 months of the study. Randomization will be performed using permuted blocks, with a block size that is known only to the statistician. Each enrolled subject will be assigned a study number and all data and specimens from the subject will be identifiable only by the number assigned.||||
34153586|NCT03275038|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34153587|NCT04086992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with infantile spasms will be randomized into either the control group that will receive traditional follow-up or the intervention group that will receive remote monitoring for follow-up. Both groups will complete surveys to collect data on parental stress, direct and indirect costs, and overall satisfaction with therapy.||||
34153588|NCT01496755|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34153589|NCT06530771|||COHORT||PROSPECTIVE|||||||
34153590|NCT05469139|||COHORT||PROSPECTIVE|||||||
34153591|NCT01439373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153592|NCT05964543|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase Ib: Dose escalation;Phase II:Arm A：Combined administration group Q-1802 plus XELOX,Arm B Standard treatment group: XELOX alone||||
34153593|NCT05628909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153594|NCT01701934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153595|NCT05755984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153596|NCT00448305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153597|NCT04863651|||COHORT||PROSPECTIVE|||||||
34153598|NCT01803022|||COHORT||PROSPECTIVE|||||||
34153599|NCT01894438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153600|NCT02195167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153601|NCT05347303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Epidat randomization will be used to assign the groups. This assignment will be hidden, so the therapists will not be aware of which group each subject belongs to. Random assignment will be done by an investigator who will have no influence on the measurements or statistical analysis. The analysis will be carried out by another researcher who will remain unrelated to the measurements and the intervention.||t|f|t|t
34153602|NCT00197925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153603|NCT01940627|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34153604|NCT00881465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153605|NCT00438334|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34153606|NCT04858282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34153607|NCT02725866|||CASE_ONLY||PROSPECTIVE|||||||
34153608|NCT06197763|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Participants, investigators, and everyone involved in study conduct or analysis or with any other interest in this double-blind study will remain blinded with regard to the randomization treatment assignments until after data collection completion. The access to the randomization code will be kept restricted until its release for analysis.~The DSMB will be provided with unblinded data in order to allow them to review efficacy and safety and to fulfill their tasks as outlined in the DSMB charter."|"prospective, double-blind, placebo cross-over, pilot study evaluating colesevelam (intestinal BA scavenger) therapy and placebo in 25 stable adult FC participants. These participants will be recruited from the cardiology clinics at the St. Boniface Hospital, specifically the Manitoba Adult Congenital Heart (MACH) Clinic.~A further 25 age- and sex- matched healthy control participants will be recruited from advertising at St. Boniface Hospital and University of Manitoba. Healthy controls will only undergo the baseline visit and will not receive the investigational drug or placebo."|t|t|t|f
34153609|NCT06175013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153610|NCT03134690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153611|NCT06526065|||COHORT||PROSPECTIVE|||||||
34153612|NCT01854281|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34153613|NCT04644666|||COHORT||PROSPECTIVE|||||||
34153614|NCT03083678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737611|NCT04332172|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|"Participants will be randomly assigned to a study condition during the baseline assessment by the study software and the assigned condition content will be provided directly to the participant rather than by study staff. The staff member who enrolls the participant will not have access to the assigned condition/content, which will aid in blinding study staff.~The biostatistician and data analyst will be blinded for all hypothesis-testing analyses by coding experimental condition with a non-identifying number, the table for which will be maintained at the PI's office."|"The design is a 3 (no brief intervention; one session; or one session plus two boosters) X 2 (SMS present or not present) factorial trial.~Conditions are:~1. General information (no intervention)~2. General information + SMS~3. Baseline brief intervention~4. Baseline brief intervention + SMS~5. Baseline brief intervention + 2 booster sessions~6. Baseline brief intervention + 2 booster sessions + SMS"|f|f|f|t
34153615|NCT05754879|||COHORT||OTHER|||||||
34153616|NCT05188131|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34153617|NCT00270686|||||PROSPECTIVE|||||||
34153618|NCT03244826|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34153619|NCT06143033|NA|SINGLE_GROUP||OTHER||NONE||||||
34153620|NCT02053961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153621|NCT02706587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34153622|NCT02790424|NA|SINGLE_GROUP||OTHER||NONE||||||
34153623|NCT05544149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153624|NCT03342625|NA|SINGLE_GROUP||OTHER||NONE||||||
34153625|NCT01769820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153626|NCT02126839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153627|NCT02936284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153628|NCT01697254|||COHORT||PROSPECTIVE|||||||
34153629|NCT02243891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737612|NCT06332794|NA|SINGLE_GROUP||OTHER||NONE||||||
33737613|NCT04734353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050072|NCT03871205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153630|NCT01978444|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this trial, patients and the follow-up staff are masked to the treatment allocation.||t|f|f|f
34153631|NCT05122429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153632|NCT04544683|NA|SINGLE_GROUP||PREVENTION||NONE||Through a research questionnaire, pre-procedure and post procedure NRS pain score for both neck and arm we will obtain data regarding cervical epidural steroid injections via a transforaminal approach for research purposes only. Also current pain medications of patient throughout treatment will be obtained for research purposes.||||
34153633|NCT01818063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153634|NCT02152774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153635|NCT03916484|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"Sequential multiple assignment randomized trials (SMART) are adaptive interventions. An adaptive intervention is a sequence of decision rules that specify how the intensity or type of treatment should change depending on the patient's needs rather than applying a one size fits all approach. The type or dose of the intervention is adjusted based on participant characteristics or response. SMARTs are an efficient and rigorous way to maximize clinical utility and real-world applicability. In this SMART, participants are initially randomized to medication adherence support with one of two intervention approaches (AQ or AQ+NSC). At 3 months, based on protocol defined intervention responsiveness, participants are re-randomized or reassigned to continue their initial intervention approach or to change to the other intervention approach for months 4 - 6 of the trial."||||
34153636|NCT03068169|||COHORT||PROSPECTIVE|||||||
34153637|NCT05001230|||CASE_ONLY||RETROSPECTIVE|||||||
34153638|NCT05266391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34153639|NCT03851211|||COHORT||PROSPECTIVE|||||||
34153640|NCT05367843|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34153641|NCT05050656|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34153642|NCT01140061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153643|NCT06334068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors, who will call patients or relatives 30 days after surgery, will be masked for the allocated group.|"The patients in the preoperative anesthesia clinic are divided into one of the following groups:~1. Short-term glycemic control group:~   Patients will be admitted to the hospital for 2-3 days before surgery. During this pilot study, patients will be admitted to the intermediate care unit to monitor and control preoperative blood glucose. We aim to maintain moderate glucose control (140 - 180 mg/dl) using basal-bolus insulin protocol plus correctional doses as needed.~2. Standard-of-care group: Patients will be admitted the day before surgery with the usual patient treatment."|f|f|f|t
34153644|NCT06506968|||OTHER||PROSPECTIVE|||||||
34153645|NCT05710276|NA|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34153646|NCT01066962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153647|NCT01846650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153648|NCT04890015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34153649|NCT05932368|||OTHER||OTHER|||||||
34153650|NCT03907462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a 24-month parallel-group randomized controlled trial.|f|f|t|t
34153651|NCT03778385|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are masked to the primary hypothesis of the study.|All subjects will participate in two randomized exercise sessions. Clinical and experimental pain assessment will be performed before, during, and after each exercise task.|t|f|f|f
34153652|NCT06228690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153653|NCT05740865|||COHORT||RETROSPECTIVE|||||||
34153654|NCT05994079|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34153655|NCT03416608|||COHORT||CROSS_SECTIONAL|||||||
34153656|NCT06117826|||OTHER||PROSPECTIVE|||||||
34153657|NCT06583564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153658|NCT05032339|||COHORT||CROSS_SECTIONAL|||||||
34153659|NCT04872517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This research will use instruction named MEAD to detect the meridian energy before and after chemotherapy or/and radiotherapy. MEAD is a non-invasive device, it will not inter the conventional treatment that conduct by hematology oncology department and radiation oncology department.||||
34153660|NCT00084487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050073|NCT01421186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050074|NCT02064192|||COHORT||PROSPECTIVE|||||||
34050075|NCT01581242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050076|NCT05579197|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34050077|NCT06366633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737614|NCT04384536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737615|NCT04594512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737616|NCT06364826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737617|NCT00312507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945115|NCT06169410|RANDOMIZED|PARALLEL||TREATMENT||NONE|Although this trial was designed as open label, other independent researchers who conducted the imaging evaluation will be in a blinded state in the imaging evaluation phase for reducing the evaluator bias.|||||
33945116|NCT02203305|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050078|NCT04762615|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34050079|NCT02036840|||CASE_ONLY||RETROSPECTIVE|||||||
34050080|NCT06682819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050081|NCT01359215|||CASE_CONTROL||PROSPECTIVE|||||||
33737618|NCT05750641|||CASE_CROSSOVER||PROSPECTIVE|||||||
34050082|NCT04645901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050083|NCT01220388|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34050084|NCT00644176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050085|NCT04735666|||COHORT||PROSPECTIVE|||||||
34050086|NCT02363413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050087|NCT02273375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050088|NCT03951974|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34050089|NCT06648356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050090|NCT06668168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Masking of ketone ester versus placebo, but ketogenic diet vs control diet is open label.||t|f|t|t
34153661|NCT04341688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Identical colored and shaped bottles containing different study drugs. This will be provided by the pharmacy services of the university hospital.|A quadruple blind randomized controlled trial followed by laboratory based analysis. Six parallel groups of participants using various gargles and nasal lavage.|t|t|t|t
34153662|NCT01950312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153663|NCT02795325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153664|NCT03851432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34153665|NCT03852095|||COHORT||PROSPECTIVE|||||||
34153666|NCT01406990|||COHORT||PROSPECTIVE|||||||
34153667|NCT00248716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153668|NCT03895255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153669|NCT02351284|||COHORT||PROSPECTIVE|||||||
34153670|NCT03505515|||COHORT||RETROSPECTIVE|||||||
34153671|NCT05011526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34153672|NCT05755568|||CASE_ONLY||RETROSPECTIVE|||||||
34153673|NCT04683120|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153674|NCT00400569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153675|NCT01548196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153676|NCT02644928|||CASE_ONLY||PROSPECTIVE|||||||
34153677|NCT01494597|NA|SINGLE_GROUP||||NONE||||||
34153678|NCT00699335|||COHORT||PROSPECTIVE|||||||
34153679|NCT02770300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34153680|NCT05553184|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The protocol will be carried out as a within-subject, randomized, cross-over study in which each subject will serve as his/her own control||||
34153681|NCT02044861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153682|NCT05532605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153683|NCT05490927|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34153684|NCT00783458|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34153685|NCT04241302|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Free Field Voice test vs Free Field Click Test||||
34153686|NCT05963971|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants who are randomized to the intervention group will receive the same virtually-delivered nutrition educational intervention.||||
34153687|NCT05180149|||COHORT||RETROSPECTIVE|||||||
34153688|NCT05994833|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34153689|NCT01836328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34153690|NCT01242852|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34153691|NCT03931798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153692|NCT02540265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050091|NCT06664619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153693|NCT05623358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34153694|NCT05199961|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single cohort of up to 100 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of which will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled at The Ohio State University Comprehensive Cancer Center.||||
34153695|NCT01014468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153696|NCT00732108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153697|NCT05237947|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34153698|NCT03230682|||COHORT||PROSPECTIVE|||||||
34153699|NCT06104098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153700|NCT04823624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153701|NCT05104970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded placebo controlled||t|t|f|f
34153702|NCT03932630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153703|NCT02514148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153704|NCT02134730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153705|NCT05551611|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34153706|NCT00741403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153707|NCT05989854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34153708|NCT04911972|||COHORT||PROSPECTIVE|||||||
34153709|NCT01573156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153710|NCT06545695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153711|NCT04351724|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three main study arms (antiviral treatments) and three substudies (A, B, C) are planned. The main study arms are exclusive, while patients from the main study arms may participate in one or more substudies.||||
34153712|NCT03734419|||OTHER||OTHER|||||||
34050092|NCT03404947|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34050093|NCT05433532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050094|NCT02237612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153713|NCT00151502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153714|NCT05949489|||COHORT||PROSPECTIVE|||||||
34153715|NCT05862090|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945117|NCT04515602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945118|NCT04000412|||CASE_ONLY||PROSPECTIVE|||||||
33945119|NCT01840332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945120|NCT03939429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind, placebo controlled ascending single- and multiple-dose|double-blind, placebo controlled ascending single- and multiple-dose|t|f|t|f
34050095|NCT01847781|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050096|NCT06513663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050097|NCT05070988|||CASE_ONLY||PROSPECTIVE|||||||
34050098|NCT00729222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050099|NCT04304482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050100|NCT06285994|||COHORT||RETROSPECTIVE|||||||
34050101|NCT05794061|||COHORT||PROSPECTIVE|||||||
33945121|NCT02380599|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33945122|NCT01461018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050102|NCT01908829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050103|NCT06661226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050104|NCT06670508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34050105|NCT02348645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050106|NCT03621449|||COHORT||PROSPECTIVE|||||||
34050107|NCT02614742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050108|NCT00795080|||CASE_CONTROL||PROSPECTIVE|||||||
34050109|NCT03130075|||CASE_ONLY||PROSPECTIVE|||||||
34050110|NCT04974151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, controlled, double-blind, triple-dummy clinical trial|t|t|t|t
34050111|NCT03807219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050112|NCT00941499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050113|NCT03636724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34050114|NCT06172907|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-Arm Pilot Study||||
34050115|NCT00694473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050116|NCT03448575|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Waivers of consent have been obtained for providers and for patients/parents/guardians. None are informed of the study design or study activities by arm. The investigator is blind to study arm assignment of providers and patients. Only automated data collection is utilized for this practical trial. Study arm is masked for the programmer/analyst pulling outcomes data from health system records. Study arm will also be masked for study staff verifying study eligibility prior to the official study enrollment. Arm is not masked for study intervention staff (consulting psychiatrists, behavioral health navigators, bridging therapists) since these staff only interact with intervention arm subjects.|Providers are preassigned to one of two study arms: usual care control or intervention arm. Patients are assigned to the same arm as the provider triggering the best practice alert and study algorithm.|t|t|t|t
34050117|NCT02287285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050118|NCT03633305|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study involves two treatment phases of six to eight weeks. In the first phase, participants choose medication (treatment as usual), online cognitive behavior therapy, or online cognitive behavior therapy combined with medication. Participants enter a second treatment phase if they still experience insomnia after the first treatment. The treatment arms for the second phase are medication, in-person cognitive-behavior therapy, or no additional treatment.||||
34050119|NCT04862923|||COHORT||PROSPECTIVE|||||||
34050120|NCT06665841|||CASE_CONTROL||PROSPECTIVE|||||||
34050121|NCT03961685|||CASE_ONLY||CROSS_SECTIONAL|||||||
34050122|NCT06565104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050123|NCT03999827|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050124|NCT00887783|RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding after randomization|||||
34050125|NCT03798470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050126|NCT04708041|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050127|NCT06602908|||COHORT||PROSPECTIVE|||||||
34050128|NCT02606942|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050129|NCT04065451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050130|NCT03601312|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcomes assessor will not have information about the participant's treatment condition, so they will not know whether or not they are receiving treatment as usual (Standard ERP) or OC-Go augmented ERP.|"All participants will receive 12 weeks of exposure/response/prevention (ERP). Sessions 1 (psychoeducation/hierarchy creation) and 12 (relapse prevention \& generalization training) will be identical across both randomization groups.~Treatment sequences for the randomization groups will be as follows:~OC-GO-FIRST - Sessions 2-6: ERP+OC-Go, Sessions 7-11: Standard ERP~STANDARD ERP-FIRST - Sessions 2-6: Standard ERP, Sessions 7-11: ERP+OC-Go"|f|f|f|t
34050131|NCT04984226|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34050132|NCT02332447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050133|NCT05577169|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention will have two arms - one group will receive diabetes education with the addition of mind-body skills, and the other group will receive only diabetes education.||||
34050134|NCT06667180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050135|NCT06057324|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the study, the participating families and researchers cannot be blinded to the intervention, although the researchers who will perform the data analysis will be blinded.|Multicentre, parallel, randomized, single-blind and controlled clinical trial|f|f|f|t
34050136|NCT01481662|||CASE_ONLY||OTHER|||||||
34050137|NCT06238986|||COHORT||PROSPECTIVE|||||||
34050138|NCT02957968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050139|NCT02780453|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050140|NCT02064842|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34050141|NCT04684459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050142|NCT06683911|||COHORT||PROSPECTIVE|||||||
34050143|NCT04984369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050144|NCT05140746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050145|NCT03451097|||CASE_ONLY||CROSS_SECTIONAL|||||||
34050146|NCT02208284|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34075721|NCT06013449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|This study is a sham-control, single-blind clinical series. Following in-clinic training, half of the participants will be sent home with Pulsed Electromagnetic Field (PEMF) devices (pre-set to deliver the same level of energy each time) and the other half will be sent home with sham mats. The sham device is identical in every way to the treatment device except the sham console does not deliver a pulsed electromagnetic field. Patients will be randomly assigned (1:1) to either the PEMF treatment or the sham device. Both groups will be instructed on how to self-administer PEMF therapy for 8 minutes. All participants will be instructed to only use the PEMF devices immediately following each instillation, while they are holding the instillation solution in their bladder.|t|f|f|f
34075722|NCT00000795||||PREVENTION||DOUBLE||||||
33945123|NCT06085690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Hospitals were divided into different groups, and the subjects and effect evaluators were blinded because they could not hide the assignment and the implementers were blinded. The main outcome indicators were laboratory objective indicators of CRBSI diagnosis||t|f|f|t
34153716|NCT01369732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153717|NCT03974373|NA|SINGLE_GROUP||TREATMENT||NONE||"We included in the present study 40 patients who sought the UNIMES Dentistry Clinic for the BFP removal procedure. All female, aged between 20 and 40 years and showing good general health. All the patients received information and had access to the informed consent form that after the necessary explanations was duly filled and signed.~Clinical parameters such as periodontal indices (depth of probing, plaque index and gingival index), characteristics of the jugal mucosa, opening of the mouth, and the amount of fat removed were evaluated. After detailed anamnesis and verified the need to remove the fat ball by constant bite on the jugal mucosa or for aesthetic reasons of facial thinning the patients were instructed to perform the blood tests, fasting blood glucose and complete blood count. With the exams presenting normal levels and compatible with health status, the patients were scheduled to perform the proposed therapy."||||
33737619|NCT05914467|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 1:1 between standard treatment and treatment guided by TDM with MIPD.||||
33737620|NCT06250686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34153718|NCT03645512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153719|NCT00148941|RANDOMIZED|PARALLEL||PREVENTION||NONE|The study was conducted in an open manner except for the consistency lots of SB213503 vaccine that were double-blinded.|||||
34153720|NCT05900492|||COHORT||PROSPECTIVE|||||||
33737621|NCT01235455|||COHORT||PROSPECTIVE|||||||
34153721|NCT04235712|||CASE_ONLY||PROSPECTIVE|||||||
34153722|NCT04855019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||prospective randomized trial, To compare the suprasacuplar-axillary nerve block combined with the periarticular injection method in shoulder arthroscopy cases.|t|f|f|f
34153723|NCT04291768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153724|NCT00376896|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34153725|NCT02177474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153726|NCT03539575|NA|SINGLE_GROUP||OTHER||NONE||||||
33737622|NCT05251792|||CASE_CONTROL||PROSPECTIVE|||||||
34153727|NCT05339230|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo study products similar to the active products|Parallel 2 group randomized trial|t|t|t|t
34153728|NCT05985928|||OTHER||OTHER|||||||
34153729|NCT01990859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737623|NCT01231425|||COHORT||PROSPECTIVE|||||||
34153730|NCT00003552||||TREATMENT||||||||
34153731|NCT03667690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153732|NCT00387036|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33737624|NCT00777452|||COHORT||PROSPECTIVE|||||||
34153733|NCT05595772|RANDOMIZED|PARALLEL||OTHER||SINGLE||The study will use simple randomization to allocate patients into 2 groups, each group will be included 10 patients.|f|f|f|t
34153734|NCT03665116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34153735|NCT04038762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153736|NCT00386165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153737|NCT02228447|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34153738|NCT03147534|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34153739|NCT03574402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153740|NCT03461094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153741|NCT04407234|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34153742|NCT00470418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737625|NCT02523833|NA|SINGLE_GROUP||OTHER||NONE||||||
34153743|NCT01810315|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33737626|NCT06572995|||COHORT||PROSPECTIVE|||||||
34153744|NCT00136669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34153745|NCT00712803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34153746|NCT00652080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153747|NCT05271448|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients enrolled to the study were randomized into continuing or discontinuing (ACEI/ARBs) group. Care providers and investigators collected their data before and after the coronary angiography. The independent variable - continuing or discontinuing (ACEI/ARBs) - was coded into A or B groups, then data was sent to the outcomes assessor.||f|f|f|t
34153748|NCT02722265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153749|NCT00330681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153750|NCT00941122|||||PROSPECTIVE|||||||
34153751|NCT02661074|||CASE_CONTROL||PROSPECTIVE|||||||
34153752|NCT00915291|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
34153753|NCT00196508|RANDOMIZED|PARALLEL||||NONE||||||
34153754|NCT04491851|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The details of patient groups will be sealed in sequentially numbered, opaque, sealed envelopes generated by Xuezhu Wang from the nuclear medicine department, Peking Union Medical College Hospital, who will not participate in other parts of the study.|"Patients will be randomly assigned into four arms:~Arm A : 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 Arm B : 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11"|t|f|f|t
34153755|NCT05501743|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization will be balanced in 2 parallel groups :~* Patients in the study treatment group (T) will receive an intra-articular injection of microfat and PRP.~* Patients in the reference treatment group (R) will undergo total wrist denervation surgery."||||
34153756|NCT06315738|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34153757|NCT03665688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33737627|NCT03762135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737628|NCT03840785|RANDOMIZED|FACTORIAL||TREATMENT||NONE|no masking|||||
33737629|NCT05686408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737630|NCT06664060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737631|NCT06601270|||COHORT||OTHER|||||||
33737632|NCT03717532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33737633|NCT06268821|NA|SINGLE_GROUP||OTHER||NONE||||||
33737634|NCT05501509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737635|NCT03903107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||CSP can be achieved successfully and safely utilizing electro-anatomic mapping (EAM) with the CARTO 3mapping system|t|f|f|f
34153758|NCT02081599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153759|NCT00082381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153760|NCT01257022|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34153761|NCT05564806|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm||||
34153762|NCT03665311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The packaging for normal saline and 25% albumin will be identical (glass bottles) and be covered. The intravenous tubing will have an opaque sleeve to mask any colour discrepancy in the 2 products|A randomized controlled trial with two parallel arms 1:1|t|t|t|t
34153763|NCT03884647|||COHORT||PROSPECTIVE|||||||
34153764|NCT01497782|RANDOMIZED|PARALLEL||||NONE||||||
34153765|NCT04741672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The control and intervention group will be formed by randomization. The intervention and control group will be defined as group 1 and group 2 for statistical analysis. Data analysis will be evaluated and reported by the statistician. Also the statistician will be blind.|This was pretest-posttest design, randomized controlled trial.|t|f|f|f
34153766|NCT00980759|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization of Radiotherapy field||||
34153767|NCT04739878|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153768|NCT00223704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153769|NCT04792684|||CASE_CONTROL||PROSPECTIVE|||||||
34153770|NCT06583772|||CASE_ONLY||CROSS_SECTIONAL|||||||
34153771|NCT02597140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34153772|NCT01898013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153773|NCT04520724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153774|NCT01247480|||COHORT||RETROSPECTIVE|||||||
34153775|NCT00237263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153776|NCT03517566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153777|NCT04809350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153778|NCT04283591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153779|NCT01426477|||COHORT||PROSPECTIVE|||||||
34153780|NCT05930236|NA|SINGLE_GROUP||TREATMENT||NONE||"the medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed under ultrasound by caudal-cranial approach, followed by an X-ray check to verify the positioning of the needle."||||
34153781|NCT00609661|||CASE_CONTROL||PROSPECTIVE|||||||
34153782|NCT03815565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the pharmacist chief knows which participant belongs to each arm|randomized|t|f|t|f
34153783|NCT05443711|||COHORT||PROSPECTIVE|||||||
34153784|NCT00218972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153785|NCT00945932|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34153786|NCT05220332|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
34153787|NCT03459456|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34153788|NCT01320592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153789|NCT06284733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|They will be assigned into three equal groups:|f|f|t|t
34153790|NCT05325385|||CASE_ONLY||OTHER|||||||
34153791|NCT03317119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153792|NCT05371548|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34153793|NCT01726985|||COHORT||PROSPECTIVE|||||||
34153794|NCT01219062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153795|NCT01626417|NA|SINGLE_GROUP||||NONE||||||
33737636|NCT00003545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050147|NCT04548115|RANDOMIZED|PARALLEL||PREVENTION||NONE||Using site randomization, each higher education institution will be randomized into one of the five RCT conditions (i.e. full ARTISAN, participatory arts, art space, storytelling and control), and each elderly care agency will be randomized into one of the same five conditions. Based on randomization outcome, one higher education institution will be paired with one elderly care agency, the paired collaborating sites will be allocated to the same RCT condition. Participant recruitment will be simultaneously conducted at each paired sites through 5 sequential rounds, and each round will recruit 2 groups, totalling 10 groups for the entire study. Each group will comprise 14 participants with youths and senior to be randomized paired as dyads, who will undergo a 5-week RCT condition with a follow-up assessment at 10-weeks. At any given time during the study, 2 groups will be run concurrently until all 10 groups complete the RCT.||||
34050148|NCT03530605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective group (non-randomized) compared to historical matched controls||||
33737637|NCT05584501|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Each site will experience a care delivery model for 3 months, followed by a 1 month washout period, and then 3 months with the alternative care delivery model.||||
33737638|NCT05852457|||COHORT||PROSPECTIVE|||||||
33737639|NCT05596669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737640|NCT02526381|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33737641|NCT03979365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737642|NCT02364102|||COHORT||PROSPECTIVE|||||||
33737643|NCT00382733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737644|NCT05351606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737645|NCT05059015|RANDOMIZED|PARALLEL||SCREENING||NONE||A randomized clinical trial with three arms will be performed: One group with the routine screening procedure based on HPV tests with cervical sampling by a health personnel ( 3 visits: sampling, colpo/biopsy, treatment of CIN2 +), a second group with a screening based on HPV self-testing and colposcopic evaluation (2 visits: colpo/biopsy, treatment of CIN2 + ); and a third group with a screening based only on HPV self-testing (1 visit: HPV + treatment according to eligibility).||||
33737646|NCT02233231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737647|NCT02718105|||OTHER||PROSPECTIVE|||||||
33737648|NCT00002312||||TREATMENT||NONE||||||
33737649|NCT06574373|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33737650|NCT05268796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737651|NCT05497908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33737652|NCT03003676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737653|NCT03037151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153796|NCT00606983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153797|NCT03837132|||CASE_CROSSOVER||PROSPECTIVE|||||||
34050149|NCT06141122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All elective colonoscopies were performed by two experienced endoscopists who were unaware of the group assignments.||f|t|f|f
34050150|NCT05377281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050151|NCT02783729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050152|NCT06445322|||COHORT||CROSS_SECTIONAL|||||||
34050153|NCT05093504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050154|NCT03010150|||COHORT||PROSPECTIVE|||||||
34050155|NCT05403853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||IVD Performance Evaluation Study||||
34050156|NCT05276349|||COHORT||PROSPECTIVE|||||||
34050157|NCT05407870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050158|NCT06613633|||COHORT||PROSPECTIVE|||||||
34050159|NCT01671995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075723|NCT01899820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34153798|NCT02578173|||COHORT||PROSPECTIVE|||||||
34153799|NCT02950675|||CASE_CONTROL||PROSPECTIVE|||||||
34153800|NCT04545463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153801|NCT02708485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153802|NCT03437824|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34153803|NCT04878952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153804|NCT02950376|||CASE_ONLY||CROSS_SECTIONAL|||||||
34153805|NCT05359601|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34153806|NCT03221361|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|"The study will be blinded regarding the statistician who is responsible for data analysis.~The participant patients will be blinded. The outcome assessor for biting force can be blinded during the measurement, the operator cannot be blinded."|prospective , parallel , randomized clinical trial|t|t|f|t
34153807|NCT02643342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153808|NCT03228212|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34153809|NCT01008085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153810|NCT05238805|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Participants will have to perform 2 scans one after the other||||
34153811|NCT04629846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34153812|NCT04084847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153813|NCT02562859|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153814|NCT01071759|||CASE_CROSSOVER||PROSPECTIVE|||||||
34153815|NCT01474070|||COHORT||PROSPECTIVE|||||||
34153816|NCT02551029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34153817|NCT03354624|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34153818|NCT00642317|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34153819|NCT05946005|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||This study was a single-blind randomized control trial conducted at five different hospitals in Makassar from December 2021 to May 2022. All mothers with vaginal delivery who experienced grade II perineal rupture were applied lidocaine cream, povidone iodine cream, honey, and controls, measured on the REEDA and visual analogue scales (VAS) and observed on days 0, 1, 3, 5, 7, and 14. Repeated ANOVA or Friedman tests were used to analyze the data obtained.|t|t|t|t
34153820|NCT05688488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34153821|NCT00428870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153822|NCT03051919|||COHORT||PROSPECTIVE|||||||
34153823|NCT02780414|||FAMILY_BASED||PROSPECTIVE|||||||
34153824|NCT06418451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153825|NCT02146625|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34153826|NCT05989958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153827|NCT00171847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153828|NCT04033783|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34153829|NCT02396368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153830|NCT04266236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34153831|NCT05082415|||COHORT||RETROSPECTIVE|||||||
34153832|NCT02469519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153833|NCT01079936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153834|NCT02161757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34153835|NCT03696901|||COHORT||OTHER|||||||
34153836|NCT04029298|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized, controlled, non-blinded pilot study||||
34153837|NCT01174212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153838|NCT03994198|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants and the investigators will be blinded the the supplement type, only the LPI will have the codes to decipher the supplement type. Supplements are referred to as A and B.|Randomized cross-over design|t|f|t|t
34153839|NCT01321957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153840|NCT02736981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153841|NCT02336542|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34153842|NCT05243303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients in both arms will not know in which of the two arms (active treatment or control group) they are randomized. The sham procedure is similar to the transcutaneous auricular vagus nerve stimulation (but does not involve the actual stimulation). Therefore, it is unlikely that patients are able to differentiate whether they are assigned to the control group or to the active treatment group.|Patients with plaque psoriasis will be randomized in one of two groups: (1) Active treatment group. These patients will receive daily transcutaneous auricular vagus nerve stimulation for 3 months; (2) Control group. These patients will receive a sham procedure instead of the transcutaneous auricular vagus nerve stimulation.|t|f|f|f
34153843|NCT03921177|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Multiple micronutrient and placebo tablets are identical in size, shape, and appearance; coding of supplements carried out independent of investigators and research team.|Cluster-randomized, placebo-controlled concurrent intervention trial|t|t|t|t
34153844|NCT00527319|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34153845|NCT02262962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34153846|NCT02448290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153847|NCT02658773|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34153848|NCT04246632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|PI is masked to Capsule results and capsule reader is masked to colonoscopy results.|Multi-Center; Prospective, Open Label, Non-Significant Risk, Pilot Study||||
34153849|NCT06303232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153850|NCT04468035|||COHORT||CROSS_SECTIONAL|||||||
34153851|NCT01862653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153852|NCT05360745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34153853|NCT06165094|||COHORT||RETROSPECTIVE|||||||
34153854|NCT02255201|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34153855|NCT01207349|||CASE_CONTROL||PROSPECTIVE|||||||
34153856|NCT03123328|NA|SINGLE_GROUP||OTHER||NONE||||||
34153857|NCT01224080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153858|NCT01201226|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34153859|NCT02207959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153860|NCT02215824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153861|NCT06328309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153862|NCT05407155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153863|NCT05504551|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||study group receives superficial cervical plexus block with lidocaine and bupivacaine control group receives superficial cervical plexus block using normal saline as a placebo|t|t|t|t
34153864|NCT00696969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153865|NCT00095173|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34153866|NCT00803322|||COHORT||PROSPECTIVE|||||||
34153867|NCT06432166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment will be supplied in capsules of the same size and color.|A phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study.|t|t|t|t
34153868|NCT02484222|||COHORT||PROSPECTIVE|||||||
34153869|NCT05687513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153870|NCT02301624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The study consisted of a 4-week Blind Induction Phase to preserve the blinded nature of Study ECU-MG-301, followed by an Open-Label Maintenance Phase.|Following the Blind Induction Phase, all participants received open-label eculizumab.||||
34153871|NCT04770792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153872|NCT02022436|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34153873|NCT05409937|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34153874|NCT05254873|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34153875|NCT00259207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153876|NCT06410456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153877|NCT01605175|||CASE_CROSSOVER||PROSPECTIVE|||||||
34153878|NCT04359979|NA|SINGLE_GROUP||TREATMENT||NONE||off label use of an approved drug for new indication||||
34153879|NCT01183468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153880|NCT03369002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153881|NCT01487824|||CASE_CONTROL||PROSPECTIVE|||||||
34153882|NCT02689167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153883|NCT04706156|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34153884|NCT02196480|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34153885|NCT02186145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153886|NCT04165629|||COHORT||PROSPECTIVE|||||||
34153887|NCT05993962|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34153888|NCT04071418|||COHORT||PROSPECTIVE|||||||
34153889|NCT03633812|||COHORT||PROSPECTIVE|||||||
34153890|NCT00345618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34153891|NCT03688620|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34153892|NCT04328272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Single blinded:~As, the disease is novel and putting the lives at risk is unethical. therefore, It is important for investigator to know the group and carry close regular monitoring of participants so that proper further intervention can be made when required."|three parallel groups randomly asserted for intervention|t|f|f|f
34153893|NCT06023615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34153894|NCT03006692|||CASE_CONTROL||PROSPECTIVE|||||||
34153895|NCT04939792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153896|NCT00336557|||CASE_CONTROL||PROSPECTIVE|||||||
34153897|NCT06512740|||OTHER||CROSS_SECTIONAL|||||||
34153898|NCT06409364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded participant, care provider, investigator and outcome assessors. Study drug and placebo identical in appearance.|A multi-centre, prospective, blinded, randomised clinical trial of fludrocortisone compared with placebo in patients presenting with aneurysmal subarachnoid haemorrhage.|t|t|t|t
34075724|NCT05157880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075725|NCT05554640|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34075726|NCT05860569|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34075727|NCT00356161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075728|NCT05305859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075729|NCT00490347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34153899|NCT02780544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34153900|NCT01123395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34153901|NCT03969186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34153902|NCT02874027|||CASE_CONTROL|||||||||
34153903|NCT01879969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153904|NCT03313336|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||This study will be a double-blind, randomized, 2-period, placebo-controlled, crossover study in healthy male and female subjects, performed at a single study center. Prior to inclusion, informed consent will be obtained. A brief medical history, including limited demographic data (gender, age and ethnicity) will be recorded, and eligibility for inclusion to the study will be established through a physical inspection of hands. Subjects will be shown how to complete the visual analogue scale (VAS). At each specific study visit, each subject will undergo a left-right comparison of two patch preparations, followed by a repeated test with an alternate combination of preparations. Thus, the study will comprise: Visit 1: EMLA Test Patch plus Placebo Patch OR EMLA Test Patch plus EMLA current Reference Patch. Visit 2: EMLA Test Patch plus EMLA current Reference Patch OR EMLA Test Patch plus Placebo Patch.|t|t|f|f
34153905|NCT00687531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050160|NCT05178992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained research assistants separate from other research personnel will collect outcomes; these research personnel will be blinded to the hypotheses and group assignments.|Participants will be randomized to either Usual Activity Program or Usual Activity Program + Robot Activity within each long term care facility. At each site, the order of the robot type (humanoid or dog) will be randomized. Each participant will participate in two sessions/week for 8 weeks (4 weeks with humanoid robot, 4 weeks with dog robot).|f|f|f|t
34050161|NCT00535782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050162|NCT04810000|||CASE_CONTROL||PROSPECTIVE|||||||
33737654|NCT03049163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737655|NCT03361410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737656|NCT06302387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind, where neither the patients nor the clinicians responsible for treatment know the specific treatment modality|The interventional study model for this trial is a two-arm, double-blind, randomized, prospective controlled clinical trial.|t|t|f|f
33737657|NCT05166291|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737658|NCT06381986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blinded, Parallel, Vehicle-Controlled|Double-Blinded, Parallel, Vehicle-Controlled|t|t|t|t
33737659|NCT04618081|||CASE_ONLY||RETROSPECTIVE|||||||
33737660|NCT01318863|||||PROSPECTIVE|||||||
33737661|NCT02425631|||COHORT||PROSPECTIVE|||||||
33737662|NCT05265949|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33737663|NCT03898817|||OTHER||PROSPECTIVE|||||||
33737664|NCT04436094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737665|NCT01177098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737666|NCT00285753|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33737667|NCT06194903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737668|NCT03098446|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Subjects will be randomly assigned to either the sitting plus exercise or the sitting without exercise group and then, after a one week washout period, complete the other task.||||
33737669|NCT03098472|||COHORT||PROSPECTIVE|||||||
33737670|NCT03096782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737671|NCT03158558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737672|NCT01713777|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33737673|NCT02772016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737674|NCT02993601|||CASE_CONTROL||PROSPECTIVE|||||||
33737675|NCT06454981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737676|NCT06129292|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33737677|NCT03097068|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737678|NCT05928338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33737679|NCT01791582|||||PROSPECTIVE|||||||
33737680|NCT04084145|||COHORT||PROSPECTIVE|||||||
33737681|NCT03001895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737682|NCT06347354|NA|SINGLE_GROUP||OTHER||NONE||||||
33737683|NCT02440880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737684|NCT06207682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737685|NCT02067403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737686|NCT02453594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737687|NCT06072612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737688|NCT05526352|||COHORT||PROSPECTIVE|||||||
33737689|NCT05024695|NA|SINGLE_GROUP||TREATMENT||NONE|Person(s) checking intraocular pressures are masked, except for day of surgery, throughout the duration of the trial.|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space. The MINIject™ SO627 implant is manufactured from proprietary STAR® silicone material.||||
33737690|NCT05066841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737691|NCT00870311|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33737692|NCT04610086|||OTHER||CROSS_SECTIONAL|||||||
34050163|NCT06097923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050164|NCT06682208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34050165|NCT04189939|||COHORT||PROSPECTIVE|||||||
34050166|NCT06512207|RANDOMIZED|PARALLEL||TREATMENT||NONE||80 cases of stage III or IV NSCLC are randomly divided into two groups of 40 cases each. The control group is to receive conventional treatments (Chemotherapy + PD-1 Monoclonal Antibody), while the experimental group is to receive conventional treatments combined with Leuprorelin acetate.||||
34050167|NCT05845762|||CASE_CONTROL||RETROSPECTIVE|||||||
34050168|NCT06667258|||COHORT||PROSPECTIVE|||||||
34050169|NCT05139602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050170|NCT01259804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050171|NCT02997072|||COHORT||PROSPECTIVE|||||||
34050172|NCT01867710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050173|NCT06665646|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34050174|NCT05935644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737693|NCT01856972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737694|NCT03149640|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33737695|NCT01961869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737696|NCT05855200|RANDOMIZED|PARALLEL||TREATMENT||NONE|Click here to enter text.|||||
33737697|NCT00530023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050175|NCT02954692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050176|NCT04056845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors are blinded from the treatment received|Randomized prospective study|f|f|t|t
33737698|NCT05572905|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||single groups assignment||||
33737699|NCT02419716|||OTHER||PROSPECTIVE|||||||
33737700|NCT00004577|||COHORT||PROSPECTIVE|||||||
33737701|NCT04679727|||COHORT||PROSPECTIVE|||||||
33737702|NCT00633984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737703|NCT02442921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737704|NCT02178943|||CASE_ONLY||PROSPECTIVE|||||||
33737705|NCT03194763|||CASE_ONLY||PROSPECTIVE|||||||
34050177|NCT03589326|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is an open-label trial, therefore investigators and participants are unblinded.|||||
34050178|NCT00191347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050179|NCT03518619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050180|NCT04779398|||COHORT||CROSS_SECTIONAL|||||||
34050181|NCT06667843|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34050182|NCT01376986|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34050183|NCT02751450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34050184|NCT03202810|||COHORT||PROSPECTIVE|||||||
34050185|NCT05782361|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34050186|NCT00776295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050187|NCT05857930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050188|NCT01578473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050189|NCT04476953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050190|NCT06086210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since the light coming from the probe was visible in the laser applications used in both groups, the patients were not able to learn which group they were in, meaning they were blinded. All outcome measures were evaluated by another researcher who did not know which group the patients were in, thus ensuring that the study was double-blind.|Two groups with laser treatment and sham-controlled treatment|t|f|f|t
34050191|NCT06285214|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34050192|NCT03651427|NA|SINGLE_GROUP||TREATMENT||NONE||Sel-controlled case series||||
34050193|NCT06537999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050194|NCT06682052|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34050195|NCT01303406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050196|NCT06640257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050197|NCT01762202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050198|NCT03723161|||CASE_ONLY||PROSPECTIVE|||||||
34050199|NCT05800730|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34050200|NCT02358096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050201|NCT06682507|||COHORT||OTHER|||||||
34050202|NCT05832905|||CASE_CONTROL||PROSPECTIVE|||||||
34050203|NCT02910700|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050204|NCT01197586|||COHORT||PROSPECTIVE|||||||
34153906|NCT05295355|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34153907|NCT00417846|||COHORT||PROSPECTIVE|||||||
34153908|NCT01605721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153909|NCT04845178|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The investigator, study nurse/other study personnel, and patients will be blinded to the treatment group. An appropriately trained person will reconstitute investigational product, fill masked-labeled syringes and provide them to the investigator, but will not perform any assessments with the patient.|Approximately 765 patients will be randomized in a 1:1:1 ratio and receive 1 of the following 3 treatments: ABP-450 Low Dose, ABP-450 High Dose, or placebo via intramuscular injection into pre-specified areas of the head and neck.|t|f|t|t
34153910|NCT03221309|||COHORT||PROSPECTIVE|||||||
34153911|NCT04354883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153912|NCT04118595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153913|NCT02113332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153914|NCT05169411|||COHORT||RETROSPECTIVE|||||||
34153915|NCT06448039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and providers will not be aware of treatment assignment until the conclusion of the study.|Double blinded placebo controlled trial|t|t|t|f
34153916|NCT01799551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153917|NCT06169488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not have access to information about participants' allocated treatment groups (lumbar interbody fusion or multidisciplinary rehabilitation)||f|f|f|t
34153918|NCT03401060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153919|NCT00673283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34153920|NCT06260553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153921|NCT01183065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153922|NCT04564677|||CASE_ONLY||PROSPECTIVE|||||||
34153923|NCT05659472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The process of randomization to determine the respondents into the intervention and control groups without being known by the researchers and respondents.~Assessment of cortisol, serotonin, and depression levels was not known by researchers, respondents, and care providers and was only known by the outcomes assessor."|The intervention group was given a combination of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis and the control group was given mindfulness-based cognitive therapy (MBCT).|t|t|t|t
34153924|NCT02911012|||COHORT||RETROSPECTIVE|||||||
34153925|NCT00965419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153926|NCT02387554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34153927|NCT00642863|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34153928|NCT04830488|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34153929|NCT02229526|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34153930|NCT00007891||||TREATMENT||||||||
34153931|NCT05071014|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical trial will be designed as a single-arm, single-institution study.||||
34153932|NCT05899296|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33737706|NCT05434312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737707|NCT01736280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737708|NCT06391996|||COHORT||RETROSPECTIVE|||||||
33737709|NCT01732835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737710|NCT05768503|RANDOMIZED|PARALLEL||TREATMENT||NONE||176 subjects will be randomized in a 1:1 ratio into either the chidamide + sintilimab + bevacizumab group or the standard second-line FOLFIRI + bevacizumab therapy group.||||
33737711|NCT01268644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737712|NCT05322317|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a prospective pilot study designed to achieve the objectives listed above. This project focuses on implementing ACP (which is an accepted best practice) and using ECHO (which is an evidence-based existing professional development model in healthcare). The research component involves data collection from clinicians and clinics in addition to what would be normally collected for as part of the training program and for quality improvement (QI).||||
33737713|NCT05195996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33737714|NCT03376204|||OTHER||PROSPECTIVE|||||||
33737715|NCT00854087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737716|NCT03412643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737717|NCT02755675|NA|SINGLE_GROUP||||NONE||||||
33737718|NCT00585065|||OTHER||PROSPECTIVE|||||||
33737719|NCT00580905|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33737720|NCT00142909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737721|NCT03563040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737722|NCT04701268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737723|NCT04634916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737724|NCT06574347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737725|NCT02037503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737726|NCT01379326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737727|NCT03836092|||COHORT||PROSPECTIVE|||||||
33737728|NCT06664645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"A prospective randomized study will be carried out in a 1:1 ratio between groups. Patients with large and extensive rotator cuff injuries will be selected at the Shoulder and Elbow clinic of Pedro Ernesto University Hospital (HUPE-UERJ), during outpatient care.~Patients with an intact long head of the biceps will be randomized into two groups, according to the use or not of the tendon: complete repair with LHB tendon reinforcement and complete repair without reinforcement."|t|f|f|t
33737729|NCT00585949|||CASE_CONTROL||PROSPECTIVE|||||||
34153933|NCT01232855|||COHORT||PROSPECTIVE|||||||
34153934|NCT03299712|NA|SINGLE_GROUP||OTHER||NONE||||||
34050205|NCT06682338|||OTHER||CROSS_SECTIONAL|||||||
34153935|NCT05684185|||COHORT||PROSPECTIVE|||||||
34153936|NCT06354387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050206|NCT06142643|NA|SINGLE_GROUP||OTHER||NONE||||||
34050207|NCT03646526|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34153937|NCT02943915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153938|NCT01143584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153939|NCT03171818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double-blinded study, meaning that both the patient (and his/her parents) and the health care providers, including neonatologist, pediatrician, nurses, physiotherapists, etc, are not allowed to know what treatment the patient has been given. Those that collect outcome parameters, such as MRI data and neurodevelopmental outcome, are also unaware of treatment allocation, meaning that blinding will be maintained during the full study-period of 18 months.|An international multicenter, randomized placebo controlled intervention study|t|t|t|t
34153940|NCT01918332|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34153941|NCT03334812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153942|NCT02831933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153943|NCT01892891|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34153944|NCT00503321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153945|NCT01374178|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153946|NCT01272765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153947|NCT02468349|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34153948|NCT04213378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153949|NCT00742755|NA|SINGLE_GROUP||SCREENING||NONE||||||
34153950|NCT03125837|||OTHER||PROSPECTIVE|||||||
34153951|NCT02974842|||CASE_ONLY||PROSPECTIVE|||||||
34153952|NCT04233619|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34153953|NCT04937283|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|segmentectomy group versus lobectomy group||||
33737730|NCT05199948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737731|NCT01831141|||COHORT||PROSPECTIVE|||||||
33737732|NCT03603886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Waitlist control group receives intervention following waitlist period.||||
33737733|NCT04162704|||CASE_ONLY||PROSPECTIVE|||||||
33737734|NCT04116554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737735|NCT02381535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737736|NCT00054002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737737|NCT00128258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737738|NCT05037396|||COHORT||RETROSPECTIVE|||||||
33737739|NCT02758236|||COHORT||PROSPECTIVE|||||||
33737740|NCT03333005|NA|SEQUENTIAL||OTHER||NONE||The first 10 patients enrolled will be administered IV APX001. The second 10 patients enrolled will be administered oral APX001||||
34050208|NCT04055493|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, interventional, prospective, two-arm, randomized, open-label, controlled (neo)adjuvant, phase-III trial evaluating the efficacy and safety of ribociclib combined with endocrine therapy (ET) versus standard-of-care chemotherapy in early breast cancer (EBC) patients with molecular HR+/HER2- subtype.||||
34050209|NCT02423031|||COHORT||PROSPECTIVE|||||||
34050210|NCT01812317|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34050211|NCT02442570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34050212|NCT04239963|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050213|NCT03148392|||COHORT||PROSPECTIVE|||||||
34050214|NCT01146379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153954|NCT03776461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Evaluator blinded assessment of photographs|Prospective, single centre, evaluator-blind study|f|f|f|t
34153955|NCT04585607|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participant hospital currently has around 90 maintenance HD patients and it is possible to recruit 74 patients for this study. Study subjects will be randomized to each treatment arm using a random number table. As outlined in the proposal, it is estimated that we may experience up to 30% of drop out during the study.||||
34153956|NCT01478191|||COHORT||RETROSPECTIVE|||||||
34153957|NCT03286816|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34153958|NCT05643534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153959|NCT06199453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153960|NCT03698656|||CASE_ONLY||PROSPECTIVE|||||||
34153961|NCT01232985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153962|NCT00288262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34153963|NCT06003088|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153964|NCT05170178|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Group with parental experience caring for infants (20 men and 20 women) Group with professional experience in caring for infants (20 women)||||
34153965|NCT00450645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153966|NCT02702414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153967|NCT03472144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Principle investigator will be non blinded and all others will be blinded|This is a single-blinded Randomized Control Trial study, in which every patient receives active gel on one side and placebo on the other (L or R to be randomly selected).|t|t|t|t
34153968|NCT00473538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153969|NCT04560153|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34153970|NCT06547489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators and site staff, and outcomes assessors will be blind to treatment with GATE-251 or placebo.|double-blind, placebo-controlled, fixed dose, parallel groups|t|t|t|t
34153971|NCT03993041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34153972|NCT00366912|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34153973|NCT04515108|||COHORT||RETROSPECTIVE|||||||
34153974|NCT04541966|||COHORT||RETROSPECTIVE|||||||
34153975|NCT05418595|||CASE_ONLY||RETROSPECTIVE|||||||
34153976|NCT03247959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050215|NCT02497963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050216|NCT00621868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050217|NCT05551754|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single blind|Placebo controlled, randomized, crossover trial in 10 healthy volunteers|t|f|f|f
33737741|NCT05628740|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|A computerized randomization scheme for Part 1 and Part 2 will be created by a blinded study statistician and it shall be considered blinded per the following: The randomization is available only to the unblinded Clinic pharmacy staff who are preparing the study drug and who will not be involved in any other aspect of the study including administration of the study drug. The randomization scheme will not be made available to the Sponsor, study participants, or members of the staff responsible for the monitoring and evaluation of safety assessments.|"Part 1: randomized, double-blind, placebo-controlled, 3-period crossover, and 1-period parallel study.~Part 2: randomized, double-blind, placebo-controlled, multiple-dose, parallel-design."|t|f|t|f
33737742|NCT06529328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|"It will be randomized control trail in which nonprobability convenient sampling will be used. two groups of 2 to 7 years age will be formed in which participants will be randomly divided. Group A: will receive , CP children will receive core stability exercises.~Group B: Experiment group B, CP children will receive trunk stability exercise."|t|f|f|f
34050218|NCT06036290|||CASE_ONLY||CROSS_SECTIONAL|||||||
33737743|NCT04587323|||COHORT||PROSPECTIVE|||||||
33737744|NCT06034158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34050219|NCT05334342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The random permuted blocks strategy will be used in this study to randomly allocate an equal number of participants into the two crossover arms by the study statistician. Diet group assignment will be coded (e.g., low-gi diet=diet a; high-gi diet=diet b). Only the kitchen staff preparing the meals will know the code. Study personnel analyzing the biological samples, entering data, and performing statistical analyses will be blinded to the diet group assignment to reduce bias. Due to the nature of dietary studies, participants will not be blinded to the randomization.|The investigator(s) propose to recruit 12 participants with chronic SCI (\>1 year) and utilize a single-blinded randomized crossover design (low-GI vs. high-GI diet) to assess postprandial BP and postprandial glycemic responses to the study diets in this population.|f|f|t|t
34050220|NCT06668792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737745|NCT01312116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737746|NCT01401530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050221|NCT00565643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737747|NCT03189251|||COHORT||RETROSPECTIVE|||||||
34050222|NCT05193617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050223|NCT05418582|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33737748|NCT02572271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737749|NCT05889624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the principal investigator will remain blinded to the randomization assignment. All other study staff including the project manager, assistant project manager, study statistician, site investigators and study staff, participants, and their parents will be aware of the treatment assignment.||f|f|t|f
34153977|NCT03489928|RANDOMIZED|PARALLEL||TREATMENT||NONE|Group assignment will be concealed until time induction is to begin, when randomization will occur. No attempt will be made at formal blinding of caregivers following concealed randomization, although neonatal assessment will be carried out by a team unaware of study group assignment.|Patients will be randomly assigned to one of three approaches to initiation of labour induction. Study group allocation will be stratified based on membrane status (ruptured/intact). Sequentially numbered opaque envelopes contain group assignment prepared using computer generated random number tables, in blocks of 4 and 6. Group 1 will receive misoprostol 50µgs, repeated at 4hr intervals until one of the following occurs: progressive labour, contraction frequency of 3 per 10 minutes, non-reassuring fetal heart rate tracing, or delivery. Group 2 will receive misoprostol 25µg initial dose and then 25-50µg placed in the vagina at 6hr intervals to the same effect. Group 3 will have induction of labour managed by the usual method here at the IWK (intravaginal or intracervical prostaglandin gel and IV oxytocin drip). All care decisions will be made by the attending physician. The patient will be reassessed before each administration of misoprostol.||||
34153978|NCT02929238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34153979|NCT00883857|||COHORT||PROSPECTIVE|||||||
34153980|NCT06469606|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33737750|NCT01162005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153981|NCT02652078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153982|NCT02114255|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34153983|NCT03943420|||CASE_CONTROL||PROSPECTIVE|||||||
34153984|NCT01532869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34153985|NCT05693987|||CASE_CONTROL||PROSPECTIVE|||||||
34153986|NCT04133272|||COHORT||OTHER|||||||
34153987|NCT00044902||||TREATMENT||||||||
34153988|NCT05439538|||COHORT||PROSPECTIVE|||||||
34153989|NCT04883034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34153990|NCT03405519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34153991|NCT01870648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34153992|NCT06036316|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33737751|NCT03154697|||CASE_ONLY||CROSS_SECTIONAL|||||||
34153993|NCT02741206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34153994|NCT00761202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34153995|NCT04839445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34153996|NCT06262217|||CASE_ONLY||PROSPECTIVE|||||||
34153997|NCT01667874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737752|NCT03176394|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737753|NCT06573320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737754|NCT01611259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737755|NCT06034080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Mutli-Center Cluster Randomized Trial||||
33737756|NCT06100614|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33737757|NCT06282484|||CASE_CONTROL||PROSPECTIVE|||||||
33737758|NCT03717337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|The design of this randomized clinical trial is a parallel group two arms trial with 1:1 allocation ratio|f|f|f|t
33737759|NCT01235910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737760|NCT05315388|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel intervention evaluation study that will consider two interventions; the conscious immersion therapy in nature (Vitamin N) and the usual intervention designed by the company for psychosocial risk reduction.||||
33737761|NCT00991302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34153998|NCT05113914|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737762|NCT02322697|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737763|NCT01662869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737764|NCT04858724|||COHORT||PROSPECTIVE|||||||
33737765|NCT04950335|||COHORT||RETROSPECTIVE|||||||
34153999|NCT02557022|||||PROSPECTIVE|||||||
34154000|NCT05540782|||COHORT||CROSS_SECTIONAL|||||||
34154001|NCT03809819|||CASE_CONTROL||RETROSPECTIVE|||||||
33737766|NCT06532656|NA|SEQUENTIAL||TREATMENT||NONE||||||
33737767|NCT03652103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups involved. First group will receive total intravenous anesthesia and erector spinae plane block catheter Second group will receive total intravenous anesthesia and routine analgesia protocol for percutaneous Nephrolithotomy procedures.|f|t|f|f
33737768|NCT04355182|||COHORT||RETROSPECTIVE|||||||
33737769|NCT02630771|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737770|NCT00051116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737771|NCT01108744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737772|NCT00021307||||TREATMENT||||||||
33737773|NCT03193294|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Participants are randomised to a 'Disclosed group' (Intervention group) or a 'Not disclosed group' (Standard Care). In the standard care group, coronary function parameters are measured but the results are not disclosed to the attending clinician or the participant.|Randomized, double-blind, parallel group, prospective|t|t|f|t
33737774|NCT04331327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737775|NCT03882619|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33737776|NCT00129415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737777|NCT01049880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764427|NCT05515614|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Mother, physician team, and study statistician will be blinded to randomization.|"Standard nutritional fortification arm (control group): mother's expressed breast milk will be fortified using Enfamil Liquid Human Milk Fortifier (LHMF) as per standard feeding protocol defined by LLUCH NICU Manual.~In targeted fortification arm (intervention group), mother's expressed breast milk will be fortified with modular components, Amino Acid power, PolyCal and safflower oil, to meet the individual nutritional needs as determined by NICU dieticians."|t|t|f|t
34050224|NCT05326178|NA|SINGLE_GROUP||OTHER||NONE||||||
34050225|NCT02482714|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050226|NCT05296668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Induction of anesthesia will be performed by the attending senior anesthesia resident who has finished at least 2 years of residency (who is independent of the study team).~All intraoperative measurements will be collected by an anesthetist who was not involved in the induction of anesthesia.~All postoperative measurements will be collected by PACU nurse who is independent of the study team"|Recruited neonates will be randomly assigned to one of two groups in a 1:1 ratio; (group C) to receive a cuffed ETT and (group U) to receive an uncuffed ETT for airway management.|t|f|f|t
34050227|NCT05030753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050228|NCT04381689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34050229|NCT04591886|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050230|NCT05801289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154002|NCT03769987|||CASE_CONTROL||PROSPECTIVE|||||||
34154003|NCT02913716|NA|SINGLE_GROUP||OTHER||NONE||||||
34154004|NCT05257902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154005|NCT04484207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34154006|NCT02169765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154007|NCT00284362|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154008|NCT00913926|||COHORT||PROSPECTIVE|||||||
34154009|NCT01705106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154010|NCT04062825|||COHORT||PROSPECTIVE|||||||
34154011|NCT04369157|||COHORT||PROSPECTIVE|||||||
34154012|NCT03143764|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Inactive employees in a selection of public and private corporations in three Norwegian cities were invited to participate. Inclusion criteria were: a desire to cycle to work, residence more than 3km from the workplace, and not physically active according to guidelines. There were 25 participants in the study and we provided them all with electrically assisted bicycles fitted with GPS bike computers to record usage. The participants were followed for three to eight months, 226 days on average||||
34154013|NCT06024018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154014|NCT00395421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154015|NCT03311347|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two arms are studied, breathing air or 100%O2. In each arm, subjects are studied at two occasions: with and without positive pressure breathing. These occasions are randomized.||||
34154016|NCT01985568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154017|NCT05899972|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In the distribution of the volunteers to the groups, the participants chose between two numbered envelopes, opaque and sealed, in order to guarantee the confidentiality of the allocation, to which group they belonged. Inside each envelope is a piece of paper with the group, control group or intervention group.||t|f|f|t
34154018|NCT05111028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154019|NCT06365983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All sample randomization procedures will be carried out by a researcher not involved in treatments and clinical examinations. An external researcher not affiliated with the study will be responsible for maintaining participant allocation confidentiality. Sides will be identified by numbers stored in opaque, sealed envelopes with the randomization sequence. Outcome assessors will be blinded to the experimental group to which participants belong.|A randomized controlled non-inferiority trial will be conducted with 24 individuals aged 18 or older, who are periodontally healthy and require root coverage in bilateral multiple RT1-type recessions involving at least two teeth on each side of the mouth. The number of teeth to be covered must be equal on both sides to avoid imbalance in patient-centered comparisons.|f|f|f|t
34154020|NCT00595010|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34154021|NCT01046214|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34154022|NCT06117124|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a cross-sectional study whose primary objectives are to compare agreement between two bone densitometry techniques in children with cerebral Palsy, and to correlate assessments using both techniques with clinical findings.||||
34154023|NCT03394352|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34154024|NCT00879528|||COHORT||PROSPECTIVE|||||||
34154025|NCT02340910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked allocation and intervention||f|f|t|t
34154026|NCT04499222|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154027|NCT06582134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154028|NCT00830492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34154029|NCT05663957|||COHORT||RETROSPECTIVE|||||||
34154030|NCT02362074|||COHORT||PROSPECTIVE|||||||
34154031|NCT02457949|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34154032|NCT02825199|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34154033|NCT04628988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154034|NCT06425432|||COHORT||CROSS_SECTIONAL|||||||
34050231|NCT01524549|||COHORT||CROSS_SECTIONAL|||||||
34050232|NCT05905523|||COHORT||PROSPECTIVE|||||||
34050233|NCT06343402|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1a: sequential/parallel, Phase 1b: parallel||||
34050234|NCT05615363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050235|NCT06684912|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34050236|NCT02068963|||COHORT||PROSPECTIVE|||||||
34050237|NCT03335228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050238|NCT04563871|NA|SINGLE_GROUP||TREATMENT||NONE||80 mg Osimertinib||||
34050239|NCT02381730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050240|NCT06682195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154035|NCT00195156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154036|NCT04780464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154037|NCT01533142|||CASE_CONTROL||PROSPECTIVE|||||||
34154038|NCT00241904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154039|NCT00448565|||CASE_ONLY||PROSPECTIVE|||||||
34154040|NCT06136130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Effect of Positioning with Material and Hand-Face Maneuver on Physiological Parameters and Stress Symptoms in Preterm Newborns||||
34154041|NCT04098731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34154042|NCT06192680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154043|NCT04575207|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|In the Flash FFR II study, clinical outcome assessors (including the follow-up research personnel, clinical events committee (CEC), data and safety monitoring board (DSMB), and core laboratory) will be blinded to randomization arm. The data safety monitoring board (DSMB) may request unblinding of grouping information due to patient safety reasons. All the study site personnel will receive training for the blinding requirements before the trial initiating to prevent disclosure of random assignment to the follow-up personnel in any unplanned way.||f|f|f|t
34154044|NCT01105377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154045|NCT05861141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154046|NCT06051006|||CASE_ONLY||PROSPECTIVE|||||||
34154047|NCT02933502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154048|NCT03184285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154049|NCT02321761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154050|NCT05215158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154051|NCT05901402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34154052|NCT00930007|||COHORT||CROSS_SECTIONAL|||||||
34154053|NCT00597493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154054|NCT00486668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737778|NCT06183229|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Randomization is performed using the Internet Interactive Response System (IWRS) before the start of the drug dosing period. During the randomization procedure, the investigator, after assessing whether the subject meets the inclusion criteria and the absence of non-inclusion criteria, will contact IWRS, the system will record the fact that the subject has been randomized and will automatically report the package number of the drug that must be given to the subject.~The study drug CYCLOFERON®, enteric-coated tablets, 150 mg (NTFF POLYSAN LLC, Russia), is supplied in the form of enteric-coated tablets, 150 mg. 10 tablets in a blister pack, 5 blister packs in a cardboard box.~The reference drug PLACEBO, enteric-coated tablets, 150 mg (NTFF POLYSAN LLC, Russia), is supplied in the form of enteric-coated tablets, 150 mg. 10 tablets in a blister pack, 5 blister packs in a cardboard box."|Double-blind, placebo-controlled, randomized, two-parallel group comparative study|t|t|t|f
33737779|NCT02197546|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737780|NCT04849949|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33737781|NCT06259565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Patients randomized to the experimental arm will receive dexmedetomidine. We will start the infusion at a mid-range dose of 0.5mcg/kg/h with titration either up or down by 0.1mcg/kg/h every 20-30 minutes to a maximum rate of 1.2mcg/kg/h to maintain light sedation (RASS = -2 to +1 or SAS = 3 to 4). The study drug will always be titrated to the lowest possible dose with preserved effect. Each bag will be composed of two 100 mcg/mL dexmedetomidine vials (2ml vials) mixed in a 96mL 0.9% sodium chloride mini-bag (4mcg/ml) and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans.~The trial protocol does not allow an initial bolus of dexmedetomidine for safety reasons."|t|t|t|t
33737782|NCT06662669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737783|NCT02839434|||COHORT||PROSPECTIVE|||||||
33737784|NCT02367313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737785|NCT03311074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking will be performed in the study and all subjects who have received Strimvelis, either in previous clinical trials or as a registered product, will be included in the analysis.|There will be no separate treatment groups in the study.||||
33737786|NCT06493890|||OTHER||CROSS_SECTIONAL|||||||
33737787|NCT00507052|NA|SINGLE_GROUP||||NONE||||||
33737788|NCT04158401|||CASE_CONTROL||PROSPECTIVE|||||||
33737789|NCT04528563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double dummy design|t|t|t|t
33737790|NCT06155045|RANDOMIZED|PARALLEL||OTHER||NONE||The interventional group was compared with the conventional group in terms of two parameters : 1) operative time 2) blood flow/min||||
33737791|NCT00452335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737792|NCT05551364|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737793|NCT02681874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737794|NCT01625052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737795|NCT02652780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737796|NCT04616144|NA|SINGLE_GROUP||TREATMENT||NONE|Miopic Group Hyperopic Group|Miopic Group Hyperopic Group||||
33737797|NCT00833196|||COHORT||PROSPECTIVE|||||||
33737798|NCT02527720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737799|NCT02563158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737800|NCT06047054|||COHORT||PROSPECTIVE|||||||
33737801|NCT04453592|||CASE_ONLY||PROSPECTIVE|||||||
33737802|NCT05638360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737803|NCT01709058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764428|NCT03743896|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|There is no possibility of subjective bias or placebo effect since the primary outcome is the drug concentration in the synovial fluid. Hence no blinding or randomization needed.|Subjects who agreed to participate in the study could decide to be part of the Control group (no intervention) or the Test group (single dose, topical application of Transdermal Glucosamine Cream)||||
33764429|NCT06285669|RANDOMIZED|PARALLEL||TREATMENT||NONE||Kinesio-Taping Application||||
34154055|NCT01171391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154056|NCT04346849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant will not be informed about the type of material. Investigator will be given the material only after the pulpotomy procedure was completed according to a random sequence number generator. Upon tooth color measurement the investigator will not be informed about the type of material|Three groups will receive the same treatment procedure but randomly assigned to one of three different materials, tooth color changes will be measured at certain time points and will be compared between the 3 groups.|t|f|t|t
34154057|NCT02389439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154058|NCT01108380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154059|NCT05583084|||COHORT||RETROSPECTIVE|||||||
34154060|NCT04378231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154061|NCT04254094|||COHORT||PROSPECTIVE|||||||
33737804|NCT05795387|RANDOMIZED|PARALLEL||OTHER||DOUBLE|As mentioned, it will not be possible to mask students or local lecturers to allocation group. PI receives the clerkship student enrolment list from the faculty, randomize at clerkship location level and merge it with the consent lists collected digitally in SurveyXact. The students that have consented to participation receives individual invitation to the designated e-module. The instructor carrying out the digital mental status examination test, has no information of arm allocation. Statistical analysis will be performed by researcher blind to arm allocation, and masking will only be broken when the primary outcomes have been analyzed and a conclusion has been formulated based on the masked allocations.|A parallel group, superiority, partial-blinded, cluster-randomized controlled trial where both interventions are an addition to the regular psychiatric clerkship.|f|f|t|t
33737805|NCT05622591|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Dose Escalation||||
33737806|NCT00030589|RANDOMIZED|||TREATMENT||NONE||||||
33737807|NCT04720534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737808|NCT03616756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737809|NCT01727531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737810|NCT02477020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737811|NCT03731299|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737812|NCT03755765|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33737813|NCT00274716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737814|NCT03105050|||OTHER||PROSPECTIVE|||||||
33737815|NCT01519518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737816|NCT04452344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This study was a double-blinded study. The participant, care provider, site directors and site research coordinators were all blinded.||t|t|t|t
33737817|NCT00040404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737818|NCT01672125|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737819|NCT04138927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737820|NCT01117116|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737821|NCT04689113|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
33737822|NCT00453765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737823|NCT00178958|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33737824|NCT06548451|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33737825|NCT01416805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737826|NCT06521918|||COHORT||PROSPECTIVE|||||||
33737827|NCT00804297|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33737828|NCT05455567|||COHORT||PROSPECTIVE|||||||
33737829|NCT01034397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737830|NCT05866003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737831|NCT03713489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737832|NCT05635747|||OTHER||PROSPECTIVE|||||||
33737833|NCT06309199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"These 2 groups was assigned using computer generate with block of 4 and ratio 1:1.~The intervention and placebo were prepare in the same container with the same color, odor and blinded to investigators, participants and guardians."|Intervention group received probiotics Control group received sunflower and MCT oil|t|t|t|f
33737834|NCT04387162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Neurologist will conduct blinded classification of frontal or nonfrontal lesions"|Multiple baseline, delayed treatment design|f|f|f|t
33737835|NCT00129519|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737836|NCT00094913|||||PROSPECTIVE|||||||
33737837|NCT06271551|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized in a 1:1 fashion to receive transdermal estradiol and androgen deprivation or solely androgen deprivation therapy. In addition subgroup of participants are randomized in a 1:1 fashion to perform resistance training or to be allocated in non-training control group.||||
33737838|NCT01298284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737839|NCT03202316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737840|NCT06339827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737841|NCT05544461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the study, the participants and researchers will be unblinded. Although the participants will not be explicitly told which group they are in, they will become aware of their group after completing the eNutri FFQ at baseline. Those randomised to the intervention group will receive their eNutri PN advice and those randomised to the control group will not receive any PN advice from eNutri and therefore know which group they have been allocated to.|||||
33737842|NCT00009230|RANDOMIZED|||TREATMENT||DOUBLE||||||
33737843|NCT06200805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737844|NCT01169389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33737845|NCT01083381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737846|NCT05468840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737847|NCT00466193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737848|NCT01997359|||CASE_CONTROL||PROSPECTIVE|||||||
33737849|NCT02605512|NA|SINGLE_GROUP||SCREENING||NONE||||||
33737850|NCT04163549|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737851|NCT00016094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737852|NCT01609556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737853|NCT01023659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737854|NCT00985348|RANDOMIZED|CROSSOVER||||NONE||||||
33737855|NCT00690638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737856|NCT01451294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737857|NCT03009071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737858|NCT04431102|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The professionals who assessed the progress of labor in the delivery room and completed the medical history did not know whether the woman belonged to the intervention or the control group.|f|f|f|t
33737859|NCT03873285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737860|NCT01696032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737861|NCT02795286|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33737862|NCT05634265|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-group pilot||||
33737863|NCT04917198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737864|NCT00844545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764430|NCT04821635|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841620|NCT04631159|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study will be a randomized controlled trial. Seventy adults (aged 20 to 60 years) diagnosed with T2DM by the physician will recruited and randomly assigned to the mobile app group and the control group. Both groups will receive education by health professionals at Southern Medical Center and they are required to wear fitness watches to record steps. Mobile app group: patients will need to download and use the Health2Sync app and report blood glucose data weekly, and be monitored and advised by medical personnel. Control group: Patients will be asked to self-manage and there is no intervention during the tracking process. Each subject will be required to measure body composition, blood pressure, blood biochemical analysis (HbA1C, fasting blood glucose, total cholesterol, low-density cholesterol, high-density cholesterol, triglycerides), and number of steps before and after 12 weeks|t|f|f|f
33841621|NCT04481698|||CASE_CONTROL||RETROSPECTIVE|||||||
33841622|NCT05783908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33841623|NCT01805453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050241|NCT02900560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050242|NCT00502892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154062|NCT04942782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|lumbopelvic stabilization and Pilates|t|f|f|t
34154063|NCT05464615|NA|SEQUENTIAL||TREATMENT||NONE|The participants and investigators will know when the dosing of penicillin being administered and increased/decreased.|Prospective non-inferiority study||||
34154064|NCT01324869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154065|NCT02670967|||||RETROSPECTIVE|||||||
34154066|NCT03576573|||COHORT||PROSPECTIVE|||||||
34154067|NCT01961063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154068|NCT02110797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154069|NCT06217588|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154070|NCT00005107||||TREATMENT||NONE||||||
34154071|NCT03761810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154072|NCT04945109|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||A randomized cross-over, 4-week trial, where participants will be allocated to start with or without daily Mankai supplementation (fresh Mankai beverage) added on top of a standardized diabetes-related healthy diet, each for two weeks. The investigators will follow postprandial and overnight glycemic response using ﬂash glucose monitoring system device. Other outcomes include clinical parameters (weight, waist circumference, blood pressure), blood, urine, fecal measurements, overall appetite/ satiety, food intake consumption, symptoms, and medical treatment.|f|f|t|t
34154073|NCT01902472|||CASE_ONLY||PROSPECTIVE|||||||
34154074|NCT04977219|||COHORT||RETROSPECTIVE|||||||
34154075|NCT05648019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154076|NCT05510674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154077|NCT06099834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34154078|NCT04672915|||FAMILY_BASED||PROSPECTIVE|||||||
34154079|NCT00851422|||CASE_ONLY||PROSPECTIVE|||||||
34154080|NCT02036866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34154081|NCT04714853|||CASE_ONLY||PROSPECTIVE|||||||
34154082|NCT00900367|||COHORT||OTHER|||||||
34154083|NCT05735249|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Central, computer-generated randomization scheme|This is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and PK of escalating single and multiple doses of ARN-75039 when administered by the oral route in healthy adult subjects. Up to 5 single ascending dose (SAD) cohorts and up to 3 multiple ascending dose (MAD) cohorts, with approximately 8 subjects per cohort, will be enrolled to receive study drug or placebo. Within each cohort, the first 2 subjects will be randomized 1:1 to receive ARN-75039 capsules or placebo. After a review of the first 3 days of blinded safety for these subjects by the Medical Monitor, an additional 6 subjects will be randomized in a 5:1 (active: placebo) ratio. Each subsequent dose escalation will be based on safety data review of the current dose level.|t|t|t|t
34154084|NCT02253784|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34154085|NCT03002714|NA|SINGLE_GROUP||||NONE||||||
34154086|NCT03137498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind placebo-controlled randomized trial where blinding will be conducted and applied to the study investigator, physicians, and nursing staff providing care to the patient. An independent biostatistician will conduct a statistical analysis with blinded data. Only the pharmacists preparing the study interventions will be unblended to the study treatments. The pharmacists procuring the interventions will not be part of data collection or analysis.||t|t|t|t
34154087|NCT01289366|||||PROSPECTIVE|||||||
34154088|NCT03541902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154089|NCT02961946|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34154090|NCT04382378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will be blinded to randomization||f|f|f|t
34154091|NCT04215874|||OTHER||PROSPECTIVE|||||||
34154092|NCT01729208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154093|NCT04480216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154094|NCT02252965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154095|NCT03695822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154096|NCT03037983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34154097|NCT05607862|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34154098|NCT01706783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154099|NCT05462418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34154100|NCT06583642|||COHORT||PROSPECTIVE|||||||
34154101|NCT01979133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154102|NCT04548518|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blinded|non-inferiority double-blinded, randomized, controlled trial|t|f|t|f
34154103|NCT06300268|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study (Open Label)||||
34154104|NCT05708339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154105|NCT04739579|||COHORT||RETROSPECTIVE|||||||
34154106|NCT02650102|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34154107|NCT04877977|||COHORT||PROSPECTIVE|||||||
34154108|NCT03121703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34154109|NCT00306709|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34154110|NCT00524615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34154111|NCT04078984|||COHORT||PROSPECTIVE|||||||
34154112|NCT02921087|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34154113|NCT02211313|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34154114|NCT03369236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and participant blinded; Sponsor open. Participants were randomized 1:1 to receive either danicopan or placebo for a period of 6 months, followed by an open-label extension.||t|f|t|f
34154115|NCT01545440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154116|NCT05768815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154117|NCT01408342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154118|NCT03267914|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomly assigned to receive fluoride therapy with either custom trays (Tray group) or by application with a toothbrush (Brush group).||||
34154119|NCT00562146|||CASE_CONTROL||PROSPECTIVE|||||||
34154120|NCT01091818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34154121|NCT03048877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
34154122|NCT00216489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154123|NCT04374955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|One-blind|One blind, Randomized controlled Trials|t|f|t|f
34154124|NCT06577415|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34154125|NCT01835834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154126|NCT06525064|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study will use a cluster-randomized stepped-wedge design that is a type of one-way crossover design. Under this design, each clinic will start the study under the control condition that involves standard usual care, and end the study in the intervention condition.||||
33737865|NCT03662750|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Exploratory, prospective, natural history, imaging cohort study||||
33737866|NCT06517537|||COHORT||PROSPECTIVE|||||||
33737867|NCT02659865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33737868|NCT04258813|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Investigators will use a SMART design with 2 randomizations - at the time of enrollment and after the 12-month measurement. At enrollment, participants will be cluster randomized to the self-guided multi-level iGuide intervention or control arm. An adaptive intervention will be used for the second randomization. PCP clinics in the intervention arm in which 90% or more of their participating patients do not meet the modified HEDIS quality metrics at the 12-month measurement will be considered 'non-responders' and randomized to a tailored/targeted intervention (iGuide2) or a control (iGuide).|f|f|t|t
33737869|NCT03398993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737870|NCT01587547|||COHORT||RETROSPECTIVE|||||||
33737871|NCT06572696|||CASE_CONTROL||PROSPECTIVE|||||||
33737872|NCT06532695|||COHORT||PROSPECTIVE|||||||
33737873|NCT04737785|||CASE_CONTROL||PROSPECTIVE|||||||
34154127|NCT01086943|NA|SINGLE_GROUP||||NONE||||||
34154128|NCT02572622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154129|NCT00498576|||CASE_CONTROL||PROSPECTIVE|||||||
34154130|NCT04768803|||COHORT||PROSPECTIVE|||||||
34154131|NCT06331689|||COHORT||RETROSPECTIVE|||||||
34154132|NCT02216682|||CASE_CONTROL||PROSPECTIVE|||||||
33737874|NCT04645212|||COHORT||PROSPECTIVE|||||||
34154133|NCT06168617|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, interventional, non-invasive, monocentric, longitudinal, non-randomized study||||
34154134|NCT03761069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154135|NCT00255528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154136|NCT05026203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737875|NCT05320653|||COHORT||PROSPECTIVE|||||||
34154137|NCT02756494|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34154138|NCT00868907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154139|NCT02645630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737876|NCT02610192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154140|NCT00102427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34154141|NCT02706197|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||There are two parallel arms of the study; however, the first 6 patients must be in the arm whose tumor will receive no therapy prior to surgical resection. If there are no safety issues, then both arms are open.||||
34154142|NCT00988572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154143|NCT03634254|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34154144|NCT03301753|||COHORT||PROSPECTIVE|||||||
34154145|NCT01652131|NA|SINGLE_GROUP||||NONE||||||
34154146|NCT05254249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Probiotic and placebo packaging are made the same, and drug code is randomized by pharmacy|A double blinded randomized clinical trial using a prospective cohort method in psoriasis vulgaris patients with purposive sampling.|t|f|t|f
33841624|NCT02056990|||COHORT||PROSPECTIVE|||||||
33841625|NCT03276650|||COHORT||RETROSPECTIVE|||||||
33841626|NCT01607879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841627|NCT00418548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33737877|NCT01771406|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737878|NCT00716261|NA|SINGLE_GROUP||TREATMENT||||||||
33737879|NCT02537080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737880|NCT05368597|||CASE_CONTROL||RETROSPECTIVE|||||||
33841628|NCT03633747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841629|NCT05494957|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment regimens containing bedaquiline, linezolid, clofazimine, and other drugs||||
33841630|NCT00619047|||COHORT||PROSPECTIVE|||||||
33841631|NCT00805805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841632|NCT01839097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841633|NCT06208007|||CASE_CONTROL||PROSPECTIVE|||||||
33841634|NCT03845231|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050243|NCT03637140|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath through a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia.|t|f|f|f
34050244|NCT02208713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050245|NCT05473572|NON_RANDOMIZED|PARALLEL||OTHER||NONE||two groups group of children who stutter group of children who do not stutter||||
34050246|NCT04698538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|People coding the data will not know the participants' treatment allocation and timepoint.||f|f|f|t
34050247|NCT05331443|||COHORT||PROSPECTIVE|||||||
34050248|NCT05952778|||OTHER||CROSS_SECTIONAL|||||||
34050249|NCT03183089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34050250|NCT06683118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050251|NCT02404688|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34050252|NCT04432831|NA|SINGLE_GROUP||TREATMENT||NONE|The first 16 weeks of this study will be a masked period (to transition from the multi-arm parent studies) during which participants may receive either faricimab or sham injection. Participants and physicians will be masked only to the faricimab treatment interval. After the Week 16 treatment procedure, this study will follow an open-label design. The BCVA examiner will remain masked for the duration of this long-term extension study.|||||
34050253|NCT05128890|||OTHER||RETROSPECTIVE|||||||
34050254|NCT01461317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050255|NCT04099368|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34050256|NCT06683014|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050257|NCT03473028|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
34050258|NCT04859790|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomly assigned to the active condition or a waitlist control condition. Participants assigned to the active condition will complete baseline measures and receive the SCAR intervention. They would then complete follow-up measures one month after they completed the SCAR intervention.~Participants assigned to the waitlist control condition will complete baseline measures and follow-up measures after a month. They will be offered the SCAR intervention after they complete the follow-up measures."||||
34154147|NCT05697068|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Index patients will be randomly assigned (in real-time) to one of the two experimental groups using a predetermined randomization schedule (blocks of 40 randomly assigned numbers, stratified by study condition). Enrollment and randomization will be conducted in groups/waves of 40 index patients per wave. Enrollment and randomization will continue for each wave until 40 index patients have been randomized.|t|f|f|t
34154148|NCT02037906|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34154149|NCT04297605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154150|NCT00219778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154151|NCT02170181|||OTHER||PROSPECTIVE|||||||
34154152|NCT05767827|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34154153|NCT04978818|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an unblinded, post-licensure study; study staff will not be blinded to participant intervention status.|Randomization of participants will be done at the site level. Participants will be assigned randomly 1:1, to the Vaxelis arm or the PedvaxHIB arm. This is an unblinded study. Study staff will log into a secure system to randomize the participant. The study vaccine associated with that randomization will be selected. A verifier will confirm that the correct vaccine was selected. After verification, study staff will administer the dose.||||
34154154|NCT02625714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154155|NCT02430987|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34154156|NCT05819320|||OTHER||CROSS_SECTIONAL|||||||
34154157|NCT00518193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154158|NCT00935441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154159|NCT02709876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154160|NCT04530500|||COHORT||PROSPECTIVE|||||||
34154161|NCT01537822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154162|NCT02879578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154163|NCT02634827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154164|NCT03922178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154165|NCT00002148||||TREATMENT||DOUBLE||||||
34154166|NCT02240602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154167|NCT05727514|NA|SINGLE_GROUP||PREVENTION||NONE|participants identity was not disclosed during the program|case series||||
34154168|NCT04508491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154169|NCT00568906|||CASE_CONTROL||PROSPECTIVE|||||||
34154170|NCT01643824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154171|NCT02437370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154172|NCT03995706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154173|NCT00289081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154174|NCT04286516|NA|SINGLE_GROUP||TREATMENT||NONE||Controlled, nonrandomized experimental study||||
34154175|NCT02477189|||CASE_ONLY||RETROSPECTIVE|||||||
34154176|NCT00445770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34154177|NCT03881865|||COHORT||PROSPECTIVE|||||||
34154178|NCT05374330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154179|NCT01203423|||COHORT||PROSPECTIVE|||||||
34154180|NCT04511065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154181|NCT02145065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154182|NCT02748928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154183|NCT00615173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154184|NCT03317782|||COHORT||PROSPECTIVE|||||||
34154185|NCT06216210|||CASE_CONTROL||RETROSPECTIVE|||||||
34154186|NCT05101278|||COHORT||PROSPECTIVE|||||||
34154187|NCT00321633|RANDOMIZED|||TREATMENT||NONE||||||
34154188|NCT02128412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154189|NCT04607369|||COHORT||PROSPECTIVE|||||||
34154190|NCT00724204|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34154191|NCT04933461|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34154192|NCT02798471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154193|NCT04316676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154194|NCT04316364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050259|NCT01468259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737881|NCT06653647|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Qualified participants will be randomized into either the Delayed Treatment group or the Immediate Treatment Group. The Delayed Treatment Group will be observed for the first 8 weeks after randomization, and then outcome data will be reassessed through abdominal pain and stool diaries and other surveys. Then, this group will be crossed over to the treatment phase and given access to the mobile app intervention for another eight weeks. After this 8-week intervention phase, outcomes will be reassessed again via an abdominal pain and stooling diary and other surveys.~Those qualified participants randomized to the Immediate Treatment Group will be given access to the mobile app intervention for eight weeks. At the end of the eight weeks, outcome measures will be reassessed through an abdominal pain and stooling diary and other surveys."||||
33737882|NCT06654999|||CASE_ONLY||PROSPECTIVE|||||||
33737883|NCT06195592|||OTHER||OTHER|||||||
33737884|NCT06573255|||OTHER||CROSS_SECTIONAL|||||||
33737885|NCT03102476|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737886|NCT01717573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737887|NCT04808609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33737888|NCT06563089|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737889|NCT05236790|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|The randomization would be concealed. The patient will be blind to the allocated groups. The endoscopist will be blind to the allocated groups until the beginning of the procedure. The pathologists will be blinded to the polyp size measurements by the endoscopists, the SCALE-EYE, or other methods.|prospective, multi-endoscopist, single center|t|f|f|f
33737890|NCT03650426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33737891|NCT05242614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome measurements will be collected by an independent trained assessor (a trained research assistant) who are blinded to the group assignment of the participants|This study is a two-arm parallel randomized controlled trial, with an intervention group (mindfulness group) and a control group. The participants in the MBI group will receive 6 weekly 90-minute group-based sessions delivered through a face-to-face and online approach. The participants in control group will receive brief education on dementia care with the same group size, duration, and frequency as the sessions in the intervention group.|f|f|f|t
33737892|NCT01968434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737893|NCT01497379|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33737894|NCT06410105|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||: Crossover Assignment A randomized, controlled, crossover, double-blind clinical study, Comparison of|t|f|f|t
33737895|NCT00699699|||||PROSPECTIVE|||||||
33737896|NCT03839667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737897|NCT06278376|||CASE_ONLY||RETROSPECTIVE|||||||
33737898|NCT06291324|||CASE_ONLY||PROSPECTIVE|||||||
33737899|NCT02948413|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737900|NCT05600400|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 fraction SBRT||||
33737901|NCT01316627|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33737902|NCT02637934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737903|NCT06536010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737904|NCT00592449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33737905|NCT01144338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33945124|NCT03420846|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are randomly assigned to two arms. Participants in the first arm receive Mohs surgery using OCT mapping to delineate tumor margins.~Participants in the Control Arm receive Mohs surgery using clinical estimation of tumor margins (ie. standard care) The average number of Mohs surgery cycles will be compared for the two arms."||||
33945125|NCT04824599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050260|NCT03376256|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34050261|NCT00155272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050262|NCT00206687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050263|NCT03397108|||CASE_CONTROL||PROSPECTIVE|||||||
34050264|NCT02046395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154195|NCT05790720|NA|SINGLE_GROUP||TREATMENT||NONE||Pharmacokinetic-pharmacodynamic model that uses the pharmacokinetic parameters of the Eleveld model and new pharmacodynamic parameters derived from frontal EEG in a population older than 65 years.||||
33945126|NCT03343665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945127|NCT00005068||||TREATMENT||||||||
34154196|NCT05767190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154197|NCT04654078|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154198|NCT02476006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154199|NCT05901025|||CASE_CONTROL||PROSPECTIVE|||||||
34154200|NCT00001967||||TREATMENT||||||||
34154201|NCT06186986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34154202|NCT06502704|||COHORT||PROSPECTIVE|||||||
34154203|NCT01650272|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34154204|NCT06350305|||OTHER||CROSS_SECTIONAL|||||||
34154205|NCT05861661|||OTHER||OTHER|||||||
34154206|NCT06416410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154207|NCT05941013|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|"The outcomes assessor is blinded for outcome measure 4. Specifically the protocol says, After each case is completed, the fluoroscopic images and ultrasound images will be interpreted by independent study team members who are blinded to the results of the other test."|||||
34154208|NCT00392990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154209|NCT00520260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154210|NCT06453291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
34154211|NCT06584253|||OTHER||CROSS_SECTIONAL|||||||
34154212|NCT01117324|||CASE_CONTROL||PROSPECTIVE|||||||
34154213|NCT01595555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154214|NCT06256926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154215|NCT05647785|||COHORT||PROSPECTIVE|||||||
34154216|NCT01786252|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34154217|NCT03647267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Visual acuity and optical coherence tomography technicians will be masked to treatment group at all visits. The goal is for study participants to remain masked to their treatment group assignment, although it is likely that the gas bubble will be visible to participants in the pneumatic vitreolysis group. Investigators and study coordinators are not masked to treatment group.||t|t|f|t
34154218|NCT00115661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154219|NCT00049712||||TREATMENT||||||||
34154220|NCT03813992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154221|NCT02969460|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34154222|NCT02023814|||COHORT||RETROSPECTIVE|||||||
34154223|NCT03811301|NA|SINGLE_GROUP||OTHER||NONE||||||
33737906|NCT06192628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients are randomly allocated using concealed envelopes, and they are not informed as to which arm they have been allocated. They both receive an exercise programme, with the active arm receiving additional behavioral change techniques to promote exercise adherence and exercise self efficacy|two-arm single blinded randomised feasibility study|t|f|f|f
34154224|NCT00049660|RANDOMIZED|||TREATMENT||||||||
34154225|NCT02239315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154226|NCT01778101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154227|NCT03954262|||COHORT||PROSPECTIVE|||||||
34154228|NCT01785823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154229|NCT01019369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737907|NCT03206021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154230|NCT00771290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154231|NCT03236987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154232|NCT05014243|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154233|NCT04361305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154234|NCT03098745|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33737908|NCT06368583|||COHORT||PROSPECTIVE|||||||
33737909|NCT06137300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737910|NCT02685527|||COHORT||CROSS_SECTIONAL|||||||
33737911|NCT01373944|||CASE_CONTROL||PROSPECTIVE|||||||
33737912|NCT05676385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomised, controlled, double-blind, cross-over, single-centre, Proof of-Concept study|t|f|t|f
33737913|NCT02304094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737914|NCT05723523|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737915|NCT05038488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|This will be a two center, randomized, double-blind, placebo- controlled, parallel group, efficacy trial to determine the efficacy of MIB-626 treatment relative to placebo in adult patients with COVID-19 infection and stage 1 acute kidney injury. Participants will be screened for eligibility and those meeting eligibility criteria will be offered participation in the study. The subjects will be randomized by minimization to receive MIB-626 or placebo twice daily for up to 14 days. The participants will be followed for 28 days after the administration of the last dose of the investigational product. Kidney function will be ascertained by daily measurements of serum creatinine, which is the standard of care in hospitalized patients with COVID-19.|t|t|t|t
33737916|NCT02708745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33737917|NCT02875106|||COHORT||PROSPECTIVE|||||||
33737918|NCT04283734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737919|NCT04403295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study coordinator conducting the randomization and study providers will not be blinded. Other staff and investigators (including the Principal Investigator) will be blind to study assignment.|In collaborative specialty care the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics|f|f|t|t
33737920|NCT04418206|NA|SINGLE_GROUP||PREVENTION||NONE||COVID-19 patients will be selected in the 4 participating centres Contact subjects and healthy volunteers will be selected only in the coordinating centre (Centre Hospitalier Universitaire de Nice)||||
33737921|NCT02664038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737922|NCT00258986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33737923|NCT04660123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737924|NCT06204822|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33737925|NCT05495750|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33737926|NCT01744730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737927|NCT02778204|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737928|NCT03737461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737929|NCT01310413|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33737930|NCT04866394|NA|SINGLE_GROUP||OTHER||NONE||It's a Phase I feasibility study, 5 fractions (hypofractionation)||||
33737931|NCT02504866|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737932|NCT03006666|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33737933|NCT00803023|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33737934|NCT02684838|||COHORT||PROSPECTIVE|||||||
33737935|NCT05166122|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33737936|NCT01478698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945128|NCT01511601|||||PROSPECTIVE|||||||
33945129|NCT05535803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945130|NCT04566016|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized parallel controlled trial.|f|f|t|t
34154235|NCT00698334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154236|NCT05030480|||COHORT||CROSS_SECTIONAL|||||||
34154237|NCT04883814|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34154238|NCT02126618|||CASE_ONLY||RETROSPECTIVE|||||||
34154239|NCT04591847|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34154240|NCT05676216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154241|NCT02050087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34154242|NCT03291990|NA|SINGLE_GROUP||OTHER||NONE||5 fraction hypofractionated stereotacic radiosurgery along with standard temozolomide||||
34154243|NCT01288547|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34154244|NCT05400993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154245|NCT01818284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154246|NCT00004245||||TREATMENT||NONE||||||
34154247|NCT01961440|||CASE_ONLY||PROSPECTIVE|||||||
34154248|NCT03267225|||OTHER||PROSPECTIVE|||||||
34154249|NCT03287427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154250|NCT00679172|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
34154251|NCT03121755|||CASE_ONLY||OTHER|||||||
33737937|NCT05227079|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"The participant will be blinded as to which forceps (ie. conventional double bite or multiple bite forceps) are used for sampling during endoscopy.~The pathologists assessing the histological quality of biopsy specimens will also be blinded to which forceps were used to obtain the samples."|"Participants will be randomized to one of two groups (group A and group B). Group A will include patients who will have their biopsies taken with the conventional double bite forceps during endoscopy. Group B will include patients who will have their biopsies taken with the multiple bite forceps.~Each patient in both groups will have the same number of biopsies taken from the same anatomical areas; the only difference will be the number of biopsies that are taken consecutively."|t|f|t|f
33737938|NCT04337567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737939|NCT02436382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737940|NCT06222996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double|The research was planned as a cross section (pre-test post-test, experimental and control group) randomized controlled study.|t|f|f|t
33737941|NCT04485533|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34154252|NCT04318600|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154253|NCT00016991||||TREATMENT||||||||
34154254|NCT00350012|||CASE_CONTROL||PROSPECTIVE|||||||
34154255|NCT03620734|||COHORT||PROSPECTIVE|||||||
33737942|NCT03864497|||COHORT||PROSPECTIVE|||||||
34154256|NCT01309685|RANDOMIZED|CROSSOVER||OTHER||||||||
34154257|NCT05825391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To ensure the reliability of the research results, a study committee consisting of 5 members will be formed. The committee comprised a 2-member data safety monitoring committee and a 3-member clinical event review committee. Each reported ischemic event and bleeding event were assessed independently by three members of the clinical event adjudication committee. These committee members were blinded to the treatment group assignments. Any disagreements were resolved by a third member of the clinical events adjudication committee. All five committee members reviewed and resolved any discrepancies through consensus.|cluster randomized controlled cohort study|f|f|f|t
33737943|NCT00439140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154258|NCT02400021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737944|NCT05010759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737945|NCT02629146|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34154259|NCT05273463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737946|NCT04303260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154260|NCT04343716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants assigned to a single diet intervention. Between-groups differences and within-group changes will be assessed.||||
33737947|NCT00515476|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33737948|NCT04901884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy||||
33737949|NCT05561686|||CASE_ONLY||PROSPECTIVE|||||||
33737950|NCT00797784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737951|NCT02376127|||COHORT||PROSPECTIVE|||||||
33737952|NCT00099476||||TREATMENT||||||||
34154261|NCT01021904|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33737953|NCT04381104|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||QUADRUPLE|The hospital pharmacy department is involved in the development of identical medicines both paracetamol and placebo. Codings are done by the hospital pharmacy department and researchers including principal investigator, care provider, outcome assessor, and even participant will remain blinded.|This will be a 2 arms individual randomized controlled trial. The intervention arm will receive 2 capsules of paracetamols of 500mg while the control arm will receive 2 capsules of placebo.|t|t|t|t
34154262|NCT03438981|||COHORT||PROSPECTIVE|||||||
33737954|NCT02780349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737955|NCT04027660|||CASE_ONLY||PROSPECTIVE|||||||
33737956|NCT04372615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154263|NCT03580226|||OTHER||RETROSPECTIVE|||||||
34154264|NCT03887221|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be 2 treatment groups. A total of 24 subjects will be randomized to receive 50mg or 100 mg Safinamide in Period 1 (Day 1) and Period 2 (Days 8 to 14) separated by a 7 days washout period.||||
33737957|NCT06024954|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||randomized controlled trial||||
33737958|NCT00529932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154265|NCT04992195|||CASE_CONTROL||PROSPECTIVE|||||||
33737959|NCT06270121|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Control group was informed that they participated in the study with a repeated measure survey about digital healthcare for elderly without detailed descriptions on the living-lab intervention.||t|f|f|f
34154266|NCT01008449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154267|NCT05131230|||CASE_CONTROL||PROSPECTIVE|||||||
34154268|NCT04965662|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individuals at high risk for acquiring HIV will be randomized (1:1) to immediate (ARM A) or deferred (ARM B) Home PEPSE provision (standard of care (SOC)); planned duration of follow-up is 48 weeks for Arm A and 72 weeks for Arm B.||||
34154269|NCT02760316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154270|NCT00585273|||COHORT||PROSPECTIVE|||||||
34154271|NCT04741763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Research coded bottles with code held by the sponsor. Gel caps will be supplied in a single 180 count bottle. 1 gel cap per day will be taken with a meal.|"Capsule type that results in null or increased MPOD (macular pigment optical density in du -density units) - either Maltodextrin Placebo or OTC commercial Night Vision Formulation consisting of 21 mg carotenoid capsule (14 mg zeaxanthin and 7mg lutein) supplied by www.zeavision.com (Chesterfield, MO) in research coded bottles with code held by the company. Gel caps will be supplied in a single 180 count bottle. 1 gel cap per day will be taken with a meal. Subjects will be called by telephone to improve compliance. Supplement compliance will ultimately be gauged by the number of tablets returned."|t|t|t|f
33737960|NCT05323383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Outcomes are assessed remotely via Qualtrics, thus the outcome assessor is blinded."|Single-blind, three-arm, parallel-group randomized design|f|f|f|t
33737961|NCT05394337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33737962|NCT02760238|||COHORT||OTHER|||||||
33737963|NCT01369628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154272|NCT05961137|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two-group design with control group enrolled first, then a training period, then a separate intervention group enrolled.||||
33737964|NCT03755063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737965|NCT01701466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737966|NCT04455386|||COHORT||PROSPECTIVE|||||||
33737967|NCT02339818|||OTHER||CROSS_SECTIONAL|||||||
33737968|NCT04532112|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention consists of a biocontainment and aerosol clearance device that will be tested in the controlled setting to assess feasibility to perform airway procedures under general anesthesia with the device. There is no specific control device for this product. The control condition for this intervention will consist of airway procedures per routine clinical protocols without the biocontainment device. This study will be performed initially in locations where a patient would undergo a scheduled airway procedure under general anesthesia on non-COVID-19 patients. All participants in this study as well as non-participants who are present in the room during the airway procedure (aerosol-generating procedure) will continue to use appropriate level of PPE per hospital protocols and policies. This device does not replace standard aerosol-protecting PPE.||||
34154273|NCT02555384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737969|NCT02541240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154274|NCT04313478|||OTHER||CROSS_SECTIONAL|||||||
33737970|NCT01038518|||COHORT||CROSS_SECTIONAL|||||||
33737971|NCT06023095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33737972|NCT00513422|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34154275|NCT03659877|NA|SINGLE_GROUP||OTHER||NONE||||||
33737973|NCT05461885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737974|NCT03856229|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After obtaining the informed consent. The subjects will be randomized 6 days after starting treatment for PCP with trimethoprim/ sulfamethoxazole plus prednisone or methylprednisolone. Stratified randomization will be generated by an electronic system, in blocks of 6 and 8, and a 1:1 ratio, according to the CD4+ T cell count (less or more than 50 cells/mm3 and assigned to each group:~* Group A or Conventional Steroids use (CoSt). Patients will receive 21 days of steroid treatment.~* Group B or Shortened Steroids use (SSt). Subjects with moderate PCP will receive 8 days of steroids and subjects with severe PCP 14 days of steroids."||||
33737975|NCT04978246|||CASE_CONTROL||PROSPECTIVE|||||||
33737976|NCT03995238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded to group assignment and participants will be reminded at the time of testing to not disclose any aspects of the training sessions. The Principal Investigator will also remain blinded to group assignment. A co-investigator, who is not involved in participant testing/intervention, will manage randomization and maintenance of group assignment codes.|Randomized controlled trial; Three groups|f|f|t|t
33737977|NCT00048724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737978|NCT02461589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737979|NCT00403455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737980|NCT04620434|||CASE_ONLY||PROSPECTIVE|||||||
33737981|NCT01978405|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33737982|NCT04981119|||COHORT||PROSPECTIVE|||||||
33737983|NCT03761459|||COHORT||PROSPECTIVE|||||||
33737984|NCT00260052|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33737985|NCT03367533|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The investigators employ a counter-balanced cross-over design in which ketamine plus perampanel is given on one day, and approximately 21 days later ketamine plus placebo is given.|t|f|t|f
33737986|NCT03819868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-mouth|t|t|f|t
33737987|NCT03042312|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737988|NCT05824884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737989|NCT00600821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737990|NCT03976986|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737991|NCT05905185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737992|NCT01351740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737993|NCT06659432|||COHORT||CROSS_SECTIONAL|||||||
33737994|NCT06570967|||COHORT||CROSS_SECTIONAL|||||||
33945131|NCT03303352|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|"At the end of the study, all slides will be scored for cellularity and quality on a 0 to 3 discrete scale, according to the previous work done by Mukai S et al \[12\], by an independent pathologist, from an institution not involved in the initial histological analysis, blinded to the type of pass (fast or slow)."|A prospective, multicenter, randomized, crossover study.|f|f|f|t
33945132|NCT00381017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945133|NCT05038397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154276|NCT05095948|||COHORT||PROSPECTIVE|||||||
34154277|NCT02047526|||||PROSPECTIVE|||||||
34154278|NCT03954613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154279|NCT01910467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154280|NCT01647334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154281|NCT05122299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737995|NCT03019497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737996|NCT04369469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737997|NCT02039531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737998|NCT04442594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The virtual reality sessions will take place twice a week during 6 weeks. Each subject will have two different virtual environment. The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.||||
34154282|NCT05987787|||COHORT||RETROSPECTIVE|||||||
34154283|NCT01440881|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34154284|NCT06180707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737999|NCT05983653|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After medical and dental history then clinical examination. A preoperative panoramic radiograph was taken as a primary survey to exclude the presence of any lesion at the area of interest and an MRI to evaluate disc position infiltration of plain anesthesia was administered to anesthetizing the auriculotemporal, posterior deep temporal, and masseter nerves. Scrubbing and draping of the patient was carried out by using betadine. Drawn canthotragal line. two needle insertion points are marked. The first will be at a distance of 10 mm from the tragus and 2 mm below the cantotragal line. The second point will be 20 mm in front of the tragus and 10 mm below this line. Two 19 gauge needles are inserted in these 2 points(upper joint space) Normal saline 200 ml is injected into the superior joint space. The second needle acts as an outflow portal~* in the 1 st study group: The lavage will be 150 ml of normal saline~* in the 2 nd study group: The lavage will be 150 ml of normal saline +PRP"||||
33738000|NCT05586867|||COHORT||PROSPECTIVE|||||||
33738001|NCT00922610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738002|NCT06214455|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33738003|NCT06377553|||COHORT||PROSPECTIVE|||||||
33738004|NCT02473575|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33738005|NCT00904774|||COHORT||PROSPECTIVE|||||||
33738006|NCT04513600|||OTHER||PROSPECTIVE|||||||
33738007|NCT00876317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33738008|NCT01099124|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738009|NCT00780962|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study medication (or placebo) will come premixed from the pharmacy. There will be no external marks on the medication (or placebo) that suggests its identity.|"Subjects will be randomized to receive either of two interventions: N-acetylcysteine (Treatment group) or Normal Saline (Placebo group).~Patients in the treatment group will receive 3 g of Nacetylcysteine in 500mL normal saline (0.9% Sodium Chloride) solution during 30 minutes before contrast administration. After contrast administration, patients will receive a continuous infusion of 200mg of N-acetylcysteine per hour, administered as an infusion of 67 mL per hour of a solution of 3 g of N-acetylcysteine diluted to a total volume of 1,000 mL with normal saline solution.~Patients in the placebo group will receive 500 mL of normal saline solution during 30 minutes before contrast administration and a continuous infusion of 67 mL per hour of normal saline solution after contrast administration.~Patients in both arms will receive the postcontrast infusion (N-acetylcysteine or saline solution) for a minimum of 2 hours."|t|t|t|t
33738010|NCT02762669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738011|NCT00812812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738012|NCT05121116|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized waitlist-controlled||||
33738013|NCT04113252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738014|NCT03231384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738015|NCT06533709|||COHORT||RETROSPECTIVE|||||||
33738016|NCT00192179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738017|NCT03652324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738018|NCT01132079|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33738019|NCT03850886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738020|NCT04578314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, controlled, parallel-group, two-armed, multicentre, open trial|f|f|f|t
33738021|NCT00131781|RANDOMIZED|PARALLEL||||SINGLE||||||
33738022|NCT06566274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738023|NCT00928148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738024|NCT02928341|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33738025|NCT03714633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessor of the parent-child interaction using the emotional availability scales is blind to if the child belongs to the intervention Group or Control Group. Several outcomes are self assessment questionnaires, with no masking.||f|f|f|t
33738026|NCT02424916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738027|NCT01540227|||COHORT||PROSPECTIVE|||||||
33738028|NCT00637169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738029|NCT02873104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738030|NCT04886167|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33738031|NCT02536521|||COHORT||PROSPECTIVE|||||||
33738032|NCT01046955|RANDOMIZED|PARALLEL||||NONE||||||
33738033|NCT00997997|||COHORT||PROSPECTIVE|||||||
33738034|NCT05163912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738035|NCT04993352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738036|NCT03533400|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants will be randomized into 2 groups via random number generator. Group 1 (control group) will be given the standard Jamboxx musical device, while Group 2 (treatment group) will be given the Jamboxx respiratory therapy device, which combines musical gameplay with incentive spirometry exercises.||||
33738037|NCT04484311|||COHORT||RETROSPECTIVE|||||||
33738038|NCT03519230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841635|NCT03953924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The leader of this study entered the cardiovascular medical ward and screened potential eligible patients according to medical records in each hospital. Leaders informed the purpose, significance, methods, sessions of the study to patients. Patients were randomly divided into two groups by using a block randomization list with a block size of 4 at 1:1. A research assistant put the generated random number into opaque consecutively numbered envelopes and sealed the envelopes, and then handed it to enrolling researchers. When enrolling a new participant, the enrolling investigators opened the sealed envelope after participant's name was written on next available envelopes. A sequentially numbered and opaque, sealed envelope system was used by a non-investigator. Additionally, all data collection was conducted by another research assistant who was blind to the study design and allocation of participants.|"No interventions were performed for the control patients during study. However, they received conventional care (Simple and unstructured patient education about diet, exercise and so on).~Patients in the intervention group received conventional care, TTM-based intervention and MI. The intervention was provided by nurses who were trained, including two researchers and a general nurse of cardiovascular ward. The primary researcher was leader of the study. The leader explained the purpose, significance and methods of the study."|t|f|f|t
33841636|NCT02097303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841637|NCT01359787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738039|NCT04874922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pregnant women diagnosed with gestational diabetes will be assigned to the case and control groups in a randomized controlled manner (with simple random numbers table). Matching will be made between groups according to age and education level.||||
33738040|NCT02790086|||COHORT||PROSPECTIVE|||||||
33738041|NCT01693601|NA|SEQUENTIAL||TREATMENT||NONE||||||
33738042|NCT01176591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33738043|NCT00698958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738044|NCT01639898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738045|NCT02954913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738046|NCT00821691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738047|NCT04788732|||COHORT||PROSPECTIVE|||||||
33738048|NCT02772068|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Two separate groups of subjects (senior controls and patients with HFpEF) receiving istaroxime|t|f|f|f
33738049|NCT01177072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738050|NCT04028388|RANDOMIZED|PARALLEL||TREATMENT||NONE||One-hundred RECIST 1.1 evaluable patients will be randomized 1:1 to treatment with ModraDoc006/r versus standard i.v. docetaxel. The treatment outcome will be estimated and used as the basis for the design of the future pivotal phase 3 trial. The sample size of 50 evaluable patients per cohort will provide a sufficiently precise point estimate of the primary endpoint radiographic Progression Free Survival (rPFS) in both groups to calculate the sample size for the pivotal study.||||
33738051|NCT06486545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738052|NCT01999010|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738053|NCT00948805|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738054|NCT00491244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738055|NCT01991834|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33738056|NCT02155439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738057|NCT01815671|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33738058|NCT00760240|||||CROSS_SECTIONAL|||||||
33738059|NCT06237426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738060|NCT05007873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738061|NCT04578223|||CASE_CONTROL||PROSPECTIVE|||||||
33738062|NCT06515860|||COHORT||PROSPECTIVE|||||||
33738063|NCT01103297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738064|NCT01921972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738065|NCT00538005||||TREATMENT||||||||
33738066|NCT04066335|||COHORT||PROSPECTIVE|||||||
33738067|NCT01116089|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738068|NCT04143347|||COHORT||RETROSPECTIVE|||||||
33738069|NCT04984642|NA|SINGLE_GROUP||SCREENING||NONE||||||
33738070|NCT03930745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738071|NCT05034991|||COHORT||PROSPECTIVE|||||||
33738072|NCT05104398|||CASE_CONTROL||PROSPECTIVE|||||||
33738073|NCT00600964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738074|NCT01653431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738075|NCT03006328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33841638|NCT04479228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841639|NCT03271853|||COHORT||PROSPECTIVE|||||||
33841640|NCT04604574|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||We plan to conduct a pre/post intervention matched comparison group study. We will compare historical treatment outcomes for past Benbowopka patients to outcomes following IHSS treatment for Indigenous patients with a history of trauma and SUD. All patient data will be anonymized at the time of data entry. Propensity matching will be undertaken for patient characteristics, including sex/gender, age, and substance use type. The National Native Alcohol and Drug Abuse Program (NNADAP) tool will be used to analyze the program objective; that is, whether completion rates improve following the implementation of the IHSS intervention. Additionally, a Client Quality Assurance Survey (attached) will be utilized to determine patient satisfaction.||||
33841641|NCT04137289|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase Ia: Dose escalation (non randomised, 1 arm) Phase Ib: Dose expansion (randomised, 4 arms)||||
34154285|NCT02847104|||||PROSPECTIVE|||||||
34154286|NCT05687019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154287|NCT04230824|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34154288|NCT03742453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738076|NCT03991741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738077|NCT00617240|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841642|NCT02784457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841643|NCT04781413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154289|NCT03178669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154290|NCT02846649|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34154291|NCT05995899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738078|NCT01423513|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33738079|NCT02137200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738080|NCT06238505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738081|NCT04632940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738082|NCT00476424|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738083|NCT06662890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738084|NCT03280355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Assessor (nurse) is masked, primary investigator is masked|Non-pharmacological, intervention based, group randomised (cluster randomised) controlled trial, 2 arms (intervention and active control group)|f|f|t|t
33738085|NCT04124549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients in the HD centers were randomly assigned to one of two wards at the time that they began to HD in this center. And in order to avoid contamination, randomization in this study was in accordance with the centers to which patients were assigned. Every HD center was randomized to either continue on usual HD care (control group) or intervention of intradialytic combined exercise based on usual HD care (intervention group).||t|f|f|f
33738086|NCT03393598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738087|NCT03826329|||COHORT||RETROSPECTIVE|||||||
33738088|NCT05166967|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random Group Assignment||||
33738089|NCT00760279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738090|NCT04978038|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, investigators, laboratory staff, safety monitoring committee and research assistants will be blinded. To maintain blinding of the participants, those allocated to the control will receive .5ml Prevnar-13 vaccine to mimic mRNA vaccine. Study vaccine will be administered by unblinded nurses.|Randomized Controlled Trial|t|f|t|t
33738091|NCT01079520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738092|NCT04763772|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33738093|NCT04942080|NA|SINGLE_GROUP||OTHER||NONE||||||
33738094|NCT06535256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738095|NCT06084585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33738096|NCT03124394|||COHORT||PROSPECTIVE|||||||
33738097|NCT03348267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33738098|NCT00982189|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33738099|NCT02520531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738100|NCT00491686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33738101|NCT03509701|||CASE_CONTROL||PROSPECTIVE|||||||
33738102|NCT03260816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators and coders assessing response over time are kept unaware of the condition to which each participant is assigned.|Randomized control trial in which participants are randomly assigned to either receive Internet-delivered Parent-Child Interaction Therapy (I-PCIT) or referrals as usual (RAU).|f|f|f|t
33738103|NCT04175262|||COHORT||RETROSPECTIVE|||||||
33738104|NCT01993264|||COHORT||PROSPECTIVE|||||||
33738105|NCT05784428|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"This study is a phase III multicentre randomized trial. All participants will be randomized in a 1:1 ratio between multiple fraction SABR (Arm 1) vs. single fraction SABR (Arm 2). Patients will be stratified by systemic therapy within the last 2 weeks (yes/no); number of sites to be treated (1 vs. multiple) and SABR to the abdominal/pelvic site (yes/no).~BC Cancer sites will also participate in the second randomization. Participants will be randomized in a 1:1 ratio to QoL reporting alone via FACT-G and EQ-5D-5L (Arm A) vs. QoL reporting and patient-reported outcome (PRO) symptom screen with healthcare provider intervention (Arm B). Patients will be further stratified by the criteria for the 1st randomization as as well as sex."||||
33738106|NCT05181605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738107|NCT02192684|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33738108|NCT04861623|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33738109|NCT01243944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738110|NCT06180005|||COHORT||PROSPECTIVE|||||||
33738111|NCT01679899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738112|NCT00801684|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33738113|NCT06346977|||COHORT||PROSPECTIVE|||||||
33738114|NCT00896220|||COHORT||PROSPECTIVE|||||||
33738115|NCT05976334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738116|NCT04694833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Studies will be conducted in a single group of (a) stroke patients and (b) healthy subjects||||
33738117|NCT01167946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738118|NCT04041505|RANDOMIZED|CROSSOVER||OTHER||NONE||"This is a modified, randomized cross-over study. The 'intervention' in this study is simply feeding infants using one of two modalities that are already familiar to the mother and infant: feeding mother's milk from the breast and from a bottle.~At each timepoint (6 weeks, 4 months, 6 months) infants will: be randomized using a balanced design (to control for order effect) to consume human milk from a bottle or from the breast for 24 hours; will then undergo a wash-out period in which they will be fed human milk as they usually would for 24 hours; then will complete the second 'treatment' (bottle or breast) for 24 hours. Due to the nature of the intervention, this study will not be blinded.~We aim to recruit 62 mother-infant pairs (= 124 participants in total)."||||
33738119|NCT05694559|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33738120|NCT05222568|||CASE_CONTROL||PROSPECTIVE|||||||
33738121|NCT03859232|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33738122|NCT03264157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study|Treatment A: BPL HRIG + active rabies vaccine Treatment B: Comparator HRIG + active rabies vaccine|t|f|t|f
34154292|NCT04212572|||COHORT||PROSPECTIVE|||||||
34154293|NCT02581969|||COHORT||RETROSPECTIVE|||||||
34154294|NCT00820417|NON_RANDOMIZED|||||NONE||||||
33738123|NCT04590547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33738124|NCT00216840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33738125|NCT05487170|NA|SEQUENTIAL||TREATMENT||NONE||||||
33738126|NCT03798808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33738127|NCT00380640|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738128|NCT02851576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738129|NCT06573749|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The placebo and bioactive whey protein concentrate supplement have been given specific codes by the funder who are providing the supplement to ensure that the participant and investigator are blinded. The funder will reveal which code corresponds to which supplement group once the principal investigator has completed statistical analysis.|Participants will be allocated to one of two groups, placebo or bioactive whey protein concentrate supplement.|t|f|t|t
33738130|NCT05868694|||COHORT||CROSS_SECTIONAL|||||||
33738131|NCT05384847|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738132|NCT00890461|||COHORT||PROSPECTIVE|||||||
33738133|NCT01632059|||COHORT||PROSPECTIVE|||||||
33738134|NCT04177108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738135|NCT06147505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738136|NCT01142245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841644|NCT05183672|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33841645|NCT01559129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841646|NCT03916679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841647|NCT00293514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841648|NCT00515671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841649|NCT00542542|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841650|NCT01363570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154295|NCT04225793|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738137|NCT06109948|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33738138|NCT04079855|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The intervention is of foods which will look identical. Volunteers will know the color of their treatment assignment but not the actual identity of their treatment. The investigators will use a double masking protocol in which investigators and outcome assessors (study staff who collect primary and secondary measures and data analysts) will not know the treatment assignments or treatment coding (color coded) scheme.||t|t|t|t
33738139|NCT02786615|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge design||||
33738140|NCT03394300|||CASE_CROSSOVER||PROSPECTIVE|||||||
33738141|NCT05795699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738142|NCT03775005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738143|NCT05474144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33738144|NCT03553745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33738145|NCT01136824|||||PROSPECTIVE|||||||
33738146|NCT06467318|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33738147|NCT00338351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33738148|NCT03985813|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Outcome assessors will be masked to the intervention condition at follow-up assessment timepoints.|"Ultimately, this study design was an open trial after unsuccessful attempts to maintain initial recruitment sites in the study.~This study initially attempted to use a stepped wedge design, which involves the sequential random rollout of an intervention over 2 time periods. Following a baseline period in which no clusters (= practices) are exposed to the intervention, the crossover is typically in one direction, from control to intervention and continues until both of the clusters have crossed-over to receive the intervention, with observations taken from each cluster and at each time period."||||
33738149|NCT04537845|||OTHER||RETROSPECTIVE|||||||
33738150|NCT03765281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33738151|NCT03388073|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Both the study participants and the research staff interacting with study participants will be blinded to the plant based extract versus placebo.|The study uses a randomized double-blinded placebo-controlled cross-over study design.|t|t|f|t
33738152|NCT06369740|||CASE_ONLY||CROSS_SECTIONAL|||||||
33738153|NCT03140891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33738154|NCT01297218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738155|NCT03060824|||COHORT||PROSPECTIVE|||||||
33738156|NCT03969771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 x 2 Mixed Factorial Design, with Group (frequently absent / control) as the between-subjects factor and Time (pre / post) as the within-subjects factor.||||
33738157|NCT06573736|||COHORT||PROSPECTIVE|||||||
33738158|NCT04363606|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738159|NCT06432010|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Exploratory prospective, monocentric, ambulatory study||||
33738160|NCT00334659|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33738161|NCT06415799|||CASE_ONLY||PROSPECTIVE|||||||
33738162|NCT04140669|||COHORT||PROSPECTIVE|||||||
34154296|NCT01620944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154297|NCT00852501|||COHORT||PROSPECTIVE|||||||
34154298|NCT02500446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738163|NCT01946308|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33738164|NCT06270303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical assessments following intervention will be conducted by assessors unaware of group allocation.|The project will be conducted as a two-armed randomized controlled trial in multiple clinical centers. The primary outcome will be assessed at 1 year post-surgery with a subsequent follow-up of 10 years.|f|f|f|t
33738165|NCT02698501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738166|NCT05627440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738167|NCT05010109|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33738168|NCT04726982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33738169|NCT01360034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738170|NCT02248922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738171|NCT00515333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738172|NCT03213093|NA|SINGLE_GROUP||SCREENING||NONE||||||
33738173|NCT06283316|||COHORT||PROSPECTIVE|||||||
33738174|NCT00780572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33738175|NCT01973829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738176|NCT01522859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738177|NCT05841810|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||The investigators will use a hybrid type 3 effectiveness-implementation sequential multiple assignment randomized trial (SMART) design to assess the impact of our multicomponent health program on implementation and outcome measures. As participants progress through multiple stages, each participant may be randomized to two or more intervention options allowing us to compare the relative effectiveness of multiple intervention options. Our experimental design follows a SMART randomized structure to introduce the more intensive care coordination component only to those who are not responding to usual care or the lower intensity and less resource intensive mHealth messaging component allowing for more efficient resource allocation.|t|f|f|f
34050265|NCT03682861|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Flavoured water placebo drink with no energy or carbohydrate drinks in opaque bottles to keep participant blinded|It is a repeated measure design where each participant will undergo all four treatment in a randomized fashion to prevent any order effect. Treatments (recovery drinks) include a placebo which will be similar in taste and flavour to other treatments and three carbohydrate containing drinks mixed in water at different concentrations. Design of the study is composed of three main stages: 1) glycogen lowering exercise, 2) glycogen replenishment and rest and 3) performance based, timed cycling exercise. All participants will arrive fasted to the laboratory, performing an exercise protocol that lowers their glycogen levels, followed by ingestion of different drinks (every 30 min) during 2 hours of a 4 hour rest and finally performing a 20 km stationary bike test for the time to finish to evaluate the effect of recovery drinks ingested.|t|f|f|f
34050266|NCT00585832|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34050267|NCT04365504|||CASE_CONTROL||PROSPECTIVE|||||||
34050268|NCT04954794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050269|NCT02565849|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050270|NCT06683547|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants, Investigators and Outcome Accessors will be blinded to the intervention and control drinks. The drinks will be flavor matched and provided in an opaque bottle. An individual not involved with the study data collection, analysis and interpretation will be designated as a study blinder and randomizer.||t|f|t|t
34050271|NCT06066437|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050272|NCT06668441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738178|NCT06611436|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738179|NCT04413318|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33738180|NCT00841126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738181|NCT00413413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738182|NCT03004534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738183|NCT05133648|||COHORT||RETROSPECTIVE|||||||
33738184|NCT02785367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738185|NCT05693922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is designed to be double-blind. This means that the participant and the researchers are unaware of each participant's assignment until the completion of all data collection. This is accomplished using the randomization codes described above. Furthermore, this study utilizes an active sham stimulation. The active sham condition includes brief stimulation, mimicking the skin sensations associated with tACS. In our previously concluded trial, participants in the delta-beta tACS and active sham groups responded similarly to the blinding questionnaire, indicating that our active sham stimulation successfully blinded the participants.|Participants will take part in a single-session behavioral activation (BA) intervention. To examine the effects of neurostimulation on treatment response, participants will be randomized to receive either delta-beta cross-frequency transcranial alternating current stimulation (tACS) or an active sham.|t|f|t|f
33738186|NCT06309082|||COHORT||PROSPECTIVE|||||||
33738187|NCT02242877|||COHORT||PROSPECTIVE|||||||
33738188|NCT01498926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738189|NCT05436457|||COHORT||PROSPECTIVE|||||||
33738190|NCT05268328|||OTHER||OTHER|||||||
33738191|NCT03374124|||COHORT||RETROSPECTIVE|||||||
33738192|NCT00490425|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33738193|NCT04948944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|treatment code provided by non-study staff|double blind randomized controlled trial|t|t|t|t
33738194|NCT02668380|||CASE_ONLY||PROSPECTIVE|||||||
33738195|NCT03766009|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Institutional cross-over||||
33738196|NCT05281367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34050273|NCT06523569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050274|NCT04075266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050275|NCT01423643|||COHORT||PROSPECTIVE|||||||
34050276|NCT06682351|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050277|NCT04756193|||COHORT||PROSPECTIVE|||||||
34050278|NCT04062344|||CASE_CONTROL||PROSPECTIVE|||||||
34050279|NCT05717062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738197|NCT06573528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738198|NCT05040412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomised|t|f|f|f
33738199|NCT06448481|RANDOMIZED|PARALLEL||OTHER||SINGLE|Two blinded observers will record their scores independently using the POSAS instrument.||f|f|f|t
33738200|NCT03266445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 8mg prior to surgery. Each group will have identical perioperative treatment plans. Primary outcome measured is pain scores following surgery.||||
33738201|NCT06211634|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154299|NCT03748459|||CASE_CONTROL||PROSPECTIVE|||||||
33738202|NCT03515148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33738203|NCT06210789|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
33738204|NCT02996721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738205|NCT05345691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Patient, Investigator)||t|f|t|f
33738206|NCT00935103|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33738207|NCT03614013|||COHORT||RETROSPECTIVE|||||||
33738208|NCT02939105|NA|SINGLE_GROUP||OTHER||NONE||||||
33738209|NCT01286285|||||PROSPECTIVE|||||||
33738210|NCT05913804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738211|NCT01513291|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33738212|NCT06663878|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive a single, peripheral intravenous (IV) infusion of MWAV201.||||
33738213|NCT02133326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738214|NCT02323464|||COHORT||PROSPECTIVE|||||||
33738215|NCT05615467|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738216|NCT02564471|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33738217|NCT05868798|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33738218|NCT04961333|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Intervention group and waiting list control group|t|f|f|f
33738219|NCT05039905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Lung cancer patient||||
33738220|NCT00685438|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33738221|NCT01646671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738222|NCT06073327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738223|NCT02602574|||CASE_CONTROL||PROSPECTIVE|||||||
33738224|NCT06058897|NA|SINGLE_GROUP||OTHER||NONE||||||
33738225|NCT03843788|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not able to be masked|This is a pilot feasibility study to evaluate effectiveness and acceptability in our patient population of TENS use throughout delivery hospitalization. We aim to have 20 participants total: 5 in control and 5 in intervention without history of opioid addiction, and 5 in control and 5 in intervention with history of opioid addiction/misuse. This sample size is comparable to other shorter term pilot studies. This pilot study will serve as the basis for larger trials in the future, with larger sample size powered to demonstrate reduction in pain scores. We anticipate recruitment for this trial will take approximately 6-9 months.||||
33738226|NCT03477890|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants are randomised to a 'Disclosed group' (Intervention group) or a 'Not disclosed group' (Standard Care). In the standard care group, coronary function parameters are measured but the results are not disclosed to the attending clinician or the participant. Coronary function is measured in all participants.|Randomized, double-blind, parallel group, prospective|t|f|f|f
33738227|NCT01950143|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33738228|NCT02838017|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738229|NCT01935011|||CASE_ONLY||PROSPECTIVE|||||||
33738230|NCT04090944|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33738231|NCT03290508|||COHORT||PROSPECTIVE|||||||
33738232|NCT01375049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738233|NCT06075602|||COHORT||PROSPECTIVE|||||||
33738234|NCT00727389|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33738235|NCT06659315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Couples will be randomized 1:1 to intervention or control arm||||
33738236|NCT03334500|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154300|NCT00288327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738237|NCT02379949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738238|NCT06419127|||COHORT||RETROSPECTIVE|||||||
33738239|NCT00497120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33738240|NCT00013897||||TREATMENT||DOUBLE||||||
33738241|NCT01917045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34154301|NCT02501200|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154302|NCT03256318|||CASE_CONTROL||PROSPECTIVE|||||||
34154303|NCT00938691|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34154304|NCT04353778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34154305|NCT02126592|||COHORT||PROSPECTIVE|||||||
33738242|NCT00820339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738243|NCT01709227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738244|NCT00852397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738245|NCT05734092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738246|NCT06075511|||COHORT||PROSPECTIVE|||||||
33738247|NCT02930434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738248|NCT01816139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154306|NCT04611906|||COHORT||PROSPECTIVE|||||||
33738249|NCT05233644|||COHORT||PROSPECTIVE|||||||
33841651|NCT04255953|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33841652|NCT05305534|||OTHER||PROSPECTIVE|||||||
33841653|NCT05871320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multi-center, Phase 0/I study, prospective single-arm, open-label study||||
33841654|NCT05518305|||COHORT||PROSPECTIVE|||||||
33841655|NCT04625699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154307|NCT04541628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154308|NCT00119496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154309|NCT01651663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154310|NCT03491202|||CASE_CONTROL||PROSPECTIVE|||||||
34154311|NCT03697681|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|triple blinded (Participant, Care Provider, investigator)|A Randomized, Double-Blinded, Placebo-Controlled Trial|t|t|t|t
34154312|NCT02861638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738250|NCT06573554|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Investigators including radiologist interpretation x ray and MRI shall be blinded to treatment allocation. Also one of the investigator as outcome assessor shall be blinded|1:1 randomization|f|f|t|t
33738251|NCT06152211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be masked to the hypothesis of the study. Outcome assessors and investigators will be masked to the group randomization. Randomization will be stratified on gender, age (\<77, ≥77), APOE ε4 carrier status, and hearing aid use. The randomization list will be prepared by an expert statistician outside of the study team.One one research coordinator will have access to the randomization allocation.|An individually randomized group treatment trial where adults ages 65 and older half of carriers of APOE ε4 and the other half of non-carriers will be randomly assigned to a 16-week: (1) community choir program or (2) a group music listening program.|f|f|t|t
33738252|NCT05101564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738253|NCT04819685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738254|NCT05981651|||COHORT||PROSPECTIVE|||||||
33738255|NCT01866189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738256|NCT02478892|||COHORT||PROSPECTIVE|||||||
33738257|NCT02990663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738258|NCT03246529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects were randomized using a 2:1 ratio to receive G-CSF + BL-8040 or G-CSF + Placebo, respectively. Randomization will use permuted blocks stratifying subjects by US geographical region (NorthEast, SouthEast, MidWest, SouthWest and NorthWest), remission status (CR vs. PR), and baseline platelet count (\< 200 × 10\^9/L or ≥ 200 × 10\^9/L).|t|t|t|f
33738259|NCT03760549|||OTHER||OTHER|||||||
33738260|NCT04008134|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking was not possible because the intervention included visible components including a handwashing station and a covered drinking water storage vessel.|||||
33738261|NCT05540886|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Staff who clean will not be blinded as this is not possible. An independent team (not involved in the delivery of the training) will collect monthly primary outcome data from pre-agreed hospital sites. The laboratory team processing the primary outcomes are also blinded.|This is a randomised cluster controlled trial using a stepped-wedge random allocation. At four distinct time points, 13 hospitals will receive the educational intervention. The unit of analysis is high frequency touches sites in the three wards of interest in each of the study hospitals.|f|f|f|t
33738262|NCT02897843|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738263|NCT05313516|NA|SINGLE_GROUP||OTHER||NONE||||||
33738264|NCT02845271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738265|NCT03323905|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot single arm feasibility trial.||||
33738266|NCT05489094|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized non blinded and controlled study||||
33738267|NCT00375193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738268|NCT04638205|||CASE_CONTROL||RETROSPECTIVE|||||||
33738269|NCT03560219|||COHORT||CROSS_SECTIONAL|||||||
33738270|NCT02091518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738271|NCT05787522|||COHORT||PROSPECTIVE|||||||
33738272|NCT02205619|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33738273|NCT03058406|||COHORT||PROSPECTIVE|||||||
33738274|NCT03548610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded physician will evaluate standardized photographs.|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into the nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical \& local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film \& 3 layers of dressings. Topical application creates a fine \<1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 \& 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours \& suture removal (if not absorbed) at 7 days.|f|f|f|t
33738275|NCT03050086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738276|NCT01117311|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33738277|NCT00187798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738278|NCT05991141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738279|NCT03160430|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33738280|NCT04901117|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a multi-center, open-label, non-inferiority, randomized controlled trial.||||
33738281|NCT00559897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738282|NCT06574321|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This evaluation is a cluster RCT using a school by year approach. 16 California schools will participate for 2 years. 8 will be randomly assigned to the intervention-first group and 8 to the comparison-first group. Each school will serve as its own control and has an equal chance of being in either the intervention-first or the comparison-first group. During their comparison group year, schools will administer their normal sexual health education programming."||||
33738283|NCT02341157|||COHORT||PROSPECTIVE|||||||
33738284|NCT01142258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33738285|NCT02443038|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34050280|NCT05987007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050281|NCT05667363|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050282|NCT05371015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After the computer program (SAS® 9.4) generates the groups of subjects in random order, a third-party person who is not the research team will put the groups into envelopes numbered one to one hundred in sequence. Which group the subjects will be assigned to will not be known to members of the research team until the trial is unblinded.|Fifty subjects were randomly assigned to the quadratus lumborum nerve block group with injection of local anesthetic (Ropivacaine), and another 50 subjects were assigned to the quadratus lumborum nerve block with normal saline injection. The total number of subjects involved is one hundred.|t|f|t|t
34050283|NCT05139303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050284|NCT06684132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34154313|NCT06084221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154314|NCT03088813|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33738286|NCT02476565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738287|NCT01299077|||CASE_ONLY||RETROSPECTIVE|||||||
33738288|NCT01123018|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33738289|NCT01196871|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A 2-stage design was used to study the effects of 2 dose levels of migalastat, while a 2- or 3-period design within each stage enabled study of the effects of one drug on the PK, pharmacodynamics, and safety of the other drug.||||
33738290|NCT00774787|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33738291|NCT00001100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738292|NCT00636454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738293|NCT01264861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738294|NCT03212586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33738295|NCT01513317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738296|NCT05535166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738297|NCT00003335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738298|NCT02091167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Sham-controlled double-blind randomized clinical trial|t|t|f|t
33738299|NCT01383941|||COHORT||CROSS_SECTIONAL|||||||
33738300|NCT01175655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738301|NCT05691075|||COHORT||PROSPECTIVE|||||||
33738302|NCT04777344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||single-center, randomized, open-label study||||
33738303|NCT04900974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738304|NCT05205603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738305|NCT03058796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738306|NCT04229719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Third professional person apply melatonin powder.||t|f|t|f
33738307|NCT00125632|NON_RANDOMIZED|CROSSOVER||||DOUBLE||||||
33738308|NCT02906007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738309|NCT05573516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738310|NCT04707235|||COHORT||PROSPECTIVE|||||||
33738311|NCT02682420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738312|NCT01602276|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33738313|NCT01699425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738314|NCT06227780|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"As the randomization and dispensing of the intervention is conducted via software, investigators, study staff, and study subjects will all be blinded to the randomized study treatment assignments."|All visits across all arms will follow identical procedures. Aim 1 and Aim 2 consist of a case-control study that will be completed over two visits, in which baseline data will be collected from participants that will be used to optimize the intervention delivered in Aim 3. Aim 3 consists of a two-visit, randomized controlled, crossover acute perturbation study to study the effect of alpha auditory entrainment (AAE) or sham stimulation on brain activity. AAE will be performed in two visits as a double-blind, sham-controlled crossover study such that each participant will receive AAE and sham in random order.|t|t|t|t
33738315|NCT03249038|||COHORT||PROSPECTIVE|||||||
33738316|NCT04097067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738317|NCT04589585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738318|NCT05089734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738319|NCT03405467|||CASE_ONLY||RETROSPECTIVE|||||||
33738320|NCT06663826|||OTHER||PROSPECTIVE|||||||
33841656|NCT00974259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841657|NCT04247334|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33841658|NCT00816790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34154315|NCT00260416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154316|NCT02123576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154317|NCT01781559|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33738321|NCT01603550|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33738322|NCT02670629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738323|NCT04354831|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||131 patients in 2 cohorts (ICU cohort and a hospitalized non-ICU cohort)||||
33841659|NCT03198468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841660|NCT02341443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841661|NCT00283244|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738324|NCT05156229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738325|NCT01782677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738326|NCT06498050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738327|NCT03754699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33738328|NCT03345602|||COHORT||PROSPECTIVE|||||||
33738329|NCT01369290|||CASE_ONLY||PROSPECTIVE|||||||
33738330|NCT00132444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33738331|NCT04420806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors are unaware of participants group status and were not allowed to ask correspondingly|One exercise versus one control group|f|f|f|t
33738332|NCT05521893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738333|NCT04771741|||CASE_ONLY||PROSPECTIVE|||||||
33841662|NCT02504983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841663|NCT06372704|||CASE_ONLY||PROSPECTIVE|||||||
33841664|NCT01627015|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33841665|NCT01855971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo medication consists in rice flour tablets, given to patients of control group with the same posology than the ones of the experimental group (2\*200mg / day).|"The study lasts 7 months :~* from day 0 to month 1, patients will receive placebo, in order to avoid the placebo effect of the treatment.~* from month 1 to month 4 : patients will be divided in two cohorts, one group receiving ECGC (experimental group), and the other placebo (control group).~* from mont 4 to month 7 : no treatment in given, only effects of cessation of treatment are observed.~Patients from both arms will receive Cognitive training."|t|f|t|f
33841666|NCT04414410|||COHORT||RETROSPECTIVE|||||||
33841667|NCT00318721|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33841668|NCT05412251|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|control group and experimental group|control group and experimental group|t|f|f|f
33738334|NCT03156465|NA|SINGLE_GROUP||TREATMENT||NONE||repeated-measure, single-subject experiment||||
33738335|NCT03606798|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33738336|NCT04214691|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33738337|NCT00679991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738338|NCT03623828|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label single-arm prospective pilot study. Included patients all undergo the same study protocol.||||
33738339|NCT03708341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo, double blind|Randomized Controled Trial. GLMM will be used to analyze the data due to its ability to handle non-normal distributions and account for both fixed and random effects.|t|t|t|t
33738340|NCT04975763|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33738341|NCT06573424|||COHORT||RETROSPECTIVE|||||||
33738342|NCT04231435|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738343|NCT01626976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33738344|NCT05081739|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33738345|NCT01421875|||OTHER||RETROSPECTIVE|||||||
33738346|NCT03985553|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Parents/grandparents/potential parents with SCI/D had the opportunity to attend and participate in a 4 week self-management program once a week related to parenting with a disability. The self-management sessions lasted approximately 2 hours once a week and were led by an occupational therapist. There was no control group or alternate intervention.||||
33738347|NCT04531449|||COHORT||PROSPECTIVE|||||||
33738348|NCT02690246|||COHORT||PROSPECTIVE|||||||
33738349|NCT03347994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose escalation||||
33738350|NCT00439400|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33738351|NCT01187589|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33738352|NCT02029924|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738353|NCT05414240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, parallel-groups design|t|f|t|f
33738354|NCT03324165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33738355|NCT06569043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33738356|NCT04982029|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a double-blind cross-over trial, in which the research staff and participants will be blinded.|The study is a double-blind, placebo-controlled, cross-over trial.|t|f|t|t
33738357|NCT05272852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738358|NCT02167035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33738359|NCT05943860|NA|SINGLE_GROUP||TREATMENT||NONE||Intra-individual comparison||||
33738360|NCT03799458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Active and sham HD-tDCS will be delivered with the same device, and participants and research technician are blinded to the condition.|120 subjects will be recruited for this study: 40 healthy controls subjects for the imaging-only group, and 80 mTBI subjects for the stimulation arm who have suffered mild TBI at least 3 months prior to study enrollment, but not more than 15 years prior to enrollment. The 80 mTBI subjects will be randomized to either active stimulation (40) or sham stimulation (40).|t|t|f|t
33738361|NCT04574622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants (including parents of patients), physiatrists who conducted ESWT and physiatrists who examined the patients' ASAS score are all blinded.||t|t|f|t
33738362|NCT01953484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738363|NCT03847181|||COHORT||RETROSPECTIVE|||||||
33738364|NCT03431194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738365|NCT06175559|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738366|NCT02904252|||COHORT||CROSS_SECTIONAL|||||||
33738367|NCT05046782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738368|NCT03898804|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study is a prospective, non-randomized, open-label, exploratory safety/feasibility trial of up to 12 subjects. The Primary Endpoint will be evaluation over the first 13 months after implantation, after which the subjects will have the option of removal of the device or continued participation in a long-term study for an additional 5 years, for a total of up to 73 months.||||
33738369|NCT06327126|||COHORT||RETROSPECTIVE|||||||
33738370|NCT05349669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738371|NCT06534294|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33738372|NCT06532227|||CASE_CONTROL||OTHER|||||||
33738373|NCT05403827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738374|NCT05852353|NA|SINGLE_GROUP||OTHER||NONE||Single Group Longitudinal Study looking at pre- and post- results of the same group of patients.||||
33738375|NCT01896895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738376|NCT05609097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized open-label blinded endpoint (PROBE) parallel-group design. Participants will be randomized to PRIME or COMBO training for an initial four weeks (Phase 1). Following this, all participants will complete an additional eight weeks of COMBO training (Phase 2). Participants will be randomized in a 1:1 ratio by an independent statistician James Patrie (permuted block randomization with block size of 4, stratified by gender), with treatment allocation revealed after baseline exercise testing. Outcomes will be assessed at baseline, four weeks and eight weeks and 36 weeks (exploratory aim 5) by a blinded assessor (UVA SoM Exercise Core Laboratory).|f|f|f|t
33738377|NCT00035906|RANDOMIZED|PARALLEL||TREATMENT||||||||
33738378|NCT03205085|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33738379|NCT03144570|||COHORT||PROSPECTIVE|||||||
33738380|NCT02252289|||COHORT||PROSPECTIVE|||||||
33738381|NCT03642821|||COHORT||PROSPECTIVE|||||||
33738382|NCT00004026|RANDOMIZED|||TREATMENT||||||||
33738383|NCT06280313|||COHORT||PROSPECTIVE|||||||
33738384|NCT01110239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738385|NCT01075659|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841669|NCT05730231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33841670|NCT02604875|||||PROSPECTIVE|||||||
33841671|NCT03749317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841672|NCT00568178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738386|NCT05907356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738387|NCT02304042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33738388|NCT03085927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738389|NCT04854200|||COHORT||PROSPECTIVE|||||||
33738390|NCT02885363|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738391|NCT06663254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Specifically, everyone except anesthesia clinicians will be blinded to treatment. Anesthesia clinicians who are not blinded will conduct treatment and record intraoperative conditions. Outcome assessors responsible for postoperative follow-up are blinded to patient randomization; Statistical analysis performed independently by the designated blinded statistician. Emergency unblinding will only be done by an investigator and/or dedicated authorized personnel (e.g., the Pharmacovigilance Department of the Sponsor).||t|f|f|t
33738392|NCT06663462|||CASE_CONTROL||PROSPECTIVE|||||||
33738393|NCT03637751|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33738394|NCT01127438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738395|NCT04401449|||COHORT||PROSPECTIVE|||||||
33738396|NCT06250725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33738397|NCT05909722|||COHORT||PROSPECTIVE|||||||
33738398|NCT03271437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738399|NCT04614428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The people assessing the outcomes will be masked|"Randomised control trial of two parallel groups;~1. Standard Care~2. Standard Care + RESILIENCE Program"|f|f|f|t
33738400|NCT03541733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738401|NCT03615651|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33738402|NCT02507102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738403|NCT04991740|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738404|NCT02565797|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33738405|NCT03488381|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738406|NCT04536844|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||This is a pragmatic noninferiority randomized controlled trial (RCT) in Norwegian RA patients in clinical remission (based on RAPID3 score). The patients will be allocated to 2 groups. One group will be followed up by an electronic app, while the second group will attend conventional prescheduled visits in the outpatient clinic of Martina Hansens Hospital. A computer-generated random number sequence will be used for the randomization of the RA patients.|t|t|t|t
33738407|NCT02002767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738408|NCT05278156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738409|NCT03995004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical capsules for melatonin and placebo Clear fluid of the same volume for IV dexamethasone vs normal saline|M: Oral Melatonin 10mg / IV Normal Saline D: Placebo cap / IV Dexamethasone 4mg DM: Oral Melatonin 10mg / IV Dexamethasone 4mg|t|t|t|t
33738410|NCT06219655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738411|NCT05647824|||OTHER||PROSPECTIVE|||||||
33738412|NCT05573295|||CASE_CONTROL||RETROSPECTIVE|||||||
33738413|NCT05600218|||COHORT||OTHER|||||||
33738414|NCT06063941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33738415|NCT05050188|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Both the investigational product and placebo will be given in a double blinded manner, while the positive control drug will be given in an open-label manner.|Two dose levels of H008 at 20 mg and 40 mg will be studied in two sequential cohorts. Each cohort will be enrolled with 12 subjects (8 on H008, 2 on placebo and 2 on positive control drug). Subjects are only allowed to participate in one of the two cohorts. Dose escalation to the next cohort will be permitted only when safety data until follow-up and PK data until 48 hours post-last dose, from all subjects in previous cohorts are reviewed, and the investigational product is deemed well tolerated.|t|f|t|f
33738416|NCT02279810|||COHORT||RETROSPECTIVE|||||||
33738417|NCT06570096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738418|NCT02481687|||COHORT||PROSPECTIVE|||||||
33738419|NCT01692197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738420|NCT04865679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738421|NCT02247310|||COHORT||PROSPECTIVE|||||||
33738422|NCT01275924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738423|NCT04535596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738424|NCT02877485|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33738425|NCT02237105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738426|NCT05262361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The optometrist will be masked for all outcome assessments.|The are two arms. Arm 1 will have participants will have office-based vergence and accommodative therapy (twice per week) immediately after enrollment while arm 2 will have participants have a 6 week delay before enrollment of therapy. There are three assessments: baseline, outcome 1 which is at 6 weeks (arm 1 would be after 12 sessions of therapy and arm 2 would not have participants in vision therapy yet), and outcome 2 which after vision therapy.|f|f|f|t
33738427|NCT06127134|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738428|NCT01384305|||||RETROSPECTIVE|||||||
33738429|NCT01587183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33738430|NCT04524520|||COHORT||PROSPECTIVE|||||||
33738431|NCT05020743|||COHORT||PROSPECTIVE|||||||
33738432|NCT02098343|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738433|NCT06022159|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738434|NCT02570321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients with corneal ulcers are randomized to topical antimicrobial plus corneal crosslinking versus topical antimicrobial alone|t|f|f|t
33738435|NCT04006158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738436|NCT03031912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33738437|NCT05301933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154318|NCT01631396|||CASE_CONTROL||PROSPECTIVE|||||||
34154319|NCT00333918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738438|NCT02141841|||||PROSPECTIVE|||||||
33738439|NCT00550784|NON_RANDOMIZED|||TREATMENT||||||||
33738440|NCT05535192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738441|NCT05383170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34154320|NCT03905850|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33738442|NCT05132335|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|"One arm: Subjects are studied under two consecutive conditions, after overnight fasting and after a liquid meal ingestion. During each condition they are examined for fatty acid uptake in subcutaneous fat and skeletal muscle by FTHA(\[18F\]-FTHA) PET/MRI as well as adipose and skeletal muscle blood perfusion by radioactive water(\[15O\]-H2O ) PET/MRI. This was done at two occasions, 2-14 days apart, to assess repeatability of the measurements.~Assigned interventions:~\[18F\]-FTHA tracer injections~\[15O\]-H2O tracer injections~PET/MRI imaging~Overnight fasting Liquid meal ingestion"|||||
33738443|NCT05760092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738444|NCT01435005|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase 3 - To compare the effects of a high versus moderate volume exercise intervention on specific biological intermediate endpoints for breast cancer in a group of previously inactive postmenopausal women.||||
33738445|NCT01970761|||CASE_ONLY||RETROSPECTIVE|||||||
33738446|NCT02894021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738447|NCT04228861|||COHORT||PROSPECTIVE|||||||
33738448|NCT00689676|||CASE_CONTROL||PROSPECTIVE|||||||
33738449|NCT00974428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738450|NCT00938431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738451|NCT04600648|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Compare the level of insulin, leptin, and sweet taste sensitivity and perception before and after short term weight loss and bariatric surgery||||
33738452|NCT03920397|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a open trial study.|Patients with recent onset type 1 diabetes wil receive an dose of allogenic adipose tissue-derived stem/stromal cells (ASCs) and oral Cholecalciferol UI/day for 24 months.||||
33738453|NCT04866134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738454|NCT06572735|||COHORT||PROSPECTIVE|||||||
33738455|NCT02563340|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738456|NCT04979221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738457|NCT03125889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738458|NCT03069690|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The intervention model is a nonrestricted sequential multiple assignment randomized trial (SMART). Participants are randomized to intervention or control during pregnant and again postpartum.||||
33738459|NCT02855502|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33738460|NCT03099382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738461|NCT05724004|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, multicenter, phase I/II study||||
33738462|NCT00226434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738463|NCT06145828|||CASE_CONTROL||PROSPECTIVE|||||||
33738464|NCT06461104|RANDOMIZED|PARALLEL||TREATMENT||NONE||This randomised controlled trial (RCT) is designed to evaluate the efficacy of a structured physical activity (PA) programme compared to a psychoeducational intervention on healthy lifestyle in female outpatients aged 18 to 40 years with a diagnosis of Borderline Personality Disorder (BPD). Participants will be randomly assigned to one of two groups: an intervention group that engages in a 12-week structured PA programme preceded by three psychoeducational sessions focused on nutrition, and a control group that receives a 12-week psychoeducational programme on nutrition and PA. The study aims to assess changes in clinical symptoms, PA-related parameters, and various physical, psychological, and biological outcomes at baseline, mid-treatment, end of treatment, and at a 3-month follow-up. This RCT adheres to the Declaration of Helsinki and involves comprehensive informed consent and data processing protocols.||||
33738465|NCT00136708|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738466|NCT03609060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738467|NCT03747081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738468|NCT02685163|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33738469|NCT01503489|||COHORT||PROSPECTIVE|||||||
33738470|NCT05801627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33738471|NCT02460640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738472|NCT02722694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738473|NCT04741659|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738474|NCT04313192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738475|NCT01428323|RANDOMIZED|PARALLEL||||NONE||||||
33738476|NCT03919175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738477|NCT05798507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738478|NCT04417491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738479|NCT02184962|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738480|NCT02104089|||CASE_ONLY||OTHER|||||||
33738481|NCT05625100|||CASE_ONLY||RETROSPECTIVE|||||||
33738482|NCT04315285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher(s) who will conduct the outcome assessments will be masked from the group allocation||f|f|f|t
33738483|NCT05005546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738484|NCT06658340|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738485|NCT01734746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738486|NCT04879303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738487|NCT05220696|||COHORT||PROSPECTIVE|||||||
33738488|NCT01241734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738489|NCT06494735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738490|NCT01557660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738491|NCT05052359|||COHORT||RETROSPECTIVE|||||||
33738492|NCT00534352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738493|NCT04331080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738494|NCT02097875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738495|NCT04603924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738496|NCT04740177|||COHORT||RETROSPECTIVE|||||||
33738497|NCT05890027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738498|NCT04113759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738499|NCT01797224|||COHORT||PROSPECTIVE|||||||
33738500|NCT03275298|||COHORT||RETROSPECTIVE|||||||
33738501|NCT01194297|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738502|NCT06407752|||OTHER||CROSS_SECTIONAL|||||||
33738503|NCT02066558|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33738504|NCT01347021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738505|NCT06214585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738506|NCT02162628|||COHORT||PROSPECTIVE|||||||
33738507|NCT04868201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33738508|NCT06534697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||All enrolled patients will receive spinal anesthesia and preoperatively FIB for analgesia. The investigators randomly define three patient groups using the envelope method: Group 1, receiving 40 ml naropin 0,25% in saline; Group 2, receiving 40 ml naropin 0,25% in dextrose 5%; and Group 3, receiving 40 ml dextrose 10%. After the regression of spinal anesthesia, all the patients receive the same multimodal pain therapy according to the visual analog scale (VAS), including Paracetamol IV, NSAID, and morphine, according to the pain protocol in our hospital. The administration of morphine is according to our hospital protocol. The primary endpoint of the study is total morphine (mg) consumption at 24 hours postoperatively, and the second goal was length of stay and the risk of falls.|t|t|t|t
33738509|NCT00618020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738510|NCT04892901|||COHORT||PROSPECTIVE|||||||
33738511|NCT06085105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33738512|NCT04323553|||OTHER||RETROSPECTIVE|||||||
33738513|NCT05070481|||OTHER||PROSPECTIVE|||||||
33738514|NCT00461526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738515|NCT04550962|||COHORT||PROSPECTIVE|||||||
33738516|NCT04641923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Once eligibility has been determined, participants will be randomized with a 1:1 ratio using a block randomization model. The randomization tool will be located on a password-protected website. In order to maintain allocation concealment, the assigned intervention (i.e. Seprafilm use) will be provided to the surgeon in an opaque, sealed envelope immediately before surgery by the research assistant. Patients and data analysts will be blinded to treatment allocation status.|The study population will consist of all consecutive adult patients undergoing a partial hepatectomy with a high likelihood of repeat hepatectomy. These will include patients with colorectal liver metastasis and those with hepatocellular carcinoma. All patients who consent to undergo a partial hepatectomy at the Foothills Medical Center and who meet the inclusion criteria will be contacted via phone prior to their surgery by a trial research assistant in order to obtain informed consent for enrolment in the trial. Patients will be randomized with a 1:1 ratio for seprafilm vs no seprafilm group.|t|f|f|f
33738517|NCT00608829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738518|NCT00077259||||TREATMENT||NONE||||||
33738519|NCT06227494|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33738520|NCT00677339|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33738521|NCT03616418|||COHORT||PROSPECTIVE|||||||
33738522|NCT02164682|||COHORT||RETROSPECTIVE|||||||
33738523|NCT01697306|RANDOMIZED|PARALLEL||||NONE||||||
33738524|NCT02833740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738525|NCT00965848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738526|NCT01168934|RANDOMIZED|PARALLEL||||NONE||||||
33738527|NCT00890903|||COHORT||PROSPECTIVE|||||||
33738528|NCT01984723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738529|NCT02009150|||CASE_ONLY||PROSPECTIVE|||||||
33738530|NCT01480115|||COHORT||PROSPECTIVE|||||||
33738531|NCT05795933|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two groups of children with bronchiolitis:~Study group: will receive a single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission.~Control group: will receive the standard recommended dose of vitamin D3 as 400 IU/day orally"||||
33738532|NCT00440271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738533|NCT02379598|||COHORT||PROSPECTIVE|||||||
33738534|NCT01879397|||COHORT||PROSPECTIVE|||||||
33738535|NCT00865527|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33738536|NCT06317805|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, two-arm, open-label, low-interventional, phase IV, multi-centre clinical trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy (background therapy with endothelin receptor antagonist - ERA and phosphodiesterase type-5 inhibitor - PDE-5i) by proportion of patients achieving low risk status according to the simplified four-strata risk-assessment tool from week 24 up to 48 weeks in 110 (55/group) treatment-naïve adult intermediate-high risk or intermediate-low risk patients with severe hemodynamic impairment with pulmonary arterial hypertension (PAH) (group I).||||
33738537|NCT02239458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33738538|NCT06660316|||COHORT||CROSS_SECTIONAL|||||||
33738539|NCT05772065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33841673|NCT00266123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841674|NCT00635661|||COHORT||PROSPECTIVE|||||||
33841675|NCT04765332|||COHORT||PROSPECTIVE|||||||
33841676|NCT00090740|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33841677|NCT02548975|||COHORT||RETROSPECTIVE|||||||
34154321|NCT05032885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154322|NCT04967339|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33738540|NCT03966404|||COHORT||PROSPECTIVE|||||||
33738541|NCT01088061|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738542|NCT05191498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738543|NCT00887341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841678|NCT00821340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841679|NCT03846453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050285|NCT03606304|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group, pre-/post-test design with a 6 month follow-up period. There are 8 weekly intervention sessions, each approximately 30-45 minutes long. The 3 telephone booster sessions occurring every two months during the followup phase are estimated to last 20 minutes.||||
34050286|NCT06666049|||COHORT||PROSPECTIVE|||||||
33738544|NCT03448367|||COHORT||PROSPECTIVE|||||||
33738545|NCT05091567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738546|NCT02838524|||COHORT||PROSPECTIVE|||||||
33738547|NCT00718042|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33738548|NCT04842240|||COHORT||PROSPECTIVE|||||||
33738549|NCT00330590|||||PROSPECTIVE|||||||
33738550|NCT03887481|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This is a crossover design of active HD-tDCS + Language/Cognitive Intervention that crossovers to Sham + Language/Cognitive Intervention in Arm 1 and Sham + Language/Cognitive Intervention that crossovers to active HD-tDCS + Language/Cognitive Intervention in Arm 2.|t|t|f|t
33738551|NCT04298255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Infertile Male with round spermatid (but not elongated spermatids and spermatozoa) in their testes. Couples can choose either option 1 or 2.||||
33738552|NCT05108493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738553|NCT04442737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738554|NCT04950608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738555|NCT01516112|||CASE_ONLY||PROSPECTIVE|||||||
33738556|NCT02720484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738557|NCT04376996|||COHORT||PROSPECTIVE|||||||
33738558|NCT05245812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738559|NCT00396734|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738560|NCT06271096|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was a randomized controlled trial carried out between November 2019 to November 2022 in the Pediatric department of Khyber Teaching Hospital. A total of 150 children who presented to the emergency department with seizures were enrolled in this study via consecutive sampling. This study was approved by the Ethical Review||||
33738561|NCT06460701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask both groups about the treatment|it will be a randomized controlled trial in which non probability convenient sampling will be used. Two groups of 2-4 age will be formed in which participants will be randomly divided. Group A will receive m-CIMT along with kinesio taping while Group B will receive only m-CIMT.|t|f|f|f
33738562|NCT05425810|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|When the digital photos are shown to evaluators from external groups, the socket fitting conditions are not disclosed.|All the participants will go through the same testing procedure. Both the experimenters and the participants know very well about the change in the experimental setup.||||
33738563|NCT04518124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738564|NCT01010984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738565|NCT05769673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33738566|NCT05960682|||CASE_ONLY||RETROSPECTIVE|||||||
33738567|NCT00653224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738568|NCT01229436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738569|NCT06573151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738570|NCT06165003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the research, control group data will be collected first. After the data of the control group is collected, the data of the experimental group will be collected.|Randomized controlled study|t|f|f|f
33738571|NCT05371210|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33738572|NCT06533306|||COHORT||RETROSPECTIVE|||||||
33738573|NCT04463901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738574|NCT00852384|NON_RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33738575|NCT05306106|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||monocentric, randomized, cross-over and ambulatory study|t|f|t|f
33738576|NCT06522451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It will be Randomized control trial in which non probability convenient sampling will be used. Two groups of age 12-42 months will be formed in which participants will be randomly divided. Group A will only receive conventional physical therapy and group B will receive conventional physical therapy with cuevas medek exercises|t|f|f|f
33738577|NCT03146702|||OTHER||PROSPECTIVE|||||||
33738578|NCT01919385|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738579|NCT00660010|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738580|NCT03459417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738581|NCT02956629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738582|NCT03950492|NA|SINGLE_GROUP||OTHER||NONE||This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have deep brain stimulation (DBS) targeting the NAc/VC.||||
33738583|NCT02635438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738584|NCT05412550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The PI and Outcomes Assessors will be blinded to participant group allocation. The participant and interventionist will not be blinded.|Two-arm randomized controlled trial|f|f|t|t
33738585|NCT00533949|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study was revised 06/18/08 to a 2x2 factorial design to evaluate the addition of cetuximab to the radiation therapy regimens.||||
33738586|NCT03617679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Active ingredient vs placebo|t|f|t|f
33738587|NCT05383846|NA|SEQUENTIAL||OTHER||NONE||Naturalistic, mixed-method, explanatory sequential measurement single case series design||||
33738588|NCT04132947|||COHORT||PROSPECTIVE|||||||
34050287|NCT03867201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050288|NCT00892333|||CASE_ONLY||PROSPECTIVE|||||||
34050289|NCT04797299|||COHORT||PROSPECTIVE|||||||
33738589|NCT04666649|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"1. Cohort1: The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 500 IU/m² of Pegcrisantaspase in an IV every 14 days ( per cycle)~2. Cohort 2: The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 750 IU/m² of Pegcrisantaspase in an IV every 14 days ( per cycle)~3. Cohort 3: The subject will take 400mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)~4. Cohort 4: The subject will take 600mg of Venetoclax every day as a pill by mouth and a dose of 1000 IU/m ² of Pegcrisantaspase in an IV every 14 days ( per cycle)"||||
33738590|NCT06573177|||COHORT||OTHER|||||||
33738591|NCT04498897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded study|A randomized, placebo-controlled study|t|t|t|t
33738592|NCT01259661|RANDOMIZED|PARALLEL||||NONE||||||
33738593|NCT05634681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738594|NCT06168175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738595|NCT05838222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Pretest-posttest experimental design with a treatment as usual group and an intervention group|t|f|t|t
33738596|NCT02265705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738597|NCT00141960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33738598|NCT04133831|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33738599|NCT06456294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738600|NCT06161454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738601|NCT01461590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738602|NCT06160024|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study addresses long-term care facilities||||
33738603|NCT01677195|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33738604|NCT02421991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738605|NCT04496609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738606|NCT01300702|||COHORT||PROSPECTIVE|||||||
33738607|NCT01871948|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33738608|NCT06161376|||OTHER||PROSPECTIVE|||||||
33738609|NCT05309382|||COHORT||PROSPECTIVE|||||||
33738610|NCT05944263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33738611|NCT06573580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33738612|NCT05565612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot randomized, double-blind, placebo-controlled study of a duration of 12 weeks|t|t|f|f
33738613|NCT01329497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738614|NCT01998867|||COHORT||PROSPECTIVE|||||||
33738615|NCT03755726|||COHORT||PROSPECTIVE|||||||
33738616|NCT03243331|NA|SEQUENTIAL||TREATMENT||NONE||Study will enroll 3 patients to the cohort 1 dose level. If 0 of 3 patients experience a DLT, the study will proceed to cohort 2. If 1 patient experiences a DLT, 3 additional patients will be enrolled into cohort 1. If 1 of 6 patients experience a DLT, the study will proceed and 3 patients will be enrolled to the cohort 2 dose level. If 0 patients experience a DLT in cohort 2, the study will proceed to cohort 3. If 1 patient experiences a DLT at cohort 2, 3 additional patients will be enrolled into cohort 2. If the study proceeds to cohort 3, 3 patients will be enrolled at this dose level. If 0 patients experience a DLT, the study will enroll an additional 3 patients at the cohort 3 dose level to better define the safety profile. If 1 of 3 patients experiences a DLT at cohort 3, 3 additional patients will still be enrolled into cohort 3. If 1 of 6 patients experience a DLT, the study will complete.||||
33738617|NCT02946294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738618|NCT01639209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738619|NCT06127420|||COHORT||CROSS_SECTIONAL|||||||
33738620|NCT05070897|||COHORT||PROSPECTIVE|||||||
33738621|NCT03913117|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33738622|NCT05112835|||COHORT||PROSPECTIVE|||||||
33738623|NCT04908813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study||t|t|t|t
33738624|NCT06573268|||CASE_CONTROL||RETROSPECTIVE|||||||
33738625|NCT04317586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738626|NCT05797805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738627|NCT04382326|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738628|NCT02804607|||COHORT||RETROSPECTIVE|||||||
33738629|NCT05889858|||CASE_ONLY||CROSS_SECTIONAL|||||||
33738630|NCT00928317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738631|NCT03243916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738632|NCT05280574|||COHORT||OTHER|||||||
33738633|NCT05760794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will be masked to their allocation and post-operative examiners will be masked at the 6 week, 6 month, and 12 month visits|Plan to enroll 52 participants with intention to treat 26 in each group - Participants will be randomized to delayed-absorbable barbed suture (2-0 V-Loc) versus delayed-absorbable interrupted suture (2-0 PDS).|t|f|f|t
33738634|NCT00537524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33738635|NCT01650389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738636|NCT01363778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738637|NCT03336008|||COHORT||PROSPECTIVE|||||||
33738638|NCT04689984|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Eligible subjects were randomly allocated to receive any of the following regiments: standard therapy consists of pregabalin, gabapentine, or amitriptyline (control group) or standard therapy and astaxanthin 6 mg tablet once daily (experimental group).||||
33738639|NCT03740217|RANDOMIZED|CROSSOVER||OTHER||NONE||Subject will be randomly allocated with different formulations of treatment or conditions (Fasting or Fed) during three periods (P1, P2 and P3).||||
33738640|NCT02690545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738641|NCT03395795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738642|NCT05132231|||OTHER||PROSPECTIVE|||||||
33738643|NCT00847574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738644|NCT06663839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738645|NCT01997775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738646|NCT05286905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738647|NCT06295133|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All volunteers will receive a stress management intervention.||||
33738648|NCT02294201|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738649|NCT00124150|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33738650|NCT02360917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33738651|NCT01586442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738652|NCT01179594|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33738653|NCT02030678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738654|NCT05437679|||COHORT||PROSPECTIVE|||||||
33738655|NCT01903694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738656|NCT06500078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738657|NCT04819360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738658|NCT00753441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738659|NCT05464511|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This will be a multi-centered, retrospective as well as prospective observational registry with patients undergoing LAAO with the dual mechanism closure Amulet device. This study will proceed with a target of 300 patients who have undergone or are planned to undergo LAAO with dual mechanism closure Amulet device. Patient level data of participating centers will be obtained from National Cardiovascular Data Registry (NCDR®) of patients who have already had the procedure. Prospective data will be collected for all patients willing to participate in the study.||||
33738660|NCT06571786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738661|NCT04212507|||CASE_CONTROL||RETROSPECTIVE|||||||
33738662|NCT05179954|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross-sectional comparison (T1D vs healthy control)||||
33738663|NCT04830826|||COHORT||PROSPECTIVE|||||||
33738664|NCT04798586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738665|NCT03455855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738666|NCT06043557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738667|NCT03239041|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33738668|NCT05415098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738669|NCT03424421|NA|SINGLE_GROUP||TREATMENT||NONE||pilot study||||
33738670|NCT05409924|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33738671|NCT02229955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738672|NCT04846140|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||3 sessions of 3 types of active brain stimulation and 1 session of placebo sham stimulation. Each participant will perform four sessions in a randomly-assigned order.|t|f|t|f
33738673|NCT03880578|||COHORT||PROSPECTIVE|||||||
33738674|NCT02366572|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33738675|NCT01063010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738676|NCT00134277|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738677|NCT06571461|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is designed as a phase III, two-arm, open-label, multi-center, randomized clinical trial comparing combination liposomal irinotecan, oxaliplatin and S-1 with gemcitabine + capecitabine when used as adjuvant therapy following resection for pancreatic ductal adenocarcinoma.||||
33738678|NCT02501330|||CASE_ONLY||PROSPECTIVE|||||||
33738679|NCT06460311|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33738680|NCT06186388|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738681|NCT06146244|||CASE_CONTROL||PROSPECTIVE|||||||
33738682|NCT01813604|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738683|NCT00120042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738684|NCT01003431|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738685|NCT06440525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738686|NCT04551105|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33738687|NCT04589559|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention involves heart rate variability biofeedback (HRVB) administered via a smartphone app (Elite HRV) that receives real-time cardiac information from a chest-worn heart rate monitor (Polar H10).||||
33738688|NCT06460194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|"The methodology uses a two armed, randomized, double-blind, placebo-controlled studydesign, . All participating soldiers will get two injections, one first injection at inclusion and a second injection after 6 weeks. The injections contain either BTX~-A or an inert placebo. Both patient and treating doctor is blinded to content of the injection.~The two patients in the primary treatment group will receive Botox at their first injection at inclusion, while the two patients in the secondary group will receive placebo as their first injection at inclusion. At 6 weeks follow up, the patients in the primary treatment group will receive their second injection of botox. The patients in the secondary treatment group now will receive their second injection, but this will be their first injection of Botox, given at their 6 weeks follow-up."|t|f|t|f
33738689|NCT02308202|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738690|NCT06574399|||COHORT||PROSPECTIVE|||||||
33738691|NCT04526691|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation and dose expansion model||||
33738692|NCT00883571|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33738693|NCT04486287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945134|NCT04025736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Inclusion criteria were Patients who were diagnosed with rotator cuff tear and failure of conservative treatment for more than 3 months. The tear size was measured by MRI and must be repairable. We excluded patients who did not provide permit, those had history of coagulopathy, who were under anticoagulation therapy before surgery, who had abnormal coagulation profile (prothrombin time or activated partial thromboplastin time) before surgery, who had renal or liver disorder, those who had uncontrolled hypertension (systolic pressure \&gt;180 mmHg), or who were allergy to local anesthetic agent or Tranexamic acid.|t|t|t|t
33945135|NCT03345927|||CASE_CONTROL||RETROSPECTIVE|||||||
33945136|NCT02643420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050290|NCT06682676|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33738694|NCT06055322|NA|SINGLE_GROUP||TREATMENT||NONE||Adapted Dialectical Behavior Therapy||||
33738695|NCT06133621|||COHORT||PROSPECTIVE|||||||
33738696|NCT05226104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738697|NCT02697019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738698|NCT03649126|||OTHER||PROSPECTIVE|||||||
33738699|NCT05002101|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study was single-blinded, where the children's mothers didn't know either their children are enrolled in the study group or the control group||t|f|f|f
33738700|NCT04654689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"* Intervention group: 30 patients will be administered daily the combination of Resveratrol (75mg) and Curcumin (200mg) liposomes with G04CB02 (0.5mg), in a single dose for 4 months.~* Control group: 30 patients, who will receive a placebo with the same dosage pattern and for the same period of time. The placebo will consist of water with sucrose replacing the liposomed polyphenols, and a soft capsule of microcrystalline methylcellulose instead of G04CB02. Both the packaging and the capsule format will be identical to those of the treatment administered in the intervention group."|t|t|t|f
33738701|NCT06227611|||COHORT||CROSS_SECTIONAL|||||||
33738702|NCT02317640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738703|NCT00874744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738704|NCT02031276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Period 1 was blinded intravenous (IV) therapy, period 2 was open label IV therapy and period 3 was open label subcutaneous (SC) therapy.||t|f|t|f
33738705|NCT05169879|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33738706|NCT05163145|||CASE_ONLY||CROSS_SECTIONAL|||||||
33738707|NCT03284268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738708|NCT04192396|||COHORT||PROSPECTIVE|||||||
33738709|NCT03568916|||COHORT||RETROSPECTIVE|||||||
33738710|NCT03525834|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label||||
33738711|NCT02984020|||CASE_ONLY||PROSPECTIVE|||||||
33738712|NCT02430077|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738713|NCT03363594|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738714|NCT04572347|||COHORT||OTHER|||||||
33738715|NCT03527992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738716|NCT00036166|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738717|NCT04777461|NA|SINGLE_GROUP||OTHER||NONE||||||
33738718|NCT06534138|||COHORT||RETROSPECTIVE|||||||
33738719|NCT04452825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is designed to test CARE delivered by telephone to improve cancer care for the population of older adults in a larger two-arm Randomized Controlled Trial (RCT).||||
33738720|NCT05754086|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738721|NCT01094275|||CASE_CROSSOVER||PROSPECTIVE|||||||
33738722|NCT01911533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738723|NCT05372198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738724|NCT00078390|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The Phase 1 part of the study will determine the tolerable dose of S-3304 in the presence of radiation and paclitaxel/carboplatin chemotherapy in a non-randomized manner.~The Phase 2 part will compare the effect combination of S-3304 in addition to chemo-irradiation therapy to the effect of radiation and paclitaxel/carboplatin chemotherapy alone on small cell lung tumors"||||
33738725|NCT01224496|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738726|NCT02210299|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738727|NCT06165705|NA|SINGLE_GROUP||TREATMENT||NONE||treatment efficacy||||
33738728|NCT04704414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Blinding of the operators of Hertel exophthalmometer for previous measurement results.|"* Accuracy and precision of smartphone in comparison with 3D face scanner and Hertel exophthalmometer~* Test-retest reliability~* Inter-operator reliability~* Before and after exophthalmos-changing intervention"||||
33738729|NCT05018845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738730|NCT02063646|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738731|NCT00404898|||OTHER||RETROSPECTIVE|||||||
33738732|NCT06387472|NA|SINGLE_GROUP||SCREENING||NONE||||||
33738733|NCT04275648|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33738734|NCT03487913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738735|NCT01867684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738736|NCT03853707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738737|NCT03207282|||COHORT||PROSPECTIVE|||||||
33841680|NCT06273280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the study design, the study is open-label. In order to reduce bias, a study nurse (blinded for allocation arm) will see or call the patient to register the heart failure medication and dose of loop diuretics at three months and optionally 12months (open-label, endpoint-blinded).|This is a prospective, randomized-controlled trial. Due to the design, the study is open-label, but the endpoint assessment is blinded.|f|f|f|t
33738738|NCT01083550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738739|NCT00175136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738740|NCT04504227|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||4-test consistency, randomized, crossover, single-blinded swallow physiology study comparing effects of different liquid viscosities on swallow coordination in infants and children|f|f|t|f
33738741|NCT02438241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738742|NCT04932174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33738743|NCT06573788|RANDOMIZED|PARALLEL||OTHER||SINGLE|Block randomized number will be prepared in advance and be hidden in the envelope. At the time of collecting the participants' baseline information, neither the participants nor the investigator knew which intervention the patients would receive. After the information was collected, the envelopes were opened to determine whether participants were assigned to the intervention or control group.|Prospective randomized clinical trial|f|f|f|t
33738744|NCT01816620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738745|NCT03835234|||COHORT||PROSPECTIVE|||||||
33738746|NCT01260441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33738747|NCT04690608|NA|SINGLE_GROUP||TREATMENT||NONE|code number will be given for each participant|cases of resistant diabetic macular edema and central retinal vein occlusion||||
33738748|NCT05513638|||OTHER||PROSPECTIVE|||||||
33738749|NCT05306067|||CASE_ONLY||CROSS_SECTIONAL|||||||
33738750|NCT04863950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738751|NCT06198439|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort study, all subjects receive the same intervention||||
33738752|NCT05393310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738753|NCT00007800|RANDOMIZED|PARALLEL||TREATMENT||||||||
33738754|NCT06110546|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33738755|NCT04986059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738756|NCT04341922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738757|NCT06393361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738758|NCT05122845|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33738759|NCT03400397|||CASE_ONLY||RETROSPECTIVE|||||||
33738760|NCT02928692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738761|NCT03639155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738762|NCT02760186|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33738763|NCT05767424|||COHORT||PROSPECTIVE|||||||
33738764|NCT05059392|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm intervention. Students are allocated to one of two intervention-groups based on personal preference, both intervention-groups receive the same intervention.||||
33738765|NCT03486041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The project coordinator at each site will conduct baseline assessments. All later assessments will be conducted by different research assistants, masked to experimental condition of the participant.|Immediate ComB and MAC participants will each be assessed at baseline (week 0). ComB will begin weekly therapy sessions, and MAC will receive weekly phone check-ins. All will be assessed at week 6 \[mid-treatment\] and week 12 \[end of controlled phase\]. After week 12, ComB enters maintenance and MAC participants start to receive delayed ComB. There is another assessment at week 25 (3-month followup for immediate ComB, post-ComB for MAC) and a final assessment at week 38 (6-month followup for immediate ComB, 3-month followup for MAC).|f|f|f|t
33738766|NCT00327782|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33738767|NCT00206674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33738768|NCT01023126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738769|NCT03976440|||OTHER||PROSPECTIVE|||||||
33738770|NCT05958992|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants will be randomly assigned to use an e-liquid|t|f|t|f
33738771|NCT05053282|||COHORT||CROSS_SECTIONAL|||||||
33738772|NCT00172575|||DEFINED_POPULATION||OTHER|||||||
33738773|NCT00844194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738774|NCT02799082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33738775|NCT04725175|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|All roles are masked with the exception of the pharmacist/dose preparer.||t|f|t|f
33738776|NCT01072487|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33738777|NCT05247944|||COHORT||RETROSPECTIVE|||||||
33738778|NCT05310825|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|The intervention and measurements were carried out by the first researcher.|The research is planned as a randomized, controlled, crossover and experimental study||||
33738779|NCT01785745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33738780|NCT03959501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738781|NCT01263873|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33738782|NCT06572722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738783|NCT01826149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33738784|NCT00003945|RANDOMIZED|||TREATMENT||||||||
33738785|NCT03702465|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel assignment with an active control||||
33738786|NCT01626365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738787|NCT01933334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738788|NCT00752505|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33738789|NCT05932316|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|The Salbutamol inhaler and the placebo inhaler will be marked as '1' and '2'. The division Nurse will be in charge of marking the inhalers and all the rest of the team and participants will be blinded. The clinicians, technicians and patients will not be able to distinguish between Salbutamol and placebo, and will not know to what arm the patient was assigned at the time of the testing and the interpretation of the results.|Each group of patients and controls will be randomly assigned to two study arms as follows: patients in both arms will perform regular spirometry. After the first series of spirometry testing, patients in the first arm will receive bronchodilators as per bronchodilator response protocol (Salbutamol, 100 mcg, 4 puffs via spacer) and patients in the second arm will receive four puffs of placebo. After a waiting time of 15 minutes, spirometry will be repeated. Following the second spirometry testing those who received salbutamol will now receive placebo and those receiving placebo will receive Salbutamol. After a second period of 15 minutes, a third series of spirometry will be recorded.|t|t|t|f
33738790|NCT05087043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33738791|NCT01470027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738792|NCT04596852|NON_RANDOMIZED|PARALLEL||SCREENING||NONE|The order of participation of evaluators is random.|||||
33738793|NCT04067141|RANDOMIZED|CROSSOVER||OTHER||SINGLE||This is a bilateral crossover study|t|f|f|f
33738794|NCT00151801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33738795|NCT05068765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33738796|NCT03106896|||CASE_CONTROL||PROSPECTIVE|||||||
33738797|NCT02174094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33738798|NCT05078723|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|We are using quantitative assays for this study which reduce the need for masking of the participant or investigator.|Human volunteers participating in this study will be given an over the counter orange peel extract and limonene levels will be measured.||||
33738799|NCT03229551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33738800|NCT03923127|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738801|NCT01553734|||COHORT||PROSPECTIVE|||||||
33738802|NCT02278497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738803|NCT01584284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738804|NCT04972435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cataract patients with PAC or PACG who schedule for phacoemulsification with intraocular lens implantation. The patients must decide preoperatively to use multifocal IOL or monofocal IOL (patient preference) after receiving clear information about those 2 IOL models. Postoperatively, the contrast sensitivity (CS)will be measured with the same method. The postoperative CS were compared between groups.||||
33738805|NCT03744819|||COHORT||PROSPECTIVE|||||||
33738806|NCT06103370|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33738807|NCT06663995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738808|NCT00634647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738809|NCT05919238|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part B recruitment will be opened upon completion of Part A light dose escalation.||||
33738810|NCT05789875|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738811|NCT04760470|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33738812|NCT05897359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738813|NCT01717417|||COHORT||PROSPECTIVE|||||||
33738814|NCT03502876|||COHORT||PROSPECTIVE|||||||
33738815|NCT03015077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33738816|NCT05852444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants of the study and outcomes assessor would not know the details of groups, and only the investigator and care provider would be aware of that, as they cannot be blinded due to the nature of this study|Participants to be divided into 2 different groups randomly, and intervention protocol to be performed as per group designation|t|f|f|t
33738817|NCT01569334|NON_RANDOMIZED|PARALLEL||||NONE||||||
33841681|NCT05212727|||CASE_ONLY||CROSS_SECTIONAL|||||||
33841682|NCT05539443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841683|NCT01204931|||CASE_CONTROL||PROSPECTIVE|||||||
33841684|NCT01255254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841685|NCT01663051|||COHORT||PROSPECTIVE|||||||
33841686|NCT06033599|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33841687|NCT04188275|||CASE_ONLY||PROSPECTIVE|||||||
33738818|NCT02984176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33738819|NCT05352074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738820|NCT01546493|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33841688|NCT05293405|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841689|NCT04096170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841690|NCT04995029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The induction phase of the study will be open label. The maintenance phase of the study will be conducted in a double-blind manner.||t|f|t|f
33841691|NCT02716636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841692|NCT04774653|||COHORT||CROSS_SECTIONAL|||||||
33841693|NCT06190106|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||only a single group is studied and their experiences are explored first after screening the psychiatric symptoms of depression, anxiety, and stress and then providing them with Cognitive Behavioral interventions to check the improvement in their Psychiatric symptoms and assess the positive and negative aspects and outcomes of Psychotherapeutic Intervention,||||
33841694|NCT01461811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841695|NCT04744545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not have information about each participant's study group.|Randomized controlled trial with two study groups.|f|f|f|t
33841696|NCT00004442||||TREATMENT||||||||
33841697|NCT01865747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841698|NCT03599258|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33841699|NCT01291940|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33841700|NCT03444623|||COHORT||PROSPECTIVE|||||||
33841701|NCT05114486|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33841702|NCT01134224|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33841703|NCT04534608|||FAMILY_BASED||PROSPECTIVE|||||||
33841704|NCT06175377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841705|NCT02773173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||neuromuscular blocking agents as type of drug|t|f|f|f
33841706|NCT02842177|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841707|NCT00329680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841708|NCT00091559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841709|NCT03163927|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33841710|NCT02510040|||COHORT||PROSPECTIVE|||||||
33841711|NCT03952052|NA|SINGLE_GROUP||OTHER||NONE||||||
33841712|NCT04162379|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841713|NCT03956251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841714|NCT02731690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841715|NCT01169012|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841716|NCT00006375||||TREATMENT||||||||
33841717|NCT02275429|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841718|NCT05634278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841719|NCT01245140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738821|NCT00194012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738822|NCT04705077|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841720|NCT05978206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841721|NCT03789175|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841722|NCT02297100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841723|NCT04324723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The researchers who called participants to ask if they sought further medical attention was not made aware of the participants' conditions.||f|f|f|t
33738823|NCT03323268|||COHORT||PROSPECTIVE|||||||
33841724|NCT03297034|||COHORT||PROSPECTIVE|||||||
33841725|NCT04458259|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion||||
33841726|NCT00325689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841727|NCT06318338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33738824|NCT02293005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738825|NCT02573987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738826|NCT03781518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738827|NCT06128135|||OTHER||CROSS_SECTIONAL|||||||
33841728|NCT02032082|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33841729|NCT03811613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841730|NCT02492230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841731|NCT03609918|||CASE_ONLY||RETROSPECTIVE|||||||
33841732|NCT02803008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738828|NCT02203019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841733|NCT04086277|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The control group was composed of women with labour, who attended the General Hospital of Zone 4 of the Guanajuato Delegation of the IMSS in the period of October-December 2016. The study group was composed of women with labour who presented at the same hospital to receive obstetric care in the period of October - December 2018.||||
33841734|NCT05148910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33841735|NCT04103567|NA|SINGLE_GROUP||OTHER||NONE||||||
33841736|NCT01346631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738829|NCT05999409|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33841737|NCT03581760|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an open-label study, no masking model is applied.|Patients enrolled in the study will be randomized into two groups - active intervention and control group.||||
33841738|NCT04025047|||COHORT||PROSPECTIVE|||||||
33841739|NCT05593172|||CASE_CONTROL||PROSPECTIVE|||||||
33841740|NCT03285698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Photographs are submitted and evaluated by a blind, independent assessor.||f|f|f|t
33738830|NCT02165722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738831|NCT03143829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are randomly assigned to either an intervention or wait control group. The intervention group receives an educational intervention at the start of the study. The wait control group receives the intervention at the end.||||
33738832|NCT00863538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738833|NCT03169153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33738834|NCT05577897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33738835|NCT03741959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded. Patients will be specifically asked not to discuss their treatment during assessments. Examiner will be requested to inform the research coordinator if he will discover to which group a patient belonged, and they will periodically be questioned by the coordinator about this.|Parallel Assignment. Single-blind RCT with two parallel group|f|f|f|t
33841741|NCT02033083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841742|NCT04589481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Three different variants of a candy are being tested by each participant. The candies are randomly assigned to the subjects, so that each subject has tested each of the three candies once. Randomization creates a different order for each participant. The study will be carried out on three different days.||||
33841743|NCT04825405|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841744|NCT04157400|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841745|NCT02005575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33841746|NCT00297505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841747|NCT04983459|||COHORT||RETROSPECTIVE|||||||
33841748|NCT01279928|||||CROSS_SECTIONAL|||||||
33841749|NCT06094946|||COHORT||PROSPECTIVE|||||||
33841750|NCT00596882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841751|NCT03235934|||COHORT||PROSPECTIVE|||||||
33841752|NCT03621787|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising, bleeding, and pain to participant. A follow-up questionnaire will assess pain, bruising, and infection risk. A final visit will assess pain, bruising, and infection risk by a physician.||||
33841753|NCT02381093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841754|NCT05378334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738836|NCT04898218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738837|NCT06061458|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33738838|NCT05245968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738839|NCT00575588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738840|NCT02061462|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841755|NCT04447508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33841756|NCT00233480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841757|NCT00056277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738841|NCT04555746|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33738842|NCT04371276|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33841758|NCT00107939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841759|NCT04920942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a multicenter, open-label, randomized controlled clinical trial involving COVID-19 designated hospitals in Malaysia. Patients are randomized at ratio of 1:1 to groups receiving ivermectin for 5 days plus standard-of-care versus standard-of-care only. Patients will be assigned to stratified randomized treatments based on a central, computer-generated randomization scheme coordinated by an independent third party. Based on national guidelines, all high risk COVID-19 patients will be admitted to hospitals, and allow discharge once criteria met|f|f|t|f
33738843|NCT02555410|||COHORT||PROSPECTIVE|||||||
33738844|NCT04606238|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33841760|NCT04954092|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33841761|NCT03480932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841762|NCT04980027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841763|NCT06049589|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33841764|NCT05171790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738845|NCT01312961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841765|NCT05996419|NA|SINGLE_GROUP||OTHER||NONE||open trial||||
33738846|NCT00583492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738847|NCT02385955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841766|NCT03065257|||COHORT||PROSPECTIVE|||||||
33841767|NCT01502683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841768|NCT03915847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841769|NCT04379505|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33841770|NCT00301938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841771|NCT02642562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841772|NCT03602300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A Phase 1, Open-Label, Four-Period, Two-Sequence, Two-Treatment, Single Dose, Randomized, Crossover Bioequivalence Study||||
33841773|NCT05903157|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33841774|NCT03841318|NA|SINGLE_GROUP||OTHER||NONE||||||
33738848|NCT05706259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738849|NCT05831852|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33841775|NCT01310608|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33841776|NCT01155089|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841777|NCT03490838|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841778|NCT04218786|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33738850|NCT03000465|||CASE_ONLY||PROSPECTIVE|||||||
33738851|NCT01511887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738852|NCT01866072|||CASE_CONTROL||PROSPECTIVE|||||||
33738853|NCT03735420|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Randomization will occur in up to 8 blocks of 4 based on biological sex. Initial randomization series will be generated using readily available random sequence generators designed to do so. A series of sequential envelopes will be generated, each containing the allocation for one participant. Envelopes will be opaque and signed across the seal. The randomization code will be kept in a sealed envelope with a signature across the label and dated the day of creation. Study product and comparator (placebo) will be compounded and placed in identical opaque capsules outside the institution."|Participants will be randomized to receive either encapsulated xanthohumol in a rice protein vehicle, or an identical capsule containing vehicle alone.|t|f|t|f
33738854|NCT03104504|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|This was an implementation study that implemented various suicide related best practices into routine care. Data for patients who presented for care were included in the respective phase of the study based on the location and date of presentation. They were not aware they were in a study.|Stepped Wedge Design|t|f|f|f
33738855|NCT03221413|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33738856|NCT00434720|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33738857|NCT01858194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738858|NCT02896231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738859|NCT00234884|||COHORT||PROSPECTIVE|||||||
33738860|NCT01475526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738861|NCT01032694|||CASE_CONTROL||PROSPECTIVE|||||||
33738862|NCT01192594|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33738863|NCT00902616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738864|NCT00414934|||CASE_CONTROL||PROSPECTIVE|||||||
33738865|NCT01384539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738866|NCT00702897|||CASE_ONLY||RETROSPECTIVE|||||||
33738867|NCT05988216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738868|NCT04898010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738869|NCT06664593|||COHORT||PROSPECTIVE|||||||
33738870|NCT00693953|||CASE_CONTROL|||||||||
33738871|NCT03036514|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Single center case-control study design||||
33738872|NCT06533839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Multicentric randomised controlled trial|t|f|f|f
33738873|NCT03105843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33738874|NCT05336500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738875|NCT05173467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738876|NCT04260581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738877|NCT06663774|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738878|NCT00165438|||CASE_ONLY||PROSPECTIVE|||||||
33738879|NCT06573892|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The patient sample will be divided into three main groups based on clinical phenotypes determined by echocardiographic examination:~HF with preserved ejection fraction (EF) (EF \> 50%) HF with mildly reduced EF (EF 49-40%) HF with reduced EF (EF \< 40%)"||||
33841779|NCT04618562|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33841780|NCT03436511|||COHORT||RETROSPECTIVE|||||||
33841781|NCT04854824|||COHORT||RETROSPECTIVE|||||||
33841782|NCT01764893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841783|NCT00538148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841784|NCT05587738|||COHORT||CROSS_SECTIONAL|||||||
33841785|NCT00177320|||COHORT||CROSS_SECTIONAL|||||||
33738880|NCT01455883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738881|NCT06422988|||COHORT||RETROSPECTIVE|||||||
33738882|NCT00335244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738883|NCT02443298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33738884|NCT04262258|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738885|NCT01842009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738886|NCT01198262|||||RETROSPECTIVE|||||||
33738887|NCT06161363|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33738888|NCT02774109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738889|NCT05063097|||COHORT||PROSPECTIVE|||||||
33738890|NCT02879461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33738891|NCT03678181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738892|NCT05544877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Based on the behavioral intervention, the administrator of the intervention who is intrinsically also the outcome assessor of the primary outcome cannot be masked. Participants are masked as they are not aware about their treatment condition. Self-rated questionnaire-based outcome measures are not subject to bias as participants are masked.|Participants are randomly assigned in blocks of 20 and stratified for psychological disorder (with/without self-reported lifetime or current diagnosis of a psychological disorder) to one of two creativity technique conditions (Brain2Business vs Solo Brainstorming).|t|f|f|f
33738893|NCT01959581|NA|SINGLE_GROUP||TREATMENT||NONE|Coders are blind to which study phase participants are in|||||
33738894|NCT00685815|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33738895|NCT01736852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738896|NCT01336127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738897|NCT02732847|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33738898|NCT03028376|||COHORT||PROSPECTIVE|||||||
33738899|NCT04352933|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
33738900|NCT00023673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738901|NCT00098215|RANDOMIZED|PARALLEL||ECT||NONE||||||
33738902|NCT06213597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738903|NCT03327480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled prospective trial||||
33738904|NCT03732248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33738905|NCT02760394|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738906|NCT01448759|NA|SINGLE_GROUP||||NONE||||||
33738907|NCT00130884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33738908|NCT00807781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738909|NCT02770391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738910|NCT06211582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738911|NCT01151553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738912|NCT03832192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33738913|NCT06573476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33738914|NCT05663489|||COHORT||PROSPECTIVE|||||||
33738915|NCT05427110|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738916|NCT03985319|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738917|NCT05508334|NA|SEQUENTIAL||TREATMENT||NONE||||||
33738918|NCT03705754|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Tattoo arm vs. control arm||||
33738919|NCT05169294|RANDOMIZED|PARALLEL||OTHER||NONE||"Children to be included in the study will be divided into intervention (n: 30) and control (n: 30) groups by randomization. Block randomization will be done using randomizer.org. Children in both groups will be given an occupational therapy home program for intervention goals.~Children in the intervention group will be given telerehabilitation and fine motor skills training for a total of 8 weeks, 45 minutes a day, 3 days a week."||||
33738920|NCT01544244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738921|NCT05987891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738922|NCT01274637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738923|NCT04590391|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33738924|NCT04442516|||COHORT||PROSPECTIVE|||||||
33738925|NCT03351894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738926|NCT06383364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33738927|NCT03991195|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33738928|NCT05067075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Blinded continuous glucose monitor will be compared with routine blood glucose monitoring||||
33738929|NCT00857194|||CASE_CONTROL||PROSPECTIVE|||||||
33738930|NCT04273464|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective comparative study of two parallell cohorts (BRAVA and DIEP reconstruction methods).||||
33738931|NCT05801978|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33738932|NCT00927017|RANDOMIZED|PARALLEL||||NONE||||||
33738933|NCT05943301|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The investigator will not know which participant is in the learning phase or in the waiting list.|Each participant will be tested by the experimenter on T0. One month later, the experimenter will assess all participants (T1). After that, a person external from the study will randomize participants to the experimental group or the controle group. The experimental group will proceed to an 8 week (1 session of 2 hours a week) training programme of self-hypnosis/self-care with a therapist specialized in hypnosis, while the group control will be on waiting list. After this learning phase, all participant will be assessed once again (T2). Then, the group control will enter the learning phase. After the completion of this learning phase/waiting list, all participants will proceed to a last evaluation (T3) to assess the self-hypnosis/self-care effect over time.|f|f|t|f
33738934|NCT05989399|||COHORT||RETROSPECTIVE|||||||
33738935|NCT01180075|||||PROSPECTIVE|||||||
33738936|NCT03411226|||CASE_ONLY||RETROSPECTIVE|||||||
33738937|NCT06215638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738938|NCT01693224|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33738939|NCT02588040|||OTHER||PROSPECTIVE|||||||
33738940|NCT00000571|RANDOMIZED|||TREATMENT||||||||
33738941|NCT02610140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738942|NCT02479425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738943|NCT06493370|NA|SINGLE_GROUP||TREATMENT||NONE||This phase 2 study is not randomized or blinded. All eligible participants will be enrolled to avoid bias and be evaluated for adverse events. Due to the small sample size, patients who do not complete neo-adjuvant therapy will be evaluated for toxicity but maybe replaced for efficacy analysis.||||
33738944|NCT05058274|||CASE_ONLY||PROSPECTIVE|||||||
33738945|NCT03752281|||COHORT||PROSPECTIVE|||||||
33738946|NCT01306552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33738947|NCT02663128|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33738948|NCT01954667|||CASE_CONTROL||PROSPECTIVE|||||||
33738949|NCT06527287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738950|NCT00151645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738951|NCT06105489|RANDOMIZED|PARALLEL||TREATMENT||NONE|Health care givers, investigators and outcome assessors cannot be masked to treatment allocation due to the characteristics of the intervention. The statistician will be masked to the treatment allocation during data analysis.|Participants will be assigned to one of two study arms, a test arm and a control arm, for the entire duration of the study.||||
33738952|NCT06367582|||COHORT||OTHER|||||||
33738953|NCT02052466|||CASE_ONLY||RETROSPECTIVE|||||||
33738954|NCT03698955|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738955|NCT02778529|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33738956|NCT04670679|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738957|NCT05166005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738958|NCT04306224|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation will consist of two distinct sub-parts (1A and 1B).||||
33738959|NCT01166984|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33738960|NCT04401007|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Two different local anesthetic volumes will be investigated: 20 mL (300 mg lidocaine) at one study visit and 30 mL (450 mg lidocaine) at the other study visit. Volunteers will be randomized to one of two intervention groups: (1) Group 20/30: A unilateral ESP block with 20 mL of local anesthetic at the first visit, and 30 mL of local anesthetic at the second visit; or (2) Group 30/20: a unilateral ESP block with 30 mL of 1.5% lidocaine with 1/200,000 epinephrine at the first visit, and 20 mL of the same local anesthetic solution at the second visit. Randomization of subjects to either Group 20/30 or Group 30/20 will be done using computer software and only the study investigator performing the ESP block will be aware of the study allocation. Volunteer subjects and the study investigators responsible for serial neurologic and other outcome assessments after injection will be blinded to the volume of local anesthetic injected.|"There will be 2 study subgroups based on the vertebral level at which the ESP block is administered: (1) Volunteer subjects in subgroup TP4 will receive the ESP block injection at the T4 transverse process (TP4) level. Injection at the TP4 level will allow us to evaluate the anesthetic effect on the chest wall. (2) Volunteers in subgroup TP8 will receive the ESP block injection at the T8 transverse process (TP8) level. Injection at the TP8 level will allow us to evaluate the anesthetic effect on the abdominal wall.~The first 12 volunteer subjects recruited will receive ESP blocks at the TP4 level and the subsequent 12 subjects will receive ESP blocks at the TP8 level."|t|f|t|f
33738961|NCT00355875|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33738962|NCT04856319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and the surgeon will be masked if antibiotics or placebo were used.||t|f|t|f
33738963|NCT06612086|NA|SINGLE_GROUP||TREATMENT||NONE||Effect of SGLT2 (Dapagliflozin)on prognosis of patient with pulmonary Hypertension and Effect on RV function By speckle tract echocardiography at Assiut University Hospital.||||
33738964|NCT03444168|||COHORT||PROSPECTIVE|||||||
33738965|NCT05090449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738966|NCT01287572|||CASE_ONLY||PROSPECTIVE|||||||
33738967|NCT05861544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33738968|NCT03898245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738969|NCT01098045|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33738970|NCT06602921|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double-blinded using supplement placebos.|24 participants will complete 4 experimental conditions in a randomized order.|t|f|t|f
33738971|NCT02259530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738972|NCT06573645|RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-repetitive stratified block randomization method is used, with the treatment assignment codes for participants (randomization table) being generated by a blinded statistician in a 1:1 ratio. The randomization table is then uploaded to the central randomization system for configuration. Once a participant's eligibility is confirmed, the researcher logs into the central randomization system, enters the participant's information, and obtains the participant's random number and drug code. The researcher administers the corresponding study treatment based on the drug code. Participants are randomized in a 1:1 ratio to either the experimental group (rituximab 500 mg/m²) or the control group (rituximab 375 mg/m²).||||
33738973|NCT06168643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33738974|NCT06085417|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The required asepsis in the area where the block would be applied was provided with 10% poviodine iodine and covered with a sterile drape. The USG probe was placed in the sagittal plane 1 cm below the intersection point between the coracoid process and the clavicle, and after visualizing the lateral, posterior and medial cords around the axillary artery, a peripheral nerve block needle was directed towards the 8 o'clock position relative to the axillary artery, in the same plane as the USG probe. When the expected distal motor response was obtained, the current of the peripheral nerve stimulator was reduced to 0.3 mA to avoid intraneural injection. If the motor response disappeared, local anesthetic was injected slowly. Sensory and motor block onset times, saturation, systolic blood pressure, diastolic blood pressure, mean arterial pressure and heart rate peak values at the 0th, 15th, 30th and 60th minutes after the block were recorded.|f|f|t|f
33738975|NCT06457152|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33738976|NCT03833544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33738977|NCT06416488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33738978|NCT02369133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33738979|NCT00477711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33738980|NCT00189085|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33738981|NCT05044741|||CASE_CONTROL||RETROSPECTIVE|||||||
33738982|NCT05457270|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33738983|NCT01353339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33738984|NCT02609126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33738985|NCT04261816|||COHORT||RETROSPECTIVE|||||||
33738986|NCT00664144|NON_RANDOMIZED|||TREATMENT||NONE||||||
33738987|NCT03195413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33738988|NCT01430130|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33738989|NCT06477172|||COHORT||PROSPECTIVE|||||||
33738990|NCT04011475|||COHORT||RETROSPECTIVE|||||||
33738991|NCT04239508|||COHORT||OTHER|||||||
33738992|NCT06508554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33738993|NCT02098863|||COHORT||PROSPECTIVE|||||||
33738994|NCT01141296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33738995|NCT04159675|||CASE_CONTROL||PROSPECTIVE|||||||
33738996|NCT02320019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33738997|NCT06014658|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33738998|NCT04592705|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33738999|NCT00506935|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33739000|NCT05460624|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessments will be conducted before randomization at baseline and by individuals blinded to the treatment assignments at follow-up. Data will be analyzed prior to unblinding.||f|f|f|t
33739001|NCT05718622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33739002|NCT00461903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739003|NCT05973487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739004|NCT01002599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739005|NCT04177524|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants are aware of the differences between the app modes, and that the order in which they test out the different app modes is randomly assigned to them. The study team is not blinded to which study arm participants are assigned to.|This study will utilize a crossover design with randomized assignment to three study arms to allow for comparison of app modes within drivers as each driver will act as their own control. The three app modes are: Background Mode (app runs in background and participants do not lock/unlock the phone), Manual Mode (participants manually unlock the phone), and Auto-Detect Mode (participants are automatically locked out of their phone if their phone camera detects them to be a driver or are automatically allowed to use their phone if the camera detects them to be a passenger).||||
33739006|NCT00690547|||||PROSPECTIVE|||||||
33739007|NCT00030797|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33739008|NCT01902043|||COHORT||PROSPECTIVE|||||||
33739009|NCT03513029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739010|NCT00023036|||FAMILY_BASED||PROSPECTIVE|||||||
33739011|NCT04832555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739012|NCT03310541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be an open label, single institution, non-randomized, pilot study.||||
33739013|NCT00345579|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33739014|NCT06325995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739015|NCT04988165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739016|NCT00944775|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||f|t|t|t
33739017|NCT04255095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739018|NCT06290154|||COHORT||PROSPECTIVE|||||||
33739019|NCT06387784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, placebo-controlled, single-blind, parallel-group study assessing acute rich-nitrate juice on pregnant women diagnosed with early and late-onset pre-eclampsia. Participants will be divided into four distinct groups: two groups for each onset category. Within each group, participants will be further divided into a control group and a treated group. The assignment of participants to these groups will be randomized using an online program.|t|f|f|f
33739020|NCT01266772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739021|NCT03189914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739022|NCT02783404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33739023|NCT05658926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739024|NCT00472914|||||PROSPECTIVE|||||||
33739025|NCT06560268|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33739026|NCT06075628|||COHORT||RETROSPECTIVE|||||||
33739027|NCT03178734|RANDOMIZED|PARALLEL||OTHER||NONE||This study aim is to compare UTI rates and patient satisfaction associated with indwelling Foley catheter vs a valved catheter in patients who are being discharged home with a catheter after urogynecologic proecures via a Randomized Clinical Trial.||||
33739028|NCT00638547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739029|NCT00690755|||COHORT||CROSS_SECTIONAL|||||||
33739030|NCT03611803|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33739031|NCT01459406|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33739032|NCT05158829|||COHORT||PROSPECTIVE|||||||
33739033|NCT04231344|||COHORT||PROSPECTIVE|||||||
33739034|NCT01099995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739035|NCT05569785|RANDOMIZED|PARALLEL||OTHER||SINGLE||A single-centre feasibility research programme|t|f|f|f
33739036|NCT04884126|||COHORT||CROSS_SECTIONAL|||||||
33739037|NCT02241304|||COHORT||PROSPECTIVE|||||||
33739038|NCT06071039|RANDOMIZED|PARALLEL||OTHER||NONE||There were two groups in the trial. The first group was the group in which the patients used the mattress developed by the researcher. This was the intervention group. In the second group, the patients used the standard operating theatre mattress. This was the control group||||
33739039|NCT04072965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group (A) Cross Education group(B) Traditional training group (C) control|t|f|f|f
33739040|NCT02350959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739041|NCT01624545|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33739042|NCT05437146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33739043|NCT00298038|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739044|NCT01575561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739045|NCT03502603|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739046|NCT02284997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33739047|NCT06395168|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739048|NCT01700816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33739049|NCT00720616|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33739050|NCT01112085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739051|NCT01782196|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33739052|NCT05071261|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33739053|NCT04840745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739054|NCT01820130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739055|NCT02841644|||COHORT||PROSPECTIVE|||||||
33739056|NCT01046110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739057|NCT02705131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739058|NCT00927446|||COHORT||CROSS_SECTIONAL|||||||
33739059|NCT00176098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33739060|NCT02804165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739061|NCT02673697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739062|NCT05269524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739063|NCT01955876|||CASE_ONLY||PROSPECTIVE|||||||
33739064|NCT06572878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739065|NCT00995449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739066|NCT00287911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739067|NCT03951129|||COHORT||PROSPECTIVE|||||||
33739068|NCT06572202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33739069|NCT03569956|RANDOMIZED|PARALLEL||OTHER||SINGLE||Subjects will be divided into two groups: the Razor group of 20 subjects, and the Regimen group of 20 subjects. In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.|f|f|t|f
33739070|NCT02112786|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33739071|NCT00088218|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739072|NCT00759967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739073|NCT04318210|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33739074|NCT01970332|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33739075|NCT04462796|NA|SINGLE_GROUP||OTHER||NONE||Pilot study||||
33739076|NCT05325086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33739077|NCT01390558|||COHORT||CROSS_SECTIONAL|||||||
33739078|NCT00637546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739079|NCT01193556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739080|NCT05702957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Two treatment groups were made by random computer generated number i.e. Group A and Group B. Two Concealed boxes labelling A and B containing study drugs were made by pharmacist.Then participants were given drug from concealed boxes according to computer generated number.|Total 230 patients were randomized in study, divided in two groups by computer generated numbers, out of which 220 patients were analyzed. .Group-A patients were given clomiphene citrate 50-150mg per day for 5 days starting from 2nd day of menses and group B patients were given letrozole 2.5-7.5mg per day for 5 days.|t|f|t|f
33841786|NCT05258422|NA|SINGLE_GROUP||TREATMENT||NONE||This study will assess the non-inferiority of treatment with single fraction of 20 Gy delivered with stereotactic body radiotherapy in comparison with historical controls treated with a single fraction of 25 Gy. Based on historical controls, the investigators anticipate an incidence rate of approximately five VT events per person-year in participants treated with 25 Gy historical comparator. Based on a Poisson distribution and using a non-inferiority margin of 8.5 events per-year (corresponding to an incident rate ratio of 1.7), recruitment of nine participants will provide 80% power when using a one-sided type I error set at 0.05.||||
33841787|NCT02022787|||CASE_CONTROL||PROSPECTIVE|||||||
33841788|NCT01515059|||COHORT||PROSPECTIVE|||||||
33739081|NCT02360540|||COHORT||PROSPECTIVE|||||||
33739082|NCT06069401|||COHORT||PROSPECTIVE|||||||
33739083|NCT03208972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739084|NCT05580575|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33739085|NCT03604718|||COHORT||PROSPECTIVE|||||||
33764431|NCT02235363|NA|SINGLE_GROUP||TREATMENT||NONE||369 consecutive patients underwent the suture suspension technique, so called thread lift, using 3-0 V-Loc 180 device for facial rejuvenation with (n=305) or without additional facial procedures (n=64). The follow-up period ranged from 22 months to 43 months postoperatively, with a mean of 34.3 months.||||
33764432|NCT03941015|||COHORT||PROSPECTIVE|||||||
33764433|NCT00710372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764434|NCT01001949|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33764435|NCT06122220|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33764436|NCT04651400|||COHORT||RETROSPECTIVE|||||||
33841789|NCT02657044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841790|NCT00963612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841791|NCT03415373|NA|SINGLE_GROUP||OTHER||NONE||"Subjects will be first randomized to receive each of the injection (A, B, C, and D) in each of the 3 visits of the study, according to the block randomization scheme produced by inVentiv. The following sequences will be used: 1st (upper right location), 2nd (lower right location), 3rd (upper left location) and 4th lower left location) where:~A. Investigational device with 50 μL saline B. Control device with 50 μL saline C. Investigational device with 100 μL saline D. Control device with 100 μL saline"||||
33841792|NCT04378673|||CASE_CONTROL||PROSPECTIVE|||||||
33739086|NCT04825223|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Stage 1 and Stage 2 (adults and adolescents) will be modified double-blind: the investigators and study staff who conduct the safety assessment and the participant will not know which vaccine is administered. Only the study staff who prepare and administer the vaccine and are not involved with the safety evaluation will know which vaccine is administered. The individual(s) responsible for the preparation / administration of the vaccines will not be authorized to collect any safety or serology data. Testing laboratories will be blinded. In order to maintain the blind in Stage 2 (adults and adolescents), a placebo injection will be used. After the 6-months safety assessment from the last dose of primary vaccination, Stage 2 will be unblinded for the administration of booster vaccinations. Stage 3 and Stage 4 (toddlers and infants) will be open-label.|"The study will be conducted in 4 stages, sequentially:~* Stage 1: adults and adolescents from the US, equally randomized to 8 vaccine groups~* Stage 2; adults and adolescents from the EU and the US, equally randomized to 11 vaccine groups~* Stage 3: toddlers from the EU, equally randomized to 6 vaccine groups~* Stage 4: infants from the EU, equally randomized to 6 vaccine groups"|t|t|t|t
33739087|NCT01415661|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33739088|NCT05194176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739089|NCT06123767|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|"The project is a double-blind study. Neither the researchers nor the participants will know what invasive procedures will be performed on a given patient. Patients, investigators, and all persons involved in performing the procedure or analysis of the data, as well as others with an interest in the study results, will remain blinded to the treatment assigned to individual patients from the beginning of the study until the closure of the database.~Staff involved in the CAS procedure (with or without blood pressure measurement) will not participate in further patient care and will not provide information to other researchers and people conducting therapy and diagnostics."||t|t|t|t
33841793|NCT00845962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841794|NCT02546921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841795|NCT03478904|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33841796|NCT04417842|||OTHER||PROSPECTIVE|||||||
33841797|NCT06458413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841798|NCT02663531|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33841799|NCT02277054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841800|NCT04361851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739090|NCT04964934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739091|NCT05331742|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33739092|NCT04401228|||COHORT||RETROSPECTIVE|||||||
33841801|NCT06102187|||COHORT||PROSPECTIVE|||||||
33841802|NCT01504477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841803|NCT01390662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841804|NCT02287298|||CASE_CONTROL||RETROSPECTIVE|||||||
33739093|NCT05762666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data obtained at the clinical follow-up will be gathered by care provider nurses at the ICU who are blind to the study protocol. All evaluations at the surgical wards especially for delirium and cognitive dysfunction will be evaluated by the same independent anesthetist who is blind to the study groups.|Group A will be followed with standard monitorization only along with pain scales and receive rescue analgesia according to them. However, Group B will acquire NOL monitorization throughout the ICU stay and have the same rescue analgesia under NOL guidance with concurrent pain scales.|f|t|f|t
33841805|NCT04845204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841806|NCT04037176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The syringes are filled and masked with opaque material of unblinded personnel who do not have patient contact.|"Eligible participants will be randomized to treatment with Omalizumab (regular dose of asthma dosing according to total IgE and weight) or placebo (3:1). Primary endpoint after 3 months treatment.~Responders (in the active as well as the placebo group) will continue treatment with the same dose of Omalizumab/placebo for a further 3 months. All non-responders will receive maximum dose of Omalizumab (according to weight, but not total IgE) for another 3 months."|t|t|t|f
33841807|NCT03574662|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841808|NCT02897505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739094|NCT06024746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739095|NCT02634658|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739096|NCT03254563|||OTHER||CROSS_SECTIONAL|||||||
33739097|NCT03063450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739098|NCT01067079|||COHORT||RETROSPECTIVE|||||||
33841809|NCT01404364|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33841810|NCT03973853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841811|NCT00981136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841812|NCT02206477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841813|NCT02831023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841814|NCT04223986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective enrollment on inclusion criteria||||
33841815|NCT01215487|||CASE_ONLY||PROSPECTIVE|||||||
33841816|NCT04281602|||CASE_CONTROL||PROSPECTIVE|||||||
33739099|NCT05626192|||COHORT||PROSPECTIVE|||||||
33739100|NCT04527263|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739101|NCT04878705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739102|NCT00936026||||||NONE||||||
33841817|NCT02870829|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841818|NCT00894205|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33841819|NCT02310100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154323|NCT05974319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Before blood sampling, the participants were assigned to the experiment 1-dry heat application, experiment 2-dry cold application and control groups.||||
33739103|NCT05896592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The project is a double-blind study. Blinding will only apply to the study arms with group 1 and 2. Neither the researcher (doctor) nor the participant (patient) will know what invasive procedures will be performed on a given patient. Patients, investigators, and everyone involved in conducting or analyzing the study, along with other persons interested in the results of the study, will remain blinded to the treatment assigned to individual patients (CNA with continuation of PM therapy vs. continuation of PM therapy without CNA) from the beginning of the study until the database is closed. The operator performing EPS, ECVS, CNA and ILR implantation will not be blinded. Operator will not be involved in the subsequent management of the patient in the study.||t|t|t|t
33739104|NCT00694460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739105|NCT00185133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33739106|NCT04277234|||CASE_ONLY||CROSS_SECTIONAL|||||||
33739107|NCT03938701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739108|NCT04121962|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33739109|NCT05720832|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33739110|NCT04279925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a radiologist consultant as a blinded independent evaluator will assess the bone density score in each subject.||f|f|f|t
33739111|NCT05739500|||CASE_CROSSOVER||PROSPECTIVE|||||||
33739112|NCT00358735|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33739113|NCT01390246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739114|NCT03403634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739115|NCT01884350|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739116|NCT05360095|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be recruited and randomized into three different groups, all running in parallel to each other.||||
33739117|NCT06298643|||COHORT||RETROSPECTIVE|||||||
33739118|NCT03624361|NA|SINGLE_GROUP||TREATMENT||NONE||MINIject glaucoma implant CS600 with Dual Operator Delivery Tool||||
33739119|NCT04183400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739120|NCT00844441||||HEALTH_SERVICES_RESEARCH||||||||
33739121|NCT04526808|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739122|NCT03555669|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will employ a multiple baseline evaluation design in two clinics to evaluate the impact of depression treatment on HIV outcomes. Patients who screen positive for depression using PHQ-9 during the pre period will comprise the comparison group, while patients who screen positive during the post period will comprise the active group."||||
33739123|NCT00982319|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33945137|NCT04083287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is erector spinae plane block group. The second one is interscalen brachial plexus block.|t|f|f|t
33739124|NCT02934139|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33739125|NCT05130567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739126|NCT04913493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739127|NCT05277467|||OTHER||CROSS_SECTIONAL|||||||
33739128|NCT02251535|NON_RANDOMIZED|PARALLEL||||NONE||||||
33739129|NCT05966831|RANDOMIZED|FACTORIAL||OTHER||SINGLE||"Group 1 will receive two interventions: Metacognitive Self-Control Training plus Virtual Reality Job Interview Training.~Group 2 will receive one intervention: Virtual Reality Job Interview Training"|f|f|f|t
33739130|NCT05279261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739131|NCT01747005|||CASE_CONTROL||PROSPECTIVE|||||||
33739132|NCT06328959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33739133|NCT01260610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739134|NCT01284400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739135|NCT03789526|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.~* Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance."||||
33739136|NCT00499369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739137|NCT05212259|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Envelope blinding chits|Randomized, Double-Blind, Placebo-controlled, Parallel Design|t|t|t|f
33739138|NCT05083767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33739139|NCT03728582|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple|Crossover assignment|t|f|t|t
33945138|NCT03077074||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33945139|NCT01041742|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33739140|NCT01992458|||||RETROSPECTIVE|||||||
33739141|NCT06017284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739142|NCT01326780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739143|NCT03653429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739144|NCT02044081|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33739145|NCT06440668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician who analyse the data is unaware of the group to which each patient belonged.|Randomised controlled clinical trial|f|f|t|f
33739146|NCT00367263|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739147|NCT03156231|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739148|NCT05577052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739149|NCT06463535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739150|NCT06338475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33739151|NCT03192891|||CASE_ONLY||RETROSPECTIVE|||||||
33739152|NCT05813054|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33739153|NCT06441513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Random numbers were sequentially sealed in a continuously numbered and opaque envelope. The envelopes were opened sequentially to allocate participants to the case tracking management or control group by the other researcher. Because of the nature of continuing care intervention, it was not possible to blind the participants about the intervention.|The process of randomization and concealment allocation was conducted by a research team who were not involved in the study. Spss26.0 software was used to program and generate a random number table, which was randomly divided into two groups.|f|f|f|t
33739154|NCT00765245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739155|NCT03265405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739156|NCT05873387|||COHORT||PROSPECTIVE|||||||
33739157|NCT01643473|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33739158|NCT06521502|||COHORT||PROSPECTIVE|||||||
33739159|NCT01813526|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33739160|NCT02186964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739161|NCT05117827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739162|NCT06251934|||COHORT||RETROSPECTIVE|||||||
33739163|NCT05352139|||COHORT||PROSPECTIVE|||||||
33739164|NCT00510029|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33739165|NCT03526523|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The staff member who will be assessing for the presence of major depressive disorder in the follow-up period (in cases where a participant's CES-D score is 16 or greater) will be unaware of the participant's treatment assignment.|A stratified randomization method will be used to balance the number of baseline stressful life events in each treatment group (\<3 vs. 3+ in the last 6 months). Randomization will be performed once baseline stressful life events are determined.|f|f|f|t
33739166|NCT00377676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739167|NCT02595684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739168|NCT01272167|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33739169|NCT03454594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739170|NCT00184275|||CASE_ONLY||PROSPECTIVE|||||||
33739171|NCT06431620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739172|NCT00358267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739173|NCT03704545|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739174|NCT02838420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739175|NCT01849341|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33739176|NCT02070159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739177|NCT05077254|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomized to:~* A study dose of mRNA COVID-19 vaccine only, or~* Immunosuppression (IS) reduction plus a study dose of mRNA COVID-19 vaccine. IS reduction will be based on the participant's IS regimen upon study entry, in accordance with the study's protocol."||||
33739178|NCT01813019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739179|NCT03598998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739180|NCT05141682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739181|NCT05841017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739182|NCT00039767||||TREATMENT||||||||
33739183|NCT04013451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739184|NCT02376413|||COHORT||PROSPECTIVE|||||||
33739185|NCT06535009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739186|NCT01022034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739187|NCT02671123|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739188|NCT00029835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739189|NCT04273100|NA|SINGLE_GROUP||TREATMENT||NONE||This study focuses on the in-operable, middle and late stage (BCLC-B and BCLC-C) HCC patients. The participants will receive the combined treatment of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib).||||
33739190|NCT06572540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739191|NCT03120650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33739192|NCT04151862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739193|NCT03147105|RANDOMIZED|PARALLEL||TREATMENT||NONE||waitlist control||||
33739194|NCT05212636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739195|NCT03143244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33739196|NCT03753958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the evaluation of clinical parameters, a single trained, calibrated examiner will examine 6 sites of each implant with a 15mm North Carolina millimeter probe for measurements of plaque index, probing bleeding, probing depth, gingival recession and loss of clinical insertion. The evaluation will be performed at the beginning of treatment, 30 and 60 days after the first application of aPDT. The evaluator will not know to which group the patient belongs.||f|f|f|t
33739197|NCT04088786|NA|SINGLE_GROUP||TREATMENT||NONE|All eligible patients will be treated with the study drug.|This is a 3+3 dose-finding cohort design.||||
33739198|NCT03246009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739199|NCT05720624|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33739200|NCT02129179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739201|NCT01936961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739202|NCT05174975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to two groups in parallel for the duration of the study||||
33739203|NCT05854290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the data collectors in this study will be blind to the dyad's allocation.|Caregiver and patient dyads will be randomly assigned to receive either CRT plus CBT, or usual care.|f|f|f|t
33739204|NCT04153578|||CASE_ONLY||RETROSPECTIVE|||||||
33739205|NCT01145079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739206|NCT05825287|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The model of research is quantitative. Participants are experimental because they are randomly selected to the interference and control group. It is a randomized controlled clinical study, a group of interventions and controls, to determine the impact of the first-time education in patients who have been diagnosed with cancer and have been treated for chemotherapy to manage symptoms and determine the quality of life of patients.||||
33739207|NCT02144675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739208|NCT02199691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739209|NCT03827798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945140|NCT04816942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739210|NCT04987918|||CASE_ONLY||PROSPECTIVE|||||||
33739211|NCT01818336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739212|NCT05239026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739213|NCT01160107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739214|NCT03176108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739215|NCT02604589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33739216|NCT06346561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739217|NCT01070927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945141|NCT00337935|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33739218|NCT02012387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739219|NCT05343312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739220|NCT04203719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739221|NCT02266381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739222|NCT05676242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739223|NCT05580900|NON_RANDOMIZED|PARALLEL||OTHER||NONE||In our quasi-experimental design, we allow participants to select whether they want to participate in a live or livestream program modality. The fatherhood curriculum is the same for both, only the mode of delivery is different.||||
33739224|NCT01336465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739225|NCT03108859|||COHORT||PROSPECTIVE|||||||
33739226|NCT01511458|||||PROSPECTIVE|||||||
34050291|NCT05094674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The participant's breath sample is taken by blowing preferably three times into a disposable TeraTube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis of its bio-chemical spectral signature. This will take place once during the study.||||
33739227|NCT01125423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739228|NCT02497326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739229|NCT00096941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739230|NCT04394351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050292|NCT06411730|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34050293|NCT03884569|||COHORT||OTHER|||||||
34050294|NCT03561376|NA|SINGLE_GROUP||TREATMENT||NONE||Split scar study (petrolatum vs. zinc oxide)||||
34050295|NCT05674123|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33739231|NCT01802411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739232|NCT04521010|||OTHER||RETROSPECTIVE|||||||
33739233|NCT04279444|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33739234|NCT01920295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739235|NCT06444113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739236|NCT00962429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739237|NCT05479526|||CASE_CONTROL||PROSPECTIVE|||||||
33739238|NCT01202838|||CASE_ONLY||PROSPECTIVE|||||||
33739239|NCT05781035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739240|NCT04133402|||COHORT||RETROSPECTIVE|||||||
33739241|NCT02691858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739242|NCT02822794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739243|NCT00963664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739244|NCT00726115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739245|NCT05481112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33739246|NCT06572618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739247|NCT00883389|||COHORT||PROSPECTIVE|||||||
33739248|NCT00400413|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33739249|NCT00786916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33739250|NCT01787864|||COHORT||OTHER|||||||
33739251|NCT01543269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739252|NCT06105307|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two groups: RN-SLEEP group (intervention) or Health Habit group (education control).||||
34050296|NCT05476627|||COHORT||PROSPECTIVE|||||||
34050297|NCT01623401|NA|SINGLE_GROUP||OTHER||NONE||||||
34050298|NCT03718481|||OTHER||PROSPECTIVE|||||||
34050299|NCT03520153|||COHORT||PROSPECTIVE|||||||
34050300|NCT05972486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050301|NCT05654870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050302|NCT01610102|||COHORT||RETROSPECTIVE|||||||
34050303|NCT05780177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical evaluator will be kept blind to treatment condition throughout the study period.|The investigators will conduct a randomized, controlled trial of a video- and telephone-based, brief insomnia treatment in Veterans who meet criteria for Insomnia Disorder and Posttraumatic Stress Disorder (PTSD) to accomplish the goal of improving psychosocial functioning.|f|f|f|t
34050304|NCT06431607|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is an observer blind study.||t|t|t|t
33739253|NCT02977949|||CASE_ONLY||PROSPECTIVE|||||||
33739254|NCT05297994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739255|NCT03258476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The proposed study has two parts: (1) a randomized, double-blind controlled clinical trial of GXR vs. placebo for up to 7 weeks followed by, (2) 10 weeks of either GXR and Mindfulness psychotherapy (as a group or individual) or placebo and Mindfulness psychotherapy (as a group or individual).|t|t|f|f
33945142|NCT01454895|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33739256|NCT02262429|||COHORT||PROSPECTIVE|||||||
33739257|NCT01835782|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33945143|NCT02514109|||CASE_CONTROL||PROSPECTIVE|||||||
33739258|NCT04536896|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Non-randomized quasi-experimental trial||||
33739259|NCT06573203|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739260|NCT02972099|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33739261|NCT01253616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739262|NCT06261697|||CASE_CROSSOVER||PROSPECTIVE|||||||
33945144|NCT04076280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739263|NCT02550613|||CASE_ONLY||PROSPECTIVE|||||||
33739264|NCT00532831|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33739265|NCT03591692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analysist do not know the group assignment.||f|f|f|t
33739266|NCT00268125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739267|NCT01743937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739268|NCT06261749|||COHORT||PROSPECTIVE|||||||
33945145|NCT00933543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739269|NCT06220396|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739270|NCT05363891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study|Arm 1- Natrunix 200mg with MTX(+Folate) Arm 2 - Natrunix 400mg with MTX(+Folate) Arm 3- Placebo with MTX(+Folate)|t|t|t|t
33739271|NCT04166305|||CASE_CONTROL||RETROSPECTIVE|||||||
33739272|NCT04691479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After confirming their participation in the study, the patient was randomly assigned to one group or another, receiving the treatment as established in the protocol according to group.||t|f|f|f
33739273|NCT01975389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739274|NCT05946018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739275|NCT05290259|||COHORT||PROSPECTIVE|||||||
33739276|NCT03565406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739277|NCT06338995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Randomized, double-blind, parallel group, placebo controlled|t|t|t|t
33739278|NCT03173196|||CASE_CONTROL||PROSPECTIVE|||||||
33739279|NCT03396744|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose finding study||||
33739280|NCT01958918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The reading center was masked for treatment assignment in order to ensure unbiased evaluation of the primary, secondary and exploratory objectives that were determined by SDOCT, autofluorescence imaging, and microperimetry and multifocal ERG (where available).~When communicating with the reading center study centers had to be vigilant not to unblind the reading center to the treatment.~Site staff performing the assessments of BCVA, contrast sensitivity (where possible), VFQ25 and IReST (reading speed) were also masked to the identity of the treatment.~The central laboratory used for analysis of all specimens collected for biomarker assessment were blinded to the identity of the treatment."||t|f|f|t
33739281|NCT02605590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739282|NCT05036187|RANDOMIZED|FACTORIAL||OTHER||NONE|There is no masking during the pilot phase where the goal is to improve the program's acceptability.|"After a pre-piloting phase (consisting of initial content piloting, interviews, and intervention refinement; anticipated n=12), participants (anticipated n=8) will receive the online weight loss treatment and will be randomized to receive 0-3 novel intervention components (targeting minority stress, negative body image, and social support) over the 3-month period. Participants will complete quantitative and qualitative assessments of intervention acceptability and appropriateness post-treatment.~Enrollment for both the pre-piloting phases (anticipated n=12) and open pilot trial phase (anticipated n=8) are reported here."||||
33739283|NCT02886533|||COHORT||PROSPECTIVE|||||||
33739284|NCT02779218|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33739285|NCT02823925|||COHORT||RETROSPECTIVE|||||||
33739286|NCT06331208|||COHORT||PROSPECTIVE|||||||
33739287|NCT03726359|NA|SINGLE_GROUP||OTHER||NONE||||||
33739288|NCT05206968|||CASE_ONLY||RETROSPECTIVE|||||||
33739289|NCT02978144|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739290|NCT05334108|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33739291|NCT02661906|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33739292|NCT02211989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33739293|NCT01709318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739294|NCT04508803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739295|NCT06515548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind Placebo|A Randomized controlled Clinical Trial.|t|f|f|t
33739296|NCT03030612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739297|NCT01142583|||COHORT||PROSPECTIVE|||||||
33739298|NCT03821428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33739299|NCT05187455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739300|NCT03470935|||COHORT||RETROSPECTIVE|||||||
33739301|NCT03770468|||OTHER||CROSS_SECTIONAL|||||||
33739302|NCT06572358|NA|SINGLE_GROUP||OTHER||NONE||Prospective, Open-label, Single-arm, Proof of science||||
33765062|NCT05272670|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized controlled trial will be used to examine the effectiveness of the digital foot self-management program. The outcomes included primary outcome of self-efficacy, and secondary outcomes of self-care behaviors, HbA1c and health promotion satisfaction. Participants in the intervention group will receive the digital foot self-management program in addition to routine care. The control group will receive routine care provided in diabetes clinic, including routine check-ups and foot care education.|t|f|f|f
33765063|NCT03892629|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33945146|NCT01403415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945147|NCT04997291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739303|NCT04480164|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"3 Sequences separated by 2 interim analyses evaluating safety and PK linearity. Sequence 1: 8 Patients randomized to placebo or NDMC 40mg/day (ratio 1:3) qd for 6 weeks. Sequence 2 will be initiated following the first interim analysis.~Sequence 2: 8 Patients randomized to placebo or NDMC 60mg/day (ratio 1:3) qd for 6 weeks. Sequence 3 will be initiated following the second interim analysis. Otherwise Sequence 2 will be extended to a total of 30 placebo and 32 patients.~Sequence 3: 60 Patients randomized to placebo or NDMC 60mg/day (ratio 28:32) bid for 6 weeks. Patients who do not tolerate 120mg/day will be authorized to step down to 60mg/day during the up titration period."|t|f|t|f
33739304|NCT05264805|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A:~Study group: Patient receiving intervention i.e 20ml of 0.25% buvivacaine infiltration at laparoscopic port site.~Group B:~Control group: no intervention"||||
33739305|NCT01700946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739306|NCT05718908|||COHORT||PROSPECTIVE|||||||
33739307|NCT03511482|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|The study will have a blinded team to perform final assesments|Open Feasibility|f|f|f|t
33739308|NCT01223079|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739309|NCT05947539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739310|NCT04334603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33841820|NCT04090177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Neither the investigators nor the biostatistician/outcomes assessor will know the intervention arm to which study participants have been assigned. A unique study ID will be assigned to each study participant and as well as a unique code to distinguish which intervention arm to which each participant is randomized.|"The treatment group receives the TEAM Wheels program over a 4-week period. Three virtual/teleconference (MS Teams) sessions will be arranged between the peer-trainer and participant, about 1 week apart. Peer trainers are experienced MWC users trained to deliver the TEAM Wheels program. After Session 1, participants engage in 4 weeks of eHealth home program training. They are asked to practice for 75-150 minutes per week, in 15-30 minute blocks, 1-2 times/day, 3-5 days/week. The control group receives no intervention over the 4-wk period (usual practice). Control group participants placed on the wait-list will receive the TEAM Wheels program following completion of the study. Any formal MWC training received during the wait-list period will be documented for potential post-hoc analysis as a confounding variable; research evidence and clinical experience confirm that in all 3 provinces formal training is not provided once MWC users are discharged from hospital."|f|f|t|t
33739311|NCT06464055|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739312|NCT03614026|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention condition and business-as-usual control condition||||
33739313|NCT05144191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739314|NCT04561362|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739315|NCT01163682|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33739316|NCT00969852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739317|NCT01124890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841821|NCT04531098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single blind, three-arm, two-stage, randomized study|t|f|f|f
33739318|NCT01431508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739319|NCT05063734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739320|NCT01581346|NA|SINGLE_GROUP||||NONE||||||
33945148|NCT00231959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841822|NCT03632122|||COHORT||RETROSPECTIVE|||||||
33841823|NCT01503762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841824|NCT05594134|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33841825|NCT03992391|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Phase 1: Treatment Development Phase 2: Pilot Group Phase 3: Open Trial||||
33841826|NCT01653977|RANDOMIZED|PARALLEL||||NONE||||||
33841827|NCT00770705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841828|NCT03438357|||CASE_ONLY||RETROSPECTIVE|||||||
33841829|NCT01118013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841830|NCT04276415|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841831|NCT00365170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945149|NCT00484666|||OTHER||OTHER|||||||
33945150|NCT01265927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945151|NCT05886374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050305|NCT05294692|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, quasi-experimental study - all Caterpillar Health app users will be subject to the intervention of utilizing financial incentives and adaptable step goals throughout the 12-week intervention||||
34050306|NCT00965640||||SCREENING||||||||
33841832|NCT03622190|||COHORT||PROSPECTIVE|||||||
33841833|NCT06509399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The part with patients was completed with a total of 72 patients, 36 in the control group and 36 in the application group.|experimental study randomised controlled|t|t|f|f
33841834|NCT05008939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841835|NCT01793597|||COHORT||PROSPECTIVE|||||||
33841836|NCT03284203|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33841837|NCT01244932|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33841838|NCT03474926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33945152|NCT00005803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945153|NCT01208376|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050307|NCT03551717|||COHORT||PROSPECTIVE|||||||
33945154|NCT03922945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945155|NCT03263052|||CASE_CROSSOVER||PROSPECTIVE|||||||
33945156|NCT04447183|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open, parallel controlled, multi-center clinical trial||||
33945157|NCT06015269|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945158|NCT05158504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050308|NCT06668324|||OTHER||PROSPECTIVE|||||||
34050309|NCT03443622|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050310|NCT02126423|||||PROSPECTIVE|||||||
34050311|NCT05525403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050312|NCT01932710|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34050313|NCT02792192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050314|NCT02515383|||COHORT||PROSPECTIVE|||||||
33841839|NCT02420951|RANDOMIZED|PARALLEL||TREATMENT||NONE||We randomized 50 patients undergoing TKA at one institution into two groups. Group 1, 25 patients, received a postoperative intra-articular catheter in combination with injection of 30 ml of 0.5% Marcaine the day after surgery before removal. Group 2, 25 patients, received no pain catheter. Both groups received intraoperative pericapsular injection and postoperative pain medication. We measured pain scores using the Visual Analog Scale (VAS) and recorded narcotic medication consumption in morphine milligram equivalents (mgs).||||
33841840|NCT05169892|||COHORT||PROSPECTIVE|||||||
33841841|NCT03449901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841842|NCT04239469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841843|NCT02388126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841844|NCT04777370|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Assessment of electromyographic (EMG) activity, IR ROM pre-post intervention, and glenohumeral translation via ultrasound will be performed by a blinded assessor.|All participants will undergo a single intervention during the first session, and then combined thoracic manipulation and a repeat of the prior intervention at the second session.|f|f|f|t
34050315|NCT06114459|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33841845|NCT03270202|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33841846|NCT01940133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841847|NCT03585816|||COHORT||PROSPECTIVE|||||||
33739321|NCT05283291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33739322|NCT02048956|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34050316|NCT01224093|||COHORT||PROSPECTIVE|||||||
33841848|NCT06398886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There have been 3 groups, CBT, Hypnosis and Waiting, each group has 13 participants, CBT and Hypnosis group has taken 8 sessions each and waiting list group took none.||||
33841849|NCT00571467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841850|NCT04637269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945159|NCT03952416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants are masked. The care provide and investigator are not mask. Only one research assistant (outcomes assessor) will be masked.|Eighty participants with spinal cord injury (SCI) who are admitted to the SCI rehabilitation (at Shirley Ryan Ability Lab) will be split into two groups. This will be randomized. Group 1 will receive the intervention, enhanced medical rehabilitation (EMR) while Group 2 will receive the standard existing rehabilitation, standard of care (SOC).|t|f|f|t
33739323|NCT05546606|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, multi-centre, randomized, controlled, open-label||||
33739324|NCT00971971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739325|NCT03632356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 stage parallel group multi-site RCT design|f|f|f|t
33739326|NCT06533683|||CASE_CONTROL||OTHER|||||||
33739327|NCT02148094|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945160|NCT02786368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050317|NCT01501461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050318|NCT05872555|||OTHER||RETROSPECTIVE|||||||
34050319|NCT02804139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050320|NCT05283148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
34050321|NCT06541379|||OTHER||CROSS_SECTIONAL|||||||
34050322|NCT01624779||FACTORIAL||TREATMENT||NONE||||||
34050323|NCT03137901|||COHORT||PROSPECTIVE|||||||
34154324|NCT06183333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical interviews and data analysis will be conducted blindly.|Randomized Controlled Trial with an Intervention Group and a Waiting List Control Group|f|f|t|t
34154325|NCT02402413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154326|NCT02986854|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154327|NCT01315444|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154328|NCT00848224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739328|NCT05501587|||COHORT||PROSPECTIVE|||||||
33739329|NCT00743353|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739330|NCT00003326||||TREATMENT||||||||
33739331|NCT03286140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessment of ulcer healing photos|"The EVRA ulcer trial is a pragmatic; multicentre randomised clinical trial with participants randomised1:1 to either:~1. 'Standard' therapy consisting of multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)~2. Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard therapy"|f|f|f|t
33739332|NCT01070290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739333|NCT03505476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects consented and enrolled will receive the same intervention. There is no control group.||||
33739334|NCT01946061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739335|NCT05884437|NA|SINGLE_GROUP||OTHER||NONE||Single-arm pilot||||
33739336|NCT06561113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739337|NCT04111341|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33739338|NCT05450289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739339|NCT01884298|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33739340|NCT01085318|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739341|NCT00346034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739342|NCT03888313|||COHORT||PROSPECTIVE|||||||
33739343|NCT02589119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739344|NCT00217906|RANDOMIZED|||TREATMENT||||||||
33739345|NCT04655456|||OTHER||CROSS_SECTIONAL|||||||
33739346|NCT03352115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739347|NCT02535195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739348|NCT00501449|||CASE_ONLY||PROSPECTIVE|||||||
33739349|NCT00471601|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33739350|NCT06314581|||COHORT||RETROSPECTIVE|||||||
33739351|NCT04064697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739352|NCT04685577|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|As this is a 2 arm study. One is experimental drug and other is placebo control. No one will know which side of body part having drug and/or placebo. If required, it will be find out but this study is designed as a double blind.||t|t|t|t
33739353|NCT04021680|||COHORT||PROSPECTIVE|||||||
33739354|NCT02677805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739355|NCT02041455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33739356|NCT01306136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739357|NCT05805280|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Enrolled patients will be randomized at a ratio 1:1 to two treatment arms by a computer-generated randomization sequence with a permutated block size 4.~a) intravascular ultrasound-guided group or b) Angiography-guided group"||||
33739358|NCT02534090|||CASE_CONTROL||PROSPECTIVE|||||||
34154329|NCT04119596|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33739359|NCT01578551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739360|NCT02515019|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739361|NCT04396405|||OTHER||PROSPECTIVE|||||||
33739362|NCT03323099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739363|NCT05759091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739364|NCT02773979|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739365|NCT03905759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33739366|NCT01683591|||CASE_ONLY||RETROSPECTIVE|||||||
33739367|NCT03737435|||OTHER||RETROSPECTIVE|||||||
33739368|NCT02248584|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739369|NCT01313559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739370|NCT06573567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33739371|NCT02134145|||OTHER||PROSPECTIVE|||||||
34154330|NCT02122224|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33739372|NCT06205810|||COHORT||PROSPECTIVE|||||||
33739373|NCT00403091|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33739374|NCT03823716|||COHORT||RETROSPECTIVE|||||||
33739375|NCT02517580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739376|NCT02202135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739377|NCT06391827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739378|NCT06167447|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33739379|NCT03009110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739380|NCT03892824|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33739381|NCT03711123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739382|NCT01711086|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33739383|NCT02522897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739384|NCT03264625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739385|NCT05658081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841851|NCT03225690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33739386|NCT04693663|NA|SINGLE_GROUP||TREATMENT||NONE||One group consisting of 40 eyes||||
33739387|NCT06574334|RANDOMIZED|PARALLEL||OTHER||SINGLE||-Quasi experimental research design was used in this study|t|f|f|f
33739388|NCT05613634|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33739389|NCT03204942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33739390|NCT00718029|||COHORT||PROSPECTIVE|||||||
33739391|NCT05323305|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739392|NCT06401681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739393|NCT02488044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739394|NCT04955938|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739395|NCT05935826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants will be randomized to the protein supplement or placebo for 8 weeks. After the 8-week period, there will be a 10-month open label extension to allow all participants to receive the protein supplement for 10-months.||t|t|t|f
33739396|NCT03881241|||CASE_ONLY||PROSPECTIVE|||||||
33739397|NCT06573658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be randomly assigned to PBT or active control group.|f|f|t|t
33739398|NCT00821626|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739399|NCT02490813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33739400|NCT00191321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739401|NCT02709070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739402|NCT06664398|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33739403|NCT05746338|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739404|NCT01060384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739405|NCT05251233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33739406|NCT01135979|||COHORT||PROSPECTIVE|||||||
33739407|NCT01412424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739408|NCT04055129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33739409|NCT05337501|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective longitudinal observational study||||
33739410|NCT05383677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739411|NCT03783351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739412|NCT00426478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33739413|NCT00913159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739414|NCT03313362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739415|NCT03767491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739416|NCT04274738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739417|NCT04257877|||OTHER||CROSS_SECTIONAL|||||||
33739418|NCT02864017|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739419|NCT04136938|||COHORT||PROSPECTIVE|||||||
33739420|NCT02875119|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739421|NCT01840592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739422|NCT05464628|NA|SINGLE_GROUP||OTHER||NONE||||||
33739423|NCT02104557|||OTHER||PROSPECTIVE|||||||
33739424|NCT00539526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33739425|NCT00829621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739426|NCT03495908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739427|NCT05898087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blinded to enrollment group (study group vs control.)||t|f|f|f
33765064|NCT02852122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765065|NCT00005816||||TREATMENT||||||||
33765066|NCT00780182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739428|NCT00129259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The staff at Northwest Lipid Research Laboratory were masked to the treatment assignment since they performed the mixed-meal tolerance test (MMTT) and the HgA1C assays. All study staff including the PI were masked to the results of the MMTT. They were notified of a detectable or undetectable fasting C-peptide result to assess for continuation to the next treatment cycle.||f|f|f|t
33739429|NCT05372484|NA|SINGLE_GROUP||SCREENING||NONE||||||
33739430|NCT01259986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739431|NCT02200042|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization ratio (Experimental:Observation) = 2:1||||
33739432|NCT03494010|||COHORT||PROSPECTIVE|||||||
33739433|NCT03930017|||COHORT||PROSPECTIVE|||||||
33739434|NCT00893893|||COHORT||PROSPECTIVE|||||||
33739435|NCT01558973|||COHORT||PROSPECTIVE|||||||
33739436|NCT04407663|||COHORT||RETROSPECTIVE|||||||
33739437|NCT01066559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739438|NCT05792449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer-generated randomisation will be used to randomly assign the participants to one of the intervention groups. Block randomisation will be used to allocate the recruited subjects into one of the interventions. A randomisation list will be generated by the study statistician and envelopes will be prepared. Although the allocation of intervention will be concealed and the study team will not know in advance which subject will receive which intervention, the blinding will not be possible once the intervention is assigned. Assessors of the initial and final MSEL were not told of the intervention status of the patient to avoid bias in outcome assessment. Blinding of the parents is not possible in the context of this study.|Participants willing to participate in the proposed research study and providing informed consent will be randomized to either the experimental (telerehab program) or control (standard program) arm of the intervention.|f|f|f|t
33739439|NCT00192725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739440|NCT03646422|||COHORT||PROSPECTIVE|||||||
33739441|NCT00993720|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739442|NCT00907270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739443|NCT05875662|||COHORT||PROSPECTIVE|||||||
33739444|NCT00752908|||CASE_CONTROL||PROSPECTIVE|||||||
33739445|NCT03045575|||COHORT||PROSPECTIVE|||||||
33739446|NCT06358924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This clinical trial was double blinded trial in which both the participant and outcome assessor were blinded to allocation, thus the participant was unaware of which experimental material had been assigned to him/her. Also the outcome assessors were blinded to the treatment that each participant had received.|"This clinical study was conducted to evaluate the effect of using different desensitizing agents:~1. As recommended by manufacturer~2. Casein phosphopeptide-amorphous calcium phosphate/fluoride (CPP-ACPF) containing desensitizing agent~3. Hydroxyapatite/fluoride/xylitol containing desensitizing agent~4. Poly (amido amine) dendrimer with carboxylic acid terminal functional group containing desensitizing agent.~On patients subjected to bleaching procedure using hydrogen peroxide containing bleaching agent.~The clinical evaluation included:~1. Post-bleaching hypersensitivity.~2. Post-bleaching long-term shade stability."|t|f|f|t
33739447|NCT03542227|||COHORT||PROSPECTIVE|||||||
33739448|NCT02503280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739449|NCT04255862|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739450|NCT03421613|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects will be randomized to receive either treatment wih 3VM1001 cream or the comparator daily for 10 days followed by 5 day wash out period before 10 days of treatment with the comparator or investigational treatment, .|Double-blind, Placebo-controlled, Crossover study to evaluate treatment and tolerability of the experimental product for treatment of post herpetic pain.|t|t|f|f
33739451|NCT01092195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739452|NCT02936076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739453|NCT00917592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739454|NCT02113020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33739455|NCT02940470|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765067|NCT01920425|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33765068|NCT05591625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Participants with PTSD symptoms (2-3 months post-hospital discharge) will be assigned to either usual care or usual care plus EMDR.~Participants without PTSD symptoms (2-3 months post-hospital discharge) will enter an observation arm, which consists of a repeat psychological assessment at 12-months post-hospital discharge."|f|f|f|t
33765069|NCT03221010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841852|NCT01962532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841853|NCT00293059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841854|NCT00153270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841855|NCT04076943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841856|NCT01428375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841857|NCT02590900|||COHORT||RETROSPECTIVE|||||||
33841858|NCT03704675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33841859|NCT05861245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841860|NCT01667094|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33841861|NCT01190059|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33841862|NCT04204746|||CASE_CONTROL||PROSPECTIVE|||||||
34050324|NCT05911646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"A simple, fixed randomization will be performed using an excel spreadsheet. A randomization formula will be used to assign each new participant a number 1 or 2. All individuals assigned the number 1 will be designated as control and all individuals assigned the number 2 will be designated as case. The randomization will continue until 65 participants is reached for one group. At that time, any new recruited patients will be automatically assigned either control or case, depending on which group has not reached 65 participants. The randomization will be done at the time of consenting."||||
34050325|NCT05114005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050326|NCT06348797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050327|NCT05508035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34050328|NCT05296343|||COHORT||CROSS_SECTIONAL|||||||
33841863|NCT04403087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841864|NCT01491724|||||CROSS_SECTIONAL|||||||
33841865|NCT05455034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739456|NCT04894435|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participants, laboratory staff, and statistical analysis personnel will be blinded to which vaccine they are receiving for those in randomized arms.~Laboratory staff and statistical analysis personnel will be blinded to which vaccine they are receiving for those in open-label arms."|"M=Moderna SpikeVax mRNA; P=Pfizer/BioNTech Comirnaty mRNA; A=AstraZeneca Vaxzervia; C=Medicago Covifenz VLP~MOSAIC 1:~* Group 1 - M, M - 28 days~* Group 2 - M, M - 112 days~* Group 3 - M, P - 28 days~* Group 4 - M, P - 112 days~* Group 5 - P, P - 28 days~* Group 6 - P, P - 112 days~* Group 7 - P, M - 28 days~* Group 8 - P, M - 112 days~* Group 9 - A, M - 28 days~* Group 10 - A, M - 112 days~* Group 11 - A, P - 28 days~* Group 12 - A, P - 112 days~MOSAIC 2:~* Group 1b - P, P, P~* Group 2b - P, P, M~* Group 3b - M, M, M~* Group 4b - M, M, P~* Group 5b - P and M in any order, M~* Group 6b - P and M in any order, P~* Group 7b - A, P or M, P~* Group 8b - A, P or M, M~* Group 9b - Any vaccine in any order, C (open-label)~MOSAIC 3:~* Group 1c - P, P, P, P~* Group 2c - P, P, P, C~* Group 3c - M, M, M, M~* Group 4c - M, M, M, C~* Group 5c - Any 3 in any order, P or M~* Group 6c - Any 3 in any order, C~* Group 7c - Any 3 in any order, C (open-label)"|t|f|t|t
33739457|NCT04862299|||COHORT||RETROSPECTIVE|||||||
33739458|NCT03115424|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double-blind design.||t|t|t|f
33739459|NCT05209191|NA|SINGLE_GROUP||PREVENTION||NONE|Participants will know if they are receiving the Student Athlete Wellness Portal intervention during the study or afterwards.|Participating athletes assigned to treatment condition.||||
33739460|NCT06531733|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||8 participants per condition (24 total across 3 conditions + 1 sham/placebo condition that everyone will experience)||||
33739461|NCT00389818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739462|NCT03156023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739463|NCT03223558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"researchers will be blinded during baseline assessment prior to group allocation.~Participants and the clinical CR team will know the group allocation and therefore cannot be blinded. University hospitals for Coventry and Warwickshire NHS trust research and design department will generate the randomisation sequence remotely using permuted block randomisation."|A single blinded parallel group randomised controlled trial will be used to determine non-inferiority of early (2 weeks post operation) vs usual care (6 weeks post operation ) CR for a period of 8 weeks.|f|f|f|t
33739464|NCT00002526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739465|NCT06572319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739466|NCT05254379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739467|NCT00721994|||COHORT||PROSPECTIVE|||||||
33739468|NCT02445235|||CASE_ONLY||PROSPECTIVE|||||||
33739469|NCT06275100|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm pilot feasibility study in acute inpatients waiting for cardiac surgery. Intervention is a prehabilitation program||||
33739470|NCT03345459|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to internet-based treatment (two-thirds of sample) or usual care (one-third of sample).||||
33739471|NCT00320346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33739472|NCT05708079|||COHORT||OTHER|||||||
33739473|NCT04358926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will receive anonymous blinded data.|Randomized controlled study|f|f|f|t
33739474|NCT06413433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739475|NCT05073536|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33739476|NCT06074250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33739477|NCT00646958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765070|NCT04344041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765071|NCT05966935|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be divided into two groups. One group will receive the Fenugreek Cumin Powder. The other group will not receive the powder||||
33765072|NCT06383702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel design|t|f|t|t
33765073|NCT03027414|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33841866|NCT04651478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind criteria will be achieved by following the same protocol with the same instruments in both groups. The evaluator will not be able to stay in the same room during the intervention and patients will not know the instructions and specific hypotheses of each protocol. The statistician will be blinded through the assignment of neutral numbers to both groups. Patients recruited will not meet in waiting rooms to avoid them to comment on their experience during the protocol. Unblinding will be permissible when any event could suppose a risk for the patient's health.|This study will be a double-blinded experimental longitudinal prospective randomized controlled trial with a parallel design. The randomization will be realized through randomization software. All the participants who fulfill the inclusion criteria and have none of the exclusion ones will be randomly allocated into two groups: AO+MI through a Brain-Computer Interface (BCI) training paradigm in Virtual Reality (VR) (AO+MI-BCI) or AO of non-related with movement illustrations (AO-control). Allocation concealment will be ensured by the inclusion of the assigned group in closed opaque envelopes that will be opened at the time of the intervention.|t|f|t|t
33841867|NCT03610347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841868|NCT01232738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945161|NCT05936801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A total 34 patients will be taken. 2 groups will be created to apply intervention. After signing consent form, 17 patients in group A will be given abdominal thrust assist technique and 17 patients in group B will be given anterior chest compression technique. Baseline treatment given to both groups will include percussion and tapping. The data collected will then be analyzed using IBM SPSS version 25|A total 34 patients will be taken. 2 groups will be created to apply intervention. After signing consent form, 17 patients in group A will be given abdominal thrust assist technique and 17 patients in group B will be given anterior chest compression technique. Baseline treatment given to both groups will include percussion and tapping.|t|f|f|f
33945162|NCT04946721|||CASE_CONTROL||PROSPECTIVE|||||||
33945163|NCT00622310|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945164|NCT04151420|||COHORT||PROSPECTIVE|||||||
33945165|NCT02287831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945166|NCT02414100|||CASE_ONLY||PROSPECTIVE|||||||
33945167|NCT00483782|RANDOMIZED|||TREATMENT||NONE||||||
33945168|NCT04586608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33945169|NCT04192292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Physiological Study||||
33945170|NCT02301468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33739478|NCT03788889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Each participant will be randomized according to a web-based randomization program employed by a research pharmacist once the Emergency Department provider deems the patient appropriate for inpatient treatment of alcohol withdrawal syndrome.~Each medication will be packaged by Santa Barbara Cottage Hospital pharmacy. In order to blind both the clinicians and the participants, the pharmacy will provide medication bags that are identical. Therefore, Emergency Department nursing staff and physicians will be unaware of which study drug is being provided to the patient. Normal saline will be used as a placebo to mimic study drugs (phenobarbital and ketamine). Pharmacy will remain unblinded and maintain records of which treatment assignment is prepared for each patient.~Treatment will be provided for the duration of the patient's hospitalization; therefore, treatment compliance will be documented in the electronic health record using the medication bag identifier."|prospective, randomized control trial|t|t|t|f
33739479|NCT05826821|||COHORT||RETROSPECTIVE|||||||
33739480|NCT05423509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The follow-up visits were performed by an advanced practice provider that did not know which treatment arm the patient is in.|randomized controlled trial between 2 treatment groups|f|f|f|t
33739481|NCT04795284|||COHORT||CROSS_SECTIONAL|||||||
33739482|NCT05809453|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Our research nurse will know whether the participant will receive cocaine or lidocaine. All others involved in the protocol, including the participant, will not know which agent they received for which trial.|"We will conduct a double-blind, placebo-controlled, crossover study. Following informed consent and screening, eligible participants will be randomized to complete the cocaine or the lidocaine (placebo) trial first, with the other agent administered during the subsequent visit. During these experimental visits, we will first obtain pre-drug temperature and cardiovascular data, which will be followed by administer of cocaine or lidocaine intranasally. Participants will then enter the chamber set to warm environmental conditions. After further instrumentation in the warm environment, participants will perform mild to moderate intensity physical activity for 60 minutes. Throughout the 60 minutes of physical activity we will record body temperature and cardiovascular responses. Upon concluding the physical activity, subjects will rest while body temperature and cardiovascular responses are obtained post-physical activity."|f|f|t|f
33841869|NCT03532659|RANDOMIZED|PARALLEL||OTHER||NONE||"Intervention with two comparison groups. The control or experimental group will be randomly defined by school~* Experimental group: will perform physical activity through the use of the active videogame associated with a gamification strategy three times a week for 50 minutes for a period of 8 weeks.~* Control group: there will be no intervention proposal, only used for data comparison."||||
34050329|NCT02698657|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33841870|NCT02243670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841871|NCT03971591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to either a guided or self-guided lifestyle intervention||||
33841872|NCT05324683|||COHORT||PROSPECTIVE|||||||
33841873|NCT04594044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations of treatment response were made by an independent evaluator who was not blinded to the treatment allocation, yet not involved in the treatment of the patient, and blinded to any previous evaluations. The evaluators were a specialized psychologist and a child and adolescent psychiatrist with several years of experience in diagnosing, evaluating and treating tic disorders. A random sample of 10% were audiotaped and evaluated by another rater with extensive experience and expertise in the use of the YGTSS|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session. Treatment effect was evaluated after 8 and 9 months, and after one year of follow-up|f|f|f|t
33841874|NCT00768170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841875|NCT06214000|||COHORT||RETROSPECTIVE|||||||
33841876|NCT03591653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841877|NCT01201577|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33841878|NCT01943175|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33841879|NCT03916458|||OTHER||RETROSPECTIVE|||||||
33841880|NCT02849613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841881|NCT06479031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841882|NCT05150977|||COHORT||RETROSPECTIVE|||||||
33945171|NCT02264327|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33945172|NCT03169127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.||||
33945173|NCT00157157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945174|NCT00216112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945175|NCT03176823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|While it is not technically possible to mask participants to the application of RIC versus sham therapies, all participants in this trial by design will be intubated in an intensive care unit with severe traumatic brain injury; it is improbable that our inability to mask the patients will compromise outcomes or induce bias as patients are unlikely to have consciousness or memory of the therapy.|This trial is a prospective double-blind parallel cohort study of patients undergoing either standard of care plus placebo (sham-RIC) or standard treatment plus a single session of upper extremity remote ischemic conditioning.|f|t|t|t
34050330|NCT06684002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050331|NCT06684015|||COHORT||PROSPECTIVE|||||||
34050332|NCT00355563|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34050333|NCT05704348|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient and the healtcare workers will be masked as to whether a pexi has been performed or not.||t|t|f|f
34050334|NCT00138398|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34050335|NCT03813836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050336|NCT06031805|||COHORT||PROSPECTIVE|||||||
34050337|NCT06185049|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||The effects of an intervention with two booster sessions will be evaluated in parallel with an intervention that only has one booster session and with an intervention without booster sessions.|t|t|t|f
34050338|NCT04847284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050339|NCT06598202|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33739483|NCT03918759|||COHORT||PROSPECTIVE|||||||
33841883|NCT04263272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33841884|NCT00685698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841885|NCT02600390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841886|NCT05521815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739484|NCT06572917|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The indomethacin and placebo will be provided to the bedside nurse as per allocation using pre-filled syringes masked with a yellow tape (as reconstituted indomethacin has a slightly yellow tinge). All members of the medical team and outcome assessors will remain blinded to the allocation throughout the trial duration.||t|t|t|t
33739485|NCT06016972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects, Investigators and their staff, and Sponsor personnel involved with the conduct and monitoring of the study will be masked to the IP identity until after the final database is locked. IP will be provided in identical packaging. Unmasked statistician preparing the masked randomization schedule.|Multi site double masked, vehicle-controlled, randomized, prospective parallel study of 7 days' QAM dosing, followed by 7 days' QPM dosing, and 7 days' BID dosing (7 days of dosing per regimen \[21-day treatment period\])of an investigational product (IP), QLS-111 or vehicle. Both eyes (OU) will be dosed.|t|t|t|t
33739486|NCT06294002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739487|NCT03272191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739488|NCT05019586|||CASE_CONTROL||OTHER|||||||
33739489|NCT06573541|||CASE_ONLY||RETROSPECTIVE|||||||
33739490|NCT03823651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739491|NCT00249145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33841887|NCT05588050|||OTHER||OTHER|||||||
33739492|NCT00354926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739493|NCT04666441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739494|NCT05071417|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase IV low-intervention, double-blind, multicenter clinical trial to evaluate the effects of 18 months of semaglutide treatment on the volume, architecture, and composition of coronary atheroma plaques in subjects with DM2 for at least 10 years and without clinical cardiovascular disease.~Patients with DM2 will be included if their previously prescribed treatment was insufficient to achieve adequate control of glycemic and glycosylated hemoglobin levels (HBA1c) to reach their therapeutic objective and the researcher has considered semaglutide treatment to be appropriate according to its clinical criteria and based on the indication of this treatment in this patient profile. The study treatment will therefore be the same treatment that the patient would receive even if they did not participate in the study; this condition is the basic norm for the inclusion of the patient in the study."||||
33739495|NCT01494779|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739496|NCT01183793|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33739497|NCT03955484|||COHORT||PROSPECTIVE|||||||
33739498|NCT05653128|||CASE_ONLY||CROSS_SECTIONAL|||||||
33739499|NCT05281692|||COHORT||PROSPECTIVE|||||||
33739500|NCT02272998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739501|NCT05637151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33739502|NCT01723904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739503|NCT06567639|||COHORT||RETROSPECTIVE|||||||
33739504|NCT06535867|||COHORT||PROSPECTIVE|||||||
33739505|NCT01014286|||OTHER||RETROSPECTIVE|||||||
33739506|NCT06133764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, investigators, and outcomes assessor will not be informed about the study|The patents will be divided into five groups according to the treatment modalities used to treat their odontogenic cysts|t|f|t|t
33739507|NCT02284737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33739508|NCT05534282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739509|NCT06664203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33739510|NCT02815111|||COHORT||PROSPECTIVE|||||||
33841888|NCT00233974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945176|NCT06050811|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The candidate prebiotic and placebo will be pre-packaged randomly off-site, and the investigator and patient will not know whether the prebiotic or the placebo is being administered. This will be unmasked for the data analysis phase.|Volunteers will be assigned randomly to take either prebiotic or placebo during an initial 28 day period. A 21 day wash-out period, during which no prebiotic or placebo will be consumed, will separate the 28 day treatment periods and there will be a further washout at the end (to ascertain the duration of prebiotic effect). There will therefore be four test periods randomly assigned (prebiotic; washout; placebo; washout; OR placebo; washout; prebiotic; washout).|t|t|t|f
33739511|NCT03881462|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841889|NCT03134677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739512|NCT04049526|||COHORT||PROSPECTIVE|||||||
33739513|NCT00014144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739514|NCT00054899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739515|NCT05123846|||COHORT||PROSPECTIVE|||||||
33739516|NCT02192268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739517|NCT06155786|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33739518|NCT02979834|||COHORT||PROSPECTIVE|||||||
33739519|NCT06563323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739520|NCT00304070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739521|NCT01016834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739522|NCT05341921|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot, randomized, controlled trial||||
33739523|NCT05761691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Two armed RCT was planned.~First: children received dental treatment under general anesthesia (Study group)~Second: Children received dental treatment under local anesthesia (Control group) in regular dental sitting."|f|f|t|t
33841890|NCT00557375|||CASE_ONLY||CROSS_SECTIONAL|||||||
33841891|NCT04654377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841892|NCT05479032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841893|NCT06493825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841894|NCT02686177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841895|NCT05850195|||OTHER||PROSPECTIVE|||||||
33841896|NCT05252442|||COHORT||OTHER|||||||
33841897|NCT00078000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841898|NCT05844670|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a prospective cohort study.||||
33841899|NCT02410460|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33739524|NCT03440632|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The physical examination and the advanced analysis of the 3D gait analysis will be done be a blinded examiner.|randomisation for the order of treatments and thereby for the total length of the 'conventional therapy phase'.|f|f|f|t
33841900|NCT01853202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841901|NCT00139880|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33841902|NCT06186271|||COHORT||PROSPECTIVE|||||||
33739525|NCT00126048|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33739526|NCT03267238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739527|NCT05252026|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||One intervention is evaluated in parallel against a active control group|t|f|t|t
33739528|NCT02284828|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33739529|NCT00893490||||TREATMENT||||||||
33739530|NCT05668494|NA|SINGLE_GROUP||SCREENING||NONE||||||
33739531|NCT03934229|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33739532|NCT01146938|NON_RANDOMIZED|PARALLEL||||NONE||||||
33739533|NCT02486406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739534|NCT06146322|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33739535|NCT02211300|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33739536|NCT01807130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739537|NCT01240616|||||PROSPECTIVE|||||||
33739538|NCT02791139|||CASE_CONTROL||PROSPECTIVE|||||||
33739539|NCT02815514|||CASE_ONLY||PROSPECTIVE|||||||
33739540|NCT03516916|||COHORT||CROSS_SECTIONAL|||||||
33739541|NCT02617589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739542|NCT00796029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739543|NCT04545814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739544|NCT01747980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739545|NCT01159418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739546|NCT00955877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739547|NCT02286882|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33739548|NCT03556319|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The dietary supplement will be delivered to the Clinical Research Center by the Investigational Pharmacy at Vanderbilt University Medical Center. Staff nurses and participants will be blinded to the capsule content.|Participants will be randomly assigned in a blinded fashion to 2-HOBA or placebo. A computer-generated randomization sequence with a block of size 3 will be used to assign participants at the ratio of 1:2 (placebo:2-HOBA) at each dose level of the treatment. All participants receiving the lower dose regimen will be completed before enrolling participants in the higher dose group.|t|t|t|f
33739549|NCT06152276|||COHORT||PROSPECTIVE|||||||
33739550|NCT03679260|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739551|NCT02172313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739552|NCT05937022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of their group assignment.|Participants are assigned to three groups in parallel for the duration of the study.|t|f|f|f
33739553|NCT03865121|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled Pilot Trial||||
33739554|NCT04641468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739555|NCT00734838|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33841903|NCT01872559|||COHORT||PROSPECTIVE|||||||
33739556|NCT06181669|||CASE_ONLY||PROSPECTIVE|||||||
33739557|NCT06030193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects, Investigators and their staff, and Sponsor personnel involved with the conduct and monitoring of the study will be masked to the IP identity until after the final database is locked. IP will be provided in identical appearing packaging. Unmasked statistician preparing the masked randomization schedule.|Multi site double masked, vehicle-controlled, randomized, prospective parallel study of 7 days' QAM dosing, followed by 7 days' QPM dosing, and 7 days' BID dosing (7 days of dosing per regimen \[21-day treatment period\])of an investigational product (IP), QLS-111 or vehicle. Both eyes (OU) will be dosed.|t|t|t|t
33739558|NCT05395377|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants enrolled in this study were able to choose from 1 of 5 intervention options based on their weight status.||||
33739559|NCT01170897|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33739560|NCT03699306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739561|NCT03526224|||CASE_CONTROL||RETROSPECTIVE|||||||
33739562|NCT04277377|||COHORT||PROSPECTIVE|||||||
33739563|NCT01059201|||COHORT||OTHER|||||||
33945177|NCT02908594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33945178|NCT01013116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050340|NCT04867707|NA|SINGLE_GROUP||TREATMENT||NONE||Single group design with 20 subjects||||
34050341|NCT05118776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739564|NCT02414087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33739565|NCT02477384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841904|NCT03355339|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739566|NCT06347185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739567|NCT04975815|||COHORT||PROSPECTIVE|||||||
33739568|NCT01993719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739569|NCT04181034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945179|NCT02610790|||COHORT||PROSPECTIVE|||||||
33739570|NCT02348489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739571|NCT06573086|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33739572|NCT06126055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739573|NCT06567808|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Factorial Assignment|f|f|f|t
33841905|NCT04116736|||COHORT||PROSPECTIVE|||||||
33841906|NCT04167787|||OTHER||PROSPECTIVE|||||||
33739574|NCT03054844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33739575|NCT06171867|NA|SINGLE_GROUP||OTHER||NONE||The device feasibility will be assessed in clinical environment with feedback from both the patient parents and nurses in NICU/PICU.||||
33739576|NCT01083433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841907|NCT02344264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739577|NCT06269614|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33739578|NCT00889421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739579|NCT04788147|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"This is an open-label, prospective study. The study is divided into two sequential cohorts of patients with one targetable primary or metastatic lesion in either the lungs or bone. Patients with multiple metastases can be accrued, but these investigations will focus on only one lesion per patient.~Cohort I seeks to identify the Recommended RefleXion FDG dose (RRFD), which is the dose of administered FDG that allows for functioning of the RefleXion system. To that end, dose levels of 15 mCi and 20 mCi (if required) are assessed sequentially in an escalation protocol.~The RRFD identified in Cohort I is utilized in Cohort II, to emulate and assess the dose delivery performance of the end-to-end BgRT workflow."||||
33739580|NCT03799575|||COHORT||PROSPECTIVE|||||||
33739581|NCT06379841|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33739582|NCT06358898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739583|NCT00900991|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739584|NCT00452504|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33739585|NCT03887936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No other parties will be masked.|Double-blind randomized placebo-controlled study comparing the effect of testosterone therapy in men with both type 2 diabetes mellitus and hypogonadism on bone quality, bone turnover markers and circulating osteoblast and osteoclast progenitors.|t|f|t|t
33841908|NCT05071638|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A hospital ethics committee reviewed the study data during the trials. None of them were involved in the study or aware of the treatment-group assignments of the infants. Nurses and physicians staff conducted the infusion are not aware of the treatment assignment, and these individuals had no contact with the staff who collected and analyzed the patients data. The parents are aware of the assignment.|This is a non-randomized, case-controlled trial that evaluates the efficacy of autologous cord blood mononuclear cells(ACBMNC) infusion as a Treatment for BPD.In this prospective clinical trial, preterm neonates less than 28 weeks who previously stored ACBMNC and then suffer BPD will be assigned to be ACBMNC infusion group, while those who do not previously stored ACBMNC or then refuse ACBMNC infusion and suffer BPD will be assigned to be control group. In the ACBMNC infusion group, when BPD occurred, the pre-stored ACBMNC will be removed and rewarmed, and then ACBMNC(5×107 cells /kg) will be intravenously injected within 24 hours. The control group receives standardized treatment without special treatment. The total number of participants is 76 and the same in both groups.|f|t|t|f
33841909|NCT00515684|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841910|NCT03704168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945180|NCT06509776|||COHORT||PROSPECTIVE|||||||
33945181|NCT00130754|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33841911|NCT02165813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Matched placebo formulation|Bayesian piecewise survival analysis|t|t|t|f
33945182|NCT03844282|||OTHER||PROSPECTIVE|||||||
33945183|NCT05824273|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33841912|NCT01546532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945184|NCT00122395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945185|NCT03429894|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.||||
33841913|NCT01714661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841914|NCT00392925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945186|NCT04218942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945187|NCT01975883|||COHORT||PROSPECTIVE|||||||
33945188|NCT00032058||||DIAGNOSTIC||NONE||||||
33841915|NCT01986764|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33945189|NCT03006549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33841916|NCT06563999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945190|NCT01094821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33841917|NCT06457685|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular System (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™) System for treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.||||
33945191|NCT00880711|||CASE_ONLY||PROSPECTIVE|||||||
33945192|NCT06049823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The operator (L.C.Y.) was blinded to the assignment and opened the envelope just before the alveolar ridge preservation procedures, while both the participants and the examiners (C.M.Y., P.Y.K.) remained completely blinded to the assignments in the study protocol.||t|f|t|t
33945193|NCT05597189|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33945194|NCT02173015|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945195|NCT00261599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945196|NCT00264693|||COHORT||PROSPECTIVE|||||||
34050342|NCT05474170|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Data extraction will be fully automated and the statistician will not know the identity of the participants or the sequence they were allocated to.||f|f|f|t
34050343|NCT03615144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.||||
34050344|NCT00052052|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050345|NCT01493284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050346|NCT03397368|||OTHER||CROSS_SECTIONAL|||||||
34050347|NCT03181269|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34050348|NCT06334328|NA|SINGLE_GROUP||OTHER||NONE||||||
34050349|NCT03154463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050350|NCT04058652|NA|SINGLE_GROUP||OTHER||NONE||||||
34050351|NCT01763580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050352|NCT02809079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050353|NCT06058442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154331|NCT05969340|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The radiologist assessing the CT imaging will be blinded to which participants have positive posterior canal BPPV.|"There are 2 groups involved:~* The experimental group~* The control group"|f|f|f|t
33841918|NCT02074176|||CASE_CONTROL||PROSPECTIVE|||||||
33841919|NCT05197283|RANDOMIZED|CROSSOVER||OTHER||SINGLE|single blind (investigator)|Crossover assignment|f|f|t|f
33841920|NCT05716724|||COHORT||PROSPECTIVE|||||||
33841921|NCT05502783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841922|NCT00771992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841923|NCT00462878|||CASE_ONLY||PROSPECTIVE|||||||
33841924|NCT04521751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a double-blind study and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.~Active treatment and placebo capsules are identical in appearance."|This is an exploratory, randomised, double-blind and placebo-controlled study.|t|f|t|t
33841925|NCT01741103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33841926|NCT05842551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33841927|NCT03789331|||COHORT||CROSS_SECTIONAL|||||||
33841928|NCT04956874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dementia caregivers were recruited initially. When dementia caregiver recruitment was completed, a small control group was recruited.||||
33841929|NCT02632604|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33841930|NCT01088984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841931|NCT05510427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841932|NCT01728337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841933|NCT04462783|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Some patients will have pulse oximeters or be given one and provide data from these.||||
33841934|NCT00334672||||TREATMENT||NONE||||||
33739586|NCT06533774|NA|SINGLE_GROUP||TREATMENT||NONE|"For objectives 1-3, it is single blinded because all test conditions are implemented in the same hearing aid with the beamformer setting being unknown to the test participant but known to the investigator who enacts program changes.~For the remaining objectives (4-8), it is non-blinded as participants will be trained on the app before completing a skills test (4), will compare impressions using versus not using the app to change their beamformer (5-7) and speech understanding with versus without amplification (8)."|This clinical investigation is an interventional study, executed at one investigation site, with a confirmatory design. The investigation model is single group, with a randomized test order where the test conditions are fully crossed-over.||||
33841935|NCT04575753|||COHORT||PROSPECTIVE|||||||
33841936|NCT05305170|||COHORT||PROSPECTIVE|||||||
33841937|NCT00402012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841938|NCT01533844|||||PROSPECTIVE|||||||
33841939|NCT00827476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841940|NCT04288518|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33841941|NCT00175201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841942|NCT02747823|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33841943|NCT05520372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841944|NCT02567760|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33841945|NCT06716021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841946|NCT02078401|||COHORT||PROSPECTIVE|||||||
33841947|NCT02543983|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841948|NCT02605551|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841949|NCT03846180|||COHORT||RETROSPECTIVE|||||||
33841950|NCT05788874|||CASE_CONTROL||PROSPECTIVE|||||||
33841951|NCT04058275|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33739587|NCT05416619|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention is provided by a wearable device for hand rehabilitation. The device is composed by 8 bipolar electrodes that are able to detect muscle activation to control a computer interface to execute sEMG-biofeedback training for hand motor recovery.||||
33739588|NCT05030922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33841952|NCT01689935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841953|NCT05048498|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841954|NCT03572426|||COHORT||CROSS_SECTIONAL|||||||
33841955|NCT03735797|||COHORT||PROSPECTIVE|||||||
33841956|NCT01109680|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33841957|NCT03377361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841958|NCT05716295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple ascending dose escalation followed by dose expansion.||||
33841959|NCT01940939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739589|NCT06330441|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33841960|NCT01518959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841961|NCT03613376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841962|NCT06010277|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841963|NCT02988050|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33841964|NCT04103996|||CASE_ONLY||PROSPECTIVE|||||||
33841965|NCT01026506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841966|NCT05423990|||CASE_ONLY||PROSPECTIVE|||||||
33841967|NCT03635099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841968|NCT04175561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analytical blinding is possible, but intervention blinding is not.|Social prescribing intervention based on RCT design|f|f|f|t
33841969|NCT04502017|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841970|NCT03638167|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841971|NCT00899873|||OTHER||RETROSPECTIVE|||||||
33841972|NCT01298687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841973|NCT03043703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cohort study||||
33841974|NCT00684151|||COHORT||RETROSPECTIVE|||||||
33841975|NCT05141552|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33841976|NCT03772587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841977|NCT03401931|||COHORT||PROSPECTIVE|||||||
33841978|NCT02876445|NA|SINGLE_GROUP||||NONE||||||
33841979|NCT01594775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33841980|NCT01255631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33841981|NCT05362045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841982|NCT00588978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33841983|NCT03619447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and anaesthesia provider will not know which intervention applied. Another anaesthesia provider who did not perform any block will follow and record to the study data.||t|t|f|f
34050354|NCT05578716|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Each formula in the study will have the same packaging besides from colour coding (green, blue, yellow). None of the study personnel are aware of which colour represents which formulae during the course of the intervention.|Participants will be randomised to either standard formula or one of two partially hydrolysed study formulae. Included in the study will also be a group of breast-fed infants acting as reference group.|t|t|t|t
34050355|NCT03643601|||COHORT||RETROSPECTIVE|||||||
34050356|NCT03169075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050357|NCT03626363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33739590|NCT03586869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739591|NCT06480526|||COHORT||PROSPECTIVE|||||||
33739592|NCT04313153|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label, Sponsor-blind study.|||||
33739593|NCT01663636|||COHORT||PROSPECTIVE|||||||
33739594|NCT01169857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739595|NCT01364064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841984|NCT06046105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study drugs will be prepared in a ready-to-inject form by a separate anesthesiologist who is not involved in the study.~This way, neither the patient nor the anesthesiologist administering the drug will be aware of the type of medication being used.~The physician who will gather patient data is also unaware of the medications administered."|Randomized controlled comparative prospective clinical trial|t|t|f|f
33841985|NCT04445987|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects that consent to enter this open-label safety study may or may not have previously completed a companion study (ARQ-154 trial)||||
33841986|NCT00900224|||COHORT||RETROSPECTIVE|||||||
33841987|NCT01784120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841988|NCT02535091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841989|NCT00219700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33841990|NCT04553562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants in the acupuncture and sham acupuncture will be blinded.||t|t|f|t
33841991|NCT03889353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841992|NCT00320528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841993|NCT00128531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33841994|NCT02327351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841995|NCT05431764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33841996|NCT03682302|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33841997|NCT04323540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33841998|NCT05526131|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33841999|NCT05692687|||CASE_ONLY||PROSPECTIVE|||||||
33842000|NCT01385852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842001|NCT02995642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945197|NCT03839316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The aim of the study is to evaluate and compare the effect of tDCS plus conventional physiotherapy and occupational therapy to sham tDCS plus conventional physiotherapy and occupational therapy on upper extremity motor function in patients with subacute stroke was aimed in our study.~32 patients will be randomly assigned to one of two groups in parallel for the duration of the study: bihemispheric tDCS (n:16), or sham tDCS (n:16). In addition to a conventional physiotherapy and occupational therapy program, bihemispheric tDCS application will be applied to one group and sham tDCS applied to the second group. A constant current stimulator(ZMI Electronics Limited,Taiwan,2012) will be used for the application of tDCS. In both groups, the tDCS application will be started simultaneously with the occupational therapy session and will last for thirty minutes."|t|f|f|t
33945198|NCT01631123|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945199|NCT03987165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||cross over design with each baby serving as its own control||||
33945200|NCT02617602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945201|NCT04468100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977910|NCT05668481|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be aware that they are receiving constructive memory support in one session and non-constructive memory support in the next session|Participants will be randomized to receive constructive memory supports in Session 1 OR to receive non-constructive memory supports in Session 1. In Session 2, participants will receive the type of memory support they did not receive in Session 1. In other words, if a participant received constructive memory support in Session 1, in Session 2 they will receive non-constructive memory support. And if a participant received non-constructive memory support in Session 1, in Session 2 they will receive constructive memory support. This cross-over design was adopted to increase the number of observations of the constructive and non-constructive memory support.|t|f|f|f
33977911|NCT06211985|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Blood tests were taken from all children included in the study to study the biomarker called 'Copeptin'.|f|f|f|t
33739596|NCT04477174|||OTHER||PROSPECTIVE|||||||
33739597|NCT04725994|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739598|NCT03238001|NA|SINGLE_GROUP||SCREENING||NONE||This study uses a paired design in which each subject undergoes blinded testing by separate testers administering DCTclock and a battery of reference standard tests to determine cognitive state.||||
33739599|NCT04166318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739600|NCT03787849|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants are not aware of anesthesia technique. Outcome assessor of DNA methylation are not aware of anesthesia technique since they will analyze blood samples.||t|f|f|t
33739601|NCT02074735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33739602|NCT01003249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945202|NCT05237843|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Each 70 sequential patient numbers were composed murky envelope while task code composed different paper that then fixed inside. At hour predisposition visit individual control opened envelope to uncover task, continued like manner (bunch A or B ).|"Group A (control group) : 35 women in this group will receive only the standard treatment in the form of low- dose aspirin (LDA) 81 mg/day (Jusprin® 81mg which manufactured by Future Pharmaceutical Company), and LMWH (Enoxaparin, Clexane® which manufactured by SANOFI company) with a dose ( .5 mg/kg) subcutaneously injected/24 hr . LDA ought to be begun before origination, while LMWH ought to be begun after confirmation of pregnancy by detecting fetal viability by ultrasound plus Placebo specially manufactured tablets in our Ain shams faculty of pharmacy .~Group B ( Hydroxychloroquine group ) : This group included 35 women who will administered Hydroxychloroquine 200 mg (Hydroquine® 200mg which fabricated by MinaPharm Company) one tablets / day in addition to the standard therapy"|t|t|t|f
33842002|NCT04202367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Seventy-four patients aging between 1 and 8 years, undergoing unilateral inguinal hernia surgery, were enrolled in the study and were randomized using closed envelope method.|Ultrasound-guided TAP block was applied following standard general anaesthesia induction. All patients received remifentanil 0,1 μg/kg/h infusion and paracetamol 15 mg/kg intraoperatively, and paracetamol 4x15 mg/kg per day postoperatively.|t|t|t|t
33945203|NCT00182572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33842003|NCT02754388|||CASE_ONLY||OTHER|||||||
33842004|NCT02233803|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842005|NCT02473731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842006|NCT01868932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842007|NCT04723966|||OTHER||CROSS_SECTIONAL|||||||
33842008|NCT00876564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842009|NCT05309252|||COHORT||PROSPECTIVE|||||||
33842010|NCT00296257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33842011|NCT04630288|||COHORT||RETROSPECTIVE|||||||
33842012|NCT05717894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||all patients were randomized one-to-one into either the control group (n=72) or the treatment (primary) group (n=78) according to the order of admission to the hospital||||
33842013|NCT01233323|||CASE_ONLY||PROSPECTIVE|||||||
33842014|NCT04812002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842015|NCT05082961|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33842016|NCT06329258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||open label||||
33842017|NCT00878683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842018|NCT01349153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842019|NCT04739969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842020|NCT05451004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842021|NCT04078295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33842022|NCT02626455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842023|NCT03518190|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33842024|NCT00403767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842025|NCT05846230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842026|NCT00544986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842027|NCT06487130|||OTHER||OTHER|||||||
33842028|NCT00031668|RANDOMIZED|||TREATMENT||NONE||||||
33842029|NCT02354820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842030|NCT05428995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842031|NCT04921891|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel Assignment|f|f|f|t
33842032|NCT00335933|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33842033|NCT03219047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842034|NCT03081364|||OTHER||PROSPECTIVE|||||||
33842035|NCT04270253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842036|NCT01274325|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33842037|NCT05925231|||COHORT||PROSPECTIVE|||||||
33842038|NCT06519305|||COHORT||PROSPECTIVE|||||||
33842039|NCT02427945|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33842040|NCT05144555|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33842041|NCT03592043|||COHORT||RETROSPECTIVE|||||||
33842042|NCT00415051|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33842043|NCT01521936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842044|NCT03101891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All eligible patients will be offered participation in the study. Participants can elect for invasive therapy with amnioinfusions or expectant management.||||
33842045|NCT00175643|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842046|NCT00344864|||COHORT||PROSPECTIVE|||||||
33842047|NCT02579135|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842048|NCT01089738|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33842049|NCT00329810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842050|NCT02882425|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33842051|NCT02682342|||CASE_ONLY||PROSPECTIVE|||||||
33842052|NCT04423523|||CASE_CONTROL||PROSPECTIVE|||||||
33842053|NCT02130323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842054|NCT02729883|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945204|NCT03150706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945205|NCT03028649|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33842055|NCT02950597|||COHORT||PROSPECTIVE|||||||
33945206|NCT03081858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842056|NCT00526253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842057|NCT04651140|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842058|NCT06270043|||COHORT||PROSPECTIVE|||||||
33842059|NCT01242579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33842060|NCT00357110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842061|NCT04996446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842062|NCT04165889|||COHORT||PROSPECTIVE|||||||
33842063|NCT04472416|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric non-blinded superiority randomized controlled trial: standardized analgesic protocol + virtual reality device vs. standardized analgesic protocol alone for abdominal VAC dressing change.||||
33842064|NCT00193752|||COHORT||PROSPECTIVE|||||||
33842065|NCT00701649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842066|NCT04940975|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33842067|NCT02104778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842068|NCT05648929|RANDOMIZED|PARALLEL||OTHER||TRIPLE|randomised double-blinded trial: A total of 14 patients will receive either Motiva SmoothSilk® or other routinely used expander (Mentor CPX™4) randomized to left or right breast after mastectomy. Patient and laboratory expert will be double-blinded.|intraindividual comparative analysis of two different devices implanted within one individual patient.|t|t|f|t
33842069|NCT00002197||||TREATMENT||NONE||||||
33842070|NCT06236139|NA|SEQUENTIAL||TREATMENT||NONE||||||
33842071|NCT04454931|||COHORT||PROSPECTIVE|||||||
33842072|NCT04694170|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33842073|NCT05410080|||CASE_CROSSOVER||PROSPECTIVE|||||||
33842074|NCT02274805|||COHORT||RETROSPECTIVE|||||||
33842075|NCT00327262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842076|NCT01666587|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33842077|NCT00647933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842078|NCT02649738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842079|NCT06387628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842080|NCT02360527|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842081|NCT05135676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842082|NCT06179888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842083|NCT04237532|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will be randomized controlled clinical trial with a cross over design where each patient will serve as his/her own control||||
33842084|NCT01641159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842085|NCT04551521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842086|NCT01567631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842087|NCT04037657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842088|NCT05116293|||COHORT||PROSPECTIVE|||||||
33842089|NCT05401006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842090|NCT04293003|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33842091|NCT05437640|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Interpretation of blood biomarkers will be blinded to the intervention assignment.|PD participants randomly assigned to first adhere to either the Protein Consistent Diet or Protein Redistribution Diet for 2 weeks. Participants will enter a 1-week washout period between the diets where they follow their typical diet and then follow the other diet prescription for 2 weeks.|f|f|f|t
33842092|NCT01162577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33842093|NCT03335436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842094|NCT03921099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33842095|NCT02479724|||COHORT||RETROSPECTIVE|||||||
33842096|NCT05330676|||COHORT||PROSPECTIVE|||||||
33842097|NCT03193775|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|"Group I: inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~-A control group (n=100) did not receive HBV vaccine"||||
33842098|NCT05059678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945207|NCT04505007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will be coded with a unique identifier.|randomized 1:1 to either arm|f|t|f|t
33945208|NCT01593566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945209|NCT05471401|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33945210|NCT05352958|||COHORT||PROSPECTIVE|||||||
33945211|NCT04027127|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Patient group; Those diagnosed with ACS over 18 years of age, planned angiography and accepted angiography. The control group consisted of volunteers without disease.|PATIENT AND CONTROL GROUP will be divided into two.|t|f|f|f
33945212|NCT01272349|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33945213|NCT03684902|NA|SINGLE_GROUP||SCREENING||NONE||||||
33945214|NCT00643006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739603|NCT02124590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739604|NCT03120091|||OTHER||PROSPECTIVE|||||||
33739605|NCT01429896|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33739606|NCT06626087|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Both radiologists will be blinded to the clinical characteristics and subsequent management of participants, with any discordance in assessment resolved by consensus before reaching a final decision.|Scanned images are randomized individually 1:1 to either the prototype AI algorithm or LI-RADS criteria interpretation by two specialist gastrointestinal radiologists|f|f|t|f
33739607|NCT06531616|||CASE_ONLY||PROSPECTIVE|||||||
33739608|NCT04382118|||COHORT||RETROSPECTIVE|||||||
33739609|NCT03960242|||COHORT||PROSPECTIVE|||||||
33739610|NCT02736162|||COHORT||RETROSPECTIVE|||||||
33739611|NCT05539950|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842099|NCT02700854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739612|NCT01458171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842100|NCT04995770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Transplant coordinators were masked from intervention assignment|Randomized controlled trial|f|t|f|f
33842101|NCT04821557|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Supplement and placebo powders will be provided to the clinic in blindly coded containers. The code was generated by parties not responsible for data collection, analysis, or interpretation.||t|f|t|t
33739613|NCT04472351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739614|NCT01326520|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33739615|NCT03054909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739616|NCT04401124|||COHORT||RETROSPECTIVE|||||||
33842102|NCT00789360|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33739617|NCT05751135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||3 parallel group mixed methods|t|f|t|t
33739618|NCT03492307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842103|NCT04860362|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739619|NCT06531668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33739620|NCT02403310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739621|NCT02027506|||CASE_CROSSOVER||PROSPECTIVE|||||||
33739622|NCT02082301|||COHORT||PROSPECTIVE|||||||
33739623|NCT01478789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33739624|NCT04934670|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized at a ratio of 1:1 between the treatment arms||||
33739625|NCT04731129|||CASE_ONLY||PROSPECTIVE|||||||
33739626|NCT01034917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739627|NCT01747759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739628|NCT02247934|||||CROSS_SECTIONAL|||||||
33739629|NCT00503841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739630|NCT03634761|RANDOMIZED|PARALLEL||OTHER||NONE|In total, 17 preschools, 17 children (one from each preschool), and 35 preschool staff (two from each preschool except from one preschool where three preschool staff participated) participated in the study. None of the participants were blind to their assigned condition.|The study used a staggered design where three waves of preschools were recruited and assigned to either the experimental or the control group. The first wave of preschools (n = 6) were divided into two groups, where group assignment was made to make the two groups comparable in regards to three variables: supervisors' experience of comprehensive programs, APERS-P-SE baseline scores, and children's adaptive behavior (Vineland II ratings). Originally, the plan was to then randomize which of these two matched groups would be the experimental group, but because of unforeseen circumstances one of the groups was made the control group because there was a lack of resources for one of the preschools to be able to be in the experimental group. However, for the following two waves of recruitment, the participating preschools (n = 11) were divided into matched pairs (based only on supervisor experience), which were then randomly assigned either as the control or the experimental group.||||
33739631|NCT01881451|||CASE_ONLY||PROSPECTIVE|||||||
33739632|NCT00204191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842104|NCT06349356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||MULTI-CENTER, PROSPECTIVE, RANDOMIZED, SHAM-CONTROLLED, SUPERIORITY, NON-SIGNIFICANT RISK|t|t|t|t
33842105|NCT03778268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The procedure is listed as follows:~1. Recruiting early stage cervical cancer patients undergoing extra-fascial/sub-extensive/extensive hysterectomy, pelvic with or without aortic lymph node resection from July 2018 to June 2020.~2. Selecting the Standard-compliant patients according to the inclusion and exclusion criteria.~3. Numbering the above patients and collecting their clinical data.~4. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~5. Identifying and removing sentinel lymph nodes.~6. Completing the total hysterectomy, biadnexectomy and pelvic with or without para-aortic lymphadenectomy.~7. Staining all nodes using hematoxylin-eosin staining.~8. Calculating the sensitivity, negative predictive value, etc."||||
33842106|NCT02698943|||COHORT||PROSPECTIVE|||||||
33842107|NCT00896727|||OTHER||RETROSPECTIVE|||||||
33842108|NCT02451176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842109|NCT00352326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842110|NCT00095953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945215|NCT01370499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945216|NCT05829434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are either treated with CPX-351 or 7+3||||
33945217|NCT05714176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945218|NCT00623753|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945219|NCT00456586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945220|NCT05901506|NA|SINGLE_GROUP||OTHER||NONE||||||
33945221|NCT05263973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Outcomes Assessor)|Music|t|f|f|t
33842111|NCT06486792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be evaluated blindly by the members of the critical event committee. They will receive medical files without the patient's name, surname, phone number, or address.|Randomized controlled trial, open-labelled, of two standard of care therapeutic strategies: therapeutic anticoagulation (choice of the investigator, VKA with target INR 2-3, or apixaban, rivaroxaban or dabigatran) vs aspirin 75-300 mg/day|f|f|f|t
33842112|NCT04137328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33842113|NCT04519866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33842114|NCT00659555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842115|NCT00632489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842116|NCT06728046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to differences in clinical management between the groups, investigators, participants, and clinical staff will be aware of group assignments. However, follow-up researchers and statisticians responsible for data analysis will remain blinded to the group assignments.||f|f|f|t
33842117|NCT06724887|NA|SINGLE_GROUP||OTHER||NONE||||||
33842118|NCT05419011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33842119|NCT06580912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842120|NCT06487104|RANDOMIZED|PARALLEL||OTHER||NONE||Single-center, two-armed randomized controlled trial with a subsequent feasibility phase, transitioning control-group patients to investigational device arm||||
33842121|NCT03030859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842122|NCT00004940||||TREATMENT||||||||
33842123|NCT05930743|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33842124|NCT05208047|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-part study: Part 1a is a single-arm design, Part 1b is a two-arm parallel design drug-drug interaction evaluation in the first treatment cycle and single-arm design in subsequent treatment cycles, and Part 2 is a randomized two-arm parallel comparator study. The DDI substudy is a single-arm, fixed-sequence, crossover design to investigate the potential for CGT9486 to be a CYP3A4 inducer.||||
33842125|NCT05594797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842126|NCT05653102|||COHORT||PROSPECTIVE|||||||
33842127|NCT00644670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842128|NCT02371590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842129|NCT05617729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842130|NCT04654637|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Arm A: fix model of cycle exercise(online supervise) and routine nutrition consult Arm B: fix model of cycle exercise(online supervise) and online nutrition consult Arm C: individualize cycle exercise(online supervise) and routine nutrition consult Arm D: individualize cycle exercise(online supervise) and online nutrition consult|f|f|f|t
33842131|NCT04230122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33842132|NCT06633003|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||Placebo-controlled crossover design.|t|f|t|f
33842133|NCT00086255||PARALLEL||TREATMENT||DOUBLE||||||
33842134|NCT02360267|||FAMILY_BASED||OTHER|||||||
33842135|NCT06031103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842136|NCT02758847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842137|NCT04801732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will randomly assigned into two groups without being informed whether they are in the control or the study(experimental) group.|Randomized controlled study design were the recruited patients will randomly allocated into two groups control group and study group by Closed Envelope method of randomization. The treatment for all patients in both groups will conducted 3 times per week for one month .The study group (A): will receive SNAGS techniques on thoracic spine with traditional treatment consist of ice application, supervised exercises (stretching and strengthening exercise) and the study group(B) will receive only traditional treatment (ice or application and supervised exercise). All patients will be diagnosed as stage II according to Neer's classification recruited from orthopedic clinic from both sexes who met all the inclusion criteria and will be informed about the study procedure and signed the informed consent prepared for this study.|t|f|f|f
33842138|NCT02602262|||COHORT||PROSPECTIVE|||||||
33842139|NCT05010343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842140|NCT02103517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842141|NCT04910451|||OTHER||RETROSPECTIVE|||||||
33842142|NCT04446806|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33842143|NCT04085484|||OTHER||RETROSPECTIVE|||||||
33842144|NCT04668040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842145|NCT00453167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842146|NCT05378477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33842147|NCT01525238|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842148|NCT05785403|||OTHER||OTHER|||||||
33842149|NCT04682938|||COHORT||PROSPECTIVE|||||||
33842150|NCT05802316|||COHORT||RETROSPECTIVE|||||||
33842151|NCT05849012|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 subjects will be randomized to receive either a low sulfur diet or usual diet.||||
33842152|NCT00440752|||COHORT||PROSPECTIVE|||||||
33842153|NCT02597244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842154|NCT02865668|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33842155|NCT03221829|||OTHER||RETROSPECTIVE|||||||
33842156|NCT02233959|||COHORT||PROSPECTIVE|||||||
33945222|NCT04116905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945223|NCT03081494|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1b study, dose escalation (N=\~12). One single arm: PDR001 in combination with regorafenib||||
33842157|NCT01941173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842158|NCT00576563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977912|NCT04638166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739633|NCT02259608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739634|NCT04736784|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33739635|NCT00393445|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33842159|NCT04770727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842160|NCT04039373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33842161|NCT04081870|||COHORT||PROSPECTIVE|||||||
33842162|NCT03795753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842163|NCT01971801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842164|NCT01585077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33842165|NCT06108518|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The blindness will be maintained by the similarity between the placebo and carvedilol tablets. The patients will be randomized by a neutral researcher using sealed envelope method with assigned code into two groups|randomized, double blind placebo controlled parallel study|t|f|t|f
33842166|NCT04265352|||COHORT||RETROSPECTIVE|||||||
33842167|NCT06618014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842168|NCT05380557|||COHORT||PROSPECTIVE|||||||
33842169|NCT02745353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842170|NCT03046121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33842171|NCT05905627|||OTHER||PROSPECTIVE|||||||
33842172|NCT01965353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842173|NCT06530641|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Once the patient is included in the study, they will be assigned an identification number and a treatment group.~* Group 1: Patients who will be administered Buckberg blood cardioplegia.~* Group 2: Patients who will be administered Custodiol crystalloid cardioplegia. A 1:1 randomization will be carried out by blocks and stratified by weight of the intervention according to the EuroSCORE II:~  * Weight 1: Any major cardiac procedure (40% of the sample).~ * Weight 2: Two major cardiac procedures (40% of the sample).~ * Weight 3: Three or more major cardiac procedures (20% of the sample)."|f|f|t|f
33842174|NCT01343862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842175|NCT02728739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842176|NCT05197998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842177|NCT02535936|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842178|NCT00724165|RANDOMIZED|PARALLEL||||NONE||||||
33739636|NCT03136068|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33842179|NCT03065075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842180|NCT01453127|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977913|NCT04267666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were assigned randomly used sealed envelope into two groups (A\&B) equally in number.|inspiratory muscle training in the form of: Inspiratory threshold muscle trainer in addition to traditional chest physical therapy intervention (Deep breath, cough training)|f|f|f|t
33977914|NCT00066131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33739637|NCT04296617|||CASE_ONLY||PROSPECTIVE|||||||
33739638|NCT03529630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739639|NCT02319239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739640|NCT00650949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739641|NCT02805842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739642|NCT04280211|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842181|NCT03799159|||CASE_ONLY||PROSPECTIVE|||||||
33842182|NCT06150859|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842183|NCT01374568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33842184|NCT04460339|||COHORT||PROSPECTIVE|||||||
33842185|NCT05956275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842186|NCT01565278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739643|NCT04575779|||COHORT||PROSPECTIVE|||||||
33842187|NCT04663412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842188|NCT00324558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842189|NCT01172470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842190|NCT00854893|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33842191|NCT04704583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized wait-list control group design|f|f|f|t
33842192|NCT00242905|||COHORT||PROSPECTIVE|||||||
33977915|NCT01246375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739644|NCT04788992|RANDOMIZED|PARALLEL||OTHER||DOUBLE||two-group cluster randomised controlled trial|t|f|f|t
33739645|NCT02560129|||COHORT||PROSPECTIVE|||||||
33842193|NCT00450541|||CASE_ONLY||PROSPECTIVE|||||||
33842194|NCT00052000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842195|NCT03647904|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes assessor will not know if individual were in the treatment group or waitlist control group|Wait list control|f|f|f|t
33842196|NCT03311464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842197|NCT02305602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842198|NCT03877497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842199|NCT05113745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Open-label treatment period, followed by a double-blind treatment period.|t|f|t|f
33842200|NCT00002324||||TREATMENT||DOUBLE||||||
33842201|NCT05681780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842202|NCT04455620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842203|NCT00556465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842204|NCT04933214|||COHORT||RETROSPECTIVE|||||||
33842205|NCT01182441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842206|NCT06627517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842207|NCT02318459|RANDOMIZED|PARALLEL||||NONE||||||
33842208|NCT02501512|||CASE_ONLY||PROSPECTIVE|||||||
33842209|NCT06729879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33842210|NCT03132831|||COHORT||RETROSPECTIVE|||||||
33842211|NCT06008093|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IIIb 2-arm, parallel randomized open label multicenter study||||
33842212|NCT05686798|NA|SEQUENTIAL||TREATMENT||NONE||||||
33842213|NCT03610711|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33842214|NCT04469049|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the MBCT intervention, however they will be separated in several distinct groups over time, due to MBCT protocol limitations.||||
33842215|NCT00565773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842216|NCT05096481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842217|NCT04022512|||CASE_ONLY||RETROSPECTIVE|||||||
33977916|NCT02369042|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34050358|NCT05201963|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||The patients will be randomly assigned into 3 equal groups using computer generated random numbers in opaque closed envelopes, each of which will include 40 patients. Group 1 control group N=40, Group 2 ((Serratus Anterior Plane Block SAPB)) N=40 Patients will receive Ultrasound guided Serratus Anterior Plane Block with injection of 30 ml levobupivacaine 0.25% and Group 3 ((Erector Spinae Plane Block ESB)) N=40 Patients will receive Ultrasound guided erector spinae plane block with injection of 30 ml levobupivacaine 0.25%. Randomization will be done by a statistician and each group of the patient will be revealed only when the included patient is transferred to the preanesthetic room.|t|t|t|t
34050359|NCT06665633|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study - to study the effect of 40 treatments of hyperbaric oxygen therapy using 100% oxygen and increased atmospheric pressure of 1.5 atmospheres for 60 minutes on chronic mild traumatic brain injury with a wait time of at least 6 months or more after the traumatic brain injury occurred in the U.S. Veterans.||||
34050360|NCT04959201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050361|NCT05048108|||COHORT||CROSS_SECTIONAL|||||||
34050362|NCT01253551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050363|NCT05896150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|Intervention : intercostal cryoanalgesia + single-injection paravertebral block Control group : single-injection paravertebral block|t|t|t|t
34050364|NCT03384836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050365|NCT01851382|||CASE_ONLY||PROSPECTIVE|||||||
34050366|NCT06685328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050367|NCT06666582|||CASE_ONLY||RETROSPECTIVE|||||||
34050368|NCT06668545|||CASE_CONTROL||PROSPECTIVE|||||||
34050369|NCT05144308|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center prospective cohort study||||
34050370|NCT05483998|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Open to Sponsor||t|f|t|f
34050371|NCT05034861|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34050372|NCT01877967|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34050373|NCT06667661|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized control trial with a waitlist control design.|f|f|t|f
34050374|NCT05944783|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|randomized|Dasatinib bioequivalence study in fed condition|f|f|t|t
34050375|NCT00972556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050376|NCT03745976|||COHORT||PROSPECTIVE|||||||
34050377|NCT05427487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 open-label, non-randomized, multi-center clinical trial. The study is run in 2 parts. Part 1a is dose escalation of IVX037 monotherapy. Part 1b is IVX037 with checkpoint inhibitor, sintilimab.||||
34050378|NCT06170658|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34050379|NCT00511082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050380|NCT04735692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and clinicians were blinded to group and treatment assignment|Patients undergo non-surgical quadrant scaling and root planing|t|f|t|f
34050381|NCT04580693|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050382|NCT05491200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050383|NCT04965155|NA|SINGLE_GROUP||TREATMENT||NONE||Isatuximab-dexamethasone pre and post transplant||||
34050384|NCT04884360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842218|NCT02136134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842219|NCT03385590|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Subjects will be blinded, on-site investigator will not be blinded due to the difficulty with blinding the foods. The off-site PI and outcome assessors will be blinded.|Children 6-36 months will be fed soy-fiber-maize or soy-maize complementary foods for 6 months.|t|f|f|t
33842220|NCT04177043|NA|SINGLE_GROUP||SCREENING||NONE||||||
33842221|NCT06729372|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33842222|NCT06451640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050385|NCT00343226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050386|NCT03421145|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The Principal Investigator and clinical examiners will be blinded to the treatment products. No clinical examiners will see the allocated rinse assigned per the randomization schedule.|prospective, randomized, blinded, clinical study to evaluate an oral rinse on plaque and gingivitis|t|t|t|t
34050387|NCT06277960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050388|NCT06523231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This phase 2 trial is a single center, randomized, controlled, double-blind. Safety and immunogenicity of the vaccine will be evaluated in infants. Subjects will be vaccinated concurrently, with each group randomized to receive 1 of 2 different vaccine doses, or a control vaccine. Participants will be randomized at a ratio of 8:3, to receive the candidate vaccine (low dose : high dose 4:4) or the control vaccine.|t|f|t|f
34050389|NCT05449496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050390|NCT05804019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two arms (Nutritional and Physical Activity Intervention Group and Usual Care Group). Approximately 100 participants will be included and cluster randomized by the nursing home to either 6 months of nutritional and physical interventions or 6 months of usual care (control).||||
33739646|NCT02341196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739647|NCT06572904|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739648|NCT00642304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842223|NCT04498637|||OTHER||PROSPECTIVE|||||||
33842224|NCT04955249|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel Assignment|t|t|t|t
33842225|NCT05434702|||CASE_ONLY||PROSPECTIVE|||||||
33842226|NCT04848389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842227|NCT05578274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842228|NCT01951352|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33842229|NCT02244970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842230|NCT02858453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842231|NCT00254826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33842232|NCT00577967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33842233|NCT05781191|||COHORT||OTHER|||||||
33842234|NCT02293577|||COHORT||PROSPECTIVE|||||||
33842235|NCT04199624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842236|NCT04701346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050391|NCT04152772|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"Individuals deemed eligible for the study will be randomized to 1) receiving active tDCS during extinction learning; sham during extinction consolidation, 2) receiving sham during extinction learning; active tDCS during extinction consolidation, 3) receiving sham during extinction learning; sham during extinction consolidation. (Anticipated enrollment: 90 participants)~SUB-STUDY: Individuals deemed eligible will all complete the same experimental tasks and questionnaires. (Anticipated enrollment: 500 participants)"|t|f|t|t
34050392|NCT00569673||||TREATMENT||NONE||||||
34050393|NCT04015921|||COHORT||CROSS_SECTIONAL|||||||
34050394|NCT06683651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050395|NCT03304665|||COHORT||CROSS_SECTIONAL|||||||
34050396|NCT06684028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050397|NCT02433821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050398|NCT04878484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"open-label, multi-site, 3+3 dose escalation study"||||
34050399|NCT01319474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050400|NCT05584540|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34050401|NCT03636204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842237|NCT03293459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050402|NCT05311839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050403|NCT06683716|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective randomised non-inferiority trial comparing two training conditions in gastrointestinal endoscopy (ERCP)||||
34050404|NCT03365635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||An interventional, prospective, non-randomized, non-blinded trial to evaluate real world strategies to identify and treat hepatitis C infected hemodialysis patients with Zepatier||||
34050405|NCT06585254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A computer-generated randomization list will be used to assign subjects into Treatment A or Treatment B. Study team members doing outcome assessments will be blinded to treatment allocation.|Randomized 6-week trial of two stimulus parameters in improving the health of PASC patients with CFS. Based on participation, then an additional 6 weeks using the device that had the best outcome in improving the health of PASC patients with CFS.|t|f|f|t
34050406|NCT03200730|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization will be conducted by an independent statistician. Treatment allocation (Family-oriented Dignity Intervention or Control) will be performed by block randomization with a fixed block size of two; each block will comprise of two patients with comparable terminal illness, along with their family caregiver, to reduce potential confounding effects of different illness types. Allocation concealment is facilitated by using sequentially number opaque sealed envelopes for consecutive and eligible families. To reduce the risk of bias, the researcher opens the next envelope to ascertain which group the family has been allocated to after baseline measures have been collected.||||
34050407|NCT03126162|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomly assigned to one of two groups - A) bladder backfilled group or B) control group. This is a blinded study and the participant will not know which group they were assigned to.|A randomized, controlled trial evaluating 2 techniques of postoperative bladder testing for patients undergoing same-day total laparoscopic hysterectomy|t|f|f|f
34050408|NCT06668766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a single center, prospective, 2-arm, nonblinded, randomized clinical trial to determine if midline catheters (10 cm) are superior to the long peripheral intravenous catheterss (4.78-cm) may with respect to dwell time, dislodgement and infiltration rates, and patient preference.||||
34050409|NCT05511467|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050410|NCT06424171|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050411|NCT02339480|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050412|NCT00697125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34050413|NCT06666192|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34050414|NCT06666621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, within-subject||||
34050415|NCT05349981|NA|SINGLE_GROUP||OTHER||NONE||Self-controlled repeated measures study design with a single cohort, intended to mimic clinical use case.||||
34050416|NCT05875779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050417|NCT03815799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34050418|NCT00719238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050419|NCT04783441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We propose a single-center, prospective, randomized study comprising 2 study arms. They will be randomized in a stratified fashion. Stratification will be according to whether or not they are on prednisone and their estimated glomerular filtration rate. This is to ensure that both arms are populated by equal numbers of patients with prednisone and with worse renal function||||
33977917|NCT03231956|||CASE_CONTROL||PROSPECTIVE|||||||
34050420|NCT06668701|||OTHER||CROSS_SECTIONAL|||||||
34050421|NCT06667570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050422|NCT01413750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977918|NCT00060866||||TREATMENT||||||||
34050423|NCT01407731|||CASE_ONLY||RETROSPECTIVE|||||||
34050424|NCT03977753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind study||t|f|t|t
34050425|NCT03396315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label study in which they would choose whether to take oral alendronate 70 mg weekly for 12 months or a single intravenous dose of zoledronic acid 5 mg.||||
34050426|NCT06665529|||CASE_ONLY||PROSPECTIVE|||||||
34050427|NCT01004640|||CASE_ONLY||PROSPECTIVE|||||||
33842238|NCT04974333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842239|NCT02585323|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33842240|NCT03917056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842241|NCT00041444|||COHORT||PROSPECTIVE|||||||
33842242|NCT02387190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33842243|NCT03698253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842244|NCT04909398|NA|SINGLE_GROUP||OTHER||NONE||||||
33842245|NCT06727669|||COHORT||PROSPECTIVE|||||||
33977919|NCT04396028|||COHORT||RETROSPECTIVE|||||||
33977920|NCT03002649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977921|NCT02779036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977922|NCT01015430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842246|NCT05189223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In Phase 3, assessment sessions will be conducted by an independent assessor who is blind to study assignment.|Participants in Phase 2 will all receive the treatment. Participants in Phase 3 will be randomly assigned to the 4-session study treatment or treatment as usual.|f|f|f|t
33842247|NCT02394626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842248|NCT05141500|NA|SINGLE_GROUP||OTHER||NONE||Participants will be in a reclined position for the study. Reference sensors will be placed on each participant to evaluate the SpO2 accuracy and performance. Sensors may be placed on non-adjacent fingers to prevent optical crosstalk. Simultaneous data collection will be set up for devices under test. The data from the test devices will be collected by the sponsor or trained UCSF staff. Data will be collected for 1-2 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.||||
33842249|NCT04004156|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label study. Patients that are unable to receive an implant due to intraoperative exclusion will receive standard of care||||
33842250|NCT04659564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842251|NCT05133973|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842252|NCT04449796|||COHORT||PROSPECTIVE|||||||
33842253|NCT06518083|||OTHER||PROSPECTIVE|||||||
33842254|NCT04161729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842255|NCT04723238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33842256|NCT02949362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842257|NCT01325753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842258|NCT04441177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre-intervention, post-intervention, and 3-month follow-up HRQOL will be assessed by the Stroke Impact Scale (SIS) 3.0. Motricity Index (MI) and Fugl-Meyer Assessment (FMA), Functional Independence Measure (FIM), and arm movement ratio (AMR) will also be checked before intervention, after intervention, and at 3-month follow-up. One blinded occupational therapist will evaluate the outcomes.|All participants are randomly allocated to study group and control group. Each participant's main study period is set as 16 days with additional follow-up time at post-intervention 3 months. Participants in the control group receive conventional rehabilitation therapy over 50 minutes on weekdays. Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.|f|f|f|t
33842259|NCT01892540|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842260|NCT04969068|NA|SEQUENTIAL||OTHER||NONE||||||
33842261|NCT00326053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33842262|NCT02290808|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33842263|NCT00531219|||COHORT||PROSPECTIVE|||||||
33842264|NCT00831662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842265|NCT02175641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842266|NCT05111353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842267|NCT00547612|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33842268|NCT00575653|||COHORT||RETROSPECTIVE|||||||
33842269|NCT01696903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842270|NCT04185896|||OTHER||OTHER|||||||
33945224|NCT06384872|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be stratified according to their sex. Two pre-established randomization list will be prepared by a statistician not involved in any other part of the study before the beginning of the study. To ensure allocation concealment, the study groups as well as the shoes will be coded and the randomization lists will be uploaded in the electronic system by an IT specialist who will not be involved in any other part of the study. The electronic system will provide the investigator with a study group code for each participant, according to the randomization lists. The investigator will upload the shoe ID according to shoe size and study group so that a cross validation will be performed by the electronic system. The investigators in charge of the recruitment, follow-up and data validity check, as well as the participants, will be blinded regarding the shoe version distributed. The shoe code will be broken after completion of data analysis.||t|t|t|t
33945225|NCT04162873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842271|NCT01612598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945226|NCT01594164|NA|SINGLE_GROUP||||NONE||||||
33977923|NCT05012345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Data from the demographic data collection and the outcome parameters will be cleaned blindly from the treatment data.|A prospective single-blinded randomised clinical trial|t|f|t|t
33842272|NCT02186600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized to 3 treatment groups: Calcium + vitamin D only; risedronate and calcium + vitamin D; bone building exercises and calcium + vitamin D||||
33842273|NCT06125145|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33842274|NCT02936726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842275|NCT03301441|||COHORT||PROSPECTIVE|||||||
33842276|NCT01298557|||CASE_CONTROL||PROSPECTIVE|||||||
34050428|NCT06234462|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34050429|NCT04373811|||COHORT||PROSPECTIVE|||||||
34050430|NCT02464774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842277|NCT04618237|||OTHER||OTHER|||||||
33842278|NCT02562443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842279|NCT03266926|||COHORT||PROSPECTIVE|||||||
33842280|NCT00678431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842281|NCT03460808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842282|NCT05102877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Randomized trial|t|t|t|t
33842283|NCT02906436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842284|NCT05277168|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-A1904 in Subjects with Advanced Solid tumors||||
33842285|NCT05049577|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|All study drugs were administered using a Minto pharmacokinetic model in a TCI device (Orchestra, Fresenius-Vial, France). The infusion pump was covered to blind the patients, investigator, and outcomes assessor|Prospective randomized and controlled study|t|f|t|t
33842286|NCT03453853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842287|NCT00130325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842288|NCT04218032|||OTHER||OTHER|||||||
33842289|NCT06176976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945227|NCT05945173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two blinded, experienced, and calibrated dentists (who specialized in esthetic dentistry with more than 15 years of clinical practice), will perform the clinical evaluation. Patients will be also blinded to group assignment. An inter-examiner and inter-examiner agreement of at least 85% will be necessary before beginning the evaluation|This is a four-arm, double-blind, randomized controlled clinical trial. Experimental group 1: 35 non-carious cervical lesions (NCCL) using an alcohol- and water-based solvent universal adhesive with evaporation of solvent for 25 seconds. Experimental group 2: 35 NCCL using an acetone-based universal solvent adhesive with solvent evaporation for 25 seconds. Control group 1: 35 NCCL using an alcohol- and water-based universal solvent adhesive with evaporation of solvent for 5 seconds. Control group 2: 35 NCCL using an acetone-based universal solvent adhesive with solvent evaporation for 5 seconds. LCNCs will be randomized to universal adhesive usage and evaporation time.|t|f|t|t
33842290|NCT00972660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945228|NCT02411032|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34050431|NCT03921840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945229|NCT04504682|NA|SINGLE_GROUP||TREATMENT||NONE|The person completing analysis will be blinded to the treatment group.|||||
33842291|NCT00522821|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33945230|NCT00086060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945231|NCT03339440|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The investigators will use a two-arm, randomized crossover controlled trial to compare routine primary care management of childhood obesity versus a novel clinic/family/community partnership program to treat childhood obesity. This design will allow for a randomized comparison of Group 1 (6-month standard control) to Group 2 (immediate 6-month intervention program) and to Group 3 (delayed crossover intervention on the standard control group). The design will also allow the investigators to observe intervention effects at 3 months in both intervention groups (Groups 2 and 3), and to track Group 2 for 6 additional months after active intervention to assess whether health benefits seen at 6 months were sustained to 12 months.||||
33945232|NCT04902547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized to either Multidisciplinary Tapering Program Only or Patient Education Workshops PLUS Multidisciplinary Tapering Program||||
33842292|NCT04588805|||COHORT||PROSPECTIVE|||||||
33945233|NCT02103400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842293|NCT03041805|||COHORT||PROSPECTIVE|||||||
33945234|NCT01408953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842294|NCT02248818|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945235|NCT06329245|||COHORT||PROSPECTIVE|||||||
33842295|NCT02225119|||CASE_CONTROL||PROSPECTIVE|||||||
33842296|NCT03098563|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Within-subjects design. Two pills will be administered at each study visit. Participants and study staff will be blind to the drug(s) administered.|This study will include 4 sessions. Participants will be randomly assigned to the order in which they receive one drug (or combination of drugs) per session at each study visit.|t|f|t|t
33842297|NCT01942200|||OTHER||PROSPECTIVE|||||||
33842298|NCT01281839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842299|NCT00369876|||DEFINED_POPULATION||OTHER|||||||
33945236|NCT00451776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945237|NCT03029572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945238|NCT02211287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33842300|NCT02523703|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945239|NCT04246359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050432|NCT02950766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945240|NCT05564962|||COHORT||PROSPECTIVE|||||||
33945241|NCT03485976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945242|NCT03319602|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Assessor blind|Comparison of level oxygenation between classical oxygenation with nasal canulae with or without adjunctive of a double trunk mask|f|f|f|t
33842301|NCT01982305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842302|NCT05826873|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Mixed methods implementation science study with a multicenter, quasi-experimental interrupted time-series design.||||
33842303|NCT04790656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842304|NCT00449618|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33842305|NCT00318539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34050433|NCT03299075|||COHORT||PROSPECTIVE|||||||
34050434|NCT06547008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34050435|NCT03346681|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients meeting inclusion criteria will be randomly assigned to the treatment or control group||||
33842306|NCT00835653|||COHORT||PROSPECTIVE|||||||
33945243|NCT04920331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945244|NCT03788109|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945245|NCT03087682|||CASE_ONLY||RETROSPECTIVE|||||||
33842307|NCT02193126|RANDOMIZED|PARALLEL||OTHER||||||||
33842308|NCT04517097|||COHORT||PROSPECTIVE|||||||
33945246|NCT02030067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842309|NCT02783027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34050436|NCT02206581|||CASE_ONLY||CROSS_SECTIONAL|||||||
34050437|NCT03764826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050438|NCT06447597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842310|NCT03843853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842311|NCT01305239|||COHORT||PROSPECTIVE|||||||
33842312|NCT00324116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050439|NCT03990194|||COHORT||PROSPECTIVE|||||||
34050440|NCT06682546|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34050441|NCT06665854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||After reaching the sample number of pregnant women for this study, pregnant women will be assigned to groups as group 1, group 2, and control group by block randomization method. This method will be used to eliminate selection bias and ensure balance between groups in terms of individuals. Random numbers table will be used in the selection of pregnant women.|t|f|f|f
34050442|NCT03644485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050443|NCT00270270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34050444|NCT06667271|||CASE_CONTROL||PROSPECTIVE|||||||
34050445|NCT02797457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050446|NCT00167726|||CASE_ONLY||PROSPECTIVE|||||||
33842313|NCT05179070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, Care Provider and Investigator didn't know about dose of carvedilol and grouping of the patient.|Devided into 2 groups. The first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks|t|t|t|f
33842314|NCT04393870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33945247|NCT05813769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33842315|NCT06395025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||one group versus a control group|t|f|f|f
33842316|NCT01834872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842317|NCT00582413|||CASE_CROSSOVER||PROSPECTIVE|||||||
33977924|NCT05501691|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|The allocation will be hidden from patients, and they will not know which teeth are lased and which will receive the placebo treatment. In addition, for blinding, the restoration procedure is performed by one person, and the cold test is performed by another person who is unaware of the distribution. Furthermore, the statistician will be blinded.|In this randomized controlled clinical trial, patients with NCCLs will be included (four teeth in each participant). The teeth will be randomly assigned into four groups according to diode laser irradiation wavelength Group 1 (placebo) laser simulation, Group 2 (445 nm) diode laser wavelength, Group 3 (660 nm) diode laser wavelength, and Group 4 (970 nm) diode laser wavelength.|t|f|t|t
33842318|NCT04906629|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842319|NCT03298477|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System. Sites have been chosen with a suitable research infrastructure and physician experience in endovascular aneurysm repair to ensure adequate enrollment. Subjects will be followed procedurally to discharge, at 30 days (primary safety endpoint), six months, one year (primary effectiveness endpoint) and annually thereafter to five years (total follow-up commitment).||||
33842320|NCT00527358|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977925|NCT06545149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33842321|NCT00853944|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33977926|NCT01226069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842322|NCT02509832|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842323|NCT05444608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A sponge soaked in saline was placed next to the babies listening to white noise, and a non-working loudspeaker was placed on the toe of the babies who smelled breast milk. The assessment was made by academics other than the researcher by muting the video recordings. The babies were considered blind because they did not know which group they were in.|This randomized controlled experimental study will performing to investigate the effect of smelling breast milk and listening to white noise in reducing pain during heel puncture|t|f|f|t
33842324|NCT02119442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842325|NCT04376151|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The intervention is a guided self-help Acceptance and Commitment Therapy (ACT) bibliotherapy, written by Steven Hayes called 'Get Out of your Mind and Into Your Life'. This book has been split into eight sections, participants will be asked to read one section each week. Each week each participant will speak with the researcher to ask any questions and review the weeks material via a guided telephone call. All telephone calls will follow a pre-determined list of questions to increase standardisation and recorded for fidelity checks.||||
33842326|NCT03921723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is non-randomized 6 period, 6 way fixed sequential design.||||
33842327|NCT04352998|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33842328|NCT03719417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842329|NCT00951015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977927|NCT02521441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842330|NCT02995759|||COHORT||PROSPECTIVE|||||||
33842331|NCT05265273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842332|NCT02304692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842333|NCT04834544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842334|NCT03430947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842335|NCT02971761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842336|NCT04927247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study||t|t|t|t
33842337|NCT04073992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842338|NCT05981742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977928|NCT05412407|NA|SINGLE_GROUP||OTHER||NONE||||||
33977929|NCT03010748|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33977930|NCT06028009|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33977931|NCT00110968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977932|NCT05865197|||COHORT||PROSPECTIVE|||||||
33977933|NCT03818945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050447|NCT04004455|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842339|NCT00208052|||DEFINED_POPULATION||PROSPECTIVE|||||||
33842340|NCT02823197|NON_RANDOMIZED|PARALLEL||||NONE||||||
33842341|NCT02724852|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842342|NCT05084859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33842343|NCT01399697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842344|NCT01516619|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33842345|NCT04940338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The drug pipettes will be covered with tape by hospital pharmacy and put into marked envelopes. The blinding will be uncovered after analyzing the data.||t|f|t|f
33842346|NCT03660644|RANDOMIZED|PARALLEL||OTHER||SINGLE|Physiotherapists will be aware of the allocation of the programmes (not possible to blind) as they will be involved with delivering information/training of the intervention components. However, a researcher blinded to group allocation will perform the quantitative analysis.||f|f|f|t
33842347|NCT00127205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739649|NCT01642394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Intervention group The complete intervention consists of group sessions (8 to 15 people) lasting 2.5 hours, once a week for six weeks. These sessions are structured with the aim of enabling participants to acquire knowledge and skills related to the disease and its management, placing a strong emphasis on proactive tools to achieve healthier lifestyles (in terms of diet, physical exercise, management of emotions, and correct use of medication, among others).~Control group Patients assigned to the control group will receive usual care for secondary prevention of DM2 in accordance with the Osakidetza primary care protocols, which are based on clinical practice guidelines."||||
33842348|NCT02758275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33842349|NCT04374214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33842350|NCT02001064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33842351|NCT01660386|RANDOMIZED|CROSSOVER||||NONE||||||
33842352|NCT05082753|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33842353|NCT06687655|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The investigators will examine the preliminary efficacy of ingesting exogenous ketones before sleep on OSA. Patients with known OSA will be asked to temporarily discontinue CPAP, a technique used in our laboratory to temporarily elicit OSA. Prior to sleep the participants will ingest Ketone-IQ (20 g to 40 g - dose to be determined by KETO-SLEEP 1 trial), or placebo. Sleep will be assessed using a home sleep test (NOX T3) and questionnaires. Glucose will be monitored using a continuous glucose monitor (CGM).|t|f|t|f
33842354|NCT01340248|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842355|NCT05044780|||COHORT||PROSPECTIVE|||||||
33842356|NCT02417077|||COHORT||RETROSPECTIVE|||||||
33842357|NCT05215028|||COHORT||CROSS_SECTIONAL|||||||
33842358|NCT06514911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842359|NCT04385862|||CASE_ONLY||PROSPECTIVE|||||||
33842360|NCT00032175|RANDOMIZED|||TREATMENT||NONE||||||
33842361|NCT02859129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842362|NCT03586791|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33842363|NCT00064740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33842364|NCT05562674|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized control trial evaluating the feasibility and acceptability of the manualized protocol the investigators develop. The investigators will compare the VVV group with a Healthy Lifestyles group."||||
33842365|NCT01709175|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33842366|NCT05578118|||COHORT||PROSPECTIVE|||||||
33842367|NCT02369068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842368|NCT03705767|||COHORT||PROSPECTIVE|||||||
33842369|NCT00043433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842370|NCT06727604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842371|NCT01527747|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33842372|NCT00821951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842373|NCT00002277||||TREATMENT||||||||
33842374|NCT05755477|||OTHER||RETROSPECTIVE|||||||
33842375|NCT01401153|RANDOMIZED|CROSSOVER||||NONE||||||
33842376|NCT04403568|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Subjects will be assigned to one of 3 cohorts, starting with cohort 1 and progressing to cohort 3||||
33842377|NCT04387500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977934|NCT01000337|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33977935|NCT01923077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842378|NCT05054803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active treatment and placebo will be released using the same syringe and blinded in a way that it is no possible to distinguish one to the other.|Double-blind, randomized, placebo-controlled, 2-arms, multicenter clinical trial|t|t|t|t
33893351|NCT03577990|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will test the effects of ITEC added to CDSMP on two study aims: 1) BP control, and 2) adherence to antihypertensive medication and lifestyle modifications. After baseline data collection, participants complete a 6-week CDSMP course and then are randomly assigned to either the treatment or control arm. All participants will continue to receive usual care for HTN.~The treatment group will receive ITEC and wireless tools to track activity, BP, weight, food intake, and self-report medication-taking after an orientation to Fitbit Plus (a cloud-based collaborative care platform designed to store and track data). All tools will be synced to the participants' smartphone. The treatment arm will receive weekly ITEC for 3 months, biweekly ITEC for 3 months, and then no ITEC for 3 months.~The control arm will receive usual care only with monthly BP measured manually for 3 months and then receive the same wireless tools with monitoring to track comparative data with the treatment arm."||||
33977936|NCT02045121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977937|NCT06136052|||CASE_ONLY||PROSPECTIVE|||||||
33977938|NCT01792882|||OTHER||PROSPECTIVE|||||||
33977939|NCT05445297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977940|NCT04026464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977941|NCT04401254|||COHORT||PROSPECTIVE|||||||
33977942|NCT01513148|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33977943|NCT05471674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977944|NCT05337709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be assigned to either intervention or the control group||||
34050448|NCT00183053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050449|NCT05261724|||COHORT||PROSPECTIVE|||||||
34050450|NCT06244212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology.||||
34050451|NCT04168827|||CASE_ONLY||PROSPECTIVE|||||||
34050452|NCT06544135|||COHORT||PROSPECTIVE|||||||
34050453|NCT02693106|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050454|NCT06682078|||COHORT||RETROSPECTIVE|||||||
34050455|NCT00417924|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34050456|NCT00526669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977945|NCT04997694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||3 Group randomized|t|f|f|f
34050457|NCT03880708|||COHORT||PROSPECTIVE|||||||
34050458|NCT02740868|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34050459|NCT06140758|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34050460|NCT05081479|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050461|NCT02987374|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050462|NCT06307470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050463|NCT06070870|NA|SINGLE_GROUP||SCREENING||NONE||||||
34050464|NCT06685224|||COHORT||PROSPECTIVE|||||||
34050465|NCT04871711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050466|NCT01713114|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33977946|NCT03020602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050467|NCT05725291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050468|NCT02211638|||COHORT||PROSPECTIVE|||||||
34050469|NCT05026437|||OTHER||PROSPECTIVE|||||||
34050470|NCT04380714|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34050471|NCT03994003|||COHORT||PROSPECTIVE|||||||
34050472|NCT01910545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050473|NCT06682130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050474|NCT04114331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050475|NCT06459050|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study was performed following a randomized, double-blind crossover design, where each participant performed two experimental sessions.|t|f|f|t
34050476|NCT00713141|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050477|NCT01003483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050478|NCT04408742|||CASE_ONLY||PROSPECTIVE|||||||
34050479|NCT06138262|NA|SINGLE_GROUP||PREVENTION||NONE||In this study there were 2 groups, namely the group that was given intervention and the group that was not given intervention / control group. The intervention group will be provided with education through a preconception nutrition education module and the leaflet, and the control group was given education using the leaflet.||||
34050480|NCT04793009|||COHORT||RETROSPECTIVE|||||||
34050481|NCT03050736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050482|NCT03745287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050483|NCT02357160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34050484|NCT01479569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050485|NCT06072209|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34050486|NCT05265923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050487|NCT00938847|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050488|NCT02726906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050489|NCT06665074|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Placebo (saline infusion)||t|f|t|t
34050490|NCT06506955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050491|NCT05698979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050492|NCT06682611|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, multi-center, multi-cohort, phase Ib/II clinical trial, divided into 8 cohorts according to tumor types. Cohorts 1-4 are SYHA1813 combined with different regimens, including safety run-in stage and cohort expansion stage. Cohorts 5-8 are SYHA1813 monotherapy and only include the expansion cohorts. In the expansion stage, cohorts 1-6 are single-arm studies, cohorts 7-8 are randomized controlled studies.||||
34050493|NCT02048098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050494|NCT06169592|||CASE_CONTROL||PROSPECTIVE|||||||
34050495|NCT03098654|RANDOMIZED|PARALLEL||TREATMENT||NONE||Once two similar HIV Care and Treatment Centers (CTCs) are matched, they will be randomized to receive either the intervention or control condition.||||
34050496|NCT01116648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050497|NCT06653465|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739650|NCT04163276|||OTHER||RETROSPECTIVE|||||||
33977947|NCT00633282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977948|NCT05014308|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33977949|NCT01743157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050498|NCT00726765|||COHORT||PROSPECTIVE|||||||
34050499|NCT06668779|||COHORT||CROSS_SECTIONAL|||||||
34050500|NCT06405828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34050501|NCT02219789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050502|NCT02640404|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050503|NCT00481598|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050504|NCT03379753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050505|NCT02627326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075730|NCT06523140|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Comparative, superior, randomised, multicentre, two-arm study (experimental group, control group, 1:1 ratio) in open-label, with a pilot phase~Control group:~Conventional follow-up: two consultations with the general practitioner and one consultation with the pulmonologist per year. The inclusion and follow-up visit at 12 months by a pulmonologist are consistent with the follow-up of COPD patients in current practice and the recommendations of SAH and SPLF.~Experimental group:~Patients will receive conventional clinical follow-up and at the same time benefit from the Bora care remote monitoring system. Patients are monitored daily remotely by Case Managers, who, when the BVS3-3 alarm is triggered on Bora Connect, call the patient to inform the patient about his symptoms, then notify the pulmonologist by transmitting the information from Bora Connect. The Case Manager re-evaluates the situation at 48h and 96h if necessary and forwards the information to the pulmonologist."||||
34075731|NCT02604030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050506|NCT06151704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both the patients and the outcome assessor are blinded to the treatment groups. Initially, the assessor measures the outcomes before the patients are included in the study. The therapist then administers the treatments for both groups, with the assessor remaining unaware of the specific treatment throughout the study. Patients are first provided with a comprehensive explanation that the study is a clinical trial consisting of two groups, and they will be randomly assigned to either the intervention group or the control group. All patients are required to wear a protective blindfold during treatment due to the laser procedure. To create authentic therapeutic conditions for the placebo group, the patient is positioned prone with a pillow under their abdomen and wears a protective blindfold. The only difference is that the laser is turned off, and an audio player simulates the sound of the laser device. Upon completion of the study, the examiner conducts the final evaluation|The present study is designed as a randomized, double-blind, controlled clinical trial, with control established through sham treatment. The variable block method, comprising four-letter blocks, will be employed for random allocation. The allocation sequence will be determined using the website Generatorslist.com|t|f|f|t
34050507|NCT01151202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050508|NCT04486053|||COHORT||CROSS_SECTIONAL|||||||
34050509|NCT01826890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050510|NCT03845582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050511|NCT06666348|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a 3-part open-label study (feasibility phase, treatment phase and follow-up phase) of orally administered mirdametinib in combination with intravenous vinblastine chemotherapy in patients with PLGG with activation of MAPK pathway.~Feasibility Phase:~The maximum tolerated/recommended phase 2 dose (MTD/RP2D) of the mirdametinib plus vinblastine combination will be assessed using a modified Rolling-6 design.~Treatment Phase:~Patients will receive mirdametinib twice daily (continuously) at a fixed dose (2mg/m2 po BID up to 4 mg BID) for a total of 13 cycles (28 days cycle). Weekly intravenous vinblastine at MTD will be given for a total of 17 cycles. If adverse events occur, two dose reductions are allowed.~Follow-up Phase:~Following the end of treatment, patients will be scheduled for a follow-up visit every 6 months for 36 months to evaluate PFS, TTP and OS."||||
34050512|NCT06569706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050513|NCT06664138|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34050514|NCT04782895|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34050515|NCT05284448|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical trial, parallel, randomized, prospective, controlled study||||
34050516|NCT06684418|||COHORT||PROSPECTIVE|||||||
34050517|NCT01214369|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34050518|NCT04655092|NA|SINGLE_GROUP||TREATMENT||NONE||Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of P1101 (ropeginterferon alfa-2b) once every 2 weeks||||
34050519|NCT03251261|||COHORT||PROSPECTIVE|||||||
34050520|NCT06194851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, quadruple masking|Eligible dyads will be randomized in a stratified 1:1 manner to the oxytocin or placebo condition.|t|t|t|t
34050521|NCT00680901|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34050522|NCT06293508|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34050523|NCT01683851|||||PROSPECTIVE|||||||
34050524|NCT00225225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050525|NCT03244540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers, and assessors were not aware of type of the block|Participants were randomized 1:1:1|t|t|f|t
34050526|NCT04675918|||COHORT||PROSPECTIVE|||||||
34050527|NCT05538975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050528|NCT06258720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050529|NCT05971511|||OTHER||RETROSPECTIVE|||||||
34050530|NCT06685692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050531|NCT04649840|||OTHER||PROSPECTIVE|||||||
34050532|NCT01082211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050533|NCT04218864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34050534|NCT06622668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050535|NCT04265430|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33842379|NCT04441853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|All personals involved the study (students, teachers, investigators and outcome assessors) had not been masked for treatment assignment.|"The convenience samples were two groups of students enrolled in a geriatric nursing course at two consecutive semesters, from the school of nursing, in a tertiary education institution in Hong Kong. Students who studying the geriatric course in the first semester were treated as intervention group, whereas students studying the same course in the second semester were assigned as control.~Students of the intervention group were invited to view a series of YouTube video, comprising five sessions, related to geriatric course content and focusing on patients' and caregivers' lived experience. Then, they were requested to participate in group discussion to stimulate their learning and understanding of patients' and caregivers' situation. Meanwhile, students of the control group were taught with the same content through the usual lecture-based method, without You Tube video."||||
33842380|NCT03085836|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842381|NCT00567203|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33842382|NCT03968380|||COHORT||CROSS_SECTIONAL|||||||
33842383|NCT05827913|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33842384|NCT02760875|||OTHER||CROSS_SECTIONAL|||||||
33842385|NCT00517400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33842386|NCT00013260|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33842387|NCT06215885|||COHORT||PROSPECTIVE|||||||
33842388|NCT02261753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842389|NCT06382675|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, single arm, multi-centric, open-label||||
33842390|NCT01012401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842391|NCT03140189|||COHORT||PROSPECTIVE|||||||
33842392|NCT00974818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050536|NCT00356902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34050537|NCT05967832|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34050538|NCT06268340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050539|NCT02282046|||COHORT||PROSPECTIVE|||||||
33842393|NCT01693900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842394|NCT03500991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842395|NCT03545477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050540|NCT05715242|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study uses a full factorial experimental design to test the impact of four intervention components, each with two levels (i.e., a 2x2x2x2).||||
34050541|NCT04982211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this study, the investigators, therapists, outcomes assessors, and research participants will be blind to study medication allocation.|This is a 2 x 2 factorial randomized controlled trial. Factor 1 is the trauma reactivation method (standard vs. mismatch trauma reactivation) and factor 2 is the study medication (propranolol vs. placebo). The design will be stratified by profession (military vs. police) and sex. After an eligibility assessment at baseline, participants meeting inclusion criteria will be randomly allocated to one of four groups with a 66.6% probability of getting enrolled in one of the two propranolol treatment groups.|t|t|t|t
33842396|NCT01786226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842397|NCT06487962|RANDOMIZED|PARALLEL||OTHER||NONE||This study uses a mixed-methods, pragmatic pilot RCT design. Mixed-methods will be used to assess study feasibility and acceptability while quantitative methods will be used to assess RCT outcomes. As a pragmatic trial, the intervention (except peer-led support sessions) and control conditions are embedded in routine FQHC diabetes care in the participating sites.||||
33842398|NCT05816174|||COHORT||PROSPECTIVE|||||||
34050542|NCT00845208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842399|NCT04752670|||COHORT||PROSPECTIVE|||||||
34050543|NCT06667882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842400|NCT01074918|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33842401|NCT06647407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Partially blinded (treatment assignment is blinded between the two investigational formulation groups, and open label between the investigation and the comparator group)~* Laboratory personnel will be blinded to the treatment assignment~* Participants, Investigators, and Site staff preparing and administering the study intervention will be unblinded between the MenPenta and comparator groups but will be blinded between the 2 MenPenta groups The Sponsor will be partially blinded. At the time of periodic data reviews, additional measures are put in place to maintain the blind of the study participants for the Sponsor staff. The data review will be conducted on the basis of blinded outputs (where data of the 2 MenPenta groups and the control group will be reviewed in aggregate, without any distinction by group). By design, the Sponsor team will have access to partially blinded data for individual participants (eg, for assessment of SAE)"||t|t|t|t
34050544|NCT02401516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050545|NCT06684366|||OTHER||CROSS_SECTIONAL|||||||
33842402|NCT04605640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842403|NCT02620605|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34050546|NCT04701229|||COHORT||RETROSPECTIVE|||||||
34050547|NCT06370728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33842404|NCT03868787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The experimental group will have an active TENS unit - Chattanooga Primera - and the control group will have a sham TENS unit. The sham TENS will be the same unit without the true TENS electrical connections. The true TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes||t|f|f|f
34050548|NCT06438380|||OTHER||RETROSPECTIVE|||||||
34050549|NCT06594146|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33842405|NCT05976373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842406|NCT00000686||||TREATMENT||NONE||||||
33842407|NCT00349934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842408|NCT05196490|||OTHER||RETROSPECTIVE|||||||
33842409|NCT00538694|RANDOMIZED|PARALLEL||||DOUBLE||||||
33977950|NCT03876561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977951|NCT03396133|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33739651|NCT05517343|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants, care providers, investigators and outcome assessors are not blinded to the assigned study arm.|"This is a single center, open-label, prospective and parallel randomized controlled trial. This study planning to recruit outpatients from the age of 40 to 79 who are scheduled to undergo sedated colonoscopy and received polypectomy during the procedure. Participants will be randomized into ordinary care group (explained at next scheduled clinic) and real-time notification group (explained immediately after colonoscopy) in 1:1 ratio. Randomization will be based on a computer-generalized randomization list and stratified by gender and baseline anxiety degree of the participants. The level of anxiety, depression of the two groups will be measured by using the Taiwan version questionnaire of Hospital Anxiety and Depression Scale right before the next scheduled clinic for histological results and compared the difference between the two groups."||||
33739652|NCT05820750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739653|NCT02184468|NA|SINGLE_GROUP||||NONE||||||
33842410|NCT02734953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842411|NCT03390959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor) The one who assess the patients in the beginning and in the final moment (investigator) not know in what group the patient is. As the investigator that will do the statistic (outcome assessor).|Two groups: Control Group (CG) and the Trained Group (TG)|f|f|t|t
33977952|NCT00429884|||||PROSPECTIVE|||||||
33977953|NCT03025607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977954|NCT00493272|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33977955|NCT00322491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977956|NCT04619810|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33977957|NCT04148313|||CASE_ONLY||PROSPECTIVE|||||||
33977958|NCT01661270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977959|NCT00079807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33977960|NCT02952495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977961|NCT02532764|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33739654|NCT05237765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33842412|NCT06273449|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"1. Conventional: The Standard of Care (SOC) workflow, which will act as a baseline compared to the other 2 groups.~2. Partial digital workflow: Adopts the same teeth profile capture method, where a physical impression of teeth profile is taken from the subject. However, instead of using physical wax pattern on the stone model for design, the stone model is scanned and, on the scan, the design is performed digitally. For fabrication of RPD, instead of using lost wax casting, the digital design is used for additive manufacturing.~3. SmartRPD digital workflow Adopts a different teeth profile capture method by using the intraoral scanner to digitally scan and save the subject's teeth profile. From the intraoral scan, a digital model of the subject's teeth profile is created but on the digital model instead, the design of RPD is digitally performed. The digital design is used for additive manufacturing."||||
33739655|NCT03348904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842413|NCT03556904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739656|NCT00081588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842414|NCT04041037|||COHORT||PROSPECTIVE|||||||
33842415|NCT03373942|||CASE_CONTROL||RETROSPECTIVE|||||||
33842416|NCT00285701|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842417|NCT00894400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739657|NCT04010617|NA|SINGLE_GROUP||TREATMENT||NONE||Observational trial with comparison to a historical control group||||
33739658|NCT00701389|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33739659|NCT05401123|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||breasting pump||||
33842418|NCT01977677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739660|NCT00263692|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33842419|NCT03858829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33842420|NCT01692951|||CASE_CONTROL||RETROSPECTIVE|||||||
33842421|NCT02006524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842422|NCT04622553|NA|SINGLE_GROUP||TREATMENT||NONE||The aim of this study is to obtain additional information regarding the long-term safety and efficacy of mexiletine for the symptomatic treatment of myotonia in paediatric subjects who have completed the initial paediatric study MEX-NM-301.||||
33842423|NCT01204411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842424|NCT03162198|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842425|NCT00165204|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33842426|NCT03101202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842427|NCT05700968|||CASE_ONLY||CROSS_SECTIONAL|||||||
33842428|NCT02906189|||COHORT||PROSPECTIVE|||||||
33842429|NCT03214653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33842430|NCT00406159|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842431|NCT00744120|||COHORT||RETROSPECTIVE|||||||
33842432|NCT01137578|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842433|NCT03250442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842434|NCT02960087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842435|NCT02754063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842436|NCT01882543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842437|NCT04869397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842438|NCT01508624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842439|NCT00834626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842440|NCT04890548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842441|NCT01581502|||CASE_ONLY||PROSPECTIVE|||||||
33842442|NCT06729801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842443|NCT06233799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842444|NCT06254937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was designed as a pretest-posttest randomized controlled experimental study. The research will be conducted in a randomized parallel controlled design.|t|f|f|f
33842445|NCT06138613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842446|NCT01598662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842447|NCT06518031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33842448|NCT06532734|||COHORT||PROSPECTIVE|||||||
34075732|NCT06067867|||COHORT||PROSPECTIVE|||||||
33739661|NCT02972697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842449|NCT02844257|||COHORT||RETROSPECTIVE|||||||
33842450|NCT02031341|||||CROSS_SECTIONAL|||||||
33739662|NCT05904600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Masking of the researchers: randomisation of the sample will be performed using STATA software by a member of the research team who will not be involved in patient recruitment or data collection. The interventions will be carried out by researchers different from those who will perform the evaluation of the outcomes.~Masking of the participants: the control group will have a training of the respiratory muscles simulated with the same device as the intervention group. They will use the device without load and with an opaque adhesive tape surrounding the device to mask the valve position."||t|t|f|t
33739663|NCT05789615|||COHORT||PROSPECTIVE|||||||
33739664|NCT05626361|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739665|NCT00621439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33842451|NCT03738423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842452|NCT02626988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842453|NCT02651025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842454|NCT04110353|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Stepped wedge design with randomisation at the level of the Hospitals not individual patients|f|f|f|t
33842455|NCT00188942|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842456|NCT03329469|||CASE_ONLY||PROSPECTIVE|||||||
33842457|NCT02358434|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842458|NCT06339853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842459|NCT00961467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842460|NCT03776539|NA|SINGLE_GROUP||TREATMENT||NONE||"Subjects will be categorized in 4 groups:~Group 1: subjects with mild renal impairment~Group 2: subjects with moderate renal impairment~Group 3: subjects with severe renal impairment~Group 4 (control group): subjects with normal renal function"||||
33842461|NCT04717453|||COHORT||PROSPECTIVE|||||||
33842462|NCT01707745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842463|NCT05822739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842464|NCT02061059|RANDOMIZED|PARALLEL||||NONE||||||
33842465|NCT01725126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842466|NCT06220162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842467|NCT00348530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33842468|NCT01430234|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842469|NCT01939444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33842470|NCT02591953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842471|NCT03900910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Mass screening and eradication of Helicobacter pylori infection in Indigenous community.||||
33842472|NCT00140335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842473|NCT01464840|||COHORT||PROSPECTIVE|||||||
33842474|NCT05912829|||COHORT||PROSPECTIVE|||||||
33842475|NCT03551327|RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient and the person delivering the intervention will not be blind to treatment allocation.|||||
33842476|NCT02190903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842477|NCT05804318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842478|NCT06144632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842479|NCT04053998|||COHORT||RETROSPECTIVE|||||||
33842480|NCT03549390|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study is a three period crossover design. There are three experimental conditions (yoga, continuous exercise and control) and participants will be randomised to one of six sequences requiring them to complete all three conditions.||||
33842481|NCT02383940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739666|NCT01672151|||CASE_ONLY||PROSPECTIVE|||||||
33739667|NCT01282710|||CASE_ONLY||CROSS_SECTIONAL|||||||
33739668|NCT01112995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739669|NCT04127032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739670|NCT02080676|||COHORT||PROSPECTIVE|||||||
33739671|NCT00634413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739672|NCT02261818|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33739673|NCT06318299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33739674|NCT05422911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739675|NCT02270060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739676|NCT05482347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be masked to which arm of the study to which they are randomized.||t|f|f|f
33739677|NCT05057676|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Investigator will be masked.|Wait list control|f|f|t|f
33739678|NCT03686774|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
33739679|NCT05257538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739680|NCT05923060|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33739681|NCT05536947|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33739682|NCT03599427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The medicine used for each individual patient will be prepared by the nurse not otherwise involved in patient data collection.|Group A receives linisol 2%, group B receives placebo.|t|t|t|t
33739683|NCT06534112|||OTHER||PROSPECTIVE|||||||
33739684|NCT05762029|||CASE_ONLY||PROSPECTIVE|||||||
33739685|NCT00228449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739686|NCT02323724|||CASE_ONLY||RETROSPECTIVE|||||||
33739687|NCT03626181|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
33739688|NCT03957122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739689|NCT04635046|||COHORT||PROSPECTIVE|||||||
33739690|NCT02947347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739691|NCT00006411|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33739692|NCT04336579|||CASE_CONTROL||OTHER|||||||
33739693|NCT06532825|||COHORT||PROSPECTIVE|||||||
33739694|NCT01785524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33739695|NCT03103529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739696|NCT02731092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739697|NCT01163734|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33739698|NCT03860389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739699|NCT03639480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739700|NCT02206802|||CASE_CONTROL||PROSPECTIVE|||||||
33842482|NCT05169593|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized, multicentre, parallel group pragmatic non-inferiority trial||||
33842483|NCT00799032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842484|NCT01484431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842485|NCT01891942|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33842486|NCT00775060|||COHORT||PROSPECTIVE|||||||
33842487|NCT00124683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33842488|NCT00223184|||COHORT||PROSPECTIVE|||||||
33842489|NCT05097196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842490|NCT00387946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842491|NCT06002711|||COHORT||OTHER|||||||
33842492|NCT00588900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842493|NCT03231124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|LEO 32731 and Placebo tablets are of identical appearance. The packaging and labelling of the IMPs and Placebo contain no evidence of their identity. It is not considered possible to differentiate between the IMPs solely by sensory evaluation.||t|f|t|f
33842494|NCT02847390|||COHORT||RETROSPECTIVE|||||||
33842495|NCT06107868|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33842496|NCT01941147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842497|NCT05072028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842498|NCT02755870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842499|NCT04293458|NA|SINGLE_GROUP||SCREENING||NONE||Multicenter, Single Arm||||
33842500|NCT01824927|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33739701|NCT00320216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739702|NCT02252081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739703|NCT05908240|NA|SINGLE_GROUP||OTHER||NONE||||||
33842501|NCT00316017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842502|NCT02790697|||COHORT||PROSPECTIVE|||||||
33842503|NCT02026492|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33842504|NCT00007670|RANDOMIZED|PARALLEL||||DOUBLE||||||
33842505|NCT04557267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Active drug and placebo are made in similar|4 parallel groups, 3 doses of study drug versus placebo|t|t|t|t
33842506|NCT05142007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34050550|NCT04053712|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A randomized single-blinded placebo-controlled cross-over 33-hour in-clinic study in adults with type 1 diabetes.|t|f|f|f
33842507|NCT02914340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842508|NCT02311673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050551|NCT01704651|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33842509|NCT01986452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842510|NCT03245905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842511|NCT05701878|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will either be given access to the self-testing mobile app or not.||||
33842512|NCT04806204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33842513|NCT00431353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842514|NCT01685229|||COHORT||PROSPECTIVE|||||||
33842515|NCT02035059|||COHORT||PROSPECTIVE|||||||
33842516|NCT05151900|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33842517|NCT00703417|||CASE_CONTROL||PROSPECTIVE|||||||
33842518|NCT06198595|||CASE_CONTROL||PROSPECTIVE|||||||
33842519|NCT00354575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33842520|NCT06172153|||COHORT||RETROSPECTIVE|||||||
33842521|NCT00371189|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33842522|NCT03585803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842523|NCT05788692|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|A unique trial identification number (trial ID) will be generated for each participant, details of which will be entered into the trial management system.|"This trial is a 2x2 factorial design, since the four groups of children are formed by the cross-classification of the two factors toothbrush type (powered/manual) and use of the App (yes/no), which both have two levels.~Children from sampled schools will be assigned randomly to one of the four experimental groups (A, B, C, D) using pre-prepared lists."|f|f|t|f
33842524|NCT04789031|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were allocated to intervention and control group. The intervention group received commercial renal-specific ONS for six months. Both groups received standard nutritional counseling during the study period.||||
33842525|NCT00513188||||TREATMENT||||||||
34050552|NCT05764616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050553|NCT06313398|NA|SINGLE_GROUP||OTHER||NONE||||||
34050554|NCT06287632|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34050555|NCT04060277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34050556|NCT04755413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050557|NCT02511392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050558|NCT02809547|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34050559|NCT02057484|||COHORT||PROSPECTIVE|||||||
34050560|NCT02640950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050561|NCT01532791|||CASE_CONTROL||PROSPECTIVE|||||||
33842526|NCT04093089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33842527|NCT02564380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842528|NCT05034172|||COHORT||PROSPECTIVE|||||||
33842529|NCT03540758|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The subject will be blinded as to the intervention being received first (Drug or Placebo).||t|f|f|f
33842530|NCT01005069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977962|NCT05616208|NA|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized, single group treatment study with a single arm and is not subject or investigator masked or blinded.||||
34050562|NCT04649788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050563|NCT03305458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050564|NCT06414109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842531|NCT01268956|||CASE_CONTROL||PROSPECTIVE|||||||
33842532|NCT01170676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842533|NCT01226862|||COHORT||PROSPECTIVE|||||||
33977963|NCT04856345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977964|NCT02564263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842534|NCT01167790|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977965|NCT02586259|||COHORT||PROSPECTIVE|||||||
33977966|NCT02016300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977967|NCT03519828|||CASE_CONTROL||RETROSPECTIVE|||||||
33977968|NCT01808664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33842535|NCT05314374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842536|NCT03203330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33977969|NCT06111911|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33977970|NCT04292561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050565|NCT04979780|||COHORT||RETROSPECTIVE|||||||
34050566|NCT00059891|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34050567|NCT03907527|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050568|NCT03748810|||CASE_CONTROL||PROSPECTIVE|||||||
34050569|NCT05849415|||OTHER||CROSS_SECTIONAL|||||||
34050570|NCT04392050|||COHORT||PROSPECTIVE|||||||
34050571|NCT02720263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050572|NCT02250482||||TREATMENT||||||||
34050573|NCT02103192|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34050574|NCT03184194|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050575|NCT03159234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050576|NCT05712629|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34050577|NCT06665087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050578|NCT01570972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050579|NCT05127304|||COHORT||RETROSPECTIVE|||||||
34050580|NCT03719248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050581|NCT02114450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34050582|NCT05161208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050583|NCT01270464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050584|NCT04275921|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34050585|NCT06282224|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34050586|NCT06682312|||COHORT||PROSPECTIVE|||||||
34050587|NCT06685471|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34050588|NCT03494400|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050589|NCT06599502|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This protocol has a modular design, with the potential for future Modules or treatment to be added via protocol amendments. Participants will receive oral doses of AZD0022, either as monotherapy or in combination with other anti-cancer agents||||
33945248|NCT05283161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The placebo will match the study drug in odor, taste, color and appearance to ensure proper masking. Eligible patients included in the pre-randomization period will be double-blind randomized in a 1:1:1:1 ratio between the experimental groups, by a biostatistician who is not involved in data collection nor analysis, to receive the CBD/THC solution at doses of 0.1mg/day, 1mg/day, 10mg/day, or placebo. A randomization sequence will be generated by computer, which creates identification codes necessary for the correct labeling of the drug and allocation of the patients in the experimental groups (https://www.sealedenvelope.com). This code will be adopted in the Case Report Form of the patient. The designation of the experimental group will be known by the data analysts, but hidden from the participants and the team involved with the treatment and research.|This single center clinical trial is a double-blinded, randomized, placebo-controlled and dose-response type, having a pre-randomization period (8 days prior to the beginning of the study), and a 120-day double-blind main period. Patients will be double-blind randomized in a 1 by 1 by 1 by 1 ratio to receive cannabidiol and tetrahydrocannabinol 1 by 1: (0.1 mg/ml) (10 research participants), cannabidiol and tetrahydrocannabinol 1 by 1 (1.0 mg/ml) (n=10), cannabidiol and tetrahydrocannabinol 1 by 1 (10 mg/ml) (10 research participants) and placebo (vehicle) (10 research participants). The administration will occur daily, once a day, during the night period, before going to bed and 30 minutes after the meal, during the next 120 days. The clinical study will have a baseline assessment (T0), one day before the start of the intervention with the solution. The tools will be reapplied after 15 (T1), 30 (T2), 60 (T3), 90 (T4) and 120 (T5) days of intervention.|t|t|t|t
33945249|NCT03759002|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050590|NCT04613141|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Assessments that occur after baseline randomization will be completed by blinded assessor. Excluding the immediate effect of stimulation on step time variability, which is impossible to blind as the participant using a stimulation device, which is not practical to conceal.~Statistician blinded."||f|f|f|t
34050591|NCT06484452|||COHORT||PROSPECTIVE|||||||
34050592|NCT05599139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050593|NCT01231867|||COHORT||RETROSPECTIVE|||||||
34050594|NCT01604980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050595|NCT03805984|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|The Sponsor will be blinded up to Week 6; at that time the Sponsor will become group-level unblinded.||t|t|t|f
34050596|NCT01108341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050597|NCT05282225|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential, multiple assignment, randomized trial (SMART) design of an adjunctive, multi-component intervention.||||
34050598|NCT01399047|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34075733|NCT03044847|||COHORT||PROSPECTIVE|||||||
33842537|NCT05614726|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33842538|NCT01476449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945250|NCT03524560|||OTHER||CROSS_SECTIONAL|||||||
33842539|NCT00883064|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945251|NCT00646737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842540|NCT04990011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945252|NCT00595439|||||PROSPECTIVE|||||||
33842541|NCT02120001|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945253|NCT02701374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842542|NCT04307940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945254|NCT05707819|||COHORT||PROSPECTIVE|||||||
33842543|NCT03617900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842544|NCT05170815|||COHORT||PROSPECTIVE|||||||
33945255|NCT00124865|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33842545|NCT01827644|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842546|NCT01620918|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945256|NCT01953419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945257|NCT00371657|||||RETROSPECTIVE|||||||
33945258|NCT03391427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All persons are blinded as the drug is formulated by the investigator who is not the care giver or outcomes assessor|Lidocaine, ketamine, combination and placebo are being evaluated for treating postoperative pain in major liver resection|t|t|f|t
33945259|NCT06231186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945260|NCT05325502|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33842547|NCT05841212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945261|NCT04881266|||COHORT||PROSPECTIVE|||||||
33842548|NCT01624077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945262|NCT04576702|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945263|NCT03196401|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single center, single-arm pilot study of checkpoint blockade therapy (anti-PD-L1) plus radiation.||||
33739704|NCT03963518|||OTHER||PROSPECTIVE|||||||
33739705|NCT02929576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739706|NCT02530619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739707|NCT01479036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739708|NCT03705039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled study|t|f|t|t
33739709|NCT06199141|||COHORT||RETROSPECTIVE|||||||
33739710|NCT04499157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842549|NCT03410004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842550|NCT02706405|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33842551|NCT05101824|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, multicenter, phase 2 study||||
33842552|NCT03236584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842553|NCT03674580|||COHORT||PROSPECTIVE|||||||
33842554|NCT05726240|RANDOMIZED|PARALLEL||TREATMENT||NONE|PROBE design|This will be a phase 2 multicenter clinical trial with random treatment allocation, open label treatment and blinded endpoint assessment (PROBE design). The intervention contrast will be intravenous acylated ghrelin in addition to standard care (intervention group) vs. standard care alone (control group).||||
33842555|NCT01093677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945264|NCT06151821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessor did not know which patients received the intervention and which patients did not|Randomized controlled trial|f|f|f|t
33842556|NCT02207855|||COHORT||RETROSPECTIVE|||||||
33842557|NCT01921153|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33842558|NCT00635128|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842559|NCT01404429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842560|NCT02896114|||COHORT||RETROSPECTIVE|||||||
33842561|NCT02799459|||COHORT||PROSPECTIVE|||||||
33945265|NCT06155851|||COHORT||PROSPECTIVE|||||||
33945266|NCT00920166|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33842562|NCT05944718|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Three arm pragmatic randomized controlled study Arm 1: use of CGM in a continuous manner from enrolment to the end of intervention period Arm 2: intermittent use of CGM (use for 2 weeks once every three months) from enrolment to the end of intervention period Arm 3 (control): standard of care||||
33842563|NCT01533818|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33842564|NCT02242097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945267|NCT01608230|||CASE_ONLY||PROSPECTIVE|||||||
33842565|NCT04955782|||COHORT||PROSPECTIVE|||||||
33842566|NCT04318288|||COHORT||RETROSPECTIVE|||||||
33842567|NCT05078788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33842568|NCT06322238|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842569|NCT00072137||PARALLEL||TREATMENT||NONE||||||
33842570|NCT02672852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842571|NCT03455803|||CASE_ONLY||PROSPECTIVE|||||||
33842572|NCT02963155|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33842573|NCT04358770|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||single-exposure, open-label, vasoconstriction response study||||
33842574|NCT01731080|||CASE_CONTROL||PROSPECTIVE|||||||
33842575|NCT01605019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842576|NCT02546622|||COHORT||OTHER|||||||
33842577|NCT00956553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33842578|NCT06064019|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842579|NCT01519089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842580|NCT02972268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945268|NCT00332930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945269|NCT01220024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945270|NCT04229342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739711|NCT04292301|NA|SINGLE_GROUP||OTHER||NONE|Study does not involve masking.|All human participants in the study will be imaged using MRI under the same acquisition protocol. The STAGE protocol is collected alongside conventional MR.||||
33842581|NCT00146731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842582|NCT01653054|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33842583|NCT04650087|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind||t|t|t|t
33842584|NCT03538938|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Research staff who conduct follow-up interviews and verification will be blind to study condition and will not have access to other participant data (e.g., smoking history) prior to the end of data collection.|Four-factor fully-crossed factorial design|f|f|f|t
33945271|NCT05984225|NA|SINGLE_GROUP||OTHER||NONE||Interventional||||
33842585|NCT01484600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945272|NCT03236701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075734|NCT00000962||||TREATMENT||||||||
33842586|NCT00225238|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33842587|NCT06256328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842588|NCT04431895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842589|NCT02449551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842590|NCT05833477|NA|SINGLE_GROUP||OTHER||NONE||||||
33739712|NCT03508557|NA|SINGLE_GROUP||OTHER||NONE||Single group before-after||||
33739713|NCT00824590|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739714|NCT05557279|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment and meeting inclusion/exclusion criteria 20 premenopausal women, 20 postmenopausal women not on estrogen supplementation||||
33842591|NCT02687438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842592|NCT06688799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842593|NCT03881982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842594|NCT06675487|||COHORT||PROSPECTIVE|||||||
33842595|NCT00743977|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33842596|NCT00685984|||CASE_CONTROL||PROSPECTIVE|||||||
33842597|NCT05155215|NA|SEQUENTIAL||TREATMENT||NONE||||||
33842598|NCT06043830|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33842599|NCT00762775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33842600|NCT06214741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842601|NCT00992043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33842602|NCT00342147|||FAMILY_BASED||PROSPECTIVE|||||||
33842603|NCT03525067|||COHORT||PROSPECTIVE|||||||
33842604|NCT03857997|||COHORT||PROSPECTIVE|||||||
33842605|NCT02655926|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33842606|NCT05031715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842607|NCT01791075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842608|NCT02299414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842609|NCT04355377|||OTHER||RETROSPECTIVE|||||||
33842610|NCT00143208|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842611|NCT00683683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842612|NCT05926440|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842613|NCT01520805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050599|NCT05184569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study. Only investigational pharmacist will be unblinded|Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
34050600|NCT05516524|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The investigators will be masked as to the order of the two sleep tests|Participants will be randomized to the initial test (home sleep apnea test or polysomnography) and then complete the alternate test within approximately one week.|f|f|t|f
34050601|NCT02944552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739715|NCT03129347|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33739716|NCT05595798|||COHORT||PROSPECTIVE|||||||
33739717|NCT02375412|||CASE_ONLY||PROSPECTIVE|||||||
33945273|NCT04678804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739718|NCT01969838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739719|NCT00585897|NA|SINGLE_GROUP||||NONE||||||
33739720|NCT00289341|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33739721|NCT01642797|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33739722|NCT02139644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739723|NCT05031624|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33739724|NCT00541762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33739725|NCT05155735|||COHORT||PROSPECTIVE|||||||
33739726|NCT00927745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739727|NCT03110159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739728|NCT04596072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739729|NCT00047463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739730|NCT05404022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739731|NCT05790343|||FAMILY_BASED||PROSPECTIVE|||||||
33739732|NCT05134376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|episiotomy application and intervention was done by midwives|This research is a randomized controlled experimental study.||||
33739733|NCT06521346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the researcher will create excel sheet to randomize the studied participants.|The total group will be divided into two group: control and intervention group Control group receives standard care in the unit Intervention group receives active cycle breathing techniques|t|f|f|f
33739734|NCT02543541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739735|NCT06532331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739736|NCT06573515|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33739737|NCT02012829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33739738|NCT02520245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739739|NCT04424368|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739740|NCT04353297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible subacute stroke patients admitted to Fondazione Santa Lucia Hospital for standard rehabilitation care will be randomized in equal proportions (1:1 ratio) between Promotoer- BCI (BCI-assisted MI training- EXP) and Control (MI training-no BCI supported).|f|f|f|t
33739741|NCT03770572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Single Treatment Group (AAV9-CLN3) - 2 Cohort Assignment (Low-dose, High-dose)~Dose escalation in this study will begin with low-dose, determined to be the minimal efficacious dose as determined in non-clinical studies. Dose escalation to a high-dose (2x the minimally effective dose (MED) as evaluated in Cohort 1) will proceed as part of Cohort 2 of the study upon demonstration of safety of the low-dose in Cohort 1 of the study."||||
33739742|NCT04978857|NA|SINGLE_GROUP||OTHER||NONE||||||
33945274|NCT04745052|||CASE_ONLY||CROSS_SECTIONAL|||||||
33945275|NCT05507840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33842614|NCT03507426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33842615|NCT03140839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blind to the condition they receive|Participants will be randomized to receive one of three conditions, either Imaginal Rescripting, Imaginal Exposure, or Supportive Counselling|t|f|f|f
33842616|NCT05012059|||COHORT||RETROSPECTIVE|||||||
33842617|NCT03585010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will conducted by independent evaluators, blind to treatment condition.||f|f|f|t
33945276|NCT03445494|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized 1:1||||
33945277|NCT03854552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945278|NCT05461846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945279|NCT05303051|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739743|NCT06536166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945280|NCT05185908|||COHORT||PROSPECTIVE|||||||
33945281|NCT06308796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739744|NCT00772174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739745|NCT05438953|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739746|NCT04726865|||OTHER||CROSS_SECTIONAL|||||||
33739747|NCT01398605|RANDOMIZED|PARALLEL||||NONE||||||
33739748|NCT05235880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739749|NCT01311830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945282|NCT03440398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945283|NCT00565721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945284|NCT04559048|||COHORT||RETROSPECTIVE|||||||
33945285|NCT04658511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945286|NCT04889989|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, prospective, multicenter clinical trial with a performance goal||||
33945287|NCT05006404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945288|NCT04984668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977971|NCT04503330|NA|SINGLE_GROUP||TREATMENT||NONE||20 patients with iatrogenic pelviureteric junction obstruction or ureteric stricture disease||||
33977972|NCT05422547|||COHORT||CROSS_SECTIONAL|||||||
34050602|NCT05103280|NA|SINGLE_GROUP||TREATMENT||NONE||Ten patients will wear assistive shoes for 3 months.||||
34050603|NCT04880707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patient, Twin block administrator and assessor assessing jaw muscle pain will all be unaware of whether the patient received sterile saline (placebo) or local anesthetic in the Twin Block injection.|Triple blind, randomized prospective pilot study comparing post wisdom molar extraction pain comparing placebo or Twin block local anesthetic nerve block injection|t|f|t|t
34050604|NCT05094635|||COHORT||CROSS_SECTIONAL|||||||
33739750|NCT05859347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to one of two groups to receive either high-frequency (10 Hz) or low-frequency (1 Hz) rTMS.|f|f|f|t
33739751|NCT01842828|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33739752|NCT01319006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33739753|NCT01876121|||CASE_ONLY||PROSPECTIVE|||||||
33739754|NCT02569697|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33739755|NCT03795844|RANDOMIZED|CROSSOVER||PREVENTION||NONE||In this study, 120 patients who are over 18 years old with laparoscopic sleeve gastrectomy will be included. 4 groups will be formed and each group will be planned to include 30 patients. In group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved. In the second group, a snake retractor with a 5 mm incision under the xiphoid will be used. In the 3rd group, liver retraction will be provided by using a 5 mm trocar from the intersection of the right midclavicular line. In the control group, liver retraction through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools.||||
33739756|NCT02341248|||CASE_CONTROL||PROSPECTIVE|||||||
33739757|NCT05427149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739758|NCT05086458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739759|NCT01025700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739760|NCT06123039|||COHORT||PROSPECTIVE|||||||
33739761|NCT06435026|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33739762|NCT03402243|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739763|NCT04397081|||CASE_CONTROL||PROSPECTIVE|||||||
33739764|NCT05189795|||CASE_ONLY||CROSS_SECTIONAL|||||||
33739765|NCT01686087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739766|NCT00903838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739767|NCT06573138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739768|NCT06574022|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Stage I:randomized trial to establish effectiveness of AT with IOB. Stage II, evaluate two BTs based on stage I results. Enroll40 patients in each group for alpha=5% and power=80% (1 interim analysis after 50% enrollment). With n1=20 and n2=20, if we obtain p-value \<0.025 for comparing number of pills used in two groups (we assume EX is better than PB), we conduct stage II. Otherwise, we continue enroll n1=40 and n2=40 and compare the mean pill counts between groups; if the observed p-value is less than 0.025, then EX superior. If the observed p-value is not significant, continue with EX. If we find EX is inferior to PB, perform a subset analysis and modify I/E criteria in stage II. In stage II, we test the efficacy of BT with superior AT. We enroll 60 patients. Randomize the ratio of 2:1 in favor of CPT. We use patients in stage I treated IOB with the superior AT in the analysis. We will have n1=40 or 60 and n2=40. At least 80% power to detect the same effect sizes.||||
33739769|NCT06475131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739770|NCT02554773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739771|NCT03462667|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739772|NCT05715645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patient and the people carrying out the functional assessments (physiotherapists) will be blinded to the analgesia received, unlike the investigator.||t|t|f|t
33945289|NCT04350749|RANDOMIZED|PARALLEL||TREATMENT||NONE|Some of the data anlysis is masked. The examiner is blinded when performing the CBCT scan analysis of the volume (Study 2) and the histological assessment of the bone biopsies (Study 3)|Clinical randomized controlled trial||||
33739773|NCT00359762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739774|NCT02563041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945290|NCT05359094|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33739775|NCT03658720|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33739776|NCT02453789|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33739777|NCT05408598|||CASE_ONLY||PROSPECTIVE|||||||
33739778|NCT01061060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739779|NCT05211024|||COHORT||PROSPECTIVE|||||||
33739780|NCT06572501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739781|NCT00000463|RANDOMIZED|||PREVENTION||DOUBLE||||||
33739782|NCT02998294|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33739783|NCT02805192|NA|SINGLE_GROUP||OTHER||NONE||||||
33945291|NCT01858675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945292|NCT01836900|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945293|NCT00517166|||CASE_ONLY||RETROSPECTIVE|||||||
33739784|NCT03864614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739785|NCT03223103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739786|NCT04962269|||CASE_CONTROL||RETROSPECTIVE|||||||
33739787|NCT02866617|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33739788|NCT06267482|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33739789|NCT05946668|||COHORT||PROSPECTIVE|||||||
33739790|NCT03464682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739791|NCT02545712|||CASE_CONTROL||RETROSPECTIVE|||||||
33739792|NCT02890498|||CASE_CONTROL||RETROSPECTIVE|||||||
33739793|NCT01942382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739794|NCT04244474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739795|NCT03532789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||overactive bladder patients|t|t|t|t
33739796|NCT01351129|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33739797|NCT00523484|||COHORT||PROSPECTIVE|||||||
33739798|NCT05036083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739799|NCT00809289|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33739800|NCT00967187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739801|NCT04638790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945294|NCT03923062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945295|NCT02492321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945296|NCT04275024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945297|NCT06347523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33945298|NCT05472168|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33945299|NCT00402376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33739802|NCT04486859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33842618|NCT05019404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors are blinded to the treatment throughout the entire study. Blinding is maintained by having patients wear large hats during the interview to obscure skin incision and providing patients strict instruction not to reveal treatment arm.|a single-center, prospective, single-blinded, double-arm, randomized, controlled trial|f|f|f|t
33945300|NCT01826305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842619|NCT00604825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842620|NCT03724331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945301|NCT00285857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842621|NCT01164618|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33842622|NCT04398823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33945302|NCT05910606|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33842623|NCT02753517|NA|SINGLE_GROUP||SCREENING||NONE||||||
33842624|NCT00696943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842625|NCT00702962||SEQUENTIAL||TREATMENT||NONE||||||
33842626|NCT01368029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842627|NCT01997905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842628|NCT04314635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842629|NCT04263753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842630|NCT02713061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842631|NCT02912390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739803|NCT03827252|||COHORT||PROSPECTIVE|||||||
33842632|NCT03670095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842633|NCT05892705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33842634|NCT05315843|||COHORT||PROSPECTIVE|||||||
33842635|NCT06044038|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33842636|NCT02135562|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945303|NCT00804323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945304|NCT04752111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|t|f
33945305|NCT00719511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945306|NCT02985996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945307|NCT04832243|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Study participants are asked to identify the number of true statements in a list, where the number of true statements is randomly assigned. Neither study participants nor outcomes assessors are provided with information about treatment assignment."||t|f|f|t
33945308|NCT05890365|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33945309|NCT04036214|||CASE_ONLY||PROSPECTIVE|||||||
33945310|NCT04346017|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945311|NCT03350763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945312|NCT00280540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945313|NCT02120274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945314|NCT00957827|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33945315|NCT05566366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945316|NCT06669585|||COHORT||PROSPECTIVE|||||||
33977973|NCT01367275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977974|NCT05634109|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, Controlled, Randomized, and Open label therapeutic trial.||||
33977975|NCT01186588|NON_RANDOMIZED|PARALLEL||||NONE||||||
33739804|NCT01319734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739805|NCT03632161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33739806|NCT04798300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739807|NCT06222723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739808|NCT02798848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33739809|NCT04387253|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33739810|NCT01330940|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33739811|NCT06038682|||CASE_ONLY||PROSPECTIVE|||||||
33739812|NCT03731494|||COHORT||PROSPECTIVE|||||||
33739813|NCT01340989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33842637|NCT06301321|||OTHER||PROSPECTIVE|||||||
33842638|NCT06331637|||COHORT||PROSPECTIVE|||||||
33842639|NCT01647555|||COHORT||PROSPECTIVE|||||||
33842640|NCT02602639|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33842641|NCT04466488|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The data identified by clinic allocation will be blinded to the PI and co-investigators and study statistician until completion of comparative analysis. There will be no other blinding.|The investigators will conduct a covariate-constrained randomization to balance, if an imbalance is detected, ensuring validity of the randomization process. Implementation will be staggered over time with each of two clinics from the intervention arms matched to control clinics for the purpose of contemporaneous study initiation. Randomization will occur either electronically or through drawing names with Department of Health representatives.|f|f|t|f
33842642|NCT05324670|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blind Cluster randomized controlled trials|Research design of the study will consists single-blind cluster randomized controlled trial (c-RCT). While Randomized Control Trial (RCT) will consists of two groups: written knowledge with explanation (experimental group) and written knowledge without explanation (control group).|t|f|f|f
33842643|NCT06728579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study where PIs, biostatisticians, and the CRC who performs outcome assessments are blinded.|Two-arm, parallel group, RCT|f|f|t|t
33842644|NCT05945004|||COHORT||CROSS_SECTIONAL|||||||
33842645|NCT01384370|||CASE_CONTROL||RETROSPECTIVE|||||||
33842646|NCT06441877|||COHORT||PROSPECTIVE|||||||
33842647|NCT06118099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842648|NCT00002870|RANDOMIZED|||TREATMENT||||||||
33842649|NCT01012297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842650|NCT04419376|||CASE_CROSSOVER||PROSPECTIVE|||||||
33842651|NCT04842370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842652|NCT02742402|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33842653|NCT00925353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842654|NCT02559427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842655|NCT04337853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842656|NCT03653208|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33842657|NCT05234840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|all patient were masked. Surgeon was blinded by leukostrip around injection syringe. Assessor was blinded from operative information.|Thirty patients were treated by transforaminal epidural injections. Fifteen patients were in triamcinolone and PRP groups each. PRP was obtained from 24 ml venous blood through standardized double-spin protocol. Participants were fifteen patients each in triamcinolone and PRP groups. The same postoperative protocols and medications were applied. The visual analogue scale of leg (LegVAS), collected at baseline, 2, 6, 12, and 24 weeks, was the primary outcome.|t|f|t|t
33842658|NCT06268067|||CASE_CONTROL||PROSPECTIVE|||||||
33842659|NCT03154970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33842660|NCT04703205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842661|NCT02643472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842662|NCT01004887|||CASE_ONLY||RETROSPECTIVE|||||||
33842663|NCT02654652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33842664|NCT04192253|NA|SINGLE_GROUP||TREATMENT||NONE||a prospective, phase ll trial to investigate the response rate of carboplatin and paclitaxel in patients with locally advanced vulvar carcinoma||||
33842665|NCT01643551|||CASE_CONTROL||PROSPECTIVE|||||||
33842666|NCT03042988|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized, 2-arm crossover study (heat vs sham)||||
33842667|NCT04608773|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Both subjects and clinicians will be blinded to Mouth Spray A and Mouth Spray B.||t|t|t|t
33842668|NCT04863482|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842669|NCT00953771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842670|NCT03790553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842671|NCT05500677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|open label study|Pain control in rib fracture||||
33739814|NCT04552873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Comparative study in 2 parallel arms, monocentric, randomized, double blind.|t|f|t|f
33739815|NCT02742103|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33739816|NCT01119261|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33739817|NCT03843502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33739818|NCT05769452|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"In this study, the intervention group was given a closed IV catheter system called BD Nexiva™; the control group received an open IV catheter called BD Insyte™ Autoguard™. Within the scope of the study, Peripheral IV Catheter Care Bundle Approach was applied to all patients."|f|f|t|f
33739819|NCT05585333|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842672|NCT06507865|||COHORT||PROSPECTIVE|||||||
33842673|NCT00417742|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842674|NCT01514305|||COHORT||CROSS_SECTIONAL|||||||
33842675|NCT00743431|||CASE_ONLY||PROSPECTIVE|||||||
33842676|NCT05601427|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842677|NCT00089882|||||PROSPECTIVE|||||||
33842678|NCT03861026|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Patients will be randomly allocated to either interventional or control groups according to a computer generated randomization code in predetermined size blocks.~Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.. The NIRS screen will be concealed in the control group to ensure blinding."|This is a prospective, randomized, controlled clinical trial|t|f|f|t
33842679|NCT00137969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842680|NCT06130670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery||||
33842681|NCT06398158|||COHORT||PROSPECTIVE|||||||
33842682|NCT05912205|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33842683|NCT06538597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33842684|NCT01125046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842685|NCT03297424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842686|NCT01635738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33842687|NCT03225326|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33842688|NCT00806091|||COHORT||PROSPECTIVE|||||||
33842689|NCT02146404|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33842690|NCT04213742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842691|NCT04702698|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33842692|NCT02672943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842693|NCT01702272|||COHORT||PROSPECTIVE|||||||
33842694|NCT03490201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects are blinded to the randomization assignment.|Pivotal medical device study|t|f|f|f
33842695|NCT03791554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Its a randomised clinical trial|t|f|f|t
33842696|NCT05623696|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Masking will only be applied to the participants in relation to whether they receive sham or actual rTMS.|Following a practice session, there will be 3 intervention arms presented in random order on 3 separate days. The three arms will be: (i) 10-20mins of 5Hz rTMS over left DLPFC (Arm 1), (ii) 5Hz rTMS over right DLPFC (Arm 2), (iii) sham rTMS (Arm 3). A standard steady state air hunger test will be conducted before and immediately after each intervention.|t|f|f|f
33842697|NCT03698110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842698|NCT05441644|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||two way mixed effect model; aggreement study||||
33842699|NCT03321877|NA|SINGLE_GROUP||OTHER||NONE||||||
33842700|NCT00403936|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33842701|NCT02893007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842702|NCT01472458|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33842703|NCT05501977|||OTHER||RETROSPECTIVE|||||||
33842704|NCT00690053|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33842705|NCT00126503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842706|NCT01643044|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33842707|NCT00704197|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842708|NCT05147571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33842709|NCT02760095|||CASE_CONTROL||PROSPECTIVE|||||||
33842710|NCT03466905|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33842711|NCT05704738|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33842712|NCT00880204|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33842713|NCT02498912|NA|SINGLE_GROUP||TREATMENT||NONE||This is a standard phase I dose escalation trial.||||
33842714|NCT03697551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842715|NCT02867215|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33842716|NCT05912101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33842717|NCT01717742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842718|NCT04061460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||at baseline, patients recieved oral hygiene instructions The same examiner (LS) performed an oral demonstration including teeth brushing, interdental cleaning and tong wash. Each patient received proper head and interdental brushes demonstration, moreover, patients were educated to brush their ventral face of their tong A single periodontist (L.S) performed the supra gingival debridment at the second appointment (2 weeks after receiving OHI) , followed 2 weeks after by a full month debridement using ultrason piezoelectric device (Newtron P5 XS Bled, Acteon, Satelec , France) with specific micro-inserts (H1, H3, H4L, H4R)||||
33842719|NCT02906163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842720|NCT03369171|NA|SINGLE_GROUP||OTHER||NONE||||||
33842721|NCT04180488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842722|NCT06451133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842723|NCT00222872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842724|NCT03704623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The emergency department (ED) nurse will do randomization by drawing one of the sealed closed envelopes that contain the analgesic to be administered.|Eligible patients will be randomized to one of the two treatment groups.|t|f|t|f
33842725|NCT01896427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33842726|NCT04613544|||COHORT||PROSPECTIVE|||||||
33842727|NCT02643264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842728|NCT00821587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842729|NCT00397670|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33842730|NCT05353205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842731|NCT06441370|||COHORT||PROSPECTIVE|||||||
33842732|NCT04442100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842733|NCT05442398|||CASE_ONLY||CROSS_SECTIONAL|||||||
33945317|NCT04606862|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a pivotal medical device clinical trial comparing the clinical outcomes in hospitalized patients monitored with the MMS Software Device for the prediction and early detection of sepsis versus patients monitored with current standard sepsis scoring systems at participating clinical trial sites. This will be conducted through a non-randomized multi-center, non-blinded, clinical trial.||||
33842734|NCT05456139|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The Investigator and diagnosticians will be kept blind to treatment arm.|The investigators will conduct an effectiveness trial of ESI-MC to address the question of whether starting evidence-based intervention earlier leads to better outcomes than starting later. The investigators will address this question by using a modified stepped wedge design and blended implementation research to analyze data obtained with ESI-MC start at 18, 24, or 30 months. he investigators will diagnostically ascertain 240 children from a pool of 360 18-month-olds with early signs of autism. The 240 children will be randomly assigned to one of three ESI-MC timing groups. The investigators will measure child active engagement and social communication change every 6 months as the primary outcome variables. Outcome measures of developmental level, autism symptoms, and adaptive behavior will be examined to measure differential treatment effects.|f|f|t|t
33842735|NCT04912687|NA|SINGLE_GROUP||SCREENING||NONE||This is a multicentric prospective cohort in which newly diagnosed advanced NSCLC patients will be included. For all patients, both tumor and liquid biopsy samples will be used for sequencing and detection of EGFR gene mutation||||
33842736|NCT03909243|||OTHER||CROSS_SECTIONAL|||||||
33842737|NCT04235153|||COHORT||PROSPECTIVE|||||||
33945318|NCT06724146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842738|NCT06037304|||OTHER||PROSPECTIVE|||||||
33945319|NCT04022265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each patient will receive two mini-implants, installed in recipient sites prepared in the distal segments of the maxilla either with a sonic device or drills. The two recipient sites will be selected prior the surgery, while the type of site preparation will be randomly decided. A researcher, neither involved in the selection of the patients nor in the surgical and prosthetic treatment, carried out electronically the randomization (randomization.com). Sealed opaque envelopes will be prepared and opened at the time of surgery and they will report the position of the sonic sites so that the surgeon will be masked about site preparation type until the surgery. The site will be indicated as mesial or distal position if the two sites will be located in the same quadrant of the maxilla, or as right or left if they will be located in opposite quadrants of the maxilla.|Clinical Trial|t|f|t|t
33945320|NCT05541133|||COHORT||PROSPECTIVE|||||||
33945321|NCT02895074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945322|NCT02109965|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33842739|NCT06224062|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945323|NCT04242121|||COHORT||PROSPECTIVE|||||||
33842740|NCT06224348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842741|NCT05504317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945324|NCT02815670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945325|NCT00039377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945326|NCT02625610|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33945327|NCT04531891|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE||Each participant will randomly be assigned to two different fatigue protocols, on separate days. The first protocol is a high-intensity, intermittent exercise protocol and will be performed until complete exhaustion. The second protocol is a time-based variant of the previous protocol and will be performed during 5 minutes.|t|f|f|t
33945328|NCT04780087|||CASE_CONTROL||PROSPECTIVE|||||||
33945329|NCT02756195|||COHORT||PROSPECTIVE|||||||
33945330|NCT04052711|NA|SINGLE_GROUP||OTHER||NONE||||||
33945331|NCT00173264|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34050605|NCT02787421|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050606|NCT03489707|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34050607|NCT06215989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075735|NCT06613022|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33945332|NCT04583410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945333|NCT05937646|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Participants will be randomly assigned to a control or an intervention and then conduct a crossover stage. For example, a participant who is in the control group (EHR) will review two patient cases in the EHR. Then, the participant will review two other patient cases in AWARE (intervention), i.e., the crossover stage. Similarly, a participant who is in the intervention group (AWARE) will review two patient cases in AWARE. Then, the participant will review two other patient cases in the EHR (control), i.e., the crossover stage.|t|f|f|f
33945334|NCT04825639|||COHORT||OTHER|||||||
33945335|NCT03516201|||COHORT||OTHER|||||||
33945336|NCT01199952|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33945337|NCT00505765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945338|NCT01310491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945339|NCT05584917|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945340|NCT01700660|||CASE_CONTROL||PROSPECTIVE|||||||
33842742|NCT06584110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized into intervention group and wait-list control group.|"BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-minutes debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support."|t|f|f|f
33842743|NCT01037556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945341|NCT04681872|RANDOMIZED|PARALLEL||PREVENTION||NONE||The Marshall Plan is a prospective randomized, parallel-group, multicenter clinical trial of superiority||||
33842744|NCT05180643|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective exploratory monocentric pilot study in the context of interventional research with minimal risks and constraints, which aims to collect qualitative and quantitative data from two pilot 8-week MBSR programs organized at the University Hospital Center. Bordeaux with two groups of patients: 10 non-fluctuating patients or with minor fluctuations (Group A) and 10 patients with mild to moderate fluctuations (Group B).||||
33842745|NCT03331913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945342|NCT04839627|||COHORT||PROSPECTIVE|||||||
33945343|NCT02512120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945344|NCT03633461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842746|NCT04057027|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33842747|NCT03333759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945345|NCT02267460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842748|NCT05553106|||CASE_CONTROL||PROSPECTIVE|||||||
33842749|NCT01677767|||COHORT||PROSPECTIVE|||||||
33842750|NCT02974439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842751|NCT06310018|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter, prospective, single-arm study||||
33842752|NCT04414059|||CASE_ONLY||PROSPECTIVE|||||||
33842753|NCT00501280|||CASE_ONLY||PROSPECTIVE|||||||
33842754|NCT02898077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842755|NCT02897362|||CASE_CONTROL||PROSPECTIVE|||||||
33842756|NCT05931029|||COHORT||RETROSPECTIVE|||||||
33842757|NCT01665131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842758|NCT03873753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33842759|NCT03988738|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Donors will be randomly assigned to one of two groups using complete block randomization until a total of 212 participants are recruited: 106 in the intervention group and 106 in the control group.|t|t|f|t
33842760|NCT04896424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842761|NCT04245553|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33842762|NCT03950700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The decision to use another substance for the irrigation of the alveolus will be taken in a randomized manner.Through numerical assignment according to the order of surgical scheduling. The patients with even numbers are irrigated on the right side with bupivacaine and on the left side with saline. Patients with odd numbers will be irrigated in the opposite way.~Patients will be considered blinded to the drug of choice, and they will not know what type of solution will be administered on each side."|In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN® THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.|t|f|f|f
33842763|NCT03122691|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo controlled, double blind drug administration||t|f|f|t
33842764|NCT01684787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842765|NCT02184975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842766|NCT05101577|||COHORT||OTHER|||||||
33842767|NCT01581177|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33842768|NCT02878707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33842769|NCT02580929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842770|NCT03083418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842771|NCT00697645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|patients in the placebo group received sham TMS|Patietns were recruited into placebo or active treatment groups|t|t|t|t
33842772|NCT03360448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Randomized|t|t|t|t
33842773|NCT06199180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients know their treatment arm. All endpoints will be adjudicated by a blinded endpoint committee.|patients will be randomised to PFA or RFA for redo PVI|f|f|f|t
33842774|NCT00693940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842775|NCT05679674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945346|NCT02012257|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33945347|NCT01845129|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33842776|NCT02241590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842777|NCT02005042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33842778|NCT05447572|||COHORT||PROSPECTIVE|||||||
33842779|NCT06163573|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental group: biological: Autologous nasal chondrocytes and ECM proteins Control group: Platelet rich plasma injections||||
33842780|NCT06718712|RANDOMIZED|PARALLEL||OTHER||SINGLE||Lower body unilateral design|f|f|f|t
33842781|NCT05085171|RANDOMIZED|FACTORIAL||OTHER||NONE||A community randomised controlled trial of 24 clinics,12 in the intervention arm and 12 in standard of care arm. Two levels of randomization planned||||
33842782|NCT01075295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842783|NCT05324085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842784|NCT04222777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Not applicable. All participants are healthy volunteers.|Fundamental research. Cinemathographic recordings will be made in healthy volunteers to determine physiological range of motion in the cervical spine. No health outcome of the intervention will be assessed.||||
33842785|NCT00658216|||COHORT||PROSPECTIVE|||||||
33842786|NCT04921475|||COHORT||PROSPECTIVE|||||||
33842787|NCT03477773|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Pilot, exploratory, randomized controlled trial||||
33842788|NCT00457652|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842789|NCT02259660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33842790|NCT01211639|||CASE_ONLY||CROSS_SECTIONAL|||||||
33842791|NCT05312164|||CASE_ONLY||OTHER|||||||
33842792|NCT04199559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842793|NCT00566605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945348|NCT05635695|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945349|NCT01711073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945350|NCT01363232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739820|NCT04741425|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"The group allocation is determined by the recruitment sequence into the study. Sealed, opaque envelopes with random codes (A and B) in blocks will be generated by a research assistant, who is blinded to the study group to maintain the randomization concealment, and the participant list with the group allocation will be prepared by another research assistant.~Outcome assessment will be blinded by using online questionnaires."||f|t|f|t
33945351|NCT03374982|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The person administering the FACES pain rating scale will be masked|This is a randomized cross-over clinical trial wherein the study subject serves as his or her own control.|f|f|f|t
33945352|NCT02534324|||COHORT||PROSPECTIVE|||||||
33945353|NCT03708926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|placebo controlled clinical trial|t|f|t|f
33945354|NCT06459635|||CASE_CONTROL||PROSPECTIVE|||||||
34050608|NCT04786223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Alzheimer's Disease Dementia||||
33739821|NCT03684798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739822|NCT02717091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739823|NCT00670124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739824|NCT05428085|||COHORT||RETROSPECTIVE|||||||
33739825|NCT05984394|||COHORT||PROSPECTIVE|||||||
33739826|NCT03531593|||COHORT||PROSPECTIVE|||||||
33739827|NCT01460524|||COHORT||PROSPECTIVE|||||||
33739828|NCT02497664|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33739829|NCT03899870|||COHORT||RETROSPECTIVE|||||||
33739830|NCT01615445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34050609|NCT06058520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is an exploratory, randomized, double blind, placebo- controlled clinical trial. Subjects and investigators will be blinded to the Microbiota transplant therapy (MTT) and placebo arms.|t|f|t|f
34050610|NCT04678232|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive PATH therapy.||||
34050611|NCT03902184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739831|NCT05977595|||COHORT||RETROSPECTIVE|||||||
33739832|NCT00951067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33739833|NCT05056246|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33739834|NCT05612542|||CASE_ONLY||RETROSPECTIVE|||||||
33739835|NCT03274700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33739836|NCT06573047|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33739837|NCT04739748|||COHORT||PROSPECTIVE|||||||
33739838|NCT02479984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739839|NCT01459796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33739840|NCT06446635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739841|NCT02316236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33739842|NCT03188640|NA|SINGLE_GROUP||TREATMENT||NONE||With-in group comparison of pre- and postoperative data.||||
33739843|NCT06573632|||CASE_ONLY||RETROSPECTIVE|||||||
33739844|NCT04629664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive FX-322 or placebo randomized 4:1.|t|t|t|t
33842794|NCT00918879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842795|NCT05263674|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of two treatment strategies||||
33842796|NCT03878992||SEQUENTIAL||BASIC_SCIENCE||NONE||All participants will be studies two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two times are identical. The trial day includes infusion of tracers (glucose, tyrosine, phenylalanine, urea, palmitate), muscle biopsies, subcutaneous fat biopsies, an intravenous bolus of 0.5 mg GH, indirect calorimetry, plethysmography, blood samples, strength test, DXA scan and spectroscopy of liver and muscle.||||
33842797|NCT02466464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842798|NCT06190964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050612|NCT04088071|||COHORT||OTHER|||||||
34050613|NCT06529731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050614|NCT05450354|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050615|NCT05669508|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34050616|NCT05667116|||COHORT||RETROSPECTIVE|||||||
34050617|NCT06363110|||COHORT||RETROSPECTIVE|||||||
33842799|NCT03130881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739845|NCT05158062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842800|NCT04164342|NA|SINGLE_GROUP||OTHER||NONE||||||
33842801|NCT05695560|||COHORT||PROSPECTIVE|||||||
33739846|NCT00612066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739847|NCT06254144|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33842802|NCT02942992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739848|NCT04362358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739849|NCT05290129|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biased coin up-and-down design.|t|t|t|t
33842803|NCT02799641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33739850|NCT01639001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739851|NCT00411307|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842804|NCT05714891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739852|NCT03025165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739853|NCT03475641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739854|NCT01975844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739855|NCT00141440|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842805|NCT02699138|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33739856|NCT04755660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|Randomized|f|f|f|t
33842806|NCT06365788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739857|NCT04226638|||CASE_ONLY||RETROSPECTIVE|||||||
33739858|NCT01892475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945355|NCT00194831|||COHORT|||||||||
33945356|NCT01639807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739859|NCT00698529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945357|NCT01661075|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33945358|NCT05921942|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients who fulfill the inclusion criteria will be recruited and randomized into one of two groups:~Group A: Patients will receive standard therapy FOLFOX PROTOCOL Group B: Patients will receive metformin (500 mg twice daily or 1000 mg once daily) on top of standard therapy"||||
33945359|NCT06152991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This clinical trial will be conducted as a double-blind study. The double-blind condition ensures that the investigational drug and the placebo are manufactured to be indistinguishable in terms of appearance, with identical formulations and characteristics, and are supplied in identical packaging. All investigational drugs for the clinical trial will be managed using unique code numbers.|Double-Blindle|t|t|t|t
33739860|NCT02908568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33945360|NCT04138758|||COHORT||RETROSPECTIVE|||||||
33945361|NCT00201682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945362|NCT06212960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945363|NCT00450814|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739861|NCT06197139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739862|NCT02579291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34050618|NCT05861492|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Phase 1: Data on current practice was collected by GPs, each providing one patient with unexplained fatigue. None of the GPs used the FDDA.~Phase 2: The GPs of phase 1 were randomized to two groups (1:1) with half of the GPs in each group.~Group 1 including additional patients without using the FDDA (control group). Group 2 including additional patients while using the FDDA (experimental group)."||||
33739863|NCT00541047|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33739864|NCT01771276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050619|NCT01364688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050620|NCT04824794|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation part is sequential while the expansion Part A cohorts are parallel. Expansion Part B is sequential to Expansion Part A RRMM cohort. In Expansion Part B, participants with RRMM are randomized (1:1) to treatment.||||
33739865|NCT02595567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739866|NCT06520748|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33739867|NCT05861115|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigators collected retrospective data and gave to the software to interpret. Echocardiography as the gold standard, and tested whether the software could correctly interpret left ventricular systolic dysfunction.||||
33842807|NCT06728410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842808|NCT02085395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945364|NCT03189680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The single-arm, 3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training (n = 35, 17 males) conceptualized but seldom implemented previously. Each of the 15 training sessions lasted 60 minutes. Patients performed each exercise under increasingly difficult conditions and speed according to principles of periodization. All patients kept an exercise log detailing the positive and negative effects of the intervention on clinical and motor symptoms. The logs and attendance were checked daily. The no-intervention control, consisting of PD patients (n = 20, 12 males) received unsupervised standard care, consisting of the prescribed medications and daily, unsupervised 30 minutes of exercises at home.|f|f|t|f
33977976|NCT05861648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34050621|NCT06310551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050622|NCT01651520|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33739868|NCT01156324|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977977|NCT05505812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739869|NCT00357305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739870|NCT05176327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739871|NCT01100177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739872|NCT02294292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739873|NCT01075321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739874|NCT04297046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After general anesthesia was given to the participant, the blocks were made. The participant did not know the type of block made to him.The outcomes assessor evaluating the participants after the surgery does not know the type of block made to the patients.||t|f|f|t
33739875|NCT03219333|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, open-label, multi-cohort, multicenter study||||
33977978|NCT01247259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739876|NCT04965779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33739877|NCT01429545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739878|NCT04139811|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739879|NCT00099697|RANDOMIZED|||PREVENTION||DOUBLE||||||
33739880|NCT06572176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Because of the nature of the device and the procedure of fluorescent, blinding couldn't be performed.|A cluster-randomized controlled pretest-posttest and follow-up research design were used.||||
33739881|NCT06463847|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739882|NCT04468295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739883|NCT00964691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739884|NCT00003863|||CASE_ONLY||PROSPECTIVE|||||||
33739885|NCT02250885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945365|NCT06063382|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be assigned either to the ADHD group or non-ADHD group based on diagnosis. Both groups will receive the same intervention, which is to perform three academic exams based on the Brazilian National High School Exam (ENEM) under three different time conditions (40 minutes, 50 minutes and 60 minutes). The order in which they will perform each exam and with which time condition will be randomized.~In order to emulate real-life conditions in which students compete for college entry and motivate them, the participants will be competing for valuable prizes (ebook readers)."||||
33945366|NCT04657809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33945367|NCT01122719|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945368|NCT01773850|||CASE_ONLY||PROSPECTIVE|||||||
33945369|NCT05881590|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Real-world study design drawing largely on routinely collected data to compare outcomes for patients recruited to a hybrid pulmonary rehabilitation programme with a propensity matched control group that has previously received standard pulmonary rehabilitation as part of usual care.||||
33945370|NCT01396811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945371|NCT04987684|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945372|NCT00606463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945373|NCT04957706|||COHORT||PROSPECTIVE|||||||
33945374|NCT01381237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945375|NCT01255449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945376|NCT04205773|||CASE_ONLY||PROSPECTIVE|||||||
33945377|NCT03397472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945378|NCT03937882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, investigators, and study personnel involved with the conduct of the study will be masked with regard to treatment assignments.|Subjects will be randomized in a 1:1 ratio RGN-259 to placebo ophthalmic solution.|t|t|t|t
33945379|NCT03383406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945380|NCT03166774|||COHORT||PROSPECTIVE|||||||
33945381|NCT04533204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were informed they would receive one of two cognition oriented treatments but were unaware of the nature of the other intervention.|Randomization to Mnemonic strategy or spaced retrieval training|t|f|f|f
33945382|NCT05204576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945383|NCT02959034|||CASE_CONTROL||PROSPECTIVE|||||||
33945384|NCT02479022|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33945385|NCT03929237|||COHORT||PROSPECTIVE|||||||
33945386|NCT02895477|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33945387|NCT04535921|||COHORT||PROSPECTIVE|||||||
33945388|NCT02070562|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33945389|NCT03190252|||COHORT||PROSPECTIVE|||||||
33945390|NCT00422227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945391|NCT04008173|||COHORT||OTHER|||||||
33945392|NCT03716128|||OTHER||CROSS_SECTIONAL|||||||
33739886|NCT05561127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739887|NCT03196765||SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation||||
33945393|NCT05141058|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33945394|NCT05105958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33945395|NCT05682638|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33945396|NCT05713019|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|Participant and Investigator will be blinded as to whether saline or ATP is being given.|Compare effect of diluent with ATP.|t|f|t|f
33945397|NCT00532441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945398|NCT04018716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945399|NCT04067687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two arm of control group and intervention group||||
33945400|NCT04758325|||OTHER||PROSPECTIVE|||||||
33945401|NCT02283411|NA|SINGLE_GROUP||OTHER||NONE||||||
33945402|NCT01682343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945403|NCT02979275|||CASE_CONTROL||PROSPECTIVE|||||||
33945404|NCT02546102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945405|NCT04914650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945406|NCT04677816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945407|NCT00887822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739888|NCT04535037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33739889|NCT01851005|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33739890|NCT05024331|||CASE_ONLY||RETROSPECTIVE|||||||
33739891|NCT04986618|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739892|NCT06535581|||OTHER||PROSPECTIVE|||||||
33945408|NCT02086240|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945409|NCT05642689|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Double blind randomized crossover study with two parallel arms|t|f|t|f
33945410|NCT06713577|||COHORT||PROSPECTIVE|||||||
33945411|NCT05180071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945412|NCT02067208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33945413|NCT06080789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945414|NCT01912482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33945415|NCT06624475|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomization||||
33945416|NCT04374604|||COHORT||PROSPECTIVE|||||||
33945417|NCT02399345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945418|NCT04706026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"There will be two study arms:~1. Open Inguinal hernia repair under general anesthesia (Control Group)~2. Inguinal hernia repair with local anesthesia (Experimental Group)"|t|f|f|f
33739893|NCT04696796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739894|NCT06452615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945419|NCT02834351|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33739895|NCT03052985|||COHORT||PROSPECTIVE|||||||
33739896|NCT00965068|RANDOMIZED|PARALLEL||TREATMENT||||||||
33945420|NCT00323934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739897|NCT05024812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739898|NCT05211219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945421|NCT06722781|RANDOMIZED|FACTORIAL||TREATMENT||NONE|The cluster randomisation sequence will be generated by a research assistant who is not involved in recruitment, treatment delivery or data analysis.|Pragmatic factorial cluster randomised controlled trial of a transdiagnostic treatment for common mental health problems||||
33945422|NCT01474291|||COHORT||PROSPECTIVE|||||||
33739899|NCT04333277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33945423|NCT06198634|||COHORT||PROSPECTIVE|||||||
33945424|NCT02651740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945425|NCT05524376|||OTHER||PROSPECTIVE|||||||
33739900|NCT04962971|||COHORT||PROSPECTIVE|||||||
33739901|NCT05252559|||COHORT||RETROSPECTIVE|||||||
33945426|NCT05965947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the group assignment of participants.|Randomized controlled trial with an intervention group and a control group.|f|f|f|t
33739902|NCT05971212|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|t|f|f
33945427|NCT02875262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945428|NCT03048981|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Before and after||||
33945429|NCT06018766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945430|NCT02531009|||COHORT||PROSPECTIVE|||||||
33945431|NCT01666301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945432|NCT00456742|||COHORT||RETROSPECTIVE|||||||
33945433|NCT01439932|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33945434|NCT01579240|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945435|NCT05707702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945436|NCT03039959|||COHORT||PROSPECTIVE|||||||
33945437|NCT03164629|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945438|NCT02713633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945439|NCT00627913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945440|NCT01778673|||COHORT||PROSPECTIVE|||||||
33945441|NCT05776511|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945442|NCT00213668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33945443|NCT05144516|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945444|NCT06097364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945445|NCT03999931|||CASE_CONTROL||OTHER|||||||
33945446|NCT00661310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33945447|NCT01365897|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33945448|NCT04550741|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This study will be an Open study.~For the primary outcome the analysis will be blind to the investigator"|||||
33945449|NCT06290934|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33945450|NCT00703729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945451|NCT05487027|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking will be possible as the home care units will have an integral part in applying the intervention. The investigators will need to have control over the units in intervention arm as they may need to assist in the early stages of intervention.|Individuals are grouped in clusters, where the clusters are the home care units in Trondheim. Half of the units will be randomized to control, half will be randomized to intervention. All units will be randomized at the same time.||||
33945452|NCT03516461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739903|NCT01110291|||CASE_ONLY||PROSPECTIVE|||||||
33739904|NCT04704245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739905|NCT06502457|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33739906|NCT03808285|||COHORT||RETROSPECTIVE|||||||
33739907|NCT06342544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739908|NCT00861341|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33739909|NCT01258205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739910|NCT00058890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739911|NCT04748380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet and 30 will be randomized to receive the home safety information at the visit in case they cancel their appointment and reschedule.|Stratifying by sex, 30 participants will be randomized to receive the CRC DA pamphlet and 30 will be randomized to receive the home safety information at the visit in case they cancel their appointment and reschedule.|t|f|f|f
33945453|NCT03751722|||COHORT||PROSPECTIVE|||||||
33945454|NCT02083406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945455|NCT01348464|||COHORT||PROSPECTIVE|||||||
33945456|NCT03707249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants were blinded by the use of eye-masks during infusion and the physical covering of infusion bags and giving sets. Investigators were unaware of the allocation to iron or saline control. Outcomes assessors were also unaware of the allocation.|2 groups were randomised to receive a dose of intravenous iron or iv saline control to manipulate body iron stores. They were subsequently investigated non-invasively and with venous blood sampling during an ascent to very high altitude.|t|f|t|t
33945457|NCT00923481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945458|NCT01619176|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945459|NCT02647931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945460|NCT06383988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945461|NCT00872131|||CASE_CONTROL||PROSPECTIVE|||||||
33945462|NCT04019080|||COHORT||RETROSPECTIVE|||||||
33945463|NCT04526262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945464|NCT01979250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945465|NCT05664412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Care providers, outcome assessors, data analysts, and a research assistant who will follow the procedures remotely will be blind. A person in the lab not directly involved in any of the previously mentioned activities will be aware of the randomization for safety reasons.|This is a randomized double-blind sham-controlled study. We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. The first arm will receive one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task). The second arm will first receive 20 sessions of sham stimulation coupled with cognitive training. After the one-month follow-up, they will receive in-phase offline theta tACS (i.e., tACS at rest, with no task).|t|t|t|t
33739912|NCT06069154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators, participants, and clinical staff will be masked to treatment group assignment, with the only exception being the unmasked individual who performs the procedure (and will not have subsequent contact with the participant).|Pragmatic, multicenter, randomized, triple-masked, sham-controlled clinical trial|t|t|t|t
33739913|NCT03588572|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The investigator learned about the experimental grouping and medication situation, but the subjects did not know until the end of the experiment.|On the basis of conventional clinical treatment in both groups, the experimental group was given drug intervention, and the control group was not given drug treatment.|t|f|f|f
34075736|NCT06517433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, dose escalation to reach MTD. The MTD will be confirmed in parallel cohorts: patients with platinum-resistant ovarian cancer; patients with non-squamous NSCLC, adenocarcinoma subtype||||
33739914|NCT02977377|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33739915|NCT05743166|||COHORT||RETROSPECTIVE|||||||
33739916|NCT05758025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739917|NCT04779957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739918|NCT06572371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739919|NCT01418300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739920|NCT02193620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739921|NCT06173154|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739922|NCT02192450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739923|NCT01144104|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33739924|NCT01030224|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33739925|NCT01018849|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33739926|NCT06420635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33739927|NCT04136106|||CASE_CONTROL||PROSPECTIVE|||||||
33739928|NCT05897645|||COHORT||PROSPECTIVE|||||||
33739929|NCT06337929|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33739930|NCT02805127|||CASE_ONLY||PROSPECTIVE|||||||
33739931|NCT02880852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739932|NCT06202885|||CASE_CONTROL||RETROSPECTIVE|||||||
33739933|NCT02703844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33739934|NCT06119659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739935|NCT06102876|||COHORT||PROSPECTIVE|||||||
33739936|NCT06572527|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes obtained with the questionnaire form were collected from the families by the teachers.|Non-randomized, parallel assignment (1:1)|f|f|f|t
33739937|NCT05378867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. Neither the subjects, nor the Investigator, nor the Sponsor knows which drug is being administered to which group. Only the Biostatistician who generated the actual randomization scheme with IWRS and the Pharmacist or nurse at the study center who prepares the study drugs and dose for the subjects will be unblinded. All other study related individuals including ancillary clinical staff, biological laboratory staff, clinical research associates, medical monitors, and scientific operation and management team at the study center will remain blinded to the treatment assignment.|A Phase 3, Multicenter, Randomized and Double-blind Study Assessing the Interchangeability between TRS003 and China-approved Bevacizumab® (also called China-approved Avastin) For First-Line Treatment of Patients with Metastatic Colorectal Cancer (CRC)|t|f|t|f
33739938|NCT05298605|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33945466|NCT06096766|||COHORT||CROSS_SECTIONAL|||||||
33945467|NCT05879016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33945468|NCT02720627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945469|NCT04031352|||COHORT||PROSPECTIVE|||||||
33945470|NCT06634381|||COHORT||CROSS_SECTIONAL|||||||
33945471|NCT04964882|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33945472|NCT04786782|||COHORT||PROSPECTIVE|||||||
33945473|NCT01978717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945474|NCT03754881|||COHORT||PROSPECTIVE|||||||
33945475|NCT01349816|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33945476|NCT02815007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945477|NCT01973205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945478|NCT05600101|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945479|NCT03726320|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
33739939|NCT01358981|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33739940|NCT04679129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739941|NCT04674059|||CASE_ONLY||PROSPECTIVE|||||||
33739942|NCT03357042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three group: Aerobic retraining intervention, standard of care intervention, healthy control|f|f|t|t
33739943|NCT04944823|||COHORT||PROSPECTIVE|||||||
33739944|NCT03540342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739945|NCT06294314|||COHORT||PROSPECTIVE|||||||
33739946|NCT02921412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33945480|NCT04322552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945481|NCT00496574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050623|NCT02266719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is divided in three groups, as follows:~Patients with complex abdominal aortic aneurysms including, juxtarenal, suprarenal and type IV thoracoabdominal aneurysms will be enrolled in the fenestrated-CMD group.~Patients with type I-III throacoabdominal aneurysms will be enrolled in the type I-III TAAAs groups and will be eligible for custom-made/ off-the-shelf branched devices.~Patients with high surgical risk with aortic arch aneurysms treated by patient-specific stent-grafts with one to three inner branches or a scallop."||||
34050624|NCT05838365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945482|NCT05404321|||COHORT||PROSPECTIVE|||||||
33945483|NCT00354120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945484|NCT00013689||||TREATMENT||||||||
33945485|NCT04061668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33945486|NCT01042431|||COHORT||PROSPECTIVE|||||||
33945487|NCT01401179|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33945488|NCT04391660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945489|NCT02452138|||COHORT||PROSPECTIVE|||||||
33945490|NCT02647021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33945491|NCT06001164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945492|NCT00693329|||COHORT||PROSPECTIVE|||||||
33945493|NCT05861882|||CASE_CONTROL||PROSPECTIVE|||||||
33945494|NCT02944604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945495|NCT02010099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945496|NCT02053415|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33945497|NCT01855919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945498|NCT00135694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945499|NCT04422301|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33945500|NCT02852239|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945501|NCT01396434|||||PROSPECTIVE|||||||
33945502|NCT00132665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945503|NCT00203827|||COHORT||PROSPECTIVE|||||||
33945504|NCT06401382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945505|NCT02283801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945506|NCT01378624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945507|NCT06606171|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33945508|NCT06205875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This trial is designed as a mono-center, double-blinded, prospective, randomized controlled superiority trail comparing 2 groups of patients|t|t|t|t
33945509|NCT05545293|||COHORT||PROSPECTIVE|||||||
33945510|NCT00277862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945511|NCT02850666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945512|NCT02516605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945513|NCT02286206|NA|SINGLE_GROUP||OTHER||NONE||||||
33945514|NCT00712608|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33945515|NCT03425240|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33945516|NCT05119283|NA|SINGLE_GROUP||TREATMENT||NONE|"After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®. Each group will consist of the same number of patients, that is, 10. Patients will receive 140 mL of the substances, to be used for 7 days, twice a day.~Clinical reassessments of patients will be made before the treatments, and at 15, 30 and 60 after the performance of the RAR and beginning of the respective mouthwashes."|Thirty patients will be recruited who will undergo scaling and coronal-root planing (RAR), and after basic periodontal treatment will be randomly divided into 3 groups according to the supporting treatment: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will receive 0.12% chlorhexidine mouthwash; G3 - patients who will be treated with PHTALOX®.||||
33945517|NCT00318032|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33945518|NCT03724318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Open-label, parallel, randomized, control trial|f|f|f|t
33945519|NCT05066516|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945520|NCT04932564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945521|NCT00262457|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945522|NCT01708473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33945523|NCT00561795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945524|NCT04406259|NA|SINGLE_GROUP||OTHER||NONE||prospective cohort, interventional , multicentric study||||
33945525|NCT00283153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945526|NCT03553121|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Doctor who evaluate bowel function will not know whether patients walked or not|walking preoperatively not walking preoperatively|t|f|t|t
33842809|NCT04961177|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"The proposed intervention will have five components:~1. We will conduct trainings for our partner agencies and their frontline health workers to increase knowledge and understanding of: 1.) Risk/protective factors for ACEs and 2.) Eligibility criteria and filing requirements and procedures for EITC.~2. Working with our partners, we will also conduct EITC educational outreach and information sessions targeted to potential EITC filers.~3. We will track program level EITC data regarding screening and assistance provided to clients by CHWs in our network and the number of clients who submit EITC claims and the amounts received.~4. We will conduct a pre/post survey with clients who submit EITC claims to determine whether EITC reduces risk factors and increases protective factors for ACEs.~5. We will disseminate this model throughout the state."||||
33842810|NCT04877353|RANDOMIZED|PARALLEL||PREVENTION||NONE||Postoperative NIV||||
33842811|NCT00082940||||TREATMENT||NONE||||||
33945527|NCT06228261|||COHORT||RETROSPECTIVE|||||||
33945528|NCT04489511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945529|NCT05949827|||COHORT||PROSPECTIVE|||||||
33945530|NCT04141098|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study. Patients will receive one implant if they meet all inclusion/exclusion criteria after a review by the Medical Advisory Board (MAB). Patients that cannot receive the implant due to an intraoperative exclusion, will receive standard of care treatment.||||
33945531|NCT03359811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945532|NCT06547502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945533|NCT02221258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945534|NCT01233076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945535|NCT02436993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945536|NCT03053180|||COHORT||PROSPECTIVE|||||||
33945537|NCT03611907|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled clinical trial is designed to highlight differences between Double Lumen Aspiration Needle and Single Lumen Needle commonly used in clinical practice primarly in terms of number of retrieved oocytes per procedure.||||
33945538|NCT00283673|RANDOMIZED|PARALLEL||||SINGLE||||||
33945539|NCT06475365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Control (no intervention) \& experimental (intervention). Both study arms will complete three (3) questionnaires at specified time points. In addition to questionnaires, the experimental group will receive an intervention of gargling warm salt water thrice daily (t.i.d.).||||
33945540|NCT03990168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945541|NCT00015912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945542|NCT05782738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945543|NCT06029439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945544|NCT05694364|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33945545|NCT03817658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945546|NCT01277757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945547|NCT05778734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||K99 Phase is a single arm study, whiles the R00 phase is a 2-arm study.|f|f|f|t
33945548|NCT00602043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945549|NCT05303428|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945550|NCT02160262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945551|NCT02260804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945552|NCT04323345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33945553|NCT04540627|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33945554|NCT00967473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945555|NCT01853319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739947|NCT04188041|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||25 primary care team members will be purposively sampled to undergo key informant interviews regarding LTBI testing and treatment knowledge, attitudinal, and skill gaps. Then, 12 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will be asked to complete quantitative surveys before and after the course as well as post-session surveys following each session. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.||||
33945556|NCT03252223|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945557|NCT04362527|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Phase 3, multicenter, international (France, Switzerland), randomized, double blinded, placebo-controlled study|t|t|t|f
33945558|NCT00206752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945559|NCT03854669|NA|SINGLE_GROUP||OTHER||NONE||||||
33945560|NCT03306589|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|This will be an open label study and no masking will be performed.|Subjects in 2 separate groups will be randomized to receive either LPS or GM-CSF at the same time.||||
33945561|NCT03796858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33945562|NCT03953651|||COHORT||PROSPECTIVE|||||||
33945563|NCT06471361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945564|NCT01873274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945565|NCT04301271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945566|NCT06331429|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945567|NCT06423521|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34075737|NCT01264809|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33739948|NCT05506982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33739949|NCT02157740|||CASE_CONTROL||RETROSPECTIVE|||||||
33739950|NCT02889081|||COHORT||PROSPECTIVE|||||||
33739951|NCT01057212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739952|NCT05309512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739953|NCT06531330|||OTHER||RETROSPECTIVE|||||||
33739954|NCT00591812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945568|NCT03749031|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945569|NCT00863564|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33945570|NCT05645731|||COHORT||PROSPECTIVE|||||||
33945571|NCT01655368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945572|NCT02982122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945573|NCT04357834|||OTHER||PROSPECTIVE|||||||
33945574|NCT00167713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945575|NCT06242886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The mothers included in the study were blind to each other in terms of application, and the researcher who collected the data was blind to the groups in the study in terms of analysis and reporting. Breast and oxytocin massage and follow-up were carried out by the researcher (FŞB), who could not be blind to the applications. Randomization was done by another researcher (AYK). To avoid bias, the researcher who commissioned the study (FŞB) was not involved in any step of the data collection and statistical evaluation process|A Single Blind, Randomized Controlled Study|f|f|t|t
33945576|NCT02434640|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33945577|NCT02347540|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33945578|NCT02000674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977979|NCT04849988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator, study nurse/other study personnel, and patients will be blinded to the treatment group. An appropriately trained person will reconstitute investigational product, fill masked syringes and provide them to the blinded investigator, but will not perform any assessments with the patient.|Approximately 60 patients will be randomized in a 1:1:1:1 ratio and receive one of the four treatments: ABP-450 low dose, ABP-450 mid dose, ABP-450 high dose, or placebo via intramuscular injection into affected neck muscles.|t|f|t|t
33977980|NCT02288832|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34075738|NCT02202798|||COHORT||PROSPECTIVE|||||||
34075739|NCT03952572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075740|NCT01290419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075741|NCT04824898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739955|NCT01528098|||CASE_CONTROL||PROSPECTIVE|||||||
33945579|NCT06305767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The Phase 2 Adjuvant Cohort of study will be conducted as a double-blind study under in-house blinding procedures. V940 and placebo will be prepared and dispensed by unblinded pharmacists and administered in a blinded fashion by blinded personnel. The participants and the investigators who are involved in the study intervention administration will be unaware of the intervention assignments.~The Phase 1 Perioperative Cohort will be conducted as an open-label study. Participants and investigators will be aware of the intervention assignments."|"The Phase 2 Adjuvant Cohort is a placebo- and active-controlled, parallel-group, multicenter, double-blind safety and efficacy study of adjuvant V940 plus pembrolizumab versus adjuvant placebo plus pembrolizumab in participants with pathologic high-risk MIUC after radical resection. Eligible participants will be randomly assigned in a 1:1 ratio to receive treatment with either V940 plus pembrolizumab or placebo plus pembrolizumab.~The Phase 1 Perioperative Cohort of this study has a single arm into which eligible participants are allocated. It will evaluate safety and preliminary efficacy of perioperative (neoadjuvant and adjuvant) V940 in combination with pembrolizumab plus EV for participants with muscle-invasive bladder cancer (MIBC)."|t|f|t|f
33945580|NCT00542321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945581|NCT05222516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Multicenter, randomized, double blind, placebo controlled|OM-85 vs. placebo|t|t|t|t
33945582|NCT02984631|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33945583|NCT00232128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945584|NCT05548270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945585|NCT00539461|||||PROSPECTIVE|||||||
33945586|NCT04797676|||COHORT||PROSPECTIVE|||||||
33945587|NCT06238882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945588|NCT04983849|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33945589|NCT05500911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||After the sinus lift procedure (performed with OSSIX® BONE on all study subjects), control group will be treated with a traditional implant surface (MultiNeO CS), test group will be treated with a bioactive surfaced implant (NINA MultiNeO NH)||||
33945590|NCT02318641|||COHORT||PROSPECTIVE|||||||
33945591|NCT06265389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945592|NCT03741075|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which was used|The current study was a double-blind randomized controlled trial will be conducted at a tertiary University Hospital|t|t|t|t
33945593|NCT03114150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33945594|NCT04030364|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33945595|NCT02406586|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33945596|NCT03382951|||OTHER||CROSS_SECTIONAL|||||||
33945597|NCT02387827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945598|NCT06341452|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open, controlled, parallel, randomized, interventional, multi-center, explorative||||
33945599|NCT01213121|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33945600|NCT03618576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945601|NCT04011514|||CASE_CONTROL||PROSPECTIVE|||||||
33945602|NCT06563102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both albuterol/budesonide and albuterol will be supplied in identical inhalers and the maximum daily dose is the same for the 2 IMPs (6 doses, ie, 12 inhalations/day).|"At Visit 2 (Week 0), participants who demonstrated ≥ 80% compliance with all at-home study procedures during the last 14 days of the Lead-in Period, and who have used their albuterol rescue inhaler at least 2 days per week during the last 14 days of the Lead-in Period (≥ 4 uses total) will be randomized to continue the study and provided with study drug.~Randomization will be stratified by Visit 1 FeNO level (\< 50 ppb / ≥ 50 ppb) and geographic region. Both albuterol/budesonide and albuterol will be supplied in identical inhalers and the maximum daily dose is the same for the 2 IMPs (6 doses, ie, 12 inhalations/day)."|t|t|t|f
33945603|NCT05318768|||COHORT||PROSPECTIVE|||||||
33945604|NCT00672464|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33945605|NCT01780441|||COHORT||PROSPECTIVE|||||||
33945606|NCT02879968|||CASE_ONLY||CROSS_SECTIONAL|||||||
33945607|NCT05018390|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The practitioner providing the actual OMT or sham Treatment will not be involved in collecting eye movement data. The persons collecting eye movement data will not know the group to which participants will have been assigned.||t|f|f|t
33945608|NCT02467504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945609|NCT06055868|||OTHER||CROSS_SECTIONAL|||||||
33945610|NCT00848302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945611|NCT04651153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34050625|NCT04370756|RANDOMIZED|PARALLEL||OTHER||SINGLE|Group allocation will be determined at random using a computer-based number in blocks of 2 to ensure equal between-group distribution (i.e. n = 2 Ex only; n = 2 BR+EX). Each number will be kept in a sealed envelope until completion of Visits 1-2.|"Participants will be enrolled in small (n = 4) cohorts or waves to facilitate social support and adherence to the supervised exercise training sessions. We anticipate having 9 waves to successfully reach our target n. This assumes that each wave will have 4 participants, hence, 4 participants x 9 waves = 36 total participants. Subsequently, participants will be randomly selected to: 1) control (EX only) or 2) EX + Beetroot Juice."|t|f|f|f
33739956|NCT01170780|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33739957|NCT02277626|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33739958|NCT02569047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739959|NCT05787769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33739960|NCT04475003|||CASE_CROSSOVER||PROSPECTIVE|||||||
33739961|NCT03292757|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33739962|NCT03025620|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33739963|NCT02127008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739964|NCT02715765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33739965|NCT01702792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739966|NCT02974361|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33739967|NCT00652457|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34050626|NCT06288360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050627|NCT02115581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33739968|NCT02418260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33739969|NCT00945516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739970|NCT00000597|RANDOMIZED|||TREATMENT||||||||
33945612|NCT05014945|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with chronic low back pain due to degenerative spinal disease for more than 6 months||||
33945613|NCT01873027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945614|NCT04677738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945615|NCT00545974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945616|NCT03378531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945617|NCT04486586|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34050628|NCT04898764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050629|NCT01840150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050630|NCT06566521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050631|NCT05564195|||COHORT||PROSPECTIVE|||||||
34050632|NCT05856786|||COHORT||PROSPECTIVE|||||||
34050633|NCT00513383|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33739971|NCT04304690|NA|SINGLE_GROUP||OTHER||NONE||||||
33739972|NCT03096548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739973|NCT05953194|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33739974|NCT03360500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33842812|NCT05012553|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33739975|NCT06211621|||COHORT||RETROSPECTIVE|||||||
33739976|NCT05558410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739977|NCT01198184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739978|NCT05660109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739979|NCT03590977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33739980|NCT00165282|RANDOMIZED|PARALLEL||||NONE||||||
33739981|NCT01826825|||COHORT||PROSPECTIVE|||||||
33842813|NCT00559312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33842814|NCT01846494|||CASE_CONTROL||PROSPECTIVE|||||||
33842815|NCT02225132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842816|NCT04589039|||COHORT||PROSPECTIVE|||||||
33842817|NCT02690259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Detection of SLN followed by a complete lymphadenectomy. In this way every patients will serve as her own control||||
33842818|NCT04315558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinded medication delivery|pragmatic, randomized, controlled, double-blinded|t|t|t|f
33842819|NCT01108926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842820|NCT04473599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are randomized to receive messages according to a random schedule (within a mico-randomized trial), delivered via a reinforcement learning policy or a control with mood ratings only.||t|f|f|f
33842821|NCT00590252|||CASE_ONLY||PROSPECTIVE|||||||
33842822|NCT01669577|||COHORT||PROSPECTIVE|||||||
33842823|NCT00742326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842824|NCT00377689|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33842825|NCT02143011|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33842826|NCT05759039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33842827|NCT00176982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842828|NCT05315505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome evaluation will be performed by a cardiopulmonary technician that has no information about the patient group|Randomization will be performed after verifying the inclusion and exclusion criteria in the study and the informed, free and informed consent of the individuals. Randomization will be carried out by permuted blocks of 4 to guarantee the same number of participants in each group.|f|f|f|t
33842829|NCT03429803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842830|NCT06176365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842831|NCT03863873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842832|NCT05872152|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped-wedge||||
33842833|NCT01291251|||COHORT||PROSPECTIVE|||||||
33842834|NCT06224127|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Subjects, assessors and investigators will not know the randomization group assignment.|Subjects will be randomized into three groups. Group 1 receives an active heating device and placebo c-tactile fiber stimulation. Group 2 active c tactile fiber stimulation and placebo heating device. Group 3 receives active c tactile fiber stimulation and an active heating device.|t|f|t|t
33842835|NCT00858377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842836|NCT03101839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842837|NCT06144021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"* During the trial period, neither the researcher nor the research subjects know the randomization information of the research subjects. In principle, the randomization code is maintained and stored by the researcher.~* In general, double blinding should not be lifted until all research subjects have completed the test and the data is locked. However, in the case of an emergency such as a health problem of a research subject during intervention, double blinding may be lifted at the discretion of the researcher. In this case, the research person must contact the principal investigator as quickly as possible.~* The date, time, and reason for lifting double blinding must be documented in an appropriate location in the case record and supporting documents. A copy of the double-blind code release confirmation document received from the principal investigator must be kept in the supporting documents."|Double-blind randomized controlled trial|t|t|t|t
33842838|NCT04562766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33842839|NCT00224887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33842840|NCT02527642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842841|NCT01516255|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33842842|NCT02420197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33842843|NCT01534065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842844|NCT06288529|||COHORT||RETROSPECTIVE|||||||
33842845|NCT02232243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842846|NCT05308797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33945618|NCT03846466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945619|NCT03794310|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33945620|NCT02819882|||COHORT||PROSPECTIVE|||||||
33945621|NCT02291952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33945622|NCT04594122|RANDOMIZED|PARALLEL||OTHER||NONE||Two groups of pork retailers will be recruited: control group and intervention group||||
33945623|NCT03861442|||COHORT||PROSPECTIVE|||||||
33945624|NCT01539473|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33945625|NCT04759001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To mask treatments to physicisans and recipients, both FMT bottles and syringes will be covered with dark-coloured paper before the infusion, and the patients will be unable to see the endoscopic display during the procedure. Moreover, the physicians who will evsaluate patients at follow-up will not aware of the treatment being administered.|Randomized controlled trial|t|t|t|t
33945626|NCT01219179|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945627|NCT05470530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33945628|NCT01016912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33739982|NCT03378596|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33945629|NCT04761835|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label, randomized trial (1:1) to either dietary peanut intake or strict avoidance prior to a double blind placebo controlled food challenge 52 weeks later.||||
33945630|NCT01274104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33945631|NCT02968095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945632|NCT05799976|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This study will use a randomized clinical trial to evaluate a health system initiative to improve care gap closure. We will randomly assign primary care practices that use AthenaClinicals electronic health record at the following locations at Ascension's health system: Alabama-Birmingham, Kansas-Wichita, Tennessee-Nashville, Texas-Austin, and Texas-Waco. These practices will have the opportunity to opt-out from the program before randomization occurs.|f|f|t|t
33945633|NCT02116439|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33945634|NCT05587621|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized trial to compare a cloud-based software system with standard care||||
33945635|NCT06699849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945636|NCT02653131|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945637|NCT02094066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945638|NCT06114589|||COHORT||PROSPECTIVE|||||||
33945639|NCT05531565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945640|NCT04839900|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A two arm, cluster-randomized controlled trial (CRCT) will be conducted to determine whether proactive iCCM (arm 1)-- year-round weekly household visits by CHWs to test people of all ages with fever or history of fever with RDTs and offer treatment with an ACT for those who test positive (and treatment or referral of diarrhea and pneumonia for children under 5 years) -- compared to standard passive iCCM (arm 2)- malaria case management for all ages, and treatment or referral of diarrhea and pneumonia for children under 5 years, conducted by CHWs -- is associated with a greater reduction in confirmed malaria cases and parasite prevalence over a 2-year follow-up period. \]~Clusters defined by CHW location will be randomly allocated to receive either proactive iCCM or standard passive iCCM."||||
33945641|NCT00390741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33945642|NCT00629135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945643|NCT01752244|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33945644|NCT00804804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945645|NCT06420921|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945646|NCT02927990|||COHORT||PROSPECTIVE|||||||
33945647|NCT02616120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945648|NCT03567811|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|All control and Chronic Fatigue Syndrome subjects were treated in identical fashion.|All subjects were participated in an identical protocol. Outcomes were compared between control and Chronic Fatigue Syndrome subjects.||||
33739983|NCT00103649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945649|NCT01160029|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945650|NCT02853097|||COHORT||PROSPECTIVE|||||||
33945651|NCT06088017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945652|NCT00275704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945653|NCT00985114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945654|NCT05164068|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33945655|NCT04976205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945656|NCT06219304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945657|NCT02023476|RANDOMIZED|CROSSOVER||||NONE||||||
33945658|NCT06316076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945659|NCT02723461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739984|NCT04260191|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33739985|NCT02323191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739986|NCT04901559|||COHORT||PROSPECTIVE|||||||
33739987|NCT03019952|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33945660|NCT03518996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945661|NCT02932982|||OTHER||PROSPECTIVE|||||||
33945662|NCT03639493|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945663|NCT01967927|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945664|NCT06722885|||COHORT||PROSPECTIVE|||||||
33945665|NCT01083121|||CASE_ONLY||PROSPECTIVE|||||||
33945666|NCT03535441|||CASE_CONTROL||PROSPECTIVE|||||||
33945667|NCT04599543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739988|NCT02733497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33739989|NCT00144573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33739990|NCT05244525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33739991|NCT01212224|||||RETROSPECTIVE|||||||
33739992|NCT02182284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33739993|NCT01061294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33739994|NCT00399438|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33739995|NCT00789217|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34050634|NCT02012790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34050635|NCT04321382|||COHORT||CROSS_SECTIONAL|||||||
33739996|NCT02658851|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33739997|NCT06385444|||COHORT||PROSPECTIVE|||||||
33739998|NCT05160805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33739999|NCT03370341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will complete active and sham simulation sessions in a randomized, counterbalanced order approximately one week apart.|t|f|f|t
33740000|NCT03120104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740001|NCT05916755|||COHORT||PROSPECTIVE|||||||
33740002|NCT00578370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740003|NCT01044810|||COHORT||RETROSPECTIVE|||||||
33740004|NCT06529497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740005|NCT04498884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|douuble-blinded|two-period two-way crossover|t|f|t|f
33740006|NCT04610749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740007|NCT00919386|||CASE_ONLY||PROSPECTIVE|||||||
33740008|NCT00322062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740009|NCT01767116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842847|NCT06049576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842848|NCT05802823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled experimental design|f|f|f|t
33842849|NCT03795129|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking will not occur.|This is a cluster randomized trial that is randomized at the clinic level.||||
33842850|NCT02766101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842851|NCT01069653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842852|NCT05202392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single-blinded with blinding of the assessor to the groups and the therapist (researcher). After the initial screening process is completed, an independent accessor will access each recruited patient, outcome measuring tolls will be used by the experts. This will be recorded as baseline measurement assessment. The treatment will base on the designed protocol||f|f|f|t
33842853|NCT01499303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842854|NCT00297921|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33842855|NCT01852318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842856|NCT03071237|||CASE_ONLY||PROSPECTIVE|||||||
33842857|NCT04782440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33842858|NCT03128502|||OTHER||CROSS_SECTIONAL|||||||
33842859|NCT03203187|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842860|NCT02006251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33842861|NCT02416960|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33842862|NCT01022112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842863|NCT04237311|||COHORT||PROSPECTIVE|||||||
33842864|NCT00336518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842865|NCT06198348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842866|NCT02360033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842867|NCT06405100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842868|NCT03171662|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842869|NCT05292859|||CASE_ONLY||PROSPECTIVE|||||||
33842870|NCT02109705|||CASE_CONTROL||PROSPECTIVE|||||||
33842871|NCT00663702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842872|NCT02777476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842873|NCT02410616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842874|NCT02530970|||COHORT||PROSPECTIVE|||||||
33842875|NCT04824495|||COHORT||PROSPECTIVE|||||||
33842876|NCT01291030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842877|NCT00229138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842878|NCT05803421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842879|NCT03257527|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33842880|NCT02757872|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||Parent (VITAL; NCT01169259) study was based upon a 2x2 factorial design|t|f|t|t
33842881|NCT02495909|||COHORT||PROSPECTIVE|||||||
33842882|NCT05587348|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33842883|NCT06347328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33842884|NCT02566057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842885|NCT04864054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In Phase 2 (expansion phase) of the Phase I/II study, subjects will be assigned in a parallel, non-randomized manner to one of two expansion cohorts: Arm A or Arm B.||||
33842886|NCT00285662|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33842887|NCT04356677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842888|NCT05816304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized and allocated to either the intervention or attention control arm of the trial. Randomization will be centrally controlled, and allocation will be concealed using a secure, web-based randomization using the Research Electronic Data Capture (REDCap) platform.|Two-arm, pragmatic prospective, parallel, multi-center, randomized controlled trial (RCT)|t|f|f|f
33842889|NCT06728267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33842890|NCT02768532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842891|NCT04394377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33842892|NCT02907970|||COHORT||CROSS_SECTIONAL|||||||
33842893|NCT05061420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842894|NCT05917470|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33842895|NCT06515821|||CASE_CONTROL||PROSPECTIVE|||||||
33842896|NCT05956457|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single cohort of 100 individuals with relapsed/refractory multiple myeloma will be enrolled in the study, all of which will be enrolled in a digital health coaching program and receive a Fitbit device for activity tracking.||||
33842897|NCT02960737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33842898|NCT05741138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842899|NCT01612585|||COHORT||RETROSPECTIVE|||||||
33842900|NCT04561518|||COHORT||PROSPECTIVE|||||||
33945668|NCT03514160|RANDOMIZED|PARALLEL||OTHER||NONE||Randomization to group exercise or an attention-control group for 12 weeks (2:1 ratio). Group exercise sessions took place once per week at a community center.||||
33945669|NCT02133612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945670|NCT01797627|||COHORT||PROSPECTIVE|||||||
33945671|NCT01503866|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945672|NCT03582631|||COHORT||PROSPECTIVE|||||||
33945673|NCT02213965|||COHORT||PROSPECTIVE|||||||
33945674|NCT06230107|NA|SINGLE_GROUP||TREATMENT||NONE||quantitative, prospective, longitudinal and experimental||||
33945675|NCT06074146|||COHORT||PROSPECTIVE|||||||
33945676|NCT02680158|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Three way cross-over study with 6 sequences.|f|f|t|f
33945677|NCT00243477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050636|NCT05406115|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34050637|NCT02239133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764437|NCT03219008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients with depressive disorder were randomly assigned to different therapy groups or TAU therapy group based on different depressive disorders subtypes.|"Part 2: all patients before receiving any medicine treatment are divided into four groups which adopt different therapy strategies :treatment with fluvoxamine, fluoxetine, mirtazapine and treatment as usual(TAU).Meanwhile，patients with different subtypes of depressive disorder were randomly assigned to different therapy groups.Each therapy groups contains 50 participants.Therefore, the total sample size is 50\*12+200=800.~Part3:To find out efficiency of different kinds of therapy strategies.p=60%, error=5%,a-0.05,the amount of samples nearly is:867,considering the nearly 30% expulsion rate, the final total sample size is 867+260=1127.Therefore,sample size in each group is nearly 376.~Part4:p=60%,error=0.05, a=0.05, exculsion rate=30%,N=867+260=1127.the amount of samples of each group is 1127/3=nearly 400."|t|f|f|t
33764438|NCT06160739|||COHORT||PROSPECTIVE|||||||
33764439|NCT02294539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764440|NCT05916092|||COHORT||PROSPECTIVE|||||||
33842901|NCT03697317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842902|NCT05986682|||COHORT||RETROSPECTIVE|||||||
33842903|NCT06575790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842904|NCT04506645|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33842905|NCT00948116|||COHORT||PROSPECTIVE|||||||
33842906|NCT06379061|||CASE_ONLY||PROSPECTIVE|||||||
33842907|NCT06194487|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33842908|NCT04987840|||COHORT||PROSPECTIVE|||||||
33842909|NCT03217695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842910|NCT04101253|NA|SINGLE_GROUP||OTHER||NONE||||||
33842911|NCT00353249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842912|NCT02997293|||COHORT||RETROSPECTIVE|||||||
33842913|NCT06696768|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33842914|NCT06565455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842915|NCT06728020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three phases: in the first, focus groups and living labs are conducted to co-create the solution with patients; in the second, as the first action of the cmRCT, an RCT is conducted to verify the effectiveness of the initial ROOMMATE system; in the third, a pilot is conducted to preliminarily test the advanced version of the ROOMMATE system.|t|f|f|t
33842916|NCT03425097|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33842917|NCT05141851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842918|NCT00685139|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33842919|NCT05768347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842920|NCT03499470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842921|NCT04940819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842922|NCT05271266|||COHORT||PROSPECTIVE|||||||
33842923|NCT05857189|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover between experimental and traditional groups after 2 weeks of lapse time. both groups will be compared to healthy control||||
33842924|NCT04747600|||COHORT||PROSPECTIVE|||||||
33842925|NCT03977857|||COHORT||RETROSPECTIVE|||||||
33842926|NCT04698759|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33842927|NCT05901064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the patients nor the health care providers know with whitch device (Harmonic Focus or diathermy) the patient will be operated.|Double blinded randomized prospective study|t|t|f|f
33842928|NCT06306755|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33842929|NCT05901909|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two groups||||
33842930|NCT00772330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842931|NCT06727968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842932|NCT03423576|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH|||there was no masking of patients or outcome assessors|||||
33842933|NCT03612583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842934|NCT01546675|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33842935|NCT01098318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842936|NCT05431374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be an assessor blind, randomized controlled trial. Due to the nature of the interventions, it will be impossible to blind clinicians in participating centres or the participants themselves. Before assessments, participants will be asked not to reveal any information about treatment to assessors. To avoid unblinding, outcome assessors will be located separately from treatment providers, and we will assign new outcome assessors in cases of unintentional unblinding.|Participants will be randomized in a 1:1 allocation to measurement-based vs. standard-care.|f|f|f|t
33842937|NCT04074668|||COHORT||CROSS_SECTIONAL|||||||
33842938|NCT00700700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842939|NCT04174391|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33842940|NCT02421575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842941|NCT03703167|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, phase Ib trial with dose expansion of the BTK inhibitor ibrutinib in combination with rituximab and lenalidomide.||||
33842942|NCT06729229|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33842943|NCT01307657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33842944|NCT02856100|||COHORT||PROSPECTIVE|||||||
33842945|NCT06045793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to which treatment arm they are assigned to.||t|f|f|f
33842946|NCT03636191|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842947|NCT03106168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842948|NCT00466154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842949|NCT01621308|||||PROSPECTIVE|||||||
33945678|NCT06722144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|There are blinding of participants and their family.|Nursing home residents were dementia and older.|t|f|f|f
33842950|NCT02861235|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33945679|NCT04501380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33945680|NCT04474717|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33945681|NCT01554033|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33945682|NCT03311295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945683|NCT01738516|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33945684|NCT02771782|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945685|NCT04170725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945686|NCT06346639|NA|SINGLE_GROUP||PREVENTION||NONE|The researchers who will analyze the saliva and venous blood samples will be blinded.|||||
33945687|NCT00859495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945688|NCT03705858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945689|NCT04293211|||COHORT||PROSPECTIVE|||||||
33945690|NCT02548442|||COHORT||PROSPECTIVE|||||||
33945691|NCT04805242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33945692|NCT06607549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945693|NCT01244646|||CASE_ONLY||PROSPECTIVE|||||||
33945694|NCT02032199|||COHORT||PROSPECTIVE|||||||
33945695|NCT02316652|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33945696|NCT00884195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945697|NCT04064099|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group pre- and post- design||||
33945698|NCT04099693|||OTHER||PROSPECTIVE|||||||
33945699|NCT05842590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945700|NCT01720901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945701|NCT06420024|NA|SINGLE_GROUP||TREATMENT||NONE||Hermeneutic Single Case Efficacy Design||||
33945702|NCT02658279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945703|NCT06280404|||COHORT||PROSPECTIVE|||||||
33945704|NCT02988115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33945705|NCT00877565|||COHORT||PROSPECTIVE|||||||
33945706|NCT00474097|||CASE_ONLY||PROSPECTIVE|||||||
33945707|NCT00981422|||CASE_CONTROL||RETROSPECTIVE|||||||
33945708|NCT02419443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945709|NCT02449733|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33945710|NCT02776631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945711|NCT01617343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945712|NCT06158087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945713|NCT04183868|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||"52-weeks, single-center, prospective, controlled, randomized, open-label, two parallel group and switch, active-comparator.~13 subjects with T2DM, poorly controlled on metformin monotherapy, and without a history of ischemic heart disease, will be treated with empagliflozin for 26 weeks and will be compared with a group of 13 subjects with T2DM, poorly controlled on metformin monotherapy, and without a history of ischemic heart disease, treated with glimepiride (both in addition to metformin) for 26 weeks. At the end of 26 weeks of treatment, subjects belonging to the first group will be shifted to glimepiride therapy, while subjects belonging to the second group will be shifted to empagliflozin treatment for 26 weeks. All subjects, then, will control themselves."|t|f|f|f
33945714|NCT03853915|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive chemoradiation will be accrued to study and will have:~1. FDG PET Scan at 3 month time point.~2. Blood sample to measure HPV DNA at time point baseline, end of radiotherapy, 4-6 weeks and 3 months post completion of definitive radiotherapy."||||
33945715|NCT01811004|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33945716|NCT01407068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945717|NCT01870765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945718|NCT01307527|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945719|NCT02348710|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33945720|NCT02433704|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945721|NCT03695471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842951|NCT00769652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842952|NCT06070025|||OTHER||OTHER|||||||
33842953|NCT02130544|||COHORT||RETROSPECTIVE|||||||
33842954|NCT00425464|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945722|NCT04318015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will happen after previous assignment of recruited individual to high-risk or low-risk exposure according to he or her activities. An independent member of the team will randomly assign treatment or placebo following a computer based program. Blinding will end in case elimination criteria are met.|Triple blinded, randomized controlled trial|t|t|t|t
33945723|NCT03616782|NA|SINGLE_GROUP||TREATMENT||NONE||Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24months or untile to progression||||
33945724|NCT04257656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945725|NCT00773994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945726|NCT03388450|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33945727|NCT06383715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842955|NCT06239389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were divided into 2 groups, one received hydroxyurea second group received thalidomide.||||
33945728|NCT02486458|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33945729|NCT04435093|||OTHER||PROSPECTIVE|||||||
33945730|NCT06453915|NA|SINGLE_GROUP||OTHER||NONE||||||
33945731|NCT04766411|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33945732|NCT03153085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945733|NCT01928186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945734|NCT04097106|||CASE_CROSSOVER||PROSPECTIVE|||||||
33945735|NCT02101866|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33945736|NCT01869920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945737|NCT00348348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945738|NCT02227420|NA|SINGLE_GROUP||||NONE||||||
33945739|NCT03253380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945740|NCT04067804|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945741|NCT04225026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945742|NCT02899884|||COHORT||PROSPECTIVE|||||||
33945743|NCT04749316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant will not be told on which treatment arm are in. Outcome assessors will be blinded on participants' treatment arm.|Acutens treatment for faecal incontinence vs sham|t|f|f|t
33945744|NCT04630067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945745|NCT02716402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945746|NCT01798433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945747|NCT05103202|||CASE_CONTROL||OTHER|||||||
33945748|NCT01379911|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945749|NCT05163964|||COHORT||PROSPECTIVE|||||||
33945750|NCT00296569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945751|NCT05604859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945752|NCT00002715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945753|NCT00332982|RANDOMIZED|PARALLEL||ECT||NONE||||||
33945754|NCT01007227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945755|NCT05327868|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33945756|NCT01256424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945757|NCT04617379|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945758|NCT04490421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945759|NCT05465200|||COHORT||PROSPECTIVE|||||||
33945760|NCT00779506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945761|NCT01385839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945762|NCT02497274|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945763|NCT03301246|NA|SINGLE_GROUP||TREATMENT||NONE||45 patients will be treated using the 1.0mm dilatation catheter and 15 patients treated with the 1.25mm dilatation catheter for a total of 60 subjects enrolled and treated. Patients may be consented, enrolled and treated until the sample size is reached, with n=60 completing the study.||||
33945764|NCT01014442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945765|NCT04670523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective randomization of patients after minor thoracic operations into two different groups. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure. If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1. In the control group, the chest tube gets removed according to the investigators' traditional standard protocol not earlier than on postoperative day.|t|t|t|t
33945766|NCT02118909|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945767|NCT04631835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945768|NCT00088660|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945769|NCT02506101|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33945770|NCT01112124|||COHORT||PROSPECTIVE|||||||
33945771|NCT01784081|||COHORT||PROSPECTIVE|||||||
33764441|NCT01655602|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33764442|NCT02923102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945772|NCT05119751|RANDOMIZED|CROSSOVER||TREATMENT||NONE||First month of treatment is taken the vestibular route and the following the sublingual||||
33945773|NCT05574920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945774|NCT06452485|||COHORT||PROSPECTIVE|||||||
33945775|NCT03287960|NA|SINGLE_GROUP||TREATMENT||NONE|During the 8 week double-blind placebo-controlled withdrawal period, participants received 4 weeks of daily setmelanotide and 4 weeks of daily placebo. Participants, investigators, and sites remained blinded as to when placebo treatment was administered.|Open-label with an 8 week Double-Blind Placebo-Controlled Withdrawal Period||||
33945776|NCT05451758|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33945777|NCT01641731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945778|NCT00466284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945779|NCT03207516|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33945780|NCT01508221|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945781|NCT05206201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945782|NCT03944096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33945783|NCT05406882|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33945784|NCT00940719|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945785|NCT01657994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945786|NCT01040000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945787|NCT06539715|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945788|NCT05090813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945789|NCT01308385|||COHORT||PROSPECTIVE|||||||
33945790|NCT01858701|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33764443|NCT02880007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764444|NCT03485911|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only Part 1 and Part 2 were blinded. As part 3 was open-label, no blinding was used||t|t|t|f
33764445|NCT05127798|||COHORT||PROSPECTIVE|||||||
33764446|NCT05713006|NA|SINGLE_GROUP||TREATMENT||NONE||Patients (≥18 years), both sex, clinical stage IIIB and IV, ALK-rearranged NSCLC treated by Thoracic Oncology Department at Instituto Nacional de Cancerología (INCan).||||
33764447|NCT03620422|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||This is a mechanistic study. The first part of the study (mild allergic asthmatics and healthy controls) is to determine reproducibility of dose responses to mannitol-induced coughs. The second part of the study (mild asthmatics only) is to determine the effect of salbutamol on mannitol-induced coughs. Salbutamol or placebo will be delivered following a mannitol cough challenge in a randomized, double-blind crossover design.|t|t|t|t
33764448|NCT06495541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764449|NCT02278016|||CASE_ONLY||PROSPECTIVE|||||||
33764450|NCT01656928|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33764451|NCT01420432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945791|NCT01773460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945792|NCT04087733|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"GROUP / TREATED EYE (OZODROP® ): OZODROP® (ozonized oil 0.5% in liposomes) ophthalmic solution, 2 drops 4 times a day. OZODROP® will be instilled in the eye that will have to undergo cataract surgery.~GROUP / CONTROL EYE: saline solution 2 drops 4 times a day. As a check it will be used the contralateral eye that will not have to undergo cataract surgery."||||
33945793|NCT00136994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945794|NCT06270160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The intervention arms will be compared to the control arm of the study using a pre- and post-intervention survey. There will also be a follow-up survey after the study is complete.||||
33945795|NCT00000649||||TREATMENT||||||||
33945796|NCT00423137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945797|NCT04340102|NA|SINGLE_GROUP||TREATMENT||NONE||This project has two phases. Phase 1: Adapt BecomeAnEX, conduct usability testing, and train digital coaches. Phase 2: Implement adapted BecomeAnEx with 60 individuals with a mental health disorder who are hospitalized on the inpatient psychiatric unit at the University of Maryland Medical Center.||||
33945798|NCT05578820|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33945799|NCT04123743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding is done to the participants, care providers, investigator, and outcomes assessor in every stage of the study.|The participants will be divided into 2 groups, experimental group and control group. Experimental group will get intervention with topical cream containing Trigonella foenum-graceum extract, while control group will get intervention with placebo topical cream. Both experimental and control group will receive Wardah brand facial wash and Parasol sunscreen SPF 33 as part of the assigned intervention as well.The participants will undergo the assigned intervention for 12 weeks.|t|t|t|t
33945800|NCT01061073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945801|NCT04465903|||OTHER||PROSPECTIVE|||||||
33945802|NCT00953849|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945803|NCT01684930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33945804|NCT01781858|||COHORT||PROSPECTIVE|||||||
33945805|NCT00772031|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945806|NCT04372121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945807|NCT06051461|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33945808|NCT02304484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945809|NCT06392009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945810|NCT01647204|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33945811|NCT00825929|||CASE_CROSSOVER||PROSPECTIVE|||||||
33945812|NCT00438815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945813|NCT05867186|||COHORT||PROSPECTIVE|||||||
33945814|NCT05720923|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33945815|NCT04827420|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||"We are proposing a hybrid type 3 implementation study design (Figure 1) to test the feasibility of delivering tobacco cessation (Advise and Refer components of AAR) via MyChart/patient portal messaging. We will assess three message types by randomly assigning patients enrolled in MyChart to receive one of three messages - Arm 1: (Choice message + Facilitated referral), Arm 2: (Quit-only + Facilitated referral), or Arm 3 (ITQL Information-only + self-referral). If the patient opts-in to be referred to the quitline, the ITQL will offer an initial intake session to establish treatment goals and then their standard treatment plan."|t|t|t|t
33945816|NCT00463632|||COHORT||PROSPECTIVE|||||||
33945817|NCT03427931|NA|SINGLE_GROUP||OTHER||NONE||||||
33945818|NCT00332059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33945819|NCT02296541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945820|NCT05441722|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945821|NCT04537312|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945822|NCT05707663|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33945823|NCT01904955|||COHORT||PROSPECTIVE|||||||
33945824|NCT03865550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945825|NCT04682158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945826|NCT01125852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945827|NCT03222245|||COHORT||PROSPECTIVE|||||||
33945828|NCT03354065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinding of the evaluator to the study group blinding of patient to study hypothesis||t|f|t|t
33945829|NCT03538496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945830|NCT03099096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945831|NCT01741558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945832|NCT05409742|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33945833|NCT01697631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945834|NCT04130633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|placebo controlled, double-blind|All participants will complete all dose conditions (study arms) in a randomized order|t|f|f|t
33945835|NCT06388538|||COHORT||PROSPECTIVE|||||||
33764452|NCT05675852|||COHORT||PROSPECTIVE|||||||
33945836|NCT06062394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33945837|NCT01101321|RANDOMIZED|CROSSOVER||||NONE||||||
33945838|NCT01430559|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33945839|NCT00561912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945840|NCT02999295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945841|NCT06006481|||OTHER||PROSPECTIVE|||||||
33945842|NCT05643794|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33945843|NCT00016068|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33977981|NCT03922438|NA|SINGLE_GROUP||PREVENTION||NONE|No masking due to the nature of the intervention and the study design|Pilot study The eligible patients will be included in the study||||
33977982|NCT05815069|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764453|NCT03654339|NA|SINGLE_GROUP||TREATMENT||NONE||The patients will be equally divided into two test groups. Group A and Group B after phase I therapy. the group A patients will be treated with laterally repositioned flap to obtain root coverage using microsurgical approach. The group B patients will be treated with laterally repositioned flap to obtain root coverage using macrosurgical approach||||
33764454|NCT04860414|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34154332|NCT04602247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study will be a single-center, prospective cross-over trial in which each subject receives all test conditions. During the screening, about 2 weeks before the start of the study, women will be assessed for eligibility. Finally, 55 eligible women will be invited to participate.~Each subject will complete six iron absorption studies in which they will receive supplemental iron doses of 6 mg iron.The experimental phase will last for 37 days. The labeled iron doses will be administered on days 1, 3, 5, 19, 21 and 23. Since only three isotopes are used in the study, after day 5, there will be a wait period of 14 days to allow for incorporation of the labeled iron into erythrocytes. On day 19, 21 and 23 the other three test doses are administered. Randomization of the interventional products listed above will be set up as such, to ensure that participants do not receive the same isotopes in a given week. On day 1, day 19 and day 37, a venous blood sample will be collected."||||
33945844|NCT06304493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Outcome collection and data analysis will be performed by investigators blinded to the patient's cluster allocation (alarms ON or OFF)."|"This is a pragmatic single-center cluster study of surgical patients receiving incentive spirometry devices during their PACU stay, with either automatic alarms ON or OFF in alternating weeks."|f|f|f|t
33945845|NCT03902158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33945846|NCT00231322|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945847|NCT03108560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945848|NCT02535858|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945849|NCT01710709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945850|NCT03601611|NA|SINGLE_GROUP||TREATMENT||NONE||"- Patients will receive tocilizumab 8 mg/kg given as an IV infusion over 60 minutes every 4 weeks (Q4W) for at least 2 cycles or until worsening or lack of improvement of diarrhea and/or colitis and/arthritis, in case of unacceptable toxicity, withdrawal of consent or clear clinical deterioration, according to investigator's judgment.~At the initial stage, 7 patients will be enrolled and evaluated for symptom improvement. In case of ≤ 4 patients with at least one grade improvement, accrual will be terminated. If ≥ 5 patients with at least one grade improvement will be observed at the first stage, 13 additional patients will be entered at the second stage to achieve a target sample size of 20 evaluable patients. Further exploration of the treatment strategy is warranted, if at least one grade improvement is observed for ≥14 patients."||||
33945851|NCT02575469|||COHORT||PROSPECTIVE|||||||
33945852|NCT03582254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945853|NCT02594150|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33945854|NCT05748860|||COHORT||PROSPECTIVE|||||||
33945855|NCT03089229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Sponsor will send all washout and test products in compliance with current Good Manufacturing Practices directly to the clinical facility prior to the start of the study. Study procedures will be in place to ensure double-blind administration of study treatments. Access to the randomization code will be strictly controlled. The quantity of all study material shipped to the clinical facility will be documented on the shipping and receiving form included within the shipment. Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, care provider, outcomes assessor, research staff, or patients. Packaging and labeling of test and control treatments will be identical to maintain the blind. Products will be identified with the codes generated by the randomization.||t|t|t|t
33945856|NCT03795233|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945857|NCT05898633|NA|SINGLE_GROUP||TREATMENT||NONE||A Bayesian Continual Reassessment Method (CRM) will be used for the RESPONSE trial to inform how the IMP dose should be adapted for the next cohort based on past trial data. The CRM is a model-based design that uses a statistical model to estimate the risk of dose limiting events (DLE) per dose level. The target level of DLEs is set at 20% The CRM model does not allow dose-skipping. The recommended phase 2 dose in terms of safety (efficacy will also be taken into account) will be the highest dose level that has an estimated probability of DLE closest but below the target DLE level of 20%.||||
33945858|NCT06112314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945859|NCT02615158|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33945860|NCT01503229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945861|NCT05434741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a pilot randomized controlled trial, which will include 50 older people with HIV. Each block (n = 4) will be 1:1 randomized to either the group intervention or information-only control.|t|f|f|f
33945862|NCT05030220|||COHORT||PROSPECTIVE|||||||
33945863|NCT02360358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945864|NCT05221840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33945865|NCT04180319|||CASE_ONLY||PROSPECTIVE|||||||
33945866|NCT04835142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945867|NCT04591782|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33945868|NCT04095494|||OTHER||PROSPECTIVE|||||||
33945869|NCT02911311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945870|NCT04259541|||COHORT||CROSS_SECTIONAL|||||||
33945871|NCT01824368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945872|NCT03814499|||OTHER||PROSPECTIVE|||||||
33842956|NCT01109641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842957|NCT04346459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842958|NCT05667103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a multicenter, parallel cohort study. The patients with acute middle cerebral artery occlusion were divided into Embotrap group and control group at a ratio of 1:1 to receive mechanical thrombectomy. The patients in control group will receive thrombectomy using stent retriever without inner channel approved by FDA or NMPA. Several aspects such as first-pass recanalization rate, the successful recanalization rate, and mRS score at 90 days will be compared between the two groups.|t|t|t|t
33842959|NCT05843422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33842960|NCT04476134|||CASE_CONTROL||RETROSPECTIVE|||||||
33842961|NCT02666144|||CASE_CONTROL||PROSPECTIVE|||||||
33842962|NCT06281795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1:1 randomization of active stimulation vs. sham stimulation|t|t|t|f
33842963|NCT05786547|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33842964|NCT03562975|||CASE_ONLY||PROSPECTIVE|||||||
33842965|NCT04168528|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33945873|NCT04585191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||There are two arms within the comparative effectiveness RCT. All eligible PCPs will receive academic detailing. Eligible and consenting patients of these PCPs will be randomly allocated to intervention vs attention control arms grouped by PCP. (There will be a secondary, parallel comparison group to measure temporal trends in care for similar patients at other facilities in our care system not involved in the clinical trial.)|f|t|f|t
33945874|NCT06524856|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The Lung Master will force the lung muscle to work more strenuously and gradually build breathing muscles. Therefore, this study will focus on determining how The Lung Master (Pulmonary Exerciser) increases lung capacity in healthy individuals, which leads to improved overall lung functioning.||||
33945875|NCT04374331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Before inclusion, the patients were informed about the duration of care as usual, which could be six weeks or three months. The patients were blinded to the group assignment due to the nature of the intervention. The researchers involved in the data analysis and statistics stages were blinded to the group assignment, too. However, those involved in the running of the study were not blinded.|prospective, parallel, two arm, randomized controlled clinical trial|t|f|f|f
33945876|NCT00187655|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33945877|NCT06090227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945878|NCT06681051|||CASE_ONLY||PROSPECTIVE|||||||
33945879|NCT02974764|||COHORT||PROSPECTIVE|||||||
33945880|NCT06373640|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945881|NCT02217020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945882|NCT04799821|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33945883|NCT00635362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33945884|NCT02357394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945885|NCT05249504|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open and Pragmatic Parallel Randomized Controlled Clinical Trial||||
33945886|NCT03108352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33945887|NCT05459987|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945888|NCT00928863|||CASE_ONLY||PROSPECTIVE|||||||
33945889|NCT01609049|||COHORT||PROSPECTIVE|||||||
33945890|NCT01499498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945891|NCT03616652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945892|NCT02539160|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945893|NCT02806804|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33945894|NCT06003582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Infant mental health service|f|f|t|f
33945895|NCT01766466|RANDOMIZED|FACTORIAL||||NONE||||||
33945896|NCT02828852|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945897|NCT05654948|||CASE_ONLY||PROSPECTIVE|||||||
33945898|NCT03965416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33945899|NCT06019208|||COHORT||CROSS_SECTIONAL|||||||
33945900|NCT00329433|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945901|NCT02247102|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33945902|NCT05031156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945903|NCT06252545|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There will be 2 groups: 20 subjects with pancreas carcinoma for phone interviews and 6 for user testing the first version of the application..||||
33945904|NCT01546909|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33945905|NCT03639038|||OTHER||PROSPECTIVE|||||||
33945906|NCT06182839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be blinded to study participants and study investigators. Therefore, investigators who will interpret the cardiac magnetic resonance imaging (MRI) and who will adjudicate adverse events will be blinded to treatment group assignment. Canagliflozin 300 mg will be encapsulated to match the placebo.|We will conduct a single centre, prospective, randomized, parallel group (Canagliflozin VS placebo), double blind interventional study.|t|t|t|t
33945907|NCT06122961|||COHORT||CROSS_SECTIONAL|||||||
33945908|NCT03242291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945909|NCT06603571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945910|NCT01287260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945911|NCT00499395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945912|NCT06384599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945913|NCT02187718|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33945914|NCT05365204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participant will know how many concentration ladders we have, but will not know the exact concentration used on him.|The participants will be assigned to sentinel lymph node biopsies using different concentrations of voluven based indocyanine green. Estimated concentration grouping (ICG mg / Voluven mL): 2.5, 0.5, 0.25, 0.125, 0.0625. Planned recruiting at least 3 participants in each diluted concentration group. The dilution rate will advance if imaging quality is improving compared with the last concentration group. The study will be completed if the best imaging quality injection protocol is found.|t|f|f|f
33945915|NCT03568851|||COHORT||PROSPECTIVE|||||||
33945916|NCT04678089|||CASE_CONTROL||PROSPECTIVE|||||||
33945917|NCT03418727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945918|NCT01777022|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33945919|NCT02449005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant, care provider, investigator/outcome assessor is not aware of the treatment modality||t|t|t|t
33945920|NCT04032002|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33945921|NCT00783055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33945922|NCT01827462|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945923|NCT01770080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945924|NCT02109731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945925|NCT03237910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945926|NCT00355251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945927|NCT03258710|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study where on-going ETV treatment is switched to TDF treatment. There is no randomization in this study.||||
33977983|NCT04240938|NA|SINGLE_GROUP||TREATMENT||NONE||Adult Dacryocystocele||||
33945928|NCT05581810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to their group assignment and treatment arms, but not to the type of intervention they are receiving. It is not possible to blind study therapists, as they have to administer the therapy.||f|f|t|t
33945929|NCT04085120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33945930|NCT03466216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945931|NCT01475539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945932|NCT00136344|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33945933|NCT00511602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945934|NCT04893382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients admitted to the severely burned unit will be randomized by the research nurse to either received PlasmaLyte or Ringer's Lactate. Research Nurse will then advise the treating team.|f|f|f|t
33945935|NCT01938443|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945936|NCT05931614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33945937|NCT01100931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945938|NCT01639599|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945939|NCT00526214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945940|NCT00173758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33945941|NCT04019028|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33945942|NCT05499546|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33945943|NCT06674733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33945944|NCT04013906|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel assignment||||
33945945|NCT03029793|||COHORT||PROSPECTIVE|||||||
33945946|NCT04994860|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33945947|NCT05799482|||COHORT||OTHER|||||||
33945948|NCT00617994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945949|NCT04518826|||CASE_CONTROL||PROSPECTIVE|||||||
33945950|NCT06227819|||COHORT||PROSPECTIVE|||||||
33945951|NCT03682471|||COHORT||PROSPECTIVE|||||||
33945952|NCT01398176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33945953|NCT01034345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945954|NCT00555711|||CASE_ONLY||CROSS_SECTIONAL|||||||
33945955|NCT06276712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded (when possible) outcome assessor will evaluate all the outcomes and will take the radiogram for centralized analysis.|A multicenters, randomized controlled trial.|f|f|f|t
33945956|NCT01190839|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33945957|NCT01687985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33945958|NCT02136927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33945959|NCT03576807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945960|NCT03031327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The packaging used for the comparator in the present investigation aimed at ensuring a complete masking of the test IMD.||t|f|t|f
33945961|NCT04594213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945962|NCT03219372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blind|1:1 drug versus placebo|t|t|t|f
33945963|NCT00126321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945964|NCT03328962|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital (intervention program and standard care will be described in details later).~The recruitment period for the control group will be from September 2017 to March 2018. Participants in the control group will be invited to answer a follow up questionnaire after 6 months. Six months after the last recruited participant to the control group, i.e. from September 2018, recruitment of participants to the intervention group will begin and last for six months, to the end of February 2019 and the participants in the intervention group will be followed for 6 months, to the end of August 2019. The figure below gives an overview of the timing of recruitment and observations."||||
33945965|NCT03487120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33945966|NCT06698133|RANDOMIZED|PARALLEL||OTHER||NONE||Participants in the intervention arm will be invited to join a private Twitter social media group that will be created solely for this study. Education content will consist of published dietary recommendations during pregnancy, healthy craving hacks, healthy snacks, ways to get exercise in during the school day, etc. Participants will also be encouraged to ask questions and post any eating struggles. The intervention will be completely virtual and outside of the initial visit. Medical advice will not be given; if requested, participants will be advised to contact their provider.||||
33945967|NCT02146911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945968|NCT04480359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945969|NCT04606225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33945970|NCT06213831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945971|NCT00658918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33945972|NCT02118272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945973|NCT01633762|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33945974|NCT04131465|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The outcomes assessors will not know the arm assignment when they assess the outcomes. The investigators analyzing the data for the initial effect size estimations will be blinded to the arm assignment. Care providers (i.e., the fieldworkers providing the home-based HIV testing) and participants cannot be blinded to the assignment to the trial arms.|This study will randomize older adults living in a rural community in South Africa to one of three trial arms.|f|f|t|t
33945975|NCT01267682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945976|NCT03107741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945977|NCT06192108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977984|NCT01180244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977985|NCT06009549|||CASE_CROSSOVER||PROSPECTIVE|||||||
33977986|NCT02578550|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977987|NCT05639634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|t|f
33977988|NCT01088126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945978|NCT04914182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Control sham: To the patients in the control group a sham control will be applied, corresponding to the device only connected, emitting the signal of being turned on but without therapeutic effect. The irradiation time and the number of application points will be the same as for the intervention group. The patient will remain masked, and the investigators that will perform the statistical analysis will be masked until the end of the analysis."|A randomized clinical trial will be conducted, participants will be assigned to the intervention group or the control group in parallel for the duration of the study.|t|f|f|t
33945979|NCT06629038|||OTHER||PROSPECTIVE|||||||
33945980|NCT06602739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945981|NCT01679756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33945982|NCT02534428|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33945983|NCT04310852|||COHORT||PROSPECTIVE|||||||
33945984|NCT06028191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33945985|NCT04543526|||CASE_ONLY||PROSPECTIVE|||||||
33945986|NCT04923776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33945987|NCT01430520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33945988|NCT04596046|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized-controlled study||||
33945989|NCT04469140|||COHORT||PROSPECTIVE|||||||
33945990|NCT04468555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent assessor blinded to the data collection was responsible for the allocation process. A list of the computer-generated number was employed to assign participants to experimental or control group|A single-blind randomized controlled trial.|f|f|t|t
33945991|NCT04692324|||COHORT||PROSPECTIVE|||||||
33945992|NCT06267859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"working with children from the frequently ill children group"|"identification of children from the group of frequently ill children"|t|f|f|f
33945993|NCT01365026|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33945994|NCT02025127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33945995|NCT06217627|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33945996|NCT05795127|||CASE_CONTROL||RETROSPECTIVE|||||||
33945997|NCT04534868|NA|SINGLE_GROUP||OTHER||NONE||||||
33945998|NCT02095912|||CASE_ONLY||RETROSPECTIVE|||||||
33945999|NCT04246918|RANDOMIZED|PARALLEL||TREATMENT||NONE|As it is a nutritional intervention study masking either the participant or the investigator is not possible.|Open Label||||
33946000|NCT06531798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946001|NCT00241891|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946002|NCT00514059|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946003|NCT06086613|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33946004|NCT00586027|||CASE_CONTROL||PROSPECTIVE|||||||
33946005|NCT02832986|||COHORT||PROSPECTIVE|||||||
33946006|NCT02230475|||COHORT|||||||||
33946007|NCT05997134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33946008|NCT00807768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946009|NCT00458055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946010|NCT00157638|RANDOMIZED|PARALLEL||ECT||NONE||||||
33946011|NCT04366869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946012|NCT04856072|NA|SINGLE_GROUP||TREATMENT||NONE||Group of 12 patients will be implanted with a deep brain stimulation system and followed up for a 12-month post-operative period.||||
33946013|NCT04695535|||OTHER||PROSPECTIVE|||||||
33946014|NCT00366665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33946015|NCT02531282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946016|NCT04495400|||CASE_CONTROL||RETROSPECTIVE|||||||
33946017|NCT05804539|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33946018|NCT02249273|||COHORT||PROSPECTIVE|||||||
33946019|NCT02488564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946020|NCT03210909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946021|NCT01856920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946022|NCT00852800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946023|NCT04542252|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33946024|NCT06080529|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33946025|NCT00267202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946026|NCT06268288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Half of the patient population will be randomized to standard management only. The other half of the population will be randomized to standard management plus use of the vagal nerve stimulator|f|f|f|t
33946027|NCT03398759|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946028|NCT04065412|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33946029|NCT02224261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946030|NCT06361381|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33946031|NCT02701933|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33946032|NCT05111652|||CASE_CONTROL||PROSPECTIVE|||||||
33946033|NCT04605120|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, Single centre||||
33946034|NCT04075903|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946035|NCT02074657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946036|NCT06677086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946037|NCT00003524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946038|NCT02628574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946039|NCT01617265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946040|NCT04697719|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This is a two-phase crossover design with run-in and wash out periods prior to each phase.|t|f|t|f
33946041|NCT05218148|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized controlled, exploratory phase II study. Patients with HER2-positive locally advanced gastric or gastroesophageal junction adenocarcinoma who have not received any anti-tumor therapy were randomized in a 1:1 ratio to receive preoperatively: Group A: SOX regimen (oxaliplatin + Seggio) ) + sintilimab + trastuzumab; group B: SOX regimen, 3 cycles of treatment, followed by D2 radical resection, and 5 cycles of adjuvant chemotherapy with the original regimen after surgery||||
33977989|NCT03361371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor is blinded to the intervention.|Prospective interventional.|f|f|f|t
33946042|NCT04362514|RANDOMIZED|PARALLEL||OTHER||NONE||"SiFAr is a parallel group, randomized controlled trial with a duration of 3 years and a recruitment period between June 2020 and July 2022. The 1:1 randomization of participants to IG or aCG is stratified by gender and bicycle type (e-bikes/unmotorized bicycle).~Baseline data collection (T0) takes place in-person in the study center and in the cycle course on two different days within approximately 14 days. Except for cognitive function, same data are collected of all participants after the 3 months intervention period (T1), regardless of their compliance. In addition, participants will be followed up 6-9 months after T1 (T2) related to seasonal time frames (after winter season). Furthermore, participants of the IG 2020 will be measured for a long-term follow-up in the third year of the study (T3)."||||
33946043|NCT01304576|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33946044|NCT05129566|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first group of patients will receive the IOL Clareon AutonoMe (Alcon, USA), and the second group of patients will receive the IOL Hoya iSert 251 (Japan), 39 eyes in each group, total 78 patients, 78 eyes.||||
33946045|NCT00579605|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946046|NCT01074320|||COHORT||PROSPECTIVE|||||||
33946047|NCT05106101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946048|NCT05647174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33946049|NCT04500925|||COHORT||RETROSPECTIVE|||||||
33946050|NCT05925530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946051|NCT03975881|NA|SINGLE_GROUP||PREVENTION||NONE||Patients aged 15 to 35 who made a suicide attempt and went through the emergency departments of the participating hospitals (Nantes, Angers, Rennes and Poitiers).||||
33946052|NCT01974310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946053|NCT05296239|NA|SINGLE_GROUP||OTHER||NONE||||||
33946054|NCT03846895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946055|NCT03947333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946056|NCT04672694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946057|NCT01500291|||COHORT||PROSPECTIVE|||||||
33946058|NCT04945291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will know the application they are using; the outcome assessor will be blinded to the user app when they fill the questionnaire and take the height and weight measurements|three- armed randomized controlled trial|f|f|f|t
33946059|NCT06724003|RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistical analyses and data reporting of the study will be carried out by statistical experts who are not among the researchers and are not familiar with the research application. The study was blinded in terms of outcome measures, statistical analysis and reporting to prevent statistical and reporting bias. In this context, the statistical expert was blinded; the researchers and students were not blinded.|This study is a randomized controlled experimental trial.|f|f|f|t
33946060|NCT00091039||||TREATMENT||||||||
33946061|NCT06230822|NA|SINGLE_GROUP||TREATMENT||NONE||VUM02 Injection (hUCT-MSCs)+Conventional treatment||||
33946062|NCT05453552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946063|NCT03776435|||COHORT||RETROSPECTIVE|||||||
33946064|NCT02358720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946065|NCT00591305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|treatment to be selected based on a randomized number table, blinded to participants|laser only vs laser+ a dietary agent (DIM)|t|f|f|f
33946066|NCT04676022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946067|NCT01670331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33946068|NCT02831595|||COHORT||PROSPECTIVE|||||||
33946069|NCT03434665|NA|SINGLE_GROUP||OTHER||NONE||Feasibility pilot study||||
33946070|NCT02103894|NA|SINGLE_GROUP||||NONE||||||
33946071|NCT03986658|NA|SINGLE_GROUP||TREATMENT||NONE||rTMS||||
33946072|NCT02833779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946073|NCT02590211|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946074|NCT02618681|||COHORT||PROSPECTIVE|||||||
33946075|NCT02648152|||COHORT||PROSPECTIVE|||||||
33946076|NCT00133276|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33946077|NCT01970020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946078|NCT01084096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946079|NCT05962658|||OTHER||CROSS_SECTIONAL|||||||
33946080|NCT02224495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33946081|NCT05903976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946082|NCT06193057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946083|NCT03276858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study|Single and multiple-dose cohorts are placebo-controlled. The midazolam cohort does not have placebo.|t|t|t|t
33946084|NCT04001790|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, wait-list controlled study of the efficacy of the Project Search plus ASD Supports Model (PS-ASD) in 32 adolescents and young adults aged 18 to 21 with autism spectrum disorder. Approximately 32 subjects will be enrolled and randomized in a 1:1 ratio to treatment or wait-list control groups.||||
33946085|NCT02140996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946086|NCT05846412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946087|NCT01617161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946088|NCT04084860|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33946089|NCT05732324|||CASE_CONTROL||PROSPECTIVE|||||||
33946090|NCT02778477|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33946091|NCT05548582|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946092|NCT03061162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946093|NCT03881072|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective study||||
33946094|NCT01054443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946095|NCT03102541|||CASE_CONTROL||PROSPECTIVE|||||||
33946096|NCT05502809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946097|NCT01934387|||CASE_ONLY||PROSPECTIVE|||||||
33946098|NCT01572129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33946099|NCT01413308|||COHORT||PROSPECTIVE|||||||
33946100|NCT04370808|||CASE_ONLY||PROSPECTIVE|||||||
33946101|NCT02681692|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33946102|NCT00042575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946103|NCT02528149|||COHORT||PROSPECTIVE|||||||
33946104|NCT01685099|||CASE_CONTROL||PROSPECTIVE|||||||
33946105|NCT06369766|||CASE_CONTROL||PROSPECTIVE|||||||
33946106|NCT03025295|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33946107|NCT00145080|RANDOMIZED|PARALLEL||||NONE||||||
33946108|NCT05602818|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33946109|NCT01734070|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33946110|NCT05033821|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33946111|NCT06440876|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946112|NCT00212082|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946113|NCT01288820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946114|NCT01489449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946115|NCT04553497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and the outcome assessor were blind to the treatment groups.|"After the patients were randomized, interferential current was applied for 3 times a week before the each exercise session by another physiotherapist. Pre-modulated bipolar method with the currier frequency of 4 kHz by a combination therapy unit (Sonopuls 692, Enraf-Nonius) with two electrodes (8×6 cm) was used. One electrode was placed on the lateral part of the deltoid muscle; the other was placed on the trapezium muscle close to the shoulder. Subjects were told that in order to produce an effect, the intensity of the stimulator must be maintained at a strong but comfortable level at all times. The sham interferential current therapy consisted of the placement of the same pads for the same time but no electrical stimulation was applied to the probes."|t|f|t|t
33946116|NCT01411917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33946117|NCT00364234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946118|NCT01428570|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33946119|NCT01393925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946120|NCT06663384|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33946121|NCT05468619|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33946122|NCT06534580|||COHORT||PROSPECTIVE|||||||
33946123|NCT03492242|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946124|NCT00712634|RANDOMIZED|||TREATMENT||DOUBLE||||||
33946125|NCT05999773|||CASE_CONTROL||PROSPECTIVE|||||||
33946126|NCT00266617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33946127|NCT04440137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"1. Collection of Samples Randomization will be carried out.~2. Research Briefing and Questionnaire Distribution Research briefing will be carried out and details of the study will be explained.~3. Questionnaire Collection and Dental Examination at baseline~   1. After obtaining informed consent, questionnaires will be distributed.~  2. Caries experience of children will be recorded using ICDAS score. Caries experience also will be recorded in DMFT with cavitated and DMFT without cavitated.~  3. Intervention group will be provided with intervention brochure, kid toothbrush and toothpaste and a free-flow cup. Control group will receive brochure with standard of care info and kid toothbrush and toothpaste.~  4. An electronic form of OHP, will be given every 3 months to both group~  5. Dental check-up will be done every 6 months at the respective woman and child clinic.~  6. After a period of 1 year, the patient will be given a questionnaire again and dental check-up to compare any difference."|t|f|f|f
33946128|NCT03414372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"This study includes 3 phases: 1) formative research to refine and enhance Tough Talks with input from YMSM and their social/sexual networks; 2) (n=8) a technical pilot to optimize functionality and technical performance; and 3) (n=156) a three-arm RCT to evaluate efficacy and effectiveness of Tough Talks among HIV-infected YMSM.~In the RCT, the investigators will conduct a combined efficacy/effectiveness trial to compare the intervention delivered online, in the clinic or standard of care clinic messaging. Primary outcomes will be assessed at intervention completion (1 month) and at 6 months and include HIV viral load and condomless anal intercourse (CAI)."|t|f|f|f
33946129|NCT00387829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946130|NCT00991458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946131|NCT02198040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946132|NCT00405756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946133|NCT05584007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To facilitate ease of recruitment and avoid treatment delay, participants will be provided with an NHS prescription for flucloxacillin 500mg QDS for the first 5 days. A blinded medication pack will be sent by next day delivery, containing flucloxacillin 500mg QDS, or matched placebo QDS for the final 2 days. Participants will be informed that the capsules in this pack may look different from the capsules they were taking on days 1-5. Participants experiencing significant clinical deterioration, as judged by their clinician, may have their antibiotic treatment changed or be prescribed additional antibiotic courses. Any changes or additional use of antibiotics will be recorded, and the patient and clinician will remain blinded unless unblinding is deemed necessary.|A phase III blinded, multi-center, non-inferiority trial assessing the effectiveness and safety of 5 days vs 7 days of oral flucloxacillin 500mg QDS for lower leg cellulitis, and to evaluate the cost-consequences of a shorter course from an NHS and personal perspective. Participants will be recruited in NHS primary care settings in England and Wales. We will primarily recruit through general practices but will explore the possibility of recruiting through out-of-the-hours and urgent care settings.|t|t|t|t
33946134|NCT05267964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are radomized into two groups prior to the surgical intervention using the radomizing programm of the medical university of graz.||t|f|t|f
33977990|NCT00143819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977991|NCT00859664|||COHORT||PROSPECTIVE|||||||
33977992|NCT01578083|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33977993|NCT04635423|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33977994|NCT00699257|||COHORT||PROSPECTIVE|||||||
33977995|NCT02737215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977996|NCT04567342|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33977997|NCT03193866|||COHORT||OTHER|||||||
34075742|NCT00027118|||COHORT||PROSPECTIVE|||||||
34075743|NCT04594655|||COHORT||PROSPECTIVE|||||||
34075744|NCT02105935|||COHORT||PROSPECTIVE|||||||
34075745|NCT04865588|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33764455|NCT00500240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764456|NCT02002182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946135|NCT05426694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the participants were masked. They did not know either they are in the interventional group or in the control group.|There were 30 subjects divided equally and randomly into Group A and Group B. Group A was receive the intervention while group B will be active control group. The duration of treatment will be equal for both groups, that is 3 sessions per week for a period of 4 weeks.|t|f|f|f
33946136|NCT05906043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cross sectional study, with observational elements and four interventions utilising a single case experimental design||||
33946137|NCT00137982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946138|NCT03145376|||CASE_CONTROL||PROSPECTIVE|||||||
33946139|NCT02985541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946140|NCT00528294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946141|NCT06393504|||COHORT||RETROSPECTIVE|||||||
33946142|NCT00953173|||COHORT||PROSPECTIVE|||||||
33946143|NCT00951587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946144|NCT04791111|||COHORT||PROSPECTIVE|||||||
33946145|NCT03642249|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33946146|NCT01139645|NON_RANDOMIZED|PARALLEL||||NONE||||||
33946147|NCT02442284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946148|NCT06065371|NA|SINGLE_GROUP||TREATMENT||NONE||3+3||||
33946149|NCT00816244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946150|NCT01132040|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946151|NCT06555172|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be individually randomized at a 1:1 ratio to 1 of 2 smartphone app conditions: (1) AIM+, a 30-day mindfulness meditation app, or (2) Resource+, a 30-day informational app that is matched to AIM+ for time and structure but provides information on local resources relevant to youth.|f|f|f|t
33946152|NCT00223158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33946153|NCT01471197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946154|NCT06175845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946155|NCT05677373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946156|NCT04234841|||COHORT||PROSPECTIVE|||||||
33946157|NCT00761891|NA|SINGLE_GROUP||OTHER||NONE||||||
33946158|NCT03205605|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33946159|NCT01977664|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946160|NCT00755976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946161|NCT03957629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946162|NCT01079260|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33946163|NCT03206333|||COHORT||RETROSPECTIVE|||||||
33946164|NCT03219996|||CASE_CONTROL||RETROSPECTIVE|||||||
33946165|NCT06394414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946166|NCT02247167|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33946167|NCT03551158|NA|SINGLE_GROUP||OTHER||NONE||||||
33946168|NCT03986905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A double-dummy design will be used to mask the treatment assignment. A double-dummy design will be used to mask the treatment assignment. A designated independent (unblinded) applicator will administer all patch application and removal, including an opaque waterproof bandage cover over the patch, to further prevent unblinding.||t|f|t|t
33946169|NCT01177241|||CASE_CONTROL||RETROSPECTIVE|||||||
33946170|NCT01009320|||COHORT||CROSS_SECTIONAL|||||||
33946171|NCT01098019|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33946172|NCT06722729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946173|NCT02460185|RANDOMIZED|PARALLEL||||NONE||||||
33946174|NCT06510894|||CASE_ONLY||PROSPECTIVE|||||||
33946175|NCT01533974|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33946176|NCT02713490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33946177|NCT04795570|||CASE_CONTROL||PROSPECTIVE|||||||
33946178|NCT06724848|||COHORT||PROSPECTIVE|||||||
33946179|NCT05086575|||COHORT||PROSPECTIVE|||||||
33946180|NCT01882101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946181|NCT00850213|||COHORT||PROSPECTIVE|||||||
33946182|NCT05797467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946183|NCT02204722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946184|NCT06125847|NA|SEQUENTIAL||TREATMENT||NONE||||||
34075746|NCT02753816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946185|NCT04910360|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946186|NCT00045565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946187|NCT06713746|||OTHER||CROSS_SECTIONAL|||||||
33946188|NCT04864964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946189|NCT02186548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946190|NCT04741880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators appointed for executing the protocol will not have access to the group in which the patient will be allocated. Randomization will be performed by automated system (RedCap) and at the time the investigator assigned for preparing the medication in the central pharmacy of the unit is requested to send the infusion. Only staff in the pharmacy sector will have access to the allocation group. The groups will remain masked even after closing the database and sending the data sheet for statistical analysis by the principal investigator, there will be no identification of the intervention performed in each group (lidocaine versus saline solution). After the end of the analysis, the result will be opened to finish the description of the results and develop the discussion of the findings.||t|t|t|t
33764457|NCT03436966|||COHORT||PROSPECTIVE|||||||
33764458|NCT05846763|||COHORT||PROSPECTIVE|||||||
33764459|NCT05233943|||CASE_CONTROL||PROSPECTIVE|||||||
33764460|NCT01412190|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764461|NCT06107764|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The study design is a crossover design i.e. all participants will receive all three rTMS interventions (iTBS, cTBS, sham rTMS). The participant will be blinded to which intervention is happening on a given study visit. The order of these visits will be determined randomly for each participant.||t|f|f|f
33946191|NCT03622294|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will be female, asymptomatic patients randomly scheduled for a screening mammogram.||||
33946192|NCT04066205|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot RCT, comparing usual care to SLEEPSMART intervention with 60 JIA children and their parents||||
33946193|NCT05245227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946194|NCT04795674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946195|NCT03935074|||CASE_ONLY||RETROSPECTIVE|||||||
33946196|NCT01973920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154333|NCT05562609|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Masking done by an independent clinical trials supply company. It will involve the removal of the original manufacturer's label and replacement with the clinical trial label bearing the randomisation number, which will be used as the pack identification. Apart from the randomisation number, all pack label texts and ampoules will be identical for each arm||t|t|t|t
33946197|NCT05431816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33946198|NCT06113731|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946199|NCT06386276|||CASE_ONLY||OTHER|||||||
33946200|NCT01494753|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33946201|NCT00958282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946202|NCT05761301|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The single ascending dose part of this study (Part A) will have a sequential interventional study model. The multi-dose part of this study (Part B) will have a parallel interventional study model and will begin after the completion of Part A.|t|t|t|f
33946203|NCT03838627|||COHORT||PROSPECTIVE|||||||
33946204|NCT01444638|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33946205|NCT04215159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946206|NCT06048601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946207|NCT03736122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946208|NCT05931094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946209|NCT06566157|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Research nurses, Independent investigators|Double blind, Placebo, Randomised|t|f|t|t
33946210|NCT00848380|||CASE_CONTROL||RETROSPECTIVE|||||||
33946211|NCT00185146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33946212|NCT03720639|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946213|NCT03455556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946214|NCT02816853|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33946215|NCT01786707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946216|NCT06050733|||COHORT||CROSS_SECTIONAL|||||||
33946217|NCT03820362|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946218|NCT06639711|NA|SINGLE_GROUP||PREVENTION||NONE||single-arm pre-post intervention study||||
33946219|NCT05222841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946220|NCT04163627|||COHORT||RETROSPECTIVE|||||||
33946221|NCT02138929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050638|NCT06134856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects in the control group will receive 1 minute of passive ankle movement into ankle dorsiflexion. The researcher will not move the subject's ankle into a point where tissue stretch/tension is perceived. This will serve as an appropriate sham treatment since it still involves the subjects perception of treatment and includes the hands-on element of manual therapy, without the use of any tissue intervention which would theoretically effect change.|Randomized control trial, treatment group and control group|t|f|f|f
34154334|NCT00147004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154335|NCT04796350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34154336|NCT02551419|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34154337|NCT02027948|NA|SINGLE_GROUP||OTHER||NONE||||||
34154338|NCT05727800|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33946222|NCT01955005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946223|NCT02688452|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33946224|NCT05642884|RANDOMIZED|PARALLEL||PREVENTION||NONE||We plan to enroll a total of 30 patients, randomized 1:1 using permuted block algorithm stratified by sex and age (e.g. 60-70, \>70y), into intervention arm (home based prehabilitation) vs an attention control (dietary counseling) group.||||
33946225|NCT03153436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33946226|NCT04177940|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946227|NCT04499521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Both groups will have two fractions of brachytherapy with a standard packing system and two fractions of brachytherapy with BrachyGel VHPS - only the timing will be different between the two groups.||||
33946228|NCT02201966|||COHORT||CROSS_SECTIONAL|||||||
33946229|NCT05311631|RANDOMIZED|PARALLEL||PREVENTION||NONE||Clusters (municipalities) are randomized to either intervention or control (standard care). Intervention coverage 6000 infants and their families in intervention municipalities. Primary trial outcome is assessed using survey data where 3339 families from the intervention and control arm will be enrolled according to the power calculation.||||
33946230|NCT04301557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154339|NCT01660503|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34154340|NCT01218399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154341|NCT04908865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154342|NCT04434014|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34154343|NCT01453335|||CASE_ONLY||PROSPECTIVE|||||||
34154344|NCT00652886|RANDOMIZED|CROSSOVER||||NONE||||||
34154345|NCT03057782|||COHORT||PROSPECTIVE|||||||
33764462|NCT02459821|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33946231|NCT05173532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The patients will be blinded to their group assignment. At the time of their group assignment, they will be told that they are in either group A (which is actually the experimental group receiving balance training) or B (which is actually the active control group receiving the breathing and stretching exercise program), and that both groups may lead to better balance, neither are expected to worsen balance, and it is uncertain which one is more effective at improving balance. After their study participation, patients will guess which group they were in, then told if they guessed correctly."||t|f|t|t
33946232|NCT04693481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomly assign subjects into the experimental groups and the control group|f|f|t|t
33946233|NCT02225626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946234|NCT03391258|NA|SINGLE_GROUP||TREATMENT||NONE||To describe the dimensional changes (based on CBCT scans) occurred 12 months after implant placement and simultaneous regeneration with L-PRF and bovine bone graft in the aesthetic zone of atrophic maxillae in full arch implant supported rehabilitations||||
33946235|NCT02862366|||COHORT||PROSPECTIVE|||||||
33946236|NCT01031667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946237|NCT03912506|||COHORT||RETROSPECTIVE|||||||
33946238|NCT01789333|NA|SINGLE_GROUP||TREATMENT||NONE||30 patients will be treated at 9 mw/cm2.||||
33946239|NCT00118885|RANDOMIZED|PARALLEL||TREATMENT||||||||
33946240|NCT00792467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946241|NCT02042742|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33946242|NCT00033683|RANDOMIZED|||TREATMENT||||||||
33946243|NCT02463097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946244|NCT05417581|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||all participants receive the same intervention||||
33946245|NCT05909046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946246|NCT02958098|||COHORT||PROSPECTIVE|||||||
33946247|NCT02080988|||COHORT||CROSS_SECTIONAL|||||||
33946248|NCT01240629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946249|NCT01364506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946250|NCT05525533|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial; the investigators will phase in the 2 interventions (Private and Public Feedback) on a staggered basis. All shops will receive No Feedback during the first 6 months. One third of shops (\~N=40) will be assigned to No Feedback between 6-12 months and Private Feedback between 12-18 months; one third of shops (\~N=40) will be assigned to Private Feedback between 6-12 months and Public Feedback between 12-18 months; one third of shops (\~N=40) will be assigned to Public Feedback between 6-18 months.||||
33946251|NCT06302829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomized||t|f|f|f
33946252|NCT03154099|||COHORT||PROSPECTIVE|||||||
33946253|NCT06715891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, randomized, parallel-group|t|t|t|t
33946254|NCT05338827|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33946255|NCT04450927|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946256|NCT00405925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946257|NCT00672490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946258|NCT06368596|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946259|NCT03980665|RANDOMIZED|PARALLEL||TREATMENT||NONE||The control arm includes HIV-infected patients with the therapy of Antiretroviral drugs.||||
33946260|NCT06332677|NA|SINGLE_GROUP||PREVENTION||NONE||study the cellular and molecular mechanisms of correlation between the SUV420H1/H2 methyltransferase and the progression of liver damage in mice (San Raffaele Institute) and to confirm these findings in human samples and in vitro 3D liver models.||||
33946261|NCT05794217|||COHORT||PROSPECTIVE|||||||
33946262|NCT01737463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33946263|NCT01334281|||CASE_CONTROL||PROSPECTIVE|||||||
33946264|NCT05944731|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Three arm pragmatic randomized controlled study||||
33946265|NCT05449431|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33946266|NCT00435266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946267|NCT00638248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33946268|NCT00993382|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33946269|NCT05638009|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33946270|NCT00766870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946271|NCT01995396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946272|NCT04298229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The Clinical Event Adjudication Committee will consist of 3 independent clinicians, which will consist of at least one endocrinologist and at least one heart failure specialist. The members of this committee will be independent of the study implementation teams and will be blinded to study arm assignment. This committee will review abstracted clinical data to determine when primary endpoints and major events have occurred. The CEAC will review data for the following study outcomes:~* Potential in-hospital worsening heart failure events~* 30-day readmission events for heart failure or diabetes-related care~* Prolonged hospitalization as a result of the following safety outcomes: hypotension requiring medical intervention or hypoglycemia requiring medical intervention~* Inpatient mortality events~* Potential ketoacidosis events"|Participants will be recruited following an initial standard evaluation in the ED and randomized within 24 hours of presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy or dapagliflozin + protocolized diuretic therapy.|f|f|f|t
33946273|NCT04916808|||COHORT||PROSPECTIVE|||||||
33946274|NCT04457310|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33946275|NCT00142207|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946276|NCT00402311|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946277|NCT05425082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946278|NCT01621763|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946279|NCT05604976|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants are randomly divided into two groups: one in which Primary PCI is initiated with a universal guiding catheter and the other with a diagnostic catheter. Compare time from sheath insertion to first device activation.||||
33946280|NCT04883905|||COHORT||PROSPECTIVE|||||||
33946281|NCT06723223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946282|NCT05986292|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33946283|NCT03569241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946284|NCT01461187|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946285|NCT01705665|||COHORT||PROSPECTIVE|||||||
33946286|NCT05704933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050639|NCT06683664|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-assigned intervention treatment with concurrent comparison clusters||||
33946287|NCT03023124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946288|NCT05171686|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm clinical trial||||
34050640|NCT04687072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050641|NCT01296945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
34050642|NCT04881695|||CASE_CONTROL||PROSPECTIVE|||||||
33946289|NCT06395441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Research staff, other than pharmacy, are blinded, and will dispense product to the patient. Option to unblind: At the end of treatment, if, in the judgment of patient or patient's attending clinician, it would be helpful for the future of patient's clinical care, the code may be broken.||t|f|t|f
33946290|NCT00784225|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33946291|NCT06521632|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The stimulator is put in an opaque box||f|f|t|t
33946292|NCT04805892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946293|NCT00121251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946294|NCT06580548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946295|NCT06165341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946296|NCT06036407|NA|SINGLE_GROUP||SCREENING||NONE|All participants undergo a hearing test (intervention).|||||
33946297|NCT05766631|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, parallel random assignment (covariate-adaptive allocation to ensure equal distribution of three variables across groups: age, gender, recent cocaine use) with assessments at baseline, as well as 3-/6-/12-months post randomization.||||
33946298|NCT06131931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946299|NCT01503190|||OTHER||RETROSPECTIVE|||||||
33946300|NCT03564860|||CASE_ONLY||PROSPECTIVE|||||||
33946301|NCT05255159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946302|NCT05451693|||COHORT||PROSPECTIVE|||||||
34154346|NCT04697732|||COHORT||PROSPECTIVE|||||||
33946303|NCT05568420|||COHORT||PROSPECTIVE|||||||
33946304|NCT03672565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946305|NCT03247140|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946306|NCT02092155|||COHORT||PROSPECTIVE|||||||
33946307|NCT00368212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946308|NCT03302260|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The nature of the intervention (i.e., the CardioPrevent® cognitive-behavioural lifestyle counsellor) does not lend itself to blinding of the participant. However, the research assistant responsible for the outcome assessments will be blinded to each participant's group allocation and will be instructed not to ask any questions pertaining to the study intervention. The study statistician will also be blinded to group allocation.||f|f|t|t
33946309|NCT03879811|NA|SINGLE_GROUP||TREATMENT||NONE||Simon two-stage design, single arm study||||
33946310|NCT03053531|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group study, with no control or comparison group.||||
33946311|NCT03050723|NA|SINGLE_GROUP||OTHER||NONE||Princess® FILLER||||
33946312|NCT05372991|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33946313|NCT05662345|||CASE_ONLY||PROSPECTIVE|||||||
33946314|NCT06219733|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 allocation into two arms||||
33946315|NCT06724705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33946316|NCT00394862|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33946317|NCT05485961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33946318|NCT06722742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946319|NCT02557308|||COHORT||PROSPECTIVE|||||||
33946320|NCT04969653|||CASE_CONTROL||RETROSPECTIVE|||||||
33946321|NCT05024721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946322|NCT06303791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Families/children who meet the inclusion criteria will be randomly assigned to one of the two conditions (intervention group or control group) using a controlled design. Block randomization will be applied to each of the diagnostic groups (ASD, ADHD) to ensure that participants were of approximately similar size (1:1 ratio) in the treatment and control conditions. After determining the size of each block in the sample (#ASD and #ADHD) the treatment allocation of each individual participant will be done randomly.A blind procedure will be used: participating families will not know the group to which participants will be assigned, and the researchers who will collect and enter the data will also have no knowledge of the condition to which the families will be assigned.|To test the proposed objectives, a design will be used with a between-groups factor (type of therapy) and a intra-groups with pre-treatment (T0), post-treatment (T1) and follow-up measurements at 6 months (T2). Participants will be randomly assigned (1:1) to the two conditions; a group that will receive the intervention of the structured psychosocial program with digital support (experimental group) and an active control group. The experimental group will undergo an evaluation prior to the intervention, one immediately after it, and a third follow-up evaluation. In the case of the control group, it will be evaluated through the pretest phases, posttest and follow-up.|t|f|f|t
33946323|NCT06722651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants will be randomly assigned to either the RDN procedure, sham procedure, or open-label control (where patients do not receive any procedure and are off medication until primary endpoint measurement). After primary endpoint measurements at Month 3, patients in the sham and open-label control groups will have the option to receive the RDN procedure, referred to as crossover patients."|t|f|f|t
33946324|NCT00004219|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33946325|NCT05463731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The main treatment period is double-blinded and the addendum is open-label.||t|f|t|f
33946326|NCT02675933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946327|NCT06355934|||COHORT||RETROSPECTIVE|||||||
33946328|NCT04115904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|compare Incidence of acute painafter single-visit ortwo-visits treatment of teeth with necrotic pulp|110 teeth with a diagnosis of pulp necrosis and apical radiolucency at the apex.Working length was established with EAL and confirmed radiographically. M4system with Flex-R files were used to complete canal preparation. Level ofdiscomfort were recorded and cases with severe postoperative pain|f|f|t|f
33946329|NCT05261126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946330|NCT06323356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050643|NCT02025140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050644|NCT03669055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154347|NCT05238883|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34154348|NCT02900521|||COHORT||PROSPECTIVE|||||||
34154349|NCT04218591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34154350|NCT06584227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154351|NCT01716455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154352|NCT00854035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946331|NCT03029052|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocenter, randomized, controlled, pilot study.||||
33946332|NCT06724783|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two parallel arm (test and control) non-inferiority, prospective, randomized controlled, monocentric, open-label clinical trial (surgical part) A three parallel arm (test, two controls) prospective, randomized controlled, monocentric, open-label clinical trial||||
33946333|NCT06722066|||COHORT||PROSPECTIVE|||||||
33946334|NCT01443468|||FAMILY_BASED||PROSPECTIVE|||||||
33946335|NCT06112366|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33946336|NCT06377670|||OTHER||RETROSPECTIVE|||||||
33946337|NCT00561262||||TREATMENT||||||||
33946338|NCT00001367|||OTHER||PROSPECTIVE|||||||
33946339|NCT04153526|||OTHER||PROSPECTIVE|||||||
33946340|NCT00300976|RANDOMIZED|PARALLEL||TREATMENT||NONE||"(Intervention study) A multi-center, open-label, randomized controlled study, which compared the efficacy of intensive therapy and conventional therapy in type 2 diabetic patients~(Follow-up study) A prospective cohort study with a 5-year long-term follow-up period"||||
33946341|NCT06279169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33946342|NCT03287089|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946343|NCT06025422|||COHORT||CROSS_SECTIONAL|||||||
33946344|NCT06723691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946345|NCT03047408|NA|SINGLE_GROUP||PREVENTION||NONE|open|||||
33946346|NCT03688191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946347|NCT03844048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946348|NCT04226053|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33946349|NCT04524663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946350|NCT00223990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both study participants and those investigators responsible for evaluation of the endpoints will be blinded as to who receives the test article versus the comparator. On vaccination days, the comparator vaccine will be in the same package as received from the manufacturer. After agitation it will appear clear and pink. The FMP1 antigen and the AS02A adjuvant will be packaged separately. The reconstituted FMPI antigen in the AS02A adjuvant/diluent will have a milky white appearance. Because the vaccines will have a markedly different appearance, contents of the syringe will be concealed as described later in this section. The two vaccine preparation teams, consisting of the study pharmacist, pharmacy assistants, and drug manager (an experienced nurse, clinician, or pharmacist), will be responsible for vaccine preparation. They will also verify that the proper vaccine and vaccine dose is prepared and delivered to each subject.|Subjects were screened no more than 45 days prior to the first inoculation and were randomized on the first day of vaccination 1:1 between two arms (FMP1/AS02A and rabies vaccine (RabAvert)).|t|f|t|f
33946351|NCT00140816|RANDOMIZED|PARALLEL||||NONE||||||
33946352|NCT05534412|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Patients will be aware that their primary care physician is participating in the study. However, they will not be informed of which arm the physician belongs to. Primary care physicians will be aware of which arm their office was assigned to based on whether or not they receive the intervention.|"Four Southern California medical groups will participate in a cluster randomized controlled trial in which 60 offices (15 per site) will be randomized to undergo a practice-based incontinence intervention or control for 6 months. After the study trial, the control offices will then undergo the intervention as part of a validation phase of the study."|t|f|f|f
33946353|NCT03825848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946354|NCT01588873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946355|NCT01080794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946356|NCT03539120|||COHORT||RETROSPECTIVE|||||||
33946357|NCT03910218|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33946358|NCT06722703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946359|NCT03644862|||COHORT||PROSPECTIVE|||||||
33946360|NCT06723119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33946361|NCT00383292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946362|NCT03159052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946363|NCT03919877|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946364|NCT06079879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946365|NCT00067431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33946366|NCT05896709|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33946367|NCT03459092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946368|NCT05852574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946369|NCT04558658|||COHORT||CROSS_SECTIONAL|||||||
33946370|NCT05247801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Participants. Caregivers of multi-pathological and polypharmacy patients (Barthel equal to or lower than 55). Recruitment will be carried out by simple randomization based on the diaries of patients seen in the last 18 months in the collaborating centers.~Intervention. Psychoeducational intervention based on virtual reality aimed at increasing self-efficacy and health literacy in medication use.~Procedure. By simple randomization, participants will be assigned to one of the two groups (control or experimental) after giving their informed consent. They will not know to which group they belong.~Treatments. The subjects in the control group will use a dosing device and will receive information on how to use it to avoid medication errors. The experimental group will receive the psychoeducational intervention and the same medication device. The experimental group will receive the psychoeducational intervention. Intervention period: 15 days. Follow-up: 12 months."|t|t|f|f
33946371|NCT04086745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946372|NCT06101381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154353|NCT00245843|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34154354|NCT03908918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154355|NCT03310177|||CASE_CONTROL||PROSPECTIVE|||||||
33946373|NCT00137527|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33946374|NCT00079079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946375|NCT03758612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is partially blinded. The repeat cohort (3b) using a different dosage formulation in Part 1 and subjects in Part 2 will be non-randomized and unblinded.||t|t|t|f
33946376|NCT03846310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation||||
34154356|NCT02974049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154357|NCT06155539|||CASE_ONLY||PROSPECTIVE|||||||
33946377|NCT02316106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946378|NCT02133716|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33946379|NCT01379339|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33946380|NCT04152200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946381|NCT03072927|||OTHER||OTHER|||||||
33946382|NCT03962166|||COHORT||PROSPECTIVE|||||||
33946383|NCT04027582|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessors of the video-recorded Simulator EPA and Patient EPA will be blinded as to what group the resident was allocated to . i.e the Low fidelity simulator group or the high fidelity simulator group|"This is a 2-arm comparison study to be conducted at Mount Sinai Hospital, Toronto.~After written informed consent, participants will be randomized to the low fidelity simulator (LFS n=15) and the high- fidelity simulator (ORSIM, n=15). Participants consist of anesthesia 1st - 2nd year residents in the Competency-based Medical Education Anesthesia Residency program, Emergency Medicine Residents, Family Practice Anesthetists and Emergency Residents with less than five prior experiences in fiberoptic intubations."|f|f|f|t
33946384|NCT01559584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946385|NCT04701931|||COHORT||PROSPECTIVE|||||||
33946386|NCT00226226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946387|NCT04096924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946388|NCT05057494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946389|NCT02545465|||COHORT||RETROSPECTIVE|||||||
33946390|NCT05169229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|A pragmatic, phase II, randomized, double-blind, placebo-controlled, multicenter drug trial.|t|t|t|t
33946391|NCT01024816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33946392|NCT01337921|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946393|NCT06724484|||CASE_CONTROL||PROSPECTIVE|||||||
33946394|NCT06196463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The operating room anesthetist will only be informed that the patient to take care of, has been enrolled in the study, while a closed non-transparent envelope, containing the indication for the treatment or standard care, numbered progressively and corresponding to the randomization number of the patient, will be given to the anesthetist on call who will perform the anesthetic block or sham block. The operating room anesthetist who will manage the patient during the operation will not be made aware of the group to which the patient belongs|The Study is a prospective randomized controlled double blind trial, The enrolment will be made in accordance to a Random Number Generator Program. After signing the informed consent, verifying the inclusion and exclusion criteria and enrolling the patient, a progressive number will be assigned to each patient in the study.|t|t|f|f
33946395|NCT00496691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946396|NCT04067310|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding will be in skin evaluation and statistical analysis.|After signing the Informed Consent Form, randomization will be carried out in two groups: Experimental, which will use the skin protector in spray and control, which will use the moisturizer Dnativ Revita Derm.|f|f|f|t
33946397|NCT03914703|||COHORT||RETROSPECTIVE|||||||
33946398|NCT00250731|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33946399|NCT06037863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946400|NCT01760317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946401|NCT03088306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33946402|NCT03251716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946403|NCT03806166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Ascertainment of the primary outcome (treatment failure) will be undertaken by an independent committee of specialists, using redacted participant clinical records, who will remain unaware of the treatment allocation of the participant, and who will ascertain treatment failure according to established objective criteria.|Non-inferiority randomised controlled trial|f|f|f|t
33946404|NCT02852876|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33946405|NCT03929549|NA|SINGLE_GROUP||OTHER||NONE||||||
33946406|NCT03852446|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33946407|NCT05725785|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946408|NCT01040507|||COHORT||RETROSPECTIVE|||||||
33946409|NCT04762810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946410|NCT01444599|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946411|NCT04099329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data masked for analysis|Leagues were randomized to intervention or control|f|f|t|f
33946412|NCT01062230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946413|NCT06605131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946414|NCT04556149|||CASE_CONTROL||PROSPECTIVE|||||||
33946415|NCT03007732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946416|NCT05743712|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946417|NCT06372444|||CASE_CONTROL||PROSPECTIVE|||||||
33946418|NCT03086252|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946419|NCT06643936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33946420|NCT00770731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946421|NCT06251505|||COHORT||RETROSPECTIVE|||||||
33946422|NCT04941261|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33946423|NCT04968223|||CASE_CONTROL||PROSPECTIVE|||||||
33946424|NCT04271904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No other parties will be masked for the study.|Eligible participants who consent to study participation will be randomized to one of two groups: placebo diet, or non-dieting control. Those on the placebo diet will be given a meal plan and recipes while the non-dieting control group will be asked to continue eating as usual. The intervention will run for 4-week period.|t|t|t|f
34154358|NCT01088594|RANDOMIZED|CROSSOVER||||NONE||||||
34154359|NCT05521321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946425|NCT02107716|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33946426|NCT06724211|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Patients will be randomized to either the experimental group, which will consist of a treatment bundle of care, or to the control group, which will consist of routine clinical care for kidney transplant patients. The treatment bundle of care will consist of: the use of plasmalyte for fluid management, maintaining mean arterial pressure \> 75 mmHg, identify and treat blood glucose \> 9 mmol/L, and a restrictive criteria for red blood cell transfusions (i.e. hemoglobin (Hb) \< 70 g/L).|t|f|t|f
33946427|NCT06723145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946428|NCT05626751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946429|NCT02731924|||COHORT||PROSPECTIVE|||||||
33946430|NCT04259749|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33946431|NCT06012071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946432|NCT04442932|||COHORT||PROSPECTIVE|||||||
33946433|NCT05867875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"During intubation procedure, blinded continuous monitoring of SpO2 and ORI (for control group) will be performed by appropriate monitor (Masimo Rad7) with data extraction at regular intervals.~Oxygen saturation will be tracked during ETI by research nurse or assistant nurse dedicated to fill the eCRF. ORI evolution will not be provided to investigators in the standard of care group."|Consecutive Intensive Care Unit (ICU) patients requiring ETI will be randomly allocated to ETI with or without ORI monitoring before beginning of preoxygenation, with stratification by centre, expert or nonexpert intubator status (experts: ≥5 years' ICU experience, or ≥1 year ICU experience plus ≥2 years' anaesthesiology training), and Non-Invasive Ventilation (NIV) or others devices for preoxygenation. Randomisation will be via an electronic case-report form, using a balanced scheme with stratification as described above.|f|f|t|f
33946434|NCT06562192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946435|NCT04639895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946436|NCT00738231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33946437|NCT04441619|RANDOMIZED|PARALLEL||OTHER||SINGLE|Assessments will be performed by an investigator who is not aware of the group assignment.|This is a mechanistic observational study|f|f|f|t
33946438|NCT05892003|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33946439|NCT03922191|||COHORT||RETROSPECTIVE|||||||
33946440|NCT04300556|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Optimization is randomized part, whereas the Dose Escalation and Dose Confirmation parts are non-randomized.||||
33946441|NCT06723509|||COHORT||RETROSPECTIVE|||||||
33946442|NCT01678287|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33946443|NCT05237570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946444|NCT06001021|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|Participants will be randomly assigned to any of the above-mentioned four arms. The outcome assessor (research assistant) will not be provided with information regarding the allocation of the participants to each group. Hence, the research assistant will be blind to getting the questionnaires filled.|"The first group receives psychopharmacological medication. The second group received CBCT (with or without Zikr). The third group receives a combination of psychopharmacological medication and CBCT The fourth group receives a combination of psychopharmacological medication, CBCT, and with or without Zikr.~The fifth group receives either a placebo or no CBCT intervention"|t|f|f|t
33946445|NCT06580756|||CASE_CONTROL||PROSPECTIVE|||||||
33946446|NCT01197846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946447|NCT00230711|RANDOMIZED|PARALLEL||||SINGLE||||||
33946448|NCT03242811|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33946449|NCT06410755|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Anonymization is achieved by using the unique number of the insole-type gait analyzer issued to the subject, and data collected through the application will be stored in accordance with the medical device company's security policy and will be discarded after the end of the study, and will be deidentified before being forwarded to the medical device company. De-anonymization is limited to cases where it is necessary in relation to the individual's treatment|"1. Overview of study design This is a researcher-led, exploratory clinical study designed with random assignment and lasts for 6 weeks.~2. Experimental group The experimental group wears the insole gait analyzer and is asked to wear the insole gait analyzer as much and as long as possible during outdoor activities. Researchers provide feedback to subjects once a week based on the collected measurement data. After 6 weeks, usability and satisfaction evaluation of the insole type gait analysis system will be conducted.~3. Control group The control group is trained in the same exercise program as the experimental group, but not receives the insole gait analyzers and not receives any exercise feedback."|t|f|f|f
33946450|NCT01157819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946451|NCT03159715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946452|NCT02598362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946453|NCT06724952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946454|NCT03781310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946455|NCT06471595|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm randomized controlled trial (RCT).||||
33946456|NCT00666640|||CASE_CONTROL||PROSPECTIVE|||||||
33946457|NCT05300126|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946458|NCT04230746|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Drug will be blinded to all.|Planning to study the urine microbiota at baseline and after administration of bactrim antibiotics in healthy volunteers. Will intermittently collect voided urine specimens for 16 s DNA analysis over a period of 6 months after 2 weeks of bactrim or placebo.|t|t|t|f
33946459|NCT05628389|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33946460|NCT03759795|RANDOMIZED|PARALLEL||PREVENTION||NONE|Randomised Controlled Trial. Wait-list control for half participants. Other half receive ACTr (acceptance and commitment training) intention.|||||
33946461|NCT01130220|||||PROSPECTIVE|||||||
33946462|NCT04084652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33946463|NCT06209476|||COHORT||CROSS_SECTIONAL|||||||
33946464|NCT04905160|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Evaluate the efficacy of treatment strategy in reducing readmissions based on an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment. Improvement of patient outcomes will be measured by reduction of composite of HF re-hospitalization and all-cause mortality through 30 days,90 days and 180 days in patients with recent acute Myocardial Infarction and recent admission for decompensated heart failure||||
33946465|NCT04085354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used.|All patients will be randomized equally divided into four groups (30 patients each).|f|f|t|t
33946466|NCT02711163|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33946467|NCT01659411|||COHORT||PROSPECTIVE|||||||
33946468|NCT02012504|||CASE_CONTROL||RETROSPECTIVE|||||||
33946469|NCT04522986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946470|NCT06724640|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33946471|NCT02950831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946472|NCT06722989|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33946473|NCT04861766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The identity of individual investigation materials will remain unknown to the independent Blinded Evaluator and all subjects.|A Controlled, Prospective, Randomized, Multi-Center, Subject and Evaluator-Blinded Study|t|f|f|t
33946474|NCT05993481|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33946475|NCT00648765|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33946476|NCT06598943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33946477|NCT03858621|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization into group fentanyl NOL-guided vs fentanyl standard will be done prior to the entrance in the OR, the day of the surgery.|2 groups of patients. Randomization into group fentanyl NOL-guided vs fentanyl standard according to randomization list for a total number of 100 patients.|t|t|f|t
33946478|NCT03264560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946479|NCT04445454|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a monocentric prospective phase I/II clinical trial, aiming at evaluating the safety and efficacy of 3 intravenous administrations of BM-MSC in 20 patients with severe to critical COVID-19 pneumonia.||||
33946480|NCT05205642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946481|NCT03809962|||OTHER||PROSPECTIVE|||||||
33946482|NCT00688792|||COHORT||PROSPECTIVE|||||||
33946483|NCT06070298|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946484|NCT05620849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946485|NCT05372419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946486|NCT06722625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946487|NCT06040437|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomized controlled trial||||
33946488|NCT06724367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946489|NCT02861248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946490|NCT03065010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946491|NCT05275855|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33946492|NCT04744870|||CASE_ONLY||PROSPECTIVE|||||||
33946493|NCT05807464|||CASE_ONLY||PROSPECTIVE|||||||
33946494|NCT06722508|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946495|NCT06668584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946496|NCT04663646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be assigned to one of the groups through a number contained in an opaque envelope. Only the physiotherapist in charge of applying the intervention sessions will know the assignment group of each participant.|Randomized clinical trial in which an intervention group will undergo optokinetic stimulation with virtual reality glasses, and the control group will receive placebo sessions.|t|f|t|f
33946497|NCT06533176|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33946498|NCT06144749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946499|NCT06624839|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946500|NCT06045468|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized clinical trial||||
33946501|NCT06546709|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This is a phase 1, randomized, controlled, recipient- and observer-blinded, dose-escalation clinical trial|t|t|t|f
33946502|NCT03104465|NA|SINGLE_GROUP||OTHER||NONE||||||
33946503|NCT05778175|||COHORT||PROSPECTIVE|||||||
33946504|NCT01632007||||TREATMENT||QUADRUPLE|||t|t|t|t
33946505|NCT05942482|||CASE_ONLY||RETROSPECTIVE|||||||
33946506|NCT05391113|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pilot study, monocentric open in three parallel groups (ASD, AD and healthy volunteers).||||
33946507|NCT05464914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33842966|NCT03222804|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The feeding patterns of eighty eligible infants (8 to 12 weeks in age) will be characterized based on a 7-day diet record that will be filled out by their mothers during the 7-day lead-in period starting with Day -7 and ending with Day -1. Of the eighty infants, twenty will be exclusive breast feeders (BF), twenty will be exclusive formula feeders (FF) and forty will be mixed-feeders (MF). Infants in all three feeding groups will consume B. infantis for twenty-one consecutive days. Participants will then enter the observational phase until their infant turns 1 year old.||||
33946508|NCT01106066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946509|NCT01377142|||COHORT||PROSPECTIVE|||||||
33946510|NCT00863265|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Phytosterols solutions were provided as food oil only (placebo) or food oil containing 2000 mg/day phytosterols (Phytosterols). Active and placebo ezetimibe tablets were provided by Merck.|This is a randomized, crossover design. There are three periods of 21 days separated by two 7 day washouts. All subjects eat a controlled low-phytosterol diet for each of the three periods. During period B placebo phytosterols and placebo ezetimibe are given. During period C phytosterol placebo and active ezetimibe are given. During period A active phytosterols and active ezetimibe are given. Periods are assigned in random order as described in Arms below.|t|t|t|t
33946511|NCT04227678|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33946512|NCT01150942|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977998|NCT05585658|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, research staff, or subjects. The following study procedures will be in place to ensure double-blind administration of study treatments. Blinded (investigators) and unblinded (study nurses responsible for administration of study medication) study personnel had to be involved in order to preserve blinding of the investigator.|Healthy volunteers participating in two cohorts. In each cohort 21 volunteers are participating in the clinical trial.|t|t|t|t
33977999|NCT01540032|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34154360|NCT05385588|NA|SINGLE_GROUP||OTHER||NONE||Prospective study, multicenter||||
34154361|NCT04966988|||COHORT||PROSPECTIVE|||||||
33842967|NCT05192148|NA|SINGLE_GROUP||OTHER||NONE||||||
33842968|NCT04092010|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33842969|NCT04422574|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33842970|NCT04997096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33842971|NCT01575301|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33946513|NCT05609188|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|"Masking the study personnel to randomization group is not possible given that staff need to discuss the randomization with participants upon enrollment. Staff responsible for the financial capability services can not be masked to randomization arm as the participants are free to discuss their experience in the program, including whether and when they are receiving payments.~The investigators and the senior biostatistician running the final model will be masked to treatment arm."|The BEEM project is a randomized controlled crossover trial in which 300 low-income Black Emerging Adults (BEA) (aged 18-24) are allocated to receive a $500/month Guaranteed Income (GI) either during the first twelve months of follow-up (phase I) or to receive GI in the second 12 months of a total of 24 months follow-up (phase II). Throughout the study all participants will be offered enrollment in financial capability programs (i.e., peer learning circles and financial coaching) to bolster GI effectiveness.|f|f|t|t
33946514|NCT04077112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946515|NCT05480891|||CASE_ONLY||CROSS_SECTIONAL|||||||
33842972|NCT05671627|||COHORT||PROSPECTIVE|||||||
33842973|NCT04949243|||COHORT||PROSPECTIVE|||||||
33842974|NCT06078345|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective interventional trial in healthy volunteers with random sequence of the three study interventions.||||
33946516|NCT06628622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33946517|NCT04913584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946518|NCT03373916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33946519|NCT04649606|||COHORT||PROSPECTIVE|||||||
33946520|NCT05959278|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33946521|NCT05618561|||COHORT||PROSPECTIVE|||||||
33946522|NCT06724263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946523|NCT03842228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946524|NCT04047472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764463|NCT04321967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will be masked and will not know which breast received the nitropaste. The investigator who applied nitropaste will know which breast was treated, but the investigator who conducts the follow-up visits will not.|"Patients who agree to participate will be randomized during their bilateral breast reduction procedure. Each patient will be randomized to LEFT BREAST or RIGHT BREAST. The randomization result will determine which breast receives the nitroglycerin paste. Their breast reduction will be done using the Wise pattern, and all incisions will be sealed with Dermabond. At the conclusion of the procedure, 1g of topical nitroglycerin (2%) will be placed on the breast which the randomizer indicated. Patients will be monitored for AEs during the remainder of their hospital stay."|t|t|f|f
33764464|NCT01431040|RANDOMIZED|PARALLEL||||NONE||||||
33764465|NCT05344261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764466|NCT03091647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764467|NCT05529758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33842975|NCT06729450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946525|NCT06333613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946526|NCT04428723|||COHORT||CROSS_SECTIONAL|||||||
33946527|NCT06328192|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946528|NCT03783884|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization of treatment and control group||||
33946529|NCT04737447|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible because of active patient's participation in the study.|"In this randomized controlled trial children with incontinence will be randomly assigned in two groups: an urophysiotherapy plus WBVT group and a control group receiving urophysiotherapy only. Statistical analysis will be randomised-controlled and prospective. Two groups will be compared:~Group A = 20 participants treated with standardized urophysiotherapy. Group B = 20 participants treated with standardized urophysiotherapy and WBVT. According to this parameters and statistical tests will be used. Primary and secondary outcomes will be statistically described by the average (mean, median), standard deviation, frequency and percentage. The analysis will be univariant. For continuant outcomes the Student's t-Test will be used. Chi-Square Test or Fisher's Exact Test will analyze small numbers in binary or categorical outcomes.~The level of significance (alpha) is 0.05"||||
33946530|NCT04758624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33946531|NCT05628012|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33946532|NCT05544500|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomised, double-blind, placebo-controlled, counterbalanced crossover study|t|f|t|t
33946533|NCT06518148|||CASE_ONLY||RETROSPECTIVE|||||||
33946534|NCT03249259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind placebo controlled study.||t|f|t|f
33946535|NCT00078663||||TREATMENT||||||||
33946536|NCT05005715|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33946537|NCT04367324|||COHORT||RETROSPECTIVE|||||||
33946538|NCT04360538|||COHORT||PROSPECTIVE|||||||
33946539|NCT02699918|NA|SINGLE_GROUP||SCREENING||NONE||||||
33946540|NCT06723561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33842976|NCT04619797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946541|NCT02543476|||CASE_ONLY||RETROSPECTIVE|||||||
33946542|NCT02551601|||CASE_ONLY||PROSPECTIVE|||||||
33946543|NCT06184100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The research team and all participants will be aware which arm they are enrolled in throughout the study.|Patients will be randomized into an interventional or control group. The control group will be given the option to receive the intervention after post-test outcome measures are recorded.||||
33946544|NCT01108588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33946545|NCT00161135|||CASE_CONTROL||OTHER|||||||
33946546|NCT06071351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind|Parallel Assignment|t|f|f|f
33946547|NCT05108818|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33842977|NCT03492125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||a limited 3+3 phase 1 dose escalation study with expansion cohorts||||
33842978|NCT05528419|RANDOMIZED|PARALLEL||TREATMENT||NONE||After screening period, eligible patients will be randomly assigned into sacubitril/valsartan group (sacubitril/valsartan 80mg QD) or valsartan group (valsartan 80mg QD).||||
33842979|NCT03454126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842980|NCT03999801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||1 main Observational study arm, 1 RGX-314 Fellow Eye Treatment substudy||||
33946548|NCT03547960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Open label controlled study|t|t|f|f
33946549|NCT01958411|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946550|NCT01000311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946551|NCT06538610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946552|NCT06722352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Two research study nurses blinded to the intervention will be trained and a rating manual provided to assist in gaining a 90% IRR.||f|f|f|t
33946553|NCT05689554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33946554|NCT02131142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946555|NCT06656702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946556|NCT05769777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946557|NCT04454021|||CASE_ONLY||RETROSPECTIVE|||||||
33946558|NCT00608426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946559|NCT05310227|NA|SINGLE_GROUP||TREATMENT||NONE||"The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache. The Nerivio™ includes several main components:~* A pair of electrodes covered with hydrogel and a removeable protective film~* An electronic circuitry and a battery~* A software that includes firmware and a software application for mobile platforms~* An armband to secure the attachment of the device and enable a discreet treatment"||||
33946560|NCT03954418|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"We wish to conduct an interventional, open-label study in which 40 women undergoing planned caesarean section will be included. In the intervention-group divided between:~10 women with IUGR-child, 10 women with diabetes, 10 healthy women. We will use a control group of 10 healthy women who will refrain from intake.~The participants will drink an artificially sweetened soft drink 2 to 4 hours before planned c-section."||||
33946561|NCT04190199|||OTHER||CROSS_SECTIONAL|||||||
33946562|NCT01933269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946563|NCT06174428|||COHORT||PROSPECTIVE|||||||
33946564|NCT04924608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946565|NCT05692726|||COHORT||PROSPECTIVE|||||||
33946566|NCT03411317|||COHORT||PROSPECTIVE|||||||
33842981|NCT03577015|||COHORT||PROSPECTIVE|||||||
33842982|NCT06715618|||COHORT||PROSPECTIVE|||||||
33842983|NCT03891771|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33842984|NCT06681428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946567|NCT05664438|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946568|NCT00154674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946569|NCT03284762|||COHORT||PROSPECTIVE|||||||
33946570|NCT05289739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946571|NCT05806450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946572|NCT05007366|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33946573|NCT05348785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946574|NCT06724237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946575|NCT05292378|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33946576|NCT01151865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946577|NCT06722586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946578|NCT03641690|||CASE_ONLY||RETROSPECTIVE|||||||
33946579|NCT04600518|||COHORT||RETROSPECTIVE|||||||
33946580|NCT06126627|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33946581|NCT03927209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946582|NCT00906516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946583|NCT03495596|||COHORT||CROSS_SECTIONAL|||||||
33946584|NCT04388436|||COHORT||PROSPECTIVE|||||||
33946585|NCT03188276|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|Thr care provider, participant, investigator and outcomes assessor all konw the process.|There are 32 treatment-naive CHC patients who treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.||||
33946586|NCT06722924|||COHORT||RETROSPECTIVE|||||||
33946587|NCT04052425|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Participants will receive ruxolitinib cream or vehicle for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to vehicle will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.|t|f|t|t
33946588|NCT01288911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946589|NCT01768182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33946590|NCT03880162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-centre, randomized parallel study|t|f|f|f
33946591|NCT06722157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946592|NCT03055208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946593|NCT01648517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946594|NCT04112862|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, interventional, explorative, open label, proof of principle study||||
33946595|NCT04159558|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946596|NCT01654666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33946597|NCT05766410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33946598|NCT05571397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||CGM will be used by 100 MICU patients with glycemic control comparison with matched 100 MICU historical controls||||
33946599|NCT04369911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946600|NCT03759340|NA|SINGLE_GROUP||TREATMENT||NONE||This Phase 2, multicenter, open-label study will evaluate the safety, tolerability, efficacy, and durability of efficacy of ATI-502 Topical Solution, 0.46% for the treatment of alopecia areata (AA), alopecia universalis (AU) and alopecia totalis (AT) in adult subjects who completed 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension.||||
33946601|NCT05056948|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946602|NCT04668157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946603|NCT04784208|||OTHER||PROSPECTIVE|||||||
33946604|NCT03979924|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946605|NCT05574959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978000|NCT03444038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978001|NCT01790165|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33978002|NCT05275400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946606|NCT05988619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Care providers administering the TMS treatment are blinded and do not know whether the participant has been randomized to receive iCBT or educational content as a supplement to the TMS treatment.||f|t|f|f
33946607|NCT00519090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946608|NCT04738123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946609|NCT05039840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946610|NCT06601478|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The intervention group will complete de MEDLIFE questionnaire and use the MEDLIFE online app where they will receive counselling on lifestyle, food choices or physical activity. Meanwhile, the control group will only complete the MEDLIFE questionnaire, but will not receive the app lifestyle intervention.|f|f|f|t
33946611|NCT06248762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Delayed waitlist control||||
33946612|NCT03465683|||COHORT||OTHER|||||||
33946613|NCT06209099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946614|NCT04295629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||60 ASA I-III patients between ages 18-65 who underwent single-sided inguinal hernia operation were randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA), Group 2 (n:30); SA and ilioinguinal block (IHNB). All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded. Ultrasoundguided ilioinguinal block was implemented and 10 ml 5% bupivacaine was injected to patients in group I with peripheric nerve block injection in the reanimation unit after the surgery.||||
33946615|NCT04843189|||COHORT||PROSPECTIVE|||||||
33946616|NCT04672200|NA|SINGLE_GROUP||OTHER||NONE||||||
33946617|NCT06425471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946618|NCT06679920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946619|NCT05829018|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Cross-sectional study|t|f|f|f
33946620|NCT05762315|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||pre-post||||
33946621|NCT05115630|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946622|NCT06286293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946623|NCT04716205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33946624|NCT04882072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946625|NCT06109766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research visitor and video coders are masked to treatment condition.||f|f|f|t
33946626|NCT05403502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946627|NCT02990273|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946628|NCT04552834|||COHORT||PROSPECTIVE|||||||
33946629|NCT03347565|||CASE_CONTROL||PROSPECTIVE|||||||
33946630|NCT00528125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946631|NCT01371955|||COHORT||PROSPECTIVE|||||||
33946632|NCT02427334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946633|NCT06077760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946634|NCT06224491|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The participant is not familiar with the order of the intervention.|These are healthy adult women. The expected number of participants is 20-30. To participate in the study, participants must agree to participate voluntarily. Contraindications for participation include psychiatric illness, cancer, acute inflammatory diseases, and pregnancy. Persons with signs of acute illness or injury or in recovery from acute illness or injury will not be eligible for testing. Subjects who, like the investigators, are students at FTVS UK will be personally approached and selected by the principal investigators. No email or phone number contacts will be used.|t|f|f|f
33946635|NCT00256490|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946636|NCT06722014|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33946637|NCT06580106|||CASE_ONLY||PROSPECTIVE|||||||
33946638|NCT02425774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33946639|NCT00142428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946640|NCT04854356|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946641|NCT05512585|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33946642|NCT06287112|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946643|NCT03043287|||CASE_ONLY||RETROSPECTIVE|||||||
33946644|NCT04885582|||COHORT||RETROSPECTIVE|||||||
33946645|NCT02496715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946646|NCT05814627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764468|NCT06112223|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33946647|NCT03094468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|Vehicle-controlled|t|t|t|f
33946648|NCT01694849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764469|NCT04158180|||OTHER||PROSPECTIVE|||||||
33764470|NCT04686162|NA|SINGLE_GROUP||OTHER||NONE||||||
33764471|NCT03399162|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946649|NCT05324800|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33946650|NCT06199479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946651|NCT04984824|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33946652|NCT06445907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946653|NCT04693858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Independent Evaluators (IEs) responsible for baseline, post-intervention, and follow-up outcomes assessment will be masked to intervention conditions.|This study involves a cluster-randomized controlled trial to compare CALM to CALM-R and a weighted waitlist control (WLC) group (4 CALM/CALM-R:1 WLC).|f|f|f|t
33946654|NCT06662747|||COHORT||PROSPECTIVE|||||||
33946655|NCT05429268|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, multicenter||||
33946656|NCT06010576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764472|NCT02187666|||COHORT||PROSPECTIVE|||||||
33764473|NCT06371963|||COHORT||CROSS_SECTIONAL|||||||
33764474|NCT03852966|NA|SINGLE_GROUP||TREATMENT||NONE||Pragmatic, within-group pilot study||||
33764475|NCT03749447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764476|NCT02930460|||COHORT||PROSPECTIVE|||||||
33764477|NCT01086865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764478|NCT03214081|||COHORT||PROSPECTIVE|||||||
33764479|NCT06363058|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33946657|NCT05968157|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33946658|NCT04446039|||COHORT||RETROSPECTIVE|||||||
33946659|NCT01693640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946660|NCT05937152|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34154362|NCT05830825|||CASE_ONLY||PROSPECTIVE|||||||
33946661|NCT06629272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Because the intervention is educational in nature, blinding is not possible. But, to preserve a certain level of blinding and protect against bias, the study will be presented as a medication optimization study and consenting patient participants will be informed that their medication profiles will be transmitted to the research team within the following months and that they will receive a customized brochure at some point during the next year that may contain recommendations for change which they can discuss with their prescribing provider. For providers, blinding will be achieved by presenting the same study timeline. Providers will be aware that they will receive a customized letter with thyroid hormone optimization recommendations and that their patients will receive an intervention at some point during the following year, and remain blinded to group allocation throughout the course of the study."||t|t|f|f
33946662|NCT04688385|NA|SINGLE_GROUP||TREATMENT||NONE||"As usual in early phase 1 and 2 studies, statistical planning is designed as such that a statistically reasoned decision for or against a subsequent phase 3 study can be made. The sample size of the study was chosen based on the assumption that, in the case of peptide specific immune response induction in ≤ 30% of the patients, the therapy concept is extended with a probability of at most 5% (type one error, one-sided). On the other hand, in the case of peptide specific immune response induction in ≥ 60% of the patients, the therapy concept should be followed with a probability of at least 80% (power).~With a sample size of n = 20 patients, this means that at least 10 patients must have an immune response, so that the therapy concept is evaluated in a randomized phase 3 study. The exact power is 87%, the exact type 1 error is 4.8% (calculations based on the binomial distribution with n = 20, p = 0.3 or p = 0.6, k \<10 or k ≥ 10)."||||
33946663|NCT05275231|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946664|NCT03698825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946665|NCT03411304|||COHORT||PROSPECTIVE|||||||
33946666|NCT04652245|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinding by overlabelling of Dymista and Placebo bottles.|The study will be a single-center, randomized, placebo-controlled, double-blind, and two-period cross-over trial.|t|f|t|f
33946667|NCT05151809|||COHORT||PROSPECTIVE|||||||
33946668|NCT02918968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946669|NCT06508593|||COHORT||PROSPECTIVE|||||||
33946670|NCT04348760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946671|NCT03542409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946672|NCT03592251|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33946673|NCT02024997|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33946674|NCT06559033|||COHORT||PROSPECTIVE|||||||
33946675|NCT03783312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Prospective, Randomized, Placebo-Controlled Clinical Trial|t|f|f|f
33946676|NCT04888507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946677|NCT04039282|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33946678|NCT02630992|NA|SINGLE_GROUP||OTHER||NONE||||||
33946679|NCT01621139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946680|NCT03799198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946681|NCT05954559|NON_RANDOMIZED|PARALLEL||OTHER||NONE||non-randomized cohort study||||
33946682|NCT06219499|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33946683|NCT02452320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946684|NCT05687149|||COHORT||OTHER|||||||
33946685|NCT05017116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946686|NCT04433000|||CASE_ONLY||RETROSPECTIVE|||||||
33946687|NCT00272194|RANDOMIZED|PARALLEL||||SINGLE||||||
33946688|NCT06205225|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Care providers who provide usual care to study participants will be unaware of the study groups and group assignments. Outcome assessors will be masked to group assignment. Outcome assessors will work in a different office from other study investigators and will have limited access to the Electronic Data Capturing system used for data collection (REDCap).|2 x 2 factorial randomized controlled trial|f|t|f|t
33946689|NCT05548179|||CASE_CROSSOVER||PROSPECTIVE|||||||
34050645|NCT03356639|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34050646|NCT06647524|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The dose will be portioned by the unblinded co-investigator to assure each participant receives the correct dose.||t|f|t|f
34050647|NCT00006321|||COHORT||PROSPECTIVE|||||||
34154363|NCT04492163|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Single group assignment||||
34154364|NCT01679886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154365|NCT03057860|||COHORT||PROSPECTIVE|||||||
34154366|NCT02542787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33842985|NCT04491877|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|The study was performed in an observer-blind fashion. Investigators and study staff who conducted the safety assessment and the participants did not know which vaccine is administered. Only the study staff who prepare and administer the vaccine and were not involved with the safety evaluation knew which vaccine was administered.||t|t|t|t
33842986|NCT06540625|||OTHER||PROSPECTIVE|||||||
33842987|NCT06611046|||CASE_CONTROL||PROSPECTIVE|||||||
33842988|NCT00334334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33842989|NCT03342989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33842990|NCT05478889|||COHORT||RETROSPECTIVE|||||||
33842991|NCT01353651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33842992|NCT04200001|||OTHER||PROSPECTIVE|||||||
33842993|NCT05195021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33946690|NCT06113458|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33946691|NCT01501019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946692|NCT04191590|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946693|NCT05822973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946694|NCT03737812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946695|NCT05926687|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Outcome coders will be blind to experimental condition|The investigators propose a sequential, multiple assignment, randomized trial (SMART) design in which the investigators will initially randomly assign 184 children with ASD, between 18 and 48 months of age, to receive either the SC or DB intervention. Following each respective manualized, 12-week intervention (first-stage intervention; SC or DB), the interventionist will measure the parents' use of intervention strategies. At this point, all parents will be re-randomized before starting the second-stage intervention. Participants will be re-randomized to receive the same intervention at a lower frequency (Reduce) or to receive the other intervention (Switch). Parents who need additional parent instructional method, such as video feedback will be randomized to receive additional tools (Augment).|f|f|f|t
33946696|NCT02850757|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33946697|NCT05332912|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Typically developing children will be compared to adolescents/young adults with Down syndrome (groups matched on non-verbal ability).~A delayed start condition (verbal experience instead of spatial ability experience) of eight weeks will be used for 1/2 of participants in each group."||||
33946698|NCT06297629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946699|NCT01376076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946700|NCT06724549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946701|NCT06011603|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33946702|NCT06412289|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|anatomopathologist is blinded about the procedure which has been executed||f|f|t|f
33946703|NCT00781027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946704|NCT03995758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeons will not be aware of the group assignment.|The patients will be randomized 1:1 to either standard laser lithotripsy or MOSES laser lithotripsy.|f|f|t|f
33946705|NCT05334615|||COHORT||PROSPECTIVE|||||||
33946706|NCT05929794|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is an open-label, 2-way crossover, non-placebo controlled pharmacokinetic assessment study in n=24 health adult subjects. In this crossover study, all subjects will receive treatment with either metronidazole gel or cream, depending on assigned study group. During different periods of the study, the metronidazole product will be applied to skin treated with a micropatch (period 1) and to skin not treated with a micropatch (period 2) on the upper arm.||||
33946707|NCT06724822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946708|NCT05784129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946709|NCT02335411|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946710|NCT05599373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946711|NCT06723626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946712|NCT03830840|||COHORT||CROSS_SECTIONAL|||||||
33946713|NCT05722327|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764480|NCT02183935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764481|NCT03635489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764482|NCT06342089|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33764483|NCT06062459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33764484|NCT02062866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764485|NCT00658138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764486|NCT05485610|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33764487|NCT02913976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764488|NCT04632901|||COHORT||PROSPECTIVE|||||||
33764489|NCT05603832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946714|NCT03265808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946715|NCT05740982|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946716|NCT04325126|||COHORT||PROSPECTIVE|||||||
33946717|NCT00430235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946718|NCT04843098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946719|NCT00271297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33764490|NCT02867514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764491|NCT01356316|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946720|NCT05674461|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33946721|NCT05159973|||CASE_ONLY||RETROSPECTIVE|||||||
33946722|NCT00499694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946723|NCT02974023|||OTHER||PROSPECTIVE|||||||
33946724|NCT05144269|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33946725|NCT04564534|||COHORT||PROSPECTIVE|||||||
33946726|NCT00967356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33946727|NCT06722794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946728|NCT04006548|||COHORT||PROSPECTIVE|||||||
33946729|NCT01151085|||CASE_ONLY||PROSPECTIVE|||||||
33946730|NCT06660420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946731|NCT03900975|||COHORT||RETROSPECTIVE|||||||
33946732|NCT03387982|||COHORT||PROSPECTIVE|||||||
33946733|NCT01081002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33946734|NCT02177227|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33946735|NCT03173950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946736|NCT02797600|||CASE_CONTROL||PROSPECTIVE|||||||
33946737|NCT05891197|||OTHER||PROSPECTIVE|||||||
33946738|NCT04634617|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946739|NCT03099434|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||Patients will be randomly assigned to one of the 3 arms, where arm 1 is two interventions combined (LDC program + Facebook app), arm 2 is one intervention (Facebook app), and arm 3 is the control group (standard-of-care).|f|t|t|f
33946740|NCT02593331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946741|NCT01939236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33946742|NCT06444399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946743|NCT04106674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapists conducting outcomes at 6 months and 1 year do not know if patients are treated with surgery or not. Patients are instructed to wear t-shirt and not talk about treatment.|Randomized controlled trial with 2 arms|f|f|f|t
33946744|NCT00405665|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33946745|NCT06191562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental, randomized control trial with no placebo|f|f|f|t
33946746|NCT05644145|NA|SINGLE_GROUP||PREVENTION||NONE|Each enrolled participant is coded, and whoever processes the sample does not know the identity of the children included|It is a seroepidemiological study to evaluate the Immunization Program. It is a serological survey of the cohort of children who participated in the preliminary investigation and seroconverted after vaccination against yellow fever.||||
33946747|NCT06300060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The synbiotic and placebo are both powders identical in taste and appearance and are equally dissolvable in cold water.|Parallel arm. Single-site, double-blinded, placebo-controlled trial.|t|t|t|t
33946748|NCT06528301|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33946749|NCT01143506|||||PROSPECTIVE|||||||
33946750|NCT04761770|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single center, phase II pilot treatment-allocation study at MSK for older patients considering allogeneic hematopoietic cell transplantation.||||
33946751|NCT04982224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33946752|NCT06058039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor will also be blinded||t|t|t|t
33946753|NCT05397002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946754|NCT04002297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946755|NCT05643573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946756|NCT04136769|NA|SINGLE_GROUP||TREATMENT||NONE||Exact single stage design||||
33946757|NCT02345902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946758|NCT00431717|||COHORT||PROSPECTIVE|||||||
33946759|NCT00508872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946760|NCT04963517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34050648|NCT05887271|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and investigator will not be blinded to treatment allocation (open label) however, the team analysing the outcomes will be blinded to treatment allocation.|Multi-centre, prospective, open-label blinded end-point randomized controlled trial of low-energy Meal Replacement Plan (MRP) versus guideline-driven care with attention control, and a nested qualitative sub-study.||||
33946761|NCT05340465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Group 1 will be unblinded. In Groups 2-5 all infants will receive Darbe, and the iron preparation and dose will be blinded.|"* Group 1 Control, oral iron up to 12 mg/kg/day per Unit protocol~* Group 2 Darbe 10 mcg/kg q week plus LMW-ID: 10 mg/kg x 1, retreat if ferritin \< 76 mcg/L~* Group 3 Darbe 10 mcg/kg q week plus LMW-ID: 20 mg/kg x 1, retreat if ferritin \< 76 mcg/L~* Group 4 Darbe 10 mcg/kg q week plus FMX 10 mg/kg x 1, retreat if ferritin \< 76 mcg/L~* Group 5 Darbe 10 mcg/kg q week plus FMX 20 mg/kg x 1, retreat if ferritin \< 76 mcg/L"|t|t|t|t
33946762|NCT05443802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946763|NCT06066359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050649|NCT06020612|||COHORT||PROSPECTIVE|||||||
34050650|NCT04980820|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"1. arm: starts with no mask - FFP2 mask - FFP3 mask~2. arm: starts with no mask - FFP3 mask - FFP2 mask"||||
34050651|NCT06303570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050652|NCT04121156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050653|NCT02821013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946764|NCT01708369|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33946765|NCT04739059|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946766|NCT04604067|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will have a PET/CT (PET1) and evaluation of circulating tumor DNA (ctDNA1) at baseline. The trial consists of four treatment cohorts (cohorts A, B, C and D) and a first assignment to treatment will be done at baseline based on the presence or absence of MYD88 L265P and/or CD79A/B mutations.||||
33946767|NCT06479850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Kessler Foundation Strength Identification and Expression (KF-STRIDE®|f|f|f|t
33946768|NCT06628193|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||sham-controlled, repeated measures design conducted across eight sessions|t|f|t|f
33946769|NCT02011646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33946770|NCT01182480|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33946771|NCT02138227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946772|NCT05515341|||COHORT||PROSPECTIVE|||||||
33946773|NCT05044143|||COHORT||PROSPECTIVE|||||||
33946774|NCT02223208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946775|NCT06246669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33946776|NCT01053143|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33946777|NCT05994989|||COHORT||PROSPECTIVE|||||||
33946778|NCT00847002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050654|NCT02510963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050655|NCT00685724|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34050656|NCT02219581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050657|NCT06452147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050658|NCT06664775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050659|NCT06016634|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort of 24 adults with sickle cell disease and hip osteonecrosis||||
34050660|NCT01934517|||CASE_ONLY||PROSPECTIVE|||||||
34050661|NCT02383368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050662|NCT03721055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050663|NCT01023256|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34050664|NCT01692249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075747|NCT06337864|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, open-label, crossover trial. Participants will be randomly assigned to receive either LNAA treatment or the classic dietary treatment for 8 weeks, followed by a washout period of 2 weeks before receiving the other intervention for 8 weeks. Additionally, a healthy control group will be recruited for baseline measures.||||
34075748|NCT02106351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946779|NCT06220929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33842994|NCT04936477|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33842995|NCT06000033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946780|NCT02530034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946781|NCT03373422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946782|NCT01914289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946783|NCT06722313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946784|NCT03373656|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946785|NCT05174013|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double blind study||t|f|t|f
33946786|NCT00994045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33946787|NCT03799341|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to receive: (1) 12 weeks of TangiblePBCM (n = 70) or (2) 12 weeks of VoucherPBCM (n = 70). CM recipients will also be followed for 6 months post treatment. The proposed design enables evaluation of CM outcome predictors within 140 CM recipients - both with respect to initial treatment response and longer term (6 month) outcomes. All participants will receive a Baseline Assessment prior to the 12 Week Treatment interval, as well as a Follow-up Assessment at the conclusion of this period. Data from Baseline and Follow-up Assessments will enable longitudinal analysis of treatment-related change in EEG and cognitive-behavioral measures in TangiblePBCM and VoucherPBCM in treatment adherent versus treatment non-adherent subgroups.||||
33946788|NCT01749241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946789|NCT05915455|NA|SINGLE_GROUP||OTHER||NONE||||||
33946790|NCT03596385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946791|NCT04322929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946792|NCT04780230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946793|NCT01854502|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33946794|NCT06502821|||COHORT||CROSS_SECTIONAL|||||||
33946795|NCT06156774|||COHORT||PROSPECTIVE|||||||
33946796|NCT04107961|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinded placebo controlled|Randomised placebo-controlled double-blind study|t|f|t|t
33946797|NCT00036621||||TREATMENT||||||||
33946798|NCT00031616||||TREATMENT||||||||
33946799|NCT06112249|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The statistician will blindly randomize the three arm groups. The only staff with access to the groups will be the research coordinator. The primary investigators are blinded.|Three are study with a control group, a peer interventionist group and staff delivered group.|t|f|t|t
33946800|NCT00790595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946801|NCT04176237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Children in schools do not know which arm they are in. Schools and Investigators do know which arm a school is in.|Schools are randomized to receive one of three conditions: (1) Intervention (the expanded SunSmart program); (2) Control (regular SunSmart program); (3) Observation only. Schools in groups (2) and (3) receive the expanded SunSmart program at the conclusion of their participation in data collection.|t|f|f|f
33946802|NCT02222792|||||PROSPECTIVE|||||||
33946803|NCT04408105|||COHORT||PROSPECTIVE|||||||
33946804|NCT04238117|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946805|NCT04040179|||COHORT||PROSPECTIVE|||||||
33946806|NCT02012894|||COHORT||PROSPECTIVE|||||||
33946807|NCT02839213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946808|NCT06027658|||CASE_CONTROL||PROSPECTIVE|||||||
33946809|NCT04087005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946810|NCT02707562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946811|NCT06433271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946812|NCT01921582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946813|NCT06724445|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33946814|NCT06205251|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33842996|NCT05655273|RANDOMIZED|PARALLEL||TREATMENT||NONE||conversion v. control||||
33842997|NCT02960243|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33842998|NCT03814148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33842999|NCT05323955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843000|NCT04761367|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Parallel Assignment|t|f|f|t
33843001|NCT05022537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843002|NCT05917847|||CASE_ONLY||RETROSPECTIVE|||||||
33843003|NCT04185038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843004|NCT06466720|||COHORT||OTHER|||||||
33843005|NCT01077453|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33843006|NCT05735600|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization occurs after the baseline interview. The investigators will prepare ordered envelopes that contain the treatment assignments, one set for each stratum. Within each stratum, the treatment assignments will be placed in blocks of 10 (i.e., five assignments for each of the treatment conditions). Participants will be informed in the assigned group without mentioning if it's the intervention or match control group. Data will be collected by the trained RS who are blind to the study conditions of the participants.|Two complementary theoretical frameworks inform the proposed study. Social-Ecological Framework suggests that families are nested within multiple social contexts that can influence children's weight. At the macro level, policies can shape child obesity by supplementing families' ability to afford food (e.g., food stamps, income supports), at the messo (community) level, the built and social environments influence child obesity by providing or inhibiting access to healthy food options and safe areas to engage in physical activity. Within the family domain, family attributes, behaviors, functioning, and parental factors, directly shape child obesity. AyUDA targets the family domain by centering obesogenic (obesity-promoting) aspects and mechanisms within families. In concert with this domain, investigators draw from Social Learning Theory to account for how to influence change within the family domain by targeting parenting attitudes and behaviors.|t|f|f|t
33843007|NCT01227837|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33843008|NCT05826470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843009|NCT05253794|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33843010|NCT02499939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34050665|NCT06683053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, double-blind, randomized study comparing the efficacy and safety of empagliflozin at doses of 10 and 25 mg in patients with HFpEF. The Kansas City Cardiomyopathy Questionnaire (KCCQ TSS) will be applied at inclusion and 8 weeks post-intervention in the two groups. And the use of echocardiogram performed upon entering the study, with assessment of ventricular and atrial strain modalities, and being repeated at the end of the treatment period to try to detect possible differences between pre and post treatment with the proposed ISGLT2.|t|f|t|f
33946815|NCT02895386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946816|NCT04881149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050666|NCT02594904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740010|NCT05051644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"General terms will be used when recruiting potential participants and in the informed consent. Study title on informed consent and recruitment materials will be Enhancing self-management skills for individuals with opioid use disorder. Study measures (both in clinic and EMA) will be described as collecting data on problems that Veterans with OUD commonly report (e.g., negative mood, pain, quality of life, stress, etc.) and may improve with increased engagement in treatment. All in person assessment for post-treatment, 3 month follow up, and 6 month follow up will be collected by a research staff member who is blind to study condition. Data from EMA surveys at each time point will be provided by study participant whom is already blinded."|Recruitment strategies will week to minimize the amount of time between screening visit and treatment start date. After completing screening visit, Veterans will begin a 7 day baseline EMA run-in period leading up to the start of the treatment week. First treatment session will be scheduled 7 days after screening visit. The feasibility of these procedures will be evaluated in Aim 1. Veterans who provide pedometer and EMA survey data on at least 3 days during baseline EMA will be randomized. Veterans will be randomized to either S2C or control in a 1:1 ratio using permuted block randomization stratified by OAT type (1=buprenorphine, 2=methadone) and sex (1=male, 2=female). A variable block size of 2 and 4 will be used to maintain balanced assignment to condition.|t|f|f|t
33946817|NCT06641141|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a multi-centre Prospective Randomized Open-label Blinded Endpoint (PROBE) Pilot Trial|f|f|f|t
33946818|NCT04114955|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33740011|NCT03058731|||CASE_CONTROL||RETROSPECTIVE|||||||
33740012|NCT03095300|NA|SINGLE_GROUP||TREATMENT||NONE||Each enrolled patient will be monitored in the supine position for one hour, placed in the prone position for two hours and re-placed in the supine position for a final 1-hour step||||
34050667|NCT05437861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34050668|NCT06666790|NON_RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE|Investigator unaided (i.e., blinded/masked) assessment followed by aided assessment of each lesion's malignancy risk.|Enrolled lesions are assessed without and then with the device result as basis for study investigator decision to biopsy or monitor a potentially malignant lesion.|f|f|t|f
34050669|NCT06115395|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Sample method:~Method of randomization was stratified random sampling method was adopted to create matched study groups. Patients admitted for bronchoscopy were classified into two categories:~1. A) Non hypoxemic group.~2. B) Hypoxemic group.~3. From each category: 50 patients were selected and allocated randomly in the study groups (either intervention or control group) using lottery method. So, each study group with included 25 patients from each category forming a total of 50 patients in each studies categories."||t|f|f|f
33740013|NCT00259753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740014|NCT02096835|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33946819|NCT03335189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33740015|NCT05339685|NA|SEQUENTIAL||TREATMENT||NONE||||||
33740016|NCT04702074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050670|NCT03926052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050671|NCT00877071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740017|NCT06052384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33740018|NCT03947645|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34050672|NCT03346889|||COHORT||PROSPECTIVE|||||||
33740019|NCT06068816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessment will be performed by blinded raters.|Subjects will be randomized to the treatment. Subjects will receive either standard care or standard care plus nutrients dense drinks. Randomization will be done by a third party who is not involved in the study.|f|f|f|t
33740020|NCT06663306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946820|NCT04978129|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946821|NCT05292352|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946822|NCT05546515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research pharmacy will manage all randomization and blinding.||t|t|t|t
33946823|NCT03684343|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050673|NCT04182204|RANDOMIZED|PARALLEL||TREATMENT||NONE||In stage 1 participants are all assigned to one group. In stage 2 participants are assigned to two groups in parallel for the duration of the study.||||
33946824|NCT02626962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946825|NCT02812823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946826|NCT03176979|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050674|NCT01636154|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34050675|NCT06560216|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"1. Frozen-thawed control without apigenin supplementation in freezing medium~2. Frozen-thawed sperm suspension with apigenin supplementation in freezing medium"||||
34050676|NCT05111600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050677|NCT06684288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34050678|NCT00217893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33740021|NCT05520216|||CASE_ONLY||CROSS_SECTIONAL|||||||
33946827|NCT05300256|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33946828|NCT06723847|||COHORT||RETROSPECTIVE|||||||
33946829|NCT06300281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will be divided into two parallel groups: The neuromuscular exercise group and the Aquatic exercise group. Both groups will participate in exercise programs for 12 weeks.||||
33946830|NCT04474171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33946831|NCT02723682|||||CROSS_SECTIONAL|||||||
33946832|NCT01475942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33946833|NCT04487275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33946834|NCT04831957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Academic trial, prospective study||||
33740022|NCT02678611|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33946835|NCT05839691|||OTHER||OTHER|||||||
33946836|NCT06722937|||COHORT||PROSPECTIVE|||||||
33946837|NCT03174028|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33946838|NCT06472934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740023|NCT04596878|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomised, placebo controlled, double-blind, parallel group, multicentre study.|t|f|t|f
33740024|NCT04419636|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946839|NCT02810210|||COHORT||PROSPECTIVE|||||||
33946840|NCT05536219|||CASE_CONTROL||PROSPECTIVE|||||||
33946841|NCT06564779|||CASE_ONLY||PROSPECTIVE|||||||
33946842|NCT01254734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946843|NCT05248685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946844|NCT02956226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946845|NCT02380417|||COHORT||PROSPECTIVE|||||||
33946846|NCT03420456|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label pilot study|Pilot study||||
33946847|NCT04522635|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Patients will be randomized for a minimum of 4 and maximum of 6 consecutive dialysis sessions to one of two sequences:~1. Sequence A: Albumin in sessions 1, 3 and 5 and saline in sessions 2, 4 and 6~2. Sequence B: Saline in sessions 1, 3, 5 and albumin in sessions 2, 4 and 6 Dialysis Procedures (Standard of Care with the exception of Albumin which is additional and for research purposes only): All dialysis sessions will include standard procedures and monitoring. Dialysis prescriptions will be individualized for each patient and will be maintained through each of the 6 sessions."||||
33946848|NCT01693042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946849|NCT04743024|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33946850|NCT05949177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33946851|NCT04686773|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33946852|NCT01858402|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33946853|NCT01595139|||CASE_ONLY||PROSPECTIVE|||||||
34050679|NCT04948541|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33740025|NCT03617809|||COHORT||PROSPECTIVE|||||||
33740026|NCT05071755|||COHORT||RETROSPECTIVE|||||||
33740027|NCT00022776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33740028|NCT02256111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740029|NCT06067074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallell study arms with the intervention volar locking plate and control treatment forearm cast. We investigate the difference in health cost between the two groups.||||
33740030|NCT03511521|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients receiving single dose steroids who become hyperglycemic will be randomized to two treatment arms in a parallel design: (1) NPH added to basal/bolus insulin; (2) increase in doses of basal and bolus insulin||||
33740031|NCT00002912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740032|NCT03169140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740033|NCT03748745|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740034|NCT06112236|||COHORT||RETROSPECTIVE|||||||
33740035|NCT06533202|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The work of sequencing, randomisation, recruitment and allocation of the trial sample will be carried out by research staff who are not involved in the assessments or interventions of each group, thus avoiding any potential bias in the trial.~Participants will also be blinded and will not know which group they have been allocated to and therefore which intervention they will receive. In order to minimise any contamination between groups, the assessment process will be carried out by external research staff who will perform the measurements and who have been previously trained and educated to avoid subjective bias in the process, as they will be unaware of the intervention group to which they have been assigned, thus masking the blinded assessment by third parties in the clinical trial. In addition, the researchers responsible for the statistical analysis of the trial will be blinded in order to increase the rigour of the trial process and thus the scientific quality."||f|f|f|t
33740036|NCT03029208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740037|NCT05253703|NA|SINGLE_GROUP||OTHER||NONE||||||
33740038|NCT04267172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Consultant assessors will be blinded to the grouping of the Surgical Residents (additional simulation training group, or control group).|The intervention to be tested is the simulation-based training and cognitive learning package. This will be delivered for 1-2 hours per week over a 4-week period in a supervised non-clinical setting to a randomised sub-group of 50% of the Surgical Residents enrolled into this study.|f|f|f|t
33740039|NCT01339650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740040|NCT05474417|||COHORT||CROSS_SECTIONAL|||||||
33740041|NCT06396897|||COHORT||PROSPECTIVE|||||||
33740042|NCT06346093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740043|NCT03042806|NA|SINGLE_GROUP||SCREENING||NONE||||||
33740044|NCT04668313|||COHORT||PROSPECTIVE|||||||
33740045|NCT01365975|||COHORT||RETROSPECTIVE|||||||
33740046|NCT06487039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group A: EB-203 2% QID Group B: EB-203 4% QID|t|f|t|f
33946854|NCT00902590|||CASE_CONTROL||PROSPECTIVE|||||||
33946855|NCT02366182|||COHORT||PROSPECTIVE|||||||
33946856|NCT06527157|||CASE_CONTROL||PROSPECTIVE|||||||
33946857|NCT05214131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946858|NCT05778617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|A randomised, double blind, parallel group, placebo controlled, Phase 3a trial of daily ambroxol hydrochloride (420mg) as a potential disease modifying treatment for Parkinson's disease.|t|t|t|t
33946859|NCT00874718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33946860|NCT06722950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33946861|NCT05273515|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot study||||
33946862|NCT01813682|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33946863|NCT06406452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946864|NCT03845452|||COHORT||RETROSPECTIVE|||||||
33946865|NCT03517150|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33946866|NCT00077727|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33740047|NCT05234346|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||An Open-Label, Pilot Study||||
33740048|NCT03779529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The olive oils will be administered as oil A or B with content unknown to participants, investigators and outcome assessors|The general linear model for repeated measurements will be used with multiple paired comparisons in order to assess differences between the groups.|t|t|t|t
33740049|NCT03893227|||CASE_CONTROL||PROSPECTIVE|||||||
33740050|NCT05821010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Doubleblind|Randomized placebo-controlled trial|t|t|t|t
33740051|NCT01334931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740052|NCT04960813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The rater will be blinded to which intervention, structured games or playgroup, child participants receive.|Children and one legal guardian/primary caregiver will be randomized 1:1 to structured games or a playgroup. The structured games and playgroup will run in parallel.|f|f|f|t
33740053|NCT03872050|||COHORT||CROSS_SECTIONAL|||||||
33740054|NCT03503747|||COHORT||CROSS_SECTIONAL|||||||
33740055|NCT00049738|||COHORT||PROSPECTIVE|||||||
33740056|NCT02406144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740057|NCT01994486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740058|NCT00127673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740059|NCT01410981|||COHORT||PROSPECTIVE|||||||
33740060|NCT01040611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33740061|NCT03185624|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33740062|NCT05873192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740063|NCT01260922|RANDOMIZED|CROSSOVER||||SINGLE||||||
33740064|NCT01164059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740065|NCT03681301|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double (Investigator, Outcomes Assessor)|Parallel Assignment|f|f|t|t
33740066|NCT02693444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33740067|NCT05711550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33740068|NCT02143622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978003|NCT05666349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740069|NCT05234099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740070|NCT06458010|NA|SEQUENTIAL||TREATMENT||NONE||0.2mg/kg, 0.4mg/kg, 0.6mg/kg||||
33740071|NCT03095989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33740072|NCT04494919|||CASE_ONLY||RETROSPECTIVE|||||||
33740073|NCT00761059|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33740074|NCT01488812|||COHORT||RETROSPECTIVE|||||||
33740075|NCT04051892|NA|SINGLE_GROUP||OTHER||NONE||The sample size will be 10 female subjects undergoing reconstruction of the nipple, S/P breast reconstruction surgery as a result of breast cancer.||||
33740076|NCT03542643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740077|NCT02376738|||CASE_ONLY||PROSPECTIVE|||||||
33740078|NCT00509197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740079|NCT02268773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740080|NCT04382794|||CASE_CONTROL||RETROSPECTIVE|||||||
33740081|NCT01924936|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
33740082|NCT00435123|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33740083|NCT06402500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients who participated in the study and the assessor of the treatment outcome did not know the type of treatment procedure received.|Split mouth study design, patients will be assigned to two different treatment protocols.|t|f|f|t
33740084|NCT01795001|||CASE_CONTROL||PROSPECTIVE|||||||
33740085|NCT06259344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Experimental: Fractioned Pain Science Education (PSE) program + Manual Therapy + Orofacial and Neck Motor Exercises (ONE) (FPSE) Six sessions of 15 minutes each of a workshop on PSE will be administered. Two protocols of ONE and Manual Therapy (MT) and ONE will be administered. The exercises will be administered for six weeks, twice a week. Half of the sessions will include orofacial therapy and exercises and half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.~Active Comparator: Full Dosage Mode PSE (FDPSE) + MT + ONE Two sessions of 45 minutes (90 minutes) of PSE will be administered. Two protocols of ONE and MT will be administered. The exercises will be administered for six weeks, twice a week. Half of the sessions will include orofacial therapy and exercises and half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds."|t|f|f|t
33740086|NCT02015377|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33740087|NCT00131287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740088|NCT05423262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740089|NCT06533670|||COHORT||PROSPECTIVE|||||||
33740090|NCT02282449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740091|NCT02311595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740092|NCT05095480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||treatment and placebo received their drugs in their group|t|t|t|t
33740093|NCT05892952|||COHORT||PROSPECTIVE|||||||
33740094|NCT04400552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33740095|NCT06065696|||COHORT||RETROSPECTIVE|||||||
33740096|NCT02426671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740097|NCT05937035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740098|NCT04223856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740099|NCT05344937|||CASE_ONLY||PROSPECTIVE|||||||
33740100|NCT00519805|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33740101|NCT06039332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740102|NCT05171569|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33740103|NCT04932265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A comparative study with the positive control, parallel groups, randomized, crossover design||||
33740104|NCT04120896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740105|NCT06396728|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||The study involves a total of 44 men who will be randomly selected to be part of two groups: one who will consume a placebo capsule and another who will consume GI BIOTICS 100B UFC daily for a period of 8 weeks.|f|f|t|f
33740106|NCT02766608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740107|NCT05107986|||COHORT||PROSPECTIVE|||||||
34050680|NCT03880968|||COHORT||PROSPECTIVE|||||||
33740108|NCT04315311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050681|NCT05721872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050682|NCT03283293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740109|NCT05456035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individuals who conduct the assessments of the outcome measures will be unaware of to which condition the participant was randomized.|The study has two intervention arms: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking),and (2) CBT only is cognitive behavioral therapy without the additional SCT training component. Adolescents are randomized to either condition.|f|f|f|t
34050683|NCT03973918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740110|NCT03855215|RANDOMIZED|PARALLEL||TREATMENT||NONE||The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam (CHC details are described in the Location section below). Prior to introduction of the tests, an educational session will be provided for local healthcare workers in both intervention and control arms about the role of antibiotics and AMR. After randomization, further training will be provided for healthcare workers in the intervention CHCs as to the use of CRP testing to guide antibiotic prescribing decisions. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI (detailed in section 5.4). Educational materials will also be developed for patients and care-givers regarding the value of CRP testing.||||
33740111|NCT01778465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740112|NCT02349711|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34050684|NCT03562286|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Intervention model: single group assignment Masking: None (Open label) Primary purpose: treatment||||
34050685|NCT04092673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation, 3+3, 3+3+3||||
33740113|NCT03077282|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Volunteers will be divided into 2 groups. One will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals and the other take Prasaprohyai 95% ethanolic extract capsule at a dose of 200 mg 3 times a day before meals for six weeks. After that, they will cease using the drug for 2 weeks (wash out period). All volunteers will be followed up in the third week, sixth week and eighth week to evaluate the safety of the medicines. The researcher will record data such as age, career, BMI, vital signs, signs and symptoms. Safety will be monitored by hematology tests such as liver function test, renal function test, lipid profile and blood sugar.~The first step in this research will be to study group 1 (100 mg). If it proves safe, the group 2 (200 mg) will be studied."||||
34050686|NCT01744184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050687|NCT06685601|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34050688|NCT04821453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective, unblinded, pilot randomized cross-over trial of 2 modes of mechanical ventilation||||
34050689|NCT04286789|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34050690|NCT02278120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050691|NCT05519228|||COHORT||RETROSPECTIVE|||||||
34050692|NCT06024473|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label pilot study|10 participants each will be assigned to the standard treatment, rTMS only or rTMS and iVCT groups||||
34050693|NCT01872598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050694|NCT06549413|||COHORT||PROSPECTIVE|||||||
34050695|NCT00896181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740114|NCT00166738|||DEFINED_POPULATION||OTHER|||||||
33740115|NCT01469676|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33740116|NCT02207868|||COHORT||PROSPECTIVE|||||||
34050696|NCT06102382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050697|NCT06038058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050698|NCT02229279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050699|NCT02050919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050700|NCT06665815|||COHORT||PROSPECTIVE|||||||
33740117|NCT01184352|||CASE_ONLY||RETROSPECTIVE|||||||
34050701|NCT06682871|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Randomization will be based on computer-generated codes and use random-sized blocks. Allocations will be concealed until the morning of surgery where they will be provided by a web-based system|"D. Protocol After eligibility is confirmed, patients will receive complete information about the study both verbally and in writing. Informed consent will be obtained from the patients prior to randomization and study-specific procedures.~Randomization will be based on computer-generated codes and use random-sized blocks. Allocations will be concealed until the morning of surgery where they will be provided by a web-based system."|t|t|t|t
33740118|NCT03551652|||CASE_CONTROL||PROSPECTIVE|||||||
34050702|NCT02562222|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34050703|NCT05945615|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants in the study will be randomized 2:1 to treatment with oxymetazoline 0.1% or the vehicle solution. Randomization schemes were created by a biostatician. This will be stored in a secure database, only accessible to the investigators. Experimental drops and placebo drops will be removed from their labeled boxes and provided to patients with instructions on use.|Blinded, randomized, cross-over trial that will analyze and compare the efficacy of oxymetazoline drops alone, oxymetazoline drops adjunct with botulinum toxin, botulinum toxin alone, and no treatment.|f|f|t|f
33740119|NCT02211833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740120|NCT03460340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants do not know if they are getting the DTMS treatment or sham.|randomized control trial (RCT)|t|f|f|f
33740121|NCT03550963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All participants included in the study will be randomized assigned into one of two groups in parallel. Group one will be provided with rice-richen meal, while group two will be provided with wheaten-richen meal. All other factors, i.e. nutrition education, following-up, and physical activity will be the same between two groups.|f|f|f|t
33740122|NCT04049994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33946867|NCT06405750|NA|SINGLE_GROUP||OTHER||NONE||Mechanistic study based on analysis of biological material collected along with electrocardiogram features on individuals undergoing open-heart surgery||||
33946868|NCT06481215|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050704|NCT06110754|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34050705|NCT06596538|||OTHER||PROSPECTIVE|||||||
33740123|NCT03142074|||COHORT||PROSPECTIVE|||||||
33740124|NCT04150575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740125|NCT01775137|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34050706|NCT06440356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740126|NCT00812929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740127|NCT05177471|||COHORT||RETROSPECTIVE|||||||
33740128|NCT01856140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740129|NCT02006030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740130|NCT02656446|||CASE_ONLY||PROSPECTIVE|||||||
33740131|NCT01438411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740132|NCT04274517|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know which treatment arm they have been randomized to||t|f|f|f
33740133|NCT04519632|||OTHER||CROSS_SECTIONAL|||||||
33740134|NCT00815126||PARALLEL||DIAGNOSTIC||NONE||||||
33740135|NCT04112849|||COHORT||PROSPECTIVE|||||||
33740136|NCT01591252|||COHORT||CROSS_SECTIONAL|||||||
33740137|NCT05560867|NA|SINGLE_GROUP||OTHER||NONE||||||
33740138|NCT03984266|||OTHER||CROSS_SECTIONAL|||||||
33740139|NCT03055234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740140|NCT03702829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740141|NCT04823338|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Interventional (Clinical trial)|f|f|f|t
33740142|NCT05531214|RANDOMIZED|PARALLEL||OTHER||SINGLE|These primary care clinicians will then be block randomized using a 1:1 ratio to either arm of treatment utilizing random number generation. Primary care clinicians will be stratified by the size of their individual practices, and patients will be stratified by EF prior to their enrollment to balance the representation of patients with HFrEF (EF \< 50%) and heart failure with mildly reduced ejection fraction (HFmrEF) (EF 41-49%), respectively.|Our pragmatic randomized controlled trial will firstly identify primary care clinicians (PCCs) currently working at the George Washington University Medical Faculty Associates (GW-MFA) who care for adult patients diagnosed with both heart failure with a reduced ejection fraction (HFrEF) and chronic kidney disease (CKD). 164 patients who meet our inclusion criteria will be first identified via their respective PCCs at the GW-MFA. These PCCs will be randomized to the control and intervention arms, and the intervention arm will be receiving recommendations from a multidisciplinary team of cardiologists and nephrologists.|t|f|f|f
33740143|NCT02841423|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33740144|NCT03128749|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|t|f|t
33740145|NCT03765957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740146|NCT03540901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33740147|NCT02787616|||COHORT||PROSPECTIVE|||||||
33740148|NCT02279303|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33740149|NCT02711657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740150|NCT04793321|NA|SINGLE_GROUP||OTHER||NONE||"A single group repeated measures design was used under which each participant had their balance tested during three conditions:~1. holding nothing (unloaded).~2. holding an infant mannequin in arms(arms).~3. holding an infant mannequin in the baby carrier(carriers)."||||
33740151|NCT05615311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740152|NCT02086591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740153|NCT02188823|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33740154|NCT04411290|||COHORT||PROSPECTIVE|||||||
33740155|NCT03397511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740156|NCT00113516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740157|NCT02843789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740158|NCT01962974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740159|NCT02120924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33740160|NCT00248222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740161|NCT06043362|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33740162|NCT04233814|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|"The Sponsor, Investigator, and study personnel working on behalf of the Investigator and Sponsor will remain blinded.~Study medication will be dispensed by unblinded pharmacy staff to study staff in a blinded manner. Other than the pharmacist(s), all study staff will remain blinded to study medication assignment."|"The first part of the study will follow a Single Ascending Dose design. Subjects receive a single dose of double-blind study medication (investigational medicinal product LTI-03 or placebo) on Day 1.~For each dose level cohort, two eligible sentinel subjects will be randomized in a 1:1 ratio to receive active:placebo study medication.~If no tolerability issues are observed by the Investigator within 48 hours post-dose, dosing will commence for the remaining six subjects in the cohort, who will be randomized in a 5:1 ratio to receive active:placebo study medication.~The second part of the study will follow a Multiple Ascending Dose design. Subjects receive double-blind study medication (LTI-03 or placebo) once-daily from Day 1 to Day 14.~For each dose level cohort, eight eligible subjects will be randomized in a 6:2 ratio to receive active:placebo study medication."|t|t|t|f
33740163|NCT04832204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740164|NCT02464969|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740165|NCT05163860|||OTHER||CROSS_SECTIONAL|||||||
33740166|NCT00614939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740167|NCT06398704|||COHORT||PROSPECTIVE|||||||
33946869|NCT00883402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34050707|NCT02522156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740168|NCT04888286|||COHORT||RETROSPECTIVE|||||||
33740169|NCT03845257|||COHORT||PROSPECTIVE|||||||
33740170|NCT05333445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740171|NCT03809845|NON_RANDOMIZED|PARALLEL||OTHER||NONE||20 Motor Neuron Disease (MND) patients and 5 Benign Fasciculation Syndrome (BFS) patients undergoing same assessments at 2-monthly intervals for one year||||
33740172|NCT02793492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740173|NCT06171152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740174|NCT00102791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740175|NCT01592630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740176|NCT06071000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33740177|NCT04352335|||COHORT||RETROSPECTIVE|||||||
33764492|NCT00032890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764493|NCT03311763|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33740178|NCT03949725|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention study model is a 2-arm randomized control trial with a 2:1 allocation of participants to the treatment condition (i.e., the Hans Kai program) or the control condition (i.e., usual care without the Hans Kai program). After 6 months in the control condition, participants in the control group will join the Hans Kai program.||||
33740179|NCT06280300|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cohort study||||
34050708|NCT04562129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740180|NCT04123639|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34050709|NCT06662448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740181|NCT03394924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050710|NCT02422966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050711|NCT04850261|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, active controlled proof-of concept trial (phase II)||||
34050712|NCT06408857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A: Open Label. Part B: Double Blind||t|t|t|t
34050713|NCT01914146|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050714|NCT03854370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and laboratory staff will not know which group cases have been assigned|Randomized to 1 of 4 surgical prep agents|t|f|f|t
34050715|NCT00112528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050716|NCT03438604|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050717|NCT06682377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050718|NCT02827019|||COHORT||RETROSPECTIVE|||||||
33740182|NCT06535113|||COHORT||OTHER|||||||
34050719|NCT06229288|RANDOMIZED|PARALLEL||TREATMENT||NONE||Drug study, multi-centre, Phase 3, Controlled , Randomized, Open, Prospective||||
33740183|NCT00779246|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740184|NCT03503968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740185|NCT01038921|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740186|NCT00777517|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33740187|NCT05804058|||CASE_CONTROL||PROSPECTIVE|||||||
33740188|NCT00310687|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34050720|NCT04010903|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cohort of subjects with/without overweight and with/without insulin resistance||||
34050721|NCT03473639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050722|NCT01242202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050723|NCT03025308|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study was originally designed and initiated as a double-blind study but the study design will change to open-label following implementation of the protocol amendment # 4.|||||
34050724|NCT02949193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050725|NCT00621166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050726|NCT06429228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050727|NCT05238025|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34050728|NCT00421018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050729|NCT04016038|||COHORT||PROSPECTIVE|||||||
34050730|NCT03247153|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050731|NCT02402257|||COHORT||OTHER|||||||
34050732|NCT05458219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154367|NCT03473899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A medical assistant at the clinic of the Principal Investigator will allocate interventions by means of opaque sealed envelopes that will be marked according to the allocation schedule. The medical assistant will be unaware of the size of the blocks.~The randomized intervention assignment as outlined above will be concealed from both patients and health care staff until recruitment will be complete and irrevocable.~Patients will be blinded in this study. The assessor will be blinded in this study. The assessor is the person who will assess the outcome of treatment during follow up. In this study, the assessor will be a medical assistant at the clinic of the Principal Investigator.~The therapist will not be blinded in this study. The therapist is the person who will administer either rESWT or sham-rESWT to the patient. In this study, the therapist will be the Principal Investigator."||t|f|f|t
34154368|NCT00006656||||TREATMENT||||||||
34154369|NCT05620745|||COHORT||PROSPECTIVE|||||||
34154370|NCT00857974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154371|NCT00292539|||COHORT||RETROSPECTIVE|||||||
34154372|NCT06222528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154373|NCT00004113||||TREATMENT||||||||
34154374|NCT03576716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154375|NCT04533867|||COHORT||PROSPECTIVE|||||||
34154376|NCT05966948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants who met the eligibility of the study who were on outpatient treatment on that day were randomized in order of queue, odd numbers as the intervention group and even numbers as the control group.|This study involves two arms assigned randomly for receiving different treatment. One arm for Hypertonic Dextrose Prolotherapy as intervention group and Normal Saline as control group.|t|f|f|f
34154377|NCT00830180|NON_RANDOMIZED|||TREATMENT||NONE||||||
34154378|NCT06200623|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154379|NCT01115374|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34154380|NCT02536222|NON_RANDOMIZED|PARALLEL||||NONE||||||
34154381|NCT00903305||PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34154382|NCT00803062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154383|NCT05797597|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34154384|NCT03561818|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154385|NCT01139567|||CASE_CONTROL||RETROSPECTIVE|||||||
34154386|NCT05880173|NA|SINGLE_GROUP||SCREENING||NONE||||||
34154387|NCT04534270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154388|NCT00455143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34154389|NCT01799824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154390|NCT03633266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154391|NCT06583967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The study will assess the effect of 12 weeks of aerobic exercise on an elliptical trainer (group 1) vs a treadmill (group 2), on gait and walking abilities, expressed in dynamic stability, balance and walking speed, in people with Multiple Sclerosis.|t|f|f|t
34154392|NCT01133938|||COHORT||RETROSPECTIVE|||||||
34154393|NCT04159792|||COHORT||PROSPECTIVE|||||||
33740189|NCT01679119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740190|NCT05561998|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The comparative intervention study is designed as a randomized controlled trial (RCT) where the use of TalkingMats as a decision aid to support influence, choice and control in home care services for people living with mild to moderate dementia will be evaluated through comparison with usual conversation methods.Two different situations where older people living with dementia have to make decisions about home care services will be studied; first a needs-assessment conversation by care managers working in eldercare concerning the choice of care and services as well as choice of provider. The next situation is when home care staff carry out a conversation regarding the planning of the provision of the decided home care services. The participants will be randomized to one of two study arms, intervention group (n=50 and control group n=50).||||
33740191|NCT01379963|||COHORT||RETROSPECTIVE|||||||
33740192|NCT06573489|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33740193|NCT01918345|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33740194|NCT05515432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740195|NCT05042622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Design Study Type: Interventional (Clinical Trial) Estimated Enrollment: 90 Participants Allocation: randomized Interventional Model: Parallel assignment Masking: None (Open Label)||||
33740196|NCT00147095|||CASE_CONTROL||PROSPECTIVE|||||||
33740197|NCT02348138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33740198|NCT00173667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740199|NCT02999113|||CASE_ONLY||PROSPECTIVE|||||||
33740200|NCT03430323|||CASE_ONLY||CROSS_SECTIONAL|||||||
33740201|NCT04696159|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33740202|NCT03038373|||CASE_CONTROL||PROSPECTIVE|||||||
33740203|NCT05041166|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This in-human study of HP \[13C\]pyruvate MRI at MSKCC will be an open-label study.||||
33740204|NCT01702129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740205|NCT05395624|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33740206|NCT04623801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740207|NCT06572254|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants in the study will be randomly assigned to either the intervention arm, where they will receive the newborn parenting education program, or the control arm, where they will not receive any intervention. The participants will not be informed of their group allocation to minimize potential bias in their reporting of outcomes. Healthcare providers and researchers involved in the delivery of the intervention and data collection will be aware of the group allocations due to the practical requirements of implementing the education program.|This study uses a parallel interventional design with two arms: an intervention group receiving a newborn parenting education program and a control group receiving no intervention. The primary aim is to compare parental confidence, feeding practices, teaching practices, and experiences between the two groups. Additionally, it assesses pre- and post-training experiences of nurses and healthcare providers and explores the readiness for large-scale implementation of the program in primary healthcare settings|t|f|f|f
33740208|NCT04198987|||CASE_ONLY||PROSPECTIVE|||||||
33740209|NCT06431750|||COHORT||PROSPECTIVE|||||||
33740210|NCT02723617|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33740211|NCT06532045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740212|NCT01889589|||||CROSS_SECTIONAL|||||||
33740213|NCT01903278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740214|NCT01911364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740215|NCT01381055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740216|NCT04971382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740217|NCT03749226|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Twenty consecutive patients heavily colonized by Gram-negative bacteria will be eligible for this study. Patients will be randomized to receive either AZLI nebulized or nothing via 1:1 randomization at study or control group.~Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator. All patients will be on conventional volume-control ventilator setting during the antibiotic therapy. Systemic antibiotics will not be used in any patient. If the attending physician saw the need to administer intravenous antibiotics after the patient has entry in the study, this patients should be removed from the study"||||
33740218|NCT05882851|||CASE_ONLY||PROSPECTIVE|||||||
33740219|NCT06068205|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740220|NCT02687880|||COHORT||PROSPECTIVE|||||||
33740221|NCT00002408||||TREATMENT||DOUBLE||||||
33740222|NCT03221257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740223|NCT00222391|||||PROSPECTIVE|||||||
33740224|NCT02533843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740225|NCT05477823|NA|SINGLE_GROUP||SCREENING||NONE||||||
33740226|NCT03063229|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33740227|NCT00909259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740228|NCT03732092|||COHORT||PROSPECTIVE|||||||
33740229|NCT03084328|||CASE_CONTROL||PROSPECTIVE|||||||
33740230|NCT00210652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740231|NCT01081587|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740232|NCT04689802|||COHORT||PROSPECTIVE|||||||
33740233|NCT04611997|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A (Study Group): Laparoscopic gastrectomy group with the use of near-infrared imaging (ICG group) Group B (Control Group): Laparoscopic gastrectomy group without the use of near-infrared imaging (Non-ICG group)||||
33740234|NCT01675180|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33740235|NCT01668095|||CASE_ONLY||RETROSPECTIVE|||||||
33946870|NCT03593031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Clinician did not know which treatment group. Subjects did not know which treatment group||t|t|t|t
33946871|NCT05239741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075749|NCT03570775|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial with newborns over 2000 grams of birth weight and diagnosis of indirect hyperbilirubinemia, requiring phototherapy. Patients were randomized to phototherapy with the LED sleeping bag or conventional phototherapy with blue light panels.||||
34075750|NCT02752438|||COHORT||PROSPECTIVE|||||||
34075751|NCT03630159|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open label)|||||
33740236|NCT04335877|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33740237|NCT05637424|||COHORT||PROSPECTIVE|||||||
33740238|NCT06037889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Our study is an open label, blinded endpoint trail. The primary outcome should be measured in a blinded manner, and the qualified evaluator is defined as: 1) Attending neurologists or above; 2) Complete the training for mRS score before the initiation of patient enrollment; 3) Blind to the antiplatelet treatment of the participants; and 4) Sign the evaluation when it is completed, and inform the other investigators of the results. All the clinical and safety events will be re-examined by the independent Clinical Event Committee (CEC), who are blinded during all procedures.|multi-center, randomized, open label, blinded endpoint, parallel controlled trial|f|f|f|t
33740239|NCT05284045|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33740240|NCT06573957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33740241|NCT00522210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740242|NCT04895397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Group A: (30 patients) modified pectoral nerve block will be done.~Group B: (30 patients) serratus plane block will be done."|t|f|t|f
33740243|NCT04293887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740244|NCT03783559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740245|NCT01923181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740246|NCT05734859|NA|SINGLE_GROUP||TREATMENT||NONE|No need of blinding|comparison between baseline and post-treatment in single group||||
33946872|NCT03793517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients enrolled in this study would receive decitabine 200mg·m-2·d-1 on day -12 and -11 pre-HSCT. The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was modified BU/CY plus ATG. In matched sibling transplantations, patients received hydroxycarbamide (80 mg·kg-1) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, but otherwise an identical regimen to the HLA-mismatched patients without ATG.BM samples from patients would be obtained to assess leukemia status after HSCT. The time points that we monitored BM samples included at time of allo-HSCT; 1 month, 2 months, 3 months, 4.5 months, 6 months, 9 months, and 12 months after allo-HSCT; and every 6 months thereafter to the defined endpoints or for at least until 5 year after transplantation.||||
33740247|NCT04981444|||OTHER||PROSPECTIVE|||||||
33740248|NCT03269591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|(Participant, Outcomes Assessor)||t|f|f|t
33740249|NCT05069662|||COHORT||PROSPECTIVE|||||||
33740250|NCT02540239|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33946873|NCT05237804|RANDOMIZED|PARALLEL||OTHER||NONE||In this study, there is a randomization of the participating centres in 4 groups.||||
33946874|NCT03127072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946875|NCT01636102|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33740251|NCT01151241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740252|NCT04471259|||CASE_CONTROL||RETROSPECTIVE|||||||
33740253|NCT02217306|||CASE_CONTROL||PROSPECTIVE|||||||
33946876|NCT04606797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33946877|NCT06326203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946878|NCT06001177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study participants and their caregivers, investigators and other staff, and sponsor staff involved in the study team will be blinded.|The study is a randomized, double-blind, placebo-controlled study with approximately 52 participants that will receive KAN-101 or placebo|t|f|t|t
33946879|NCT06525337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals will be randomized to the intervention or control at the baseline. SAS version 9.4 will be used to create the randomization list.|All participants were randomized in a balanced fashion and stratified by sex and AHI number into either one of the two intervention groups STANDARDCARE group (STAND) compared to no sleep ring and health coaching CONTROL group (CON) group|f|t|f|f
33946880|NCT03503617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946881|NCT06427577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946882|NCT00756379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Study Intervention: PET diagnostic imaging offered in addition to current standard of care for the detection of coronary atherosclerosis.~Comprehensive program of atherosclerotic risk factor modification, involving treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program.~This is addition to standard current medical therapy as provided by primary referring physician. No experimental medication or procedure will be used. Clinic visits for patients education and consulting in the comprehensive program will be performed five times during the first year and semiannually thereafter."|f|f|f|t
33946883|NCT05538507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients were divided into 6 groups according to the enrollment criteria, with 30 cases in each group. Group I AD patients were given donepezil 10 mg, memantine 20 mg and smart soup, group II AD patients were given donepezil 10 mg, memantine 20 mg and placebo; group III AD patients were given donepezil 10 mg and smart soup, group IV AD patients were given donepezil 10 mg and and placebo; group V MCI patients were given smart soup, and group VI MCI patients were given placebo.|t|t|t|t
33946884|NCT02564094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946885|NCT00038571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946886|NCT02117466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946887|NCT06666608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946888|NCT06482515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33946889|NCT05151458|||COHORT||PROSPECTIVE|||||||
33946890|NCT00917943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740254|NCT01324024|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33740255|NCT05191706|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study||||
33740256|NCT02782481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740257|NCT00013793|RANDOMIZED|||TREATMENT||||||||
33740258|NCT02423382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740259|NCT00956150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740260|NCT00672477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740261|NCT02533882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33740262|NCT05235529|||COHORT||PROSPECTIVE|||||||
33764494|NCT04664725|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740263|NCT03049059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized split face|f|f|f|t
33740264|NCT06208527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and all care providers and investigators are blinded during the trial and during data analysis.|Randomized double-blinded placebo-controlled study with a duration of 1 year. 100 participants randomized to either Placebo (n=50) or NR 2000 mg (n=50).|t|t|t|f
33740265|NCT06663137|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
33740266|NCT00403546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740267|NCT05567991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740268|NCT06420284|||CASE_CONTROL||PROSPECTIVE|||||||
33740269|NCT00097591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740270|NCT06573333|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomised Controlled Trails|t|t|t|f
33740271|NCT03226652|||COHORT||PROSPECTIVE|||||||
33740272|NCT01474135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740273|NCT05387759|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740274|NCT02170727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740275|NCT04749264|||CASE_CONTROL||PROSPECTIVE|||||||
33740276|NCT02866578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33740277|NCT00920452|||||PROSPECTIVE|||||||
33740278|NCT05233891|||COHORT||PROSPECTIVE|||||||
33740279|NCT00351780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740280|NCT05027191|||CASE_CONTROL||PROSPECTIVE|||||||
33740281|NCT00831805|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33740282|NCT05494112|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||healthy men and women volunteers, between 18 and 40 years of age, over a 90-day period.||||
33740283|NCT03813303|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33740284|NCT04378075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740285|NCT03886038|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740286|NCT03113539|NA|SINGLE_GROUP||OTHER||NONE||||||
33740287|NCT06460623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740288|NCT05313243|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects are scheduled to receive up to 16 cycles of combinatorial treatment with brentuximab + pembrolizumab, followed by up to 19 additional cycles of pembrolizumab monotherapy||||
33740289|NCT05187962|||COHORT||PROSPECTIVE|||||||
33740290|NCT02376452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740291|NCT05307172|||COHORT||PROSPECTIVE|||||||
33740292|NCT00414752|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33740293|NCT02466945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946891|NCT04726787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946892|NCT02724189|||CASE_CROSSOVER||PROSPECTIVE|||||||
33946893|NCT04312711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will receive three-dimensional time-of-flight magnetic resonance angiography (3D-TOF-MRA) and ultrasound to detect the stenosis degree of AVF.||||
33946894|NCT04535544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946895|NCT04529031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33946896|NCT05598411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946897|NCT03833609|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will use a three-arm prospective randomized open-label study. Participants will be randomized to one of the three following groups in a ratio of 2:2:1: A) an online yoga training program (+ physical activity (PA) electronic educational pamphlet) (n=10), B) an online aerobic dance training program (+ PA electronic educational pamphlet) (n=10) and C) a wait list control group (+ PA electronic educational pamphlet) (n=5). The total intervention period is 12 consecutive weeks. The frequency and duration of the intervention is based on other trials of yoga and physical activity interventions in pediatric and adult rheumatology.||||
33946898|NCT05852301|||COHORT||PROSPECTIVE|||||||
33946899|NCT02790476|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33946900|NCT04492514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33946901|NCT03433443|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of this study it was not possible to mask the participants, care providers or the investigator. We did not use any objective outcome measures assessed by outcome assessors.|||||
33946902|NCT06012149|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized controlled superiority trial evaluating if the new method Braining is superior to structured advice on physical activity, concerning increasing physical activity.~The trial is a multicenter study conducted at 3-6 sites. Participants are individually randomized in blocks of 2-4 at each site."||||
33946903|NCT00237315|||COHORT||PROSPECTIVE|||||||
33946904|NCT06248203|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not be blinded; adolescents must assent, and parents consent, to receive mental health care and teachers will be aware they are delivering care. One research assistant (RA) will not be blinded to observe teachers' fidelity. Otherwise, personnel are blinded.|The study will be conducted as a non-randomized cluster-controlled pre-post study. Given the nature of the intervention, each school will be a cluster. All schools will initially receive the control condition (EUC) and will be transitioned into the intervention arm (Tealeaf). A qualitative exploration of context and process will be embedded within the framework of the study. An embedded approach has been chosen to facilitate a high level of integration between the qualitative and quantitative components of the study.|f|f|f|t
33946905|NCT04593082|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946906|NCT02760680|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33946907|NCT05350839|||OTHER||CROSS_SECTIONAL|||||||
33946908|NCT06416462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33946909|NCT05645146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33946910|NCT03414606|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740294|NCT04849234|||COHORT||PROSPECTIVE|||||||
33740295|NCT05855629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740296|NCT00286143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740297|NCT06428201|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33740298|NCT03901248|||CASE_CONTROL||PROSPECTIVE|||||||
33740299|NCT06659523|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Double-blind, placebo-controlled study|t|f|t|f
33740300|NCT05346510|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946911|NCT06493214|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||In Stage 1 of the intervention, 30 child participants will enroll in the InPACT at Home exercise program, aiming to complete three 8-minute videos per day, five days a week. After four weeks, response rates will be evaluated. In Stage 2, ten participants will continue the program, while the other 20 will receive additional support via daily text messages or personalized activity calendars. In Stage 3, participants will be re-randomized to receive further support through either Tailoring or Coaching, with feasibility and response rates assessed throughout the 60-day study.||||
33946912|NCT03159455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946913|NCT01393444|NA|SINGLE_GROUP||||NONE||||||
33946914|NCT03083795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.~Participants in the control group will be treated with standard diabetes care."|f|f|f|t
33946915|NCT06724302|||COHORT||PROSPECTIVE|||||||
33946916|NCT02058849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946917|NCT05119738|||COHORT||PROSPECTIVE|||||||
33946918|NCT06672445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946919|NCT04920786|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Six dose groups are planned: 5 dose levels of TB006 in healthy subjects and 1 ethno-bridging group in healthy subjects of Chinese descent.|t|t|t|f
33946920|NCT01819168|||||RETROSPECTIVE|||||||
33946921|NCT06269484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33946922|NCT05666804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946923|NCT04548401|||COHORT||PROSPECTIVE|||||||
33946924|NCT05661006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Subjects will be randomized on the first day of Visit 1 using simple randomisation using ratio 1:1 between test and placebo group.~After the general subject's health is checked (vital signs), subjects will be assigned Subject Number, which will be pre-randomised to correspond with one of interventions (test group, placebo group).~To assure double blind approach, study products will be packed in neutral packaging, and pre-labelled with Subject Number (S-XXX) and instructions for use. Selected site will be provided enough product i.e. subject boxes with corresponding Subject Number to cover initially planned number of included subject."|This was a randomized, parallel, double-blind, placebo-controlled study included healthy elderly adults (age \> 65 years) who tested study products. On screening visit, participants underwent measuring of body weight \& height, and blood collection for measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP. Duration of study intervention for individual participant 56 ± 3 days, with one week pre-intervention monitoring of food intake (3x 24-h dietary records). On day 1 of the intervention period, participants were randomised in a 1:1 ratio.|t|t|t|t
33946925|NCT04358809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blinded, two arms, placebo controlled, clinical trial|t|t|t|t
33946926|NCT05608707|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Randomised controlled trial, a two-by-two factorial design will define the individual and combined impact of two intervention conditions over 12 weeks||||
33946927|NCT06032091|||COHORT||PROSPECTIVE|||||||
33946928|NCT06723613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33946929|NCT04994938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946930|NCT06672237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized in a 1:1 ratio to nexiguran ziclumeran or placebo with opportunity for crossover.|t|t|t|t
33946931|NCT05894070|||COHORT||PROSPECTIVE|||||||
33946932|NCT01823575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946933|NCT04991753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946934|NCT01977651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946935|NCT04398797|RANDOMIZED|PARALLEL||PREVENTION||NONE||Step-wedge, open label, cluster randomized controlled trial with 1 year follow up. Area home care teams from three Danish municipalities are randomized to cross-over from the control phase to the intervention phase. Participants automatically follow their area home care team into the allocated group.||||
33946936|NCT06248216|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The study coordinator will not be blinded as they will need to administer consents and interact with participants. However, lead study investigators and outcomes assessors will be blinded to treatment group.|This will be a 10-week crossover design where the participants will undergo one intervention for five weeks and the other intervention for the other five weeks. Participants will be randomly assigned the order of interventions they will undergo.|f|t|t|t
33740301|NCT01259193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740302|NCT05747118|||OTHER||CROSS_SECTIONAL|||||||
33946937|NCT00596466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740303|NCT02717793|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33946938|NCT01273142|||CASE_ONLY||PROSPECTIVE|||||||
33946939|NCT06713928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33946940|NCT04890054|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33946941|NCT04063748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participant does not know whether (s)he receives treatment or placebo. The investigator and the outcomes assessor are blind to this information too. The care provide (speech therapist) would know after communication with the participant.~In case of the HA-study, participants either receive an intervention or do not receive an intervention. Therefore, they cannot be masked."|Participants are assigned to either the test or the placebo group.|t|f|t|t
33946942|NCT06723379|||COHORT||PROSPECTIVE|||||||
33946943|NCT01205464|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33946944|NCT03539627|||COHORT||PROSPECTIVE|||||||
33946945|NCT04811079|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34075752|NCT05074134|NA|SINGLE_GROUP||OTHER||NONE||||||
34075753|NCT05088499|||OTHER||PROSPECTIVE|||||||
34075754|NCT00437164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740304|NCT02710630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740305|NCT05929014|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The participants who will participate in one of two studies will be randomly received 1 mA or 1.5 mA or 2 mA or sham with the washout period for at least 2 weeks. The participants could not participate in both studies.|t|f|t|t
33946946|NCT03660657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking of: patients, cardiologist and cardiac surgeons (clinical assessment), investigators obtaining other parameters (quality of life, biochemical and clinical parameters), investigators for statistical analysis|Standard treatment + ozone therapy (O3/O2) versus Standard treatment + oxygen (O2) as placebo|t|t|t|t
33946947|NCT05144646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33946948|NCT02708524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946949|NCT04029246|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33946950|NCT04503655|RANDOMIZED|PARALLEL||OTHER||NONE||In this study, there is a randomization of the participating centres in two groups.||||
33946951|NCT00433368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33946952|NCT06013579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33946953|NCT05081791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Post-training assessments will be conducted by a blinded assessor||f|f|f|t
33946954|NCT03116789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, Parallel, open lable Study||||
33946955|NCT05885958|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946956|NCT03626935|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33946957|NCT03044327|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740306|NCT05087940|||COHORT||PROSPECTIVE|||||||
33740307|NCT03430466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740308|NCT06497517|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|||||
33740309|NCT00828646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740310|NCT01010581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740311|NCT03037944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33740312|NCT02681926|||COHORT||PROSPECTIVE|||||||
33740313|NCT03395535|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|All clinical tests and outcomes are by masked observers.||f|f|f|t
33740314|NCT03136601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740315|NCT01886547|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33740316|NCT00672880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740317|NCT06574282|||COHORT||PROSPECTIVE|||||||
33740318|NCT01591681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740319|NCT01392352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740320|NCT05820022|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33740321|NCT06534060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740322|NCT02322606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740323|NCT03857438|||COHORT||PROSPECTIVE|||||||
33740324|NCT03108534|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33740325|NCT01787604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740326|NCT02201602|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740327|NCT02207829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33740328|NCT05927441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33740329|NCT04574895|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Team biostatistician will remain blinded to the group assignments for performing outcome statistics.||f|f|f|t
33740330|NCT05944900|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization (1:1 ratio) will be stratified according to the risk of haemostasis disorders (Presence of at least one risk factor (medication interfering with hemostasis, innate or acquired coagulation disorder, thrombocytopenia) vs. no risk).||||
33740331|NCT02011841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740332|NCT05754320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740333|NCT04104035|||COHORT||PROSPECTIVE|||||||
33740334|NCT04946240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740335|NCT00466323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740336|NCT05900947|||COHORT||PROSPECTIVE|||||||
33740337|NCT05145231|||OTHER||CROSS_SECTIONAL|||||||
33740338|NCT04715594|||COHORT||RETROSPECTIVE|||||||
33740339|NCT06534333|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740340|NCT05779657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Enrolled children will be equally randomized into study and control group using computer generated numbers, which will be sealed into sequentially numbered opaque envelopes by a person not belonging to the research team. For each enrolled participant, the envelope in order will be opened, and the assigned study drug will be used. A pharmacist will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, and investigators will be unaware of group assignment and drug/placebo therapy.|"Two groups of children with continuing seizures after stabilization phase (5 minutes)~Study group (Ket-Mid): will receive intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes.~Control group (Pla-Mid): will receive intravenous isotonic saline (as a placebo) in the same way.~At the same time, both groups will receive intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes."|t|t|t|t
33740341|NCT02642913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740342|NCT06535269|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority, prospective, randomized, single-center, parallel-group clinical trial.||||
33740343|NCT00000838||||TREATMENT||||||||
33740344|NCT03634592|||COHORT||PROSPECTIVE|||||||
33764495|NCT00003640||||TREATMENT||||||||
33764496|NCT00084214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764497|NCT01417611|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33764498|NCT04693936|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with Hashimoto's disease and patients with psoriasis and healthy individuals will be randomly assigned to intervention group and to control group. The intervention will be a nutraceuticals supplements combination in the context of Mediterranean diet. The duration of the intervention will last 6 months||||
33764499|NCT03253016|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33946958|NCT06078813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume_1 (PTV_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV_2 will remain the same through all dose levels. All doses are prescribed to the target volume.||||
33946959|NCT05947981|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33740345|NCT05014009|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|While the study team will not point participants to the specific differences between the two training programs (MD vs. LS), an exchange between participants about the training elements in each group cannot be avoided given that the participants are all students at the same faculty. Given that the study team will supervise the training sessions, collect the data, and assess the outcomes, blinding of investigators will not be possible but the analysis will be designed to minimize sources of investigator bias.|Participants will be assigned to multidirectional training group (MD) or a linear sprint training group (LS) in a quasi-randomized way. Both groups will complete an 8-week training program and will complete baseline, follow-up, and retention testing (4 weeks post follow-up).||||
33740346|NCT05447169|||OTHER||PROSPECTIVE|||||||
33740347|NCT05884034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33740348|NCT05885347|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33740349|NCT03933293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740350|NCT03957174|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Overencapsulated drug/placebo capsule used. Investigator and participant blind to allocation. Randomisation schedule drawn up by independent researcher and kept in locked cabinet.|Three group parallel design|t|f|t|t
33946960|NCT00556140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946961|NCT05999227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740351|NCT05367453|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740352|NCT05812027|||CASE_ONLY||PROSPECTIVE|||||||
33740353|NCT06535308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study will proceed sequentially from Cohort 1 through 8, and the decision to proceed to the next dosage level will be determined by the Safety Review Committee (SRC) based on the safety and tolerability results of the previous dose stage|t|t|t|f
33740354|NCT02129686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33740355|NCT03209908|||CASE_CONTROL||PROSPECTIVE|||||||
33740356|NCT06535178|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33740357|NCT00164801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740358|NCT03200522|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and nutrition staff will be aware of randomization assignments. All other study staff and the investigators will be blinded to assignment during the study.|This is a randomized crossover pilot trial to evaluate the feasibility of a Western and prudent diet feeding study in Baltimore City adults with asthma.|f|f|t|t
33740359|NCT00090012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740360|NCT02765945|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740361|NCT03335657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33740362|NCT03282084|||OTHER||PROSPECTIVE|||||||
33740363|NCT05158946|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial comparing an experimental condition (Treatment As Usual + Future Oriented Group Training) and a control condition (Treatment As Usual)||||
33740364|NCT04523129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740365|NCT02067013|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740366|NCT01348529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740367|NCT02981992|||COHORT||PROSPECTIVE|||||||
33740368|NCT01095744|||CASE_CONTROL||PROSPECTIVE|||||||
33740369|NCT05430386|NA|SEQUENTIAL||TREATMENT||NONE||||||
33740370|NCT03762226|||COHORT||PROSPECTIVE|||||||
33740371|NCT01714024|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740372|NCT05836038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740373|NCT04286347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740374|NCT05745740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740375|NCT01116960|||OTHER||PROSPECTIVE|||||||
33740376|NCT05040217|NA|SINGLE_GROUP||TREATMENT||NONE||This study aims to reduce neuronal loss and rebuild synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). A total of 12 subjects will be enrolled: subjects 1-6 will have a diagnosis of AD and subjects 7-12 will have a diagnosis of MCI. The gene therapy vector will consist of adeno-associated virus serotype 2 (AAV2) and will be stereotaxically administered into the brain under MRI guidance. Subjects will be followed over a pre-determined study time duration of 24 months, and indefinitely thereafter.||||
33740377|NCT03231371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740378|NCT05502016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33740379|NCT05407545|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740380|NCT02443389|||COHORT||OTHER|||||||
33740381|NCT00390390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740382|NCT00607841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33740383|NCT02670590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740384|NCT01866436|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33740385|NCT01794949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740386|NCT05035979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740387|NCT02509741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740388|NCT03144726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33740389|NCT06026566|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||crisscross|t|f|f|f
33740390|NCT02647359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740391|NCT06662916|||CASE_CONTROL||RETROSPECTIVE|||||||
33740392|NCT00991601|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33740393|NCT05712226|NA|SINGLE_GROUP||OTHER||NONE|Annotators of capnography data were blinded to the values provided by the investigational device|||||
33740394|NCT04295941|||COHORT||PROSPECTIVE|||||||
33740395|NCT02305940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946962|NCT05868187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946963|NCT04530227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740396|NCT05584449|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33740397|NCT01911052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33946964|NCT06285019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740398|NCT03435094|||CASE_ONLY||PROSPECTIVE|||||||
33946965|NCT01985555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946966|NCT05617014|||COHORT||PROSPECTIVE|||||||
33946967|NCT06723782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946968|NCT02735382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33946969|NCT04393259|||COHORT||PROSPECTIVE|||||||
33946970|NCT01590628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740399|NCT00633035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740400|NCT01602315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740401|NCT04542993|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|single blinded|Placebo controlled Resveratrol and Zinc combination therapy|t|f|f|f
33740402|NCT04068298|||CASE_ONLY||PROSPECTIVE|||||||
33946971|NCT05507346|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33946972|NCT04868188|||CASE_ONLY||PROSPECTIVE|||||||
33946973|NCT05638594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740403|NCT02784418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740404|NCT02418546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33740405|NCT02149589|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33740406|NCT05344105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patient will not know which study group he is in. The anesthetist, who will perform the regional block, will give the block to be applied in a sealed envelope by an assistant staff outside the study, and at the same time, the patient will not know which block has been made. The anesthesiologist who made the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another investigator blinded to the study.||t|t|t|f
33740407|NCT04930029|||CASE_CONTROL||PROSPECTIVE|||||||
33946974|NCT04826042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740408|NCT06280352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized|t|f|f|t
33740409|NCT04345146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740410|NCT01485952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740411|NCT02044887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33740412|NCT05534789|||COHORT||RETROSPECTIVE|||||||
33946975|NCT06536569|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740413|NCT06572280|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33740414|NCT04833257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740415|NCT01422759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740416|NCT04012398|||OTHER||CROSS_SECTIONAL|||||||
33740417|NCT00911365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740418|NCT03843359|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an Open-label study.|In Part 1A, escalating doses of GSK3745417 will be evaluated and in Part 2A, escalating doses of GSK3745417 in combination with dostarlimab will be evaluated as guided by the Bayesian Logistic Regression Model (BLRM).||||
33946976|NCT02914873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740419|NCT04479891|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pyrotinib alone and then combined with itraconazole||||
33740420|NCT06572813|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 (Evaluation of Drug Tolerance) Primary objective: To evaluate the tolerability of bortezomib, PD-1 mAb and mFOLFIRINOX in patients with advanced metastatic pancreatic cancer, and to determine the dose of bortezomib in the combination regimen; Secondary objectives: To evaluate the immunogenicity characteristics and safety of the combination regimen of bortezomib, PD-1 mAb and mFOLFIRINOX in patients with advanced metastatic pancreatic cancer; Phase 2 (Dose Expansion) Primary objective: To evaluate the tolerability and efficacy of the combination regimen of bortezomib, PD-1 mAb and mFOLFIRINOX in subjects with advanced metastatic pancreatic cancer; Secondary Objective: To evaluate the immunogenicity and safety of bortezomib, PD-1 mAb and mFOLFIRINOX in subjects with advanced metastatic pancreatic cancer; and to explore biomarkers related to combination therapy.||||
33740421|NCT04294186|||CASE_ONLY||CROSS_SECTIONAL|||||||
33740422|NCT04409964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33946977|NCT01143558|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33740423|NCT00767000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740424|NCT04880941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Progressive Relaxation Exercise and control group|This study is an experimental study with pre-test and post-test control groups.|t|f|f|f
33740425|NCT01312545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33740426|NCT03751904|NA|SINGLE_GROUP||OTHER||NONE||||||
33740427|NCT05660525|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2x2x2x2||||
33740428|NCT06311500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33740429|NCT00504244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740430|NCT04359836|||OTHER||OTHER|||||||
33740431|NCT03738150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740432|NCT01927445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33740433|NCT05776394|||COHORT||PROSPECTIVE|||||||
33740434|NCT02838602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740435|NCT05351216|||CASE_CONTROL||PROSPECTIVE|||||||
33740436|NCT03296189|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|10 mls of solution will be handed to operating surgeon by the scrub nurse. The nurse will be the only person aware of the solution content and it will be documented discreetly. The operating surgeon, the investigator and the patients will not be aware of the solution used.|Three arm double-blinded prospective randomised controlled trial|t|t|t|f
33740437|NCT05875584|||CASE_CONTROL||PROSPECTIVE|||||||
33740438|NCT03713567|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33740439|NCT00272376|||FAMILY_BASED||RETROSPECTIVE|||||||
33740440|NCT05410912|||CASE_CONTROL||RETROSPECTIVE|||||||
33740441|NCT02973659|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33740442|NCT04257903|||CASE_CONTROL||RETROSPECTIVE|||||||
33740443|NCT01307501|NA|SINGLE_GROUP||TREATMENT||NONE||All participants received the same treatment.||||
33740444|NCT05740930|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33946978|NCT06377449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, randomized, single-center study with 2 groups of patients (investigating and control arms)|t|t|f|t
33946979|NCT02643992|||COHORT||CROSS_SECTIONAL|||||||
33946980|NCT03742895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946981|NCT05530499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33946982|NCT06588855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33946983|NCT01453699|||COHORT||PROSPECTIVE|||||||
33946984|NCT05815758|||COHORT||OTHER|||||||
33740445|NCT03505658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740446|NCT00665119|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33740447|NCT05009589|||COHORT||PROSPECTIVE|||||||
33740448|NCT01273272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740449|NCT04894474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740450|NCT03894423|||CASE_ONLY||PROSPECTIVE|||||||
33740451|NCT03598504|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Clinical measures of spasticity before, during, and after the intervention will be implemented by an evaluator blind to the treatment effects||f|f|f|t
33740452|NCT00968617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740453|NCT00486343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740454|NCT02258633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740455|NCT01583725|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740456|NCT00289796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33740457|NCT04872179|||COHORT||PROSPECTIVE|||||||
33740458|NCT00426023|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33740459|NCT06111092|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"* data analysts are blind to the study arm so that their interpretation and analysis of the data is unbiased.~* in Aim 2, the two adapted intervention protocols will be created, each based on data from either the design thinking or focus group sessions. These protocols will then be rated for acceptability, feasibility and cultural appropriateness using standardized measures and stakeholder input. This rating will be performed by individuals who are blinded to study arm that was used for adaptation of each protocol."|"The aim of this study is to improve the health and well-being of Hispanic/Latino autistic children by improving the utilization of the evidence-based autism intervention Ayres Sensory Integration and to improve stakeholder engagement in the research process for effective outcomes. Specific aims of this project are:~1. Compare DT and FG on measures of stakeholder engagement~2. Compare the acceptability and feasibility of the adapted intervention manuals (one based on FG and another on DT data).~Design: A randomized mixed methods design is used to evaluate stakeholder engagement. Phase one will compare two stakeholder engagement methods (Design Thinking -DT, and Focus Group - FG) and evaluate stakeholder engagement. Phase two uses data from phase one to culturally adapt the intervention (two separate intervention protocols will be adapted, one from FG data and another from DT data) and obtain stakeholder input on acceptability and feasibility for the Hispanic/Latino population"|t|f|f|t
33740460|NCT02148562|||||PROSPECTIVE|||||||
33740461|NCT01420406|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740462|NCT01047683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740463|NCT02297152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740464|NCT04159831|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33740465|NCT06323226|||COHORT||PROSPECTIVE|||||||
33740466|NCT02741947|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33740467|NCT01361087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740468|NCT02809495|||CASE_CONTROL||PROSPECTIVE|||||||
33740469|NCT01699399|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33740470|NCT04415359|||CASE_ONLY||OTHER|||||||
33740471|NCT00171977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740472|NCT06574256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The universe of the study consisted of 114 women. The sample of the study consisted of 90 women. Inclusion Criteria for the Study Patients diagnosed with gynecological cancer and starting chemotherapy treatment for the first time in the hospital Speaking Turkish, having no communication problems Agreeing to participate in the study voluntarily Patients aged 18 and over Exclusion Criteria for the Study Illiterate Do not have a smart phone or computer Receiving radiotherapy together with chemotherapy Patients who do not know they have been diagnosed with cancer The intervention and control groups were randomized according to the literature; taking into account age group, education status, type and stage of gynecological cancer.~When determining the intervention and control groups, patients who applied to the chemotherapy unit on Monday and Tuesday were included in the intervention group, and patients who applied on Wednesday and Thursday were included in the control group."||||
33946985|NCT03772574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740473|NCT05548075|||OTHER||PROSPECTIVE|||||||
33740474|NCT03769441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, care providers and researchers will be blinded, except for the nurse who will administer the medication.|The study is designed as a 24 week, multicentre, randomized placebo-controlled clinical trial with two parallel arms to investigate the effect of ferric(III) carboxymaltose on exercise tolerance, cardiac function, skeletal muscle function, quality of life, the gut microbiota and on the immune system, to be performed at the University Medical Center Groningen (UMCG) and the Erasmus MC, University Medical Center Rotterdam.|t|t|t|t
33946986|NCT06589271|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||non-randomized, self-controlled, single-dose|t|f|t|f
33946987|NCT02369380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946988|NCT00556088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33946989|NCT03054116|||COHORT||PROSPECTIVE|||||||
33946990|NCT03262246|||COHORT||RETROSPECTIVE|||||||
33946991|NCT02426359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33946992|NCT03426774|RANDOMIZED|CROSSOVER||OTHER||NONE||Evaluation of the effects of GentleJogger and Gentle Jumper on noninvasive biometric data in various postures in two specify age groups a) Younger 25-59 yrs b) Older \> 60 yrs Each Subject will serve as his or her own Sham Control||||
33946993|NCT05555134|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33946994|NCT02503969|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33946995|NCT04348123|NA|SINGLE_GROUP||SCREENING||NONE||||||
33946996|NCT03604198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946997|NCT03007472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33946998|NCT01224288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33946999|NCT03166891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075755|NCT03923153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34075756|NCT00000757||||PREVENTION||DOUBLE||||||
33740475|NCT00975975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740476|NCT03032692|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740477|NCT06312098|||COHORT||RETROSPECTIVE|||||||
33740478|NCT06107218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33740479|NCT01405157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33740480|NCT04077008|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34075757|NCT01073826|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33740481|NCT02731131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740482|NCT01496651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740483|NCT06263777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33740484|NCT04182776|||COHORT||PROSPECTIVE|||||||
33740485|NCT02358486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740486|NCT00853450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740487|NCT01455649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740488|NCT01355744|||COHORT||PROSPECTIVE|||||||
33740489|NCT04339335|||COHORT||PROSPECTIVE|||||||
33740490|NCT05324475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention nutrients will be delivered as powder in sachets identified as B (BCAA, 4 gr) or C (mixture of micronutrients, 4 gr), placebo sachets identified as A will contain maltodextrin, (4 gr); the sachets will be mixed by the patients in a juice. Blinding will be maintained until interim evaluation and after for the full trial. In order to assure the blinding the sachets will be opaque identified by a single letter ready to be mixture with a juice with similar taste and texture between the different formulations|three arms study double blind placebo controlled|t|t|t|t
33740491|NCT03294434|||COHORT||PROSPECTIVE|||||||
33740492|NCT01200381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740493|NCT00147186|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33740494|NCT00557115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740495|NCT05611528|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33740496|NCT02412267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740497|NCT06326372|||COHORT||PROSPECTIVE|||||||
33740498|NCT05520957|||CASE_ONLY||RETROSPECTIVE|||||||
33740499|NCT06240026|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"Electrodes for taVNS and earlobe stimulation will be placed onto the participant during both stimulation sessions. These electrodes have identical wires which are connected to a digitimer for the control of the stimulation.~Researchers doing the stimulation will have no other role in the study and will not participate in patient assessment.~Participants will be blinded to which stimulation type is termed 'taVNS'. And only individuals having no prior experience with taVNS will be recruited. Care will be taken not to set research appointments with participants close one to the others to avoid waiting room conversations between participants. Efficacy of blinding will be assessed at the end of the study."|Participants will part-take in two identical stimulation sessions, differing only by the use of active taVNS in one session and an active control of left earlobe stimulation in the other. The sequence of sessions will be counter-balanced and randomized between participants.|t|f|t|f
33740500|NCT01513772|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33740501|NCT00746603|NA|SINGLE_GROUP||OTHER||NONE||||||
33740502|NCT06572553|NA|SINGLE_GROUP||TREATMENT||NONE|All roles know what drug they injected.|"1. Chinese patients aged 18 years or older ;~2. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;~3. Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation;~4. Patients who have received at least one treatment with faricimab during the course of the study;~5. have signed an informed consent form."||||
33740503|NCT00606424|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33740504|NCT01979926|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33740505|NCT04876508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33740506|NCT05464147|NA|SINGLE_GROUP||TREATMENT||NONE|All imaging analyses will be performed at an independent core laboratory (Cardiovascular Department, San Giovanni Addolorata Hospital, Rome, Italy) by experienced operators blinded to procedural data and clinical outcomes.|||||
33740507|NCT02912351|||COHORT||RETROSPECTIVE|||||||
33740508|NCT05403047|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33740509|NCT01190241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740510|NCT04534829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In terms of blinding, the principal investigators will be blinded to which arm each study participant is randomized to. It is not possible to blind study participants, as they will be aware of the imaging modality used to perform the procedure. The clinicians serving as private investigators (one in each study arm) will not be blinded to the procedure they are performing. Therefore, this is a single-blinded study|Patients who present with pain thought to be originating from the SIJ will be screened for study participation with fluoroscopy-guided sacral lateral branch blocks (LBB). If a patient has an initial successful sacral LBB (defined as 70% reduction in pain), or has prior successful SIJ RFA, they will be approached for consent to be contacted for study participation. Upon obtaining written consent for study participation, patients will be randomized into one of two groups; US-guided SIJ RFA or fluoroscopy-guided SIJ RFA (current gold-standard). Upon being randomized to either group they will then undergo a second confirmatory sacral LBB under their respective image guidance to confirm candidacy for RFA. If this second, confirmatory LBB is successful (70% pain relief) they qualify for RFA. Then, SIJ RFA will be performed under each respective imaging modality and patients will be followed to document pain improvement, functional outcomes, quality of life and medication use for 18 months.|f|f|f|t
33740511|NCT00004926||||TREATMENT||||||||
33740512|NCT00002684||||TREATMENT||||||||
33740513|NCT01169324|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33740514|NCT00215293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740515|NCT02268591|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740516|NCT04237298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740517|NCT06383182|||COHORT||PROSPECTIVE|||||||
33740518|NCT01049555|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740519|NCT06057896|||COHORT||RETROSPECTIVE|||||||
33740520|NCT03239652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740521|NCT01739322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740522|NCT04227483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740523|NCT00819897|||||PROSPECTIVE|||||||
33740524|NCT01690403|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740525|NCT02621762|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075758|NCT06612476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075759|NCT02923999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34154394|NCT02549131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33740526|NCT00066092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740527|NCT01033747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050733|NCT06665438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||patients randomly allocate to one of three groups (n =25) for intra articular injection using Sealed envelope method as follows: Group (C), receive 18 ml saline only and serve as the control group(C). Group (B) receive 18ml 0.25% bupivacaine. Group(D)received 18 ml 0.25% bupivacaine and dexmedetomidine 1 μg/kg, the study drugs will injected in the knee joint by the surgeon through the arthroscope after completing the procedure (without knowing the drugs used)|t|t|f|f
33740528|NCT02080091|||COHORT||PROSPECTIVE|||||||
33740529|NCT02664428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33740530|NCT05089396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740531|NCT03041272|||COHORT||PROSPECTIVE|||||||
33740532|NCT04632446|||COHORT||PROSPECTIVE|||||||
33740533|NCT00238927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740534|NCT00005787||||SUPPORTIVE_CARE||||||||
33740535|NCT01554046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740536|NCT06572709|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740537|NCT01427712|||COHORT||PROSPECTIVE|||||||
33740538|NCT05853094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740539|NCT04980638|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm, genotype-match controlled for primary estimand, non randomized study. The primary efficacy outcome will be compared to genotype matched untreated male relatives with XLHED or to genotype-matched controls from an external XLHED database (clinical and natural history studies from which untreated genotype-matched controls will be identified).||||
33740540|NCT05626647|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33740541|NCT05148494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant will receive information pertaining to which arm of the trial they have been randomized to by the research coordinator. The surgeons, residents, any other physicians involved in the care of the patient, and nursing staff will all be blinded to the treatment arm.|A single center, 2-arm, single blinded randomized controlled trial|f|t|t|t
33740542|NCT05655182|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33740543|NCT02516059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740544|NCT02588118|||CASE_CONTROL||PROSPECTIVE|||||||
33740545|NCT05442411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant is blineded to the treatment as they was givemn intraopeartively the pain score assessor is blinded since the assessment was done postoperatively|randomised contrrolled trial|t|f|f|t
33740546|NCT06531525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740547|NCT03884972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740548|NCT06368128|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial with participants allocated to either a control or intervention group; comparison between groups and within groups||||
33740549|NCT03345563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be instructed not to discuss their arm assignment with study personnel during their assessments. We avoided the use of the terms Tai Chi and Qigong for participant recruitment, patient-faced materials, and intervention implementation. Questionnaires will be self-administered, administered in person or by telephone based on participant need and preference. Some investigators, the data manager, biostatisticians, biometric testing and lab technicians will be blinded to intervention allocation. The technicians who analyze biospecimens will be blinded to all other data.|After obtaining informed consent and baseline assessments, cancer survivors aged 55 years and older with some level of fatigue will be randomized to the BMT arm or intensity-matched Body Training (BT), or Usual Care (UC) arms. Patient-reported assessments (surveys) will occur at baseline (within 2-weeks pre- intervention), mid-intervention (6 weeks), 1-week post-intervention (13 weeks), and at 3 months and 12 months post-intervention. Phlebotomy is done at baseline, 1 week post intervention (13 weeks), and 3 months and 12 months post intervention. Dietary assessments are done at baseline, and week 13 (1 week post intervention), 3 months and 1 year post-intervention. Physical activity is assessed weekly throughout the intervention. Sleep diaries are collected at all time points.|f|t|f|t
33740550|NCT02526134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740551|NCT05924828|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740552|NCT04327284|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a single site, randomized, controlled, prospective, and parallel arms study.||||
33740553|NCT05297045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740554|NCT00000465|RANDOMIZED|PARALLEL||TREATMENT||||||||
33740555|NCT05296616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33740556|NCT01660178|||||RETROSPECTIVE|||||||
33740557|NCT03757559|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Nested-randomized, single site, double-blind, double-dummy, placebo- and active-controlled, crossover design with administration of a single oral dose. Based on the assigned treatment sequence, each participant was randomly allocated to receive a single oral dose of the investigational medicinal product (IMP) in each of 7 periods. One administration of placebo (Treatment G) always followed cebranopadol 800 micrograms (Treatment C). Each IMP administration was given under fasted conditions and was separated by a washout period of at least 14 days.|t|t|t|t
33740558|NCT05940285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740559|NCT01266239|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33740560|NCT03109834|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel arms in weight loss phase and weight stabilization phase (1. randomization at baseline I); 2 parallel arms in weight maintanance phase (2. randomization at baseline II)||||
33740561|NCT00710333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33764500|NCT06112730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050734|NCT02779764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050735|NCT01451970|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050736|NCT06661590|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34050737|NCT02741440|||COHORT||PROSPECTIVE|||||||
33764501|NCT00001790||||TREATMENT||||||||
33764502|NCT04951674|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34050738|NCT06683963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050739|NCT02145442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050740|NCT04259931|||COHORT||PROSPECTIVE|||||||
34050741|NCT01430988|||CASE_CONTROL||PROSPECTIVE|||||||
34050742|NCT03703011|NA|SINGLE_GROUP||OTHER||NONE||||||
33740562|NCT06377735|NA|SINGLE_GROUP||TREATMENT||NONE||Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.||||
33947000|NCT04311515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All subjects, investigators, and study site personnel will be blinded to dose assignment.~The Data Safety Monitoring Board (DSMB) will have access to unblinded safety data and will conduct review of these data at regular intervals during the study"|randomized, double blind, placebo controlled, parallel phase 2a|t|t|t|t
33740563|NCT04167397|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized in permuted blocks and be allocated to either initial practice either alone or in a group of 2, 3 or 4 participants.|f|f|f|t
33740564|NCT02682654|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33740565|NCT01183091|||COHORT||PROSPECTIVE|||||||
33740566|NCT03424746|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33740567|NCT02829034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740568|NCT04276272|||COHORT||PROSPECTIVE|||||||
33740569|NCT00588289|||||PROSPECTIVE|||||||
33740570|NCT06572189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740571|NCT00291382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740572|NCT01351805|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33740573|NCT02348164|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33740574|NCT02835014|||COHORT||PROSPECTIVE|||||||
33740575|NCT01754714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740576|NCT05812482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740577|NCT00750945|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33740578|NCT00293540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740579|NCT06381479|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33843011|NCT00798590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843012|NCT05716893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843013|NCT04239677|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"One investigator (Anesthesiologist) conducts randomized group assignment. The day of surgery, the researcher informs to surgeon, perfusionist about patient's group assignment.~But, other researcher (ROTEM test), postoperative management do not know the patient's group assignment."|Prospective randomized trial with 2 parallel groups; the retrograde autologous priming group and conventional crystalloid solution-based priming group.|t|f|f|t
33843014|NCT04417738|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|One experimenter will act as the blinder and treater. Only he will know whether the patient receives the active or sham treatment and only he will prepare and provide the treatment. The patient and outcomes assessors will be blind to the treatment.|Patients will come to the lab on 3 consecutive weekly visits. On the first, they go through the consent process and if signed, will have a clinical interview and ROS then be given baseline measures and then treated with transcranial photobiomodulation, following which they will undergo post-treatment measures. The treatment the first week will be randomized to active or sham and the second week they will receive the opposite treatment. The third week will be a follow-up of the second treatment.|t|f|f|t
33843015|NCT05435482|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843016|NCT06729502|||COHORT||PROSPECTIVE|||||||
33843017|NCT06727032|||CASE_CONTROL||RETROSPECTIVE|||||||
33843018|NCT05651867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843019|NCT06728540|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33843020|NCT04893577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subject and principal investigator will be unblinded, and only efficacy assessments will be done by a qualified trained blinded assessor.|This will be a randomized, efficacy assessor-blinded, parallel group, pilot study.|f|f|f|t
33843021|NCT02228902|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843022|NCT04589650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigator staff, and persons performing the assessments will remain blinded to the identity of the treatment from the time of randomization until primary analysis i.e. the last participants (Groups 1 and 2) completes Week 48 from randomization or discontinues earlier.||t|t|t|t
33843023|NCT04241107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843024|NCT05330988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843025|NCT00293501||||TREATMENT||NONE||||||
33843026|NCT03723018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator analyzing the data will be blinded to which study arm participants were assigned to.||f|f|t|f
33843027|NCT02982551|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843028|NCT04638920|||COHORT||PROSPECTIVE|||||||
33843029|NCT04064398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33843030|NCT06723171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo controlled|t|t|t|t
33843031|NCT03488693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843032|NCT06260397|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33843033|NCT06714851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||"Double-blind, randomized, placebo-controlled, single-center study with stratification by gender (\~40% men, \~60% women) and menopausal status for women (\~50% non-menopausal women, \~50% menopausal women).~An ancillary subgroup with extended duration of supplementation."|t|f|t|f
33843034|NCT03974477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33843035|NCT00830089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740580|NCT02510157|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
33740581|NCT04734379|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
33740582|NCT05976529|||CASE_CONTROL||RETROSPECTIVE|||||||
33843036|NCT03625544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intra-patient model, so each patient receives both conditions and serves as its own control|f|f|f|t
33843037|NCT00881062|NA|SINGLE_GROUP||||NONE||||||
33843038|NCT05611112|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stepped wedge cluster-randomised controlled trial with a one-year follow-up.||||
33947001|NCT04790630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34050743|NCT02023411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33740583|NCT05622773|NA|SINGLE_GROUP||OTHER||NONE||Pretest posttest single group quasi-experimental research||||
33740584|NCT05792800|||OTHER||CROSS_SECTIONAL|||||||
33740585|NCT00487201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050744|NCT06308302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34050745|NCT00756236|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33740586|NCT03890302|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33740587|NCT05167838|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1; Fresh embryo transfer in PCO patients Group 2: Frozen ET in PCO patients||||
33740588|NCT00145834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740589|NCT02109055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740590|NCT04938037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740591|NCT05980312|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized clinical trial||||
33740592|NCT05492318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An Open-label, Single-center, Three-part Study in Healthy Subjects||||
33740593|NCT02048761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740594|NCT03529526||SEQUENTIAL||TREATMENT||NONE||"This is a dose-escalation trial, all participants will receive treatment with KN046. Participants enrolled in this trial may receive one of the following doses dependent upon time of enrolment into the study.~Cohort 1: 0.3 mg/kg Cohort 2: 1 mg/kg Cohort 3: 3 mg/kg Cohort 4: 5 mg/kg Cohort 5: 10 mg/kg"||||
33740595|NCT05848739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33740596|NCT00938925|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33740597|NCT02229097|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740598|NCT03333746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740599|NCT05872139|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind, placebo-controlled||t|f|f|t
33740600|NCT03766646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|After recruitment, patients were randomised into one of two arms, speech or non-speech. Both the investigator and the participant were aware of the intervention assigned|Patients were assigned to either the 'Speech' arm or 'Non-speech' arm of the study||||
33740601|NCT02578524|||CASE_CONTROL||RETROSPECTIVE|||||||
34050746|NCT06668727|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33740602|NCT00185029|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740603|NCT05482607|||COHORT||RETROSPECTIVE|||||||
34050747|NCT04115787|||COHORT||RETROSPECTIVE|||||||
33740604|NCT02041429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The multi-arm nature of this study is due to the dose-escalation design.||||
33740605|NCT00753324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740606|NCT03455283|||COHORT||PROSPECTIVE|||||||
33740607|NCT04506450|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33740608|NCT04943926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We will use an independent statistician who will analyse the data anonymously and be blinded to information regarding dietary arms.|Randomised controlled trail (RCT)|f|f|f|t
33740609|NCT01820429|||COHORT||PROSPECTIVE|||||||
34050748|NCT04778943|||COHORT||RETROSPECTIVE|||||||
34050749|NCT03831360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050750|NCT02735512|||CASE_CONTROL||PROSPECTIVE|||||||
34050751|NCT02015416||SEQUENTIAL||TREATMENT||NONE||Phase 1, open label, multicenter ascending dose study.||||
33740610|NCT03089190|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Double-blind|A double-blind, randomized crossover design with four arms including three experimental conditions and placebo|t|t|t|t
33740611|NCT02125058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740612|NCT06316804|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Random assignment to the 3 arms in a 1:1:1 allocation ratio will be determined centrally by the PI according to a random schedule. There is no practical way to blind the study participants to treatment and accomplish the objectives of the study. However, the study participants will be unaware of the aims of the arm to which they were assigned. Because they will not be blinded to the video exposure, the study participants assigned to one of the video contact arms will be aware that they are being exposed to a video-based contact intervention, and the study participants assigned to the waitlist control arm will be aware that they are being waitlisted. The research coordinator/team member (who will be conducting the outcome assessments) will be blinded to treatment assignment status.|Participants will be randomly assigned to one of three intervention arms.|t|f|f|t
33740613|NCT06532838|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33740614|NCT01034904|||COHORT||PROSPECTIVE|||||||
33740615|NCT01266759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740616|NCT00298233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740617|NCT01734668|||||PROSPECTIVE|||||||
33740618|NCT05090072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"All participants were blinded to the allocated intervention, from the beginning to the end of the trial. Investigator only had access to the allocation group after participants enrollment on the trial, sociodemographic data collected, and phase 1 Advance Directives fulfilled.~Preliminary data analysis was made without knowledge of the participants' allocated group"|"After enrollment and some sociodemographic data were collected, participants were asked to, separately, fulfill the Advance Directives document, concerning patients' last wishes. Caregivers also fulfill one document with their own end-of-life preferences.~The pair was then randomly assigned to one of the two parallel groups (Advance Directives or Control Group).~Both groups had a conference meeting with the same palliative care physician, in the same room, with the same average duration (40 to 50 minutes). The Advance Directives Group discussed patients' answers to the Advance Directive document, and the Control Group talked about patients' clinical status.~Two months later, caregivers only, were asked to fulfill another Advance Directive document as patients' surrogates."|t|f|f|f
33843039|NCT03127722|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843040|NCT06404801|||CASE_CONTROL||PROSPECTIVE|||||||
33843041|NCT00000500|RANDOMIZED|||PREVENTION||DOUBLE||||||
33843042|NCT01809834|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33843043|NCT00378664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843044|NCT04045964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050752|NCT01585753|||||PROSPECTIVE|||||||
34050753|NCT01866657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34050754|NCT05326828|||COHORT||PROSPECTIVE|||||||
33740619|NCT01032941|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33740620|NCT06148597|||COHORT||PROSPECTIVE|||||||
33740621|NCT00143858|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33740622|NCT03299140|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33740623|NCT01421810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740624|NCT01154634|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33740625|NCT05106868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740626|NCT00085410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740627|NCT06059469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740628|NCT02056301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740629|NCT06657547|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33740630|NCT01478945|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33740631|NCT05148000|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label single site study for treatment of GL and LCL with single treatment of QM1114-DP||||
33740632|NCT01462344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740633|NCT03046680|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33740634|NCT01024127|||COHORT||CROSS_SECTIONAL|||||||
33740635|NCT03634579|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Interventional, Single-Arm, Unblinded trial||||
33740636|NCT01898195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740637|NCT05734482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Biological: CMAB015 Biological: Cosentyx（Secukinumab ）|t|t|t|f
33740638|NCT04317300|NA|SINGLE_GROUP||TREATMENT||NONE||12 weeks of varenicline||||
33740639|NCT06173817|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective, single arm study~* Enrolment target: 30 evaluable patients~* Intervention: standard of care with sodium bicarbonate and fomepizole, plus iHV device treatment~* Rescue therapy: haemodialysis at investigators discretion"||||
33740640|NCT02567422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740641|NCT03330834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740642|NCT00558675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740643|NCT06534203|||OTHER||OTHER|||||||
33740644|NCT03320447|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33740645|NCT05802745|||COHORT||PROSPECTIVE|||||||
33740646|NCT04695301|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE||Men and women affected by COVID-19, over 18 years of age, admitted to HIAE partner hospitals who have been in hospital for more than 10 days or in need of treatment in semi-intensive or intensive care units will be selected. Follow-up will be carried out for 3 months, with remote reevaluations. During this period, the rehabilitation program will be offered for 3 months, through a digital platform.|t|f|f|f
33740647|NCT02317575|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33740648|NCT01384344|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740649|NCT03250962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740650|NCT02455908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740651|NCT06283849|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Explanatory sequential mixed methods study of N=30 Black adults aged 55 and older with T2D.||||
33740652|NCT03854123|||COHORT||RETROSPECTIVE|||||||
33740653|NCT01068431|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33740654|NCT01673334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740655|NCT05748028|||COHORT||PROSPECTIVE|||||||
33740656|NCT01668576|||COHORT||CROSS_SECTIONAL|||||||
33740657|NCT03177993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740658|NCT02509689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740659|NCT06572436|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33740660|NCT00721526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740661|NCT03578900|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740662|NCT03062891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740663|NCT05658692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740664|NCT00771680|||COHORT||PROSPECTIVE|||||||
33740665|NCT00399152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740666|NCT01701375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740667|NCT06263868|||CASE_CONTROL||PROSPECTIVE|||||||
33740668|NCT06571123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33740669|NCT06489808|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740670|NCT02061345|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740671|NCT00597740|||||PROSPECTIVE|||||||
33740672|NCT02329405|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33740673|NCT05204524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740674|NCT04321460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740675|NCT02391948|||COHORT||PROSPECTIVE|||||||
33843045|NCT06632457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740676|NCT04795505|||COHORT||PROSPECTIVE|||||||
33740677|NCT05864339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not know if they are given the the conventional tutorials or the newly designed empathy tutorials.|This study was designed based on Kolb's Experiential Learning Theory (ELT). This study is a 2-arm, randomized controlled trial (RCT) (allocation ratio 1:1), by comparing the empathy, self-efficacy, skill, attitude, and practice between master nursing students who participated in the designed empathy tutorial (viewing videos of four smokers' real-life scenarios, reading four smokers cases text materials, and drawing Health Empathy Map) (intervention group) and those who participated in a conventional tutorial (viewing videos of four smokers' real-life scenarios, reading four smokers cases text materials) (control group).|t|f|f|f
33740678|NCT00009737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740679|NCT02925975|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33764503|NCT04707196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764504|NCT00053001||||SUPPORTIVE_CARE||NONE||||||
33764505|NCT02410993|||COHORT||PROSPECTIVE|||||||
33764506|NCT04944355|||COHORT||CROSS_SECTIONAL|||||||
33764507|NCT03328000|||COHORT||PROSPECTIVE|||||||
33764508|NCT05363657|||COHORT||PROSPECTIVE|||||||
33764509|NCT05377970|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764510|NCT02848716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764511|NCT02006875|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33843046|NCT06317467|||OTHER||OTHER|||||||
33740680|NCT05446415|NA|SINGLE_GROUP||TREATMENT||NONE|Study is randomized by the RedCap program, until the time of surgical intervention Researcher and Participant do not know the model. On the day of the Bariatric Surgery, the Participant's data are placed in the program to generate randomization, after the result, only the Researcher and team will know the model chosen by the program.|"Roux-en-Y bypass gastroplasty (GDYR) by laparoscopy, with production of a gastric pouch with a volume between 30 and 50 ml, with a biliopancreatic loop measuring 100 (G1) and 200 cm (G2), anastomosis of the alimentary loop of 100 cm in the groups G1 and G2.~Immunohistochemistry analysis assays were made from intestinal biopsies in 3 segments: gastrointestinal anastomosis (GEA = Point A), enteroenteral anastomosis (EEA = Point B ) and (Ileocecal valve =Point C).~Expression and secretion of GLP-1 and PYY3-36, incretins hormones by Lcells."||||
33740681|NCT01834365|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33740682|NCT03021187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740683|NCT04982042|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors will be blinded to the data due to the fact that we have a group of patients undergoing the Outpatient Rehabilitation Program and another group of patients undergoing the Home Rehabilitation Program with follow-up by Tele-Rehabilitation|To compare the effects of an Outpatient and Home Pulmonary Rehabilitation Program aimed at patients with pulmonary sequelae resulting from COVID-19 and with other chronic lung diseases on clinical symptoms, level of physical activity, functional status, quality of life, survival and in health maintenance costs by the government.|f|f|f|t
33740684|NCT05909189|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The LEAD Intervention is a web-baed platform that integrates the LEAD Guide with self-paced educational modules that guide care recipient-care partner pairs through conversations and the process of dementia-focused advance care planning. The aims of this study are: 1. To describe the acceptability, usability, and feasibility of the LEAD Intervention. Methods: Conduct a process evaluation using survey-based outcome assessments and qualitative analysis of participant-recorded advance care planning conversation(s)to identify facilitators and/or barriers to intervention participation. 2. To assess the initial efficacy of the LEAD Intervention on the primary outcome and secondary outcomes as perceived by both the care recipient and the care partner. 3. To examine advance care planning congruence as a mechanism of action for the LEAD Intervention.||||
33740685|NCT06574100|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||We plan this study as a single-site (potentially multi-site), randomized, two-arm study, with one arm being a two-sequence crossover, single buccal, or oral dose in fasted healthy male adults, and the second arm being a two-sequence cross-over, single high oral dose PK study in fasted vs fed-state healthy male adults. Participants will be randomized into four groups (n = 16 in Arm 1, 8 per group (2 groups), all males; n = 4 in Arm 2, 2 per group (2 groups) all males) (ages 18 - 35) based on which formulation each group will receive. Individuals in study arm 1 will complete the study in the fasted state (10 hours of fasting). Individuals in study arm 2 will follow the fed-state protocol as outlined by the United States FDA's bioequivalent studies guideline||||
33740686|NCT04823143|||COHORT||PROSPECTIVE|||||||
33740687|NCT05341089|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33740688|NCT04231656|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||"The primary outcome will be based on measurements performed during a sequence of position changes.~Sequence A will consist of starting from 0° position, shift to position +20°, then tilt to -20°, and finally back to the 0° position.~Sequence B will consist of starting from 0° position, shift to position -20°, then tilt to +20°, and finally back to the 0° position.~Patients will be randomized to take sequence A before the procedure, and then the sequence B at the end of the procedure, or vice-versa (sequence B before sequence A).~The randomization is not intended to compare the two groups with each other, but only to compensate for a possibleorder-effect in the execution of the maneuvers."|t|f|f|f
33740689|NCT06559397|||CASE_CONTROL||PROSPECTIVE|||||||
33740690|NCT02606136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740691|NCT01541657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740692|NCT03939273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double-blind placebo-controlled trial|t|t|t|t
33740693|NCT06097052|||COHORT||RETROSPECTIVE|||||||
33740694|NCT06532903|RANDOMIZED|PARALLEL||TREATMENT||NONE|The external evaluators will determine the degree of facial dysfunction according to House Brackman and the score found in the Sunnybrook system, values that will be recorded on a blind evaluation sheet. The procedure will be carried out after the first session and upon discharge of the patients. That is, they will carry out an initial and final evaluation of the patients, without knowing the physical treatment they received.|"Two groups will be defined:~* Control: Patients with peripheral facial paralysis who will receive standard kinesic treatment (facial muscle reeducation without selective muscle electrostimulation)~* Study: Patients with peripheral facial paralysis who will receive standard kinesic treatment (with muscle reeducation) and selective muscle electrostimulation.~People who voluntarily attend the University Kinesiology Service in the indicated period will be selected based on the aforementioned inclusion and exclusion criteria, thus constituting an intentional sample. Patients will be assigned to each group in a systematic random manner."||||
33740695|NCT02137629|||CASE_ONLY||PROSPECTIVE|||||||
33740696|NCT02677545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740697|NCT06534606|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive SNAGs and the second will receive Sternocleidomastoid Release along with SNAGS. Both groups will be recruited concurrently.||||
33740698|NCT06152094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740699|NCT04117828|RANDOMIZED|PARALLEL||OTHER||NONE||40 participants will be included in the study and will be divided into four groups. The AKU faculty and staff will be invited to MDL with fasting of 12 hr. Written informed consent (a copy will also be provided to the participant) will be taken from each individual.Following vitals will be measured body weight, height and blood pressure. 1st group will be the control that will consume 50 g of glucose and 2nd, 3rd, and 4th group will consume 50 g of different kinds of dates. Their blood sugar level will be checked at 0, 30, 60, 90 and 120 mins. Glycemic index and glycemic load will be calculated and will be compared.||||
33947002|NCT03762187|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Neither patients nor counselors were aware of participants' assigned condition|Participants are randomized to one of the two conditions.|t|t|f|f
33947003|NCT06420115|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33947004|NCT05058599|||COHORT||PROSPECTIVE|||||||
33947005|NCT06315634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740700|NCT06141642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33740701|NCT00661063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740702|NCT02667912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33740703|NCT03565718|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33740704|NCT06098599|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740705|NCT05368805|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33740706|NCT03566719|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740707|NCT04975373|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740708|NCT01427244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740709|NCT00766415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740710|NCT03383432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740711|NCT00188097|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33740712|NCT04279574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740713|NCT01690650|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740714|NCT04030377|||COHORT||PROSPECTIVE|||||||
33740715|NCT02454426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740716|NCT05051241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740717|NCT04133935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Upon recruitment to the study, the surgeon will then open a sequentially numbered, opaque, sealed envelope that will randomize the patient to either receiving Burch colposuspension or LOU. The patient will not be made aware of the group they were allocated to.~A clinical staff who was not involved with the surgery and blinded to the allocation of the patient will complete the Post-operative Follow-up Form at each visit."|Double-blinded, randomized controlled trial|t|f|f|t
33740718|NCT02410681|||COHORT||PROSPECTIVE|||||||
33740719|NCT03243747|||COHORT||PROSPECTIVE|||||||
33740720|NCT01428492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740721|NCT00127608|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33740722|NCT05454293|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33740723|NCT00306228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740724|NCT02240082|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740725|NCT02842567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740726|NCT06024447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740727|NCT02266238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740728|NCT01224041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740729|NCT04870567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33740730|NCT04297878|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two parallel groups||||
33740731|NCT06126562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740732|NCT04020731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740733|NCT00476944|RANDOMIZED|PARALLEL||||NONE||||||
33740734|NCT04287062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740735|NCT04408963|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740736|NCT01278524|||COHORT||PROSPECTIVE|||||||
33740737|NCT04787666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740738|NCT00025350|RANDOMIZED|||TREATMENT||DOUBLE||||||
33740739|NCT01621841|||CASE_CONTROL||PROSPECTIVE|||||||
33740740|NCT00529945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740741|NCT06531447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740742|NCT01793857|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33740743|NCT02599168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33740744|NCT02692989|||COHORT||RETROSPECTIVE|||||||
33740745|NCT03811912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740746|NCT01071382|||COHORT||RETROSPECTIVE|||||||
33740747|NCT02802553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740748|NCT02447731|||COHORT||PROSPECTIVE|||||||
33740749|NCT01807585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740750|NCT06573827|||CASE_ONLY||PROSPECTIVE|||||||
33740751|NCT03059173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740752|NCT04939259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The order of the programs is blinded so that subjects don't know which slot (2 or 3) contains the music program or the general program. Slot 1 always has a general program for everyday speech understanding.|All participants will wear the new devices at the same time. They will have the general listening program and the new music program available in the same device. They will switch between the programs to make the comparison in multiple environments.|t|f|f|f
33740753|NCT00501150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740754|NCT01037309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740755|NCT01751568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740756|NCT05189574|||COHORT||RETROSPECTIVE|||||||
33843047|NCT01925222|||COHORT||CROSS_SECTIONAL|||||||
33843048|NCT03517813|||CASE_CROSSOVER||PROSPECTIVE|||||||
33843049|NCT04237870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843050|NCT06481904|||COHORT||PROSPECTIVE|||||||
33843051|NCT05923749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843052|NCT00085553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843053|NCT04750564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740757|NCT01070004|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33740758|NCT02139852|||OTHER||OTHER|||||||
33740759|NCT02346565|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33740760|NCT02769091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740761|NCT03474159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740762|NCT03082339|||COHORT||PROSPECTIVE|||||||
33764512|NCT03960671|NA|SINGLE_GROUP||OTHER||NONE||||||
33764513|NCT04251871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764514|NCT03077464|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-randomized parallel group design, testing pretest to post-test changes.||||
33764515|NCT00026858||||TREATMENT||||||||
33764516|NCT01336621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764517|NCT06340425|||COHORT||RETROSPECTIVE|||||||
33764518|NCT04755270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This research was conducted with the randomized control group pretest-posttest trial model.||||
33843054|NCT01400178|||||CROSS_SECTIONAL|||||||
33740763|NCT05243108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The experiment designers used seed number 1234 to generate a random sequence of 120 random numbers on SAS software and divided the 120 random numbers into two groups based on the size of the random numbers. The larger number is Group A, and the smaller number is Group B. Both intervention drugs and placebos are produced by pharmaceutical companies without any labels and look exactly the same. Neither the trial designer nor the pharmacist participated in the trial. The researchers were responsible for recruiting subjects and assigning serial numbers according to inclusion criteria. Caregivers are responsible for dispensing, reviewing, and documenting medications. Investigators are responsible for measuring and filling out questionnaire items. Medical examinations and sample collection are carried out by hospital professionals.|completely randomized design|t|t|t|t
33947006|NCT01636596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947007|NCT06576934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740764|NCT02131298||CROSSOVER||BASIC_SCIENCE||NONE||||||
33740765|NCT03117335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Parallel Assignment|t|t|t|t
33740766|NCT04533841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded research|Clinical trial|t|t|t|t
33740767|NCT05747677|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33740768|NCT02359721|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33740769|NCT06057415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The randomization will occur web-based, and will be protected from selection bias by using concealed, stratified and blocked randomization.~The group of preterm infants will randomly be assigned to 2 treatment groups according to 6 strata.~* Gestational age 24+0 - 26+0 weeks + Appropriate for gestational age (AGA)~* Gestational age 24+0 - 26+0 weeks + Small for gestational age (SGA)~* Gestational age 26+1 - 28+0 weeks + AGA~* Gestational age 26+1 - 28+0 weeks + SGA~* Gestational age 28+1 - 29+6 weeks + AGA~* Gestational age 28+1 - 29+6 weeks + SGA"|f|f|f|t
33740770|NCT00256789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740771|NCT00766376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740772|NCT06296342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740773|NCT00659646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740774|NCT01358513|||COHORT||PROSPECTIVE|||||||
33740775|NCT00000435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740776|NCT03173222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740777|NCT01910844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740778|NCT01902849|||CASE_CONTROL||PROSPECTIVE|||||||
33740779|NCT06043414|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The operative team will be blinded to the assigned treatment group until the patient's edibility is confirmed immediately prior to abdominal fascial closure. Once eligibility is confirmed the surgical team will be unblinded in order to proceed with abdominal fascia closure according to the assigned treatment group.|This is a two-arm prospective, single-blinded randomized control trial for clinical research.|f|t|f|f
33740780|NCT00630877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740781|NCT00272701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740782|NCT02782819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740783|NCT05471973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740784|NCT01682837|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33740785|NCT04887870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740786|NCT04889560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (neuropsychologist for cognitive assessments)||f|f|f|t
33947008|NCT01479777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740787|NCT06308913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740788|NCT02505646|||COHORT||PROSPECTIVE|||||||
33740789|NCT04813341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947009|NCT06722287|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||20 family caregivers will be asked to utilize each of the five CAMMA intervention components over a five-week period (i.e., about one component per week). At the initial home visit, research staff will set up network configuration (e.g., WiFi) and demonstrate step-by-step guidelines for using the features on the smartphone. The caregiver will then be asked to perform these tasks, to ensure that they have understood the instructions.||||
33947010|NCT03665558|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33947011|NCT01878708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740790|NCT03891524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Treatment arms and study drug dose regimens will be blinded.||f|f|f|t
33740791|NCT00271336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740792|NCT03750136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33740793|NCT00575848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33740794|NCT05855889|||COHORT||PROSPECTIVE|||||||
33740795|NCT02696005|||COHORT||PROSPECTIVE|||||||
33740796|NCT01817972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740797|NCT02762409|||COHORT||PROSPECTIVE|||||||
33740798|NCT03217136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740799|NCT01513304||||TREATMENT||||||||
33740800|NCT02660359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740801|NCT03701477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary investigator and outcomes assessors will be masked. The care provider and participants won't be masked.|control and intervention arms|f|f|t|t
33740802|NCT04095858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740803|NCT04198610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33740804|NCT06097039|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740805|NCT05401292|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33740806|NCT05036629|NA|SINGLE_GROUP||OTHER||NONE||Exploratory individual statistical analyzes on MRI data functional. No group analysis possible on these updates of MRI protocols||||
33740807|NCT05968612|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33740808|NCT01067742|||COHORT||PROSPECTIVE|||||||
33740809|NCT01055392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33740810|NCT04191902|||COHORT||PROSPECTIVE|||||||
33740811|NCT06535997|||COHORT||OTHER|||||||
33740812|NCT06038877|||OTHER||PROSPECTIVE|||||||
33740813|NCT04919538|||COHORT||PROSPECTIVE|||||||
33764519|NCT00438620|||CASE_ONLY||PROSPECTIVE|||||||
33764520|NCT03757234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050755|NCT05672628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740814|NCT05226130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the research team involved in data collection and subjects will be blinded (double-blind study design). Subjects will be randomly assigned to receive either active or sham stimulation. Devices will be marked with an identification number to mask treatment condition. An unblinded Co-Investigator, not involved in data collection and subject contact, will assign randomization, provide device identification number, and keep the key linking condition to identification numbers.|Devices include a sham and an active noninvasive vagal nerve stimulator (nVNS). Devices are identical in appearance, and both produce reliable sensation on the skin when applied to the neck area (transcutaneous cervical stimulation). Stimulation duration is approximately 120 seconds for both sham and active devices. Subjects receive the same instructions to self-administer stimulation twice a day for 120 minutes on each side (right and left).|t|f|t|t
33740815|NCT02573324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sub-study was open-label.||t|t|t|f
33740816|NCT01706510|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740817|NCT03846024|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33740818|NCT01059617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33740819|NCT03191344|||COHORT||PROSPECTIVE|||||||
33740820|NCT01204892|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33740821|NCT03313596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740822|NCT06159894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33740823|NCT04590755|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are allocated to the intervention or control group by the researcher.|Non-Randomized Controlled Trial with Intervention and Control Group|t|f|f|f
33740824|NCT03888144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740825|NCT02455986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740826|NCT06574204|||COHORT||PROSPECTIVE|||||||
33740827|NCT05576467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33740828|NCT04118621|||COHORT||PROSPECTIVE|||||||
33740829|NCT01803906|||CASE_ONLY||PROSPECTIVE|||||||
33740830|NCT05522036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740831|NCT01879761|||COHORT||PROSPECTIVE|||||||
33740832|NCT00725894|||COHORT||PROSPECTIVE|||||||
33740833|NCT03834194|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33947012|NCT03457701|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an Open-label study.|Participants will be randomly assigned either to remain on their current therapy (either epoetin alfa or darbepoetin alfa) or be switched to daprodustat in either of the treatment periods.||||
33843055|NCT01370590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33843056|NCT01507987|||COHORT||PROSPECTIVE|||||||
33843057|NCT06433557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947013|NCT05040282|NA|SINGLE_GROUP||OTHER||NONE||||||
33947014|NCT06198179|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be randomized controlled trial (RCT) used to measure the effects of upper limb action-observation training (UP-CAT) with and without visual feedback in children with cerebral palsy. subjects with cerebral palsy meeting pre determined inclusion and exclusion criteria will be be divided into two groups using non-probability sampling techniques.||||
33740834|NCT03112772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740835|NCT06206005|||COHORT||RETROSPECTIVE|||||||
33843058|NCT05557175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The therapist and the participants will be blinded in the recruitment, randomization and treatment allocation|Active and Sham rTMS groups|t|t|f|f
33947015|NCT06423118|||COHORT||CROSS_SECTIONAL|||||||
33947016|NCT02033642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740836|NCT05350293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740837|NCT05747846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740838|NCT02063503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740839|NCT01235039|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33740840|NCT01772953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740841|NCT03137862|RANDOMIZED|PARALLEL||OTHER||DOUBLE||double blind prospective study|t|f|t|f
33740842|NCT01877421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947017|NCT04081246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947018|NCT06723860|||COHORT||OTHER|||||||
33947019|NCT00848965|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33740843|NCT02874547|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740844|NCT02158039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740845|NCT03162003|||COHORT||PROSPECTIVE|||||||
33740846|NCT06173791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only investigators will know which material was used for the sinus lift.|This is a two-independent arm, parallel-design randomized, prospective trial designed to compare two standard of care techniques|t|f|f|f
33740847|NCT03295201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33740848|NCT01467323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740849|NCT04153409|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomised assignment|t|t|t|t
33740850|NCT01756014|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33740851|NCT04663815|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized clinical trial.||||
33740852|NCT02923037|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33843059|NCT01743391|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843060|NCT02974777|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947020|NCT05577819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947021|NCT06063538|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||To demonstrate that there is no systemic presence of amiodarone, the first three patient will receive 600 mg amiodarone into the intact pericardial space (IPS). Amiodarone serum levels will be tested at post operative days 2 and 6. The study will only proceed if there is a serum amiodarone level less than 25% of the normal therapeutic level. This should insure lack of systemic toxicity. After the first 3 patients have demonstrated low amiodarone blood levels, a total of up to 60 patients will be enrolled in the study.||||
33947022|NCT04888936|||FAMILY_BASED||OTHER|||||||
33740853|NCT02431975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764521|NCT02391558|||OTHER||CROSS_SECTIONAL|||||||
33764522|NCT06175585|||COHORT||PROSPECTIVE|||||||
33764523|NCT04943042|||COHORT||OTHER|||||||
33764524|NCT02260128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740854|NCT06536218|RANDOMIZED|CROSSOVER||OTHER||NONE|"Control Group; It is planned to conduct a one-session (60-minute), unstructured, active participation-based group application (the week when the first session is applied to the intervention group) in which participants share their experiences with each other about stress and stressful experiences.~Intervention Group: Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the patients who underwent PSG are determined according to the randomization criteria and receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to have an online individual interview with patients who agree to participate in this study."|Conscious awareness is a skill that is inherent in human nature and can be developed through training and programs. This skill will provide the individual with the opportunity to achieve inner peace, help him find ways to cope with stress and make him feel less anxiety. Internalization of the skills gained by doing conscious awareness practices is related to the participation of the individuals in the group in the process and their individual experiences in performing the practices. Although group support is effective in the acquisition of these skills, using the acquired skills in daily life is also important for the continuity of the level of conscious awareness (Mason and Hargreaves, 2001).||||
33740855|NCT03108339|||COHORT||PROSPECTIVE|||||||
33740856|NCT06057051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740857|NCT05015894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740858|NCT00667784|||CASE_CONTROL||PROSPECTIVE|||||||
33740859|NCT01702883|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
33740860|NCT04592757|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33740861|NCT04307095|||CASE_CONTROL||RETROSPECTIVE|||||||
33740862|NCT03619694|||COHORT||PROSPECTIVE|||||||
33740863|NCT03971617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740864|NCT00105027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740865|NCT00876668|||CASE_CONTROL||PROSPECTIVE|||||||
33947023|NCT00239694|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740866|NCT00005619|||COHORT||PROSPECTIVE|||||||
33740867|NCT04202159|||COHORT||PROSPECTIVE|||||||
33740868|NCT02946866|||COHORT||PROSPECTIVE|||||||
33740869|NCT04547959|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, non-comparative and interventional post market clinical follow-up||||
33740870|NCT01621360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740871|NCT00165724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740872|NCT01825551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740873|NCT03937375|||COHORT||PROSPECTIVE|||||||
33740874|NCT03948074|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"An N-of-1 trial is a crossover trial, usually randomized and often blinded, conducted in a single patient. This type of trial provides an objective, data-driven way to determine the most effective intervention for an individual patient from among a set of competing interventions and to investigate the side-effect profiles of each intervention.~It is possible to analyze the results produced by each N-of-1 trial in a series separately in order to determine whether (i) the active treatment(s) involved in the trial were effective for the corresponding patient or (ii) the novel treatment(s) involved in the trial were effective relative to the established treatment. It is also possible to aggregate the results produced by a series of simultaneous N-of-1 trials (all conducted in a similar way) using either meta-analytic methods or mixed effects modelling in order to obtain information on how to treat subsets of the target patient population or even the entire patient population at large."|t|t|t|t
33740875|NCT03981406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740876|NCT00826501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740877|NCT03056846|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33740878|NCT03822169|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33740879|NCT05729074|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Part A: Double-blind study (Only a person in charge of the IP application is unblinded) Part B: Open Label Study||t|f|t|t
33740880|NCT00384085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740881|NCT00734526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740882|NCT02376426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33740883|NCT02388321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740884|NCT02161718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740885|NCT05786677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740886|NCT06567912|||COHORT||PROSPECTIVE|||||||
33740887|NCT04198623|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33740888|NCT02823145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740889|NCT02904239|||COHORT||PROSPECTIVE|||||||
33740890|NCT02873169|||COHORT||RETROSPECTIVE|||||||
33947024|NCT02370173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947025|NCT06724120|||COHORT||RETROSPECTIVE|||||||
33947026|NCT04187066|||CASE_CONTROL||PROSPECTIVE|||||||
33947027|NCT04344431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947028|NCT03107273|||CASE_CONTROL||PROSPECTIVE|||||||
33947029|NCT00457951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947030|NCT04575909|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Key personnel will be blinded to participant testing timepoint by having separate personnel administer treatment and assessments for each participant.|A crossover trial design with randomized order of intervention (REACT/no-intervention, no-intervention/REACT). Half of participants will be randomly assigned to REACT in Phase I, and the other half will be randomly assigned to start with no-intervention in Phase I. In Phase II, participants will receive the alternative intervention not received during Phase I.|f|f|f|t
33947031|NCT05788484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947032|NCT02461173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947033|NCT03986814|||COHORT||CROSS_SECTIONAL|||||||
33947034|NCT01718574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947035|NCT00421928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740891|NCT06303765|NA|SINGLE_GROUP||TREATMENT||NONE||multiple baseline study||||
33740892|NCT02575664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33740893|NCT01334697|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33740894|NCT01111500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740895|NCT01501318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33740896|NCT05910775|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only outcome assessors collecting MADRS are masked.|Patients who are deemed clinically appropriate for esketamine will be approached for participation in the study.|f|f|f|t
33740897|NCT02238301|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33740898|NCT04612270|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33740899|NCT04289389|||COHORT||PROSPECTIVE|||||||
33740900|NCT06364046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740901|NCT00338338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33740902|NCT04457648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740903|NCT03453333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740904|NCT03823547|||COHORT||PROSPECTIVE|||||||
33740905|NCT00472667|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33740906|NCT05579496|||COHORT||PROSPECTIVE|||||||
33740907|NCT06572761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740908|NCT01337245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740909|NCT05494398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740910|NCT04998240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is an observer-blind study. So in this study only the outcome assessors should be blinded namely the clinical staff in charge of the clinical outcomes assessment and the laboratory analysts.|The primary analysis of this study will be a non-inferiority comparison between heterologous versus homologous boost arms 4 weeks after second vaccination within each group of the studied COVID-19 vaccines, i.e., the A1 arm (BBIBP-CorV, Ad26.COV2.S) will be compared with the A2 arm (BBIBP-CorV, BBIBP-CorV), and the B1 arm (Ad26.COV2.S, BBIBP-CorV) will be compared with the B2 arm (Placebo, Ad26.COV2.S). All 360 participants will be used for the primary analysis and the secondary analysis.|f|f|f|t
33740911|NCT03273764|||COHORT||PROSPECTIVE|||||||
33740912|NCT06535087|||CASE_CONTROL||PROSPECTIVE|||||||
33740913|NCT02966080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33740914|NCT06272916|||COHORT||PROSPECTIVE|||||||
33740915|NCT00064805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740916|NCT06434532|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||waitlist control|f|f|f|t
33740917|NCT03175640|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33740918|NCT02227160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740919|NCT04629222|||CASE_CONTROL||RETROSPECTIVE|||||||
33740920|NCT05685485|||COHORT||PROSPECTIVE|||||||
33740921|NCT03526913|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Comparison of combined autologous PRP and skin grafting to skin grafting alone in chronic leg ulcers (comparing one ulcer to another in bilateral cases, or one half of ulcer to the other in big ulcers)|t|f|f|f
33740922|NCT02591394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740923|NCT01197040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740924|NCT04909697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740925|NCT01804959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33740926|NCT05517239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740927|NCT03701659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33740928|NCT00397423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33740929|NCT03250000|||COHORT||PROSPECTIVE|||||||
33740930|NCT02991209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740931|NCT02065466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740932|NCT01746823|||CASE_CONTROL||PROSPECTIVE|||||||
33740933|NCT05961293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740934|NCT05413538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740935|NCT06535698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740936|NCT00499889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740937|NCT01551862|||COHORT||PROSPECTIVE|||||||
33740938|NCT01640301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740939|NCT02889549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33740940|NCT04596163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Single-centred, double-blinded, randomized, placebo-controlled trial|t|t|f|t
33740941|NCT06202261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740942|NCT02174536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740943|NCT02721212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33740944|NCT01020201|||COHORT||PROSPECTIVE|||||||
33740945|NCT03013647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740946|NCT03791398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study of de-escalating arms to determine the MTD and then expand the trial.It is not randomized.||||
33740947|NCT06662604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33740948|NCT03856346|||CASE_ONLY||PROSPECTIVE|||||||
33740949|NCT01471535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740950|NCT03868904|||COHORT||PROSPECTIVE|||||||
33740951|NCT03774641|||CASE_ONLY||PROSPECTIVE|||||||
33740952|NCT02042482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740953|NCT01972061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740954|NCT05758662|||COHORT||CROSS_SECTIONAL|||||||
33740955|NCT06116773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|our study was conducted as single (assessor) blind.|two groups: training group and control group.|f|f|f|t
33740956|NCT02639884|NA|SINGLE_GROUP||OTHER||NONE||||||
33740957|NCT03732014|||CASE_ONLY||CROSS_SECTIONAL|||||||
33740958|NCT06221865|||COHORT||PROSPECTIVE|||||||
33740959|NCT01759745|||CASE_CONTROL||PROSPECTIVE|||||||
33740960|NCT02480621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33740961|NCT00217698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740962|NCT01491477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740963|NCT00780845|||COHORT||PROSPECTIVE|||||||
33740964|NCT04089644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single center prospective randomized controlled trial|t|f|f|t
33740965|NCT02262845|||COHORT||PROSPECTIVE|||||||
33740966|NCT01925183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33740967|NCT04819997|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33740968|NCT04795271|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive personalized orthopedic treatment, depending on the plantar discharge needs that each patient needs. This treatment may include the use of an insole or insole and orthopedic footwear.||||
33740969|NCT05085457|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"Participant will not know if the ExPreS or just RSBI were calculated before extubation. The SBT will be the same for both groups.~Investigator and outcomes assessor will not have access to whole patients' data, just the primary and secundary outcomes to perform the statistical analysis."|Patients will be randomized to receive the intervation of Control group or ExPreS group.|t|f|t|t
33740970|NCT04572633|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, non-randomized prospective trial.||||
33740971|NCT02464501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740972|NCT01017172|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33740973|NCT02866682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740974|NCT03237689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The only entity knowledgeable of randomization is the Johns Hopkins University Investigational Drug Service Pharmacy. They are responsible for randomizing and encapsulating the drug and placebo tablets|"The design is a two-phase study of HIV+ women who: 1) first participate in a double-blind, placebo-controlled cross-over study of a single, low dose (10 mg) of hydrocortisone versus placebo on cognition; and 2) then participate in a mechanistic, randomized, double-blind, placebo controlled trial of daily LDH for 4 weeks on cognition and side effects.~Below includes the number of arms for the second study phase and is the phase of the study being considered a Phase 0 clinical trial. All information to follow will pertain to this phase of the study."|t|t|t|t
33740975|NCT00688805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||||||||
33740976|NCT03219112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740977|NCT05269264|||CASE_CONTROL||OTHER|||||||
33740978|NCT02893215|||COHORT||PROSPECTIVE|||||||
33740979|NCT03778216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33740980|NCT05913297|||COHORT||PROSPECTIVE|||||||
33740981|NCT04170647|||COHORT||PROSPECTIVE|||||||
33947036|NCT04647006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33740982|NCT04671511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740983|NCT01661660|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33947037|NCT06724315|||COHORT||PROSPECTIVE|||||||
33740984|NCT05874934|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot study||||
33740985|NCT05847777|||CASE_ONLY||CROSS_SECTIONAL|||||||
33740986|NCT00767546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740987|NCT00889122|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33740988|NCT03917290|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon clearance to Return to Play (RTP) after concussion, all participants will be randomized to either a Neuromuscular training (NMT) group or usual care (no sports injury prevention training). Those in the NMT group will complete training for 20-30 minutes, two times per week, beginning at RTP and continuing at this frequency until the end of the current athletic season.||||
33740989|NCT00977041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740990|NCT02449759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33740991|NCT02942160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33740992|NCT01678040|||COHORT||PROSPECTIVE|||||||
33740993|NCT04585334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, double dummy|PAES, double blind, double dummy, multicenter, randomized, controlled clinical study|t|f|t|f
33740994|NCT04552782|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33740995|NCT05912946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33740996|NCT03299595|||COHORT||CROSS_SECTIONAL|||||||
33740997|NCT02756039|||COHORT||PROSPECTIVE|||||||
33740998|NCT04277598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|"During Safety Lead In Phase 12 patients will be randomized to one of two study arms at a ratio of 3:1 between APO-2 and placebo.~During the Main Phase 108 patients will be randomized to one of the four study arms at a ratio of 1:1:1:1 between APO-2 (three doses) and placebo."|t|f|t|f
33740999|NCT02439346|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741000|NCT00363766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741001|NCT01280435|||||PROSPECTIVE|||||||
33741002|NCT05927402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33741003|NCT01702233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741004|NCT04489095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||After informed consent is obtained, patient will undergo TAVR as per usual standard of care. Using the same femoral vein access as is used standard for a portion of the TAVR procedure, an EPS(Electrophysiology study) will be performed during the TAVR procedure, immediately before and after valve implantation. The patient will recover on a general telemetry floor as per usual care, and the next day will undergo another EPS. This is not uncommonly done clinically for some patients after TAVR. At that point, based on the baseline EKG, intra-procedure findings, and EPS findings, the patient will either have a pacemaker implanted, a 30-day event monitor ordered, or neither of the above.||||
33741005|NCT03952884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33741006|NCT01200121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741007|NCT02585739|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33741008|NCT05649384|||CASE_ONLY||PROSPECTIVE|||||||
33741009|NCT00824109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741010|NCT04831125|||COHORT||PROSPECTIVE|||||||
33741011|NCT01543256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741012|NCT05153018|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741013|NCT04289753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster-randomized by primary care clinic using a constrained randomization process.|f|f|f|t
33741014|NCT01287442|||CASE_ONLY||RETROSPECTIVE|||||||
33741015|NCT01790698|||COHORT||PROSPECTIVE|||||||
33741016|NCT03224468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33741017|NCT00206063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741018|NCT03892486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33741019|NCT01831089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741020|NCT04002752|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33741021|NCT01769794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947038|NCT06724328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741022|NCT05058781|||CASE_CONTROL||PROSPECTIVE|||||||
33741023|NCT02081794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741024|NCT01694706|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741025|NCT02746692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741026|NCT02325882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741027|NCT00812292|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741028|NCT04087057|||CASE_ONLY||PROSPECTIVE|||||||
33741029|NCT05776108|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study|||||
33741030|NCT03891212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Using a central randomization system, participants will be randomized (1:1) into groups receiving either placed in prone position or in supine position (within 24 h of diagnosis of SP) for 5-7 days with a 28-day follow-up. Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.|t|f|f|f
33741031|NCT05257889|||OTHER||CROSS_SECTIONAL|||||||
33741032|NCT02177344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33741033|NCT02798198|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741034|NCT01963689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741035|NCT05134805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741036|NCT00871481|NA|SINGLE_GROUP||TREATMENT||SINGLE||||||
33741037|NCT05748639|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is designed as a 2-arm, parallel-group, randomized controlled trial with 12-, 24-, 36-, and 52-week follow-up, to evaluate the effect of the treatment group (QG-A) versus a control group (MM) on alcohol use outcomes.||||
33741038|NCT04100226|RANDOMIZED|PARALLEL||OTHER||NONE||"Arm 1(interventional group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive Vitamin D supplementation and ca in addition to current treatment.~Arm 2(control group): interstitial lung diseases patients with vitamin D deficient / insufficient will receive current treatment without vitamin D supplementation"||||
33741039|NCT02278276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741040|NCT02091804|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33741041|NCT04949230|||CASE_ONLY||RETROSPECTIVE|||||||
33741042|NCT01929356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741043|NCT04365322|||COHORT||PROSPECTIVE|||||||
33741044|NCT01465490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741045|NCT04062305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741046|NCT04790045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741047|NCT05850533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741048|NCT05038059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||3 groups assigned 2 with interventions and 1 control group.|t|f|f|t
33741049|NCT02021435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741050|NCT04193202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741051|NCT06315491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741052|NCT06192511|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33741053|NCT05905965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741054|NCT02033005|||COHORT||PROSPECTIVE|||||||
33741055|NCT03430154|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33741056|NCT01176903|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741057|NCT03946332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947039|NCT04941768|||COHORT||PROSPECTIVE|||||||
33947040|NCT06417801|||COHORT||PROSPECTIVE|||||||
33947041|NCT05183633|||OTHER||CROSS_SECTIONAL|||||||
33947042|NCT05228873|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33947043|NCT03028506|||COHORT||RETROSPECTIVE|||||||
33947044|NCT00193076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947045|NCT02257502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947046|NCT00823771|||CASE_CONTROL||PROSPECTIVE|||||||
33947047|NCT04272320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947048|NCT00158002|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33741058|NCT00512759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741059|NCT05924646|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Study participants and investigators will be blinded throughout the duration of the study.|Randomized cross-over trial with two arms: high salt and normal salt (placebo).|t|f|t|f
33741060|NCT00277017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741061|NCT01784705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741062|NCT05218252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741063|NCT01097226|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33741064|NCT04135131|RANDOMIZED|PARALLEL||SCREENING||NONE|chronic low back pain patients, which has home exercises or pilates|Prospective, randomized-single blinded study||||
33741065|NCT05417711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In the whole clinical research process, the subjects and researchers participating in the efficacy and safety evaluation should be in a blind state, that is, neither of them knows the specific intervention measures given to the subjects. For participant, the treatment equipment is exactly the same between the two groups. Also, 10 seconds sham stimulation at the beginning of treatment is set in the control group for minimizing risk of participants being able to guess treatment allocation. The randomized allocation is completed by a unified randomization center. Therefore, the investigators in each center just know A or B for the allocation information of each participant. For outcomes assessors, they are only responsible for baseline and follow-up assessment during the study."|The subjects included in the study are randomized by a unified randomization center. The randomization center will number the subjects with the random number table generated by the computer, and then arrange them in the order of number. The subjects will be randomly divided into groups in turn, and the subjects in the groups will be numbered with the random number table. The first half of the subjects with a larger number in the groups will be divided into the experimental group (tVNS paired with TMNMT), and the rest into the control group (TMNMT).|t|t|t|t
33741066|NCT01071395|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33741067|NCT06001398|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33741068|NCT03111225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The observation stage is a case- control study, the treatment stage is an A-B-A design.||||
33741069|NCT03119285|||OTHER||PROSPECTIVE|||||||
33741070|NCT00297453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741071|NCT04338815|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741072|NCT03207750|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33741073|NCT00273611|RANDOMIZED|PARALLEL||||NONE||||||
33741074|NCT06193993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741075|NCT05604729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Computerised randomisation, colour coded intervention.|Double blinded|t|t|t|t
33741076|NCT02662712|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33741077|NCT01661959|||CASE_CONTROL||PROSPECTIVE|||||||
33741078|NCT05390489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741079|NCT01669343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741080|NCT05316857|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741081|NCT04407897|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective investigator-initiated phase II multicentre-study, investigating the toxicity and efficacy of SABR for infra-diaphragmatic tumors.||||
33741082|NCT02721589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741083|NCT05906407|||COHORT||PROSPECTIVE|||||||
33741084|NCT00131157|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33741085|NCT04504877|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Volunteers, administrative staff, laboratory technicians, doctors who will carry out the assessments by phone, and statisticians will be blind to the treatment group and will not know about the group treatment information.||f|t|t|t
33741086|NCT00765167|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33741087|NCT01971905|||COHORT||RETROSPECTIVE|||||||
33741088|NCT00422539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741089|NCT04090736|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, prospective, multicenter, open label study.||||
33741090|NCT05749263|||COHORT||PROSPECTIVE|||||||
33741091|NCT05014100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741092|NCT04332744|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:2||||
33741093|NCT01148810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741094|NCT00879294|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33741095|NCT03483623|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This protocol is a Quasi Experimental Cross Factor study. The subject sample is nonrandomized. Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels on four different surface combinations.||||
33741096|NCT01592513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33741097|NCT06129058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and outcomes assessor will be blind to tDCS or sham condition.|Randomized sham-controlled|t|t|f|t
33741098|NCT00148057|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33741099|NCT00874783|||CASE_CONTROL||PROSPECTIVE|||||||
33741100|NCT04091841|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33741101|NCT04718246|NA|SINGLE_GROUP||OTHER||NONE||||||
33947049|NCT05959551|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Randomization will happen after baseline assessment. After-intervention assessment will only consist of self-report and computerized assessment. Participants will not aware of the treatment group that they were assigned to.|4 active treatment groups + 1 inactive treatment group|t|f|f|f
33947050|NCT04642326|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Parallel, Multicenter Randomized Controlled Study Investigating||||
33947051|NCT01249482|||CASE_CONTROL||PROSPECTIVE|||||||
33947052|NCT05882045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947053|NCT02561689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947054|NCT02173470|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34154395|NCT02357589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741102|NCT02684591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741103|NCT03391843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741104|NCT01376752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741105|NCT06228092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized study|t|t|f|t
33741106|NCT01984398|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741107|NCT00153101||PARALLEL||PREVENTION||||||||
33741108|NCT04018027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741109|NCT05075317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741110|NCT02310438|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33741111|NCT02799433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741112|NCT01773915|||COHORT||PROSPECTIVE|||||||
33741113|NCT05036642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741114|NCT01954017|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741115|NCT00648869|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741116|NCT05492136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33741117|NCT06155981|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be aware of the type of drink they receive.|Two groups of night-call staffs will be receiving different interventions.|t|f|f|f
33741118|NCT03669081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33741119|NCT05356559|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blinded|Parallel randomised control trial.|t|f|t|t
33741120|NCT02890381|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741121|NCT04365036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741122|NCT00208208|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33741123|NCT00816634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741124|NCT05204459|||COHORT||PROSPECTIVE|||||||
33741125|NCT01595516|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33741126|NCT03727893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741127|NCT04689386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947055|NCT04149145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947056|NCT04502862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Interim analysis for sample size re-estimation|t|t|t|t
34154396|NCT01399320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154397|NCT04422704|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154398|NCT01750905|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33741128|NCT06535815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Monocentric, prospective, randomized, interventional trial||||
33741129|NCT03510481|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33741130|NCT00556530|||FAMILY_BASED||PROSPECTIVE|||||||
33741131|NCT01298739|||COHORT||PROSPECTIVE|||||||
33741132|NCT04521257|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33741133|NCT06249243|||CASE_ONLY||CROSS_SECTIONAL|||||||
33741134|NCT01523691|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33741135|NCT03468439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741136|NCT04599881|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Open-label study||||
33843061|NCT03152097|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33843062|NCT05804370|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843063|NCT06244992|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843064|NCT05100004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will receive either active or sham stimulation to the DLPFC. Patients will be randomized to either condition with a 50:50 chance.|t|t|t|t
33843065|NCT01588964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843066|NCT01759524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843067|NCT05050240|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33843068|NCT06052137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843069|NCT05060640|||COHORT||PROSPECTIVE|||||||
33843070|NCT01698021|||COHORT||PROSPECTIVE|||||||
33843071|NCT02544477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947057|NCT03948061|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33947058|NCT03007680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947059|NCT04236986|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All subjects will complete a baseline PET \[11C\]PBR28 scan. A subset of subjects will complete a second PET \[11C\]PBR28 scan 3-hours after systemic LPS challenge (1.0 ng/kg; IV).||||
33947060|NCT00017108|RANDOMIZED|||TREATMENT||||||||
33947061|NCT02928900|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge cluster RCT||||
33947062|NCT02735772|NA|SINGLE_GROUP||TREATMENT||NONE||All Patients included in the study will undergo repair of paravaginal defect using tge new technique described in this study||||
33843072|NCT05047718|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947063|NCT06209268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843073|NCT03387137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33947064|NCT01992146|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33843074|NCT03829475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947065|NCT02363504|||CASE_CONTROL||OTHER|||||||
33843075|NCT01099475|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33843076|NCT02317887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947066|NCT06234501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154399|NCT06480149|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study included 2 groups, experimental and control. The pain levels of the patients in the intervention group were evaluated one hour after surgery. Classical shoulder massage was applied to both shoulders of the patient for 10-15 minutes each.~Patients in the control group were not massaged, only pain and sleep assessments were performed simultaneously with the intervention group."||||
34154400|NCT03291652|||CASE_CONTROL||PROSPECTIVE|||||||
33843077|NCT00000747||||TREATMENT||NONE||||||
33843078|NCT05470491|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843079|NCT04910139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843080|NCT04020055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843081|NCT06396351|||OTHER||PROSPECTIVE|||||||
33843082|NCT03787459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947067|NCT03360695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|1. A consensus panel of disease-specific oncologists who are blinded to intervention arm will review all patients at 24 weeks of care and evaluate for disruptions in cancer care.||f|f|f|t
33947068|NCT04291885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33947069|NCT06144229|||CASE_ONLY||PROSPECTIVE|||||||
33947070|NCT00649220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947071|NCT04338685|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label, multi-center, single-arm, multiple-ascending dose escalation||||
33947072|NCT02185729|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947073|NCT05040373|||COHORT||PROSPECTIVE|||||||
33947074|NCT06187064|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pilot of novel care model for low-barrier care and adherence support for uptake and sustained use of biomedical HIV prevention and medications for opioid use disorder for women who inject drugs||||
33843083|NCT00259402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843084|NCT01482689|RANDOMIZED|PARALLEL||||NONE||||||
33843085|NCT04255199|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843086|NCT02296736|||COHORT||RETROSPECTIVE|||||||
33843087|NCT02284217|NA|SINGLE_GROUP||SCREENING||NONE||||||
33843088|NCT06395818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|using closed envelop for participants the data will be given to outcomes assessors without defining the intervention for each group|parallel assignment|t|f|f|t
33843089|NCT02223559|||COHORT||PROSPECTIVE|||||||
33843090|NCT05526469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33843091|NCT06607627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843092|NCT00841217|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33843093|NCT03787836|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will first be randomized as controls or exercisers. All exercisers will complete a 16 week exercise program, then be randomized into two groups. The first group will increase the exercise intensity and conduct another 12 week program. The second group will continue the original program for an additional 12 weeks.||||
33947075|NCT03200041|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33947076|NCT04690673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Healthy volunteers||||
33947077|NCT02896686|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34154401|NCT05124171|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34154402|NCT06319859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34154403|NCT04150952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947078|NCT06084312|||OTHER||OTHER|||||||
33843094|NCT03550391|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an international multi-centre, open-label, randomized phase III trial comparing stereotactic radiosurgery compared with hippocampal-avoidant whole brain radiotherapy (HA-WBRT) plus memantine for 5-15 brain metastases||||
33843095|NCT06430476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|masking: Participants will be notified that they would engage in a diary recording activity for two weeks, but would be blinded to whether they were receiving the intervention or active control version. Participants will also be instructed not to reveal their exercise components (i.e., relaxation exercises or rumination exercises) to the trained research assistants, who will also be responsible for obtaining outcomes. Trained research assistents would assess outcomes and the principal investigator would randomise participants to the two conditions based on anonymised IDs. Treatment provided to participants as usual by their usual care providers (e.g., doctors) would not be notified about the randomisation conditions.|"EMA arm: participants will receive three ecological momentary assessment (EMA) prompts daily with the prompts spread out throughout the day. Within each prompt, participants will answer 14 questions regarding affect, suicidality, and rumination. Afterwards, they will be shown a video clip extracted from a popular and longstanding soap opera in Chinese that lasts between three to four minutes. Each prompt would take around 8 minutes to complete. In total, participants will complete 70 EMA prompts during the intervention period.~EMI arm: participants will receive two EMA prompts and one EMI prompt daily. The EMA prompts would be identical to the ones in the EMA arm without the video clip at the end. The EMI prompt would contain an interactive task designed to counter ruminative thoughts."|t|t|t|t
33843096|NCT06729203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947079|NCT02889861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947080|NCT04784806|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33947081|NCT05642091|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33947082|NCT05117658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947083|NCT06187454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33843097|NCT00159939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947084|NCT06709612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This study has 3 cohorts of ascending doses. Each cohort has 3 arms: AMT-143, Ropivacaine Solution and Saline Placebo.~AMT-143 is formulated as 385 mg/mL on a ropivacaine HCl equivalence basis in hydrogel containing sodium hyaluronate and methylcellulose. Each syringe has been filled with 0.52 g hydrogel, and several syringes may be combined to provide each study dose. The dose required for each participant will be prepared in the study site pharmacy prior to surgery following aseptic procedures.~Saline placebo will consist of 0.9% sodium chloride injection USP and will be administered in an amount matching the volume of AMT-143 to be used in each of the Cohorts 1 to 3.~The active comparator, ropivacaine hydrochloride 1% solution will be administered at a volume of 5 mL (50 mg) for all 3 cohorts."|t|f|f|f
33947085|NCT02028182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947086|NCT01451203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947087|NCT06300047|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The usual care group is defined as the group who receives usual care and serves as the control group. This group is defined prior to the implementation of the intervention. We include a two month wash out period between our two groups to avoid care providers 'holding on' to patients they feel may benefit from the intervention||||
33947088|NCT01604642|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947089|NCT04140942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843098|NCT03318224|||COHORT||CROSS_SECTIONAL|||||||
33843099|NCT05735171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843100|NCT06715878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843101|NCT03950752|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33843102|NCT03541200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843103|NCT00589121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843104|NCT02766777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843105|NCT06359041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843106|NCT05113368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947090|NCT04823663|||COHORT||OTHER|||||||
33947091|NCT04751851|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The participants will be randomly divided into four arms :~* Group A.1: Medium duration withdrawal programme with ACT~* Group A.2: Long duration withdrawal programme with ACT~* Group B.1: Medium duration withdrawal programme without ACT~* Group B.2: Long duration withdrawal programme without ACT"||||
33947092|NCT04285957|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947093|NCT04533672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947094|NCT02704858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843107|NCT06727643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher taking the measurements will not be aware of the application made.|2 different tape types will be applied to 2 different groups and the results will be compared.|f|f|f|t
33843108|NCT06269705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only unblinded team (pharmacist, unblinded coordinator, drug administrator) will know the treatment assignment. A site-specific blinding plan will be developed to ensure blinding. Unblinded team will only interact with the subject at treatment and will not have any blinded roles on the study (only exception- informed consent). The subject and the assessor responsible for assessments/safety monitoring will be blinded. Site and Sponsor personnel/representatives will be blinded, with the following Sponsor/representative exceptions: unblinded monitors for performing drug accountability, unblinded clinical manager for reviewing unblinded monitoring visit reports and escalation of site unblinded issues, inventory manager for addressing product-related issues, and regulatory personnel for safety reporting. Information regarding treatment assignments will be kept securely at Sponsor.||f|f|t|f
33843109|NCT00299494|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33843110|NCT02760498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843111|NCT04974372|||COHORT||PROSPECTIVE|||||||
33843112|NCT00127686|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33843113|NCT06244576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843114|NCT05313659|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33843115|NCT00673621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843116|NCT06259578|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843117|NCT03814551|||COHORT||PROSPECTIVE|||||||
33843118|NCT06401746|||COHORT||PROSPECTIVE|||||||
33843119|NCT02042794|||||PROSPECTIVE|||||||
33947095|NCT06347458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947096|NCT04939805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947097|NCT06520046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947098|NCT05943132|RANDOMIZED|PARALLEL||PREVENTION||NONE||24 Community-based Organizations (CBOs) (360 children), their caregivers at home and 72 CBO caseworkers are enrolled. Randomization takes place at the level of the CBO so that half of the CBOs receive MISC and the other half receives TAU.||||
33947099|NCT04926337|||COHORT||PROSPECTIVE|||||||
34154404|NCT00534833|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154405|NCT00187525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154406|NCT01773304|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34154407|NCT04846465|||OTHER||RETROSPECTIVE|||||||
34154408|NCT06256419|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33741137|NCT01100463|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741138|NCT02233712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741139|NCT04828759|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741140|NCT03072901|||COHORT||PROSPECTIVE|||||||
33741141|NCT00803894|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33741142|NCT00000123|RANDOMIZED|||TREATMENT||DOUBLE||||||
33741143|NCT04364282|||COHORT||PROSPECTIVE|||||||
33741144|NCT04606953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this single-blind, randomized controlled trial, the follow-up action evaluator is in a blind condition. The evaluator does not know the group to which the participants belong.|"In this single-blind, randomized controlled trial, patients are randomly assigned to either a cognitive training experimental group (n=15) or a standard care control group (n=15)."|f|f|f|t
33741145|NCT01858454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741146|NCT05797779|NA|SINGLE_GROUP||OTHER||NONE||||||
33741147|NCT04574362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741148|NCT02669186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741149|NCT02992639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741150|NCT00062244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741151|NCT02066298|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741152|NCT02932631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741153|NCT02885233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741154|NCT00582582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741155|NCT00659165|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33741156|NCT06033989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741157|NCT01316744|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33741158|NCT00002934|NA|SINGLE_GROUP||SCREENING||NONE||||||
33741159|NCT04250324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741160|NCT02939222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741161|NCT02717949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741162|NCT02676206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33741163|NCT04751253|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33741164|NCT01316848|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741165|NCT04779645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double-blind|Single-center, double-blind, placebo-controlled, multi-dose study.|t|t|t|t
33741166|NCT04777279|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33741167|NCT00548782|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741168|NCT04537091|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33741169|NCT05623709|||COHORT||PROSPECTIVE|||||||
33741170|NCT01363323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741171|NCT00452634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741172|NCT04221516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741173|NCT01625793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33741174|NCT05598346|||CASE_CONTROL||RETROSPECTIVE|||||||
33741175|NCT01187238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741176|NCT04028375|||CASE_CONTROL||PROSPECTIVE|||||||
33741177|NCT02352493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741178|NCT04099459|||OTHER||PROSPECTIVE|||||||
33741179|NCT02671669|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33741180|NCT00511862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741181|NCT06464835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741182|NCT03196921|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients with symptomatic cryptococcal meningitis will be enrolled in treatment arm Patients that are CRAG positive will be enrolled the in prevention arm||||
33741183|NCT04522947|NA|SINGLE_GROUP||OTHER||NONE||All participants complete the same fMRI protocol which includes delivery of appetizing taste stimuli and tasteless stimuli while in the scanner.||||
33741184|NCT01065961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741185|NCT00439777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741186|NCT04954365|||COHORT||OTHER|||||||
33741187|NCT01859455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741188|NCT03814447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741189|NCT06177639|||COHORT||PROSPECTIVE|||||||
33741190|NCT03878940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741191|NCT02401672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741192|NCT05446740|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|The study will be observer-blind with regards to the study intervention and open-label with regards to the dose level for participants and investigators and open-label for the sponsor. For dose cohorts 6, 7, 10 and 11 the study will be single-blind.||t|t|t|t
33741193|NCT04757012|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33741194|NCT04652193|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741195|NCT02863016|||COHORT||PROSPECTIVE|||||||
33741196|NCT02291718|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741197|NCT03892941|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33764525|NCT02459223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764526|NCT02938169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843120|NCT01115127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843121|NCT03856515|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33843122|NCT06729489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843123|NCT06316310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"All eligible participants will be randomly assigned into two group at a ratio of 1:1, the Acupoint Thread Embedding group and the Sham Acupoint Thread Embedding group (the control group).~group)."|t|f|t|t
33843124|NCT04965675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843125|NCT01422642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843126|NCT06050616|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33843127|NCT06147297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Intervention group: Receive the music-based program, and complete the survey before- and after- the program.~Waitlist group: Invited to complete the survey before- and after the 4-week waiting period. Then the waitlist group will also be offered the program, and invited to complete an optional post-program survey."|f|f|t|t
33843128|NCT05000931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843129|NCT06728904|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33843130|NCT00706290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843131|NCT05672901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33843132|NCT05171478|||COHORT||PROSPECTIVE|||||||
33843133|NCT04806373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind. Pharmacist will be unblinded.|single center, prospective, randomized, double-blind, placebo-controlled trial with two arms|t|t|t|f
33843134|NCT06145438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843135|NCT04446728|RANDOMIZED|PARALLEL||OTHER||NONE|This is an implementation trial in which institutions are assigned to conditions. There is no masking.|||||
33843136|NCT04556487|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33843137|NCT06064968|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention and control group||||
33843138|NCT06184126|RANDOMIZED|PARALLEL||TREATMENT||NONE|Once the participant has been enrolled in the study, they will be randomized to either the control arm or one of the experimental arms. No masking is being performed. Once randomization has occurred, participants, care providers, and the investigators will know which group the participants are in.|This is a prospective, non-blinded, randomized clinical control trial.||||
33843139|NCT02550938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843140|NCT03211234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843141|NCT02842151|NA|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33843142|NCT03556956|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicentre, open-label, randomized, parallel groups, seamless phase 2-3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus Best Supportive Care in third or fourth line of treatment of patients with metastatic colorectal cancer.||||
33843143|NCT02506075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33843144|NCT00830505|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33843145|NCT01720160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843146|NCT06718335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843147|NCT00263016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843148|NCT06729216|||CASE_ONLY||CROSS_SECTIONAL|||||||
33843149|NCT04739943|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be given access to one or more devices or smartphone/tablet applications. They will then be followed with surveys as well as data from chart review to see how use of one or more elements for remote monitoring may affect their quality of life and overall care.||||
33947100|NCT00271882|||COHORT||PROSPECTIVE|||||||
33843150|NCT06333028|||CASE_ONLY||PROSPECTIVE|||||||
33843151|NCT04351958|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-Post Pilot Study||||
33843152|NCT06728514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group A will receive ESPB and Group B will receive PVB|t|f|f|t
33843153|NCT04656496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33843154|NCT00330148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843155|NCT02580721|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
33947101|NCT00403429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947102|NCT02123186|||COHORT||PROSPECTIVE|||||||
33947103|NCT02546193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843156|NCT05299697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843157|NCT02074189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843158|NCT00964886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843159|NCT01978327|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33843160|NCT04629833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843161|NCT01506973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843162|NCT02255253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843163|NCT06168539|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Measuring data of microemboli counts is masked for the patient.|Each patient is randomized to start with either standard or intervention vice versa. Paired analyses are done.||||
33843164|NCT03865927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Following screening assessments, IPF patients who meet all inclusion/exclusion criteria will be randomly assigned to receive one of the following treatments in a ratio of 1:1:~• Arm A (n=30) - GKT137831 Treatment:~GKT137831 will be administered orally, at a dose of 400 mg bid, for a total of 24 weeks.~• Arm B (n=30) - Placebo Treatment:~Arm B subjects will receive matching placebo for the same duration.~Participants will be followed in face-to-face visits with trial personnel every 6 weeks for 24 weeks to assess drug effects and monitor safety during their treatments, and by phone surveillances one month thereafter."|t|t|t|f
33843165|NCT05401877|||CASE_CONTROL||RETROSPECTIVE|||||||
33843166|NCT06075316|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The participants will have their alerts sent to the clinicians when concerning symptoms are reported.||||
33947104|NCT02976909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843167|NCT03919903|||OTHER||CROSS_SECTIONAL|||||||
33947105|NCT00895999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154409|NCT02787915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947106|NCT01002846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947107|NCT06724874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154410|NCT00898456|||COHORT||RETROSPECTIVE|||||||
33843168|NCT06554340|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will use a two-arm RCT design to examine the effect of a home-based exercise training program versus an attention control condition on markers of functional recovery, cognition and mobility disability, in persons with MS with hypertension. The primary outcomes will be cognitive performance via the BICAMS battery and mobility disability via the timed 25-foot walk, with secondary effects designed to understand the potential mechanistic role of BP, arterial stiffness, and endothelial function on functional recovery in response to the intervention.||||
33843169|NCT05864820|||COHORT||PROSPECTIVE|||||||
33843170|NCT03397875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843171|NCT01846377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33843172|NCT06010927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33843173|NCT02844218|||COHORT||RETROSPECTIVE|||||||
33843174|NCT04986839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Infants will be randomized. Outcome assessor of the treatment will be blinded to the trial participants. No allocation concealment is done.|The study involves two-arm parallel assignment where one group receives standard treatment (Ibuprofen) and the other group receives investigational medicinal product (Paracetamol) to treat Patent Ductus Arteriosus|f|f|f|t
33843175|NCT06419998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843176|NCT06644170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843177|NCT05746559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843178|NCT06729346|||OTHER||PROSPECTIVE|||||||
33843179|NCT05532735|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843180|NCT05216159|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon obtaining consent, eligible participants will be randomly assigned to either the intervention group or the control group. The study will run for eight weeks, with a four week intervention period and a follow-up at the end of week eight.||||
33843181|NCT05902949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843182|NCT04465799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"ENTREN is based on a exhaustive previous literature review. It uses a cognitive-behavioural perspective, has a duration of 6 months and includes a module for children treatment centred on emotional regulation. Some contents from LEARN Program for Weight Management were adapted to childhood stages for the ENTREN programme, which includes five main dimensions: lifestyle, physical activity, health attitudes, social relationships, and nutrition. Spanish health guidelines from the Health Ministry, aimed to promote healthy eating habits and physical activity, were also taken into account. Motivational interviewing techniques have also been integrated into the sessions to promote children's and families' commitment to their health. Specifically, family content has been developed to adapt parental democratic educational style and improve communication with their children. A previous pilot study of ENTREN programme was conducted to describe its feasibility and acceptability in Primary Care."|f|t|f|t
33843183|NCT06133153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blinfolded during treatments; the blinded evaluating investigator will be blinded to device allocation and will have no access to unblinding information in the study files|Parallel-Group randomized study with a randomization ratio of 2:1 (Study Device : Comparator Device)|t|f|f|t
33843184|NCT05071820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843185|NCT06717971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Because of the design of the study and the nature of the interventions, blinding the staff and participants of the LTCFs is impossible. The assessors, measuring the outcomes, and the interpreter, analyzing the data, will be blinded in this study.|"The training program for the intervention group utilized the Nintendo Switch game WarioWare: Move It,. Participants engaged with the game through Joy-Con controllers, completing rapid micro-games designed to meet specific movement-oriented objectives. The WarioWare: Move It training program was administered twice weekly, with each session lasting 60 minutes over 12 weeks. Each session comprised three 10-minute gaming segments, interspersed with rest periods of 1 to 5 minutes to sustain participant engagement and mitigate mental fatigue. The standard care program for the control group is grounded in routine practices of long-term care facilities, aiming to sustain and enhance the physical and mental well-being of elderly residents through structured group activities. These activities encompass tailored fitness exercises, horticultural therapy, and sedentary group engagements for older adults. The program is conducted twice a week, with each session lasting 60 minutes over 12 weeks."|f|f|f|t
33843186|NCT03356392|||COHORT||PROSPECTIVE|||||||
33843187|NCT04157725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843188|NCT06715852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A parallel cluster RCT design|f|f|t|t
33843189|NCT05332236|||FAMILY_BASED||PROSPECTIVE|||||||
33843190|NCT00522405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843191|NCT05714969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843192|NCT06000059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843193|NCT01208389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843194|NCT04869358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843195|NCT05862129|||CASE_CONTROL||PROSPECTIVE|||||||
33843196|NCT03907644|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33843197|NCT04129164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843198|NCT00107094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843199|NCT01996553|||COHORT||PROSPECTIVE|||||||
33843200|NCT06718296|||OTHER||CROSS_SECTIONAL|||||||
33843201|NCT05385315|||COHORT||PROSPECTIVE|||||||
33843202|NCT04555785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33843203|NCT05751785|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33843204|NCT01456572|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33843205|NCT03912363|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33843206|NCT06532617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843207|NCT06365619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843208|NCT04889209|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|study sites will administer product to which they have been assigned|||||
33843209|NCT03374449|RANDOMIZED|PARALLEL||OTHER||NONE|Endpoint validated by an adjudication commitee blinded to the arm.|The aim of this study is to evaluate the impact of Renin-Angiotensin System inhibitors management (Continuation or discontinuation 48 hours before surgery) on outcome in patients undergoing scheduled major non-cardiac surgery (surgery with an expected duration of more than 2 hours from the surgical incision and a post-operative hospital stay of least 3 days)||||
33843210|NCT00044798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843211|NCT06079554|||COHORT||PROSPECTIVE|||||||
33843212|NCT03139604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33843213|NCT06280040|||COHORT||PROSPECTIVE|||||||
33843214|NCT03816761|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|f|f|t
33843215|NCT01056497|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33843216|NCT00230880|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33843217|NCT06705348|||COHORT||PROSPECTIVE|||||||
33843218|NCT03545802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843219|NCT02013921|||COHORT||PROSPECTIVE|||||||
33843220|NCT05336214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33843221|NCT06092424|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Patients will be investigated at high altitude (HA, 2840m) and low altitude (LA, sea level)||||
33843222|NCT06264128|NA|SINGLE_GROUP||TREATMENT||NONE|There is no specific intent to mask although participants will be naive to CPAP-type therapy, but they will be able to feel the difference.|All participants will undergo the same therapy combinations. CPAP (Continuous Positive Airway Pressure) and 2 level of TPAP (TheraPAP - novel CPAP approach pressure is reduced below therapy pressure from inspiration through mid exhalation specifically for comfort) will be assessed against each other in a round robin both backward and forward (6 total binary comparisons) for 2 levels of baseline pressure.||||
33843223|NCT03735667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843224|NCT01763515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843225|NCT05404737|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33843226|NCT02084563|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33843227|NCT06437782|||COHORT||PROSPECTIVE|||||||
33843228|NCT01891175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843229|NCT02918305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843230|NCT05596253|||CASE_ONLY||PROSPECTIVE|||||||
33843231|NCT06148623|NA|SINGLE_GROUP||OTHER||NONE||||||
33843232|NCT06324695|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843233|NCT04573348|||OTHER||PROSPECTIVE|||||||
33843234|NCT03546140|||COHORT||PROSPECTIVE|||||||
33843235|NCT05797168|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study consists of individual modules, each evaluating the safety and tolerability of AZD5335 dosed as monotherapy or in combination with specific treatments.~* Module 1 (AZD5335 monotherapy)~* Module 2 (AZD5335 in combination with saruparib)~* Module 3 (AZD5335 in combination with bevacizumab)~* Module 4 (AZD5335 in combination with carboplatin +/- bevacizumab)"||||
33843236|NCT06729723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843237|NCT01857089|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843238|NCT06659861|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843239|NCT02685098|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843240|NCT00066651||||TREATMENT||NONE||||||
34154411|NCT02249182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843241|NCT06464653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843242|NCT01233362|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33843243|NCT04310930|RANDOMIZED|PARALLEL||TREATMENT||NONE|"The FORMAT trial may include placebo controlled double blind randomised interventions in the future, but the initial intervention program is randomised but open label.~There will be three stages of randomisation in the intervention program of this study, dictating the treatment the participant will receive. Randomisation at each level will be conducted using the method of minimisation. Each randomisation level will be planned to enable flexibility via pre-planned adaptations."|There are 2 different phases of treatment; intensive therapy (IT) followed by consolidation therapy (CT). Intervention cohort participants will be randomised to 1 of 3 treatment arms for 6 weeks of IT. After the first 6 weeks of IT participants who are culture positive for MABS are randomised to either prolonged IT (additional 6 weeks of IT) then CT, or to commence CT. If, at week 6 participants are MABS culture-negative they will commence CT. Participants commencing CT are randomised to one of two treatment arms for 50 weeks. There are 12 possible paths through the trial. This standing platform trial design enables assessment of short IT, prolonged IT, and CT components individually as well as the overall combination of IT and CT. After 100 patients have completed short IT an interim analysis will be conducted, and Bayesian adaptive randomisation (BAR) will be implemented. New interventions may be added or stopped in the future due to lack of benefit at interim analyses.||||
33843244|NCT05061472|||COHORT||PROSPECTIVE|||||||
33843245|NCT01413087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843246|NCT05849337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843247|NCT02092623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843248|NCT01008579|||COHORT||PROSPECTIVE|||||||
33843249|NCT01142115|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33843250|NCT06137274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843251|NCT06423690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843252|NCT03561298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843253|NCT04035902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843254|NCT06500468|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Partipants will be randomised into either of the 2 arms: PillSense Group (Treatment arm) or Standard group (where they will receive standard of care) for the duration of the study.||||
33843255|NCT03578653|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843256|NCT05922501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843257|NCT01068275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843258|NCT06150170|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843259|NCT06166875|||COHORT||PROSPECTIVE|||||||
33843260|NCT06729008|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947108|NCT05957315|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33947109|NCT03270280|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Triple Blind|Healthy Individuals with Chronic Periodontitis Only|t|t|t|t
33947110|NCT02515890|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||There are 3 single drug arms completed by a few participants. The majority of participants participated in a crossover design with two drugs, midazolam \& ketamine.|t|f|f|f
34154412|NCT04294147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154413|NCT02870530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843261|NCT06122675|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The differences in primary outcome scores are calculated while on intervention (effective stimulation) versus placebo (sham stimulation), using an N-of-1 trial design. Each N-of-1 trial consists of a baseline assessment prior to DBS surgery (4 weeks), DBS surgery and open label phase to determine optimal stimulation settings (20 weeks), followed by a randomized three-cycle sequence of paired 8-week exposure periods, with each pair including intervention then placebo or vice versa (24 weeks). The DBS intervention exposure will be at the personalized optimal stimulation settings determined during the open-label phase.|t|t|f|t
33843262|NCT03998332|||COHORT||RETROSPECTIVE|||||||
33843263|NCT06266624|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843264|NCT03712059|||COHORT||PROSPECTIVE|||||||
33843265|NCT03791086|||COHORT||PROSPECTIVE|||||||
33843266|NCT05162274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843267|NCT01803282|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843268|NCT06569394|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Participants will be blind to medication assignment, as will all care providers and investigators.|Double-blind placebo controlled clinical trial|t|t|t|t
33843269|NCT02627703|||||PROSPECTIVE|||||||
33843270|NCT06645366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843271|NCT04672811|NA|SINGLE_GROUP||OTHER||NONE||||||
33843272|NCT02437201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33843273|NCT04939363|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomized, single arm||||
33843274|NCT03169790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843275|NCT05606510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843276|NCT05734105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843277|NCT02535975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843278|NCT04687462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher performing the surgery can know which instruments are used for each knee joint according to the random number table assignment result, but the subjects undergoing surgery will be conducted as a single blinded study where it is not possible to know which instruments are used for each side.|This study is a prospective, single-centered, randomized controlled clinical trial. Patients undergoing bilateral total knee replacement arthroplasty(TKRA) for both knee osteoarthritis will receive written consent from the patient through informed consent before the surgery. Among the patients undergoing total arthroplasty for both knee joints, only patients who have agreed with written consent will receive the surgery. In one patient who has been decided to be erolled for the stedy, we will set one knee joint as the experimental group, and the other knee joint as the control group. The experimental group will undergo TKRA using Exult total knee system and the control group will get TKRA using Lospa total knee system.|t|f|f|f
33843279|NCT06560957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843280|NCT06499298|||COHORT||RETROSPECTIVE|||||||
33843281|NCT01769326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843282|NCT06136741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized initially to 1 of 4 groups (A dose regimen, B dose regimen, C dose regimen, or D dose regimen \[placebo\]) for the blinded induction period. At Week 16, the start of the blinded maintenance period, patients who responded well to treatment will be re-randomized within their previously assigned groups to either maintenance regimen 1 or maintenance regimen 2. At Week 16, patients without an adequate response during the blinded induction period may be assigned to receive open label escape therapy through the maintenance period of the study (up to Week 52); however, patients receiving escape therapy with inadequate improvement in disease severity will be discontinued from the study therapy at Week 32. Any patients enrolled into the blinded maintenance period with acute exacerbation of atopic dermatitis may be eligible to receive open label escape therapy instead.|t|t|t|t
33843283|NCT04419870|||CASE_CONTROL||PROSPECTIVE|||||||
33843284|NCT03952091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843285|NCT05492942|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33843286|NCT03529682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843287|NCT05916313|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843288|NCT06036706|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843289|NCT05432232|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multi-center, single-arm, pilot trial.||||
33843290|NCT02541370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843291|NCT05819385|||COHORT||OTHER|||||||
33843292|NCT02776995|NA|SINGLE_GROUP||OTHER||NONE||||||
33843293|NCT06654102|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||4 test sites will be defined on the subjects' backs. Each test site will contain 7 subsites||||
33843294|NCT04604561|||CASE_ONLY||PROSPECTIVE|||||||
33843295|NCT05133349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843296|NCT06360289|||COHORT||PROSPECTIVE|||||||
33843297|NCT03711032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843298|NCT06084767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||68Ga-TCR-FAPI PET/CT was used for patients with suspected malignant tumors||||
33843299|NCT04870255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to receive: active L-DLPFC stimulation, active DMPFC stimulation, or sham stimulation. Group size ratio will be 1:1:1.|t|t|t|t
33947111|NCT03160131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33947112|NCT05127642|||CASE_CONTROL||RETROSPECTIVE|||||||
33947113|NCT05881538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluators and care providers will be masked to the allocation of the patients. Given the nature of the intervention, it is not possible to mask patients or monitors in charge of supervising the execution of the exercise training.|Multicenter study, randomized controlled trial in two parallel groups (ratio 1:1), double blinded.|f|t|f|t
33947114|NCT04038411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947115|NCT06420206|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34154414|NCT00494507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154415|NCT03253328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154416|NCT03841370|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154417|NCT06393881|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, multiple-dose crossover phase 1 clinical trial||||
34154418|NCT03113695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154419|NCT01248637|||OTHER||OTHER|||||||
34154420|NCT02295605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843300|NCT01223352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843301|NCT04238949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pilot Randomized Controlled Trial||||
33843302|NCT05669014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843303|NCT06194552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843304|NCT02673346|||COHORT||CROSS_SECTIONAL|||||||
33843305|NCT02716259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843306|NCT00586612|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843307|NCT02290080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843308|NCT04113642|||OTHER||CROSS_SECTIONAL|||||||
33843309|NCT02106962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843310|NCT06463340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843311|NCT03820752|||COHORT||RETROSPECTIVE|||||||
33843312|NCT05689775|||COHORT||PROSPECTIVE|||||||
33843313|NCT01929824|||COHORT||PROSPECTIVE|||||||
33843314|NCT00831753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33843315|NCT04409171|||COHORT||PROSPECTIVE|||||||
33843316|NCT04085445|||CASE_CONTROL||PROSPECTIVE|||||||
33843317|NCT00004094||||TREATMENT||||||||
33843318|NCT02683785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843319|NCT00856440|||||PROSPECTIVE|||||||
33843320|NCT04571788|||OTHER||PROSPECTIVE|||||||
33741198|NCT04177693|RANDOMIZED|PARALLEL||OTHER||NONE||"The 36 women will be randomized to one of the following groups:~1. EGCG daily alone.~2. EGCG daily with clomiphene citrate 100mg for 5 days.~3. EGCG daily with letrozole 5mg for 5 days."||||
33741199|NCT03293342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Each patient receives a project number. A codebook between project number and journal number is stored at Tannhelsetjenestens kompetansesenter sør in Arendal. All data will be registered online using Nettskjema to collect data directly into Services for sensitive data (TSD). The research data from each patient will only be identified by the project number.~All data will be stored and analysed using the TSD platform. TSD complies with the directive of privacy and electronic communication in Norway. TSD is developed and operated by USIT, the UiO centre for IT."|Randomized Clinical Trial|f|f|f|t
33741200|NCT05091034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator responsible for evaluating the efficacy of the intervention and the research assistants conducting assessment interviews with adolescents and their caregiver will be blind to assigned arm conditions.|Participants will be assigned to 1 of 2 groups, an e-health intervention group or an education only control group.|f|f|f|t
33843321|NCT00542672|||COHORT||PROSPECTIVE|||||||
33741201|NCT06574087|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741202|NCT02972580|||COHORT||PROSPECTIVE|||||||
33741203|NCT01982916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741204|NCT05640934|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741205|NCT03450031|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741206|NCT02984501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741207|NCT02013323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843322|NCT01519505|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741208|NCT03023735|||FAMILY_BASED||PROSPECTIVE|||||||
33741209|NCT04879472|||COHORT||PROSPECTIVE|||||||
33741210|NCT05453305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33741211|NCT06534866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial|t|f|f|f
33741212|NCT02680691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764527|NCT01105806|||COHORT||PROSPECTIVE|||||||
33764528|NCT02856139|||CASE_ONLY||PROSPECTIVE|||||||
33843323|NCT02961439|||OTHER||PROSPECTIVE|||||||
33843324|NCT05930483|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33843325|NCT01498757|||COHORT||PROSPECTIVE|||||||
33843326|NCT02729064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33843327|NCT03921385|||COHORT||PROSPECTIVE|||||||
33843328|NCT00890695|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomised trial of nutrition products||||
33843329|NCT05751954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843330|NCT04474444|||CASE_ONLY||RETROSPECTIVE|||||||
33843331|NCT04116892|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33843332|NCT05920720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843333|NCT04891562|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843334|NCT03523611|||COHORT||PROSPECTIVE|||||||
33843335|NCT04912453|RANDOMIZED|PARALLEL||TREATMENT||NONE||All neonates with confirmed NEC and require surgical intervention will be included. This is a local multi-centre study and neonates from the three centres which perform neonatal surgery will participate. At laparotomy, the diseased segment of intestine will be resected and the patients will then receive either primary anastomosis or enterostomy according to randomisation done pre-operatively.||||
33843336|NCT03993262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study drug will be provided blinded by the local pharmacy.|1:1 randomization will be done centrally and stratified by site. Block randomization of variable block sizes will be used.|t|t|t|t
33843337|NCT05702697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843338|NCT02247453|NA|SINGLE_GROUP||SCREENING||NONE||||||
33843339|NCT01518153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843340|NCT05751278|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33843341|NCT06424470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843342|NCT03288207|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33843343|NCT01367288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947116|NCT06432062|||CASE_CROSSOVER||PROSPECTIVE|||||||
33947117|NCT06377488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947118|NCT06176092|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947119|NCT02078141|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947120|NCT06724042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947121|NCT06076902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind study in which only patients will not be aware of treatment (with or without rotator cuff augmentation with polyester patch)||t|f|f|f
33947122|NCT06469216|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34154421|NCT03218930|NA|SINGLE_GROUP||OTHER||NONE||||||
33947123|NCT05282901|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric, phase II trial with a single-arm of treatment in two independent cohorts with Tebentafusp-naive patients, and with patients previously treated by Tebentafusp||||
33843344|NCT00668265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33843345|NCT03725657|||CASE_ONLY||PROSPECTIVE|||||||
33843346|NCT04094441|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||one arm, the interventional design is related to additional pulmonary function tests||||
33843347|NCT04803721|||CASE_CONTROL||PROSPECTIVE|||||||
33843348|NCT01291459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843349|NCT00449722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33843350|NCT02473705|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33843351|NCT06634823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843352|NCT06091293|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study has one arm. All participants will receive the NICO intervention.||||
33843353|NCT06619756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843354|NCT06552767|||CASE_CONTROL||PROSPECTIVE|||||||
33843355|NCT02060370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843356|NCT05774197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The STAMP+CBT application uses multi-media educational materials and survey algorithms assessing pain, medication usage, mood, stress, and sleep to improve pain management in this population. The primary objective is to determine the feasibility and acceptability during the 6-week study of the STAMP+CBT app (4-week intervention period and a 2-week post intervention period). Specifically, in this study 35 patients are enrolled and will be evaluated for their adherence to daily and weekly comprehensive symptom based self-assessments within the STAMP+CBT app.||||
33843357|NCT04225689|RANDOMIZED|PARALLEL||OTHER||NONE|Electronic random block-size randomisation will be performed by a researcher not involved in study recruitment. Allocation to study arm will be revealed to participants after provision of informed consent.|||||
33843358|NCT02619903|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Test versus control for dental treatment in attenuating exacerbations in COPD.|f|f|t|t
33843359|NCT02238821|||OTHER||PROSPECTIVE|||||||
33843360|NCT04844073|NA|SEQUENTIAL||TREATMENT||NONE||||||
33843361|NCT01357291|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843362|NCT03218748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843363|NCT01450384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843364|NCT06728995|||COHORT||RETROSPECTIVE|||||||
33843365|NCT03309540|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|University of Brussels Medical expertise and rehabilitation center IJsselstein|Level of evidence 1b, One way, RMANOVA, mixed, Pilot RCT, design|t|f|f|f
33843366|NCT02782312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843367|NCT04641676|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33843368|NCT04394429|||CASE_ONLY||OTHER|||||||
33843369|NCT05190783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the children and their parents are blinded from the material that will be used and the technique||t|f|f|f
33843370|NCT03764176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947124|NCT02886117|||CASE_ONLY||PROSPECTIVE|||||||
33947125|NCT01263652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947126|NCT03878576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33947127|NCT01258751|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947128|NCT04983927|||CASE_CONTROL||RETROSPECTIVE|||||||
33947129|NCT05705310|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|A separate researcher, not involved in the delivery of the intervention or assessment of outcomes, will generate the randomisation sequence which will be concealed in sealed opaque envelopes|A stepped-wedge cluster randomised controlled trial design will be employed involving random and sequential crossover of clusters from control to intervention until all clusters are exposed|f|f|f|t
33947130|NCT04765761|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient will be blinded to the study intervention as designated by the randomized group he/she would be allocated to. The investigator however will not be blinded to the group allocation.|Patients will be randomly allocated into 2-groups. Group-1 will be the 'PLMA with Introducer' group and group-2 will be the 'PLMA without Introducer' group.|t|f|f|f
33843371|NCT05189600|||COHORT||PROSPECTIVE|||||||
33843372|NCT05551325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Due to the nature of the intervention participants, care providers, and investigators will be able to ascertain group assignment.~Primary and secondary outcome assessors of urine 6-sulfatoxymelatonin levels, sleep scoring, and glucose levels via continuous glucose monitoring will be masked from group assignment.~Exploratory outcome assessors will be able to ascertain group assignment as they will be at the patient's bedside or in the medical record during the process of recording outcomes."|1:1 randomization of patients to control or intervention|f|f|f|t
33843373|NCT05692596|||CASE_ONLY||PROSPECTIVE|||||||
33843374|NCT05060549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33843375|NCT04900675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"After randomisation to the two light intervention study arms, it is only explained to the test persons that the influence of regular exposure to light in the morning is being investigated.~The control light condition comprises dim, reddish light. The reddish color tone in this light intervention should mask allocation to the study arm. A no-light intervention group (study arm 3) will be established as an additional control condition.~Data analysis will be carried out by a member of the project team who is blinded to study arm allocation."|placebo-controlled, randomized trial|t|f|f|t
33947131|NCT00028496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947132|NCT04798560|||COHORT||PROSPECTIVE|||||||
33947133|NCT05146193|||COHORT||PROSPECTIVE|||||||
33947134|NCT03911401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947135|NCT02873806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947136|NCT04548349|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843376|NCT02767336|NA|SINGLE_GROUP||||NONE||||||
33843377|NCT05049135|||OTHER||PROSPECTIVE|||||||
33843378|NCT06533059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947137|NCT06146010|||CASE_ONLY||OTHER|||||||
33947138|NCT02326909|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947139|NCT04668482|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33947140|NCT01020812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154422|NCT02394717|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843379|NCT06644924|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"AS MDI and placebo MDI will be blinded to all participants, study site staff, endpoint assessors, and sponsor personnel. Placebo MDI is designed to mimic the appearance, smell, and taste of AS MDI. No double-dummy will be used. Packaging and labelling of AS MDI and placebo MDI will be designed to ensure blinding.~The IRT will provide to the investigator(s) or pharmacist(s) the kit identification number to be allocated to the participant at the dispensing visits. Routines for this will be described in the IRT user manual that will be provided to each study site.~Randomized Ventolin Evohaler is open label. However, to reduce bias, dosing will be performed under the supervision of study staff, and spirometry assessments will be performed by different study personnel who will only enter the room after dosing is completed; thus, the study personnel conducting the spirometry assessments will be blinded to the identity of the study intervention."||t|t|t|t
33843380|NCT03377699|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|||||
33843381|NCT01555840|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33843382|NCT04548323|||COHORT||PROSPECTIVE|||||||
33843383|NCT00954187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33843384|NCT06727695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843385|NCT04148157|||COHORT||PROSPECTIVE|||||||
33843386|NCT03745742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843387|NCT06307106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33843388|NCT06331468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843389|NCT06633926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be masked to the study hypothesis. Research staff involved with data analysis will be blinded to group assignment until the database is locked. The statistician will remain blinded until the completion of the analysis.||t|f|f|t
33843390|NCT02555839|||COHORT||CROSS_SECTIONAL|||||||
33843391|NCT06729567|||COHORT||RETROSPECTIVE|||||||
33843392|NCT02810704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33843393|NCT04108143|NA|SINGLE_GROUP||OTHER||NONE||||||
33843394|NCT00198276|NA|SINGLE_GROUP||TREATMENT||NONE||MedPulser Electroporation with Belomycin||||
33843395|NCT04981795|||COHORT||PROSPECTIVE|||||||
33843396|NCT05452174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843397|NCT00736905|NON_RANDOMIZED|PARALLEL||||NONE||||||
33843398|NCT00383110|||COHORT||CROSS_SECTIONAL|||||||
33947141|NCT04281966|RANDOMIZED|PARALLEL||PREVENTION||NONE||The current project utilizes a randomized controlled cluster trial to assess the efficacy of the ASEP intervention and thereby theoretically test the efficacy of third-party-policing. Data will be collected from high schools that are in either socially disadvantaged areas or have students who reside in socially disadvantaged areas. A total of 69 high schools were identified as eligible for the Trial based upon measures of social disadvantage. The 69 eligible high schools were randomly assigned to participate in the ASEP (experiment) or business-as-usual (control) conditions. Young people from schools who take part in the ASEP (experiment) will be recruited from the experimental schools. Official data will be obtained about the young people (identified for those in the experimental condition who consent; de-identified for the young people in the control schools).||||
33947142|NCT05115682|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study will include a group of individuals with type 2 diabetes and a group of individuals with normal glucose tolerance. Each group of participants will complete either a morning (09:00) or an afternoon (16:00) exercise bout. After a one-week washout period, the participants will complete an additional exercise bout at the opposing time.||||
33947143|NCT04276493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741213|NCT03269032|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The study will have two phases, Phase 1 will study healthy subjects, who will follow a typical American diet for 2 weeks, and then cross-over to a Mediterranean-style diet for 2 weeks. Phase 2 will study subjects who have IBS-D. As above, they will first eat a typical American diet for 2 weeks, and then cross-over to a Mediterranean-style diet.|t|f|f|f
33741214|NCT05011903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741215|NCT00725426|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33741216|NCT02769143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741217|NCT00781326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741218|NCT06483360|||CASE_CONTROL||PROSPECTIVE|||||||
33741219|NCT05404438|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33741220|NCT04284423|||COHORT||PROSPECTIVE|||||||
33741221|NCT05257993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741222|NCT03280277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741223|NCT05419206|||OTHER||RETROSPECTIVE|||||||
33741224|NCT03073603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741225|NCT03570736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741226|NCT03309436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33741227|NCT03548844|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a a two-arm, open labelled, prospective, randomized phase III studies. Eligible patients with ypT0-1cN0 rectal cancer patients will be randomly assigned, in a 1:1 ratio, to receive either observation (local excision group) or complementary rectal excision (total mesorectal excision group).||||
33764529|NCT03139396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33764530|NCT02924324|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33764531|NCT03134014|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33764532|NCT01370005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764533|NCT00308932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764534|NCT01148862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764535|NCT00150384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764536|NCT00633919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764537|NCT05074355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764538|NCT01921881|NA|SINGLE_GROUP||||NONE||||||
33764539|NCT02473458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764540|NCT05549765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764541|NCT04238052|||COHORT||PROSPECTIVE|||||||
33764542|NCT01862822|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741228|NCT05734313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained clinical interviewers blind to treatment assignment will administer structured clinical interviews to assess primary outcomes of anxiety and depression symptom severity at each assessment. Time in Range will be calculated from CGM data by an analyst who is blind to assignment. Hemoglobin A1c (HbA1c) will be collected via mailed kits at each assessment and analyzed by a lab blind to assignment. Anxiety and Depression severity data will be measured longitudinally throughout the trial, at baseline, immediately post-intervention, and at 9- and 12-months post-randomization by independent assessors blind to the assignment.|There will be two arms in this trial, (1) The Unified Protocol for Cognitive Behavioral Therapy (UP-CBT) Intervention Arm paired with use of continuous glucose monitor (CGM) and (2) CGM only. The active comparison condition of CGM only allows for the evaluation of whether directly targeting emotional disorders with UP-CBT adds value beyond the state-of-the-art approach to glycemic management in Type 1 Diabetes. To the extent that the relationship between emotional disorders and diabetes is bidirectional, a common assumption across research studies in this area, the comparison condition should benefit anxiety and depression outcomes through improved glycemic control and diabetes self-management.|f|f|f|t
33741229|NCT02117570|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33843399|NCT05467293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Before the initiation of study run-in at Visit 1, each subject who provides written informed consent will be assigned a screening number. All screening numbers will be assigned in strict numerical sequence at a site and no numbers will skipped or omitted. Each subject who meets all the inclusion and none of the exclusion criteria at Visit 1 and Visit 2 will be assigned a randomization number at the end of Visit 2. The Interactive Web Response System (IWRS) will be used to assign all randomization numbers.|"multicenter, randomized, double-masked, placebo-controlled clinical study. Subjects will be randomized to one of the following treatment arms at Visit 2 (Day 1):~* 0.3% YP-P10 Ophthalmic Solution: 1 drop BID in each eye (N = \~80)~* 1% YP-P10 Ophthalmic Solution: 1 drop BID in each eye (N = \~80)~* YP-P10 Placebo Ophthalmic Solution (vehicle): 1 drop BID in each eye (N = \~80)"|t|t|t|f
33843400|NCT03588559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843401|NCT05877898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843402|NCT05334316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843403|NCT06484920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843404|NCT01837849|||CASE_CONTROL||PROSPECTIVE|||||||
33843405|NCT00322075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843406|NCT04743791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Dupilumab and placebo will be provided in identically matched 1.14 mL pre-filled syringes. To protect the blind, each treatment kit of 1.14 mL (dupilumab / placebo) glass pre-filled syringes will be prepared such that the treatments (dupilumab and its matching placebo) are identical and indistinguishable and will be labeled with a treatment kit number. The randomized treatment kit number list will be generated by Sanofi Regeneron||t|t|t|t
33843407|NCT06401070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843408|NCT06151899|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (Participant)|After the study is explained to mothers who meet the inclusion criteria and agree to participate in the study, their signatures on informed consent forms will be taken. Randomization will be random assignment to a control group or two intervention groups (1:1) with sequentially numbered, sealed, opaque envelopes containing randomly generated numbers after mothers have obtained informed consent. Randomization will be carried out via www.random.org using a table of random numbers.|t|f|f|f
33843409|NCT00691795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843410|NCT02135081|||COHORT||PROSPECTIVE|||||||
33843411|NCT02154464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843412|NCT00012831|||||PROSPECTIVE|||||||
33843413|NCT05661916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843414|NCT03633292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33843415|NCT04153149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843416|NCT02951520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843417|NCT03350932|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Children will not be aware about the type of comparison that will be made with the data; and they will not be aware in which group they will participate in.|"Two groups of children will be constituted: the first group, the control group, will have to perform a sensory imagination task about neutral facts. The second group, the food sensory imagination group, will have to perform a sensory imagination task foods."|t|f|f|f
33843418|NCT06345651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In both conditions the identical setup is used consisting of Neuronavigation, EEG and TMS. Only in the experimental condition the treatment will be EEG-informed. In the control condition the treatment will be applied indepentently of the EEG signal.|The study is a single-site randomized standard TMS therapy-controlled double-blind paral-lel-group design clinical trial.|t|f|t|t
33843419|NCT06116890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843420|NCT06295354|||COHORT||PROSPECTIVE|||||||
33843421|NCT03336359|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843422|NCT06191055|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33843423|NCT02280889|||COHORT||PROSPECTIVE|||||||
33843424|NCT06480344|||CASE_CONTROL||RETROSPECTIVE|||||||
33843425|NCT06374108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843426|NCT06242808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It's not possible to mask the participant, care provider, or investigator due to the nature of the study, people will know if they're receiving food resource coaching. However, the investigator analyzing data will not be aware of what group assignment number corresponds to each group.|Repeated-measures between-subjects randomized controlled trial|f|f|f|t
33843427|NCT00019175||||TREATMENT||||||||
33843428|NCT01905150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843429|NCT04206657|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843430|NCT06718361|||COHORT||PROSPECTIVE|||||||
33843431|NCT05243563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843432|NCT06328439|NA|SEQUENTIAL||TREATMENT||NONE||Cohort1: 7.5mg Cohort2: 15mg Cohort3: 30mg Cohort4: 45mg Cohort5: 60mg||||
33843433|NCT06601075|||OTHER||PROSPECTIVE|||||||
33764543|NCT05845476|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33764544|NCT01423071|||CASE_CONTROL||PROSPECTIVE|||||||
33843434|NCT06729398|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33843435|NCT06145477|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33947144|NCT02843282|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947145|NCT04893174|NA|SEQUENTIAL||TREATMENT||NONE||Cohort 1 : Low does UMC119-06-05 + Hyaluronic acid； Cohort 2 : High does UMC119-06-05 + Hyaluronic acid||||
33947146|NCT02929017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33947147|NCT06623032|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33947148|NCT02433015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33947149|NCT06694935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947150|NCT06118840|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|"Study participants, nurses acquiring for patients' consent and radiographers acquiring head computered tomograhy angiography exams will be blinded to the randomization as it is automatically performed after the exam has been acquired.~A Sham-AI for the automatic detection of intracranial aneurysms has been delicately designed to mimic the True-AI model with a sensitivity close to zero and a similar specificity to True-AI. Thereforem, the participating radiologists interpreting head computered tomograhy angiography exams will also be blinded to the allocation of the AI models."||t|t|t|t
33947151|NCT06510322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947152|NCT03035331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947153|NCT02491918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33947154|NCT05679401|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, controlled, randomised, multi-centre trial||||
33947155|NCT06297603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843436|NCT05444231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33843437|NCT06182774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843438|NCT05623059|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an unblinded pharmacokinetic (PK) study to determine optimal dosing for future studies. This study will start with a one-time dose and progress to twice daily dosing for 3 days, every 12 hours. Study cohort will be 9 subjects with asthma. DHEA dose will be 50 mg via slow release capsules. Endpoints will be serum DHEA and DHEA-S levels at 10, 20, 30, 60 min \& 2, 4, 6, 8, 12h after administration. After a one-week washout period, the protocol will be repeated using 100 mg of SR-DHEA.||||
33843439|NCT01334424|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33843440|NCT06584357|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33843441|NCT06446687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843442|NCT04427943|||COHORT||PROSPECTIVE|||||||
33843443|NCT05860582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843444|NCT00656708|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843445|NCT03368742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843446|NCT05157243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants will be randomized 1:1 to receive 600mg NTZ or placebo twice daily for 5 days.|t|t|t|t
33843447|NCT04885985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843448|NCT02179567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843449|NCT06704334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843450|NCT06204809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843451|NCT06223360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843452|NCT01213953|||CASE_ONLY||PROSPECTIVE|||||||
33843453|NCT04566562|||COHORT||PROSPECTIVE|||||||
33843454|NCT01630447|||CASE_ONLY||PROSPECTIVE|||||||
33843455|NCT04975308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843456|NCT05420233|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843457|NCT05316116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843458|NCT04734652|RANDOMIZED|PARALLEL||TREATMENT||NONE||"80 participants for the Intervention Arm ART regimen which is a fixed-drug combination of a single tablet co-formulated regimen containing Bictegravir 50mg Emtricitabine 200mg and tenofovir alafenamide 25mg (BIC/FTC/TAF; Biktarvy®) that will be taken twice a day during rifampicin-containing TB treatment and 2 weeks after stopping TB treatment, thereafter the BIC/FTC/TAF single tablet co-formulation will be taken once daily.~40 participants in the Control ARM: Dolutegravir 50mg /Lamivudine 300mg/ Tenofovir 300mg (TLD- fixed-drug combination single tablet) plus Dolutegravir 50mg evening dose during TB treatment and for two weeks after completion of TB treatment, then TLD once daily thereafter- as per Standard of Care (SOC)"||||
33843459|NCT05329194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843460|NCT04050657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33843461|NCT00468559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843462|NCT06710886|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The participants will listen to the brief music demo together after completing the pre-assessment. After the demo is completed, participants will listen to the 15-minutes of music. For those who opt out of listening to the 15-minutes of music, they will be asked to complete the post-assessment. Following the 15-minute music session, the remaining participants will be asked to complete the post-assessment.||||
33843463|NCT01661608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843464|NCT03878277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843465|NCT01333813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843466|NCT05755906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843467|NCT03106454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33843468|NCT00776477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843469|NCT02566200|||COHORT||PROSPECTIVE|||||||
33843470|NCT04412928|||COHORT||RETROSPECTIVE|||||||
33843471|NCT00569842|||CASE_ONLY||PROSPECTIVE|||||||
33843472|NCT00252109|||||RETROSPECTIVE|||||||
33947156|NCT01406548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947157|NCT06058013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor will also be blinded||t|t|t|t
33947158|NCT05136989|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33947159|NCT05169567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154423|NCT06289452|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34154424|NCT02528682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154425|NCT04118894|||OTHER||PROSPECTIVE|||||||
34154426|NCT05286216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34154427|NCT03125772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154428|NCT03194113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154429|NCT02173587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34154430|NCT05586841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154431|NCT03986684|||OTHER||CROSS_SECTIONAL|||||||
33843473|NCT03793036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgeons, anesthetists, and outcome assessors were masking to the treatment allocation. Masking was possible because group allocation was performed by a nurse from the surgical ward, and the attending surgeon and anesthetist welcomed the participants at the operating room the next morning without knowledge of the type of intervention. The outcome study were evaluated by independent assessors who were also masked because they evaluated patients after surgery on a daily base during hospital stay without knowledge of the type intervention.|The diagnostic protocol for colon cancer was performed in patients at the surgery department. The patients with diagnosed colon tumor were prepared for the surgical procedure. After that, patients were examined to a preoperative anesthetic visit. During the visit, participants were assessed according to eligibility for enrollment in the study. The participants who have met the eligibility criteria have explained the nature of the study protocol. Those who agreed to participate in the study were randomized to one of two study groups for the duration of the study.|f|t|t|t
33843474|NCT00650884|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843475|NCT01141153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843476|NCT05163769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843477|NCT00759252|||COHORT||CROSS_SECTIONAL|||||||
33843478|NCT06208449|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843479|NCT06380296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843480|NCT04533100|||OTHER||PROSPECTIVE|||||||
33843481|NCT06254612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843482|NCT05152953|||COHORT||CROSS_SECTIONAL|||||||
33843483|NCT00734357|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843484|NCT06419374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843485|NCT02604888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843486|NCT01805752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843487|NCT05169333|||COHORT||OTHER|||||||
33843488|NCT00655525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843489|NCT06417775|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33843490|NCT01269723|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33843491|NCT04702321|||COHORT||OTHER|||||||
33843492|NCT04181372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843493|NCT05609903|||COHORT||RETROSPECTIVE|||||||
33843494|NCT03477487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Ascending dose-ranging study||||
33843495|NCT05556096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a treatment study with 2 parallel intervention groups. The study is blinded for sponsor staff, sponsor designees, investigative site personnel, other staff directly associated with the conduct of the study, and study participants.|t|f|t|f
33843496|NCT01075958|||||CROSS_SECTIONAL|||||||
33843497|NCT03073252|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|Care provider will randomize participants and keep the participant, investigator and outcomes assessor blinded to the randomization.|subject will consume either the 13g or 30g protein breakfast in a randomized cross-over manner|t|f|t|t
33843498|NCT03652727|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843499|NCT05898841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843500|NCT03685175|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843501|NCT06438120|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants will receive chatbot-based positive psychology exercises including positive introduction, personal strengths, using strengths, three good things, gratitude letter/visit, hope and optimism, active/constructive responding, and savoring.||||
33843502|NCT01674829|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843503|NCT06618794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33843504|NCT03442153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The product in not drug or medical device (but a dietary supplement). There are 76 participants divided inti 2 groups : experimental group (38) and Placebo group (38). The period of the intervention: 90 days|t|f|t|f
33843505|NCT04224857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|matching placebo|Study participants will be randomized to either receive AMT-101 or placebo|t|f|t|f
33843506|NCT00005927|||COHORT||PROSPECTIVE|||||||
33843507|NCT04891705|||OTHER||PROSPECTIVE|||||||
33843508|NCT06211322|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33843509|NCT04672785|||COHORT||PROSPECTIVE|||||||
33843510|NCT00095056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843511|NCT03014479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843512|NCT02442089|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33843513|NCT04811014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843514|NCT06675825|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33843515|NCT05350280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843516|NCT03464851|||COHORT||PROSPECTIVE|||||||
33843517|NCT04337541|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The participants recruited are people working outside of their home, who have not previously been infected with COVID-19 and who do not wear facial masks (e.g. healthcare personnel) when working. They will be randomized for~1. Normal behavior according to the authority's recommendations or~2. Normal behavior according to the authority's recommendations and use of facial masks~Participants will be instructed in using the facial mask consistently when outside their home (and at home when receiving visits from others. The instruction is given in writing and via an instruction video. The participants will be contacted once weekly to optimize compliance. It will be registered if the participants are diagnosed with COVID-19. Participants will perform antibody screening at study start and end. Participants, who are not tested positive for COVID-19 in the study period will perform a swab self-test if experiencing symptoms or when the study ends (instruction video)."||||
33843518|NCT02654353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843519|NCT06252753|||COHORT||OTHER|||||||
33843520|NCT06729710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843521|NCT04579783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843522|NCT04730141|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||quasi-experimental study||||
33843523|NCT06453070|||OTHER||CROSS_SECTIONAL|||||||
33843524|NCT05896384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843525|NCT01562041|NA|SINGLE_GROUP||OTHER||NONE||||||
33843526|NCT03714087|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One historic control group (UDEA1)comparing with intervention group (UDEA2) ( before and after)|f|f|t|f
33843527|NCT04048902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843528|NCT03952598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843529|NCT05202873|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33843530|NCT04828837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843531|NCT05714124|||COHORT||CROSS_SECTIONAL|||||||
33843532|NCT04246021|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a nonrandomized, single arm, open-label study stratified by iron-deficiency status.||||
33843533|NCT04734743|NA|SINGLE_GROUP||OTHER||NONE||||||
33843534|NCT03055429|NA|SINGLE_GROUP||OTHER||NONE||||||
33843535|NCT06728384|||COHORT||PROSPECTIVE|||||||
33843536|NCT05155332|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843537|NCT06727942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized into two groups: the intervention group and the control group. All participants will exercise on the Virtuix Omni 360-degree self-paced, non-powered treadmill-simulator in the lab for 5-weeks (2 days/week, 30 minutes/session, 10 sessions total. The treadmill-simulator is a first-of-its-kind motion platform on which an individual can walk and run at a self-paced speed in 360 degrees without risk of falling or colliding with other people. The V-TARGET intervention group will self-pace their locomotor action (walking/running) on the Omni treadmill-simulator while they wear the Pico Neo 2 head-mounted display (HMD) headset and use the Neuro Rehab VR XR Therapy system to experience daily activity exercises/games, including Retail Therapy, Explore (gait training), Lunchtime Adventure, and Nature Walk. The control group will not do any VR exercise but will only complete the pre-post and 1-month follow-up assessment upon signing up the study.|t|f|f|f
33843538|NCT00619749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33843539|NCT05936151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase 2b||t|f|t|f
33843540|NCT05527262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843541|NCT05702814|||CASE_CONTROL||RETROSPECTIVE|||||||
33843542|NCT01280357|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33843543|NCT06027671|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The investigators will perform individual randomization blocked by the correctional facility. Study staff will open numbered envelopes with the allocation following enrolment. Participants will be randomized 1:1:1:1 to one of the study arms using sequential envelopes with study arm determination sealed inside. Randomization will be stratified by study site and by sex. The randomization lists for each site/sex combination will be generated through randomly permuted blocks of four and eight study assignments with an equal number of group assignments within each block. Study assignments will be masked to staff performing outcome assessments (in-person and telephonic interviews) and the investigators until all outcome data have been collected.|This is a hybrid type 1 effectiveness-implementation study with a factorial design to compare care as usual, Full-SPARCS, ART-SPARCS, or Group-SPARCS. The investigators will recruit participants from correctional facilities in the Department of Correctional Services (DCS) Gauteng Region, South Africa. Study activities for the intervention arm will be delivered in community venues near to where participants live in Tshwane District, Ekurhuleni District, and City of Johannesburg.|f|f|t|t
33843544|NCT03231241|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33843545|NCT05654142|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33843546|NCT06728202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective randomized (1:1) clinical trial study formed of 2 competitive groups where 46 implants will be placed in 2 groups (23 for each group) to compare the Gained bone width in patients with atrophic maxillae (Horizontal defect) .|f|f|f|t
33843547|NCT02533024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843548|NCT03934372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843549|NCT01926093|||COHORT||PROSPECTIVE|||||||
33843550|NCT05890859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843551|NCT04531826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843552|NCT02491476|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843553|NCT06350760|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||To-arm interventions are carried out, measuring at the pre-intervention moment and at the post-intervention moment.|t|f|f|t
33843554|NCT00359983|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947160|NCT00261352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33947161|NCT06722105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Multi-center, three-arm, randomized, double-blind, placebo-controlled trial|t|f|t|f
34050756|NCT03377270|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|outcomes assessor (those completed the swallow studies, those scoring)|Randomized-controlled trial with 2 arms (intervention and control)|f|f|f|t
34050757|NCT00675428|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154432|NCT04216576|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34154433|NCT00634062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154434|NCT04657783|||COHORT||PROSPECTIVE|||||||
34154435|NCT02687581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154436|NCT02104947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154437|NCT04256252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741230|NCT06131918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not be given information about the medication.|Four parallel treatment arms will be included.|t|f|f|f
33741231|NCT01045447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741232|NCT02897804|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33741233|NCT06536075|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741234|NCT02172209|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741235|NCT05035082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741236|NCT04589065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741237|NCT00460512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741238|NCT05233072|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741239|NCT01504438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741240|NCT04363905|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double (Participant, Outcomes Assessor)||t|f|f|t
33741241|NCT02515162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741242|NCT00319423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33843555|NCT04642534|||COHORT||PROSPECTIVE|||||||
33843556|NCT02893787|||OTHER||PROSPECTIVE|||||||
33843557|NCT06224283|||COHORT||RETROSPECTIVE|||||||
33843558|NCT06728306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33843559|NCT02277184|NA|SINGLE_GROUP||OTHER||NONE||||||
33843560|NCT00801762|||||PROSPECTIVE|||||||
33843561|NCT02879526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843562|NCT00232453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843563|NCT06140836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843564|NCT04480736|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33843565|NCT05849480|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843566|NCT02771821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843567|NCT05877716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843568|NCT05543707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843569|NCT02299089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843570|NCT06727474|||COHORT||PROSPECTIVE|||||||
33843571|NCT01955408|||COHORT||PROSPECTIVE|||||||
33843572|NCT06506422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded|double-blinded randomized placebo control trial|t|f|t|t
33843573|NCT01427725|||COHORT||PROSPECTIVE|||||||
33843574|NCT01205854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843575|NCT01969682|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843576|NCT01460862|||COHORT||RETROSPECTIVE|||||||
33843577|NCT02260713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843578|NCT02361268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843579|NCT06347796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843580|NCT05982795|||COHORT||PROSPECTIVE|||||||
33843581|NCT06679621|RANDOMIZED|PARALLEL||OTHER||NONE||The randomized design is for Aim 3 of our study.||||
33843582|NCT01844960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843583|NCT05850728|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pharmacologically-guided adaptive design, in which the dose is increased or decreased if needed, based on results from prior participant arms||||
33843584|NCT06151093|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33843585|NCT06003842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two different Kinesio® Tex taping techniques were applied to the participants. One of these applications is for the upper trapezius muscle and the other is a taping technique applied to support the correct postural posture and trapezius muscle. Banding was applied bilaterally.|f|f|f|t
33843586|NCT06648928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843587|NCT06673966|||COHORT||PROSPECTIVE|||||||
33843588|NCT04875299|||COHORT||PROSPECTIVE|||||||
33843589|NCT01514708|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843590|NCT06297226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843591|NCT00407108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843592|NCT00649636|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33843593|NCT06432972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843594|NCT05986643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random computer generation|To maintain the gold standard approach of complete randomisation but we have tightened the inclusion criteria to stipulate both a history of falls and freezing of gait (FoG).|f|f|t|f
33843595|NCT04076592|||COHORT||PROSPECTIVE|||||||
33843596|NCT03494153|||COHORT||PROSPECTIVE|||||||
33843597|NCT00932542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154438|NCT05192434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study personnel who administer survey assessments will be blinded to study participants' assignment to the expressive writing group (treatment) or the neutral writing group (control).|Our concurrent nested mixed methods RCT will test the efficacy of addressing trauma as a potent trigger of substance use and psychological comorbidity through Expressive Writing (EW) among WWID receiving Contingency Management (CM). We will enroll 360 WWID who initiate PrEP. After a run-in period, participants will be randomized to either: 1) EW+CM (n=180); or 2) Neutral Writing+CM (n=180).|f|f|t|f
34154439|NCT01603095|||CASE_ONLY||PROSPECTIVE|||||||
34154440|NCT04842981|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154441|NCT03074682|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33843598|NCT01249027|||COHORT||PROSPECTIVE|||||||
33843599|NCT00241553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33843600|NCT06398301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843601|NCT00538317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843602|NCT02108964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843603|NCT04606186|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Study participants, meeting the inclusion criteria and not fulfilling the exclusion criteria, will be assigned to the study group or to the control group using a randomization plan. Randomization plan will be generated by the Center for Clincal Studies of the University Hospital of Erlangen. The lab manager will prepare storage boxes, in which exactly 168 lozenges will be stored. Half of the boxes will contain test-lozenges (study group), half or them will contain placebo-lozenges (control group). The storage boxes for the test and the placebo group will be identical and blinded. The storage boxes will be labelled with pseudonyms in accordance to the randomization plan generated by the Center for Clinical Studies. Therefore, study participants will not have knowledge of the group affiliation. The collection of the samples and the measuring of the clinical parameters will be performed by one orthodontist, who will be blinded to the randomization of the study participants.|Monocentric, randomized, double-blind, placebo-controlled, clinical study|t|f|t|f
33843604|NCT05412563|||COHORT||PROSPECTIVE|||||||
33843605|NCT03269682|||CASE_ONLY||CROSS_SECTIONAL|||||||
33843606|NCT05914870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33843607|NCT03940703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843608|NCT03099564|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33843609|NCT00637754|||COHORT||PROSPECTIVE|||||||
33843610|NCT01949389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843611|NCT06651359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050758|NCT03783403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050759|NCT02778074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050760|NCT05567211|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33843612|NCT06042413|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A total of 1000 participants who are identified as higher risk (≥2.5%) for 30-day mortality and MACCE based on the risk prediction algorithm will be screened and randomized (1:1) to the intervention group (Group A, n=500). The control group (Group B) will receive standard of care (n=500). Based on the preoperative MoCA score, patients will be stratified into normal baseline cognition (MoCA score \>= 26) or baseline cognitive dysfunction (MoCA score of 23-25, inclusive) for randomization to balance the baseline cognitive function between the standard of care group and intervention group.~All patients scheduled for IONM from Aim 1 will be screened for Aim 2. Eligible participants (estimated \~50%, n=500) will be stratified according to their Aim 1 intervention groups and prospectively randomized to either standard of care intraoperative intervention (n=250) (Group C) or proactive bundled interventions (Group D, n=250)."||||
33843613|NCT05905159|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33843614|NCT02770417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843615|NCT02589275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843616|NCT00754364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843617|NCT05419024|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33843618|NCT03882177|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843619|NCT06718647|||COHORT||RETROSPECTIVE|||||||
33843620|NCT01228331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843621|NCT04939701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843622|NCT03321305|||CASE_ONLY||CROSS_SECTIONAL|||||||
33843623|NCT02992691|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843624|NCT06727708|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial uses a randomised parallel group design with minimisation to ensure balanced allocation based on age, gender and baseline handgrip strength. Participants will be assigned to one of two intervention groups, \&#39;Tone Your Body\&#39; or \&#39;Boost Performance\&#39;. Each group follows a 12-week BioCircuit training programme designed to improve physical fitness, muscle strength and body composition. Both programmes include strength and endurance exercises in a circuit format.||||
33843625|NCT02731144|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843626|NCT02260323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33843627|NCT05850598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843628|NCT00471458|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33843629|NCT06405568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization will be concealed to the investigators throughout the trial; the investigators will not take part in the assessments or intervention delivery. The randomization will be concealed to study staff and participants until informed consent and baseline data are obtained. Study staff will be unblinded to group allocation upon randomization to enable delivery of the intervention arm and control arm corresponding materials, whereas the randomization will remain concealed to participants. To support blinding, all participants will be informed they are being enrolled in a study investigating ways to promote PA and will be kept blind to the fact that the intervention arm receives more materials than the control arm, and thus all (including participants allocated to the control arm) will receive materials (i.e., a copy of PA recommendations). Moreover, we do not anticipate participants to have contact with participants of the other arm.|The proposed study is a parallel-arm randomized controlled trial. Individuals enrolled in the Ontario Breast Screening Program for High-Risk Screening will be invited by mail to contact research staff who will obtain informed consent. Individuals who self-report engaging in \>150 minutes of moderate-to-vigorous intensity physical activity (PA) each week or a condition that makes it unsuitable for participation in this study (e.g., hypertension) will be excluded. Participants will receive a copy of PA recommendations plus a PA motivation package (intervention arm), or just a copy of PA recommendations (control arm); the control arm will receive the PA motivation package after study completion. All participants will complete primary (PA) and secondary (quality of life, BMI) outcome measures at baseline (pre-randomization) and after six weeks online. All outcomes will be analyzed according to intention-to-treat principles according to their randomized allocation and performed using SPSS.|t|f|t|f
33843630|NCT02330289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33843631|NCT04127500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33843632|NCT03892252|||CASE_CONTROL||PROSPECTIVE|||||||
33843633|NCT05855135|NA|SINGLE_GROUP||TREATMENT||NONE||"Single arm, prospective, multicenter study of 300 subjects that will establish that the device can appropriately sense and convert episodes of induced VF on the table in the implant procedure room, spontaneous episodes of VT/VF that occur during the study follow-up period, and ensure that the inappropriate shock rate is not unacceptably high."||||
33843634|NCT05917665|||CASE_CROSSOVER||PROSPECTIVE|||||||
33843635|NCT03215862|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33843636|NCT06352099|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33843637|NCT00596700|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33843638|NCT05145049|||CASE_ONLY||PROSPECTIVE|||||||
33843639|NCT04193436|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33843640|NCT04215484|||CASE_CONTROL||PROSPECTIVE|||||||
33843641|NCT01541098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33843642|NCT05316272|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Masking of the study pill (DHEA or placebo) is described as noted above. Exercise cannot be masked.|Two-by-two crossed design of DHEA versus control and exercise versus no exercise control.|t|f|t|t
33843643|NCT06153355|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33843644|NCT06071897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843645|NCT04851639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||any patient with advanced or metastatic prostate cancer||||
33843646|NCT06728592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154442|NCT00153192|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34154443|NCT02188849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154444|NCT00375518|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34154445|NCT03390309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154446|NCT03821116|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34154447|NCT01868386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154448|NCT03632746|||CASE_ONLY||PROSPECTIVE|||||||
34154449|NCT04029103|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154450|NCT05977829|||COHORT||RETROSPECTIVE|||||||
34154451|NCT02073019|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34154452|NCT03300986|||COHORT||PROSPECTIVE|||||||
34154453|NCT05656482|||COHORT||PROSPECTIVE|||||||
34154454|NCT04777292|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34154455|NCT02128074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843647|NCT03729401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor)||f|f|t|t
33843648|NCT00733928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843649|NCT05242952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843650|NCT06371638|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33843651|NCT01350180|||COHORT||PROSPECTIVE|||||||
33843652|NCT05211947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843653|NCT06336356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843654|NCT01638429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843655|NCT02978378|||COHORT||PROSPECTIVE|||||||
33843656|NCT05474430|||COHORT||CROSS_SECTIONAL|||||||
33843657|NCT00421031|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33843658|NCT05465083|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843659|NCT06703229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33843660|NCT05798793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843661|NCT03329859|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33843662|NCT02449369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843663|NCT04716270|||CASE_ONLY||PROSPECTIVE|||||||
33843664|NCT05846646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843665|NCT04602559|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multicenter, interventional, open-label, prospective exploratory study in a population of patients with primary or secondary pelvic and/or genital lymphedema||||
33843666|NCT06144970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33843667|NCT00818779|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843668|NCT02218606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843669|NCT05457725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participant and outcome assessor are not aware of the experimental vs. control|Between subject design (experimental vs. control)|t|f|f|t
33843670|NCT04629573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843671|NCT06502691|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843672|NCT02892695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843673|NCT04490759|||COHORT||PROSPECTIVE|||||||
33843674|NCT03054051|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843675|NCT02163005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843676|NCT05518617|||COHORT||CROSS_SECTIONAL|||||||
34050761|NCT06305455|||COHORT||RETROSPECTIVE|||||||
33843677|NCT06347874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual doing the outcome assessments will be blinded.|This is a randomized prospective controlled trial. This will be single blinded trial. The individual doing the outcome assessments will be blinded. Randomization will be 1:1.|f|f|f|t
33843678|NCT03303768|||COHORT||PROSPECTIVE|||||||
33843679|NCT04389203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Unilateral tubal disconnection and spontaneous pregnancy||||
33843680|NCT06723158|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized group allocation (1:1 block size of 2 for randomization)||||
33843681|NCT04431167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher responsible for performing the blood flow measurement will be blinded to the allocation of groups|Experimental group and no intervention group (usual care group)|f|f|f|t
33843682|NCT06073002|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33843683|NCT05170633|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33843684|NCT05194332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843685|NCT03002220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843686|NCT06550089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843687|NCT00712140|RANDOMIZED|||TREATMENT||||||||
33843688|NCT06715150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843689|NCT04245059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843690|NCT06729138|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33843691|NCT03370744|||CASE_CONTROL||PROSPECTIVE|||||||
33843692|NCT02797080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843693|NCT06402565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator-Blinded Study|A total of 40 subjects ((25 in the treatment group and 15 in the control group) will be randomized to receive either NOX1416 + SOC or Placebo + SOC.|f|f|f|t
33843694|NCT06303505|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843695|NCT05640999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843696|NCT05447650|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33843697|NCT00555269|||||PROSPECTIVE|||||||
33843698|NCT01189175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843699|NCT06487624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843700|NCT04623177|||COHORT||PROSPECTIVE|||||||
33843701|NCT06438263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843702|NCT06240598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective study for biospecimen collection during standard of care procedures and during second look laparoscopy (SLL), which constitutes the only investigational procedure in this study.||||
33843703|NCT06723197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843704|NCT01072630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050762|NCT05607680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050763|NCT06684236|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34050764|NCT02137850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076330|NCT04248946|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|In the MRI stream all participants will receive anodal, cathodal, and sham (placebo) tDCS sessions in a randomised order. In the Bedside stream participants will receive active tDCS (either anodal or cathodal) and sham sessions also in a randomised order. A researcher not involved in data collection or analyses will programme the stimulator to deliver the specific polarity needed in each session in a double-blind manner. Sham tDCS will be delivered according to published guidelines: this mimics the physical sensations of active stimulation but does not have a neuromodulatory effect|This is a double-blind randomised crossover feasibility study of tDCS in a small cohort of PDOC individuals. The study is divided into two streams to accommodate differences in the resources available across recruitment sites: 1. MRI stream, which will include MRI and electrophysiology assessments; this is available to patients receiving care at the Wellington Hospital in London only. 2. Bedside stream, which will include electrophysiology assessments only, available to patients in specialist units at NHS (National Health Service) and non-NHS sites|t|t|t|t
33947162|NCT06380985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The identity of ApBM and Sham will not be known to investigators or patients. To maintain the blind, the participant and the research coordinator (naïve to ApBM) administering the participant's training will be blind to whether 1 or 2 is ApBM or Sham. The research coordinator will receive the patient assignment from statistical software at time of randomization. The key that determines assignment of ApBM or Sham to condition 1 or 2 will be known by an addiction research program affiliate PI otherwise uninvolved in the current study. They will document this key in a locked electronic file. The study blind will be broken on completion of the study and after the study database has been locked."|This will be a Phase II double-blind, randomized, sham-controlled clinical trial.|t|f|t|f
33947163|NCT02958449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947164|NCT05889780|RANDOMIZED|FACTORIAL||TREATMENT||NONE|It is not possible to mask staff or participants in this trial.|In the proposed study, infusion patients that screen positve for food insecurity that enroll in the study will be randomized to receive one of three evidence-based food security programs: 1) Pantry only - Referrals to an onsite food pantry or receipt of emergency food boxes if the onsite pantry is not open by 2024, 2) Pantry + nutritious no-prep, ready-to-eat meals, or 3) Pantry + $75 grocery vouchers for three-months.||||
33947165|NCT04201223|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947166|NCT06117163|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A type 2 hybrid effectiveness-implementation trial with a stepped-wedge design||||
33947167|NCT05147831|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33947168|NCT05231785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947169|NCT05962463|||COHORT||PROSPECTIVE|||||||
33947170|NCT02045940|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33947171|NCT02654405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947172|NCT04116073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947173|NCT03730259|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947174|NCT05333432|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study is a non-comparative multicenter prospective cohort. It follows annually two population groups according to their initial panel of PC predisposing genes. Therefore, it is not randomised.The follow-up is the same for all the participants: it is non-comparative.~Participant is benefiting of a substantial and close medical surveillance during 3 years: each participant undergoes 4 annual mpRMI of which 2 are added by the research."||||
33947175|NCT02924922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947176|NCT00014066||||TREATMENT||||||||
34076331|NCT03559504|||CASE_ONLY||PROSPECTIVE|||||||
34076332|NCT04833517|||COHORT||PROSPECTIVE|||||||
34076333|NCT05610488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076334|NCT06521047|||OTHER||OTHER|||||||
34076335|NCT00313469|||||PROSPECTIVE|||||||
34076336|NCT06296446|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34076337|NCT03498313|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double-blind|Crossover 3-condition placebo-controlled trial|t|f|t|f
34076338|NCT00225186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076339|NCT01604889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843705|NCT05248126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"This protocol aims to compare two different ways of engaging with the patient and teaching. The notion of blinding per se is not adapted to this protocol, which is carried out, for all practical purposes, in an open fashion. Nevertheless, the Zelen randomisation procedure, which aims to maintain the comparator arm ignorant of the existence of the experimental arm in order to avoid resentful demoralisation effects, may also result in a partial blinding effect."|"This prospective, randomized (1:1), controlled, pilot trial with a single-Zelen consent procedure will compare changes in quality of life, asthma control, lung function and health resource consumption between one group of patients with asthma participating in a classic treatment education program (the standard education arm) with a similar, second group of patients participating in a novel, chatbot-guided treatment education program (the Vik arm)."||||
33843706|NCT05864833|||COHORT||PROSPECTIVE|||||||
33843707|NCT05083390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843708|NCT04419298|||COHORT||PROSPECTIVE|||||||
33843709|NCT05665504|||CASE_ONLY||PROSPECTIVE|||||||
33843710|NCT06727812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843711|NCT01952067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843712|NCT03606200|||COHORT||OTHER|||||||
33843713|NCT00954980|||COHORT||PROSPECTIVE|||||||
33843714|NCT06250244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843715|NCT00440921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33843716|NCT04425304|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33843717|NCT00667147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843718|NCT05349227|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Wait list control trial in which up to 625 patients will be randomized to receive either 6-months of digital coaching immediately followed by 6-months of monitoring or 6-months of monitoring followed by 6-months of digital health coaching. All participants will receive 12 months of patient reported outcomes collection and activity tracking via wrist-worn devices, as well as microbiome collection at baseline and month 6 only.||||
33843719|NCT06151574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843720|NCT04831073|||COHORT||RETROSPECTIVE|||||||
33843721|NCT00993005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843722|NCT06104813|||OTHER||OTHER|||||||
33843723|NCT04958239|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843724|NCT06511453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843725|NCT03621462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843726|NCT00673036|||COHORT||PROSPECTIVE|||||||
33843727|NCT02051959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947177|NCT02278874|||COHORT||PROSPECTIVE|||||||
33947178|NCT04730024|||CASE_ONLY||PROSPECTIVE|||||||
33947179|NCT05003206|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947180|NCT06216600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study investigators and outcomes assessors will be blinded.|Type 1 hybrid study randomizing particpants 1:1 to either WE RISE or control (list of resources). Followed by one arm observational study.|f|f|t|t
33947181|NCT03198559|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Single arm, single site,||||
33947182|NCT02463526|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33843728|NCT06708572|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Protocol of cohort study will be conducted on 40 infants with the final diagnosis of biliary atresia type 3 (supported by the liver histology and intra-operative findings) divided into two groups one of them is for GCSF after Kasai operation, and the other group will be without GCSF therapy and their data will be collected retrospectively.||||
33843729|NCT00704899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843730|NCT05172960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947183|NCT03975465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Researchers assessing the outcomes will not know the arm to which the subject was randomized.|Subjects will be randomized to an 8-week program of either Expiratory Muscle Strength Training (EMST) or Standard Care in order to examine the impact of EMST on swallowing function|f|f|f|t
33843731|NCT06218654|||COHORT||PROSPECTIVE|||||||
33843732|NCT06502327|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843733|NCT01575600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33843734|NCT06164587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843735|NCT04757662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843736|NCT02837003|||COHORT||PROSPECTIVE|||||||
33843737|NCT06251284|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the real substance (saline nasal spray).|A cross-over design will be employed by giving a saline nasal spray introduced either as oxytocin or as saline.|t|f|f|f
33843738|NCT06709404|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33843739|NCT02005770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843740|NCT00669279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947184|NCT03151200|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33947185|NCT03679117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized trial in which participants are assigned to mindfulness training or treatment as usual.|f|f|f|t
33947186|NCT05620186|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Registry, no comparison||||
33947187|NCT03813316|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Model Description by adding another sentence as follows: Randomization with be cluster-based by investigator to either standard care or specific individualized training for adding DPP-4 inhibitors and/or SGLT2 inhibitors to metformin"||||
33947188|NCT03982381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment is blinded to outcome analysis team, until after database lock|Prospective randomized, open label, blinded endpoint design (PROBE). Multicenter study.|f|f|f|t
33947189|NCT05660070|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33947190|NCT00489411|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33947191|NCT06116916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947192|NCT01560806|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33947193|NCT05028569|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33947194|NCT01958944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947195|NCT06382428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947196|NCT02064491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947197|NCT04115202|||COHORT||PROSPECTIVE|||||||
33947198|NCT04274985|||OTHER||PROSPECTIVE|||||||
33947199|NCT06445959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947200|NCT01491802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33947201|NCT03937531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects will be enrolled consecutively during either the surgical preoperative evaluation or in the preoperative holding area before surgery. Participation in the study would not alter their surgical treatment plan. Randomization will be determined through computer-generated random number blocks of six. A sequentially numbered, opaque, sealed envelope will be opened for each subject after the recruitment and consenting process, and subjects will be assigned to one of two groups: retrograde fill void trial (RVT) vs spontaneous void trial (SVT).||||
33947202|NCT02682706|||COHORT||PROSPECTIVE|||||||
33947203|NCT04392531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947204|NCT06005792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947205|NCT06379854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947206|NCT06567340|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Trial statisticians will be blinded to allocation.|A pragmatic, single-blind, multi-site, parallel group cluster RCT. Cluster randomisation will be used to allocate Talking Therapies Teams and their patients to either intervention or usual care arms. In the experimental arm, treatment selection will be guided by an AI tool (StratCare app). In the USC arm, treatment will be selected following usual clinical practice and guidelines.|t|f|f|t
33947207|NCT01390376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947208|NCT04705259|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|Education intervention where the facilities will be made aware of best practice guidelines and protocols with respect to antibiotic prescribing|Stepped wedge randomised control study||||
33947209|NCT02285582|||CASE_ONLY||OTHER|||||||
33947210|NCT04111913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947211|NCT01559649|||COHORT||PROSPECTIVE|||||||
33947212|NCT05637931|||CASE_CONTROL||RETROSPECTIVE|||||||
34076340|NCT00696345|||CASE_CONTROL||PROSPECTIVE|||||||
33843741|NCT01341054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843742|NCT03397043|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants blinded to the protein dose consumed in a given metabolic trial|||||
34076341|NCT03110133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34154456|NCT02793791|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154457|NCT00337090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33843743|NCT01173276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843744|NCT03525145|||COHORT||PROSPECTIVE|||||||
33843745|NCT05421663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843746|NCT04224012|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843747|NCT03047395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843748|NCT01886651|||COHORT||RETROSPECTIVE|||||||
33843749|NCT04120571|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Single centre - Crossover randomised controlled trial' design|t|f|f|f
33843750|NCT06727591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843751|NCT03596762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843752|NCT06622655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947213|NCT06408103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluators responsible for data collection will not have knowledge of the cognitive status or the assignment of participants to study groups. Additionally, the person responsible for subjecting the data to different statistical tests will not be aware of the participants' assignment to the study.||f|f|t|t
33947214|NCT02500732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug was encapsulated in opaque capsules by study personnel not involved in the day to day operations of the study.||t|t|t|t
33947215|NCT06403540|||CASE_ONLY||PROSPECTIVE|||||||
33947216|NCT04327531|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33947217|NCT06429722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor will also be blinded||t|t|t|t
33947218|NCT02226276|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947219|NCT05998304|NA|SINGLE_GROUP||OTHER||NONE||||||
33947220|NCT01111058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947221|NCT06108531|||CASE_CONTROL||PROSPECTIVE|||||||
33947222|NCT04056325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Phase 2a: single-blinded (participant and lab technician) Phase 2b: double-blinded (participant, Care Provider) PK sub-studies are single-blinded (participant)|Phase 2a: Parallel study with 7 treatment arms (including a placebo arm) Phase 2b: Parallel study with 2 treatment arms|t|t|f|t
33947223|NCT02876211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947224|NCT05972681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be blinded to the patient, the nurse carrying for the patient and providing the randomized, unlabeled syringe, the provider performing the perineal repair, the research team asking the maternal satisfaction questions, and the researcher analyzing the data. To assure blinding, the selection of the medication given, and the preparation of such medication will be performed by the labor and delivery anesthesia team. No one involved directly in the perineal laceration repair, or obtaining research information, nor the patient, will know what was injected.||t|t|t|t
33947225|NCT05489432|RANDOMIZED|PARALLEL||TREATMENT||NONE||An effectiveness-implementation hybrid type 1 study design comprised of a randomized controlled trial to test the effectiveness of prehabilitation to improve the overall health status of KTCs, and a mixed-methods study to gather information on its potential for further implementation.||||
33843753|NCT02234791|||COHORT||PROSPECTIVE|||||||
33843754|NCT00418769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843755|NCT04138108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33843756|NCT04224974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947226|NCT01348828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843757|NCT03553199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843758|NCT05677919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843759|NCT00835744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843760|NCT00814177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843761|NCT02753543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843762|NCT05440851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"While blinding of treatment allocation is an important mechanism for mitigating bias, the nature of acute hypoxemic respiratory failure and the complexity of interventions to be tested in PRACTICAL may make it difficult to blind treatment allocation in some cases. Blinded allocation will be implemented where possible.~Where possible, clinical outcomes will be collected by research personnel who are masked to randomized treatment assignment. Even where research personnel cannot be blinded to treatment assignment, bias arising will be mitigated by selection of relatively objective endpoints not easily influenced by knowledge of treatment assignment."||t|f|f|t
33843763|NCT06723886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Crossover, controlled, randomized, blind study|t|f|f|t
33843764|NCT04141059|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33843765|NCT02149953|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947227|NCT05502406|RANDOMIZED|PARALLEL||TREATMENT||NONE||compare two treatment techniques the study type will be parallel experimental study.||||
33843766|NCT01483547|||CASE_CONTROL||PROSPECTIVE|||||||
33843767|NCT05017103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843768|NCT05750498|||COHORT||PROSPECTIVE|||||||
33843769|NCT03837977|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a randomised controlled trial. One hundred and two eligible participants will be randomised (1:1)||||
33843770|NCT04853641|||CASE_CONTROL||RETROSPECTIVE|||||||
33843771|NCT04417595|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo controlled|Randomizes, parallel arm, double-blind, placebo controlled clinical trial|t|t|t|t
33843772|NCT06310356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947228|NCT06236373|||COHORT||CROSS_SECTIONAL|||||||
33947229|NCT05630638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947230|NCT05606523|||CASE_CONTROL||PROSPECTIVE|||||||
33947231|NCT02330406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33947232|NCT01319422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947233|NCT00442741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947234|NCT05557266|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Blinding of trial participants and care providers is not possible because of obvious differences between the interventions.|A randomized controlled trial of three groups is proposed, with pretest, posttest and three follow-ups at 1,3, and 6 months.|f|f|t|t
33947235|NCT04544592|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947236|NCT05602558|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33947237|NCT04129879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients undergone for laparoscopic surgery for endometriosis had both approaches with either bare eye and with the help of methylene blue contrast agent||||
33947238|NCT01730222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947239|NCT04225117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947240|NCT03010046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947241|NCT03246685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947242|NCT05246852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33947243|NCT02473341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947244|NCT05814367|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33947245|NCT02104726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076342|NCT01638715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076343|NCT00789620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33947246|NCT04798664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective randomized controlled trial using opt-out consent with longitudinal follow-up of patients over 12 months. Based on the expected accrual at each of the four health systems, we expect that overall there will be 470 participants in basic usual care (Arm 1), and 910 participants in each of intervention arms 2-4.|f|f|f|t
33843773|NCT01608126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33843774|NCT06287203|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will not be made aware of their condition at baseline; however, they will know their condition once they receives their estimates (or not, in the case of the control condition) and are taken to their follow-up resources.|||||
33947247|NCT03351426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is double blind. Neither the participants or the investigator delivering the intervention and collecting the outcomes will be aware of the group allocation. This is achieved via sham tDCS procedure and blinding of tDCS parameters with code system.||t|f|f|t
33843775|NCT05816772|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33947248|NCT04936646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947249|NCT06718413|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||study because each participant will receive both Human Recombinant Hyaluronidase and the placebo at some point during the study. For example, if the participant is assigned to receive the study drug for the first set of injections, the participant will receive placebo for the second set of injections.|t|t|t|t
33947250|NCT00213876|||CASE_ONLY||PROSPECTIVE|||||||
33843776|NCT02958046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947251|NCT02398292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843777|NCT00616902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843778|NCT05138744|NA|SINGLE_GROUP||TREATMENT||NONE||Single case design (multiple baselines)||||
33947252|NCT06724250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947253|NCT00999453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843779|NCT01486290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843780|NCT04484116|||COHORT||PROSPECTIVE|||||||
33843781|NCT02334475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33947254|NCT02106715|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33947255|NCT01977066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947256|NCT06722040|||COHORT||PROSPECTIVE|||||||
33947257|NCT04468139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947258|NCT04678180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of outcome was blinded to any previous evaluations|"Group 1: a combination of treatment using virtual training (secure interactive video training) and training at the hospital. In total, nine sessions using a combined training of HRT and ERP~Group 2: a combination of treatment using self-instructive videos and training at the hospital. In total, nine sessions using a combined training of HRT and ERP"|f|f|f|t
33947259|NCT02327897|||COHORT||PROSPECTIVE|||||||
34076344|NCT05796700|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076345|NCT03421379|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154458|NCT03473795|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34154459|NCT00311259|||||OTHER|||||||
34154460|NCT04849715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154461|NCT05329870|||COHORT||RETROSPECTIVE|||||||
34154462|NCT05322369|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34154463|NCT01660620|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33843782|NCT06085495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843783|NCT06013696|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33843784|NCT02437461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843785|NCT02951689|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33843786|NCT06267092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33843787|NCT03064217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843788|NCT03283540|||COHORT||PROSPECTIVE|||||||
33843789|NCT05558618|||COHORT||CROSS_SECTIONAL|||||||
33843790|NCT01351467|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33843791|NCT03887780|||COHORT||PROSPECTIVE|||||||
33843792|NCT05465447|||CASE_ONLY||PROSPECTIVE|||||||
33843793|NCT00682981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843794|NCT03651778|||CASE_ONLY||PROSPECTIVE|||||||
33843795|NCT03626870|||COHORT||PROSPECTIVE|||||||
33843796|NCT02636725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843797|NCT04773743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843798|NCT06390839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843799|NCT06117852|||COHORT||PROSPECTIVE|||||||
33843800|NCT05512143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843801|NCT05776043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Two arms with a subsequent stratification based on the SGLT2 inhibitor type.|t|t|t|t
33843802|NCT06728618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843803|NCT05527652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Aggregate and stratified outcomes will be revealed only to the unblinded statisticians with a firewall related to outcomes between statistician and investigators. Dr. Zopf will be blinded to all aggregate/stratified outcomes and Dr. O'Brien will be blinded to polysomnography and quality of life outcomes.|Eligible patients will be randomized 1:1 to receive (1) immediate therapy with the ssNPA device or (2) a waitlist control group who will receive standard of care (SoC) for the first 8 weeks and then be offered the ssNPA at week 8 for the rest of the study period (till week 16).|f|f|t|t
33843804|NCT00870077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843805|NCT02613377|||COHORT||PROSPECTIVE|||||||
33843806|NCT04631900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33843807|NCT00859222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843808|NCT05954910|||COHORT||PROSPECTIVE|||||||
33843809|NCT00385177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843810|NCT02940587|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843811|NCT06716658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843812|NCT00565851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947260|NCT06722404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All children were initially fed F-75 (75 kcal/ 100mL) therapeutic milk (Phase I) and then progressed to F-100 (100 kcal/ 100mL) (Phase II) and Plumpy'nuts (F-100 in spread form with iron fortification) (Phase III) with follow-up for 48 days. Synbiotics treatments were given from the onset of F-75 till the child progressed.The control group received standard therapeutic foods (F-75, F-100 and Plumpy'nuts), whereas the intervention group received therapeutic foods plus synbiotics containing Oligomate that was fortified in F75 at the rate of 7.5 g/L containing 4.1 g/L GOS for 1 g/100 kcal dose and at the rate of 11.5 g/L containing 6.1 g/L GOS for 1.5 g/100 kcal dose while in F100 and Plumpy'nuts it was fortified at the rate of 10 g/L containing 5.5 g/L GOS for 1 g/100 kcal dose|t|t|f|f
33947261|NCT02491463|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33947262|NCT06724562|||COHORT||PROSPECTIVE|||||||
33947263|NCT06722378|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33947264|NCT06091891|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33947265|NCT05025891|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33947266|NCT02709980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947267|NCT05289245|||COHORT||PROSPECTIVE|||||||
33947268|NCT01405989|RANDOMIZED|CROSSOVER||||NONE||||||
33947269|NCT04081727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947270|NCT00173810|||DEFINED_POPULATION||PROSPECTIVE|||||||
33947271|NCT02672748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary data analyst will not know which set of results are from people in the gardening vs. the control condition.||f|f|f|t
33947272|NCT05186688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947273|NCT05866757|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Patients will be divided in the following groups:~Group 1: Patients with biochemically detectable disease who have failed to achieve Complete remission (CR) or Very good Partial Remission (VGPR) by IMWG criteria and/or MRD-positive and/or high risk features. They will continue maintenance therapy until disease progression with monitoring every 3 months as per standard of care (SOC), or more often if required.~Group 2: Patients in biochemical remission, who meet IMWG criteria for very good partial response (VGPR) or complete response (CR and and sustained MRD (defined as MRD-negative at two time points that are at least 1 year apart) without high risk features This group will be divided in the following subgroups:~Subgroup A: Patients who prefer to continue on maintenance therapy. Maintenance will continue until disease progression.~Subgroup B: Patients who prefer to discontinue maintenance therapy."||||
33947274|NCT04742868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the researcher will evaluate each patient without knowing the type of grafting that will be applied||f|f|t|f
33947275|NCT05219110|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cluster crossover||||
33947276|NCT01431599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947277|NCT04196894|||CASE_CONTROL||PROSPECTIVE|||||||
33947278|NCT05836649|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33947279|NCT05707806|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33947280|NCT06724354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is a randomized controlled intervention study to investigate the effect of the care bundle application on surgical site infection rate in cranial brain surgery.||||
33947281|NCT00078689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843813|NCT06723340|NA|SINGLE_GROUP||OTHER||NONE||||||
33843814|NCT03547973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843815|NCT06617923|NA|SINGLE_GROUP||TREATMENT||NONE||two-stage, non-randomized||||
33843816|NCT06729593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947282|NCT06514170|||OTHER||PROSPECTIVE|||||||
33947283|NCT05364554|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947284|NCT05600855|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947285|NCT06464081|||OTHER||OTHER|||||||
33947286|NCT00004173||||TREATMENT||||||||
33947287|NCT05623319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947288|NCT00462501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947289|NCT02036892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947290|NCT06715761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076346|NCT00887705|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34076347|NCT05569122|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Aim 1 will have the 3 study interventions/study visits occur in random order. The interventions will be performed in primary mitochondrial disease patients and healthy controls~Aim 2 will have all participants complete the study interventions/visits in the same order. Patients will be from the PICU"||||
34076348|NCT00429767|||CASE_ONLY||PROSPECTIVE|||||||
34154464|NCT05244733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154465|NCT04113525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34154466|NCT05244551|NA|SEQUENTIAL||TREATMENT||NONE||||||
34154467|NCT02547168|NA|SINGLE_GROUP||SCREENING||NONE||||||
34154468|NCT04384523|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||This is a Phase 1 randomized, double blinded, placebo-controlled, single dose escalation study in healthy volunteers to evaluate safety, tolerability, PK, PD and immunogenicity of OsrHSA.|t|f|t|f
33843817|NCT06295393|||COHORT||PROSPECTIVE|||||||
33843818|NCT03486860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843819|NCT06597539|||OTHER||PROSPECTIVE|||||||
33843820|NCT04969419|||COHORT||RETROSPECTIVE|||||||
33843821|NCT03884946|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two randomly assigned arms will receive the same intervention (i.e., an app) at staggered intervals. At the end of one month, participants in the immediate arm will have received the app, but participants in the delayed arm will not. At this point, the two groups represent an RCT.||||
33843822|NCT04396574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843823|NCT05434052|||OTHER||CROSS_SECTIONAL|||||||
33843824|NCT04733027|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 dose escalation Part 2 expansion cohort and short dose escalation cohort Randomization in the escalation dose cohort once MTD defined||||
33843825|NCT05354622|||COHORT||PROSPECTIVE|||||||
33843826|NCT06421155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843827|NCT02458222|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33843828|NCT05474339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947291|NCT05789901|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The investigators adopt a platform trial design, which is defined as a study designed to evaluate multiple interventions in the context of a single disease in a perpetual manner, with therapies allowed to enter or leave the platform on the basis of a decision algorithm.. Platform trials can also integrate elements of basket trial design, which aims to study a single intervention for different diseases. In the current case, with different healthcare settings and diseases or conditions under study, the investigators would have a mix of platform trial and basket trial designs for an adaptative platform trial design. Such will allow flexibility in handling multiple interventions adapted to different populations while retaining platform trial characteristics, such as early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms. Meanwhile, there is no initial fixed duration or sample size for each arm."||||
33947292|NCT00207831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947293|NCT02210026|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947294|NCT06724744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947295|NCT05365828|||CASE_CONTROL||PROSPECTIVE|||||||
33947296|NCT05725174|||COHORT||PROSPECTIVE|||||||
33947297|NCT05653388|||COHORT||PROSPECTIVE|||||||
33947298|NCT05751421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947299|NCT05859334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947300|NCT05653882|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947301|NCT00407979|||CASE_CONTROL||PROSPECTIVE|||||||
33947302|NCT01556503|||COHORT||CROSS_SECTIONAL|||||||
33947303|NCT05732961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947304|NCT03504059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947305|NCT04881669|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33947306|NCT02141776|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34154469|NCT06166108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947307|NCT05372614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947308|NCT06515834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947309|NCT05791201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947310|NCT06374511|||COHORT||PROSPECTIVE|||||||
33947311|NCT02889926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947312|NCT06722638|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947313|NCT05930210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947314|NCT06724055|||CASE_CONTROL||RETROSPECTIVE|||||||
33947315|NCT00934661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154470|NCT03044184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Intravenous normal saline or transamine will be administered to subjects. Both will be of equal volume, colour and in similar intravenous fluid packaging.~The outcomes assessor will be unaware of the subject group allocation."|Randomised placebo-controlled parallel group clinical trial|t|f|f|t
34154471|NCT00246246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947316|NCT05428176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Neuropsychologists blinded to arm assignment||f|t|f|f
33947317|NCT06723249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33947318|NCT05586204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33947319|NCT01263366|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947320|NCT05482776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The people who will participate in the study will be randomly divided into two groups: experimental group (EG) and control group (CG). The experimental group will carry out a HIFT training program and the control group will follow their physical and cognitive exercise routine, which will be recorded for their control.|f|f|f|t
33947321|NCT05057975|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective, controlled, randomized, parrallel, open label, multicenter and national||||
33947322|NCT06661603|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947323|NCT04109573|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947324|NCT06083038|||COHORT||PROSPECTIVE|||||||
33947325|NCT02040415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947326|NCT00175552|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33947327|NCT04620356|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33947328|NCT00684658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33947329|NCT06658041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking was not possible in this study.|A quasi-experimental randomised controlled trial with propensity score-matching of an (i) intervention arm and (ii) active control arm.||||
33947330|NCT06665009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947331|NCT06724393|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33947332|NCT05056909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741243|NCT01577134|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33741244|NCT04402333|||COHORT||PROSPECTIVE|||||||
33947333|NCT02452892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947334|NCT06366191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947335|NCT06023927|||COHORT||PROSPECTIVE|||||||
33947336|NCT05078658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947337|NCT01670552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947338|NCT00287261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947339|NCT06724731|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947340|NCT04920097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and interventionists cannot be masked to the three arms. The PI and Co-Is will be blinded regarding arm assignment and will not contact or interact with the participants during the intervention and outcome assessments. Data collector for outcome assessments will be blinded since there will be no seeds placed on the ears when the data are collected.||f|f|t|t
33947341|NCT06056505|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment randomization to 3D or 2D modelling||||
33947342|NCT06722027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This is a longitudinal, randomized pilot study of 80 employees working in inter-professional oncologic teams. Employees will be randomized by team (using a random number generator in Microsoft Excel) to receive CCSH-TI or to a TAU treatment as usual (TAU) group."||||
33947343|NCT05728710|||COHORT||PROSPECTIVE|||||||
33947344|NCT05028894|||COHORT||PROSPECTIVE|||||||
34076349|NCT00854672|||CASE_CONTROL||PROSPECTIVE|||||||
33843829|NCT03691272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized with a random number generator to receive either sham or rTMS. Allocation will be concealed through the use of sequentially numbered, sealed, opaque envelopes.||t|t|t|t
33843830|NCT06729840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant doesnot know injected substance|3 groups|t|f|f|f
33843831|NCT05027633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843832|NCT05789069|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843833|NCT05963347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843834|NCT04133909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843835|NCT06338930|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33843836|NCT03812302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||68-Ga HA-DOTATATE PET/CT will be performed in all participants as part of study protocol. Participants will receive an intravenous infusion of 3MBq/kg of 68Ga HA-DOTATATE (to max 200 MBq), followed by CT and PET imaging 60 minutes later. Tracer uptake in each vascular territory will be interpreted qualitatively and quantitatively.||||
33843837|NCT00964275|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843838|NCT00037830|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33843839|NCT06573294|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843840|NCT01162863|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33843841|NCT06034743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843842|NCT03401008|||COHORT||CROSS_SECTIONAL|||||||
33843843|NCT04516642|||COHORT||PROSPECTIVE|||||||
33843844|NCT05127187|||COHORT||CROSS_SECTIONAL|||||||
33843845|NCT01208649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843846|NCT01915225|||COHORT||PROSPECTIVE|||||||
33843847|NCT06598436|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||The investigators propose a prospective, multilevel, nonblinded 2x2 randomized controlled trial to determine the effectiveness of a clinic-level intervention and a patient-level intervention, as well as the potential synergistic impact of both interventions on process outcomes and clinical measures of diabetes control. Five of the 11 participating clinics will be randomized to receive practice facilitation for 24 months. After implementing the clinic-level intervention, the investigators will begin recruiting/randomizing eligible patients in a 1:2 ratio to receive tailored digital coaching (n=200) or usual care (n=400) for 3 months.|f|f|f|t
33843848|NCT06728670|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Intravenous TXA injection group and intramuscular TXA injection group.|t|f|f|f
33843849|NCT02787044|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33843850|NCT04061044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843851|NCT03593226|NA|SINGLE_GROUP||TREATMENT||NONE||"Part 1- Accelerated escalation This is an accelerated escalation dose study designed to assess the safety and tolerability of escalating doses of AGI-134, as well as the Maximum Tolerated Dose (MTD) and the part 2 dose (RP2D).~Part 2 - Will comprise of two cohorts aiming to assess the safety, tolerability and anti-tumour activity of AGI-134 as a monotherapy"||||
33843852|NCT06685848|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33843853|NCT00468143|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33843854|NCT06717152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843855|NCT04720872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|Randomized clinical trial|t|f|t|t
33843856|NCT06581588|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33843857|NCT05961787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843858|NCT05460832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843859|NCT04229264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843860|NCT06729047|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33843861|NCT00316602|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843862|NCT04538911|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33843863|NCT04959188|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33843864|NCT05785546|||COHORT||PROSPECTIVE|||||||
33843865|NCT05845710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843866|NCT06108011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843867|NCT00689975|RANDOMIZED|||||||||||
33843868|NCT05880004|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843869|NCT06189885|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33843870|NCT00867308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843871|NCT03882580|||COHORT||PROSPECTIVE|||||||
33843872|NCT04529122|||OTHER||PROSPECTIVE|||||||
33843873|NCT06589310|||COHORT||PROSPECTIVE|||||||
33843874|NCT00969826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843875|NCT05053607|NA|SINGLE_GROUP||OTHER||NONE||A single cohort of 50 individuals with relapsed/refractory multiple myeloma will be enrolled in the study, all of which will be enrolled in a digital health coaching program and receive a Fitbit device for activity tracking. Individuals from both study sites will be enrolled to this single cohort.||||
33843876|NCT00504608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33843877|NCT05215275|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33843878|NCT04489134|RANDOMIZED|CROSSOVER||OTHER||SINGLE|the biologists performing the tacrolimus assays will be blind to the treatment received|This is a pharmacokinetic, monocentric, prospective, randomized, crossover study with blind assessment (biologists performing tacrolimus dosages will be blind to the treatment received).|f|f|f|t
33843879|NCT06426212|||CASE_ONLY||RETROSPECTIVE|||||||
33843880|NCT06476847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33843881|NCT03753698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843882|NCT05619757|||OTHER||CROSS_SECTIONAL|||||||
33843883|NCT06470828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843884|NCT05557513|RANDOMIZED|PARALLEL||PREVENTION||NONE||For primary objective (Ag-RDT (arm 1) and no Ag-RDT (arm 2)) 74 clusters (37 in each arm) Approximate 5,500 participants in arm 1 and 5,500 participants in arm 2||||
33843885|NCT03856489|||CASE_ONLY||PROSPECTIVE|||||||
33843886|NCT05215665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843887|NCT02997228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947345|NCT06068790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|This study will be a randomized controlled trial in which patients who meet inclusion criteria will be randomized to one of two groups, HoLEP performed with either 1) 22Fr sheath set or 2) 28Fr sheath set. After HoLEP, data will be analyzed using chi-square test for incontinence vs no incontinence between 22Fr and 28Fr groups at 1 week, 4 weeks and 12 weeks post operatively|We hypothesize there will be lower rates of immediate urinary incontinence, and urethral stricture formation in patients undergoing HoLEP with smaller 22Fr sheaths compared to 28 Fr.||||
33843888|NCT04210167|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is a randomized controlled study||||
33947346|NCT04620005|||OTHER||CROSS_SECTIONAL|||||||
33843889|NCT00474526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33843890|NCT05427084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843891|NCT04278014|||COHORT||PROSPECTIVE|||||||
33843892|NCT03701269|||CASE_ONLY||RETROSPECTIVE|||||||
33843893|NCT00003489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843894|NCT00608868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33843895|NCT02412371|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"All participants will be treated with open-label paclitaxel and carboplatin (Phase 1 and Phase 2).~Participants in Phase 1 will be treated with open-label veliparib. In Phase 2, the Sponsor, Investigator, study site personnel and participant were to be be blinded to each participant's treatment with veliparib or placebo throughout the course of the study."|"In the dose escalation phase (Phase 1) of the study participants will be enrolled sequentially to receive ascending dose of veliparib in combination with carboplatin + paclitaxel + thoracic radiotherapy.~In the Phase 2 portion of the study participants were to be randomized in a 1:1:1 ratio to one of three treatment arms."||||
33843896|NCT02423148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33843897|NCT06430905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33843898|NCT01994967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843899|NCT06527599|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pilot Sequential, Multiple-Assignment Randomized Trial (Pilot SMART)||||
33843900|NCT01966172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33843901|NCT06682039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blind to study condition.||t|f|f|f
33843902|NCT01695252|RANDOMIZED|||TREATMENT||||||||
33843903|NCT06729125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843904|NCT06729697|||OTHER||CROSS_SECTIONAL|||||||
33843905|NCT06617897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843906|NCT01528345|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33843907|NCT03656172|||COHORT||PROSPECTIVE|||||||
33843908|NCT05027035|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||open-label, multi center, intervention pilot study||||
33843909|NCT01602029|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33843910|NCT05857761|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A computer will randomize participants to either participate in the active- or the sham group. At end of treatment participants will be asked to answer if they have received sham- or active treatment in order to assess the success of participant-blinding.|The intervention study will be conducted as a randomized, sham-controlled, parallel group clinical trial consisting of an active (n=31) and a sham group (n=31).|t|f|f|f
33843911|NCT00480935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843912|NCT02911233|||||PROSPECTIVE|||||||
33843913|NCT05397691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33843914|NCT03262259|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Nine pairs of intervention and comparison cities followed over multiple years.||||
33843915|NCT04711733|||OTHER||PROSPECTIVE|||||||
33843916|NCT01600898|||COHORT||PROSPECTIVE|||||||
33843917|NCT02167009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843918|NCT02904070|NA|SINGLE_GROUP||||NONE||||||
33843919|NCT00700778|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33843920|NCT04827901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a phase II, randomized, parallel-arm, placebo-controlled clinical trial were 60 patients with major depressive disorder will be randomized in 1:1 fashion to XEN1101 (N=30) or matching placebo (N=30).|t|t|t|t
33843921|NCT02126761|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33843922|NCT05677997|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33843923|NCT00283751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843924|NCT05684718|NA|SINGLE_GROUP||TREATMENT||NONE||Fixed sequence||||
33843925|NCT04222361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33843926|NCT04243707|||COHORT||RETROSPECTIVE|||||||
33843927|NCT05797610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843928|NCT04613583|||OTHER||OTHER|||||||
33843929|NCT06162572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843930|NCT06564701|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Speech intelligibility testing will be conducted on a single group of participants, first using one remote mic system, and then the other. The order of devices will be counter-balanced across participants.||||
33843931|NCT01582841|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33843932|NCT00412412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843933|NCT04793789|||CASE_ONLY||OTHER|||||||
33843934|NCT03775486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843935|NCT05910944|||COHORT||PROSPECTIVE|||||||
33843936|NCT05597787|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33843937|NCT03553576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and outcomes assessor will be blinded to the assigned randomization.|Two group randomized controlled trial|t|f|f|t
33843938|NCT02994303|||CASE_ONLY||PROSPECTIVE|||||||
33843939|NCT02843061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843940|NCT04571450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843941|NCT05619653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo|multicentre randomised double-blind, placebo-controlled clinical trial 1:1 randomisation|t|t|t|t
33843942|NCT05179213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947347|NCT05955651|||OTHER||PROSPECTIVE|||||||
33947348|NCT00384072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33947349|NCT06616857|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33947350|NCT06171659|||COHORT||PROSPECTIVE|||||||
33947351|NCT06175871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Clinical trial design|f|f|t|f
33947352|NCT02679560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947353|NCT03378921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947354|NCT03158532|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33947355|NCT02502994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947356|NCT00938457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947357|NCT06649929|RANDOMIZED|PARALLEL||OTHER||SINGLE||Couples will be randomized 1:1 to intervention and control|f|f|f|t
33947358|NCT04855539|||COHORT||PROSPECTIVE|||||||
33947359|NCT00679692|||||PROSPECTIVE|||||||
33947360|NCT03802747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The first 6 patients will receive durvalumab alone with Y-90 and SBRT followed by 4 months of durvalumab. The next 6 patients will received durvalumab with Y-90 and SBRT followed by 4 months of durvalumab + tremelimumab.Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. There will be no dose escalation. For patients who will receive both Durvalumab and Tremelimumab, the Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses. There will be no dose escalation.||||
33947361|NCT04499118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947362|NCT02045017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947363|NCT04506632|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33947364|NCT06381947|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is an investigator-initiated, phase 4, open-label, multicentre, 2-way crossover trial||||
33947365|NCT02688881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947366|NCT04373720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947367|NCT03642639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947368|NCT00354991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947369|NCT00066274|RANDOMIZED|||TREATMENT||||||||
33947370|NCT03853993|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The phase I clinical trial has single arm, and the phase III clinical trial has 3 parallel arms.|t|f|t|f
33947371|NCT00452166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33947372|NCT05035810|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|It is not possible to blind participants to the social incentives they will receive. For the injection aspect of the study, both the investigator and participant will be unaware of the injection being given and the syringe will be covered to obscure the view of the patient.|Participants are randomized with a software application to receive social incentives to promote physical activity. They will also be randomized to receive corticosteroid injections in a crossover design.|t|f|t|f
33947373|NCT00551694|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947374|NCT04982497|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33947375|NCT06098430|||COHORT||PROSPECTIVE|||||||
33947376|NCT01045902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947377|NCT04582331|||CASE_CONTROL||PROSPECTIVE|||||||
33947378|NCT06357832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33947379|NCT04672434|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947380|NCT01021423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947381|NCT04274569|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33947382|NCT00929227|||COHORT||PROSPECTIVE|||||||
33947383|NCT06199193|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: Control healthy humans with normal diet (n=30) Group 2: Alzheimer patients with normal diet (n=30). Group 3: Alzheimer patients with designed supplements(n=30)||||
33947384|NCT00888277|||CASE_ONLY||PROSPECTIVE|||||||
33947385|NCT04260360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947386|NCT02076646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947387|NCT05587933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947388|NCT06452420|||COHORT||PROSPECTIVE|||||||
33947389|NCT06161766|||COHORT||RETROSPECTIVE|||||||
33947390|NCT06456346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947391|NCT01992926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33947392|NCT05538442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947393|NCT05278663|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33947394|NCT05642325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947395|NCT03012035|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33947396|NCT06556615|||OTHER||PROSPECTIVE|||||||
33947397|NCT06722833|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947398|NCT05156749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947399|NCT03672136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947400|NCT05167669|NA|SINGLE_GROUP||TREATMENT||NONE||Number of participants: 10 patients with radiologically confirmed bone metastases and eligible for a course of palliative EBRT. Eligible patients will be mainly discussed and recruited in a dedicated tumor-board for bone metastases performed in a weekly basis at HUG.||||
33947401|NCT05239390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947402|NCT02278042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33947403|NCT03313297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment groups will be allocated in a double-blind manner. Participants will be blinded to the treatment they receive (placebo or drug) throughout all stages of the study. Investigators will also be blinded to the treatment until all samples have been collected and processed. Blinding will be generated by a dedicated trials pharmacy representative who is not otherwise associated with this study.|Double-blind, randomised, parallel group, placebo-controlled phase II pilot trial|t|t|t|t
33947404|NCT01546311|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947405|NCT03730051|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33947406|NCT03970603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947407|NCT06724172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33947408|NCT05672459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947409|NCT04431856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947410|NCT00148109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947411|NCT05635110|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33947412|NCT03235674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947413|NCT06723210|||COHORT||CROSS_SECTIONAL|||||||
33947414|NCT03165227|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33947415|NCT05225701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded: The initial interview by the evaluator will be recorded and the video/audio will be shared with an independent evaluator who does not know the case for evaluation. Once the evaluation is completed, users will be randomly assigned to one of the study conditions. The randomization will be carried out by an independent researcher through the random.stg software in a 1: 1: 1 ratio by saturation of blocks of 12 per condition. The coordinator will inform the participant if he / she will participate in the study and, depending on the characteristics of the study design condition, he / she will be assigned to the self-guided/ guided intervention.|A randomized controlled study will be carried out, in accordance with the guidelines set out in the consort (http://www.consort-statement.org) and CONSORT E-Health (https://www.jmir.org/2011/4/e126/). An experimental design will be used between subjects with three independent groups, with intrasubject measurements in four evaluation moments: pretest, posttest, follow-up at 3, 6 and 12 months (Solomon et al. ,2009). Participants will be randomly assigned to one of three conditions: a) Transdiagnostic guided internet-delivered intervention with synchronous assistance; b) Transdiagnostic self-guided internet-delivered intervention; c) waiting list.|t|t|t|t
33947416|NCT03234023|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947417|NCT05697445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947418|NCT02931331|||COHORT||PROSPECTIVE|||||||
33947419|NCT04255433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947420|NCT05299060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators are the ones who performed the insertion of the catheters and the subsequent data collection, but neither the patients nor the healthcare staff knew which patient was wearing tissue adhesive.|Classical parallel model with an intervention group, to which cyanoacrylate tissue adhesive was applied, and a control group.|t|t|f|f
33947421|NCT02184312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947422|NCT05342870|NA|SEQUENTIAL||TREATMENT|||This is one arm non-randomized approach. Since it is a sequential approach of medication administration, the anesthesiologist and patients were blinded to whatever dose was given.|||||
33843943|NCT00847080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947423|NCT04201652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized into one of two interventional groups for the duration of the study.|t|f|f|t
33947424|NCT06522763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947425|NCT00777582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33947426|NCT06212310|||COHORT||PROSPECTIVE|||||||
33947427|NCT04717986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Asses the effect of Dapagliflozin on mayor adverse cardiovascular effects in patients with acute myocardial infarction compared against placebo.|t|t|f|t
33947428|NCT03391063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947429|NCT05794204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor/CRO clinical operations team will also be masked. Sponsor/CRO biostats team and drug supply manager will be unmasked.|Patients will be randomized in a 1:1:1 fashion|t|t|t|t
33947430|NCT00957736|||CASE_ONLY||RETROSPECTIVE|||||||
33947431|NCT06526026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947432|NCT05747157|NA|SEQUENTIAL||TREATMENT||NONE||||||
33947433|NCT05813925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33947434|NCT00131001|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947435|NCT04162717|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947436|NCT00943007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947437|NCT01393652|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33741245|NCT02065128|||CASE_CONTROL||PROSPECTIVE|||||||
33741246|NCT02283528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741247|NCT05335356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded (Patient, Investigator),||t|f|t|f
33741248|NCT04242316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947438|NCT00877526|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33741249|NCT00296101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741250|NCT03503942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741251|NCT02453113|NA|SINGLE_GROUP||OTHER||NONE||||||
33843944|NCT06728644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843945|NCT00588692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741252|NCT01657201|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741253|NCT02033889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741254|NCT02726815|||COHORT||PROSPECTIVE|||||||
33843946|NCT04514510|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33843947|NCT04476251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843948|NCT03440060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843949|NCT05595252|||COHORT||RETROSPECTIVE|||||||
33843950|NCT02826928|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33843951|NCT06077500|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843952|NCT05478759|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 Veterans with mTBI and PTSD will be randomized to multimodal and attention training or inactive control arm.||||
33843953|NCT01161381|||CASE_ONLY||PROSPECTIVE|||||||
33741255|NCT00030550|RANDOMIZED|||TREATMENT||DOUBLE||||||
33741256|NCT05282004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843954|NCT05418751|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33843955|NCT06727890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33843956|NCT06729242|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Six interventions will be carried out in a single group, being three aerobic sessions, two in two luteal phases and another in follicular phase, and other three session of high intensity interval exercise (HIIT).||||
33843957|NCT04080453|||COHORT||PROSPECTIVE|||||||
33947439|NCT03491384|||COHORT||PROSPECTIVE|||||||
33947440|NCT06094075|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two groups (randomization used for allocation), tested before and after the intervention.|f|f|f|t
33947441|NCT06191757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a randomized controlled experimental study||||
33947442|NCT01694095|||CASE_ONLY||PROSPECTIVE|||||||
33947443|NCT06723977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|While written consent was obtained from the individuals included in the study, a different form was used for each group. For this reason, participants could not be blinded. In addition, since the data collection and application process had to be actively managed, researcher blinding was not possible. The randomization table was prepared by an independent statistician to avoid the possibility of bias.|The study was conducted with 20 caregivers of individuals diagnosed with schizophrenia in the intervention group and 20 caregivers of individuals diagnosed with schizophrenia in the control group.||||
33947444|NCT04806178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947445|NCT06096857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843958|NCT06728059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a research study about the UVA Automated Insulin Delivery System known as Adaptive NETwork (AIDANET). This system consists of a Reinforcement Learning trained Bolus Priming System (BPS_RL) added to the AIDANET algorithm and running on Diabetes Assistant (DiAs) phone wirelessly connected to Tandem t:AP insulin pump and Dexcom Continuous Glucose Monitor (CGM). One part of the algorithm, called the Bolus Priming System (BPS), gives insulin automatically to help keep blood sugar levels in a healthy range.~In this study, the Bolus Priming System is being tested in a new way. This system uses a type of smart learning called reinforcement learning (RL), which helps the algorithm make better choices about how much insulin to give. The new version of the system looks at blood sugar and insulin levels over the past 3 days to find patterns and give a better insulin dose before meals. This should provide an improvement over the old system, which only uses the last 30 minutes of data."||||
33843959|NCT03815110|||COHORT||PROSPECTIVE|||||||
33843960|NCT03165747|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Only the Emory Investigational Drug Service (IDS) pharmacy will know which dose of probiotic was given to the subject. The study team, parents, subjects, individuals entering the data, statistician, individuals performing laboratory tests and DEXA scans, research center nurses and investigators will remain blinded as to which treatment the subjects received. Each subject will be assigned a unique identifier, which will be used in the database. In addition, all lab specimens will only include the patient's unique identifier. Permuted block sizes will not be disclosed to the blinded study personnel to minimize the likelihood of their being able to predict the next randomization assignment in the series. Investigators and all study personnel will remain blinded until the final subject has completed her final visit and primary and secondary endpoints have been analyzed.||t|t|t|t
33843961|NCT02828813|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33843962|NCT05816226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Cream containers labeled by randomly-generated numbers, by person not involved in analysis or patient interaction.~Statistical analysis done by person not aware of the treatment received by each group"||t|t|t|t
33843963|NCT06728722|||COHORT||PROSPECTIVE|||||||
33843964|NCT06024434|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33843965|NCT05602792|NA|SEQUENTIAL||TREATMENT||NONE||||||
33843966|NCT03856190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33843967|NCT02015208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843968|NCT06395090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843969|NCT03100487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33843970|NCT03614949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843971|NCT00005328|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33843972|NCT03563157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843973|NCT06723184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single blind pre-post test randomized controlled design|t|f|f|f
33843974|NCT04451967|||COHORT||PROSPECTIVE|||||||
33843975|NCT02925598|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|t|f|f
33843976|NCT03896152|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label study||||
33843977|NCT06715579|||CASE_ONLY||OTHER|||||||
33843978|NCT02921321|||COHORT||PROSPECTIVE|||||||
33843979|NCT03767829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843980|NCT06161519|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33843981|NCT03995966|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A randomized crossover design will be employed. Specifically, the approach will include using randomly permuted block randomization, stratified by subtype (Subtype 2 or Subtype 3 ASIB). If the treatment based on the first approach is deemed ineffective, a 3-day washout period will occur (where no treatment is applied), followed by the initiation of the second approach to treatment.|f|f|f|t
33843982|NCT06308887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843983|NCT00827099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843984|NCT03843762|||CASE_ONLY||PROSPECTIVE|||||||
33843985|NCT01073644|||COHORT||PROSPECTIVE|||||||
33843986|NCT06603987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33843987|NCT02604303|||COHORT||PROSPECTIVE|||||||
33947446|NCT02613910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947447|NCT02788981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33843988|NCT06165302|NA|SINGLE_GROUP||OTHER||NONE||||||
33843989|NCT05246527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Exercise condition: cycle on an ergometer with moderate or high intensity Control condition: watching a movie||||
33843990|NCT03668223|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33843991|NCT00352638|RANDOMIZED|||||||||||
33843992|NCT06659640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33843993|NCT04207151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33843994|NCT02236988|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33947448|NCT04827992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947449|NCT05726617|NA|SINGLE_GROUP||TREATMENT||NONE||pilot clinical trial, single arm||||
33947450|NCT06722560|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33947451|NCT06724926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076350|NCT05714787|||COHORT||RETROSPECTIVE|||||||
34076351|NCT02233699|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33947452|NCT05847023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The LUNA Assessors (2 staff) were blinded to group allocation throughout the study. The statistician leading on analysis of initial efficacy findings was blinded to group allocation.|The study is a single-blind, waitlist, randomised controlled trial of LUNA for people with chronic post-stroke aphasia. Participants will complete assessments at three time points: T1 (weeks 1\&2), T2 (weeks 13 \& 14) and T3 (weeks 25 \& 26). Following T1, participants will be randomised to an immediate or delayed condition. Those in the immediate condition will receive LUNA therapy between T1 and T2. Those in the delayed condition will receive LUNA therapy between T2 and T3. All participants will be invited to participate in in-depth individual semi-structured interviews post-therapy to explore their experiences of taking part in the study.|f|f|f|t
33947453|NCT06172166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947454|NCT00984100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947455|NCT02763566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947456|NCT06722820|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33947457|NCT01388946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33947458|NCT06724913|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33947459|NCT02248272|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947460|NCT06163768|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947461|NCT03921008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947462|NCT00919620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947463|NCT00496782|NA|SINGLE_GROUP||SCREENING||NONE||||||
33947464|NCT04062097|||CASE_CONTROL||PROSPECTIVE|||||||
33947465|NCT00512226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947466|NCT00287612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947467|NCT04337762|||CASE_CONTROL||PROSPECTIVE|||||||
33947468|NCT00705471|||COHORT||RETROSPECTIVE|||||||
33947469|NCT02628184|||OTHER||RETROSPECTIVE|||||||
33947470|NCT00707551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947471|NCT03319160|||COHORT||OTHER|||||||
33947472|NCT04918251|||COHORT||PROSPECTIVE|||||||
33947473|NCT01325376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947474|NCT02348671|||COHORT||PROSPECTIVE|||||||
33947475|NCT04771130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947476|NCT05478473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947477|NCT05796401|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Phase III, Prospective Randomised Open, Blinded End-point (PROBE) controlled trial stratified according to the developmental burden and centre, with 2x2 factorial designs (equivalent to a 4-arms clinical trial) in a 1:1:1:1 ratio.|f|f|f|t
33947478|NCT06281236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947479|NCT06040905|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33947480|NCT02354040|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33947481|NCT04462328|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947482|NCT02632773|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33947483|NCT06079606|||COHORT||PROSPECTIVE|||||||
33947484|NCT05216302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33947485|NCT00945815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947486|NCT06541665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947487|NCT06722807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947488|NCT02221882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947489|NCT06722196|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33947490|NCT02478853|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33947491|NCT01623518|NA|SINGLE_GROUP||||NONE||||||
33947492|NCT00241566|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33947493|NCT03280576|||COHORT||PROSPECTIVE|||||||
33947494|NCT03737617|RANDOMIZED|PARALLEL||TREATMENT||NONE|1 group receiving standard care|1 Group receiving active immunoglobulin replacement therapy||||
33947495|NCT01539512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947496|NCT05346887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947497|NCT03416166|||CASE_ONLY||PROSPECTIVE|||||||
33947498|NCT05999292|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33947499|NCT03431688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947500|NCT06723028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947501|NCT03319368|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947502|NCT06453473|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome measures will be obtained by two research assistants in each country who are blinded to group allocation. Participants will not fully be blinded to group allocation since they notice whether perturbation occur during training. However, both groups will be told that the primary aim of the study is to improve cycling skills by training on an indoor, stationary bicycle.|"BiPerAge is a parallel group (1:1), randomized controlled trial with a duration of 3 years and a recruitment period between September 2024 and December 2025.~Baseline data collection (T0) takes place in-person in the study center and in the cycle course on two different days within approximately 14 days. Except for cognitive function, same data are collected of all participants after the 3 months intervention period (T1), regardless of their compliance. In addition, participants will be followed up 6-9 months after T1 (T2) related to seasonal time frames (after winter season)."|f|f|f|t
33947503|NCT06044168|NA|SINGLE_GROUP||TREATMENT||NONE||There will be only one group in this feasibility study. There will be no control group.||||
33947504|NCT03836079|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33947505|NCT06280079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947506|NCT01641952|||COHORT||PROSPECTIVE|||||||
33947507|NCT05142904|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre 1:1 randomized clinical trial where patients are allocated to either radiofrequency ablation (RFA) or radioactive iodine (RAI) (I-131). Patients who are not suitable for randomization (e.g. no informed consent or contra-indication for RFA) are asked for consent to participate in a prospective cohort where participants are asked to fill out questionaires and data is collected.||||
33947508|NCT02218866|||CASE_CONTROL||PROSPECTIVE|||||||
33947509|NCT06018389|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study employs a parallel group cluster randomized controlled trial design with three conditions: 1) structural condition targeting school and parent levels, 2) structural condition combined with group MI which also targets the student level, and 3) assessment-only control condition (interventions offered after the last follow-up survey).||||
33947510|NCT03635541|||COHORT||OTHER|||||||
33947511|NCT00722462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947512|NCT05834894|||OTHER||RETROSPECTIVE|||||||
33947513|NCT03707106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947514|NCT02062541|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33947515|NCT05122364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two groups of cochlear implanted children one group will take sessions online (case group) and the other group will take sessions face to face (control group)||||
33947516|NCT06180655|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947517|NCT02861157|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947518|NCT05602623|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33947519|NCT02662348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947520|NCT02821975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947521|NCT01754363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947522|NCT05579509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel and crossover design. Subjects in Arm 2 may crossover to Arm 1 if they receive pharmacologic sedation.|f|f|f|t
33947523|NCT06008938|||COHORT||PROSPECTIVE|||||||
33947524|NCT05685355|||CASE_ONLY||PROSPECTIVE|||||||
33947525|NCT01794221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947526|NCT02978625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947527|NCT04463719|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33947528|NCT01441089|||CASE_ONLY||PROSPECTIVE|||||||
33947529|NCT05798663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947530|NCT04678726|||COHORT||PROSPECTIVE|||||||
33947531|NCT02645682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947532|NCT04551248|||COHORT||RETROSPECTIVE|||||||
33947533|NCT04456816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Exploratory, randomized, double-blind, multi-center, placebo-controlled 12-weeks study with repeated doses of AP1189|t|f|t|t
33947534|NCT03798652|||COHORT||OTHER|||||||
33947535|NCT04802759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947536|NCT04347460|||COHORT||PROSPECTIVE|||||||
33947537|NCT05782504|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal, single-arm, mixed-methods||||
33947538|NCT04176172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947539|NCT03326882|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33947540|NCT05626556|NA|SINGLE_GROUP||OTHER||NONE||||||
33947541|NCT04932980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|two-armed, randomized, double-blind|t|f|t|f
33947542|NCT02784730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33947543|NCT06522373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947544|NCT06725004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947545|NCT00245492|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33947546|NCT01724723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947547|NCT05534620|NA|SINGLE_GROUP||OTHER||NONE||||||
33947548|NCT01315158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947549|NCT02467712|||||RETROSPECTIVE|||||||
33947550|NCT06165471|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33947551|NCT05471154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind: another researcher than the one collecting data will program the codes of the ad verum vs. sham stimulation so that both participant and researcher (collecting data) are blinded|In this study, High-Definition transcranial direct current stimulation is used as treatment/intervention (HD-tDCS). HD-tDCS will be applied with a current of 2 mA during 20 minutes. Participants are semi-randomly assigned to the two experimental groups (active stimulation vs. sham) by the coordinating researcher, taking into account the sex of the participant. The sham condition will use the same montage but stop stimulation after a short ramp-up of 1 minute).|t|f|f|t
33947552|NCT04265794|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled trial (sites are randomized to the intervention or control condition)||||
33947553|NCT06345573|||COHORT||PROSPECTIVE|||||||
33947554|NCT04357431|||OTHER||CROSS_SECTIONAL|||||||
33947555|NCT04985916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||vehicle controlled, parallel group|t|f|t|f
33947556|NCT03428139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947557|NCT05549804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947558|NCT05999747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947559|NCT05324774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947560|NCT00784173|||CASE_ONLY||PROSPECTIVE|||||||
33947561|NCT05493748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental, before-after trial.||||
33947562|NCT01751490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947563|NCT02369874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947564|NCT05333549|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947565|NCT01493440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947566|NCT00682539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947567|NCT05696184|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In a heterogeneous group of gastroesophageal reflux disease (GERD) patients, determine and characterize pressure phenomena of the upper esophageal sphincter (UES) incompetence confirmed by concurrent endoscopy.||||
33947568|NCT01624818|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33947569|NCT02615665|||COHORT||RETROSPECTIVE|||||||
33947570|NCT01144858|||COHORT||PROSPECTIVE|||||||
33947571|NCT03775642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947572|NCT03222180|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Persons administering and scoring study questionnaires will be blinded to the participants' group assignments,|The study design consists of randomization of parents of 150 children with T1D to either Website (n=100) or Usual Care (n=50) for 6 months followed by all participants reverting to the Website condition for the subsequent 6 months.|f|f|f|t
33947573|NCT01753765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947574|NCT04815005|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947575|NCT04086511|||OTHER||CROSS_SECTIONAL|||||||
33947576|NCT05715190|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental study||||
34076352|NCT04985045|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076353|NCT04978324|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947577|NCT06722963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent anesthesiologist randomly divided the patients into 35 groups of patients each using computer-generated random numbers fentanyl group and nalbuphine group (Group F and Group N). We discreetly placed the randomization results in envelopes until the end of the study. Both nalbuphine and fentanyl are colorless liquids, and they were digitally encoded so that the researchers who were responsible for postoperative follow-up and data processing were blinded to the group allocation during the whole study period. All patients were also blinded to the group allocation||t|t|t|t
33947578|NCT01663688|||CASE_ONLY||PROSPECTIVE|||||||
33843995|NCT06728358|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33843996|NCT05269966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947579|NCT02185443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947580|NCT04117282|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups study and control||||
33947581|NCT05721482|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Randomized control trial of behavioral intervention||||
33947582|NCT01161173|||COHORT||PROSPECTIVE|||||||
33947583|NCT04961190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947584|NCT02960191|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33947585|NCT00339482|||COHORT||PROSPECTIVE|||||||
33947586|NCT02919709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947587|NCT04130165|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Outcome assessor (lab technician/research assistant) will not be aware of the group allocation or nutritional intake of the infant while completing data analysis.~We cannot blind participants or care providers as provision of matched donor human milk will require preparation which deviates from standard protocol, and the bedside nurse will need to conduct this preparation."|Pilot Randomized Control Trial|f|f|f|t
33947588|NCT05731726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947589|NCT01934842|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947590|NCT06723067|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33947591|NCT05405621|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947592|NCT02049476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947593|NCT03892967|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947594|NCT05656729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947595|NCT06165159|||COHORT||PROSPECTIVE|||||||
33947596|NCT01698606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947597|NCT03596645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947598|NCT03297463|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947599|NCT05807477|||CASE_ONLY||PROSPECTIVE|||||||
33947600|NCT03095365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947601|NCT06515886|||COHORT||CROSS_SECTIONAL|||||||
33947602|NCT04102761|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Subjects will be assigned to one of three arms of the study. The first group will receive a trigger point injection of saline into the deep tissue. The second group will receive an injection of approximately 1-2 mL of Platelet RP into the painful disc/discs. The third group will receive an injection of approximately 1-2 mL of Bone Marrow Concentrate into the painful disc/discs. No more than three discs will be injected.|t|f|f|f
33947603|NCT06291909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33947604|NCT06422078|||COHORT||PROSPECTIVE|||||||
33947605|NCT04142697|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33947606|NCT04553926|||COHORT||PROSPECTIVE|||||||
33947607|NCT00003977||||TREATMENT||||||||
33947608|NCT06722001|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33947609|NCT04188639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947610|NCT05504356|||COHORT||PROSPECTIVE|||||||
33947611|NCT01438281|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33947612|NCT06619587|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947613|NCT06724458|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34076161|NCT03134729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Given the trial Design, it would be impossible to blind the caregiver about the type of treatment.~Serratus Plan Block will be performed after the induction of General Anesthesia, the patients will thus be unaware wether being assigned to the Experimental or Control Arm.~Clarification (May 28, 2018):~* Nurses assess NRS (Pain Perception) and directly manage rescue doses delivery~* Physiotherapists deliver rehab. respiratory exercises and directly assess patient's performance.~Since their reports are directly elicited in Clinical Report Forms, they are considered outcome assessors.~Both Nurses and Physiotherapists are unaware of treatment allocation."|"Eligible patients will be randomized between two groups:~Systemic analgesic therapy only (Endovenous/ Oral)~Systemic analgesic therapy plus loco regional therapy administered under Us. guidance before the procedure (Serratus Plane Block).~Allocation to one treatment group or another will be randomized with the aim of create two unbiased groups formed out of the same group of patients. Randomization will be provided by a software. Group allocation and treatment is overt to the investigators, but not to the patient."|t|f|f|t
33843997|NCT00684723|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33843998|NCT06393439|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33843999|NCT03164694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844000|NCT00682747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844001|NCT06142773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33844002|NCT03773575|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844003|NCT05020587|NA|SINGLE_GROUP||TREATMENT||NONE||Two open pilot trials of a novel time-limited potentially morally injurious event (PMIE)-focused therapy group (N \~= 12), led by two therapists.||||
33844004|NCT04224376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844005|NCT00848588|||COHORT||PROSPECTIVE|||||||
33844006|NCT06601010|||OTHER||PROSPECTIVE|||||||
33844007|NCT00419978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844008|NCT00706953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947614|NCT03313700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947615|NCT05718921|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||This study includes two sequential parts of single dose and multiple dose with placebo control|t|t|t|f
33947616|NCT02662959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947617|NCT00511030|||CASE_ONLY||PROSPECTIVE|||||||
33947618|NCT04057651|||COHORT||PROSPECTIVE|||||||
33947619|NCT05142462|||COHORT||OTHER|||||||
33947620|NCT06723795|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The interviewer in the 3 and 6 months phone call follow-up will be blinded to group allocation.|"Given the unique intervention, it is expected that the department's daily practices may change during the study due to exposure to the intervention (increased cardiovascular screening and treatment in COPD patients). This could directly impact the intervention's effectiveness. Therefore, randomization will be implemented across internal medicine wards, ensuring that the intervention and control groups remain separate, and teams will not be exposed to other wards' randomization results.~COPD patients will be identified by their treating physicians and referred to the research team.~After completion of the study follow-up by 50 participants in each group, an interim-analysis will be made. In case that the primary analysis will be achieved, the research team will consider the continuation of recruitment due the lack of funding."|f|t|f|t
33947621|NCT06260995|||COHORT||PROSPECTIVE|||||||
33947622|NCT06111963|||CASE_CONTROL||PROSPECTIVE|||||||
33947623|NCT06724692|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, monocentric, cross-over, open-label study||||
33947624|NCT02148042|||CASE_CONTROL||PROSPECTIVE|||||||
33947625|NCT05805306|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33947626|NCT05003765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"This study will consist of 4 arms (groups):~Control Group (CTRL): No Block (Saline) Treatment Group1 (TRT1): SPIP Block with bupivacaine Treatment Group 2 (TRT2): SPIP Block with Bupivacaine +Magnesium as Adjuvant Treatment Group 3 (TRT3): SPIP Block with Bupivacaine +Magnesium + Buprenorphine both as Adjuvant~Patients are assigned randomly to each group."|t|t|f|t
33947627|NCT05180734|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33947628|NCT06495645|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947629|NCT06520865|||CASE_CONTROL||PROSPECTIVE|||||||
33947630|NCT06298721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844009|NCT04447105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will receive general anesthesia, therefore they can not know their anesthetic method.~Physicians involved in this study will investigate the outcomes."|A prospective randomized single-blinded study|t|f|f|f
33844010|NCT00564746|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947631|NCT06724224|||COHORT||OTHER|||||||
33947632|NCT03953300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844011|NCT01696552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844012|NCT04671966|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Subjects are studied (bloods and MRI) before and after intervention (2 day fast or 2 day fast with GnRH antagonist and estrogen add back).||||
33947633|NCT03877484|||CASE_ONLY||PROSPECTIVE|||||||
33947634|NCT03050749|NA|SINGLE_GROUP||OTHER||NONE||Princess® VOLUME||||
33947635|NCT05206305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947636|NCT00706901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947637|NCT03785782|||COHORT||PROSPECTIVE|||||||
33844013|NCT02265289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947638|NCT03194724|||CASE_ONLY||CROSS_SECTIONAL|||||||
33844014|NCT04002843|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Parallel Assignment Preliminary, mono-centric and prospective pilot study on information obtained using a medical device marketed according to CE standards. The study consists of three clinical electrophysiological evaluations.~The hemiplegic population after stroke, spasticity in in one elbow flexor muscle (biceps brachialis, anterior brachialisl) will be divided into two groups with three clinical and electrophysiological evaluations before injection, at the theoretical peak of efficacy (4-6 weeks) and three to six months after injection:~* Virgin BTA patients, first injection~* Injected group: Patients already injected, cumulative dose in one elbow flexor muscle (biceps brachialis, anterior brachialisl) \> 400 IU"||||
33947639|NCT06723093|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study design is a cohort study with a propensity score-matched control group and difference-in-difference analysis to evaluate intervention effectiveness. A hybrid type 1 effectiveness-implementation study framework is used that incorporates mixed methods to determine clinical effectiveness and explore implementation and participant well-being.||||
33947640|NCT04565769|||CASE_CONTROL||PROSPECTIVE|||||||
33947641|NCT01214382|NA|SINGLE_GROUP||||NONE||||||
33947642|NCT00887562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947643|NCT05933057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947644|NCT06722209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The statistician will not know which group the intervention is for. Data entry will be made as A and B.|prospective randomized controlled trial with experimental and control groups|f|f|f|t
33947645|NCT04022473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947646|NCT00401310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947647|NCT02132065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947648|NCT06722859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To compare the outcomes of open and microsururgical decompression in degenerative spinal stenosis in lumbar spine|To compare the outcomes of open and microsururgical decompression in degenerative spinal stenosis in lumbar spine|f|f|f|t
33947649|NCT02719093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947650|NCT05934682|||COHORT||PROSPECTIVE|||||||
33947651|NCT02180659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947652|NCT02259777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947653|NCT03907059|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33947654|NCT03247023|||CASE_ONLY||PROSPECTIVE|||||||
33947655|NCT03380091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947656|NCT00431106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947657|NCT04819022|||COHORT||PROSPECTIVE|||||||
33947658|NCT02974738|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947659|NCT06407375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947660|NCT00439010|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33947661|NCT06272487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947662|NCT06522074|||COHORT||PROSPECTIVE|||||||
33947663|NCT02007798|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33947664|NCT02318485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947665|NCT03963349|||OTHER||OTHER|||||||
33947666|NCT00383344|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34076162|NCT04085848|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33947667|NCT04148508|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Researchers will be blinded to condition. Participants join a cohort and all receive an App, but are not explicitly told which condition they are in.|Phase III superiority parallel 3-arm randomised multi-centre, multinational cohort randomized controlled trials (cmRCT)|t|f|t|t
33947668|NCT06461650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947669|NCT05123482|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study consists a master protocol with sub studies each evaluating the safety and tolerability of AZD8205 dosed as monotherapy, or in Combination with Anticancer Agents in Participants with Advanced Solid Tumours:~Sub Study 1 (AZD8205 monotherapy)~* Part A dose Escalation~* Part B dose Expansion Sub Study 2 (AZD8205 in combination with rilvegostomig)~* Part A dose Escalation~* Part B dose Expansion"||||
33947670|NCT05609838|RANDOMIZED|PARALLEL||OTHER||SINGLE|The researcher knew which of the participants belonged to the experimental and control groups, but the participants did not know. It is a single-blind study.|Two groups (experimental group and control group)|t|f|f|f
33947671|NCT04796142|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33947672|NCT03808415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947673|NCT02839330|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33947674|NCT02118467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33947675|NCT05733208|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33947676|NCT04246281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947677|NCT03738462|||CASE_ONLY||PROSPECTIVE|||||||
33947678|NCT01773434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947679|NCT03447015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The principal researcher will be kept blind for those participants who are in the intervention and control groups. Completing the second part of the study tool, which is related to maternal and infant health outcomes, will be in maternal ward and by the primary investigators 24 to 48 hours after birth.|A randomised controlled study will be conducted with primiparous women. In the intervention group women will be encouraged to ambulate and women in the control group will receive usual maternity care|f|f|t|f
33947680|NCT04525066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947681|NCT05482646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947682|NCT00976989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947683|NCT01256866|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947684|NCT06056076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Just participants were unaware of their intervention type|Single blind Randomized control trial|t|f|f|f
33947685|NCT06375044|NA|SEQUENTIAL||TREATMENT||NONE||||||
33947686|NCT06339957|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947687|NCT00743158|||CASE_ONLY||PROSPECTIVE|||||||
33947688|NCT06566742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947689|NCT06247280|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947690|NCT04828330|||CASE_CROSSOVER||PROSPECTIVE|||||||
33947691|NCT06537414|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33947692|NCT03326323|||COHORT||PROSPECTIVE|||||||
33947693|NCT04506658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947694|NCT01187173|||COHORT||PROSPECTIVE|||||||
33947695|NCT05819775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947696|NCT06724939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The operator was not blinded to the allocation of the material because of the distinct application approach for the restorative materials, which prohibited doing so. However, the participants(children) ,their caregivers, and the statistician were blinded to the restorative material used.|"The children will be randomly divided into 2 main groups according to the type of carious lesion:Group I occlusal lesions.Group II occluso-proximal lesions.~Then the children will be randomly sub grouped according to the type of restorative materials that will be used:Group IA and group IIA with filtek 3M bulk-fill resin composite .Group IB and IIB with surefil one restorative materials"|f|f|f|t
33947697|NCT05631158|||CASE_CONTROL||PROSPECTIVE|||||||
33947698|NCT03498963|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947699|NCT06016296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assessments will be scheduled two weeks before and after the intervention with a team of evaluators who will not have information about the training groups, nor will the participants know their identities. That is, a double-blind shield|The study includes an experimental design (randomized controlled trial), double-blind, with repeated measures, parallel groups and a quantitative approach.|t|f|t|t
33947700|NCT06188351|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33947701|NCT01050998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947702|NCT06592794|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33947703|NCT06470334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947704|NCT04675229|||OTHER||CROSS_SECTIONAL|||||||
33947705|NCT05571969|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase Ib, two-part, multi-center study. In Part 1, the study will evaluate the safety and tolerability, antitumor activity, pharmacokinetics, and determine the maximum tolerated dose (MTD) of 2X-121 monotherapy (at BID regimen) in patients with advanced solid tumors. In Part 2, the study will evaluate the safety and tolerability, antitumor activity, and pharmacokinetics of 2X-121 (MTD) and dovitinib as combination therapy, and determine the MTD of dovitinib when given in combination with the MTD of 2X-121 determined in Part 1.||||
33844015|NCT02271438|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33844016|NCT04523675|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33844017|NCT05937893|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33844018|NCT01500811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844019|NCT03475654|RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective randomized controlled trial||||
33844020|NCT05499273|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33844021|NCT05007925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844022|NCT06728748|||COHORT||RETROSPECTIVE|||||||
33844023|NCT06226272|||COHORT||OTHER|||||||
33844024|NCT04519905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844025|NCT05056857|||CASE_CONTROL||OTHER|||||||
33844026|NCT06644274|||OTHER||PROSPECTIVE|||||||
33844027|NCT06727487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844028|NCT04716062|||COHORT||RETROSPECTIVE|||||||
33844029|NCT01035645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947706|NCT05952037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947707|NCT03267199|||COHORT||PROSPECTIVE|||||||
33947708|NCT01445366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33947709|NCT05539378|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double (participant and outcomes assessor)||t|f|f|t
33947710|NCT03740152|NA|SINGLE_GROUP||TREATMENT||NONE|Participant receives all three types of light: continuous, pulse, and sham. They do not know when they receive each type of light, but they do know that they will receive all three.|||||
33947711|NCT05647746|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The sleep technologists who assess the sleep study outcomes will be blinded to the device generating the diagnostic data|As the study investigate performances of the diagnostic equipment, the three diagnostic devices can be applied to the single group of patients at the same time|f|f|f|t
33947712|NCT02996266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947713|NCT03978949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33947714|NCT00429546|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33947715|NCT04515979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947716|NCT02566629|||CASE_CONTROL||PROSPECTIVE|||||||
33947717|NCT04971018|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33947718|NCT05804669|NA|SEQUENTIAL||TREATMENT||NONE||||||
33947719|NCT02960022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947720|NCT06724419|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33947721|NCT06722339|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE||Within subject, randomized, double-blind, sham-controlled trial|t|f|t|f
33947722|NCT06722469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know what arm they are randomized into.|Participants will be randomized to either join the whatsapp chatbot intervention and standard text reminder group.|t|f|f|f
33947723|NCT06724185|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33947724|NCT02708446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947725|NCT06573034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will be kept unaware of both their assigned condition and the study hypotheses. The research staff responsible for conducting the intervention and assessments will be blinded to the study hypotheses.Different researchers will be assigned to handle the procedures of recruitment, intervention, data collection, and analyses. Outcome assessors and data managers will not participate in participants' screening and allocation, and outcome assessors will maintain blindness to group allocation.|The two arms will include an active control condition (i.e., sham wall squat) and the Daoist Zhanzhuang condition.|t|f|f|t
33947726|NCT00003526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947727|NCT06206408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947728|NCT04766528|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33947729|NCT06039449|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Only applies to Cohort B||t|t|t|t
33947730|NCT03950531|||COHORT||RETROSPECTIVE|||||||
33947731|NCT01692457|||CASE_ONLY||PROSPECTIVE|||||||
33947732|NCT06308094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Two independent blinded trained readers will detect, interpret and quantify interstitial fibrosis using CT images, to ascertain intra- and inter-observer variability. The readers will determine the region of interest (ROI), myocardial and blood pool attenuation values in the pre-contrast and 5 minutes delayed acquisition.|||||
33947733|NCT00750061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947734|NCT01388699|||CASE_CONTROL||OTHER|||||||
33947735|NCT06715904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Sex research||||
33947736|NCT04854928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, Double-blind, Placebo-controlled Randomization 1:1, active to placebo|t|t|t|f
33947737|NCT05921734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33947738|NCT04477239|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Randomization will be performed using a random sequence generator to conceal the sequence from the rest of the researchers and to ensure that only the investigator who will manipulate the gluten doses will know the allocation pertaining to each individual. This investigator will not carry out any assessment or any other intervention during the trial period. Until study completion, the enrolled subjects, the clinicians and the person who will perform the statistical analysis will be blinded to the group assigned.||t|t|f|t
33947739|NCT06066242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947740|NCT05970120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947741|NCT04657627|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomised to one of two groups for 13 weeks: (i) PACE plus calorie information intervention group or (ii) calorie-only information comparator group.|t|f|f|f
33947742|NCT01779466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947743|NCT02596074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947744|NCT06722547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33947745|NCT03674385|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled open label study||||
33947746|NCT04613752|NA|SINGLE_GROUP||OTHER||NONE||||||
33947747|NCT06724341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947748|NCT03274791|||CASE_CONTROL||RETROSPECTIVE|||||||
33947749|NCT01052220|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized to intervention group of standard care.||||
33947750|NCT06510257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947751|NCT06185140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study evaluator will not know the assignment of participants.|parallel randomized controlled trial with a simply assignment (1:1)|f|f|f|t
33947752|NCT01138995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947753|NCT05934422|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33947754|NCT06394427|||COHORT||RETROSPECTIVE|||||||
33947755|NCT03857126|||COHORT||PROSPECTIVE|||||||
33947756|NCT02470351|||COHORT||PROSPECTIVE|||||||
33947757|NCT00016211|RANDOMIZED|||TREATMENT||||||||
33947758|NCT01097720|||COHORT||PROSPECTIVE|||||||
33947759|NCT04709640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947760|NCT05694949|||COHORT||PROSPECTIVE|||||||
34076163|NCT02797028|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34076354|NCT02750332|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34076355|NCT03970525|||CASE_CONTROL||PROSPECTIVE|||||||
34076356|NCT04777760|||COHORT||PROSPECTIVE|||||||
33947761|NCT04312152|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants, all care providers, investigators and outcome assessors are blind to treatment status, as well as patients and family. Three investigators with no contact with patients and families provide the appropriate blisters to patients. One investigator not involved in outcome assessment interacts with families for any question regarding the trial or medical issues, screening outcome assessors from contacts by families in between assessments (0-4-8 months). Families are requested to refrain from commenting their experience and trial outcome on social media.|Each patient receives active compound \[Q10 ubiquinol + Vit. E and polyvitamin B\] for 4 months and placebo \[Vit. E and B\] for another 4 months. The total duration of the trial is 8 months. Half of the patients receive the active compound during months 1-4 and placebo during months 5-8, while the remaining half receives placebo during months 1-4 and active compound during months 5-8. Patients are assessed at T0, T4 and T8 mo. Administration of active compound and placebo is in double-blind.|t|t|t|t
33947762|NCT06360159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Intervention group (Massage): Babies in the intervention group will be massaged three times a day for 3 days, each session lasting 15 minutes, in accordance with the field massage technique. Massage application will be applied 1 hour after the babies are fed. For massage application, apply oil, solution and cream etc. to the baby's skin will not be used. During the massage application, the baby will be placed in prone and supine positions. Massage will be applied to the newborns in the intervention group by the assistant researcher.~Control group: Apart from clinical routine practices, salivary cortisol samples will be taken from newborn babies in the control group and abdominal circumference of the babies will be measured."|t|f|f|t
33947763|NCT00100711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947764|NCT02930889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947765|NCT02319265|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33947766|NCT03993314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947767|NCT03115723|||COHORT||PROSPECTIVE|||||||
33947768|NCT05635162|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised||||
33947769|NCT06717256|RANDOMIZED|PARALLEL||OTHER||DOUBLE||randomized controlled trial|t|f|f|t
33947770|NCT06357442|||COHORT||PROSPECTIVE|||||||
33947771|NCT06082661|||OTHER||OTHER|||||||
33947772|NCT05965089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|Single-ascending doses in healthy subjects and multiple ascending doses in patients with mild to moderate chronic plaque psoriasis|t|f|t|t
33844030|NCT04449328|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947773|NCT06526104|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, phase II study of patients with advanced HCC with Child-Pugh B cirrhosis who are eligible for first-line treatment with T300+D.||||
33947774|NCT06456424|NA|SINGLE_GROUP||TREATMENT||NONE||Single patient||||
33947775|NCT01456559|||CASE_ONLY||PROSPECTIVE|||||||
33947776|NCT04189874|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33947777|NCT06723236|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33947778|NCT00942669|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947779|NCT01451177|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33947780|NCT03920774|||COHORT||PROSPECTIVE|||||||
33978004|NCT05817799|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Subjects of group B oral intervention group were given oral L-carnitine supplementation in the form of L-Carnitine tablets 500 mg thrice daily under strict monitoring for 5 months. The vitals were monitored daily during the course of supplementation.~Subjects of group B intravenous group were given Intra venous L-Carnitine as a dose of 20mg/kg IV bolus infused over 2-3 minutes, administered into intra venous line after every hemodialysis session ( thrice a week) for 5 months.~Complete general physical examination was done on every dialysis session. Patients were strictly monitored for the development of any signs of distress during the course of supplementation the drug. The patients and their attendants were educated about monitoring the vitals at home daily and to inform nephrologist immediately in case of any signs of allergy or distress. The supplementation was given after obtaining ethical approval and informed consent and under direct supervision of a Nephrologist."||||
33978005|NCT02285140|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33844031|NCT06470620|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844032|NCT05310422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844033|NCT05453240|||COHORT||RETROSPECTIVE|||||||
33844034|NCT03714698|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Both groups received the similar medication (atypical antipsychotic drugs) during the study. Patients in the control group participated in a non-specific activity programme including conventional exercise training, hobby and social interaction activities routinely twice a week, at the community mental health center during six weeks. The PEG participated in a supervised Pilates exercise program twice per week for six weeks (totally 12 sessions).|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks, while the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study|t|f|f|t
33844035|NCT05695586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33844036|NCT06441266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844037|NCT03231800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|This is a randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study in children with ADHD in a laboratory classroom setting|t|t|t|t
33844038|NCT00003187|RANDOMIZED|||TREATMENT||||||||
33844039|NCT06352814|||CASE_CROSSOVER||PROSPECTIVE|||||||
33844040|NCT03932305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-masked for investigators and patients|1:1 randomisation to placebo or lutein tablets|t|t|t|t
33844041|NCT00450021|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844042|NCT06332560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844043|NCT00165100|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844044|NCT05305729|||COHORT||PROSPECTIVE|||||||
33844045|NCT05618912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Each patient will have the surgical scar treated with either type of intervention|f|f|t|t
33844046|NCT06728319|||OTHER||RETROSPECTIVE|||||||
33844047|NCT02185222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844048|NCT00003253||||DIAGNOSTIC||||||||
33844049|NCT05846802|||COHORT||PROSPECTIVE|||||||
33844050|NCT03848676|||OTHER||PROSPECTIVE|||||||
33947781|NCT05473039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study multivitamin product with probiotics (Seidivid Ferty4®) and placebo will be supplied as capsules with an identical external appearance packaged in blisters in a white box with no label, marked only with the study code and patient code.|"This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a dietary supplement with probiotics, with two parallel group of subjects.~Based on previous studies, considering this study as a non-inferiority versus placebo study the calculated sample size of subjects is 210 (105 subject for each arm).~Once the informed consent is signed, the patient will be assigned a patient code and will be given the treatment box (white and with no label) corresponding to her code. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion. Throughout the COH period the patient will continue taking the study supplement and will undergo the regular ultrasound controls of the egg donation program for evolutive control of the number and growth of follicles, without interruption until the day of the GnRH-agonist trigger."|t|t|t|t
33947782|NCT05128656|RANDOMIZED|PARALLEL||SCREENING||NONE||Case control longitudinal study, Interventional minimal risk study||||
33947783|NCT05243472|RANDOMIZED|PARALLEL||PREVENTION||NONE||This program is designed as a parallel randomized intervention. The primary purpose of this program is Prevention.||||
33947784|NCT03113773|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33947785|NCT06631105|||CASE_ONLY||RETROSPECTIVE|||||||
33947786|NCT06525987|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes will be assessed by investigators blinded to participants' allocation.|"The trial will adopt a wait list delish in which one group will be randomized to immediate intervention while the other group will be randomized to delayed intervention."|f|f|f|t
33947787|NCT05710848|NA|SINGLE_GROUP||TREATMENT||NONE||Singe group assignment||||
33947788|NCT06706999|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33947789|NCT00000856||PARALLEL||TREATMENT||||||||
33947790|NCT02008162|||COHORT||PROSPECTIVE|||||||
33947791|NCT05940584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To minimise observer bias, the assessors will be blinded and will have no knowledge of the group allocation. The assessors will only be involved at the assessment time points, but at no other stage of this study.||f|f|f|t
33947792|NCT06560723|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Non Applicable|"The subjects included in this study will be described globally and then by group (experimental group and control group) using the usual parameters: mean, standard deviation, median, interquartile range, extreme values for quantitative variables; frequency and cumulative frequency (if relevant) for qualitative variables.~For the primary endpoint, the variation in the SF-36 score between M0 and M24 will be calculated and compared between the two groups using Student's t test. This crude comparison will be supplemented by an adjusted comparison based on a linear regression model, taking into account sociodemographic and clinical characteristics deemed relevant to account for potential patient selection bias. These characteristics differ from one center to another, leading to a potential confounding bias, hence the proposed adjustment"||||
33947793|NCT03027258|NA|SINGLE_GROUP||OTHER||NONE||||||
33947794|NCT03851536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947795|NCT01698749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947796|NCT01590095|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33947797|NCT02849873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947798|NCT02056808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947799|NCT00504816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947800|NCT04916132|||COHORT||PROSPECTIVE|||||||
33947801|NCT05905354|NA|SEQUENTIAL||TREATMENT||NONE||3+3 dose climb||||
33947802|NCT06445972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947803|NCT02270385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33947804|NCT05665543|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33947805|NCT02403115|||COHORT||PROSPECTIVE|||||||
33947806|NCT04637373|NA|SINGLE_GROUP||PREVENTION||NONE||This prospective descriptive study is taking place in a single university affiliated medical center.||||
33947807|NCT05340842|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33947808|NCT00001231|||COHORT||PROSPECTIVE|||||||
33947809|NCT03661281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947810|NCT06033352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1 within-patient (split-face) random allocation|f|f|f|t
33947811|NCT03994965|NA|SINGLE_GROUP||TREATMENT||NONE||Proof-of-principle study, investigator initiated, open label study||||
33947812|NCT00667537|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33947813|NCT02356770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947814|NCT05988866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study visit staff and the laboratory are blinded regarding the patient's study group.||f|f|t|t
33947815|NCT01611142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947816|NCT06723704|||COHORT||CROSS_SECTIONAL|||||||
33947817|NCT04586127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947818|NCT05330923|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947819|NCT01347827|||OTHER||PROSPECTIVE|||||||
33947820|NCT04273594|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33947821|NCT06371573|||COHORT||RETROSPECTIVE|||||||
33947822|NCT01348074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947823|NCT01718860|||COHORT||PROSPECTIVE|||||||
33947824|NCT06597734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947825|NCT01336647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947826|NCT00714831|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33947827|NCT06443437|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33947828|NCT06145100|||COHORT||PROSPECTIVE|||||||
33947829|NCT01266967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947830|NCT06235983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947831|NCT04375033|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized 1:1 and assigned to receive at each 28-day research visit either: 1) a 28-day take-home supply of SL buprenorphine, prescribed at the clinically determined dose, or 2) injectable sub-cutaneous buprenorphine administered in the clinic (target dose = 300mg; 100mg dose may be used for those who cannot tolerate 300mg).||||
33947832|NCT06723106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947833|NCT05535478|NA|SINGLE_GROUP||OTHER||NONE||||||
33947834|NCT06464198|||COHORT||PROSPECTIVE|||||||
33947835|NCT01395420|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33947836|NCT04568161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947837|NCT05648695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947838|NCT06509048|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33947839|NCT01728675|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947840|NCT00387101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947841|NCT01759173|||COHORT||PROSPECTIVE|||||||
33947842|NCT06580002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947843|NCT00509275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947844|NCT00009750||||TREATMENT||NONE||||||
33947845|NCT05525559|NA|SEQUENTIAL||TREATMENT||NONE||||||
33947846|NCT06682494|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33947847|NCT05644782|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, placebo-controlled, cross-over, single center clinical trials.||||
33947848|NCT04920175|||COHORT||PROSPECTIVE|||||||
33947849|NCT02505464|||CASE_ONLY||PROSPECTIVE|||||||
33947850|NCT06724679|NA|SINGLE_GROUP||OTHER||NONE||This study is a multicentric, prospective, exploratory interventional pilot trial aimed at assessing the feasibility of using an immersive VR device in a functional restoration program (FRP) for patients with chronic low back pain.||||
33947851|NCT02726997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947852|NCT05114031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Subjects, clinical investogators as well as outcome assessors (laboratories) will be blinded to treatment.|Randomised, double-blind, parallel, 2-arm, placebo-controlled study.|t|f|t|t
33947853|NCT01078467|||||PROSPECTIVE|||||||
33947854|NCT03090646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"An analyst on the Johns Hopkins University (JHU) study team (blind to group allocations) will use Stata 15 multiprocessor (MP) for Linux (College Station, Texas, USA) to generate a list of sequential group assignments. This list will be used to create sequentially numbered, sealed, opaque envelopes that will be used to allocate participants to the control or intervention arms. Study personnel who create the sealed envelopes will not be involved in patient recruitment. Study personnel who conduct recruitment will not be permitted to view the list of sequential group assignment, and the envelopes will not be opened until after patients consent to participate. Therefore, group allocation will be concealed to both participants and recruiters until after study enrollment.~The study is not blinded to providers, patients, or study personnel conducting data collection, but will be blinded to outcome assessors."|This is a randomized, controlled, nonblinded, two-arm, superiority trial with a 1:1 allocation ratio. Participants allocated to the intervention arm will receive up to three gift cards to a major online retailer in the mail after completion of the required 6-month, 1-year, and 2-year follow-up activities. Participants will be followed for the federally-mandated 2-year follow-up period.|f|f|f|t
33947855|NCT05714163|||OTHER||CROSS_SECTIONAL|||||||
33947856|NCT05421689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will receive two treatments of intramuscular injection of 1 AMDC-GIR dose of 150 x 10⁶ cells or identical placebo. Both patients and study investigators at all sites will be blinded to the treatment assignment of patients.|Double-blind, randomized, placebo-controlled, multicenter clinical trial|t|t|t|t
33947857|NCT02651662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947858|NCT05090592|||CASE_ONLY||PROSPECTIVE|||||||
33947859|NCT06285890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947860|NCT04159740|||CASE_CONTROL||PROSPECTIVE|||||||
33947861|NCT05058677|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076357|NCT05057221|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, interventional, single-arm, open label trial, with 1:1 matched de-identified retrospective control cohort.||||
34076358|NCT00311688|||||PROSPECTIVE|||||||
33947862|NCT05672810|||COHORT||RETROSPECTIVE|||||||
33947863|NCT04526639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33947864|NCT03734874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947865|NCT06723431|||CASE_CONTROL||RETROSPECTIVE|||||||
33947866|NCT04114227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947867|NCT05663749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947868|NCT06557967|||COHORT||RETROSPECTIVE|||||||
33947869|NCT05375045|||COHORT||OTHER|||||||
33947870|NCT05619263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33947871|NCT05055466|||COHORT||OTHER|||||||
33947872|NCT05579600|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33947873|NCT05398809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947874|NCT04307017|NA|SINGLE_GROUP||OTHER||NONE||||||
33947875|NCT00206700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947876|NCT06400420|||COHORT||PROSPECTIVE|||||||
33947877|NCT05191199|||COHORT||RETROSPECTIVE|||||||
33947878|NCT03383276||SEQUENTIAL||TREATMENT||NONE||||||
33947879|NCT04516798|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Self controlled experimental study||||
33947880|NCT03841331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947881|NCT03540628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Eligible patients will be randomized in equal blinded proportions by the pharmacy department to receive thiamine, vitamin C and hydrocortisone in the experimental arm or continue with hydrocortisone plus placebo and usual standard of care treatment as discussed previously.|"Enrollment for this study will be initiated in patients with septic shock that require addition of a second pressor agent.~The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care. If the patient needs additional pressor support or therapy, that will be recorded in the results.~The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. If the patient needs additional pressor support or therapy that will be recorded in the results."|t|t|t|f
33947882|NCT06722755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33947883|NCT00003695|RANDOMIZED|||TREATMENT||||||||
33947884|NCT04347174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator, patient and study staff will be blinded to the study treatment.|Randomized, blinded, two arms, active comparator controlled, clinical trial|t|t|t|t
33947885|NCT06722131|||COHORT||PROSPECTIVE|||||||
33947886|NCT06636123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947887|NCT06724471|||COHORT||PROSPECTIVE|||||||
33947888|NCT03702192|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947889|NCT04398160|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33947890|NCT01695681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947891|NCT06623422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947892|NCT06018376|||CASE_ONLY||PROSPECTIVE|||||||
33947893|NCT02033720|||COHORT||RETROSPECTIVE|||||||
33947894|NCT05846659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947895|NCT03557073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the provider and the outcomes assessor are blinded to participant's study arm.|Participants are randomized to receiving a postoperative phone call or not receiving a postoperative phone call by a physician.|f|t|f|t
33947896|NCT04446468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be blinded to treatment allocation and will remind the participant at each contact to not disclose their treatment status.|Participants are assigned to one of two groups in parallel: PEACE plus standard psychiatric discharge care vs. standard psychiatric discharge care alone|f|f|f|t
33947897|NCT01583699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947898|NCT05121818|||CASE_ONLY||PROSPECTIVE|||||||
33947899|NCT02316782|||COHORT||PROSPECTIVE|||||||
33947900|NCT00592423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947901|NCT05239065|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33947902|NCT06724380|||OTHER||RETROSPECTIVE|||||||
33947903|NCT05520359|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Randomized order of visits with individual and combined effects of mobility devices and spinal stimulation.||||
33947904|NCT03389217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947905|NCT05972824|||CASE_ONLY||OTHER|||||||
33947906|NCT00375011|||COHORT||PROSPECTIVE|||||||
33947907|NCT06723990|||COHORT||PROSPECTIVE|||||||
33947908|NCT06050486|NA|SINGLE_GROUP||TREATMENT||NONE||The interventional model is a simple one-arm study (intervention), with 3 assessment waves (pretest, posttest and follow-up).||||
33947909|NCT04430387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessor will be blind to group assignment of the patients|Recruited subjects will be randomly assigned to one of the three study groups for isolation during their dental cleaning, which are: Group 1- The saliva ejector; Group 2- The high-volume evacuator (HVE); Group 3- The DryShield.|f|f|f|t
33947910|NCT06082713|||CASE_CONTROL||RETROSPECTIVE|||||||
33947911|NCT05775666|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and 3+3 design dose escalation phase followed by dose expansion phase||||
33947912|NCT06050928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947913|NCT04856566|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33947914|NCT03764813|||COHORT||PROSPECTIVE|||||||
33947915|NCT01252914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947916|NCT05907343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947917|NCT06519578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947918|NCT06723652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947919|NCT03171272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947920|NCT00620126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947921|NCT06019793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947922|NCT02600559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947923|NCT06724536|||CASE_ONLY||PROSPECTIVE|||||||
33947924|NCT05026866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947925|NCT06443138|NA|SINGLE_GROUP||PREVENTION||NONE||Implementation of a personalized pre-habilitation program at home before surgery||||
33947926|NCT06619444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33947927|NCT05937295|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, open-label, multicenter, interventional clinical trial||||
33947928|NCT06709976|||COHORT||PROSPECTIVE|||||||
33947929|NCT05746195|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947930|NCT01795846|||||PROSPECTIVE|||||||
34154472|NCT06289309|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both participants and outcomes assessor will be blinded to the respective group assignment.|A prospective, randomized study with 2 arms: NeveTrend vs. NerveAssure mode (n=132 patients and 264 nerves at risk, each). Patients referred to the Department of Endocrine Surgery, Jagiellonian University Medical College in Krakow, for first-time thyroid surgery from March 1, 2024 onwards will be registered. Eligible patients with either benign or malignant thyroid disease will be assessed for the study. The study protocole has been approved by the Institutional Review Board (Bioethics Committee of the Jagiellonian University).|t|f|f|t
34154473|NCT01705678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34154474|NCT01598597|||COHORT||PROSPECTIVE|||||||
34154475|NCT03585049|||COHORT||PROSPECTIVE|||||||
33947931|NCT02395757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947932|NCT02874469|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947933|NCT04485104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947934|NCT04227665|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Explorative design|t|t|t|t
33947935|NCT04321525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33947936|NCT03534817|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33947937|NCT01750034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947938|NCT00439920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947939|NCT06400823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The study has a parallel design, with two different groups.~1. TENS+VR group~2. Conventional therapy group"|t|f|f|f
33978006|NCT00623103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978007|NCT05089123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33947940|NCT05295810|RANDOMIZED|CROSSOVER||TREATMENT||NONE|All participants will be fitted with a face mask connected to a tube supplied with gas from the RespirAct™ system. The participants will not be informed about the concentration of gases during each active stand test. After the study completion they will be informed about the order of interventions.|"Male and female NOH patients (n=40) will be recruited from the Calgary Autonomic Clinic, along with sex and age-matched controls from the community. Participants will complete five Active Stand Tests during which they will be asked to target different end-tidal (ET) CO2 levels. Participants will complete the following breathing protocol during an active stand test:~1. Breathing normal room air (ETCO2 free to fluctuate),~2. ETCO2 clamped at baseline,~3. ETCO2 clamped at +5mmHg,~4. ETCO2 clamped at +10mmHg,~5. ETCO2 clamped at +10mmHg with ETO2 clamped at 50mmHg."||||
33947941|NCT01273246|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33947942|NCT06724666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33947943|NCT06489041|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Group Assignment||||
33947944|NCT02528643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947945|NCT04051515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A team of assessors, different from the researchers implementing the exercise, will record all dependent variables. A blind researcher will randomize participants|Participants will be randomized into one of two exercise groups, intradialysis or home-based program|f|f|t|t
33947946|NCT00184730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947947|NCT06716710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947948|NCT02451449|||CASE_ONLY||CROSS_SECTIONAL|||||||
33947949|NCT06520761|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33947950|NCT04855682|||COHORT||CROSS_SECTIONAL|||||||
33947951|NCT05812183|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Surgery is comapred with medical treatments for obesity. Some of the medical treatments will include treatments using FDA-approved medications|f|f|f|t
33947952|NCT06484387|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33947953|NCT06723496|||CASE_CONTROL||PROSPECTIVE|||||||
33947954|NCT02253134|||||PROSPECTIVE|||||||
33947955|NCT05693233|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947956|NCT06006962|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm study: AgeWISE-AP intervention arm and a no treatment waitlist control group arm.||||
33947957|NCT06723925|||COHORT||OTHER|||||||
33947958|NCT00444028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33947959|NCT02662140|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33947960|NCT03133208|||COHORT||PROSPECTIVE|||||||
33947961|NCT04603339|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm feasibility study||||
33947962|NCT05934409|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||It will be a randomized crossover study prior to bariatric surgery (visits A0 and A1) followed by a longitudinal follow-up study after surgery (visits B0 and C0) in two groups (type 2 diabetes vs. controls). Inside each group, the protocol will be carried out as a within-subject, in which each subject will serve as his/her own control.||||
33947963|NCT06526247|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single site, controlled trial. All participants will be randomized at the individual level to SAH or TAU, with a 1:1 allocation ratio.||||
33947964|NCT06724575|||COHORT||PROSPECTIVE|||||||
33947965|NCT06722768|||COHORT||PROSPECTIVE|||||||
33947966|NCT04950452|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33947967|NCT02585089|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33947968|NCT02654184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947969|NCT05524805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947970|NCT02366546|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33947971|NCT05893160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33947972|NCT06235034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33947973|NCT06722898|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33947974|NCT02146365|||COHORT||PROSPECTIVE|||||||
33947975|NCT00175110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947976|NCT05614544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blind, placebo- and active-controlled 4 period, 4 way crossover design to assess the abuse potential of HSK3486||t|f|f|f
33947977|NCT05818774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33947978|NCT04179864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947979|NCT06723080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33947980|NCT02195479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947981|NCT05691530|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33947982|NCT06722326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33947983|NCT01437982|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33947984|NCT00502866|||||CROSS_SECTIONAL|||||||
33947985|NCT06717217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947986|NCT04691570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947987|NCT06722456|||CASE_CONTROL||PROSPECTIVE|||||||
33947988|NCT04478591|||COHORT||PROSPECTIVE|||||||
33947989|NCT00873496|||CASE_CONTROL||PROSPECTIVE|||||||
33947990|NCT06718348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33947991|NCT06487806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947992|NCT00316966|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33947993|NCT02649673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947994|NCT04711031|||COHORT||PROSPECTIVE|||||||
33947995|NCT06377267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33947996|NCT04621604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947997|NCT00057642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33947998|NCT06148298|||OTHER||OTHER|||||||
33947999|NCT04816591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948000|NCT05659875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948001|NCT01848769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948002|NCT06008782|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33948003|NCT00516698|||CASE_ONLY||PROSPECTIVE|||||||
33948004|NCT05832073|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The design of this trail is based on random, two-blind, placebo control. The subjects and investigators will not know the masking status, unless the specific subjects who required treatment for serious adverse events .|There were 152 healthy people aged 10-50 years, divided into two test groups: 76 rabies mAb CBB 1 alone and 76 rabies mAb CBB 1 combined with rabies vaccine administration, which were divided into 4 groups according to different doses|t|f|t|t
33948005|NCT01077908|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948006|NCT06031948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948007|NCT04725864|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two main arms, of which the experimental arm is split in two arms with different duration of treatment||||
33948008|NCT06612645|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation study||||
33948009|NCT04948697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948010|NCT06545708|||CASE_CONTROL||PROSPECTIVE|||||||
33948011|NCT00881374|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33948012|NCT05140109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948013|NCT03045107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A big dressing covering all incisions will be applied at the end of each operation in both arms.||t|f|t|t
33948014|NCT06087822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The IMD and placebo are comparable in appearance, texture, taste, and smell, and indistinguishable in packaging and labelling, so that study participants, CRO and investigators are blinded to treatment assignment|Randomized, double-blinded, placebo-controlled, multicenter clinical investigation according to Medical Device Regulation article 62|t|t|t|t
33948015|NCT04271111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know what condition they are assigned to.|Participants will be randomized into active treatment or control condition.|t|f|f|f
33948016|NCT03773354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948017|NCT06724627|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Three independent dermatologists set the gold standard diagnosis by reviewing skin image capture by primary care providers using smartphone cameras. Study will measure how primary care providers move closer to the gold standards with the support of AI image assessment. The study also measures impact on health equity by enabling at-home, remote assessment of skin images captured by patient smartphones, followed by assessment of AI for provider review.||||
33948018|NCT06142032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33948019|NCT05854719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Children with hearing impairment/loss are offered with the possibility for a two-month speechreading training at home. Altogether 30 children willing to participate in speechreading training will be recruited into the intervention group. Those not willing to participate in intervention will serve as controls (with no intervention). Normally hearing children will not take part in intervention, they only serve as controls.||||
33948020|NCT02315716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948021|NCT03486873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948022|NCT06723743|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33948023|NCT00010634|RANDOMIZED|||TREATMENT||||||||
33948024|NCT01886105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948025|NCT06347848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two parallel groups randomized control study||||
33948026|NCT06723405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948027|NCT02675660|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33948028|NCT03037138|NA|SINGLE_GROUP||PREVENTION||NONE||Use of blood flow profiling for prevention of postdialysis washed-out feeling through same group scale before and after profiling||||
33948029|NCT01283061|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948030|NCT05730621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948031|NCT05042882|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33948032|NCT04008459|||COHORT||PROSPECTIVE|||||||
33948033|NCT03625102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a single-center, phase IIa, double blind, and randomized, placebo-controlled trial of Antroquinonol in patients with hepatitis B infection. Subjects with diagnosis of hepatitis B meet inclusion/exclusion criteria will be randomized into 3 groups:~1. Antroquinonol 100 mg PO BID~2. Antroquinonol 50 mg PO BID~3. Placebo"|t|t|t|t
33948034|NCT04112108|||COHORT||OTHER|||||||
33948035|NCT02070718|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33948036|NCT05801679|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33948037|NCT05433584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948038|NCT02962999|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33948039|NCT00368069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948040|NCT04089943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948041|NCT06724614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948042|NCT05908474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A 30-day placebo-controlled randomised trial study in overweight adults who have not been diagnosed with Diabetes|t|f|t|f
33948043|NCT02977741|||COHORT||PROSPECTIVE|||||||
33948044|NCT03814746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Study||t|t|t|t
33948045|NCT00477542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948046|NCT05605366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948047|NCT02471898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948048|NCT03646929|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34154476|NCT06482450|RANDOMIZED|PARALLEL||OTHER||NONE||"The investigators will perform a pseudo-randomized controlled trial in which parents of patients with odd birthdates (e.g. April 13) and vaccines due at the index appointment who also have a MYchart account will receive a text message directing the parent to the LTS server with integration into the provider workflow. Patients with an even birthdate (e.g. April 14) who have a MYchart account will receive a regular text message and e-mail appointment reminder with a vaccine primer (e.g. Vaccines are due and reserved for the participant's child), but no patient- or provider-facing CDS.~Among patients without a MYchart account, those with odd birthdates will receive a link to the LTS website (patient-facing CDS) but no integration into the provider workflow. As in the control group above, those without a MYchart account and an even birthdate (e.g. April 14) will receive a text message and e-mail appointment reminder with a vaccine primer but no patient- or provider-facing CDS."||||
34154477|NCT01849419|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33948049|NCT05874609|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33948050|NCT06230523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948051|NCT06721988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948052|NCT00643331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948053|NCT05697406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will be evaluated pre and post hyperpolarized 13-C pyruvate injection for change in pyruvate signal compared to background.||||
33948054|NCT01952821|||CASE_ONLY||PROSPECTIVE|||||||
33948055|NCT06297642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948056|NCT05849649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33948057|NCT01428882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33948058|NCT04088227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948059|NCT00830310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948060|NCT03606473|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||\[C-11\]NPA d-amphetamine||||
33948061|NCT05337410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Students enrolled in the YES IDEAS program comprise the treatment group. Students enrolled in other after-school programs (not YES IDEAS) comprise the control group.||||
33948062|NCT01322412|||OTHER||PROSPECTIVE|||||||
33948063|NCT05059444|||COHORT||PROSPECTIVE|||||||
33948064|NCT05274620|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33948065|NCT03441828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|in the assessment of the surgical field quality surgeons are blind respect the level of neuromuscular block received by patients|"After enrollment, patients will be randomized in the two study groups:~Deep Neuromuscular Block group (group DNMB) Moderate Neuromuscular Block group (group MNMB)"|f|t|f|f
33948066|NCT04421638|||COHORT||RETROSPECTIVE|||||||
33948067|NCT01796899|RANDOMIZED|CROSSOVER||||NONE||||||
33948068|NCT04823494|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33948069|NCT05356039|||COHORT||PROSPECTIVE|||||||
33948070|NCT02860650|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948071|NCT04098991|||COHORT||PROSPECTIVE|||||||
33948072|NCT00469339|||COHORT||RETROSPECTIVE|||||||
33948073|NCT03612869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948074|NCT03521531|||COHORT||PROSPECTIVE|||||||
33948075|NCT06690086|||CASE_ONLY||PROSPECTIVE|||||||
33948076|NCT02737410|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948077|NCT04319939|||COHORT||PROSPECTIVE|||||||
33948078|NCT03431129|||CASE_CONTROL||PROSPECTIVE|||||||
33948079|NCT06722274|||CASE_CONTROL||RETROSPECTIVE|||||||
33948080|NCT05664672|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33948081|NCT04830813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948082|NCT04708366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948083|NCT04308668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Asymptomatic participants are randomized and analyzed separate from symptomatic participants.|t|t|t|t
33948084|NCT01625559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948085|NCT03997695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948086|NCT05664178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948087|NCT05565950|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33948088|NCT03601429|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33948089|NCT01119118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948090|NCT04943601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948091|NCT06715397|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33948092|NCT03473691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948093|NCT06124859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948094|NCT04123951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948095|NCT04217174|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948096|NCT05684042|||COHORT||RETROSPECTIVE|||||||
33948097|NCT00977600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948098|NCT06723054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and the investigators will be blinded to the randomization sequence as well as the prevention group. They will both not be aware of which mouthwash was used by the participant.|This study is designed to be a double-blind, randomized, controlled, parallel, single-center, intention-to treat (ITT), trial with an allocation ratio of 1: 1: 1 and of a non-inferiority framework. The participants will be randomly allotted to one of the three study groups.|t|f|t|f
33948099|NCT02185820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948100|NCT06315335|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33948101|NCT05869188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948102|NCT06467877|||COHORT||RETROSPECTIVE|||||||
33948103|NCT02977052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948104|NCT02272738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948105|NCT06648408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948106|NCT02303327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948107|NCT02061293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948108|NCT04416009|||COHORT||PROSPECTIVE|||||||
33948109|NCT01194323|||CASE_CONTROL||PROSPECTIVE|||||||
33948110|NCT00935675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948111|NCT00197704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076359|NCT05216445|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants and intervention facilitator will be unaware at the time of allocation that which group they are being assigned to (sealed envelopes- a randomizing researcher different from the facilitator will generate the sequences and assign an ID(1-50) to one of the groups based on the sequence). The sealed envelopes will be given to the facilitator who will open the envelope in the interview and inform the participants about their allocated group.|||||
34076360|NCT04906226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Randomized Controlled Trial||||
33948112|NCT06011629|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33948113|NCT00054821|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948114|NCT04928508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076361|NCT04848142|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33948115|NCT01432743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076362|NCT05688865|||COHORT||PROSPECTIVE|||||||
34076363|NCT02585349|||COHORT||PROSPECTIVE|||||||
33948116|NCT06446427|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|"Participants cannot be masked to whether they are at high or low altitude and whether they have spent a night at high altitude. However, they will not know whether they receive air (baseline, interventions 1 and 3) or supplementary oxygen nasally at the same flow rate (intervention 2).~Outcome Assessors will be fully blinded. They assess the medical performance on video recordings of the simulated scenarios, and will not know which time point a specific scenario has taken place (baseline, interventions 1-3) and whether participants receive air or supplementary oxygen."|The investigators imply a repeated measures design. A group of 20 participants will perform in simulated medical scenarios sequentially under four different circumstances (baseline, interventions 1-3)|t|f|f|t
33948117|NCT00001426||||TREATMENT||||||||
33948118|NCT01194765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948119|NCT06724133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948120|NCT01021449|||CASE_CONTROL||PROSPECTIVE|||||||
34154478|NCT03080363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948121|NCT05835310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948122|NCT01388322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948123|NCT05179811|||COHORT||PROSPECTIVE|||||||
33948124|NCT04590482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participant- care provider -investigator- outcomes assessor||t|t|t|t
33948125|NCT05419765|||COHORT||CROSS_SECTIONAL|||||||
33948126|NCT06723548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948127|NCT03226639|||COHORT||PROSPECTIVE|||||||
33948128|NCT00043134|RANDOMIZED|||TREATMENT||NONE||||||
33948129|NCT00473187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948130|NCT04914975|NA|SINGLE_GROUP||TREATMENT||NONE||repeated measures interventional single subject design||||
33948131|NCT01955291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948132|NCT02822118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948133|NCT05836389|||COHORT||CROSS_SECTIONAL|||||||
33948134|NCT06633965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomized 1:1 to assess a 1-week usual care period before use of the AIDANET system (Group A) or after use of the AIDANET system (Group B).||||
33948135|NCT04667793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948136|NCT06722443|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33948137|NCT05016570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigators will be blind to intervention allocation because the intervention and questionnaire is to be undertaken independently and remotely by the participants. Although the intervention is not masked from participants, they will not be informed of the purpose of the study or the different conditions until after they have completed all study measures.|Participants are randomly assigned to one of three groups. They will receive the same lung screening information but the format of this information will be determined by which group they have been randomised to. All participants will complete a questionnaire immediately after viewing the lung screening information.|f|f|t|f
33948138|NCT05835154|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33948139|NCT04513015|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"IBD subjects (40 children and 40 adults, 50% with CD and 50% with UC) will be enrolled in different conditions: at diagnosis, in remission, at relapse. For each IBD subject an age and gender matched control subject will be enrolled (40 children and 40 adults).~In a subgroup of subjects (20 children and 20 adults, 50% with CD and 50% with UC) in clinical remission/mild disease a dietetic approach will be proposed. Patients on steroids and patients with strictures will not be enrolled for this part of the study. Patients will be randomized in 2 groups: Group Antioxidant diet will receive 8 weeks of antioxidant dietary treatment and group Normal diet will continue a normal dietetic scheme (corresponding to a isocaloric, normolipidic diet for age and sex)."||||
33948140|NCT04513210|||CASE_CONTROL||PROSPECTIVE|||||||
33948141|NCT02093156|||||PROSPECTIVE|||||||
33948142|NCT06716008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948143|NCT03650218|NA|SINGLE_GROUP||OTHER||NONE||||||
33948144|NCT06722300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948145|NCT06202079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948146|NCT02894762|||CASE_ONLY||PROSPECTIVE|||||||
33948147|NCT06096532|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948148|NCT00021125||||TREATMENT||||||||
33948149|NCT02390869|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948150|NCT04499248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948151|NCT01249404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948152|NCT06724198|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, effect study||||
33948153|NCT01138709|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33948154|NCT06725030|NA|SINGLE_GROUP||OTHER||NONE||||||
33948155|NCT06723769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948156|NCT01150149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948157|NCT02930928|||COHORT||PROSPECTIVE|||||||
34154479|NCT01153698|||COHORT||PROSPECTIVE|||||||
34154480|NCT01748825|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34154481|NCT05312294|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34154482|NCT01255124|||COHORT||PROSPECTIVE|||||||
34154483|NCT01657734|||CASE_ONLY||PROSPECTIVE|||||||
34154484|NCT03358134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948158|NCT06713967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948159|NCT04553185|||COHORT||CROSS_SECTIONAL|||||||
33948160|NCT03432130|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33948161|NCT06125951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948162|NCT03440450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None, open label|Open label, dose escalation||||
33948163|NCT01069692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948164|NCT00577382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948165|NCT04828746|RANDOMIZED|PARALLEL||OTHER||NONE||Patients assigned to either pre-procedural ultrasound-guided anatomy review and skin marking prior to a lumbar puncture v standard of care, palpation only guided lumbar puncture.||||
33948166|NCT05879614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948167|NCT01390194|||CASE_CONTROL||PROSPECTIVE|||||||
34154485|NCT04720300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948168|NCT03301792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948169|NCT00891124|||COHORT||PROSPECTIVE|||||||
33948170|NCT05443633|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The subject codes will be used for blinding of the participants, care-providers, and assessors|individuals will be randomized to the active intervention or control group (standard care)|t|t|f|t
33948171|NCT03471507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The bottles will be labelled by pharmacy either Drug A or Drug B according to their designation with a label affixed to cover any drug manufacturing labeling. Only the dispensing pharmacy will not be blinded."|Subjects will be randomized to one of two study groups (Bonipar or diclofenac topical solution 1.5%), utilizing a predetermined randomization schedule in a 1:1 ratio.|t|t|t|t
33948172|NCT05378464|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33948173|NCT06382298|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are blinded to oil intervention group. Investigator blinded to participant's oil intervention group.|Three groups of 28-day parallel feeding trials with two groups receiving 20% of energy needs from CSO, or matched PUFA diet, and one group serving as control receiving 20% of energy needs as a mixture of oils that match the fatty acid profile of the average American intake.|t|f|t|f
33948174|NCT05850455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948175|NCT00003401||||TREATMENT||||||||
33948176|NCT04178330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948177|NCT04151615|||CASE_ONLY||PROSPECTIVE|||||||
33948178|NCT00845598|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33948179|NCT01889342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948180|NCT06109714|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33948181|NCT03291665|||CASE_ONLY||CROSS_SECTIONAL|||||||
33948182|NCT04872374|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33948183|NCT00762281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948184|NCT05338905|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948185|NCT02285673|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948186|NCT02258893|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33948187|NCT03230539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A proof-of concept, randomized 3-month study to evaluate the effects of three contraceptive intrauterine systems delivering Copper and a daily dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA)||||
33948188|NCT04532749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948189|NCT02190994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948190|NCT05269225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948191|NCT06509880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomized into two groups - main and control - using the envelope method. No surnames were indicated on the medical records. The researcher did not know to which group the patient would fall. The nurse did not know which group the patient was in when carrying out medical appointments. The physician-researcher was from another clinic and even from another city, who performed the laboratory analysis did not know the age, sex or diagnosis of the patient who was identified from the envelope. The social worker was from another clinic and when processing the results of the quality of life tests did not know to whom they belonged.|The goal of this study type: clinical trial is to primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc. and improve the quality of life and reduce one-year mortality in palliative treatment of metastatic forms of colorectal cancer.|t|f|t|t
33948192|NCT02454621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33948193|NCT06723639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948194|NCT01979640|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948195|NCT00390676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948196|NCT05223504|||COHORT||PROSPECTIVE|||||||
33948197|NCT05834244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948198|NCT04520347|||COHORT||PROSPECTIVE|||||||
33948199|NCT00542646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948200|NCT01938027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948201|NCT01558466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948202|NCT05566795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Tovorafenib versus standard of care chemotherapy||||
33948203|NCT02689713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33948204|NCT03701971|RANDOMIZED|PARALLEL||OTHER||NONE||evaluation of the benefit of music therapy on pruritus in patients with pruritic dermatitis compared to the application of an emollient||||
33948205|NCT03328572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33948206|NCT03455400|||COHORT||PROSPECTIVE|||||||
33948207|NCT04930562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948208|NCT03451630|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||We chose an individual, stratified randomized trial design to randomly assign each enrollee to one of the three interventions arms, minimizing and balancing confounding variables. We will utilize an unequal randomization ratio of 2:2:1 for High-Touch, High-Tech, and ODP, respectively. While the less resource intensive ODP, in fact, improve meaningful outcomes for certain patient subgroups, our health care system has invested heavily in High-Touch and High-Tech as evidence-based solutions for chronic disease care. We will use a mixed-methods approach that incorporates both qualitative and quantitative data.||||
33948209|NCT00610922|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33948210|NCT04281095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948211|NCT06284486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948212|NCT05607342|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, pilot clinical trial||||
33948213|NCT02289326|||CASE_ONLY||PROSPECTIVE|||||||
33948214|NCT02096601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948215|NCT03801070|||CASE_CONTROL||RETROSPECTIVE|||||||
33948216|NCT05754970|NA|SINGLE_GROUP||TREATMENT||NONE||To prevent allocation bias among patients, each healing abutment was designed with two surfaces that alternated between laser-treated/machined and ma-chined/laser-treated. The experimental healing abutment was removed after 30 ± 7 days, which coincided with the soft tissue biopsy.||||
33948217|NCT05298527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was conducted as the randomized controlled experimental trial.||||
33948218|NCT02295124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33948219|NCT06221852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948220|NCT05523427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948221|NCT01784172|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33948222|NCT00204711|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33948223|NCT04273802|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort A: first line treatment Cohort B: after hypomethylating-agents failure||||
33948224|NCT00501748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948225|NCT02567331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948226|NCT03754270|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a randomized, open, parallel-group intervention study. The two treatment groups are:~A.Patients with moderate OSA are treated with lifestyle advice (n = 50) B. Patients with moderate OSA are treated with CC and lifestyle advice (n = 50).~Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position."||||
33948227|NCT04790682|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948228|NCT02210559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948229|NCT00000968||||PREVENTION||DOUBLE||||||
33948230|NCT03308799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33948231|NCT02208466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948232|NCT01707667|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948233|NCT04942951|||CASE_CONTROL||PROSPECTIVE|||||||
33948234|NCT01733758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948235|NCT03588494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients were randomly assigned to a regimen of W1-CCRT(one treatment cycle of intravenous pump of recombinant human endostatin before chemoradiotherapy), or W2-CCRT(two treatment cycle of intravenous pump of recombinant human endostatin before chemoradiotherapy), or CCRT.|t|t|t|f
33948236|NCT01582932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948237|NCT04850170|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The subjects in this study are the patients with head and neck cancer after completion of the radiotherapy. Radiation-induced fibrosis is inevitable and there is no effective treatment to prevent it now. Therefore, there are two parts in this study :~The first part is a pilot study. There will be 10 subjects included and manual therapy and rehabilitation will be arranged for 6 months. The manual therapy would be once a week at most, and the rehabilitation would be twice a week at most.~The second part is a randomized controlled study. 60 patients would be randomized divided into two groups. The group 1 is manual therapy(once a week at most) and rehabilitation(twice a week at most), and the group 2 is rehabilitation only(twice a week at most)."||||
33948238|NCT03081962|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The election of the intervention will be performed following a randomization model. Only the care provider will know the assigned group.||t|f|t|t
33948239|NCT02425670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948240|NCT05947656|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study consists of two (2) cohorts. Nine (9) eligible patients will be enrolled to each cohort. The only difference between the two cohorts is the overall number of weeks of treatment (2 weeks for Cohort 1 vs. 3 weeks for Cohort 2). The study investigator will advise on which cohort the patients are enrolling into as it will depend on when the patients enter the study. The safety monitoring committee (SMC) will review all safety data for Cohort 1 and confirm that it is safe to proceed with the study before the study treatment for Cohort 2 can start.||||
33948241|NCT06269562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948242|NCT00727246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948243|NCT02335359|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948244|NCT03490253|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigators and those completing the statistical analyses will not be aware of the true study assignments|This study is a randomized, controlled, one-center superiority trial with three-arm groups and a primary endpoint of increase in daily steps during a 6 month intervention by a smartphone app. Randomization will be performed as block randomization with a 1:1:1 allocation. Patients will be automatically randomized into groups trough our secure server during on-boarding of the app. Patients need to be informed of the nature and frequency of the messages they will be receiving and discuss this with investigators during the course of the study. Therefore, investigators and patients will not be blinded. We used the SPIRIT checklist when writing our report.|f|f|f|t
33948245|NCT05680545|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, open-label, pharmacokinetic study||||
33948246|NCT01704482|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948247|NCT03237325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948248|NCT00475774|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
33948249|NCT06304064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948250|NCT06509425|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33948251|NCT03183661|||CASE_ONLY||PROSPECTIVE|||||||
33948252|NCT05156775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948253|NCT02883608|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33948254|NCT03678909|||COHORT||PROSPECTIVE|||||||
33948255|NCT01857570|||COHORT||PROSPECTIVE|||||||
33948256|NCT05671731|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants collecting data did not know group assignment of participants.|cluster randomized controlled feasibility trial|f|f|f|t
33948257|NCT02304770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948258|NCT03331302|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||COPD patients with standard vs study diagnostic methods (imaging procedures)||||
33948259|NCT00045136||||TREATMENT||||||||
33948260|NCT04668066|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33948261|NCT04807816|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1) phase II trial. Patients will be randomized between arm A (gemcitabine + berzosertib) and arm B (gemcitabine) with two patients randomized in arm A for one patient randomized in arm B.||||
33948262|NCT03165851|||COHORT||RETROSPECTIVE|||||||
33948263|NCT04956068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948264|NCT02583165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948265|NCT04952376|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Arm 1: Patient is informed via SMS of vaccine availability and advised to schedule an appointment.~Arm 2: Same as Arm 1 but delivered as a personalized message text from the PCP. Arm 3: Patients assigned to Arm 3 will receive the same message in the Arm 2 intervention. In addition, they will be given interactive or 2-way SMS options to obtain additional information about COVID vaccine."||||
33948266|NCT02550418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948267|NCT04037579|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33948268|NCT00000362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948269|NCT04697342|RANDOMIZED|PARALLEL||OTHER||SINGLE|The head nurse is blinded, and the unit nurses are randomly arranged according to the unit to participate in any education training||t|f|f|f
33948270|NCT00070070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study was open-label, and eligible patients were sequentially entered at the time they presented in clinic. Patients were sequentially assigned to one of four groups according to HLA-A2 characteristic and previous Bacille Calmette Guerin (BCG) therapy.||||
33948271|NCT01784094|||COHORT||CROSS_SECTIONAL|||||||
33948272|NCT06011668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948273|NCT02042807|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33948274|NCT00359684|||COHORT||PROSPECTIVE|||||||
33948275|NCT00542074|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33948276|NCT01966029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948277|NCT05090111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948278|NCT00974896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948279|NCT06724809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948280|NCT02479594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948281|NCT05762276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Cohorts A-D are blinded / Cohort E \& F are open label||t|t|t|t
33948282|NCT05267652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948283|NCT06724289|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible participants will receive 25 mg of psilocybin.||||
33948284|NCT00857701|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948285|NCT06723288|||COHORT||CROSS_SECTIONAL|||||||
33948286|NCT02059473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948287|NCT06723132|||COHORT||RETROSPECTIVE|||||||
33948288|NCT06514508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948289|NCT03651375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948290|NCT04493658|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948291|NCT05245266|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948292|NCT03011931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948293|NCT06235177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Recent studies suggest that neurotrophic factors play an important role in the pathogenesis of depression as well as the therapies for depression.|The purpose of this study is to find individuals who do not have a primary psychological disorder prior to a medical condition, behavior change, or a shift in the mind and body from a traumatic experience, PTSD, Dementia, Stress, and physical limitations that has caused a psychological issue.The other purpose is to assist the participants in naturopathy/holistic medicine treatments, which will allow them to not only recover from their current condition, but to also have an overall well-being, become more sustainable in their daily lives, and have an overall sense of health.||||
33948294|NCT05874921|||COHORT||OTHER|||||||
33948295|NCT01575158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154486|NCT04651608|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE||One of the 2 procedure groups randomized with sealed envelope was applied acupressure with pressure to the P-6 point on the wrist of the child by the researcher in the first application, the other is applied with sea-band, and it was followed for 24 hours. Acupressure application was performed on both wrists for 2 minutes each with pressure, and 15 minutes each with sea-band. In the next chemotherapy treatment, a placebo of the first procedure (placebo pressure/placebo sea-band) was applied to each child, which ensured the control group of their own.|t|t|f|t
34154487|NCT03846284|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|The group allocation is concealed in sealed, opaque envelopes, which are not opened until participant consent has been obtained. The participants, their anesthetists, and staff providing postoperative care are blinded to group assignment. The drugs are prepared in equal aliquots with code numbers. Closed envelop will be used|, prospective, blind,controlled clinical trial|t|t|t|t
33844051|NCT06288594|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this pilot randomized controlled trial, no masking is applied, as the nature of the interventions makes it impractical. Participants are informed of their group assignment since those in the second group are aware of their additional video call sessions with psychotherapists. The therapists conducting the sessions also need to be aware of the intervention they are delivering to properly adhere to the treatment protocol. This open-label approach is necessary to facilitate the intended psychotherapeutic interactions and to ensure that the intervention is delivered with fidelity, as per the study design.|"This is a three-arm, parallel randomized controlled trial. Upon enrollment, participants are randomly assigned to one of three groups. The first group will use the TraumaRelief application in addition to weekly video calls with a psychologist. The second group will use the TraumaRelief mobile application exclusively. The third group will serve as a control and receive no intervention. The primary outcomes will be measured at baseline, five weeks, one month, and three months post-intervention to assess the efficacy and acceptability of the mobile application and the added benefit of psychological support."||||
33948296|NCT02438293|||COHORT||PROSPECTIVE|||||||
33948297|NCT06240468|||COHORT||PROSPECTIVE|||||||
33948298|NCT04001166|||COHORT||RETROSPECTIVE|||||||
33948299|NCT01899417|||CASE_CONTROL||RETROSPECTIVE|||||||
33948300|NCT01092312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844052|NCT04042376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844053|NCT06728527|||COHORT||PROSPECTIVE|||||||
33844054|NCT04500769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844055|NCT05183789|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948301|NCT02831881|||COHORT||PROSPECTIVE|||||||
33948302|NCT05119101|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948303|NCT02016638|NA|SINGLE_GROUP||SCREENING||NONE||||||
33948304|NCT00267501|||OTHER||PROSPECTIVE|||||||
33948305|NCT03714139|RANDOMIZED|PARALLEL||OTHER||DOUBLE|One of the researchers , neither involved in the selection of the patients nor in the surgical and prosthetic treatment, will carry out electronically the randomization (randomization.com). Will be prepared sealed opaque envelopes and opened at the time of surgery.|Split mouth, At least one site will be used as a test and one as a control where experimental mini-implants will be installed.|f|f|t|t
33948306|NCT02739711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948307|NCT01466309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948308|NCT03822039|||COHORT||PROSPECTIVE|||||||
33948309|NCT00656942|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948310|NCT05571982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948311|NCT02928198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948312|NCT03372304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients and outcome assessors will be blinded to the delivery administrations. Investigators will not be present while programming of the infusion pump is taking place. The display of the infusion pump will be concealed at all times after initiation. Furthermore, throughout the trial, the infusion pump will be concealed from the patient through a non-transparent bag. Trial interventions will not be visible in electronic patient charts. The infusion pump is making a discrete noise when administering medications. To make sure that the PCA group and the continuous infusion group is blinded to interventions, a sham administration is activated every 8th hour. This sham administration will be 0.1 mL of ropivacaine 0.2%. Such a small dose of LA will not have any anesthetic effect nor pose a risk for the patient.|3 arms (API, CI and PCA only)|t|t|t|t
33948313|NCT06724653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomly assignment to 3 groups ( drug tapering_RAS blocker, beta blocker, drug maintaining)|f|f|f|t
33948314|NCT05970042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948315|NCT03389633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948316|NCT05568212|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In the group of individuals progressing during durvalumab theray, patients will be randomized to the experimental arm (durvalumab+chemotherapy) or to the standard arm (chemotherapy alone). The standard arm will act as a calibration arm.~In the second groups patients will be randomized to the experimental arm durvalumab+chemotherapy followed by maintenance durvalumab+olaparib or to the other experimental arm durvalumab+chemotherapy followed by maintenance durvalumab."||||
33948317|NCT06089265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|all HFI participants will get the medication, no placebo will be used. Controls will get no medication or placebo.|open label, pilot study||||
33948318|NCT03990012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948319|NCT03975218|||COHORT||PROSPECTIVE|||||||
33948320|NCT02836795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948321|NCT03048175|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Code was assigned to each participant. No info on whether they belong to cases or control was given to researchers and statistician.|Case-control intervention trial: cases are treated for pathology. Controls do not have pathology.|f|f|t|t
33948322|NCT06239142|||COHORT||CROSS_SECTIONAL|||||||
33948323|NCT06407843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33948324|NCT02694380|||OTHER||OTHER|||||||
34154488|NCT04721743|||COHORT||PROSPECTIVE|||||||
34154489|NCT02690714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154490|NCT04716101|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34154491|NCT02300519|||COHORT||PROSPECTIVE|||||||
33948325|NCT05195242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948326|NCT01915953|||||PROSPECTIVE|||||||
33948327|NCT00399542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948328|NCT01391260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948329|NCT06723730|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33948330|NCT02046551|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33948331|NCT03108664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948332|NCT03648021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948333|NCT02007824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948334|NCT03282409|||COHORT||PROSPECTIVE|||||||
33948335|NCT00334893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948336|NCT03056534|||COHORT||PROSPECTIVE|||||||
33948337|NCT01699321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948338|NCT04393961|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE|This is a device feasibility trial. There is no blinding or masking.|This study will include four arms. The experiences across all 4 arms will be exactly the same. Each arm has a slightly different experience with COVID-19.||||
33948339|NCT06722911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948340|NCT00936052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154492|NCT03338153|||COHORT||PROSPECTIVE|||||||
33948341|NCT02161809|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33948342|NCT06037486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076364|NCT03927859|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||This is a Multiphase Optimization Strategy (MOST) trial. All patients will be randomized to one of 4 (or 3 for one of the sites) intervention conditions in a fractional factorial design.||||
33844056|NCT06728345|||COHORT||PROSPECTIVE|||||||
33844057|NCT02302378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33844058|NCT05052788|||CASE_CONTROL||OTHER|||||||
33844059|NCT02984722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844060|NCT06081153|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33844061|NCT00440440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33844062|NCT06729619|||COHORT||PROSPECTIVE|||||||
33844063|NCT06095271|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844064|NCT00271726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076365|NCT04296708|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076366|NCT02888366|||OTHER||PROSPECTIVE|||||||
34154493|NCT02237638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154494|NCT00158951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154495|NCT01900743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050765|NCT05335395|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Although the nature of the intervention precludes formal masking of fieldworkers during data collection, we believe that this is unlikely to lead to bias for the following reasons: the data collection will be carried out completely independently of the campaign team; emphasis throughout training will be on understanding early child development, rather than on evaluating the radio campaign; the assessments will follow standardized data collection protocols; and the coders of the responsive parenting videos will be blind to their allocation status. In addition, the strict blinding procedures for data analysis described above have been designed to avoid any bias in methodological decisions or interpretation of findings all analyses will first be conducted blind to intervention allocation as. Finally, the randomisation was carried out and the code held by the independent trial statistician; it will only be shared with the campaign team."|This a cluster RCT. Local radio stations in the 8 intervention clusters will broadcast the SUNRISE campaign which will be promoting responsive caregiving and providing opportunities for early learning to support child development during the first 3 years of life. Radio stations in the 7 control clusters will broadcast as normal.|f|f|t|t
34050766|NCT04041687|||COHORT||PROSPECTIVE|||||||
34050767|NCT02697890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34050768|NCT06290843|||COHORT||PROSPECTIVE|||||||
34050769|NCT01921790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050770|NCT05927350|||COHORT||CROSS_SECTIONAL|||||||
34050771|NCT03104439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050772|NCT00863473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154496|NCT06000410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) All clinic staff who may be involved in making assessments of safety will be blinded to treatment assignment.|This is a prospective, multicenter, randomized, double-blind, placebo-controlled study of ASA in patients with OA of the knee. Patients will be randomly assigned in a 1:1 ratio to receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline) or 4 mL of normal saline.|t|t|t|t
33844065|NCT02304705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844066|NCT00080678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844067|NCT06727955|||COHORT||PROSPECTIVE|||||||
33844068|NCT03775928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844069|NCT04855838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33948343|NCT01699061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33948344|NCT02681549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948345|NCT05166161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948346|NCT04400773|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two group pre-test post-test.|f|f|f|t
33948347|NCT04370470|||OTHER||PROSPECTIVE|||||||
33948348|NCT00429026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948349|NCT02010359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948350|NCT02641691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948351|NCT03072576|||COHORT||PROSPECTIVE|||||||
33948352|NCT03647995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The randomization will be taken care of by the hospital pharmacy which will not be in contact with the patient.~The intern/resident who will recruit a patient in the study will not be in direct contact with the pharmacy.~The order will be sent to the pharmacy which, following a randomization sheet, will then send a neutral box containing a probiotic or a placebo product.~Only once the trial comes to an end, the investigator will receive from the pharmacy the randomization sheet and will then know which patient was given a probiotic and which was given a placebo regimen."||t|t|t|t
33948353|NCT00716365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948354|NCT03539666|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33948355|NCT02301065|||COHORT||PROSPECTIVE|||||||
33948356|NCT04296331|||COHORT||OTHER|||||||
33948357|NCT02190604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948358|NCT04214145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948359|NCT06410326|||OTHER||RETROSPECTIVE|||||||
33948360|NCT03608566|||COHORT||PROSPECTIVE|||||||
33948361|NCT05103462|NA|SINGLE_GROUP||TREATMENT||NONE|The study has only one arm|Prospective, longitudinal cohort design||||
33948362|NCT00012350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948363|NCT06724835|NA|SINGLE_GROUP||TREATMENT||NONE||Model Description||||
33948364|NCT01246193|RANDOMIZED|CROSSOVER||||NONE||||||
33948365|NCT03401502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|"* Treatment group:Ranolazine 1000 mg:~* Control group: Placebo"|t|t|t|t
33948366|NCT03455842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948367|NCT04104620|||COHORT||OTHER|||||||
33948368|NCT04982393|||COHORT||PROSPECTIVE|||||||
33948369|NCT03028324|NA|SINGLE_GROUP||OTHER||NONE||||||
33948370|NCT00231621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948371|NCT06722092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948372|NCT05689801|NA|SINGLE_GROUP||OTHER||NONE||||||
33948373|NCT00960869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948374|NCT03186950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948375|NCT03364452|||OTHER||CROSS_SECTIONAL|||||||
33948376|NCT03735056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33948377|NCT02431559|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33948378|NCT03068507|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participant didn't know their group allocation. The doctor of assessment was blinded to group allocation.|patients were randomly assigned to the prehabilitation group and control group by computer-based random numbers concealed in sealed envelopes|t|t|t|t
33948379|NCT01801475|RANDOMIZED|PARALLEL||||NONE||||||
33948380|NCT04136041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948381|NCT05147311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948382|NCT01660152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948383|NCT06136650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948384|NCT06211842|||FAMILY_BASED||RETROSPECTIVE|||||||
33948385|NCT06089681|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948386|NCT00325351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844070|NCT05436197|RANDOMIZED|PARALLEL||OTHER||NONE|"Participants: While the families will not be told explicitly if they have been assigned to the intervention or control group, they may be able to determine their group based on when their workshop is scheduled (i.e., immediately versus after completion of all study measures).~Research Coordinator: The research coordinator will be aware of the group allocations as they will be in charge of coordinating random assignment and have to schedule participants into workshops and other measures based on their specific allocation."|All participants will complete the baseline measure and then be randomly assigned to group 1 (intervention) or group 2 (control), in a computer generated 1:1 sequence.||||
33844071|NCT04217603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be stratified using the variables sex (Female and male) and age (\<60 and \>60). Additionally a block 2-4 pattern will be used to assure a random and evenly distributed patient population in the different strata. Randomization will be carried out by the research coordinator; the rest of the personnel will be blinded to the allocation of the patients to the different groups.|"This prospective, randomized placebo controlled, double-blind clinical trial will be conducted at Beth Israel Deaconess Medical Center (BIDMC) in accordance with Good Clinical Practice Standards and under IRB supervision. We plan to enroll a total of 32 patients with ECAC randomized by an opaque envelope technique into two different groups: group 1 (CPAP) and group 2 (sham-CPAP)~* Group 1: This group will perform a 6MWT with CPAP~* Group 2: This group will perform a 6MWT with a sham-CPAP"|t|t|t|f
33844072|NCT06332807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050773|NCT06665165|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34050774|NCT02858336|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34076367|NCT03461198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076368|NCT06218615|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34076369|NCT06611618|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34076370|NCT03185286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844073|NCT01725373|||COHORT||PROSPECTIVE|||||||
34076371|NCT05833282|||COHORT||RETROSPECTIVE|||||||
33948387|NCT01884675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948388|NCT03456557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948389|NCT06023472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"On the day of oocyte retrieval, recruited women will be randomly assigned into one of the following two groups according to a computer-generated randomization list with a 1:1 ratio and a block size of 10. The randomization list will be prepared by a designated research nurse who is not involved in care of the women and opened by a laboratory staff.~1. The microfluidic chip group and~2. The density gradient centrifugation group~The women and clinicians will be blinded to the treatment groups they are assigned. Only the laboratory staff in the IVF laboratory performing sperm preparation will be aware of the group assignment."|"On the day of oocyte retrieval, recruited women will be randomly assigned into one of the following two groups according to a computer-generated randomization list with a 1:1 ratio and a block size of 10. The randomization list will be prepared by a designated research nurse who is not involved in care of the women and opened by a laboratory staff.~1. The microfluidic chip group and~2. The density gradient centrifugation group"|t|t|t|t
33948390|NCT01323829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948391|NCT03556202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Initially double-blind (until original, pivotal studies AMAK \[NCT03482011\] and AMAJ \[NCT03535194\] are locked and unblinded), then open-label.|||||
33948392|NCT02257970|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33948393|NCT00281736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948394|NCT06032494|||COHORT||PROSPECTIVE|||||||
33948395|NCT04217941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded||t|f|f|f
33948396|NCT00000658||||TREATMENT||NONE||||||
33948397|NCT00265382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948398|NCT00071006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948399|NCT06190548|||COHORT||RETROSPECTIVE|||||||
33948400|NCT02620228|NA|SINGLE_GROUP||OTHER||NONE||||||
33948401|NCT00000131|RANDOMIZED|||TREATMENT||||||||
33948402|NCT00063076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948403|NCT02691845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948404|NCT00004808||||TREATMENT||||||||
33948405|NCT01509638|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33948406|NCT00229866|||||RETROSPECTIVE|||||||
33948407|NCT01871870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948408|NCT01600677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33948409|NCT03228173|||COHORT||CROSS_SECTIONAL|||||||
33948410|NCT01572012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948411|NCT00189917|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948412|NCT01343329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948413|NCT00629382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948414|NCT00288431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948415|NCT03267394|||COHORT||PROSPECTIVE|||||||
33948416|NCT06650982|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33948417|NCT05619185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948418|NCT05341531|||COHORT||PROSPECTIVE|||||||
33948419|NCT02989701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948420|NCT00984386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948421|NCT04833465|||COHORT||PROSPECTIVE|||||||
33948422|NCT06105593|||CASE_ONLY||RETROSPECTIVE|||||||
33948423|NCT04282551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel study with three arms of 13 weeks in total per participant.|t|t|t|t
33948424|NCT04707768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948425|NCT03004898|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33948426|NCT05483062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948427|NCT00346476|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33948428|NCT05351970|||COHORT||RETROSPECTIVE|||||||
33948429|NCT02688751|||OTHER||PROSPECTIVE|||||||
33948430|NCT02263976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948431|NCT03478982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948432|NCT04830358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34050775|NCT06665061|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The anesthesiologists and surgeons performing the anesthesia and assisting with the surgery were only informed of the mechanical ventilation mode to be used. Patients were unaware of their group assignment because mechanical ventilation was initiated after anesthesia induction when they were unconscious. The anesthetic nurses and doctors evaluating the patients postoperatively were also unaware of the group assignments.|This study enrolled patients aged 27-77 years who underwent elective laparoscopic myomectomy at our institution from February 2023 to August 2024. The patients had an ASA classification of I-III. Patients were excluded if they had an allergy to the anesthetic drugs used in the study, adverse effects to the analgesics included, liver cirrhosis or kidney dysfunction, or cardiopulmonary impairment.|t|f|t|t
34050776|NCT01279395|||COHORT||PROSPECTIVE|||||||
34050777|NCT02913404|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050778|NCT06078267|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There is a study group that uses the device \& the data is monitored and sent to the physician. The second group is a control group that will not use the device and will continue with normal standard of care.|f|f|f|t
33948433|NCT06400160|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|An Open-label, Multi-center, and Dose-escalation, Phase I/IIa Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety, and the Anti-tumor Effect of TB511 Monotherapy in Patients with Advanced Solid Tumors Refractory or Intolerant to Standard of Care (SoC) and Pembrolizumab Combination Therapy in Patients with Advanced Solid Tumors Relapsed or Refractory||||
34050779|NCT05231772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948434|NCT03593109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050780|NCT05744960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized design in which clinics will be randomized within healthcare systems||||
34050781|NCT03631914|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33948435|NCT03728101||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34050782|NCT04726618|||CASE_ONLY||PROSPECTIVE|||||||
34050783|NCT06667999|RANDOMIZED|PARALLEL||TREATMENT||NONE|Domains may be open-label or blinded (masked). Outcome assessment of health-related quality of life and cognitive function will always be blinded.|Randomised, embedded, multifactorial, adaptive, primarily Bayesian, domain-based platform trial.||||
34050784|NCT05269706|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Study will be conducted using a cross-over design, separated by a 1-week washout period.|t|t|t|f
34050785|NCT05269875|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34050786|NCT03799692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050787|NCT05473780|||COHORT||PROSPECTIVE|||||||
34050788|NCT01065376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050789|NCT01071980|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33948436|NCT05910268|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33948437|NCT05540678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050790|NCT06429969|||CASE_CONTROL||PROSPECTIVE|||||||
34050791|NCT06411600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050792|NCT01775982|||COHORT||PROSPECTIVE|||||||
33948438|NCT00491595|RANDOMIZED|PARALLEL||||DOUBLE||||||
33948439|NCT05420402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050793|NCT02073448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050794|NCT04049383|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be two phases of this study. A dose escalation phase to determine the safe CAR-20/19-T cell dose in patients B-cell ALL. Once the desired dose has been identified there will be a six-patient dose expansion phase at the specified dose level.||||
34050795|NCT02191722|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34050796|NCT05670041|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34050797|NCT03613909|NA|SINGLE_GROUP||OTHER||NONE||Repeated measures, single-subject experiment. Each subject received the same treatment.||||
34050798|NCT03417232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050799|NCT05525572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050800|NCT05499182|||COHORT||CROSS_SECTIONAL|||||||
34050801|NCT03677323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050802|NCT06587412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34050803|NCT04794608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050804|NCT02856724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050805|NCT05477524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34050806|NCT03492814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34050807|NCT00004422|RANDOMIZED|||TREATMENT||||||||
34050808|NCT05172440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050809|NCT05347238|||COHORT||PROSPECTIVE|||||||
34050810|NCT02912260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050811|NCT03224611|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34050812|NCT02807571|||COHORT||OTHER|||||||
34050813|NCT04757610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050814|NCT06667739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, masking to receipt (or not) of the intervention is impossible. One assessor will collect all data. They will be masked to group allocation.|This pilot study is a parallel group randomized controlled trial with an embedded qualitative component.|f|f|f|t
34076372|NCT02788643|||COHORT||PROSPECTIVE|||||||
34076373|NCT02923583|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34076374|NCT02953483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741257|NCT03512340|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts. Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will enroll up to 48 patients with advanced solid tumors and lymphoma/CLL.~Part B will include 5 monotherapy expansion cohorts: in advance solid and hematologic cancers (100 patients total)."||||
33741258|NCT06046534|||COHORT||RETROSPECTIVE|||||||
33741259|NCT01849367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741260|NCT02490124|||COHORT||PROSPECTIVE|||||||
33741261|NCT03897608|||CASE_ONLY||PROSPECTIVE|||||||
33741262|NCT02015234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741263|NCT00723801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741264|NCT00006508||||DIAGNOSTIC||||||||
33948440|NCT06046989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants who are conducting the MRI brain imaging will be blinded to the participants' condition (i.e., whether they are in the control or experimental group).|This study will include two arms and is a randomized controlled trial. For the experimental arm, a total of 120 participants will be enrolled in the BEAM group in cohorts of 24. The other 120 participants will be in the treatment-as-usual group where they will not have access to BEAM but will be able to access other resources or treatment.|f|f|f|t
34050815|NCT04964544|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 6-month, single-arm, uncontrolled technology-assisted Self-Selection and Actual Use Study to evaluate the use of nonprescription rosuvastatin 5 mg in combination with a Web App. It is an open-label study where participants qualify for treatment based on the medical history, laboratory and blood pressure data they enter into the Web App, accessed on their own device on the internet.||||
34050816|NCT04376944|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050817|NCT01862263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050818|NCT05247242|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34050819|NCT01005823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050820|NCT06144710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A：Open-label Part B：Double-blind|"This Study consists of Parts A and B. Part A ：Single dose of SG301 SC Injection in healthy volunteers. This part will consist of 1 mg/kg dose group (n=4) and 2 mg/kg dose group(n=4) , all 4 participants in each group will receive a single dose of SG301 SC Injection by abdominal subcutaneous injection.~Part B：Multiple doses of SG301 SC Injection/SG301 SC placebo in SLE patients. The MAD will be performed at a ratio of 8:2 in 4 dose groups (n=10/group), namely 2 mg/kg, 4 mg/kg, 8 mg/kg, and 12 mg/kg dose groups. The SG301 SC Injection or SG301 SC placebo will be subcutaneously injected every 2 weeks \[Q2W\] in a 2-week cycle for a total of 6 doses in the MAD study."|t|t|t|f
34050821|NCT04500483|||COHORT||PROSPECTIVE|||||||
33948441|NCT02090920|||CASE_ONLY||PROSPECTIVE|||||||
34050822|NCT01089764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050823|NCT00000818||||TREATMENT||NONE||||||
33948442|NCT02631434|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33948443|NCT05392543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050824|NCT03444948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050825|NCT03843749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050826|NCT06659783|||COHORT||PROSPECTIVE|||||||
34050827|NCT02476812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050828|NCT02074098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34050829|NCT03138031|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single Group Assignment. Prospective and non-randomized clinical trial||||
34050830|NCT05781516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050831|NCT00484835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050832|NCT01115920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050833|NCT00595985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050834|NCT05787808|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not posible in this study|The patients are randomised (1:1) into to parallel groups and followed up in 16 weeks. All the patients are switched to the same treatment for the following 16 weeks||||
34050835|NCT03694964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind study: treatment (experimental group) vs placebo (control group).|After signing the informed consent form, the patients will be randomized either in the experimental group (Citrulline (ProteiCIT®): 10 g / day) or in the control group (placebo).|t|t|t|f
34050836|NCT06166407|||COHORT||PROSPECTIVE|||||||
34050837|NCT02738255|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34050838|NCT01532843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050839|NCT05999617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050840|NCT04168502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050841|NCT05377957|||COHORT||PROSPECTIVE|||||||
34050842|NCT05948605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Site staff are blinded to the subject's assigned Arm.|Multi-center, double-blinded, prospective, randomized, sham-controlled study|t|t|t|f
34050843|NCT02251106|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34050844|NCT02339350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050845|NCT00829140|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34050846|NCT02458339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050847|NCT05195047|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study is double-blinded, which neither participants nor investigators know the results of intervention. In addition, laboratory test of blood samples will also be conducted without knowing the randomization results of participants to ensure the evaluation of outcome measure is objective.|A prospective, randomized, double-blind, placebo parallel controlled clinical trial.|t|f|t|t
34050848|NCT05156762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050849|NCT04323488|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||subjects are seen before and after receiving 8 weeks of reading instruction||||
34050850|NCT00078078|||COHORT||PROSPECTIVE|||||||
34050851|NCT01999998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050852|NCT00531713|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34050853|NCT06665685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study design will enroll arm 1 of 60 patients who will wear the device, BioButton, during their nursing home care. Arm 2 will consist of 10 nurses who have been assigned to care for one or more of the patients in Arm 1 to discuss device feasibility in terms of clinical care.||||
34050854|NCT06264557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050855|NCT06667245|||COHORT||PROSPECTIVE|||||||
34050856|NCT01554865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050857|NCT06668129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34050858|NCT02524743|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
34050859|NCT05278143|||COHORT||PROSPECTIVE|||||||
33741265|NCT06538532|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33741266|NCT06060405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741267|NCT03910335|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741268|NCT05491733|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33741269|NCT00001663||||TREATMENT||||||||
33741270|NCT04564352|||CASE_CONTROL||OTHER|||||||
33948444|NCT06722495|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm exploratory clinical study aimed at evaluating the efficacy and safety of combining stereotactic body radiation therapy (SBRT) with subsequent treatments in patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) who are unresponsive to neoadjuvant immunochemotherapy. The study plans to enroll 20 patients diagnosed with stage III-IVb (AJCC 8th) LA HNSCC who have received two cycles of platinum-based chemotherapy and PD-1 inhibitor immunotherapy, but achieved stable disease (SD) according to RECIST 1.1 criteria. These patients will receive SBRT (8Gy\*3F) during the third cycle of immunochemotherapy, followed by standard surgery and postoperative radiotherapy/chemoradiotherapy. The primary endpoint is the objective response rate (ORR) of the primary lesion after the third cycle, with secondary endpoints including overall ORR, pathologic complete response (pCR), major pathologic response (mPR), and partial pathologic response (pPR).||||
34050860|NCT04890236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050861|NCT02179970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050862|NCT01478672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34050863|NCT00392938|||CASE_ONLY||PROSPECTIVE|||||||
34050864|NCT02935361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050865|NCT05705193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050866|NCT06684561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050867|NCT05989074|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34050868|NCT04123535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948445|NCT04893720|||COHORT||PROSPECTIVE|||||||
33948446|NCT01303159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050869|NCT06585527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050870|NCT06667167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050871|NCT00771017|RANDOMIZED|||TREATMENT||NONE||||||
33741271|NCT00182689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948447|NCT05258968|NA|SINGLE_GROUP||OTHER||NONE||University students will be recruited to participate in 1 educational session on the Injeti Self Esteem Model.||||
34050872|NCT03115138|NA|SINGLE_GROUP||OTHER||NONE||||||
34050873|NCT06152614|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33948448|NCT03628872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner was blinded to treatment allocation during baseline and at the 3 month re-evaluation||f|f|f|t
34050874|NCT03121196|||OTHER||CROSS_SECTIONAL|||||||
33948449|NCT03744858|||CASE_CONTROL||PROSPECTIVE|||||||
34050875|NCT01935856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050876|NCT00287989|RANDOMIZED|||TREATMENT||NONE||||||
34050877|NCT03809767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050878|NCT06684301|||COHORT||PROSPECTIVE|||||||
34050879|NCT02726711|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33948450|NCT05069909|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34050880|NCT06491654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person analyzing the data collected (investigators, statisticians) will not know to which group each person belongs.|Prospective single-center randomized clinical trial.|f|f|f|t
33948451|NCT01560676|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33948452|NCT05803668|||CASE_ONLY||RETROSPECTIVE|||||||
34050881|NCT05570786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050882|NCT04443062|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, two-arm, open label, multi-center, phase II study||||
34050883|NCT03299426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34050884|NCT04764331|NA|SINGLE_GROUP||TREATMENT||NONE||5 subjects who are willing to participate in a novel treatment for Revian Red All LED cap will be enrolled in this study. The cap uses two wavelengths of light, 620 nm and 660 nm.||||
34050885|NCT04288687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050886|NCT06682013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34050887|NCT00833482|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33948453|NCT05349539|||CASE_CONTROL||PROSPECTIVE|||||||
33948454|NCT02643121|||COHORT||PROSPECTIVE|||||||
34050888|NCT06664047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospectively Randomized Controlled Trial|t|f|f|f
34050889|NCT02952846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050890|NCT04582929|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|complete Double Blind randomized controlled trial|Crossover Assignment Double Blind randomized controlled trial|t|t|t|t
34050891|NCT03065959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34050892|NCT04779528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050893|NCT04680416|||COHORT||PROSPECTIVE|||||||
34050894|NCT03054298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34050895|NCT06665152|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The patients did not know which file system was used in their treatment. The investigator was also not disclosed the intervention's name; rather, a code name was given to them.~Outcomes accessor also did not know the exact name but was provided with a code name."|Comparison of postoperative pain in two groups of patients, who underwent root canal treatment with two different file systems. total 74 patients divided into two groups and given different interventional treatment to monitor pain after treatment.|t|f|t|t
34050896|NCT00926848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research personnel who were collecting outcomes data were unaware of the subjects' group assignment.|Patients and partners in the PaTH intervention group formally joined and participated in the full cardiac rehabilitation (CR) program consisting of 18-36 exercise and 18 educational sessions. In the usual care group, only patients received the exercise and educational sessions; partners received the educational sessions only.|f|f|f|t
34050897|NCT05250102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050898|NCT02659280|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34050899|NCT05536024|||COHORT||PROSPECTIVE|||||||
34050900|NCT03847753|||COHORT||PROSPECTIVE|||||||
34076375|NCT04013867|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076376|NCT05573451|||COHORT||PROSPECTIVE|||||||
34076377|NCT03788161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741272|NCT04468048|||COHORT||PROSPECTIVE|||||||
33741273|NCT02859194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741274|NCT02439086|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33741275|NCT06214546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741276|NCT03021759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34050901|NCT03407157|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The randomisation process will assign each participant with a unique study ID number. This study ID number will be required when allocating study drug bottles and lozenge packages and for recording data on the case report form (CRF). The drug bottle number and lozenge packs will be dispensed by a study team member directly to the participant. Probiotics and placebos will look and taste identical and drug bottles and lozenge packs and labels will look identical.|Randomisation will be centrally controlled using iSTAR, a web-based computerised randomisation platform at the BC Children's Hospital Research Institute, run by the PRE-EMPT (Pre-eclampsia Eclampsia Monitoring Prevention and Treatment) research group, UBC. PRE-EMPT will provide the randomisation platform, and web-linked drug supply management system. Randomisation will occur in random blocks of 2 and 4. Women will be randomised on a 1:1 ratio to probiotic:placebo.|t|t|t|t
34050902|NCT03366766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050903|NCT01883817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050904|NCT05481385|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34050905|NCT06663202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34050906|NCT06661798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050907|NCT02537431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050908|NCT04310397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050909|NCT01881204|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34050910|NCT03946449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050911|NCT02162719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050912|NCT05108298|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Other - Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms.||||
34050913|NCT03892382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.|Patients will be randomly assigned to real or placebo (sham) stimulation.|t|f|t|t
34050914|NCT05377554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This protocol describes prospective, open-label, blinded, randomized controlled, multicenter pivotal studies.|f|f|t|f
34050915|NCT06228352|||CASE_CONTROL||PROSPECTIVE|||||||
34050916|NCT00792974|||CASE_CONTROL||PROSPECTIVE|||||||
34050917|NCT06097624|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Examiners and researchers who are going to run the data analysis will be blinded to the assignment||f|t|f|t
34050918|NCT03362190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050919|NCT02053142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050920|NCT00823043|||COHORT||PROSPECTIVE|||||||
34050921|NCT03867487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double blind clinical trial in which the study team and the participants are blinded to whether the subject received placebo or study drug.||t|t|t|t
34050922|NCT01800643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050923|NCT03430479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34050924|NCT06666660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34050925|NCT06387212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050926|NCT01779310|||CASE_ONLY||PROSPECTIVE|||||||
34050927|NCT04024111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Assessor is blind to the participant's allocation to the intervention and active control group and the participants and carers are told they are participating in different social groups|The participants will be randomly allocated into an intervention group (KONTAKT Australia) and an active control group (Social Art group).|t|t|f|t
34050928|NCT04817488|||CASE_CONTROL||PROSPECTIVE|||||||
34050929|NCT04101682|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34050930|NCT05210114|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050931|NCT05262309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050932|NCT02780726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050933|NCT00489086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050934|NCT04729179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The project medication is manufactured specifically for research purposes, and the cannabidiol and cannabidiol placebo pills are identical in appearance, taste, and smell. The cannabidiol and placebo tablet packages are labelled with a unique Dispensing Unit Number (DUN). It is concealed to all involved parties (the participant, care provider, investigator qand outcomes assessor), but the database manager, wether the DUN can be identified as cannabidiol package or a placebo package.|A randomized, double-blind, placebo-controlled, parallel-group, single center trial|t|t|t|t
34050935|NCT02449304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050936|NCT05942014|||OTHER||CROSS_SECTIONAL|||||||
34050937|NCT06684080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050938|NCT02397122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050939|NCT06249347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cases were prospectively treated in a 2-arm 1:1 design according to ablation strategy, divided into the Promised group (n = 83) or the PVI combined LAAC group (n =83).|t|f|f|f
34050940|NCT06685705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patients will be randomly allocated into one of 3 study designed groups using serial number opaque closed envelopes.||t|t|t|f
34050941|NCT03151616|||COHORT||RETROSPECTIVE|||||||
34050942|NCT05797974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050943|NCT06664866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050944|NCT06684054|||COHORT||PROSPECTIVE|||||||
33741277|NCT04632667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|For post measurements, all data collection staff will be blinded to the intervention status.|Schools will be cluster randomized to the intervention or comparison group|f|f|t|f
33741278|NCT01040130|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33741279|NCT03324061|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741280|NCT02242786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741281|NCT04180982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741282|NCT02700646|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33741283|NCT02009618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34050945|NCT05048381|||COHORT||RETROSPECTIVE|||||||
34050946|NCT04073433|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050947|NCT03875274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050948|NCT05346315|||COHORT||PROSPECTIVE|||||||
34050949|NCT05630040|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This study will have a blinded assessor and all participants will be blinded.|"This will be a placebo controlled, double blind, randomized control trial with a crossover design built in.~Those randomized to the sham group will be given the opportunity to crossover into the active VNS arm once they have completed the sham arm (Week 12)."|t|f|f|t
34050950|NCT05051254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050951|NCT02905981|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050952|NCT05771896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34050953|NCT06360432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent assessor who is blinded to the group allocations will assess the participants' outcomes.|A two-arm, assessor-blinded, parallel design pilot randomized control trial (RCT) consisting of a M-health and a control group will be adopted to evaluate the effectiveness of the EatWellLog App in improving older adults' sarcopenic obesity (SO) status and other SO-related parameters by enhancing the self-management abilities and longer-term adherence to daily diet management among participants in the M-health group using the App, compared to the control group.|f|f|f|t
34050954|NCT05928429|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A national, multicenter, interventional, randomized, non-blinded clinical trial evaluating the preventive effects of cryotherapy for CIPN.||||
34050955|NCT05542706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34050956|NCT00746707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34050957|NCT05156892|NA|SEQUENTIAL||TREATMENT||NONE||Dose Escalation (3+3) design with Dose Expansion||||
34050958|NCT03457116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050959|NCT06528925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The information showing that the patients included in the research sample are assigned to group A and B according to the randomization table will be placed in an opaque envelope. This envelope will be kept by the researcher (GAU) and when the researchers (GB and EKD) go to the patient for the application, they will open the envelope after filling out the Informed Consent Form and learn which group the patient is in. While the researchers (GB and EKD) will be blinded in assigning the patients to the groups, they will not be blinded in the application and evaluation phase due to the application of virtual reality glasses. When the research is completed, the data will be transferred to the computer environment by a statistician who does not know the A and B groups, and the data will be analyzed by a statistician independent of the research and the findings will be reported. Thus, the data analysis and statistics phase will also be blinded to group assignment."|The study was planned as a prospective, two-arm (1:1), randomized controlled trial.|f|f|t|t
34050960|NCT05655910|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three parallel comparison groups will be created based on assessment of nutritional status and randomization.||||
34050961|NCT04528212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
34050962|NCT01128998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050963|NCT01703247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34050964|NCT05774483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050965|NCT00872261|||COHORT||PROSPECTIVE|||||||
34050966|NCT00066794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34050967|NCT00819598|||CASE_ONLY||PROSPECTIVE|||||||
34050968|NCT04444193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050969|NCT02799004|||COHORT||PROSPECTIVE|||||||
34050970|NCT03386253|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|t|f
34050971|NCT06195839|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34050972|NCT00905892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34050973|NCT05440435|||CASE_ONLY||PROSPECTIVE|||||||
34050974|NCT01073228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050975|NCT05296044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34050976|NCT00467727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34050977|NCT04546139|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34050978|NCT05331755|||COHORT||RETROSPECTIVE|||||||
34050979|NCT06666894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34050980|NCT00896272|||||RETROSPECTIVE|||||||
34050981|NCT04457102|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentric prospective interventional or retrospective observational study depending on the sub-part considered. It is segmented into 5 sub-parts each investigating the interest of MANIV for a specific motion management technique.||||
34050982|NCT01356043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34050983|NCT05335447|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34050984|NCT06110806|NA|SINGLE_GROUP||TREATMENT||NONE||This single-site clinical trial includes non-randomizing, dose-optimizing (20 sessions) clinical trial design to examine feasibility and appropriate duration of treatment. A final assessment will take place 3-months post intervention.||||
34076378|NCT06071741|||COHORT||PROSPECTIVE|||||||
34076379|NCT01963897|||COHORT||PROSPECTIVE|||||||
34076380|NCT05716997|||CASE_ONLY||PROSPECTIVE|||||||
33741284|NCT03737214|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open-label, uncontrolled, single-arm, extension study||||
33741285|NCT00358241|RANDOMIZED|PARALLEL||||DOUBLE||||||
33741286|NCT05915065|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This study will enroll one, non-random group of amputees to participate in 2-4 in person or virtual research visits, participate in a home trial and complete questionnaires pre home trial, at various points during the home trial and upon conclusion of the home trial.||||
34076381|NCT01947101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076382|NCT04778839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076383|NCT04187443|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076384|NCT04789525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741287|NCT06574295|||COHORT||PROSPECTIVE|||||||
33741288|NCT00617149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741289|NCT01621373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741290|NCT02881281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33741291|NCT05360238|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741292|NCT03229330|RANDOMIZED|PARALLEL||TREATMENT||NONE|All subjects involved are aware of the procedures applied due to the features of the therapies used.|||||
33741293|NCT00279123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741294|NCT01517113|||||PROSPECTIVE|||||||
34050985|NCT06299358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the study, interviews will be conducted at different times so that mothers or caregivers do not encounter mothers/caregivers in other groups. In this way, participant blinding will be ensured. Since the study will be conducted with newborns, no study will be conducted on other blinding techniques and biases. In order to prevent bias in the data evaluation process, each baby will be numbered by the researcher during the application and these numbers will be used by the statistical expert in statistical evaluations. The statistical expert will not learn the identity information of the participants and will only perform statistics according to the numbering.|"Type and Purpose of the Study The study was designed as a randomized experimental study. Sample of the Study G\* Power 3.1.9.7. program was used to calculate the sample size (Faul et al., 2007). As a result of the analysis, the sample size was calculated as 28 people for each of the three groups, and considering the possible data losses, it was decided to take 30 people for each group.~In the study, computer-aided randomization (random.org) program was used to determine the groups. Stratified randomization was preferred to ensure group similarity. In stratification, the number of weeks of age, gender and feeding patterns of the babies were used. After stratification, block randomization was used to decide which group the babies would be in.~SPSS 22.0 package program will be used for data analysis."|t|f|f|t
34050986|NCT05829343|||COHORT||PROSPECTIVE|||||||
34050987|NCT03988881|||COHORT||PROSPECTIVE|||||||
34050988|NCT03730467|||COHORT||CROSS_SECTIONAL|||||||
34050989|NCT06598462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34050990|NCT02769949|||OTHER||OTHER|||||||
34050991|NCT05272761|||CASE_ONLY||PROSPECTIVE|||||||
34050992|NCT04417803|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34050993|NCT04611191|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34050994|NCT03611777|||COHORT||CROSS_SECTIONAL|||||||
34050995|NCT04466761|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34050996|NCT06384976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34050997|NCT02320058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34050998|NCT06664944|||COHORT||PROSPECTIVE|||||||
34050999|NCT05160246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051000|NCT05771324|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The participants who were assigned to the researcher groups that evaluated the hematological test results of the babies and followed the growth were kept confidential from the interventions.~The person evaluating the outcomes was kept confidential from the participant and the interventions.~Participants did not know about the other intervention group."|The sample size of the study consisted of 62 people according to the power analysis. Block and stratified randomization methods were used in the selection of the experimental groups. When the literature is examined, there are studies showing the effect of mothers' education level and previous complementary food experiences on the transition to solid food. Accordingly, stratification was made according to the education level of the mothers and the number of children. Thus, two people were assigned homogeneously in each block according to the education level of the mothers and the number of children. Randomization was done by the Outcome Evaluator independently of the investigators. The research was carried out according to the Consort 2010 Flow Chart and the study was concluded with 56 people.|t|f|t|t
34051001|NCT05287919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051002|NCT03190915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051003|NCT05303766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051004|NCT06137742|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"Part A is an investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose.~Part B is a 24-week, randomized, double blind, placebo-controlled study."|Part A is a sequential study. Part B is a parallel group study.|t|t|t|t
34051005|NCT06180486|RANDOMIZED|PARALLEL||OTHER||NONE|Patients, research assistants, surgeons, and anesthesiologists are all unblinded|Randomized control trial of two groups, intervention vs waitlist control||||
34051006|NCT04423770|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34051007|NCT04495985|||COHORT||PROSPECTIVE|||||||
34051008|NCT01181713|||CASE_CONTROL||PROSPECTIVE|||||||
34051009|NCT01037595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051010|NCT00683124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34051011|NCT06666907|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34051012|NCT06162715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051013|NCT01758731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051014|NCT02957435|NA|SINGLE_GROUP||OTHER||NONE||||||
34051015|NCT03173690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The care provider performing medicines reconciliation at ward is semimasked. The masking might be broken if the patients tells if he/she has been interviewed earlier in the study|The included patients are randomized to either intervention or control group. The intervention group receives medicines reconciliation at the intensive care unit. The control group receive standard pharmaceutical care, which now does not include medicines reconciliation. After the patients are transferred to care at the ward, medicines reconciliation is performed for all patients.|f|t|f|f
34051016|NCT04183413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a parallel three-arm cluster-randomized trial without a baseline assessment.||||
34051017|NCT02499653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051018|NCT00954512|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051019|NCT00623935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051020|NCT03543969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051021|NCT01585662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051022|NCT06667713|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Randomized Controlled Trial (RCT)||||
34051023|NCT04630613|||COHORT||CROSS_SECTIONAL|||||||
34051024|NCT04660994|||CASE_CONTROL||PROSPECTIVE|||||||
34051025|NCT01213641|||COHORT||PROSPECTIVE|||||||
34051026|NCT03628131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051027|NCT05926973|||COHORT||RETROSPECTIVE|||||||
34076385|NCT03215537|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076386|NCT03863847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34154497|NCT01640899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154498|NCT03039153|||COHORT||RETROSPECTIVE|||||||
34051028|NCT04778462|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"1. sixty subjects from both genders with their age between 20 and 26 years old~2. Symptoms of active TrPs unilateral on at least one side of the upper fiber of trapezius muscle presence of at least one trigger point symptoms lasting from 0 to 2 weeks age~3. The patients will be randomly assigned into three different groups Group (A) will receive extracorporeal shock wave plus stretch, strength exercise and ischemic compression Group (B) will receive high-power pain threshold ultrasound plus stretch, strength exercise and ischemic compression Group (C) will receive conventional treatment (stretch, strength exercise and ischemic compression."|t|f|f|f
34051029|NCT04030390|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34051030|NCT05449587|||COHORT||OTHER|||||||
34051031|NCT06069076|||CASE_CONTROL||RETROSPECTIVE|||||||
34051032|NCT01421628|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34051033|NCT05405946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The group will be randomized as parallel groups. CCRT Group in comparison with TAU Group. Randomization will be performed using permuted blocks with a fixed size of 8 patients assigned in a relationship 4:4 according to the computerized assignment.||||
34051034|NCT04563975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051035|NCT03268200|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34051036|NCT03557216|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic clinical trial||||
34051037|NCT01065870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051038|NCT05742009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator cannot see the measurement results.|||||
34051039|NCT06667973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051040|NCT06120569|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34051041|NCT06509958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051042|NCT06243783|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34051043|NCT01182597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051044|NCT00089778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051045|NCT04743193|||OTHER||PROSPECTIVE|||||||
34051046|NCT04837508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051047|NCT06666478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051048|NCT02096757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051049|NCT04483089|||COHORT||PROSPECTIVE|||||||
34051050|NCT04828226|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"After randomisation in RedCap, a study nurse otherwise not involved in the trial will store group allocation in an envelope (labelled with the patients study identifier, name and date of birth) in a closed cupboard accessible to the post-anaesthesia care team member preparing the study drug, but not the treating or assessing team. After a patient's trial completion, the envelope and its content will be destroyed.~Therefore, the treating team, the patient as well as the data collecting personnel is blinded to group allocation. The bottles containing study drug or placebo are identical and are identically labelled with Study Drug and the patients name by the independent post-anaesthesia care member preparing the study drug before ECT sessions start. Data analysts will be blinded as well because allocation to verum or placebo is only known to the study nurse randomising patients and preparing the envelopes needed for drug preparation."|This is a prospective, randomised, placebo-controlled, triple blind, single-centre, two-arm parallel groups superiority trial assessing incidence and severity of postictal delirium.|t|t|t|t
34051051|NCT05794984|||OTHER||CROSS_SECTIONAL|||||||
34051052|NCT04253626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051053|NCT00004235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051054|NCT06682533|||COHORT||PROSPECTIVE|||||||
34051055|NCT02963428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34051056|NCT06685042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051057|NCT04454684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This study will be open label|Examining safety and effects of three sessions of MDMA-assisted psychotherapy||||
34051058|NCT05412290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051059|NCT05927740|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|110|2 groups ( group 1 hyperemesis gravidarum ) (group 2 control group)|t|f|f|f
34051060|NCT05080114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051061|NCT02831010|||COHORT||PROSPECTIVE|||||||
34051062|NCT03466203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051063|NCT01860040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051064|NCT04661241|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|As a pilot study, the results of our method will be blinded to the clinician who will operate the MRgFUS tremor therapy in order to compare the locations of the proposed target, surgical lesion and stereotactic coordinates.|All patients in this study will be recruited from New York University Langone Health in cooperation with the NYU Neurosurgery and the Center for Neuromodulation. The Department of Neurosurgery will make initial contact with prospective patients who will undergo the MRgFUS tremor treatment. The patient's treating physician will determine suitability based on the subject's known clinical status and ability to be informed consent to participate in the study.|f|t|f|f
34051065|NCT04314557|||CASE_ONLY||PROSPECTIVE|||||||
34051066|NCT04287946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051067|NCT05481125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051068|NCT01579838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051069|NCT05262088|||COHORT||PROSPECTIVE|||||||
34051070|NCT06614543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051071|NCT04432714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051072|NCT02779699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741295|NCT06235749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33741296|NCT05527496|||CASE_CONTROL||RETROSPECTIVE|||||||
33741297|NCT06425172|||COHORT||PROSPECTIVE|||||||
33741298|NCT04544046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051073|NCT05918783|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part B recruitment will be opened upon completion of Part A light dose escalation.||||
34051074|NCT04028895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051075|NCT02372812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33741299|NCT04877912|||COHORT||PROSPECTIVE|||||||
33741300|NCT06089304|||COHORT||RETROSPECTIVE|||||||
33844074|NCT05336630|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be unblinded to their treatment on the 5 (+/- 2) day follow-up call.|Patients will be randomized to either ERCP with forceps assisted cannulation or ERCP with no forceps.|t|f|f|f
33844075|NCT05271721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844076|NCT05523947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051076|NCT05898984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The doses will be administered to all subjects in a crossover design. The doses administered as a single dose for the Test product (T: CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI) and Reference product 1 (R1: CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI) in this study are equivalent to the TDD authorised for asthma and the maximum TDD authorized for Reference product 2 (R2: BDP HFA \[QVAR REDIHALER®, BDP 80 μg\]) in regular treatment of asthma.||||
34051077|NCT03783585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051078|NCT04793529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844077|NCT04211662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||open-label, two-arm Randomized Control Trial (RCT)||||
33844078|NCT05859451|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051079|NCT00536627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051080|NCT06111196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051081|NCT06665347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051082|NCT06620731|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051083|NCT06662409|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051084|NCT03244631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective randomized|f|f|f|t
34051085|NCT03715972|||COHORT||OTHER|||||||
34051086|NCT04013360|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34051087|NCT06572748|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34051088|NCT06288841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051089|NCT06665139|||CASE_CONTROL||OTHER|||||||
34051090|NCT04515264|||OTHER||PROSPECTIVE|||||||
34051091|NCT01298869|||CASE_ONLY||PROSPECTIVE|||||||
34051092|NCT06666309|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34051093|NCT03378297|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The first treatment cohort has a randomized design 2:1 (olaparib 32:control 16). The study is unblinded. In the following treatment arms are initiated each will included patients (n=32) will be offered the study-prespecified treatment drug.||||
34051094|NCT06682884|NA|SINGLE_GROUP||TREATMENT||NONE||Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer||||
34051095|NCT05209776|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051096|NCT06651827|NA|SINGLE_GROUP||OTHER||NONE||||||
34051097|NCT06402448|||OTHER||CROSS_SECTIONAL|||||||
34051098|NCT05709951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding||t|f|f|f
34051099|NCT05382091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051100|NCT05601323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051101|NCT01024868|||CASE_ONLY||PROSPECTIVE|||||||
34051102|NCT06475937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051103|NCT01802736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051104|NCT04004065|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34051105|NCT01769508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948455|NCT04130204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Topical lotion is provided in de-identified sachets|Randomized, placebo-controlled, double-blind|t|t|t|t
33948456|NCT00005990||||TREATMENT||||||||
33948457|NCT05129358|NA|SINGLE_GROUP||OTHER||NONE||Open-labeled||||
33948458|NCT00602082|RANDOMIZED|||TREATMENT||||||||
33948459|NCT00002600||||TREATMENT||||||||
33948460|NCT00138723|RANDOMIZED|PARALLEL||||DOUBLE||||||
33948461|NCT00372658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948462|NCT01472575|||CASE_ONLY||RETROSPECTIVE|||||||
33948463|NCT00107666|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33948464|NCT05362318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948465|NCT01439308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948466|NCT03804723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a 36 month, randomized, double-blind, placebo-controlled, parallel-groups, equivalence multicenter trial in patients with inactive SLE to evaluate if low disease activity can be sustained with withdrawal of glucocorticoids|t|f|t|t
33948467|NCT02711085|||COHORT||PROSPECTIVE|||||||
33948468|NCT05338749|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33948469|NCT05681975|||OTHER||CROSS_SECTIONAL|||||||
33948470|NCT06373380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be conducted using a double-blind design.|This will be a randomized multi-centered, double-blind, placebo-controlled trial|t|f|t|t
33948471|NCT00184418|||COHORT||CROSS_SECTIONAL|||||||
33948472|NCT01993290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051106|NCT02793674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051107|NCT03257852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051108|NCT06642207|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33844079|NCT00488475|||COHORT||PROSPECTIVE|||||||
33948473|NCT01362231|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948474|NCT04654299|||COHORT||PROSPECTIVE|||||||
33948475|NCT03292770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All included patients will be blinded of the procedure.|All participants will be randomized by an intention to treat approach. All other components of the IVF/ICSI cycle including stimulation medications, monitoring protocols, etc. will be at the discretion of the participant's primary physician; while this information will be documented it will not constitute criteria for enrolment. The group allocation will take place the day of the embryo transfer. The clinician will randomize all included patients into one of the two study groups using an open computer-generated list.|t|f|f|t
33948476|NCT00609934|NA|SINGLE_GROUP||||NONE||||||
33948477|NCT02514642|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34051109|NCT03689374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051110|NCT04128904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051111|NCT01177709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051112|NCT04229329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948478|NCT00136266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948479|NCT06380374|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33948480|NCT04749862|||OTHER||PROSPECTIVE|||||||
33948481|NCT01128699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948482|NCT03054272|||COHORT||PROSPECTIVE|||||||
33948483|NCT00116610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948484|NCT05156346|NON_RANDOMIZED|PARALLEL||OTHER||NONE|LEAVES-PT will be an open label trial where both participants and researchers are aware to which arm participants have been assigned to.|LEAVES-PT was planned to be a single-centre, pragmatic randomised two-armed parallel-group controlled trial to evaluate the clinical effectiveness on grief of a 10-week open-label intervention of an internet-based self-help spousal bereavement support service (LEAVES) in Portugal vs. usual care. The plan was for participants registered in ULSBA's primary care services to be invited to participate and randomised to one of two arms: LEAVES support service + usual care or usual care. For ethical purposes, participants allocated to the control group will be offered (but not monitored) the LEAVES support service at no cost after the end of the study if requested. However, due to recruitment barriers, the study became a pre-post study with only 1 intervention arm.||||
34051113|NCT03196661|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|This trial achieved the goal of random and blind method through blinded method for vaccine. All the testing vaccines and reference vaccines are provided by sponsor, and entrust Medical statistics unit to blind.|Subjects were inoculated with influenza A (H7N9) virus inactivated vaccine/split influenza vaccine or placebo.|t|t|t|t
34051114|NCT04888442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051115|NCT06667609|||OTHER||PROSPECTIVE|||||||
34051116|NCT06472531|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051117|NCT01844661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051118|NCT04042350|||OTHER||RETROSPECTIVE|||||||
34051119|NCT03578796|||COHORT||PROSPECTIVE|||||||
34051120|NCT03613649|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34051121|NCT00136136|||COHORT||PROSPECTIVE|||||||
34051122|NCT06588751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.|t|f|t|t
34051123|NCT05208528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051124|NCT03349554|NA|SINGLE_GROUP||OTHER||NONE||||||
34051125|NCT05360160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051126|NCT00491309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051127|NCT01959763|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34051128|NCT05040672|||COHORT||PROSPECTIVE|||||||
34051129|NCT00162045|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051130|NCT00595738|||COHORT||PROSPECTIVE|||||||
34051131|NCT01928602|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34051132|NCT05279235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel|t|t|t|t
34051133|NCT02587598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051134|NCT04561557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34051135|NCT06662526|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051136|NCT05607004|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This multicenter open-label study consists of two cohorts: PK and Treatment~The PK Cohort is a dose finding study to identify the dose to use in the Treatment Cohort.~The Treatment Cohort is a randomized 1:1 two-arm study with potential to switch to a single modified regimen based on Ki-67% at Week 4."||||
34051137|NCT04270409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051138|NCT00462592|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34051139|NCT05091684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051140|NCT05828303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051141|NCT04144348|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Observer blind|Parallel for the Adult Cohort, followed by Sequential Assignment for the Pediatric Cohort|t|t|t|f
34051142|NCT02166411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051143|NCT03994133|||COHORT||PROSPECTIVE|||||||
34051144|NCT03507764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051145|NCT04144582|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34051146|NCT06044350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051147|NCT02976753|||COHORT||PROSPECTIVE|||||||
34051148|NCT04518098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors who collect outcome data will be blinded to group allocation. Participants will be advised to refrain from disclosing their group allocation to the outcome assessor.||f|f|f|t
33948485|NCT02377258|||COHORT||PROSPECTIVE|||||||
34051149|NCT04482998|||COHORT||RETROSPECTIVE|||||||
34051150|NCT06522945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051151|NCT04447352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051152|NCT02513498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051153|NCT01937910|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34051154|NCT05627674|RANDOMIZED|PARALLEL||PREVENTION||NONE||Clinicians will be randomized on a 1:1:1 basis to usual care, RiskProfile-Clin, or RiskProfile-Gen. Patients will be assigned to the same arm as their clinician.||||
34051155|NCT02336360|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741301|NCT01462734|||CASE_ONLY||PROSPECTIVE|||||||
33741302|NCT01136837|||COHORT||PROSPECTIVE|||||||
33741303|NCT02745626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844080|NCT02166996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33844081|NCT01149577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844082|NCT03293160|||COHORT||OTHER|||||||
33844083|NCT04807673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844084|NCT02539745|||CASE_CONTROL||PROSPECTIVE|||||||
33844085|NCT02309151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948486|NCT04669275|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33844086|NCT06076395|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Patients will be randomly allocated by a computer-generated list (www.randomization.com) into one of the study groups in the day of the study . The randomization sequence will be concealed in sealed envelopes and will be opened by an independent nurse. The data collector and data analysis will be blind to group assignments.|"For group A pressure control ventilation will be adjusted as follows:~Inspiratory pressure will be adjusted to achieve an expired tidal volume of 7 ml/Kg, respiratory rate will be adjusted to achieve an end ETCO2 at 32-35 mmHg, inspiratory to expiratory ratio at 1:2, PEEP at 4 cm H 2 O and FiO2 at 0.5 providing that the maximum airway pressure will be limited to 25 cmH2O.~For group B volume control ventilation will be adjusted as follows:~tidal volume (VT) adjacent to 7 ml/Kg, respiratory rate will be adjusted to achieve an end ETCO2 at 32-35 mmHg and I/E at: 1:2 and positive end expiratory pressure (PEEP)at 4 cmH2O and FiO2 at 0.5."|t|f|f|t
33844087|NCT04859270|||COHORT||PROSPECTIVE|||||||
33844088|NCT00631839|||COHORT||PROSPECTIVE|||||||
33948487|NCT01000909|||COHORT||PROSPECTIVE|||||||
33948488|NCT04501874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948489|NCT06062810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|No-placebo and random and double blind|"* The usual approach group (high dose)~* The study approach group (low dose)"|t|t|t|t
33948490|NCT05901766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Individually randomized controlled trial|f|f|f|t
33948491|NCT06723483|||CASE_ONLY||PROSPECTIVE|||||||
33948492|NCT03156946|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||stepped wedge||||
33948493|NCT03732274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948494|NCT01527331|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33948495|NCT01345266|NA|SINGLE_GROUP||OTHER||NONE||||||
33948496|NCT01298817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33948497|NCT03763448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants, outcome assessors, data analysts and chief investigators are masked during the study procedure.||t|f|t|t
33948498|NCT05403944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948499|NCT02244827|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948500|NCT06365164|||CASE_ONLY||PROSPECTIVE|||||||
33948501|NCT00814502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948502|NCT01172327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33948503|NCT04235127|||CASE_CONTROL||OTHER|||||||
33948504|NCT00038428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948505|NCT06515847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental study||||
33948506|NCT06713954|||COHORT||CROSS_SECTIONAL|||||||
33948507|NCT04941833|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33948508|NCT01269138|||COHORT||PROSPECTIVE|||||||
33948509|NCT00277823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948510|NCT03479957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948511|NCT04837807|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigators will be masked to the dosage group. Subjects will not be masked because it is not possible with the dosage interventions.|All subjects will be treated with Systane Hydration PF. Half will start with the unit-dose version and half with start with the multi-dose version. Subjects will switch to the other dosing option in the middle of the study.|t|f|f|f
33948512|NCT01830621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948513|NCT03666494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948514|NCT03240042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants are randomly allocated into one of the two group: nasoendotracheal and oroendotracheal group|t|f|f|t
33948515|NCT02156570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948516|NCT01085331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948517|NCT06722573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34051156|NCT03452488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each treatment kit showed a preprinted kit number affixed on the primary, secondary and tertiary container. The kit number was assigned via the eCRF after a participant is qualified and was randomized. Neither the Investigator and his staff, nor the Sponsor was aware of the treatment that corresponds to the kit number. The assigned treatment cannot be retrieved from the system, unless a specific unblinding procedure was engaged by the investigator when this was judged necessary by the responsible physician of the investigator center in the context of a severe or serious adverse event.||t|f|t|f
34051157|NCT06375993|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose Escalation Design||||
34051158|NCT05328206|||COHORT||PROSPECTIVE|||||||
33844089|NCT06290128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind treatment in part A and open-label treatment in Part B.|t|t|t|t
34051159|NCT04540341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34051160|NCT06665334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948518|NCT04084925|||COHORT||RETROSPECTIVE|||||||
33844090|NCT06643039|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33844091|NCT04300751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a randomized, double-blind, double-dummy, placebo-controlled, within-subjects design||t|f|t|f
33844092|NCT00464984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948519|NCT04271423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948520|NCT05423275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and the clinical outcome assessor is masked as to whether the study device is active or inactive.|Randomized, two-group, parallel, relapse prevention design|t|f|f|t
33948521|NCT02241408|||COHORT||PROSPECTIVE|||||||
33948522|NCT00700466|||COHORT||PROSPECTIVE|||||||
33948523|NCT01929551|RANDOMIZED|FACTORIAL||||NONE||||||
33948524|NCT02368860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051161|NCT06665932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051162|NCT03784209|||OTHER||PROSPECTIVE|||||||
34051163|NCT02729363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051164|NCT03734302|NA|SINGLE_GROUP||OTHER||NONE||||||
34051165|NCT06667297|||COHORT||PROSPECTIVE|||||||
34051166|NCT06665958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948525|NCT05611944|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The groups will be masked to the Outcome assessor by assigning groups A and B instead of group names and the assessor will be kept blinded about which group is the I\&S group.|The participants will be randomized by the random number container method into an equal number of I\&S groups and control groups through the parallel assignment.|f|f|f|t
33948526|NCT00719706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948527|NCT05673486|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051167|NCT04713592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051168|NCT03086928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|f|t
34051169|NCT06480240|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Dose escalation: Interval (3+3) model~Cohort expansion: parallel-group with randomized dosage optimization"||||
33948528|NCT00371748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051170|NCT04957641|||COHORT||RETROSPECTIVE|||||||
34051171|NCT05423197|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051172|NCT05018403|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Quadruple: Participant, Investigator, Outcomes Assessor and Care provider.|Five groups of participants will be assigned to receive AON-D21 or placebo in ascending dose order. Doses will be escalated based on safety and pharmacokinetic data.|t|t|t|t
33948529|NCT00003266|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33948530|NCT00453076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051173|NCT02901119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34051174|NCT04336319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051175|NCT02464475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051176|NCT02463344|||COHORT||PROSPECTIVE|||||||
33948531|NCT03781050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051177|NCT06665100|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051178|NCT01323595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051179|NCT06665516|||CASE_ONLY||OTHER|||||||
34076387|NCT05380154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators (investigator, evaluator at each institution, photographer, Independent Evaluation Committee, etc.), except for the injection mixing officer, employees of the sponsor, and test subjects are blinded during the test. Each institution appoints an independent injection formulation officer and prohibits interchange with the drug substance test group to make sure that the blinded method of the test is performed accurately||t|t|t|t
33948532|NCT05741762|||OTHER||RETROSPECTIVE|||||||
33948533|NCT02859025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948534|NCT06111599|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with chronic limb-threatening ischemia||||
33948535|NCT06724497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948536|NCT04399694|||CASE_ONLY||PROSPECTIVE|||||||
33948537|NCT02110589|NON_RANDOMIZED|PARALLEL||||NONE||||||
33948538|NCT02311075|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33948539|NCT02415491|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948540|NCT05920382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assessment of the results will be carried out by personnel hired for this purpose, who will be unaware of the patient's group allocation. Similarly, neither the investigators nor the collaborators present on the day of the intervention will be aware of the results of the applied technique. The data analysts will also be blinded to the study arm.|"Randomized double-blind clinical trial with two arms:~Radiofrequency Arm (RFA): Thermal radiofrequency will be applied to the sensory nerves of the knee, along with local anesthetic and corticosteroid infiltration.~Control Arm (CA): Simulated radiofrequency will be applied to the sensory nerves of the knee, along with local anesthetic and corticosteroid infiltration."|t|t|f|t
33948541|NCT01046175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948542|NCT03334604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948543|NCT01716221|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33948544|NCT05588466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948545|NCT00690612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948546|NCT06722612|||COHORT||OTHER|||||||
33948547|NCT01447069|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948548|NCT04746170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In RCT, blinding will be done in terms of participants and statistics.|The study was planned as a randomized controlled trial. The pregnant will be followed in single rooms. Pregnant women in the experimental group will be given labor dance with music for 15 minutes per hour until the cervical opening starts from 3 cm (latent phase) and the cervical opening reaches 8 cm.|t|f|f|t
33948549|NCT04430140|||CASE_ONLY||PROSPECTIVE|||||||
33948550|NCT04997200|RANDOMIZED|CROSSOVER||OTHER||NONE|The analyst analyzing the data will be blinded.|"Performed in randomized order on two separate days, at least seven days apart and no more than six weeks apart.~* Intervention: A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.~* Control: Normal night's sleep (at least six hours of sleep) in the patient's home.~The participants wear an actigraph during 48 hours before the test to ensure adherence to the allocated condition (sleep deprivation or control)."||||
33948551|NCT02862743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948552|NCT01002573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948553|NCT00938002|||CASE_CONTROL||PROSPECTIVE|||||||
33948554|NCT01435876|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34076388|NCT00018642|RANDOMIZED|PARALLEL||TREATMENT||||||||
34076389|NCT00029393||||TREATMENT||NONE||||||
33741304|NCT01286818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948555|NCT04058665|||COHORT||RETROSPECTIVE|||||||
33948556|NCT01746082|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948557|NCT05693519|||COHORT||RETROSPECTIVE|||||||
33948558|NCT00253071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948559|NCT00660153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948560|NCT06253507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948561|NCT02454387|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33948562|NCT00411892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844093|NCT00540865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844094|NCT05119179|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, before and after clinical trial||||
33948563|NCT03613974|NA|SINGLE_GROUP||TREATMENT||NONE|the patients and the assessment staff will not be aware with the given lidocaine concentration|||||
33948564|NCT03427320|NA|SINGLE_GROUP||OTHER||NONE||||||
33844095|NCT05223530|||COHORT||PROSPECTIVE|||||||
33844096|NCT00666692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948565|NCT04587362|||COHORT||CROSS_SECTIONAL|||||||
33948566|NCT04077060|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33948567|NCT02513680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948568|NCT03853434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33948569|NCT03394053|||FAMILY_BASED||PROSPECTIVE|||||||
33948570|NCT02035891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948571|NCT02274363|||COHORT||CROSS_SECTIONAL|||||||
33948572|NCT03733665|||COHORT||OTHER|||||||
33844097|NCT01843790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948573|NCT05682066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844098|NCT06358729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Order of nipple size use is counter-balanced, caregivers are blind to nipple size and amount of milk in the bottle (i.e., the bottle is covered) to minimize their influence over the infant's consumption. Research assistants will not be blind to nipple size as they will need to set the bottles ups for the mothers.||t|f|f|f
33844099|NCT06007222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844100|NCT02627404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844101|NCT04508582|||COHORT||OTHER|||||||
33844102|NCT01906970|NA|SINGLE_GROUP||OTHER||NONE||||||
33948574|NCT00821847|||COHORT||CROSS_SECTIONAL|||||||
33948575|NCT00531921|||CASE_ONLY||PROSPECTIVE|||||||
33948576|NCT05078229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948577|NCT05650255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948578|NCT00004058||||TREATMENT||||||||
33948579|NCT00314262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948580|NCT06335225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948581|NCT05070494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33948582|NCT00187005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948583|NCT05288491|||COHORT||RETROSPECTIVE|||||||
33948584|NCT05065151|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Within subject crossover counterbalanced study.||||
33948585|NCT01866605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948586|NCT03096457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group 1 (Paromomycin cream) will be compared to Group 3 (Vehicle cream). Both creams will have very similar physical characteristics and package. Group 2 (intralesional injection of pentamidine) will not be masked.|Patients will be randomized between Paromomycin cream applied topically once daily for 20 days (group 1--40 patients), pentamidine administered intralesionally at 120 ug/mm2 on days 1, 3, 5 (group 2-20 patients), and cream vehicle applied topically once daily for 20 days (group 3-20 patients).|t|f|t|f
33948587|NCT03572465|||CASE_ONLY||CROSS_SECTIONAL|||||||
33948588|NCT05026060|||COHORT||PROSPECTIVE|||||||
33948589|NCT05514301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A high definition colonoscopy will be performed by a high experienced endoscopists. The endoscopists will be blinded to a second monitor with the Polydeep evaluation. A second observer will annotate the lesions detected during colonoscopy withdrawal and will inform the endoscopists if Polydeep detects a lesion that is not detected by the endoscopists.||||
33948590|NCT05416268|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This study is an open label, prospective study comparing the Diopsys NOVA and LKC RETeval devices using the Diopsys Lid Electrodes and the LKC RETeval Self-Adhering Electrode Arrays.||||
33948591|NCT03781167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948592|NCT05973422|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33948593|NCT01321866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948594|NCT04451070|||COHORT||PROSPECTIVE|||||||
33948595|NCT02059265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948596|NCT01169662|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33948597|NCT02961361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948598|NCT02111473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948599|NCT02079376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33948600|NCT03792373|||COHORT||PROSPECTIVE|||||||
33948601|NCT00145106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948602|NCT04098003|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Matching placebo capsules will be formulated|This is a randomized, placebo controlled, double blind (participant and outcomes assessor) trial to investigate the effects of rosuvastatin on the gut microbiome. Healthy volunteers will be randomized to rosuvastatin 20 mg daily or placebo for eight weeks in a 2:1 ratio.|t|f|f|t
33948603|NCT00665418|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33948604|NCT00556972|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33948605|NCT05054985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948606|NCT01608321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|rTMS sham involves using the same paddle applied to the head, the side (one shielded internally from the magnetic pulse by aluminum) turned toward the head is randomized. A small shock is also given in both circumstances to disguise the sensation produced by the active rTMS.|Double-blind study of rTMS versus sham|t|t|t|f
34076390|NCT00828113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076391|NCT04796766|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34076392|NCT02084901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844103|NCT05045820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844104|NCT05272943|||COHORT||PROSPECTIVE|||||||
33844105|NCT02065687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844106|NCT00002229||||TREATMENT||NONE||||||
33844107|NCT00920322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844108|NCT03847792|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33844109|NCT03053687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844110|NCT06729476|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33844111|NCT04431557|||CASE_CONTROL||PROSPECTIVE|||||||
33948607|NCT04508504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be randomized to one of two groups with a computer generated arm assignment. The sealed envelopes will be opened immediately prior to nerve block. One group will receive a PENG block and the other will receive a placebo block. The provider performing the block will not be blinded, however all other members of the care team, the patient, and the investigator collecting data will be blinded to the randomization.|Randomized, double blind, placebo controlled|t|f|t|t
33948608|NCT02400658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948609|NCT05956782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One staff person who is the outcome assessor will be blinded to group assignment.|A 6-month, two-group, longitudinal pilot RCT study with a pre- and post-test design. The intervention is 12 weeks followed by a 12 week taper. Two groups include an intervention group and an attention control group.|f|f|f|t
33948610|NCT01215968|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33948611|NCT00135265|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|t|t|f
33948612|NCT02293876|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33948613|NCT04043949|||CASE_CONTROL||PROSPECTIVE|||||||
33948614|NCT01476891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948615|NCT02331459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33948616|NCT00777504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948617|NCT03796897|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33948618|NCT05723120|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33948619|NCT01775176|||COHORT||PROSPECTIVE|||||||
33948620|NCT02442427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948621|NCT03774069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948622|NCT03750058|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33948623|NCT01723358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948624|NCT00172770|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33948625|NCT03076827|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients receiving total hip replacement or hip hemiarthroplasty are divided into two groups: the morning surgery group and the afternoon surgery group. After surgery, cortisol, IL-6, IL-8 and VAS were measured and compared.||||
33948626|NCT00912756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948627|NCT05842668|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948628|NCT04381351|||COHORT||PROSPECTIVE|||||||
33948629|NCT01321086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948630|NCT03924570|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped Wedge Trial||||
33948631|NCT02222701|||COHORT||PROSPECTIVE|||||||
33948632|NCT00066573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948633|NCT04001374|||COHORT||PROSPECTIVE|||||||
33948634|NCT01584193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948635|NCT03294811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33844112|NCT06515145|RANDOMIZED|PARALLEL||TREATMENT||NONE|As it is a Medicinal intervention masking of the either of participants or investigator or other investigator is not possible|"Intervention : High Volume Therapeutic Plasma Exchange (HVPE)+ Standard Medical Treatment (SMT) The high-volume strategy would be performed by centrifugation technique \~ 8-9 litres of plasma would be exchanged in each patient over 6-8 hours.~Active Comparator - The Standard volume Plasma Exchange + Standard medical Treatment The Standard volume strategy group Therapeutic Plasma Exchange would be performed varying from 1.5- 2.5 times the plasma - volume."||||
33948636|NCT05853276|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33948637|NCT00892710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948638|NCT03142282|RANDOMIZED|PARALLEL||TREATMENT||NONE||Radiation: SBRT or IMRT Drug: Maintenance chemotherapy||||
33948639|NCT04299958|||COHORT||PROSPECTIVE|||||||
33948640|NCT04661917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948641|NCT01194076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948642|NCT02410057|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33948643|NCT05586789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844113|NCT00102739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844114|NCT02428764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844115|NCT06457451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948644|NCT02582216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948645|NCT00381134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948646|NCT05816213|||COHORT||PROSPECTIVE|||||||
33948647|NCT02695316|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33948648|NCT02700893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948649|NCT03346109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948650|NCT02311764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948651|NCT05777629|||OTHER||CROSS_SECTIONAL|||||||
33948652|NCT06715709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33948653|NCT04784676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|allocation concealment by opaque sealed envelopes, the participants and assessors were blinded|randomized clinical trial parallel group, two arms, superiority trial, allocation ratio 1:1|t|f|f|t
33948654|NCT06069466|||CASE_ONLY||PROSPECTIVE|||||||
33948655|NCT03526627|||COHORT||PROSPECTIVE|||||||
33948656|NCT02616341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948657|NCT00553670|||CASE_ONLY||PROSPECTIVE|||||||
33948658|NCT06514638|||OTHER||CROSS_SECTIONAL|||||||
33948659|NCT06722534|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants in the control group receive identically appearing placebo twice daily for 6 months|Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months|t|t|t|t
33948660|NCT00895817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33948661|NCT03534570|||COHORT||PROSPECTIVE|||||||
33948662|NCT01258803|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33948663|NCT02706327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948664|NCT04551326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076393|NCT06518733|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34076394|NCT03967288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subject, obstetrical provider, investigator, and outcomes assessor will be blinded. The anesthesia provider will be unblinded.||t|t|t|t
34076395|NCT02486120|||CASE_ONLY||CROSS_SECTIONAL|||||||
33948665|NCT06723002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants will be randomly assigned to one of three groups:~Intervention Group 1:Patients in this group will receive the study drug (olive leaf extract) at a dose of 500 mg (two capsules) twice daily, for a total of 1000 mg per day, for one month.~Intervention Group 2:Patients in this group will receive the study drug (olive leaf extract) at a dose of 250 mg (one capsule) twice daily, for a total of 500 mg per day, for one month.~Control Group:Patients in this group will receive a placebo, with one capsule prescribed twice daily, for one month."|t|f|t|f
33948666|NCT03512704|||COHORT||PROSPECTIVE|||||||
33948667|NCT01063296|||CASE_ONLY||PROSPECTIVE|||||||
33948668|NCT04447573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051180|NCT03269617|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Samples were provided in coded bottles whose identity is known only to the product manufacturer. Blinding will persist until all samples have been processed and the data statistically analyzed.|The PHAGE Study is a randomized, double-blind, placebo controlled crossover trial that investigates the utility of four supplemental bacteriophage strains (LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae) to modulate the gut microbiota, and therefore ameliorate common inflammation-related GI distress symptoms (e.g., gas, bloating, diarrhea, constipation, etc) experienced by healthy individuals.|t|f|t|t
34051181|NCT01488422|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34051182|NCT06666959|||COHORT||PROSPECTIVE|||||||
34051183|NCT03103321|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34051184|NCT03032328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051185|NCT03268382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051186|NCT01895270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051187|NCT00280358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051188|NCT03297918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomised|Interventional, single-center, randomised clinical trial|t|f|f|f
33948669|NCT00807651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948670|NCT05816525|||COHORT||PROSPECTIVE|||||||
34051189|NCT03778931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051190|NCT05504798|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34051191|NCT05437874|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|colors were designated for each drink|A Randomized Crossover Clinical Trial|t|t|t|f
34051192|NCT00998075|RANDOMIZED|CROSSOVER||||NONE||||||
33948671|NCT06238544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051193|NCT06045299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051194|NCT04767555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051195|NCT05550909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blind randomised controlled trial. The treating physician and staff involved with assessing all laboratory outcomes of the study are blinded, but no placebo will be used. The study pharmacist will be unblinded and responsible for randomisation and treatment administration.||f|f|f|t
33948672|NCT01510704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948673|NCT04959266|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33948674|NCT04371705|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33948675|NCT05948670|RANDOMIZED|PARALLEL||OTHER||DOUBLE||1:1 randomization|t|f|t|f
34051196|NCT01489254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051197|NCT02949843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948676|NCT06243679|||COHORT||PROSPECTIVE|||||||
34051198|NCT00239746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741305|NCT00111943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34051199|NCT06584396|||COHORT||PROSPECTIVE|||||||
34051200|NCT03957473|||COHORT||PROSPECTIVE|||||||
34051201|NCT02244463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051202|NCT01931956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051203|NCT03936920|||OTHER||CROSS_SECTIONAL|||||||
33948677|NCT04885218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1209 combined with lipid-lowering agents|t|t|t|t
34051204|NCT02288091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051205|NCT02397954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051206|NCT02966678|||COHORT||PROSPECTIVE|||||||
34051207|NCT05903053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051208|NCT04581109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051209|NCT04228146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051210|NCT04743583|||CASE_CROSSOVER||PROSPECTIVE|||||||
34051211|NCT05413564|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34051212|NCT03583541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34051213|NCT06667492|||COHORT||CROSS_SECTIONAL|||||||
34051214|NCT04369677|||CASE_CONTROL||PROSPECTIVE|||||||
34051215|NCT06523556|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741306|NCT01931839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741307|NCT00377195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051216|NCT06662864|||COHORT||RETROSPECTIVE|||||||
34051217|NCT00220428|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34051218|NCT06547125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051219|NCT03098238|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34051220|NCT00125749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051221|NCT00435487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051222|NCT01068067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051223|NCT02675621|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34051224|NCT06045403|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051225|NCT03155685|||COHORT||PROSPECTIVE|||||||
34051226|NCT00620360|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34051227|NCT02792452|||COHORT||PROSPECTIVE|||||||
34051228|NCT04159428|||COHORT||PROSPECTIVE|||||||
34051229|NCT03740347|||COHORT||CROSS_SECTIONAL|||||||
34051230|NCT06666920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051231|NCT02272842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051232|NCT00310752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051233|NCT05892276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051234|NCT01509417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051235|NCT06641193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051236|NCT04782453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and outcomes assessor will be masked. The screeners will recruit participants into the study, who will then be randomized to one of the two study arms. The data team will assign a masked outcome assessor to collect outcome data.|A parallel-arm individual randomized controlled trial, with a nested qualitative study. We will randomize participants in the intervention and control groups with 1:1 allocation ratio.|f|f|t|t
34051237|NCT03554174|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34051238|NCT00721851|||||PROSPECTIVE|||||||
34051239|NCT03301844|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A randomized, controlled study with a closed sequential design||||
34051240|NCT06034938|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-comparative, single arm pilot trial||||
34051241|NCT00002038||||TREATMENT||||||||
34051242|NCT02176863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051243|NCT06664892|NA|SEQUENTIAL||TREATMENT||NONE||||||
34051244|NCT05620732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948678|NCT06137040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since the study is randomized, the participant and the provider will not know which group the enrolled patient will be in until the patient is randomized to a group.|Experiment group will receive magnesium sulfate within the first hour with all of the other first line treatments vs. control group will not receive magnesium sulfate within the first hour of treatment.|t|t|f|f
34051245|NCT06684951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34051246|NCT03939780|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051247|NCT02604498|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051248|NCT02733354|||COHORT||PROSPECTIVE|||||||
34051249|NCT05955001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34051250|NCT01098201|||COHORT||PROSPECTIVE|||||||
34051251|NCT01183208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34051252|NCT03858725|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051253|NCT02136212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051254|NCT04844034|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34051255|NCT06580301|NA|SEQUENTIAL||TREATMENT||NONE||||||
34051256|NCT03277469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051257|NCT01753661|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34051258|NCT03015610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051259|NCT04583540|||COHORT||CROSS_SECTIONAL|||||||
34051260|NCT02780141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051261|NCT04570527|||CASE_CONTROL||RETROSPECTIVE|||||||
34051262|NCT06482268|NA|SINGLE_GROUP||OTHER||NONE||This study will be conducted as a single-center, open-label, uncontrolled study to evaluate the safety of transplantation of CT1-DAP001 as the primary objective, and as a secondary objective, to evaluate efficacy. Seven (7) subjects with PD will be followed up for 24 months after transplantation of approximately 4.2-5.4 × 106 dopaminergic progenitors per side into the bilateral putamen.||||
34051263|NCT06502600|||CASE_CONTROL||RETROSPECTIVE|||||||
34051264|NCT05052632|||COHORT||PROSPECTIVE|||||||
34051265|NCT01431690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051266|NCT05561907|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomly assigned in a 1:1 ratio to surgical gastrojejunostomy (SGJ) or endoscopic gastrojejunostomy (EGJ).||||
34051267|NCT02667964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051268|NCT06518174|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051269|NCT04736446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"During pre-scenario sessions (device workshop and 20-minute self-training session) the teams will not have been allocated to one of the study paths.~Allocation will be discovered as late as possible (after manikin's and defibrillatory characteristics presentation as well as the simulated patient's condition is given). From the moment of the allocation, it will be no more contact between investigators and participants. Due to the nature of the study with us of a supraglottic device, we are not able to blind participants, however they will be unaware of study outcomes. Assessment bias will be limited by using a high-fidelity manikin (SimMan 3G, Laerdal®, Stavanger, Norway) to collect study outcomes. Data analyst will be blinded to group allocation."|Prospective, multicenter, randomized, controlled trial|t|f|f|t
34051270|NCT06668688|||OTHER||CROSS_SECTIONAL|||||||
34051271|NCT06330246|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34051272|NCT04146493|||COHORT||CROSS_SECTIONAL|||||||
33741308|NCT00765115|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33741309|NCT01081860|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741310|NCT02223390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741311|NCT04931849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948679|NCT01737359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948680|NCT05718024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948681|NCT04923399|||CASE_CONTROL||PROSPECTIVE|||||||
33948682|NCT04100759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948683|NCT02198157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051273|NCT06682702|RANDOMIZED|PARALLEL||TREATMENT||NONE||Model description training and control group||||
34051274|NCT06529016|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot clinical trial||||
34051275|NCT06666530|||FAMILY_BASED||PROSPECTIVE|||||||
34051276|NCT06668337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051277|NCT03766165|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051278|NCT00380289|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34051279|NCT06186479|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34051280|NCT06585514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051281|NCT05663645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34051282|NCT02657057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051283|NCT06306404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051284|NCT05805800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051285|NCT04183582|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Experimental Arm - single group study||||
34051286|NCT00631410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051287|NCT06605950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 of this study is double-blind while Part 2 is open-label.||t|t|t|t
34051288|NCT03685357|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34051289|NCT00153543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051290|NCT05670795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051291|NCT05431530|||COHORT||PROSPECTIVE|||||||
34051292|NCT05972941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34051293|NCT04525014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051294|NCT02050217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051295|NCT00119691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051296|NCT06099132|||COHORT||PROSPECTIVE|||||||
34051297|NCT01172223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051298|NCT04500964|||COHORT||PROSPECTIVE|||||||
34051299|NCT04115475|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051300|NCT04411511|||COHORT||PROSPECTIVE|||||||
34051301|NCT01226498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34051302|NCT01736774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051303|NCT03368885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34051304|NCT03596723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051305|NCT06663423|||COHORT||CROSS_SECTIONAL|||||||
34051306|NCT06684509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051307|NCT01261572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051308|NCT04167631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051309|NCT05884099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|Intervention : intercostal cryoanalgesia + single-injection paravertebral block Control group : single-injection paravertebral block|t|t|t|t
34051310|NCT02249195|||||PROSPECTIVE|||||||
34051311|NCT05656352|||COHORT||PROSPECTIVE|||||||
34051312|NCT04807205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051313|NCT06366347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051314|NCT01662791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051315|NCT01472016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051316|NCT06111105|||COHORT||PROSPECTIVE|||||||
34051317|NCT04560972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051318|NCT02076893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051319|NCT04144543|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Pain scores of the babies before, during and after the procedure were evaluated independently by the researcher and the nurse other than the one who performed heel-stick sampling. Cohen's Kappa test was performed in the evaluation of the NIPS pain scores to test the concordance of the scores given to the same situation by 1 nurse and 1 researcher and it was found that the concordance of the scores given by 2 nurses was perfectly concordant (almost completely concordant) (Kappa Coefficient=0.953, p=0.027).|"White Noise Group:~The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.~Facilitated Tucking Group:~The baby's arms and legs were held in flexed positions close to the midline of the torso in side-lying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.~White Noise+Facilitated Tucking Group:~The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position."|f|t|t|f
34051320|NCT04525768|||CASE_CONTROL||RETROSPECTIVE|||||||
34051321|NCT02807506|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051322|NCT04109820|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Non randomized case control study design.||||
34051323|NCT04240704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051324|NCT05325645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051325|NCT04704492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051326|NCT02872974|||COHORT||PROSPECTIVE|||||||
34154499|NCT05321251|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment will be randomized / assigned randomly, but neither the patients, care providers, or investigators will be masked to treatment once it is being provided.|This will be a randomized controlled trial for the treatment of neurotrophic keratitis. Topical insulin drops will be compared to the current gold standard treatment temporary tarsorrhaphy. Patients will be recruited in Vancouver, Edmonton, Toronto, Montreal, and Halifax. Patients with neurotrophic corneal ulcers will be identified through the Ophthalmology on call resident clinics in each location. They will be directly referred to a physician in their city who is participating in this study. At least 12 patients will be enrolled in each group (as per power calculation): topical insulin drops or tarsorrhaphy.||||
34154500|NCT01217372|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154501|NCT02253485|||CASE_CONTROL||PROSPECTIVE|||||||
34154502|NCT04390841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948684|NCT06068127|||CASE_ONLY||RETROSPECTIVE|||||||
34154503|NCT01083589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154504|NCT02034851|||CASE_CONTROL||PROSPECTIVE|||||||
33948685|NCT04828993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948686|NCT06044857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948687|NCT06724770|NA|SINGLE_GROUP||OTHER||NONE||Participants voluntarily adhere to the intervention. The intervention consists of the review and use of the e-Resilience tool. It is a toolkit that provides training in skills to strengthen the resilience of teams working in healthcare institutions. Participants complete knowledge questionnaires before and after the intervention. There is no control group.||||
33948688|NCT05361005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948689|NCT00927277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948690|NCT04182529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051327|NCT06428552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051328|NCT06093165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Primary radiotherapy treatment|||||
34051329|NCT02355184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051330|NCT01826136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051331|NCT01085630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051332|NCT06666283|NA|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34051333|NCT03145961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"atients will undergo blinded serial ctDNA screening every 3 months from the point of registration and completion of primary treatment for their triple negative breast cancer. If a ctDNA positive result occurs on or before their 12 month ctDNA screening assessment the patient will be randomised by the ICR-CTSU in a 2:1 ratio to the pembrolizumab treatment arm or observation arm. The patient and their treating team will only be informed of the randomisation if they are allocated to the treatment arm.~For patients allocated to the observation group, the treating team and patient will not be informed that randomisation has taken place in order to remain blinded to the positive ctDNA result. Such patients will continue to have blood samples collected for ctDNA analysis every 3 months up to 2 years from starting ctDNA screening."||t|t|f|f
34051334|NCT04015089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34051335|NCT05839197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051336|NCT05866744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051337|NCT06068881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051338|NCT04366297|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34051339|NCT06666803|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34051340|NCT03545295|RANDOMIZED|PARALLEL||TREATMENT||NONE||the cadavers will be randomized to receive the intervention (Quadratus Lumborum Block) by different techniques (QLB 2/ QLB3) and different volumes (10, 20, 30 ml)||||
34051341|NCT05778435|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34051342|NCT04913155|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Randomized reporting of coronary calcium score and emphysema score|Population-based Screening Study -Prospective, randomized comparator controlled|t|f|f|f
34051343|NCT04505540|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051344|NCT02320773|||OTHER||PROSPECTIVE|||||||
34051345|NCT02200536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051346|NCT00006485|NON_RANDOMIZED|||TREATMENT||NONE||||||
34051347|NCT00750516|||CASE_CONTROL||PROSPECTIVE|||||||
34051348|NCT02345265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051349|NCT04671771|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, multi-center, single-arm study||||
34051350|NCT06665321|RANDOMIZED|PARALLEL||TREATMENT||NONE||After recruitment finished, participants will be randomized to either IPDT treatment or wait-list control condition.||||
34051351|NCT06056960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34051352|NCT06513013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051353|NCT04308278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34051354|NCT04502225|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized comparison of the effects of two amounts of head elevation (9 and 12 inches) achieved by tilting the bed or raising the head of the bed (up to four comparisons made) on supine blood pressure||||
34051355|NCT05650619|||COHORT||OTHER|||||||
34051356|NCT06667544|NA|SINGLE_GROUP||TREATMENT||NONE||PK-guided single-patient cohort followed by, A U-BOIN (Utility-based Bayesian Optimal Interval) design, with an incorporated Accelerated Titration (AT) step in the first dose level and then will enroll a minimum of 3 patients per dose level.||||
34051357|NCT06407557|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051358|NCT06260865|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter randomized controlled trial||||
34051359|NCT01377740|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34051360|NCT06277323|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel randomized trial at the physician level.|t|t|f|f
34051361|NCT06461078|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, Open-label, Single-dose, Two-way Crossover||||
34051362|NCT06061523|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34051363|NCT01864109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051364|NCT06137131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051365|NCT04128306|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051366|NCT02497040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34051367|NCT06666816|||COHORT||CROSS_SECTIONAL|||||||
33844116|NCT02549456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844117|NCT06728631|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The mixed control group includes patients who have previously experienced at least one instance of oral cancer and are also diagnosed with oral precancerous lesions. These patients will undergo routine follow-up or treatments other than the interventions used in this study's experimental group.||||
33844118|NCT04380441|||CASE_CONTROL||PROSPECTIVE|||||||
33844119|NCT05343260|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33844120|NCT06729060|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||The study has a randomised controlled single-blind experimental design.|f|f|t|t
33844121|NCT04642807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844122|NCT06470997|||OTHER||PROSPECTIVE|||||||
33844123|NCT04549896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844124|NCT03838120|NA|SEQUENTIAL||PREVENTION||NONE||A total of 48 ASA I-II patients underwent upper limb surgery operation by administering USG guided-infraclavicular blockage were included in the study. brachial plexus were seen and the minimum effective LA volume was investigated starting with total 30 ml of %0.5 bupivacain. After accomplishing the blockage, volume was decreased 2ml. Block administration time, block onset times, anesthesia times and time to first analgesic requirement were recorded.||||
33844125|NCT05812820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo DIA30, LiveSpo CLAUSY, and RO water are indistinguishable in terms of smell. However, due to the opaque plastic container of the LiveSpo product suspension, the color and turbidity of the suspension are unrecognizable to investigators, except for the Principal Investigator (PI), analyzer, nurses, patient's parents, and patients.|A randomized, double-blind, controlled clinical trial|t|t|t|f
33844126|NCT02215525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948691|NCT02553993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051368|NCT05622305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the research coordinator cannot be blinded to group condition though the research assistants making reminder calls and data analysts will not be aware of group status.|A parallel-group Ontario-wide RCT with experimental (workshop) and TAU (control) groups will address our objectives. Participants will be randomly assigned in a 1:1 ratio to the treatment or control groups.|f|f|t|t
34154505|NCT02191813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154506|NCT04499989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized trial|double blind randomized trial|t|t|t|t
34154507|NCT03270891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154508|NCT04477655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154509|NCT01779635|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized initiation with oXiris versus M150 (conventional filter), with cross-over for subsequent circuits.||||
34051369|NCT06666257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051370|NCT06627192|||CASE_CONTROL||PROSPECTIVE|||||||
34051371|NCT05747573|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34051372|NCT06384521|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34051373|NCT06665659|||COHORT||RETROSPECTIVE|||||||
34051374|NCT01194128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34154510|NCT03977493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051375|NCT04089566|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
34051376|NCT00184132|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051377|NCT03409432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051378|NCT06525025|||OTHER||PROSPECTIVE|||||||
34154511|NCT02883101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051379|NCT02584595|||COHORT||PROSPECTIVE|||||||
34051380|NCT04256317|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051381|NCT06597448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data analysts will be blinded. Data is deidentified and a study ID number is assigned. Research assistants following up with T2 and T3 questionnaires and phone interviews will be blinded.|Participants who have met the eligibility requirements and signed the consent form are randomized and allocated in a 1:1 ratio to one of two groups: Intervention (those who participate in the 9-week CBT group along with treatment as usual) and Control (continue with treatment as usual alone). Control group participants receive a list of mental health resources. Both groups complete online questionnaires at 3 timepoints: enrollment (T1), 9 weeks later (T2-post intervention for those in the intervention group) and 6 months later (T3).|f|f|t|t
34051382|NCT06457412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051383|NCT06233916|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34051384|NCT00454220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051385|NCT03218826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051386|NCT06662487|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34051387|NCT01436877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051388|NCT06665126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study employs a triple-blind design to ensure unbiased results. The three groups in the study (test product, active placebo, and excipient placebo) will receive capsules that are identical in appearance, taste, and packaging. Neither the participants, the investigators, nor the outcomes assessors will know which group the participants are assigned to.|Participants will be randomized into 3 groups (test product, active placebo, excipient placebo).|t|f|t|t
34051389|NCT06665035|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34154512|NCT04326049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051390|NCT01906307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154513|NCT01123707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group composed of eligible rollover participants who completed one of the previous studies: 31-08-255 \[NCT01111539\], 31-08-256 \[NCT01111552\], or 31-08-263 \[NCT01111565\]||||
34154514|NCT06583746|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34051391|NCT04218331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051392|NCT01514838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051393|NCT05352672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051394|NCT04953689|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group is assigned the intervention, one group is assigned to a waitlist control condition.||||
34051395|NCT03202940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051396|NCT06611540|NA|SINGLE_GROUP||PREVENTION||NONE|SC and CC samples will be handled similarly for post-collection processing and will be shipped to designated testing laboratories for HPV testing as per Roche-specified frequency and stability nformation. The sample tubes/containers will be pre-labeled to ensure that the testing laboratories cannot make linkages between an individual's sample pairs (SC, CC) thereby permitting unbiased and blinded testing and reporting.|||||
34051397|NCT03919695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34051398|NCT02100995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051399|NCT05600309|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open-label)|||||
34051400|NCT01598233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741312|NCT04923386|||CASE_ONLY||RETROSPECTIVE|||||||
33741313|NCT00799994|||CASE_ONLY||PROSPECTIVE|||||||
33741314|NCT00793910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33741315|NCT02371369|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) in Part 1, Open-label (no masking) in Part 2||t|t|t|t
33741316|NCT03119103|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741317|NCT03319043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization sequences will be concealed in lightproof, sealed envelopes kept by a specified project manager and the sponsor, who are not involved in the recruitment, intervention, assessment, or statistical analysis. The treatment allocation will be blinded to the participants and investigators throughout the study, and the outcome assessors and statisticians will not be involved in the participants' screening and allocation. Each patient will receive a unique randomized number corresponding to the drug according to the group allocation. Furthermore, the intervention group type will be replaced by the letter A, B as blind codes of allocation. The blind codes will not be disclosed until the statistical analysis is completed.|A total of 120 eligible participants will be randomly allocated to the placebo group and treatment group in a 1:1 ratio. Randomized sequences of each center and every packed drug were generated by an independent professor at the Drug Clinical Research Center of Shanghai University of TCM, using a stratified block randomization method with 30 blocks of block size 8 based on the PROC PLAN function of the SAS 9.2 software analysis system (SAS Institute, Cary, NC, USA).|t|t|t|f
33741318|NCT05894200|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33741319|NCT00020410||||TREATMENT||||||||
33741320|NCT02753751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33741321|NCT02444702|||COHORT||CROSS_SECTIONAL|||||||
33844127|NCT03363854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of the investigational medicinal products (IMPs) will contain no evidence of their identity.~Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded health-care professional at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments."||t|f|t|f
33844128|NCT01540864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051401|NCT06666010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051402|NCT04333407|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Multicentre Randomised Controlled Trial||||
34051403|NCT01328145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844129|NCT00452777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154515|NCT05397639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
34051404|NCT03798509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844130|NCT03539588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051405|NCT02913014|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34154516|NCT02202538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051406|NCT01945853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051407|NCT05701956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051408|NCT06226805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will receive a single dose of blinded investigational drug or placebo.|t|t|t|t
34051409|NCT06666868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Vaccine clients are blinded to the hypothesis. Providers are aware of the intervention.|Cluster trial involving at least 8 community pharmacies allocated in a 1:1 ratio to: 1) repeat use or 2) first-time use of the CARD system for vaccination delivery in 2024-2025 fall/winter vaccination season.|t|f|f|t
34051410|NCT04164173|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessment respiratory therapist will be blinded to respiratory therapy modalities.||f|f|f|t
34051411|NCT04064970|||COHORT||PROSPECTIVE|||||||
34051412|NCT02415894|||COHORT||PROSPECTIVE|||||||
34051413|NCT06664970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051414|NCT06683105|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051415|NCT03078010|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized open-label phase II study to assess the association between antibiotic treatment strategies and the change in the relative abundance of Clostridiales.||||
34051416|NCT05789888|||COHORT||OTHER|||||||
34051417|NCT06668402|||COHORT||PROSPECTIVE|||||||
34051418|NCT06667024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051419|NCT01663285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844131|NCT03227406|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051420|NCT00574470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844132|NCT00704405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844133|NCT04620343|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33844134|NCT03476759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844135|NCT00148070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844136|NCT04445532|||COHORT||PROSPECTIVE|||||||
33844137|NCT04731519|RANDOMIZED|PARALLEL||OTHER||NONE||Two stage model including a open label single group for treatment development purposes and, following this, an experimental and control group.||||
33844138|NCT02207504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844139|NCT00348270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34051421|NCT03562611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051422|NCT04292262|||COHORT||PROSPECTIVE|||||||
34051423|NCT00020644||||TREATMENT||||||||
34051424|NCT05842447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051425|NCT04210908|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized control trial||||
34051426|NCT01098500|||COHORT||RETROSPECTIVE|||||||
34051427|NCT04635995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051428|NCT06482294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||crossover design according to the AB/BA scheme||||
34051429|NCT00901017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051430|NCT05426486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051431|NCT05487404|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34051432|NCT06665737|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group A: Early receiving G-CSF Group B: Late receiving G-CSF||||
34051433|NCT05821517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051434|NCT02041117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051435|NCT05244278|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Allocation will be concealed; the the patients and the participating endoscopists will not be informed of the treatment group.|pragmatic double-blinded, randomized, multi-endoscopist, multicenter|t|t|f|t
34051436|NCT01399411|||COHORT||PROSPECTIVE|||||||
34051437|NCT00177853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051438|NCT06666322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051439|NCT02984761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051440|NCT01575652|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844140|NCT03423628|NA|SINGLE_GROUP||TREATMENT||NONE||"AZD1390 will be administered to patients in three different Arms (A, B and C), with each arm receiving standard of care radiation therapy (RT) for their disease setting.~In arms A and C, AZD1390 will be administered in three cycles: Cycle 0 (before RT), Cycle 1 (during RT) and Cycle 2 (after RT).~In arm B, AZD1390 will be administered in cycle 1 only (during RT). Within each arm, AZD1390 will be administered in dose escalating cohorts, first in an intermittent and then in a consecutive fashion, to achieve daily administration prior to RT.~\*\*Arm B has now closed to recruitment\*\*~For Arm A, there is an optional food effect assessment during cycle 0. \*Note: the optional food effect assessment is currently not open to recruitment\*"||||
33844141|NCT06575842|||COHORT||PROSPECTIVE|||||||
34051441|NCT05774665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study will be placebo controlled. Participants will receive identical capsules with omega-3 fatty acids or placebo. Randomization will be set by our research pharmacy and no participants or study personnel will know treatment assignment.|Double blind randomized placebo controlled clinical trial|t|t|t|t
34051442|NCT04007562|||COHORT||RETROSPECTIVE|||||||
33844142|NCT05564260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34051443|NCT06570148|||OTHER||PROSPECTIVE|||||||
34051444|NCT02674308|||COHORT||PROSPECTIVE|||||||
33844143|NCT00979576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33844144|NCT02622529|||COHORT||PROSPECTIVE|||||||
33844145|NCT02081443|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844146|NCT04536038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33844147|NCT02999074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33844148|NCT03307005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-site, randomized, parallel, placebo controlled, double blind study|t|f|t|f
33844149|NCT02078908|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33844150|NCT00654251|||COHORT||PROSPECTIVE|||||||
33844151|NCT05394753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33844152|NCT04668430|NA|SINGLE_GROUP||OTHER||NONE||||||
33844153|NCT06505590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33844154|NCT06160817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study employs a double-blind design. The treating clinician, responsible for administering the sharp debridement, is the sole individual aware of the patients' treatment group assignments. Both the participants and the key study personnel, including the principal investigator responsible for data collection and the data analyst responsible for data interpretation, are blinded to the treatment allocation. This approach aims to minimize potential biases and ensure a rigorous evaluation of the effects of weekly and biweekly sharp debridement on granulation tissue and healing time in patients with diabetic foot ulcers.|This study employs a prospective, randomized controlled trial design with parallel assignment. The primary objective is to assess the impact of two different debridement modalities, specifically weekly and biweekly sharp debridement, on granulation tissue and healing time in patients with diabetic foot ulcers (DFUs). The study includes three stratified groups based on the location of the ulcer: digital DFUs, DFUs under metatarsal heads, and DFUs in the plantar region of midfoot/heel. Participants meeting inclusion criteria will be randomly assigned to either the weekly or biweekly sharp debridement groups within each location-based stratum. The study aims to elucidate the optimal frequency of debridement based on ulcer location. Outcome measures include the assessment of granulation tissue and healing time. The trial is conducted at the University Podiatry Clinic, and the anticipated duration is from january to april 2024|t|f|t|t
33844155|NCT05084170|||COHORT||PROSPECTIVE|||||||
33844156|NCT03951298|||COHORT||PROSPECTIVE|||||||
33844157|NCT01316406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844158|NCT03540563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective observational study||||
33844159|NCT03765008|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33844160|NCT05416944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In patients in the routine management group, the treating anesthesiologists will be blinded to data of preoperative automated blood pressure monitoring to avoid performance bias. Participants are blinded to group allocation.||t|f|f|f
33844161|NCT00701857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844162|NCT05298059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This is a double-blind study, so that to blind study participants, all treatments were performed in exactly the same way. To simulate the CPP-ACPF paste, a paste without active ingredient was manipulated, but with the same color, texture and smell of the CPP-ACPF paste. To simulate the application of the laser, the operator performed the clinical procedure of applying the laser to three bridges of each tooth, but without activating it. The sound emitted by the laser at each point was simulated by a cell phone application.~To blind the evaluator of the results, he only had access to the patient's name and sensitivity data, but he did not have access to the group to which the participant belonged."||t|f|f|t
33844163|NCT01879553|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33844164|NCT02627417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844165|NCT04464785|||COHORT||PROSPECTIVE|||||||
33948692|NCT02934126|||CASE_ONLY||RETROSPECTIVE|||||||
34051445|NCT03521115|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Parents and Teens were either assigned to the full intervention or provided with didactic materials available on the internet. Family is considered the level of participant|Randomized Controlled Trial|t|f|f|f
34051446|NCT04253639|||COHORT||CROSS_SECTIONAL|||||||
34051447|NCT03045432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051448|NCT04910685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In Part 1 of the study, participants with ISM will be randomly assigned to 1 of 3 doses of elenestinib + BSC or to placebo + BSC. Once the recommended dose (RD) of elenestinib is identified in Part 1, participants with ISM in Part 2 will be randomly assigned to receive elenestinib at the RD + BSC or matching placebo + BSC. Participants will be randomized 2:1 to elenestinib:placebo. In Part 3, participants who have completed treatment in Part 1 or Part 2 of the study (including those initially randomized to placebo) will participate in a long-term open-label extension, receiving elenestinib at the RD + BSC. In Part M of the study, participants with monoclonal mast cell activation syndrome will receive elenestinib + BSC at the RD in an open-label fashion. In Part S of the study, participants with smoldering systemic mastocytosis (SSM) will receive open-label elenestinib + BSC. The study also includes PK groups that will enroll patients with ISM|t|t|t|t
34154517|NCT01351155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154518|NCT04787055|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34154519|NCT03312426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34154520|NCT02268994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154521|NCT03669237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154522|NCT06549660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (placebo or active PMBT) and will be instructed not to inform the patients or other researchers as to the type of treatment (placebo or active PBMT). Therefore, the researcher responsible for the treatment, the investigator and the outcome assessor will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or active PBMT).||t|t|t|t
34154523|NCT06545591|||CASE_CONTROL||PROSPECTIVE|||||||
34154524|NCT03752749|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34154525|NCT00169091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948693|NCT05123703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051449|NCT04688320|RANDOMIZED|PARALLEL||TREATMENT||NONE|"All eligible patients will be randomized in two equal groups for administration recombinant nonimmunogenic staphylokinase (Fortelyzin) or alteplase (Actilize) by using envelope method of randomization."|"At clinical centers, patients will be equally randomly distributed by the envelope method into two groups to receive Fortelizin® or Alteplase®.~The drugs will be administered after the signed informed consent. Fortelizin® will be administered intravenously at a dose of 15 mg as a single bolus for 10-15 seconds. Alteplase® will be administered in accordance with the instructions for use. All patients will be examination for 30 days."||||
34051450|NCT01852201|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34051451|NCT05587504|NA|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will participate in 5 sessions. Sessions differ by the tobacco product used (see study arms). The sessions will be ordered by latin-square; however, session order is NOT expected to change any outcomes and order effects are not relevant to the study.||||
34154526|NCT03920930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigator and treating physicians are different in this trial, that means, the assessor of primary study endpoint will be blinded regarding group allocation. Patients receive either early or late local infiltration technique perioperatively. Patients will be blinded against early or late local infiltration technique. Blinding of the treating physician will not be possible.||t|f|t|t
34154527|NCT04805710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051452|NCT04707703|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33844166|NCT04564339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, all investigative site personnel, and any Alexion employee, or designee, directly associated with the conduct of the study will be blinded to participant treatment assignments during the 26-week Initial Evaluation Period. Both the participants and the investigative site personnel will remain blinded for the remaining 24-week Extension Period.||t|f|t|t
33844167|NCT05441982|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33844168|NCT01447940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844169|NCT02552979|||||PROSPECTIVE|||||||
33844170|NCT06540885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All the anaesthesiologists and patients involved in the study were blinded to group allotment. Patient allotment will be revealed prior to the surgery via the sealed envelope to an anaesthetic nurse or doctor (who is not involved in study) for drug preparation. Participants will receive 2 separate injections of the study drugs/placebo. The first injection given prior to commencement of general anaesthesia comprises of palonosetron 1.5mcg/kg (maximum dose of 75mcg) diluted with normal saline 0.9% to make up a 5ml preparation (for Group P), or a 5ml preparation of normal saline 0.9% as placebo (for Group G). The second injection will be administered at the start of wound closure, comprising either 5ml of preparation of normal saline 0.9% as placebo (for Group P), or IV Granisetron 1mg diluted into a 5ml preparation of normal saline 0.9% for Group G.|After taking informed consent and recruitment of eligible participants, they will be randomized using a sequentially numbered, opaque sealed envelope (SNOSE) method. 74 radio-opaque envelopes will be prepared according to two groups: 37 participants for each Palonosetron Group (Group P) and Granisetron Group (Group G). Group P will receive Intravenous (IV) palonosetron 1.5mcg/kg prior to the commencement of general anaesthesia; while Group G) will receive IV granisetron 1mg at the start of wound closure.|t|f|t|f
33844171|NCT06520826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844172|NCT05591885|RANDOMIZED|PARALLEL||OTHER||SINGLE||A randomized controlled trial:The study center will recruit 100 male or female subjects aged 40-75 years as needed. Enrolled subjects will be divided into 2 groups, with 50 subjects in each group. Study subjects will be administrated with either the Amway product or a placebo for three months (12 weeks). At least 42 subjects in each group (84 in total) are required to complete the study.|f|f|t|f
33844173|NCT04865133|||CASE_ONLY||OTHER|||||||
33844174|NCT05872191|||COHORT||PROSPECTIVE|||||||
33844175|NCT00120211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051453|NCT04131647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Weight management program|t|f|f|f
33844176|NCT00937677|||CASE_CONTROL||PROSPECTIVE|||||||
33844177|NCT06241573|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051454|NCT06234631|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The participants and the study team at each site will be blinded except for the site research pharmacist and the site project manager (PM) and/or PM delegate.|Participants will be randomized once before surgery and once the day of surgery.|t|t|t|f
33844178|NCT01577459|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33844179|NCT04302974|||COHORT||RETROSPECTIVE|||||||
33844180|NCT00261976|||COHORT||PROSPECTIVE|||||||
34051455|NCT01858116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051456|NCT00526357|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33844181|NCT04020185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I includes a monotherapy arm and an immune checkpoint inhibitor (ICI) combination therapy arm Phase II includes three arms, Arm A monotherapy, Arm B immuno-oncology (IO) combination therapy, Arm C IO combination therapy||||
34154528|NCT00924508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844182|NCT03187964|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33844183|NCT04195139|RANDOMIZED|PARALLEL||TREATMENT||NONE||"All participants will receive radiotherapy (weekdays over 21 days) concurrently with temozolomide (TMZ) tablets 75mg/m2 daily for 21 days.~After a 4 week break, participants will receive either experimental or standard treatment.~Experimental treatment: Participants assigned to this group will receive nivolumab intravenous infusions (days 1 and 15 every 28 days with concurrent adjuvant temozolomide tablets days 1-5, every 28 days) for 6 cycles.~Standard treatment: Participants assigned to this group will receive the standard treatment of adjuvant temozolomide (days 1-5 every 28 days) for 6 cycles."||||
33844184|NCT03457051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051457|NCT06478433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective prospective single-center controlled non-randomized for-profit interventional study.||||
34051458|NCT01911481|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
34051459|NCT05744310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051460|NCT06662474|RANDOMIZED|PARALLEL||PREVENTION||NONE||The present study is a prospective, multi-arm study at determining the cognitive impairment decline rate after 12 weeks of different interventions for each study group .||||
34154529|NCT01545427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154530|NCT05859243|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34154531|NCT00829959|||COHORT||PROSPECTIVE|||||||
33844185|NCT00979550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051461|NCT05320835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Equal attention|Randomized Clinical Trial (RCT)|t|f|f|f
34051462|NCT03482297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and investigators will be blinded as to the experimental interventions (active or sham abdominal binder, and placebo or midodrine pills)|Randomized, double-blind, sham-controlled, parallel-group, 3-study days inpatient study to compare the efficacy of the automated abdominal binder versus sham treatment in improving orthostatic tolerance in patients with primary autonomic failure disabled by neurogenic orthostatic hypotension.|t|f|t|f
34051463|NCT06041542|||COHORT||CROSS_SECTIONAL|||||||
34051464|NCT02524886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844186|NCT01618253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844187|NCT01036438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844188|NCT00384189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844189|NCT02798042|||COHORT||PROSPECTIVE|||||||
33844190|NCT03079453|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Thirty patients ages 18 to 48 years who underwent tonsillectomy included in this prospective randomized clinical trial. The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy. Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.Blinded observers made examinations of the groups postoperative on the first and fifth days and evaluated the uvula edema by using the uvula edema scale that the investigators developed.|f|f|f|t
33844191|NCT05656235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844192|NCT06727760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33844193|NCT01253135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844194|NCT03440957|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844195|NCT06238570|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844196|NCT06069310|||OTHER||PROSPECTIVE|||||||
33844197|NCT04996004|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844198|NCT04818008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844199|NCT05945212|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33844200|NCT05372562|||CASE_CONTROL||RETROSPECTIVE|||||||
33844201|NCT04018638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844202|NCT02060877|||COHORT||PROSPECTIVE|||||||
33844203|NCT03031470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844204|NCT05326412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844205|NCT03683992|||COHORT||PROSPECTIVE|||||||
33844206|NCT00784901|||CASE_ONLY||RETROSPECTIVE|||||||
34154532|NCT02593825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051465|NCT05314322|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34051466|NCT00941863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051467|NCT06121011|||COHORT||PROSPECTIVE|||||||
34051468|NCT04210284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154533|NCT02219074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051469|NCT04435977|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignement||||
34051470|NCT03388775|||COHORT||PROSPECTIVE|||||||
34154534|NCT03538106|||COHORT||RETROSPECTIVE|||||||
34154535|NCT03860363|||COHORT||PROSPECTIVE|||||||
34154536|NCT01960153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34154537|NCT01399866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051471|NCT04261413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154538|NCT05580068|RANDOMIZED|PARALLEL||TREATMENT||NONE||monocentric randomized controlled study (RCT)||||
34051472|NCT06498024|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The allocation of this intervention order will be blinded for the investigators and the participants. Treatment will be given blinded names, such as A and B, but it may be possible to determine what each treatment is due to its appearance, however we will not be informing the participants what the treatments are. The study staff who will be preparing and overseeing the treatments may not be blinded due to the different appearances of the treatments. However, the staff that will conduct the trial results analyses will not be un-blinded until the analyses are complete.|The project will consist of 2 acute double-blind cross-over trials. The trials will follow the same study design but investigate 2 types of wild rice products. The wild rice products will be provided by the Myera group.|t|f|t|f
34051473|NCT00177840|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34154539|NCT02143492|||CASE_ONLY||PROSPECTIVE|||||||
34154540|NCT02051634|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34154541|NCT05036967|||COHORT||RETROSPECTIVE|||||||
34154542|NCT00604890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844207|NCT05833100|NA|SINGLE_GROUP||SCREENING||NONE||A minimum of 350 different subjects, both naive and non-naive SMBG users, is required. At least 10% of the study participants should be naive to SMBGs and may include non-diabetic subjects.||||
33844208|NCT06728891|||OTHER||PROSPECTIVE|||||||
33844209|NCT04296266|NA|SINGLE_GROUP||OTHER||NONE||||||
33844210|NCT06729281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33844211|NCT03058575|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Outcomes Assessors will be blind to who is on Arm1 and who is on Arm 2.|This is a randomized, 2-period crossover study.|f|f|f|t
33844212|NCT05263206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844213|NCT04694261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors will not be aware about the allocation of assignments between intervention and control arm|The assessments will be carried out parallel in the intervention and the control arm.|f|f|f|t
33844214|NCT06728813|||CASE_ONLY||CROSS_SECTIONAL|||||||
33844215|NCT06205485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051474|NCT06683287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051475|NCT06666452|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|It is not possible to blind the intervention to the participants and the healthcare professionals in this study.|||||
34051476|NCT02126267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051477|NCT05831176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051478|NCT05147922|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844216|NCT04331678|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844217|NCT03623945|||COHORT||PROSPECTIVE|||||||
33844218|NCT06729359|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844219|NCT05484414|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33844220|NCT04886726|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33844221|NCT01249950|||||PROSPECTIVE|||||||
33844222|NCT00330252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844223|NCT06649331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844224|NCT04601675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Drug: Ozurdex intravitreal steroid Other Name: Dexamethasone Intravitreal Implant Drug: Bevacizumab antiVEGF Other Name: Avastin|f|f|f|t
33844225|NCT06695130|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study is modified double-blind:~* Investigator, participants, and laboratory personnel will be blinded~* Clinical site staff preparing/administering the study vaccines will be unblinded~* Sponsor study staff will be blinded, except for dedicated staff involved in interim analysis, who will be unblinded at the time of interim analysis, and for dedicated staff involved in assessing criteria for safety surveillance"||t|t|t|t
33844226|NCT06088342|||OTHER||CROSS_SECTIONAL|||||||
33844227|NCT00043472|||COHORT||OTHER|||||||
33844228|NCT02227979|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33844229|NCT06130280|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II prospective trial.||||
33844230|NCT01457482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844231|NCT00195468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844232|NCT05677360|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Hybrid Type 1 implementation design which will allow the team to examine both effectiveness of HPV MISTICS and implementation outcomes in a single study. Implementation outcomes will be evaluated using the RE-AIM Qualitative Evaluation for Systematic Translation (RE-AIM QuEST) framework, a mixed-methods framework to identify implementation barriers and facilitators while assessing implementation outcomes (e.g., reach, adoption, implementation, maintenance/sustainability) with a focus on evaluating equity across these outcomes.||||
33844233|NCT00309205|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33844234|NCT06728150|||CASE_ONLY||PROSPECTIVE|||||||
33844235|NCT06729151|||COHORT||PROSPECTIVE|||||||
33844236|NCT02039921|||||RETROSPECTIVE|||||||
33844237|NCT05847673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33844238|NCT01652495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844239|NCT00699153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844240|NCT03849677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844241|NCT00218231|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33844242|NCT05815550|||COHORT||RETROSPECTIVE|||||||
33844243|NCT05157269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844244|NCT04196491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844245|NCT05684263|RANDOMIZED|PARALLEL||OTHER||NONE||There are three conditions in the study, which correspond to what education the participant will receive. The participant will be randomly assigned to one of the three conditions.||||
33844246|NCT04873427|||CASE_ONLY||RETROSPECTIVE|||||||
34154543|NCT05178485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Subjects will be blinded to group assignment. The physicians who are the treating providers of the subjects and who will perform the injections will also be blinded to group assignment. At each clinic visit for a subject's injection, the study coordinator will inform the clinic nurse of the group assignment, and the nurse will draw up the corresponding 2 mL injectate (either the bupivacaine/triamcinolone mixture or saline) and wrap the syringe in foil. The syringe will then be provided to the physician for the injection.|This is a double-blind, randomized, placebo-controlled trial. A total of 40 subjects will be randomized to experimental group (receiving bupivacaine/triamcinolone mixture) or control group (receiving saline injection). Two injections will be given one week apart.|f|t|t|f
33844247|NCT06092970|||COHORT||PROSPECTIVE|||||||
33844248|NCT02015364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33844249|NCT05306210|||COHORT||PROSPECTIVE|||||||
33844250|NCT02372968|||COHORT||PROSPECTIVE|||||||
33844251|NCT05877911|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients were randomly assigned to treatment group or control group by block randomisation in a 1:1 ratio.~Treatment group: Receive HIPEC using sodium thiouracil and hydration Control group: Receive HIPEC only using hydration."||||
33844252|NCT06487429|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Single arm||||
33844253|NCT02316951|||CASE_ONLY||PROSPECTIVE|||||||
33844254|NCT02387970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844255|NCT06153342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The sponsor, investigators, and study staff will be masked throughout the study. The study site will have the capacity to unmask in case of emergency.~Following completion of the study, the randomization code will be unmasked once all data has been entered into the study database for every subject, and the database has been locked."||t|t|t|t
33844256|NCT06528847|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, interventional, single-arm, phase 2 clinical trial.||||
33844257|NCT00045526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844258|NCT06729853|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844259|NCT00452023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154544|NCT04267081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter two-stage, two-arm, open label phase II study.||||
33844260|NCT04284605|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33844261|NCT00000998||||TREATMENT||||||||
33844262|NCT04893252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844263|NCT02097953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154545|NCT03459638|||OTHER||CROSS_SECTIONAL|||||||
34154546|NCT01699568|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34154547|NCT01227863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33844264|NCT04852341|||COHORT||RETROSPECTIVE|||||||
33844265|NCT06729528|||COHORT||PROSPECTIVE|||||||
33948694|NCT02608073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948695|NCT00072982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948696|NCT05011669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948697|NCT00638820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154548|NCT05552066|NON_RANDOMIZED|PARALLEL||OTHER||NONE||1st stage: the current circuit remains unchanged (with sytematic medical or nursing validation to confirm chemotherapy administration).||||
33844266|NCT05540470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an intervention study, multicentre and international using mixed methods and quasi-experimental design that associates an effectiveness evaluation and an implementation research approach, thus characterising a hybrid design.~We intend to combine several components that will contribute to achieve the primary and secondary objectives:~* The intervention per se, which is the core of the study, and combines delivery of the intervention (Module A, Module B or Module A and B) with data collection at inclusion and during a 14-day follow-up.~* Pre- and post-intervention research (cross-sectional studies), being preponderant for the evaluation of primary objectives (with a quasi-experimental design).~* A qualitative evaluation of the implementation of the intervention at multiple levels (target population, professionals involved in the study, stakeholders).~* The modelling study of surveillance data from national malaria programmes."||||
34154549|NCT03028779|NA|SINGLE_GROUP||OTHER||NONE||||||
33844267|NCT04368364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34154550|NCT04545710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154551|NCT00723359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844268|NCT05734638|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Randomized control trial of behavioral intervention||||
33844269|NCT05038163|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844270|NCT05691946|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|"It was a double blinded study:~* Participants were blind to the taping (sham taping or kinesiology taping).~* Outcome assessor was blind to the participants' group."|A randomised placebo-controlled with pretest-posttest both groups.|t|f|f|t
33844271|NCT06682793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844272|NCT01158287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948698|NCT05784467|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Each group will receive the same intervention components, but one group will be facilitated in English and the other, Spanish.||||
33948699|NCT04337827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948700|NCT00603824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948701|NCT00475839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33948702|NCT01487109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948703|NCT01041027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948704|NCT02635906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948705|NCT00085995|||CASE_ONLY||PROSPECTIVE|||||||
33948706|NCT06722599|||COHORT||OTHER|||||||
34154552|NCT06077032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154553|NCT02547051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154554|NCT04277039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154555|NCT03507738|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154556|NCT00524017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154557|NCT04984382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154558|NCT06514833|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Assessors responsible for conducting the neurodevelopment tests are blinded to the group allocation.||f|f|f|t
34154559|NCT06527443|||COHORT||PROSPECTIVE|||||||
33741322|NCT03449303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be seen in two separate clinic rooms. Intervention and placebo will have identical packaging and labeling with the addition of an A or B.|The study design uses a randomized, single-blind, placebo-controlled quantitative (QUAN) strand paralleled by a photovoice methodology qualitative (QUAL) strand.|t|f|f|f
33741323|NCT04876027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741324|NCT02813031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741325|NCT01978119|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33741326|NCT05036148|||COHORT||RETROSPECTIVE|||||||
33741327|NCT04168749|||COHORT||RETROSPECTIVE|||||||
33741328|NCT01003418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741329|NCT05927129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741330|NCT01538875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741331|NCT03495960|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multicenter open label phase II trial. The patients will be stratified according to their suitability to tolerate an induction chemo-immunotherapy regimen containing high-dose methotrexate.~Patients eligible for high-dose methotrexate-based induction chemotherapy will enter the run-in phase of Part A of the study and after the induction phase will be randomly assigned to procarbazine or lenalidomide maintenance monotherapy. Forty assessable patients per treatment arm are required.~Patients ineligible for high-dose methotrexate-based induction chemotherapy will be treated în Part B with concomitant whole-brain radiotherapy, temozolomide and rituximab and will receive temozolomide as maintenance.According to the Simon's two-stage minimax design, 46 patients will be treated in the first stage. If ≤ 16 patients will be progression-free at 2 years from maintenance treatment start, the study will be stopped. Otherwise, 19 additional patients will be treated for a total of 65"||||
33741332|NCT03771729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741333|NCT00217789|||CASE_ONLY||PROSPECTIVE|||||||
33741334|NCT02911402|||COHORT||PROSPECTIVE|||||||
33741335|NCT02447198|||COHORT||PROSPECTIVE|||||||
33741336|NCT04897048|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33741337|NCT02988427|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741338|NCT06300645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741339|NCT01778192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33741340|NCT00856856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741341|NCT00930358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741342|NCT04620317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741343|NCT06533514|||COHORT||OTHER|||||||
33764545|NCT05830435|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||"In this study, a three-arm single blind randomized placebo-controlled trial will be conducted. The following conditions will be set up.~1. TSST-VR Friendly (control)~2. TSST-VR-Neutral~3. TSST-VR-Unfriendly Participants will be divided into three groups by means of block randomization"|t|f|f|f
33764546|NCT04200079|||COHORT||PROSPECTIVE|||||||
33764547|NCT02440802|||CASE_ONLY||PROSPECTIVE|||||||
33764548|NCT06310499|||COHORT||RETROSPECTIVE|||||||
33844273|NCT03400111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients in the first group will undergo active irradiation with low-level laser therapy but they will consume placebo tablets. Patients in the second group will consume real Panadol-extra tablets but they will be subjected to a placebo red-beam as if they are irradiated with a laser beam. Patients in the third group will be subjected to both placebo procedures (i.e. placebo red-beam and not low-level laser therapy and placebo tablets).||t|f|f|t
33844274|NCT06728124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844275|NCT00262145|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33844276|NCT03405675|||COHORT||PROSPECTIVE|||||||
33844277|NCT06717672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844278|NCT06609109|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33948707|NCT04004299|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking|Single arm open label multicenter study with diagnostic intervention using capillary blood sampling||||
33948708|NCT04747860|||COHORT||PROSPECTIVE|||||||
33948709|NCT01774734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33948710|NCT02606721|||COHORT||CROSS_SECTIONAL|||||||
33948711|NCT01761565|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154560|NCT06583291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154561|NCT00005453|||||RETROSPECTIVE|||||||
34154562|NCT01515449|||COHORT||PROSPECTIVE|||||||
34154563|NCT00997594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154564|NCT02158208|||COHORT||PROSPECTIVE|||||||
34154565|NCT02299284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154566|NCT05785936|||OTHER||PROSPECTIVE|||||||
34154567|NCT04794127|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, pilot, open-label study||||
34154568|NCT05464368|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||Cohort 1Summary: BBBM/Amyloid PET scan A+;CDR .5 or1,Inclusive;arterial lines(N=8) Cohort 2Summary:BBBM/Amyloid PET scan A-;CDR 0;arterial lines; (N=8) Cohort3 Roche Supplement Summary: BBBM/Amyloid PET scan A+; CDR 0,.5 and/or 1(approx. 1/3rdof participants in each CDR score); can shorten total scan time or add break(N=22)||||
34154569|NCT04917913|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34154570|NCT05535556|||CASE_CONTROL||PROSPECTIVE|||||||
34154571|NCT04855656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154572|NCT00500396|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154573|NCT01019850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154574|NCT02979223|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34154575|NCT04994678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded study with random allocation.|Participants will be randomly allocated to interventional group (virtual Reality Training Group) and Control Group (Aerobic Training Group) for whole duration of study.|f|f|f|t
34154576|NCT06284512|||COHORT||PROSPECTIVE|||||||
34154577|NCT05563831|||COHORT||OTHER|||||||
34051479|NCT06580509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"To maintain blinding, all personnel except the investigational pharmacist and/or statistician will be unaware of the administered drug.~The randomization schedule will be pre-determined by a central randomization process and prepared as use next boxes to streamline the process at enrollment"|Two arm randomized, double-blind, controlled clinical trial|t|f|t|f
34154578|NCT03802591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051480|NCT03903094|||COHORT||RETROSPECTIVE|||||||
34051481|NCT05260463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051482|NCT06683690|||CASE_CONTROL||PROSPECTIVE|||||||
34154579|NCT01969032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051483|NCT02771691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051484|NCT01455272|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154580|NCT00767767|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34154581|NCT01835730|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34154582|NCT01160432|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34154583|NCT00435851|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33844279|NCT00400725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844280|NCT02818244|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33844281|NCT01283152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844282|NCT04614168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be divided into two groups using stratified sampling to match for age, sex and BMI.||||
33844283|NCT03666572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"3 treatment arms for infants with SAM~* Placebo (Lactose)~* B. infantis alone (Bif)~* B. infantis + prebiotic Lacto-N-neotetraose \[LNnT\] (Bif+prebiotic)~Age at enrollment~* 2-3.9 months of age~* 4-5.9 months of age~  1. open-label treatment arm for 18 non-malnourished primarily breastfed infants - B. infantis alone (Bif)"|t|t|f|t
33844284|NCT01250561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844285|NCT00069537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844286|NCT05327816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33844287|NCT02328625|||CASE_ONLY||PROSPECTIVE|||||||
33844288|NCT04657068|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33948712|NCT00197691|||COHORT||PROSPECTIVE|||||||
33948713|NCT04510662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948714|NCT02377674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948715|NCT00990782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948716|NCT04352075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, monocentric randomised, double blind|t|t|t|t
34154584|NCT05971043|||CASE_ONLY||PROSPECTIVE|||||||
34154585|NCT00467233|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34154586|NCT05024903|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34154587|NCT04167137|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalating, open-label||||
34154588|NCT03087292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154589|NCT02696239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154590|NCT01300572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154591|NCT06264856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154592|NCT03245983|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34154593|NCT02964767|||COHORT||PROSPECTIVE|||||||
34154594|NCT01344070|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33844289|NCT06728943|NA|SEQUENTIAL||TREATMENT||NONE||Direct semi-rigid ureteroscopy will initially be attempted without endodilatation (KARL STORZ, 43 cm, 6°, 7 Fr.). On failure to advance the semi-rigid ureteroscope through the ureter, intra-ureteric instillation of 20 ml of aminophylline (250 mg/10 mL) through ureteric stent and another trial to pass the same scope will be done after 10 minutes of intra-ureteral aminophylline instillation.||||
34154595|NCT01707082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33844290|NCT02642263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051485|NCT04533412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Research coordinators (RCs) and investigators are blinded to study randomization and treatment arm for each participant.|"For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.~The attention control is designed to isolate the impact of screening for self-management barriers. The attention control will consist of 4 visits by a COPD educator who will review a COPD education booklet.~Participants are randomized based on COPD Assessment Test (CAT) scores: CAT \<10 vs CAT \>10"|f|f|t|t
34154596|NCT02195141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844291|NCT03727542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Serum level of MMP-9 will be measured initially in the blood samples collected from the patients with permanent pacemaker implantation while they were on sinus rhythm and the second samples will be collected at the end of the 3 weeks of short AVD (60 msec. shorter than patients' native PR interval) pacing to ensure wide QRS rhythm.||||
34051486|NCT03858361|||COHORT||PROSPECTIVE|||||||
33844292|NCT04193540|||COHORT||PROSPECTIVE|||||||
34051487|NCT05038722|||COHORT||PROSPECTIVE|||||||
34051488|NCT00827723|||CASE_ONLY||PROSPECTIVE|||||||
34051489|NCT01283295|||COHORT||PROSPECTIVE|||||||
34051490|NCT02496091|||COHORT||CROSS_SECTIONAL|||||||
34051491|NCT06392113|||COHORT||PROSPECTIVE|||||||
34051492|NCT05780151|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel-group, open-label, multi-centre study||||
34051493|NCT02906228|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34051494|NCT04988906|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Before-and-After Design||||
34051495|NCT04114201|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were operated consecutively with conventional and patient-specific Instrumentation.||||
34051496|NCT01730027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051497|NCT05864898|||COHORT||CROSS_SECTIONAL|||||||
34051498|NCT03173742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051499|NCT03400709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34051500|NCT06667635|||COHORT||PROSPECTIVE|||||||
34051501|NCT02602132|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051502|NCT05971238|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be exposed to the same environmental conditions (same indoor and outdoor scenes for the same duration) and the captured eye-movement data of every participant will be of the same type. Participants will be exposed to different orders of scene sequences.||||
34051503|NCT04677556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051504|NCT01919684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051505|NCT00334529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844293|NCT06529419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|This is a parallel-group treatment study with 4 arms that is patient and Investigator blinded. Patients will be randomly assigned in a 1:1:1:1 ratio to one of the 4 treatment arms.|t|t|t|t
33844294|NCT05458570|||COHORT||PROSPECTIVE|||||||
33844295|NCT06436443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Single (Participant) They did not know if they were in the control and intervention group at the time of randomization.|||||
33844296|NCT06692738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind masking|"Arm A: Rilvegostomig in combination with carboplatin and paclitaxel or nab-paclitaxel followed by rilvegostomig~Arm B: Pembrolizumab in combination with carboplatin and paclitaxel or nab-paclitaxel followed by pembrolizumab"|t|t|t|t
33844297|NCT05775991|||OTHER||OTHER|||||||
33844298|NCT04592120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors and data analysts will be blind to study condition|At baseline, community coalitions will be randomly assigned to either the Coalition Check-Up experimental condition or the technical assistance as usual comparison condition.|f|f|f|t
33844299|NCT02683772|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients were masked to the mode of treatment. The Core Lab was masked to the mode of treatment for all patients.||t|f|f|f
33844300|NCT03152058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33844301|NCT05505240|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33844302|NCT00193232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844303|NCT02469103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844304|NCT04594486|||CASE_ONLY||PROSPECTIVE|||||||
33844305|NCT05366036|||COHORT||PROSPECTIVE|||||||
33844306|NCT02770612|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33844307|NCT00355303|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844308|NCT06476379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051506|NCT02292953|||CASE_ONLY||PROSPECTIVE|||||||
34051507|NCT04321356|||COHORT||RETROSPECTIVE|||||||
34051508|NCT00002641|RANDOMIZED|||TREATMENT||||||||
34051509|NCT02240927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051510|NCT03261726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051511|NCT06034457|||COHORT||PROSPECTIVE|||||||
34051512|NCT06350435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051513|NCT04864340|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34051514|NCT04262323|||COHORT||PROSPECTIVE|||||||
34051515|NCT06582719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051516|NCT05225298|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34051517|NCT05902091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051518|NCT01344993|NA|SINGLE_GROUP||OTHER||NONE||||||
34051519|NCT06301607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051520|NCT02878564|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764549|NCT04061590|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844309|NCT04160026|RANDOMIZED|PARALLEL||PREVENTION||NONE|"The feasibility study in the routine setting was not masked, this was a 3-arm study where interventions were delivered by ministry of health staff.~The acceptability study was nested in the clinical trial which was a 3-arm placebo controlled multicentre trial (see NCT02909712) ."|"The feasibility study is cluster randomised, where a health facility is a cluster.~The acceptability studies are nested within the feasibility study and the IMPROVE clinical trial."||||
34051521|NCT01680159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051522|NCT06611553|NA|SINGLE_GROUP||PREVENTION||NONE|The study will have no blinding for participants and study staff. However, a unique study sample label schema will be utilized for both sample types when tested that will not permit linkages or identification of sample pairs thereby permitting unbiased testing and reporting.|||||
34051523|NCT03405506|||COHORT||PROSPECTIVE|||||||
34051524|NCT05565378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051525|NCT06565026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844310|NCT02757690|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33844311|NCT05424497|||CASE_CONTROL||PROSPECTIVE|||||||
33844312|NCT06728826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844313|NCT04701619|NA|SINGLE_GROUP||OTHER||NONE||All patients undergoing a reperfusion procedure as part of an ischemia stroke will be able to participate in the study.||||
33844314|NCT02535039|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844315|NCT05308706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind, sham/placebo controlled trial.|All participants receive an Apollo System device. However, participants are randomly assigned to receive a device that uses the current pattern of vibrations as in the commercial Apollo System device or receive a device that uses an ultra-low frequency pattern of vibrations (sham device).|t|f|t|f
33844316|NCT04411693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844317|NCT05784441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844318|NCT01743989|RANDOMIZED|PARALLEL||TREATMENT||NONE||"All participants received 24 months of study treatment. After 24 months of treatment, eligible participants (i.e. those deemed to have achieved sustained molecular response) were randomized to one of the two study arms on a continued open-label basis.~Participants not achieving sustained molecular response after 24 months of treatment were not randomized but remained in the study until the 5-year study period was completed (Not randomized arm)."||||
33844319|NCT05181787|||CASE_CONTROL||PROSPECTIVE|||||||
33844320|NCT05695846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Data analysis staff will be blinded with regard to patient status.|GERD patients with complaints of regurgitation and supra-esophageal symptoms||||
33948717|NCT04860531|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants are assigned for intra-articular injection of lumbar facet joint to either; Group (I) to be injected with autologous platelet rich plasma and Group (II) to be injected with corticosteroids(a mixture of 0.5% lidocaine and 5mg/ml of betamethasone) . The treated segments will be determined by clinical signs and MRI detected facet joint synovitis .||||
34051526|NCT02932527|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051527|NCT05277636|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"5-period random order, placebo-controlled, double-blind cross-over study with four active substance conditions and placebo:~1. MDMA (125 mg), 2. S-MDMA (125 mg), 3. R-MDMA (125 mg), 4. R-MDMA (250 mg), 5. Placebo"|t|t|t|f
34051528|NCT00335569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34051529|NCT05802407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051530|NCT01297439|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34051531|NCT02482467|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051532|NCT00991094|||CASE_ONLY||PROSPECTIVE|||||||
34051533|NCT06335693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764550|NCT04194996|||COHORT||PROSPECTIVE|||||||
33764551|NCT05399095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants, care providers, surgeons, and investigators will be masked until the first postoperative day after DMEK. Investigators will open the opaque envelope with the study assignment together with the participant and inform care providers on the positioning regimen for the next 4 days.~The primary outcome will be assessed by a masked investigator using a trained and validated neural network for image segmentation."|Stratification will be performed according to the surgical procedure (DMEK alone or DMEK combined cataract surgery). Within each strata, participants will be randomized in a 1:1 ratio to 5 days (intervention) and 1 day (control) postoperative supine positioning.|t|t|t|t
33764552|NCT03499015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|only surgeon knows treated side, documentation of side only visible to surgeon and investigator|single-sided treatment, contralateral side with same pathology works as control|t|t|f|t
33764553|NCT00871884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764554|NCT01287520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764555|NCT03798002|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33764556|NCT04891796|||COHORT||CROSS_SECTIONAL|||||||
33764557|NCT05288725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Corticosteroid as control both participant and investigator blinded.||t|f|t|f
33764558|NCT02886091|||COHORT||PROSPECTIVE|||||||
33764559|NCT00958022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764560|NCT06625125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor will be blinded to the participants' random assignment to either the experimental or control group.||f|f|f|t
33764561|NCT05301062|||COHORT||PROSPECTIVE|||||||
33764562|NCT05997121|||COHORT||OTHER|||||||
33764563|NCT02130453|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33764564|NCT01866163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764565|NCT00546325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764566|NCT03971708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764567|NCT05354063|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33764568|NCT03347747|||COHORT||PROSPECTIVE|||||||
33764569|NCT02734680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764570|NCT03545347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33764571|NCT05984316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764572|NCT02673710|||COHORT||OTHER|||||||
33764573|NCT03354325|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34051534|NCT00331331|||CASE_ONLY||OTHER|||||||
33844321|NCT03760731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blind to treatment condition.|"Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.~Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI."|f|f|f|t
34051535|NCT00184717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051536|NCT03277729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051537|NCT04334343|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051538|NCT04550676|RANDOMIZED|PARALLEL||OTHER||NONE|Outcomes assessors will be blinded for endpoints, as feasible.|Participants will first be randomized to continuous moderate intensity or high-intensity interval training for 16 weeks. After 16 weeks, participants will be re-randomized to 12-week coaching intervention or control.||||
34051539|NCT02067884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051540|NCT03875482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051541|NCT00801203|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34051542|NCT06683833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Outcome assessors and analyst will be blinded to the intervention group assigned to the patients.~* Participants will be blinded from knowing the material used."||t|f|f|t
34051543|NCT01855243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051544|NCT03193112|||COHORT||PROSPECTIVE|||||||
34051545|NCT06365710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051546|NCT05193344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded for group assignment at the 3, 6, and 12 month follow-up visit.|Single center prospective randomized open blinded end-point (PROBE)|f|f|f|t
34051547|NCT06666166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076396|NCT06408337|RANDOMIZED|PARALLEL||TREATMENT||NONE||The initial phase of the trial is non-randomized and involves the sequential recruitment of 5 subjects. All of them will be implanted with the autologous substitute for the human palatal mucosa of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT), after reconstruction of the palate. In the second phase, the remaining patients (10) will be recruited, who will be randomized 1:1, so that 5 of these patients will be implanted with the investigational medication while undergoing standard surgical reconstruction. (uranostaphyllorrhaphy), while the other 5 will only undergo standard surgical reconstruction and will constitute the control group.||||
34076397|NCT01607216|||COHORT||PROSPECTIVE|||||||
33764574|NCT04255342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764575|NCT01279330|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33764576|NCT06365645|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|Participants who consent will be unaware of the existence of another version of M.Bapp. Obstetric care providers will be aware of participant's enrollment in this trial but not of the study group and will be encouraged to provide standardized care. The research team and outcomes assessors will be blindd to the randomization group.||t|t|t|t
33764577|NCT02294825|||COHORT||PROSPECTIVE|||||||
33764578|NCT06624592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764579|NCT02601716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764580|NCT00008463||||TREATMENT||||||||
33764581|NCT03437590|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764582|NCT04122391|||CASE_CONTROL||PROSPECTIVE|||||||
33764583|NCT00987064|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33764584|NCT04525547|||COHORT||PROSPECTIVE|||||||
33764585|NCT03529448|NA|SEQUENTIAL||TREATMENT||NONE||Phase Ib, intra-patient dose escalation trial.||||
33764586|NCT05715359|||COHORT||RETROSPECTIVE|||||||
33764587|NCT02760056|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind, randomized, controlled|Dose escalation with monitoring for safety and tolerability, as well as reliability of VEP testing.|t|t|t|t
33764588|NCT06445075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active treatment, randomized, double-blind, placebo-controlled|Parallel Assignment|t|t|t|t
33764589|NCT05590546|||OTHER||RETROSPECTIVE|||||||
33764590|NCT04534114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764591|NCT01861522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764592|NCT03768765|||COHORT||PROSPECTIVE|||||||
33764593|NCT03325543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764594|NCT05440383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764595|NCT01543412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764596|NCT01290211|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764597|NCT05447624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33764598|NCT02152228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764599|NCT05502419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a another person who will be unaware of the group the participant belongs to.|This study is a randomized controlled trial which will consist of two groups. Once will recieve conventional physcial therapy and the sencond will recieve conventional physcial therapy and slump stretching.Both groups will be recruited concurrently.|f|f|f|t
33764600|NCT01182935|||COHORT||PROSPECTIVE|||||||
33764601|NCT04494438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764602|NCT04728334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764603|NCT00770432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764604|NCT04947371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764605|NCT03781830|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single center prospective trial. Participants in this study will use the mHealth application to manage and track their immunosuppression medical regimen post-transplant.||||
33764606|NCT02825134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764607|NCT02894619|||COHORT||PROSPECTIVE|||||||
33764608|NCT04918368|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764609|NCT01266694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051548|NCT06624007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The researchers will interview participants, explain the purpose of the study and they will ask them to sign the consent. intervention group will apply Pediatric nursing excellence(PNE) model for children having orthopedic surgery, while the control group will provide routine care only for children having orthopedic surgery.~They will randomly assign in two intervention and control groups (50 each) using a computer-generated table of random numbers and they are unaware of which group they have been assigned to as well as the outcome assessor is unaware"|"Group A: intervention group: Nurses who will apply Pediatric nursing excellence(PNE) model for children having orthopedic surgery.~Group B: Control group: Nurses who will provide routine care only for children having orthopedic surgery."|t|f|f|t
34051549|NCT02388815|NA|SINGLE_GROUP||||NONE||||||
33844322|NCT05946187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization is performed by a researcher not involved in data management. The researcher who evaluates the outcomes of interest is masked.|This randomized controlled trial will compare two groups: a Treatment As Usual control group with an Stepped-care intervention group. The Stepped-care approach organizes interventions with two different intensities (Steps 1-2), delivered entirely via private groups on Facebook®. A logarithm will guide when patients move to another step based on the presence of certain key symptoms. Participants will be recruited at the São João Hospital Center and at the Hospital of Braga. All participants will be contacted by the researcher after their medical appointment. Patients meeting the criteria will be invited to participate in the study and sign an informed consent form. Objectives and procedures of the investigation will be explained. The study will be introduced as a program to support bariatric patients in the long term in different modalities, which aims to monitor relevant variables and investigate patients' perceptions of the utility of these interventions.|f|f|f|t
33844323|NCT01056900|||CASE_ONLY||RETROSPECTIVE|||||||
34051550|NCT05706220|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844324|NCT00451724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34051551|NCT02475265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844325|NCT03057522|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective, randomized, controlled study evaluating whether a home exercise program can increase the running cadence of recreational runners.|f|f|f|t
34051552|NCT02737085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844326|NCT01853475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051553|NCT05368363|||COHORT||PROSPECTIVE|||||||
34051554|NCT06652438|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33844327|NCT00692731|||COHORT||PROSPECTIVE|||||||
33844328|NCT05396534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm, single-blind, single-center, randomized controlled trial|t|t|f|f
33844329|NCT01531673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844330|NCT04385381|NA|SINGLE_GROUP||TREATMENT||NONE||facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.||||
33844331|NCT03410498|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844332|NCT00338143||||TREATMENT||||||||
33844333|NCT03241927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844334|NCT03732859|||CASE_ONLY||PROSPECTIVE|||||||
33844335|NCT05560243|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility of a tobacco cessation program tailored to patients living with HIV||||
33844336|NCT01835691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33844337|NCT01774877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844338|NCT03784001|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participants will only know they are taking part in a Mood and Writing Study and will not know which condition they are in."|Participants will be randomly assigned to one of three conditions: Gratitude, Gratitude + Expectations, or Events Control Participants in the two gratitude conditions will login to an online Google form three times a week for two weeks and make entries of up to five things they are grateful for. The form for participants in the gratitude + expectation condition will also provide information about benefits of gratitude. An everyday events control will be used to provide a neutral comparison condition. This group will be instructed to type up to five things or events of note from their day on their form.|t|f|f|f
33844339|NCT00545753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33844340|NCT04865198|||OTHER||CROSS_SECTIONAL|||||||
33844341|NCT02915484|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33948718|NCT03580031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Cohort groups with parallel allocation|t|f|t|f
33948719|NCT02218034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34051555|NCT05573477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized in a 1:1:1:1 ratio to 4 treatment arms. After completion of treatment period, participants will enter 12-week extension period and take 1 tab/day of ATB-1011 and ATB-1012.|t|f|t|f
34051556|NCT05011786|||CASE_CONTROL||RETROSPECTIVE|||||||
34051557|NCT05730582|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34051558|NCT06174298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34051559|NCT03687398|||CASE_CONTROL||PROSPECTIVE|||||||
34051560|NCT04717050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051561|NCT00003762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051562|NCT00922506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051563|NCT05150808|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Cluster Randomised Trial|t|t|f|f
34154597|NCT00360568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051564|NCT04977336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154598|NCT05945160|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm non-blinded controlled clinical trial. Subjects will be randomized 1: 1 either into the investigational antioxidant arm or the standard of care, no study drug arm.||||
34051565|NCT06684171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154599|NCT00002218||||TREATMENT||NONE||||||
34051566|NCT01281670|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34154600|NCT03672526|NA|SINGLE_GROUP||OTHER||NONE||||||
34051567|NCT01421225|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051568|NCT06435143|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a feasibility study of testing Prelivia in an in-patient setting||||
34154601|NCT04541511|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* 31 healthy subjects~* 6 patients"||||
34154602|NCT04186871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
33844342|NCT03280147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be provided objective clinical information related to episodes of all illnesses during follow-up with all patient identifiers removed and the record identified only by a unique code number. All imaging films and investigation reports provided to the outcome assessor will be similarly bereft of patient identifiers and coded by a unique code number. The outcome assessor will not be involved in the rest of the study. The outcome assessor will adjudicate whether the given episode of illness is a relapse.|Randomized, outcome-assessor blinded, active-controlled, multi-centric, non-inferiority trial|f|f|f|t
33844343|NCT03746587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded, randomized, placebo controlled|Randomized|t|t|t|f
33844344|NCT02756221|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33844345|NCT03503058|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844346|NCT03871582|||OTHER||CROSS_SECTIONAL|||||||
33844347|NCT04893343|||COHORT||RETROSPECTIVE|||||||
33844348|NCT06728566|RANDOMIZED|PARALLEL||OTHER||SINGLE|The analysts who perform the statistical analysis of the data will be blinded to the group assignments of the participants. This means that they will not know which participants received the immersive virtual reality training and which received the standard theoretical training. During data collection and management, the data will be anonymized and coded to prevent any identification of the participant's group assignment by those handling the data.|The type of experimental design will be a Randomized Controlled Clinical Trial, with an analyst blind, to evaluate the efficacy and safety of the intervention. Participants will be randomly assigned to one of two groups, the group receiving the intervention, with work-at-heights training using immersive virtual reality, before practical training in a real field, and the control group, receiving the existing standard intervention (prior theoretical training only). This allows us to compare the results between the groups and determine if the intervention is effective compared to the control.|f|f|f|t
33844349|NCT05991934|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot micro-randomized trial (within-subject randomization) with 10 young adult smokers will investigate the feasibility of delivering smoking cessation messages based on CBT and mindfulness/ACT for reducing smoking urge 15 minutes after message delivery.||||
33844350|NCT01758900|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33844351|NCT03546400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844352|NCT06568601|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patient randomized, open-label, parallel group||||
33844353|NCT05889702|||COHORT||PROSPECTIVE|||||||
33844354|NCT00231452|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33844355|NCT06686654|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Stage 1 Sentinel and Main Cohorts: observer-blind; for safety evaluation purposes, the Sponsor Safety Management Team (SMT) will be unblinded for the Sentinel Cohort (including early safety data review \[ESDR\]) and will be blinded for the Main Cohort.~Stage 2 Expansion Cohort: observer-blind until all participants complete the Month 6 visit, then open-label Booster Cohort: observer-blind; for safety evaluation purposes, the Sponsor SMT will be blinded"|Dose-ranging, parallel, multi-center, placebo-controlled|t|t|t|t
33844356|NCT05661422|||COHORT||PROSPECTIVE|||||||
34051569|NCT00299897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34051570|NCT00096616|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34154603|NCT04899453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051571|NCT02230696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34154604|NCT02277912|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34051572|NCT00262132|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34051573|NCT03603730|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||There will be multiple study visits consisting of a screening, baseline testing, consumption of a liquid meal, and fMRI brain and gut imaging sessions. Visits will include active and inactive taVNS delivered to the outer ear at a moderate, non-painful level.||||
34051574|NCT06667479|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel, randomized design, matched for biological age||||
34075760|NCT04993209|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An electronic central randomization system will be used to designate the investigational product (IP) that each participant must receive. A team study non-blind, qualified member (nurse/pharmacist) will obtain the corresponding randomization, will separate the respective IP, will blind the product and deliver it to blind staff. The product will be in a syringe that is in a blister labeled with the sponsor's name, IP code, administration route, IP dose and expiration date. The study non-blind staff will not have contact with the participants, will not have access to identification data or any other involvement with the study, besides randomizing the participant, separating the syringe containing placebo or vaccine, checking if the information on the blister label corresponds the information on the cartridge label and the syringe is labeled with the clinical trial code, ID, corresponding visit and investigator's name. Blinding is maintained with the opacity of the label.|Stage A (blinding form) will verify the product safety and support the decision on the dose selection among 1 μg, 3 μg and 10 μg, based on the immune response assessment. These results will also explore the response against 2 variants of concern in SARS-CoV-2: γ and β.|t|t|t|f
34154605|NCT01836926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154606|NCT03294850|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154607|NCT05691647|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking will not be applicable due to the nature of the study, in which participants randomized to receive chronotherapy plus treatment as usual will be admitted to the ward for a one-night sleep deprivation, and the participants and researchers will understand which intervention arm the participant is receiving. Researchers and participants will not be aware of randomization until after baseline-assessments are completed. Analyses will be conducted by a statistician who is blinded to intervention allocation.|||||
34075761|NCT06174831|||CASE_CONTROL||RETROSPECTIVE|||||||
34154608|NCT05385250|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II prospective observational clinical trial||||
34154609|NCT03246659|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34154610|NCT00675220|||COHORT||PROSPECTIVE|||||||
34154611|NCT00961714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154612|NCT01039493|||||CROSS_SECTIONAL|||||||
34154613|NCT04700904|||CASE_ONLY||PROSPECTIVE|||||||
34154614|NCT00115232|||COHORT||PROSPECTIVE|||||||
33844357|NCT06316895|||COHORT||PROSPECTIVE|||||||
33844358|NCT02656706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844359|NCT04795765|||COHORT||PROSPECTIVE|||||||
33844360|NCT04645199|||COHORT||PROSPECTIVE|||||||
33844361|NCT00159263|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34154615|NCT03300921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm A: 50mcg IV weekly Arm B: 12mcg PO daily||||
33844362|NCT04777201|NA|SINGLE_GROUP||TREATMENT||NONE|The first 12 weeks of the main study will be a masked period (to transition from the multi-arm parent studies) during which participants may receive either faricimab or sham injection. Participants and physicians will be masked only to the faricimab treatment interval. After the Week 12 treatment procedure, this study will follow an open-label design. The BCVA examiner will remain masked for the duration of the main long-term extension study.|||||
33844363|NCT03017820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844364|NCT06225505|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"Upon detection of ctDNA during Step1, patients will be centrally assigned to the control or the experimental arm (1:1) using the eCRF.~Randomization will be stratified by RCB score (I/II vs. III/NA because no neoadjuvant chemotherapy) and by time to molecular relapse (\< 12 months vs. ≥ 12 months between surgery and molecular relapse)."|"CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon ctDNA detection for the surveillance of patients with a non-metastatic TNBC at high risk of relapse.~68Ga-FAPI-46 is the radiopharmaceutical product. There is no study treatment (standard of Care)."|t|t|t|f
33844365|NCT06729684|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33844366|NCT04885855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075762|NCT02249104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075763|NCT02686164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844367|NCT04326322|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075764|NCT03851848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33844368|NCT04700631|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34075765|NCT00208013|||CASE_ONLY||CROSS_SECTIONAL|||||||
33844369|NCT02943239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33844370|NCT06364787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844371|NCT05709340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33844372|NCT01044225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844373|NCT05052021|||COHORT||PROSPECTIVE|||||||
33844374|NCT04032613|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study uses a pre-intervention / post-intervention design to assess outcomes. The study measures the pre-intervention to post-intervention changes in participant: 1) vascular access knowledge, and 2) confidence in navigating dialysis vascular access care process steps.||||
33844375|NCT03976492|||CASE_CONTROL||PROSPECTIVE|||||||
33844376|NCT05635942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Technicians, who performed culture, antimicrobial susceptibility testing or urea breath test were blinded to treatment allocation.||f|f|f|t
33844377|NCT00154934|||CASE_CONTROL||PROSPECTIVE|||||||
34154616|NCT04538079|||COHORT||PROSPECTIVE|||||||
34075766|NCT04024605|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34075767|NCT01653145|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34154617|NCT00051922|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34075768|NCT00416819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075769|NCT05020691|||COHORT||RETROSPECTIVE|||||||
34075770|NCT04385433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075771|NCT05441033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075772|NCT06444503|||COHORT||PROSPECTIVE|||||||
34075773|NCT05869669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Phase 2b (hypothesis-testing), multi-center, randomized, double-blind, placebo-controlled study|t|t|t|t
34075774|NCT03797898|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34154618|NCT03040986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075775|NCT03895359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075776|NCT01676103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154619|NCT03759106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844378|NCT01012362|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844379|NCT00633646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844380|NCT05979415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded||t|t|t|t
33844381|NCT00433212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844382|NCT02850289|||COHORT||PROSPECTIVE|||||||
33948720|NCT04523363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those assessing the outcomes from the medical chart will be blinded to the randomization process and the assigned study arm. Patients, the primary investigator, and their care providers will be aware of their treatment status.|This is a prospective, single center, randomized study evaluating metformin in the treatment of pregnant women with prediabetes on maternal and neonatal outcomes.|f|f|f|t
33948721|NCT00000172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33948722|NCT00663208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948723|NCT00451191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075777|NCT01211756|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34154620|NCT02714283|||COHORT||RETROSPECTIVE|||||||
34154621|NCT01471925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154622|NCT03779087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154623|NCT00294255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154624|NCT03649724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154625|NCT04326088|||CASE_CONTROL||RETROSPECTIVE|||||||
34154626|NCT02759081|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34154627|NCT02860572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154628|NCT04450095|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34154629|NCT05876338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154630|NCT01032499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154631|NCT06584305|||COHORT||PROSPECTIVE|||||||
34154632|NCT06005519|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154633|NCT04348006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154634|NCT03123991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34051575|NCT04068376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"To ensure that the groups are balanced regarding varying levels of education, study participants were not stratified and randomly allocated in blocks of four to one of the intervention groups or the control group. An independent researcher who will not participate in the study will use the Random Allocation Software to generate the allocation sequence.31 Each stratum will have its own seed. This researcher will generate uniform random integers to create the allocation order within each block. She will hold the randomization file on her computer and will give out the allocations of individual participants one at a time to the three groups. The allocations will be concealed from participants and the study staff involved in enrollment and baseline evaluation.~The recruitment and application of the intervention for groups 1 and 2 in stages, first in Care Unit 1 and then in Care Unit 10."|"A double-blind randomized clinical trial entitled Mind and Movement: Towards the Cognitive Health of Older Adults will be conducted. The study will include two intervention groups and one control group: (1) a double-task exercise program with a squared mat led by a coach (a health professional) for 24 weeks (T1-GR); (2) the same exercise program led by a coach (a health professional) for 12 weeks and then led by caregivers of older adults for another 12 weeks (T2-GR); and (3) a control group of an aerobic-balance-stretching exercise program led by a coach for 24 weeks (C-GR)."|t|f|t|f
34051576|NCT02161237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051577|NCT00479050|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34051578|NCT03100968|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon enrollment into the study, participants will be randomized 1:1 to either ultrasound or palpation. Randomization will be performed via random drawing: the provider will randomly select a card assigning the method of midline identification (i.e., ultrasound or palpation). Anesthesia providers will not be randomized. Any qualified provider available to place the epidural will be the person to perform the procedure.||||
34154635|NCT04814056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154636|NCT04095091|||OTHER||PROSPECTIVE|||||||
34051579|NCT00981669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051580|NCT04739072|||COHORT||PROSPECTIVE|||||||
34051581|NCT01257763|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34051582|NCT03991650|||CASE_CONTROL||PROSPECTIVE|||||||
34051583|NCT06321861|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each participant will take part in three similar sessions differing by the substance they receive: caffeine (intervention group), placebo, no substance. Sessions will be about one week apart.|t|f|t|t
34051584|NCT04308499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34154637|NCT01975597|||CASE_ONLY||PROSPECTIVE|||||||
34154638|NCT03327558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single center, laboratory-blinded, randomized, two-treatment, two-sequence, four-period, full replicate, crossover bioequivalence study|t|t|f|f
34154639|NCT01432990|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34154640|NCT04090463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844383|NCT04799743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants will be randomly assigned to resveratrol group and placebo group with 1:1 ratio. Block randomization with block size of 6 will be carried out in 1:1 ratio according to the sequence generated with Random Allocation Software (Version 2.0.0), Isfahan, Iran. Treatments will be assigned according to the codes which are kept in opaque sealed envelopes with consecutive randomization numbers. Treatment assignments will not be revealed and blinded to patients and PI (outcome assessor) until the whole study is completed.|Randomized, Double-Blind, Placebo-Controlled Parallel Group Clinical Trial|t|t|t|t
33844384|NCT01303653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844385|NCT01419054|||COHORT||PROSPECTIVE|||||||
33844386|NCT04198064|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33844387|NCT06233604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33844388|NCT03942484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844389|NCT06728696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to the type of the intervention and the whole-time frame of the study will be 6 months.|Randomized, parallel design, two arms clinical trial.|t|f|f|t
33844390|NCT04329468|NA|SINGLE_GROUP||OTHER||NONE||||||
33844391|NCT04228926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844392|NCT05131269|RANDOMIZED|PARALLEL||TREATMENT||NONE|A sealed envelope of the randomized sequence was given to the investigator and care provider, and participants were recruited consecutively according to the permutation sequence. Participants were masked from the therapy by receiving treatment individually in different rooms and occasions. On the day of the assessment, the physician and laboratory technicians were blinded from group allocation|This study involves two arms assigned randomly for receiving different treatments. One arm for Prolotherapy and Normal Saline in the comparison group.||||
33844393|NCT06728605|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844394|NCT04538560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844395|NCT03112629|||COHORT||PROSPECTIVE|||||||
33844396|NCT00124787|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33948724|NCT02039869|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33948725|NCT06518382|||COHORT||RETROSPECTIVE|||||||
33948726|NCT02652676|NA|SINGLE_GROUP||OTHER||NONE||||||
33948727|NCT06354660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948728|NCT01024270|RANDOMIZED|||||SINGLE|||f|t|f|f
33948729|NCT06199856|||COHORT||CROSS_SECTIONAL|||||||
33948730|NCT00715052|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33948731|NCT04522128|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33764610|NCT04631705|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"This study consists of an open-label dose escalation phase in both healthy volunteers (Groups 1A-1C) and SARS-CoV-2-infected participants (Groups 2A-2C).~After completion of the dose escalation phase, SARS-CoV-2-infected individuals will be enrolled into a randomized placebo-controlled expansion cohort (Group 2D)."|t|t|t|f
33764611|NCT04618822|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A three-armed randomized controlled trial|f|f|t|t
33764612|NCT05057104|||COHORT||PROSPECTIVE|||||||
33764613|NCT02558361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764614|NCT03971838|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33948732|NCT03193996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948733|NCT05863039|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948734|NCT01642472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844397|NCT04706299|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Participants will perform a RE protocol under 2 different conditions, once without a mask and once while wearing a surgical mask. A coin flip wil be utlize to minimize the possibility of familiarization or training effects, and maintain complete randomness of the assignment of which RE conditions is performed first, in addition to which leg is tested first. This simple randomization method to determine the assignment will follow (heads = No mask, tails = surgical mask and heads = dominant leg 1st, tails = nondominant leg 1st, on the 1st and 2nd coin toss, respectively). Study participants will be asked which leg they prefer to kick a ball with to identify their dominant leg for data collection purposes|This is a prospective study conducted using a randomized-control crossover design where participants will complete resistance exercise (RE) protocol utilizing a Biodex System 4 and Advantage V5 software with a standard leg attachment, on 2 separate days with at least 48 hours and no greater than seven days between tests.||||
33764615|NCT03290612|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Vitamin C and Placebo doses will be blinded by the research pharmacy, so that participants and investigators are masked to the identity of the tablet. Data analysis will be blinded to the conditions as well until the completion of the study.||t|t|t|t
34051585|NCT04163133|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single center, open-label, randomized controlled clinical trial (1:1 treatment ratio). On the day of regular trigger timing day (three follicles reach 17mm) or two day later. 36(±2) hours after trigger, oocyte retrieval will be applying in both group with same protocol.||||
33844398|NCT06697028|||COHORT||CROSS_SECTIONAL|||||||
33844399|NCT05668741|NA|SEQUENTIAL||TREATMENT||NONE||||||
33844400|NCT06032143|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33844401|NCT03718351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844402|NCT05599555|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33844403|NCT01656200|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844404|NCT04670289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, Controlled, Randomised, Double Blind, Single Centre Trial|t|f|t|f
33844405|NCT02315300|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33844406|NCT01511705|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844407|NCT00299442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844408|NCT06323980|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 Randomized (Stemless to Stemmed)||||
33844409|NCT04109716|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33844410|NCT02296723|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844411|NCT00564577|NA|SINGLE_GROUP||SCREENING||NONE||||||
34051586|NCT03657342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051587|NCT02122705|||CASE_ONLY||PROSPECTIVE|||||||
33844412|NCT06667908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844413|NCT02341742|||COHORT||CROSS_SECTIONAL|||||||
34051588|NCT01046058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844414|NCT05139251|NA|SINGLE_GROUP||OTHER||NONE||||||
34051589|NCT01740908|||CASE_CONTROL||PROSPECTIVE|||||||
34051590|NCT06666504|||COHORT||OTHER|||||||
34051591|NCT05038501|||OTHER||RETROSPECTIVE|||||||
33844415|NCT04635475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Testing RISE bundle to improve RTL care after concussion||||
33764616|NCT05867719|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764617|NCT00486135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154641|NCT02859441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051592|NCT04136379|||COHORT||PROSPECTIVE|||||||
33844416|NCT05096221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844417|NCT03800953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844418|NCT06728930|||OTHER||CROSS_SECTIONAL|||||||
33844419|NCT06728865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844420|NCT04903392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33844421|NCT05945589|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Simple randomization was administered by a dedicated research team member using an automated randomizer. Consenting participants were randomly assigned a number, where 1 = Intervention group, and 2 = Control group. Participants and other members of the research team were blinded to the randomization outcomes, and the outcome of the allocation was revealed after completion of the baseline assessment.|Intervention group participants will be invited to engaged in a 12-week participatory art program at the gallery. Participants in the control condition will not offered any art-based activities. All participants were advised not to participate in concurrent health art-based interventions during the research period.|t|f|t|t
33764618|NCT03704532|||COHORT||PROSPECTIVE|||||||
34051593|NCT05511532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764619|NCT01595243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764620|NCT05728567|||COHORT||PROSPECTIVE|||||||
34154642|NCT02089126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764621|NCT05779553|||CASE_CONTROL||RETROSPECTIVE|||||||
33844422|NCT03663673|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single center, clinical pilot study to test the hypothesis that lipid rich EpiCeram® is superior in improving skin barrier function compared to Aveeno Daily Moisturising Sheer Hydration Lotion®.||||
33844423|NCT02842762|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||Sequence of measurements, during sinus rhythm and during pacing is randomized.|t|f|f|t
33844424|NCT06728774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844425|NCT06324201|||CASE_ONLY||PROSPECTIVE|||||||
33844426|NCT05715385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34051594|NCT00053157||||SUPPORTIVE_CARE||||||||
34051595|NCT02810717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34051596|NCT04232917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051597|NCT00279682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051598|NCT02979912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844427|NCT03205397|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051599|NCT01980511|||COHORT||PROSPECTIVE|||||||
34051600|NCT00129688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051601|NCT04303520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051602|NCT03582982|NA|SINGLE_GROUP||OTHER||NONE||||||
34051603|NCT02033967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051604|NCT02691819|||CASE_ONLY||PROSPECTIVE|||||||
33844428|NCT02988362|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844429|NCT03592745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the participants and investigators performing and analyzing clinical and objective outcome measures will remain blind to condition. Participants will be told that they have a 50-50 chance of receiving either active or sham stimulation, but they will not be told which condition they receive.|This is a double-blind, sham controlled treatment study in which patients will have a 50/50 chance of receiving robotic arm therapy with either active transcutaneous vagus nerve stimulation (tVNS) or sham tVNS (placebo).|t|f|t|t
34051605|NCT03565042|||OTHER||PROSPECTIVE|||||||
33844430|NCT03465904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844431|NCT02296502|||COHORT||PROSPECTIVE|||||||
33844432|NCT05202210|||COHORT||PROSPECTIVE|||||||
33844433|NCT02726100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33844434|NCT00369252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844435|NCT04646967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33844436|NCT05366426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The prospective, randomized and controlled interventional study with a three-month follow-up period will be carried out in a single center. Female patients with a clinical diagnosis of stress urinary incontinence will be included in the study.|Randomised controlled Trial|t|f|t|f
33844437|NCT02459002|||COHORT||PROSPECTIVE|||||||
33948735|NCT03929458|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33948736|NCT06023589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Participants will be randomized in a 2:1 ratio to either tezepelumab or matching placebo both administered subcutaneously|t|t|t|f
33948737|NCT00694226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948738|NCT05241574|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A dose escalation study, either radiotherapy dose escalation or chemotherapy dose escalation.||||
34051606|NCT04777786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blinded to participant group allocation.|Randomized clinical trial design|f|f|f|t
34075778|NCT06383026|||COHORT||PROSPECTIVE|||||||
33764622|NCT03640546|||CASE_ONLY||PROSPECTIVE|||||||
33764623|NCT04367038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764624|NCT01276561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764625|NCT03880695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764626|NCT05458258|||CASE_CONTROL||PROSPECTIVE|||||||
33764627|NCT00723437|NA|SINGLE_GROUP||||NONE||||||
33764628|NCT02873819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764629|NCT06100055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and clinicians will be aware of treatment allocations. The need to collect data on frequency and volume of irrigation, as well as reasons for discontinuing means that assessor blinding is not possible with respect to these outcomes. However, the statistician involved in the analysis will only receive coded data and therefore will be blinded.|This is a superiority trial with parallel group design where each participant will receive only one of the two types of intervention (rectal irrigation).|f|f|f|t
33764630|NCT01568502|||COHORT||PROSPECTIVE|||||||
33764631|NCT04942808|||OTHER||RETROSPECTIVE|||||||
33764632|NCT03715712|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33764633|NCT03579264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764634|NCT02571322|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33764635|NCT06625541|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33764636|NCT02337517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764637|NCT03392207|||COHORT||PROSPECTIVE|||||||
33764638|NCT01202487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764639|NCT00888901|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33764640|NCT02696122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764641|NCT03996044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764642|NCT01164228|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764643|NCT02204579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764644|NCT00664638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764645|NCT04960553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764646|NCT01218529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764647|NCT03332641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33764648|NCT02225379|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764649|NCT02665702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764650|NCT05496972|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764651|NCT00310895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764652|NCT05563792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will be blinded to the treatment assignment when administering baseline outcome assessments|A randomized control trial with behavioral intervention|f|f|f|t
33764653|NCT04179981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparing outcomes in patients with OVS after randomization to PAP therapy vs. conservative care in a parallel group fashion|f|f|f|t
33764654|NCT06288802|||OTHER||CROSS_SECTIONAL|||||||
33764655|NCT05647551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764656|NCT02057003|||COHORT||PROSPECTIVE|||||||
33764657|NCT06624683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764658|NCT00363610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764659|NCT01313546|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33764660|NCT03485014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764661|NCT00377702|||||RETROSPECTIVE|||||||
33764662|NCT02070900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764663|NCT03848364|NA|SINGLE_GROUP||PREVENTION||NONE||Stroke Centers who agree to participate will designate a Stroke coordinator who will recruit at least 2 schools from their area with 4th and/or 5th grades. Coordinators will receive a customizable electronic training package to introduce content, and recruit strategies to engage schools. They will in turn coordinate with School Champions (school designated member), who will receive program training, to implement the program. School Champion will be responsible for the distribution of Opt-Out consent forms, scheduling programming (including computer use), and coordinating with the Stroke Champion and research staff. Regarding maintenance, Stroke Coordinators and School Champions will complete and exit survey, and to promote annual implementation in recruited schools.||||
33844438|NCT03859245|RANDOMIZED|PARALLEL||TREATMENT||NONE||To assess differences between the control and experimental groups, a mixed model will be fit for each variable separately using both baseline (week 0) and post program (week 36) values for each subject. Models will include week, group, and their interaction as fixed effects, gender as a covariate, and subject as random effect. To assess significant differences, we will use the difference at week 36 adjusted for the baseline difference, report p-values, least squares mean, and 95% confidence intervals. Further analysis of treatment effects over time will be examined by comparing the within-group differences over time.||||
33844439|NCT04021979|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33844440|NCT06502223|||COHORT||PROSPECTIVE|||||||
33844441|NCT04894175|||COHORT||PROSPECTIVE|||||||
33844442|NCT03340831|||COHORT||PROSPECTIVE|||||||
33844443|NCT03337659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33844444|NCT06728553|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33844445|NCT02615002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844446|NCT04546217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will not be involved nor present during the training sessions. Also the outcome assessments will be performed without the presence of the interventionist.||f|f|f|t
34051607|NCT03494231|NA|SINGLE_GROUP||TREATMENT||NONE||The modified accelerated titration design (ATD) 2A and Bayesian optimal interval design (BOIN)||||
34051608|NCT00934115|||COHORT|||||||||
34051609|NCT06049186|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of live birth rates between calorie-restricted diets and metformin interventions prior to ovulation induction therapy in patients with overweight/obese polycystic ovary syndrome combined with Infertility.||||
34154643|NCT01179152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154644|NCT03878901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34051610|NCT04922255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844447|NCT05206097|NA|SINGLE_GROUP||OTHER||NONE||||||
33844448|NCT04932577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844449|NCT04611009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are blinded towards their participation in the two arms Clinical scales, kinematic writing anlysis and functional MRI will be analyzed by persons, who are blinded to the type of training group allocation|randomized, controlled, double blinded trial|t|f|f|t
33844450|NCT06515613|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1a is a dose escalation assessing 9 different dose levels and phase 1b will evaluate 2 doses from the phase 1a.||||
33844451|NCT00153153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33844452|NCT06651229|NA|SEQUENTIAL||TREATMENT||NONE||||||
33844453|NCT04751942|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized control cohort study||||
33844454|NCT02550353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844455|NCT06727786|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844456|NCT02817802|||OTHER||PROSPECTIVE|||||||
33844457|NCT03240705|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The questionnaires will be coded as to not be able to identify study arm.||f|f|t|t
33844458|NCT06728917|||OTHER||PROSPECTIVE|||||||
33844459|NCT02713646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844460|NCT06728800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844461|NCT01599494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051611|NCT04042389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34051612|NCT01404754|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34051613|NCT06444269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051614|NCT01095978|||||PROSPECTIVE|||||||
34051615|NCT00465296|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34051616|NCT02141412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33844462|NCT00342888|||CASE_CONTROL||RETROSPECTIVE|||||||
33844463|NCT01217853|||COHORT||PROSPECTIVE|||||||
33844464|NCT05003609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded outcome assessor - blinded / different therapist (strength) and central follow-up for blinded assessment of PROMs|1;1 allocation, stratified by site,|f|f|f|t
33844465|NCT01364792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33844466|NCT04331457|||COHORT||PROSPECTIVE|||||||
33844467|NCT05887154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844468|NCT03831386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844469|NCT04976244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844470|NCT04119024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844471|NCT05384938|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-arm, multicentre, interventional, Phase 4 study investigating the safety, tolerability, and effectiveness of Fasenra (benralizumab) in adult patients of severe asthma with eosinophilic phenotype over a period of 24 weeks.||||
33844472|NCT00133562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33844473|NCT04548102|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group versus control group||||
33844474|NCT05646888|||COHORT||PROSPECTIVE|||||||
33844475|NCT04905459|||CASE_ONLY||CROSS_SECTIONAL|||||||
33844476|NCT03396276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844477|NCT01911390|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33844478|NCT02412787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844479|NCT05900180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844480|NCT03328221|||OTHER||PROSPECTIVE|||||||
33844481|NCT05165927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ACT's that collect data during visits will be blinded to what group the subject is in to prevent bias.||f|f|f|t
33844482|NCT04843605|||COHORT||PROSPECTIVE|||||||
33844483|NCT01120730|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33844484|NCT02430051|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844485|NCT05897320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051617|NCT01946958|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34051618|NCT01392027|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34051619|NCT06279650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34051620|NCT02045862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051621|NCT06666179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051622|NCT05983991|NA|SINGLE_GROUP||OTHER||NONE||||||
34051623|NCT05956132|||COHORT||RETROSPECTIVE|||||||
33844486|NCT01694316|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33844487|NCT02392052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051624|NCT01302444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051625|NCT05272384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844488|NCT00305136|||COHORT||PROSPECTIVE|||||||
34051626|NCT05502133|||COHORT||PROSPECTIVE|||||||
34051627|NCT01312168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051628|NCT03733080|||CASE_ONLY||CROSS_SECTIONAL|||||||
33844489|NCT02559895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844490|NCT06310408|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1 group give nasal mask~1 group give nasal prong"||||
33844491|NCT06729463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844492|NCT02276417|||COHORT||PROSPECTIVE|||||||
34051629|NCT06668857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844493|NCT04958200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eight-week and 16-week assessments will be completed by assessor who is masked to intervention condition. Baseline assessment takes place before randomization|Compare intervention to a treatment as usual comparison condition|f|f|f|t
33844494|NCT05743387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are not blinded to the intervention due to the nature of the intervention. Due to the cluster level randomization and TwiCs approach participants are blinded to the allocation (i.e. participants in the control villages are not aware of the intervention being implemented in the intervention villages). The main outcome and the safety endpoints are assessed by an independent study physician blinded to the allocation. The statistician and data managers cannot be blinded to the allocation.|Cluster-randomized controlled trial nested within the ComBaCaL cohort study following a trial within cohort (TwiC) approach. 50% of the villages being part of the overarching ComBaCaL cohort will be randomized stratified by district and access to health facility to receive the intervention.|f|f|f|t
34051630|NCT04681911|NA|SINGLE_GROUP||TREATMENT||NONE||In order to improve the curative effect and prolong the survival rate, we added Inetetamab to the current second-line treatment regimen of Pyrotinib combined with chemotherapy||||
33844495|NCT04904939|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The pathologist was blind to bronchoscopic mucosal changes.||f|f|f|t
33844496|NCT02045420|||CASE_CONTROL||RETROSPECTIVE|||||||
33844497|NCT04548544|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33844498|NCT06415149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844499|NCT02819167|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844500|NCT02277353|||COHORT||PROSPECTIVE|||||||
33844501|NCT02675647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844502|NCT05038800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844503|NCT01244087|||CASE_ONLY||PROSPECTIVE|||||||
33844504|NCT02433574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844505|NCT04695184|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a non randomised prospective cohort study design.||||
33844506|NCT02079480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33844507|NCT03901482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844508|NCT01935973|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844509|NCT05689203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844510|NCT01173497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844511|NCT03435679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844512|NCT06728163|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844513|NCT01239459|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33844514|NCT01778543|||COHORT||PROSPECTIVE|||||||
33844515|NCT03520751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844516|NCT00250445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844517|NCT05262140|||COHORT||PROSPECTIVE|||||||
33844518|NCT03778554|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled, open-label, blinded endpoint (PROBE design)||||
33844519|NCT03799835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844520|NCT02409524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948739|NCT01220817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948740|NCT04064190|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2, open label, non randomized single arm study with two cohorts and a safety run-in for first six patients||||
34051631|NCT02029989|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34051632|NCT01375621|||CASE_CONTROL||PROSPECTIVE|||||||
34051633|NCT04126915|||COHORT||PROSPECTIVE|||||||
34051634|NCT03857451|||COHORT||PROSPECTIVE|||||||
34051635|NCT05318248|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34051636|NCT03190668|RANDOMIZED|PARALLEL||PREVENTION||NONE||Simple randomization will be used with each patient has probability 0.5 to be assigned in Group I or Group II. Computer program will generate a uniform random variable between 0 to 1, with subject assigned to Group I if the value is less than 0.5 and assigned to Group II if the value is greater than 0.5.||||
33948741|NCT02528331|NA|SINGLE_GROUP||||NONE||||||
33948742|NCT00151658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948743|NCT06390995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948744|NCT05290636|NA|SINGLE_GROUP||OTHER||NONE||||||
33948745|NCT02221362|||CASE_CONTROL||PROSPECTIVE|||||||
33948746|NCT03977922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948747|NCT00242645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34051637|NCT03702075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051638|NCT06664697|||COHORT||PROSPECTIVE|||||||
34051639|NCT06668038|NA|SINGLE_GROUP||OTHER||NONE||||||
34051640|NCT03033316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051641|NCT00787982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051642|NCT01145300|||COHORT||PROSPECTIVE|||||||
34051643|NCT04774419|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase II stud y Adjuvant Checkpoint Blockade Plus Radiation in Locally Advanced, Mismatch Repair Deficient/Microsatellite Instability-High (MMR-D/MSIH) Endometrial Cancer with safety run-in of adjuvant checkpoint blockade with radiation in women with Stage III-IVA, dMMR/MSI-H endometrial cancer||||
34051644|NCT06478888|||COHORT||PROSPECTIVE|||||||
34051645|NCT06205901|||COHORT||PROSPECTIVE|||||||
34051646|NCT06610630|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33844521|NCT03214640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are 4 arms for this study--two are active comparators and two are experimental. The first arm is palpation with spinal block. The second arm is palpation with neuraxial block. The third arm is ultrasound with spinal block. The fourth arm is ultrasound with neuraxial block. Randomization is done twice - first for randomization of spinal block subjects between using palpation versus ultrasound method; and again randomization for neuraxial block (combined spinal epidural) subjects between using palpation versus ultrasound method. There will be a total of 120 planned evaluable subjects. This consists of planned evaluable randomized 60 subjects receiving spinal block for cesarean delivery (30 for palpation and 30 for ultrasound); and planned evaluable randomized 60 subjects receiving neuraxial (combined spinal epidural) block for labor analgesia.||||
34051647|NCT05500248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34051648|NCT03484442|||CASE_ONLY||PROSPECTIVE|||||||
34051649|NCT06665425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844522|NCT06055608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844523|NCT06619860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844524|NCT02846272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051650|NCT03834766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|AMPH ER Tab 5, 10, 15 \& 20 mg Vs. Matching Placebo|This is a randomized, double-blind (DB), placebo-controlled, parallel study|t|t|t|t
34051651|NCT01993953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051652|NCT02419612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844525|NCT01002300|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33844526|NCT04227184|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33844527|NCT03208036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, interventionists, and the outcome assessors will be blind to participant condition. The neuromodulation device can be pre-programmed to deliver either tDCS or sham stimulation when an ID code is entered. The study personnel randomizing participants and programming the equipment will not have contact with participants.|This is a double-blind, double-baseline, sham-controlled study in which participants are randomized to receive either tDCS or sham stimulation concurrent with cognitive training.|t|t|f|t
33844528|NCT03947697|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33844529|NCT04233762|||COHORT||PROSPECTIVE|||||||
33844530|NCT06188897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33844531|NCT06608147|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844532|NCT04652960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844533|NCT06663592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844534|NCT00150423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051653|NCT03270319|||COHORT||PROSPECTIVE|||||||
34051654|NCT03726294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051655|NCT04435756|||COHORT||PROSPECTIVE|||||||
34051656|NCT05828680|||CASE_ONLY||PROSPECTIVE|||||||
34051657|NCT06015503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154645|NCT00992823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051658|NCT04259658|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective phase II clinical study: Patients with cutaneous metastases will be recruited at the Department of Oncology, Zealand University Hospital (ZUH). One cohort of 24 patients with respectively disseminated breast cancer or other solid tumour malignancies, will be included. This will be a non-randomized trial.~All patients will have been offered the standard of care and all available alternatives before entering the protocol. Calcium electroporation will not be compared to other means of treatment.~All patients will be treated once and patients with over 3 metastases will be offered retreatment of some of their metastases. A maximum of 2 treatments per patient will be conducted with an interval of minimum 4 weeks. The patients will be followed with regular examinations for 3 months, starting from first treatment day."||||
34154646|NCT03763136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study adopts a single-blind design plus double-blind management principle. To ensure the study results are evaluated without bias, participants and outcomes assessors will not be informed the randomization details."||t|f|f|t
34154647|NCT02380040|||CASE_CONTROL||PROSPECTIVE|||||||
34051659|NCT04391322|||OTHER||PROSPECTIVE|||||||
34051660|NCT06053892|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The assignment into the study groups is going to be performed by 1:1 randomization using randomisation cards which are drawn by author-ised study staff.|||||
34051661|NCT01951612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051662|NCT02730377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051663|NCT03285568|||COHORT||RETROSPECTIVE|||||||
34051664|NCT03953053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051665|NCT03305861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154648|NCT05655013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Part 1: 1-year randomized open label, interventional study in 200 postmenopausal women.~Part 2: 2-year randomised, double-blind, interventional study in the women completing part 1."|t|f|t|f
34154649|NCT01113580|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154650|NCT05825885|||COHORT||PROSPECTIVE|||||||
33844535|NCT02570919|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844536|NCT04613232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844537|NCT02395029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844538|NCT03573076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844539|NCT06727565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844540|NCT00952055|||COHORT||PROSPECTIVE|||||||
33844541|NCT00763776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948748|NCT05126966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154651|NCT03393949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154652|NCT04887987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154653|NCT01596036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34154654|NCT02589535|||CASE_CONTROL||PROSPECTIVE|||||||
34154655|NCT04232111|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind||t|f|t|t
34154656|NCT02474953|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34154657|NCT04292223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154658|NCT04565795|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with clinical symptoms consistent with unilateral ureteral or renal stone fragments post-uncomplicated ureteroscopy (UURS).||||
33844542|NCT06727500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844543|NCT03361553|||CASE_ONLY||PROSPECTIVE|||||||
33844544|NCT05586477|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Double-blind||t|f|f|f
33844545|NCT05540613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844546|NCT06558344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844547|NCT06578741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844548|NCT04285398|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33844549|NCT01249807|||COHORT|||||||||
33844550|NCT02324400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33844551|NCT03632941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844552|NCT04958642|NA|SINGLE_GROUP||TREATMENT||NONE||In Part C, all participants receive adrabetadex||||
33844553|NCT01202903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844554|NCT06727578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844555|NCT02531945|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844556|NCT06557850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844557|NCT06688422|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844558|NCT04994353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844559|NCT00063427|NON_RANDOMIZED|||TREATMENT||NONE||||||
34051666|NCT06668389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154659|NCT03114631|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051667|NCT05295732|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-Blinded|"• Period 1 - Induction (3 weeks): At the beginning of the 3-week Induction Period, eligible subjects will be randomized (2:1 ratio) to either TMB-001 0.05% once-a-day (QD) or Vehicle QD treatment, with use of mandatory standardized bland emollient (Cetaphil™) provided by the Sponsor.~• Period 2 - Treatment (9 weeks): The dosing frequency in the 9-week treatment period will be increased in each treatment group to TMB-001 0.05% BID or Vehicle BID. Mandatory bland emollient will be discontinued.~• Period 3 - Maintenance (12 weeks): At Week 12, eligible subjects in the TMB-001 treatment group will be randomized (1:1 ratio) to an open-label treatment with TMB-001 0.05% BID or TMB-001 0.05% QD.~Vehicle-treated subjects who achieved \<1-point reduction in IGA score from Baseline are eligible to cross over to the TMB-001 0.05% BID treatment group."|t|t|t|t
34051668|NCT05274841|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051669|NCT04689373|||COHORT||PROSPECTIVE|||||||
34051670|NCT06684964|||COHORT||PROSPECTIVE|||||||
34051671|NCT06665997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051672|NCT05332275|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051673|NCT01744379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051674|NCT00285116|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051675|NCT06666088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34051676|NCT06668012|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multicenter, open, comparative study, where all eligible patients with vaginal dysbiosis (vaginal pH \>4.5) will be assigned to one of the 3 study groups (1:1:1) according to the randomization list for random assignment to groups B and C:~A. Symptomatic patients: Treatment with Palomacare® vaginal gel for 6 days B. Asymptomatic patients: Treatment with Palomacare® vaginal gel for 6 days C. Asymptomatic patients: Monitored follow-up"||||
34051677|NCT02671084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34154660|NCT06023043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844560|NCT02725021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844561|NCT04927884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844562|NCT02928159|NA|SINGLE_GROUP||||NONE||||||
33844563|NCT04013568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants choose the initial intervention (12-week exercise program (Group1) vs monitoring (Group2)).||||
33844564|NCT06433947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844565|NCT04624087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33844566|NCT04142359|||COHORT||OTHER|||||||
33844567|NCT00106587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844568|NCT04839952|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||This is a small feasibility study. We will enroll 24 participants on the intervention arm and 12 participants to an education-only control arm.||||
33844569|NCT01355900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844570|NCT02651532|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844571|NCT02910284|||COHORT||PROSPECTIVE|||||||
33844572|NCT03282669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844573|NCT06239636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844574|NCT00529958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33844575|NCT03374943|NA|SEQUENTIAL||TREATMENT||NONE||The study will use a 3+3 methodology for the 3 dose levels proposed. In brief, three patients will be recruited per dose level. In the absence of any Dose Limiting toxicity (DLT) in a cohort, escalation to the next dose level will occur.||||
33844576|NCT05494593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844577|NCT02762643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844578|NCT05860634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844579|NCT02773667|||CASE_ONLY||PROSPECTIVE|||||||
33844580|NCT03568773|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental, controlled and randomized study.||||
33844581|NCT06094387|||CASE_CONTROL||PROSPECTIVE|||||||
33844582|NCT02522559|NA|SINGLE_GROUP||OTHER||NONE||||||
33844583|NCT06728033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As the clinical management differs between groups, researchers, participants, and clinical staff will be aware of the group allocations; however, follow-up personnel, outcome assessors, and statisticians will remain blinded to group assignments.||f|f|f|t
33844584|NCT06616597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844585|NCT03261687|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomised controlled feasibility study||||
33844586|NCT02562170|RANDOMIZED|PARALLEL||||NONE||||||
33844587|NCT05930613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844588|NCT01012414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844589|NCT01887704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844590|NCT02240953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844591|NCT06520124|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Not possible to mask as participant and/or investigator could identify which lens is 'different' from single-vision through visual inspection.|Participants will wear the treatment lens in front of one eye and a single vision lens in front of the other eye (Arms A1 and A2). This will be randomised by eye dominancy and crossed-over after one year (Arms B1 and B2).||||
33844592|NCT06729255|NA|SINGLE_GROUP||PREVENTION||NONE||"We will be performing a prospective cohort with retrospective loss-of-resistance comparator, proof of concept study involving patients undergoing epidural labor analgesia at OHSU University Hospital.~This is an open-label (unblinded) study.~The study will involve one arm:~1) A prospectively enrolled convenience sample of patients that receive epidural labor analgesia with the assistance of the EpiZact device.~Results will be matched with a sample of patients identified through retrospective chart review that have received standard of care epidural labor analgesia with the loss-of-resistance technique."||||
33844593|NCT05490342|||COHORT||RETROSPECTIVE|||||||
33844594|NCT02696876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844595|NCT05824598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The pain scores will be assessed by a psychologist blinded to group allocation|"Monocentric, single blind with parallel arm design. Standard descriptive analysis and linear and logistic regression models will be performed.~To correct any imbalances between the 2 groups due to the low sample size, an analysis adjusted for the main confounders listed below is planned: age, gender, previous cognitive impairment, previous presence of anxiety and depression beyond the clinically acceptable threshold.~Sample size estimation was performed using G\*Power v3.1 software. The sample size was calculated separately for the two outcomes of interest that will make up the composite score: reduction in pain assessed using the Numerical Rating Scale (NRS) and reduction in anxiety and depression assessed using the Hospital Anxiety and Depression Scale (HADS).~It was then decided to conservatively adopt the higher number of the two estimates."|f|f|f|t
33844596|NCT02241005|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33844597|NCT00955175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844598|NCT03806881|||COHORT||PROSPECTIVE|||||||
33844599|NCT02713087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844600|NCT06728111|||COHORT||RETROSPECTIVE|||||||
33844601|NCT03250988|||COHORT||CROSS_SECTIONAL|||||||
33844602|NCT00835900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844603|NCT01510080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33844604|NCT02358759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33844605|NCT05180539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33844606|NCT01807000|NA|SINGLE_GROUP||OTHER||NONE||||||
33844607|NCT05822830|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 3b||||
33844608|NCT02133222|NA|SINGLE_GROUP||SCREENING||NONE||||||
33844609|NCT03814577|RANDOMIZED|PARALLEL||SCREENING||NONE|Single (Investigator)|Prospective Randomized Clinical Study||||
33844610|NCT03292900|||COHORT||RETROSPECTIVE|||||||
33844611|NCT01091805|||CASE_ONLY||PROSPECTIVE|||||||
33844612|NCT05521503|||CASE_ONLY||PROSPECTIVE|||||||
33844613|NCT01828489|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33844614|NCT05495737|||COHORT||PROSPECTIVE|||||||
33844615|NCT06131606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|By drawing lots, the first set was chosen to correspond to the experimental group and the second set to correspond to the control group for the two groups.|This controlled randomized study|t|f|f|f
34051678|NCT02196688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051679|NCT04627597|||COHORT||CROSS_SECTIONAL|||||||
33844616|NCT06236555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844617|NCT06729099|||COHORT||OTHER|||||||
33844618|NCT03001375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051680|NCT03660189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33844619|NCT06681870|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844620|NCT05852704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, care providers, investigators and outcomes assessors are all blinded to treatment allocation.|In a multicenter, prospective, randomized, controlled clinical trial to compare dapagliflozin 10 mg once daily and placebo in preventing post-operative atrial fibrillation and kidney injury in patients undergoing coronary artery bypass surgery (CABG).|t|t|t|t
33844621|NCT01369771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844622|NCT04083105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sedation provider who will administer the pain scale tests and the participant will be masked to the subject's assigned study arm (30% or 70% nitrous oxide with midazolam). The attending pediatric dentist and dental assistant will not be blinded for patient safety.|Participants receiving moderate sedation for a dental procedure will be recruited and divided into one of two study arms.|t|t|f|f
33844623|NCT00938496|||||PROSPECTIVE|||||||
33844624|NCT06303258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
33844625|NCT05199987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844626|NCT01332630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844627|NCT05870839|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33844628|NCT01062802|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33844629|NCT04929275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844630|NCT04322903|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33948749|NCT05596695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34051681|NCT02437396|||CASE_CONTROL||PROSPECTIVE|||||||
34051682|NCT04836026|||CASE_ONLY||PROSPECTIVE|||||||
34051683|NCT06059391|RANDOMIZED|PARALLEL||TREATMENT||NONE|This trial is observer-blinded because of the handling of the vaccine and the placebo may vary. The investigators, treating clinicians, participants, and other study staff, including the nurses involved in soliciting or recording of adverse events, will be blinded through the day 180 visit.|||||
34051684|NCT00968981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051685|NCT03639207|||OTHER||RETROSPECTIVE|||||||
33844631|NCT04767243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patient and statistician will be masked about the treatment regimen|"45 sites with vertical intrabony alveolar defects will be selected. These defect sites will be allocated randomly into 3 groups as Group I, Group II and Group III.~* Group I will be treated with open flap debridement and filled with A-PRF~* Group II will be treated with open flap debridement and filled with Bioactive glass (Perioglas®)~* Group III will be treated with open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF."|t|f|f|t
33844632|NCT05709600|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844633|NCT04137523|||OTHER||OTHER|||||||
33844634|NCT03694132|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||patients vs. health subjects||||
33844635|NCT06560151|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33844636|NCT01073787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844637|NCT02169362|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33844638|NCT00000632|RANDOMIZED|||PREVENTION||||||||
33844639|NCT05183464|||CASE_CONTROL||PROSPECTIVE|||||||
33844640|NCT02015455|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33844641|NCT06229652|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33844642|NCT04732065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844643|NCT06728657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844644|NCT06050200|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The Investigator performing statistical analysis will blinded to which study group the patient was assigned to.~The patient will not be aware which of the two radiological methods (PVE or LVD) was performed."|"This is a prospective, interventional randomized study. Patients will be randomly assigned to three groups in a 12:71:71 ratio: PVE, LVD and ALPPS groups, respectively.~Randomization will be performed directly after recruitment."|t|f|t|f
33844645|NCT06641973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844646|NCT04491552|||COHORT||PROSPECTIVE|||||||
33844647|NCT02113124|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844648|NCT00304395|||COHORT||RETROSPECTIVE|||||||
33844649|NCT06233227|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33844650|NCT01305200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33844651|NCT06727877|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33844652|NCT03026192|||COHORT||PROSPECTIVE|||||||
33844653|NCT02952118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33844654|NCT06629181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33844655|NCT00542776|||COHORT||PROSPECTIVE|||||||
33844656|NCT00260286|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33844657|NCT00219102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33844658|NCT06623357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844659|NCT02544009|||COHORT||PROSPECTIVE|||||||
33844660|NCT02389452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844661|NCT00635427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844662|NCT00005645||||TREATMENT||||||||
33844663|NCT00427505|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844664|NCT06665984|||CASE_CONTROL||PROSPECTIVE|||||||
33844665|NCT06064539|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844666|NCT05617664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844667|NCT02057653|||COHORT||RETROSPECTIVE|||||||
33844668|NCT05728866|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844669|NCT06431217|||COHORT||PROSPECTIVE|||||||
33844670|NCT06200129|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33844671|NCT04385108|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33844672|NCT04316351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844673|NCT02228759|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844674|NCT04630847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844675|NCT05121558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and investigators, will be blinded to the patient's group assignment.|3-arm parallel randomized controlled trial (RCT) comparing yoga to a non-physical education control (EC) and usual care.|f|t|t|f
33844676|NCT06619951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051686|NCT06491589|||COHORT||PROSPECTIVE|||||||
34051687|NCT03973931|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will be a pragmatic, randomized controlled study with four treatment arms. Once patients are identified through pharmacy refill data to have a 7-day gap in any prescribed CV medication refills, they will be randomized to one of four arms, described in Intervention below. Randomization will be stratified within each of the clinics, and within strata defined by number of other CV medication classes that are prescribed at randomization (1-4), using blocks of 4 patients to ensure balance within clinics over time. Thus, within each clinic and number of other medication stratum, each set of 4 consecutively enrolled subjects will be randomized to the four study arms. Treatments will be initiated immediately upon randomization, in response to the 7-day gap.||||
34051688|NCT06665178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844677|NCT01472549|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844678|NCT06727929|||COHORT||PROSPECTIVE|||||||
33844679|NCT04417465|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844680|NCT00939159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844681|NCT05602727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844682|NCT05929066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844683|NCT04821830|||CASE_ONLY||PROSPECTIVE|||||||
33844684|NCT00296985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33844685|NCT03178838|||OTHER||RETROSPECTIVE|||||||
33844686|NCT02695342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844687|NCT06196827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844688|NCT02103205|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844689|NCT03957824|||COHORT||PROSPECTIVE|||||||
33844690|NCT03953755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844691|NCT04174703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care providers will not be told which condition each participant was assigned to.|Half of the study participants (n=80) will be placed into the self-compassionate letter-writing intervention group, and half of the study participants (n=80) will be placed into a control group.|f|t|f|f
34051689|NCT02690298|||COHORT||PROSPECTIVE|||||||
34051690|NCT05526846|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051691|NCT04201158|||OTHER||CROSS_SECTIONAL|||||||
34051692|NCT04550806|||CASE_CROSSOVER||PROSPECTIVE|||||||
34051693|NCT05948761|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34051694|NCT04762485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844692|NCT04567277|NA|SINGLE_GROUP||TREATMENT||NONE||The study has a single group including patients with high grade subarachnoid hemorrhage (WFNS 3-4) for whom EVD was inserted. EVD was tried converted into VPS within 7-10 days of insertion.||||
33844693|NCT02652325|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34051695|NCT01534598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844694|NCT03767140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients didn´t know what kind of therapy they were submitted The acupuncturist was a nurse, able to do invasive procedures with no knowledge of Chinese Medicine, and totally blind in terms of the verum or sham acupuncture.|"The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture.~The method used to randomized was flipping a coin, when got heads they went to verum group and when got tails they went to sham group."|t|f|t|f
34051696|NCT01960270|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34051697|NCT04563533|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The subjects, investigators, monitors, and data analysts are not aware of treatment allocation.|A single-center, randomized, blinded, multi-cohort, placebo-controlled trial design was adopted.|t|t|t|t
34051698|NCT04494061|||COHORT||PROSPECTIVE|||||||
34051699|NCT02119689|||COHORT||PROSPECTIVE|||||||
33844695|NCT02004470|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33844696|NCT06728709|||COHORT||PROSPECTIVE|||||||
34051700|NCT03830684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051701|NCT04026828|||CASE_CONTROL||PROSPECTIVE|||||||
33844697|NCT05240079|NA|SINGLE_GROUP||OTHER||NONE||||||
33844698|NCT02920580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33844699|NCT03247387|||CASE_ONLY||PROSPECTIVE|||||||
33844700|NCT00004444|RANDOMIZED|||TREATMENT||||||||
33844701|NCT02775773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844702|NCT05580562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844703|NCT06127407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844704|NCT01382277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844705|NCT06729086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844706|NCT06298669|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33844707|NCT04200937|||COHORT||PROSPECTIVE|||||||
33844708|NCT01367639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051702|NCT03879525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome group assignment will not be blinded to the primary investigator or primary study coordinator, as it will be necessary for these individuals to know outcome assessment allocation in order for outcome collection to occur. When possible, outcome group assignment will not be shared with the epilepsy provider managing the participant, in an effort to reduce any potential bias in retention that could be introduced by the provider in clinical interactions with the participant.||f|f|f|t
33844709|NCT05118828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844710|NCT06427889|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33844711|NCT04276753|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33948750|NCT03195166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|consecutive patient|"The aim of this study was to investigate the hemodynamic effects of continuous spinal anesthesia in elderly patients. An oral intake of 250 ml of water was taken 2 hours before surgery.~Radial arterial catheter was putted under local anesthesia and connected to the FloTrac sensor/Vigileo haemodynamic monitoring system.~Fluid therapy was limited to 4 ml/kg/h until tourniquet release.~Subarachnoid puncture was performed at the L3-S1 interspace. An initial dose of 2,5 mg isobaric 0,5% bupivacaine was injected. Additional 2,5 mg isobaric 0,5% bupivacaine doses were injected every 10 minutes until sensory blockade reached T10.~Ephedrine 6 to 9 mg was given if systolic arterial pressure \< 90 mmHg. Investigators measured blood pressure (systolic, diastolic and mean), stroke volume and cardiac output every 5 minutes from beginning of the operation and until 2 hours after the end.~Number of hypotension episodes and ephedrine consumption were noted."||||
33948751|NCT01062607|||COHORT|||||||||
33948752|NCT03534921|||CASE_CONTROL||RETROSPECTIVE|||||||
33948753|NCT00953589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948754|NCT03836014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948755|NCT06055452|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948756|NCT02144142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948757|NCT00820365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948758|NCT02163759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051703|NCT02062164|||CASE_CONTROL||PROSPECTIVE|||||||
34051704|NCT05180721|NA|SINGLE_GROUP||OTHER||NONE||||||
34051705|NCT04193956|||COHORT||PROSPECTIVE|||||||
34051706|NCT00352222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051707|NCT04799054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34051708|NCT03970005|||CASE_ONLY||PROSPECTIVE|||||||
34051709|NCT06219824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051710|NCT03060174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34051711|NCT06077773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051712|NCT03659916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051713|NCT04057547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051714|NCT05465538|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051715|NCT06667947|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34051716|NCT00883467|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34051717|NCT02021188|||CASE_ONLY||PROSPECTIVE|||||||
34051718|NCT06262945|||COHORT||RETROSPECTIVE|||||||
34051719|NCT02938988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051720|NCT03826264|||COHORT||PROSPECTIVE|||||||
34051721|NCT00330343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051722|NCT02232828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844712|NCT05305612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be conducted by blinded and unblinded staff. The participants, investigators, care provider and outcome assessors will be blinded. However, in every center the dedicated unblinded study nurse will randomize the patient and prepare two syringes either with saline or UFH. The syringes will be labeled with number 1 and number 2 and will be provided to the anestesiologist taking care of patient during the procedure. The injection from syringe nr 1 will be administered after obtaining the venous access and 5 minutes before the start of TSP. The injection from syringe nr 2 will be administered after TSP defined as introduction of trans-septal sheath into the left atrium. The unblinding nurse responsible for the randomization procedure and preparation of syringe nr 1 and syringe nr 2 and will be not involved in any other procedures or care of the patients enrolled into the study.|"Patients will be randomized to:~Early unfractionated heparin administration. The iv. bolus of UFH (100Units/kg) will be given after obtained femoral vein access and at least 5 minutes prior to the start of the TSP.~Late unfractionated heparin administration. The iv. bolus of UFH (100Units/kg) will be given immediately after TSP, defined as the introduction of transseptal sheath into the left atrium."|t|t|t|t
33844713|NCT06728787|||COHORT||OTHER|||||||
33844714|NCT06665256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study investigator and the participant will be unblinded to the study treatment. A blinded assessor will perform the efficacy assessments to minimize bias in data collection.||f|f|f|t
33844715|NCT02862717|||COHORT||PROSPECTIVE|||||||
34051723|NCT00316615|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34051724|NCT05475990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051725|NCT06437717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051726|NCT06666634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051727|NCT05483686|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34051728|NCT00798343|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33844716|NCT01638143|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34051729|NCT03572725|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34051730|NCT05343039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051731|NCT01279122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844717|NCT00004242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844718|NCT00856037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844719|NCT06002932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Intervention||||
33844720|NCT04055207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Veterans in the Infections Disease clinic at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) will be randomly assigned to either an offer of VA Video Connect (VVC) delivered HIV care or to usual care for HIV. All treatment as usual options for HIV care will be available to all patients in both treatment arms, however only the Veterans in the VVC arm will be actively offered this VA-approved technology.||||
33844721|NCT05440916|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844722|NCT01301690|||COHORT||PROSPECTIVE|||||||
33844723|NCT06241547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33844724|NCT06375447|||COHORT||PROSPECTIVE|||||||
33844725|NCT05880901|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33844726|NCT05308264|NA|SEQUENTIAL||TREATMENT||NONE||||||
33844727|NCT05612503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844728|NCT05642832|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33844729|NCT06142266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be randomly allocated to either the intervention or control group in a 1:1 ratio using computer-generated randomization|randomized controlled trial conducted at Chest Department at Assiut University Hospital|t|f|f|f
33844730|NCT06480695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A study team member not associated with the trial will perform the randomization scheme for the supplementation. Exercise groups will not be blinded but data will not be analyzed until the end or re-labeled by another team member so assessors are unaware while analyzing the data.|Subjects will be randomized to one-month of either high or moderate aerobic exercise training and then further randomized to nitrate or placebo.|t|t|t|t
33844731|NCT04650542|NA|SINGLE_GROUP||TREATMENT||NONE|Parallel Assignment|"* Experimental: HBI-3000, 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2~* Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2"||||
33844732|NCT01998100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844733|NCT06355362|||COHORT||PROSPECTIVE|||||||
33844734|NCT06059638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948759|NCT02549391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948760|NCT04804306|||CASE_CONTROL||PROSPECTIVE|||||||
33948761|NCT01580696|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation study of E39 + GM-CSF in HLA-A2+ patients with HLA-A2- patients followed as a control arm||||
34051732|NCT01520779|||COHORT||RETROSPECTIVE|||||||
34051733|NCT00682370|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34051734|NCT05137067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active product and placebo will be in identical packets.|Randomized interventional parallel study|t|t|t|t
34051735|NCT01002612|||COHORT||CROSS_SECTIONAL|||||||
34051736|NCT01843140|||COHORT||PROSPECTIVE|||||||
34051737|NCT06685523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Four group:~* Peri-implant healty~* Mechanical curette~* Er:YAG laser~* Diyot laser"|f|f|t|t
34051738|NCT01264744|||CASE_CONTROL||RETROSPECTIVE|||||||
34051739|NCT04259424|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects enrolled will receive the same treatment. Upper extremity motor function outcome measures will be assessed.||||
34051740|NCT05547477|||CASE_ONLY||CROSS_SECTIONAL|||||||
34051741|NCT02994225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051742|NCT04949646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded regarding the allocation group. Blinding will not exist at the level of the surgeon, the anaesthesiologist, and the investigator responsible for the data recording|The study will employ a prospective, parallel randomized-controlled design|t|f|f|f
34051743|NCT05996341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051744|NCT06277869|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Stepped wedge cluster randomised trial||||
34051745|NCT01676740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051746|NCT05548205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844735|NCT06500793|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single center, open-label study. Part 1 will assess impact of nafamostat (IR solution / ER beads) on oxycodone plasma levels when administered with 100 mg PF-614. Nafamostat will be increased from 1-10 mg if required to inhibit conversion of PF614 to oxycodone in an overdose situation (greater than 3 dose units taken simultaneously). Part 1 is intended to identify a nafamostat IR/ER combination that does not impact oxycodone release if 2 PF614 dose units are taken simultaneously yet show that nafamostat with 3 to 5 dose units inhibits conversion of PF614 to oxycodone in an OD situation (5 x 100 mg PF614 dose level). Results from Part 1 will define the dose units for Part 2 and 3. Part 2 will assess the impact of food on the exposure of PF-614 and nafamostat coadministered and PF-614 and nafamostat administered alone. Part 3 will assess multiple dosing (BID for 4.5 days) of 25 mg and 100 mg PF614 alone and co-administered with the selected nafamostat dose in the fasted state.||||
33844736|NCT05834205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844737|NCT03025035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844738|NCT01744795|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33844739|NCT05052177|||COHORT||RETROSPECTIVE|||||||
33844740|NCT05140408|||CASE_ONLY||RETROSPECTIVE|||||||
33844741|NCT05952076|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33844742|NCT06333353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, care providers, investigators and outcome assessors will remain blinded to real/sham intervention. The outcomes assessor and the investigator will remain blinded to intervention duration.|Parallel Assignment|t|t|t|t
33844743|NCT05550090|||COHORT||PROSPECTIVE|||||||
33844744|NCT02231073|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34051747|NCT06666023|||COHORT||PROSPECTIVE|||||||
34051748|NCT01161680|||COHORT||PROSPECTIVE|||||||
33844745|NCT01497353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844746|NCT06498011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be blinded to the hypotheses being tested in this study i.e the participant will not be informed about the feasibility testing of the iCOSMO training intervention. The participants will also not be informed which amongst the two interventions is the experimental or control interventions, respectively. The outcome assessor will be blinded to the intervention delivered to participants.||t|f|f|t
33844747|NCT05553522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844748|NCT04375280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844749|NCT06549790|NA|SEQUENTIAL||TREATMENT||NONE||||||
33844750|NCT05039216|||COHORT||PROSPECTIVE|||||||
33844751|NCT05499845|||OTHER||PROSPECTIVE|||||||
33844752|NCT06024278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844753|NCT03325491|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844754|NCT03183219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33844755|NCT01552603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844756|NCT06509906|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844757|NCT06378996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Prospective, single arm, interventional cohort study including 3 different patient cohorts:~* Patients with MVP (not previously known with AMVP) and mild to moderate mitral valve regurgitation~* Patients with AMVP and mild to moderate mitral valve regurgitation~* Patients with MVP and severe mitral valve regurgitation scheduled for surgical intervention"||||
33844758|NCT05657652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844759|NCT00366080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33844760|NCT00781989|||COHORT||PROSPECTIVE|||||||
33948762|NCT03250728|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948763|NCT02467543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948764|NCT06716632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948765|NCT05741242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051749|NCT04233567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051750|NCT03865615|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Within-subject, randomized, placebo-controlled, counterbalanced, crossover design.|t|t|t|t
34051751|NCT03966924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051752|NCT00062881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051753|NCT05120518|||COHORT||PROSPECTIVE|||||||
34051754|NCT00987870|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33948766|NCT04196023|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33948767|NCT03201601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948768|NCT02497261|||COHORT||PROSPECTIVE|||||||
33948769|NCT03122327|||CASE_ONLY||PROSPECTIVE|||||||
33948770|NCT06427720|||CASE_CONTROL||RETROSPECTIVE|||||||
33948771|NCT03417648|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34051755|NCT03250390|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051756|NCT00839527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051757|NCT05399862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised, double-blind, placebo-controlled trial|t|t|t|t
34051758|NCT03204929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051759|NCT05374746|||CASE_ONLY||CROSS_SECTIONAL|||||||
34051760|NCT03798301|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, open-label, single-arm, pilot study||||
34051761|NCT06682715|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"A randomized study design will be used to compare the effects of whey vs maltodextrin (placebo) on university football players. The study will be performed during the time period of 7 weeks.In the 1st and 7th week, each participant will have their body composition analysed using InBody-270, USA. Parameters of interest in BIA are fat-mass, fat-free mass, BMI. Nutrition knowledge will be assessed using modified The Nutrition for Sports Knowledge Questionnaire and endurance performance will be assessed using Rockport fitness test (1mile test) / harvard step test for maximal oxygen calculation.~Supplemental drinks will include 24g whey protein or iso-caloric amount of maltodextrin for placebo. Participants will be directed to perform their regular training sessions 5-6times/ week.~Groups Dose Duration Treatment group(n=15) 24g whey protein 5 weeks Placebo group(n=15) Isocaloric maltodextrin 5 weeks"|t|f|f|f
34051762|NCT05711186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34051763|NCT05113771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051764|NCT05036057|||COHORT||PROSPECTIVE|||||||
33948772|NCT03364699|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33844761|NCT05301491|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two randomized controlled groups~Forty female patients who were diagnosed with chronic low back pain and met the inclusion criteria of the study were divided into two groups.These individuals are going to be divided into groups as the odd numbers to study group and even numbers to the control group.~Inclusion criteria of patients;~* Those who agree to participate in the study voluntarily~* Having low back pain lasting longer than 3 months,~* Having values between 4 and 7 on the Visual Analog Scale.~* Female individuals between the ages of 18-65~Exclusion criteria of patients; Those with a Body Mass Index (BMI) greater than 35 kg/m², pregnant women, those with following problems; neural findings, malignancy, inflammation, arthritis, metabolic bone disease, column vertebralis or lower extremity surgery, cardiovascular system diseases, severe osteoporosis, communication and hearing disorders, and those who illiterate, receive other treatment for low back pain."||||
33844762|NCT05526521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844763|NCT03767582|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844764|NCT06632756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844765|NCT01419327|||CASE_ONLY||PROSPECTIVE|||||||
33844766|NCT05653427|NA|SEQUENTIAL||TREATMENT||NONE||||||
33844767|NCT05977036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844768|NCT02844634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844769|NCT00503139|||CASE_ONLY||PROSPECTIVE|||||||
33844770|NCT01253018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844771|NCT05737862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1 group receives capsules of powdered Moringa leaves (active comparator), and the other group receives IFA tablets as part of routine clinical care.|t|t|f|f
33844772|NCT06423664|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm pilot study to assess feasibility of study procedures.||||
33844773|NCT01409304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844774|NCT04881383|||COHORT||PROSPECTIVE|||||||
33844775|NCT04998929|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844776|NCT06728475|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33844777|NCT06584916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase 3b|t|f|t|f
33844778|NCT00218049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844779|NCT06728501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844780|NCT06683599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33844781|NCT06073782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33844782|NCT04241848|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ambulation training while using the powered orthotic exoskeleton for 36 sessions||||
33844783|NCT06350682|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33844784|NCT06172192|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33844785|NCT03754114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be blinded to the treatment assignment of the participant.||f|f|f|t
33844786|NCT05808777|||COHORT||PROSPECTIVE|||||||
33844787|NCT05020535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, study staff, analytic staff (to patient identifiers), sponsor staff (only to treatment allocation, unblinded to enable handling and review of data and drug accountability prior to database lock)|Parallel 1:1|t|t|t|t
33844788|NCT04601025|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33844789|NCT00599703|||COHORT||PROSPECTIVE|||||||
33844790|NCT05978141|||COHORT||PROSPECTIVE|||||||
33844791|NCT01876459|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33844792|NCT06127875|||COHORT||PROSPECTIVE|||||||
33844793|NCT05936359|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844794|NCT01432587|||COHORT||PROSPECTIVE|||||||
33844795|NCT02180243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|RBANS assessment was blinded||f|f|f|t
33978008|NCT05177627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Students participating in the study will be randomly assigned to two groups:~1. experimental group with educational interventions of integration of the FoC framework (learning according to the FoC framework with the contents of the current curriculum);~2. control group without intervention (learning according to the current educational model and the contents of the current curriculum); A researcher not involved in the educational interventions and data collection of the study at the University of Genoa will randomly assign in a 1: 1 ratio the students to the two groups extracted from the lists of students provided by the universities based on a table of random numbers."|f|f|f|t
33978009|NCT03015090|NA|SINGLE_GROUP||OTHER||NONE||||||
33978010|NCT00972881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978011|NCT02495324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978012|NCT03706196|||COHORT||PROSPECTIVE|||||||
34051765|NCT02032862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051766|NCT06420011|||COHORT||RETROSPECTIVE|||||||
34051767|NCT03103373|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study is a clinical trial, prospective and random type, in which 60 patients, of both genders, aged between 18 and 80 years, who will undergo major abdominal surgery, divided in two groups.~Patients will be randomly divided into two groups with 35 patients:~Conventional Group, Transthoracic Echocardiogram Group"||||
34051768|NCT05284591|||OTHER||PROSPECTIVE|||||||
34051769|NCT02713269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051770|NCT05517109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051771|NCT02458768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051772|NCT00642096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34051773|NCT04173975|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Participants will receive a 6-week training program in a clinical setting in add-on to the standard neuro-rehabilitation treatment.~The add-on rehabilitation training will be focused on lower limb with specific activities for knee instability, and will comprise 3 weeks using the BELK orthosis knee module and 3 weeks without any orthosis."|f|f|f|t
34075779|NCT03131115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075780|NCT01158560|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34075781|NCT02037815|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34075782|NCT02190864|||COHORT||PROSPECTIVE|||||||
34075783|NCT04508686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075784|NCT01050946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051774|NCT06497972|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The allocation of this intervention order will be blinded for the investigators and the participants. Treatment will be given blinded names, such as A and B, but it may be possible to determine what each treatment is due to its appearance, however we will not be informing the participants what the treatments are. The study staff who will be preparing and overseeing the treatments may not be blinded due to the different appearances of the treatments. However, the staff that will conduct the trial results analyses will not be un-blinded until the analyses are complete.|This is Trial 1 of a project that will consist of 2 acute double-blind cross-over trials. The trials will follow the same study design but investigate 2 types of wild rice products. The wild rice products will be provided by the Myera group.|t|f|t|f
34051775|NCT02056457|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34154661|NCT05354687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will not know which group they are in. The knowledge test will be filled online by the participants. A nurse other than the researchers served as an evaluator during the skill assessments. The evaluator is unaware of which group the students belong to. The analysis of the tests data will be done by the statistician. No information will be given to the statistician about which group the participants are in.|a three-group, pre-test - post-test, randomized controlled experimental study.|t|f|f|t
34051776|NCT05631691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In this study, participants will be screened initially and then by randomization groups will be formed for intervention and comparison group.||||
34051777|NCT02266472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051778|NCT04775706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051779|NCT06040970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051780|NCT06431555|||COHORT||PROSPECTIVE|||||||
34154662|NCT04517643|NA|SINGLE_GROUP||OTHER||NONE||To investigate whether the dose predicted by pre-therapy 99mTc MAA SPECT predicts the dose to the liver from the 90Y microspheres as assessed by post-therapy 90Y SPECT/CT or PET/CT.||||
34051781|NCT05575401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the beginning of the study, each surgeon will receive an 80-item numbered list for which a random generator has been used to assign lateral pharyngoplasty or no lateral pharyngoplasty to each study participant. Each participant recruited for the study will undergo the correlating procedure at the time of surgery. Thus, the surgeon is necessarily not blinded, but the participant and parents would be blinded, and informed consent for the procedure would be for tonsillectomy +/- adenoidectomy, possible lateral pharyngoplasty.|Participants ages 3-17 years undergoing tonsillectomy for any reason will be randomized to either undergo tonsillectomy +/- adenoidectomy (standard of care practice) or tonsillectomy +/- adenoidectomy with lateral pharyngoplasty (research intervention). Parents of participants in both arms will be given post-operative worksheets to document pain scores, pain medication administration, estimates of daily per os intake, and any complications.|t|f|f|f
34051782|NCT04679012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154663|NCT02808468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051783|NCT06664983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075785|NCT03476057|||COHORT||PROSPECTIVE|||||||
34154664|NCT00665964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075786|NCT05682833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split mouth RCT|t|t|f|f
34075787|NCT00571662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075788|NCT05722717|||CASE_CONTROL||PROSPECTIVE|||||||
34154665|NCT03937492|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34075789|NCT03003247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075790|NCT00045799|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34154666|NCT04772508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and statistician are masked about treatment modality|Group A (Control): 15 sites received only SRP, Group B: 15 sites received SRP with subgingival placement of amnion membrane, Group C: 15 sites received SRP with subgingival placement of Amnion membrane hydrated with Taurine.|t|f|f|t
34154667|NCT04378114|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34154668|NCT01707381|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154669|NCT04044976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A cohort of preterm infants will be given caffeine in the delivery room||||
34154670|NCT03370666|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority||||
34154671|NCT02409342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154672|NCT00554372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154673|NCT04544579|||COHORT||PROSPECTIVE|||||||
34154674|NCT05019534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154675|NCT06200883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34154676|NCT01918059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154677|NCT04217044|||COHORT||OTHER|||||||
34154678|NCT04956653|||OTHER||RETROSPECTIVE|||||||
34154679|NCT00500825|||COHORT||PROSPECTIVE|||||||
33844796|NCT05488145|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33844797|NCT06650189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33844798|NCT03479853|||CASE_CONTROL||PROSPECTIVE|||||||
33978013|NCT06495814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844799|NCT04546503|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigator responsible for assessing sedation and adjusting dosages hypnotic and morphinic (according to objectives) will not be aware of the result of the randomization.|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~group with locoregional anesthesia: Sedation using midazolam and sufentanil: Multi-Daily adjustment of doses every 4 hours using Behavioral Pain Scale score \<4 and Ramsay Score \> 4 + peronerval block catheter from 0 to 24h after admission in intensive care unit using ropivacaine 0.2% with a continuous infusion at 1mL/10 Kg /H"|f|f|t|f
33844800|NCT04395872|||CASE_ONLY||RETROSPECTIVE|||||||
33844801|NCT05078593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844802|NCT00489944||||TREATMENT||||||||
33844803|NCT06442007|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Three arm study. Schools would be the unit of cluster.|f|f|f|t
33844804|NCT06049992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844805|NCT06079372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051784|NCT06663280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Intervention group: Participants in the intervention group were patients with hypertension who had been provided ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were gathered using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1). Control group: Participants in the control group were patients with hypertension who were not provided with ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were collected using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1).~In addition, after the end of the observation period (from t0 to t1), the participants in the control group were offered an extension of a further 3 months on average using ADELE (from t1 to t2)."|t|f|f|f
34051785|NCT05243680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844806|NCT05043116|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844807|NCT05688852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will employ a double-blind design. Participants, Investigators, study center staff, persons performing the assessments, and the Sponsor are to remain blinded to the identity of the Induction and Maintenance Period treatment from the time of randomization until the interim database lock for the study||t|t|t|t
33844808|NCT04900792|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844809|NCT01503385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844810|NCT01509144|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34051786|NCT04818645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Events Review Committee: A blinded three-member Events Review Committee will review de-identified source documents obtained from each of the enrolling sites that will only be labelled with a subject ID. No data will be provided indicating the randomized treatment arm to the study and appropriately redacted with no ICM data provided. The information will be used to determine the nature of any clinical and adverse events. Available medical records and source documents will be used to determine cause-specific mortality.|Subjects will be randomized in a 2:1 fashion to undergo implant of an ASSERT ICM implant with remote monitoring and symptom-triggered mobile app transmissions versus conventional follow-up without an ICM. Randomization will be stratified by the degree of LV dysfunction to ensure balanced enrollment of HF subjects with mild LV dysfunction (LVEF = 36%-49%) and those with preserved LVEF (≥ 50% \[i.e. heart failure with preserved ejection fraction - HFpEF\]).|f|f|f|t
33844811|NCT02907398|||COHORT||OTHER|||||||
33844812|NCT01481987|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34051787|NCT05272228|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33844813|NCT00662142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844814|NCT02738853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844815|NCT04018274|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33844816|NCT03333876|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844817|NCT05532514|||OTHER||CROSS_SECTIONAL|||||||
33844818|NCT04726085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844819|NCT05885243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844820|NCT04094168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844821|NCT04165031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844822|NCT05108675|||COHORT||PROSPECTIVE|||||||
33844823|NCT01373151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844824|NCT05723159|||COHORT||PROSPECTIVE|||||||
33844825|NCT03369327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051788|NCT03229928|||COHORT||PROSPECTIVE|||||||
34154680|NCT04255303|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34051789|NCT04795193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154681|NCT02381275|||COHORT||PROSPECTIVE|||||||
34051790|NCT03373994|||COHORT||PROSPECTIVE|||||||
34051791|NCT01166802|||CASE_ONLY||PROSPECTIVE|||||||
34051792|NCT06619808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051793|NCT04570865|NA|SINGLE_GROUP||TREATMENT||NONE||The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.||||
34051794|NCT00593034|||CASE_ONLY||CROSS_SECTIONAL|||||||
34051795|NCT05509465|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE|This study is open label, meaning that no masking occurs.|The two intervention groups (EC+ and EC-) consist of the same participants. Every day the same participants have to divide their violin playing time equally between playing with EC+ and EC-. Each day the order of the interventions is decided by the participants.||||
34075791|NCT06612346|||COHORT||PROSPECTIVE|||||||
33844826|NCT04860297|NA|SINGLE_GROUP||PREVENTION||NONE||This is an open-label, single intervention study; there is no randomization||||
34154682|NCT01960517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154683|NCT00789672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34154684|NCT03760679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34154685|NCT04219644|NA|SINGLE_GROUP||OTHER||NONE||||||
34154686|NCT04956458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844827|NCT04303715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844828|NCT06593496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844829|NCT03112460|||COHORT||PROSPECTIVE|||||||
33844830|NCT06471504|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844831|NCT05618808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978014|NCT01952249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978015|NCT06007391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844832|NCT01420887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844833|NCT04377685|||COHORT||RETROSPECTIVE|||||||
33844834|NCT01609244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844835|NCT01008410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844836|NCT02791178|||CASE_ONLY||PROSPECTIVE|||||||
33844837|NCT00886795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844838|NCT04881773|||CASE_ONLY||RETROSPECTIVE|||||||
33978016|NCT01712880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978017|NCT04471675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844839|NCT03055052|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34051796|NCT03400150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study subjects are blinded to group assignment.|Subjects will be randomized in a 2:1 ratio (balloon implantation:control)|t|f|f|f
34051797|NCT06666153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051798|NCT02636231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844840|NCT05029713|||COHORT||RETROSPECTIVE|||||||
33844841|NCT01787149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844842|NCT02885844|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33844843|NCT03181789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33844844|NCT02019667|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33844845|NCT03525392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844846|NCT00591851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844847|NCT04734054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844848|NCT00363688|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844849|NCT06727630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844850|NCT02192528|||COHORT||PROSPECTIVE|||||||
33844851|NCT06143540|||COHORT||PROSPECTIVE|||||||
33844852|NCT04512859|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33844853|NCT05523505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844854|NCT03391817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844855|NCT00548262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844856|NCT05767060|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33844857|NCT02124811|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33844858|NCT03286101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844859|NCT04620304|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33844860|NCT06729320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844861|NCT04192695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective cohort study||||
33844862|NCT03679715|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The design is a unicentre (Jewish General Hospital; Montreal, Quebec, Canada), clinical, randomized, controlled, single blinded (i.e.; investigators), superiority trial, with two parallel arms (Intervention and Control groups), comparative (comparison between Intervention and Control groups) and analyzed with the intention-to-treat.|f|f|t|f
33844863|NCT05622916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will be blind from the allocation by mimicking the topical solution|One group will receive the intervention, whereas the comparison group will receive standard care|t|f|f|f
33844864|NCT00391859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844865|NCT01856452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844866|NCT02323451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844867|NCT04844619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844868|NCT05447091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are not aware of the treatment group they are assigned to. The PI is not aware of the treatment condition in which participants are. Finally, the assessors are blinded to the group assignment as well.||t|f|t|t
33844869|NCT04864262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844870|NCT06226324|||CASE_CONTROL||PROSPECTIVE|||||||
33844871|NCT00362245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844872|NCT01711268|||COHORT||PROSPECTIVE|||||||
33844873|NCT03264911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||prospective, randomized, interventional, placebo-controlled, double-blinded, multicentric clinical trial|t|t|t|t
33844874|NCT05850559|||COHORT||PROSPECTIVE|||||||
33844875|NCT04749251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be performed as a single center study, conducted at Aarhus University Hospital, Denmark. In the randomization process patients are stratified according to NIHSS (0-17 or \> 17) and age (18-65 or \> 66)|t|f|f|f
33844876|NCT02283970|||COHORT||PROSPECTIVE|||||||
33844877|NCT00963053|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33844878|NCT06409689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844879|NCT01327495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33844880|NCT00449267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844881|NCT01482923|||COHORT||PROSPECTIVE|||||||
33844882|NCT02525718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154687|NCT03526510|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Trial||||
34154688|NCT03615066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051799|NCT02618837|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051800|NCT04870424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051801|NCT06168734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind design is used to maintain blinding for all personnel involved with the evaluation of patient efficacy and safety during the study. With the exception of the unblinded pharmacist or designee, unblinded study monitors and scientists conducting plasma assays and analyses for PK assessments, the sponsor, investigator, patient, and study site staff, will remain blinded to study drug.|The study will randomize approximately 316 patients with vHABP or VABP into 2 groups in a 1:1 ratio (158 patients to cefepime-taniborbactam; 158 patients to meropenem).|t|f|t|f
34154689|NCT00005116||||DIAGNOSTIC||NONE||||||
34051802|NCT02814786|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154690|NCT05532280|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, two-way crossover, open-label, laboratory blind, bioequivalence study||||
33844883|NCT04682743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844884|NCT03384160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Surgical procedures were always performed by the same surgeon and assistant, who was unaware of the group that belonged to the patient, as well as the patient himself. This randomization was performed involving numbers and envelopes, being only the investigator's knowledge.|"The sample will consist of 32 lower third molars, semi-inclusively or included. This study will be a randomized, double blind, controlled, split-mouth clinical trial, divided into two groups simultaneously, namely:~Group 1 (16 teeth) - using anesthetic mepivacaine in third molar extraction. Group 2 (16 teeth) - using anesthetic articaine in third molar extraction"|t|t|f|f
33844885|NCT01241825|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33844886|NCT01579500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051803|NCT05253586|||COHORT||PROSPECTIVE|||||||
33844887|NCT06729658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blinded randomized placebo-controlled intervention with 2 arms: BCI intervention with Placebo; BCI intervention with Levodopa|t|f|t|f
33844888|NCT01075828|||CASE_ONLY||PROSPECTIVE|||||||
34051804|NCT00993343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844889|NCT01331486|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33844890|NCT06330012|NA|SINGLE_GROUP||SCREENING||NONE||||||
33844891|NCT06242860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844892|NCT02297321|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948773|NCT05780749|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The stage 2 of this study is a double-blinded study. Neither patients, nor investigators, nor trial staff, nor the sponsor study team will be aware of treatment assignments prior to the database lock at the conclusion of the study. The study products are DDI-IBS-001 and its matching placebo. DDI-IBS-001 and placebo will be provided as sachets containing 1980mg of powder to be dissolved in a glass of water (about 250 ml) and taken orally, with the same composition except for the active ingredient.|"This is a prospective, randomized, double-blind, placebo controlled, multicenter, parallel group study. Patients will be recruited in multiple centers in Belgium.~Patients will be treated for a total of 12 weeks. The study consists of a 2 weeks run-in period followed by a 8 weeks treatment period with DDI-IBS-001. At the end of the 8 weeks treatment, patients will be divided in responders and non-responders based on their global symptoms' relief score (patients will be considered responders with a weekly SGA score mean of 3 points or less for at least 50% of the 6 last weeks of treatment before week 10 \[week 4 to 10\]).~Responder patients will be randomised in a 2:1 allocation ratio to receive either DDI-IBS-001 or placebo, for 4 additional weeks. Non-responder patients will continue the treatment with DDI-IBS-001 for additional 4 weeks. The study period will be followed by a follow-up period of 4 weeks during which patients will have free access to DDI-IBS-001."|t|t|t|t
33948774|NCT02164058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948775|NCT03709342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948776|NCT00511706|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33948777|NCT03892876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948778|NCT03598712|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 3 prospective, randomized, monocentric controlled study||||
33948779|NCT05609656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948780|NCT04228718|||COHORT||PROSPECTIVE|||||||
33948781|NCT04959682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948782|NCT02635503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948783|NCT00117975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948784|NCT06447870|||COHORT||PROSPECTIVE|||||||
33948785|NCT02997787|||CASE_CONTROL||RETROSPECTIVE|||||||
33948786|NCT00791583|||COHORT||PROSPECTIVE|||||||
33948787|NCT03030131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948788|NCT02334046|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33948789|NCT04951596|||OTHER||RETROSPECTIVE|||||||
33948790|NCT01261299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948791|NCT02935816|||CASE_ONLY||PROSPECTIVE|||||||
33948792|NCT05965921|||CASE_ONLY||PROSPECTIVE|||||||
33948793|NCT00589823|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33948794|NCT04466657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33948795|NCT02282839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34051805|NCT02000622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051806|NCT03242876|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34051807|NCT05138276|RANDOMIZED|PARALLEL||PREVENTION||NONE|Triple (Participant, Care Provider, Outcomes Assessor)|||||
34051808|NCT03264924|||CASE_ONLY||PROSPECTIVE|||||||
34051809|NCT04602481|||COHORT||PROSPECTIVE|||||||
34051810|NCT02682823|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34154691|NCT02848391|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051811|NCT00483236|||COHORT||PROSPECTIVE|||||||
34051812|NCT02000336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051813|NCT03453034|NA|SINGLE_GROUP||OTHER||NONE||||||
33948796|NCT01573988|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051814|NCT05969483|||COHORT||PROSPECTIVE|||||||
34051815|NCT05961306|||COHORT||PROSPECTIVE|||||||
34051816|NCT06348433|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34051817|NCT04028869|||COHORT||RETROSPECTIVE|||||||
34051818|NCT00574353|NA|SINGLE_GROUP||SCREENING||NONE||||||
34051819|NCT02350686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051820|NCT05542628|||OTHER||CROSS_SECTIONAL|||||||
34051821|NCT05173168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051822|NCT04429555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, parallel-group study.|t|f|t|f
34051823|NCT05263856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051824|NCT04796623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051825|NCT01675570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051826|NCT05463744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051827|NCT06035289|||COHORT||PROSPECTIVE|||||||
34051828|NCT04599348|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
34051829|NCT03609931|||CASE_ONLY||PROSPECTIVE|||||||
34051830|NCT02117921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051831|NCT05853549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051832|NCT01072435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051833|NCT06668272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051834|NCT00533702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051835|NCT03470155|||CASE_ONLY||PROSPECTIVE|||||||
34051836|NCT02209142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051837|NCT01760486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051838|NCT02833844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051839|NCT04441320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051840|NCT01219764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051841|NCT01290978|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075792|NCT01834456|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075793|NCT04878068|||COHORT||RETROSPECTIVE|||||||
34051842|NCT06648200|RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled patients were randomly assigned to one of two groups. Patients in group 1 received toripalimab combined with etoposide and platinum Chemotherapy; patients in group 2 received toripalimab and JS004 combined with etoposide and platinum Chemotherapy.||||
34051843|NCT05467904|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34154692|NCT05392036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051844|NCT00270153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154693|NCT03936972|||COHORT||RETROSPECTIVE|||||||
34051845|NCT05900869|||COHORT||PROSPECTIVE|||||||
34051846|NCT01334671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051847|NCT03099213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051848|NCT02906631|||COHORT||PROSPECTIVE|||||||
34051849|NCT02738879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948797|NCT02159872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948798|NCT06197776|||CASE_ONLY||PROSPECTIVE|||||||
34051850|NCT03814720|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34051851|NCT06022276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948799|NCT03859908|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will be randomized through a selection of a sealed envelope with computer generated random numbers by the Operating Room nurse, and the substance will be applied when participant will be already with anesthesia|Pragmatic, randomized controlled trial of two substances|t|f|f|f
34051852|NCT01607060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948800|NCT02906527|||COHORT||RETROSPECTIVE|||||||
34051853|NCT02035033|||||PROSPECTIVE|||||||
34051854|NCT03088163|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33948801|NCT01015170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948802|NCT02319018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948803|NCT04277104|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33948804|NCT05252507|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34051855|NCT04951570|||COHORT||PROSPECTIVE|||||||
34051856|NCT03812770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948805|NCT04136509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The specialis tasked with histomorphometric, micro-CT and CBCT analysis has no knowledge on the intervention method.||f|f|f|t
33948806|NCT00633334|||COHORT||CROSS_SECTIONAL|||||||
34051857|NCT00415116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051858|NCT06685536|||OTHER||PROSPECTIVE|||||||
34051859|NCT06619496|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||comparative prospective observational cohort study||||
34051860|NCT02666196|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34051861|NCT06661681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluators will be blinded to the treatment group|This is a superiority randomized controlled trial, single-blinded, with two parallel groups.|f|f|f|t
34051862|NCT00102375|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051863|NCT05037357|||CASE_ONLY||PROSPECTIVE|||||||
34051864|NCT04466098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomly assigned (2:1) to receive either 300 × 10\^6 MSC or vehicle placebo control. Randomization will be stratified by risk (high versus standard risk based on the presence of preexisting co-morbidities), using permuted block sizes of 3. The allocation sequence will be accessed by each cell processing laboratory through ONCORE. Personnel in the cell processing laboratories are not masked to the treatment group, but patients, clinical staff, and investigators will be unaware of treatment assignment. To maintain masking of the investigators and clinicians, bags containing the study products and intravenous tubing had opaque coverings applied in the cell laboratories.|This is a randomized (2:1 ratio) placebo controlled trial.|t|t|t|f
34051865|NCT01863316|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34051866|NCT06278363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant Masking: Participants are unaware of the treatment they are receiving. This helps prevent biases in reporting outcomes based on knowledge of the treatment.~Care Provider Masking: The individuals providing care, such as therapists or nurses, are also unaware of the treatment assigned to each participant. This prevents them from inadvertently influencing outcomes based on their knowledge of the treatment.~Investigator Masking: The individuals responsible for collecting and analyzing the data are blinded to the treatment allocation. This helps ensure impartiality and prevents biases in data interpretation.~Outcomes Assessor Masking: Individuals responsible for assessing the outcomes of the study, such as evaluating patient progress or interpreting test results, are blinded to the treatment group to which participants belong. This prevents biases in outcome assessment."|We aim to assess the effectiveness of an intervention in stroke subjects to increase awareness of sexual health, effectively manage sexual dysfunctions, reduce their frequency, and enhance psychophysical well-being.|t|t|t|t
33948807|NCT01046617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948808|NCT06724107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinding|randomized clinical trial|t|f|t|f
34154694|NCT02545335|||COHORT||PROSPECTIVE|||||||
34154695|NCT03216746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34154696|NCT06089512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34154697|NCT00663403|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33948809|NCT01283282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33948810|NCT00830011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948811|NCT04408625|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33948812|NCT02213666|||CASE_ONLY||PROSPECTIVE|||||||
33948813|NCT03978689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I dose escalation and expansion||||
33948814|NCT05710809|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator = Statistician||f|f|t|t
33948815|NCT02231502|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33948816|NCT00361790|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33948817|NCT03230760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948818|NCT06722391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33948819|NCT03961347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||A randomized, double-blinded, placebo-controlled clinical trial will be carried out in subjects between 18-45 years old with T1D.|t|t|t|t
33948820|NCT04631224|||COHORT||PROSPECTIVE|||||||
33948821|NCT06724796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978018|NCT02770950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051867|NCT03687593|||OTHER||OTHER|||||||
34051868|NCT04895735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051869|NCT01513265|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34051870|NCT03315286|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34051871|NCT02669901|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34051872|NCT06403163|||COHORT||PROSPECTIVE|||||||
34051873|NCT02481999|||COHORT||PROSPECTIVE|||||||
34154698|NCT03704714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154699|NCT00125021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154700|NCT05118334|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051874|NCT03014297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051875|NCT06164847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be unaware of the hypothesis of this study to decrease performance biases. The statistician will be blinded to group allocation.|Two groups (HEP, PT+AERO and HEP, PT-standard care) will receive the protocol at the same time period.|t|f|f|t
34051876|NCT05784324|||COHORT||OTHER|||||||
34051877|NCT04335981|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34051878|NCT04231929|NA|SINGLE_GROUP||OTHER||NONE||||||
34051879|NCT04724343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051880|NCT03774524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|a double-blinded randomized placebo-controlled trial|A Double-Blind Randomized Clinical Trial|t|t|t|t
34051881|NCT04434469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051882|NCT00093587|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34051883|NCT00076752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051884|NCT04185012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Randomization will occur by assigning a unique sequential study code to a balanced number of randomly assorted treatment vials.~An online open source randomization software will be used to assign treatment groups, and this will be done by an external person from those who will follow and treat the patients.~Patients randomization will be blinded to the patients themselves and to all the personnel that will have contact with them during the trial"|Double-blind, placebo-controlled clinical trial. Patients will be divided in two arms with 1:1 randomization to Treatment or Placebo.|f|f|t|f
34154701|NCT05259839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051885|NCT06328816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154702|NCT03485196|||COHORT||PROSPECTIVE|||||||
34051886|NCT03835156|||COHORT||PROSPECTIVE|||||||
34154703|NCT02593318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154704|NCT02481609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051887|NCT05877690|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34051888|NCT06008145|||COHORT||CROSS_SECTIONAL|||||||
34051889|NCT01538134|||CASE_CONTROL||PROSPECTIVE|||||||
34051890|NCT03641625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both patients and outcomes assessor are blinded to group assignment.|International, multi-center, pragmatic, randomized controlled (1:1 ratio) trial|t|f|f|t
34154705|NCT04292613|||OTHER||PROSPECTIVE|||||||
34154706|NCT01052077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051891|NCT03544099|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional||||
34051892|NCT04448522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154707|NCT05172804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154708|NCT05308771|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051893|NCT06470893|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154709|NCT02448589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154710|NCT06485466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154711|NCT06429774|||COHORT||PROSPECTIVE|||||||
34154712|NCT04924153|||COHORT||PROSPECTIVE|||||||
33978019|NCT02623088|||COHORT||PROSPECTIVE|||||||
34051894|NCT05571124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure that allocation is concealed, one of the researchers will randomly create the codes in opaque envelopes with the username and password for participants to log into the web platform. The evaluators will be blinded to the data collection as each participant will be assigned a code for identification. The participants will not be blinded as they are aware of the intervention they are carrying out.||f|f|t|t
34051895|NCT04000542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34051896|NCT01020604|||COHORT||PROSPECTIVE|||||||
34051897|NCT01782417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051898|NCT01986127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34051899|NCT04960241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A physiotherapist will assess the outcomes at baseline after which the patients are randomized. The same physiotherapist will then deliver the allocated intervention and no longer assess outcomes for this patient. A different physiotherapist, who is blinded to treatment allocation, will assess outcomes at the follow-up visits in this patient. At all follow-up visits, patients will be asked not to disclose any information regarding group allocation, and the physiotherapists will be instructed not to ask questions regarding group allocation.~The patients are blinded to the trial hypothesis in order to prevent ascertainment bias. The principal investigator is not an outcome assessor and will not be blinded."|Homebased telerehabiltation. Homebased rehabilitation. No physical rehabilitation.|f|t|f|t
34051900|NCT03164564|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34051901|NCT02113098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051902|NCT03603145|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled open label||||
34051903|NCT03865810|||COHORT||PROSPECTIVE|||||||
34051904|NCT00602498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34051905|NCT06450873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051906|NCT02539290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34051907|NCT05529875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34051908|NCT01658124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051909|NCT01498146|||OTHER||PROSPECTIVE|||||||
34051910|NCT00196729|RANDOMIZED|PARALLEL||||NONE||||||
34051911|NCT03645746|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34051912|NCT04068012|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154713|NCT05126628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Care Provider)|This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.|t|t|f|f
33948822|NCT04318626|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||A. Group A: Patients with acute stroke/TIA, n=50. B. Group B: Normal control, n=30.|f|f|t|f
33948823|NCT03933358|||COHORT||PROSPECTIVE|||||||
33948824|NCT03500302|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot clinical trial to study HIV+ patients with baseline coronary endothelial dysfunction and assess changes in that function from the baseline measure to 1 and 6 weeks following initiation of therapy with evolocumab so as to test the hypotheses that PCSK9 inhibition with evolocumab improves coronary endothelial function (CEF) measured directly and non-invasively with MRI at 1 week and 6 weeks after initiation of evolocumab.||||
33948825|NCT06724523|||COHORT||PROSPECTIVE|||||||
33948826|NCT00635193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948827|NCT02569931|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33948828|NCT01352871|||CASE_ONLY||PROSPECTIVE|||||||
33948829|NCT06723600|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33948830|NCT01536899|||COHORT||PROSPECTIVE|||||||
33948831|NCT00106769||||TREATMENT||||||||
33948832|NCT06369402|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948833|NCT02140268|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948834|NCT02926768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948835|NCT06193018|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948836|NCT06374576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34051913|NCT05256654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154714|NCT02348060|||COHORT||PROSPECTIVE|||||||
34154715|NCT00771524|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34051914|NCT06234202|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34051915|NCT06619171|||COHORT||PROSPECTIVE|||||||
34154716|NCT03465995|||CASE_ONLY||PROSPECTIVE|||||||
34051916|NCT05033262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34051917|NCT04130542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154717|NCT06238206|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051918|NCT04321369|||CASE_ONLY||RETROSPECTIVE|||||||
34051919|NCT05949047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Participants will be randomized to the Distancing group, the Reinterpretation group, or a no regulation Look Only control group."||||
34051920|NCT01173731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051921|NCT06654830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051922|NCT06078358|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051923|NCT02135107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154718|NCT00580762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154719|NCT00880594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154720|NCT05009667|||COHORT||PROSPECTIVE|||||||
34154721|NCT02333019|RANDOMIZED|PARALLEL||||NONE||||||
34154722|NCT05247359|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34154723|NCT06344156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154724|NCT03504631|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154725|NCT06355219|||COHORT||RETROSPECTIVE|||||||
34154726|NCT00952887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154727|NCT04611451|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34154728|NCT04793334|||COHORT||PROSPECTIVE|||||||
34154729|NCT06142006|||COHORT||PROSPECTIVE|||||||
34154730|NCT00328861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154731|NCT05141084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154732|NCT04060966|||COHORT||PROSPECTIVE|||||||
34154733|NCT01996124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34154734|NCT00120224|||DEFINED_POPULATION||PROSPECTIVE|||||||
33948837|NCT01090648|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33948838|NCT03863821|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Participants with COPD who done pulmonary function test will enroll to this study. Left-side heart failure, COPD AE within 3 months, diagnosed neuromuscular disease, and unable to perform 6-MWT will be exclude.~Participants will received HHHNFC or non-HHHFNC support during the 6-MWT."||||
33948839|NCT00671645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948840|NCT06136624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948841|NCT03722641|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33948842|NCT05674682|NA|SINGLE_GROUP||PREVENTION||NONE||MSM and TGW, aged 18 yo or more||||
33948843|NCT05760781|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34154735|NCT01882504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154736|NCT04957056|||OTHER||RETROSPECTIVE|||||||
34154737|NCT03846609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be randomly assigned to study or control group. The patients will not know their assignment until completion of the study.|The patients will be assigned into study group \[procedure performed with use of double balloon interventional platform (DiLumen)\] or control group \[procedure done without the use of double balloon interventional platform (DiLumen)\]|t|f|f|f
34154738|NCT02214745|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34154739|NCT03247127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Hippocampal avoidance -whole brain radiotherapy(HA-WBRT), which delivers radiation to whole brain and moreover, to reduce mean dose to hippocampal neural stem-cell compartment to minimize the neurocognitive function impairment||||
34154740|NCT02816463|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34154741|NCT01852422|||COHORT||PROSPECTIVE|||||||
33948844|NCT04899609|||COHORT||CROSS_SECTIONAL|||||||
34051924|NCT01033032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051925|NCT06089408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34051926|NCT06138509|||CASE_CONTROL||PROSPECTIVE|||||||
34051927|NCT05524896|||COHORT||RETROSPECTIVE|||||||
34154742|NCT01364025|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34154743|NCT04479124|||COHORT||RETROSPECTIVE|||||||
34154744|NCT06217003|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154745|NCT06137651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154746|NCT03296150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154747|NCT05910008|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34154748|NCT00527982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154749|NCT03671915|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Closed loop vs. Open loop||||
34154750|NCT01406015|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33978020|NCT05296915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Personnel responsible for HRV analysis and determination of inflammatory biomarker levels will be blinded.|In order to achieve the objectives of the research project, we will perform a national, monocentric interventional on a medical device study, controlled in 3 parallel and randomized groups with a 1:1:1 allocation ratio.|f|f|t|f
33978021|NCT03231475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154751|NCT05995236|||OTHER||OTHER|||||||
33978022|NCT02716129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34154752|NCT03870412|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34154753|NCT00810784|||CASE_CONTROL||RETROSPECTIVE|||||||
33978023|NCT04905433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34051928|NCT00073983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051929|NCT02655510||SEQUENTIAL||TREATMENT||NONE||A phase 2 dose escalating study was carried out. F-652 (10, 30 or 45 μg/kg) administered on day 1 and 7 was tested in 3 patients each with moderate (MELD scores: 11-20) and severe AH (MELD scores: 21-28).||||
34051930|NCT00476268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051931|NCT06092164|||COHORT||PROSPECTIVE|||||||
34051932|NCT06666101|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE||"This is a randomized, controlled, double-blind, 2x2 factorial study among polyvascular subjects over 75 years of age (presence of two or more clinical locations of atherosclerosis) Patients were defined as having polyvascular disease in cases of vascular lesions in ≥2 disease territories or any combination of coronary, peripheral, or carotid artery disease according to the ROCKET AF trial. Coronary artery disease was defined as a history of percutaneous coronary intervention, myocardial infarction, or coronary artery bypass graft surgery. Peripheral artery disease was defined as intermittent amputation for arterial insufficiency, claudication, or a history of vascular reconstruction or bypass surgery. The presence of carotid stenosis was defined as a history of ≥50% stenosis in at least one carotid artery as defined on any imaging modality.~A total of 80 participants will be studied (20 participants in each arm)"|t|f|t|f
34154754|NCT00715858|NON_RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34154755|NCT04421248|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Preparation of identical single dose capsules of methylphenidate and placebo prepared by study pharmacy.|This is a randomized, blinded, placebo-controlled, single-dose crossover study. The objective is to estimate, in a rigorous, unbiased manner, the effect of 10 mg methylphenidate (MPH) on two putative biomarkers of ADHD, measured using Transcranial Magnetic Stimulation (TMS). Outcomes will be evaluated via repeated measures, mixed model analysis with MEP amplitude as the dependent variable and Treatment and Treatment-Sequence as class variables. Participants will include 144 children with ADHD. Study measures will also be compared in 70 matched, typically developing children who do not have ADHD and who will not receive methylphenidate or placebo.|t|f|t|t
34154756|NCT03521479|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The double-blinding only applies between groups A and B. Subjects for groups C and D will be recruited on an open label basis.|"Subjects will receive on a double blind basis one of two treatment regimens:~* Group A: 15 subjects, treated with 2% SADBE on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.~* Group B: 15 subjects, treated with 2% SADBE on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.~And subjects will be recruited on an open label basis to two other treatment regimens:~* Group C: 15 subjects, treated with 2% SADBE on day 0, month 3, and month 6.~* Group D: 15 subjects, treated with 2% SADBE on day 0 and month 6."|t|t|t|t
34154757|NCT01737853|||CASE_CROSSOVER||PROSPECTIVE|||||||
34154758|NCT03440489|NA|SINGLE_GROUP||SCREENING||NONE||skeletal muscle dysfunction in patient with idiopathic pulmonary fibrosis six minute walking test||||
34154759|NCT06583603|||COHORT||CROSS_SECTIONAL|||||||
34154760|NCT04623840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34154761|NCT03995355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154762|NCT00299117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34154763|NCT03419065|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34154764|NCT00122044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154765|NCT01895946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154766|NCT02459678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34154767|NCT03391128|||CASE_ONLY||PROSPECTIVE|||||||
34154768|NCT02164370|||CASE_CONTROL||PROSPECTIVE|||||||
34154769|NCT05358574|||COHORT||OTHER|||||||
34154770|NCT05378061|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34154771|NCT01289054|||COHORT||PROSPECTIVE|||||||
34154772|NCT03150628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154773|NCT05331794|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34154774|NCT01338857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154775|NCT01543425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34154776|NCT06584214|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Study staff performing the testing using the Determine™ Syphilis Advanced and Determine™ Syphilis TP testing will be blinded to the participants' syphilis infection status.|||||
34154777|NCT02207218|||COHORT||PROSPECTIVE|||||||
34154778|NCT05108558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Photography will be obtained where possible, with outcomes assessed based on the photographs. The care provider obtaining measurements will also be blinded as to baseline outcomes and results with follow-up assessments.|"Patients meeting criteria who have consented will be randomized to either control or CCH x 6 months, followed by a cross-over phase where controls will receive CCH. See Figure 1 for full study schema.~1. Control. Men in this cohort would undergo baseline assessments followed by no treatment for 6 months and then repeat assessments. Men would then cross-over to the CCH treatment phase and undergo up to 8 injections (or until curvature is \<15 degrees, whichever comes first). Final assessments would then be performed 6 weeks following the final injection.~2. CCH followed by observation. Men in this cohort would undergo baseline assessments followed by up to 8 injections of CCH (or until curvature is \<15 degrees). Assessments would then be performed 6 weeks after completion of treatment. Men then would not undergo any additional treatments for 6 months, after which they would have final assessments performed."|f|t|f|t
34154779|NCT03897842|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34154780|NCT03771703|||COHORT||RETROSPECTIVE|||||||
34051933|NCT04410120|||OTHER||PROSPECTIVE|||||||
34154781|NCT01298271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154782|NCT01124591|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34154783|NCT06143982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A two-arm, mutli-center, randomized controlled trial (RCT). Adolescents (12-18 years old) with (s)PTSD will be randomly allocated by an independent researcher to the intervention group (n=50) versus a waitlist control group (WLCG; n=50), stratified by center. If allocated to the intervention group, participants follow the Brief Intensive Trauma Treatment (BITT). When allocated to the WLCG, participants receive BITT after a 3 months waiting period. Measurements are done at comparable time intervals for both groups: at pre-treatment (T0), directly after BITT or WLCG (T1) and at 3 (T2), 6 (T3) and 9 (T4) months follow-up.|f|f|t|t
34154784|NCT00856804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154785|NCT03245398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, physicians, nurses and investigators will all be blinded. Based on the randomization list, individual envelopes with the correct combination of mebendazole tablets and placebos will be prepared. The randomization code is then sealed in an envelope. Unblinding will only occur in case of a SAE, SUSAR or other kind of emergency.||t|t|t|t
34154786|NCT06069635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154787|NCT02657902|||COHORT||RETROSPECTIVE|||||||
34154788|NCT02209974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154789|NCT06010407|||OTHER||PROSPECTIVE|||||||
34154790|NCT04230213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154791|NCT00525096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154792|NCT00924339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154793|NCT04891484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|Two groups were enrolled in this study. They will randomized into two groups •Group S:patients will be injected with 10 ml normal saline intravenous 5 min before spinal anesthesia •Group O:patient swill be injected with 4 mg Ondansetron diluted with normal saline IV 5 minutes before spinal anesthesia|f|f|t|t
34154794|NCT00742729|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34154795|NCT02277808|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34154796|NCT00345722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154797|NCT05184166|||COHORT||OTHER|||||||
34154798|NCT00565136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154799|NCT05694299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analist who will perform the statistical analyses (TS) will be masked (i.e., will analyze groups labelled as 'A' and 'B').||f|f|t|f
34154800|NCT02800980|||COHORT||PROSPECTIVE|||||||
34154801|NCT06397235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154802|NCT01453907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154803|NCT05313737|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34154804|NCT02600091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154805|NCT01521377|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34154806|NCT01894022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154807|NCT04582955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154808|NCT04599036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154809|NCT06583434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154810|NCT06583499|RANDOMIZED|PARALLEL||OTHER||NONE||There are two groups: the study group, which will receive educational intervention, and the control group, which will not.||||
34154811|NCT00156871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154812|NCT06474403|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|This clinical trial incorporates a double-blind design. Neither participants nor the surgeons performing the procedures will be informed about whether a patient is receiving the modified Sugarbaker's operation or a standard parastomal hernia repair technique. The intent is to prevent any potential bias in surgical performance and postoperative care. Outcome assessors analyzing recovery data, hernia recurrence rates, and complication rates will also be blinded to the intervention received by each participant. This ensures an unbiased collection and interpretation of data, enhancing the validity of the trial outcomes. Specific measures will have been taken to maintain blinding, including the use of identical operative room setup and post-surgical care protocols, with only the core surgical team aware of the specific intervention being applied. All study personnel involved in data collection, analysis, and patient follow-up will remain blinded until data lock|This randomized controlled trial aims to assess the efficacy and safety of a modified Sugarbaker technique in the laparoscopic total extraperitoneal repair of parastomal hernias.|t|f|t|f
33948845|NCT06259825|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomization schedule was computer generated. Separate sealed opaque envelopes were prepared for male, female and couple participants. Participants and all investigators involved in participant recruitment, data collection and entry, sample collection, processing and analysis, will be masked to the randomization groups until data entry is completed and the database is locked.|"This will be a randomised double-blind interventional study.~Participants will be randomized to either of two arms;~* Control / Placebo Intervention: Consumption of at least 4 portions of standard chicken-meat and at least 4 standard eggs per week, for 4 months.~* Experimental Intervention: Consumption of at least 4 portions of omega-3-PUFA enriched chicken-meat and at least 4 omega-3-PUFA enriched eggs per week, for 4 months."|t|t|t|f
33948846|NCT02822027|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154813|NCT04788056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Saline and Bupivacaine are both clear fluids and look identical. Research pharmacy will prepare blinded solutions for use in study.||t|t|t|t
34154814|NCT03858530|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154815|NCT02596945|||COHORT||PROSPECTIVE|||||||
34154816|NCT06021509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154817|NCT00223249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948847|NCT01744405|||COHORT||PROSPECTIVE|||||||
33948848|NCT04309149|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948849|NCT05252351|||COHORT||PROSPECTIVE|||||||
33948850|NCT00517517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948851|NCT04082494|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33948852|NCT06469333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948853|NCT01125449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154818|NCT03972878|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||The study is a cross-over, randomized intervention trial. Each subject consumed in a randomly order seven foods test with a one-week wash out between different treatments. The portion size of each foods test was calculated in order to provide the same calories.|f|f|t|t
34154819|NCT01053975|||COHORT||PROSPECTIVE|||||||
34154820|NCT01060046|||CASE_CONTROL||PROSPECTIVE|||||||
34154821|NCT06039358|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The placebo and the caffeine ingestion protocols will be identical in format and presentation. To minimize any influence of the flavor or the look of the ingested substance, both conditions will imply the consumption of opaque capsules (ingested with water) in which there will be 6mg/kg of caffeine or placebo.|The assessed sessions, which will be identical, will be the control, the caffeine, and the placebo ones. The last two sessions mentioned will be performed in a randomized order.|t|f|t|t
34154822|NCT05800275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154823|NCT02861859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154824|NCT01893775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154825|NCT03869879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Directing physical therapist will assess eligibility, and randomize participants. Physical therapy aide will conduct baseline measures (questionnaires, ABC scale, and 2min walk). The four treating physical therapists are split into two groups: two therapists will provide traditional physical therapy, while the two other therapists will provide visual feedback-aided therapy for their participants. A second, blinded physical therapy aide will complete a follow-up assessment (ABC scale, 2min walk).|Eligible participants are randomized into two groups. One group will receive standard physical therapy for their gait or balance issue while the other will receive visual feedback-aided physical therapy.|f|f|t|t
34154826|NCT04951700|||COHORT||PROSPECTIVE|||||||
34154827|NCT02145351|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34154828|NCT05491434|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34154829|NCT00336635|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34154830|NCT04932642|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|According to availability and the feasibility of the enrolment's requirements, patients will be allocated to aHIIT+RT group with morbid obesity, or to another exercise group of RT+HIIT with morbid obesity.|We will compare a concurrent training group (HIIT+RT) with morbid obesity with another experimental group of concurrent training with morbid obesity, but with another exercise order (RT+HIIT).|t|f|t|f
34154831|NCT05241145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigational products, IVMED-80 or Placebo (IVMED-80 vehicle solution) eye drops, were masked to all sponsor and site personnel with the exception of those directly involved with the production, labeling and shipping of product to the study sites. During the study, the identity of the test articles and randomization were not revealed. An unmasked study coordinator managed test article receipt, dispensing and inventory at the study site. Investigators who interacted with study patients to assess safety and efficacy were masked as to the identity of the test articles and treatment group assignments.|This study used a three-arm, parallel design. Eligible study patients were randomly assigned to 1 of 3 treatment group following a 1:1:1 schedule.|t|t|t|t
34154832|NCT01506011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154833|NCT03594812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34154834|NCT04719117|||OTHER||PROSPECTIVE|||||||
34154835|NCT06330610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154836|NCT02698150|||COHORT||PROSPECTIVE|||||||
34154837|NCT04685525|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34154838|NCT01714362|||COHORT||PROSPECTIVE|||||||
34154839|NCT05105217|||CASE_CONTROL||RETROSPECTIVE|||||||
34154840|NCT01984996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154841|NCT02307162|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34154842|NCT03262441|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open-label, randomized pilot trial to determine whether MMF given over 22 months meaningfully decreases the size of the HIV reservoir. Study participants will be followed closely for at least 22 months with safety labs and serial measurements of the HIV reservoir (specifically, cell-associated HIV DNA and mRNA (ca-DNA \& ca-RNA), quantitative viral outgrowth assay (QVOA), and single copy plasma viral load (scVL)). Go/no-go decision will occur after 12 months based on pre-defined thresholds of reduction in the HIV reservoir measured with ca-DNA."||||
34154843|NCT02068287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154844|NCT00248456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154845|NCT02754206|||CASE_CONTROL||PROSPECTIVE|||||||
34154846|NCT03054324|||CASE_ONLY||PROSPECTIVE|||||||
34154847|NCT00323726|||||RETROSPECTIVE|||||||
34154848|NCT02490007|||CASE_CONTROL||RETROSPECTIVE|||||||
34154849|NCT01627964|||CASE_ONLY||RETROSPECTIVE|||||||
34154850|NCT00923845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154851|NCT02291588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154852|NCT03537196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients with detectable HCV RNA, eligible for treatment, will receive Direct Acting Antiviral drugs.||||
34154853|NCT04893694|||OTHER||CROSS_SECTIONAL|||||||
34154854|NCT03302637|||CASE_CONTROL||PROSPECTIVE|||||||
34154855|NCT00017407||||TREATMENT||||||||
34154856|NCT00306540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154857|NCT04666194|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participant did not know which polypectomy technique was used. Endoscopists could not be blinded|There were 3 arms: cold forceps, cold snare, hot snare. Randomization was computer generated. Subjects were assigned to one of the 3 arms. Up to 5 study polyps were removed under research protocol from each subject using the same technique||||
34154858|NCT02853435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154859|NCT02424682|||CASE_ONLY||PROSPECTIVE|||||||
33948854|NCT00781001|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33948855|NCT05276726|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33948856|NCT01361282|||CASE_ONLY||CROSS_SECTIONAL|||||||
33948857|NCT01955902|||COHORT||PROSPECTIVE|||||||
33948858|NCT01972282|||COHORT||PROSPECTIVE|||||||
33948859|NCT00329706|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33948860|NCT04907201|||COHORT||PROSPECTIVE|||||||
33948861|NCT02509429|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154860|NCT04137250|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a double-blind clinical trial with specific population, prospective, reproducible, comparative and longitudinal.~It is proposed to study 28 patients, being randomly divided into two groups. We include patients of age between 18 years and 45 years, who have an anterior cruciate ligament injury diagnosed clinically and by image (magnetic resonance) and patients with or without associated meniscal injury, without previous reconstruction surgery and with previous informed Consent.~We exclude patients with multiligamentous injury and/or those who have diagnosis of moderate or severe ostearthritis, chronic degenerative diseases (diabetes mellitus, hypertension) and contralateral ACL injury.~We eliminate patients that for own initiative, wants to stop participating and those who didn't complete all follow-up appointments."||||
34154861|NCT05077293|||CASE_CROSSOVER||PROSPECTIVE|||||||
34154862|NCT01690806|||CASE_CONTROL||PROSPECTIVE|||||||
34154863|NCT02374567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154864|NCT00147316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154865|NCT01925248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154866|NCT02809378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34154867|NCT06386679|NA|SINGLE_GROUP||TREATMENT||NONE||Ten elderly patients from both gender diagnosed with knee osteoarthritis, will be enrolled according to specific inclusion and exclusion criteria. These patients will be injected with amniotic fluid mesenchymal stem cells developed for chondrogenic treatment. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.||||
34154868|NCT02943421|||COHORT||PROSPECTIVE|||||||
34154869|NCT01300260|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34154870|NCT04872790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154871|NCT04713501|NA|SINGLE_GROUP||TREATMENT||NONE||PARTS is a live-online group program intended to alleviate and resolve symptoms of stress and PTSD for patients in a community health care system.||||
34154872|NCT02923076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154873|NCT02661516|||COHORT||RETROSPECTIVE|||||||
34154874|NCT00446173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154875|NCT01483911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34154876|NCT03597594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with SCID will receive TCRα/β-CD19 -depleted graft followed by CD45RA-depleted DLI.||||
34154877|NCT03203291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154878|NCT04202133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154879|NCT05084898|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"BIinding in this study involves the use of a placebo arm. The placebo lamps will look exactly like the active far-UVC lamps, but they will produce regular fluorescent light and have no disinfection properties.~The trial will be blinded to everyone involved in the study except for one member of the lead coordinating team who must remain unblinded to provide lamp allocation guidance to the installing electricians. This person will not be involved in data collection or analysis, nor will they have access to participant identifying information, only their deidentified study ID."|Residents of three LTC facilities, will be cluster-randomized based on the 'neighbourhoods' they live in (social groups of 18-36) with a 1:1 allocation ratio. Randomization will be stratified by the LTC facility.|t|t|t|t
34154880|NCT03441230|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34154881|NCT02832336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34154882|NCT05018104|||COHORT||RETROSPECTIVE|||||||
33948862|NCT03971968|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33948863|NCT02081352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948864|NCT04398030|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33948865|NCT04337697|||COHORT||PROSPECTIVE|||||||
33948866|NCT01945866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948867|NCT00802295|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33948868|NCT03157219|||COHORT||PROSPECTIVE|||||||
33948869|NCT01223599|||CASE_ONLY||PROSPECTIVE|||||||
33948870|NCT05196386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948871|NCT03878368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948872|NCT00006401|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33948873|NCT01411761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33948874|NCT04553328|RANDOMIZED|PARALLEL||OTHER||SINGLE||The patients were divided randomly into two groups (30 patients in each group) according to the type of block they received: Group (T) received ultrasound guided (US) combined ipsilateral transverse abdominis plane (TAB) and ilioinguinal- iliohypogastric (ILIH) nerve block. Group (I) received US guided ipsilateral illioinguinal- illiohypogastric nerve block only.|f|f|f|t
33948875|NCT02924467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33948876|NCT06424756|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||For the experimental visits, participants will receive an antioxidant supplement in capsule form or a matching placebo pill in a randomized, double-blinded, crossover fashion. During each visit, participants will be given a single dose of the treatment to which they are randomized upon arrival at the laboratory (i.e., either 80 mg MitoQ or placebo will be administered on Visit 3, and the other treatment will be given on Visit 4). Peak concentrations of the antioxidant (MitoQ) occur after approximately 1 hour, allowing for appropriate time to prepare the participant for the experimental procedures.|t|f|t|t
33948877|NCT00381602|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33948878|NCT06465394|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33948879|NCT01225458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33948880|NCT05877508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948881|NCT01013207|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948882|NCT05275166|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33948883|NCT01574924|||COHORT||PROSPECTIVE|||||||
33948884|NCT02078557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948885|NCT03561272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33948886|NCT03112720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948887|NCT00755560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948888|NCT02013726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33948889|NCT01610726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154883|NCT02699255|||COHORT||RETROSPECTIVE|||||||
34154884|NCT02568592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33948890|NCT05384600|||COHORT||OTHER|||||||
33948891|NCT02050646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|t|t|f
33948892|NCT01526720|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34154885|NCT04462965|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33948893|NCT03157804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948894|NCT00359580|||COHORT||OTHER|||||||
33948895|NCT04469101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154886|NCT05533970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948896|NCT02279602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948897|NCT04897126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||1:1 stratified block random grouping according to the center|t|t|t|t
33948898|NCT02032394|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33948899|NCT06615245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Each participant will eventually get to try virtual reality, but participants will not be informed that some people receive a more immersive virtual reality than other people. In other words, participants will remain blind to the high tech vs. Low tech VR manipulation.|within subject repeated measures design with treatment order randomized|t|f|f|t
33948900|NCT02910895|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948901|NCT02874235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|External psychologist performs primary outcome measurement not knowing participants treatment||f|f|f|t
33948902|NCT00475657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948903|NCT06367959|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33948904|NCT02299466|||COHORT||PROSPECTIVE|||||||
34051934|NCT05037136|||OTHER||PROSPECTIVE|||||||
34051935|NCT03646214|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor reading the sleep studies will have the treatment arm masked.|Controlled clinical trial|f|f|f|t
34051936|NCT06667518|||COHORT||CROSS_SECTIONAL|||||||
34051937|NCT04026893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051938|NCT00688701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34051939|NCT05685264|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051940|NCT06109649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051941|NCT03467867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051942|NCT05461521|||COHORT||PROSPECTIVE|||||||
34051943|NCT04880798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051944|NCT05236374|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Crossover comparison of a mixed diet including green leafy vegetables, fruits, whole grains, seeds, and nuts; with beef versus non-meat sources of additional protein and zinc, over two 4-week metabolic study periods.||||
34051945|NCT02175082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and those performing outcome assessments were not aware of group allotment, nor was the PI. The therapists supervising the exercise interventions were aware of the group allotment|Subjects were randomized to a delay start or immediate start group and then for the cycling, the intervention was randomized to : forced pace (80-90 revolutions per minute with equals 15 miles per hour cycling rate or self-selected with both groups working at similar aerobic levels|t|f|t|t
34051946|NCT03337945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single center, single dose, open label, single period study to characterize cytochrome P450 (CYP) isoforms by the use of the Basel Phenotyping cocktail in patients at different stages of liver cirrhosis||||
34051947|NCT03369834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Control Group (GC=13) LED red group (GLED-V = 13) Infrared LED Group (GLED-IV = 13) Mixed Group (GM = 13) Sham Group (GP = 13)|f|f|t|t
34051948|NCT04370704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051949|NCT00679289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose-escalation cohorts||||
34051950|NCT06572579|||OTHER||PROSPECTIVE|||||||
34051951|NCT03548142|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34051952|NCT03401840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051953|NCT02986282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34051954|NCT04870099|NA|SINGLE_GROUP||TREATMENT||NONE||Guided self-help||||
34051955|NCT02223936|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34051956|NCT06667102|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"The PI will implement an experimental single case research design to track doses of SISI training and its efficacy in increasing teacher faithfulness to SISI.~The PI will implement an experimental single case research design to identify causal relations between SISI and target sign language skills.~The PI will implement a pre- and post- data to track deaf children's baseline growth in sign language skills prior to receiving SISI.~The PI will implement a quasi-experimental study to identify the efficacy of SISI in improving deaf children's sign language skills."||||
34051957|NCT05040607|||COHORT||RETROSPECTIVE|||||||
34051958|NCT04863781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051959|NCT02056366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051960|NCT02358109|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34051961|NCT05529615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34051962|NCT03992573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051963|NCT06667791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051964|NCT00971087|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051965|NCT05908123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051966|NCT04596709|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34051967|NCT04080843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051968|NCT00264069|||COHORT||PROSPECTIVE|||||||
34075794|NCT03184311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study personnel involved in the study measurements will be blinded to whether patients are allocated to the intervention or control group. Furthermore, the statistician will be blinded to treatment allocation. To ensure blinding, the study measurements will be performed in different rooms and by different staff than those involved in the training intervention. It is not possible to blind participating patients and investigators performing the randomization and training sessions.|"* Intervention group: 12-week high-intensity interval training on a bicycle ergometer.~* Control group: 12-week moderate-intensity continuous training on a bicycle ergometer."|f|f|f|t
34075795|NCT06014320|||COHORT||PROSPECTIVE|||||||
34075796|NCT02630563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075797|NCT02829047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948905|NCT03585595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants and study physicians/nurses will not be masked to patient randomization assignments due to different BP targets between the two randomization groups. However, study personnel who collect clinical outcome data at the baseline and follow-up examinations will be masked to patient assignments. The members of the Outcome Adjudication Committee will also be masked to patient randomization.|Patients with a recent ischemic stroke will be randomized to an intensive treatment strategy (a systolic BP target of \<120 mmHg) or a standard treatment strategy (a systolic BP target of \<140 mmHg) for up to four years.|f|f|f|t
33948906|NCT01978067|||CASE_ONLY||PROSPECTIVE|||||||
34075798|NCT03610074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Adult patient displaying an hypernatremia upper than 150mmol/L or an hypernatremia upper than 145mmol/L associated with a water deficiency upper than 3L||||
34075799|NCT05091983|||COHORT||PROSPECTIVE|||||||
34075800|NCT04613518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948907|NCT02767908|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075801|NCT00062348||||TREATMENT||NONE||||||
34075802|NCT03035513|||OTHER||CROSS_SECTIONAL|||||||
33948908|NCT02563964|||CASE_CONTROL||PROSPECTIVE|||||||
34075803|NCT00707967|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33948909|NCT03142984|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33948910|NCT00584610|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33948911|NCT06498570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948912|NCT01008059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948913|NCT02730312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948914|NCT01644968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948915|NCT03044691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33948916|NCT01605370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33948917|NCT04721431|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The people will assigned to groups depend on body mass index. The biceps brachii (BB), biceps femoris (BF) tone, and viscoelastic properties (stiffness and elasticity) will be evaluated bilaterally using the ''MyotonPRO'' device.|f|f|t|t
33948918|NCT06722716|||CASE_CONTROL||PROSPECTIVE|||||||
33948919|NCT05495724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948920|NCT04310904|||COHORT||PROSPECTIVE|||||||
33948921|NCT01463059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948922|NCT06246981|||OTHER||PROSPECTIVE|||||||
33948923|NCT02185131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33948924|NCT04479696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948925|NCT06130618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948926|NCT05083975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both the patient and the investigator cannot be blinded due to the different techniques.||f|f|f|t
33948927|NCT01907373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948928|NCT02038699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948929|NCT03501134|||COHORT||PROSPECTIVE|||||||
33948930|NCT04433858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948931|NCT03054493|||OTHER||CROSS_SECTIONAL|||||||
33948932|NCT06224569|NON_RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||The study will employ an N-of-1 study design in which 30 participants will be recruited and studied over 12 weeks. In each N-of-1 study, interventions will be delivered for six days at a time, with a one day washout in between each intervention, in four blocks of three weeks, such that each intervention is received once in each three-week block. Three intervention sequences for each arm were determined by randomly selecting four out of the six possible combinations of three interventions, and ordering the four combinations so that no intervention was preceded, or followed, by itself.|t|t|t|t
33948933|NCT03228615|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This clinical trial uses prospective repeated measures in a before-after study design. Following enrollment of the usual care group (i.e., 50% recruitment goal has been reached), physicians will be trained to use the intervention. We will then enroll the intervention group.||||
33948934|NCT03447431|||COHORT||RETROSPECTIVE|||||||
33948935|NCT04948606|||COHORT||PROSPECTIVE|||||||
33948936|NCT00981331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33948937|NCT02862002|RANDOMIZED|PARALLEL||||NONE||||||
33948938|NCT00598442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948939|NCT02764229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948940|NCT00253747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948941|NCT01715480|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33948942|NCT05324839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33948943|NCT02743117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33948944|NCT00636857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948945|NCT05896072|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33948946|NCT05580601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948947|NCT01700218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948948|NCT01465958|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33948949|NCT01836666|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33948950|NCT01062529|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33948951|NCT05341011|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33948952|NCT03265158|||OTHER||PROSPECTIVE|||||||
33948953|NCT02692404|||COHORT||PROSPECTIVE|||||||
33948954|NCT06409182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient will swallow wireless sensor capsule to determine if there's||||
33948955|NCT05323773|||COHORT||PROSPECTIVE|||||||
33948956|NCT02144311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075804|NCT02020369|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34075805|NCT05854485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076398|NCT04226781|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34076399|NCT02240017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076400|NCT03243825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076401|NCT05710900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot implementation study||||
34076402|NCT00368147|||COHORT||PROSPECTIVE|||||||
34051969|NCT04379596|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will consist of 2 phases: a dose escalation phase (Part 1) and dose expansion phases (Part 2, Part 3 and Part 4). Part 1 will enroll HER2-overexpressing (IHC 3+ or IHC 2+/ISH+), previously treated gastric, gastro-esophageal junction (GEJ) or esophageal cancer patients, and Part 2 will enroll HER2-overexpressing patients who have not received prior treatment for metastatic or unresectable disease. Part 3 and Part 4 will enroll HER2-expressing patients who have not received prior treatment for metastatic or unresectable disease.~In addition to safety and tolerability, this study will also assess ORR, DoR, DCR, OS, PFS and other measures of antitumor activity among treatment groups. Tumor evaluation using RECIST v1.1 will be conducted at screening and every 6 weeks until RECIST 1.1 objective disease progression or withdrawal of consent."||||
34051970|NCT06666075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34051971|NCT01433445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34051972|NCT05290064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33948957|NCT01164631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33948958|NCT04487626|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34051973|NCT01951534|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34051974|NCT04619329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948959|NCT01493791|RANDOMIZED|PARALLEL||TREATMENT||||||||
34051975|NCT06093737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34051976|NCT01702480|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33948960|NCT04936126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will remain blind to the treatment allocation|Prospective, parallel-arm, randomized, single-blind, controlled clinical trial|f|f|f|t
34051977|NCT05421702|RANDOMIZED|PARALLEL||TREATMENT||NONE||Operable colon cancer cases||||
34051978|NCT03861299|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participating center will randomise eligible and willing patients through the webbased clinical database and randomisation application ALEA. The Clinical Trial Centre (CTC) of the Erasmus MC will build the randomisation application by use of a dynamic allocation algorithm (minimization), in which patients are allocated to keep the imbalance between treatment groups to a minimum at every stage of recruitment within the covariates age (≤55 years vs \>55years), Karnofsky performance scale (80-90 vs \>90), and left or right hemisphere. Treatment allocation and allocated subject number will be shown immediately on screen and will in addition automatically be emailed to local investigators and other study personnel||||
34051979|NCT02764957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34051980|NCT01432912|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33948961|NCT00535262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948962|NCT04740762|RANDOMIZED|PARALLEL||PREVENTION||NONE||Following recruitment, the pregnant women were divided into a study and a control group by randomization (1:1 randomization)||||
33948963|NCT06557356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33948964|NCT05248633|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33948965|NCT04465643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154887|NCT04829253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not be therapists in the study and will be blind to treatment allocation. The only exception involves assessors in charge of evaluating care usage (e.g. ER visits and inpatient) as they will probably find out the treatment condition. These assessors will not participate in the assessment of primary or other secondary outcome measures.||f|f|f|t
34154888|NCT00971295|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154889|NCT02629003|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34154890|NCT03092635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154891|NCT06584487|||CASE_CROSSOVER||PROSPECTIVE|||||||
34154892|NCT05167591|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154893|NCT00005120||||TREATMENT||DOUBLE||||||
34154894|NCT04558359|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34154895|NCT02973308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34154896|NCT00267852|||COHORT||PROSPECTIVE|||||||
34154897|NCT03582995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154898|NCT05788497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154899|NCT03046030|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154900|NCT03432559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|the investigator doing the transesophageal examination will not be informed about the results of the endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, and gastric body||||
34154901|NCT01354366|||COHORT||PROSPECTIVE|||||||
34154902|NCT04255641|||COHORT||RETROSPECTIVE|||||||
34154903|NCT04674488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154904|NCT00099866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154905|NCT03079219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154906|NCT03854383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948966|NCT06717321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948967|NCT01314508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948968|NCT03710824|||COHORT||PROSPECTIVE|||||||
33948969|NCT04482894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33948970|NCT04311814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We conducted a monocentric interventional study, carried out as part of routine care||||
33948971|NCT02337543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948972|NCT05075109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948973|NCT00594958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34051981|NCT00338520|||COHORT||PROSPECTIVE|||||||
34051982|NCT05194891|||COHORT||PROSPECTIVE|||||||
34051983|NCT06667388|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34051984|NCT00024037||||SUPPORTIVE_CARE||||||||
34051985|NCT06116682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051986|NCT02165189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34051987|NCT02394496|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34051988|NCT06431893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051989|NCT04151160|||CASE_CONTROL||PROSPECTIVE|||||||
33948974|NCT05214911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind, double-dummy||t|f|t|f
33948975|NCT03343002|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34154907|NCT03940118|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Closed envelop to be opened after inclusion/exclusion criteria are met and informed consent obtained|Randomized, four groups of different respiratory tract secretion suctioning methods: 1) catheter (conventional), 2) catheter after hypertonic saline, 3) mechanical insufflation-exsufflation, and 4) mechanical insufflation-exsufflation with hypertonic saline|f|f|t|f
34154908|NCT06172725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154909|NCT01717326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154910|NCT00950742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154911|NCT01255995|||COHORT||PROSPECTIVE|||||||
34154912|NCT02604914|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154913|NCT05850338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data of the study were entered by a person other than the researcher. Statistical analysis was performed by a person other than the researcher. Blinding was done during the evaluation of the data. Intervention and control groups were coded as 1 and 2. The analysis of the data coded in terms of groups was made by the statistician. After the statistical analysis, the coding for the intervention and control groups was explained. Statistical bias was controlled by this blanking technique.|A randomised controlled trial|f|f|f|t
34154914|NCT06320314|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34154915|NCT00810992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154916|NCT04132674|NA|SINGLE_GROUP||OTHER||NONE||||||
34154917|NCT00793078|||CASE_CONTROL||PROSPECTIVE|||||||
34154918|NCT02353728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34154919|NCT04985669|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Quasi experimental||||
34154920|NCT01943240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34154921|NCT04844528|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34154922|NCT00324376|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154923|NCT05699564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154924|NCT03615339|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Unlabelled bottles of treatment|||||
34154925|NCT06583694|||CASE_ONLY||PROSPECTIVE|||||||
34154926|NCT06372496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154927|NCT04772781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948976|NCT02403427|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34154928|NCT06050785|||COHORT||PROSPECTIVE|||||||
34154929|NCT05346653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154930|NCT01440205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34154931|NCT01953913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154932|NCT00999297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34154933|NCT06197620|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34154934|NCT04001283|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34154935|NCT03010280|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34154936|NCT03083002|||COHORT||PROSPECTIVE|||||||
34154937|NCT01088022|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34154938|NCT05155774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will check outcome on blinded study models.||f|f|f|t
34154939|NCT00733681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154940|NCT00128115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34154941|NCT01500668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34154942|NCT03727906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"The experimental paradigm will consist of three in-lab counterbalanced non-consecutive (≥2 days in-between) polysomnography (PSG) nights in which we will modulate the level of pre-sleep psychophysiological arousal in a group of insomnia and non-insomnia adolescents.~1. no pre-sleep arousal manipulation night;~2. pre-sleep arousal down-regulation night (pre-sleep relaxation-driven Virtual reality ANS downregulation);~3. pre-sleep arousal up-regulation night (pre-sleep anticipation of stress using the Trier Social StressTest)."||||
34154943|NCT05082311|||COHORT||PROSPECTIVE|||||||
34154944|NCT03098303|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154945|NCT05160129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154946|NCT05096312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154947|NCT05441865|||OTHER||PROSPECTIVE|||||||
34154948|NCT01660880|||CASE_ONLY||CROSS_SECTIONAL|||||||
34154949|NCT03797456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154950|NCT00234169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948977|NCT04196959|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Non-blinded.|Single group, open label.||||
33948978|NCT04651660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948979|NCT04937543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948980|NCT01491152|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33948981|NCT03176602|||COHORT||PROSPECTIVE|||||||
33948982|NCT02316704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33948983|NCT03332225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Treatment with recombinant human interferon-gamma or anakinra|t|t|t|t
34154951|NCT05151757|NA|SINGLE_GROUP||SCREENING||NONE||This is a before and after study in which non physician graders will undergo testing on the standard image set at baseline, and then complete a training course. They will then undergo a post course test on the standard image set. Their performance in the post course will be compared to baseline performance.||||
34154952|NCT02256163|||FAMILY_BASED||PROSPECTIVE|||||||
34154953|NCT02294734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34154954|NCT01618149|||COHORT||PROSPECTIVE|||||||
34154955|NCT00201942|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154956|NCT02406404|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34154957|NCT04318925|||COHORT||PROSPECTIVE|||||||
34154958|NCT06508840|||OTHER||PROSPECTIVE|||||||
34154959|NCT00039663||||TREATMENT||||||||
34154960|NCT00545896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154961|NCT06242015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34154962|NCT05885802|||COHORT||PROSPECTIVE|||||||
33948984|NCT00395317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33948985|NCT05480852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34154963|NCT04465292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154964|NCT00488696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948986|NCT02077868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948987|NCT04155606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948988|NCT04408326|||CASE_CONTROL||RETROSPECTIVE|||||||
33948989|NCT04988620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and clinical personell ordering and evalutaing the effect of transfusion will be blinded, so will also the investigators performing the statistical evaluation of the results. The project co-workers preparing the whole blood units and perforing laboratory analysis will not be blinded.|Test group ( Whole Blood stored for 15-21 days) versus Control group(s) (Whole Blood stored for less than 7 days, Whole Blood stored for 8-14 days and/or Standard Blood Component treatment)|t|t|f|f
33948990|NCT00914940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33948991|NCT01367366|||COHORT||PROSPECTIVE|||||||
33948992|NCT00752895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34154965|NCT02220712|NA|SINGLE_GROUP||OTHER||NONE||||||
34154966|NCT00128986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34154967|NCT06502808|||CASE_ONLY||PROSPECTIVE|||||||
34154968|NCT06312319|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34154969|NCT05651815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154970|NCT01940536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34154971|NCT04405076|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Part A is observer-blind. During Part B participants may request to be unblinded by scheduling a Participant Decision clinic visit. Part C is open-label.||t|f|t|f
34154972|NCT01541449|||CASE_CONTROL||RETROSPECTIVE|||||||
34154973|NCT05330091|||COHORT||PROSPECTIVE|||||||
34154974|NCT06395259|||CASE_ONLY||PROSPECTIVE|||||||
34154975|NCT05998174|NA|SINGLE_GROUP||TREATMENT||NONE||pilot trial||||
34154976|NCT01297725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34154977|NCT00986362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154978|NCT02371031|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34154979|NCT04735146|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34154980|NCT02922179|||COHORT||RETROSPECTIVE|||||||
34154981|NCT00180011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34154982|NCT00005314|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34154983|NCT03383380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154984|NCT01900808|||COHORT||PROSPECTIVE|||||||
34154985|NCT02335593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34154986|NCT03410121|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34154987|NCT01844778|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34154988|NCT04915417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154989|NCT03265782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34154990|NCT03478735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34154991|NCT01996085|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34154992|NCT03025243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34154993|NCT03160885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of the investigational medicinal products (IMPs) will contain no evidence of their identity.~Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded healthcare professional (HCP) at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments."||t|f|t|f
34154994|NCT01575925|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34154995|NCT01881568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34154996|NCT03853070|||COHORT||PROSPECTIVE|||||||
34154997|NCT00761826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34154998|NCT00002458||||TREATMENT||||||||
34154999|NCT04496011|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be included by convenience (according to the inclusion and exclusion criteria) in non-probabilistic form. The included individuals will be randomized by (nome do Sofwate) in two lists: one for the control group and other for the experimental group. Once defined that the patient will be part of the experimental group, a bicycle ergometer will be kept in the patient's accommodation during the period of hospitalization due to restrictions imposed by the Infection Control Department. Thus, the equipment will remain in the patient´s room during the hospitalization, while the other patients will be allocated to the control group.||||
34155000|NCT03295773|||CASE_ONLY||PROSPECTIVE|||||||
34155001|NCT04194073|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155002|NCT03508609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155003|NCT03918525|||OTHER||CROSS_SECTIONAL|||||||
34155004|NCT03433352|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34155005|NCT02731443|||COHORT||PROSPECTIVE|||||||
34155006|NCT00346229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155007|NCT02777827|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34155008|NCT03796351|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34155009|NCT03855605|||CASE_ONLY||CROSS_SECTIONAL|||||||
33948993|NCT05694923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center clinical randomized trial open labelled study patients of non diabetic non alcoholic fatty liver from outpatient clinic at assiut university will be randomized and recruited into arms Group A Will receive empaglifizon sodium glucose cotransporter in minimum dose 10 mg Group B Will be Instructed for diet control||||
33948994|NCT04169789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33948995|NCT06722079|||OTHER||RETROSPECTIVE|||||||
33948996|NCT03426735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33948997|NCT03509766|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Neither the subject nor the technician are masked as to which device is being placed. However, the investigator who reads the skin prick test results is blinded as to which device is which.||f|f|t|f
33948998|NCT01409382|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33948999|NCT06537830|||OTHER||OTHER|||||||
33949000|NCT01247649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949001|NCT02136446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34051990|NCT06269380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The biopsies obtained from patients who underwent esophagogastroduodenoscopy and were found to have normal endoscopic findings will be evaluated. The histopathological findings and their frequencies in these biopsies will be examined to assess the necessity of routine biopsy during esophagogastroduodenoscopy.||||
34155010|NCT01277484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155011|NCT02505113|||CASE_CONTROL||PROSPECTIVE|||||||
34155012|NCT00642447|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34155013|NCT02676934|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34155014|NCT00121368|||||PROSPECTIVE|||||||
34155015|NCT03001687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34155016|NCT02359227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155017|NCT05211817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Block randomisation for carnosine, identically looking control and intervention treatment|Randomised controlled trial with complex lifestyle intervention and carnosine supplementation.|t|t|t|t
34155018|NCT04260945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155019|NCT00847197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155020|NCT05448391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051991|NCT02228239|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34051992|NCT05795816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155021|NCT01358994|||COHORT||RETROSPECTIVE|||||||
34051993|NCT00001016||||TREATMENT||NONE||||||
34155022|NCT02990676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34051994|NCT05146427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||All participants will be randomized to active or sham enhancement for one week. For the second week, they will then receive the alternate condition.|t|f|f|f
34155023|NCT02436954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155024|NCT04286815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34051995|NCT06379971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Phosphatidylcholine versus placebo|t|f|t|t
34051996|NCT05890352|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34051997|NCT05001087|||COHORT||OTHER|||||||
34155025|NCT02687087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34051998|NCT03069599|||COHORT||PROSPECTIVE|||||||
34051999|NCT02683382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052000|NCT00880230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052001|NCT03229447|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will develop and test the feasibility of an interactive eLearning modality and an eLearning + an organizational approach (change team intervention; a Technology Transfer model) to advance knowledge and facilitate inclusion of MAT in the criminal justice system for opioid-addicted clients. Courts recruited for the study will receive eLearning and half of these courts will be randomly assigned to the change team.||||
34052002|NCT04721119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052003|NCT06665204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Given the nature of the CPG-adherent and SoC intervention arms, it is not possible to blind treating physical therapists to treatment assignments; however, study participants will be blinded to their group assignments. Research personnel will be trained to endorse clinical equipoise of the two intervention arms during the informed consent process to limit unintentional biases.~Further, all baseline and follow-up assessments will be administered remotely and distributed by a research team member who was not present for the study intervention (i.e., physical therapy treatment), limiting the potential influence of unblinded assessors on the outcomes of the study. Research team members facilitating remote baseline and follow-up assessments will be instructed to not answer or provide any direct guidance regarding completion of patient-reported outcome measures."|Upon completing the informed consent, eligible participants will complete baseline questionnaires, then be randomized to 1) a CPG-adherent (intervention) arm in which PFP care is provided by research physical therapists based on CPG recommendations, and 2) a SoC (comparator) arm, in which management decisions are made by non-research physical therapists in alignment with their personal and organizational practice standards but with no specific directives from the research team.|t|f|f|f
34052004|NCT01180699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34052005|NCT01944917|||CASE_CONTROL||PROSPECTIVE|||||||
34052006|NCT03764878|||COHORT||PROSPECTIVE|||||||
34052007|NCT05248256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052008|NCT06559865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052009|NCT06665048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Two-arm study|t|t|t|t
34052010|NCT05712213|||COHORT||PROSPECTIVE|||||||
34155026|NCT06583993|NA|SINGLE_GROUP||TREATMENT||NONE||The subjects with advanced ICC will be treated by HNF4α srRNA intravenously via a peripheral vein.||||
34155027|NCT06017869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155028|NCT05175742|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|observer-blinded||t|t|t|t
34155029|NCT01516398|||CASE_ONLY||PROSPECTIVE|||||||
34052011|NCT06562634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34052012|NCT05130710|||CASE_CONTROL||PROSPECTIVE|||||||
34052013|NCT03981900|||COHORT||PROSPECTIVE|||||||
34052014|NCT00519428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052015|NCT05484856|NA|SINGLE_GROUP||TREATMENT||NONE||This is prospective, open label, single arm clinical study that will establish the safety and efficacy of adipose derived stromal cells in patients with osteoarthritis disease. Total 140 subjects were enrolled in the study. Each subject will receive intra-articular Autologous ADSC with PRP along with standard treatment for osteoarthritis disease.||||
34052016|NCT02796066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052017|NCT00432224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052018|NCT04946084|NA|SINGLE_GROUP||OTHER||NONE||||||
34052019|NCT04857814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052020|NCT01482143|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155030|NCT05409898|||COHORT||PROSPECTIVE|||||||
34155031|NCT03327194|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric prospective interventional single-subject design||||
34155032|NCT01588938|||COHORT||PROSPECTIVE|||||||
34155033|NCT01896362|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34155034|NCT02464514|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34155035|NCT03993522|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155036|NCT03238833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155037|NCT06440551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155038|NCT02314832|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155039|NCT06580210|||CASE_ONLY||PROSPECTIVE|||||||
34155040|NCT01669083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155041|NCT02428205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155042|NCT01184417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155043|NCT00721838|||CASE_CONTROL||PROSPECTIVE|||||||
34155044|NCT04166617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34155045|NCT06258408|NA|SEQUENTIAL||TREATMENT||NONE||||||
34155046|NCT00004275||||TREATMENT||||||||
34052021|NCT06308029|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomized, multi-centric, three-arm controlled trial||||
33949002|NCT06499428|||COHORT||OTHER|||||||
34052022|NCT06180369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052023|NCT00960986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052024|NCT03573531|||CASE_CONTROL||PROSPECTIVE|||||||
33949003|NCT06724159|||COHORT||OTHER|||||||
34052025|NCT05741853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052026|NCT05847738|||COHORT||RETROSPECTIVE|||||||
34052027|NCT00201461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949004|NCT04882514|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Stage 1: The investigators will verify the immediate safety of the J8-K4S2 and p\*17-K4S2 vaccines using a test dose in 10 volunteers.~If there are no safety concerns following the Stage 1 challenge, the study will proceed to a phase 2 double-blind randomized clinical trial. The Rabavert vaccine will be used as a comparator against the 2 investigational arms."|t|t|t|f
34052028|NCT02849860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052029|NCT05286736|||CASE_CONTROL||PROSPECTIVE|||||||
34052030|NCT06631521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052031|NCT02836379|||COHORT||PROSPECTIVE|||||||
33949005|NCT02137473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34052032|NCT03998644|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052033|NCT06376565|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33949006|NCT06724588|||CASE_ONLY||PROSPECTIVE|||||||
33949007|NCT05681676|||CASE_ONLY||RETROSPECTIVE|||||||
33949008|NCT03664570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Three-way crossover||||
33949009|NCT02264925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949010|NCT04197856|RANDOMIZED|PARALLEL||SCREENING||NONE|Since the intervention in this trial is an offer of sending physical direct letters to at-risk relatives, neither the health care providers nor the study participant can be blinded to the allocation. However, the final data analysis will be performed by a statistician blinded to the study arm allocations and subgroups.|Multi-centre, parallel assignment, balanced ratio, investigator-blinded, randomised, controlled superiority trail in Sweden.||||
33949011|NCT03626337|||COHORT||PROSPECTIVE|||||||
34052034|NCT04198038|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33949012|NCT04804319|||OTHER||OTHER|||||||
34052035|NCT01062243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052036|NCT05678868|||COHORT||PROSPECTIVE|||||||
33949013|NCT02129439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949014|NCT01809847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052037|NCT03513809|||COHORT||PROSPECTIVE|||||||
33949015|NCT05954117|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||patient undergoing surgery for esophageal adenocarcinoma or for gastroesophageal adenocarcinoma||||
33949016|NCT00953576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The Phase I dose escalation schedule was to evaluate up to 4 dose levels of lapatinib as well as one step down dose for ketoconazole (-1). This is not a 'parallel assignment' since this dose escalation design proceeds in sequence not in parallel.||||
33949017|NCT06551467|NA|SINGLE_GROUP||TREATMENT||NONE||This study utilized a single-arm repeated-measures design to monitor changes in the online intervention over time and increase the precision of the outcomes.||||
33949018|NCT01459016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949019|NCT04145531|NA|SEQUENTIAL||TREATMENT||NONE||||||
34052038|NCT04072393|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155047|NCT05148104|||CASE_ONLY||CROSS_SECTIONAL|||||||
34155048|NCT05526898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155049|NCT00064792|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34155050|NCT01505816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155051|NCT06303219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155052|NCT05556694|||COHORT||PROSPECTIVE|||||||
34155053|NCT05684029|||COHORT||PROSPECTIVE|||||||
34155054|NCT04454242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34155055|NCT01860950|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34155056|NCT00705146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155057|NCT00085891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155058|NCT04783077|RANDOMIZED|PARALLEL||OTHER||NONE||A pilot stratified randomized control trials of WhatsApp compared to control and docudrama (before/after) among first time donors.||||
34155059|NCT03116256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participant will be randomised into one of the following group:~1. VLCD (N=12),~2. VLCD + RET (N=12)~3. VLCD + HIIT (N=12)"||||
34155060|NCT05029739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded for group assignment at the 12 weeks and 12 month follow-up visit.|Multicenter prospective randomized open blinded end-point (PROBE)|f|f|f|t
34155061|NCT06195410|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34076403|NCT02004938|||COHORT||PROSPECTIVE|||||||
34076404|NCT05231343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155062|NCT02741427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155063|NCT00391625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155064|NCT02479139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155065|NCT02193308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155066|NCT04952246|||CASE_CONTROL||RETROSPECTIVE|||||||
34155067|NCT05009329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155068|NCT01745042|||COHORT||CROSS_SECTIONAL|||||||
34052039|NCT03879980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Forty-four healthy patients with American Society of Anesthesiologists (ASA) classification I or II gave written consent to participate and were randomly allocated into QL block group or control (non-QL block) group. Randomisation used blocks of 4 into 2 groups using a list of random numbers and was performed by sealed envelopes. The surgeries were performed by 3 urology surgeon consultants with comparable distributions. Patients and principal investigator were blinded to group allocation.||t|f|t|f
34052040|NCT03655093|||COHORT||PROSPECTIVE|||||||
34155069|NCT03492801|||CASE_ONLY||PROSPECTIVE|||||||
34052041|NCT06278883|NA|SINGLE_GROUP||SCREENING||NONE||Everyone who consents is enrolled in the risk assessment pipeline.||||
34052042|NCT00215696|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34052043|NCT02759055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34052044|NCT06465199|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052045|NCT01558856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052046|NCT03152838|||CASE_CONTROL||RETROSPECTIVE|||||||
34052047|NCT00613691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052048|NCT05665075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052049|NCT06667726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052050|NCT02353442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155070|NCT05621174|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34155071|NCT05506527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|lottery method|randomized clinical trial|t|f|f|f
34155072|NCT02933957|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34155073|NCT00753363|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34155074|NCT06429800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155075|NCT05284344|||COHORT||PROSPECTIVE|||||||
34155076|NCT06501612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34155077|NCT00293020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155078|NCT00562991|||OTHER||PROSPECTIVE|||||||
34155079|NCT02992509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155080|NCT05672550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155081|NCT04391803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155082|NCT04584242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155083|NCT05825560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155084|NCT02337881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155085|NCT04420663|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This prospective controlled trial study will be performed between August 2019 and August 2020. We will enroll patients with large volume pleural effusion referred to our Cardiothoracic Department, Faculty of Medicine, Ain Shams University to perform therapeutic thoracentesis. All the patients will sign an informed consent for pleural pressure monitoring during and after therapeutic thoracentesis.||||
34155086|NCT02513472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155087|NCT01356199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34155088|NCT02747368|NA|SINGLE_GROUP||SCREENING||NONE||||||
34155089|NCT02834247|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34155090|NCT04125277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155091|NCT05293626|NA|SEQUENTIAL||TREATMENT||NONE||0.5E9 vg, 0.05 mL/eye/dose (low dose) 1.5E9 vg, 0.05 mL/eye/dose (starting dose) 3.0E9 vg, 0.05 mL/eye/dose (intermediate dose) 4.5E9 vg, 0.05 mL/eye/dose (high dose)||||
34155092|NCT01796821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155093|NCT03515642|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34155094|NCT00951652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155095|NCT00876434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155096|NCT04079114|||COHORT||PROSPECTIVE|||||||
34155097|NCT05455502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155098|NCT05018663|||CASE_ONLY||PROSPECTIVE|||||||
34155099|NCT01868477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155100|NCT05373342|||COHORT||PROSPECTIVE|||||||
34155101|NCT05254327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Lab performing PK sample analysis will be blinded to the subjects and relationship of specimens to treatment with BMX-001||f|f|f|t
34155102|NCT05501951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155103|NCT06168266|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155104|NCT05391256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155105|NCT06510010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155106|NCT05938127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
34155107|NCT06304779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Lidocaine group: Patients receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively Control group: Patients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.|t|f|f|t
34052051|NCT02798289|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34052052|NCT06666543|||FAMILY_BASED||RETROSPECTIVE|||||||
34052053|NCT01707108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052054|NCT02889263|||COHORT||RETROSPECTIVE|||||||
34052055|NCT01945970|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34052056|NCT03969563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neuropsychologist doing the assessments pre- and post-intervention will not be aware of the participant's group assignment.|Participants are assigned to either the MBSR or Brain Health education class, in parallel for the duration of the study.|f|f|f|t
34052057|NCT05413369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052058|NCT06420557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052059|NCT04722510|NA|SINGLE_GROUP||TREATMENT||NONE||Randomized clinical trial||||
34052060|NCT06429345|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155108|NCT02868229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155109|NCT01298765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155110|NCT05028270|||COHORT||RETROSPECTIVE|||||||
34155111|NCT03036618|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34155112|NCT00187447|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34155113|NCT02540668|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34155114|NCT03071289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844893|NCT04458805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part A) followed by a multiple ascending dose (MAD) part (Part B). The decision to escalate between dose levels and proceed to Part B will be based upon review of blinded available safety data by a Safety Review Committee.~Part A: 35 healthy volunteers will be enrolled in a total of 5 cohorts. Each cohort will enroll 7 participants with 5 participants randomized to receive NX-13 and 2 participants randomized to receive placebo.~Part B: 21 healthy volunteers will be enrolled in a total of 3 cohorts. Each cohort will enroll 7 participants with 5 participants randomized to receive NX-13 and 2 participants randomized to receive placebo."|t|t|t|t
33844894|NCT02755818|||COHORT||CROSS_SECTIONAL|||||||
34052061|NCT04925258|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit a group of parents and primary caregivers (e.g., mothers, fathers, adoptive parents, grandparents) who report elevated levels of parenting stress (above the 50th percentile of population norms on the Parenting Stress Index), and are the legal guardians of a child in the 3- to 4-year-old age range. Those parents will be randomly assigned to one treatment condition or the control condition. Parents in the treatment condition will participate in an 8-week parenting program that includes a combination of activities, parenting training, as well as drop-in sessions with a trained psychology student (MA-level or higher) or psychologist. The control group will receive services-as-usual (referral list for online and telehealth parenting and family mental health services).||||
34052062|NCT05073341|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|non randomisation|Quasi experimental design||||
34052063|NCT06411535|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34052064|NCT04641962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind treatment period: Participant, Caregiver, Investigator||t|t|t|f
34052065|NCT02420808|||CASE_ONLY||PROSPECTIVE|||||||
34052066|NCT01190358|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34052067|NCT05494008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076405|NCT02895347|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34076406|NCT04739033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34076407|NCT02958579|||COHORT||PROSPECTIVE|||||||
34076408|NCT00953290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155115|NCT00003336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155116|NCT01238328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155117|NCT02508909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844895|NCT02697370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844896|NCT02654691|||COHORT||PROSPECTIVE|||||||
33844897|NCT05520333|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155118|NCT02610452|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155119|NCT04840134|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155120|NCT05972837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155121|NCT02941666|||CASE_CONTROL||PROSPECTIVE|||||||
34155122|NCT05905731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155123|NCT03772665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Masked|This is a multicenter, randomized, double-masked, placebo-controlled study to evaluate the efficacy and safety of emixustat compared to placebo in subjects who have Macular Atrophy secondary to Stargardt disease.|t|t|t|t
34155124|NCT04580095|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34155125|NCT01162811|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34155126|NCT00158691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155127|NCT02486965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34155128|NCT05270798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155129|NCT02999412|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34155130|NCT04523597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34155131|NCT05629468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155132|NCT00746434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155133|NCT06471075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155134|NCT06261359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155135|NCT04995549|NA|SINGLE_GROUP||OTHER||NONE||||||
34155136|NCT03651609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Three examiners will perform one part of diagnostic evaluation that will include: (1) patients' history and focused neurological examination, (2) (EDx) and (3) US studies. They will be blinded to the findings of the other parts of the evaluation.|Patients with suspected UNE will be prospectively recruited in a single secondary referral center. First of three blinded examiners will obtain patients' history and perform focused neurological examination. The second examiner will perform electrodiagnostic (EDx) and the third ultrasonographic (US) studies. Patients with UNE under the HUA and in the RTC groove will be randomly distributed in two groups for surgical HUA release and conservative treatment. During surgical intervention the surgeon will cut the HUA with minimal incision technique. All patients (including surgically treated) will be given pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA, control neurological examination will be performed every 3 months. At 1 year follow-up we will use identical protocol as at the time of initial diagnostic evaluation.|f|f|t|f
34155137|NCT01227005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155138|NCT04598412|||OTHER||CROSS_SECTIONAL|||||||
33844898|NCT05973786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label, except for the assessors of the primary outcome|Parallel randomization to the 2 arms, treatment as usual (TAU) or early-intensified pharmacological treatment (EIPT).|f|f|f|t
33844899|NCT04344080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844900|NCT00518544|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33844901|NCT04865341|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33844902|NCT00866970|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33844903|NCT04436575|||COHORT||PROSPECTIVE|||||||
34155139|NCT03298763|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"Phase I:~Single centre, accelerated dose dose de-escalation design with a modified Bayesian continual reassessment method (mCRM) to estimate the recommended Phase II dose (RP2D) of MSCTRAIL in combination with pemetrexed/cisplatin chemotherapy.~Phase II:~Multicentre, randomised double blind placebo controlled trial comparing MSCTRAIL at the RP2D and pemetrexed/cisplatin chemotherapy versus pemetrexed/cisplatin chemotherapy alone."|t|f|f|f
34155140|NCT05917171|NA|SINGLE_GROUP||OTHER||NONE|Non-random pilot trial with no masking due to single group assignment.|Single group pilot study to assess feasibility and acceptability.||||
34155141|NCT06153472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors will be blinded.|2|f|f|f|t
34155142|NCT00912457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155143|NCT01949610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155144|NCT02119390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34155145|NCT01364389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155146|NCT00795873|||COHORT||PROSPECTIVE|||||||
34155147|NCT00697710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155148|NCT03496805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study. Only the lead-site investigational pharmacy team and the statistician will unblinded. The blind will be maintained until the study is complete.||t|t|t|f
34155149|NCT01336023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155150|NCT01722435|||COHORT||PROSPECTIVE|||||||
34155151|NCT05664802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Centralized, computer-based group assignment using permuted blocks.|t|f|f|f
34155152|NCT01335269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155153|NCT01764958|||COHORT||PROSPECTIVE|||||||
34155154|NCT04088591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155155|NCT00527904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155156|NCT04478604|||OTHER||PROSPECTIVE|||||||
34155157|NCT01073930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155158|NCT01135095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155159|NCT01320202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155160|NCT01646242|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155161|NCT03550417|||CASE_CONTROL||RETROSPECTIVE|||||||
34155162|NCT05336149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844904|NCT02614053|||COHORT||PROSPECTIVE|||||||
33844905|NCT00817700|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33844906|NCT06531993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pectin, a class of heteropolysaccharides based on polygalacturonic acid, is a safe and non-toxic natural food additive recommended by the Joint FAO/WHO Committee on Food Additives with no daily additive limit . Pectin is mainly obtained from apple pomace, citrus peels and sugar beets, ancurrently, commercial pectin contains ≥65% Gal-A (galacturonic acid)|t|f|f|f
33844907|NCT00089921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844908|NCT05267340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33844909|NCT05929209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844910|NCT02928276|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844911|NCT00942760|||||CROSS_SECTIONAL|||||||
33844912|NCT05673031|||CASE_ONLY||PROSPECTIVE|||||||
33844913|NCT05932251|||CASE_CONTROL||PROSPECTIVE|||||||
33844914|NCT06040593|||COHORT||RETROSPECTIVE|||||||
33844915|NCT06009757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The study is single-blind. The patient does not know which guidance catheter will be used.~Due to the nature of the intervention (different form of guiding catheter), staff may not be blind to the allocation, but they are strongly encouraged not to disclose the participant's allocation status during follow-up assessments. The sponsor's team will not know what type of treatment the patient's number corresponds to. Under no circumstances will they have access to the list of matches between the patient number and the allocated treatment."|Thus the aim of this non-inferiority study is to compare the efficacy and safety for patients with coronary artery disease during a percutaneous coronary intervention between Guidex® Guiding catheter (DEMAX) and Launcher™ coronary guide catheters (Medtronic).|t|f|f|f
33844916|NCT02544451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844917|NCT06335875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844918|NCT00075842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33844919|NCT06729866|NA|SINGLE_GROUP||TREATMENT||NONE||In persistent atrial fibrillation patients, traget electrogram was mapped firstly , pulse field ablation of pulmonary veins, posterior wall of left atrium and target electrogram was ablated, until the atrial fibrillation converted to sinus rythm or stable atrial tachycardia. The mapping and ablation procedure was repeated until AF terminated or no target electrogram was found.||||
33844920|NCT06378385|||CASE_ONLY||RETROSPECTIVE|||||||
33844921|NCT02184364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33844922|NCT00717223|||CASE_ONLY||CROSS_SECTIONAL|||||||
33844923|NCT06729749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33844924|NCT01980927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844925|NCT03373721|||COHORT||PROSPECTIVE|||||||
33844926|NCT01711164|||CASE_CONTROL||PROSPECTIVE|||||||
33844927|NCT00223717|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33844928|NCT05913193|||COHORT||PROSPECTIVE|||||||
33844929|NCT03472053|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in 1:1 ratio to either BIO-11006 plus Standard of Care (intervention) or Standard of Care (Pemetrexed plus Carboplatin) (intervention).||||
33949020|NCT05677516|||COHORT||PROSPECTIVE|||||||
33949021|NCT00001256||||TREATMENT||||||||
34155163|NCT01853605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155164|NCT05772013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|OPACE is a double-blind, adaptive design, placebo-controlled phase IV randomized controlled trial.||t|t|t|t
34155165|NCT00543335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155166|NCT03892239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34155167|NCT01012544|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155168|NCT05320003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155169|NCT03466736|||COHORT||PROSPECTIVE|||||||
34155170|NCT00782483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155171|NCT04673539|||OTHER||CROSS_SECTIONAL|||||||
34155172|NCT06366230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155173|NCT02985853|||CASE_CONTROL||PROSPECTIVE|||||||
34155174|NCT02973854|||CASE_ONLY||PROSPECTIVE|||||||
34155175|NCT04660396|||COHORT||PROSPECTIVE|||||||
34155176|NCT03720288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155177|NCT03408184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel Assignment|f|f|f|t
34155178|NCT05825976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155179|NCT06358092|||COHORT||PROSPECTIVE|||||||
34155180|NCT03094715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, open label, blinded endpoint (PROBE), European, two-arm, randomized, controlled, post-market study|f|f|f|t
34155181|NCT01999725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155182|NCT03463603|||COHORT||CROSS_SECTIONAL|||||||
34155183|NCT01301170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155184|NCT03420885|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was a single-blind controlled trial in which the outcome assessor was blinded to group allocation.|A total of 60 patients were divided into a treatment group and a control group, with 30 cases in each group. The control group received health education，and the treatment group was treated with Ba Duan Jin plus health education program.|f|f|f|t
34155185|NCT03945149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||"This safety and tolerance study is designed as a monocentric, randomized, parallel arms, double-blind, placebo-controlled clinical trial.~Three visits planned: a screening visit (V0) for subjects selection, a randomization visit (V1 with product dispensation, 2 weeks after V0) and a end-of-study visit (V2, 5 weeks after V1). between V1 and V2, a telephone interview will be organized with each subject to evoke the tolerance of the product at mid-term.~An additional end-of-study visit could be planned if the biological results of the V2 visit are not satisfactory, according to the opinion of the investigator."|t|t|t|t
34155186|NCT05185414|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Diagnostic track: apply rna sequencing on lissencephaly patients without genetic diagnosis to establish diagnosis~Research track: apply rna sequencing on lissencephaly patient with an established genetic diagnosis to investigate additional diagnositc yield, suited sampling tissue and rna patterns"||||
34155187|NCT05475236|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will not be told which group (tDCS or sham) they are assigned to. Outcomes Assessors will not be told which group the participant was randomized to.|Participants will randomized to either receive transcranial direct current stimulation (tDCS) or sham|t|f|f|t
34155188|NCT06228859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155189|NCT03387358|||OTHER||OTHER|||||||
34155190|NCT03104257|||OTHER||OTHER|||||||
34155191|NCT02332291|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34155192|NCT00156390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155193|NCT00186901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155194|NCT04726228|||COHORT||PROSPECTIVE|||||||
34155195|NCT01068769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155196|NCT06016868|||COHORT||PROSPECTIVE|||||||
34155197|NCT04929080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155198|NCT05126849|NA|SINGLE_GROUP||OTHER||NONE||||||
34155199|NCT05463250|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34155200|NCT06259175|||OTHER||OTHER|||||||
34155201|NCT00691743|||CASE_ONLY||CROSS_SECTIONAL|||||||
34155202|NCT01161537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34155203|NCT01301859|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34155204|NCT00741442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155205|NCT02681315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155206|NCT04649177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155207|NCT06002516|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter randomized controlled open-label superiority trial, with two parallel arms, usual care (control arm) versus the RELIEF pathway (intervention arm). Patients will randomly be assigned (1:1) to usual care or the RELIEF pathway with use of stratification for disease severity, age and sex.||||
34155208|NCT04412707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155209|NCT06423131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||TCRαβ depleted HSCT compare to traditional Beijing haploidentical HSCT||||
33844930|NCT05316623|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|Quadruple blind|One placebo group and one intervention group|t|t|t|t
33844931|NCT03788603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155210|NCT02327988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155211|NCT06583954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34155212|NCT01959438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155213|NCT01776723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155214|NCT04976361|NA|SINGLE_GROUP||OTHER||NONE||||||
34155215|NCT04138290|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study is designed as an open label, one arm study||||
34155216|NCT02211066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155217|NCT06526091|||COHORT||PROSPECTIVE|||||||
34155218|NCT06077942|||OTHER||RETROSPECTIVE|||||||
34155219|NCT04790071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomised controlled|f|f|f|t
34155220|NCT00983385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155221|NCT02221388|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155222|NCT04152798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155223|NCT00028327|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34155224|NCT06584019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34155225|NCT03296943|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The containers for essential oil and perfume are identical dark-glass tubes with a roll-on-cap on top and double-covered with a plain cap on each tube.||t|t|t|t
34155226|NCT01114438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844932|NCT05145153|||COHORT||PROSPECTIVE|||||||
33844933|NCT01854138|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844934|NCT00031642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844935|NCT01169740|||COHORT||PROSPECTIVE|||||||
33844936|NCT04321668|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Proof of Concept (PoC), monocentric, non-comparative, interventional trial||||
33844937|NCT03243682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155227|NCT06584032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155228|NCT06203769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155229|NCT03603106|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||TRIPLE||"Part I: Sequential administration within each group of healthy subjects was established.~Part II: The administration to patients within the same day was sequential to ensure the well-being of the patients. At least a 1-hour interval between 2 administrations had to be respected."|t|t|t|f
34155230|NCT01150565|NON_RANDOMIZED|PARALLEL||||NONE||||||
34155231|NCT01879943|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34155232|NCT04014569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155233|NCT06426914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155234|NCT02683642|||OTHER||PROSPECTIVE|||||||
34155235|NCT03273309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34155236|NCT03524638|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155237|NCT02056327|||CASE_ONLY||CROSS_SECTIONAL|||||||
34155238|NCT00446082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155239|NCT05477797|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly divided into two groups（Id，Rd）after risk stratification.||||
34155240|NCT00577499|||CASE_ONLY||PROSPECTIVE|||||||
34155241|NCT04892927|||COHORT||CROSS_SECTIONAL|||||||
34155242|NCT02655575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155243|NCT06481566|NA|SINGLE_GROUP||TREATMENT||NONE||Almonertinib Combined With Upfront Stereotactic Ablative Body Radiotherapy for Residual Primary Lung Lesions||||
33949022|NCT01566747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949023|NCT06546995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949024|NCT04009122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949025|NCT00475527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949026|NCT04742439|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33949027|NCT06450990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This clinical trial is an Interventional, phase I-II, randomized, double-blind, parallel assignment, placebo-controlled, multiple-dosing regimen. The hypothesis of the trial is the superiority of the active treatment (dose #1 and/or dose #2) versus the placebo.|t|t|t|t
33949028|NCT06704516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949029|NCT04519827|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33949030|NCT06723535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949031|NCT04435652|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The first stage is a single-arm clinical trial, and the second stage is a controlled clinical trial.||||
33949032|NCT04221373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors are not part of intervention. They will not know which group participants will be in.|A two-group, single blinded (raters are not part of intervention) and randomized clinical trial (RCT) with stratification for traumatic or non-traumatic injury will be performed. A total of 30 people with non-progressive SCI, who are over 18 years and eligible for locomotor training as part of acute inpatient rehabilitation (AIR) will be randomized. We expect to recruit, consent, and screen 40 people to accommodate a 25% drop-out rate due to unpredictability during inpatient stay for a target sample of 30 participants to complete the protocol. Eligible participants will be randomized into either the intervention group or the control group. Each group will have 15 participants stratified for 7 having traumatic and 8 having non-traumatic etiologies|f|f|f|t
33949033|NCT02477319|||OTHER||PROSPECTIVE|||||||
33949034|NCT06058572|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Interventional Arm : Tab Rifaximin 200 mg along with allogeneic stem cell transplant~Standard Arm : Allogeneic stem cell transplant alone (with no anti-microbial prophylaxis)"||||
33949035|NCT02139020|||COHORT||PROSPECTIVE|||||||
33949036|NCT06723938|||COHORT||OTHER|||||||
33949037|NCT02806206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33949038|NCT00020995|RANDOMIZED|||PREVENTION||||||||
33949039|NCT04717310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949040|NCT01413373|||COHORT||RETROSPECTIVE|||||||
33949041|NCT01545375|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33949042|NCT06722690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949043|NCT04822701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This trial consists of two phases:~Exploratory Phase II:~Randomised, double-blind, placebo controlled, doubledummy,Phase II, parallel group design comparing different doses and modes of administration of BI 767551 to placebo.~Confirmatory Phase III:~Randomised, double-blind, placebo-controlled, parallel group, Phase III comparing BI 767551 to placebo."|t|t|t|t
33949044|NCT05570721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be exposed to a mental stress task (the TSST)||||
33949045|NCT03873662|||COHORT||PROSPECTIVE|||||||
33949046|NCT02721043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949047|NCT03252808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949048|NCT03871231|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Non-randomized, non-blinded, prospective, single-arm, acute, early-feasibility study||||
33949049|NCT04691674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949050|NCT05975762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949051|NCT02516462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949052|NCT02779842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155244|NCT03067623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155245|NCT01069705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155246|NCT01948063|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34155247|NCT01463202|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155248|NCT00064051||||TREATMENT||NONE||||||
34155249|NCT01512992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34155250|NCT06583486|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Single-arm and long-term follow-up||||
34155251|NCT04038567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|PIs and analysts blinded to allocation. Outcomes completed by participants using web-based interface and thus outcomes assessors as such are blinded.|Factorial experimental trial as part of a multi-phase optimization strategy (MOST) design|f|f|t|t
34155252|NCT06072079|||COHORT||OTHER|||||||
34155253|NCT06130462|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34052068|NCT04303026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The treatment and placebo is administered through an infusion. Both will be administered in an identical infusion bag and are colorless. The mixing is performed by the same person who randomizes, less than 24 hours before administration. The bags are then put in a refrigerator and picked up later by a study nurse for administration. There is no personal contact."|70 participants are allocated randomly to either treatment group or placebo group by a member not part of the study group through an internet based website (Studyrandomizer.com) Participants cannot cross over, but they can withdraw from the study or treatment/Placebo or request alternate treatment (surgery)|t|t|t|f
34052069|NCT02207842|||COHORT||PROSPECTIVE|||||||
34052070|NCT05069402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The physician is unaware of the type of the intervention. The type of intervention is given by the independent person to dietitian instructing the patient how to use the product.|randomisation into 3 arms|f|t|t|t
34052071|NCT04016779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052072|NCT02329067|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34052073|NCT01048775|||COHORT||PROSPECTIVE|||||||
34052074|NCT02880774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052075|NCT06668454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052076|NCT05793450|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052077|NCT02344251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34052078|NCT02269228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34052079|NCT02663102|||OTHER||PROSPECTIVE|||||||
34052080|NCT01773161|||COHORT||PROSPECTIVE|||||||
34052081|NCT06025513|NA|SINGLE_GROUP||TREATMENT||NONE||Pre / Post comparison with device treatment for 16 weeks.||||
34155254|NCT05845853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomly assigned into one of the two groups. We will use a simple randomization method to allocate participants to the groups. A random number generator available online from www.randomization.com will be used.|This will be a double blinded, randomized, controlled, pre-post test clinical trial|t|f|t|f
34155255|NCT05533320|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33844938|NCT00680446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155256|NCT03665272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155257|NCT05360719|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Outcomes assessor collecting data will be masked to group (wait list control vs immediate group)|waitlist control repeated measures|f|f|f|t
34155258|NCT01605110|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33949053|NCT00006354||||TREATMENT||||||||
34155259|NCT01978223|||CASE_CONTROL||PROSPECTIVE|||||||
34155260|NCT03612765|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33949054|NCT05315687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949055|NCT04667208|||OTHER||CROSS_SECTIONAL|||||||
33949056|NCT00811499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949057|NCT02992743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949058|NCT00273260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949059|NCT03142230|RANDOMIZED|PARALLEL||OTHER||SINGLE|The statistician is not aware of the control and experimental arms, called arms A and B in the results he must analyze.|Prospective, controlled, randomized, multicentric, open-label, randomized study|f|f|f|t
33949060|NCT03997383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949061|NCT01961310|||COHORT||CROSS_SECTIONAL|||||||
33949062|NCT01715493|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33949063|NCT00753402|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34155261|NCT00432770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33949064|NCT01768169|||COHORT||PROSPECTIVE|||||||
34155262|NCT01623869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052082|NCT05500638|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|At the end of the study, the data of the participants at T0, T1 and T2 times were recorded and stored by the system. The participants, the researcher and the instructor who made the statistics did not see the results of the research.|A total of two groups as 1 intervention (virtual reality) and control group (usual care)|t|f|t|t
34052083|NCT01623843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052084|NCT03290456|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34052085|NCT00761670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052086|NCT06277271|NA|SINGLE_GROUP||OTHER||NONE||||||
34052087|NCT01469832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155263|NCT01642108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052088|NCT06223971|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155264|NCT02446080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155265|NCT02202369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155266|NCT00547027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155267|NCT01357460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844939|NCT04996732|||COHORT||PROSPECTIVE|||||||
33844940|NCT03825731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844941|NCT06607978|||CASE_CONTROL||RETROSPECTIVE|||||||
33844942|NCT00396019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844943|NCT04422327|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study, with intervention period followed by follow-up (wash out) period.||||
33844944|NCT06611007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844945|NCT01630421|||FAMILY_BASED||PROSPECTIVE|||||||
33844946|NCT00329147|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844947|NCT04245943|NA|SINGLE_GROUP||OTHER||NONE||||||
33844948|NCT05310305|||COHORT||RETROSPECTIVE|||||||
33844949|NCT01631227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844950|NCT04136821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, parallel, randomized, placebo-controlled trial|t|f|t|t
33844951|NCT04059627|NA|SINGLE_GROUP||OTHER||NONE||Twelve community-dwelling adults who are also active member of cardiac rehab support group, aged above 50, and undergone coronary revascularisation for acute myocardial infarction at least 1 year before were recruited.||||
33844952|NCT00419081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052089|NCT06666686|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33844953|NCT06409429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844954|NCT00453193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949065|NCT02190162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33949066|NCT03491982|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33949067|NCT05420610|||CASE_CONTROL||RETROSPECTIVE|||||||
34155268|NCT03669289|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-post within-subject design||||
34155269|NCT06187077|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155270|NCT01041521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155271|NCT06526559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization is done using a web-based platform, group assignment will only be known to the surgeon (care provider). It would be concealed to the patient, investigator, and outcomes assessor||t|f|t|t
33949068|NCT05986708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34155272|NCT05042284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155273|NCT00006196|RANDOMIZED|||DIAGNOSTIC||DOUBLE||||||
34155274|NCT00411814|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34155275|NCT00695422|||COHORT||PROSPECTIVE|||||||
34155276|NCT03916081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155277|NCT02012712|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155278|NCT03735108|||CASE_CONTROL||PROSPECTIVE|||||||
33949069|NCT02043002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949070|NCT02160769|||CASE_CONTROL||PROSPECTIVE|||||||
33949071|NCT05499052|||COHORT||PROSPECTIVE|||||||
33949072|NCT06724094|||CASE_CONTROL||RETROSPECTIVE|||||||
33949073|NCT02583854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949074|NCT05585008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949075|NCT01343238|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33949076|NCT00364338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155279|NCT06484907|||OTHER||PROSPECTIVE|||||||
33949077|NCT00538460|||COHORT||PROSPECTIVE|||||||
33949078|NCT02155816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949079|NCT05140902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155280|NCT00557453|||CASE_CONTROL||PROSPECTIVE|||||||
34155281|NCT06356389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind||t|f|t|f
34155282|NCT03364738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155283|NCT05094908|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open, randomized, non-comparative, exploratory study with two arms. After the informed consent process and the verification of eligibility criteria, the volunteers will be randomly assigned to one of the interventions (30- or 45-day arnica tincture regimen) of the study.~All individuals will have a telephone follow-up in the middle of the treatment, in addition, follow-up visits will be made at the end of the therapy, on day 45 post-treatment ± 5 days, on day 60 post-treatment ± 5 days (optional visit), on days 90 post-treatment ± 14 days and 180 days post-treatment-14 + 28 days to evaluate the therapeutic response. The participant will keep a record of the daily application (morning, afternoon and evening) of the study medication to document its application."||||
34155284|NCT00627055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155285|NCT05080374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155286|NCT03366467|RANDOMIZED|CROSSOVER||OTHER||NONE||The participants will be randomly assigned into two groups. Group 1 will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2). For the second group, the procedure is reversed (RDE at Time 1 and SADE at Time 2).||||
34155287|NCT04039308|||CASE_ONLY||RETROSPECTIVE|||||||
34155288|NCT06224231|||COHORT||PROSPECTIVE|||||||
34155289|NCT03696589|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm cohort study with pre and post intervention assessments||||
34155290|NCT06526052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Independent evaluators will be unaware (masked) of the condition to which participants are randomized.|Participants are randomly assigned to one of three conditions in parallel for the duration of the study|f|f|f|t
34155291|NCT06153407|||COHORT||PROSPECTIVE|||||||
34155292|NCT00005824||||TREATMENT||NONE||||||
34155293|NCT02776254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155294|NCT03182907|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34155295|NCT03534622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155296|NCT05791240|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155297|NCT04635514|||CASE_ONLY||PROSPECTIVE|||||||
34155298|NCT00085449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155299|NCT02518373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155300|NCT04623229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155301|NCT00378053|||DEFINED_POPULATION||OTHER|||||||
34155302|NCT03964688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blind placebo-controlled randomized trial|t|t|t|t
34155303|NCT05977088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155304|NCT03954119|||COHORT||PROSPECTIVE|||||||
33949080|NCT04021602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949081|NCT02905084|||COHORT||PROSPECTIVE|||||||
33949082|NCT02501642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949083|NCT05707546|||OTHER||CROSS_SECTIONAL|||||||
33949084|NCT05059431|||CASE_ONLY||PROSPECTIVE|||||||
33949085|NCT02184234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949086|NCT00449735|||COHORT||RETROSPECTIVE|||||||
33949087|NCT06723353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949088|NCT01360411|||CASE_ONLY||PROSPECTIVE|||||||
33949089|NCT06123598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be assigned to one of two study groups by the person conducting the intervention.~All participants receive mental practice (real or sham) and the exercise program.~The evaluators are unaware of the assignment at all times."||t|f|t|t
33949090|NCT06713655|||COHORT||PROSPECTIVE|||||||
33949091|NCT03664700|||COHORT||PROSPECTIVE|||||||
33949092|NCT02491333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949093|NCT04624295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949094|NCT05371340|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Double blind placebo controlled|t|f|t|t
33949095|NCT01585285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949096|NCT03442270|||OTHER||PROSPECTIVE|||||||
34155305|NCT05061628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949097|NCT06722118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, randomized, double-blind, placebo-controlled study|t|t|t|t
34155306|NCT00456651|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155307|NCT00459654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155308|NCT01323140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155309|NCT02731612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155310|NCT05890469|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34155311|NCT06584162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155312|NCT03936647|RANDOMIZED|PARALLEL||TREATMENT||NONE||Standard best conventional treatment option (surgical or endovascular) vs WEB embolization device||||
33949098|NCT04786327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949099|NCT05141422|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study is a single-centre, single-arm, open-label and fixed-sequence clinical trial.||||
33949100|NCT01404104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949101|NCT06217601|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949102|NCT01345227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949103|NCT06724406|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34052090|NCT06500065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052091|NCT04971148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients will be randomized to receive different HFNC flow settings (matching their peak tidal inspiratory flow \[PTIF\], 1.33 times of PTIF, 1.67 times of PTIF and 2 times of PTIF)||||
34052092|NCT03432793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052093|NCT00825461|||CASE_CONTROL||PROSPECTIVE|||||||
34052094|NCT01188824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052095|NCT03654716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052096|NCT06338488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In the dry needling application, patients will be blinded to the groups they are randomized into. The evaluator will also be unaware of which group the patients belong to. The practitioner will perform the procedures in both groups using ultrasound guidance, targeting the standard trigger points in the painful shoulder's trapezius and infraspinatus muscles in the study group, and targeting subcutaneous fatty tissue in the same regions in the sham group.|Prospective double-blind randomized sham-controlled study.|t|f|t|t
34052097|NCT03788408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052098|NCT06601569|||OTHER||CROSS_SECTIONAL|||||||
34052099|NCT02409563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34052100|NCT01708486|||||PROSPECTIVE|||||||
34052101|NCT05468242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052102|NCT03474016|||OTHER||OTHER|||||||
34052103|NCT01348308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052104|NCT04257032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052105|NCT04519320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052106|NCT02760836|||CASE_ONLY||PROSPECTIVE|||||||
34052107|NCT04084834|NA|SINGLE_GROUP||TREATMENT||NONE||A pre-post single arm feasibility study||||
34052108|NCT02891434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052109|NCT03473366|RANDOMIZED|CROSSOVER||OTHER||NONE||The sequence of standard vs Tao mask will be determined by random number generator. Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication. The duration of the study procedures is variable but would last approximately 30-60 seconds, seldom exceeding 5 minutes additional time to the study patient from what is necessary in a non-study patient. The number of ventilations to achieve adequate ventilation is variable with both the standard mask and the Tao mask. After grading mask ventilation the study intervention is complete and the remainder of surgical and anesthesia care will be based on the clinical needs and decisions of the care team.||||
34052110|NCT02643797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052111|NCT01859117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052112|NCT05848492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052113|NCT02982174|||COHORT||PROSPECTIVE|||||||
34052114|NCT01710189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052115|NCT03788434|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|To reduce potential bias and increase study data integrity, study participants, care providers, site investigators, and study outcomes assessors were masked to study treatment assignment.|"This Phase 2 study evaluated the safety and efficacy of the study drug, VE303, at preventing subsequent CDI-associated diarrhea compared with placebo, following completion of at least 1 successful course of SOC antibiotics for subjects with pCDI at high risk for recurrence or subjects with rCDI.~Participants in the study were randomized into 3 arms in a 1:1:1 ratio of high dose VE303, low dose VE303, and placebo."|t|t|t|t
34052116|NCT05591222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052117|NCT01343277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052118|NCT05102474|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052119|NCT05280457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052120|NCT06251635|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants will be masked to:~1. Knowing whether they were assigned to the olanzapine or placebo conditions~2. Knowing the order of the intranasal spray condition (insulin or placebo).~Investigators will know when participants receive oral olanzapine or placebo and intranasal insulin or saline (required in order to schedule study assessments, and given the order of assessments on the MRI day). A separate staff member who is unaware of drug condition will administer cognitive assessments to mitigate bias of these outcomes."|This study will follow a single-blind, crossover design wherein each participant will complete an MRI based protocol of brain insulin action. Participants will take part in two research visits during the follicular phase of their menstrual cycle (i.e., between day 4-10 of their menstrual cycle) and two visits during the luteal phase (between day 16-22, or within 5 days of next expected menses depending on individual cycle duration). In each cycle phase, participants will be given two doses of either oral olanzapine or oral placebo. After an overnight fast, fasting bloodwork will be obtained, followed by two MRI scans: one with intranasal placebo and one with intranasal insulin challenge (160 IU; 80 IU per nostril). Between scans they will have a short break and be asked to complete cognitive assessments/questionnaires.|t|f|f|t
34052121|NCT06482684|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052122|NCT00287196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155313|NCT04651127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155314|NCT01770015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155315|NCT03723109|||COHORT||PROSPECTIVE|||||||
34155316|NCT06118957|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155317|NCT04563988|||OTHER||RETROSPECTIVE|||||||
34155318|NCT01366729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34155319|NCT02518191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155320|NCT03170193|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Within each dose cohort participants were randomized in a 3:1 ratio to receive either AMG 529 or placebo.|t|t|t|t
34155321|NCT03784807|||CASE_CONTROL||PROSPECTIVE|||||||
34155322|NCT04941846|||COHORT||RETROSPECTIVE|||||||
34155323|NCT05145244|||COHORT||PROSPECTIVE|||||||
34155324|NCT03964402|||OTHER||PROSPECTIVE|||||||
34155325|NCT00393614|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34155326|NCT01616368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155327|NCT05700227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155328|NCT00377364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155329|NCT05392803|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The Investigational Drug Service will create the randomization tables and provide the investigators with the appropriate device (active or sham), leaving all participants, investigators, and the statistician masked to treatment group assignment.|Participants will be randomized to either active or sham treatment for 30 days; and will then crossover and receive the alternative treatment for 30 additional days. The primary analysis will compare the initially-randomized active and sham treatment groups--thus, a parallel group (inter-participant) comparison; but secondary analyses will compare intra-participant changes as well.|t|t|t|t
34155330|NCT03739515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"To minimise the possibility of selection bias, a person independent of the recruitment process will complete random group allocation. Computer generated random numbers will be created and placed in sealed envelopes by this independent person. These numbers will be stored in the pre-sealed envelopes in a locked drawer in the Health Research Institute at the Clinical Education and Research Centre (CERC). Allocation will be revealed after recruitment by a telephone call from the dedicated research nurse to this independent person, who will open the next envelope in the sequence and give the randomisation information to the research nurse. Each envelope will be opened on enrolment of an eligible participant. After allocation is revealed, the appropriate intervention will be organised by the team.~In addition, the outcome assessment will be conducted by a research nurse blinded to the patient allocation in order to reduce potential detection bias."|Eligible participants will be randomly assigned to either the experimental group (ED-based HSCP intervention) or the control group (ED routine care). By assigning participants at random, it is possible to infer that any observed group differences are attributable to the independent variable (the intervention under investigation).|f|f|f|t
34155331|NCT05172089|||OTHER||PROSPECTIVE|||||||
34155332|NCT01710098|||CASE_CONTROL||PROSPECTIVE|||||||
34155333|NCT02458443|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34155334|NCT06523244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949104|NCT03816969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|An online randomization program (http://www.randomizer.org) will be used to generate random list and to allocate patients into the study groups. Random allocation numbers will be concealed in opaque closed envelops. The patient and investigator assessing study outcomes will all be blinded to the study groups allocation.|It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube, a communication orifice at the junction of the peri-glottic cuff and the airway tube. This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation.|t|f|t|f
33949105|NCT06085222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949106|NCT05731830|||CASE_CROSSOVER||OTHER|||||||
33949107|NCT06175052|NA|SINGLE_GROUP||OTHER||NONE||||||
33949108|NCT03748628|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949109|NCT04585828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949110|NCT03093480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949111|NCT01899573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949112|NCT03096899|||CASE_ONLY||PROSPECTIVE|||||||
33949113|NCT02319642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949114|NCT03131531|||COHORT||PROSPECTIVE|||||||
33949115|NCT01418066|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33949116|NCT03914456|NA|SINGLE_GROUP||TREATMENT||NONE||Seven SCI patients with ASIA C and D participated in this study. They were submitted to a motor-task functional magnetic resonance imaging study (fMRI) before and after the rehabilitation treatment.||||
33949117|NCT00926146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949118|NCT04971486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33949119|NCT05780359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949120|NCT04550143|||COHORT||PROSPECTIVE|||||||
33949121|NCT04298307|||COHORT||PROSPECTIVE|||||||
33949122|NCT06426680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949123|NCT04637087|NA|SINGLE_GROUP||SCREENING||NONE||||||
33949124|NCT02906319|||CASE_ONLY||CROSS_SECTIONAL|||||||
34052123|NCT02233296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34052124|NCT02111785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949125|NCT06234566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949126|NCT02722902|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34155335|NCT04077931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The women were randomly assigned to the treatment group(A) (n=25) or the control group (B) (n=25) by an independent person who selected numbers from sealed envelopes that containing numbers chosen by a random number generator.|To investigate the blood oxygenation response to aerobic and breathing exercises in pregnant women. Participants and methods: A total of forty pregnant women participated in the study who were at the beginning of 3rd trimester. Their ages ranged from 25 to 30 years and their body mass index (BMI) was less than 30 kg/m2. They were assigned into two groups (A) performed aerobic exercises in a form of walking for 20-30 min. on treadmill at 60-75% of the target heart rate (THR) of each women, 3 times per week in addition to deep breathing exercises in form of diaphragmatic and lateral costal breathing, group (B) who performed deep breathing exercises only in form of diaphragmatic and lateral costal breathing. The program continued for 3 months, 3 times per week. The oxygen saturation (SaO2) was measured twice time firstly, at the beginning of 3rd trimester of pregnancy then after 3 months that at 24, 36 gestation weeks.|f|f|f|t
33949127|NCT00810654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949128|NCT06518616|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33949129|NCT05350761|||FAMILY_BASED||OTHER|||||||
33949130|NCT06713460|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the difficulty of masking conditions, the groups and participating personnel (research team) will not be blinded.|Participants will be randomly assigned to either the control or intervention group by an external investigator through computer-generated random numbers.||||
33949131|NCT04004975|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|one-armed controlled clinical trial||||
33949132|NCT02115802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949133|NCT03955874|||COHORT||PROSPECTIVE|||||||
33949134|NCT01999959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052125|NCT06667050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949135|NCT03339999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949136|NCT03899038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052126|NCT06668805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052127|NCT01197625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052128|NCT06663956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052129|NCT05318092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052130|NCT00630721|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34052131|NCT06337890|||CASE_CONTROL||PROSPECTIVE|||||||
34052132|NCT01287949|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34052133|NCT03279939|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34052134|NCT02855229|||COHORT||CROSS_SECTIONAL|||||||
34052135|NCT03224416|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Masking only applies to those participants who are randomly assigned to the placebo condition, which is described in detail above.|"The alcohol/placebo/nonalcohol design involves three conditions. In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence. In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims. In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions."|t|f|f|f
34052136|NCT01598090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052137|NCT06544096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052138|NCT04915768|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34052139|NCT02339324|NA|SINGLE_GROUP||TREATMENT||NONE||PI will be leaving this institution and has elected to close this trial to accrual||||
34052140|NCT04460625|||COHORT||RETROSPECTIVE|||||||
34052141|NCT04411277|||COHORT||PROSPECTIVE|||||||
34052142|NCT06126029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155336|NCT03102268|||COHORT||PROSPECTIVE|||||||
34155337|NCT03172130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155338|NCT05765786|||COHORT||PROSPECTIVE|||||||
34155339|NCT04798716|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Open-label for the first 15 patients treated in dose escalation.~The final 40 participants are included in RCT. Double; participant and physician are masked."|Nested Cohort with Escalating Dose. The trial has three cohorts of 5 patients each. The subsequent cohort will receive an escalating dose of exosomes via intravenous infusion. The final group of 40 participants will be randomized 1:3 (placebo:intervention).|t|t|f|f
34155340|NCT01407445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155341|NCT03546088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155342|NCT01209221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155343|NCT05243589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded||f|f|f|t
34155344|NCT01727336|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part 1 of the study involved a dose escalation phase to select a dose for Part 2 of the study. In Part 1, a total of 29 subjects escalated through 3 dose levels of dalantercept: 0.6, 0.9 and 1.2 mg/kg once every 3 weeks. In Part 2, dalantercept (0.9 mg/kg once every 3 weeks) plus axitinib 5 mg PO BID) was compared with placebo plus axitinib 5 mg PO BID. Part 2 enrolled 131 subjects for a total of 160 subjects in the study|t|t|t|t
34155345|NCT03502174|||COHORT||PROSPECTIVE|||||||
34155346|NCT03642730|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Masking is not applicable, since software study|||||
34155347|NCT02013245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155348|NCT05433597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052143|NCT04699513|RANDOMIZED|PARALLEL||PREVENTION||NONE||a randomized controlled trial||||
34052144|NCT00937586|||COHORT||PROSPECTIVE|||||||
34052145|NCT00002059||||TREATMENT||DOUBLE||||||
34052146|NCT02676817|||CASE_CONTROL||PROSPECTIVE|||||||
34052147|NCT04858490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052148|NCT06587191|||OTHER||RETROSPECTIVE|||||||
34155349|NCT05800912|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessor was blinded to group allocation. A blinded assessor collected all baseline and post-intervention measures and entered the data.||f|f|f|t
34155350|NCT01534195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155351|NCT02101489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844955|NCT06729788|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|For the application of ICON, The cleaned fissure was etched using an Icon-Etch in its special syringe for 2 minutes. Then the tooth was rinsed off using water for at least 30 seconds and dried with oil-free and water-free air. Followed by application of the Icon-Dry applied into the fissure and let sit for 30 seconds. The excess of the Icon-Dry was removed and dried with oil-free and water-free air.an ample amount of Icon-Infiltrate is applied into the fissure away from the direct light of the dental unit and let sit for 3 minutes. After excess removal, it will be cured with a light source\* according to the manufacturer's instructions. A second layer of the Icon Infiltrate was applied and cured in the same way.||t|f|t|t
33844956|NCT02285153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind||t|t|t|t
33844957|NCT03517865|||COHORT||OTHER|||||||
33844958|NCT06197984|||COHORT||PROSPECTIVE|||||||
33844959|NCT04094688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33844960|NCT06513065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33844961|NCT01998074|NA|SINGLE_GROUP||TREATMENT||||||||
33844962|NCT02028078|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34052149|NCT00000672||||TREATMENT||||||||
34052150|NCT01133002|||COHORT||PROSPECTIVE|||||||
34052151|NCT04709692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There are 6 treatment arms (three cohorts, each with P. falciparum and P.vivax arms).Cohort progression will be managed independently for each treatment arm. Interim analysis will determine whether the data for each arm meets the success criteria||||
34052152|NCT06668558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||investigator-initiated, multicenter, multicohort, phase II trial||||
34052153|NCT05408871|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with head and neck squamous cell carcinoma who plan to undergo tumor resection and lymph node resection (Aim1). Patients with metastases to the brain from melanoma, lung cancer, breast cancer (Aim 2).12 patients with head and neck cancer will be recruited for Aim 1. 12 patients with brain metastases will be recruited for Aim 2.||||
34052154|NCT00593359|||COHORT||PROSPECTIVE|||||||
34052155|NCT02343445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052156|NCT05733702|||COHORT||PROSPECTIVE|||||||
34052157|NCT04614610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Lidocaine or placebo will be dispensed from the pharmacy in identical bags labeled Lidocaine (x)mg or Placebo. The pharmacy will maintain randomization and blinding until the end of the study."|Patients presenting to the emergency department for an acute sickle cell crisis who are refractory to one dose of intravenous opiate therapy will be randomized to either lidocaine 1.5mg/kg (max: 200mg) or matching dextrose placebo along with either morphine 0.1-0.15mg/kg IV or hydromorphone 0.01-0.02mg/kg IV.|t|t|t|f
34052158|NCT00582504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34052159|NCT06482788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052160|NCT02210130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052161|NCT04286581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Patients who are scheduled for elective ambulatory surgery under general anesthesia will be randomized to one of two groups. Group 1 will receive an I-gel laryngeal mask airway (LMA) and group 2 will receive an Ambu Auragain LMA.|t|f|f|f
34052162|NCT02878265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052163|NCT01246869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052164|NCT05109884|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052165|NCT06623123|RANDOMIZED|PARALLEL||TREATMENT||NONE|researchers to data generated|||||
34052166|NCT05826288|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34052167|NCT06320236|||COHORT||PROSPECTIVE|||||||
34052168|NCT06432075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052169|NCT04339647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster Randomised Controlled Trial|f|f|f|t
34052170|NCT04798729|||COHORT||PROSPECTIVE|||||||
34052171|NCT03253289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052172|NCT01423396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052173|NCT01471340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052174|NCT04079517|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized Clinical Trial|f|t|t|t
34052175|NCT06327503|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052176|NCT01511874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052177|NCT06191328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052178|NCT02272907|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052179|NCT00543517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052180|NCT04588051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052181|NCT06668844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34052182|NCT05061277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052183|NCT00767728|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34052184|NCT05046379|||OTHER||PROSPECTIVE|||||||
34052185|NCT05622058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34052186|NCT01062542|||COHORT||PROSPECTIVE|||||||
34052187|NCT05452499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076409|NCT00366782|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34076410|NCT03064711||PARALLEL||BASIC_SCIENCE||NONE||||||
34076411|NCT05618015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, it is not possible to blind participants or the treating physiotherapist. To reduce the bias risk, the outcome assessor was blinded to treatment allocation.||f|f|f|t
34076412|NCT04038112|NA|SINGLE_GROUP||TREATMENT||NONE||systematic case replication series||||
34076413|NCT03363607|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34076414|NCT01417975|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34155352|NCT05763771|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155353|NCT05852860|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34155354|NCT04048408|||CASE_CONTROL||PROSPECTIVE|||||||
34155355|NCT05405153|||OTHER||CROSS_SECTIONAL|||||||
34155356|NCT00873184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155357|NCT02918357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155358|NCT01659684|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155359|NCT02403401|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155360|NCT04445337|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label use of stellate ganglion block.||||
34155361|NCT03434561|||COHORT||PROSPECTIVE|||||||
34155362|NCT04130698|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34155363|NCT03668093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155364|NCT02331017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155365|NCT05581771|||COHORT||RETROSPECTIVE|||||||
34155366|NCT03249987|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34155367|NCT05377944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155368|NCT05873491|||OTHER||PROSPECTIVE|||||||
34155369|NCT05406869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155370|NCT05329064|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949137|NCT05921851|||CASE_CONTROL||PROSPECTIVE|||||||
33949138|NCT00921141|||CASE_ONLY||PROSPECTIVE|||||||
33949139|NCT05632094|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical controlled randomized clinical trial (phase II) will be conducted in Poison Center. The total required sample size is 40 patients who suffer from acute clozapine intoxication.||||
33949140|NCT04353323|||COHORT||PROSPECTIVE|||||||
33949141|NCT05036876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949142|NCT05180123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949143|NCT05982652|||OTHER||PROSPECTIVE|||||||
33949144|NCT03541616|||COHORT||PROSPECTIVE|||||||
33949145|NCT04231903|||CASE_CONTROL||PROSPECTIVE|||||||
33949146|NCT06519396|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949147|NCT01864746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949148|NCT01682876|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33949149|NCT02710825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949150|NCT03142464|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controls - convention postoperative IV fluids; intervention arm - no IV fluids postoperative||||
33949151|NCT04911361|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, prospective, randomized controlled, open label study of the efficacy of relieving both signs and symptoms of dry eye syndrome in patients with exacerbations of this disease. Patients will be randomized to receive treatment of either Dextenza or loteprednol etabonate 0.5% suspension QID for 2 weeks.||||
33949152|NCT03964142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949153|NCT04754009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949154|NCT00053911|RANDOMIZED|||TREATMENT||||||||
33949155|NCT00618046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949156|NCT05839912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949157|NCT06724861|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The outcome assessor will not be aware of randomization and allocation. Primary investigator and statistician will receive data ready for analysis.|A Randomized Controlled Trial will be conducted in a within-subject cross-over design (AB BA). Full assessments will be conducted at baseline, after last treatment session. A short assessment will be conducted at the beginning of all sessions. The early intervention group (AB) will be assessed at one-month follow-up in addition. The later intervention group (BA) will be assessed at baseline, and after a month before treatment commences and immediately after last treatment|f|f|t|t
33949158|NCT04301024|||OTHER||PROSPECTIVE|||||||
33949159|NCT03960788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949160|NCT02305199|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33949161|NCT02475109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949162|NCT01579682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949163|NCT02427542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949164|NCT03148509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949165|NCT01296581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949166|NCT02087020|||COHORT||RETROSPECTIVE|||||||
33949167|NCT02196025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949168|NCT02740751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33949169|NCT01963910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33949170|NCT04103593|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Exercise trial of 12-weeks high-intensity circuit exercise delivered by VTEL to older Veterans living with HIV that compares exercise group to standard of care sedentary control group|f|t|f|t
33949171|NCT01308476|||||PROSPECTIVE|||||||
33949172|NCT02502916|||COHORT||PROSPECTIVE|||||||
33949173|NCT05879458|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label||||
33949174|NCT03493477|||OTHER||PROSPECTIVE|||||||
33949175|NCT03846960|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||intervention of a device product being evaluated in a small clinical trial to determine the feasibility of the product||||
33949176|NCT00593268|||OTHER||OTHER|||||||
33949177|NCT01283802|||COHORT||PROSPECTIVE|||||||
33949178|NCT03406780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949179|NCT05531916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Evaluator blind design was adopted, and all evaluations were made after the participants had received the intervention and withdrawn the intervention. At this time, the blinded evaluator did not know the tribal groups, while both the participants and researchers knew the trial groups.|The Account and IWRS end of the clinical trial randomization system of Sun Yat-sen University Cancer Center (SYSUCC) randomly determined the limb (left or right) of the participants to receive intervention, and the hand and foot on the same side were classified into the same group during the randomization process.|f|f|f|t
33949180|NCT06256861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34155371|NCT03235089|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both subject and investigator will be masked to lens type for each eye. A different investigator will select the study lenses for insertion by the subject, from those performing the assessments in order to maintain masking.|This will be a non-dispensing, double-masked, contralateral study comparing test contact lens against a nelfilcon A control lens. Subjects will be randomized to wear the test lens in one eye and the control lens in the other. It is anticipated that this study will involve up to 2 scheduled visits, at Baseline (BL) and 6 hours.|t|f|t|f
34155372|NCT01563172|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34155373|NCT05788913|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34155374|NCT06276166|||COHORT||PROSPECTIVE|||||||
34155375|NCT02470884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155376|NCT02077400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052188|NCT06216808|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The HyperQure RDN System consists of a generator that generates RF(Radiofrequency) energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds. The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA.||||
34155377|NCT03513627|||COHORT||PROSPECTIVE|||||||
33949181|NCT01607489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949182|NCT01869959|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33949183|NCT01789307|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33949184|NCT04394299|||CASE_ONLY||RETROSPECTIVE|||||||
34052189|NCT03476408|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33949185|NCT00001568||||TREATMENT||||||||
33949186|NCT00107601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949187|NCT05455294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase 1 study with a dose escalation design and an expansion cohort.||||
34052190|NCT00964990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052191|NCT06445842|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052192|NCT04614922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052193|NCT05044546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052194|NCT03933696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly assigned to receive the active or placebo lighting condition|t|t|f|f
34052195|NCT03677336|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Blinded and packaged medication will be provided to the investigational site and dispensed to the participants. The participants, their treating physicians and the investigators will be blinded for the randomization of subjects to the treatment groups. Of both treatment medications, OD and MVP, a placebo version will be available and administered in both oocyte donation cycles. The medication will be given in a double blind double dummy fashion. All the tablets and capsules will be identical in appearance, shape, smell and taste, and packaged in the proper proportion to assure desired dosages and maintenance of the blinding.|A randomised, cross-over, double blind double dummy study|t|t|t|t
34052196|NCT05238870|||OTHER||PROSPECTIVE|||||||
34052197|NCT06024096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052198|NCT05709028|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label study. Statisticians will be blind to groups when analysing results|Randomised controlled trial with an intervention arm and an active control arm (standard-of care)||||
34052199|NCT01902810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052200|NCT01985607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34052201|NCT02586519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34155378|NCT04981210|||CASE_ONLY||PROSPECTIVE|||||||
34155379|NCT06175624|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||25 patients with periodontitis, 25 with gingivitis and 25 healthy periodontals (total of 75 individuals) will be included in our study. At the beginning of the study, periodontal clinical measurements (gingival index, plaque index, probing depth, gingival recession, clinical attachment level, and bleeding on probing), serum and gingival crevicular fluid samples will be taken from all individuals. Non-surgical periodontal treatment will be applied in quadrant wise within 2 weeks to individuals with gingivitis and periodontitis. 12 weeks after treatment; the clinical measurements and the collection of serum and gingival crevicular fluid will be repeated. Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.|f|f|t|f
34155380|NCT02854748|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155381|NCT01720810|||CASE_ONLY||PROSPECTIVE|||||||
33949188|NCT00766727|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155382|NCT01979458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155383|NCT01006642|||CASE_CONTROL||PROSPECTIVE|||||||
34155384|NCT03483545|NA|SINGLE_GROUP||OTHER||NONE||||||
34155385|NCT03360058|RANDOMIZED|PARALLEL||OTHER||NONE||Primary care practices are either assigned to immediate or delayed access to the online training and print pieces with the delayed group acting as our controls for number of referral to weight management services per practice||||
34155386|NCT00837850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155387|NCT05134480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants and the clinical site staff, including the investigators and outcomes assessor will be masked to all donor tissue parameters except storage solution.|Prospective, randomized, double-masked (participant and clinical site) clinical trial|t|t|t|t
34155388|NCT00901121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155389|NCT00391924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155390|NCT01453608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949189|NCT06149494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949190|NCT06181903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949191|NCT02687724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949192|NCT01400659|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949193|NCT04601389|RANDOMIZED|PARALLEL||OTHER||NONE||Interventional||||
33949194|NCT04651257|||COHORT||PROSPECTIVE|||||||
33949195|NCT04570033|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052202|NCT02357706|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34155391|NCT01189591|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||||||
34155392|NCT00418327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155393|NCT04341948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155394|NCT04369950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155395|NCT03219684|||COHORT||CROSS_SECTIONAL|||||||
34155396|NCT04369976|NA|SEQUENTIAL||PREVENTION||NONE||The use of a short arm human centrifuge intervention program (SAHC) combined with exercise, compared to a standard of care (SOC) rehabilitation program in physically impaired patients with MS, stroke, severe Chronic Obstructive Pulmonary Disease (COPD) and elderly people with balance and gait disorders (risk of falls). The patients will be randomly assigned to the centrifuge training (SAHC intervention), SOC training or a passive control group. The SAHC intervention consists of 3 sessions per week. The session duration is 1 hour. The intervention will last for 3 months.||||
34155397|NCT05194527|||COHORT||PROSPECTIVE|||||||
34155398|NCT01912339|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34155399|NCT03483155|||OTHER||PROSPECTIVE|||||||
34155400|NCT04794075|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Quasi-experiment group||||
34155401|NCT05551884|||COHORT||PROSPECTIVE|||||||
34155402|NCT01496820|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34155403|NCT01423734|||COHORT||PROSPECTIVE|||||||
34155404|NCT01704404|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34155405|NCT06339931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155406|NCT04505579|||COHORT||PROSPECTIVE|||||||
34155407|NCT03750331|RANDOMIZED|PARALLEL||OTHER||NONE||Non-inferiority Randomized Controlled Trial comparing Non-inferiority Randomized Controlled Trial comparing (i) a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule (every other week up to 6 months post-transplant, once a month up to year 1, every three months up to year 2 and every 6 months thereafter) to (ii) a group of patients assisted by Ap'TELACARE and consulting their Transplant Centre following a less stringent schedule of consultations (every month up to 6 months, every other month up to year 1, every six months up to year 2 and once a year thereafter).||||
34155408|NCT06299462|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with a matched sibling donor will be assigned to the PTCy+ATG2.5±1.5 arm, while patients with an matched unrelated donor will be assigned to the PTCy+ATG5.0 arm||||
34155409|NCT01710631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155410|NCT04888013|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34155411|NCT03420833|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants randomly assigned to have CRT-ON or OFF. At 6 months, participant CRT function will be crossed over.|Single-center, randomized cross-over study|t|f|t|f
34155412|NCT02906267|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34155413|NCT00534976|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34155414|NCT03797300|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155415|NCT04354584|||CASE_ONLY||PROSPECTIVE|||||||
34155416|NCT01158391|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155417|NCT00364143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155418|NCT05864937|||CASE_ONLY||RETROSPECTIVE|||||||
34155419|NCT06405477|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34155420|NCT05532904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155421|NCT04059120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The blindness will be on the part of the subjects do not recognize the type of stretching training that is being done|The model of the physical training program to follow is. The subjects will perform a physical exercise for 12 weeks divided into three blocks of 4 periods, organized in 3 weeks of training, plus 1 rest, which simulate physical loads similar to the periods of competition used in high-performance sports. The evaluations will be made prior to the training (basal measurement) and at the end of each of the blocks during the rest period. The physical load will be organized as follows: The control group (CG) will perform muscle strength exercises with intensities of 45 to 90% of 1RM, as well as aerobic resistance with efforts of 60 to 90% of the theoretical maximum heart rate, which will be controlled with a Polar brand heart rate monitor model FT7. Like the CG, the experimental group (EG) will perform the same physical load of muscular strength and aerobic resistance in combination with specific stretching exercises|t|f|f|f
34155422|NCT01805557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155423|NCT03509259|||COHORT||PROSPECTIVE|||||||
34155424|NCT02349685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155425|NCT02292706|||COHORT||PROSPECTIVE|||||||
34155426|NCT06253169|||COHORT||PROSPECTIVE|||||||
34155427|NCT05253781|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind design. An unblinded pharmacist does the drug packaging and has the code for drug identification. All other members of the research team and patients are blinded and do not know what each drug is.|The clinical trial aspect is a multi-centre parallel, double blind, superiority randomized controlled trial, with women allocated in a 1:1 ratio. Participants are randomized into two groups. One group receiving low dose aspirin (LAD) 100mg daily from 12 weeks or from enrollment to 36 weeks gestational age. The second group receives a placebo tablet that looks exactly like the LAD in colour, size and shape also one tablet daily from 12 weeks or from enrollment to 36 weeks gestational age.|t|t|t|t
34155428|NCT05196087|||COHORT||PROSPECTIVE|||||||
34052203|NCT05280925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants assigned to both groups will be masked to experimental hypotheses. Research personnel who will be conducting assessment sessions, including weight and HbA1c measurements, will not be informed of participants' group assignments|24-week remote randomized controlled trial. Analysis plan: repeated measures ANOVA, with group (EFT/control) and area (urban vs. rural) as between-subjects factors, and time (baseline, week 8, and week 24 assessments) as within-subjects factors|t|f|f|t
34052204|NCT05183308|||OTHER||PROSPECTIVE|||||||
34052205|NCT04975750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052206|NCT03459898|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052207|NCT02177903|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052208|NCT06130579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052209|NCT06031688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052210|NCT02256982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052211|NCT05688033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052212|NCT04588870|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34052213|NCT00965341|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34052214|NCT00426296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052215|NCT03467061|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34052216|NCT01676896|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34052217|NCT05204862|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052218|NCT05013151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949196|NCT01980056||SEQUENTIAL||TREATMENT||NONE||Dose level 1: Vosaroxin 50 mg/m\^2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg/m\^2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg/m\^2 IV on Days 1, 4, 8 and 11 of 28 day cycle||||
33949197|NCT00970801|||COHORT||PROSPECTIVE|||||||
33949198|NCT06649786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949199|NCT02031601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949200|NCT04752007|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One group will be measured using conventional RSA and the other using low dose CT.||||
33949201|NCT05825911|||COHORT||PROSPECTIVE|||||||
33949202|NCT02340117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155429|NCT03214068|||CASE_CONTROL||OTHER|||||||
33949203|NCT05128552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33949204|NCT01333501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949205|NCT01917149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949206|NCT03699358|||COHORT||RETROSPECTIVE|||||||
33949207|NCT01132027|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052219|NCT04278651|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34155430|NCT04128735|||COHORT||PROSPECTIVE|||||||
34155431|NCT01204216|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155432|NCT05407857|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"We will avoid all the outcomes assessors knowing the allocation and intervention groups.~The participant will only know what treatment is applied until the start of the intervention. We will also suggest the participants not to discuss their interventions and restrict the chance of communication between different intervention groups."|Three groups (on site intervention group, remote intervention group, and control group)|f|f|f|t
34155433|NCT03147443|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.|randomized, double-blind, crossover comparisons of individualized herbal decoction with control decoction within individual patients. Each n-of-1 trial has 3 pairs of treatment periods. The duration of each treatment period will be 4 weeks.|t|t|f|t
34155434|NCT01058629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155435|NCT05688020|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study is designed as a prospective, double-blinded, controlled, non-inferiority pilot study.|t|t|t|t
34155436|NCT06437470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A triple-blinded randomized controlled trial will be conducted, ensuring that participants, the research assistant (who serves as the examiner for all participants) and the statistician are blinded to the treatment group.||t|f|f|t
34155437|NCT04132596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
34155438|NCT03004755|||COHORT||PROSPECTIVE|||||||
33949208|NCT03950947|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33949209|NCT06158295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949210|NCT02738931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949211|NCT00779857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949212|NCT03704194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized controlled feasibility trial|f|f|f|t
34052220|NCT06187883|||COHORT||RETROSPECTIVE|||||||
34052221|NCT05351879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052222|NCT06665230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052223|NCT06666712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052224|NCT05050123|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052225|NCT01719913|RANDOMIZED|CROSSOVER||||NONE||||||
34052226|NCT03841162|||COHORT||PROSPECTIVE|||||||
34052227|NCT00745238|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34052228|NCT00808639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052229|NCT01754961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052230|NCT06338917|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants in both groups are not aware of the existence of the other group. The health provider in the control group is aware of the existence of the intervention group but does not know which intervention is being carried out.||t|t|f|f
34052231|NCT00723255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052232|NCT03201770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052233|NCT06480721|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be randomised in equal proportions between two arms: the investigational arm and the control arm.||||
34052234|NCT04674917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052235|NCT06280274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
34052236|NCT01033955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052237|NCT01187771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052238|NCT05733143|||CASE_ONLY||PROSPECTIVE|||||||
34052239|NCT00150800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052240|NCT01290679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052241|NCT05212662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052242|NCT01041846|||CASE_ONLY||PROSPECTIVE|||||||
34052243|NCT01878422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052244|NCT06668298|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||All patients who met the inclusion criteria were randomly divided into two groups based on the use of postoperative analgesic pumps: the sufentanil group and the oliceridine group. The sufentanil group received a treatment regimen of sufentanil 2 µ g · kg-1; The treatment regimen for the oliceridine group is oliceridine 0.4mg · kg-1.|t|t|t|t
34052245|NCT05121103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052246|NCT00836888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052247|NCT01542437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949213|NCT00188058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949214|NCT00761462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949215|NCT02857062|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, in use tolerance study in babies and children.||||
33949216|NCT00229931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949217|NCT00696332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949218|NCT01460979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949219|NCT03152721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient not aware of which information has been provided to his/her physician. Post data collection the groups will be assigned coded group names so that the conditions are masked to the assessor.|1:1 randomisation to intervention and control group. The effect of providing the objective measurement and self assessment scales compared to only self assessment scales on the management decisions will be evaluated. A secondary outcome is the ability of the measurement to identify sub-optimally treated individuals in comparison with self assessment scales.|t|f|f|t
33949220|NCT01781130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949221|NCT02772159|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949222|NCT00299624|||COHORT||PROSPECTIVE|||||||
33949223|NCT01300715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949224|NCT06405646|||COHORT||PROSPECTIVE|||||||
33949225|NCT03857165|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind|Single ascending dose with placebo control|t|t|t|t
33949226|NCT00677066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949227|NCT03082040|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33949228|NCT01911546|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949229|NCT05942742|||COHORT||PROSPECTIVE|||||||
33949230|NCT02182726|||COHORT||PROSPECTIVE|||||||
33949231|NCT02472600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949232|NCT02595411|||OTHER||CROSS_SECTIONAL|||||||
33949233|NCT06509438|NA|SINGLE_GROUP||TREATMENT||NONE||before/after clinical trial||||
33949234|NCT04648943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949235|NCT03783026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949236|NCT04869202|||COHORT||PROSPECTIVE|||||||
33949237|NCT04853316|||CASE_CONTROL||PROSPECTIVE|||||||
33949238|NCT01842412|||CASE_CONTROL||PROSPECTIVE|||||||
33949239|NCT04290871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33949240|NCT00802152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949241|NCT03344029|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An observer-blind procedure will be followed in the study such that neither the Investigator, subject, nor the Sponsor will know which vaccine has been administered.|Blind-observer, monocenter, randomized, comparative, Phase IV study|t|f|t|t
33949242|NCT01048710|||COHORT||PROSPECTIVE|||||||
33949243|NCT01258010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949244|NCT02110966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949245|NCT03406286|||CASE_ONLY||PROSPECTIVE|||||||
33949246|NCT05079711|||COHORT||PROSPECTIVE|||||||
33949247|NCT04035707|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|qualification according surgical operation|The study included 126 women given a general volatile anesthesia: group I - 66 - using the rocuronium and group II - 60 - without neuromuscular relaxants. Informations about perioperative fluid therapy and doses of rocuronium were noticed. The blood samples were collected to perform tryptase concentration analysis: preoperatively - before anesthesia and postoperatively - after recovery from anesthesia.|f|f|t|f
33949248|NCT06523348|||COHORT||RETROSPECTIVE|||||||
33949249|NCT04745624|||CASE_CONTROL||RETROSPECTIVE|||||||
33949250|NCT03461393|||COHORT||RETROSPECTIVE|||||||
33949251|NCT05382026|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33949252|NCT04675502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949253|NCT00981695|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33949254|NCT00830726|||CASE_CONTROL||PROSPECTIVE|||||||
33949255|NCT01241591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949256|NCT02430064|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949257|NCT01813162|RANDOMIZED|CROSSOVER||||NONE||||||
33949258|NCT03465215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigators will include 29 CD patients with a symptomatic intestinal stricture requiring surgery. From these patients, the investigators will collect fullthickness surgical specimen from the non-stenotic and stenotic intestinal wall and will perform analysis using digital holographic microscopy and in histopathological analysis.||||
33949259|NCT04326309|||COHORT||PROSPECTIVE|||||||
33949260|NCT01098266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949261|NCT03062748|||CASE_ONLY||CROSS_SECTIONAL|||||||
33949262|NCT03416023|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm multicentre open clinical study||||
33949263|NCT00482976|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33949264|NCT02101957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076415|NCT04391777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34076416|NCT04010461|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All subjects will receive all interventions in a cross-over design. The three intervention sessions (visits 3, 4 \& 5) will be given in counter-balanced order, stratified by gender. Subjects will be blind to the nature of the questions being asked; however, they will be told that different stimulation paradigms will be used, which will be evident to the subjects as they go through the procedures.|All participants will have 3 MRI sessions subsequent to the baseline visit and these will occur in a counterbalanced order.|t|f|f|f
34076417|NCT01096953|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076418|NCT02942069|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076419|NCT02767778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076420|NCT01039766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076421|NCT00424593|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34076422|NCT01495052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34076423|NCT01057667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076424|NCT01157611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076425|NCT03588897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Normal diet versus normal diet + nutritional support in elderly patients||||
34052248|NCT03359668|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The investigator will read the randomized non-contrast CTs separately from the contrast-enhanced CTs|Each patient had CT imaging with and without IV contrast|f|f|t|f
34052249|NCT02805179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052250|NCT00611663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052251|NCT06307756|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34052252|NCT05194761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052253|NCT00522639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052254|NCT06074796|||COHORT||RETROSPECTIVE|||||||
34052255|NCT00832871|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34052256|NCT03417089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34052257|NCT00102531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052258|NCT04544696|||OTHER||CROSS_SECTIONAL|||||||
34052259|NCT02048566|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34052260|NCT00890084|||||PROSPECTIVE|||||||
34052261|NCT03915431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052262|NCT02960165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052263|NCT05864612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The four instrument delivery methods to be used in this pragmatic trial represent distinct prompts \&amp; cues for screening instrument completion. Examining these multiple instrument delivery methods will generate outputs that will support flexibility in instrument delivery modalities across multiple sites in future multicenter studies in this area. These 4 distinct delivery methods are used to deliver identical standard care validated anxiety and depression screening instruments.||||
34052264|NCT05803798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Treatment group = LLLT+IPL (EYE-LIGHT) before laser refractive surgery|f|t|t|f
34052265|NCT06468878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052266|NCT03388645|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34052267|NCT05120531|||CASE_CONTROL||PROSPECTIVE|||||||
34052268|NCT03057054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34052269|NCT06502795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization process will be conducted by a researcher not involved in data collection, using computer-generated random numbers from the Random Allocation Software (version 2.0), in a 1:1 ratio. Randomization codes will be placed in opaque, sequentially numbered envelopes, sealed with a tamper-proof seal, and will be opened only after the envelope has been irreversibly assigned to the participant. The evaluator and the patient will be blinded to the allocation in the experimental and control groups. At the end of the intervention, a masking test will be conducted.|This is a randomized clinical trial with two parallel groups, balanced 1:1 allocation, and double-blind design.|t|f|t|f
34052270|NCT00857168|RANDOMIZED|PARALLEL||||NONE||||||
34052271|NCT06038344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052272|NCT03104049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052273|NCT01140256|||COHORT||PROSPECTIVE|||||||
34052274|NCT02408289|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34052275|NCT05830734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will all receive BCL surgery and all have two small incisions in in the lumbar region with local anesthetic injection and compression bandages. Only the intervention group with have fatty cells harvested and injected in the surgical wound. The out comes assessor is blinded to which treatment has been given.|Double blinded randomized controlled trial|t|f|f|t
34052276|NCT06665698|||COHORT||PROSPECTIVE|||||||
34052277|NCT01337466|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052278|NCT06668233|||COHORT||PROSPECTIVE|||||||
34052279|NCT01300416|||COHORT||PROSPECTIVE|||||||
34052280|NCT04695574|NA|SINGLE_GROUP||OTHER||NONE||Three-blinded, cross-sectional, repeated-measures clinical measurement reliability trial||||
34052281|NCT00537316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052282|NCT03680586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052283|NCT01363453|||CASE_ONLY||PROSPECTIVE|||||||
34052284|NCT03192670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052285|NCT06622902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052286|NCT01883050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052287|NCT06668415|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. Both groups; Group A and B will undergo Hydrodilation but Group A will be followed by Spencer Technique whereas Group B will be followed by Passive Stretching.||||
34052288|NCT05819112|||COHORT||RETROSPECTIVE|||||||
34052289|NCT06617949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052290|NCT04180137|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052291|NCT04737798|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34052292|NCT02593578|||OTHER||PROSPECTIVE|||||||
34052293|NCT02644720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052294|NCT03429244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Two separate Radiologists (one from Nuclear Medicine and one from MRI) will do the imaging reads in a blinded fashion.|68Ga-PSMA-11 PET will be performed and we will study how the knowledge of the results helps inform treatment decisions.||||
34052295|NCT04480671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Postoperative pelvic exams measuring anatomic recurrence of pelvic organ prolapse will be performed by a qualified examiner masked to the original surgery randomization.||f|f|f|t
34052296|NCT03480191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052297|NCT05039814|||CASE_CONTROL||RETROSPECTIVE|||||||
34052298|NCT05761561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34052299|NCT05326347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052300|NCT05813119|||CASE_ONLY||CROSS_SECTIONAL|||||||
34052301|NCT02406079|NA|SINGLE_GROUP||SCREENING||NONE||||||
34052302|NCT00003427||||TREATMENT||||||||
34052303|NCT03528369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052304|NCT05196867|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34052305|NCT01704690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052306|NCT00672581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052307|NCT04809740|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34155439|NCT00496288|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052308|NCT04535531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052309|NCT05484440|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
34052310|NCT05522205|RANDOMIZED|PARALLEL||OTHER||NONE|One group has immediately access to regulated cannabis access in pharmacies and the other group has to wait six months until they have regulated cannabis access.|||||
34052311|NCT01388244|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34155440|NCT03581838|||OTHER||PROSPECTIVE|||||||
34155441|NCT04078581|NA|SINGLE_GROUP||SCREENING||NONE||||||
34155442|NCT01100775|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34155443|NCT04223908|||CASE_CONTROL||RETROSPECTIVE|||||||
34155444|NCT02300740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155445|NCT02445066|NA|SINGLE_GROUP||OTHER||NONE||||||
34155446|NCT00442221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155447|NCT03700437|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155448|NCT05596188|||COHORT||CROSS_SECTIONAL|||||||
34155449|NCT05930691|||CASE_CONTROL||PROSPECTIVE|||||||
34155450|NCT06260306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The PI who will be performing the data analysis will be blinded to participants' random group allocation. The other investigators who will be collecting the outcome data will know the group allocation.||f|f|t|f
34155451|NCT05119400|||COHORT||PROSPECTIVE|||||||
34155452|NCT06525090|||OTHER||CROSS_SECTIONAL|||||||
34052312|NCT01447082|||||RETROSPECTIVE|||||||
34052313|NCT05566574|NA|PARALLEL||TREATMENT||NONE||Single arm, phase I/II trial to assess safety and tolerability of RP-3500 and palliative RT.||||
34052314|NCT03109665|||COHORT||CROSS_SECTIONAL|||||||
34155453|NCT03761342|RANDOMIZED|CROSSOVER||OTHER||SINGLE|While participants will be made aware that there are different versions of NUSMart, the exact details of the arms will not be revealed to ensure validity of results. It will be deleterious to the study to reveal the differences between study arms as that would likely confound participant responses. Since there are 3 shopping conditions (unknown to participants), each participant will be randomly assigned at baseline to 1 of 6 groups that vary the sequence of shopping conditions and which shops will result in an actual food delivery.||t|f|f|f
34155454|NCT04791085|||OTHER||CROSS_SECTIONAL|||||||
34155455|NCT05184816|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label, non-randomized, single-center, dose escalation phase 1a study of intrathecal deferoxamine (IT-DFO) in patients with leptomeningeal metastases (LM) from solid tumor malignancies, followed by a phase 1b dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with LM from solid tumor malignancies.||||
34155456|NCT04694378|||CASE_ONLY||PROSPECTIVE|||||||
34155457|NCT01433094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155458|NCT01303926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155459|NCT02685904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155460|NCT01794676|||FAMILY_BASED||PROSPECTIVE|||||||
34052315|NCT04293029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052316|NCT04245540|NA|SINGLE_GROUP||OTHER||NONE||Single arm, open-label trial evaluating safety and tolerability.||||
34052317|NCT06462950|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34052318|NCT06271707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a double blind randomized prospective controlled trial. Randomization will be 1:1.||t|f|t|t
34052319|NCT06411925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052320|NCT02877810|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34052321|NCT00329537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052322|NCT03917316|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052323|NCT06666218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052324|NCT05283343|||COHORT||PROSPECTIVE|||||||
34052325|NCT03925233|||CASE_ONLY||RETROSPECTIVE|||||||
34052326|NCT01727544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052327|NCT00784303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052328|NCT05845021|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34052329|NCT03310801|||COHORT||RETROSPECTIVE|||||||
34052330|NCT01629290|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34052331|NCT05948501|||CASE_CONTROL||PROSPECTIVE|||||||
34052332|NCT06122870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052333|NCT06592508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052334|NCT00369070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052335|NCT03303573|||COHORT||RETROSPECTIVE|||||||
34052336|NCT01107808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155461|NCT01620762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155462|NCT00118950|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34155463|NCT05196555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155464|NCT05941832|||COHORT||PROSPECTIVE|||||||
34052337|NCT03638999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Prior to initiation of study enrollment, envelopes containing study randomization assignments will be created, sequentially numbered, sealed and given to the study pharmacist. Once a patient provides consent and meets study inclusion and exclusion criteria, study pharmacist will be notified of enrollment and will randomize the patient by opening the next subsequent randomization envelope.|Participants will be randomized in 1:1 ratio to either intervention or control group. Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml, whereas subjects in the control group will receive 1 ml of 0.9% injectable normal saline, prior to the start of the procedure. Study team, with the exception of the pharmacist, will be blinded to randomization results.|t|t|t|f
34155465|NCT03588936|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155466|NCT05282433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155467|NCT04995861|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34155468|NCT01329939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155469|NCT04386135|||COHORT||PROSPECTIVE|||||||
34155470|NCT00532506|RANDOMIZED|PARALLEL||||DOUBLE||||||
34052338|NCT00831714|||COHORT||PROSPECTIVE|||||||
34052339|NCT06668636|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will employ an interrupted time series design.||||
34155471|NCT03488277|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34155472|NCT02006849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155473|NCT00855972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155474|NCT02036008|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34155475|NCT03992443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155476|NCT04090619|||CASE_ONLY||PROSPECTIVE|||||||
34155477|NCT04942405|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34155478|NCT03208088|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34155479|NCT03997110|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, Randomized, Active Controlled Trial||||
34155480|NCT03800511|||CASE_ONLY||PROSPECTIVE|||||||
34155481|NCT04957368|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34155482|NCT02213484|||COHORT||PROSPECTIVE|||||||
34155483|NCT04085913|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|During the consenting process, participants will be informed about the randomization aspect of the study. However, they will not be told what category/group they will be randomized into. To help with the randomization, the study team will enter the needed patient information into www.randomizer.org, which will categorize the patients into the desired groups.|Prospective, randomized research study to evaluate postoperative pain medication usage in patients scheduled and receiving thyroid/parathyroid surgery. Patients will be randomized into three different study groups, each receiving a different regiment of treatment.|t|f|f|f
34155484|NCT02683863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155485|NCT00119821|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34155486|NCT03706183|||CASE_CONTROL||PROSPECTIVE|||||||
34155487|NCT03640221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Cedars-Sinai Medical Center pharmacy will be responsible for filling individual patient containers, labeling the containers and performing the blinding of the supplies.~subjects will receive two bottles of either:~* Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide; or~* Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)"|A double-blind, randomized, parallel 2- arm study, therapy will be randomly allocated 2:1 to Ertugliflozin oral tablet daily (n=20) or hydrochlorothiazide 12.5mg oral tablet (n=10) and followed for three months.|t|t|t|f
34155488|NCT01183455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155489|NCT05768035|NA|SEQUENTIAL||TREATMENT||NONE||"* Phase I/II, open-label, dose-escalation, single arm, multicenter study.~* This study will comprise two segments:~  * A phase I dose-escalation segment: Three (3) prespecified dose-levels of SMART101 will be evaluated in three consecutive cohorts of patients whatever the type of conditioning regimen the patients will receive before the HSCT to define the SMART101 recommended dose (RecD).~ * A phase II segment: once all patients from the dose-escalation segment have completed their treatment period  and the SMART101 RecD has been defined, a total number of 34 patients will be enrolled at the RecD in the phase II segment of the study."||||
34052340|NCT00003407|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155490|NCT05755802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation, perform the block, and administer bupivacaine solution|Prospective, randomized, double blind study|t|f|f|t
34155491|NCT03845959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Three arms: basic dose, 1.5 basic dose and placebo.|t|t|t|t
34155492|NCT02317978|||COHORT||RETROSPECTIVE|||||||
34155493|NCT02898298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155494|NCT00995657|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34155495|NCT04380805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155496|NCT00461461|RANDOMIZED|CROSSOVER||||NONE||||||
34155497|NCT02807870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155498|NCT05315089|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33949265|NCT06003283|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open label multicenter pragmatic randomized controlled superiority trial. Patients will be 1:1 randomized to either the experimental arm or the active comparator arm.~Study visits are scheduled every 12 weeks (3 months). Recruitment period: 1 year. Trial duration: 2 years."||||
33949266|NCT02264340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949267|NCT05160766|RANDOMIZED|PARALLEL||PREVENTION||NONE|No blinding is foreseen in this trial|This is a randomised controlled, adaptive, multicentre Phase II Part B protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2. This trial foresees testing of different vaccines as a fourth vaccine dose ( second booster) for comparative assessment of their immunogenicity and safety against SARS-CoV-2 and SARS-CoV-2 variants in the elderly.||||
33949268|NCT02751658|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949269|NCT00082134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949270|NCT04447963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052341|NCT00059696|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34052342|NCT04008329|||COHORT||PROSPECTIVE|||||||
34052343|NCT00692471|||CASE_CONTROL||PROSPECTIVE|||||||
34052344|NCT00714012|||||PROSPECTIVE|||||||
34076426|NCT04733586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076427|NCT01986803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076428|NCT00662077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076429|NCT04987866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076430|NCT03920358|||COHORT||PROSPECTIVE|||||||
34155499|NCT05150938|||COHORT||RETROSPECTIVE|||||||
34155500|NCT00659230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155501|NCT04313114|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34155502|NCT00061633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155503|NCT03274518|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigator who collects laboratorial, hemodynamics and bioimpedance data will be blinded for intervention (online hemodiafiltration or expanded hemodialysis)||f|f|t|f
34155504|NCT04083157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052345|NCT03514485|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The Principal Investigator (PI) will be masked to the participant-level intervention group. Unmasking will occur if there is an adverse event that warrants investigation or if the Data Safety and Monitoring Board (DSMB) instructs the PI to become unmasked.|A factorial design has enhanced statistical power and can handle cluster randomization of schools. Statistical methods will be used to estimate variation in the effect across schools over time. Linear mixed effects models with random intercepts and slopes for school, and fixed effects for the school-level intervention, time, and time-by-intervention interaction will be applied. Second, marginal models using generalized estimating equations will produce robust estimates that adjust for clustering at the school level. Third, assumption-free, randomization-test-based methods do not rely on assumptions of parametric models. Investigators will use conventional levels of statistical significance (p=0.05) for all pre-specified comparisons for our objectives. Variability of the intervention effect across schools will reflect consistency of intervention effects and thus generalizability in new settings. Both mixed effects models and permutation-test methods will estimate variance components.|f|f|t|f
34052346|NCT00286780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052347|NCT04696354|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34052348|NCT05891223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34052349|NCT03724877|||COHORT||PROSPECTIVE|||||||
34052350|NCT06069999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052351|NCT04764370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052352|NCT05161975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||We will carry out a double-blinded, randomized, placebo controlled clinical trial. We will recruit 18-60 years old men and women who have sustained ankle injury and arrived to LSMU Kauno ligonine for treatment. The volunteers will be randomly assigned to the vitamin K2 (MK-7, 330 micrograms) or placebo group. We expect to see 3-mm difference in muscle thickness between the groups. The gastrocnemius muscle thickness is reported to be 17.49 ± 3.81 mm (Kirmaci et al. 2021). Thus, 25 volunteers in each group are needed (statistical power = 80%, p \< 0.05) for the study. We will recruit 30 volunteers into each group as some volunteers might drop out of the study. We will recruit equal number of 18-39 year old and 40-59 year olds into both groups (n =15 each) to minimize effects of age.|t|t|t|t
34052353|NCT02884752|||CASE_ONLY||RETROSPECTIVE|||||||
34052354|NCT05679531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052355|NCT00819559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052356|NCT01712867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052357|NCT06666647|||COHORT||RETROSPECTIVE|||||||
34052358|NCT01080469|RANDOMIZED|CROSSOVER||||NONE||||||
34052359|NCT03377504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind (outcomes assessor)|Prospective randomized single blind controlled study|f|f|f|t
34052360|NCT04450524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not know in which group they belong: intervention or control.||t|f|f|f
34052361|NCT04106895|||CASE_ONLY||RETROSPECTIVE|||||||
34052362|NCT05777902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052363|NCT00644410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052364|NCT06666595|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34052365|NCT05646381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study||t|f|t|f
34052366|NCT01927549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949271|NCT04155567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949272|NCT02549612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949273|NCT03304886|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949274|NCT03730623|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial with118 participants. Randomization to Control group/standard care or Intervention group: 12 week exercise supervised by physiotherapist, Nurse+ dietitian, pedometer and exercise log-book, smoking cessation and text-message follow up. 6 and 12 month follow up. Primary and secondary endpoints.||||
33949275|NCT05891795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking will occur by the investigational pharmacy.||t|f|t|t
33949276|NCT01631591|||OTHER||OTHER|||||||
33949277|NCT04198974|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The evaluation team will be blinded to the intervention conditions until 24 months|Hybrid effectiveness/implementation randomized control trial|f|f|f|t
33949278|NCT02120456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949279|NCT02291705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949280|NCT03023358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949281|NCT02563574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949282|NCT03957291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant will be masked to which drug they receive, the investigator performing the analysis will also be masked|Randomized prospective trial|t|f|f|f
33949283|NCT05428358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949284|NCT03165409|||CASE_ONLY||RETROSPECTIVE|||||||
33949285|NCT01347931|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949286|NCT04233827|||COHORT||PROSPECTIVE|||||||
33949287|NCT05778682|RANDOMIZED|PARALLEL||TREATMENT||NONE|None, patients and physicians will know the protocol|||||
34052367|NCT01259349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052368|NCT04564378|||OTHER||OTHER|||||||
34052369|NCT06668090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052370|NCT00005889||||TREATMENT||||||||
34052371|NCT04821895|||CASE_ONLY||PROSPECTIVE|||||||
34052372|NCT02559596|||CASE_CONTROL||RETROSPECTIVE|||||||
34052373|NCT00534716|||||PROSPECTIVE|||||||
34052374|NCT01154348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052375|NCT03734146|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcomes assessor was blinded to treatment group allocation.|randomized controlled trial|f|f|f|t
34052376|NCT00068393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052377|NCT00311064|RANDOMIZED|PARALLEL||||DOUBLE||||||
34052378|NCT03634995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052379|NCT06033430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the control group will undergo the same procedure as those in the intervention group, with needles placed superficially in an area slightly further away from the scar tissue. Furthermore, to minimize bias, the data analyst will be blinded to the grouping of the participants, and each participant will be identified by a unique numerical code.||t|f|f|f
34076431|NCT01909804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949288|NCT01973673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949289|NCT02570945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949290|NCT05110118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949291|NCT05697276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949292|NCT00386191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33949293|NCT02516449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34155505|NCT03287362|RANDOMIZED|PARALLEL||TREATMENT||NONE||Incoming patients from the clinic of Max Planck Institute of Psychiatry are continuously screened for study eligibility and - after they have given informed consent - are block wise randomly assigned to one of 3 study arms (schema therapy, cognitive behavioral therapy, individual supportive therapy)||||
34155506|NCT01873651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155507|NCT03939936|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155508|NCT01209078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155509|NCT00680797|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949294|NCT01700894|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33949295|NCT02708576|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33949296|NCT06014515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will undergo two PET/CT scans with two different radiotracers.||||
33949297|NCT03642002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Outcomes Assessor will be unfamiliar with desired outcomes||||
33949298|NCT03123627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949299|NCT01881867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949300|NCT00443573|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949301|NCT05119114|||CASE_ONLY||PROSPECTIVE|||||||
33949302|NCT01619709|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949303|NCT02463500|||CASE_ONLY||PROSPECTIVE|||||||
33949304|NCT01061398|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33949305|NCT02042573|RANDOMIZED|PARALLEL||||NONE||||||
33949306|NCT01302366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949307|NCT03741530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949308|NCT00993941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949309|NCT01206296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949310|NCT04284046|||COHORT||RETROSPECTIVE|||||||
33949311|NCT02791906|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33949312|NCT04817319|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949313|NCT02477072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33949314|NCT00106717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33949315|NCT04085562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949316|NCT01821391|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||"2 intra-individual groups:~* Metvix NDL-PDT / Metvix c-PDT~* Metvix NDL-PDT / Placebo c-PDT"|f|f|t|f
33949317|NCT02734290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949318|NCT01196754||||SCREENING||||||||
33949319|NCT01796873|||CASE_CONTROL||PROSPECTIVE|||||||
33949320|NCT02444676|||COHORT||PROSPECTIVE|||||||
33949321|NCT06119789|NA|SINGLE_GROUP||TREATMENT||NONE||simon two stage model||||
33949322|NCT01250691|||COHORT||CROSS_SECTIONAL|||||||
33949323|NCT01243762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949324|NCT01156129|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33949325|NCT01661426|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||The study employed a 2 x 2 crossover design: LF vs. LC diets and more IR vs. more IS. Study participants were classified as more IR or more IS based on the median AUC for insulin concentrations measured from an oral glucose tolerance test (OGTT) prior to randomization. Participants above the median were considered more IR and those below the median were considered more IS. A random number generator was used to stratify the randomization to LF vs. LC by insulin resistance status and gender. Participants followed their assigned diet for 6 months and then switched to the opposite diet for another 6 months.|t|t|t|t
33949326|NCT00722618|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33949327|NCT02112565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949328|NCT01220921|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33949329|NCT04037540|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was used in the study|The patients with Jones fracture were randomized into one of the two study groups - operational or conservative approach.||||
33949330|NCT03061916|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33949331|NCT05115760|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33949332|NCT00779142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949333|NCT03528265|||COHORT||CROSS_SECTIONAL|||||||
33949334|NCT00766129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949335|NCT05284162|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33949336|NCT00851695|||COHORT||RETROSPECTIVE|||||||
33949337|NCT00938366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949338|NCT01294280|||CASE_ONLY||RETROSPECTIVE|||||||
33949339|NCT02096406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949340|NCT02526368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949341|NCT02995239|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949342|NCT02087865|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33949343|NCT04487782|||COHORT||CROSS_SECTIONAL|||||||
33949344|NCT04901520|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||3 intervention groups and one control group, assessed in 4 different times (baseline, 4th, 8th, and 12th weeks of intervention)|t|f|f|f
33949345|NCT01004822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949346|NCT03243552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Phase IIa Proof of Mechanism 16-week, randomized, double-blind, controlled trial of L-DOPA versus placebo.|t|t|t|t
33949347|NCT02891876|||CASE_ONLY||PROSPECTIVE|||||||
33949348|NCT03934034|||COHORT||PROSPECTIVE|||||||
33949349|NCT01488695|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34052380|NCT03124407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study medications were number coded only and identical in physical characteristics. Randomization coding was held only at the manufacturing site until data base lock.|Active treatment compared to drug vehicle as placebo|t|t|t|f
34155510|NCT06134843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessors will evaluate pain and scarring using the Visual Analog Scale (VAS) Vancouver Scar Scale (VSS) without knowledge of the participants' treatment group assignment.|single center, single-blind, randomized, controlled interventional study|t|f|f|t
34155511|NCT04417231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155512|NCT00646399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155513|NCT03570801|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial with randomization ratio 1:1||||
34155514|NCT02868047|||CASE_ONLY||PROSPECTIVE|||||||
34155515|NCT01876693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155516|NCT02130505|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155517|NCT05419726|||COHORT||PROSPECTIVE|||||||
34155518|NCT01590654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155519|NCT02353390|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34155520|NCT02624531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155521|NCT00715767|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155522|NCT03479710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155523|NCT01087216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34155524|NCT06388317|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are unaware of the other intervention arm (i.e., adaptive step goals versus static step goals).|Retrospective, quasi-experimental study.|t|f|f|f
34155525|NCT04569357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind placebo-controlled randomized|t|t|t|t
34155526|NCT02372981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155527|NCT03229941|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34155528|NCT02606058|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34155529|NCT03140462|||CASE_ONLY||RETROSPECTIVE|||||||
34155530|NCT04832880|RANDOMIZED|PARALLEL||TREATMENT||NONE||Factorial design with four-stages (K=4). Three interim analyses are pre-planned. At each stage, the use of remdesivir and/or baricitinib might be suspended due to futility or ef-ficacy. Overall, we will accept a two-sided alpha error of alpha=0.05 and a beta error of β=0.10.||||
34155531|NCT02235545|||CASE_ONLY||PROSPECTIVE|||||||
34155532|NCT05324228|||COHORT||PROSPECTIVE|||||||
34155533|NCT04248088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|f|t
34155534|NCT01299116|RANDOMIZED|PARALLEL||PREVENTION||NONE||Partially randomized patient preference trial||||
33949350|NCT05469711|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Subjects will receive notification to their device on day 1 of the run in period informing them of their group allocation Investigators (PI and CI) will be blinded as to patient allocation. Sub-investigator will be familiar with Playphysio device and will NOT be blinded. This investigator will not be involved in recording of any data but will be available to assist with technical issues faced by patients and provide standard clinical reviews.~Statistician will be blinded to group allocation Playphysio team will not be blinded and will be able to assist with Playphysio queries that arise"|"The study is a single centre, randomised control study with open label participation. Subjects will be randomised 1:1 to either Arm 1 - active arm or Arm 2 - control arm. The trial will last for 4 months 112 days). The first month will be used as a run in period to gather adherence data on both groups with no games available on any of the devices. The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.~Arm 1: intervention-Pp plus gamification Arm 2: control- Pp only - Pp acting as adherence monitor only with no feedback given in real time to patient."|f|f|t|f
33949351|NCT05477849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949352|NCT03874507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949353|NCT00525499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949354|NCT02147574|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33949355|NCT04935528|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33949356|NCT02701907|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33949357|NCT02661165|||COHORT||RETROSPECTIVE|||||||
33949358|NCT04831255|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects receive the ZILRETTA injection||||
33949359|NCT03134001|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Study includes 2 groups: test group comprised patients receiving oral analgesics via the PCoA™ Acute and control group of nurse providing analgesics.||||
33949360|NCT00305292|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
33949361|NCT01040806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949362|NCT02555891|||||RETROSPECTIVE|||||||
34052381|NCT03395184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052382|NCT03339726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076432|NCT03671876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34076433|NCT04611542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155535|NCT00411632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155536|NCT01509911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155537|NCT01211821|RANDOMIZED|CROSSOVER||||NONE||||||
34155538|NCT06457698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects were randomly assigned into two groups: HA injection or HA injection + PRP. Codes were prepared and distributed in the two groups for this allocation. The treatment assignment was made by an independent person who was not involved in performing any other procedures in the study, such as the preoperative injection or the TMJ arthrocentesis. An envelope containing a code was selected and assigned to the patient. Subjects were blinded until the end of the study. The surgeon was unblinded because they could distinguish the color of the two viscosupplements.||t|f|f|t
34155539|NCT06329206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155540|NCT02858063|||COHORT||PROSPECTIVE|||||||
34155541|NCT05037617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Once a patient is found to be ≥6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician. Nurses will use the blinded vials for ongoing infusion. Patients and caregivers will be blinded.|Once a patient is found to be \>=6 cm dilation, the patient will received a blinded vial of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.|t|t|t|t
34155542|NCT01454765|||||PROSPECTIVE|||||||
34155543|NCT03468647|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155544|NCT02464722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34155545|NCT02574689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155546|NCT00960479|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33844963|NCT06005545|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, 3- arm randomized, non-blinded, single center pivotal clinical investigation, performed to evaluate the effectiveness and safety of the Endoclean device with 2 comparator arms.~Arm 1: Passive ultrasonic irrigation group (PUI); shaping up to WL with 25.06, Arm 2: Endoclean (EC) group; shaping up to WL with 20.06; EC application tip kept 3mm short of WL, irrigation protocol with NaOCl (sodium hypochlorite) Arm 3: Conventional group; shaping up to WL of 25.06, irrigation protocol with NaOCl (sodium hypochlorite)"||||
33844964|NCT01544543|||COHORT||RETROSPECTIVE|||||||
33844965|NCT02558127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33844966|NCT01139476|||COHORT||CROSS_SECTIONAL|||||||
33844967|NCT06411808|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|All participants and study personnel involved in the delivery and assessment of the treatment outcomes are blinded to the phase order to maintain the integrity of the study results.|Participants will receive dental care in both a standard and a sensory-adapted dental environment in a randomized order to compare effects on anxiety and behavior.|t|t|t|t
33844968|NCT01929629|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33844969|NCT02174666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33844970|NCT06729606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155547|NCT00773747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155548|NCT00367835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155549|NCT06246578|NA|SINGLE_GROUP||OTHER||NONE||Comparison of nearly simultaneous interstitial glucose values obtained by Dexcom G 7 and Libre 2 sensors for continuous glucose monitoring and blood glucose measured with Contour Next one||||
34155550|NCT00005994|RANDOMIZED|||||||||||
34155551|NCT00569764|||CASE_ONLY||PROSPECTIVE|||||||
34155552|NCT01057563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155553|NCT03803436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will compare survival in the population of patients enrolled in the COLT trial with the OS in the COLT-eligible population enrolled in the parallel TRIPLETE trial conducted by the GONO Group.||||
34155554|NCT02728388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155555|NCT01281033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155556|NCT00802893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155557|NCT02516592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155558|NCT03458689|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Information connecting the patients to the data are kept locked and will be destroyed after the end of the investigation||t|f|f|f
34155559|NCT03875664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155560|NCT05492357|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Human patients:~20 patients who need tooth/ teeth extraction would be selected according to the following criteria:~INCLUSION CRITERIA:~1. Men and women over 18 years of age~2. Indication of a simple extraction~3. Delivery of signed informed consent~EXCLUSION CRITERIA:~1. Need for multiple extractions~2. Presence of severe swelling prior to surgery in the extraction area~3. Regular treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or other anti-inflammatory drugs~4. Presence of hematologic disease~5. Previous radiation, chemotherapy, or immunosuppressive treatments~6. Uncontrolled diabetes mellitus, metabolic bone disease, ongoing treatment with bisphosphonates drugs, or pregnancy"||||
34155561|NCT02172404|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34155562|NCT05612425|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to one of two conditions||||
34155563|NCT02376803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155564|NCT00383942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155565|NCT01636128|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34155566|NCT01853878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155567|NCT00372697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155568|NCT03413709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155569|NCT05808413|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The survey company, Dynata, will collect all data and manage group assignments. Participants' intervention group assignments will be unavailable to the investigator.|Participants will be randomly assigned to one of: 1) a control video, 2) the control + an altruistic video, or 3) the control + altruistic video + individualistic video. A 1:1:1 randomization ratio will be used.|f|f|t|f
34155570|NCT02364934|||COHORT||PROSPECTIVE|||||||
34155571|NCT02157961|||COHORT||PROSPECTIVE|||||||
34155572|NCT06136065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A total of 100 patients will be enrolled. The proportion of 68-Gallium-Fibroblast Activating Protein Inhibitor-46 Positron Emission Tomography /Computerized Tomography positive patients or lesions will be calculated as well as 95% confidence intervals (CI). Median and ranges or mean and standard deviation, as appropriate, will be used to describe 68-Gallium-Fibroblast Activating Protein Inhibitor-46 (68Ga-FAPI-46) uptake. The number and percentage of treated patients undergoing grade 1 to 4 adverse events will be tabulated according to CTCAE version 5.0.||||
34155573|NCT05124132|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34155574|NCT05417087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155575|NCT02370797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155576|NCT02651220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155577|NCT02831517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155578|NCT05933343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155579|NCT04897763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, open prospective study||||
34155580|NCT04438291|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34155581|NCT02358226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34155582|NCT01089153|||CASE_ONLY||PROSPECTIVE|||||||
34155583|NCT03791151|||COHORT||PROSPECTIVE|||||||
34155584|NCT04292743|NA|SEQUENTIAL||TREATMENT||NONE|Open label|Dose escalation of Eryaspase in combination with FOLFIRINOX||||
34155585|NCT03028935|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155586|NCT00005667|||CASE_CONTROL||OTHER|||||||
34155587|NCT01447186|||COHORT||PROSPECTIVE|||||||
34155588|NCT04840329|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155589|NCT06393023|||COHORT||PROSPECTIVE|||||||
34155590|NCT04751877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155591|NCT03064919|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals will be developed. The investigators will then conduct an experimental study to determine the effectiveness of this curriculum on children's ability to regulate energy intake in the laboratory. Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Data describing variables likely to impact the success of the curriculum will be collected, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.||||
34155592|NCT03156374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Parallel use of ovulation test and standard hospital monitoring, for agreement of methods||||
34155593|NCT03153995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155594|NCT03190460|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34155595|NCT04887896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose.|t|t|t|t
34155596|NCT02697435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Research Coordinators who perform the data measure portion of the baseline are masked from knowing which group (usual care or patient care) the participant ends up in. This is also true of monthly follow-up calls."||f|f|t|f
34155597|NCT01970969|||COHORT||PROSPECTIVE|||||||
34155598|NCT05435417|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34155599|NCT04036500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155600|NCT00615030|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33844971|NCT06729736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844972|NCT02712073|||COHORT||PROSPECTIVE|||||||
33844973|NCT01283516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844974|NCT05031000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33844975|NCT06729294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33844976|NCT04281459|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33844977|NCT03013153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844978|NCT02878226|||CASE_ONLY||PROSPECTIVE|||||||
33844979|NCT01901419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled trial|t|f|f|t
33844980|NCT00349362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33949363|NCT04802421|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The patient will not know the allocation group because he will be anesthetised before randomisation. The care provider (anesthetist) will not know the allocation group because the intervention will be applied by an independent investigator not involved in care of the patient.|randomised parallel groups. randomisation between 2 groups equilibated by randomised blocks of 4, 6 or 8|t|t|f|f
33949364|NCT02456272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949365|NCT01795534|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33949366|NCT05467995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949367|NCT05856357|||COHORT||PROSPECTIVE|||||||
33949368|NCT03132610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949369|NCT00008216|||COHORT||PROSPECTIVE|||||||
33949370|NCT04793126|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients were subjected to clinical evaluation and urodynamic testing before surgery. All cases underwent surgical repair of pelvic organ prolapse. Follow-up clinical examination was performed at 1, 3, and 6 months postoperatively, and urodynamic examination was repeated 6 months after repair.||||
33949371|NCT03426995|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This will be a double blind (sponsor open) study with respect to allocation of GSK3358699 or placebo to subjects. All site staff will be blinded with the exception of un-blinded pharmacists. Investigators will be un-blinded with respect to the LPS and GM-CSF allocation. The food effect part of the study (Part B) will be open-label|Study will be conducted as Part A, B and C. Part A will consist of 2-interlocking cohorts, where each subject will receive maximum 2-single ascending oral doses of GSK3358699 and 1 dose of placebo, in Treatment Periods (TP) 1 to 3. In TP 4 subjects will receive GSK3358699, dose evaluated in TP (1 to 3) or placebo, with cantharidin induced blisters and either LPS or GM-CSF in vivo challenge. Part B will comprise of single cohort taking part in two-way cross over, with open label phase where each subject will receive single oral dose of GSK3358699 (based on Part A), under fed and fasted conditions in each TP. Part C will consist of 3 cohorts with multiple ascending doses, with every cohort having one repeat dose TP with 14 days of daily dosing of either GSK3358699 or placebo. Subjects on Day 14 will receive cantharidin induced blisters with either LPS or GM-CSF in vivo challenge. An optional, cohort 7 may be included for further dose evaluation of GSK3358699 or alternate dosing schedule.|t|f|t|f
33949372|NCT03445936|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Subject is blinded of the mesh used. Outcome at 10 month follow-up is assessed by surgeon who was not involved in the operation.|This is a prospective randomized controlled multicenter trial|t|f|f|t
33949373|NCT02054507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949374|NCT05386199|||CASE_CONTROL||PROSPECTIVE|||||||
33949375|NCT04167826|||CASE_ONLY||CROSS_SECTIONAL|||||||
33949376|NCT06158906|||OTHER||PROSPECTIVE|||||||
33949377|NCT02909127|||COHORT||PROSPECTIVE|||||||
33949378|NCT01872832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949379|NCT02267421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949380|NCT01070849|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33949381|NCT06418789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949382|NCT01167699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949383|NCT05297162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949384|NCT02875743|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949385|NCT00161291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949386|NCT05059561|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949387|NCT04213001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949388|NCT04165850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949389|NCT03377803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949390|NCT02807025|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949391|NCT03730064|NA|SINGLE_GROUP||OTHER||NONE||||||
34155601|NCT01891474|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155602|NCT03043651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844981|NCT04892914|NA|SINGLE_GROUP||TREATMENT||NONE||Embr thermal device||||
33844982|NCT06488508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster randomization of 25 kindergartens to the intervention group (professional development) and 25 kindergartens to the control group (standard of care)|f|f|f|t
33844983|NCT05911906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open label.|One study group will receive Remdesivir.||||
33844984|NCT01663922|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33844985|NCT04162938|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34052383|NCT05448417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients were randomized to receive one hour each of the two non-invasive ventilation modes before and after, and one hour of washout after receiving the first mode of ventilation before receiving the second intervention.||||
34052384|NCT01243216|RANDOMIZED|PARALLEL||||NONE||||||
34052385|NCT01363752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052386|NCT06203132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052387|NCT00254176|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34052388|NCT05838430|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Blinding only applies to the medication arm. The randomization schedule was developed by our statistician and sent directly to research pharmacy for implementation.~The four arms are as follows:~1. Solriamfetol + CBT-I~2. Placebo + CBT-I~3. Solriamfetol Only~4. Placebo Only~All conditions engage in monitoring and assessment."|A 2x2 mixed model design. The two factors will be 1) treatment (+/- solriamfetol and +/- CBT-I) and 2) Time (pre-post assessment, with additional follow-up data).|t|t|t|t
34052389|NCT05365672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052390|NCT00729157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052391|NCT01698242|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052392|NCT04349462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center prospective pilot study of post critical illness dysphagia .||||
34052393|NCT02130804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34052394|NCT01663779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052395|NCT03918902|||COHORT||OTHER|||||||
34052396|NCT03186274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34052397|NCT04002882|||COHORT||PROSPECTIVE|||||||
34052398|NCT02233920|||COHORT||PROSPECTIVE|||||||
34052399|NCT05981261|NA|SINGLE_GROUP||OTHER||NONE||This is a within-subject design where each participant is exposed to experimental pain in infraspinatus muscle, gluteus medius muscle, and tibialis anteior muscle in a randomized order.||||
34052400|NCT05918484|||COHORT||RETROSPECTIVE|||||||
34052401|NCT02416882|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34052402|NCT02980341|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052403|NCT05793879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052404|NCT04529785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052405|NCT06460883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052406|NCT05827042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052407|NCT01671046|||COHORT||PROSPECTIVE|||||||
34052408|NCT03808597|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052409|NCT04815265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34052410|NCT03024203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052411|NCT02410434|NA|SINGLE_GROUP||||NONE||||||
34052412|NCT06206577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052413|NCT00487006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052414|NCT04463589|||CASE_ONLY||PROSPECTIVE|||||||
34052415|NCT00006007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052416|NCT05590897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Breath Alert, as the device that will be used to determine the presence of halitosis, is blinded to groups/participants.||f|f|f|t
34052417|NCT02295020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052418|NCT05742360|||COHORT||PROSPECTIVE|||||||
33844986|NCT04171323|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33844987|NCT01109927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33844988|NCT06729034|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blind study in which participants/care providers/investigators/outcomes assessors are blinded to study intervention.. In case of an emergency, the investigator has the responsibility for determining if unblinding of a participant's intervention assignment is warranted. Participant safety must always be the first consideration in making such a determination. The participant will be carrying a card with contact information of investigator and the medical monitor. The card will be in Norwegian and in English and inform that the person is part of a blinded trial and that he/she may be under anticoagulation with apixaban. In case of major bleeding, the investigator must be contacted who may unblind the participant so that emergency treatment can be considered. In case of a life-threatening bleed, there is no time for contacting the investigator. Then measures must be taken as if the participant is under anticoagulation treatment with apixaban|Randomized study, crossover design, double-blind|t|t|t|t
34052419|NCT04507139|||CASE_ONLY||OTHER|||||||
34052420|NCT00379444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052421|NCT03512717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052422|NCT06456697|||COHORT||RETROSPECTIVE|||||||
34052423|NCT00979875|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34052424|NCT04459715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052425|NCT05616507|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Type : Interventional (Clinical Trial) Actual Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment, matching sex, age, and performance status||||
34052426|NCT00444041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052427|NCT06137963|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patient will be blinded because they will be told that they are getting the DPP within 0-6 months. RA's will not know what group patients are in because Transform10 will be asking all of the questionnaires via their platform.|double-blind randomized control trial||||
34052428|NCT02825758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052429|NCT01541423|||CASE_ONLY||PROSPECTIVE|||||||
34052430|NCT05420298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052431|NCT03547063|||COHORT||PROSPECTIVE|||||||
34052432|NCT02716116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052433|NCT03813784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155603|NCT05963997|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155604|NCT00820716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33844989|NCT04909827|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A total of thirty primary mandibular molars in healthy subjects will be selected.~The molars will be randomly assigned equally into two treatment groups~1. Group A: 3D printed microfilled hybrid composite Endocrowns~2. Group B: pr efabricated zirconia crowns Pulpotomy"||||
33844990|NCT06416644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844991|NCT05623176|||COHORT||RETROSPECTIVE|||||||
33844992|NCT01974778|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34155605|NCT06128603|||COHORT||RETROSPECTIVE|||||||
34155606|NCT02106494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155607|NCT06321770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized, Double-Blind, Placebo-Controlled Study|Randomized, Double-Blind, Placebo-Controlled Study|t|f|t|f
34155608|NCT02541734|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34155609|NCT04522349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized crossover trial (AB/BA)||||
34155610|NCT01906528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155611|NCT05541445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155612|NCT00490074|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33844993|NCT00626626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33844994|NCT04593043|||COHORT||RETROSPECTIVE|||||||
33844995|NCT05174221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33844996|NCT04621175|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double (participant and investigator)|randomized, cross-sectional, longitudinal study|t|f|t|f
33844997|NCT00152984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34052434|NCT05655286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052435|NCT05919225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open-lable, multicentre, randomized, low-intervention, non-pharmacological, clinical trial||||
34052436|NCT06546956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052437|NCT06451562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052438|NCT01077037|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34052439|NCT03036865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34052440|NCT03699280|RANDOMIZED|PARALLEL||OTHER||SINGLE||"The study is a randomised control trial involving mixed methods of qualitative and quantitative analysis. The study will include 40 patients attending the outpatient hysteroscopy clinic and randomised to either a VR intervention group or standard procedure by computer-generated randomisation.~All patients will fill in a questionnaire before and after the procedure. Patients who have been randomised to the VR arm will have a semi-structured interview regarding their experience with VR.~The clinician performing the procedure will fill in a questionnaire per patient regarding the ease of the procedure and perceived pain levels of the patient. The Clinician performing the procedure and nursing staff's perception regarding feasibility of using the VR equipment for each patient who had the intervention was also assessed through the questionnaire."|f|f|f|t
34052441|NCT05642962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052442|NCT05904431|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052443|NCT01273623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052444|NCT04411979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052445|NCT02996123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34052446|NCT05451953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel group open-label randomized controlled trial.|f|f|f|t
34052447|NCT01942356|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34052448|NCT00210197|||||PROSPECTIVE|||||||
34052449|NCT01923298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052450|NCT01913535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||sequential parallel comparison design (SPCD) with two phases|t|t|t|t
34052451|NCT00160706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052452|NCT04287855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052453|NCT02143154|||COHORT||PROSPECTIVE|||||||
34052454|NCT05713396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052455|NCT02274870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052456|NCT02819180|||COHORT||PROSPECTIVE|||||||
34052457|NCT01813214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052458|NCT06586788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052459|NCT06254001|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two groups:~1. Nicotine replacement therapy~2. Nicotine replacement therapy and bupropion"||||
34052460|NCT06618196|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Any persons accompanying the subject for the site visits, including parents, other family members, and/or legally acceptable representatives, will be shielded from view by physical barriers while the study vaccine is administered. The unblinded site personnel for the preparation/administration of study vaccines will keep the unblinded information separate from those persons for any study related procedures/assessments after administration of study vaccines, which includes all safety follow-up procedures. Blinded site personnel will be responsible for all safety and immunogenicity follow-up procedures after study vaccine administration.||t|t|t|f
34052461|NCT04875702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052462|NCT04622514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment committee members will be blinded to the group assignment.||f|f|f|t
34052463|NCT03199807|NA|SINGLE_GROUP||TREATMENT||NONE||NRT+radiotherapy||||
34052464|NCT01311375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34052465|NCT06253390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052466|NCT03644823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052467|NCT01871493|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34052468|NCT03177031|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052469|NCT05311436|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052470|NCT01817582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052471|NCT00004465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052472|NCT06055413|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34052473|NCT00963027||CROSSOVER||TREATMENT||NONE||||||
34052474|NCT03133182|||COHORT||RETROSPECTIVE|||||||
34052475|NCT02808728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052476|NCT06244056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.|t|t|t|f
34052477|NCT06094660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052478|NCT06029452|||COHORT||RETROSPECTIVE|||||||
34052479|NCT04995250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155613|NCT02620488|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34155614|NCT02174341|||CASE_CONTROL||OTHER|||||||
33844998|NCT03300739|||CASE_ONLY||PROSPECTIVE|||||||
33844999|NCT03668639|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845000|NCT00652470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845001|NCT03900416|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to the intervention group (i.e., mindfulness with ecological momentary assessment) or the control group (i.e., ecological momentary assessment only).||||
33845002|NCT06727851|||COHORT||PROSPECTIVE|||||||
33845003|NCT06729177|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This research uses the noncurrent multiple baseline design across teacher participants.||||
34052480|NCT01797016|||CASE_CONTROL||PROSPECTIVE|||||||
34052481|NCT03413956|||COHORT||RETROSPECTIVE|||||||
34052482|NCT04216693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052483|NCT01198288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052484|NCT00276991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052485|NCT04199078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052486|NCT05525585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052487|NCT00143078|||COHORT||PROSPECTIVE|||||||
34052488|NCT05742269|||COHORT||PROSPECTIVE|||||||
34052489|NCT02568020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052490|NCT04550975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind. Assessor will be blinded to the study. Due to the nature of the intervention, the facilitator and participants cannot be blinded||f|f|f|t
34052491|NCT02247440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052492|NCT03118492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052493|NCT02775149|||CASE_ONLY||PROSPECTIVE|||||||
34052494|NCT05325489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052495|NCT00256854|RANDOMIZED|PARALLEL||TREATMENT||||||||
34052496|NCT05133271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052497|NCT04677751|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075806|NCT03668665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The images taken from the wound as a progress control during the study should be evaluated anonymously by both the surgeon and the patient using the Manchester Scar Scale and the Patient and Observer Scar Assessment Scale."|The wound is divided into two halves (top and bottom). During the in-patient stay, half of the split skin removal sites are treated with Ready Medical Post Treatment on the 1st, 4th and 7th postoperative days in addition to conventional treatment with moist dressings (Mepilex and Fixomull). The other half of the wound should only be treated with conventional dressings as a control. Half of those treated with Ready Medical Post Treatment receive a new dressing after each application.|t|t|t|f
33845004|NCT04012840|||COHORT||PROSPECTIVE|||||||
34075807|NCT02363387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075808|NCT06201039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, clinicians, data collectors, outcome adjudicators and data analysts will not have access to details of group assignment.||t|t|t|t
34155615|NCT03779581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The researcher, surgeons, and physiotherapist did not participate in randomization, treatment, or outcome assessments. The assessor was blinded. A computer-generated sequence inside pre-sealed opaque envelopes with sequentially numbered opaque envelopes randomly allocated individuals to the groups. To ensure a fair distribution of curve types between the two groups (54 per group), a random size (4-8) blocked randomization was stratified for the six curve types. Participants were asked not to reveal their group affiliations to ensure evaluators were blind. The statistician was also insulated from group allocation coding. During routine clinic visits, a trained technician blinded to study participation took radiographs. An expert blinded to groups and time measured the radiographs.|1431 of the 108 subjects visiting out-patient Department of our hospital met the inclusion criteria. All the subjects diagnosed with kyphoscoliosis signed the informed consent approved by the ethical committee of the hospital. The diagnosis was based on the diagnosis by an experienced radiologist. Subjects with idiopathic kyphoscoliosis and Cobb's angle greater than 60 degree and normal pulmonary function were included. The subjects with other cardiovascular pathologies, congenital disorders and inability to commute were excluded from this study.|t|t|t|t
34155616|NCT00003354|RANDOMIZED|||TREATMENT||||||||
34155617|NCT02755896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155618|NCT05100446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34155619|NCT04897178|||CASE_CONTROL||RETROSPECTIVE|||||||
34155620|NCT04129892|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155621|NCT04305561|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective paired cohort study.|f|f|t|f
34155622|NCT03052049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155623|NCT04918732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155624|NCT03130192|||COHORT||PROSPECTIVE|||||||
34155625|NCT05393973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845005|NCT00002003||||TREATMENT||||||||
33845006|NCT06297759|||COHORT||PROSPECTIVE|||||||
34075809|NCT04710875|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34075810|NCT00974363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075811|NCT02773095|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075812|NCT03742986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075813|NCT01667445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075814|NCT03118817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052498|NCT06667531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Immediately after the placement of the implant, the subject was randomly assigned to one of the six treatment groups by opening a numbered sealed envelope from a computer-generated randomization list. Consequently, the surgeon was unaware of each subject's group assignment until the implant was installed. From that point onward, based on the random assignment, the intermediate abutments of the three heights were screwed with a torque lower than the implant insertion torque to the internal connection either immediately during the same installation procedure (one-abutment-one-time protocol) or delayed during the second surgery procedure at 8 weeks after the installation (two-stage protocol: submerged implant).|"This controlled clinical trial aims to evaluate changes in peri-implant marginal bone levels during the first year of function around platform-switched implants placed 1.5 mm subcrestally and connected to intermediate abutments of heights 1.5, 2, and 3 mm, placed immediately at the time of the first surgery or delayed at the time of the second surgery.~54 patients received at least one single screw-retained crown on an implant replacing a posterior tooth (60 implants). The implants were divided into six treatment groups based on the height (1.5 mm; 2 mm; 3 mm) and timing of placement (immediate: surgery 1; delayed: surgery 2) of the intermediate abutment: group 1 (height 3; surgery 1), group 2 (height 2; surgery 1), group 3 (height 1.5; surgery 1), group 4 (height 3; surgery 2), group 5 (height 2; surgery 2), group 6 (height 1.5; surgery 2). Mesial and distal linear radiographic measurements (from the implant shoulder to the bone crest) were performed at five follow-up times: implant"|t|f|t|f
34052499|NCT06459349|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided to group A (n=21) which will receive intervention exteroceptive and proprioceptive sensory stimulation and to group B (n=21) which will receive sensorimotor therapy for 50 minutes per session, 03 times a week, for 06 weeks .||||
34052500|NCT05002673|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155626|NCT03970291|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155627|NCT01513122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155628|NCT06572852|||CASE_CONTROL||OTHER|||||||
34155629|NCT00082199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155630|NCT00320424|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34155631|NCT05768984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Permission will be taken from Hacettepe University Oncology Hospital for the research. However, due to the pandemic conditions, to protect the health of both researchers and participants, group studies were moved to the online platform and the sessions were planned as online (zoom sessions). The sample size of the study was calculated with the G-Power 3.1 program. Since a similar study could not be found in the literature, it was determined that the sample should consist of 56 people, 28 in the intervention group and 28 in the control group, by calculating with .80 power and .05 error level, based on the medium effect size for the .25 variance analysis suggested by Cohen. However, it is foreseen that it would be appropriate to reach 10% more people (Total 62) of the total number calculated considering that there may be a loss of participants during the process and to be participants in the 31 intervention and 31 control group.|f|f|f|t
34155632|NCT00724633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155633|NCT06551259|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34155634|NCT03549715|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|The sample size will be balanced between 2 arms. Initially, 12 patients (6 in each arm) will be included and randomized between durvalumab + ddMVAC (ARM A) or durvalumab + tremelimumab + ddMVAC (ARM B)||||
34155635|NCT01962870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155636|NCT01805037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155637|NCT00999518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155638|NCT00001317||||TREATMENT||||||||
34155639|NCT05887531|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741344|NCT06536296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|We will utilize infant-adapted headphones to deliver the intervention in a blinded fashion. The research team (investigators and outcome assessors) will remain blinded to the type of recording delivered for each infant.|The eligible participants in both institutions will be consecutively approached to enroll in the study. Once informed consent has been obtained, each participant will be randomly assigned to one of the three study groups: M (music), MPV (music with parent voice), or SC (standard care), with 81 infants per each group. We designed the MBI in collaboration with board certified music therapists (MT) at the two institutions. While MBI recordings will be obtained at each NICU timepoint for each infant (with both M and MPV; SC group will wear headphones open to environmental sounds, as a control group), each infant will only listen to one of the three types of recordings according to their group assignment.|f|t|t|t
33741345|NCT02108938|||CASE_CONTROL||PROSPECTIVE|||||||
33741346|NCT00387218|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33741347|NCT00849342|||CASE_ONLY||PROSPECTIVE|||||||
33741348|NCT00465166|||COHORT||RETROSPECTIVE|||||||
33845007|NCT04690894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33845008|NCT05377437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845009|NCT01143181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845010|NCT02654951|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33845011|NCT05041010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845012|NCT04744493|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, open-label, single-center, and sponsor-initiated clinical trial. The clinical trial follows the Clinical Investigation Plan, GCP.||||
33845013|NCT02392520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845014|NCT05947032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845015|NCT06021457|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Subjects will be randomized 1:1 to RBT-1 or placebo|t|t|t|t
33845016|NCT05456776|||COHORT||PROSPECTIVE|||||||
33845017|NCT04415983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845018|NCT02365727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845019|NCT04289831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33845020|NCT04949061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845021|NCT02250677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845022|NCT00579267|||CASE_ONLY||CROSS_SECTIONAL|||||||
33845023|NCT01205152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845024|NCT01744938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845025|NCT04716777|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to one of two conditions 8-week treatment or 8-week waitlist.||||
34155640|NCT02940639|||COHORT||PROSPECTIVE|||||||
34155641|NCT05133661|||COHORT||PROSPECTIVE|||||||
34155642|NCT06101277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155643|NCT01955538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155644|NCT03771274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155645|NCT02283788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155646|NCT02971553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155647|NCT02764684|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155648|NCT04119011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|placebo and probiotic are labelled A or B, this is prepared by the manufacturer and blinded from the participant and investigator, the unblinding takes place only after completion of the data collection|randomized placebo-controlled trial|t|f|t|f
34155649|NCT00924443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949392|NCT04490551|RANDOMIZED|PARALLEL||SCREENING||NONE||The researchers conduct a parallel group randomized controlled trial. Asymptomatic individuals will be randomized to either risk-based screening or FIT-only screening.||||
33949393|NCT05255939|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949394|NCT01511367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949395|NCT06378112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"* Group 1 (test group): Guided bone regeneration procedure with GTO® as bone graft and soft collagenated cortical membrane (OsteoBiol® Lamina; Tecnoss srl) as graft stabilizer.~* Group 2 (control): Guided bone regeneration procedure with Apatos Mix® cortico-cancellous heterologous bone mix (OsteoBiol®; Tecnoss srl) as bone graft and soft collagenated cortical membrane (OsteoBiol® Lamina; Tecnoss srl) as graft stabilizer."|t|f|t|f
33949396|NCT03494452|||COHORT||CROSS_SECTIONAL|||||||
33949397|NCT05277610|||COHORT||RETROSPECTIVE|||||||
33949398|NCT04631432|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949399|NCT00912431|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33949400|NCT04180956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The participants, who are the care providers, are blind to condition in that they are simply told when to show up for patient exams and the workshop (intervention condition). The outcomes assessors who rated microaggressions was blind to condition.|This is a randomized controlled trial, wherein doctors are prospectively assigned to either an intervention or waitlist control condition.|t|t|f|t
33949401|NCT06341582|||COHORT||PROSPECTIVE|||||||
33949402|NCT00538434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949403|NCT03514823|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949404|NCT03233191|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomized to either Digital Breast Tomography (TM) or Full Field Digital Mammography (DM)||||
33949405|NCT01001091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949406|NCT05448469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949407|NCT01597284|||OTHER||PROSPECTIVE|||||||
33949408|NCT00717665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949409|NCT03948321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator assesses photographs without prior knowledge of intervention||f|f|f|t
33949410|NCT03699722|RANDOMIZED|PARALLEL||PREVENTION||NONE||At the baseline visit, participants will be randomly assigned to intervention or control conditions in a 3:1 ratio, stratified by site. Participants will remain in those assigned groups for the duration of the study.||||
33949411|NCT03110367|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into three groups:~1. Attention Control Group~2. Normal Reminiscing~3. Intervention Group"||||
33949412|NCT03557775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Perceptual ratings of voice quality and of videostroboscopic images of the larynx will be rater by external judges, who will be blinded to the group assignment and to the assessment time (pre or post treatment).||f|f|f|t
33949413|NCT02137031||||TREATMENT||||||||
33949414|NCT01780948|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33949415|NCT00094146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33949416|NCT01328613|||||OTHER|||||||
33949417|NCT04057586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33949418|NCT02358707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949419|NCT02945566|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33949420|NCT00509223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949421|NCT03033641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949422|NCT05376540|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33949423|NCT02331680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949424|NCT05360212|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33949425|NCT03568968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants and investigators are blinded.|Randomized double-blinded study. N = 400 participants are randomized in a 1:1 ratio to either nicotinamide riboside (500 mg x 2 per day) or placebo.|t|f|t|f
33949426|NCT00612963|||CASE_ONLY||PROSPECTIVE|||||||
33949427|NCT04805632|||COHORT||PROSPECTIVE|||||||
33949428|NCT00243620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949429|NCT04303741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949430|NCT01102829|||COHORT||PROSPECTIVE|||||||
34155650|NCT02690649|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155651|NCT03934853|NA|SINGLE_GROUP||OTHER||NONE||||||
34155652|NCT04856904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155653|NCT02409719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155654|NCT00407316|||DEFINED_POPULATION||OTHER|||||||
34155655|NCT01417455|||||PROSPECTIVE|||||||
34155656|NCT02021630|||FAMILY_BASED||PROSPECTIVE|||||||
34155657|NCT00719888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155658|NCT06303063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155659|NCT00166530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155660|NCT02583555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34155661|NCT00644436|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34155662|NCT03869606|||CASE_CONTROL||PROSPECTIVE|||||||
34155663|NCT04870372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741349|NCT06074926|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Membership in the intervention versus control group will not be discussed as such, but participants will know whether they receive the repeated exposure (control group) or associative conditioning (intervention group) activities."|||||
33949431|NCT05673954|||CASE_CONTROL||PROSPECTIVE|||||||
34052501|NCT05641285|||COHORT||PROSPECTIVE|||||||
34052502|NCT00879346||CROSSOVER||BASIC_SCIENCE||NONE||||||
33949432|NCT06463132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1A, PEP Low Dose Arm 1B, PEP High Dose Arm 2A, PEP-EUFLEXXA Low Dose Arm 2B, PEP-EUFLEXXA High Dose||||
34052503|NCT04210388|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The overall treatment period will start with a 2-period, 2-dose treatment crossover, followed by a 3-period, 3-dose treatment crossover.~The following treatments will be given:~Treatment A: AZD5718 (Formulation A) Treatment B: AZD5718 (Formulation B) Treatment C: AZD5718 (Formulation C) Treatment D: AZD5718 (Formulation D) AZD5718 (AZD5718 film-coated tablet, Reference treatment)"||||
34052504|NCT05770271|NA|SINGLE_GROUP||TREATMENT||NONE|An open label, single arm and before and after treatment comparison study|||||
34052505|NCT00570427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052506|NCT05236777|||COHORT||PROSPECTIVE|||||||
34052507|NCT02263391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34052508|NCT05916859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052509|NCT05600270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded study with masking of participant|Randomized, Controlled, Single-Blinded Trial|t|f|f|f
34052510|NCT05697029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052511|NCT00402558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052512|NCT05230368|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a monocenter pilot open label phase I trial. This trial will evaluate new procedures in LRA administration in 3 successive cohorts of 5 patients each receiving 1, 2 and 4 cycles respectively.||||
34052513|NCT04265638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052514|NCT02364323|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34052515|NCT01430403|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34052516|NCT01406145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052517|NCT02175394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052518|NCT06667817|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be aware of which study group they are assigned to. Investigators will also be aware of what study group participants are assigned to.|||||
34052519|NCT05585541|||CASE_ONLY||PROSPECTIVE|||||||
34052520|NCT05778838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052521|NCT02637401|||CASE_ONLY||PROSPECTIVE|||||||
34052522|NCT05935163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052523|NCT03734328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled trial|f|f|f|t
34052524|NCT02591823|||CASE_CONTROL||PROSPECTIVE|||||||
34155664|NCT02261766|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34155665|NCT06414577|NA|SINGLE_GROUP||TREATMENT||NONE||liposomal irinotecan administered intravenously at a dose of 70 mg/m2 on day 1, along with nituzumab given at a dose of 400 mg via intravenous injection on the same day.||||
34155666|NCT02346617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155667|NCT00966550|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33741350|NCT01072682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741351|NCT02426632|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33741352|NCT05155436|NA|SINGLE_GROUP||TREATMENT||NONE||The people residing in Mirpur at Dhaka city have been included in this study with matching the inclusion criteria which are as follows: Age ≥40 years for men and ≥ 50 years for women who had menopause for 1 year; Systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg (average across two visits as detailed in 'Measurements' section below); Adults not currently (in the past month) taking BP medications||||
33741353|NCT01446848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741354|NCT03753126|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33949433|NCT02679300|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33949434|NCT02936466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949435|NCT00968565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949436|NCT04753931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind||t|f|f|f
33949437|NCT01855607|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33949438|NCT00650806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949439|NCT05011357|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single blind||t|f|f|f
34052525|NCT06667206|RANDOMIZED|PARALLEL||PREVENTION||NONE|All participants receive the same vaccines but are randomised to the timing of administration of the vaccines.|Equal numbers of participants are randomised to 3 arms.||||
34052526|NCT01728662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052527|NCT00131950||||SCREENING||||||||
34052528|NCT02556294|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052529|NCT04885179|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052530|NCT04696185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All events will be adjudicated by the Clinical Events Adjudication Committee (CEAC), without information about the therapy (intervention or control) (blinded endpoint)|"Dapa-TAVI is a pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical trial. Patients being discharged after TAVI who meet all inclusion criteria, and none of the exclusion criteria, will be eligible for the enrollment. Patients will be 1:1 randomized to 1 of these 2 arms:~* Intervention group: Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg.~* Control group: no SGLT-2 inhibitor therapy with dapagliflozin."|f|f|f|t
34052531|NCT06667986|||OTHER||PROSPECTIVE|||||||
34052532|NCT04091412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34075815|NCT06410651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075816|NCT05855434|||CASE_ONLY||CROSS_SECTIONAL|||||||
34075817|NCT00149396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075818|NCT05868538|||CASE_CONTROL||PROSPECTIVE|||||||
34075819|NCT04019717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will receive 8 or 12 weeks of treatment, based on treatment response.||||
34155668|NCT03229733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155669|NCT03068767|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Group 1: vitamin D supplement Group 2: controls||||
34155670|NCT03138161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155671|NCT01647776|||CASE_CONTROL||PROSPECTIVE|||||||
34155672|NCT02333786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34155673|NCT05870878|RANDOMIZED|PARALLEL||PREVENTION||NONE||Block randomisation with stratification factor: pregnancy status (yes/no)||||
34155674|NCT06351254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34155675|NCT06315127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155676|NCT04365166|||CASE_ONLY||PROSPECTIVE|||||||
34155677|NCT01091012|RANDOMIZED|PARALLEL||||NONE||||||
34155678|NCT06500312|||COHORT||PROSPECTIVE|||||||
34052533|NCT04738617|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Testing will be blinded to the interventions and to the goals of the current research. Two external professionals, with a master's degree in Sports Science and experienced in collecting the data will be responsible for collecting the tests at all time points. In each test, they will be further blinded to the previous results. Additionally, two researchers will assist in operationalizing the tests; these researchers will be blinded to the participants' allocation, but not to the study's goals.|Two weeks of familiarization with protocols and testing. Then, randomization with cross-over design. Two weeks of intervention, followed by two weeks of wash-out, followed by two weeks of intervention.|f|f|f|t
34155679|NCT01024842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052534|NCT06192927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052535|NCT01210196|||OTHER||PROSPECTIVE|||||||
33845026|NCT04510311|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All subjects (30 anticipated) will receive a PET/CT scan using the novel radiotracer \[18F\]3F-PHPG as an imaging agent. Within 60 days after the \[18F\]3F-PHPG PET/CT scan, approximately 12 of the subjects will also receive an FDA approved radiotracer \[123I\]MIBG one day prior to whole-body planar scintigraphy and SPECT/CT scans. The \[123I\]MIBG scans are standard clinical imaging procedures.||||
33845027|NCT02097173|RANDOMIZED|CROSSOVER||||NONE||||||
33845028|NCT05717439|||CASE_CONTROL||PROSPECTIVE|||||||
33845029|NCT05109182|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The following will be blinded: Chief Investigator, Senior Statistician, Research Nurses, Trial Steering Committee~The following will be unblinded: Principal Investigators at site, Trial Manager/monitor, Junior Statistician, Trial Participants, Treating clinicians, Data Monitoring Committee"|"This RCT, is a multi-centre main trial and will recruit patients selected for minimally-invasive robotic-assisted renal cancer surgery during the enrolment period. The study will compare current surgical planning method to planning with the addition of virtual 3D models in randomised patient groups.~There are no clinical treatment changes/interventions in addition to the standard-of-care procedures. Participants will have 3D models of their anatomy built, clinical team and participant feedback will be obtained in the form of a survey, and the measurability of the key trial outcomes will be assessed as outlined below.~Patient participation in the trial is expected to take no longer than 9 weeks, including a 4-week follow-up, from the initial participant information meeting. Methods used to assess outcomes will employ medical data analysis, participant opinion and observational measurements."|f|f|t|f
34052536|NCT01010295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052537|NCT03878836|||COHORT||PROSPECTIVE|||||||
34052538|NCT06668051|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052539|NCT06654141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155680|NCT01829022|||CASE_ONLY||PROSPECTIVE|||||||
34155681|NCT04185389|||COHORT||OTHER|||||||
34155682|NCT01630889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155683|NCT04433065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155684|NCT01401608|||COHORT||PROSPECTIVE|||||||
34155685|NCT04988009|||COHORT||PROSPECTIVE|||||||
34155686|NCT02122367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155687|NCT01054625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155688|NCT01622777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155689|NCT04356716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to the investigational sildenafil arm with a dose of 40-80mg daily, or the records review arm when taking sildenafil off-label.||||
34155690|NCT05880498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155691|NCT00004689|RANDOMIZED|||TREATMENT||NONE||||||
34155692|NCT06232785|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34155693|NCT02220426|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155694|NCT05236244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845030|NCT06223906|||COHORT||RETROSPECTIVE|||||||
33845031|NCT02016040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155695|NCT05818280|||COHORT||PROSPECTIVE|||||||
34155696|NCT04112394|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34155697|NCT00692419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845032|NCT04620564|||COHORT||PROSPECTIVE|||||||
33845033|NCT02408601|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34155698|NCT05526339|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155699|NCT02978950|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34155700|NCT02919527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155701|NCT02673684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155702|NCT03997825|||OTHER||PROSPECTIVE|||||||
34155703|NCT05795153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155704|NCT06121024|||COHORT||RETROSPECTIVE|||||||
34155705|NCT04816058|||CASE_CONTROL||PROSPECTIVE|||||||
34155706|NCT04870918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|There will be blinding to assess outcomes, that is, review of medical records and phone calls in order to have knowledge about rehospitalization.|One group will have self-care guidelines and the other will not. Medical appointments will be the same for both groups.|f|f|f|t
34155707|NCT00839761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155708|NCT03090204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155709|NCT00193921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155710|NCT06009328|||COHORT||PROSPECTIVE|||||||
34155711|NCT00773773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845034|NCT01493427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155712|NCT04751188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34155713|NCT01078844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155714|NCT01340573|||COHORT||PROSPECTIVE|||||||
34052540|NCT03817905|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34052541|NCT04353440|||COHORT||PROSPECTIVE|||||||
34052542|NCT03105635|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants are patients Care providers are practices||t|t|f|f
34052543|NCT00161642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052544|NCT02222350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052545|NCT03046316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052546|NCT01720498|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34052547|NCT02348151|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34052548|NCT03793673|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34052549|NCT01901354|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052550|NCT00688675|||||RETROSPECTIVE|||||||
34052551|NCT03619083|||COHORT||PROSPECTIVE|||||||
34052552|NCT03227146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052553|NCT04630236|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052554|NCT00924495|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34052555|NCT02985008|||COHORT|||||||||
34052556|NCT06439381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155715|NCT02537184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34155716|NCT06478303|||CASE_CONTROL||PROSPECTIVE|||||||
34155717|NCT01153555|||COHORT||PROSPECTIVE|||||||
34155718|NCT03725761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155719|NCT05532891|||COHORT||RETROSPECTIVE|||||||
34155720|NCT02818049|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155721|NCT04790292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155722|NCT04767984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155723|NCT04003987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patients and the research staff doing assessments will be blinded to the randomization|"1. ESP Block Group~2. TAP Block Group"|t|f|f|t
34155724|NCT05801614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155725|NCT04715698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155726|NCT05987956|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|No-placebo and random and double blind|"* The usual approach group (NDC...01)~* The study approach group (NDC...86)"|t|t|t|t
34155727|NCT02903732|||||CROSS_SECTIONAL|||||||
34155728|NCT04180566|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155729|NCT04730531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845035|NCT04174794|||COHORT||PROSPECTIVE|||||||
33845036|NCT00240799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845037|NCT02655068|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845038|NCT00269438|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33845039|NCT05793008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845040|NCT04343287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Masking||t|f|t|f
33845041|NCT00318162|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33845042|NCT03538301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845043|NCT03313375|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Subjects will have a randomized order of treatment (exercise bouts). Each subject will complete all three (control, cont. exercise, aerobic interval), but in a randomized order.|f|f|t|f
33845044|NCT06228391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845045|NCT01619553|||CASE_CONTROL||PROSPECTIVE|||||||
33845046|NCT00335439|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33845047|NCT04207177|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The main study is based on treatment allocation outside of thsi protocol but a subgroup of living donor recipients will be randomized to wither one week tacrolimus or mycophenolate mofetil treatment before transplantation.||||
34052557|NCT03261050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052558|NCT04886219|||OTHER||PROSPECTIVE|||||||
34052559|NCT02712138|||COHORT||PROSPECTIVE|||||||
34052560|NCT05301283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052561|NCT00750139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052562|NCT04082117|NA|SINGLE_GROUP||OTHER||NONE||Educational genetic counseling video||||
34052563|NCT04223635|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052564|NCT02353897|||COHORT||PROSPECTIVE|||||||
34052565|NCT02932774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052566|NCT02838719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34052567|NCT01075646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052568|NCT05764538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052569|NCT03683693|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Matched cohort: historical standard of care group (patients from the period January 2016 - April 2018) versus interventional group (patients from May 2018 on)||||
34052570|NCT02545478|||COHORT||PROSPECTIVE|||||||
34052571|NCT03387228|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessor and statistician performing data analysis will be masked for the group allocation of all the participants.|Feasibility of a two group randomized clinical trial.|f|f|f|t
34052572|NCT03453879|||CASE_ONLY||PROSPECTIVE|||||||
34052573|NCT00656851|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34052574|NCT06372249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052575|NCT01640769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052576|NCT05044936|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated Measures||||
34052577|NCT05283226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052578|NCT05544773|||COHORT||PROSPECTIVE|||||||
34052579|NCT01582633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052580|NCT02715362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052581|NCT00517140|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155730|NCT01378468|||COHORT||PROSPECTIVE|||||||
34052582|NCT05929729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052583|NCT00831298|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052584|NCT06666881|RANDOMIZED|PARALLEL||OTHER||SINGLE|group random|This project can determine the baseline skeletal muscle mass of Head and Neck cancer patients and hopes to monitor its changes after exercise training through imaging tools and find the most suitable imaging modalities. To understand the role of systemic inflammatory markers in sarcopenia,exercise training and Head and Neck cancer cancer prognosis. This study hopes to serve as a basis and reference for clinical treatment selection, imaging follow up, interventional treatment or rehabilitation. The results of this research should benefit patients in Taiwan and abroad, and to promote the medical treatment and health of patients.|t|f|f|f
34052585|NCT02376569|||COHORT||PROSPECTIVE|||||||
34052586|NCT00438100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052587|NCT05028127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052588|NCT02411058|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34052589|NCT05082558|||COHORT||RETROSPECTIVE|||||||
34052590|NCT00465803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052591|NCT02538887|||CASE_ONLY||PROSPECTIVE|||||||
34052592|NCT03089697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052593|NCT00738790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052594|NCT02818985|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34052595|NCT05438004|NA|SINGLE_GROUP||OTHER||NONE||||||
34052596|NCT00804102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34052597|NCT03881696|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34052598|NCT00847769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34052599|NCT04929288|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052600|NCT05441111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052601|NCT02657213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052602|NCT03200704|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label, within patient study||||
34052603|NCT05077176|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination (CoronaVac or TURKOVAC) Against SARS-CoV-2||||
34052604|NCT01106677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052605|NCT06668493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052606|NCT02984163|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34052607|NCT03256058|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34052608|NCT05153200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|MSK-US assessors will be blinded to treatment allocation, pain scores, and disease activity measures.||f|f|f|t
34052609|NCT03108586|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Patients, clinical operators responsible for dental treatment, and the examiner who will assess the outcomes will be blind to the allocation group of the participants.||t|t|f|t
34052610|NCT01633684|||CASE_CONTROL||PROSPECTIVE|||||||
34052611|NCT01159366|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052612|NCT03964714|||COHORT||PROSPECTIVE|||||||
34052613|NCT03890913|||CASE_ONLY||PROSPECTIVE|||||||
34052614|NCT03091036|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34052615|NCT05283135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052616|NCT06207149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34052617|NCT04597541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052618|NCT02465879|NA|SINGLE_GROUP||||NONE||||||
34052619|NCT05407974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052620|NCT03234517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052621|NCT02340260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052622|NCT06084884|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
34052623|NCT06159556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcome assessor will not be aware which participant is in what arm. The participant and the care provider will know about the treatment allocation.|The proposed study is a 12 week parallel- group , free living, observer-blind randomized controlled study with 80 adult men and women|f|f|t|t
34052624|NCT06384001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34052625|NCT06666751|||COHORT||RETROSPECTIVE|||||||
34052626|NCT00419601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052627|NCT03722758|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34052628|NCT04798989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052629|NCT00809640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34052630|NCT05026099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052631|NCT04633629|||COHORT||PROSPECTIVE|||||||
34052632|NCT00474201|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34052633|NCT03864861|||COHORT||PROSPECTIVE|||||||
34052634|NCT06667193|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel, randomized design, matched for biological age||||
34052635|NCT03076788|||COHORT||PROSPECTIVE|||||||
34052636|NCT03587883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomized, double-masked and cross-over dietary intervention study in healthy adults.|t|t|t|t
34052637|NCT06014593|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The device will be tested to measure biomarkers in a group of 55 Heart Failure patients and 20 healthy subjects.||||
34052638|NCT06658405|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study uses a non-randomized design with two cohorts: vaccinated patients in a single-arm clinical trial and non-vaccinated patients in an observational study, chosen to reflect real-life scenarios and ensure comprehensive data collection despite the absence of randomization..||||
34052639|NCT01437891|||CASE_CONTROL||PROSPECTIVE|||||||
34052640|NCT04673747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052641|NCT03574142|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open-label Study|Single group||||
34155731|NCT03124082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized double blind trial|t|f|t|t
33949440|NCT06073106|||COHORT||PROSPECTIVE|||||||
34155732|NCT03295617|||COHORT||RETROSPECTIVE|||||||
34155733|NCT03962530|||COHORT||PROSPECTIVE|||||||
34155734|NCT02083497|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34155735|NCT06167707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155736|NCT00002822|RANDOMIZED|||TREATMENT||||||||
34155737|NCT00005818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155738|NCT00051896||||TREATMENT||DOUBLE||||||
34155739|NCT00662545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155740|NCT04583956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155741|NCT03876275|||COHORT||PROSPECTIVE|||||||
34155742|NCT01025830|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155743|NCT06579846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155744|NCT03424603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845048|NCT03320161|||COHORT||PROSPECTIVE|||||||
33845049|NCT04824690|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33845050|NCT00004583||||TREATMENT||DOUBLE||||||
33845051|NCT01445600|||||PROSPECTIVE|||||||
33949441|NCT05431673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3 Groups A will receive Doxycycline B will receive Ciprofloxacin and Doxycycline C will receive Rifampin|t|f|f|f
33949442|NCT05390294|||COHORT||OTHER|||||||
33949443|NCT05023499|||COHORT||RETROSPECTIVE|||||||
33949444|NCT00267826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155745|NCT02828020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155746|NCT01674777|RANDOMIZED|CROSSOVER||||NONE||||||
34155747|NCT03579641|||COHORT||PROSPECTIVE|||||||
34155748|NCT02168608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34155749|NCT04300608|||COHORT||CROSS_SECTIONAL|||||||
34155750|NCT02572765|||COHORT||PROSPECTIVE|||||||
34155751|NCT01824433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155752|NCT01511081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155753|NCT02343809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845052|NCT00181870|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845053|NCT02104297|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33845054|NCT04349839|||COHORT||PROSPECTIVE|||||||
33845055|NCT02395146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845056|NCT04408703|||COHORT||PROSPECTIVE|||||||
33845057|NCT06610175|||COHORT||PROSPECTIVE|||||||
33845058|NCT02908932|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33845059|NCT01732822|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845060|NCT01302080|||COHORT||PROSPECTIVE|||||||
33845061|NCT05774132|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845062|NCT05452304|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33845063|NCT06728072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845064|NCT06729580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845065|NCT02689843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33845066|NCT05682703|||COHORT||OTHER|||||||
33845067|NCT01012817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845068|NCT02830126|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33845069|NCT05228743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845070|NCT04495075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Assessing investigator was blinded to the intervention that was received by the participant.|Laboratory Controlled Crossover Study|f|f|t|t
33845071|NCT06018727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33845072|NCT04357600|NA|SINGLE_GROUP||TREATMENT||NONE||The study model is considered as a single group assignment since all the participants are being administered with the same treatment.||||
33845073|NCT04012476|NA|SINGLE_GROUP||PREVENTION||NONE||Single group: patients undergoing total thyroidectomy with intraoperative infusion of intravenous indocyanine green A prospective unicentric and open clinical trial in which the fluorescence intensity of the parathyroid glands after indocyanine administration will be compared between two groups of patients: those with post-thyroidectomy hypocalcemia and patients who do not present it.||||
33845074|NCT06623344|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33845075|NCT05057780|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Resident participants did not know which curriculum was intervention and which was control. Patient participants did not know what communication curriculum their resident physician had completed.|cluster randomized controlled trial|t|t|f|f
33845076|NCT03455608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845077|NCT02095288|||OTHER||OTHER|||||||
33845078|NCT05746208|NA|SEQUENTIAL||TREATMENT||NONE||||||
33845079|NCT03815682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845080|NCT06370052|||CASE_ONLY||PROSPECTIVE|||||||
33845081|NCT02471105|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33845082|NCT03122223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845083|NCT03977181|RANDOMIZED|PARALLEL||PREVENTION||NONE|The allocation of study arm is concealed to study staff during randomization|Investigators will perform a 3-arm randomized controlled trial, with participants randomized to one of the following arms: Arm 1) a group-based community health club akin to an ART adherence club; Arm 2) one-on-one adherence counseling and support; or Arm 3) community-based medication dispensary.||||
34155754|NCT03092505|||CASE_ONLY||PROSPECTIVE|||||||
34155755|NCT01992211|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||6 x 3||||
34155756|NCT01478906|||||PROSPECTIVE|||||||
34155757|NCT03786471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"* 2150 dyads of persons with dementia and their respective primary caregiver~* 1000 in each intervention arm, and 150 in the usual care arm"|f|f|t|t
34155758|NCT02643732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155759|NCT01111279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155760|NCT01313338|||CASE_ONLY||PROSPECTIVE|||||||
34155761|NCT05249244|||COHORT||RETROSPECTIVE|||||||
34155762|NCT06156241|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Non-Randomized, Phase 1/2a dose escalation using 4X10\^6/kg, 6X10\^6/kg and 8X10\^6/kg and 10X10\^10/kg cohorts of 3 patients using an adaptive Bayesian design based upon infusional toxicity/safety.||||
34155763|NCT00002230||||TREATMENT||||||||
34155764|NCT04381650|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study has 2 Phases. Phase 1 is dose escalation phase with sequential drug assignment. Phase 2 is parallel assignment.||||
34155765|NCT01029847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155766|NCT01226576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155767|NCT03625999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34155768|NCT06347263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blinding of the operator and patient is not applicable.~- Outcome assessor (primary and secondary outcomes) \& biostatistician will be blinded"||f|f|f|t
34155769|NCT03659136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155770|NCT01278797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||||||
34155771|NCT05040074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155772|NCT00622388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155773|NCT05769140|||COHORT||PROSPECTIVE|||||||
34155774|NCT03304873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155775|NCT06536192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34155776|NCT00168454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155777|NCT04600583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155778|NCT01816867|||CASE_ONLY||PROSPECTIVE|||||||
34155779|NCT02980133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155780|NCT03578328|||COHORT||RETROSPECTIVE|||||||
34155781|NCT03342118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155782|NCT03219346|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155783|NCT03596580|||OTHER||CROSS_SECTIONAL|||||||
34155784|NCT03618316|NA|SINGLE_GROUP||OTHER||NONE||||||
34155785|NCT02021955|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34155786|NCT04415411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the research, it was not possible to blind the participants to group assignment. Additionally, due to the study being conducted for a doctoral thesis, data collection (pre and posttest), interviews, interventions and evaluation of data carried out by the same researcher who was not blinded.|In this study, there are two groups as intervention group and control group. Investigator, administered not any application to control group. Nursing care which based on the Theory of Human Caring was given to intervention group for 4 weeks.||||
34155787|NCT02223806|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155788|NCT02767661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155789|NCT05024708|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34155790|NCT00837343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052642|NCT04250532|||OTHER||PROSPECTIVE|||||||
34075820|NCT02871609|||COHORT||PROSPECTIVE|||||||
34075821|NCT01212094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155791|NCT02703480|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Split-mouth study|t|f|f|f
34155792|NCT02019875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34155793|NCT01361490|||OTHER||PROSPECTIVE|||||||
34155794|NCT00994643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155795|NCT04534881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155796|NCT00500955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155797|NCT01085292|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34155798|NCT00769457|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075822|NCT01078064|||CASE_ONLY||CROSS_SECTIONAL|||||||
34155799|NCT03646565|||CASE_ONLY||OTHER|||||||
34155800|NCT05945251|||CASE_CONTROL||PROSPECTIVE|||||||
34155801|NCT02205528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155802|NCT03214042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155803|NCT03752658|||COHORT||PROSPECTIVE|||||||
34155804|NCT04439981|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects were divided by 2 groups: control group (n=10), treated by ice cream without any Curcuma extract supplementation; and treatment group (n=10), treated by ice cream supplemented by Curcuma extract.||||
34155805|NCT03719989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155806|NCT05582174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|random sequence was investigator-blinded||f|f|t|f
34155807|NCT00477152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155808|NCT00232856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155809|NCT02363296|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34155810|NCT05131633|||COHORT||PROSPECTIVE|||||||
34155811|NCT01670773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34155812|NCT03040037|||COHORT||PROSPECTIVE|||||||
33949445|NCT03620669|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm open-label multicenter phase II trial||||
33949446|NCT04624282|||COHORT||PROSPECTIVE|||||||
33949447|NCT03117556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All patients with unresectable pancreatic cancer will be considered for participation in this study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment with narcotic analgesia alone.||||
33949448|NCT02067728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949449|NCT02529722|||COHORT||CROSS_SECTIONAL|||||||
33949450|NCT00096031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949451|NCT03013972|||COHORT||PROSPECTIVE|||||||
33949452|NCT01640600|||CASE_CONTROL||OTHER|||||||
33949453|NCT05092217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949454|NCT00281931|NON_RANDOMIZED|||TREATMENT||NONE||||||
33949455|NCT04054531|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949456|NCT01429194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949457|NCT00458133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949458|NCT01162109|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33949459|NCT04576676|||CASE_CONTROL||PROSPECTIVE|||||||
33949460|NCT00396357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949461|NCT03981523|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three of 6 parallel groups will receive one of three different oral benznidazole (BZN) dosing regimens and the other three will receive one of the three different nifurtimox (NFX) regimens.||||
33949462|NCT02183948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33949463|NCT04809415|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33949464|NCT06372158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33949465|NCT04163419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949466|NCT01449474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949467|NCT02525575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949468|NCT03599882|||COHORT||PROSPECTIVE|||||||
33949469|NCT02009072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949470|NCT01734499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949471|NCT03530267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949472|NCT03917966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949473|NCT05874882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|the supervisor will place the mouthwash in dark bottle with number so neither the examiner nor the patient will know the type of the mouthwash|the study include three groups. one of them is the study group in which the patient will use resveratrol mouthwash as adjunct to scaling, the second group use chlorhexidine mouthwas as adjunct to scaling while the third group will use a placebo. all the participants and the examiner are blinded regarding the type of the mouthwash they will be using|t|t|t|t
33949474|NCT00752063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949475|NCT04427241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949476|NCT03214016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33949477|NCT00936468|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33949478|NCT06189482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949479|NCT03831282|NA|SINGLE_GROUP||OTHER||NONE||||||
33949480|NCT04772339|||COHORT||PROSPECTIVE|||||||
33949481|NCT04895423|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949482|NCT05151887|RANDOMIZED|CROSSOVER||PREVENTION||NONE|In this trial, neither the participants, nor the researchers who perform the trial days will be blinded to the intervention allocation. However, the researchers performing the sample analysis are blinded to intervention allocation and are not involved in the research study during the trial days.|The present study utilizes a randomized, counter-balanced, cross-over design in healthy older male and female participants. In total, 16 healthy older men and women (1:1 ratio of men:women) will participate in the study (20 including potential drop-out). Participants will be randomly assigned to either receive the meal including meat or exclusively plant based foods during the Test Day 1. During Test Day 2, participants will receive the other meal.||||
33949483|NCT03868059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949484|NCT00518609|||||PROSPECTIVE|||||||
33949485|NCT01065662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949486|NCT02525367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949487|NCT02032433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949488|NCT02345499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33949489|NCT00816062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949490|NCT01061346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33949491|NCT00984646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155813|NCT04859816|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34155814|NCT04930094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
34155815|NCT00604045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155816|NCT04050813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155817|NCT03034824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34155818|NCT03291860|||COHORT||PROSPECTIVE|||||||
34155819|NCT03963427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155820|NCT00155701|||DEFINED_POPULATION||OTHER|||||||
34155821|NCT02409771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155822|NCT02556060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155823|NCT00465777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155824|NCT00351507|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34155825|NCT01840527|||CASE_CONTROL||PROSPECTIVE|||||||
34155826|NCT05693506|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped Wedge||||
34155827|NCT04886791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blinded for which surgery they will undergo|Single-blinded, multicentre, randomised controlled trial|t|f|f|f
34155828|NCT00428389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155829|NCT03900273|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155830|NCT04510103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The test moisturizers were assigned a product code; each moisturizer was assigned to a subject's right or left lower leg per a randomization schedule. Subjects were blinded to the product identities, and evaluators were blinded to which product was used on each leg. Procedural group was unblinded and based on scheduling at Visit 1.|Subjects were assigned to one of two procedural groups (Regression or Non-Regression) based on Visit 1 scheduling. Subjects were provided with a commercial cleanser to use during a 3-day period with no moisturizers and no hair removal allowed on their lower legs, and to continue using throughout the study. At Visit 2, all subjects received the two test moisturizers to use split-leg (right vs. left lower leg randomized) to use for 6 weeks. Subjects returned for evaluations at Week 2 (Visit 3), Week 4 (Visit 4), and Week 6 (Visit 5). At Week 6, subjects in the Regression group entered a 2-week regression period (no moisturizer usage) and returned for evaluations at Regression Days 1, 4, 7, 10, and 14. Meanwhile, at Week 6, subjects in the Non-Regression group (exploratory) continued using the moisturizers; they returned for evaluations at Week 6 + Days 1, 2, 3, and 4.|t|f|t|t
34155831|NCT01246336|||OTHER||PROSPECTIVE|||||||
34155832|NCT01700153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155833|NCT05096949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized parallel design||||
34155834|NCT06583356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155835|NCT01506284|||||PROSPECTIVE|||||||
34155836|NCT05485623|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Approximately 120 women will be recruited to accommodate 20% drop out. A comparison between FC scan and in-clinic scan (ground truth - GT) will be performed in order to assess the safety, feasibility and efficacy of the Pulsenmore FC device in the two operation modes.~Naïve subjects who haven't use the FC device will be allocated to use the CG-mode. While experienced patients who already used the FC device will be offered to use the AG mode for a second cycle."||||
34155837|NCT03777319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomly assigned to either to the spironolactone treatment group or to the standard clinical dose of corticosteroids.||||
34155838|NCT05198843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155839|NCT02672124|||COHORT||RETROSPECTIVE|||||||
34155840|NCT05804032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155841|NCT02812927|RANDOMIZED|PARALLEL||||NONE||||||
34155842|NCT04046978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34155843|NCT04720092|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34155844|NCT04496427|||OTHER||PROSPECTIVE|||||||
34155845|NCT01870310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155846|NCT02211456|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845084|NCT04730817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors at both pre- and post-observations will be blinded to the group label.|"A total of 400 subjects with cognitive frailty will be assigned into 2 groups. Half the participants will be assigned to the intervention group in which they will undertake VR simultaneous motor-cognitive training and others will be assigned to the control group in the form of passive (wait list) control, i.e., they will not be given any kind of treatment.~The following dosage will be employed onto the intervention group using the VR simultaneous motor-cognitive training that we proposed. I.e.,~Course: eight weeks Session duration: 30 minutes Frequency: twice per week"|f|f|f|t
33845085|NCT03825549|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33845086|NCT03505177|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Supplementation during 3 weeks with 4.5g of chitin-glucan||||
33949492|NCT01710839|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33949493|NCT01797458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949494|NCT01326312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949495|NCT05158075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The psychologists that conduct the assessments (screening, assessment sessions and follow-ups) will be blinded to the group allocation during the whole project. Moreover, since all assessments will be computerized and online, they are not subject to the biases of the evaluator. Further, all participants will be blind to their condition. Also, the people who perform the statistical analyses will be blind to the condition of the groups, through the coding of the interventions. Only the therapist performing the interventions will not be blind to the allocation of the participants.|Parallel group randomized controlled trial|t|f|f|t
33949496|NCT03252652|||OTHER||CROSS_SECTIONAL|||||||
33949497|NCT03175809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blinded (outcome assessor)|Randomized clinical trial|f|t|t|t
33949498|NCT04980599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949499|NCT01233427|||COHORT||PROSPECTIVE|||||||
33949500|NCT04673552|||COHORT||RETROSPECTIVE|||||||
33949501|NCT00563927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949502|NCT04619043|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949503|NCT03045926|NA|SINGLE_GROUP||OTHER||NONE||The study is interventional Phase 1 without individual benefit.||||
33949504|NCT01901029|||COHORT||CROSS_SECTIONAL|||||||
33949505|NCT06363227|||COHORT||RETROSPECTIVE|||||||
33949506|NCT03603626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949507|NCT00593385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949508|NCT05809219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052643|NCT05706844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physcians and nurses in the surgical department are not able to be blinded. But outcome assesors (ie. physiotherapists, research personel) are not aware of the treatment allocation.|"Each of the three arthroplasty procedures are investigated in a 2-arm randomised trial:~Total hip arthroplasty - either spinal anaesthesia or general anaesthesia.~Total knee arthroplasty - either spinal anaesthesia or general anaesthesia.~Unicompartmental knee arthroplasty - either spinal anaesthesia or general anaesthesia."|f|f|f|t
34052644|NCT02118142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33845087|NCT04847791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients are blind as Placebo administration consists of capsule identical with the same amount as an inert compound, starch of corn powder, and dispensed according to the same pattern of use. Care provider and investigator are blind as they do not know the capsule content (blisters are labelled: group 'A' or group 'B')|Prospective randomized double-blind placebo- controlled designed trial|t|t|t|t
33845088|NCT05069675|||COHORT||RETROSPECTIVE|||||||
34052645|NCT03701841|||COHORT||PROSPECTIVE|||||||
34052646|NCT00004875|||COHORT||PROSPECTIVE|||||||
33845089|NCT02048475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845090|NCT06155188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845091|NCT04427059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052647|NCT02764801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052648|NCT06436248|||COHORT||PROSPECTIVE|||||||
33845092|NCT03605576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052649|NCT00622661|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34052650|NCT05768763|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In the evaluation Phase B, the SEARCH SAPPHIRE study will evaluate the effects of Dynamic Prevention and Dynamic Treatment intervention packages based on data from Phase A (NCT04810650) and new advances from outside the study delivered in a precision community health model, on HIV incidence and other health outcomes, in a pair-matched community randomized design."||||
34052651|NCT02009124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052652|NCT06173635|NA|SINGLE_GROUP||OTHER||NONE||||||
34052653|NCT03929601|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This study is double blinded.|This protocol will enroll 74 participants who will be treated with a course of rituximab-pvvr (weekly infusion for 4 weeks), followed by treatment with abatacept or placebo starting at 4 months after initial rituximab-pvvr treatment and continuing to month 24. The abatacept/placebo treatment will be self-administered by participants (or their families/guardians, where most appropriate, particularly with pediatric participants) weekly for 20 months. Rituximab-pvvr will be given by IV infusion over at least 3 hours, at a dose of 375mg/m2 on four visits each one week apart, starting at Week 0 of the study. Abatacept/placebo will be given by a subcutaneous formulation weekly for 20 months, beginning at Week 16 (Month 4) of the study. Dosing will be determined by weight: Up to 25 kg: 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL).|t|t|t|t
34052654|NCT01539772|||COHORT||PROSPECTIVE|||||||
34052655|NCT04895462|||COHORT||RETROSPECTIVE|||||||
34052656|NCT04923581|RANDOMIZED|FACTORIAL||PREVENTION||NONE||A factorial trial following the Multiphase optimization Strategy (MOST)||||
34052657|NCT03321708|||COHORT||PROSPECTIVE|||||||
34052658|NCT04843124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052659|NCT02004886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052660|NCT04692480|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"Nulliparous women planning to exclusively breastfeed will be consented and will complete a survey regarding demographics and breastfeeding education experience. Participants will be randomized to viewing a standard breastfeeding education PDF (Control) or to watching an educational video entitled Breastfeeding in the First Hour, It's in Your Hands(Intervention group). Both activities will occur on a tablet. Participants will undergo routine intrapartum care. On the day of discharge, patient's will complete a survey that includes the Breastfeeding Self-Efficiency Scale-Short Form, the Perception of Insufficient Milk Questionnaire, and questions regarding in hospital breastfeeding educational experiences. Data will be compared between the two groups to determine if antepartum video education improved perception of breast milk supply and efficiency and increases exclusive breastfeeding rates. At 6 months postpartum, women will be surveyed by phone regarding their breastfeeding status."|f|t|t|f
34052661|NCT04546399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052662|NCT05213884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052663|NCT06326996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be assigned a random number, double-blind randomized, \& longitudinal study design.|Post-CABG patients with and without thiamine treatment.|t|f|f|f
34052664|NCT01144039|RANDOMIZED|PARALLEL||TREATMENT||||||||
34052665|NCT03374930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052666|NCT01246037|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34052667|NCT02846116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052668|NCT01927003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052669|NCT01188876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052670|NCT03549442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Three separate phases. Phases A and C are non-randomized, Phase B is randomized||||
34075823|NCT06301789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Effect of adding Mg sulphate as an adjuvant to bupivacaine for postoperative analgesia in cases of lower abdominal cancer surgeries||||
33845093|NCT05477563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845094|NCT06524765|||COHORT||CROSS_SECTIONAL|||||||
33845095|NCT00004487||||TREATMENT||||||||
33845096|NCT03798782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33845097|NCT01395888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845098|NCT00958841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845099|NCT02580305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845100|NCT01262027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949509|NCT04116307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741355|NCT05264376|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research assistant conducting the diagnostic interviews after the end of the prevention program and at 3-month follow-up won't know whether the participant was in the Diabetes Body Project or the educational control group.|The Diabetes Body Project and educational control are both designed to last six weeks, for one hour each week. They both focus on diabetes-specific health issues as well as generic issues with thin-idealization.|f|f|t|f
33741356|NCT04071873|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845101|NCT01644448|RANDOMIZED|PARALLEL||||NONE||||||
33845102|NCT04907565|||CASE_CONTROL||PROSPECTIVE|||||||
33845103|NCT06454994|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||Hemi-face, intra-individual study|t|f|f|t
33845104|NCT00727311|||CASE_ONLY||PROSPECTIVE|||||||
33949510|NCT01173666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949511|NCT02360904|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741357|NCT02703935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33741358|NCT03036566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741359|NCT00608712|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33741360|NCT00574860|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741361|NCT02256475|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741362|NCT04879238|NA|SINGLE_GROUP||TREATMENT||NONE||Yoga and Mindfulness intervention||||
33741363|NCT05059405|||OTHER||PROSPECTIVE|||||||
33741364|NCT04790253|RANDOMIZED|PARALLEL||TREATMENT||NONE||After eligibility checks, patients will be randomized between the 2 arms, and stratified by stage of disease (limited versus extensive), immunotherapy as part of the first-line treatment (yes/no), and ECOG Performance Status (0 or 1 versus 2).||||
33741365|NCT05829408|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741366|NCT04125693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741367|NCT05519839|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33741368|NCT00004327||||TREATMENT||||||||
33741369|NCT05242679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm parallel pre-test-post-test experimental design.|t|f|f|t
33741370|NCT02755493|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741371|NCT05005611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double-blind.|Skin Care in children.|t|f|t|f
33741372|NCT04529577|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Patients and outcomes assessors are blinded. Staff involved in device programming are not blinded.|Randomized double blinded crossover design.|t|t|f|t
33741373|NCT04183933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741374|NCT03556761|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study medication (furosemide) and placebo will be stored at room temperature at the University of Pennsylvania research pharmacy. Pharmacy will be responsible for labeling and randomizing the medications.|Double blind, randomized, placebo control design|t|t|t|t
33741375|NCT01590602|||CASE_ONLY||PROSPECTIVE|||||||
33741376|NCT02506998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741377|NCT00811083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741378|NCT00235534|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33741379|NCT01264302|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741380|NCT02464735|||COHORT||PROSPECTIVE|||||||
33741381|NCT02973451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741382|NCT00836641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741383|NCT06133491|||CASE_ONLY||PROSPECTIVE|||||||
33741384|NCT06447038|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33741385|NCT04589819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double-blinded study. All investigators will have access to the subjects results/outcomes, but will not know which randomization group the subject is in.|There will be a 1:1 randomization into either the placebo arm or the 20mg teriparatide treatment arm. Soldiers will then receive training on how to self-administer study medication in a supervised setting. Both arms will receive 500mg of supplemental calcium to take orally, daily. They will then be released for the four week convalescent leave.|t|t|t|t
33741386|NCT03866174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741387|NCT03908684|||COHORT||PROSPECTIVE|||||||
33741388|NCT06066112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741389|NCT04695691|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome Assessor is blinded to study design and time point being assessed.|||||
33741390|NCT04289649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741391|NCT06325098|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with nephrotic syndrome (SSNS, SRNS)||||
33741392|NCT02731001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741393|NCT00520416|||||PROSPECTIVE|||||||
33741394|NCT01327534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741395|NCT01220908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741396|NCT02092948|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741397|NCT04478097|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34155847|NCT05407779|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Stage 1. The first cohort will include one subject (sentinel volunteer) who will receive BCD-180 at a dose 1. Starting from the 2nd cohort, the study will have a classic 3 + 3 design.~Subjects will be monitored for 14 days following drug administration to assess the presence of dose limiting toxicity (DLT). In the absence of DLT, another cohort with a higher dose level will be formed.~After all subjects have completed the main study period (Days 1-57), the safe dose range of BCD-180 will be determined based on assessed PD, PK, safety and immunogenicity endpoints.~Further follow-up of the subjects included in stage 1 will continue up to a year.~Stage 2. Two cohorts of healthy Asian volunteers (Cohorts 8 and 9) will be included. Subjects will receive a single infusion of BCD-180 at selected doses planned for further clinical development based on the results of the main period of stage 1."||||
34155848|NCT06548932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155849|NCT02797782|||CASE_ONLY||CROSS_SECTIONAL|||||||
34155850|NCT03505528||SEQUENTIAL||TREATMENT||NONE||"An open, non-randomised, cumulative cohort group design (across 5 groups) with a target toxicity fraction of 30% and a margin of 10%. This means that a dose will be escalated between groups when the observed toxicity rate is \< 20%, de-escalated when \> 40% and maintained otherwise.~The toxicity fraction is the number of participants receiving that dose who experience a DLT."||||
34155851|NCT00208533|NA|SINGLE_GROUP||TREATMENT||NONE|The care provider is unaware of the treatment arm the child is enrolled.|||||
34155852|NCT04200144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34155853|NCT00250276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33949512|NCT05234281|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Five groups of patients will be enrolled in this project, all in parallell, no randomization||||
33949513|NCT00313716|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33949514|NCT05748145|NA|SINGLE_GROUP||OTHER||NONE||Proof of concept||||
33949515|NCT02442739|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33949516|NCT00713882|||COHORT||CROSS_SECTIONAL|||||||
33949517|NCT05390060|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949518|NCT05670470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949519|NCT01342809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949520|NCT00116246|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33949521|NCT03058861|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949522|NCT01520038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949523|NCT04284176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949524|NCT02208427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949525|NCT03454191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33949526|NCT04632134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949527|NCT01756651|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33949528|NCT00406939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949529|NCT03374774|||COHORT||PROSPECTIVE|||||||
33949530|NCT01904266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33949531|NCT04208061|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33949532|NCT00201630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949533|NCT05392465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949534|NCT03562676|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949535|NCT05723406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33949536|NCT03401827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949537|NCT01455168|||CASE_CONTROL||PROSPECTIVE|||||||
33949538|NCT04167449|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33949539|NCT04017065|||CASE_ONLY||PROSPECTIVE|||||||
33949540|NCT03907774|||CASE_ONLY||PROSPECTIVE|||||||
33949541|NCT00060320|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33949542|NCT02103608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949543|NCT00845351|NA|SINGLE_GROUP||||NONE||||||
33949544|NCT02352831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949545|NCT05681221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||TAP is an efficient antibacterial for the disinfection of the periapical area in the necrotic primary second molars as well as the infected dentinal tubules. It is effective against the persistent odontogenic infections.|t|t|t|f
33949546|NCT00202254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949547|NCT06406959|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33949548|NCT06231849|||COHORT||PROSPECTIVE|||||||
33949549|NCT02179580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949550|NCT00148174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949551|NCT02181075|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parts I and II of the study were not randomised, and both Parts of the study are detailed further in the published protocol summary, detailed in References section. After a minimum of 5 patients were treated in Part 1 (Arm 1), Part 2 (Arm 2) of the study could be opened.||||
33949552|NCT04993547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33949553|NCT00777920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155854|NCT05050864|RANDOMIZED|PARALLEL||OTHER||NONE||"Name : internal ventricular shunt (neurosurgery)~Description :~The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial.~Intervention 2 Name : endovacascular stenting (interventional neuroradiology)~Description~The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better vscription : enous drainage from the brain to increase the absorption of cerebrospinal fluid"||||
34155855|NCT04557709|||COHORT||RETROSPECTIVE|||||||
34155856|NCT06426849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155857|NCT04488016|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155858|NCT03825016|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155859|NCT06543329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This prospective interventional randomized comparative clinical trial was carried out on 300 pregnant women scheduled for elective caesarean section at operative theater|t|f|f|t
34052671|NCT06602271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pain intensity (11-point NRS) assessments at rest (NRS-R; minimum 15-minute rest) and with movement (NRS-A, where movement is defined as moving from a supine to sitting position) will be recorded at scheduled times during the inpatient period after Time 0 and immediately before each use of rescue medication.|t|t|t|t
34155860|NCT00260624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155861|NCT04845425|||COHORT||RETROSPECTIVE|||||||
34052672|NCT06666335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052673|NCT06487338|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34155862|NCT04443309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155863|NCT00002122||||TREATMENT||DOUBLE||||||
34155864|NCT05673070|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the participants nor the investigators will know the group assignment. Supplements will be prepared by the pharmacy and marked with randomly generated ID numbers. Grouping will be revealed by pharmacy at end of the trial.|Prenatal arm: pregnant women at gestational week 12-14 will be randomized to either receive a Ritual prenatal MVI (n=35) or a control commercially available prenatal MVI (n=35) through out pregnancy|t|f|t|f
34155865|NCT05946525|||COHORT||RETROSPECTIVE|||||||
34052674|NCT00006280|RANDOMIZED|||TREATMENT||DOUBLE||||||
34155866|NCT00136552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052675|NCT05548400|||OTHER||PROSPECTIVE|||||||
34052676|NCT06419543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052677|NCT01550081|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34052678|NCT00041977|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34155867|NCT05437432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155868|NCT02904148|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34155869|NCT03009084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34155870|NCT05248477|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34155871|NCT02524873|||COHORT||RETROSPECTIVE|||||||
34155872|NCT06441149|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34155873|NCT02508428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155874|NCT06582368|||COHORT||PROSPECTIVE|||||||
34155875|NCT01189643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155876|NCT04072263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Carboplatin-paclitaxel day1, q3 weeks, 6x, plus TIL starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x.~Minus or plus:~IFNα (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total."||||
34155877|NCT00417963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155878|NCT05503225|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 1:1 recruitment ratio of treatment to control group will be recruited. A sample size of 25 patients per arm will be required, therefore a total sample size of 50 will be required. Assuming a 30% rate of lost-to-follow-up, a sample size of 72 will be required.||||
34155879|NCT01627028|||CASE_CROSSOVER||PROSPECTIVE|||||||
34155880|NCT01153360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34155881|NCT03502902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155882|NCT04552106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded, single-center, randomized, exploratory, dose-finding study. 1:1:1:1:1 randomisation to 5 groups of different doses for 28 days.||||
34155883|NCT03372863|||OTHER||PROSPECTIVE|||||||
34052679|NCT06410950|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052680|NCT04310605|||COHORT||PROSPECTIVE|||||||
34075824|NCT05701254|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34155884|NCT06409494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34155885|NCT02199561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155886|NCT00888589|||CASE_ONLY||PROSPECTIVE|||||||
34155887|NCT06468670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155888|NCT01076413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34155889|NCT02696759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155890|NCT02724527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155891|NCT01124461|||COHORT||PROSPECTIVE|||||||
34155892|NCT03162081|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34155893|NCT01068158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155894|NCT03207594|||COHORT||PROSPECTIVE|||||||
34155895|NCT00038558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155896|NCT06385054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34052681|NCT04772196|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive either standard of care or supplemental Vitamin D3 following total ankle arthroplasty, ankle arthrodesis, or first metatarsophalangeal joint arthrodesis.||||
34052682|NCT03153982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052683|NCT00832845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052684|NCT05484349|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|In this double blind clinical trial, Tizanidine Hydrochloride was identical in appearance to the Tizanidine Hydrochloride placebo. Patients, investigators (persons who screen patients, assess endpoints, and assess protocol compliance), and sponsor personnel associated with clinical research should be blinded.|A total of 189 patients were planned to be enrolled, and all subjects were randomly assigned to group A (Tizanidine Hydrochloride 1 mg Tid) , group B (Tizanidine Hydrochloride 2 mg Tid) and group C (placebo 1 tablet Tid) according to a 1:1 :1ratio, with 63 subjects in each group.|t|t|t|t
34052685|NCT02297776|||COHORT||PROSPECTIVE|||||||
34052686|NCT02410798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052687|NCT01985087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052688|NCT04139512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The present study was designed as a randomized controlled trial comparing immediate restoration procedure in the esthetic zone with a one abutment one-time technique and using a conventional (control group) versus full digital workflow (test group),|f|f|f|t
34155897|NCT05809492|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||patients between the ages of 18-50 with a diagnosis of cystic fibrosis FEV1 \>70%, FEV1 40-70% and FEV1 \<40% who are clinically stable are patients with cystic fibrosis Deciency FEV1 \>70%, FEV1 \<40%.||||
34155898|NCT03012204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34155899|NCT06120439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The follow-up personnel and data analysts are blind.|The nerve block group was named the test group (T Group), and the laryngeal mask general anesthesia group was named the control group (C Group). The T Group received PECS II combined with intercostal nerve blockade, while the C Group underwent laryngeal mask insertion after general anesthesia induction.|f|t|f|t
34155900|NCT03263338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155901|NCT00614484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155902|NCT00106353||PARALLEL||TREATMENT||NONE||||||
34155903|NCT04316026|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34155904|NCT06229327|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845105|NCT05445453|NA|SINGLE_GROUP||OTHER||NONE||This study is experimental, prospective, open-label, non-randomized, pre-post intervention with a single group of participants who will be their own control.||||
33845106|NCT00064545|||CASE_CONTROL|||||||||
33845107|NCT02361281|||CASE_CONTROL||RETROSPECTIVE|||||||
33845108|NCT03304197|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Doubly-blinded \& randomised using an online randomisation website.||t|f|t|f
33845109|NCT04242043|||CASE_ONLY||PROSPECTIVE|||||||
33845110|NCT00359125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845111|NCT06180031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845112|NCT00163280|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845113|NCT04274205|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups Acute coronary syndrome group who got brief psychotherapy in five session in 5 days.. 30 minutes in 1 session Acute coronary syndrome group who did not get brief supportive psychotherapy as control Double opened RCT||||
33845114|NCT03156868|||OTHER||PROSPECTIVE|||||||
33845115|NCT02909764|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33845116|NCT01016743|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845117|NCT02712905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845118|NCT03507751|||CASE_CONTROL||PROSPECTIVE|||||||
33845119|NCT06256237|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients received toripalimab and JS004 Combined With etoposide and platinum Chemotherapy.||||
33845120|NCT06728735|||COHORT||OTHER|||||||
33845121|NCT04197739|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized prospective, open label, non-inferiority trial~Study participants will be 65 years or older, who were admitted to the medical ward due to a UTI will be assigned to one of the following study arms:~1. Intervention arm: in which patients will receive a fixed dose of amikacin, 500 mg, once a day.~2. Comparator arm: in which patients will receive a weight adjusted dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according plasma concentrations, using the Barnes Jewish Hospital nomogram."||||
33845122|NCT01593475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845123|NCT02077101|NON_RANDOMIZED|PARALLEL||||NONE||||||
33845124|NCT01056952|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845125|NCT01555476|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33845126|NCT04182295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845127|NCT03856385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845128|NCT02613234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845129|NCT05218070|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33845130|NCT00694824|||COHORT||CROSS_SECTIONAL|||||||
33845131|NCT02940184|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33845132|NCT00334464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845133|NCT04902677|||OTHER||CROSS_SECTIONAL|||||||
33845134|NCT04984447|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33845135|NCT02125045|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33845136|NCT03942159|||COHORT||PROSPECTIVE|||||||
33845137|NCT03262662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845138|NCT05148962|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845139|NCT00193167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845140|NCT01028313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845141|NCT00954551|||COHORT||PROSPECTIVE|||||||
33845142|NCT06445413|NA|SINGLE_GROUP||OTHER||NONE||||||
33845143|NCT06728098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33845144|NCT04311840|||COHORT||PROSPECTIVE|||||||
33845145|NCT04435678|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155905|NCT06469528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single centre, open-label prospective, randomised controlled trial; patients randomised 1:1 to low-dose colchicine 0.5mg OD vs guideline directed medical therapy|f|f|f|t
34155906|NCT05322226|NA|SINGLE_GROUP||OTHER||NONE||||||
34155907|NCT01423266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34155908|NCT06294847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155909|NCT05547308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155910|NCT00167310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155911|NCT01705093|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33845146|NCT04914429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155912|NCT03094065|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two-arms, parallel group, randomized controlled trial|t|f|f|f
34155913|NCT06434467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155914|NCT02522130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155915|NCT04107207|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double blind crossover|t|f|t|f
34155916|NCT03447847|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34155917|NCT02750839|||COHORT||RETROSPECTIVE|||||||
34155918|NCT01138501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155919|NCT00811174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155920|NCT04015466|||COHORT||PROSPECTIVE|||||||
34155921|NCT03036189|RANDOMIZED|PARALLEL||TREATMENT||NONE||delayed control group design||||
34155922|NCT04986930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845147|NCT03582943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are masked to their group assignment.|Single blinded, randomized, controlled trial|t|f|f|f
33845148|NCT06263127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33845149|NCT05237401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845150|NCT06728215|||COHORT||OTHER|||||||
33845151|NCT01903824|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33845152|NCT02862587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845153|NCT04044898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845154|NCT01297153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845155|NCT03339245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind||t|f|t|f
33845156|NCT01234051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845157|NCT01159210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845158|NCT04573088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33845159|NCT05944952|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants will be randomized to either the low-dose (n=20) or high dose (n=20) group and dispensed medication daily for one week.||||
33845160|NCT02204501|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33845161|NCT05550467|||COHORT||RETROSPECTIVE|||||||
33845162|NCT02736383|||COHORT||RETROSPECTIVE|||||||
33845163|NCT03828747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845164|NCT00263172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845165|NCT02942277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33845166|NCT01325311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845167|NCT05526651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study divided into 2 arms, true electroacupuncture group and sham electroacupuncture group|t|t|f|t
33845168|NCT01998503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845169|NCT06128083|||OTHER||PROSPECTIVE|||||||
33845170|NCT06728878|||OTHER||PROSPECTIVE|||||||
33845171|NCT01133782|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845172|NCT02276144|||COHORT||PROSPECTIVE|||||||
33845173|NCT06729333|||COHORT||PROSPECTIVE|||||||
33845174|NCT01361191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845175|NCT05009953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845176|NCT01603134|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845177|NCT05840575|||COHORT||PROSPECTIVE|||||||
33845178|NCT01081132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845179|NCT00528931|NA|SINGLE_GROUP||OTHER||NONE||||||
33845180|NCT01018667|||CASE_CONTROL||PROSPECTIVE|||||||
33845181|NCT01427959|||COHORT||PROSPECTIVE|||||||
33845182|NCT04630041|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33845183|NCT06674915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845184|NCT01699659|||CASE_ONLY||RETROSPECTIVE|||||||
33845185|NCT04074525|||COHORT||OTHER|||||||
33845186|NCT00717431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845187|NCT02885558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33845188|NCT03974139|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845189|NCT01258595|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845190|NCT06729827|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33845191|NCT03395262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33845192|NCT02503852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomization via manual treatment assignment by the unblinded Clinical Supply Manager prior to the start of liposuction.~Subjects randomized into the study are assigned their study Arm corresponding to the next available number in the computer-generated randomization schedule. Dose preparation ios performed by designated unblinded qualified personnel and supplied to the blinded treating team."|Subjects arm randomized prior to liposuction 2:2:2:1 ratio to one of 4 Arms. Low Dose ADR, High Dose ADRC, non enriched fat only, and no fat (control normal saline).|t|t|t|t
33845193|NCT00957177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845194|NCT06727617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845195|NCT02523859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845196|NCT01986270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845197|NCT01749111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845198|NCT04547283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinicians were unblinded to treatment allocation and enrolled patients were considered unblinded. Clinical and safety outcomes were collected from the electronic health record by study investigators blinded to treatment assignment.||f|f|f|t
33845199|NCT02819427|||CASE_ONLY||PROSPECTIVE|||||||
33949554|NCT04924465|||COHORT||RETROSPECTIVE|||||||
34052689|NCT06447662|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052690|NCT03846674|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34052691|NCT02976779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052692|NCT05462860|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Proof of concept||||
34052693|NCT05872867|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052694|NCT04589546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052695|NCT03215511|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155923|NCT06444802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155924|NCT03350906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155925|NCT06343909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34155926|NCT02592460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155927|NCT03137628|||CASE_CONTROL||PROSPECTIVE|||||||
34155928|NCT01786395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155929|NCT04667546|NA|SINGLE_GROUP||OTHER||NONE||||||
34155930|NCT00157664|||COHORT||PROSPECTIVE|||||||
34155931|NCT00211887|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34155932|NCT05984888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34155933|NCT03133351|||COHORT||PROSPECTIVE|||||||
34155934|NCT04566432|||COHORT||PROSPECTIVE|||||||
34155935|NCT02141139|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155936|NCT06279507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will not know what treatment they receive. Co-investigators will not know what the participants are injected. Outcome assessor will not know which treatment participant receive.|"The participants would be allocated into one treatment group;~* Intervention group : Hyaluronic acid injection~* Placebo group : Normal saline"|t|t|t|t
34155937|NCT01730586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155938|NCT00376857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34155939|NCT02406105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845200|NCT04482959|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomization will be simple and balanced (1:1) and will be carried out by a nurse through sealed, unlabeled, opaque envelopes containing computer-generated random numbers. The participants, caregivers and investigators will be blinded to group assignment.|Randomized controlled trial (RCT).|t|t|t|f
34155940|NCT05826847|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Three phase-study:~1. Multimodal physiological description~2. Randomized crossover trial~3. Pilot randomized trial"||||
34155941|NCT03376685|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a 6-week exercise training study, with two possible parallel training groups: endurance (END) or sprint (SIT) training.||||
33845201|NCT03578887|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33845202|NCT04838275|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845203|NCT01174576|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33845204|NCT06452225|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34155942|NCT05735535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155943|NCT06584266|||COHORT||OTHER|||||||
34155944|NCT06066008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155945|NCT04913662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845205|NCT06078293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845206|NCT06203782|||COHORT||PROSPECTIVE|||||||
33845207|NCT00495443|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33845208|NCT02472990|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33845209|NCT00864201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845210|NCT06419413|||COHORT||PROSPECTIVE|||||||
33845211|NCT01194687|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33845212|NCT00685451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845213|NCT02828787|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845214|NCT06444815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845215|NCT03199118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949555|NCT04738799|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded to continuous glucose monitoring readings.||t|f|f|f
33949556|NCT06506617|||COHORT||PROSPECTIVE|||||||
33949557|NCT03532048|RANDOMIZED|PARALLEL||OTHER||NONE|In this feasibility study there will be no masking.|Feasibility study with a randomized wait-list control group design||||
33949558|NCT05112224|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The dentist and data analyzer were blinded.|One group received the intervention and another received the routine program.|f|t|f|t
33949559|NCT00077896||||TREATMENT||||||||
33949560|NCT03143933|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33949561|NCT04014556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949562|NCT02235207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34052696|NCT02923362|||COHORT||PROSPECTIVE|||||||
34052697|NCT01880086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052698|NCT04934189|NA|SEQUENTIAL||PREVENTION||NONE||The proposed curriculum will be systematically refined based on delivery of the intervention to 3 groups of 16 TW each in a 20-hour training program, in 5 4-hour sessions.||||
34052699|NCT05317585|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective, single center, randomized study evaluating pregnancy glycemic monitoring strategies between women with continuous glucose monitors and standard of care fingerstick glucose monitoring.||||
34052700|NCT03361969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155946|NCT00006433||||TREATMENT||||||||
34155947|NCT05681910|||COHORT||RETROSPECTIVE|||||||
33949563|NCT02067923|||COHORT||PROSPECTIVE|||||||
33949564|NCT02068001|||COHORT||PROSPECTIVE|||||||
33949565|NCT06102473|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949566|NCT04973527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949567|NCT05059366|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The study is a repeated-measures cross over design.||||
34052701|NCT03344692|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34052702|NCT03355885|||COHORT||CROSS_SECTIONAL|||||||
34155948|NCT03491111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34155949|NCT00895310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155950|NCT01616251|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34155951|NCT01905449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155952|NCT02280317|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation sequential assignment||||
34155953|NCT01971008|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||N/A (the Intervention type in the present study was an elastic abdominal binder, which is a medical device)|t|f|f|f
34155954|NCT00242099|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34155955|NCT00065845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34155956|NCT06362720|||CASE_ONLY||RETROSPECTIVE|||||||
34155957|NCT03878758|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not see any labeling for the Pen Needles used for the injections|BD Nano (Test Device) will be compared to other currently marketed devices (controls) through a series of abdominal saline injections|t|f|f|f
34155958|NCT02752373|||OTHER||PROSPECTIVE|||||||
34155959|NCT01587430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155960|NCT06205082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34155961|NCT05564585|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34155962|NCT00151372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155963|NCT01648816|||COHORT||PROSPECTIVE|||||||
34155964|NCT03422666|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-blinded study with participant blinded to treatment|On visits 3 \& 4, participants will receive either teduglutide or placebo, in random order, 5 hours after a high-fat drink|t|f|f|f
34155965|NCT05689866|||COHORT||PROSPECTIVE|||||||
34155966|NCT03248089|||OTHER||OTHER|||||||
33741398|NCT03566641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Out study is a single-blinded randomized clinical trial. The patient will be informed about the type of dressing used for their wound care, but the investigator and the outcome assessor will be blinded for which type of dressing used for each participant patient.|Comparing the rate of occurrence of surgical site infection, total hospital cost and length of stay between two groups: group 1 represents patients who receive Prevena for postoperative wound care and group 2 represents patients who receive standard care dressing for the same purpose.|f|f|t|t
33741399|NCT00917046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33741400|NCT02428036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741401|NCT02417246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33741402|NCT00058305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949568|NCT02384590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949569|NCT04141566|||COHORT||PROSPECTIVE|||||||
33949570|NCT01331525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949571|NCT01240109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33949572|NCT06642441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949573|NCT05821166|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization into intervention group (additional MWB-HT) and standard care (chemotherapy / immunotherapy) and control group (no MWB-HT), only standard care||||
33949574|NCT04250506|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Single-center, randomized, double-blind, placebo- and moxifloxacin-controlled, Phase 1 study|t|t|t|t
33949575|NCT04938869|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33949576|NCT03641235|||COHORT||PROSPECTIVE|||||||
33949577|NCT04429607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949578|NCT00156624|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33949579|NCT05825794|||OTHER||CROSS_SECTIONAL|||||||
33949580|NCT03851562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949581|NCT03780920|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33949582|NCT01535872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949583|NCT02503215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949584|NCT02566174|||COHORT||PROSPECTIVE|||||||
33949585|NCT03959306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949586|NCT02290704|||OTHER||PROSPECTIVE|||||||
33949587|NCT05868707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949588|NCT03661112|||OTHER||PROSPECTIVE|||||||
33949589|NCT04985877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33949590|NCT03592082|RANDOMIZED|PARALLEL||TREATMENT||NONE|none - open label study|||||
33949591|NCT05783011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33949592|NCT00994266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949593|NCT01445015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949594|NCT04988035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949595|NCT04001478|||CASE_CONTROL||PROSPECTIVE|||||||
33949596|NCT05235633|||COHORT||CROSS_SECTIONAL|||||||
33949597|NCT06516783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949598|NCT04516291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949599|NCT01275118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949600|NCT01092130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949601|NCT04479774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants random allocation into control and experimental groups|t|f|t|f
33949602|NCT03947632|||CASE_ONLY||CROSS_SECTIONAL|||||||
33949603|NCT05181501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949604|NCT01945034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33949605|NCT00379821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949606|NCT01727804|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33949607|NCT01592526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33949608|NCT02717910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33845216|NCT06728683|NA|SINGLE_GROUP||TREATMENT||NONE||Participants in the focus group will all be given the same set of study tasks. They will participate in a 60-minute virtual focus group and then rate the proposed Assist-MH product components. Participants in the pilot test will complete the same study tasks as others in their respective group: one group for providers and one group for students. All providers will (a) attend a brief webinar to review research methods and be trained to use Assist-MH, (b) use Assist-MH over a 2-month period with at least 3 students, (c) obtain parent consent for students to use Assist-MH and evaluate their experience, (d) complete pre \& post provider outcomes measures, and (e) rate their experiences with the prototype. All students will (a) use Assist-MH, (b) complete pre \& post student outcomes measures, and (c) rate their experiences with the prototype.||||
33845217|NCT06727864|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking will not be done|Two months of isoniazid (H), pyrazinamide (Z), rifampicin (R), and pyrazinamide (Z) Subsequent orders are for H(E)Z for another two months||||
33845218|NCT04772898|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33845219|NCT05438940|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845220|NCT00071175|||FAMILY_BASED||RETROSPECTIVE|||||||
33845221|NCT03537495|RANDOMIZED|PARALLEL||TREATMENT||NONE||TB meningitis patients will be randomised into three treatment groups to either receive no linezolid (control group); or 600 mg QD or 1200 mg QD linezolid next to high dose rifampicin (\~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days. All patients will receive dexamethasone according to standard dosing in TBM.||||
33845222|NCT04812197|NA|SINGLE_GROUP||OTHER||NONE||||||
33845223|NCT01076647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845224|NCT04796012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845225|NCT01227200|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33845226|NCT02527863|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33845227|NCT05143398|RANDOMIZED|PARALLEL||TREATMENT||NONE||After 1 week of standard diet (1650kcal/day with 18% protein) without physical activity, patients will be randomized into one of the 4 arms described below (20 subjects per study arm): 1st arm: low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE); 2nd arm: low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein; 3rd diet: low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr). 4th diet: low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid). All patients perform daily aerobic physical activity/5 days/week for 4 weeks.||||
33845228|NCT04406415|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This is a double-blinded study. Subjects will not be informed of their treatment assignment (active or placebo); however, investigators and clinical site staff will have access to the randomization codes.|Double-blind, placebo-controlled, Multiple Ascending Dose (MAD) study with 4 active drug cohorts|t|f|f|f
33845229|NCT01854398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33845230|NCT04781257|||COHORT||PROSPECTIVE|||||||
33949609|NCT02787655|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33949610|NCT05745974|||COHORT||PROSPECTIVE|||||||
33949611|NCT01627769|||OTHER||CROSS_SECTIONAL|||||||
33949612|NCT01726556|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33949613|NCT04366011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949614|NCT02504099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949615|NCT04121091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949616|NCT05991401|NA|SINGLE_GROUP||TREATMENT||NONE||3-period||||
33949617|NCT03127267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949618|NCT02605135|||COHORT||PROSPECTIVE|||||||
33949619|NCT06010199|||COHORT||OTHER|||||||
33949620|NCT04100902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949621|NCT02366026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949622|NCT04253249|||CASE_ONLY||PROSPECTIVE|||||||
33949623|NCT05364164|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949624|NCT05913921|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949625|NCT02777866|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33949626|NCT01898832|||CASE_CONTROL||PROSPECTIVE|||||||
33949627|NCT00040209||||TREATMENT||||||||
33949628|NCT00636402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33949629|NCT05528614|||CASE_ONLY||RETROSPECTIVE|||||||
33949630|NCT06172374|||OTHER||OTHER|||||||
33949631|NCT02071472|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33949632|NCT04651569|||COHORT||RETROSPECTIVE|||||||
33949633|NCT01387061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949634|NCT02730975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949635|NCT04567849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants (i.e., patients) will not be informed specifically of their assignment to different arms throughout the study. Providers will not be randomized to study arms or informed of patient assignment.|Throughout the study, patients will be randomized equally across all three arms.|t|t|f|f
33949636|NCT06325072|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients selected based on the inclusion criteria will be evaluated by a multidisciplinary team of experts. All the selected patients will undergo genetic testing by clinical exome sequencing and in silico filtering for a panel of genes described as causing or in association with CKD. Identified variants will be classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines. Reverse phenotyping will be performed according to the results of genetic testing. The results of the diagnostic work-up will be evaluated by a multi-disciplinary team of experts in order to establish conclusive diagnosis.||||
33949637|NCT00455039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949638|NCT01424657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949639|NCT05754359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949640|NCT03573466|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949641|NCT06505330|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33949642|NCT00452127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949643|NCT04165174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845231|NCT06057194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical trial of a prospective cohort compared to a retrospective (historical control) cohort.||||
33845232|NCT02111317|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845233|NCT05506774|||COHORT||RETROSPECTIVE|||||||
33845234|NCT05977959|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33845235|NCT06728956|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845236|NCT05570773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33845237|NCT04134988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845238|NCT04330924|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33845239|NCT01317173|||COHORT||PROSPECTIVE|||||||
33845240|NCT00766545|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845241|NCT05820516|||COHORT||OTHER|||||||
33949644|NCT04621292|||CASE_CONTROL||PROSPECTIVE|||||||
33949645|NCT01182688|||CASE_CONTROL||RETROSPECTIVE|||||||
33949646|NCT01143129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949647|NCT02538432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949648|NCT04582968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949649|NCT01493154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949650|NCT01851824|NA|SINGLE_GROUP||||NONE||||||
33949651|NCT02847663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949652|NCT02675699|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33949653|NCT03487159|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study model includes 2 study arms:~1. Patients with chronic liver diseases who will undergo a routine liver biopsy, Shear Wave elastography and the MRE in order to evaluate the liver fibrosis stage.~2. Patients with chronic liver diseases who will undergo a routine Shear Wave elastography and the MRE in order to evaluate the liver fibrosis stage.~Demographic and clinical information will be collected from the patient's medical files."||||
33949654|NCT00777790|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949655|NCT01848392|||COHORT||PROSPECTIVE|||||||
33949656|NCT05550103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949657|NCT00031265|RANDOMIZED|||TREATMENT||||||||
33949658|NCT02191033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949659|NCT05335161|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Six patients with PAD will be asked to complete daily (90 min/day) home-based leg HT for 12 weeks using the newly developed system. Outcomes will be measured at baseline and at 12-week follow-up.||||
33949660|NCT00031902||||TREATMENT||||||||
34052703|NCT05313022|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34052704|NCT02901275|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE||Each participant completed each of the 5 study conditions (identified here as arms).|t|f|t|t
34052705|NCT04090138|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Each subject and their associated information will be identified by a 4-digit alpha-numerical identification code.||t|f|t|t
34052706|NCT03431025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052707|NCT04158882|||COHORT||PROSPECTIVE|||||||
34052708|NCT05404256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34052709|NCT05094765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052710|NCT03098498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The examiner performing the assessment of periodontal attachment gain is not aware of the type of the preceding intervention therapy (one-stage vs. two-stage) provided to the patient.|controlled prospective parallel group intervention trial|f|f|f|t
34052711|NCT04688528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052712|NCT01930695|||CASE_ONLY||PROSPECTIVE|||||||
34052713|NCT00950040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052714|NCT04263896|RANDOMIZED|PARALLEL||PREVENTION||NONE||Following enrollment subjects will be randomized into the intervention/treatment arm and control arm through a randomizing process in the investigator's database.||||
34052715|NCT02161484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052716|NCT03264781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052717|NCT01574638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052718|NCT05855174|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|In this single-blinded crossover design, the participants will be blinded to which intervention the participants are receiving (i.e., high protein or low protein drinks).|Crossover intervention; all participants will have a low protein and a high protein session.|t|f|f|f
34052719|NCT00828074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052720|NCT04195620|RANDOMIZED|FACTORIAL||OTHER||SINGLE|The investigator will be naïve to participant treatment condition. All other individuals will know or it will be obvious to them.|2x2 factorial design assessing different levels of loneliness and those individuals being randomized to one of two conditions involving either high levels of self-disclosure or low levels of self-dislcosure|f|f|t|f
34052721|NCT04744233|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Multiple dose cross-over study.||||
34052722|NCT03083561|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34052723|NCT01893216|||COHORT||CROSS_SECTIONAL|||||||
34052724|NCT04960683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052725|NCT02697123|||COHORT||PROSPECTIVE|||||||
34052726|NCT06668675|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052727|NCT03250767|||CASE_ONLY||PROSPECTIVE|||||||
34052728|NCT04069832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052729|NCT05669430|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052730|NCT02303223|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34052731|NCT00381043|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34052732|NCT04392388|||COHORT||PROSPECTIVE|||||||
34052733|NCT04917861|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34052734|NCT05146544|||COHORT||CROSS_SECTIONAL|||||||
34052735|NCT06648031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052736|NCT00915408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052737|NCT00593710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052738|NCT03662191|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34052739|NCT00687479|||CASE_ONLY||PROSPECTIVE|||||||
34052740|NCT06668753|||COHORT||PROSPECTIVE|||||||
33845242|NCT02101619|||CASE_ONLY||PROSPECTIVE|||||||
33845243|NCT05648630|RANDOMIZED|PARALLEL||TREATMENT||NONE|Two separate groups of subjects (patients with PAD) receiving PB125 or Placebo|Two separate groups of subjects (patients with PAD) receiving PB125 or Placebo||||
33845244|NCT05407181|||OTHER||CROSS_SECTIONAL|||||||
33845245|NCT05161221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845246|NCT02478268|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845247|NCT01026532|||OTHER||PROSPECTIVE|||||||
34155967|NCT00147303|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34155968|NCT02386826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155969|NCT04689789|||CASE_CONTROL||PROSPECTIVE|||||||
34155970|NCT00855049|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34155971|NCT00639626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155972|NCT00305487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155973|NCT06579690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34155974|NCT00794885|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34155975|NCT06547255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34155976|NCT05107765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34155977|NCT06454877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34155978|NCT00748319|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34155979|NCT03897855|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155980|NCT02020408|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34155981|NCT06379269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34155982|NCT05740332|NA|SINGLE_GROUP||OTHER||NONE||||||
34155983|NCT05454124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34155984|NCT03515564|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155985|NCT05378737|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34155986|NCT02171741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34155987|NCT02421588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34155988|NCT04199442|||COHORT||PROSPECTIVE|||||||
34155989|NCT03244163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845248|NCT05626790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845249|NCT06727903|||COHORT||PROSPECTIVE|||||||
33845250|NCT06007768|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845251|NCT04761900|||COHORT||RETROSPECTIVE|||||||
33845252|NCT01720680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845253|NCT02989818|||COHORT||PROSPECTIVE|||||||
33845254|NCT02182947|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845255|NCT04654975|||COHORT||RETROSPECTIVE|||||||
33845256|NCT06465953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845257|NCT03395977|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Febuxostat and Rasburicase will be prepared by an independant pharmacist.|"This is a prospective, randomized, placebo-controlled, double-blinded and 3 ways cross-over study.~Three populations : healthy male subjects under 40 y \[1\] ; healthy male and female participants between 40 and 65 years \[2\] and subjects with hypertension \[3\]. Minimum 15 participants in each group are needed.~The populations 2 and 3 will be studied together with subgroups analyses of the results for the status of hypertension, of treatment, age and gender.~For 5 subjects in each group, we will perform a fourth session with Placebo PO and Rasburicase IV. That session will be non-randomized and blinded only for the subject."|t|f|t|f
33845258|NCT06329973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845259|NCT04766359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33845260|NCT02060539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845261|NCT04642248|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33845262|NCT01170104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845263|NCT00131729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33845264|NCT01980680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845265|NCT05229276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subjects/participants were not aware of the arms/treatment given as they were under general anesthesia during the application of interventions being studied. Besides, during the informed consent for the elective sternotomy procedure, subjects were extensively given explanation of the purpose, methods, benefits and risks of the procedure including the randomized nature of the allocation to either arms of the study.~Principal investigators as well as outcomes assessor were kept unaware of the randomization of interventions as they both were restricted for assessing the patients' medical record and the patient identity were coded in the primary database."|A single-blind, single center, parallel phase 4 randomized clinical trial was conducted with two intervention arms: an intervention arm with the use of Sternum GuardTM and a control arm with the use of bone wax in which the subjects' recruitment and treatment were conducted simultaneously by means of a block randomization.|t|f|t|t
33845266|NCT04237168|||COHORT||PROSPECTIVE|||||||
33845267|NCT00506441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845268|NCT02367547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845269|NCT06728189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845270|NCT04101318|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33845271|NCT00910039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845272|NCT00717327|||||CROSS_SECTIONAL|||||||
33845273|NCT05617430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949661|NCT06502002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Dexmedetomidine or placebo infusion will be blinded (by pharmacist preparing the study drug) to the patient, treating physicians, and investigators|This will be a randomized, placebo-controlled, double-blinded, pilot trial with two parallel groups (1:1 ratio) receiving either dexmedetomidine) or placebo|t|t|t|t
33949662|NCT03415815|||COHORT||RETROSPECTIVE|||||||
33949663|NCT05669612|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Protein supplements will be provided in a randomized, double-blinded manner. Both the participants and research testers will be masked from knowing the specifics of the supplement intervention.|Participants will be randomly assigned to each of 4 protein-related products in a double-blind, crossover, single centre study|t|f|t|f
34155990|NCT01368081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34155991|NCT04984772|||COHORT||PROSPECTIVE|||||||
34155992|NCT01817959|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34155993|NCT00888342|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155994|NCT02624427|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155995|NCT05374629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group had the shared decision-making of smoking cessation which was guided by the smoking cessation health educator. The control group received routine smoking cessation health education by another smoking cessation health educator. Both groups will receive a post-test three months after the intervention.||||
34155996|NCT03791775|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler \& Co. GmbH, Wiesbaden, Germany).~The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding"||||
34155997|NCT05247281|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34155998|NCT05487417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, the outcome of minocycline group and routine treatment group was compared. Placebo control was not used, so outcomes assessor blind was used.||f|f|f|t
34155999|NCT05758428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156000|NCT04522479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician blindness|The early follicular and mid luteal prolonged regimens were randomly enrolled in a ratio of 1 to 1|f|f|t|f
34156001|NCT02804035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156002|NCT05793840|||COHORT||PROSPECTIVE|||||||
34156003|NCT00478686|||CASE_CONTROL||RETROSPECTIVE|||||||
34156004|NCT02915978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156005|NCT00501865|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34156006|NCT00278616|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156007|NCT01307462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156008|NCT02116088|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34156009|NCT01547065|||CASE_ONLY||PROSPECTIVE|||||||
34156010|NCT04682535|||COHORT||PROSPECTIVE|||||||
34156011|NCT00667849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156012|NCT06384755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845274|NCT04916587|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||We will conduct a stepped wedge, cluster randomized pragmatic trial without transition periods. Five clinics (clusters) will receive the intervention at different points in time and following a random order. The full trial will last 15 months, conducted in six 10-week time periods. Control status refers to clinics following the ACEs state requirements (i.e., PEARLS screenings, ACEs health related condition checklist, wellness exam and follow up education). Intervention status refers to clinics experiencing the implementation strategies in addition to the state required ACEs process. During the baseline period (weeks 1-10), we will collect pre-implementation data on PEARLS screening rates, ACEs-related health conditions checklist, mental health referrals and child socio-demographics across clinics. Following baseline, five clinics will receive the intervention at five separate steps, following a random order. Outcomes will be collected in week 10/each step.||||
34156013|NCT03167528|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156014|NCT00407017|RANDOMIZED|PARALLEL||||DOUBLE||||||
34156015|NCT05150522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156016|NCT01395680|||||PROSPECTIVE|||||||
34156017|NCT02642380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156018|NCT03114384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156019|NCT02391519|||CASE_CONTROL||PROSPECTIVE|||||||
33845275|NCT02083120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845276|NCT00699049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156020|NCT03857542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156021|NCT04718493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156022|NCT03300063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156023|NCT00902707|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34156024|NCT04302545|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and outcome assessors are kept blind by just entering the random number assigned to the subject on the papers and notes are written without details of adhesiolysis. The completed outcome performas are sent to the assessors with the only random number entered and without the assigned group. The random number file is opened only after receiving results from the statistician. The care providers in theatre and principle surgeon cannot be blinded in this study.|Subjects will be assigned into cystoinflation group and control group after parallel assignment. In the cystoinflation group, the intervention will be retro-fill of the bladder with 300cc saline and clamping the drainage port of the catheter till the completion of adhesiolysis. In contrast, the urinary catheter of control group patients will be put on free drainage.|t|f|f|t
34156025|NCT00365274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156026|NCT05176834|NA|SINGLE_GROUP||OTHER||NONE||||||
34156027|NCT04494126|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only the anaesthesiologist who is administering the medications is unmasked until completion of the data collection period.|Randomized, double-blind, Parallel assignment|t|f|t|t
34156028|NCT00815594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156029|NCT03614299|||COHORT||PROSPECTIVE|||||||
34156030|NCT04369625|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Assessors are blind regarding the randomization (group affiliation) of the families.|Each of the four interventions will be evaluated in a separate prospective, randomized-controlled trial (RCT); overall, four randomized-controlled trials will be performed. Each of the four control groups receive treatment as usual (TAU). Each of the four studies will include two groups: one intervention group (IG) and one control group (TAU), i.e. CHIMPS-T vs. KG (TAU), CHIMPS-MFT-group vs. KG (TAU), CHIMPs-P vs. KG (TAU), iCHIMPS vs. KG (TAU).|f|f|t|f
33845277|NCT01572168|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156031|NCT01223183|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects inhale isotonic saline on one imaging day and 7% hypertonic on the other. The order is randomized. There is a period of 5-24 days between imaging days.||||
34156032|NCT05236504|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34156033|NCT06141291|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34156034|NCT05340790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156035|NCT00429533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34156036|NCT01688193|||CASE_CROSSOVER||PROSPECTIVE|||||||
34156037|NCT03534375|||COHORT||CROSS_SECTIONAL|||||||
34156038|NCT02646813|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34156039|NCT06317168|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34156040|NCT02413047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156041|NCT04071704|||COHORT||CROSS_SECTIONAL|||||||
34156042|NCT04787354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845278|NCT01781078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845279|NCT00476866|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156043|NCT05158725|RANDOMIZED|CROSSOVER||SCREENING||NONE||Multi-center, three-arm, randomized, controlled, open-label study||||
33845280|NCT01432184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156044|NCT04599595|||COHORT||PROSPECTIVE|||||||
33845281|NCT03479762|||COHORT||RETROSPECTIVE|||||||
33845282|NCT05210478|||COHORT||PROSPECTIVE|||||||
33845283|NCT00339859|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845284|NCT05330598|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single arm trial||||
33845285|NCT04809597|||CASE_ONLY||RETROSPECTIVE|||||||
33845286|NCT05090670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845287|NCT04860076|||COHORT||RETROSPECTIVE|||||||
33845288|NCT06424795|||CASE_CONTROL||PROSPECTIVE|||||||
33845289|NCT00336258|||CASE_ONLY||PROSPECTIVE|||||||
33845290|NCT01129700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741403|NCT03356002|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The colonoscopists will be blinded to the C-Scan system results and FIT results and the reviewers of C-Scan system results will be blinded to Fit and colonoscopy results||f|t|t|f
33845291|NCT05539144|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33845292|NCT06363682|||COHORT||PROSPECTIVE|||||||
33845293|NCT01129102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33845294|NCT06531577|||COHORT||PROSPECTIVE|||||||
33845295|NCT03268447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Placebo and P8 will be administered via a parallel design|t|t|t|f
33845296|NCT05869578|||COHORT||OTHER|||||||
33845297|NCT04404777|||COHORT||OTHER|||||||
33845298|NCT04738292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845299|NCT06728007|||COHORT||RETROSPECTIVE|||||||
33845300|NCT04389151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845301|NCT06271876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the outcome assessor will not know in which group is each participant, and the investigator will receive the data without knowing which data is from which group||f|f|t|t
33845302|NCT05112653|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845303|NCT00266227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845304|NCT00060424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845305|NCT06179849|||OTHER||RETROSPECTIVE|||||||
33845306|NCT04817943|||COHORT||PROSPECTIVE|||||||
33845307|NCT04879953|||OTHER||RETROSPECTIVE|||||||
33845308|NCT00129480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845309|NCT05907525|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33845310|NCT06727838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845311|NCT01460459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33845312|NCT03056300|NA|SINGLE_GROUP||OTHER||NONE||||||
33845313|NCT02513303|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33845314|NCT00389701||||TREATMENT||NONE||||||
34156045|NCT04691908|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156046|NCT01754272|||||RETROSPECTIVE|||||||
34156047|NCT03412864|||CASE_ONLY||PROSPECTIVE|||||||
34156048|NCT01267526|||COHORT||PROSPECTIVE|||||||
34156049|NCT05695144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156050|NCT05494034|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33845315|NCT00546013|||COHORT||PROSPECTIVE|||||||
33845316|NCT03544853|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845317|NCT02735577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845318|NCT05863728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845319|NCT02022904|NA|SINGLE_GROUP||||NONE||||||
33949664|NCT04782882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistical and reporting blinding were provided in the study.||f|f|f|t
33949665|NCT03822741|||CASE_ONLY||CROSS_SECTIONAL|||||||
33949666|NCT04017416|||OTHER||PROSPECTIVE|||||||
33949667|NCT03015233|||CASE_ONLY||PROSPECTIVE|||||||
33949668|NCT01338311|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34156051|NCT03465930|||CASE_ONLY||CROSS_SECTIONAL|||||||
34156052|NCT00122369|RANDOMIZED|PARALLEL||||NONE||||||
34156053|NCT00863291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34156054|NCT00325520|||COHORT||PROSPECTIVE|||||||
34156055|NCT03595527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741404|NCT05177809|||COHORT||PROSPECTIVE|||||||
33741405|NCT01866020|||CASE_ONLY||PROSPECTIVE|||||||
33741406|NCT02640729|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741407|NCT02441452|RANDOMIZED|PARALLEL||||NONE||||||
33741408|NCT01166932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33741409|NCT01465334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741410|NCT00364481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741411|NCT04892654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741412|NCT04483453|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33741413|NCT03969810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741414|NCT02182544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33741415|NCT02657850|||COHORT||PROSPECTIVE|||||||
34156056|NCT05752669|||COHORT||PROSPECTIVE|||||||
34156057|NCT01108523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156058|NCT04934657|||COHORT||PROSPECTIVE|||||||
34156059|NCT01345669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156060|NCT03663335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study CCFZ533A2201 is a randomized, 60-month, active-controlled, partially-blinded, multicenter, dose range finding study to evaluate the efficacy, safety, tolerability, PK and PD of CFZ533 in 2 different cohorts, as compared to standard of care comprised of tacrolimus, MMF and corticosteroids.|t|t|t|f
33845320|NCT04137744|RANDOMIZED|PARALLEL||SCREENING||SINGLE||2 groups of patients each 37 patient with early breast cancer one underwent ARM +ve LN biopsy with ALND, the other underwent ARM+ve LN preservation with completion of ALND|t|f|f|f
33845321|NCT06533566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33845322|NCT05652647|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845323|NCT06727825|||OTHER||RETROSPECTIVE|||||||
33845324|NCT05120258|||CASE_CROSSOVER||PROSPECTIVE|||||||
33845325|NCT06727994|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The studyis of a semi-separate typeand all women can be trained|The studyis of a semi-separate typeand all women can be trained||||
34156061|NCT05700032|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34156062|NCT05818267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156063|NCT00745433|||OTHER||PROSPECTIVE|||||||
34156064|NCT01005758|NON_RANDOMIZED|||TREATMENT||NONE||||||
34156065|NCT03399474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156066|NCT00408434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156067|NCT01180010|||CASE_ONLY||PROSPECTIVE|||||||
34156068|NCT05426941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156069|NCT00336414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34156070|NCT03332446|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34156071|NCT02948738|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34156072|NCT01793883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156073|NCT06584435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156074|NCT04025229|NA|SINGLE_GROUP||OTHER||NONE||Participants will complete HIIT training prior to surgery||||
34156075|NCT04364152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156076|NCT06470646|||COHORT||PROSPECTIVE|||||||
34156077|NCT00668668|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156078|NCT05226312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomize Control experimental study||||
34156079|NCT04591444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The present study is a parallel, randomized, triple blind clinical trial.|t|f|t|t
34156080|NCT04065542|||OTHER||PROSPECTIVE|||||||
34156081|NCT01628965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156082|NCT00003066||||TREATMENT||||||||
34156083|NCT06553872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156084|NCT02238860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156085|NCT00421135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156086|NCT01835002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156087|NCT04271033|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm registry||||
34156088|NCT04769245|||CASE_ONLY||RETROSPECTIVE|||||||
34156089|NCT06006403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156090|NCT05179759|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Complete double-blinding is not possible in this mental health intervention trial as trial participants and the intervention team will be aware of their status. However, to minimize bias and the risk of unmasking, the field team will be separated into intervention and data collection teams. The data collection team will be blinded to intervention allocation at the cluster-level and treatment status at the individual child level. Additionally, while over time it may be likely that children and caregivers are aware of the intervention delivered, they will not be explicitly informed of this allocation.|The study will be conducted as a stepped-wedge cluster randomized trial. Given the nature of the intervention, each school will be a cluster and each step will be an academic year. Randomization will occur at the school level. All schools will initially receive the control condition (EUC) and will be randomly and sequentially transitioned into the intervention arm. A qualitative exploration of context and process will be embedded within the framework of the randomized control trial. An embedded approach has been chosen to facilitate a high level of integration between the qualitative and quantitative components of the study.|f|f|f|t
34156091|NCT01990612|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized trial of 6000 women at 38 weeks 0 days to 38 weeks 6 days randomized to one of two arms: elective induction of labor between 39 weeks 0 days and 39 weeks 4 days; or expectant management (unless a medical indication arises) until at least 40 weeks 5 days.||||
34156092|NCT02864160|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 group study with concurrrent random assignment to intervention or control group using random assignment list that was pre-generated||||
34156093|NCT05620264|||CASE_ONLY||CROSS_SECTIONAL|||||||
34156094|NCT02825732|||COHORT||RETROSPECTIVE|||||||
34156095|NCT04757545|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two armed randomized controlled trial|f|f|f|t
34156096|NCT02878837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156097|NCT02870634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156098|NCT01939639|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34156099|NCT04623814|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34156100|NCT06301932|||COHORT||RETROSPECTIVE|||||||
34156101|NCT01196416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156102|NCT00745043|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33845326|NCT03950843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156103|NCT04356235|||COHORT||PROSPECTIVE|||||||
34156104|NCT01540669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156105|NCT04536207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).|They were assigned randomly into two equal groups.Group (A) study group received the same medical care and cryotherapy, three times / weak for three successful months. And group (B) control group received medical care and standard chemotherapy only.|t|f|t|f
33845327|NCT02546479|||COHORT||PROSPECTIVE|||||||
33845328|NCT02735655|||COHORT||PROSPECTIVE|||||||
34156106|NCT06464016|||COHORT||RETROSPECTIVE|||||||
34156107|NCT02841462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845329|NCT03651622|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This initial pilot and feasibility study uses a Sequential, Multiple Assignment, Randomized Trial (SMART) design to identify acceptable and effective dietary strategies to optimize both glycemic control and weight management. The study will be done at UNC and Stanford. Sequential randomization will occur at 0, 3.5, and 7 months. Following the baseline measurement visit and two week run-in period, participants will be randomized to one of three diets (stratified by site with block size of 4). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the assigned diet is not acceptable or effective will be re-randomized (or re-assigned if only one diet remains untried). 10.5 months of follow-up time allows for evaluation of the effect of diets on initial weight loss and on early maintenance of initial weight loss. Decision criteria for re-randomization will incorporate clinical outcomes (glycemic control and weight change) and acceptability of the diet.||||
33845330|NCT02217475|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33845331|NCT00669370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845332|NCT00531648|||CASE_CONTROL||OTHER|||||||
33845333|NCT00943345|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|f|t
33845334|NCT06220136|||COHORT||PROSPECTIVE|||||||
33845335|NCT01580891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845336|NCT05064384|||OTHER||PROSPECTIVE|||||||
33949669|NCT00058097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949670|NCT02208518|||CASE_ONLY||PROSPECTIVE|||||||
33949671|NCT03518372|||COHORT||PROSPECTIVE|||||||
34156108|NCT05820984|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Authors will be blinded to the intervention allocation. Editors will not be informed about the randomisation. To avoid potential bias, peer reviewers and authors will not be informed of the study hypothesis, design and intervention. All submitting authors and invited reviewers are routinely told that BMJ has a research programme and their article/review may be included in this research.~Outcomes will be assessed in duplicate by blinded outcome assessors"||t|f|f|f
34156109|NCT00490048|NA|SINGLE_GROUP||SCREENING||NONE||||||
34156110|NCT00006400|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34156111|NCT01554800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156112|NCT06224803|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34156113|NCT00206713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156114|NCT02724709|||CASE_ONLY||PROSPECTIVE|||||||
34156115|NCT04137458|NA|SINGLE_GROUP||OTHER||NONE||||||
34156116|NCT06348628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156117|NCT03243448|||CASE_CONTROL||PROSPECTIVE|||||||
34156118|NCT01575314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156119|NCT03989362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156120|NCT00447616|||OTHER||PROSPECTIVE|||||||
33949672|NCT02890420|||COHORT||PROSPECTIVE|||||||
33949673|NCT03521622|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34156121|NCT03401268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156122|NCT02227199|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34156123|NCT01549977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156124|NCT01130896|||COHORT||PROSPECTIVE|||||||
33949674|NCT02267031|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33949675|NCT02341482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156125|NCT00621140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156126|NCT04565951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will be blinded by limiting details about the study hypotheses and differences between the study arms. Blinding will also be achieved because no study personnel are involved in intervention delivery. The biostatistician will be blinded for analyses involving study group comparisons.|"Participants will be randomized 1:1 to either the intervention or the control group. Block-randomization schemes using random block sizes to assign the two study arms will be created in R using the blockrand package before study start and pre-loaded into survey software. The intervention, called VA S.A.V.E., is an online, video-based training tailored to veterans and their close supports. The control group will consist of a sham training - a different online, video-based training course developed by the PsychArmor Institute for military service members, veterans, and their loved ones. Topics in this sham training may include information relevant to transitioning veterans and their loved ones, such as preparing finances, networking, searching for a job, and using educational benefits. The length of the training will be matched to the intervention (24 minutes) and the sham training will also contain other design features similar to the intervention (e.g., motion graphics)."|t|f|t|f
34156127|NCT00344422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949676|NCT05537259|||COHORT||PROSPECTIVE|||||||
34156128|NCT01584362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156129|NCT03458156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156130|NCT05290116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156131|NCT01831674|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156132|NCT01468350|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33949677|NCT01519700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33949678|NCT03712462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The novel acceptance-based behavioral weight loss therapy is being compared to standard behavioral weight loss therapy for individuals with binge eating disorder.|t|f|f|f
33949679|NCT05872165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949680|NCT06101940|||COHORT||PROSPECTIVE|||||||
33949681|NCT04111224|||CASE_CONTROL||PROSPECTIVE|||||||
33949682|NCT04493255|NA|SINGLE_GROUP||OTHER||NONE||||||
33949683|NCT00021554||PARALLEL||TREATMENT||||||||
33949684|NCT00001422||||TREATMENT||||||||
33949685|NCT04718792|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
33949686|NCT03138265|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||||||
33949687|NCT05710666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949688|NCT03778021|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Interviewers were not informed of school or school assignment at follow-up|Group Randomized Trial|f|f|f|t
34156133|NCT01458015|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34156134|NCT00900029|||COHORT||PROSPECTIVE|||||||
34156135|NCT02371408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156136|NCT05571020|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34156137|NCT01093391|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156138|NCT04811482|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study in which all individuals will be enrolled in the intervention.||||
33845337|NCT05162573|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multicenter prospective phase I study investigating standard of care treatment for node-positive prostate cancer (7 weeks EBRT and 3 years ADT) complemented with 1 or 2 concurrent cycles of systemic 177Lu-PSMA-617 delivered in week 2 (and 4) of EBRT. The tolerability of adding 177Lu-PSMA-617 will be evaluated using a Bayesian Optimal Interval (BOIN) dose-escalation design based on the occurrence of grade 3 acute toxicity.||||
33845338|NCT01209234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33845339|NCT01156298|||COHORT||PROSPECTIVE|||||||
33845340|NCT03457870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978024|NCT06438874|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study will involve individuals diagnosed with type 2 diabetes mellitus (T2DM) who are currently receiving treatment with a glucagon-like peptide 1 (GLP1) agonist compared to a control group of individuals diagnosed with type 2 diabetes mellitus (T2DM) who are receiving treatment with drugs other than glucagon-like peptide 1 (GLP1) agonists. The study will not involve changes to medications for the participants.||||
33978025|NCT02172248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978026|NCT04518774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978027|NCT03346564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33978028|NCT00101608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978029|NCT04496466|||COHORT||PROSPECTIVE|||||||
33978030|NCT01801670|||COHORT||PROSPECTIVE|||||||
34052741|NCT05547295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34052742|NCT06429215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34052743|NCT06653608|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this triple-blind trial, participants, care provider and outcome assessor were unaware of the study groups.||t|t|f|t
34052744|NCT00774254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34052745|NCT06223750|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34052746|NCT00655707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156139|NCT03687606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052747|NCT04662866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded medication|Randomised controlled trial (RCT), 4 parallel groups|t|t|t|t
34052748|NCT00737204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34052749|NCT00545389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052750|NCT01954537|||COHORT||PROSPECTIVE|||||||
34052751|NCT01369030|||COHORT||PROSPECTIVE|||||||
34052752|NCT03317964|||CASE_CONTROL||PROSPECTIVE|||||||
34052753|NCT02630225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052754|NCT05246163|||CASE_ONLY||CROSS_SECTIONAL|||||||
34052755|NCT00004406|RANDOMIZED|||TREATMENT||DOUBLE||||||
34052756|NCT00006251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052757|NCT06666465|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Patients participating in the study will be included in a group by gender-based stratified block randomization method. Patients in the intervention group will experience the operating room environment with VR glasses (n: 30), while patients in the control group (n: 30) will receive standard nursing care.||||
34052758|NCT04241744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|placebo controlled||t|t|f|f
34052759|NCT03358589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|it is a single-arm study|Prospective cohort||||
34052760|NCT00137475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052761|NCT06342622|||OTHER||RETROSPECTIVE|||||||
34052762|NCT05969366|||COHORT||RETROSPECTIVE|||||||
34052763|NCT03031249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052764|NCT01595464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052765|NCT05017896|||COHORT||PROSPECTIVE|||||||
34052766|NCT04604509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052767|NCT02105246|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052768|NCT05735587|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34052769|NCT02039518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052770|NCT01955772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052771|NCT03884517|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34156140|NCT02144025|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156141|NCT06560905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients will receive PSMA-PET-CT||||
33845341|NCT02510898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845342|NCT04730193|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants, investigator, and outcomes assessors are blinded|subject will take drug A on first session and measurements will be performed at baseline and 1 hour after treatment; subject will come for second visit in 5-7 days and take drug B, measurements will be performed at baseline and 1 hour after treatment|t|f|t|t
33845343|NCT00879073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845344|NCT02261987|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33845345|NCT00948649|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
33845346|NCT01875289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845347|NCT04709952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845348|NCT02025959|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33845349|NCT00133510|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33978031|NCT04687163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33978032|NCT01501942|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33978033|NCT04822870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052772|NCT01620775|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34052773|NCT02150733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052774|NCT02989779|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34052775|NCT06625307|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34052776|NCT04498689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052777|NCT00387140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052778|NCT00526708|||CASE_ONLY||PROSPECTIVE|||||||
34052779|NCT06617819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845350|NCT05317364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Participants are assigned to receive either topical vaginal estrogen or placebo cream and will continue this therapy for duration of study.|t|f|t|f
33949689|NCT03540602|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|To ensure that all subjects and researchers are unaware of the treatment assignments we will have one outside individual that will possess the knowledge of which subjects are given which supplement and which were given a placebo. This information will remain confidential until the study has been concluded. At the conclusion of the study, participants will be informed of which condition they were assigned. in an event of an emergency or the participant decides not to participate his condition will be revealed.|"20 male participants will start with a familiarization visit where they will receive either the placebo supplement or the polyphenol rich supplement that they will take for 7 days. After taking the supplement, the participants will come back and run through the acute resistance exercise protocol as well as return the next day for a post test. Next, the participants will undergo a wash out phase where they will not take any supplementation. At the end of these 2 weeks, the participants will then take the other supplement (i.e. if they took the polyphenol rich supplement in the first phase they will take the placebo supplement in the second phase). After a week of taking their assigned supplement, participants will complete the acute resistance exercise protocol and the post test."|t|f|t|f
33949690|NCT04031469|||OTHER||OTHER|||||||
33949691|NCT01953380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33949692|NCT01171274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33949693|NCT04369040|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33949694|NCT02869373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949695|NCT03560765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33949696|NCT03717441|||COHORT||PROSPECTIVE|||||||
33949697|NCT01589185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949698|NCT00544570||||TREATMENT||||||||
33949699|NCT03662477|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33949700|NCT03015662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949701|NCT06060912|RANDOMIZED|PARALLEL||TREATMENT||NONE||AMPIRI is an investigator-initiated, prospective, randomized, multicenter, open-label, non-inferiority other clinical investigation.||||
33949702|NCT03107065|NA|SINGLE_GROUP||OTHER||NONE||||||
33949703|NCT05833269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949704|NCT02120690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949705|NCT02129257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949706|NCT00274573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33949707|NCT00389766||||TREATMENT||NONE||||||
33949708|NCT02012751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949709|NCT04259398|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33949710|NCT00240331|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33949711|NCT03024294|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33949712|NCT01452386|||||PROSPECTIVE|||||||
33949713|NCT02147015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949714|NCT02568111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33949715|NCT00961727|||CASE_CROSSOVER||PROSPECTIVE|||||||
33949716|NCT02168465|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949717|NCT01353209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949718|NCT01471652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949719|NCT05334576|NA|SINGLE_GROUP||PREVENTION||NONE||Crizanlizumab (SEG101) at 5.0 mg/kg dose administered over two years per standard of care in patients with sickle cell disease and silent cerebral infarcts.||||
33949720|NCT04056650|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33949721|NCT05728658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845351|NCT06017934|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34156142|NCT06543030|||COHORT||PROSPECTIVE|||||||
34156143|NCT00761722|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156144|NCT00558181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156145|NCT05553392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33845352|NCT00085462||||TREATMENT||NONE||||||
34156146|NCT04356352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|assessor asking for pain scores will be blinded from the randomization|subjects randomized to receive either lidocaine, esmolol, or placebo immediately prior to the administration of propofol for their surgical procedure to treat injection site pain caused by propofol|t|t|f|f
34156147|NCT05229029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156148|NCT06388603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156149|NCT05457088|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||1st group will receive a dietary plan having dietary protein of 1.5gr/kg/day.2nd group will receive a dietary plan having dietary protein of 0.8gr/kg/day.|t|f|t|t
33845353|NCT01618721|||COHORT||PROSPECTIVE|||||||
33949722|NCT01643967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156150|NCT02982941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156151|NCT01215825|||COHORT||RETROSPECTIVE|||||||
34156152|NCT04729335|||CASE_ONLY||PROSPECTIVE|||||||
34156153|NCT00083135||||TREATMENT||||||||
34156154|NCT00524472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156155|NCT01580202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845354|NCT01451892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33845355|NCT05180331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845356|NCT03428529|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33845357|NCT03232853|||OTHER||PROSPECTIVE|||||||
33845358|NCT05523843|||COHORT||PROSPECTIVE|||||||
33845359|NCT01517295|RANDOMIZED|PARALLEL||||NONE||||||
33845360|NCT02308787|||CASE_ONLY||RETROSPECTIVE|||||||
33949723|NCT06323655|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34156156|NCT03973294|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Patients undergoing elective micro laryngeal surgery will be assigned to subglottic JV via the new LaserJet catheter and supraglottic JV via the jet laryngoscope vice versa. The sequence of JV modes will be randomized (subglottic followed by supraglottic or supraglottic followed by subglottic JV).||||
34156157|NCT00358969|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156158|NCT05567926|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34156159|NCT01776866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156160|NCT02267538|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156161|NCT01496846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156162|NCT00293436||||TREATMENT||NONE||||||
34156163|NCT01103063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156164|NCT05090033|||COHORT||PROSPECTIVE|||||||
34156165|NCT03721497|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, placebo-controlled and double-blinded study|t|t|t|t
34156166|NCT04897880|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156167|NCT04087135|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||Each participant will performe the intubation three time using the tools provided, for the same simulation situation: (a) direct laryngoscopy, (b) videolaryngoscopy McGrath and (c) videolaryngoscopy McGrath with suction.|t|f|f|f
34156168|NCT04954157|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|There is no masking taking place in this study.|Each group of subjects will be required to perform the same test, depending on what phase of the study they are recruited into. If the subject currently has been diagnosed with COVID-19 and fits all other criteria, they will be placed in the COVID-19 group. If the subject has not been diagnosed with COVID-19 and are considered healthy at that time, they will be placed on the healthy group.||||
34156169|NCT00799591|||||PROSPECTIVE|||||||
34156170|NCT01747434|||COHORT||CROSS_SECTIONAL|||||||
34156171|NCT06583811|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34156172|NCT01589393|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34156173|NCT05830071|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34156174|NCT03322150|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34156175|NCT02697188|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156176|NCT06341933|||OTHER||PROSPECTIVE|||||||
34156177|NCT00597415|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34156178|NCT03311789|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled patients will be treated with PD-1 inhibitor in combination with gemcitabine/cisplatin chemotherapy.||||
34156179|NCT06245213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment in Part A and Part B.|t|t|t|t
34052780|NCT01128101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052781|NCT02857400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34052782|NCT03837366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Individuals processing outcome data are blinded to experimental condition.|Participants are randomized to one of two groups. One group received an activity tracker and the other received an activity tracker in combination with Health Coaching.|f|f|f|t
34052783|NCT04461860|||COHORT||OTHER|||||||
34052784|NCT04368039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052785|NCT00840307|||CASE_ONLY||PROSPECTIVE|||||||
34052786|NCT06069349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052787|NCT00451893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052788|NCT02989649|||COHORT||PROSPECTIVE|||||||
34052789|NCT00368784|||CASE_CONTROL||PROSPECTIVE|||||||
34052790|NCT04081090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34052791|NCT06228768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Both clinicians and participants will be blinded to study arm.|Participants will be randomized 1:1 to two different sets of acupressure points|t|t|t|f
34052792|NCT05369208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052793|NCT01355198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052794|NCT06259903|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Study medication will be supplied in labelled vials, clearly identifying the contents and indicating that the product is an investigational drug. An unblinded pharmacist at the clinical site will be responsible for drawing up the appropriate amount of study medication into a syringe and labelling the syringe for administration to the specific patient according to the randomization scheme.|Five subjects in cohort 1 will be administered a single subcutaneous dose of 40 mg MD-18 and two will receive placebo. The cohort will be staggered with 2 active and one placebo patient treated on day 1 and the remainder on Day 3 if there are no safety concerns. The same dosing regimen will be observed for each incremental cohort, with the remaining planned doses being 80, 160, 240 and 320 milligram (mg).|t|f|t|f
34052795|NCT05628038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052796|NCT02058784|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34052797|NCT04749654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34052798|NCT01095900|||CASE_CONTROL||PROSPECTIVE|||||||
34052799|NCT05978713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34052800|NCT02429024|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052801|NCT03142542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|placebo-controlled|t|t|t|f
34052802|NCT01203761|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052803|NCT05160532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052804|NCT05514873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052805|NCT01833624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052806|NCT01310634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052807|NCT06668532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34052808|NCT04008771|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This study was a prospective, open label feasibility study||||
34052809|NCT06392139|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052810|NCT05817617|||COHORT||PROSPECTIVE|||||||
34052811|NCT04271839|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052812|NCT04973540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052813|NCT03214380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052814|NCT04323033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052815|NCT01646021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075825|NCT02154932|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34156180|NCT01963156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156181|NCT03937960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156182|NCT02800083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156183|NCT06584175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156184|NCT00359099|||||RETROSPECTIVE|||||||
34156185|NCT01497249|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34156186|NCT06524622|||COHORT||PROSPECTIVE|||||||
34156187|NCT04757051|||CASE_ONLY||PROSPECTIVE|||||||
34156188|NCT05975060|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34156189|NCT00284310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156190|NCT06339970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156191|NCT03893162|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34156192|NCT01418742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156193|NCT00901199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156194|NCT04478448|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34156195|NCT05642299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156196|NCT00138775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33949724|NCT03315780|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34156197|NCT06038734|||CASE_CONTROL||PROSPECTIVE|||||||
34156198|NCT06086834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156199|NCT03940391|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33845361|NCT01378689|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33949725|NCT00690573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845362|NCT05635305|RANDOMIZED|PARALLEL||TREATMENT||NONE||BE study (cohort 1) will be managed in parallel with the DDI study (cohort 2)||||
33845363|NCT00258557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949726|NCT05206669|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants were not informed of the study design and were unaware of the other message conditions.|The current study employed a 2 x 3 mixed factorial design. Participants consisted of two groups: 1) Hispanic or Latino parents of adolescents (age 11-17), and 2) Hispanic or Latino young adults (age 18-26). Participants were randomly assigned to one of three message conditions: cancer, genital warts, or control messages.|t|f|f|f
33949727|NCT04530734|||COHORT||PROSPECTIVE|||||||
33949728|NCT04002466|||OTHER||CROSS_SECTIONAL|||||||
33949729|NCT04245982|||CASE_ONLY||CROSS_SECTIONAL|||||||
33949730|NCT01319994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949731|NCT00700115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949732|NCT04173520|||CASE_ONLY||PROSPECTIVE|||||||
33949733|NCT02925650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949734|NCT05798624|||OTHER||PROSPECTIVE|||||||
33949735|NCT00591552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949736|NCT02381366|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949737|NCT02651246|||COHORT||PROSPECTIVE|||||||
33949738|NCT05427968|||CASE_CONTROL||RETROSPECTIVE|||||||
34052816|NCT03324516|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be given assigned a research limb the morning of the surgery|||||
34052817|NCT02121015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052818|NCT00482677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052819|NCT02490787|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34052820|NCT02937142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052821|NCT06622356|||CASE_CONTROL||RETROSPECTIVE|||||||
34052822|NCT00288067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052823|NCT03065764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052824|NCT02247492|||OTHER||PROSPECTIVE|||||||
34052825|NCT05500274|RANDOMIZED|PARALLEL||PREVENTION||NONE||Using a two-arm 1:1 randomized controlled trial design, 800 participants will be enrolled into either a: 1) COVID-19 prevention education arm (Education Arm) or, 2) a network mobilization change agent intervention (Motivational Arm); the latter is a Type I network intervention that includes specific training on mobilization of network members which we have adapted to COVID-19 from HIV prevention.||||
34156200|NCT02092025|||COHORT||PROSPECTIVE|||||||
34156201|NCT00551603|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156202|NCT01811186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156203|NCT01221493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156204|NCT05275036|||CASE_CONTROL||PROSPECTIVE|||||||
34156205|NCT04320901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156206|NCT01169935|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34156207|NCT02577016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156208|NCT05949632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of 2 parts. In the Part 1 dose-escalation, participants will be enrolled in up to 6 dose levels of INCB099280 administered in combination with axitinib. In the Part 2 dose expansion, participants will be enrolled into 1 of 2 disease-specific cohorts at the dose(s) identified in Part 1.||||
33845364|NCT00353288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845365|NCT01018238|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33845366|NCT04744272|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33845367|NCT03231280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845368|NCT02495792|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33845369|NCT06727981|||COHORT||PROSPECTIVE|||||||
33845370|NCT05559320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845371|NCT06319716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33949739|NCT06248866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|extracorporeal shock wave therapy and traditional treatment|f|f|t|t
33949740|NCT02219477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949741|NCT06415188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study was conducted on children aged 3-6 years. The study was completed with a total of 40 children and parent pairs in the experimental and control groups. Simple randomization method was used in the study. The randomization table for which group the children would be in was made by an independent statistician. Letters A and B were used to represent the experimental and control groups. Which letter represented which group was determined by lottery. While therapeutic play intervention was applied in the experimental group, routine intervention was applied in the control group.|t|f|f|f
34052826|NCT06667752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34052827|NCT01672749|||COHORT||PROSPECTIVE|||||||
34052828|NCT04532645|||COHORT||RETROSPECTIVE|||||||
34052829|NCT05660005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel group study|f|f|f|t
34052830|NCT02353494|||COHORT||PROSPECTIVE|||||||
34156209|NCT03653988|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||RANDOMIZED CONTROLLED DOUBLE BLIND STUDY|t|f|f|t
33845372|NCT03915964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845373|NCT04411160|||COHORT||PROSPECTIVE|||||||
33845374|NCT01416389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845375|NCT03412201|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, randomized, parallel group study||||
33845376|NCT01708304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845377|NCT04817761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845378|NCT05253157|||OTHER||RETROSPECTIVE|||||||
33845379|NCT02955147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845380|NCT00846729|||COHORT||PROSPECTIVE|||||||
33845381|NCT02093949|||COHORT||PROSPECTIVE|||||||
33845382|NCT05369195|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In order to blind the radial artery will also be punctured in control group and an aortography will be performed. Researchers participating in the randomization of patients and in the procedure will not be included in the remaining stages of the study.||t|f|f|t
33845383|NCT06250790|||COHORT||PROSPECTIVE|||||||
33845384|NCT04809506|||COHORT||PROSPECTIVE|||||||
33845385|NCT04138264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33845386|NCT00736268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845387|NCT02597335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845388|NCT06727916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845389|NCT05628168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|t|f|t|f
33845390|NCT00036387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845391|NCT06729814|||COHORT||PROSPECTIVE|||||||
33845392|NCT01383564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33845393|NCT03570489|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized parallel design||||
33845394|NCT02320981|||CASE_ONLY||PROSPECTIVE|||||||
33845395|NCT04464278|||CASE_CONTROL||PROSPECTIVE|||||||
33845396|NCT02877888|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33845397|NCT03732742|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33949742|NCT06176222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949743|NCT05900674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||PROBE study (Prospective Randomized Open, Blinded End-point)|f|f|f|t
33949744|NCT05992558|||COHORT||PROSPECTIVE|||||||
33949745|NCT04505176|||COHORT||PROSPECTIVE|||||||
33949746|NCT01587716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949747|NCT00681434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949748|NCT00493701|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33949749|NCT04731740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel arms based on the inclusion/exclusion criteria: Pembrolizumab+Lenvatinib or Pembrolizumab+Chemotherapy||||
33949750|NCT05138510|||COHORT||PROSPECTIVE|||||||
33949751|NCT03713112|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 2 arms of rehabilitative and/or subacute care patients consist of the intervention arm (receiving weekly multidisciplinary rounds up to the point of discharge, using 5 steps of deprescribing at the bedside, targeted to deprescribe selected medications \[Beers' List of inappropriate Medications 2015; selected supplements and selected symptomatic medications\]) and control arm (receving usual care)||||
33949752|NCT04554355|RANDOMIZED|PARALLEL||OTHER||SINGLE|"1. those who entered data (student helpers) were exlcuded from fieldwork and intervention dilivery, data analysis and report writing.~2. after data entry, only the PI knew the values of the two groups and stored the data separately in another file with passwords requested for access.~3. data were analysed by a researcher, who was not involved in proposal writing and did not know which value means which group."|RCT|f|f|f|t
33949753|NCT01593761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949754|NCT05920057|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33949755|NCT01380041|||CASE_ONLY||PROSPECTIVE|||||||
33949756|NCT02603341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949757|NCT02468973|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949758|NCT05849051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949759|NCT06091826|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33949760|NCT03698058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949761|NCT05079984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949762|NCT05654116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Trained coders who code the outcome variables of the study (from video-recorded material) will be blind to the intervention vs control condition, and to the baseline vs follow-up condition.||f|f|f|t
33949763|NCT04008290|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33949764|NCT01934101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949765|NCT06506526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33949766|NCT01813760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949767|NCT01400607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949768|NCT04249934|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patient and observer will be blinded to which group they were assigned.||t|f|f|f
33949769|NCT03198819|||CASE_CONTROL||PROSPECTIVE|||||||
33949770|NCT01875900|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33949771|NCT00470301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949772|NCT00588120|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949773|NCT00823875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949774|NCT03506334|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Tether group 40 patients and Fusion (control) group 40 patients||||
33949775|NCT01195662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949776|NCT00270400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978034|NCT03901014|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The nature of the diet does not allow for masking|||||
34156210|NCT03764683|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The investigators are proposing the use of SPCD for this study. The Sequential Parallel Comparison Design aims to reduce the impact of high placebo response and decrease sample size. The design has been accepted by and published on by FDA. The SPCD model has two relatively short phases of treatment of equal duration. Only non-responders to placebo (P) during the first phase are included in the analyses of the second phase. Randomization is unbalanced (for example, a 2:3:3 assignment of DD, PP, and PD).|t|f|t|f
34156211|NCT02207491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156212|NCT00718705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156213|NCT01887353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156214|NCT00053144||||TREATMENT||||||||
34156215|NCT01266590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156216|NCT04715971|||COHORT||CROSS_SECTIONAL|||||||
34156217|NCT05926830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156218|NCT02082730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156219|NCT05164614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy women volunteers||||
34156220|NCT04487925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156221|NCT05781464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156222|NCT00420121|||COHORT||RETROSPECTIVE|||||||
34156223|NCT01846741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156224|NCT06431269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156225|NCT06024668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Individuals with Acquired Monocular Vision/ Blindness in One Eye||||
34156226|NCT04043468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34156227|NCT06303323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156228|NCT01673620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156229|NCT01954108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156230|NCT03077269|||CASE_ONLY||PROSPECTIVE|||||||
34156231|NCT01742806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156232|NCT03845738|||COHORT||RETROSPECTIVE|||||||
34156233|NCT05471089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were unaware of the treatment group. Researchers in charge of assessment were blinded. Investigator in charge of data analysis was blinded about treatments. Only care providers known about the different treatments|Double-blind Randomized Controlled Trial|t|f|t|t
34156234|NCT02113228|||||PROSPECTIVE|||||||
34156235|NCT01132742|||COHORT||PROSPECTIVE|||||||
34156236|NCT00360724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949777|NCT05463393|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Patients were randomized in a double-blind, placebo-controlled fashion into two groups using sealed envelopes|f|f|t|f
34156237|NCT04016077|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33845398|NCT06728371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|By drawing sequentially numbered, coded sealed, opaque envelops each containing the group assignment of either methadone or morphine group. The sealed envelopes for randomization will be prepared by a third party who takes no further part in the study. The study syringes containing the drug solution will be prepared by a nurse not involved in the study with blind labelling. The primary care team, blinded to the group allocation, will perform all surgical procedures using standardized techniques. Anaesthetists and nurses blinded to group allocation will record data intraoperatively, in ICU, and at regular intervals in the cardiac wards.|Single centred, parallel, double blinded, randomized controlled trial|t|t|f|t
33949778|NCT00752427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949779|NCT05665257|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33949780|NCT00822185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949781|NCT06477731|||COHORT||PROSPECTIVE|||||||
33949782|NCT03049592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949783|NCT04544748|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33949784|NCT04392882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33949785|NCT00903357|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33949786|NCT00852657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949787|NCT04156113|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949788|NCT02863458|||COHORT||OTHER|||||||
34156238|NCT04300036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34156239|NCT02713828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156240|NCT06420180|||OTHER||PROSPECTIVE|||||||
34156241|NCT04294836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind masking|Phase II clinical trial, randomized and placebo controlled|t|f|t|f
34156242|NCT01290744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156243|NCT00410007|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34156244|NCT06041126|||OTHER||CROSS_SECTIONAL|||||||
34156245|NCT03709394|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized study||||
34156246|NCT03851055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156247|NCT00088894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156248|NCT05446571|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156249|NCT03018977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156250|NCT03323801|NA|SINGLE_GROUP||TREATMENT||NONE||20 mg 13-cis retinoic acid twice daily (BID) with meals for 32 weeks||||
34156251|NCT04672122|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
34156252|NCT06291064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949789|NCT01616992|||CASE_CONTROL||PROSPECTIVE|||||||
33949790|NCT03792880|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33949791|NCT01874912|||COHORT||CROSS_SECTIONAL|||||||
33949792|NCT04056234|||OTHER||PROSPECTIVE|||||||
33949793|NCT05277909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949794|NCT05146999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel assignment|t|t|t|f
33949795|NCT00139269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949796|NCT05732610|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an open label study to evaluate the usability of the MGC Health COVID-19 \& Flu A+B Home Multi Test using information from the Quick Reference Instructions (QRI).||||
33949797|NCT02177370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33949798|NCT03026426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33949799|NCT01115166|||COHORT||PROSPECTIVE|||||||
34052831|NCT01869699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741416|NCT05166252|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Families are assigned to the 2 conditions in a random order without knowing the aim of the intervention.|The study has an AB/BA crossover design, in which each participant receives the intervention and the control in a randomized order.|t|f|f|f
33741417|NCT03868436|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|||||
33741418|NCT04598282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845399|NCT06182891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949800|NCT01578109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949801|NCT05872113|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33949802|NCT02714413|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33949803|NCT02899273|||COHORT||PROSPECTIVE|||||||
33949804|NCT03558906|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949805|NCT00576940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949806|NCT00314275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949807|NCT04622280|||COHORT||PROSPECTIVE|||||||
34052832|NCT06277635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34052833|NCT03187847|||COHORT||PROSPECTIVE|||||||
34052834|NCT05380284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34052835|NCT03280082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052836|NCT03308435|||COHORT||PROSPECTIVE|||||||
34052837|NCT01167543|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34052838|NCT05967988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will assess the outcome him/herself. The statistician will also be blinded to the group assignment.||t|f|f|f
34052839|NCT00774553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845400|NCT02886182|||CASE_CONTROL||PROSPECTIVE|||||||
33845401|NCT06729554|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective, multicenter, randomized and controlled study with a waiting list. Intervention is psychoeducation using Education \& Care in RARE, a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases.||||
33845402|NCT03347097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845403|NCT04647552|||OTHER||PROSPECTIVE|||||||
33845404|NCT00960453|RANDOMIZED|CROSSOVER||||NONE||||||
33845405|NCT02686827|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33845406|NCT03245853|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with a diagnosis of progressive keratoconus will be evaluated for suitability as a candidate for CXL. Subjects that are candidates for CXL will be asked to participate in this study and will undergo required screening testing. Informed consent will be obtained from each subject prior to study-oriented testing.||||
33949808|NCT06405048|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33949809|NCT03395652|||COHORT||PROSPECTIVE|||||||
33949810|NCT03000075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949811|NCT04980196|||CASE_ONLY||PROSPECTIVE|||||||
33949812|NCT02956980|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33949813|NCT03310281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978035|NCT02252562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978036|NCT01245790|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052840|NCT01597375|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34052841|NCT02868567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052842|NCT05051267|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052843|NCT02314260|||CASE_ONLY||PROSPECTIVE|||||||
34052844|NCT03128177|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the participant and investigator are blinded to the diet|Crossover study of high (6 g) and low (1.5 g) sodium diet|t|f|t|f
34052845|NCT05761249|||COHORT||PROSPECTIVE|||||||
34052846|NCT04982354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052847|NCT01883180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052848|NCT05640726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052849|NCT00733239|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34052850|NCT04088279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052851|NCT01687465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34052852|NCT05007990|||FAMILY_BASED||PROSPECTIVE|||||||
34052853|NCT00327028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34052854|NCT01729338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052855|NCT05642312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052856|NCT00342381|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34052857|NCT06147063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052858|NCT04814550|||COHORT||PROSPECTIVE|||||||
34052859|NCT03902522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052860|NCT03828552|||OTHER||PROSPECTIVE|||||||
34052861|NCT03335007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34052862|NCT05379270|NA|SINGLE_GROUP||OTHER||NONE||||||
34052863|NCT05836740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Minocycline drug used in the study is indistinguishable from the Minocycline placebo (the shape, color, and appearance are identical).~In addition, to ensure the blind method, the drug packaging and batch numbers of the two groups are identical, and the packaging batch numbers are uniformly marked.~During the implementation of the study, except for the authorized personnel of the company's supply chain, research management department, and subject security department, members of each research execution group, research center personnel, and CRO data processing personnel cannot view the randomization scheme. The blind method was also used to evaluate the outcome. The participants were randomly divided into groups and blinded to the members of the adjudication committee."|This trial was a prospective, randomized, multicenter, double-blind, placebo-controlled parallel trial. Participants were randomly assigned according to the ratio of the experimental group: control group =1:1.|t|t|t|t
34052864|NCT01666743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052865|NCT04128969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052866|NCT00978250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052867|NCT03517553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052868|NCT04594226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156253|NCT06432504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Parallel Assignment|t|f|f|f
34156254|NCT00317096|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34156255|NCT00274677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156256|NCT05216341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Stage 1: open label~Stage 2: double blind"|"Stage 1 - open label, dose-finding study, single ascending dose design~Stage 2 - double-blind, placebo-controlled, parallel-arm study"|t|t|t|t
34156257|NCT05371457|||CASE_ONLY||CROSS_SECTIONAL|||||||
34156258|NCT05325840|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34156259|NCT03817268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34156260|NCT05222386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a pragmatic comparative effectiveness trial using a stepped-wedge design to randomize neurology practices (clusters).||||
33845407|NCT06727773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Participants will be randomized to MEM+EX (memantine + exercise), memantine, or placebo using a computer-generated randomization scheme that stratifies for an equal balance of age. All study personnel and participants will remain blinded until data collection is complete.|t|t|t|f
33845408|NCT05249491|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845409|NCT03640572|||COHORT||PROSPECTIVE|||||||
33845410|NCT01862107|||OTHER||OTHER|||||||
33845411|NCT04606108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845412|NCT00400127|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33845413|NCT06208254|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33845414|NCT05089656|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A participant will receive a single, one-time dose of OAV101.|t|t|t|t
33845415|NCT03763890|||CASE_CROSSOVER||PROSPECTIVE|||||||
33845416|NCT05107128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33845417|NCT02046629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845418|NCT01719705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845419|NCT01071655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845420|NCT00126230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845421|NCT03388697|||COHORT||PROSPECTIVE|||||||
33845422|NCT04097353|RANDOMIZED|PARALLEL||PREVENTION||NONE||Families will be randomly assigned to the Harvesting Hope for Kids (HH4K) intervention or the enhanced usual care (Surviving Strong for Kids (SS4K) education group after the baseline assessment.||||
33845423|NCT01511783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052869|NCT05257824|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. short-term dual antiplatelet group: for 6 months~2. long-term dual antiplatelet group: for 12 months"||||
34156261|NCT03937414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845424|NCT02070679|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33845425|NCT04359043|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This was a quasi-experimental study with two treatment arms: intervention vs. TAU. Subjects were not randomized.||||
33845426|NCT04921787|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a multi-site, cluster randomized, two group implementation trial comparing a low versus high intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented. Approximately 24 hospitals meeting defined eligibility requirements, including a desire to address OUD among inpatients through the use of MOUD, will be randomized 1:1 to implement a low- or high-intensity strategy. Hospitals will be randomized with intervention implementation and oversight assigned to one of 3-4 geographically diverse hub academic medical centers with existing clinical and research expertise in HBOT. The randomization will be stratified by site/hub.||||
34156262|NCT02369419|||COHORT||PROSPECTIVE|||||||
34156263|NCT04371666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156264|NCT03145948|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34156265|NCT02241343|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34156266|NCT00410605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156267|NCT03691571|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized, blinded single center pilot study|t|f|f|f
34156268|NCT06394245|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33949814|NCT05082922|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Data is collected using a secure digital platform. Outcome assessors will be blinded to baseline length allocations.|This study employs a sequential single-case experimental AB design with randomized waiting period lengths (4, 5 or 6 weeks). Included in the design is also standardized pre-post and follow up measurement allowing for single group analysis of change. In addition, we collect qualitative data from patients, practitioners and clinical managers, detailing how the treatment and its implementation are experienced.|f|f|f|t
33949815|NCT03661346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949816|NCT01744834|||COHORT||PROSPECTIVE|||||||
33949817|NCT02612766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949818|NCT04899570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949819|NCT01097174|||CASE_ONLY||OTHER|||||||
33949820|NCT00919607|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33845427|NCT04917640|||COHORT||PROSPECTIVE|||||||
33845428|NCT01216800|RANDOMIZED|||TREATMENT||||||||
33845429|NCT02629653|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33845430|NCT00192868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845431|NCT06030206|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33845432|NCT01600248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845433|NCT02497521|||CASE_ONLY||PROSPECTIVE|||||||
33845434|NCT05398445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845435|NCT00350103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845436|NCT00467350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845437|NCT03860103|||CASE_CONTROL||PROSPECTIVE|||||||
33949821|NCT01059695|||COHORT||RETROSPECTIVE|||||||
33949822|NCT01697124|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33949823|NCT00382499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949824|NCT02881866|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34052870|NCT01618123|||COHORT||PROSPECTIVE|||||||
34052871|NCT06184945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||pragmatic, stepped-wedge, cluster-randomized, hybrid type III effectiveness-implementation trial|f|f|f|t
34052872|NCT00504699|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34052873|NCT01826565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052874|NCT04562831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052875|NCT02222233|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052876|NCT04724629|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, adaptive, open-label, randomized study design (1: 1: 1: 1 ratio), with an active comparator, superiority study, in severe to critical COVID19 subjects.||||
34052877|NCT04217837|||COHORT||PROSPECTIVE|||||||
34052878|NCT04737824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052879|NCT02728154|||COHORT||PROSPECTIVE|||||||
34052880|NCT05702242|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052881|NCT03796416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052882|NCT05196984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34052883|NCT05538234|||CASE_ONLY||PROSPECTIVE|||||||
34052884|NCT01354392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052885|NCT06605989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34052886|NCT00978081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052887|NCT02225366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052888|NCT04722744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34052889|NCT05887167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052890|NCT05380193|||COHORT||PROSPECTIVE|||||||
34052891|NCT06619314|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34052892|NCT00976820|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34052893|NCT03283644|||CASE_CONTROL||PROSPECTIVE|||||||
34052894|NCT05658055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052895|NCT01996410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052896|NCT00372606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34052897|NCT05402969|||COHORT||OTHER|||||||
34052898|NCT03089268|||COHORT||PROSPECTIVE|||||||
34052899|NCT01876784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34052900|NCT03533114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052901|NCT06450054|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34052902|NCT02562638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052903|NCT02556073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052904|NCT01669174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34052905|NCT01306318|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052906|NCT00191282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052907|NCT06604962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each random number concealed within the small opaque envelope, later all numbers concealed within the large opaque envelope. An independent researcher who was not part of the study generated 36 random (computer generated) numbers, and an office clerk was involved in the allotment of the specified interventions. The intervention provider, outcome assessors and statistician are blinded to interventions.|This is an experimental study to study the effects of intramuscular electrical stimulation using different electrode placements over sham comparator group|t|t|f|t
34052908|NCT05896566|RANDOMIZED|PARALLEL||TREATMENT||NONE||Window of opportunity trial with no therapeutic intent, no efficacy.||||
34052909|NCT01453322|||CASE_ONLY||PROSPECTIVE|||||||
34052910|NCT01690728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34052911|NCT03984435|||CASE_ONLY||RETROSPECTIVE|||||||
34052912|NCT03782298|||CASE_ONLY||RETROSPECTIVE|||||||
34052913|NCT03553069|||COHORT||PROSPECTIVE|||||||
34052914|NCT05154500|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Double blind randomized trial of naturally biofortified with iron or zinc potatoes to be carried out in Huancavelica.||||
34075826|NCT00229749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075827|NCT02958787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075828|NCT04218721|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants get access to the ehealth application||||
34156269|NCT03122782|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34156270|NCT02481817|||COHORT||PROSPECTIVE|||||||
33845438|NCT03760445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"3 parts - two different populations Part 1 - escalation - parallel dose escalation in 1L AML subjects and in R/R subjects (up to 8 dose cohorts per arm.~Part 2 - expansion - parallel expansion in 3 cohorts of 1L AML, and 1 cohort of R/R AML after recommended dose of expansion was determined.~Part 3 - DDI - parallel enrollment or R/R AML subjects into 2 DDI Cohorts (one with CYP3A4 inhibitor, one with CYP3A4 substrate)."||||
34156271|NCT02472704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156272|NCT04530864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845439|NCT04425759|||COHORT||PROSPECTIVE|||||||
33845440|NCT04024488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers participating for youth who are enrolled into the TI-CBT arm will receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months.~The other arm is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers of youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months."||||
33845441|NCT00132873|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33845442|NCT02053792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845443|NCT06251518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845444|NCT01974401|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33845445|NCT03117829|NA|SINGLE_GROUP||OTHER||NONE||||||
33949825|NCT05603975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study was double-blind, including subjects, anesthesia operators, data collectors and dressing change operators. Nurse Song Yi opened the random envelope, diluted the drugs with normal saline according to the grouping information and filled them into a 10ml syringe. The syringe was labeled (marked with subject number, name and hospitalization number), and the grouping information was destroyed after confirmation, and confidentiality was strictly observed. Fully equipped drugs are given to the anesthesiologist and empty envelopes are given to the data collector.||t|t|t|t
33845446|NCT02154880|||COHORT||PROSPECTIVE|||||||
33845447|NCT02780908|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33845448|NCT06729437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
33949826|NCT01226992|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845449|NCT06728839|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33845450|NCT02727244|||CASE_ONLY||PROSPECTIVE|||||||
33949827|NCT02917421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949828|NCT02997852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845451|NCT05362864|||COHORT||PROSPECTIVE|||||||
33845452|NCT05562167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, placebo controlled|Randomized, placebo-controlled, parallel arm design|t|f|t|f
33949829|NCT01876901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two multicenter parallel single-arm phase II trials.~One trial assessing 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) in centers who routinely performing this intervention.~One trial assessing colo-anal anastomosis (CAA) in centers who routinely performing this intervention."||||
33845453|NCT06728137|||COHORT||PROSPECTIVE|||||||
33949830|NCT03131375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33949831|NCT00061269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845454|NCT02390700|||COHORT||PROSPECTIVE|||||||
33845455|NCT00875498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949832|NCT00660101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949833|NCT02391194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949834|NCT05100693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845456|NCT00022659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949835|NCT00379639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33949836|NCT03704285|||CASE_CONTROL||PROSPECTIVE|||||||
33949837|NCT05921539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949838|NCT04276532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052915|NCT06330792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Physiotherapists will be randomly subdivided into two equal groups in number. Group (A) (Experimental Group): This group will receive biomechanical awareness advices while working and core stability exercises.~Group (B) (Control Group): This group will receive core stability exercises only."|t|t|f|f
34052916|NCT00266578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052917|NCT06054776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052918|NCT05372055|||COHORT||PROSPECTIVE|||||||
34052919|NCT02062073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052920|NCT04538547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052921|NCT03945370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Placebo-controlled, single-blind, cross-over study|t|f|t|f
34052922|NCT06532864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator of the statistical analysis was unaware of the grouping of the subjects|Participants were randomly assigned to experimental and control groups. The experimental group performed Mawangdui Guided Technique exercises, which consisted of five 45-minute sessions per week for 12 weeks. The control group maintained a routine of sleep education in addition to their daily activities.|f|f|f|t
34052923|NCT03834974|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33845457|NCT05133700|||OTHER||RETROSPECTIVE|||||||
33949839|NCT04842318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949840|NCT04957628|||CASE_CONTROL||PROSPECTIVE|||||||
33845458|NCT00307112|||||PROSPECTIVE|||||||
33949841|NCT05367895|||CASE_CONTROL||RETROSPECTIVE|||||||
34052924|NCT00222365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34052925|NCT01137110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052926|NCT04522973|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
34156273|NCT00049608||||TREATMENT||NONE||||||
34156274|NCT05164757|||COHORT||PROSPECTIVE|||||||
34052927|NCT05723913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741419|NCT04964089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For masking purposes, sham injections will be administered at every monthly visit if an active treatment is not administered. To preserve masking, two investigators are required for this study. The masked Investigator will be responsible for the examinations and safety assessments. The unmasked Investigator will perform the injections and post-treatment assessments.|Participants will be randomized 1:1 into one of two treatment arms: KSI-301 or aflibercept.|t|t|f|t
33741420|NCT00932893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741421|NCT00651989|||COHORT||CROSS_SECTIONAL|||||||
33741422|NCT04409756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741423|NCT00905333||CROSSOVER||||NONE||||||
33741424|NCT04790149|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 groups receiving parallel different interventions||||
33741425|NCT06449911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052928|NCT01329042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052929|NCT03671109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind placebo-controlled|Superiority clinical trial|t|t|t|t
34052930|NCT00555919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052931|NCT02180984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only provider of the stimulation aware of allocation arm (real or sham)|Repetitive transcranial magnetic stimulation applied to people with binge eating disorder (real x sham stimulation) only (not for control groups without binge eating disorder)|t|f|t|t
34052932|NCT04875715|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34052933|NCT01323010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052934|NCT02890147|||COHORT||PROSPECTIVE|||||||
34052935|NCT05113979|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) at least 6-months after cataract surgery with Bausch and Lomb Model LI61A0 and LI61SE||||
34052936|NCT03067688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
34052937|NCT04080557|||COHORT||RETROSPECTIVE|||||||
34052938|NCT00751049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052939|NCT04891770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052940|NCT00861848|||OTHER||PROSPECTIVE|||||||
34052941|NCT03808324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34052942|NCT05938829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34052943|NCT02810470|RANDOMIZED|CROSSOVER||||NONE||||||
34052944|NCT04874233|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34052945|NCT04187625|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm study||||
34052946|NCT05354102|NA|SINGLE_GROUP||TREATMENT||NONE||One dose level of BMC128 will be investigated in combination with Nivolumab using a 3+3 model (Part A), followed by an expansion cohort (part B)||||
34052947|NCT02543372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052948|NCT02463929|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34052949|NCT01793480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052950|NCT03692793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052951|NCT02548351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34052952|NCT00611949|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34052953|NCT00760695|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34052954|NCT06667154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052955|NCT04544293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subject will be randomized 1:1 to treatment with inhaled molgramostim or placebo|t|t|t|t
34052956|NCT02900651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052957|NCT04641663|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants will be taking either 60%, 80% or 100% of the recommended daily dose of the dietary supplement.||||
34052958|NCT05622318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052959|NCT01083186|||||PROSPECTIVE|||||||
34052960|NCT03425409|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
34052961|NCT02741674|||COHORT||RETROSPECTIVE|||||||
34052962|NCT05568121|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052963|NCT05252390|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential assignment will be applied in Phase 1 and Phase 1 b dose escalation cohorts. Parallel assignment will be applied in Phase 1b backfill cohorts and Phase 2.||||
34052964|NCT05605496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The 3 cohorts of patients will be conducted and analyzed independently. The sample size calculation will use an adaptive Simon 2-stage design based on the strategy developed by Lin and Shih (Biometrics 2004). This method allows checking the result at the first stage, adjusting the power and success rate if necessary, and adapting the decision rule accordingly.||||
34052965|NCT02847494|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34052966|NCT00744549|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34052967|NCT01322594|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34052968|NCT03784625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||dose escalation model||||
34052969|NCT02628457|||COHORT||RETROSPECTIVE|||||||
34052970|NCT04582058|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional Group (IG): Mobile Health to patients with an orientation about daily activities and protocol of physical exercise Control Group (CG): normally follow up, without mobile health||||
34052971|NCT00799721|||COHORT||PROSPECTIVE|||||||
34075829|NCT02431312|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34075830|NCT06573229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075831|NCT00024440|RANDOMIZED|||TREATMENT||NONE||||||
34075832|NCT02044757|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075833|NCT03962621|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34075834|NCT00818155|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33949842|NCT02545699|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845459|NCT02807935|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845460|NCT05427500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33845461|NCT01662375|||FAMILY_BASED||PROSPECTIVE|||||||
33845462|NCT04956991|||CASE_CONTROL||RETROSPECTIVE|||||||
33845463|NCT04396652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"* The patients will be blind through the use of closed sealed envelops.~* The measurement will be collected by anesthesia nurse not participating in the study and blinded to its group."|Prospective randomized controlled study|t|f|f|t
33949843|NCT02116374|||COHORT||PROSPECTIVE|||||||
33845464|NCT05032872|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33949844|NCT01483365||PARALLEL||SUPPORTIVE_CARE||NONE||||||
33949845|NCT02780206|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845465|NCT04660136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949846|NCT03542175|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm Phase I study.||||
33949847|NCT06723964|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33949848|NCT02686437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949849|NCT04366258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845466|NCT05754164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845467|NCT05070585|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The subjects will receive a sprout juice or a placebo juice made of alfalfa sprouts.|Randomized, placebo controlled, cross-over study|t|f|t|f
33949850|NCT01995656|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33949851|NCT02254629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845468|NCT02946905|||COHORT||OTHER|||||||
33845469|NCT02913053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845470|NCT01992601|RANDOMIZED|CROSSOVER||||NONE||||||
33845471|NCT04669015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845472|NCT00733876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845473|NCT05995132|||COHORT||PROSPECTIVE|||||||
33845474|NCT03345576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be masked to the type of electrical stimulation (LPWS vs. standard NMES)||t|f|f|f
33845475|NCT02718430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949852|NCT06165575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949853|NCT03547921|||COHORT||PROSPECTIVE|||||||
33949854|NCT00939068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949855|NCT05923372|||COHORT||OTHER|||||||
33949856|NCT01156974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949857|NCT01005810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949858|NCT05765318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949859|NCT04567680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent evaluator will assess outcomes for each study participant.||f|f|f|t
33949860|NCT04537286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949861|NCT02043626|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34052972|NCT05087966|NA|SINGLE_GROUP||PREVENTION||NONE||A broad recruitment strategy will be used to recruit participants within the greater San Diego. Potential participants will be requested to contact study personnel via email or telephone. A trained member of the study team will contact each potential participant to explain the study, obtain verbal consent for pre-enrollment screening, and conduct the screening process. For those who meet screening criteria, a trained member of the study team will provide more information about the study and engage in an informed consent process at an in-person appointment. Following informed consent, participants will complete self-report questionnaires and clinician-based interviews in person. At baseline, 3-month, and 6-month follow-ups, participants will be asked to complete measures of suicidal coping and thwarted belongingness. At the 3- and 6-month follow-up, satisfaction with mental health services and satisfaction with interpersonal relationship with patient navigator will be assessed.||||
34052973|NCT00798668|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34052974|NCT04440891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845476|NCT06728436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33845477|NCT05594940|||CASE_ONLY||PROSPECTIVE|||||||
33845478|NCT06727799|||OTHER||PROSPECTIVE|||||||
33845479|NCT00391287|||COHORT||PROSPECTIVE|||||||
33845480|NCT01588132|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33949862|NCT00013910|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33949863|NCT00563602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949864|NCT03955263|||COHORT||PROSPECTIVE|||||||
33949865|NCT02426164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949866|NCT06397248|||CASE_CONTROL||OTHER|||||||
33949867|NCT02478606|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33949868|NCT02823223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949869|NCT04554563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
33949870|NCT00638950|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33949871|NCT03333564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33949872|NCT00394498|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33949873|NCT06282263|RANDOMIZED|PARALLEL||OTHER||NONE||"This study was a pre-test, post-test, follow-up design and control group intervention study conducted to examine the effect of Awareness Development Programme on Suicide Prevention for Oncology Nurses on oncology nurses' knowledge, stigma and perception of efficacy regarding suicide risk management."||||
33949874|NCT06442111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33949875|NCT05269199|||COHORT||PROSPECTIVE|||||||
33949876|NCT00501969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949877|NCT05894824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949878|NCT01129167|||COHORT||RETROSPECTIVE|||||||
33949879|NCT01355237|||COHORT||PROSPECTIVE|||||||
33949880|NCT02835989|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33949881|NCT02027831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949882|NCT03586427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949883|NCT00000147||||TREATMENT||SINGLE||||||
33949884|NCT02967055|||COHORT||PROSPECTIVE|||||||
33949885|NCT00138281|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156275|NCT03021772|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33845481|NCT05638698|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two arm, open-label, phase II randomized trial of TG01 vaccine and QS- 21 (vaccine arm) or TG01 vaccine and QS-21 plus Balstilimab (Vaccine + PD1i arm) in patients with surgically resected Stage 1-3 RAS mutant pancreatic cancer who have positive circulating tumor DNA (ctDNA+) in the blood despite prior standard therapy including chemotherapy/radiation therapy where applicable; no evidence of disease by imaging.||||
33845482|NCT06455735|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845483|NCT02753153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33949886|NCT00271037|||COHORT||PROSPECTIVE|||||||
33845484|NCT02869529|||COHORT||PROSPECTIVE|||||||
33949887|NCT05671042|||COHORT||RETROSPECTIVE|||||||
33949888|NCT01487746|||CASE_CONTROL||PROSPECTIVE|||||||
33949889|NCT06179823|||COHORT||RETROSPECTIVE|||||||
33845485|NCT01715662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845486|NCT02863770|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949890|NCT00682006|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33949891|NCT05244902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pediatric patients will be divided into two groups as obese and non-obese. Children above the 95% percentile will be considered as obese.||||
33949892|NCT00747682|||COHORT||RETROSPECTIVE|||||||
33949893|NCT03256591|RANDOMIZED|PARALLEL||OTHER||NONE|No masking will be done|Investigators will conduct a prospective, randomized controlled trial to determine if the implementation of a simulation facilitator training program for HBB compared with no facilitator training in simulation is superior in terms of the acquisition of knowledge, acute care skills, and teamwork skills of pre-service medical students. Investigators will randomly randomly assign study participants to either intervention or control arm in a 1:1 ratio.||||
33949894|NCT00005874||||TREATMENT||||||||
33949895|NCT00914511|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949896|NCT04496076|||COHORT||PROSPECTIVE|||||||
33949897|NCT01307189|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33949898|NCT05216289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double-blind, placebo-controlled clinical trial|t|t|t|f
33949899|NCT05228327|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A prospective randomized controlled clinical trial||||
33949900|NCT00006049||||TREATMENT||||||||
33949901|NCT05574673|||OTHER||PROSPECTIVE|||||||
33949902|NCT04884204|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33949903|NCT00846573|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33949904|NCT04898517|||CASE_ONLY||PROSPECTIVE|||||||
33949905|NCT03805763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949906|NCT01860066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949907|NCT00234533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949908|NCT03711747|||COHORT||PROSPECTIVE|||||||
33949909|NCT00557765|||CASE_ONLY||PROSPECTIVE|||||||
33949910|NCT05628337|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomized trial, prospective, single centre, study intervention (texting motivation messages vs. placebo control), follow-up with administrative database linkage||||
33949911|NCT00570492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949912|NCT04908787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949913|NCT00270738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949914|NCT05359289|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33949915|NCT06566937|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention Group: Participants in this group will receive the e-health intervention.~Control Group: Participants in the control group will receive standard care without the digital intervention."||||
33949916|NCT04817410|NA|SINGLE_GROUP||SCREENING||NONE||||||
33949917|NCT05084118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33949918|NCT05784142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949919|NCT02058940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949920|NCT02440490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33949921|NCT06149000|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Neither the participants or the researchers will know which treatment is being received during the trial. This will be achieved by using identical looking placebos for control and ensuring all aspects of the treatment administration and assessment are indistinguishable.|The study will be a randomized, double blind, crossover interventional trial. Participants will be randomly assigned to one of 2 groups of 20. 1. Experimental Group: Participants in this group will wear Avulux lenses during the testing sessions. 2. Control Group: Participants in this group will wear placebo lenses that resemble Avulux lenses but do not have the same optical properties.|t|f|t|f
33949922|NCT00465101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949923|NCT05729035|||COHORT||CROSS_SECTIONAL|||||||
33949924|NCT06510712|||COHORT||PROSPECTIVE|||||||
33949925|NCT05963685|||COHORT||PROSPECTIVE|||||||
33949926|NCT04918186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949927|NCT03193424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Double Group Assignment,apatinib plus docetaxel comparison to docetaxel.|f|f|t|f
33949928|NCT00710840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949929|NCT03112759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized into one of two arms: treatment with cognitive behavioral therapy and narcotics as needed or treatment with conventional narcotic analgesics alone. Patients undergoing CBT intervention will participate in eight weekly therapy sessions.||||
33949930|NCT02531074|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949931|NCT00267917|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052975|NCT03992703|||COHORT||RETROSPECTIVE|||||||
34052976|NCT04351373|NA|SINGLE_GROUP||OTHER||NONE||||||
34052977|NCT00856869|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34052978|NCT03743324|||COHORT||PROSPECTIVE|||||||
34052979|NCT04034251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34052980|NCT01562301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052981|NCT00589134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34052982|NCT06647654|||CASE_CONTROL||RETROSPECTIVE|||||||
34052983|NCT02014233|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34052984|NCT06618560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34052985|NCT00000743||||TREATMENT||NONE||||||
33741426|NCT01079221|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741427|NCT02362399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741428|NCT05547932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The patients will be under general anesthesia and will not know if they received a block procedure or not.~The investigator, the data collector and the outcome assessor will be completely blind to the study groups. Only the care provider who will perform the block procedures will know the study groups."|Prospective, randomized, controlled study|t|f|t|t
33741429|NCT02138214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741430|NCT05904964|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned to disitamab vedotin or endocrine therapy||||
33741431|NCT03272100|||CASE_CONTROL||PROSPECTIVE|||||||
33741432|NCT06204159|RANDOMIZED|PARALLEL||OTHER||NONE||Exploratory||||
33741433|NCT02504645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741434|NCT01210768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741435|NCT01474603|||CASE_ONLY||PROSPECTIVE|||||||
33741436|NCT04481256|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.||||
33741437|NCT04660981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741438|NCT01358526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741439|NCT03892889|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33741440|NCT04911543|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33741441|NCT04018872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741442|NCT02791048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741443|NCT00745732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741444|NCT05507606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741445|NCT03396783|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33741446|NCT03609801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845487|NCT01395459|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33845488|NCT06042322|||COHORT||RETROSPECTIVE|||||||
33845489|NCT03804970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33845490|NCT02651597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33845491|NCT04625179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845492|NCT00039390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845493|NCT01255332|||CASE_ONLY||PROSPECTIVE|||||||
33845494|NCT01720277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33845495|NCT06424431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845496|NCT06204445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Coffee is provided as ground coffee in unmarked 1 kg packets labeled A or B for blinding, with instructions on how to prepare the coffee brew. The polyphenol-rich coffee is slightly roasted to emulate flavor, color and aroma for blinding.~Assessor will only be presented results marked as intervention A and B. Only the PIs will know the order in which both coffees were consumed by volunteers"|After a run-in period, participants are randomly allocated to one of each arm. Each intervention last 12 weeks, separated by a 4-week wash-out.|t|f|f|t
33845497|NCT04833127|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845498|NCT02506049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845499|NCT04042025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845500|NCT02236143|||CASE_CONTROL||PROSPECTIVE|||||||
33845501|NCT05293665|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Platform trial with multiple sub-studies. Each sub-study has two treatment arms: active comparator and IMP.|t|f|t|t
33845502|NCT06180642|||COHORT||CROSS_SECTIONAL|||||||
33845503|NCT05084287|||CASE_CONTROL||PROSPECTIVE|||||||
33845504|NCT05091177|||CASE_CONTROL||PROSPECTIVE|||||||
33845505|NCT00622323|||COHORT||PROSPECTIVE|||||||
33845506|NCT02811679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845507|NCT02140840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845508|NCT03111459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845509|NCT00169078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845510|NCT02448433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845511|NCT03275597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845512|NCT04344002|||COHORT||OTHER|||||||
33845513|NCT05662787|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non- randomized, multi-center study for treatment of stenotic lesions with the Bolt Intravascular Lithotripsy system||||
33845514|NCT03330405|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34052986|NCT05870956|||COHORT||RETROSPECTIVE|||||||
34052987|NCT02818829|||COHORT||PROSPECTIVE|||||||
34052988|NCT02047656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34052989|NCT06487221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34052990|NCT01740076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34052991|NCT02749994|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34052992|NCT06623175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34052993|NCT00826254|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34052994|NCT06317142|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741447|NCT03533348|||CASE_CONTROL||PROSPECTIVE|||||||
34052995|NCT03348930|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34052996|NCT06666933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34052997|NCT06647667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"1. Patients will receive high intensity interval training (HIIT)~2. Patients will receive moderate intensity continuous training (MICT)"||||
34052998|NCT05040087|RANDOMIZED|PARALLEL||TREATMENT||NONE|While the study is unblinded, investigators will be blinded to the randomization plan.|||||
34052999|NCT05336396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34075835|NCT02155699|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34075836|NCT03028675|||CASE_CONTROL||PROSPECTIVE|||||||
34075837|NCT02806856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076434|NCT03204643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156276|NCT03908814||SEQUENTIAL||TREATMENT||NONE||||||
34156277|NCT04408040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156278|NCT04416906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single arm, single-centre prospective study||||
34156279|NCT00151476|||COHORT||OTHER|||||||
34156280|NCT04243733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156281|NCT05521789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156282|NCT04279665|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156283|NCT06208111|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized control trial design will be used in this study. it would be two arm study and there would be two groups an experimental and a waitlist control group. The experimental group will receive intervention and another group will be placed on the waitlist. in this research parallel group design would be used. we will give treatment to all participants in a parallel way. The allocation ratio and framework would be equivalency i.e, the treatment group and control group be equal number of participants||||
34156284|NCT03801603|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156285|NCT03956524|RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy adult volunteers will be randomized in a 1:1:1 ratio to receive single dose of test or the comparator vaccines.||||
34156286|NCT06172478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156287|NCT05305963|||CASE_CONTROL||PROSPECTIVE|||||||
33845515|NCT05404581|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are blinded to stimulator status in the crossover phase of the study. Primary outcomes are determined by an assessor who is blinded to stimulation status.|Subjects who respond favorably to trial stimulation of the insula will be enrolled in a crossover study of DBS where they will be randomized to 3 months of active stimulation and 3 months of sham stimulation.|t|f|f|t
33845516|NCT02866630|||COHORT||PROSPECTIVE|||||||
33949932|NCT04920838|RANDOMIZED|PARALLEL||TREATMENT||NONE|Investigators and all the staff in clinical sites will not be masked. Data manager and statician will not be masked too. However, the sponsor will be masked.|"This is a multicentre, multiple country, randomised, open-label, adaptive, platform clinical study aiming to determine the efficacy and safety of various treatment regimens for prevention of the need for hospitalisation for specialised care due to severe progression of COVID-19.~The study is designed with the ability to incorporate the adding or dropping of treatment arms and that will include similar inclusion and non-inclusion criteria, the same primary and secondary endpoints, common data entry procedures, a shared database and a single statistical methodology for analysis of the primary endpoint."||||
33949933|NCT05006820|||COHORT||RETROSPECTIVE|||||||
33949934|NCT04411030|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33949935|NCT05332171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"It is aimed to evaluate patients with Lung Cancer who meet the inclusion criteria of the study. Individuals will be randomly assigned to physical activity counseling and training groups. The number of participants in the groups will be determined by power analysis.~Criteria for inclusion in the study;~* Patients whose chemotherapy and radiotherapy has ended, at least 6 months and maximum 5 years after surgery~* Being between the ages of 18-65~* 3 and 5 years according to the Modified Borg Scale Patients with severe fatigue Exclusion criteria;~* Uncontrollable hypertension, diabetes mellitus, heart failure and atrial fibrillation~* Any acute infection during the evaluation~* Orthopedic, neurological, psychological, etc., which will limit the evaluations. with problems"|t|f|f|f
33949936|NCT01169623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33949937|NCT01012531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33949938|NCT00455572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949939|NCT02646566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949940|NCT03710681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33949941|NCT02980484|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized double-blind sham-controlled trial with an optional open-label crossover extension for subjects randomized to sham group.|t|t|t|t
33949942|NCT02088359|||COHORT||PROSPECTIVE|||||||
33949943|NCT06353581|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33949944|NCT02696382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33949945|NCT05573425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949946|NCT02277665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949947|NCT00390338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949948|NCT03247608|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33949949|NCT03217058|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge design evaluating implementation of computerized screening and behavioral interventions delivered by primary care providers.||||
33949950|NCT04269317|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded assessed of the improvement would be done between Last FU images and before first treatment after randomization of the images.|||||
33949951|NCT02553486|||||PROSPECTIVE|||||||
33949952|NCT02885831|||COHORT||PROSPECTIVE|||||||
33949953|NCT04373265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949954|NCT00547404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949955|NCT03773159|||COHORT||PROSPECTIVE|||||||
33949956|NCT03353025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949957|NCT02500134|||CASE_ONLY||CROSS_SECTIONAL|||||||
33949958|NCT01609608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33949959|NCT00561041|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33949960|NCT01846039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949961|NCT05950529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Oral Malodor examiners are blinded and the subjects do not know which of the 2 lozenges they are taking||f|f|f|t
33949962|NCT02545270|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33949963|NCT06186466|||CASE_ONLY||RETROSPECTIVE|||||||
33949964|NCT03006042|||CASE_ONLY||PROSPECTIVE|||||||
34156288|NCT02180841|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34156289|NCT01359189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156290|NCT01359228|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34156291|NCT02785068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156292|NCT04903795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053000|NCT03156608|RANDOMIZED|PARALLEL||SCREENING||NONE||Women will be randomized to either standard monitoring with external Doppler and tocodynamometer or monitoring with the Novii Fetal ECG/EMG system using a computer generated randomization scheme through REDCap. Randomization will occur in blocks based on the subject's BMI. Women with a BMI \< 30 will be randomized separate from women with a BMI \> 30.||||
34053001|NCT02754674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053002|NCT03559049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053003|NCT02064322|||COHORT||PROSPECTIVE|||||||
34156293|NCT05501470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Randomisation will be carried out using sealed envelopes, using a randomisation code prepared by the trial statistician, which will be stratified by study centre. Each woman who gives consent will be given a trial identification (TID) number which will match the number on the randomisation envelopes.~The trial will be blinded with an identical placebo (by Next Gen Pharma India Pvt. India). Samples will be run and analysed using TID only, with all data cleaning and re-assays carried out blinded. The trial statistician will unblind lab data once databases are finalised."||t|t|t|f
34156294|NCT05581836|||CASE_CONTROL||RETROSPECTIVE|||||||
34156295|NCT05981183|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156296|NCT05067738|NA|SEQUENTIAL||OTHER||NONE||2 phases||||
34053004|NCT03727126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156297|NCT03242356|||COHORT||PROSPECTIVE|||||||
34156298|NCT06583369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053005|NCT00464516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053006|NCT03435952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156299|NCT00158041|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34053007|NCT04403646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053008|NCT06287827|||COHORT||PROSPECTIVE|||||||
34053009|NCT06620640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053010|NCT05001516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm1:LM302 0.2 mg/kg i.v., QW×3 weeks group; Arm2:LM302 0.4 mg/kg i.v., QW×3 weeks group; Arm3:LM302 0.8 mg/kg i.v., QW×3 weeks group; Arm4:LM302 1.6 mg/kg i.v., QW×3 weeks group; Arm5:LM302 2.4 mg/kg i.v., QW×3 weeks group; Arm6:LM302 2.8 mg/kg i.v., QW×3 weeks group;||||
33845517|NCT04004104|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The assessor (different from the PI) will not be present when the two exercise tests are performed. Additionally, the results will not be labeled with the specific position of the exercise test. In this manner, the assessor will be blinded to the exercise position and this blinding will strengthen the validity of the research outcomes.|Participants will be randomized (through a random-number generator, and with cancelled allocation) to start with either an upright exercise test (control arm) or a supine exercise test (intervention arm) on a bicycle ergometer, and then complete the alternate test within 4 weeks.|f|f|f|t
34156300|NCT02211430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845518|NCT01226342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053011|NCT04064411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156301|NCT05482841|||CASE_ONLY||PROSPECTIVE|||||||
34156302|NCT01931163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156303|NCT03223376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156304|NCT05652387|NA|SINGLE_GROUP||PREVENTION||NONE||Descriptive/Evaluative||||
34156305|NCT04833296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156306|NCT03565614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Older adults (65+) applying for social care and services delivered by a municipality (Eskilstuna) in the county of Södermanland, Sweden. Presumptive participants are identified by the municipality care mangers. After informed consent, the users are randomized to either the intervention or control group. Exclusion criteria: Life-threatening disease, diagnosed mental illness, or severe cognitive dysfunction that would prevent the participant from expressing wants.||||
34053012|NCT04930159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156307|NCT02491606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156308|NCT01481077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053013|NCT02877394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053014|NCT03039855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156309|NCT01271374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845519|NCT06728852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156310|NCT01670435|||CASE_ONLY||PROSPECTIVE|||||||
34156311|NCT01677858|NA|SEQUENTIAL||TREATMENT||NONE||||||
34156312|NCT02337192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156313|NCT03269058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845520|NCT00688883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845521|NCT00218114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845522|NCT04777877|||OTHER||PROSPECTIVE|||||||
33845523|NCT00174148|||DEFINED_POPULATION||OTHER|||||||
33845524|NCT01015040|RANDOMIZED|CROSSOVER||||NONE||||||
33845525|NCT04805788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845526|NCT03745911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845527|NCT04535310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845528|NCT06728176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845529|NCT02576587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845530|NCT04725877|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845531|NCT00204321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156314|NCT01250041|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
34156315|NCT06525142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The investigators will compare the pre- and post-test methods bwtween the experimental groups and the control group. The fathers of enrolled preterm infants will fill in the structured questionnaires at the time before the intervention (Baseline data) and one month later after the intervention.|f|f|f|t
34156316|NCT00068302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845532|NCT05604001|NA|SINGLE_GROUP||TREATMENT||NONE||patients with symptomatic submucosal fibroides were elected for hysteroscopy laser ablation of the fibroid||||
34053015|NCT04231500|||CASE_CONTROL||PROSPECTIVE|||||||
34053016|NCT01913431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076435|NCT04361422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076436|NCT04884100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156317|NCT06349668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949965|NCT02620566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33949966|NCT04822727|||COHORT||PROSPECTIVE|||||||
33949967|NCT02950285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949968|NCT03580746|||COHORT||RETROSPECTIVE|||||||
33949969|NCT01553708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33949970|NCT00594334|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33949971|NCT04704908|||COHORT||PROSPECTIVE|||||||
33949972|NCT03349203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949973|NCT02582593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33949974|NCT01758991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomisation by computer|tDCS|t|t|t|t
33949975|NCT00814762|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33949976|NCT03105427|||CASE_ONLY||PROSPECTIVE|||||||
33949977|NCT04314115|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33949978|NCT01604512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33949979|NCT02748096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949980|NCT03653780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33949981|NCT03257566|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33949982|NCT05864209|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949983|NCT01692990|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33949984|NCT03297710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949985|NCT02850159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33949986|NCT01121224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33949987|NCT05395845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949988|NCT03754400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33949989|NCT04395625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During data analysis, anonymization is ensured by assigning a number to each patient, so that the investigator is blinded to the patient's group.|Single-center 2-arm parallel randomized controlled trial with a 1:1 allocation ratio, following a split-mouth design.|f|f|f|t
33949990|NCT02356731|||||PROSPECTIVE|||||||
33949991|NCT02233673|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33949992|NCT01741727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33949993|NCT05007938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053017|NCT03465618|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Two expert PET scan readers, who are board-certified in Nuclear Medicine, will be designated to read and evaluate PET-CT scans. Volumetric region-of-interest analysis and extraction of the mean and maximum standard uptake values (SUVs) will be provided. Both readers will initially be blinded to the patient's clinical information for scan interpretation. A second interpretation will then be performed after both readers are provided with clinical information about the primary tumor site.|This is a two-year microdosing study that will enroll up to 10 surgical or non-surgical patients harboring pituitary adenomas, high grade gliomas or metastatic brain tumors.|f|f|f|t
34053018|NCT00643825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053019|NCT03943264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053020|NCT05046769|||COHORT||PROSPECTIVE|||||||
34053021|NCT02345460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053022|NCT05507476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34053023|NCT00246272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053024|NCT06038461|NA|SINGLE_GROUP||TREATMENT||NONE||Surufatinib Combined With Temozolomide and S-1||||
34053025|NCT04433715|||CASE_CONTROL||PROSPECTIVE|||||||
34053026|NCT05120466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053027|NCT00811785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053028|NCT04794374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053029|NCT02238912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053030|NCT03508960|||COHORT||PROSPECTIVE|||||||
34053031|NCT06247007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34053032|NCT06616675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053033|NCT05115214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053034|NCT01665222|RANDOMIZED|CROSSOVER||||NONE||||||
34053035|NCT06623539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open-label, three-arm, randomized controlled trial||||
34053036|NCT05403814|||CASE_ONLY||PROSPECTIVE|||||||
34053037|NCT02171013|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34053038|NCT06088004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053039|NCT01510600|||COHORT||RETROSPECTIVE|||||||
34053040|NCT01378169|||COHORT||PROSPECTIVE|||||||
34053041|NCT04515706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053042|NCT06159491|NA|SEQUENTIAL||TREATMENT||NONE||"Phase I will follow a 3+3 design in phase I with starting dose of 200mg with possibility of de-escalation if more than 1/3 or 1/6 experience DLT. Phase I will require 6-12 patients to select the MTD.~Phase II, if MTD selected in Phase I, will follow a Simon's two stage design. The null hypothesis that the true response rate is 55% will be tested against a one-sided alternative that the response rate is 80%. In the first stage, 6 patients treated at the MTD from Phase I will be included. If there are 3 or fewer responses in these 6 patients, the study may be stopped. Otherwise, 12 additional patients will be accrued for a total of 18. The null hypothesis will be rejected if 13 or more responses are observed in 18 patients. This design yields a type I error rate of 9% and power of 82% when the true response rate is 80%."||||
34053043|NCT03990571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053044|NCT02511054|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053045|NCT04829032|||COHORT||PROSPECTIVE|||||||
34053046|NCT05871151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will receive either active or sham taVNS + exercise, but they will not be aware of whether they are receiving the active treatment or the sham treatment.|Randomized Controlled Trial with two parallel groups|t|f|f|f
34053047|NCT03545594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Independent Outcome Assessor(s) blinded to the intervention arm by masking the ID and randomization arm on the assessment and outcome forms.|Randomized controlled trial|f|f|f|t
33949994|NCT00806806|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33949995|NCT03220880|||COHORT||PROSPECTIVE|||||||
34053048|NCT01608243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053049|NCT01571999|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34156318|NCT06430723|||CASE_CONTROL||RETROSPECTIVE|||||||
34053050|NCT03829618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156319|NCT02721095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156320|NCT01510743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156321|NCT05239767|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|NSAID will be masked. Acetaminophen or no acetaminophen will not||t|t|t|t
34156322|NCT03989401|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34156323|NCT04236739|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a randomized controlled trial. At baseline, participants will be randomized with variable block randomisation method to either group A in which case they receive IMPACT-treatment, or group B that will receive standard care. Standard care consists of optional physical therapy and pain medication. After 9 months, participants in group B can receive the intervention as well.||||
34156324|NCT00011310|||DEFINED_POPULATION||PROSPECTIVE|||||||
34156325|NCT04360876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants confirmed to meet all eligibility criteria who have provided informed consent will be randomized 1:1 to dexamethasone versus placebo. A randomized group assignment will be provided to the investigator or research assistant. Randomization will be performed according to a central randomization scheme and will stratified by site in permuted blocks of varying size.|Single-center, Phase 2a, pragmatic, randomized, double-blinded, placebo-controlled|t|t|f|f
34156326|NCT05693792|||COHORT||PROSPECTIVE|||||||
34156327|NCT06210230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156328|NCT00285168|||COHORT||PROSPECTIVE|||||||
34156329|NCT02339194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34156330|NCT02401984|||COHORT||CROSS_SECTIONAL|||||||
34156331|NCT04188145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053051|NCT05067374|||COHORT||PROSPECTIVE|||||||
34053052|NCT00231114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053053|NCT00305955|||COHORT||PROSPECTIVE|||||||
34053054|NCT04079413|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34053055|NCT05025384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants are electronically randomized in the REDCap database.|Infants will be randomized in a 1:1 ratio to two groups - intervention vs. no intervention.||||
34053056|NCT03648671|||COHORT||PROSPECTIVE|||||||
34053057|NCT00097955|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34053058|NCT06027918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053059|NCT04092946|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, prospective, interventional study||||
34053060|NCT02017795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34053061|NCT06145698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053062|NCT01641497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053063|NCT05899023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34053064|NCT05248230|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34053065|NCT01864369|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053066|NCT03989206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053067|NCT03781258|NA|SINGLE_GROUP||OTHER||NONE||Patients implanted with the HeartMate 3 LVAS will be screened for participation in the study with established stability at 6 months after implantation of the device. If inclusion criteria are met, patients will be transitioned to a single anti-thrombotic therapy with Acetylsalicylic Acid (ASA) or equivalent and anticoagulation with warfarin will be withdrawn. ASA will be administered in a minimum dose of 100 mg per day with dosage adjustments based on VerifyNow testing up to a maximum of 200 mg daily. The primary endpoint will be analyzed at 90 and 180 days after initiation of the single antiplatelet therapy.||||
34053068|NCT05342051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||immersion in radon, calcium, natrium, bicarbonate content 42 ℃ thermal-mineral water 15 times in 3 weeks, plus usual care. The total mineral substance of the water is 1530 mg/l. The suggested daily time spent in water is 20 minutes altogether with breaks.|f|f|t|t
34053069|NCT05306314|||COHORT||RETROSPECTIVE|||||||
34053070|NCT05454787|||COHORT||PROSPECTIVE|||||||
34053071|NCT06117501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053072|NCT05599087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053073|NCT06071143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053074|NCT04079192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subject will be blinded to the study treatment.|Patients who meet all the eligibility criteria will be randomized 2:1 to receive treatment with either a BA9-DCB or a Sequent Please® Paclitaxel Coated Balloon.|t|f|f|f
34053075|NCT01910987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156332|NCT06341023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blinded to group existence and assignment and outcome assessors will be blinded to group assignment|Randomized controlled trial|t|f|f|t
34156333|NCT01160913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156334|NCT03424460|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Two populations:~* Population n°1: prospective, with 3 arms~* Population n°2: retrospective, with 2 arms"||||
34156335|NCT00387725|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34156336|NCT04776863|||CASE_CONTROL||PROSPECTIVE|||||||
34156337|NCT04807257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156338|NCT00853138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156339|NCT02050659|||COHORT||PROSPECTIVE|||||||
34156340|NCT02381340|||COHORT||PROSPECTIVE|||||||
34156341|NCT04667104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156342|NCT00917488|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156343|NCT04165499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156344|NCT01982461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156345|NCT00761527|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34156346|NCT00379067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156347|NCT06293313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The determination of which university would be included in the control and experimental groups in the research was made through a randomization method. The selection was done blindly by an independent academician unrelated to the research. As a result of the randomization, the control group and the experimental groups.|A total of two groups, a control group and a experimental group wo mindfulness group|f|f|t|t
34156348|NCT02484482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156349|NCT01674205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34156350|NCT00533624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156351|NCT04703491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participant is masked to the intervention assigned to them. All outcome measures are self-reported by the participants through a computer program without any involvement of the experimenters.||t|f|f|t
34156352|NCT05688332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156353|NCT06576219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156354|NCT04358965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156355|NCT02403232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156356|NCT02783599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156357|NCT03287037|NA|SINGLE_GROUP||TREATMENT||NONE||Sixty patients with unipolar depression (major depressive disorder) and 60 with bipolar depression were treated with 10 sessions of tDCS.||||
34156358|NCT01707901|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34156359|NCT00744107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156360|NCT00888953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156361|NCT03449472|||CASE_ONLY||PROSPECTIVE|||||||
34156362|NCT05474391|||COHORT||RETROSPECTIVE|||||||
34156363|NCT04240158|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34156364|NCT05799794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Clinicians, supervisors and study staff will be aware of the implementation support conditions that participants have been randomized into in Aim 2.|"Aim 1a: We will utilize Ideation to develop coaching strategies with supervisors.~Aim 1b: We will conduct a web-based Single-Case experiment (SCED) to gather preliminary evidence for how effectively different strategies emerging from Aim 1 impact our theorized mechanism (Implementation Climate-e.g., CBT use expected).~Aim 1 activities are not part of the clinical trial (which starts with Aim 2 activities).~Aim 2: We will utilize a 2-arm randomized controlled trial to compare the Implementation Coaching strategy optimized in Aim 1, added onto the Initiative's standard/as usual implementation. The groups will engage in the implementation support for 6 months and will complete a survey before and after the implementation support is terminated."||||
34156365|NCT05669651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34156366|NCT05921799|||COHORT||PROSPECTIVE|||||||
34156367|NCT04949074|||COHORT||PROSPECTIVE|||||||
34156368|NCT06039618|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34156369|NCT04038450|||OTHER||OTHER|||||||
34156370|NCT00546949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156371|NCT04449172|||COHORT||CROSS_SECTIONAL|||||||
34156372|NCT04597073|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34156373|NCT03305978|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|blinding evaluation of criteria|Major Patient Addressed for Thoracic CT without Injection of Contrast|f|f|f|t
34156374|NCT03876899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, randomized, placebo-controlled trial|t|t|t|t
34156375|NCT01167660|||COHORT||PROSPECTIVE|||||||
34156376|NCT01683370|||CASE_ONLY||PROSPECTIVE|||||||
34156377|NCT02396589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156378|NCT02830451|||CASE_ONLY||PROSPECTIVE|||||||
34156379|NCT05041140|||COHORT||PROSPECTIVE|||||||
34156380|NCT01609998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156381|NCT06485388|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34156382|NCT04451993|||CASE_CONTROL||PROSPECTIVE|||||||
34156383|NCT05531227|||CASE_ONLY||RETROSPECTIVE|||||||
34156384|NCT00218699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34156385|NCT04916379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156386|NCT01337544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156387|NCT04909957|||COHORT||RETROSPECTIVE|||||||
34156388|NCT01258283|||COHORT||PROSPECTIVE|||||||
34156389|NCT04678947|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156390|NCT04073485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156391|NCT05389033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34156392|NCT05597553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Mineral trioxide aggregate (MTA) is a bioactive, biocompatible, antibacterial material with good stability and excellent sealing ability that has been used as a dressing material in pulp capping procedures in permanent teeth|t|t|t|f
34156393|NCT05006027|||COHORT||PROSPECTIVE|||||||
34156394|NCT06506825|||COHORT||RETROSPECTIVE|||||||
34156395|NCT04313270|||CASE_ONLY||PROSPECTIVE|||||||
34156396|NCT02286635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156397|NCT03063905|||CASE_CONTROL||OTHER|||||||
34156398|NCT02353195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156399|NCT02449590|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34156400|NCT04508153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized to either the leva® arm or Kegel arm on a 1 to 1 ratio using block randomization. Prior to initiation of the trial, a randomization sequence will be generated by the ObvioHealth system. Participants will be automatically allocated the next available slot in the sequence at the time of their randomization and assigned to the leva® or Kegel group accordingly|A virtual prospective randomized controlled study to evaluate the efficacy of using the leva® PDHS to perform PFMT (leva arm) compared to standard care of a PFM exercise home program (Kegel arm) for the treatment of SUI or SMUI.|f|f|t|t
34156401|NCT01558050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156402|NCT02566590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156403|NCT00759408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156404|NCT01791478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156405|NCT03075709|||OTHER||PROSPECTIVE|||||||
34156406|NCT04492111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient not aware of the type of implant. Investigator of clinical conditions not aware of the type of implant.|Randomized clinical trial of parallel design with a 1:1 allocation ratio|t|f|t|f
34156407|NCT00517361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156408|NCT03268291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study will include 2,000 patients. Patients will be randomized into two groups: standard outpatient observation (n = 1 000), the Trust program (n = 1 000)."||||
34156409|NCT04858295|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34156410|NCT04596748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, randomized, placebo-controlled|t|t|t|f
34156411|NCT05937789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156412|NCT01754571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34156413|NCT01309971|||COHORT||CROSS_SECTIONAL|||||||
34156414|NCT05484869|||COHORT||RETROSPECTIVE|||||||
34156415|NCT04775264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156416|NCT03054779|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34156417|NCT02843828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156418|NCT03725813|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A quasi- experimental study with non-equivalent control group design, pretest-posttest study.||||
34156419|NCT02636023|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156420|NCT02589106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156421|NCT01601262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156422|NCT04391205|||OTHER||PROSPECTIVE|||||||
34156423|NCT03452709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156424|NCT03151187|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"All programs in Canada utilize a joint OSCE where trainees in all programs do the same OSCE stations twice a year. This allows programs to compare their trainees with the performance of trainees at other centres. This OSCE's typically occur in the Spring and Fall of every year. Our OSCE station will be used as a station in one of these joint OSCE's.~In our study, the timing of the educational intervention will randomized; we will utilize a cluster randomization method by grouping sites by the size of their training program. Sites in each group will then be randomized to have trainees complete the educational intervention either before or after doing the OSCE station we have developed."||||
34156425|NCT02681341|||CASE_ONLY||PROSPECTIVE|||||||
34156426|NCT02427776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156427|NCT06584461|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34156428|NCT06578065|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter, randomized, open-label, controlled with parallel groups clinical trial||||
34156429|NCT00963794|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34156430|NCT02020317|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156431|NCT06201286|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34156432|NCT00286871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156433|NCT00757822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156434|NCT04008251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156435|NCT05406102|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34156436|NCT01386203|||CASE_CONTROL||PROSPECTIVE|||||||
34156437|NCT02528786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156438|NCT05348239|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single centre, single-arm, interventional phase II study.||||
34156439|NCT02487030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156440|NCT00385749|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156441|NCT04471324|NA|SINGLE_GROUP||OTHER||NONE||||||
34156442|NCT04792411|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156443|NCT01894243|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34156444|NCT01548508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156445|NCT03875352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The study was designed as open-label, no masking was used in the protocol.|The study subjects were randomized into two study arms, in both of which two interventions were performed.||||
34156446|NCT03077204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156447|NCT05933668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156448|NCT05411939|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a randomized control trial in which participants will be assigned to one of two arms. Patients in the control arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon. Patients in the treatment arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon that includes discussion of the SDMT. All patients will complete pre- and post-visit surveys designed to measure the severity of their knee osteoarthritis and their willingness to proceed with different treatment modalities.|t|f|f|f
34156449|NCT05704790|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156450|NCT04398550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators, subjects, and remaining study staff will not be intentionally unblinded. Due to the nature of the study, subjects, study staff, and investigators interacting with the subjects will likely be able to figure out what diet the subject is assigned to, however, the exact diet will not be explicitly revealed to them.||t|f|t|f
34156451|NCT03100773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156452|NCT00605345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156453|NCT04186338|||CASE_CONTROL||PROSPECTIVE|||||||
34156454|NCT05485285|||COHORT||OTHER|||||||
33845533|NCT01081665|||||PROSPECTIVE|||||||
34156455|NCT02359513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156456|NCT03799276|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156457|NCT02021903|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34156458|NCT00033553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156459|NCT00399399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156460|NCT00371904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741448|NCT03494257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be unaware of their groupe assignment. The investigator who will measure the IOP will also be masked to group assignment.|Prospective randomized double-masked comparative study|t|f|t|f
33845534|NCT04767100|||COHORT||PROSPECTIVE|||||||
34156461|NCT04377555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053076|NCT03572816|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a parallel group, randomized controlled trial with open allocation including all patients with calcaneus fractures independent of kind of initial therapy.||||
34053077|NCT00581347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34053078|NCT05204173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156462|NCT01279681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156463|NCT03319212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053079|NCT01899742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156464|NCT04791631|||COHORT||PROSPECTIVE|||||||
34156465|NCT02921711|||COHORT||PROSPECTIVE|||||||
34156466|NCT01394913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156467|NCT05416736|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
34156468|NCT04581551|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34156469|NCT01114828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156470|NCT03631017|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an open label, investigator initiated single arm, first in human study of a PARP1/2 imaging agent in patients with head and neck squamous cell carcinomas scheduled to undergo surgery.||||
34156471|NCT00964561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156472|NCT02819401|||COHORT||PROSPECTIVE|||||||
34156473|NCT03325036|||COHORT||PROSPECTIVE|||||||
33845535|NCT01056705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34053080|NCT01966068|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33845536|NCT00659880|||COHORT||PROSPECTIVE|||||||
33845537|NCT00015899||||TREATMENT||||||||
33845538|NCT04859569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845539|NCT03627273|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33845540|NCT01651221|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33845541|NCT00287690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845542|NCT06729164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845543|NCT05616000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33845544|NCT05792618|||COHORT||PROSPECTIVE|||||||
33845545|NCT03236038|||OTHER||PROSPECTIVE|||||||
33845546|NCT02800551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845547|NCT03089138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845548|NCT03435692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053081|NCT02666378|||COHORT||PROSPECTIVE|||||||
34053082|NCT05283980|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Enrolled subjects will be randomized to one of the two study groups, in a 1:1 randomization ratio. Patients randomized to Group 1, or the bupivacaine group, will receive up to 25cc of 0.25% bupivacaine hydrochloride for the PECs blocks. In Group 2, patients will receive up to 25cc of normal saline. Use of placebo is a standard control procedure in clinical trials and will allow for the assessment of unbiased quantitative data on the efficacy across all treatment groups.|This is prospective, randomized, triple-blinded placebo-controlled study. Subjects will be randomize to undergo PECs block in the pre-procdure/ pre-operative area with either ).25% bupivacaine or 0.9% normal saline. They will then undergo the CIED placement in electrophysiology lab as current standard of care.|t|t|t|f
34053083|NCT05633992|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34053084|NCT06620536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053085|NCT06665243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053086|NCT03116555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053087|NCT06666777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Psychologists administering the Bayley-III Socio-Emotional Questionnaire and ESB Battery, as well as evaluating parenting behavior using the PICCOLO, will be blinded to each participant's group assignment. However, due to the nature of the assessments and treatment, the therapists conducting OPISCoS cannot be blinded.||f|f|f|t
34053088|NCT01062035|||CASE_CONTROL||PROSPECTIVE|||||||
34053089|NCT04021121|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34053090|NCT02078375|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34053091|NCT06648382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053092|NCT05383365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741449|NCT02806986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053093|NCT06668350|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34053094|NCT05901233|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The order of administration for active and sham stimulation phases will be masked for the participant, study partner, study clinician, and primary investigator.|Participants undergo 4 weeks of video-implemented script training (VISTA) or Lexical Retrieval Training (LRT) with either sham or tDCS, a 2-month washout phase, and then another 4 weeks of LRT or VISTA with the other condition (sham or tDCS). Order will be randomized.|t|t|t|t
34156474|NCT06006624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34156475|NCT05725993|||COHORT||PROSPECTIVE|||||||
34156476|NCT04164420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to one of two groups in parallel for five weeks. To either oral neuromuscular training and orofacial sensory-vibration stimulation or to only orofacial sensory-vibration stimulation.|f|f|f|t
33845549|NCT05101148|NA|SEQUENTIAL||TREATMENT||NONE||||||
33845550|NCT01228253|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845551|NCT02081417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33845552|NCT04801277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized double blinded|t|f|f|t
34156477|NCT02161055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156478|NCT05014997|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34156479|NCT00793130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156480|NCT01743040|||CASE_ONLY||PROSPECTIVE|||||||
34156481|NCT03245775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156482|NCT04481360|||COHORT||PROSPECTIVE|||||||
34156483|NCT05414552|||COHORT||RETROSPECTIVE|||||||
34156484|NCT06238804|||COHORT||RETROSPECTIVE|||||||
34156485|NCT00637962|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34156486|NCT03416452||PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156487|NCT04342208|||CASE_ONLY||CROSS_SECTIONAL|||||||
34156488|NCT01797913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156489|NCT01525095|||CASE_CONTROL||PROSPECTIVE|||||||
34156490|NCT02587819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156491|NCT04773834|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156492|NCT03596684|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34156493|NCT00568126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study subjects and investigator clinicians were blinded to the treatment assignment.|Subjects were randomized in a double blind manner to maca root or placebo. Improvement in sexual functioning was compared between the two treatment groups.|t|f|t|f
34156494|NCT04552808|NA|SEQUENTIAL||TREATMENT||NONE||This study is divided into four cohorts: healthy subjects in cohort A and C, moderate liver function impairment subjects in cohort B, and severe liver function impairment subjects in cohort D. Cohorts A and B, C and D should be matched in terms of gender, age, and body mass index (BMI).||||
34156495|NCT05860465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156496|NCT06141876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156497|NCT02483117|||COHORT||PROSPECTIVE|||||||
33949996|NCT02227043|||COHORT||PROSPECTIVE|||||||
34156498|NCT00141128|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34156499|NCT03404297|RANDOMIZED|PARALLEL||TREATMENT||NONE|The trial is open label but the randomization scheme will be determined by an automatic randomization algorithm performed independently of the investigators|"The study will include two different types of evaluation based on the disease process that the patient has. For patients with chronic leg ulcers, a retrospective, observational approach will be used to track the efficacy of locally sourced compression in improving wound healing.~For patients with Kaposi Sarcoma associated leg lymphedema, they will be randomized to to receive immediate compression therapy or delayed compression therapy."||||
34156500|NCT03817112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33949997|NCT02049008|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33949998|NCT02071823|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33949999|NCT03271580|||COHORT||PROSPECTIVE|||||||
34156501|NCT01088399|||COHORT||PROSPECTIVE|||||||
34156502|NCT04201613|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34156503|NCT06583408|||COHORT||PROSPECTIVE|||||||
34156504|NCT06027450|||COHORT||RETROSPECTIVE|||||||
34156505|NCT02653937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156506|NCT03408964|||COHORT||PROSPECTIVE|||||||
34156507|NCT03197051|||OTHER||PROSPECTIVE|||||||
34156508|NCT04016844|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive tDCS in one session and SHAM in the other session.||||
34156509|NCT02166268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156510|NCT03960892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156511|NCT00856297|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156512|NCT03680300|RANDOMIZED|PARALLEL||PREVENTION||NONE||60 athletes with hamstring tightness divided into 3 group.they will be Allocated by using a manual lottery system||||
34156513|NCT04807049|||COHORT||PROSPECTIVE|||||||
34156514|NCT05665907|||COHORT||PROSPECTIVE|||||||
34156515|NCT00364741|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34156516|NCT04486872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156517|NCT05792917|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34156518|NCT00087854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156519|NCT00774982|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34156520|NCT02899702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741450|NCT03388580|||CASE_ONLY||RETROSPECTIVE|||||||
33741451|NCT02830217|||COHORT||PROSPECTIVE|||||||
33741452|NCT03017508|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33741453|NCT05185024|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33741454|NCT06418971|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33845553|NCT00944515|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845554|NCT02314481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845555|NCT05939856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845556|NCT03543800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845557|NCT00537589|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845558|NCT05374213|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental design is a RCT with two conditions: 1) treatment condition and 2) wait-list control condition. Outcome measures will focus on self-reported ratings of (primary) depression, anxiety, and stress and (secondary) well-being measures.||||
33845559|NCT05193903|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||1 intervention group, 1 control group (Cross-sectional study)||||
33845560|NCT06161727|||CASE_CONTROL||PROSPECTIVE|||||||
33950000|NCT05620966|||COHORT||PROSPECTIVE|||||||
33950001|NCT03058549|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33950002|NCT05868031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33950003|NCT01405040|||COHORT||PROSPECTIVE|||||||
33950004|NCT04964076|||OTHER||CROSS_SECTIONAL|||||||
34156521|NCT05455931|||CASE_ONLY||PROSPECTIVE|||||||
34156522|NCT00145132|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156523|NCT03764306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were randomly assigned to one of the two treatment arms: surgical endarterectomy or carotid angioplasty with stenting under proximal protection|f|f|t|f
34156524|NCT04975100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The recruited patients will be randomized by block randomization into two treatment groups using computer-generated random codes with an allocation of 1:1. The random allocation code of the participants will be generated by the investigator who will not be involved in patient recruitment. For allocation concealment, sequentially numbered, identical-looking drug dispensing containers will be used.||t|f|t|f
34156525|NCT05574088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||!) apical patency 2) Control group ( Non apical patency )|t|f|f|f
34156526|NCT02071069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156527|NCT02240264|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34156528|NCT01359501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845561|NCT04560010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the anesthesiologist or surgeon will be blinded to the patient's group assignment, as they will be the one performing the treatment. All other stakeholders (patient, other caregivers, and research staff collecting the data) will be blinded to the patient's group assignment.|Subjects scheduled to undergo TSA (anatomic and reverse) will be randomized to receive one of two treatment options. This study will utilize a simple randomization approach to generate two-equal groups. All subjects have an equal chance (1:2) of getting randomized into one of the twp treatments groups: (1) Two doses of IV TXA, one before incision and the second 3 hours later. (2) control group - no TXA given. Randomization of each subject will be done on day of surgery. The randomization schedule will be generated using a computer software program such as randomization.com|t|f|f|t
33845562|NCT06253078|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33845563|NCT06167200|||COHORT||CROSS_SECTIONAL|||||||
33845564|NCT01144052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845565|NCT04007380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845566|NCT00020735|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845567|NCT06203067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845568|NCT05635201|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845569|NCT00990795|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33845570|NCT00008359|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34053095|NCT03702010|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Single-blind, multicenter, crossover|t|f|f|f
33845571|NCT00363350|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33845572|NCT00801554|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845573|NCT05102318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845574|NCT03806101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845575|NCT05225727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845576|NCT00313625||||TREATMENT||NONE||||||
33845577|NCT01640470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845578|NCT06352684|||COHORT||RETROSPECTIVE|||||||
33845579|NCT02054559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845580|NCT00962377|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845581|NCT05670730|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"AOC 1044-CS1 (EXPLORE44) is a 2-part study:~Part A: 5 cohorts with single ascending doses conducted in healthy adult volunteers~Part B: 3 cohorts with multiple ascending doses in participants with DMD mutations amenable to exon 44 skipping"|t|t|t|t
33845582|NCT03835351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845583|NCT00244998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950005|NCT03341559|||COHORT||PROSPECTIVE|||||||
33950006|NCT03690102|RANDOMIZED|PARALLEL||OTHER||NONE||"Parallel Assignment~Participants are randomized to one of three groups (stratified for course type, using computer-generated lists with variable block sizes):~Participants are given a cardiac arrest scenario test either before or after a European Resuscitation Council standardized basic life support course. Two of the groups receive instructions in cardiopulmonary resuscitation from a dispatcher when they call the Emergency Medical Services."||||
33950007|NCT03135873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950008|NCT00210366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950009|NCT06042556|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950010|NCT00190385|RANDOMIZED|FACTORIAL||||NONE||||||
33950011|NCT05394974|||CASE_CONTROL||PROSPECTIVE|||||||
33950012|NCT01481064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950013|NCT04844359|||CASE_ONLY||PROSPECTIVE|||||||
33950014|NCT00030056|RANDOMIZED|||TREATMENT||||||||
33950015|NCT03374709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950016|NCT05696665|RANDOMIZED|PARALLEL||TREATMENT||NONE||GROUP A Conventional drugs only 40 GROUP B:Conventional drugs +1000 mg chamomile 30 mg saffron in a capsule form GROUP C:GROUP C Conventional drugs +500mgApigenin +30mg Crocin 40||||
33950017|NCT00483119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950018|NCT02147132|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33950019|NCT01285726|||COHORT||PROSPECTIVE|||||||
33950020|NCT00048438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33950021|NCT02405182|||CASE_CONTROL||PROSPECTIVE|||||||
33950022|NCT01415999|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950023|NCT01407965|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33950024|NCT00812968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950025|NCT06167304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950026|NCT02182076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950027|NCT02002429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950028|NCT06235086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950029|NCT02873598|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.||||
33950030|NCT03804554|||COHORT||RETROSPECTIVE|||||||
33950031|NCT04331431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950032|NCT01322061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33950033|NCT06264076|NA|SINGLE_GROUP||TREATMENT||NONE|Non-blind|Prospective, single-group, non-blind, interventional study||||
33950034|NCT05685446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33950035|NCT05858216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within participant repeated measures design||||
33950036|NCT03116958|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950037|NCT03133429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950038|NCT04427423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients were blinded from the treatment groups that either he/she are in experimental or control group.|All the patients will be randomly allocated into treatment and control groups 50 in experimental and 50 in control group. The treatment group will receive positional with stabilization exercises while the control group will be treated with stabilization exercises only.|t|f|f|f
33950039|NCT05951894|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950040|NCT04747691|||CASE_ONLY||PROSPECTIVE|||||||
33950041|NCT06309069|||COHORT||RETROSPECTIVE|||||||
33950042|NCT04940624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950043|NCT02672475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950044|NCT04353570|||COHORT||CROSS_SECTIONAL|||||||
34053096|NCT02486640|||COHORT||PROSPECTIVE|||||||
33950045|NCT05534958|||COHORT||PROSPECTIVE|||||||
33950046|NCT01388036|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33950047|NCT03780673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participants nor the researchers will know which group the participants has been allocated to|Phase III, multicentre, double-blind placebo-controlled, randomized clinical trial|t|f|t|f
33950048|NCT03793504|||COHORT||PROSPECTIVE|||||||
33950049|NCT05790252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950050|NCT03628573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950051|NCT03744208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950052|NCT03392922|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33950053|NCT00731094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950054|NCT04156802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This randomized, double-blind, sham-controlled study will parametrically evaluate the longitudinal effects of 16 days of rTMS to the MC (Aim 1) or the MPFC (Aim 2) on self-reported pain and the brain's response to pain. This will be done in a cohort of patients recruited from Wake Forest University clinics and the outer community with chronic lower back pain that may or may not be using prescription opiates for 3 or more months without adequate pain relief. Participants will be randomized to receive TMS to the MC, MPFC,or sham (50% at each site), using a Latin square randomization. Resting state connectivity will be collected. Quantitative Pain Testing will be collected 11 times. MRI data will be collected 3 times: before the 1st visit of TMS, after the 12th visit of TMS, and after the 16th visit of TMS.|t|t|f|f
33950055|NCT02455960|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33950056|NCT04433260|||COHORT||CROSS_SECTIONAL|||||||
33950057|NCT04448548|||CASE_ONLY||RETROSPECTIVE|||||||
33950058|NCT02620826|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053097|NCT02983149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34053098|NCT03963050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053099|NCT01163669|||COHORT||PROSPECTIVE|||||||
34053100|NCT05710991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053101|NCT04740034|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34053102|NCT01662453|||CASE_CONTROL||RETROSPECTIVE|||||||
33845584|NCT01534143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845585|NCT06003140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845586|NCT03053518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigators will recruit approximately 5 cohorts of 4 participants each for the sample size of 20 participants. A new cohort will be randomized approximately every 4 weeks. The maximum number of study participants at any point in the study will be 10.||||
33845587|NCT03329755|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33845588|NCT00656097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845589|NCT06544512|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE||intervention and control|t|f|t|t
33845590|NCT00862719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845591|NCT06729411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845592|NCT01425892|||COHORT||PROSPECTIVE|||||||
33845593|NCT06008587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950059|NCT02730832|NA|SINGLE_GROUP||||NONE||||||
33950060|NCT03172910|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33950061|NCT03841591|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950062|NCT02950727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950063|NCT00913874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950064|NCT02799576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950065|NCT01154530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950066|NCT06084442|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique."||||
33950067|NCT01398540|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34053103|NCT00027183|||CASE_CONTROL||PROSPECTIVE|||||||
34053104|NCT06064838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double-blind, placebo-controlled clinical trial will be conducted at the specialty clinic Indianilla in Mexico City, during the period from August 2023 to September 2024 with post-covid patients with chronic fatigue.|t|t|t|f
34053105|NCT02338219|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053106|NCT00974467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053107|NCT02938793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053108|NCT06105970|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34053109|NCT03583060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34053110|NCT02655016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053111|NCT05447819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"It is not possible to blind the observer when implant migration is evaluated using RSA. The patient-reported outcomes are solely evaluated by the patients before the follow-up examination without involving surgeons or observer~Blinding of the patients:~The patients will be blinded to their allocated treatment the first two years after surgery.~Blinding of Statistician:~The randomization is blinded to the statistician who perform the analysis"|"Based on the sample calculation the investigators intend to include a total number of 122 patients of which the first 56 patients will be studied using MB-RSA and DXA. The patients are allocated into two groups of equal of size:~1. DELTA Xtend Reverse Shoulder System Lateralized Glenosphere Line Extension (intervention group)~2. Standard DELTA Xtend Reverse Shoulder System (control group)."|t|t|f|t
34053112|NCT03211780|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.||||
34053113|NCT04818762|||COHORT||PROSPECTIVE|||||||
34053114|NCT01893060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053115|NCT01382524|||COHORT||PROSPECTIVE|||||||
34053116|NCT04392128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053117|NCT00811902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053118|NCT06260423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053119|NCT02619110|RANDOMIZED|PARALLEL||||NONE||||||
34053120|NCT04398485|NA|SEQUENTIAL||TREATMENT||NONE||||||
34053121|NCT03095560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34053122|NCT01168908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053123|NCT04274504|||COHORT||PROSPECTIVE|||||||
34053124|NCT05176418|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||This will be a double-blind, placebo-controlled study employing a mixed design: nicotine dose as the between-subject and delivery rate as the within-subject factors.|t|f|t|f
34053125|NCT03403296|||COHORT||RETROSPECTIVE|||||||
34053126|NCT02606006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053127|NCT02647970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34053128|NCT06662461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053129|NCT02992977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053130|NCT05874427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34053131|NCT04482075|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053132|NCT06609473|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053133|NCT04313179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053134|NCT05315206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Only after the signing of the informed consent, a single investigator (enrolling physician), not involved in the clinical and instrumental evaluations, will decide whether to assign the selected patient to one of two groups: treated-Citicoline or treated-Placebo.~Randomization will be done by dividing the selected patients into two groups based on similar characteristics of: age, perimetric defect and, mainly,retinal cortical time (RCT) values."|"Patients selected according to the inclusion / exclusion criteria, after signing the informed consent, will be randomized into two groups:~1. In a group of patients with open angle glaucoma (OAG), Citicoline in oral solution (10 ml / day, Neurotidine®) will be administered for 12 months (Citicoline Treated Group, TC Group)~2. in another group of patients with OAG will be administered Placebo (Containing all excipients of Neurotidine ®) (10 ml / day) for 12 months (Placebo Treated Group, TP Group)"|t|t|t|f
34053135|NCT05716256|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053136|NCT04494945|NA|SINGLE_GROUP||SCREENING||NONE||||||
34053137|NCT04401761|||COHORT||PROSPECTIVE|||||||
34053138|NCT00935636|||COHORT||PROSPECTIVE|||||||
34053139|NCT02873962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34053140|NCT03886519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053141|NCT06666140|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34053142|NCT02523924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053143|NCT00796952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34053144|NCT01746420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053145|NCT01665885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053146|NCT03408470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34053147|NCT02441127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053148|NCT01594190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34053149|NCT00048802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34053150|NCT06649240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial||f|f|f|t
34053151|NCT03092765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053152|NCT05762718|||COHORT||CROSS_SECTIONAL|||||||
34053153|NCT05122910|NA|SINGLE_GROUP||OTHER||NONE||||||
34053154|NCT06347055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34053155|NCT02611570|||COHORT||PROSPECTIVE|||||||
34053156|NCT04417192|NA|SINGLE_GROUP||TREATMENT||NONE||This study has 2 cohorts. Cohort 1 is Olaparib monotherapy Cohort 2 is Olaparib plus Pembrolizumab combination therapy||||
34053157|NCT05935748|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization during Expansion phase|Lead-in/Dose Escalation (doublet \& triplet combination) and Dose Expansion (doublet \& triplet combination)||||
34053158|NCT03830957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34053159|NCT00653770|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053160|NCT06094257|||CASE_CONTROL||PROSPECTIVE|||||||
34053161|NCT00244335|||CASE_CONTROL||PROSPECTIVE|||||||
34053162|NCT03546036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study participants were kept blind to treatment allocation by the information that they would be assigned to one of two types of chain blanket, without any information of the difference in weight. The outcome assessor and investigator did not participate in randomization and treatment and were blind to treatment allocation.|Randomization to intervention or control parallell groups on a 50/50 basis.|t|f|t|t
34053163|NCT06311149|||COHORT||PROSPECTIVE|||||||
34053164|NCT05192590|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will enroll primary care physicians practicing in the US. Participants are randomly assigned to either control, intervention 1, or intervention 2 arms upon enrollment. All eligible and consented participants will complete two rounds of three patient simulations.~The intervention 1 and intervention 2 arms only will receive educational material about the Aegis test in between these two rounds. Intervention 1 arm participants only will receive the CDMT results whether they select it or not, and Intervention 2 participants will receive the CDMT results only if they select it in the second round of simulated cases"||||
34053165|NCT06018896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053166|NCT02393807|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34053167|NCT00956592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053168|NCT01931995|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34053169|NCT02064504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053170|NCT04842617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR6390 Tablets compared with placebo|t|t|t|t
34053171|NCT03986788|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Comparison of cerebral blood flow in 1G, 1.8 G and 0G conditions||||
34053172|NCT03755843|||COHORT||PROSPECTIVE|||||||
34053173|NCT06620679|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34053174|NCT05665972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34053175|NCT03374592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
34053176|NCT01504607|||CASE_ONLY||PROSPECTIVE|||||||
34053177|NCT01520558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053178|NCT02651155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053179|NCT05169437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156529|NCT05405101|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|PROBE (Prospective, Randomised, Open-label with Blind Endpoint) multi-centre comparison of thermal ablation with laparoscopic adrenalectomy in the treatment of unilateral asymmetric primary aldosteronism.|PROBE: Prospective Randomised open blinded end point study. Patients are randomized using a minimization program. 2:3 Surgery: Ablation|f|f|f|t
34156530|NCT03406897|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a two-arm, open label, randomized trial. All four groups will receive standard intensive diabetes treatment with insulin and dietary management.~Group I: Fourteen (14) adults (18-65 years) of established T1D \> 6 months (\>180 days) and up to 10 years of T1D duration Group II: Fourteen (14) adults (18-65 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days) Group III: Fourteen (14) children (6-17 years) of established T1D \> 6 months (\>180 days) and up to 10 years of T1D duration Group IV: Fourteen (14) children (6-17 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days)~Participants in each group will be randomly assigned in a 1:1 ratio to receive either one year of high dose Omega-3 fatty acids and Vitamin D combination (Arm A) or Vitamin D alone (Arm B). Both arms will receive Vitamin D supplementation."||||
34156531|NCT02815644|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156532|NCT00761943|||CASE_ONLY||PROSPECTIVE|||||||
34156533|NCT00528801|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34156534|NCT05095350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156535|NCT06529861|||COHORT||CROSS_SECTIONAL|||||||
34053180|NCT06481111|||CASE_ONLY||PROSPECTIVE|||||||
34053181|NCT03014128|||COHORT||PROSPECTIVE|||||||
34053182|NCT03758222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156536|NCT01569048|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34156537|NCT01723761|||COHORT||PROSPECTIVE|||||||
34156538|NCT03100175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156539|NCT01850407|NA|SINGLE_GROUP||SCREENING||NONE||||||
34156540|NCT03372174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156541|NCT03739346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156542|NCT05014685|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34156543|NCT03438136|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Half of the participants will participate in the intervention, and the other half will be assigned to a no contact control group.||||
34156544|NCT04204044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment will be assigned to each participant using lottery method|GROUP A ( Metformin 500 mg TDS), GROUP B( Myoinositol 2000 mg x BD ), GROUP C.(both metformin,\& myoinositol)|t|t|t|f
33741455|NCT05168319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and assessors were blind to group assignment until the study was completed.|fifty NP patients were randomly assigned to 3 groups.|t|f|f|t
33845594|NCT03814772|||COHORT||CROSS_SECTIONAL|||||||
33845595|NCT02764047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156545|NCT04161261|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||We will have 2 groups of patients. An Intraoperative group (undergoing cochlear implantation) and a post operative group (with pre existing facial nerve stimulation). The study compares the effectiveness of different pulse shapes within each group, rather than performing a between-group comparison||||
34156546|NCT01354119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156547|NCT02356848|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34156548|NCT00238238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156549|NCT00249678||||TREATMENT||||||||
34156550|NCT01504841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156551|NCT01753089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053183|NCT06246968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156552|NCT04560387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053184|NCT06188455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156553|NCT04338971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845596|NCT02328859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845597|NCT05842200|||CASE_ONLY||CROSS_SECTIONAL|||||||
34053185|NCT00247078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845598|NCT05352659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Provider skills assessors will be masked to condition.|Randomized controlled trial|f|f|f|t
33845599|NCT03730129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156554|NCT04423081|||COHORT||PROSPECTIVE|||||||
34156555|NCT02237755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156556|NCT02929459|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845600|NCT01182883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845601|NCT03798041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845602|NCT03390764|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter randomized controlled trial||||
33845603|NCT03576729|||OTHER||PROSPECTIVE|||||||
33845604|NCT03570567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053186|NCT05694884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053187|NCT02622412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053188|NCT01878084|NA|SINGLE_GROUP||TREATMENT||NONE||"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)~The extraction sockets will be allocated either to the control : Extraction socket will be left empty~or~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"||||
34053189|NCT03736408|||COHORT||PROSPECTIVE|||||||
34053190|NCT04726748|||COHORT||PROSPECTIVE|||||||
34156557|NCT05400304|||COHORT||RETROSPECTIVE|||||||
34156558|NCT05862311|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34156559|NCT00520156|||DEFINED_POPULATION||PROSPECTIVE|||||||
34156560|NCT05182268|||COHORT||RETROSPECTIVE|||||||
34156561|NCT02227394|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34156562|NCT00878059|||||CROSS_SECTIONAL|||||||
34156563|NCT00917839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156564|NCT01714999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156565|NCT01099397|||COHORT||PROSPECTIVE|||||||
34156566|NCT05262296|||COHORT||PROSPECTIVE|||||||
34156567|NCT02103777|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156568|NCT04611802|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34156569|NCT01938040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34156570|NCT00769509|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||f|t|t|t
34156571|NCT04198077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is conceived as single blinded: only the patients will be not aware of the group allocation.|The study is designed as multicentre, open label, two parallel groups, randomized superiority clinical trial. The included patients will be randomized in 1:1 ratio in conservative and conventional group. A block randomisation will be used with variable block sizes (block size 4-6-8), stratified by center. Central randomisation will be performed using a secure, web-based, randomisation interface. The allocation sequence will be generated by the study statistician using computer generated random numbers.|t|f|f|f
34156572|NCT04560075|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be masked to the intervention condition at follow-up assessment time points.|This study will use a parallel study design, where participants are randomized into two intervention groups (T2C and PE) and will receive interventions in parallel.|f|f|f|t
34156573|NCT05118399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156574|NCT06226584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156575|NCT01398748|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34156576|NCT01192412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156577|NCT03544866|||COHORT||PROSPECTIVE|||||||
34156578|NCT01159392|||CASE_ONLY||PROSPECTIVE|||||||
33845605|NCT06727747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinician who screened patients for eligibility||t|f|t|t
34156579|NCT03460561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34156580|NCT05623657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156581|NCT00296140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, outcome-blinded (PROBE) design. Intervention based on the Chronic Care Model|f|f|f|t
34156582|NCT03162237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156583|NCT01771159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156584|NCT04165603|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34156585|NCT06075121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34156586|NCT01964638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156587|NCT01874444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34156588|NCT05363111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156589|NCT04646330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156590|NCT02726724|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34156591|NCT02425514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Treatment group: Bioactive Glass-Ceramic Spacer (NovoMax™) Active comparator: a PEEK cage Filled with β-Tricalcium Phosphate|t|f|f|f
34156592|NCT01622387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156593|NCT02913950|||OTHER||OTHER|||||||
34156594|NCT00027911||||TREATMENT||||||||
34156595|NCT01329848|||COHORT||PROSPECTIVE|||||||
34156596|NCT04723680|||COHORT||PROSPECTIVE|||||||
34156597|NCT03762018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156598|NCT02161068|||OTHER||RETROSPECTIVE|||||||
34156599|NCT01428167|||CASE_CONTROL||PROSPECTIVE|||||||
34156600|NCT04861376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156601|NCT01600937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156602|NCT01488201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34156603|NCT06223126|||COHORT||PROSPECTIVE|||||||
33845606|NCT00347607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156604|NCT00348309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156605|NCT01712425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156606|NCT03767751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156607|NCT04724967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845607|NCT02688218|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34156608|NCT03006874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156609|NCT04638114|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34156610|NCT03274856|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34156611|NCT02415270|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156612|NCT01980290|||COHORT||PROSPECTIVE|||||||
34156613|NCT04934644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156614|NCT03129360|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34156615|NCT06407531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"While the principal investigator and another co-researcher collected data, the co-researcher collected and recorded the data without having any knowledge of the results of the study.~Data analysis will be completed by an independent researcher."|30 minutes before colonoscopy, the patients' systolic, diastolic blood pressure and heart rate were measured and recorded. Anxiety levels were determined with VAS. Afterwards, the patients were shown videos using virtual reality glasses. 5-10 minutes before the colonoscopy, the patients' systolic, diastolic blood pressure and heart rate were measured and recorded. Anxiety levels were determined with VAS.|f|f|t|t
34156616|NCT00544791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156617|NCT02147288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156618|NCT00102284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845608|NCT04419194|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34156619|NCT05914207|NA|SINGLE_GROUP||TREATMENT||NONE||Children and adolescents who are diagnosed with Vestibular Migraine||||
34156620|NCT02038075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34156621|NCT03515096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156622|NCT03779815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156623|NCT02772185|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34156624|NCT03392649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156625|NCT05191875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156626|NCT06584500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156627|NCT06145347|||COHORT||RETROSPECTIVE|||||||
34156628|NCT03098225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Ophthalmology blinded to treatment||f|f|t|f
34156629|NCT05262647|||CASE_ONLY||PROSPECTIVE|||||||
34053191|NCT05987904|||CASE_ONLY||PROSPECTIVE|||||||
34053192|NCT05062980|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1: 3+3 dose escalation to identify RP2D.~Phase 2: RP2D expansion cohort followed by parallel randomization in a 2:1 ratio to either investigational arm or control arm."||||
34053193|NCT03896737|RANDOMIZED|PARALLEL||TREATMENT||NONE||Dara-VCD versus VTd||||
34053194|NCT01171703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053195|NCT06498219|||CASE_CONTROL||RETROSPECTIVE|||||||
34053196|NCT01820572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053197|NCT06665750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053198|NCT01070095|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053199|NCT06588426|||COHORT||PROSPECTIVE|||||||
34053200|NCT04342767|||CASE_CONTROL||PROSPECTIVE|||||||
34053201|NCT03078296|||COHORT||CROSS_SECTIONAL|||||||
34053202|NCT04590508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Randomization will occur in up to 8 blocks of 4 based on biological sex. Initial randomization series will be generated using readily available random sequence generators designed to do so. A series of sequential envelopes will be generated, each containing the allocation for one participant. Envelopes will be opaque and signed across the seal. The randomization code will be kept in a sealed envelope with a signature across the label and dated the day of creation. Study product and comparator (placebo) will be compounded and placed in identical opaque capsules outside the institution."|Participants will be randomized to receive either encapsulated xanthohumol in a rice protein vehicle, or an identical capsule containing vehicle alone.|t|f|t|t
34053203|NCT00562302|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053204|NCT02636998|||COHORT||PROSPECTIVE|||||||
34053205|NCT05556161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be blinded of which treatment group subject is assigned to.|In parallel arm design, subjects are randomized to one or more study arms and each study arm will be allocated a different intervention. After randomization each subject stays in their assigned treatment arm for the duration of the study. Subjects receive the same treatment throughout the trial. The results are then compared.|t|f|f|f
34053206|NCT01814293|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053207|NCT01797549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053208|NCT05182359|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053209|NCT05415605|NA|SINGLE_GROUP||OTHER||NONE||||||
34053210|NCT03428672|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34053211|NCT01092039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053212|NCT03790228|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib combined with Pemetrexed and Carboplatin||||
34053213|NCT00852215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053214|NCT00247650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053215|NCT06026670|||OTHER||PROSPECTIVE|||||||
34053216|NCT00676312|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34053217|NCT03483961|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053218|NCT02683057|||COHORT||PROSPECTIVE|||||||
34053219|NCT02683278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053220|NCT03144271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053221|NCT00637000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053222|NCT02630329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053223|NCT04164251|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34053224|NCT05301179|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||In a partial factorial cross-over design, subjects will be assigned to one of two protein daily intakes and complete two different levels of dietary protein quality.||||
34053225|NCT06162013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded trial.|130 patients with PSP, 165 patients with MSA, and an undetermined number of patients with CBS will be stratified into cohorts by disease and randomized 1:1 per disease to receive either 3000mg NR a day or placebo (Fig 1). Follow up will be 18 months and consist of both in-clinic visits and decentralized patient-reported outcomes. NADAPT follows a basket trial design with parallel cohorts, essentially encompassing three trials in one, and drawing added value from the parallel enrolment and follow up.|t|t|t|t
33845609|NCT05851703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845610|NCT06525740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33845611|NCT03618043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845612|NCT05672420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845613|NCT05332353|||COHORT||PROSPECTIVE|||||||
33845614|NCT06728488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both surgical groups will be randomly assigned into groups using simple randomization through the -www.randomize.net- application, and a single-blind design will be implemented.|Comparison of the analgesic efficacy and duration of analgesic effect of PENG block application with PENG block and pulse radiofrequency ablation in chronic hip pain.|t|f|f|f
33845615|NCT02535429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33845616|NCT02209870|||COHORT||PROSPECTIVE|||||||
33845617|NCT04586764|||COHORT||PROSPECTIVE|||||||
33845618|NCT05714917|||CASE_ONLY||PROSPECTIVE|||||||
33845619|NCT00659659|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33845620|NCT04712539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845621|NCT00447746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845622|NCT00178867|||COHORT||PROSPECTIVE|||||||
33845623|NCT03620058|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33845624|NCT01656252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845625|NCT03501602|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33845626|NCT00252837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845627|NCT04787887|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33845628|NCT06598449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845629|NCT02166294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845630|NCT01194375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053226|NCT06619067|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34053227|NCT03391544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076437|NCT01999439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156630|NCT06204081|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One experimental group of pwP (H\&Y stage 4, FOG) wear the sole a. 3 min. without using cues when FOG appears and b. 3 min. with using auditive cues when FOG appears. By randomisation of the conditions, the effect of cues on gait is studied.||||
34156631|NCT00356343|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34156632|NCT06169111|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34156633|NCT03188510|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34156634|NCT04138680|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-blind sham controlled randomized trial||||
34156635|NCT00089466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156636|NCT06206915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156637|NCT00466349|||FAMILY_BASED||OTHER|||||||
34156638|NCT00152308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156639|NCT04179253|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||One hundred women with unexplained infertility recruited for office micro hysteroscopic session||||
34156640|NCT05573126|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34156641|NCT04209595|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34156642|NCT05186506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156643|NCT01748721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156644|NCT02687100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156645|NCT03759691|||CASE_ONLY||CROSS_SECTIONAL|||||||
34156646|NCT03410303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156647|NCT05009290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR3680 + ADT compared with placebo + ADT|t|t|t|t
34156648|NCT05633173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The patients to be included in the study were randomized into two groups, Group E and C, using the closed envelope method in the preoperative period.|f|f|f|t
33845631|NCT05524753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded to whether or not the client received the intervention or control/waitlist.|This study uses a waitlist control group.|f|f|f|t
33845632|NCT04748653|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The intervention incorporates 15 health education sessions, 6 psychosocial counseling sessions, 15 physiotherapy sessions, and an economic investment.||||
33845633|NCT02833870|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33845634|NCT04305717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant masking: Patients will be blinded to the treatment groups. ReDS tests will be performed for all study patients, but due to the inherent characteristics of this design, only the treating physicians will be blinded in the standard of care arm.~Outcome assessor masking: Two independent cardiologist will assess the outcomes blinded to the intervention arm."|"The ReDS-SAFE HF trial is a 2-arm randomized clinical trial, in which inpatients with ADHF will be randomized to:~1. Standard of care strategy, with a discharge scheme based on current clinical practice, or~2. ReDS-guided strategy, with a discharge scheme based on specific target value given by the device."|t|f|f|t
33845635|NCT03598959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845636|NCT06729515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"PCA group Immediately post-surgery, patients in the PCA group received a programmed PCA infusion (YG-B-3; Jiangsu Yaguang Medical Device Co., Ltd., China) containing either ketorolac (180 mg) or sufentanil (200 µg) in 100 mL, delivered as a 2 mL/h basal infusion with 0.5 mL boluses; lockout interval: 15 min.~CEA group Following epidural catheter placement in the operating room, the CEA group received an initial bolus of 2% lidocaine (3 mL). Once sensory blockade was confirmed, continuous epidural infusion of 0.1% ropivacaine (8 mL/h) commenced.~RISS group RISS blocks were performed at the T4-T10 level under ultrasound guidance (EPIQ5 with L12-4 linear 7.5 MHz transducer; Philips Healthcare, Best, Netherlands). A 19-gauge, 40-cm catheter was advanced 3-5 cm beyond the needle tip into the subserratus plane, its position confirmed by injecting 5 mL of 0.2% ropivacaine. A further 15 mL of 0.2% ropivacaine was then administered. The catheter was connected to a PCA pump programmed to deliver"|t|f|f|f
33845637|NCT04018677|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33845638|NCT03419832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33845639|NCT06728423|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845640|NCT01969370|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33845641|NCT01698190|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33845642|NCT05589805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845643|NCT06610084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This research is a randomised controlled experimental study||||
33845644|NCT01736800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845645|NCT00209716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845646|NCT02278770|||COHORT||PROSPECTIVE|||||||
33845647|NCT06727656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845648|NCT03943316|||OTHER||PROSPECTIVE|||||||
33845649|NCT01378052|||CASE_CONTROL||RETROSPECTIVE|||||||
33845650|NCT04823676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active and placebo capsules are indistinguishable in form, color and taste, and provided in coded boxes. List containing the correspondence between codes and treatment group assignment is prepared by a pharmacist not participating in the study and kept in a sealed envelope until the end of the study.|Randomized, double-blind, placebo-controlled|t|t|t|t
34156649|NCT00862056|||COHORT||PROSPECTIVE|||||||
34156650|NCT03057275|||COHORT||PROSPECTIVE|||||||
34156651|NCT04901273|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This is a double-blind randomized controlled trial with 1:1 allocation. Patient blinding will be provided during the injection treatment.|The study is a double-blinded RCT with possibility ,after 6 months, to cross-over from control arm (saline solution ) to the treatment arm (Homologous PRP). After 6 months, patients in the control arm have the possibility to cross-over into the treatment arm, in which case they will be followed for an additional 12 months.|t|f|f|t
34156652|NCT01105156|||CASE_ONLY||RETROSPECTIVE|||||||
34156653|NCT02578056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156654|NCT01653990|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34156655|NCT02728466|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34156656|NCT01023724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156657|NCT06372691|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34156658|NCT03382808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156659|NCT02819687|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34156660|NCT01523509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156661|NCT06083298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)|Parallel Assignment|t|f|t|t
34156662|NCT06526533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156663|NCT03605914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156664|NCT00665548|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34156665|NCT02566694|||CASE_CONTROL||RETROSPECTIVE|||||||
34156666|NCT04510896|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Each patient is requested to take the InheRET personal and family health history form. If consented patients fail to complete the form within one week of consenting, they may receive up to three (3) weekly reminder emails. The survey will take less than 10 minutes for low-risk patients. Completion time for higher risk patients depends on the size of the family, the number of conditions to report, and the patient's skill level with completing online forms. The InheRET form can be completed from any web-enabled device at the patient's convenience. Follow-up surveys will be sent as follows:~1. Consented participants fail to complete the InheRET health history for 2 months after consent to determine reason(s) for not completing.~2. Consented participants who complete the InheRET health history - 6 and 12 months after completion to identify actions taken since completion including genetic counseling, genetic testing, screening, lifestyle changes, and prophylaxis."||||
34156667|NCT05964036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156668|NCT04519697|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34156669|NCT01054001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156670|NCT04979611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156671|NCT01500902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156672|NCT04115098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156673|NCT01235234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156674|NCT06034249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled trial (RCT) design was used. Participants will be ask to attend the six-week course encompassed various mindfulness practices, including breathing observation, body scanning, mindful yoga, mindful walking, holistic meditation, and non-selective awareness practices. The control group will only be given the mindfulness-based audio files for six weeks.||||
34156675|NCT01743820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156676|NCT05777512|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This is a randomized single crossover study design, with each of two 10-day study blocks. Infants will be individually randomized to the study intervention (jejunal feeding) in Block 1 or Block 2. The first 48 hours of each study block will be considered run-in/washout periods.||||
34156677|NCT03841435|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156678|NCT05293236|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34156679|NCT02870608|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34156680|NCT01832532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156681|NCT02397148|NA|SINGLE_GROUP||||NONE||||||
34156682|NCT01380067|||CASE_CONTROL||PROSPECTIVE|||||||
34156683|NCT05663671|||COHORT||CROSS_SECTIONAL|||||||
34156684|NCT00869518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156685|NCT03547544|||CASE_ONLY||CROSS_SECTIONAL|||||||
34156686|NCT00240500|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156687|NCT05400772|||OTHER||PROSPECTIVE|||||||
33845651|NCT01047813|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34156688|NCT00321815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156689|NCT05485337|||COHORT||OTHER|||||||
34156690|NCT05608551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156691|NCT02769169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845652|NCT00270140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845653|NCT02862522|||COHORT||PROSPECTIVE|||||||
33845654|NCT05271370|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845655|NCT00002888|RANDOMIZED|||TREATMENT||||||||
34156692|NCT03193736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156693|NCT05091125|||COHORT||PROSPECTIVE|||||||
34156694|NCT00039858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156695|NCT04145986|||COHORT||PROSPECTIVE|||||||
34156696|NCT00087659|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156697|NCT02868684|||COHORT||PROSPECTIVE|||||||
34156698|NCT04791696|||COHORT||RETROSPECTIVE|||||||
34156699|NCT03078855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34156700|NCT03574116|||OTHER||RETROSPECTIVE|||||||
34156701|NCT00787748|||||CROSS_SECTIONAL|||||||
34156702|NCT00713895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156703|NCT06583889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156704|NCT01192568|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Pre-Amendment 3: All subjects, site personnel and Watson and CRO personnel directly involved in the execution of the study were blinded. Post-Amendment 3: All subjects Open-label|This study was initiated as a double-blind, placebo-controlled study with an open-label extension and was amended (in Protocol Amendment 3) to continue to enroll subjects under only open-label treatment.|t|t|t|t
34156705|NCT06524817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156706|NCT02464410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156707|NCT01050244|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34156708|NCT00512785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156709|NCT02873338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156710|NCT02429791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156711|NCT01709656|RANDOMIZED|PARALLEL||||NONE||||||
34156712|NCT05691205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156713|NCT01819350|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34156714|NCT00487071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156715|NCT04132921|||CASE_CONTROL||RETROSPECTIVE|||||||
34156716|NCT02021695|||COHORT||PROSPECTIVE|||||||
34156717|NCT03144986|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A pilot study to investigate the efficacy and safety of deep-rTMS delivered with the H-coil able to reach insula in subjects with long standing treatment resistant severe anorexia nervosa (TrAN)||||
34156718|NCT03041896|||COHORT||RETROSPECTIVE|||||||
34156719|NCT04314011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156720|NCT01325805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053228|NCT03216590|RANDOMIZED|PARALLEL||PREVENTION||NONE||After signing an informed consent participants will be randomised to one of the two study groups.||||
34156721|NCT01764828|NA|SINGLE_GROUP||OTHER||NONE||||||
34156722|NCT04371601|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group: conventional symptomatic treatments such as antiviral (oseltamivir), hormones, oxygen therapy, mechanical ventilation and other supportive therapies; Experimental group: On the basis of the above-mentioned conventional symptomatic treatment and supportive therapy, umbilical cord mesenchymal stem cells were given at 106 / Kg body weight / time, once every 4 days for a total of 4 times. Peripheral intravenous infusion was given within 3 days of first admission.||||
34156723|NCT02816281|||CASE_ONLY||RETROSPECTIVE|||||||
34156724|NCT04115137|||COHORT||PROSPECTIVE|||||||
34156725|NCT04383054|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34156726|NCT00979771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741456|NCT03283670|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each participant receives the 3 inhalation types in randomized, one hour sessions separated by at least 4 weeks|t|f|f|t
34053229|NCT00199706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34156727|NCT03163901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156728|NCT04440332|||COHORT||PROSPECTIVE|||||||
34156729|NCT03954587|||OTHER||PROSPECTIVE|||||||
34156730|NCT00477646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156731|NCT01678612|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156732|NCT05889637|||COHORT||PROSPECTIVE|||||||
34156733|NCT05068219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To minimize assessment bias, investigators and evaluators (doctor and ultrasound operator) will be unaware of the intervention group. Only the physiotherapist, who will realize the procedure, and the patient will know the arm of randomization.||f|f|t|t
34156734|NCT06584370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156735|NCT04725500|NA|SINGLE_GROUP||OTHER||NONE||||||
33741457|NCT04614259|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34156736|NCT01474720|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156737|NCT00327964|||COHORT||PROSPECTIVE|||||||
34156738|NCT05502510|||COHORT||PROSPECTIVE|||||||
34156739|NCT04474821|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34156740|NCT00764673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156741|NCT00781859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156742|NCT04054375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156743|NCT01711450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156744|NCT00966212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156745|NCT00077649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053230|NCT02588716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34156746|NCT01276678|||CASE_CONTROL||PROSPECTIVE|||||||
34053231|NCT01975571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156747|NCT03157765|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156748|NCT01022424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156749|NCT00268970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156750|NCT05749328|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053232|NCT02171338|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34156751|NCT03167021|||OTHER||PROSPECTIVE|||||||
34156752|NCT06085924|||COHORT||RETROSPECTIVE|||||||
34156753|NCT04310566|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34053233|NCT02091986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053234|NCT02051140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156754|NCT00053872|RANDOMIZED|||TREATMENT||||||||
34156755|NCT06191172|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34156756|NCT02564809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34156757|NCT06131138|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor who will take the readings is blind.|Randomized clinical trials|f|f|f|t
34156758|NCT05574842|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Due to the nature of the double-duty interventions, participant allocation concealment will not be possible. However, data collectors, participants, and nutrition behavior change communicators will be blinded from the study hypotheses. Besides, by using and labeling a non-identifiable unique number, the data entry clerk will be blinded until data analysis will be finalized.|A two-arm parallel cluster randomized control trial|t|t|f|t
33741458|NCT00001631||||TREATMENT||||||||
33845656|NCT06043427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845657|NCT03141905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156759|NCT00148876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156760|NCT06031363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156761|NCT01413321|||CASE_CONTROL||PROSPECTIVE|||||||
34053235|NCT01630863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053236|NCT01211457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053237|NCT06243367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053238|NCT02807012|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34053239|NCT03088046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156762|NCT01318148|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156763|NCT01985425|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156764|NCT06043973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156765|NCT01445197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156766|NCT05189028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156767|NCT01038232|||||OTHER|||||||
34156768|NCT02302391|||COHORT||PROSPECTIVE|||||||
34156769|NCT04350242|||COHORT||RETROSPECTIVE|||||||
34156770|NCT00687674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156771|NCT01012778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156772|NCT05228483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156773|NCT02922426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156774|NCT01462396|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34156775|NCT03029091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is an open-label study which means that all participants receive the study medicine.||||
34156776|NCT02554578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845658|NCT03980808|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Participants will not know until the conclusion of the study if they were in the intervention group or the control group. Those on the control group will be offered the opportunity to view the video intervention when data collection concludes.|"Quasi-experimental pre and post-test design. There will be one intervention group and one control group as detailed below:~The intervention group will take the pretest, view the video intervention, take the posttest, and at 30-days following take another posttest.~The control group will take the pretest and posttest, and at 30-days following take another posttest.~For those that are assigned to the control groups, at the completion of the study they will be offered the opportunity to view the ASL-ADE intervention.~The study model was revised to not use the Solomon-Four Group Design because the initial decision to use that design was to measure if there was a pre-test effect. There were no effects for the pre and post-test measures; therefore, we combined the arms into an intervention/no-intervention group, aligning with the primary outcome measures: (1) health literacy, and (2) related health behaviors. The original submission indicated a two-arm study, not a four-arm."|t|f|f|f
33845659|NCT02952534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053240|NCT04370366|||COHORT||PROSPECTIVE|||||||
33845660|NCT03775434|NA|SINGLE_GROUP||TREATMENT||NONE|This is a single arm open label study. Subjects will be assigned to the study treatment arm. Each participant will be scheduled to receive investigational product (IP).|All subjects will receive active product||||
33845661|NCT06100081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845662|NCT03913923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845663|NCT02588105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845664|NCT01844024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33845665|NCT02534506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845666|NCT03659864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participant and lead clinical fellow will be blinded. All staff involved in initial data generation will be blinded.|Cohort study with double blind randomised cross over design|t|f|t|f
33845667|NCT05101018|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Arm 1: romosozumab administered monthly from baseline to month 11 followed by denosumab at month 12 and 18.~Arm 2: denosumab administered at baseline, month 6, 12, and 18"||||
33845668|NCT04600830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A simple blind masking will be carried out to reduce biases in the interpretation of the results. The researchers responsible for the observation, measurement of the ankle ROM and Counter Movement Jump, will not be informed of the treatment performed at the time of immediate post-treatment and post-treatment at 24 hours.||t|f|t|f
33845669|NCT05983380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked regarding whether they are assigned to the intervention or comparison group.|Two groups will be compared, with treatment occurring at the same time. One group will receive the experimental exercises plus the usual treatment, the comparison group will only receive the usual treatment for breast cancer-related lymphedema.|t|f|f|f
34053241|NCT02357095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053242|NCT05126667|||COHORT||RETROSPECTIVE|||||||
33845670|NCT03818724|||CASE_ONLY||PROSPECTIVE|||||||
34053243|NCT03258840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053244|NCT04811274|||CASE_CONTROL||PROSPECTIVE|||||||
34053245|NCT05622877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053246|NCT05265728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053247|NCT02034981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053248|NCT04490044|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomisation will be done by the researcher and will be blinded to participants' identification.|Following enrolment and baseline testing participants will be randomised into one of three study arms (Arm 1, Arm 2, Arm 3) and emailed instructions on how to proceed.|f|f|t|f
34053249|NCT00352092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053250|NCT06096883|||COHORT||RETROSPECTIVE|||||||
34053251|NCT01717482|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053252|NCT04427475|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34053253|NCT06059430|||CASE_ONLY||RETROSPECTIVE|||||||
34053254|NCT06622928|||COHORT||PROSPECTIVE|||||||
34053255|NCT01895881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845671|NCT04746053|NA|SINGLE_GROUP||OTHER||NONE||||||
33950068|NCT06157346|||COHORT||PROSPECTIVE|||||||
33950069|NCT05784168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950070|NCT00828009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950071|NCT04121832|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a controlled clinical trial with crossover and comparison between usual care and biofeedback training, plus usual care|f|f|t|t
33950072|NCT00965458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950073|NCT03772210|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Device used to apply stimulation can be operated in SHAM mode, where subject experiences sensation of the tDCS stimulation starting, but the device is turned off shortly after SHAM mode initiates.|"Structural (T1-weighted) and high angular resolution diffusion images of participant heads will be obtained. Current density distributions in normal participants will be imaged using an F3-F4 montage at three different current intensities. Measures will be repeated at intervals of at least one week. Each time, the montage will be reapplied and subjects re-imaged. Because the imaging method is quantitative, these measures will be used to provide an indication of baseline replicability. Both intra- and inter-subject variations in measured current and electric field distributions will be determined.~Participant performance on a 3-back/0-back memory task will be compared in both Sham and Active subjects, using either 1, 1.5 or 2 mA intensity stimulation."|t|f|f|f
33950074|NCT00920582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33950075|NCT00647309|||COHORT||PROSPECTIVE|||||||
33950076|NCT05959174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950077|NCT05477927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950078|NCT03306875|NA|SINGLE_GROUP||OTHER||NONE||||||
33950079|NCT06145945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950080|NCT00717899|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076438|NCT02851459|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076439|NCT06288243|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076440|NCT04616716|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34076441|NCT03880552|||COHORT||PROSPECTIVE|||||||
34076442|NCT01105312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156777|NCT01973725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156778|NCT04079075|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156779|NCT04766008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156780|NCT03405428|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156781|NCT05784298|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34156782|NCT03684382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Consenting participants are randomly allocated to either the intervention or the control group.|Participants who have completed the online consent form, affirmed their study participation and completed the baseline assessments are then randomly allocated to either the NeW-I group or the control group via the online NeW-I platform that is developed for the purpose of this study. Such random assignment reduces the potential of bias.||||
34156783|NCT01833572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156784|NCT03108417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156785|NCT02732431|NA|SINGLE_GROUP||OTHER||NONE||||||
34156786|NCT06584474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156787|NCT05816434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156788|NCT02493231|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34156789|NCT05809063|||COHORT||PROSPECTIVE|||||||
34156790|NCT06123143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A standardized maintenance/weaning protocol will be implemented for the treatment group (standardized NIS wean), while the control group (routine care) will undergo weaning based on unit-specific practices. All infants in the treatment group will remain on CPAP until either 32 or 34 weeks CGA, depending on their gestational age at birth. Infants born at 27 6/7 weeks or less will continue on CPAP until at least 34 weeks if they are in the treatment group, whereas infants born between 28 0/7 and 29 6/7 weeks will stay on CPAP until at least 32 weeks if they are in the treatment group. The weaning protocol in the treatment group will incorporate algorithms outlining stability criteria, failure criteria, and algorithms for registered nurses (RNs) and respiratory therapists (RTs), including steps to take in such situations. The control group will be weaned according to the unit's or medical team's practices.||||
34156791|NCT04840225|||CASE_CONTROL||PROSPECTIVE|||||||
34156792|NCT06085014|||COHORT||OTHER|||||||
34156793|NCT00938444|||COHORT||PROSPECTIVE|||||||
34156794|NCT03295019|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34156795|NCT02225899|||COHORT||PROSPECTIVE|||||||
34156796|NCT03511235|||COHORT||RETROSPECTIVE|||||||
34156797|NCT01571011|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34156798|NCT03155438|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34156799|NCT03991663|||COHORT||PROSPECTIVE|||||||
33741459|NCT03765437|NA|SINGLE_GROUP||PREVENTION||NONE||The study design is considered Phase 3 for the purpose of registration. This is a safety assessment study designed to provide safety data in Vietnamese participants.||||
33741460|NCT03971643|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||IV infusions of vilobelimab diluted in sodium chloride||||
33950081|NCT04704791|NA|SINGLE_GROUP||OTHER||NONE||||||
33950082|NCT01896518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34053256|NCT04684628|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"There will be two groups depending upon the disease status. Cohort 1- Participant will be in Cohort 1 if have biochemical reoccurrence (post-prostatectomy or post radical radiotherapy) or have biochemical relapse with rising PSA in spite of taking hormone treatment (this situation is characterized as non-metastatic castration resistant prostate cancer M0CRPC).~Cohort 2- Participant will be in Cohort 2 if have high risk prostate cancer and have not received any definitive treatment.~Participants of both cohorts will receive the same study drug for imaging procedure. Participants of both the cohort will undergo one PET/CT scan at 45 minute after a single dose injection of 68Ga-PSMA-11."||||
34053257|NCT06079177|||COHORT||PROSPECTIVE|||||||
34053258|NCT05703880|||COHORT||RETROSPECTIVE|||||||
34053259|NCT04158102|NA|SINGLE_GROUP||OTHER||NONE||||||
34053260|NCT03681990|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34053261|NCT02892422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053262|NCT02375594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053263|NCT03992989|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34053264|NCT05625945|||COHORT||CROSS_SECTIONAL|||||||
34076443|NCT00102843|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34076444|NCT02999334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34076445|NCT01414478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076446|NCT02826161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156800|NCT03718897|||COHORT||PROSPECTIVE|||||||
34156801|NCT03135938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156802|NCT00880191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33950083|NCT04051931|||OTHER||CROSS_SECTIONAL|||||||
33950084|NCT01518894|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33950085|NCT02249546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950086|NCT03572621|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950087|NCT01024894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950088|NCT00742404||||TREATMENT||NONE||||||
33950089|NCT01642862|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950090|NCT02727374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950091|NCT02451631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950092|NCT01453296|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33950093|NCT05234073|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Teachers will be randomly distributed between the control and intervention groups without knowing which one they will participate in or the progress of the other class's processes.|Teachers from the Public Education Network will be randomly assigned to paired classes. While one is attending the four-week online course classes and responding to the perceived mood states assessment questionnaires, the next class will be the control group and will be on hold until the next month answering the same emotional assessment questionnaires.|t|f|f|f
33950094|NCT04804579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950095|NCT06457659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950096|NCT02255045|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33950097|NCT00692198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950098|NCT00363376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845672|NCT01702324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845673|NCT02112708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845674|NCT00942305|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33845675|NCT02191410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845676|NCT06329700|||COHORT||RETROSPECTIVE|||||||
33845677|NCT04870229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845678|NCT01470053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845679|NCT04007250|||COHORT||PROSPECTIVE|||||||
33845680|NCT00711945|||COHORT||PROSPECTIVE|||||||
33845681|NCT04063475|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Cyanoacrylate beside sutures for Fixation of FGG||||
33845682|NCT06729671|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33845683|NCT03483259|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible subjects who did not meet the exclusion criteria were randomly assigned to one of the three groups: group A, B, and C (administration TRR, RTR and RRT, 9 subjects in each group, where T is the test formulation and R is the reference formulation) .||||
33845684|NCT05557500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845685|NCT05651828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845686|NCT06409000|||COHORT||CROSS_SECTIONAL|||||||
33845687|NCT04109105|||CASE_ONLY||PROSPECTIVE|||||||
33845688|NCT03947307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blind to the difference between kinesio- and sham-taping, allowing a double blinded design for the evaluation of the effect of kinesio- versus other tapes. Patient blinding for kinesiotaping versus manual lymphatic drainage is not feasible. The assessment of the primary outcome i.e. the assessment of leg circumference on day 1 and 8 will be performed by a blinded assessor unaware of the treatment allocation.|comparing the use of kinesiotape for the treatment of postoperative edema after knee joint arthroplasty to standard treatment (manual lymphatic drainage and compression in form of stockings or compressive bandages), as well as to sham interventional treatment|t|f|f|t
33845689|NCT03311477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845690|NCT00929110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845691|NCT05901623|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33845692|NCT03421977|||OTHER||PROSPECTIVE|||||||
33845693|NCT03904225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845694|NCT04266600|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33845695|NCT05323357|||CASE_ONLY||PROSPECTIVE|||||||
33845696|NCT06274229|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33845697|NCT01806623|NA|PARALLEL||TREATMENT||NONE||||||
33845698|NCT03045835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845699|NCT00922753|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33845700|NCT03748069|||COHORT||PROSPECTIVE|||||||
33845701|NCT02611336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845702|NCT05287711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be masked.|Participants will receive motivational enhancement therapy for alcohol use problems and this will be compared to an alcohol psychoeducational intervention.|f|f|f|t
33845703|NCT03896620|||OTHER||OTHER|||||||
33845704|NCT00848939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845705|NCT02797275|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33845706|NCT05221359|NA|SINGLE_GROUP||TREATMENT||NONE||"All patients enrolled will undergo period with subcutaneous delivery of insulin, as a baseline data collection. Then, patients will receive the ExOlin device, undergo post-implantation FU, and then get insulin therapy via ExOlin. Explantation of the device, when required, will be accompanied by a safety FU.~During all study phases, NovoRapid insulin will be used."||||
33845707|NCT06311344|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845708|NCT04222764|||COHORT||PROSPECTIVE|||||||
33845709|NCT04930302|||OTHER||PROSPECTIVE|||||||
33845710|NCT06384508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are unaware of different baseline lengths|Single Case Experimental Design (ABC) with two different baseline lengths|t|f|f|f
33845711|NCT02880267|NA|SINGLE_GROUP||OTHER||NONE||||||
33845712|NCT01253070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845713|NCT00399243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076447|NCT01775007|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34076448|NCT02319252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076449|NCT01407809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076450|NCT05581823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076451|NCT05987826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076452|NCT00171990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34076453|NCT05636813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot, pronostic, open-label, non-randomized, descriptive, study||||
34076454|NCT00235573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076455|NCT03330587|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34076456|NCT01834170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076457|NCT03463629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076458|NCT02048124|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34076459|NCT06612775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076460|NCT01047280|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34076461|NCT05911126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded placebo-controlled|Participants will be allocated in 3 groups, first group receiving 2 medications, second group receiving 1 medication and placebo and a third group receiving 1 medication placebo|t|t|t|f
34076462|NCT02595502|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34076463|NCT03522636|||CASE_CONTROL||PROSPECTIVE|||||||
34076464|NCT04596969|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Material was provided in coded plain packaging. Participants and researchers were unaware of what was being received.|Human subjects|t|f|t|f
34076465|NCT02381678|||CASE_ONLY||RETROSPECTIVE|||||||
34076466|NCT00037063||||PREVENTION||||||||
34076467|NCT06150300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076468|NCT01976481|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34076469|NCT00485069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076470|NCT02211378|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34156803|NCT03063268|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34156804|NCT06354478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both patients and Investigator for postoperative pain will be blinded:~* Group 1(D): (n=30) Patients will receive oral placebo starch capsules 1 hour preoperatively and intraoperative intravenous infusion of dexmedetomidine with general anaesthesia.~* Group 2(G): (n=30) Patients will receive oral gabapentin capsules for 1 hour preoperatively and intraoperative intravenous saline infusion with general anaesthesia.~* Group 3(DG): (n=30) Patients will receive oral gabapentin capsules for 1 hour preoperatively and intraoperative intravenous infusion of dexmedetomidine with general anaesthesia."||t|f|t|f
34156805|NCT04218539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156806|NCT04551950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156807|NCT01564732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156808|NCT04999345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156809|NCT05997212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind. The participants will be the only ones blinded. The rTMS coil will be put backwards in the Sham group.|Single-blind randomize clincial trial with parallel groups|t|f|f|f
33845714|NCT05266443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both investigators and subjects will be blinded to the treatment products.|This is a randomized and parallel study involving patients with IBS who attended gastroenterology clinics at Universiti Kebangsaan Malaysia Medical Center (UKMMC). The recruited subjects will be categorized according to their CESD-R scores and randomly allocated into receiving either placebo or probiotic-containing cultured milk drink for 12 weeks.|t|f|t|f
34156810|NCT02123368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156811|NCT06525701|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The control group will not have an exercise regimen. The PI will be blinded to randomization.|The intervention group will complete a core workout lasting 20 minutes twice a week for 4 weeks|f|f|t|f
34156812|NCT05034250|||CASE_CONTROL||PROSPECTIVE|||||||
34156813|NCT03981627|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34156814|NCT02188654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156815|NCT05483517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34156816|NCT01076387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156817|NCT00418574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156818|NCT02108314|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34156819|NCT03600532|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned in even numbers to TMBI \& TAU or recruited as part of a CCG||||
34156820|NCT02110264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156821|NCT02249039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156822|NCT02361008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34156823|NCT00682955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156824|NCT01549119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156825|NCT03743701|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845715|NCT02824354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156826|NCT05316506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34156827|NCT02545244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34156828|NCT03405818|NA|SINGLE_GROUP||TREATMENT||NONE||This was a single group study.||||
33845716|NCT04654026|||CASE_CONTROL||PROSPECTIVE|||||||
33845717|NCT02396329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33845718|NCT00534144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33845719|NCT00834327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845720|NCT02739555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845721|NCT02124603|||CASE_ONLY||CROSS_SECTIONAL|||||||
33845722|NCT01014208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845723|NCT00904046|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33845724|NCT00899808|||CASE_CONTROL||RETROSPECTIVE|||||||
33845725|NCT00939822|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33845726|NCT05738824|||COHORT||PROSPECTIVE|||||||
33845727|NCT06611878|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and instructors cannot be blinded due to the nature of the intervention. External evaluators will remain blinded after randomization; success of blinding will be verified at the end of each participant's participation.|Randomised crossover design|f|f|t|t
33845728|NCT02124447|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33845729|NCT04509037|||COHORT||RETROSPECTIVE|||||||
34156829|NCT00011622|||DEFINED_POPULATION||OTHER|||||||
34156830|NCT00483938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156831|NCT02422849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156832|NCT01397942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156833|NCT02567565|||CASE_ONLY||PROSPECTIVE|||||||
34156834|NCT04866901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34156835|NCT05640895|||CASE_ONLY||PROSPECTIVE|||||||
34156836|NCT02725229|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34156837|NCT02547584|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156838|NCT02597387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156839|NCT04382742|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34156840|NCT02822261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156841|NCT04481217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34156842|NCT02376023|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34156843|NCT04611828|NA|SINGLE_GROUP||OTHER||NONE|Participants will be blind to the device condition|||||
34156844|NCT03899987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156845|NCT04241406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34156846|NCT05052567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156847|NCT02982057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156848|NCT05084092|NA|SINGLE_GROUP||TREATMENT||NONE||Intraoperative Radiation Therapy (IORT)||||
34156849|NCT00006208||||TREATMENT||DOUBLE||||||
34156850|NCT03863808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156851|NCT00588354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156852|NCT00989963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156853|NCT03042884|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156854|NCT00196456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156855|NCT02399657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156856|NCT00258323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741461|NCT02259621|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741462|NCT03313986|||CASE_ONLY||PROSPECTIVE|||||||
33741463|NCT01542528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741464|NCT00697749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741465|NCT04170127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741466|NCT03095417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33741467|NCT04286035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33741468|NCT05319314|NA|SEQUENTIAL||TREATMENT||NONE||||||
33741469|NCT01265953|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33741470|NCT02032901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741471|NCT04083989|||OTHER||PROSPECTIVE|||||||
33741472|NCT01887431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741473|NCT00701051|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845730|NCT05181670|||OTHER||CROSS_SECTIONAL|||||||
33845731|NCT00063531|||COHORT||PROSPECTIVE|||||||
33845732|NCT00106210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845733|NCT04260048|||COHORT||PROSPECTIVE|||||||
33845734|NCT06729307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33845735|NCT06533358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845736|NCT01145209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845737|NCT00920075|||OTHER||OTHER|||||||
33845738|NCT04234919|||COHORT||PROSPECTIVE|||||||
33845739|NCT00710021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845740|NCT06727682|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster-randomised pilot study with four specialised care units of nursing homes and two clusters. Two specialised care units will be randomized in the experimental cluster, and the other ones will be randomized in the control cluster.||||
33845741|NCT01244529|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33845742|NCT05694013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845743|NCT05955300|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical trial with 2 groups||||
33845744|NCT04367259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845745|NCT05651152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (participants and site staff \[excluding site pharmacy staff\])||t|f|t|f
33845746|NCT02271776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33845747|NCT00490724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845748|NCT00092287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845749|NCT04687059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076471|NCT04131712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Primary outcome assessors are blinded to treatment.||f|f|f|t
34076472|NCT04214574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the study, blinding of the anesthesiologist was not possible||t|f|f|t
34076473|NCT00291369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076474|NCT00627497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076475|NCT02766153|||OTHER||PROSPECTIVE|||||||
34076476|NCT04706819|||COHORT||OTHER|||||||
34076477|NCT01699334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076478|NCT05502302|||COHORT||PROSPECTIVE|||||||
34076479|NCT06289439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel group placebo-controlled randomized clinical trial|f|f|t|t
34076480|NCT03062215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076481|NCT06145503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this single-blind, randomized, controlled clinical trial, certain measures were taken to minimize bias throughout the study. The researcher responsible for collecting data from the participants with chronic stroke was unaware of the patient's allocation to either the intervention or control groups. Simultaneously, the principal investigator in charge of the dance intervention group remained blinded to the initial assessments conducted for both the dance intervention and control groups.|The sample size was determined as 36 chronic stroke patients in total (18 for each group) for the two groups (dance intervention group, control group) with an effect size of 1,000 and a targeted test power of 0.90 (90%) in the G\*Power 3.1.9.6 program with an error of α=0.05 and a reference to a previous study on the subject. During the course of the research, and in anticipation of potential dropouts or patient mortality, the sample size for each group was increased, resulting in a total of 40 chronic stroke patients, with 20 patients in each group, being included in the study.|t|f|f|f
34076482|NCT04396691|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076483|NCT00339300|||CASE_CONTROL||RETROSPECTIVE|||||||
34076484|NCT04705012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not participate in the treatment, is blinded to what implant receives which treatment and leaves the room following examination prior to treatment|Examiner blinded split-mouth clinical trial|f|f|f|t
34076485|NCT01083043|||CASE_ONLY||PROSPECTIVE|||||||
34076486|NCT03374475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076487|NCT05283811|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34076488|NCT02789969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076489|NCT00305227|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34076490|NCT04435808|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076491|NCT01673581|||COHORT||PROSPECTIVE|||||||
34076492|NCT01081626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076493|NCT04683796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment package will be labelled as randomization number. Participants will also be blinded to the treatments they receive by using the identical type of eye drop bottle. Clinical and research staffs involved in the outcome assessments will be blinded to the treatment allocation. Lastly, data analysts will also be blinded.|Patients will be randomly allocated to receive either 100% APRP or 100% AS (the same treatment for both eyes).|t|t|t|t
34076494|NCT03076112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076495|NCT01089842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34076496|NCT00526422|||COHORT||CROSS_SECTIONAL|||||||
34076497|NCT01029262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156857|NCT00514371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156858|NCT02585050|||CASE_ONLY||RETROSPECTIVE|||||||
34156859|NCT05304897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156860|NCT04213716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Bottles of nanosilver solution \& distalled water will be covered and coded either A or B by assistant supervisor, and then given to the operator.~Participants will be blinded as regard to either intervention or control Participant and operator who is also the outcome assessor are blinded."|Interventions: (60) Intracanal medication of 1ml combined nanosilver particle solution 30ppm / 100 mg calcium hydroxide Control : (60) Intracanal medication of 100 mg powder of calcium hydroxide mixed with 1ml distilled water|t|f|f|t
34156861|NCT01231087|||COHORT||PROSPECTIVE|||||||
34156862|NCT05901883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156863|NCT05131191|||CASE_CONTROL||PROSPECTIVE|||||||
34156864|NCT05025878|||OTHER||OTHER|||||||
34156865|NCT06148506|||COHORT||PROSPECTIVE|||||||
34156866|NCT03465267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor does not know the allocation of participants.||f|f|f|t
34156867|NCT04938011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156868|NCT02585921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34156869|NCT01239823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156870|NCT06299644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156871|NCT05466357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156872|NCT03322917|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective interventional non-comparative consecutive case series.||||
34156873|NCT05252663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156874|NCT01023672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156875|NCT02736565|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34156876|NCT00815893|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34156877|NCT03107494|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Treatment with Gala Airway Treatment System (RheOx)||||
34156878|NCT02008773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156879|NCT01371734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156880|NCT02451462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34156881|NCT00996983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156882|NCT00139555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34156883|NCT05691114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156884|NCT01195324|RANDOMIZED|CROSSOVER||||NONE||||||
34156885|NCT05938673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and examiners will be blinded to stimulation status|randomized, double-blind, placebo-controlled, parallel, phase III clinical trial.|t|f|f|t
34156886|NCT05049109|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34156887|NCT02075892|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34156888|NCT03137329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156889|NCT02489669|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34156890|NCT00006158||||TREATMENT||NONE||||||
34156891|NCT04836884|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34156892|NCT00801398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156893|NCT05268172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156894|NCT02401451|NA|SINGLE_GROUP||SCREENING||NONE||||||
33845750|NCT06728969|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will include a group of subjects who have ADHD and subjects who are healthy controls based on the specialist clinician assessment.~Following the specialist clinician assessment each subject will undergo a test using the FDA cleared T.O.V.A and MindTension's MT1."||||
33845751|NCT04532229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845752|NCT05388929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845753|NCT02627092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845754|NCT00955253|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The order of administration of guanfacine and placebo was counterbalanced across patients, according to a pregenerated randomisation scheme. The clinician who administered the drugs and the tests was blind to the randomisation and the drug.|Patients were tested on five consecutive days. On days 1, 3 and 5, they were tested on a task battery. On day 2, individuals received active drug or placebo, and on day 4 they received placebo if they had previously received active drug and vice versa. The order of administration of guanfacine and placebo was counterbalanced across patients, according to a pregenerated randomisation scheme. The clinician who administered the drugs and the tests was blind to the randomisation and the drug. The analyses presented here were performed by a different researcher, only after all data were collected. On both treatment days, patients were tested on the task battery twice: once immediately before guanfacine/placebo administration and once 2 hours after.|t|t|t|f
33845755|NCT00094289||||TREATMENT||||||||
34156895|NCT05670418|||CASE_CONTROL||PROSPECTIVE|||||||
34156896|NCT04031989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Repository study designed to collect signals using the CorVista Capture in subjects scheduled for Right Heart Catheterization||||
34156897|NCT01743742|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34156898|NCT04920110|||COHORT||PROSPECTIVE|||||||
34156899|NCT02366156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34156900|NCT05927363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Participants will not know whether they have been randomized to the group receiving the usual, standard rehabilitation or the group following the Therapeutic Consolidation Educational Program Involving a Patient Partner Associated With a Healthcare Professional."||t|f|f|f
33741474|NCT04344821|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Double (Participant, Investigator)|Randomized, placebo controlled, repeated measures intervention trial|f|f|t|f
33845756|NCT05881252|||CASE_CONTROL||PROSPECTIVE|||||||
34156901|NCT05318872|||COHORT||PROSPECTIVE|||||||
34156902|NCT06477185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study|Randomized placebo-controlled trial|t|t|t|t
34156903|NCT04481061|NA|SINGLE_GROUP||SCREENING||NONE||Adolescents between 13-21 years of age will be given the option to learn categories of genomic results. Results will be returned based on their choices||||
34156904|NCT00933465|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34156905|NCT06507488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741475|NCT04791358|||COHORT||PROSPECTIVE|||||||
33741476|NCT03219528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741477|NCT01677234|||COHORT||PROSPECTIVE|||||||
33741478|NCT05841745|||COHORT||RETROSPECTIVE|||||||
33741479|NCT02965560|||COHORT||PROSPECTIVE|||||||
33741480|NCT05919537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845757|NCT03561662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845758|NCT00098332||||TREATMENT||NONE||||||
33845759|NCT06299800|||COHORT||RETROSPECTIVE|||||||
33845760|NCT01252602|||COHORT||PROSPECTIVE|||||||
33845761|NCT00831129|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33845762|NCT03993951|||COHORT||PROSPECTIVE|||||||
33845763|NCT04719546|||CASE_CONTROL||RETROSPECTIVE|||||||
33845764|NCT04413487|||CASE_ONLY||PROSPECTIVE|||||||
33845765|NCT05187364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845766|NCT01756378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845767|NCT00453791|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33845768|NCT03629379|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||prospective, interventional study||||
33845769|NCT04611308|||CASE_CONTROL||PROSPECTIVE|||||||
33845770|NCT04898959|||COHORT||PROSPECTIVE|||||||
33845771|NCT02595073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845772|NCT04587752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845773|NCT02969239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845774|NCT06609421|||COHORT||PROSPECTIVE|||||||
33845775|NCT05484362|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|A researcher not involved in data analyses was responsible for participant allocation and test food consumption.|Crossover, double blind, randomized clinical trial|t|f|t|f
33845776|NCT05141240|||COHORT||RETROSPECTIVE|||||||
33845777|NCT05377775|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, open-label, single-arm, non-randomized clinical trial.||||
33845778|NCT06028555|||COHORT||PROSPECTIVE|||||||
33845779|NCT00158314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845780|NCT02575716|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33845781|NCT00924118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845782|NCT05398991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845783|NCT00592059|||CASE_ONLY||PROSPECTIVE|||||||
33845784|NCT00730106|||COHORT||CROSS_SECTIONAL|||||||
33845785|NCT06012422|NA|SINGLE_GROUP||SCREENING||NONE||There is no randomization in our study, all elderly individuals who meet the inclusion and exclusion criteria will be evaluated.||||
33845786|NCT05625451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized parallel-group trial with concealed allocation, assessor blinding and intention-to-treat|t|f|f|t
33845787|NCT02864108|||COHORT||PROSPECTIVE|||||||
33845788|NCT00266370|||CASE_CONTROL||OTHER|||||||
33845789|NCT04538001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845790|NCT06251362|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|t|f|t
34053265|NCT06208735|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I, first-in-human, open-label multicenter trial of CLIC-2201 CAR-T cells in participants with relapsed or refractory CD22-positive B-cell malignancies. The trial will consist of a 3+3 dose-escalation/de-escalation method in both cohorts (Cohort A: individuals who are 18 years or older and diagnosed with relapsed or refractory B-NHL and Cohort B: pediatric individuals who are 1-21 years old and diagnosed with relapsed or refractory B-ALL) to evaluate the safety and tolerability of increasing dose levels of CLIC-2201 in order to estimate the MTD.||||
34053266|NCT02648893|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34053267|NCT04315233|NA|SINGLE_GROUP||TREATMENT||NONE||modified 3+3 dose escalation followed by an expansion cohort at the identified Recommended Phase 2 Dose (RP2D). Dose escalation will be open to the enrollment of patients diagnosed with triple-negative breast cancer or ovarian cancer. However, dose expansion will only be open to the enrollment of patients diagnosed with triple-negative breast cancer||||
34053268|NCT06438523|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intervention:~Intervention 1 : Vital pulp therapy using A-PRF as capping material. Intervention 2 : Vital pulp therapy using A-PRF mixed with Nano-Chitosan as capping material.~Control/Comparator:~Vital pulp therapy using Chitosan as capping material."||||
34053269|NCT01386398|RANDOMIZED|||TREATMENT||NONE||||||
34053270|NCT04830384|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Not all participants in this study will receive the actual, fully functioning device. One-quarter of the subjects will receive a fully functioning device with laser and music; one-quarter will receive laser only; one-quarter will receive music only; one quarter will receive a placebo or inactive device.|t|t|t|t
34053271|NCT00829972|||CASE_CONTROL||PROSPECTIVE|||||||
34053272|NCT04695262|||COHORT||PROSPECTIVE|||||||
34053273|NCT04675957|||COHORT||RETROSPECTIVE|||||||
34053274|NCT02648854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053275|NCT00796705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053276|NCT04424082|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053277|NCT04430764|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053278|NCT02157649|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053279|NCT02319174|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34053280|NCT05551546|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053281|NCT06504953|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053282|NCT03891043|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34053283|NCT06494410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053284|NCT06281210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053285|NCT03395470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156906|NCT00357617|NON_RANDOMIZED|||TREATMENT||NONE||||||
33845791|NCT01293045|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34156907|NCT06431789|||OTHER||OTHER|||||||
34156908|NCT00429169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156909|NCT03193710|||CASE_CONTROL||PROSPECTIVE|||||||
34156910|NCT03888729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be assigned to one of the following two groups in parallel for the duration of the study, based on treatment indication to be put on SOF/VEL or SOF/VEL/VOX:~* sofosbubir/velpatasvir (SOF/VEL) FDC once daily for 12 weeks will be administered to HCV-infected individuals naïve to DAA therapy regimen (in this group we consider also HCV-infected individuals who have failed interferon-based therapy) who meet other eligibility criteria;~* sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) FDC once daily for 12 weeks will be administered to HCV treatment-experienced participants (i.e. HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen) who meet other eligibility criteria."||||
34156911|NCT02522325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34156912|NCT04720742|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||- Experimental group: the intervention will consist of an Analytical Treatment Interruption (ATI) of up to 18 months of duration, and during the first 8 months, a temporary immune intervention including the combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074, which will be infused once per month.||||
34156913|NCT03680443|||CASE_ONLY||RETROSPECTIVE|||||||
34156914|NCT04462367|||COHORT||OTHER|||||||
34156915|NCT04036812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156916|NCT01505439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156917|NCT05297513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34156918|NCT05884775|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156919|NCT01730703|||COHORT||PROSPECTIVE|||||||
34156920|NCT02486783|||COHORT||PROSPECTIVE|||||||
34156921|NCT06176638|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to one of two treatment conditions at the community level: 1) Usual Care; (2) Combination intervention consisting of: MFG + Virtual TAHC peer mentoring program. Community will be defined as geographically designated areas of Omaha, and the City of Lincoln, Nebraska. Youth in will receive the usual mental health counseling provided through their school counselors. Those in the combination intervention will receive 16 MFG sessions along with their biological parents and 16 virtual TAHC sessions with their peers (excluding parents).||||
34156922|NCT05191108|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomize Controlled clinical trial|t|f|f|t
34156923|NCT01867086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156924|NCT04267055|||COHORT||PROSPECTIVE|||||||
34156925|NCT04501796|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blind.||t|t|t|t
34156926|NCT05160376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156927|NCT03148093|||OTHER||PROSPECTIVE|||||||
34156928|NCT00214058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34156929|NCT03889730|||COHORT||RETROSPECTIVE|||||||
34156930|NCT05107622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156931|NCT04625764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156932|NCT03691662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156933|NCT02085278|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34156934|NCT02794519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34156935|NCT03262636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156936|NCT06408415|||COHORT||PROSPECTIVE|||||||
34156937|NCT04414566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156938|NCT02930304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156939|NCT03415438|||COHORT||PROSPECTIVE|||||||
34156940|NCT03123016|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled subjects will be randomized to treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks, while the contralateral side of the body is covered by a special garment to prevent any UVB treatment||||
34156941|NCT06576128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156942|NCT05809362|||COHORT||PROSPECTIVE|||||||
34156943|NCT00707954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156944|NCT05595733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34156945|NCT04707300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156946|NCT00959127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156947|NCT03485521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The randomization list is established by the researcher before the search begins.~A document describing the randomization procedure is kept confidential."|It is a pilot study, monocentric with randomization of para-medical personnel The randomization list is established by the researcher before the search begins. The strengths of the 3 treatment groups are balanced (15 per group). A document describing the randomization procedure is kept confidential.|f|t|f|f
34156948|NCT01895959|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34156949|NCT04802187|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156950|NCT00495625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156951|NCT03024190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34156952|NCT01499966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156953|NCT01755455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34156954|NCT01555333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156955|NCT02400541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34156956|NCT01251835|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34156957|NCT01184924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34156958|NCT04336033|RANDOMIZED|PARALLEL||OTHER||NONE||A 12-week, open-label, multicenter, randomized controlled pilot study (RCT) will be implemented to evaluate the feasibility, acceptability as well as preliminary efficacy of the newly developed renal diet app in enhancing dietary adherence among CKD patients at different stages in Malaysia. Participants will be randomly assigned in the ratio of 1:1 into two arms.||||
34156959|NCT02757118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156960|NCT01829139|||CASE_CONTROL||PROSPECTIVE|||||||
34156961|NCT04992845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156962|NCT00714311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845792|NCT02233543|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33845793|NCT01059968|||||PROSPECTIVE|||||||
34156963|NCT04373746|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156964|NCT05008198|||CASE_ONLY||PROSPECTIVE|||||||
33950099|NCT02044094|NA|SINGLE_GROUP||TREATMENT||NONE|The investigational drug, RBP-6000, was administered unblinded. The hydromorphone challenges used to measure the effectiveness of RBP-6000 were known and randomized in blinded fashion only to determine the order in which they were administered, with participant and clinical staff blinded to the order of dosing.|All subjects were dispensed the same 300 mg dose of the investigational drug, RBP-6000. They were all also exposed to 0 mg, 6 mg, and 18 mg of hydromorphone for challenges sequentially in a randomized manner.||||
33950100|NCT05603000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a randomized controlled trial, consisting of an intervention arm (EFFT) and a waitlist control (delayed intervention) arm, which will occur concurrently.|f|t|f|t
33950101|NCT05460312|||COHORT||PROSPECTIVE|||||||
34156965|NCT01380834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156966|NCT01622465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34156967|NCT03422965|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34156968|NCT04224961|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34156969|NCT04974437|||CASE_CROSSOVER||PROSPECTIVE|||||||
34156970|NCT03576911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156971|NCT04785924|NA|SINGLE_GROUP||TREATMENT||NONE||A study of outcomes with use of an antibiotic, IMI/REL which can be compared with retrospective data of CRE-containing infections treated with MVB and CZA.||||
34156972|NCT01192308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156973|NCT02956798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156974|NCT02371603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34156975|NCT04764318|||COHORT||PROSPECTIVE|||||||
34156976|NCT01834079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156977|NCT05159804|||COHORT||PROSPECTIVE|||||||
34156978|NCT05113381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156979|NCT04736628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34156980|NCT00005085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156981|NCT04483336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|During the local anesthesia by the care provider, subjects in the test group had to wear VR goggles while control subjects watched a cartoon video on a TV screen. The pain and anxiety outcomes were assessed during the local anesthesia administration. Due to the nature of the study, it was not possible to mask the participants, care provider, or the outcome assessor. The investigator who statistically analyzed the data but was not involved in the dental procedures was masked to the group allocation.|Subjects receiving dental local anesthesia were randomly assigned to wear VR goggles or watch a cartoon video on a regular screen.|f|f|t|f
34156982|NCT02718716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156983|NCT05169606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34156984|NCT06256341|||COHORT||PROSPECTIVE|||||||
34156985|NCT03796026|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34156986|NCT00883441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34156987|NCT06256263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34156988|NCT03938506|||OTHER||PROSPECTIVE|||||||
33741481|NCT05889936|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility trial with pre, peri and post measurements||||
33741482|NCT01298063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741483|NCT04509531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation will be concealed to the participants, researchers -who will be in class the assessment days if possible depending on the Covid-19 scenario- and teachers.|Participants will be randomized in a 1:1 ratio blocked by gender to one of two groups: experimental condition (SA, ITP and resilience condition) versus control condition (anti-grooming/sexting condition) in parallel for the duration of the study.|t|f|f|t
33950102|NCT00975793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053286|NCT01893281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053287|NCT04113434|||COHORT||PROSPECTIVE|||||||
34053288|NCT05357144|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|No blinding or masking to treatment status throughout the intervention.|Randomized controlled trial; Catchment areas will be randomly assigned 1:1 to intervention or comparison arms (n=60-70 intervention drug shops; \~3-4 drug shops per area) using a constrained approach to ensure balance in key covariates.|f|f|t|f
34053289|NCT04827628|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To blind the participant, the mixture is given in the darker bottle, and placebo is given the artificial taste similar to the intervention group. This adjustment also blinds the care provider. The outcome assessor is blinded from the allocation of the group.|a non-randomized trial is implemented involving three arms consists of an obese group as the intervention and two control groups, people with normal Body Mass Index, and Obese.|t|t|f|t
34053290|NCT05285566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053291|NCT06665581|||COHORT||RETROSPECTIVE|||||||
34053292|NCT00057304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"All potential participants entered the placebo run-in phase. At the end of the placebo run-in phase, eligible participants who met the final inclusion/exclusion criteria were randomized to the double-blind treatment period.~treatment"|t|f|t|f
34053293|NCT06195371|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053294|NCT04613661|||CASE_ONLY||CROSS_SECTIONAL|||||||
34053295|NCT05769400|||CASE_ONLY||PROSPECTIVE|||||||
34053296|NCT04097262|RANDOMIZED|FACTORIAL||OTHER||NONE||This study will utilize a three factor design, with one between-subject factor and two within-subject factors. The between-subject factor is participation in a federal food assistance program. The within-subject factors are price change condition and price change scenario.||||
34156989|NCT03589027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, non-randomized, open-label, parallel, two-group, sparse-sampling pharmacokinetic (PK) study to describe levonorgestrel (LNG) PK parameters in two treatment groups (Rilpivirine or Darunavir- based ART) in 60 HIV-1 infected women.||||
34156990|NCT03082092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients receiving elective unilateral primary total knee replacement in Queen Elizabeth Hospital during May 2017 to October 2017 will be assessed for eligibility according to the inclusion and exclusion criteria. 50 subjects will be recruited and randomized using computer into intervention group and placebo group by a nurse otherwise not involved in the trial. The randomization will be concealed in an opaque envelope.~On the day of operation, a surgeon otherwise not involved in the trial will prepare the methylprednisolone and saline (placebo). The envelope will be opened by the list anesthetist. The operating surgeons, anesthetists, assessors (physiotherapists) and the patients were all blinded to the allocation."|single-centre, double-blind, placebo-controlled randomized controlled trial|t|t|t|t
34156991|NCT03787797|||COHORT||PROSPECTIVE|||||||
34156992|NCT06493240|NA|SINGLE_GROUP||TREATMENT||NONE|Masking is not practically possible|||||
34156993|NCT06333366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34156994|NCT04831177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34156995|NCT02754258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053297|NCT02057029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053298|NCT06234098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053299|NCT04259203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34053300|NCT06666374|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34053301|NCT00936325|||COHORT||PROSPECTIVE|||||||
34053302|NCT00624195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053303|NCT05193916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053304|NCT03527810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053305|NCT00055653||||TREATMENT||NONE||||||
34053306|NCT01842295|NA|SINGLE_GROUP||SCREENING||NONE||||||
34053307|NCT06128252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized controlled clinical study|f|f|f|t
34053308|NCT03693105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will receive either active or sham stimulation to the DLPFC. Patients will be randomized to either condition with a 50:50 chance.|t|t|t|t
34053309|NCT03596281|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort A and B will be opened for inclusions at the same time. Once safety of the dual combinations confirmed in cohorts A and B, cohort C will be opened for inclusions.||||
34053310|NCT04804670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34053311|NCT02723903|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053312|NCT01892111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053313|NCT01259310|||CASE_CONTROL||PROSPECTIVE|||||||
34053314|NCT06506318|||CASE_CONTROL||RETROSPECTIVE|||||||
34053315|NCT03996356|||COHORT||PROSPECTIVE|||||||
34053316|NCT00205868|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053317|NCT06470035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34053318|NCT02752165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053319|NCT00283855|RANDOMIZED|FACTORIAL||||NONE||||||
34053320|NCT02019147|||CASE_CONTROL||PROSPECTIVE|||||||
34053321|NCT03179553|||COHORT||PROSPECTIVE|||||||
34053322|NCT05522322|||COHORT||CROSS_SECTIONAL|||||||
34053323|NCT03932175|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor will assess only anonymized data from the two study groups, wherein every group will also be de-identified in relation to its study arm.|Two-groups, randomised parallel study with 1:1 ratio|f|f|f|t
34053324|NCT05322135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053325|NCT04736927|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053326|NCT06550011|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation||||
34053327|NCT05036668|NA|SINGLE_GROUP||OTHER||NONE|Open-Label|Cryptosporidium controlled human infection model||||
34053328|NCT01354665|||COHORT||PROSPECTIVE|||||||
34053329|NCT03721692|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34053330|NCT03330262|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34053331|NCT06021938|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34053332|NCT00908791|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053333|NCT02538289|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053334|NCT00429936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053335|NCT03577977|||COHORT||RETROSPECTIVE|||||||
34053336|NCT00441376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053337|NCT01190410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053338|NCT03727048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053339|NCT04871061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization of the study will be done by a doctor who will not participate in patient follow-up with closed envelopes using computer generated randomization codes.||f|t|f|t
34053340|NCT01409525|||COHORT||PROSPECTIVE|||||||
34053341|NCT05901012|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This study employs a double-blind design. The participant and investigator will all be blind to the order of substance administration during the dosing sessions. Each participant will undergo two dosing sessions on the same day, one with N,N-Dimethyltryptamine (DMT) at a dosage of 60 mg, and another with a placebo containing 1 mg of DMT. The order of substance administration (DMT or placebo) will be randomized and unknown to all parties involved in the study until data collection is complete to ensure unbiased results|This is a double-blind, randomized, placebo-controlled crossover design. 25 participants will be evaluated, who will undergo two dosing sessions on the same day: with DMT (60 mg, inhaled) and with placebo (1 mg DMT, inhaled). Each session will last approximately 2 hours, the substance order will be randomized.|t|f|t|f
34053342|NCT03404726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053343|NCT00355576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053344|NCT02158468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053345|NCT01804790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053346|NCT04212312|||COHORT||RETROSPECTIVE|||||||
34053347|NCT05924815|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34053348|NCT00001810||||TREATMENT||||||||
34053349|NCT04282317|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34053350|NCT03912649|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053351|NCT03892577|||CASE_ONLY||PROSPECTIVE|||||||
34076498|NCT00577733|||||PROSPECTIVE|||||||
34156996|NCT05856019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053352|NCT05230342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A team researcher will use Stata 12, to perform randomization with a 1:1 allocation using random block sizes of 4. Patients and researchers who will evaluate the outcomes and perform the statistical analysis will be blinded to the assigned group.|The groups will receive the treatment simultaneously|t|t|f|f
34156997|NCT01092052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741484|NCT01993524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34156998|NCT02251938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34156999|NCT06114927|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33845794|NCT01231009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34157000|NCT03442218|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157001|NCT04920383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157002|NCT06551935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157003|NCT01800136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157004|NCT04629651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157005|NCT02669992|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34157006|NCT01813448|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33845795|NCT03625180|||CASE_ONLY||PROSPECTIVE|||||||
33845796|NCT05322993|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Endoscopists will perform colonoscopies in three consecutive phases; 1. without artificial intelligence (AI), 2. with AI, 3. without (AI).||||
33845797|NCT00316628|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33845798|NCT02311231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845799|NCT03339583|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Study design implied that every patient underwent two different treatment courses in random sequence: hypnotic or structured educational program (BBT-I) delivered in two sessions.~Subjects were randomly assigned to one of treatment sequences by card sorting method. Patients of the zopiclone-first group underwent the medication therapy for the first two weeks followed by educational program. Patients of the BBT-I-first group received two-week educational program followed by medication therapy.~Each treatment course was separated by 2-weeks washout period that provided the opportunity to evaluate the sustainability of treatment effect.~Before and after each treatment course and after each washout period subjects completed set of questionnaires."||||
33845800|NCT00351208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34053353|NCT04884425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Consenting participants will be randomised into either the PEMF device group or the waiting list control group. There will be 30 participants in the PEMF group and 30 in the waiting list control group.||||
34053354|NCT02729038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053355|NCT06124027|||COHORT||PROSPECTIVE|||||||
34053356|NCT06619015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, the subjects will be randomized to receive either pramlintide or placebo, in addition to semaglutide for the last two weeks of the study.|t|t|t|f
34053357|NCT03633162|||COHORT||RETROSPECTIVE|||||||
34053358|NCT04455477|||OTHER||PROSPECTIVE|||||||
34053359|NCT00319592|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053360|NCT00747474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053361|NCT05956158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34053362|NCT02233101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053363|NCT05670288|||COHORT||PROSPECTIVE|||||||
34053364|NCT03934723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053365|NCT06043778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this trial, the Outcome Assessors administering study assessments at baseline, midpoints and the endpoint will be masked to the intervention arm that participants are allocated to receive. The Study Investigators will also be masked to the intervention arm that participants are allocated to receive. Masking Outcome Assessors and Study Investigators will minimize potential bias due to knowledge of which arm the participant is allocated to, and can ensure unbiased ascertainment of study outcomes is possible. For allocation concealment, the intervention allocation for each participant will not be revealed to the participant until they have been enrolled into the trial, to avoid selection bias.||f|f|t|t
34053366|NCT04287725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053367|NCT00422695|||COHORT||PROSPECTIVE|||||||
34053368|NCT01275508|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053369|NCT04510506|RANDOMIZED|PARALLEL||OTHER||NONE||This is a longitudinal randomized controlled study designed to assess changes in control of Type 1 Diabetes in pubertal adolescents over a two year period.||||
34053370|NCT03631615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053371|NCT01772745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053372|NCT03928262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||36 healthy Chinese male and female subjects randomized in a 1:1:1 ratio to receive a single SC administration of benralizumab, Treatment 1, Treatment 2 and Treatment 3 (12 subjects per group). Each subject will participate in only 1 treatment group.|t|t|t|f
34053373|NCT04973371|RANDOMIZED|PARALLEL||SCREENING||NONE|The allocation of study arm is concealed to study staff during randomization. Neither study staff nor participants will be blinded to study treatment arms after the point of randomization. Nonetheless, strict policies will be in place to preserve randomization integrity.|"An exploratory study to 1) investigate the acceptability and feasibility of home-based TB testing of household contacts using a new portable GeneXpert point-of-care (PoC) platform, and 2) determine the potential impact of such a home-based testing program on early detection of TB disease and linkage-to-care (LTC). In this study, all participants enrolled in the Treatment arm will be tested for TB at their household, using the GeneXpert device. Participants enrolled in the Control arm will receive a referral letter, which can be used to access treatment at the nearest health facility. No single participant will be randomized, the whole house will receive a Blanket Randomisation."||||
34053374|NCT06358443|NA|SINGLE_GROUP||PREVENTION||NONE||One armed observational study||||
34053375|NCT02075528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053376|NCT04016922|||COHORT||PROSPECTIVE|||||||
34053377|NCT02688062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053378|NCT00851916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157007|NCT02226887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34157008|NCT02315560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845801|NCT05310149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845802|NCT05559515|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||a cluster-randomized controlled trial of NDPP-Flex versus the standard NDPP|t|f|t|t
33845803|NCT01308944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845804|NCT03993600|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Three groups will be done : healthy volunteer, cystic fibrosis patient and heterozygotes subject||||
33845805|NCT01994759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845806|NCT04616872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-blind, Placebo-control Trial.|t|t|t|t
34053379|NCT03843541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both rater and patient will be blinded.|There will be 3 treatment groups of NAC, ambroxol and placebo. A total of 333 patients will be randomized to NAC or ambroxol or placebo in a 1:1:1 ratio. Approximately 111 patients will be randomized in each treatment group.|t|f|f|t
34053380|NCT04057131|||OTHER||PROSPECTIVE|||||||
34053381|NCT01978990|||COHORT||PROSPECTIVE|||||||
34053382|NCT00985998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053383|NCT06618352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053384|NCT00171938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053385|NCT03463707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053386|NCT05851313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34053387|NCT06618456|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are randomly assigned to one of the two groups (experimental group / control group). In the experimental group participants undergo a VR-supported trance induction. The participants in the control group are the same VR-environment but do not receive a trance induction. Then there is an automatic transition to the altitude confrontation (also in VR) in both groups. The experimental group receives hypnotic suggestions via audio, that partially refer to a tree positioned next to the participants in the VR-altitude-confrontation. In the control group this tree is replaced by a parasol in the VR and the text via audio. Besides from that they receive the same text as the experimental group.||||
34053388|NCT06209970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053389|NCT04115592|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34053390|NCT00268567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053391|NCT06624306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053392|NCT03486444|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34053393|NCT05844176|||COHORT||PROSPECTIVE|||||||
34053394|NCT05897086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053395|NCT02859428|||COHORT||PROSPECTIVE|||||||
34053396|NCT03030989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34053397|NCT05528107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053398|NCT02006797|RANDOMIZED|CROSSOVER||||NONE||||||
34053399|NCT06354998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053400|NCT02593526|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34053401|NCT00543972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053402|NCT05016401|||CASE_ONLY||PROSPECTIVE|||||||
34053403|NCT06665282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053404|NCT05667831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Before the subjects were assigned, neither the participants, nurses nor the researchers knew whether the subjects were in the experimental group or the control group. When the patients met the inclusion criteria, the research assistant informed the clinical nurses of the results of the case assignment(experimental group or control group).|Subjects who meet the inclusion criteria of this study will be randomly assigned by the research assistant to the experimental group or the control group by generating random numbers on the computer.|t|t|f|f
34053405|NCT06665919|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"To evaluate CYP2C19 allele genotype-guided clopidogrel treatment outcomes after the ePCI study participants were randomly allocated into parallel study arms. Experimental arm participants have undergone CYP2C19 genotyping. Carriers of normal \*2, \*3 alleles - normal metabolizers phenotype separated as the experimental arm and participants randomly allocated in the comparators arm without CYP2C19 genotyping - the unspecified metabolizers phenotype, have been intervened with clopidogrel-based preventive antiplatelet treatment. Carriers of LoF \*2, \*3 alleles - the poor metabolizers phenotype, have been separated in the experimental arm, assigned as the additional comparators and intervened with preventive antiplatelet treatment alternative to clopidogrel. Clinical and non-clinical outcome measures are expected to be compared between parallel study groups."|t|t|f|t
34053406|NCT00395941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053407|NCT05601622|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053408|NCT02327403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053409|NCT05963607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be masked to study group to the extent possible (blanket weights are self-evident). Data will be collected online/remotely with no interaction from the study team except for study reminders or technical assistance.|Randomized controlled study with two study arms.|t|f|f|t
34053410|NCT01167881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34053411|NCT03486678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053412|NCT03342027|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||4 conditions: (1) bupropion + Positively Smoke Free (an 8 session tailored behavioral intervention for PLWH smokers); (2) bupropion + Standard of Care (brief advice to quit); (3) Placebo + Positively Smoke Free; and (4) Placebo + Standard of Care.|f|f|t|t
34053413|NCT04025437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Neoadjuvant Radiotherapy||||
34053414|NCT04158674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053415|NCT02715505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053416|NCT05847751|||COHORT||PROSPECTIVE|||||||
34053417|NCT04265599|||COHORT||CROSS_SECTIONAL|||||||
34053418|NCT06554847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053419|NCT04423952|||CASE_CONTROL||PROSPECTIVE|||||||
34053420|NCT06621758|||COHORT||PROSPECTIVE|||||||
34053421|NCT01760967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053422|NCT04091100|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals were randomly allocated into electroacupuncture and myofascial release groups||||
34053423|NCT03705650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053424|NCT04937933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34053425|NCT00281632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157009|NCT05299008|||COHORT||PROSPECTIVE|||||||
34157010|NCT01445314|||COHORT||OTHER|||||||
34157011|NCT00859937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157012|NCT01377831|||COHORT||PROSPECTIVE|||||||
34157013|NCT03748719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053426|NCT06622798|||COHORT||RETROSPECTIVE|||||||
34053427|NCT00971464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741485|NCT04420299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to the dosing regimen (treatment dose or prophylactic dose).|randomized, single-blind, parallel control group|t|f|f|f
33845807|NCT01953705|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053428|NCT02005692|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33845808|NCT03049033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34053429|NCT06097689|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34053430|NCT03005652|RANDOMIZED|PARALLEL||OTHER||SINGLE||"The trial will compare outcomes in two groups of participants randomised to one of two study arms, either receiving:~(i) an 8-week mindfulness-based intervention, using a secular form of mindfulness training; or (ii) an 8-week validated health-educational programme (comparison condition, see section 6.3 for description) The randomization will be performed with a 1:1 allocation. The primary outcome will be change in symptoms of anxiety from baseline to 8 weeks."|f|f|f|t
34157014|NCT05535829|||COHORT||RETROSPECTIVE|||||||
34157015|NCT03907150|||COHORT||PROSPECTIVE|||||||
34157016|NCT01552356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845809|NCT02365922|||COHORT||PROSPECTIVE|||||||
33845810|NCT03433508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845811|NCT03991208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33845812|NCT01455389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845813|NCT03121248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845814|NCT02441231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33845815|NCT04871880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845816|NCT02752698|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33845817|NCT00120588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33845818|NCT04706559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, there will be three investigators i.e, one principal investigator, and two co-investigators. Among them, one of the co-investigators will be blinded who will act as an assessor.|Assessor blinded, randomized controlled trial.|f|f|f|t
33845819|NCT03427853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind,|randomized, double-blind, parallel-group, placebo-controlled, single-dose escalation|t|f|t|f
33845820|NCT06249659|||CASE_CONTROL||PROSPECTIVE|||||||
33845821|NCT01843153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845822|NCT02597647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33845823|NCT00236600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845824|NCT02230098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33845825|NCT03893669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845826|NCT04492449|||OTHER||OTHER|||||||
33845827|NCT02965677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845828|NCT02399254|||COHORT||PROSPECTIVE|||||||
33845829|NCT02158988|RANDOMIZED|PARALLEL||TREATMENT||NONE||intraperitoneal (in the abdominal cavity) chemoperfusion with Mitomycin C and Cisplatin||||
33845830|NCT03881176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845831|NCT01253304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845832|NCT02297139|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845833|NCT02497248|||COHORT||PROSPECTIVE|||||||
33845834|NCT05559788|||COHORT||PROSPECTIVE|||||||
33950103|NCT03077854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950104|NCT02575261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950105|NCT04252196|NA|SINGLE_GROUP||OTHER||NONE||Device usability single group||||
33950106|NCT00860756|RANDOMIZED|PARALLEL||||NONE||||||
33950107|NCT05623189|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This phase 2b, double-blind, placebo-controlled, multicenter study will evaluate the effect of HTD1801 on histologic improvements in adult subjects with non-alcoholic steatohepatitis (NASH) and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes. Approximately 210 subjects with biopsy-confirmed NASH and evidence of stage 2 or stage 3 liver fibrosis will be randomized 2:1 to receive HTD1801 1250 mg twice daily (BID) or placebo BID. Subjects will receive investigational product for up to 60 weeks.|t|t|t|t
33950108|NCT00015587|||CASE_CONTROL||PROSPECTIVE|||||||
33950109|NCT03273088|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33950110|NCT06187207|||COHORT||PROSPECTIVE|||||||
33950111|NCT04901182|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33950112|NCT00456326|||||RETROSPECTIVE|||||||
33950113|NCT04657861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950114|NCT01869231|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33950115|NCT02735720|||COHORT||PROSPECTIVE|||||||
33950116|NCT06283654|||OTHER||PROSPECTIVE|||||||
33950117|NCT04284241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950118|NCT04115488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950119|NCT01551238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950120|NCT04638218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950121|NCT00286936|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33950122|NCT04938726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All involved with blinded, except for the study pharmacist|Two-way ANOVA with repeated measures on time|t|t|t|t
33950123|NCT01946295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950124|NCT00807859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950125|NCT05333861|||COHORT||OTHER|||||||
33950126|NCT04762706|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33950127|NCT00082069|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33950128|NCT03004612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33950129|NCT04310241|||COHORT||PROSPECTIVE|||||||
33950130|NCT01483495|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950131|NCT06371027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950132|NCT06033924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33950133|NCT05776407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950134|NCT00478504|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33950135|NCT00501072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157017|NCT02634502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950136|NCT05083494|||COHORT||PROSPECTIVE|||||||
33950137|NCT00039429||||TREATMENT||NONE||||||
33950138|NCT02127866|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33950139|NCT03742128|||COHORT||CROSS_SECTIONAL|||||||
33950140|NCT00726882|NA|SINGLE_GROUP||||NONE||||||
33950141|NCT06653491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950142|NCT05912192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950143|NCT01040624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950144|NCT00862667|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950145|NCT01193478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950146|NCT01043809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950147|NCT00698373|||||PROSPECTIVE|||||||
33950148|NCT02228148|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33950149|NCT02988830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950150|NCT05710367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950151|NCT03068429|NA|SINGLE_GROUP||OTHER||NONE||4-weeks open label trial of sertraline up to 200mg/day treatment for obsessive compulsive disorder||||
33950152|NCT04243811|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950153|NCT05786027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950154|NCT02778893|NA|SINGLE_GROUP||TREATMENT||||||||
34053431|NCT03146689|NA|SINGLE_GROUP||OTHER||NONE||N-of-1 trial series: several within-individual, randomised, multiple cross-over trials aggregated into a series.||||
34053432|NCT00330109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053433|NCT06337916|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053434|NCT00657033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053435|NCT00254800|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053436|NCT03871790|||COHORT||PROSPECTIVE|||||||
34053437|NCT06664840|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study is to conduct a validity study to test the agreement between MyRareDiet and the validated interview-based 24-hour diet recall method used in the National Health and Nutrition Examination Survey (NHANES).||||
34053438|NCT05728606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053439|NCT03197324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053440|NCT01032239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053441|NCT05024240|RANDOMIZED|PARALLEL||SCREENING||NONE||There will be group of patients with disorders od cerebellum and control group of healthy age-matching probands||||
34053442|NCT06256692|||COHORT||PROSPECTIVE|||||||
34053443|NCT03200756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053444|NCT04992104|||COHORT||PROSPECTIVE|||||||
34053445|NCT05958264|||CASE_ONLY||PROSPECTIVE|||||||
34053446|NCT06409390|NA|SEQUENTIAL||TREATMENT||NONE||||||
34053447|NCT02078453|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34053448|NCT02251145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053449|NCT06235047|||COHORT||RETROSPECTIVE|||||||
34157018|NCT00927238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157019|NCT06006117|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm A - Experimental arm: Mosunetuzumab-Lenalidomide~Arm B - Comparator arms (Investigator Choices):~* Rituximab-Lenalidomide~* Rituximab-Bendamustine~* Rituximab-CHOP"||||
34157020|NCT01714401|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33741486|NCT00001022||||TREATMENT||DOUBLE||||||
33741487|NCT02462395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950155|NCT04890691|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|"Participants in both groups will receive light therapy to mask their status in the treatment (BLT-1, therapeutic light) or control (BLT-2, placebo light) group.~Participants will use a special ID to mask the PI to identify who is in the treatment group."|This a randomized, double-blind, placebo-controlled clinical trial to explore the effects of light therapy for migraine combined with sleep disturbance.|t|f|t|f
33950156|NCT04867980|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741488|NCT03458052|||OTHER||PROSPECTIVE|||||||
33741489|NCT04598516|||COHORT||PROSPECTIVE|||||||
33741490|NCT00553384|||||PROSPECTIVE|||||||
33950157|NCT02668445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950158|NCT04555772|||OTHER||RETROSPECTIVE|||||||
33950159|NCT01569321|NA|SINGLE_GROUP||||NONE||||||
33950160|NCT04061837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950161|NCT00150137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950162|NCT01681927|||CASE_ONLY||PROSPECTIVE|||||||
33950163|NCT03143712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950164|NCT02268214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950165|NCT01229865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950166|NCT00665327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978037|NCT06123507|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Client-actors were masked to condition. Investigators were masked while determining participants' perceptual understanding scores (i.e., how accurate participants were at inferring the client-actor's thoughts and feelings). In-lab research assistants were not masked to condition.|This randomized mixed-methods parallel two-arm feasibility trial used a 1:1 allocation ratio in Excel. This study's primary purpose was to assess the feasibility, appropriateness, and acceptability of a randomized pilot trial where some health-care students received a Full educational Intervention on perspective-taking and others received a Partial Intervention.|f|f|f|t
33978038|NCT05626595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978039|NCT04908826|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34053450|NCT04579835|||COHORT||PROSPECTIVE|||||||
34157021|NCT03698123|NA|SINGLE_GROUP||OTHER||NONE|Researchers analyze the data will be blinded to the group assignment.|"Study participants will participate in the study 3 nights with one control night and two dietary interventions nights.The order of the 2 dietary intervention groups will be randomized per block.~There are two possible combinations and the order will be randomized using a computer-generated random-number sequence. There will be at least a 24-hour wash-out period between study nights to minimize the carry-over effects of the cross-over design as well as learning effects of the computerized cognitive tests.~A: Control- no intervention, B: intervention 1 arm, C: Intervention 2 The order of the blocks will be randomized. block a: A, B, C block b: A, C, B"||||
34157022|NCT04786808|||COHORT||PROSPECTIVE|||||||
34157023|NCT05279950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157024|NCT02097654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|For outcome data, details were extracted from patients' case records to determine if trigger list adverse clinical events had occurred following randomization. These trigger list events represented the great majority of adverse drug reactions (ADRs) and were independently adjudicated by a blinded end-point committee comprised of the co-PI's, such that no co-PI adjudicated potential ADRs at his own site.|Block randomized parallel arm trial.|f|f|f|t
34157025|NCT03022682|||COHORT||PROSPECTIVE|||||||
34157026|NCT05325346|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157027|NCT03240770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157028|NCT02075788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34157029|NCT02595294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157030|NCT05090852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157031|NCT06017505|||CASE_ONLY||OTHER|||||||
34157032|NCT06257173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental and control groups will be determined using https://www.randomizer.org.|This research will be conducted as an experimental study with pretest-posttest randomised control group design.|t|f|f|f
34157033|NCT06583317|||COHORT||PROSPECTIVE|||||||
34157034|NCT01865799|||CASE_ONLY||RETROSPECTIVE|||||||
34157035|NCT03650140|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34157036|NCT02376972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157037|NCT04292314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Four experimental groups, one control group.~Each experimental group receives different experimental treatments plus traditional treatment in the hospital and the control group receives only traditional treatment."|t|t|f|f
34157038|NCT00889642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157039|NCT03736876|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multi-site independent randomized group treatment trial (IGRT). 1,209 youth randomized to intervention or control conditions within schools. Sample accrues over 2.5 years (Years 2-4)||||
34157040|NCT06393179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157041|NCT03267888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157042|NCT00516256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34157043|NCT03795727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157044|NCT06402032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157045|NCT03263260|||OTHER||PROSPECTIVE|||||||
34157046|NCT02846701|NA|SINGLE_GROUP||OTHER||NONE||||||
34157047|NCT05926024|||COHORT||PROSPECTIVE|||||||
34157048|NCT05463523|||CASE_ONLY||PROSPECTIVE|||||||
34157049|NCT00114998|||COHORT||PROSPECTIVE|||||||
34157050|NCT02275156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157051|NCT04615039|||COHORT||OTHER|||||||
34157052|NCT00235716|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34157053|NCT02416895|||COHORT||PROSPECTIVE|||||||
34157054|NCT02051322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978040|NCT00797108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978041|NCT00211159|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34157055|NCT03672058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157056|NCT04752358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157057|NCT01252030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33741491|NCT04241939|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741492|NCT02897544|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741493|NCT05872230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978042|NCT04259840|||COHORT||CROSS_SECTIONAL|||||||
33978043|NCT05451836|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Interrupted time series quasi-experimental design||||
34157058|NCT06060587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157059|NCT05492201|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157060|NCT05894785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157061|NCT00461279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157062|NCT02990572|||OTHER||OTHER|||||||
34157063|NCT03771950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After screening for eligibility, fulfilling inclusion criteria and consenting to participation the baseline assessment will be conducted by an OT at enrolment. After this the patients will be randomised either to the intervention or control group in using lots in sealed envelopes based on a computer generated group allocation. The lots are kept in sealed envelopes prepared by a person not involved in the study. An OT will open the envelope and inform the patient about group allocation. All care providers will be blinded for baseline and post-test outcomes. A research co-worker who are involved in data management will be blinded for group allocation.||f|f|f|t
34157064|NCT06583304|||COHORT||CROSS_SECTIONAL|||||||
34157065|NCT00083005||||TREATMENT||NONE||||||
34157066|NCT06124261|||CASE_CONTROL||PROSPECTIVE|||||||
34157067|NCT05793242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34157068|NCT04649684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157069|NCT03533244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157070|NCT00863005||PARALLEL||||||||||
34157071|NCT01211314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157072|NCT05113030|||OTHER||CROSS_SECTIONAL|||||||
34157073|NCT03688516|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34157074|NCT01625546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157075|NCT01930721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157076|NCT04209933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157077|NCT06202040|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34157078|NCT00583063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157079|NCT05100576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34157080|NCT01957410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157081|NCT06584123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient's who have previously undergone 11C-Methionine PET during routine clinical care will be invited to undergo 18F-Fluoro-ethyl-tyrosine PET (FET PET).||||
34157082|NCT05258916|||COHORT||RETROSPECTIVE|||||||
34157083|NCT03088943|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Echo exams will be stored for later analysis by blinded assessors.|Patients will receive a series of perioperative echocardiographical measurements by TTE as well as TEE prior to induction, postinduction, and post cardiopulmonary bypass|f|f|f|t
34157084|NCT04908358|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Participant will not be informed of condition. The investigators will work with blinded data (but can know the condition during intervention)|Randomized cross-over followed by placebo-controlled study (allocation to placebo or control condition takes APOE-E4 status into account and the previous ordering of the cross-over design)|t|f|f|f
34157085|NCT00268008|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34157086|NCT01601665|||COHORT||PROSPECTIVE|||||||
34157087|NCT05766657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind: Apart from clinical nutritionists who will be involved in dietary counseling, physicians and all project staff who will be responsible for patient selection and follow-up, along with biostatisticians, will be blinded to the intervention groups.|Randomized, multicenter, 2-arm, parallel-group, single-blind controlled clinical trial (1:1 allocation ratio)|t|t|f|f
34157088|NCT03955991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157089|NCT00306059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157090|NCT03296449|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34157091|NCT03472586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157092|NCT02200887|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157093|NCT00133666|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33741494|NCT02396641|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741495|NCT02805257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741496|NCT00467181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33741497|NCT04634487|||COHORT||OTHER|||||||
33741498|NCT00114686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978044|NCT05586425|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978045|NCT02641964|||CASE_CONTROL||RETROSPECTIVE|||||||
33978046|NCT00062283||||TREATMENT||NONE||||||
33978047|NCT02398188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978048|NCT04089709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized using an online randomization tool. Study folders will be placed in order and include the consent form and exercise sheet if randomized to the treatment group. Those randomized to the control group will be given an information sheet on distal radius fractures. Patients will be consented by an unblinded research assistant in order for the treating physician to remain blinded.|Participants will be randomly assigned to one of two groups, treatment or no treatment. Randomizations will be balanced at random accrual points.|f|f|f|t
33978049|NCT05291078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157094|NCT06549426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157095|NCT03301298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157096|NCT00996255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157097|NCT01754493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157098|NCT04266054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34157099|NCT02052401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34157100|NCT03172572|||COHORT||RETROSPECTIVE|||||||
34157101|NCT02333604|||CASE_ONLY||PROSPECTIVE|||||||
34157102|NCT03915470|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind.||t|f|t|f
34157103|NCT05562258|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two conditions in a parallel design including a 12-week intervention. Participants will be recruited from the Center of Excellence in Eating and Weight Disorders Program (EWDP) until the recruitment goal of 70, 35 in each group, is reached.||||
34157104|NCT02115412|||OTHER||CROSS_SECTIONAL|||||||
34157105|NCT06462781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157106|NCT02650830|||COHORT||PROSPECTIVE|||||||
34157107|NCT03190616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157108|NCT02003417|||COHORT||PROSPECTIVE|||||||
34157109|NCT00398320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157110|NCT04140045|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34053451|NCT02824601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34157111|NCT01628055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157112|NCT03873935|||OTHER||CROSS_SECTIONAL|||||||
33741499|NCT00647920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053452|NCT00691769|||CASE_CONTROL||PROSPECTIVE|||||||
34053453|NCT03274141|||COHORT||PROSPECTIVE|||||||
34053454|NCT04796506|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Interpretation of polysomnography and cognitive performance will be blinded to intervention assignment.|PD subjects will be randomized (1:1) to the progressive resistance training (PRT) rehabilitation group or the delayed exercise (DE) control group (wait 12 weeks and begin resistance training). Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the arm assignment in the second 12-week period of the trial for the original PRT group. Specifically, participants with an increase in SWS (responders) will continue in PRT for the 2nd 12 weeks of the trial, while non-responders (participants without increase in SWS) will transition to endurance training (ET) to assess if PRT followed by ET can enhance response in these non-responders.|f|f|f|t
34053455|NCT03308591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053456|NCT06621979|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Single-center, ambispective, interventional, non-randomized pilot study||||
34053457|NCT03386396|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||One group will be given a high protein/low carbohydrate shake and one group will be given a high carbohydrate/low protein shake|t|t|t|t
34053458|NCT01734538|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34053459|NCT04703374|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053460|NCT00514644|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34053461|NCT00899171|||||RETROSPECTIVE|||||||
34053462|NCT03538977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the evaluation of pain, respiratory effort and state of sleep and wakefulness, specific scales previously validated for this population will be used: NIPS (Neonatal Infant Pain Scale) scale, Silverman Andersen respiratory severity score, and the Brazelton Neonatal Behavioral Assessment Scale, respectively. Patients will be filmed during the five moments of assessment, and two physiotherapists blinded to the groups will watch the filming and perform the evaluation using the scales previously mentioned.|PTNB with a diagnosis of BPD will be randomized into two groups: conventional physiotherapy (GP) and conventional physiotherapy plus hydrotherapy (GH). The PTNB randomized to GH will be submitted to 11 hydrotherapy sessions. The PTNB from both groups will be submitted to evaluation of heart rate (HR), peripheral oxygen saturation (SpO2), respiratory rate (RR), pain, respiratory distress, sleep state, and wakefulness. The level of salivary cortisol and muscular activity (EMG) will also be evaluated.|f|f|f|t
34053463|NCT01148303|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34053464|NCT00482404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34053465|NCT04471233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Care providers, and investigators will all be blinded to patient group identity.|Intervention is preoperative and 14 days postoperatively. Patients will be assigned to either multimodal analgesia regimen. No crossing over of patients will occur.|f|t|t|t
34053466|NCT05673837|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053467|NCT04019470|||COHORT||PROSPECTIVE|||||||
34053468|NCT06004856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053469|NCT00965978|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053470|NCT01120886|||COHORT||PROSPECTIVE|||||||
34157113|NCT05998382|NA|SINGLE_GROUP||TREATMENT||NONE||It will be realized with the participation of 24-72 months old children with autism spectrum disorder and their parents who were exposed to earthquake. The program will be announced via social media. After the applicants are evaluated, the families who will participate in the program will be given detailed information about the study and informed consent will be obtained. Before the training begins, families will be asked to fill out the Sociodemographic Data Form, Social Communication Checklist-Revised-Preschool Turkish Version, Depression Anxiety Stress Scale, ½-5 years old Child Behavior Checklist. Families will participate in the training program that will last 6 weeks. At the end of the 6th week, families will be asked to fill in the Social Communication Checklist-Revised-Preschool Turkish Version, Depression Anxiety Stress Scale, ½-5 years old Child Behavior Checklist Scale again. The change from time t1-baseline to time t2-6 weeks later was calculated by arithmetic method.||||
34157114|NCT00280085|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157115|NCT04091243|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open randomized parallel group controlled trial||||
34157116|NCT01750723|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157117|NCT02599233|||COHORT||PROSPECTIVE|||||||
34157118|NCT02503501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157119|NCT01357252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157120|NCT01439477|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34157121|NCT06245382|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|This will be a double-blinded design where the product (experimental of control) will be randomly assigned and given to the participant by a third party individual.|Individuals will be randomly assigned to either an experimental or a control condition.|f|f|t|f
34157122|NCT01810718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157123|NCT00544427|||CASE_ONLY||PROSPECTIVE|||||||
34157124|NCT06389851|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study evaluates the effects on NAFLD, Intestinal Integrity and Microbiota of a diet enriched with tomatoes compared to a diet without tomatoes||||
34157125|NCT02956187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157126|NCT01088620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157127|NCT05846555|||COHORT||PROSPECTIVE|||||||
34157128|NCT02105675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157129|NCT05352425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157130|NCT06576206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the the both group about treatment|it will be randomized control trial in which non probability convenient sampling will be used. Two groups of age 6-12 will be formed in which participants will be randomly divided. Group A will receive conventional physical therapy exercise program including core strengthening, balance and coordination exercise, fine motor activities and group b will receive BIN therapy and finger gnosia|t|f|f|f
33741500|NCT04511715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33741501|NCT05331183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053471|NCT00638521|||COHORT||PROSPECTIVE|||||||
34053472|NCT04324346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34053473|NCT01245543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053474|NCT01564888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053475|NCT01873456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053476|NCT04578834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053477|NCT06621849|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053478|NCT00673751|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34053479|NCT00510913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053480|NCT05098119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053481|NCT04818606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|RAs recruited onto the study team to conduct study visits will not have access to information regarding participant group assignment. Study leads providing the intervention will have the opportunity to run baseline participant visits but will not be allowed to run follow-up study visits for participants in any cohort to which they have delivered an intervention. The Principal Investigator and statistician will be completely blinded to group assignments|Control Group = treatment as usual (TAU) Intervention Group = 8-week virtual mindfulness session|f|f|t|t
33741502|NCT03286959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33741503|NCT02641080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741504|NCT03230279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Study Population: Chronic SIJ dysfunction patients presenting at selected Ochsner Health System healthcare centers~Recruiting mode: Participation will be offered by the principal investigator or the sub-investigators during an outpatient visit in the neurosurgery or pain management clinic."|f|f|f|t
33741505|NCT01764334|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Blinding of FFR result|Diagnostic intervention using fractional flow reserve|t|t|t|t
33845835|NCT02964325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Though this is not a blinded study, treatment assignment is obtained through electronic system and should not be shared those performing the primary outcome assessment or assessors of adverse events.||f|f|t|t
33845836|NCT00294606|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33845837|NCT02450045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845838|NCT03943472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33845839|NCT01821352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33845840|NCT00475124|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33845841|NCT06378359|||COHORT||PROSPECTIVE|||||||
33845842|NCT00399191|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845843|NCT05415670|||COHORT||PROSPECTIVE|||||||
33845844|NCT00465998|||CASE_ONLY||PROSPECTIVE|||||||
33845845|NCT06417697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845846|NCT00446043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845847|NCT05939232|||COHORT||PROSPECTIVE|||||||
33845848|NCT03390582|||COHORT||CROSS_SECTIONAL|||||||
34157131|NCT02140749|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34157132|NCT01680744|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34157133|NCT00139919|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33845849|NCT01979627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157134|NCT02233855|||COHORT||PROSPECTIVE|||||||
33845850|NCT04142229|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover Assignment||||
33845851|NCT03206892|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|using sequentially numbered, opaque sealed enveloped; each envelope contains the method of intervention according to the random sequence and will be opened just before the intervention.|women fulfilled the inclusion criteria and consented will be included in the study and randomly assigned into two groups using computer random sequence generator.|t|f|f|t
34157135|NCT04659525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157136|NCT06362551|||CASE_ONLY||RETROSPECTIVE|||||||
34157137|NCT05539313|||COHORT||PROSPECTIVE|||||||
34157138|NCT01456312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845852|NCT05774834|||COHORT||CROSS_SECTIONAL|||||||
34157139|NCT02205242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157140|NCT04085757|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157141|NCT04053309|||COHORT||PROSPECTIVE|||||||
34157142|NCT05432986|||COHORT||PROSPECTIVE|||||||
34157143|NCT01506999|||COHORT||PROSPECTIVE|||||||
34157144|NCT05043389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157145|NCT00982839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157146|NCT05335941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157147|NCT05431504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157148|NCT04120363|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157149|NCT01815840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157150|NCT03458650|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34157151|NCT03637569|||COHORT||PROSPECTIVE|||||||
34157152|NCT03843983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157153|NCT04741490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053482|NCT06665594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053483|NCT01240980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157154|NCT02085109|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34157155|NCT05002179|RANDOMIZED|PARALLEL||PREVENTION||NONE||Monocentric, 2-armed, randomized, open-label, no-treatment-controlled,||||
34157156|NCT03308994|||COHORT||OTHER|||||||
34157157|NCT00492336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157158|NCT05389176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157159|NCT02624453|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34157160|NCT02736916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157161|NCT03105349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157162|NCT02484352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157163|NCT00214006|||CASE_ONLY||PROSPECTIVE|||||||
34157164|NCT01459744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34157165|NCT01646606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34157166|NCT01629953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157167|NCT01516463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157168|NCT00795301|RANDOMIZED|||TREATMENT||||||||
34157169|NCT01372332|||CASE_CONTROL||PROSPECTIVE|||||||
34157170|NCT03507010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157171|NCT05150717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157172|NCT02186678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157173|NCT05604742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157174|NCT01870726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157175|NCT03636646|||COHORT||RETROSPECTIVE|||||||
34157176|NCT03388047|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34157177|NCT02854020|||COHORT||RETROSPECTIVE|||||||
34157178|NCT02462018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157179|NCT04557501|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157180|NCT04440657|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157181|NCT00006249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157182|NCT06017791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157183|NCT01092910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741506|NCT00338026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741507|NCT02687334|||COHORT||PROSPECTIVE|||||||
33741508|NCT02908269|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845853|NCT06400940|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, post-registration, interventional, randomized, in parallel groups,||||
33845854|NCT01360710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845855|NCT02880540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845856|NCT04494854|||COHORT||PROSPECTIVE|||||||
33845857|NCT03093376|NA|SINGLE_GROUP||TREATMENT||NONE||Child participants receive effortful control (EC) training.||||
33845858|NCT04714749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845859|NCT02021552|||COHORT||PROSPECTIVE|||||||
33845860|NCT03667430|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33845861|NCT03949153|NA|SINGLE_GROUP||OTHER||NONE||||||
33845862|NCT05559762|||COHORT||PROSPECTIVE|||||||
33845863|NCT03250923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845864|NCT03922516|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33845865|NCT02541877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845866|NCT05833490|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|participants will be blind to the experimental condition.||t|f|f|f
33845867|NCT02781090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845868|NCT00045227|RANDOMIZED|||TREATMENT||||||||
33845869|NCT06610747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978050|NCT01890382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978051|NCT02624843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978052|NCT03467568|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Salt / placebo will be consumed by capsule under a double blind procedure|The study has four arms. Salt alone; salt plus water; placebo alone, placebo plus water|t|f|t|f
33978053|NCT02704351|||COHORT||RETROSPECTIVE|||||||
34157184|NCT01013857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157185|NCT04912817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A pilot RCT (1:1:1 group allocation) will be used to examine the feasibility of the trial protocol for a definitive trial into the effectiveness of Off-the-shelf VR, Custom VR (Fruity Feet) and Standard Virtual PT (SVPT) in adolescents with chronic pain undergoing functional rehabilitation at home.|t|f|f|f
34157186|NCT00669383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157187|NCT05171712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157188|NCT02879084|||COHORT||PROSPECTIVE|||||||
34157189|NCT05240625|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The subject and the pathologist who performs the histopathological review will be blinded to the received procedure, while the operator for colonoscopy will not be blinded to the study arm assigned to the subject.||t|f|f|t
34157190|NCT04676035|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157191|NCT02245594|||COHORT||PROSPECTIVE|||||||
34157192|NCT06172075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157193|NCT06408012|||COHORT||CROSS_SECTIONAL|||||||
34157194|NCT05268952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157195|NCT03617146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the behavioral intervention, neither participants nor clinic staff can be blinded to allocation. However, to avoid bias in assessing outcomes, the analyst who will abstract the outcomes data from the electronic health record will not have access to information about the allocation. Hence retrieval of data on baseline and follow up diabetes distress scores, HbA1c, and diabetes self-management behaviors, and the creation of the analysis dataset will be done without knowledge or consideration of allocation status.|Two-arm parallel randomized controlled trial|f|f|f|t
34157196|NCT02774369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157197|NCT06584149|||COHORT||PROSPECTIVE|||||||
34157198|NCT03220386|NA|SINGLE_GROUP||PREVENTION||NONE||Patients screened positive for nasal MSSA or MRSA colonization during their treatment in the emergency department receive a standardized decolonization Treatment (Octinidin nasal ointment and skin washing)||||
34157199|NCT03330795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157200|NCT05582941|||CASE_CONTROL||RETROSPECTIVE|||||||
33978054|NCT00998699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978055|NCT01200472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157201|NCT06095609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study retrospectively reviewed the medical record from the medical team. Patients before 2019/01/01 who didn't receive physiotherapy are regarded as control group. Patients after 2019/01/01 are assigned to the experiment group.||||
34157202|NCT04382222|||COHORT||RETROSPECTIVE|||||||
34075838|NCT04242979|NA|SINGLE_GROUP||SCREENING||NONE||"Tool (I):~An interview questionnaire(in English) sheet for the physicians will be carried out evaluating :~1. the use of albumin in validated indications.~2. the prescriptions of albumin for non validated clinical situations.~TOOL (II):~Designed evidence-based indications for HA use supported by the international guidelines.~It includes general information about albumin prescription, mechanism of action of albumin in liver cirrhosis, prevention of PPCD, prevention of renal failure after SBP, diagnosis of HRS, treatment of HRS, other potential clinical indication for albumin."||||
34157203|NCT04523961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33845870|NCT02133209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845871|NCT05253495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845872|NCT01215188|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978056|NCT00602329|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33978057|NCT01834963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978058|NCT04815902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33978059|NCT01586858|||COHORT||PROSPECTIVE|||||||
33978060|NCT01202747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978061|NCT00585780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization into Prazosin/Placebo treatment was conducted by the Yale Stress Center biostatistician using an Urn randomization procedure that balanced groups on gender, age, nicotine smoking status, education years and lifetime history of DSM-IVTR anxiety disorders, including Post Traumatic Stress Disorder (PTSD). Random assignment of each patient was provided to the Yale Investigational Drug Service (IDS) Pharmacist, who formulated identical, matched tablets of Prazosin and Placebo, and provided dosing in weekly blister packs labeled by day and time of dosing for each subject to study staff for dispensing. All study personnel, including investigators, physicians, study staff and patients remained blind to medication group.|Interaction effects of Alcohol withdrawal distress with Prazosin versus Placebo effects during the trial.|t|t|t|f
33978062|NCT04128007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978063|NCT06250595|||CASE_CONTROL||OTHER|||||||
33978064|NCT00147381|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978065|NCT01512043|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33978066|NCT01785836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075839|NCT04312243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075840|NCT02106780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075841|NCT01675505|||COHORT||PROSPECTIVE|||||||
34075842|NCT02809924|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075843|NCT01736735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157204|NCT03455816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157205|NCT04927403|||COHORT||PROSPECTIVE|||||||
33845873|NCT02901158|||COHORT||PROSPECTIVE|||||||
33845874|NCT05106413|NA|SINGLE_GROUP||OTHER||NONE||||||
33845875|NCT00857129|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33845876|NCT05978973|NA|SINGLE_GROUP||OTHER||NONE||||||
33845877|NCT01887886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845878|NCT00254631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33845879|NCT03970655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33845880|NCT00621075|||COHORT||RETROSPECTIVE|||||||
33845881|NCT04668404|||CASE_ONLY||PROSPECTIVE|||||||
33845882|NCT00561366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845883|NCT01423227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845884|NCT05010239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel group, single-blinded, randomized controlled trial||||
33845885|NCT00998790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845886|NCT00224679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33845887|NCT02766465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are enrolled without a known donor. All patients have 180 days from confirmation of eligibility to confirm a donor. Patients with a donor will be assigned to the Donor Arm and receive HCT; patients without a donor will be assigned to the no donor arm and continue receiving standard of care for their SCD.||||
33845888|NCT00151281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845889|NCT06129578|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33978067|NCT00560235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978068|NCT02048865|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978069|NCT03056274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978070|NCT04572100|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33978071|NCT02222428|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978072|NCT02314338|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33978073|NCT04438356|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||wait list control group RCT||||
33978074|NCT05450770|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Category 2, multi-centric intervention research comparing 2 parallel groups of 40 HIV + subjects and 20 HIV- subjects included in the ANRS EP46 NOVAA trial.||||
33978075|NCT05390346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978076|NCT03500848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978077|NCT05717699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978078|NCT04669210|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978079|NCT01694485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978080|NCT01850290|||CASE_ONLY||PROSPECTIVE|||||||
33978081|NCT05097872|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978082|NCT06544304|NA|SINGLE_GROUP||OTHER||NONE||||||
33978083|NCT02184728|NA|SINGLE_GROUP||||NONE||||||
33978084|NCT02041702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned to one of two groups in parallel for the duration of the study||||
34157206|NCT05805891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845890|NCT04289012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157207|NCT03774784|||COHORT||PROSPECTIVE|||||||
34053484|NCT06621745|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study used a randomized experimental design to test the effectiveness of a gratitude intervention smartphone app. Participants were asked to answer 90 questions in an online survey on emotional well-being and personality traits at the beginning and end of the three-week research period. The intervention group used the Gratitude Intervention App (GIA), and the Predicting Risk and Outcomes of Social InTerActions (PROSIT) app, which is a mobile sensing app. All participants used the PROSIT app in the background of their mobile devices throughout the three-week study period. In addition, those allocated to the intervention group practiced gratitude intervention tasks during the same three-week period using the GIA app. This study was approved by the Dalhousie University Research Ethics Board (REB 2021-5460).||||
34053485|NCT03394898|||COHORT||PROSPECTIVE|||||||
34053486|NCT04427163|||OTHER||PROSPECTIVE|||||||
34157208|NCT06514313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157209|NCT01768195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157210|NCT02384018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34157211|NCT05872347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157212|NCT04387578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assignment|f|f|f|t
34157213|NCT00511238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157214|NCT00727155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157215|NCT01106508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157216|NCT04797351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the intervention participants will be interviewed by a health professional, not involved in the study, to assess feedback - regarding facilitators, program sessions, interest and usefulness.|"Participants are randomly distributed into 2 groups:~Experimental Group: Treatment as Usual (Public health services and psychiatric support) + 1 Pre-session + 12 session DBT Skills Group Experimental Group Condition 2: Specialized support (Psychoeducation in Bipolar Disorder + Psychological support) + (1 Pre-session) 12 session DBT Skills group + TAU Control Group Condition 1: TAU + Waiting List"|f|f|f|t
34157217|NCT03400163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157218|NCT00856544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157219|NCT00422383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157220|NCT04527146|RANDOMIZED|FACTORIAL||OTHER||NONE||Enrolled participants will be randomized into one of 4 groups based on pre- and post-genetic test counseling: (1)IMAGINE-PD/Virtual, (2)IMAGINE-PD/Telephone, (3)Virtual/Virtual, and (4)Virtual/Telephone.||||
34157221|NCT03203434|||COHORT||PROSPECTIVE|||||||
34157222|NCT02815423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157223|NCT02476695|||COHORT||PROSPECTIVE|||||||
34157224|NCT04499287|RANDOMIZED|CROSSOVER||OTHER||NONE||randomized, controlled, crossover||||
34157225|NCT02024724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157226|NCT00601549|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34157227|NCT00894946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157228|NCT02389400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157229|NCT05222126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845891|NCT00503100|||CASE_CONTROL||PROSPECTIVE|||||||
33845892|NCT02874417|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053487|NCT03481374|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34053488|NCT06043960|||OTHER||OTHER|||||||
34053489|NCT04932031|||COHORT||PROSPECTIVE|||||||
34157230|NCT00615992|||COHORT|||||||||
34157231|NCT04600934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157232|NCT02229409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053490|NCT02557932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053491|NCT02704572|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053492|NCT06600152|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomization model.||||
34053493|NCT06667427|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053494|NCT00639535|||CASE_ONLY||PROSPECTIVE|||||||
34157233|NCT00240669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157234|NCT00696839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157235|NCT05854342|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34157236|NCT01302197|||OTHER||PROSPECTIVE|||||||
34157237|NCT04959305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157238|NCT05740306|||COHORT||PROSPECTIVE|||||||
34157239|NCT05240001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157240|NCT03778502|||COHORT||PROSPECTIVE|||||||
34157241|NCT04159129|||COHORT||PROSPECTIVE|||||||
34157242|NCT06366087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157243|NCT00995423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157244|NCT00169208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053495|NCT06520982|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157245|NCT06160492|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized, open, parallel-group, multicenter, conventional treatment-controlled trial||||
34157246|NCT03560167|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34157247|NCT03223259|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34053496|NCT06096207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053497|NCT02691013|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34053498|NCT05835011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157248|NCT03360799|||COHORT||PROSPECTIVE|||||||
34157249|NCT03554447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157250|NCT03719911|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm 24-week pre-post study||||
34157251|NCT05405140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157252|NCT04228601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157253|NCT03927144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157254|NCT04894890|||COHORT||PROSPECTIVE|||||||
34157255|NCT02657447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157256|NCT02829580|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741509|NCT01722331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741510|NCT01546415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741511|NCT04871139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741512|NCT01368458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741513|NCT01409694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741514|NCT02199782|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34053499|NCT03956680|NA|SEQUENTIAL||TREATMENT||NONE||||||
34053500|NCT01058616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053501|NCT03132064|||COHORT||PROSPECTIVE|||||||
34053502|NCT03995589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053503|NCT03206047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053504|NCT06621394|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|data analysis will be conducted blinded|2x2 factorial design|f|f|f|t
34053505|NCT06323746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Permuted block randomization to ensure an equal number of allocations in each of the two groups (intervention and wait list group). Each random block will be stored in opaque sealed envelopes consecutively numbered with a third researcher. Once each participant officially joins the study the researcher will open the subsequent envelop.||f|f|f|t
34053506|NCT04211532|||COHORT||PROSPECTIVE|||||||
34053507|NCT00278122||||TREATMENT||NONE||||||
34053508|NCT01608087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34053509|NCT01767506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053510|NCT03960866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34053511|NCT05189301|||CASE_CONTROL||PROSPECTIVE|||||||
34053512|NCT04071548|NA|SINGLE_GROUP||TREATMENT||NONE||Single site interventional exercise study||||
34053513|NCT04314531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053514|NCT06621368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053515|NCT05796284|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34053516|NCT06246123|||COHORT||PROSPECTIVE|||||||
34053517|NCT06368895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053518|NCT04158895|||COHORT||PROSPECTIVE|||||||
34053519|NCT03400176|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053520|NCT05033730|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34053521|NCT02009397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053522|NCT03933579|||COHORT||PROSPECTIVE|||||||
34053523|NCT04293913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was planned as a randomized controlled clinical trial with two arms: Patients who had undergone cardiac surgery were randomly assigned to intervention (illustrated communication material were used) and control (routine methods in the communication were used) groups when they were connected to the mechanical ventilator.||||
34053524|NCT05036577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053525|NCT05657990|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34053526|NCT05785585|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053527|NCT02884557|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34053528|NCT02490462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053529|NCT05738967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053530|NCT02396420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053531|NCT00581321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053532|NCT05637047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053533|NCT06649318|||CASE_CONTROL||PROSPECTIVE|||||||
34053534|NCT04450784|||COHORT||OTHER|||||||
34053535|NCT06364501|NA|SEQUENTIAL||TREATMENT||NONE||||||
34053536|NCT00207558|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34053537|NCT06018025|||COHORT||PROSPECTIVE|||||||
34053538|NCT04481230|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||dose escalation model||||
34053539|NCT05996835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053540|NCT03339193|||COHORT||PROSPECTIVE|||||||
34053541|NCT02041143|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34053542|NCT04182269|||OTHER||PROSPECTIVE|||||||
34053543|NCT06602466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34053544|NCT04040452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Double-blind|Randomized, placebo-controlled|t|t|t|f
34053545|NCT04901351|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34053546|NCT01539551|||COHORT||PROSPECTIVE|||||||
34053547|NCT06660745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||50 children and adolescents with CF aged between 9-17 participated in this study.The subjects were assigned to two groups randomly, based on their medical record numbers, with even numbers placed in the intervention group and odd numbers in the control group. intervention group received twelve-week telenursing training via the SendBig website and Skype messenger and control received routine care.|t|f|f|f
34053548|NCT06667037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053549|NCT05290909|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34053550|NCT06647589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053551|NCT05390151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053552|NCT00405522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053553|NCT00154778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053554|NCT05645419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053555|NCT03999736|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34053556|NCT01345981|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34053557|NCT05888389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053558|NCT03775863|||COHORT||PROSPECTIVE|||||||
34053559|NCT02372929|||CASE_ONLY||PROSPECTIVE|||||||
34053560|NCT02898727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075844|NCT00763789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34075845|NCT02408731|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34075846|NCT06579677|||COHORT||PROSPECTIVE|||||||
34075847|NCT02121171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075848|NCT01678118|||CASE_ONLY||RETROSPECTIVE|||||||
34075849|NCT06611943|||OTHER||CROSS_SECTIONAL|||||||
34075850|NCT01754064|||COHORT||PROSPECTIVE|||||||
33950167|NCT06532162|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"We will employ two providers to ensure a double-blinded set-up. The first provider (Provider A) will open the allocation envelopes without the presence of the participant or second provider (Provider B).~Provider A will then enter the patient's room and introduce themselves. They will place the speculum, and administer either the intervention, placebo, or control and then leave the room after injection-related bleeding has stopped. After 3 minutes, the second provider (Provider B) will enter the room to place the IUD (including sounding and tenaculum placement) and will be unaware of the participant's treatment arm.~A standardized script will be used with all participants: You may or not may feel a poke.~Both lidocaine and the control (normal saline) are odorless and clear, minimizing the risk of unblinding. All data will remain blinded until data analysis."|"The proposed study is a double-blind, triple arm, placebo-controlled randomized clinical trial. Participants will be recruited from Mount Sinai Hospital outpatient gynecology clinics. Recruitment, consent, randomization, procedure, and post-procedure survey will occur during the same visit. Each participant will be randomly assigned to one of three arms:~1. Intervention (10 cc 1% lidocaine paracervical block)~2. Placebo (10 cc paracervical injection of normal saline)~3. Control (gently tapping the cervicovaginal junction with a capped needle)"|t|f|t|t
33950168|NCT06019169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot study, prospective, monocentric controlled in open label, Randomization ratio 1:1||||
33950169|NCT00645606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950170|NCT05287165|NA|SEQUENTIAL||TREATMENT||NONE||||||
33950171|NCT04188613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33950172|NCT02334891|||COHORT||PROSPECTIVE|||||||
33950173|NCT04131439|||CASE_ONLY||PROSPECTIVE|||||||
33950174|NCT03484572|||CASE_ONLY||CROSS_SECTIONAL|||||||
33950175|NCT02883400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950176|NCT04129645|||COHORT||PROSPECTIVE|||||||
33741515|NCT06196723|||COHORT||RETROSPECTIVE|||||||
33950177|NCT01411124|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33950178|NCT03218657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950179|NCT04115501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research fellows and ICU physicians who record and assess the primary and secondary outcomes will be blinded to the group assignment. The principal investigator (PI) of every center and the physicians who conduct the anesthesia and monitoring intraoperatively in operating room are unblinded.||f|f|f|t
33950180|NCT03199989|RANDOMIZED|PARALLEL||TREATMENT||NONE||a prospertive randomized clinical trial||||
33950181|NCT01967446|||CASE_CONTROL||PROSPECTIVE|||||||
33950182|NCT00889928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950183|NCT02903849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33950184|NCT04128059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This clinical trial is designed as a double blind randomized placebo-controlled study|Parallel Assignment|t|f|t|f
33950185|NCT01919437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950186|NCT04136717|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950187|NCT04761926|NA|SINGLE_GROUP||OTHER||NONE||||||
33950188|NCT02713100|||OTHER||PROSPECTIVE|||||||
33950189|NCT06023485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33950190|NCT01361308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950191|NCT00016731|||CASE_CONTROL||RETROSPECTIVE|||||||
34053561|NCT06359171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigating physician who will carry out the inclusion visit will know the result of the randomization which will be carried out during the consultation. The second evaluator, who will carry out the end-of-study visit, will not know the patient's group. As a result, the assessment will be neutral and the second assessor will evaluate the patient without being influenced by the study group.|"The investigators plan to conduct a multicenter, prospective, comparative, randomised trial. Participants will be randomized to one of two groups: control or experimental. In each group (control or experimental), each participant will be able to use the application for a period of 6 months.~* Control group: physician's advice with examples of self-exercise (knee osteoarthritis booklet) + prescription for 12 physiotherapy sessions + delivery of a GARMIN connected bracelet.~* Intervention group: download the application + adapted physical activity session with an APA/physiotherapist + delivery of the knee osteoarthritis booklet + prescription for 12 physiotherapy sessions + delivery of a GARMIN connected bracelet."|f|f|t|f
34053562|NCT00416130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053563|NCT05451784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053564|NCT06174038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34053565|NCT05246189|||COHORT||RETROSPECTIVE|||||||
34053566|NCT05983120|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34053567|NCT04866628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053568|NCT04009668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053569|NCT01341483|||COHORT||PROSPECTIVE|||||||
34053570|NCT03909919|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34053571|NCT01337713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34053572|NCT06221488|||COHORT||PROSPECTIVE|||||||
34053573|NCT03777332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053574|NCT00342563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053575|NCT01949012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053576|NCT04828265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053577|NCT03452384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34053578|NCT03064685|||CASE_CONTROL||RETROSPECTIVE|||||||
33741516|NCT02621905|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33741517|NCT05090501|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will not be informed of the opposite group details, and it is not expected that they meet other participants during the meeting or intervention periods.|This trial is designed as a randomised, controlled, participant blinded, superiority trial with two groups. Randomization will be performed as block randomization with a 1:1 allocation.|t|t|f|f
33741518|NCT03735966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741519|NCT04557722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741520|NCT05590091|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33741521|NCT06534177|||CASE_CONTROL||PROSPECTIVE|||||||
33950192|NCT03071952|||CASE_CROSSOVER||PROSPECTIVE|||||||
33950193|NCT03085940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950194|NCT04847427|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33950195|NCT05383157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950196|NCT04600206|||COHORT||PROSPECTIVE|||||||
33950197|NCT05781204|||COHORT||PROSPECTIVE|||||||
33950198|NCT02059681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950199|NCT00776828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950200|NCT00473928|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33950201|NCT02122874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33950202|NCT03091907|||CASE_CONTROL||RETROSPECTIVE|||||||
33950203|NCT00906776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950204|NCT03081130|||COHORT||PROSPECTIVE|||||||
34157257|NCT02908750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157258|NCT02820025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157259|NCT01480310|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34157260|NCT03043391|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib study to evaluate feasibility, safety, and preliminary evidence of efficacy of the optimal adult dose in a pediatric population||||
34157261|NCT06130592|RANDOMIZED|PARALLEL||OTHER||NONE||study prospective,randomized ,two groups (low risk of AMC vs hight risk of AMC), multicentre||||
34157262|NCT00177255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157263|NCT03305315|||OTHER||PROSPECTIVE|||||||
33741522|NCT02395354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157264|NCT01305785|||COHORT||PROSPECTIVE|||||||
34157265|NCT06446791|NA|SINGLE_GROUP||OTHER||NONE||"Girls with congenital webbed neck deformity underwent the same surgical technique.~Outcomes were analysed with long-term follow-up."||||
34157266|NCT02082704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33741523|NCT02473614|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33741524|NCT01841749|NA|SINGLE_GROUP||||NONE||||||
34157267|NCT04554771|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized phase II proof-of-concept study with tocilizumab and standard of care paclitaxel, carboplatin and radiation followed by surgical resection of the oesophagus for patients with surgically resectable adenocarcinomas of the oesophagus or oesophageal junction. Patients will be grouped for serum ADAM12 with a cutoff of 203 ng/mL. Patients in both groups will be randomized to receive tocilizumab 8mg/kg on day 1, 15 and 29 or not in addition to paclitaxel 50mg/m2, carboplatin AUC 2 on day 1, 8, 15, 22 and 29 and radiation 41.4 Gy in 23 fractions. Surgery will be planned approximately in week 13-15, which is 8 to 10 weeks after the end of chemoradiation.||||
34157268|NCT06100393|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Order of IMD and comparator is blinded.|||||
33741525|NCT00363714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157269|NCT05248139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33741526|NCT06038773|||COHORT||RETROSPECTIVE|||||||
34157270|NCT04735991|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34157271|NCT05226299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to group assignment (active treatment vs. placebo).|One group will receive the placebo treatment while the second group receives the active treatment.|t|f|f|f
34157272|NCT03969927|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participant and the research assistant providing the training are not masked. The rest of the study conductors are masked regarding participant arm allocation.||f|f|t|t
34157273|NCT06395532|||COHORT||PROSPECTIVE|||||||
34157274|NCT05821218|||OTHER||OTHER|||||||
33741527|NCT00875394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741528|NCT04806815|||COHORT||OTHER|||||||
34157275|NCT04386694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (PMBT/sMF or placebo) and will be instructed not to inform the patients or other researchers as to the type of treatment (PMBT/sMF or placebo). Therefore, the therapist responsible for the treatment, the investigators and the outcome assessors will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (PBMT/sMF or placebo).||t|t|t|t
34157276|NCT02675530|NA|SINGLE_GROUP||||NONE||||||
34157277|NCT06011369|RANDOMIZED|PARALLEL||TREATMENT||NONE||PROSPECTIVE, CONTROLLED, RANDOMIZED||||
33950205|NCT03358017|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After providing informed consent for study participation, patients fulfilling the eligibility criteria will be randomized to receive standard anthracyclines/taxanes based neoadjuvant chemotherapy (ARM A) or the combination of zoledronate and atorvastatin associated with the above mentioned neoadjuvant chemotherapy (ARM B).~Randomization will use a biased-coin minimization procedure having as stratification factor the type of neoadjuvant chemotherapy chosen by the center and the p53 level in the FFPE diagnostic core biopsy determined by IHC (\<30% vs \>30% vs unknown).~Randomization and e-CFR will be handled by HeavyBase , an Open Source push based peer to peer electronic data management system."||||
33950206|NCT02648646|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950207|NCT02679924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950208|NCT06358300|||CASE_CONTROL||PROSPECTIVE|||||||
33950209|NCT03740854|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33950210|NCT03799237|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster Randomized Controlled Trial||||
34157278|NCT02225834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157279|NCT05178446|||OTHER||RETROSPECTIVE|||||||
34157280|NCT02161380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157281|NCT03437577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157282|NCT03785964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"For the double-blind phase, the participant, investigator, and all other clinical site personnel will be blinded to the assigned treatment allocation. All sponsor personnel will also be blinded except for the sponsor's quality assurance designee(s), safety designee(s), and clinical supply material designee(s).~Once participants are eligible, they will roll into the open-label phase where they will receive nirogacestat. In the open-label phase, the participant, investigator, all other clinical site personnel, and the sponsor are not blinded."||t|t|t|t
34157283|NCT00187473|||COHORT||OTHER|||||||
33950211|NCT04561700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34157284|NCT01309776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157285|NCT06208774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157286|NCT03328351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||triple-blind (The researcher was blinded to the outcome measures, whereas the assessor, who performed the outcome measures was blinded to the patient groups. The patient was blinded to treatment)|t|f|f|t
34157287|NCT04000581|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741529|NCT02409485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950212|NCT00003701|RANDOMIZED|||TREATMENT||||||||
33950213|NCT03163823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950214|NCT01598246|||CASE_CONTROL||PROSPECTIVE|||||||
33950215|NCT02869204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950216|NCT02349100|||CASE_CONTROL||PROSPECTIVE|||||||
33950217|NCT00720668|||CASE_ONLY||PROSPECTIVE|||||||
33950218|NCT05936775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950219|NCT04085926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary outcome (ulcer healing) will be assessed by a cast technician not blinded to group allocation, but it will be verified from a photograph by a blinded assessor. The statistician comparing the primary outcome between groups will be blinded to group allocation.||f|f|t|t
33950220|NCT01629121|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33950221|NCT05144971|||COHORT||PROSPECTIVE|||||||
33950222|NCT01538602|||CASE_ONLY||PROSPECTIVE|||||||
33950223|NCT05186376|||CASE_ONLY||RETROSPECTIVE|||||||
33950224|NCT06107465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950225|NCT04893915|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950226|NCT00037908|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33950227|NCT00900328|||COHORT||RETROSPECTIVE|||||||
33950228|NCT05461742|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950229|NCT01269528|||CASE_CONTROL||PROSPECTIVE|||||||
33950230|NCT03445325|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950231|NCT06286878|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Single-center, prospective, randomized, double-blind, placebo-controlled clinical study.|t|f|t|f
33950232|NCT02681991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950233|NCT03174457|||CASE_ONLY||PROSPECTIVE|||||||
33950234|NCT00382434|||||PROSPECTIVE|||||||
33950235|NCT00118209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950236|NCT04099589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950237|NCT04992091|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33950238|NCT04189393|||COHORT||PROSPECTIVE|||||||
33950239|NCT06439186|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950240|NCT05541107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950241|NCT01311531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950242|NCT02035865|||COHORT||CROSS_SECTIONAL|||||||
34053579|NCT02721810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34053580|NCT01628653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053581|NCT02151734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053582|NCT03589638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, Randomized, double blind Clinical Trial|t|f|f|f
34053583|NCT05320783|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34053584|NCT01178879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053585|NCT06260410|||COHORT||PROSPECTIVE|||||||
34053586|NCT05696925|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34053587|NCT04369131|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will engage in three baseline sessions to document blood pressure fluctuations associated with central nervous system dysregulation when changing from a sitting or supine position to a standing position involving the use of a head-up tilt table and no FES. Then, participants will engage in tilt table sessions in which the researchers randomly alternate the placement of FES pads across four conditions: (a) no FES, (b) calves only FES, (c) quads and abdominal only FES, and (d) calves, quads, and abdominal FES. Sessions will occur three to four times weekly until a participant demonstrates no OH upon tilt table adjustment to 90° (i.e., upright position) or the participant discharges from Quality Living, Inc., whichever comes first.||||
34053588|NCT06178731|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a non-blinded, randomized sham-controlled trial for effectiveness and feasibility of virtual reward reality training and rTMS for MDD with two arms. Patients with MDD who meet inclusion and exclusion criteria will be identified and recruited from the practices of Sunnybrook psychiatrists. Subjects will undergo either: i) VR RT + rTMS (n = 17) or ii) VR sham + rTMS (n = 17). Each treatment session involves: 12-15 min VR viewing, 15 min descriptive and imaginal recounting followed immediately by 3 min rTMS delivery with iTBS to the left DLPFC. The study will proceed according to the schedule laid out below. Both patients and treating team will be aware of all treatment parameters at all times.||||
34053589|NCT02796352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053590|NCT05174949|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This sham-controlled cross-over study design will include three visits: 1) anodal stimulation targeting ipsilesional primary motor cortex, 2) cathodal one at the contralesional premotor cortex, 3) a sham stimulation visit. The sequence of the stimulations will be randomized and double-blinded. After each intervention, there will be at least 2 weeks wash-out period before participants receive the next intervention and assessments.|t|f|f|t
34053591|NCT01665820|||COHORT||PROSPECTIVE|||||||
34053592|NCT05451550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053593|NCT06127524|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||nursing home residents residing at any time in the facility during a 12 month baseline followed by 8 month intervention||||
34053594|NCT02589327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053595|NCT01535508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053596|NCT01906021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053597|NCT05219292|||COHORT||PROSPECTIVE|||||||
34053598|NCT00453531|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34053599|NCT01579045|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34053600|NCT04204668|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arm, randomized trial||||
34157288|NCT04638426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053601|NCT06606444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053602|NCT05146739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950243|NCT04283513|NA|SINGLE_GROUP||TREATMENT||NONE||This protocol is an open-label, single-arm, multisite protocol to provide IV ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS).||||
33950244|NCT01545401|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950245|NCT00594009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950246|NCT06470126|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The groups were randomly divided by investigator.|The teeth of the participants were randomly divided into three groups.|f|f|t|f
33950247|NCT05461469|||CASE_ONLY||PROSPECTIVE|||||||
33950248|NCT04899531|||COHORT||PROSPECTIVE|||||||
33950249|NCT05487066|||COHORT||PROSPECTIVE|||||||
33950250|NCT00306800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33950251|NCT04975867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors of neurocognitive outcomes at 1 and 6 months after CO exposure will be blinded to the allocated treatment group.||f|f|f|t
33950252|NCT02198820|||COHORT||PROSPECTIVE|||||||
33950253|NCT00938275|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950254|NCT04595825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053603|NCT06647602|||COHORT||PROSPECTIVE|||||||
34053604|NCT02683655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053605|NCT01630408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053606|NCT00186836|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34053607|NCT05495152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053608|NCT06017752|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34053609|NCT06489327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053610|NCT04921527|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053611|NCT06112158|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Web-supported and face-to-face training on breast cancer information and screening will be provided to the experimental group.and outcome assessments will be performed by a investigator who was blinded to group allocation.|Two groups with randomized controlled trial|t|f|f|f
34053612|NCT06617520|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34053613|NCT06084819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053614|NCT05365646|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34053615|NCT01000532|||COHORT||PROSPECTIVE|||||||
34053616|NCT00740909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053617|NCT03155178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34053618|NCT02718690|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34053619|NCT01895608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053620|NCT05115227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053621|NCT04081025|||COHORT||CROSS_SECTIONAL|||||||
34053622|NCT05639816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are blinded to the treatment|Included patients are randomized to two group, study group and control group an followed up parallelly.|t|f|f|f
34053623|NCT03897374|||CASE_CONTROL||PROSPECTIVE|||||||
34053624|NCT00468754|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34053625|NCT04586738|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Evaluations will be done an outcome assessor that do not know the intervention group||t|t|t|t
34053626|NCT02942381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053627|NCT05629611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053628|NCT00417716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053629|NCT01967706|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34053630|NCT04949750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053631|NCT01216956|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
34053632|NCT01981538|||COHORT||PROSPECTIVE|||||||
34053633|NCT00484562|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053634|NCT01265979|||||PROSPECTIVE|||||||
34053635|NCT05737576|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover Assigned to HR011408 or NovoRapid®|t|f|t|f
34053636|NCT01246349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053637|NCT04441840|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The supplements were delivered in identical containers, each marked with a separate code marked on the outside of the supplement container. Once data collection, data entry, and statistical analysis was completely finished, the study code was broken.||t|f|t|f
34053638|NCT06086561|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053639|NCT05590637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053640|NCT06615518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053641|NCT03499899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053642|NCT04174183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053643|NCT06085443|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053644|NCT03580109|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigator doesn't know the group of randomization of the patient. The spa therapy organisation is managed by the coordination center.|"2 groups:~* Immediate spa therapy: the patient carries out the spa therapy with education therapeutic soon after the enrolment in the study~* Late spa therapy: the patient carries out the spa therapy with education therapeutic after the 6-month follow up"|f|f|t|f
34053645|NCT02554058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053646|NCT05353244|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The Principal Investigator, statisticians, and participants will be blinded to the condition (PrTMS vs Sham). Only the providers of the treatment will be aware of the treatment condition.|"Participants will be randomly assigned to an active or sham intervention group. Each participant will complete 30 PrTMS or sham sessions. Through the course of the 6-week study, participants will be asked to wear a lab-provided sleep tracking ring (Oura).~Each participant, regardless of group, will complete daily and weekly surveys and assessments including a qEEG and cognitive assessments. At the intake, midpoint, and exit, a battery of surveys will be administered as well."|t|f|t|t
34053647|NCT02416128|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34053648|NCT01190267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053649|NCT02529124|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34053650|NCT04738097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34053651|NCT02837939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34053652|NCT05774093|||COHORT||PROSPECTIVE|||||||
34157289|NCT03563196|||COHORT||PROSPECTIVE|||||||
34157290|NCT01185977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741530|NCT01601301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741531|NCT06573099|||COHORT||PROSPECTIVE|||||||
33950255|NCT06505473|||CASE_CONTROL||RETROSPECTIVE|||||||
33950256|NCT06152666|||OTHER||RETROSPECTIVE|||||||
33950257|NCT04701957|RANDOMIZED|PARALLEL||OTHER||SINGLE|recruitment : open medical follow-up : masked dietitians : open||f|f|t|f
33950258|NCT02973282|||COHORT||PROSPECTIVE|||||||
33950259|NCT04177862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950260|NCT05040295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950261|NCT00855634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950262|NCT04105465|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A double blind system was applied. Since randomisation was performed in theatre, the patient was unaware of the side that the PJ device was applied. This was not mentioned in the operation notes either. As a result, the nursing team on the inpatient ward were also blinded to the randomisation.|The trial design was conceived as a single site, double blind, crossover study in which each patient would be their own control would offer the most useful information.|t|f|f|t
33950263|NCT02983357|||CASE_ONLY||PROSPECTIVE|||||||
33950264|NCT02223624|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33950265|NCT00131937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950266|NCT02357017|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33950267|NCT01454037|||COHORT||PROSPECTIVE|||||||
33950268|NCT05227534|NA|SINGLE_GROUP||SCREENING||NONE||||||
33950269|NCT00069069|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33950270|NCT03334201|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-blind|Randomized, single-blind crossover|f|f|t|f
33950271|NCT03896802|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33950272|NCT06355518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950273|NCT05696691|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053653|NCT06668610|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The study will adopt a double-blinded crossover randomised controlled design. The whole intervention will consist of two treatment phases (sham vs real multifocal stimulation) and multiple assessment phases performed before and after each rehabilitation cycle (T1, T2, T3). Recruited participants will be randomly assigned to a SHAM-REAL stimulation group or a REAL-SHAM stimulation group by computer-generated random numbers. Throughout the entirety of the study, all participants will undergo conventional cognitive stimulation therapy, involving paper-and-pencil exercise and computerised activity on several cognitive domains including memory, attention, and executive functions (Bahar-Fuchs et al., 2019; Woods et al., 2012)."|t|f|t|t
34053654|NCT00660933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053655|NCT05015998|||COHORT||RETROSPECTIVE|||||||
34053656|NCT04025411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34053657|NCT01497964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053658|NCT06621160|||OTHER||OTHER|||||||
34053659|NCT06277882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053660|NCT05425459|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34053661|NCT04375722|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Participant, care provider, investigator and outcomes assessor are all blinded. One study team member will be designated as unblinded.|In the within-subject design healthy participants and stroke survivors will receive tACS stimulation at 10 Hz, 40 Hz, and sham settings in a randomized order with \>48 hours washout period in between stimulation sessions.|t|t|t|t
34053662|NCT04248140|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Two exposures (WiFi and sham) are applied in a randomized double-blind counterbalanced cross-over study|t|t|t|t
34053663|NCT06422663|||CASE_ONLY||PROSPECTIVE|||||||
34053664|NCT01443338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053665|NCT00401557|||OTHER||PROSPECTIVE|||||||
34053666|NCT04483375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157291|NCT00573014|||COHORT||PROSPECTIVE|||||||
34157292|NCT01428739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157293|NCT04359485||PARALLEL||OTHER||SINGLE|||t|f|f|f
34157294|NCT06524440|||COHORT||CROSS_SECTIONAL|||||||
34157295|NCT06173908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157296|NCT00293618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157297|NCT05218525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is single-blinded, in which the participants do not know the treatment group that they have been assigned, i.e. the participants do not know if the COPD prediction algorithm runs in the background of their profile or not. The specialized COPD community nurses cannot be blinded, as they need to be trained in the use of the COPD prediction algorithm.|A prospective, parallel two-armed randomized controlled trial|t|f|f|f
34157298|NCT02720406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157299|NCT06013384|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34157300|NCT05603598|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157301|NCT05775731|||COHORT||PROSPECTIVE|||||||
34157302|NCT02124096|||COHORT||PROSPECTIVE|||||||
34157303|NCT03139344|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34157304|NCT03212534|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34157305|NCT00604695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157306|NCT02023684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34157307|NCT05356585|||COHORT||PROSPECTIVE|||||||
34157308|NCT01007838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157309|NCT06077890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34157310|NCT02782221|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34157311|NCT02141360|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157312|NCT03854461|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All outcomes will be conducted blind, including the primary outcome (diet quality score), laboratory analysis and cardiometabolic health marker assessment.|Randomised parallel group dietary intervention: two group.|f|f|f|t
34157313|NCT05670613|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34157314|NCT02842749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157315|NCT00866814|||CASE_ONLY||PROSPECTIVE|||||||
34157316|NCT04854382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34157317|NCT01716780|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34053667|NCT00438737|RANDOMIZED|||TREATMENT||NONE||||||
33741532|NCT05706558|||COHORT||RETROSPECTIVE|||||||
34053668|NCT02926729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053669|NCT04131309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053670|NCT02263248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34053671|NCT05830981|RANDOMIZED|FACTORIAL||OTHER||NONE||A quasi-experimental pretest-posttest design study.||||
34053672|NCT02329210|||COHORT||PROSPECTIVE|||||||
34053673|NCT03475121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053674|NCT01258062|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34053675|NCT03461419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157318|NCT00384332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157319|NCT04072887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157320|NCT01678625|||CASE_CONTROL||PROSPECTIVE|||||||
34053676|NCT06328881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157321|NCT04692532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157322|NCT06524323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157323|NCT05762406|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34157324|NCT01847976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053677|NCT03381300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157325|NCT00304655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157326|NCT06247904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be equally randomized to either the Active rTMS or Sham rTMS group following the Baseline Assessment. Device will be set up to active/sham mode prior to intervention using a unique patient and intervention code by an unblinded study team member. Subjects, outcome assessors and staff administering rTMS intervention (care provider) will be blinded to the device setting (Active/Sham).||t|t|f|t
34157327|NCT01452581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157328|NCT02513576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157329|NCT04651491|||COHORT||PROSPECTIVE|||||||
34157330|NCT06399250|||COHORT||CROSS_SECTIONAL|||||||
34157331|NCT00648557|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34157332|NCT01081899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34053678|NCT04010526|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34157333|NCT00650403|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34157334|NCT01347996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157335|NCT02812719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34157336|NCT03774030|NA|SINGLE_GROUP||OTHER||NONE||a group of hearing-impaired particpants with mild or severe hearing loss||||
34157337|NCT03521245|||CASE_ONLY||RETROSPECTIVE|||||||
34157338|NCT02340416|||COHORT||PROSPECTIVE|||||||
34157339|NCT04706728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|All participants are given a tablet with two playlists to choose from in each arm. Either two playlists with nature sounds, or two playlists with music.|Randomized Controlled Trial (RCT) with three arms, of which one is listening to playlists with sounds from nature for four weeks, one is listening to playlists with expert-curated music for four weeks, one is listening to playlists with expert-curated music for two weeks.||||
34157340|NCT01107847||PARALLEL||DIAGNOSTIC||NONE||||||
34157341|NCT02591485|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34157342|NCT05034601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34157343|NCT00003968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157344|NCT01943591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157345|NCT04680975|NA|SINGLE_GROUP||TREATMENT||NONE||Belumosudil 200 mg PO BID||||
34157346|NCT01372176|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34157347|NCT06325865|||COHORT||CROSS_SECTIONAL|||||||
34157348|NCT02098278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34157349|NCT00307203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157350|NCT06330337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34157351|NCT02146001|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34157352|NCT05906459|||OTHER||PROSPECTIVE|||||||
33741533|NCT05095584|NA|SINGLE_GROUP||PREVENTION||NONE||crosssectional||||
34157353|NCT01932502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157354|NCT05652712|||CASE_CONTROL||RETROSPECTIVE|||||||
33741534|NCT01114646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741535|NCT05814341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157355|NCT00648700|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33741536|NCT04770714|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34157356|NCT06075407|||COHORT||PROSPECTIVE|||||||
34157357|NCT01408459|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33741537|NCT01754558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157358|NCT01439594|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34157359|NCT03009617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34157360|NCT02065817|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157361|NCT00474617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157362|NCT02263443|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34157363|NCT05641636|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053679|NCT00178932|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053680|NCT01450826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053681|NCT01777828|||COHORT||PROSPECTIVE|||||||
34053682|NCT01865669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053683|NCT06137638|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34075851|NCT04579003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know which treatment techniques are given in the specified groups.|Both groups were treated simultaneously with their specified treatment techniques within given duration.|t|f|f|f
34157364|NCT05510336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157365|NCT05921253|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Prospective, randomized, sham controlled, double-blinded study of low-level tragus stimulation vs. sham treatment.|t|t|t|f
34157366|NCT01139177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157367|NCT00486824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157368|NCT04683445|||COHORT||PROSPECTIVE|||||||
34157369|NCT01688115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34157370|NCT01958359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34157371|NCT02805855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157372|NCT00822536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157373|NCT00964821|||CASE_CONTROL||PROSPECTIVE|||||||
34157374|NCT04471506|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34157375|NCT01676688|||COHORT||PROSPECTIVE|||||||
34157376|NCT00268060|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34157377|NCT06272500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157378|NCT03986333|||CASE_CONTROL||PROSPECTIVE|||||||
34157379|NCT04869306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157380|NCT05654454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157381|NCT06507696|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Assignment Randomized controlled||||
34157382|NCT05293158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157383|NCT02888288|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34157384|NCT05838092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157385|NCT03776591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157386|NCT01998308|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34157387|NCT00451516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34157388|NCT00851929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157389|NCT02518633|||CASE_CONTROL||PROSPECTIVE|||||||
34157390|NCT02762214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157391|NCT01971385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157392|NCT00296920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157393|NCT03676140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157394|NCT00932867|||COHORT||PROSPECTIVE|||||||
34157395|NCT00495300|||OTHER||PROSPECTIVE|||||||
34157396|NCT06297382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental and control groups will be determined using https:// www.randomizer.org.|This research will be conducted as an experimental study with pretest-posttest randomised control group design.|t|f|f|f
34157397|NCT02905669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157398|NCT03363880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157399|NCT04677504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157400|NCT03102060|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157401|NCT02955342|||COHORT||PROSPECTIVE|||||||
34157402|NCT01538524|||CASE_ONLY|||||||||
34157403|NCT00881816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157404|NCT00627341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157405|NCT05296564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157406|NCT02904018|||||PROSPECTIVE|||||||
34157407|NCT05246813|||CASE_CONTROL||PROSPECTIVE|||||||
34157408|NCT02617654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157409|NCT05814952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741538|NCT05117606|NA|SINGLE_GROUP||OTHER||NONE||Within subject comparison - of two screening methodologies (standard equipment with direct patient sensors vs LYNG contactless sensors). The number patients in the study is chosen to have a broad view on patients population found in a general hospital setting, for example a range of height, weight, gender, age.||||
34157410|NCT03471741|||OTHER||RETROSPECTIVE|||||||
34157411|NCT06583681|NA|SINGLE_GROUP||OTHER||NONE||||||
34157412|NCT00264264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157413|NCT03191045|||COHORT||PROSPECTIVE|||||||
34157414|NCT00516165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157415|NCT03701919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157416|NCT01526395|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741539|NCT04574544|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Evaluation of the anthropometric and biochemistry parameters of children before and after an intervention.||||
34157417|NCT03252002|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34157418|NCT03874884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157419|NCT04362423|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157420|NCT04028141|||CASE_ONLY||PROSPECTIVE|||||||
34157421|NCT01549925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157422|NCT06371521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Investigators and Participants are both blinded to whether the participants will be consuming Sportlegs or Placebo during a given study visit.|Randomized, Placebo-Controlled, Double Blind Crossover Intervention|t|f|t|t
34157423|NCT05351866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157424|NCT00653380|RANDOMIZED|CROSSOVER||||NONE||||||
34157425|NCT03604796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157426|NCT04284475|||COHORT||PROSPECTIVE|||||||
34157427|NCT02673502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157428|NCT00439062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34157429|NCT00759421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157430|NCT05705427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be double-blinded, with study staff and participants blinded to allocation to the TDF vs placebo arm. Blinding to medication type will be achieved via use of over-encapsulation of TDF and placebo pills. Laboratory technicians who perform point-of-care hepatitis B core related antigen testing, HBV viral load testing and hepatitis B e antigen testing will be blinded to study arm.|Pregnant women will be randomized at the time of enrollment (at 28-32 weeks' gestation) in a 1:1 ratio to receive tenofovir disoproxil fumarate (TDF) vs placebo, with an expected 140 women in the TDF arm and 140 in the placebo arm. A permuted block randomization technique will be employed to ensure equal distribution between the two arms at the two maternity centers. A biostatistician from the University of North Carolina (UNC) will design the randomization scheme, which will utilize the randomization-and-concealment feature within the REDCap database; the biostatistician will not be directly involved in study enrollment activities. REDCap personnel at UNC will ensure proper design and use of the randomization-and-concealment feature, and study personnel will receive training on the randomization process prior to study roll-out.|t|t|t|t
34157431|NCT06230939|||CASE_ONLY||PROSPECTIVE|||||||
34157432|NCT01546688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157433|NCT06583707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157434|NCT01497301|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34157435|NCT04254601|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study is a pretest-post test single blind randomized controlled trial, conducted at Faculty of Physical Therapy, Cairo University.||||
34157436|NCT01002274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157437|NCT03902834|NA|SINGLE_GROUP||OTHER||NONE||||||
34157438|NCT03194243|||COHORT||PROSPECTIVE|||||||
34157439|NCT05952388|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34157440|NCT03775746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157441|NCT02808910|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34157442|NCT00002138||||TREATMENT||||||||
34157443|NCT01270815|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34157444|NCT03215199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34053684|NCT02967289|RANDOMIZED|PARALLEL||TREATMENT||NONE|"The primary end-point is the Disease Free Survival (DFS) at 3 years, defined as the time from the date of randomization up to the date of:~* first local, regional or distant relapse;~* second colorectal cancer;~* death from any cause included treatment-related death. Other primary cancer (except second primary colorectal) will be ignored. Second primary cancer will be recorded to have the opportunity of evaluating other definition of DFS."|The trial is a phase III, multicenter, open-labeled randomized trial comparing the association 5-fluorouracil, folinic acid, irinotecan and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, 5FU (mFOLFOX 6) chemotherapy protocols in patients with high-risk stage III colon cancer in the adjuvant setting.||||
34053685|NCT03590535|||COHORT||PROSPECTIVE|||||||
34053686|NCT05705882|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34053687|NCT03689543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157445|NCT02856204|||COHORT||PROSPECTIVE|||||||
34157446|NCT01719133|NA|SINGLE_GROUP||SCREENING||NONE||||||
34157447|NCT06442670|||CASE_CONTROL||PROSPECTIVE|||||||
34053688|NCT02380261|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34053689|NCT01193465|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34053690|NCT01605123|||CASE_CONTROL||PROSPECTIVE|||||||
34053691|NCT00744588|||CASE_ONLY||CROSS_SECTIONAL|||||||
34053692|NCT02683252|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34053693|NCT05245916|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34053694|NCT06648265|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Crossover assignment (each subject serves as their own control with one arm receiving TXA and the other not)|t|f|t|t
34053695|NCT04839419|||COHORT||PROSPECTIVE|||||||
34053696|NCT04477590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Habitual medicine will be embedded in bigger capsules along with a placebo to be able to randomly allocate medicine/placebo. The first meal in the morning will be also masked by either providing a non-caloric or caloric vanilla-flavored beverage resulting in the fed/fasted condition in a blinded fashion.|Cross-over randomized, pretest-posttest control group experimental design.|t|f|t|f
34053697|NCT05277792|||COHORT||PROSPECTIVE|||||||
34053698|NCT06664320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34053699|NCT06665880|||COHORT||PROSPECTIVE|||||||
34053700|NCT06506643|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I (a dose-escalation part) will explore multiple dose levels, pharmacokinetics (PK), and select a single dose level to explore in Phase II of the study. A conventional 3+3 design will be utilized. Once a dose level is selected, an additional cohort of 3-6 patients will be enrolled to assess more effectively the safety during 2 treatment cycles and confirm Phase II dose (P2D).||||
34053701|NCT05462132|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Decisions will be made based on a blinded review of tolerability, clinical observations, safety laboratory assessments, and, optionally, PD.|Dose-escalation decisions will be made once at least 6 subjects in a cohort have received IMP and have had at least 24 hours of post-dose observation. Dose escalation will be up to approximately 3-fold per cohort.|t|t|t|f
34053702|NCT06305741|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053703|NCT05801939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053704|NCT05099614|NA|SINGLE_GROUP||OTHER||NONE||||||
34053705|NCT04756570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be evaluated by an another investigator who does not aware of groups.|Three groups with one control group|f|f|f|t
34053706|NCT01346189|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33741540|NCT05075252|||COHORT||PROSPECTIVE|||||||
34053707|NCT05570006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053708|NCT00135798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053709|NCT05592847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34053710|NCT00095745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053711|NCT01083888|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157448|NCT02819791|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157449|NCT02707328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157450|NCT03398850|||COHORT||CROSS_SECTIONAL|||||||
34157451|NCT03314311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157452|NCT05213520|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 participants will be randomized into 1 of 2 groups 1) n=15 the experimental group that will receive the alternate day intermittent energy restriction intervention and 2 n=15 will be active control group that will follow a standard reduced calorie diet.||||
34157453|NCT05942599|NA|SINGLE_GROUP||OTHER||NONE||Phase 1, open label, non-randomised||||
34157454|NCT04698993|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34157455|NCT05856981|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741541|NCT06439758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34157456|NCT05231460|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Treating surgeon will not be blinded to randomizations. Anesthesiologist providing the Tap Block will be blinded to narcotic arm and unblinded to Tap vs No Tap. Study Coordinator will be blinded to Tap vs No Tap. Statistician will be unblinded to both groups at end of study for final analysis.|"Each subject will be randomized at 1:1 ratio to receive either the Narcotic Pain Regimen or the Non-narcotic Pain Regimen and will also be randomized at 1:1 ratio to receive either TAP block or no TAP block. Eligible subjects will therefore be randomized to one of four arms with approximately equal sizes:1) narcotic regimen with TAP block; 2) narcotic regimen with no TAP block; 3) non-narcotic regimen with TAP block; 4) non-narcotic regimen with no TAP block.~The primary comparison will be between narcotic and non-narcotic regimens (arms 1 and 2 combined versus arms 3 and 4 combined). Comparison of TAP block versus no TAP block (arms 1 and 3 combined versus arms 2 and 4 combined) will performed as a secondary analysis."||||
34157457|NCT02260947|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157458|NCT03856827|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
34157459|NCT02085304|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157460|NCT02741765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34157461|NCT03346200|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34157462|NCT04916912|||CASE_CONTROL||RETROSPECTIVE|||||||
34157463|NCT01240200|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157464|NCT02356289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157465|NCT04839549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157466|NCT03150420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157467|NCT04260347|||COHORT||RETROSPECTIVE|||||||
34157468|NCT01122849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157469|NCT02164266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157470|NCT06396624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34157471|NCT02014168|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34157472|NCT02523781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157473|NCT00397436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157474|NCT02215135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157475|NCT00771771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157476|NCT00305149|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34157477|NCT00067379|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157478|NCT00627133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157479|NCT04926311|||CASE_ONLY||PROSPECTIVE|||||||
34157480|NCT04702425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157481|NCT06040853|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34157482|NCT03522220|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34157483|NCT03540199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
34157484|NCT05758350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157485|NCT06436703|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study will be an observer-blinded and Sponsor-unblinded study.||t|t|t|t
34157486|NCT00003512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157487|NCT00535119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157488|NCT05502445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"A prospective, correlational, comparative and randomized study, with hospitalized elderly over 60 years, at a private hospital.~Patients will be randomized through a numerical sequence list, into Intervention Group (IG) or Control Group (CG). Before the nutritionist performs the first assessment, the envelope to determine which group the patient would be allocated will be selective.~The CG will follow the flow of nutritional assessment and monitoring while the IG will receive daily visits to monitor food intake, leaflet and educational video on the importance of protein and its source foods. In both groups, a questionnaire on knowledge of protein sources and its importance will be applied, and we will calculated the 24-hour recall of a regular day and for three days of hospitalization. Patients will be assessment by Mini Nutritional Assessment-Short Form and SARC-F and will be the measurements of calf circumference and hand grip strength."||||
34157489|NCT04771637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157490|NCT01122615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741542|NCT06283758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741543|NCT04455919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized wait-list controlled design|f|f|f|t
33741544|NCT04191759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||One single group of 16 healthy volunteers||||
33741545|NCT01747681|||CASE_ONLY||RETROSPECTIVE|||||||
33741546|NCT04245735|||CASE_CONTROL||PROSPECTIVE|||||||
33741547|NCT04199247|RANDOMIZED|PARALLEL||TREATMENT||NONE||Within 1 week of injury, participants will be randomized to either a sub symptom threshold exercise program (intervention group) or usual care (recommendation from their doctor). Those in the intervention group will participate in an exercise program 5x/week, 20-30 minutes/session, for 2 months.||||
33741548|NCT05495503|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34053712|NCT05098665|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is not possible to mask this type of intervention for participant or care provider, but outcomes will be assessed in a blinded fashion.|Randomised Controlled Trial of telemonitoring intervention versus usual care|f|f|f|t
33741549|NCT02448615|||COHORT||PROSPECTIVE|||||||
33741550|NCT03832543|||CASE_ONLY||PROSPECTIVE|||||||
33741551|NCT04148079|||COHORT||PROSPECTIVE|||||||
33741552|NCT02897947|||COHORT||PROSPECTIVE|||||||
33741553|NCT05274945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053713|NCT01687569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34053714|NCT01970475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053715|NCT04877431|||COHORT||RETROSPECTIVE|||||||
34053716|NCT00399412|||COHORT||PROSPECTIVE|||||||
34053717|NCT00351741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053718|NCT06022614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053719|NCT06499168|||COHORT||PROSPECTIVE|||||||
34053720|NCT00318500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34053721|NCT00471718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053722|NCT04605549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053723|NCT03065088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors are blinded to group allocation|This is a feasibility study run as a randomised controlled trial (RCT). This is a multi-centre trial with three centres, Trondheim, Amsterdam, and Stuttgart, with two behaviour change exercise programmes (aLiFE and eLiFE) and a control group, with a 6 months intervention period and 6 month follow up.|f|f|f|t
34053724|NCT00214149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053725|NCT03546426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053726|NCT03819595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053727|NCT03376308|||CASE_CROSSOVER||PROSPECTIVE|||||||
34053728|NCT05546216|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34053729|NCT00759460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053730|NCT06440408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053731|NCT02659514|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34053732|NCT00818467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053733|NCT03070769|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053734|NCT03638284|NA|SINGLE_GROUP||TREATMENT||NONE|N/a-open label study|All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Participants will have neurocognitive assessments at baseline and at study completion (i.e. the last day of receiving tDCS).||||
34053735|NCT01470651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053736|NCT04928170|||COHORT||PROSPECTIVE|||||||
34053737|NCT05128630|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, multi-center, single arm phase 2 trial||||
34053738|NCT02925182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34053739|NCT05482373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34053740|NCT02297178|||COHORT||PROSPECTIVE|||||||
34053741|NCT06622343|||COHORT||RETROSPECTIVE|||||||
34053742|NCT00638443|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34053743|NCT05531526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind, randomized, placebo-controlled|A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer's Disease|t|t|t|t
34053744|NCT04274244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinding: The researchers who performed the measurements will be different from those who performed the surgery; therefore, the examiner will be blinded during the entire duration of the study.||t|f|t|f
34053745|NCT05186246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053746|NCT06575179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053747|NCT04410016|NA|SINGLE_GROUP||OTHER||NONE|This is an evaluation of a service - the Wellbeing Centres at Nottingham University Hospitals National Health Service (NHS) Trust - which are a form of 'intervention' for staff provided during the coronavirus pandemic. Therefore the investigators will conduct interviews with people who have used the centres, or who have acted as support workers within them. The investigators will survey all staff in the Trust, and interview up to 45 participants.|All staff have access to the Staff Wellbeing Centres (usual practice). In this study the investigators will conduct a questionnaire survey with all Nottingham University Hospitals National Health Service (NHS) staff about their mental wellbeing, and use of this facility. The investigators will conduct qualitative interviews with users and non-users of the Wellbeing Centres (staff) as well as the Wellbeing Buddies (support workers).||||
34053748|NCT04711928|||CASE_ONLY||CROSS_SECTIONAL|||||||
34053749|NCT03505593|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053750|NCT02716831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053751|NCT05104216|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects aged ≥60 with chronic bronchitis and COPD who have completed the schedule of two doses for 3 months receive a third dose of inactivated COVID-19 vaccine.||||
34053752|NCT04664478|||COHORT||PROSPECTIVE|||||||
34053753|NCT06621680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053754|NCT01077609|||COHORT||RETROSPECTIVE|||||||
34053755|NCT00005768|RANDOMIZED|||TREATMENT||DOUBLE||||||
34053756|NCT06523023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Allocation concealment will be ensured with the help of an independent statistician, who will be responsible for conducting the randomisation but will not be involved in any other parts of the project.||f|f|f|t
34053757|NCT01916512|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053758|NCT00757458|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34053759|NCT01292694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34053760|NCT06668285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||randomised controlled trial|f|f|t|t
34053761|NCT04033341|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075852|NCT05766774|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study team, including the investigators, statistician, and coordinator, will be blinded to diet allocation throughout. All major assessments and assays will be performed by individuals who will be blinded to the diet. Participants will not be informed of their allocated diet.|A double-blind, randomized, parallel-group design clinical trial.|t|f|t|t
34075853|NCT00649792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157491|NCT05419934|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34157492|NCT05169424|||COHORT||RETROSPECTIVE|||||||
34157493|NCT02736435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157494|NCT03186417|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This is a dose escalation study using three groups (or cohorts) of patients randomly assigned within treatment groups to MSCs or placebo. The first group will consist of 5 patients who receive MSCs and one patient who receives placebo, the second and third group will consist of five patients each who receive MSCs and two patients who receive placebo. The three doses are 2 million hMSCs/kg (Cohort 1), 4 million hMSCs/kg (Cohort 2), and 6 million hMSCs/kg (Cohort 3) and placebo control of normal saline.|t|t|t|t
34157495|NCT04808739|||COHORT||RETROSPECTIVE|||||||
34157496|NCT06525584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34157497|NCT05552352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-armed, randomized with controlled parallel groups.||||
34157498|NCT05260762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157499|NCT05386693|||COHORT||PROSPECTIVE|||||||
34157500|NCT04813887|||COHORT||PROSPECTIVE|||||||
34157501|NCT02395614|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34157502|NCT05972746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157503|NCT02076126|||CASE_CONTROL||RETROSPECTIVE|||||||
34157504|NCT05755672|||CASE_ONLY||PROSPECTIVE|||||||
34157505|NCT05599243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind placebo controlled||t|t|t|f
34157506|NCT05593627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157507|NCT01129661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157508|NCT04228367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157509|NCT01344083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34157510|NCT03955627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Masked parties will not be told the arm to which the participant is assigned. Patient study records will indicate if they are in the study, but not the arm assignment. All participants will receive standard information about AI use and participate in four assessments.|Randomized Clinical Pilot. Enhanced Standard Care v. Treatment (education plus exercise).|t|t|f|t
34157511|NCT01632436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157512|NCT02229929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157513|NCT06134102|||COHORT||CROSS_SECTIONAL|||||||
34157514|NCT03100058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157515|NCT05127239|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|The research assistant who assisted in the production of serial numbers was not involved in recruitment, intervention, or data collection. In addition, the researcher who performed the data analysis did not participate in recruitment, intervention or data collection.||f|f|f|t
34157516|NCT02065505|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34157517|NCT06464263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157518|NCT02743676|||CASE_ONLY||RETROSPECTIVE|||||||
34157519|NCT04734301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34157520|NCT05813691|||COHORT||PROSPECTIVE|||||||
34157521|NCT04431492|||CASE_ONLY||PROSPECTIVE|||||||
34157522|NCT02630303|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34157523|NCT03801226|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34157524|NCT06329505|||CASE_ONLY||PROSPECTIVE|||||||
34157525|NCT02716181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157526|NCT06239103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34157527|NCT03064971|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157528|NCT00932412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157529|NCT00448747|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Multi-center, randomized, open-label, cross-over trial to compare AEZS-130 to an established GH stimulation test, L-ARG+GHRH, in the diagnosis of GH deficiency and in terms of safety. Following Amendment no. 3 (version 27 May 2010) , no cross-over was performed anymore due to unavailability of L-ARG+GHRH with resulting single arm testing of AEZS-130. Thus, two treatment arms were applicable only as long as GHRH as substance was available.||||
34157530|NCT04448769|NA|SINGLE_GROUP||SCREENING||NONE||A study of seroprevalence and symptom collection, or absence of symptoms, on a cluster (household) sample of the Grand Nancy Metropolitan population randomly selected.||||
34157531|NCT01344330|||OTHER||PROSPECTIVE|||||||
34157532|NCT03700489|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34157533|NCT05913024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157534|NCT02502890|||CASE_CONTROL||PROSPECTIVE|||||||
34157535|NCT05888753|||COHORT||RETROSPECTIVE|||||||
34157536|NCT02997059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741554|NCT02719405|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34157537|NCT01894932|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157538|NCT04374045|||COHORT||PROSPECTIVE|||||||
34157539|NCT00098579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157540|NCT04440813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157541|NCT03834831|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Parallel Assignment||||
34157542|NCT00336297|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34157543|NCT01745796|||COHORT||PROSPECTIVE|||||||
34157544|NCT02211612|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34157545|NCT01918956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157546|NCT04202887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants will be blinded to their group allocation. Upon request for labor epidural analgesia, the epidural will be performed by one of the anesthesiologists working in the delivery room who will receive an envelope with the woman's randomization. The investigator performing the gastric ultrasound will be blinded to the subject's randomization as well.|A double-blinded randomized controlled study|t|f|t|t
34157547|NCT01586221|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34157548|NCT06124391|||COHORT||PROSPECTIVE|||||||
34157549|NCT04991129|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential||||
34157550|NCT05545839|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34157551|NCT04588116|NA|SINGLE_GROUP||TREATMENT||NONE||A feasibility study with a pre-test post-test design without control group embedded in a mix-method approach.||||
34157552|NCT03985371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157553|NCT01618825|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157554|NCT02395523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157555|NCT02329899|||COHORT||PROSPECTIVE|||||||
34157556|NCT02096627|||CASE_CONTROL||PROSPECTIVE|||||||
34157557|NCT05463016|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Double blind randomized crossover trial|t|t|t|t
34157558|NCT02396355|||OTHER||PROSPECTIVE|||||||
34157559|NCT03781778|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Assignment to the active versus control group will be blinded using a computer program and will be designated as diet A and diet B. Investigators will be unblinded once the study and data analyses have been completed."|Blinded, block randomization based on sex and BMI.|t|f|t|f
34157560|NCT03676907|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34157561|NCT06294340|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157562|NCT02435927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157563|NCT06160427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be randomized to one of the two arms by unblinded research personnel. Unblinded key study personnel will prepare the injection of either CTM Boost or PRP using an opaque sleeve to obscure the contents of the injection. Both patients and investigators will be blinded to treatment arm.~Each participant will undergo an antecubital blood draw of 60 milliliers (mL). Staff will wait about 20 minutes after the blood draw to injection time. This will be done to maintain blinding due to the 17 minutes it takes for the system to produce PRP. For patients in the CTM arm, the PRP blood draw serves as a placebo draw and the specimen will be discarded afterwards, in order to maintain blinding"|Two-arm, double-blinded, randomized controlled trial with the primary objective of evaluating non-inferiority of CTM (study intervention arm) to PRP (active comparator arm) for rotator cuff tendinopathy pain and function.|t|t|t|f
34157564|NCT03421912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Arm A : Use of Cicaplast balm B5 since de first day of iEGFR initiation treatment for 30 days Arm B : Use of Dexeryl cream since de first day of iEGFR initiation treatment for 30 days||||
34157565|NCT00461084|||COHORT||PROSPECTIVE|||||||
34157566|NCT02313974|||COHORT||PROSPECTIVE|||||||
34157567|NCT00066027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157568|NCT06447402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to patient allocation||f|f|f|t
34157569|NCT00416455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157570|NCT02699710|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157571|NCT01412788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157572|NCT05670158|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study will recruit individuals eligible for cochlear implantation surgery. In parallel, the control group will be formed from normal hearing patients - candidates for other otological interventions. The two groups will be matched by age and gender of participants.||||
34157573|NCT01890564|||CASE_ONLY||PROSPECTIVE|||||||
34157574|NCT03401671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157575|NCT00681928|||CASE_CONTROL||PROSPECTIVE|||||||
34157576|NCT04487652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised placebo-controlled, double blinded, mono-centric trial|t|f|f|t
34157577|NCT00033891|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34157578|NCT02233023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157579|NCT00112125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157580|NCT06584201|||CASE_CONTROL||PROSPECTIVE|||||||
34157581|NCT02087111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157582|NCT03314272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157583|NCT00000470|RANDOMIZED|PARALLEL||TREATMENT||||||||
33741555|NCT02517060|||COHORT||PROSPECTIVE|||||||
33741556|NCT00523029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157584|NCT02695693|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157585|NCT04374240|NA|SINGLE_GROUP||TREATMENT||NONE||AdNRGM plus CB1954||||
34157586|NCT03320135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34157587|NCT03214406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157588|NCT01903629|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34157589|NCT06284668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34157590|NCT03548467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
34157591|NCT05722808|||COHORT||RETROSPECTIVE|||||||
34157592|NCT01098305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157593|NCT05161286|||CASE_ONLY||CROSS_SECTIONAL|||||||
34157594|NCT00475189|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157595|NCT00195663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157596|NCT06383260|||OTHER||CROSS_SECTIONAL|||||||
34157597|NCT04305847|||OTHER||RETROSPECTIVE|||||||
34157598|NCT03197376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157599|NCT00682526|||CASE_CONTROL|||||||||
34157600|NCT02661867|||COHORT||PROSPECTIVE|||||||
34157601|NCT05675501|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34157602|NCT03963648|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157603|NCT04467034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157604|NCT03321422|||COHORT||PROSPECTIVE|||||||
33741557|NCT03965260|||COHORT||PROSPECTIVE|||||||
34157605|NCT04584957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator check the random list only when the patients is enrolled|After gynecologic oncologic laparotomic surgery and standard abdominal wall closure patients are randomized to one of the two arms of the study: sperimental arm (ciNPWT- closed incisional negative pressure wound therapy) and control arm (standard dressing)|f|f|t|f
34157606|NCT01822392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157607|NCT04166097|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157608|NCT01921764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157609|NCT02151890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157610|NCT00870545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741558|NCT01821781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157611|NCT00502008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34157612|NCT04205617|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre/post quasi experimental||||
34157613|NCT01966224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157614|NCT06049030|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34157615|NCT02082600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34157616|NCT00898833|||CASE_CONTROL||RETROSPECTIVE|||||||
34157617|NCT02331667|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34157618|NCT00842543|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157619|NCT06576401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157620|NCT00241592|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34157621|NCT02815592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157622|NCT02669121|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157623|NCT05864547|||COHORT||PROSPECTIVE|||||||
34157624|NCT06480318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34157625|NCT01059994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157626|NCT06144047|NA|SINGLE_GROUP||OTHER||NONE||||||
34157627|NCT00030862||||TREATMENT||||||||
34157628|NCT01611194|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157629|NCT01737216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950274|NCT06542393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized (intervention group) for anemic patients Non-randomized (control group) for non-anemic patients|t|t|f|f
33950275|NCT03693482|||OTHER||OTHER|||||||
34075854|NCT02413957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075855|NCT06608940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075856|NCT02508376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34075857|NCT01853293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075858|NCT00003925||||TREATMENT||||||||
34157630|NCT01583842|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34157631|NCT04010591|||OTHER||PROSPECTIVE|||||||
34157632|NCT02458781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157633|NCT04747587|||CASE_CONTROL||PROSPECTIVE|||||||
34157634|NCT00777361|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34157635|NCT04241471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157636|NCT00214916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157637|NCT02599779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157638|NCT05613023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741559|NCT00982020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950276|NCT05671822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950277|NCT02507609|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33950278|NCT06372262|||COHORT||RETROSPECTIVE|||||||
33950279|NCT02547064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950280|NCT04064450|||COHORT||PROSPECTIVE|||||||
33950281|NCT00937430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950282|NCT00744029|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33950283|NCT06650423|||COHORT||PROSPECTIVE|||||||
33950284|NCT01194349|||CASE_ONLY||RETROSPECTIVE|||||||
34075859|NCT04494295|||CASE_ONLY||PROSPECTIVE|||||||
34075860|NCT01061697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075861|NCT02580253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075862|NCT06184009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075863|NCT02529254|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34075864|NCT01973686|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34075865|NCT02001532|||CASE_CONTROL||PROSPECTIVE|||||||
34075866|NCT05886842|||COHORT||PROSPECTIVE|||||||
34157639|NCT03517228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157640|NCT05538143|||COHORT||PROSPECTIVE|||||||
34157641|NCT02177682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157642|NCT04688255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using an active control (stretching) and both arms described as exercise intervention|Randomized controlled trial (RCT)|t|f|f|t
34157643|NCT01725594|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34157644|NCT03794154|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34157645|NCT05934903|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participant will not know the treatment arm, and the outcomes assessor reading electroencephalogram will not know treatment arm. The device does not have a sham mode so study personnel applying the device will be aware of the treatment arm.|Double blind block randomized into stimulation arm versus sham stimulation arm.|t|f|f|t
34157646|NCT03233464|||OTHER||CROSS_SECTIONAL|||||||
34157647|NCT02471222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157648|NCT02128880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157649|NCT01240135|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34157650|NCT04358224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157651|NCT02941224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157652|NCT00520910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34157653|NCT05295108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial comparing intervention with attention control condition.||||
34157654|NCT05192655|||COHORT||PROSPECTIVE|||||||
34157655|NCT06477913|NA|SINGLE_GROUP||OTHER||NONE||||||
34157656|NCT03707470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants to be provided with 2 different types of compression garments and a sham treatment (sham ultrasound) for recovery from muscle damaging exercise|Randomised, controlled, parallel trial|t|f|f|f
34157657|NCT02560012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157658|NCT00002609||||TREATMENT||||||||
34157659|NCT00003763||||DIAGNOSTIC||||||||
34157660|NCT02267161|NA|SINGLE_GROUP||SCREENING||NONE||||||
34157661|NCT01921127|||COHORT||RETROSPECTIVE|||||||
34157662|NCT04385134|||COHORT||PROSPECTIVE|||||||
34157663|NCT04312347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157664|NCT04601805|||OTHER||PROSPECTIVE|||||||
34157665|NCT02006979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34157666|NCT04479202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157667|NCT00778908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157668|NCT00544037|||COHORT||PROSPECTIVE|||||||
34157669|NCT05144867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157670|NCT02136628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157671|NCT05170321|||COHORT||RETROSPECTIVE|||||||
33845893|NCT03755375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the assessment, participants were blinded randomized by a mask researcher using random.org and allocated into three groups of treatment (TENS, Postural and Conventional) held over 10 sessions once a week.|Randomized control trial. All patients will be randomized by the computer (www.random.org) in 3 groups of treatment. Then, they were assessed by specialized physiotherapists through a medical history data; application of validated questionnaires of pain, urinary symptoms, sexual function and quality of life; pelvic floor muscles physical and surface electromyographic assessment. Patients were randomized to 3 different treatment groups, and treatment consisted by 10 sessions, once a week. TENS group was treated using Biofeedback , manual therapy and transcutaneous electrostimulation. Postural group was treated using Biofeedback , manual therapy and postural exercises. Conventional group was treated using Biofeedback and manual therapy. All participants were evaluated post treatment and at 3 months of follow-up using the same procedures of the initial assessment.|t|f|f|f
33845894|NCT01002170|||CASE_ONLY||PROSPECTIVE|||||||
33845895|NCT05203068|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845896|NCT00673400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845897|NCT01941433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33845898|NCT04028934|||COHORT||PROSPECTIVE|||||||
33845899|NCT01803412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33845900|NCT02746198|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845901|NCT03515343|||COHORT||PROSPECTIVE|||||||
33845902|NCT01868724|||COHORT||PROSPECTIVE|||||||
33845903|NCT00564889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845904|NCT05908253|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33845905|NCT01852968|||CASE_CONTROL||PROSPECTIVE|||||||
33845906|NCT00579800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845907|NCT00215735|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33845908|NCT05381545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845909|NCT03499145|||COHORT||PROSPECTIVE|||||||
34075867|NCT04328025|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization in a 1:1 ratio to either monthly peer delivery of HIV self-testing, STI self-sampling and PrEP (intervention arm) or quarterly in-clinic HIV testing and PrEP prescription (control arm)||||
34075868|NCT05439421|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants will be blinded to which stimuli have the claims of interest and which do not.|Participants will be randomized to see 6 packages and 10 advertisements, with or without the claim of interest on each.|t|f|f|f
34075869|NCT00014612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075870|NCT01301300|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34075871|NCT04464967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075872|NCT01726062|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34157672|NCT03592563|||CASE_CONTROL||PROSPECTIVE|||||||
34157673|NCT04233541|||COHORT||PROSPECTIVE|||||||
33845910|NCT06475430|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33845911|NCT01134068|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845912|NCT00306267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845913|NCT02063373|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33845914|NCT02295943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845915|NCT00197587|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33845916|NCT00677599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33845917|NCT01593059|||||PROSPECTIVE|||||||
33845918|NCT01701687|||COHORT||PROSPECTIVE|||||||
33845919|NCT02908295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33845920|NCT02016859|||CASE_CONTROL||PROSPECTIVE|||||||
33845921|NCT05595031|||COHORT||RETROSPECTIVE|||||||
33845922|NCT05931432|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33845923|NCT02055391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845924|NCT05110170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845925|NCT02157701|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33845926|NCT04110704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845927|NCT05278039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be naive to experimental condition.|Randomized-controlled trial|t|f|f|t
33845928|NCT04502732|||OTHER||PROSPECTIVE|||||||
33845929|NCT00006230||||TREATMENT||||||||
33845930|NCT00473148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845931|NCT00715754|||COHORT||PROSPECTIVE|||||||
33845932|NCT00201643|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845933|NCT02708563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845934|NCT02436434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33845935|NCT00006353||||TREATMENT||||||||
33845936|NCT04021329|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"The current study will be a two arms cross over Randomized Controlled Trial (RCT) with Repeated Measures.~Moreover, the Consolidated Standards of Reporting Trials (CONSORT) group flow diagram and SPIRIT Checklist will be followed to carry out and report this study."|t|f|f|f
34157674|NCT00406536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34157675|NCT04864951|NA|SINGLE_GROUP||SCREENING||NONE||||||
34157676|NCT00586885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157677|NCT04314583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34157678|NCT06388798|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34157679|NCT05118373|NA|SINGLE_GROUP||OTHER||NONE||Nation-wide mass media behaviour change campaign.||||
33845937|NCT02861469|||||PROSPECTIVE|||||||
33845938|NCT04116580|||COHORT||RETROSPECTIVE|||||||
33845939|NCT00626990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845940|NCT00502463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845941|NCT00707759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845942|NCT02317432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33845943|NCT06470984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845944|NCT02158351|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157680|NCT03085745|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157681|NCT01304004|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34157682|NCT01238302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157683|NCT01228526|||CASE_ONLY||PROSPECTIVE|||||||
34157684|NCT05006482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157685|NCT06106191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157686|NCT01812265|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157687|NCT03733496|||COHORT||PROSPECTIVE|||||||
34157688|NCT02290977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157689|NCT00973687|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34157690|NCT06049303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157691|NCT00487292|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34075873|NCT03458624|||CASE_ONLY||PROSPECTIVE|||||||
34075874|NCT02081378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741560|NCT01563861|||OTHER||RETROSPECTIVE|||||||
33741561|NCT00564083|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34075875|NCT04633226|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34075876|NCT03127319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075877|NCT01222000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075878|NCT01008865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075879|NCT00151437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075880|NCT01136577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075881|NCT00994747|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34075882|NCT02871622|||COHORT||PROSPECTIVE|||||||
34075883|NCT06283953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Blinding of care team delivering the interventions and of caregiver participants receiving the interventions is not possible for this study.~The outcome assessors collecting the readmission data and statistician conducting analyses will be blinded to the assignment."||f|f|f|t
34075884|NCT02019342|||COHORT||OTHER|||||||
34075885|NCT03875469|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34075886|NCT00941200|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34075887|NCT02372344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34075888|NCT03180203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The participant will not know which ventilation mode will be or is used. The primairy investigator and care providers are aware of which ventilation mode is used since it is not possible to blind the care providers because they will need to change ventilating parameters if necessary.~The outcome assesor for the percentages of time will be masked. Also are the radiologists, who judge the postoperative thoracic x-ray, masked."||f|f|f|t
34075889|NCT00203658|RANDOMIZED|||TREATMENT||NONE||||||
34075890|NCT06240481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075891|NCT03421964|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075892|NCT05028309|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34075893|NCT01801111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075894|NCT05319496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075895|NCT06305611|||COHORT||PROSPECTIVE|||||||
34075896|NCT00099164|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34075897|NCT01936363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075898|NCT00181675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34075899|NCT06206512|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Crossover, double blinded, two-period, two-treatment, two-sequence, double dummy|t|t|t|t
34075900|NCT04598217|||OTHER||PROSPECTIVE|||||||
34075901|NCT01367249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075902|NCT04456491|||CASE_CONTROL||PROSPECTIVE|||||||
34075903|NCT03839394|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075904|NCT03172598|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34075905|NCT04610138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, investigators, and coordinators will be blinded to the investigational product. The study data will remain blinded until database lock and authorization of data release according to standard operating procedures.|Participants will be randomized 1:1:2 to receive ZnAg (low dose): ZnAg (high dose) placebo in a double-blind fashion in addition to standard supportive care. Within the active treatment arm, participants will be randomized to receive either low or high dose ZnAg.|t|t|t|t
34075906|NCT01218542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075907|NCT02210520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34075908|NCT05713357|||COHORT||PROSPECTIVE|||||||
34075909|NCT03568578|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34075910|NCT02813928|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075911|NCT02574364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34075912|NCT04621032|||COHORT||PROSPECTIVE|||||||
34075913|NCT04258124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075914|NCT02143219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075915|NCT05293522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34075916|NCT05317429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Blinding will be conducted by a member of staff who is independent of the study team. For all studies, an effort will be made to blind the research team and study participants to the test and reference meals. Whilst we recognize that this approach is 'gold standard' it may not be possible in all circumstances, for example due to the different appearance of some food products.|Randomised crossover study|f|f|t|t
34075917|NCT03423212|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075918|NCT00003483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075919|NCT05219968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34075920|NCT00339547|||CASE_CONTROL||OTHER|||||||
34075921|NCT06420037|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34075922|NCT01935024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075923|NCT04576728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All bottles will be indistinguishable.|Subjects will be randomized on a 1:1 basis either to trimodulin or to placebo treatment stratified by center.|t|t|t|t
34075924|NCT03421938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075925|NCT03339817|NA|SINGLE_GROUP||OTHER||NONE||||||
34075926|NCT00080015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075927|NCT03418259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo device|Double blinded randomised clinical trial|t|f|t|f
34075928|NCT00631254||PARALLEL||BASIC_SCIENCE||NONE||||||
34053762|NCT04917458|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Patients included into the study will be randomized into two groups and receive placebo (as control group) or 4000 IU Vitamin D (as therapy group) once a day for 90 days. Randomization and blinding code preparation will be performed by using block permuted randomization technique with a block size combination of 4 and 6. The randomized intervention code was hidden in a closed envelope to avoid knowing the sequence of the therapy given.~All packaging and labeling of the study products will be prepared by Pharmacy Departement Ciptomangunkusumo General Hospital. The study products will be prepared in such packages which will be recognized as products for clinical trial only. In order to keep the blinding procedures, the study drugs will all be provided by Pharmacy Department in a double-blind double-dummy preparation. Placebo tablet will also be prepared by Pharmacy Department and made identical in appearance with the active tablets."|This is a prospective, randomized, double blind, and controlled clinical study to investigate the effects of cholecalciferol on depressive symptoms in type 2 diabetes mellitus patients. Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.|t|t|t|t
34053763|NCT05757427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients will have an MBI scan with Wavelia in addition to standard of care procedures||||
34053764|NCT05400070|NA|SINGLE_GROUP||TREATMENT||NONE||Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.||||
34053765|NCT04097795|||CASE_CONTROL||PROSPECTIVE|||||||
34053766|NCT03194750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34053767|NCT06358846|RANDOMIZED|PARALLEL||PREVENTION||NONE||Control arm =75 Interventional arm = 75||||
34053768|NCT01326468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053769|NCT04699110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053770|NCT05596201|||OTHER||PROSPECTIVE|||||||
34053771|NCT05659979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34053772|NCT05698472|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34053773|NCT05627310|||OTHER||OTHER|||||||
34053774|NCT03909750|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053775|NCT00749684|||COHORT||PROSPECTIVE|||||||
34053776|NCT02338297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053777|NCT03784144|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Each test will be assessed in different days following a randomized order.||||
34053778|NCT05218395|||CASE_CONTROL||PROSPECTIVE|||||||
34053779|NCT05970276|NA|SINGLE_GROUP||TREATMENT||NONE|All participants receive same amount of TES stimulations over the course of the study, but they are blind to which night they receive the stimulation.|All participants receive same amount of TES stimulations, but in randomized order (stimulation either on the second night or the last night).||||
34053780|NCT00746824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053781|NCT02270359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053782|NCT05711056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053783|NCT04243473|||COHORT||PROSPECTIVE|||||||
34053784|NCT03134534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053785|NCT03606538|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|No masking; open-label|Matched group comparison of pharmacokinetics and metabolism of single dose of 80 mg MDMA in participants with moderate hepatic impairment and participants with normal hepatic function and matched on age, weight and gender.||||
34053786|NCT00005876||||TREATMENT||||||||
34053787|NCT06513572|||COHORT||PROSPECTIVE|||||||
34053788|NCT06334653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34053789|NCT04680065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Up to 9 study participants meeting eligibility criteria will be randomized in a 2:1 fashion to receive either the investigational medicinal product or sham surgery in this Phase 1 trial.|t|t|t|t
34053790|NCT02828124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053791|NCT02791321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053792|NCT05115786|||OTHER||RETROSPECTIVE|||||||
34053793|NCT01707355|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
34053794|NCT04716257|||CASE_ONLY||PROSPECTIVE|||||||
34053795|NCT00217074|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34053796|NCT04007068|||COHORT||PROSPECTIVE|||||||
34053797|NCT02199353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053798|NCT00196066|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34053799|NCT04811612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053800|NCT03448627|||CASE_CONTROL||PROSPECTIVE|||||||
34053801|NCT06617871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1:1|t|f|f|t
34053802|NCT05002647|||COHORT||RETROSPECTIVE|||||||
34053803|NCT00031681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053804|NCT02997644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34053805|NCT02622373|||CASE_CONTROL||PROSPECTIVE|||||||
34053806|NCT01619137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34053807|NCT03279549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053808|NCT03767686|||COHORT||PROSPECTIVE|||||||
34053809|NCT02117908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34053810|NCT01846429|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053811|NCT02302742|||COHORT||PROSPECTIVE|||||||
34157692|NCT03722394|NA|SINGLE_GROUP||TREATMENT||NONE||Observational cohort||||
34157693|NCT05665803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split mouth RCT|t|f|f|t
34157694|NCT02523573|||CASE_ONLY||PROSPECTIVE|||||||
34157695|NCT04193592|NA|SINGLE_GROUP||TREATMENT||NONE||open label drug||||
34157696|NCT03326206|||CASE_CONTROL||PROSPECTIVE|||||||
34157697|NCT01991041|||COHORT||PROSPECTIVE|||||||
34157698|NCT04951505|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157699|NCT00600899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157700|NCT02717052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pilot I and Pilot III not randomised|t|t|t|t
34053812|NCT01522287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053813|NCT02166307|||CASE_ONLY||RETROSPECTIVE|||||||
34075929|NCT05630443|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||prospective randomized controlled study||||
34053814|NCT05453279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind allocation to inhalation formulation (active or placebo)|This study will be a single center, Phase I, randomized, double-blind, placebo controlled, single and multiple ascending dose (SAD/MAD) study evaluating safety, tolerability, and PK after administration via oral inhalation in healthy subjects.|t|t|t|f
34053815|NCT04469582|||COHORT||PROSPECTIVE|||||||
34053816|NCT04894552|NA|SINGLE_GROUP||OTHER||NONE||Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.||||
34053817|NCT06524492|||COHORT||PROSPECTIVE|||||||
34053818|NCT03722953|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053819|NCT03410407|||CASE_ONLY||RETROSPECTIVE|||||||
34053820|NCT05279976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34053821|NCT06618235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157701|NCT05842018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157702|NCT00579072|||CASE_CONTROL||PROSPECTIVE|||||||
34053822|NCT05380544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Use of sham therapy for participant. Blinded outcome assessors.|Pilot RCT and Qualitative study|t|f|f|t
34053823|NCT06545773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053824|NCT02567734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053825|NCT06620393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053826|NCT03931772|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a pilot, open trial evaluating a novel automated hypnosis intervention for smoking cessation and pain and reduction||||
34053827|NCT05498103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
34053828|NCT06621927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two separate groups simultaneously diet and control||||
34053829|NCT05883436|NA|SEQUENTIAL||TREATMENT||NONE||The Dexa-C Study will be conducted at up to 10 investigative sites in the United States. It is anticipated that at least 40 single level subjects and at least 40 multiple level subjects will be enrolled into the Study.||||
34053830|NCT00940966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053831|NCT05098912|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34053832|NCT06623435|||CASE_CONTROL||OTHER|||||||
34053833|NCT02770404|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34053834|NCT00409968|||CASE_ONLY||PROSPECTIVE|||||||
34157703|NCT06366360|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each patient was assigned to a group that received 2 rehabilitations for 4 weeks, 1) both Immersive virtual reality therapy and a conventional rehabilitation first, and then conventional rehabilitation alone, or 2) A conventional rehabilitation alone and then both Immersive virtual reality therapy, and conventional rehabilitation.|t|f|f|t
34157704|NCT03471780|||COHORT||PROSPECTIVE|||||||
34157705|NCT00185224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157706|NCT03250208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|All participants and research team members are masked in this randomized placebo-controlled trial. The investigational pharmacist is unmasked.|Participants are randomized to receive placebo or a probiotic using a 1:2 allocation, respectively|t|t|t|t
34157707|NCT02210975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157708|NCT06054139|||COHORT||PROSPECTIVE|||||||
34157709|NCT05152576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157710|NCT03821610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053835|NCT02349919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34053836|NCT03199482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|investigator|dexamethazone|t|t|f|f
34053837|NCT05123664|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|All capsules have the same appearance||t|t|t|t
34075930|NCT04365348|||COHORT||PROSPECTIVE|||||||
34075931|NCT01945346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075932|NCT05501392|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Outcome assessors were blinded to study design.|There were three sequential data collection periods through the process.|f|f|f|t
34075933|NCT01639612|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075934|NCT01637714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075935|NCT02449421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075936|NCT01470703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075937|NCT05382546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157711|NCT00555217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34157712|NCT02425059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34157713|NCT03052595|||CASE_CONTROL||PROSPECTIVE|||||||
34157714|NCT00793325|||CASE_ONLY||PROSPECTIVE|||||||
34157715|NCT03141632|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind study|Double-blind, placebo control, cross-over design|t|t|t|t
34157716|NCT06335017|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34157717|NCT04424342|||OTHER||CROSS_SECTIONAL|||||||
34157718|NCT04801862|||COHORT||PROSPECTIVE|||||||
34157719|NCT04375059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157720|NCT05230784|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34157721|NCT00008229||||TREATMENT||||||||
34157722|NCT00305630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157723|NCT01262534|||CASE_ONLY||CROSS_SECTIONAL|||||||
34157724|NCT02112292|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34157725|NCT02659436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157726|NCT00793169|||COHORT||PROSPECTIVE|||||||
34157727|NCT02610946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741562|NCT02546245|RANDOMIZED|PARALLEL||||NONE||||||
34157728|NCT03202134|||COHORT||PROSPECTIVE|||||||
34157729|NCT06414447|||OTHER||PROSPECTIVE|||||||
34157730|NCT03322410|NA|SINGLE_GROUP||OTHER||NONE||||||
34157731|NCT06584058|NA|SINGLE_GROUP||OTHER||NONE||||||
34053838|NCT06619366|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The follow-up assessments will be conducted at the PI's telephone interview laboratory. Over the study period, investigators will be blinded to participants' group status. The survey firm interviewers who conduct baseline assessment and randomization, will not be involved in follow-up interviews. The interviewers who conduct the follow-up interviews will not have access to participants' group status. The coaches will not be involved in follow-up assessments. Given our description of study objectives, participants may know their group status. After the 12-month interview, group status will be linked with interview data by study identification numbers.|This is an assessor-blinded RCT with two arms. Participants will be recruited from communities across the country, NOT from medical settings. After screening and baseline assessment, participants will be randomized into: (1) intervention, and (2) control group in a 1:1 ratio. Participants in the intervention group will receive the coach-guided PDRC.|f|t|t|t
34157732|NCT01188304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157733|NCT03722524|||OTHER||PROSPECTIVE|||||||
34157734|NCT04397562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157735|NCT06096662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The results are assessed by independent assessors blinded to in which phase (pre-post-follow up) the data is obtained, and to group (Therapy group or control group).|Parallel assignment|f|f|f|t
34157736|NCT03990428|||COHORT||PROSPECTIVE|||||||
34053839|NCT01330394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157737|NCT02735954|||COHORT||CROSS_SECTIONAL|||||||
34053840|NCT06112431|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||f|t|t|t
34157738|NCT03330639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized parallel group|t|f|f|f
34157739|NCT03829722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157740|NCT00603122|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157741|NCT02473367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157742|NCT04650464|||CASE_CONTROL||RETROSPECTIVE|||||||
34157743|NCT00475605|||COHORT||PROSPECTIVE|||||||
34157744|NCT04429724|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157745|NCT02609789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157746|NCT03222401|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|All doses of F598 will be administered on an open-label basis. Investigators will be unblinded, and subjects will be aware if they are randomized to the control group or one of the active dose groups; however, subjects in one of the active dose groups will not be informed of their randomized dosage.|"Subjects will be enrolled in 6 identical cohorts of 4 subjects each. Within each cohort, subjects will be randomized to:~1. Control (n=1)~2. F598, 1 mg/kg (n=1)~3. F598, 3 mg/kg (n=1)~4. F598, 10 mg/kg (n=1)"|t|f|f|f
34157747|NCT00370565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157748|NCT06330207|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34157749|NCT02022163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157750|NCT03991429|||COHORT||PROSPECTIVE|||||||
34157751|NCT00979927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157752|NCT06418659|NA|SINGLE_GROUP||TREATMENT||NONE||The subjects with advanced HCC will be treated by CD-801 intravenously via a peripheral vein.||||
34157753|NCT00245037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157754|NCT03002883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157755|NCT01022866|||COHORT||PROSPECTIVE|||||||
34157756|NCT02346253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053841|NCT01380262|||COHORT||PROSPECTIVE|||||||
34053842|NCT06621836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34053843|NCT05470621|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34053844|NCT00880061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053845|NCT04507256|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The study will be blinded for all placebo controlled dose groups, ie, the Principal Investigator (PI), all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.||t|f|t|f
34053846|NCT03830788|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075938|NCT01275690|||CASE_ONLY||PROSPECTIVE|||||||
34075939|NCT03653845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157757|NCT04253002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157758|NCT02153580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157759|NCT03218176|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34157760|NCT02650063|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157761|NCT01003652|||COHORT||PROSPECTIVE|||||||
34157762|NCT03113981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157763|NCT04899947|||OTHER||PROSPECTIVE|||||||
34157764|NCT02103972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157765|NCT01604291|||COHORT||PROSPECTIVE|||||||
34157766|NCT04039217|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34157767|NCT05860153|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33741563|NCT01771003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157768|NCT02465203|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34157769|NCT02544919|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34157770|NCT04686383|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34157771|NCT02682992|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157772|NCT04384055|||CASE_CONTROL||PROSPECTIVE|||||||
34157773|NCT05334134|||COHORT||PROSPECTIVE|||||||
34157774|NCT04202614|||COHORT||RETROSPECTIVE|||||||
34157775|NCT06293768|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The study involves the enrollment of 300 patients (150 patients undergoing continuous monitoring and 150 as a control). 50 of the patients undergoing continuous monitoring come from the group A and 100 from group B, same ratio in the control group.~Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization"||||
34157776|NCT04077515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053847|NCT04625465|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Participants will be enrolled into a measurement burst daily diary design comprised of four 14-day bursts of daily surveys with three 14-day intervals that do not include daily surveys. There are three intervention conditions: (A) no intervention; (B) attention-control text messaging; or (C) CBT text messaging intervention. Between bursts 1 and 2 (Interval 1), all participants will be assigned to condition A (no intervention) such that all will complete the first two bursts (28 days) before receiving an intervention. Between bursts 2 and 3 (Interval 2) and bursts 3 and 4 (Interval 3), couples will be randomized to one of the following eight patterns of conditions: AA, AB, AC, BA, BB, BC, CA, or CB. There is no CC condition because the CBT intervention is not intended to be given in multiple two-week intervals."|t|f|f|f
34053848|NCT06062602|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This substudy is not blinded. This is a cohort substudy of a Master Protocol (PBI-MST-01, NCT 04541108) framework that describes the experimental workflow for use of the CIVO platform. Comparisons will not be made between substudy cohorts.||||
34157777|NCT02622893|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157778|NCT02119663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157779|NCT04951466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157780|NCT04791618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157781|NCT00042991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053849|NCT05407428|||COHORT||PROSPECTIVE|||||||
34053850|NCT05189327|||OTHER||PROSPECTIVE|||||||
34053851|NCT04986410|||COHORT||RETROSPECTIVE|||||||
34053852|NCT02441335|||CASE_CONTROL||PROSPECTIVE|||||||
34053853|NCT01660347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34053854|NCT06616337|||COHORT||RETROSPECTIVE|||||||
34053855|NCT00489229|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34053856|NCT04560283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053857|NCT05104567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053858|NCT01865201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053859|NCT04958707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigator who interview the participants will be blinded during the study.|Phase 1: 20 in-depth interviews to determine what knowledge and skills related to dementia patient care the carers need providing Phase 2: 60 carers will be randomly allocated into the interventional or controlled group. The intervention duration will be 8 weeks with providing knowledge and skills related to patient care.|f|f|t|f
34157782|NCT04770948|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34053860|NCT00489775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34053861|NCT05622682|||COHORT||PROSPECTIVE|||||||
34053862|NCT03756714|||COHORT||RETROSPECTIVE|||||||
34053863|NCT03064854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053864|NCT06369896|||COHORT||PROSPECTIVE|||||||
34053865|NCT02163226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053866|NCT01056198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053867|NCT04907643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34053868|NCT01249924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053869|NCT03993574|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34053870|NCT06293989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053871|NCT05489263|||CASE_CONTROL||PROSPECTIVE|||||||
34053872|NCT05509179|||COHORT||RETROSPECTIVE|||||||
34053873|NCT06193603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant) Participants in the control group will undergo a similar procedure to those in the intervention group. Two cups will be placed on the lumbar region, but the sham cups will have small holes (\<2mm in diameter) to release negative pressure quickly. Additionally, to reduce bias, the data analyst will be blinded to the group assignments of the participants. Each participant will be identified by a unique numerical code to maintain anonymity.||t|f|f|f
34053874|NCT04374162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34053875|NCT05622071|NA|SINGLE_GROUP||TREATMENT||NONE|Tislelizumab will be administered every 3 weeks IV for a maximum of 2 years|Multicentre, national, monotherapy, open-label, phase II single-arm study||||
34053876|NCT01194531|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34053877|NCT06149650|||COHORT||PROSPECTIVE|||||||
34157783|NCT01726218|||CASE_CONTROL||PROSPECTIVE|||||||
34157784|NCT05843929|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Randomized controlled study|"Patients with inclusion criteria and without exclusion criteria will be randomized into two groups with Randomization with sequence concealment, centralized in computer support.~OxMaR (Oxford Minimization and Randomization) After signing the informed consent, the patients will be divided into two groups.~1. Group with Laser speckle contrast imaging technique (LSDI), 3D foot creator~2. Group not LSCI, 3D foot Creator"||||
34157785|NCT04542031|NA|SINGLE_GROUP||OTHER||NONE||||||
34157786|NCT04426539|||COHORT||PROSPECTIVE|||||||
34157787|NCT05018078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157788|NCT03830346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34157789|NCT00038233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741564|NCT00893659|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33741565|NCT02451345|NA|SINGLE_GROUP||OTHER||NONE||||||
34053878|NCT01898221|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34053879|NCT02002312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053880|NCT03992170|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients will receive Daratumumab (16 mg/Kg day) every week for 8 weeks intravenous (8 infusions) and then every 2 weeks for 16 weeks intravenous (8 more infusions).~If MRD positive by NGF, the patients will receive Daratumumab every 4 weeks for 80 weeks intravenous; if MRD negative by NGF, the patients can stop the treatment."||||
34053881|NCT02079467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157790|NCT02286232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157791|NCT06477666|||COHORT||CROSS_SECTIONAL|||||||
34157792|NCT05878951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741566|NCT00004867|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741567|NCT06260657|||COHORT||PROSPECTIVE|||||||
33845945|NCT05755542|||COHORT||CROSS_SECTIONAL|||||||
33845946|NCT00000444|RANDOMIZED|||TREATMENT||NONE||||||
34157793|NCT00516867|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157794|NCT01078649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157795|NCT02335606|||CASE_ONLY||PROSPECTIVE|||||||
34053882|NCT04181983|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053883|NCT04859153|||COHORT||PROSPECTIVE|||||||
34157796|NCT03363620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34053884|NCT04501081|||FAMILY_BASED||PROSPECTIVE|||||||
34053885|NCT02315495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34053886|NCT05396105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053887|NCT06183476|NA|SINGLE_GROUP||TREATMENT||NONE||Amplify-RHYTHM focuses on timed light exposure and weekly remote coaching session to optimize circadian and sleep behaviors.||||
34053888|NCT05502744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053889|NCT06270875|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Data collectors and principal investigator will be blind to participant condition; participants will be instructed NOT to discuss their assignment with data collectors. Trials participants will know their intervention condition as will the palliative care coach involved in delivering the intervention.||f|f|t|t
34053890|NCT03341442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053891|NCT06080880|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
34053892|NCT00140270|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34053893|NCT01329809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053894|NCT05127850|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34053895|NCT00575718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053896|NCT05416983|||COHORT||PROSPECTIVE|||||||
34053897|NCT02337452|||FAMILY_BASED||PROSPECTIVE|||||||
34053898|NCT02360631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053899|NCT05915182|||COHORT||PROSPECTIVE|||||||
34053900|NCT05523193|||COHORT||PROSPECTIVE|||||||
34053901|NCT03495674|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34053902|NCT02479698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053903|NCT02414178|||OTHER||PROSPECTIVE|||||||
34053904|NCT05167370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053905|NCT06561360|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized phase II multi-center, open-label, study of vemurafenib plus obinutuzumab (experimental arm) vs. cladribine plus rituximab (standard of care arm) in patients with previously untreated HCL.||||
34053906|NCT00721279|||||PROSPECTIVE|||||||
34053907|NCT03957603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053908|NCT01003704|||CASE_ONLY||RETROSPECTIVE|||||||
34053909|NCT06561464|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053910|NCT04001387|||CASE_ONLY||PROSPECTIVE|||||||
34053911|NCT05855590|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Randomized, double-blind, prospective trial to establish the effect of intraoperative tranexamic acid in early surgical debridement of severe burns. The study was carried out between the months of January 2022 to December 2022.|t|f|t|f
34053912|NCT05043597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34053913|NCT05889364|||OTHER||RETROSPECTIVE|||||||
34053914|NCT00672386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053915|NCT06210776|||COHORT||PROSPECTIVE|||||||
34157797|NCT01306916|||COHORT||PROSPECTIVE|||||||
34157798|NCT01548066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157799|NCT05168020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will receive one of two matched interventions. They will not be told whether they are receiving the active or control intervention|Participants are randomized in to one of two conditions|t|f|f|f
34157800|NCT01835223|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34157801|NCT04965532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Eighty patients undergoing liver radiofrequency ablation surgery under elective general anesthesia were selected, of whom 40 received preoperative adjuvant chemotherapy and the other 40 were nonchemotherapy patients, who were divided by randomization according to the method of anesthesia maintenance, respectively.Chemotherapy patients were divided into PC group with 20 cases using all intravenous anesthesia and SC group with 20 cases using sevoflurane anesthesia.The nonchemotherapy patients were divided into PN group with 20 cases using all intravenous anesthesia and Sn group with 20 cases using sevoflurane anesthesia.|f|f|t|f
34053916|NCT00552981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053917|NCT03826628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157802|NCT04375514|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34157803|NCT05002491|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Isocaloric feeding phase followed by ad-libitum feeding phase||||
34157804|NCT03653728|||COHORT||PROSPECTIVE|||||||
34157805|NCT02439034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157806|NCT02736344|||COHORT||PROSPECTIVE|||||||
34157807|NCT04569227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157808|NCT04274335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157809|NCT05196191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will not be told which treatment group they receive until the end of study participation.|Subjects meeting criteria will be randomized 4:1 treatment (Viagenex Max) or sham (standard of care).|t|f|f|f
34157810|NCT00650845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741568|NCT03913364|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Obese mothers and normal-weight mothers will each be randomized in two groups to receive the probiotic product or the placebo. Colostrum and breastmilk samples will obtained at days 2 and 30 post-partum, respectively, and infant fecal samples at day 30.|t|t|t|f
33741569|NCT02999308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741570|NCT04837638|||COHORT||CROSS_SECTIONAL|||||||
33845947|NCT02134418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34053918|NCT05241405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053919|NCT03566043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Dose escalation||||
34053920|NCT06617247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, parallel, double-blind, placebo-controlled two-arm clinical trial to achieve the main objective of the study.|t|t|t|t
34053921|NCT03608657|||COHORT||PROSPECTIVE|||||||
34053922|NCT04635124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The design of the study is a stratified and randomized complete block design. Each nursing home is a block. The participants are allocated randomly to one of the three visit types (1) Visits with a dog, no activity (D); 2) Visits with a dog, with activity (DA); or 3) Visits without dog, with an activity (A), balancing for the level of cognitive impairment, measured by the MMSE-scale. This was achieved by ranking the participants according to MMSE score within sex and allocating them to the three visit types by using different numerical orders in each nursing home (1, 2, 3; 3, 1, 2; 2, 3, 1 etc.).||||
34053923|NCT04387708|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34053924|NCT01864915|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34053925|NCT05046886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization is performed by the statistician blind to participant identity and baseline data. It is not possible to blind interventionists to randomization group. Outcome assessors will be blind to randomization assignment to the extent possible.||f|f|f|t
34053926|NCT01677884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053927|NCT06573281|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner||t|t|t|t
34053928|NCT05478304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34053929|NCT06339164|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053930|NCT05272735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34053931|NCT06463392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34053932|NCT03891472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053933|NCT05848674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1: Intervention; Group 2: Control.||||
34053934|NCT06235411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053935|NCT01391195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053936|NCT02776644|||COHORT||RETROSPECTIVE|||||||
34053937|NCT05845905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34053938|NCT05659563|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, international, open-label, two-arms, one stage, phase II, window of opportunity, clinical trial||||
34053939|NCT04197869|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group will take a pre-operative course of polyethylene glycol daily for seven days prior to procedure date. The control group will not be given any intervention preoperatively. All patients will take polyethylene glycol postoperatively.||||
34053940|NCT05687188|||COHORT||PROSPECTIVE|||||||
34053941|NCT03862794|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053942|NCT04155541|||CASE_ONLY||PROSPECTIVE|||||||
34053943|NCT06471036|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to either the intervention or standard of care group.||||
34053944|NCT00725179|||CASE_ONLY||RETROSPECTIVE|||||||
34053945|NCT01748422|||COHORT||PROSPECTIVE|||||||
34053946|NCT00692848|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34053947|NCT05970549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|There will be no masking involved. The proposed study is a single center retrospective and prospective cohort, controlled, single-center, phase 1 study evaluating the safety and radiographic outcomes associated use of the IRRAS catheter compared to standard of care external ventricular drains.|The IRRAflow® System is an active fluid exchange system in which intracranial pressure (ICP) monitoring, active controlled irrigation and passive drainage are combined in one system. The system consists of 3 items; control unit (i) and two sterile disposable parts: (ii) Intelligent Digital Cassette (Tube Set) and (iii) dual-lumen Catheter.||||
34053948|NCT04190511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34053949|NCT06488495|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34053950|NCT05197647|||COHORT||PROSPECTIVE|||||||
34053951|NCT04948203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053952|NCT02893982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053953|NCT03740555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34053954|NCT06085963|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||"20 non-atopic controls will be randomized to dissolved placebo-tablet or saline solution in a cross over design. . This will be performed in a one side blinded challenge where 10 subjects will start with placebo-tablet dissolved in 0,9% saline solution and 10 will start with 0,9% saline solution only. After 30 minutes subjects will receive the other solution.~Thereafter 70 patients will initially receive a NAC with 0,9% saline solution to ensure negative reactivity to the challenge as method. If negative after 30 minutes NAC will continue with one puff (1x0.1 ml) dissolved ITULAZAX® (1 SQ-Bet/ml) in each nostril."|t|f|f|f
34053955|NCT05919992|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Placebo-controlled|Double-blind, randomized, placebo-controlled cross-over study|t|f|t|f
34053956|NCT04178707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Microdialysis is used to investigate the inner enviorment of anal fistulas. The patient will be its own control with measurements at prior to intervention and after operative procedure.||||
34053957|NCT06410001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053958|NCT03509428|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Masking of CPET assessors and dual reporting, masking of personnel involved in outcome data collection, masking of sarcopenia assessors|2x2 factorial design randomised controlled interventional trial|f|f|t|t
34053959|NCT06562153|||COHORT||PROSPECTIVE|||||||
34053960|NCT02377479|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34053961|NCT03324230|||COHORT||PROSPECTIVE|||||||
34053962|NCT02455258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34053963|NCT05239494|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will be assigned to wear Dailies Total 1 Sphere contact lenses. They will report to 3 in person visits over the course of one month.||||
34053964|NCT06232057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized controlled study will be conducted with women who had a cesarean in the Obstetrics and Gynecology clinic of a public hospital in northern Turkey.||||
34053965|NCT03737708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053966|NCT02751879|||COHORT||RETROSPECTIVE|||||||
34053967|NCT02180295|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34053968|NCT06618690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34053969|NCT00556686|||CASE_CONTROL||PROSPECTIVE|||||||
34053970|NCT01629810||CROSSOVER||TREATMENT||NONE||||||
34157811|NCT05490940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is examiner- and patient blinded. While the operating surgeon is not blinded, postoperative examinations will be performed by physicians who do not know the group assignment of the patient.|Prospective, randomised, investigator-blinded, monocentric study|t|f|f|t
34157812|NCT00277784|||CASE_ONLY||PROSPECTIVE|||||||
34157813|NCT04532905|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only participants will be masked for group allocation.|The study will include two groups: 1) control (untrained) and 2) strength training (trained)|t|f|f|f
34157814|NCT00001582|||COHORT||PROSPECTIVE|||||||
34053971|NCT05483296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Entirely blinding the differences between the experiment's light conditions is unattainable (for both participants and experimenters) because of the visibly perceivable differences in brightness between them. However, the melatonin and objective EEG measurements should not be significantly affected by any expectancy effects. Participants will not be told the expected effects of the different light exposure conditions to minimise the expectancy effects for behavioural measures (i.e., PVT) and subjective measurements. Information on the hypothesized outcomes will be withheld from the volunteers and study helpers until after completing all sessions. During the analysis, light intensity conditions and participant IDs will be coded to withhold information from the analytic team about the light intensity.|The protocol is a full within-subject trial (cross-over). All participants will conduct three 18-hour experiment sessions and go through the same protocol except for the sequence of the experiment sessions (counter-balanced and randomised).||||
34053972|NCT04441957|||COHORT||PROSPECTIVE|||||||
34053973|NCT05104697|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Investigators will use a within-subject, counterbalanced design comparing TMS vs Sham in a brief 2-visit protocol|t|f|t|t
34053974|NCT00616616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053975|NCT06424106|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||All participants will complete two experiments conducted in random order. On one day they will receive a graded glucagon infusion while on the other they will receive a glucose infusion that replicates the glucose concentrations observed in the first study day||||
34053976|NCT04337164|||OTHER||RETROSPECTIVE|||||||
34053977|NCT04349189|||CASE_ONLY||PROSPECTIVE|||||||
34053978|NCT02042326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053979|NCT05244044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of the 6MWT (the primary outcome) is blinded. Also the assessor of the lung function, MIP/MEP and hand grip strength is blinded.||f|f|f|t
34053980|NCT04080518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The assignment of consented patients will occur in a blinded fashion using a randomization scheme generated by a statistician who is not part of the study team and has no contact with the study subject. Once eligibility criteria are met, study participants will be randomly assigned to receive either Dapagliflozin 10mg or matching, identically appearing placebo. Stratified random sampling (by gender) will be performed in order to minimize selection bias. Access to the randomisation code will be controlled and documented. Relevant parties will be blinded to the treatment group assignment.|This study will be a 4-week double blind, placebo-controlled, randomized study with 2 treatment arms.|t|t|t|f
34053981|NCT06440330|||COHORT||PROSPECTIVE|||||||
34053982|NCT01698879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053983|NCT04582916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34053984|NCT05738551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Three-arm randomized controlled trial||||
34053985|NCT02877095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053986|NCT01101945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053987|NCT00287872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34053988|NCT06059690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single center, prospective surgical study examining the association between imaging measurements and brain tumor tissue features obtained using image-guided biopsies.||||
34053989|NCT03794076|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participant, care providers, Investigators and assessors will all be blinded. Study staff responsible for randomization will be unblinded.|This study will be a randomized placebo-controlled sequential parallel comparison design (SPCD).|t|t|t|t
34053990|NCT04311749|||COHORT||PROSPECTIVE|||||||
33845948|NCT05084235|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34053991|NCT05759624|||COHORT||PROSPECTIVE|||||||
34053992|NCT01532336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34053993|NCT06621342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|2. It is not possible to blind clinical staff for the procedure. It is not necessary for the integrity of the study to blind participants as we are assessing their pregnancy outcomes. Regardless of which group they are assigned, participants will partake in routine prenatal care, as well as two additional study visits. They will know which group they have been assigned at the time of the procedure based on if they receive the treatment prior to implantation or not.|40 patients will be enrolled in each of the control and test groups, using a confidence interval of 95% and a 5% margin of error Total participants expected = 80.|t|f|t|t
34053994|NCT05431023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053995|NCT00284778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053996|NCT01380717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34053997|NCT05803213|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The assessors do not know the group assignment. The investigators who handle data analysis and statistics do not know the group assignment.||f|f|t|t
34157815|NCT06413238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will involve capsules with different combinations of curcumin, saffron, and placebos, labeled as ABCD. The capsules will be identical in appearance and smell to maintain blinding. The researcher, participants, and pharmacist will be unaware of the capsule contents. This three-way blind method aims to eliminate bias in the study.|In Arm curcumin, participants will receive two curcumin capsules, each with a dose of 500 mg, in addition to routine treatments. In Arm saffaron, participants will use one 15 mg saffron capsule and one placebo capsule, in addition to routine treatments. In Arm combination, participants will use one 500 mg curcumin capsule and one 15 mg saffron capsule, in addition to routine treatments. In Arm plasebo , participants will use two placebo capsules (500 mg starch flour), in addition to routine treatments|t|t|t|t
34157816|NCT00003712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157817|NCT02397057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157818|NCT05494437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157819|NCT00984555|||CASE_CONTROL||PROSPECTIVE|||||||
34053998|NCT03726775|NA|SINGLE_GROUP||TREATMENT||NONE||IV infusion of durvalumab will start at fixed dose on Day1 of RT and subsequently every 3 weeks during the course of RT. Durvalumab with be continued via IV infusion at a fixed dose for an additional 6 months following RT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.||||
34053999|NCT05148234|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34157820|NCT02709603|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157821|NCT00306527|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34054000|NCT06339411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157822|NCT02964442|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34157823|NCT01126944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157824|NCT02561442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34157825|NCT04384939|NA|SINGLE_GROUP||OTHER||NONE||||||
34157826|NCT01142622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157827|NCT00857857|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34157828|NCT02679170|||COHORT||OTHER|||||||
34157829|NCT02942485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157830|NCT02173171|||COHORT||PROSPECTIVE|||||||
34157831|NCT00766714|RANDOMIZED|PARALLEL||||NONE||||||
34157832|NCT04621812|||CASE_ONLY||PROSPECTIVE|||||||
34157833|NCT00180583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157834|NCT05370833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34157835|NCT03133286|||COHORT||PROSPECTIVE|||||||
34157836|NCT03656991|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a stepped-wedge, randomized controlled trial. Possible subjects will be randomized to 1 of 4 groups. Each patient will serve as his or her own control. Within each stratum of four, patients will be randomly assigned to intervention initiation times (\~130 per initiation time). Intervention initiation times will occur every other month up to a maximum of six months.||||
34157837|NCT02130596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157838|NCT04860141|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* Only the allocator knows the computer generated randomization scheme and this will be strictly controlled. The allocator will not be directly involved in the patient care.~* The allocator will also pre-package a pill in a small bag so that a distributor does not know which medication is being given to the patient.~* Gabapentin and placebo pills will be formulated by an investigational pharmacist to ensure both pills are identical in shape and form to further reduce bias."||t|t|t|f
34157839|NCT02327494|||COHORT||PROSPECTIVE|||||||
34157840|NCT05063682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157841|NCT02715986|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157842|NCT01304537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157843|NCT05507151|||COHORT||PROSPECTIVE|||||||
34157844|NCT04190732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34157845|NCT05515991|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34157846|NCT05089864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157847|NCT04563962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157848|NCT02106403|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
34157849|NCT00215059|||COHORT||PROSPECTIVE|||||||
34157850|NCT03824600|||COHORT||PROSPECTIVE|||||||
34157851|NCT02183233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34157852|NCT01886703|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34157853|NCT00005949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157854|NCT06511622|||COHORT||RETROSPECTIVE|||||||
34157855|NCT01916343|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34157856|NCT04879173|||CASE_ONLY||PROSPECTIVE|||||||
34157857|NCT02806453|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34054001|NCT06623097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157858|NCT00235144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157859|NCT02226874|||CASE_CONTROL||RETROSPECTIVE|||||||
33845949|NCT01800682|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157860|NCT03910114|||COHORT||RETROSPECTIVE|||||||
34157861|NCT03849222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||participants are allocated at random to receive one of 4 interventions according to the research plan.|t|f|f|t
34157862|NCT00685789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157863|NCT02080299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34157864|NCT00555672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157865|NCT05056506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34157866|NCT05325333|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-participant design in which each child learns words under two conditions.||||
34157867|NCT01559766|||||CROSS_SECTIONAL|||||||
34157868|NCT06583616|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157869|NCT00975949|||||PROSPECTIVE|||||||
34157870|NCT00209703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054002|NCT04774237|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34054003|NCT01901653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054004|NCT05900141|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study|Open-label extension (OLE) study||||
34054005|NCT02481401|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054006|NCT00266643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34054007|NCT01692210|||COHORT||PROSPECTIVE|||||||
34157871|NCT00032357|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34157872|NCT03217994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157873|NCT06330259|||CASE_ONLY||PROSPECTIVE|||||||
34157874|NCT04627207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157875|NCT04278976|RANDOMIZED|PARALLEL||OTHER||DOUBLE|To determine the level of competency achieved for each participant, an Objective Structured Clinical Examination (OSCE) will be performed at the end of the 3rd (R3) and 5th (R5) year of training in ICM. The OSCE will be performed simultaneously at four accredited simulation centers. The performances will be video recorded. All the video recordings will be later rated by two blinded raters, members of the experts panel, using specific checklists which include 25 items with a detailed description of the critical performance elements, the competencies technical (diagnosis and treatment) and non-technical (communication, team leadership, resource management) associated with each item, as well as specific information about what is expected to be done by the trainee. The participants will be unknown to raters. The members of the experts panel will not be part of the staff of the participants ICU Departments.|Multicenter cluster randomized trial of 14 ICU Department´s from 14 academic referral hospitals located in Spain|f|f|t|t
34157876|NCT03160820|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34157877|NCT02623621|||COHORT||PROSPECTIVE|||||||
34157878|NCT00002847||||TREATMENT||||||||
34157879|NCT01802125|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34157880|NCT05795985|||COHORT||PROSPECTIVE|||||||
34157881|NCT00892775|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34054008|NCT00737347|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34157882|NCT04788173|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34054009|NCT01963377|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34054010|NCT01329003|||||CROSS_SECTIONAL|||||||
34054011|NCT00049465|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34157883|NCT03190278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157884|NCT00988091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054012|NCT05787535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157885|NCT00373178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157886|NCT03546114|||OTHER||CROSS_SECTIONAL|||||||
34054013|NCT05405361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the double-blinded rollover treatment period (DTP),the investigator, trial nurse/coordinator, participant, and the sponsor's designated contract research organization (CRO), and sponsor trial team (except the sponsor's clinical trial supplies team) are blinded to IMP. The interactive response technology (IRT) system is used for blinding.||t|t|t|f
34054014|NCT02680834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054015|NCT02480374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054016|NCT01453478|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34054017|NCT03119753|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34054018|NCT01556568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075940|NCT05104073|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cohort of 60 infants will be recruited and randomized 2-3 weeks after birth to an intervention arm characterized by calibrated formula feeding recommendations or a control group with ad lib feeds as per usual care.||||
34075941|NCT01747356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157887|NCT02048163|||CASE_CROSSOVER||PROSPECTIVE|||||||
34157888|NCT00118742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157889|NCT00006773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157890|NCT03625336|||CASE_ONLY||PROSPECTIVE|||||||
34157891|NCT06455865|NON_RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34157892|NCT04227132|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Patients will be informed to take part in an experimental study on the rehabilitation of attention delivered through a computer game. Specific information about the rationale of the study will not be conveyed to patients. Both trainings will be administered, with the aim to support patients' autonomy in performance.|Both experimental and control trainings will be administered consecutively to all patients. Each type of training will be delivered for 10 sessions, with order of training randomized across participants.||||
34157893|NCT03268941|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study has two parts: Part 1 (double-blind) and Part 2 (open-label).||t|t|t|f
34157894|NCT00916019|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157895|NCT04688229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors with collect outcome measures in a lab area separate from treatment location. Outcome assessors have no role in randomization or treatment|Randomized study intervention vs standard of care rehabilitation in a 2:1 ratio balancing diagnostic groups|f|f|f|t
34157896|NCT02219958|||COHORT||PROSPECTIVE|||||||
34157897|NCT03406117|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34157898|NCT03825211|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34157899|NCT06521203|||CASE_CONTROL||RETROSPECTIVE|||||||
34157900|NCT00321867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157901|NCT01802710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157902|NCT04519281|||COHORT||PROSPECTIVE|||||||
34157903|NCT05271760|||CASE_CONTROL||PROSPECTIVE|||||||
34157904|NCT06082856|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34157905|NCT01195480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157906|NCT04010877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157907|NCT01462617|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157908|NCT01291407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157909|NCT02967068|||COHORT||OTHER|||||||
34157910|NCT03536234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157911|NCT04146935|NA|SINGLE_GROUP||OTHER||NONE||||||
34157912|NCT06094790|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34157913|NCT03536507|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34157914|NCT03207633|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34157915|NCT03265457|||CASE_CONTROL||PROSPECTIVE|||||||
34157916|NCT03689816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157917|NCT02328534|||COHORT||RETROSPECTIVE|||||||
34157918|NCT00465647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34157919|NCT02258646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34157920|NCT06066398|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||single group will be undergone thoracoscopy where pleural forceps biopsy, pleural brush and pleural lavage will be taken||||
34157921|NCT06465342|||COHORT||PROSPECTIVE|||||||
34157922|NCT04619498|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of this study, blinding of the participants, investigators and outcome assessors will not be possible. However, data analyses will be performed by a statistician who will be blinded to the allocation arm (PediAppRREST tablet app, PALS pocket reference card, no cognitive aid).|Randomized, controlled, three-parallel arm study||||
34157923|NCT03405649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Women contacting the lab will be divided into those women who have babies less than 20 weeks of age (Group A) and those whose babies are greater than 20 weeks of age (Group B). Each of these groups will be given a separate postpartum exercise program that will run concurrently. These groups were divided by baby age because we felt early postpartum women and babies are a different group than those women with babies 6 months and older.||||
34157924|NCT03666689|||COHORT||PROSPECTIVE|||||||
34157925|NCT01045694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157926|NCT01775605|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34157927|NCT01137370|||COHORT||PROSPECTIVE|||||||
33741571|NCT03794089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Baseline assessment, monthly follow-up assessments, and post assessment will be conducted by research assistants who are masked to participant condition|Randomized clinical trial with randomization to the intervention condition or control condition|f|f|f|t
33845950|NCT02275793|||COHORT||PROSPECTIVE|||||||
33845951|NCT05389917|||COHORT||PROSPECTIVE|||||||
33845952|NCT00935727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845953|NCT00721149|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33845954|NCT03041974|||COHORT||PROSPECTIVE|||||||
33845955|NCT05560334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845956|NCT05110352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845957|NCT05396768|||COHORT||CROSS_SECTIONAL|||||||
33950285|NCT04044404|||COHORT||PROSPECTIVE|||||||
33950286|NCT05033691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950287|NCT00172549|||DEFINED_POPULATION||OTHER|||||||
33950288|NCT04227730|||COHORT||PROSPECTIVE|||||||
33950289|NCT06429813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950290|NCT00204542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950291|NCT04746001|||CASE_ONLY||PROSPECTIVE|||||||
33950292|NCT01952873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950293|NCT04503109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950294|NCT04037826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be performed by Sponsor. Products will be send to research centers in blind bottles. Tablets for active and placebo have the same color and taste. Labelling will be performed in research centers.|Randomized, double blind, controlled clinical trial, with two branches. Randomization will be centralized performed by sponsor. L. reuteri Gastrus at dose of 2x108 Colony Forming Units (CFU) or placebo will be adminsitrated twice per day|t|t|t|t
33950295|NCT01716546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950296|NCT02623569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950297|NCT02307175|||CASE_CONTROL||PROSPECTIVE|||||||
33950298|NCT04177901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33950299|NCT03605277|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33950300|NCT05056311|NA|SINGLE_GROUP||OTHER||NONE||||||
33950301|NCT03156426|||CASE_ONLY||PROSPECTIVE|||||||
33950302|NCT01914107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950303|NCT02205281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33950304|NCT00883766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950305|NCT04846010|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|To restore the damaged structure and function of cells, participants come for the treatment with their diagnosis and experiment medics from their conventional practitioners. There have no masking for anybody.|This clinical study designed with a sequential assignment: participants receive their medical herbs depending on their pathological states; through one course of the treatment, we will review their symptoms and corresponding indicators of visceral damage。||||
33950306|NCT06467591|||COHORT||RETROSPECTIVE|||||||
33950307|NCT00517452|||COHORT||PROSPECTIVE|||||||
33950308|NCT02584972|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157928|NCT02321345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34157929|NCT00147121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157930|NCT02909374|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157931|NCT05275101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34157932|NCT02671097|NA|SINGLE_GROUP||||NONE||||||
34157933|NCT04374006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157934|NCT02486393|||COHORT||PROSPECTIVE|||||||
34157935|NCT02504580|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34157936|NCT02421289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34157937|NCT05900232|NA|SINGLE_GROUP||SCREENING||NONE||||||
34157938|NCT05602701|||COHORT||PROSPECTIVE|||||||
33950309|NCT00542165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950310|NCT00859313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054019|NCT06260111|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessor will be blinded only for the secondary outcomes. The person responsible for statistical analyses will also be blinded.|The design of the study consists of a randomized, controlled trial with parallel groups (photobiomodulation + usual care versus a control group with only usual care), allocation ratio of 1:1.|f|f|t|t
34054020|NCT04028427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054021|NCT06624930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All participants will be blinded to group assignment. Coordinating Research Assistants (RAs) will be the primary individuals responsible for scheduling all data collection assessments.~The participants will attempt to book all 3 assessments with same RA assessor who meets the following criteria:~* Are not a Qualified Exercise Professional (QEP) delivering one-on-one behavioural counselling~* Are not a QEP that is running group webinar will not be involved in any data collection~* Are not aware of participant's group allocation~At the beginning of all data collection sessions, participants will be reminded not to disclose their any information about the activities performed for the study group assignment to the study assessor (RA)."|two group, parallel randomized controlled trial|t|f|f|t
34054022|NCT02951533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054023|NCT01220765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054024|NCT02965196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054025|NCT00122538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054026|NCT04181047|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-blinded randomized controlled trial.||||
34075942|NCT06280898|||COHORT||RETROSPECTIVE|||||||
34157939|NCT02506023|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34157940|NCT03765892|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157941|NCT04317989|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This trial will evaluate the effect of primary care practice facilitation on evidence-based screening, counseling, and Medication-Assisted Treatment (MAT). Practices are considered the participants; the intervention is conducted on the practice level. All enrolled practices receive the practice facilitation intervention.||||
34157942|NCT04474015|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Groups A, B and C are run sequentially.||||
34157943|NCT05766176|||CASE_ONLY||PROSPECTIVE|||||||
34157944|NCT05636761|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33950311|NCT04536480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33950312|NCT00181051|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950313|NCT01445834|||||RETROSPECTIVE|||||||
33950314|NCT02293720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950315|NCT02001662|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33950316|NCT05056363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950317|NCT01285180|||COHORT||PROSPECTIVE|||||||
33950318|NCT00591916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950319|NCT02163525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950320|NCT00036868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950321|NCT00471237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950322|NCT02628197|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950323|NCT05847621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950324|NCT02301949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950325|NCT05952154|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental Group: Beating-heart myectomy device||||
34054027|NCT05450003|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||the study will evaluate 3 groups of patients each consists of 10 participants receiving different type of irrigation activation.|t|f|f|f
34054028|NCT06558747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054029|NCT04712019|RANDOMIZED|PARALLEL||TREATMENT||NONE||One leg receives ciNPT and the other leg receives standard silver containing dressing.||||
34054030|NCT02784613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054031|NCT05246059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054032|NCT03983473|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34054033|NCT04979195|||CASE_CONTROL||PROSPECTIVE|||||||
34054034|NCT01154296|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34054035|NCT05763394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34054036|NCT06618391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054037|NCT02059668|||COHORT||PROSPECTIVE|||||||
34054038|NCT06010238|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stepped wedge cluster randomized clinical trial||||
34054039|NCT06667323|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-assigned intervention treatment with concurrent comparison clusters||||
34054040|NCT02993952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054041|NCT03005275|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34054042|NCT06473454|RANDOMIZED|PARALLEL||TREATMENT||NONE||three goups , randomise controlled trial||||
34054043|NCT05876624|||OTHER||CROSS_SECTIONAL|||||||
34054044|NCT00654992|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34054045|NCT01813253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054046|NCT04638946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054047|NCT04866940|NA|SINGLE_GROUP||SCREENING||NONE||||||
34054048|NCT01354743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054049|NCT05988463|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, dose escalation treatment study||||
34054050|NCT06217575|RANDOMIZED|PARALLEL||TREATMENT||NONE||Behavioral intervention||||
34054051|NCT02202993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054052|NCT05024097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054053|NCT02918435|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34054054|NCT06344351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054055|NCT02012842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34054056|NCT05983003|||COHORT||RETROSPECTIVE|||||||
34054057|NCT06178952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants as well as the principal investigator, evaluating investigators, and the teams responsible for conducting stimulations, neuropsychological testing, and MR testing will be blinded. Specific individuals responsible for the organization of the study, who are neither involved in stimulation nor data collection, will not be blinded and will apply the verum or sham standoff device to the NEUROLITH system for a specific patient. As the stimulation team members won't have knowledge of the standoff device in use, they will remain completely blinded.|Prospective, \[multicenter\], double-blind, randomized, parallel group, placebo-controlled trial|t|t|t|t
34054058|NCT03994705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054059|NCT01589900|||COHORT||RETROSPECTIVE|||||||
34054060|NCT05533957|NA|SINGLE_GROUP||TREATMENT||NONE||This is an interventional study at low risk.||||
34054061|NCT00921102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054062|NCT04090528|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized, open-label, multi-institution phase II trial||||
34054063|NCT03836261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054064|NCT03430895|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, phase II study with a Simon minimax design testing the combination of durvalumab and tremelimumab in patients with non-TCC of the urothelial tract.||||
34054065|NCT03111472|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||30-40 participants will receive the intervention. The intervention will be a guide to help people with Parkinson's and their caregivers to self-manage falls. There will be no control group.||||
34054066|NCT02901743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054067|NCT00905281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054068|NCT02011711|||COHORT||PROSPECTIVE|||||||
34054069|NCT00370318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054070|NCT04042766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054071|NCT05610384|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34054072|NCT06617221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054073|NCT01751334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054074|NCT05700812|NA|SINGLE_GROUP||TREATMENT||NONE||Three phase study. Phase one will only include gathering baseline data without intervention. Phases two and three each include a different intervention.||||
34054075|NCT00991757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054076|NCT04194762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Intervention arm for each patient is masked for the raters|non pharmacological, randomised, double arm intervention. Treadmill training vs cycling training in equal intensity of exercise conditions.|f|f|t|t
34054077|NCT05409001|||CASE_ONLY||RETROSPECTIVE|||||||
34054078|NCT02379351|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34054079|NCT02192372|||COHORT||PROSPECTIVE|||||||
34054080|NCT03340220|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054081|NCT03831412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054082|NCT02748135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054083|NCT00650117|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34054084|NCT04631861|||CASE_CONTROL||RETROSPECTIVE|||||||
34054085|NCT06067399|||CASE_CONTROL||PROSPECTIVE|||||||
34075943|NCT01234597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054086|NCT04054973|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single arm pilot trial of L-arginine and Kuvan combination therapy||||
34054087|NCT02848365|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34054088|NCT03976687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054089|NCT00065104|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34054090|NCT00596128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054091|NCT04084730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054092|NCT02413385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34054093|NCT05178303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054094|NCT04868604|NA|SINGLE_GROUP||TREATMENT||NONE||This study is to be conducted in 3 phases, a dosimetry phase, a dose escalation phase and a cohort expansion phase.||||
34054095|NCT05798364|||COHORT||PROSPECTIVE|||||||
34054096|NCT06514040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054097|NCT06499233|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054098|NCT00981045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054099|NCT04916743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The lab tech will be blind to whether the sample under evaluation belongs to the intervention group or the control group. Outcome adjudicators, and data analysts will be kept blinded to the allocation. Moreover, all investigators, staff, and participants will be kept masked to outcome measurements and trial results.|Participants will be randomly allocate to intervention group or control group and will be examined in the same way.|f|f|f|t
34054100|NCT04569149|||CASE_ONLY||OTHER|||||||
34054101|NCT01192529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34054102|NCT00032188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054103|NCT03898479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054104|NCT00124007|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34054105|NCT00824382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34054106|NCT04775901|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34054107|NCT06094413|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A mixed-methods study design was used to assess the effectiveness of a multicomponent training program on quality of life, fear of falling, and physical performance in older adults. The study included a pre-mid-post-test design with an intervention group who performed an 8-week multicomponent training program and a comparison group composed of patients who do not perform the intervention.||||
34054108|NCT06621459|||COHORT||RETROSPECTIVE|||||||
34054109|NCT06051123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Phase 2 study|t|t|t|t
34054110|NCT04537910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34054111|NCT02874079|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34157945|NCT05704660|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and research assistant will be blinded to the groups' allocation. The participant blinding success will be appraised by asking them to guess in what group there were at the trial termination. Besides, the research assistant blinding success will be appraised via detecting the group allocation (Experimental vs. Control) by research assistant at the end of data collection phase. The randomization will be generated on a computer and an independent coworker will carry out the randomization. The participant's identification number will be used to determine the sequence of randomization. Participants will be randomized in a 1:1 ratio between the intervention and active control condition.||t|f|f|t
34054112|NCT01905553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054113|NCT02958280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054114|NCT03975556|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be unaware of the which educational messages are considered intervention or control. Investigators will not be in contact with participants and will only receive coded data. Outcome assessor will be unaware of treatment allocation of participant.||t|f|t|t
34054115|NCT05730244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054116|NCT00614120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054117|NCT05748158|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34054118|NCT03845634|||COHORT||PROSPECTIVE|||||||
34054119|NCT05140629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34157946|NCT04629690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be unaware if the participant was in control or intervention arm|Randomised control trial|f|f|f|t
34157947|NCT00268541|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34157948|NCT00680459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34157949|NCT03870204|||COHORT||PROSPECTIVE|||||||
34157950|NCT03152591|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34157951|NCT02412046|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157952|NCT01732016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157953|NCT00656435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157954|NCT06282913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34157955|NCT04740216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157956|NCT06366425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34157957|NCT04667741|||OTHER||PROSPECTIVE|||||||
34054120|NCT01296542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054121|NCT01233960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054122|NCT04725942|||COHORT||PROSPECTIVE|||||||
34054123|NCT03539770|||CASE_CONTROL||PROSPECTIVE|||||||
34054124|NCT05991609|||COHORT||CROSS_SECTIONAL|||||||
34054125|NCT03628989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054126|NCT00831974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054127|NCT00584272|||CASE_ONLY||RETROSPECTIVE|||||||
34054128|NCT05839782|||COHORT||CROSS_SECTIONAL|||||||
34054129|NCT04869696|||OTHER||PROSPECTIVE|||||||
34157958|NCT06583824|||COHORT||PROSPECTIVE|||||||
33845958|NCT04259151|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|To minimize bias, this study will be randomized and conducted in single blind. The patient will not be aware of the activation or not of the assistance module placed on the electric wheelchair. Indeed, the investigative team will be in charge of the activation of the robotic module.|"Each patient included will test a wheelchair equipped with a collision avoidance assistance module in 2 conditions, assistance activated or not.~This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream."|t|f|f|t
33845959|NCT01132443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845960|NCT04487704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950326|NCT05915780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols \& possible efforts will be put to mask the both groups about their treatments|It is a randomized control trial, used to compare the effect of aerobic exercises on static \& dynamic balance in children with down's syndrome. Subjects with down syndrome meeting the predetermined inclusion \& exclusion criteria will be divided into two groups using simple random sampling technique|t|f|f|f
33950327|NCT06219148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will remain masked to study objectives and their collaborative condition assignment. Research assistants and care providers (music therapists, social workers) will not be masked; social workers and music therapists will know if they are collaborating or not. Principal investigator Reschke-Hernandez and co-investigator Gibson will remain masked to allocation; research assistants will conduct allocation and assignment will be kept in a separate secure document that is not accessible to the PI or co-I.|"To ensure a balanced number of individuals in each study condition, a research team member will stratify participants as with or without dementia according to either their self-reported physician's diagnosis or score on the MoCA (score \<18 = with dementia). Participants will then be randomly assigned to either the collaborative or non-collaborative condition using a random number table."|t|f|t|f
33950328|NCT02861404|||CASE_ONLY||PROSPECTIVE|||||||
33950329|NCT05101473|NA|SINGLE_GROUP||TREATMENT||NONE||"The trial is a single-center single-group feasibility trial in outpatient clinical settings.~The trial will be reported with reference to the extended CONSORT guidelines."||||
33950330|NCT00987506|||COHORT||PROSPECTIVE|||||||
33950331|NCT02551874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950332|NCT05931601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950333|NCT01280305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950334|NCT04734366|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33950335|NCT02618096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950336|NCT04856852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950337|NCT03568136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950338|NCT01967810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950339|NCT01301157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950340|NCT02315651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33950341|NCT02978729|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950342|NCT00633217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950343|NCT00220311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950344|NCT01881711|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33950345|NCT06652451|||COHORT||RETROSPECTIVE|||||||
33950346|NCT04904952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950347|NCT04465591|||COHORT||CROSS_SECTIONAL|||||||
33950348|NCT06190860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33950349|NCT03808298|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33950350|NCT03704558|||CASE_ONLY||RETROSPECTIVE|||||||
33950351|NCT01636011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33950352|NCT06653582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950353|NCT01347905|||COHORT||PROSPECTIVE|||||||
33950354|NCT04324814|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation is designed according to a modified 3+3 scheme, in which 3 to 6 subjects will be enrolled in each dose group. Four dose levels of SHR-1701 are planned. After completion of dose escalation, selected cohort(s) will be expanded.||||
34054130|NCT02092480|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34054131|NCT06642155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will not be aware of whether they are receiving the ResponsiblePlay© intervention or the knowledge-based intervention. This single-blind design helps reduce bias related to participants' expectations.|Participants will be randomly assigned to one of two groups-the MTM-based ResponsiblePlay© intervention group and the knowledge-based intervention group, which will run in parallel.|t|f|f|f
34054132|NCT03762239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34054133|NCT02262689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054134|NCT06178653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054135|NCT05537441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34054136|NCT05221346|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34054137|NCT02683044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054138|NCT02845960|||COHORT||PROSPECTIVE|||||||
34054139|NCT03046901|NA|SINGLE_GROUP||PREVENTION||NONE||The study will be conducted as a prospective open-label pilot study of up to 20 patients who will receive oral vancomycin for 3-12 months as treatment for recurrent PSC after liver transplantation. There will be no masking or randomization.||||
34054140|NCT03355157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157959|NCT00015808||||TREATMENT||||||||
34157960|NCT01438450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157961|NCT00931775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34157962|NCT04146662|||OTHER||CROSS_SECTIONAL|||||||
34157963|NCT05931549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157964|NCT05374551|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34157965|NCT00718692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157966|NCT03073993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34157967|NCT01857297|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34157968|NCT04331002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The knee will be aspirated and one group will receive a single 32 mg Zilretta injection and the other group will receive a 5 mL saline injection. The syringes will be blinded to ensure that both the investigator administering the injection and the patient will be blinded to the group assignment.|"After providing informed consent prior to ACL reconstruction with meniscal involvement, synovial fluid will be collected and assessed for the concentration of pro-inflammatory cytokine interleukin-1alpha (IL-1a). This will be done to identify patients that present with persistent inflammation after surgery that may be at increased risk of cartilage degradation.~Patients with elevated IL-1a, defined as concentrations \> 5 pg/mL, will then be randomized to one of two groups. The threshold of 5 pg/mL was based on our pilot study of 19 patients.~For those with elevated IL-1a, eight weeks after surgery the knee will be aspirated and one group will receive a single 32 mg Zilretta injection and the other group will receive a 5 mL saline injection."|t|t|t|t
34157969|NCT05310331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157970|NCT04520256|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34157971|NCT01590693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157972|NCT04836845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34157973|NCT06332105|RANDOMIZED|CROSSOVER||TREATMENT||NONE||2-stage, 15-week randomized crossover trial.||||
34157974|NCT05486611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34157975|NCT04325620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157976|NCT01210586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845961|NCT05873764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845962|NCT04693195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two-arm, parallel assignment|t|t|t|t
33845963|NCT02837224|||OTHER||RETROSPECTIVE|||||||
33845964|NCT05331313|||COHORT||PROSPECTIVE|||||||
33845965|NCT01883232|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33845966|NCT00003236|RANDOMIZED|||TREATMENT||||||||
33845967|NCT06609525|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33845968|NCT05898347|||CASE_ONLY||PROSPECTIVE|||||||
33845969|NCT03914001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845970|NCT05537116|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to conditions using a random number generator.||||
33845971|NCT02371291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845972|NCT01971359|||CASE_ONLY||PROSPECTIVE|||||||
33845973|NCT03211767|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33845974|NCT02144792|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845975|NCT05958550|||COHORT||PROSPECTIVE|||||||
33845976|NCT05776641|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33845977|NCT05871684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845978|NCT02801032|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33845979|NCT03698500|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33845980|NCT04654845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will not be aware of the type of procedure he has been assigned for.|Participants with irreversible pulpitis are randomly assigned to one type of intervention.|t|f|f|f
33950355|NCT00796367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950356|NCT02894801|||COHORT||RETROSPECTIVE|||||||
33950357|NCT01687127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33950358|NCT04864704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950359|NCT02568501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33950360|NCT05806658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single (Outcomes Assessor)|Parallel randomised controlled trial|f|f|f|t
33950361|NCT01312363|||CASE_ONLY||PROSPECTIVE|||||||
33950362|NCT04768881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950363|NCT04435431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950364|NCT03853226|||OTHER||PROSPECTIVE|||||||
33950365|NCT01260064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950366|NCT01821131|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33950367|NCT00103389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950368|NCT04132206|||COHORT||PROSPECTIVE|||||||
33950369|NCT00917904|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33950370|NCT03796572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized envelopes used to allocate treatment groups.|Double-blinded randomized control trial|t|f|t|f
33950371|NCT04240782|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950372|NCT04911569|NA|SINGLE_GROUP||TREATMENT||NONE||Non-blinded, non-randomized, non-controlled||||
33950373|NCT05996211|||COHORT||PROSPECTIVE|||||||
33950374|NCT05139485|||COHORT||PROSPECTIVE|||||||
33950375|NCT02863588|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33950376|NCT05190094|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, open-label study.||||
33950377|NCT06479317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950378|NCT01441882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950379|NCT00227591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950380|NCT05071521|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33950381|NCT00000509|RANDOMIZED|PARALLEL||TREATMENT||||||||
33950382|NCT04001270|||CASE_CONTROL||RETROSPECTIVE|||||||
34054141|NCT06052423|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm||||
34054142|NCT05546346|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34054143|NCT06304883|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open-label, single group, long-term extension study.||||
34054144|NCT00639574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054145|NCT04014166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054146|NCT03075345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34054147|NCT03991169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054148|NCT01383629|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34054149|NCT00754208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054150|NCT03358108|||CASE_CONTROL||PROSPECTIVE|||||||
34075944|NCT03462784|||OTHER||CROSS_SECTIONAL|||||||
34075945|NCT00402792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34157977|NCT06527417|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this randomized controlled and prospective study, investigators included 15 participants with complete thoracic spinal cord injury. Investigators divided the participants into two groups, where one group received the electromyography-triggered electrical stimulation applied to the erector spinae and multifidus muscles, and the control group received trunk eccentric exercises only, applied three times a week for four weeks.||||
34157978|NCT06015087|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34157979|NCT01808235|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34157980|NCT05529836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To ensure blinding, we will choose the Park Sham Device (PSD) as a placebo control in the single-blind clinical trial, use a way of not energizing the electroacupuncture device, and use black eye masks to shield participants' eyes. The treatment device will also be of the same size and material, and the treatment method will maintain consistent frequency and intensity.||t|f|f|f
34157981|NCT01827527|||COHORT||PROSPECTIVE|||||||
34157982|NCT06183073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34157983|NCT05165758|||COHORT||PROSPECTIVE|||||||
34157984|NCT01280695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157985|NCT06550518|||COHORT||RETROSPECTIVE|||||||
34157986|NCT02768519|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34157987|NCT03731247|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||One group of skin cancer patients One group without skin cancer patients||||
34157988|NCT03941626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157989|NCT05998577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157990|NCT04924998|||COHORT||PROSPECTIVE|||||||
34157991|NCT04352023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|2, 4, 6 block randomization|"Randomized controlled trial, prospective, single institute Experimental: A IV-PCA group IV-PCA drug: Fentanyl 3000 mcg and Oxycodone 100 mg were mixed Normal saline 200 ml Procedure/Surgery: Patient-controlled analgesia Intravenous patient-controlled analgesia Patient-controlled epidural analgesia~Experimental: B PCEA group PCEA drug: Morphine 5 mg and Ropivacaine 750 mg were mixed Normal saline 400 ml loading of preadministered Morphine 1 mg and Ropivacaine 11.25 mg Procedure/Surgery: Patient-controlled analgesia Intravenous patient-controlled analgesia Patient-controlled epidural analgesia"|t|t|t|f
34157992|NCT03453580|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34157993|NCT05760768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34157994|NCT01521663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34157995|NCT01792115|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34157996|NCT02718092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34157997|NCT01445080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34157998|NCT03288922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34157999|NCT03882658|||COHORT||RETROSPECTIVE|||||||
34158000|NCT04293107|||COHORT||PROSPECTIVE|||||||
34158001|NCT02953574|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158002|NCT03333629|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34158003|NCT06474312|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study is a Cluster Randomized Control Trial (CRCT) research / study. The selection and approval of 64 Government schools was obtained will be done by the local PI based on comparable demographics (i.e. similar levels of socio-economic status) in the Nowgong block of Chhatarpur district. Two of the four schools will receive the intervention (intervention arm) and the other two will be the control arm.~A sample size of n = 170 young people in each arm will be recruited from participating schools who are studying in 7th and 8th classes, aged between 12 - 17 years old. Sample size was calculated using optimal design software.~The demographic data (e.g. age, father and mother completed years of education, caste, religion, etc.) as well as psychometric measures will be collected at baseline (prior to intervention) and endline (post intervention).~All participants below 18 years of age will only be recruited after parental consent and self-assent."||||
34158004|NCT05930184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Periwound-TAP block using 0.25%Bupivacain 20ml and local wound infiltration using 0.25%Bupivacain 20ml|t|t|t|t
34158005|NCT00879203|||CASE_CONTROL||PROSPECTIVE|||||||
34158006|NCT01166204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158007|NCT00231413|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"This study was performed in a double-blinded manner. Blinding was maintained for all subjects and investigators and their study staff participating in this study with regard to the individual subject treatment (vaccine treatment) assignments allocated in this study.~GSK personnel directly involved in the conduct of this study were also blinded to the subjects' treatment assignments."||t|f|t|f
34158008|NCT02436538|||CASE_ONLY||RETROSPECTIVE|||||||
34158009|NCT05716360|||COHORT||PROSPECTIVE|||||||
34158010|NCT03180125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158011|NCT01477489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158012|NCT01022099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158013|NCT05177367|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34158014|NCT05787925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158015|NCT05513053|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158016|NCT01755871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158017|NCT00874848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158018|NCT02604563|||COHORT||PROSPECTIVE|||||||
34158019|NCT02306642|||COHORT||RETROSPECTIVE|||||||
34075946|NCT04300712|NA|SINGLE_GROUP||OTHER||NONE||||||
34075947|NCT04848636|||COHORT||CROSS_SECTIONAL|||||||
34075948|NCT00378885|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34075949|NCT05679245|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34075950|NCT04710069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Attending surgeons are not aware of participant treatment arm until after the participant undergoes their operation||f|t|f|f
34075951|NCT05177640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075952|NCT03291639|||CASE_ONLY||PROSPECTIVE|||||||
34075953|NCT05549583|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34075954|NCT06453395|||CASE_CONTROL||RETROSPECTIVE|||||||
34054151|NCT03385304|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The orthopaedic team (including the study coordinators) cannot be blinded to the treatment allocation as the antiseptic solutions are visually distinguishable and these individuals need to lead the implementation of the cluster-crossover protocol at their clinical site. The Adjudication Committee Members and data analysts will be blinded to the study treatment. All interpretation of study results will initially be done in a blinded manner by developing two interpretations of the results. One interpretation will assume treatment A is povidone-iodine, the other interpretation will assume it is CHG. Once the data interpretations for each assumption are finalized, the data will be unblinded and the correct interpretation will be accepted.|Treatment allocation will be determined using a cluster-randomized crossover trial design. The order of treatment allocation for each orthopaedic practice will be randomly assigned using a computer generated randomization table. Each site will start with the initially allocated study solution and eventually crossover to the other solution for their second recruitment period. This process of alternating treatments will repeat approximately every 2 months as dictated by the initial randomization.|f|f|f|t
34054152|NCT01597388|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34054153|NCT06202664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients enrolled will be divided into two groups through computer generated random numbers. Standard ASA monitoring will be done. Intervention will be done at the time of induction of anesthesia that is opioid based analgesia vs Erector Spinae block bilaterally at T6 level. In both groups intra-operative rise in Heart Rate or Blood Pressure or both by more than 20% from baseline value particularly upon skin incision and generation of pneumoperitoneum will indicate inadequate analgesia. This will then be supplemented with 0.5 Mcg/kg of IV Fentanyl increments along with 1g IV Paracetamol and 30 mg IV Ketorolac . Post operatively if VAS score is greater than 4 then rescue analgesia in the form of 1g of IV Paracetamol will be given. This will be supplemented with 15 mg of IV Ketorolac if VAS score is greater than 6. IV Tramadol at dose of 50mg will be given if the VAS score is greater than 8.|t|f|f|t
34054154|NCT06036043|||COHORT||PROSPECTIVE|||||||
34054155|NCT03896711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind, pilot, randomized controlled trial where outcome assessors are masked to treatment arm allocation.|Activity-based companion care program. MEMORI Corps is a companion care model that provides regular companionship and personalized activities to community-living persons with dementia (PWD) delivered by trained volunteer Companion Guides 55 years of age or older. Core intervention components include: (1) detailed virtual assessment of health, well-being, and interests of PWD; (2) personalized activity plans; (3) specialized training of volunteer Companion Guides in virtual program delivery; (4) regular companionship and personalized activities delivered to PWD over 12 weeks; (5) family caregiver education on activity plans and ways to utilize respite opportunities; and (6) multidisciplinary expert support of volunteer companion guides. The goals of the program are to reduce social isolation and improve health and well-being for PWD, reduce burden and support family CGs, and to provide health benefits and meaningful engagement for older volunteer Companion Guides.|f|f|f|t
34158020|NCT01001793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158021|NCT01557907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158022|NCT03406013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845981|NCT03284229|NA|SINGLE_GROUP||TREATMENT||NONE||As per the 25th SEC (Cardiovascular \& Renal) meeting which deliberated the proposals on 30-10-2015 and recommended the firm (Spectranetics Corporation - Sponsor) shall conduct a Bridging study in Indian Population at least 25 patients with coronary artery disease. The directorate suggested that the sponsor submit a protocol for the study in India for clinical trial approval. Considering the 5 dropouts, Sponsor has set up this protocol to conduct the Excimer Laser Coronary Atherectomy (ELCA®) study in India on 30 eligible patients across 05 sites as a Stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA) in single or multi-vessel coronary artery disease.||||
33845982|NCT01011153|||COHORT||CROSS_SECTIONAL|||||||
33845983|NCT05701306|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33845984|NCT05559970|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33845985|NCT02008877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33845986|NCT01361594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950383|NCT03195270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will be recruited based on established criteria for chronic pain. For the PET/MRI scan, the participants will be injected with 10 mCi±1 mCi of \[18F\]FTC-146 via the antecubital vein in a bolus injection. PET and MRI scans will be acquired simultaneously using a hybrid PET/MRI scanner. Following the scan, participants will be contacted to check for adverse drug events, and any events will be recorded in the case report. The biodistribution of radiotracer will be analyzed using regions of interest (ROI) marked on anatomical structures on magnetic resonance images and quantifying the signal in PET images within the same ROIs. Pharmacokinetic information will be derived using mathematical modeling. Data from chronic pain patients will be compared to historical data from asymptomatic controls.||||
33950384|NCT04233372|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950385|NCT04946773|||COHORT||PROSPECTIVE|||||||
33950386|NCT01225601|||COHORT||PROSPECTIVE|||||||
33950387|NCT01165892|||COHORT||PROSPECTIVE|||||||
33950388|NCT02659657|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950389|NCT01729559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33950390|NCT00664066|||COHORT||PROSPECTIVE|||||||
33950391|NCT06181552|||COHORT||PROSPECTIVE|||||||
33950392|NCT05377762|||OTHER||PROSPECTIVE|||||||
34054156|NCT01051544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054157|NCT00301496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054158|NCT05732142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34158023|NCT02087969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158024|NCT00950248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158025|NCT02700828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158026|NCT00681733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34158027|NCT05289479|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34158028|NCT02712528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158029|NCT04892771|||COHORT||RETROSPECTIVE|||||||
34158030|NCT00746694|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158031|NCT05917054|||OTHER||PROSPECTIVE|||||||
34158032|NCT00003883|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34158033|NCT02235896|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158034|NCT04844853|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34158035|NCT05640037|||COHORT||PROSPECTIVE|||||||
34158036|NCT02485704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158037|NCT06443983|RANDOMIZED|PARALLEL||OTHER||NONE||In this study, students will be divided into two groups: those who take an AI-supported case lesson and those who take a standard case lesson.||||
34158038|NCT00556816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158039|NCT02274740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158040|NCT03799939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are unaware of the randomization group.|Chimney trial is a prospective randomized controlled multicenter trial.|t|f|f|f
34158041|NCT04020835|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158042|NCT04896281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158043|NCT04771702|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The intervention is to have patients in 20 min stable anaesthesia before start of surgery in order to validate the use of exhaled propofol versus pharmakokinetic modelling and measured plasma concentration||||
34158044|NCT01178203||PARALLEL||TREATMENT||||||||
34158045|NCT03813914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158046|NCT00523081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34158047|NCT03686475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinding||t|t|f|t
34158048|NCT02138968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158049|NCT02850380|NA|SINGLE_GROUP||||NONE||||||
34158050|NCT01675193|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34158051|NCT02450162|||CASE_CONTROL||PROSPECTIVE|||||||
34158052|NCT03565146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158053|NCT04469660|||COHORT||PROSPECTIVE|||||||
34158054|NCT01119092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158055|NCT06324084|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158056|NCT03893682|NA|SEQUENTIAL||TREATMENT||NONE||||||
34158057|NCT03027349|||CASE_CONTROL||RETROSPECTIVE|||||||
34158058|NCT05351112|||COHORT||OTHER|||||||
34158059|NCT06555328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158060|NCT01249547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158061|NCT04904874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158062|NCT05465343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158063|NCT05985967|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34158064|NCT05546229|||CASE_ONLY||PROSPECTIVE|||||||
34158065|NCT05729243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158066|NCT00310817|RANDOMIZED|||PREVENTION||DOUBLE|||t|f|t|f
34158067|NCT05912972|||COHORT||OTHER|||||||
34158068|NCT04396158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||self controlled case series||||
34158069|NCT03781440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34158070|NCT06208995|||COHORT||PROSPECTIVE|||||||
34158071|NCT03105336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158072|NCT01691040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158073|NCT05745519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158074|NCT02659072|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34158075|NCT05220358|NA|SINGLE_GROUP||TREATMENT||NONE||self-controlled case series to evaluate the change in immunologic parameters following the addition of FOS to baseline ARV regimens among virologically suppressed INRs through 48 weeks of treatment.||||
34158076|NCT03308253|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34158077|NCT02420236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158078|NCT02074839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158079|NCT01153724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158080|NCT02781168|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34158081|NCT00999440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158082|NCT02725541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158083|NCT01865643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158084|NCT03549377|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34158085|NCT04924270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158086|NCT05999500|||COHORT||PROSPECTIVE|||||||
34158087|NCT03515356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158088|NCT05293184|||CASE_ONLY||PROSPECTIVE|||||||
33845987|NCT06476652|||COHORT||PROSPECTIVE|||||||
33845988|NCT02159508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158089|NCT05321407|||CASE_CONTROL||PROSPECTIVE|||||||
34158090|NCT00003364|RANDOMIZED|||TREATMENT||||||||
34158091|NCT05933707|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34158092|NCT06167876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158093|NCT04489472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158094|NCT03964324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158095|NCT03492034|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158096|NCT01444846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158097|NCT06583902|||CASE_CONTROL||OTHER|||||||
34158098|NCT05716932|||CASE_ONLY||RETROSPECTIVE|||||||
34158099|NCT04435028|||OTHER||PROSPECTIVE|||||||
34158100|NCT01387464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158101|NCT01389037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158102|NCT01438606|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34158103|NCT03392818|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
34158104|NCT03559933|NA|SINGLE_GROUP||TREATMENT||NONE||The pdSTIM Leads are temporarily inserted near the right and left phrenic nerves and connected to the PEPNS System console. Duration of stimulation in PEPNS study is up to 48 hours to allow periodic electrical stimulation in daily sessions until the patients is weaned or 48 hours since initiation of stimulation session has elapsed.||||
34158105|NCT01679873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34158106|NCT01590160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158107|NCT00837993|||CASE_ONLY||PROSPECTIVE|||||||
34158108|NCT01047163|||COHORT||CROSS_SECTIONAL|||||||
34158109|NCT03345537|||COHORT||PROSPECTIVE|||||||
34158110|NCT01760772|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34158111|NCT01839812|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33845989|NCT03845140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845990|NCT00675675|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33845991|NCT01184040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950393|NCT01874379|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950394|NCT05018533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Not applicable to a drug allotment and a dispensing staff||t|t|t|t
33950395|NCT03779373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized controlled trial|t|f|f|f
34054159|NCT00217776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054160|NCT03319264|NA|SINGLE_GROUP||SCREENING||NONE||||||
34054161|NCT06408545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054162|NCT04053140|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34054163|NCT01118260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054164|NCT05753891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054165|NCT00893165|||CASE_CROSSOVER||PROSPECTIVE|||||||
34054166|NCT02101931|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34054167|NCT05032092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open, Prospective, Multicentre IVD (in vitro diagnostic device) Study||||
34054168|NCT06618469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|For masking the participants, the investigators will not inform participants of what group they will be in. For outcome assessor, data collectors and data analysts independent people will be use, and if this is not possible, a random code will be created for each participant so that it is not possible to identify which group belongs to.|This is a randomized, duoble-blind (sport scientiest assistance/care assistance-outcome assessor), 6 arms prospective parallel design clinical trial. The older adults will be recruited from the Municipal Activity Centers for Older People located in Valencia and will be randomized in a prospective clinical trial study with a 6 parallel arms study design to a tubes or bands or water resistance training modalities performed at different intensities or a control group over a 32 weeks period.|f|t|f|t
34054169|NCT06619977|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054170|NCT02768116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054171|NCT04529252|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075955|NCT05627518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34075956|NCT05855837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34158112|NCT04578184|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34158113|NCT04922307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158114|NCT02908789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34158115|NCT03704909|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34158116|NCT00626171|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34158117|NCT04569981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Movement disorder specialists who performed the MDS-UPDRS III ratings were blinded to the group assignment.|The participants were randomly assigned to either the climbng group or the unsupervised active group|f|t|f|f
34158118|NCT00959205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158119|NCT06359080|NA|SINGLE_GROUP||TREATMENT||NONE||"Open Label Study~This will be an one-arm, open label study. Participants who were in the placebo condition in the previous study, will receive the treatment. Participants who were in the active condition in the previous study will repeat the course of treatment after the intermission of 3-6 months (depending on when they completed the study)."||||
34158120|NCT04681963|||COHORT||CROSS_SECTIONAL|||||||
34158121|NCT03577678|NA|SINGLE_GROUP||OTHER||NONE||Surgery was made to fix the new prosthesis||||
34158122|NCT05099835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158123|NCT06348667|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34158124|NCT01085864|||OTHER||PROSPECTIVE|||||||
34158125|NCT02240355|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34158126|NCT01918280|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158127|NCT04701567|||COHORT||RETROSPECTIVE|||||||
34158128|NCT02120326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34158129|NCT02596789|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158130|NCT01806909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158131|NCT05186168|||COHORT||PROSPECTIVE|||||||
34158132|NCT02580461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34158133|NCT01992263|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34158134|NCT02069392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158135|NCT03170960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation followed by Dose Expansion||||
34158136|NCT01630291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158137|NCT05162313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants are newborns. The care provider will be the attending physician performing the tracheal intubation procedure as per local protocols, including the colourimetric capnometry analysis. However, he/she will remain blind and not aware of the flow sensor data until the end of the procedure.|Simultaneous assignment, as the two methods to confirm the endotracheal tube position, namely the colorimetric capnometer and the flow sensor signal, will be evaluated simultaneously in each recruited patient.||||
34158138|NCT00509626|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34158139|NCT01248741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158140|NCT01657292|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158141|NCT00230958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158142|NCT01561053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34158143|NCT02431078|||COHORT||PROSPECTIVE|||||||
34158144|NCT02487862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34158145|NCT02865902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158146|NCT04233450|||CASE_ONLY||CROSS_SECTIONAL|||||||
33950396|NCT01297738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33950397|NCT00402506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33950398|NCT06091176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33950399|NCT06045910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950400|NCT05002738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33950401|NCT00790270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950402|NCT01477541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33950403|NCT03686085|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34158147|NCT00081055|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34158148|NCT04407741|RANDOMIZED|PARALLEL||TREATMENT||NONE||In phase I period, patients that meet inclusion and exclusion criteria are enrolled to evaluate the safety, feasibility and pharmacokinetics of SHR2554 plus SHR1701. In the following phase II period, based on the recommended dose level from phase I study, enrolled patients are randomized to trial group (SHR2554 plus SHR1701) and control group (SHR1701) to assess the clinical efficacy of SHR2554 plus SHR1701 and immunomodulating effect of SHR2554 to SHR1701 in each cohort.||||
34158149|NCT03226470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158150|NCT05346406|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34158151|NCT06435923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158152|NCT04607811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34158153|NCT00958646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34158154|NCT02176239|||COHORT||PROSPECTIVE|||||||
34158155|NCT02338700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158156|NCT04724798|||CASE_ONLY||RETROSPECTIVE|||||||
34158157|NCT03806686|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Since the vials of ID93+GLA-SE and placebo control (normal saline) and their appearances after preparation are different, for double-blinding of the study, the study nurse who administers the study drug or the study pharmacist who stores and manages the study drug will be unblinded to maintain the quality of study blinding. Additionally, an unblinded study monitor will be responsible for confirming the quantity and release of the study drugs. Unblinded study personnels and unblinded study monitor should only be involved in the duties related to administration and/or recording of the study drug, and must not be involved in other duties that may break double-blinding of the study.|Participants will be assigned to one of three groups: Low dose ID93+GLA-SE, High dose ID93+GLA-SE, or Control Group.|t|t|t|t
34158158|NCT05300789|||COHORT||RETROSPECTIVE|||||||
34158159|NCT05761002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158160|NCT04456192|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study was designed as a prospective trial where two similar groups of women only differing in body mass participate in the same intervention.||||
34158161|NCT03370224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158162|NCT02286024|||CASE_ONLY||PROSPECTIVE|||||||
34158163|NCT06369116|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE||Participants are recruited and enrolled to conduct INSTI HCV Self Test and then participate in the usability portion of the study.|f|t|f|f
34158164|NCT00565123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158165|NCT01635881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158166|NCT03872856|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group randomized comparison trial||||
34158167|NCT06546852|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study sample, conducted with an experimental design, consisted of 71 patients (36 experimental and 35 control) who received dialysis treatment in a private dialysis centre affiliated with the Istanbul Provincial Health Directorate.|t|f|f|f
34158168|NCT00437411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741572|NCT04968067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To minimize subject contamination, the different groups will be assigned different follow-up dates. The research assistants who are responsible for collecting data will be blinded to the group allocations. To ensure allocation concealment, each computer generated sequence will be put in a sequentially numbered, opaque sealed envelope. The envelope will be opened by RA1 after the participant has completed the baseline questionnaire.|This study will employ a prospective randomized controlled trial (RCT) with two arms, namely, the App group, NTA (nursing telephone advice) group. This design is guided by the CONSORT checklist|f|f|t|t
33741573|NCT01431066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33845992|NCT05739682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both final irrigating solutions are colorless and will be delivered inside the root canal using a plastic syringe without the patient knowing the type of solution used.~The microbial samples will be sent to the lab for microbial count assessment with a code without identification of the type of irrigating solution used."||t|f|f|t
33845993|NCT01363544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33845994|NCT00001145||||TREATMENT||||||||
33845995|NCT05114473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the nature of the intervention, participants can't be blinded to allocation, but are strongly inculcated not to disclose the allocation their status at the follow up assessments. Care providers will be different from outcome assessors and will be both blinded by an external investigator.|Two groups receiving intervention and one serving as control|f|t|t|t
33845996|NCT04825561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33845997|NCT04096833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the care giver (nurse) will know the assignment of participants to the treatment groups.|Randomized Controlled Trial|t|f|t|t
33845998|NCT00867204|||CASE_CONTROL||PROSPECTIVE|||||||
34158169|NCT03828851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33845999|NCT02677428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846000|NCT03140280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846001|NCT02272673|||CASE_CROSSOVER||PROSPECTIVE|||||||
33846002|NCT04330001|NA|SINGLE_GROUP||OTHER||NONE||||||
33846003|NCT04068961|||COHORT||RETROSPECTIVE|||||||
33846004|NCT01548534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33950404|NCT01965600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33950405|NCT03878108|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950406|NCT03233009|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33950407|NCT04249908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950408|NCT03444129|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950409|NCT05174208|||COHORT||RETROSPECTIVE|||||||
33950410|NCT02821546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33950411|NCT02189538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33950412|NCT00683670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950413|NCT02213627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950414|NCT02400697|||COHORT||PROSPECTIVE|||||||
33950415|NCT06249087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33950416|NCT00990366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950417|NCT05144919|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741574|NCT01263340|||COHORT||RETROSPECTIVE|||||||
34054172|NCT04739722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This phase 3 clinical trial (CRC-PREVENT) was a blinded, prospective, cross-sectional study to support a premarket approval application for a class III medical device. Subjects were recruited onto the clinical trial if they were average-risk subjects, or had a self-reported family history of CRC, aged 45 and older. All participants completed the ColoSense test, which incorporated a commercially available fecal immunochemical test (FIT), concentration of 8 RNA transcripts, and participant-reported smoking status. Stool samples were collected prior to participants completing a colonoscopy at their local endoscopy center. The ColoSense test result (positive or negative) was compared with index lesions observed on colonoscopy. The primary outcomes included ColoSense sensitivity for detecting colorectal cancer, advanced adenomas, or serrated precancerous lesions, and ColoSense specificity for all other findings.||||
34054173|NCT06136182|||COHORT||RETROSPECTIVE|||||||
33741575|NCT03855189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741576|NCT02855294|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741577|NCT00260923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33741578|NCT04379908|||CASE_ONLY||CROSS_SECTIONAL|||||||
33741579|NCT01731171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741580|NCT00870779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741581|NCT04440111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33741582|NCT02566395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741583|NCT06531720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A randomized, double-blind study was conducted, based on the CONSORT study protocol for randomized clinical trials.|"According to randomization patients suffering from oral mucosa lesion (OML) were divided into three groups:~* Group I: oral mucosa lesions treated with 0,2% CHX topical use,~* Group II: oral mucosa lesions treated with 8,7% CHS topical use and~* Group III: oral mucosa lesions as control group-CON with no specific OML treatment.~The efficacy of oral topical medications in aiding regeneration and healing of oral soft mucosa, caused by the use of removable prosthetic restorations was analyzed. The evaluation of the efficacy of these agents was based on a comparison of the area of OML before and after the treatment. Patients in the control group were not using any topical medication."|t|t|t|f
33741584|NCT02800044|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33741585|NCT06458634|||COHORT||RETROSPECTIVE|||||||
33741586|NCT05186324|||OTHER||OTHER|||||||
33741587|NCT06178666|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||A feasibility study of a controlled human infection model (CHIM) with intradermal bacillus Calmette-Guérin (BCG) injection in Malawi||||
33741588|NCT04419896|||CASE_ONLY||OTHER|||||||
33741589|NCT04426058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741590|NCT03666676|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741591|NCT03524391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741592|NCT01806337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741593|NCT03062826|||CASE_ONLY||PROSPECTIVE|||||||
33741594|NCT01213758|||COHORT||PROSPECTIVE|||||||
33741595|NCT01539291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741596|NCT01806480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33741597|NCT00920192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741598|NCT00335907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741599|NCT01149304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741600|NCT02014961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33741601|NCT05490459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741602|NCT00674310|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741603|NCT02341300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33741604|NCT00958919|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741605|NCT04824846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741606|NCT02087800|||CASE_CROSSOVER||PROSPECTIVE|||||||
33741607|NCT01699997|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741608|NCT00510666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846005|NCT00396760|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33741609|NCT02842775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741610|NCT03907501|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This study will employ double-blind masking and only the project manager will be aware if the participant is assigned to take the synbiotic, triphala alone, or placebo. At the end of the 8 weeks, participants will be made aware of their randomly assigned supplement.|Interested and eligible participants will be randomly assigned to either an 8-week synbiotic group, herb alone, or placebo control with a goal to obtain 60 patients who complete the study (20 in each group) after an estimated 20% attrition. Placebo control subjects will be given the option of having the 8-weeks of herbal synbiotic for directed personal use upon conclusion of the study.|t|f|t|t
33741611|NCT03790891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741612|NCT05926297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patients will be unaware of the type of treatment performed, with prior written informed consent. So, they will be divided in the two groups of study after a process of randomization|The study will be designed as a double-arm randomized controlled clinical trial. Mucositis will be treated with NaOCl-based gel + NSMD + HA-based gel in Test group and with NSMD alone in Control group. All clinical parameters will be recorded and the final evaluation will be performed.|t|f|f|f
33741613|NCT04134897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741614|NCT01594905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846006|NCT05286320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846007|NCT06611202|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group pretest-post-test design||||
33846008|NCT00738894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846009|NCT06598410|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846010|NCT05574517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind trial in which participants were unaware of the study group and the intervention.|Participants are randomly assigned to an experimental or control group in parallel.|t|f|f|f
33741615|NCT04674345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846011|NCT00591539|||COHORT||PROSPECTIVE|||||||
33846012|NCT01790841|||CASE_CONTROL||PROSPECTIVE|||||||
33846013|NCT04288102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled study|t|t|t|t
34158170|NCT01351961|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158171|NCT03007602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34158172|NCT03144375|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34158173|NCT00303225||||TREATMENT||||||||
34158174|NCT02384512|||COHORT||PROSPECTIVE|||||||
34158175|NCT02481245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158176|NCT05669872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158177|NCT03851198|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34054174|NCT03060343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158178|NCT04410406|RANDOMIZED|PARALLEL||TREATMENT||NONE|Recognizing that number and appearance of tablets received in each study arm will be noticeably different, this study will not be completely masked to participants or care providers. To minimize bias, administration of study medications will be performed by a staff member with no role in assessing AEs. AE assessments and all other outcome measures will be assessed by observers masked to the treatment assignment as best as possible.|This trial is a single-site, Phase III, randomized, open-label, masked-observer superiority trial with four treatment arms (IA, MoxA, IDA, and MoxDA). Block randomization by gender will be used to assign treatment arms.||||
34158179|NCT00625781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34158180|NCT04972461|||COHORT||PROSPECTIVE|||||||
34158181|NCT00635882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158182|NCT00077324|||CASE_ONLY||PROSPECTIVE|||||||
34158183|NCT03682913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158184|NCT00119366|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This study will assess the feasibility and safety of patients with advanced AML or high-risk MDS treated with Iodine-131 BC8 antibody at a starting dose of 22 Gy delivered to the normal organ receiving the highest dose combined with fludarabine and 2 Gy total body irradiation (TBI), plus cyclosporine (CSP)/mycophenolate mofetil (MMF), followed by matched related or unrelated allogeneic hematopoietic stem cell transplantation (HSCT). Determination of the maximum tolerated dose (MTD) will be the major study endpoint.~Dose-escalation/de-escalation of radiolabeled BC8 antibody (I-131-BC8) is conducted using a two-stage approach. Under this plan, dose levels during the first stage are increased (or decreased) for individual patients until a dose-limiting toxicity (DLT) is observed, at which point the second stage proceeds with each dose level administered to a cohort of four patients."||||
34158185|NCT05519007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158186|NCT01267890|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158187|NCT02792153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158188|NCT04453189|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34158189|NCT03579810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158190|NCT06575374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158191|NCT01839149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158192|NCT02176161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158193|NCT04971720|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
34158194|NCT04532775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|drugs used in this study are used within covered color coded syringes and participants are randomized to any of study groups via sealed opaque envelopes|prospective randomized controlled blinded study|t|f|t|f
34158195|NCT00193180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054175|NCT04652908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatment arm subjects receiving PMSC-ECM (Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix). Additionally, we will follow a contemporaneous cohort of patients undergoing routine fetal or postnatal MMC repair without PMSC-ECM (non-PMSC untreated contemporaneous cohort). 35 participants will be enrolled under the treatment arm and 20 participants will be enrolled under the untreated contemporaneous cohort.~The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study."||||
34054176|NCT03329170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34054177|NCT06388200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is outcome assessor blinded study||f|f|f|t
34054178|NCT04203992|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We aim to enroll 284 male and female student-athletes between the ages of 13 and 16. Participants will be assigned to either an intervention group (n = 142) or a comparison group (n = 142).||||
34054179|NCT03016481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054180|NCT04711174|||OTHER||PROSPECTIVE|||||||
33741616|NCT01814345|||OTHER||PROSPECTIVE|||||||
33741617|NCT00727857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741618|NCT00483522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741619|NCT00278707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741620|NCT01231698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741621|NCT04211103|NA|SINGLE_GROUP||TREATMENT||NONE||single arm phase II trial||||
33846014|NCT00822653|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846015|NCT02630589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054181|NCT02496351|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34054182|NCT01576445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054183|NCT02668809|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34054184|NCT03843632|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34054185|NCT03290755|||OTHER||PROSPECTIVE|||||||
34054186|NCT06257342|||COHORT||RETROSPECTIVE|||||||
34054187|NCT05413018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054188|NCT01684098|NA|SINGLE_GROUP||OTHER||NONE||||||
34054189|NCT03928808|NA|SINGLE_GROUP||OTHER||NONE||Open Label Pilot Study||||
34054190|NCT00272233|||DEFINED_POPULATION||PROSPECTIVE|||||||
33846016|NCT02457988|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846017|NCT04524026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846018|NCT01161875|||COHORT||PROSPECTIVE|||||||
33846019|NCT02941900|||COHORT||PROSPECTIVE|||||||
34054191|NCT05916456|||OTHER||CROSS_SECTIONAL|||||||
33741622|NCT03111498|RANDOMIZED|PARALLEL||OTHER||NONE||"video-recorded vacuum procedure on a special VAD-training phantom in a randomized setting: (1) theory-based training programme (2) practice-based training programme (one-to-one teaching).~Video-recorded vacuum procedure on the VAD- training phantom before randomization, directly after training programme, 4-8 weeks after training programme in order to determine retention of skills."||||
33741623|NCT01895465|NA|SINGLE_GROUP||||NONE||||||
33741624|NCT03950063|||CASE_ONLY||RETROSPECTIVE|||||||
33741625|NCT03934268|||COHORT||PROSPECTIVE|||||||
33741626|NCT04378933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741627|NCT05649657|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33741628|NCT00840970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intra-patient control where one ethmoid sinus was randomized to receive the intervention (treatment arm) while the contralateral ethmoid received the active comparator (control arm)|t|t|t|t
33741629|NCT01312909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741630|NCT06475157|||CASE_CONTROL||RETROSPECTIVE|||||||
33741631|NCT05827224|||COHORT||RETROSPECTIVE|||||||
33741632|NCT05230329|||COHORT||PROSPECTIVE|||||||
33741633|NCT03818217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking is not possible, because of the used interventions|"Intervention group: 20 persons with dementia will receive a socially assistive humanoid robot coach (including a theratainment app for physical and cognitive exercises).~The control group (also 20 persons with dementia) will get a Tablet training including the same theratainment app as in the intervention group, but without the robot."||||
33741634|NCT02390804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741635|NCT05229679|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33741636|NCT00288496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741637|NCT04173221|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Sublingual SDF-Measurement at admission and after 24h, with or without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with or without communication and interpreting checklist to the treating physician|f|f|t|f
33741638|NCT06535295|||CASE_CONTROL||PROSPECTIVE|||||||
33741639|NCT06502314|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33741640|NCT03484013|||OTHER||RETROSPECTIVE|||||||
33741641|NCT01172938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741642|NCT04144400|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33741643|NCT00418535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741644|NCT01842789|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33741645|NCT02664402|||CASE_ONLY||CROSS_SECTIONAL|||||||
33741646|NCT03404024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741647|NCT05840653|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This research is planned to be carried out as a Solomon Four-Group Experimental model. In the Solomon 2x2 designs, two of the four groups consisting of randomly assigned members by randomization constitute the experimental group and the other two constitute the control group. In the Solomon model, for statistical operations, pretesting is performed on two groups, one for the experimental group and the other for the control group, while the posttest process is performed on all four groups (Erkuş, 2011). The Solomon model is formed by using the pretest-posttest control group model and the posttest control group model together. In this way, the Solomon four-group experimental model is the strongest experimental model that preserves both internal and external validity (Karasar, 2011).|t|f|f|t
33741648|NCT02905526|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33741649|NCT01281293|||COHORT||PROSPECTIVE|||||||
33741650|NCT03407352|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33741651|NCT04591834|||OTHER||PROSPECTIVE|||||||
33741652|NCT03471689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741653|NCT06158711|||COHORT||RETROSPECTIVE|||||||
34054192|NCT01123941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34054193|NCT02231879|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741654|NCT02820987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741655|NCT03065387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741656|NCT04908891|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741657|NCT04920760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants, laboratory technicians, and statisticians will be blinded to the study arm allocation. Investigators and the ICU medical staff, however, will be unblinded due to the nature of intervention.|The current phase II, prospective, single-center, single-blinded, randomized placebo-controlled trial, will compare the standard care alone (as the control arm) or in combination with ˝vitamin A supplementation˝ (as the intervention arm) with an allocation ratio of 1:1 in a parallel-group design.|t|f|f|f
33741658|NCT03270761|||CASE_ONLY||CROSS_SECTIONAL|||||||
33741659|NCT00019682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741660|NCT01229345|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33741661|NCT00501384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741662|NCT04285606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054194|NCT03624062|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34054195|NCT05701072|||OTHER||PROSPECTIVE|||||||
33741663|NCT05101252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054196|NCT01958424|||COHORT||PROSPECTIVE|||||||
34054197|NCT03104062|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34054198|NCT04025775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054199|NCT03876366|||OTHER||CROSS_SECTIONAL|||||||
34054200|NCT03375671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054201|NCT02316899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054202|NCT01864070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054203|NCT05234866|||COHORT||PROSPECTIVE|||||||
34054204|NCT05243485|||COHORT||PROSPECTIVE|||||||
34054205|NCT06503367|||COHORT||PROSPECTIVE|||||||
34054206|NCT03425578|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34054207|NCT01846481|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741664|NCT05857046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The placebo and melatonin group will be assigned a sequentially numbered envelope that will be delivered to the patient. It will contain their medication, which was previously randomized by someone not involved in the study. Therefore, neither the researcher, the doctor, nor the patient will know which group they belong to. It is important to mention that the placebo tablets contain lactose and will have no effect on the patient's body.|A phase IIIb clinical trial, randomized double-blind, parallel|f|f|f|t
33741665|NCT05234398|||OTHER||PROSPECTIVE|||||||
33741666|NCT03841786|RANDOMIZED|CROSSOVER||OTHER||NONE||Eligible subjects will consume a phosphorus supplemented diet (study diet) and a sodium and potassium chloride supplemented diet (control diet), with cross-over to the other diet following a 24-day wash-out period. The order in which the diets are consumed will be randomly assigned.||||
33741667|NCT02222220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33950418|NCT06523322|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The 8-week Let's Cook Together program is intended to increase: caregiver knowledge of the benefits of a whole foods approach to eating; preparedness for caregiving; and caregiver self-efficacy for managing patients' nutrition-related side effects. The entire program will be delivered remotely. Caregivers will be recruited to participate in an 8-week remote culinary medicine intervention, including four remote synchronous culinary workshops (one 90-minute introductory event and three, 90-minute culinary/cooking sessions), and four bi-weekly caregiver coaching telephone calls (lasting 15-20 minutes).||||
33950419|NCT03118401|RANDOMIZED|PARALLEL||PREVENTION||NONE||"At the end of the first 4 weeks of collection of the data on an individual stool diary with usual care of the resident, a randomization will be carried out dividing the patients according to the following groups:~1. / Experimental group Implementation period: From the stool diary: - determine the stool profile of each resident over 1 week (W5)~2. / Control group: without modification of practices and without data collection from W5 to W6.~At the end of this second period, data were collected on an individual stool diary in each of the two groups for 4 weeks"||||
33950420|NCT05033769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950421|NCT00313482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950422|NCT02341339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950423|NCT04233255|||COHORT||PROSPECTIVE|||||||
33950424|NCT03890731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950425|NCT05161234|||COHORT||PROSPECTIVE|||||||
33950426|NCT04943627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950427|NCT05031559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were not made aware whether they were in the control group or in one of the intervention groups.||t|f|f|f
33950428|NCT00619658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950429|NCT02868294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950430|NCT03589066|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two different formulations of LY03003, i.e. Formulation A and Formulation B||||
33950431|NCT06404294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed by someone who are not involved in this study. Outcomes assessor will review the patients' medical record masked for the type of intervention.The investigators performing the final statistic analyses will also be blinded to the treatment allocation.||f|f|t|t
33950432|NCT00763126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950433|NCT02305069|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33950434|NCT01695707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950435|NCT02000466|||COHORT||PROSPECTIVE|||||||
33950436|NCT04425876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950437|NCT01399619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950438|NCT01153659|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950439|NCT00002110||||TREATMENT||DOUBLE||||||
33950440|NCT03935282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950441|NCT04600531|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||sham-controlled, counterbalanced study|t|f|f|t
33950442|NCT02824042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950443|NCT00238680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950444|NCT05554666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950445|NCT03283033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33950446|NCT01521975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950447|NCT06126601|||CASE_ONLY||PROSPECTIVE|||||||
33950448|NCT06294327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950449|NCT03292731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||An open labelled rct for secondary analysis of safety of 500 mg dose. A pharmacodynamic study of 17-OHPC concentration and rate of sPTB||||
33950450|NCT04158518|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950451|NCT00003576|RANDOMIZED|||TREATMENT||||||||
33950452|NCT01440075|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950453|NCT04963751|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized trial is proposed that will assess whether patient involvement in pre-operative counseling for ERAS improves post-surgical pain scores. Subject compliance will be assessed to ERAS-prescribed medications, and functionality (return to school). Each patient who is enrolled in the study will be assigned to 1) pre-operative counseling with their caregiver or 2) caregiver-only counseling.||||
34054208|NCT03352193|||CASE_CONTROL||PROSPECTIVE|||||||
34054209|NCT06490380|||OTHER||RETROSPECTIVE|||||||
34054210|NCT00449085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054211|NCT05784753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded study personnel will participate in all data collection time points, meeting with participants at four time points during the study and confirming completeness of questionnaires.|Participants will be randomized following a 2-2-1 (HEART Camp Connect - HEART Camp - Enhanced Usual Care) scheme to fully examine comparative effects between virtual and in-person treatment groups.|f|f|t|t
34054212|NCT04988971|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34054213|NCT02926586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950454|NCT05764629|||COHORT||PROSPECTIVE|||||||
33950455|NCT05097404|||COHORT||PROSPECTIVE|||||||
33950456|NCT03076710|||COHORT||PROSPECTIVE|||||||
33950457|NCT02662075|NA|SINGLE_GROUP||OTHER||NONE||||||
33950458|NCT01829321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950459|NCT02270021|RANDOMIZED|PARALLEL||SCREENING||NONE||clinic sites were randomized not subjects||||
33741668|NCT04204421|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741669|NCT02817451|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741670|NCT01681082|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741671|NCT01063205|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34158196|NCT05419544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group, listened to holy Quran recitation for 10 minutes twice a day 4 hours a part (10 am and 2 pm) for 2 consecutive days (usually the 2nd and the 3rd day post-operative) after extubation and gaining alertness. We have chosen Surah Al-Rehman because it is considered as the most rhythmic surah of the Quran and the recitation of Qari Abdul Basit is very soothing and effective as he has recited from the deep of the heart. The listing was by a disposable head phones for an I pad for each hospital.||||
33741672|NCT00345397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741673|NCT04636892|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741674|NCT03211936|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33741675|NCT01659918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741676|NCT03210506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741677|NCT04182022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741678|NCT05875324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741679|NCT02326402|||CASE_ONLY||PROSPECTIVE|||||||
33741680|NCT04897516|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase III, open-label, prospective, controlled, multicenter, non-inferiority study to compare the efficacy of the Drug: 1. Short regimen of benznidazole :Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.~2. Drug: Short regimen of benznidazole : Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks. And 3. Drug: Standard treatment with benznidazole : Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks"||||
33741681|NCT02740348|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33741682|NCT02448303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741683|NCT01525082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741684|NCT02136173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741685|NCT00747591|||CASE_ONLY||RETROSPECTIVE|||||||
33741686|NCT02804919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158197|NCT00699660|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34158198|NCT02109809|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741687|NCT02566837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741688|NCT01487330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741689|NCT04060940|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will be randomly assigned to an 8-session or 16-session version of ERT.||||
33741690|NCT02755389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741691|NCT02450994|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33950460|NCT00167414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950461|NCT01014104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950462|NCT05005923|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950463|NCT04436497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158199|NCT00550381|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34158200|NCT01128192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34158201|NCT04020497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34158202|NCT02567019|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741692|NCT06367374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741693|NCT01797146|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33950464|NCT05099744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized at a ratio of 1:1 for the four groups conditions. Randomization will be performed through an online random number generator by a researcher external to the team of this study, to ensure the concealment of the allocation of participants by the several groups. Only the participants will be blind to the group to which they have been allocated.||t|f|t|f
33950465|NCT00883129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950466|NCT05098678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950467|NCT06308523|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33950468|NCT02808559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950469|NCT02350868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950470|NCT00100282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33950471|NCT04377074|||OTHER||CROSS_SECTIONAL|||||||
33950472|NCT02848781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950473|NCT05361200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not be told which group they were assigned to|Randomized controlled study with 2 arms|t|f|f|f
33950474|NCT06567444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A single-blind study design was adopted in which all assessors were blinded to the treatment condition of the students. There were three experimental groups, with 26 participants in the ADHD group, 38 participants in the RD group, and 24 participants in the ADHD+RD group. The typically developing control group had 32 participants.|f|f|f|t
33950475|NCT05472480|||COHORT||CROSS_SECTIONAL|||||||
33950476|NCT05471882|||COHORT||RETROSPECTIVE|||||||
33950477|NCT05317949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950478|NCT00006292||||TREATMENT||||||||
33950479|NCT01472666|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33950480|NCT02660216|||COHORT||PROSPECTIVE|||||||
34158203|NCT04109326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* The experimental arm APAD: tailored PA program associated with individual nutritional counseling whilst hospitalization and at home during the 26-week duration of adjuvant treatment~* The control arm: standard of care"||||
33950481|NCT02900131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950482|NCT03217916|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950483|NCT03410693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158204|NCT05464823|NA|SINGLE_GROUP||OTHER||NONE||||||
34158205|NCT06583525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158206|NCT04116125|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158207|NCT02615340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All study personnel, patients, and their families will remain blinded. Treatment allocation will only be known to the clinical trials pharmacist, who will perform subject randomization.||t|t|t|t
33741694|NCT06087445|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|We will have an independent outcome rater conduct assessments who is not involved in the intervention, however, because this is a single-arm trial there is no way to truly 'mask' the assessor.|Participants with chronic cervical spinal cord injury will complete a 12-week intervention protocol (3x/week) in an outpatient setting where they will practice functional activities using their hand/forearm while wearing the NeuroLife EMG-FES Sleeve System. We will assess functional outcomes using standardized clinical measures at 6 timepoints (double baseline, 4 weeks, 8 weeks, post-intervention, and 4 weeks post-intervention).||||
33741695|NCT02509624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741696|NCT01252251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741697|NCT01902017|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741698|NCT01463605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741699|NCT00934193|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158208|NCT02649894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158209|NCT01487772|||COHORT||PROSPECTIVE|||||||
34158210|NCT04760405|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741700|NCT06416215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741701|NCT04396951|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||A pre and post intervention quasi-experimental epidemiological study without control group, will be carried out in large burned patients that will assess the influence on the metabolic expenditure of the inclusion of active external reheating in the control of the environmental temperature.||||
33950484|NCT00657176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950485|NCT02664974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950486|NCT02181543|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33950487|NCT00145795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158211|NCT06146829|||COHORT||RETROSPECTIVE|||||||
34158212|NCT06537674|||COHORT||PROSPECTIVE|||||||
33950488|NCT04393987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The research was using quasi-experimentally research methods. The research was carried out with 19 patients enrolled in the Community Mental Health Center and 21 outpatients who were monitored in the Psychiatry Outpatient Clinic of a university and who met the inclusion criteria. The data were collected using the Participant Information Form, Medication Adherence Rating Scale, Social Functioning Scale, and World Health Organization Quality of Life Instrument Short Form. Treatment compliance training was given to the intervention group (n=19) individually once a week for a total of five sessions. No intervention was applied to the control group (n=21) following the pretest application. Post-tests were applied to the intervention group after the training and follow-up tests were applied to both groups three months after the training.||||
33950489|NCT02353234|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33950490|NCT00812045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950491|NCT03737357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950492|NCT06650085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950493|NCT03321773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950494|NCT04144140|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950495|NCT01882166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950496|NCT02728141|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
33950497|NCT03824015|RANDOMIZED|PARALLEL||OTHER||NONE||Six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.||||
33950498|NCT01135251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33950499|NCT05527249|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33950500|NCT01674010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950501|NCT04194138|||COHORT||PROSPECTIVE|||||||
33950502|NCT05182840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950503|NCT06276647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950504|NCT00002037||||TREATMENT||NONE||||||
33950505|NCT02015312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950506|NCT05628818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950507|NCT01084824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950508|NCT05829746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950509|NCT02070952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950510|NCT00111007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950511|NCT03093129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950512|NCT02854202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950513|NCT05371262|RANDOMIZED|PARALLEL||TREATMENT||NONE||Children were randomly assigned to receive an initial L-T4 dose of 10-12.5 μg/kg/day (Group A) or 12.6-15 μg/kg/day (Group B). Randomization was designed according to a block scheme (8 blocks of 6 patients and 6 blocks of 4 patients which were randomly alternated) which guaranteed the frequency balance in the two groups during the enrolment without altering the causality of the assignment. Random allocation sequence was generated using the function sample in R statistical platform.||||
33950514|NCT06409741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950515|NCT03484858|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized cross over design||||
33950516|NCT00819923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950517|NCT00347776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34158213|NCT05232331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind. Dentists in charge of assessing dental clinical parameters, as well as researchers performing the analysis of the oral microbiota, will be unaware of the group assignment.||f|t|f|f
34158214|NCT05354271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34158215|NCT03746717|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open 2-arm prospective randomized controlled trial||||
34158216|NCT04523883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158217|NCT01528722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950518|NCT04197401|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34158218|NCT02745028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950519|NCT06650176|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33950520|NCT04328168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participant|A total of 28 patients who were followed-up in our clinic and received botulinum toxin injection of lower extremities in the last month were randomized to two groups in the study. Group 1 received conventional physiotherapy and Group 2 received robot-assisted gait training.|t|f|f|f
33950521|NCT04997577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of the number and types of treatment groups.||t|f|f|f
33950522|NCT05968469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950523|NCT00394121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950524|NCT05791123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950525|NCT04836832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158219|NCT03316703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158220|NCT04680481|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33741702|NCT05507710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participant is blinded for the study arm. A second evaluator of postinterventional fat necrosis is blinded for the study arm.|"This is a two-armed randomized controlled trial:~* interventional arm: evaluation of flap perfusion based on 1) clinical parameters, and 2) fluorescence imaging using ICG~* conventional arm: evaluation of flap perfusion based on clinical parameters only"|t|f|f|t
33741703|NCT05902195|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessor-blinded.|A 2-arm, assessor-blind, randomised controlled trial will be conducted.|f|f|f|t
33741704|NCT01053923|||CASE_ONLY||PROSPECTIVE|||||||
33950526|NCT04281147|||COHORT||RETROSPECTIVE|||||||
33950527|NCT01642329|||COHORT||PROSPECTIVE|||||||
33950528|NCT04335760|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950529|NCT05334992|RANDOMIZED|PARALLEL||TREATMENT||NONE||Mindfulness Based Cognitive Therapy; Behavior Activation; Group Therapy||||
33950530|NCT02510131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950531|NCT01780961|||CASE_ONLY||PROSPECTIVE|||||||
33950532|NCT01429727|||COHORT||OTHER|||||||
33950533|NCT05863780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950534|NCT05059470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950535|NCT01932541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950536|NCT00051766|RANDOMIZED|FACTORIAL||ECT||NONE||||||
33950537|NCT02189928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950538|NCT00674440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950539|NCT05078359|||COHORT||RETROSPECTIVE|||||||
33950540|NCT02279082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950541|NCT03005717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950542|NCT01301625|||COHORT||PROSPECTIVE|||||||
33950543|NCT04712968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33950544|NCT01800500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950545|NCT01211210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950546|NCT00908375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950547|NCT04803032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950548|NCT02514434|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33950549|NCT03260621|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950550|NCT01934777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950551|NCT00003758||||TREATMENT||||||||
33950552|NCT00594568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950553|NCT02786381|||||CROSS_SECTIONAL|||||||
33950554|NCT00006001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950555|NCT01108861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950556|NCT06231992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34054214|NCT03768011|||COHORT||PROSPECTIVE|||||||
34054215|NCT00558662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054216|NCT02312596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054217|NCT06292598|||CASE_CONTROL||PROSPECTIVE|||||||
34054218|NCT05454969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a randomized controlled trial to examine pre-post differences between individuals that use the app versus the standard of care.||||
34054219|NCT04634240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054220|NCT00431028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054221|NCT01185743|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34054222|NCT06375616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054223|NCT00452673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054224|NCT06623864|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34054225|NCT03020199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054226|NCT06124755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054227|NCT04310709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054228|NCT06437821|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950557|NCT05672277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950558|NCT02341326|||CASE_CONTROL||PROSPECTIVE|||||||
33950559|NCT03225950|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950560|NCT05653648|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33950561|NCT04961944|||COHORT||PROSPECTIVE|||||||
33950562|NCT03799445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950563|NCT05320926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054229|NCT05156554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054230|NCT03555565|||COHORT||PROSPECTIVE|||||||
34054231|NCT01739218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054232|NCT01098656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158221|NCT01072994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158222|NCT00947115|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158223|NCT03775512|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158224|NCT00338923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158225|NCT04286659|||CASE_CONTROL||OTHER|||||||
34158226|NCT00721188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158227|NCT04348981|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158228|NCT00697372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158229|NCT04102072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054233|NCT06619197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Prospective exploratory study of single-center feasibility. Research involving human subjects 2. This feasibility study will estimate the improvement in pain provided by reflexology, acceptability and feasibility, rate of inclusion.~The research will take place in 2 centers, the short-stay hospitalization unit (UHCD) and the continuous monitoring unit (USC) of the Women\&#39;s Mother and Child Hospital of the Hospices Civils de Lyon.~This study involves subjects under 18 years of age, suffering from sickle cell disease, hospitalized in the unit UHCD or the unit USC."||||
34054234|NCT05680051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054235|NCT06442098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Alternating Treatment Single Subject Design||||
34054236|NCT06094283|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double blind, placebo controlled|In each cohort, the first 2 sentinel subjects will be randomized in a 1:1 ratio to receive either YCT-529 or placebo. The remaining 6 subjects in each cohort will be enrolled in the dosing cohort such that 5 subjects will be randomized to receive YCT-529 and 1 subject will be randomized to receive placebo; therefore, a total of 6 subjects will be randomized to receive YCT-529 and 2 subjects will be randomized to receive placebo at each dose level.|t|t|t|t
34054237|NCT00563810|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
34054238|NCT05346211|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34158230|NCT04511858|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Prospective study of physiopathology on subjects specializing in endurance and ultra-endurance: comparing running vs. cycling. Cross-over: each subject will carry out the 2 experimental conditions (running and cycling) according to a randomized order of passage, respecting a wash-out of 2 weeks.||||
34158231|NCT01465815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054239|NCT06304792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054240|NCT01763073|||OTHER||CROSS_SECTIONAL|||||||
34054241|NCT06299111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054242|NCT00797134|||COHORT|||||||||
34054243|NCT06608875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (participant, care provider, investigator, outcomes assessor).|Consolidation Arm: hyper-personalized feedback based-motor rehabilitation with targeted auditory stimulation during sleep (HPF intervention, TASS intervention)|t|t|t|t
34054244|NCT02478034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34054245|NCT05069545|||COHORT||PROSPECTIVE|||||||
34054246|NCT04196413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054247|NCT01789411|||COHORT||PROSPECTIVE|||||||
34054248|NCT06181292|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34054249|NCT02861326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158232|NCT01178502|||COHORT||RETROSPECTIVE|||||||
34158233|NCT00003917|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34158234|NCT06104332|||COHORT||PROSPECTIVE|||||||
34158235|NCT04659473|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34158236|NCT03422497|||COHORT||CROSS_SECTIONAL|||||||
34158237|NCT01970670|||COHORT||PROSPECTIVE|||||||
34158238|NCT04360837|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158239|NCT00806728|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158240|NCT03239444|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34054250|NCT00697086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158241|NCT01110369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158242|NCT06583265|||COHORT||PROSPECTIVE|||||||
34158243|NCT00766051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158244|NCT01000324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158245|NCT02345213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054251|NCT02644629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054252|NCT05019196|||COHORT||PROSPECTIVE|||||||
34054253|NCT06420934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Masking will be provided to data analysis expert.||f|f|t|t
34054254|NCT06433622|||CASE_CONTROL||PROSPECTIVE|||||||
34054255|NCT01063270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054256|NCT06624176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054257|NCT05825833|||OTHER||CROSS_SECTIONAL|||||||
34054258|NCT03572530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054259|NCT05554536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054260|NCT04623879|||COHORT||PROSPECTIVE|||||||
34158246|NCT02534246|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|t|f|f
34158247|NCT06428370|||COHORT||RETROSPECTIVE|||||||
34158248|NCT03192761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor is not involved in the surgical procedures. Participants wear long trousers at follow-up procedures to mask surgical incisions.|When the patient has been anaesthetized for surgery, the method of reconstruction is defined by opening a sealed envelope in the operating theatre.|f|f|t|t
34158249|NCT01376414|||COHORT||PROSPECTIVE|||||||
34158250|NCT05712278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158251|NCT01020552|||||CROSS_SECTIONAL|||||||
34158252|NCT01424033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158253|NCT02110095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158254|NCT00130611|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34158255|NCT05337462|||CASE_ONLY||PROSPECTIVE|||||||
34158256|NCT00014833|||COHORT||RETROSPECTIVE|||||||
34158257|NCT02734303|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34158258|NCT02424175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158259|NCT06491784|RANDOMIZED|PARALLEL||OTHER||NONE|Open label, no masking|1:1 randomisation, feasibility study||||
34158260|NCT04880369|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The study planned to include 150 women.|t|t|t|t
34158261|NCT02453503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158262|NCT02578186|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34158263|NCT06386991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158264|NCT05615740|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study subjects will be enrolled into two groups - healthy pediatric population and children with diabetes mellitus.||||
34158265|NCT00642161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158266|NCT04180904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In a study assessing dietary behavioral interventions, absolute blinding of the participants is not possible because of obvious differences between intervention diets. However, we will avoid naming the allocated dietary intervention and withhold information about our research hypothesis from the patients. Participants in the control group will receive the same schedule of visits and patient reported outcomes. The study rheumatologists (outcome assessors) will be blinded to the allocated group and the participants will be asked to avoid discussing the details of their diet with them.|In this randomized controlled pilot trial, we will test different diets to determine the impact on disease outcomes among patients with psoriatic arthritis. This is a 24-week trial that will enroll 90 patients with active psoriatic arthritis despite stable therapy among three sites in the US and Canada. Dietary interventions will be enhanced with gamification, including feedback and competition. Biomarker samples including blood, urine and stool specimens will be collected and banked for exploratory analyses.|f|f|f|t
34158267|NCT00391950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158268|NCT00940498||||TREATMENT||NONE||||||
34158269|NCT01257945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158270|NCT05030350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158271|NCT00576225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158272|NCT04266925|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34158273|NCT00891384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158274|NCT03469791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority cohort study||||
34158275|NCT04590716|||COHORT||PROSPECTIVE|||||||
34158276|NCT03364309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158277|NCT03512392|RANDOMIZED|PARALLEL||TREATMENT||NONE|Group assignment and early (up to 28 day) data will be locked and unavailable to investigators undertaking 6-month follow up.|Randomised, open-label, allocation concealed, pilot trial||||
34158278|NCT00307788|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34158279|NCT00973323|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158280|NCT03536559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The drug formulations will be identical in appearance (size, shape, volume, color) and smell. The packaging and labeling will be designed to maintain blinding to the Investigator's team and to patients. There are no visible differences between the active drug, and placebo dosing units|randomized, double-blind, parallel group, placebo controlled study|t|t|t|t
34158281|NCT06445816|||CASE_ONLY||PROSPECTIVE|||||||
34158282|NCT02990039|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34158283|NCT00415922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158284|NCT02222376|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158285|NCT03631134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158286|NCT06331988|||CASE_ONLY||PROSPECTIVE|||||||
34054261|NCT04541108|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"This Master Protocol is designed as an umbrella concept trial for the ongoing evaluation of multiple agents in individual CIVO Phase 0 substudies. Based on regulatory guidance on Phase 0 clinical trial design, approximately up to 15 participants are planned to be enrolled in each substudy in order to complete with approximately up to 12 evaluable tumor samples. Each substudy is considered an Experimental Arm with specified tumor types, inclusion and exclusion criteria, and investigational agents and combinations to be evaluated. Tumor type examples accessible for CIVO injection include, but may not be limited to, Head and Neck Cancer, Melanoma, Soft Tissue Sarcoma, Breast Cancer, or Lymphoma. Comparisons will not be made between experimental arms/substudies.~The following substudy(ies) is(are) currently active:~- MST01-AZN-05 (NCT06366451) evaluating rilvegostomig, volrustomig, sabestomig, and pembrolizumab.~New substudies will be continuously added as they become active."||||
34158287|NCT01973413|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158288|NCT00258804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741705|NCT02529020|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33741706|NCT06266221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741707|NCT04352010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741708|NCT02005341||||TREATMENT||||||||
33741709|NCT05801601|RANDOMIZED|PARALLEL||PREVENTION||NONE||This research project will used an individual randomized controlled trial design in which youth at each intervention site will be randomized 1:1 into the experimental condition (Many Ways of Being) or the comparison condition (a career readiness program).||||
33741710|NCT00262834|NA|SINGLE_GROUP||TREATMENT||NONE||Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgical resection of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.||||
34054262|NCT00587184|||COHORT||RETROSPECTIVE|||||||
34054263|NCT06623487|||COHORT||PROSPECTIVE|||||||
34054264|NCT06200311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|endpoints will be adjudicated by a blinded clinical endpoint committee|Eligible patients with ACMP and AF will be randomised to AF ablation and pharmacological rhythm management|f|f|f|t
34054265|NCT04463056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054266|NCT05350865|||COHORT||PROSPECTIVE|||||||
34054267|NCT02621489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054268|NCT06617845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054269|NCT03953313|||COHORT||PROSPECTIVE|||||||
34054270|NCT06093646|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Masking will not be applied; eligible participants (with psychological distress) who consent to participate in this study will be offered the Ebola+D intervention|Screen participants attending 11 healthcare facilities at Mubende for psychological distress using the locally validated Luganda or English version of the WHO- Self Report Questionnaire (SRQ-20). Those individuals found to have significant psychological distress (a score of 6 and above) will be offered Ebola+D intervention. The intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker. A cohort of EVD affected individuals accessing the Ebola +D mental health intervention will be recruited and followed up for 12 months with assessments at three time points; baseline, 3 months and 12 months.||||
33741711|NCT00908440|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33741712|NCT04485403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741713|NCT00588562|||COHORT||OTHER|||||||
33741714|NCT02422277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741715|NCT01055639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33741716|NCT00648232|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33741717|NCT02861690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741718|NCT04352699|||COHORT||RETROSPECTIVE|||||||
33741719|NCT01965067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741720|NCT00847873|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33741721|NCT05961202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741722|NCT06432712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Interventional or control group will be selected randomly through sealed envelope by an independent researcher not involved in the study.|This is a single-blind, randomized parallel-arm study with two arms. Participants will be randomly assigned to either receive dexamethasone infiltration or only analgesic therapy. They will remain in their assigned group throughout the study.||||
34054271|NCT00778284|RANDOMIZED|CROSSOVER||||NONE||||||
34054272|NCT02286570|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34054273|NCT04024306|||OTHER||CROSS_SECTIONAL|||||||
34054274|NCT01958216|NA|SINGLE_GROUP||||NONE||||||
34054275|NCT05969392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054276|NCT06618066|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33741723|NCT02686112|||||RETROSPECTIVE|||||||
34054277|NCT06620484|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34054278|NCT06356844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054279|NCT04807309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Similar tablets will be generated.|Randomized double blind 2:1 ratio|t|t|t|t
34054280|NCT05179018|||CASE_CONTROL||RETROSPECTIVE|||||||
34054281|NCT04178824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054282|NCT00507078|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34054283|NCT04266886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054284|NCT03178240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054285|NCT02763982|||CASE_ONLY||CROSS_SECTIONAL|||||||
34054286|NCT01565668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054287|NCT05905666|NA|SINGLE_GROUP||TREATMENT||NONE||The research period was divided into a control stage (first to fourth week: standard of care) and the experimental stage (fifth to eighth week: health education and counseling). In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.||||
34054288|NCT01904292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054289|NCT06009107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054290|NCT03156842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054291|NCT03316469|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34054292|NCT00669643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054293|NCT04141891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34054294|NCT04946942|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34054295|NCT03097367|||CASE_ONLY||RETROSPECTIVE|||||||
34054296|NCT00923182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054297|NCT06411951|||COHORT||OTHER|||||||
34054298|NCT02123615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054299|NCT05311228|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups, one group intervention and one group control||||
34054300|NCT06029933|||COHORT||RETROSPECTIVE|||||||
34054301|NCT01990196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054302|NCT04984863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054303|NCT05661981|||COHORT||PROSPECTIVE|||||||
34054304|NCT04765657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054305|NCT01712165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34054306|NCT03414996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054307|NCT00878566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054308|NCT04464720|NA|SINGLE_GROUP||PREVENTION||NONE||This is a trial with a single group, where they receive the intervention following one week of baseline data collection.||||
34054309|NCT05414396|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34054310|NCT01050010|NA|SINGLE_GROUP||SCREENING||NONE||||||
34054311|NCT06623890|||COHORT||PROSPECTIVE|||||||
34054312|NCT06341907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054313|NCT03846687|||CASE_ONLY||PROSPECTIVE|||||||
34054314|NCT06620952|||CASE_ONLY||RETROSPECTIVE|||||||
34054315|NCT06610201|||COHORT||PROSPECTIVE|||||||
34158289|NCT04044742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatment assigned to each subject is blinded to the subject, investigators, and sponsor study team.||t|f|t|f
34158290|NCT00013013|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34158291|NCT05041972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158292|NCT01922791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34158293|NCT06262464|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33741724|NCT03086447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054316|NCT03241628|||CASE_ONLY||PROSPECTIVE|||||||
34054317|NCT05928884|||COHORT||PROSPECTIVE|||||||
34054318|NCT05883774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054319|NCT05314842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054320|NCT05705492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34054321|NCT04183738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Observational cohort nested within the parent open label phase III/IV randomised controlled trial of simplified second-line therapy, D²EFT.||||
34054322|NCT00877409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054323|NCT04490642|||COHORT||CROSS_SECTIONAL|||||||
34054324|NCT02622763|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34054325|NCT02416193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741725|NCT02448784|||COHORT||PROSPECTIVE|||||||
34158294|NCT03657849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective diagnostic accuracy study||||
33741726|NCT00023452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741727|NCT03200392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of investigator and participants was not applicable due to surgical procedure and use of laser either for root surface bio-modification or during connective tissue harvesting. The blinded outcome assessor performed the clinical measurements at each selected defect site during the study period. She was not involved in any other part of the study protocol.||f|f|f|t
33950564|NCT05623774|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a crossover design dose calibration study in healthy volunteers to identify a dose of IkT-001Pro film-coated tablets that would be equivalent to imatinib free base 400 mg film-coated tablets containing imatinib mesylate||||
34158295|NCT03862235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158296|NCT04346446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158297|NCT04007419|NA|SINGLE_GROUP||OTHER||NONE||The study includes focus group interviews with mature Latina and Promotora to inform the development of a web-based educational and communication intervention, as well as an evaluation of the intervention using a nonrandomized, quasi-experimental pragmatic design, pre-post only with no control group to test the impact of the eLearning module on lay health educators' knowledge of organ donation and confidence holding discussions about and promoting organ donation. Additionally, we will examine the impact of the Promotoras de Donación intervention, which will engage trained lay health educators to lead small group sessions with mature Latina, on the women's attitudes about organ donation and donor registration, and rates of donor registration.||||
33741728|NCT01354821|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950565|NCT03018756|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33950566|NCT02103985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950567|NCT02992782|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33950568|NCT05665946|||CASE_CONTROL||PROSPECTIVE|||||||
33950569|NCT06604806|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33950570|NCT06539845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34054326|NCT04487483|RANDOMIZED|PARALLEL||OTHER||NONE||The study is a two-arm pilot RCT where participants are randomly assigned to either the intervention or control group.||||
34054327|NCT04281901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A person unaware of the participants and their random allocation will measure inflammation area with computer software provided by ZEN Lite, Zeiss.|Participants treated with PVRP will receive PVRP-soaked ear wicks at the day of recruitment, additionally 1 month later and then followed-up twice in 1-month intervals. Participants not treated with PVRP will be treated with standard conservative nonsurgical measures with the same follow-up time.|f|f|f|t
34054328|NCT03614078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054329|NCT03429751|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34054330|NCT04694365|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34054331|NCT00639444|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054332|NCT05427760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34054333|NCT05097092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054334|NCT05617040|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 will follow a 3+3 design and determine the RP2R (dose level of both ChAdOx1-PCAQ and MVA-PCAQ, and route of administration of MVA-PCAQ) that will be used in Phase 2. Phase 2 will consist of 2 sequential stages. Stage 1 will enroll 19 additional participants at the RP2R. If 4 or more participants treated at the RP2R have a PSA response, Stage 2 will be opened to enrolment of up to 100 additional participants.||||
34054335|NCT05952700|||CASE_ONLY||PROSPECTIVE|||||||
34054336|NCT02155673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054337|NCT03554863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054338|NCT03150654||SEQUENTIAL||TREATMENT||NONE||sequential self-controlled clinical trial||||
34054339|NCT03467217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, clinical staff, and data monitoring committee will not have knowledge of the interventions assigned to individual participants.||t|t|t|f
34054340|NCT04894149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34054341|NCT05879406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized, double-blind, placebo controlled study evaluating the efficacy and safety|Randomized, double-blind, placebo controlled study evaluating the efficacy and safety|t|t|f|f
34054342|NCT06076018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||In the study planned as a randomized clinical study, patients who use and do not use intrathecal morphine will be assigned to 2 groups, 30 people in each group, by the sealed envelope method. Patients, surgeons, and physicians who will perform postoperative evaluation and fill out the questionnaire will be blinded to the randomization of the groups.|t|f|f|t
34054343|NCT05885035|NA|SINGLE_GROUP||TREATMENT||NONE||The model group will consist of females who present with cellulite dimples in the buttocks. Women are ideal for this study because they have more cellulite dimpling and a predisposition to dimpling due to the anatomy of their fibrous septa.||||
34054344|NCT05233150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34054345|NCT05682378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054346|NCT04015076|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34054347|NCT02076503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054348|NCT05896501|||COHORT||PROSPECTIVE|||||||
34158298|NCT02783092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158299|NCT06232213|||COHORT||PROSPECTIVE|||||||
34158300|NCT02430116|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34158301|NCT01472952|||COHORT||PROSPECTIVE|||||||
34158302|NCT03781453|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Quasi-experimental, pre-post study design||||
33741729|NCT01540149|||CASE_ONLY||PROSPECTIVE|||||||
33741730|NCT04563858|||COHORT||PROSPECTIVE|||||||
34158303|NCT02058563|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158304|NCT06443684|||COHORT||PROSPECTIVE|||||||
34158305|NCT02692001|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34158306|NCT04309708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized, Controlled, Parallel, Multi-center study|t|f|t|f
34158307|NCT06535620|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34158308|NCT00236236|||DEFINED_POPULATION||PROSPECTIVE|||||||
34158309|NCT00785473|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741731|NCT05303987|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|A coordinator and anesthesiologist will be unblinded.||t|t|t|t
33741732|NCT01053026|||CASE_CONTROL||PROSPECTIVE|||||||
33741733|NCT04915469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a pre-post study design. The post-group receive an intervention of a standardized enhanced adherence counseling package||||
33741734|NCT03022357|||COHORT||PROSPECTIVE|||||||
33741735|NCT05101187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Adjudicator and sponsor-blinded.||f|f|t|f
33741736|NCT02886845|||CASE_CONTROL||PROSPECTIVE|||||||
33741737|NCT02121145|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741738|NCT04427280|||COHORT||PROSPECTIVE|||||||
33741739|NCT06534736|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups.Sample will be divided into two groups , Group A and Group B.Group A i.e Control group will receive Post Faciliation Stretch only for 4 weeks on alternative days.Group B i.e intervention hgroup will undergo Scapular Stabilization exercises along with post facilitation stretch for 4 weeks on alternative days||||
33741740|NCT05819749|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an in-person, phone, or video based behavioral intervention. It will involve a diabetes wellness coach assisting participants to use behavioral activation and motivational interviewing to set goals related to diabetes self-care and co-morbidities or social conditions that get in the way of diabetes self-care. There will be encouragement to work on diabetes medication adherence and to address any un/under-treated behavioral health conditions.||||
33741741|NCT04747366|||COHORT||PROSPECTIVE|||||||
33846020|NCT03686332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"All patients included will have unresectable advanced penile cancer. Patients will be discussed in multi-disciplinary rounds to establish this criterion. Two treatment groups will be distinguished.~Arm A: Patients with locoregional lymph node disease who have not received extensive inguinal or pelvic irradiation on the involved area before. Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.~Arm B: Patients who are not expected to derive benefit from radiotherapeutic treatment. This group will mainly consist of patients with distant metastases or previously treated locoregional disease and will only be treated with atezolizumab."||||
33846021|NCT00924690|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33846022|NCT00201708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846023|NCT03126669|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33846024|NCT00063752|NON_RANDOMIZED|||TREATMENT||NONE||||||
33846025|NCT06079619|||CASE_CONTROL||RETROSPECTIVE|||||||
33846026|NCT01792050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846027|NCT02817880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846028|NCT02999685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846029|NCT00031798|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34054349|NCT00619567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054350|NCT02253316|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741742|NCT01411189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741743|NCT02270580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33741744|NCT04844424|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33741745|NCT01255358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741746|NCT02199457|NA|SINGLE_GROUP||OTHER||NONE||||||
33741747|NCT01320163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741748|NCT05900024|NA|SINGLE_GROUP||OTHER||NONE||||||
33846030|NCT02794415|NA|SINGLE_GROUP||OTHER||NONE||||||
33846031|NCT01964924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846032|NCT05180500|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33846033|NCT04131166|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846034|NCT05537168|||COHORT||RETROSPECTIVE|||||||
33846035|NCT03189459|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective cohort study (Aims 1 \& 2) stepped wedge trial of caregiver peer mentoring (Aim 3)||||
33846036|NCT05859516|||CASE_ONLY||PROSPECTIVE|||||||
33846037|NCT00073268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33846038|NCT04593420|||COHORT||PROSPECTIVE|||||||
33846039|NCT00478387|||COHORT||PROSPECTIVE|||||||
33846040|NCT02889575|||COHORT||PROSPECTIVE|||||||
33846041|NCT06151600|||OTHER||PROSPECTIVE|||||||
34158310|NCT02209896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158311|NCT02502825|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34158312|NCT03687346|||COHORT||PROSPECTIVE|||||||
34158313|NCT03087903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158314|NCT02210416|||CASE_CONTROL||RETROSPECTIVE|||||||
34158315|NCT05122091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158316|NCT04386954|||COHORT||PROSPECTIVE|||||||
34158317|NCT02563938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158318|NCT06256744|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||children, adolescents and adults||||
34158319|NCT03558490|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34158320|NCT05700383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158321|NCT03470402|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomization in which both a provider and his/her enrolled patients will be enrolled in either the intervention or control arm.||||
34158322|NCT00742716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158323|NCT03618862|||COHORT||PROSPECTIVE|||||||
33741749|NCT04174521|||COHORT||RETROSPECTIVE|||||||
34158324|NCT00154973|||||RETROSPECTIVE|||||||
34158325|NCT06029335|||COHORT||PROSPECTIVE|||||||
33741750|NCT05772767|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741751|NCT01116934|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846042|NCT04184843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846043|NCT03818360|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33846044|NCT03955562|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study will be a matched-cohort study, in which twelve bridge sites will be matched to twelve comparison sites. The bridge sites have been defined and identified by B2P staff in conjunction with government officials through a systematic needs assessment carried out in 2014. Of the twelve bridge sites that have been confirmed for the study, seven are located in the Southern Province, and five are located in the Western Province. Comparison sites were identified from a 2018 needs assessment carried out by B2P. As with the bridge sites, seven of the comparison sites are in the Southern Province and five are in the Western Province. The table of bridge and control sites with their respective districts and provinces can be found in Appendix A.||||
33846045|NCT04484103|||COHORT||RETROSPECTIVE|||||||
33846046|NCT00365677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054351|NCT00792688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054352|NCT02188472|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34158326|NCT03922620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158327|NCT01279616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158328|NCT04583800|||COHORT||PROSPECTIVE|||||||
34158329|NCT02218593|||OTHER||RETROSPECTIVE|||||||
34158330|NCT02396563|||CASE_CONTROL||PROSPECTIVE|||||||
34158331|NCT05723107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158332|NCT04280731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158333|NCT05641922|NA|SINGLE_GROUP||OTHER||NONE||||||
34158334|NCT03009734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158335|NCT05287893|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Different doses of pyronaridine will be administered across and within cohorts in order to effectively characterise the PK/PD relationship. Each cohort will comprise up to three dose groups, with participants randomised to a dose group on the day of dosing. The highest dose of pyronaridine administered will be no more than 720 mg; the lowest dose administered will be no less than 180 mg. The proposed dosing regimen for the Cohort 1, assuming six participants are enrolled, is as below. If less than six participants are enrolled the Safety Data Review Team (SDRT) will meet between Day 0 and Day 8, to decide on the dose/s to be administered.||||
34158336|NCT01371552|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34158337|NCT05075590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158338|NCT06003153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158339|NCT01105273|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158340|NCT01086371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158341|NCT05327972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158342|NCT00762047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158343|NCT05159570|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34158344|NCT02711930|||COHORT||PROSPECTIVE|||||||
34158345|NCT04983420|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34158346|NCT00671229|||COHORT||PROSPECTIVE|||||||
34158347|NCT03445689|||OTHER||PROSPECTIVE|||||||
34158348|NCT00458458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158349|NCT04984577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741752|NCT04631666|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"This study consists of an open-label dose escalation phase in healthy volunteers (Groups 1A-1C) and an additional open-label lead-in phase in SARS-CoV-2-infected individuals (Group 2C).~After completion of the dose escalation phase, SARS-CoV-2-infected individuals will be enrolled into a randomized placebo-controlled expansion cohort (Group 2D).~An additional higher dose cohort may be included for healthy volunteers (Group 1D)."|t|t|t|f
33741753|NCT05104658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking is not possible as the primary outcome is participation in rehabilitation activities. However, health professionals at the hospital are allocated to either intervention or control group, to minimise cross-contamination.|The participants will be block randomised according to vulnerability to either the intervention or the control study arm||||
34158350|NCT05895240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741754|NCT01394861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741755|NCT02243787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741756|NCT03860194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741757|NCT02288429|||CASE_ONLY||PROSPECTIVE|||||||
33741758|NCT04896957|||COHORT||PROSPECTIVE|||||||
34054353|NCT00020943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054354|NCT03152331|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive receptive awareness training with neurofeedback.||||
33741759|NCT06397794|||OTHER||OTHER|||||||
33741760|NCT00210834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741761|NCT01871298|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33741762|NCT05025293|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The patients are randomized by an electronic system (Viedoc). The randomization is masked for the investigator, the care providers, the participants and the outcomes assessor. Only un-blinded authorized study personnel who prepare the study medicine will see the allocation. The study medicine will be kept in a locked box. Blinded authorized personnel will give the study medication to the patients. The infusions will be covered by a locked box not allowing the patients or others to know the type of infusion.|Double-blinded randomized controlled non-inferiority trial|t|t|t|t
33741763|NCT01713595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741764|NCT05058911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial with repeated measurments and two conditions: the experimental group (Exp-CBT) and an active control group (T-CBT).|t|f|f|f
33741765|NCT03934021|||CASE_CONTROL||PROSPECTIVE|||||||
33741766|NCT02157311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741767|NCT01168050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741768|NCT06532539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741769|NCT00616967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741770|NCT06535529|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, randomized, two-armed parallel comparator study.||||
33741771|NCT02322944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33741772|NCT03869229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33741773|NCT00245557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741774|NCT01853150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765074|NCT05582980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The allocation concealment was further ensured by the administration of HD-tDCS using study mode of the device in which a five-digit numerical code specific to individual participant was entered into the device (Eldith DC stimulator Plus, NeuroConn, Ilmenau, Germany) that resulted in either active or sham stimulation, i.e., the researcher got the randomization code and a unique five-digit numerical code for an individual participant from the study coordinator while HD-tDCS administrator entered the code for study mode into the device. The study coordinator had continuous access to the randomization list and unblinded the study after the final visit of the last participant. Not until the unblinding of the trial did the participants, HD-tDCS administrators, researchers and clinical raters know the actual stimulation types."||t|t|t|t
33765075|NCT06335732|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34054355|NCT02155517|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34054356|NCT05803096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The operating urologist and study participant will be blinded to group assignment for the duration of the study.|Subjects will be randomized 1:1 to either SANO (treatment) or oxygen (placebo control) after completion of baseline assessment. The results of the randomization will not be disclosed to patients as part of the study (patient-blinded).|t|t|f|f
34054357|NCT01075230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054358|NCT00675168|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34054359|NCT06011395|||COHORT||PROSPECTIVE|||||||
34054360|NCT01376921|||COHORT||OTHER|||||||
34054361|NCT05555979|||COHORT||PROSPECTIVE|||||||
34054362|NCT02354755|||COHORT||PROSPECTIVE|||||||
34054363|NCT05113641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158351|NCT05492786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient-participants will not be explicitly told about the different arms, although clinician-participants will see the different arms and may notice these differences.||t|f|f|f
34158352|NCT03749278|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcomes assessor will not have knowledge of the intervention assigned to individual participants||f|f|t|t
34158353|NCT06578351|||CASE_CONTROL||PROSPECTIVE|||||||
34158354|NCT01671917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158355|NCT01645410|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950571|NCT03728166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Investigators will randomize patients by Attending Physician ID# to minimize the influence of an alert effect on the care of patients not randomized to the alert group but who have the same Attending Physician (thereby reducing what is called the cluster-effect). While investigators will randomize patients by Attending Physician of Record to minimize cluster-effect, the observational unit will be the patient."|U.S.-based, single-center, randomized controlled trial|t|f|f|f
33950572|NCT04640168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950573|NCT04704752|||CASE_ONLY||PROSPECTIVE|||||||
33950574|NCT03517657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients are stratified by Fugl Meyer score. After stratification, patients will be randomized to one of two groups|f|f|t|t
33950575|NCT03230331|||CASE_CONTROL||PROSPECTIVE|||||||
33950576|NCT02405624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950577|NCT03246152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950578|NCT02489682|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34054364|NCT04132453|||COHORT||PROSPECTIVE|||||||
34054365|NCT05401110|NA|SINGLE_GROUP||TREATMENT||NONE||"Single arm phase I dose escalation study with expansion cohorts.~1. Part I: Progressive disease on at least one prior EGFR TKI~2. Part II, Cohort 1: Progressive disease on osimertinib or other prior EGFR TKIs~3. Part II, Cohort 2: Receiving osimertinib as front line treatment for less than 12 weeks. Persistent ctDNA with EGFR mutation between weeks 6-12 from the start of osimertinib treatment."||||
34054366|NCT04624958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054367|NCT03700333|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34054368|NCT01996865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054369|NCT05081843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054370|NCT06622980|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm pre-post study with the educational intervention taking place outside of the clinical setting.||||
34054371|NCT06522555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054372|NCT04697004|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 200 randomized subjects will be randomized 1:1 to SMR Stemless Reverse and SMR Reverse Shoulder System.||||
34054373|NCT05059041|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34054374|NCT03599856|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A prospective single center (Catharina Hospital Eindhoven) controlled before-and-after study.||||
34054375|NCT06620120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054376|NCT02720744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054377|NCT00831545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054378|NCT05742139|||OTHER||PROSPECTIVE|||||||
34054379|NCT03970148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054380|NCT01437709|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054381|NCT00885742|NA|SINGLE_GROUP||||NONE||||||
34054382|NCT05234086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will evaluate encrypted images and tables containing healing valoration data.||f|f|f|t
34054383|NCT06622174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054384|NCT06621147|||CASE_CONTROL||RETROSPECTIVE|||||||
34054385|NCT03605862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054386|NCT03931473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34054387|NCT03776110|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Single center, multiple dose, dose escalation (within dose-group randomized, double-blind, placebo-controlled, 2-way cross-over)|t|t|t|t
34054388|NCT05310786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054389|NCT05104801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054390|NCT00545246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054391|NCT06138743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054392|NCT02523066|||CASE_ONLY||PROSPECTIVE|||||||
34054393|NCT03477747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Subject, Investigator)|Double-blind randomise controlled trial|t|t|t|t
34054394|NCT04889404|||COHORT||PROSPECTIVE|||||||
34054395|NCT02964754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054396|NCT03808636|||COHORT||PROSPECTIVE|||||||
34054397|NCT01909323|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34054398|NCT02289287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054399|NCT04483817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective interventional study|f|f|t|f
34158356|NCT05621993|||COHORT||PROSPECTIVE|||||||
34158357|NCT05006950|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34158358|NCT03416127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158359|NCT04429698|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34158360|NCT03318016|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2~* Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2~* Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2~* Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2~* Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2~ATO and Cyclophosphamide will be repeated every 28 days."||||
34158361|NCT03382054|||COHORT||RETROSPECTIVE|||||||
34158362|NCT04793113|NA|SINGLE_GROUP||OTHER||NONE||||||
34158363|NCT04584593|NA|SINGLE_GROUP||OTHER||NONE||||||
34158364|NCT06067464|||COHORT||PROSPECTIVE|||||||
34158365|NCT05686291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34158366|NCT03057652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each of the participants will receive training with each of the 3 wearable robotic exoskeletons (WRE) examined in this study, and the order of receipt will be randomized.||||
34158367|NCT04379401|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Clinical study with a randomized (double-blind) cross-over design|t|t|t|f
34158368|NCT06412172|||COHORT||RETROSPECTIVE|||||||
34158369|NCT05736601|||CASE_CONTROL||PROSPECTIVE|||||||
34158370|NCT00314470|||COHORT||RETROSPECTIVE|||||||
34158371|NCT03514875|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||1:1 Randomized, cross-over design|t|f|t|f
34158372|NCT02623582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158373|NCT03848936|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158374|NCT02487004|||COHORT||PROSPECTIVE|||||||
34158375|NCT00599755|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158376|NCT05113537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158377|NCT01128946|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34158378|NCT02711007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158379|NCT03182517|||OTHER||CROSS_SECTIONAL|||||||
34158380|NCT02038127|||COHORT||PROSPECTIVE|||||||
34158381|NCT01209429|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34158382|NCT03679624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158383|NCT01718444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950579|NCT00632866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054400|NCT04532190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and staff measuring outcomes will be blinded to whether the participant is receiving active or sham rTMS.|Sham-rTMS vs. Active rTMS|t|f|f|t
33950580|NCT04981249|||COHORT||RETROSPECTIVE|||||||
33950581|NCT04983589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950582|NCT05011162|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a virtual, single-arm, pragmatic, non-significant risk study.~Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia."||||
33950583|NCT04480554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study will enroll 225 HIV-positive subjects who meet DSM-5 opiate use disorder criteria and who are using opiates (primarily heroin). All subjects will receive a 48-week integrated treatment program for opiate use disorder with either (randomly assigned) daily directly observed oral methadone (MET) and buprenorphine/naloxone (BUP/NX) or monthly injection extended-release naltrexone (XR-NTX).||||
33950584|NCT02795481|||CASE_CONTROL||PROSPECTIVE|||||||
33950585|NCT03722459|NA|SINGLE_GROUP||OTHER||NONE||||||
33950586|NCT02563366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950587|NCT02945501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33950588|NCT03911557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950589|NCT03090945|||COHORT||PROSPECTIVE|||||||
33950590|NCT03890133|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33950591|NCT04498975|||COHORT||PROSPECTIVE|||||||
33950592|NCT00834366|RANDOMIZED|CROSSOVER||||NONE||||||
33950593|NCT04249557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950594|NCT01994369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950595|NCT01147432|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33950596|NCT01419834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950597|NCT03386630|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized clinical trial, without masking techniques, is proposed in pregnant women who are to undergo elective caesarean section by subarachnoid anesthesia with hyperbaric bupivacaine associated with sufentanil or morphine||||
33950598|NCT01172860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950599|NCT06519201|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33950600|NCT06046404|RANDOMIZED|PARALLEL||TREATMENT||NONE|cluster randomization|||||
33950601|NCT02513901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950602|NCT04149366|||COHORT||PROSPECTIVE|||||||
33950603|NCT01754311|||CASE_CONTROL||RETROSPECTIVE|||||||
33950604|NCT00256256|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33950605|NCT04498260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950606|NCT06336629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950607|NCT00272389|||DEFINED_POPULATION||OTHER|||||||
33950608|NCT02022566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950609|NCT04766788|||COHORT||PROSPECTIVE|||||||
33950610|NCT00000565|RANDOMIZED|||TREATMENT||||||||
33950611|NCT03879824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950612|NCT02222246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950613|NCT00917670|||CASE_ONLY||PROSPECTIVE|||||||
33950614|NCT04851704|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention-control trial, where both intervention and control group participants are assessed at baseline, and then the intervention groups get the intervention, and all group participants are assessed at follow up.||||
33950615|NCT03186794|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33950616|NCT03909867|||CASE_ONLY||CROSS_SECTIONAL|||||||
33950617|NCT05980637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950618|NCT06566781|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950619|NCT06021769|||COHORT||PROSPECTIVE|||||||
33950620|NCT02613559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950621|NCT02046993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950622|NCT04357756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950623|NCT02064400|||CASE_ONLY||CROSS_SECTIONAL|||||||
33950624|NCT02335229|||COHORT||PROSPECTIVE|||||||
33950625|NCT05696457|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled clinical trial||||
33950626|NCT06652542|||OTHER||CROSS_SECTIONAL|||||||
33950627|NCT03080207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950628|NCT04614480|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950629|NCT01224600|||COHORT||PROSPECTIVE|||||||
33950630|NCT02246205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054401|NCT04102254|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34054402|NCT06137573|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34054403|NCT06090903|NA|SINGLE_GROUP||SCREENING||NONE||||||
33950631|NCT01031433|||||PROSPECTIVE|||||||
34158384|NCT00056953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158385|NCT03282097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158386|NCT01485549|||CASE_CONTROL||PROSPECTIVE|||||||
34158387|NCT04239690|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Prevalence and severity of BPD at 36 weeks post-menstrual age is determined by the oxygen challenge test performed by a trained respiratory nurse blinded to treatment at each study site.|Parallel assignment|f|f|f|t
33950632|NCT00205361|||COHORT||PROSPECTIVE|||||||
33950633|NCT00656669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054404|NCT05933200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950634|NCT01863394|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950635|NCT01355380|||COHORT||PROSPECTIVE|||||||
33765076|NCT01934413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33950636|NCT02665754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765077|NCT03614962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765078|NCT00004390|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33950637|NCT01400191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33950638|NCT03158454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33950639|NCT01985880|||CASE_CONTROL||PROSPECTIVE|||||||
33950640|NCT00694070|||CASE_ONLY||CROSS_SECTIONAL|||||||
33950641|NCT05805579|||COHORT||PROSPECTIVE|||||||
33950642|NCT03135730|||COHORT||PROSPECTIVE|||||||
33950643|NCT05116410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33950644|NCT04647773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950645|NCT03768076|||CASE_ONLY||RETROSPECTIVE|||||||
33950646|NCT06291870|||COHORT||PROSPECTIVE|||||||
33950647|NCT00161148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33950648|NCT00886977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950649|NCT05277987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950650|NCT02464176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950651|NCT03705221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950652|NCT04288960|||COHORT||CROSS_SECTIONAL|||||||
33950653|NCT02800382|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33950654|NCT01987570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950655|NCT06160258|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The study employs a two-arm, randomized parallel design. Individuals, ages 19+, will be randomly assigned to one of two 4-week intervention conditions in which they receive either precooked intact novel whole grains (RTE condition) or dried, bulk novel whole grains (DRIED condition) to consume at home."|t|f|f|f
33950656|NCT04996212|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33950657|NCT06396806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950658|NCT00552656|||COHORT||PROSPECTIVE|||||||
33950659|NCT01719263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950660|NCT06143176|NA|SINGLE_GROUP||TREATMENT||NONE||Control group will be recruited by propensity matching with the experimental group according to the dataset from retrospective data||||
33950661|NCT00343148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950662|NCT04269161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950663|NCT02267174|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33950664|NCT04917588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950665|NCT03371602|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33950666|NCT03825887|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blinded|patients with AML , ALL and bone marrow transplantation with oral mucositis grade3 or 4 were randomized into two group: patient using of PCA Morphine (Group A) patient using of PCA Nalbuphine (Group B). Patients of both groups will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg / hour.|t|t|t|t
33950667|NCT03195946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950668|NCT02113904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950669|NCT00494234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950670|NCT03621566|||COHORT||PROSPECTIVE|||||||
33950671|NCT03615742|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Blinding of exposures will be performed by the air pollution exposure laboratory (APEL) engineer, who will not interact with volunteers. Visually indistinguishable placebo and budesonide inhalers will be coded by research pharmacy staff. All assays will be performed by personnel who do not know the exposure conditions of individual samples.|Volunteers will visit our lab four different times to be exposed to: 1) placebo \& filtered air, 2) placebo \& diesel exhaust, 3) budesonide and filtered air, and 4) budesonide and diesel exhaust|t|f|t|t
33950672|NCT04028739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950673|NCT04025866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950674|NCT05468866|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950675|NCT02554084|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950676|NCT04679116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, non randomised||||
33950677|NCT01617031|||COHORT||PROSPECTIVE|||||||
33950678|NCT04179929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950679|NCT00280839|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33950680|NCT05765994|||COHORT||PROSPECTIVE|||||||
33950681|NCT03764241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950682|NCT05888545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33950683|NCT02119858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950684|NCT00965562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950685|NCT06428734|||COHORT||PROSPECTIVE|||||||
34054405|NCT05555524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A two computer allocation sequence will be generated. They will be placed in an opaque, sealed envelope and kept with the head nurse of each hemodialysis unit. After completing the baseline data, the clinical researchers open the envelops and assign the patients to one group. The baby oil and the placebo distilled water will be placed on identical bottles and participants will not be informed about group assignments. The clinical researcher will label the groups as A or B; only the clinical researchers will know the group allocation. Both the outcome assessor and the statistician will be blinded.|two-group pre-test and repeated post-test study|t|f|f|t
34054406|NCT06521645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054407|NCT03955081|||OTHER||PROSPECTIVE|||||||
34054408|NCT06593886|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054409|NCT02341495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765079|NCT05453175|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33765080|NCT02456805|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33765081|NCT01712243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33765082|NCT02206308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765083|NCT02786264|||COHORT||RETROSPECTIVE|||||||
33765084|NCT03154372|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33741775|NCT06114797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participants in both groups will not recognize the type of applied treatment whether it is saline mouthwash or chamomile mouthwash.~Outcome assessor will not know whether the patients they are assessing are from the control or the intervention group."|"Treatment protocol (for the intervention group):~* Chamomile will topically be applied to the oral mucosa as oral rinse based on the Morales-Bozo I et al., (2017) administration protocol.~* Based on this protocol, patients will have oral rinses 3 times per day.~* Patients will be instructed to perform chamomile rinses in the oral mucosa.~* Patients will be instructed not to swallow the chamomile oral rinse.~The control group (placebo):~Patients in the control arm followed the same protocol with normal saline rinses. As stated by Kim JO and Kim NC, 2014, that use of 4% hypertonic saline solution mouthwash by elderly provided better oral health by decreasing xerostomia, oral tongue plaque, halitosis, and the number of oral bacteria.~So the patients in the control group will be benefited from the saline oral rinse."|t|f|f|t
33741776|NCT00352534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741777|NCT02520934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158388|NCT04994301|||COHORT||PROSPECTIVE|||||||
34158389|NCT02846441|||COHORT||RETROSPECTIVE|||||||
34158390|NCT04454073|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158391|NCT04658043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158392|NCT05958680|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158393|NCT03482492|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158394|NCT02679287|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158395|NCT04338763|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158396|NCT02644577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158397|NCT03970369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741778|NCT03773744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741779|NCT03549689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054410|NCT00447031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054411|NCT02114996|||CASE_CONTROL||PROSPECTIVE|||||||
34054412|NCT06422104|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The TMS intensity and cortical location delivered at each TMS visit will be masked|Double-blind cross-over design with participants receiving TMS at two cortical locations.|t|f|f|t
34054413|NCT04998279|||COHORT||OTHER|||||||
34054414|NCT04025931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054415|NCT00041106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054416|NCT01144676|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34054417|NCT02269410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054418|NCT06622616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study will be masked by using identical packaging for both the study group and the control group (placebo), which participants will consume at home or at the place where they eat, during the 12 weeks of the intervention. The packaging of the products will be carried out by the company supplying A. domesticus powder, Nutrinsect SRL (Italy), which is authorised to produce A. domesticus powder according to EFSA approval.~The researchers will administer the product (with identical external appearance for both groups) individually to each participant.~The randomisation will be carried out blindly, so that each of the participants and the researcher will not know which group (study or control) they have received. For this purpose, the product under study will be labeled with the protocol code and the letters A or B (or batch number) that will correspond to the functional and/or control product."|"A pilot nutritional intervention study will be conducted that will be longitudinal, prospective, double-blind, randomized and parallel.~The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not)."|t|f|t|f
34054419|NCT06540079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054420|NCT06648070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial|t|f|f|f
34054421|NCT05522881|||CASE_CONTROL||OTHER|||||||
34054422|NCT04670744|||COHORT||RETROSPECTIVE|||||||
34054423|NCT03747315|||CASE_CONTROL||PROSPECTIVE|||||||
34158398|NCT01517464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158399|NCT02112864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158400|NCT03034330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158401|NCT00305539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158402|NCT06185075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158403|NCT01907425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158404|NCT06307093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158405|NCT06254287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158406|NCT03975686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158407|NCT03629353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741780|NCT02062502|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33741781|NCT03499158|||OTHER||RETROSPECTIVE|||||||
33741782|NCT02511249|||COHORT||PROSPECTIVE|||||||
33741783|NCT03119090|||COHORT||PROSPECTIVE|||||||
33741784|NCT02157558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741785|NCT01665235|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741786|NCT03217045|||CASE_CONTROL||RETROSPECTIVE|||||||
34158408|NCT00002812|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158409|NCT00216216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158410|NCT02479815|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158411|NCT05015569|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients will be blinded to the difference between garment groups.|Treatment allocation will be determined using a block randomized crossover trial design.|t|f|f|f
34158412|NCT01621607|||||RETROSPECTIVE|||||||
34158413|NCT05311787|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients over 18 years old with esophageal diseases who are required surgical treatment include in trial.||||
33741787|NCT04848285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741788|NCT04174092|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741789|NCT03830671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741790|NCT03421197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized|t|t|t|t
33741791|NCT01025713|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741792|NCT05928533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741793|NCT04488731|||OTHER||CROSS_SECTIONAL|||||||
33741794|NCT04173533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741795|NCT01921348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741796|NCT03956602|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33741797|NCT02398097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158414|NCT06579911|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants are randomly divided into two groups. One group (the experimental group) receives the combination of high-frequency micro-ultrasound, multiparametric MRI-targeted biopsy, and systematic biopsy. The other group (the control group) receives the current standard care, which includes only multiparametric MRI-targeted biopsy and systematic biopsy. This setup allows direct comparison of the detection rates of clinically significant prostate cancer between the new combination of interventions and the standard approach.||||
33741798|NCT03594994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741799|NCT01084044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741800|NCT04280198|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Membership in the intervention vs. control group will not be discussed as such, but participants will know whether they receive intervention activities early (intervention group) or after the post-test assessment (control group)"|||||
34158415|NCT01631461|||CASE_CONTROL||PROSPECTIVE|||||||
34158416|NCT06340893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to group and will be different to those conducting the interventions.|Participants will be randomly assigned to the exercise intervention group or to the restful play (sham) condition.|f|f|f|t
34158417|NCT00697177|||COHORT||PROSPECTIVE|||||||
34158418|NCT04079998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Biopsies obtained will be sent to Indiana University for blinded processing and analysis.|Participants will have two wound sites that will be randomized to receive either the standard of care treatment or the Procellera® (electroceutical) dressing.|f|f|f|t
34158419|NCT04027894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158420|NCT03258775|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34158421|NCT04009395|||OTHER||OTHER|||||||
33741801|NCT00795600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741802|NCT05219201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741803|NCT06395285|NA|SINGLE_GROUP||TREATMENT||NONE|As this is an open label study, there are no blinding requirements for safety data.|"ROSAH syndrome patients will receive oral (PO) doses of DF-003 once daily (QD) for a duration of 28 days (4 weeks). In this study, 8 patients will be evaluated in one cohort. The cohort will have a minimum of 6 patients. Additional patients (maximum of 12 patients) may be enrolled in the event of insufficient data.~Patients will receive loading doses of 140 mg on Days 1, 2, and 3, followed by a maintenance dose of 45 mg QD starting on Day 4 through Day 28. Individual dose modification is not allowed in this study. If the overall cohort dose needs modification, this will be determined based on review of all available safety and pharmacokinetics (PK) data from this study."||||
33741804|NCT06059703|NA|SINGLE_GROUP||OTHER||NONE||||||
33741805|NCT06241365|||COHORT||RETROSPECTIVE|||||||
33765085|NCT03516864|||CASE_CROSSOVER||PROSPECTIVE|||||||
33765086|NCT02041923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765087|NCT03328143|NA|SINGLE_GROUP||OTHER||NONE||||||
33765088|NCT01068301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950686|NCT03868956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158422|NCT05154318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158423|NCT03998969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158424|NCT06471114|||COHORT||RETROSPECTIVE|||||||
34158425|NCT05020210|||CASE_CONTROL||PROSPECTIVE|||||||
34158426|NCT03654885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765089|NCT00336271|||DEFINED_POPULATION||OTHER|||||||
33950687|NCT05375942|||COHORT||RETROSPECTIVE|||||||
33950688|NCT00003876||||TREATMENT||||||||
33950689|NCT03832426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950690|NCT05797142|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Virtual reality glasses and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33950691|NCT02430545||CROSSOVER||BASIC_SCIENCE||NONE||||||
33950692|NCT00703222|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
33950693|NCT05307926|||COHORT||PROSPECTIVE|||||||
33950694|NCT01852786|||CASE_CONTROL||PROSPECTIVE|||||||
33950695|NCT04778397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950696|NCT02095834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950697|NCT01033110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950698|NCT01744275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950699|NCT02396849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950700|NCT05288335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950701|NCT04661865|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The researchers will interview participants, explain the purpose of the study and they will ask them to sign the consent. All participants will receive iron supplementation and they will learn how to take tablets.~They will randomly assign in two intervention and control groups (98 each) using a computer-generated table of random numbers and they are unaware of which group they have been assigned to as well as the outcome assessor is unaware"|Group A: intervention group who will receive iron supplementation and Heath Information Package Program (HIP program) Group B: Control group: will receive iron supplementation and routine care|t|f|f|t
33950702|NCT02413723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950703|NCT00821600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950704|NCT03922048|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33765090|NCT01540994|NA|SINGLE_GROUP||TREATMENT||NONE||Radiotherapy||||
34158427|NCT02863328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741806|NCT05684887|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a cluster randomized trial conducted in eight (8) Health Districts with a high number of people being tested for SARS-CoV-2 in the Littoral region in Cameroon, comparing two strategies for COVID-19 contact tracing of SARS-CoV-2 infected index patients:~* The standard of care (SOC) implements the contact tracing using a manual process based on current routine approach (use of the Mamal Pro application without digital contact tracing module).~* The intervention (ITV) will implement the contact tracing using a digitalized process (addition of the Mamal Pro digital contact tracing module to the Mamal Pro app).~The randomization unit (cluster) will be the district with selected testing units and/or health facilities where SARS-CoV-2 infected patients (index cases) are diagnosed."||||
33741807|NCT05187377|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Mount Sinai Pharmacy will be responsible for randomizing research participants and preparing investigational drug/placebo. The participant, caregivers, and study team will all remain blinded for the duration of the study.|"A randomized, double-blind, placebo-controlled, crossover design, with 12 weeks in each treatment phase (rhGH and placebo) and a four week wash-out period between phases.~During each phase, participants will be monitored at Baseline, Week 2, Week 4, Week 8, and Week 12."|t|t|t|t
34054424|NCT03937908|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|Randomization will use an arm equivalence design to promote equal numbers of participants for each order schema. All participants will be blinded to the dose they will be receiving at each visit. The investigators have developed a formulation that tastes and looks very similar at each dose. The investigator administering the intervention and the analyst performing the liquid chromatography analysis of collected plasma will be blinded as to the dose of the product administered. The liquid chromatography analyst will also be blinded as to the time point of collection.|This is an outpatient open-label clinical study using a blinded randomized crossover design of two doses.|t|f|f|t
34054425|NCT00899405|||COHORT||PROSPECTIVE|||||||
34054426|NCT04747613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054427|NCT02889198|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34054428|NCT00790231|||COHORT||PROSPECTIVE|||||||
34054429|NCT05171296|||CASE_ONLY||PROSPECTIVE|||||||
34054430|NCT00308087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054431|NCT02935504|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34054432|NCT00877942|||CASE_CONTROL||PROSPECTIVE|||||||
34054433|NCT03627338|||COHORT||PROSPECTIVE|||||||
34054434|NCT05343364|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34054435|NCT06370871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054436|NCT06618716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34054437|NCT03087097|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34158428|NCT05062486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158429|NCT01229722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158430|NCT03487185|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study is an unmasked randomized controlled multi-center clinical trial.|"Women who are between 14 weeks 0 days and 21 weeks 5 days with a singleton gestation and obstructive sleep apnea (OSA) will be randomized to one of two arms at participating MFMU Network clinical center:~* Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling~* Initial sleep advice counseling alone"|f|f|t|t
34158431|NCT02218008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158432|NCT04955327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158433|NCT04885413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158434|NCT01126788|||COHORT||PROSPECTIVE|||||||
34158435|NCT02466009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158436|NCT01365858|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
34158437|NCT03570359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All patients will be randomised to one of two treatment groups (SNG001 or placebo).~In Part 1 the ratio will be 4:1 and in Part 2 the ratio will be 1:1, both according to a pre-specified randomisation schedule. In Part 2, prior to randomisation to SNG001 or placebo, patients will be stratified into two groups; those with cold symptoms without a moderate COPD exacerbation (Group A), and those who have a moderate COPD exacerbation with or without cold symptoms (Group B).~For both parts of the study, patients will be randomised according to a pre-specified randomisation schedule."||t|t|t|t
34158438|NCT03070899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158439|NCT05270239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158440|NCT05219058|||COHORT||PROSPECTIVE|||||||
34158441|NCT01192919|||COHORT||PROSPECTIVE|||||||
34158442|NCT04480632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental and open-label intervention study. In this study, the application of convalescent plasma is considered as an intervention, but randomization will not be performed by investigators; one arm will be patients who received ABO compatible convalescent plasma and the comparison group will be those patients with intervention indication but without compatible ABO plasma units within the institution.||||
34158443|NCT04153045|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34158444|NCT03261453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34158445|NCT01204021|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34158446|NCT01189981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34158447|NCT06251583|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34158448|NCT05077345|||CASE_ONLY||PROSPECTIVE|||||||
34158449|NCT05466331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158450|NCT06583330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158451|NCT05096000|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the participants nor the outcomes assessors will know the intervention in which each participant is assigned to.||t|f|f|t
34158452|NCT00763841|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34158453|NCT04262128|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741808|NCT06431919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind randomized controlled trial||t|t|t|t
33741809|NCT04450823|||OTHER||CROSS_SECTIONAL|||||||
33741810|NCT05218655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741811|NCT05941650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective study, randomized single blind clinical trial|t|f|f|f
33741812|NCT04007952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed regarding the treatment that they received until they complete 1-year follow-up. Imaging will be reviewed at the end of the study period by surgeons who are blinded to treatment group.|This will be a double-blinded, registry-based, randomized control trial comparing anterior gastropexy to no anterior gastropexy in paraesophageal hernia repair. This will be a two-arm trial with intervention 1: intervention 2 and control allocation ratio of 1:1.|t|f|f|t
33741813|NCT05889403|||COHORT||PROSPECTIVE|||||||
33741814|NCT04823598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33741815|NCT01954654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741816|NCT02618473|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33741817|NCT06415201|||OTHER||CROSS_SECTIONAL|||||||
33741818|NCT00517920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741819|NCT03103282|||COHORT||PROSPECTIVE|||||||
33741820|NCT05900102|||COHORT||RETROSPECTIVE|||||||
33741821|NCT01081977|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33741822|NCT01620463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741823|NCT00099983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741824|NCT04957602|||COHORT||PROSPECTIVE|||||||
33741825|NCT00242034|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741826|NCT02471924|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33741827|NCT04258020|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741828|NCT05361473|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33741829|NCT06408272|||COHORT||PROSPECTIVE|||||||
33741830|NCT06141798|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic Randomization Trial||||
33741831|NCT00861939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741832|NCT00711685|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741833|NCT02917109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741834|NCT01808313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741835|NCT04712318|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Myopic group 100 eyes hyperopic group 30 eyes||||
34054438|NCT06158997|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked examiner for all clinical assessments will not involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the two groups.|Prospective, comparative pilot study|f|f|t|t
33741836|NCT05109910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741837|NCT03495336|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33741838|NCT01717235|RANDOMIZED|CROSSOVER||||NONE||||||
33741839|NCT05244356|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33741840|NCT04976920|||COHORT||PROSPECTIVE|||||||
33741841|NCT03963895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33741842|NCT01750567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741843|NCT01678326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741844|NCT05456295|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded, to the greatest extent possible, to the different CDO designs and will only be introduced to each device as CUFF-A, CUFF-B, CUFF-C, CUFF-D.|All participants will be cast and fit with CDOs with four different proximal cuff designs. CDOs will be labeled as CUFF-A, CUFF-B, CUFF-C, CUFF-D. Testing order of the proximal cuff designs will be randomized to prevent influence of study results.|t|f|f|f
33741845|NCT01253343|||COHORT||PROSPECTIVE|||||||
33741846|NCT02171286|||OTHER||OTHER|||||||
33741847|NCT02688634|||COHORT||PROSPECTIVE|||||||
33741848|NCT02591693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741849|NCT04827004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741850|NCT00948831|||COHORT||PROSPECTIVE|||||||
33741851|NCT05542368|||CASE_CONTROL||OTHER|||||||
33741852|NCT04413539|||CASE_ONLY||RETROSPECTIVE|||||||
33741853|NCT03290716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33741854|NCT04681521|RANDOMIZED|PARALLEL||PREVENTION||NONE||placebo controlled randomized trial||||
33741855|NCT05093452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741856|NCT01490060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33741857|NCT02565641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741858|NCT06149260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741859|NCT02473952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741860|NCT02596724|||COHORT||PROSPECTIVE|||||||
33741861|NCT02486003|||CASE_CONTROL||PROSPECTIVE|||||||
33741862|NCT00782613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741863|NCT01272934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741864|NCT06341218|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33741865|NCT02356016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741866|NCT01888601|||COHORT||PROSPECTIVE|||||||
33741867|NCT00201071|||FAMILY_BASED||PROSPECTIVE|||||||
34054439|NCT06410703|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34054440|NCT05994521|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|As with most procedural interventional trials, blinding of the endoscopist is not feasible. To limit detection biases, outcome assessors and patients are blinded to the treatment allocation. Outcome assessors are independent individuals not involved with patient consent or randomization and not present at the index procedure.|Patients will be randomly allocated, intra-procedurally during the ERCP, to one of the two approaches.|t|f|t|t
34158454|NCT03042143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The cell therapy facility and clinical trials pharmacist will be unblinded. The unblinded individuals will keep the treatment information confidential and will not discuss or release information on treatment allocation to the patient, the investigator, or other unauthorised personnel.~As in prior studies of MSCs, the infusion bag containing either the cell product or placebo will be masked at the time of preparation in the clinical site's cell therapy facility so that the contents of the infusion bag are not visible to the investigators or to the clinicians who are administering the study drug. The contents of the infusion bag will be administered through a masked infusion set."|"The phase 1 trial is an open label dose escalation pilot study in which cohorts of subjects with moderate to severe ARDS will receive increasing doses of a single infusion of Realist Orbcel-C in a 3+3 design. Initially 3 cohorts with 3 subjects/cohort.~In the completed Phase 1 REALIST trial, infusion of 400 million cells was achieved without any dose limiting toxicity at day 7 and has been approved by the DMEC as the intervention dose for this study.~The phase 2 trial is a randomised, double-blind, allocation concealed placebo-controlled study using the maximal tolerable dose as determined by the DMEC in patients with moderate to severe ARDS due to COVID-19 or other causes of ARDS."|t|t|t|t
34158455|NCT01755039|||COHORT||PROSPECTIVE|||||||
34158456|NCT05365373|||OTHER||RETROSPECTIVE|||||||
34158457|NCT01832155|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34158458|NCT04342117|||COHORT||PROSPECTIVE|||||||
34158459|NCT05357508|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34158460|NCT05028868|||COHORT||PROSPECTIVE|||||||
34158461|NCT04933487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158462|NCT04673578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo capsules will be dispensed similar in appearance to celecoxib capsules. Unique randomization codes will be used for each participant to avoid inadvertent loss of blinding for all participants in the event that one is unblinded. Data analysis and manuscript writing will be performed after unblinding.|Participants will be randomly assigned to celecoxib or placebo arms. Participants will have the option of participating in a 12-week open-label celecoxib extension after completing the randomized portion of the study.|t|t|t|t
33741868|NCT06057012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741869|NCT00054535||||TREATMENT||NONE||||||
33741870|NCT01987713|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33741871|NCT06306482|||CASE_CONTROL||PROSPECTIVE|||||||
33741872|NCT00708825|||COHORT||RETROSPECTIVE|||||||
34158463|NCT04039737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158464|NCT01840345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158465|NCT05776953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, treating provider, and the investigator will be blinded.||t|t|t|f
34158466|NCT03125551|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Each participant will be blinded to the dietary supplement which they will be taking. The medical technologist doing the ROTEM will be blinded to the dietary supplements as well.|Five- armed, placebo- controlled ( 4 intervention groups and 1 placebo group)|t|f|f|t
34158467|NCT04151134|||COHORT||PROSPECTIVE|||||||
34158468|NCT01900652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158469|NCT02975674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34158470|NCT01588600|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34158471|NCT00176462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158472|NCT06018623|||OTHER||PROSPECTIVE|||||||
34158473|NCT03373838|||OTHER||PROSPECTIVE|||||||
34158474|NCT00254670|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33741873|NCT01046643|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33741874|NCT02332486|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741875|NCT06127069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized parallel arm clinical trial|f|f|t|f
33741876|NCT03640910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741877|NCT03561779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The Subjects are injected investigational Product (YYD302 or Synovian Inj.)|t|f|t|f
33741878|NCT03384758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741879|NCT06086912|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is a single-center, randomized, open-label, three-period, and three-sequence crossover design trial, consisting of three sequences (sequence 1, sequence 2 and sequence 3) and three periods (first period, second period and third period). Each sequence receives a same dose of HR17031 at every period.||||
33741880|NCT06532006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741881|NCT00302224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33741882|NCT00600600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741883|NCT00770016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741884|NCT01027910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741885|NCT04624698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741886|NCT00983229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33741887|NCT02348216|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741888|NCT01506245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741889|NCT05319678|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33741890|NCT05437627|||CASE_CONTROL||PROSPECTIVE|||||||
33741891|NCT02930096|||CASE_CONTROL||PROSPECTIVE|||||||
33741892|NCT01633489|||COHORT||PROSPECTIVE|||||||
33741893|NCT04116931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741894|NCT02162810|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34158475|NCT01356446|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34158476|NCT05397249|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants are blind to their conditions.|This study is designed as an experimental longitudinal study using a 2 X 3 factorial repeated measures design. The 2 level factor is mindfulness and mindfulness plus spirituality. The 3 level factor is the dose of the intervention (i.e., control, one class a week, and two classes a week).|t|f|f|f
34158477|NCT01324362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158478|NCT02445521|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158479|NCT00365040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158480|NCT01810497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34158481|NCT05984485|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Primary TME~2. neoadjuvant chemotherapy plus TME"||||
34158482|NCT05345301|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158483|NCT03062111|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34158484|NCT01696890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158485|NCT04247295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 arms of randomised treatment methods, each participant will be either assigned to the traditional cast or the woodcast assigned.|t|f|f|f
34158486|NCT02556489|||COHORT||PROSPECTIVE|||||||
34158487|NCT02243735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158488|NCT06153368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158489|NCT05842148|||OTHER||PROSPECTIVE|||||||
34158490|NCT04887753|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158491|NCT01450098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33741895|NCT01614210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158492|NCT05332652|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant in Group 1-3 will be blinded to the stimulation protocol that they will be receiving.|"Subjects from Study 1 whose ARAT score is \< = 42 at 3 months post-stroke will proceed to Study 2. Subjects who are agreeable for transcranial direct current stimulation (tDCS) will be randomized into 3 groups with 17 subjects in each group, by stratified randomization, according to the lesion location (cortical vs. subcortical), and type of stroke (haemorrhagic vs. ischemic). Subjects who refuse tDCS will be enrolled in the control group without receiving any tDCS stimulation.~* Group 1 will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb;~* Group 2 to receive 1mA anodal tDCS to the contralesional premotor cortex;~* Group 3 to receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1.~* Group 4: Subjects who fulfill the inclusion criteria of Study 2 but refuse tDCS stimulation."|t|f|f|f
34158493|NCT06043908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158494|NCT00856726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158495|NCT00728091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158496|NCT00066963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34158497|NCT03213834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Change in pleural fluid volume on chest CT scan from randomization (day 0) to prior to chest tube removal will be measured by a radiologist blinded to treatment allocation using image J software|Subjects will be randomly assigned to receive one of two standard-of-care treatments for severe pleural infection.|f|f|f|t
34158498|NCT03060278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158499|NCT05813002|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The assessor, who took the measurements for all groups will be blinded to the subject's group.|A prospective, parallel-group, randomized clinical trial participants will be randomly assigned to one of three different groups. One group will receive the standard neural mobilization, the second group will receive Distal-Proximal neural mobilization, and the third group will receive Proximal-Distal neural mobilization, all targeting the median nerve.|f|f|f|t
33741896|NCT00450424|RANDOMIZED|PARALLEL||||NONE||||||
34158500|NCT05350852|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158501|NCT05844358|||COHORT||PROSPECTIVE|||||||
34158502|NCT05813704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158503|NCT04046224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158504|NCT04767503|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34158505|NCT02105038|RANDOMIZED|CROSSOVER||||NONE||||||
34158506|NCT06455501|||COHORT||PROSPECTIVE|||||||
34158507|NCT01635855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158508|NCT03929640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158509|NCT06315946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158510|NCT02296255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158511|NCT02967510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158512|NCT03402828|||COHORT||PROSPECTIVE|||||||
34158513|NCT05824169|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158514|NCT00005397|||COHORT||PROSPECTIVE|||||||
34158515|NCT02575170|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34158516|NCT01708135|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34158517|NCT01037738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158518|NCT04573608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158519|NCT05383456|||OTHER||PROSPECTIVE|||||||
34158520|NCT02461940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34158521|NCT04282525|||CASE_ONLY||PROSPECTIVE|||||||
34158522|NCT04436172|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158523|NCT03749772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was performed by the principal investigator. The interventions were carried out individually, so the participants were unaware of the existence of another study arms.||t|f|f|t
34158524|NCT00465023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158525|NCT02057159|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34158526|NCT05526287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158527|NCT01206582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158528|NCT02088021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158529|NCT02474407|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158530|NCT00269854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158531|NCT00902460|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158532|NCT05569980|||COHORT||PROSPECTIVE|||||||
34158533|NCT04957121|||COHORT||RETROSPECTIVE|||||||
34158534|NCT06010446|||COHORT||RETROSPECTIVE|||||||
34158535|NCT00564213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158536|NCT04891354|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During the administration, the infusion set is masked for the subject.|"In Part I, each subject will receive a 30 minute i.v. infusion of placebo followed by a 1-hour i.v. infusion of PDNO in parallel with a carrier sodium bicarbonate buffer, the infusion of which will start 5 minutes prior to start of placebo infusion and continue until 15 minutes after end of PDNO infusion. Between the end of placebo infusion and prior to the start of PDNO infusion, there will be a 20-minute stabilisation period with infusion of sodium bicarbonate buffer only.~In Part II, each subject will receive a 30 minute i.v. infusion of placebo followed by 2 x 30 minute infusions of PDNO at 2 ascending dose levels and one 3-hour infusion of PDNO at a third dose level."|t|f|f|f
34158537|NCT06584526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158538|NCT04302233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a prospective, multicentric, controlled, single-blind, randomized trial in two parallel arms|t|f|f|f
34158539|NCT05748457|||COHORT||RETROSPECTIVE|||||||
34158540|NCT06464562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34158541|NCT01658761|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34158542|NCT01873625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158543|NCT01970267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158544|NCT03227666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Intervention group recieving exercise and control group recieving no exercise|f|f|f|t
34158545|NCT04045379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcomes assessor will not know which therapy was used by the patient|The patient will be randomized in block to receive one of the three intravaginal therapies: LASER, Radiofrequency and topic estriol|f|f|f|t
34158546|NCT00887926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158547|NCT00206336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158548|NCT05368194|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34158549|NCT04357808|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, open-label, single-center, comparative trial of sarilumab plus standard of care vs. standard of care in a 2:1 ratio.||||
34158550|NCT00765570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158551|NCT00179946|||||PROSPECTIVE|||||||
34158552|NCT01157026|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158553|NCT00612196|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34158554|NCT06030167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158555|NCT02612922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158556|NCT03406338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Before examination the patients will wear thin gloves in the treated hands to conceal possible surgical scars so the examiner will be blinded to the group allocation.|Randomized parallel Group, ratio 1:1.|f|f|f|t
34158557|NCT03576859|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34158558|NCT04988750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158559|NCT01388140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158560|NCT02083042|||COHORT||PROSPECTIVE|||||||
34158561|NCT02638168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158562|NCT05215795|||OTHER||PROSPECTIVE|||||||
34158563|NCT02670694|||CASE_CONTROL||PROSPECTIVE|||||||
34158564|NCT03004235|||COHORT||PROSPECTIVE|||||||
34158565|NCT06438055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158566|NCT01561742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158567|NCT00652951|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34158568|NCT06490042|||CASE_CONTROL||PROSPECTIVE|||||||
34158569|NCT00219505|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34158570|NCT00117039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158571|NCT01629758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158572|NCT00661817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158573|NCT00580385|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158574|NCT01969435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158575|NCT03165916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158576|NCT00258791|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34158577|NCT04326582|||COHORT||PROSPECTIVE|||||||
34158578|NCT03161106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158579|NCT00851461|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158580|NCT00006133|RANDOMIZED|||TREATMENT||DOUBLE||||||
34158581|NCT06058325|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"The investigators will use a cross-over design, which means participating schools have both a control and intervention period during academic year 2023-2024. Schools will be randomized into group A or B, starting with either an intervention or control period.~During the intervention period, schools will organize a healthy lunch for all children during four days a week for a duration of half an academic year (approximately 18 weeks). During the control period, children will bring their own lunch box."||||
34158582|NCT00416325||||PREVENTION||||||||
34054441|NCT04671381|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participant randomization will occur by generating three groups of random participant numbers and then assigning each participant to their designated group. Only the PI and the project manager will have access to the randomization lists. The PI will generate the randomization lists and the Project Manager will assign the participants accordingly to each group. Audiologists will be blinded to the intervention condition for participants. Specifically, two audiologists (A1 and A2) will conduct the initial hearing evaluations. A2 will perform the OTC HA settings and orientations and a third audiologist (A3) will perform the follow-up speech perception testing.|Prior to the hearing evaluation, participants will be randomly placed in one of three groups. The three groups include those who will receive the current best practices care from an audiologist (ABP), those who will receive the ABP plus an aural rehabilitation program (ABP+AR), and finally, those who will receive only an OTC HA without assistance from an audiologist for providing programming, maintenance or care information (OTC-only). The AR programming will be provided by trained Community Health Advisors (CHAs). Both the ABP and OTC-only groups initially will attend general health information sessions in-place of the AR program. Once the ABP+AR groups have completed their AR sessions, the ABP and the OTC-only groups will attend the AR programming sessions. By using this service-delivery model, it will be possible to analyze the effectiveness of the AR programming, separate from any benefits that might occur simply by meeting with others in a group setting.|t|t|f|t
34054442|NCT04109287|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be scanned, asked to use the NMES device for 30 minutes and scanned again.||||
34158583|NCT04269876|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34158584|NCT02276443|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158585|NCT03304119|||COHORT||PROSPECTIVE|||||||
34158586|NCT01176812|||CASE_ONLY||OTHER|||||||
34158587|NCT03587441|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158588|NCT01359202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158589|NCT02120391|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34158590|NCT01112748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158591|NCT01578122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158592|NCT00470925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158593|NCT04177212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158594|NCT03238625|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34158595|NCT03790917|||COHORT||PROSPECTIVE|||||||
34158596|NCT01574651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158597|NCT00970229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158598|NCT06479941|||COHORT||PROSPECTIVE|||||||
34158599|NCT04747652|||COHORT||PROSPECTIVE|||||||
34158600|NCT04467281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This will be a phase II clinical trial.||||
34158601|NCT01834352|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34158602|NCT00126360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158603|NCT02106520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158604|NCT03878680|||COHORT||PROSPECTIVE|||||||
34158605|NCT00315016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158606|NCT01478308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158607|NCT01612559|||COHORT||PROSPECTIVE|||||||
34158608|NCT02373774|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34158609|NCT01053039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158610|NCT04958174|||COHORT||PROSPECTIVE|||||||
34158611|NCT02355210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158612|NCT02449395|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158613|NCT00174135|||||OTHER|||||||
34158614|NCT02639520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158615|NCT00067795|||||PROSPECTIVE|||||||
34158616|NCT05013203|||COHORT||PROSPECTIVE|||||||
34158617|NCT05465291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34158618|NCT05660317|||COHORT||PROSPECTIVE|||||||
34158619|NCT06245668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Sealed opaque envelopes containing study participation numbers will be used to assign each patient. A researcher not involved in patient follow-up will use the web-based Research Randomizer ('Urbaniak and Plous 2013') tool to give each participation number to a random group with a 1:1 ratio.~A nurse not an active investigator in the study will have each participant choose an envelope containing the study participation number. They will inform the anesthetist who will administer the methods which group the patient is in immediately before administration. Researchers, patients, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program, 'Research Randomizer ('Urbaniak and Plous 2013')'.|t|t|t|t
34158620|NCT05677009|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, unblinded, single-center study examining the safety, efficacy, and tolerability of BUFEO device compared to standard of care in hospitalized, oxygen-dependent subjects. In this single-visit study, each visit is expected to be approximately 120 minutes. The total study duration to complete 20 subjects (10 males and 10 females) is expected to be 4 weeks.||||
34158621|NCT02652260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158622|NCT03368846|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158623|NCT03402022|||COHORT||RETROSPECTIVE|||||||
34158624|NCT03117478|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34158625|NCT00774800||CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34158626|NCT03430232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||For part I: crossover model For part II: parallel model|t|t|t|t
34158627|NCT00174369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158628|NCT05307042|||COHORT||PROSPECTIVE|||||||
34158629|NCT01447953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158630|NCT03151330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Women who are found to have an elevated risk of preterm birth will receive counseling regarding potential interventions and compared to historical controls||||
33741897|NCT02810535|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33741898|NCT04133844|||COHORT||PROSPECTIVE|||||||
33741899|NCT05699863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study has three three groups, including obese (BMI 30,0 - 39,9 kg/m2) individuals (obese group) and lean (BMI 18,5 - 24,9 kg/m2) age and sex-matched control individuals (control group).~Based on initial enrolment into the obese group, individuals with NAFLD (\>5% hepatic steatosis) and metabolic syndrome (according to International Diabetes Foundation (IDF) consensus) will undergo a 4-5 month lifestyle intervention (intervention group)."||||
33741900|NCT04995380|||COHORT||PROSPECTIVE|||||||
33741901|NCT06050460|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The study will be blinded for all placebo controlled dose groups, ie, the principal investigator (PI), all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.||t|f|t|f
33741902|NCT04968548|||CASE_CONTROL||PROSPECTIVE|||||||
33741903|NCT01971398|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34054443|NCT03655912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the patient or the care provider will be aware of the treatment modality group the patient is in. In order to achieve that, patients in different modality groups will be evaluated in different days preventing information of group modality gossip between the patients parents.||t|t|f|f
34054444|NCT03852628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To minimize bias, a placebo drug is employed as the comparison group to active study drug and the study is conducted in a double-masked fashion in that both the participants and the Independent Assessors who are assessing study outcomes are masked to treatment assignment. The only individuals at the site with access to treatment assignment information are the research pharmacists.|proof-of-concept study|t|f|t|t
34054445|NCT02689869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054446|NCT05229523|||CASE_ONLY||PROSPECTIVE|||||||
34054447|NCT05394792|||COHORT||PROSPECTIVE|||||||
34054448|NCT01038401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054449|NCT05075824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054450|NCT00576160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34054451|NCT03189667|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized clinical trial||||
34054452|NCT01604863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054453|NCT02222311|||CASE_CONTROL||PROSPECTIVE|||||||
34054454|NCT06665828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054455|NCT01053962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054456|NCT04112602|||CASE_CONTROL||PROSPECTIVE|||||||
34054457|NCT02735525|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158631|NCT06525896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158632|NCT02965430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158633|NCT01603485|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158634|NCT03494582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158635|NCT05297188|||CASE_CONTROL||PROSPECTIVE|||||||
34054458|NCT03592537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care provider, Investigator, Outcomes Assessor) The trial will be planned that neither the doctors nor the patients will be aware of the group allocations. The study drugs will be prepared by an anesthesiologist not involved in performing the aneshesia, patient care or in data collection.|comparison of the effect of intrathecal fentanyl with the effect of intrathecal midazolam as postoperative analgesia in children undergoing infraumbilical surgery|t|t|t|t
34054459|NCT01351480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158636|NCT00915707|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34158637|NCT03662594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34158638|NCT03878784|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34054460|NCT03421314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple||t|t|t|f
34054461|NCT03075891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34054462|NCT05253716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054463|NCT02991729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054464|NCT05016141|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||comparative prospective longitudinal (12-months) observational cohort study||||
34054465|NCT05981703|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34054466|NCT06271668|||COHORT||PROSPECTIVE|||||||
34054467|NCT04787471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054468|NCT05010512|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34158639|NCT00612560|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34158640|NCT04299841|||OTHER||PROSPECTIVE|||||||
34158641|NCT06010511|||CASE_ONLY||PROSPECTIVE|||||||
34158642|NCT06351059|||COHORT||CROSS_SECTIONAL|||||||
34158643|NCT04256681|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158644|NCT01085877|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158645|NCT03860805|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158646|NCT00328458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158647|NCT00896025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label-comparator is historical data.||||
34158648|NCT05569642|||COHORT||CROSS_SECTIONAL|||||||
34158649|NCT05942443|RANDOMIZED|PARALLEL||TREATMENT||NONE|Splints are fabricated by the orthotist and outcome assessments are performed by a physiotherapist.|Patients were randomly assigned in a 1:1 ratio to either the MCP-blocking orthosis group or the RME orthosis group, using a simple random sampling method.||||
34158650|NCT02813161|||CASE_ONLY||PROSPECTIVE|||||||
34158651|NCT00475904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158652|NCT05015270|||CASE_CONTROL||RETROSPECTIVE|||||||
33741904|NCT04455100|NA|SINGLE_GROUP||OTHER||NONE||||||
33741905|NCT04391231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be a double-blinded randomized placebo-controlled study.|This study will be a double-blinded randomized placebo-controlled study to determine the efficacy of Pentoxifylline in reducing RBC hemolysis caused by Impella support.|t|t|t|t
33741906|NCT05193994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Participants will be randomised in a 2:1 ratio to receive either triumeq or placebo|t|f|t|f
33741907|NCT04497701|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741908|NCT04602520|||COHORT||PROSPECTIVE|||||||
33741909|NCT00222768|||||PROSPECTIVE|||||||
33741910|NCT04157829|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33950705|NCT03312504|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants (teachers and students) are not aware of what arm they are randomized to; however, they are aware that there are two arms. The primary investigators performing the analysis and overseeing all decisions are blinded to the schools receiving the intervention vs control program.|Randomized controlled trial. Upon enrolment into the study, a school will be randomly assigned to the intervention (neuromuscular training warm-up) or control group (standard-of-practice warm-up). Schools that have been randomized to the control arm will be invited to participate in the study in the following year as an intervention school. Schools that have been randomized to the intervention arm will be invited to participate in the study in the following year as a maintenance school (will continue with the intervention).|t|f|t|f
33741911|NCT06052969|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, single-arm early feasibility study.||||
33950706|NCT01796769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950707|NCT01615965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950708|NCT02151552|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33950709|NCT05957159|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All subjects will be asked to complete both PKAB and CFN PET Imaging scans, AUD subset will participate in a detoxification program||||
33950710|NCT01564680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950711|NCT00665028|||COHORT||PROSPECTIVE|||||||
33950712|NCT03696420|||CASE_ONLY||PROSPECTIVE|||||||
33950713|NCT04334356|NA|SINGLE_GROUP||PREVENTION||NONE||In this pilot study, all participants will receive the active web app intervention.||||
33950714|NCT01825421|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950715|NCT04361669|||CASE_CONTROL||PROSPECTIVE|||||||
33950716|NCT01711424|||COHORT||PROSPECTIVE|||||||
33950717|NCT04261153|NA|SINGLE_GROUP||OTHER||NONE||||||
33950718|NCT00461591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950719|NCT03082079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950720|NCT02039882|||CASE_CONTROL||PROSPECTIVE|||||||
33950721|NCT03991520|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33950722|NCT04852185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participant- and observer-blinded, cluster-randomised controlled Phase IV trial|t|t|t|t
33950723|NCT01065246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950724|NCT03208621|||COHORT||PROSPECTIVE|||||||
33950725|NCT02302118|||COHORT||RETROSPECTIVE|||||||
33950726|NCT05853081|||COHORT||PROSPECTIVE|||||||
33741912|NCT03738865|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33741913|NCT05239806|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33950727|NCT05319509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950728|NCT01731821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054469|NCT05943288|||CASE_CONTROL||PROSPECTIVE|||||||
34054470|NCT06032052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054471|NCT01542723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054472|NCT01491204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054473|NCT00003779|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34054474|NCT00539149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34054475|NCT03731559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054476|NCT02184585|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34054477|NCT00800657|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34054478|NCT00648622|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34054479|NCT02190032|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34054480|NCT04510246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Given the nature of the intervention, it is impossible to blind either the health care worker or the general practitioner to allocation. However, the analysis will be conducted by an analyst at the Burnet Institute who will not have contact with the general practitioners and will be blinded to intervention allocation.|This study will be a two-armed cluster randomised controlled trial with randomisation at the level of the general practitioner.|t|f|t|f
34054481|NCT01645878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054482|NCT06342999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054483|NCT00137007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054484|NCT05930795|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34054485|NCT06231693|||CASE_ONLY||OTHER|||||||
34054486|NCT01275755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054487|NCT01524939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054488|NCT06344026|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, dose escalation of bilateral injection of ANPD001 dopaminergic precursor cells to the putamen||||
34158653|NCT03161080|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34158654|NCT01181869|||CASE_ONLY||PROSPECTIVE|||||||
34158655|NCT01609881|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34158656|NCT04480658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158657|NCT05678257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158658|NCT02503150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158659|NCT04543292|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158660|NCT01911117|||CASE_ONLY||PROSPECTIVE|||||||
34158661|NCT04152408|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34158662|NCT01061502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34158663|NCT03323177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158664|NCT00256802|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34158665|NCT00609570|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34158666|NCT06244680|||COHORT||PROSPECTIVE|||||||
34158667|NCT05545683|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158668|NCT00390039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158669|NCT02133092|||CASE_ONLY||PROSPECTIVE|||||||
34158670|NCT02992392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158671|NCT00079573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34158672|NCT03179397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Enrolled subjects will not be told which IOL they have received until the end of the study||t|f|f|f
34158673|NCT01110031|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34158674|NCT03662516|RANDOMIZED|CROSSOVER||OTHER||NONE||"Natural log transformed AUCinf, AUClast, and Cmax of EE and LN will be analyzed separately using a mixed effect model with sequence, period and treatment as fixed effects and subject within sequence as a random effect. Estimates of the adjusted mean differences (Test Reference) and corresponding 90% CIs will be obtained from the model. The adjusted mean differences and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios. OC (EE and LN) alone will be the Reference treatment, while the OC (EE and LN) coadministered with PF 04965842 will be the Test treatment.~The absent of an effect of PF 04965842 on OC (EE and LN) will be concluded if the lower bound of 90% confidence interval for the ratio of adjusted geometric mean for AUCinf is ≥80%."||||
34158675|NCT01732770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158676|NCT05246709|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized control study||||
34158677|NCT03928717|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34158678|NCT05047952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158679|NCT05852236|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE|Non-Randomized|||||
34158680|NCT06464445|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Repeated Measure Design||||
34158681|NCT00829114|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158682|NCT00364091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158683|NCT00160836|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34158684|NCT04987580|||COHORT||PROSPECTIVE|||||||
34158685|NCT03836911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34158686|NCT00847886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158687|NCT00583037|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34158688|NCT03190889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects are masked from group assignment. Group assignment is randomized.|Overall Strategy. This is a prospective, randomized, repeated measures single- blind clinical trial. The purposes of this study are to 1) stratify patient risk for second ACL injury, and 2) determine the effects of differential treatment intervention, including targeted neuromuscular training (TNMT), home program only (HOME) and standard clinical (STAN) training, on clinical, biomechanical, and neuromuscular performance measures associated with an increased ACL injury risk. After the initial ACL injury and study enrollment, all patients will participate in standardized pre-operative rehabilitation. They will then undergo surgery by a fellowship-trained sports medicine surgeon at Mayo Clinic, Rochester, MN. Data for Aim 1 will be obtained from biomechanical, neuromuscular and clinical testing performed during Pre-Testing. Data for Aim 2 and the Exploratory Aim will be obtained from biomechanical and clinical test results obtained from Pre- and Post-Testing time points.|t|f|f|f
34158689|NCT03276546|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158690|NCT01760343|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34158691|NCT04503720|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34158692|NCT01925547|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33950729|NCT03721614|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Active Control Device :- Xience family Everolimus Coronary Stent Systems||||
33950730|NCT05289921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158693|NCT03971448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blinding is not feasible since the patient and families will know which immobilization method was applied. Therefore, the individual performing the outcome assessments will be a different person from the research team and will be masked to treatment allocation. The families will be instructed not to reveal the allocation to the research team member in order to minimize the chances of unblinding during follow-up encounters. In spite of the latter, there is potential for accidental unblinding. The frequency of this will be documented and reported.|Enrolled children will be randomly assigned to either a fiberglass above-knee walking cast (AKWC) or the Landmark Pediatric Walker Boot (LPWB).|f|f|f|t
34158694|NCT05587192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158695|NCT00349778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158696|NCT05159115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158697|NCT05451563|NA|SINGLE_GROUP||OTHER||NONE||||||
34158698|NCT03749811|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|"Participant does not know in which of the groups he/she is allocated. Only a care provider (an attending anesthesiologist who is responsible for the patient's anesthesia) knows the group which the patient belongs to.~Investigator and outcomes assessor does not know in which of the groups the patient is allocated, since the group name will be just recorded as A or B until data analysis of the last participant is done."|Interventional group: remifentanil infusion under pupillometry monitoring. Control group: remifentanil infusion without pupillometry monitoring (remifentanil dose is determined by conventional method, i. e., hemodynamic change probably related to noxious stimuli)|t|f|t|t
34158699|NCT00264771|||||PROSPECTIVE|||||||
34158700|NCT01145339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158701|NCT02893696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158702|NCT06572124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34158703|NCT03520907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34158704|NCT01924494|||COHORT||PROSPECTIVE|||||||
34158705|NCT03511157|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34158706|NCT03559647|||COHORT||PROSPECTIVE|||||||
34158707|NCT05441852|||COHORT||PROSPECTIVE|||||||
33741914|NCT01083030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950731|NCT01958619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950732|NCT01367626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950733|NCT03019666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950734|NCT03539419|||COHORT||PROSPECTIVE|||||||
33950735|NCT01519635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950736|NCT04231799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The person who will bathe the baby will not know the postnatal age of the baby. he will not know at what time of birth the baby's first bath is applied.~The two assessors who will measure the results will not know the postnatal age of the baby and in which group."|Randomized controlled multicenter double blind trial|f|t|f|t
33950737|NCT02780180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950738|NCT05347173|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Intrathecal injectate will be prepared according to the group by an anesthesiologist who is not involved in data collection|"Via the sealed envelope method; the patients will be randomly assigned to three equal groups according to the administration of adjuvant to intrathecal Bupivacaine and its dose;~* Bupivacaine group (B gp) will include patients who will receive 2.5 ml hyperbaric bupivacaine (0.5%) +0.5 ml normal saline.~* Bupivacaine-Dexmedetomidine group (BDgp) will include patients who will receive 2.5 ml hyperbaric bupivacaine (0.5%) plus Dexmedetomidine (10 µg in 0.5 ml normal saline).~* Bupivacaine-Nalbuphine group (BN gp) will include patients who will receive 2.5 ml hyperbaric bupivacaine (0.5%) plus Nalbuphine (1 mg in 0.5ml normal saline)."|t|f|t|f
33950739|NCT04060901|RANDOMIZED|PARALLEL||PREVENTION||NONE||CRC teams will be randomized to one of two cohorts; the first cohort will receive the intervention during the first period while the second cohort waits to receive the intervention during the second period.||||
33950740|NCT03637101|||COHORT||PROSPECTIVE|||||||
33950741|NCT00137306|RANDOMIZED|PARALLEL||||NONE||||||
33950742|NCT05401552|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||cross-over design||||
33950743|NCT03965754|||CASE_CONTROL||PROSPECTIVE|||||||
33950744|NCT01927159|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33950745|NCT02937727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950746|NCT01144572|||COHORT||PROSPECTIVE|||||||
33950747|NCT01103375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950748|NCT05423639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial (RCT).|t|f|f|t
33950749|NCT02492152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950750|NCT04494191|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33950751|NCT01588899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950752|NCT03957343|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33950753|NCT06257849|||COHORT||PROSPECTIVE|||||||
33950754|NCT02052206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950755|NCT03511391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950756|NCT01535209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950757|NCT02402608|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33950758|NCT00330772|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33950759|NCT03106701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950760|NCT05097261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33741915|NCT06162247|||COHORT||PROSPECTIVE|||||||
33741916|NCT03937167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33741917|NCT01415505|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33741918|NCT04287920|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950761|NCT05957939|NA|SINGLE_GROUP||TREATMENT||NONE||a case study||||
33950762|NCT04868838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158708|NCT02192177|||CASE_CONTROL||PROSPECTIVE|||||||
34158709|NCT00293995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158710|NCT06026878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158711|NCT00651638|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34158712|NCT02413489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158713|NCT06583278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158714|NCT02663622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Study was double blind for the first 6 participants in each arm. At that point, the recommended phase II dose (RP2D) was determined, and the selected arm enrolled additional participants in an open label fashion.|t|t|t|t
33846047|NCT03764527|RANDOMIZED|PARALLEL||TREATMENT||NONE|The AQ+AS (AA) group received their drugs under direct observation once daily for 3 days. The Coartem (CO) group received their drugs twice daily, the second (evening) dose also under supervision. Drug treatment was thus not be blinded.|A comparative randomised study comparing oral treatment with AQ + AS and CO of uncomplicated falciparum malaria in children.||||
33846048|NCT05786703|||OTHER||PROSPECTIVE|||||||
33846049|NCT01127152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158715|NCT01385241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34158716|NCT06040164|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158717|NCT00044473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158718|NCT06361017|||COHORT||PROSPECTIVE|||||||
34158719|NCT00407303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158720|NCT03203083|||COHORT||CROSS_SECTIONAL|||||||
34158721|NCT01773187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158722|NCT00342992|||COHORT||PROSPECTIVE|||||||
34158723|NCT00465335|||||PROSPECTIVE|||||||
34158724|NCT01357551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158725|NCT04489082|NA|SINGLE_GROUP||TREATMENT||NONE||The present study is being undertaken as an open-label study to evaluate the safety and feasibility of near infrared therapy as an intervention for patients with refractory depression, anxiety, cognitive impairment due to a neurodegenerative disease (e.g., Alzheimer's), and traumatic brain injury.||||
34158726|NCT03475589|NA|SINGLE_GROUP||OTHER||NONE||||||
34158727|NCT05235542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158728|NCT01957813|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34158729|NCT00958165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158730|NCT02945813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846050|NCT05882409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846051|NCT01445587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950763|NCT02430168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950764|NCT04066842|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950765|NCT06214429|||COHORT||PROSPECTIVE|||||||
33950766|NCT02687815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950767|NCT01680757|NA|SINGLE_GROUP||||NONE||||||
33950768|NCT06509217|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33950769|NCT05327517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950770|NCT02316574|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33950771|NCT00564382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950772|NCT01778296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950773|NCT03998696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950774|NCT01005186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950775|NCT06322004|||OTHER||PROSPECTIVE|||||||
33950776|NCT04612465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950777|NCT02392377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950778|NCT04903938|||COHORT||CROSS_SECTIONAL|||||||
33950779|NCT03619512|||COHORT||RETROSPECTIVE|||||||
33950780|NCT04386798|NA|SINGLE_GROUP||OTHER||NONE||||||
33950781|NCT00655226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158731|NCT06584318|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158732|NCT04343755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158733|NCT02716623|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158734|NCT04441255|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34158735|NCT01379196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158736|NCT01154426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158737|NCT06426836|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158738|NCT05865717|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34158739|NCT05533424|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34158740|NCT00868127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158741|NCT03361982|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34158742|NCT03867357|||COHORT||PROSPECTIVE|||||||
34158743|NCT03079596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158744|NCT00544336|||COHORT||PROSPECTIVE|||||||
34158745|NCT04578067|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster intervenrion trial||||
34158746|NCT06451081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158747|NCT05460143|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158748|NCT06259539|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34158749|NCT05244083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158750|NCT00248586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158751|NCT03944408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158752|NCT03842449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158753|NCT06186258|||COHORT||RETROSPECTIVE|||||||
34158754|NCT01448499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950782|NCT00152659|||OTHER||RETROSPECTIVE|||||||
33950783|NCT01608048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158755|NCT00882960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158756|NCT01986608|RANDOMIZED|CROSSOVER||||NONE||||||
34158757|NCT03850535|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158758|NCT02248623|||COHORT||PROSPECTIVE|||||||
34158759|NCT01152034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950784|NCT01970423|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33950785|NCT04535518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and physicians will not be masked to the assignment. Pediatric cardiologists who assess coronary artery lesions (CAL) by echocardiography will be masked to the allocation.||f|f|f|t
33950786|NCT04946669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950787|NCT02066909|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33950788|NCT06333431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Parallel Assignment experimental model using randomized pretest and posttest with control group|t|f|t|f
33950789|NCT01102166||CROSSOVER||TREATMENT||NONE||||||
33950790|NCT04329156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950791|NCT02092207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33950792|NCT02379442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950793|NCT00283621|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33950794|NCT01656109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054489|NCT04183153|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34054490|NCT06368830|||COHORT||PROSPECTIVE|||||||
34054491|NCT01871181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34054492|NCT06517888|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34054493|NCT04068129|||COHORT||PROSPECTIVE|||||||
34158760|NCT04345315|||COHORT||OTHER|||||||
34158761|NCT01511913|||COHORT||PROSPECTIVE|||||||
34158762|NCT03658824|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to blind the assessor to phase or baseline duration of participants in the case-series, as the length of time between assessments will reveal this. Nevertheless, the assessor and clients will be asked not to disclose which therapist is treating them. Use of self-report measures as the primary outcome measure is intended to minimise potential biases on the side of the researcher.|This is a case series using a multiple baseline design whereby participants are randomly allocated to one of 6 durations of wait at baseline before commencing treatment.||||
34158763|NCT05741112|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will have a diagnosis of Long COVID-19, Chronic Fatigue Syndrome or Postural Orthostatic Tachycardia Syndrome.||||
34158764|NCT01041820|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158765|NCT05727657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158766|NCT01600989|||COHORT||PROSPECTIVE|||||||
34158767|NCT04401241|||OTHER||RETROSPECTIVE|||||||
34158768|NCT01500486|||COHORT||PROSPECTIVE|||||||
34158769|NCT06061835|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158770|NCT01180296|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158771|NCT03945968|||COHORT||PROSPECTIVE|||||||
34158772|NCT04093440|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158773|NCT00765063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158774|NCT00002201||||TREATMENT||NONE||||||
34158775|NCT03809494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator for this study is the person that will be performing the injections throughout the study and will know the participant's treatment (TNC or saline). The investigator that is aware of the participant's treatment will not be performing the follow-up visits.||t|t|f|t
34158776|NCT00153465|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34158777|NCT04238507|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||DOUBLE|In the OR, the investigator will open an opaque numbered envelope with the randomization order for the performance of BMV.|: The proposed experiment is a repeated-measures unblinded randomized controlled trial (RCT), with randomization of the order of use, comparing BMV using a Guedel air or the UA device on the same participant.|t|f|t|f
34158778|NCT05712954|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A randomized controlled trial model with pretest-posttest control group|t|t|t|t
34158779|NCT02775916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158780|NCT05403671|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34158781|NCT06100913|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34158782|NCT06437977|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel||||
34158783|NCT00285402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158784|NCT00117260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158785|NCT04427020|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Protein and probiotics were delivered separately. Upon arrival a faculty member (who was not an investigator) blinded both the protein and probiotic samples and kept the code sealed in an envelope until all statistical analysis was complete. Once all data collection, data entry, and statistical analysis was completely finished, the study code was broken.||t|f|t|f
34158786|NCT01600833|||COHORT||RETROSPECTIVE|||||||
34158787|NCT04098861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A single-center, randomized open-labeled, prospective, crossover study.||||
34158788|NCT05992350|||OTHER||PROSPECTIVE|||||||
34158789|NCT01958983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158790|NCT03274063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laboratory staff measuring biochemical traits will be blind to treatment allocation.|Participants will be randomised in a ratio of 2:1 to either supported self management or usual care.|f|f|f|t
34158791|NCT02076035|||COHORT||PROSPECTIVE|||||||
34158792|NCT06438666|NA|SINGLE_GROUP||TREATMENT||NONE||20 participants between 14-18 years old will receive 4 sessions of anodic transcranial direct current stimulation. The results will be measured before and after the 4 sessions.||||
34158793|NCT02681289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054494|NCT05800197|||COHORT||RETROSPECTIVE|||||||
34054495|NCT04170348|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Masking will be performed by the Research Pharmacy; all other research staff and participants will be blinded to allocation.|Controlled, double-masked, randomized Phase 2 clinical trial|t|t|t|t
34054496|NCT06544707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054497|NCT01790828|||||PROSPECTIVE|||||||
33741919|NCT02185352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741920|NCT03934385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33741921|NCT05854147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33741922|NCT00922428|||COHORT||PROSPECTIVE|||||||
33741923|NCT02377986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741924|NCT03288376|||CASE_ONLY||PROSPECTIVE|||||||
33741925|NCT03129334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054498|NCT02348346|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33741926|NCT06532266|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33741927|NCT00507793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741928|NCT04465994|||CASE_CONTROL||RETROSPECTIVE|||||||
33741929|NCT02001727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741930|NCT00003801||||SUPPORTIVE_CARE||||||||
33741931|NCT06573346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846052|NCT04410601|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|THE STUDY IS OPEN TO ALL SURGICAL CLINICS OVER THE WORLD EAGER TO JOIN; EXCEL WITH FORMS TO BE FILLED ARE AVAILABLE, please contact the principle/co-investigators by phone/e-mail.|Dysphagia among patients who have undergone total hyroidectomy for benign/malign thyroid disease. The preoperative factors (demographics; co-morbidities such as diabetes, multiple sclerosis, Parkinson's; body mass index; routine ear-nose-throat-ENT consultation), operative factors (over-manipulation, injury to larynx/neural plexus, easy/hard tracheal intubation, closure of strap muscles/stay open) and postoperative evaluation 1-No dysphagia, 2-Dysphagia with at least one other complication (nerve injury, hypocalcemia), 3-Dysphagia without any other surgical complications; ENT\&neurology consultations, survey.||||
34054499|NCT02394340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054500|NCT04865601|||CASE_CONTROL||RETROSPECTIVE|||||||
34158794|NCT05643339|||COHORT||PROSPECTIVE|||||||
34054501|NCT05113888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study was divided into three groups: Qizhi Weitong granule high-dose group, Qizhi Weitong granule low-dose group and placebo group|t|f|t|f
34054502|NCT04912440|||COHORT||RETROSPECTIVE|||||||
34054503|NCT05416515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054504|NCT06491394|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34054505|NCT06618625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33846053|NCT01170390|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34054506|NCT04959097|||COHORT||PROSPECTIVE|||||||
34158795|NCT06154356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized controlled study|f|f|f|t
33846054|NCT01153321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33846055|NCT00225017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741932|NCT03659552|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single group assignment||||
33741933|NCT01153594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741934|NCT02929810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741935|NCT03000894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33741936|NCT04273958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study will be a randomized controlled study. In order to minimize bias, one investigator will randomize the patient to one of the two groups, set up the medium to which the patient is assigned, and be present during the procedure. Patients will evaluate their pain and anxiety levels themselves using an electronic tablet, without the help of the investigator.|Each patient will be randomized in a 1:1 ratio between the two arms of the study|f|f|t|f
33741937|NCT03614689|||COHORT||PROSPECTIVE|||||||
33741938|NCT02853409|||CASE_CONTROL||PROSPECTIVE|||||||
33846056|NCT02665338|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33846057|NCT00902928|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846058|NCT02880787|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846059|NCT04143945|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33846060|NCT01282502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846061|NCT02880410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846062|NCT04293692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33846063|NCT01886859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846064|NCT05404724|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||itraconazole and SHR0302 tablets are used in combination||||
33846065|NCT01422551|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33846066|NCT01195948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846067|NCT02992600|||COHORT||PROSPECTIVE|||||||
33846068|NCT03245151|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846069|NCT02712710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846070|NCT04837651|||COHORT||PROSPECTIVE|||||||
33846071|NCT00864253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741939|NCT05184413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator at each center responsible for conducting the study evaluations will be blinded to group assignment. A second investigator will be responsible for generating randomization, sequencing, enrolling participants, and assigning participants to treatment. Patients will be blinded to the assigned group||f|f|f|t
33741940|NCT05507411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741941|NCT04093934|RANDOMIZED|PARALLEL||TREATMENT||NONE||'stepped wedge design'||||
33741942|NCT02747940|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33741943|NCT01658683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33846072|NCT02374177|||||RETROSPECTIVE|||||||
33846073|NCT03282825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846074|NCT04954729|||CASE_CONTROL||PROSPECTIVE|||||||
34054507|NCT04804748|||COHORT||PROSPECTIVE|||||||
34076499|NCT04378569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"There are 2 cohorts of subjects.~* Cohort 1 (Phase 1) is a multiple dose cohort in which subjects with chronic hand eczema will be assigned to ARQ-252 cream 0.3% QD x 2 weeks to be applied to both hands (approximately 4% of BSA).~* Cohort 2 (Phase 2b) is a parallel group, double blind, vehicle-controlled cohort in which subjects with chronic hand eczema will be randomized to ARQ-252 cream 0.3% QD, ARQ-252 cream 0.3% BID, ARQ-252 cream 0.1% QD, vehicle cream BID or vehicle cream QD x 12 weeks to be applied to both hands (approximately 4% of BSA)."|t|t|t|f
33741944|NCT01870843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741945|NCT05972447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054508|NCT04907669|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After recruitment and the baseline survey, we will assign participants into Group 1 and Group 2 by block randomization in R program. At the check point in the SMART trial, we will re-assign participants into Group 1a, Group 1b, Group 1c, Group 2a, Group 2b, and Group 2c based on their suicide risk by simple randomization in R program. The allocation ratio in randomization will be 1:1. The randomization will be performed by a statistician in the research team. Patients, LHSs, nurses who perform recruitment and baseline survey, the statistician who performs randomization, and investigators who perform follow-ups will be blinded to the assignment.|After recruitment and baseline survey, participants will be randomized into two groups Group 1 and Group 2 where BCIs will be implemented monthly and weekly. Participants' suicide risk will be evaluated at three months after discharge. At the check point, for participants in Group 1, if the suicide risk increased, they will be re-randomized into Group 1a and Group 1b where BCIs will be implemented weekly and bi-weekly; otherwise, they will remain receiving BCIs monthly as Group 1c. For participants in Group 2, if the suicide risk increased or did not change, they will remain receiving BCIs weekly as Group 2a; otherwise, they will be re-randomized into Group 2b and Group 2c where BCIs will be implemented monthly and bi-weekly.|t|f|t|f
34054509|NCT05566834|NA|SINGLE_GROUP||TREATMENT||NONE||Minnelide™ is a water soluble disodium salt variant of triptolide, a diterpenoid, an HSP70 inhibitor. Studies using orthotopic pancreatic cancer cell lines and human xenograft transplants demonstrate that Minnelide™ prevents tumor progression, increases survival, and causes tumor regression.||||
34054510|NCT04973631|||COHORT||RETROSPECTIVE|||||||
34054511|NCT05697237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054512|NCT02774122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158796|NCT06574516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinding of investigators and outcome assessor was possible however no blinding of the participant||f|t|t|t
34158797|NCT03680183|||CASE_CONTROL||PROSPECTIVE|||||||
34158798|NCT01939327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158799|NCT06115590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||8-day parallel-group design with decentralized data collection||||
34158800|NCT01847040|||COHORT||PROSPECTIVE|||||||
34158801|NCT02621294|NA|SINGLE_GROUP||||NONE||||||
34158802|NCT00258817|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158803|NCT00787189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158804|NCT02881762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158805|NCT02162602|||COHORT||PROSPECTIVE|||||||
34054513|NCT02511314|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34158806|NCT00485992|||||RETROSPECTIVE|||||||
34158807|NCT05623241|||COHORT||PROSPECTIVE|||||||
34158808|NCT01545115|||COHORT||PROSPECTIVE|||||||
34158809|NCT01435629|||OTHER||RETROSPECTIVE|||||||
34158810|NCT00850538|||COHORT||PROSPECTIVE|||||||
34054514|NCT05675527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34158811|NCT02234804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158812|NCT03061929|||COHORT||PROSPECTIVE|||||||
34158813|NCT04616222|||COHORT||RETROSPECTIVE|||||||
34158814|NCT00028236||||TREATMENT||||||||
34158815|NCT04996485|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34158816|NCT05897892|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Treatment group consumed mangrove sword bean food bar during 15 days. Control group consumed sword bean food bar during 15 days.|Treatment group consumed mangrove sword bean food bar during 15 days. Control group consumed sword bean food bar during 15 days. Balanced nutrition education undertaken to all subjects at two groups once at the first week of study.|t|f|f|f
34158817|NCT00406679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158818|NCT05325021|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158819|NCT06470503|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34054515|NCT05789589|NA|SEQUENTIAL||TREATMENT||NONE||||||
34158820|NCT00543387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158821|NCT01406197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054516|NCT00858312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34054517|NCT00688935|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34054518|NCT05887843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054519|NCT01369108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054520|NCT04409457|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Two participant groups (one with and one without bulimia nervosa) will be scanned using MRI after they have fasted and after they have consumed a standardized meal. The order of these two scans will be counterbalanced across groups.|f|f|f|t
34158822|NCT02406170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076500|NCT00687986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076501|NCT06421701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076502|NCT06236321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158823|NCT01882530|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34158824|NCT01904045|||OTHER||PROSPECTIVE|||||||
34158825|NCT03120715|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34158826|NCT01378767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158827|NCT05591391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158828|NCT04784819|||CASE_ONLY||PROSPECTIVE|||||||
34158829|NCT06449495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158830|NCT02748070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158831|NCT01569100|||COHORT||PROSPECTIVE|||||||
34158832|NCT00538070|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34158833|NCT02391181|RANDOMIZED|CROSSOVER||||NONE||||||
33741946|NCT01219738|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33741947|NCT04278326|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741948|NCT06534307|||COHORT||PROSPECTIVE|||||||
33741949|NCT02010385|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33741950|NCT01242488|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33741951|NCT04402645|||COHORT||PROSPECTIVE|||||||
33741952|NCT05273892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33741953|NCT04497441|||OTHER||PROSPECTIVE|||||||
34158834|NCT05173727|||OTHER||CROSS_SECTIONAL|||||||
34158835|NCT04102995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158836|NCT01847989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741954|NCT05739058|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||This four-week prospective clinical investigation will assess the safety and feasibility of a medical device emitting LED violet-blue light. Violet-blue light treatment is tested on a total of twenty-two patients with chronic wounds, divided into three groups, each group only receiving one dosage. Three dosages (low, medium and high) of violet-blue light treatment is tested. ID 1-7 are assigned to the low group, ID 8-15 are assigned to medium group and ID 16-22 are assigned to the high dosage group.||||
34158837|NCT04764227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158838|NCT01665391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158839|NCT00770601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158840|NCT02559128|||OTHER||CROSS_SECTIONAL|||||||
34158841|NCT03046576|||COHORT||OTHER|||||||
34158842|NCT02146391||CROSSOVER||TREATMENT||NONE||||||
34158843|NCT03731091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34158844|NCT00154479|||DEFINED_POPULATION||PROSPECTIVE|||||||
34158845|NCT03543137|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158846|NCT01472068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741955|NCT00881725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741956|NCT02709967|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33741957|NCT01952340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33741958|NCT02175446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33741959|NCT03677518|||CASE_ONLY||RETROSPECTIVE|||||||
33741960|NCT05605470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33741961|NCT04640051|||COHORT||PROSPECTIVE|||||||
33741962|NCT01366833|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33741963|NCT02094989|||||PROSPECTIVE|||||||
33741964|NCT02054962|||COHORT||PROSPECTIVE|||||||
33741965|NCT02879838|||COHORT||PROSPECTIVE|||||||
33741966|NCT04680377|||COHORT||PROSPECTIVE|||||||
33741967|NCT01231711|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33741968|NCT00987298|||COHORT||CROSS_SECTIONAL|||||||
33741969|NCT04836260|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||open-label non-controlled, non-randomised interventional study||||
34158847|NCT03047239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33741970|NCT00768001|||COHORT||PROSPECTIVE|||||||
34158848|NCT01420354|||CASE_ONLY||CROSS_SECTIONAL|||||||
34158849|NCT05058924|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single Center pilot feasibility RCT||||
34158850|NCT04770402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158851|NCT00662116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158852|NCT06508671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158853|NCT04519346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158854|NCT03157284|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34158855|NCT00720343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158856|NCT04520399|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158857|NCT02293603|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34158858|NCT04294602|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Study||||
34158859|NCT03427723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||accuvein versus standard||||
33741971|NCT05003921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158860|NCT05887050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Supplements were blinded by the sponsor prior to initiation of any research activities. All research activities, including statistical analysis, were completed by the research team while blinded.|All participants were randomly assigned to receive either the active product or a placebo. Subjects were instructed to consume their respective supplement daily for 12 weeks, approximately 15-30 minutes prior to their evening meal.|f|f|t|f
34158861|NCT03187444|NA|SINGLE_GROUP||OTHER||NONE|Open|all participants receive the same intervention throughout the protocol||||
34158862|NCT00453804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158863|NCT03023293|||COHORT||PROSPECTIVE|||||||
34158864|NCT06025981|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||"The model is that of a prospective, longitudinal, multicenter, randomized controlled trial (RCT), open-label and analytical:~* RCT: A rehabilitation intervention with SWalker (experimental group) and a conventional one (control group) will be implemented, following randomization.~* Prospective longitudinal: Study requiring follow-up of patients during the hip fracture rehabilitation period.~* Open multicenter: Inclusion is not limited to any individual who meet the inclusion criteria from Valle de la Oliva-Majadahonda, Ciempozuelos, Mirasierra and Moratalaz nursing homes.~* Analytical: Results are presented in a descriptive way and entering into the analytical statistics of comparison and relationship. analytical comparison and relationship."|t|f|t|f
34158865|NCT03106974|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34158866|NCT01734642|||COHORT||PROSPECTIVE|||||||
33741972|NCT02467777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741973|NCT01055743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741974|NCT00969891|||COHORT||PROSPECTIVE|||||||
33741975|NCT02241226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741976|NCT03779386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741977|NCT01636310|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33741978|NCT01223664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741979|NCT05097339|||OTHER||PROSPECTIVE|||||||
33765091|NCT00628836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765092|NCT00357045|RANDOMIZED|PARALLEL||||DOUBLE||||||
33765093|NCT05626764|||OTHER||OTHER|||||||
33765094|NCT00698386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34158867|NCT06265506|RANDOMIZED|PARALLEL||TREATMENT||NONE||"We will test the efficacy of our CM model against an evidence-based online intervention, CBT4CBT, by randomizing participants to six months of:~1. CBT4CBT and reinforcement for submitting blood samples (no requirement for abstinence) (Control Condition), or~2. CBT4CBT and reinforcement for PEth tests that are consistent with alcohol abstinence (CM Condition)."||||
33765095|NCT00744263|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33765096|NCT03622879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158868|NCT03282513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158869|NCT06555484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Acute effects of oxygen on memory testing in healthy adult volunteers|t|f|f|t
34158870|NCT00374933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054521|NCT03858803|RANDOMIZED|FACTORIAL||PREVENTION||NONE||"Random assignment to one of three experimental arms:~Arm 1: Parents complete intervention immediately, adolescents complete intervention 6 month later Arm 2: Both parents and adolescents participate in intervention simultaneously Arm 3: Comparison condition in which both parents and adolescents are offered their respective interventions after the final assessment"||||
34158871|NCT05900791|||COHORT||CROSS_SECTIONAL|||||||
33741980|NCT02819726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In Part A, patients are randomized in a 1:1:1 ratio to receive one course (baseline and Week 2) of SAIT101 (n=94) versus Rituxan® (n=94) versus MabThera® (n=94).~At Week 24, patients are evaluated for the second course (Week 24 and 26) of the infusion.~In Part B, eligible patients in the SAIT101 arm receive the second course of SAIT101 treatment. Eligible patients in the MabThera® arm receive the second course of MabThera® treatment. Eligible patients in the Rituxan® arm are randomized in a 1:1 ratio to receive SAIT101 or Rituxan® treatment. Patients are followed up for safety until Week 52."|t|t|t|t
33741981|NCT03793101|||CASE_CONTROL||RETROSPECTIVE|||||||
33741982|NCT05969353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33741983|NCT02061631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765097|NCT00517985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765098|NCT01865305|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34054522|NCT03823079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054523|NCT01936181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054524|NCT06514053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054525|NCT06617182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054526|NCT00330330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34054527|NCT04390425|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the subject nor the operating surgeon know the which group the subject is randomized to.|There are two groups for this study. The control group receives standard pneumatic tourniquet pressure and the experimental group receives limb occlusion pressure. It is randomized and double-blinded.|t|f|t|f
34054528|NCT01307137|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054529|NCT06243601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158872|NCT03803384|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The Partcipant and Investigator is blinded to the type of oxygen supply (constant flow or auto-regulated flow).||t|f|t|f
34158873|NCT00230932|||COHORT||CROSS_SECTIONAL|||||||
34158874|NCT04417608|||COHORT||PROSPECTIVE|||||||
34158875|NCT00539305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158876|NCT02091765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158877|NCT05495165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||60 patients entered a 5-day educational device and then followed monthly for 8 months remotely by a smart phone application and dietary consultations.||||
34158878|NCT04543695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158879|NCT02168218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34158880|NCT00729963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158881|NCT02167516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158882|NCT05739461|||OTHER||RETROSPECTIVE|||||||
34158883|NCT00496639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158884|NCT03646474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34158885|NCT04705506|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, prospective, randomized, placebo-controlled trial||||
34158886|NCT00826618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158887|NCT02751476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158888|NCT03996031|||COHORT||PROSPECTIVE|||||||
34158889|NCT03071822|NA|SINGLE_GROUP||TREATMENT||NONE||Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses.||||
34158890|NCT05258019|||CASE_CONTROL||PROSPECTIVE|||||||
34158891|NCT00332228|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34158892|NCT04182672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158893|NCT03205176|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34158894|NCT02777255|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34158895|NCT03795220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is a single blinded study; therefore, the study medication will be blinded for the treating doctors, but not for the patients, the non-treating doctors or the study nurses. Patients will only be seen by a treating doctor at the day of blastocyst transfer and at the day of the pregnancy scan. The participants will not take progesterone the morning of the blastocyst transfer, but immediately after to keep the treating doctors blinded. Patients will be instructed in not disclosing their study group to the treating doctor.|Randomized, controlled multicenter trial with inclusion of 604 mNC-FET cycles. We will include 604 patients divided 1:1 (302:302) in each arm +/- progesterone supplementation and these will further be divided 1:1 in blastocyst warming and transfer +6 and +7 days after hCG injection. Patients randomised to progesterone supplementation will start administering medicine four days after the ovulation trigger up til the day of the pregnancy test. If the pregnancy test is positive, medication will continue for 30 days more.|f|f|t|f
34158896|NCT06496165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34158897|NCT05311267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765099|NCT03735160|||CASE_ONLY||PROSPECTIVE|||||||
33765100|NCT01391923|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33765101|NCT02692911|||COHORT||PROSPECTIVE|||||||
34054530|NCT03699228|||OTHER||PROSPECTIVE|||||||
34054531|NCT04172012|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigational product (probiotic) and placebo product have both been produced by the same manufacturer and is delivered in identical bottles.|Placebo-controlled double-blinded randomized clinical trial|t|t|t|t
34054532|NCT00703794|||OTHER||PROSPECTIVE|||||||
34054533|NCT00694252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054534|NCT03495739|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34054535|NCT06667869|||COHORT||PROSPECTIVE|||||||
34054536|NCT02772874|||CASE_ONLY||CROSS_SECTIONAL|||||||
33765102|NCT03209414|||COHORT||PROSPECTIVE|||||||
34158898|NCT02377648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950795|NCT04555798|RANDOMIZED|PARALLEL||SCREENING||SINGLE||100 patients from those who showed no improvement after 10 days ventilation and still had respiratory failure and in need of high ventilatory parameters (as mentioned before), fulfilled \> 2 parameters on SOFA score as illustrated in table (2), \> 6 on CPIS score as illustrated in table (3) and developed circulatory failure (septic shock) with nor-adrenaline infusion and only on high dose of nor-adrenaline included in our study (\>5microgram/kg/minute intravenous infusion as circulatory support). Since the parameters of those 100 patients selected are considered indication for arteriovenous extracorporeal membranous (A-V ECMO), so patients randomly allocated in two groups 50 patients in each. Randomization sequence was created using Excel 2007 (Microsoft, Redmond, WA, USA) with a 1:1 allocation using random block sizes of 2 and 4 by an independent doctor. In this way, sequence generation and type of randomization can be expressed at the same time|t|f|f|f
34158899|NCT00572208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950796|NCT06375902|||CASE_CONTROL||PROSPECTIVE|||||||
33765103|NCT03729024|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the same treatment; however, each subject will have their eyes randomized to primary or fellow assignment. If only one eye of a patient meets study eligibility, that eye will automatically be designated as the primary eye.||||
33765104|NCT05092230|||CASE_ONLY||RETROSPECTIVE|||||||
34158900|NCT05797636|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The specific session that a participant is in will be known to the experimenter (there is no way for the experimenter not to know since they are administering stimulation). To mitigate the impact on participants, they will be instructed that the brain will be stimulated on two different days, making no reference to possible differential effects across brain regions. The experimental condition will not be explained to the participant until the end of their participation, during debriefing.|The study will involve two sessions of within-subject, sham-controlled continuous theta burst stimulation delivered either at the left dorsolateral prefrontal cortex or angular gyrus.||||
33950797|NCT03462875|||COHORT||CROSS_SECTIONAL|||||||
34158901|NCT00672906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158902|NCT02100969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158903|NCT03967054|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study pharmacist in charge of the drug stock room will originate the masking and maintain the masking from all other investigators. The masking codes will be written on three paper copies and put in identical and sealed opaque envelopes, which will be kept in three different areas.|Parallel-assignment trial with two arms randomized in a 1:1 ratio.|t|t|t|t
34158904|NCT04139356|NA|SINGLE_GROUP||OTHER||NONE||Clinical experimental trial of changes in pulse-oxymetry measurements with deep inspirations||||
34158905|NCT02983864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158906|NCT01755728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158907|NCT02816528|||COHORT||PROSPECTIVE|||||||
34158908|NCT03168178|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Low risk women will be randomized to standard antibiotic treatment versus no antiobiotics.||||
34158909|NCT04370353|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34158910|NCT03421106|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34158911|NCT02489942|||COHORT||PROSPECTIVE|||||||
34158912|NCT04067414||SEQUENTIAL||TREATMENT||NONE||A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV). A 3×3 dose escalation design of BZ019 will be adopted.||||
34158913|NCT06068036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The collection will be performed by a previously trained examiner, blinded to the allocation of groups. All participants will be instructed not to comment on information about the training received. All statistical analyzes will be performed by an independent examiner, blinded to all procedures performed in the study, including with regard to group allocation.||f|f|f|t
34158914|NCT03463785|||COHORT||PROSPECTIVE|||||||
34158915|NCT05112003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158916|NCT00549445|||COHORT||RETROSPECTIVE|||||||
34158917|NCT02139488|||OTHER||PROSPECTIVE|||||||
33950798|NCT04254926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A pragmatic, two-arm parallel-group, waitlist randomized controlled trial (WLRCT) is conducted in which participants are randomized into (i) intervention, or (ii) waitlist control groups. The intervention group (IG) receives the Revie ⊕ intervention early on and the control group (CG) the same intervention but later on (i.e., after eight weeks).|f|f|f|t
33950799|NCT05138458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multi-ascending dose escalation||||
33950800|NCT03590158|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950801|NCT05689164|NA|SINGLE_GROUP||OTHER||NONE||||||
34054537|NCT05129137|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||An open-label, randomized, four-period, four treatments, cross-over trial in healthy volunteers||||
34054538|NCT03247465|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The 20 first included patients will be control group, the 20 following patients will be the fusion group.||||
34158918|NCT01339897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158919|NCT04022252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158920|NCT03813511|||COHORT||PROSPECTIVE|||||||
34158921|NCT05551104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158922|NCT06268964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158923|NCT03727932|NA|SINGLE_GROUP||SCREENING||NONE||||||
34158924|NCT04918511|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A minimum of 3 and up to 6 evaluable patients will be enrolled per dose level. After the first cohort, the doses for the following dose cohorts will be adaptively escalated/de-escalated based on observed dose limiting toxicities in previous cohort.||||
34158925|NCT04180332|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|None were masked|cross sectional study||||
34158926|NCT05310812|||COHORT||PROSPECTIVE|||||||
34158927|NCT01771250|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34054539|NCT05296954|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34158928|NCT04064762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158929|NCT05501834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158930|NCT05407038|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34158931|NCT05719675|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention will focus on three phases: (1) Dispositional alteration, where the aim will be to achieve an awareness of the disease by altering any of the factors that give rise to the performance of behaviors that interfere with adherence to treatment; (2) Alteration of one's own behavior, which would be focused on the development of healthy habits consistent with the indications of the health team for the proper management of the disease; and (3) Alteration of others' behaviors, focused on the development of skills in participants so they can alter the behaviors of significant others by means of health promotion strategies.||||
34158932|NCT03394586|||COHORT||OTHER|||||||
34158933|NCT02170870|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34158934|NCT02189291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34158935|NCT03118089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741984|NCT03806738|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.~Patients randomized to standard of care will receive their standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months until a treatment decision is made."||||
33741985|NCT00648479|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33741986|NCT03663413|||COHORT||PROSPECTIVE|||||||
33741987|NCT06328699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33741988|NCT03041610|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33741989|NCT02744924|NA|SINGLE_GROUP||OTHER||NONE||||||
34054540|NCT02830958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054541|NCT04362540|||COHORT||PROSPECTIVE|||||||
34158936|NCT06231979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158937|NCT04872660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158938|NCT01487889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158939|NCT01517555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34158940|NCT02470481|||CASE_ONLY||PROSPECTIVE|||||||
34158941|NCT00466921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34158942|NCT05423964|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34158943|NCT03601702|||CASE_ONLY||PROSPECTIVE|||||||
34158944|NCT04099784|||OTHER||PROSPECTIVE|||||||
34158945|NCT06272123|||CASE_CONTROL||OTHER|||||||
34158946|NCT02902848|||COHORT||PROSPECTIVE|||||||
34158947|NCT02078128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34158948|NCT06166368|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33741990|NCT04473404|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34158949|NCT04826640|||COHORT||PROSPECTIVE|||||||
34158950|NCT02744196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158951|NCT06312436|||CASE_CONTROL||RETROSPECTIVE|||||||
34158952|NCT03443804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158953|NCT03624595|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158954|NCT00663754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34158955|NCT01593592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34158956|NCT01286025|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34158957|NCT04068116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158958|NCT00856947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34158959|NCT00988949|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34158960|NCT03225703|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will complete a unilateral exercise intervention and be randomly assigned an exercise leg. This allows for internal control, non exercise leg. The exercise and control leg will be analysed for significant differences following completion of the intervention.||||
34158961|NCT05370443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|No one in the control groups will know what the experimental groups will be offered. The the statistician who will perform the primary analyses will be blinded to group allocation.|This study is quantitative in nature and experimental in design. Specifically, this is a parallel cluster-randomized controlled trial. The schools will be the unit of randomisation (clusters). Arabic schools will be randomised in a 1:1 ratio to be either in the intervention (Life Skills educational program) or control group (waiting list). The participants will be asked to fill out the online form of the DASS-21 questionnaires (the screening stage). Then participants with a score of mild to extra-sever on at least one (depression, stress or anxiety) will be included in the life skills intervention study and will fill the second two parts of the questionnaires (GES and Brief Cope Scale).|t|f|f|t
34158962|NCT05630677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158963|NCT02210260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34158964|NCT04714034|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||only one cohort, nested within the SwissPrEPared Study, which is a large, multicentric, nation-wide cohort study that longitudinally follows individuals interested in PrEP over a period of 3 years (see also NCT03893188 on clinicaltrials.gov).||||
34158965|NCT01205971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34158966|NCT01224366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158967|NCT00654979|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158968|NCT05696756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158969|NCT06351449|||COHORT||PROSPECTIVE|||||||
34158970|NCT00734968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158971|NCT02595255|||CASE_CONTROL||PROSPECTIVE|||||||
34158972|NCT04622449|||CASE_ONLY||PROSPECTIVE|||||||
34158973|NCT00858637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158974|NCT01700543|||COHORT||PROSPECTIVE|||||||
34158975|NCT06399237|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34158976|NCT03051386|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34158977|NCT03644667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34158978|NCT03233516|||CASE_CONTROL||PROSPECTIVE|||||||
34158979|NCT04766775|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||ll of the patients enrolled in the study (aged 4 to 10 years old) will receive Silver Diamine Fluoride (SDF) treatment to the decayed primary tooth/teeth by having the application of Silver Diamine Fluoride (SDF) onto the tooth cavity. The weight of the SDF capsule and brush will be measured before and after the SDF application. This step approximates the amount of SDF applied to the tooth surface. Urine and hair samples will be taken to assess the silver and fluoride levels. Urine samples will be taken before the SDF treatment, in the first and second 24 hours after the SDF treatment. For the hair samples, it will be taken before the SDF treatment as well as day 7,14,30,60,75, and 90 after the SDF treatment. After the day 90 review, if caries remains active, the SDF treated teeth will be restored or undergo a six-monthly SDF application.||||
34158980|NCT01716741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158981|NCT00257361|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34158982|NCT01147354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34158983|NCT05219539|||COHORT||RETROSPECTIVE|||||||
34158984|NCT01706588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33741991|NCT00147147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741992|NCT03165201|||COHORT||PROSPECTIVE|||||||
33741993|NCT00664612|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33741994|NCT03650881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741995|NCT00131794|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33741996|NCT00761839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158985|NCT05740943|NA|SINGLE_GROUP||TREATMENT||NONE||A Simon two-stage design was applied. Primary endpoint for this study was pCR. The unacceptable response rate for pCR was less than 20% and desirable response rate was 40%. The error rate for alpha was set as 0.05 and 0.2 for beta. The Optimal assay was chosen and 43 patients were to be enrolled to meet adequate statical power. 13 patients would be enrolled in stage I and at least 3 patients achieved pCR were required to proceed stage II enrollment. Overall, if 12 patients achieved pCR, the study would be determined as positive. 10% drop-off rate should be considered and at least 48 patients should be enrolled.||||
34158986|NCT04731272|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34158987|NCT06418672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34158988|NCT05810350|NA|SINGLE_GROUP||TREATMENT||NONE||Aumolertinib||||
34158989|NCT03567746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34158990|NCT00093652||||TREATMENT||NONE||||||
34158991|NCT02463682|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34158992|NCT02955537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34158993|NCT02861092|||COHORT||RETROSPECTIVE|||||||
34158994|NCT04702022|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34158995|NCT04904666|||OTHER||PROSPECTIVE|||||||
34158996|NCT02570555|||OTHER||OTHER|||||||
34158997|NCT00832429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34158998|NCT01418079|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34158999|NCT01749150||PARALLEL||TREATMENT||NONE||||||
34159000|NCT00930878|||COHORT||PROSPECTIVE|||||||
34159001|NCT06438432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159002|NCT03642496|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33741997|NCT03965052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding will correspond to the principal investigator and coinvestigator. In addition, the statistical analysis will be carried out in a blinded manner for the final analysis. Blinding can not be guaranteed in the subject.~The masking will be done through the secondary container. The primary packaging will not be masked by the morphological difference between them. The sponsor and the research center will have two teams blinded / not blinded.~They will be identified by means of identical labels. Which, in accordance with current and applicable regulations, must contain at least:~* Name, address and telephone number of the sponsor.~* Pharmaceutical form and route of administration.~* Lot Number.~* Legend Exclusively for clinical studies~* Date of Expiry."|double blind, with randomization.|f|f|t|t
33741998|NCT00423436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159003|NCT02937558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34159004|NCT04086914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33741999|NCT01853449|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33742000|NCT03554122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33742001|NCT00032292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159005|NCT05799417|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|This study is designed as non-randomized clinical study where acoustic stimuli of different characteristics are played and compared to within-subject baselines across various sedation and/or sleep states.|The investigators forecast a maximal enrollment of 80 participants. However, an interim-analysis will be conducted after 10-14 participants to check estimated effect-size of intervention.||||
34159006|NCT03512379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Robot-assisted surgery group Free-hand surgery group Navigation-assisted surgery group|f|f|f|t
34159007|NCT02478164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159008|NCT02303145|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34159009|NCT00550693|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159010|NCT06433089|||COHORT||RETROSPECTIVE|||||||
34159011|NCT04279522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159012|NCT01711125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159013|NCT03225378|||COHORT||PROSPECTIVE|||||||
34159014|NCT04188704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159015|NCT00004050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846075|NCT05870605|||OTHER||CROSS_SECTIONAL|||||||
33742002|NCT01496352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846076|NCT01983189|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33846077|NCT00151632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950802|NCT03732534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950803|NCT01382875|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33742003|NCT01371318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33742004|NCT00910481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742005|NCT05818449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846078|NCT03097081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846079|NCT00929747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846080|NCT04365023|||COHORT||RETROSPECTIVE|||||||
33742006|NCT05421598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742007|NCT04192097|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33742008|NCT04946513|||CASE_ONLY||RETROSPECTIVE|||||||
33742009|NCT03455075|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33742010|NCT05394623|||OTHER||PROSPECTIVE|||||||
33742011|NCT05906693|||COHORT||CROSS_SECTIONAL|||||||
33846081|NCT00847067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33846082|NCT00455377|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846083|NCT02570204|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33846084|NCT03552952|||COHORT||PROSPECTIVE|||||||
33846085|NCT01755429|||||RETROSPECTIVE|||||||
33846086|NCT02484053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846087|NCT00380510|||||OTHER|||||||
33846088|NCT00357331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double Blind Placebo Controlled Trial|t|f|t|t
33846089|NCT06287645|||CASE_ONLY||CROSS_SECTIONAL|||||||
33846090|NCT04041453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846091|NCT01048801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846092|NCT03995862|||CASE_ONLY||PROSPECTIVE|||||||
33950804|NCT02775409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950805|NCT00666952|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950806|NCT00743873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950807|NCT06455930|NA|SINGLE_GROUP||TREATMENT||NONE|In this phase of the study, masking cannot be done as all participants will receive the intervention.|In this foundational study, only one group will participate and receive the intervention.||||
33950808|NCT01683565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950809|NCT03268252|||OTHER||PROSPECTIVE|||||||
33950810|NCT05406466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950811|NCT05072431|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950812|NCT04851509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeons cannot be blinded to the treatment allocation of the surgical intervention due to having to perform the static or dynamic rotational lock. Participants will be blinded to the form of locking they receive. Research personnel completing the outcome measures will be blinded. Data analyst(s) and the radiographic reviewer(s) will be blinded to the treatment arm.|Randomized trial design utilizing alternating treatment allocation to assign patients to treatment arms, treatment allocations will last for two months at a time.|t|f|f|t
33950813|NCT01173380|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33950814|NCT00843232|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950815|NCT02689973|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33950816|NCT02463604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33950817|NCT01801306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742012|NCT01719965|||COHORT||PROSPECTIVE|||||||
33742013|NCT05806697|NA|SINGLE_GROUP||OTHER||NONE||||||
33742014|NCT05601531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742015|NCT01888315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742016|NCT00087074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742017|NCT05194410|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742018|NCT05306652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742019|NCT03434717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT||||
33950818|NCT06050031|||COHORT||PROSPECTIVE|||||||
33950819|NCT03315442|RANDOMIZED|PARALLEL||SCREENING||NONE||20 healthy adults, (11 males; 9 females) averaging 26.1 years of age, stood on a MatScan™ pressure mat, which measured center of pressure (CoP), anteroposterior (AP) and mediolateral (ML) postural sways during eight different balance tests (BALT's). BALT's were designed to alter or cancel the systems involved in postural control: visual, vestibular and somatosensory. Subjects were randomly assigned to a caffeine group and an energy drink group. MANOVA analysis was performed for all variables of interest.||||
33742020|NCT03574454|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The assessors interpretation of disease status using WB-MRI scans will be fully blinded to the reference standard (i.e. the Expert Panel's interpretation of the same scan).|Cross-sectional diagnostic test accuracy design: development of a machine-based algorithm to augment expert classification of disease status and response to treatment in myeloma patients using retrospective interpretation of WB-MRI scans and disease-free (healthy volunteers) for comparison purposes.|f|f|f|t
34054542|NCT06066346|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase II trial||||
33742021|NCT03862118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"•The procedure:~* The face will be washed thoroughly immediately before the procedure.~* Disinfection with alcohol 70% will be done.~* A topical anesthetic cream will be applied to the face and left for 30 minutes then it will be removed.~* The obtained platelet rich plasma will be delivered by intradermal method using mestherapy needle."||||
33742022|NCT05688813|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A nurse was blinded to collect the pain score. An anesthesiologist was blinded to data collection about the analgesic requirements and postoperative complications.||f|t|f|t
33765105|NCT05477147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765106|NCT04670003|||COHORT||PROSPECTIVE|||||||
33765107|NCT06152016|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33765108|NCT04380532|NA|SINGLE_GROUP||TREATMENT||NONE||Healthy volunteers||||
33765109|NCT04342780|||COHORT||CROSS_SECTIONAL|||||||
33765110|NCT03966222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized controlled trial.||||
33765111|NCT03788460|||COHORT||OTHER|||||||
34054543|NCT03488134|||COHORT||PROSPECTIVE|||||||
34054544|NCT05387460|||COHORT||RETROSPECTIVE|||||||
34054545|NCT04763655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054546|NCT06498466|||OTHER||PROSPECTIVE|||||||
34054547|NCT05551520|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34054548|NCT02012738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054549|NCT05329584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054550|NCT03640975|||CASE_CONTROL||PROSPECTIVE|||||||
34054551|NCT05502146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054552|NCT03028857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054553|NCT01253174|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054554|NCT04085172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study contains two parts (Part A and Part B), where Part A will be double blind, double dummy parts of the study followed by Part B as an open label part of the study.||t|f|t|t
34159016|NCT03226925|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One group of patients with healthy volunteers and two groups with lung/upper abdomen cancer patients||||
34159017|NCT00738751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159018|NCT04503018|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34159019|NCT03003403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950820|NCT06301126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33950821|NCT01255865|||CASE_CROSSOVER||OTHER|||||||
34159020|NCT05495867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159021|NCT05456620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator (LP) will be blinded to the assigned treatment throughout the data collection period. During the study, patients will be asked not to discuss their treatment exercises with the principal investigator but to consult an independent second sports physician (AB) if they have any questions about the therapy.||f|f|t|t
33950822|NCT01489345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950823|NCT06274281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the type of intervention performed by the patient.|This is an experimental single-blind randomized-controlled trial (RCT) with 2-parallel arms comparing the effects between the experimental group (EG) and control group (CG). After screening, a simple randomization list will be generated by a physician using an automated randomization system (alloca-tion ratio 1:1) to assign eligible patients to either the EG or the CG. Group allocation will be kept concealed.|f|f|f|t
34054555|NCT06647706|||COHORT||PROSPECTIVE|||||||
34159022|NCT03893500|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34159023|NCT00868803|||OTHER||PROSPECTIVE|||||||
34159024|NCT00369499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159025|NCT00258167|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34054556|NCT00815815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159026|NCT06337812|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34159027|NCT03683953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34054557|NCT01589874|||COHORT||PROSPECTIVE|||||||
34054558|NCT03531528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054559|NCT00425061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054560|NCT02544425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054561|NCT00776113|RANDOMIZED|CROSSOVER||||NONE||||||
34054562|NCT05843058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34054563|NCT04776018|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34054564|NCT01084668|||COHORT||PROSPECTIVE|||||||
34054565|NCT03385044|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The randomization table of a treatment sequence will be managed by the third person who will not involve in this study.|Two methods of cuff sealing will be applied in a random sequence to each patient.|t|f|f|t
34054566|NCT06276777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and both assessors will be blind to the type of material used.||t|f|f|t
34054567|NCT04756583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34054568|NCT04136977|||COHORT||PROSPECTIVE|||||||
34054569|NCT00310206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742023|NCT06216626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The current protocol is an open-label parallel randomised controlled trial. Participants will be randomised into one of two study arms: a prebiotic fibre intervention arm or control arm (standard of care - Heart UK's Healthy Eating Guidelines).~Participants in the fibre intervention arm will consume 10g of a powdered fibre mix daily for 12 weeks. Both groups will not receive any additional nutrition support beyond Heart UK Healthy Eating Guidelines during the intervention. Participants will be instructed to maintain their normal lifestyle and diet, and avoid consuming other probiotic or prebiotic (fibre-based) products during the study."||||
33742024|NCT00902200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742025|NCT05027217|||COHORT||RETROSPECTIVE|||||||
33742026|NCT03579836|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742027|NCT05360524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742028|NCT00761501|RANDOMIZED|CROSSOVER||||NONE||||||
33742029|NCT00750789|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33742030|NCT06337136|||COHORT||PROSPECTIVE|||||||
33742031|NCT01748994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33742032|NCT00755586|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742033|NCT00744536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742034|NCT02419157|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33742035|NCT03637998|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742036|NCT05685810|||COHORT||OTHER|||||||
33742037|NCT06175728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054570|NCT03188068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742038|NCT06560541|RANDOMIZED|PARALLEL||TREATMENT||NONE|Although the participants will not be blinded to the investigator product (IP), they will be masked from the brand of the IP.|||||
33742039|NCT06112210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33742040|NCT00961974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742041|NCT05036122|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33742042|NCT05015153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742043|NCT00661492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742044|NCT04554862|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33742045|NCT00719446|||COHORT||PROSPECTIVE|||||||
33742046|NCT01597206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33742047|NCT05928325|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742048|NCT02948985|||CASE_ONLY||PROSPECTIVE|||||||
33742049|NCT01847508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742050|NCT01202773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742051|NCT00587145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742052|NCT00614029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33846093|NCT05174936|RANDOMIZED|PARALLEL||PREVENTION||NONE||The proposed multimodal intervention will include three sessions: the PLWH sessions (individual resilience-building), the Family member intervention (social support for PLWH\&#39;s resilience building and fostering resilience at the family level), and HCP intervention (reducing the institutional stigmatizing attitudes and practices toward PLWH)||||
33846094|NCT02384265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950824|NCT06650449|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study follows a case-control interventional model. Participants are divided into two groups: an intervention group using a mobile app based on Cognitive Behavioral Therapy (CBT) techniques, and a control group receiving no intervention. The app delivers weekly tasks over a 3-month period aimed at reducing emotional distress and depressive symptoms in healthcare workers. Both groups will be assessed at the start and end of the study using the PHQ-9 and GHQ-12 questionnaires to evaluate changes in mental health. The design allows for a comparison of mental health outcomes between those who receive the app-based intervention and those who do not.||||
33950825|NCT00077766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950826|NCT05246631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33950827|NCT02608827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950828|NCT02079974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950829|NCT02951182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950830|NCT05398458|||CASE_ONLY||RETROSPECTIVE|||||||
34054571|NCT06621017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054572|NCT05069259|||COHORT||PROSPECTIVE|||||||
33742053|NCT00772018|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33742054|NCT06532448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846095|NCT04193826|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33846096|NCT02349425|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33846097|NCT00484445|||COHORT||RETROSPECTIVE|||||||
33846098|NCT03385343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846099|NCT03452930|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950831|NCT00459498|||||OTHER|||||||
33950832|NCT05489016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950833|NCT00246675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950834|NCT00582634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950835|NCT00540982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950836|NCT04629209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950837|NCT04111939|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950838|NCT04575233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33950839|NCT03890380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950840|NCT02718573|||CASE_ONLY||PROSPECTIVE|||||||
33950841|NCT01657591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950842|NCT05794126|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33950843|NCT04940832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950844|NCT00083226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950845|NCT04559802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950846|NCT04355481|||COHORT||PROSPECTIVE|||||||
34054573|NCT05929196|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34054574|NCT05210465|||OTHER||PROSPECTIVE|||||||
34054575|NCT00343785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054576|NCT06083727|||CASE_ONLY||PROSPECTIVE|||||||
34054577|NCT03828110|||COHORT||RETROSPECTIVE|||||||
34159028|NCT01121432|||COHORT||PROSPECTIVE|||||||
34054578|NCT03455010|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Masking is not possible because the experimental condition is obvious. Participants and testers cannot influence outcome parameters.|Controlled multimodal data collection (biological, biomechanical) with block randomization.||||
34159029|NCT00000422|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34159030|NCT05014191|||COHORT||PROSPECTIVE|||||||
34054579|NCT06569667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34054580|NCT02220179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34054581|NCT01405417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054582|NCT00262470|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34159031|NCT02806960|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34054583|NCT00489905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054584|NCT02339116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159032|NCT03818451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159033|NCT05429398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159034|NCT04948424|||COHORT||RETROSPECTIVE|||||||
34159035|NCT06104111|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159036|NCT03384641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159037|NCT05492864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159038|NCT04016259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34159039|NCT05487911|NA|SINGLE_GROUP||TREATMENT||NONE||MDD subjects enrolled will receive TMS||||
34159040|NCT01090440|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159041|NCT00934128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159042|NCT01247194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159043|NCT01504685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159044|NCT01769196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159045|NCT03306511|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34159046|NCT00385138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159047|NCT05481489|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, non comparative, open, unicentric.||||
34159048|NCT02684149|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34159049|NCT02000297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159050|NCT00866073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159051|NCT03478033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participates are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
34159052|NCT04683367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159053|NCT03209856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054585|NCT02572596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054586|NCT03439540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34159054|NCT01699165|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159055|NCT05355948|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
34159056|NCT01267942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34159057|NCT00870987|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34159058|NCT00313105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159059|NCT04348032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159060|NCT06554015|||CASE_CONTROL||PROSPECTIVE|||||||
34159061|NCT05888987|||OTHER||OTHER|||||||
34159062|NCT00225498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159063|NCT02902393|||CASE_ONLY||PROSPECTIVE|||||||
34159064|NCT02113033|NA|SINGLE_GROUP||TREATMENT||NONE||Equilia VNS device||||
34159065|NCT02241902|||COHORT||PROSPECTIVE|||||||
34159066|NCT03607955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159067|NCT05618067|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34159068|NCT05504993|||CASE_ONLY||CROSS_SECTIONAL|||||||
34159069|NCT01393639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159070|NCT04611087|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34159071|NCT04130672|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blinded study|A Prospective Randomized Controlled Study|f|f|t|f
34159072|NCT05347706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be double-blinded. A nutritionist who is not directly involved in inpatient care will prepare and label the formula with the participant's randomization number, date and time feeding, then deliver the formula to the nurse caring for the infant. The medical and nursing teams caring for the infants will be unaware of the type of formula used for feeding. The trial statistician will perform data analysis and be kept unaware of treatment group assignment until the results are finalized.||t|t|t|t
34159073|NCT01640444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159074|NCT02800525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159075|NCT04306588|NA|SINGLE_GROUP||SCREENING||NONE||||||
34159076|NCT01366885|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34159077|NCT05224453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Single-blinded, randomized, experimental study|f|f|f|t
33950847|NCT05423665|||CASE_CONTROL||PROSPECTIVE|||||||
34159078|NCT04909658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The following people were all blinded to the group membership of the parents: the physicians (who carried out the clinical baseline assessment \[T0\] and post-treatment investigation \[T1\]), the primary researchers, and the data entry assistants. In the fourth stage, participants underwent ACT or PT training therapies. Treatments were carried on by expert therapists who were blinded to all clinical information and also to the aim of the study. At the end of treatment, participants from both groups were given a final evaluation \[T1\], using the same protocol as at a baseline.|A single-blind, randomized controlled study was conducted at our CNR center in Messina. The first stage was based on the recruitment of the parents for the study. Next, the eligible individuals underwent a clinical examination at baseline \[T0\]. In the third stage, participants were randomly assigned to two groups using a computer-generated randomization code. The following people were all blinded to the group membership of the parents: the physicians (who carried out the clinical baseline assessment \[T0\] and post-treatment investigation \[T1\]), the primary researchers, and the data entry assistants. In the fourth stage, participants underwent ACT or PT training therapies. Treatments were carried on by expert therapists who were blinded to all clinical information and also to the aim of the study. At the end of treatment, participants from both groups were given a final evaluation \[T1\], using the same protocol as at a baseline.|f|f|t|t
34159079|NCT00008528||PARALLEL||TREATMENT||||||||
34159080|NCT00369642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159081|NCT00221832|||FAMILY_BASED||PROSPECTIVE|||||||
33950848|NCT05199649|NA|SINGLE_GROUP||SCREENING||NONE||||||
33950849|NCT01211041|||CASE_ONLY||RETROSPECTIVE|||||||
33950850|NCT03829995|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The study is a open-label trial. The pharmacist know, whether the patient is randomized to the intervention group or the control group.|The intervention group is compared with the control group.||||
33950851|NCT01739946|||CASE_CONTROL||PROSPECTIVE|||||||
33950852|NCT02262572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950853|NCT06330506|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33950854|NCT02396524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34159082|NCT03256201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34054587|NCT04029363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054588|NCT02141815|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34054589|NCT06272864|||COHORT||PROSPECTIVE|||||||
34159083|NCT01835665|NA|SINGLE_GROUP||||NONE||||||
34159084|NCT01196832|||CASE_CONTROL||PROSPECTIVE|||||||
34159085|NCT01913002|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159086|NCT00881647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159087|NCT00851786|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34159088|NCT03204370|||COHORT||PROSPECTIVE|||||||
34159089|NCT01740401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159090|NCT05529810|||CASE_ONLY||RETROSPECTIVE|||||||
34159091|NCT03111329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Open label during intervention, assessor of outcomes will be blinded to group allocations|Randomization into 2 groups (interventional and control) with crossover rescue strategy.|f|f|f|t
34159092|NCT05367544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159093|NCT04264364|||COHORT||PROSPECTIVE|||||||
34159094|NCT05467358|||COHORT||RETROSPECTIVE|||||||
33950855|NCT04768283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950856|NCT03378024|||CASE_ONLY||PROSPECTIVE|||||||
34054590|NCT00890357|||COHORT||PROSPECTIVE|||||||
34054591|NCT04627532|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34054592|NCT02441270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054593|NCT04675515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054594|NCT05770102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054595|NCT04778059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054596|NCT06061081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054597|NCT04567368|||CASE_ONLY||CROSS_SECTIONAL|||||||
34054598|NCT06000501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054599|NCT04446650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054600|NCT01645891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159095|NCT04042324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159096|NCT03374540|||COHORT||RETROSPECTIVE|||||||
34054601|NCT05073328|||COHORT||RETROSPECTIVE|||||||
34159097|NCT03369912||PARALLEL||TREATMENT||TRIPLE|"This is a patient, investigator and sponsor-blinded study. Patients, investigators and sponsor will remain blinded to study treatment throughout the study.~With the exception of any unblinded site staff identified below, all site staff (including study investigator and study nurse) will be blinded to study treatment throughout the study.~Drug product will be supplied in patient specific kits, so an unblinded pharmacist who is independent of the study team will be required in order to maintain the blind. Appropriate measures must be taken by the unblinded pharmacist to ensure that the treatment assignments are concealed from the rest of the site staff."|This is a randomized, patient, investigator and sponsor blinded, placebo-controlled study in pregnant women with primary HCMV infection. This study is a non-confirmatory trial.|t|f|t|t
34159098|NCT00727792|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159099|NCT02187068|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34054602|NCT00904865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159100|NCT05309148|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34159101|NCT03348176|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Investigators coding parental outcome measures of the study from videomaterial are masked for study-arm||f|f|t|f
34159102|NCT01620814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159103|NCT04649463|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized parallell groups open||||
34159104|NCT00269555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34159105|NCT01966835|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34159106|NCT03408613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159107|NCT00928694|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159108|NCT02644785|||COHORT||PROSPECTIVE|||||||
34159109|NCT03015935|||COHORT||PROSPECTIVE|||||||
34159110|NCT01079494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34159111|NCT05696496|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||the 2 groups (patients with Sleep Disorder Group (TS+) and the control group (TS-)) will receive the same intervention.||||
34159112|NCT01920308|||COHORT||PROSPECTIVE|||||||
34054603|NCT04811053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34159113|NCT03060954|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34159114|NCT03568669|||CASE_ONLY||PROSPECTIVE|||||||
34159115|NCT02389036|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Cluster, crossover, randomized clinical trial|f|f|f|t
34054604|NCT01583075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34054605|NCT03440307|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blinded study|Participants randomized to intervention or control.|f|f|f|t
34054606|NCT01613222|NA|SINGLE_GROUP||OTHER||NONE||||||
34054607|NCT05093985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34054608|NCT06263998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054609|NCT01928342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054610|NCT05257005|||COHORT||PROSPECTIVE|||||||
34054611|NCT05360446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor personnel participating in the study conducted will be blinded also.|Multi-center, randomized, double-blind, placebo-controlled, parallel-group|t|t|t|f
34054612|NCT05030194|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34054613|NCT05893147|RANDOMIZED|PARALLEL||OTHER||NONE||72 in the overall platform AND at least 12 in each domain.||||
34054614|NCT05412940|||COHORT||PROSPECTIVE|||||||
34054615|NCT05531578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054616|NCT03192618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054617|NCT04629781|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, multicenter, single-stage phase 1b trial in patients with mCRPC. A 3+3 design is used||||
34054618|NCT06268405|NA|SINGLE_GROUP||SCREENING||NONE||||||
34159116|NCT01598922|RANDOMIZED|PARALLEL||TREATMENT||NONE||For the clinical trial there were only 2 arms: MDD and MAC. There were no Healthy Controls in the CBT vs attention monitoring trial; both groups were depressed.||||
34159117|NCT01162902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159118|NCT05512169|||COHORT||PROSPECTIVE|||||||
34159119|NCT03259061|||COHORT||PROSPECTIVE|||||||
34159120|NCT06339307|||COHORT||PROSPECTIVE|||||||
34054619|NCT03839875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054620|NCT01040195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054621|NCT05484154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054622|NCT05571644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054623|NCT05527093|NA|SINGLE_GROUP||OTHER||NONE||||||
34054624|NCT04892693|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, phase II study||||
34054625|NCT02533102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054626|NCT04660500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34054627|NCT01950104|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34054628|NCT05652179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33950857|NCT03743571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly assigned to receive either sham or anodal (2 mA) tDCS targeting the mPFC during exposure therapy for public speaking anxiety.|t|t|f|f
33950858|NCT01234246|||COHORT||PROSPECTIVE|||||||
33950859|NCT03564015|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, randomized, open-label, controlled trial||||
33950860|NCT03448562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950861|NCT00752206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950862|NCT06536478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950863|NCT04861688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950864|NCT06363552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950865|NCT00236730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33950866|NCT01826929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33950867|NCT03446157|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, single-arm, phase II clinical trial of combination therapy with cetuximab and palbociclib in refractory KRAS, NRAS, and BRAF wild-type metastatic colorectal cancer (CRC) patients||||
33950868|NCT05598762|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33950869|NCT00727675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950870|NCT00346775|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33950871|NCT01855594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950872|NCT00005658||||TREATMENT||||||||
33950873|NCT01298362|||COHORT||PROSPECTIVE|||||||
33950874|NCT03833908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950875|NCT01305694||PARALLEL||TREATMENT||NONE||||||
33950876|NCT02100215|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33950877|NCT01671865|||COHORT||PROSPECTIVE|||||||
33950878|NCT05677412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Experimental within-subject study design||||
33950879|NCT05903092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950880|NCT03264573|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33950881|NCT00252668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054629|NCT05390528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054630|NCT04995653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There are 2 parts or cohorts for the trial. Cohort 1 is an open-label study. Cohort 2 is double-blind, randomized, placebo-controlled study.|t|f|t|f
34054631|NCT02832375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34159121|NCT05882149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Randomized, double-blind, parallel, placebo-controlled intervention study. The total duration of the intervention will be 12 weeks. The study will have two arms of intervention.~The intervention product will be: sugar-free chewing gum with single strain probiotic and zinc.~The Placebo product will be: sugar-free chewing gum. The placebo products and the intervention products will present the same format and appearance, in order to ensure the double-blind intervention"|t|f|t|t
34159122|NCT00825903|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34159123|NCT04051983|||OTHER||OTHER|||||||
34159124|NCT00411372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159125|NCT06434246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159126|NCT06109207|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34159127|NCT02602418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159128|NCT02440685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study terminated early so no all groups per protocol were conducted||||
33950882|NCT05100628|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33950883|NCT04703465|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33950884|NCT06235060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||It is an experimental study with a pretest-posttest design with two intervention groups.||||
33950885|NCT05111548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33950886|NCT03130634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950887|NCT05953610|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective cohort study will include an anticipated 150 study participants undergoing soft palate surgery. The randomized crossover (interventional) study will include the anticipated 90 who do not achieve successful treatment of their obstructive sleep apnea with surgery.||||
33950888|NCT01245829|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33950889|NCT00388713|||DEFINED_POPULATION||PROSPECTIVE|||||||
33950890|NCT01133912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950891|NCT04353427|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33950892|NCT03482388|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomly assigned in a 1:1 ratio to the study intervention or control||||
33950893|NCT06520488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950894|NCT05294133|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33950895|NCT00587561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950896|NCT06650462|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants randomly assigned to intervention or control group; repeated measure assessments at 0 months, 3 months, 6 months||||
34054632|NCT06291922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054633|NCT03225079|||OTHER||OTHER|||||||
34054634|NCT02956369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34054635|NCT05157542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054636|NCT03754855|||CASE_ONLY||CROSS_SECTIONAL|||||||
34054637|NCT02181322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054638|NCT04546009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054639|NCT04649736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054640|NCT02031640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054641|NCT04566978|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34054642|NCT02487771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054643|NCT02247635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054644|NCT00501124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054645|NCT03285503|NA|SINGLE_GROUP||OTHER||NONE||||||
34054646|NCT04092543|||COHORT||PROSPECTIVE|||||||
34054647|NCT00559403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34054648|NCT06648876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054649|NCT06410495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054650|NCT04502147|||CASE_ONLY||RETROSPECTIVE|||||||
34054651|NCT06621589|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a quasi-experimental design with a single group of participants receiving nutritional counseling. The participants will undergo pre- and post-intervention assessments to measure changes in knowledge, attitudes, behaviors, and health indicators.||||
34054652|NCT00465582|||||PROSPECTIVE|||||||
34054653|NCT06142942|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All pre- and post-testing is completed by researchers not involved in training, and thus are blinded to which group participants are assigned to. This prevents any potential bias when researchers are completing post-testing sessions.|Following pre-testing participants are assigned to one of the four groups based on their baseline cardiorespiratory fitness to ensure no differences between groups at baseline. Participants will train 2, 3, or 4 days a week, or be assigned to the control group (no training) and re-test following the 4 week intervention.|f|f|f|t
34054654|NCT01746953|||COHORT||PROSPECTIVE|||||||
34054655|NCT03800836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054656|NCT04886089|||COHORT||PROSPECTIVE|||||||
34054657|NCT00720512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054658|NCT03946683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054659|NCT05896462|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Having closed the skin and cleaned with savlon and 70% isopropyl alcohol, patients in the C group had the apposed skin edge covered with dry sterile gauze while in PI group, 10% povidone iodine-soaked gauze dressing was used to cover the apposed skin edge|t|t|f|t
34054660|NCT06667895|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||This study will be conducted in two phases, a pilot phase and a main experimental phase. The two phases involve different outcome measures. Both phases follow a double-blinded, randomized, within-subject design.|t|f|t|t
34054661|NCT06619262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a prospective randomized assessor-blind comparison study.|t|f|t|t
34054662|NCT04748458|||COHORT||RETROSPECTIVE|||||||
34054663|NCT06620796|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054664|NCT06623955|||CASE_CONTROL||PROSPECTIVE|||||||
34054665|NCT04679636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054666|NCT05220462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054667|NCT01381913|||CASE_CONTROL||PROSPECTIVE|||||||
34054668|NCT05761210|||CASE_CONTROL||PROSPECTIVE|||||||
34054669|NCT06537076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054670|NCT01785719|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The researchers plan to recruit two cohorts of obese women to the study: (1) those with irregular menstrual cycles and/or PCOS and (2) those with regular menstrual cycles. Both of the cohorts will receive the same intervention.||||
34054671|NCT06265701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Investigators will utilize a single-blind approach where participants will not be made aware of the purpose of the intervention. Participants in both arms will be told that the purpose of the study is to determine the efficacy of a novel five-session journaling intervention, which explores concepts related to self-continuity. This is partly true for those in the experimental arm. The main purpose of the study is twofold: (1) to explore the efficacy of the experimental journaling intervention's in reducing levels of derailment and (2) to test the hypothesis that decreasing derailment- a temporal discordance of the self- will lead to a decrease in depressive symptoms."||t|f|f|f
34054672|NCT06647719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054673|NCT05367284|||COHORT||PROSPECTIVE|||||||
34054674|NCT03891862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33950897|NCT03984552|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33950898|NCT00874952|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33950899|NCT02389621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950900|NCT02851069|||COHORT||PROSPECTIVE|||||||
33950901|NCT04888377|||COHORT||PROSPECTIVE|||||||
33950902|NCT04066894|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33950903|NCT02353273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950904|NCT04619758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33950905|NCT05432349|||COHORT||PROSPECTIVE|||||||
34054675|NCT02210247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054676|NCT05892718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054677|NCT01775358|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34054678|NCT05749770|||COHORT||PROSPECTIVE|||||||
34054679|NCT03108170|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34054680|NCT03403751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor personnel and clinical research associates (CRAs) will also be blinded to study treatment.|1:1 randomization of study drug (Reltecimod) and placebo (normal saline)|t|t|t|t
34054681|NCT00046852|RANDOMIZED|||TREATMENT||||||||
34054682|NCT01328899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159129|NCT02703324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34159130|NCT02003092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159131|NCT06324396|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center, open-label, prospective, investigation to quantify the effects of liver congestion and fibrosis has on hepatic statin transport (SA1) and response (SA2) in children, adolescents, and young adults with Fontan circulation.||||
34159132|NCT02641301|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159133|NCT01301833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159134|NCT04047979|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Single center, open label mechanistic study in which older adult subjects will receive Zoster vaccine recombinant, adjuvanted Vaccination will occur on Day 0 and Day 60. There will be no randomization, study participant or clinical study personnel blinding, or masking.||||
34159135|NCT04660474|||COHORT||PROSPECTIVE|||||||
34159136|NCT03219632|||CASE_CONTROL||PROSPECTIVE|||||||
34159137|NCT01192945|||COHORT||PROSPECTIVE|||||||
34159138|NCT00182338|||COHORT||PROSPECTIVE|||||||
34159139|NCT00502788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159140|NCT00731146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159141|NCT01609504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159142|NCT03315572|||COHORT||CROSS_SECTIONAL|||||||
34159143|NCT03733613|||OTHER||OTHER|||||||
34159144|NCT02682082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34159145|NCT06078436|RANDOMIZED|PARALLEL||TREATMENT||NONE||From the time of diagnosing cardiogenic shock (CS) caused by HFrEF within 12 hours, random allocation will be conducted. If assigned to the hemodynamic monitoring group with pulmonary artery catheter (PAC), the catheter will be inserted and hemodynamic parameters will be monitored until recovery from CS. The non-monitoring group will receive CS treatment without inserting a PAC.||||
34159146|NCT06552650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159147|NCT05692102|||OTHER||CROSS_SECTIONAL|||||||
34159148|NCT02699320|||CASE_CONTROL||RETROSPECTIVE|||||||
34159149|NCT01585571|||CASE_CONTROL||PROSPECTIVE|||||||
34159150|NCT02239952|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159151|NCT00791908|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34159152|NCT01623375|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159153|NCT01821703|RANDOMIZED|CROSSOVER||||DOUBLE|||t|t|f|f
34159154|NCT06367283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159155|NCT01111344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159156|NCT01898429|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33950906|NCT06159946|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33950907|NCT06650865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33950908|NCT03040960|||CASE_CONTROL||PROSPECTIVE|||||||
33950909|NCT05358704|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, open label, multi-institutional, Phase II trial of chemoradiation (CRT) followed by FOLFOXIRI for T3/T4 or lymph node positive rectal adenocarcinoma using a total neoadjuvant therapy (TNT) approach.||||
33950910|NCT06129851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950911|NCT03950934|||COHORT||PROSPECTIVE|||||||
33950912|NCT03088566|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The randomisation will be determined by sequencing patients into on of the two groups following the grouping found in closed envelopes.|Randomised controlled study. One group will be foot screened following the routine described in the web program, the D-Foot. The other group will be foot screened by the use of conventional methods.|t|f|f|f
33950913|NCT03131791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||group A : shock wave, group B: Botulinum Toxin Injection|f|f|t|t
33950914|NCT02908204|||COHORT||RETROSPECTIVE|||||||
33950915|NCT00050050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054683|NCT03706885|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Only the Statistician and Pharmacists are unmasked||t|t|t|t
34054684|NCT00375050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34054685|NCT00311519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34054686|NCT02704520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054687|NCT03902717|||COHORT||PROSPECTIVE|||||||
34159157|NCT05454657|RANDOMIZED|PARALLEL||TREATMENT||NONE||Heart rate variability biofeedback + treatment as usual vs. treatment as usual only||||
34159158|NCT01491997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34159159|NCT04282707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospectively collected cohort of 30 patients. Compared with historical cohort.||||
34159160|NCT02830321|||CASE_CONTROL||PROSPECTIVE|||||||
34159161|NCT02397044|||CASE_CONTROL||PROSPECTIVE|||||||
34159162|NCT03918915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159163|NCT04833114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159164|NCT03813589|||COHORT||PROSPECTIVE|||||||
34159165|NCT05523050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950916|NCT00283517|||COHORT||PROSPECTIVE|||||||
33950917|NCT04264806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950918|NCT00295256|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950919|NCT01786837|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33950920|NCT01359774|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950921|NCT00373282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33950922|NCT03280472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950923|NCT04773366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled patients are stratified into 4 risk groups. Patients in each risk group are assigned to one treatment regimen.||||
33950924|NCT00302068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950925|NCT04944485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessors, statistician and the patients will be blinded to intervention/control assessment methods; Triple blinded study. Also, it will not be allowed amongst the examiners to exchange any information throughout the entire study period.||t|f|f|t
33950926|NCT01874821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950927|NCT00021476|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33950928|NCT06008015|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950929|NCT05592639|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950930|NCT04583072|||COHORT||PROSPECTIVE|||||||
33950931|NCT00300261|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33950932|NCT03446846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor also masked.||t|f|t|f
33950933|NCT06392217|||CASE_ONLY||OTHER|||||||
33950934|NCT02598791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33950935|NCT00921934|||COHORT||PROSPECTIVE|||||||
33950936|NCT03742869|||CASE_CONTROL||PROSPECTIVE|||||||
33950937|NCT02422186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950938|NCT00732732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159166|NCT05525650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159167|NCT01858740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159168|NCT03580980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34159169|NCT04435275|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34159170|NCT02628353|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34159171|NCT02421718|||COHORT||PROSPECTIVE|||||||
34159172|NCT02870101|NA|SINGLE_GROUP||OTHER||NONE|All information collected anonymously.|||||
34159173|NCT03867643|||COHORT||PROSPECTIVE|||||||
34159174|NCT02830815|||CASE_CROSSOVER||PROSPECTIVE|||||||
34159175|NCT04857580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159176|NCT00745758|||COHORT||PROSPECTIVE|||||||
34159177|NCT01856582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159178|NCT00711971|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34159179|NCT03658447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159180|NCT03306719|||CASE_CONTROL||PROSPECTIVE|||||||
34159181|NCT00753454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159182|NCT04215900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159183|NCT04842383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants in the study and the outcomes assessor on day 0 and day 180 will be prevented from having knowledge of which of the two strengths of cannabinoid topicals were used.|40 subjects will be randomly assigned into two treatment groups, 500mg of cannabinoids per ounce and 1000mg of cannabinoids per ounce. The change in hair follicle numbers will be compared statistically between the two groups.|t|f|f|t
34159184|NCT01349712|||CASE_ONLY||PROSPECTIVE|||||||
34159185|NCT03932760|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33950939|NCT04538716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950940|NCT04279873|||COHORT||PROSPECTIVE|||||||
33950941|NCT00734318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950942|NCT01846442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950943|NCT03011385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33950944|NCT03644966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950945|NCT05417373|||OTHER||OTHER|||||||
34159186|NCT00158288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159187|NCT01934010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159188|NCT00334984|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34159189|NCT02917395|NA|SINGLE_GROUP||||NONE||||||
34159190|NCT02206035|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34159191|NCT03469687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159192|NCT02702180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159193|NCT06442488|||COHORT||PROSPECTIVE|||||||
34159194|NCT04845763|||COHORT||PROSPECTIVE|||||||
34159195|NCT05703581|||COHORT||RETROSPECTIVE|||||||
33742055|NCT01089140|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33950946|NCT05151874|||CASE_ONLY||PROSPECTIVE|||||||
33950947|NCT02223520|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33950948|NCT01984840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950949|NCT02568176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950950|NCT02407483|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950951|NCT00131027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950952|NCT00395395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33950953|NCT04718363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950954|NCT03320980|||CASE_CONTROL||RETROSPECTIVE|||||||
33950955|NCT02226380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950956|NCT01283659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950957|NCT01377207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33950958|NCT02817919|||COHORT||PROSPECTIVE|||||||
33950959|NCT06059508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950960|NCT00198107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950961|NCT06097416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950962|NCT05466916|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||In Aims 2 and 3, a single-arm, pre-/post-study design will be used to assess feasibility and acceptability, and preliminary effects of the intervention.||||
33950963|NCT00151775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33950964|NCT04120116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33950965|NCT00235300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950966|NCT06324968|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33950967|NCT05354349|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double Blind||t|f|t|f
33950968|NCT06465160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33950969|NCT02983305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950970|NCT03800576|||CASE_ONLY||RETROSPECTIVE|||||||
33950971|NCT03827031|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33950972|NCT00282516|RANDOMIZED|PARALLEL||ECT||NONE||||||
33950973|NCT04780126|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33950974|NCT00781482|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33950975|NCT04429776|RANDOMIZED|PARALLEL||TREATMENT||NONE||50 Participants: randomised 1:1 to either feedback of test results to treating clinician or no feedback to treating clinician (25 participants each arm)||||
33950976|NCT00488098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950977|NCT03066466|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, two arms||||
33950978|NCT01737203|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33950979|NCT05326958|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33950980|NCT05419960|||CASE_ONLY||CROSS_SECTIONAL|||||||
33950981|NCT02837250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33950982|NCT03358407|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33950983|NCT06192407|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Each of the two experimental diets will be masked and only the dietician and statistician will be unblinded. Subjects will be assigned to one of two diet orders and the masking will be matched across the sexes.|In this crossover study, the investigators will administer two experimental diets in a random order for one week, and each experimental diet will be preceded by a one-week, low fat control diet for a total four-week study period.|t|t|t|t
33950984|NCT05608616|||OTHER||RETROSPECTIVE|||||||
33950985|NCT00996073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159196|NCT04599465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159197|NCT02956941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159198|NCT03787355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Intervention versus Control.|t|f|t|t
34159199|NCT01578577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159200|NCT02181764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159201|NCT06089837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159202|NCT02682199|||COHORT||PROSPECTIVE|||||||
33950986|NCT00730366|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159203|NCT06507826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were unaware of condition assignment until after the study.||t|f|f|f
34159204|NCT06196606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159205|NCT01202630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742056|NCT03629795|||COHORT||PROSPECTIVE|||||||
33950987|NCT03096249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33950988|NCT00350935|||CASE_CONTROL||PROSPECTIVE|||||||
33950989|NCT05195385|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33950990|NCT04983628|||COHORT||PROSPECTIVE|||||||
33950991|NCT02637518|||COHORT||PROSPECTIVE|||||||
33950992|NCT03039829|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33950993|NCT06260462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950994|NCT02009111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33950995|NCT00835861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33950996|NCT06192875|||COHORT||CROSS_SECTIONAL|||||||
33950997|NCT01975506|||COHORT||CROSS_SECTIONAL|||||||
33950998|NCT02696980|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33950999|NCT00646217|RANDOMIZED|PARALLEL||||NONE||||||
33951000|NCT01396252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951001|NCT01476527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951002|NCT01800812|NON_RANDOMIZED|||||NONE||||||
33951003|NCT05891210|||COHORT||PROSPECTIVE|||||||
33951004|NCT06465459|||COHORT||PROSPECTIVE|||||||
33951005|NCT00582127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34159206|NCT05777395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be aware of which group the participant belongs to.|This is a randomized controlled trial having two groups. One group will receive conventional physical therapy along with Maitland oscillatory mobilizations and the second will receive Kaltenborn sustained stretch mobilizations with conventional physical therapy. Both groups will be recruited concurrently.|f|f|f|t
34159207|NCT01456065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159208|NCT00793507|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159209|NCT03688464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159210|NCT01059318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742057|NCT03346759|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for one of the first two menstrual cycles during the study. Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the other of the first two menstrual cycle during the study. Subjects used tampons A and B in a randomly assigned order. Subjects then used tampons of their choosing for the third menstrual cycle of the study.||||
33742058|NCT05636540|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a pilot observational study to determine the feasibility of \[18F\]FTT PET/CT to evaluate PARP-1 enzyme expression in pheochromocytoma/paraganglioma.||||
33742059|NCT01607905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742060|NCT00229008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742061|NCT01745263|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33846100|NCT03131505|||OTHER||PROSPECTIVE|||||||
34159211|NCT01065701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846101|NCT03670966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159212|NCT03979885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159213|NCT02737345|||COHORT||PROSPECTIVE|||||||
34159214|NCT04555018|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34159215|NCT00627367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159216|NCT01023360||CROSSOVER||SCREENING||NONE||||||
34159217|NCT04619732|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159218|NCT03591315|||COHORT||PROSPECTIVE|||||||
34159219|NCT04701736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159220|NCT05830175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Basic randomization via SPSS v24.0 program|"Demographic data, gait parameters, balance parameters and craniovertebral angle values of individuals were evaluated with clinical data evaluation form, Spatio-Temporal Gait Analysis (LEGSystm), Portable computerized kinesthetic balance device (SportKAT 550) and photometer, respectivelyThe evaluations were performed 2 times before and after the treatment.~In addition to the 1 hour Bobath treatment, the study group received 15 minutes of cervical region joint and soft tissue mobilizations 3 times per week along 4 weeks. The control group was treated with Bobath 3 days per week along 4 weeks and each session was 75 minutes."|t|f|f|f
34159221|NCT00890110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159222|NCT05373264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||An investigator driven, multicenter, placebo-controlled, randomized clinical trial.|t|t|t|t
34159223|NCT01877213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159224|NCT04903054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846102|NCT01797614|||CASE_ONLY||PROSPECTIVE|||||||
34159225|NCT02434042|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34159226|NCT03232866|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159227|NCT06180239|||COHORT||RETROSPECTIVE|||||||
34159228|NCT04800146|||CASE_ONLY||PROSPECTIVE|||||||
34159229|NCT03842241|||OTHER||CROSS_SECTIONAL|||||||
33846103|NCT00573638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846104|NCT05335551|||COHORT||PROSPECTIVE|||||||
33846105|NCT05910151|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33846106|NCT01737424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159230|NCT01610336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159231|NCT04602442|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.|The trial has three groups, each with 30 subjects (n=90). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.|t|t|f|f
34159232|NCT01047982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34159233|NCT00534547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742062|NCT03165045|||COHORT||PROSPECTIVE|||||||
33846107|NCT00784940|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33846108|NCT04512703|||COHORT||PROSPECTIVE|||||||
33846109|NCT04585867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846110|NCT04712695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846111|NCT06273059|||COHORT||CROSS_SECTIONAL|||||||
33846112|NCT03664362|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33846113|NCT00112827|NA|SEQUENTIAL||TREATMENT||NONE||||||
33951006|NCT02079493|||COHORT||PROSPECTIVE|||||||
33951007|NCT02888782|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33951008|NCT04712058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951009|NCT05570734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951010|NCT03832907|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951011|NCT06462924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951012|NCT03582098|||COHORT||RETROSPECTIVE|||||||
33951013|NCT00329225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159234|NCT04767906|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with hepatocellular carcinoma with prior non-response or disease progression during a PD-1 or PD-L1 inhibitor treatment will be treated with Cabozantinib.||||
34159235|NCT03066414|||COHORT||PROSPECTIVE|||||||
34159236|NCT00288236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159237|NCT04371939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159238|NCT01162915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159239|NCT05231239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159240|NCT05970471|||OTHER||PROSPECTIVE|||||||
34159241|NCT01463306|NA|||TREATMENT||NONE||||||
34159242|NCT00921843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159243|NCT03137225|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomization - the order of modes will be assigned based on a random number table using a 5 block design to match the DSMB reporting needs.||||
34159244|NCT02155920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159245|NCT02490592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159246|NCT01663064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159247|NCT00309400|||||RETROSPECTIVE|||||||
34159248|NCT00281346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159249|NCT00217568||||TREATMENT||NONE||||||
34159250|NCT05276921|||COHORT||PROSPECTIVE|||||||
34159251|NCT04887259|NA|SEQUENTIAL||TREATMENT||NONE||||||
34159252|NCT01043991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742063|NCT06299202|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742064|NCT00043446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742065|NCT03644979|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||1) Skydiving visit, 2) Negative control visit||||
34159253|NCT05248880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159254|NCT00866255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159255|NCT02315534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159256|NCT02944786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159257|NCT05643651|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator, Participant and Care provider will not be masked. However, sonographer who is responsible for assessing coronary artery lesions should be masked.||f|f|f|t
34159258|NCT03024125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159259|NCT01802190|||||PROSPECTIVE|||||||
33742066|NCT02691455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742067|NCT06573944|||COHORT||RETROSPECTIVE|||||||
33765112|NCT00267696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765113|NCT02775318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765114|NCT06261047|||COHORT||PROSPECTIVE|||||||
33765115|NCT05309538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups , group A contro group and group B experimental group|t|f|f|f
33765116|NCT00528476|||CASE_CONTROL||PROSPECTIVE|||||||
33765117|NCT01406002|NA|SINGLE_GROUP||||NONE||||||
33951014|NCT04928924|||COHORT||PROSPECTIVE|||||||
34159260|NCT00000228||||TREATMENT||||||||
34159261|NCT03413306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159262|NCT03209466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159263|NCT01224743|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34159264|NCT05310981|RANDOMIZED|PARALLEL||PREVENTION||NONE||two-arm parallel, open-labelled, pilot randomized controlled trial||||
33951015|NCT06176417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951016|NCT03075826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951017|NCT02783300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label study.|This will be a three-part study where Part 1 is dose escalation, including assessment of Food Effect and Relative Bioavailability, Part 2 is disease specific expansion cohorts to better characterize the clinical activity and safety profile of GSK3326595 and Part 3 is dose determination of GSK3326595 in combination with pembrolizumab.||||
33951018|NCT03423004|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33951019|NCT00615407|||||CROSS_SECTIONAL|||||||
33951020|NCT02770534|||CASE_CONTROL||PROSPECTIVE|||||||
33951021|NCT04114461|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||2X2||||
33951022|NCT03678649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951023|NCT01001195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951024|NCT04524351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951025|NCT03526848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951026|NCT00093327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33951027|NCT04034329|||COHORT||PROSPECTIVE|||||||
33951028|NCT06289959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951029|NCT01339273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951030|NCT05735860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled / two-arm parallel assignment|t|f|f|f
33951031|NCT03504501|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Monocenter, randomized, double-blind, parallel-group, placebo controlled, cross-over design with a series of three experiments (Noonan Syndrome: 2 experiments; Neurofibromatosis type 1 1 experiment) and n=14 participants per experiments|t|f|t|t
33951032|NCT04489862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951033|NCT06230276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951034|NCT01993238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951035|NCT02682966|||COHORT||PROSPECTIVE|||||||
33951036|NCT01913613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951037|NCT05174429|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm.||||
33951038|NCT03329404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951039|NCT05542966|||COHORT||PROSPECTIVE|||||||
33951040|NCT04504292|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33951041|NCT05679570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951042|NCT03677609|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951043|NCT02184988|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33951044|NCT00344968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951045|NCT00322517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951046|NCT06392282|||COHORT||PROSPECTIVE|||||||
33951047|NCT03062852|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951048|NCT06180473|||COHORT||PROSPECTIVE|||||||
33951049|NCT01473602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33951050|NCT00883831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951051|NCT01159652|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33951052|NCT01771172|||COHORT||PROSPECTIVE|||||||
33951053|NCT04281121|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951054|NCT01315626|||||RETROSPECTIVE|||||||
33951055|NCT04575415|||COHORT||PROSPECTIVE|||||||
33951056|NCT00497822|RANDOMIZED|PARALLEL||||SINGLE||||||
33951057|NCT02074449|||CASE_ONLY||PROSPECTIVE|||||||
33951058|NCT00944528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951059|NCT01481480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951060|NCT02962440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951061|NCT05245461|||CASE_CONTROL||PROSPECTIVE|||||||
34159265|NCT04120402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomized to received either EP-104IAR or placebo (vehicle) in a parallel group fashion.|t|t|t|t
34159266|NCT05225857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159267|NCT06142617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159268|NCT01855360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159269|NCT06200792|||CASE_ONLY||PROSPECTIVE|||||||
34159270|NCT04844268|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Blinding was done to all cohorts. Subjects, clinical study staff, statisticians, and investigators were masked to treatment assignment. Laboratory staff that manipulates the vaccine and the placebo were not blinded.~Subjects received injections of either vaccine or placebo, delivered in the deltoid muscle in accordance with the study protocol. In order to internal contents were not differentiated, the injections were applied with opaque syringes."||t|t|t|t
34159271|NCT03853863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment will be conducted by independent researchers who are not involved in subject allocation.|the single-blinded randomized control trial|f|f|t|f
10140681|NCT06553599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742068|NCT05219877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study uses a single-blinded design because the outcome assessed in this study is urinalysis which is the objective outcome. The urinalysis evaluator is blinded to the drug regimen obtained by the research subjects.|This study is an experimental study with a single-blinded randomized clinical trial design to compare the proportion of UTIs in a group of patients receiving levofloxacin 500 mg single dose one hour before urodynamic examination and patients receiving levofloxacin 500 mg once daily for three days post-urodynamic examination. To determine the sample treatment group, blocked randomization technique is used in this study.|f|f|f|t
33742069|NCT01577394|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742070|NCT02382120|||CASE_ONLY||PROSPECTIVE|||||||
33742071|NCT02318329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742072|NCT02081651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742073|NCT03223389|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33742074|NCT01031823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742075|NCT03582306|RANDOMIZED|CROSSOVER||PREVENTION||NONE||4 week intervention and control periods will be delivered and separated by a 4 week washout. The order of intervention and control periods will be randomly allocated||||
33742076|NCT01323439|||OTHER||PROSPECTIVE|||||||
33742077|NCT00265057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742078|NCT04098627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Statistical Analysis Blinded||f|f|f|t
33846114|NCT00953745|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||This study is designed to help understand the mechanism of action of aripiprazole in MDD augmentation. Subjects will undergo exposure to en an existing antidepressant (Lexapro 10-20mg) for 10 weeks; subjects failing to completely respond to the monotherapy antidepressant treatment will receive augmentation with aripiprazole for six weeks. We have included two placebo phases to the study in which the subjects received one placebo along with the Lexapro for the first 6 weeks and a second placebo along with Lexapro for the next two weeks (weeks 7 and 8). This double placebo design is to ensure that subjects receiving aripiprazole augmentation have a legitimate response (non-placebo) to the aripiprazole augmentation. Since the N of this study is small and a small % of patients with placebo response could skew the imaging data significantly, the use of a double placebo prior to the start of the true aripiprazole augmentation should reduce or eliminate a placebo response.|t|f|f|f
33846115|NCT02440945|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33846116|NCT02169544|||COHORT||RETROSPECTIVE|||||||
33846117|NCT03788759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Proof of concept 4-month prospective, randomized, double-blind, controlled trial|t|t|t|t
33846118|NCT03387748|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||non-factorial, cross-sectional study (with control group)||||
33846119|NCT01871805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951062|NCT00605969|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742079|NCT02970344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742080|NCT00226941|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential design for 4 dose combinations (arms) through phase 1||||
33742081|NCT05126238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159272|NCT05340036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the intervention, therapists cannot be blinded to allocation, but are strongly instructed not to disclose the allocation status to the participant at the follow up assessments. Mrs. Esraa will feed data into the computer in separate datasheets so that the assessors can analyze data without having access to information about the allocation and the procedure.||t|f|f|t
34159273|NCT05386381|||OTHER||RETROSPECTIVE|||||||
33951063|NCT03564977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159274|NCT00779025|RANDOMIZED|PARALLEL||||NONE||||||
33951064|NCT04456062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951065|NCT05022121|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33951066|NCT00194038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951067|NCT05751824|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33951068|NCT01662076|NA|SINGLE_GROUP||||NONE||||||
33951069|NCT01393574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951070|NCT04409509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951071|NCT02638818|||COHORT||PROSPECTIVE|||||||
33951072|NCT05811507|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33951073|NCT00843817|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951074|NCT04423107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951075|NCT04595617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951076|NCT01422031|||COHORT||PROSPECTIVE|||||||
33951077|NCT04775693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951078|NCT05385783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951079|NCT02259426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951080|NCT04689334|||COHORT||PROSPECTIVE|||||||
33951081|NCT06652971|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951082|NCT06538493|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951083|NCT03496597|||COHORT||PROSPECTIVE|||||||
33951084|NCT02345538|||COHORT||PROSPECTIVE|||||||
33951085|NCT02951143|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33951086|NCT01652040|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33951087|NCT00578448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951088|NCT03733379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951089|NCT04025697|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33951090|NCT04446182|NA|SINGLE_GROUP||TREATMENT||NONE||The RP2D will be determined by a 3+3 dose de-escalation design. Once an RP2D has been confirmed, Part 2 will open as an expansion cohort. (As this study was terminated after enrolling 3 patients, Part 2 of the planned study did not occur.)||||
33951091|NCT04487886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33951092|NCT02329834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951093|NCT00004107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951094|NCT04647175|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33951095|NCT03480399|||COHORT||PROSPECTIVE|||||||
33951096|NCT05005468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951097|NCT02996838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951098|NCT02804295|NA|SINGLE_GROUP||||NONE||||||
33951099|NCT04744935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951100|NCT05612126|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33951101|NCT00161031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33951102|NCT01225029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159275|NCT02110862|||CASE_ONLY||CROSS_SECTIONAL|||||||
34159276|NCT02975258|||COHORT||PROSPECTIVE|||||||
33742082|NCT05487157|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33742083|NCT05987267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742084|NCT04368936|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742085|NCT02908438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742086|NCT05643066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951103|NCT01798056|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33951104|NCT00649714|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951105|NCT06133465|||COHORT||RETROSPECTIVE|||||||
33951106|NCT01462409|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33951107|NCT01717300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951108|NCT01161212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951109|NCT04380493|||COHORT||RETROSPECTIVE|||||||
33951110|NCT00296777|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951111|NCT00604760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159277|NCT01771237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951112|NCT06651580|||COHORT||PROSPECTIVE|||||||
33951113|NCT03452722|||COHORT||PROSPECTIVE|||||||
33951114|NCT06004518|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||It was planned in a randomized controlled type.|t|f|f|f
33951115|NCT05514327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951116|NCT05100927|||COHORT||PROSPECTIVE|||||||
33951117|NCT01203475|||COHORT||PROSPECTIVE|||||||
33951118|NCT00975000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742087|NCT06034600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental, single-blind randomized controlled trial|t|f|f|f
33951119|NCT05308134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34159278|NCT02373644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159279|NCT01487850||||DIAGNOSTIC||||||||
34159280|NCT00757094|||CASE_CROSSOVER||PROSPECTIVE|||||||
33742088|NCT03174886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are unaware of the dosage strength they are receiving. The AADvac1 vials are numbered, and the coding unknown to the patient. The investigator handles the vaccine vials and administers the IMP.|Patients will be allocated to one of two dosage strengths of AADvac1. No placebo is used. No active comparator is used.|t|f|f|f
34159281|NCT01252706|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159282|NCT02775448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159283|NCT05639530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34159284|NCT01191177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159285|NCT06256393|||COHORT||PROSPECTIVE|||||||
34159286|NCT04262076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||split mouth design|t|f|f|t
34159287|NCT00379912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159288|NCT02290041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Phase 1: uncontrolled, single arm biosafety evaluation (n=5) Phase 2: placebo-controlled, randomized, evaluation (n=10)|t|f|t|t
34159289|NCT02624895|||OTHER||PROSPECTIVE|||||||
34159290|NCT00476658|||COHORT||PROSPECTIVE|||||||
34159291|NCT05311930|NA|SINGLE_GROUP||OTHER||NONE||This is a single-arm open-label trial. After enrollment, patients received an initial dose of 2.5 mg of hetropoda for 4 weeks, and blood routine monitoring was performed regularly during treatment.||||
34159292|NCT02377999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159293|NCT05332938|||COHORT||RETROSPECTIVE|||||||
34159294|NCT03477838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159295|NCT03631758|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34159296|NCT01189695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159297|NCT02481739|||||RETROSPECTIVE|||||||
34159298|NCT02499705|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34159299|NCT05498467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159300|NCT03976206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The volunteers will be randomly arranged to enter the experimental group or the control group.|In the experimental group, VSELs will be injected in left preauricular area of every volunteer, followed by skin pathology to compare the improvement of skin aging with the skin of right preauricular area. In the control group, platelet-rich plasma will be injected to the left preauricular area of every volunteer.|f|f|t|f
34159301|NCT03539601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigational products above are masked for appearance, and will be placed into identical cartons. Once removed from the product cartons, the investigational products could be discerned from each other based on commercial product tube shape/size and should only be handled by unblinded site personnel.~Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment."||t|t|t|t
34159302|NCT06288074|||COHORT||RETROSPECTIVE|||||||
34159303|NCT00079092||||TREATMENT||NONE||||||
34159304|NCT05405335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||parallel groups randomized clinical trial||||
33742089|NCT01988818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742090|NCT01252472|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742091|NCT01105533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742092|NCT02761564|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33742093|NCT00558285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742094|NCT05233826|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33742095|NCT01273831|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33742096|NCT04793412|NA|SINGLE_GROUP||TREATMENT||NONE||The study is conducted as a multicenter, prospective, two-phase clinical trial, evaluating the efficacy and safety of cochlear implantation in children with asymmetric hearing loss (AHL) or single-sided deafness (SSD). A hearing aid (HA) phase occurs over a minimum of 4 mos prior to obtaining a cochlear implant (CI). A CI phase occurs over the 15-month period after initial activation of the CI.||||
33742097|NCT05336240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data analysts on the study team||f|f|f|t
33742098|NCT01503125|||COHORT||PROSPECTIVE|||||||
33742099|NCT05893108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment given to participants is not known by any of the outcome assessors.|Two groups received different treatment at the same time. Both outcomes were measured at the same time before and after treatment with 4 measurements.|f|f|f|t
33742100|NCT05684484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"It will be conducted on 52 patient having with mild to moderate degree ulcerative colitis disease divided into two groups~1. Group 1 (n=26): Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid) for 3 months.~2. Group 2 (n=26): Patients will receive previous conventional treatment and Roflumilast (500 mcg ) orally once daily for 3 months"|t|t|t|t
33742101|NCT02073045|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742102|NCT00917345|||CASE_CONTROL||PROSPECTIVE|||||||
33742103|NCT04632992|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742104|NCT03197493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who complete 3 months of escalation dose carbidopa-levodopa, will receive 9 additional months of therapy with the highest dose used in protocol 0002, carbidopa-levodopa 25-100 mg 2 tablets TID. If that dose was not well tolerated in study 0002, the patient will receive the intermediate dose, carbidopa-levodopa 25-100 mg, 1 tablet TID.||||
33742105|NCT03465540|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33951120|NCT02415907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951121|NCT04722627|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33742106|NCT02344186|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33742107|NCT03251703|||OTHER||RETROSPECTIVE|||||||
33742108|NCT01617291|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742109|NCT05507268|||COHORT||RETROSPECTIVE|||||||
33742110|NCT05520138|||COHORT||RETROSPECTIVE|||||||
33742111|NCT00003878||||TREATMENT||||||||
33846120|NCT04972305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742112|NCT06027060|||CASE_CONTROL||PROSPECTIVE|||||||
33742113|NCT01801059|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33846121|NCT05698576|NA|SINGLE_GROUP||TREATMENT||NONE||Voluntary participation in a Prospective controlled cohort||||
33742114|NCT04955626|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33742115|NCT01476046|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33742116|NCT05933915|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single blind randomized controlled trial|t|f|f|f
33742117|NCT02019719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742118|NCT02416323|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33742119|NCT03963557|||COHORT||CROSS_SECTIONAL|||||||
33846122|NCT03716115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846123|NCT01401777|||CASE_CONTROL||PROSPECTIVE|||||||
33846124|NCT01815762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846125|NCT03428087|||COHORT||CROSS_SECTIONAL|||||||
33846126|NCT04677634|NA|SINGLE_GROUP||OTHER||NONE||||||
33846127|NCT03241108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33951122|NCT02800109|||COHORT||PROSPECTIVE|||||||
33951123|NCT00886626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951124|NCT05547516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951125|NCT02047929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951126|NCT00338377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951127|NCT05127109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Utilization of structured nutrition delivery pathway on 300 adult abdominal trauma and surgery patients admitted to a Duke University Medical Center (DUMC) intensive care unit (ICU) from surgical intervention to hospital discharge.||||
33951128|NCT06327334|||COHORT||PROSPECTIVE|||||||
33951129|NCT00008034||||TREATMENT||||||||
33951130|NCT05508308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Preterm infants on bCPAP are managed with each mode of oxygen control for 24 hours, prior to crossing over to the other mode of control. Change over simply involves flicking the computer switch from manual to automated control (or vice versa) and it is enacted immediately. It does not require any adjustment or interruption of the CPAP and it does not involve additional action from clinical staff. While the fraction of inspired oxygen (FiO2) adjustments have their effect relatively rapidly, we will apply a 1 h washout period (dropping this data from analysis) to avoid contamination between arms.||||
33951131|NCT05479617|||COHORT||PROSPECTIVE|||||||
33951132|NCT05158907|NA|SINGLE_GROUP||PREVENTION||DOUBLE|The clinician will not get the opportunity to see the patient reported scale until the end of patient's participation in the study.|Patient reported adverse event scale will be given to study participants|f|t|t|f
33951133|NCT00910000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742120|NCT02264223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742121|NCT04858737|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33742122|NCT06398353|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33742123|NCT01573676|||CASE_ONLY||PROSPECTIVE|||||||
33742124|NCT06279260|||COHORT||CROSS_SECTIONAL|||||||
33742125|NCT05487924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33742126|NCT06529367|||COHORT||CROSS_SECTIONAL|||||||
33951134|NCT04885842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A randomized controlled clinical study ,two parallel groups design. The research sample consisted of 18 patients (11 famales,7 males)Patients were randomly assigned to 2 groups using the sample randomization principle. Each group included 8 patient (9 control group applying brackets only)(9 group injection I-PRF with brackets).||||
33846128|NCT03759431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846129|NCT03805087||SEQUENTIAL||TREATMENT||NONE||||||
33846130|NCT04737187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846131|NCT05003518|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||A factorial design will be used testing the four components, with a total of 16 conditions. The purpose of this factorial experiment is to estimate the main effects of the four intervention components and interactions between the components, not to compare the 16 experimental conditions to each other.|t|f|t|f
33846132|NCT00469105|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33846133|NCT00992225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846134|NCT03957889|||COHORT||PROSPECTIVE|||||||
34054688|NCT01426464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054689|NCT01685489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054690|NCT04495504|NA|SINGLE_GROUP||TREATMENT||NONE||Placement by the surgeon of two catheters in BLS position before the surgical incision. Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter followed by a continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.||||
34159305|NCT00930228|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, placebo-controlled, crossover study|t|t|t|t
34054691|NCT02721524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054692|NCT04186702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A clinical trial design strategy in which parties involved in the trial, the investigator and participants, do not know which participants have been assigned which interventions. Type of masking include: double-blind masking.|interventional model|t|t|t|t
34054693|NCT00129727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054694|NCT00372723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054695|NCT06358209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054696|NCT06622759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054697|NCT01603745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054698|NCT01647516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054699|NCT04939012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34054700|NCT06345157|||CASE_ONLY||PROSPECTIVE|||||||
34054701|NCT00542906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054702|NCT06621173|NA|SINGLE_GROUP||TREATMENT||NONE||The subjects with metastatic colorectal cancer will be treated by HNF4α srRNA intravenously via a peripheral vein.||||
34054703|NCT03855020|||COHORT||PROSPECTIVE|||||||
34054704|NCT03579186|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Patients undergoing a clinical gait assessment will be recruited for this study. Those that consent to participate will complete their clinical gait assessment as part of their normal evaluation. Subjects will then complete a gait assessment while wearing experiencing optokinetic stimulation. The investigators will compare baseline gait and postural control before and during OKS stimulation.||||
34159306|NCT02489383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159307|NCT00854815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159308|NCT00105690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34159309|NCT04321434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34159310|NCT02914574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159311|NCT06069947|NA|SINGLE_GROUP||TREATMENT||NONE||SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.||||
33742127|NCT06047769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33742128|NCT05302765|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The control arm consists of lumbar puncture performed in routine fashion without the administration of intravenous fluids prior to procedure. The experimental arm will undergo normal saline intravenous fluids administration (20 milliliters/kilogram) prior to lumbar puncture. Bolus to be complete prior to lumbar puncture in the experimental group.||||
33742129|NCT02326103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765118|NCT05596513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||received the intensive motor-learning approaches that focuses on training of the affected hand (motor-learning approaches such as - constraint-induced movement therapy (CIMT) and hand-arm bimanual intensive training (HABIT) of the control group but from a vertical surface|t|f|f|f
34054705|NCT03996174|||OTHER||OTHER|||||||
34054706|NCT03425682|||CASE_ONLY||PROSPECTIVE|||||||
34054707|NCT00154804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054708|NCT02205008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054709|NCT01953874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054710|NCT04231877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054711|NCT04322019|||CASE_ONLY||PROSPECTIVE|||||||
34054712|NCT06622746|||CASE_CONTROL||RETROSPECTIVE|||||||
34054713|NCT02963558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054714|NCT05335031|||COHORT||PROSPECTIVE|||||||
34054715|NCT03580408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159312|NCT01941459|||COHORT||PROSPECTIVE|||||||
33742130|NCT06478784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind system will be maintained in which the exploring neurologists and the patient will not know the assigned therapeutic group. Randomly assigned to one or the other group.|We will include patients with multiple sclerosis in the ACTIVE GROUP (resistance training) and patients with multiple sclerosis CONTROL GROUP (low intensity aerobic training).|t|f|t|f
33742131|NCT00053131|RANDOMIZED|||TREATMENT||||||||
33951135|NCT05557201|||COHORT||PROSPECTIVE|||||||
33951136|NCT01317199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase 1 (Arms 1) - open label Phase 2 (Arms 2-4) - randomized, double-blind|Arm 1: participants in dose-escalation phase (Phase 1) Arms 2-4: Randomized, double-blind (Phase 2); control, low-dose, high-dose|t|f|t|f
33951137|NCT02763410|||CASE_CONTROL||PROSPECTIVE|||||||
33951138|NCT05493059|||CASE_ONLY||RETROSPECTIVE|||||||
33951139|NCT00894309|||COHORT||PROSPECTIVE|||||||
33951140|NCT01133366|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951141|NCT02926352|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33951142|NCT05460195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951143|NCT04343508|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33951144|NCT05283109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951145|NCT06116357|NA|SINGLE_GROUP||TREATMENT||NONE||primary hypertensive patients||||
33951146|NCT03081637|||COHORT||RETROSPECTIVE|||||||
33951147|NCT01767649|||COHORT||PROSPECTIVE|||||||
33951148|NCT05915507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054716|NCT04981834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054717|NCT01968707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34054718|NCT02985606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34054719|NCT05068674|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I will be a standard 3+3 dose-escalation study to evaluate 3 doses of allogeneic hESC-CMs||||
34054720|NCT02637895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054721|NCT03298945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parallel groups|f|f|f|t
34054722|NCT03814512|NA|SINGLE_GROUP||PREVENTION||NONE||This is a pilot study testing the intervention arm of the RCT. No control group.||||
34054723|NCT01684982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054724|NCT06354361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants will be randomised into two groups.~One group will receive nine sessions of Trauma-Informed Goal Management Training, and the other group will receive nine sessions of standard Goal Management Training.~Each group session will be 2 hours long, and offered virtually (using Zoom for Healthcare)."|t|f|f|t
34054725|NCT06510556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054726|NCT03589976|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34054727|NCT02988440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054728|NCT06619613|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34054729|NCT02856607|||||PROSPECTIVE|||||||
34054730|NCT05299944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054731|NCT05483101|||CASE_CONTROL||PROSPECTIVE|||||||
34054732|NCT00226668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054733|NCT01054300|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34054734|NCT05091736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054735|NCT06221592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34054736|NCT01393509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054737|NCT02698202|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34054738|NCT06622629|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054739|NCT03581734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory staff will remain blinded throughout the study|We propose to conduct an open-label, randomized controlled study in Dhaka, Bangladesh, among healthy children aged 1 - 3 years old who have received either no dose or one dose of OPV and has not received any dose of IPV or OCV at any time before enrolment based upon immunization card record or history from parents after full informed consent. Participants will be randomized to one of three groups ; (i) OPV only, (ii) OCV only, or (iii) co-administered OPV and OCV|f|f|f|t
34054740|NCT00906100|||CASE_ONLY||PROSPECTIVE|||||||
34054741|NCT01171781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054742|NCT03122743|||COHORT||PROSPECTIVE|||||||
34054743|NCT00564837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054744|NCT05204160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846135|NCT00167167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846136|NCT04493775|NA|SINGLE_GROUP||TREATMENT||NONE|Neither the researcher delivering the intervention nor the participant will know the selected sequence at the start, however, it will not be possible for either the researcher or the participant to be completely blinded to the sequence once it is underway, given that the differences in duration of stimulation are likely to be quite apparent.|||||
33846137|NCT01534689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742132|NCT00162851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846138|NCT04258202|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33846139|NCT00626197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846140|NCT05474495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742133|NCT02545894|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742134|NCT02498808|||CASE_CONTROL||PROSPECTIVE|||||||
33846141|NCT00918892|||OTHER||RETROSPECTIVE|||||||
33742135|NCT02696850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951149|NCT05946629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomized trial is a single-blind study. The physician performing the index procedure as well as study site personnel present at the index procedure will not be blinded, however every effort will be made to maintain blinding for the following:~* Subjects and their families~* Site personnel involved in conducting study assessments during follow-up Unblinding will only occur to protect subject rights, welfare, or well-being. The angiographic and pK substudy cohorts will not be blinded.~The Clinical Events Committee (CEC) will be blinded to the treatment arm during the adjudication process."|Single-Blind Randomized Control Trial|t|f|f|t
33951150|NCT02543918|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33742136|NCT03103867|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742137|NCT00835406|RANDOMIZED|CROSSOVER||||NONE||||||
33742138|NCT05760066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742139|NCT04414644|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized within subjects, cross-over design||||
33742140|NCT01364272|||COHORT||PROSPECTIVE|||||||
33742141|NCT01469689|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33742142|NCT01705457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742143|NCT02248545|||CASE_CONTROL||RETROSPECTIVE|||||||
33742144|NCT06535282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742145|NCT00712153|||CASE_ONLY||PROSPECTIVE|||||||
33742146|NCT03864900|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both participants and care providers were unaware of the group assignment.|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.|t|t|f|f
33742147|NCT05625204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742148|NCT02449824|||COHORT||PROSPECTIVE|||||||
33742149|NCT00406029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742150|NCT05871164|||COHORT||PROSPECTIVE|||||||
33742151|NCT03798691|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846142|NCT00858169|||COHORT||PROSPECTIVE|||||||
33846143|NCT05217875|||COHORT||PROSPECTIVE|||||||
33846144|NCT01671397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846145|NCT03066349|||CASE_CONTROL||PROSPECTIVE|||||||
33951151|NCT00792597|||COHORT||PROSPECTIVE|||||||
33951152|NCT00934518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054745|NCT01537874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054746|NCT01628796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054747|NCT03138252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054748|NCT00380081|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34054749|NCT06618872|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Participants will have first a Tau-PET (experimental) and then an amyloid PET (standard of care) or the opposite||||
33742152|NCT01370746|||COHORT||PROSPECTIVE|||||||
33742153|NCT00215852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742154|NCT05476003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All blocks will be performed by the same anesthesiologist while the measurements will be recorded by anesthesiologist who has no idea about patient allocation.||f|f|f|t
33742155|NCT03191084|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33742156|NCT04492046|||CASE_ONLY||PROSPECTIVE|||||||
33742157|NCT01672632|NA|SINGLE_GROUP||OTHER||NONE||||||
33742158|NCT01383070|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33742159|NCT05809570|||COHORT||CROSS_SECTIONAL|||||||
33742160|NCT04103229|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33742161|NCT05307224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It was planned to use block randomization for the random assignment of patients to the experimental and control groups.|control group (usual care) and experimental group (mandala painting)|t|f|f|f
33742162|NCT06421233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33742163|NCT04170192|||COHORT||PROSPECTIVE|||||||
33742164|NCT00174213|||DEFINED_POPULATION||OTHER|||||||
33742165|NCT05582538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742166|NCT04952649|||COHORT||PROSPECTIVE|||||||
33742167|NCT05811377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Study design: Cross-sectional prospective study on consented, age matched 10 HIC, 10 NHIC, and 10 asymptomatic controls.~To demonstrate the clinical feasibility of our MRI based permeability assay, the investigators propose to first calibrate the MRI based bladder permeability assay by detecting significant differences in Gadobutrol permeability between 10 HIC patients (true-positive for bladder permeability) and 10 asymptomatic patients with no abnormal cystoscopic findings (true-negative for bladder permeability). After calibrating the MRI based bladder permeability assay, the investigators will have 10 NHIC patients submit to the assay to determine if they have either low or high Gadobutrol permeability."||||
33742168|NCT01243333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742169|NCT01494285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742170|NCT05982743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742171|NCT02995668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33742172|NCT03574220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742173|NCT05359042|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients will be randomized 2:1 to intervention arm or the standard of care arm||||
33742174|NCT02886572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742175|NCT03236402|||COHORT||CROSS_SECTIONAL|||||||
33742176|NCT03322306|||COHORT||PROSPECTIVE|||||||
33742177|NCT02578485|RANDOMIZED|CROSSOVER||||NONE||||||
33742178|NCT00119444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742179|NCT06223945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33742180|NCT05153837|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742181|NCT01206335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742182|NCT05810922|RANDOMIZED|PARALLEL||OTHER||NONE||one group consuming 50 g of arbutus berry/day one group consuming 200 g of arbutus berry/day||||
33742183|NCT02038738|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742184|NCT00924950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742185|NCT05778214|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33742186|NCT04621305|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742187|NCT05681884|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized during the enrollment phase of the study in a 1:1 ratio to one of two treatment arms.||||
33742188|NCT00803634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742189|NCT03710434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742190|NCT00887172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742191|NCT01444534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742192|NCT04498936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742193|NCT03807362|NA|SINGLE_GROUP||TREATMENT||NONE||A single center, open label pilot study||||
33742194|NCT00022516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742195|NCT00560833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054750|NCT00658775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054751|NCT06245525|||OTHER||OTHER|||||||
34054752|NCT06206551|||COHORT||OTHER|||||||
34054753|NCT01463592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054754|NCT02836236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054755|NCT05035667|||CASE_ONLY||PROSPECTIVE|||||||
34054756|NCT04631484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, Outcomes Assessor|International, multicenter, randomized, single blind, third party (outcome assessor) blinding|t|f|f|t
34054757|NCT06621134|||CASE_CONTROL||PROSPECTIVE|||||||
34054758|NCT02285569|||COHORT||PROSPECTIVE|||||||
34054759|NCT04773184|||COHORT||PROSPECTIVE|||||||
34054760|NCT04347356|||OTHER||PROSPECTIVE|||||||
34054761|NCT04456868|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34054762|NCT01700075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054763|NCT01176695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054764|NCT02449317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34054765|NCT04360174|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential: Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies||||
34054766|NCT03219359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054767|NCT03692975|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34054768|NCT02909231|||COHORT||PROSPECTIVE|||||||
34054769|NCT06219291|||COHORT||PROSPECTIVE|||||||
34054770|NCT06647563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054771|NCT05764733|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Masking applies to drug only. All assessments will be conducted by trained and blinded assessors.|This is a 2x2 factorial design.|t|t|t|t
34054772|NCT00725608|||COHORT||PROSPECTIVE|||||||
34054773|NCT04677140|||CASE_ONLY||PROSPECTIVE|||||||
34054774|NCT04098328|||COHORT||PROSPECTIVE|||||||
34054775|NCT06618989|||COHORT||PROSPECTIVE|||||||
34054776|NCT02541669|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34054777|NCT06307496|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742196|NCT04081207|NA|SINGLE_GROUP||TREATMENT||NONE||Participant cohorts: We will use a 2 (groups) X 4 (measurement time points) switching replications design\[18\] to examine the effects of AAC on aphasia severity and spoken language (AIM 1), elucidate the neurobiological mechanism of AAC-induced language recovery (AIM 2), and identify AAC treatment responder subgroups (Exploratory Aim). This design will allow Group 2 to serve as the control group; however, they will still receive AAC treatment; thus, allowing us to increase the total N who receives AAC treatment to 20 people.||||
34054778|NCT05341206|RANDOMIZED|PARALLEL||TREATMENT||NONE|The color of Herbal gargle is yellowish while normal saline is transparent. Therefore, the study belongs to open label trial.|The treatment group receive Herbal gargle and control group receive normal saline.||||
33742197|NCT01099319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742198|NCT02445079|||COHORT||PROSPECTIVE|||||||
33742199|NCT03208387|||CASE_CONTROL||PROSPECTIVE|||||||
33742200|NCT04266977|NA|SINGLE_GROUP||TREATMENT||NONE||restrictive use of DEX, based on standardized clinical and radiological criteria.||||
33742201|NCT04994366|||COHORT||PROSPECTIVE|||||||
33742202|NCT04908267|||CASE_ONLY||RETROSPECTIVE|||||||
33742203|NCT04141293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33742204|NCT06531759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742205|NCT03074006|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742206|NCT01629082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742207|NCT00984269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054779|NCT06619353|||COHORT||PROSPECTIVE|||||||
34054780|NCT01048060|||COHORT||PROSPECTIVE|||||||
34054781|NCT02111746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking included all patients, who were blinded to the contents of the intraoperative injection, as well as partial blinding of the surgical team who were masked from the treatment allocation up until the time of injection following which the knowledge of drug was inevitable as Exparel® has a milky appearance as opposed to the colorless bupivacaine hydrochloride (standard) formulations.|Prospective, blinded, controlled randomized clinical trial with 2-armed parallel-group sequential design|t|f|t|f
34054782|NCT06511206|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33742208|NCT00687258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742209|NCT05418621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742210|NCT03397901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742211|NCT02826226|||CASE_CROSSOVER||PROSPECTIVE|||||||
33742212|NCT01814722|||COHORT||PROSPECTIVE|||||||
33742213|NCT06429306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742214|NCT01557946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label administration of citalopram to participants with major depressive disorder. MRI scans performed at baseline and days 3, 7, and 42. An age- and gender-matched group of healthy volunteers did not receive citalopram and received on MRI scan to perform between-group baseline analyses.||||
33742215|NCT04842695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||clinical study in which participants are assigned to 2 groups.Group K receive kegel´s exercise and the group A receive kegel´s exercise plus electroacupuncture in a point called R7.|t|f|f|t
34054783|NCT01298726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34054784|NCT01659970|||COHORT||PROSPECTIVE|||||||
34054785|NCT02979951|||COHORT||PROSPECTIVE|||||||
34054786|NCT06617611|||COHORT||PROSPECTIVE|||||||
34054787|NCT04805697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054788|NCT00282906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054789|NCT05846399|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A double-blinded protocol will be performed. Investigators and participants will be blinded to study interventions. Both will be blinded to reduce the risk of bias. All three interventions will be packaged in identical capsule vials. The placebo arm will have all capsules filled with microcrystalline cellulose and no active drug, the one day intervention arm will be packaged in identical capsule vials with the first day of active drug and four days filled with placebo, five day intervention group will be packaged in identical capsule vials with all capsules filled with active drug. Blinding will remain throughout the duration of the study. Following completion of patient participation (day 30+/-2). Investigators and participants will be notified of the respective treatment arms. Final results will be available to investigators and participants following completion of the study.|Prospective, Randomized, Placebo-controlled, Double-blinded, Clinical Trial|t|t|t|f
34054790|NCT04305249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054791|NCT01389479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34054792|NCT04042922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34054793|NCT04653337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054794|NCT03361865|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will be unblinded after the last participant completes Week 9 imaging assessment for efficacy analysis and after appropriate EC/IRB approvals have been received.|||||
34054795|NCT06618222|||OTHER||OTHER|||||||
34054796|NCT06605222|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-7787 injection monotherapy||||
34054797|NCT00841347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34054798|NCT05273060|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054799|NCT05481723|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34054800|NCT04070690|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054801|NCT02780024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054802|NCT06646328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34054803|NCT04760041|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34054804|NCT03045276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34054805|NCT03141229|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Note: Either teacher and pupils are included in this study. We anticipate a number of 100 teacher and 500 pupils participating. Data from teacher and pupils will be analyzed separately.|t|f|f|t
34054806|NCT04536857|||CASE_CONTROL||PROSPECTIVE|||||||
34054807|NCT06649422|||COHORT||PROSPECTIVE|||||||
34159313|NCT03999840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In order to have a balanced distribution of risk factors for disease recurrence and considering the small number of patients and of expected events, before randomization patients will be stratified according to previous history of disease relapse (after eculizumab interruption and/or after a course of plasma therapy) YES or NO.|"This will be a prospective, randomized, double blind, placebocontrolled trial organized in a Core Study, an Extension follow-up period and a Safety Period.~The study duration for each patient is 108 weeks (core study 32 weeks, extension follow up 52 weeks and safety follow up 24 weeks)."|t|t|t|t
34159314|NCT05517057|||COHORT||PROSPECTIVE|||||||
34159315|NCT03944291|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Bupivacaine|t|t|t|t
34159316|NCT03547895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with decompensated cirrhosis with frequent hepatic encephalopathy (HE) or difficult to treat ascites were included if they had chronic active HCV||||
34159317|NCT05844267|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34159318|NCT05633888|NA|SINGLE_GROUP||OTHER||NONE||||||
34159319|NCT03051308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34159320|NCT04178720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159321|NCT04346836|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34159322|NCT05496569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159323|NCT00005644||||TREATMENT||||||||
33742216|NCT03328897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159324|NCT04572451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159325|NCT06152107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159326|NCT00365924|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34159327|NCT00554047|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33742217|NCT03789539|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Subjects will undergo screening procedures within 2-6 days prior to first vaccination which will include medical history, vital signs, physical examination and safety blood and urine lab tests.~On the first treatment visit, eligible subjects will undergo pre-dose physical examination, ECG, vital signs, and a blood sample for circulating IgE. They will then receive an IM injection of either vaccine or placebo, according to the above treatment assignment, into the deltoid muscle preferably of non dominant arm. The subjects will remain under medical supervision for 72 hrs at which time they will be released from the Clinical research center.~The second treatment will take place 21 days after the first vaccination. Procedures will be the same as that of Visit 1 Additional follow-up visits will take place at 4-7th,14th,24-27th and 42nd days. Blood and urine samples will be collected for safety."|t|t|t|t
33742218|NCT06054646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33742219|NCT00426075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742220|NCT02212223|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742221|NCT04502160|||COHORT||RETROSPECTIVE|||||||
34054808|NCT03694418|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped Wedge Design||||
34054809|NCT04323306|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Quadruple for part 1. Double-blind, randomized, placebo-controlled, sequential ascending single dose study Open label for part 2.|"Part 1: 8 participants per cohort for 7-8 cohorts (56-64 participants total). Single ascending dose commencing at 5 mg with maximum 400 mg as determined by Safety Review Committee (SRC).~Part 2:~Open label, 2-period cross-over, randomized, pilot food effect study to provide preliminary information on the effect of a high-fat meal on the pharmacokinetics of a single-dose oral administration of MMV533"|t|t|t|t
34054810|NCT01609439|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33742222|NCT01387529|||COHORT||PROSPECTIVE|||||||
33742223|NCT04541381|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded||f|f|f|t
33742224|NCT05286918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054811|NCT06648447|||COHORT||PROSPECTIVE|||||||
34054812|NCT03755869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054813|NCT02892604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054814|NCT05279729|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34054815|NCT06002529|NA|SINGLE_GROUP||OTHER||NONE||||||
34054816|NCT03747068|||COHORT||RETROSPECTIVE|||||||
34054817|NCT06624163|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34054818|NCT03917472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A masked evaluating investigator will be responsible for all aspects of the study except the injections and the safety assessment following the injections. An unmasked treating investigator was to perform the injections and assess patient safety following the injections.||t|f|t|t
34054819|NCT02872610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054820|NCT06252701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A pilot open label crossover trial||||
34054821|NCT06621303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054822|NCT02870816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054823|NCT02792114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054824|NCT05780970|||COHORT||PROSPECTIVE|||||||
34054825|NCT02196376|||CASE_ONLY||PROSPECTIVE|||||||
34054826|NCT01486472|||COHORT||PROSPECTIVE|||||||
34054827|NCT04050124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054828|NCT05820711|NA|SEQUENTIAL||TREATMENT||NONE||||||
34054829|NCT04998721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054830|NCT00996411|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34054831|NCT05684510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054832|NCT05397067|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Two types of intervention will be tested. The first is the provision of a Peer Specialist (PS), and the second is the use of vouchers (food, transportation, phone)||||
34054833|NCT02370628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054834|NCT00791661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054835|NCT04157114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|Parallel Assignment|t|t|t|t
34054836|NCT04725812|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm open label study.||||
34054837|NCT06620809|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34054838|NCT06545916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054839|NCT06353126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159328|NCT02781610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159329|NCT04573686|||COHORT||PROSPECTIVE|||||||
34159330|NCT00559247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159331|NCT02632487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34159332|NCT02481778|||COHORT||PROSPECTIVE|||||||
34159333|NCT04417153|||COHORT||PROSPECTIVE|||||||
34159334|NCT00066404||||TREATMENT||||||||
34159335|NCT04259008|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants randomized to standard trace element dose in parenteral nutrition vs. omission of manganese.|t|t|f|f
34159336|NCT01969630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159337|NCT04205734|||COHORT||CROSS_SECTIONAL|||||||
34159338|NCT01947751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159339|NCT03616509|NA|SINGLE_GROUP||TREATMENT||NONE||First phase: 2m with placebo Second phase: 12 m with growth hormone||||
34159340|NCT00988273|||CASE_CONTROL||PROSPECTIVE|||||||
34159341|NCT05280600|||COHORT||PROSPECTIVE|||||||
34159342|NCT00169156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159343|NCT04922138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159344|NCT01255319|||CASE_ONLY||PROSPECTIVE|||||||
34159345|NCT01402739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159346|NCT05412368|||OTHER||OTHER|||||||
34159347|NCT00003154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159348|NCT00202956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159349|NCT05181124|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34159350|NCT05385055|||COHORT||CROSS_SECTIONAL|||||||
34159351|NCT02843672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159352|NCT05361044|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159353|NCT04102527|||OTHER||PROSPECTIVE|||||||
34159354|NCT02091843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159355|NCT05639192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159356|NCT02519595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159357|NCT04558372|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|The person who operates breath test is blinded to the results of swab. The swab taker is blinded to the result of breath sample. The patients also do not know the results of the interpretation of the breath sample. Patients will receive information on the results of the oro/ nasopharyngeal swab in accordance with the COVID-19 health service standards. The final data processor is also blinded to the results of nose and throat swabs. The breath sampling data is saved in graphic form which interpretation will be carried out later by the data processor at the final stage.|"3 groups:~1. COVID-19 patients~2. non COVID-19 patients~3. suspected COVID-19 patients"|t|f|t|t
34159358|NCT04674657|||OTHER||PROSPECTIVE|||||||
34159359|NCT05665296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159360|NCT01237236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159361|NCT01529034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159362|NCT06289218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159363|NCT00000706||||TREATMENT||NONE||||||
34159364|NCT03833414|||COHORT||RETROSPECTIVE|||||||
34159365|NCT04787172|||CASE_ONLY||PROSPECTIVE|||||||
34159366|NCT04647097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessors of the outcomes will be blinded regarding allocation. The medical team providing the visits and treatment during hospitalization rwill not be aware of the allocation. Patients and the study nurse can not be blinded, due to the nature of the intervention.|Randomized controlled trial and a cohort study|f|f|f|t
34159367|NCT04119232|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will conduct a two-arm randomized, controlled trial comparing a control group that uses wearable devices to track physical activity to an intervention group that uses the same wearable devices and participates in a team-based model of social incentives that gamifies physical activity. Patients will be randomized to one of the two arms.||||
34159368|NCT01712204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34159369|NCT00590343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742225|NCT05201157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742226|NCT01992536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742227|NCT04181710|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33742228|NCT01789944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742229|NCT04225845|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742230|NCT01626235|||||PROSPECTIVE|||||||
33742231|NCT02376049|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33742232|NCT03265028|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33742233|NCT01774903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742234|NCT01076595|||COHORT||PROSPECTIVE|||||||
33742235|NCT06159816|||COHORT||PROSPECTIVE|||||||
33742236|NCT03977844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|"Client-level participants are unaware of which arm to which the agencies from which they have been recruited have been assigned at the community agency level randomization.~Providers are unaware of which clients have been recruited into the study, as well as to which arm the clients have been assigned at the individual level randomization for the technological mobile phone intervention.~Outcomes assessors at follow-up assessments are unaware of which arm the participants have been assigned at either the community or individual level."|Community agencies are randomized to participate in either of two intervention arms. Clients recruited at agencies in either community-level intervention arm are randomized at individual level to participate in one of two technology interventions. 2 arms at community level of randomization, 2 arms at individual level of randomization.|t|t|f|t
34159370|NCT05612334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||First, they were informed about the benefits of exercise and walking. They were also informed about the duration and type of exercise and what should be considered before, during, and after exercises. Then, an informative training booklet prepared by the researcher containing the same information was given to them. An exercise program (5 minutes warm-up-30 minutes walking-5 minutes cooling down) was demonstrated to the patient by the researcher, and then the patient performed the first exercise under the supervision of the researcher. Beginning with the second exercise, the patient performed a 40-minute exercise program, 3 days a week, for 3 months. During this period, the researcher regularly made phone calls once a week to motivate the patient and check whether the patient performed the exercise program.||||
34159371|NCT04342078|||COHORT||PROSPECTIVE|||||||
34159372|NCT06508515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33742237|NCT00432380|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742238|NCT04996784|||COHORT||PROSPECTIVE|||||||
33742239|NCT03593083|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low alitude and High altitude||||
33742240|NCT00013312|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742241|NCT02451748|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||In this study we determine whether expression of IL-7 and IL-7 receptor (R) is modulated by anti-tumor necrosis factor (TNF) treatment. For this purpose blood is obtained from RA patients prior to anti-TNF (Cimzia treatment; day 0) and after 3 months as well as 6 months of therapy. Transcription levels of IL-7 and IL-7R are examined from the peripheral blood obtained from day 0, 3 and 6 months of therapy. Results of this study will be reported in the MS in preparation.||||
33742242|NCT02736539|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742243|NCT00001402||||TREATMENT||||||||
33742244|NCT02498665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742245|NCT05156723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742246|NCT03574129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||An adolescent transition package composed of a disclosure booklet and transition tool||||
33742247|NCT02334735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742248|NCT01854554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742249|NCT00501605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159373|NCT00946543||||TREATMENT||||||||
34159374|NCT00632619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742250|NCT05522140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33742251|NCT04321837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742252|NCT06068894|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||3 arms: GOS, hGOS, or placebo, with 16 participants per arm.|t|t|t|t
33742253|NCT02755935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742254|NCT05149508|||CASE_ONLY||RETROSPECTIVE|||||||
33951153|NCT05483569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be divided into two groups using the block randomization method. Participants will be randomly distributed into 2 blocks of 15 participants. Each group using random number generation technique by computer. All evaluations will be made by the researcher who did not participate in the study.|There will be two groups in this study. Each group will consist of 15 women aged 25-65 years with Lower Extremity Lymphedema Caused by Gynecological Cancer Treatment. A total of 30 participants will take part in the study. CDP program and placebo fascial release techniques will be applied to the participants in Group 1 and, in addition to the CDP program, the participants in Group 2 will be given multidimensional diaphragmatic breathing exercises and fascial release techniques will be applied.|f|f|f|t
33951154|NCT02736734|NA|SINGLE_GROUP||||NONE||||||
33951155|NCT03194165|||COHORT||RETROSPECTIVE|||||||
33951156|NCT02469402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951157|NCT01377857|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33742255|NCT00619021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742256|NCT02983578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951158|NCT06385509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054840|NCT04504825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, randomized, multicenter international Phase 3 study.|"This is a double-blind, randomized, multicenter, international Phase 3 study of CAEL-101 combined with SoC PCD treatment versus placebo combined with SoC PCD treatment in Mayo stage IIIb PCD treatment-naïve AL amyloidosis patients.~Approximately 124 patients will be enrolled using a 2:1 randomization ratio and stratification will be based on geographic region across investigator sites.~The primary evaluation treatment period (PETP) part of the study will stop when the last patient is randomized in the PETP plus 18 months. Patients in both study intervention groups will be followed from randomization until death from any cause, heart transplant, left valve assist device (LVAD) implantation or until the end of study."|t|t|t|t
34054841|NCT04332341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054842|NCT04205409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054843|NCT03863171|||COHORT||PROSPECTIVE|||||||
34054844|NCT01945697|||CASE_CONTROL||PROSPECTIVE|||||||
34054845|NCT05888441|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34054846|NCT05330702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054847|NCT06618937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054848|NCT04603768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054849|NCT02984969|||COHORT||PROSPECTIVE|||||||
34076503|NCT02537951|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||subjects are first undergoing measurements of AFI intensities following increasing nociceptive stimulus intensities, consequently it is tested whether the AFI activity can be blocked by lidocaine/prilocaine and a 8% capsaicin patch, i.e. whether the AFI activity is specific for nociceptor-acitivity||||
34076504|NCT01806168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33742257|NCT02745379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742258|NCT01698060|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33742259|NCT02528201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742260|NCT02720146|||||PROSPECTIVE|||||||
33742261|NCT00276445|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33742262|NCT03081338|||COHORT||PROSPECTIVE|||||||
33742263|NCT06536309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742264|NCT05043077|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33742265|NCT04724811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon is masked The investigator is masked|Prospective randomised non-inferiority study|f|t|t|f
33742266|NCT05123209|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742267|NCT00148343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742268|NCT01682291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33742269|NCT00987207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742270|NCT04443218|||COHORT||OTHER|||||||
33846146|NCT03811262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"ESP block and PECS block will be executed by an anesthesiologist that will not follow the patient during the surgery.~Anesthesiologist responsible for the surgery will be not aware of the block executed on the patient Anesthesiologist and surgeon responsible for postoperative therapy will be not aware of the block executed on the patient"|"This is a single-centre, prospective; double blinded randomised interventional clinical trial.~Patients will be randomly allocated to group PECS or ESP using a closed envelope technique.~Group PECS will receive PECS II block as described by Blanco using 30 ml Levobupivacaine 0.25% Group ESP will receive ESP block as described by forero using 30 ml Levobupivacaine 0.25% at T5 level.~Blocks will be executed after general anesthesia induction. All partecipants will receive Fentanyl 2 mcg/kg and Propofol 2 mg/kg for induction. Anesthesia will be mantained with Propofol to obtain a BIS level between 40-50. Patients will receive Fentanyl 33 mcg whenever blood pressure and/or hear rate raise more than 20% from baseline after surgical stimulation. At the end of the surgery patients will receive acetominophen 1 g. postoperative therapy: acetominophen 1g/8hr and ketoprofen 100 mg/12hr.~Patients will receive 2 mg Morphine whenever a NRS \> 3."|t|t|f|t
33951159|NCT06006026|NA|SEQUENTIAL||TREATMENT||NONE||"Interventional Study Model: Sequential Assignment According to the principle of the 3+3 design, 3 dose groups with 3 patients in each dose group will be set up. If no dose limited toxicity (DLT) is observed in three groups, a total of 9 patients will be included. If DLT is present in one dose group during dose escalation, 3 cases are amplified in this dose group; if no DLT is observed in 3 cases of amplification, proceed to the next dose group, and so on, up to 18 patients. DLT is defined as local anesthetic systemic toxicity. If blood samples cannot be obtained for any reasons, new patients will be recruited until there are at least 3 patients in each group with blood samples at every time point ."||||
33951160|NCT03628534|NA|SINGLE_GROUP||TREATMENT||NONE||Thermedical SERF Ablation System and Durablate Catheter||||
34054850|NCT03699462|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"One researcher (Anesthesiologist) conducts randomized group assignment, and the researcher is not involved in other aspects of anesthesia and research.~Therefore, other researchers, and all those involved in anesthesia, surgery, and postoperative management do not know the patient's group assignment."|Groups are divided into 2 groups; those receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea), and those receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery|t|t|f|t
34054851|NCT04264390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34054852|NCT01413789|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054853|NCT05911828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054854|NCT06418477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054855|NCT04760249|||OTHER||RETROSPECTIVE|||||||
34054856|NCT04237844|||CASE_CONTROL||RETROSPECTIVE|||||||
34054857|NCT05731037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742271|NCT03007316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742272|NCT05170698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 groups one with the first intervention arthroereisis and bar excision the second with bar excision and osteotomies it may be one or multiple|t|t|t|f
33765119|NCT04930744|RANDOMIZED|PARALLEL||TREATMENT||NONE|Senior study leadership, Drs. Kornfeld, Wallis, Churchyard, Singhal will be blinded. Participants, study personnel and clinicians are not blinded.|Participants are assigned to one of two or more groups, Standard ATT or Standard ATT plus Metformin in parallel for 11 weeks starting 1 week after ATT initiation.||||
33765120|NCT04676490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This is behavioral intervention|f|f|f|t
33742273|NCT03319927|RANDOMIZED|PARALLEL||PREVENTION||NONE||This randomized control study will include 88 child care centers in four CA counties and be conducted in 9-month cycles over five years. The counties will be matched and randomized to the intervention group (integrated pest management) or attention control group (physical activity). Each study cycle will include Recruitment, Baseline Assessments, Intervention, and Post-Intervention Assessments. Baseline Assessments are completed as director interviews, child care provider surveys, research assistant objective observations using standardized Checklists, review of written policies, child anthropometrics, center dust samples to measure pesticides, and silicone wristband personal samplers worn by 5 children per center for a 7-days. During the 7-month Intervention phase, CCHCs will conduct one workshop per center on the intervention topic (IPM or physical activity) and provide seven monthly consultations per center. The Post-Intervention stage will repeat all the baseline assessments.||||
33742274|NCT00123240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742275|NCT05288998|||CASE_CONTROL||PROSPECTIVE|||||||
33742276|NCT00045994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34054858|NCT02107105|||COHORT||PROSPECTIVE|||||||
33742277|NCT03893448|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33742278|NCT02660944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742279|NCT01538745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742280|NCT05581693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742281|NCT05835726|||COHORT||OTHER|||||||
33742282|NCT06095414|||COHORT||PROSPECTIVE|||||||
33765121|NCT02255396|||||CROSS_SECTIONAL|||||||
33765122|NCT04156997|||COHORT||CROSS_SECTIONAL|||||||
33765123|NCT01822067|||CASE_CONTROL||PROSPECTIVE|||||||
34054859|NCT03070340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054860|NCT01181544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054861|NCT03806699|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Since the vials of ID93+GLA-SE and placebo control (normal saline) and their appearances after preparation are different, for double-blinding of the study, the study nurse who administers the study drug or the study pharmacist who stores and manages the study drug will be unblinded to maintain the quality of study blinding. Additionally, an unblinded study monitor will be responsible for confirming the quantity and release of the study drugs. Unblinded study personnels and unblinded study monitor should only be involved in the duties related to administration and/or recording of the study drug, and must not be involved in other duties that may break double-blinding of the study.|Participants will be assigned to one of three groups: low dose vaccine, high dose vaccine, or placebo|t|t|t|t
34054862|NCT00532194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054863|NCT06621095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054864|NCT00567489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054865|NCT01088880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054866|NCT01486901|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34054867|NCT05672017|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators, outcome assessors and analysts will be masked. It is not possible to mask participants.||f|f|t|t
34054868|NCT04662528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054869|NCT03696108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054870|NCT04497870|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34054871|NCT01868698|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34054872|NCT03287284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34054873|NCT04792593|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Single Group Assignment||||
34054874|NCT04017832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34054875|NCT04197674|||COHORT||PROSPECTIVE|||||||
34054876|NCT02234596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765124|NCT06129201|||OTHER||CROSS_SECTIONAL|||||||
33846147|NCT03986281|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34054877|NCT00401713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054878|NCT02002039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054879|NCT05108077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054880|NCT06619873|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34054881|NCT04804267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054882|NCT03409107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double-blind study. The participant, investigator, site staff, and study team will be blinded to the assigned study treatment.|Participants will be randomized to receive Daprodustat or placebo in a randomized manner.|t|f|t|f
34054883|NCT04715542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized-controlled, double-blind, multicentric superiority trial|t|t|t|t
34054884|NCT01701193|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34054885|NCT05613998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054886|NCT00797628|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34054887|NCT06321068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054888|NCT01005940|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34054889|NCT05431829|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34054890|NCT03643289|||COHORT||PROSPECTIVE|||||||
34054891|NCT01064258|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159375|NCT04207060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blinding: Study medication will be labelled indomethacin 50 mg or placebo capsule with the subject's name, hospital or clinic number, study IRB number, and subject number. Placebo and indomethacin capsules will be identical in appearance. The investigators, study coordinator, and clinical caregivers will remain blinded to subject allocation throughout the data ascertainment and data entry phase of the study.~The success of blinding will be evaluated by asking the investigator, the study coordinator, and the subject the following question during each telephone follow-up visit: Which treatment group is this subject/were you assigned to: placebo, active drug, or unsure?"|Subjects will be assigned to receive indomethacin or placebo according to a computer generated randomization list composed of randomized blocks of sizes of 2 or 4. Within each block, equal number of subjects will be assigned to indomethacin and placebo. Separate sets of blocks will be provided for Mayo Clinic and Ohio State. The randomization lists will be computer generated by the study statistician (Dr Li), and kept in a secure computer file and paper study binder in the Mayo and Ohio State Research Pharmacies. No investigators or study personnel other than Dr Li will have knowledge of the randomization list. Dr Li will not participate in any aspect of subject recruitment, subject allocation, conduct of the study, or data ascertainment, but will perform data analysis.|t|t|t|t
34159376|NCT01273324|||COHORT||PROSPECTIVE|||||||
33742283|NCT06533124|RANDOMIZED|PARALLEL||OTHER||SINGLE||Patients were randomly assigned in a 1:1 ratio, with one group receiving UF treatment alone and the other receiving UF treatment plus USCOM monitoring. The allocation of study participants was processed through an interactive web response system with a non-stratified permutated block size. Treating clinicians were unaware of patients' group assignments; there were a total of 40 patients.|f|f|t|f
33742284|NCT00186303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742285|NCT03354000|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33742286|NCT01913041|||COHORT||PROSPECTIVE|||||||
34159377|NCT00794950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159378|NCT02760641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34159379|NCT01659749|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33742287|NCT02628119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33742288|NCT04118634|||COHORT||PROSPECTIVE|||||||
33742289|NCT04765969|||CASE_ONLY||PROSPECTIVE|||||||
33742290|NCT03584594|||CASE_ONLY||PROSPECTIVE|||||||
33742291|NCT03120975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking for care providers and investigators is unfortunately not feasible. Outcome assessors and data analysts will be blinded to the study arm allocation.|Parallel group, cluster-randomized superiority trial|f|f|f|t
33742292|NCT03502343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159380|NCT03747640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159381|NCT06116006|NA|SINGLE_GROUP||OTHER||NONE||||||
34159382|NCT00571805|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34159383|NCT02452450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34159384|NCT04043039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159385|NCT01836302|||CASE_ONLY||PROSPECTIVE|||||||
34159386|NCT05879497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159387|NCT02919254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34159388|NCT01717001|||CASE_CONTROL||PROSPECTIVE|||||||
34159389|NCT00284219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159390|NCT05977062|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34159391|NCT03439930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159392|NCT02238158|||COHORT||PROSPECTIVE|||||||
34159393|NCT04301219|||OTHER||CROSS_SECTIONAL|||||||
34159394|NCT06432335|NA|SINGLE_GROUP||OTHER||NONE||||||
34159395|NCT02059603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159396|NCT01336153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159397|NCT00704860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159398|NCT05727982|||CASE_CONTROL||PROSPECTIVE|||||||
34159399|NCT03196440|||OTHER||CROSS_SECTIONAL|||||||
34159400|NCT06233006|||OTHER||CROSS_SECTIONAL|||||||
34159401|NCT05098171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159402|NCT05320172|NA|SINGLE_GROUP||TREATMENT||NONE||Fifty milliliters of whole blood will be placed in five 10-ml vacutainer tubes containing anticoagulant-citrate-dextrose solution (1.4 ml) and centrifuged at 200g for 11 min. The upper two layers of the centrifuged blood, the plasma and buffy coat layer will be separated in a sterile manner and diluted to 20 % (v/v) with a sterile saline solution. The final preparation is divided into 5-ml bottles wrapped in aluminum foil for protection from ultraviolet light. The patients are instructed to store these bottles at -20 °C until required. The bottles being used will be maintained under refrigerated conditions at 4 °C.||||
34159403|NCT02688985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159404|NCT05641415|||COHORT||PROSPECTIVE|||||||
34159405|NCT00998088|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34159406|NCT06524908|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159407|NCT01989806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742293|NCT01016795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742294|NCT02405455|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cervical pessary vs. Cervical cerclage||||
33742295|NCT04642105|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Hospital-based study: 15 patients will be selected in this study which will last 5 days.~Home-based study: 60 patients will be selected in this study which will last a maximum of 1 year."||||
33742296|NCT01991262|||COHORT||PROSPECTIVE|||||||
34054892|NCT06201975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical outcome assessor (A.A) will not be aware of which treatment will be being administered, thus yielding a single-blind controlled study.|"The experimental group will receive scaling and root debridement and locally delivered 0.5 ml non-diluted Thyme honey on sites with PPD ≥ 5 mm. Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters.~The control group will receive scaling and root debridement with normal saline irrigation on sites with PPD ≥ 5 mm."|f|f|f|t
34054893|NCT03018496|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33742297|NCT06573905|||COHORT||RETROSPECTIVE|||||||
34159408|NCT03143504|||COHORT||PROSPECTIVE|||||||
34159409|NCT01479361|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159410|NCT04471090|||CASE_ONLY||PROSPECTIVE|||||||
34159411|NCT06530732|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||RCT||||
33742298|NCT05570695|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Double-blinding will be enabled through the usage of sham conditions which comprise an identical sequence of events as the verum conditions and participant-specific numeric codes encoding the order of conditions. During each session, these codes will automatically (1) determine the predefined training conditions and (2) generate file names. Thus, the experimenter will be blinded during data acquisition as well as during subsequent preprocessing and analysis steps.|Each participant will participate in 4 experimental conditions differing with respect to the administered neurofeedback training: (1) attention right training, ARTNF; (2) attention left training, ALTNF; (3) sham attention right training, ARTsham; (4) sham attention left training, ALTsham. During neurofeedback, noxious stimuli will be applied to the dorsum of the left hand using cutaneous laser stimulation (Nd:YAP laser, Stimul 1340, DEKA M.E.L.A. srl, Calenzano, Italy; stimulation settings: 4 ms duration, 7 mm stimulus diameter, 3.5 J laser intensity) while pain ratings will be recorded.||||
34159412|NCT01481454|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742299|NCT06534073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159413|NCT04148742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742300|NCT02632578|||COHORT||PROSPECTIVE|||||||
33742301|NCT06200857|||COHORT||RETROSPECTIVE|||||||
33742302|NCT05903560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742303|NCT02200822|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33742304|NCT06208618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind|A single-center, single-blind, parallel-group, randomized controlled design|t|f|f|f
34054894|NCT02996851|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34054895|NCT05591066|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34054896|NCT02100670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054897|NCT04159415|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34159414|NCT05037019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159415|NCT05651672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159416|NCT01882699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159417|NCT01806675|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|All human subject participants were to be evaluated with both 18F-FPPRGD2 PET/CT and 18-FDG PET/CT imaging scans.|||||
34159418|NCT00330122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159419|NCT01429181|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159420|NCT06135935|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||In this double blind randomized controlled cross over design trial, patients will be randomized to receiving new KDD product or analog first. On the subsequent visit the opposite product will be provided.|t|f|f|f
34159421|NCT06393647|||CASE_ONLY||PROSPECTIVE|||||||
34159422|NCT03715244|||COHORT||PROSPECTIVE|||||||
34159423|NCT02627989|||OTHER||PROSPECTIVE|||||||
34159424|NCT05126836|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||n-of-1 design|t|t|t|t
34054898|NCT03697759|NA|SINGLE_GROUP||TREATMENT||NONE|Since there is no randomization, all participants receive the intervention. Consequently, there is no blinding.|This study is a pilot study preceding a randomized controlled trial. In the pilot study all enrolled participants are offered the intervention.||||
34054899|NCT02070731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742305|NCT05689632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants and the investigator do not know which supplements are taken.|Prospective, randomized, placebo-controlled, double-blind study|f|f|f|t
33742306|NCT05996887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33742307|NCT03050476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742308|NCT02066935|||OTHER||CROSS_SECTIONAL|||||||
34054900|NCT05503602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33742309|NCT05106582|||CASE_ONLY||RETROSPECTIVE|||||||
33742310|NCT06531746|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33742311|NCT01466816|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33742312|NCT06189287|||COHORT||PROSPECTIVE|||||||
33742313|NCT05456581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33742314|NCT00650468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742315|NCT05355389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be double-blinded: patients will not be made aware of the rationale and predictions of the study. The teleconsultations will be carried out by a trained MS nurse, while the baseline and follow-up testing and analyses are carried out by an investigator who is blinded to the treatment allocation of the patients.|Patients will be randomly assigned to either the cognitive-motor, the cognitive or the motor telerehabilitation group, stratified by baseline activity level and cognition.|t|f|t|t
33742316|NCT04592692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742317|NCT00152295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742318|NCT01762761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742319|NCT04726709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742320|NCT05178628|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized, multicenter, open-label, blinded-endpoint Phase III clinical trial||||
33742321|NCT06536179|||COHORT||OTHER|||||||
33742322|NCT03153332|||OTHER||PROSPECTIVE|||||||
33742323|NCT06292273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized, double blind case control|f|f|t|t
33742324|NCT05377320|||COHORT||PROSPECTIVE|||||||
33742325|NCT06635005|NA|SINGLE_GROUP||PREVENTION||NONE|This is a single arm study with a dietary pattern as intervention.|||||
34054901|NCT01943968|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054902|NCT00830817|||CASE_CONTROL||PROSPECTIVE|||||||
34054903|NCT03073694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34054904|NCT01907295|||COHORT||PROSPECTIVE|||||||
34054905|NCT04792840|||COHORT||PROSPECTIVE|||||||
34054906|NCT06620198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors, Patients and their caregivers will be blinded for the entire duration of the study.|Randomized Clinical Trial|t|f|f|t
34054907|NCT03596606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal evaluator will be blinded in relation to the study groups. The person responsible for taking the variables (baseline data, reassessments and data analysis) will be a therapist and a medical doctor unrelated to the recruitment and treatment. Due to the nature of the interventions, it is not possible to mask the therapist responsible for the interventions.|Both groups will be treated with Osteopathic Treatment and in one of them it will be added the intervention with cognition targeted myofunctional motor control exercises.|f|f|t|f
33742326|NCT03669003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742327|NCT04096092|||COHORT||PROSPECTIVE|||||||
33742328|NCT06019104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742329|NCT02440152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34054908|NCT06622317|||COHORT||PROSPECTIVE|||||||
34054909|NCT05759520|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742330|NCT04351152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind||t|f|t|f
33742331|NCT06535789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will complete two in-clinic meal sessions, with random assignment to receive either technosphere insulin (TI) or RAA insulin for the first meal and the other insulin for the second meal.||||
33742332|NCT00337714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742333|NCT03041415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will not be told the intervention assigned of the participating housing sites|group-randomized design to either a person-level physical activity intervention alone, or the person-level physical activity intervention plus a citizen science intervention aimed at making the local neighborhood more activity-supportive.|f|f|f|t
33742334|NCT01162265|||COHORT||PROSPECTIVE|||||||
34054910|NCT05662059|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blinded|Sham-Controlled|t|f|t|f
34054911|NCT06547424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054912|NCT03096769|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34054913|NCT02951221|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34054914|NCT02290236|||||PROSPECTIVE|||||||
33742335|NCT02281006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33742336|NCT03349710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742337|NCT03926182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742338|NCT00179088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742339|NCT03498183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All the patients will have the scintigraphie with MIBI-Tc99m/Iodine-123||||
33742340|NCT06572566|||CASE_CONTROL||PROSPECTIVE|||||||
33742341|NCT02627677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742342|NCT05039268|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742343|NCT01316367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742344|NCT02811562|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742345|NCT04135053|NA|SINGLE_GROUP||PREVENTION||NONE||A prospective dose ranging human challenge study. Nasal inoculation with reconstituted, previously lyophilised Neisseria lactamica with dose escalation / de-escalation.||||
33742346|NCT03591744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742347|NCT03635229|||COHORT||PROSPECTIVE|||||||
33742348|NCT00788554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742349|NCT01964573|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33742350|NCT05148715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742351|NCT05358145|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33742352|NCT04000451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742353|NCT01229228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742354|NCT06296940|RANDOMIZED|PARALLEL||TREATMENT||NONE||We are conducting a randomized controlled trial of approximately 50 randomized subjects (up to 100 total enrollments) who will be assigned 1:1 to treatment as usual (TAU) or TAU+WET.||||
33742355|NCT03437499|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33742356|NCT02842398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742357|NCT00339677|||OTHER||PROSPECTIVE|||||||
33742358|NCT06534190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742359|NCT05668195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The children in the group are randomly divided into a test group and a control group, and further divided into 4 groups according to whether they were also treated with medication (methylphenidate) or not. Children receiving methylphenidate are required to be titrated to a stable dose before training, and those who did not change medication, stop medication, or adjust dose during training are included in the analysis. The test group receive systematic aerobic exercise and intelligent monitoring system in executive skill training, the control group receive systematic executive skill training, for 13 weeks. The research team, together with other teams, has initially developed a set of closed-loop training and is further exploring it in training.|t|f|f|f
33742360|NCT04815603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742361|NCT06262620|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33742362|NCT02779179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742363|NCT04613128|||COHORT||PROSPECTIVE|||||||
33742364|NCT06481241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742365|NCT02596451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742366|NCT05745857|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||"Arm 1: Oral bevacizumab-800CW If oral administration is feasible the investigators will move on to arm 2, if it does not seem feasible the investigators will move on to arm 3.~Arm 2: Oral cetuximab-800CW The investigators will move on to combined oral bevacizumab-800CW/cetuximab-800CW if oral cetuximab-800CW seems feasible. If it does not seem feasible, they will administer oral bevacizumab-800CW to a control group of non-dysplastic Barrett's esophagus patients.~Arm 3 (only performed if oral administration does not work) Topical administration of bevacizumab-800CW compared to combined topical administration of bevacizumab-800CW/cetuximab-800CW. This group will be expanded if combined administration increases lesion detection. If this is not the case, the investigators will include a control group of non-dysplastic patients with Barrett's esophagus as a control group who will receive topical bevacizumab-800CW."||||
34054915|NCT05401448|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34054916|NCT05013879|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Repeated measures with two within-subjects factors: time and taped/untaped leg||||
33742367|NCT04511676|||CASE_ONLY||PROSPECTIVE|||||||
33742368|NCT02295111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742369|NCT02057055|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742370|NCT02783586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33742371|NCT05776485|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33742372|NCT02631798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742373|NCT06432127|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33742374|NCT05275777|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase Ib: A 3+3 dose escalation design will be used to determine the RP2D dose of ADG106 in combination with ddAC and paclitaxel respectively.~Phase II: ADG106 will be combined with ddAC followed by paclitaxel as neoadjuvant chemotherapy in patients with stage I-III HER2 negative breast cancer."||||
33742375|NCT00173836|||CASE_CONTROL||PROSPECTIVE|||||||
33742376|NCT06535074|||COHORT||PROSPECTIVE|||||||
33742377|NCT01301963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742378|NCT00347308|||||PROSPECTIVE|||||||
33742379|NCT01455441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742380|NCT00554866|NA|SINGLE_GROUP||||NONE||||||
33742381|NCT03110614|||COHORT||PROSPECTIVE|||||||
33742382|NCT01748435|||COHORT||PROSPECTIVE|||||||
33742383|NCT05159752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742384|NCT05635214|||COHORT||PROSPECTIVE|||||||
33742385|NCT06321718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Through website computer program randomization program to distribute cases into two groups using their order number|"96 Patients will be enrolled. Choice of type of anesthesia will be established according to every individual patient, but spinal anesthesia will be preferred over general anesthesia. The block will be administered under supervision of the supervisor senior staff before induction of anesthesia. 2 groups well be assessed~1. Group (A) will receive PENG + LFCN block~2. The second group (B): S-FICB"|t|f|f|f
33742386|NCT04393883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742387|NCT04262986|||COHORT||CROSS_SECTIONAL|||||||
33742388|NCT03216174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742389|NCT02744313|||CASE_ONLY||PROSPECTIVE|||||||
33742390|NCT01419418|||COHORT||PROSPECTIVE|||||||
33742391|NCT02303964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742392|NCT03604250|NA|SINGLE_GROUP||PREVENTION||NONE||This is a pilot trial with a single group of 14 participants: 10 with prediabetes or at least 2 of the metabolic syndrome criteria (half males, half females) 4 healthy people (do not have prediabetes nor any of the metabolic syndrome criteria) of 11 weeks (77 days) duration.||||
33742393|NCT02620553|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34054917|NCT01457586|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34054918|NCT05103904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054919|NCT03357133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
28257564|NCT05380518|||COHORT||OTHER|||||||
34054920|NCT04569422|||CASE_CONTROL||PROSPECTIVE|||||||
34054921|NCT01378377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054922|NCT00442858|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34054923|NCT04367870|||COHORT||PROSPECTIVE|||||||
34054924|NCT04842188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34054925|NCT04079257|||OTHER||PROSPECTIVE|||||||
33742394|NCT02663817|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33742395|NCT03544034|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking|A pre-post study in two hospitals. Implementation will be done at the organization level (for all 65 and older patients admitted to hospitalist service in these two hospitals.||||
33742396|NCT02243540|||COHORT||RETROSPECTIVE|||||||
33742397|NCT02235766|||CASE_ONLY||PROSPECTIVE|||||||
33742398|NCT02541253|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34054926|NCT00655148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34054927|NCT02756780|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34054928|NCT06648057|||COHORT||PROSPECTIVE|||||||
34054929|NCT02527759|||COHORT||PROSPECTIVE|||||||
34054930|NCT06461715|||OTHER||RETROSPECTIVE|||||||
34054931|NCT00522691|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34054932|NCT06623604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; classes would not be disrupted. Exercises in the program include light and moderate movements that may be performed by a healthy student between the ages of 9 and 11. Sport physicians have advised that there is no need for any health screening, as children\&amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s hearts, pulses, and muscles are not affected by light and moderate exercises. The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week. The researcher performing the exercises received education in an earlier study that included physical exercises and yoga movements. During the program, students did a total of 180 hours of physical activity.|t|f|f|f
34054933|NCT05642429|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34054934|NCT06391541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34054935|NCT06621030|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention consists of inducing different glycaemic states in people with diabetes.||||
34054936|NCT06126835|||COHORT||RETROSPECTIVE|||||||
34054937|NCT03523143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054938|NCT00922467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34054939|NCT06313086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34054940|NCT02046083|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34054941|NCT00142740|||CASE_CONTROL||PROSPECTIVE|||||||
34054942|NCT03671564|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34054943|NCT03134846|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Phase 1: 3x3 Dose-escalation with 3 different doses Cetuximab-IRDye800CW Phase 2: Prospective cross sectional diagnostic study. After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients.||||
34054944|NCT03470558|||COHORT||PROSPECTIVE|||||||
34054945|NCT05251363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742399|NCT02445820|||COHORT||RETROSPECTIVE|||||||
33742400|NCT05330663|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742401|NCT02338362|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33742402|NCT00647231|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
33742403|NCT01977118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33742404|NCT05743985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742405|NCT04781764|||OTHER||OTHER|||||||
33742406|NCT01259544|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33742407|NCT06342362|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33742408|NCT00475826|RANDOMIZED|CROSSOVER||||SINGLE||||||
33742409|NCT06288113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742410|NCT05831293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33742411|NCT00401570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742412|NCT02873923|||COHORT||RETROSPECTIVE|||||||
33742413|NCT04841343|||CASE_ONLY||PROSPECTIVE|||||||
34054946|NCT06328400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34054947|NCT05958004|||COHORT||PROSPECTIVE|||||||
34054948|NCT06209398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054949|NCT06414824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054950|NCT05225675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054951|NCT06027554|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind, placebo-controlled||t|f|t|t
34054952|NCT00786331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054953|NCT06012656|||COHORT||PROSPECTIVE|||||||
34054954|NCT06619379|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34054955|NCT01543763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054956|NCT00964938|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34054957|NCT02279745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054958|NCT05259150|RANDOMIZED|PARALLEL||PREVENTION||NONE||effectiveness implementation hybrid Type 3 design||||
34054959|NCT00251303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742414|NCT02692248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742415|NCT06158633|||COHORT||PROSPECTIVE|||||||
33742416|NCT01591746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33742417|NCT06534567|||COHORT||PROSPECTIVE|||||||
33765125|NCT03279848|||COHORT||CROSS_SECTIONAL|||||||
33765126|NCT03184896|||COHORT||PROSPECTIVE|||||||
33765127|NCT02961374|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33742418|NCT05824832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Prospective randomized single-blinded clinical trial. 1:1 Randomization with 2 groups.~Group 1: 50% of participants will receive an Interscalene brachial plexus blocks with the addition of buprenorphine, dexamethasone, and clonidine during surgery.~Group 2: 50% of participants will receive an Interscalene block alone during surgery."|t|f|f|f
33742419|NCT04638010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742420|NCT00326508||||TREATMENT||||||||
33742421|NCT05457335|||COHORT||PROSPECTIVE|||||||
33742422|NCT00533390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742423|NCT04833829|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33742424|NCT04221802|||CASE_ONLY||PROSPECTIVE|||||||
33742425|NCT01573702|NA|SINGLE_GROUP||TREATMENT||NONE||For all patients, all sites of progressive disease will be treated with local ablation (primarily stereotactic radiosurgery) followed by the EGFR-TKI erlotinib until disease progression.||||
33742426|NCT03286491|||COHORT||PROSPECTIVE|||||||
33742427|NCT00966316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742428|NCT01070875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742429|NCT02579993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742430|NCT04039516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742431|NCT05630716|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742432|NCT02835534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742433|NCT01319318|||COHORT||PROSPECTIVE|||||||
33742434|NCT03799562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized, double-blind, placebo-controlled trial. All roles will be masked with the exception of the research pharmacist.|Participants will be randomized to receive the active study medication (pregnenolone) or placebo.|t|t|t|t
33742435|NCT05582863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742436|NCT05388448|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Laboratory personnel are blinded to treatment arm|A total of 105 participants (7 groups of 15 participants receiving IP) will be enrolled, 20 in stage 1 and 85 in stage 2. Participants will be between 18 and 65 years old (inclusive), with newly diagnosed, smear or Xpert MTB/RIF-positive, rifampicin susceptible pulmonary TB.||||
33742437|NCT00618657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742438|NCT00209313|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33742439|NCT03747029|||CASE_CONTROL||RETROSPECTIVE|||||||
33742440|NCT05198232|RANDOMIZED|PARALLEL||OTHER||SINGLE|The two different tempo groups will participate in the program using separate HIPPA-compliant Zoom sessions in different rooms at the community programs. The high-tempo group will be called Group 1 and the low-tempo group will be called Group 2.|Participants will be quasi-randomized to one of three groups: control (normal activities), low-tempo Zumba®, and high-tempo Zumba®. This quasi-randomization enables the groups to be matched on relevant demographics (disability type, age, sex). This design will enable the investigators to determine the effects of Zumba® and the impact of exercise tempo.|t|f|f|f
33742441|NCT04017026|||COHORT||RETROSPECTIVE|||||||
33742442|NCT04587089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical, radiographic and microbiological evaluations will be made by an assessor who will not know to which group the participants belong.||f|f|f|t
33742443|NCT02270346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33742444|NCT00268528|||COHORT||PROSPECTIVE|||||||
33742445|NCT05586828|||COHORT||RETROSPECTIVE|||||||
33742446|NCT00194922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742447|NCT06388018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742448|NCT06151262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742449|NCT04621448|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Dyads will be enrolled and randomized in blocks of 16 (n=8 immediate start, n=8 waitlist). The randomization sequence will be generated in advance by Dr. Barnes' team using a random number generator and will be maintained in a secure location. Individuals who collect or analyze outcome data will be unaware of the randomization sequence and blinded to group assignment.|Delayed-start control group|f|f|f|t
33742450|NCT02706457|||COHORT||RETROSPECTIVE|||||||
33742451|NCT02378142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742452|NCT05812573|||CASE_ONLY||RETROSPECTIVE|||||||
33742453|NCT04532892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|During the whole study, neither the investigators nor the subjects will be aware of the product they test. Every effort will be made to maintain the blind during the study.|Monocentric, double-blind, randomized, placebo-controlled, 2-parallel arm study on outpatients|t|t|t|t
33742454|NCT06334770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742455|NCT06533618|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33742456|NCT02106338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742457|NCT01058200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742458|NCT03719066|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized to receive two doses of Shanchol oral cholera vaccine with dose intervals of either 2 weeks, 6 months or 11 months.||||
33742459|NCT03891810|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design was a randomized control trial with baseline, post-intervention (8 wks from baseline), and follow-up (12 wks from baseline) assessments. College students were randomized to either a Calm College Intervention group or a delayed response group. Participants were randomized after the completion of baseline and informed consent.||||
33742460|NCT04495712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, providers, investigators, and outcome assessors were blinded to treatment assignment. The pharmacy maintained a key to randomization that was not broken until the study was completed and all outcomes had been assessed.|This was a prospective, double-blind, randomized trial that assigned patients to receive either spironolactone 25 mg/day or a placebo.|t|t|t|t
33742461|NCT02962830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742462|NCT02669329|NA|SINGLE_GROUP||OTHER||NONE||||||
33742463|NCT02018055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742464|NCT06534658|||COHORT||PROSPECTIVE|||||||
33742465|NCT05298085|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33765128|NCT01619332||PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765129|NCT05536102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054960|NCT03376971|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34054961|NCT04810494|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34054962|NCT03360409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742466|NCT04256733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be blinded to group assignment (active treatment vs placebo).|One group will receive the placebo treatment while the second group receives the active treatment.|t|f|f|t
33742467|NCT04198779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, multicentric, randomized, controlled, open, 2 parallel arms study, in 11 centers.||||
33742468|NCT04109989|NA|SINGLE_GROUP||OTHER||NONE||||||
33742469|NCT02832895|NA|SINGLE_GROUP||OTHER||NONE||||||
33742470|NCT02952079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742471|NCT01199081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742472|NCT03900936|||COHORT||PROSPECTIVE|||||||
33742473|NCT02088996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742474|NCT00882843|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742475|NCT01468246|||COHORT||PROSPECTIVE|||||||
33742476|NCT00681317|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33742477|NCT03839238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742478|NCT04593992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33742479|NCT06121713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33742480|NCT01882634|NA|SINGLE_GROUP||SCREENING||NONE||||||
33742481|NCT01233817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742482|NCT03756558|NA|SINGLE_GROUP||TREATMENT||NONE||Performance goal||||
33742483|NCT03294447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742484|NCT03871387|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and Care Providers will be blinded.|"1. Deep group~   * Continuous rocuronium infusion during surgery~  * Maintain TOF = 0 \& PTC= 1\~2 (Deep neuromuscular block)~2. Control group~   * Continuous rocuronium infusion during surgery~  * Maintain TOF 1\~2 (Moderate neuromuscular block)"|t|t|f|f
33742485|NCT06182670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Monocentric, single blinded, randomized clinical trial, parallel design.|t|f|f|f
33742486|NCT05778045|||CASE_CROSSOVER||PROSPECTIVE|||||||
33742487|NCT04861649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742488|NCT03943368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742489|NCT05642572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742490|NCT06534359|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization procedures will be masked to initial pH-MII testing results.|||||
33742491|NCT01990443|RANDOMIZED|PARALLEL||||NONE||||||
33742492|NCT03268811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742493|NCT01267071|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742494|NCT00055328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742495|NCT02408614|||CASE_CROSSOVER||PROSPECTIVE|||||||
33742496|NCT03663114|||OTHER||PROSPECTIVE|||||||
33742497|NCT06082180|RANDOMIZED|PARALLEL||TREATMENT||NONE||test group: prophylactic central neck dissction; control group: no central neck dissection||||
33742498|NCT02680600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054963|NCT02197832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054964|NCT05002959|||COHORT||OTHER|||||||
33742499|NCT02678546|||||CROSS_SECTIONAL|||||||
33742500|NCT02943746|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33742501|NCT05124158|||COHORT||PROSPECTIVE|||||||
33742502|NCT03373591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33742503|NCT02559908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742504|NCT06391294|||OTHER||OTHER|||||||
33742505|NCT01716247|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33742506|NCT03132116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742507|NCT03826277|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742508|NCT03223818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33742509|NCT04544826|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33742510|NCT05209113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients included in the study do not know which group they will be included in.|This study was designed as a randomized controlled trial. Patient groups were determined by a biostatistician using the block randomization method. The block width is taken as 4 and seed number fixed at 123.|t|f|f|f
33742511|NCT06535724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054965|NCT05542524|||CASE_ONLY||RETROSPECTIVE|||||||
34054966|NCT04613193|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. BP-AVALVE I: 60 patients will be randomized (1:1) to either strict BP control (N=30) or conventional treatment (N=30). Treatment period will be 12 months.~2. BP-AVALVE II: 200 patients will be randomized (1:1) to either strict BP control as in study 1 (N=100) or conventional care as in study 1 (N=100). Average treatment period will be 2 (1-3) years.~3. BP-AVALVE III: Patients from BP-AVALVE-II continue in the randomized design until they develop symptoms of AS or have been followed for 10 (7-13) years. Patients will be reexamined at the end of the study period or in case they develop symptoms or LV failure and thus indication of valve replacement.~Since the medicinal products used in this study is not the subject of the trial, the Danish Medicines Agency has classified this study as a clinical trial, in which medicinal products are used as a tool to induce a well-known physiological response. Therefor no further approval from the Danish Medicine Agency is required."||||
34054967|NCT06408220|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34054968|NCT06615258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34054969|NCT01787487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054970|NCT01725932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054971|NCT02389790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054972|NCT05433909|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Biological non-pharmacological Pilot study.||||
34054973|NCT02677038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054974|NCT03991897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The staff members who perform the measurements are blinded for the allocation.|"After baseline assessment, patients will be randomized in one of the treatment groups.~Randomization is performed according to 'www.randomization.com'. This free generator randomizes each subject to a single treatment by using the method of randomly permuted blocks.~Assessments are performed by a person blinded to the treatment allocation groups.~Randomization will be stratified for baseline lymphedema volume (3-9.9%, 10.0-19.9% and ≥20%), affected limb (arm or leg) and gender (females or males). The staff members who perform the measurements are blinded for the allocation."|t|t|t|f
34054975|NCT06471946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054976|NCT04376086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34054977|NCT00743730|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34054978|NCT02197286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054979|NCT05705154|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised using block randomisation into either standard intervention arm or standard intervention plus the new co-designed intervention.||||
34054980|NCT06622564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||After CPB Tranexamic Acid + Before CPB Placebo versus Before CPB Tranexamic Acid + After CPB Placebo|t|t|t|t
34054981|NCT00752258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054982|NCT03397329|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34054983|NCT06407661|NA|SINGLE_GROUP||PREVENTION||NONE||The study was a one-group quasi-experimental study design in a pretest-posttest design.||||
34054984|NCT06647537|||OTHER||PROSPECTIVE|||||||
34054985|NCT05709353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, double-blind between group comparison of change in PTSD symptoms and alcohol consumption|t|f|t|f
34054986|NCT04606992|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot feasibility||||
34054987|NCT01791946|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34054988|NCT04238143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054989|NCT05492006|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34054990|NCT03133273|RANDOMIZED|PARALLEL||OTHER||SINGLE|The result of Oncogramme® will not give to the patient.|"Patients corresponding to the inclusion criteria and having a histologically proven metastatic CRC on biopsies or primary tumor excision and / or one or more metastatic sites will be recruited prospectively and randomized into two groups.~1. Usual care group: no Oncogramme will be made.~2. Oncogramme group: Taking of tumor fragments on the histological piece by an anatomopathological physician at the time of the histological examination and placing samples in the transport medium. The Oncogramme will be performed by Oncomedics on all specimens. Results will be returned to clinicians within 15 days.~For both groups, the adjuvant treatment will be decided in the multidisciplinary consultation meeting (MCM), according to the recommendations in force and adapted to the general medical condition of the patient. For patients in the Oncogramme group, chemotherapy will be adapted to Oncogramme."|t|f|f|f
34054991|NCT02822573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34054992|NCT06288399|||COHORT||RETROSPECTIVE|||||||
34054993|NCT03921970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will be blinded to the study|Fourty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic sleeve gastrectomy under general anesthesia will be included in this prospective randomized study. Patients with a history of bleeding diathesis, receiving anticoagulant treatment, known local anesthetics and opioid allergy, infection of the skin at the site of the needle puncture, pregnancy or lactation, and patients who do not accept the procedure will be excluded from the study. Randomization will be achieved using a randomizing computer program. Patients will be randomly divided into two groups (Group ESP = ESP group, Group C = Control group) including 20 patients each, before entering the operating room.|f|f|f|t
34054994|NCT03727152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34054995|NCT06648811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34054996|NCT06322576|NA|SINGLE_GROUP||TREATMENT||NONE||"Cohort 1of this study involves only Dosimetry for (10 patients).~(Cohort 2 may be added based on dosimetry analysis of Cohort 1. Planned Treatment for would be for 20 patients, single arm)."||||
34054997|NCT02580669|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34054998|NCT01321138|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34054999|NCT06649162|||COHORT||PROSPECTIVE|||||||
34055000|NCT06317714|||COHORT||PROSPECTIVE|||||||
34055001|NCT03148457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055002|NCT04669951|NA|SINGLE_GROUP||OTHER||NONE||The patients will be drawn from the existing clinical biobank. The biobank is located at the department of pathology, Rigshospitalet. From this clinical biobank, a new temporary research biobank will be made. Supplementary sections from formalin-fixed paraffin embedded (FFPE) blocks containing tumor tissue will be cut and Haematoxylin and eosin (HE) and immunohistochemical (IHC) staining will be performed.||||
34055003|NCT04735081|||COHORT||RETROSPECTIVE|||||||
34055004|NCT01167049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055005|NCT04873102|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II pilot study designed to assess the safety and efficacy of danazol for treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with telomere mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for a duration of 24 months. The goal will be to treat a total of 10 patients with telomere gene mutations and/or shortened telomere lengths.||||
34055006|NCT06617156|||COHORT||PROSPECTIVE|||||||
34055007|NCT06619132|||COHORT||RETROSPECTIVE|||||||
34055008|NCT03665922|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Double-blind randomized placebo controlled design|t|f|t|t
34055009|NCT01435096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055010|NCT06070857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055011|NCT06564506|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055012|NCT03928756|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34055013|NCT00614523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34055014|NCT04123106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055015|NCT06190730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Voice-Assisted Remote Symptom Monitoring System (VARSMS) will be installed on Amazon Echo Dot||||
34055016|NCT03494062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34055017|NCT03308136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"1. The subjects were randomly assigned to subcutaneous anesthesia group (group A) and muscle anesthesia group (group B), and the assigned results are unknown.~2. The Outcomes Assessor is not related to the study, and does not know its contents."|subcutaneous anesthesia group (group A) muscle anesthesia group (group B)|t|f|t|f
34055018|NCT05723328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pseudo cluster randomized controlled design (Borm et al., 2005) will take advantage of the unit's two separate residential areas||||
33742512|NCT00358046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33742513|NCT06003595|||COHORT||PROSPECTIVE|||||||
33742514|NCT01336374|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34055019|NCT04119076|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two school allocated to receive the intervention, three schools allocated to the control group||||
34055020|NCT05121051|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34055021|NCT00926172|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34055022|NCT06619041|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study staff who measure the primary outcome (weight) and conduct other outcome assessments at 6-months will remain masked to the treatment arm assignment of participants throughout the trial.|Brief, virtual, dyadic weight management intervention|f|f|f|t
34055023|NCT06618079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055024|NCT05180019|||COHORT||PROSPECTIVE|||||||
34055025|NCT05448365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be a double-clind, placebp-controlled trial|Women with uterine fibroids|t|t|t|t
34055026|NCT04530058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055027|NCT00200109|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34055028|NCT02996552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055029|NCT05469048|||COHORT||PROSPECTIVE|||||||
34055030|NCT01028638|||COHORT||PROSPECTIVE|||||||
34055031|NCT06649305|||COHORT||PROSPECTIVE|||||||
34055032|NCT01676155|||CASE_CONTROL||PROSPECTIVE|||||||
34055033|NCT03228524|RANDOMIZED|PARALLEL||TREATMENT||NONE||Recruited patients will be randomized to receive 2660 mg D-aspartate oral dosing once daily or placebo, in addition to the conventional treatment provided by the relevant staff, for a period of 6 weeks. Patients will also be undergoing a Therapeutic Exercise Program (ET). All conventional therapies taken by patients will be recorded by the operators. Patients will be divided into two D-aspartate + ET and Placebo + ET groups and will be evaluated at zero time before starting treatment (T-0W) after 6 weeks to evaluate the effects at the end of treatment (T-6W) , And at 12 weeks (T-12W) to evaluate the maintenance of long-term effects.||||
34055034|NCT04861285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be done to the assessors who analyzed dental impression to reduce bias to gingival tissue displacement assessment|Study subject (tooth) will be randomized in a 1:1:1 allocation ratio between the 3 gingival retraction techniques.|f|f|f|t
34055035|NCT01839617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055036|NCT03922737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055037|NCT05554913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055038|NCT03648437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo, 0.45 % saline, is similar to paracetamol, both being clear liquids, so the staff will remain unaware which drug the patient receives. The study drug will be kept and prepared away from the neonatal intensive care unit, at the separate ward 55 office, in a locked cabinet. The study drug will be prepared by the research nurse, the pharmacist of the ward, or during nighttime, by a nurse who does not participate in the study patients' treatment in any way.|multicenter, randomized, placebo-controlled, double-blind, clinical trial|t|t|t|f
34055039|NCT03107689|||COHORT||PROSPECTIVE|||||||
34055040|NCT06322095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055041|NCT02146755|||COHORT||RETROSPECTIVE|||||||
34055042|NCT05667974|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34055043|NCT06386068|NA|SINGLE_GROUP||TREATMENT||NONE||A replicated multiple baselines single-case experimental design with three baseline phases. Baseline randomization into three tiers.||||
34055044|NCT04513080|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|In Phase 1, participants will be masked to the incentive condition to which they are randomized but will be aware of which treatment condition they are receiving.|Phase 1 will test the effectiveness of two forms of participant retention methods into a SMART (sequential, multiple assignment, randomized). In Phase 1, participants (n=200) will be randomized to an incentive level and then randomized to treatment arms. Phase 2 (n=1000) will be the subsequent SMART design comparing message-based psychotherapy (MBP) to video-chat psychotherapy (VCP) in level 1 and for those who do not respond to care after 6 weeks, those participants will be randomized to either MBP+monthly VCP or MBP+weekly VCP.|f|f|f|t
34055045|NCT02613039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055046|NCT03868748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055047|NCT06332573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055048|NCT05623670|||COHORT||PROSPECTIVE|||||||
34055049|NCT04881032|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 : dose escalation Phase 2 : randomized||||
34055050|NCT01000220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055051|NCT05963633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055052|NCT06620744|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34055053|NCT01113645|||COHORT||PROSPECTIVE|||||||
34055054|NCT04446845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055055|NCT06400459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked|Double-masked|t|t|t|t
34055056|NCT01047826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055057|NCT05748392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055058|NCT00348790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055059|NCT01446133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055060|NCT01103453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055061|NCT00071656|RANDOMIZED|PARALLEL||TREATMENT||||||||
34055062|NCT06347900|||CASE_CONTROL||PROSPECTIVE|||||||
34159425|NCT03745521|||COHORT||PROSPECTIVE|||||||
34159426|NCT01361178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159427|NCT05021146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742515|NCT01863017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742516|NCT03049124|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742517|NCT06434961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742518|NCT01565967|||COHORT||PROSPECTIVE|||||||
33742519|NCT01491243|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33742520|NCT00443547|||COHORT||PROSPECTIVE|||||||
33765130|NCT04244435|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34055063|NCT06252142|||CASE_CONTROL||OTHER|||||||
34159428|NCT02656953|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34159429|NCT03688074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.|t|t|t|f
34159430|NCT04205721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are either in intervention or control schools (intervention schools received the new curriculum); participants did not know about this prior assignment.|Randomized cluster design whereby schools were assigned to intervention or control schools before the trial began.|t|f|f|f
34159431|NCT05769205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||females with ovarian masses||||
34159432|NCT06514404|||CASE_ONLY||PROSPECTIVE|||||||
34159433|NCT00349869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors masked to study condition|Randomized controlled trial|f|f|f|t
34159434|NCT01478724|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34159435|NCT05687162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed which condition they were assigned to or what the other conditions involve. The investigators will not interact with participants or see which condition they are in during the intervention.|"In each study, participants will be randomly assigned to complete one of three online programs, assessing DVs at baseline and 4 and 8 weeks later.~Note that studies 1-3 have 3 arms, and study 4 has 2 arms, so in total 11 arms are included in this project."|t|f|t|f
34159436|NCT00474214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34159437|NCT02397538|RANDOMIZED|CROSSOVER||||NONE||||||
34159438|NCT05422937|||COHORT||RETROSPECTIVE|||||||
34159439|NCT00289926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159440|NCT00668603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159441|NCT03582891|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Subjects with Parkinson's disease who are being implanted in the STN will be blinded to the type of stimulation received (open-loop or closed-loop phases) during the chronic adaptive DBS testing phase (period 4) at home. Each of these subjects will have blinded open-loop or closed-loop stimulation for a total of one month.~The use of objective measures of motor function such as wearable devices, in addition physician administered rating scales, is a strategy to reduce observer bias. For physician administered scales, all exams will be videotaped so that these can be reviewed by a blinded neurologist evaluator."|Investigators will run a pilot clinical trial in which individualized classifier/control strategies for each hemisphere in each subject will be embedded within the RC+S for a total of one month (x4 one week blocks) of feedback-controlled stimulation will be compared with a total of one month of empirically optimized open-loop stimulation, (x4 one week blocks), administered in randomized order with adaptive stimulation. During these 1-month trials, patients and neurologists will be blinded to the state of the stimulator.|t|f|f|t
34159442|NCT04944849|||COHORT||PROSPECTIVE|||||||
34159443|NCT04056897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742521|NCT05009849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Arm I: Yoga \& Conventional Exercises Arm II: Conventional Exercises All eligible patients will be randomly to either of the arm as mentioned above.||||
33742522|NCT05906121|||COHORT||PROSPECTIVE|||||||
33742523|NCT06454513|||COHORT||RETROSPECTIVE|||||||
33742524|NCT05881941|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||. There are 3 groups in the study. These were intervention group 1 using sound-insulated music and nebulizer with figured mask, intervention group 2 using silent nebulizer, and control group using nebulizer used in routine||||
33742525|NCT04827199|NA|SINGLE_GROUP||TREATMENT||NONE||"The subjects will be implanted with the ARTUS® medical device and then be followed up for 10 years post-implant, with the primary endpoints measured at 3-month post-device activation visit.~As there is no comparator, there is no randomization and no blinding in the study.~Clinical performance outcomes will be measured for each subject at baseline (before implantation) and post-implantation."||||
33742526|NCT06567509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In both the phases ,both groups will have different careproviders and therapists treating, so blinding is not required. But the Assessors need to be blinded.|This study will have two phases First phase(Pilot RCT study) Second phase (Randomized control trial)|f|f|f|t
33742527|NCT00172510|||DEFINED_POPULATION||OTHER|||||||
33742528|NCT01115439|||CASE_ONLY||PROSPECTIVE|||||||
33742529|NCT03047616|||COHORT||PROSPECTIVE|||||||
33742530|NCT04855734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study arm allocation will be concealed from the Research Assistant (RA) Assessor to prevent bias during the administration of outcome questionnaires, process measures, and chart abstraction.|Investigators propose a pilot, two-arm, intent-to-treat, single-blinded, single-site, controlled RCT. Family/child dyads (N=30) will be enrolled and randomized to either the FACE-Rare intervention or treatment as usual (TAU) at a 1:1 ratio.|f|f|f|t
33742531|NCT02429063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742532|NCT01916018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742533|NCT00142974|RANDOMIZED|PARALLEL||||DOUBLE||||||
33742534|NCT04480645|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study||||
33742535|NCT04695093|||COHORT||PROSPECTIVE|||||||
33742536|NCT00819182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33742537|NCT02759900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742538|NCT02073513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742539|NCT03361813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33742540|NCT00726531|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33742541|NCT01799174|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33742542|NCT02099006|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33742543|NCT06636292|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33742544|NCT02577705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765131|NCT01262443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765132|NCT00500721|NON_RANDOMIZED|PARALLEL||||NONE||||||
33765133|NCT04466215|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Parallel Assignment, Double-Blind, Randomized|t|t|t|t
33765134|NCT04963361|||OTHER||CROSS_SECTIONAL|||||||
33765135|NCT04215263|||COHORT||PROSPECTIVE|||||||
33765136|NCT05102630|||COHORT||OTHER|||||||
33765137|NCT03889613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The patients are started on vedolizumab and are prospectively followed by capsule. There is no predefined intervention that stems from diagnostic observations||||
33742545|NCT06164912|RANDOMIZED|PARALLEL||OTHER||DOUBLE|One research assistant will carry out the TMS neurofeedback or pseudofeedback on the patient, the other will conduct the functional tests on the patient so as to not bias the scoring of the functional tests.|Participants will undergo transcranial magnetic stimulation (TMS) neurofeedback (NF) incorporated into a computer game that is tailored to train the individuals to produce larger than baseline motor evoked potentials (MEPs) in the stroke affected limb, by practising and engaging different mental imagery strategies. Pulses of TMS will be applied over the motor cortex of the stroke affected hemisphere, resulting in MEPs that will be recorded from the target muscles of the stroke affected limb.The brain computer interface (BCI) will process the amplitude of these MEPs in real-time, and will display this information on screen to the patient in the form of a game, where their goal is to push a rectangular bar (MEP amplitude) over the line (baseline amplitude when resting).|t|f|t|f
33742546|NCT00389324|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055064|NCT02656290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742547|NCT04388293|||COHORT||PROSPECTIVE|||||||
33742548|NCT02983955|NA|SINGLE_GROUP||||NONE||||||
33742549|NCT01359553|||CASE_ONLY||CROSS_SECTIONAL|||||||
33742550|NCT01405391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742551|NCT04044729|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33742552|NCT06425120|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742553|NCT06386666|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742554|NCT04757649|NA|SINGLE_GROUP||PREVENTION||NONE||A broad recruitment strategy will be used to recruit participants within the greater San Diego. Potential participants will be requested to contact study personnel via email or telephone. A trained member of the study team will contact each potential participant to explain the study, obtain verbal consent for pre-enrollment screening, and conduct the screening process. For those who meet screening criteria, a trained member of the study team will provide more information about the study and engage in an informed consent process at an in-person appointment. Following informed consent, participants will complete self-report questionnaires and clinician-based interviews in person. At baseline and 3-month follow-up, participants will be asked to complete measures of suicidal coping and thwarted belongingness. At the 3-month follow-up, satisfaction with mental health services and satisfaction with interpersonal relationship with patient navigator will be assessed.||||
33742555|NCT02340039|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33742556|NCT06115759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will not be actively informed on their study arm, but will receive conventional or interventional rehabilitation instructions, and might be able to deduct their allocation arm.~The researcher will be blinded for intervention or control group allocation."||t|f|f|t
33742557|NCT05970029|RANDOMIZED|PARALLEL||OTHER||DOUBLE|At the time of analgesic request the nurse will open an envelop in which the participant assignment will be described. While the nurse (the communicator) is not blinded, the participants are blinded. The pain intensity reports will be recoded by the participants via a secured link, hence the participants are also the outcome assessor.|Parallel design - subjects are allocated into one of two study arms|t|f|f|t
33742558|NCT00463450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33742559|NCT02060890|||OTHER||PROSPECTIVE|||||||
33742560|NCT02290665|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33742561|NCT01198600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055065|NCT01614782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055066|NCT03845361|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34055067|NCT02589249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34055068|NCT06573372|||OTHER||CROSS_SECTIONAL|||||||
34055069|NCT02712762|||COHORT||CROSS_SECTIONAL|||||||
34055070|NCT01891162|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055071|NCT05831696|NA|SINGLE_GROUP||OTHER||NONE||Participants will be their own control||||
34055072|NCT00782184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055073|NCT03207542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055074|NCT05445232|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34055075|NCT06482723|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34055076|NCT01686191|||COHORT||RETROSPECTIVE|||||||
34055077|NCT03479359|||COHORT||PROSPECTIVE|||||||
34055078|NCT04448132|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34055079|NCT00045370||||TREATMENT||||||||
34055080|NCT05845567|NA|SINGLE_GROUP||TREATMENT||NONE|The study was conducted as open label. Blinding procedures were not applicable.|||||
34055081|NCT06393257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into one of the two groups. No cross-over of the study group will be made||||
34055082|NCT01128218|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34055083|NCT02879656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34055084|NCT00015444|||COHORT||OTHER|||||||
33742562|NCT01389219|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33742563|NCT06045624|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33742564|NCT03575130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742565|NCT03067441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742566|NCT02842060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33742567|NCT04725331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055085|NCT06560229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34055086|NCT05045027|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"AIM 1: Previous scan data from healthy subjects is collected and analyzed. AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.~AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection."||||
34055087|NCT06163742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055088|NCT01070667|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34055089|NCT01795625|||COHORT||PROSPECTIVE|||||||
34055090|NCT06623812|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34055091|NCT04737395|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
34055092|NCT04676958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34055093|NCT06041308|||COHORT||RETROSPECTIVE|||||||
34159444|NCT06242301|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33846148|NCT04517149|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In Phase 1, up to 2 dose exploration cohorts will be enrolled; each cohort will initially recruit up to 3 patients to receive a single uniocular IVT injection of 4D-125 in a standard 3+3 design. The cohort will be expanded in the event of a dose limiting toxicity (DLT). Any cohort may be expanded by an additional 3 subjects (to a maximum of 12 patients) to provide additional safety information and/or to confirm the selected dose for expansion. Once the dose level has been selected, the Phase 2 Dose Expansion Cohort will be opened to dose an additional 6-12 adult patients, and includes a pediatric sub-population of up to 6 patients. For adult participants only, the contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent.||||
33846149|NCT04050176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants assigned to Blinded Taper group will not know rate of tapering. Outcomes assessor will be blinded.|Two groups: Blinded and Unblinded.|t|t|t|t
33846150|NCT00301587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846151|NCT00833287|||CASE_ONLY||PROSPECTIVE|||||||
33846152|NCT04100876|||CASE_CONTROL||RETROSPECTIVE|||||||
33846153|NCT05970952|||COHORT||PROSPECTIVE|||||||
33846154|NCT02141022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846155|NCT01010659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846156|NCT01865175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846157|NCT06599606|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846158|NCT04705701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33846159|NCT01691170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846160|NCT00568412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846161|NCT04836403|||CASE_CONTROL||PROSPECTIVE|||||||
33846162|NCT06397300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients will be randomly assigned into two equal comparable groups using computer- generated random numbers in opaque closed envelopes, each of which will include 30 patients. Randomization will be done by statistician and each group of the patient will revealed only when the included patient is transferred to preanesthetic room.|"To determine the analgesic effect of US Bilateral Erector Spinae Plane Block, US Bilateral Quadratus Lumborum Block and Lumbar Epidural for Postoperative Analgesia in Patients Undergoing Total Abdominal Hysterectomy regarding the following:~1. Post-operative opioid (morphine) consumption in the 1st 24 hours~2. Postoperative Numeric Pain Rating Scale. 3. Effect on hemodynamics: Mean arterial blood pressure and Heart rate. 4. Intraoperative fentanyl consumption. 5. Duration of analgesic effect"|t|f|t|f
33846163|NCT05170438|NA|SINGLE_GROUP||TREATMENT||NONE||"1.Safety run-in phase: 3-6 cases Traditional 3+3 design is applied for the determination of initial lenvatinib dose.2 Extension phase:3.~The estimated number of patients in current trial is calculated with Simon's minimax two-stage analysis"||||
33846164|NCT00126802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951161|NCT06239207|RANDOMIZED|PARALLEL||TREATMENT||NONE||A parallel study is a type of clinical study in which two or more groups of participants receive different interventions. Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial. Assignment to a group usually is randomized. Study participants are only exposed to the treatment that is assigned to the particular study arm they are enrolled in. So in this study the patients are randomized into two groups by paper lottery method. After regional nerve block under aseptic conditions, Group A patients are injected exosomes intradermally at a strength of 2 to 10 billion particles/5ml, at a dose of 0.1 ml/cm2 of scalp, and group B patients are injected PRP intradermally in scalp||||
33951162|NCT02784028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055094|NCT06018558|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"The following team members will be masked:~Bio-Statistician, Data Programmer, Imaging Reading Center Team, Head of Clinical Development and Medical Affairs."|"Study will be conducted in 2 phases:~Phase 1 will be 3+3 design will be used for sequential dose-escalation cohorts in which subjects will receive a single subretinal injection of OCU410 in the study eye.~Phase 2 will be a dose-expansion phase of the study, where the subjects will be randomized in 1:1:1"|f|f|f|t
34055095|NCT06090409|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055096|NCT01232881|||||PROSPECTIVE|||||||
34055097|NCT06622447|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 14-week of durantion, which includes 2-weeks run-in period and 12 weeks intervention period (βGluCnCs or placebo group)||||
34055098|NCT04993508|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34055099|NCT05370586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"andomised-controlled trial with two parallel study groups. Participants will be randomised 1:1 to the study or control group. The study group will be treated with PENG block following randomisation, whereas the control group will receive the standard treatment, i.e., fascia iliaca block.~The study aims to demonstrate the superiority of the new intervention over the standard approach."|t|t|f|f
34055100|NCT05566717|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076505|NCT06444334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both the participants as in group 1 or control laser device is off (not active)while in group 2 laser device is active. Outcome Assessor is blinded as the cases is coded and unknown for the Assessor|22 implants were divided randomly into 2 groups. Group1: control group (no laser irradiation), group2: diode laser irradiation group|t|f|f|t
34076506|NCT04624815|||CASE_ONLY||PROSPECTIVE|||||||
34076507|NCT04961164|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34076508|NCT02026765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076509|NCT01219439|||OTHER||PROSPECTIVE|||||||
34159445|NCT01772732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159446|NCT04187846|||CASE_ONLY||PROSPECTIVE|||||||
34159447|NCT02268825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159448|NCT05055817|||COHORT||PROSPECTIVE|||||||
34159449|NCT04188093|||OTHER||PROSPECTIVE|||||||
34159450|NCT05536570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients who have neck pain and arm paresthesia following a side-on collision||||
34159451|NCT06448624|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double blind randomized controlled trial|t|t|t|t
34159452|NCT06400953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159453|NCT01431781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742568|NCT01786356|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33742569|NCT04660357|||COHORT||CROSS_SECTIONAL|||||||
33742570|NCT04157244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Wait-list controlled design||||
33742571|NCT00359112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33742572|NCT04408469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33742573|NCT03359096|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Washout Period 1 (Study Week 1): The patient will not use Hypoglossal Nerve Stimulation (HGNS) for 1 week. Randomization Visit (Study Week 2): The patient will be randomized to sub-therapeutic HGNS (sham) or therapeutic HGNS (treatment) for 28 days. Sympathetic and Vascular testing (Study Week 6). Washout Period 2 (Study Week 6-7): The patient will not use HGNS for 7 days. The patient will be switched to the other intervention arm (treatment to sham vs. sham to treatment) for 28 days. Sympathetic and Vascular testing (Study Week 11).|t|f|t|t
33742574|NCT02574923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742575|NCT06494111|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742576|NCT01034085|||||OTHER|||||||
33742577|NCT01391377|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33742578|NCT05902715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742579|NCT06151249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Chemotherapy+Meritup Chemotherapy+Placebo|An add-on study design to assess the superiority of Meritup over placebo will be utilized in this study to evaluate whether Meritup can decrease fatigue in patients with fatigue. The study will be conducted as a double-blind, randomized trial.|t|f|f|f
33742580|NCT04376541|||COHORT||PROSPECTIVE|||||||
33742581|NCT02249572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study investigator masked to whether patient has had radiosurgery og no active treatment. Scars due to radiosurgery frame hidden With surgical cap at all study consultations in all pts. Radiologist measuring tumor size masked as to treatment|Block randomization of 100 individuals to radiosurgery or expectative treatment of vestibular schwannoma.|f|f|t|t
33846165|NCT04972942|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1: 3 dose levels to determine safety. Followed by dose expansion cohort.||||
33846166|NCT04127851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Multicenter, Randomized, Single-blind Study for Evaluating the Efficacy of HA 0.15% Compared with Cyclosporine 0.05% in Moderate to Severe Dry Eye Syndrome|f|f|f|t
33846167|NCT01994837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846168|NCT04569201|||COHORT||PROSPECTIVE|||||||
33846169|NCT00285870|||||PROSPECTIVE|||||||
33846170|NCT05487196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is designed as a randomized, quadruple blinded, parallel arm, controlled, non-inferiority trial in 3 groups allocated in a 1:1:1 ratio|t|t|t|t
33846171|NCT01788839|||COHORT||PROSPECTIVE|||||||
34055101|NCT05685134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will occur during the electrophysiology procedure, and its automatic computerized process will ensure allocation concealment. The study protocol, for obvious reasons, precludes masking the principal investigator (electrophysiology specialist). Participants randomized to the control group will undergo a sham procedure consisting of femoral venous punctions, catheter insertion, programmed electrical stimulation and electroanatomic mapping, with a similar duration to the ablation procedure. Medical follow-up will be standardized with the same protocol for both treatment groups. All medical documents will be unidentified before being evaluated. Outcome raters and statisticians will also be blinded.|Prospective, single-centre, randomized, sham-controlled, and masked pilot study with two parallel arms, with a 1:1 allocation ratio to ablation or control group.|t|f|f|t
34055102|NCT06620471|||COHORT||PROSPECTIVE|||||||
34055103|NCT05367271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055104|NCT01500187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055105|NCT02720679|||COHORT||PROSPECTIVE|||||||
34055106|NCT02289781|||COHORT||PROSPECTIVE|||||||
34055107|NCT02289508|||COHORT||PROSPECTIVE|||||||
34055108|NCT06324071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34055109|NCT05969223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055110|NCT00109681|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34055111|NCT05068778|||CASE_ONLY||PROSPECTIVE|||||||
34055112|NCT04270864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab.||||
34055113|NCT05959096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34159454|NCT03521141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to participant arm assignment until delivery of lab results at month 6.|Assessing parallel precision care interventions (groups 1, 2) and control group.|f|f|f|t
34159455|NCT00848783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159456|NCT02879825|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33742582|NCT02827149|||COHORT||OTHER|||||||
33742583|NCT03607383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055114|NCT01531530|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055115|NCT02643849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055116|NCT02247596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055117|NCT02370589|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34055118|NCT06364215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055119|NCT05363072|||OTHER||RETROSPECTIVE|||||||
34055120|NCT06621940|RANDOMIZED|PARALLEL||OTHER||SINGLE|The content of the diet will be given to the participants without specifying it.|It consists of two parallel groups receiving a high-protein diet and a normal-protein diet.|t|f|f|f
34055121|NCT04018456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants/ outcome assessor will be blinded||t|f|f|t
34055122|NCT05299931|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055123|NCT01909518|||COHORT||RETROSPECTIVE|||||||
34055124|NCT02153671|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055125|NCT01123603|||CASE_CONTROL||PROSPECTIVE|||||||
34055126|NCT05970588|RANDOMIZED|PARALLEL||OTHER||SINGLE|The control group will receive no intervention and will be inherently not blinded to their group allocation. All analyses will be completed by an individual blinded to participants' group allocation.|A block randomization strategy will be implemented to ensure equal allocations to intervention/control groups in groups of 6 (3 per group). Even and odd numerals will represent designation to the Intervention and Control groups, respectively. For example, if the first 3 participants are randomized to the control group, the next 3 will be allocated to the intervention group. To ensure all control participants will be offered the intervention after their control period, the first 3 participants for the final block of 6 (block 7) will be randomized to the control group first. Randomization will occur after Visit 1 assessments are complete.|f|f|f|t
34055127|NCT06620991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055128|NCT00026442||||TREATMENT||||||||
34055129|NCT06350318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055130|NCT06602427|||COHORT||PROSPECTIVE|||||||
34055131|NCT04441684|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34055132|NCT04216589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055133|NCT05540158|||COHORT||PROSPECTIVE|||||||
34055134|NCT00070382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055135|NCT05176483|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation followed by expansion phase with parallel assignment.||||
34055136|NCT00382590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055137|NCT06039371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055138|NCT05797415|||COHORT||PROSPECTIVE|||||||
34055139|NCT04725058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055140|NCT05867797|||CASE_ONLY||PROSPECTIVE|||||||
34055141|NCT01521156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34055142|NCT01652430|||COHORT||CROSS_SECTIONAL|||||||
34055143|NCT00864825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055144|NCT06473597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055145|NCT00875199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055146|NCT03130673|||CASE_ONLY||RETROSPECTIVE|||||||
34055147|NCT03249597|||COHORT||PROSPECTIVE|||||||
34055148|NCT06255522|NA|SINGLE_GROUP||OTHER||NONE||||||
34055149|NCT01495611|||CASE_ONLY||PROSPECTIVE|||||||
34055150|NCT06522282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742584|NCT03927885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159457|NCT00767819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742585|NCT03827629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742586|NCT00720954|RANDOMIZED|||DIAGNOSTIC||||||||
33742587|NCT00786357|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34055151|NCT06431399|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055152|NCT04725318|||COHORT||PROSPECTIVE|||||||
34055153|NCT04616573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055154|NCT02078895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055155|NCT05803070|||COHORT||PROSPECTIVE|||||||
34055156|NCT06423963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055157|NCT00302484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055158|NCT06320015|||CASE_CONTROL||PROSPECTIVE|||||||
34055159|NCT03632629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055160|NCT05989711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-blind, Placebo-controlled|t|t|t|t
34055161|NCT03003039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055162|NCT04353167|||COHORT||PROSPECTIVE|||||||
34055163|NCT05587829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055164|NCT06623825|||COHORT||PROSPECTIVE|||||||
34055165|NCT04184362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055166|NCT06347861|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34055167|NCT02573766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34055168|NCT05201534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055169|NCT02530411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055170|NCT06622603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055171|NCT03221426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study||t|t|t|t
34055172|NCT05784974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055173|NCT06621563|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34159458|NCT03812315|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator and the participants will not be blinded to the treatment type as each group has to be given different instruction according to their treatment protocol. However, the statistician and the microbiologist will be blinded to the treatment group.|The study is a two parallel arms randomized controlled clinical trial where 60 high caries risk children of 6-8 years will be selected from outpatient clinic of Pediatric Dentistry and Dental Public Health Department, Faculty of Dentistry, Alexandria University, after securing the necessary consents. The children will be divided randomly into two equal groups (30 children each)|f|f|f|t
34159459|NCT00757055|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159460|NCT05344586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055174|NCT02077530|||COHORT||PROSPECTIVE|||||||
34159461|NCT04327726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be aware of their group assignment, and the medications will be prepared by an anesthetist who is not involved in the study. The anesthetist who will assess the participants after the intervention is blinded to the group allocation and single experienced operator who is unaware of patient group and study purpose will perform all Trans-Cranial Doppler (TCD) measurements.||t|f|t|t
34159462|NCT05313087|||COHORT||PROSPECTIVE|||||||
34055175|NCT06053398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055176|NCT04284930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055177|NCT02402023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34055178|NCT06620497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055179|NCT05629234|NA|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
34055180|NCT02179606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055181|NCT03343717|RANDOMIZED|PARALLEL||OTHER||TRIPLE||randomized clinical trial|t|t|t|f
34055182|NCT04648982|||CASE_ONLY||RETROSPECTIVE|||||||
34055183|NCT01878812|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055184|NCT00559624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055185|NCT06419686|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34055186|NCT03326349|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34055187|NCT06141616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34055188|NCT01513109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055189|NCT06564519|NA|SINGLE_GROUP||OTHER||NONE||||||
34055190|NCT00110227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055191|NCT02968433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055192|NCT03824132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055193|NCT03832790|||COHORT||PROSPECTIVE|||||||
34055194|NCT00995046|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34055195|NCT06597617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055196|NCT03452046|||COHORT||PROSPECTIVE|||||||
34055197|NCT04116827|||CASE_ONLY||PROSPECTIVE|||||||
34055198|NCT04990323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159463|NCT01957202|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34159464|NCT01138488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159465|NCT06407245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159466|NCT06303596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The evaluator who collects the data is blinded to the allocation of groups.||f|f|f|t
34159467|NCT02813239|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34159468|NCT02843841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159469|NCT05992363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159470|NCT04872543|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II trial to evaluate the efficacy of ASTX727 in patients with PRC2-loss MPNST.||||
34159471|NCT02586727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159472|NCT03962075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159473|NCT06148883|RANDOMIZED|PARALLEL||TREATMENT||NONE|open labelled clinical study|This is a randomized in 2 parallel group study||||
33742588|NCT06461858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33742589|NCT04906018|||COHORT||PROSPECTIVE|||||||
33742590|NCT01286779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055199|NCT06596460|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single centre, prospective, interventional study in 40 patients undergoing TAVI in a National Health Service (NHS) hospital||||
33742591|NCT01601587|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055200|NCT06648564|||CASE_CONTROL||PROSPECTIVE|||||||
34055201|NCT01570270|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34055202|NCT05889585|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055203|NCT04654754|RANDOMIZED|CROSSOVER||OTHER||SINGLE|the device utilized in the study will be labeled as 1,2,3,4 and 5, the investigator who performed the statistical analysis will be blinded for the device|five oxygen and humidification different devices will be used for the enrolled patients, with 5 minutes each. Aerosol particle concentrations at 1 foot away from the patients will be measured.|f|f|f|t
34055204|NCT03300869|||OTHER||RETROSPECTIVE|||||||
34055205|NCT02144480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055206|NCT06623708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055207|NCT04064242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be assigned to one of two treatment arms, either CMK389 or placebo.|t|t|t|t
34055208|NCT05356533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055209|NCT04424212|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated to either control or intervention group. Participants in the control group will receive the same treatment once the intervention group has finished the treatment.||||
34055210|NCT05340933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055211|NCT03140072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33951163|NCT06499272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||ontrol Group (CG), which received their usual sessions of conventional occupational therapy, and an Experimental Group (EG), which received therapy with NeuronUP, plus their conventional occupational therapy sessions.|t|f|f|t
33951164|NCT03288428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind||t|t|t|f
33951165|NCT03556254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951166|NCT05597930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951167|NCT00626067|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33951168|NCT00519909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33951169|NCT00761969|||COHORT||PROSPECTIVE|||||||
33951170|NCT06038669|||COHORT||PROSPECTIVE|||||||
33951171|NCT06318494|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951172|NCT01639625|NA|SINGLE_GROUP||||NONE||||||
33951173|NCT00718627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951174|NCT03717220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951175|NCT06538389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33951176|NCT06377462|||COHORT||PROSPECTIVE|||||||
33951177|NCT01403636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951178|NCT00685074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951179|NCT02866721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951180|NCT05660135|||OTHER||PROSPECTIVE|||||||
33951181|NCT02616107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33951182|NCT02160184|NA|SINGLE_GROUP||TREATMENT||||||||
33951183|NCT00381680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951184|NCT04828980|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33951185|NCT06126185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951186|NCT00739830|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951187|NCT05242900|||CASE_ONLY||PROSPECTIVE|||||||
33951188|NCT01211158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951189|NCT03754595|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel groups: 2DLaparoscopic pancreatoduodenectomy and 3DLaparoscopic pancreatoduodenectomy||||
33951190|NCT01757795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055212|NCT02218736|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34055213|NCT01654653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055214|NCT01803503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055215|NCT01254318|||COHORT||RETROSPECTIVE|||||||
34055216|NCT06620666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For masking the participants, the investigators will not inform participants of what group they will be in. For outcome assessor, data collectors and data analysts independent people will be use, and if this is not possible, a random code will be created for each participant so that it is not possible to identify which group belongs to.|This is a randomized, duoble-blind (sport scientiest assistance/care assistance-outcome assessor), 12 arms prospective parallel design clinical trial. The older adults will be recruited from the researchers setting and will be randomized in a prospective clinical trial study with a 12 parallel arms study design to a resistance training modalities performed at different intensities or a control groups over a 12-16 weeks period.|f|t|f|t
34055217|NCT04722367|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34055218|NCT02686866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055219|NCT05026905|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055220|NCT03185715|NA|SINGLE_GROUP||OTHER||NONE||||||
34055221|NCT06247384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055222|NCT00000161|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34055223|NCT02331550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055224|NCT04822194|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Participants will be randomized to either the Distancing or Reinterpretation group."||||
34055225|NCT06066723|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055226|NCT06623747|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34159474|NCT01060319|||COHORT||PROSPECTIVE|||||||
34159475|NCT04057846|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-center, open-label, randomized, superiority trial||||
34159476|NCT03369249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951191|NCT02743182|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951192|NCT04647448|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33951193|NCT05136482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951194|NCT06484816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951195|NCT04420559|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33951196|NCT04383652|||COHORT||PROSPECTIVE|||||||
33951197|NCT06592924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951198|NCT01898390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055227|NCT06618742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055228|NCT06157164|||OTHER||PROSPECTIVE|||||||
34055229|NCT06620965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There are two groups: the Mulligan group, which applies Mulligan mobilization techniques, and the PNF group, which applies PNF techniques.|t|f|f|f
34055230|NCT00047970|||||PROSPECTIVE|||||||
34055231|NCT00455559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055232|NCT05398952|||CASE_CONTROL||PROSPECTIVE|||||||
34055233|NCT00604942|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34055234|NCT04453072|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055235|NCT01170026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159477|NCT05036317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both subjects and investigators will be blinded.|1:1 randomized, placebo-controlled, parallel-group double-blind superiority trial|t|f|t|f
34159478|NCT01421953|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34159479|NCT06426329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159480|NCT06078852|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159481|NCT03079089|NA|SINGLE_GROUP||OTHER||NONE||Patients with refractory or relaps lymphoid hematological disorders||||
34159482|NCT02601833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846172|NCT01386762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846173|NCT06172387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846174|NCT04014595|||COHORT||PROSPECTIVE|||||||
34055236|NCT05460221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055237|NCT02389569|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34055238|NCT01472653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055239|NCT00539162|NA|SINGLE_GROUP||SCREENING||NONE||||||
34055240|NCT06506045|||COHORT||PROSPECTIVE|||||||
33742592|NCT00844454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742593|NCT00813930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33742594|NCT00871559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742595|NCT04414982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33742596|NCT03636152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Double Blind Placebo Controlled Study|t|t|t|t
33742597|NCT03190382|NA|SINGLE_GROUP||OTHER||NONE||||||
33742598|NCT05773417|||COHORT||PROSPECTIVE|||||||
33742599|NCT00383435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742600|NCT05831098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The result of the Reveal TP (Syphilis) Antibody Test will not be revealed to the participant.|||||
33742601|NCT00139750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33742602|NCT05746039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742603|NCT04421144|NA|SINGLE_GROUP||TREATMENT||NONE||case series||||
33742604|NCT00668460|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742605|NCT04169841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742606|NCT05860036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742607|NCT01681693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742608|NCT01663493|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33742609|NCT02063789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742610|NCT02055352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742611|NCT05205135|||OTHER||CROSS_SECTIONAL|||||||
33742612|NCT03491735|||CASE_ONLY||PROSPECTIVE|||||||
33742613|NCT01053858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742614|NCT02553330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742615|NCT04461522|||COHORT||PROSPECTIVE|||||||
33742616|NCT03219944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742617|NCT00171587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742618|NCT01621750|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33742619|NCT01185574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742620|NCT02909634|||COHORT||PROSPECTIVE|||||||
33742621|NCT04491500|||OTHER||PROSPECTIVE|||||||
33742622|NCT00298428|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742623|NCT02197923|||CASE_CONTROL||PROSPECTIVE|||||||
33742624|NCT04558346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742625|NCT05622981|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single arm, non-blinded, non-randomized, behavioral intervention with no comparator arms.||||
33742626|NCT01332305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742627|NCT00374530|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33742628|NCT01086072|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33742629|NCT04634357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742630|NCT00462384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742631|NCT00253864|||COHORT||PROSPECTIVE|||||||
33742632|NCT05676411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33742633|NCT03039413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742634|NCT06389812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742635|NCT03783169|||CASE_CONTROL||PROSPECTIVE|||||||
33742636|NCT00221936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742637|NCT01226745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742638|NCT04239989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742639|NCT05569395|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33742640|NCT05205772|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will be blinded as to which site is being stimulated, experimental site or control site.||t|f|f|f
33742641|NCT01385059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742642|NCT01519206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742643|NCT04720417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742644|NCT03758898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The patients were randomised using randomisation software and divided into two groups each comprising 74 patients. Chest physiotherapy and mobilisation was applied to the patients in the first group, and only mobilisation was applied to the patients in the second group.|f|f|t|f
33742645|NCT02215317|||COHORT||PROSPECTIVE|||||||
33742646|NCT06006182|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Double blinded|The crossover design can differentiate the diet treatment effect from other effects like secular trends and differential carryover, utilizes a perfect control (the experimental subject is the same person as the control), the subjects will experience all treatments (best for subject retention), and this study design does not require very many participants to provide adequate study power. The alpha is set at 0.05, and the power at 80%. Based on the calculations, the required number of participants in order to see a difference is 22. However, since a crossover study assumes a \>20% dropout rate, the minimum of 20% is added to the minimum sample size of 22 at an alpha of 0.05 and a power of 80 (14). Therefore, we will be recruiting 30 adults. Since a parallel design would require 58 per treatment group (total=116), it was determined by the PIs that the crossover design was the best design for this study.|t|f|f|f
33742647|NCT05117645|||COHORT||PROSPECTIVE|||||||
33742648|NCT01316822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742649|NCT01870700|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33742650|NCT02546544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742651|NCT06632041|||COHORT||PROSPECTIVE|||||||
33742652|NCT03889717|RANDOMIZED|PARALLEL||TREATMENT||NONE||after randomization ,two different groups of premature neonates are enrolled in the study baseline calcium,phosphorus and alp and vitamin D withdrawn at the 1st 48 hrs, then neonates started to administer vitamin D drops after they reached 100 cc per kg per day until they complete 40th week gestational age .follow up labs will be done at this age to determine which dose is better in vitamin d deficiency prevention||||
33742653|NCT02357836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742654|NCT04825457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33742655|NCT02687152|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33742656|NCT04805970|||OTHER||PROSPECTIVE|||||||
33742657|NCT00788840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742658|NCT03999606|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33742659|NCT03789422|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind|Multicentric controlled randomized crossover study, double-blind|t|f|t|f
33742660|NCT04824547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742661|NCT02376907|||COHORT||RETROSPECTIVE|||||||
33742662|NCT02752997|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33742663|NCT00002980||||TREATMENT||||||||
33742664|NCT05505708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742665|NCT03571295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33742666|NCT06275646|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control trial||||
33742667|NCT02332031|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33742668|NCT00693992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055241|NCT05462054|||CASE_ONLY||PROSPECTIVE|||||||
34055242|NCT02063945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055243|NCT02347891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055244|NCT01056991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34055245|NCT06169137|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34055246|NCT02276053|||COHORT||PROSPECTIVE|||||||
34055247|NCT06610045|||COHORT||CROSS_SECTIONAL|||||||
34055248|NCT06570343|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34055249|NCT00174967|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34055250|NCT01460654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055251|NCT04779580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055252|NCT01689246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055253|NCT05681468|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial (3-parallel arm study).||||
34055254|NCT00525811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34055255|NCT04306744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double-blind, randomized, sham-controlled pilot study|t|f|f|t
34055256|NCT01491685|||CASE_CONTROL||PROSPECTIVE|||||||
34055257|NCT04852679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742669|NCT03564496|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants (N=60) (20 Healthy Controls and 40 participants with neurological disorders, ie. multiple sclerosis) will be recruited to complete self-report measures and a brief cognitive assessment and then undergo an hour long stand-alone MRI scan while simultaneously undergoing tDCS stimulation.|t|f|f|f
33742670|NCT00388687|||DEFINED_POPULATION||PROSPECTIVE|||||||
33742671|NCT04344067|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to either the control group or the treatment (far infrared therapy) group||||
33742672|NCT02067247|NA|SINGLE_GROUP||SCREENING||NONE||||||
33742673|NCT00112073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055258|NCT02855359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055259|NCT04402996|||OTHER||CROSS_SECTIONAL|||||||
34055260|NCT00177281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055261|NCT02642003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055262|NCT06144606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055263|NCT02409745|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34055264|NCT04931485|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors will be blinded to the treatment allocation.|Patients will be randomized to receive either fluid resuscitation/de-resuscitation according to the REDUCE protocol or standard of care.|f|f|f|t
34055265|NCT06272136|NA|SINGLE_GROUP||OTHER||NONE||||||
34055266|NCT01158040|||COHORT|||||||||
34055267|NCT04032106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are not aware of the research questions being tested in the trial.||t|f|f|f
34055268|NCT06420492|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study in which everyone will receive active treatment.||||
34055269|NCT04926103|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label study with all UC patients receiving FMT.||||
34055270|NCT04967547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055271|NCT04318522|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33742674|NCT01281930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33742675|NCT01194674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742676|NCT00591292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742677|NCT04346758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742678|NCT05093517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the study drug or placebo randomization.|A randomized 2-arm placebo controlled trial|t|f|f|f
33742679|NCT03961594|NA|SINGLE_GROUP||OTHER||NONE||"Inclusions will be based on the formal preliminary indication of a volume expansion test to avoid over inclusions and side effects of an undesired volume expansion.~The collection of data is done in daily practice, relies on routine care and does not require additional devices"||||
33742680|NCT06576063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be collected using individual study codes for participants. Study codes do not reveal which group the participant has belonged to.|Randomized clinical study on a medical device.|f|f|f|t
33742681|NCT03161834|||OTHER||PROSPECTIVE|||||||
33742682|NCT01005589|||COHORT||RETROSPECTIVE|||||||
33846175|NCT00002248||||TREATMENT||DOUBLE||||||
33846176|NCT05374200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed envelopes||t|f|f|f
33846177|NCT00833768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846178|NCT04183036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33846179|NCT05448105|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33846180|NCT03819790|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into either of two arms by an interactive system in a 1:1 ratio. Randomization will be stratified based on the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors.||||
33846181|NCT02939963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846182|NCT04563208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|t|f|f
33846183|NCT03210922|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The anesthetic induction and nasotracheal induction are performed by one anesthesiologist. Another anesthesiology calculated the intubation time according to the video recording.|The patients are randomized into one of the two group: the collar group or the non-collar group before anesthetic induction. In the collar group, the patient was put on a Miami cervical collar and then anesthetic induction and nasotracheal intubation are performed. the non-collar group receive the same anesthetic care without a collar as a control.|f|f|f|t
33846184|NCT06397326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Two groups:~Experimental: Return to work coordinator + PRATICAdr 2.0 Control group: Return to work coordinator only"|f|f|t|t
33846185|NCT01603901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951199|NCT03433482|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity and immunogenicity) will all be unaware of which vaccine was administered. To do so, vaccine preparation and administration will be done by authorized medical personnel who will not participate in any of the study clinical evaluations.||t|t|t|t
33951200|NCT05669378|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Partial masking as the outcome assessors will not deliver intervention.|To test the efficacy of ATP+, we will conduct a randomized control trial with 52 facilities - where 26 facilities will be randomized to receive the intervention and while the remaining facilities will receive the standard of care as a waitlist control group and will receive the intervention at 3-month post randomization.|f|f|f|t
33951201|NCT00482664|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33951202|NCT05893524|||COHORT||PROSPECTIVE|||||||
33951203|NCT01420770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951204|NCT04071925|||COHORT||PROSPECTIVE|||||||
33951205|NCT01966458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951206|NCT00795886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159483|NCT03977103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159484|NCT01318837|NON_RANDOMIZED|PARALLEL||||NONE||||||
34159485|NCT00252408|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159486|NCT05348200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be randomized in one of the 5 Treatment Groups in a 1:1:1:1:1 ratio.|t|t|t|f
34159487|NCT01038167|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34159488|NCT02546492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159489|NCT05705557|||CASE_ONLY||PROSPECTIVE|||||||
34159490|NCT06237400|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34159491|NCT02669212|NA|SINGLE_GROUP||SCREENING||NONE||||||
34159492|NCT04413097|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Once consent is obtained and the research staff is notified of a subject's impending birth, our research team member will open a randomization card and set the oxygen blender on the special bed to either an FiO2 of .30 or 1.0 and cover the blender. The research team member will not be involved in the clinical care for the infant and will blind the clinical care team from the randomized assignment.||t|t|t|t
34159493|NCT06294392|RANDOMIZED|PARALLEL||PREVENTION||NONE||Informal kinship caregivers will be randomly assigned to receive the KEEP-CK program either immediately or after waiting 10 months using a randomized blocked design. Blocking factors include: (a) the length of time that the child has been living in informal kinship care (\<=6 months, 7 months to \<2 years, or \>=2 years); (b) child age (4 to 12 years, or 13+ years); and (c) low (or not low) resource families, defined by an annual household income below (or above) 150% of the federal poverty level.||||
34159494|NCT05413720|NA|SINGLE_GROUP||OTHER||NONE||||||
34159495|NCT02017925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159496|NCT06271395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159497|NCT01356706|||COHORT||PROSPECTIVE|||||||
34159498|NCT00994422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742683|NCT02391402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742684|NCT01028209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159499|NCT02430883|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34159500|NCT01403493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159501|NCT01009008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159502|NCT00344500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159503|NCT05542654|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|f|f|t|f
34159504|NCT06085781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742685|NCT02362880|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33742686|NCT05479318|||COHORT||RETROSPECTIVE|||||||
33951207|NCT01530776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951208|NCT00938015|||COHORT||RETROSPECTIVE|||||||
33742687|NCT03443466|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|Parallel Assignment||||
33742688|NCT05266690|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Individual coding|Monocentric, controlled, randomized, double-blind, complete 4x4 cross-over clinical trial|t|t|t|t
33742689|NCT05216172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This is a double blind placebo study: both the patient and the study team will be blinded to the treatment intervention.~Pharmacy staff who dispense the study medication will not be blinded, nor will Sponsor Office staff responsible for reporting unblinded SUSAR reports to the MHRA."|Single site, placebo controlled, double blind randomised clinical trial|t|t|t|t
33742690|NCT00884481|||COHORT||PROSPECTIVE|||||||
33951209|NCT00939861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742691|NCT00444158|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33742692|NCT00965523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742693|NCT04857359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742694|NCT02800707|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33742695|NCT01365000|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742696|NCT06272734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951210|NCT01711736|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742697|NCT05511987|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33742698|NCT05976620|||COHORT||PROSPECTIVE|||||||
33951211|NCT01735695|||CASE_ONLY||PROSPECTIVE|||||||
33742699|NCT02824276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33742700|NCT05413876|||COHORT||CROSS_SECTIONAL|||||||
33742701|NCT02009176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951212|NCT02826005|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33951213|NCT00403962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33951214|NCT01740297|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1b was an open-label, multicenter single-arm part of the study to evaluate safety of talimogene laherparepvec in combination with ipilimumab.~Phase 2 was an open-label multicenter, randomized design to further assess safety and to evaluate efficacy of talimogene laherparepvec in combination with ipilimumab."||||
33951215|NCT03788317|||CASE_ONLY||PROSPECTIVE|||||||
33951216|NCT02513732|||COHORT||RETROSPECTIVE|||||||
33951217|NCT00478218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951218|NCT01441622|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33951219|NCT01510340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951220|NCT04020822|NA|SINGLE_GROUP||OTHER||NONE||||||
33742702|NCT06063629|RANDOMIZED|PARALLEL||PREVENTION||NONE||Minimization randomization||||
33742703|NCT03865212|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742704|NCT00001101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33742705|NCT05056103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742706|NCT00003498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742707|NCT04121728|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|"Investigational Medicinal Product (IMP), e.g Placebo and Ginkgo Biloba, is located and dispensed by Central Pharmacy.~Only pharmacists are not blinded but they are neither involved in the conduct of the study not the analysis of the results"|randomized double-blind crossover design|t|t|t|t
33742708|NCT04913857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||To implement a SMART Program to promote cognitive health among patients with MCI, and the use of active mind strategy in preventing dementia among the older adults||||
33742709|NCT06634732|||COHORT||PROSPECTIVE|||||||
33742710|NCT01637753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951221|NCT01278823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951222|NCT03417245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951223|NCT02008487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33951224|NCT06649656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951225|NCT04456621|NA|SINGLE_GROUP||TREATMENT||NONE||Proton beam radiotherapy : 5 fractions of 12 GyRBE or 10 fractions of 7 GyRBE||||
33951226|NCT06286995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A) Sequence generation: was done using random sequence number generated by computer software B) Allocation concealment Mechanism:folded,numbered papers were placed in tightly sealed envelopes containing patients' coding|This study was designed to be randomized,single- blinded, single-center clinical trial|f|f|t|t
33951227|NCT05821023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will be randomly assigned to one of six study groups||t|f|f|f
33951228|NCT06651008|||CASE_ONLY||RETROSPECTIVE|||||||
33951229|NCT03563404|||COHORT||PROSPECTIVE|||||||
33951230|NCT04387812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076510|NCT03074877|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076511|NCT06312384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|each patient will be couded and only the princeiple investigator is the only person how know the type of intervantion|"Group 1 \[Control group\]:~The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane will be applied \[conventional GTR\].~Group 2 \[Study group\]:~The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane will be applied, in this group 3D surgical template will be applied."|f|f|f|t
34076512|NCT03193047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076513|NCT05909020|||OTHER||PROSPECTIVE|||||||
34076514|NCT03539978|||OTHER||PROSPECTIVE|||||||
34076515|NCT04494269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076516|NCT03555487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055272|NCT05285995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All patients were screened by researchers for eligibility and then enrolled in the study if eligible and if they provided consent. We divided the subjects into three groups, animation group, music group and control group. According to the 1:1:1 balance of three groups, the statistician set the block length to 3, and carried out a random design of the single-blind block group. According to the sequence of the children entering the study, each group of 3 persons was randomly divided into 3 subjects in each block according to the random number table. The blind copy shall be kept by the personnel of the unit who have nothing to do with the experiment. The randomization plan will be saved by the statistician, and the researcher only has the number of each subject. After opening the envelope according to the number, they know whether the subject is the control group or the intervention group. Investigators involved in the intervention were not involved in the analysis of the study data.|"In the music group, on the basis of the routine preoperative care, the preferred music was selected from the music library as the intervention content on the day of surgery according to the preference of the children in the 1-day preoperative visit. If there was no preference, the music was played randomly. The children in animation group also chose their favorite cartoons as the intervention content on the basis of preoperative care. During the intervention period, the children in intervention group were also accompanied by a nurse, who was also responsible for the implementation and maintenance of the intervention program.~The control group received routine care, which included routine preoperative visits and psychological comfort to the children."|t|f|f|t
34055273|NCT06614465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846186|NCT05922059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A receptionist will inform the treating therapist about the patient's allocation later after the baseline measurements are performed.~An independent, a physiotherapist (assessor) from the Department of Physiotherapy (with \> 10 years of clinical experience in physiotherapy) who is blinded to the allocation (treatment group) of the patients will collect the demographic data and baseline outcome measurements. Then, the assessor will leave the room to remain blind to conditions. At the same time, the treating physiotherapist, the main researcher, (with \> 10 years of clinical experience in musculoskeletal physiotherapy) will apply the treatment protocol according to the patient's allocated group. The treating therapist will be blind to the outcome measurements until the patients end their role in the study. Patients will be asked not to discuss their treatment experience with the assessor."|Group A (transcutaneous vagus nerve stimulation + standard-care physiotherapy), Group B (HRV-BF + standard-care physiotherapy), or Group C (standard-care physiotherapy alone).|t|f|f|t
33846187|NCT01276379|NA|SINGLE_GROUP||SCREENING||NONE||||||
33846188|NCT00329173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846189|NCT01140295|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34055274|NCT06649253|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34055275|NCT06076304|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34055276|NCT01891565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34055277|NCT05293873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055278|NCT05743101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055279|NCT02089958|||COHORT||PROSPECTIVE|||||||
34055280|NCT04503213|||CASE_ONLY||PROSPECTIVE|||||||
34055281|NCT01946893|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34055282|NCT00003134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055283|NCT02899559|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34055284|NCT03598920|||COHORT||PROSPECTIVE|||||||
34055285|NCT00209963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34055286|NCT05172973|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055287|NCT01943851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055288|NCT05050734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055289|NCT02662764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055290|NCT06483815|||OTHER||RETROSPECTIVE|||||||
34055291|NCT05599984|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055292|NCT04756154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34055293|NCT06316193|||OTHER||CROSS_SECTIONAL|||||||
34055294|NCT03348475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055295|NCT00725647|||COHORT||PROSPECTIVE|||||||
34055296|NCT06648538|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this study, it is impossible for participants to be blinded, as they know whether or not the Phonix Care tool is configured on their screens. However, we measure our primary and secondary judgment criteria at the first measurement time, before assigning subjects to one of the two groups. At the first stage, measurements are therefore collected blind to the conditions. In addition, the data analyses are carried out blind to the groups.|"For each participant:~15 days of pre-intervention monitoring for Control group and Experimental Group~Affectation in each group:~Control group: 5 months of monitoring Experimental group: 5 months of therapeutic educational app (Phonix Care) 15 days of post-intervention monitoring for Control group and Experimental Group"|f|f|t|f
34055297|NCT05740683|||CASE_CONTROL||PROSPECTIVE|||||||
34055298|NCT06621888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055299|NCT06115044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055300|NCT05774795|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055301|NCT06267976|||COHORT||PROSPECTIVE|||||||
34055302|NCT03442478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055303|NCT04562077|||CASE_CONTROL||PROSPECTIVE|||||||
34055304|NCT02928783|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34055305|NCT02826668|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34055306|NCT06466590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will perform 4 exercises in virtual reality with HMD (Head Mounted Display). Then, they will use the VRSQ-F instrument under study on 2 times separated by 15 minutes. The primary objective is to assess the reliability and validity of this instrument through repeated measures and comparison to SSQ||||
34055307|NCT01937091|||CASE_CONTROL||RETROSPECTIVE|||||||
34055308|NCT02648477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076517|NCT00929838|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33742711|NCT05917730|||CASE_CONTROL||PROSPECTIVE|||||||
33742712|NCT01201525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33742713|NCT00038493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742714|NCT02343341|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33846190|NCT06206187|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33846191|NCT00601159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846192|NCT03492749|||CASE_ONLY||PROSPECTIVE|||||||
33846193|NCT04450017|||CASE_ONLY||RETROSPECTIVE|||||||
33846194|NCT00652327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846195|NCT01342341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33951231|NCT05709392|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Comparison of a cohort of premature infants born in gestational week 30+0 till 34+6 taken care of at birth in the traditional way and another cohort of infants taken care of with a new method. The study will be prospective and the control group will be enrolled first before and the active group after the new method has been introduced.||||
33846196|NCT02342431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846197|NCT04670718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951232|NCT00659945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33951233|NCT01171794|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33951234|NCT01223261|||COHORT||PROSPECTIVE|||||||
34055309|NCT03896529|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Behavioral (Psychological stress manipulation). Between-subjects design. Participants will be assigned to either a stress-manipulated or control (no stress induced) group.||||
34055310|NCT03575299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055311|NCT01335074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055312|NCT02588651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055313|NCT00245297|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34055314|NCT06614998|||CASE_ONLY||PROSPECTIVE|||||||
33951235|NCT03821519|NA|SINGLE_GROUP||TREATMENT||NONE||Patients relapse after haplo-HSCT for hematologic malignancies||||
33951236|NCT01761461|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33951237|NCT00576667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951238|NCT05499104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951239|NCT03188250|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951240|NCT02841332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951241|NCT00483717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951242|NCT04270331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A before-after study||||
33951243|NCT00909857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33951244|NCT01166126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742715|NCT04703881|NA|SINGLE_GROUP||OTHER||NONE||||||
33742716|NCT05034692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742717|NCT00059657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33742718|NCT04474184|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33742719|NCT05970393|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742720|NCT03854344|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Only subjects in first phase will be blinded to their randomization group. Study subject number will be linked to their randomization group. Blinding may be broken if the subject experiences an adverse reaction to the medication utilized for their group so that they are aware that they cannot receive the medication in the future.|Phase 1 -randomized pre-operatively to receive either lidocaine or liposomal bupivicaine Phase 2- all enrolled into regional nerve block group|t|f|f|f
33765138|NCT01734434|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33765139|NCT04903223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single center, open-label, prospective, investigation to quantify the effects hepatocellular fat has on hepatic statin transport (SA1) and response (SA2) in children and adolescents.||||
33765140|NCT01635075|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33765141|NCT01129635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951245|NCT00003104||||TREATMENT||NONE||||||
33951246|NCT04941014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|Assignment|t|f|f|f
33951247|NCT05649865|||COHORT||PROSPECTIVE|||||||
34055315|NCT05580978|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34055316|NCT05670236|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Arm 1: Clinically defined unilateral symptomatic knee osteoarthritis;~Arm 2: Healthy Controls"||||
34055317|NCT01508052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33765142|NCT00891306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846198|NCT00351312|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33846199|NCT03951506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846200|NCT03189940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846201|NCT05103371|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055318|NCT05218356|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|the study is a double-blind study: neither the participants nor the investigators will be aware of arm allocation of each study participant. Blindness is important to avoid bias. Monitoring and reporting of the success of blindness are important for the reader's confidence of the trial results. Groups should be marked by capital letter and blindness should maintain throughout the study.|This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate COVID-19 symptoms. COVID-19 symptoms (fever, cough, myalgia and changes in smell or taste) onset must be within 7 days prior enrolment.|t|t|t|t
34055319|NCT04480476|||CASE_ONLY||RETROSPECTIVE|||||||
34055320|NCT02068781|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34055321|NCT02829723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951248|NCT04746495|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"* Lab results will be reviewed by an un-blinded co-investigator.~* Dose adjustments will be done by an un-blinded co-investigator who is licensed to prescribe the study drug.~* The study blind will be broken on completion of the clinical study."||t|f|t|f
33951249|NCT00978120|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951250|NCT04869618|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742721|NCT05054023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Randomization was performed centrally according to a computer-generated random list performed by a blinded study investigator who was not involved in any other part of the trial.~All protocol treatments were administered in opaque tube with identical appearances and were numbered according to the randomization sequence by an independent nurse who was not involved in monitoring or follow-up of the subjects.~the outcome assessor was also blinded to the treatment allocation."|"The Soulagel was supplied in 50 ml tubes that contained rosemary essential oil (Romarinus offienalus), mint essential oil, clove essential oil (Eugenda caryophyllus), harpgophytum natural extract (Harpagophytum procumbens), meadowsweet natural extract (Filipendula ulmaria), aqua, methyl salicylate, menthol, camphre, carbomer, triethanolamine, polysorbate-20, sodium polyacrylate, trideceth-6, methylchloroisothiazolinone, methylisothiazolinone , magnesim Chloride and magnesium nitrater (Soulagel®; Belpharma Tunisia). Piroxicam gel was supplied in 50g tubes that contained 0.5% piroxicam.~Study treatments were applied on the injured site3 times per day for 7 days. The gel must be gently rubbed on the skin over the injured site for 2 minutes."|t|t|f|t
33742722|NCT05195411|||COHORT||RETROSPECTIVE|||||||
33742723|NCT00824681|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33742724|NCT02256501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33742725|NCT03855722|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742726|NCT03585647|||COHORT||PROSPECTIVE|||||||
33742727|NCT01049906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33742728|NCT05146791|||COHORT||RETROSPECTIVE|||||||
33742729|NCT02919852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742730|NCT03647514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742731|NCT01605045|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742732|NCT05816421|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742733|NCT06077006|||CASE_CONTROL||PROSPECTIVE|||||||
33742734|NCT04762745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742735|NCT01255111|||COHORT||PROSPECTIVE|||||||
33742736|NCT05471934|||COHORT||PROSPECTIVE|||||||
33742737|NCT03890341|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765143|NCT05819814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33765144|NCT05208853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846202|NCT04999618|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, clinicians and the research team, completing baseline and follow-up assessments were masked to group allocation.||t|f|t|t
33846203|NCT03090139|||COHORT||RETROSPECTIVE|||||||
33846204|NCT02153073|||COHORT||PROSPECTIVE|||||||
33846205|NCT02137889|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846206|NCT02019303|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33846207|NCT01637805|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33846208|NCT02850510|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846209|NCT04023773|NA|SINGLE_GROUP||TREATMENT||NONE||Eighteen extended criteria donor livers will be transplanted after receiving sequential hypothermic and normothermic machine perfusion preservation prior to transplantation.||||
33846210|NCT04900571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846211|NCT06363071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846212|NCT04916093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33846213|NCT04212637|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846214|NCT05645341|||COHORT||PROSPECTIVE|||||||
33846215|NCT02391753|||COHORT||PROSPECTIVE|||||||
33846216|NCT00310934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33765145|NCT00529919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33765146|NCT01222221||||TREATMENT||NONE||||||
33742738|NCT03331120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A pilot double-blind randomized controlled trial, 24 patients will be randomized into two groups (study and control) using random number generator. The both groups will receive conventional treatment consisting of moist hot pack, soft tissue mobilization, manual therapy, therapeutic exercise. Additionally, the study group will receive ambulatory mirror image functional re-training through wearing 3D adjustable CTPCO.|f|f|t|t
33742739|NCT06300021|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Monocentric, randomized, cross-over, open-label, pharmacokinetic study||||
33742740|NCT00548821|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742741|NCT03032120|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742742|NCT01506739|RANDOMIZED|CROSSOVER||||NONE||||||
33742743|NCT03466580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A stepped wedge cluster randomized controlled trial. All clusters (i.e., specialized palliative care (SPC) units) will start as controls and will change to intervention at various times determined by randomization. In this way, all SPC units will contribute to control and intervention groups, thus accounting for variation between SPC units.||||
33765147|NCT03806647|||COHORT||RETROSPECTIVE|||||||
33765148|NCT04591535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765149|NCT01083641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765150|NCT02462850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951251|NCT02010671|||CASE_ONLY||CROSS_SECTIONAL|||||||
34055322|NCT00528060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055323|NCT02062944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055324|NCT02714088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055325|NCT02368379|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055326|NCT03053063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34055327|NCT05098210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055328|NCT01673412|NA|SINGLE_GROUP||||NONE||||||
34055329|NCT03568682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055330|NCT03962790|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34055331|NCT00731562|RANDOMIZED|CROSSOVER||||NONE||||||
34055332|NCT06619600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055333|NCT02952131|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055334|NCT01084200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34055335|NCT05209048|||CASE_CONTROL||RETROSPECTIVE|||||||
34055336|NCT06068829|||COHORT||RETROSPECTIVE|||||||
34055337|NCT02071862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055338|NCT05031650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055339|NCT01259895|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34055340|NCT03633422|||COHORT||OTHER|||||||
34055341|NCT06481891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055342|NCT01992653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055343|NCT04497376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055344|NCT05581641|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|observer-blinded trial||t|t|t|f
34055345|NCT04289207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055346|NCT04531254|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055347|NCT04086212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross-over, controlled, open label.||||
34055348|NCT00493662|RANDOMIZED|CROSSOVER||||SINGLE||||||
34055349|NCT04413552|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"Part I: Double-blind;~Part II: Open-label"|"Part I - sequential escalating dose cohorts; within each dose cohort participants will be randomized to INDV-2000 or matching placebo in a 3:1 ratio.~Part II - single cohort crossover study in which participants will receive INDV-2000 on 2 occasions separated by a 1-week washout period, once under fasting conditions and once after a standard high-fat breakfast."|t|f|t|t
34055350|NCT00271011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055351|NCT02777970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055352|NCT00793624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34055353|NCT03322774|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34055354|NCT06534255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055355|NCT05525442|||COHORT||RETROSPECTIVE|||||||
34055356|NCT03093649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055357|NCT02428049|||CASE_ONLY||PROSPECTIVE|||||||
34055358|NCT03048695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055359|NCT03911661|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055360|NCT05136339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34055361|NCT01077739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055362|NCT02589236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055363|NCT06646159|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055364|NCT01328106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055365|NCT06329687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055366|NCT00006398|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076518|NCT00320242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076519|NCT04658797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055367|NCT03886779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The study is investigator-masked to treatment group assignment for the duration of the study.~Should the masking need to be broken, the study staff may reveal the treatment to the Investigator. The date, time, and reason for the unmasking must be documented as soon as"|This is a single center, randomized, investigator masked, parallel group, and active-comparator controlled study to evaluate the clinical outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% for the treatment of ocular inflammation associated with cataract surgery|f|f|t|f
34159505|NCT00704288|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159506|NCT04603118|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients who applied to the neurology clinics and were diagnosed with IIH were included in the study. The control group consisted of 22 individuals who applied with other complaints than headaches. ONSD was measured from both eyes before and after the LP. After pre-LP measurements were taken, opening and closing cerebrospinal fluid pressure was measured. In the control group, ONSD was measured with optic USG.||||
34159507|NCT04406025|||COHORT||CROSS_SECTIONAL|||||||
34159508|NCT04720677|||COHORT||PROSPECTIVE|||||||
34159509|NCT04584437|NA|SINGLE_GROUP||TREATMENT||NONE||"Prevention: The use of infrared sauna weekly will prevent COVID-19 infections. High doses of Vitamin C daily and supplements prevent Covid-19 infections. Drinking at least 4 litres of Vital Water daily will enhance ones health and prevent Covid-19 infections..~Treatment: Infrared radiation for 60 minutes or the use of higher doses of Vitamin C as supplement."||||
34159510|NCT02647424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159511|NCT03492541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159512|NCT05209373|RANDOMIZED|PARALLEL||PREVENTION||NONE|"A third-party with no involvement in intervention delivery or data analysis will use a random numbers list generated by the IBM Statistical Package for the Social Sciences (SPSS) 28© (statistical software) to allocate participants to the two intervention conditions. The random number list will not be accessible to research staff involved in recruitment and intervention delivery. The results of allocation will not be revealed until participants begin the intervention sessions in their respective conditions.~Complete blinding of facilitators and participants is not possible; facilitators and participants will know if they are in the individual or group condition but will be blind to participants' pre-intervention self-compassion score."|||||
34159513|NCT00004932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159514|NCT04035239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055368|NCT02468154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055369|NCT03809468|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34076520|NCT00040599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159515|NCT00411255||CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34159516|NCT00413790|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34159517|NCT03875742|RANDOMIZED|CROSSOVER||OTHER||NONE||"70 anesthesia residents with low experience in interfascial blocks ( less than 15 interfascial blocks)will be asked to execute a Trasversus Abdominis Plane Block on Trasversus Abdominis Plane Block Ultrasound Training Model (BluePhantom) two times and they will be randomized in two groups.~First group will execute the first Trasversus Abdominis Plane Block using UltraPlex 360(Braun) and the second Trasversus Abdominis Plane Block using STIMUPLEX D SH, 30°(Braun).~Second group will execute the first Trasversus Abdominis Plane Block using STIMUPLEX D SH, 30°(Braun) and the second Trasversus Abdominis Plane Block using Ultraplex(Braun)."||||
34159518|NCT05542758|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive the 12-week high-intensity intervention.||||
34159519|NCT01807299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33742744|NCT05369234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Cohort 1-Lip,oral cavity, hard palate, tongue, tonsil, pharyngeal, laryngeal, neck cancers receiving chemotherapy and radiation therapy will be randomized to receiving either aloe vera juice + standard of care treatments or standard of care treatments.~Cohort 2--Esophageal, mediastinal, chest wall cancers receiving chemotherapy and radiation will be randomized to receiving aloe vera juice + standard of care treatments or standard of care treatments."||||
33742745|NCT05550246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and outcome assessors will be blinded to physiological predicted responder status|||||
33742746|NCT01785589|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33742747|NCT02194621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742748|NCT02981394|||CASE_ONLY||PROSPECTIVE|||||||
33742749|NCT03006406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33742750|NCT02683538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742751|NCT01772992|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33742752|NCT00438516|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33742753|NCT00875953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742754|NCT05123248|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants randomized to both the non-blinded continous glucose monitoring sensors and the blinded continous glucose monitoring sensors.||||
33742755|NCT02331134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33742756|NCT03832946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a double-blind study. The blinding will be maintained throughout the study.|"All subjects eligible for the study will be randomised into one of the two treatment arms:~A. GB0139 3 mg once a day B. Placebo once a day"|t|t|t|t
33846217|NCT03636425|||OTHER||CROSS_SECTIONAL|||||||
33846218|NCT03022253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951252|NCT05932979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will be assigned by simple randomization using a table of random numbers to the pharmacological intervention groups.~The study treatment and treatment assignment codes will be kept in custody by someone outside the research team. In addition, it will be in charge of the delivery, reception and meticulous counting of the capsules to guarantee the blindness and adherence to the treatment by the patients.~This study is considered double-blind since both the principal investigator and the patient are unaware of the pharmacological intervention to which the patients will be assigned. Blinding will be possible thanks to the homologation of the drug and the placebo in both groups with capsules identical in shape, size and colour. In the same way, the medicine will be delivered in bottles of the same size, shape and color, identified only with the allocation code.~The blind may be broken in the presence of serious adverse events."|Randomized, double-blind clinical trial with a placebo control group.|t|f|t|f
33951253|NCT04096716|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33951254|NCT02322866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951255|NCT04634565|NA|SINGLE_GROUP||OTHER||NONE||||||
33951256|NCT00118872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951257|NCT06174792|||COHORT||PROSPECTIVE|||||||
33951258|NCT04649437|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33951259|NCT04478773|NA|SINGLE_GROUP||SCREENING||NONE||||||
33742757|NCT06331221|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33742758|NCT01734512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742759|NCT00444548|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33742760|NCT00931177|||COHORT||PROSPECTIVE|||||||
33742761|NCT03365765|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study has one Intervention Type of Drug.||||
33742762|NCT01290367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33742763|NCT05947448|||COHORT||PROSPECTIVE|||||||
33951260|NCT04818866|||COHORT||PROSPECTIVE|||||||
33951261|NCT02469558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951262|NCT00931866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742764|NCT00931021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742765|NCT03351023|||COHORT||PROSPECTIVE|||||||
33742766|NCT03129893|||OTHER||PROSPECTIVE|||||||
33742767|NCT01098448|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33742768|NCT04120506|NA|SINGLE_GROUP||TREATMENT||NONE||Objective: To show non-inferiority of rapid (defined as 10') intravenous (IV) infusion versus standard IV infusion rate (60') of VPRIV with regard to safety, pharmacokinetic(PK) profile, and efficacy in patients who have been receiving VPRIV for a minimum of 3 months at a constant dosage.||||
33742769|NCT00381394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742770|NCT04091399|NA|SINGLE_GROUP||TREATMENT||NONE||"1. Collection personal data of patients suffered from alveolar osteotis~2. Patient cohort selection according inclusion and exlusion criteria~3. Extraction wound examination and characteriyation of a dry socket~4. Treatment of alveolar osteoitis using a tested drug~5. Extraction wound healing process and its evaluation~6. Data analysis"||||
33742771|NCT06478927|NA|SINGLE_GROUP||TREATMENT||NONE||Palbociclib Capsules||||
33742772|NCT01646476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951263|NCT02246244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951264|NCT00493935|||||PROSPECTIVE|||||||
33951265|NCT03830073|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33951266|NCT02711514|||CASE_ONLY||PROSPECTIVE|||||||
33951267|NCT03418025|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742773|NCT01627392|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33742774|NCT04937569|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742775|NCT06536062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742776|NCT02370654|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33742777|NCT05168774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951268|NCT01312948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742778|NCT02133846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742779|NCT05658861|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34159520|NCT01427426|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34159521|NCT04084509|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34159522|NCT04954924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159523|NCT01901627|||COHORT||PROSPECTIVE|||||||
33742780|NCT05869812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sponsor- investigator, Dr. Ashley Herda, will provide the participants with the investigational product or placebo in identical, yet coded product containers and the product manufacturer, MTI BioTech, Inc., will retain the blind code until completion of the study.|This study will be conducted in a randomized, double-blind, placebo-controlled clinical trial where practitioners and participants will be blinded to the supplementation treatment (experimental product versus placebo control)|t|f|t|f
33742781|NCT06157931|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label parallel-group pilot RCT||||
33742782|NCT00612612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742783|NCT04824313|||COHORT||OTHER|||||||
33742784|NCT01990053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742785|NCT04320680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||diagnosis and follow up of a lupus cohort||||
33742786|NCT01335711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742787|NCT01136291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33742788|NCT05768308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742789|NCT05980936|||CASE_ONLY||CROSS_SECTIONAL|||||||
33742790|NCT00093145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951269|NCT06118216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951270|NCT04045054|NA|SINGLE_GROUP||OTHER||NONE||||||
33951271|NCT06542822|||COHORT||PROSPECTIVE|||||||
33951272|NCT05137431|||COHORT||PROSPECTIVE|||||||
33951273|NCT01149174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33951274|NCT02980666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951275|NCT05607056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators will be provided with coded and identical products. Each individual involved in the study will be blinded to the assignment until study completion. Considering the established safety profile of the probiotic strains no necessity is foreseen for urgent unblinding of treatment assignment. With this in mind, no copies of the treatment assignments will be stored at the enrollment sites. If needed, the Investigators may receive information about the assignment of a particular subject only after review and approval by the Medical monitor. No information about the subjects will be shared with the company conducting the randomization.|Prospective, multicenter, double-blind, placebo-controlled, randomized, parallel-arm clinical study|t|f|t|f
33951276|NCT04179188|||COHORT||PROSPECTIVE|||||||
33951277|NCT02778269|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33951278|NCT06336603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951279|NCT00190294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951280|NCT02272569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951281|NCT04156438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159524|NCT00390663|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34159525|NCT02148055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159526|NCT06525129|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34159527|NCT03053843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34159528|NCT01158781|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34159529|NCT05720299|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34159530|NCT00673777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159531|NCT00001094||||TREATMENT||NONE||||||
33742791|NCT04258696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33742792|NCT01881308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742793|NCT02582905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742794|NCT04896489|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33742795|NCT04121598|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33742796|NCT01777919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742797|NCT06384677|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34159532|NCT05942547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study will be a randomized double-blind placebo-controlled parallel study that will involve 48 non-diabetic patients with confirmed diagnosis of NASH.~. The patients will be randomized in a 1:1 ratio by a neutral researcher using sealed envelopes methods with assignment codes for each available allocation to receive either diosmin 600 mg twice daily (Diosmin group; n = 24) or placebo twice daily (Placebo group; n = 24). The study duration will be 12 weeks."|t|f|t|f
33951282|NCT03413618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor does not involve in randomisation and treatment process, has no information about the patient's belonging to one of the study groups|Randomized open-labeled clinical trial with a masked outcomes assessor|f|f|f|t
33951283|NCT02307695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951284|NCT06540872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951285|NCT05214976|NA|SINGLE_GROUP||TREATMENT||NONE||Camrelizumab for Injection in combination with Famitinib malate capsule and Paclitaxel||||
33951286|NCT01224223|||||PROSPECTIVE|||||||
33951287|NCT01089907|||CASE_ONLY||RETROSPECTIVE|||||||
33951288|NCT02083159|||COHORT||PROSPECTIVE|||||||
33951289|NCT02260596|||COHORT||RETROSPECTIVE|||||||
33951290|NCT03077581|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33951291|NCT04131452|||CASE_CONTROL||PROSPECTIVE|||||||
33951292|NCT05756166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951293|NCT02325739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951294|NCT02279472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951295|NCT06137794|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951296|NCT03297593|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-stage single-arm multicenter phase II trial.||||
33951297|NCT02544607|NA|SINGLE_GROUP||OTHER||NONE||||||
33951298|NCT00066859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34159533|NCT03075358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159534|NCT03791411|||OTHER||PROSPECTIVE|||||||
34159535|NCT01761019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159536|NCT05839249|||CASE_ONLY||RETROSPECTIVE|||||||
34159537|NCT00099658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159538|NCT01992835|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33742798|NCT05009563|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742799|NCT01823744|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33742800|NCT01692704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742801|NCT05443035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent assessor blinded to the allocation to the different groups will perform evaluations after 48 hours and at three-month intervals for a follow-up period of 12 months.||f|f|f|t
33742802|NCT04354181|||CASE_CONTROL||PROSPECTIVE|||||||
33742803|NCT01173393|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33742804|NCT06046313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742805|NCT04446663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742806|NCT04989998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742807|NCT05164510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742808|NCT04118218|NA|SINGLE_GROUP||OTHER||NONE||||||
33742809|NCT00214877|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33742810|NCT01360359|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33742811|NCT01836692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742812|NCT05800522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are to be masked to what treatment condition they are assigned to, whether they receive the treatment or control condition. Treatment conditions are termed group 1 and group 2.|A two-armed parallel randomized effectiveness trial in Norwegian frontline services.|t|f|f|f
33742813|NCT01218646|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33742814|NCT00845910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742815|NCT04905680|RANDOMIZED|PARALLEL||OTHER||NONE||"This is an experimental-control study design where up to 260 individuals at risk of developing diabetes (blood glucose levels of 6.1 to 6.9 mmol/L) will be randomly allocated to the experimental and control groups (1:1 randomization).~Participants in the control group will not receive any health coaching and are not required to carry out any study activities after they have completed the baseline lifestyle tracking session. At the end of the study, they will attend a 20- to 30-minute session with a coach to have their baseline lifestyle tracking results explained to them and receive personalised suggestions on lifestyle modifications."||||
33742816|NCT05294640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and provider performing procedure will be masked to local anesthesia type||t|t|f|f
33742817|NCT03424876|||COHORT||RETROSPECTIVE|||||||
33742818|NCT02323594|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33742819|NCT06148129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742820|NCT06300541|||COHORT||PROSPECTIVE|||||||
33742821|NCT00975234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742822|NCT01471002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742823|NCT00244608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33742824|NCT01034124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742825|NCT03344991|RANDOMIZED|PARALLEL||PREVENTION||NONE||Infants will be randomized to either open crib (standard of care) or mylar-lined cardboard box following care in a radiant warmer||||
33742826|NCT04912505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm with sequential variations of daily aspirin intake time||||
33742827|NCT04155931|||OTHER||PROSPECTIVE|||||||
33742828|NCT04706234|||COHORT||PROSPECTIVE|||||||
33742829|NCT05372601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742830|NCT02707055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33742831|NCT04056806|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized controlled trial||||
33742832|NCT04483869|||OTHER||CROSS_SECTIONAL|||||||
34159539|NCT05345717|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study on 5 subjects||||
34159540|NCT02387463|||COHORT||PROSPECTIVE|||||||
34159541|NCT05945446|||CASE_CONTROL||PROSPECTIVE|||||||
33742833|NCT06532487|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Hybrid type II effectiveness-implementation trial with a cluster randomized design.|t|f|f|f
33742834|NCT04602624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742835|NCT02578394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742836|NCT00353704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742837|NCT01022814|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742838|NCT01641887|||COHORT||PROSPECTIVE|||||||
33951299|NCT03130556|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742839|NCT05907369|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants are blind to which of the interventions is active or a sham. Interventional sessions look the same for all participants regarding duration and activities (including doing a computerized EC task and receiving tDCS).|The two interventions include evaluative conditioning (EC) training and cathodal tDCS over OFC. Each is present in two forms: active and sham. So, there are four interventional conditions, including sham EC-sham tDCS, active EC- sham tDCS, sham EC-active tDCS, and active EC-active tDCS.|t|f|f|f
33742840|NCT01468402|||COHORT||PROSPECTIVE|||||||
33846219|NCT05718089|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|"Participants will be randomly allocated, following successful completion of the baseline measurements. An independent statistician generates a computer-generated randomization schedule including six possible sequence orders using balanced blocks, stratified by sex.~The schedule will be forwarded to a secretary not involved in any study procedures and will be stored on a password-protected computer. Sequentially numbered (according to the sequence) opaque, sealed envelopes will be prepared and stored in a locked cabinet in an access restricted room. The envelopes will be lined with aluminum foil to render the envelope impermeable to light. Following the baseline measurements, a study nurse, not involved with any study procedures, will open the envelope, and inform the researcher about the order. The participant be informed about the trial condition upon arrival to lab for the experiments (i.e. on the first morning of each set of trial conditions)."||f|f|f|t
33846220|NCT06477497|||COHORT||PROSPECTIVE|||||||
33951300|NCT05897931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951301|NCT03803371|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33951302|NCT00307775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951303|NCT05891288|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33951304|NCT00351611|RANDOMIZED|||TREATMENT||TRIPLE|||t|t|t|f
33951305|NCT05946096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor was masked and had no idea about which participants were assigned to which group|38 children with CP were randomly assigned to 2 groups. 1 group was interventional group and second group was control group. Both the groups were provided with therapy ( interventional group was provided with conventional therapy and intervention. control group was provided with conventional therapy only) and results were analyzed based on performance of both groups.|f|f|f|t
33846221|NCT05938140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846222|NCT05837962|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33951306|NCT05295459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951307|NCT04853953|||COHORT||RETROSPECTIVE|||||||
33951308|NCT01700686|||CASE_ONLY||PROSPECTIVE|||||||
33951309|NCT04755491|||COHORT||PROSPECTIVE|||||||
33951310|NCT00267475|||||PROSPECTIVE|||||||
33951311|NCT00344266|||COHORT||PROSPECTIVE|||||||
33951312|NCT04089657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951313|NCT04420975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951314|NCT01358266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951315|NCT00135811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951316|NCT00838175|||COHORT||RETROSPECTIVE|||||||
33951317|NCT05229718|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951318|NCT06648603|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Statistician unaware of the arms allocation|Cluster randomized trial with 2x2 factorial design - 40 clusters, 10 clusters per study arm (4 arms)|f|f|f|t
33951319|NCT03175068|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33951320|NCT03248557|||COHORT||OTHER|||||||
34055370|NCT06618820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be blinded to randomization assignment until completion of their one year follow up visits. The care provider, investigators and outcome assessor will be blinded to randomization assignment until completion of data analysis. The investigators and care providers will not be blinded to randomization assignment if an adverse event occurs.||t|t|t|t
34055371|NCT03716843|||CASE_ONLY||PROSPECTIVE|||||||
34055372|NCT03290547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055373|NCT05969314|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the maximum tolerated dose (MTD). First 3 patients will receive the study preparation once a day at 9 am (+/- 60 min) (i.e 5 mg of CBD and 5 mg of THC in a 400 mg capsule). Subsequent cohorts will be administered doses of 10 (10 mg of THC and CBD each), 20 (20+20) and 30 (30+30) mg in a classical 3+3 dose escalation study. Briefly, 3 patients will be enrolled at dose level. Dose escalation to the next dose level will continue as long no DLT is observed in 3 patients (the incidence of DLT is ≤ 1/6) In any cohort, if 1/3 patients develop DLT, then 3 more patients will be added at that dose. The dose level at which more than 1/6 patients develop DLT will be considered the MTD and no further escalation will be done beyond the MTD. One dose level below the MTD will be considered for future trials. If MTD is not achieved, the highest dose (30+30) will be considered for future trials. If toxicity is seen at 30 mg, then de-escalation to 25 mg may be considered.||||
34055374|NCT06620705|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The patient will be blinded to the treatment allocation. The assessor of the ECG endpoints and echocardiographic endpoints will be blinded to the treatment allocation.|Randomized patient and assessor blinded non-inferiority cross-over trial.|t|f|f|t
34055375|NCT03026140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055376|NCT00055770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055377|NCT02267772|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055378|NCT02773212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055379|NCT03546972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055380|NCT06451835|||CASE_ONLY||PROSPECTIVE|||||||
34055381|NCT03465774|||CASE_ONLY||PROSPECTIVE|||||||
34055382|NCT02140216|||COHORT||PROSPECTIVE|||||||
34055383|NCT03078179|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34055384|NCT06090643|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34055385|NCT04791319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055386|NCT06647758|||OTHER||RETROSPECTIVE|||||||
34055387|NCT01729000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055388|NCT00095641||||TREATMENT||||||||
34055389|NCT06284395|||COHORT||RETROSPECTIVE|||||||
34055390|NCT04143594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055391|NCT02876991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055392|NCT05224960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, multicenter study|t|t|t|t
34055393|NCT00387751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055394|NCT00992628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34055395|NCT01639547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055396|NCT03451916|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||, subjects will be randomized using a 1:1 allocation scheme to either 150×10\^6 PLX-PAD cells or to placebo treatment, respectively|t|f|t|t
34055397|NCT05633979|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159542|NCT03331757|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants were assigned to the interventions using a sequence of random numbers extracted from computer software. A researcher not involved with the collection and the analysis of the scientific data, was responsible for the randomization of the volunteers to the intervention days examining the test foods. All test meals (glucose and honeys) were diluted in 300ml water and were served in dark paper cups covered with a lid in order to achieve double blind conditions.|Eleven healthy participants consumed in random order 50g available carbohydrates as glucose (tested three times) and 50g available carbohydrates as fir, chestnut, healther, thyme, pine, citrus, tested once, on separate occasions|t|f|t|f
34159543|NCT03620084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159544|NCT05777135|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34055398|NCT03004170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessor is blind to participant condition.||f|f|f|t
33742841|NCT01996020|||CASE_ONLY||PROSPECTIVE|||||||
33742842|NCT05219318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159545|NCT01201408|||COHORT||PROSPECTIVE|||||||
34159546|NCT06291831|||COHORT||RETROSPECTIVE|||||||
34159547|NCT00765804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159548|NCT04871958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"All patients admitted at the COVID-19 non-ICU with a diagnosis of Type 2 or Secondary diabetes mellitus (DM) for whom intensive insulin therapy (basal plus at least two boluses) is indicated are eligible for the primary study.~After stratification for admission ward, type of DM (known/unknown type 2, steroid use), age, and gender, participants will be randomized to one of the following interventions:~1. Real-time CGM, multiple daily injections managed according to CGM~2. Real-time CGM, insulin pump (V-Go) managed according to CGM~3. Blind CGM, multiple daily injections managed according to POC glucose testing."|f|f|f|t
34159549|NCT00788788|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159550|NCT01711645|NA|SINGLE_GROUP||PREVENTION||||||||
34159551|NCT01212393|||OTHER||PROSPECTIVE|||||||
34159552|NCT00197899|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34159553|NCT01528189|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34159554|NCT05621148|||COHORT||RETROSPECTIVE|||||||
34159555|NCT05856266|NA|SINGLE_GROUP||OTHER||NONE||"This is a low-interventional study, with the drugs being prescribed and used according to clinical practice.~The interventions in the study are the addition of the mandatory joint examinations HEAD-US (ultrasound) and HJHS (functional joint assessment)."||||
34159556|NCT02443168|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159557|NCT06272110|||COHORT||RETROSPECTIVE|||||||
34159558|NCT04248023|RANDOMIZED|PARALLEL||SCREENING||NONE|Based on the intervention of practice facilitation, it is not able to blind practices or clinicians from the intervention.|This study is a practice level randomized controlled trial. 125 practices across Virginia will receive the intervention (practice facilitation to enhance screening and treatment of unhealthy alcohol use (UAU)) or act as a control group (will receive practice facilitation at 3 month lag behind intervention groups.) The investigators will survey 60 patients from each practice at three time intervals to evaluate the current state and what changes are implemented and reported over the course of the study. An additional 60 patient chart review from each practice will be preformed. The investigators will use an implementation-effectiveness design to measure outcomes. Effectiveness outcomes include increased screening rate of patients; increased treatment of any kind for patients with UAU; and reduction of UAU. Implementation outcomes will include the barriers and facilitators to screening and evaluating for UAU.||||
34159559|NCT03447028|||COHORT||CROSS_SECTIONAL|||||||
34159560|NCT01843062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159561|NCT05132218|||COHORT||PROSPECTIVE|||||||
34159562|NCT00133601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159563|NCT00862693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159564|NCT04522141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34159565|NCT00724984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951321|NCT06127862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Participants were assigned to the groups by a single-blind design. For allocation, intervention and control groups were coded as A and B. Which letter would be the intervention or control group was determined by the coin toss method before the allocation."|This research is a randomised control study with pretest-posttest design.|t|f|f|f
33951322|NCT03013569|||CASE_ONLY||PROSPECTIVE|||||||
33951323|NCT00138866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951324|NCT01929928|||COHORT||PROSPECTIVE|||||||
33951325|NCT04984304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951326|NCT02398942|||COHORT||PROSPECTIVE|||||||
33951327|NCT00040326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33846223|NCT03684668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All forms with the questionnaires will be consecutively numbered before the beginning of the study and randomly allocated to one of the study groups. This assignment list will be given to the secretary who will allocate the questionnaires to the corresponding group and deliver them to the corresponding researcher. After completion, all forms will be collected and merged and then delivered again to the secretary who will randomly assign number 1 or 2 to one of the groups and will write this number in the upper right edge of each completed questionnaire according to the original assignment list. The researcher that will introduce data in the database will include a field for this number but will not know to which of the groups it belongs. Statistical analysis will be then carried comparing groups 1 and 2. This will not be uncovered until all results are obtained and are ready for discussion.|"This is a behavioral intervention where 120 university students will be randomly assigned to the intervention or de control group. Intervention consists in a psychoeducational activity enhanced using meta-universes or three-dimensional virtual worlds. Each selected student will undergo a three-session educational activity before a personal computer and wearing 3D lenses. The first session is called Knowledge about STI; the second session is entitled Use of the male condom and the third session is called Talking about sexuality issues. The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University. The control group will not receive this intervention."|f|f|f|t
33846224|NCT03895905|||CASE_CONTROL||RETROSPECTIVE|||||||
33846225|NCT00358176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846226|NCT02217501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846227|NCT03085654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33846228|NCT02330705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951328|NCT04080362|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|The clinical trial was designed as a single group assignment study. The participants with moderate to severe and severe mitral valve regurgitation will receive a transapical beating-heart mitral valve repair surgery using MitralStitchTM mitral valve repair system.||||
33951329|NCT05991206|||COHORT||PROSPECTIVE|||||||
33951330|NCT03348306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951331|NCT00421746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33951332|NCT03919734|||COHORT||RETROSPECTIVE|||||||
33951333|NCT05820880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951334|NCT01340807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951335|NCT00065169|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33951336|NCT05562596|||CASE_ONLY||RETROSPECTIVE|||||||
33951337|NCT03801863|||CASE_CONTROL||PROSPECTIVE|||||||
33951338|NCT04629534|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951339|NCT05386511|||COHORT||RETROSPECTIVE|||||||
33951340|NCT00422058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951341|NCT01254695|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33951342|NCT04299126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951343|NCT02027246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951344|NCT03843866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951345|NCT02842736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951346|NCT02048527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33951347|NCT03330340|||COHORT||PROSPECTIVE|||||||
33951348|NCT02507531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951349|NCT04943523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Parallel Group Randomised Controlled Trial|t|t|t|t
33951350|NCT00413322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951351|NCT04871451|NA|SEQUENTIAL||TREATMENT||NONE||Approximately 60 subjects from ABP-19000 study, irrespective of treatment allocation, will have the option to continue treatment with ABP-450 via intramuscular injection into affected neck muscles.||||
33951352|NCT04800991|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||HDT-202(application)||||
33951353|NCT06419699|||COHORT||PROSPECTIVE|||||||
33951354|NCT06653543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951355|NCT05707286|||CASE_ONLY||PROSPECTIVE|||||||
33951356|NCT04706065|||CASE_CONTROL||PROSPECTIVE|||||||
33951357|NCT03907111|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each of the participants was been treated with 2 different treatments on different areas of the same wound at the same time.|t|f|f|f
33951358|NCT03575806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951359|NCT04260594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951360|NCT01083511|||CASE_ONLY||PROSPECTIVE|||||||
33951361|NCT04780360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33951362|NCT05123066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|They will be allocated randomly into two groups of equal numbers, group I (the aquatic training group) and the group II (land exercises).||t|t|f|t
33951363|NCT01863108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951364|NCT02840019|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33951365|NCT04485871|NA|SINGLE_GROUP||PREVENTION||NONE|However, subjects will not know into which group they were stratified.|Subjects (N=48) will be recruited with the same inclusion/exclusion criteria and will received the same omega-3 intervention. After completion of recruitment, subjects will be stratified into 2 groups (24/group) based on a baseline plasma PCSK9 for group characterisation and comparison.||||
33951366|NCT04717323|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951367|NCT02558634|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33951368|NCT00774774|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951369|NCT06194149|||COHORT||RETROSPECTIVE|||||||
33951370|NCT03755856|||COHORT||CROSS_SECTIONAL|||||||
33951371|NCT03545568|NA|SINGLE_GROUP||TREATMENT||NONE||Open label individual patient clinical trial study of small sample size||||
33951372|NCT02027766|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33951373|NCT04186637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951374|NCT04490772|||COHORT||PROSPECTIVE|||||||
33951375|NCT04124302|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34159566|NCT05973253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159567|NCT00658463|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159568|NCT05858372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846229|NCT04638634|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34159569|NCT05892328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The proposed trial will be a randomized, 3 arm, placebo-controlled, parallel study design|t|f|f|f
34159570|NCT02675608|||CASE_CONTROL||RETROSPECTIVE|||||||
34159571|NCT03320720|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159572|NCT06038422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159573|NCT02632357|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34159574|NCT02860104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159575|NCT02481531|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34159576|NCT04921228|NA|SINGLE_GROUP||OTHER||NONE||||||
34159577|NCT06127628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of participants and outcomes assessor|Parallel groups|t|f|f|t
34159578|NCT00709072|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34159579|NCT06177691|||COHORT||PROSPECTIVE|||||||
34159580|NCT04119193|||COHORT||PROSPECTIVE|||||||
34159581|NCT04548856|RANDOMIZED|PARALLEL||TREATMENT||NONE||The stratified patients will be randomized into two groups (100 to the microsurgical clipping group and 100 to the endovascular embolization group). Each group will be divided into 2 subgroups of 50 people each: the first subgroup includes patients in the acute period of aneurysm rupture, the second subgroup includes patients with unruptured aneurysms.||||
34159582|NCT02189512|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846230|NCT01973244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846231|NCT00888927|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33846232|NCT02507453|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846233|NCT03657823|||COHORT||PROSPECTIVE|||||||
33846234|NCT05589324|||CASE_CROSSOVER||PROSPECTIVE|||||||
33846235|NCT05985785|RANDOMIZED|PARALLEL||OTHER||SINGLE||Treatment arms include BMAC injections (ARM1) and corticosteroid injections (ARM 2). Patients in the corticosteroid injection group (ARM 2) will receive a sham incision. Follow-up will be up to six months (12-months if crossover (ARM 3)).|t|f|f|f
34159583|NCT01415401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159584|NCT01018485|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159585|NCT01618006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34159586|NCT04998981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159587|NCT03411421|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34159588|NCT05334628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34159589|NCT00050947||||TREATMENT||||||||
34159590|NCT01358058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159591|NCT01923662|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34159592|NCT03060200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34159593|NCT00525005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159594|NCT02272712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846236|NCT04440852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846237|NCT04465253|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33846238|NCT05894395|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants with two previous lifetime doses of MMR-containing vaccine will be randomized to receive a single M-M-R-VaxPro booster vaccination (3rd lifetime MMR-containing vaccine dose) or no intervention.||||
33846239|NCT03114839|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a dietary intervention study with a repeated measures design, comparing the upper gastrointestinal microbiota profiles in healthy male subjects before and after consumption of a probiotic drink containing Lactobacillus casei strain Shirota.||||
33846240|NCT00165373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846241|NCT02009098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846242|NCT03889704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846243|NCT03759314|||OTHER||RETROSPECTIVE|||||||
33846244|NCT02155751|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33846245|NCT06090006|NA|SINGLE_GROUP||SCREENING||NONE||In our study sites, a contemporaneous comparison group is not required since no routine screening is currently taking place, and as a result, assessments at baseline will serve as the counterfactual for internal comparisons||||
33846246|NCT00673959|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33846247|NCT05958030|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|The study is a single-blind study where study participants will be blinded to the order of both devices (investigational device and placebo) during baseline visit.|All study participants will interact with both investigational device and placebo in a pre-defined sequence.|t|f|f|t
33846248|NCT04966845|||CASE_CROSSOVER||PROSPECTIVE|||||||
33846249|NCT03507777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33846250|NCT04387305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Bayesian adaptive response|t|t|t|t
33846251|NCT03013075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846252|NCT02703181|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33846253|NCT02116790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846254|NCT02237729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34055399|NCT04197102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each nightly dose of CBD/Placebo oil will be tagged with a code # on the plastic syringe containing the CBD oil or placebo oil. All oils will have identical color and mint flavor. Two independent staff not connected to the study will be unblinded to the participants' assignment to condition.||t|t|t|t
34159595|NCT06210100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial testing iTBS versus sham|t|f|t|t
34055400|NCT05674916|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34055401|NCT03484936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055402|NCT05260385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055403|NCT03275259|NA|SINGLE_GROUP||TREATMENT||NONE|The participants and evaluator are blinded. They will not be informed about the parameters applied in this study.|||||
34055404|NCT06540664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055405|NCT01512069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34055406|NCT05247099|||COHORT||PROSPECTIVE|||||||
34055407|NCT04310631|||COHORT||RETROSPECTIVE|||||||
34055408|NCT03142152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055409|NCT04831697|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34055410|NCT06623461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055411|NCT03819322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159596|NCT00816192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159597|NCT04373928|RANDOMIZED|PARALLEL||TREATMENT||NONE||According to randomized principles, patients with pancreatic cancer will be assigned to intervention group. Collecting the tumor tissue of intervention group and testing the best medicine by Mini PDX, which the person of intervention group receive the best medicine.||||
34159598|NCT00243711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159599|NCT03933228|||COHORT||RETROSPECTIVE|||||||
34159600|NCT00401349|||OTHER||PROSPECTIVE|||||||
34159601|NCT02861898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159602|NCT00614848|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34159603|NCT00438165|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34159604|NCT00423449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159605|NCT03487497|||COHORT||RETROSPECTIVE|||||||
34159606|NCT01295957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159607|NCT00559221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159608|NCT04768543|||CASE_ONLY||CROSS_SECTIONAL|||||||
34159609|NCT05876468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Clinical trials with a single arm||||
34159610|NCT00020124||||TREATMENT||||||||
34159611|NCT01890408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159612|NCT00303485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846255|NCT01734629|||COHORT||PROSPECTIVE|||||||
33846256|NCT04333251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846257|NCT02352168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055412|NCT02866149|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34055413|NCT00308594|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34055414|NCT02194712|||COHORT||PROSPECTIVE|||||||
34055415|NCT02141568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055416|NCT06619522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055417|NCT03183713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159613|NCT01436474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055418|NCT06073054|NA|SINGLE_GROUP||SCREENING||NONE||||||
34055419|NCT02327338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34055420|NCT05353582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055421|NCT03254316|||COHORT||PROSPECTIVE|||||||
34055422|NCT00850304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055423|NCT06618911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055424|NCT04513847|||CASE_CONTROL||OTHER|||||||
34055425|NCT06502964|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Each participant will receive both placebo and active study drug: 10-day administration each of placebo TDS and ALTO-101T TDS (in random order), with a 6- to 14-day washout period between conditions.|t|t|t|t
34055426|NCT02590575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055427|NCT00224939|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34055428|NCT06649266|RANDOMIZED|PARALLEL||TREATMENT||NONE|All participants will be blinded to the trial treatment for the first 16 weeks after the first dose. Then, investigators and other clinic staff will be unblinded, i.e., they will know which treatment the participants receive at all times.|Partly blinded, placebo-controlled clinical trial with an active and a deferred active group.||||
34159614|NCT03029923|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34159615|NCT06098248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159616|NCT04070417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159617|NCT06380075|NA|SINGLE_GROUP||OTHER||NONE||||||
34159618|NCT01229787|||||CROSS_SECTIONAL|||||||
34159619|NCT02779647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159620|NCT01683825|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159621|NCT00002399||||TREATMENT||DOUBLE||||||
33742843|NCT03257982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33742844|NCT03125668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33742845|NCT02789787|||COHORT||PROSPECTIVE|||||||
33742846|NCT00214136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742847|NCT05668182|||COHORT||OTHER|||||||
33742848|NCT05409443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the group to which they are randomized. Given inherent approach differences between techniques, the physician performing the procedure cannot be blinded. However, staff responsible for outcome collection will remain blinded.|To compare pain and disability outcomes in patients with confirmed SIJC pain after randomization to either N-SIJRFA or C-SIJRFA.|t|f|f|t
33742849|NCT04634201|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33742850|NCT00613951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742851|NCT05364294|||COHORT||CROSS_SECTIONAL|||||||
33742852|NCT01542775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742853|NCT04345848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742854|NCT00057915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742855|NCT06044298|||COHORT||PROSPECTIVE|||||||
33742856|NCT01547650|||CASE_CONTROL||PROSPECTIVE|||||||
33742857|NCT00010517|RANDOMIZED|||TREATMENT||DOUBLE||||||
33742858|NCT00834457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742859|NCT03450551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742860|NCT05651477|||COHORT||PROSPECTIVE|||||||
33742861|NCT02239510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742862|NCT06529653|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33742863|NCT02069600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34159622|NCT01863329|||CASE_ONLY||PROSPECTIVE|||||||
34159623|NCT00319254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159624|NCT04678388|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34159625|NCT04472455|||COHORT||PROSPECTIVE|||||||
34159626|NCT04890288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34159627|NCT02982421|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34159628|NCT00889525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159629|NCT05899374|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be recruited through APFertilidade and Fertility Europe (European Umbrella organisation of patients' associations). Consenting participants will be randomly allocated (www.random.org) to the experimental group (immediate access to KindMap-EG-KindMap) and waiting-list control group (access to KindMap after T2-WL-CG).||||
34159630|NCT04979117|||CASE_CONTROL||PROSPECTIVE|||||||
34159631|NCT04298437|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"80 parents (40 depressed; 40 non-depressed) and their children with EBD will be recruited to complete an assessment to determine objective emotional, cognitive, and behavioural markers. A subset of 20-40 depressed parents who meet inclusion criteria will be recruited for group treatment.~The aim is to recruit 6-8 parents (and their co-parents) per group for each of 3 consecutive groups (target n = 36). These parents will be invited to participate in 2 individual and 8 weekly group treatment sessions. Following treatment, parents will be invited to a post-group assessment"||||
34159632|NCT00705367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159633|NCT00964652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159634|NCT05097495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159635|NCT01325688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159636|NCT05489367|||COHORT||CROSS_SECTIONAL|||||||
34159637|NCT00335296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159638|NCT00566462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159639|NCT00491582|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159640|NCT03027089|||COHORT||PROSPECTIVE|||||||
34159641|NCT01100359||||TREATMENT||NONE||||||
33846258|NCT03755076|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will perform bilateral arm movements in a virtual reality environment under different perceptual conditions to identify a condition that improves coordination between arms.||||
33846259|NCT05444023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846260|NCT01307579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846261|NCT00018239|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34055429|NCT05303194|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The study has two phases: 1) an initial adaptation phase; and 2) a feasibility testing phase. For the adaptation phase 5 Hispanics with multiple chronic condition and without dementia will be invited to participate. These participants will need to consent to be part of the study. For the second phase, the investigators will determine if participants with dementia have capacity by asking their primary care providers or by administering the telephone version of the Montreal Cognitive Assessment. If a score of less than 12 is obtained, the caregiver will be asked to consent for both participants.||||
34055430|NCT04985448|||CASE_CONTROL||RETROSPECTIVE|||||||
34055431|NCT06618417|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33846262|NCT04559763|||OTHER||PROSPECTIVE|||||||
33846263|NCT01846351|||||RETROSPECTIVE|||||||
33846264|NCT05064527|||CASE_CONTROL||PROSPECTIVE|||||||
33846265|NCT01204710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055432|NCT05954845|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||participants will have colonic biopsies taken following a colonoscopy/rectosigmoidoscopy previously indicated for spinal cord injured patients. Biopsies will be obtained from the right and left colon.||||
34055433|NCT06644469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be unaware of whether they are receiving vibration therapy, and the individual performing the assessment will be different from the one administering the treatment||t|f|t|f
34055434|NCT02999230|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34055435|NCT00990392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055436|NCT06215183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The evaluation was made by the participants in the study.|The study is a randomized controlled trial.|t|f|f|f
34055437|NCT05690438|||COHORT||PROSPECTIVE|||||||
34055438|NCT06142877|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two groups: 1) social media use reduction (intervention), or 2) social media use as usual (control).||||
34055439|NCT01978470|NA|SINGLE_GROUP||||NONE||||||
34055440|NCT06144736|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients are classified as low risk or high risk for recurrence upon study enrollment. Low risk patients undergo a robot-assisted retroperitoneal lymph node dissection and metastasis resection (RA-RPLND) in a unilateral dissection field (template) without adjuvant therapy. High risk patients also undergo a retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field, but additionally have the option to receive adjuvant therapy with one cycle of PEB two to four weeks after the RA-RPLND."||||
34055441|NCT03062527|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34055442|NCT03933670|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055443|NCT06621706|||CASE_CONTROL||PROSPECTIVE|||||||
34055444|NCT03005223|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055445|NCT01605188|||CASE_CROSSOVER||PROSPECTIVE|||||||
34055446|NCT02103959|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34055447|NCT06462482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055448|NCT01287468|||||PROSPECTIVE|||||||
34055449|NCT06189157|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055450|NCT04726644|||CASE_ONLY||PROSPECTIVE|||||||
34055451|NCT06616051|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The person who will conduct the follow-up will be masked during the trial. Community medicine resident not involved in the research will be appointed for follow up. Coding list of children screened positive for visual impairment with parent's contact number will be provided for twice weekly telephonic follow up of children regarding proportion of referred children who will attend the hospital.|This study will be a Multicenter, Concurrent parallel group, single blinded Randomized Control Trial with 1:1 allocation ratio.|f|f|f|t
34055452|NCT00306358|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055453|NCT04888429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055454|NCT00020046||||TREATMENT||||||||
33846266|NCT04270591|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib：300 mg QD Glumetinib Phase II：300 mg QD Glumetinib||||
33846267|NCT02204332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055455|NCT02520427|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055456|NCT06021951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34055457|NCT04173728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159642|NCT04384029|||COHORT||OTHER|||||||
34159643|NCT04845984|||COHORT||RETROSPECTIVE|||||||
34159644|NCT03609411|||CASE_CONTROL||RETROSPECTIVE|||||||
34159645|NCT01321372|||COHORT||PROSPECTIVE|||||||
34159646|NCT05050461|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There will be an arm foses and an arm for controls||||
34159647|NCT04423692|||OTHER||PROSPECTIVE|||||||
34159648|NCT04693286|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34159649|NCT02502045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34159650|NCT01009606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159651|NCT03723369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159652|NCT01683448|||COHORT||RETROSPECTIVE|||||||
34159653|NCT03043235|||CASE_CONTROL||PROSPECTIVE|||||||
34159654|NCT02279095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846268|NCT00003773||||TREATMENT||||||||
33846269|NCT04155736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846270|NCT02569593|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33846271|NCT05789368|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33846272|NCT02979405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33846273|NCT00156689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846274|NCT05613387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Part 1: A single-centre, placebo-controlled, double-blind (within cohorts), randomised multiple ascending dose trial.~Part 2: A single-centre, placebo-controlled, double-blind (within cohorts), randomised multiple ascending dose trial, using dose up-titration."|t|t|t|t
33846275|NCT00083213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846276|NCT02874053|||OTHER||CROSS_SECTIONAL|||||||
33846277|NCT02746432|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33846278|NCT04385550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846279|NCT04766723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846280|NCT02117453|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846281|NCT03000205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846282|NCT01791374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846283|NCT03456427|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33846284|NCT00658255|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951376|NCT05841862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be masked to the assignment of which eye is receiving active treatment or sham treatment. Clinical personnel who perform clinical assessments will also be masked to the participants' eye assignment. Masked evaluators will not be permitted in the room during the injections and will be instructed to avoid areas where they may observe study activities which may potentially lead to their becoming unmasked.||t|f|f|t
33951377|NCT05649709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951378|NCT05280886|||COHORT||PROSPECTIVE|||||||
33951379|NCT02822729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951380|NCT01786642|||COHORT||PROSPECTIVE|||||||
34055458|NCT02599909|||COHORT||PROSPECTIVE|||||||
34055459|NCT06640985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055460|NCT04569162|||CASE_ONLY||OTHER|||||||
33951381|NCT05804695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846285|NCT02751268|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33846286|NCT03472248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951382|NCT03961932|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33951383|NCT01716442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951384|NCT03126201|||CASE_ONLY||RETROSPECTIVE|||||||
33951385|NCT03542864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Duodenal-Enteral medical supervised feeding response||||
33951386|NCT05737394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33951387|NCT01334502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951388|NCT04437732|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33951389|NCT04749901|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951390|NCT04689126|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33951391|NCT00273637|||DEFINED_POPULATION||OTHER|||||||
33951392|NCT04897659|||COHORT||RETROSPECTIVE|||||||
33951393|NCT01541644|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33951394|NCT01371903|||COHORT||PROSPECTIVE|||||||
33951395|NCT05473234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951396|NCT05945368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951397|NCT04125082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951398|NCT04532086|||COHORT||PROSPECTIVE|||||||
33951399|NCT01831297|||COHORT||PROSPECTIVE|||||||
33951400|NCT05443776|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE||6 different. products used, each compared between each other|t|t|t|f
33951401|NCT03504956|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33951402|NCT00499980|||DEFINED_POPULATION||OTHER|||||||
33951403|NCT01785199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951404|NCT02876185|||COHORT||PROSPECTIVE|||||||
33951405|NCT05169866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951406|NCT05602480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|One arm, open label in subjects aged 3 months and above; Randomized, blinded and active comparator in subjects aged 2 months.||t|t|t|t
33951407|NCT05732025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951408|NCT02871869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951409|NCT04065997|||COHORT||PROSPECTIVE|||||||
33951410|NCT02716415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951411|NCT01604226|||||PROSPECTIVE|||||||
33951412|NCT05772728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951413|NCT03952377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind||t|f|f|t
33951414|NCT03843775|NA|SINGLE_GROUP||TREATMENT||NONE||This phase I/II study consists of a Phase I part followed by an efficacy analysis (Phase II) of the dosing schedule deemed safe in patients with advanced cancer with activating non-V600 BRAF mutant tumors. As patients in the phase I part of the start will start at the lower dose level 1, they will not be included in the stage one efficacy cohort.||||
33951415|NCT00524901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951416|NCT03667781|||COHORT||PROSPECTIVE|||||||
33951417|NCT01678391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951418|NCT05839366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951419|NCT02853513|||COHORT||PROSPECTIVE|||||||
33951420|NCT01561573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951421|NCT05141110|RANDOMIZED|CROSSOVER||TREATMENT||NONE||single-dose, crossover study||||
33951422|NCT00002738||||TREATMENT||||||||
33951423|NCT04732884|RANDOMIZED|PARALLEL||OTHER||SINGLE|Radiologists assessing the primary outcome osseous non-union will be blind to the treatment allocation.|Monocentric, prospective, randomized, controlled trial|f|f|f|t
34055461|NCT05523232|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two group parallel design.|f|f|f|t
34055462|NCT03492398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double blind, placebo-controlled, single and multiple dosing, dose escalation study|t|t|t|t
34055463|NCT06449001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055464|NCT00730119|||CASE_ONLY||PROSPECTIVE|||||||
34055465|NCT00496275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055466|NCT00293124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055467|NCT03227172|||COHORT||RETROSPECTIVE|||||||
34055468|NCT04507802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055469|NCT03440762|NA|SINGLE_GROUP||SCREENING||NONE||Single group pre-post educational intervention||||
34055470|NCT05091931|||COHORT||PROSPECTIVE|||||||
34055471|NCT03555864|||CASE_CROSSOVER||PROSPECTIVE|||||||
34055472|NCT05109442|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055473|NCT05117281|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34055474|NCT00754520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055475|NCT01305889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055476|NCT04483492|||COHORT||PROSPECTIVE|||||||
34055477|NCT06433661|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055478|NCT06622395|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This is a prospective, single-center study aimed at testing the validity of the remote diagnostic modality for patients aged 24 months to 5 years with neurodevelopmental disorders (NDD) and suspected Autism Spectrum Disorder (ASD), involving second or third-line professional intervention. The study is designed sequentially in groups using the Fleming model (Group-Sequential Tests for One Proportion in a Fleming Design). The adopted model includes two interim stages.||||
34055479|NCT03367052|RANDOMIZED|PARALLEL||TREATMENT||NONE||542 DDD patients (age from 20 to 70) from several hospitals matching the inclusion criteria will be randomly assigned to two groups (271 patients in each group). One group will be treated with two level ProDisc-C vivo disc replacement. The other group will be treated with hybrid construct. Clinical outcomes and radiological analysis will be compared between the two groups at 1.5, 3, 6, 12, 24, 36, 60, and 84 months after the surgical treatments.||||
34055480|NCT02183259|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055481|NCT06618170|||CASE_ONLY||CROSS_SECTIONAL|||||||
34055482|NCT02510105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055483|NCT05161455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055484|NCT04685460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055485|NCT05724628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055486|NCT01747889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055487|NCT05990348|||CASE_CROSSOVER||PROSPECTIVE|||||||
34055488|NCT01335217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055489|NCT00536549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34055490|NCT03721952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34055491|NCT06622200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34055492|NCT05249322|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34055493|NCT00485043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055494|NCT04476407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055495|NCT01322672|||CASE_ONLY||PROSPECTIVE|||||||
34055496|NCT05356364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055497|NCT04558775|||COHORT||PROSPECTIVE|||||||
34055498|NCT03805217|||OTHER||PROSPECTIVE|||||||
34055499|NCT03663465|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|two groups of participants and investigator|case control study|t|f|t|f
34055500|NCT06186830|||OTHER||PROSPECTIVE|||||||
34055501|NCT03454828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055502|NCT06620900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055503|NCT05205343|||COHORT||PROSPECTIVE|||||||
34055504|NCT05117554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055505|NCT03030144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055506|NCT01567566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055507|NCT06665295|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055508|NCT05893004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055509|NCT05248113|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Test of feasibility of electrical stimulation of the cochlear nerve with a conventional bipolar nerve stimulator||||
34055510|NCT03425266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants are not aware of whether they are in the treatment or control group. Providers are not informed which group a patient is in, however, because the intervention generates a summary page that the patient may choose to send to their provider, the provider would be aware of a patients' group assignment if they shared the summary with the provider.|Participants are randomly assigned to either the new intervention (PainApp) or a website designed for people with chronic pain before an upcoming appointment with their provider.|t|t|f|f
34055511|NCT00727844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055512|NCT02535130|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34055513|NCT00418366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055514|NCT03309657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open label pharmacokinetic study where enrolled critically ill patients with infection receive a single dose of ceftolozane-tazobactam (in addition to other active therapy).||||
34055515|NCT05449535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|JYB1904/JYB1904 Placebo Arm: double-blind (participant and investigator); Omalizumab Arm: non-blind.|JYB1904/JYB1904 Placebo Arm: dose escalation. Omalizumab Arm: one dose level .|t|f|t|f
34055516|NCT03326128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of which medication condition they have been assigned to; however, the study team and the care provider will know which dose of medication they are distributing.|Participants will be randomly assigned to receive either 300 or 450 mg of Bupropion.|t|f|f|f
34055517|NCT05887076|||COHORT||RETROSPECTIVE|||||||
34055518|NCT03277053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34055519|NCT03471728|||COHORT||PROSPECTIVE|||||||
34055520|NCT00443989|||COHORT||PROSPECTIVE|||||||
34055521|NCT02381301|||COHORT||PROSPECTIVE|||||||
34055522|NCT06074809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055523|NCT06667648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055524|NCT02568228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34055525|NCT03676114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159655|NCT00083525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159656|NCT05669053|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The datasets given to the statistician will be blinded to the condition.||f|f|f|t
33846287|NCT01699503|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33846288|NCT06204952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846289|NCT05104359|||COHORT||RETROSPECTIVE|||||||
33846290|NCT01163292|||COHORT||PROSPECTIVE|||||||
33846291|NCT00319410|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846292|NCT04850872|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846293|NCT03827083|||OTHER||PROSPECTIVE|||||||
33846294|NCT02075476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33846295|NCT06533696|||CASE_CONTROL||OTHER|||||||
34055526|NCT05123092|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Randomization will be done via computer-generated random numbers that will be placed in separate closed envelopes and will be opened by study investigators just after induction of general anesthesia. Neither the patients, the study investigators, the attending clinicians nor the data collectors will be aware of the allocation of groups till the study ends.|"The patients will be allocated in 1:1 ratio to one of the two groups:~group erector spinae plane block (n=41), and group intrathecal morphine (n=41)."|t|t|t|t
34055527|NCT02438605|||CASE_CONTROL||PROSPECTIVE|||||||
34055528|NCT06647784|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055529|NCT05250531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055530|NCT02520882|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055531|NCT05509569|||COHORT||PROSPECTIVE|||||||
34055532|NCT04809857|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055533|NCT00102648|NA|SINGLE_GROUP||TREATMENT||||||||
34055534|NCT02760212|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34055535|NCT06621693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055536|NCT02280616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055537|NCT00927511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055538|NCT05766488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned into one of two groups and receive either the treatment intervention (CGM) or standard of care intervention (traditional glucometer) simultaneously upon enrollment.||||
34055539|NCT05249114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055540|NCT04521621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055541|NCT06617884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who carries out the neurological examination after the training phase is blinded.|All patients initially take part in a one-week familiarization phase without training and are then randomly assigned to one of the two training protocols or to the control group without additional training. The two different training protocols are: 20 minutes of training per day, four days per week; or 40 minutes of training per day, only two days per week. The patients who were assigned to the control group without additional training can also complete the training after the end of the study.|f|f|t|f
34055542|NCT01734915|||COHORT||PROSPECTIVE|||||||
34055543|NCT02656134|||COHORT||PROSPECTIVE|||||||
34055544|NCT05178641|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34055545|NCT01915667|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055546|NCT04790162|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a randomized mixed methods (i.e., quantitative and qualitative methodology) intervention study with an experimental meditation group (HEART) and a wait-listed control group (CON). The wait-listed group will be offered the meditation after the 90-day data point.||||
34055547|NCT04199767|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Neither participants or site personnel will know which dose of insulin is being administered. Exceptions will be the study nurse who is directly involved in preparing the insulin.|At study entry, participants will be randomized to receive either 20 or 40 International Units of insulin first and the opposite substance on a second visit.|t|t|t|t
34055548|NCT05496413|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34055549|NCT06101017|||CASE_ONLY||PROSPECTIVE|||||||
34055550|NCT01271101|||COHORT||PROSPECTIVE|||||||
34055551|NCT04357912|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055552|NCT01310517|||CASE_ONLY||PROSPECTIVE|||||||
34055553|NCT06426472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34055554|NCT03201874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055555|NCT06513962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055556|NCT06279533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|PK characteristics of multiple ascending doses study is double-blinded, placebo-controlled design, and FE study is open-label design|PK characteristics of multiple ascending doses study is parallel design, and FE study is crossover design|t|t|t|f
34055557|NCT01582178|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34055558|NCT06498622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055559|NCT01740271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055560|NCT01021761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055561|NCT01759849|||COHORT||PROSPECTIVE|||||||
34055562|NCT00893997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055563|NCT01780402|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34055564|NCT03941158|||COHORT||RETROSPECTIVE|||||||
34055565|NCT04638881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34055566|NCT06547086|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33846296|NCT01134172|||CASE_CONTROL||PROSPECTIVE|||||||
33846297|NCT00157508|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33846298|NCT04664400|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-participant design with behavioral manipulations.||||
33846299|NCT01401400|||COHORT||RETROSPECTIVE|||||||
33846300|NCT05880264|||CASE_ONLY||PROSPECTIVE|||||||
33846301|NCT04598503|||CASE_CONTROL||PROSPECTIVE|||||||
33846302|NCT01569477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846303|NCT01322425|||CASE_CONTROL||PROSPECTIVE|||||||
33846304|NCT03095131|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34159657|NCT02303028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159658|NCT04840212|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159659|NCT05499468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159660|NCT00056004|RANDOMIZED|||PREVENTION||DOUBLE||||||
34159661|NCT00709618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159662|NCT02978833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159663|NCT04631848|||COHORT||PROSPECTIVE|||||||
34159664|NCT00595478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159665|NCT03858374|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159666|NCT04118049|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Investigators performing vaginal specimens are blinded to treatment arm.|Participants will be randomized to the treatment arm versus standard care arm.|f|f|f|t
34159667|NCT04386642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and outcome assessors are blinded to the drug that will be prepared by a pharmacist in the similar unlabelled 50-ml syringe.|The patients will be randomized into two parallel groups by block of four randomization.|t|f|f|t
34159668|NCT04993443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159669|NCT00309270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159670|NCT04814147|||CASE_ONLY||PROSPECTIVE|||||||
34159671|NCT04091880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34159672|NCT02451124|NA|SINGLE_GROUP||SCREENING||NONE||||||
34159673|NCT03084601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34159674|NCT06409247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159675|NCT06136013|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"This project will consist of a randomized cross-over exercise intervention involving 2 groups: Group 1, individuals with T2DM; Group 2, age-matched older adults with overweight/obesity. Each study will consist of 3, 2-week blocks of 3 days per week of supervised post-prandial exercise using high-intensity interval training (HIIT). Between each training block, a 2-week washout period, where participants avoid structured exercise, will take place. This has been shown to be enough time to eliminate any exercise effects on insulin sensitivity and glycemic control.~The cross-over groups are the following:~1. morning HIIT.~2. afternoon HIIT.~3. evening HIIT.~Each participant will serve as their own control, helping to account for the biological variability within the individual, as well as their individual chronotype, such as sleep/wake cycles. Participants will be randomly selected to a block order."||||
34159676|NCT02322970|||COHORT||PROSPECTIVE|||||||
34159677|NCT01098175|||CASE_CONTROL||PROSPECTIVE|||||||
33742864|NCT02899728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742865|NCT05954897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742866|NCT02308033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742867|NCT05223543|||COHORT||PROSPECTIVE|||||||
33742868|NCT02258477|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33742869|NCT05715580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33765151|NCT02377037|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33765152|NCT06266091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765153|NCT02966002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765154|NCT05852028|||COHORT||PROSPECTIVE|||||||
34159678|NCT06478563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded to the investigator (to the formulation).||f|f|t|f
34159679|NCT01378325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34055567|NCT02733185|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34055568|NCT05636787|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective non-blinded clinical phase II trial||||
34055569|NCT01945437|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055570|NCT00748189|RANDOMIZED|||TREATMENT||NONE||||||
34055571|NCT00813683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055572|NCT05207917|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2 intervention groups with either sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) surgery; in addition one small exploratory group undergoing undergoing single anastomosis sleeve ileal (SASI) bypass||||
34055573|NCT06605430|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants will be randomized 1:1 to early cannabis (EC) (n=16) versus delayed cannabis (DC) (n=16). The EC group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the EC group will be observed as per standard of care for the remaining 8 weeks. The DC group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program.||||
34055574|NCT03007290|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34055575|NCT03475472|||COHORT||PROSPECTIVE|||||||
34055576|NCT04255732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055577|NCT00321880|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055578|NCT06202625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055579|NCT04827082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not know if patient have received the treatment or not|A randomized control trial|f|f|f|t
34055580|NCT03751800|||COHORT||PROSPECTIVE|||||||
33742870|NCT06210256|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|To guarantee the blinding of the surgeons and data recorders, a cover was placed over the patient's head and the DLT connector during the surgical operation. An independent investigator, who blinded to treatment assignment, carried out the postoperative assessment of lung collapse quality and subsequent follow-up visits. The anesthesiologist, who performed the DLT intubation, was the only study personnel unblinded to the randomization scheme and was not involved in data collection and analysis.||t|t|t|t
33742871|NCT02825394|||COHORT||PROSPECTIVE|||||||
33742872|NCT03060941|RANDOMIZED|PARALLEL||PREVENTION||NONE||The 500 participants in the physical activity intervention will be randomly assigned to one of sixteen intervention groups (see Table below). Randomization will be stratified by clinical site. The randomization scheme will be conducted by the study statistician. The randomization scheme will consist of balanced blocks within each stratum, with block size will be varied and randomly permuted. Allocation will occur following completion of baseline assessments.||||
33742873|NCT00268749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742874|NCT04410692|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33742875|NCT05662501|NA|SINGLE_GROUP||OTHER||NONE||||||
33742876|NCT02685800|||COHORT||PROSPECTIVE|||||||
33742877|NCT03736525|RANDOMIZED|PARALLEL||OTHER||NONE|"Participants who will be found suitable for participation and who will agree online to participate in the study, will be randomized into intervention and wait list control groups, using an online software Research Randomizer. The wait list control group will not receive any special treatment during the study. Both groups will be asked to answer the online questionnaires, and after the end of the intervention period the wait list control group will get access to the Facebook group also, to compensate them for participation."|"Participants will be randomized online to intervention and wait list control groups. Intervention group only will be exposed to a new Facebook group, opened specifically for this study. The Facebook group will have a privacy setting of closed group, meaning that only members of the group can see posts. This is to prevent possible contamination, ensuring that members of the control group will not be exposed to the intervention. The intervention period will be 3 months. Participants in both groups will fill pre, mid and post intervention questionnaires. At the end of 3 months, we will change the settings of the group and open it to all, including the wait list control group. That way the control group will get access to the treatment as well, to compensate them for participation."||||
33742878|NCT06243653|||COHORT||PROSPECTIVE|||||||
33742879|NCT03877367|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study will be a patient and outcome assessor blinded, cross-over randomized clinical trial. Participants will randomized into two groups.|t|f|f|t
33742880|NCT03174977|NA|SINGLE_GROUP||OTHER||NONE||||||
33742881|NCT04218019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055581|NCT05525988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055582|NCT00742872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055583|NCT06618703|NA|SINGLE_GROUP||PREVENTION||NONE||Intervention research with minimum risks and constraints||||
34055584|NCT06374277|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Eligible patients who sign consent forms and complete baseline surveys will be randomized to the Med AAAction intervention group or the usual care in a 1:1 ratio, stratified by health system. The participants will be enrolled before hospital discharge. The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.||||
34055585|NCT02947204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34055586|NCT05971602|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742882|NCT00522249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055587|NCT03948035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055588|NCT06523881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055589|NCT04421560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055590|NCT05129475|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34055591|NCT05331248|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055592|NCT05053048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised controlles trial, double-blind. Block randomization with block size 10.|t|t|t|t
34055593|NCT06313476|||OTHER||PROSPECTIVE|||||||
34055594|NCT06553729|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34055595|NCT06305676|||CASE_CONTROL||PROSPECTIVE|||||||
34055596|NCT04570852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective cohort study||||
34055597|NCT02977325|||||PROSPECTIVE|||||||
34055598|NCT06348966|||COHORT||PROSPECTIVE|||||||
34055599|NCT05186636|||OTHER||PROSPECTIVE|||||||
34055600|NCT03936465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055601|NCT06464848|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055602|NCT00394836|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34055603|NCT06080594|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In a within-subject parallel-group longitudinal design, participants sustain an exercise training intervention with one leg, while the contralateral leg serves as an inactive control.||||
34055604|NCT04425473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055605|NCT06271603|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34055606|NCT05350332|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34055607|NCT00163982|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34055608|NCT00790998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055609|NCT05831839|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Participants of the multicentre prospective cohort study CO-FLOW (NL NL74252.078.20) suffering from persistent cognitive complaints as measured with the Cognitive Failure Questionnaire (CFQ ) of the CO-FLOW-study, a multicentre prospective cohort study, will be invited (if they have agreed to be approached for further reaerch)|t|f|f|f
34055610|NCT00588211|||OTHER||PROSPECTIVE|||||||
34055611|NCT05839405|||COHORT||CROSS_SECTIONAL|||||||
34055612|NCT04404920|||OTHER||CROSS_SECTIONAL|||||||
34055613|NCT05629494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055614|NCT04805580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2 groups (25 in each group) group intrathecal block group quadratus lumborum block|f|t|f|t
34055615|NCT06375746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055616|NCT05963386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159680|NCT05144711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"An informed consent will be obtained from the participant but he will not be informed whether selective or non selective excavation was done for him.~the outcome assessor will be blinded to the procedure, and if required masking of the crowns of teeth on radiographs will be done before evaluation."|Cases randomly assigned into the two groups using a block method|t|f|f|t
34159681|NCT03627208|||COHORT||RETROSPECTIVE|||||||
34159682|NCT00897468|||CASE_ONLY||PROSPECTIVE|||||||
34159683|NCT03424356|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|f|t
34159684|NCT05426915|||OTHER||PROSPECTIVE|||||||
34159685|NCT01441323|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34159686|NCT04526041|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159687|NCT00192413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159688|NCT05218642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Assignment|t|t|t|t
34159689|NCT02608463|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"All subjects will participate in Part A, receive standard of care and complete the painDETECT Questionnaire (PDQ) to be assigned to 1 of 3 groups based on the PDQ score.~Subjects in Part A will complete the following at study entry and each study visit: the Beck Depression Inventory (BDI), Visual Analogue Scale (VAS), Pain Catastrophizing Scale (PCS), and measures of pain intensity, interference, behavior. At each visit after study entry, subjects will complete the Patients' Global Impression of Change scale (PGIC); clinicians will complete the Clinical Global Impression-Global Improvement scale (CGI-I).~Subjects in Part B will receive rTMS and be followed daily until day 29 after last rTMS session. For each session, subjects will complete a VAS prior, immediately after, and 60 minutes post, day 22 \& day 29; a BDI on Days 1, 5, 12, 22, \& 29; on days 5, 12, 22, \& 29 subjects will complete the PGIC; clinicians will complete the CGI-I."||||
34159690|NCT00358436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742883|NCT02077023|||COHORT||PROSPECTIVE|||||||
33742884|NCT04102501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742885|NCT04735133|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742886|NCT03734224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742887|NCT01954706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742888|NCT03403725|NA|SEQUENTIAL||TREATMENT||NONE||Cohort1 0.05mg/kg STEP 1 Solid Tumors Cohort2 0.10mg/kg STEP 1 Solid Tumors Cohort3 0.20mg/kg STEP 1 Solid Tumors Cohort4 0.40mg/kg STEP 1 Solid Tumors Cohort5 0.80mg/kg STEP 1 Solid Tumors Cohort6 1.60mg/kg STEP 1 Solid Tumors Cohort7 2.40mg/kg STEP 1 Solid Tumors Cohort8 3.36mg/kg STEP 1 Solid Tumors + GCSF Cohort7b 2.40mg/kg STEP 1 Solid Tumors +GCSF Cohort7c 2.00mg/kg STEP 1 Solid Tumors +GCSF Cohort5 0.80mg/kg STEP 2 NHL||||
33742889|NCT05294757|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||three groups: control, exercise, and fragile|t|f|f|f
33742890|NCT05694624|||CASE_CONTROL||PROSPECTIVE|||||||
33742891|NCT02007486|||CASE_CONTROL||PROSPECTIVE|||||||
34055617|NCT01008956|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055618|NCT01785511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34159691|NCT00465842|||OTHER||PROSPECTIVE|||||||
33846305|NCT01637948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34159692|NCT03067389|||CASE_CONTROL||PROSPECTIVE|||||||
34159693|NCT00748423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159694|NCT02150447|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33846306|NCT00515853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33846307|NCT02948673|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33846308|NCT05658432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, parallel assignment, superiority, controlled trial||||
33846309|NCT00550303|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846310|NCT04848701|NA|SINGLE_GROUP||SCREENING||NONE||||||
33846311|NCT00185965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846312|NCT02639039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846313|NCT05842239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846314|NCT01503593|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846315|NCT00504998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846316|NCT01932125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846317|NCT06489405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846318|NCT03347890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, single-centre, double-blind, placebo controlled, parallel group, clinical trial.|t|t|t|t
33846319|NCT00810433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846320|NCT02605655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846321|NCT03831126|||CASE_ONLY||PROSPECTIVE|||||||
33846322|NCT02754739|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This study was initially designed as a single center, double-blind, placebo-controlled, 2-group factorial randomized trial (placebo or pravastatin 40mg once daily for 24 weeks). Subjects were randomly assigned, in a 1:1 ratio, to receive pravastatin in a blinded fashion at a dose of 40 mg once daily or placebo. However, because of the problem of expiration date of the placebo drug, the study was converted to an open-label trial, and subjects without any medications were enrolled in an open-label control group in contrast to the pravastatin group. Therefore, the study cohort comprised the pravastatin group, placebo group, and the open-label control group. The placebo group and the open-label control group were classified as the control group.|||||
33846323|NCT04688190|||COHORT||RETROSPECTIVE|||||||
33846324|NCT02207569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846325|NCT02776839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846326|NCT00162448|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33846327|NCT04180033|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be invited to undergo a colonoscopy surveillance.||||
33846328|NCT04876872|||OTHER||PROSPECTIVE|||||||
33846329|NCT02249598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846330|NCT00372645|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33846331|NCT00989625|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055619|NCT05740189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055620|NCT02128347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055621|NCT05634954|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Patients will be enrolled into 1 of 2 groups in a sequential manner. Group 1 will allow to study \[18F\]GEH121224 Biodistribution and Radiation Dosimetry. Group 2 will allow to study \[18F\]GEH121224 PET/CT Scan Test Retest.||||
34055622|NCT01684579|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055623|NCT00468442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055624|NCT06463652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055625|NCT06648720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34055626|NCT06328010|||COHORT||PROSPECTIVE|||||||
34055627|NCT06567613|||COHORT||PROSPECTIVE|||||||
34055628|NCT05856994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055629|NCT04288141|||COHORT||PROSPECTIVE|||||||
34055630|NCT05942105|||COHORT||RETROSPECTIVE|||||||
34055631|NCT03805451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055632|NCT06249854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159695|NCT01193114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159696|NCT04967027|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34159697|NCT00513435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159698|NCT04888169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34159699|NCT01443702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159700|NCT05984602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159701|NCT02069119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159702|NCT02535546|||COHORT||PROSPECTIVE|||||||
34159703|NCT01425125|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846332|NCT04317365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846333|NCT05219994|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||After screening, participants will complete two study visits.||||
34055633|NCT06215560|||COHORT||PROSPECTIVE|||||||
34055634|NCT06618443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055635|NCT02366234|||COHORT||PROSPECTIVE|||||||
34055636|NCT04376125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159704|NCT00320515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159705|NCT05004220|||CASE_CROSSOVER||PROSPECTIVE|||||||
34159706|NCT03450382|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Open label, quasi-experimental clinical trial comparative study.||||
33846334|NCT00534898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846335|NCT02683551|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846336|NCT00720772|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846337|NCT03932812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33846338|NCT00021736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159707|NCT06267534|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34159708|NCT06415227|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159709|NCT05109923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34159710|NCT02776059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055637|NCT03713008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients included in the study will receive 4 ml/kg fluid bolus.||||
34055638|NCT06642519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055639|NCT04887090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055640|NCT03492671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055641|NCT04161079|||COHORT||RETROSPECTIVE|||||||
34055642|NCT03895606|||CASE_ONLY||PROSPECTIVE|||||||
34055643|NCT04316039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055644|NCT01344577|||COHORT||PROSPECTIVE|||||||
34055645|NCT04058535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055646|NCT03490461|||COHORT||RETROSPECTIVE|||||||
34055647|NCT00702442|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34055648|NCT05214586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055649|NCT06204094|NA|SINGLE_GROUP||TREATMENT||NONE||Radiation: node-sparing short-course radiotherapy (5Gy\*5d) Drug: PD-1 antibody (Sintilimab) Drug: Capecitabine Drug: Oxaliplatin||||
34055650|NCT05496283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34055651|NCT04036305|||COHORT||PROSPECTIVE|||||||
34055652|NCT02600845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055653|NCT02976675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055654|NCT06622187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055655|NCT01594892|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of the single intervention - dose-intensified SBRT||||
34055656|NCT05146986|||OTHER||PROSPECTIVE|||||||
34055657|NCT04403503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|One author (H.G.K.) randomly assigned the patients, with 1:1 allocation ratio, into GS and GS+CY groups by making simple randomization without blocking (computer-generated randomization scheme) (Figure 1). Number-labeled opaque envelopes containing the name of assigned method were used for allocation concealment. The surgical procedures were carried out by (B.T.Y.) whereas another author (E.C.) acquired the intra- and post-operative data. No information regarding to the applied hemostatic was given to the patients to preserve the patient blinding.||t|t|t|t
34055658|NCT06105749|NA|SINGLE_GROUP||SCREENING||NONE||contrast-enhanced mammography||||
32812484|NCT06728397|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Trial statisticians will be blinded to allocation.|A pragmatic, single-blind, multi-site, parallel group cluster RCT. Cluster randomisation will be used to allocate Talking Therapies Teams and their patients to either intervention or usual care arms. In the experimental arm, treatment selection will be guided by an AI tool (StratCare app). In the USC arm, treatment will be selected following usual clinical practice and guidelines.|t|f|f|t
34055659|NCT00319384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055660|NCT05274581|||COHORT||PROSPECTIVE|||||||
34159711|NCT04085497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|The patients were divided into two groups, each comprising 40 patients. KT and exercise were given to the patients in the first group, and only exercise was given to the patients in the second group. The inclusion criteria included patients between the ages of 20 and 55 who were diagnosed as MPS by MPP test and MRI imaging and did not develop cartilage damage. Patients with meniscal tear, chondral injury or instability of the knee were excluded.|f|f|t|f
34159712|NCT03036020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159713|NCT03833466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159714|NCT05271812|||COHORT||PROSPECTIVE|||||||
34159715|NCT02689115|||CASE_ONLY||CROSS_SECTIONAL|||||||
34159716|NCT02978196|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34055661|NCT00382525|||COHORT||PROSPECTIVE|||||||
34055662|NCT06621108|||COHORT||PROSPECTIVE|||||||
34055663|NCT04651049|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34055664|NCT05496959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055665|NCT06461247|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not feasible to apply blinding to the study design due to the nature of the intervention.|"Standard Care Group (n=70): Participants will be having liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner.~Intervention Group (n=70): Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy keto breakfast.~Both groups will be recommended to keep within the calorie limit to 800kcal and 50g net carbohydrates per day."||||
34055666|NCT02900105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055667|NCT01223469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055668|NCT06144320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055669|NCT05856149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055670|NCT02933619|||OTHER||RETROSPECTIVE|||||||
34055671|NCT02781753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055672|NCT03096678|||CASE_CONTROL||PROSPECTIVE|||||||
34159717|NCT01067144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34159718|NCT00192816|||DEFINED_POPULATION||OTHER|||||||
34159719|NCT02428569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34159720|NCT00791752|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34159721|NCT00214981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159722|NCT02519205|||COHORT||PROSPECTIVE|||||||
34159723|NCT01984502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159724|NCT05490576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159725|NCT04153682|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34159726|NCT02900768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159727|NCT02152319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34159728|NCT05700994|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||This is a cluster-randomized pragmatic trial using a hybrid type 1 effectiveness-implementation framework and stepped-wedge design.||||
34055673|NCT05856370|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33742892|NCT02722889|||COHORT||RETROSPECTIVE|||||||
33742893|NCT03612193|||COHORT||PROSPECTIVE|||||||
33742894|NCT03757247|||OTHER||PROSPECTIVE|||||||
33742895|NCT02349958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33742896|NCT00006172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742897|NCT00931151|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33742898|NCT04719585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742899|NCT00489450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765155|NCT05797792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation of the primary outcome measure (microvascular hypoperfusion on CTP) will be conducted at the Imaging Central Core Laboratory by blinded evaluators. The evaluation of key clinical outcome at 3 months will be conducted by central blinded evaluators following a structured questionnaire of the modified Rankin Scale (mRS|Multicenter, prospective, randomized, open, blinded end-point assessment phase III trial|f|f|f|t
33765156|NCT00192062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765157|NCT06622720|||CASE_CONTROL||RETROSPECTIVE|||||||
33765158|NCT00314067|RANDOMIZED|PARALLEL||||NONE||||||
33765159|NCT06006845|||COHORT||RETROSPECTIVE|||||||
34055674|NCT00312481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055675|NCT06648967|NA|SINGLE_GROUP||OTHER||NONE||||||
34055676|NCT06643416|RANDOMIZED|PARALLEL||TREATMENT||NONE||40 Adult patients aged 18 or above who received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer, who develop paronychia (affecting fingernails, toenails or both),as an adverse event from EGFR-TKI use will be included in this study. Patients will be randomized in 1:1 ratio using computer-generated randomization list to receive either combination of topical timolol 0.5% eye drops and betamethasone valerate 0.1% lotion application twice daily or betamethasone valerate 0.1% lotion application twice daily.||||
34055677|NCT05672407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34055678|NCT05880082|NA|SINGLE_GROUP||TREATMENT||NONE|The study was a one-arm open study|||||
34055679|NCT03820817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055680|NCT03683186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055681|NCT01778738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055682|NCT05481593|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34055683|NCT04860687|||COHORT||PROSPECTIVE|||||||
34055684|NCT03719287|||COHORT||CROSS_SECTIONAL|||||||
34055685|NCT05715489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055686|NCT02584998|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34055687|NCT02883075|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34055688|NCT00438243|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34055689|NCT04207931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"To help ensure subject privacy and confidentiality, only a unique study identifier will appear on the data collection form. The data collected will be stored on the Research Electronic Database CaptureTM with access limited to designated study personnel.~Blinded investigators from Wake Forest Baptist Department of Dermatology will later review photographs of each subject taken at baseline and at month 18 and will assign severity scores to the photographs based on the Central Scalp Alopecia Scale. These investigators will not know when each photograph was taken."|Treatment groups that patients will be randomized to include 1) topical steroid plus oral antibiotic group, and topical minoxidil after 8 months 2) topical steroid plus intralesional steroid group and topical minoxidil after 8 months.|f|f|f|t
34055690|NCT05088590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055691|NCT04294706|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34055692|NCT00432276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055693|NCT00665587|||COHORT||PROSPECTIVE|||||||
34055694|NCT03509077|||OTHER||PROSPECTIVE|||||||
34055695|NCT03430401|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34055696|NCT02484651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055697|NCT06454591|||COHORT||PROSPECTIVE|||||||
34055698|NCT03597009|NA|SINGLE_GROUP||TREATMENT||NONE||We will conduct a Phase Ib/II trial that includes a safety run-in period using 3 +3 dose escalation rules to evaluate the feasibility of administering talimogene laherparepvec into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter.||||
34055699|NCT05200013|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34055700|NCT06621628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|masking was done by sealed envelopes|to evaluate the efficacy of the Polarized light therapy and Hand Grip Strengthening exercises in patients with CREST syndrome.|t|f|f|f
34055701|NCT01875627|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34055702|NCT01120080|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34055703|NCT04954742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055704|NCT01219894|||CASE_CONTROL||PROSPECTIVE|||||||
34055705|NCT06621901|RANDOMIZED|PARALLEL||OTHER||SINGLE|The content of the diet will be given to the participants without specifying it.|It consists of two parallel groups receiving a high-protein diet and a normal-protein diet.|t|f|f|f
34055706|NCT06333574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055707|NCT02358525|||CASE_CONTROL||PROSPECTIVE|||||||
34055708|NCT05521334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055709|NCT05756790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Couples will be randomized 1:1||||
34055710|NCT01092819|||COHORT||PROSPECTIVE|||||||
34055711|NCT00970632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742900|NCT00610051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The party or parties involved in the study trials who are prevented from having knowledge of the interventions assigned to individual participants|This multicenter, double-blind, placebo-controlled, randomized, parallel-group trial will study up to approximately 700 patients with advanced HFrEF who are not expected to receive heart transplant or LVAD placement for 6 months after enrollment. Eligible patients will be randomized (1:1) to receive either alprostadil 250 μg/day, regardless of body weight, or placebo (normal saline) given in a continuous infusion. Study drug administration will continue until study closure so long as clinically tolerated and the mortality endpoint has not been achieved; patients are to be followed for survival regardless of whether or not they remain on study drug. The difference in mortality rates between the two groups will be compared after approximately 350 deaths, LVAD placements, or heart transplantations have occurred. The study will include an embedded pilot evaluation of secondary nonfatal clinical endpoints and AESIs/ tolerability for purposes of possible protocol modification.|t|t|t|t
33742901|NCT03790982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Parallel Assignment, Multiple Groups, Multiple Centers|t|f|t|f
34055712|NCT05803447|||CASE_CROSSOVER||PROSPECTIVE|||||||
33742902|NCT06387043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742903|NCT04023006|||CASE_ONLY||PROSPECTIVE|||||||
33742904|NCT02239523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742905|NCT05056350|NA|SINGLE_GROUP||OTHER||NONE||||||
34055713|NCT06647901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742906|NCT05209893|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33742907|NCT01889420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055714|NCT05093959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care providers, investigators, and outcomes assessors will be unmasked at the end of data collection of all participants.||t|t|t|t
33742908|NCT05239091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, Outcomes Assessor, and Investigator (statistician) will be blinded|Prospective, randomized, triple blinded, clinical trials|t|f|t|t
33742909|NCT05546281|||CASE_ONLY||CROSS_SECTIONAL|||||||
33742910|NCT05287867|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single-blind||t|f|f|f
33742911|NCT05571943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742912|NCT01476215|RANDOMIZED|CROSSOVER||||NONE||||||
33742913|NCT05869305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34055715|NCT06620029|NA|SEQUENTIAL||TREATMENT||NONE||Dose finding stage followed by an expansion cohort.||||
34055716|NCT02275780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055717|NCT03358771|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34055718|NCT06295991|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34055719|NCT00157248|NON_RANDOMIZED|||PREVENTION||NONE||||||
34055720|NCT05511207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Clinical/Functional evaluation of patients will be performed by expert physiotherapists blinded to group allocation.~Data analysis (EEG, EMG, cinematic) will be performed by neuroscientists blinded to group allocation."|Eligible patients admitted to Fondazione Santa Lucia will be randomized in equal proportions between target intervention (RECOM) and control (CTRL)|f|f|f|t
34055721|NCT01071486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055722|NCT05835362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Youth will be randomized within provider to either the question prompt list only group (N=35), the pre-visit video only group (N=35), the combined question prompt list/video intervention group (N=35), or the control group (N=35). This will ensure group balance. The investigators are including a usual care control group because the team needs to control for the many factors that might influence communication (such as youth age, parent educational level, etc.) By randomizing families to the four groups, these factors should be evenly distributed across the groups.|f|t|t|t
34055723|NCT00759785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055724|NCT04393064|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||75 preterm and 75 fullterm will be recruited in this study; all will be hemodynamically stable on discharge then doing FEES||||
34055725|NCT00979589|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055726|NCT05043012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055727|NCT00516191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055728|NCT06621212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159729|NCT04202237|||COHORT||PROSPECTIVE|||||||
34159730|NCT01063647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159731|NCT03611673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159732|NCT04875091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159733|NCT02197091|||CASE_ONLY||PROSPECTIVE|||||||
34159734|NCT04428957|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159735|NCT04086199|||COHORT||RETROSPECTIVE|||||||
34159736|NCT05083312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159737|NCT00239889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159738|NCT03523572|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 will be a sequential dose-finding (dose escalation) study, Part 2 will consist of a single group of four cohorts who receive the recommended dose (determined during Part 1)||||
34159739|NCT02008227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159740|NCT04567394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomized 1:1 to the intervention or waitlist control. Participants who complete the 6 months of waitlist control will then have the opportunity to receive the intervention.|f|f|t|t
34159741|NCT05967650|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159742|NCT00108316|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34159743|NCT04803227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, Placebo-controlled, Randomized, 1:1 active: placebo.|t|t|t|f
34159744|NCT03369977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159745|NCT05799768|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159746|NCT04357483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single Blind|Arm1 (intervention) : flowable thrombin containing collagen hemostat matrix Arm2 (Control) : thrombin coated L-dopa contained collagen patch|t|f|f|f
34159747|NCT01625000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159748|NCT01033916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159749|NCT02809339|||COHORT||PROSPECTIVE|||||||
34159750|NCT05342272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34159751|NCT03089541|NA|SINGLE_GROUP||TREATMENT||NONE||30 non-treatment seeking young adult e-cigarette/cigarette dual users (15 males/15 females) will participate in a contingency-management reinforced 1 week observation period||||
34159752|NCT03804853|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159753|NCT00034827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159754|NCT02602119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159755|NCT04647123|||CASE_CONTROL||PROSPECTIVE|||||||
34159756|NCT05868837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159757|NCT05065853|||OTHER||CROSS_SECTIONAL|||||||
34159758|NCT05018650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159759|NCT01629459|NA|SINGLE_GROUP||TREATMENT||NONE||Resistance exercise training||||
34159760|NCT05426070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34159761|NCT03954821|||COHORT||OTHER|||||||
34159762|NCT03603483|RANDOMIZED|PARALLEL||TREATMENT||NONE||Aortic Root Enlargement in Patients with aortic stenosis with Small Aortic Annulus||||
34159763|NCT06108206|NA|SINGLE_GROUP||TREATMENT||NONE||Adaptive Radiation to the Brain||||
34159764|NCT03634930|||COHORT||PROSPECTIVE|||||||
34159765|NCT00741013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159766|NCT05541575|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159767|NCT03781505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized control trail|t|f|t|t
34159768|NCT01825967|||CASE_ONLY||PROSPECTIVE|||||||
34055729|NCT03203408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To prevent the patients from knowing the nature of their treatment, the investigational products OSTENIL PLUS and SYNVISC-ONE were packed in identical neutral packs. OSTENIL PLUS and SYNVISC-ONE differ in appearance (product volume and viscosity, prefilled syringe) and were therefore readily identifiable by the investigator administering the investigational product (i.e. injecting investigator). The double-blind masking could be ensured thanks to the intervention of an observer who did not know the nature of the treatment, namely the evaluating investigator. The treatment was therefore administered blind to the evaluating investigator and the patient but not to the injecting investigator.|This study was a multicentre, prospective, double-blind, randomised, controlled non-inferiority study in two parallel groups of patients followed up for six months.|t|f|f|t
33742914|NCT04257318|NA|SINGLE_GROUP||OTHER||NONE||||||
33742915|NCT05806762|||COHORT||PROSPECTIVE|||||||
33742916|NCT01320410|NON_RANDOMIZED|||TREATMENT||SINGLE||||||
34055730|NCT03177434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34055731|NCT00569647|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34055732|NCT02624245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055733|NCT04958681|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055734|NCT03175692|||CASE_ONLY||CROSS_SECTIONAL|||||||
34055735|NCT05212701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055736|NCT06621992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055737|NCT06622837|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34055738|NCT02131818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34159769|NCT04301544|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34159770|NCT02470325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159771|NCT06583863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159772|NCT03628976|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34159773|NCT02376868|||COHORT||PROSPECTIVE|||||||
34159774|NCT04123145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159775|NCT04909203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159776|NCT03162419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159777|NCT04710147|||OTHER||OTHER|||||||
34159778|NCT05370872|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The individual responsible for comparing return-to-work outcome between groups will be blind to the group assignments|Cluster randomized controlled trial. Clinicians will be randomly assigned to administer the functional testing protocol in-person (care-as-usual) or remotely (the intervention). Clients will complete the functional testing protocol based on the group assignment of the clinician to whom they were referred to.|f|f|f|t
34159779|NCT04087577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34159780|NCT04983355|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34159781|NCT03579043|RANDOMIZED|FACTORIAL||SCREENING||NONE||To see if caloric compensation occurs during 3-day exposure to non-nutritive sweeteners, a 3x4 mixed factorial design will be used, with a between-subject factor of intervention group (NNS, NS, and control) and within-subject factor of time (baseline, day 1 of beverage exposure, day 2 of beverage exposure, and day 3 of beverage exposure).||||
34159782|NCT05365126|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot/feasibility Cohort study||||
34159783|NCT03302247|NA|SINGLE_GROUP||TREATMENT||NONE||Nivolumab 240mg, IV on day 1, 15 + Gemcitabine 1000mg/m2, IV on day 1, 8, 15 of 28 days cycle||||
34159784|NCT04820413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159785|NCT01963845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159786|NCT02865655|||COHORT||PROSPECTIVE|||||||
34159787|NCT00662168|||CASE_ONLY||RETROSPECTIVE|||||||
34159788|NCT03593044|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will take drops for one week and measurements will be taken before and after treatment period.||||
34159789|NCT04063592|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective clinical trial in which intervention subjects will serve as their own control||||
34159790|NCT00748371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34159791|NCT01848119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159792|NCT03257683|||CASE_ONLY||PROSPECTIVE|||||||
34159793|NCT00691184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159794|NCT03469713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159795|NCT05179525|NA|SEQUENTIAL||TREATMENT||NONE||This is an open-label, 1-sequence study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany) in subjects with schizophrenia who are on stable oral risperidone treatment. The study consists of a screening visit, 1 treatment period with inpatient and outpatient visits, and a follow-up visit.||||
34159796|NCT03833219|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33765160|NCT01226914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||prospective randomized placebo-controlled double-blind trial.|t|t|t|f
33765161|NCT04113681|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients will be stratified into two groups:~* Group 1: Patients between 18-50 years old with KL grade 3-4~* Group 2: Patients age 50 years old and over with KL grade 1-4"||||
34055739|NCT04258254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participating children are matched on age, gender, and level of functioning. Matched pairs will be randomized to a) multimodal or b) general movement or c) standard of care, seated play group.|f|f|f|t
34055740|NCT04117672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Egg powder enriched for antisecretory factor and placebo egg powder with the same color, taste and texture,|Participants with severe TBI and scheduled for multimodal monitoring will be randomised to active or placebo treatment.|t|t|t|t
34055741|NCT05469269|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The data analyst will be blinded to the study arm assignments.||f|f|f|t
34055742|NCT02086084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055743|NCT03265821|||COHORT||RETROSPECTIVE|||||||
34055744|NCT03380702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL|t|t|t|f
34055745|NCT02809105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055746|NCT06452199|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomised controlled double-blinded intervention trial|t|t|t|t
34055747|NCT04470505|||COHORT||PROSPECTIVE|||||||
34055748|NCT03129191|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055749|NCT06523907|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055750|NCT06613854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055751|NCT06350461|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055752|NCT05729399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055753|NCT03535454|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34055754|NCT02208661|||COHORT||PROSPECTIVE|||||||
34055755|NCT02908672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055756|NCT06623513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33765162|NCT04313959|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055757|NCT01858779|||COHORT||PROSPECTIVE|||||||
34055758|NCT06581809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||multicenter, open-label/randomized, 2-arm parallel, superiority trial, national.||||
34055759|NCT00712881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055760|NCT06624215|||COHORT||RETROSPECTIVE|||||||
34055761|NCT03164473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055762|NCT05960227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, placebo-controlled clinical trial, method of randomization in blocks of 5 by frequency of occurrence. In patients with acute renal injury, patients will be allearorized to receive intravenous iron dextran in 1 single exhibition according to the Mg granted by the Virizzi formula compared to placebo.|t|t|t|f
34055763|NCT02809859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055764|NCT03726203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055765|NCT00707278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055766|NCT03273465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (Subject, Caregiver, Investigator)|This is a placebo-controlled, double blinded interventional study evaluating oral, fecal microbiota transplantation, administered in patients with mild-moderate UC.|t|t|t|f
34055767|NCT02417922|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34055768|NCT04892628|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34055769|NCT00895128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055770|NCT05177354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055771|NCT00690196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055772|NCT00039494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055773|NCT03441971|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34055774|NCT06028516|||COHORT||PROSPECTIVE|||||||
34055775|NCT06602856|||COHORT||PROSPECTIVE|||||||
34055776|NCT06622135|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055777|NCT01202370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055778|NCT04569747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055779|NCT00866086|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055780|NCT06623318|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigation will be designed as a retrospective cohort study, in which assignment to the IV Ensure device is determined based on patient discharge status (home IV for antimicrobial therapy) and current device allocation. Patients will be assigned to IV Ensure subsequent to their initial health encounter for their admitting diagnosis. The non-treatment group will be assigned to home infusion therapy using the current standard of care of OU Medicine. This group is required in order to assess whether the usage of the IV Ensure device is associated with a reduction in subsequent readmission risk due to infection.||||
34055781|NCT05996107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055782|NCT05763875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor Personnel participating in the study conduct will also be blinded.|Multi-center, randomized, double-blind, placebo-controlled, parallel groups|t|t|t|f
34055783|NCT06299904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055784|NCT01921244|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34055785|NCT00868725|||CASE_ONLY||CROSS_SECTIONAL|||||||
34055786|NCT06363838|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055787|NCT01916603|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
34055788|NCT06054243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055789|NCT00409110|||CASE_ONLY||PROSPECTIVE|||||||
34055790|NCT00874835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055791|NCT01826357|||COHORT||RETROSPECTIVE|||||||
34055792|NCT06648590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055793|NCT03272659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055794|NCT02558621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055795|NCT00656487|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34055796|NCT00033176|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34055797|NCT06157801|||COHORT||PROSPECTIVE|||||||
34055798|NCT06618209|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055799|NCT06154395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055800|NCT02113995|RANDOMIZED|PARALLEL||||NONE||||||
34055801|NCT01735344|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055802|NCT03540004|||COHORT||PROSPECTIVE|||||||
34055803|NCT00483197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055804|NCT01932736|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34055805|NCT03573960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055806|NCT02212990|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055807|NCT05923775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055808|NCT05277142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055809|NCT05382793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single-center, randomized, controlled, dose-response metabolic balance study with cross-over design||||
33742917|NCT03517644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Using a cover story, participants are instructed to think that there are three experimental groups: a treatment condition, a placebo condition, and a control condition. Therefore, participants from the open-label groups do know that they receive a placebo, but do not know which specific mechanism is being addressed in their condition.|Participants are assigned to one of four experimental groups in parallel for the duration of the study|t|f|f|f
33742918|NCT05404529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742919|NCT03547661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742920|NCT05877729|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34055810|NCT04988022|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34055811|NCT04074746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055812|NCT01795092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055813|NCT01785225|NA|SINGLE_GROUP||||NONE||||||
34055814|NCT06648343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055815|NCT06416787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34055816|NCT06649136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|joint assessor blinding||f|f|f|t
34159797|NCT01746225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159798|NCT05706441|||COHORT||PROSPECTIVE|||||||
34159799|NCT03124836|NA|SINGLE_GROUP||OTHER||NONE||||||
34159800|NCT06530966|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34159801|NCT01177189|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Participants will consume either a daily oral antioxidant cocktail or a placebo. The oral antioxidant cocktail consists of vitamin C, vitamin E, and alpha lipoic acid.|t|f|t|t
34159802|NCT01558453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159803|NCT00760318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159804|NCT00227812|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34159805|NCT01037686|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34159806|NCT00195286|||CASE_ONLY||PROSPECTIVE|||||||
34159807|NCT05728398|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159808|NCT00571038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159809|NCT00125320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159810|NCT05267951|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Functional measurements and all other assessments will be done by an examiner who does not know the order of the intervention arm.|"Participants who participate in Aim 1 Section of the study will receive open-loop and closed-loop stimulation intervention arms in a randomized order.~The order of the two interventions in the Aim 2 Section of the study will be the same for all participants enrolled in the Aim 2 Section of the study."|f|f|f|t
34159811|NCT01248949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159812|NCT06040762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33742921|NCT04405024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159813|NCT04529343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assisting Hand Assessment was planned to be used in the evaluation of upper extremity functions as the primary outcome assessment tool. The person making this assessment will be blind to the study groups.|The virtual reality group will be given upper extremity rehabilitation via virtual reality glasses (3 days a week for 6 weeks and 45 minutes each session) and upper extremity exercises 2 days a week, while the control group will only be given upper extremity exercises 2 days a week.|f|f|f|t
33742922|NCT05774808|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742923|NCT00855829|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33742924|NCT05363033|||CASE_ONLY||PROSPECTIVE|||||||
34055817|NCT05066282|||COHORT||RETROSPECTIVE|||||||
34055818|NCT05209126|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159814|NCT00276809|NON_RANDOMIZED|||TREATMENT||NONE||||||
34159815|NCT04026217|||COHORT||PROSPECTIVE|||||||
34159816|NCT03355066|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34159817|NCT00640497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159818|NCT04405973|||COHORT||RETROSPECTIVE|||||||
34159819|NCT05594628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Adolescent female basketball players that is not currently doing any prevention programme and not currently injured in last 6 months that will make them not to attend any training that happened|After first evaluation groups are randomly assigned to 2 groups. Both groups keep attending basketball trainings. One group is just going to keep attending basketball trainings, one group is going to keep attending usual basketball trainings and going to receive neuromuscular training that will be added in warming up exercises|t|f|f|f
34159820|NCT02606331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159821|NCT04314674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All the patients, the anesthesiologist who will evaluate the postoperative cranial CT will be blind to study group|Group 1: %3 HS bolus 3 mL.kg-1 Group 2: %3 HS infusion 20 ml/h Group 3: %20 mannitol 0,6 gr.kg-1|t|f|t|f
34159822|NCT06583759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159823|NCT01080846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159824|NCT01957371|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34159825|NCT01777776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159826|NCT01260597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159827|NCT02564978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159828|NCT00907504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159829|NCT00587704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34159830|NCT01451385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159831|NCT05822622|||OTHER||CROSS_SECTIONAL|||||||
34159832|NCT01974011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951424|NCT05297604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the placeb group will be treated in the same way as the active laser group. The person in charge of the application will simulate the irradiation with the equipment kept off, so that the participant does not identify the group to which he/she belongs to, and the device activation sound (beep) will be turned on at the time of application.||t|f|f|f
33951425|NCT03762642|||COHORT||RETROSPECTIVE|||||||
34055819|NCT03788746|||COHORT||PROSPECTIVE|||||||
34055820|NCT03565029|NA|SINGLE_GROUP||TREATMENT||NONE||one-stage phase II trial seeking to establish whether an oxaliplatin-based chemotherapy preceding standard neo-adjuvant fluoropyrimidines-based chemo radiotherapy, can safely spare demolitive surgical intervention in patients with operable rectal cancer, without increasing the risk of distant relapse. The trial also has a translational component aimed at establishing whether selected genomic, epigenetic, and transcriptomic markers are predictive of tumor and patient outcome.||||
34055821|NCT03885180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159833|NCT03326700|RANDOMIZED|PARALLEL||TREATMENT||NONE||176 men with unilateral inguinal hernia were randomized in two groups. Group T(n=88) were operated TEP and Group L(n:88) were operated by LH repair. Patients demografigs, perioperative findings were recorded. For all patients preoperative, postoperative 7th,30th and 90th day SF 36 and IIEF were filled up.||||
34159834|NCT01286077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159835|NCT02059304||||SCREENING||||||||
33742925|NCT00002872|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34055822|NCT00670293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742926|NCT03457259|RANDOMIZED|PARALLEL||OTHER||NONE||60 patients in each group, with a total of 2 groups||||
33742927|NCT04193813|||COHORT||PROSPECTIVE|||||||
33742928|NCT00382343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742929|NCT02232529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
33742930|NCT04573335|||COHORT||CROSS_SECTIONAL|||||||
33742931|NCT04296565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742932|NCT02012374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742933|NCT02807948|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742934|NCT00592995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742935|NCT03064425|||COHORT||PROSPECTIVE|||||||
33742936|NCT02289391|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33742937|NCT02863562|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33742938|NCT02394743|||CASE_CONTROL||RETROSPECTIVE|||||||
33742939|NCT06215846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742940|NCT05718765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33742941|NCT05883306|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33742942|NCT02167022|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33742943|NCT01043874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742944|NCT03171233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742945|NCT05978596|||COHORT||PROSPECTIVE|||||||
33742946|NCT02053233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742947|NCT03994861|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Patients with musculoskeletal disorders are compared to matched healthy controls.|t|f|t|f
33742948|NCT05104606|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33742949|NCT01977911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742950|NCT01285375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742951|NCT06497257|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742952|NCT04979819|NA|SINGLE_GROUP||SCREENING||NONE||Validity and Reliability||||
33742953|NCT03815071|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33742954|NCT02389543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742955|NCT02039505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742956|NCT06329635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The assigned intervention will be performed only by a separate unblinded dedicated physician who signs the confidential agreement. The attending/investigating physician and patient are blinded to the intervention assignment."||t|t|t|t
33742957|NCT01388387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742958|NCT04620473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742959|NCT01243450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951426|NCT05250739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent assessor blinded to the data collection was responsible for the allocation process. A list of the computer-generated number was employed to assign participants to experimental or control group|A single-blind randomized controlled trial.|f|f|t|t
33951427|NCT02818582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055823|NCT00001029||||TREATMENT||||||||
34055824|NCT05887570|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Outcomes Assessor is blinded.|Educational Intervention|f|f|f|t
34055825|NCT03074435|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a cluster-randomized, parallel with baseline, trial. The study is bi-centric for the evaluation of two arms (LLIN+IRS and LLIN+BCC)||||
34055826|NCT01806961|||COHORT||PROSPECTIVE|||||||
34055827|NCT04636385|||OTHER||CROSS_SECTIONAL|||||||
33742960|NCT05400096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742961|NCT00119509|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33742962|NCT03291444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742963|NCT02255110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742964|NCT05937438|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled would be randomly assigned to experimental arm (esophagectomy followed by postoperative radiotherapy with immunotherapy) and controlled arm (esophagectomy followed by postoperative radiotherapy).||||
33742965|NCT02559986|||COHORT||CROSS_SECTIONAL|||||||
33742966|NCT04916639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742967|NCT02806739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742968|NCT05026957|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33742969|NCT01045850|||COHORT||PROSPECTIVE|||||||
33742970|NCT02435719|||COHORT||PROSPECTIVE|||||||
33951428|NCT01477775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055828|NCT03664310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055829|NCT00915486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055830|NCT05814094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33951429|NCT06375577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both the participants and investigators will be blinded to what supplement they are consuming on each visit. Each supplement will taste the same, and be placed into identical packaging, and be randomly labelled (e.g., A, B, C). This will be done to avoid potential bias.|"This will be a double-blind randomised crossover design. There will be 1 group of participants who will complete all three conditions at random:~Condition 1 - consume Voom Pocket Rocket. Condition 2 - consume SIS Isotonic Energy Gel. Condition 3 - consume Maurten Gel 160.~All participants will undergo the same measures - blood sampling for blood glucose, blood lactate, and insulin, and monitoring of gas exchange during each study visit."|t|f|t|f
33951430|NCT05979389|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, research staff, or patients. The following study procedures will be in place to ensure double-blind administration of study treatments Access to the randomization code will be strictly controlled. A color and size-matched placebo capsule that looks identical to the bicalutamide capsule will be used.~Packaging and labeling of test and control treatments will be identical to maintain the blind.~The study blind will be broken on completion of the clinical study, after all study endpoints have been ascertained by blinded study coordinators and after the study database has been locked.~During the study, the blind may be broken only in emergencies when knowledge of the patient's treatment group is necessary for further patient management. The University of California San Francisco investigational pharmacy would then be notified and responsible for unblinding."|"The following treatment regimens will be used:~* Experimental treatment - bicalutamide, 50 mg once daily~* Placebo or Comparator - one capsule, once daily"|t|t|t|t
33951431|NCT02923557|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33951432|NCT00483574|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951433|NCT04706585|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33951434|NCT05376657|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33951435|NCT06102070|||COHORT||PROSPECTIVE|||||||
33951436|NCT02014909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055831|NCT05566873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be masked to condition assignment.|Eligible individuals will be randomized to either a continuing remote educational physical activity program along with general human and planetary health information (control), or to the educational physical activity program plus a remote citizen science program aimed at physical and social environmental barriers to walking and other physical activities.|f|f|f|t
34055832|NCT06060613|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34055833|NCT04212208|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055834|NCT04792463|||FAMILY_BASED||PROSPECTIVE|||||||
34055835|NCT02767492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055836|NCT06148428|||COHORT||PROSPECTIVE|||||||
34055837|NCT00792246|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055838|NCT04271319|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (participant, care provider)|"Device: Avazzia Pro-Sport Ultra® device~High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics."|t|f|t|f
34055839|NCT03196427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055840|NCT03140332|NA|SINGLE_GROUP||OTHER||NONE||||||
34055841|NCT02836964|||CASE_ONLY||PROSPECTIVE|||||||
34055842|NCT04711330|||COHORT||PROSPECTIVE|||||||
34055843|NCT04500106|||COHORT||PROSPECTIVE|||||||
34159836|NCT01055314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159837|NCT06166199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors are blinded for which patient is randomised to which group.|"This is a randomised-controlled single blinded multicenter study. The trial will follow the Consolidated Standards of Reporting Trials, www.consort-statement.org and comprise two arms.~After information of the study and written informed consent, the patients are block-randomised (from the aerobic capacity results) to either an intervention group doing supervised high-intensity interval training combined with resistance training or a control group. Both groups receive standard care."|f|f|f|t
34159838|NCT00531869|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34159839|NCT03694834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159840|NCT01984918|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34159841|NCT05003596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|data without intervention identification will be analyzed by outcome assessor||f|f|f|t
34159842|NCT05629130|NA|SINGLE_GROUP||TREATMENT||NONE|no masking - all treatement|longitudinal, prospective study.||||
34159843|NCT05725980|||OTHER||RETROSPECTIVE|||||||
34159844|NCT01331980|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34159845|NCT04280796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|participants are not fully instructed about the purpose before and during the test but will be debriefed after testing|"Study comprises an intervention that is neither a therapeutic or transplant product nor a transplant. Study involves minimal risks for participants. Used methods are within the range of standard methods frequently used in pain research. All participants will perform 2 psychophysical tasks to assess sensory-discriminative \& emotional-motivational pain responses independently from each other.~Substudy1: An operant learning paradigm will be implemented to dissociate these responses, increasing the sensory-discriminative compared to emotional-motivational pain responses by contingent monetary reinforcement \& vice versa. Substudy2: Responses of chronic pain patients will be compared to those of healthy participants to characterize possible alterations. Operant learning will be operationalized to decrease emotional-motivational pain responses, which are assumed to be increased in patients. Substudy3: Participants will perform a psychophysical task to assess metacognition in pain perception."|t|f|f|f
34159846|NCT05330767|||COHORT||PROSPECTIVE|||||||
34159847|NCT00853151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159848|NCT02336672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159849|NCT02393937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159850|NCT05205174|NA|SINGLE_GROUP||OTHER||NONE||||||
34159851|NCT05808140|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34159852|NCT00572013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159853|NCT00248807|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159854|NCT00629915|||COHORT||PROSPECTIVE|||||||
34159855|NCT00104624||||TREATMENT||NONE||||||
34055844|NCT01601327|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34055845|NCT05108532|||COHORT||OTHER|||||||
34055846|NCT01277653|||COHORT|||||||||
34055847|NCT05141916|||OTHER||OTHER|||||||
34159856|NCT02848807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34055848|NCT06519344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159857|NCT05355792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159858|NCT02055378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34159859|NCT03222297|||CASE_CONTROL||PROSPECTIVE|||||||
34159860|NCT02732782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159861|NCT00630435|RANDOMIZED|CROSSOVER||||NONE||||||
34159862|NCT00122174|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159863|NCT04473248|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The results of the Spartan COVID-19 System tests will not be shared with the participant or the lab, but the lab results will be shared with Spartan once analysis of the Spartan System samples is complete.|Each Patient enrolle dint he study will experience the same modes of sample collection and sample analysis.|t|f|f|f
34159864|NCT02435420|||COHORT||OTHER|||||||
34159865|NCT00966251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34159866|NCT00352430||||TREATMENT||||||||
34159867|NCT04981652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant was blinded by formulating intervention beverages to have a similar taste profile with noncaloric, non-nutritional flavouring additives|Participants randomly assigned to one of three intervention groups (whole milk, skim milk or almond beverage)|t|f|f|f
34159868|NCT03020342|||CASE_ONLY||PROSPECTIVE|||||||
34159869|NCT03831035|||COHORT||PROSPECTIVE|||||||
34159870|NCT03896945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159871|NCT05041270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blinded (patient, anesthesiologist in the operating room and outcomes assessor)|The patients will be divided randomly by a computer-generated randomization table into three equal groups|t|t|f|t
34159872|NCT05194800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159873|NCT01885624|NA|SINGLE_GROUP||OTHER||NONE||||||
33951437|NCT00544778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951438|NCT02654561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951439|NCT06230705|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33951440|NCT03755960|RANDOMIZED|PARALLEL||TREATMENT||NONE|The statistician will be blinded to the study intervention.|multicenter, open label, randomized||||
33951441|NCT02920866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951442|NCT00201266|||CASE_CONTROL||PROSPECTIVE|||||||
33951443|NCT01955824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951444|NCT06210867|||COHORT||PROSPECTIVE|||||||
33951445|NCT02057549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055849|NCT02946073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055850|NCT04865406|||COHORT||PROSPECTIVE|||||||
34055851|NCT04245215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055852|NCT05568615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055853|NCT05691608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055854|NCT05326308|||COHORT||PROSPECTIVE|||||||
34055855|NCT03289325|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34055856|NCT05477212|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055857|NCT01437917|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34159874|NCT02356718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159875|NCT05154526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34159876|NCT05020080|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159877|NCT01695356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159878|NCT05905367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159879|NCT02904733|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34159880|NCT04870125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study drug assignment will be blinded to the subject, clinical team, study coordinators, and other study staff with the exception of the administering study staff (respiratory therapist and physician or physician alone), who will be unblinded to the treatment assignment to ensure subject safety.|2:1 randomization to iCO versus placebo medical air|t|t|f|f
34159881|NCT03094533|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34159882|NCT04830891|||COHORT||PROSPECTIVE|||||||
34159883|NCT01385904|||CASE_ONLY||PROSPECTIVE|||||||
34159884|NCT02742376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34159885|NCT03016091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159886|NCT05572164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951446|NCT01901952|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33742971|NCT05003817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742972|NCT05879744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33742973|NCT01019330|||COHORT||PROSPECTIVE|||||||
33742974|NCT03141502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33742975|NCT00745017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33742976|NCT02324491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33742977|NCT05996354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742978|NCT02548962|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742979|NCT04269772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742980|NCT05749913|||OTHER||CROSS_SECTIONAL|||||||
33742981|NCT03112044|NA|SINGLE_GROUP||TREATMENT||NONE||Investigators aim to transplant 20 HCV- recipients with end-stage lung disease from transplant wait-list using lungs from HCV+ donors. Donor lungs will be selected based on usual donor selection criteria evaluating blood gas analysis, chest imaging, bronchoscopy findings, and assessment in the operating room. Once lungs meet criteria for transplantation, they will be retrieved in standard fashion, transported to Toronto General Hospital in cold static preservation, placed on EVLP for 6 hours, and transplanted to consented recipients.||||
33742982|NCT02754167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33742983|NCT05173519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33742984|NCT05451303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33742985|NCT00133289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33742986|NCT02330835|RANDOMIZED|PARALLEL||||NONE||||||
33742987|NCT04448184|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951447|NCT01973699|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33742988|NCT04504045|NA|SINGLE_GROUP||OTHER||NONE||||||
33742989|NCT06533163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33742990|NCT05631067|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33742991|NCT02888405|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34055858|NCT04546529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34055859|NCT05249127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055860|NCT05856539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to randomization (whether or not they received an ESP block preoperatively). Co-investigators will not be blinded as the anesthesiologist will need to perform the ESP block.|This is a single-center, prospective, randomized controlled trial.|t|f|f|f
34055861|NCT05685004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded over-read of sequential MRI assessments||f|f|f|t
34055862|NCT05466994|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055863|NCT06350526|||CASE_ONLY||RETROSPECTIVE|||||||
34076164|NCT06609486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."||||
33742992|NCT05263388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33742993|NCT03883672|NA|SINGLE_GROUP||OTHER||NONE||||||
33742994|NCT04088981|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||randomized, cross-over|f|f|f|t
33742995|NCT06098521|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized waiting list controlled trial||||
33742996|NCT01246726|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33742997|NCT05497843|NA|SEQUENTIAL||TREATMENT||NONE||||||
33742998|NCT03663075|RANDOMIZED|FACTORIAL||TREATMENT||NONE|This study evaluated the effect of groups sessions or individual support. This is not a pill so it is impossible to mask participants.|Two factor design evaluating two separate treatment modalities||||
34055864|NCT06590389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomizer.org website was used for randomization of the research sample. It consists of four rooms, patient room numbers 634, 635, 636 and 637. The room numbers obtained during randomization were assigned to the 1st group intervention (21 cases of open abdominal surgery) and the 2nd group to the control group (21 cases of open abdominal surgery) by simple random method. By entering the room numbers into two unique sets, patients sleeping in the rooms in the 1st set (634-636) and meeting the inclusion criteria were included in the intervention group. Patients sleeping in the rooms in the 2nd set (635-637) and meeting the inclusion criteria were included in the control group. was included in the group. In the study, each patient was included in the research group after informed consent was obtained. In case of refusal, consent was obtained from the next patient in the room and the process of obtaining consent was continued until the number of samples was completed.|The research was designed as a randomized controlled, 2-group (intervention and control) pre-test post-test comparative experimental research.|t|f|f|f
33742999|NCT02250404|||CASE_ONLY||CROSS_SECTIONAL|||||||
33743000|NCT06535126|NA|SINGLE_GROUP||TREATMENT||NONE||"Objectives of the study: Determine the safety and tolerability of CanProFem-AK, 100 mg suppositories in healthy volunteers.~The study includes the following stages:~Stage 1 of the study (introductory stage) included recruitment and screening of healthy volunteers - study participants, signing of informed consent, medical examination and laboratory tests.~Stage 2 of the study (baseline control stage) involved clinical measurements taken before the start of the study (baseline measurements) for each subject. These measurements were conducted to obtain baseline data, which were then compared with the results obtained after the study's conclusion.~Stage 3 of the study included medical observation after the vaginal administration of one suppository, including gynecological examination and bacterial culture sampling from the vagina at 3, 6, 9, 12, and 24 hours. Additional blood and urine tests will be performed after 24 hours."||||
33743001|NCT01103206|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33743002|NCT01143259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055865|NCT06497764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743003|NCT01538017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743004|NCT03065413|||OTHER||PROSPECTIVE|||||||
33743005|NCT03724162|||CASE_ONLY||PROSPECTIVE|||||||
33743006|NCT04812353|NA|SINGLE_GROUP||OTHER||NONE||||||
33743007|NCT03936244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743008|NCT03691805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded as to their assigned study arm.|Half of the participants will receive transcranial direct current stimulation, while the others will receive sham stimulation.|t|f|f|f
33743009|NCT01891825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743010|NCT02804958|||COHORT||RETROSPECTIVE|||||||
33743011|NCT03176160|||COHORT||PROSPECTIVE|||||||
33743012|NCT02650531|||COHORT||PROSPECTIVE|||||||
33743013|NCT05793905|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple Masking: Patients, Investigators and Statistician|This clinical research aims to evaluate the effectiveness of buffered lidocaine in the treatment of bilateral primary molars|t|f|t|t
34055866|NCT06643364|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All athletes who participated in the study, the researcher who performed the measurements and the people who performed the statistical evaluation did not know which athlete was in which group.|There are two groups: one group is the control group and the other is the vision training group, in which vision training is applied|f|f|t|t
34055867|NCT05383092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective randomized pilot study studying the parameters of two groups receiving physical activity management over a period of 6 months||||
34055868|NCT05002998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked except for the pharmacy staff.|"* 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:~  * Placebo if a participant is a treatment responder at Week 12 or~ * Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12~* 8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)~* 16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)"|t|t|t|t
34055869|NCT00477750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055870|NCT01447446|||COHORT||PROSPECTIVE|||||||
34055871|NCT06620510|||COHORT||RETROSPECTIVE|||||||
34055872|NCT00065637|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34076165|NCT03916445|||CASE_ONLY||PROSPECTIVE|||||||
34076166|NCT03601195|||COHORT||PROSPECTIVE|||||||
34076167|NCT02848664|||COHORT||PROSPECTIVE|||||||
34076168|NCT05471388|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159887|NCT03808012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159888|NCT01983085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159889|NCT04177979|RANDOMIZED|PARALLEL||OTHER||SINGLE|The OSCE assessors were blinded|Randomized single blinded trial|f|f|f|t
34159890|NCT03383510|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34159891|NCT01251913|||COHORT||PROSPECTIVE|||||||
34159892|NCT05792189|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, non randomized study|t|f|f|f
34159893|NCT00001954||||TREATMENT||||||||
33743014|NCT01828502|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055873|NCT06581003|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|To reduce performance bias participants will blinded to condition. To reduce detection bias, investigators, Independent Evaluators (IE), and data analysts will also be blinded to treatment condition (i.e. HBOT or placebo/sham group). Treatments will be coded as treatment 1 or 2 in the database. Because the primary and secondary outcome data will be collected using a self-report questionnaire, the possibility of interpretation does not exist. Only in case of safety issues, the patient assignment could be unblinded.|Blinded Group Sequential Adaptive Randomized Controlled Trial|t|t|t|t
33743015|NCT01140035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743016|NCT02410395|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33743017|NCT06393062|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The patients included in the study were randomized by a block randomization method by an independent researcher, hidden from the patients and the responsible clinicians, using a computerized number tool.|t|t|f|t
33743018|NCT06390735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This two armed trial will include an intervention group and a waitlist control group.|f|f|t|t
33743019|NCT03155750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743020|NCT00734305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743021|NCT04031339|||COHORT||PROSPECTIVE|||||||
34055874|NCT05966506|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743022|NCT02695238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743023|NCT00765908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33743024|NCT03727204|||COHORT||PROSPECTIVE|||||||
33743025|NCT04071002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743026|NCT03251469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33743027|NCT01907451|||COHORT||PROSPECTIVE|||||||
34055875|NCT02351908|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34055876|NCT02557204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34055877|NCT02437331|||CASE_ONLY||PROSPECTIVE|||||||
34055878|NCT00725790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055879|NCT02977611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055880|NCT03946878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055881|NCT06482125|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients are selected randomly using a computer-generated device to become a control arm or a treatment arm|Pediatrics ages 3 months to 10 years|t|f|f|f
33743028|NCT06237283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743029|NCT06288815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743030|NCT03314987|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double blind (participant, investigator)|placebo controlled, randomized, double-blind|t|f|t|f
33743031|NCT00968669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743032|NCT01076400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743033|NCT02306915|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33743034|NCT00882674|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743035|NCT02641548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055882|NCT02550392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055883|NCT04010929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055884|NCT05980923|||CASE_ONLY||PROSPECTIVE|||||||
34055885|NCT03465501|||CASE_CONTROL||RETROSPECTIVE|||||||
33765163|NCT01516411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765164|NCT04923295|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and post intervention||||
33765165|NCT03940508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765166|NCT05156463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33765167|NCT00811447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765168|NCT04322006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055886|NCT04083469|RANDOMIZED|PARALLEL||OTHER||NONE||"Investigators will conduct a social network survey for 6th graders. Students will be asked to identify their close peers based on several dynamics: friendship, opinion leadership, academic support, and personal support. Social network analyses will identify opinion leaders based on network centrality measures. Surveys will be administered before and after the intervention.~Investigators will adapt modules from CATCH My Breath, an evidence-based e-cigarette intervention supported by University of Texas and MD Anderson Cancer Center. The 8 schools will be randomized to receive the intervention led by either (1)an adult content-expert or (2)a peer-nominated opinion leader to students who nominated them or (3)a peer-nominated opinion leader to students who did not nominate them. Primary outcomes will be acceptability and feasibility measures, including (1)recruitment and (2)retention rates. Secondary outcomes will include intention-to-use e-cigarettes and knowledge about e-cigarettes."||||
34055887|NCT02010658||CROSSOVER||OTHER||||||||
34055888|NCT06623760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34055889|NCT02781857|||CASE_CONTROL||PROSPECTIVE|||||||
34055890|NCT05069142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessors are blind to group status|Pilot Parallel-Group Randomized Controlled Trial|f|f|f|t
34055891|NCT05137847|||COHORT||PROSPECTIVE|||||||
34055892|NCT06519643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The investigators will compare the pre- and post-test differences between the experimental group and the control group. Both the experimental and control groups will fill in the structured questionnaires online at the time before the intervention (Baseline data) and at 0, 6, 12, 18, and 24 months after the intervention.|t|f|f|t
34055893|NCT05564026|||FAMILY_BASED||PROSPECTIVE|||||||
34055894|NCT01679067|||COHORT||PROSPECTIVE|||||||
34055895|NCT04325698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055896|NCT05546723|NA|SEQUENTIAL||TREATMENT||NONE||Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.||||
34055897|NCT05149352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As the interventions in these studies are psychotherapies, both participants and care providers cannot be masked from the treatment allocation. To ensure the objectivity of the research measures, the outcome assessors will be blinded to the allocated treatment condition.|Participants will be randomized to one of two treatment conditions. In one condition (control group) participants will receive a regular depression treatment that they would usually receive for their depression ('treatment as usual', TAU). In the other condition (intervention group) participants will receive trauma-focused therapy (TFT), additional and parallel to their depression treatment (TAU). In both treatment groups (TAU and TAU+TFT), treatment will be provided during a period of 12 weeks.|f|f|f|t
34055898|NCT02920138|||CASE_CONTROL||PROSPECTIVE|||||||
34055899|NCT04669964|||CASE_ONLY||PROSPECTIVE|||||||
34055900|NCT05189093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055901|NCT01154088|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34055902|NCT05795140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055903|NCT00006617||||TREATMENT||NONE||||||
34055904|NCT03535740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055905|NCT04506905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
34055906|NCT04738422|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055907|NCT06621550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34055908|NCT04486027|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34055909|NCT04430842|NA|SEQUENTIAL||TREATMENT||NONE||The dose escalation scheme for this trial employs an mTPI-2 design.||||
34055910|NCT05514587|||COHORT||PROSPECTIVE|||||||
34055911|NCT06341543|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055912|NCT04446195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34055913|NCT00984139|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34055914|NCT02658734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34055915|NCT06617988|||COHORT||PROSPECTIVE|||||||
34055916|NCT02662400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055917|NCT06620380|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II interventional randomized non-comparative clinical study||||
34055918|NCT03740529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055919|NCT03624543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055920|NCT01759810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055921|NCT00550134|||CASE_CONTROL||PROSPECTIVE|||||||
34055922|NCT03898362|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||6 months using one device then crossover and 6 months using other device||||
34055923|NCT06477068|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Experimental group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department, in addition to being supported through the telemedicine medication reminder app on smartphones.~Control group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department."||||
34055924|NCT06621316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multicenter, randomized, double-blind, placebo parallel-controlled Ib/II clinical trial|t|t|t|t
34055925|NCT02744664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055926|NCT00207792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055927|NCT02455817|||CASE_ONLY||RETROSPECTIVE|||||||
34055928|NCT06035861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34055929|NCT04142320|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34055930|NCT06649396|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055931|NCT06243952|NA|SINGLE_GROUP||TREATMENT||NONE||monocentric, single-arm, non-blinded, non-randomized, interventional||||
34055932|NCT05589155|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34055933|NCT06618768|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34055934|NCT05160038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055935|NCT02584127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34055936|NCT05028777|||COHORT||OTHER|||||||
34055937|NCT06617936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055938|NCT01867294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33951448|NCT03379038|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The two groups were progressive physical therapy group and maintenance physical therapy group. For any given subject, spasticity, defecation frequency and constipation severity evaluations were completed on the same day. Each subject in PPT group completed 6 weeks of physical therapy sessions which were aimed to decrease spasticity, increase ROM, and improve strength and functional activity level. Each subject was evaluated for changes in symptoms on, 2nd week, 4th week and 6th week. In MPT group same protocol was used but the aim was to maintain current status of level of spasticity, ROM, strength and functional activity. After 6 weeks of physical therapy sessions were completed both groups underwent a 2-week washout period to eliminate the effects of 6-week physical therapy. After the washout period subjects were crossed over from PPT group to MPT group and vice versa.||||
33951449|NCT05031975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951450|NCT01243853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33951451|NCT03224169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951452|NCT00736216|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33951453|NCT03367455|||COHORT||RETROSPECTIVE|||||||
34055939|NCT02036658|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||To investigate treatment outcome and mediators of Cognitive-Behavioral Group Therapy (CBGT) vs. Mindfulness-Based Stress Reduction (MBSR) vs. Waitlist (WL) in patients with generalized social anxiety disorder (SAD), unmedicated patients with a primary diagnosis of Social Anxiety Disorder (SAD) will be randomized to CBGT vs. MBSR vs. WL and will complete assessments at baseline, post-treatment/WL, and at 1-year follow-up, including the Liebowitz Social Anxiety Scale - Self-Report (primary outcome; Liebowitz, 1987) as well as measures of treatment-related processes.|f|f|t|t
34055940|NCT02517242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055941|NCT03961386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34159894|NCT03682692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization and treatment: Potentially eligible patients should receive a 24-hour ambulatory blood pressure monitoring measurement before randomization. After stratification by centers and whether receive antihypertensive treatment, eligible patients will be randomly divided into two groups, taking benazepril 10 mg/amlodipine besylate 5mg fixed-dose combination (1 tablet once a day) or benazepril 10 mg/hydrochlorothiazide 12.5 mg fixed-dose combination (1 tablet once a day). If the systolic/diastolic blood pressure higher than 140/90 mmHg during follow-up visits, the dosage can be increased to 2 tablets once a day. If the systolic/diastolic blood pressure still ≥140/90 mmHg, bisoprolol 5 mg (1 tablet once a day) or doxazosin controlled-release tablets 4 mg (1 tablet once a day) or spironolactone 20 mg (1 tablet once a day) can be added during the following follow-up visits.|t|f|f|f
34159895|NCT00005773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159896|NCT02523378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159897|NCT01461707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34159898|NCT00391313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34159899|NCT04590573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951454|NCT01969331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34159900|NCT03778996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159901|NCT02330692|||COHORT||PROSPECTIVE|||||||
34159902|NCT02606799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34159903|NCT02454257|||COHORT||RETROSPECTIVE|||||||
34159904|NCT01597713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159905|NCT05243082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159906|NCT00163020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159907|NCT00166439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159908|NCT02947737|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34159909|NCT03594136|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951455|NCT02777554|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743036|NCT05571917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All investigators (Drs. Pearson, Witkiewitz, Hurlocker, Ilgen, and Lin) will be blinded. The research coordinators located within each site will not be blinded, as they will be involved in coordinating participant screening and randomization. Data analysis will be conducted by a study statistician blinded to participant condition.|A research coordinator who is not involved in the intervention phases of the study will randomize individuals to study arm. A block randomization method stratified by site and gender will be used with a random block size based on group scheduling, where groups will start with a group size of three to ten participants. The coordinator will generate a randomization list prior to the implementation phase. To further maintain masking, a research assistant who is not involved in the intervention phases of the study will administer all assessment measures.|f|f|t|t
33743037|NCT00724971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743038|NCT06297538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951456|NCT05198739|NA|SINGLE_GROUP||OTHER||NONE||||||
33951457|NCT04547829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951458|NCT00772434|||CASE_ONLY||PROSPECTIVE|||||||
33951459|NCT01135147|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951460|NCT05378568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33951461|NCT01983332|||COHORT||PROSPECTIVE|||||||
33846339|NCT04606771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. Patients will take savolitinib 300mg tablets QD within 15 minutes after the start of a meal except for the day on which PK samples are taken. Patients will take osimertinib 80mg tablet once daily with/without food except for the day on which PK samples are taken. On the day when PK samples are taken both savolitinib \& osimertinib will be administered after a meal prepared by the clinic~2. Patients will take savolitinib 300mg tablets QD within 15 minutes after the start of a meal except for the day on which PK samples are taken. Patients will take placebo to osimertinib 80mg tablet once daily with/without food except for the day on which PK samples are taken. On the day when PK samples are taken both savolitinib \& placebo to osimertinib will be administered within 15 minutes after a meal prepared by the clinic~In addition to comparing the ORR between groups, this study will also assess safety and tolerability, DoR, DCR, OS, PFS and other measures of antitumor activity"|t|f|t|f
33846340|NCT02080559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846341|NCT04107168|||COHORT||PROSPECTIVE|||||||
33846342|NCT00380224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33951462|NCT00076544|NON_RANDOMIZED|||TREATMENT||NONE||||||
33951463|NCT05220774|||COHORT||PROSPECTIVE|||||||
33951464|NCT05044182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951465|NCT02478216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951466|NCT02267616|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will evaluate the use of the Etonogestrel Implant or hormonal intrauterine device (IUD) for contraception past the FDA approved duration. The Etonogestrel Implant is currently approved for 3 years of use, and the hormonal IUD is currently approved for 5 years.||||
33951467|NCT02689609|||COHORT||PROSPECTIVE|||||||
33951468|NCT03752021|||CASE_ONLY||CROSS_SECTIONAL|||||||
33951469|NCT03904602|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33951470|NCT04472910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951471|NCT04409327|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951472|NCT06205940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized controlled trial|f|f|f|t
33951473|NCT02195882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951474|NCT01722058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951475|NCT06649760|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951476|NCT06487390|NA|SINGLE_GROUP||OTHER||NONE||||||
34055942|NCT02339129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34055943|NCT02027597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34055944|NCT06260943|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055945|NCT06117709|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34055946|NCT06438133|||COHORT||PROSPECTIVE|||||||
34055947|NCT04668638|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||"Patients will be divided into two groups:~* Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.~* Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis."|f|f|f|t
34055948|NCT06624202|NA|SINGLE_GROUP||PREVENTION||NONE||Biomechanical data collection will occur during youth football practices and games.||||
34055949|NCT01676922|||COHORT||PROSPECTIVE|||||||
34055950|NCT05015140|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33951477|NCT03094923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33951478|NCT01714726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055951|NCT00402532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951479|NCT00353392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33951480|NCT05044910|||COHORT||PROSPECTIVE|||||||
33951481|NCT02946515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34055952|NCT04887935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055953|NCT06648239|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34055954|NCT06622382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055955|NCT03578458|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34055956|NCT06618482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34055957|NCT04391738|||COHORT||RETROSPECTIVE|||||||
34055958|NCT06648577|||COHORT||PROSPECTIVE|||||||
34055959|NCT00654875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055960|NCT06212271|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34055961|NCT00666003|||COHORT||PROSPECTIVE|||||||
34055962|NCT04558567|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34055963|NCT04760509|||CASE_ONLY||RETROSPECTIVE|||||||
34159910|NCT00484978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159911|NCT00294294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34159912|NCT02457676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743039|NCT01267123|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34159913|NCT00015795||||TREATMENT||||||||
34159914|NCT01576497|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34159915|NCT02276703|||OTHER||PROSPECTIVE|||||||
34159916|NCT00348673|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33743040|NCT03871647|||COHORT||PROSPECTIVE|||||||
34159917|NCT06364462|||COHORT||PROSPECTIVE|||||||
33743041|NCT02114892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743042|NCT04064281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the particularity of dietary intervention studies, it is hard to blind researchers and kitchen staff. Therefore, this trial only blinds subjects. In order to ensure blinding, they will be not told which group they have been assigned and the two groups will eat their assigned diet in different rooms. And outcomes assessors will also be blinded to the two diet groups.|All subjects will enter 1-week run-in feeding period during which they will eat the control diet. After a 1-week run-in period, subjects will be randomly divided into the intervention group and the control group, stratified by gender. The two groups will eat their assigned diet for 4 consecutive weeks.|t|f|f|t
33743043|NCT01547572|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33743044|NCT00389935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743045|NCT05267301|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Self elected consumers who choose to purchase this iwi EPA andiwi Heart product containing 1000-1100 mg of AlmegaPLR||||
33743046|NCT03981003|||CASE_ONLY||PROSPECTIVE|||||||
34055964|NCT04606485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Acupressure was applied to both the intervention and placebo groups, by a single nurse researcher, trained in the application of acupressure. The nurse had received a certificate for attendance of an acupressure course which included theoretical and practical lessons for specialization on the subject of acupressure. Patients in the placebo group were unaware of their group. Patients were isolated from others by using acupressure in single rooms or by using a curtain around the bed. Thus, it was ensured that the patients were not affected by each other.~Another nurse researcher blinded to the groups collected the data. The statistics specialist who analysed and reported the data was also blinded to the groups. Analysis and reporting were also defined as groups 1 and 2. Thus the 3-way blinded technique was used in this study."||t|f|t|t
34055965|NCT04368143|||COHORT||PROSPECTIVE|||||||
34055966|NCT06401915|||CASE_CROSSOVER||PROSPECTIVE|||||||
34055967|NCT01758107|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34055968|NCT02290834|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34055969|NCT06540651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34055970|NCT02853669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34055971|NCT03692325|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34055972|NCT06455319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2). Verapamil extended release capsule will be given via open label administration at 120, 240 or 360 mg daily based on weight and echocardiogram (ECG) findings|t|t|t|t
34055973|NCT06084715|||COHORT||PROSPECTIVE|||||||
34055974|NCT04101916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The aim is 20 participants and the anticipated dropout percentage is 20%, therefore maximum number of randomized patients will be 24. If there will be no dropouts, only 20 patients will be recruited.|t|f|f|t
34055975|NCT02410421|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34055976|NCT01639066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055977|NCT04277650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The ML directed twice-weekly evaluation arm was unblinded. Participants and providers were blinded to ML identification of high risk participants in the once weekly evaluation (standard of care) arm.|Participants identified by the machine learning (ML) algorithm as high risk were randomized to either once weekly or twice weekly clinical evaluations||||
34055978|NCT05883293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055979|NCT00587197|||CASE_ONLY||PROSPECTIVE|||||||
34055980|NCT02734043|||CASE_ONLY||RETROSPECTIVE|||||||
34055981|NCT05913206|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and the investigator team will be blinded to which condition the participant is randomized.||t|f|t|f
34055982|NCT02289547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34055983|NCT03721835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34055984|NCT03087422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743047|NCT04494412|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multi-center and single arm study||||
33743048|NCT03616210|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33743049|NCT02580149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743050|NCT02073968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743051|NCT06290362|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||The current 8-week randomized, single-blind factorial trial was conducted with a control group and one intervention group. Over eight weeks, participants received cognitive behavioral-based intervention through online sessions. Pre-/post-test and follow-up assessments employed.|t|f|f|f
33743052|NCT02427529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33743053|NCT05453474|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All patients had either one or two blood samples collected. Each blood sampled had either all cells lyzed or cells were split between lysis and whole genome amplification. Hence, the study is considered to have to seperate analysis each with two arms.||||
33743054|NCT02302261|||||PROSPECTIVE|||||||
33743055|NCT03650205|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743056|NCT03305679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33743057|NCT02013765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743058|NCT02882802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743059|NCT04596566|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743060|NCT01408589|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33743061|NCT00780091|||CASE_CONTROL||PROSPECTIVE|||||||
33743062|NCT06257147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743063|NCT06347419|||COHORT||PROSPECTIVE|||||||
34055985|NCT03825835|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Outcome assessed will be unaware of group allocation||f|f|f|t
34055986|NCT04514744|RANDOMIZED|PARALLEL||OTHER||NONE||In a randomized fashion, one participant will have one leg assigned to unilateral immobilization, and the other leg will undergo unilateral resistance exercise training, for 8 days.||||
34055987|NCT05100953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34055988|NCT06624033|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|single-centre randomized, cross-over controlled trial.|participants may receive 6 products in 6 interventions sequentially during the protocol|t|f|f|f
34055989|NCT06292858|NA|SEQUENTIAL||TREATMENT||NONE||||||
33743064|NCT05425004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743065|NCT04756219|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33743066|NCT05778305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33743067|NCT04410432|||COHORT||PROSPECTIVE|||||||
33743068|NCT00733265|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846343|NCT05996432|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846344|NCT00004426|RANDOMIZED|||TREATMENT||DOUBLE||||||
33743069|NCT01389908|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743070|NCT01407861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743071|NCT05289102|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a non-blind, two-arm randomized controlled multi-center trial||||
33743072|NCT00059475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743073|NCT00623220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743074|NCT06670404|||CASE_ONLY||PROSPECTIVE|||||||
33743075|NCT02076464|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743076|NCT04268017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951482|NCT00557986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951483|NCT01246388|||COHORT||PROSPECTIVE|||||||
33743077|NCT06452459|||COHORT||CROSS_SECTIONAL|||||||
33951484|NCT06651034|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental study||||
33951485|NCT03269565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951486|NCT00465322|||||PROSPECTIVE|||||||
33743078|NCT00004093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951487|NCT05716516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951488|NCT00710008|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33951489|NCT04066127|RANDOMIZED|PARALLEL||OTHER||SINGLE|Acute cellular rejection assessment will be performed by a blinded access||f|f|f|t
33951490|NCT02905695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951491|NCT05140473|||COHORT||CROSS_SECTIONAL|||||||
33951492|NCT00925795|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33951493|NCT05590182|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The randomization that allocates the patient either in the study arm (CO2) or in the control arm (iodine-CM) will occur right before angiography. Stenosis graduation and length will be measured after diagnostic angiography and before intervention. The interventional angiography will be conducted with the opposed contrast media used for diagnostic angiography. If contrast media containing iodine was used for diagnostic angiography, CO2 must be used for interventional angiography and if CO2 was applied for diagnostic angiography, contrast media containing iodine must be used for interventional angiography. The calculated values through the software-quantification-tool, including also a final sequence of the distal outflow with the same contrast media used during intervention, are be compared and statistically analyzed.||||
33951494|NCT04806672|||COHORT||PROSPECTIVE|||||||
33951495|NCT01595399|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951496|NCT01743495|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33951497|NCT04566965|||CASE_CONTROL||PROSPECTIVE|||||||
33951498|NCT05207423|||COHORT||RETROSPECTIVE|||||||
33951499|NCT00622752|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33743079|NCT02811237|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743080|NCT02343458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743081|NCT00001257|||COHORT||OTHER|||||||
33743082|NCT01844323|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33743083|NCT00418171|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743084|NCT05363345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33743085|NCT04287933|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33743086|NCT00686400|||CASE_CONTROL||PROSPECTIVE|||||||
33743087|NCT02169934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743088|NCT03701555|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33743089|NCT00954369|NON_RANDOMIZED|PARALLEL||||NONE||||||
33743090|NCT01564225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951500|NCT05215509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33743091|NCT01129310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951501|NCT00145288|||CASE_CONTROL||PROSPECTIVE|||||||
33951502|NCT01852227|||CASE_ONLY||RETROSPECTIVE|||||||
33951503|NCT00101140||||TREATMENT||||||||
33951504|NCT00359866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951505|NCT03356470|||COHORT||PROSPECTIVE|||||||
33951506|NCT06089590|||COHORT||PROSPECTIVE|||||||
34055990|NCT05190211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TGr) and Video Group (VGr).|t|f|f|f
34055991|NCT04183140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients admitted with STEMI at the cardiology department and admitted to the catheter laboratory for primary percutaneous coronary intervention will be included in the study. There will be two groups in the study.In the first group, patients treated with transulnar access will be included. In the second group, patients using transradial access will be included. Patients will be treated by the same operator respectively. Peri-procedural data and in-hospital cardiac outcome data of patients in both groups will be recorded.||||
34055992|NCT03676296|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34055993|NCT03811288|||COHORT||CROSS_SECTIONAL|||||||
34055994|NCT00032136|RANDOMIZED|||TREATMENT||NONE||||||
34055995|NCT00968136|||COHORT||PROSPECTIVE|||||||
34055996|NCT06577519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055997|NCT01438294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34055998|NCT00546117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34055999|NCT06622421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The collaborator who will collect the data and the statistician will not be aware of the assignment group. Each patient will be identified with a unique code (PIEZOPZ_n.) that will be known only to the principal investigator.|This is a prospective randomized and controlled study with parallel groups (1:1) of superiority|f|f|t|t
34056000|NCT06619249|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||A randomized, double-blind, placebo-controlled, cross-over study|t|f|t|f
34159918|NCT06499831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The radiation oncologist is blinded to result from FET-FET/MRI while planning on standard fo care MRI.|This study will assess differences in management based on standard of care MRI versus intended care based on FET-PET-MRI. Changes in management will be recorded as a simulation but patients will still receive routine standard of care.||||
34159919|NCT06174610|||COHORT||PROSPECTIVE|||||||
34159920|NCT00532298|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33743092|NCT05995912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743093|NCT00353275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743094|NCT01188239|||COHORT||PROSPECTIVE|||||||
33743095|NCT01924325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743096|NCT01575340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743097|NCT01973790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743098|NCT03152305|||CASE_CONTROL||PROSPECTIVE|||||||
33743099|NCT04020120|||COHORT||PROSPECTIVE|||||||
33743100|NCT04369027|||CASE_ONLY||PROSPECTIVE|||||||
33846345|NCT05529680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the patients were randomly assigned into two equal groups (20 patients for each group) by using the closed envelope method.|"Forty patients suffering from post-mastectomy shoulder dysfunction were randomly assigned into two equal groups each one has 20 patients.~Group A (study group): Who received scapular mobilization and strengthening exercises in addition to their conventional physical therapy program.~Group B (control group): Who received a conventional physical therapy program in form of joint mobilization, posterior capsule stretching, and range of motion exercise."|t|f|f|f
33846346|NCT04304625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double blinding is performed according to current Good Manufacturing Practices (BPF). The packaging and labelling of the experimental drugs are carried out by the PUI of CHU Angers, in accordance with the regulation of the clinical trials in force. PUI of CHU Angers will produce batches of vials (tranexamic acid or placebo according to randomization) according to the model:~* TXA: 1g - 10ml~* Placebo: NaCl 0.9% - 10mL"|Multicenter double-blind randomized controlled trial|t|f|t|f
33846347|NCT02144727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846348|NCT03746782|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846349|NCT03590366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This is a double blind study. Participants will be assigned to study treatment in accordance with the randomization schedule generated for the allocation of vehicle or B244 prior to the initiation of the trial. Randomization will be centrally-based and performed using an appropriate IWRS (an automated randomization system).~Each participant scheduled to receive investigational product (IP) will receive a randomization number at the time of randomization. The randomization number will be used to identify the study medication kit assigned to the participant and indicate the treatment to be administered to that participant."|Randomization will be 1:1 so that equal numbers of patients will be treated in each arm of the study.|t|t|t|t
33846350|NCT03929445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33846351|NCT00961480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846352|NCT04761107|||OTHER||PROSPECTIVE|||||||
33846353|NCT06218160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846354|NCT02072785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846355|NCT05070442|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33846356|NCT06427421|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846357|NCT03343327|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846358|NCT06017843|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Individuals visiting camps will be masked to the intervention status.|"The MATCH-AI evaluation is designed as a stepped-wedge cluster randomized trial. In this study, clusters (mobile X-ray van teams) will successively switch over in groups of 3 to the intervention in a randomly assigned order until all clusters are eventually exposed to the intervention.~In the intervention arm, TB active case finding camps will be conducted primarily in locations guided by MATCH-AI a modelling software that predicts TB hotspots. In the control sites, field-teams will continue to utilize existing approaches such as local knowledge, historical data etc towards camp site-selection."|t|f|f|f
33846359|NCT00171041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846360|NCT04887779|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, no blinding or randomization||||
33846361|NCT04254822|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846362|NCT04953559|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33846363|NCT00005275|||COHORT||PROSPECTIVE|||||||
34056001|NCT01798407|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|During staggered withdrawal phase, double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen every 2 weeks until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase. See masking description below.|t|t|t|t
34056002|NCT05575752|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33743101|NCT00799812|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33743102|NCT01311986|||CASE_CONTROL||PROSPECTIVE|||||||
33743103|NCT02652728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743104|NCT03415620|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The randomized controlled phase will recruit 110 parturients.||||
33743105|NCT01390012|RANDOMIZED|PARALLEL||||NONE||||||
33743106|NCT02754635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743107|NCT01895504|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33743108|NCT01123759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743109|NCT05483426|NA|SINGLE_GROUP||OTHER||NONE||||||
33743110|NCT01509859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743111|NCT05227989|||COHORT||PROSPECTIVE|||||||
33743112|NCT05706727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The patients will be randomly allocated to the two groups of study by sealed envelope method. Group M patients who will receive intravenous bolus dose of mephentermine 6mg and Group P who will receive intravenous bolus dose of phenylephrine 50 mcg The drug preparations phenylephrine 50mcg/ml and mephenterime 6mg/ml will be done and labelled with code numbers by anesthesia assistant for all the patient and it is provided to anesthesiologist for administration who is not involved in the study as they will not be actively involved in the study nor in the patient care. The other anesthesia assistant or intern will be monitoring and recording information on proformas. Therefore investigator and participant of the study were blinded to the study drugs.|Comparative Interventional|t|t|t|t
33743113|NCT00752375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743114|NCT01303627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743115|NCT05377177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A sham component will be used over the right DLPFC for unilateral aiTBS treatment. This treatment component will mitigate concerns of expectancy, and will lead to blinding for patients. The Cool B65 A/P coil is unmarked, with one side producing active treatment and the other sham treatment with concurrent electrical stimulation, which accurately mimics active stimulation.|Patients enrolled in the study will be randomized to bilateral vs. unilateral aiTBS in a 1:1 ratio . Treatments will be over 1 week.|t|f|f|t
33743116|NCT02523534|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743117|NCT04209660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase II study evaluating the efficacy of lenvatinib plus pembrolizumab in the treatment of progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) and recurrent/metastatic non-ACC salivary gland cancers (R/M SGC). Patients will be enrolled in two cohorts: Cohort 1, patients with R/M ACC (ACC group), and Cohort 2: patients with R/M SGC (non-ACC group)."||||
33743118|NCT02824068|||CASE_CONTROL||RETROSPECTIVE|||||||
33743119|NCT04180826|||CASE_CONTROL||PROSPECTIVE|||||||
33743120|NCT00411021|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33743121|NCT01744236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743122|NCT03498534|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743123|NCT02083523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743124|NCT02252055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743125|NCT02568696|||CASE_ONLY||PROSPECTIVE|||||||
33743126|NCT05287477|||OTHER||PROSPECTIVE|||||||
33743127|NCT00666510|||CASE_CONTROL||RETROSPECTIVE|||||||
33743128|NCT02855060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743129|NCT04711265|||COHORT||PROSPECTIVE|||||||
33743130|NCT01687517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743131|NCT05903274|NA|SEQUENTIAL||TREATMENT||NONE||3 + 3 dose escalation/de-escalation design||||
33743132|NCT06298006|||COHORT||PROSPECTIVE|||||||
33743133|NCT01584063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33743134|NCT05548790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1 was informed via silent video with subtitle, group 2 was informed via video with background audio, group 3 was informed with written information brochure, group 4 (control group) was informed verbally.|t|f|t|f
33743135|NCT00207441|RANDOMIZED|PARALLEL||||NONE||||||
33743136|NCT05858528|||COHORT||PROSPECTIVE|||||||
33743137|NCT01850160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743138|NCT03133910|||COHORT||PROSPECTIVE|||||||
33743139|NCT01346891|||CASE_CONTROL||RETROSPECTIVE|||||||
33743140|NCT00499187|||CASE_CONTROL||PROSPECTIVE|||||||
33743141|NCT02298218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743142|NCT01855009|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33743143|NCT04108312|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33743144|NCT03562715|||CASE_CONTROL||RETROSPECTIVE|||||||
33743145|NCT01899924|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951507|NCT04408950|||COHORT||PROSPECTIVE|||||||
33951508|NCT04440761|||COHORT||PROSPECTIVE|||||||
33743146|NCT01019655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743147|NCT04425226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743148|NCT05794867|||COHORT||PROSPECTIVE|||||||
33743149|NCT04413604|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743150|NCT06024304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pilot, patient blinded randomized trial|t|f|f|f
33743151|NCT06189040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants were blinded up to the venous blood draw used to assess the primary endpoint (day 112 for the long-interval treatment arm, day 56 for all other treatment arms). Afterwards, participants were unblinded because the registration of all administered COVID-19 vaccines was required by the Belgian government.||t|f|f|t
33743152|NCT03574792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743153|NCT00965627|||COHORT||RETROSPECTIVE|||||||
33743154|NCT05262153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743155|NCT04828382|||COHORT||PROSPECTIVE|||||||
33743156|NCT01798550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743157|NCT02283814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743158|NCT01979653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743159|NCT05007457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Partecipants, care providers and investigators are blinded only at the time of enrollment, subsequently they will learn about the group in which the partecipants were placed|Randomized controlled trial|f|f|f|t
33743160|NCT06489548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33743161|NCT03885193|||CASE_CONTROL||PROSPECTIVE|||||||
33743162|NCT06336070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743163|NCT03783923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743164|NCT03748498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All procedures were conducted by one clinician , and assignment was concealed from the clinician who performed the laser applications.|This study was designed as a randomized, placebo-controlled trial of 2 groups.|f|f|t|f
33743165|NCT02121847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743166|NCT01736826|||COHORT||PROSPECTIVE|||||||
33743167|NCT03697291|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|unlabeled ECG print|Single center, prospective, cross over study|f|f|f|t
33743168|NCT05707234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective, single-center, randomized controlled clinical trial||||
33743169|NCT04209582|||CASE_ONLY||PROSPECTIVE|||||||
33846364|NCT01681901|||COHORT||CROSS_SECTIONAL|||||||
33846365|NCT03446326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846366|NCT02101528|||COHORT||CROSS_SECTIONAL|||||||
33846367|NCT03900364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinded||t|f|f|f
33846368|NCT06473467|||COHORT||CROSS_SECTIONAL|||||||
33846369|NCT01127763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846370|NCT02976571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33846371|NCT03170895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951509|NCT05385510|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a Phase Ib, open-label, non-randomised, controlled trial. 100 children with confirmed HIV infection will be recruited to group 1. 20 children without HIV infection will be recruited to group 2. All children will receive R21/Matrix-M™||||
33743170|NCT01958151|||COHORT||PROSPECTIVE|||||||
33743171|NCT06532110|||COHORT||CROSS_SECTIONAL|||||||
33743172|NCT04095377|||COHORT||RETROSPECTIVE|||||||
33743173|NCT04000165|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33743174|NCT02995967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743175|NCT01732367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743176|NCT01592708|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846372|NCT05967364|RANDOMIZED|PARALLEL||PREVENTION||NONE||Classes will be randomized at Initial Technical Training. 396 classes of USAF personnel will be randomized at a 1:2 ratio to Wingman-Connect or to an active control (N=2,970 Airmen) and followed for one year.||||
33846373|NCT05297006|||COHORT||PROSPECTIVE|||||||
33846374|NCT05176041|||COHORT||RETROSPECTIVE|||||||
33951510|NCT00696891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33951511|NCT04845451|||CASE_ONLY||PROSPECTIVE|||||||
34159921|NCT02301026|||COHORT||PROSPECTIVE|||||||
33743177|NCT05515302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|None are masked in the study.|open label Randomized controlled trial||||
33743178|NCT04307719|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33743179|NCT00003289||||TREATMENT||||||||
33743180|NCT04543734|||OTHER||PROSPECTIVE|||||||
33743181|NCT04777682|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159922|NCT03100591|NA|SINGLE_GROUP||OTHER||NONE||||||
33743182|NCT06463015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743183|NCT04755595|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, prospective, rater-blinded, pilot study to evaluate patient satisfaction with facial aesthetic treatment using a combination of botulinum toxin and dermal fillers. The three types of injectables are Botox Cosmetic (onabotulinumtoxinA), Juvéderm Voluma XC (hyaluronic acid gel filler), and Juvéderm Volbella XC (hyaluronic acid gel filler). Twenty individuals who belong to the millennial generation and meet eligibility criteria will be enrolled. Study participants will receive all three injectables during a single procedure. The primary endpoint is the change in satisfaction after facial aesthetic treatment, using the FACE-Q Satisfaction with Facial Appearance Overall Scale.||||
33743184|NCT04603989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743185|NCT03595345|||COHORT||RETROSPECTIVE|||||||
33743186|NCT00434057|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743187|NCT05578404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|t|f|f
33951512|NCT04148027|||COHORT||PROSPECTIVE|||||||
33951513|NCT05588765|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Seal Envelope method|Randomized Control Trial|t|f|f|f
34159923|NCT02828436|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34159924|NCT05725083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34159925|NCT04168671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Asthma vs severe asthma||||
34159926|NCT05152329|||COHORT||PROSPECTIVE|||||||
34159927|NCT04027751|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34159928|NCT01078363|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34159929|NCT03009799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159930|NCT02455466|||CASE_ONLY||PROSPECTIVE|||||||
34159931|NCT01618695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159932|NCT02154256|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34159933|NCT00463619|||COHORT||PROSPECTIVE|||||||
34159934|NCT05929625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study design is single blinded; only the subject will be unaware of the group assignment. The operator providing the treatment will be aware of the subject's group assignment and will perform the treatment with the setting according to the subject's group.|The study is a prospective multicenter single-blinded two-arm study. The subjects will be enrolled and assigned into two study groups; group A (RF \& US) and B (only RF) which will receive a treatment with different settings.|t|f|f|f
34159935|NCT02153996|||COHORT||PROSPECTIVE|||||||
34159936|NCT01939184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159937|NCT02401503|NA|SINGLE_GROUP||TREATMENT||NONE||Initial treatment: 66 patients Re-treatment: 7 patients (of the initial cohort)||||
34159938|NCT03878849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159939|NCT03461640|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34159940|NCT00752479|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34159941|NCT00103740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743188|NCT00408993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743189|NCT03906058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743190|NCT03660683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743191|NCT00919282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951514|NCT06651086|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Observational Coders Direct Assessor|Participating mental health programs from California and Colorado will be randomized to one of two conditions: Unstuck and On Target training and Unified Protocol for Children training. Therapists will be recruited from each participating program and enrolled as a dyad with target children. Autistic children will be enrolled at the beginning of therapist participation and before intervention training. Non-autistic children will be enrolled after intervention training and implementation or approximately 6 months after therapist enrollment. Participating therapists and child clients served in those programs will receive the same condition as their enrolled program.|f|f|f|t
33951515|NCT02808182|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33951516|NCT04216134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951517|NCT04951895|||COHORT||RETROSPECTIVE|||||||
33951518|NCT03079648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34159942|NCT02445326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159943|NCT05820854|||COHORT||CROSS_SECTIONAL|||||||
34159944|NCT05343377|NA|SINGLE_GROUP||SCREENING||NONE||||||
34159945|NCT01272635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159946|NCT01031979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159947|NCT06413979|NA|SINGLE_GROUP||TREATMENT||NONE||Interrupted Time Series Study||||
34159948|NCT01612130|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34159949|NCT01736371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33951519|NCT00323830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951520|NCT05341427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951521|NCT01068535|||CASE_CONTROL||PROSPECTIVE|||||||
33951522|NCT00661037|||COHORT||PROSPECTIVE|||||||
33951523|NCT02621528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951524|NCT00383929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951525|NCT06316401|||COHORT||RETROSPECTIVE|||||||
33951526|NCT00495950|||CASE_ONLY||PROSPECTIVE|||||||
33951527|NCT03414099|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Ketum and placebo drinks will be matched for taste and appearence. Each study participant will receive a sequence of ketum and placebo drinks in random order.|Within-subject, repeated measures|t|t|t|t
33951528|NCT05129527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951529|NCT02070367|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951530|NCT01970280|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951531|NCT04700592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951532|NCT04921319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, unblinded clinical trial of 152 critically ill patients with sepsis admitted to the intensive care unit.||||
33743192|NCT04119284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743193|NCT06103981|||COHORT||PROSPECTIVE|||||||
33743194|NCT02384148|||COHORT||CROSS_SECTIONAL|||||||
33743195|NCT05248893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743196|NCT05402267|||CASE_CONTROL||RETROSPECTIVE|||||||
33743197|NCT06428747|||COHORT||PROSPECTIVE|||||||
33743198|NCT00659269|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33743199|NCT00372359|||CASE_ONLY||PROSPECTIVE|||||||
33743200|NCT06247176|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There will be two groups, one group will be subjects with autism spectrum disorder and the second group will be subjects who are neurotypical. Each group will participate in the same habituation protocol.||||
33743201|NCT06311123|||COHORT||PROSPECTIVE|||||||
33743202|NCT03073889|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33743203|NCT05217732|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|double-blind, placebo-controled study|single ascending doses in part 1 and fasting/nonfasting crossover in part 2|t|t|t|f
33743204|NCT04510064||SEQUENTIAL||TREATMENT||NONE||Patients were treated with domestic PD-1 antibody (Camrelizumab for injection) commbined with mFLOT regimen, and HER-2 positive patients were added Herceptin therapy. If primary tumor and metastatic lesions could be converted to R0 resection after 6-9 cycles of immunochemotherapy, then proceeded to surgery,otherwize treated according to the principles of palliative care. Patiens after surgery continued prior immunotherapy to 12 cycles or intolerable toxicity.||||
33743205|NCT06529666|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33743206|NCT04783701|||COHORT||PROSPECTIVE|||||||
33743207|NCT00377767|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33743208|NCT04121104|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33743209|NCT00674284|||COHORT||RETROSPECTIVE|||||||
33743210|NCT02863991|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743211|NCT03989817|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33743212|NCT06635356|||OTHER||PROSPECTIVE|||||||
33743213|NCT00374842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33743214|NCT01473654|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33743215|NCT05031910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743216|NCT05651581|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743217|NCT03269812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743218|NCT05399498|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label treatment study||||
33743219|NCT00759109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743220|NCT03125265|||COHORT||PROSPECTIVE|||||||
33743221|NCT03047447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743222|NCT03297879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743223|NCT00447863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743224|NCT03175653|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and investigators will be aware of the arm to which they have been assigned.|Randomized Controlled Trial||||
33743225|NCT02009475|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33743226|NCT04957667|||COHORT||CROSS_SECTIONAL|||||||
33743227|NCT05473195|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-centre, open-label, clinical trial in two stages. All treatments will be administered orally (PO) on days 1-7.||||
33743228|NCT05724186|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a mono-centre, prospective, one-arm, unmasked clinical trial, which consists of 6 visits, across 12 months. The objective of this clinical trial is to compare the test myopia control spectacle lens to the single vision control spectacle lens from the previous clinical trial, otherwise termed as historical control group.~After obtaining informed consent and assent, a comprehensive eye examination will be conducted during the screening visit on all 40 myopic children between the age of 8 to 13 years old. Eligible children will return in a separate visit (baseline visit) to collect the study spectacles and the assessment of study spectacles, biometry and instructions to use study spectacles are established in the same visit. A follow up visit will be conducted in 3, 6 and 12 months time, where 12 months is the end of study. All of the eye examinations and assessments are non-contact and non-invasive to the eyes."||||
33765169|NCT02692690|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765170|NCT00622713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765171|NCT01782742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765172|NCT02750176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765173|NCT02672384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846375|NCT01587027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33846376|NCT06340282|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This clinical randomized controlled trial will be conducted in the Acute Geriatric Unit of a tertiary hospital in Spain. A total of 212 acute patients will be enrolled according to the following criteria: age \> 75, Barthel Index \< 60, able to collaborate, expected length of stay \> 5 days, absence of clinical instability and severe dementia (GDS 7) or other end-stage disease. Patients will be randomly assigned to a control group (CG) or any of the three intervention groups (IG): IVR, ME, or IVR + ME. The IVR group will watch ad-hoc videos showing Spanish regional landscapes and villages, approximately 4 minutes per day for three consecutive days. The ME group will undergo aerobic and strength exercise for progressive training of the upper and lower limbs. The IVR + ME group will do both cognitive and physical intervention. The primary outcomes will be cognitive and physical measures at discharge. Mood, quality of life, isometric strength, and acceptance of IVR will be also assessed.|f|f|t|t
33846377|NCT04095559|||COHORT||PROSPECTIVE|||||||
33951533|NCT02457780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951534|NCT00128336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951535|NCT03058159|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951536|NCT03008824|||COHORT||PROSPECTIVE|||||||
33951537|NCT03186287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951538|NCT00856570|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33951539|NCT04910191|NA|SINGLE_GROUP||SCREENING||NONE||||||
33951540|NCT04922164|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33743229|NCT06234345|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental Group: Fluticasone Propionate 250 mcg/Formoterol Fumarate dihydrate 12 mcg/Glycopyrronium Bromide 25 mcg in the pharmaceutical form of hard capsule with powder for inhalation - 1 capsule per inhalation twice a day~Comparator Group: Beclomethasone Dipropionate 100 mcg/Formoterol Fumarate dihydrate 6 mcg/Glycopyrronium Bromide 12.5 mcg in pharmaceutical form aerosol solution in pressurized metered dose device (pMDI) for inhalation (Trimbow® - Chiesi Farmacêutica Ltda.) - 2 triggering twice a day"||||
33846378|NCT06394232|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subjects will be enrolled into 3 sequential, ascending dose-level (DL) cohorts to enroll a maximum of 18 subjects.~There will be three Cohorts~1. DL1-Cohort 1: Eyecyte-RPE™ 100,000 cells~2. DL2-Cohort 2: Eyecyte-RPE™ 200,000 cells~3. DL3-Cohort 3: Eyecyte-RPE™ 300,000 cells"||||
33846379|NCT03294694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846380|NCT01927705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846381|NCT01143870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846382|NCT02714790|||COHORT||RETROSPECTIVE|||||||
33846383|NCT01326429|||CASE_ONLY||PROSPECTIVE|||||||
33951541|NCT01457690|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743230|NCT01153633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743231|NCT03778736|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33743232|NCT02950493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846384|NCT00513487|RANDOMIZED|PARALLEL||||NONE||||||
33846385|NCT01800734|NA|SINGLE_GROUP||||NONE||||||
33846386|NCT05542082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846387|NCT00188123|||CASE_ONLY||CROSS_SECTIONAL|||||||
33846388|NCT02092688|||CASE_CONTROL||PROSPECTIVE|||||||
33846389|NCT02045875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846390|NCT05745701|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743233|NCT03895710|||COHORT||PROSPECTIVE|||||||
33846391|NCT02380924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743234|NCT03359980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951542|NCT02679716|NA|SINGLE_GROUP||SCREENING||NONE||||||
33951543|NCT04855201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951544|NCT02203604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743235|NCT00347282|||||PROSPECTIVE|||||||
33951545|NCT06323265|||CASE_ONLY||PROSPECTIVE|||||||
33951546|NCT03226366|||COHORT||RETROSPECTIVE|||||||
33951547|NCT05769348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will not know if they are receiving active or sham treatment||t|f|t|t
33951548|NCT04692974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Randomization will be carried out by a research assistant not involved in the study.~The assessors will be blind to the treatment assignment of the participant when administering the questionnaires."|Intervention and control group design|f|f|t|t
33743236|NCT05029648|||COHORT||RETROSPECTIVE|||||||
33743237|NCT02873624|||COHORT||PROSPECTIVE|||||||
34056003|NCT06649097|||CASE_ONLY||PROSPECTIVE|||||||
34056004|NCT06124521|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34056005|NCT00887523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056006|NCT00474786|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743238|NCT02773589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743239|NCT05761431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056007|NCT06622993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056008|NCT06452849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159950|NCT06335316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159951|NCT04780412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34159952|NCT00132808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743240|NCT02672046|||COHORT||PROSPECTIVE|||||||
33743241|NCT04306380|||CASE_ONLY||PROSPECTIVE|||||||
33743242|NCT05750381|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A Staff member, not part of the study group will be assigned to distribute blinded samples. The investigator will not be are of the dose groups.|"Participants will be randomly assigned to one of two groups applying balm containing Micrococcus luteus Q24 or placebo balm.~Group A: Probiotic Micrococcus luteus Q24 balm (dose:1e7 colony forming units per application of balm).~Group B: Placebo balm (dose:0 colony forming units per application of balm)."|f|f|t|f
33846392|NCT03720951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846393|NCT02767960|||CASE_CONTROL||PROSPECTIVE|||||||
33846394|NCT01470001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846395|NCT02811406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846396|NCT06525714|NA|SINGLE_GROUP||TREATMENT||NONE||A randomized-controlled study||||
33846397|NCT04500249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|neither participant nor operator is aware of rescue analgesia protocol||t|f|f|f
33846398|NCT00625547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33846399|NCT03495843|||COHORT||CROSS_SECTIONAL|||||||
33846400|NCT04973787|||COHORT||PROSPECTIVE|||||||
33846401|NCT02566044|NA|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33846402|NCT04291222|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33846403|NCT04268927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846404|NCT03192787|||COHORT||PROSPECTIVE|||||||
33846405|NCT06605053|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A two-arm, cluster randomized implementation trial in routine healthcare settings providing day-to-day vertical HIV prevention services in Dar es Salaam (urban) and Kagera (rural) regions of Tanzania to pilot test a co-produced intervention package for feasibility, acceptability, and preliminary effect.||||
33846406|NCT01786759|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33951549|NCT00994123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951550|NCT01606501|||COHORT||PROSPECTIVE|||||||
33951551|NCT02483754|||OTHER||CROSS_SECTIONAL|||||||
33951552|NCT02406066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951553|NCT05416346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951554|NCT00094900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159953|NCT06262724|NA|SINGLE_GROUP||TREATMENT||NONE||All patients were subjected to the same intervention.||||
34159954|NCT04099615|||COHORT||PROSPECTIVE|||||||
34159955|NCT01286883|||CASE_ONLY||PROSPECTIVE|||||||
34159956|NCT02324816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159957|NCT01166425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159958|NCT05442138|||COHORT||PROSPECTIVE|||||||
34159959|NCT00082914||||TREATMENT||NONE||||||
34159960|NCT05225363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159961|NCT00434642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159962|NCT05039944|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159963|NCT00992459|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34159964|NCT05987163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159965|NCT02583295|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34159966|NCT01945203|||COHORT||PROSPECTIVE|||||||
34159967|NCT01702246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159968|NCT00887510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159969|NCT03250182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159970|NCT00881348|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743243|NCT05516199|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Assignment||||
33743244|NCT06372093|NA|SINGLE_GROUP||SCREENING||NONE||||||
33743245|NCT05561959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled clinical trial|t|f|t|f
33743246|NCT00111657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743247|NCT00010218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743248|NCT03043612|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
33846407|NCT04629469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846408|NCT03103984|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846409|NCT04013087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34056009|NCT05172869|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"Patients who will undergo surgery will be divided into two randomized groups, each containing 34 patients, in the preoperative unit with a randomization program, as the group in which FICB was applied with the suprainguinal approach (Group S) and the group in which FICB was applied with the infrainguinal approach (Group I).~FICB can be applied with ultrasound-guided suprainguinal or infrainguinal approaches. Studies on the superiority of the two methods used in clinical practice are limited. In this study, it is aimed to compare the suprainguinal (Group S) and infrainguinal (Group I) approaches of FICB applied in the preoperative period in femoral fractures. These two methods will be compared in terms of postoperative pain scores (11-point numeric scale), morphine consumption (by intravenous patient controlled analgesia for postoperative 24 hours) and possible side effects-complications."|t|t|t|t
34056010|NCT05028075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34056011|NCT06618573|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinded|"SLE patient at the Hasan Sadikin Rheumatology Outpatient Clinic and registered as Lupus Registry study participants with remission or mild SLE disease activity. Subjects fulfilled inclusion criteria will be randomly divided into two groups: treatment group receiving INH 5 mg/kg/day (maximum 300 mg/day) with pyridoxine 10 mg/day and control group receiving placebo.~Monitor ALT/AST and SLE disease activity after two weeks, continued monthly for the first three months (1st, 2nd, 3rd) then every three months for up to a year (6th, 9th, 12th months). Routine SLE medication is continued and routinely recorded at every visit."|t|t|t|f
34056012|NCT02860000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056013|NCT05116202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056014|NCT05613608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled, parallel group study.|t|t|t|t
34056015|NCT02183805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056016|NCT04220021|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive medication||||
34056017|NCT00630175|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34056018|NCT02215551|||COHORT||PROSPECTIVE|||||||
34056019|NCT03744962|||COHORT||PROSPECTIVE|||||||
34056020|NCT01022294|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34056021|NCT03248310|||CASE_CONTROL||PROSPECTIVE|||||||
34056022|NCT03443310|NA|SINGLE_GROUP||PREVENTION||NONE||Patients who have symptomatic DVT undergo diagnostic venous duplex examination.||||
34056023|NCT00989456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056024|NCT04114357|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056025|NCT02719912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056026|NCT03256240|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.||||
34056027|NCT04972968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159971|NCT05512780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159972|NCT01317901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159973|NCT02756117|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34159974|NCT01898039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159975|NCT06233565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34159976|NCT02954393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34159977|NCT04350996|||COHORT||PROSPECTIVE|||||||
34159978|NCT02611843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34159979|NCT01178099|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34159980|NCT04063163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159981|NCT00432341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34159982|NCT01858766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159983|NCT01578655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34159984|NCT00262899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846410|NCT04522622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846411|NCT04891237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.~The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.~So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance."|Prospective, randomized, double-blind, placebo-controlled, multicentre, parallel-group study|t|t|t|t
33846412|NCT03003455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846413|NCT05684549|||COHORT||PROSPECTIVE|||||||
33846414|NCT06227052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research coordinators who will be collecting pain scales from patients will be blinded to intervention assignment.||t|f|f|f
33846415|NCT06462703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846416|NCT03518567|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846417|NCT05594381|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846418|NCT00526500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846419|NCT02554227|||OTHER||PROSPECTIVE|||||||
33846420|NCT05344664|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33846421|NCT00423631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951555|NCT05471141|RANDOMIZED|PARALLEL||OTHER||SINGLE|All participants will be informed that they will receive intervention but one group starts first and the other group will start with a 4-month delay.|Group 1 will receive the intervention Cognition ECHO during Phase 1 and Group 2 will serve as the control. About one month after Group 1 has completed the attendance of all five sessions of Cognition ECHO, Group 2 will start receiving the intervention Cognition ECHO and Group 1 will wait for the follow-up till Week 41 of the study in November 2023.|t|f|f|f
33951556|NCT00122954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951557|NCT03683264|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33951558|NCT01751191|||COHORT||PROSPECTIVE|||||||
33951559|NCT04888780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The research had an experimental design with pre-test and post-test control groups. The participants were randomly assigned to the experimental and control groups.|t|f|f|f
33951560|NCT00308555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951561|NCT06542666|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33951562|NCT00294190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951563|NCT06615635|NA|SINGLE_GROUP||TREATMENT||NONE||This is an International Multicenter, Pivotal, Single Arm, Open Label pivotal trial with DaRT for the treatment of Immunocompromised Cutaneous Squamous Cell Carcinoma||||
33846422|NCT05515276|||OTHER||CROSS_SECTIONAL|||||||
33846423|NCT05745389|||COHORT||PROSPECTIVE|||||||
33846424|NCT04107298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846425|NCT01081600|||COHORT||PROSPECTIVE|||||||
33846426|NCT02506517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846427|NCT03520101|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized trial including patients with surgical aortic bioprosthetic dysfunction in the presence of a small stented surgical valve. Patients will be randomized to either receive an Edwards (SAPIEN XT or SAPIEN 3) valve or a Core Valve Evolut R or Evolut PRO system.||||
33846428|NCT05928351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the blinded assessor|Randomized|f|f|f|t
33846429|NCT04434287|||COHORT||OTHER|||||||
33846430|NCT06532396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A participant and investigator-blinded, randomized, placebo-controlled design will be used to minimize bias in this study.|This study will be a randomized, double-blind, placebo-controlled multiple ascending dose (MAD) study in healthy participants with the primary goal of evaluating the safety and tolerability of QRL-101.|t|f|t|f
33846431|NCT04835350|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||"Pilot prospective controlled monocentric open-label, randomized study evaluating the feasibility and safety of Pancreas4All automated closed loop system."||||
33846432|NCT03293004|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|All nutritional interventions taste and look similar and are prepared for subjects in opaque bottles|A double blinded cross over design where subject are randomized to consume all 5 intervention doses.|t|f|t|f
33846433|NCT02935985|||COHORT||PROSPECTIVE|||||||
33846434|NCT03161600|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33846435|NCT00146627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846436|NCT01290289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33951564|NCT05038085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||parallel randomized controlled trial|f|f|f|t
33951565|NCT01813786|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33951566|NCT02826239|||CASE_CROSSOVER||PROSPECTIVE|||||||
33951567|NCT06083194|||COHORT||PROSPECTIVE|||||||
33951568|NCT00625846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951569|NCT01250418|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33951570|NCT05416034|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846437|NCT05845034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846438|NCT01783964|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846439|NCT03800043|||COHORT||PROSPECTIVE|||||||
33846440|NCT02405143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951571|NCT02163746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846441|NCT00858364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33846442|NCT04155047|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||A Randomized, Double-blind, Placebo-controlled, 2-Way Crossover Study|t|t|t|t
33846443|NCT02966327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33846444|NCT06381778|||CASE_ONLY||OTHER|||||||
33743249|NCT04107090|RANDOMIZED|PARALLEL||OTHER||NONE||"The study was conducted on 44 preterm neonates who were mechanically ventilated for respiratory distress syndrome (RDS). Then they were allocated randomly to one of 2 groups in order by admission:~Group A: it included 22 patients on whom the recruitment manoeuvre was applied guided by lung ultrasonography.~Group B: it included 22 patients on whom the recruitment maneuver was not ultrasound guided. This is considered the control group."||||
33743250|NCT00422474|||||PROSPECTIVE|||||||
33743251|NCT06390410|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846445|NCT02141620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33846446|NCT06609759|||COHORT||PROSPECTIVE|||||||
33846447|NCT01364103|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33846448|NCT04035278|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846449|NCT04369781|||COHORT||CROSS_SECTIONAL|||||||
33846450|NCT04505423|||COHORT||RETROSPECTIVE|||||||
33846451|NCT05710497|||COHORT||PROSPECTIVE|||||||
33846452|NCT03807310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Next to the 166 COPD patients that receive the nutritional supplement, a subgroup of 30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will not be included in the intervention arm.|t|f|t|t
33846453|NCT03255668|||OTHER||CROSS_SECTIONAL|||||||
33846454|NCT06126003|||COHORT||PROSPECTIVE|||||||
33743252|NCT04975568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743253|NCT06358482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846455|NCT06292052|||COHORT||RETROSPECTIVE|||||||
33846456|NCT04325360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The tDCS machine is equipped with a sham option, determined by a code, that will not be disclosed to the participants, outcome assessor and principal investigator until the moment of data analysis. Randomization will be done through envelopes that will contain the codes of types of stimulation (real vs sham), which will be prepared by a third party.|Prospective double-blind randomized controlled trial|t|t|t|t
33951572|NCT04143568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33951573|NCT02300194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743254|NCT05228613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Observer blind: Investigational Product and Active Comparator are masking. Lot number is masking||t|f|t|f
33743255|NCT03087266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||single-centre randomized controlled clinical trial with a 3- month follow-up|f|f|t|t
33743256|NCT06025955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846457|NCT06092008|||COHORT||PROSPECTIVE|||||||
33846458|NCT03207451|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951574|NCT05587075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33951575|NCT05260528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951576|NCT01977703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33743257|NCT02045758|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743258|NCT00930111|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33846459|NCT05581056|||COHORT||PROSPECTIVE|||||||
33846460|NCT02321202|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33846461|NCT01400529|||CASE_ONLY||CROSS_SECTIONAL|||||||
33846462|NCT04253873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951577|NCT05879341|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33951578|NCT04383925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Following informed consent, the mother selects, from a stack of envelopes, a closed envelope that contains a sealed randomization lot indicating allocation to either BCG-Japan or BCG-Russia. The mother, inclusion assistant and vaccinator will thus not be blinded to the intervention allocation. All assistants assessing outcomes during the follow-up procedures outlined and providers of care will be blinded to the randomization allocation.|Outcome assessor-blinded RCT|f|t|f|t
33951579|NCT00012766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951580|NCT00004646|RANDOMIZED|||TREATMENT||DOUBLE||||||
33951581|NCT00078273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951582|NCT01686607|||COHORT||RETROSPECTIVE|||||||
33951583|NCT01018680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951584|NCT05245292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951585|NCT04772456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056028|NCT01317121|||CASE_CONTROL||PROSPECTIVE|||||||
34056029|NCT06443398|||COHORT||PROSPECTIVE|||||||
34056030|NCT06316739|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Non-randomized wait-list controlled trial. The intervention will be implemented in 2 neighborhoods (in the Bronx, New York City) sequentially. Outcomes among participants in the immediate intervention neighborhood will be compared to outcomes among participants in the delayed intervention neighborhood.||||
34056031|NCT05282446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded||t|t|t|f
34056032|NCT05847257|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A prospective clinical study. The study initially included 74 patients, on follow-up 7 cases were lost and the final analysis involved 67 cases. These patients were further divided into two groups randomly, group A (29) patients received letrozole 2.5mg twice weekly for 3 months, and group B (38) patients receive letrozole 2.5mg twice a week plus Co Q10 400 mg per day for 3 months.~Patients with idiopathic Oligo-Astheno-Teratozoospermia (iOAT) syndrome were selected during their visit to the specialized center of infertility/ Nahrain University. Before taking part, each subject provided their written, informed consent. The duration of this study was from December 2021 till October 2022."||||
34159985|NCT03877302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 60 women participated in the study in 2 groups of 30 for reflexology and control groups. By giving appropriate position in the first stage of delivery to the pregnant women in the experimental group, 10-minute massage was applied to both feet including 5-minute massage for each foot starting first from the right foot by using vaseline under the supervision of a doctor to facilitate the hand movements, then the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. The control group was composed of pregnant women who received routine treatment, care and applications of the hospital.||||
33743259|NCT04475744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743260|NCT05626829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34159986|NCT04298957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34159987|NCT04368780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No Intervention: Control group Experimental: Experimental group|Parallel Assignment||||
34159988|NCT04869969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and the statistician were blinded to the type of the intervention|percutaneous nephrolithotomy to be performed in both supine and prone position|t|f|f|t
34159989|NCT04139850|||COHORT||PROSPECTIVE|||||||
34159990|NCT03069157|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be done by computer generated numbers and concealed by serially numbered,opague and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. Prior to surgery the appropriate numbered envelopes will be opened by the nurse, the card inside will determine the patient group||t|t|t|t
34159991|NCT04967404|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The experiment will follow a double-blind design where all participants and investigators will be blinded to the treatments given.|Participants matched on cycling time-trial performance and then randomly assigned to treatment or placebo groups|t|t|t|t
34159992|NCT01884272|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34159993|NCT03623568|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34159994|NCT06125782|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34159995|NCT06468189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34159996|NCT05990361|||OTHER||CROSS_SECTIONAL|||||||
33743261|NCT03673436|||COHORT||PROSPECTIVE|||||||
33743262|NCT04080973|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||cohort study of all patients presenting with renal colic||||
33743263|NCT05868083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743264|NCT00418392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765174|NCT03696797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both groups will not know assignment as all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so participant will not know whether blood was actually removed.||t|f|f|f
33765175|NCT03724396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846463|NCT02643043|NA|SINGLE_GROUP||OTHER||NONE||||||
33846464|NCT03284801|||CASE_ONLY||PROSPECTIVE|||||||
33846465|NCT02794922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34159997|NCT01494077|||||PROSPECTIVE|||||||
34159998|NCT00958061|||COHORT||CROSS_SECTIONAL|||||||
34159999|NCT05731479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160000|NCT05971537|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160001|NCT04120272|||CASE_CONTROL||PROSPECTIVE|||||||
34160002|NCT01248767|||COHORT||OTHER|||||||
34160003|NCT04339608|||COHORT||PROSPECTIVE|||||||
34160004|NCT02156778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33743265|NCT04302792|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All samples provided to the participant are labelled with 3 digit random codes.|This is a 3 stage study design. The first stage will be a qualitative part with interviews and focus group sessions. In the second and third stages participants will evaluate food products. The second and third stages of the study will be conducted single blind as it is not feasible to blind the researcher.|t|f|f|f
33743266|NCT04015193|||COHORT||PROSPECTIVE|||||||
33743267|NCT03567226|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743268|NCT04161911|||COHORT||RETROSPECTIVE|||||||
33743269|NCT02233660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743270|NCT01213017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743271|NCT04629794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743272|NCT01932164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743273|NCT02546752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33743274|NCT03599063|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33743275|NCT02775383|||COHORT||PROSPECTIVE|||||||
33743276|NCT03495024|NA|SINGLE_GROUP||TREATMENT||NONE||A 12 week exploratory, open-label, proof-of-concept, pilot study of smoking cessation treatment with varenicline in 10 schizophrenia or schizoaffective disorder patients who are actively smoking and have pre-existing TD while receiving stable doses of antipsychotics.||||
33743277|NCT00809757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743278|NCT05436574|NA|SINGLE_GROUP||OTHER||NONE||||||
33743279|NCT03081000|||CASE_ONLY||CROSS_SECTIONAL|||||||
33743280|NCT05343871|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be observer-blind. Participants, data collectors (e.g., Investigator), and data evaluators (e.g., trial statisticians) are blinded. Only the staff involved in vaccine delivery will be unblinded and aware of which vaccine the participant is receiving (group allocation). Study staff who collect information on symptoms and adverse events, laboratory staff and statisticians conducting the analysis will all be blinded to the vaccine and dosage received.||t|t|t|t
33743281|NCT01764100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743282|NCT02050984|||CASE_ONLY||PROSPECTIVE|||||||
33743283|NCT03094689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743284|NCT06425393|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients who are diagnosed to have H. pylori infection by either histology, rapid urease test or urea breath test will be recruited. At least 1 household member of each H. pylori infected subject will also be recruited.||||
33743285|NCT01903655|RANDOMIZED|PARALLEL||||NONE||||||
33743286|NCT00416052|||CASE_ONLY|||||||||
33743287|NCT02732535|||CASE_CONTROL||PROSPECTIVE|||||||
33743288|NCT06535672|RANDOMIZED|PARALLEL||PREVENTION||NONE||Stratified randomized controlled trial||||
33743289|NCT04877301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743290|NCT00184860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743291|NCT00216151|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33846466|NCT00187564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846467|NCT00066014|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846468|NCT02601118|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33846469|NCT03208777|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846470|NCT01318018|||CASE_CONTROL||PROSPECTIVE|||||||
33846471|NCT04695522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846472|NCT04073446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33846473|NCT06571565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator and the researcher working on the antioxidant panel will be blinded.|As a randomized controlled single blind|f|f|t|f
33846474|NCT00728897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846475|NCT03804489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Decision aids|t|f|f|t
33846476|NCT05841329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846477|NCT01134952|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846478|NCT00837694|||OTHER||PROSPECTIVE|||||||
33846479|NCT05894902|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subjects will be consecutively accrued to one of three study groups, starting at the lowest dose, Level 1 (low dose), and proceeding to the next higher dose level. Each subject will receive one dose of the Study Drug orally at the Clinical Study Site, according to their assigned dose Level. Dose levels vary by volume:~Level 1: 0.5 mL/kg (low; 50% of usual dose) N=4 (2M/2F) Level 2: 1 ml/kg (medium; 100% of usual dose) N=4 (2M/2F) Level 3: 2 ml/kg (high; 200% of usual dose) N=4 (2M/2F)"||||
33846480|NCT01629732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846481|NCT01758887|||CASE_CONTROL||PROSPECTIVE|||||||
33951586|NCT05188768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951587|NCT03723460|||COHORT||PROSPECTIVE|||||||
33951588|NCT03071809|||CASE_CONTROL||PROSPECTIVE|||||||
33951589|NCT02401217|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33951590|NCT03760952|||CASE_ONLY||PROSPECTIVE|||||||
33951591|NCT00320073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951592|NCT00869362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951593|NCT02787148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951594|NCT03919669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951595|NCT06374693|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33951596|NCT01304199|||CASE_ONLY||PROSPECTIVE|||||||
33951597|NCT03176576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951598|NCT02689505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951599|NCT04778319|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33951600|NCT05935449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951601|NCT06082427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951602|NCT01281475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951603|NCT05686928|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Multi-center, open-label study||||
33951604|NCT05232318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951605|NCT04469712|||CASE_CONTROL||PROSPECTIVE|||||||
33951606|NCT01912469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951607|NCT00179101|||DEFINED_POPULATION||OTHER|||||||
33951608|NCT04176068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056033|NCT06563544|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Physiological pilot study with a randomized crossover design comparing FCV and VCV||||
34056034|NCT02589522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743292|NCT02139501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743293|NCT06283004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056035|NCT03944759|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34056036|NCT02396303|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34056037|NCT04889196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056038|NCT00003764|RANDOMIZED|||TREATMENT||||||||
34056039|NCT00000864||||TREATMENT||||||||
34056040|NCT05341336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056041|NCT06511596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To reduce bias in the determination of closure, an independent blinded reviewer will review the image obtained from the wound measurement device in each case where the Investigator determines the wound has achieved closure.||f|f|f|t
34056042|NCT01565226|||CASE_ONLY||PROSPECTIVE|||||||
34056043|NCT05798741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056044|NCT06329960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056045|NCT06478849|||COHORT||PROSPECTIVE|||||||
34076169|NCT03925337|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"In this study, the colonoscopist will carefully inspect segments of colon during advancement and then again on withdrawal of the colonoscope. Those who qualify will be randomized into two arms, as detailed in the bullets below: scope Insertion will be the same for both arms, without the aid of the research software. Below are two groups that qualifying subjects will be randomized into:~* Group of patients in Arm-1- recruited patients will receive Standard Colonoscopy followed by AI-Assisted Combined Colonoscopy~* Group of patients in Arm-2- recruited patients will received AI-Assisted Combined Colonoscopy followed by Standard Colonoscopy"||||
34076170|NCT02907242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076171|NCT04014010|||COHORT||RETROSPECTIVE|||||||
34076172|NCT01820897|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076173|NCT01660867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076174|NCT02478515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076175|NCT06404619|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743294|NCT05045521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743295|NCT06268912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743296|NCT03598491|||COHORT||PROSPECTIVE|||||||
33743297|NCT05077267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743298|NCT05490667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743299|NCT02331992|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743300|NCT02912533||||||NONE||||||
33743301|NCT05430412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056046|NCT06320431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The trial will have allocation concealment and blinded endpoint assessment, but open-label treatment. Given the time sensitive nature of acute stroke treatment, blinding the enrolling personnel to treatment assignment is not practical. Clinical site staff, including the Principal Investigator (PI), sub-investigators, clinic site staff, and the Sponsor will not be blinded to treatment allocated or received. In the event of an emergency the PI will be already unblinded.~The trial will have blinded endpoint assessment on Day 90, with central blinded assessors contacting the participants."|"Randomization will be stratified by: (1) planned emergency endovascular thrombectomy (EVT) and (2) known use or history to suggest use of a standard-dose direct oral anticoagulant (DOAC) within the last 24 hours. Randomization will be centralized, secure and concealed, using a web-based server and permuted blocks of varying sizes will be used.~This will result in four pre-defined strata: (i) EVT+ / DOAC+ (ii) EVT+ / DOAC- (iii) EVT- / DOAC+ and (iv) EVT- / DOAC-.~Patients in strata 1, 2 and 3 will be randomized to standard-dose IV tenecteplase (0.25 mg/kg body weight) vs. Low-dose tenecteplase (0.18 mg/kg body weight) or no IV thrombolysis (1:1:1 randomization). Patients in strata 4 will be randomized to standard-dose intravenous (IV) tenecteplase (0.25 mg/kg body weight) vs. Low-dose IV tenecteplase (0.18 mg/kg body weight) only (1:1 randomization).~Emergency EVT is defined as anticipated arterial puncture time in the enrolling hospital ≤ 60 minutes from randomization."|f|f|f|t
34056047|NCT04514640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34160005|NCT00582777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160006|NCT02769221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160007|NCT03623152|||CASE_ONLY||CROSS_SECTIONAL|||||||
34160008|NCT02994875|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34160009|NCT02524002|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34160010|NCT01433562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160011|NCT06189131|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The participants will be divided into two groups and allocation to the relevant group is based on whether the patient has required a surgical intervention during the study period. This determines which outcomes are relevant and reflects two important groups of patients admitted to emergency general surgery. The allocation to each group is finalised following completion of the data collection as the decision for operative management or conservative manage of certain pathologies can change.||||
34160012|NCT03536832|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34160013|NCT02357121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160014|NCT04370106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34160015|NCT00607867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160016|NCT05472922|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-blinded prospective randomized controlled single center trial.||||
34160017|NCT04499625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056048|NCT04150484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients between 18 and 70 years of age with breast cancer II-III operable in follow-up, seen in the Oncology service of the Virgen de las Nieves Hospital in Granada and residents in the city or metropolitan area of Granada, which had completed, in the 12 months prior to its inclusion, treatment with surgery, radiotherapy and / or systemic chemotherapy treatment (including biological treatment).~Randomized assignment was made based on age, stage, hormone receptor and her2 status, establishing two groups: a group of dietary intervention, physical exercise and mindfulness and another control group. A longitudinal follow-up was carried out for 6 months from the beginning of the intervention."||||
34160018|NCT05178602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160019|NCT03359252|NON_RANDOMIZED|PARALLEL||OTHER||NONE||non-stent assisted coiling of unruptured intracranial aneurysms stent assisted coiling of unruptured intracranial aneurysms||||
34160020|NCT01104727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160021|NCT01080755|||COHORT||PROSPECTIVE|||||||
34160022|NCT06346015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The relevant neuroimaging evaluation process is blinded to the evaluator to ensure the objectivity of the evaluation results.||f|f|f|t
34160023|NCT06205238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to group allocation to reduce detection bias.||f|f|f|t
34160024|NCT03226496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056049|NCT00704444|||OTHER||PROSPECTIVE|||||||
34056050|NCT06620978|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34056051|NCT03841968|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34056052|NCT01000350|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056053|NCT06078709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056054|NCT03602391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056055|NCT06580600|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||randomised (1:1) to receive OCS or No OCS (both of which are standard of care)||||
34056056|NCT05002894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160025|NCT04518540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes assessors who do all the scales are concealed of group allocation.||f|f|f|t
34160026|NCT06524193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this study, where the mode of therapy received is obvious to the patients, double blinding is not possible. However, single blinding will be adopted in this study. Although all outcome measures data collection will be conducted by the study team clinicians, the coding of data, video and audio analysis will be conducted anonymously by research staff members who do not have knowledge about the group assignments and the time-point of the data collection.||f|f|f|t
34160027|NCT00897221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160028|NCT00003199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160029|NCT00002913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160030|NCT02663830|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34160031|NCT00950898|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160032|NCT02949063|||CASE_ONLY||PROSPECTIVE|||||||
34160033|NCT03261791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160034|NCT01020656|||COHORT||RETROSPECTIVE|||||||
34160035|NCT03807414|||COHORT||PROSPECTIVE|||||||
34160036|NCT00976833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160037|NCT01616680|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33846482|NCT03212495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|, Patients were randomly allocated (using random table assignment) into two groups to receive one of the following intra-articular solutions (prepared by an individual not involved in the study) which were injected into the knee joint through the cannular sheath after withdrawal of camera, by the orthopaedic surgeon (who was also unaware of the nature of the study drugs) before the arthroscope removed.|Patients will be randomly allocated to one of two groups each including 50 patients; the group received either intraarticular dexametomidine or neostigmine .|t|t|f|f
33846483|NCT00469690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846484|NCT02415517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were enrolled in Treatment-Group, Waitinglist-Group, or Shamtraining-Group|Pre-Test, Intervention, Post-Test, Follow-Up|t|f|f|f
33951609|NCT03679234|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects and their parent/caregiver will be blinded to the intervention product. Care Providers at sites, Investigators, and Outcomes Assessors are unblinded to the intervention product.|||||
33951610|NCT05278975|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33951611|NCT06519539|||CASE_ONLY||PROSPECTIVE|||||||
33951612|NCT01920841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951613|NCT03029754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33951614|NCT03681912|||COHORT||RETROSPECTIVE|||||||
33951615|NCT03964896|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33951616|NCT02778295|||COHORT||PROSPECTIVE|||||||
33951617|NCT03957161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056057|NCT06516055|NA|SINGLE_GROUP||TREATMENT||NONE||Rating scales and sexual activity log to establish baseline over one month then open-label treatment with dose titration based on results to determine change, with statistical analysis of group differences between month prior to treatment vs treatment.||||
34056058|NCT05071040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056059|NCT01921192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056060|NCT03001349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056061|NCT03698838|||OTHER||PROSPECTIVE|||||||
34056062|NCT01624857|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34056063|NCT06619327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056064|NCT04188431|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Patients are allocated by block randomisation using sealed envelope system. An external person dedicated by Sponsor is in charge to randomize groups of treatment allocation through a website-generated list and to conceal the lists. Each centre receives the sealed opaque envelopes which contain treatment allocation. The envelope will be opened just before surgery.~A member of the team not involved in the anaesthesia care will open an envelope and prepare the tested medication according to the result of randomization (Dexamethasone or NaCl). The repartition ratio between the 2 arms is 1:1 with a block size of 10."|Double-blind (investigator-surgeon-patient blinded), randomized, placebo control, multi-centre, international, pragmatic, Non-inferiority trial.|t|t|t|t
34056065|NCT04919122|||COHORT||PROSPECTIVE|||||||
34056066|NCT03335423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"In part 1 a single group of healthy volunteers will ingest a single dosis of metformin and then have a blood sample drawn after 3 and 10 hours.~In part 3, 18 healthy subjects will be randomized to ingest: a) oral metformin b) intravenous metformin c) 4 pills of codeine with the 5th taken together with oral metformin and d) 4 pills of codeine with the 5th taken together with intravenous metformin."||||
34056067|NCT06579183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056068|NCT01730534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056069|NCT05902351|||COHORT||CROSS_SECTIONAL|||||||
34056070|NCT06316869|||COHORT||PROSPECTIVE|||||||
34056071|NCT00602290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056072|NCT05545631|||CASE_CONTROL||PROSPECTIVE|||||||
34160038|NCT05185050|||OTHER||CROSS_SECTIONAL|||||||
34160039|NCT01196351|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34160040|NCT02061514|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34160041|NCT00932581|||CASE_CONTROL||PROSPECTIVE|||||||
34160042|NCT01776034|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160043|NCT02163109|||COHORT||PROSPECTIVE|||||||
34160044|NCT01336413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160045|NCT02547558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160046|NCT04954768|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34160047|NCT01112878|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33846485|NCT00301678|RANDOMIZED|||PREVENTION||||||||
33846486|NCT01180205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846487|NCT00623701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846488|NCT00298259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846489|NCT02533817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33951618|NCT02825875|||COHORT||PROSPECTIVE|||||||
33951619|NCT01891136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951620|NCT03316209|||COHORT||PROSPECTIVE|||||||
33951621|NCT01961778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951622|NCT00026156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951623|NCT05422105|||CASE_ONLY||PROSPECTIVE|||||||
33951624|NCT03063931|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33951625|NCT04209166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33951626|NCT06443216|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33951627|NCT06017362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951628|NCT06425822|||COHORT||PROSPECTIVE|||||||
33951629|NCT00775827|RANDOMIZED|CROSSOVER||||NONE||||||
33951630|NCT01770665|||COHORT||PROSPECTIVE|||||||
33951631|NCT01055184|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33951632|NCT00172783|||||OTHER|||||||
34160048|NCT01685697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743302|NCT02605057|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33743303|NCT02564198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743304|NCT05150158|||COHORT||RETROSPECTIVE|||||||
33743305|NCT04434404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was a parallel randomized (simple randomization; odd number took silymarin and even number took l carnitine) controlled prospective open label one.|t|f|f|f
33951633|NCT03741816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743306|NCT06104735|NA|SINGLE_GROUP||TREATMENT||NONE||"Each participant will undergo multiple conditions and verifications in an n-of-1 design."||||
34160049|NCT05862376|||CASE_ONLY||CROSS_SECTIONAL|||||||
34160050|NCT00117299|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743307|NCT02614976|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33743308|NCT03103620|||CASE_ONLY||PROSPECTIVE|||||||
34160051|NCT05240365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160052|NCT03489889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160053|NCT05658705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and investigators cannot be blinded due to the type of study. To minimize the potential influence of this limitation, we will assign the most professional vascular doctor to perform the same operation on the two groups of patients, and statisticians will be blind.||f|f|f|t
34160054|NCT04239651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because it will not be possible for participants to be blinded, treatment allocation will be made explicit to them as soon as randomization is concluded. Primary outcome assessors will be blinded to treatment group allocation by not involving them in discussions about study participants and not granting them access to the database which contains the randomization code. After data collection is complete, all data will undergo a blind review for the purposes of finalizing the planned analysis.|This is a prospective, two-arm randomized controlled trial. 100 patients diagnosed with resistant depression in psychiatric care clinic in Edmonton, Alberta, Canada will be randomized to one of two conditions: (1) enrolment in rTMS sessions alone (2) enrolment in the rTMS sessions plus iCBT.|f|f|f|t
34160055|NCT02586948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160056|NCT05508919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160057|NCT05767359|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160058|NCT00121186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160059|NCT04548804|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The treating physician is not informed about the results of the procedure.|Both groups (control and diseased) will undergo a body surface potential mapping and a cardiac + low dose CT-scan.|f|t|f|f
34160060|NCT02265250|||COHORT||PROSPECTIVE|||||||
34160061|NCT03240094|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160062|NCT04364295|||COHORT||PROSPECTIVE|||||||
34160063|NCT06238284|||CASE_ONLY||RETROSPECTIVE|||||||
34160064|NCT05388617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be enrolled in Group A if they present with abdominal fat and are able to be present for up to 8 treatment visits spaced approximately 1 week apart. Subjects will enroll in Group B for training and experience purposes only and will be able to attend up to 8 treatments spaced at least 3 days apart.||||
34160065|NCT04040829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to treatment allocation, but patients, cognitive remediation therapists and supported education specialists will not be blind. We will ask participants to not disclose their group allocation to the assessor. Furthermore, each patient will be assessed by a different assessor for each time point (T0, T1, T2, T3) to ensure blindness.|This study is a two arm single blind randomized trial comparing Cognitive remediation therapy + Supported education + Treatment as usual with Supported Education + Treatment as usual alone|f|f|f|t
34160066|NCT01854034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160067|NCT06141265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160068|NCT02817243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160069|NCT00550966||PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34160070|NCT05373849|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34160071|NCT00544219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160072|NCT01811134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160073|NCT03478800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743309|NCT00736996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743310|NCT06039748|||COHORT||PROSPECTIVE|||||||
33743311|NCT06634667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743312|NCT04547972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A within participant design will be used wherein each participant will be assigned to both training conditions. One arm and one leg will train with higher-loads and one arm and one leg will train with lower-loads; limb allocation will be randomized.||||
33743313|NCT02552836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743314|NCT04546087|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743315|NCT03011216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743316|NCT01645709|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33743317|NCT00094380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743318|NCT05647447|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm pilot||||
33743319|NCT02505932|||CASE_CONTROL||PROSPECTIVE|||||||
33743320|NCT01141361|||COHORT||PROSPECTIVE|||||||
33743321|NCT03300388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33765176|NCT01047722|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33765177|NCT00002093|RANDOMIZED|||TREATMENT||||||||
33765178|NCT01007968|NA|SINGLE_GROUP||OTHER||NONE||||||
33951634|NCT03521674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765179|NCT04402528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765180|NCT00685321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846490|NCT04819776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846491|NCT01923090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846492|NCT03170791|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33846493|NCT05789329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A computer-generated masked randomization sequence will be provided and held by a statistician not otherwise involved in the study. Randomization will be stratified by site and gender.|Participants will be randomly assigned to Trauma Informed Guilt Reduction Therapy (TrIGR) or Cognitive Processing Therapy (CPT).|f|f|f|t
33951635|NCT06317701|||COHORT||PROSPECTIVE|||||||
33951636|NCT05798325|NA|SINGLE_GROUP||OTHER||NONE||||||
33951637|NCT04189666|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33951638|NCT03371095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743322|NCT03074422|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|No masking|"Patients will be randomly attributed to either the hypnosis group or the control group, by a randomization process. The investigators plan to allocate patients in two groups; in the first group, patients will undergo hypnosis during the fixation of the stereotactic frame. In the second group (control group), the frame disposal will be performed following the actual standard of care, with a LA performed during the procedure."||||
33743323|NCT00618514|RANDOMIZED|PARALLEL||||NONE||||||
33743324|NCT03171025|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2, single arm, open label trial||||
33743325|NCT03706599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33743326|NCT06634511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743327|NCT06535217|||COHORT||RETROSPECTIVE|||||||
33743328|NCT00145431|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33743329|NCT04459611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743330|NCT00366626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743331|NCT05013892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743332|NCT00439959|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33743333|NCT06350019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743334|NCT02536508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind||t|f|t|f
33743335|NCT05203029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33846494|NCT03078777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33846495|NCT06094699|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33846496|NCT00228124|||||OTHER|||||||
33846497|NCT02549495|||OTHER||PROSPECTIVE|||||||
33846498|NCT03392259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846499|NCT01511094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846500|NCT02601300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056073|NCT03998163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056074|NCT06514716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the specific nature of the interventions, it may not be possible to blind participants or operators; however, to minimize potential bias, outcome assessors will be blinded to the treatment assignments.|Participants will be randomized into two groups: Group A receiving geniculate artery embolization (GAE) with intra-articular corticosteroid injection (IACI) and Group B receiving GAE alone.|f|f|f|t
34056075|NCT01104246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056076|NCT01264237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056077|NCT06259695|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056078|NCT01550705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056079|NCT05895890|||COHORT||PROSPECTIVE|||||||
34056080|NCT05397171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Substudy 1:~* Part A: Part A is an AZD8853 monotherapy dose escalation which may enroll up to 45 participants.~* Part B: Dose escalation will be followed by Part B, where up to 40 participants will be enrolled to doses determined to be safe during Part A. Additionally, a sub-set of participants will also receive an investigational radiopharmaceutical, Zirconium-89 crefmirlimab berdoxam, to evaluate the presence of CD8+ T cells in and around cancerous tumours.~* Part C: Part C is an efficacy expansion where up to 80 participants may be enrolled based on doses and indications recommended during Part B."||||
34056081|NCT06621615|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a phase I clinical trial of dose escalation/dose extension/efficacy extension of CVL006 injection monotherapy in patients with advanced solid tumors in a single arm, open label, multicenter manner||||
34056082|NCT06275711|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-test post-test quasi-experimental study||||
34056083|NCT02573558|||COHORT||RETROSPECTIVE|||||||
34056084|NCT02521558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056085|NCT06315478|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056086|NCT01300299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056087|NCT00519233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056088|NCT05630521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Study staff will be blinded to the randomization sequence. Due to the nature of the intervention, participants and investigators delivering the intervention cannot be blinded.~Study staff collecting outcome data will be blinded to participant group assignment."||f|f|f|t
34056089|NCT04722991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-masked study||t|t|t|t
34056090|NCT04491747|||COHORT||PROSPECTIVE|||||||
34056091|NCT03544931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34056092|NCT06648122|||OTHER||PROSPECTIVE|||||||
34056093|NCT02499146|NA|||OTHER||NONE||||||
34056094|NCT02728583|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34056095|NCT03144843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicenters ramdomized double-blind phase II study.|t|t|t|f
34056096|NCT00867828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056097|NCT03994770|NA|SINGLE_GROUP||OTHER||NONE||Once the BATP is developed 20 stroke subjects will be recruited and the BATP's Assessment Module will be administered in order to verify its operation. After this is complete 10 stroke subjects will be randomly selected from this group and will undergo three one-hour training sessions over the course of one week to assess the operation of the BATP's Training Module.||||
34056098|NCT04450134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double-blind for researchers and participants|Placebo + exercise vs histamine blockade + exercise|t|t|t|t
34056099|NCT06483048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846501|NCT05550545|||COHORT||RETROSPECTIVE|||||||
33846502|NCT05988359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846503|NCT05920824|||COHORT||PROSPECTIVE|||||||
33846504|NCT02468219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study will be divided into four phases: phase 1 (pre-procedure rehabilitation); phase 2 (early post-procedure rehabilitation); phase 3 (late post-procedure rehabilitation), and phase 4 (follow-up).|t|f|t|t
33846505|NCT00399373|||COHORT||PROSPECTIVE|||||||
33846506|NCT01712945|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33846507|NCT06263764|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33846508|NCT04220619|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"Conventional ACLS and Rescue TEE ALCS patients after codes will be observed for survival. Care teams will be blinded to the methodology of ACLS.~A post-hoc analysis will also be performed for independent ECHO reads."|Convenience Sampled, Prospective Arm1: Conventional ACLS Arm2: Image Guided RescueTEE ACLS|f|t|f|t
33846509|NCT02910050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846510|NCT02799264|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846511|NCT05059743|NA|SINGLE_GROUP||OTHER||NONE||||||
33846512|NCT05746364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846513|NCT00362739|||CASE_CONTROL||PROSPECTIVE|||||||
33846514|NCT02547545|||COHORT||PROSPECTIVE|||||||
33846515|NCT00466375|||FAMILY_BASED||OTHER|||||||
33846516|NCT02549105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846517|NCT06424132|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants in from the three different study groups (lean, obese, and obese with type 2 diabetes) will receive the same intervention: cold environmental exposure followed by a rewarming period||||
33846518|NCT04844645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The experiment involved two groups: a mini program trial group and a control group.||||
34056100|NCT02266290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056101|NCT02375555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846519|NCT01318395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846520|NCT01157767|||COHORT||PROSPECTIVE|||||||
33846521|NCT00285025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846522|NCT03186053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33846523|NCT05865132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846524|NCT03859154|||COHORT||PROSPECTIVE|||||||
33846525|NCT01167764|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846526|NCT04718779|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846527|NCT06265493|||COHORT||RETROSPECTIVE|||||||
33846528|NCT00774930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846529|NCT00291642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846530|NCT06009484|||COHORT||PROSPECTIVE|||||||
34056102|NCT05644821|RANDOMIZED|PARALLEL||OTHER||NONE||Intention-to-treat principle, comparison (regarding superiority) of primary endpoint using mixed linear model for repeated measures: dependent variable: primary endpoint, influencing factors: Indicator for intervention/control group, time, group\*time, center, tumor stage, and age group; downstream sequential-rejection testing of equality of expected values in the individual strata via appropriate contrasts; control of multiple error for at least one false rejection (final test principle); supplementary: mixed linear models with additional independent variables; sensitivity analyses on the influence of missing values (multiple imputation); subgroup analyses according to center, stage, and age group||||
34056103|NCT06620094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a pre-test, post-test randomized controlled experimental study. Therefore this study there is two groups: Intervention and control.|t|f|f|f
34056104|NCT04653753|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056105|NCT05570851|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study model is a randomized control pilot trial consisting of two arms, control and intervention group. Control condition will consist of a provider-delivered alcohol cessation intervention with usual-care-advice. The intervention condition will consist of a text based intervention designed to promote alcohol cessation in addition to usual-care-advice.||||
34056106|NCT06629298|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||One Experimental Group and one Control Group|t|f|f|f
34056107|NCT02340442|||COHORT||PROSPECTIVE|||||||
34056108|NCT02407457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056109|NCT06649123|||COHORT||PROSPECTIVE|||||||
34056110|NCT04598451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056111|NCT05306782|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|"Participants will be randomly assigned to real neuromodulation or to sham modulation (in addition to speech therapy)"||t|t|f|t
34056112|NCT04955665|||COHORT||RETROSPECTIVE|||||||
34056113|NCT03942068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056114|NCT05622929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized clinical trial||||
34056115|NCT06413056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized controlled, Double Blinded Clinical Trial.|"Primary aim; to study the effectiveness of micafungin in treatment of fungal infection in preterm neonates.~Secondary aim; to test the safety of micafungin in treatment of fungal infection in preterm neonates.~Tertiary aim; to compare the effectiveness and safety of micafungin versus amphotericin B in treatment of invasive fungal infection."|t|t|t|t
34056116|NCT06620913|||COHORT||RETROSPECTIVE|||||||
34056117|NCT06260267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056118|NCT04766957|NA|SINGLE_GROUP||TREATMENT||NONE||open study, only one arm||||
34056119|NCT01885286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056120|NCT05860439|||COHORT||CROSS_SECTIONAL|||||||
33846531|NCT04040790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846532|NCT01725789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846533|NCT00016601||||TREATMENT||||||||
33846534|NCT00180063|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056121|NCT06424275|||CASE_ONLY||PROSPECTIVE|||||||
34056122|NCT06618430|||OTHER||CROSS_SECTIONAL|||||||
34056123|NCT01752881|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056124|NCT00036491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056125|NCT03783130|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34056126|NCT05139459|||COHORT||PROSPECTIVE|||||||
34056127|NCT06342011|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34056128|NCT00514904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056129|NCT02193139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056130|NCT06620770|||CASE_CONTROL||PROSPECTIVE|||||||
34056131|NCT01138592|||COHORT||PROSPECTIVE|||||||
34056132|NCT00878150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056133|NCT00510016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34056134|NCT06623617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056135|NCT05670223|NA|SINGLE_GROUP||OTHER||NONE||||||
34056136|NCT01330368|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056137|NCT00550979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056138|NCT01129349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056139|NCT02027662|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34056140|NCT02545361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056141|NCT06622057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056142|NCT05854303|||CASE_CONTROL||PROSPECTIVE|||||||
34056143|NCT02757937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846535|NCT04807712|||COHORT||PROSPECTIVE|||||||
33846536|NCT01057329|||CASE_ONLY||PROSPECTIVE|||||||
33846537|NCT01123070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846538|NCT01323972|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846539|NCT06488989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846540|NCT00523861|RANDOMIZED|CROSSOVER||||NONE||||||
33846541|NCT01788462|||COHORT||PROSPECTIVE|||||||
33846542|NCT03693859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846543|NCT02514239|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33846544|NCT02405728|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846545|NCT01908192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056144|NCT06620276|NA|SINGLE_GROUP||OTHER||NONE||Assessing the feasibility of providing Acceptance and Commitment Therapy (ACT) to patients diagnosed with Alcohol Use Disorder and Treatment-Resistant Depression who are undergoing ketamine sessions.||||
34056145|NCT06620887|||COHORT||RETROSPECTIVE|||||||
34056146|NCT05840315|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three stages of single arm non-randomized feasibility trial set-up, testing an interventions feasibility, combined with the usual rehabilitation program.||||
34056147|NCT00166257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056148|NCT02910271|||COHORT||CROSS_SECTIONAL|||||||
34056149|NCT06597565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056150|NCT06545656|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study aims to enroll a minimum of 10 AFAB and 10 AMAB participants.||||
34056151|NCT06616025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All study personnel involved in the surgical procedure will be unblinded. Patient, Care Providers and outcomes evaluators will be blinded.|Treatment vs. Standard of Care|t|t|f|t
34056152|NCT03912714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056153|NCT06194747|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be masked as to whether the implementation bundle has been dissemination or implemented within the site they receive treatment.|A stepped-wedge cluster randomized trial. This is a unidirectional crossover design in which clusters switch treatments at different time points, enabling statistically rigorous assessment of interventions while reducing ethical and resource limitations for quality improvement studies.|t|f|f|f
34056154|NCT06295627|||CASE_CONTROL||RETROSPECTIVE|||||||
34056155|NCT03625635|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Masking during data analysis. Technicians and investigators will not be aware of the participants personal data and particularities.|||||
34056156|NCT00562289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056157|NCT00632684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056158|NCT02453217|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34056159|NCT01917812|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34160074|NCT04153916|NA|SINGLE_GROUP||TREATMENT||NONE|The Principle Investigators of the Clinical study will code the patients by the study enrolment number provided at the day of enrolment and is not disclosed to the sponsor|elicit a complete or a partial eyelid closure \& To optimize the location of the Neurotrigger's electrodes, and define the level of the pain generated, if any, during device implementation and stimulation, as well as the method for the personal adjustment of the precise pattern of stimulation (strength, intensity, other features) to achieve eye blinking for different patients.||||
34160075|NCT04124705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160076|NCT05168228|||COHORT||OTHER|||||||
34160077|NCT00510744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160078|NCT02156414|||COHORT||PROSPECTIVE|||||||
34160079|NCT02048085|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34160080|NCT02858947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160081|NCT04036526|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Present clinical trial is a randomized placebo-controlled study for selection of dosing schedules and application methods of GamLPV, a live intranasal Bordetella pertussis vaccine. The study is blinded for volunteers.|t|f|f|f
34160082|NCT05138627|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled study||||
34160083|NCT03481699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation was concealed to the participants, researchers -who were in class the assessment days- and teachers.|Participants were randomized in a 1:1 ratio blocked by gender to one of two groups: experimental condition (ITP intervention) versus control condition (educational intervention) in parallel for the duration of the study.|t|f|f|t
34160084|NCT05238545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Study groups in PD and MSA group with gluten-free diet and on regular gluten-containing diet. Randomization: patients will be randomized by diagnosis, age and disease duration, a numbered envelope in 1:1 ration to gluten-free diet group and regular gluten-containing diet group will be used.|f|f|t|t
34160085|NCT03301610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This prospective study has been designed as quasi-experimental study. This study seeks to explore both a treatment and control group in efforts to compare outcomes which are dependent on the type of intervention. Study participants will be assigned into one of two study arms, intervention or control, based on random assignment determined by the location they are bedded in hospital. One of two patient care units will offer standard education, the other unit will offer the mobile, iPad based education. The patient care unit to offer the mobile, iPad based education will be selected at random.||||
34160086|NCT01286740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160087|NCT01207752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160088|NCT03451123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group assignment||||
33951639|NCT03986216|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a small clinical trial to determine the feasibility of the product for the purpose of home-based arm/hand practice. We will recruit 2-4 stroke participants to participate the small clinical trial (i.e., the home based practice).||||
34160089|NCT00023101|||DEFINED_POPULATION||PROSPECTIVE|||||||
34160090|NCT00005514|||COHORT||PROSPECTIVE|||||||
34160091|NCT05698602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160092|NCT03592485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
34160093|NCT03282929|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Pharmacokinetics and pharmacodynamics of epinephrine in healthy male and female subjects with different skin-to-muscle depth (STMD) of the thigh after injections with four different marketed auto-injectors||||
33951640|NCT02966366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951641|NCT03542825|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded (participant and care giver)|3 groups of pregnant women will be assigned for each intervention|t|t|f|f
33951642|NCT01785251|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951643|NCT05769465|||COHORT||OTHER|||||||
33951644|NCT05208398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open label randomized controlled clinical trial, two parallel active groups, with blinded primary study outcome assessor.|f|f|f|t
33951645|NCT05110300|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention, subjects and investigators will not be able to be masked to the intervention. The assessor will not be able to be masked to group assignments, as the presence or absence of certain variables in the dataset, namely the perturbation level, will immediately reveal group assignment.|This will be a multisite, randomized, active-comparator controlled clinical trial.||||
33951646|NCT02462564|||CASE_ONLY||PROSPECTIVE|||||||
33951647|NCT03441373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951648|NCT00937859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951649|NCT02433522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951650|NCT04233606|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will complete two trials under two different hydration states: isovolemic increase in plasma osmolality and isovolemic control (maintain normal plasma osmolality)||||
33951651|NCT00564876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951652|NCT00625768|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951653|NCT05359861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951654|NCT01169116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951655|NCT02783976|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33951656|NCT03818334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951657|NCT00773201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846546|NCT05791071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects and their parents/caregivers will be blinded to whether they are receiving Floreo VR therapy vs active VR exposure control. Research staff administering the therapy or control will not be blinded to the therapy; however, the clinicians doing pre/post assessments will be blinded.|The two parallel groups include an experimental group that will receive the Floreo VR Building Social Connections program and a control group that will receive non-interventional active VR programing.|t|f|t|t
33846547|NCT00507195|||||PROSPECTIVE|||||||
33846548|NCT00672945||||TREATMENT||||||||
33951658|NCT00190476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951659|NCT02430155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951660|NCT04796259|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34160094|NCT00719355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160095|NCT02720692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160096|NCT04071158|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but the participant and all other study personnel, including the principal investigator, will be blinded.||t|t|t|t
34160097|NCT03854513|||COHORT||PROSPECTIVE|||||||
33846549|NCT05335746|||CASE_CONTROL||PROSPECTIVE|||||||
33846550|NCT05630820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double blinded study in which investigators/site staff and the Sponsor will remain blinded to treatment assignment.|This is a multicenter, randomized, double-blind, placebo-controlled study.|t|t|t|t
33846551|NCT04821024|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33951661|NCT00219349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951662|NCT06296901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951663|NCT01529697|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34056160|NCT06293118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were unaware of the allocation.|"1. Ischemic conditioning group~2. control group (Sham)"|t|f|f|f
34056161|NCT05504486|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056162|NCT04390672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056163|NCT03091881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34056164|NCT00792376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056165|NCT02703272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056166|NCT02863107|||COHORT||PROSPECTIVE|||||||
34056167|NCT06124248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who carries out the T1 follow-up measurement (end of the intervention period), will be blinded for treatment allocation.||f|f|t|f
34056168|NCT04774861|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056169|NCT05923242|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34056170|NCT00199797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056171|NCT04962724|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34056172|NCT00534079|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34056173|NCT06591884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056174|NCT00006024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056175|NCT02726438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056176|NCT06622811|NA|SINGLE_GROUP||SCREENING||NONE||||||
34056177|NCT03815591|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056178|NCT06619158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34160098|NCT03659071|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34160099|NCT05269108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The 1st group: Fluoroscopy-free RIRS. The 2nd group: Fluoroscopy-guided RIRS.|f|f|f|t
34160100|NCT00913939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160101|NCT03999060|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160102|NCT05909839|||COHORT||PROSPECTIVE|||||||
34160103|NCT01600079|||COHORT||PROSPECTIVE|||||||
34160104|NCT01020370|||COHORT||PROSPECTIVE|||||||
34160105|NCT00465088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160106|NCT06527924|||COHORT||PROSPECTIVE|||||||
34160107|NCT06268938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33951664|NCT01465048|NON_RANDOMIZED|PARALLEL||||NONE||||||
33951665|NCT01659762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951666|NCT01725100|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34160108|NCT02696213|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34160109|NCT03257839|||OTHER||PROSPECTIVE|||||||
33951667|NCT05184491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951668|NCT00398476|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33951669|NCT06536998|||COHORT||PROSPECTIVE|||||||
33951670|NCT00612300|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33951671|NCT02867748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951672|NCT01469416|RANDOMIZED|CROSSOVER||||NONE||||||
33951673|NCT04479410|||COHORT||RETROSPECTIVE|||||||
33951674|NCT01450670|||COHORT||PROSPECTIVE|||||||
34056179|NCT01179841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056180|NCT01125670|RANDOMIZED|CROSSOVER||||NONE||||||
34056181|NCT03360006|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056182|NCT04484636|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Experimental Study||||
34056183|NCT01961895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056184|NCT06618950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34056185|NCT02175134|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056186|NCT02018172|||COHORT||PROSPECTIVE|||||||
34056187|NCT04889157|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34056188|NCT00346047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056189|NCT01490606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056190|NCT01864876|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160110|NCT04949022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160111|NCT00098683||||TREATMENT||NONE||||||
34160112|NCT05950698|||COHORT||PROSPECTIVE|||||||
34160113|NCT06584045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160114|NCT04189549|||COHORT||PROSPECTIVE|||||||
33846552|NCT03644303|NA|SINGLE_GROUP||TREATMENT||NONE|Interpretation of the two paired WB DW MRI scans (baseline and 6 months) will be conducted by one assessor will be blinded to the identity of the baseline scan to ensure minimisation of any potential bias.|Single arm, prospective interventional cohort study||||
34056191|NCT04505722|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056192|NCT05919472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743336|NCT02300883|||CASE_ONLY||PROSPECTIVE|||||||
33743337|NCT01813500|||CASE_CONTROL||PROSPECTIVE|||||||
33743338|NCT00907569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743339|NCT03112616|||COHORT||PROSPECTIVE|||||||
33743340|NCT04577144|||COHORT||PROSPECTIVE|||||||
33743341|NCT05710068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split lesion study|f|f|f|t
33743342|NCT06280365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743343|NCT05046457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34056193|NCT02202044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743344|NCT05213845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846553|NCT02935660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846554|NCT03593551||SEQUENTIAL||TREATMENT||NONE|The order for five treatments and one control are randomly allocated to participants. Each participant will attend all six sessions (five treatments and one control)|within study design||||
33846555|NCT06132438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846556|NCT05079568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind, randomized.||t|t|t|t
33846557|NCT02521987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34056194|NCT00169715|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056195|NCT03101826|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking.|All participants will receive the active (filtered music) intervention.||||
34056196|NCT06499610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056197|NCT06645353|||COHORT||CROSS_SECTIONAL|||||||
34056198|NCT06267560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Eligible participants will be randomized after the screening period or Guideline recommended SOC implementation period (if needed) in a 2:1 ratio to subcutaneous injections of pelacarsen (TQJ230) 80 mg QM or placebo QM either to be self-administered or administered by caregiver or site personnel approximately every 30 days for up to 12 months.||t|t|t|t
34056199|NCT05838339|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators aim to conduct a pilot three-arm controlled trial with a mixed methods approach. Schools will be assigned to one of three groups: 1) co-creation intervention group (shortened co-creation process), 2) standard implementation group (no co-creation process), and 3) control group. After the implementation of the intervention, effect and process will be evaluated.||||
34056200|NCT01084317|||COHORT||RETROSPECTIVE|||||||
34056201|NCT05562765|||OTHER||CROSS_SECTIONAL|||||||
34160115|NCT05575193|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients receiving the intervention of acupressure are in the experimental group, while those who do not receive it are in the control group. The experimental group will receive the acupressure at the hemodialysis center for a total of 12 weeks, three times a week. The patients will receive 4 acupuncture points, including Quchi acupoint, Xuehai acupoint, Sanyinjiao acupoint, and Zusanli acupoint. Each acupoint will be pressed for 3 minutes, and totally 4 acupuncture points are 12 minutes. The effectiveness will be evaluated at the fourth week, eighth week and twelfth week. The effectiveness assessment in the study will use the Visual Analog Scale (VAS), 5D Pruritus Scale, and Pittsburgh Sleep Quality Scale."||||
34160116|NCT02275741|||COHORT||PROSPECTIVE|||||||
34160117|NCT02462720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160118|NCT01331109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160119|NCT04267406|||CASE_CONTROL||PROSPECTIVE|||||||
34160120|NCT03101501|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34160121|NCT02745808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160122|NCT05789563|RANDOMIZED|CROSSOVER||OTHER||NONE||All participants go through all study arms, in random order. Two measuring devices are active simultaneously during each measurement on each participant and their functioning is compared.||||
34160123|NCT04625374|||COHORT||RETROSPECTIVE|||||||
34160124|NCT05383716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160125|NCT03062293|NA|SINGLE_GROUP||TREATMENT||NONE|Ultrasound image time points are blinded to the assessor by a party not involved in the study|Repeat measures within subject design||||
34160126|NCT04203004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160127|NCT00325117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160128|NCT02358421|||CASE_ONLY||PROSPECTIVE|||||||
34160129|NCT05695274|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34160130|NCT00582998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160131|NCT02278861|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160132|NCT05062408|||CASE_ONLY||PROSPECTIVE|||||||
34160133|NCT02903498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160134|NCT01907763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160135|NCT00939562|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34160136|NCT00004052||||TREATMENT||||||||
34160137|NCT02134470|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34160138|NCT03492606|||COHORT||RETROSPECTIVE|||||||
34160139|NCT02255084|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34160140|NCT02813291|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34160141|NCT03291405|||OTHER||PROSPECTIVE|||||||
34160142|NCT00513942|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33743345|NCT04336202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743346|NCT00005853||||TREATMENT||||||||
33743347|NCT05842057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be blinded to the treatment they receive. To minimize bias on the surgical team during the nerve sparing process, the surgical team will be blinded to arm allocation until after the prostate is removed.||t|t|f|f
33743348|NCT05780645|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33743349|NCT02040597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743350|NCT06536283|||CASE_ONLY||PROSPECTIVE|||||||
33743351|NCT00451581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33743352|NCT03691038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743353|NCT02973958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33951675|NCT05952570|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This research is a randomized multi-center clinical trial in which 100 hemodialysis patients will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1.~* Group A: 50 patients will receive oral protein nutritional supplement (Fresubin protein powder 25mg/5scoops per hemodialysis session) 1 hour before the start of the session (predialytic) for 3 months.~* Group B: 50 patients will receive a routine nutrition regimen for 3 months. (control group)"||||
33951676|NCT06539793|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33846558|NCT02643303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In Phase 1, Cohort 1A was opened first and after the safety of durvalumab and poly-ICLC was demonstrated, Cohorts 1B and 1C were open in parallel. In Phase 2, all tumor types were opened in parallel, and subjects included in Cohort 1C were included and reported in their respective tumor type in Phase 2.||||
33846559|NCT06131489|||OTHER||PROSPECTIVE|||||||
33846560|NCT03437681|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The project is a within-subject consecutive design examining 18 healthy individuals after baseline and after 4 nights of insufficient sleep.||||
33951677|NCT01852669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951678|NCT00439127|||DEFINED_POPULATION||OTHER|||||||
34160143|NCT01698723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160144|NCT02630914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951679|NCT01935492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951680|NCT02106676|||CASE_CONTROL||PROSPECTIVE|||||||
34160145|NCT05505006|NA|SINGLE_GROUP||TREATMENT||NONE||"* Institution of an Anemia Clinic to identify all cancer patients with anemia before surgery~* Treatment of treatable causes of anemia in all cancer patients within three weeks before surgery; in particular, iron deficiency (ID), folate deficiency and B12 deficiency~* Collection of data concerning transfusions in the peri-operative period~* Collection of peri-operative outcomes such as in-hospital mortality, myocardial infarction, ischemic stroke, acute renal failure, pneumonia, or sepsis, and Hb levels at discharge~* Comparison of data relating to transfusions and outcomes with those obtained in a historical cohort of anemic patients eligible for oncological surgery for malignant tumors, matched by age, sex, and pathology enrolled in the three years 2017-2019~* Evaluation of hepcidin levels in anemic cancer patients (explorative aim)"||||
33951681|NCT02786121|||COHORT||PROSPECTIVE|||||||
33951682|NCT05247606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33743354|NCT03752164|NA|SINGLE_GROUP||OTHER||NONE||||||
33743355|NCT02736084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743356|NCT04853004|||COHORT||PROSPECTIVE|||||||
33743357|NCT06191705|||OTHER||CROSS_SECTIONAL|||||||
33743358|NCT03593668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743359|NCT06434701|NA|SINGLE_GROUP||SCREENING||NONE||||||
33951683|NCT02854865|||CASE_ONLY||PROSPECTIVE|||||||
33951684|NCT00498004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951685|NCT03361566|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34160146|NCT03288636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743360|NCT04101799|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Controlled trial||||
33743361|NCT03812458|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel multicentric randomized clinical trial||||
33743362|NCT01181921|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743363|NCT01196975|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33743364|NCT04558957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743365|NCT01191489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743366|NCT04336215|||COHORT||PROSPECTIVE|||||||
33743367|NCT00437489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743368|NCT00003457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743369|NCT05387291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subjects do not know which group they are in, as some are given the usual intervention (control group) and others the intervention (intervention group).|Subjects will be randomly assigned to one group (intervention) or the other (control).|t|f|f|f
33743370|NCT02328664|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743371|NCT04251468|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951686|NCT05463978|||OTHER||RETROSPECTIVE|||||||
33951687|NCT03359499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951688|NCT03066011|||COHORT||PROSPECTIVE|||||||
33951689|NCT06084039|||COHORT||RETROSPECTIVE|||||||
33951690|NCT06116799|RANDOMIZED|PARALLEL||TREATMENT||NONE||19 patients with plantar fasciitis will be allocated to carbon fiber insole group 19 patients with plantar fasciitis will be allocated to polyurethane insole group 19 patients with plantar fasciitis will be allocated to polyethylene insole group||||
33951691|NCT03182972|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Both the patients and the pharmacists recruited for the study will not be informed whether they are in the control or intervention group|University College Hospital, Ibadan will serve as the intervention group while University of Ilorin Teaching Hospital, Ilorin will serve as the control group.|t|t|f|f
33951692|NCT01904201|||COHORT||CROSS_SECTIONAL|||||||
33951693|NCT05577975|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33951694|NCT03317925|||COHORT||PROSPECTIVE|||||||
33951695|NCT01685320|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33951696|NCT01976104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951697|NCT05201898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951698|NCT04785846|||CASE_ONLY||PROSPECTIVE|||||||
33951699|NCT03155269|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33951700|NCT03405545|NA|SINGLE_GROUP||PREVENTION||NONE||1 group of participants that performs 12 weeks of HIIT with metabolic measurements before and after this training period||||
33951701|NCT00833391|RANDOMIZED|CROSSOVER||||NONE||||||
33951702|NCT02401724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743372|NCT03335358|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Waitlist control design; participants are assigned to receive intervention or be waitlisted for 4-6 weeks and then receive intervention.|f|f|f|t
33743373|NCT01296568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743374|NCT04177511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743375|NCT03895060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743376|NCT03091751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743377|NCT00916877|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160147|NCT00001146||||TREATMENT||||||||
34160148|NCT05796492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160149|NCT02602158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160150|NCT04347629|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34160151|NCT03419988|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial: exercise intervention versus non-exercise control||||
34160152|NCT01966913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160153|NCT00317304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160154|NCT03081871|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33743378|NCT02796326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743379|NCT06636500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-Controlled|t|t|t|t
33743380|NCT05581446|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34160155|NCT03456232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160156|NCT03865641|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||viartual reality based rehabilitation||||
33743381|NCT00097812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33743382|NCT00775918|RANDOMIZED|CROSSOVER||||NONE||||||
33743383|NCT05575947|||OTHER||RETROSPECTIVE|||||||
33743384|NCT05794854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Assessor of dual x-ray absorptiometry results was blinded to group allocation||f|f|f|t
33743385|NCT05412862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and treating study staff will be aware of the participant's treatment condition. However, follow-up assessments will be performed by a study staff member that is masked to the participant's treatment condition.|Randomized, single-blinded, controlled trial|f|f|f|t
33743386|NCT04444154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The plaque index readings, i.e. the taking of 3 macrophotographic shots (with reflex camera, allowing the MOP plaque index to be assessed in a second step), and the clinical index of gingival inflammation will be performed at each appointment (except during the dedicated session of group 3) by an examiner who will be blind from the group belonging to each patient|prospective, monocentric, controlled, randomized study|f|f|f|t
33743387|NCT03102099|||CASE_CONTROL||PROSPECTIVE|||||||
33743388|NCT02751281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743389|NCT05528081|||CASE_CONTROL||PROSPECTIVE|||||||
33743390|NCT00559559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743391|NCT03357601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant will be match-paired to either HIIT or MCEET group based on their time to complete a mile run. There will be rank from 1 to 40, where number one will be assigned randomly to one group while two goes to the other group. Then, number three goes to the second group and fourth is assigned to the first group. Alternating patterns will be continued thereafter.||||
33743392|NCT01100164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743393|NCT01165281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743394|NCT05711069|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743395|NCT04098692|NA|SINGLE_GROUP||OTHER||NONE||||||
33743396|NCT03952247|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33743397|NCT05950802|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be enrolled in two stages: the dose escalation stage to assess the safety and tolerability of a modified LD regimen, and once the MTD is determined, a cohort expansion phase to further characterize the toxicity and efficacy profile and determine the RP2D. The study will enroll approximately 18-24 patients in the dose escalation stage (Part 1), and approximately 20 further patients at cohort expansion (Part 2)||||
33743398|NCT04425083|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33743399|NCT02280603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743400|NCT02793700|||OTHER||PROSPECTIVE|||||||
33743401|NCT04092426|||CASE_ONLY||PROSPECTIVE|||||||
33743402|NCT01817205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743403|NCT05006365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743404|NCT01952912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765181|NCT00247364|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33765182|NCT02405364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765183|NCT06040996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765184|NCT01327118|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33765185|NCT06625788|||COHORT||PROSPECTIVE|||||||
34160157|NCT00656864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34160158|NCT00101985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160159|NCT04500886|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160160|NCT04332718|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multicentre, two-arm, unblinded, randomised controlled trial||||
34160161|NCT01303601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34160162|NCT02272374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160163|NCT00142311|||CASE_CONTROL||PROSPECTIVE|||||||
34160164|NCT01838915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846561|NCT04540887|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center clinical series evaluating symptom relief following a 4-week trial of PEMF therapy. From our registry of IC/BPS patients at Wake Forest Baptist Health Urology we will recruit women, ages 18-80, who have met all inclusion and exclusion criteria. Upon enrollment, each participant will be taught how to administer home treatment with the Bio Electro Magnetic Energy Regulation (BEMER) PEMF devices which consist of a total body mat (B.Body) plus a targeted pelvic mat (B.Pad) and control unit. Following the brief in-clinic training, participants will be sent home with the PEMF devices (preset to deliver the same level of energy every time) and self-administer therapy sessions, twice daily (once in the morning, once in the evening) for 8 minutes at a time. Participants will complete questionnaires as well as keep a 3-day voiding diary to record any changes in IC/BPS symptoms/pain at enrollment, 4 weeks after using PEMF therapy, and 12 weeks post-enrollment.||||
33846562|NCT02323178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846563|NCT04164121|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind||t|t|t|t
33846564|NCT03026127|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33846565|NCT02894567|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846566|NCT03014011|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33846567|NCT03654521|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34160165|NCT04003740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160166|NCT06271889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Which of the participants is the control or intervention group will be selected by randomization.|Randomized parallel controlled experimental design|t|f|f|f
34160167|NCT01910415|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33846568|NCT02902939|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846569|NCT01877239|||OTHER||PROSPECTIVE|||||||
33846570|NCT04201340|||COHORT||PROSPECTIVE|||||||
33846571|NCT02240459|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34160168|NCT03840954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34160169|NCT01822262|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160170|NCT01916434|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160171|NCT05077332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the participant is blinded in LDOS-21-001-01 (Addendum #1; inpatient study); All are blinded in LDOS-21-001-02 (Addendum #2; outpatient study).|Subjects randomized 1:1, study drug:placebo|t|t|t|f
34160172|NCT00586053|||COHORT||PROSPECTIVE|||||||
33846572|NCT01891201|||COHORT||PROSPECTIVE|||||||
33846573|NCT00477659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846574|NCT06478342|||COHORT||PROSPECTIVE|||||||
34160173|NCT02675010|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160174|NCT01764555|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160175|NCT02816489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34160176|NCT02746640|||CASE_ONLY||PROSPECTIVE|||||||
33846575|NCT03024905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33846576|NCT00386282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846577|NCT02245633|||COHORT||CROSS_SECTIONAL|||||||
33846578|NCT03148444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The random assignment will be performed by a researcher from the cardiologic team performing the implantation by means of choosing one of two closed envelopes. The treatment will not be placebo-controlled, and therefore the neither the patients nor the attending physicians will not be blinded to the final results of the assignment.|We propose to organize a randomized open-label study in which patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) will be randomly assigned to one of the two groups. Patients in one group will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxythromycin 150 mg bid) while in the other group no recommendations regarding antibiotic treatment will be given. Both groups will receive antibiotic prophylaxis before the procedure according to the current recommendations. In both groups, the aseptic technique during the procedure will be observed, and proper hygienic measures past the implantation will be taken.|f|f|t|t
33846579|NCT03353129|||COHORT||PROSPECTIVE|||||||
33846580|NCT03051789|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators cannot mask participants to their treatment (intervention) status due to the nature of interventions provided. However, counsellors conducting the HIV and HSV-2 testing and laboratory technicians will be blinded to the study arm. Investigators and trial statisticians will be masked. Field staff who conduct home visits to confirm dropout will also be masked when feasible. Bias will also be minimised by use of block randomisation stratified by school size and WASH facilities at baseline. An independent person will prepare the sealed envelopes with the study allocation. Study arm allocation will not be recorded in the central database to ensure the trial statistician and data managers remain blinded throughout the study. This information will be recorded separately and only be merged with the main database following approval of the statistical analytics plan (SAP), closure of the databases and submission of a copy to the independent statistician of the DMEC.||f|f|t|t
33846581|NCT05807529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846582|NCT04069481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups of participants. One group receives the dance intervention. The control group will receive mindful meditation, strengthening \& stretching exercises.|f|f|f|t
33846583|NCT04554043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846584|NCT03497416|||CASE_CONTROL||PROSPECTIVE|||||||
33846585|NCT06323551|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled||||
33846586|NCT01767571|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33846587|NCT05599841|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33846588|NCT01428232|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846589|NCT02505386|NON_RANDOMIZED|PARALLEL||||NONE||||||
33846590|NCT05022901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846591|NCT01597609|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33846592|NCT02214056|||COHORT||PROSPECTIVE|||||||
34160177|NCT05181956|||CASE_ONLY||OTHER|||||||
34160178|NCT00614146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160179|NCT02444325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160180|NCT05747183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743405|NCT05783180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two teams will be involved in the trial unblinded team that will randomized the subjects and dispense the investigational product and the blinded team that will be involved in the clinical evaluations and data collection.|"Treatment Group: Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD) + SOC (N=20).~Control group: Placebo +SOC (N=20) Intervention groups At baseline, subjects will be randomized in a 1:1 ratio to either treatment or control groups."|t|f|t|t
33951703|NCT03572348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized using software in a 1:1 ratio in either the vessel-sparing group or the transecting group. Randomisation will be stratified per participating center and single blinded; double blindation is impossible as the surgeon has to know which technique to perform.|Prospective, interventional, multicentric, single-blinded, randomized, controlled, non-inferiority, phase II trial|t|f|f|f
33951704|NCT02874820|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951705|NCT06538376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The outcomes assessors (radiologists) will evaluate deidentified DDR scans and deidentified traditional x-rays for all study patients in a blinded fashion, and will not be able to compare readings of or diagnoses from each scan for individual patients until after the analysis is complete.|All participants enrolled in the study will receive the same intervention- there are not separate control and intervention groups. The intervention is a new portably dynamic digital radiography (DDR) scan and will be compared to the patients clinically indicated gold standard diagnostic test (i.e. portable chest x-ray, VQ scan, CT, CT-angio, etc.).||||
33951706|NCT02382107|||CASE_ONLY||CROSS_SECTIONAL|||||||
33951707|NCT02265991|||COHORT||PROSPECTIVE|||||||
33951708|NCT04739202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951709|NCT02020356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33951710|NCT05865002|NA|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation 3+3 Design"||||
33951711|NCT00689494|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33951712|NCT05328999|||COHORT||PROSPECTIVE|||||||
33951713|NCT00692601|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33951714|NCT01065077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951715|NCT02029729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951716|NCT03733301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951717|NCT04895904|||COHORT||RETROSPECTIVE|||||||
34160181|NCT05795192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Block randomized, double-blind design controlling with IWRS||t|f|t|f
33951718|NCT05749549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951719|NCT02431507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951720|NCT04520633|||COHORT||PROSPECTIVE|||||||
33951721|NCT00540475|||CASE_CONTROL||PROSPECTIVE|||||||
33951722|NCT05354401|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34160182|NCT05848427|||COHORT||PROSPECTIVE|||||||
34160183|NCT02060136|||CASE_CROSSOVER||PROSPECTIVE|||||||
34160184|NCT05728268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160185|NCT01865448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160186|NCT02898896|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34160187|NCT02363959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160188|NCT00839644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743406|NCT02612012|||COHORT||PROSPECTIVE|||||||
33743407|NCT03942718|RANDOMIZED|PARALLEL||TREATMENT||NONE||The three study arms (TAU, aerobic exercise, anerobic exercise) will be included in parallel. After 12 weeks, the patients in the control group will be invited to participate in the training group.||||
33951723|NCT02288949|||COHORT||PROSPECTIVE|||||||
33951724|NCT02515175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951725|NCT03692767||SEQUENTIAL||TREATMENT||NONE||||||
33951726|NCT06132711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951727|NCT06641245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind randomized non-inferiority trial|t|t|t|t
33951728|NCT06519162|||CASE_CONTROL||PROSPECTIVE|||||||
34076176|NCT03077893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sham devices will look identical to active devices. This is a double-blind study.|"Subjects deemed responders after active treatment will be randomized in a 1:1 ratio to either active treatment or a sham device."|t|t|t|t
34076177|NCT02377856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076178|NCT02864732|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076179|NCT00594893|RANDOMIZED|PARALLEL||||NONE||||||
34076180|NCT05362370|||COHORT||PROSPECTIVE|||||||
33765186|NCT01396395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765187|NCT00739817|||||PROSPECTIVE|||||||
33765188|NCT00007280|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33765189|NCT02408237|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||TRIPLE|||t|f|t|t
33765190|NCT00596596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076181|NCT01167400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076182|NCT04153474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076183|NCT01953042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076184|NCT04215562|NA|SINGLE_GROUP||OTHER||NONE||||||
34076185|NCT01851655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34160189|NCT06371846|||COHORT||PROSPECTIVE|||||||
34160190|NCT00630344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160191|NCT01122693|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34160192|NCT03221842|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Randomized-withdrawal|t|t|t|t
34160193|NCT05962892|||COHORT||CROSS_SECTIONAL|||||||
34160194|NCT05615207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject group allocation will be concealed from individuals involved in pre \& post test outcome measurements.|Randomized Controlled Trial - participants will be randomized into the Standard of Care (physical practice) or the Motor Imagery group. Blocked randomization will be implemented to ensure even comparison between groups . Then each person will receive one on one training based on the item(s) on the BBS with which they had difficulty.|f|f|t|t
34160195|NCT02219373|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34160196|NCT00793312|||COHORT||PROSPECTIVE|||||||
33743408|NCT06634043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization sequence will be carried out using a computer-generated list (StataⓇ v15.1) with a 1:1 allocation ratio according to a block randomization procedure. Allocation concealment will be kept by means of opaque-sealed envelopes that will be opened immediately after the anesthesia.|The present study protocol is a two-arm, randomized controlled clinical trial with a follow-up period of 6 months. The protocol of this study has been prepared according to the SPIRIT 2013 Statement. The study will be conducted at the Universidad Alfonso X el Sabio (UAX). Subjects will be recruited consecutively from the Department of Periodontology of Clinica Universitaria de Odontologia (CUO-UAX). The study will be coordinated by the principal investigator. Patients attending the Department of Periodontology (CUO-UAX) will be consecutively screened for eligibility and included in the study by one team member responsible in recruitment .|t|f|t|t
33743409|NCT05255016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Simple block randomization will be used to assign subjects in a 1:1 ratio to 2 treatment arms. Subjects will be randomized consecutively (not stratified by site) to ensure balance between the treatment arms at any point in the study|t|f|f|f
33743410|NCT00034034|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33743411|NCT02519504|||CASE_CONTROL||PROSPECTIVE|||||||
33743412|NCT00680407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743413|NCT06635239|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743414|NCT05951322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome asseser is blinded.|Participants were identified and recruited over 5-month period. Thirty-six patients diagnosed clinically with shoulder impingement syndrome (according to location of trigger points at rotator cuff muscles and aggravation of pain with overhead activities) were randomly assigned in two groups.|f|f|f|t
33743415|NCT04262999|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33743416|NCT00004010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743417|NCT03846843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33743418|NCT01459276|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33743419|NCT01269892|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33743420|NCT04798781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743421|NCT01410838|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33743422|NCT05515055|||COHORT||PROSPECTIVE|||||||
33743423|NCT04265079|NA|SINGLE_GROUP||OTHER||NONE|Study focusses on within participant comparison and cannot be blinded.|||||
33743424|NCT02525107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743425|NCT01184014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743426|NCT03736200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743427|NCT01271335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743428|NCT06417281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743429|NCT05378945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743430|NCT04066218|||COHORT||CROSS_SECTIONAL|||||||
33743431|NCT04772716|||COHORT||PROSPECTIVE|||||||
33743432|NCT02817789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951729|NCT06450509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Individuals who analyze the audio recordings and score the questionnaires will not know the group assignments of the families.|Participating infants and their parents will be randomized into two different treatment modalities, either weekly individualized intervention sessions or monthly group sessions. Both groups will receive the intervention for a duration of 10 months. Note that in each family, the infant and both caregivers, where available, will be enrolled. In each treatment arm, there will be 10 infants and up to 20 caregivers, for a total of 20 infants and up to 40 caregivers.|f|f|f|t
33951730|NCT02984904|||||CROSS_SECTIONAL|||||||
33951731|NCT05329012|||CASE_ONLY||PROSPECTIVE|||||||
33951732|NCT06459427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951733|NCT05066776|||COHORT||PROSPECTIVE|||||||
33951734|NCT02249065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951735|NCT06474780|||OTHER||PROSPECTIVE|||||||
33951736|NCT02005302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951737|NCT02384980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951738|NCT04939337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951739|NCT04908696|||OTHER||PROSPECTIVE|||||||
33951740|NCT02900508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951741|NCT01103908|||||PROSPECTIVE|||||||
33951742|NCT02616458|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33951743|NCT00957840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951744|NCT04865536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33951745|NCT05732103|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33951746|NCT00735748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743433|NCT01181934|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33743434|NCT02613481|NA|SINGLE_GROUP||OTHER||NONE||||||
33743435|NCT00333034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33743436|NCT00815841|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33743437|NCT04046874|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33743438|NCT04864808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743439|NCT03586635|||OTHER||PROSPECTIVE|||||||
33743440|NCT04844281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951747|NCT04714710|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|placebo (sodium chloride solution 0.9%) similar to potassium canrenoate diluted in sodium chloride solution 0.9%|Single center, double blinded randomized controlled clinical trial|t|t|t|f
33743441|NCT02958644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056202|NCT04754438|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomized trial intervention will provide e-CBT for GAD through the Online Psychotherapy Tool (OPTT), a secure, cloud-based, digital mental health platform. Participants will be randomly assigned to either an e-CBT program tailored to GAD or a mental health coaching program over 12 weeks to address their anxiety symptoms. In the e-CBT group, participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform. There will be 12 weekly sessions that include approximately 30 slides each along with interactive content, delivered through OPTT. In the mental health coaching group, participants will have weekly interaction with a therapist through the chat function in OPTT where the coach will check in on the participant and touch on a specific subject each week.||||
34056203|NCT06216535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization list will be maintained in a password-protected folder by an unblinded staff member with no participant contact and by the investigational pharmacy.|This study is a two-arm, 24-week, randomized, single-center, double-blind, parallel group trial designed to evaluate the efficacy of treatment with escitalopram vs. placebo to reduce asthma exacerbations in n = 105 participants, ages 18-65 years, with moderate-to-severe asthma.|t|t|t|t
34056204|NCT02638571|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056205|NCT00272207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056206|NCT00251082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743442|NCT01834820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33743443|NCT00178490|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33846593|NCT00288184|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33846594|NCT03078543|NA|SINGLE_GROUP||TREATMENT||NONE||Subject is a candidate for primary total knee arthroplasty due to degenerative joint disease||||
33846595|NCT03599609|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846596|NCT03723252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846597|NCT06611254|||COHORT||PROSPECTIVE|||||||
33846598|NCT02297659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33846599|NCT02548598|||COHORT||CROSS_SECTIONAL|||||||
33951748|NCT00696826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951749|NCT00104858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951750|NCT01646268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951751|NCT00734188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951752|NCT05429749|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951753|NCT05360017|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter, randomized, controlled, excellent effect, open trial design||||
34056207|NCT03886961|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056208|NCT00002104||PARALLEL||TREATMENT||||||||
34056209|NCT01046279|||||PROSPECTIVE|||||||
34056210|NCT06016569|NA|SINGLE_GROUP||SCREENING||NONE||||||
34056211|NCT04393220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056212|NCT00208598|||DEFINED_POPULATION||OTHER|||||||
34056213|NCT00546676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056214|NCT02852200|||COHORT||OTHER|||||||
34056215|NCT01395550|||||RETROSPECTIVE|||||||
34056216|NCT04115917|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The first eye to undergo scleral depression was randomly assigned, then that eye was randomized two either of the scleral depression methods. The contralateral eye then had the alternative method of scleral depression performed.||||
34056217|NCT05798013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056218|NCT00368693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056219|NCT00844766|||COHORT||PROSPECTIVE|||||||
34056220|NCT02405169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056221|NCT01940315|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056222|NCT03603951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056223|NCT05026580|||COHORT||RETROSPECTIVE|||||||
33743444|NCT05392634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743445|NCT01439139|||CASE_ONLY||CROSS_SECTIONAL|||||||
33743446|NCT02893722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33743447|NCT03867734|NA|SINGLE_GROUP||TREATMENT||NONE||Demonstration Study||||
33743448|NCT05377398|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study is a multilayered intervention study with RCT study design. The selection of participants will be based on purposive sampling. The participants will fill in the baseline questionnaire that screens the current state of mental health, mental wellbeing and healthy lifestyle and substance use among the participants.~Participants are then randomly allocated 1:1 to intervention (N=250) and control groups (N=250). The participants in the intervention group are offered 1) Digital individual-level intervention and 2) Individual-level or group-based intervention. In addition, all participants in the intervention group with elevated risk for substance use will also be targeted with 3) A mini-intervention for substance use."||||
33743449|NCT02199847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33743450|NCT04845958|||COHORT||CROSS_SECTIONAL|||||||
33743451|NCT02525133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765191|NCT06625216|||COHORT||PROSPECTIVE|||||||
33846600|NCT02668549|||COHORT||RETROSPECTIVE|||||||
33846601|NCT03482466|NA|SINGLE_GROUP||TREATMENT||NONE||"12 PTSD patients will be exposed to the real time functional MRI neurofeedback training. The investigators will assess PTSD symptoms both clinically and with a take home wearable device that will collect data on physical activity, heart rate, and sleep patterns."||||
33951754|NCT04325191|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participant will not know if they are receiving the melatonin or placebo pills.|This is a randomized crossover design trial.|t|f|f|f
34056224|NCT06501820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Sham transcranial magnetic stimulation is extremely effective. It involves current ramp up and down, resulting in potential tingling of the scalp similar to active stimulation. The investigator will also be blinded; they will enter a code into the stimulation box that results in either active or sham stimulation.|Two group, repeated measures, double blind active or sham stimulation|t|f|t|f
34056225|NCT05659862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951755|NCT03962751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951756|NCT03512106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Acupuncture sham will be applied (placebo).|Chinese traditional acupuncture will be applied.|f|f|f|t
33951757|NCT06261827|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33951758|NCT03093558|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34056226|NCT05168332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (participant)|Experimental group Control group|t|f|f|f
33743452|NCT03793192|RANDOMIZED|PARALLEL||OTHER||SINGLE|Allocation sequence will be concealed|Intervention versus Enhanced Usual Care|f|f|f|t
33743453|NCT03413787|||CASE_ONLY||PROSPECTIVE|||||||
33743454|NCT01527201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743455|NCT02369029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743456|NCT05665218|||CASE_ONLY||PROSPECTIVE|||||||
33743457|NCT06336135|||COHORT||PROSPECTIVE|||||||
33743458|NCT03219983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743459|NCT04434040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743460|NCT02021279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743461|NCT02997566|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33743462|NCT04943289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743463|NCT00663312|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33743464|NCT00709384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743465|NCT05763134|||COHORT||PROSPECTIVE|||||||
33743466|NCT03746860|||COHORT||PROSPECTIVE|||||||
33743467|NCT04989764|||CASE_ONLY||RETROSPECTIVE|||||||
33951759|NCT06142448|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33743468|NCT05890183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An assessor of functional outcome will be blind to treatment condition.|Randomization to Combined Cognitive Training and Exercise (CT\&E) vs. Cognitive Training and Healthy Living Group (CT\&HLG)|f|f|f|t
33743469|NCT06532955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743470|NCT00506961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33951760|NCT00804362|||COHORT||PROSPECTIVE|||||||
33951761|NCT03403010|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Children are randomized into the intervention group (conventional, usual therapy including the use of rehabilitation-specific gaming) or the control group (PT, usual physiotherapy not including gaming), followed by a cross-over. After the intervention period of 3 months, wash-out period will be organized to evaluate follow-up effects.||||
33743471|NCT01617629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846602|NCT04420949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to mask this behavioral intervention. The study team small; thus, masking of the study team is also not possible.|The study will be conducted in three phases. The first phase is for baseline testing. The second phase is when treatment occurs. The third phase is for follow up testing. Participants will be tested twice during the baseline and follow up phases. Six treatment sessions will occur during the treatment phase.||||
33951762|NCT03866811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will be blinded to study enrollment arm.|A randomized controlled trial with two arms|f|f|f|t
33846603|NCT03007043|||COHORT||PROSPECTIVE|||||||
33846604|NCT01151852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951763|NCT05132543|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33951764|NCT03235063|||COHORT||PROSPECTIVE|||||||
33951765|NCT05033795|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33951766|NCT04882085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951767|NCT01002417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951768|NCT04121468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multiple baseline|t|t|t|t
33846605|NCT03909529|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Spironolactone Oral Suspension|An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover, drug-drug interaction study in healthy adult human subjects under fasting condition for spironolactone oral suspension (Carospir®)||||
33846606|NCT05770518|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomized controlled trial with active treatment control group||||
33846607|NCT03017898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846608|NCT05552300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846609|NCT00658788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846610|NCT03093103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Placebo and Empagliflozin pills|Randomised placebo-controlled double blind trial|t|t|t|f
33846611|NCT04252443|NA|SINGLE_GROUP||OTHER||NONE||The research population consisted of 190 nurses working in a university hospital. Because all of the nurses in the research population could not be reached, a sample was selected using a simple random sampling method. One hundred twenty-seven nurses were interviewed in the research population, with a 95% confidence interval and a 5% sampling error.||||
33846612|NCT00436852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846613|NCT05892510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846614|NCT03992131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846615|NCT04636736|||COHORT||CROSS_SECTIONAL|||||||
33846616|NCT06209853|||OTHER||CROSS_SECTIONAL|||||||
33846617|NCT04959539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951769|NCT02329951|||COHORT||PROSPECTIVE|||||||
34056227|NCT01845168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056228|NCT00003913||||TREATMENT||NONE||||||
34056229|NCT05143268|||COHORT||PROSPECTIVE|||||||
34056230|NCT01607229|||||CROSS_SECTIONAL|||||||
34056231|NCT06621381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056232|NCT01468428|||CASE_CONTROL||PROSPECTIVE|||||||
34056233|NCT05565040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846618|NCT00282672|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33846619|NCT01689571|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33951770|NCT03503565|||COHORT||PROSPECTIVE|||||||
33951771|NCT03436940|RANDOMIZED|CROSSOVER||OTHER||NONE||cluster randomized cross-over trial||||
34056234|NCT04641260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34056235|NCT01362244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056236|NCT00000238||||TREATMENT||||||||
34056237|NCT01844180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056238|NCT06114875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34056239|NCT01389570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056240|NCT00336024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056241|NCT03761758|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
34056242|NCT00006013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056243|NCT05132712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056244|NCT05393115|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33846620|NCT05460403|||COHORT||RETROSPECTIVE|||||||
33951772|NCT05353920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33951773|NCT05646342|||COHORT||PROSPECTIVE|||||||
33951774|NCT03323021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951775|NCT05173025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951776|NCT02413749|||CASE_CONTROL||PROSPECTIVE|||||||
33951777|NCT04766346|NA|SINGLE_GROUP||OTHER||NONE||||||
33951778|NCT05144724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951779|NCT00978640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33951780|NCT01283009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951781|NCT04979325|||COHORT||CROSS_SECTIONAL|||||||
33951782|NCT05069376|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were not informed the allocation until the stent was removed.|Arm 1: Intra-ureteral placement of double-J stent Arm 2: Conventional placement of double-J stent|t|f|f|f
33951783|NCT02223637|||COHORT||PROSPECTIVE|||||||
33951784|NCT06096909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056245|NCT04475926|||COHORT||PROSPECTIVE|||||||
34056246|NCT06006494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Aerobic exercises, resistant exercises and yoga|f|f|f|t
34056247|NCT02464761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056248|NCT05081700|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056249|NCT06649058|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056250|NCT06630078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056251|NCT04760288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056252|NCT05918991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals completing classroom behavioral observations are masked to participant intervention assignment.||f|f|f|t
34056253|NCT04852276|||COHORT||PROSPECTIVE|||||||
34056254|NCT03150992|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34056255|NCT00527384|||||PROSPECTIVE|||||||
34056256|NCT00515359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056257|NCT03813186|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34056258|NCT06145581|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34056259|NCT06624098|NA|SINGLE_GROUP||TREATMENT||NONE|TIPS was performed within 72 hours after variceal bleeding.|Early transjugular intrahepatic portosystemic shunt (TIPS) within 72 hours after acute variceal bleeding.||||
34056260|NCT00538044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34056261|NCT02632240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34056262|NCT04878432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056263|NCT02085616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056264|NCT06648083|||COHORT||RETROSPECTIVE|||||||
34056265|NCT00478010||||HEALTH_SERVICES_RESEARCH||NONE||||||
34056266|NCT04919824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056267|NCT06643767|NA|SINGLE_GROUP||SCREENING||NONE|Open label study; no masking|At least 444 women presenting for screening mammograms will undergo the Bexa Breast Exam (BBE). Each woman will receive digital breast tomosynthesis and a BBE on the same day. All women with a positive finding on either digital breast tomosynthesis (mamo-positive), BBE (bexa-positive), or both modalities will undergo a diagnostic ultrasound examination and/or diagnostic mammography of all positive findings.||||
34056268|NCT06624280|||COHORT||RETROSPECTIVE|||||||
34056269|NCT03475199|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective, multicentric, controlled, national study||||
34056270|NCT06642389|||CASE_ONLY||PROSPECTIVE|||||||
34056271|NCT01330277|||COHORT||PROSPECTIVE|||||||
34056272|NCT01748617|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34056273|NCT03722745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34056274|NCT04987099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only a Laboratory Manager, who will label the supplements with participant ID, will have access to participants' study assignments.||t|t|t|t
34056275|NCT06620419|NA|SINGLE_GROUP||TREATMENT||NONE||Perineal-applied electrical stimulation shaped for males.||||
34056276|NCT06078449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056277|NCT04638894|||OTHER||PROSPECTIVE|||||||
34056278|NCT05115422|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study of the virtual 'Coping with Brain Fog' intervention for AYAs with cancer living in Manitoba.||||
34056279|NCT02688998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34160197|NCT04248543|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34160198|NCT01351116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160199|NCT05204030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This 4-year study will evaluate the efficacy of a Twitter-based pilot intervention through a randomized controlled trial that will enroll a total of 600 parents/caregivers of children ages 9-14, whose child(ren) has not started the vaccine series. The intervention will consist of 2 arms and 12 monthly cohorts. After enrollment in the project, 300 participants will be randomized into the intervention arm and 300 participants will be enrolled into the control arm. Participants will be presented the intervention one month before their child's next wellcare visit.|t|f|f|f
34160200|NCT02235636|||CASE_CROSSOVER||PROSPECTIVE|||||||
34160201|NCT05280353|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||MULTICENTRIC, PROSPECTIVE, RANDOMIZED CLINICAL TRIAL||||
34160202|NCT03260296|||OTHER||CROSS_SECTIONAL|||||||
34056280|NCT05839652|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34056281|NCT04775342|||OTHER||CROSS_SECTIONAL|||||||
34056282|NCT05160207|||COHORT||PROSPECTIVE|||||||
34160203|NCT00548145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160204|NCT04057430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160205|NCT00506688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056283|NCT04381507|||COHORT||PROSPECTIVE|||||||
34160206|NCT03747679|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|single blind|This will be a single-blind, randomized, multiple-period (dosing over 4 days) study in healthy male and/or female participants. Approximately 8 participants will assess the sensory attributes of each of the formulation options using Bosutinib Taste Assessment Questionnaire|t|f|f|f
34160207|NCT04231604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160208|NCT04800237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160209|NCT00386243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160210|NCT00851279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160211|NCT06363539|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control trial||||
34160212|NCT05747703|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants will be randomly assigned in a 1:1 to the Ria Treatment Platform or a waitlist control condition||||
34160213|NCT03063281|||CASE_CONTROL||RETROSPECTIVE|||||||
34160214|NCT03647644|||CASE_CONTROL||PROSPECTIVE|||||||
34160215|NCT04811495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160216|NCT06327828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160217|NCT00714805|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34160218|NCT05326867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers, and investigators are blinded|This study was a double blind randomized controlled trial. Data collection was carried out consecutively on 84 subjects with 42 subjects in each group of lidocaine infiltration without needles and lidocaine infiltration with 23G needles|t|t|t|f
34160219|NCT04367246|||COHORT||PROSPECTIVE|||||||
34160220|NCT01347242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160221|NCT02117180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160222|NCT02558777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34160223|NCT05303818|NA|SINGLE_GROUP||PREVENTION||NONE|Patients information will be masked.|68 patients will be selected for the study. All patients must complete an informed consent form regarding the objectives and risks involved in this research||||
34160224|NCT03095729|||COHORT||CROSS_SECTIONAL|||||||
34160225|NCT02697318|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34160226|NCT03191227|||COHORT||CROSS_SECTIONAL|||||||
34160227|NCT03779048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Phase 1 is observational. Phase 2 is a double-blind, placebo-controlled, randomized controlled trial.|t|t|t|t
34160228|NCT02799498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160229|NCT01258023|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160230|NCT06422013|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34056284|NCT01506765|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34056285|NCT06459505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment|Parallel Assignment It will be Randomized control trial in which non probabilty convenient sampling will be used. Two groups of 7-11 age will be formed in which participants will be randomly divided. Group A will Adapted Physical Activities and group B will only receive conventional Physical Therapy used for hemiplegic cerebral palsy.|t|f|f|f
34056286|NCT03091192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160231|NCT05003258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160232|NCT02434419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160233|NCT03083301|||COHORT||RETROSPECTIVE|||||||
34160234|NCT05613829|||COHORT||RETROSPECTIVE|||||||
34160235|NCT01698099|||COHORT||RETROSPECTIVE|||||||
34160236|NCT02638649|||CASE_ONLY||PROSPECTIVE|||||||
34160237|NCT02249611|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34160238|NCT02774148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160239|NCT01402713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34160240|NCT05512416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160241|NCT00387543|||||RETROSPECTIVE|||||||
34160242|NCT05854979|||CASE_CONTROL||PROSPECTIVE|||||||
34160243|NCT00381693||||TREATMENT||NONE||||||
34056287|NCT02265549|||COHORT||RETROSPECTIVE|||||||
34056288|NCT05234879|NA|SINGLE_GROUP||OTHER||NONE||||||
34056289|NCT02686242|||COHORT||RETROSPECTIVE|||||||
34056290|NCT02459847|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056291|NCT00000861||||TREATMENT||DOUBLE||||||
34056292|NCT02553499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056293|NCT05425043|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34056294|NCT05286138|||OTHER||PROSPECTIVE|||||||
34160244|NCT04483609|||CASE_ONLY||CROSS_SECTIONAL|||||||
34160245|NCT02231684|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33743472|NCT01776151|||OTHER||PROSPECTIVE|||||||
33743473|NCT06306534|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743474|NCT01722591|NA|SINGLE_GROUP||||NONE||||||
33846621|NCT04559321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind. Patient and doctor who performs the statistical analysis will not know which group each patient belongs to.|116 cases will be subjected to a simple randomization with a table of random numbers, 58 patients will undergo a percutaneous mini nephrolithotomy and lithotripsy with LithoClast Trilogy EMS; and the remaining 58 will undergo 100W Holmium laser lithotripsy.|t|f|f|t
33846622|NCT03980600|NA|SINGLE_GROUP||TREATMENT||NONE||Single center clinical investigation with patients selected by the clinicians. The donor sites were treated and compared intra-individually in the same patients.||||
33846623|NCT05837767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743475|NCT01813240|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33743476|NCT00899223|||OTHER||PROSPECTIVE|||||||
33743477|NCT05786924|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33743478|NCT05528120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743479|NCT06387251|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743480|NCT02475408|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846624|NCT02440659|||COHORT||PROSPECTIVE|||||||
34056295|NCT03212092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo with the appearance as the dietary supplements|The study is a pragmatic multicenter randomized double-blind placebo-controlled intervention trial with an intervention period of 4 months. Since the washout period of several components of dietary supplements is unknown we chose a parallel design.|t|t|t|t
34056296|NCT05958771|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34056297|NCT03991013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will be a phase 2, randomised, double-blind, placebo-controlled trial of tenofovir-lamivudine-dolutegravir fixed-dose combination daily with a lead-in supplementary 50 mg dose of dolutegravir versus matching placebo taken 12 hours later for the first 14 days in patients failing a first-line tenofovir-emtricitabine/lamivudine-efavirenz regimen.|t|t|t|t
34056298|NCT03580434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056299|NCT03081806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056300|NCT00697736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056301|NCT03163056|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to each of the three treatment conditions in accordance with a computer-generated randomization list. The three treatment conditions will be actively running in parallel.||||
34056302|NCT02664467|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34056303|NCT05709119|||COHORT||PROSPECTIVE|||||||
34056304|NCT00356252|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34056305|NCT00846677|RANDOMIZED|CROSSOVER||||NONE||||||
34056306|NCT06221397|||COHORT||CROSS_SECTIONAL|||||||
34056307|NCT02091596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056308|NCT03198832|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective double-blind controlled clinical study with a 6-month follow-up.|t|f|f|t
34056309|NCT01318590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34056310|NCT03369067|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056311|NCT03657524|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076186|NCT06008210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A parallel two-arm single-blinded randomised controlled trial will be conducted.|f|f|f|t
34076187|NCT03900338|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33743481|NCT02977546|||COHORT||PROSPECTIVE|||||||
33743482|NCT03950193|||CASE_ONLY||PROSPECTIVE|||||||
33743483|NCT00333593|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33743484|NCT00731315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33743485|NCT03251846|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-arm, single-subject clinical trial||||
33743486|NCT05008510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Central reader for scans will be blinded|This study is a multicenter, randomized, open-label, three treatment-arm, efficacy and safety study. Subjects will be randomized to the three treatment arms.|f|f|f|t
33743487|NCT00177229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743488|NCT01807273|||COHORT||PROSPECTIVE|||||||
33846625|NCT05103787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743489|NCT06057246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743490|NCT00698568|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33743491|NCT06458361|||COHORT||RETROSPECTIVE|||||||
33743492|NCT00058266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765192|NCT00259415|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33765193|NCT02629211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765194|NCT02387996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160246|NCT05377619|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Identical capsules containing prucalopride, buspirone or placebo.|N-of-1 trial testing the effect of prucalopride, buspirone and placebo on the prevention of alcohol-induced gastric glitch|t|f|t|f
33846626|NCT04887064|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846627|NCT00800553|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33846628|NCT00480480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846629|NCT01148147|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33846630|NCT06452498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, treating clinicians, and trial investigators will be blinded to the allocated treatment. Masking will be removed once the database has been locked, after which data analysis will be undertaken.|Two-arm trial with intervention arm (metformin) and comparator arm (placebo), aside from usual care for all patients.|t|t|t|t
33846631|NCT06609980|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Analysis will be done on de-identified samples so the outcomes assessor will be unaware||f|f|f|t
34160247|NCT02309008|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34160248|NCT04142281|||CASE_ONLY||PROSPECTIVE|||||||
34160249|NCT04742114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The subjects were divided into two groups. The first group use the breathing mask without the positive pressure valve, and the second group use the breathing mask with a positive pressure valve, that is EPAP breathing mask.|t|t|t|f
34160250|NCT05253885|||OTHER||CROSS_SECTIONAL|||||||
33846632|NCT03360734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846633|NCT06218862|||COHORT||RETROSPECTIVE|||||||
33765195|NCT00001202||||TREATMENT||||||||
33765196|NCT06481579|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33846634|NCT01451827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846635|NCT00138567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846636|NCT02168504|||COHORT||CROSS_SECTIONAL|||||||
33846637|NCT00496951|||COHORT||PROSPECTIVE|||||||
33846638|NCT00693667|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846639|NCT00733187|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846640|NCT03908957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056312|NCT05709444|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy.||||
34056313|NCT04696861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients who screen positive for suicidal ideation will be enrolled in the study, complete the baseline survey, and then randomly assigned to the intervention (3 sessions of counseling) or enhanced standard of care (brief safety planning).||||
34056314|NCT04228757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A unique ID number will be assigned by ClaimIt to each enrolled subject and associated with the correct study product kit number; this number will be used throughout the study. Both the study product and placebo will be labeled identically except for kit number and will be distinguishable only by the individual participant ID and kit number.|Randomized, double-blind, placebo-controlled intervention|t|t|t|f
34056315|NCT01953432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076188|NCT05709288|NA|SINGLE_GROUP||TREATMENT||NONE||Hemophilia B patients||||
34160251|NCT04852198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with 2 groups||||
34160252|NCT00242996||||TREATMENT||NONE||||||
34160253|NCT04119674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160254|NCT04150094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34160255|NCT02545764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160256|NCT05932472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160257|NCT00189605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160258|NCT03071393|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subjects will be asked to participate in two visits at least 7 days apart. Subjects will be assessed on various clinical outcomes before and after an exposure to one of two treatments. In one visit, subjects will be assessed before and after acute intermittent hypoxia, consisting of brief exposures of breathing low oxygen air, alternated with brief exposures to room air. In the other visit, subjects will be assessed before and after an exposure to a sham treatment, consisting of breathing brief exposures of normal oxygen air, alternated with brief exposures to room air. Subjects will undergo acute intermittent hypoxia or a sham treatment in a randomized order.||t|f|f|f
34160259|NCT01444885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160260|NCT01928901|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34160261|NCT04406558|||COHORT||PROSPECTIVE|||||||
34160262|NCT04829916|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160263|NCT05332132|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34160264|NCT01818102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160265|NCT06169813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160266|NCT00366691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160267|NCT00325390|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34160268|NCT06393166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846641|NCT02757040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846642|NCT03664934|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Outcome assessor blinded if a patient or a healthy control||f|f|f|t
33846643|NCT06012227|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33846644|NCT03490630|||COHORT||PROSPECTIVE|||||||
33846645|NCT00965367|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33846646|NCT06609551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846647|NCT04984538|||COHORT||OTHER|||||||
33846648|NCT01464372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846649|NCT02920437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846650|NCT01315691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846651|NCT01622114|RANDOMIZED|PARALLEL||||NONE||||||
33846652|NCT05867823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will be single blind since the researchers will know the assigned arm. Participants will know the group they belong, but not the hypotheses of the study or the superiority that is sought of one intervention over the other. However, data evaluators will remain blind to the allocation of patients to group.||t|f|f|t
33846653|NCT02571153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846654|NCT05087901|||COHORT||PROSPECTIVE|||||||
33846655|NCT02528526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846656|NCT02823405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846657|NCT06341660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846658|NCT05903547|RANDOMIZED|PARALLEL||TREATMENT||NONE||Women undergoing cesarean delivery will be recruited and randomized to skin closure with either the Dermabond Prineo system or standard subcuticular suture.||||
33846659|NCT02888210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846660|NCT03942185|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846661|NCT02840344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846662|NCT05845281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The patients weredivided in two groups. Thirty patients were assigned to each group. Standard general anesthesia procedure was applied to all patients. Perioperative hemodynamic monitoring was performed. Group ESP underwent an erector spina block after the surgical procedure. Intravenous patient-controlled analgesia with tramadol was applied to group PCA patients. VAS score, need for additional analgesia, patient satisfaction (Likert scale), mobilization times and vital signs were recorded at 30 minutes, 1th, 3th, 6th and 12th hours after the operation.|f|f|t|f
33846663|NCT01340677||CROSSOVER||||NONE||||||
33743493|NCT04040127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Syringe with the intervention and control will be covered with masking tape in order for both the provider and the participant to be blind.|The experiments outlined in this proposal are designed to test the hypothesis that the in vivo injection of cord blood stem cells (InvitRx®) into the root canal system will facilitate teeth initially diagnosed with irreversible pulpitis, to form normal healthy pulpal tissue.|t|t|f|f
33743494|NCT03448549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients enrolled are randomized into SOX group and XELOX group|f|t|t|t
33743495|NCT05378711|NA|SINGLE_GROUP||TREATMENT||DOUBLE|Participants serve as their own controls by being randomly assigned to switch from placebo to active medication at staggered start dates per single case design methodology.|||||
33743496|NCT05257525|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743497|NCT01946711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743498|NCT01704339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743499|NCT02176889|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33743500|NCT02405286|||COHORT||PROSPECTIVE|||||||
33743501|NCT03792594|||CASE_CONTROL||PROSPECTIVE|||||||
33743502|NCT05719974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743503|NCT02646423|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33743504|NCT05388903|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33743505|NCT01919099|||COHORT||PROSPECTIVE|||||||
33743506|NCT04449705|||CASE_ONLY||PROSPECTIVE|||||||
33743507|NCT00504829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743508|NCT06525181|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743509|NCT04329104|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33743510|NCT01794325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743511|NCT02937246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743512|NCT06635954|||COHORT||PROSPECTIVE|||||||
33846664|NCT05858125|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33846665|NCT01342289|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants were initially enrolled on the 90-day arm. When that arm completed enrollment, participants were enrolled on the 120-day arm while safety of the 90-day arm was evaluated. The 90-day arm was found to be safe, so participants were then enrolled on the 60-day arm for the remainder of the study.||||
33846666|NCT00225823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846667|NCT06571760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846668|NCT00490490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160269|NCT03637478|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"The E-SOC Model consists of the delivery of intensively integrated clinical care within pediatrics, combined with community-based parent support from family support specialists. Innovations include child mental health specialists joining the pediatrics team for huddles, psychiatry notes shared with pediatricians via the Electronic Medical Records and active inclusion of pediatricians in pre-evaluation discussions with the E-SOC Team and post-evaluation recommendations for the families. In addition, the E-SOC model includes active communication with school personnel, child welfare, and community-based resources, when needed."||||
34160270|NCT00629811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160271|NCT00032981|RANDOMIZED|||TREATMENT||||||||
34160272|NCT01035281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160273|NCT05496296|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Randomized, Prospective, Controlled, Open-label, Parallel Group, Multicenter||||
34160274|NCT04117529|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160275|NCT05836883|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Single-blind|Multicenter, Placebo-controlled, Dose-escalation Design, Randomized Controlled Trial.|t|f|f|f
34160276|NCT05994027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160277|NCT00637416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160278|NCT04306263|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34160279|NCT02779790|||||PROSPECTIVE|||||||
34160280|NCT05210387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160281|NCT05076890|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34160282|NCT02034838|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34160283|NCT03614325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160284|NCT06583629|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34160285|NCT04371965|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled open label trial, parallel design||||
34160286|NCT01991522|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34160287|NCT06279832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||As far as the sample size concerns, the number of images required for the analysis are a figure of at least 100 positive cases (15). We considered as positive patients with a favorable prognostic profile according to PORTEC-4a and also low and intermediate risk class according to ESGO/ESTRO/ESP 2020 recommendations.Therefore, we estimate to enroll at least 1000 patients in order to reach the 100 positive cases.||||
34160288|NCT02945514|||COHORT||PROSPECTIVE|||||||
34160289|NCT00196144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33743513|NCT04644328|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A total of 13 states, comprising 829 counties, centrally report COVID-19 cases at the ZCTA level. Two separate experiments were run within the study, one around Thanksgiving and one around Christmas. For each experiment, approximately half of the counties were randomized to high-intensity treatment with the remaining randomized to low-intensity treatment. In high-intensity counties, 3/4 of ZCTAs were treated and 1/4 were not. In low-intensity counties, 1/4 of ZCTAs were treated and 3/4 were not. In treated ZCTAs, Facebook users received ads with messages from physicians and other health personnel urging them to stay home and wear masks to stop the spread of COVID-19. Users in non-treated ZCTAs received no such ads. After exclusions, 820 counties were randomized to high- or low-intensity treatment during Thanksgiving and 767 counties were during Christmas.||||
33743514|NCT00673049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846669|NCT01912508|||CASE_CONTROL|||||||||
33846670|NCT04619251|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33743515|NCT04307212|RANDOMIZED|FACTORIAL||OTHER||NONE||A 3-way factorial design will be employed with training status as a between-subjects variable, and exercise intensity and time as within-subjects variables. The order of exercise intensity will be counterbalanced across subjects.||||
33743516|NCT01908777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846671|NCT05330689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846672|NCT06335485|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients are randomized to either the intervention group or general group, for the intervention group patients will be randomly assigned to attend 4 weekly online virtual CBT sessions that will provide information on stress and pain reduction techniques before surgery, and 2 sessions following patient surgery.||||
33846673|NCT02338180|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33846674|NCT02018939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846675|NCT03635528|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||t|t|f|f
33951785|NCT04698018|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33743517|NCT02763384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743518|NCT02359669|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33951786|NCT05629260|||COHORT||PROSPECTIVE|||||||
33951787|NCT03648073|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951788|NCT01035021|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743519|NCT00138931|||FAMILY_BASED||OTHER|||||||
34160290|NCT03235947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a randomized, parallel-group, controlled clinical trial conducted in a single center that will include renal transplant recipients over the age of 18 to assess the efficacy and safety of disodium fosfomycin in the perioperative period of renal transplantation. The intervention group will receive intravenous fosfomycin 4 g disodium three hours prior to: renal transplant surgery, removal of the urinary catheter and withdrawal of the ureteral catheter. The control group will receive placebo at the same time. Both groups will receive standard prophylaxis consisting of trimethoprim / sulfamethoxazole (160/800 mg) orally every 24 hours when the GFR is greater than 30 mL / min / 1.73m2.|t|t|t|t
34160291|NCT02289794|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34160292|NCT03887234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Either the two operation methods is chosen by opening a sealed envelope.|Prospective randomized follow-up study. Two groups.|f|f|t|f
34160293|NCT06155461|||COHORT||PROSPECTIVE|||||||
34160294|NCT04712708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160295|NCT04392609|||CASE_CONTROL||RETROSPECTIVE|||||||
34160296|NCT05950984|||OTHER||PROSPECTIVE|||||||
34160297|NCT04383327|RANDOMIZED|PARALLEL||OTHER||SINGLE|Research staff performing outcome assessment will be blind to the study conditions.|A cluster randomized controlled trial (cRCT), single blind and mixed-methods design will be applied|f|f|f|t
34160298|NCT01771796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160299|NCT02277925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160300|NCT01411956|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34160301|NCT03325842|||COHORT||CROSS_SECTIONAL|||||||
34160302|NCT02596230|||COHORT||PROSPECTIVE|||||||
34160303|NCT05643950|RANDOMIZED|PARALLEL||OTHER||NONE|Data analysis will be blinded to the intervention arm as well as the laboratories that will carry out the analysis of the urine and catheter samples.|||||
34160304|NCT05137769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160305|NCT00001894||||TREATMENT||||||||
34160306|NCT04680429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743520|NCT05450432|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 100 participants will be enrolled in the study to receive intravenous ketamine and intranasal esketamine. Participants will be compared against matched historical control subjects identified through electronic medical records.||||
33743521|NCT02956330|||COHORT||RETROSPECTIVE|||||||
34160307|NCT02569684|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34160308|NCT00244101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160309|NCT01663012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160310|NCT00479856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743522|NCT00680316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743523|NCT01329029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743524|NCT03557437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743525|NCT04231630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743526|NCT02488434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743527|NCT05599594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"In the study, the evaluation and statistical analysis will be blinded. Statistical analyzes will be carried out by a faculty member other than researchers. A non-aware of the experiment and control groups will be aware of the assessment of initiatives. Data entries will be entered with A, B and C code without the test or control group specified. Writing the analysis and research report of the data will be carried out to be coded as A, B and C group. After the statistical analysis is made and the research report is written, the encoders for the experiment and the control group will be explained by the encoder by the encoder. The data collection tool described below before the venture and the control group will be applied below"|"3 groups will be formed from the students identified with the symptoms of premenstrual syndrome. 1.Gruba Neroli, 2.Gruba Lemongrass, to Group 3~(Placebo Group) will be given water vapor and the states of premenstrual syndrome among the groups and the status of premenstrual symptoms will be evaluated. Pre-process pre-test will be applied to all groups. After each application will be tested again. The final test will be applied to each participant's first day of menstruation."|t|f|f|t
33846676|NCT00017368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846677|NCT00564551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951789|NCT04543747|||COHORT||PROSPECTIVE|||||||
33951790|NCT03726242|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Parallel, randomized placebo controlled and crossover study|t|t|t|t
33951791|NCT06207045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951792|NCT02729597|||COHORT||PROSPECTIVE|||||||
33951793|NCT02129465|||COHORT||PROSPECTIVE|||||||
33951794|NCT04876482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951795|NCT06231901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951796|NCT06455670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951797|NCT00905437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33951798|NCT02770352|||OTHER||PROSPECTIVE|||||||
33951799|NCT05198414|||OTHER||CROSS_SECTIONAL|||||||
33951800|NCT06370884|NA|SINGLE_GROUP||OTHER||NONE||This is a phase 1 pilot clinical trial that will evaluate the initial safety and feasibility of intestinal microbiota transplantation (IMT) in patients undergoing colon resection.||||
33951801|NCT06012357|||OTHER||RETROSPECTIVE|||||||
33951802|NCT02892916|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951803|NCT05085717|||COHORT||PROSPECTIVE|||||||
33951804|NCT01528839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951805|NCT04135248|||COHORT||PROSPECTIVE|||||||
33951806|NCT06652581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double Blind||t|f|f|t
33951807|NCT01164280|NA|SINGLE_GROUP||TREATMENT||||||||
34160311|NCT02524158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160312|NCT06356051|||CASE_CONTROL||PROSPECTIVE|||||||
34160313|NCT00695526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34160314|NCT04610398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34160315|NCT03020706|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
34160316|NCT01725061|||COHORT||PROSPECTIVE|||||||
34160317|NCT01359943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160318|NCT05345275|||OTHER||OTHER|||||||
34160319|NCT01468792|||COHORT||PROSPECTIVE|||||||
34160320|NCT02287467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160321|NCT05921175|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective single-arm crossover study in participants with incomplete chronic traumatic spinal cord paraplegia.||||
34160322|NCT02898402|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34160323|NCT05921838|||OTHER||CROSS_SECTIONAL|||||||
34160324|NCT03112655|NA|SEQUENTIAL||DIAGNOSTIC||NONE|The reference laboratory, generating the results for the index test, is masked for results obtained at the clinical trial site (determining the standard reference).|||||
34160325|NCT02465372|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160326|NCT01406977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160327|NCT03019094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160328|NCT02474602|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34160329|NCT03963843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160330|NCT00390650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160331|NCT03255551|||CASE_CONTROL||PROSPECTIVE|||||||
34160332|NCT04717817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|lungfunction assessor, radiologist (thorax X-ray) and physician (hospital ward) are blinded||f|f|f|t
34160333|NCT00812773|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34160334|NCT05377138|NA|SINGLE_GROUP||OTHER||NONE||MYDAWA clients determined to be eligible for PrEP or PEP following online screening and a remote meeting with a MYDAWA clinical officer will be delivered a blood-based HIV self-test followed by daily oral PrEP or PEP) at home and continued remote HIV prevention (i.e., PrEP) support for a small fee.||||
34160335|NCT01900587|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160336|NCT02540070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160337|NCT04373005|||COHORT||PROSPECTIVE|||||||
34160338|NCT01949090|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160339|NCT02035917||||TREATMENT||||||||
34160340|NCT01817439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743528|NCT04106999|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A blinded syringe with either the placebo or study drug will be given to the anesthesiologist involved in that patient's care. All other care providers will be blinded to the study group|1 group will receive placebo drug delivery (Normal Saline infusion). The 2nd group will receive the study drug infusion (Dexmedetomidine)|t|t|f|t
34160341|NCT04916236|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part A: Phase I study - Dose-escalation of RMC-4630 and LY3214996 combination to determine RP2D/MTD.~Dose level will be escalated according to standard 3+3 design.~Part B: Phase Ib study - To further characterize the safety, tolerability and PK/PD of the RP2D of the RMC-4630 and LY3214996 combination.~Expansion cohort in which patients with KRASm PDAC will be treated with the RP2D found in Part A of the study."||||
34160342|NCT00615004|||COHORT||RETROSPECTIVE|||||||
34160343|NCT00764062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34160344|NCT04269356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743529|NCT04361357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34160345|NCT02692755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160346|NCT00730080|||CASE_CONTROL||PROSPECTIVE|||||||
34160347|NCT01103570|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34160348|NCT05370053|RANDOMIZED|PARALLEL||SCREENING||NONE||During the hepatology evaluation for elevated liver enzymes or fatty liver at the University of Kansas Medical Center, the hepatologists (8 total) make a clinical decision on whether patients shall receive vibration-controlled transient elastography (VCTE). At the end of the clinic visit, patients were enrolled and randomized to receiving an enhanced liver fibrosis (ELF) test. If randomized to receiving the ELF testing, the hepatologist will receive the ELF result within 1 week. The hepatologist is free to the clinical information at hand to make clinical decisions. Possible decisions include: 1)defer liver biopsy without making a clinical diagnosis of cirrhosis 2)order liver biopsy, where the result may show F0-2 fibrosis, 3)order liver biopsy, where the result may show F3-4 fibrosis, 4)clinical diagnosis of cirrhosis without liver biopsy||||
34160349|NCT01431053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160350|NCT04270539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who are responsible for conducting the cognitive tests are blinded to the group allocation.|Experimental group (with daytime classroom nap) versus control group (without nap)|f|f|f|t
34160351|NCT02095080|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160352|NCT04308629|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34160353|NCT02416154|||COHORT||CROSS_SECTIONAL|||||||
34160354|NCT04876352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Physiotherapist, neurologists, neuropsychologists and radiologist assessing the patients are blinded to group allocation.|Single-blind randomized controlled trial. 40 PD patients are randomly divided into two groups: 20 in the VR-training (experimental) and 20 in the RS-training (active comparator). The assessors are blinded to the group allocation. In addition, a group of 15 healthy age- and sex-matched control is included at baseline|f|f|f|t
33951808|NCT04999904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to group assignment|The study will be implemented using multi-site, parallel randomized clinical trial. Individuals will be randomly allocated between a control and experimental arm, stratified between lateral ankle sprains and chronic ankle instability.|f|f|f|t
33951809|NCT04877405|||CASE_ONLY||RETROSPECTIVE|||||||
33951810|NCT02145949|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951811|NCT03279120|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33951812|NCT02435082|||COHORT||PROSPECTIVE|||||||
33951813|NCT00621309|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33951814|NCT00261859|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|t|f
33951815|NCT00084188||||TREATMENT||||||||
33951816|NCT02089022|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33951817|NCT03577665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951818|NCT05075551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Owing to differentiating the acupuncture effect from placebo effect, the participants and outcomes assessors are needed to be masked.|The eligible participants will receive either acupuncture or sham acupuncture randomly assigned at the ratio of 1:1 after signing the Informed consent. Before they accept the treatment, they are acquired to finish the clinical scales and get the fMRI scan. Sanyinjiao (SP6), Zhibian (BL54), Shenshu (BL23), and Huiyang (BL35) have been chosen as acupoints. In the group of both acupuncture and sham acupuncture, the course of treatment is 2 times a week in three months (totally 24 times). There are 3 clinic visits and 3 telephone contacts for emergency. At the ending of the treatment, all the volunteers will be asked to finish the clinical scales and get the fMRI scan again. As the step of following up, all the patients will be asked to finish the clinical scales and get the fMRI scan again to evaluate the efficacy of avoiding the recurrence of acupuncture.|t|f|f|t
33951819|NCT01081431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076189|NCT06407219|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will not know which mode they are completing on which day. Caregivers may be told if they ask, and investigators and outcome investigators will know the randomization.|This study is a randomized cross-over design, where participants will complete a training session in both the endurance mode and the strength mode of the Trexo robotic gait trainer. The session completed first will be randomized.|t|f|f|f
33743530|NCT04279808|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized controlled trial|t|t|f|f
33743531|NCT03524404|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743532|NCT01060865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743533|NCT01995123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743534|NCT02507089|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33743535|NCT05153434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743536|NCT00059813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743537|NCT05648591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743538|NCT01462994|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743539|NCT03022851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743540|NCT06296173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Until surgical closure, all will be blinded to treatment allocation. Only specific healthcare professionals (anesthesiologist, respiratory therapist, operating room nurses, unblinded research assistant) will be present during emergence to maintain blinding. Other healthcare team members will remain blinded. Outcome adjudicators, Executive and Steering committee members, and the data analyst will also be blinded. No mechanism for unblinding is planned, as both interventions follow the same diagnostic and treatment algorithms for adverse effects.|During surgical closure, the definitive ARISCAT score and exclusion criteria will be assessed. Patients will be randomized equally (1:1) using web-based allocation-concealed methods, with stratification by center and ARISCAT risk category. An unblinded research assistant will reveal group allocation to the anesthesiologist and monitor the emergence procedure.|t|f|f|t
33743541|NCT01173848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743542|NCT04057495|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743543|NCT02433353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743544|NCT06533982|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33743545|NCT05604339|||COHORT||PROSPECTIVE|||||||
33743546|NCT06232408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743547|NCT05704959|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743548|NCT06635343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743549|NCT00318006|RANDOMIZED|PARALLEL||||NONE||||||
33743550|NCT03512561|||COHORT||PROSPECTIVE|||||||
33743551|NCT05843968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743552|NCT00153738|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33743553|NCT01858662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743554|NCT00723775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743555|NCT05839769|||CASE_CONTROL||PROSPECTIVE|||||||
33743556|NCT02571452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743557|NCT06535685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951820|NCT03486015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951821|NCT03448380|||COHORT||PROSPECTIVE|||||||
33951822|NCT02026986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33951823|NCT01275170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951824|NCT00002329||||TREATMENT||DOUBLE||||||
33951825|NCT02764606|||COHORT||PROSPECTIVE|||||||
33951826|NCT00143013|||||PROSPECTIVE|||||||
33846678|NCT03134105|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will enroll patients with recent myocardial infarction being seen in cardiology clinics. All patients will receive wearable fitness trackers and apps that capture this data and transmit it to the coordinating center; patients will also provide information on angina frequency every other week via emailed surveys. Sites will be randomized to have their providers receive either monthly updates on step count and patient reported angina or a single report at the end of the study period. Providers receiving monthly reports will receive a single report with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.||||
33846679|NCT01279213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846680|NCT05621889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846681|NCT00809601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846682|NCT06113887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A total of 10 groups, 5 intervention groups and 5 control groups|t|f|f|f
33846683|NCT01290653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33846684|NCT03449251|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Identical, colourless solution||t|f|t|t
33846685|NCT02347423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846686|NCT05821855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846687|NCT02661919|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846688|NCT04278196|||CASE_CONTROL||PROSPECTIVE|||||||
33846689|NCT00080353||||TREATMENT||||||||
33846690|NCT02217579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846691|NCT04888962|||CASE_CONTROL||PROSPECTIVE|||||||
33846692|NCT05715918|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
33846693|NCT01487447|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846694|NCT01384929|||COHORT||PROSPECTIVE|||||||
33846695|NCT02270541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33846696|NCT06532786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33846697|NCT03505034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846698|NCT06502886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blinded randomized clinical trial||f|f|f|t
33846699|NCT03032900|||OTHER||PROSPECTIVE|||||||
33846700|NCT02624791|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|participants and research assistant blind to hypothesis||t|f|t|f
33846701|NCT04512131|||COHORT||PROSPECTIVE|||||||
33846702|NCT05705843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"* Participant will be blinded to their mode of vancomycin administration.~* Lab will be blinded to which group subject samples come from when doing concentration level testing."|This study is a prospective, randomized, single-blinded, controlled trial. The anticipated total number of participants in this study is 20 patients in each treatment arm: 20 patients will be given IV Vancomycin, 20 patients will be given IO vancomycin. This sample size is based on previous studies examining vancomycin concentration in primary TKA between IO vs IV|t|f|f|t
33846703|NCT00221026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846704|NCT04488770|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This will be a double-blind study with participants and the site staff blinded.|Part 1 will consist of two cohorts (Cohorts 1 and 2) with a maximum of four periods in a cross-over design conducted in two separate cohorts. Part 2 consists of a maximum of four ascending repeat-dose cohorts (Cohorts 3 to 6) for which participants, will receive a single oral dose of GSK3882347 or placebo for 7 days.|t|f|t|f
33951827|NCT01985776|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34076190|NCT02418793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076191|NCT00553488|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076192|NCT00558987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34076193|NCT01895725|||COHORT||PROSPECTIVE|||||||
34076194|NCT05816915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with NAFLD and metabolic syndrome will be randomly assigned to a standard care or a professional lifestyle modification counselling during a 1-yr follow-up.||||
34076195|NCT01136018|||||PROSPECTIVE|||||||
34076196|NCT00105742|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076197|NCT00714974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076198|NCT03138057|||CASE_CROSSOVER||PROSPECTIVE|||||||
34076199|NCT02855775|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076200|NCT03198858|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34076201|NCT06325800|||CASE_CONTROL||OTHER|||||||
34076202|NCT03319433|||COHORT||PROSPECTIVE|||||||
34076203|NCT05946226|NA|SEQUENTIAL||TREATMENT||NONE||A classic 3+3 model will be used to dose escalation 3 doses will be used: 1×10\^8, 2.5×10\^8 and 5×10\^8 CAR-T cells/ patients||||
34076204|NCT02701621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34076205|NCT01979874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076206|NCT00660296|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34076207|NCT02534597|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34076208|NCT03535857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743558|NCT05861674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743559|NCT04708873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be a single blinded study. Only the participants will be masked.|Participants will be randomly allocated to Interventional Group A (High intensity aerobic \& resistance interval training) or Interventional Group B/ Control Group (Moderate intesity continuous training) for the whole duration of the study.|t|f|f|f
33743560|NCT05710523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The I-ACE training encompasses a training on the non-pharmacological therapies' methodology and a training on awareness of body language which favors a passage from implicit to explicit knowledge. It allows the reading of the subjective relational experience of the care situation by the professional caregiver and a comparison of shared readings of the situation itself by the group of colleagues, and with the residents. Participants will follow:~Two sessions, each lasting 4 hours, on theoretical introduction to the non-pharmacological therapies' methodology; Ten monthly supervisions, each lasting one and half hours, on discussion of clinical cases and implementation of the non-pharmacological therapies with person with dementia.~Ten monthly supervisions, each lasting two hours, on theatrical exercises guided by an expert actor, with the help of a psychologist-psychotherapist who promotes understanding and awareness of self-reading in the relationship with the other."|f|f|f|t
33743561|NCT02465229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743562|NCT00898677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743563|NCT03818373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||all participants receive the same intervention throughout the protocol||||
33846705|NCT03167372|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study aims to assess the feasibility of conducting a randomized trial comparing two N-of-1 trials of light therapy in cancer survivors with depressive symptoms. In the first N-of-1 trial, participants will compare bright white light with dim red light therapy. In the second N-of-1 trial, participants will compare dim white light with dim red light. Participants will be randomized in a 2:1 ratio to either the N-of-1 bright white light vs dim red light experimental arm (N=20) or to a dim white vs dim red light therapy active comparator (N=10).||||
33743564|NCT04783753|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846706|NCT01693705|||CASE_CONTROL||RETROSPECTIVE|||||||
33846707|NCT02892227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846708|NCT00128102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846709|NCT00447655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846710|NCT00620295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743565|NCT00710424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33743566|NCT00000218||||TREATMENT||||||||
33743567|NCT03023891|NA|SINGLE_GROUP||OTHER||NONE||||||
33846711|NCT01813877|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846712|NCT04662177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomised controlled prospective trial in two groups.|Randomised controlled prospective trial in two groups. Group 1 will receive anaesthesia with propofol and co-administration of dexmedetomidine in conjunction with electrophysiological studies measuring somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs). Group 2 will receive standard anaesthesia with propofol alone, in conjunction with electro¬physio¬logical studies measuring SSEPs and MEPs.|t|f|f|f
33846713|NCT06037928|||CASE_ONLY||RETROSPECTIVE|||||||
33743568|NCT04358445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Non randomized， non parallelized and history case-controled quasi-experiment||||
33846714|NCT00492102|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33846715|NCT03776227|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846716|NCT04287595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846717|NCT01808326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846718|NCT04949542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846719|NCT04553289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34076209|NCT04007965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076210|NCT01510821|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34076211|NCT04252677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076212|NCT06612970|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34076213|NCT06561633|||COHORT||PROSPECTIVE|||||||
34076214|NCT01526408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34076215|NCT03522116|||COHORT||PROSPECTIVE|||||||
34076216|NCT02636569|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076217|NCT05535374|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34076218|NCT03164447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076219|NCT00409279|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34076220|NCT04572828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160355|NCT02779413|||COHORT||PROSPECTIVE|||||||
34160356|NCT00772265|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34076221|NCT01042834|||COHORT||PROSPECTIVE|||||||
34076222|NCT00697853|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076223|NCT00823238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160357|NCT00558298|NON_RANDOMIZED|||TREATMENT||NONE||||||
34160358|NCT00079716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160359|NCT02338050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160360|NCT00943241|||CASE_ONLY||PROSPECTIVE|||||||
34160361|NCT00005084||||TREATMENT||||||||
34160362|NCT04270084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160363|NCT04607746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160364|NCT05746156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Results of the lymphatic map will be blinded to the radiation oncologist|||||
34160365|NCT03371784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1:1 model randomization|t|f|t|t
34160366|NCT01824355|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160367|NCT01458418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160368|NCT05844241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34160369|NCT00546000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160370|NCT01651325|NA|SINGLE_GROUP||||NONE||||||
34160371|NCT03325595|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study. Subjects and investigator will be masked.||t|f|t|f
34160372|NCT03466853|||COHORT||CROSS_SECTIONAL|||||||
34160373|NCT06418490|||COHORT||PROSPECTIVE|||||||
34160374|NCT04345679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743569|NCT02555046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160375|NCT02889211|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160376|NCT01996280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160377|NCT01770236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160378|NCT04787978|NA|SINGLE_GROUP||PREVENTION||NONE||single-arm pilot program||||
34160379|NCT03084835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160380|NCT00048347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160381|NCT00522977|||||PROSPECTIVE|||||||
34160382|NCT00904904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33743570|NCT03985618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Brewin partially randomized control trial, patient preference trial. In this design, each eligible patient is asked for her preference for mode of delivery. Patients with a preference are given their delivery mode of choice. If a patient does not have a preference, randomization takes place. Advantages to this design include the fact that preferences are taken into account in care allocation and that almost all those who are eligible enter the study.||||
33743571|NCT02752620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743572|NCT05716581|||COHORT||PROSPECTIVE|||||||
33743573|NCT00223418|RANDOMIZED|PARALLEL||||NONE||||||
33743574|NCT02186951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743575|NCT04134663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33743576|NCT05469568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743577|NCT06163105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743578|NCT01289067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743579|NCT01274546|||CASE_ONLY||PROSPECTIVE|||||||
33743580|NCT01886976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743581|NCT05020483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743582|NCT04666272|||COHORT||PROSPECTIVE|||||||
33743583|NCT01298791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33743584|NCT00242255|||CASE_ONLY||CROSS_SECTIONAL|||||||
33743585|NCT01281358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34160383|NCT00055692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160384|NCT02454478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160385|NCT04382885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160386|NCT01670721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160387|NCT02681471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160388|NCT03529981|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|On-demand intervention was provided on only some physiologically detected stress events|randomized, controlled factorial within subject design|t|t|t|t
34160389|NCT05798221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33743586|NCT01153646|NA|SINGLE_GROUP||||NONE||||||
33846720|NCT02627053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846721|NCT01056718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056316|NCT06434220|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|"We conduct a randomized, double-blind, controlled before-after (CBA) study of board-certified ED attending physicians not currently caring for patients in the BCH ED over a period of six to twelve weeks. In this experiment, the treatment consists of an ML recommendation provided to the ED physicians, who predict admission decisions for individual patients before and after receiving it. The control surveys receive the original POPP model recommendation, and treatment surveys receive a fairness-aware model, determined in prior work to mitigate biases in performance with respect to patient demographics"||t|t|t|f
34056317|NCT06475729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056318|NCT06617975|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, single-arm, superiority study with external comparison (control group of a reference RCT)||||
34056319|NCT06604234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Placebo-controlled study|t|t|t|t
34056320|NCT03627416|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.|16 patients with HSP or AMN will receive either active and sham stimulation in random order|t|f|f|t
33743587|NCT00004179|RANDOMIZED|||TREATMENT||||||||
33743588|NCT00270491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743589|NCT01286259|NA|SINGLE_GROUP||OTHER||NONE||||||
33743590|NCT02187757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743591|NCT01020721|||FAMILY_BASED||PROSPECTIVE|||||||
33743592|NCT06634563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque sealed envelope|Mindfulness Meditation and cognitive behavioral training|f|f|f|t
33743593|NCT04159688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743594|NCT04607187|||OTHER||PROSPECTIVE|||||||
33743595|NCT06634654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743596|NCT06074094|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33846722|NCT01859988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846723|NCT05269745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846724|NCT02396628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056321|NCT04115995|||CASE_ONLY||PROSPECTIVE|||||||
34056322|NCT02609100|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34056323|NCT02599597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056324|NCT01187498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056325|NCT01044290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34056326|NCT05022524|NA|SINGLE_GROUP||TREATMENT||NONE||N-of-1 type prospective study||||
33846725|NCT03554629|NA|SINGLE_GROUP||OTHER||NONE||||||
33846726|NCT03481543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743597|NCT04917679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743598|NCT01024764|||||PROSPECTIVE|||||||
33743599|NCT04389840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|The first 12 subjects were to be randomized 1:1 (dociparstat:placebo) All other subjects were to be randomized 2:1 (dociparstat:placebo)|t|t|t|t
33743600|NCT02024334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743601|NCT01592435|||CASE_ONLY||PROSPECTIVE|||||||
33743602|NCT01217931|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743603|NCT05103761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be randomly assigned to either the ketogenic diet or the LGIT diet for 8 weeks. Once they complete the first diet, they will go under a washout period for 8 weeks before they start the second diet.||||
33743604|NCT02293187|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33743605|NCT04598152|NA|SINGLE_GROUP||OTHER||NONE||"The first part of the study consists of screening procedures that are meant to determine if potential participants are eligible to take part in the remainder of the study.~If you qualify to take part in the scanning portion of the study, you will have 2 scanning sessions on separate days approximately a week apart. For each scan session you will undergo a functional Magnetic Resonance Imaging (fMRI) scan that lasts approximately 30 minutes and no more than 1 hour. The total time you will spend for each scan session will be between 1-3 hours.~During the scanning session you will receive transcranial direct current stimulation (tDCS). Prior to scanning, sponge-electrodes will be placed on your scalp. These electrodes will be connected to a stimulator. This stimulator will apply weak currents to the brain while the MRI takes pictures of your brain's responses. The stimulation current that you will experience is usually less than a 6-volt battery but may be increased up to 15-volts."||||
33743606|NCT05703282|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743607|NCT00107419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743608|NCT02069054|||CASE_CONTROL||PROSPECTIVE|||||||
33743609|NCT00801827|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743610|NCT01513850|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743611|NCT05449223|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33743612|NCT04324684|||CASE_CONTROL||PROSPECTIVE|||||||
33743613|NCT01131312|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Computer random assignment to HPV testing (HC2), cytology (ThinPrep), or immediate colposcopy.||t|f|f|f
33743614|NCT01259713|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743615|NCT02998242|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743616|NCT01086657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743617|NCT06530316|||COHORT||PROSPECTIVE|||||||
33743618|NCT06627504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056327|NCT04285424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743619|NCT02534103|||CASE_ONLY||PROSPECTIVE|||||||
33743620|NCT04631822|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33743621|NCT01359735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056328|NCT04946032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The anesthesiologist placing the epidural will know the group assignment.||t|f|t|t
34056329|NCT06444763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743622|NCT04968470|||CASE_ONLY||PROSPECTIVE|||||||
33846727|NCT02070224|NA|SINGLE_GROUP||OTHER||NONE||||||
33846728|NCT05841992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846729|NCT01827995|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33846730|NCT03887949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846731|NCT04196790|||COHORT||PROSPECTIVE|||||||
33846732|NCT05154877|||COHORT||PROSPECTIVE|||||||
33846733|NCT05565495|NA|SEQUENTIAL||TREATMENT||NONE||||||
33846734|NCT03026751|||CASE_ONLY||PROSPECTIVE|||||||
33846735|NCT04110639|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33846736|NCT03710668|||CASE_CONTROL||PROSPECTIVE|||||||
33846737|NCT01914601|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33846738|NCT00157313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951828|NCT04366115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The pharmacist will prepare the infusion solution and medication for delivery to the patient's bedside for administration. The active and placebo medications look identical, preventing care-givers and the participant from breaking the blind.|This is a two-armed randomized, double-blinded, placebo control controlled study. Each arm (one arm of COVID-19 mediated ARDS and one arm of influenza (A or B) mediated ARDS will be randomized to 3:1 (active to placebo)|t|t|t|f
33951829|NCT00484042|||DEFINED_POPULATION||OTHER|||||||
33951830|NCT01832896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951831|NCT00363272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951832|NCT00112086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951833|NCT01826006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34056330|NCT00372710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056331|NCT04994912|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34056332|NCT04983667|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomized allocation to one of two supplements, one has the active compound, the other is a placebo. Identical containers and labels have been designed. Both groups will receive the customary iron sulfate and folic acid supplementation along pregnancy|Parallel 1:1 randomization to one of two interventions, the active compound or the placebo|t|t|f|t
34056333|NCT06473025|RANDOMIZED|PARALLEL||OTHER||NONE||"* Treatment arm 1: Update mothers' beliefs on the height-for-age and weight-for-age percentiles of their child relative to a reference group of healthy children based on WHO standards~* Treatment arm 2: Treatment 1 + information on the impacts of child undernutrition on health (risk of chronic and infectious diseases, mortality), education (high school test scores, years of education), and labor market (earnings) outcomes, synthesized from existing literature~* Control arm: Status-quo, no intervention"||||
34056334|NCT05948566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Model Description: The first 50 subjects will be randomized equally to the five arms. Response Adaptive Randomization updates will occur every 50 subjects, thereafter, (favoring doses with maximum utility). For each block of 50 subjects, 13 will be allocated to control.|t|t|t|t
34056335|NCT06621069|||COHORT||RETROSPECTIVE|||||||
34056336|NCT02345889|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34056337|NCT04768127|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will compare two intervention groups (early intervention and later intervention) to two control groups.||||
34056338|NCT06623136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056339|NCT02347215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056340|NCT03551951|||COHORT||PROSPECTIVE|||||||
34056341|NCT05640297|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled trial||||
34076224|NCT02793765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076225|NCT04256759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846739|NCT03916874|||COHORT||PROSPECTIVE|||||||
33846740|NCT00239551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846741|NCT06412601|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846742|NCT01856868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846743|NCT00606060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846744|NCT04220840|||CASE_CONTROL||RETROSPECTIVE|||||||
33846745|NCT02435121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846746|NCT02601976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846747|NCT02644291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846748|NCT02707549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33846749|NCT02883998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846750|NCT02512640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33846751|NCT03698903|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33846752|NCT03218397|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Primary service/provider: The primary service, including the prescribing provider, will be unaware of group assignment at the time of randomization, so initial antibiotic choice will not be affected by group assignment. Once rapid results become available and/or AS interventions are made, treating providers may become aware of group assignment.||f|t|f|f
33846753|NCT03415737|||CASE_ONLY||PROSPECTIVE|||||||
33846754|NCT02904031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846755|NCT00876681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951834|NCT02999516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33951835|NCT00548340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951836|NCT00003582||||TREATMENT||||||||
33951837|NCT03881748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research assistant blind to group assignment will distribute and collect the results of the FACT/GOG-Ntx subscale, FACT-G, TNSc, NPS, QST, GPT, Unipedal Stance balance test, and medication use per the study calendar. In addition, data about the subject's past medical history including cancer details and relevant medical conditions (e.g., diabetes mellitus and peripheral vascular disease) will be collected. This data will not be seen by the acupuncturists while the subject is receiving treatment.|Participants will be randomly assigned to one of two groups: 1) manual acupuncture twice a week for 20 treatments or 2) electro-acupuncture twice a week for 20 treatments. Multiple assessments will be performed at baseline and approximately every 2 weeks for a total of 16 weeks while subjects are on study.|f|t|f|f
34056342|NCT06621641|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A prospective, randomized controlled trial will be conducted to evaluate the effectiveness of a newly developed HFNC (High-Flow Nasal Cannula) weaning protocol in infants aged 1-24 months with bronchiolitis, compared to the standard weaning protocol.~Participants:~Infants aged 1-24 months admitted with bronchiolitis and receiving HFNC therapy will be included. Exclusion criteria include infants born before 32 weeks of gestation or those with cardiopulmonary, genetic, congenital, or neuromuscular abnormalities.~Randomization and Groups:~Participants will be randomly assigned to one of two groups:~Control Group: Will follow the existing HFNC weaning protocol. Intervention Group: The intervention group will follow the newly developed multidisciplinary HFNC weaning protocol."||||
34056343|NCT05720494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056344|NCT05885295|||COHORT||PROSPECTIVE|||||||
34056345|NCT02375490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056346|NCT00001044||||PREVENTION||DOUBLE||||||
34056347|NCT01444729|||OTHER||PROSPECTIVE|||||||
34056348|NCT05170100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056349|NCT04547218|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056350|NCT06166043|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients will receive standard care first. The same group of patients will later be included in the intervention.||||
34056351|NCT01757912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056352|NCT05565443|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm, open-label, intervention only clinical study. One arm to enroll 7 GBA PD patients, the second arm to enroll 7 idiopathic PD patients. The study involves focused ultrasound procedures targeting bilateral putamen in patients with Parkinson's Disease.||||
34160390|NCT06122038|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In a double-blind, placebo-controlled fashion, participants will be randomly assigned to one of two supplementation groups. One group will be assigned to ingest rice flour which will serve as a placebo group. The other group will be assigned to ingest 500 mg/day of Tart Cherry Extract Powder (NordicCherry, SpecNova, LLC). All study materials will be prepared into gelatin capsules of identical size, color, shape, and transparency.|This study will utilize a randomized, double-blind, placebo group study design|t|f|t|f
34160391|NCT04322617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160392|NCT02240511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34160393|NCT01803256|||||CROSS_SECTIONAL|||||||
34160394|NCT02770989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160395|NCT01361893|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34160396|NCT05156957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160397|NCT00253123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160398|NCT04220944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160399|NCT02240771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160400|NCT02042209|||COHORT||PROSPECTIVE|||||||
34160401|NCT03917095|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34160402|NCT02381015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34160403|NCT00523601|||||PROSPECTIVE|||||||
34160404|NCT03030469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160405|NCT04859426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160406|NCT01426022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160407|NCT02542826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160408|NCT04395690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were not told what type of anesthesia was being used and surgeons obtains the method of anesthesia to be used in this particular patient thirty minutes before intervention started.|48 receiving infiltrative anesthesia and 48 patients receiving Inferior Alveolar Block Nerve anesthesia. (n=96)|t|f|t|f
34160409|NCT04521985|||COHORT||PROSPECTIVE|||||||
34160410|NCT05017467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|280|280 operated patient with carpal tunnel release surgery.|t|f|f|f
34160411|NCT02618161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160412|NCT04499560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160413|NCT00275067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160414|NCT01841580|||CASE_ONLY||PROSPECTIVE|||||||
34160415|NCT01096693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34160416|NCT00089531||||TREATMENT||||||||
34160417|NCT03127176|||CASE_CONTROL||PROSPECTIVE|||||||
34160418|NCT01687101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160419|NCT00051909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160420|NCT04370613|||COHORT||CROSS_SECTIONAL|||||||
34160421|NCT03658733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160422|NCT05081206|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34160423|NCT04137185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160424|NCT04895826|||CASE_CONTROL||PROSPECTIVE|||||||
33846756|NCT05147844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846757|NCT05599932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846758|NCT02823990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846759|NCT02835300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846760|NCT05365360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846761|NCT03711344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||East Asian youth diagnosed with Anxiety and/or depression will be randomly assigned to either the experimental group (receives the cultural adapted version of cognitive behavioral therapy) or the control group (non-culturally adapted cognitive behavioral therapy). It is a randomized control trial design.|f|f|f|t
33846762|NCT02851225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846763|NCT05452200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846764|NCT05980481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846765|NCT00741559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846766|NCT04480138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846767|NCT02417519|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33846768|NCT03020576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33846769|NCT00701831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846770|NCT04285138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Phantom exercises involved imagining moving the phantom limb and then attempting to perform these movements~The phantom exercises will be administered as follows:~(i) subjects will be asked in which position they felt the phantom limb; (ii) they will be asked to place the intact limb in the same position as they felt their phantom limb; (iii) they will be asked to move both limbs in the opposite direction; (iv) they will be then asked to return to the starting position again."|t|f|f|f
33846771|NCT04306406|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33846772|NCT04184232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846773|NCT06084923|||CASE_ONLY||PROSPECTIVE|||||||
33846774|NCT00410982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846775|NCT00760474|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33846776|NCT03033225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846777|NCT01635777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846778|NCT04469127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846779|NCT04716335|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33846780|NCT00169377|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33846781|NCT03319849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects and all personnel at the image reading center remained masked to the treatment assignment throughout the study. In addition, the refractionist, VA examiner, and photographers/imagers were masked to treatment assignment (NT-501 implantation or sham procedure) at all follow-up visits. The ophthalmologist, surgeon, and clinic coordinator were instructed not to discuss the assigned treatment with the subject.|After confirming eligibility in conjunction with the reading center, the study eye of each subject was randomized (1:1) to either have NT-501 implanted or to undergo the sham procedure.|t|f|f|t
33846782|NCT05880745|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||age-gender matched patient and healthy groups||||
33846783|NCT05922254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846784|NCT06088459|NA|SEQUENTIAL||TREATMENT||NONE||"This study is divided into three dose groups climbed from low-dose group to high-dose group in turn according to the 3+3 dose escalation principle.~Three dose groups were preset in this study: dose group 1 and low-dose group \[a single dose of 1mg was administered three times at week 0, 4 and 8, respectively, with cumulative administration of 3mg\]; Dose group 2, middle-dose group \[single dose of 4mg, administered 3 times at week 0, 4, 8, respectively, cumulative administration of 12mg\]; Dose group 3, high-dose group \[a single dose of 8mg, administered at week 0, 4 and 8, a total of 3 times, cumulative administration of 24mg\].~After the completion of treatment, the subjects shall continue to receive safety follow-up until 28 days after the last administration."||||
33846785|NCT00110877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846786|NCT04076787|||COHORT||RETROSPECTIVE|||||||
33846787|NCT03789838|||COHORT||PROSPECTIVE|||||||
33846788|NCT04468945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846789|NCT03988244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846790|NCT01657786|NA|SINGLE_GROUP||||NONE||||||
33846791|NCT05292092|||COHORT||PROSPECTIVE|||||||
33846792|NCT01094938|||OTHER||OTHER|||||||
33846793|NCT01272128|||COHORT||PROSPECTIVE|||||||
33846794|NCT03939559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Home exercise training and assessments will be provided by different physiotherapists. The evaluator physiotherapist will be blind to the treatment group to which the patient belongs|Patients who meet the inclusion criteria of the study will be included in the study and will be randomized into two groups.|f|f|f|t
33846795|NCT04318613|||CASE_ONLY||CROSS_SECTIONAL|||||||
33846796|NCT02007915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846797|NCT02822859|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33846798|NCT05003427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846799|NCT03100877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846800|NCT01004055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846801|NCT04479267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846802|NCT04518332|||CASE_ONLY||PROSPECTIVE|||||||
33846803|NCT01308138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33846804|NCT02741323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846805|NCT03438877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846806|NCT02703064|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||open level||||
33846807|NCT01102621|||CASE_CONTROL||PROSPECTIVE|||||||
33846808|NCT05444868|||OTHER||OTHER|||||||
33846809|NCT03141697|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33846810|NCT06150274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846811|NCT03802604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846812|NCT04261192|||COHORT||PROSPECTIVE|||||||
33846813|NCT04421846|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846814|NCT04212520|||COHORT||PROSPECTIVE|||||||
33846815|NCT02002793|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33951838|NCT06212609|NA|SINGLE_GROUP||OTHER||NONE||||||
33951839|NCT04330066|||COHORT||PROSPECTIVE|||||||
33951840|NCT04953039|||COHORT||PROSPECTIVE|||||||
33951841|NCT06578078|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomised clinical trial, multicentre, open label, of RAASi associated with SZC versus modification of RAASi without added chelator in patients over 70 years of age, who after the stabilization of an acute HF episode and comorbid CKD, have HK or are at high risk of developing HK.||||
34160425|NCT02773485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160426|NCT00567359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160427|NCT04079816|NA|SINGLE_GROUP||OTHER||NONE||||||
34160428|NCT02728089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160429|NCT04417335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||placebo-controlled adaptive multi-centre randomized controlled trial|t|f|f|f
34160430|NCT05536687|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160431|NCT05322720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160432|NCT01354925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160433|NCT04917965|||COHORT||PROSPECTIVE|||||||
34160434|NCT03753412|||COHORT||PROSPECTIVE|||||||
33743623|NCT01679535|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743624|NCT06184698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951842|NCT00698009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951843|NCT05880069|||OTHER||OTHER|||||||
33951844|NCT00908362|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33951845|NCT00341627|||FAMILY_BASED||RETROSPECTIVE|||||||
33951846|NCT02800317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743625|NCT04442555|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33743626|NCT06175819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The intervention of each group|Prospective interventional randomized clinical trial|t|f|f|f
33951847|NCT05803876|||CASE_ONLY||PROSPECTIVE|||||||
33951848|NCT00852267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33951849|NCT05292248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951850|NCT00101374||||TREATMENT||||||||
34160435|NCT01068899|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34160436|NCT00274963|NON_RANDOMIZED|||TREATMENT||||||||
34160437|NCT02674347|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34160438|NCT03565016|||COHORT||PROSPECTIVE|||||||
34160439|NCT03671304|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This project will enroll 50 participants receiving treatment for RCC in an eight-week study. Using a microrandomized design, participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.||||
33743627|NCT01640158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743628|NCT06635564|||COHORT||PROSPECTIVE|||||||
33743629|NCT04616651|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34160440|NCT01149720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160441|NCT05564312|||COHORT||PROSPECTIVE|||||||
34160442|NCT00781833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160443|NCT06267222|NA|SINGLE_GROUP||TREATMENT||NONE|THE INVESTIGATOR NOT BE INFORMED ABOUT THE TREATMENT|This is a pragmatic clinical trial that will be carried out using the CONSORT-Pragmatic Trials (Zwarenstein et al., 2008).||||
34160444|NCT00273429|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33846816|NCT06139497|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33846817|NCT02405403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846818|NCT02919930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743630|NCT00354354|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33743631|NCT05203419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743632|NCT02089776|||||PROSPECTIVE|||||||
33743633|NCT01299493|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33743634|NCT04026100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743635|NCT00297817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33743636|NCT01318889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743637|NCT03207529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743638|NCT05124457|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization to receive either insulin NPH or insulin detemir||||
33743639|NCT03697785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33743640|NCT06403592|||COHORT||PROSPECTIVE|||||||
33743641|NCT05990062|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The protocol consists of three phases with iterative design and development process involving input from Veterans with disabilities at various stages. In addition, 5 certified Prosthetists with at least five years of experience working with Veterans with transradial arm amputations will also be recruited to provide guidance and to assist with the design and development of the K-Socket Harness (KSH).||||
33743642|NCT02311179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743643|NCT05877001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743644|NCT01600300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743645|NCT01263743|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743646|NCT00918294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743647|NCT02621606|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743648|NCT06262035|||COHORT||CROSS_SECTIONAL|||||||
33743649|NCT03737370|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33743650|NCT05348681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743651|NCT05669391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33743652|NCT00127959|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743653|NCT01133652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743654|NCT02699281|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33743655|NCT02397395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743656|NCT04283929|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846819|NCT01636232|||CASE_CONTROL||PROSPECTIVE|||||||
33951851|NCT01148875|||COHORT||PROSPECTIVE|||||||
33743657|NCT02221115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33743658|NCT00233935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33743659|NCT00901290|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33951852|NCT05557526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34160445|NCT06457711|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Collaborative consultation encouraged patients to participate. Patient can choose their group of intervention. Dietary regimen were tailored on each patient: the intervention was adapted to patients' needs and to their body composition.|The investigators enrolled 50 patient to divide in 20 patients in the KD group, 20 in the IF group and 10 in the FD. Seven patients dropped out from their assigned groups as follows: FD (n = 2), IF (n = 3), and KD (n = 2).||||
34160446|NCT06209502|||CASE_CONTROL||PROSPECTIVE|||||||
34160447|NCT02410239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160448|NCT02016079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160449|NCT00666406|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160450|NCT02191332|||COHORT||PROSPECTIVE|||||||
33743660|NCT00323102|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33743661|NCT00775749|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33743662|NCT01391104|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33743663|NCT04307823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743664|NCT03870763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743665|NCT00993447|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33743666|NCT06266923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743667|NCT01579344|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33743668|NCT02235597|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34160451|NCT04104776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160452|NCT03562312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743669|NCT04700306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743670|NCT02600130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743671|NCT01691300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743672|NCT06533241|||OTHER||RETROSPECTIVE|||||||
33743673|NCT01156701|||FAMILY_BASED||RETROSPECTIVE|||||||
33743674|NCT03354676|||COHORT||CROSS_SECTIONAL|||||||
33743675|NCT00974168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743676|NCT04622358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743677|NCT03021382|||COHORT||RETROSPECTIVE|||||||
33743678|NCT00982670|||CASE_CONTROL||PROSPECTIVE|||||||
33743679|NCT03750487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743680|NCT00567827|||COHORT||PROSPECTIVE|||||||
33743681|NCT04880551|||CASE_ONLY||PROSPECTIVE|||||||
33743682|NCT01203189|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33846820|NCT04104828|||OTHER||PROSPECTIVE|||||||
33846821|NCT05830227|||COHORT||PROSPECTIVE|||||||
33846822|NCT01940068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33846823|NCT05600686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846824|NCT04165876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"The stimulation protocol is blinded and randomized using the software's double-blinding function.~The subjects are randomly assigned to one of four groups receiving the corresponding stimulation protocol. One of which is a sham-stimulation (placebo), that imitates the experience of real stimulation."|Longitudinal, sham-controlled, parallel groups design.|t|t|t|t
33846825|NCT05930886|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33846826|NCT03210545|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blinded||t|f|t|f
33846827|NCT05116813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056353|NCT05177926|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single arm study, in which all participants will receive study drug.||||
34056354|NCT05616117|||COHORT||PROSPECTIVE|||||||
34056355|NCT01217385|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743683|NCT02855905|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743684|NCT00985218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743685|NCT01223313|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743686|NCT02167633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743687|NCT06099171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743688|NCT01308580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743689|NCT06182865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056356|NCT03195647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056357|NCT02814227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056358|NCT03862430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056359|NCT03706859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056360|NCT01222754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056361|NCT04930042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056362|NCT05745207|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34056363|NCT06514755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the specific nature of the interventions, it may not be possible to blind participants or operators; however, to minimize potential bias, outcome assessors will be blinded to the treatment assignments.|Participants will be randomly assigned to one of two groups: one undergoing sequential genicular nerve ablation (GNA) followed by geniculate artery embolization (GAE), and the other receiving GAE alone.|f|f|f|t
34160453|NCT03845647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34056364|NCT03737500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160454|NCT04152915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160455|NCT04468841|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a non-therapeutic protocol. The intervention in this study will involve collection of a standard-of-care pre-treatment tumor biopsy (archival tissue, if available) to identify the tumor-specific s cfDNA signature.||||
34160456|NCT05045300|||COHORT||RETROSPECTIVE|||||||
34160457|NCT01740414|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34160458|NCT01323868|||COHORT||PROSPECTIVE|||||||
34160459|NCT02744638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34160460|NCT01427933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160461|NCT04141540|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||It's a study with a comparative monocentric cross-sectional analysis model.||||
34160462|NCT00542607|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33743690|NCT01623076|||COHORT||PROSPECTIVE|||||||
33743691|NCT03600285|NA|SINGLE_GROUP||OTHER||NONE||||||
33743692|NCT02449538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056365|NCT06607835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study phase is not applicable as whilst cannabis suppositories are part of this research study, participants are not randomised into cannabis groups. Participants would already be using cannabis suppositories for at least one month and are used as part of the individuals sexual intimacy.~Randomisation was based on whether participants were using cannabis suppositories and consisted of one of four groups, including a cannabis suppository-only group, mindful- compassion only group, a combined mindful-compassion and cannabis suppository group and a care-as-usual group"||||
34056366|NCT03916367|||COHORT||RETROSPECTIVE|||||||
34056367|NCT06509750|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34160463|NCT01651871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160464|NCT03420274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This will be a cluster randomized trial examining a shared decision-making intervention.|f|f|f|t
34160465|NCT04459520|RANDOMIZED|PARALLEL||SCREENING||NONE|Open label (participants will be randomized to receive different scenarios, but will not be aware of the other two scenario types)|Parallel 3-arm, cross-sectional, behavioral intervention study||||
33743693|NCT02078115|||COHORT||PROSPECTIVE|||||||
33743694|NCT03934502|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33743695|NCT02802345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743696|NCT02093299|||COHORT||PROSPECTIVE|||||||
33846828|NCT03928639|||COHORT||PROSPECTIVE|||||||
33846829|NCT04183439|||OTHER||OTHER|||||||
33846830|NCT03689959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951853|NCT03856502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951854|NCT03057769|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33951855|NCT00186173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951856|NCT04300049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single arm before and after glucagon vs. saline||||
33951857|NCT06391047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants were randomly allocated to both groups and they did not know which one was experimental or control group.|It was a randomized controlled trial with two groups. One group was experimental while other group was active control group.|t|f|f|f
33846831|NCT03009825|||COHORT||CROSS_SECTIONAL|||||||
33846832|NCT02793388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846833|NCT05303701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846834|NCT04963452|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33951858|NCT00077870||||TREATMENT||||||||
33846835|NCT05108545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846836|NCT04127708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846837|NCT05302492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951859|NCT02557191|||COHORT||PROSPECTIVE|||||||
33951860|NCT04108416|||CASE_ONLY||RETROSPECTIVE|||||||
33846838|NCT00171808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846839|NCT02296333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33846840|NCT03534284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator, the participant, and the care provider will be blinded to the drug assignment (trazodone vs. placebo) for those subjects randomized into the medication intervention arm.|SLEEP-HD is a parallel group randomized controlled trial wherein 125 HD patients with chronic insomnia, treated in community-based dialysis facilities in Seattle and Albuquerque, will be randomized 1:1:1 over 31 months to 6-week treatment with telehealth CBT-I, trazodone, or medication placebo.|t|t|t|f
33846841|NCT01549938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33846842|NCT02064348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846843|NCT02822105|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846844|NCT02943291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846845|NCT06147908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056368|NCT03796819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients would not be told about the lymphadenectomy|routine hepatoduodenal lymphadenectomy|t|f|f|t
34056369|NCT05212688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Acupuncture vs Control||||
34056370|NCT06619925|||COHORT||PROSPECTIVE|||||||
33846846|NCT04472000|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|All study participants and trial personnel but the persons generating the randomization list and preparing the blinded drug packs at the Inselapotheke and Spitalapotheke Lindenhof will be blinded to the assigned treatment. Blinding will be upheld until all analyses are completed. Vitamin C and placebo will be provided in identical looking capsules in drug packs, which will also look identical except for the consecutive code number which is unique on each pack.|"Participants will be randomly allocated to the two treatment arms, vitamin C or placebo, in a 1:1 ratio. The randomisation will be stratified by type of surgery performed. Allocation will be concealed using sequentially coded drug packs that are otherwise identical. Drug packs will be coded as 01-01 to 01-50 for stratum 1, 02-01 to 02-50 for stratum 2, 03-01 to 03-50 for stratum 3, and 04-01 to 04-50 for stratum 4.~The 4 strata differ in the type of operation performed:~1. Rotator cuff surgery with resection of the acromioclavicular joint~2. Rotator cuff surgery without resection of the acromioclavicular joint~3. Shoulder arthroscopy with resection of the acromioclavicular joint~4. Shoulder arthroscopy without resection of the acromioclavicular joint Vitamin C will be administered orally at 1000 mg/day (500 mg b.i.d.) for 50 days post surgery."|t|t|t|f
33846847|NCT00700492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951861|NCT03372265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients and outcome assessors will be blinded to the delivery administrations. Investigators will not be present while programming of the infusion pump is taking place. The display of the infusion pump will be concealed at all times after initiation. Furthermore, throughout the trial, the infusion pump will be concealed from the patient through a non-transparent bag. Trial interventions will not be visible in electronic patient charts. The infusion pump is making a discrete noise when administering medications. To make sure that the PCA group and the continuous infusion group is blinded to interventions, a sham administration is activated every 10th hour. This sham administration will be 0.1 mL of ropivacaine 0.2%. Such a small dose of LA will not have any anesthetic effect nor pose a risk for the patient.|3 arms (API, CI and PCA only)|t|t|t|t
33743697|NCT06370637|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|A total of 40 patients will be enrolled in the study. If the patient agrees to participate and written consent is given to participate, the research coordinator will assess the eligibility criteria of the patient based on the inclusion and exclusion criteria. Participants will be provided 2x2cm patch test on the forearm to test for contact dermatitis to the cream D after obtaining consent. Participants do not react to the Cream D will be randomized. Participants who react will be excluded from the study. The research coordinator will have a list for arm 1 and arm 2 where the code for the participant enrolled will be entered daily. The first participants to be enrolled on any given day will be assigned to arm 1, and the second patient to arm 2. The research coordinator will have 40 envelopes with the protocols coded with arm 1 or arm 2, and cream containers also coded with arm 1 and arm 2.|The aim of this study is to evaluate the efficacy and safety of a plant extract incorporated into a standard barrier in the treatment of MASD from diarrhea and/or fecal incontinence. The goal of this research is to conduct an open-label outpatient study of this novel cream in a population with MASD secondary to diarrhea and/or fecal incontinence.|t|f|f|f
33743698|NCT00850616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33743699|NCT03556657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743700|NCT01389973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743701|NCT01448746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33743702|NCT04950101|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33743703|NCT04744363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded and unblinded site teams|A Phase 1, first-in-human, randomized, double-blind, single-dose, parallel-group, 3-arm study comparing the pharmacokinetic, safety, tolerability, and immunogenicity profiles of AVT04, EU approved Stelara®, and US licensed Stelara® in healthy adult subjects|f|f|t|f
33743704|NCT02845908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743705|NCT01404494|||||PROSPECTIVE|||||||
33743706|NCT05826236|||COHORT||CROSS_SECTIONAL|||||||
33743707|NCT06173219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160466|NCT06311422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160467|NCT05645523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160468|NCT00230841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34160469|NCT04504838|||COHORT||PROSPECTIVE|||||||
34160470|NCT02391363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160471|NCT06189924|||COHORT||PROSPECTIVE|||||||
34160472|NCT02618044|||COHORT||PROSPECTIVE|||||||
34160473|NCT00917761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160474|NCT01884896|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160475|NCT03979859|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34160476|NCT00038064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160477|NCT03893032|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34160478|NCT01991236|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160479|NCT00214513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160480|NCT04340544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160481|NCT05771740|||CASE_CONTROL||PROSPECTIVE|||||||
34160482|NCT00880295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160483|NCT04561908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, single-center, randomized, controlled study|t|f|f|f
34160484|NCT01944540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160485|NCT02907684|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34160486|NCT01222780||SEQUENTIAL||TREATMENT||NONE||Phase 1 Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo® (Vincristine Sulphate Liposomes Injection) in Children and Adolescents with Refractory Cancer||||
34160487|NCT05696886|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group A received Pethidine alone in the period between January 2021 and December 2021, while Group B got Tramadol with pethidine in the period between January 2022 and December 2022. Doses were based on the patient's actual body weight.|Group A received Pethidine alone in the period between January 2021 and December 2021, while Group B got Tramadol with pethidine in the period between January 2022 and December 2022. Doses were based on the patient's actual body weight.|t|f|f|f
34160488|NCT00412243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160489|NCT01068002|||COHORT||PROSPECTIVE|||||||
33743708|NCT06238323|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33743709|NCT01760954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743710|NCT01430494|||COHORT||PROSPECTIVE|||||||
33743711|NCT03399760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One blinded|"Two Arms injectable platelet rich fibrin group: consisted of two subgroups~* Experimental group : injectable platelet rich fibrin assisted upper canine retraction~* Control group: conventional upper canine retraction"|f|f|f|t
33743712|NCT00781560|||||PROSPECTIVE|||||||
33743713|NCT06365736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743714|NCT06535438|||COHORT||RETROSPECTIVE|||||||
33743715|NCT02277080|||OTHER||PROSPECTIVE|||||||
33743716|NCT01075074|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33743717|NCT01108640|||COHORT||PROSPECTIVE|||||||
33743718|NCT00970151|||COHORT||PROSPECTIVE|||||||
33743719|NCT02945865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743720|NCT05637463|||OTHER||CROSS_SECTIONAL|||||||
33743721|NCT04393701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743722|NCT00395044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33743723|NCT04388982|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33743724|NCT02286544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160490|NCT01487265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160491|NCT01504412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160492|NCT05456984|||CASE_ONLY||CROSS_SECTIONAL|||||||
34160493|NCT03742583|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33743725|NCT04517721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will receive same care at the pre-discharge phase. However in the post-discharge phase where participants are not likely to interact with each other, persons in the control group will continue to receive the usual care whilst persons in the treatment group receives the new intervention. The assigned group of participants will not be disclosed to the outcome assessors.|Eligible participants will be randomised to either the control or intervention groups with the former receiving the existing care at the hospital and the latter receiving the both the new intervention and existing standard of care.|t|f|f|t
33743726|NCT06170333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056371|NCT00290134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34056372|NCT05930028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056373|NCT00260598|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34056374|NCT06424990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056375|NCT05540041|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
34056376|NCT02224027|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34056377|NCT06401226|||OTHER||PROSPECTIVE|||||||
34056378|NCT06620718|NA|SINGLE_GROUP||TREATMENT||NONE|measurement the distance of root migration at sixth month|A total of 78 patients were initially included in the study, but five patients were excluded from the study due to their failure to attend regular follow-up visit, resulting in a final analysis of 73 patients (Figure 1). These patients were divided into two age groups: The first group, consisting of patients aged 18-30, included 17 males and 23 females. The second group, consisting of patients aged 31-55, included 17 males and 16 females.||||
34056379|NCT00288600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34056380|NCT05637775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors performing clinical evaluation and data analysts will be blinded to patient allocation.|Eligible subacute cervical SCI patients admitted to Fondazione Santa Lucia Hospital for standard rehabilitation care will be randomized in equal proportions (1:1 ratio) between BCI-assisted MI training- EXP) and Control (MI without BCI - CTRL).|f|f|f|t
34056381|NCT06514703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this randomized controlled trial, a partial blinding strategy is employed where only the outcomes assessors are blinded to intervention group assignments. Given the distinct nature of the CT-guided and fluoroscopic-guided procedures, it is impractical to blind participants and care providers. Operators performing the ablation and participants will be aware of the imaging technique used. However, to ensure unbiased evaluation of clinical outcomes, outcomes assessors will not know participants' group assignments. This measure is crucial for preventing observer bias in assessing primary and secondary outcomes such as pain relief, functional improvement, and patient satisfaction.||f|f|f|t
34056382|NCT06665217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056383|NCT06648044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056384|NCT05769868|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33743727|NCT03876041|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743728|NCT00737841|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33743729|NCT06526572|||CASE_ONLY||PROSPECTIVE|||||||
33743730|NCT06381908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is labelled as a single-blinded study because the investigators are blinded to the group allocation (the group allocation and diet handling is managed by a researcher not involved in other aspects of the data collection or processing). The participants are not informed about their allocated condition, however, it is conceivably possible for them to recognize this based on the food provided. However, the direction of the hypothesis will not be evident to the participants. Moreover, we include questionnaires before the post-tests related to their perceived diet allocation and their perception of the effect of the diet on the test assessments.|The study is performed as a randomized single-blinded parallel group design. Randomization is performed into two groups using minimization based on a predetermined estimated VO2max middle value of 30.|f|t|t|t
33743731|NCT06025331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and health personnel examining the participants will be blinded. It will not be possible to blind the surgeons due to the nature of the intervention.||t|f|f|t
33743732|NCT04519840|||OTHER||CROSS_SECTIONAL|||||||
33743733|NCT04036916|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743734|NCT01851057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743735|NCT04532697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All the participants, outcome assessors and the investigator are all masked, only the staff preparing the study product know the treatment arm.|All patients will recruited in parallel.|t|t|t|t
33743736|NCT03787667|||COHORT||PROSPECTIVE|||||||
33743737|NCT04890340|||CASE_CONTROL||PROSPECTIVE|||||||
33743738|NCT02052349|NA|SINGLE_GROUP||||NONE||||||
34056385|NCT06405789|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|A random allocation sequence was generated by an off-site statistician who was not involved in the participants' interventions. The statistician was given a class list of 69 people and asked to randomly assign them to groups A and B. The statistician did not know what A and B meant.|A randomized controlled design with intervention and control groups.|f|f|f|t
34056386|NCT06506019|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive a single dose of orally administered 25mg of psilocybin taken in conjunction with supportive therapy.||||
34056387|NCT01239212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056388|NCT01396096|||CASE_ONLY||PROSPECTIVE|||||||
34056389|NCT04319627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056390|NCT02888392|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34056391|NCT06538740|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"This study is a single blinded, randomized, trial comparing two study groups (intervention and control)"|t|f|f|f
34056392|NCT01311518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056393|NCT05923866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056394|NCT05874375|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056395|NCT06624124|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056396|NCT03729570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056397|NCT04553640|RANDOMIZED|CROSSOVER||OTHER||NONE||"Phase 1: A stratified randomized controlled delayed intervention trial to assess the effectiveness of the intervention relative to a control condition. Participants will undergo a pretest \& then stratified randomization to groups A or B (depending on clinical experience). Participants in group A will be exposed to the intervention (virtual patient curriculum + Feedback) and participants in group B will be exposed to the control (Online articles on dizziness and traditional ED residency training). The groups will then reverse so that now group B is exposed to the intervention. Outcomes will be measured for all participants at T0 (pretest), T1 (crossover point), and T2 (intervention end).~Phase 2: This will be a non-randomized study between intervention group (those ED providers who participated in our curriculum) vs. new control group (matched ED providers who did not participate in our curriculum)."||||
34056398|NCT06649513|||CASE_ONLY||PROSPECTIVE|||||||
34056399|NCT03768440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34056400|NCT06648187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056401|NCT05245721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34056402|NCT06179017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Endpoint-blined|Intervention group: Endovascular treatment Control group:Best medical treatment|f|f|f|t
34056403|NCT04943302|NA|SEQUENTIAL||TREATMENT||NONE||Phase II, non-randomized, single institution study using a two-stage Simon optimal design. There will first be a safety run-in of 6 patients who will be evaluated for toxicity in cycle 1. Unexpected toxicities will trigger an early safety interim analysis to ensure the regimen is tolerable. In the first stage, 19 patients, including the 6 patients in the safety run-in, will be accrued. If 6 or fewer of these 19 patients achieves hematologic PR, the study will be stopped. Otherwise, up to 20 additional patients will be accrued for a maximum of 39 patients.||||
34056404|NCT04511962|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34056405|NCT06619054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160494|NCT05819697|||COHORT||PROSPECTIVE|||||||
34160495|NCT02977858|||CASE_CONTROL||PROSPECTIVE|||||||
34160496|NCT00334243|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160497|NCT03890744|NA|SINGLE_GROUP||TREATMENT||NONE||14 evaluable patients will be treated in the first stage (Stage A) of this Simon two-stage minimax designed trial. If 0 or ≥ 2 objective responses at week 8 (with confirmation at week 12) are observed in Stage A, no further patients will be enrolled. If 1 objective response is observed, an additional 10 patients with recurrent or metastatic HER-2 negative breast cancer will be included in the second stage (Stage B).||||
34160498|NCT06366841|||COHORT||PROSPECTIVE|||||||
34160499|NCT05547568|||COHORT||RETROSPECTIVE|||||||
34160500|NCT02150915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951862|NCT06041100|NA|SINGLE_GROUP||PREVENTION||NONE||"All participants will complete three test sessions:~1. An initial assessment (baseline)~2. A 4-week assessment and~3. A 12-week assessment.~4. Around 8-10 participants will be invited for a follow-up assessment 6-weeks post after the trial has ended.~All participants will be instructed to wear the device 30 minutes daily during moderate to intensive physical activities. They will be required to provide a weekly overview of their usage and experience with the device."||||
33951863|NCT02253849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160501|NCT03132701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34160502|NCT06298786|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34160503|NCT01485328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34160504|NCT02837185|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34160505|NCT05476016|NA|SINGLE_GROUP||SCREENING||NONE||Screening among individuals with or without known diabetes||||
34160506|NCT03483493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34160507|NCT04364360|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group intervention||||
34160508|NCT03106636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160509|NCT01063153|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34160510|NCT05954000|RANDOMIZED|SEQUENTIAL||OTHER||NONE||The study utilizes a modified Time-To-Event Continual Reassessment Method Dose-Finding Design||||
34160511|NCT05476172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160512|NCT06072417|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Patients living permanently \>2500m around Quito (Equador) will be assessed at 2840m and after relocation to sea level||||
34160513|NCT01229306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160514|NCT02211248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160515|NCT04966949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160516|NCT03906539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160517|NCT02836405|||COHORT||CROSS_SECTIONAL|||||||
34160518|NCT02536924|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34160519|NCT00350844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160520|NCT03081650|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be conducted as an open label, non-randomized trial.||||
34160521|NCT00791089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160522|NCT01242605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160523|NCT04375345|||OTHER||RETROSPECTIVE|||||||
34160524|NCT05982886|||COHORT||RETROSPECTIVE|||||||
34160525|NCT05511571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160526|NCT02380911|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34160527|NCT00278746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160528|NCT03977766|NA|SINGLE_GROUP||OTHER||NONE||||||
34160529|NCT03948841|||OTHER||CROSS_SECTIONAL|||||||
34160530|NCT02564185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160531|NCT04030793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34160532|NCT02352753|NA|SEQUENTIAL||TREATMENT||NONE||||||
34160533|NCT02533492|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160534|NCT06284083|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||The study group consisted of 90 newly diagnosed OSAS patients who were admitted to the Clinic for Chest Diseases of the Research and Practice Hospital of Sivas Cumhuriyet University Faculty of Medicine. For the definitive diagnosis of OSAS, the patients were hospitalized overnight in the Sleep Center and polysomnography test was performed. OSAS patients, who were randomly selected without discrimination in terms of age and gender, were connected to the PSG device for one night and various measurements were taken and the values were recorded. The apnea/hypopnea index (AHI) was defined as the sum of the apnea and hypopnea number per hour of sleep. Volunteer patients were grouped into three based on apnea-hypopnea index (AHI) scores: mild OSAS (n=30; 5 ≤ AHI ≤ 13.70), moderate (n=30; 15.80 ≤ AHI ≤ 26.60) and severe (n=30; 34.10 ≤ AHI ≤ 86.30). The mean SpO2 percentages of the PSG device were measured from the fingertip with a system-defined pulse oximeter.|t|f|t|t
34160535|NCT03700567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160536|NCT02648568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160537|NCT01919801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34160538|NCT05385003|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160539|NCT05501717|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34160540|NCT01930838|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34160541|NCT05581069|NA|SINGLE_GROUP||TREATMENT||NONE|The assessment battery is multi-modal and includes evaluation by an independent evaluator (IE) who is uninvolved in STEPS delivery or training.|This is a single-arm (non-randomized) trial in which providers are community-based practitioners.||||
33743739|NCT04097132|||COHORT||PROSPECTIVE|||||||
33743740|NCT06114693|||COHORT||PROSPECTIVE|||||||
33743741|NCT04665856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743742|NCT05799495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743743|NCT02584049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951864|NCT02948530|||CASE_CROSSOVER||PROSPECTIVE|||||||
34160542|NCT06127719|||COHORT||PROSPECTIVE|||||||
34160543|NCT04255589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160544|NCT05505864|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34160545|NCT06209827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data collector was not involved in outcomes assessment.|cluster-randomized, parallel-group trial in which health centres were the units of randomization and patients were the units of analysis|f|f|f|t
34160546|NCT05564039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160547|NCT00942825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160548|NCT04521244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160549|NCT01210898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160550|NCT02003170|||CASE_CONTROL||PROSPECTIVE|||||||
34160551|NCT03570541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160552|NCT03056339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160553|NCT04852939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160554|NCT03939975|NA|SINGLE_GROUP||TREATMENT||NONE||The study subjects were those who with advanced HCC that progressed on first-line sorafenib and treated with anti-PD-1 therapy in combination with incomplete thermal ablation.||||
34160555|NCT04523337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants conducting the 6- and 15-month outcome assessments are blinded to the condition assignment.||f|f|f|t
34160556|NCT05873972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160557|NCT01060696|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34160558|NCT02450513|||COHORT||PROSPECTIVE|||||||
34160559|NCT04910035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Outcomes Assessor)||f|f|f|t
34160560|NCT05118698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160561|NCT03566082|||COHORT||PROSPECTIVE|||||||
34160562|NCT00005030|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160563|NCT01240278|||COHORT||PROSPECTIVE|||||||
34160564|NCT03058900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind||t|t|f|t
34160565|NCT06496880|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, Double Blind, Placebo-controlled, Parallel Group|t|t|t|t
34160566|NCT02152761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, interventional, multicenter, placebo-controlled, phase IIa/IIb trial in patients|t|t|t|t
34160567|NCT01279603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160568|NCT02152176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160569|NCT01302028|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34160570|NCT03694431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization of registered nurses stratified by site (n=15) to either standard or tech-supported HBPC||||
34160571|NCT04921904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160572|NCT00660179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160573|NCT02454777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160574|NCT02181283|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34160575|NCT03852667|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The leading investigators, as well as the outcome assessors are masked and do not know to which arm the subjects are allocated to.|The randomization schedule was extracted from the website www.sealedenvelope.com . The randomization was expected to have the same amount of one gender in each group. The control group was group A, the group that only received PNE was group B and the group who received PNE and exercise therapy was group C.|f|f|t|t
34160576|NCT00978146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160577|NCT01849094|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160578|NCT04482582|RANDOMIZED|PARALLEL||TREATMENT||NONE||We are proposing a prospective, randomized trial evaluating efficacy of image-guided percutaneous intercostal cryoneurolysis (pICN) for pain control after traumatic rib fractures in persons \>=65 years. Eligible patients would be enrolled by the trauma service after consent or assent is obtained. Patients will be randomized to either pICN within 72 hours of presentation or existing standard-of-care.||||
33743744|NCT06535061|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||After the newborns left intubation in the postoperative period, physical parameters were measured before, during, after venous blood collection, before, during, after heel blood collection, and before, during and after intravenous intervention, and were evaluated with the Neonatal Infant Pain Scale (NIPS).||||
33951865|NCT03588312|||CASE_ONLY||RETROSPECTIVE|||||||
34160579|NCT05274269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160580|NCT02302872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743745|NCT05140278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160581|NCT06584240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|JHM03 and Placebo|t|t|t|t
34160582|NCT05266677|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34160583|NCT02159976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160584|NCT02501499|||CASE_ONLY||RETROSPECTIVE|||||||
34160585|NCT02024139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34160586|NCT00654082|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34160587|NCT02699567|||CASE_CONTROL||PROSPECTIVE|||||||
34160588|NCT03676244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160589|NCT03045718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160590|NCT04402723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34160591|NCT02694900|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160592|NCT04361578|||COHORT||PROSPECTIVE|||||||
34160593|NCT00133042|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34160594|NCT00003811||||TREATMENT||||||||
34160595|NCT05318404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160596|NCT01455896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160597|NCT02930902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160598|NCT03312842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160599|NCT01423292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160600|NCT03145259|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The same 12 volunteers received all treatments in three separate study arms.||||
34160601|NCT04756648|NA|SEQUENTIAL||TREATMENT||NONE||||||
34160602|NCT04090242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160603|NCT05492097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled study||||
34160604|NCT00104650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160605|NCT05034419|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34160606|NCT04888754|||COHORT||PROSPECTIVE|||||||
34160607|NCT06421571|||OTHER||PROSPECTIVE|||||||
34160608|NCT00227227|||||PROSPECTIVE|||||||
34160609|NCT05733052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743746|NCT04561570|||COHORT||PROSPECTIVE|||||||
33743747|NCT01205685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160610|NCT00481923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743748|NCT02405715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160611|NCT04304872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34160612|NCT00123175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160613|NCT00903435|||CASE_CONTROL||PROSPECTIVE|||||||
34160614|NCT01564147|RANDOMIZED|PARALLEL||||NONE||||||
34160615|NCT05632302|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160616|NCT05411289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34160617|NCT05711823|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor do not know which patients received antiemetic therapy.|Aprepitant in combination with Granisetron and dexamethasone|f|f|f|t
34160618|NCT02932748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160619|NCT04168099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33951866|NCT03903575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All 32 patients will be randomly allocated in a 1:1 ratio to either en masse (n=16) group or the two-step anterior retraction (n=16) group.|f|f|f|t
33951867|NCT02665858|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34160620|NCT05624073|||COHORT||PROSPECTIVE|||||||
34160621|NCT03933761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160622|NCT03156283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34160623|NCT06288737|||CASE_CROSSOVER||PROSPECTIVE|||||||
34160624|NCT03454607|NA|SINGLE_GROUP||OTHER||NONE||||||
34160625|NCT03749720|NA|SINGLE_GROUP||PREVENTION||NONE||Case-control study with 141 case patients newly diagnosed cervical cancer and a control group of 10 healthy women with no prior cervical dysplasia and 25 women with cervical dysplasia (CIN3), respectively.||||
34160626|NCT06236685|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study will be conducted on patients provided with mechanical ventilation either on intensive care units or during anesthesia. Extended monitoring of ventilation, including electric impedance tomography and esophageal pressure readings will be applied.||||
34160627|NCT05033236|||COHORT||PROSPECTIVE|||||||
34160628|NCT04776512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34160629|NCT00004030||||TREATMENT||||||||
34160630|NCT03503760|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Participant and care provider were unaware of the treatment as the machine does not make any sound or heat during the session. Only the nurse that physically connect the cable to the generator knows if the patient recieve or not the therapy but she was not involved in clinical evaluation.|"Patients have been randomized in two groups using Research randomizer avaliable at www.randomizer.org.~The first group of patients true-sham received 6 twice a week sessions of true ELF therapy of one hour with LIMFA Therapy®, following the antinflammatory, analgesic and biorhythm settings of the device. Then, after a wash-out period (three weeks), it received the sham therapy (no therapy) twice a week for three weeks.~The second group sham-true received 6 twice a week sessions of sham therapy (no therapy) and then, after the wash-out period (three weeks), it received 6 session of true ELF therapy twice a week for three weeks.~A set of questionnaires were administrated: before first session, after first session, after the wash-out period, after second session and after three week follow-up in both groups."|t|t|f|f
34160631|NCT05426278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||2 groups will be made - One group will be interventional and the Other will be the Control group|t|f|f|f
34160632|NCT01524146|||CASE_ONLY||PROSPECTIVE|||||||
34160633|NCT02500953|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34160634|NCT05791227|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Measurements shown in Picture Archiving and Communication System (PACS) without direct communication between sonographer and cardiologist. Annotations are shown without identifiers on how the annotations were done. Cardiologists are blinded to source of preliminary interpretation.|Studies will be randomized 1:1 to either sonographer preliminary report finding or AI preliminary report finding with final adjudication by the cardiologist. With AI preliminary report, the preliminary interpretations will be generated by AI (artificial intelligence) technology \[a semantic segmentation model\] and the PACS system's native reporting workflow will be used visualize measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd). The study team will assess how much cardiologists edit and change this preliminary interpretation is from the final interpretation.|t|t|t|f
34160635|NCT00206440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160636|NCT05678634|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160637|NCT02749565|||COHORT||PROSPECTIVE|||||||
34160638|NCT02989883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160639|NCT03566706|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34160640|NCT00126776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160641|NCT05535413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160642|NCT00434109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160643|NCT02913378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160644|NCT01843023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160645|NCT00972530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160646|NCT02214290|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33951868|NCT01321528|||CASE_ONLY||PROSPECTIVE|||||||
33951869|NCT05500729|||COHORT||CROSS_SECTIONAL|||||||
33951870|NCT06647862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951871|NCT01001286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160647|NCT05835180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160648|NCT00534963|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34160649|NCT03690895|||CASE_ONLY||RETROSPECTIVE|||||||
34160650|NCT01428531|||||PROSPECTIVE|||||||
34160651|NCT04847765|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33951872|NCT04209426|||COHORT||RETROSPECTIVE|||||||
33951873|NCT04144309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33951874|NCT01872663|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33951875|NCT00062075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951876|NCT00165191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951877|NCT03051152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951878|NCT05081115|||CASE_ONLY||PROSPECTIVE|||||||
33951879|NCT01620749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951880|NCT02209220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951881|NCT05517291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951882|NCT04523116|||OTHER||PROSPECTIVE|||||||
33951883|NCT05749900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056406|NCT05963516|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056407|NCT06630585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056408|NCT06263153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056409|NCT03420807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects will undergo 1) clinical characterization, 2) ophthalmic evaluation, 3) evaluation with the device (camera) and 4) brain imaging session (MRI + amyloid PET).||||
34056410|NCT01942044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33743749|NCT06615531|||COHORT||PROSPECTIVE|||||||
33743750|NCT06052852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multiple ascending dose and dose-expansion of BDC-3042 administered as a single agent or in combination with cemiplimab||||
33743751|NCT00525317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743752|NCT02491320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743753|NCT03713762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33743754|NCT01146236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33743755|NCT05215574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743756|NCT03096418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743757|NCT06037759|||COHORT||PROSPECTIVE|||||||
33743758|NCT05081414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||PEAC-IC encompasses one presential session and five weekly telephone sessions, focusing on the promotion of self-care and a patient book with all information discussed in the presential session and more 2 diaries, one for the daily weight monitoring and other to assess the symptoms and the and another for monitoring symptoms, making decisions about them and the results obtained. The participants in the intervention group in addition to the patient book will also receive a mechanical scale and a liquid control jar to control the edema and water intake, respectively.|f|f|f|t
33743759|NCT04818411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743760|NCT05284968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743761|NCT02602301|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33743762|NCT06221605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double (Participant, Investigator)||t|f|f|f
33743763|NCT04773587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743764|NCT01595919|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33743765|NCT00671281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056411|NCT03496272|||CASE_ONLY||OTHER|||||||
34056412|NCT01118624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056413|NCT05977127|RANDOMIZED|PARALLEL||PREVENTION||NONE|Only laboratory personnel is masked. Because of the different administration routes it is not possible to mask the participants or investigators|open-label, randomised, proof-of-concept intervention study||||
34056414|NCT02086682|||COHORT||PROSPECTIVE|||||||
34056415|NCT03205761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056416|NCT03426865|||CASE_ONLY||PROSPECTIVE|||||||
33743766|NCT03791125|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33743767|NCT06636188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34056417|NCT05994118|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE||Subcutaneous injection of Saline solution (NACL 0.9%) in the buttock|t|t|t|t
34056418|NCT02835651|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34056419|NCT03247491|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34056420|NCT05728853|||OTHER||CROSS_SECTIONAL|||||||
34056421|NCT05773651|||CASE_ONLY||PROSPECTIVE|||||||
34056422|NCT01899716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056423|NCT00810446|||CASE_ONLY||PROSPECTIVE|||||||
34056424|NCT01828541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056425|NCT06008197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056426|NCT06641349|||COHORT||CROSS_SECTIONAL|||||||
34056427|NCT01461720|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056428|NCT05497388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34056429|NCT01993589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056430|NCT03912532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056431|NCT04103827|||COHORT||PROSPECTIVE|||||||
34056432|NCT03770416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056433|NCT03350061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056434|NCT02149823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34056435|NCT06622369|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomised controlled study|f|f|f|t
34056436|NCT01945801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34056437|NCT04604275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34056438|NCT05314140|||COHORT||PROSPECTIVE|||||||
34056439|NCT03520699|||CASE_ONLY||PROSPECTIVE|||||||
33951884|NCT04423289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056440|NCT05930145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient \& Outcomes adjudicator||t|f|t|f
34056441|NCT04153890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Care provider and outcome assessor including data collectors will be blinded to group assignment.|This study is a low-risk randomized control trial design to test the implementation of the FamPALcare intervention with advanced HF patients and their primary family caregivers.|f|t|f|t
34056442|NCT01424514|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34056443|NCT06602349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056444|NCT02889835|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Single group with a split mouth design in which each subject received all three treatments. Of the 53 total subjects, 3 study subjects actually received duplicate treatment, i.e., they received 6 dental restorations.|t|f|f|f
34056445|NCT06511570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056446|NCT01125709|||CASE_CROSSOVER||PROSPECTIVE|||||||
34160652|NCT01626092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160653|NCT03991455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056447|NCT01984892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160654|NCT04926246|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Study in up to three parts:~Trial part 1: five-period crossover Optional trial part 2: four-period crossover Optional trial part 3: four-period crossover"||||
34160655|NCT00943332|||COHORT||PROSPECTIVE|||||||
34160656|NCT00291603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160657|NCT01661894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160658|NCT03464019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care providers, investigators, and outcomes assessor were blinded to the treatment.|"NODE-301 study comprised 6 arms:~* 2 arms consisting of participants enrolled in Part 1 that treated a perceived episode of PSVT with randomized study drug (etripamil NS 70 mg or placebo) in a 2:1 ratio.~* 1 arm consisting of participants that only received the Test Dose in Part 1.~* 2 arms consisting of participants enrolled in Parts 2 and 3 that treated a perceived episode of PSVT with randomized study drug (etripamil NS 70 mg with optional second dose of 70 mg etripamil or placebo) in a 1:1 ratio and could be enrolled in the open-label period to treat an additional PSVT episode with etripamil~* 1 arm consisting of participants that only received the Test Dose in Parts 2 and 3."|t|t|t|t
34160659|NCT06259994|||COHORT||OTHER|||||||
34160660|NCT03703089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160661|NCT04229628|||CASE_ONLY||PROSPECTIVE|||||||
34160662|NCT03239080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160663|NCT00535002|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34056448|NCT04933084|RANDOMIZED|PARALLEL||PREVENTION||NONE||Triple-armed randomized control trial||||
34056449|NCT05288595|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible Patients with a hematologic disease who could benefit from HCT with an eligible mismatched related or unrelated donor per donor selection criteria. Patient/recipient admitted of HCT/start of preparative regimen and stem cell infusion||||
34056450|NCT02137109|||CASE_ONLY|||||||||
34056451|NCT05918419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056452|NCT00855205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056453|NCT05806567|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34056454|NCT03933644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160664|NCT06334640|||COHORT||CROSS_SECTIONAL|||||||
34160665|NCT00870012|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34160666|NCT00414518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160667|NCT01768364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160668|NCT05846373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34160669|NCT04099121|NA|SINGLE_GROUP||OTHER||NONE||||||
34160670|NCT03325374|||CASE_CONTROL||PROSPECTIVE|||||||
34160671|NCT01821859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160672|NCT00005024|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34160673|NCT03606187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160674|NCT00834262|||CASE_ONLY||PROSPECTIVE|||||||
34056455|NCT06138002|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056456|NCT01136889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34056457|NCT01276522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056458|NCT01355211|||COHORT||PROSPECTIVE|||||||
34056459|NCT06385340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||It's a randomized, evaluator blinded, intra-individual controlled study conducted in one center in Germany, in adult subjects having AK (grade I to III) lesions on the forearms and back of hands and meeting specific inclusion/exclusion criteria.|f|f|t|f
34056460|NCT05814536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056461|NCT04867993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056462|NCT02893553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056463|NCT00525941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34056464|NCT02838836|||COHORT||PROSPECTIVE|||||||
34056465|NCT03937401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056466|NCT00664859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056467|NCT03687372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded vehicle solution is packaged to match the active study drug and will be stored under the same conditions.|Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study|t|t|t|t
34160675|NCT02369393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34160676|NCT01413139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160677|NCT00491933|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951885|NCT01678586|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33951886|NCT03252236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951887|NCT06549439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951888|NCT04416412|||COHORT||PROSPECTIVE|||||||
33951889|NCT03226782|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33951890|NCT06297239|||COHORT||PROSPECTIVE|||||||
33951891|NCT01012609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951892|NCT03445663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951893|NCT06522828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056468|NCT02536118|||COHORT||PROSPECTIVE|||||||
34056469|NCT04923750|||CASE_ONLY||PROSPECTIVE|||||||
33743768|NCT00375089|||COHORT||PROSPECTIVE|||||||
33743769|NCT00723177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33743770|NCT06669013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participant Group/Arm~1. Generalized / metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy.~2. Generalized / metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy.~3. Generalized / metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy."|patients with advanced/metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced/metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced/metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.|t|f|f|f
33743771|NCT01228162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743772|NCT00016289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743773|NCT06531356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951894|NCT00182208|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33951895|NCT04635956|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention of platinum/etoposide/bevacizumab/camrelizumab||||
34160678|NCT05367297|||COHORT||PROSPECTIVE|||||||
33951896|NCT03602846|||OTHER||RETROSPECTIVE|||||||
33951897|NCT04536818|||COHORT||PROSPECTIVE|||||||
33951898|NCT04898946|||COHORT||PROSPECTIVE|||||||
33951899|NCT04588740|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This is a randomized, double-blind, placebo-controlled, cross-over design. This means that all subjects will complete both supplementation phases in a randomized order.|t|f|t|f
33951900|NCT03740126|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multicenter, randomized controlled trial||||
33951901|NCT05725642|||COHORT||PROSPECTIVE|||||||
34160679|NCT00096980|RANDOMIZED|||TREATMENT||NONE||||||
34160680|NCT05254483|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34160681|NCT04583332|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post experimental study||||
34160682|NCT01598467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160683|NCT03036969|||COHORT||PROSPECTIVE|||||||
34160684|NCT06402006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160685|NCT04138446|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Interventional, non-pharmacological, randomized, controlled, single-blinded, cross-over|t|f|f|t
34160686|NCT01546662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34160687|NCT00292019|||COHORT||PROSPECTIVE|||||||
34160688|NCT05791968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants in the control group will have the standard blood bank donation venipuncture, but no blood will be withdrawn (sham donation).|Randomized, control group, trial (RCT)|t|f|t|t
34160689|NCT02717039|||COHORT||CROSS_SECTIONAL|||||||
34160690|NCT00191230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160691|NCT00003515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160692|NCT02139865|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34160693|NCT05396144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and healthcare providers (e.g. gastroenterologist performing the procedure and nurse administering conscious sedation) will not know if the patient is receiving either 5% or 50% inhaled nitrous oxide|Patients will be randomized to either receive 5% or 50% inhaled nitrous oxide in addition to typical sedative agents which will be given at the direction of the doctor performing the procedure. There is a 50% chance you will be assigned to receive either 5% or 50% nitrous oxide|t|t|f|f
33951902|NCT05428306|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951903|NCT05458791|||COHORT||PROSPECTIVE|||||||
33951904|NCT02008955|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33951905|NCT02900157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951906|NCT05549271|||COHORT||OTHER|||||||
33951907|NCT01151501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951908|NCT02675881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33951909|NCT05912673|||COHORT||PROSPECTIVE|||||||
33951910|NCT01096017|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33743774|NCT01480700|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743775|NCT04013542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743776|NCT05652751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this trail, it's difficult to blind researchers, because they perform sham EA or EA, and inject NGF or placebo on patients. However, patients, independent outcome assessors and independent statisticians will be blinded to group allocation throughout the entire trial.|people who are14 days to 6 months after stroke onset|t|t|f|t
33743777|NCT00370162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743778|NCT06412276|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know the treatment group to which they have been assigned.|participants will be randomly assigned to one of five conditions.|t|f|f|f
33743779|NCT03870230|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33743780|NCT04197947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743781|NCT05531539|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33743782|NCT00534729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743783|NCT06122766|||COHORT||PROSPECTIVE|||||||
33743784|NCT04944875|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33951911|NCT05102162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951912|NCT06533410|||COHORT||PROSPECTIVE|||||||
33951913|NCT00031096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951914|NCT03938454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056470|NCT06043479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||control group and intervention group||||
33951915|NCT04434612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951916|NCT01286896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951917|NCT02788890|NON_RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|The care provider was not aware of study objectives. The outcomes assessor was not involved in the data collection.||f|t|f|t
33951918|NCT02183168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951919|NCT03959748|||CASE_ONLY||PROSPECTIVE|||||||
33951920|NCT04113746|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The Research Coordinator who is administering the follow-up survey will be masked||f|f|f|t
33951921|NCT04353115|||CASE_ONLY||PROSPECTIVE|||||||
33951922|NCT00554268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951923|NCT05711459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951924|NCT01713075|||COHORT||PROSPECTIVE|||||||
33951925|NCT03770806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research coordinator in charge of checking in with subjects during the six month follow-up period is blind to the pain treatment condition of the subject (Groin block vs. Mid-thigh block|Subjects who choose to have medication alone with no block for their routine care will be in an observational group only with no randomization. Subjects who elect to have a nerve block placed for their routine treatment will be randomized per the research protocol to have the block placed at either the groin or the mid-thigh. Subjects in each study group will perform the same study procedures. This study will follow subjects for the first 6 months of their recovery to observe routine care pain treatments and evaluate whether the methods of pain control determine (a) severity and duration of postoperative pain, (b) the speed of recovery of muscle function, and (c) pain responses and aggressiveness of pursuing physical therapy maneuvers|f|f|f|t
34056471|NCT04482660|NA|SINGLE_GROUP||OTHER||NONE||||||
34056472|NCT00059878|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34076226|NCT04297397|||CASE_ONLY||RETROSPECTIVE|||||||
34076227|NCT04297202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846848|NCT04571840|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Radiologist assessing MRI for suspicion of prostate cancer is blinded to the contrast sequence when reporting the biparametric MRI. After this report, they are unblinded to the contrast sequence and report the multiparametric MRI. All biopsies conducted as a result of MRI findings will be labelled as bpMRI and mpMRI, and diagnostic accuracy will be assessed against histology findings.|Within-person controlled, paired cohort, diagnostic evaluation study. Participants undergo two index tests and a reference test.|f|t|f|f
33846849|NCT01202097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056473|NCT03576755|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, research staff, or patients. The following study procedures will be in place to ensure double-blind administration of study treatments Access to the randomization code will be strictly controlled. A color and size-matched placebo capsule that looks identical to the spironolactone capsule will be used.~Packaging and labeling of test and control treatments will be identical to maintain the blind.~The study blind will be broken on completion of the clinical study, after all study endpoints have been ascertained by blinded study coordinators and after the study database has been locked.~During the study, the blind may be broken only in emergencies when knowledge of the patient's treatment group is necessary for further patient management. The UCSF investigational pharmacy would then be notified and responsible for unblinding."|"The following treatment regimens will be used:~* Experimental treatment - spironolactone, 100 mg once daily~* Placebo or Comparator - one capsule, once daily"|t|t|t|t
34056474|NCT02715700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056475|NCT06648733|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056476|NCT03887507|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056477|NCT03376451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||EndoSearch recruits two groups of patients : affected by endometriosis and unaffected (controls) but both of them need a surgery for different indication (endometriosis for patients and other for controls (i.e dermoid cyst).||||
34056478|NCT03476174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056479|NCT05052606|||OTHER||PROSPECTIVE|||||||
34056480|NCT06421675|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, single-arm, phase II study of single-agent elranatamab in patients with relapsed and/or refractory multiple myeloma.||||
34056481|NCT06623929|||CASE_CONTROL||PROSPECTIVE|||||||
34056482|NCT01292421|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33846850|NCT06607354|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Describe it was the participant|Describe parallel arms|t|f|f|f
33846851|NCT02404727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846852|NCT05457075|||CASE_ONLY||PROSPECTIVE|||||||
33846853|NCT03341325|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33846854|NCT01666938|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33846855|NCT03196895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056483|NCT04761549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056484|NCT02581475|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34056485|NCT06528535|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056486|NCT01007136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056487|NCT06622213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will not know which treatment each participant will receive (single blinding). Participants will know the type of treatment they received.|group 1: mucoadhesive film with Acmella oleracea extract, group 2: 0.1% triamcinolone acetonide, and group 3: mucoadhesive film without Acmella oleracea extract.|f|f|f|t
34056488|NCT02043951|||COHORT||PROSPECTIVE|||||||
34056489|NCT03655678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056490|NCT05870449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056491|NCT00800306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056492|NCT02620384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056493|NCT04096443|NA|SINGLE_GROUP||TREATMENT||NONE||Pre/post pilot investigational study||||
34056494|NCT02864927|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056495|NCT04892212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056496|NCT02224820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056497|NCT02796859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056498|NCT06623851|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34056499|NCT00620334|||COHORT||PROSPECTIVE|||||||
34056500|NCT06444464|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34056501|NCT04537117|||OTHER||CROSS_SECTIONAL|||||||
34056502|NCT06328244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056503|NCT06621225|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||Patients were randomly allocated into one of three study groups: the primary intervention arm, where colonoscopy was performed using the CADe in combination with the MED; the second group underwent colonoscopy solely with the MED, while the control group underwent colonoscopy solely with the WLE. Randomization was executed by a scheduler responsible for patient appointments at the practice, ensuring impartial allocation, with the investigators maintaining no involvement in subject assignment to study arms. We used a Convolutional Neural Network-based CADe system, GI Genius, acquired for licensed use from Medtronic Inc., Minneapolis, MN. The MED employed was the EndoCuff Vision (ECV) developed by Olympus America, Center Valley, PA, which constitutes part of the standard equipment available. All detected lesions were identified and excised throughout the colonoscopy procedures, and specimens were promptly sent for histopathological analysis.|t|t|t|f
34056504|NCT05567432|RANDOMIZED|PARALLEL||TREATMENT||NONE||In about 20 participants , the investigators will control bleeding and cut tissues and blood vessels using the diathermy and in the other 20 , investigators will do homeostasis with ligasure.||||
34056505|NCT05420857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056506|NCT00449943|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34056507|NCT02947256|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056508|NCT06622863|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056509|NCT06621797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|In this study, participants are masked to the specific intervention they are receiving during each phase. They are unaware of whether they are receiving caffeine only, caffeine combined with L-theanine, or caffeine combined with diaphragmatic breathing exercises. The researcher administering the interventions and conducting assessments is aware of the interventions, ensuring that the study remains single-blind. No other parties are masked in this trial.|In this randomized, single-blind crossover study, each participant will experience all three intervention conditions: (1) caffeine only, (2) caffeine combined with L-theanine, and (3) caffeine combined with diaphragmatic breathing exercises. The crossover design allows each participant to serve as their own control, reducing variability and allowing for direct comparisons between the effects of each intervention on reaction time and accuracy. Interventions are spaced apart by washout periods to ensure that the effects of one intervention do not carry over to the next. This model is ideal for studying the short-term effects of multiple interventions on esports performance.|t|f|f|f
34056510|NCT03813147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056511|NCT06136481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be blinded to their study arm because of the nature of the intervention, but outcome assessors will be blinded.||f|f|f|t
34056512|NCT02261662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056513|NCT05871398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056514|NCT05817383|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34056515|NCT06618261|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized controlled trial|t|f|t|f
34056516|NCT06153186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056517|NCT06606574|NA|SINGLE_GROUP||TREATMENT||NONE|Therapists completing the assessments will be blinded to the patient's baseline characteristics, imaging findings, and current ITB dosage.|||||
34056518|NCT03500458|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34056519|NCT01367496|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056520|NCT05418894|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160694|NCT03360474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Descriptive analysis will be conducted on demographic (e.g., age, gender) variables to report characteristics of the sample. The data to be collected are reflected in the attached measures. Days spent in the ICU and total days spent in the hospital will be analyzed using standard t-tests to assess difference in length of stay in ICU and overall hospitalization for 60 days prior to initiation of the delirium protocol and 60 days following the initiation of the protocol.||||
33743785|NCT02430025|||COHORT||PROSPECTIVE|||||||
33743786|NCT04894253|||CASE_ONLY||PROSPECTIVE|||||||
33743787|NCT02872064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743788|NCT04092660|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre Randomized Control Trial||||
33743789|NCT06068686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|70 enrolled patients will be divided into two groups (35 each); both groups will be patients who are uncontrolled and already on metformin, group I will receive vildagliptin as an add-on therapy while group II will receive glimepiride.|t|f|t|f
33743790|NCT01012882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743791|NCT00335660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33743792|NCT02792582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743793|NCT06319885|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are informed in the study material that they are allocated to groups that receive different text messages. They receive no further information on the intervention groups.|Participants are assigned to either one out of six intervention conditions with different types of text messaging (including one assessment-only control condition).|t|f|f|f
33743794|NCT03391648|||OTHER||RETROSPECTIVE|||||||
33743795|NCT00147966|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743796|NCT03203213|NA|SINGLE_GROUP||PREVENTION||NONE||monocentric study||||
33743797|NCT00440765|||CASE_ONLY|||||||||
33743798|NCT04423965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743799|NCT03343262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160695|NCT01183949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743800|NCT05237622|NA|SINGLE_GROUP||OTHER||NONE||||||
33743801|NCT02604784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two parallel cohorts according to patients characteristics Patient with indication for systemic standard chemotherapy will be accrued in Cohort A (for a Phase II repeated single dose PIPAC).~Patient with no indication for sistemic standard chemotheralpy will be accrued in Cohort B ( for a Phase, single ascending dose PIPAC)"||||
33743802|NCT05449639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743803|NCT00898716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743804|NCT06227000|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743805|NCT01381172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743806|NCT02090738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846856|NCT02270138|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34160696|NCT03068754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The Treatment Period is defined as Randomized (2:1, Arm A: Arm B), Double-blind (with care provider and outcomes assessor also blinded).~The Extension Period has no masking, because all who participate receive open label study drug."|Participants will be assigned to treatment group randomly (like flipping a coin). They will have a 2 out of 3 chance of receiving the study drug, and a 1 out of 3 chance of receiving placebo during the treatment period. All participants who continue into the extension period receive Acthar.|t|f|t|f
34160697|NCT01542710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160698|NCT00291486|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34160699|NCT01819896|||COHORT||CROSS_SECTIONAL|||||||
34160700|NCT02161991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34160701|NCT04091321|||COHORT||RETROSPECTIVE|||||||
34160702|NCT02196935|||COHORT||PROSPECTIVE|||||||
34160703|NCT03781141|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Blinded assessment for wound healing||f|f|f|t
34160704|NCT02966561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160705|NCT01770171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160706|NCT06300073|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Examiner and data recorder will not have access to the room for test materials dispensing and instructions.|single-use, randomized, two-period, cross-over study|f|f|f|t
34160707|NCT00589771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160708|NCT02457468|||COHORT||PROSPECTIVE|||||||
34160709|NCT04548791|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34160710|NCT00584259|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34160711|NCT01363908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160712|NCT03909308|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34160713|NCT03223337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study and no blinding will be performed.|All subjects will receive 6 mg of daprodustat as a single oral dose in parallel way throughout the study period.||||
34160714|NCT04239742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|scans will be anonymized for study outcome assessment.|every individual gets two diagnostic PET CT scans within 2 weeks apart.||||
34160715|NCT02434562|||COHORT||PROSPECTIVE|||||||
34160716|NCT00437814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846857|NCT06610227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846858|NCT02886273|||COHORT||PROSPECTIVE|||||||
33846859|NCT03981861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846860|NCT00480402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846861|NCT01728311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846862|NCT01446120|RANDOMIZED|CROSSOVER||||NONE||||||
33846863|NCT03184038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846864|NCT05012501|||CASE_CONTROL||OTHER|||||||
33846865|NCT05016518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846866|NCT05737368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846867|NCT04763421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846868|NCT01167361|||CASE_ONLY||PROSPECTIVE|||||||
33846869|NCT05399277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33846870|NCT03626987|||COHORT||RETROSPECTIVE|||||||
33951926|NCT06481397|NA|SINGLE_GROUP||TREATMENT||NONE|Unblinded|All study patients will be assigned to receive procedure with the investigational device (Onco-Seraph 100).||||
34056521|NCT03760367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are randomly assigned to one of the two arms and perform the treatment without knowing whether they use the blue covarine toothpaste or the control toothpaste. Treatment outcomes are assessed by a) a blinded operator and b) the blinded participants in a different room. Allocation of treatment groups will be revealed to the principal investigator after all data have been collected.|Participants are assigned to one of two groups - blue covarine toothpaste and control toothpaste group.|t|f|t|t
34056522|NCT03410472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the individual performing the outcome measures will me masked to the assignment of the subjects.|This is a randomized parallel design study|f|f|f|t
34056523|NCT03651687|||COHORT||PROSPECTIVE|||||||
34056524|NCT06620562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a single-center double-blind randomized placebo-controlled trial.|t|t|t|t
34056525|NCT02128425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160717|NCT05688696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34160718|NCT01926990|||COHORT||PROSPECTIVE|||||||
34160719|NCT02378545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160720|NCT05977764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160721|NCT05138315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160722|NCT01198639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34160723|NCT02951078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34160724|NCT02657304|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34160725|NCT00954499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34160726|NCT04355819|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34160727|NCT01412268|||||PROSPECTIVE|||||||
34160728|NCT03487211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients shall be provided medication with numeric labels|Randomized Control Trial|t|f|f|f
34160729|NCT05971927|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34160730|NCT00852787|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34160731|NCT05371912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The TMS coil will be placed on the scalp at a 90 degree angle and will be turned on to create the perception of delivering the stimulation to the brain.|The patients will be randomized at the time of recruitment to either receiving left or right IPL stimulation. A shamming technique will be applied to the opposite hemisphere. Both the patient and the neuropsychologist obtaining and interpreting the outcome measures will be blinded regarding the hemispheric side of rTMS intervention. Only the clinician delivering the rTMS treatment will have a knowledge about the treatment targeting.|t|t|f|t
33951927|NCT06032260|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Neither the participant nor the investigators were aware of the composition of the administered food. The two types of foods were identical for packages, color, flavor, smell, and appearance. Furthermore, the researchers who analyzed data and the laboratory personnel who performed the biochemical analyses were blinded to the group assigned.|crossover randomized double-blind trial|t|f|t|t
33951928|NCT05828030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951929|NCT05724615|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||"This is a multilevel, pragmatic, 3-arm randomized clinical trial to assess completion of lipid panel testing. We will identify primary care patients eligible for lipid screening and randomize them in a 1:2:2 ratio to one of three arms during the intervention phase testing approaches requiring different degrees of p patient and clinician effort:~Arm 1: Usual care Arm 2: Outreach + Bulk ordering Arm 3: Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance"|f|f|t|t
33951930|NCT04592666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951931|NCT02046720|NA|SINGLE_GROUP||SCREENING||NONE||||||
33951932|NCT03976674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160732|NCT01221350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34160733|NCT04346992|||CASE_CONTROL||PROSPECTIVE|||||||
34160734|NCT00003727||||TREATMENT||NONE||||||
34160735|NCT03735992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160736|NCT03898414|||OTHER||RETROSPECTIVE|||||||
34160737|NCT01807598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160738|NCT04280627|||COHORT||PROSPECTIVE|||||||
34160739|NCT01902121|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160740|NCT01467921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160741|NCT03181399|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive supplementation at the maximum tolerated dose.||||
34160742|NCT03770117|||CASE_CONTROL||RETROSPECTIVE|||||||
34160743|NCT01873040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160744|NCT00825812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160745|NCT00145574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160746|NCT03400475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the study coordinator will know whether the intervention is simvastatin or control.||t|f|t|t
34160747|NCT03114332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34160748|NCT03992846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846871|NCT02845843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a recursive two-stage group sequential multicenter placebo-controlled double-blind randomized controlled trial. The trial is initially designed to include 2 two-stage components. The first two-stage component is designed to adjust sample size and determine futility stopping, but not efficacy stopping (n=34). The second two-stage component is designed to determine efficacy stopping and possibly readjustment of sample size.|t|t|t|t
33846872|NCT01376232|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33846873|NCT02316327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160749|NCT02794233|NA|SINGLE_GROUP||OTHER||NONE||||||
34160750|NCT01581060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846874|NCT02239900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846875|NCT01296802|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33846876|NCT04399811|||COHORT||PROSPECTIVE|||||||
33846877|NCT00611520|||COHORT||PROSPECTIVE|||||||
33846878|NCT05081531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846879|NCT00084344|RANDOMIZED|||SCREENING||DOUBLE||||||
34056526|NCT02961322|NA|SINGLE_GROUP||OTHER||NONE||||||
34056527|NCT04865549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056528|NCT04884113|||COHORT||PROSPECTIVE|||||||
34056529|NCT06648863|||COHORT||CROSS_SECTIONAL|||||||
34056530|NCT06374225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056531|NCT06302296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056532|NCT00138073|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34056533|NCT03616444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A double-blind design is used in this study for the investigators and subjects. The blinding codes are separately sealed and stored by the independent third-party organization. Trial granules are randomly coded as subject unique identification codes, and used by each clinical site according to the assigned drug numbers and in the order of case enrollment. Clinical monitors and investigators must be blinded at all times.|colorectal adenomatous polyp patients after colonoscopy under colonoscopy|t|f|t|f
34056534|NCT06648434|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056535|NCT06237244|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056536|NCT06622915|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34056537|NCT06618963|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||30 subjects with food allergy 10 subjects without food allergy||||
34056538|NCT01013844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056539|NCT06618365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective randomized intervention using open label randomization.|t|f|f|f
34056540|NCT00481052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056541|NCT02999529|NA|SINGLE_GROUP||OTHER||NONE||||||
34056542|NCT01310556|||CASE_CONTROL||PROSPECTIVE|||||||
34056543|NCT05573490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participant and outcomes assessor (study coordinator) will be masked to intervention assignment. Principle investigator will not be masked given the size of the study team.|Participants will be randomized into one of two conditions: (1) Computerized Cognitive Training + Tai Chi Exercise or (2) Active Control.|t|f|f|t
34056544|NCT03359486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056545|NCT01039922|||COHORT||PROSPECTIVE|||||||
34056546|NCT03185806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056547|NCT06588907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056548|NCT04101929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056549|NCT03839771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056550|NCT01387451|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056551|NCT05721846|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34056552|NCT03415789|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056553|NCT03698994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056554|NCT06488209|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Parts 1 and 2 of the study will be single-blind and Part 3 will be double-blind.||t|t|f|f
34056555|NCT02326922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056556|NCT04476342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056557|NCT06649409|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be conducted in a single-center, randomized, open-label, 3-arm, parallel-group, positive- and negative-controlled design.||||
34160751|NCT03630757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were randomly divided into 2 groups of 20 people. A randomized list is prepared in a computer environment by a statistician for randomization. In this list, the odd numbers for the control group and the MT group were given double numbers. The group identification is printed on sequentially numbered cards placed in sealed envelopes. After enrollment, the numbered envelope was opened by the patient and the blind investigator. For the study group, manual therapy (MT) was given and the home exercise program was given and for the control group only home exercise program was given. In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk). The treatment program has been implemented by a physiotherapist who specializes in this area.|f|f|t|f
34160752|NCT06583382|||COHORT||OTHER|||||||
34160753|NCT02013297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160754|NCT05223049|||COHORT||CROSS_SECTIONAL|||||||
34160755|NCT03941717|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be made explicitly aware of which group (intervention or control) that they have been allocated. Participants in each group will be provided with a tablet and guided through an audio activity. Further, participants will not be made aware of the kind of intervention being used, however, it is possible that participants may become aware of the nature of their treatment allocation in the mindfulness group.|The study will be a single-site, two-arm, parallel group RCT with an intervention group (mindfulness-based intervention) and control group (unfocused-attention task, no active components).|t|f|f|f
34160756|NCT02497885|||COHORT||PROSPECTIVE|||||||
34160757|NCT01314131|NA|SINGLE_GROUP||||NONE||||||
34160758|NCT00136045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160759|NCT04289961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective translational research study||||
34160760|NCT01518842|NA|SINGLE_GROUP||TREATMENT||NONE||intravitreal injection of autologous bone marrow stem cells||||
34160761|NCT02714764|||CASE_ONLY||PROSPECTIVE|||||||
33743807|NCT06496256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All subjects who sign a consent and meet inclusion and exclusion criteria will be randomized to the treatment or the control arm.|Prospective, randomized, controlled, single-blinded multicenter study|t|f|f|f
33743808|NCT05898542|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled study, intervention and control groups||||
33743809|NCT02542748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743810|NCT06371794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The ethics committee of the foundation FPG considers the study interventional since patients will undergo skin biopsy procedures ( around 4 mm)||||
33743811|NCT05809518|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743812|NCT01094080|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33743813|NCT04244461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743814|NCT02181530|||COHORT||RETROSPECTIVE|||||||
33743815|NCT01141894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743816|NCT00337766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743817|NCT06141135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation information will be handled by embryology team at BIVF.|Prospective randomized control trial|t|t|t|t
33743818|NCT05588518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743819|NCT02805569|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33743820|NCT05663047|RANDOMIZED|PARALLEL||TREATMENT||NONE||An academically initiated randomized controlled clinical trial where Prevent It 2.0 is compared with waitlist control||||
33743821|NCT01839734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743822|NCT03216837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33743823|NCT06635616|||COHORT||PROSPECTIVE|||||||
33743824|NCT02332070|||COHORT||RETROSPECTIVE|||||||
33743825|NCT02317458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743826|NCT03836053|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1b Primary objective Establish the safety and tolerability of AMG 420 at dose levels of 400 mcg/day and 600 mcg/day in subjects with relapsed and/or refractory multiple myeloma (RRMM)~Phase 1b Key Secondary/Secondary objectives:~Estimate overall response rate (ORR) and duration of response (DOR) Evaluate the rate of minimal residual disease (MRD)-negativity at the time of CR Establish the safety and tolerability of AMG 420 in subjects with extramedullary relapsed MM Characterize the PK of AMG 420 when administered as 4-week continuous IV infusion Evaluate other measures of anti-myeloma activity of AMG 420: Time to response, PFS, OS, TFI, BOR"||||
33743827|NCT03845608|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33743828|NCT01134874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743829|NCT04855253|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The Phase I study consists of two components: dose finding to establish a maximum tolerated dose (MTD) of E7777 and a small extension component to provide an estimate of efficacy at the MTD.~A single dose of E7777 is given on Day -7, two days prior to the start of lymphodepleting chemotherapy. Up to 3 dose levels will be tested. The MTD is determined by using the continual reassessment method (CRM). Enrollment begins with Dose Level 1 using a cohort of two patients. Twenty one (21) days after the 2nd patient's tisagenlecleucel infusion the next cohort of 2 patients are assigned to the most appropriate strategy based on updated toxicity probabilities corresponding to the desired maximum toxicity rate of ≤ 25% as determined by the study statistician (or designee). Enrollment continues in cohorts of 2 separated by a minimum of 28 days until 20 patients are enrolled or 10 sequential patients are enrolled at the same dose level. No intra-cohort staggering is required."||||
33743830|NCT00991926|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33743831|NCT02672904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743832|NCT01620892|||COHORT||CROSS_SECTIONAL|||||||
33743833|NCT00412087|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743834|NCT02630212|||CASE_CONTROL||PROSPECTIVE|||||||
33743835|NCT02513654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743836|NCT00949026|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33743837|NCT01970033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743838|NCT03874000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743839|NCT02673658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743840|NCT02639702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743841|NCT00659334|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33743842|NCT06532669|||COHORT||PROSPECTIVE|||||||
33846880|NCT04701359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking of both patients and outcome assessors. Only care provider (i.e. surgeon) and investigator aware of implant-type used. During follow-up, neither care provider nor investigator allowed to assess patients' study-specific outcome. As implants look identical on X-rays, allocation to one or another group cannot be verified by independent outcome assessors.|Two-hundred patients with knee osteoarthritis included altogether. Patients randomly assigned to group A (receiving total knee arthroplasty \[TKA\] with TiN-coating) or group B (receiving TKA with CoCr-alloy).|t|f|f|t
33743843|NCT03726905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The control group will be assigned an imitation of respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0|Parallel assignment|t|f|f|t
33846881|NCT00558922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846882|NCT03636477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846883|NCT02791425|NA|SINGLE_GROUP||OTHER||NONE||||||
33846884|NCT02142296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846885|NCT01687907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846886|NCT03627013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33846887|NCT02883348|||COHORT||PROSPECTIVE|||||||
33743844|NCT02524704|||CASE_ONLY||CROSS_SECTIONAL|||||||
33743845|NCT05525624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The research will be conducted in a double-blind design and the data of the research will be collected by the clinical nurse. Parents participating in the research will not know that they are in the intervention or control group. Telephone support during the research process will be provided by an independent interviewer.|Transition Model is discharge model in preterm infants.|f|f|t|t
33743846|NCT03651180|||OTHER||PROSPECTIVE|||||||
33743847|NCT00874029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846888|NCT01680640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846889|NCT04476368|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846890|NCT01869387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846891|NCT06611215|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding of both study team and participants will be ensured by only providing access to the randomization list to the science and quality team. The relationship between the randomization number and the group assignment will be unknown to the participants, clinical study team, and the Sponsor, i.e. the study will be double-blinded.|This is a 4 arm double blind randomized placebo controlled trial for 2 prebiotic supplements with respective placebos as parallel groups - 2 treatments and 2 placebos.|t|f|t|f
33846892|NCT01055301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846893|NCT02147899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846894|NCT06002893|NA|SINGLE_GROUP||TREATMENT||NONE||Cholesfytol NG®) supplement treatment||||
33846895|NCT00441662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846896|NCT01664962|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33846897|NCT00370305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846898|NCT03994354|||COHORT||PROSPECTIVE|||||||
33846899|NCT05086276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33846900|NCT01177800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160762|NCT01946737|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34160763|NCT01915043|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||f|t|t|t
34160764|NCT05465993|||COHORT||RETROSPECTIVE|||||||
34160765|NCT01391936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160766|NCT00665535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160767|NCT06413797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160768|NCT05145868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34160769|NCT00456287|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160770|NCT02160652|||CASE_ONLY||PROSPECTIVE|||||||
34160771|NCT00563459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34160772|NCT02354872|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34160773|NCT04287387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160774|NCT01379950|||COHORT||PROSPECTIVE|||||||
34160775|NCT04063969|||CASE_ONLY||CROSS_SECTIONAL|||||||
34160776|NCT02073682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160777|NCT02137096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160778|NCT03031366|RANDOMIZED|PARALLEL||TREATMENT||NONE||TIPS creation using real-time 3D roadmap||||
34160779|NCT03482037|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||two sequential cohorts, each corresponding to a dose level.|t|t|t|f
34160780|NCT03936257|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34160781|NCT01237613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160782|NCT02718209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846901|NCT06359925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846902|NCT03796702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33846903|NCT05630872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846904|NCT02097940|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33846905|NCT05356442|||OTHER||CROSS_SECTIONAL|||||||
33846906|NCT03291288|NA|SEQUENTIAL||TREATMENT||NONE||Open-label, single sequence study with 2 parts||||
33846907|NCT02275000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846908|NCT01270074|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33846909|NCT05478239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846910|NCT00060762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846911|NCT02751320|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33846912|NCT02530164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846913|NCT00040027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33846914|NCT01776905|||CASE_CONTROL||PROSPECTIVE|||||||
33846915|NCT02800018|||COHORT||RETROSPECTIVE|||||||
33846916|NCT00223639|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33846917|NCT02432196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846918|NCT03619304|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||oral squamous cell carcinoma cell lines|f|f|f|t
33846919|NCT02622776|NA|SINGLE_GROUP||SCREENING||NONE||||||
33846920|NCT03025685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846921|NCT05769712|||CASE_ONLY||CROSS_SECTIONAL|||||||
33846922|NCT03032432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33846923|NCT02030002|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Split-mouth||||
33846924|NCT03495947|||COHORT||PROSPECTIVE|||||||
33846925|NCT03965351|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33846926|NCT02651857|NA|SINGLE_GROUP||OTHER||NONE||||||
33846927|NCT06097351|||COHORT||RETROSPECTIVE|||||||
33846928|NCT00409266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846929|NCT01719419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33846930|NCT01076153|||COHORT||PROSPECTIVE|||||||
33846931|NCT04542889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846932|NCT06103968|||COHORT||PROSPECTIVE|||||||
33846933|NCT04666623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators, patients, care providers, outcome assessors, and study statisticians will remain blinded with respect to the treatment allocation. Allocation sequence will be concealed for everyone involved in the trial, except for the pharmacist and the nurse responsible for patient's allocation.|placebo-controlled, double-blinded with two parallel groups, superiority trial.|t|t|t|t
33846934|NCT02816177|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846935|NCT00341432||||TREATMENT||||||||
33846936|NCT00580242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846937|NCT03924765|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The model used is a repeated measures single arm study. Multiple conditions including using and not using the device will be tested on the same subjects to have multiple test points on a per subject basis.||||
33846938|NCT05568238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846939|NCT00609375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846940|NCT00377494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34160783|NCT02092792||PARALLEL||TREATMENT||NONE||||||
34160784|NCT04789369|||CASE_ONLY||CROSS_SECTIONAL|||||||
33846941|NCT01066429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846942|NCT04203095|||CASE_CONTROL||PROSPECTIVE|||||||
33846943|NCT01378780|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846944|NCT02247973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846945|NCT00271687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160785|NCT01969695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160786|NCT02987270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160787|NCT02936024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160788|NCT00894361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160789|NCT03202719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743848|NCT00567242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743849|NCT04257370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation of wound closure at defined time points will be done by an assessor blinded to the treatment group.|Patients will be randomised to receive either Kerecis™ Omega3 Wound plus standard of care, or standard or care alone.|f|f|f|t
33743850|NCT03735550|||COHORT||CROSS_SECTIONAL|||||||
33743851|NCT04623294|||CASE_CONTROL||PROSPECTIVE|||||||
33743852|NCT01560520|||COHORT||PROSPECTIVE|||||||
33743853|NCT03579979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743854|NCT04502329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized control trial The first participant assigned Intermittent Energy Restriction Group, the others assigned Continous Energy Restricition group or Intertermittent Energy Restriction Group respectively.|f|f|f|t
33743855|NCT06226844|||CASE_CONTROL||PROSPECTIVE|||||||
33743856|NCT05800392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743857|NCT04936282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743858|NCT05442580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Three dose levels of CART-38 cells will be evaluated using a 3+3 dose escalation design in two parallel disease cohorts as follows:~* Cohort A: Relapsed/Refractory Acute Myeloid Leukemia (AML)~* Cohort B: Multiple Myeloma (MM)"||||
33743859|NCT04505046|||COHORT||PROSPECTIVE|||||||
33743860|NCT01279226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743861|NCT03879018|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743862|NCT05952505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743863|NCT05273164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33743864|NCT03754023|||COHORT||PROSPECTIVE|||||||
34160790|NCT01040442||PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34160791|NCT00255541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160792|NCT03441087|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34160793|NCT00302211|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34160794|NCT02376179|||COHORT||PROSPECTIVE|||||||
34160795|NCT05982496|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Cohort A~* candidates to surgery as first treatment regardless of cN~* ER+ Her2 negative BC with ki67\>10% Cohort B~* ER positive BC treated with induction ET Cohort C~* candidates to neoadjuvant chemotherapy Cohort D~* Metastatic LumA or ER-positive Lob BC, at first diagnosis or in progression"||||
34160796|NCT02183766|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34160797|NCT05705362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160798|NCT00000358||||TREATMENT||||||||
34160799|NCT04119128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160800|NCT00606619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160801|NCT01196026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160802|NCT01440816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160803|NCT04625439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160804|NCT03908359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160805|NCT04709445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a non-randomised prospective cohort study design.||||
34160806|NCT00434187|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34160807|NCT02750319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160808|NCT02115763|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160809|NCT01883544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160810|NCT03197922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures, including the Parent-nominated Target Problem (PTP), will be conducted by separate independent evaluators (IE) each of who are blind to treatment assignment.|56 participants will be assigned to 2 weeks of the Multidisciplinary Intervention for Encopresis (MIE) treatment, 56 will be assigned to treatment as usual (TAU) as a control group. Twenty-six participants were assigned to the study arm with one week of MIE, which has been discontinued.|f|f|f|t
34160811|NCT05194930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded from group assignment and the treatment content. Participants will be blinded to the content of the treatment arm to which they are not assigned.||t|f|f|t
34160812|NCT03743116|||COHORT||PROSPECTIVE|||||||
34160813|NCT03968835|||CASE_ONLY||PROSPECTIVE|||||||
34160814|NCT02531724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160815|NCT04878965|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will be provided with a smartwatch to wear.||||
34160816|NCT00252603|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34160817|NCT02771197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160818|NCT00351910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160819|NCT05323474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160820|NCT03871699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160821|NCT04653194|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label 1:1 non-inferiority randomised clinical trial||||
34160822|NCT04677010|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Statistics will be made by an investigator blinded to what results are from before, in-between and after the two periods of rest and exercise respectively.|One group consisting of patients with either cerebral palsy or muscular dystrophy will do a 10 weeks run-in period with no exercise immediately followed by 10 weeks of exercise. They will be testet before and after the run-in period and after the exercise period.|f|f|f|t
34160823|NCT03277027|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-randomized single group Accelerometer was weared for a week to check physical activity and sleep in children with cerebral palsy.||||
34160824|NCT05433922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160825|NCT00959595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34160826|NCT00473200|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34160827|NCT00004223||||TREATMENT||||||||
34160828|NCT05977673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160829|NCT02687139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160830|NCT02457156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34160831|NCT04043572|||CASE_CONTROL||PROSPECTIVE|||||||
34160832|NCT04591158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Providers are blinded from the subject's information from the clinical interviews when assessing LUS ultrasound findings, but will be unblinded when there is a disagreement between clinical and LUS findings. This allows information about the course of a subject's illness to not affect the LUS ultrasound findings.|||||
34160833|NCT02921490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743865|NCT04011150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743866|NCT04483479|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 2b, non-randomized, open-label study.||||
33743867|NCT03431168|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743868|NCT04624737|||COHORT||PROSPECTIVE|||||||
34160834|NCT05811169|||COHORT||PROSPECTIVE|||||||
34160835|NCT03661333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160836|NCT03258086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160837|NCT02832635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160838|NCT06323382|||COHORT||PROSPECTIVE|||||||
34160839|NCT03485235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160840|NCT05170763|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This is a randomized, double-blind, placebo-controlled dose escalation phase 1 trial, including single dose and 7-day repeat doses of PA9159 nasal spray.|Arm 1-4, the treatment is given once for one day, with escalation doses of 10 μg, 20 μg, 40 μg, 80 μg. Arm 5-6, PA9159 at the escalation dose of 20 μg and 40 μg is given once a day for 7 days. 10 health subjects will be enrolled for each dose group, randomized proportionally at 4:1 ratio to receive either the investigational product PA9159 or placebo nasal spray, with a total of 60 subjects.|t|t|t|t
34160841|NCT06241105|NA|SINGLE_GROUP||TREATMENT||NONE||Lenvatinib plus Toripalimab||||
33743869|NCT05888376|||COHORT||RETROSPECTIVE|||||||
33743870|NCT05883852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743871|NCT02818738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743872|NCT04223453|||COHORT||PROSPECTIVE|||||||
33743873|NCT02632149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743874|NCT01194115|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743875|NCT01748916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33743876|NCT05846581|||COHORT||PROSPECTIVE|||||||
33743877|NCT02099734|||OTHER||PROSPECTIVE|||||||
33743878|NCT01233986|||CASE_CONTROL||PROSPECTIVE|||||||
33743879|NCT00736242|||CASE_ONLY||PROSPECTIVE|||||||
33743880|NCT05467644|||COHORT||RETROSPECTIVE|||||||
33846946|NCT04136743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to treatment group when analyzing data for publication.||f|f|f|t
33846947|NCT01144481|||COHORT||PROSPECTIVE|||||||
33846948|NCT01579331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846949|NCT02570087|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33846950|NCT00537953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743881|NCT01373086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743882|NCT00863850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743883|NCT02488486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743884|NCT05774600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33743885|NCT00838344|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33743886|NCT00235703|||DEFINED_POPULATION||OTHER|||||||
33743887|NCT03808662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743888|NCT01387568|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33743889|NCT04771169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743890|NCT02170168|||COHORT||PROSPECTIVE|||||||
33743891|NCT02461121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743892|NCT06628206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor|"This is a Phase 1b, multi-center, randomized, double-blind, parallel-group, placebo-controlled multiple ascending doses (MAD) study in participants with rheumatological conditions (rheumatoid arthritis, and psoriatic arthritis).~There will be 2 cohorts, one for each indication. Each cohort will consist of \~12-25 participants (Total \~up to 50 participants). The first cohort is for RA and in this cohort the first 3-4 participants will receive LPX-TI641 at 60 mg QD for 28 days. Based on review of available safety, PD, PK of these initial participants by the sponsor and the PI, the dose of LPX-TI641 60 mg or 120 mg QD will be selected and the rest of cohort will be randomized in 3:1 ratio for LPX-TI641: placebo 28 days. The psoriatic arthritis cohort can enroll concurrently or sequentially. Participants in these cohorts will be randomized in a 3:1 ratio for LPX-TI641: placebo and treated for 28 days."|t|f|t|t
33846951|NCT02413853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846952|NCT05999643|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33846953|NCT06326593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33846954|NCT01239043|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33846955|NCT03870217|||COHORT||PROSPECTIVE|||||||
33846956|NCT03527238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33846957|NCT03699553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||40 participants will be randomized to the LARKSPUR Study. 20 will receive the online intervention and 20 will report their daily emotions for the same duration as the intervention. The 20 individuals assigned to the emotion reporting (control group) arm will receive the online intervention after completing the final assessment, 12 weeks after baseline.||||
33846958|NCT06415539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33846959|NCT05716048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846960|NCT04270396|||COHORT||PROSPECTIVE|||||||
33846961|NCT05244564|RANDOMIZED|PARALLEL||TREATMENT||NONE||All receive the 3MDR intervention, but are randomized to delivery via AR HMD vs via curved high definition gaming computer monitor||||
33846962|NCT05530694|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge cluster randomized trial||||
33846963|NCT02549014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33846964|NCT01985451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846965|NCT04292353|||COHORT||PROSPECTIVE|||||||
34160842|NCT05645965|||COHORT||OTHER|||||||
33743893|NCT01186523|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743894|NCT00549250|||||PROSPECTIVE|||||||
34160843|NCT05711472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34160844|NCT01311609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743895|NCT05956431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33743896|NCT00502125|||CASE_ONLY||PROSPECTIVE|||||||
33743897|NCT00326378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743898|NCT02671487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743899|NCT05527028|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be blinded to participant group allocation.|Pilot study for single site trial.|f|f|f|t
33743900|NCT06572670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743901|NCT03317704|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33743902|NCT02276482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160845|NCT01232998|||COHORT||PROSPECTIVE|||||||
34160846|NCT04368715|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double- blinded||t|f|f|t
34160847|NCT04191317|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms, each receiving a different intervention.||||
34160848|NCT02292563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160849|NCT04706481|||COHORT||PROSPECTIVE|||||||
34160850|NCT06725290|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34160851|NCT01652339|RANDOMIZED|CROSSOVER||||NONE||||||
34160852|NCT00270062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160853|NCT02212041|NA|SINGLE_GROUP||OTHER||NONE||||||
34160854|NCT01342588|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34160855|NCT00889824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160856|NCT00622375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34160857|NCT04007016|||COHORT||RETROSPECTIVE|||||||
34160858|NCT01574066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160859|NCT06352749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigators in charge of doing the statistical analysis and assessing the outcome measures will be blinded to group allocation. Due to the characteristics of the study, blinding the participants and the care provider (i.e., the professional conducting the exercise sessions) to the group allocation is not possible.|Each group will be assigned to control, online intervention or face-to-face intervention|f|f|t|t
33743903|NCT06108063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The Investigator or properly trained and delegated study team member (Physician Assistant) will write the prescription for the study medication. The subject's randomization number will be communicated directly to the Vail Health pharmacy. The Vail Health pharmacy will maintain an unblinded, de-identified randomization spreadsheet that documents group allocation for each subject. The Vail Health Pharmacy oversees and manages drug disbursement for research.|prospective, randomized, double-blind, placebo controlled clinical trial|t|t|t|t
33743904|NCT05061121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|assigned randomly into Three equal groups the by using permuted block method|"Design of the study:~Single-blinded randomized controlled trial design. Patients will be randomly assigned into 3 equal groups using the statistical package for social science (SPSS 20).~Group A (Mulligan's SNAGs) Group B (Myofascial release) Group C (Mulligan's SNAGs + Myofascial release)"|t|f|f|f
33743905|NCT03893513|||CASE_ONLY||CROSS_SECTIONAL|||||||
33743906|NCT00656838|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33846966|NCT03537547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Coordinators at site are blinded, Sponsor and associates are unblinded.|Participants will be randomized to have their study clinician have access to their pharmacogenetic report (provide through the GeneSight Psychotropic tool) in order to make treatment decisions, or to not have access to their report for the first 12 weeks. At Visit 5, Week 12, all participants will receive a copy of their pharmacogenetics report and all clinicians will be unblinded for 'open label' to be able to use the results to guide treatment options for an additional 12 weeks.|t|f|f|t
33846967|NCT06610214|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"The assessor of the primary outcome measure will be blinded.~The secondary outcome measure concerning drug related readmissions will be blinded.~The secondary outcome measure concerning medication adherence is not possible to blind since it is dependent on the patients' discharge date, and the date will reveal the allocation."|We plan a prospective intervention study primarily with a before-and-after design. A secondary analysis using an Interrupted Time Series (ITS) design will be conducted with an exploratory approach.|f|f|f|t
33846968|NCT06034418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846969|NCT05267431|||OTHER||CROSS_SECTIONAL|||||||
33846970|NCT01244178|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34160860|NCT02761382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160861|NCT05130749|||OTHER||CROSS_SECTIONAL|||||||
34160862|NCT02348996|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160863|NCT06240949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34160864|NCT03449719|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Phase II study is suitable to investigate the interaction of systemic therapy (ADT and abiraterone) with locoregional therapy (SBRT). The duration of the study equal to 40 months was defined taking into account both the expected time of occurrence of investigated endpoints and feasibility considerations related to patient availability.||||
34160865|NCT04221646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160866|NCT00543777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160867|NCT06245252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160868|NCT05260827|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Randomised controlled cross-over study|f|f|t|f
34160869|NCT00716846|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160870|NCT00266955|||||RETROSPECTIVE|||||||
34160871|NCT00666224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160872|NCT01593553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160873|NCT03863756|||CASE_ONLY||PROSPECTIVE|||||||
34160874|NCT05824962|||CASE_ONLY||PROSPECTIVE|||||||
34160875|NCT05236257|||COHORT||RETROSPECTIVE|||||||
34160876|NCT02231619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160877|NCT05917418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34160878|NCT00596830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160879|NCT01340053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160880|NCT02047214||SEQUENTIAL||TREATMENT||NONE||||||
34160881|NCT02309801|RANDOMIZED|CROSSOVER||||NONE||||||
34160882|NCT02321553|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34160883|NCT02135237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056558|NCT04682652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A total of 100 subjects will be enrolled in the double-arm study, subjects will be randomized to GAE or observation in a 2:1 ratio (67 assigned to GAE, 33 assigned to observational). Subjects in the observation group will have the option to crossover to the GAE treatment arm after they've completed their 6-month follow-up time point. Subjects who crossover to treatment arm will undergo the GAE procedure and undergo all subsequent follow-up visits (1 month, 3 month, 6 month, 12 month, 24 month).||||
34056559|NCT06007963|||CASE_ONLY||PROSPECTIVE|||||||
34056560|NCT02336269|||CASE_ONLY||PROSPECTIVE|||||||
34056561|NCT01649648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056562|NCT06217783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056563|NCT01294007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056564|NCT00370981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056565|NCT02396017|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34056566|NCT06620874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056567|NCT05100368|||COHORT||RETROSPECTIVE|||||||
34056568|NCT01740128|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34056569|NCT06161831|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34056570|NCT02893176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056571|NCT06620081|RANDOMIZED|CROSSOVER||OTHER||NONE||This pilot study is a randomized crossover clinical trial||||
34056572|NCT04664946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056573|NCT04504266|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34056574|NCT01547975|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34056575|NCT04982692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056576|NCT01308112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056577|NCT04378959|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Identical lidocaine and placebo patches will be provided to research pharmacies at participating sites, along with site-specific randomization tables. Care providers, investigators, patients and outcome assessors will all be blinded to treatment allocation.|4 week treatment periods, separated by a 1 to 3 week washout period|t|t|t|t
34056578|NCT02123836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056579|NCT03673748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both Experimental and Control arms will receive a similar endovenous injection with either cells or placebo. Blind to participant, investigator and care providers.|Control arm (placebo) and experimental arm (mesenchymal stem cells)|t|t|t|f
34056580|NCT02168374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056581|NCT05856344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056582|NCT05288387|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34056583|NCT05563012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056584|NCT05319743|||COHORT||RETROSPECTIVE|||||||
34056585|NCT06617910|||CASE_CONTROL||RETROSPECTIVE|||||||
34056586|NCT06461143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group 1: Intraosseous anesthesia (n=40) Group 2: lnferior alveolar nerve block (n=40)~Individuals suitable for split-mouth design will be assigned to the opposite anesthesia arm, and their second teeth will be treated and measured."|f|f|f|t
34056587|NCT05958316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056588|NCT06624150|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|triple blind|Pilot mechanistic trial examining cognitive training and brain stimulation effects on cognitive performance. Participants are randomly assigned to active or sham (fake) brain stimulation conditions.|t|f|t|t
34056589|NCT05789784|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056590|NCT02433925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34056591|NCT04630249|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34056592|NCT05965635|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single centre, experimental study||||
34056593|NCT02585817|NA|SINGLE_GROUP||OTHER||NONE||||||
34056594|NCT03470012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056595|NCT03760406|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056596|NCT06337565|||OTHER||PROSPECTIVE|||||||
34056597|NCT03250091|||COHORT||PROSPECTIVE|||||||
34056598|NCT04066296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The PI, co-Investigators, and clinicians will be blinded to the patient's treatment arm. The pharmacist will be unblinded.|Double blinded, randomized|t|t|t|t
34056599|NCT02344290|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056600|NCT02235051|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34056601|NCT02062424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056602|NCT02085668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056603|NCT00834639|RANDOMIZED|CROSSOVER||||NONE||||||
34056604|NCT06648252|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm Randomized and Controlled Trial||||
34056605|NCT06113094|||CASE_ONLY||RETROSPECTIVE|||||||
34160884|NCT00558116|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34160885|NCT03483415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, controlled, single-blind|t|f|f|f
34160886|NCT01363661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34160887|NCT06090084|||OTHER||PROSPECTIVE|||||||
34160888|NCT06174129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34160889|NCT02630511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized double-blind cross over design|t|f|f|t
34160890|NCT02452424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160891|NCT04703764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160892|NCT02116452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34160893|NCT05502354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34160894|NCT04425382|||OTHER||RETROSPECTIVE|||||||
34160895|NCT00006343||||TREATMENT||||||||
34160896|NCT05040568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743907|NCT03198000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743908|NCT03926507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743909|NCT06446037|NA|SINGLE_GROUP||OTHER||NONE||||||
33743910|NCT03039673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33743911|NCT01823094|||CASE_ONLY||PROSPECTIVE|||||||
33743912|NCT01346657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33743913|NCT00584688|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33743914|NCT06469827|||COHORT||PROSPECTIVE|||||||
33743915|NCT01017406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743916|NCT00311077|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33743917|NCT01515085|||CASE_ONLY||PROSPECTIVE|||||||
33743918|NCT05923281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33743919|NCT03936491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743920|NCT01295541|||COHORT||PROSPECTIVE|||||||
33743921|NCT06281691|||COHORT||PROSPECTIVE|||||||
33743922|NCT04132609|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE||Participants will complete the standard attentional bias task (control) or CBM up to 3x/week during MAT clinic visits for 4 weeks.|t|f|t|t
33743923|NCT05481021|||OTHER||CROSS_SECTIONAL|||||||
33743924|NCT00614211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743925|NCT02438449|||COHORT||PROSPECTIVE|||||||
34160897|NCT01629173|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34160898|NCT04340453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"participants and care providers were only blinded to the other groups intervention.~The Investigator and outcomes assessor are blinded to patient allocation and data code."|This a randomized controlled trial with first primary end point at four weeks and second primary end point at two months. Participants will be allocated randomly into one of two intervention groups. Group1 (Knee and hip focused exercises) Group 2 (knee and hip focused exercises with BFR)|f|f|t|t
34160899|NCT03100604|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33951933|NCT04424186|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||A cluster-randomized stepped wedge study. A design that is initiated with a period without interventions followed by a form of cross-over, in which each cluster systematic cross from control to intervention.|f|f|t|t
34160900|NCT05969704|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34160901|NCT04744714|||COHORT||PROSPECTIVE|||||||
34160902|NCT02386449|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34160903|NCT00308971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160904|NCT06224179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160905|NCT02919072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34160906|NCT01419886|||COHORT||PROSPECTIVE|||||||
33743926|NCT04050592|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33743927|NCT00396604|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33743928|NCT05422118|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33743929|NCT04153370|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33743930|NCT03867877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33743931|NCT02352064|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160907|NCT01994265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34160908|NCT00381147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34160909|NCT02672462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160910|NCT01090193|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160911|NCT05458804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor was blind for the group allocation||f|f|f|t
34160912|NCT03870399|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, unicentric, single-stage clinical study||||
34160913|NCT00310596|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34160914|NCT05802862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160915|NCT04336072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomly assigned to groups. Outcome assessors will be blinded to participants and interventions|After obtaining informed consent from parents and informed assent from eligible adolescents with comorbid ADHD and PTSD, participants will be randomized into: a) RFPP group therapy or trauma focused cognitive behavioral group therapy|t|t|f|t
34160916|NCT02677272|||CASE_ONLY||RETROSPECTIVE|||||||
34160917|NCT02595619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160918|NCT06236386|NA|SINGLE_GROUP||OTHER||NONE||"This study will use a convergent mixed methods (QUAN + QUAL) design to measure the reach, effectiveness, adoption, implementation, and maintenance of translating VR evidence into practice.~Qualitative data will be collected after the colonoscopy procedure by using a customized satisfaction survey, measuring the experience and satisfaction of patients and clinicians. Six months after launching this study, clinicians will be surveyed about their continuation of using VR during colonoscopy procedures.~Individual quantitative and qualitative results will be merged initially through a convergent data analysis integration strategy that will compare both strands side by side. This strategy contributes to the overall interpretation of the findings."||||
34160919|NCT02518763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743932|NCT00378417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33743933|NCT03509935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33743934|NCT02942199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743935|NCT05476224|||COHORT||PROSPECTIVE|||||||
33743936|NCT05298176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743937|NCT05263531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743938|NCT04489446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants will be randomised to either sildenafil or placebo for up to seven days.|t|t|t|t
33743939|NCT06015776|||COHORT||PROSPECTIVE|||||||
33743940|NCT01315548|||CASE_CONTROL||PROSPECTIVE|||||||
33743941|NCT05410574|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33743942|NCT03207412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33743943|NCT00952653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743944|NCT00844623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743945|NCT06050421|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33846971|NCT03368729|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There are two phases to this study. Phase 1 will enroll 6-12 patients and Phase 2 will enroll up to 40. Trastuzumab will be given intravenously at 6 mg/kg on Day 1 for each 21 day cycle in both phases. Niraparib will be given by mouth every day at a dosage of 200 mg for phase 1 participants and 200 mg (or 100 mg) for phase 2 participants. Tumor measurement and response will be monitored by MRI or CT scans after cycles 3 and 6 and then every 12 weeks for up to 2 years or until disease progression. Blood and tissue samples will be collected for pharmacokinetics, biomarkers, and laboratory evaluations.||||
33846972|NCT03262142|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33846973|NCT05259072|NA|SINGLE_GROUP||OTHER||NONE||||||
33846974|NCT06041048|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33846975|NCT01802905|NA|SINGLE_GROUP||||NONE||||||
33846976|NCT06606301|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33846977|NCT02393300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846978|NCT06436339|||COHORT||CROSS_SECTIONAL|||||||
33846979|NCT01034605|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33846980|NCT01572103|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33846981|NCT00182559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846982|NCT02863289|||COHORT||RETROSPECTIVE|||||||
33846983|NCT04537416|||COHORT||CROSS_SECTIONAL|||||||
33846984|NCT00943111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846985|NCT01141647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846986|NCT04689282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846987|NCT01655693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846988|NCT04198753|||CASE_CONTROL||PROSPECTIVE|||||||
33846989|NCT01628562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33846990|NCT01716897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33846991|NCT00439322|||||PROSPECTIVE|||||||
34056606|NCT06056882|||COHORT||PROSPECTIVE|||||||
34056607|NCT01370824|||||PROSPECTIVE|||||||
34056608|NCT05718427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
34056609|NCT00002701|RANDOMIZED|||TREATMENT||||||||
34056610|NCT05592561|RANDOMIZED|PARALLEL||OTHER||SINGLE|The researchers will prepare the caffeine, placebo, tyrosine, and theanine containing sweetened and flavor matched beverages immediately before subjects ingested them. The subjects will not be told which treatment they will be receiving. There will be no indicative labels on the water bottle provided to them which contained the crystal light which will be mixed with either 200 mg of caffeine, 200 mg of theanine, 2000 mg tyrosine or crystal light only (placebo)|"Subjects will be randomly assigned to one of four treatments:~1. placebo ingestion~2. caffeine ingestion~3. theanine ingestion~4. tyrosine ingestion~nutrient ingestion takes place 40 min prior to being exposed to a mental stress task."|t|f|f|f
34056611|NCT01014897|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34056612|NCT04439019|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date Patients are encouraged to attend sessions with a family members. We intend to demonstrate improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation."||||
34056613|NCT01093326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056614|NCT02026024|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056615|NCT04501783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056616|NCT01037127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846992|NCT00171717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33846993|NCT04144101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33846994|NCT04715165|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056617|NCT06620848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056618|NCT03249246|||COHORT||CROSS_SECTIONAL|||||||
34056619|NCT05735262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056620|NCT06537934|||COHORT||PROSPECTIVE|||||||
34056621|NCT01852552|||COHORT||PROSPECTIVE|||||||
34056622|NCT06603961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056623|NCT00904202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056624|NCT02434172|||COHORT||PROSPECTIVE|||||||
34056625|NCT06623942|||CASE_CONTROL||PROSPECTIVE|||||||
34056626|NCT00504491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056627|NCT05432947|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743946|NCT06535412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743947|NCT01947881|||COHORT||PROSPECTIVE|||||||
33743948|NCT00905580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33743949|NCT02961972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|creatine or placebo supplementation|creatine or placebo supplementation|t|f|f|f
33743950|NCT04571346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be blinded to the type of intervention as well as the data collector and the statistician|Female patients complaining of stress urinary incontinence will be selected for our study, at the urology department, Ain-shams University hospitals. Those patients will be randomized into 2 equal groups with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee, group 1 represents the classical TOT procedure while group 2 represents the 2 paramedian vertical incisions technique. Patients will be blinded to the type of intervention. Informed consent will be obtained for all patients before the surgery, Careful evaluation will be done including history taking, examination with a stress test and urodynamic study. Patients with neurological disease, pelvic organ prolapse, previous urethral or pelvic floor surgery will be excluded from our study.|t|f|t|t
33743951|NCT03397446|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be instructed to take LDX once daily for two months. The trial will begin with a 4-week titration period followed by a 4-week maintenance period for a total treatment duration of 8 weeks. The treatment phase will be followed by a 1-week follow-up.||||
33743952|NCT05071001|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33743953|NCT02895594|||CASE_ONLY||RETROSPECTIVE|||||||
33743954|NCT06259968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743955|NCT01283789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33846995|NCT03434990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor won't have any knowledge about the study purposes and will be unaware of the group allocation. The statistical analysis will also be performed blinded for group allocation.|This is a randomized controlled trial, characterized by the application of manual therapy, in which subjects will be randomly allocated into two groups: spinal manipulation plus myofascial release and spinal manipulation. The participants will be individuals with non-specific chronic low back pain. The study will be reported following the recommendations of the CONSORT Statement. For the present study, non-specific chronic low back pain was defined as uninterrupted low back pain for more than 12 weeks, with unknown causes.|f|f|f|t
33846996|NCT06609603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33846997|NCT04160065|NA|SEQUENTIAL||TREATMENT||NONE||||||
33846998|NCT06065254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33846999|NCT04220762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056628|NCT04023552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056629|NCT02691936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056630|NCT02447497|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056631|NCT06619535|||COHORT||RETROSPECTIVE|||||||
34056632|NCT06228924|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056633|NCT06648005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056634|NCT06503406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160920|NCT00200668|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160921|NCT00761696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160922|NCT01566500|||||CROSS_SECTIONAL|||||||
34160923|NCT00771966|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34160924|NCT05020275|||CASE_ONLY||PROSPECTIVE|||||||
34160925|NCT00961428|||||PROSPECTIVE|||||||
34160926|NCT05549791|||COHORT||PROSPECTIVE|||||||
34160927|NCT03833063|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||placebo controlled, randomized, cross-over|t|t|t|t
34160928|NCT01966289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160929|NCT01514201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160930|NCT03556709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160931|NCT06404489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34160932|NCT03495102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34160933|NCT04489199|||COHORT||PROSPECTIVE|||||||
34160934|NCT02744885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34160935|NCT04991662|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34160936|NCT02781480|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||AAV2/5-OPTIRPE65||||
34160937|NCT01964625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34160938|NCT06309589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743956|NCT02863640|||COHORT||RETROSPECTIVE|||||||
33743957|NCT00595244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33743958|NCT06668961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743959|NCT06646666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743960|NCT00796718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743961|NCT02124642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33743962|NCT06264921|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Randomized for the Expansion Phase|Dose Escalation and Dose Expansion||||
33743963|NCT06636630|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will enroll patients requiring evisceration with implant placement due to conditions such as end-stage painful blind eye, intraocular tumors, or severe ocular trauma. Patients will be randomly assigned to one of two surgical techniques: Double Flap Technique (Group A) or Quadriple Flap Technique (Group B).||||
33743964|NCT01287585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847000|NCT05362500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847001|NCT02355990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847002|NCT04547868|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, multicentre, open-label, three-arm parallel group Vanguard feasibility randomized controlled trial||||
33847003|NCT06095687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blind to participant condition.|Replicated single case experimental design|f|f|f|t
33847004|NCT01346475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847005|NCT00859729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160939|NCT05972005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this type of trial, the researchers responsible for assessing the outcomes remain unaware of the treatment assignments. The purpose of single-blind masking is to minimize bias and ensure that the assessment of outcomes is not influenced by researchers' expectations or knowledge of the treatment.|"This randomized controlled trial (RCT) will be conducted over a period of 14 weeks, utilizing a parallel-group design. It will be a single-blind trial, meaning that the assessors will not be aware of participants assigned intervention. The trial will include repeated measures, with follow-ups conducted up to 12 months after the participants are discharged from the hospital.~In terms of its design, this trial is considered to be rather pragmatic to very pragmatic, as indicated by a score of 37 out of 45 on the PRECISE-2 tool. The PRECISE-2 tool is used to assess the level of pragmatism in clinical trials, helping to identify trials that closely resemble real-world conditions and are applicable to everyday practice."|f|f|f|t
33743965|NCT06318676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34160940|NCT05433025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33743966|NCT01540123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33743967|NCT02270320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33743968|NCT00872495|||CASE_CONTROL||PROSPECTIVE|||||||
33743969|NCT00034762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33743970|NCT05914610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951934|NCT03014570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951935|NCT05978375|||COHORT||PROSPECTIVE|||||||
34160941|NCT02678507|||CASE_ONLY||PROSPECTIVE|||||||
34160942|NCT03944512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Consenting women will be assigned to pravastatin or placebo in a 1:1 ratio according to a randomization sequence prepared and maintained centrally by the Data Coordinating Center (DCC). The two study medication arms of the study (pravastatin or placebo) are double masked; neither the patient nor the clinical staff will be aware of the treatment assignment.|"The study is a randomized controlled multi-center clinical trial of 1,550 women with a prior history of preeclampsia that required delivery at less than or equal to 34 weeks 0 days gestation, randomized to one of two arms at participating Maternal Fetal Medicine Units Network clinical centers.~* 20 mg pravastatin daily~* Identical appearing daily placebo"|t|f|t|f
34160943|NCT01052506|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34160944|NCT05538676|||OTHER||PROSPECTIVE|||||||
34160945|NCT05416879|||OTHER||PROSPECTIVE|||||||
34160946|NCT02496299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34160947|NCT05796895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There will be two groups in parallel. The first will be the intervention group in which children will be provided with the videogame intervention for eight weeks. Children will play the videogame and learn about symptom management strategies through the game tasks. The children will complete the tasks, score points, and progress to the next game. The videogame will be connected to a web-based portal through which the research team will retrieve data regarding the progress of the children's gameplay.||||
34160948|NCT06170918|NA|SEQUENTIAL||TREATMENT||NONE||The initial dose is 0.4mg/kg and the dose interval is 0.2mg/kg||||
34160949|NCT05981027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160950|NCT02200276|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34160951|NCT06087484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160952|NCT03632772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160953|NCT04160663|NA|SINGLE_GROUP||PREVENTION||NONE||Carotid Ultrasound testing before and after a clinically scheduled cardioversion procedure.||||
34160954|NCT03562494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Sham Surgery Controlled, Double-blind, Multi-center|t|t|f|t
34160955|NCT04249921|||CASE_CONTROL||RETROSPECTIVE|||||||
33765197|NCT03921346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding to the direct IV drugs and doses intended for use will be maintained during recruitment to minimize preparation bias. Allocation concealment will be ensured with an allocation software and not released until the paramedics start the scenario. Study team members will be revealed to the participants just before the scenario starts. Paramedics will be unblinded when the simulated scenario starts. Although the intervention could not be masked, all investigators will remain unaware of the outcomes until all data will be unlocked for analysis at the end of the trial. All scenarios will be video-recorded for later analysis. Post-scenario video review will be done without blinding by two reviewers, but undertaken independently and blinded to each other's reviews. In case of disagreement, a third independent evaluator will help reach a consensus. The data analyst will be blinded to treatment allocation.|Prospective, multicenter, randomized, controlled trial|t|f|f|f
33765198|NCT01775514|||COHORT||PROSPECTIVE|||||||
33847006|NCT03309813|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"Subjects were randomized to an Exablate Test Arm or a Sham Control Arm. After completing the Month 3 Sham study visit, Sham Controls could elect to receive the actual Exablate ablation (same as test arm) and continue follow-up in a Crossover Arm."|t|t|t|t
33847007|NCT01901432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160956|NCT06003660|||COHORT||PROSPECTIVE|||||||
34160957|NCT00003419||||TREATMENT||||||||
34160958|NCT06164834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160959|NCT06521372|||CASE_CONTROL||PROSPECTIVE|||||||
34160960|NCT03487744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34160961|NCT00241774|||COHORT||PROSPECTIVE|||||||
34160962|NCT03186729|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomised-controlled trial, parallel groups|f|f|f|t
34056635|NCT06599099|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Discontinuation: In all cases, the sequence will be as follows in one-week segments: 100% Active (Sham discontinuation), 75% Active, 50% Active, 25% Active, and 0% Active (stim off). They will be told that DBS will be discontinued at some point during the 4 weeks. The programmer will be unblinded and perform sham activation. Relapse is defined as a 25% increase of the MADRS over two consecutive visits compared to discontinuation baseline. Escape criteria will include withdrawing consent or significant clinical deterioration warranting unblinding or reinstatement of treatment. Following exit from the discontinuation period, treatment will recommence as clinically indicated including stimulation resumption or continued observation with device off. A stepwise discontinuation over 4 weeks is intended to mitigate rebound effects, striking a balance between scientific need and subject well-being, with escape criteria allowing us to re-initiate therapy if needed for patient safety."|This model will include 10 subjects between the ages of 22 and 64 with severe, TRBD. These subjects will undergo surgery with DBS leads targeting the ventral capsule/ventral striatum (VC/VS) bilaterally to assess the safety and preliminary efficacy of VC/VS DBS. Subjects will undergo behavioral and clinical testing to provide further insight for alleviating and preventing recurrence of depression and emergence of mania.|t|f|f|t
34056636|NCT01869621|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056637|NCT05669898|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm parallel assignment involves two groups of participants receiving multimodal analgesia after unilateral total knee arthroplasty. One group receives a single-injection adductor canal block combined with intravenous morphine patient-controlled analgesia, and the other group receives continuous adductor canal infusion in combination with intermittent intravenous non-steroidal anti-inflammatory drug.||||
34056638|NCT00522535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056639|NCT00662662|||COHORT||PROSPECTIVE|||||||
34056640|NCT01972451|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34056641|NCT06648629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators will have a research staff members who are responsible for administering baseline appts (with randomization) and post-treatment study appointments. The outcome assessor will be blind to intervention condition. Interventionists will not collect any outcome data. Study investigators and the Data Safety Monitoring Board (DSMB) members will be presented with interim data (e.g., study completion reports) that are blinded to treatment condition.|Participants will be randomly assigned to one of the following two pre-specified treatment groups: Acceptance and Commitment Therapy or Brief Alcohol Intervention.|f|f|f|t
34056642|NCT04525079|RANDOMIZED|SEQUENTIAL||SCREENING||QUADRUPLE|||t|t|t|t
34056643|NCT03673345|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056644|NCT06421545|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056645|NCT02727582|||COHORT||RETROSPECTIVE|||||||
34056646|NCT02428803|||CASE_CROSSOVER||PROSPECTIVE|||||||
34056647|NCT02491372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056648|NCT05307016|||COHORT||PROSPECTIVE|||||||
34056649|NCT00636194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34056650|NCT00707876|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34056651|NCT01088243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056652|NCT06620575|||COHORT||RETROSPECTIVE|||||||
34056653|NCT04108494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056654|NCT03808350|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Family members and patients will be told the study is being done to understand engagement, but will not be told about the main intervention||t|f|f|f
34056655|NCT04346212|||COHORT||PROSPECTIVE|||||||
34056656|NCT04546321|||OTHER||PROSPECTIVE|||||||
34056657|NCT03338803|||COHORT||RETROSPECTIVE|||||||
34056658|NCT03439215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056659|NCT06620289|||COHORT||PROSPECTIVE|||||||
34056660|NCT03852368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34056661|NCT04202913|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056662|NCT03068819|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056663|NCT05836974|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056664|NCT05526807|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056665|NCT02156895|||CASE_ONLY||PROSPECTIVE|||||||
34056666|NCT04530266|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34056667|NCT01608815|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056668|NCT02915536|||||CROSS_SECTIONAL|||||||
34056669|NCT00775840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056670|NCT00359736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056671|NCT03560726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056672|NCT03246165|||CASE_CONTROL||PROSPECTIVE|||||||
34056673|NCT05960448|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant will not know whether or not they are receiving spinal stimulation at any given session||t|f|f|f
34056674|NCT00003829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056675|NCT00591617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056676|NCT03780465|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The pharmacist preparing the study medication and the study nurse administering the study medication are not masked.||t|f|t|t
34056677|NCT02533557|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34056678|NCT04448067|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study utilized a parallel intervention of meals with 0, 60 or 120 g of lentils 5 days per week for 8 in overweight or obese adults with elevated waist circumference.||||
34056679|NCT06362018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34056680|NCT04001894|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34056681|NCT05617638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076228|NCT05419297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two designated staff will be unblinded, and be responsible for providing the subjects with envelopes containing either drug or placebo. Principal investigator and the remainder of the staff will be blinded throughout the duration of the study.|A double blind, placebo controlled, phase IV clinical trial. Following a two week washout of opioid medication, a two week single blind placebo lead in, subjects will be randomized into two groups. One group to receive placebo film, and the other to be titrated to effect with buprenorphine buccal film.|t|t|t|f
34076229|NCT03629769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076230|NCT02236312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056682|NCT03543098|RANDOMIZED|PARALLEL||TREATMENT||NONE|These are unblinded trials as the participants will know when they are receiving surgery and when they are receiving rehabilitation. The data that are collected as part of the standard of care clinical follow-up will be recorded by the clinicians that know the participant's surgery assignment. The primary outcome and most of the secondary outcomes are patient self-report. Given that our interventions are either early or delayed surgery and/or rehabilitation, it is difficult for us to estimate the direction of potential bias (if any) that could come from the unblinded nature of this study.|Two parallel prospective randomized multi-center clinical trials. Trial 1 will evaluate the effects of both the timing of surgery and post-operative rehabilitation. Trial 2 will evaluate only the effects of timing of post-operative rehabilitation.||||
34056683|NCT06623734|||COHORT||PROSPECTIVE|||||||
34056684|NCT06619548|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34056685|NCT05332990|||CASE_CONTROL||RETROSPECTIVE|||||||
34056686|NCT04571970|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm||||
34056687|NCT00916968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056688|NCT04291664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056689|NCT05294159|||OTHER||PROSPECTIVE|||||||
34056690|NCT03756727|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34056691|NCT04432090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34056692|NCT00591058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056693|NCT06619145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056694|NCT04535050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056695|NCT03363451|||CASE_ONLY||RETROSPECTIVE|||||||
34056696|NCT05957536|NA|SEQUENTIAL||TREATMENT||NONE||||||
34056697|NCT04999306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Hypnosis vs Cognitive Behavioral Therapy||||
34160963|NCT04577430|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34160964|NCT03876119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The solutions of alteplase or placebo are limpid, transparent and colorless. Alteplase (Actilyse 10 mg powder and solvent for solution for injection and infusion) and placebo will be provided in kind by Boëhringer Ingelheim. The secondary conditioning of the investigation treatment will be performed by Alcura Health Spain S.A.|Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke patients treated with MT, in which two therapies are compared: rt-PA or placebo.|t|t|t|t
34160965|NCT06240104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34160966|NCT00566852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34160967|NCT03538366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160968|NCT05822180|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34160969|NCT03139123|||COHORT||PROSPECTIVE|||||||
34160970|NCT04679194|NA|SEQUENTIAL||TREATMENT||NONE||||||
34160971|NCT04789889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160972|NCT01022138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160973|NCT00756990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160974|NCT02041338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160975|NCT03276897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160976|NCT01076036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160977|NCT02450292|||CASE_ONLY||PROSPECTIVE|||||||
34160978|NCT06153537|||COHORT||PROSPECTIVE|||||||
34160979|NCT02745834|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34056698|NCT04694950|||COHORT||PROSPECTIVE|||||||
34160980|NCT02089789|||COHORT||PROSPECTIVE|||||||
34160981|NCT03356678|||CASE_ONLY||RETROSPECTIVE|||||||
33765199|NCT06623201|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study where all participants receive the same treatment||||
33765200|NCT04034459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160982|NCT02769910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160983|NCT00623870||PARALLEL||TREATMENT||NONE||||||
34160984|NCT03657290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a randomized, open-label, single-dose, three-period, six- sequence crossover study in healthy adults. A total of 54 eligible subjects will be randomized to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Refer to Treatment Sequences below. Each sequence is comprised of 3 treatments||||
34160985|NCT04971356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34160986|NCT05765123|||COHORT||CROSS_SECTIONAL|||||||
34160987|NCT03654508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicentre, double-blind, precision medicine, randomized trial|t|t|f|f
34160988|NCT03423316|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34160989|NCT06526819|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34160990|NCT00858208|||CASE_ONLY||PROSPECTIVE|||||||
34160991|NCT05242172|||COHORT||RETROSPECTIVE|||||||
33765201|NCT05834036|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765202|NCT02339896|||CASE_ONLY||PROSPECTIVE|||||||
33765203|NCT02844491|||COHORT||PROSPECTIVE|||||||
33765204|NCT04519021|||OTHER||CROSS_SECTIONAL|||||||
33765205|NCT00647101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765206|NCT06625489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part A is a double-blind study and Part B is an open-label study.||t|f|t|f
33765207|NCT01484808|||CASE_CONTROL||RETROSPECTIVE|||||||
33765208|NCT03185832|||COHORT||PROSPECTIVE|||||||
33951936|NCT01667016|||OTHER||PROSPECTIVE|||||||
33951937|NCT05046145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants do not know what treatment they will receive. The outcomes assessor does not know treatment aplicado in participants sham or real).|The study will be a randomized, double-blind, parallel clinical trial. Participants will receive real tDCS or tDCS sham for 10 sessions during the treatment period. The interstice period of the total intervention will be 15 days (2 subsequent weeks, 10 working days, to apply the intervention). The probabilistic, simple randomized sample will consist of participants with randomized food cravings into two groups, there will be subdivision to receive or not neuromodulation, according to the flowchart.|t|f|f|t
33951938|NCT03583931|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Clinical Trial||||
33951939|NCT02938819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951940|NCT01574976|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33951941|NCT04514224|||COHORT||PROSPECTIVE|||||||
33951942|NCT06448169|||COHORT||PROSPECTIVE|||||||
33951943|NCT03304132|||CASE_CONTROL||PROSPECTIVE|||||||
34056699|NCT05093530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled trial.|t|f|t|f
34056700|NCT02223650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056701|NCT06512935|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Single centre, randomized crossover study. This study will include preterm infants with recovering RDS born at age \< 34 weeks of gestational age on respiratory support via conventional mechanical ventilation or on HFJV.~Infants will be randomized to the order of testing, increasing the PEEP (+1 cmH2O and +2 cmH2O) or decreasing the PEEP (+1 cmH2O and +2 cmH2O) with baseline measurements and Echo done at original PEEP and at each subsequent PEEP."|f|f|f|t
34056702|NCT05001295|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34056703|NCT03126006|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"It's an assessor blinded, parallel group, randomized controlled trial aimed at determining the superiority of non-surgical periodontal therapy over no dental treatment among pregnant women.~The main objective of this trial is to determine whether the provision of NSPT to pregnant women with periodontitis is effective in reducing the incidence of low birth weight, preterm birth and still birth when compared to the pregnant women who were subjected to no NSPT. Outcomes of interest are pre-term birth (\<37 weeks) gestation, low birth weight (\<2500g) or still birth with either one occurring being considered as a positive outcome."|f|f|t|t
34056704|NCT01196689|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056705|NCT00410020|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056706|NCT05170503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056707|NCT01032421|||COHORT||PROSPECTIVE|||||||
34056708|NCT02819245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056709|NCT03126019|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056710|NCT05220566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34056711|NCT06621355|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056712|NCT00170313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34056713|NCT04689048|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective, single-site, single-arm, phase 1 proof-of-concept study to assess the potential clinical utility of 18F-fluciclovine PET/CT as a functional integral biomarker for patients with large brain metastases (\>2 cm) treated with Staged Stereotactic Radiosurgery (SSRS).||||
34056714|NCT05275868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056715|NCT02953587|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34056716|NCT05948124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34056717|NCT01230424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056718|NCT06648278|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34056719|NCT04723953|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056720|NCT03764540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056721|NCT02994459|||COHORT||CROSS_SECTIONAL|||||||
34056722|NCT03180658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056723|NCT03622398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Total knee arthroplasty is performed on patients with knee osteoarthritis. One group will receive a highly cross-linked polyethylene liner and one group will receive a conventional polyethylene liner. Other parts of procedures will be the same.|t|f|f|t
34056724|NCT05456867|||CASE_CONTROL||PROSPECTIVE|||||||
34056725|NCT00520481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056726|NCT01783639|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056727|NCT05081180|NA|SEQUENTIAL||TREATMENT||NONE||||||
34056728|NCT02226705|NA|SINGLE_GROUP||TREATMENT||NONE||Endoscopic surgical treatment||||
34056729|NCT02559791|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34056730|NCT00095186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056731|NCT01770366|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056732|NCT06505135|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is designed as a prospective, randomized interventional trial to evaluate the effectoutcome of the treatment of rotator cuff tear with combined standard surgical attachment (standard care) of the supraspinatus tendon and supplementary injection of micro-fragmented tissue into the supraspinatus muscle (cell treatment group) compared to standard care only.||||
34056733|NCT05164640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056734|NCT03499691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056735|NCT06512454|||COHORT||PROSPECTIVE|||||||
34056736|NCT01271816|||COHORT||PROSPECTIVE|||||||
34056737|NCT06579937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056738|NCT00427206|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34056739|NCT01983072|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34056740|NCT05482321|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056741|NCT01968356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056742|NCT06475885|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Responses from the participants were coded as Group 1 and Group 2 by an independent individual, and the information regarding which code corresponded to which group was not shared with the statistician. The statistician performed the data analysis and wrote the results report, which was then communicated to the researcher. Only after this stage did the researcher learn which code corresponded to which group."|A comparative study of two groups compared with a control group.|f|f|f|t
34056743|NCT02580474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056744|NCT06618586|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|None (Open Label)|This is a hybrid type 3 implementation-effectiveness cluster randomized trial at 20 US birth hospitals. In a crossover design separated by a 1-month washout period, we will test 2 strategies for recruitment of mothers into the 2-month-long TodaysBaby mobile safe sleep education program: 1) The original TodaysBaby implementation strategy (HT), in which hospital staff recruit mothers and view the first 2 videos with them; and 2) A new low-touch (LT) hospital implementation strategy, in which mothers are attracted to TodaysBaby through direct-to-consumer marketing and sign themselves up using a QR code.||||
34056745|NCT05755607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The way of surgery.|The key difference in treatment between the two groups is the surgical approach, with the LPD group undergoing laparoscopic-assisted pancreaticoduodenectomy and the RPD group undergoing robotic-assisted pancreaticoduodenectomy, with all treatments remaining the same except for the surgical approach.|f|f|f|t
34056746|NCT03270475|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056747|NCT05310500|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33743971|NCT04584372|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The two treatment arm will consist of a 4-week high-nitrate (HI-NI) intervention (using nitrate-rich beetroot juice) and a 4-week low-nitrate (LO-NI) intervention using nitrate-depleted beetroot juice as the placebo. All products will be obtained from the same supplier (James White Drinks Ltd., UK). The nitrate-depleted beetroot juice is generated for research purposes only. The two juices will be indistinguishable by taste, color, smell and packaging. The investigators involved in the data acquisition and analysis will be blind to the trial allocation until the study has been completed and all analyses have been performed.|"Prospective, mono-center, randomized, double-blind, placebo-controlled, crossover study~The study will involve a randomized, placebo-controlled crossover design, with two 4-week treatment periods separated by a 4-week washout period. The two treatments will consist of a 4-week high-nitrate (HI-NI) and a 4-week low-nitrate (LO-NI, i.e., placebo) intervention in older adults with treated grade 1 hypertension, on the background of a low-nitrate diet and unaltered lifestyle."|t|f|t|t
34056748|NCT01670734|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33743972|NCT04020510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056749|NCT04482595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo-controlled|t|t|t|t
34056750|NCT02784626|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33743973|NCT06459921|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056751|NCT03430661|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34056752|NCT02017912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056753|NCT05047731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743974|NCT02696317|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33743975|NCT03248284|||COHORT||PROSPECTIVE|||||||
33743976|NCT02395484|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33743977|NCT05494879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743978|NCT01787526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33743979|NCT01575847|||||PROSPECTIVE|||||||
33743980|NCT04730297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a single-center, 2-stage, prospective, randomized, triple-blind parallel-group, placebo-controlled, clinical trial|t|t|t|f
33743981|NCT06057389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33743982|NCT01925716|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33743983|NCT06535477|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"Assessing frailty in elderly patients using Fried Frailty and Short Emergency Geriatric Assessment scales combined with measurement - via the AbilyCare device - of the two markers of balance and gait"||||
33847008|NCT03676491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study design is an explanatory mixed methods design in two parts. The first part is a two-arm parallel group, single center randomized controlled trial (n=120). Experimental group and waitlist control group receive standard treatment according to national guidelines. The experimental group use a sound pillow and The Music Star App at bedtime as a sleep aid in 4 weeks.The second part is an interview study (n=4). Qualitative data from a semi-structured interview on the use of music and sleep are used to discuss findings from the RCT.|f|f|f|t
33847009|NCT00762736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847010|NCT01125514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33847011|NCT05593445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study will be a 12 week double-blind period followed by a 12 week open label period.|t|t|t|f
33847012|NCT00393783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847013|NCT05784623|||COHORT||PROSPECTIVE|||||||
33847014|NCT00105599|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33847015|NCT02614456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847016|NCT01330732|||CASE_ONLY||PROSPECTIVE|||||||
33847017|NCT02103244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847018|NCT01384266|||COHORT||PROSPECTIVE|||||||
33847019|NCT02551718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847020|NCT05854095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847021|NCT01327443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847022|NCT05145140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847023|NCT04278859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33847024|NCT03383822|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33847025|NCT03462173|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33847026|NCT01051934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847027|NCT05573880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33847028|NCT03114800|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33847029|NCT04398290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847030|NCT01147276|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33847031|NCT05361239|||COHORT||PROSPECTIVE|||||||
33847032|NCT04439162|NA|SINGLE_GROUP||SCREENING||NONE||RCT||||
33951944|NCT03495167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951945|NCT03546270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951946|NCT02853825|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33951947|NCT02395393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056754|NCT05109637|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056755|NCT02049840|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, post-market, single arm, mutlicenter||||
34056756|NCT05524818|||COHORT||PROSPECTIVE|||||||
34056757|NCT03042169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056758|NCT04902703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is double-blind, placebo-controlled in the Alzheimer's Disease population, and will include individuals with mild AD and moderate AD. Individuals who meet inclusion/exclusion criteria will be randomized in a double-blind manner, to receive either sargramostim 250 µg/m2/day subcutaneously (5 days per week) or placebo (5 days per week) in an approximate 2:1 randomization ratio.|t|t|t|f
34056759|NCT05964816|||COHORT||PROSPECTIVE|||||||
34056760|NCT04766489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056761|NCT00181350|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056762|NCT01117233|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34056763|NCT06298474|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Cluster Randomized Trial (CRT) will be conducted with each LTC facility being considered a cluster. All PLWD at an Experimental facility will be invited to use the intervention twice per week for 3 months, while all PLWD at a Control facility will receive standard care/programming for 3 months. Individual random assignment is not feasible, due to the high likelihood of contamination in a study involving the facilitation of activities in a LTC environment. LTC Facilities Eight (8) LTC facilities will participate in the study-i.e., 4 NHs and 4 ALFs. Half of the sites will be randomly assigned to the Experimental Group and the other half to the Control Group. So, 2 NHs and 2 ALFs will be assigned to the Experimental Group, while 2 NHs and 2 ALFs will be assigned to the Control Group.||||
34056764|NCT05136313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||TRE intervention comparing MHO vs MUO||||
34056765|NCT06618495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056766|NCT00536224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056767|NCT03932149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056768|NCT06618248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056769|NCT02362776|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056770|NCT05499260|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34056771|NCT02897726|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34056772|NCT05019846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056773|NCT01226368|||COHORT||PROSPECTIVE|||||||
34076231|NCT05201846|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34160992|NCT00891241|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34160993|NCT01147055|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34160994|NCT06122974|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Subject will be blinded from their treatment assignment through the 12-month follow-up visit.|"Phase A will enroll 20 subjects and evaluate 30-day safety data~Phase B will enroll 345 to 518 subjects. Subjects from Phase A will be rolled into Phase B."|t|f|f|f
34160995|NCT00735722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34160996|NCT05249569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34160997|NCT05909384|||OTHER||OTHER|||||||
34160998|NCT04826939|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34160999|NCT00286429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161000|NCT05600244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161001|NCT03165422|||COHORT||RETROSPECTIVE|||||||
34161002|NCT02386163|||CASE_ONLY||PROSPECTIVE|||||||
34161003|NCT04246658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161004|NCT06273397|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an Open, Multicenter, Prospective, and Randomized study with three treatment arms. The outcomes to be assessed in the initial phase will be at 4 days post-randomization, followed by evaluation at 90 days after hospital discharge.||||
34161005|NCT01486342|||||PROSPECTIVE|||||||
34161006|NCT03262168|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants compete a six minute walk test (6MWT). Those who achieve less than 450 metres will be assigned to study group one. Participants who achieve greater than 450 metres on 6MWT will be assigned to study group two.||||
34161007|NCT04550494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161008|NCT05805046|||COHORT||PROSPECTIVE|||||||
34161009|NCT01582399|RANDOMIZED|PARALLEL||||NONE||||||
33951948|NCT02224794|||COHORT||PROSPECTIVE|||||||
33951949|NCT00124709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33951950|NCT02726516|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33951951|NCT02713724|RANDOMIZED|PARALLEL||||NONE||||||
33951952|NCT00346970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951953|NCT03359278|||COHORT||PROSPECTIVE|||||||
33951954|NCT01583465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951955|NCT01969201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33951956|NCT04166188|NA|SINGLE_GROUP||OTHER||NONE||||||
33951957|NCT02835794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951958|NCT02058459|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34161010|NCT04867733|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161011|NCT00535600|||||PROSPECTIVE|||||||
34161012|NCT00745537|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34161013|NCT06011837|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33743984|NCT03522662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951959|NCT06650722|||COHORT||PROSPECTIVE|||||||
33951960|NCT00882804|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33951961|NCT00658203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33951962|NCT01256229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951963|NCT01429142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951964|NCT01471600|RANDOMIZED|PARALLEL||||NONE||||||
33951965|NCT05392699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951966|NCT06367751|NA|SINGLE_GROUP||OTHER||NONE||This is a trial using routinely collected health care data from an ongoing registry (AO_2023-00091) in cancer patients with advanced solid malignancies receiving first line systemic anti-cancer treatment for advanced disease. All patients will receive routine diagnostics, treatment and follow-up. All patients with a new cancer diagnosis will be assessed for eligibility based on the routinely collected information available in the registry. We will then randomly decide which eligible patients are invited to participate in the trial. If patients accept the invitation and intend to get a measurement of ctDNA, they have to provide written informed consent. The study comprises an external comparator arm with 75 (anticipated) cancer patients, and an active comparator arm with 150 (anticipated) cancer patients.||||
33951967|NCT01340794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951968|NCT00604175|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33951969|NCT04302753|||CASE_ONLY||RETROSPECTIVE|||||||
33951970|NCT02160054|||CASE_ONLY||PROSPECTIVE|||||||
33951971|NCT03741543|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||a 12-week health promotion course||||
33951972|NCT01920269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951973|NCT01381068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951974|NCT02901184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951975|NCT00469066|||CASE_ONLY||PROSPECTIVE|||||||
33951976|NCT02064231|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33951977|NCT06242262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951978|NCT02466191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951979|NCT01667523|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33951980|NCT01813942|||||RETROSPECTIVE|||||||
33951981|NCT05917080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Biomechanical Relationship of pronated foot \& Anterior knee pain|t|f|t|f
33951982|NCT04557293|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33951983|NCT04088617|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo masked with flavouring and participants consume in opaque containers|Crossover assignment|t|f|f|t
33951984|NCT00707252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056774|NCT03344575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient undergoing surgery and the physician performing the follow-up are masked to the allocation.|Double-blind randomized controlled trial.|t|f|f|t
34056775|NCT01215058|||COHORT||CROSS_SECTIONAL|||||||
34056776|NCT02410083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056777|NCT06619717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056778|NCT00169728|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34056779|NCT03710070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161014|NCT03719742|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34161015|NCT00185575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161016|NCT02150278|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34161017|NCT06379776|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34161018|NCT01817504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161019|NCT01568294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161020|NCT00994526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34161021|NCT00133861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33743985|NCT00793208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743986|NCT06013176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Eligible patients will be identified pragmatically and will be independently randomized to study arms using a three-arm design.|f|f|t|f
33951985|NCT03585166|||CASE_CONTROL||PROSPECTIVE|||||||
33951986|NCT04892875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951987|NCT05700526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the doctor and the patient will not be aware of the graft preparation method.|The study in defined as a randomized clinical trial with two groups and will be double-blind. The randomization will be based on the realization method of the grafts.|t|t|f|f
34161022|NCT03005548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161023|NCT01247168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161024|NCT04637425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161025|NCT03387020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743987|NCT03267680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743988|NCT01069783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743989|NCT05890053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743990|NCT02500225|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33743991|NCT04475601|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized (2:1), open, multicentre, clinical controlled trial||||
33743992|NCT04570826|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A meditation master practitioner with at least 10 years of experience implemented in the Faculty of Health Sciences of the University of Granada a FAM program during four weeks, two sessions per week, each Friday. The caregiver attendance to two continues sessions during a total of four hours, two hours per session with thirty minutes of rest between both of them.||||
33743993|NCT05759598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33951988|NCT04684979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design will be based on a total of 90 patients, 30 recipients of related matched and 60 recipients of mismatched related or unrelated PBSCT.||||
33951989|NCT02583594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33951990|NCT03148912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951991|NCT04766658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33951992|NCT02798302|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33951993|NCT05478356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33951994|NCT01042288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33951995|NCT02553291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33951996|NCT03652129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33951997|NCT02619565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33951998|NCT05437731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33743994|NCT01559402|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33743995|NCT00487110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33743996|NCT03524326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33743997|NCT03243526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|patient will be blinded and person who will do lung ultrasound|two groups one recieve fluid guided by CVP and othe by PPV|t|f|f|t
33743998|NCT03356912|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33743999|NCT06404580|||CASE_CONTROL||RETROSPECTIVE|||||||
33744000|NCT05956652|||CASE_ONLY||PROSPECTIVE|||||||
33744001|NCT02790385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33744002|NCT02399267|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33744003|NCT06405373|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33951999|NCT05028985|||COHORT||PROSPECTIVE|||||||
33952000|NCT05966142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate vs. delayed pharmacogenetic testing and genotype-guided pain or depression therapy||||
33952001|NCT06015061|||COHORT||PROSPECTIVE|||||||
33952002|NCT00701012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33952003|NCT02459756|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33952004|NCT02768506|||COHORT||PROSPECTIVE|||||||
33952005|NCT06126107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blind to condition.|Participants will be urn randomized according to gender, age and intensity of drinking to the three conditions collected at screening. They will be assigned to one of 3 text-messaging programs.|t|f|f|f
33952006|NCT02986048|||COHORT||PROSPECTIVE|||||||
33952007|NCT04782973|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33744004|NCT06371885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double mask for both groups (participant)|Interventional (clinical trial)|t|f|f|f
33952008|NCT05719701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952009|NCT06493110|||COHORT||PROSPECTIVE|||||||
33952010|NCT00902759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952011|NCT02481024|||OTHER||CROSS_SECTIONAL|||||||
33952012|NCT04029142|||COHORT||PROSPECTIVE|||||||
33952013|NCT05346458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single centre, prospective, feasibility study of the iKOs™ coronary pressure and flow rapid-exchange microcatheter and iKOr™ console in patients with coronary heart disease undergoing coronary physiology investigations.||||
33952014|NCT01424631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952015|NCT00186082|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33952016|NCT06251765|||COHORT||PROSPECTIVE|||||||
33952017|NCT00790972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952018|NCT00000518|RANDOMIZED|||TREATMENT||||||||
33952019|NCT05897411|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33952020|NCT05890235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952021|NCT00709449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952022|NCT03367676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765209|NCT01478711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765210|NCT00654134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33952023|NCT00363935|RANDOMIZED|PARALLEL||||DOUBLE||||||
33952024|NCT05631509|||COHORT||CROSS_SECTIONAL|||||||
33952025|NCT00250666|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33952026|NCT05450900|RANDOMIZED|PARALLEL||OTHER||SINGLE|Every other enrollee|One cohort receives active drug ovidrel plus biotin supplementation One cohort receives active drug ovidrel plus a placebo|t|f|f|f
33952027|NCT01694927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952028|NCT03459066|||OTHER||CROSS_SECTIONAL|||||||
33952029|NCT04145739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952030|NCT05352607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be 2 groups one is control group will receive a conventional physiotherapy treatment and the second group will receive a conventional physiotherapy treatment plus TENS therapy.|f|f|f|t
33952031|NCT06344676|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33952032|NCT06311981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952033|NCT06426901|RANDOMIZED|PARALLEL||OTHER||SINGLE||group1 ,experimental group group 2 control group|t|f|f|f
33952034|NCT01821508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952035|NCT05209321|||COHORT||PROSPECTIVE|||||||
33952036|NCT06496984|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952037|NCT02866201|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952038|NCT01654211|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34161026|NCT04942613|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcomes assessor will be blinded to group allocation|Participants will be randomized to 1 of 2 groups: Group1 will receive the intervention first for 12 weeks, and Group2 will receive the waitlist control for 12 weeks. At the end of 12 weeks, Group2 will crossover to the intervention.|f|f|f|t
34161027|NCT05627024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In addition to the anesthesiologist on the day of surgery, the patients and all participants, statistical analysts, ward staff, surgeons, and treatment-outcome assessors are blinded to group assignment.||t|f|t|t
34161028|NCT01435135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34161029|NCT04389723|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34161030|NCT00363623|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34161031|NCT01712802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161032|NCT03475485|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||TRIPLE|Capsules are identical in appearance. Only unblinded pharmacy personnel at the study site will be aware of the ingestion allocation of active ID-Capsules or placebo capsules.|This study is a prospective, blinded, clinical study evaluating the safety and effectiveness of the ID-Cap System under direct observation in the clinical setting. Subjects will ingest a series of active ID capsules containing ingestible sensors and a series of empty placebo capsules that will be randomly administered. The ID-Capsule System's feasibility/ability to properly record actual ingestions (Positive Detection Accuracy) and to not record blank ingestions (Negative Detection Accuracy) will be evaluated.|t|f|t|t
34161033|NCT05701696|||CASE_ONLY||CROSS_SECTIONAL|||||||
34161034|NCT06324292|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The participants allocated into two groups; a conventional denture followed by a digital group (CG) and a digital denture followed by a conventional one group (DG).|t|f|t|t
34161035|NCT02172378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34056780|NCT06620601|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056781|NCT01483482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056782|NCT01250132|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056783|NCT02106416|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161036|NCT02402140|RANDOMIZED|PARALLEL||||NONE||||||
34161037|NCT05981469|||COHORT||PROSPECTIVE|||||||
34161038|NCT04887519|||COHORT||OTHER|||||||
34161039|NCT01732276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161040|NCT00633529|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34161041|NCT05555706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161042|NCT00751803|RANDOMIZED|PARALLEL||TREATMENT||||||||
34161043|NCT05582772|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE|Given the nature of the intervention, it is not possible to blind patients or the project team to allocation, however, the statistician is blinded|This model will provide within-group change scores for both co-primary outcomes (i.e., grade 3-5 toxicity and QOL) along with standard deviations and responsiveness measure. These data will guide selection of the single or dual primary outcome for the definitive phase III RCT as well as inform sample size calculations. Importantly, they will not be used to determine the clinically important difference used to plan for the phase III RCT. These 2 co-primary outcomes were selected based on literature review, clinical input, and patient-partner input.||||
34161044|NCT05137899|RANDOMIZED|PARALLEL||TREATMENT||NONE||Neoadjuvant Atezolizumab/Bevacizumab versus neoadjuvant SBRT in patients with biopsy proven solitary HCC with PVTT involving the portal vein branches.||||
34161045|NCT00650767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161046|NCT03016065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34161047|NCT01650168|||COHORT||PROSPECTIVE|||||||
34161048|NCT00498589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161049|NCT02797392|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34161050|NCT04299035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161051|NCT03162471|||OTHER||PROSPECTIVE|||||||
34161052|NCT03292107|||COHORT||PROSPECTIVE|||||||
34161053|NCT02313584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161054|NCT03813459|||COHORT||PROSPECTIVE|||||||
34161055|NCT00269867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161056|NCT04962867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161057|NCT00391027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161058|NCT04108195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161059|NCT01763606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161060|NCT04923568|NA|SINGLE_GROUP||OTHER||NONE||||||
34161061|NCT03814408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161062|NCT01848327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161063|NCT02661243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161064|NCT03707015|||CASE_ONLY||RETROSPECTIVE|||||||
34161065|NCT04786795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161066|NCT04872699|||COHORT||PROSPECTIVE|||||||
33765211|NCT06096324|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34056784|NCT00236158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056785|NCT04291482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator and Outcomes Assessor will be blinded to participants study arm allocation. It is impossible to blind study participants and intervention providers, it is behavioural trial.|This is a two-group intervention trial adopting a randomised controlled design. It is a hybrid trial assessing intervention effectiveness, cost-effectiveness and implementation with embedded within person assessment.|f|f|t|t
34056786|NCT06369519|||COHORT||RETROSPECTIVE|||||||
34076232|NCT02786654|||COHORT||PROSPECTIVE|||||||
34076233|NCT06273527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952039|NCT01056458|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33952040|NCT02226575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952041|NCT01277172|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33952042|NCT06202950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952043|NCT03632057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952044|NCT00083356||||TREATMENT||||||||
33952045|NCT04216953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952046|NCT01998165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952047|NCT02484209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33952048|NCT06050382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952049|NCT05809440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a parallel-group, non-blinded, randomized controlled trial conducted at the University of Malaya Medical Centre, Malaysia. Patients were recruited from the transplant clinic, the renal day care unit and the nephrology ward. Participants were randomly assigned to either intervention or control based on computer generated random number with 1:1 allocation ratio. Allocations were concealed with sealed envelopes.|t|f|f|f
33952050|NCT06355180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized to either the esketamine group or the MECT group, but due to the differences in treatment modalities, it will not be possible to blind the subjects and investigators. To ensure the objectivity of the measurements, independent assessors will be established. These assessors are psychiatrists trained in the consistency of the scales and will remain blinded to the group allocation of the subjects throughout the entire assessment process.||f|f|f|t
33952051|NCT03160092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952052|NCT05588401|NA|SEQUENTIAL||OTHER||NONE||||||
33952053|NCT00627094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952054|NCT06497595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952055|NCT04711642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Eligible patients will be enrolled and randomly assigned by a computer generated randomization list in a 1:1:1 ratio to the intervention groups (2) or the control group. After cataract surgery, all groups will be given a topical steroid-antibiotic (tobramycin 0.3% and dexamethasone acetate 0.1%) commercially available and commonly used by ophthalmologists worldwide postoperatively, in a 3-week tapered regimen (every 2 hours the first day, then every 4 hours for 6 days, then 3 times a day for 1 week and twice a day for 1 week). The 2 study groups will be also prescribed lubricant eye drops from the postoperative day 7 containing sodium hyaluronate 0.1% (in 2 different commercially available formulations) to instill 4 times daily for the following 3 months. Study group patients will be instructed to instill the lubricant eyedrops at least 10 minutes after the tobramycin-dexamethasone eyedrops. At postoperative visits, patients will be asked about compliance with the assigned treatment.|f|f|t|t
33952056|NCT01428388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952057|NCT04726631|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952058|NCT04494334|||COHORT||CROSS_SECTIONAL|||||||
33952059|NCT02350114|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952060|NCT01359306|||COHORT||RETROSPECTIVE|||||||
33952061|NCT01734109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952062|NCT02530086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952063|NCT04507282|||COHORT||PROSPECTIVE|||||||
33952064|NCT04822467|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34056787|NCT05940493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All site study personnel, except the unblinded dispenser and verifier, will be aware of whether participants are receiving abemaciclib or placebo until the study is formally unblinded.||t|t|t|t
34056788|NCT01317797|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34056789|NCT00396552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056790|NCT01451138|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34056791|NCT04056273|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34056792|NCT05030909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Trial Design This is a randomised control trial with a sequential waitlist control design to measure treatment effect sizes on primary and secondary outcomes of participant and parental wellbeing. We also will assess the methods of delivery, face validity and acceptability of treatment. Teenagers (aged 12-19) from the community will be recruited and allocated randomly to either two gender-specific groups to receive the same intervention over 6 weeks or to a comparison group who will be offered the intervention later. This balances the need for control groups while also widening access to the intervention for recruited participants. The study will be community-based in one site (Ōtautahi, Christchurch, New Zealand), with an emphasis on widening access to mental health supports in a minority community by maintaining cultural sensitivity and reducing stigma associated with mental illness.||||
34056793|NCT00756392|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34056794|NCT03805373|||COHORT||CROSS_SECTIONAL|||||||
34056795|NCT05161520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056796|NCT03281187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the differences on test and comparator product a double-dummy design will be used retaining the blind of the study. Therefore each participant will receive an active product and inactive medication (placebo).||t|f|t|f
34056797|NCT06387667|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Immunocompromised ICU Patients with Respiratory tract infections||||
33847033|NCT03230877|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33847034|NCT02816775|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33847035|NCT06049225|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33847036|NCT04174898|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, Unblinded, non-randomized||||
34056798|NCT05225415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled|t|t|t|t
34056799|NCT01539954|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056800|NCT00224458|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056801|NCT03748576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34056802|NCT04891406|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34056803|NCT02952625|NA|SINGLE_GROUP||OTHER||NONE||||||
34056804|NCT04803422|RANDOMIZED|CROSSOVER||TREATMENT||NONE|An electronic randomization sequence in the program R will be applied to randomize centers (clusters) 1:1. After randomization the allocation will not be concealed|||||
34056805|NCT03962543|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive mirdametinib (PD-0325901) at a dose of 2 mg/m\^2 twice daily (maximum dose of 4 mg twice daily), calculated based on body surface area. Dose will be administered in a 3-week on, 1-week off schedule.||||
34056806|NCT04349865|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056807|NCT00001111||||TREATMENT||||||||
34056808|NCT06636084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056809|NCT02129790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056810|NCT05994274|||COHORT||PROSPECTIVE|||||||
34056811|NCT06620692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056812|NCT06647732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056813|NCT04557462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056814|NCT03108599|RANDOMIZED|PARALLEL||PREVENTION||NONE||In the randomized controlled trial, participants will be randomly assigned to either the control or intervention groups. Following a baseline period, intervention participants will receive the enhanced cab portion of the intervention on its own. Then, for the following intervention phase, intervention participants will participate in the behavioral sleep program in addition to continuing the enhanced cab intervention.||||
34056815|NCT04006262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056816|NCT02985073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056817|NCT01849068|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34056818|NCT04175782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34056819|NCT00230022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847037|NCT00467701|||CASE_ONLY||CROSS_SECTIONAL|||||||
33847038|NCT02272296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847039|NCT02998580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847040|NCT00777088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847041|NCT02796300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847042|NCT04229875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847043|NCT05785377|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The injectate used for TAPB will be prepared according to the group by an anesthesiologist who won't be involved in the data collection|according to the computer-generated random number codes that will be placed in sealed envelopes, the patients will be randomly allocated into two groups; Group-B and Group-BN according tho the local anesthetic injected in Ultrasound-guided bilateral Tranversus abdominis plane block|t|f|t|f
33847044|NCT03554668|||COHORT||PROSPECTIVE|||||||
33847045|NCT02101385|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34056820|NCT01430780|||CASE_CONTROL||PROSPECTIVE|||||||
34056821|NCT03018366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056822|NCT02930746|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056823|NCT02284659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056824|NCT04938219|RANDOMIZED|PARALLEL||OTHER||NONE||Women undergoing caesarean section under neuraxial anaesthesia will be randomised into either the treatment group or control group (2 arms).||||
34056825|NCT06647615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056826|NCT03110861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056827|NCT06260033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056828|NCT06648109|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a crossover controlled trial to recruit 40 people, divided into two groups of 20 subjects each using randomised grouping and named Group A and Group B. Group A will receive the sleep electric blanket intervention for a period of 7 days and Group B will serve as the control group without additional intervention, followed by a washout period of 7 days. A 1-stage baseline as well as a 3-stage follow-up including questionnaires, physical and grip strength measurements, blood index tests, and dormitory environment measurements were required.||||
34056829|NCT01091545|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34056830|NCT02026817|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34056831|NCT06072677|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34056832|NCT00595517|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34056833|NCT03672123|||COHORT||PROSPECTIVE|||||||
34056834|NCT03809377|||COHORT||PROSPECTIVE|||||||
34056835|NCT02892513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056836|NCT03530787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|"Subjects will be randomized to two groups:~AZ Group (n= 17) Control Group (n=17)"|t|f|t|t
34056837|NCT05666128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056838|NCT00862342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056839|NCT05386277|NA|SINGLE_GROUP||OTHER||NONE||||||
34056840|NCT00005046||||TREATMENT||||||||
34056841|NCT06629233|NA|SINGLE_GROUP||OTHER||NONE||||||
34056842|NCT00687349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056843|NCT06624241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056844|NCT04794205|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34056845|NCT06612463|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The capsules used in both trials were identical in appearance. The caffeine and placebo supplements were prepared by a laboratory technician who was independent of the study.|"2 types of Intervention: caffeine or placebo. Arm 1: Caffeine trial: Participants ingested a capsule containing 3 mg/kg caffeine (Wako Pure Chemical Industries, Ltd., Osaka, Japan) 60 min prior to the match.~Arm 2: Placebo trial: Participants ingested a capsule containing starch (Chung-Yu Biotech Co LTD, Taichung, Taiwan) at the same time point.~The capsules used in both trials were identical in appearance. The caffeine and placebo supplements were prepared by a laboratory technician who was independent of the study."|t|f|t|t
34056846|NCT05389657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34056847|NCT05248295|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34056848|NCT05399017|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-randomized, open-labeled, self-control study, single arm.||||
34056849|NCT03023111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056850|NCT05283382|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|double blind|Drug group vs. Placebo group|t|f|t|f
34056851|NCT05051605|||COHORT||PROSPECTIVE|||||||
34056852|NCT05501015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056853|NCT00334633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056854|NCT01918150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34056855|NCT04364802|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161067|NCT05882461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In sequence of eligibility, participants will be randomized to the treatment arm or the control arm, with a 1:1 allocation ratio stratified by gender. The randomization sequence will be generated by a trained person that is not related to the study participants in any way. The investigators and study staff will be blinded to the randomization sequence until the end of the study. Participant randomization will be performed in REDCap. REDCap maintains an automated audit trail which includes the assigned study identification number, treatment allocation, and date and time of the allocation assignment.|The investigators will conduct a two-arm Randomized Control Trial (RCT), comparing a group assigned to receive the 90Second Caregiver Caregiver health letter, with a usual care control group.|f|f|t|t
34161068|NCT04694027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056856|NCT01950559|||COHORT||PROSPECTIVE|||||||
34056857|NCT06615713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056858|NCT03841539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Raters - (psychometrician, brain magnetic resonance imaging (MRI), dual energy x-ray absorptiometry (DEXA), and phlebotomy) will be blinded to the intervention group and will perform outcome assessments.|Participants will be randomized to a dietary intervention; Mediterranean or Low-Fat, and will follow this eating pattern for 12 months.|f|f|f|t
34056859|NCT04197921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056860|NCT01333358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056861|NCT03108040|||COHORT||CROSS_SECTIONAL|||||||
34056862|NCT06621823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161069|NCT05566171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765212|NCT05661721|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33952065|NCT05584241|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized delayed start design. Participants are randomized to receive, at baseline, either 'Diagnostic Disclosure Protocol' (cognitive testing/diagnosis) with an option to receive biomarker results after 6 months or 'Biomarker Disclosure Protocol' (cognitive testing, diagnosis, positron emission tomography-based amyloid and tau imaging. They are further categorized by biomarker status (+/positive or -/negative) for reporting purposes.||||
33952066|NCT03826446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056863|NCT06186817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056864|NCT04500600|||CASE_ONLY||CROSS_SECTIONAL|||||||
34056865|NCT06460844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056866|NCT03097055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34056867|NCT04902313|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Collection of data and analysis will be made by researcher with limited knowledge of participant status.|Interventional group of cancer patients, and observational group of pediatric patients with other chronic conditions.|f|f|f|t
34056868|NCT02587572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056869|NCT03586674|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161070|NCT04863872|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two-arm randomized controlled trial comparing the effectiveness of 2 approaches for preventing severe hypoglycemia among participants with type 2 diabetes who are at risk for severe hypoglycemia. Participants were randomly assigned to one of two interventions: 1) Proactive Care Management, consisting of outreach from Kaiser Permanente Washington (KPWA) nurses using standard KPWA clinical tools; 2) the same Proactive Care Management plus my hypo compass, a structured educational intervention.|f|f|t|t
34161071|NCT06361589|||COHORT||PROSPECTIVE|||||||
34161072|NCT02352844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161073|NCT05550935|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|"An attempt will be made to keep the research team performing the measurements masked to the healthy subject assignment until the first day of the Constant Work-Rate Exercise Test (first random order).~An attempt will be made to keep the participant masked by simulation with HFNC at 2 L/min and separation of one week between the two exercise tests to forget the effect of the high flow and sound of the device."|Participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study||||
33847046|NCT06259552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This study is an open-label, dose escalation study of single agent SPX-303|"Part 1: After the first dose escalation cohort of one patient, further dose escalation cohorts will recruit patients to receive SPX-303 in a 3+3 design; cohorts will be expanded in the event of a DLT. A safety dose expansion of up to 10 patients will confirm the MTD or MAD.~Part 2: Once the MTD or MAD has been established, the RP2D and preliminary efficacy will be determined by evaluating two dose levels in specific indications."||||
33847047|NCT00875602|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847048|NCT05189392|RANDOMIZED|PARALLEL||TREATMENT||NONE||21 patients with visible opsite patch and 21 patients with PICO||||
33847049|NCT03866798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847050|NCT03927339|||COHORT||PROSPECTIVE|||||||
33952067|NCT04380662|||COHORT||PROSPECTIVE|||||||
33952068|NCT03680209|||COHORT||PROSPECTIVE|||||||
33952069|NCT01440608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952070|NCT04219046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double-blind, placebo-controlled|t|t|t|f
33952071|NCT02738892|||COHORT||PROSPECTIVE|||||||
33952072|NCT06372392|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33952073|NCT03908840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056870|NCT06621862|||COHORT||PROSPECTIVE|||||||
34056871|NCT02609724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056872|NCT06530758|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34056873|NCT02454712|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076234|NCT02764502|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33765213|NCT03315936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765214|NCT06017830|NA|SINGLE_GROUP||SCREENING||NONE||||||
33765215|NCT06230614|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33765216|NCT01231841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765217|NCT04888247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765218|NCT04568967|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33765219|NCT02691195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765220|NCT02390427|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765221|NCT05624840|||COHORT||PROSPECTIVE|||||||
34076235|NCT05871840|||OTHER||OTHER|||||||
34076236|NCT03021317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076237|NCT04591106|||COHORT||PROSPECTIVE|||||||
34076238|NCT01684514|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33952074|NCT01761123|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952075|NCT01591109|||||RETROSPECTIVE|||||||
33952076|NCT00457795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952077|NCT03147209|NA|SINGLE_GROUP||OTHER||NONE||This is a feasibility pilot study for a health coaching intervention for truck drivers||||
33952078|NCT06561620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952079|NCT04246411|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33952080|NCT05299359|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952081|NCT02402556|RANDOMIZED|PARALLEL||||NONE||||||
33952082|NCT03229902||SEQUENTIAL||TREATMENT||NONE||single-case research design involving a series of AB designs||||
33952083|NCT00336531|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952084|NCT05513807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952085|NCT05480904|||COHORT||PROSPECTIVE|||||||
33952086|NCT05852106|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study will be conducted in two hospitals affiliated with a foundation in Istanbul, located in the Marmara Region of Turkey. The imaging used in this study, including patients examined and diagnosed by the pediatric cardiology specialist doctor from the researchers involved, will be checked with a specialist radiology doctor in another hospital belonging to the same foundation. Patients included in the study will be determined with images that can be modeled and meet the inclusion and exclusion criteria. The target sample will include parents of children scheduled to undergo cardiac surgery. The study will be explained to the legal guardian/parent of the identified volunteer patients, and those who wish to participate and give written consent will be included.|f|t|f|f
33952087|NCT04518800|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952088|NCT01203982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33952089|NCT02705534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952090|NCT01587807|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34076239|NCT01676701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076240|NCT01814410|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34076241|NCT05747859|||COHORT||RETROSPECTIVE|||||||
34161074|NCT05580939|RANDOMIZED|PARALLEL||OTHER||NONE||The study was conducted with a mixed-method design. In this study, there are two groups as intervention group and control group. Investigator, administered not any application to control group. Intervention group will use the web-based simulation application for 4 weeks.||||
34161075|NCT03785379|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the baseline assessment, patients will be randomly assigned either to: 1) 1-year caloric restriction with an immediate start of 12-week supervised structured exercise training (SSET) (Early-SSET intervention), followed by no exercise at health centers for 3 months; or: 2) 1-year caloric restriction with no exercise at health centers for 3 months and then a 12-week SSET from month 4 to month 6 (Late-SSET intervention). During the last 6 months participants' activity will be unrestricted.||||
34161076|NCT02629822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161077|NCT04753749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161078|NCT04906304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161079|NCT06163222|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34161080|NCT03210961|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind treatment|Combination single and multiple ascending dose design. Cohorts of participants are assigned to receive interventions based on acceptable safety, tolerability, and pharmacokinetics of previous dose cohort|t|t|t|t
34161081|NCT00960492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161082|NCT01002183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161083|NCT04807218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161084|NCT01805479|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34161085|NCT02709811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161086|NCT00519272|||CASE_ONLY||PROSPECTIVE|||||||
33744005|NCT04545268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Investigator will collect baseline data before the participant is randomized. The intervention/sham will be set-up by the Investigator. The Investigator who is trained in both NMES and Sham intervention will then look at the randomization schedule and set up and train the participants on equipment use|This is a single-blinded, randomized controlled longitudinal study design to determine if NMES will increase muscle mass and strength and improve exercise capacity thus improving likelihood of engagement with a structured exercise program. Patients will be randomized to either intervention that includes NMES or to a sham control group. In order to ensure that the two groups are comparable between treatment and sham interventions, the participants will be randomized according to gender. Randomization via minimization will be used in order to avoid an unbalanced number of women in the two comparison groups due to chance. A file of the computer-generated random assignments will be kept.|f|f|f|t
33744006|NCT04223102|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744007|NCT02595203|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744008|NCT00404157||||TREATMENT||||||||
33744009|NCT03876067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33744010|NCT01031147|||COHORT||PROSPECTIVE|||||||
33744011|NCT04539717|||CASE_ONLY||PROSPECTIVE|||||||
33744012|NCT01438866|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744013|NCT02966067|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33744014|NCT01546194|||COHORT||PROSPECTIVE|||||||
33744015|NCT03819335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744016|NCT04748354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessor and study investigators are blinded to group allocation of participants. Participant cannot be blinded due to the nature of the intervention.|Usual care vs. Usual Care with Exercise|f|f|t|t
33744017|NCT00746954|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33744018|NCT01054729|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33744019|NCT06048523|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744020|NCT04191772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will receive an intervention (exercise program) or no intervention (sedentary control group). Participants will be persons with MS and healthy controls.||||
33744021|NCT02623673|||CASE_ONLY||RETROSPECTIVE|||||||
33744022|NCT01786694|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744023|NCT02665000|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33744024|NCT04972500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744025|NCT04722913|||COHORT||PROSPECTIVE|||||||
33952091|NCT04156009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the treatment group, the aromatherapy tablets will be activated for max aromatherapy. For the control group, the tablets will not be activated and will be devoid of scent. For both groups, the tablet will be wrapped in masking tape to maintain the blind for subjects.||t|f|f|f
33952092|NCT01713374|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33952093|NCT03911700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952094|NCT06389708|||COHORT||PROSPECTIVE|||||||
33952095|NCT05818046|NA|SINGLE_GROUP||SCREENING||NONE||||||
33952096|NCT04745572|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33952097|NCT06649916|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33952098|NCT04801017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952099|NCT00011037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33952100|NCT04217239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33952101|NCT00744068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33952102|NCT04833816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952103|NCT02378870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161087|NCT02843503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161088|NCT04385459|||COHORT||RETROSPECTIVE|||||||
34161089|NCT05275595|||OTHER||RETROSPECTIVE|||||||
34161090|NCT01281540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161091|NCT06207526|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm-feasibility-design is used. All participants will receive the intervention immediately after the baseline assessment (T0). All participants are allowed to continue standard scheduled treatment.||||
34161092|NCT05152771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744026|NCT05190081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention groups were formed as single-task training, dual-task training, and control group. Distribution was made into groups using a simple randomized number selection technique.||||
33744027|NCT05897593|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The outcomes assessor will be masked to group allocation (AR-delivered therapy + standard care, or traditional standard care alone). Participants will be asked not to reveal details of the group allocation prior to assessments.|Study 1: Single-Subject Experimental Design Studies will be Implemented (A-B Design) Study 2: Qualitative Interviews regarding technology acceptance Study 3: Feasibility randomized controlled trial (control and intervention groups)|f|f|f|t
33744028|NCT01528228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33744029|NCT01615029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744030|NCT06669637|||COHORT||PROSPECTIVE|||||||
33744031|NCT00016133||||TREATMENT||||||||
33744032|NCT05792553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744033|NCT05441930|RANDOMIZED|PARALLEL||TREATMENT||NONE||Once eligible, subject eyes will be randomized to determine which eye will receive the first surgery. After the first surgery, study participants will receive the control treatment consisting of commercially available topical medications. For the second cataract surgery, study participants will receive a single Levofloxacin Ocular Implant in the posterior sulcus in the surgical eye at the end of cataract surgery. No sham dosing will be conducted in the eyes in the control arm.||||
33744034|NCT02393313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744035|NCT03888573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomly assigned into two groups; A and B. Patients within Group (A) will receive stretching protocols to the cervical musculature at the side of symptoms. Group (B) will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.|t|f|f|t
33744036|NCT05043337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33744037|NCT01673633|||CASE_CONTROL||PROSPECTIVE|||||||
33744038|NCT01323699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744039|NCT00512135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744040|NCT06069492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Research staff performing laboratory assays||f|t|t|t
33744041|NCT04396886|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33744042|NCT02470208|||OTHER||PROSPECTIVE|||||||
33744043|NCT02837744|||COHORT||PROSPECTIVE|||||||
33744044|NCT04993690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose Escalation and determination of MTD; multiple dose levels of LP-168 to be evaluated||||
33744045|NCT00023829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744046|NCT00150631|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33744047|NCT00738842|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744048|NCT05096338|||COHORT||PROSPECTIVE|||||||
33847051|NCT00156637|RANDOMIZED|PARALLEL||||NONE||||||
33847052|NCT03235102|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33847053|NCT03888157|||COHORT||PROSPECTIVE|||||||
33847054|NCT05153720|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33847055|NCT04963790|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients in the intervention group will receive a series of tailored messages on COVID-19 vaccination. Patients assigned to the control group will receive health messages unrelated to the COVID-19.||||
33847056|NCT00105001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847057|NCT04306016|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors will be blinded to the group allocation and will not be involved in data analysis and results reporting.|An assessor-blinded two-arm randomised controlled trial (RCT) will be conducted.|f|f|f|t
33847058|NCT04580927|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multi-site open-label, randomized control trial, evaluating a nurse-led breastfeeding self-efficacy enhancing intervention for women who had hypertensive disorders of pregnancy recruited at three sites in Canada. Participants that plan to breastfeed will be randomly divided into two groups: one will be given the BSE intervention, the other will not. Both groups will receive same standard postpartum care: routine postpartum hospital breastfeeding support, community breastfeeding support, and postpartum medical visits with obstetrics care provider and cardiovascular risk assessment. Participants who had high blood pressure in pregnancy and are not planning to breastfeed will not be randomized and will receive standard postpartum care excluding breastfeeding care. Outcomes for all participants will be assessed by completion of questionnaires, collecting blood pressure measurements and blood tests and long-term follow-up via linkage with administrative health data.||||
33847059|NCT00967031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952104|NCT06653556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952105|NCT04308356|||COHORT||PROSPECTIVE|||||||
33952106|NCT03205839|RANDOMIZED|PARALLEL||TREATMENT||NONE|Entire study completed online, including randomisation.|||||
33952107|NCT06178276|||COHORT||CROSS_SECTIONAL|||||||
33952108|NCT05254041|NA|SINGLE_GROUP||OTHER||NONE||||||
33952109|NCT03158857|||COHORT||PROSPECTIVE|||||||
33952110|NCT04281030|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33952111|NCT00673712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952112|NCT04688034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952113|NCT03331952|||COHORT||PROSPECTIVE|||||||
33952114|NCT00207116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952115|NCT03526549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|"Investigators, participants, and site personnel were blinded to the treatment administered in the EN3835-302/303 parent studies until all Day 180 visit assessments were completed.~CCH-aaes retreatment in this study was provided in an open-label manner."|||||
33952116|NCT05344391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952117|NCT02399046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952118|NCT00470249|NA|SINGLE_GROUP||TREATMENT||NONE||In this non-randomized prospective trial, patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant were treated with carboplatin at a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 and gemcitabine 1500 mg/m2 on day 2 of every 2-week cycle. The primary end point was overall response rate.||||
33952119|NCT00270205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952120|NCT01728428|||||RETROSPECTIVE|||||||
33847060|NCT04913389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|An independent pharmacist will prepare identically looking active and placebo capsules labelled with secret codes. Codes will be concealed to investigators and patients until completion of data analysis.|randomized, placebo-controlled, double-blind|t|t|t|t
33847061|NCT02402673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847062|NCT02422017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847063|NCT01569672|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33847064|NCT03277092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847065|NCT05155176|||COHORT||PROSPECTIVE|||||||
33847066|NCT05444582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847067|NCT00964964|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33847068|NCT04798859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Independent Outcome Assessor(s) will be blinded to group allocation. Participants will be provided with new IDs in final database, blinding researchers to which group is the intervention group during analysis.|Randomized Controlled Trial|f|f|t|t
33847069|NCT00144352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847070|NCT03909438|||CASE_ONLY||PROSPECTIVE|||||||
33847071|NCT02673073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847072|NCT05043922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847073|NCT05940428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847074|NCT01857128|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952121|NCT03774420|||COHORT||PROSPECTIVE|||||||
33952122|NCT00683891|||CASE_ONLY||PROSPECTIVE|||||||
33952123|NCT02333175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952124|NCT06514365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952125|NCT03290131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952126|NCT06540131|||OTHER||PROSPECTIVE|||||||
33952127|NCT04165824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952128|NCT02384031|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33952129|NCT05814224|NA|SINGLE_GROUP||OTHER||NONE||||||
33952130|NCT00357734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952131|NCT04231253|||OTHER||OTHER|||||||
33952132|NCT04962191|||COHORT||RETROSPECTIVE|||||||
33952133|NCT02991911|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952134|NCT01238861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952135|NCT02592369|||COHORT||PROSPECTIVE|||||||
33952136|NCT01484691|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33952137|NCT04642040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056874|NCT05775003|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Eligible study participants will be randomly assigned to one of three supplementation groups: placebo (resistant starch) supplementation + exercise group, 500 mg BAIBA supplementation + exercise group, and a 500 mg BAIBA supplementation + 40 mg Grains of Paradise + exercise group.|This study will be conducted using a double-blind, placebo-controlled, parallel group design. Eligible study participants will be randomly assigned to one of three supplementation groups: placebo (resistant starch) supplementation + exercise group, 500 mg BAIBA supplementation + exercise group, and a 500 mg BAIBA supplementation + 40 mg Grains of Paradise + exercise group.|t|f|t|f
34056875|NCT04932824|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34056876|NCT04761120|||COHORT||PROSPECTIVE|||||||
34056877|NCT02543892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34056878|NCT05144503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056879|NCT06649539|NA|SINGLE_GROUP||TREATMENT||NONE|Investigators will be blinded to baseline curvature measurements.|prospective, single-blinded clinical trial||||
34056880|NCT03064100|||CASE_ONLY||PROSPECTIVE|||||||
34056881|NCT01944618|||||PROSPECTIVE|||||||
34056882|NCT03982446|||COHORT||RETROSPECTIVE|||||||
34056883|NCT01955525|||COHORT||PROSPECTIVE|||||||
34056884|NCT06160128|||COHORT||OTHER|||||||
34056885|NCT00937040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056886|NCT00598546|||COHORT||PROSPECTIVE|||||||
33847075|NCT01828632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33952138|NCT00138827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33952139|NCT03581500|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952140|NCT04787575|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multicentre, randomized, parallel group study||||
33952141|NCT01947010|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33952142|NCT01756586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952143|NCT00062829|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33952144|NCT06182410|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33952145|NCT06653530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952146|NCT01118949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952147|NCT03296397|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952148|NCT06650007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952149|NCT01577082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952150|NCT00845559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056887|NCT01952119|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34056888|NCT06622122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34056889|NCT05517824|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||prospective, single-blinded, pre-post comparative study|f|f|f|t
34056890|NCT05251948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056891|NCT03105986|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34056892|NCT02010281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056893|NCT05670314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Randomisation will be performed using an online software (sealedenvelope.com). The inulin vs placebo allocation will be double blinded. The exercise part of the intervention will not be blinded|2x2 intervention with 30 individuals per block: placebo, diet only, exercise only, diet + exercise|t|f|t|f
34056894|NCT05304949|||COHORT||PROSPECTIVE|||||||
34076242|NCT04846192|||COHORT||RETROSPECTIVE|||||||
33952151|NCT06282185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In a single blinded (investigators blinded to group allocation) randomized controlled pilot, conducted in the CWZ, 20 patients with advanced prostate cancer will be randomized across: 1) supervised training program for twelve weeks + usual care + advice about exercise, or 2) usual care + advice about exercise.|randomized controlled trial with an intervention arm and an usual care group|f|f|t|t
33952152|NCT06382324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor of polysomnography did not know the data belongs which group|"Intervention method:~* Mindfulness napping group: listening to a record of mindfulness meditation practice for 40 minutes.~* Control group: listening to light music for 40 minutes."|f|f|f|t
33744049|NCT03197792|NA|SINGLE_GROUP||SCREENING||NONE||Patients with chronic post-embolic pulmonary hypertension eligible to pulmonary endarterectomy surgery will be evaluated for venous congestion and right ventricular failure after weaning of cardiopulmonary bypass, and followed until the 7th postoperative day for the development of postoperative organ dysfunction and/or death.||||
33744050|NCT04671862|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744051|NCT00125489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744052|NCT03661853|RANDOMIZED|PARALLEL||TREATMENT||NONE||4 arms: 3 CBT microinterventions + control condition||||
33744053|NCT06534801|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952153|NCT04866602|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"In Period 1, 16 participants will be enrolled and randomised to one of two treatments in a ratio of 1:1, and to the alternative treatment in Period 2, as described below:~* Treatment 1: Single dose of Atoguanil . (Atovaquone 500 mg + Proguanil 348 mg administered as 4 tablets of 125 mg: 87 mg).~* Treatment 2: Single dose of Malarone® . (Atovaquone 1000 mg + Proguanil HCl 400 mg administered as 4 tablets of 250 mg: 100 mg), Both doses are administered in the fed state and with 240mL of drinking water."||||
34056895|NCT03203226|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be recruited at a company which provides supported employment. The primary recruitment strategy will be the information provided to the potential participants and legal guardians by the medical staff of the company. Informed consent will be obtained from the participants and their legal guardians. Afterwards they will be randomly assigned (1:1 ratio) by centre through sealedopaque envelopes to either the control or the intervention group by coin-tossing sequence generation.~It has been designed an experimental multicentre simple randomized study, with random allocation to a control group (CG) or to an experimental group (EG). This study is an open-label trial as the assessors who were experienced specialist in working with people with ID (psychologists, nurses, physicians, physiotherapists) are not blinded to group allocation."||||
34076243|NCT01480388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076244|NCT04232020|||COHORT||RETROSPECTIVE|||||||
34076245|NCT01293994|||COHORT||PROSPECTIVE|||||||
34076246|NCT00764569|||OTHER||OTHER|||||||
33744054|NCT04575428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744055|NCT00110240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33744056|NCT01751022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744057|NCT04941300|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33744058|NCT06525883|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744059|NCT00841581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744060|NCT04511689|||COHORT||PROSPECTIVE|||||||
33744061|NCT01250860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744062|NCT02626559|||CASE_ONLY||PROSPECTIVE|||||||
33744063|NCT01428960|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33744064|NCT05629026|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||cross-sectional sample of patients with primary or secondary lymphoedema.||||
33744065|NCT05054335|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33744066|NCT03579459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33744067|NCT06635460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In the randomization scheme of the study, stratified and blocked randomization methods will be utilized. Age and gender variables will be used for the stratification of adolescents. Blocks will be formed as follows: for the age variable, 12-14 years and 15-18 years will be the categories, while for the gender variable, the categories will be female and male. An online tool for generating blocked randomization lists will be employed. To achieve the calculated sample size for the study, each stratum will be repeated 7 times (2X2X7), resulting in a total inclusion of 56 adolescents, with each group comprising 28 participants."|f|f|f|t
33744068|NCT05162820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Capsules will be of similar appearance and provided in un-identified bottles (A,B)|Randomized, Double-Blind, Placebo-Controlled Study|t|f|t|f
33744069|NCT02451657|||COHORT||PROSPECTIVE|||||||
33744070|NCT06444282|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076247|NCT04358016|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056896|NCT06622252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The first phase of this study involved qualitative and quantitative data collection and intervention feasibility testing using a single-arm within-subjects design.~Our Community Based Participatory Research (CBPR) work to date has identified several barriers and targets for intervention.~Accordingly, the newly designed intervention was split into three major components - Healthy Literacy, Caregiver Wellness, and Complementary Alternative Medicine. The second phase of this study is a preliminary randomized control trial."||||
33952154|NCT06250998|||COHORT||RETROSPECTIVE|||||||
34056897|NCT03259828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952155|NCT04054440|||COHORT||RETROSPECTIVE|||||||
34056898|NCT06620263|||CASE_CROSSOVER||PROSPECTIVE|||||||
34076248|NCT03000946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076249|NCT04396132|NA|SINGLE_GROUP||OTHER||NONE||||||
34076250|NCT04157088|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952156|NCT00998166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952157|NCT03022526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33952158|NCT01383759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952159|NCT04392791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952160|NCT02569502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952161|NCT05321342|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Half of the schools each year will be recruited from the School District of Philadelphia (SDP) and half from the Anne Arundel County Public Schools (AACPS) in Maryland. Within site, half of the schools will be assigned to the BCCU intervention and half will be in the control (business as usual condition; data collection only, plus an offer of a classroom management PD after research participation ends)."||||
33952162|NCT05843253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Ribociclib and Everolimus||||
33952163|NCT04681859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952164|NCT04505592|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Patients and study investigators will be blinded to subject treatment.|Subjects will be randomized in a 2:1 ratio to treatment or control in blocks of 15, performed twice per dose (low and high) with randomization stratified by site.|t|t|t|f
33952165|NCT02267343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952166|NCT04887922|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"* Prior to surgery, participants will be randomized into three groups: (1) control group with no IS, (2) standard IS, and (3) digital IS + text message.~* Following surgery, patients will be re-randomized into two groups: (1) standard IS, and (2) digital IS + text message."||||
33952167|NCT02921646|NA|SINGLE_GROUP||OTHER||NONE||||||
33952168|NCT01789034|||COHORT||PROSPECTIVE|||||||
33952169|NCT00620191|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952170|NCT03148834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952171|NCT03893279|||COHORT||PROSPECTIVE|||||||
33952172|NCT01613066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952173|NCT03202329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952174|NCT06021873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Monocentric, interventional, prospective, randomized 1:1, with comparison of two surgical approaches||f|f|t|f
33952175|NCT01278381|||CASE_ONLY||PROSPECTIVE|||||||
33952176|NCT03056456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33952177|NCT05859594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistical analysis of the data will be done by an expert independent of the research.|Prospective, parallel, two arm, randomized controlled clinical trial|f|f|f|t
33952178|NCT03962426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33952179|NCT00987584|||COHORT||PROSPECTIVE|||||||
33952180|NCT05071846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952181|NCT02046655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952182|NCT06175468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952183|NCT00714025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952184|NCT06567067|||OTHER||PROSPECTIVE|||||||
33952185|NCT03814824|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33952186|NCT02974270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952187|NCT03882567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952188|NCT06417853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study will be mixed and will contain open label and double-blinded groups; the active comparator groups (Group 1: H7N9 unadjuvanted IM and Group 4: H7N9 with MF59® IM) will be open-label whilst groups (Groups 2, 3 and 5 to 8: VXS-1219 and VXS-1219A) will be double-blinded.||t|f|t|f
33952189|NCT02511587|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952190|NCT03651440|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33952191|NCT05026424|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Site pharmacy will not be blinded to product assignment, study staff and participants will be blinded to product assignment. Product will be provided in unlabeled cups.|This will be a randomized crossover design. The subjects will be randomized to one of two interventions on two separate study days, one week apart.|t|f|f|f
33952192|NCT05538039|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
33952193|NCT00785252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076251|NCT05828316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34076252|NCT02584478|RANDOMIZED|PARALLEL||TREATMENT||NONE||Overall duration of the study will be approximately 42 months. Part 1 and 2 of this study are not randomized and have no concurrent controls. AL3818 and chemotherapy will be administered in an open-label fashion. Phase III/Part 3 is unblinded and randomized. Within each one of the three background chemotherapy groups, subjects will be randomized at a 1:1 ratio stratified by prior angiogenesis inhibitors mainly Avastin use status (Yes or No) and number of prior treatment (≤3 or \>3) to receive AL3818 plus background chemotherapy (Active Arm) or background chemotherapy alone (Control Arm).||||
34076253|NCT05927792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants, their legal guardians, and the assessors were unaware of the grouping except for the intervention operator.||t|f|f|t
33952194|NCT01458535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847076|NCT03934138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the subjects in the the conventional placebo group will be masked. In the educated open label placebo group, subjects will be aware that the cream is inert.|"2 groups : Educated open label placebo And Conventional placebo~Each of the subjects will undergo the Cold Pressure text procedure under the condition of interest and a control."|t|f|f|f
33847077|NCT06371859|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Sealed envelopes will be used and opened at the time of inclusion of each participant. Each participant will be randomized to either AI support or no support. The allocation of participants will be performed by (XYZ) who does not have access to the randomization order.|Randomized controlled trial|t|f|t|f
33847078|NCT01638832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847079|NCT03096080|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33847080|NCT06475963|||OTHER||OTHER|||||||
33847081|NCT04688619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847082|NCT00912262|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33847083|NCT05421351|||COHORT||PROSPECTIVE|||||||
33847084|NCT06459700|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33847085|NCT02468180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847086|NCT02406391|||CASE_ONLY||CROSS_SECTIONAL|||||||
33847087|NCT05810129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind study||f|f|f|t
33847088|NCT03384277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847089|NCT01896323|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33847090|NCT04076189|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33847091|NCT01802151|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33847092|NCT02243111|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33847093|NCT00254046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847094|NCT04416373|||COHORT||PROSPECTIVE|||||||
33847095|NCT05154981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847096|NCT01315808|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33847097|NCT02858843|NA|SINGLE_GROUP||SCREENING||NONE||||||
33847098|NCT02734030|||OTHER||CROSS_SECTIONAL|||||||
33847099|NCT04296539|||OTHER||CROSS_SECTIONAL|||||||
33847100|NCT01405833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847101|NCT02646007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847102|NCT00337259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847103|NCT00006011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847104|NCT05718063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33847105|NCT05341401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847106|NCT04399759|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33847107|NCT04938700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847108|NCT01097707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847109|NCT06424405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33847110|NCT01729442|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847111|NCT00727610|||COHORT||PROSPECTIVE|||||||
33847112|NCT06273592|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Outcomes assessor will be blinded to randomization group and order of testing.|Randomized crossover design|f|f|f|t
33847113|NCT00601770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847114|NCT00603252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847115|NCT04850677|||COHORT||PROSPECTIVE|||||||
33847116|NCT02324608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847117|NCT04708353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded ( patient and outcome assessors)|The patients will be allocated randomly using computer generated randomization table into three equal groups|t|f|f|t
33847118|NCT02819557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847119|NCT00473005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847120|NCT01412762|||CASE_ONLY||PROSPECTIVE|||||||
33847121|NCT05861700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Blood acid-base and uremic solute levels were measured in twenty chronic HD patients during 4-hour treatments with A) constant Dbic of 35 mmol/L; B) Dbic of 35 mmol/L for the first two hours and 30 mmol/L for the second two hours; and C) Dbic of 30 mmol/L for the first 2 hours and 35 mmol/L later. Treatment interventions were fixed during a given week, arterial blood samples were obtained predialysis and every hour during the treatment, during the second and third treatments of the week.||||
33847122|NCT00566592|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33847123|NCT03001076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847124|NCT02914418|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33847125|NCT04261426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847126|NCT00099827|RANDOMIZED|PARALLEL||||NONE||||||
33847127|NCT06419400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847128|NCT01446757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33847129|NCT02869516|||COHORT||PROSPECTIVE|||||||
33847130|NCT01125631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952195|NCT00552422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952196|NCT03291249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952197|NCT02037594|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33952198|NCT03128801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952199|NCT00678652|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33952200|NCT01880580|||COHORT||PROSPECTIVE|||||||
34076254|NCT02735980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076255|NCT00827515|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34076256|NCT02937181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076257|NCT01255904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33744071|NCT05759234|NA|SEQUENTIAL||TREATMENT||NONE||"At this stage, it is planned that HS248 will adopt the traditional 3+3 method of increasing doses at four dose levels of 20 mg, 40 mg, 60 mg and 80 mg. All dosage components are divided into single administration stage and multiple administration stage. After 5 days of observation after single administration, it enters the stage of multiple administration. In the stage of multiple administration, HS248 is administered once a day (qd) for 28 days. a treatment cycle. 33 days after the first administration (the 5-day observation period in the single-administration phase and the first cycle in the multiple-administration phase) is the dose-limiting toxicity (DLT) observation period of this study"||||
34161093|NCT05611021|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The outcomes assessor is blind for the condition performed by the patients.|The patients will perform three experimental conditions, in randomized order (walking, arm-cranking and control). The exercise conditions will be composed of 15 bouts of 2 minutes exercise with an intensity equivalent to 13-15 on the Borg's subjective perceived exertion scale.|f|f|t|t
34161094|NCT01740024|NA|SINGLE_GROUP||||NONE||||||
34161095|NCT03058055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744072|NCT04944342|||OTHER||PROSPECTIVE|||||||
33744073|NCT02105506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744074|NCT02266628|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34161096|NCT01682785|||CASE_ONLY||PROSPECTIVE|||||||
34161097|NCT04043650|NA|SINGLE_GROUP||PREVENTION||NONE||"At each decision time-a time point when an intervention component can be delivered-each day of the study each participant is randomized between intervention or no intervention (delivery of a contextually tailored activity suggestion or no suggestion; morning motivational message or no motivational message)"||||
33744075|NCT03264872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847131|NCT03803839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomized into two treatment groups; either the clodronate or a placebo group. All patients, surgeons and other personnel in the operating theatre were blinded as to the patients' study group.|In this prospective, double-blinded, randomized, placebo-controlled clinical trial with two years follow-up period the investigators rinsed the proximal intramedullary cavity of the femur with either clodronate (60 mg clodronate in 1000 ml saline) or saline (1000 ml saline) prior to the application of the femoral stem.|t|t|t|f
33847132|NCT06474819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33847133|NCT01077427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847134|NCT05659498|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking the participant and provider is not possible due to the nature of the intervention||f|f|f|t
33847135|NCT00847808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33847136|NCT01382368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33847137|NCT02784951|||COHORT||PROSPECTIVE|||||||
33847138|NCT02996474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847139|NCT01034163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847140|NCT04961619|||COHORT||PROSPECTIVE|||||||
33847141|NCT05418088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847142|NCT01685723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847143|NCT05417776|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847144|NCT00794144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33847145|NCT03301129|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33847146|NCT05893368|||CASE_CONTROL||PROSPECTIVE|||||||
33847147|NCT04392661|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33847148|NCT02022995|||CASE_CONTROL||RETROSPECTIVE|||||||
33847149|NCT00903604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33847150|NCT00736892|||COHORT||PROSPECTIVE|||||||
33847151|NCT03690583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34076258|NCT02635919|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076259|NCT04202497|NA|SINGLE_GROUP||OTHER||NONE||||||
34076260|NCT06611709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Kinesiotaping vs sham-taping|t|f|f|f
34076261|NCT02993198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076262|NCT01493050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076263|NCT02949947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076264|NCT04354415|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a randomized controlled trial comparing patients undergoing open carpal tunnel or trigger finger release with or without the use of a tourniquet. This was an equivalence trial in terms of operative time, bleeding scores and peri-operative complication rates. In addition, peri-operative subjective patient experience was investigated for both techniques. This was measured based on a numerical rating scale (NRS) for pain, anxiety and overall satisfaction.||||
34076265|NCT03319316|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm open-label randomized study in each of two separate cohorts (non-squamous and squamous NSCLC) according to histology.||||
34076266|NCT05737264|||COHORT||PROSPECTIVE|||||||
34076267|NCT03871192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and the evaluator don't know if the injection was performed inside the joint or around the nerve|the patients are randomly assigned to intraarticular injection or nerve block|t|f|f|t
34076268|NCT02862964|||CASE_ONLY||PROSPECTIVE|||||||
34076269|NCT04560959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161098|NCT02124681|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34161099|NCT06060054|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Visit type was masked to neuroimaging assessors and blood biomarker analysis laboratory.|Cross-over randomized study|f|f|f|t
34161100|NCT00729625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34161101|NCT00327301|||CASE_ONLY||PROSPECTIVE|||||||
34161102|NCT05579808|||COHORT||RETROSPECTIVE|||||||
34161103|NCT02360228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161104|NCT03158441|||COHORT||PROSPECTIVE|||||||
34161105|NCT01073202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34161106|NCT02735343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161107|NCT00577824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056899|NCT05264792|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|"It is not possible to mask collection of implementation outcomes at the facility level or to blind the primary health center staff to arm allocation.~For patient-level outcomes, outcome assessors and investigators will be masked. Patients who enroll in the study will not be informed about the allocation of their respective facility; therefore, it is unlikely that they would become aware of arm allocation. The study outcome assessors will be blinded to arm allocation of the participants' facilities, and the patient outcome assessments will be conducted at the patient's home or a mutually agreed location, other than the facility. The study team will also ensure separation between the Support Coaching Team delivering the Enhanced Implementation Support strategy and the outcome assessors to avoid any communication that could indicate the arm allocation of participants and facilities.~The statistician who will analyze the final outcome data will also be blinded to arm allocation."|This study employs a 2-arm parallel cluster-randomized controlled trial design, where the cluster is defined as the Primary Health Centre-Health and Wellness Centre (PHC-HWC). Clusters (14 PHCs-HWCs) are randomly allocated to one of the two implementation support strategies: 1) Routine (existing) implementation support as provided by District Program Management (DPM) team to the facilities (control condition); 2) Enhanced Implementation support consisting of remote coaching provided by the study team in addition to aforementioned Routine Support (intervention condition).|f|f|t|t
34056900|NCT04450407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056901|NCT04097158|||COHORT||PROSPECTIVE|||||||
34056902|NCT06057493|||OTHER||PROSPECTIVE|||||||
34056903|NCT04889521|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056904|NCT06622538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization in two groups|t|f|f|f
34056905|NCT01985438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056906|NCT03192995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||12-week parallel group pilot study with 2:1 random assignment to 20 mg of extended-release oral lorcaserin versus placebo|t|t|t|f
34056907|NCT06622590|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Three stages will be conducted according to the age-escalating principle.|t|f|t|f
34056908|NCT00201240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056909|NCT01772186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161108|NCT06530368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161109|NCT02411435|NA|SINGLE_GROUP||||NONE||||||
34161110|NCT00002404||||TREATMENT||DOUBLE||||||
34161111|NCT06314607|||COHORT||CROSS_SECTIONAL|||||||
34161112|NCT01392365|||||PROSPECTIVE|||||||
34161113|NCT04951583|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a multi-center single-arm, open-label Simon two-stage, phase II trial in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and melanoma treated with immune checkpoint inhibition.~Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT)."||||
34161114|NCT06267391|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The participants randomized in a 2:1 ratio to the ReCET treatment arm or the sham control arm.|t|t|t|t
34161115|NCT01233141|||COHORT||PROSPECTIVE|||||||
34161116|NCT04848272|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label placebo-controlled dose-escalation Phase 1 study||||
34161117|NCT03852719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744076|NCT02575599|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744077|NCT01735539|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744078|NCT00452101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33744079|NCT05385016|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744080|NCT01490177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744081|NCT04463641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744082|NCT06534281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744083|NCT00949247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744084|NCT04914572|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"* The first arm of the study includes the use of mindful walking through the therapeutic rainforest trail from Kent Ridge Park to Hort Park and Hort Park back to Kent Ridge Park.~* The second arm of the study includes a walk through the therapeutic rainforest trail from Kent Ridge Park to Hort Park and Hort Park back to Kent Ridge Park.~* The third arm of the study includes a walk through the Kent Ridge Road Trail curated by the Office of Facility Management."||||
33744085|NCT05063344|||COHORT||PROSPECTIVE|||||||
33744086|NCT06634888|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744087|NCT00581945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744088|NCT02061384|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744089|NCT01450358|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33744090|NCT05152693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33744091|NCT01343056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33847152|NCT04602078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847153|NCT03942900|||COHORT||PROSPECTIVE|||||||
33847154|NCT04510090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847155|NCT02685345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847156|NCT06608290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were classified as a group of cases with parasternal blockade and as a group of controls without parasternal blockade, with a ratio of cases to controls of 1:1. In the case-control groups, patients with elevated serum lactate levels greater than 2 mmol/L and those who remained below this limit were identified.||||
33847157|NCT06472830|||CASE_ONLY||PROSPECTIVE|||||||
33847158|NCT05476302|||CASE_ONLY||RETROSPECTIVE|||||||
33847159|NCT02465853|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847160|NCT04802720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study will utilize a randomized, controlled, repeated measures design to investigate the efficacy of Emotion Regulation Therapy for Cancer Caregivers (ERT-C) vs. Cognitive Behavioral Therapy for Cancer Caregivers.||||
33847161|NCT06098404|||COHORT||PROSPECTIVE|||||||
33847162|NCT06000345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33847163|NCT04627779|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847164|NCT03954392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individuals who conduct the assessments of the outcome measures will be unaware of to which condition the participant was randomized|The study has two intervention arms: (1) CBT + SCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT-only is cognitive behavioral therapy without the additional SCT training component. Adolescents are randomized to either condition. We will stratify randomization by gender, age (12-14; 15-17), race/ethnicity (minority status), and medication use.|f|f|f|t
33847165|NCT06487117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847166|NCT04449120|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study uses a randomized controlled trial design with one-month intervention program and three months of follow-up in order to test the effects of a culinary intervention program to improve cooking and healthy eating behaviour in type 2 diabetic patients.~The culinary intervention program will be given over a one-month period, one day a week for four weeks. Participants in the control group (CG) will receive dietary training based on Mediterranean diet at the baseline visit and a leaflet explaining this dietary pattern. The participants assigned to the culinary intervention program will receive the same nutritional recommendations and four online cooking classes."||||
33847167|NCT02885324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847168|NCT01044017|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33847169|NCT06370520|||COHORT||PROSPECTIVE|||||||
33847170|NCT03182361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847171|NCT05347251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952201|NCT05041218|||COHORT||PROSPECTIVE|||||||
33952202|NCT06651073|||OTHER||OTHER|||||||
33952203|NCT00731640|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952204|NCT06566729|||COHORT||PROSPECTIVE|||||||
33952205|NCT00709904|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952206|NCT03239548|||OTHER||OTHER|||||||
33952207|NCT03384576|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33952208|NCT03361709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952209|NCT01890876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952210|NCT04683874|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33952211|NCT02439593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hyperthermia with chemoradiotherapy vs. Chemoradiotherapy alone||||
33952212|NCT05925036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind.|This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of a single intravenous infusion of autologous bone marrow-derived mesenchymal stromal cells in subjects with painful chronic pancreatitis.|t|t|t|t
33952213|NCT05832788|||OTHER||CROSS_SECTIONAL|||||||
33952214|NCT06121986|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33952215|NCT00615927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952216|NCT00014300||||TREATMENT||||||||
33952217|NCT04481087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952218|NCT01808508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952219|NCT04045041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952220|NCT01042379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952221|NCT03525769|||COHORT||PROSPECTIVE|||||||
33952222|NCT00453336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847172|NCT04551404|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"The crossover within-person design with 2 groups, 2 active conditions and appropriate control/pseudo-placebo/sham session is double-blinded. Overall, participants will undergo 20 stimulation visits and 6 additional assessment visits.~Prior to conducting the above study, a pilot study of 40 patients and just 6 visits will be conducted to validate clinical procedures and outcomes. This procedure was approved by the ethics committee."|t|f|f|f
33952223|NCT02206984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952224|NCT05287581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33952225|NCT00066417||||TREATMENT||NONE||||||
33847173|NCT06609629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847174|NCT06610266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847175|NCT01640236|||||PROSPECTIVE|||||||
33847176|NCT02040259|||COHORT||PROSPECTIVE|||||||
33847177|NCT03941951|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The prescribers are assigned to receive the intervention if they have prescribed any of the antibiotics ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam, ceftolozane-tazobactam or isavuconazole from January 2010 to June 2021.||||
33847178|NCT00112424|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847179|NCT02929329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847180|NCT02639832|||COHORT||PROSPECTIVE|||||||
33847181|NCT02784249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847182|NCT00505245|||COHORT||PROSPECTIVE|||||||
33847183|NCT05188339|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847184|NCT01860378|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33847185|NCT06600776|NA|SINGLE_GROUP||TREATMENT||NONE|Both the researchers and the participants are aware of the intervention being administered (premeal vs. post-meal dosing of Ultra Rapid Lispro Insulin). There is no blinding in the study, as participants will know when they are administering the insulin (whether at mealtime or post-meal), and the researchers will also have access to this information during data collection and analysis.|"Single Intervention Group: The study involves a single group of participants, all of whom are individuals with Type 1 Diabetes Mellitus (T1DM) using the Medtronic 780G hybrid closed-loop system with Ultra Rapid Lispro Insulin (URLi).~Comparison Within Subjects: Participants will be asked to use the insulin dosing at mealtime during one period and post-meal during another. The study aims to compare the effects of premeal vs. post-meal dosing on glycemic control within the same group of individuals rather than comparing two different groups of participants.~So, participants serve as their own control(in this case, mealtime vs. post-meal dosing)."||||
33847186|NCT00587626|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33847187|NCT03406650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952226|NCT01335620|NA|SINGLE_GROUP||TREATMENT||NONE||HIV affected over 60 years old||||
33952227|NCT04966702|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label, assessor-blinded|The BOHEMIA trials are open-label with random assignment to one of 3 treatment arms in Mozambique and 2 in Kenya: (a) ivermectin in humans, (b) ivermectin in humans + livestock (only in Mozambique), or (c) albendazole control.||||
33952228|NCT03223506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952229|NCT04079972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952230|NCT00221416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952231|NCT03971422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952232|NCT03749434|||CASE_ONLY||PROSPECTIVE|||||||
33952233|NCT03563729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Six patients are enrolled in each arm. If clinical benefit is observed, each arm will be expanded to enroll a total of 20 patients.||||
33952234|NCT03204006|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33952235|NCT05924009|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33952236|NCT04527406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor conduct independent statistical analysis and evaluation|The research subjects are randomly assigned to the early surgery group (experimental group) or traditional surgery group (control group) at a ratio of 1:1|f|f|f|t
33952237|NCT00625313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952238|NCT02279888|||COHORT||PROSPECTIVE|||||||
33952239|NCT05152498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952240|NCT05284227|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33952241|NCT01269346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952242|NCT05486975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952243|NCT00230113|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33952244|NCT03541408|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33952245|NCT02696837|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33952246|NCT03628781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952247|NCT00958659|||CASE_CONTROL||RETROSPECTIVE|||||||
33952248|NCT05663333|||OTHER||PROSPECTIVE|||||||
33952249|NCT02058264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952250|NCT06650358|||COHORT||OTHER|||||||
33952251|NCT01979549|||COHORT||PROSPECTIVE|||||||
33952252|NCT00738140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952253|NCT01114126|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33952254|NCT04552158|NON_RANDOMIZED|PARALLEL||OTHER||NONE||All Patients will be subjected to assessment of their nutritional status at day 0 and after 3 months of only medical management for the control group and of combined medical and nutritional management using Mediterranean dietary pattern for the experimental group||||
34161118|NCT00180765|||OTHER||OTHER|||||||
34161119|NCT03117985|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161120|NCT03499834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161121|NCT03704259|||CASE_ONLY||PROSPECTIVE|||||||
33847188|NCT06610162|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This cross-sectional study will compare fasting and overfeeding effects on 24-hour EE and its components in pre- and postmenopausal women. We will study participants under three conditions in the room calorimeter: 1) eucaloric feeding (energy intake = EE); 2) acute, 24-hour fasting; and 3) acute, 24-hour overfeeding of a low-protein diet (i.e., 200% of energy requirements). Participants will complete the eucaloric study and then complete the overfeeding and fasting studies in random order. There will be a 1-4-week washout between conditions. Studies in premenopausal women will be performed during the mid-luteal phase (i.e., days 16-24) when both E2 and progesterone are elevated and, thus, when the potential hormonal effects are maximal.||||
33847189|NCT02802189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847190|NCT00034060||||TREATMENT||||||||
33847191|NCT05812417|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33847192|NCT04579718|||COHORT||PROSPECTIVE|||||||
33847193|NCT02587988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847194|NCT01410968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847195|NCT04013048|NA|SINGLE_GROUP||OTHER||NONE||||||
33847196|NCT00069173|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33847197|NCT03091231|||COHORT||PROSPECTIVE|||||||
33847198|NCT02536677|||COHORT||PROSPECTIVE|||||||
33847199|NCT00770029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847200|NCT01514253|RANDOMIZED|CROSSOVER||||DOUBLE|||f|t|t|f
33847201|NCT04278222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847202|NCT00603304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847203|NCT00442273|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952255|NCT06153758|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||4-Part||||
33952256|NCT02006810|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33952257|NCT02701660|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33952258|NCT04342130|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33952259|NCT01006031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952260|NCT00103376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952261|NCT05665556|||COHORT||PROSPECTIVE|||||||
33952262|NCT00536991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952263|NCT03206307|||COHORT||CROSS_SECTIONAL|||||||
33952264|NCT03930524|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Sequential Multiple Assignment Randomized Trial||||
33952265|NCT04801069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952266|NCT03784755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952267|NCT04381793|NA|SINGLE_GROUP||TREATMENT||NONE||Open pilot study to assess efficacy and antibody effects||||
33952268|NCT05200975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Percentage of patients attaining the cefuroxime PK-PD target of 50%T\>MIC. This will be investigated for patients with adequate renal function receiving a regular cefuroxime dose and impaired renal function receiving a guideline recommended reduced dose.||||
33952269|NCT00726440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952270|NCT02872584|||CASE_ONLY||PROSPECTIVE|||||||
33952271|NCT00206037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161122|NCT04305171|||COHORT||PROSPECTIVE|||||||
34161123|NCT01994044||||TREATMENT||||||||
34161124|NCT06403917|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34161125|NCT01735981|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants completed one arm of the study and then crossed over into the other arm of the study|f|f|t|f
34161126|NCT05411744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161127|NCT02209701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161128|NCT01959139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161129|NCT00726232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161130|NCT03205683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161131|NCT03919474|||CASE_CONTROL||OTHER|||||||
34161132|NCT03190434|||CASE_ONLY||RETROSPECTIVE|||||||
34161133|NCT00156416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33952272|NCT06652022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952273|NCT03309072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomly assigned to one of two groups: (1) active tDCS with Face Name associate memory task (2) sham tDCS with Face Name associate memory task|t|f|f|t
33952274|NCT06650904|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||48 nurses serving pediatric patients working in a private hospital||||
33952275|NCT05843539|||COHORT||CROSS_SECTIONAL|||||||
33952276|NCT01112969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952277|NCT04912973|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952278|NCT05862870|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
33952279|NCT06027047|||COHORT||PROSPECTIVE|||||||
33952280|NCT01102881|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33952281|NCT06538194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952282|NCT02300272|||COHORT||PROSPECTIVE|||||||
33952283|NCT04100369|||COHORT||PROSPECTIVE|||||||
33952284|NCT02865616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952285|NCT03441620|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34056910|NCT01870375|||COHORT||PROSPECTIVE|||||||
34056911|NCT05809258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and assessor will be blinded. The block performer anaesthetist and the patient will know the technique.|Two parallel arms of interventions, no crossover.|f|f|t|t
34056912|NCT02525601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056913|NCT03950375|||CASE_ONLY||PROSPECTIVE|||||||
34056914|NCT02244346|||COHORT||PROSPECTIVE|||||||
34056915|NCT05545345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34056916|NCT00743015||CROSSOVER||TREATMENT||||||||
34056917|NCT04046848|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34056918|NCT04743804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056919|NCT06046001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056920|NCT04190498|||COHORT||PROSPECTIVE|||||||
34056921|NCT02852668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34056922|NCT01854879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056923|NCT06041425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056924|NCT04824391|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34056925|NCT04984473|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34056926|NCT03652636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161134|NCT01888224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161135|NCT00282659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34161136|NCT05249894|||COHORT||RETROSPECTIVE|||||||
34161137|NCT02338089|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161138|NCT02199925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161139|NCT05080530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161140|NCT01800630|NA|SINGLE_GROUP||OTHER||NONE||||||
34161141|NCT04617730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161142|NCT01447732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161143|NCT02269930|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161144|NCT00003202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161145|NCT01186055|||CASE_CROSSOVER||PROSPECTIVE|||||||
34161146|NCT01554449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34161147|NCT05860426|||COHORT||PROSPECTIVE|||||||
34161148|NCT00823667|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161149|NCT04666896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161150|NCT04339673|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized parallel controlled||||
34161151|NCT03761238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161152|NCT01776606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161153|NCT00475709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744092|NCT05489926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744093|NCT06168708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744094|NCT06391112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There is a control and experimental group||||
33744095|NCT05634226|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744096|NCT03346668|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
33744097|NCT01449305|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33744098|NCT01753193|NA|SINGLE_GROUP||TREATMENT||NONE||This is an Open Label Extension study.||||
33744099|NCT01024387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744100|NCT02693990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744101|NCT02095262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744102|NCT05696106|||OTHER||OTHER|||||||
33744103|NCT03087591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744104|NCT00627705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744105|NCT00931073|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33744106|NCT01177111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744107|NCT05386160|RANDOMIZED|PARALLEL||TREATMENT||NONE||This research is a single-center prospective, randomized controlled study. Patient were divided into two groups, the control group is phacoemulsification surgery group and the intervention group is phacoemulsification surgery combine intravitreal injection of Ranibizumab group.||||
33744108|NCT05531994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744109|NCT01910519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34056927|NCT06130891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056928|NCT01087840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056929|NCT02685813|||COHORT||CROSS_SECTIONAL|||||||
34056930|NCT00443664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056931|NCT03164655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056932|NCT03165760|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomization is decided when patients are schedueld and according a randomization table||||
34056933|NCT00258349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056934|NCT05463237|||COHORT||PROSPECTIVE|||||||
34161154|NCT00342849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161155|NCT05875298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|physical therapy protocol and medication|f|f|t|t
34161156|NCT00034086||||TREATMENT||NONE||||||
34161157|NCT01068366|||CASE_CONTROL||PROSPECTIVE|||||||
34161158|NCT05342766|||CASE_CROSSOVER||PROSPECTIVE|||||||
34161159|NCT02133885|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34161160|NCT03039335|||COHORT||RETROSPECTIVE|||||||
33847204|NCT05343520|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The pregnant women who met the sampling criteria were assigned to the experimental or control groups with the numbers given by the generator on the website www.random.org. Odd numbers represented the experimental group, while even numbers represented the control group. In order to prevent the interaction of the pregnant women in the experimental and control groups with each other, a special examination room was arranged in the Antenatal Polyclinic and the study was carried out there. Pelvic floor muscle exercise was taught by the researcher (GY). Since the researcher knew which group the pregnant women in the sample were in, the study was single-blind. However, statistical analysis is double-blind because the statistics of the data are made by a different person.||t|f|f|t
33847205|NCT02699723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847206|NCT02666859|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Virtual Reality Prosthetic Training||||
33847207|NCT03629743|||COHORT||PROSPECTIVE|||||||
33847208|NCT02999802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33847209|NCT04100278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective, randomization, parallel, controlled study.||||
33847210|NCT06168695|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-arm clinical trial||||
33847211|NCT02008851|NA|SINGLE_GROUP||||NONE||||||
33847212|NCT00943839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847213|NCT03057990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847214|NCT00113100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847215|NCT01658332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847216|NCT05614193|||CASE_ONLY||PROSPECTIVE|||||||
33847217|NCT05965804|||OTHER||CROSS_SECTIONAL|||||||
33847218|NCT04497064|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33847219|NCT01992952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847220|NCT04736901|||COHORT||OTHER|||||||
33847221|NCT04294953|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33847222|NCT01454687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847223|NCT03567824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The second phase of the study where subjects are randomized to either active or placebo will be blinded to both participant and investigator.|All subjects will be treated open label for the first 3 months on study, then randomized to receive either active or placebo for an additional 3 months.|t|f|t|f
33847224|NCT00356408|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847225|NCT02851888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33847226|NCT06316453|||COHORT||PROSPECTIVE|||||||
33847227|NCT00490230|NON_RANDOMIZED|PARALLEL||||NONE||||||
33952286|NCT02365701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952287|NCT05316376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathological slides of omentum will be independently reviewed by two pathologists who will be blinded to the randomization to determine the CRS.|Dd-nab-paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks), combined with carboplatin (AUC = 5, days 1), dd-nab TC regimen every 4 weeks will be given to the patients in study group, while for the patients in control group, paclitaxel (175 mg/m2, day 1) combined with carboplatin (AUC=6, day1) will administered.|f|f|t|f
33952288|NCT05598502|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study statistician will be masked.|Individual randomization||||
33952289|NCT00437294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952290|NCT05143489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952291|NCT01418365|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952292|NCT00740129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952293|NCT02116309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952294|NCT06327048|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Blind the evaluator|Non-randomized intervention study|f|f|f|t
33952295|NCT06026969|||COHORT||PROSPECTIVE|||||||
34161161|NCT04131075|||COHORT||PROSPECTIVE|||||||
34161162|NCT01956968|||CASE_ONLY||CROSS_SECTIONAL|||||||
34161163|NCT04375111|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34161164|NCT00694018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161165|NCT05655949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161166|NCT06281093|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161167|NCT06206018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161168|NCT04696679|||OTHER||CROSS_SECTIONAL|||||||
33847228|NCT06609824|NA|SEQUENTIAL||PREVENTION||NONE||||||
34161169|NCT02930915|||COHORT||CROSS_SECTIONAL|||||||
34161170|NCT00261027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161171|NCT04257526|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33952296|NCT02325206|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33952297|NCT05170217|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33847229|NCT03959410|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33847230|NCT06610773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847231|NCT03472716|||COHORT||PROSPECTIVE|||||||
33952298|NCT03673111|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33847232|NCT05181059|||COHORT||CROSS_SECTIONAL|||||||
33847233|NCT00128089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952299|NCT03042338|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33952300|NCT05156060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952301|NCT01959217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847234|NCT05008523|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|"Participants are randomized to the experimental or the control arm for occupational risk reduction trainings. Trainings are not designated as experimental or control.~CHANGE TO PROTOCOL: Control dropped to enable recruitment. Outcome measures are the same."|The Opioids and Police Safety Study employed a pragmatic trial design evaluated in a simultaneous embedded mixed-method approach.||||
33847235|NCT04819659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33952302|NCT02290652|||COHORT||RETROSPECTIVE|||||||
33847236|NCT00818168|||COHORT||PROSPECTIVE|||||||
33847237|NCT04938492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847238|NCT04481308|||OTHER||PROSPECTIVE|||||||
33952303|NCT03597126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952304|NCT04054323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952305|NCT06421662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952306|NCT05163249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952307|NCT04985825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952308|NCT01752608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952309|NCT00580879|||COHORT||PROSPECTIVE|||||||
33952310|NCT04899362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952311|NCT02804659|||CASE_CONTROL||PROSPECTIVE|||||||
33952312|NCT00572910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33952313|NCT05298566|||CASE_ONLY||CROSS_SECTIONAL|||||||
33952314|NCT03143075|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Raters are blind to Inflammation group or Non-inflammation group allocation"|"Match/mismatch design (based on CRP levels), all subjects receive the same dose of EPA, no one receives placebo. Raters are blind to Inflammation group or Non-inflammation group allocation"|t|f|t|t
33952315|NCT04205864|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Application of Thrombin gel matrix after Pelvic lymphadenectomy. And compare this application with Conventional Pelvic Lymphadenectomy.|t|f|f|t
33952316|NCT02332044|RANDOMIZED|CROSSOVER||||NONE||||||
33952317|NCT02333110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33952318|NCT04897724|NA|SINGLE_GROUP||TREATMENT||||||||
33952319|NCT01959282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952320|NCT06651333|||COHORT||PROSPECTIVE|||||||
33952321|NCT04478994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952322|NCT01079000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952323|NCT01177865||||HEALTH_SERVICES_RESEARCH||||||||
33952324|NCT04666935|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention group will be instructed to include the Oslo Sports Trauma Research Center (OSTRC) Injury Prevention Program as a warm up before training session (3 times per week) during one season (6 months).The control group will practice their usual warm up.~Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions."||||
33952325|NCT03804060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952326|NCT01294865|||CASE_CONTROL||PROSPECTIVE|||||||
33952327|NCT05208710|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33952328|NCT03055273|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33952329|NCT00592137|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33952330|NCT01725204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952331|NCT05562739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is part 2 of a study with the participants being recruited from Placebo non-responders in Part 1 of the study"|t|t|t|t
33952332|NCT06422299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952333|NCT06208670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33952334|NCT06652880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The intervention is access to a digital application that provides parenting and recovery support on the participant\&#39;s smartphone.|f|f|t|f
34056935|NCT03966937|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a single blinded randomized controlled trial in which patients will be randomized into groups by sealed envelope method.|There will be two treatment groups of participants, One group will receive Dry Needling for releasing trigger points in Quadriceps along with therapeutic exercises whereas other will receive only therapeutic exercises|t|f|f|f
33952335|NCT03551457|||COHORT||PROSPECTIVE|||||||
33952336|NCT06283056|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label clinical study.||||
33952337|NCT04558515|||CASE_CONTROL||PROSPECTIVE|||||||
33952338|NCT06346743|RANDOMIZED|PARALLEL||TREATMENT||NONE||"To compare the effects of Fenofibrate adjuvant to phototherapy with conventional phototherapy for exaggerated neonatal hyperbilirubinemia in the form of bilirubin reduction, duration of phototherapy, hospital stay \& observation of side-effects.~After informed consent, single dose of Fenofibrate will be given to the group A (intervention group) and Group B (non-intervention) will only be given phototherapy. Then every 24-hourly sample for serum bilirubin will be sent for lab analysis, for 3 days. A randomized control trial is conducted."||||
33952339|NCT01077791|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33952340|NCT06087029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952341|NCT06124716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statisticians and investigators will be blinded to allocation status. Study participants will be informed that the study is testing the effectiveness of a home BP monitoring program, but not that the study is comparing two models of care.|Mixed methods design with qualitative RE-AIM inquiry nested within a pragmatic multi-site randomized trial|f|f|t|f
33952342|NCT02676271|||COHORT||RETROSPECTIVE|||||||
34056936|NCT03784794|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A Fibrinogen Concentrate, Protrombin Complex Concentrate, trhromboelastometry guided Group B Cryoprecipitates, fresh frozen plasma, standard coagulation lab test||||
34056937|NCT01287091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847239|NCT04680806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Allocation of the patients into the two treatment groups was carried out using randomization table with allocation ratio 1:1.~Participants, investigator, the tree external clinical examiners were blinded about the allocation of the patient in the treatment group.~Care provider didn't interfere in collecting and analysing the data."|"Participants were randomly allocated to the two treatment groups: -Group A was treated by an Er,Cr:YSGG laser 2780 nm.~-Group B: was treated with diode 940 nm Laser."|t|t|t|t
33847240|NCT03695458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phototherapy pad with six clusters of 12 diodes each one will be placed in both legs. Only one researcher, that will be not involved with any procedure during data collection and analysis, will know about the phototherapy program used in which leg and randomization procedure. The light aspect is the same independent of the program (active or placebo) applied and all participants will wear a opaque glasses to protect against irradiation and also assure the blinding.|Randomized, triple-blind and placebo-controlled|t|t|t|t
33847241|NCT01637181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847242|NCT01556191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847243|NCT00535756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847244|NCT00951002|||CASE_ONLY||PROSPECTIVE|||||||
33847245|NCT06426420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847246|NCT04391998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847247|NCT01215201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33847248|NCT04101214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking is with sham dry needling, simulating to insert the needle, so no real masking 100%||t|f|f|t
33847249|NCT03167359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847250|NCT01526239|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33847251|NCT00253084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33847252|NCT03162562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847253|NCT00913848|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847254|NCT00677716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847255|NCT04315350|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||After study day 1, participants are randomized (1:1:1) to one of three treatments: 1) Prednisolon and Curcumin, 2) Prednisolon and placebo or 3) Placebo and placebo.|t|t|t|t
33847256|NCT05470647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847257|NCT00531739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847258|NCT05255887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33847259|NCT04313608|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33847260|NCT02722642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847261|NCT06181487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|In order to avoid mutual interference between the experimental group and the control group, a blinding method needs to be used in the study. In this study, a single blind experiment will be conducted to blind the participating athletes. During the sample grouping process, participating athletes will not know the specific grouping situation.||t|f|f|f
33847262|NCT05301647|||CASE_CONTROL||PROSPECTIVE|||||||
33847263|NCT00526838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847264|NCT00415038|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33847265|NCT01755208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847266|NCT00677001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847267|NCT02958631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847268|NCT03899623|||COHORT||CROSS_SECTIONAL|||||||
33952343|NCT01738282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952344|NCT01976325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952345|NCT00838760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952346|NCT03381898|NA|SINGLE_GROUP||TREATMENT||NONE|The outcomes assessment and the care providers will be blind to the aims of the study.|This is a feasibility and safety trial of a single arm a telehealth intervention (pharmacy, physical therapy, and speech therapy) to people with Parkinson's disease.||||
33952347|NCT01531881|||COHORT||PROSPECTIVE|||||||
33952348|NCT06558682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056938|NCT01130519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847269|NCT06349746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and outcomes assessor will be masked about the grouping of the study|this study will be conducted to compare one group receiving selected therapeutic exercises and other group recieve cervical and thoracic mobilization added to selected therapeutic exercise Program on pain intensity, Pain-free shoulder flexion and scaption active ROM, muscle strength of external rotator and abductors, shoulder functional status in patients with Shoulder Impingement Syndrome.|t|f|f|t
33847270|NCT00921687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33847271|NCT00178308|||DEFINED_POPULATION||PROSPECTIVE|||||||
33847272|NCT00628004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33847273|NCT01788553|||CASE_ONLY||PROSPECTIVE|||||||
33847274|NCT03666377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a prospective randomized, controlled trial.|f|f|f|t
33847275|NCT01823939|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847276|NCT04155723|||CASE_CONTROL||PROSPECTIVE|||||||
33847277|NCT05660759|||COHORT||RETROSPECTIVE|||||||
33847278|NCT01099215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952349|NCT05251779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952350|NCT00186875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952351|NCT06332924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In the project, it was calculated that the experimental and control groups should have at least 30 observations each, and the sample of the study was calculated as 60 pregnant women. It was aimed to interview a total of 60 pregnant women, 30 in the control group and 30 in the experimental group.|t|f|f|f
33952352|NCT02531958|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33952353|NCT06269042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the outcome assessor will not know in which group is each participant, and the investigator will receive the data without knowing which data is from which group||f|f|t|t
33952354|NCT03544697|||COHORT||RETROSPECTIVE|||||||
33952355|NCT01387958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952356|NCT01819012|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952357|NCT05635682|||CASE_CONTROL||PROSPECTIVE|||||||
33952358|NCT02434029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952359|NCT06481618|||OTHER||PROSPECTIVE|||||||
33952360|NCT05814380|||FAMILY_BASED||PROSPECTIVE|||||||
33952361|NCT01953523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952362|NCT05344417|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33952363|NCT03396601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and Care Providers will be masked with regard to medication administered. Outcomes Assessors will not be present during IV infusion of medication.||t|t|t|t
33952364|NCT05248919|RANDOMIZED|PARALLEL||TREATMENT||NONE||268 patients accepted into the study will be divided into two groups (134 per group) and randomly allocated 1:1 (stratified by the presence or absence of cirrhosis) to receive: i) 12 weeks treatment with sofosbuvir/velpatasvir or ii) 24 weeks treatment with sofosbuvir/velpatasvir. Approximately an additional 50 patients with decompensated cirrhosis will form the observational group iii) who will receive 24 weeks of sofosbuvir/velpatasvir. Patients will be assessed for sustained virological response (SVR) from the point of randomisation at 12 (+/-1 week) and 24 weeks (+/-1 week) and then finally at 36 weeks (+/-2 weeks).||||
33952365|NCT05558735|||CASE_CONTROL||PROSPECTIVE|||||||
33952366|NCT06132087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952367|NCT01153971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952368|NCT01878968|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33952369|NCT02203773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952370|NCT06334627|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33952371|NCT04198246|||COHORT||PROSPECTIVE|||||||
33952372|NCT03673124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952373|NCT04087486|||COHORT||PROSPECTIVE|||||||
33952374|NCT03115320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952375|NCT04293601|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Newborns' interventional group are compared with infants born in 2018 who have received standard care interventions according to local protocol.||||
33952376|NCT00375024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952377|NCT02261558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34056939|NCT06622772|RANDOMIZED|PARALLEL||TREATMENT||NONE|All analyses were done by statisticians masked to treatment allocation.|||||
34056940|NCT04747067|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||It is a pilot crossover study, 25 ESRD patients were dialyzed using dialyzer; BIOPURE 260 HF on a single session on two hemodialysis modalities (conventional HD and online post-dilution HDF) with washout period of 2 weeks using high flux dialyzers with maximum surface area 2.0 m2.||||
34056941|NCT06373458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056942|NCT00180492|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33952378|NCT06507709|NA|SINGLE_GROUP||OTHER||NONE||Case series single group with no control||||
33952379|NCT01433029|||COHORT||PROSPECTIVE|||||||
33952380|NCT00671866|||COHORT||CROSS_SECTIONAL|||||||
33952381|NCT05252169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952382|NCT01484717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952383|NCT06652906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952384|NCT05534698|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, open-label, parallel, randomized, controlled trial comparing revascularization by CABG versus by PCI in patients with severe CAD and at high risk||||
34056943|NCT04569968|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be performed by an another investigator.|Two groups as an intervention and control.|f|f|f|t
34056944|NCT04748601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study|t|t|t|t
33952385|NCT06361368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952386|NCT06246370|||CASE_CONTROL||PROSPECTIVE|||||||
33952387|NCT01978977|||COHORT|||||||||
33952388|NCT04235725|||CASE_ONLY||PROSPECTIVE|||||||
33952389|NCT02863874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33952390|NCT03053102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952391|NCT00467051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952392|NCT05558709|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34056945|NCT06621199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056946|NCT02614222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34056947|NCT02467257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34056948|NCT04106050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34056949|NCT01057472|||COHORT||PROSPECTIVE|||||||
34056950|NCT04733937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33952393|NCT06038370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952394|NCT03317691|||COHORT||RETROSPECTIVE|||||||
33952395|NCT01406327|||OTHER||OTHER|||||||
33952396|NCT03194594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded||t|t|t|t
33952397|NCT05629559|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952398|NCT06650436|||COHORT||PROSPECTIVE|||||||
33952399|NCT05692570|NA|SINGLE_GROUP||TREATMENT||NONE||Single-sequence, three-periods||||
33952400|NCT05643807|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847279|NCT03389373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Provider and investigator will know if child has clinical caries or not at the time of saliva sample.|Children will have a saliva sample analyzed for amount of bacteria. Children who have higher bacteria counts are at higher risk of developing cavities.||||
33847280|NCT00215969|||CASE_CONTROL||PROSPECTIVE|||||||
33847281|NCT00313131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847282|NCT03278860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind within-subject design|t|f|t|t
33847283|NCT02187159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847284|NCT03455621|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33847285|NCT00546026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847286|NCT04393558|||COHORT||PROSPECTIVE|||||||
33847287|NCT03409627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847288|NCT00002459||||TREATMENT||||||||
33847289|NCT04723914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847290|NCT00285428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847291|NCT03802461|RANDOMIZED|PARALLEL||TREATMENT||NONE||Asymptomatic adult patients intestinally colonized with CPE will either randomized to receive fecal microbiota transplantation (intervention) or standard of care (no intervention).||||
33847292|NCT00427310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847293|NCT03896659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33847294|NCT00444275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847295|NCT05331573|||COHORT||PROSPECTIVE|||||||
33847296|NCT05446233|NA|SINGLE_GROUP||OTHER||NONE||||||
33847297|NCT02169167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847298|NCT04196127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33847299|NCT05336851|||CASE_CONTROL||PROSPECTIVE|||||||
33847300|NCT02389582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847301|NCT04664803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847302|NCT00662818|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33847303|NCT03344276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"In this pilot study 20 patients, undergoing CAS for CS, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months) and at 2 time points after invention (1 month and 2 months). The two preoperative time points will serve as the control group and the two postoperative time points will serve as the intervention group.~Patients will serve as their own controls, classifying the study as a within-subjects design. Patients will also have venous blood drawn to ascertain the change in serum markers associated with endothelial dysfunction and inflammation before and after intervention. Finally, patients will have magnetic resonance imaging (MRA) one month before intervention and 2 months after intervention in order to assess changes in global cerebral blood flow."||||
33847304|NCT01415531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847305|NCT01291823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847306|NCT04421443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will know the baseline condition they have been assigned to: 3, 5 or 8 evaluation days before the intervention.|In the present investigation, all consecutive patients who have been selected to undergo bariatric surgery and present anxiety or depressive symptoms or at least one diagnosis of emotional disorder, are asked to participate. Once inclusion criteria are accomplished, each patient will be randomly assigned to one of the multiple baseline groups: 3, 5 or 8 evaluation days before the intervention. The study includes eleven assessment points (baseline, pre-treatment, post-treatment and eight follow-ups, one every three months until two years after treatment completion).|t|f|f|f
33847307|NCT06611189|||COHORT||PROSPECTIVE|||||||
33847308|NCT01242800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847309|NCT05483738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants are masked with anonymized identifier (ID)|Matched case-control study||||
33847310|NCT06610604|||COHORT||PROSPECTIVE|||||||
33847311|NCT04473898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||It is planned to include 3 groups in the study. The group 1 will be informed about covid-19 and hygiene. Aerobic exercise will be offered to Group 2, aerobic exercise + breathing exercises will be offered to Group 3. The persons to be included in the groups will be determined randomly.|t|f|f|f
33847312|NCT05253287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group 1 - Growth Hormone + Standard medical therapy Group 2 - Standard Medical Therapy|f|f|f|t
33847313|NCT04906746|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, pilot study, Intrapatient dose escalation||||
33847314|NCT00567034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33847315|NCT04551716|||COHORT||PROSPECTIVE|||||||
33847316|NCT03142425|||COHORT||PROSPECTIVE|||||||
33847317|NCT03259373|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847318|NCT01104597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33847319|NCT04537494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952401|NCT01655810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952402|NCT03495765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952403|NCT03598075|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||In a Randomized, double blind, cross over experiment. Migraine without aura patients will received amylin or CGRP in two separate days apart by a week.|t|t|t|f
33952404|NCT00312936|RANDOMIZED|CROSSOVER||||NONE||||||
33952405|NCT02844231|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33847320|NCT03635372|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33847321|NCT02738203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847322|NCT02754349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847323|NCT04152304|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study. One group before and after design||||
33847324|NCT05414994|||CASE_CONTROL||PROSPECTIVE|||||||
33847325|NCT00003827||||TREATMENT||||||||
33847326|NCT03758859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Randomisation is between eyes i.e. eye exposed to blinking alone vs eye exposed to lubricant drops|||||
33847327|NCT02474485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847328|NCT00350233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847329|NCT03950076|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|open label study where outcomes assessor is blinded to treatment allocation|Prospective, randomized, open, blinded end-point (PROBE), multicenter international trial|f|f|f|t
33847330|NCT02195154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847331|NCT06606210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952406|NCT01961765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952407|NCT04379232|||COHORT||RETROSPECTIVE|||||||
33952408|NCT04960137|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33952409|NCT02844829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952410|NCT00585468|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952411|NCT02158949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952412|NCT02413710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33952413|NCT00118560|NON_RANDOMIZED|PARALLEL||||NONE||||||
33952414|NCT01240369|||CASE_ONLY||CROSS_SECTIONAL|||||||
33952415|NCT06650501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952416|NCT05964400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952417|NCT03421873|||COHORT||PROSPECTIVE|||||||
33952418|NCT06617546|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33952419|NCT04491474|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33952420|NCT00733642||PARALLEL||TREATMENT||NONE||||||
33952421|NCT02209272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952422|NCT02173275|||COHORT||PROSPECTIVE|||||||
33952423|NCT03323034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952424|NCT03126175|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|Parallel Assignment||||
33952425|NCT04759352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33952426|NCT03842202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33952427|NCT01857011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952428|NCT00741026|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33952429|NCT04698668|||COHORT||RETROSPECTIVE|||||||
33952430|NCT00003726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952431|NCT03183739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33952432|NCT06525506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952433|NCT02003248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952434|NCT05632055|||CASE_CONTROL||PROSPECTIVE|||||||
33952435|NCT00762073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952436|NCT03716440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952437|NCT01495793|NA|SINGLE_GROUP||OTHER||NONE||||||
33952438|NCT03245359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952439|NCT03818542|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952440|NCT02753582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952441|NCT01628159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952442|NCT03190109|||COHORT||CROSS_SECTIONAL|||||||
33952443|NCT06396208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7) as control group Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2) as intervention group|f|f|t|f
33952444|NCT06045377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952445|NCT02231606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33952446|NCT05434975|NA|SINGLE_GROUP||OTHER||NONE||||||
33952447|NCT06329375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Participants will be prospectively randomized into either a nutrition program (intervention), or receiving state-of-the-art standard of care (SOC) in a 4:1 ratio. Patients in the intervention group will be provided the following two resources in addition to SOC:~1. Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge),~2. Education at discharge and continuing outreach to enhance knowledge for better diet and food options"||||
33952448|NCT06440044|||COHORT||RETROSPECTIVE|||||||
33952449|NCT00168766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847332|NCT04647435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847333|NCT02086604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847334|NCT00573079|||OTHER||PROSPECTIVE|||||||
33952450|NCT06650059|||CASE_ONLY||PROSPECTIVE|||||||
33952451|NCT03901339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952452|NCT05726123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33952453|NCT05874544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952454|NCT03839693|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||sequential cohort, dose escalating study|t|t|t|t
33952455|NCT01748162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952456|NCT02476058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33952457|NCT00995462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952458|NCT02080624|NA|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33952459|NCT05285553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952460|NCT03844802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The therapist in charge of the evaluation will remain unaware of participants' allocation group||f|f|f|t
33952461|NCT05252273|||OTHER||PROSPECTIVE|||||||
33952462|NCT01556659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952463|NCT03988049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Assessors will be reviewing and scoring the photos after the study is completed.|All subjects will receive half of their faces treated with each laser. Subjects will be randomized to determine which side of the face is treated with each laser.|f|f|f|t
33952464|NCT01310725|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33952465|NCT02594566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161172|NCT06071650|RANDOMIZED|PARALLEL||OTHER||NONE|Because of the nature of the study and the interventions offered, it will not be possible to blind participants or research assistants to allocation groups.|"A prospective, two-arm randomised parallel group clinical trial. Prehabilitation is routinely offered as the standard of care to all patients who are scheduled for curative resectional surgeries for upper gastrointestinal (UGI) cancer at Imperial College Healthcare Trust and lung cancer at Guy's and St Thomas' NHS Foundation Trust.~Consecutive patients referred for prehabilitation will be approached for enrolment into the study. If willing to participate, written informed consent will be gained (e-consent). Following enrolment all participants will be provided with a wearable fitness tracker and will be randomised to one of two groups (1:1 randomisation) - Group A or Group B. The only difference between the two groups is the prescription of exercise, all other activities and data collected are the same.~Randomisation following recruitment and using a computer programme."||||
34161173|NCT00722956|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161174|NCT04289311|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34161175|NCT03832751|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33744110|NCT01822860|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33744111|NCT05447546|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-Blinded|SAD portion in 4 cohorts, with 8 subjects in each cohort, 4 ascending single doses, MAD portion in 4 cohorts, with 8 subjects in each cohort, 4 multiple ascending doses.|t|t|t|f
33744112|NCT01144312|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952466|NCT04470830|||COHORT||PROSPECTIVE|||||||
33952467|NCT02832245|||OTHER||PROSPECTIVE|||||||
33952468|NCT02503696|||CASE_ONLY||PROSPECTIVE|||||||
33952469|NCT00824993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952470|NCT04020614|||OTHER||CROSS_SECTIONAL|||||||
33744113|NCT05413187|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|During the trial procedures, SCRC coordinators and the sponsors will be exposed to the trial randomization. All other personnel including principle investigator, investigators, research assistants etc. will be blinded to the randomization and trial arms.|"Approximately forty children between the ages of two to eight years old with a documented diagnosis of Autism.~The trial population will be randomized in a 1:1 ratio."|t|f|t|f
33744114|NCT03787940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33744115|NCT00325299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33744116|NCT03769623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Diameter: 2.0mm, 2.25mm, 2.5mm, 2.75mm Length: 10mm, 15mm, 20mm, 25mm, 30mm|f|f|f|t
33744117|NCT00841867|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33744118|NCT02653521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744119|NCT01877447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744120|NCT01709019|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33744121|NCT01446380|||COHORT||PROSPECTIVE|||||||
33744122|NCT03399110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744123|NCT03116919|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Crossover feeding trial||||
33744124|NCT06349902|||COHORT||OTHER|||||||
33744125|NCT00922662|||COHORT|||||||||
33744126|NCT04749719|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744127|NCT01628276|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33744128|NCT00174993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744129|NCT00084058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744130|NCT00714168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744131|NCT04929145|||CASE_CONTROL||PROSPECTIVE|||||||
33744132|NCT02265237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952471|NCT02424357|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The surgeon will be unaware of the randomization until the end of the surgery. All microbiology personnel and patients will be unaware of the interventional group||t|t|t|f
33952472|NCT01905631|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33952473|NCT04828551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"Study participants will not be randomized to individual treatment groups. To ensure a uniform distribution of scanner combinations, participants will follow a block-allocation pattern with different scanner combinations for different participants, however, patients and operators will not be blinded to ultrasound scanners being used.~All efforts will be made to keep ultrasound operators blinded to clinical and laboratory data, however, it is not believed that this will significantly affect the ultrasound acquisition. The Visit 2 operator will be asked to not review the Visit 1 exam results.~Central analysts will be blinded to key clinical and laboratory findings to minimize potential bias. Blinding of the central analysts will be outlined in a separate Image Review Charter."|||||
33952474|NCT02021019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952475|NCT06566638|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either the control arm (SOC) or the treatment arm (SOC plus NucleoCapture) in a 1:1.||||
33952476|NCT01584050|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33952477|NCT04984694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors were blinded to the group allocation.|"Parallel assignment A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a three-arm parallel assignment involves three groups of participants. One group receives intervention (Computerized Virtual Reality program), one group receives social interaction, and the other group is the control group. So during the trial, participants in one group receive intervention in parallel to participants in the other group, who receive social interaction."|f|f|f|t
33952478|NCT00561600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952479|NCT01201122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33952480|NCT03041818|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33847335|NCT03691480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847336|NCT05396872|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33847337|NCT00035191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847338|NCT00107887|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33952481|NCT03381807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952482|NCT00241059|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33952483|NCT04401995|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952484|NCT06566235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33952485|NCT02495636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952486|NCT01988194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952487|NCT00616889|||COHORT||PROSPECTIVE|||||||
33952488|NCT04895046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952489|NCT04441437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952490|NCT03811652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952491|NCT04891445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33952492|NCT02230332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952493|NCT01015118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952494|NCT03217474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952495|NCT01092676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33952496|NCT04837586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952497|NCT03984994|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The study employs 2 interventions: resistance training and aerobic exercise training. One group of participants will undergo resistance training then aerobic exercise training; the other group will undergo aerobic exercise training then resistance training.|f|f|f|t
33952498|NCT01412307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952499|NCT03716830|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Both participants and study staff will be blinded to the treatment group of participants. Only the licensed acupuncturist will be aware of the type of acupuncture the participant will be receiving.|Participants will be randomized to one of four groups: 1) verum acupuncture + real tDCS, 2) sham acupuncture + real tDCS, 3) verum acupuncture + sham tDCS, and 4) sham acupuncture + sham tDCS.|t|f|t|f
33952500|NCT02837666|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33952501|NCT04066101|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33952502|NCT02736006|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33952503|NCT04833569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952504|NCT04756466|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33952505|NCT02585375|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33952506|NCT03036540|||COHORT||PROSPECTIVE|||||||
33952507|NCT00817427|NON_RANDOMIZED|PARALLEL||||NONE||||||
33952508|NCT03497000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952509|NCT00061568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952510|NCT00058994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952511|NCT04720976|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952512|NCT00090259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952513|NCT03514446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952514|NCT03669627|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Observer-blind|Participants will be randomly assigned to one of three groups: Group 1 will receive aTIV as a primer and QIV as a booster, Group 2 will receive QIV as both primer and booster, and Group 3 will receive aTIV as both primer and booster.|f|f|t|f
33952515|NCT01082601|||COHORT||PROSPECTIVE|||||||
33847339|NCT06610656|RANDOMIZED|PARALLEL||OTHER||DOUBLE|n this study, both participants and investigators are masked to the group assignment. Participants will not be aware of whether they are receiving pacifier therapy alone or in combination with white noise therapy. Investigators will not know the specific group assignments during the intervention to minimize bias in observations and assessments.|This study uses a parallel assignment design in which participants are assigned to one of two intervention groups. Group 1 will receive pacifier and white noise therapy, while Group 2 will receive pacifier therapy only. Each group will be treated independently, and there will be no crossover between the groups.|t|f|f|t
33847340|NCT03975777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33847341|NCT05191940|NA|SINGLE_GROUP||OTHER||NONE||||||
33847342|NCT01089881|||CASE_ONLY||PROSPECTIVE|||||||
33847343|NCT00539435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847344|NCT06611332|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33847345|NCT06086600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847346|NCT03782675|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33847347|NCT05711602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The assignment to the groups will be of simple random type and hidden. Those responsible for admitting patients to the intervention phase will not know what group has been assigned each. This assignment will be made in advance by a researcher who will not intervene in the later stages of evaluation, intervention, data recording and elaboration of database. The assignment will be communicated through sealed and totally opaque envelopes.~All measurements given above will be made both to the control group and to the experimental group just prior to the start of the intervention, and immediately after and six months after the end of this period, and the results will be recorded in a data record"|Randomized controlled trial|f|t|t|t
33847348|NCT01888900|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847349|NCT06609837|||COHORT||CROSS_SECTIONAL|||||||
33847350|NCT03046108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847351|NCT02773563|||CASE_CONTROL||PROSPECTIVE|||||||
33847352|NCT03037853|||COHORT||PROSPECTIVE|||||||
33847353|NCT03972150|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33847354|NCT04079751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will not be informed of their study allocation.|Patients will be randomized to either Neutral mechanical alignment or Anatomical alignment using randomly generated numbers permuted in blocks of 4.|t|f|f|f
33847355|NCT00721591|||COHORT||PROSPECTIVE|||||||
33847356|NCT02907229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847357|NCT00173992|NON_RANDOMIZED|PARALLEL||ECT||NONE||||||
33847358|NCT00307684|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33847359|NCT01080716|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33847360|NCT02930226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847361|NCT05094024|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33847362|NCT02720302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847363|NCT02145559|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847364|NCT03674359|||COHORT||PROSPECTIVE|||||||
33952516|NCT03500237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952517|NCT02928991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952518|NCT04216992|||COHORT||PROSPECTIVE|||||||
33952519|NCT04666870|||CASE_CONTROL||RETROSPECTIVE|||||||
33952520|NCT06135272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952521|NCT02341573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952522|NCT06647043|NA|SINGLE_GROUP||OTHER||NONE||All study subjects will receive the same study products for 3 months.||||
33952523|NCT03237000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~* Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~* Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."||||
33952524|NCT02848859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952525|NCT04069208|NA|SINGLE_GROUP||TREATMENT||NONE||Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days||||
33952526|NCT06103162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952527|NCT05036486|||CASE_ONLY||PROSPECTIVE|||||||
33952528|NCT04070157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, study personnel (including the Investigator, study coordinator(s), pharmacist/designee), and the Sponsor will be blinded to the identity of the study drug (active or placebo) administered to subjects.||t|t|t|t
33952529|NCT02556112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952530|NCT00750373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952531|NCT02248428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952532|NCT02894541|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952533|NCT02996942|||COHORT||PROSPECTIVE|||||||
33952534|NCT05159648|||COHORT||PROSPECTIVE|||||||
33952535|NCT00702286|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33952536|NCT05969626|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952537|NCT04680390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952538|NCT06148077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33952539|NCT06005077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients and principle investigator knew which group they were assigned to. Only the outcome assessor didn't know which patient was assigned to which group.||f|f|f|t
33952540|NCT04943536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952541|NCT01013402|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33952542|NCT04114474|||COHORT||PROSPECTIVE|||||||
33952543|NCT06145399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952544|NCT00998621|||||PROSPECTIVE|||||||
33952545|NCT03591666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952546|NCT00054639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952547|NCT02288234|||CASE_ONLY||RETROSPECTIVE|||||||
33952548|NCT02928562|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33952549|NCT04122677|||COHORT||PROSPECTIVE|||||||
33952550|NCT02592070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952551|NCT04054934|||CASE_CROSSOVER||PROSPECTIVE|||||||
33952552|NCT03302221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Doppler Ultrasonography Assessed Vascular Changes|f|f|f|t
33847365|NCT04289051|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33847366|NCT00555594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847367|NCT00418340|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847368|NCT01035359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847369|NCT00398268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847370|NCT05185934|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Sixty patients with COVID-19 infection will be randomized to receive food supplement Endocalyx (n=30) or placebo (n=30) for 4 consecutive months.|t|f|t|f
33847371|NCT05927662|||COHORT||PROSPECTIVE|||||||
33847372|NCT01453543|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33847373|NCT04948281|||COHORT||RETROSPECTIVE|||||||
33847374|NCT04224207|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective, open-label clinical trial; The statistical comparisons were made primarily between the baseline and final values from the same eye. The parametric results for visual functions and structural changes were analyzed.||||
33847375|NCT05303558|||COHORT||RETROSPECTIVE|||||||
33847376|NCT00557947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847377|NCT05832697|RANDOMIZED|CROSSOVER||TREATMENT||NONE||4 by 3 cross-over study||||
33847378|NCT03882541|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33847379|NCT00375440|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33847380|NCT02136082|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33847381|NCT03236675|||COHORT||PROSPECTIVE|||||||
33847382|NCT01668472|||COHORT||PROSPECTIVE|||||||
33847383|NCT01879722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847384|NCT02342470|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33847385|NCT01551459|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847386|NCT02299180|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33847387|NCT04285203|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33847388|NCT00160602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847389|NCT05833204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon will not be blinded. Conversely, patients and co-investigators who will assess study outcomes and perform patients' follow-ups will be masked regarding the allocation arm until the study's conclusion.|Multicenter, parallel arms, open-label, randomized controlled trial.|t|f|f|t
33847390|NCT05138354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33847391|NCT01757197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847392|NCT05775081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847393|NCT04428372|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33847394|NCT01543984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33847395|NCT03821779|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||First phase (go-no-go) with 10 subjects in 1 arm Second phase with 20 subjets (2 arms) in a cross-over design.||||
33847396|NCT06529055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33847397|NCT01302067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847398|NCT02341729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847399|NCT01796548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847400|NCT00568724|||CASE_CONTROL||PROSPECTIVE|||||||
33847401|NCT04576403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A designated person will number the all mittens using a randomization list. The rest of the study personnel (care provider, investigator, outcome assessor) will thereby not be aware of which mittens that functions and which that do not.|Participants will be randomised 1:1 to either intervention og control group by use of a randomization list|t|t|t|t
33847402|NCT04490122|||COHORT||PROSPECTIVE|||||||
33847403|NCT01695031|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33847404|NCT05439382|||COHORT||RETROSPECTIVE|||||||
33847405|NCT04361955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study N = 180 participants 60 participants with diagnosis of essential tremor having DBS implanted 70 participants with diagnosis of Parkinson Disease having DBS implanted 50 healthy controls||||
33847406|NCT01353859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847407|NCT02275975|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33847408|NCT01440998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847409|NCT06010329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847410|NCT04601753|||COHORT||PROSPECTIVE|||||||
33847411|NCT04452968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952553|NCT00942110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952554|NCT02424851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952555|NCT06405152|||OTHER||RETROSPECTIVE|||||||
33952556|NCT02303275|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33847412|NCT03975959|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The protocol administration will take about 20 minutes. It will be conducted by an experienced clinical neuropsychologist or clinical oncologist in each center during standard care. According to the results on the questionnaires and test, patients will be addressed and managed by a neuropsychologist, a clinical psychologist, psychiatrist or a speech therapist.||||
33847413|NCT04235829|||COHORT||PROSPECTIVE|||||||
33847414|NCT02963740|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33847415|NCT01791387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847416|NCT00297427|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33847417|NCT04175080|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33847418|NCT05686538|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label.|Genetic randomization. Patients with related donors are included in the intervention group. Patients with unrelated donors are included in the control group.||||
33847419|NCT00927030|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33847420|NCT06162962|||COHORT||RETROSPECTIVE|||||||
33847421|NCT04811131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a parallel group, double blind, vehicle-controlled study in which subjects with non-segmental vitiligo will be randomized to ARQ-252 0.3% cream BID or vehicle cream BID, and active phototherapy or sham phototherapy for 24 weeks to affected areas of vitiligo on the face, neck, hands, forearms, and elbows, (Up to 15% total body BSA)|t|t|t|t
33847422|NCT06431308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847423|NCT03237572|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot, 2-arm randomized study||||
33847424|NCT01348568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847425|NCT04135690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847426|NCT00836745|||CASE_ONLY||PROSPECTIVE|||||||
33847427|NCT02753569|||COHORT||PROSPECTIVE|||||||
33847428|NCT05170061|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33847429|NCT01602107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847430|NCT03534128|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33847431|NCT00621777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847432|NCT06294405|||OTHER||OTHER|||||||
33847433|NCT02370927|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33847434|NCT05014711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind||t|f|f|f
33847435|NCT00685906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33847436|NCT02408380|||COHORT||PROSPECTIVE|||||||
33847437|NCT02235389|||CASE_CONTROL||PROSPECTIVE|||||||
33847438|NCT00741364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847439|NCT00336700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056951|NCT00585013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056952|NCT05896722|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34056953|NCT05651919|||CASE_CONTROL||PROSPECTIVE|||||||
33847440|NCT06381544|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33847441|NCT02138175|||COHORT||PROSPECTIVE|||||||
33847442|NCT06122844|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33847443|NCT04203459|||CASE_CONTROL||PROSPECTIVE|||||||
33847444|NCT00379288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847445|NCT05599945|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33847446|NCT06419426|||OTHER||PROSPECTIVE|||||||
33847447|NCT01763398|||COHORT||PROSPECTIVE|||||||
33847448|NCT01389505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33847449|NCT03228745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847450|NCT03738644|||COHORT||PROSPECTIVE|||||||
33847451|NCT06610513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the study\&amp;#39;s nature, masking could not be performed.|||||
33847452|NCT05548153|||CASE_CONTROL||PROSPECTIVE|||||||
33847453|NCT06459934|||COHORT||PROSPECTIVE|||||||
33952557|NCT03821805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33952558|NCT05489952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33952559|NCT06014008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952560|NCT01227031|||CASE_CONTROL||PROSPECTIVE|||||||
33952561|NCT02260570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33952562|NCT02154152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952563|NCT05340049|RANDOMIZED|CROSSOVER||TREATMENT||NONE||120 pupils aged 3-8 years were divided into three treatment groups set as follows: Placebo group (n=41) Rhythmic Movement Therapy Group (n=40) Craniosacral Therapy Group (n=39) Such participants were included according to the number of Active Primitive Reflexes (Moro, asymmetric and symmetric cervical) and/or Cranial Blocks (swaying of the dura mater, sphenoid bone and cranial parietal areas) presented by each of them||||
33952564|NCT01726426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952565|NCT03485573|||COHORT||PROSPECTIVE|||||||
33952566|NCT04122339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952567|NCT03058081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952568|NCT06032026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952569|NCT05493683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952570|NCT00002074||||TREATMENT||||||||
33847454|NCT01869816|||COHORT||CROSS_SECTIONAL|||||||
33847455|NCT02807818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33952571|NCT06342791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|laser acupuncture|two groups|t|f|f|f
33952572|NCT05774080|||COHORT||OTHER|||||||
33952573|NCT02996604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34056954|NCT02071706|NA|SINGLE_GROUP||OTHER||NONE||||||
34056955|NCT03521297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single(Investigator)||f|f|t|f
33952574|NCT03583840|RANDOMIZED|PARALLEL||SCREENING||NONE|"It is not possible to blind the participants as the intervention is a website. Participants in the intervention arm will need to go through the website and will know its contents while participants in the control arm will not.~There is no care provider in this study as the intervention is delivered via a website.~The assignment of intervention or control arm to the participants will be done automatically by the website. After signing the consent form, participants will enter a website which will randomise them to either intervention or control arm. The investigators do not play a role in this.~The outcome assessment only involves the participants answering a questionnaire themselves. No Outcome Assessor is required to assess any outcome from the participants."|||||
33952575|NCT03522506|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33952576|NCT05643859|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33952577|NCT01232764|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33952578|NCT02570217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952579|NCT00694330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952580|NCT05668377|||COHORT||PROSPECTIVE|||||||
34056956|NCT02990585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056957|NCT06618183|||COHORT||PROSPECTIVE|||||||
33744133|NCT02446808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744134|NCT03305120|||CASE_CONTROL||PROSPECTIVE|||||||
33744135|NCT03178552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744136|NCT06213025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33744137|NCT05409417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744138|NCT03032926|||CASE_ONLY||PROSPECTIVE|||||||
33744139|NCT05080764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744140|NCT03956498|NA|SINGLE_GROUP||OTHER||NONE||||||
33744141|NCT05923944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33744142|NCT06128616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744143|NCT00404339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744144|NCT00968604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744145|NCT02160873|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33744146|NCT06442436|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33744147|NCT00695331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744148|NCT06635057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744149|NCT04852614|||CASE_ONLY||PROSPECTIVE|||||||
33744150|NCT04045457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744151|NCT04576208|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744152|NCT06139575|NA|SEQUENTIAL||TREATMENT||NONE||||||
33744153|NCT06559488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"While it was not possible to mask participants and surgeons to the treatment allocation due to the nature of the surgical intervention, efforts were made to mask the outcome assessors. This involved:~Centralized Data Collection: All data related to patient outcomes (visual acuity, VH grading, complications) were collected on standardized forms and sent to a central data management center.~Coded Data Entry: Patient identification numbers were used instead of names to prevent bias.~Masked Data Analysis: The statistician conducting the analysis was blinded to group allocation."|"A parallel group design was employed. Patients requiring vitrectomy for diabetic non-clearing vitreous hemorrhage (VH) were divided into two groups:~Intervention Group: Underwent vitrectomy followed by an intravitreal injection of bevacizumab (1.25 mg/0.05 mL).~Control Group: Underwent vitrectomy alone."|f|f|f|t
33744154|NCT04906200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744155|NCT00086346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744156|NCT02216331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744157|NCT01344460|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744158|NCT06114420|||COHORT||PROSPECTIVE|||||||
33744159|NCT03339076|NA|SINGLE_GROUP||TREATMENT||NONE||"This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the M3 in establishing urinary drainage and allowing the control of micturition when indwelling for \<28 days in male patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.~1. Study Timeline and Calendar~The maximum indwelling time for the DEVICE should be \<28 days, at which time the DEVICE will be removed, and the patient will be offered the option of insertion of a new M3 Catheter or return to the bladder drainage technique used prior to M3 Catheter insertion. All patients will be followed until patient is off study or until end of study, whichever occurs first."||||
33744160|NCT04218929|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33744161|NCT04529213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3-arm parallel trial|t|f|f|t
33744162|NCT05115162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744163|NCT00587873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744164|NCT00244738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744165|NCT03674229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744166|NCT06342557|||COHORT||OTHER|||||||
33744167|NCT05059691|||COHORT||PROSPECTIVE|||||||
33744168|NCT04841057|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blinded to participant at time of surgery. Randomization during operation|Patients undergoing gastric bypass|t|f|f|f
33744169|NCT02948179|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744170|NCT03526900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744171|NCT06094153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33744172|NCT06485232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744173|NCT00290823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744174|NCT04538014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744175|NCT05903001|||COHORT||PROSPECTIVE|||||||
33744176|NCT00129987|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33744177|NCT01118390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744178|NCT03452917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744179|NCT03013010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952581|NCT06556576|RANDOMIZED|PARALLEL||PREVENTION||NONE||The randomization will occur at the country level. Within each country (France, Germany, Romania, and Spain), schools will be randomized to either the intervention or control group. This means that in each country, schools will be assigned to one of the two groups, and all students, their families, teachers, and other school staff within those schools will be placed in the respective group. The same procedure will be followed independently within each of the four countries.||||
33847456|NCT03248492|RANDOMIZED|PARALLEL||TREATMENT||NONE|In Part 1, about 60 trastuzumab emtansine (T-DM1) resistant/refractory patients initially will be randomized into three treatment groups (low, medium and high doses) for Pharmacokinetics (PK), then about another 60 will be randomized into low and high doses to determine recommended dose (RD). After that, about 100 will receive the recommended dose in an open-label continuation stage (Part 2). About 10 TDM-1 intolerant patients will join the continuation stage as an exploratory only arm.|HER2-positive patients will be classified into two groups: T-DM1 resistant/refractory (experimental) and T-DM1 intolerant (exploratory only).||||
33847457|NCT05132127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847458|NCT02099045|||COHORT||PROSPECTIVE|||||||
33847459|NCT06240559|||CASE_ONLY||PROSPECTIVE|||||||
33847460|NCT04059302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The ultra sound technician that will be evaluating the primary outcome measures will be blinded to participant condition.||f|f|f|t
33847461|NCT02185001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952582|NCT03801200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952583|NCT01906762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33952584|NCT04886401|||COHORT||RETROSPECTIVE|||||||
33952585|NCT03010475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952586|NCT05531695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33952587|NCT02074982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952588|NCT04746534|||COHORT||OTHER|||||||
33952589|NCT06651242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33952590|NCT00783939|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33952591|NCT01536522|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE||feasibility and palatability of a food product for asthma|t|t|t|t
33952592|NCT03933709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Throughout the study, the physical therapy given was the same for the three groups and was applied by CRIT therapists. These staff members were not involved in the protocol. The evaluators did not have access to any information about the treatment given to each child, and this ensured the blind part to the study was met.|Exploratory Study|f|f|f|t
33952593|NCT02921607|||COHORT||OTHER|||||||
33952594|NCT04074109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|End-of-treatment assessments will be conducted by an assessor who is blind to treatment modality.|Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33952595|NCT06384534|RANDOMIZED|CROSSOVER||OTHER||NONE||Each participant is its own control||||
33952596|NCT06042465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952597|NCT03879759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Study 1: NAC vs Placebo (PL) (4 weeks outpatient) Study 2: NAC vs PL (3 days inpatient) Study 2: NAC vs PL (neuromaging session before vs after treatment)|t|t|t|t
33952598|NCT06129500|NA|SINGLE_GROUP||TREATMENT||NONE||"This project will follow an ABA case-series design.~In an ABA design, for an individual receiving a treatment there is a measurement period (baseline) before the treatment phase, and then again after the treatment phase, to allow exploration of the apparent stability of any changes observed over the treatment period.~Participants will be assigned to a two-week baseline phase, up to twelve-session intervention phase, and a two-week post-intervention phase. This will allow for three baseline measurements, to establish symptom and mood stability prior to treatment, and a two-week post-intervention measurement phase to explore the stability of any intervention-related changes.~Symptoms will be measured weekly across the baseline period, treatment phase and post-treatment periods. Participants will also complete additional self-report measures and be invited to participate in a semi structured interview to gather qualitative feedback post treatment."||||
33952599|NCT00160719|||CASE_ONLY||PROSPECTIVE|||||||
33952600|NCT05298124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952601|NCT05270772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952602|NCT03140813|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33952603|NCT06650839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952604|NCT05252585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952605|NCT06616753|||COHORT||PROSPECTIVE|||||||
33952606|NCT00721513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952607|NCT00778206|||CASE_ONLY||PROSPECTIVE|||||||
33952608|NCT03480243|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33952609|NCT03361839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non randomized||||
33952610|NCT04510870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34056958|NCT04611867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056959|NCT05979935|||CASE_CONTROL||PROSPECTIVE|||||||
34056960|NCT03080766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056961|NCT03244670|||COHORT||PROSPECTIVE|||||||
34056962|NCT00865917|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34056963|NCT06612099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056964|NCT03382301|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34056965|NCT03440294|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34056966|NCT02429388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952611|NCT03605758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952612|NCT06445517|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952613|NCT02889627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952614|NCT04472273|||COHORT||OTHER|||||||
34056967|NCT03785912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056968|NCT06174376|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34056969|NCT05284929|||CASE_CONTROL||RETROSPECTIVE|||||||
34056970|NCT00858299|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34056971|NCT06614296|||CASE_CONTROL||RETROSPECTIVE|||||||
34056972|NCT00738881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056973|NCT00916344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847462|NCT05129228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For follow-up visits, in person and via phone, the provider will be blinded. Physicians analyzing Coronary CT Angiograms (CCTA) will be blinded to the randomization arm.|OCT-guided saphenous vein CABG|t|t|f|t
33952615|NCT05053594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For each patient, an opaque envelope will be prepared, sealed and numbered sequentially containing the group to which the patient will be allocated. A list of randomized computer-generated numbers (www.random.org) will be used for this purpose. No surgeon, assistant, nurse and anesthesiologist involved in anesthesia control or data collection will be aware of the dose of neostigmine to be administered. An anesthesiologist not involved in the study will be responsible for preparing the solution containing neostigmine and atropine (diluted with saline solution until complete 10mL) according to the group to which each patient belongs. The syringes will be similar and identified only with a label with the word reversal."|Prospective, controlled, randomized clinical trial|t|t|t|f
33847463|NCT04534153|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a single-center, randomized, double-blind, 3-period crossover trial. Subjects will be randomized to receive fexofenadine only under Treatment Arm 1 or fexofenadine and 3 mg SLS under Treatment Arm 2 or fexofenadine and 30 mg SLS under Treatment Arm 3.|t|f|f|t
33952616|NCT00690365|||CASE_ONLY||PROSPECTIVE|||||||
33847464|NCT04552899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847465|NCT00439231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952617|NCT04136522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952618|NCT04011891|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33952619|NCT04384887|||CASE_CONTROL||PROSPECTIVE|||||||
33952620|NCT00620776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056974|NCT06342219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34056975|NCT06333275|||COHORT||PROSPECTIVE|||||||
34056976|NCT03824886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34056977|NCT06620354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056978|NCT04412200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056979|NCT00765895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34056980|NCT06215924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056981|NCT00086112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34056982|NCT06031935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056983|NCT03193801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056984|NCT00705718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34056985|NCT03839290|||OTHER||PROSPECTIVE|||||||
34056986|NCT04283682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056987|NCT01764789|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34056988|NCT00029536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This was a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Randomization was carried out separately for women with and without catamenial epilepsy, 2:1 to progesterone or placebo.|t|t|t|t
34056989|NCT05462223|NA|SEQUENTIAL||TREATMENT||NONE||A prospective, single-arm, multicenter, open-label study of the VRS-AVF for use as adjunctive therapy in the surgical creation of an end-to-side brachiocephalic (BC) AVF.||||
34056990|NCT06620146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34056991|NCT00428051|||||PROSPECTIVE|||||||
34056992|NCT00641576|||CASE_ONLY||PROSPECTIVE|||||||
34056993|NCT02737631|NA|SINGLE_GROUP||SCREENING||NONE|All participants receive the same interventions|||||
34056994|NCT03450785|||COHORT||PROSPECTIVE|||||||
34056995|NCT03660475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34056996|NCT03652233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847466|NCT02852070|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33847467|NCT06396364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Patients were randomized in two groups at the time of the diagnosis in the emergency department. The treatment group (T: 89 patients) were treated with a third-generation cryotherapy device (Z- One®, Zamar) which was applied daily for 2 hours two times a day up to the day of surgery. The leg was immobilized in a walking boot which was removed when the cryotherapy device was applied. The control group (C: 80 patients) did not use cryotherapy before surgery, the leg was immobilized into a half cats and elevation of the injured limb was indicated.~Pain was evaluated according to the Visual Analogue Scale (VAS) and the analgesic drug demand (including morphine or acetaminophen). The Bod"|f|f|f|t
33847468|NCT05680623|||COHORT||PROSPECTIVE|||||||
33847469|NCT05772273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847470|NCT05191472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847471|NCT06065683|||COHORT||PROSPECTIVE|||||||
33847472|NCT05599659|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The clinical trial is a prospective cohort study analysing the effect of palliative care interventions on quality of life, patient satisfaction, carepartner burden and health care utilization patterns in patients living with parkisonism and their carepartners.~Participants will:~* Receive multidisciplinary palliative care.~* Answer questions related to the quality of life, patient satisfaction, carepartner burden and health care utilization patterns."||||
33847473|NCT00614965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847474|NCT04869007|||COHORT||PROSPECTIVE|||||||
33847475|NCT06172751|||COHORT||RETROSPECTIVE|||||||
33847476|NCT04929405|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33847477|NCT02549196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33847478|NCT00562055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847479|NCT02808078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161176|NCT06051344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||. Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo|t|f|t|f
34161177|NCT02652156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161178|NCT02738554|NA|SINGLE_GROUP||OTHER||NONE||||||
34161179|NCT00064961||PARALLEL||PREVENTION||SINGLE||||||
34161180|NCT04124640|||OTHER||PROSPECTIVE|||||||
34161181|NCT06155552|||CASE_CROSSOVER||PROSPECTIVE|||||||
33744180|NCT00745927|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33744181|NCT03143218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"A double-blind, individually randomised trial to compare the incidence of clinical episodes of malaria across three study arms:~1. Seasonal vaccination with the malaria vaccine RTS,S/AS01~2. Seasonal malaria chemoprevention with SP/AQ~3. Combination of these two interventions"|t|t|t|f
33744182|NCT01283269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33744183|NCT00658346|||CASE_CONTROL||PROSPECTIVE|||||||
33952621|NCT01374516|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952622|NCT03541785|||COHORT||PROSPECTIVE|||||||
33952623|NCT05637515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952624|NCT03523676|||COHORT||RETROSPECTIVE|||||||
33952625|NCT04838015|||CASE_ONLY||RETROSPECTIVE|||||||
33952626|NCT05180682|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants were non randomly allocated to two groups and and were analyzed in the end of the study.|t|t|f|f
33952627|NCT06652867|||CASE_CONTROL||PROSPECTIVE|||||||
34161182|NCT02814942|||COHORT||PROSPECTIVE|||||||
34161183|NCT03012711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34161184|NCT06064383|||CASE_ONLY||OTHER|||||||
34161185|NCT06353906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161186|NCT05532202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants naive to treatment condition and Assessors naive to treatment condition and assessment time point|Randomized Controlled Pilot Trial Study|t|f|f|t
34161187|NCT06020703|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34161188|NCT05334407|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Timing of treatment will be concealed to the therapist and to the examiners. All laboratory assessments will be performed blindly.|2x2 factorial design (4 month follow up) and longitudinal follow-up to 12 months|f|t|f|t
33952628|NCT01124500|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33952629|NCT04580875|NON_RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||Prospective cohort study. within the same facility, cases were enrolled consecutively but at some instances, in 2 or the 3 facilities at the same time, a portion of cases were managed simultaneously.|f|f|t|t
33952630|NCT00198588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161189|NCT02989753|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161190|NCT02264691|||COHORT||PROSPECTIVE|||||||
34161191|NCT00264537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161192|NCT01389869|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34161193|NCT02701153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161194|NCT02177708|||COHORT||PROSPECTIVE|||||||
34161195|NCT01309568|||CASE_ONLY||PROSPECTIVE|||||||
34161196|NCT01771523|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34161197|NCT01103427|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34161198|NCT03840707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161199|NCT02104466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161200|NCT00769912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161201|NCT02914665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161202|NCT00370916|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34161203|NCT00838240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161204|NCT03565380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The reassessments at 6-, 12-, 24-, and 52 weeks, and prospective falls evaluation will be conducted by assessors blinded to group allocation. Due to the nature of the trial, the certified Tai Chi instructor who provides treatments and participants will not be blinded to group allocation.||f|f|f|t
34161205|NCT05107570|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34161206|NCT04994548|||COHORT||RETROSPECTIVE|||||||
34161207|NCT05904795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161208|NCT03769038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161209|NCT03710642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161210|NCT01510158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34161211|NCT05499533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Once selected, patients will be assigned to one of two treatment groups. (test group- hybrid funnel technique; control group- conventional drill technique) Patients are placed in one of the two treatment groups according to the chronological order in which they will be recruited. Age, sex, surgical implant site (upper, lower, anterior, posterior) and clinical l characteristics will be taken into account to obtain two homogeneous study groups.~First Hybrid Funnel Technique will be performed, then Conventional drill Technique will be performed."||||
34161212|NCT05938998|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34161213|NCT05456971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Throughout the study period (18 months), only two products will be used for the aesthetic procedures (Art Filler® Volume and Art Filler® Lips). 100 subjects will be injected in order to have at least 100 midface regions and 100 lips treated and assessed at 3 or 6 weeks for the primary end point.||||
34161214|NCT00043732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34161215|NCT03265340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161216|NCT02032498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847480|NCT03480308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization Will be Done Using Computer Generated Tables|"Patients will receive ultrasound guided paravertebral block and stratified into 3 groups according to medication used :~Group 1 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg Group 2 : bupivacaine (0.5%) 20 ml , dexamethasone 4 mg Group 2 : bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg"|f|f|t|f
33847481|NCT01691768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847482|NCT05419973|||COHORT||PROSPECTIVE|||||||
33847483|NCT02797431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847484|NCT01205334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847485|NCT02907307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952631|NCT05425550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952632|NCT04389008|||COHORT||RETROSPECTIVE|||||||
33952633|NCT03366142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952634|NCT00312650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952635|NCT01395342|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952636|NCT03522285|||CASE_ONLY||PROSPECTIVE|||||||
33952637|NCT02880709|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33952638|NCT02774577|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|similar procedures for variables, collected into similar device and positioning, using a sham device, patented, witch reproduce infra-physiologic vibrations and sound like an actual vibrating platform|acute wbv session, measuring ergospirometric variables during protocol and blood pressure, borg exertion, borg dyspnoea, blood lactate, heart rate and SpO2 before and after protocol.||||
33952639|NCT06354127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847486|NCT01605916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847487|NCT03223662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952640|NCT00592982|||COHORT||PROSPECTIVE|||||||
33952641|NCT04024527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847488|NCT02407158|||COHORT||PROSPECTIVE|||||||
33847489|NCT04192019|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Time to hypoglycaemia during 60 minutes of aerobic exercise in individuals with type 1 diabetes using mini and micro doses of Dasiglucagon compared to no Dasiglucagon|t|f|f|f
33847490|NCT00336089|RANDOMIZED|||||||||||
33847491|NCT03149809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessor|Randomized Controlled Non-Inferiority Trial|f|f|f|t
33847492|NCT01145898|||COHORT||PROSPECTIVE|||||||
33847493|NCT05310851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"There are three groups in our study. One group will be given a pacifier and the other group will be given a 5-minute oral stimulation program. The other group is the control group.~39 babies will be included, with 13 babies in each group."||||
33952642|NCT01977131|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33952643|NCT02796365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33952644|NCT03857308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33952645|NCT06217562|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Pragmatic embedded cluster-randomized cluster-crossover comparative effectiveness trial. Study hospitals will be assigned to a vasopressin-initiation strategy (cluster randomized) and the hospital will then alternate monthly between the tested vasopressin-initiation strategies in a randomized sequence (cluster-crossover).|f|f|f|t
33952646|NCT05329441|||CASE_ONLY||PROSPECTIVE|||||||
33952647|NCT06369077|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Technician measuring IOP and assessing dry eye is masked regarding phase 2 and phase 3 crossover assignment order.|"Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later.~At each study visit, dry eye signs will be assessed and brief dry eye survey will be administered."|f|f|f|t
33952648|NCT01256086|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33952649|NCT01478204|||COHORT||PROSPECTIVE|||||||
34161217|NCT05606276|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Following a familiarization session, subjects will be assigned to an order for performing both an eccentric and a cycle (sham) session (i.e., crossover design, the order being randomized). These will be performed 3-7 days apart.|f|f|t|f
34161218|NCT03590353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161219|NCT00894868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161220|NCT01922908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161221|NCT01672424|||CASE_CONTROL||PROSPECTIVE|||||||
34161222|NCT04096287|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33847494|NCT03693326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847495|NCT04518605|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33847496|NCT05480579|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33847497|NCT00727779|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847498|NCT02480959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161223|NCT01714765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161224|NCT06027099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161225|NCT03842059|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34161226|NCT03019718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161227|NCT00599794|||COHORT||PROSPECTIVE|||||||
34161228|NCT04295239|NA|SINGLE_GROUP||OTHER||NONE||Monocentric, prospective and pilot study||||
34161229|NCT03574636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161230|NCT00962325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161231|NCT01989247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161232|NCT05993910|||OTHER||PROSPECTIVE|||||||
34161233|NCT00787865|||CASE_CONTROL||PROSPECTIVE|||||||
33847499|NCT04310280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator) Double Blind (Participant, Investigator)|Parallel assignment Randomized split-plot design|t|f|t|f
33847500|NCT00497731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847501|NCT05498987|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33847502|NCT03688451|NA|SEQUENTIAL||TREATMENT||NONE||Sequential dose cohorts||||
33847503|NCT05485545|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33847504|NCT00350350|||COHORT||PROSPECTIVE|||||||
33847505|NCT00751387|||||CROSS_SECTIONAL|||||||
33847506|NCT01200589|RANDOMIZED|||TREATMENT||NONE||||||
33847507|NCT05978115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33847508|NCT06610591|||COHORT||PROSPECTIVE|||||||
33847509|NCT03302078|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847510|NCT02839525|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33847511|NCT04792918|||COHORT||PROSPECTIVE|||||||
33847512|NCT05251194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847513|NCT02769767|||COHORT||RETROSPECTIVE|||||||
33847514|NCT04070560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847515|NCT00720980|||CASE_ONLY||RETROSPECTIVE|||||||
33847516|NCT00051259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847517|NCT03733847|||COHORT||PROSPECTIVE|||||||
33847518|NCT04360343|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33847519|NCT03063125|||COHORT||PROSPECTIVE|||||||
33847520|NCT00944398|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33847521|NCT05696587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment arm will undergo a 4-week multimodal rehabilitation program with outcome measures recorded at baseline and at 4 weeks. Healthy control will be assessed for psychological outcome measures at baseline and at 4 weeks, with no intervention applied.||||
33847522|NCT05991843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847523|NCT05184712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847524|NCT05570097|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Before - after study:~First: control group as a standard treatment in Poland, review, then:~interventional group"||||
33847525|NCT00000167|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33847526|NCT06275139|RANDOMIZED|PARALLEL||PREVENTION||NONE||Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment.||||
33847527|NCT04680338|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847528|NCT04241601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The trial will be double-blind, with active and placebo doses appearing identical at point of issue and administration. The CUH central pharmacy will be unblinded and provided with a copy of the concealment list. Data analysis for the trial will be performed by a statistician who will be unblinded after the database lock.~The statistician, or delegate, may be unblinded for individual patients after their treatment period has concluded, to facilitate rapid reporting of safety events."|a randomised, double-blind, placebo controlled, parallel group experimental medicine trial|t|t|t|t
33847529|NCT04550338|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Once patient is consented, pharmacy will randomize to one of two arms and prepare coded sets of drugs|Placebo-controlled, double-blind, randomized, controlled trial|t|t|t|t
33847530|NCT00901706|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33847531|NCT06611267|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33847532|NCT02135354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* The identity of the study drug will be concealed by the use of a format that is identical in packaging, labelling, schedule of administration and appearance.~* Patients will be randomly assigned in a 1:1 ratio to receive either azithromycin or placebo, with a permuted block size of ten and sequential assignment, stratified by the center.~* Randomization of the study drug is based on an online generated randomization schedule (http://www.randomization.com). Unique randomization codes are locally obtained through a secured Web-based program.~* At all times, randomization codes are kept strictly confidential during the study, with the exception of an ad hoc independent safety committee adjudicating cardiovascular side effects and mortality after 300 patients.~* Nevertheless, code breaks will be available at the site and un-blinding may occur in the case of an emergency which will require knowledge of the treatment assignment."||t|t|t|f
33847533|NCT02581631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847534|NCT02081430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847535|NCT04023500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded, patients and dentist who performs baseline and follow-up measurements.||t|f|t|f
33847536|NCT01533480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847537|NCT00510237|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33847538|NCT06069817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847539|NCT03386110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847540|NCT02586571|||COHORT||PROSPECTIVE|||||||
33847541|NCT00924027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847542|NCT01467882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847543|NCT04683068|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33847544|NCT05847959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847545|NCT03851718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847546|NCT04611321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847547|NCT02961803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847548|NCT06251297|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients will receive a 30-minute reflexology session during each Oxaliplatin infusion.||||
33847549|NCT03408561|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33847550|NCT00898209|||COHORT||PROSPECTIVE|||||||
33952650|NCT00548392|||CASE_ONLY||PROSPECTIVE|||||||
34161234|NCT06334848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161235|NCT06727292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|the product is also masked|single-center, ,double-blind, randomized pilot study|t|t|t|t
34161236|NCT05258149|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34161237|NCT01295645|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161238|NCT03770221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161239|NCT00536471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847551|NCT04461444|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33847552|NCT03583567|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|normal saline will be used as placebo in control group||t|t|t|t
33847553|NCT03186573|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind study|Randomized clinical trial|t|f|t|f
33847554|NCT01178697|RANDOMIZED|||TREATMENT||SINGLE|||f|f|t|f
33847555|NCT05468892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847556|NCT05167305|||CASE_ONLY||CROSS_SECTIONAL|||||||
33847557|NCT00688870|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33847558|NCT02662452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847559|NCT05252104|||COHORT||RETROSPECTIVE|||||||
33847560|NCT00142181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847561|NCT05022160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847562|NCT04677179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847563|NCT02771080|||COHORT||RETROSPECTIVE|||||||
33847564|NCT01181427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847565|NCT04662905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847566|NCT06092476|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|In this study, both the study team and the study subjects are blinded to the treatment through the 24 week follow-up visit. While the endoscopist is not blinded to individual treatments, he is blinded to cohort level data and is not responsible for patient follow-up. At the 24 week visit, the subject and study team are unblinded. The subjects who received the sham treatment undergo DMR treatment.|The study is a single-center, randomized, double-blind, sham-controlled trial|t|t|t|t
33847567|NCT05893706|||OTHER||OTHER|||||||
33847568|NCT01769768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847569|NCT01258842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33847570|NCT00532493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847571|NCT04699773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847572|NCT04612933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847573|NCT01050790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847574|NCT06191822|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33847575|NCT03300973|RANDOMIZED|PARALLEL||TREATMENT||||||||
33847576|NCT01001182|||COHORT||PROSPECTIVE|||||||
33847577|NCT04976504|||COHORT||PROSPECTIVE|||||||
33847578|NCT00234845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847579|NCT01375400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847580|NCT05253989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Control Group comprises 28 patients. Receive no intervention, but do receive regular assessments. Control Group patients can then decide to be involved in one of the intervention arms.~Intervention Groups are split evenly between FES and non-FES. Non-FES group receives VR intervention (VR training for rehabilitation). FES group receives the same, but with the addition of FES during the intervention."||||
33847581|NCT05599620|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33847582|NCT01757444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952651|NCT05847309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|We will compare patients extubated before 6 hours and between 6 to 12 hours after endovascular treatment with general anesthesia for stroke. The patient will not know the hours that he was on mechanical ventilation (masking participant). Investigators evaluating the primary endpoint (mRS at three months) and other secondary endpoints will not know to which group they were randomized. Only the research physicians who treat the patient in the ICU during the first 24 hours know the assigned group.|Intervention study, prospective, randomized, parallel and blind for the end point evaluators. (Prospective Randomized, Blinded End-point))|t|f|t|f
33952652|NCT05158972|||COHORT||PROSPECTIVE|||||||
33952653|NCT06477289|||COHORT||PROSPECTIVE|||||||
33952654|NCT00690846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952655|NCT05922540|||COHORT||PROSPECTIVE|||||||
33952656|NCT05159713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinician rated rated measures Children's Depression Rating Scale Revised (CDRS-R) and Clinical Global Assessment Scale (CGAS) will be completed by a blinded assessor.||f|f|f|t
33952657|NCT06651164|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33952658|NCT02351297|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33952659|NCT00005607||||TREATMENT||||||||
33952660|NCT02387723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952661|NCT03690375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952662|NCT02376582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33952663|NCT00900276|||OTHER||PROSPECTIVE|||||||
33847583|NCT00473265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847584|NCT04662099|NA|SEQUENTIAL||TREATMENT||NONE||||||
33847585|NCT04394468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847586|NCT02384187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33847587|NCT00816478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847588|NCT06533826|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847589|NCT03789604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847590|NCT04713891|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952664|NCT01016366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952665|NCT03659032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessors who receive participants and do the measurement are masked|Parallel assignment|f|f|t|t
33952666|NCT06539611|||COHORT||PROSPECTIVE|||||||
33952667|NCT02351050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33847591|NCT01488877|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33952668|NCT02454699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847592|NCT05007080|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33847593|NCT02942433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847594|NCT00776217|RANDOMIZED|CROSSOVER||||NONE||||||
33847595|NCT05420376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847596|NCT01566877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847597|NCT02503033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847598|NCT01710644|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33847599|NCT04598568|||CASE_ONLY||PROSPECTIVE|||||||
33847600|NCT00543374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847601|NCT00703937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847602|NCT02156726|||COHORT||RETROSPECTIVE|||||||
33847603|NCT01315210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847604|NCT05016362|||COHORT||PROSPECTIVE|||||||
33847605|NCT00958503|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33847606|NCT00012324|RANDOMIZED|||TREATMENT||NONE||||||
33847607|NCT02093104|||CASE_ONLY||PROSPECTIVE|||||||
33847608|NCT04357054|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||hysteroscopic bubble suction and tubal peristalsis||||
33847609|NCT01034176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847610|NCT02835118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847611|NCT00610740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847612|NCT00482690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847613|NCT05402696|||COHORT||PROSPECTIVE|||||||
33847614|NCT00741390|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33847615|NCT00935818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847616|NCT02831543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847617|NCT01639560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847618|NCT03689660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Nope||f|f|f|t
33847619|NCT05769647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The patients will be informed about the study and their consent will be obtained without explaining which group they are in. Since the researcher manages the implementation process of the study, researcher blinding cannot be done. In addition, it will be ensured that the researcher learns which group the patients are in after the patients accept to participate in the study. Thus, the internal validity of the research will be ensured. Since data is collected from the patients in the sample group at the time of admission to the ward, interaction between patients will be prevented.~At the same time, blind technique will be applied in terms of statistical analysis in the research. The data will be recorded on the computer by the researcher without using the expression of experimental and control groups, and data analysis will be done by another statistician other than the person who made the randomization."||t|f|f|t
33847620|NCT04159623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847621|NCT00287703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847622|NCT04454775|||COHORT||PROSPECTIVE|||||||
33847623|NCT00872989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847624|NCT04189952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847625|NCT00472810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847626|NCT01733537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34056997|NCT06515483|RANDOMIZED|PARALLEL||OTHER||SINGLE|The clinical examiner will remain blind to the individual subjects' treatment group during the entire study. If the treatment assignment must be unblinded for a subject, such as in the case of an emergency, the Investigator will provide written documentation of the unblinding request. Unblinding would involve withdrawing the subject from the study. Otherwise, blinding will not be broken, unless required in the circumstances detailed above, until all subjects have completed the final study visit and the database has been monitored, locked, and approved by the Investigator.|A sufficient number of subjects will be screened to participate, and 64 will be randomized. We intend to randomize a nearly equal number of female and male subjects. A unique screening number will identify all subjects screened for study participation. Screening numbers will be assigned according to appearance at the study site. Subjects who meet all inclusion and exclusion criteria will be randomized into the study. Block randomization will be used to assign subjects to one of the two sequences: control regiment or experimental regimen. Randomization will be stratified by gender. Randomization numbers will be assigned using randomization schedules provided by the IU Department of Biostatistics and Health Data Science statistician.|f|f|f|t
34056998|NCT03831334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34056999|NCT03184337|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be assigned to one of two groups.|t|f|f|f
34057000|NCT01652326|||COHORT||RETROSPECTIVE|||||||
34057001|NCT01156649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057002|NCT01584219|||COHORT||PROSPECTIVE|||||||
34057003|NCT05351827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34057004|NCT04236518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34057005|NCT02070627|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057006|NCT01210677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057007|NCT01099501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057008|NCT01446276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34057009|NCT04248504|||COHORT||PROSPECTIVE|||||||
34057010|NCT02047994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057011|NCT04336449|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34057012|NCT03173846|||COHORT||PROSPECTIVE|||||||
34057013|NCT05529017|||COHORT||PROSPECTIVE|||||||
34057014|NCT03367546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057015|NCT04062032|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057016|NCT06426862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33744184|NCT05152979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The results are assessed by independent assessors blinded to in which phase (pre-post-follow up) the data is obtained, and partly to conditions for therapy (In-Clinic or Telepractice).|Parallel assignment|f|f|f|t
34057017|NCT03472300|||COHORT||PROSPECTIVE|||||||
34057018|NCT05398185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be randomly assigned to one of two trial arms using sequentially numbered, opaque, sealed envelopes containing the intervention assignment, which the staff member opens at the moment of randomization||t|f|f|f
34057019|NCT02416531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057020|NCT01007331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33744185|NCT00572572|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33744186|NCT00435370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744187|NCT04993924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744188|NCT05360875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744189|NCT01175226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744190|NCT00782730|||||PROSPECTIVE|||||||
33744191|NCT03969238|||OTHER||OTHER|||||||
33744192|NCT01466998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744193|NCT06169917|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744194|NCT04001829|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744195|NCT01822652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744196|NCT01176253|||CASE_CONTROL||PROSPECTIVE|||||||
33744197|NCT05633784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Consenting eligible patients were randomized to either an Intervention or a Control group (1:1).~A computer (www.randomization.com) generated tables to allocate patients in fixed blocks of four. In order to prevent selection bias, the list of randomization will be managed by personnel not directly involved in the enrolment of the patient. Due to the nature of the intervention, neither the patients nor the physicians were blinded to patients' group allocation. However, outcome assessors and data analysts will be blinded to the allocation."||f|f|f|t
33744198|NCT03627403|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, non-randomized, prospective, single-arm study||||
33744199|NCT03867331|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33744200|NCT05600608|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All study participants will receive the same formulation, dose and amount of the oral stimulant drink. Breath samples will be taken at baseline and then at the same time points following consumption of the drink.||||
33744201|NCT00208429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744202|NCT04892134|||COHORT||PROSPECTIVE|||||||
33744203|NCT04695327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744204|NCT03418844|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Patients and healthy volunteers will complete several self-questionnaires on living conditions and quality of life. Patients will also perform a cardiac, pulmonary, auditory and biological assessment||||
34057021|NCT02967913|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34057022|NCT05195684|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single group study of trauma nightmares, sleep and psychophysiological and neural (fNIRS) responses to imagery of actual trauma and of trauma-related nightmares. Within-subject comparison of psychophysiological and neural responses to imagery of trauma compared to trauma-related nightmare and imagery of unrelated neutral content. Correlational study of psychophysiological and neural responses with clinical self-report measures.||||
33847627|NCT01825733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33847628|NCT02293213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744205|NCT05522504|||COHORT||PROSPECTIVE|||||||
33744206|NCT04989270|||COHORT||RETROSPECTIVE|||||||
33744207|NCT06207916|||OTHER||CROSS_SECTIONAL|||||||
33744208|NCT00123227|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33744209|NCT03269474|||COHORT||PROSPECTIVE|||||||
33744210|NCT00583557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744211|NCT02846987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744212|NCT02353793|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744213|NCT01242527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744214|NCT02801045|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33847629|NCT05598073|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744215|NCT04750252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744216|NCT02574975|RANDOMIZED|PARALLEL||||NONE||||||
33744217|NCT03236103|NA|SINGLE_GROUP||PREVENTION||NONE||Open label single group interventional study||||
33744218|NCT05960539|||OTHER||PROSPECTIVE|||||||
33744219|NCT04679220|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||One side of the mouth received preheated composite however in the other side the composite was placed in non-heated state following the manufacturer instructions.|t|t|t|f
33744220|NCT00222339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33744221|NCT05127343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744222|NCT04367168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind placebo-controlled clinical trial to test the security and efficacy of colchicine at a dose of 1.5 mg PO at day 1 followed by 0.5 mg PO BID to complete 10 days of treatment|t|t|t|t
33744223|NCT06384651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blind patient is blinded. Surgeon is not blinded. Lab technician measuring tissue concentrations are blinded. Research coordinator is not blinded.|This study is a prospective, randomized, single-blinded, controlled trial. 20 patients in each treatment arm: 20 patients will be given IV vancomycin, 20 patients will be given IO vancomycin|t|f|f|t
33744224|NCT06512662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744225|NCT02649686|NA|SINGLE_GROUP||OTHER||NONE||||||
33744226|NCT02635477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33744227|NCT06485778|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2 single arm trial enrolling post operative oral tongue squamous cell carcinoma patients with pT1-2N0-N2b.||||
33744228|NCT04812912|||COHORT||PROSPECTIVE|||||||
33744229|NCT05372445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33744230|NCT02921802|||CASE_ONLY||PROSPECTIVE|||||||
33744231|NCT00941603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744232|NCT02386566|||COHORT||PROSPECTIVE|||||||
33744233|NCT00053833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744234|NCT01108081|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
33744235|NCT04915794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33744236|NCT06670092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744237|NCT04576884|||CASE_ONLY||PROSPECTIVE|||||||
33744238|NCT05955638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744239|NCT06477445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33847630|NCT05089253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057023|NCT00381238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057024|NCT01714843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057025|NCT01253668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057026|NCT05526378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34057027|NCT02317835|NA|SINGLE_GROUP||||NONE||||||
33847631|NCT06610487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847632|NCT02828540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057028|NCT06647979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847633|NCT00002851|RANDOMIZED|||TREATMENT||||||||
34057029|NCT05484076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34057030|NCT00811317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057031|NCT02074969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057032|NCT01173055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34057033|NCT04913350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057034|NCT03817411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057035|NCT06623383|||COHORT||CROSS_SECTIONAL|||||||
34057036|NCT02034396|NA|SINGLE_GROUP||SCREENING||NONE||||||
34161240|NCT05192460|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, open-label, single-arm exploratory study||||
34161241|NCT04756817|||COHORT||PROSPECTIVE|||||||
33847634|NCT05827861|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33847635|NCT04294927|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847636|NCT05726032|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|double-blind placebo-controlled study|Proof of concept, randomized, cross over, phase II double-blind placebo-controlled study|t|t|t|f
33847637|NCT01593345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057037|NCT05665166|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I-II prospective, single-centre, non-randomised, open label, safety and proof of concept study||||
33847638|NCT02577822|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33847639|NCT00237289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847640|NCT03250234|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33847641|NCT02920489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847642|NCT04876235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847643|NCT00097578|||COHORT||PROSPECTIVE|||||||
33847644|NCT02334423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847645|NCT05077020|||COHORT||RETROSPECTIVE|||||||
33847646|NCT02652364|||CASE_ONLY||PROSPECTIVE|||||||
33847647|NCT00167089|RANDOMIZED|PARALLEL||||NONE||||||
33847648|NCT05478850|||COHORT||PROSPECTIVE|||||||
33847649|NCT01929785|||CASE_CONTROL||PROSPECTIVE|||||||
33847650|NCT01940224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33847651|NCT03814031|||COHORT||PROSPECTIVE|||||||
33847652|NCT02706613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847653|NCT00281515|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33847654|NCT01534572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34057038|NCT04621526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057039|NCT06098872|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label pilot study assessing the potential efficacy of Trametinib in improving AVM angioarchitecture for patients who are already planned to undergo surgical resection as part of their standard of care.||||
34057040|NCT05814900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161242|NCT04748614|||COHORT||RETROSPECTIVE|||||||
34161243|NCT06244667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161244|NCT03047421|||COHORT||PROSPECTIVE|||||||
34161245|NCT04182243|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The research is a descriptive study to evaluate the working conditions and job satisfaction of nurses, paramedics, and EMTs working in Northern Cyprus. There are 138 nurses, paramedics, and EMTs working in 112 ambulance services. In the research, a complete census conducted without any sampling, and 132 staff interviewed. Four of the six nurses who were not interviewed were on long-term leave and were not on duty at the time of the study. Two nurses who were not included in the survey stated that they did not agree to participate in the study. The researcher conducted the study by appointment in the work environment between October 20 - November 10, 2016, to the health personnel participants working in 112 Emergency Departments of the Ministry of Health.||||
34057041|NCT04290988|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||To evaluate the effects of EEG neurofeedback on communication skills in participants with post-stroke aphasia and primary progressive aphasia (PPA), this study will utilize a randomized double-blind, sham-controlled, within-subject crossover trial design.|t|t|t|t
34057042|NCT02056106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057043|NCT05720026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161246|NCT03403439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161247|NCT05690048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Interventional, randomized, controlled, single blind trial phase II with two arms (verum/placebo) in a parallel group design|t|f|f|f
34161248|NCT04775641|||OTHER||PROSPECTIVE|||||||
34161249|NCT06010784|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Research staff responsible for data collection are blinded to the arm allocation of the participant. At the end-point, however, a set of questions about the participant's experience in the program may unblind staff collecting the data. To minimize influence of unblinding, those set of questions will be ask at the end of the data collection period and ensure structured interview techniques are followed.|Community-based trial, two arms randomized on a 1:1 ratio, stratified by SNAP beneficiary status.|f|f|t|t
34161250|NCT05921565|NA|SINGLE_GROUP||TREATMENT||NONE||To explore individual differences in responses to the weight loss intervention as well as mechanisms underlying its effects, additional survey measures will be administered. These measures will include: demographics, other health information, motivations for losing weight (TSR-Q), personality (BFI-10), chronic stress (Life Events Inventory) perceived stress (PSS-10), stress in past week, the positive and negative affect scale, PROMIS scale of cognitive function PROMIS scales of physical function, PROMIS scales of mental health, PROMIS scales of social health, fear of cancer recurrence, and self-efficacy for diet and exercise. PROMIS items will be assessed using computerized adaptive testing versions with items drawn from banks specific to the individual constructs assessed.||||
34161251|NCT01103388|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161252|NCT00213265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161253|NCT02223715|||CASE_ONLY||PROSPECTIVE|||||||
34057044|NCT05032274|NA|SINGLE_GROUP||PREVENTION||NONE||single group pretest-posttest design||||
34057045|NCT05406505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34161254|NCT01177527|||CASE_ONLY||PROSPECTIVE|||||||
34161255|NCT03000855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161256|NCT04474275|||CASE_CONTROL||PROSPECTIVE|||||||
34161257|NCT00246701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161258|NCT02246426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161259|NCT00006116||||TREATMENT||||||||
34161260|NCT00087334||||TREATMENT||NONE||||||
33744240|NCT06635083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants with pectus excavatum deformity between the ages of 10 and 14 who apply to the clinic where the study will be conducted by dividing into two groups using the random allocation software computer program.The outcomes assessor will not know which groups individuals assigned to.|Quasi-experimental single-blind randomized comparative study|f|f|f|t
33744241|NCT05004324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744242|NCT00408369|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33744243|NCT02606838|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33744244|NCT00001112||||TREATMENT||NONE||||||
33744245|NCT03058770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744246|NCT05398471|||CASE_CROSSOVER||PROSPECTIVE|||||||
33744247|NCT00059683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847655|NCT05115643|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057046|NCT00710684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057047|NCT05060146|RANDOMIZED|PARALLEL||OTHER||SINGLE||Step wedge|f|f|f|t
34057048|NCT02548000|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33847656|NCT06429644|||COHORT||RETROSPECTIVE|||||||
33847657|NCT02736461|||CASE_CONTROL||RETROSPECTIVE|||||||
33847658|NCT05382143|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33847659|NCT00751361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847660|NCT06390878|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847661|NCT04323176|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Implementation of Village Model||||
33847662|NCT05732051|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The IMP and matching placebos will be provided by the manufacturers of ChromaDex. The Data Safety Committee will have the treatment allocation list.|Double-blind, randomised, placebo-controlled|t|t|t|t
33847663|NCT05229042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blank||t|t|t|t
33847664|NCT05571345|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"This study will involve 2 double-blind phases. Within each of the double-blind Qualification and Treatment Phases, treatments will be matched in appearance and subjects will ingest the same number of oral capsules in each treatment period.~Neither the subject nor the blinded site personnel will know which treatment is being administered to each subject during the double-blind Qualification and Treatment Phases.~In the Treatment Phase, under normal circumstances, the blind will not be broken until all subjects have completed treatment."|The Treatment Phase will consist of 5 treatment periods. Subjects will receive each of the following 5 treatments (1 per treatment period) in a randomized, double-blind, crossover manner, following a fasting period of at least 8 hours. Pharmacodynamic, pharmacokinetic and safety assessments will be conducted prior to dosing and for 24 hours after each study drug administration. Each study drug administration will be separated by a washout interval of approximately 120 hours. All subjects will remain in clinic for the duration of the Treatment Phase.|t|t|t|t
33847665|NCT04565093|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The data will be collected by the care provider (nurses \& assistant anesthetists) and outcome assessors (physiotherapists) who will be unaware of group allocation and will record their findings in the patient's file and on a predesigned form. Patient's demographic data, duration of surgery, tourniquet time, PACU stay, postoperative heart rate, mean arterial pressure, pain score, knee range of motion (ROM), time-up-go (TUG), time to hospital discharge, patient and surgeon satisfaction, and any complication will be recorded.|This study is conducted to evaluate posterior knee pain after unilateral Total Knee Arthroplasty (TKA) comparing iPACK (Interspace between the popliteal artery and the capsule of the posterior knee) and Periarticular Local Infiltration Analgesia (LIA) under spinal anesthesia. All patients will receive Adductor Canal Block (ACB) to cover pain from anteromedial aspect of knee. 169 adult patients will be recruited in this study and will be divided into two groups; group-1 iPACK (n=85) will receive Adductor Canal Block (ACB) + iPACK and group 2 LIA (n=84) will receive ACB+ periarticular Local Infiltration Analgesia (LIA). The primary outcome, severity of pain (NRS) will be evaluated in Post Anesthesia Care Unit (PACU). The secondary outcome, time to mobilization (ROM and TUG tests) along with pain score will be recorded in the ward after 2 hours of surgery then every 12 hours until the patient discharged home.|t|t|f|t
33847666|NCT00414908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847667|NCT00246220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847668|NCT02854878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847669|NCT00809744|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33847670|NCT06102980|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|After EUS-SWE, a clinical research coordinator will open the label to confirm the patient's cohort. The patient will undergo the EUS-guided two-lobe liver biopsy only if the patient belongs to the liver steatosis group.||f|f|t|t
33847671|NCT03814096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847672|NCT00152932|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
33847673|NCT00001159|||CASE_ONLY||RETROSPECTIVE|||||||
33847674|NCT01818583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847675|NCT02842450|||COHORT||PROSPECTIVE|||||||
34161261|NCT05504044|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34161262|NCT04054076|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a 10 year follow-up of an original randomized clinical trial (RCT) study (n= 114 patients) with type 1 and type 2 diabetes. The participants were referred to the department of Prosthetics \& Orthotics (DPO) at Sahlgrenska University Hospital and were randomised to: 1) use prefabricated insoles, 2) soft custom-made insoles or 3) hard custom-made insoles. The groups were followed 2 years with follow-ups every 6 months. Data regarding plantar pressure, gait characteristics, kinetics and kinematics and presence of risk factors will be collected 10 years after inclusions. Comparisons will be made with a group of patients with diabetes being first times visitors to the Department of Prosthetics \& Orthotics.||||
34161263|NCT00590863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161264|NCT03793361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161265|NCT00311883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161266|NCT03018639|||CASE_ONLY||PROSPECTIVE|||||||
34161267|NCT03357016|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collected on the volunteers will be made anonymous.||t|f|f|f
34057049|NCT03260517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057050|NCT06027684|||OTHER||OTHER|||||||
34057051|NCT05385952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to randomized treatment and treatment used.|Randomization 2:1|t|f|f|f
34057052|NCT00965679|||||PROSPECTIVE|||||||
34057053|NCT00278148|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34057054|NCT05811585|||COHORT||RETROSPECTIVE|||||||
34057055|NCT03634033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Main Study: Randomized 2-Arms. Administrative Supplement: Cohort (Pilot) Study.|f|f|f|t
34057056|NCT03081559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057057|NCT03499457|NA|SINGLE_GROUP||OTHER||NONE||||||
34057058|NCT00972816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34057059|NCT00400192|||COHORT||PROSPECTIVE|||||||
34057060|NCT04824235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33847676|NCT04764643|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33847677|NCT00231803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847678|NCT04019990|NA|SINGLE_GROUP||OTHER||NONE||"13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. J-Tech medical tracker freedom will use for measuring upper extremity muscle power and range of motion. Medicine ball throw test will use for plyometric power. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.~The exercise programme will conduct 3 days a week, with 2 days a week as a group under the supervision of a physiotherapist in the rehabilitation center and 1 day at the homes of the participants without any supervision. The home programme will be monitored by contacting the players over the telephone. The training is planned to progress every 3 weeks, and progression programme will plan individually according to player progression."||||
33847679|NCT00695032|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33847680|NCT05531162|NA|SINGLE_GROUP||OTHER||NONE||a group of parabolic flyers with and without prior experience of microgravity||||
33847681|NCT03229070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847682|NCT04138576|||OTHER||PROSPECTIVE|||||||
33847683|NCT03971383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847684|NCT00639782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847685|NCT00575120|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847686|NCT06594107|||COHORT||PROSPECTIVE|||||||
33847687|NCT04748432|||COHORT||PROSPECTIVE|||||||
33847688|NCT01174290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847689|NCT02321332|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33847690|NCT03466073|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|visibly indistinguishable therapy|Sequential dose escalation|t|t|t|t
33847691|NCT05457465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847692|NCT03541031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Only one individual (unblind coordinator) will know which patients are receiving placebo and which are receiving active micronutrients. She will have no contact with the subjects. All research and clinical staff and all patients will be blinded to what they are actually receiving. The unblind coordinator has verified that the placebos appear identical in appearance to the active micronutrients. The placebos have been manufactured by the same companies that make the actual micronutrients.|This is a double-blind, randomized clinical trial that will assign 120 stable adult outpatients with bipolar disorder, type I or II (DSM-V criteria) to supplementation with a 36-ingredient vitamin/mineral mix (Micronutrient) and an omega-3 fatty acid supplement (Fish oil) (N=72) or to matched double placebo (N=48) in a 3:2 ratio for a year.|t|t|t|t
33847693|NCT02314780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057061|NCT03792529|||COHORT||PROSPECTIVE|||||||
34057062|NCT06016088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057063|NCT06619340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057064|NCT05448326|||COHORT||PROSPECTIVE|||||||
34057065|NCT04690790|||COHORT||PROSPECTIVE|||||||
34057066|NCT05368402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Appearance, including packaging and labelling, of the IMP (capsules, packaging) will not allow to recognize actual treatment (either ladarixin or placebo).~During the trial, blinding will be broken by the Investigator for emergency purposes only, where knowledge of the blinded treatment could influence further patient care."|Patients across all genders, 21-65 years, inclusive, with established insulin-requiring T1D and IR, will be assigned (1:1) to receive either oral ladarixin 400 mg b.i.d. for 7 cycles (26 weeks) of 14 days on/14 days off (treatment group) or matched placebo (control group) for a total of 28 weeks.|t|t|t|t
34057067|NCT00570544|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34057068|NCT04157127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label study where all subjects will receive the DC vaccine. The amount of cells in the vaccine will vary based on the cohort determination and dose escalation schema. Six arms are specified to allow differentiation of the cohorts and their respective dose levels.||||
34057069|NCT03320850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057070|NCT05163821|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057071|NCT03647735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057072|NCT00153127|RANDOMIZED|PARALLEL||||DOUBLE||||||
33847694|NCT02309931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33847695|NCT00410943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847696|NCT00607347|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952669|NCT05375110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952670|NCT00564473|||||PROSPECTIVE|||||||
33952671|NCT05310604|||COHORT||PROSPECTIVE|||||||
33952672|NCT02314130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952673|NCT04139369|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33952674|NCT01982539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952675|NCT00000549|RANDOMIZED|||PREVENTION||||||||
33952676|NCT02684526|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33952677|NCT02526017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33952678|NCT05254691|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective exploratory study with invasive measurements in a 20 bed tertiary paediatric intensive care facility at the Beatrix Children's Hospital/University Medical Centre Groningen.||||
33952679|NCT02801734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33952680|NCT04334122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952681|NCT05309317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33952682|NCT01363531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952683|NCT02262507|NA|SINGLE_GROUP||OTHER||NONE||||||
33952684|NCT01370291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952685|NCT04530422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization applied through computer-generated number and concealed using sequentially numbered, sealed opaque envelope to assign the patient to group 1 either group 2|"This randomized controlled clinical trial is a prospective, comparative, single blind, randomized study that was conducted on 250 patients, divided into two equal groups. The group I received Sofosbuvir plus Ledipasvir and Group II received Oseltamivir, hydroxychloroquine HCQ plus Azithromycin (the local medical committee of Almaza Fever Hospital guided standard treatment protocol for COVID-19)"|t|f|f|f
33952686|NCT01891669||||TREATMENT||NONE||||||
34057073|NCT05632198|||OTHER||CROSS_SECTIONAL|||||||
34057074|NCT06623916|||COHORT||PROSPECTIVE|||||||
34057075|NCT04283292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|investigational pharmacists and designated personell will the only unblinded study staff.|Randomized to capsaicin or placebo in a 1:1 ratio (like the flip of a coin).|f|t|t|f
34057076|NCT06620783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057077|NCT00453674|||COHORT||PROSPECTIVE|||||||
34057078|NCT04561102|||CASE_ONLY||PROSPECTIVE|||||||
34057079|NCT00559780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057080|NCT01765244|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bioengineered anterior human corneal substitute Amniotic membrane corneal graft||||
34057081|NCT02631460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057082|NCT05621135|||OTHER||PROSPECTIVE|||||||
34057083|NCT02563262|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057084|NCT01825356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057085|NCT06648369|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded Endpoint Assessment|Single-center, randomized-controlled (2:1), two-arm parallel group, open treatment, blinded endpoint clinical trial (PROBE)|f|f|f|t
34057086|NCT05714046|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled study||||
34057087|NCT02395640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057088|NCT01528397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057089|NCT04258969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34057090|NCT00446355|||CASE_CONTROL||RETROSPECTIVE|||||||
34057091|NCT05555225|||CASE_CONTROL||RETROSPECTIVE|||||||
34057092|NCT05866562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057093|NCT06365008|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.||||
33744248|NCT03738410|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a qualitative/quantitative trial that utilizes a Sequential to Parallel intervention study design model. The initial 15 participants (first 5 each that speak English, Spanish, or Haitain Creole) will participate in the Qualitative arm. These participants may also be eligible to roll over into the quantitative portion of the study and randomized to either the control group or the mHealth Intervention group.||||
33744249|NCT01640756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744250|NCT03259035|NA|SINGLE_GROUP||TREATMENT||NONE||This is a two staged, single arm phase II trial of chemotherapy (FOLFOX or CAPOX) followed by tumour excision in patients with early stage rectal cancer||||
33744251|NCT03874676|||OTHER||OTHER|||||||
33744252|NCT02512718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744253|NCT02818205|||CASE_CONTROL||PROSPECTIVE|||||||
33744254|NCT02192437|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744255|NCT01892748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744256|NCT01337089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744257|NCT04035941|NA|SINGLE_GROUP||PREVENTION||NONE||Study design: A before-and-after feasibility study with follow up to six months.||||
33847697|NCT03691675|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy||||
33847698|NCT00447889|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33847699|NCT00136942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847700|NCT03154853|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33847701|NCT02765802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847702|NCT01353768|||COHORT||RETROSPECTIVE|||||||
33847703|NCT04940403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to the treatment allocation.|Study participants will be randomized to either 1) manual robot-assisted upper-limb rehabilitation, and 2) unimanual+bimanual robot-assisted upper-limb rehabilitation|f|f|f|t
33847704|NCT04782336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847705|NCT05169398|NA|SINGLE_GROUP||TREATMENT||NONE||EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent||||
33847706|NCT04660591|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|only participants were blinded from treatment group.|two comparative groups, standard and long femoral stem arthroplasty|t|f|f|f
33847707|NCT01568853|NA|SINGLE_GROUP||SCREENING||NONE||||||
33847708|NCT05295420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847709|NCT02386176|||COHORT||PROSPECTIVE|||||||
33952687|NCT03301207|NA|SINGLE_GROUP||OTHER||NONE||||||
33952688|NCT02575807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952689|NCT06567496|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed methods randomized controlled trial with a waitlist control group incorporating focus groups||||
33952690|NCT04812548|NA|SEQUENTIAL||TREATMENT||NONE||||||
33952691|NCT01546701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952692|NCT00594581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952693|NCT03508076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952694|NCT03945929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher, who did not know which patient was in which group, collected the data on the assessment of PIC procedure-associated pain and satisfaction levels immediately after PIC insertion using face-to-face interviews.||f|f|t|f
33952695|NCT06650891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34057094|NCT04030962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057095|NCT05392439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057096|NCT02433041|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33952696|NCT01904331|||COHORT||CROSS_SECTIONAL|||||||
33952697|NCT04780776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952698|NCT05409300|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952699|NCT02826174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952700|NCT01146340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952701|NCT03562052|||COHORT||PROSPECTIVE|||||||
33952702|NCT05117307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33952703|NCT06236399|||COHORT||CROSS_SECTIONAL|||||||
33952704|NCT04832711|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33952705|NCT00808769|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33952706|NCT05542173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057097|NCT03736330|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous D-CIK (1.0-1.5\*10\^10 cells) will be transferred to patients via intravenous infusion. Before cell transfer, D-CIK were incubated with anti-PD-1 antibody.||||
34057098|NCT06137703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|All investigators, Sponsor personnel, clinical monitors, independent PK analyst, and participants in the study will be unblinded to the treatment allocation as the primary and secondary endpoints are based on objective criteria of laboratory findings.|Randomized, open-label, single dose, 4-period cross-over, comparative bioavailability study in healthy volunteer participants.||||
34057099|NCT01805076|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33744258|NCT04782323|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a parallel-group dose-ranging study with 8 arms that is participant, investigator and observer-blinded||t|t|t|f
33744259|NCT05157646|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744260|NCT06496828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744261|NCT05907668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744262|NCT04074980|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744263|NCT06019650|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33744264|NCT01985594|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33744265|NCT01056744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744266|NCT04696068|||CASE_CONTROL||PROSPECTIVE|||||||
33744267|NCT05547581|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744268|NCT02959489|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33847710|NCT04237025|NA|SINGLE_GROUP||TREATMENT||NONE||"This study will employ a prospective, single cohort pre- and post-intervention research design. Supervised and individually prescribed Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized instruction and progression of training. Training will be conducted for a total of 14 one-hour sessions over a 6-week period.~In addition to the supervised NW training sessions, participants will be asked to complete independent NW exercise at least 2 times weekly during the 6-week training period. Following the completion of the 6-week supervised NW training period, participants will be asked to independently continue their NW exercise as least three times per week for the 3-month follow-up period. Independent NW exercise logs and adherence will be monitored during both the supervised training phase and the 3-month follow-up phase."||||
33847711|NCT03535597|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomized Controlled prospective study||||
33847712|NCT01394978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847713|NCT04672629|||COHORT||PROSPECTIVE|||||||
33847714|NCT02423278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847715|NCT03635723|||COHORT||PROSPECTIVE|||||||
33847716|NCT05406167|||OTHER||PROSPECTIVE|||||||
33847717|NCT05198102|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33847718|NCT00550589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847719|NCT00363597|||CASE_ONLY||PROSPECTIVE|||||||
33847720|NCT00481624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847721|NCT04521348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847722|NCT01010347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847723|NCT04556903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each participant will be requested to draw either number one or number two from a box. Number one will be allocated to Group A and number two will be allocated to group B. The A group will receive mCIMT after applying conservative treatment and Group B will receive BAT for 5 days a week for 8 weeks.|f|f|f|t
33847724|NCT01579279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847725|NCT06139081|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34057100|NCT01552915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057101|NCT03875092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744269|NCT04901611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33744270|NCT03433742|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744271|NCT01703962|||CASE_CONTROL||PROSPECTIVE|||||||
33744272|NCT02228213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744273|NCT06535191|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The study uses a factorially designed randomized controlled trial \[2 conditions (treatment vs. waitlist) x 3 intervals pre-, post-, 3-month follow-up\].||||
33744274|NCT03277313|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33744275|NCT03708939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744276|NCT02206529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744277|NCT05683340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744278|NCT04445584|||COHORT||PROSPECTIVE|||||||
33744279|NCT00364858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744280|NCT03877718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33744281|NCT06636175|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||For Cohort 1B, 6 healthy volunteers and 6 patients with either multiple myeloma (MM) or lymphoma will be recruited (healthy volunteers will be split equally with 3 men and 3 women enrolled, all efforts will be made to keep the number of subjects with MM and lymphoma enrolled equal to Cohort 1B but it will not be a requirement).||||
33744282|NCT04639414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind placebo-controlled||t|f|t|t
33744283|NCT06534788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a single blinded study because the treatment of both study group and control group will be done by the researcher and only the participants will be kept blinded about the allocation of participants to either the active comparator group or experimantal group.|Randomized Controlled Trial|t|f|f|f
33744284|NCT04278053|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Both the participants and the researchers were blinded to the supplements until all data collection had been completed.|Randomized, double-blind, crossover design|t|f|t|f
33744285|NCT06397404|||COHORT||PROSPECTIVE|||||||
33744286|NCT01863680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161268|NCT05610527|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Prospective cohort study of females with IBD: 100 hormonal contraceptive users and 100 naturally cycling participants||||
34161269|NCT01048658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34161270|NCT06040944|||COHORT||RETROSPECTIVE|||||||
34161271|NCT06458985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161272|NCT01407757|||CASE_ONLY||RETROSPECTIVE|||||||
34161273|NCT01756404|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34161274|NCT00917618||PARALLEL||TREATMENT||NONE||||||
34161275|NCT03648515|||OTHER||CROSS_SECTIONAL|||||||
34161276|NCT06411236|||OTHER||CROSS_SECTIONAL|||||||
34161277|NCT06225687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33847726|NCT04933773|RANDOMIZED|CROSSOVER||OTHER||SINGLE||All participants go through all study arms, in random order. Two pulse oximeters with different averaging time settings are active simultaneously during measurement on each participant and the measured signal is compared.|t|f|f|f
33847727|NCT05352243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33847728|NCT05564780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33847729|NCT04601870|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057102|NCT04789291|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057103|NCT00635453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34057104|NCT02625441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057105|NCT06113341|||COHORT||PROSPECTIVE|||||||
34057106|NCT03765723|||COHORT||PROSPECTIVE|||||||
34057107|NCT06618131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057108|NCT01892085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057109|NCT03820219|RANDOMIZED|PARALLEL||TREATMENT||NONE|The treatment allocation will be hidden for the purposes of analysis. It will be impossible to blind physicians or participants to the treatment group given the obvious difference in appearance of the Prevena™ System versus standard wound dressing.|Consenting patients will be randomized to receive either standard sterile wound dressing or the Prevena™ System at the time of closure of the surgical wound.||||
34057110|NCT05351099|||COHORT||PROSPECTIVE|||||||
34057111|NCT00875433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057112|NCT01312233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057113|NCT05704335|||COHORT||CROSS_SECTIONAL|||||||
34057114|NCT06622018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057115|NCT02211690|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34057116|NCT04457375|||COHORT||PROSPECTIVE|||||||
34057117|NCT04913337|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34057118|NCT06149065|||COHORT||CROSS_SECTIONAL|||||||
34057119|NCT03268824|||OTHER||CROSS_SECTIONAL|||||||
34057120|NCT04154462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"A two-arm randomized field experiment is being used to assess the effect of medical scribes on productivity, wait times, and patient satisfaction. OVAC will work with participating VAMCs to identify providers to participate in the pilot. A varied provider pool will limit selection bias but must be balanced with recruitment and retention of providers. The goal is to keep the provider-scribe pairs consistent throughout the pilot.~Each VAMC site randomized to treatment will have two VA employee scribes and two contract scribes. Two medical scribes, ideally one employee and one contract, will be assigned to one physician, with two physicians and/or Licensed Independent Practitioners (LIP) participating at each facility. Scribes will work with others if the provider partner is not available during a scheduled shift. Power analyses have been conducted to determine the minimum effect size for each outcome with 80% power, which will be useful for putting the final results into context."||||
34057121|NCT05261334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161278|NCT06552637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator and care provider blinded to device programming, therapy imperceptible to patient, data analysis through independent entities|Initial randomization into Control and Therapy arms for 6 month primary endpoints, afterwards crossover of Control arm into Therapy arm for 12 month secondary endpoints.|t|t|t|t
34161279|NCT05916469|||COHORT||PROSPECTIVE|||||||
34161280|NCT05751369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161281|NCT00078247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161282|NCT05498519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161283|NCT05096689|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Cohort, Single center||||
34161284|NCT01909089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161285|NCT00849849|||CASE_ONLY||PROSPECTIVE|||||||
34161286|NCT00719680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161287|NCT05527821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161288|NCT03470207|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34161289|NCT01429701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161290|NCT04886778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||44 obese participants who meet the inclusion/exclusion criteria are randomly assigned to group A and group B at a ratio of 1:1. As the experimental group, group A was treated with a 12-week low-carbohydrate diet combined with probiotic compound preparations, and group B was treated as a control group with a 12-week low-carbohydrate diet combined with placebo treatment. Since the probiotic compound preparation is made of Lactobacillus reuteri, Lactobacillus gasseri, Lactobacillus acidophilus, Bifidobacterium lactis and resistant dextrin (water soluble dietary fiber), in order to eliminate the effect of resistant dextrin (water-soluble meal fiber) on the experimental results, the placebo is prepared from resistant dextrin (water-soluble meal fiber) and is packaged to be consistent with the appearance of the probiotic compound preparation.|t|t|t|f
34161291|NCT01356459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161292|NCT05741398|NA|SINGLE_GROUP||TREATMENT||NONE|no masking during this study.|Single-center, Prospective, Open Label, with Before-After Study Design||||
34161293|NCT01267305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161294|NCT02121249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161295|NCT03579277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To the extend possible based on the nature of the study, subjects and researchers will be masked from the treatment arms.|Subjects are assigned to one of two treatment arms|f|f|t|f
34161296|NCT05590507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161297|NCT05267119|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34161298|NCT02262702|||COHORT||RETROSPECTIVE|||||||
33847730|NCT02774967|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33847731|NCT02647775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847732|NCT02961543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33847733|NCT01240187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847734|NCT04318847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952707|NCT05858515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The block size and treatment allocation will only be known to the biostatistician creating the randomization list and will not be shared with trial investigators or any other study personnel. This list will be directly uploaded into REDCap's randomization module. This maintains the concealment of future allocations and has been used successfully for several of our large RCTs. The details of the randomization procedure including details regarding stratification and block sizes will fully be reported in the trial publication to enable readers to assess the risk of bias. Randomization assignments will be accessible 24 hours a day, 7 days a week to the study coordinators and staff|Randomized, placebo-controlled, double-blind, parallel-design superiority design|t|t|t|t
33847735|NCT04546490|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will not know to which group they have been assigned in each of the interventions Participants will be assigned an individual code by which the outcome assessor will not be able to know what treatment(s) each individual received|"Patients, aged 18-50 years with mechanical neck pain for at least the last month, will be randomly divided into three groups: one will be given Pressure Release technique, another Ischemic Pressure technique, and a last one will be assigned as a control group.~They will be crosslinked after the first treatment. The variables will be evaluated before and immediately after treatment."|t|f|f|t
33847736|NCT05331092|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33847737|NCT03130153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847738|NCT06013527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33847739|NCT01910181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847740|NCT04501211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847741|NCT03914729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, multi-centre, parallel-arm randomized controlled trial|t|f|f|t
33952708|NCT03422276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study uses masked outcome assessment, which means study researchers will make every effort to ensure that staff members who collect outcomes data from both patient and caregiver participants at 3-, 6-, 9- and 12 months are unaware of patient participants' treatment group allocation.||f|f|f|t
33952709|NCT05238701|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33952710|NCT00319488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952711|NCT04510558|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be blinded for the study group.|Patients will be recruited during the preoperative consultation. Patients will be given written information related to the study and will sign an informed consent form. Investigators will be contacted and perform randomization using the RedCap (Research Electronic Data Capture) software system on a 1:1 allocation ratio between study groups. The surgery planning form will be forwarded to the investigators, which will indicate if a mesh should be added or not to the stoma closure procedure.|t|f|f|f
33952712|NCT03429465|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34057122|NCT00750841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057123|NCT04299139|||OTHER||OTHER|||||||
34057124|NCT01756105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057125|NCT05537792|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The model used is a repeated measures single arm study.||||
34057126|NCT04616560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057127|NCT00463762|||||PROSPECTIVE|||||||
34057128|NCT04047134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057129|NCT04112160|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34057130|NCT04878445|||COHORT||PROSPECTIVE|||||||
34057131|NCT00033202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057132|NCT01185223|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057133|NCT02793401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057134|NCT04188015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057135|NCT01882881|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34057136|NCT01258179|||COHORT||PROSPECTIVE|||||||
34057137|NCT02584894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057138|NCT04040634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057139|NCT06645054|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057140|NCT00504725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057141|NCT06050655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057142|NCT06025253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057143|NCT06104761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double ( participant , Outcomes Assessor|Effect of instrument assisted sopf tissue mobilization on upper cross syndrome|t|f|f|t
34057144|NCT00697034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057145|NCT03826810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical evaluations of complete removal of caries lesion, microbiological and radiographic analysis were made by two blind examiners, who did not know to which group the participants belonged.||f|f|f|t
34057146|NCT02987517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057147|NCT03122613|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blinded using identical looking products in both arms||t|f|t|f
34057148|NCT06628752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and the outcome assessor are blinded to whether the participant receives active or sham stimulation.|Randomized controlled trial.|t|f|f|t
34057149|NCT02052596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057150|NCT03187067|||COHORT||PROSPECTIVE|||||||
34057151|NCT02889705|||COHORT||PROSPECTIVE|||||||
34057152|NCT01665846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057153|NCT05890690|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Study staff and participants are blinded upon the nature of each study visit. The preparation of the study medication or placebo will be performed by unblinded study staff who is otherwise not involved in the trial.|double-blind, randomized, placebo-controlled cross-over proof-of-concept and pilot study|t|f|t|f
34057154|NCT01797081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057155|NCT06619405|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057156|NCT00182728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057157|NCT06356753|||COHORT||PROSPECTIVE|||||||
34057158|NCT00422344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847742|NCT04650243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The specimen and information collectors will also be masked in the clinical trial|In our study, the 90 recruited patients of refractory PBC will be distributed randomly into two experimental groups and one control group. The two experimental groups will receive reduced dosage of UDCA at 250mg bid and 250mg qd respectively, while the control group will receive standard dosage of UDCA. The effect of therapy will be evaluated every three months.|f|f|t|t
33847743|NCT04873401|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Groups are randomly assigned to either condition/arm; after 6 months they each cross over into the other arm||||
33847744|NCT01572376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33847745|NCT06228794|||COHORT||PROSPECTIVE|||||||
33847746|NCT04962932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33847747|NCT03222388|||CASE_ONLY||PROSPECTIVE|||||||
33847748|NCT04860167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847749|NCT03446781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847750|NCT06355505|||OTHER||PROSPECTIVE|||||||
33847751|NCT04937972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847752|NCT06445751|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33847753|NCT03446833|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33847754|NCT04661800|NA|SINGLE_GROUP||SCREENING||NONE||Model description: Successive monocentric cross-sectional study on the screening of smell and taste disorders carried out as part of a cardiology hospitalization programmed for the cardiology follow-up of his pathology in a population of patients diagnosed with AC. All subjects will have an ENT check-up including: an ENT examination with a nasal endoscopy, an evaluation of the olfactory function by Sniffin's stick tests (test which consists of smelling smelling pens) an evaluation of taste (test which consists of discriminating between acid, bitter, sweet and salty using blotting papers placed on the tongue). Nutritional status will be assessed by a mini-questionnaire, measurement of weight, brachial circumference and tricipital skin fold, calculation of body mass index (BMI), orosomucoid dosage.||||
33847755|NCT02644395|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847756|NCT01814813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847757|NCT00484822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847758|NCT03238365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847759|NCT02508220|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33847760|NCT06609707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847761|NCT00155090|||DEFINED_POPULATION||OTHER|||||||
33847762|NCT00220051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847763|NCT03237039|NA|SINGLE_GROUP||SCREENING||NONE||symptomatic elderly subjects||||
33847764|NCT04316247|||CASE_CONTROL||RETROSPECTIVE|||||||
33847765|NCT04186364|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952713|NCT04406363|||OTHER||CROSS_SECTIONAL|||||||
33952714|NCT01292369|||CASE_CONTROL||PROSPECTIVE|||||||
33952715|NCT00029107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952716|NCT01237717|||CASE_ONLY||CROSS_SECTIONAL|||||||
33952717|NCT01905891|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33952718|NCT00826878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952719|NCT00442572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952720|NCT04698707|||CASE_CONTROL||RETROSPECTIVE|||||||
33952721|NCT00152594|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33952722|NCT03611452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952723|NCT02060526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952724|NCT05779059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952725|NCT04130477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Tunnel attachments as an auxiliary with clear aligners|f|t|t|t
33952726|NCT05681299|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||Participant blind|t|f|f|f
33952727|NCT05127707|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33952728|NCT01463631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161299|NCT06473792|RANDOMIZED|PARALLEL||PREVENTION||NONE|For reexamination at T1, the investigators were blinded to the intervention.|||||
34161300|NCT02764658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34161301|NCT02748395|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34161302|NCT00317330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161303|NCT03785158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor|This is a randomised, placebo-controlled, two arm parallel design pilot RCT|t|t|t|t
34161304|NCT05301829|||COHORT||PROSPECTIVE|||||||
34161305|NCT01294969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161306|NCT00213499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161307|NCT02253953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34161308|NCT00668811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847766|NCT02621203|||COHORT||PROSPECTIVE|||||||
33847767|NCT06270706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33847768|NCT02813876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33847769|NCT01814852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847770|NCT04445727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33847771|NCT05896423|||COHORT||PROSPECTIVE|||||||
33847772|NCT04037618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847773|NCT03914638|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33847774|NCT01739842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847775|NCT03828643|||CASE_CONTROL||RETROSPECTIVE|||||||
33847776|NCT04120636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952729|NCT05551026|||COHORT||PROSPECTIVE|||||||
33952730|NCT04793958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952731|NCT03864406|NA|SINGLE_GROUP||OTHER||NONE||||||
33952732|NCT04111666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952733|NCT01572610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952734|NCT03225339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All analyses conducted will be blinded.||f|f|f|t
33952735|NCT02524366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952736|NCT01412411|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33952737|NCT06520839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33847777|NCT03432260|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Staggered parallel design.||||
33847778|NCT00100087|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847779|NCT06186661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847780|NCT04820218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects who had previously tested with an EyeQue ophthalmic refraction device and ordered try-on glasses will be asked to measure their visual acuity with and without their try-on glasses.||||
33847781|NCT02307461|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33847782|NCT06599671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847783|NCT01563159|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33847784|NCT01269515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847785|NCT04764461|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847786|NCT00355485|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33847787|NCT04147520|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847788|NCT04999124|NA|SINGLE_GROUP||SCREENING||NONE||||||
33847789|NCT05949073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33847790|NCT05525689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847791|NCT05786105|||COHORT||PROSPECTIVE|||||||
33847792|NCT04081623|||CASE_ONLY||PROSPECTIVE|||||||
33847793|NCT01427751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847794|NCT06277544|||COHORT||PROSPECTIVE|||||||
33847795|NCT00163397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847796|NCT01038739|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33847797|NCT01329692|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33847798|NCT04925505|||CASE_CONTROL||PROSPECTIVE|||||||
33847799|NCT02698605|NA|SINGLE_GROUP||||NONE||||||
33847800|NCT03581383|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||3 Arms: Two intervention models plus a control group representing standard practice Arm 4: And intervention model to record patient experiences with telemedicine||||
33847801|NCT03858699|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33847802|NCT02160236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847803|NCT00823576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847804|NCT04648722|||COHORT||RETROSPECTIVE|||||||
33847805|NCT00653523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847806|NCT04554017|NA|SINGLE_GROUP||OTHER||NONE||||||
33847807|NCT06272552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33847808|NCT04033666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome accessor and the investigator when evaluating the child and the spreadsheet data will not know which therapy the patient was submitted to.|This is a randomized clinical trial comparing high-flow nasal cannula intervention with non-invasive ventilation with two levels of pressure in children hospitalized for acute asthma|f|f|t|t
33847809|NCT00211211|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34161309|NCT01053988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161310|NCT02056093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847810|NCT02900066|||COHORT||PROSPECTIVE|||||||
33847811|NCT06439459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847812|NCT04831151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847813|NCT05473559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33847814|NCT00888628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847815|NCT00151580|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33847816|NCT05794308|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33847817|NCT04341402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847818|NCT05043766|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Part A will utilize a randomized, open label, multiple-ascending dose design with up to 3 separate dose groups of 8 subjects per group.~Part B will utilize an open-label, single-dose, randomized, 4-way crossover design with 13 subjects in each treatment sequence."||||
33847819|NCT04101552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847820|NCT02280369|||COHORT||CROSS_SECTIONAL|||||||
33847821|NCT04512794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The subject population will consist of men and women 18 years of age or older presenting for a de novo ablation of a symptomatic, complex atrial arrhythmia including atrial fibrillation/atrial tachycardia/atrial flutter||||
33847822|NCT05297669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847823|NCT03693885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847824|NCT00183157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847825|NCT03097484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847826|NCT05955131|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Blood samples will be codified, and the keys will be saved by Felipe Ávila. The personal in charge of the blood analyses (quantification of methylglyoxal and 3-deoxyglucosone) will register their results using the codes and therefore will not know the type of sample analyzing or the volunteer that provided the sample.|This study involves an acute nutritional intervention with crossover design, in which each volunteer will eat one out of tree meals (control bread, supplemented bread or glucose), randomly, once by week. Blood samples will be taken at 0min and 30, 60 and 120 min postprandial. The volunteers will complete their participation after the intake of the three meals, hence, their participation in the study will finish after 3 weeks.|f|f|t|f
33847827|NCT04599504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847828|NCT06357403|||COHORT||PROSPECTIVE|||||||
33847829|NCT03458936|||COHORT||PROSPECTIVE|||||||
33847830|NCT00200629|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847831|NCT01477164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33847832|NCT03488420|||COHORT||PROSPECTIVE|||||||
33847833|NCT00531453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847834|NCT06212882|||COHORT||PROSPECTIVE|||||||
33847835|NCT03696823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847836|NCT01580254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34161311|NCT04750304|||COHORT||PROSPECTIVE|||||||
33847837|NCT03869190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161312|NCT00952081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161313|NCT02874508|||CASE_ONLY||PROSPECTIVE|||||||
34161314|NCT05594407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161315|NCT01794260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057159|NCT05269420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057160|NCT03234218|||COHORT||PROSPECTIVE|||||||
34057161|NCT00854425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057162|NCT00716352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
34057163|NCT01796197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057164|NCT06042569|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization module also conceals allocation from other study personnel except the biostatistician and the designated study coordinator by limiting their user's right.|||||
34057165|NCT00962364|||CASE_ONLY||PROSPECTIVE|||||||
34057166|NCT05853367|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057167|NCT02651415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057168|NCT03091049|||CASE_CONTROL||PROSPECTIVE|||||||
34057169|NCT06295640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Randomized, controlled, cross-over design for men. Randomized, controlled, 2x2 factorial cross-over design for women taking the menstrual cycle phase into account.|t|f|f|f
34057170|NCT05315700|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Interval 3+3 dose escalation design||||
34057171|NCT06647771|||OTHER||RETROSPECTIVE|||||||
34057172|NCT02831985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057173|NCT02032381|NA|SINGLE_GROUP||SCREENING||NONE||||||
34057174|NCT05778032|||COHORT||PROSPECTIVE|||||||
34057175|NCT05228769|||COHORT||RETROSPECTIVE|||||||
34057176|NCT02658006|||COHORT||PROSPECTIVE|||||||
34057177|NCT02416648|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34057178|NCT06316154|||COHORT||PROSPECTIVE|||||||
34057179|NCT00348595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057180|NCT06620003|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Sponsor|Participants will be randomized 4:1 to receive the cAd3-Marburg vaccine at 1.0 × 10\^11 PU dose or placebo at Day 1.|t|t|t|t
34057181|NCT05174858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participant will be blind from the treatment|Study subject will be randomized in a 1:1 allocation ratio between the 2 treatment groups|t|f|f|f
34057182|NCT03929159|||COHORT||PROSPECTIVE|||||||
34057183|NCT02350946|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34057184|NCT02564640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057185|NCT01815606|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34057186|NCT05359549|||CASE_ONLY||PROSPECTIVE|||||||
34057187|NCT03275675|||OTHER||PROSPECTIVE|||||||
34057188|NCT01021475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057189|NCT00059605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057190|NCT00189306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057191|NCT00388336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057192|NCT06647992|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34057193|NCT02815124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057194|NCT03061656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057195|NCT01424046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057196|NCT01881997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34057197|NCT05481229|||COHORT||PROSPECTIVE|||||||
34057198|NCT06618378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be 3 groups followed at the same time.|f|f|f|t
34057199|NCT06395298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Masking: Double blind~* Masking methodology:~The Sant Joan de Déu Hospital Neonatal Unit carries out its care activity under the NIDCAP model, which includes care centered on the user and the family/mother or caregiver.~Currently, the design of the neonatal unit has individual boxes for the family member, which will allow the intervention to be carried out, as well as the orientations carried out by the health personnel with privacy and thus avoiding the identification of the different intervention models.~For the realization of the blind, it is proposed to make two video capsules in which the activities to be carried out will be collected, both by the control group and the experimental group, interspersing in the case of the experimental the PIOMI activities with the basic nursing care without doing reference to the intervention model assigned in the recording. Access to the video will be in quick response code format."|"* Assignment: Random and parallel using the OxMaR (Oxford Minimization and Randomization) software~* Age range: 29-30 gestational weeks, both sexes will participate~  * Control group:~Will receive the traditional intervention model of the Neonatal Intensive Care Unit (non-nutritive suction and kangaroo method)~o Experimental group: Application of the PIOMI (Premature Infant Oral Motor Intervention) protocol, for 5 minutes twice a day, in a period of 10 days o Both groups will receive gustatory and olfactory stimulation~* Intervention model: Parallel assignment~* Description of the intervention model: Comparison of two groups, treated with the application of the care model in the NICU (Neonatal Intensive Care Unit) and the application of PIOMI (Premature Infant Oral Motor Intervention)"|t|t|t|t
34057200|NCT00611182|||COHORT||PROSPECTIVE|||||||
34057201|NCT01553240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057202|NCT04604418|||COHORT||PROSPECTIVE|||||||
34057203|NCT04399408|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34057204|NCT06648304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057205|NCT05000203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A single blind will be performed by masking the data analysis. It will not be carried out in blinding of the participants due to impossibility given the nature of the education study. As far as possible, the control group will not be identified as pregnant women with severe fear of childbirth in the delivery area, since it is about receiving the usual care||f|f|f|t
34161316|NCT03332836|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161317|NCT01636986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161318|NCT04561440|||COHORT||RETROSPECTIVE|||||||
34161319|NCT03776201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161320|NCT05936983|||CASE_CONTROL||PROSPECTIVE|||||||
34161321|NCT04289792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161322|NCT01405612|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34161323|NCT06725160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34161324|NCT06671106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single center, examiner-blind, parallel-arm, randomized trial|f|f|t|t
34161325|NCT05026216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161326|NCT02128724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744287|NCT04852081|||COHORT||RETROSPECTIVE|||||||
33744288|NCT01699880|||CASE_CONTROL||PROSPECTIVE|||||||
33744289|NCT03946839|||CASE_CONTROL||PROSPECTIVE|||||||
33744290|NCT05427331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057206|NCT03588078|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive one dose of protocol therapy||||
34057207|NCT02998385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057208|NCT04451616|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057209|NCT04898543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057210|NCT02493010|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057211|NCT06648902|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34057212|NCT05288894|||COHORT||PROSPECTIVE|||||||
34057213|NCT00134849|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34161327|NCT06080685|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34161328|NCT04633928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161329|NCT04579159|NA|SINGLE_GROUP||SCREENING||NONE||||||
34161330|NCT00721240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161331|NCT01999400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34161332|NCT03505203|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to one of two conditions: (1) Sleep Soothe (responsive parenting), where parents are given information on how to respond to their baby's cues related to sleeping and fussiness, and (2) Sleep Safe (safety control), where parents are given information on a safe sleep environment, as well as other strategies they can use to keep their baby safe.||||
34161333|NCT04274621|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34161334|NCT02960464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161335|NCT03761901|||COHORT||RETROSPECTIVE|||||||
33744291|NCT01775891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744292|NCT01579123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744293|NCT06535984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|In the data collection process, the person collecting data was not blinded.|Participants were divided into four groups: three intervention groups and one control group. Infants were assigned to these groups using simple random sampling to ensure homogeneity and prevent selection bias. The sample size was calculated using the G-Power 3.0.10 program. With a confidence interval (CI) of 95%, α = 0.05, effect size = 0.159, and power (1 - β) = 0.80, a total sample size of 108 was calculated for the four groups, with at least 27 infants in each group. The study included 120 infants divided into the swaddling group (n=30), white noise group (n=30), white noise + swaddling group (n=30), and control group (n=30)|t|t|t|t
33744294|NCT03822923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744295|NCT00650546|NA|SINGLE_GROUP||OTHER||NONE||||||
34057214|NCT06060990|NA|SINGLE_GROUP||OTHER||NONE|None (Open Label)|Single Group Assignment||||
34057215|NCT01535534|||COHORT||PROSPECTIVE|||||||
34161336|NCT06112691|||COHORT||PROSPECTIVE|||||||
34057216|NCT05477485|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057217|NCT03603470|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057218|NCT00074997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057219|NCT00533689|NON_RANDOMIZED|PARALLEL||||NONE||||||
34057220|NCT04467242|||CASE_ONLY||RETROSPECTIVE|||||||
34057221|NCT02916394|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34057222|NCT04586218|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled superiority trial|t|f|f|t
34057223|NCT06649526|||OTHER||OTHER|||||||
34057224|NCT03969303|||COHORT||PROSPECTIVE|||||||
34057225|NCT04781829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Physician-specific Step Wedge||||
34057226|NCT05333939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||placebo controlled randomized controlled trial|t|t|t|t
34057227|NCT00403650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057228|NCT03231540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057229|NCT05817487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161337|NCT04247737|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||25 healthy individuals and 150 patients with irritable bowel syndrome keep a gluten-free diet for six weeks||||
34161338|NCT02088489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161339|NCT01005095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34161340|NCT03914755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161341|NCT00971139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744296|NCT01914848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33744297|NCT06470932|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744298|NCT03956303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744299|NCT03264989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744300|NCT01175668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847838|NCT05664893|NA|SEQUENTIAL||TREATMENT||NONE||step 1 : 600mg of ribociclib step 2 : 400mg of ribociclib step 3 : 200mg of ribociclib||||
34057230|NCT03369028|||COHORT||PROSPECTIVE|||||||
34057231|NCT06003907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||conservative and traditional physiotherapy|f|f|f|t
34057232|NCT06648512|||COHORT||PROSPECTIVE|||||||
33744301|NCT00090389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33744302|NCT05870306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"105 patients undergoing a first-time ablation procedure for AF will be consecutively enrolled and randomized on a 1:1 basis to PVI alone vs PVI plus slow conduction ablation.~An enrollment log with all the patients included in the study, even drops out, will be collected. Data will be collected at enrollment, baseline and at three, six and 12-month follow-up visit."|t|f|f|f
33744303|NCT04984044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Diagnosed case of Type 2 Diabetes Mellitus with peripheral neuropathy|t|f|t|f
34057233|NCT06028958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome accessor will be unaware of the treatment group.||f|f|f|t
34057234|NCT04927377|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The principal investigator and biostatistician will be masked to the randomization of the participants into the two treatment groups.||f|f|t|t
34057235|NCT05824052|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Synovial fluid samples taken from patients will be prepared to form 3 separate groups, one fluid will not be treated, one will be injected with 10 gamma and the other with 30 gamma ozone.|t|f|f|f
34057236|NCT06620549|||COHORT||PROSPECTIVE|||||||
34057237|NCT02004821|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057238|NCT02262000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057239|NCT06619223|||COHORT||PROSPECTIVE|||||||
34161342|NCT04195217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The biostatistician will analyze the two arms blindly|"This is a interventional study at risk and minimal constraints, paramedical, mono-centric, institutional in view of a validation of innovative practices in the care of the patient, excluding health products.~It is a superiority, randomized, controlled parallel arms study comparing the usual management and usual care associated with art therapy."|f|f|f|t
34161343|NCT04327024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161344|NCT01939847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161345|NCT00377208|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34161346|NCT02581215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Site pharmacy staff will be unblinded to the study treatment. Subjects, site investigators, site analysis teams, and other site personnel will be blinded to the study treatment.||t|t|t|t
34161347|NCT03081026|||COHORT||CROSS_SECTIONAL|||||||
34161348|NCT03683017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161349|NCT02931552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34161350|NCT06140966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161351|NCT05516719|||COHORT||CROSS_SECTIONAL|||||||
34161352|NCT04853719|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|2 arms, active comparator (vascular dose) versus aspirin alone||||
34161353|NCT04381169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161354|NCT01659229|||COHORT||PROSPECTIVE|||||||
33744304|NCT04519229|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34161355|NCT00878748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161356|NCT02134925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34161357|NCT05044858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161358|NCT00659932|RANDOMIZED|PARALLEL||TREATMENT||||||||
33744305|NCT00275093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744306|NCT05046938|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Among the students who meet the food addiction criteria, the students who meet the inclusion criteria and agree to participate in the research will be randomly assigned to the intervention and control groups (n1=29; n2=29). After these students are stratified according to the change (pre-contemplation and contemplation stage) phase, a simple random assignment process within the strata will be done by an independent researcher to avoid selection bias. Random assignment will be done through a simple random numbers table. The independent researcher who does not know which group is the intervention group and which group is the control group will collect the data.|randomized controlled experimental design|f|f|t|f
33744307|NCT05588089|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||The study is of a semi-separate type and all women can be trained.|t|f|f|f
33744308|NCT06532292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744309|NCT02030977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744310|NCT01383538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744311|NCT00709163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744312|NCT05559918|||COHORT||PROSPECTIVE|||||||
33744313|NCT05212974|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744314|NCT04717011|||CASE_ONLY||PROSPECTIVE|||||||
33744315|NCT05976074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744316|NCT02946736|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33744317|NCT01420796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3 arms were designed to evaluate the effect of swallowing and breathing exercises to dysphagia in PD patients. The groups were allocated randomly in A) swallowing exercises; b) Breathing exercises or C) Swallowing and breathing exercises|f|f|f|t
33744318|NCT06110312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744319|NCT00768274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744320|NCT03906370|||COHORT||PROSPECTIVE|||||||
33744321|NCT00990223|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33744322|NCT03647501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to their group status for the duration of the study assessments and procedures (up to 24 months post-operatively).|All subjects will be randomized in the trial to receive either the Nexxt Spine Nexxt MatrixxTM 3D-printed titanium cage or the HonourTM PEEK cage supplemented with a pedicle screw system and milled local autograft bone. Subject randomization will be stratified according to smoking status.|t|f|f|f
33744323|NCT04148443|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot study Randomized controlled multicenter trial Ratio 1:1||||
33744324|NCT01242475|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33744325|NCT03866993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744326|NCT02043782|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33744327|NCT01569516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952738|NCT05938413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952739|NCT02913638|||OTHER||CROSS_SECTIONAL|||||||
33744328|NCT00001059||||TREATMENT||||||||
33744329|NCT05785598|||COHORT||RETROSPECTIVE|||||||
33744330|NCT06218173|||COHORT||RETROSPECTIVE|||||||
34161359|NCT06126341|||COHORT||PROSPECTIVE|||||||
34161360|NCT04926948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161361|NCT02698514|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34161362|NCT03079895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary care physician will not receive feedback about which arm the patient was assigned to.|Randomized controlled trial. Control arm will receive treatment as usual for depression from primary care physician. Intervention arm will also receive treatment as usual, and access to an internet-based self-help tool for treatment of depression, along with coaching emails and/or phone calls, encouraging their participation and answering questions about how to use the program.|f|t|f|f
34161363|NCT02655549|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161364|NCT05011513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Eligible participants with a confirmed diagnosis of SARS-CoV-2 infection will be randomized (1:1) to receive PF-07321332/ritonavir or placebo orally every 12 hours for 5 days (10 doses total).|t|t|t|t
33847839|NCT03468400|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33847840|NCT04836689|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Infants will be monitored by TcCO2 during three consecutive time periods of one hour each on a high and low rate of NIPPV, when in a stable condition. NIPPV rate will start high/low, changed to low/high and switched back to starting rate||||
33847841|NCT04847076|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to intervention or control groups at a 1:1 ratio.||||
33847842|NCT01344954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33847843|NCT00061152||||TREATMENT||NONE||||||
33847844|NCT04006353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847845|NCT02865226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847846|NCT02650687|||COHORT||PROSPECTIVE|||||||
33847847|NCT03656952|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33847848|NCT06235437|NA|SEQUENTIAL||TREATMENT||NONE||Subjects will receive one of 8 dose levels of ASD141 (0.01, 0.03, 0.1, 0.3, 1, 3, 10, and 30 mg/kg) once every week (QW) in a 28-day cycle. BOIN design with accelerated titration||||
33847849|NCT05068141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847850|NCT06433973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847851|NCT00319462|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847852|NCT05565638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847853|NCT00467285|||CASE_CONTROL||PROSPECTIVE|||||||
33847854|NCT02121951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33847855|NCT06060015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|You do not know the dose of bupivacaine you receive|Clinical trial open controlled parallel randomized simple|t|f|t|f
33847856|NCT00098501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847857|NCT03681847|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847858|NCT00998803|||COHORT||PROSPECTIVE|||||||
33847859|NCT05873478|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|one group is taking intervention and other is control group||t|f|f|f
33847860|NCT04129827|||COHORT||CROSS_SECTIONAL|||||||
33847861|NCT02031549|||COHORT||PROSPECTIVE|||||||
33847862|NCT01350739|RANDOMIZED|PARALLEL||||NONE||||||
33847863|NCT02208011|||COHORT||PROSPECTIVE|||||||
33847864|NCT02878005|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33847865|NCT03930290|||COHORT||PROSPECTIVE|||||||
33847866|NCT04064073|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847867|NCT05728320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33847868|NCT01033422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847869|NCT05351359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33847870|NCT02684448|||COHORT||RETROSPECTIVE|||||||
33847871|NCT06092619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Neither the therapists nor the evaluators of the GMFM may be blinded to the type of treatment administered due to the organization of the Rehabilitation service where the study is carried out, as well as the face-to-face requirements for carrying out the Vojta therapy and the evaluation. of that scale. However, the assessment of the Infant Motor Profile (IMP) is performed by observing a protocolized video recording. This would allow the quantification of this escape by an evaluator external to the service (in this case the external Principal Investigator). This would allow not only to blind the evaluator regarding the type of intervention that the child receives, but also if the video belongs to pre or post intervention. To do this, the videos will be sent encrypted and randomized for quantification"|A randomized clinical trial has been designed that will assess gross motor function from the start of the rehabilitation intervention (with Vojta therapy or other methodologies).|f|f|f|t
34161365|NCT01407666|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161366|NCT05455528|||COHORT||RETROSPECTIVE|||||||
33847872|NCT06292468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847873|NCT00085670|||COHORT||OTHER|||||||
33847874|NCT02586428|||||PROSPECTIVE|||||||
33847875|NCT02461329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847876|NCT00003453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847877|NCT00727701|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847878|NCT00901173|||CASE_CONTROL||PROSPECTIVE|||||||
33847879|NCT04873739|||COHORT||RETROSPECTIVE|||||||
33847880|NCT03836716|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized open label||||
33847881|NCT05451823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847882|NCT05586139|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Individually randomized and controlled trial,~Stratified by severity of malnutrition:~* 2 arms for Severe Acute malnutrition~* 2 arms for Moderate acute Malnutrition"||||
33744331|NCT06100926|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33744332|NCT01260246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057240|NCT06349512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC.||||
34057241|NCT01702675|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33744333|NCT04059926|||CASE_ONLY||PROSPECTIVE|||||||
34057242|NCT04346901|NA|SINGLE_GROUP||OTHER||NONE||||||
34057243|NCT00783315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Persons who measured weight and other outcomes were masked to randomized assignment.|"Three Group:~1. advice only comparison group~2. remotely delivered behavioral weight loss group~3. in-person behavioral weight loss group"|f|f|f|t
34057244|NCT03743103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057245|NCT05961410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057246|NCT04643418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057247|NCT06620224|NA|SINGLE_GROUP||SCREENING||NONE||a non-randomized real world data||||
34057248|NCT01726387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057249|NCT01668524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057250|NCT01609634|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33744334|NCT06388343|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33744335|NCT03186846|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33744336|NCT01877109|||COHORT||PROSPECTIVE|||||||
33744337|NCT04612179|||COHORT||PROSPECTIVE|||||||
33744338|NCT03786497|||COHORT||PROSPECTIVE|||||||
33744339|NCT00518024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33744340|NCT04658251|||COHORT||PROSPECTIVE|||||||
33744341|NCT00070850|||DEFINED_POPULATION||PROSPECTIVE|||||||
33744342|NCT01011010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847883|NCT05712772|RANDOMIZED|CROSSOVER||OTHER||NONE||All participants will receive blue and red light exposures; order of red vs. blue light will be counterbalanced across participants.||||
33847884|NCT00133406|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33847885|NCT06380673|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33847886|NCT00465387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847887|NCT05322746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847888|NCT05517187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847889|NCT04301531|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"In the intervention arm, all participants are tested using RDTs and treated if they carry the malaria parasite. This is carried out six times in two years.~In the control arm participants are only tested and treated if confirmed to be carrying the parasite at baseline and evaluation."||||
33847890|NCT02350985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847891|NCT06193304|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33847892|NCT00821717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847893|NCT06213259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847894|NCT00765453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847895|NCT02969811|||COHORT||PROSPECTIVE|||||||
33847896|NCT04339959|||OTHER||PROSPECTIVE|||||||
33847897|NCT03069703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The central laboratory performing the immunogenicity assessment (ELISA and OPA) will be blinded for the trial arm in order to limit measurement bias.||f|f|f|t
33847898|NCT06139185|||CASE_CONTROL||PROSPECTIVE|||||||
33847899|NCT02201615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33847900|NCT00080093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847901|NCT06493227|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33847902|NCT00905385|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33847903|NCT03392285|||COHORT||PROSPECTIVE|||||||
33847904|NCT03422198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847905|NCT04752410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847906|NCT00000689||||TREATMENT||NONE||||||
33847907|NCT01027832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847908|NCT03095677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33847909|NCT03114787|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33847910|NCT01983254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847911|NCT01357941|||COHORT||PROSPECTIVE|||||||
33847912|NCT02248181|||COHORT||PROSPECTIVE|||||||
33847913|NCT02940600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847914|NCT03848143|NA|SINGLE_GROUP||TREATMENT||NONE||Single subject experimental design||||
33847915|NCT04677829|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Study drug will be administered and assessed in double-blinded fashion.|Escalating dose level cohorts; each cohort with an active and a placebo arm|t|t|t|t
33847916|NCT05458700|||COHORT||PROSPECTIVE|||||||
33847917|NCT04997447|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized Controlled Trial, with 2 parallel groups||||
33847918|NCT05048654|||COHORT||OTHER|||||||
33847919|NCT03683303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33847920|NCT01867333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847921|NCT03256981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847922|NCT06423547|||COHORT||PROSPECTIVE|||||||
33847923|NCT01100827|||COHORT||RETROSPECTIVE|||||||
33847924|NCT04288375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847925|NCT02573194|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33847926|NCT02265627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952740|NCT01422876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952741|NCT03638479|||CASE_CONTROL||PROSPECTIVE|||||||
33952742|NCT06504290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952743|NCT00139243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952744|NCT05859464|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952745|NCT02965027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952746|NCT02585193|NA|SINGLE_GROUP||OTHER||NONE||||||
33952747|NCT01735136|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33952748|NCT00163527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952749|NCT06574386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952750|NCT03106740|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33952751|NCT06246630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952752|NCT05511155|||CASE_CROSSOVER||PROSPECTIVE|||||||
33952753|NCT03488537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a Multi center prospective cohort study in subjects eligible for colonoscopy with suspicion for malignant or premalignant lesions of the colon.||||
33952754|NCT05624515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33952755|NCT02742415|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33952756|NCT00719407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952757|NCT00706927|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33952758|NCT04532827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization will be pre-programmed and the allocation sequence will be carried out and concealed by a researcher who is not otherwise involved in trial at FIOH. This study compares eHealth intervention with treatment as usual. Thus it is not possible to blind the study participants. However, eHealth therapists are blinded for study participant compared with patients in eHealth intervention for other reasons, I.e. study participants and patients referred to the program as treatment as usual by their physician. Further, data analyst will be blinded to intervention arms.||f|t|f|t
33952759|NCT00943826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952760|NCT04869475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952761|NCT02494804|NON_RANDOMIZED|PARALLEL||||NONE||||||
33952762|NCT00153751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952763|NCT06653049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|In this trial, participants were blinded to their condition (whether they were in the RL intervention or control group) throughout the study. The outcomes assessor, who analysed the data, was also blinded to the participants' condition to reduce potential bias in interpreting the results. Neither the care providers nor the investigators were masked, as they were responsible for managing the intervention and monitoring the trial's progress, ensuring the smooth operation of the app and data collection. No other parties were masked in this trial.||t|f|f|t
33952764|NCT04715880|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33952765|NCT03592680|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||One group receives Vitamin C, the other group received placebo.|t|t|t|f
33952766|NCT01205139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952767|NCT06567600|NA|SINGLE_GROUP||TREATMENT||NONE||low-dose gemcitabine and cisplatin combined with PD-1/PD-L1 inhibitors||||
33952768|NCT01407627|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33952769|NCT05880758|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Statistician will be blinded to intervention allocation; blinding of study participants is not possible due to the intervention type.|3-arm, parallel study design|f|f|f|t
33952770|NCT06264765|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blind patients and postoperative follow-ups will not know which group the patient is in the study.|randomized double blinding|t|t|f|f
33952771|NCT06381115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952772|NCT04242901|||COHORT||PROSPECTIVE|||||||
33952773|NCT04675489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects to receive bilateral implantation of Vivity Extended Vision Toric Intraocular Lens||||
33952774|NCT00052507||||TREATMENT||NONE||||||
33952775|NCT03876795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952776|NCT06466967|||COHORT||PROSPECTIVE|||||||
34057251|NCT06252051|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952777|NCT01095458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952778|NCT01720927|||CASE_ONLY||PROSPECTIVE|||||||
33952779|NCT06439134|||CASE_CONTROL||PROSPECTIVE|||||||
33952780|NCT04027777|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33952781|NCT05731973|RANDOMIZED|PARALLEL||OTHER||NONE||Single center, prospective, unblinded, randomized clinical trial. Block randomization, including stratification based on age (12-16 years and 17-24 years) and sex, with an allocation ratio of 1:1 will be performed.||||
33952782|NCT02860026|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33952783|NCT03384498|||COHORT||PROSPECTIVE|||||||
33952784|NCT02313246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952785|NCT06648213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33952786|NCT02524262|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33952787|NCT02602470|||COHORT||CROSS_SECTIONAL|||||||
33952788|NCT04812886|NA|SINGLE_GROUP||OTHER||NONE||||||
33952789|NCT02237066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952790|NCT02393404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952791|NCT05822388|||COHORT||PROSPECTIVE|||||||
34057252|NCT04395781|||COHORT||OTHER|||||||
34057253|NCT00773578|||COHORT||PROSPECTIVE|||||||
34057254|NCT05603195|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34057255|NCT03398512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057256|NCT06647745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057257|NCT02076737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847927|NCT03310034|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, dubbel-blind, cross-over trial|t|f|t|f
33847928|NCT00415077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847929|NCT03780218|||CASE_CONTROL||PROSPECTIVE|||||||
33847930|NCT02982824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33847931|NCT03848013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33847932|NCT06146127|||COHORT||RETROSPECTIVE|||||||
33847933|NCT03182192|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Comparison of patients with hypoglycemia to control patients||||
33847934|NCT03822793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomized double blind study||t|f|t|f
33847935|NCT00056992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847936|NCT04031807|||COHORT||RETROSPECTIVE|||||||
33952792|NCT06471023|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"An unblinded personnel at the CRO will be responsible for study product labelling/blinding. The study products will subsequently be distributed to the study site.~Delegated unblinded site personnel will be responsible for study product accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records) throughout the course of the study. The investigator will have oversight in a blinded manner."||t|f|t|t
33952793|NCT05340309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952794|NCT05396326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952795|NCT05076812|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33952796|NCT04859959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952797|NCT04791410|||COHORT||PROSPECTIVE|||||||
33952798|NCT04707612|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33952799|NCT01564810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952800|NCT06540937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952801|NCT02344212|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952802|NCT04158466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33952803|NCT04589793|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33952804|NCT03032939|||CASE_ONLY||PROSPECTIVE|||||||
33952805|NCT06244134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952806|NCT05831475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomized by the coordinator to a study arm:~Arm 1- older adult paired with older adult (40) Arm 2- older adult paired with younger adult (20 older, 20 younger)"||||
33952807|NCT03185949|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"* Interventional Group: These subjects will undergo catheter-based embolization.~* Sham Control Group: These subjects will not undergo femoral artery catheterization. Instead, lidocaine will be injected subcutaneously at the femoral artery site in the Sham Control group. Since all patients will have received at least sedation, they will not be aware of what has been done, and thus be blind to their treatment assignment"|This study is a prospective, sham controlled, single-blind 12-month trial with 1:1 randomization. A maximum of 40 subjects (obese men and women who have a body mass index (BMI) of 35.0-50.0 kg/m2) will be enrolled in the study. Eligible subjects will be randomized to treatment with Endobar Therapy (n = 20) or sham procedure control (n = 20). Endobar Therapy involves catheter-based embolization of the left gastric artery. All subjects in both Endobar Therapy and Sham Control groups will receive Lifestyle Therapy (behavioral and diet education). At the end of 6 months all subjects randomized to the Sham Control group will receive catheter-based embolization of the left gastric artery. Both Endobar Therapy and Sham Control crossover to Endobar Therapy groups will be followed for a total of 12 months|t|f|f|t
33952808|NCT06491433|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952809|NCT02363868|||COHORT||RETROSPECTIVE|||||||
33952810|NCT00956813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33952811|NCT05246982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952812|NCT03504839|NA|SINGLE_GROUP||TREATMENT||NONE||Consecutive patients consented for SICD as per standard indications for device implantation||||
33952813|NCT04149236|||OTHER||CROSS_SECTIONAL|||||||
33952814|NCT03585894|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Each participant will receive PACAP28 intravenous infusion over 20 min in both experiment days but treated in randomized order with sumatriptan or ketorolac.|t|t|t|f
33952815|NCT01898884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952816|NCT00407966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952817|NCT00622622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057258|NCT04235374|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants as hospitals will be randomized to treatment or control|randomized trial with treatment and control sites. Patients are followed for 12 months. Facilities are worked with for 12 months.|t|f|f|f
34057259|NCT05996640|||OTHER||CROSS_SECTIONAL|||||||
34057260|NCT05176548|||COHORT||PROSPECTIVE|||||||
34057261|NCT05700916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34057262|NCT04442451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each participant will attend 3 sessions per week for 8 weeks. A training session will start with a 10-minute warm up on a bike ergometer. Each leg will then perform low-load resistance training (\~20% of 1-RM) for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions while seated in a knee extension weight machine. One leg will be randomized to always perform the training with blood flow restriction (BFR leg) while the contralateral leg performs the exercise training without blood flow occlusion (Control leg).||||
34057263|NCT04599725|||CASE_ONLY||PROSPECTIVE|||||||
34057264|NCT01300338|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057265|NCT04087629|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057266|NCT06622876|||COHORT||RETROSPECTIVE|||||||
34057267|NCT02546791|||COHORT||RETROSPECTIVE|||||||
34057268|NCT04229602|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33847937|NCT01789567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952818|NCT06449352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33952819|NCT02494882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952820|NCT01612962|||COHORT||RETROSPECTIVE|||||||
33952821|NCT02294565|NA|SINGLE_GROUP||||NONE||||||
33847938|NCT01770106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847939|NCT01373073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057269|NCT06617728|||COHORT||PROSPECTIVE|||||||
33744343|NCT05166018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The patient will be required to complete a guided digital questionnaire at each follow-up assessment.~This questionnaire will be completed online by the patient in the Surgery Medical Outcomes (SuMO system) system developped by the Society Cortexx Medical Intelligence. The system access procedures and connection codes will be known to the patient by the investigating physician. Patients will, throughout the study, be automatically informed via the SUMO system of the availability of data to be completed. The security of patient data is guaranteed by encrypted and separate storage of medical data, in order to comply with applicable regulatory requirements."||||
33744344|NCT03662945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||1 intervention group and 1 control group||||
33744345|NCT02607579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744346|NCT01660763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744347|NCT04863352|||COHORT||CROSS_SECTIONAL|||||||
33744348|NCT05227508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"* Study arm- min. 80 patients~* Placebo arm- min. 40 patients"|t|t|t|f
33744349|NCT00942929|||COHORT||PROSPECTIVE|||||||
33744350|NCT01038908|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33744351|NCT05284994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744352|NCT03424681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744353|NCT02813226|NA|SINGLE_GROUP||OTHER||NONE||||||
33744354|NCT00856050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744355|NCT03903133|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33744356|NCT02385448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744357|NCT05881044|||OTHER||CROSS_SECTIONAL|||||||
33744358|NCT05776563|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744359|NCT00135954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744360|NCT04864015|RANDOMIZED|PARALLEL||PREVENTION||NONE||A investigator-initiated single center open-label randomized trial||||
33847940|NCT04289168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33847941|NCT00143676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847942|NCT05490901|||COHORT||PROSPECTIVE|||||||
33847943|NCT04444973|||COHORT||PROSPECTIVE|||||||
33847944|NCT04674787|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34057270|NCT06546631|||CASE_ONLY||PROSPECTIVE|||||||
34057271|NCT06177769|||OTHER||OTHER|||||||
34057272|NCT04230512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomly assigned conditions of pump function to characterize the effects of added movement on socket-reaction torques||||
34057273|NCT06648018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057274|NCT06376136|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34057275|NCT05994911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057276|NCT05025358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057277|NCT01282164|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34057278|NCT03928548|||COHORT||PROSPECTIVE|||||||
34057279|NCT03139006|||COHORT||PROSPECTIVE|||||||
34057280|NCT01766752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057281|NCT01735968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057282|NCT06051435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057283|NCT04430023|||OTHER||RETROSPECTIVE|||||||
34057284|NCT04699201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The participant will not know if the umbilical incision has been close by standard technique or with the preventive mesh.~Also the radiologists performing the ultrasounds after 12 months will not have the information of Prosthesis/Control patient allocation"|Bicentric Randomized Controlled Trial. 2 allocation groups, parallel. Single blind. Enrollment: consecutive cases Time Perspective: Prospective|t|f|f|f
34057285|NCT06417177|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34161367|NCT04057521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||For the purpose of program evaluation; 6,259 participants who met eligibility criteria for CHECK were randomized. These participants had no previous exposure to CHECK and were randomized to either enrollment into the CHECK program or to usual care (comparison group). Purposive randomization to CHECK or usual care by age, disease and risk level was conducted by Mathmatica.||||
34161368|NCT05285540|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34161369|NCT02451514|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161370|NCT04778826|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Compare the oncological outcome and immune competence between patients who undergo lung lobectomy with standard lymphadenectomy and those who undergo combined lobectomy and video assisted bilateral mediastinal lymphadenectomy||||
34161371|NCT03653143|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will initially undergo brief telephone screen to assess eligibility. Parents/guardians will complete surveys during the Baseline assessment and ERP/EEG testing will be done for participants who are able to undergo their assessments in-person. Participants will then be randomly assigned to either the treatment group or the control/waitlist group. The immediate group will start with 3 months of JASPER intervention and then have 3 months of their usual clinical care. The control/waitlist group will start with 3 months of their usual clinical care and then undergo 3 months of JASPER intervention. The 3-month treatment phase will involve weekly sessions with the JASPER interventionist, each 60 minutes long. Surveys and ERP/EEG assessments (as possible) will be repeated at the 3 month and at 6 month research visits for all participants.||||
34161372|NCT03374033|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34161373|NCT00432406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161374|NCT01035489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744361|NCT06021717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, nurses who cared for the patients, the anesthetist who performed the anesthesia and the investigators who gathered the data were blinded to patients' group allocation.|"Participants were randomly allocated into either Group A or Group B by computer-generated randomization a day before planned surgery.~Group A will receive PCA ketamine-morphine 0.5 mg/ml in 1:1 ratio while group B will receive PCA morphine 1mg/ml,"|t|t|t|f
33744362|NCT00941239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744363|NCT01234506|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33744364|NCT00951600|RANDOMIZED|CROSSOVER||||NONE||||||
33744365|NCT01699594|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33744366|NCT04915963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33744367|NCT00069810|||COHORT||PROSPECTIVE|||||||
33744368|NCT00569504|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744369|NCT03153917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744370|NCT01082666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744371|NCT05436782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744372|NCT00004181||||TREATMENT||||||||
33744373|NCT00817089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Groups 1 and 3 get placebo in session 1 and placebo in session 2, Groups 2 and 4 get placebo in session 1 and naltrexone in session 2|t|t|t|t
33744374|NCT00237744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744375|NCT03246360|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744376|NCT03998826|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be participant and operator-blind where the participant and operator will not know the intervention done.|Parallel Assignment Type: Two arm, parallel, randomized clinical trial. Allocation ratio: 1:1 Framework: Superiority.|t|t|t|t
33744377|NCT02861781|||COHORT||PROSPECTIVE|||||||
33744378|NCT04975594|||COHORT||PROSPECTIVE|||||||
33744379|NCT02219932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744380|NCT05130112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744381|NCT03615157|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants will be randomized in two groups: Home-based and Supervised exercise groups||||
33744382|NCT04775446|||COHORT||OTHER|||||||
33744383|NCT02910622|||COHORT||PROSPECTIVE|||||||
33744384|NCT03882125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744385|NCT01153152|||CASE_ONLY||RETROSPECTIVE|||||||
33744386|NCT02300714|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33744387|NCT01629329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744388|NCT06077396|NA|SINGLE_GROUP||PREVENTION||NONE||Patients who underwent radial artery cannulation in liver transplantation||||
33744389|NCT00221793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744390|NCT06336096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744391|NCT06386484|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The PolarCap System consists of a high-powered portable cooling system, designed to reduce brain temperature by controlled cooling of the scalp and neck with a circulating coolant (PolarCap Coolant, PolarCool AB, Lund, Sweden). The coolant is maintained at 0°C and flows through a silicone-based head cap. An insulating neoprene cover is put on top of the cap for isolation.|f|t|t|t
33744392|NCT00852904|||COHORT||PROSPECTIVE|||||||
33744393|NCT03249623|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||After randomisation, for patients randomised in the Beacon group, the Beacon system will actively advice clinicians on ventilatory settings to adapt the ventilator to patient's individual clinical situation and corresponding clinical intervention.|t|f|f|f
33744394|NCT04332705|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33744395|NCT05680168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744396|NCT00596765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744397|NCT04200066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744398|NCT04100447|NA|SINGLE_GROUP||PREVENTION||NONE||This is an investigator-initiated, open label, Phase 1 study to evaluate LB1148 for safety, tolerability, and preliminary efficacy in subjects undergoing elective bowel resection. All subjects will receive LB1148 prior to surgery.||||
33744399|NCT05814523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744400|NCT04452461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744401|NCT06410066|||COHORT||OTHER|||||||
33744402|NCT04318340|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33744403|NCT05675345|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744404|NCT00005981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057286|NCT02319967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057287|NCT03266458|||COHORT||PROSPECTIVE|||||||
34057288|NCT03108404|||COHORT||RETROSPECTIVE|||||||
34057289|NCT00826592|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34057290|NCT00791362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057291|NCT04055311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be randomized based on a randomization table developed by study statistician. Care providers are not informed of the assigned study condition. Patients complete assessments through Redcap survey. Data analyst will be blinded to the nature of the numerical assignment of intervention vs control condition.|The RSBC intervention will be evaluated in a 12-month randomized controlled trial among patients and caregiver dyads (N=287 initial; 238 final sample) against a time and attention comparison condition that focuses on general wellness.|f|t|f|t
34057292|NCT00508287|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34057293|NCT02333721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057294|NCT00154050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34057295|NCT06618677|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||single center, prospective, single blind low versus standard FODMAPs diet trial with crossover|t|f|f|f
34057296|NCT02228304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34057297|NCT01063920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34057298|NCT06618027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057299|NCT03187236|||COHORT||PROSPECTIVE|||||||
34057300|NCT01046851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34057301|NCT06222060|||COHORT||PROSPECTIVE|||||||
34057302|NCT06623565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057303|NCT03867149|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33952822|NCT05432466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, the Investigator, and other members of the staff involved with the study will remain blinded to the two study treatments (celiprolol and placebo).|"This is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy study to evaluate celiprolol in patients genetically confirmed as COL3A1-positive vEDS using a decentralized clinical trial design.~The double-blind portion of this study is intended to end at Month 40 assuming that at least 46 vEDS-related clinical events have occurred. If the number of vEDS-related events is fewer than 46 at Month 40, the study will continue until the required number of events have occurred prior to ending the double-blind portion of the study.~Following the double-blind treatment period or occurrence of a vEDS-related clinical event, patients have the option to participate in an OLE period.~A total of approximately 150 patients who meet all the inclusion and none of the exclusion criteria will be enrolled and randomized 2:1 to receive either celiprolol or placebo, respectively.~An approximately 40-month treatment period followed by an optional open-label extension study."|t|t|t|t
33952823|NCT05659082|NA|SINGLE_GROUP||OTHER||NONE||||||
33952824|NCT00138801|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33952825|NCT03330652|||COHORT||PROSPECTIVE|||||||
33952826|NCT03153319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952827|NCT03500029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33952828|NCT02997475|||CASE_CONTROL||PROSPECTIVE|||||||
33952829|NCT05872282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952830|NCT05045339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33952831|NCT03382691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952832|NCT02729727|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33952833|NCT05276934|||COHORT||PROSPECTIVE|||||||
33952834|NCT01638130|||COHORT||PROSPECTIVE|||||||
33952835|NCT00472004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952836|NCT01187511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952837|NCT06651216|||CASE_CONTROL||PROSPECTIVE|||||||
33952838|NCT01754805|NA|SINGLE_GROUP||OTHER||NONE||||||
33952839|NCT05068700|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a cluster-randomized trial. Nurses working in the four departments will be invited to choose to participate in the randomized controlled trial component of the study. If they choose to participate, they will be randomized to use capnography either with or without the Integrated Pulmonary Index (IPI) enabled.||||
34057304|NCT00900549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161375|NCT02001935|NA|SINGLE_GROUP||||NONE||||||
34161376|NCT00583284|||CASE_ONLY||PROSPECTIVE|||||||
34161377|NCT05851820|||OTHER||RETROSPECTIVE|||||||
34161378|NCT06263816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study will be a national multicentric, phase III, superiority double-blinded randomized controlled trial with two parallel arms: carvedilol versus placebo. The primary end-point will be assessed by the local investigator (hepatologist), blinded of the randomization arm|t|f|t|t
34161379|NCT03672292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161380|NCT02451995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161381|NCT04929470|||COHORT||PROSPECTIVE|||||||
34161382|NCT02581735|||COHORT||PROSPECTIVE|||||||
34161383|NCT02906397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161384|NCT05484115|RANDOMIZED|PARALLEL||TREATMENT||NONE||HERCULES is a post-market, prospective, global, multicenter, randomized (1:1), two-arm, superiority trial designed to compare ESAR to standard EVAR clinical outcomes in treatment of infrarenal AAA in patients having wide proximal aortic neck diameters (≥ 28mm and ≤ 32mm).||||
34161385|NCT01800591|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34161386|NCT04304586|||CASE_ONLY||RETROSPECTIVE|||||||
34161387|NCT00025558||||TREATMENT||||||||
34161388|NCT03701672|||COHORT||PROSPECTIVE|||||||
33952840|NCT00834028|||CASE_ONLY||PROSPECTIVE|||||||
33952841|NCT00589966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33952842|NCT03225313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33952843|NCT01477658|||COHORT||PROSPECTIVE|||||||
33952844|NCT05417477|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective exploratory pilot study. We plan to recruit 40 patients with Chronic Inflammatory Rheumatism (CIR) and 40 patients with Osteoarthritis (OA) by several investigating teams, for a total of 80 patients.||||
33952845|NCT02649127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952846|NCT06425718|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33952847|NCT02110875|||CASE_ONLY||CROSS_SECTIONAL|||||||
33952848|NCT04160273|NA|SINGLE_GROUP||SCREENING||NONE||||||
33952849|NCT04548817|||COHORT||PROSPECTIVE|||||||
34057305|NCT06590402|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Blinding of the patient/parent or guardian and research staff collecting data will be maintained via the SNOSE technique (Sequentially Numbered Opaque Sealed Envelope), whereby prior to study start, a research staff member not otherwise involved in the study will prepare envelopes with the randomization written on the card and secured in the envelopes, and the study ID number written outside the envelope."|A double-blinded pilot parallel group-randomized trial (GRT), subjects are enrolled and randomized based on their condition, and there is no cross-over of the groups|t|f|f|t
33952850|NCT03327935|RANDOMIZED|PARALLEL||TREATMENT||NONE|Baseline data are collected prior to the randomization and thus are masked. But during and after the intervention both participants and investigators are unblinded.|3 groups of 50 patients each by randomization||||
33847945|NCT04772820|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This project is a single-group unblinded feasibility study to explore a new telephone-based behavioral activation intervention to support homebound older people. If this intervention appears to be feasible, acceptable, and to show preliminary evidence of efficacy the aim will be to evaluate it in a phase III efficacy trial.||||
33847946|NCT05299593|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Open label|Single group, open label||||
33847947|NCT00642733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952851|NCT04909879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952852|NCT00859352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33952853|NCT01725217|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952854|NCT05388526|||OTHER||CROSS_SECTIONAL|||||||
33952855|NCT02647632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952856|NCT03325569|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33952857|NCT01717729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33952858|NCT04985032|||CASE_ONLY||PROSPECTIVE|||||||
33952859|NCT02835664|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33952860|NCT05518058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952861|NCT04800510|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded to the different design variations of each device, and will only be introduced to each device as CDO-A, CDO-B or CDO-C.|All participants will use three generic sized carbon fiber custom dynamic orthoses (CDOs). Each CDO will differ from the others in design and will be labeled as CDO-A, CDO-B and CDO-C. Participants will be randomly assigned to one of six CDO testing sequences (ABC, ACB, BCA, BAC, CAB, CBA) to prevent testing order from influencing study results.|t|f|f|f
33952862|NCT05487859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847948|NCT01241487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847949|NCT03526276|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized controlled trial involving 118 children ages between 4 and 5 years. They will be examined and chosen randomly for the study. Children will be divided equally into three groups: Group 1 will use CPP-ACP twice daily, Group 2 will apply fluoridated toothpaste twice daily, Group 3 will apply fluoridated toothpaste and CPP-ACP twice daily. Quantitative assessment of white spot lesions will be carried out using QLF before remineralizing agent application (baseline) and at 3, and 6 month intervals.||||
33847950|NCT01133795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847951|NCT01557114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33847952|NCT06222268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33952863|NCT02127788|||COHORT||PROSPECTIVE|||||||
33952864|NCT05248854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know the their grup.|A randomized controlled trial , prospective, single bllinded.|t|f|f|f
33952865|NCT01504126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952866|NCT00539006|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33952867|NCT05077033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952868|NCT03472391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952869|NCT01292291||||DIAGNOSTIC||||||||
33847953|NCT06189638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Antimicrobial Peptide PL-5 Topical Spray and placebo will not be identical in physical appearance. In order to ensure the objectivity of evaluation, the Sponsor, investigators, and other persons involved in the subject evaluation and trial implement (e.g., the Sponsor, subjects, investigators, clinical research associates, data managers, statistician, etc.) should be blinded. Blinded persons including investigators should not try to identify the group of subjects. Blind codes encrypted electronically will be stored in the Sponsor's department of medicine supply during clinical trials, and unblinding is not allowed before database lock.|Eligible subjects will be randomized (1:1:1) to receive twice a day, 14 days treatment of Antimicrobial Peptide PL-5 Topical Spray (1‰), Antimicrobial Peptide PL-5 Topical Spray (2‰) and placebo of Antimicrobial Peptide PL-5 Topical Spray (vehicle).|t|f|t|t
33847954|NCT01666964|||CASE_ONLY||PROSPECTIVE|||||||
33952870|NCT06063980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952871|NCT06519318|||OTHER||PROSPECTIVE|||||||
33952872|NCT04719208|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33952873|NCT06415032|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre, pragmatic randomised controlled trial||||
33952874|NCT02684370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952875|NCT04340570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33952876|NCT00617266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952877|NCT00959088|||CASE_ONLY||CROSS_SECTIONAL|||||||
33952878|NCT04998669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952879|NCT05214339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057306|NCT05367817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
34057307|NCT06017089|NA|SINGLE_GROUP||TREATMENT||NONE||In this single-arm intervention trial, all participants will use the study system (pump and CGM) in closed-loop mode for 8 weeks.||||
34057308|NCT05642260|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|neither the participant nor the outcome assessor are aware of the groups allocation.|parallel group prospective (24 weeks) randomised single-blinded pragmatic controlled trial.|f|f|f|t
34057309|NCT04724902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The evaluations will be carried out by a blind evaluator with no information about the identification of the group to which the volunteer belongs.~After the completion of the collections, the data will appear by a blind biostatistician, with no information on the identification of the groups."|Randomized controlled clinical trial following guidelines from CONSORT (Consolidated Standards of Reporting Trials), TIDieR (Template for Intervention Description and Replication) and OARSI recommendations for clinical trials with patients with knee osteoarthritis.|f|f|t|t
34057310|NCT05142150|||COHORT||PROSPECTIVE|||||||
34057311|NCT04939246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057312|NCT04326296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057313|NCT05195918|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|All participants will be on one of the standard of care drugs (nintedanib or pirfenidone) and blindly given EGCG or placebo.|There will be two stages in this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study. Participants will first be randomized to one of the four groups to receive 300 mg EGCG or placebo with one of the standard of care drugs (nintedanib or pirfenidone) for 12 weeks and 4 weeks follow-up. Once all 25 subjects at stage one have completed the study, a staged safety analysis will occur prior to opening stage two study with a higher group dose of 600 mg EGCG.|t|t|t|t
34057314|NCT05431946|||CASE_CONTROL||PROSPECTIVE|||||||
34057315|NCT04186806|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All subjects completing the wash-in procedures and meeting inclusion/exclusion criteria will undergo a pre-study 5-hour visit (the day before randomization) to assess the effect of water on their dry mouth symptoms. The subjects will return the next day for confirmation that inclusion/exclusion criteria and the wash-in procedures continue to be met or followed. Eligible subjects will be randomized at this baseline visit in a 1:1 ratio to one of two treatment orders: A-\>B (AB) or B-\>A (BA).|f|f|f|t
34057316|NCT02215863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161389|NCT04872595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This phase 2 study is to assess the effects of personalized rabbit ATG (P-rATG) dosing on CD4+ immune reconstitution (CD4+IR) based on a pharmacokinetic/pharmacodynamic (PK/PD) model in patients with hematologic malignancies undergoing peripheral blood mobilized, ex-vivo CD34+ T cell depleted, allogeneic, hematopoietic cell transplantation (CD34+/TCD allo-HCT)1.||||
34161390|NCT02814175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161391|NCT06027008|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention, blinding of healthcare professionals and any research personnel involved in the delivery of the intervention is not possible.|Randomized feasibility trial||||
34161392|NCT01149915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161393|NCT02741141|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34161394|NCT01010971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161395|NCT05846815|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Prospective, interventional, case control clinical investigation. Comparison of groups.~Equivalence study. Intervention model: cross-over assignment both groups are given both ARVO and Conners Continuous Performance Test 3rd Edition™ (CPT 3) tests.~Allocation: Propensity matching is used to ensure inter-group homogeneity in background variable with possible interaction effect to ARVO and CPT 3 score. Propensity matching: age and sex."||||
34161396|NCT04158583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847955|NCT04474509|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-arm Individually Randomized Group Treatment Trial||||
33847956|NCT05602389|RANDOMIZED|PARALLEL||OTHER||DOUBLE|A randomized, placebo-controlled, double-blind study.|Study Products: VL-G-A57 (Arm 1), VL-G-E12 (Arm 2) \& Placebo (Arm 3) Dose: 700 mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days|t|f|t|f
33847957|NCT02811952|||CASE_CONTROL||PROSPECTIVE|||||||
33847958|NCT04391634|NA|SINGLE_GROUP||TREATMENT||NONE||prospective crossover study||||
33847959|NCT06303271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33847960|NCT04842929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847961|NCT01626027|||COHORT||PROSPECTIVE|||||||
33847962|NCT00279643|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847963|NCT04279132|||COHORT||PROSPECTIVE|||||||
33847964|NCT04419272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled study. A designated unblinded study team member will perform the randomization and provide group assignment to the local Research Pharmacies. The unblinded study team member and Research Pharmacies will hold the randomization key, while all other individuals are blinded to study group assignment.|Parallel group (methylphenidate vs. placebo), followed by open-label methylphenidate|t|t|t|t
33847965|NCT00596401|||COHORT||PROSPECTIVE|||||||
33847966|NCT06444204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847967|NCT01967147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33847968|NCT05923515|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33847969|NCT03093623|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33847970|NCT06610305|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33952880|NCT04150107|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open-Label|This is an open-label crossover study in which all subjects will receive placebo run-in during Period 1 followed by Period 2, where subjects will be randomly assigned to either daily Treatment A (taken at Bedtime) and Treatment B (taken daily before each of three daily meals). At visit 5, the start of Period 3, subjects will stop their treatment (either A or B) and be CROSSED OVER to the other treatment (patients on treatment A during Period 2 will be crossed over to Treatment B and patients who were on Treatment B during Period 2 will be crossed over to Treatment A in Period 3).||||
33952881|NCT00609635|||COHORT||PROSPECTIVE|||||||
33952882|NCT03362411|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33952883|NCT04480502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952884|NCT00926042|||COHORT||PROSPECTIVE|||||||
33952885|NCT01305460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161397|NCT02717143|||COHORT||PROSPECTIVE|||||||
34161398|NCT00952393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161399|NCT04886713|||COHORT||PROSPECTIVE|||||||
34161400|NCT04473027|||COHORT||PROSPECTIVE|||||||
34161401|NCT02255461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161402|NCT03177928|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34161403|NCT06546046|NA|SINGLE_GROUP||SCREENING||NONE||||||
33952886|NCT02816658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952887|NCT03891602|||COHORT||PROSPECTIVE|||||||
33952888|NCT06327204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952889|NCT03078504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952890|NCT00335816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952891|NCT02706015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952892|NCT03087227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34161404|NCT00526591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161405|NCT03402724|||COHORT||PROSPECTIVE|||||||
33952893|NCT02505841|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33952894|NCT06342661|||CASE_CONTROL||RETROSPECTIVE|||||||
33952895|NCT05185791|||CASE_CONTROL||PROSPECTIVE|||||||
33952896|NCT00292006|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952897|NCT06302075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952898|NCT03804372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952899|NCT03215602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|One blinded outcome assessor (physiotherapists) will perform measurements of muscle strength, functional capacity and pain sensitization. The MRI scans will be performed by blinded radiologists. Patients in both groups will be blinded for parallel group assignments. Statistical analysis will be performed by a blinded statistician and a blinded interpretation of the results will be performed before breaking the randomization code.|Parallel group, assessor- and patient blinded randomized controlled trial|t|f|t|t
33952900|NCT04445259|||COHORT||RETROSPECTIVE|||||||
33952901|NCT03910309|||COHORT||PROSPECTIVE|||||||
33847971|NCT00141219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847972|NCT00322543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33847973|NCT01752296|||CASE_ONLY||CROSS_SECTIONAL|||||||
33847974|NCT04811976|||CASE_CONTROL||RETROSPECTIVE|||||||
33847975|NCT06610968|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blinded intervention. Those measuring the blood samples' hormonal will also be blinded to the intervention group but will not have a role in data analysis.|Participants will be randomized to either a treatment or control group upon enrollment and blinded to group assignment. The treatment intervention will consist of three weeks of one 5000 IU cholecalciferol capsule (Pure Encapsulations, LLC) daily, with breakfast. The control group will also take a daily, with breakfast, placebo capsule (Zeebo) for the three-week intervention.|t|f|f|f
33847976|NCT03103490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33847977|NCT06349642|||COHORT||PROSPECTIVE|||||||
33847978|NCT04847232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847979|NCT02027636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847980|NCT00976872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33847981|NCT04490200|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The outcome assessor won't have any knowledge about the study purposes and will be unaware of the group allocation.~Participants will be blinded as they will not distinguish the novel respirator (VESTA) from the conventional N95 respirator (both will have the same shape, color and size).~The statistical analysis will also be performed blinded for group allocation."|This is a randomized controlled clinical trial, characterized by the application of semi facial respirators, in which participants will be randomly and concealed allocated into two groups: VESTA respirator (GExp) and Conventional N95 respirator (CG). The participants will be healthcare professionals working in hospital environments contaminated by SARS-Cov-2. The study will be reported following the recommendations of the CONSORT Statement.|t|t|f|t
33847982|NCT03888053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33847983|NCT01917539|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33847984|NCT03084341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33847985|NCT02176993|||COHORT||PROSPECTIVE|||||||
33847986|NCT04747327|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant will not know the s/he has been randomized to a particular condition. S/he will not know about the other conditions, or the differences between them.|participants will be randomized to receive a message related to a behavior and a behavior change intervention (e.g., type of incentive).|t|f|f|f
33847987|NCT06331702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33847988|NCT02075073|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33847989|NCT00122252|||CASE_ONLY||PROSPECTIVE|||||||
33847990|NCT00111410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33847991|NCT06431477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847992|NCT03646591|||COHORT||PROSPECTIVE|||||||
33847993|NCT00657020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33847994|NCT05658497|||COHORT||PROSPECTIVE|||||||
33847995|NCT06479616|NA|SINGLE_GROUP||OTHER||NONE||||||
33952902|NCT05199714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, crossover||||
33952903|NCT06653231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|f|t
33952904|NCT02789241|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33952905|NCT04899219|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective, open-label, single-dose, parallel-group, Phase 1 study.||||
33952906|NCT00262483|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33952907|NCT06220916|||COHORT||PROSPECTIVE|||||||
33952908|NCT02160223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161406|NCT02411019|||COHORT||PROSPECTIVE|||||||
34161407|NCT02197663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161408|NCT04922606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161409|NCT03683342|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34161410|NCT03255577|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a prospective single-arm study design.||||
34161411|NCT00595491|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161412|NCT04383782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161413|NCT04355546|||COHORT||PROSPECTIVE|||||||
33744405|NCT03111927|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Double blind - Infant Formula arms are blinded;~* Reference Arm - unblinded epidemiological reference arm~* Allocation: Randomized for formula arms, efficacy study"|"Multicenter, double blind, randomized, controlled, parallel group clinical trial, consisting of 2 arms randomized to receive either the investigational or the control product, and a nonrandomized, nonblinded arm of fully breastfed infants.~3 groups: enriched level of myelin-relevant nutrients in an Infant Formula, standard level of myelin-relevant nutrients in an Infant Formula, breastfed infants"|t|f|t|f
33744406|NCT02730819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744407|NCT03939286|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In total, about 50 study participants will be examined in a prodromal or symptomatic early stage of Alzheimer's disease. These should be distributed equally randomized into two groups: a movement group (n = 25) with intensified training (equipment, coordination, balance) and a control group with continuation of physical activity as usual and participation in a psychoeducational program (n = 25).||||
33744408|NCT03144557|NA|SINGLE_GROUP||OTHER||NONE||||||
33744409|NCT05318729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744410|NCT03769220|||COHORT||PROSPECTIVE|||||||
33744411|NCT05732168|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33744412|NCT04900051|||COHORT||PROSPECTIVE|||||||
33847996|NCT02141451|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A Fast-Track Design with 1 patient enrolled per dose level until a grade 2 or greater treatment emergent adverse event occurs. A treatment emergent adverse event is any event not present prior to the initiation of the treatment (INCB7839) or any event already present that worsens in either intensity or frequency following exposure to the treatment. At that point, dose escalation will convert to a standard 3+3 design with two additional patients enrolled at the same dose level. If dose level 3 is completed without dose limiting toxicity (DLT) in the 1st 3 patients, an additional 3 patients will be enrolled at this level (without the staggering required by the DLT rules) prior to moving to the phase II component.~Once the phase I dose escalation is completed, an additional 12 patients will be enrolled at the MTD (or dose level 300mg bid, if no DLT) to obtain a more detailed toxicity profile as well as a preliminary estimate of progression free survival at 6 months post-transplant."||||
33847997|NCT00296400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33847998|NCT00618527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33847999|NCT05882552|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|During the procedure, the participants will not be informed of the results of the gaze tilt test. The tilted gaze target test will be conducted by a professional ophthalmologist who is not involved in the consultation and is unaware of the actual diagnosis of the study participants. The investigators will ensure that the normal consultation process is followed without being informed of the results of the gaze tilt test. The statistical analysis will be performed by a third-party outcomes assessor.|The enrolled study participants will be randomly assigned to two groups and undergo a crossover design in which they will sequentially undergo the tilted gaze target test and conventional examination methods, including oculomotor examination, Bielschowsky tilt test, alternate prism cover test, prism adaptation test, and monocular cover test.|t|t|t|f
33848000|NCT00271531|||COHORT||PROSPECTIVE|||||||
33848001|NCT00470366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848002|NCT02871258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848003|NCT02138955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848004|NCT01879059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33848005|NCT02138084|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848006|NCT06529510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848007|NCT03621631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848008|NCT03488303|||COHORT||PROSPECTIVE|||||||
33848009|NCT04461093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Potential patients are identified and consented for study during pre-operative assessment. Both patients and assessors are blinded in this trial.~Participants and assessors are being blinded of the treatment or medications given intra-operatively. The acupressure wristband and anti-emetics will be given after general anaesthesia. The wristband will be removed prior to emergence, participants will not aware of the methods used to prevent nausea and vomiting. Postoperative participants will be assessed by independent nurses who are not involved in the study."|Double blinded, Randomized Controlled Trial|t|t|t|t
33848010|NCT03113838|||COHORT||PROSPECTIVE|||||||
33848011|NCT04005573|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33952909|NCT00718146|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33952910|NCT00207025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952911|NCT05899933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The experimental protocol is designed as a double-blind, randomized clinical trial with a 12-month duration and a parallel design|t|f|t|f
33952912|NCT06329765|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pretest-posttest||||
33952913|NCT04029766|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33952914|NCT06566469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33952915|NCT00144859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33952916|NCT01160770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952917|NCT01841710|||COHORT||CROSS_SECTIONAL|||||||
33952918|NCT03054675|||CASE_CONTROL||PROSPECTIVE|||||||
33952919|NCT04551612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33952920|NCT01891227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952921|NCT04621227|NA|CROSSOVER||OTHER||NONE||Crossover||||
33952922|NCT00380861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952923|NCT05971732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33952924|NCT02793258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952925|NCT03179137|||CASE_ONLY||PROSPECTIVE|||||||
33952926|NCT04492488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952927|NCT04725214|NA|SINGLE_GROUP||TREATMENT||NONE||Adjuvant therapy with Anlotinib and Temozolomide for MGMT nonmethylated glioblastoma after concurrent chemo-radiotherapy||||
33952928|NCT01782638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744413|NCT00709722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744414|NCT03176693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744415|NCT05498259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744416|NCT05548595|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind|Randomization at 1:1 ratio for active or placebo|t|f|t|f
33744417|NCT04272450|||OTHER||CROSS_SECTIONAL|||||||
33744418|NCT03825380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33744419|NCT01227850|||CASE_ONLY|||||||||
33744420|NCT01384617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744421|NCT06635278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor will be blinded to the participants' group assignment||f|f|f|t
33744422|NCT02537912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33744423|NCT03943095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Examiner-Blind|Single center, 8-week, randomized, controlled, parallel design, exploratory clinical study in healthy participants with dentin hypersensitivity. Eligible participants will be stratified by the maximum Baseline Schiff sensitivity score of their two selected test teeth).|f|f|t|t
33952929|NCT05712603|||COHORT||PROSPECTIVE|||||||
33952930|NCT05564507|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33952931|NCT03504527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952932|NCT05647395|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33952933|NCT05981131|||OTHER||OTHER|||||||
33952934|NCT03740035|||COHORT||PROSPECTIVE|||||||
34057317|NCT06564948|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Preliminary effectiveness of FSJS+Navigator model on suicide severity and clinical outcomes using CAT-SS/MH, mental health, and mental health treatment/criminal legal outcomes will be assessed. Assessments occur at baseline, 1, 3, and 6 months, providing key statistics (distribution, correlation of outcome over time, missingness) needed to inform a fully-powered Hybrid II trial. Improvement in medically treated suicide attempts and CAT-SS indicators will be assessed over time using repeated measures ANOVA. This study is a non-experimental longitudinal design comparing treatment group (FSJS+Navigator) to 2 control groups (FSJS Only and Treatment As Usual). We will assess the following as moderators of intervention effects: sex, race/ethnicity, past suicide attempt, past behavioral health treatment, Area Deprivation index, mental health professional shortage area score, per capita incarceration, and other area-level social determinants of health variables using stratified and DDD models.|f|f|f|t
34057318|NCT05882838|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34057319|NCT06647914|||COHORT||PROSPECTIVE|||||||
34057320|NCT03958214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All interviews are conducted by research assistants who are blind to study condition.|Families are blocked within home visitor caseload and randomly assigned to receive the new curriculum or usual practice Early Head Start home visits for 12 weeks.|f|f|f|t
34057321|NCT06505915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34057322|NCT01275651|||CASE_ONLY||RETROSPECTIVE|||||||
34057323|NCT00247169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057324|NCT00962975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057325|NCT01612637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057326|NCT05012904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Randomization was done using the closed envelope method. A total of 60 cards with 30 parent involvement and 30 control labels were placed in sealed envelopes by the nurse who conducted the study. Children were asked to choose one of these envelopes and placed in the selected group. Children were randomized into two groups: a parent involvement group (n = 30) and a control group (n = 30)."||||
34057327|NCT01191775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057328|NCT02615015|||COHORT||CROSS_SECTIONAL|||||||
34057329|NCT00090987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057330|NCT04567927|||COHORT||PROSPECTIVE|||||||
34057331|NCT02161003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057332|NCT05189067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057333|NCT05455359|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34057334|NCT04247464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057335|NCT03079791|||CASE_ONLY||PROSPECTIVE|||||||
34057336|NCT02742116|||COHORT||PROSPECTIVE|||||||
34057337|NCT00534885|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34057338|NCT01662921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057339|NCT06648174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057340|NCT05330273|NA|SEQUENTIAL||TREATMENT||NONE||||||
34057341|NCT00090701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057342|NCT00176644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057343|NCT03332420|||COHORT||PROSPECTIVE|||||||
34057344|NCT05581498|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34057345|NCT03585153|||COHORT||PROSPECTIVE|||||||
34057346|NCT00004087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161414|NCT06397105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All instruments and questions of the screening and baseline assessment will be assessed as an assisted self-assessment in the presence of a trained assessor fluent in the participant's mother tongue blind to the allocation status of the participants.The follow-up assessments are administered either as an online self-assessment, as an assisted online self-assessment or as an self-assessment in presence. In either case, the trained assessors are blind to the allocation status.|The pilot RCT will inform us about the feasibility of PM+ under usual practice conditions.|f|f|f|t
34161415|NCT05674019|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Neurodevelopemental Group Non-neurodevelopmental Group||||
34161416|NCT05154656|||COHORT||PROSPECTIVE|||||||
34161417|NCT06079021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Application of CytoSorb treatment to ACLF patients||||
34161418|NCT02227667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161419|NCT01588665|||CASE_ONLY||PROSPECTIVE|||||||
34161420|NCT05160870|||COHORT||PROSPECTIVE|||||||
34161421|NCT06113055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161422|NCT05035732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952935|NCT02450929|||OTHER||PROSPECTIVE|||||||
33952936|NCT05878496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952937|NCT00759369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057347|NCT04888403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057348|NCT00978939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161423|NCT00000355||||TREATMENT||||||||
34161424|NCT04759105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization result will be a treatment code. The treatment code of the patient will be transmitted to local pharmacy. Blinding or masking will be carried out at all stages of packaging and conditioning for shipping following the treatment allocation. Injections used for all groups will be clear and indistinguishable from each other.|Patients will be randomized in 2 arms of 26 patients and followed up for 12 months.|t|t|f|t
34161425|NCT05391633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|NICU Investigator will provide the intervention versus placebo, with subject identification unlinked to randomization status. EEG reader, qEEG pruner and qEEG analyst will remain blinded to subject allocation until all data is extracted from each subject's EEG and medical record. To further prevent bias, group assignment unidentified as to control versus intervention will be maintained until all statistical analysis is complete.|Crossed design, between-group and within-group pre- and post-intervention changes in primary variable.|f|f|t|t
34057349|NCT06311435|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients will be assigned a random number from the electronic health record. The only information shared with the sponsor will be Pt ID number, age, gender and state of residence.|Participants will be placed into one of fourteen possible cohorts based on their presenting complaints.|t|f|f|f
34161426|NCT06226038|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34161427|NCT00284700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34161428|NCT02625844|||CASE_CONTROL||PROSPECTIVE|||||||
34057350|NCT03558152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161429|NCT01332383|||||PROSPECTIVE|||||||
34057351|NCT01301781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161430|NCT01318408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161431|NCT05158517|||COHORT||PROSPECTIVE|||||||
34161432|NCT01302353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161433|NCT05908903|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34161434|NCT00955539|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34161435|NCT00939536|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34161436|NCT01550809|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34161437|NCT05233592|||COHORT||PROSPECTIVE|||||||
34057352|NCT01248169|||||PROSPECTIVE|||||||
34057353|NCT06492265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057354|NCT00784238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057355|NCT00567385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057356|NCT05320718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057357|NCT05821296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057358|NCT03061201|NA|SEQUENTIAL||TREATMENT||NONE|Open Label|Dose selection based on safety and kinetics of circulating FVIII levels observed in previously dosed participants.||||
34057359|NCT06623838|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057360|NCT00869284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057361|NCT04178642|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective multi-center phase II, randomized, unmasked comparative study (ratio 1:1), evaluating the efficacy of an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin-Lipiodol (experimental group) after percutaneous tumor ablation of hepatocellular carcinoma of size less than 3 cm, versus the absence of adjuvant treatment (standard group), on hepatic recurrence at 1 year.~It is planned to include 138 patients with hepatocellular carcinoma (CHC) less than 3 cm, non-metastatic, with cirrhosis graded A / B7 on Child Pugh scoring system, and receiving treatment by percutaneous tumor destruction."||||
34057362|NCT03775122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057363|NCT05973019|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects receive 12 times rTMS intervention||||
34057364|NCT03384784|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34161438|NCT00270309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161439|NCT04847934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34161440|NCT05681494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161441|NCT05726006|||CASE_ONLY||PROSPECTIVE|||||||
34161442|NCT05697562|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided in 2 groups: Anticoagulation group (A) and No Anticoagulation group (NA), based on their regular medication. In both groups, A and NA, are 2 study arms, resp. DG HAL as standard clinical practice versus SRAE (group A) and RBL as standard clinical practice versus SRAE (arm NA). See figure below.||||
34161443|NCT06050694|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34161444|NCT05195658|||COHORT||PROSPECTIVE|||||||
34057365|NCT00220324|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34057366|NCT03020875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057367|NCT03653351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057368|NCT04818385|||COHORT||PROSPECTIVE|||||||
34057369|NCT04384861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because the SMART training \& Focus Groups were done in groups, ACTIVE participants were not masked from each other or the Investigators. Because the CONTROL participants did not attend any in-person meetings, they were masked from each other, the ACTIVE participants and the Investigator.|Physician volunteers were first divided by gender and then randomly assigned to either the CONTROL (no SMART Wellness training) or ACTIVE (received SMART Wellness training) arms of the study.|t|f|f|f
34161445|NCT05708456|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33952938|NCT03299439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952939|NCT06542809|NA|SINGLE_GROUP||SCREENING||NONE||||||
33952940|NCT06515639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952941|NCT04082416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33952942|NCT06174922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952943|NCT06653920|||COHORT||RETROSPECTIVE|||||||
33952944|NCT02500173|||OTHER||PROSPECTIVE|||||||
33952945|NCT06002828|||COHORT||PROSPECTIVE|||||||
33952946|NCT03583801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952947|NCT01351324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33952948|NCT02320734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33952949|NCT01103076|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33952950|NCT04451512|||COHORT||PROSPECTIVE|||||||
33952951|NCT00226447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952952|NCT01366846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952953|NCT01280760|||COHORT||PROSPECTIVE|||||||
33952954|NCT00288782|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33952955|NCT06452862|||COHORT||PROSPECTIVE|||||||
33952956|NCT06651463|NA|SINGLE_GROUP||OTHER||NONE||||||
33952957|NCT04656249|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are confirmed with biliary tract cancers by imaging and histological examination and meet with the inclusive criteria, including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, common bile duct cancer and gallbladder cancer.||||
33952958|NCT01473537|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33952959|NCT04633434|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Behavioral (e.g., Psychotherapy, Lifestyle Counseling) In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.||||
33952960|NCT02452775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952961|NCT02088866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952962|NCT02513095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952963|NCT01607437|||CASE_ONLY||RETROSPECTIVE|||||||
33952964|NCT00681876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952965|NCT02477462|||CASE_CONTROL||PROSPECTIVE|||||||
33952966|NCT05562232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33952967|NCT05488067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952968|NCT05805072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952969|NCT02188927|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33952970|NCT05925478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952971|NCT01113073|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952972|NCT02586909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952973|NCT03735680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33952974|NCT01151709|||COHORT||CROSS_SECTIONAL|||||||
33952975|NCT02599298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952976|NCT01357382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952977|NCT02258958|||COHORT||PROSPECTIVE|||||||
33952978|NCT05568875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only investigator conduction the analyses will be blinded to group allocation|Multicenter randomized controlled trial with a qualitative study nested within the trial|f|f|t|f
33952979|NCT01826201|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33952980|NCT06111976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33952981|NCT05837884|NA|SINGLE_GROUP||SCREENING||NONE||||||
33952982|NCT01721941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33952983|NCT01369836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33952984|NCT04930484|||OTHER||CROSS_SECTIONAL|||||||
33952985|NCT03383302|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, phase Ib/II open label study of nivolumab administered on completion of SBRT to patients with early stage NSCLC.||||
33952986|NCT04028531|||OTHER||OTHER|||||||
33952987|NCT06234683|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized 1:1 to receive either a web-based educational video about pneumococcal vaccination and a reminder email to be vaccinated or a reminder email alone.|f|f|t|f
33952988|NCT01284842|||CASE_ONLY||CROSS_SECTIONAL|||||||
33952989|NCT02415634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952990|NCT03340246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33952991|NCT05543226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33952992|NCT00212446|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33952993|NCT03209154|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33952994|NCT00702975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33952995|NCT00623441|||COHORT||PROSPECTIVE|||||||
33952996|NCT03741335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessors will be masked to the participants assigned study arm. Participants will not be formally masked from knowing whether or not they are assigned to an experimental or control group, but every effort will be made not to overemphasize expected outcomes.|3-group, single-blind, parallel design randomized controlled trial|f|f|f|t
33952997|NCT00463593|||COHORT||PROSPECTIVE|||||||
33952998|NCT01207219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33952999|NCT05726110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953000|NCT06536894|||OTHER||CROSS_SECTIONAL|||||||
33953001|NCT01327066|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33953002|NCT05131152|RANDOMIZED|PARALLEL||TREATMENT||NONE||The recruitment of subjects must meet the diagnosis criteria of DEWS.||||
33953003|NCT01222962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953004|NCT06652620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33953005|NCT00314847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953006|NCT03864510|||COHORT||PROSPECTIVE|||||||
33953007|NCT01068418|NA|SINGLE_GROUP||OTHER||NONE||||||
33953008|NCT01894542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953009|NCT02130648|||CASE_ONLY||PROSPECTIVE|||||||
33953010|NCT03815227|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33953011|NCT06566144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)||t|f|t|t
33953012|NCT04434534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33953013|NCT00566397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953014|NCT01664260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953015|NCT01042691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953016|NCT02114866|||CASE_ONLY||PROSPECTIVE|||||||
33953017|NCT03096106|||CASE_ONLY||PROSPECTIVE|||||||
33953018|NCT06018363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953019|NCT02702375|||COHORT||PROSPECTIVE|||||||
33848012|NCT04903730|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Only Parts A, B and BD of the study will be double blinded. The Sponsor, PI and their designee/s, MM, study personnel, and participants are not to make any effort to determine which IP therapy is being received. Unmasked pharmacy personnel will be used in this study to prepare the IP.|"This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult volunteers. This study consists of 3 parts and an optional fourth part:~* Part A: double-blind, placebo-controlled, single ascending dose (SAD).~* Part B: double-blind, placebo-controlled, multiple ascending dose (MAD).~* Part C (optional): open-label, single-dose, crossover. The decision to proceed with Part C will be made by the Sponsor after reviewing unblinded safety and PK data from Part D of the study.~* Part D: double-blind, placebo-controlled, 5 mg single dose (SD) followed by a twice daily (BID) 5 mg dose (total daily dose of 10 mg) of AER-901 in a propylene glycol formulation vs. placebo."|t|t|t|f
34057370|NCT01668966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057371|NCT05028413|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057372|NCT06620328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057373|NCT05153148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment and randomization information will be kept confidential and will not be released to the investigator, the study staff, the contract research organization (CRO), or the sponsor's study team until after the conclusion of the study.||t|f|t|f
34057374|NCT05342922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant,Investigator, Outcomes Assessor)|Parallel Assignment Allocation: Randomized Intervention Model: Parallel Assignment|t|f|t|t
33744424|NCT03792113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study design follows a double blinded design where the investigator and the outcome assessor are unaware of the intervention to the subject|Patients diagnosed with periodontitis, in the age group of 18 to 60 years with good systemic health and presence of a minimum of 3 teeth with periodontal pocket depth (PPD) of ≥6mm and clinical attachment level (CAL) of ≥5mm|f|f|t|t
33744425|NCT00198640|NON_RANDOMIZED|PARALLEL||ECT||NONE||||||
33744426|NCT06309147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo|Double blind, parallel, 3-arm, placebo controlled|t|t|t|t
33744427|NCT03839381|||CASE_ONLY||PROSPECTIVE|||||||
33744428|NCT03850119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient, investigator, outcome assessor will be blinded for which side of the scar was treated and which was a control. Only the surgeon, who will not be involved in the assessment, will not be blinded.|monocentric randomized controlled double-blinded prospective interventional study|t|t|t|t
33744429|NCT00244075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744430|NCT02014116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744431|NCT02756624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744432|NCT03535649|||COHORT||OTHER|||||||
33953020|NCT00959075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953021|NCT02435875|||COHORT||PROSPECTIVE|||||||
33953022|NCT06537336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The patients in the treatment group underwent aerobic and volumetric incentive spirometry breathing exercises. The control group performed only aerobic exercise. The aerobic exercise program was conducted over 8 weeks using a stationary bicycle. Patients were initially selected based on the inclusion and exclusion criteria, and informed consent was obtained. Before and after the intervention, lung function tests using spirometry and QoL measurements were conducted using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 (EORTC-QLQ-C30).|t|f|f|f
33953023|NCT03028077|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33953024|NCT03226574|NA|SEQUENTIAL||TREATMENT||NONE||"The design uses a traditional 3+3 rule-based design that does not stipulate any prior assumption of the dose-toxicity curve. Dose escalation is permitted between successive cohorts based upon a specified algorithm, using discrete dosage steps."||||
33953025|NCT03520582|||COHORT||OTHER|||||||
33953026|NCT01611285|||OTHER||OTHER|||||||
33953027|NCT03917654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33953028|NCT01652807|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953029|NCT03668743|||CASE_CONTROL||RETROSPECTIVE|||||||
33953030|NCT01612988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953031|NCT04914234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953032|NCT06192069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33953033|NCT06571955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953034|NCT06246331|||CASE_ONLY||RETROSPECTIVE|||||||
33953035|NCT04518449|||COHORT||PROSPECTIVE|||||||
33953036|NCT05857501|||COHORT||PROSPECTIVE|||||||
33953037|NCT03948646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953038|NCT03197506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057375|NCT00459706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057376|NCT01993498|NA|SINGLE_GROUP||OTHER||NONE||For each patient, in addition to standard medical follow-up collected at selection, and yearly after acute treatment cancer phase during 5 years, the CANTO-specific follow-up includes 16 patient-reported questionnaires.||||
34057377|NCT03777813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057378|NCT00732758|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34057379|NCT00514826|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34057380|NCT06622694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057381|NCT05922319|||COHORT||RETROSPECTIVE|||||||
34057382|NCT01585350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057383|NCT05662293|||COHORT||PROSPECTIVE|||||||
34057384|NCT01995175|NA|SINGLE_GROUP||OTHER||NONE||||||
34057385|NCT03783234|||COHORT||PROSPECTIVE|||||||
34057386|NCT02413242|||COHORT||PROSPECTIVE|||||||
34057387|NCT02983435|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34057388|NCT01828333|||||PROSPECTIVE|||||||
34057389|NCT05535751|||CASE_ONLY||RETROSPECTIVE|||||||
34057390|NCT05588869|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057391|NCT00645281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057392|NCT04833725|||COHORT||PROSPECTIVE|||||||
34057393|NCT03242174|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34057394|NCT02461524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057395|NCT05297084|||COHORT||PROSPECTIVE|||||||
33953039|NCT04529941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will not be aware whether the ScNS is turned on or off. However, after three weeks from the initial surgery, control subjects that decide to the second procedure will be aware of what group they were randomized to.|"Patients will have a 1:1 randomization to receive subcutaneous electrical nerve stimulation (ScNS) to observe if the stimulation can reduce atrial fibrillation burden in patients with symptomatic atrial fibrillation (AF). All subjects will undergo the implant of a neurostimulator lead.~The experimental group will receive stimulation and the control group will not receive stimulation. All subjects will complete the same follow up visits comparing the 2 groups. The control group will have an option to cross over to the experimental group 3 weeks post-randomization to receive the stimulation. They will repeat the baseline visit, procedure visit and all follow-up visits post-procedure."|t|f|f|f
33953040|NCT05993299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953041|NCT02325414|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953042|NCT06611085|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled study||||
33953043|NCT04059055|||OTHER||PROSPECTIVE|||||||
33953044|NCT03744494|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient, unaware of which surgery was done, would grade the scrotal appearance three months afterwards|Three groups of patients subjected to a type of orchidectomy each|t|f|f|f
33953045|NCT02017782|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34057396|NCT00881439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057397|NCT06598384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057398|NCT03136341|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Videos will be randomly provided to an outside assessor to determine benefit as a secondary outcome measure|Participants are randomized to receive either study drug or placebo at the initial phase and cross over 12 weeks later and receive the alternative treatment|t|f|t|t
34057399|NCT05454384|||COHORT||RETROSPECTIVE|||||||
34057400|NCT01451944|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34057401|NCT03166540|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Sample codification, done by the PI, will be hidden to the researchers analysing the samples.||f|f|f|t
34057402|NCT01644526|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34057403|NCT04691817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057404|NCT03047720|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057405|NCT00811824|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34057406|NCT06559384|||CASE_ONLY||PROSPECTIVE|||||||
34057407|NCT04458025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057408|NCT01381991|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34057409|NCT03347734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants do not have information about treatment content and groups. He is only aware of exercise therapy applied to him.The ophthalmologist performed evaluations without knowledge of the groups in which the participants were included and of exercise therapy administered.|Randomized Controlled Double-Blind Study|t|f|f|t
34057410|NCT04631328|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057411|NCT04605380|||OTHER||RETROSPECTIVE|||||||
34057412|NCT02918903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057413|NCT01203826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057414|NCT02089334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057415|NCT03338595|||COHORT||PROSPECTIVE|||||||
34057416|NCT00065650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057417|NCT05492487|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised into either the megace group or the Mirena group. There will be sealed envelopes containing a paper with either Mirena or megace printed on each of them. Participants can chose an envelope at random. The patient and PI will not be blinded of the selection in the study.||||
34057418|NCT06649461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057419|NCT03364764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057420|NCT06213896|||CASE_ONLY||PROSPECTIVE|||||||
34057421|NCT01862939|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34057422|NCT03665961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057423|NCT06618508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057424|NCT01373112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057425|NCT02817516|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34057426|NCT04159649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057427|NCT06622733|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057428|NCT06302842|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34057429|NCT05435625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057430|NCT03136458|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parallel assignment|t|f|t|f
34057431|NCT04342741|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The patients were randomised to cervical ripening with foley catheter as inpatient or outpatient setting.||||
34057432|NCT05427318|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057433|NCT00827749|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057434|NCT05614778|||CASE_ONLY||PROSPECTIVE|||||||
34057435|NCT06195631|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057436|NCT06298695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A multicenter parallel group randomized controlled clinical intervention trial|f|f|f|t
34057437|NCT04085224|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34057438|NCT06098417|||COHORT||PROSPECTIVE|||||||
34057439|NCT05072964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057440|NCT04780516|||COHORT||PROSPECTIVE|||||||
33953046|NCT06542679|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The planned study will be a single-blind trial. Due to the nature of the study, blinding of the researcher will not be possible, but participant blinding and statistician blinding will be implemented. During the data analysis phase, the statistical unit will perform the analyses without knowing which data belong to the intervention group and which belong to the control group. This will ensure the blinding of the statistician.|This study is designed as a single-blind parallel group randomized controlled trial with the aim of developing a mobile health application based on the Information-Motivation-Behavioral Skills (IMB) Model and Social Cognitive Theory for gestational weight management, and to examine the effect of the mobile application on weight management during pregnancy.|t|f|f|f
33953047|NCT03996694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33953048|NCT01198327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953049|NCT03286530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953050|NCT05592704|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33953051|NCT01448226|||CASE_CONTROL||RETROSPECTIVE|||||||
33744433|NCT03110289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||We will randomly allocate 108 patients with active ulcerative colitis (Mayo score 4-10, endoscopic Mayo score 2 or 3) in a 1:1 ratio, using a pre-established randomization list, to either 'superdonor' faecal microbiota transplantation or autologous fecal microbiota transplantation (=sham)|t|t|t|t
33953052|NCT04374136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953053|NCT01489306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953054|NCT05584202|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Part 1: open-label Part 2: observer-blinded, randomized, placebo-controlled|Part 1: sequential Part 2: parallel|t|t|t|t
33953055|NCT05429112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33953056|NCT03696537|NA|SEQUENTIAL||TREATMENT||NONE||"Standard 3+3 phase I design of dose escalation using 3 patients per dose level cohort with an expansion to 6 patients at the MTD will be used in Phase I. We will treat 3 patients at the initial dose level of TMI. If no dose-limiting toxicity (DLT) is observed, the next cohort of three patients is treated at the next higher dose level. If 1 of the 3 patients demonstrates DLT, an additional 3 patients are treated at that dose level. If only 1 of the 6 shows DLT, the next cohort of three patients is entered at the next dose level. If 2 or more of the 6 demonstrate DLT, the MTD is defined as the previous dose level. If no DLT is observed in the final dose level, the number of patients treated will be expanded to 6. In phase II, we will enroll additional patients at the defined MTD level.~\*Stopping criteria was met during the first dose level cohort in Phase l. The trial will not continue into Phase II as originally planned."||||
33953057|NCT06474260|NA|SINGLE_GROUP||TREATMENT||NONE||"A prospective dual site intervention in India addressing mental health issues amongyoung adults. The study will consist of three phases.~Phase 1 will utilize a case study research design to explore and describe theparticipatory methods used for introduction of One All.~Phase 2 will utilize a mixed methods study design to evaluate facilitator trainingcomponents of One All implementation and intervention.~Phase 3 will utilize a pre-post study design to evaluate the intervention for intendedoutcomes at the end of Year 1."||||
33953058|NCT05940558|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953059|NCT01763125|||CASE_CONTROL||OTHER|||||||
34057441|NCT02987972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34057442|NCT02706886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057443|NCT04612881|||CASE_CONTROL||PROSPECTIVE|||||||
34057444|NCT01893580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34057445|NCT05995886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057446|NCT06622460|NA|SINGLE_GROUP||OTHER||NONE||||||
34057447|NCT00124202|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||f|t|t|t
34057448|NCT05093426|||COHORT||PROSPECTIVE|||||||
34057449|NCT03031574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057450|NCT05818358|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34057451|NCT03584464|NA|SINGLE_GROUP||OTHER||NONE||||||
34161446|NCT01499615|||CASE_ONLY||PROSPECTIVE|||||||
34161447|NCT06070935|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34161448|NCT02511886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161449|NCT00190723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161450|NCT03778450|||COHORT||RETROSPECTIVE|||||||
34161451|NCT00701272|||CASE_CONTROL||PROSPECTIVE|||||||
34161452|NCT01478334|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161453|NCT01928641|||CASE_ONLY||PROSPECTIVE|||||||
34161454|NCT05300776|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33744434|NCT06535360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744435|NCT06380192|||COHORT||CROSS_SECTIONAL|||||||
33744436|NCT06240312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744437|NCT00424437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744438|NCT06635980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744439|NCT04837365|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744440|NCT01552044|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33744441|NCT02169908|NA|SINGLE_GROUP||||NONE||||||
33744442|NCT00855517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744443|NCT02459067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744444|NCT05458921|||COHORT||RETROSPECTIVE|||||||
33744445|NCT01545011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744446|NCT01492881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744447|NCT06193421|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm study using ambroxol in newly diagnosed patients with motor Parkinson's disease.||||
33744448|NCT04907240|||COHORT||PROSPECTIVE|||||||
34161455|NCT01921504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161456|NCT04740775|RANDOMIZED|PARALLEL||OTHER||NONE||2-arm, non-comparative, open-label, prospective study||||
34161457|NCT03218436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161458|NCT01990963|||COHORT||PROSPECTIVE|||||||
34161459|NCT02597725|||COHORT||PROSPECTIVE|||||||
34161460|NCT02901418|||CASE_CONTROL||PROSPECTIVE|||||||
34161461|NCT02210858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161462|NCT05524584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161463|NCT00863499|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953060|NCT06168084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953061|NCT06652464|||CASE_CONTROL||PROSPECTIVE|||||||
34161464|NCT06407284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848013|NCT04277351|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|One of three different tACS conditions is administered to all participant during three experimental days. The conditions differ in the frequency of stimulation (condition 1 and 2) and in whether the stimulation is active or faked (sham). The order of the three stimulation conditions is counterbalanced across participants, who are not aware of which tACS condition they are undergoing.||t|f|f|f
33848014|NCT05438628|||COHORT||PROSPECTIVE|||||||
33953062|NCT04281849|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848015|NCT05026762|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33953063|NCT04867486|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33953064|NCT02149277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953065|NCT01412294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848016|NCT06285279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848017|NCT05648604|NA|SINGLE_GROUP||OTHER||NONE||||||
33848018|NCT01171807|RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding procedures were applicable in this study which was designed as an open one.|||||
33953066|NCT00299949|||CASE_ONLY||PROSPECTIVE|||||||
33953067|NCT00285259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953068|NCT04354740|||COHORT||PROSPECTIVE|||||||
33953069|NCT05497219|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33953070|NCT06593574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953071|NCT04174443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953072|NCT01876927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953073|NCT00840762|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33953074|NCT05635929|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Open Label|Single group, interventional, open-label study.||||
33953075|NCT00981565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953076|NCT02346071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953077|NCT01754012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953078|NCT04993937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33953079|NCT01682681|||COHORT||PROSPECTIVE|||||||
33953080|NCT03727113|||CASE_CONTROL||PROSPECTIVE|||||||
33953081|NCT03872908|||COHORT||PROSPECTIVE|||||||
33953082|NCT03899220|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot Randomized Controlled Trial||||
33953083|NCT02940392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953084|NCT04796168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33953085|NCT04583592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953086|NCT03954899|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33953087|NCT01329562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953088|NCT05259059|||COHORT||PROSPECTIVE|||||||
33953089|NCT00040001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953090|NCT01467518|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33953091|NCT06426316|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33953092|NCT02632448|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33953093|NCT03479619|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33953094|NCT04798430|NA|SINGLE_GROUP||TREATMENT||NONE|lipids blinded to participant, investigator and sponsor at Day 1 only|open label extension trial||||
34161465|NCT02717494|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953095|NCT00679042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953096|NCT01751659|||COHORT||PROSPECTIVE|||||||
33953097|NCT01389856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953098|NCT05662319|NA|CROSSOVER||TREATMENT||NONE||One way cross-over||||
33953099|NCT01967511|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33953100|NCT01071278|||||PROSPECTIVE|||||||
34161466|NCT04082715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161467|NCT04639024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161468|NCT01105000|||COHORT||CROSS_SECTIONAL|||||||
33953101|NCT02364882|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34161469|NCT06453681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized controlled study|t|t|t|t
34161470|NCT05277558|||CASE_CONTROL||PROSPECTIVE|||||||
34161471|NCT05833997|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161472|NCT01295593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161473|NCT04136730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161474|NCT01895595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34161475|NCT05294224|||CASE_ONLY||PROSPECTIVE|||||||
33848019|NCT01960777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848020|NCT01131182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848021|NCT03712904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848022|NCT02879929|||COHORT||PROSPECTIVE|||||||
33848023|NCT04090255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33953102|NCT03038165|||COHORT||PROSPECTIVE|||||||
33953103|NCT03252665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953104|NCT04889378|||COHORT||PROSPECTIVE|||||||
33953105|NCT03644927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953106|NCT04359758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161476|NCT04334993|NA|SINGLE_GROUP||TREATMENT||NONE|NR|This is a national, multicenter, phase II clinical trial||||
34161477|NCT02549001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161478|NCT01520376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34161479|NCT05682976|||COHORT||PROSPECTIVE|||||||
34161480|NCT00644488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161481|NCT06476353|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34161482|NCT00002203||PARALLEL||TREATMENT||||||||
34161483|NCT01947764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161484|NCT04276519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants didn't know in which group they were allocated.|Experimental group and a control group. Prospective, randomised, clinical study.|t|f|f|f
34161485|NCT02317848|NA|SINGLE_GROUP||SCREENING||NONE||||||
34161486|NCT01828229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34161487|NCT00387634|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34161488|NCT06422689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161489|NCT03450954|||CASE_CONTROL||RETROSPECTIVE|||||||
34161490|NCT00265317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161491|NCT01867502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161492|NCT05932225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161493|NCT02444052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161494|NCT06056557|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, interventional clinical study to determine the safety and efficacy in using BWI IRE ablation system in a variety of atrial arrhythmias. All patients will receive the intervention.||||
34161495|NCT05154253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161496|NCT06486896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744449|NCT02023385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744450|NCT05466318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744451|NCT02657278|NA|SINGLE_GROUP||SCREENING||NONE||||||
33744452|NCT03068403|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744453|NCT01776645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744454|NCT01989481|||COHORT||PROSPECTIVE|||||||
33744455|NCT05870098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Laboratory staff will be masked and will not be able to link pooled samples (sent under a unique study number) to comparator standard care separate samples (sent under a unique patient identifier).|Diagnostic accuracy study Single group receiving standard care plus two new comparators||||
33744456|NCT00345774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33744457|NCT05234138|||COHORT||PROSPECTIVE|||||||
33744458|NCT02337647|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744459|NCT00836823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744460|NCT03043664|NA|SINGLE_GROUP||TREATMENT||NONE||Keytruda (pembrolizumab) 200 mg intravenous (IV) infusion every 3 weeks and Somatuline Depot (lanreotide) 90 mg subcutaneous (SQ) injection every 3 weeks.||||
33744461|NCT01151670|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33744462|NCT00001214|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744463|NCT02357212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161497|NCT02347306|||||RETROSPECTIVE|||||||
34161498|NCT00830466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161499|NCT05584280|||COHORT||PROSPECTIVE|||||||
34161500|NCT06304623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161501|NCT01060852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161502|NCT06168682|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized single centre trial||||
34161503|NCT02369913|||COHORT||PROSPECTIVE|||||||
34161504|NCT04672733|||COHORT||PROSPECTIVE|||||||
34161505|NCT00531635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161506|NCT05518357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161507|NCT03987516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161508|NCT01255098|||CASE_CONTROL|||||||||
33848024|NCT01620268|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848025|NCT06438497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848026|NCT02704754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848027|NCT05108129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blocks will be administered after induction of general Anesthesia so participants will be blinded to which intervention they have had.~Study investigators will not be aware of what group the participant belongs to when assessing the patient at post-operative period"|Parallel Assignment Allocation: Randomized Intervention Model: Parallel Assignment|t|t|t|t
33848028|NCT00072228||||TREATMENT||||||||
33848029|NCT00925132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848030|NCT05210751|||OTHER||CROSS_SECTIONAL|||||||
33848031|NCT01462032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33848032|NCT03306017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33848033|NCT06363396|||COHORT||PROSPECTIVE|||||||
33848034|NCT03007446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848035|NCT00209196|||CASE_ONLY||PROSPECTIVE|||||||
33848036|NCT00874692|RANDOMIZED|PARALLEL||||NONE||||||
33848037|NCT06610253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33848038|NCT06610565|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 randomization into two arms: one intervention, where will receive nutritional counseling and the study diet for 5 days each month for 6 months, and a control one, where they will receive only nutritional counseling.||||
33848039|NCT06055790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848040|NCT04224337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848041|NCT00899782|||CASE_ONLY||PROSPECTIVE|||||||
33848042|NCT02866097|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33848043|NCT00457860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848044|NCT04615884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33848045|NCT03810768|||COHORT||PROSPECTIVE|||||||
33848046|NCT02368028|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848047|NCT02864030|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33848048|NCT03705832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind placebo controlled|t|t|t|t
33848049|NCT05120726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953107|NCT06650826|||CASE_ONLY||PROSPECTIVE|||||||
33953108|NCT04748549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors of the Confusion Assessment Method (CAM) and Montreal Cognitive Assessment (MoCA) will be blinded to group assignment.|"Research participants will be randomized to one of three groups (2:2:1 allocation):~1. Immersive VR group~2. Music group~3. Sham VR + usual care control~The first 6 patients enrolled will be assigned to the VR group for the purposes of a pilot phase with the objective of identifying and refining any issues with the intervention. Data for these patients will not be included in the statistical analysis."|f|f|f|t
33953109|NCT03885349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33953110|NCT01456351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953111|NCT02738606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953112|NCT04279483|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigator will not know the condition assignment of individual participants unless reassessment is triggered by the stopping rule.|Random assignment of retail environment (7-11, CVS, control \[no store\]) to visit 5 times per week during the 4-week intervention period|f|f|t|f
33953113|NCT03187639|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||FORECAST is a randomised controlled trial comparing 1400 patients with new onset pain who are assigned to either routine assessment or FFRct assessment (n=700 per group)||||
33953114|NCT05636618|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors||||
33953115|NCT05661903|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33953116|NCT02973789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953117|NCT04241081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33953118|NCT02131753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161509|NCT00279916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161510|NCT00649428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161511|NCT01551849|||CASE_ONLY||PROSPECTIVE|||||||
34161512|NCT03213288|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34161513|NCT02952833|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34161514|NCT00696046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161515|NCT01887184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161516|NCT01961622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848050|NCT04662853|||OTHER||PROSPECTIVE|||||||
33848051|NCT05680844|||COHORT||CROSS_SECTIONAL|||||||
33848052|NCT03678428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848053|NCT05573867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848054|NCT04801121|||CASE_CONTROL||PROSPECTIVE|||||||
33848055|NCT04339530|||OTHER||CROSS_SECTIONAL|||||||
33848056|NCT02905136|||COHORT||PROSPECTIVE|||||||
33848057|NCT00423943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848058|NCT05198895|NA|SINGLE_GROUP||SCREENING||NONE||Screening among individuals with or without known diabetes||||
33848059|NCT02818725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848060|NCT02682277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848061|NCT05792358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848062|NCT02812693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848063|NCT02234973|||CASE_ONLY||PROSPECTIVE|||||||
33848064|NCT04074759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Two arm trial with multiple cohorts||||
33848065|NCT05541510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants who are confirmed for SARS-CoV-2 infection by PCR with CT values ≤28 will be randomized (1:1:1) and received AD17002 0 (placebo), 20 or 40 μg via intranasal route on Day 1, 3 and 5.|t|t|t|t
33848066|NCT02387229|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848067|NCT05866068|||COHORT||PROSPECTIVE|||||||
33848068|NCT00001689||||TREATMENT||||||||
33953119|NCT05679193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||parallel-group, phase 2, double-blind, 2-arm study|t|t|t|f
33848069|NCT03572387|RANDOMIZED|PARALLEL||TREATMENT||NONE||ll study enrollees will receive Lupron. After one month, they will be assigned in a 1:1 randomization to either the '5-AZA+ATRA' group or the 'delay therapy' group. Patients in the '5-AZA + ATRA' group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles. In the 'no therapy' group, patients will initially be observed for 3 cycles and then receive treatment for 3 cycles, in the absence of prohibitive toxicities. After the treatment period, all patients will be followed for up to 24 months from the start of the study or until the events leading to discontinuation are observed.||||
33848070|NCT03989518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33848071|NCT00130260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848072|NCT05379478|||COHORT||PROSPECTIVE|||||||
33848073|NCT03803124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33848074|NCT02274571|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33848075|NCT02155491|||COHORT||PROSPECTIVE|||||||
33848076|NCT04242836|||COHORT||PROSPECTIVE|||||||
33848077|NCT04375332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848078|NCT06460753|||COHORT||RETROSPECTIVE|||||||
33848079|NCT06100003|||COHORT||PROSPECTIVE|||||||
33848080|NCT04700332|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33848081|NCT05608187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study, and the allocation of treatments will not be disclosed to subjects, Investigator or Independent Evaluators until database lock after all subjects (who were not withdrawn) completed Week 26.||t|t|t|t
33848082|NCT00569101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848083|NCT03056989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33848084|NCT05444218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848085|NCT00214578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953120|NCT02594254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953121|NCT00000667||||PREVENTION||NONE||||||
33953122|NCT05848518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33953123|NCT00761735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953124|NCT03713125|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33953125|NCT05278624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Identical tubes will be dispensed numerically with 50% containing vehicle and 50% containing vehicle plus active|Single site double blind vehicle controlled|t|f|t|f
33953126|NCT03958045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953127|NCT06650735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33953128|NCT03337373|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33953129|NCT04517630|||COHORT||PROSPECTIVE|||||||
33953130|NCT05186974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953131|NCT04998396|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161517|NCT04355208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848086|NCT04351568|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33848087|NCT04319523|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848088|NCT01895101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848089|NCT04848077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848090|NCT00581555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953132|NCT00024557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953133|NCT06085586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953134|NCT06652841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953135|NCT01556490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953136|NCT03277859|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will be block randomized in a stratified manner to SAA-TBI or a waitlist using a 1:1 ratio. The waitlist group will initially receive 8 weeks of enhanced treatment as usual (ETU).|f|f|f|t
33953137|NCT04027634|RANDOMIZED|PARALLEL||OTHER||SINGLE|The data of the five metabolic indexes, height, and BW were collected by a research assistant.|The participants were divided into experimental and control groups through block randomization.|t|f|f|f
33953138|NCT03146819|||CASE_CONTROL||OTHER|||||||
33953139|NCT00870415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953140|NCT04125498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The gynecologist, the radiologist and the statistician will be blinded to group allocation.~Participants will have similar manual treatments."|randomized triple-blinded|t|f|t|t
33953141|NCT00616304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33953142|NCT03352544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953143|NCT00323362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953144|NCT00004454||||TREATMENT||||||||
33953145|NCT02328170|||COHORT||CROSS_SECTIONAL|||||||
33953146|NCT03994991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will be randomized to active TMS vs sham TMS groups with approximately a 2:1 ratio. At the end of the study, the investigators expect 24 patients to have active TMS and 12 patients to have sham TMS sessions.~Patients in the sham TMS group will have appointments at the same time as the active TMS patients. The TMS device used for the sham TMS group patients will be identical to the active TMS group. Only the stimulation will be different."||t|f|f|t
33953147|NCT04999137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057452|NCT03144752|||COHORT||PROSPECTIVE|||||||
34057453|NCT01544608|||CASE_ONLY||RETROSPECTIVE|||||||
34057454|NCT05976685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057455|NCT00897962|||OTHER||OTHER|||||||
34057456|NCT01323413|||COHORT||RETROSPECTIVE|||||||
34057457|NCT02973334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34057458|NCT05108142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34057459|NCT02222363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057460|NCT00006066||||TREATMENT||||||||
34057461|NCT01328548|||CASE_CONTROL||PROSPECTIVE|||||||
34057462|NCT06621043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057463|NCT03238885|||COHORT||PROSPECTIVE|||||||
34057464|NCT05070429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057465|NCT06389149|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||There will be a peripheral artery disease (PAD) group and an age-matched healthy control group. Within each of these groups will be a 1:1 randomized, crossover study design.|f|f|f|t
34057466|NCT04712591|||COHORT||PROSPECTIVE|||||||
34057467|NCT03615716|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study has 2 groups of participants. Only one group, middle school boys (N=20), will receive the intervention. But, pre- and post-assessments will be conducted with 2 groups: (1) boys, (2) caregivers. Caregivers (N=20) will give their perspectives of boys' behavior pre- and post- intervention.||||
34057468|NCT01468753|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33953148|NCT06357065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization and blinding procedures: We invited 6 first-year high school classes to participate and, using a computer-generated procedure, will be randomized to the IG and to CG. The participants will be informed of the result of randomization after they agreed to participate in the study. The nature of the intervention makes its blinding infeasible.|"Study design, setting: This is a cluster randomized field trial aimed to evaluate the previously tested MOV-ES intervention.~Population: First year of high school students in a city in south-central Chile. Three secondary schools in the urban area of Talca (1 public, 1 private subsidized, and 1 private non-subsidized) with at least three classes per school year will be randomly selected. This methodological option was adopted because, in Chile, school administration is associated with the socioeconomic level of families."|f|f|t|f
34057469|NCT06163040|||COHORT||PROSPECTIVE|||||||
34057470|NCT05906212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057471|NCT00805870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057472|NCT00156039|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057473|NCT05811052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057474|NCT00689624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057475|NCT03627377|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs. The RCFs will be divided randomly into four cohorts of three RCFs each. Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15). All the study participants will be assessed quarterly during the 15-month period.||||
33953149|NCT05572944|||COHORT||PROSPECTIVE|||||||
33953150|NCT03250611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953151|NCT03047512|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Pilot descriptive study|t|f|f|f
33953152|NCT02127021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33953153|NCT03910439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057476|NCT00801697|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34057477|NCT03104400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057478|NCT01443494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057479|NCT00451295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34057480|NCT01385488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057481|NCT01297127|||COHORT||PROSPECTIVE|||||||
34057482|NCT03702114|||CASE_CONTROL||PROSPECTIVE|||||||
34057483|NCT01048112|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057484|NCT04985175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects were randomized assigned to QPL group or usual care group.||||
34057485|NCT00621595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057486|NCT02144207|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34057487|NCT05236972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057488|NCT05454046|||COHORT||PROSPECTIVE|||||||
34057489|NCT04142164|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34057490|NCT06620315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34057491|NCT00645125|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34057492|NCT01011166|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34057493|NCT06011161|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot. All participants will participate in the same treatment.||||
34057494|NCT05428163|||COHORT||PROSPECTIVE|||||||
34057495|NCT04658524|||COHORT||CROSS_SECTIONAL|||||||
34057496|NCT02317770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057497|NCT02750475|NA|SINGLE_GROUP||OTHER||NONE||||||
34057498|NCT06142175|||CASE_ONLY||OTHER|||||||
34057499|NCT02033070|||COHORT||PROSPECTIVE|||||||
34057500|NCT05065034|||CASE_ONLY||RETROSPECTIVE|||||||
34057501|NCT06485349|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blinded control|"Excess-weight women with mild anxiety symptomatology will be assigned in a control double-blind and randomized manner to one of two groups: olive leaf extract (OLE) (n=35) 750 mg 20% oleuropein or placebo (n=35). Participants would have sessions biweekly:~1. (Day 0, 30, 60, and 90): Anxious symptomatology, weight, height, body fat, and muscle percentage (blood extraction at day 0 and day 90).~2. (Day 15, 45, 75): Adherence, 24-hour recall, and Food frequency questionnaire (FFQ).~Supplementation starts at day 0 and ends at day 89. Anxious symptomatology is evaluated, monthly, alternatively with the Hamilton Anxiety Scale (HAS) and Beck Anxiety Inventory (BAI). Adherence will be verified every 15 days as well as a 24-hour dietary recall and FFQ. ELISA assays will be used for TNF-α, IL-6, Cortisol, and leptin quantifications. It will be performed with 12h overnight fasting, in the morning; and lipid profile and glycosylated hemoglobin will be measured through biochemical tests."|t|f|t|f
34057502|NCT05541978|||COHORT||RETROSPECTIVE|||||||
33953154|NCT03564678|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33953155|NCT04114591|||COHORT||RETROSPECTIVE|||||||
33953156|NCT01905176|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33953157|NCT00370929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953158|NCT05785273|||COHORT||PROSPECTIVE|||||||
33953159|NCT03751852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953160|NCT00661791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953161|NCT06163898|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953162|NCT01139138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953163|NCT03087448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953164|NCT01100398|||COHORT||PROSPECTIVE|||||||
33953165|NCT03660059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953166|NCT06652477|||CASE_CONTROL||PROSPECTIVE|||||||
33953167|NCT06652607|||COHORT||PROSPECTIVE|||||||
33953168|NCT03724305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744464|NCT03884283|NA|SINGLE_GROUP||OTHER||NONE||||||
33744465|NCT04870801|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|Open label|Following screening, six healthy adults will report to the Human Performance Clinical Research Laboratory on two separate occasions, each separated by \~7-14 days. During each visit, study participants will undergo physiological monitoring prior to and during inhalation of hypoxic (FiO2=0.15) gas mixtures. During one of these visits, following initiation of hypoxic gas breathing, colon administration of RMO will commence.||||
33744466|NCT03999619|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors will not be aware of the group status of children|Randomized Wait-list Controlled Design|f|f|f|t
33744467|NCT05068934|||COHORT||CROSS_SECTIONAL|||||||
33744468|NCT01957189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744469|NCT06312540|||COHORT||PROSPECTIVE|||||||
33744470|NCT06161909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744471|NCT04258787|||CASE_CONTROL||PROSPECTIVE|||||||
33744472|NCT03445468|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33744473|NCT02779257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057503|NCT04980651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057504|NCT00793546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744474|NCT04859166|||OTHER||PROSPECTIVE|||||||
33744475|NCT03070522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo|Randomized placebo controlled trial|t|t|t|t
33744476|NCT01568047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744477|NCT03348254|||COHORT||OTHER|||||||
33744478|NCT02082054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744479|NCT03362255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744480|NCT04866264|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Pilot study (exploratory case-crossover study) for user feasibility and validation of the eNutrition Optimizer||||
33744481|NCT00319098|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33744482|NCT01981135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34057505|NCT01783600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057506|NCT05085106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The study is designed as single dose escalation in the healthy subjects，the subjects are divided from low dose to high dose into 5 single-dose groups of 0.025%, 0.05%, 0.1%, 0.2% and 0.3%, with both male and female subjects in each group.~The study is designed as multiple dose escalation in the healthy subjects，the subjects are divided into low dose and high dose groups of 0.1% and 0.2% with both male and female subjects in each group.~The study was designed as double-blind, all the single-dose groups containing 10 subjects except the single-dose group of 0.025% containing 8 subjects，and with 2 placebo controls in each group."|t|f|t|t
34057507|NCT06184113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057508|NCT04658706|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34057509|NCT03594019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057510|NCT01329926|||CASE_ONLY||PROSPECTIVE|||||||
34057511|NCT06648460|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single group study in which individuals with depression and matched controls will perform an effort-based decision-making task.||||
34057512|NCT03375879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigator will place a contact lens on both eyes and immediately take it off from one (this will be the sham lens eye). Randomization of the lens placement will be determined by a flip of a coin (heads - keep lens on right eye. Tails - keep lens on left eye). Investigator will randomly generate for each patient whether the contact lens will be kept on right or left eye, sham contact lens will be placed on other eye, placing it and immediately removing it. Therefore, the patient will not know which eye has a lens.|The investigators will place a contact lens on both eyes and immediately take it off from one (this will be the sham lens eye). Randomization of the lens placement will be determined by a flip of a coin (heads - keep lens on right eye. Tails - keep lens on left eye). Investigator will randomly generate for each patient whether the contact lens will be kept on right or left eye, sham contact lens will be placed on other eye, placing it and immediately removing it. Therefore, the patient will not know which eye has a lens.|t|f|f|f
34057513|NCT00721344|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34057514|NCT02474589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057515|NCT01897662|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33744483|NCT03732287|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A dose escalation strategy of differing temperatures and duration to test safety and efficacy of cooling anesthesia for intravitreal injection||||
33744484|NCT00063947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744485|NCT04302922|||COHORT||PROSPECTIVE|||||||
33744486|NCT00349089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744487|NCT04276545|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33744488|NCT02843568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744489|NCT03358667|||COHORT||PROSPECTIVE|||||||
33744490|NCT02591654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744491|NCT02909972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744492|NCT05787418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33744493|NCT00877448|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33953169|NCT00929552|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953170|NCT04539106|||COHORT||RETROSPECTIVE|||||||
33953171|NCT04698837|||OTHER||OTHER|||||||
33953172|NCT06466369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|Parallel, double-blinded, prospective, randomized controlled study.|t|t|f|f
33953173|NCT03128931|NA|SINGLE_GROUP||OTHER||NONE||||||
33953174|NCT02724176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953175|NCT01736982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953176|NCT04520087|NA|SINGLE_GROUP||TREATMENT||NONE||pilot study||||
33953177|NCT01977482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953178|NCT05498545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953179|NCT05615428|||COHORT||RETROSPECTIVE|||||||
33953180|NCT00761085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953181|NCT03107715|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Sequential presentation of 2 prototype interventions with pre/post test and follow up||||
33953182|NCT03487146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057516|NCT02140528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057517|NCT03411694|||COHORT||CROSS_SECTIONAL|||||||
34057518|NCT03871738|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057519|NCT00005711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057520|NCT00222482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34057521|NCT06158659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Two arms of participants will be assigned masked products (investigational formula and control formula) after randomization, while the participants of breastfeeding arm will not be assigned study products.||t|t|t|t
34057522|NCT04564469|||COHORT||PROSPECTIVE|||||||
34057523|NCT00005941||||TREATMENT||NONE||||||
34057524|NCT05676099|||OTHER||OTHER|||||||
33744494|NCT01577706|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744495|NCT02940990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953183|NCT06199518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953184|NCT04424732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953185|NCT03209973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953186|NCT00683462|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33953187|NCT02736331|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33953188|NCT01075126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953189|NCT03725358|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||three supply-side interventions (including control condition) are being crossed with three levels of subsidies for LARCs||||
33953190|NCT04633187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953191|NCT06651892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953192|NCT06011499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessors are blinded to participant group assignment after completing the baseline assessment and prior to randomization. Adverse events will be reviewed on a quarterly basis by the research team in a blinded fashion||f|f|f|t
33953193|NCT05322200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953194|NCT04604353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor will receive baseline and 12 month risk based on Pooled Cohort Equation and photographic evidence of treatment adherence|Randomization to provision of PRS-based or CCS-based risk|f|f|f|t
33953195|NCT05901194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953196|NCT02244385|||COHORT||PROSPECTIVE|||||||
33953197|NCT06567886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34057525|NCT06183203|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority randomised controlled trial||||
34057526|NCT05497336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057527|NCT00524004|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34057528|NCT06390774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057529|NCT04412837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, treating physician, and assessors will be blinded to study group.|This will be a randomized double blinded parallel group clinical trial to determine safety and efficacy of 35mg CBD patch vs placebo patch in patients with knee osteoarthritis.|t|t|t|f
33953198|NCT04957316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953199|NCT04486573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953200|NCT02355314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953201|NCT02409225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953202|NCT04572737|NA|SINGLE_GROUP||TREATMENT||NONE||before and after intervention study||||
33953203|NCT05003752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953204|NCT01863160|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33953205|NCT05025904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned to one of 3 groups: real-time fMRI neurofeedback (rt-fMRI NFB), EEG neurofeedback (aborted), and cognitive behavioral therapy (CBT).||||
33953206|NCT03781817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953207|NCT00939367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33953208|NCT06016231|||COHORT||CROSS_SECTIONAL|||||||
33953209|NCT06116292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953210|NCT02544126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953211|NCT03184467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953212|NCT05259748|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|The control group included in the study was not informed about the planned interventions to the experimental group before the study. Necessary information about the intervention study performed on the experimental group was given to the control group after the study was completed.|This study is conducted in pretest-posttest randomized controlled experimental research type.|t|f|f|f
33953213|NCT05153655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953214|NCT01789476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953215|NCT06515925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33953216|NCT00924313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953217|NCT00066586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33953218|NCT01701895|||CASE_ONLY||PROSPECTIVE|||||||
33953219|NCT02495974|||CASE_ONLY||PROSPECTIVE|||||||
33953220|NCT06491719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953221|NCT00001080||PARALLEL||TREATMENT||||||||
33953222|NCT03320031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953223|NCT01067729|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953224|NCT01711814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953225|NCT06027788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of the study precludes masking surgeons from treatment assignment. Investigators will, however, be blinded to all data from other clinical sites, except serious unexpected adverse events possibly or probably related to the intervention for Institutional Review Board (IRB)/Research Ethics Board (REB) reporting purposes. Patients will be blinded as to treatment assignment. All neurocognitive scoring and delirium assessments will be analyzed by neurocognitive core laboratory personnel who will be blinded to treatment assignment and clinical outcomes.|Patients will be randomized 1:1 to the embolic protection device or to a standard cannula in the OR immediately after sternotomy and confirmation by the surgical team of the patient's suitability for the proposed intervention (CardioGard embolic protection device).|f|f|f|t
33953226|NCT01723371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953227|NCT02611076|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33953228|NCT03596476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953229|NCT06650345|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants were categorized into two groups, specifically the control group (consisting of 30 individuals) and the exercise group (also comprising 30 individuals), based on their participation in an exercise program.||||
33953230|NCT03723668|||COHORT||OTHER|||||||
33953231|NCT00807040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953232|NCT06170528|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33953233|NCT02339246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33953234|NCT01295242|||||PROSPECTIVE|||||||
33953235|NCT00449761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953236|NCT06249035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||TEE will be performed on all patients that are eligible for inclusion.||||
33953237|NCT04466371|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953238|NCT03194295|RANDOMIZED|PARALLEL||TREATMENT||NONE||Meets criteria of a phase II non-pharmacological treatment intervention.||||
33953239|NCT06096246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and physician - blinded randomisation to intervention (DCCV, or Pulmonary Vein Isolation plus DCCV) Once subject participation in the trial is complete, the patient and physician will be unblinded.|Randomised, blinded, controlled trial with 2 arms|t|f|t|f
33953240|NCT00938392|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33953241|NCT00681447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953242|NCT04443426|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33953243|NCT04009681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953244|NCT06522841|||OTHER||OTHER|||||||
33953245|NCT03257800|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, controlled and double blind assignment|t|f|t|t
33953246|NCT06147856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953247|NCT01554696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953248|NCT03931902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953249|NCT06636019|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33953250|NCT05400590|||CASE_CONTROL||PROSPECTIVE|||||||
34057530|NCT01488669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161518|NCT02067936|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34161519|NCT02084550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34161520|NCT00972725|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057531|NCT05877417|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||double blind placebo controlled|t|f|t|f
34057532|NCT05451433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind randomized control trial||t|t|t|f
34057533|NCT04299048|NA|SEQUENTIAL||TREATMENT||NONE||||||
34057534|NCT01506154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057535|NCT06181357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057536|NCT04172402|NA|SINGLE_GROUP||TREATMENT||NONE||Advanced Biliary Tract Cancer||||
34057537|NCT05619718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057538|NCT01619644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057539|NCT02083055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057540|NCT02975245|||COHORT||PROSPECTIVE|||||||
33953251|NCT03771391|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|At the point of randomisation every effort will be made to ensure that participants are unaware of the cluster they are randomised to; this is to help ensure that compliance is not affected by participants knowing when they will start the new treatment.|The study has a stepped wedge design, which is chosen over the alternative cross-over study as it allows that all participants start on the amino acid supplement and avoids the difficulty of the 'wash-out' period being the same as one of the treatment strategies being offered.|t|f|f|f
34161521|NCT04392843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Two subjects will undergo two metabolic studies, one after having remained fasted and one after having eaten breakfast and lunch.||||
34161522|NCT00959738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161523|NCT01190501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161524|NCT06502782|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34161525|NCT00203424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161526|NCT01641601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34161527|NCT04043442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Single Blind. A single blind will be maintained. Veterans will not know when they are receiving which treatment. Researchers will be unblinded to treatment order.~rTMS Device and Blinding Procedures. PLACEBO and ACTIVE rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P, which can be switched to active or placebo (A/P). The PLACEBO rTMS looks, sounds, and feels like ACTIVE rTMS. Each rTMS treater will be assigned a specific site of stimulation (Group 1, 2, 3, or 4) and will be blinded to the anatomical location of the other 3 sites. rTMS treaters and assessment administrators will be different people for each participant."|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P and Magpro C-B60|t|f|t|t
34161528|NCT00932321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161529|NCT03285269|||COHORT||PROSPECTIVE|||||||
34161530|NCT01960582|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34161531|NCT02761343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161532|NCT03136289|||OTHER||CROSS_SECTIONAL|||||||
34161533|NCT04505332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161534|NCT05936398|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744496|NCT01230593|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744497|NCT05496582|||CASE_CONTROL||RETROSPECTIVE|||||||
33953252|NCT03790475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953253|NCT00623688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953254|NCT01051076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953255|NCT02806700|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953256|NCT03207607|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Coded snacks in shaded tetrapaks were provided to participants||t|f|f|t
33953257|NCT06565897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953258|NCT00843739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953259|NCT03047889|||CASE_ONLY||RETROSPECTIVE|||||||
33953260|NCT02847078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33953261|NCT02998372|||OTHER||CROSS_SECTIONAL|||||||
33953262|NCT02765906|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33953263|NCT02303977|NA|SINGLE_GROUP||TREATMENT||NONE||a prospective, single-arm, non-randomized, phase II trial designed to evaluate the efficacy of combination gemcitabine and albumin-bound paclitaxel for advanced adenocarcinoma non-small cell lung cancer progressing after first-line platinum-based chemotherapy.||||
34161535|NCT05234047|||CASE_ONLY||PROSPECTIVE|||||||
34161536|NCT04734067|||COHORT||PROSPECTIVE|||||||
34161537|NCT03753555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744498|NCT01700608|||CASE_ONLY||PROSPECTIVE|||||||
33953264|NCT05311111|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind during the analyze|Prospective, single-center, single-blind, randomized controlled trial|f|f|f|t
34057541|NCT04683939|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34057542|NCT01953835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057543|NCT06624293|||CASE_ONLY||PROSPECTIVE|||||||
34057544|NCT05990192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057545|NCT05203549|||COHORT||PROSPECTIVE|||||||
34057546|NCT02863510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057547|NCT05768750|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Participants will participate in 2 phases : control phase (12-week usual care) followed by an intervention phase (12-week home-based rehabilitation program).||||
34057548|NCT06621810|||CASE_ONLY||OTHER|||||||
34057549|NCT01097421|||||PROSPECTIVE|||||||
34057550|NCT03373058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953265|NCT03775694|||CASE_ONLY||RETROSPECTIVE|||||||
33953266|NCT03205046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953267|NCT02492009|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33953268|NCT03289182|||COHORT||PROSPECTIVE|||||||
33953269|NCT05473546|||COHORT||PROSPECTIVE|||||||
34057551|NCT04481893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34057552|NCT05708677|||COHORT||PROSPECTIVE|||||||
34057553|NCT00389337|||DEFINED_POPULATION||OTHER|||||||
34057554|NCT02444364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057555|NCT05124080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057556|NCT02046005|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057557|NCT00227630|NON_RANDOMIZED|||TREATMENT||||||||
34057558|NCT02312453|NA|SINGLE_GROUP||||NONE||||||
34057559|NCT01446237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953270|NCT00579787|||CASE_CONTROL||PROSPECTIVE|||||||
33953271|NCT03062878|||CASE_CONTROL||PROSPECTIVE|||||||
34161538|NCT04637737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161539|NCT03831217|||COHORT||PROSPECTIVE|||||||
34161540|NCT03305770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744499|NCT04722965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744500|NCT04829838|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33744501|NCT01296828|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744502|NCT06670144|||COHORT||PROSPECTIVE|||||||
33744503|NCT04666493|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 12 week, single site, single group, open-label trial of the Facing Your Fears intervention.||||
33744504|NCT02429128|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744505|NCT05016492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744506|NCT04040985|NA|SINGLE_GROUP||OTHER||NONE||||||
33744507|NCT02534974|RANDOMIZED|PARALLEL||PREVENTION||||||||
33744508|NCT05684016|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33744509|NCT03558867|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33744510|NCT02556021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744511|NCT06635044|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33744512|NCT02312739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744513|NCT02571218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744514|NCT05846516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||For Part C: parallel and randomized||||
33744515|NCT04992715|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744516|NCT01204190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744517|NCT00202670|||COHORT||PROSPECTIVE|||||||
33953272|NCT03488862|||COHORT||PROSPECTIVE|||||||
33953273|NCT04905589|RANDOMIZED|CROSSOVER||OTHER||NONE||Open-label - randomization-concealed trial randomized in a 1:1:1 ratio||||
33953274|NCT05736549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||We will conduct a randomized study based on a randomization table generated by a biostatistician on the day of the surgery by the same investigator who will also prepare the study medication and perform the nerve block procedure. Patients follow up will be performed by investigators blinded to group assignments.|t|f|f|f
33953275|NCT05665816|||OTHER||PROSPECTIVE|||||||
33953276|NCT02570399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953277|NCT01699100|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33953278|NCT02387944|||COHORT||PROSPECTIVE|||||||
33953279|NCT01991756|||COHORT||PROSPECTIVE|||||||
33953280|NCT03949946|||CASE_CONTROL||PROSPECTIVE|||||||
33953281|NCT06344650|||CASE_CROSSOVER||PROSPECTIVE|||||||
33953282|NCT06026514|NA|SEQUENTIAL||PREVENTION||NONE||Recombinant, Live-Attenuated, Bovine/Human Parainfluenza Virus Vector Vaccine Expressing the 6P-Prefusion-Stabilized Version of the SARS-CoV-2 Spike Protein, Administered in two Sequential Doses as Nasal Spray to Adults 18 to 50 Years of Age||||
33953283|NCT00728273|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33953284|NCT02787746|NA|SINGLE_GROUP||TREATMENT||NONE||multi-center, single-arm, open labeling clinical trial||||
33953285|NCT05368376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953286|NCT01503086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33953287|NCT04401046|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33953288|NCT01194661|||COHORT||OTHER|||||||
33953289|NCT05206279|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study||||
33953290|NCT06652399|||COHORT||PROSPECTIVE|||||||
33953291|NCT06035328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953292|NCT00209560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953293|NCT04130555|||CASE_ONLY||PROSPECTIVE|||||||
33953294|NCT00684645|||CASE_ONLY||PROSPECTIVE|||||||
33953295|NCT06642662|||COHORT||PROSPECTIVE|||||||
33953296|NCT04453475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of an online depression session as a flipped classroom and/or an online lecture with socio-medical content, which are combined in such a way that the differential effects can be evaluated. For this purpose, a control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups)."||||
34057560|NCT04169672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057561|NCT04105946|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34057562|NCT01661933|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34057563|NCT06649565|||COHORT||PROSPECTIVE|||||||
33953297|NCT05726409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953298|NCT03442894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects in the dry needling and sham dry needling groups will be masked (blinded) to whether or not they are receiving the sham or actual dry needling.|3 groups: Standard physical therapy treatment (SPT), SPT plus dry needling and SPT plus sham dry needling|t|f|f|f
33953299|NCT04232761|||COHORT||PROSPECTIVE|||||||
33953300|NCT05860452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Dedicated anaesthetic nurse will prepare the syringes for administering the TAP block for each participant. She will be the only person to know which group each participant has been allocated to. Since local anaesthetic and normal saline have no color the anaesthetist performing the block will be, as will the doctors and nurses in postoperative care, blinded to the group each participant has been allocated to.||t|t|t|t
33953301|NCT00747110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953302|NCT04000958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057564|NCT01632904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953303|NCT02530749|||COHORT||PROSPECTIVE|||||||
34057565|NCT06406075|NA|SINGLE_GROUP||OTHER||NONE||||||
34057566|NCT01746498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057567|NCT04076423|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparator: the patient will continue taking the dual therapy. Experimental: the patient Will beging to take triple therapy.||||
34057568|NCT02971436|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34161541|NCT01292096|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34161542|NCT02885246|||OTHER||RETROSPECTIVE|||||||
33953304|NCT05186116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953305|NCT01568255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a randomized, double-blinded, and placebo-controlled pilot study of13 females with moderate to severe myopathic pain while on statins who were enrolled and randomized at a 1:1 ratio.|The study was prospective, randomized, and double blinded pilot Ergocalciferol 50,000 IU once weekly for 8 weeks compared to Placebo in statin myalgic women. Subjects screened for eligibility underwent baseline and exit visits. For baseline and exit visits, subjects had safety labs drawn for lipid and vitamin D levels, completed Brief Pain Inventory (BPI) severity and interference questionnaires, as well as a Short Form (SF-12) questionnaire and medical history.Additionally, subjects underwent physical exams for baseline visits. After physical exams, subjects were then randomized to Placebo or Ergocalciferol treatment.|t|f|t|f
33953306|NCT06652165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953307|NCT00231530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953308|NCT00718809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953309|NCT06537973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"Since the researcher must provide training and manage the process, researcher and participant blinding cannot be done.~Blinding in data entry; Randomization will be done by an independent researcher outside the scope of the research and the list created will be hidden from the researcher and the participants. Participants will not be informed about which group they are in until the intervention begins."|Parallel group (experiment-control) randomized controlled experimental||||
33953310|NCT02843490|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744518|NCT05954143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744519|NCT01598480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161543|NCT06303102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744520|NCT04255160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34161544|NCT05230472|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Block size was unknown to the investigators, who was enrolled the patients and then called the statistics department to obtain the randomization and treatment numbers after checking the inclusion and non-inclusion criteria.|"Patients were randomly allocated to simvastatin (60 mg) or control given via a nasogastric tube or orally from study inclusion to ICU discharge, death, or day 28, whichever occurred first. Simvastatin or control were started on the same day as antibiotic therapy for suspected VAP. The simvastatin dosage was halved in patients with renal failure (creatinine clearance \<30 mL/min). A computer-generated random- number table was prepared by statisticians to assign patients in blocks of 4 to receive either simvastatin or control.~Block size was unknown to the investigators, who was enrolled the patients and then called the statistics department to obtain the randomization and treatment numbers after checking the inclusion and non-inclusion criteria."|t|t|t|f
34161545|NCT03386487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 2B|t|t|t|t
34161546|NCT03319134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomly assigned to one of three groups: (1) active HD-tDCS with retrieval memory task, (2) sham HD-tDCS with retrieval memory task, (3) active cathodal HD-tDCS with retrieval memory task|t|f|f|t
34161547|NCT03314064|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single group study where the eligible subjects will receive DTG 50 mg once daily.||||
34161548|NCT04587310|||COHORT||RETROSPECTIVE|||||||
34161549|NCT02342899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161550|NCT00982826|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34161551|NCT02593942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34161552|NCT03441386|NA|SINGLE_GROUP||TREATMENT||||Three counterbalanced experimental sessions for the same group||||
34161553|NCT06098534|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161554|NCT03004352|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34161555|NCT01647893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34161556|NCT04354675|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34161557|NCT02202343|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161558|NCT00031759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161559|NCT02926638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161560|NCT04898244|||CASE_ONLY||PROSPECTIVE|||||||
34161561|NCT06453967|||COHORT||PROSPECTIVE|||||||
34161562|NCT03831100|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Eligible participants will complete baseline questionnaires measuring BID and psychological, social, and emotional wellbeing. Participants will then be randomized to BRIGHT (n=24) or AC (n=24) and undergo weekly, tablet-based BRIGHT or AC for 5 weeks.~The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.~The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. Participants in the AC arm will thus undergo 5 weekly, 60-minute, tablet-based video sessions in which they undergo non-manualized discussions with a non-trained member of the study team."||||
33953311|NCT06567756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953312|NCT06649890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33953313|NCT04596618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants receive two cooling treatments on separate study visits: 1) passive cooling 2) forearm immersion cooling||||
33953314|NCT06177626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will know that the participant has received balance or aerobic training, but will not be aware of which group the participant belonged.|Single blinded randomized controlled trial|f|f|f|t
33953315|NCT06507059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953316|NCT01928810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33953317|NCT00717808|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33953318|NCT01058707|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The Escalation Phase was sequential and the Expansion Phase was parallel.||||
34161563|NCT01552863|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34161564|NCT06310421|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34161565|NCT01978041|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34161566|NCT01181817|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161567|NCT06009055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744521|NCT01126983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33744522|NCT06213883|NA|SINGLE_GROUP||OTHER||NONE||Individuals Complete Exercise and Rest Sessions in-lab. We are evaluating the impact of exercise on affect, body image, and biomarkers||||
33744523|NCT02685254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744524|NCT02205710|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33744525|NCT05006170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Each participants will undergo ARTs medication switch to DTG dispersible tablet, and ABC/3TC dispersible tablet||||
33953319|NCT05168943|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33744526|NCT02692300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Anesthesia practitioner is not blinded to intervention. Subject is blinded and primary outcome assessor is blinded to intervention.||t|f|t|f
33953320|NCT04470856|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Participants receive an 20sec-EEOT at the initial phase of the study, then they receive a fluid challenge during the second phase of the study||||
33953321|NCT03714399|||COHORT||PROSPECTIVE|||||||
33953322|NCT03931707|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953323|NCT04672369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953324|NCT05970848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomly allocated into one of the two groups by the randomization module in REDCap. Patients and outcomes assessor will be blinded to their grouping.|Group S patients will receive topical lidocaine anesthesia via the spray nozzle by the spray as-you-go technique during flexible bronchoscopy. Group C patients will receive topical lidocaine anesthesia with the conventional method by the spray as-you-go technique during flexible bronchoscopy.|t|f|f|t
34161568|NCT04532034|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33744527|NCT04239313|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953325|NCT03055286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953326|NCT03969160|NA|SINGLE_GROUP||OTHER||NONE||||||
33953327|NCT04327869|||CASE_CONTROL||PROSPECTIVE|||||||
33953328|NCT01683786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953329|NCT03290105|||COHORT||PROSPECTIVE|||||||
33953330|NCT06651918|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33953331|NCT00139802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953332|NCT05213065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953333|NCT02468167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953334|NCT06144645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953335|NCT04649931|||COHORT||PROSPECTIVE|||||||
33953336|NCT03857425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953337|NCT02698319|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34161569|NCT02732548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161570|NCT02384733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161571|NCT00345865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161572|NCT03301350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161573|NCT02285387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161574|NCT06056583|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||This is a phase 1 study design of an approved drug to evaluate the time-course for the expression and activity of OCT1 and BCRP in the mammary gland 3-5 weeks, 3-4 months and 6-8 months postpartum.||||
34161575|NCT05023993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161576|NCT01629277|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161577|NCT00206843|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34161578|NCT03531086|||COHORT||PROSPECTIVE|||||||
34161579|NCT02895100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161580|NCT05900063|||CASE_ONLY||RETROSPECTIVE|||||||
34161581|NCT00452868|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34161582|NCT01604252|||COHORT||PROSPECTIVE|||||||
34161583|NCT05356780|||COHORT||PROSPECTIVE|||||||
34161584|NCT01005498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161585|NCT03315312|RANDOMIZED|PARALLEL||PREVENTION||NONE||Split-mouth design||||
33744528|NCT06053489|||COHORT||RETROSPECTIVE|||||||
33744529|NCT01990235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33744530|NCT05397522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An exploratory-descriptive qualitative study will be conducted. There will be three groups in the study with each of them will consist of ten participants. Within the scope of the study, each group will perform a similar exercise program, 2 sessions a week, for 6 weeks, in one of the 3 groups below; Group 1: Exercising under the supervision of a face-to-face physiotherapist, Group 2: Exercise under the observation of the physiotherapist via video-conference (telerehabilitation), Group 3: Exercising in the absence of the observer (home based exercise program).|f|f|f|t
33744531|NCT02504632|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744532|NCT05520580|RANDOMIZED|PARALLEL||SCREENING||SINGLE||prospective randomized study|t|f|f|f
33744533|NCT04932304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848091|NCT04674696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848092|NCT00962403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848093|NCT06432322|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Self-administered by the participant wearing an eye mask, following instructions and under supervision of appropriately trained medical staff where resuscitation facilities are available, via a single-use device delivering 28 mg as two sprays (i.e., one spray per nostril).|Within-subject, cross-over design|t|f|f|t
33848094|NCT01505218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848095|NCT06610734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848096|NCT05991531|||COHORT||PROSPECTIVE|||||||
33848097|NCT00405366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848098|NCT00312923|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33848099|NCT06610188|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participants were blinded to groups.|Individuals were randomly assigned to one of two groups: prebiotic (n=17) and placebo (n=17) groups.|t|f|f|f
33848100|NCT04479345|||COHORT||CROSS_SECTIONAL|||||||
33848101|NCT02107183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33848102|NCT06008327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848103|NCT04434573|||OTHER||PROSPECTIVE|||||||
33848104|NCT02262624|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848105|NCT01725893|||CASE_ONLY||RETROSPECTIVE|||||||
33848106|NCT02070939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33848107|NCT05610202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848108|NCT06403709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848109|NCT01630694|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33848110|NCT05390021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848111|NCT00299663|||||CROSS_SECTIONAL|||||||
33848112|NCT04406740|||COHORT||PROSPECTIVE|||||||
33848113|NCT05347368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848114|NCT06317532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848115|NCT05997784|||COHORT||PROSPECTIVE|||||||
33848116|NCT01955967|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33848117|NCT04343872|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33848118|NCT05684744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848119|NCT00703209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848120|NCT05094557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848121|NCT03835429|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized clinical controlled trial design||||
33848122|NCT01831947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848123|NCT01767701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848124|NCT03990545|||CASE_CONTROL||PROSPECTIVE|||||||
33848125|NCT02957851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33848126|NCT04751266|||COHORT||PROSPECTIVE|||||||
33848127|NCT01239485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953338|NCT06653309|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33953339|NCT02596009|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33953340|NCT03718559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953341|NCT06181409|||COHORT||PROSPECTIVE|||||||
33953342|NCT06364007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953343|NCT06326476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953344|NCT00333437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953345|NCT01054209|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953346|NCT04997031|||OTHER||CROSS_SECTIONAL|||||||
33953347|NCT02049931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953348|NCT02195271|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33953349|NCT04601246|||COHORT||PROSPECTIVE|||||||
33953350|NCT00735215|||CASE_ONLY||PROSPECTIVE|||||||
33953351|NCT03476395|||OTHER||CROSS_SECTIONAL|||||||
33953352|NCT04516356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled experimental study to determine the effect of Korean hand acupressure applied after thyroidectomy on postoperative nausea-vomiting and retching.||||
33953353|NCT03125239|NA|SINGLE_GROUP||TREATMENT||NONE||open-label phase 1 study using a 3+3 design with planned dose escalation||||
33953354|NCT00916773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953355|NCT00211575|RANDOMIZED|PARALLEL||||NONE||||||
33953356|NCT00648739||SEQUENTIAL||TREATMENT||NONE||||||
33953357|NCT05595460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953358|NCT04753606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablet made to resemble active|Placebo-controlled, double-blind, randomized|t|t|t|t
33953359|NCT04670510|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33953360|NCT04444882|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953361|NCT06541509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953362|NCT04071327|||COHORT||PROSPECTIVE|||||||
33953363|NCT00474994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953364|NCT02222168|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33953365|NCT04928625|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Single-Arm, Multi-Center Phase I Clinical Study TO EVALUATE the Safety||||
33953366|NCT06242275|||COHORT||PROSPECTIVE|||||||
33953367|NCT02187406|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33953368|NCT05991622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953369|NCT04667507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953370|NCT00803582|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33953371|NCT05079204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator which perform the periodontal examination will be blinded of the motivation procedure||f|f|t|f
33953372|NCT05703009|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33953373|NCT01497860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953374|NCT00968539|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33953375|NCT02912507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953376|NCT06427382|||OTHER||PROSPECTIVE|||||||
33953377|NCT03602976|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|All subjects will receive appropriately dosed UDCA after six months of observation|Subjects will act as their own controls by undergoing a six-month initial observational period prior to initiating the six-month UDCA intervention||||
33953378|NCT00435513|||CASE_CONTROL||RETROSPECTIVE|||||||
33953379|NCT00581334|||COHORT||PROSPECTIVE|||||||
33953380|NCT06650371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33953381|NCT06026449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, self-controlled pilot clinical trial||||
33953382|NCT02317796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953383|NCT06491264|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind, sham-controlled|In this within-subjects design, participants will each receive 5 sessions of tES in a counterbalanced order. tES will be applied using different stimulation intensities that are personalized to each person using MRI scans. tES will also have different 4 different waveforms (theta, gamma, theta-gamma ranges or none).|t|f|t|f
33953384|NCT05156866|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953385|NCT02181127|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33953386|NCT04827576|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953387|NCT00029159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953388|NCT03393039|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33953389|NCT03076307|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||||||||
33953390|NCT03390010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33953391|NCT02201732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953392|NCT06568289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953393|NCT04968873|NA|SINGLE_GROUP||SCREENING||NONE||||||
33953394|NCT05543629|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953395|NCT03900481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953396|NCT03146078|||COHORT||PROSPECTIVE|||||||
33953397|NCT04104152|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33953398|NCT04518527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953399|NCT05527301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953400|NCT01100073|||COHORT||PROSPECTIVE|||||||
33953401|NCT02064127|||COHORT||RETROSPECTIVE|||||||
33953402|NCT02590146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33953403|NCT00106613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953404|NCT02297438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953405|NCT05401773|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33953406|NCT00540735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953407|NCT02753777|||CASE_ONLY||PROSPECTIVE|||||||
33953408|NCT00905476|||COHORT||PROSPECTIVE|||||||
33953409|NCT02688179|||COHORT||PROSPECTIVE|||||||
33953410|NCT06338176|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057569|NCT06307691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"patients will be randomly selected into either group using computer generated randomization using (www.randomizer.org). The randomized numbers will be allocated to each site in each patient and will be placed in opaque, sealed and sequentially numbered envelopes. patients will be randomly allocated to test and control groups using randomization schedule.~Masking/blinding:~* Participants will be blinded~* Blinding of the operator will be blinded~* The outcome assessor will be blinded~* The biostatistician will be blinded"||t|f|t|t
34057570|NCT01729052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34057571|NCT01566942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057572|NCT00412217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057573|NCT01266785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057574|NCT06269263|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot study of home-based cardiac rehabilitation||||
34057575|NCT02195310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057576|NCT02382835|||CASE_CONTROL||RETROSPECTIVE|||||||
34057577|NCT00492596|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34057578|NCT04656197|||CASE_CONTROL||PROSPECTIVE|||||||
34057579|NCT04873453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled, parallel group study.|t|t|t|t
34057580|NCT06622512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding This study will employ a double-blind design, in which both the participants and the clinical evaluator responsible for conducting clinical and radiographic assessments will be blinded to the group assignments. Participants will be informed that they may receive one of three possible treatment options but will not know which specific technique is being applied to them. The RPWT will be administered by a final-year resident physician in Physical Medicine and Rehabilitation, who will be aware of the group allocation but will have no involvement in the outcome assessments. To ensure further blinding, the data collection and analysis personnel will also be blinded to the intervention groups. All treatment sessions will be conducted under standardized conditions, with identical instructions, setup, and environment for all groups to reduce potential bias.|Randomization After having obtained written informed consent the patients will be randomly assigned to one of three treatment groups, RPWT at the two most painful points (control group), RPWT at the medial interarticular line (medial group) or RPWT at the medial and lateral interarticular lines (medial and lateral group). Randomization will be carried out using the paper envelope randomization method. For this purpose, we will prepare a series of opaque papers, each indication one of the three possible assignments. These papers will be placed in an opaque bag, and during the enrollment process, each patient will draw a paper from the bag at random. The patient´s group assignment will be determined by the designation on the drawn paper.|t|f|t|f
34057581|NCT05619536|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34057582|NCT03445234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blueberry freeze dried powder or placebo powder|Randomized parallel group|t|f|t|f
34161586|NCT04086095|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Premature babies with Respiratory Distress Syndrome and the medical need for surfactant administration (defined as FiO2 ≥ 0.3 or mod. Silverman Andersen Respiratory Severity Score ≥ 5) while treated with CPAP-support and in a gestational age \>26+0 weeks.||||
34161587|NCT02399774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161588|NCT00394706|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34161589|NCT01014819|||COHORT||CROSS_SECTIONAL|||||||
34161590|NCT02312297|RANDOMIZED|CROSSOVER||||NONE||||||
34161591|NCT04957394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161592|NCT00315380|||COHORT||PROSPECTIVE|||||||
34161593|NCT01079416|||COHORT||PROSPECTIVE|||||||
34161594|NCT03769558|||COHORT||RETROSPECTIVE|||||||
34161595|NCT05426135|||COHORT||PROSPECTIVE|||||||
34161596|NCT00394550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953411|NCT02676232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953412|NCT06566092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned one of three arms depending on their tumor type.||||
33953413|NCT04690946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Clinical Trial|t|f|t|f
33953414|NCT06653192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953415|NCT00233675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953416|NCT00285012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953417|NCT01797068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953418|NCT04385719|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33953419|NCT06103656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33953420|NCT06054750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy will have access to the randomization scheme. All other members of the study team are blinded.|Randomized control trial|t|t|t|t
33953421|NCT02098707|||COHORT||PROSPECTIVE|||||||
33953422|NCT00714909|||COHORT||PROSPECTIVE|||||||
33953423|NCT00401414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953424|NCT04936568|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A quasi-experimental, longitudinal, pretest-posttest study will be carried out. Two different cohorts of 150 advanced cancer patients each will be enrolled before (pretest) and after (posttest) the introduction of the PCRS in outpatient clinics.||||
33953425|NCT01070225|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33953426|NCT01113060|||COHORT||PROSPECTIVE|||||||
33953427|NCT00928629|NA|SINGLE_GROUP||SCREENING||NONE||||||
33953428|NCT01971099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953429|NCT06325722|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33953430|NCT05688800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Control group: will receive conventional physical therapy treatment Experimental group 1: will receive conventional physical therapy treatment in addition to pressure release Experimental group 2: will receive conventional physical therapy treatment in addition to thoracic spine manipulation|t|f|f|t
33953431|NCT02351206|||CASE_CONTROL||RETROSPECTIVE|||||||
33953432|NCT05688137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups of equal size, total n = 365 patients. Simple intraoperative randomization prior to closure of the abdominal wall after fulfilling all the inclusion criteria and none of the exclusion criteria.||||
33953433|NCT04460092|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33953434|NCT01605539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33953435|NCT04045665|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter randomized clinical trial comparing OAC to no-OAC in addition to concomitant antiplatelet therapy in 3,200 eligible patients who develop POAF after isolated CABG. The trial will be conducted by the Cardiothoracic Surgical Trials Network (CTSN), the German Society for Thoracic and Cardiovascular Surgery (DGTHG) and other European sites, the United Kingdom and Brazil..||||
33953436|NCT01516060|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33953437|NCT00708656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953438|NCT00673868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953439|NCT01212432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953440|NCT05485506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953441|NCT05623826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are informed of the two group design, individual group allocation is released to participants at the end of the study participation.|Parallel group design with control group completing only EMA, not EMI|t|f|f|t
33953442|NCT05468034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33953443|NCT03669952|||CASE_ONLY||PROSPECTIVE|||||||
33953444|NCT01504074|||COHORT||PROSPECTIVE|||||||
33953445|NCT03310931|||CASE_CONTROL||PROSPECTIVE|||||||
34057583|NCT06439589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057584|NCT03863457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057585|NCT03593421|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||open label, adaptive design, dose finding study||||
34057586|NCT06620653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|the participants will be randomised using REDCAP software but there will be no masking performed|Randomised controlled trial. half of the participants will be in the tele monitoring group while the other half will be in the current standard of care group||||
34057587|NCT00058968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161597|NCT04031859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161598|NCT03088917|||COHORT||PROSPECTIVE|||||||
34161599|NCT04343456|||CASE_CONTROL||RETROSPECTIVE|||||||
34161600|NCT03686293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Acute meal test||||
34161601|NCT04761133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161602|NCT02144857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34161603|NCT04635319|||COHORT||RETROSPECTIVE|||||||
34161604|NCT00921778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161605|NCT01502228|NA|SINGLE_GROUP||OTHER||NONE||||||
34161606|NCT05267158|||COHORT||PROSPECTIVE|||||||
34161607|NCT04632589|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34161608|NCT03705546|||COHORT||PROSPECTIVE|||||||
34161609|NCT04120961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161610|NCT05297591|||COHORT||PROSPECTIVE|||||||
34161611|NCT00300313|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34161612|NCT01216137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34161613|NCT00032734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34161614|NCT02145117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161615|NCT02737124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34161616|NCT03449069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161617|NCT04459871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161618|NCT03971409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161619|NCT05357027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161620|NCT04849169|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34161621|NCT05599971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161622|NCT02458833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161623|NCT02076282|||||CROSS_SECTIONAL|||||||
34161624|NCT00529425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161625|NCT04451499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161626|NCT06213155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161627|NCT05414630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161628|NCT04576026|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and investigators will be blinded as an individual not involved in the project will assemble and distribute the treatment (drinks) according to a coding system that is kept confidential until the study is completed. Participants will complete the protocol twice and the treatment order will be systematically rotated to avoid any order effect. taste and texture of treatments will be matched and will be distribute in opaque bottles to keep participant blinded|This will be a double blind repeated measures cross over study. There will be two treatments involved: Ketone esters supplements and iso-caloric carbohydrates (placebo). Participants will complete the protocol twice and the treatment order will be systematically rotated to avoid any order effect. Design of the study is composed of a mental fatiguing task, followed by a 45 minute simulated soccer game (second half). Cognitive function will be assessed during the 45 minutes of exercise. All participants will perform the protocol in a fed state (4 h after consumption of their last meal)|t|f|t|f
34161629|NCT00301418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161630|NCT05938803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34161631|NCT00229398|||||RETROSPECTIVE|||||||
34161632|NCT03897660|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Neither the participant nor the research nurse will know the administration order of the different treatments administered. All plasma samples collected during the research project will be anonymized i.e. it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.|Double-blind controlled-randomized pharmacokinetic (PK) pilot study with crossover design (10 men and 10 women), with a minimum of 6 days between treatments|t|t|t|t
34161633|NCT03619772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161634|NCT05659368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161635|NCT00933998|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161636|NCT03077230|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34161637|NCT03196544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161638|NCT01426672||PARALLEL||TREATMENT||NONE||||||
34161639|NCT01944124|RANDOMIZED|PARALLEL||PREVENTION||||||||
34161640|NCT02527785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953446|NCT04271241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor are in-blind about the participants' allocation|Four groups in parallel (three intervention groups and one control) tested at the beginning, during, after and after six weeks (follow-up) from intervention|f|f|f|t
33744534|NCT03052179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Either participant or the investigator will be blinded. The key of randomisation will be held by the third statistician party, and the company which supply and labeled the product study.|Double blind, randomized, placebo-controlled|t|f|t|f
33744535|NCT00999479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744536|NCT00856401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744537|NCT05496504|||COHORT||RETROSPECTIVE|||||||
33744538|NCT04357626|||COHORT||RETROSPECTIVE|||||||
33744539|NCT01574300|||OTHER||PROSPECTIVE|||||||
33744540|NCT05934045|||OTHER||RETROSPECTIVE|||||||
33953447|NCT06649682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953448|NCT04755088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953449|NCT02604849|||CASE_CONTROL||RETROSPECTIVE|||||||
33953450|NCT04148469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33953451|NCT06540690|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Controlled clinical study, non-randomized, prospective, blinded, with a three-month follow-up.|f|f|f|t
33953452|NCT06649370|||OTHER||PROSPECTIVE|||||||
33953453|NCT06562556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group A: (Experimental group) Thirty patients, will receive a combined treatment program containing respiratory muscle training by the breather device with a conventional exercise program for MTMD for four consecutive weeks (3 sessions/ week). Group B: (Control group) Thirty patients, who will receive a conventional exercise program for MTMD for four consecutive weeks (3 sessions/ week)|f|t|f|f
34057588|NCT03467763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, care providers, and investigators will be masked to the identity of the trial medication until the conclusion of the trial, and unblinding.|This study is an N-of-1 trial design that will recruit 20 previously metformin-intolerant patients for re-challenge with metformin in a double-blind scenario. Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo. Initial treatment, placebo or metformin XR, will be decided randomly.|t|t|t|f
34161641|NCT01732315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34161642|NCT03243357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34161643|NCT00933868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744541|NCT02465593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161644|NCT02075151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161645|NCT04267835|||COHORT||PROSPECTIVE|||||||
34161646|NCT05150015|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Pilot feasability study||||
34161647|NCT02956317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34161648|NCT04215640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161649|NCT04270968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161650|NCT02300116|||||PROSPECTIVE|||||||
34161651|NCT05375721|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33744542|NCT04710797|RANDOMIZED|PARALLEL||TREATMENT||NONE||comprehensive staging surgery with or without lymphadenectomy||||
33744543|NCT04833023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study statistician will be blinded to the treatment allocation and outcome assessments (for example, Richmond Agitation and Sedation Scale).||f|f|f|t
33744544|NCT05119959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848128|NCT04642313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be single blind study, Participants will not be aware of the treatment group, they are receiving|Participants will be divided into 4 groups and will receive 4 different treatments at same time|t|f|f|f
33848129|NCT02905955|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33848130|NCT05424562|||COHORT||PROSPECTIVE|||||||
33848131|NCT05578781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial (RCT)|f|f|f|t
33848132|NCT03819998|||CASE_CONTROL||PROSPECTIVE|||||||
34057589|NCT06350695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective randomized-control 1:1 single blind study|t|f|f|f
34057590|NCT04751773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the exercise intervention instructors cannot be blinded, given the nature of the intervention. The outcome assessors of the primary and key secondary outcomes (adverse events and markers of surgical stress, respectively) will be blinded. For practical reasons, the outcome assessors of the following secondary outcomes will be not be blinded: resting cardiovascular factors, aerobic capacity, muscle strength, functional performance, and body composition and anthropometrics.||f|f|t|t
34057591|NCT05366985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057592|NCT03837964|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057593|NCT02170090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057594|NCT02634034|RANDOMIZED|CROSSOVER||||NONE||||||
34057595|NCT05977075|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34057596|NCT03959826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057597|NCT03613558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057598|NCT03616067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057599|NCT04367493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comparative, randomized, non-blind intervention study||||
34057600|NCT03694444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161652|NCT02697578|||COHORT||PROSPECTIVE|||||||
34161653|NCT03940300|NA|SINGLE_GROUP||TREATMENT||NONE||"Eligible and consented participants in this program will be asked to complete 12 visits. Over the course of these visits, participants will collect 10 weekly organic vegetable prescriptions signed by a qualified medical practitioner, as well as complete health screenings and questionnaires during the first and last visits. At each prescription pick-up visit, each participant will receive a week's dose of organic vegetables. The outcome measures will be collected at Visit 1 after obtaining informed consent and at Visit 12 after the completion of 10 weeks of prescriptions. Additionally, participants will be invited to submit via cell phone photographs of meals featuring their prescribed vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."||||
34161654|NCT05917106|||COHORT||PROSPECTIVE|||||||
34161655|NCT00006195||||TREATMENT||NONE||||||
34161656|NCT01199419|||COHORT||PROSPECTIVE|||||||
34161657|NCT05924594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161658|NCT04805437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Orthotist and research nurse will know what type of brace the participant receives, but will not tell the participant which type he/she has received. Investigators, care providers and outcome assessors will be blinded for type of brace.||t|t|t|t
34161659|NCT04327791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161660|NCT00313417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161661|NCT00837070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161662|NCT03642509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Open-label study with blinded outcome assessment by an independent clinical event committee||f|f|f|t
34161663|NCT00685113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161664|NCT03956212|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161665|NCT00828763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161666|NCT03903419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161667|NCT03409783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Devices are assigned per the randomization schedule, with the sham device identical to the active device in every way except that no neuromodulation is delivered. The neuromodulation that the active device delivers can be done in a way that causes no sensation, so subjects are not unmasked.|Single blind, randomized, sham controlled study|t|f|f|f
34161668|NCT02790801|||COHORT||PROSPECTIVE|||||||
33744545|NCT05150730|NA|SINGLE_GROUP||TREATMENT||NONE||One group (n=88) of participants has analyzed pre and post-intervention. In total six groups with 10 to 19 participants each, participated in a multi-professional care program, held over the years 2017 and 2018. The care program had between 16 and 21 meetings, which took place once a week.||||
33744546|NCT06635772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744547|NCT00399477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744548|NCT01088451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744549|NCT04054583|||OTHER||OTHER|||||||
33744550|NCT04076228|||CASE_ONLY||PROSPECTIVE|||||||
33744551|NCT05052970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848133|NCT04246151|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Blinding will be done in a double-blind fashion. The patients, their caregiver, and the investigator will be blinded to the study treatment.|Patients will be randomized to receive either a probiotic, oral vancomycin, or placebo in a parallel-group 1:1:1 design.|t|t|t|f
33848134|NCT02916303|||CASE_ONLY||RETROSPECTIVE|||||||
33848135|NCT01139580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848136|NCT00038012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848137|NCT06610331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848138|NCT04619979|||CASE_CONTROL||PROSPECTIVE|||||||
33848139|NCT05643352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848140|NCT02610907|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33848141|NCT05571371|||CASE_CONTROL||RETROSPECTIVE|||||||
33848142|NCT05338801|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participant will be blinded to study condition||t|f|f|f
33848143|NCT01636323|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33848144|NCT01986075|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Following an initial 4 week period where participants received computer-assisted behavioral intervention based on the community reinforcement approach with contingency management (CRA + CM), individuals who failed to achieve abstinence will continue the behavioral treatment (CRA + CM) and will be randomly assigned, in parallel, to a behavioral therapy enhancement strategy that will include either Mixed Amphetamine Salts-Extended Release (80mg) or placebo.|t|t|t|t
33848145|NCT02317913|||CASE_ONLY||RETROSPECTIVE|||||||
33848146|NCT01224392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848147|NCT04967638|||COHORT||RETROSPECTIVE|||||||
33848148|NCT03069755|||COHORT||RETROSPECTIVE|||||||
33848149|NCT01507519|NA|SINGLE_GROUP||TREATMENT||NONE||BioMime™ Sirolimus-Eluting Coronary Stent System||||
33848150|NCT02845206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33848151|NCT00076154|||CASE_ONLY||PROSPECTIVE|||||||
33848152|NCT03041051|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33953454|NCT03099616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The patient will be blinded to the type of anaesthesia intervention.The attending anaesthesiologist will however not be blinded to the technique utilized to administer GA and recovery immediately after extubation inside the OR. The postoperative patient recovery profile will be evaluated by an independent assessor blinded to the technique of GA.|"40 patients belonging to ASA physical patients status II and III of either sex, scheduled to undergo laparoscopic/robotic bariatric surgery (sleeve gastrectomy, Rouxen- Y gastric bypass) under general anaesthesia. The patients will be randomly allocated by computer generated numbers to one of the following two groups of 20 patients each.~Group-1 \[CLADS Group, n=20\]: Anaesthesia will be induced and maintained with Propofol administered using the automated CLADS.~Group-2 \[Desflurane Group, n=20\]: Anaesthesia will be induced with Propofol administered using the automated CLADS and will be maintained with Desflurane."|t|f|f|t
33953455|NCT05074459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953456|NCT00584831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953457|NCT05319652|NA|SINGLE_GROUP||OTHER||NONE||||||
33953458|NCT04067505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953459|NCT05423769|||COHORT||PROSPECTIVE|||||||
33953460|NCT02743598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953461|NCT04389294|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33953462|NCT01017965|||CASE_ONLY||PROSPECTIVE|||||||
34161669|NCT01433172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161670|NCT02012660|||||RETROSPECTIVE|||||||
34161671|NCT06408038|NA|SINGLE_GROUP||OTHER||NONE||||||
34161672|NCT05318703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34161673|NCT00927212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161674|NCT03236077|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744552|NCT04418882|||COHORT||RETROSPECTIVE|||||||
33744553|NCT04686903|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 paralel groups: Group A Epiduroscopy in patients with FBSS (50 patients) Group B Racz catheter epidural procedure in patients with FBSS (50 patients) Group C Caudal epidural block in patients with FBSS (50 patients)||||
33744554|NCT05978882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848153|NCT05447286|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double blind, placebo controlled.||t|t|t|t
33848154|NCT00202917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848155|NCT05810259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744555|NCT05108194|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will be enrolled in the intervention and all participants and study staff will be aware.|All participants will enroll in the intervention after a two week assessment phase.||||
33744556|NCT05631795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848156|NCT05987202|||COHORT||RETROSPECTIVE|||||||
33848157|NCT02458703|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33848158|NCT06402396|||COHORT||PROSPECTIVE|||||||
33848159|NCT05595447|NA|SINGLE_GROUP||TREATMENT||NONE||Brentuximab plus PD-1 blocked x 8 plus ASCT (PEAM condicioning) plus maintanance Brentuximab plus PD-1 x 8 cycles||||
33848160|NCT02745574|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33848161|NCT04772859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The primary outcome (BMI Z-score) and some secondary outcomes (body fat percentage and waist circumference), will be measured by a person blinded to the assignment group.||f|f|f|t
33848162|NCT03133559|||CASE_CONTROL||PROSPECTIVE|||||||
33848163|NCT01165853|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33848164|NCT00116753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744557|NCT03815851|RANDOMIZED|PARALLEL||PREVENTION||NONE|Investigators, surgical team and patients were not blinded to the assignment. In the the drain group, a 28 G latex tube was placed in the pelvic cavity intraoperatively and in the no-drain group, no drain was positioned. 30-day postoperative complications were assessed.|A Randomized Clinical Trial||||
33744558|NCT03704818|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33744559|NCT02127203|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848165|NCT04490382|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848166|NCT01367925|||CASE_CONTROL||PROSPECTIVE|||||||
33848167|NCT01302860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848168|NCT00620282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848169|NCT03090243|||COHORT||PROSPECTIVE|||||||
33848170|NCT02211235|||CASE_CONTROL||PROSPECTIVE|||||||
33848171|NCT05158816|||COHORT||RETROSPECTIVE|||||||
33848172|NCT01247285|RANDOMIZED|CROSSOVER||||NONE||||||
33848173|NCT00560560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848174|NCT02094287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848175|NCT01850446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848176|NCT04520490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848177|NCT02776722|||OTHER||PROSPECTIVE|||||||
33848178|NCT04373824|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||25 subjects in each Arm||||
33848179|NCT04012801|||CASE_CONTROL||RETROSPECTIVE|||||||
33848180|NCT00001629||||TREATMENT||||||||
33848181|NCT05962801|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled clinical trial||||
33953463|NCT05638438|||COHORT||RETROSPECTIVE|||||||
33953464|NCT06641687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33953465|NCT02175927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953466|NCT00924820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953467|NCT03707938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953468|NCT04836637|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33953469|NCT05123807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953470|NCT02724215|||CASE_CONTROL||PROSPECTIVE|||||||
33953471|NCT00117013||||TREATMENT||||||||
33953472|NCT06540352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953473|NCT06106217|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33953474|NCT04238494|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Multicomponent assessment: clinical, biological, functional, cognitive and MRI (muscle and brain)||||
33953475|NCT04003103|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33953476|NCT01934062|||COHORT||RETROSPECTIVE|||||||
33953477|NCT05950204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33848182|NCT04491565|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33848183|NCT04539535|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33953478|NCT01060007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953479|NCT06411431|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Surgical intervention and related care will follow current standard practices with the following items representing the randomized arms under investigation:~* Subjects within the Early Removal group will have their chest tube removed on POD#1, within 24 hours from the end of the surgery.~* Subjects in the Standard Removal group will have their chest tube would be removed on POD#2."||||
33953480|NCT06103617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953481|NCT05349760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|IRT and unblinded pharmacists|2:1 randomization of active to placebo|t|f|t|f
33953482|NCT03949634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953483|NCT01408836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953484|NCT03542929|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A researcher was performed the interventional protocol and a different researcher was made the evaluations||f|f|f|t
33953485|NCT03612830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Laparoscopic and Endoscopic cooperative sugery,Robotic and Endoscopic cooperative sugery|t|f|f|t
33953486|NCT06648226|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953487|NCT06022666|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33953488|NCT01824095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953489|NCT03313388|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33953490|NCT01238666|||CASE_ONLY||PROSPECTIVE|||||||
33953491|NCT05797948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953492|NCT02397109|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953493|NCT02558075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33953494|NCT00369798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953495|NCT04054011|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive deoxycholic acid (1-4 treatment sessions) for treatment of upper inner thigh fat.||||
33953496|NCT02448212|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33953497|NCT04375566|||COHORT||PROSPECTIVE|||||||
33953498|NCT00327080||||TREATMENT||||||||
33953499|NCT04973670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953500|NCT06382766|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953501|NCT02612649|||COHORT||PROSPECTIVE|||||||
33953502|NCT05705349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161675|NCT06467461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161676|NCT01756196|||CASE_ONLY||PROSPECTIVE|||||||
34161677|NCT05743361|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34161678|NCT04867746|||COHORT||CROSS_SECTIONAL|||||||
34161679|NCT04527367|||COHORT||PROSPECTIVE|||||||
34161680|NCT01633164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34161681|NCT02553395|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34057601|NCT05801510|NA|SINGLE_GROUP||TREATMENT||NONE||All partiticipants will receive seven sessions of CMT over a 7 week period. All participants will complete questionnaires at baseline and at 10 weeks||||
34161682|NCT04089761|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, open-label, multicenter study||||
34161683|NCT00694668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161684|NCT00407472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161685|NCT03032341|||CASE_CONTROL||PROSPECTIVE|||||||
34161686|NCT05220306|NA|SEQUENTIAL||DIAGNOSTIC||NONE||"Phase I/Derivation Cohort (100 patients):~This phase will use the MouthLab to capture vital signs. This data will help create Aidar's algorithm-based decompensation index (AIDI) that utilizes changes in vital signs to identify individuals who test positive for SARS-CoV-2 or with COVID-19 infection and are at risk of developing clinical decompensation.~Phase II/Validation Cohort (400 patients):~This phase will use the MouthLab to capture vital signs and use Aidar's algorithm-based decompensation index (AIDI) to identify individuals at risk of clinical decompensation."||||
34161687|NCT05702138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161688|NCT05844020|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161689|NCT00256724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161690|NCT01559051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161691|NCT02598206|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34161692|NCT00936000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34161693|NCT00001870||||TREATMENT||||||||
34161694|NCT06125444|||COHORT||RETROSPECTIVE|||||||
34161695|NCT06128577|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161696|NCT01670903|||COHORT||PROSPECTIVE|||||||
34161697|NCT01561521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161698|NCT02175979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161699|NCT04383457|||COHORT||PROSPECTIVE|||||||
34161700|NCT01004926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057602|NCT00574210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057603|NCT06618404|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34161701|NCT01460758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161702|NCT00727051|||CASE_ONLY||CROSS_SECTIONAL|||||||
34161703|NCT01602289|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161704|NCT06160947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, it will not be possible to blind patients, study personnel, or clinicians to treatment allocation. However, data analysts and investigators responsible for interpreting results will be blinded to treatment allocation until all data have been analyzed and interpreted.|Cluster-randomized, 2-arm, data analyst-blinded feasibility trial|f|f|t|f
34161705|NCT02578199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057604|NCT02375880|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161706|NCT03186027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator, care provider and participants do not know which individuals have been assigned in each arm or comparison group.|"Active Dietary Supplement: ReConnect (CoQ10 plus NADH) and excipients. ReConnect supplementation (CoQ10: 200mg/day plus NADH 20 mg/day) divided into 2 daily dose (2 tablets/ before breakfast and 2 tablets/ before lunch).~Excipient Dietary Supplement: Placebo (serine plus vitamin C) Placebo supplementation divided into two daily dose (2 tablets/before breakfast and 2 tablets/ before lunch)"|t|t|t|f
34057605|NCT04558606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Monocetric, pragmatic, single blinded, randomized clinical trial, parallel design.|f|f|t|f
34057606|NCT04253405|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized controlled study||||
34057607|NCT01296061|||COHORT||PROSPECTIVE|||||||
33848184|NCT02825173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848185|NCT02710318|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33848186|NCT02955732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848187|NCT01675245|||CASE_ONLY||PROSPECTIVE|||||||
33848188|NCT05039099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848189|NCT05401825|||COHORT||PROSPECTIVE|||||||
33848190|NCT00501839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848191|NCT03975751|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057608|NCT00640653|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057609|NCT05331768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy|This was a randomized clinical trial. Eligible patients were randomised to receive banding ligation plus terlipressin infusion for 24 hours or banding ligation plus terlipressin infusion for 72 hours|t|f|f|f
34057610|NCT05970770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057611|NCT06192992|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34057612|NCT05222022|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects participated in a design validation to evaluate the mechanism of action of the device to measure eye movement. This is not an applicable clinical trial to evaluate the effect of an intervention on biomedical or other health-related outcomes.||||
34057613|NCT00355706|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34057614|NCT02008747|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161707|NCT04149561|||COHORT||CROSS_SECTIONAL|||||||
34161708|NCT04618744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study will consist of a Screening Phase, Placebo Run-in Phase, Treatment Phase, and an End-of-Study Phase. Approximately 36 subjects will be randomized in a 2:1 ratio to receive either 8 mg ORMD-0801, 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) or matching placebo.|t|t|t|t
34161709|NCT06519812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161710|NCT06423924|||COHORT||RETROSPECTIVE|||||||
34057615|NCT05692531|NA|SINGLE_GROUP||PREVENTION||NONE||"This is an evaluation of a virtual event. The investigators will conduct a social media metrics analysis (of the social media-based run-up to the event as well as the actual event) via responses to polls embedded within the social media-based run-up, and sentiment assessment and analysis during the event itself. The investigators will conduct flash polls during the event using sentiments that reflect key stigmatization process-related aspects of the scenarios being depicted, for example asking attendees to rate the actors on specific qualities on a scale of 1 to 10 (for example, respect admire dislike annoyed tactful sensitive shady etc.); the investigators will repeat this after the scenarios are screened and integrate the immediate results into the discussion of the filmed scenarios. The investigators will conduct flash polls on confidence confronting stigmatizing language toward someone who is considering taking PrEP."||||
34057616|NCT03644836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057617|NCT05686161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study uses an observer-blinded design, and the investigators and participants will all remain blinded before unblinding and do not know which group the participant belongs to.|a randomized observer-blinded parallel controlled trial#Experimental group#mRNA vaccine# and positive control group#inactive vaccine#|t|f|t|f
34057618|NCT00878969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34057619|NCT05269888|||CASE_CONTROL||PROSPECTIVE|||||||
34057620|NCT03085992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057621|NCT05550987|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random selection to two groups (study group and control group)||||
34057622|NCT00177307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057623|NCT05725265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057624|NCT04662788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057625|NCT02650947|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34057626|NCT03202537|NA|SINGLE_GROUP||OTHER||NONE||||||
34057627|NCT05716906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057628|NCT02684409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057629|NCT04058106|||CASE_ONLY||PROSPECTIVE|||||||
34057630|NCT01575275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057631|NCT05574803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blinded|t|f|t|t
34057632|NCT02863081|||COHORT||PROSPECTIVE|||||||
34057633|NCT04761081|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057634|NCT02618694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057635|NCT04055376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomly assigned to one of two study groups. Subjects in the first group will use the GENUS device with active settings for 6 or 9 months, and subjects in the second group will use the GENUS device with sham settings for 6 or 9 months. At the end of the 6 or 9 month period, all subjects will be given an option to continue the usage of the GENUS device for additional 6 or 9 months. For these additional 6 or 9 months, the device will be set to active settings for all subjects who choose to remain in the study. A 36-month compassionate use extension will be offered at the completion of all of the study visits.|t|t|f|f
34057636|NCT03200847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057637|NCT05213793|||CASE_ONLY||PROSPECTIVE|||||||
34057638|NCT02409381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057639|NCT01730651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057640|NCT03935542|||COHORT||RETROSPECTIVE|||||||
34057641|NCT00968058|||CASE_ONLY||PROSPECTIVE|||||||
34057642|NCT03051698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057643|NCT06619288|||COHORT||OTHER|||||||
34057644|NCT05336292|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of three groups; intervention based on meaningful life(MLI); intervention based on meaningful life and emotional regulation (MLI+ER) or control group.||||
34057645|NCT05615870|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Families will be masked as to whether their Winix units are equipped with or without HEPA/carbon filters.~Study coordinators, investigators, and other team members who interact with participants' parent(s)/guardian(s) to obtain surveys, troubleshoot equipment setup and operation, or have other interactions will remain masked through the duration of the study for individual participants. This includes masking as to which intervention the participants receive and household air quality measurements, including the baseline measurements (separate personnel will need to be on the receiving end for air quality measurement data). This will require more than one study coordinator or additional staff/technician on the study team."|This is a multi-center, parallel, double-blind, randomized controlled clinical trial|t|t|t|f
34057646|NCT04002999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057647|NCT00274079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34057648|NCT06042361|NA|SINGLE_GROUP||PREVENTION||NONE||Two-phased approach: formative first phase, testing second phase. Enrollment based on residential property clusters.||||
34057649|NCT00297531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34057650|NCT02119221|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057651|NCT01374048|||CASE_ONLY||PROSPECTIVE|||||||
34057652|NCT05721248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057653|NCT06376422|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking, patient decides which group|||||
34057654|NCT01841450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057655|NCT00655733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953503|NCT03240809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953504|NCT04368117|RANDOMIZED|PARALLEL||TREATMENT||NONE||Severely burn injured with a 15% TBSA of burn injury or larger who require a skin graft surgery||||
33953505|NCT03570307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953506|NCT00219024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953507|NCT02452008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953508|NCT02361801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33953509|NCT01019746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953510|NCT04756167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher who will make the measurements will not know the treatment groups of the individuals.|The individuals are randomly allocated into conventional and myofascial release groups|f|f|f|t
33953511|NCT04859699|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848192|NCT01635205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848193|NCT04997681|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||2x2 factorial design|t|f|f|t
33848194|NCT04781400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848195|NCT00412061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848196|NCT01423721|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848197|NCT01593956||||TREATMENT||||||||
33848198|NCT03292432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a Phase II, two-arm, randomized, open-label study.||||
33848199|NCT03732599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Technologists who do the vision testing on participants are masked as to which arm the participant was randomized"|This is a randomize study, in which half of the participants will be receiving either the standard deep anterior lamellar keratoplasty (DALK) (with a blade) technique or the femtosecond laser technique that creates the initial incisions instead of a blade.|f|t|f|f
33848200|NCT03082118|NA|SINGLE_GROUP||TREATMENT||NONE||All women enrolled are treated.||||
33848201|NCT01303679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161711|NCT00983320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161712|NCT04865419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161713|NCT03716219|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34161714|NCT06341556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161715|NCT02333799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848202|NCT06415513|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||intervention group: Autonomous Sensory Meridian Response; control group: no intervention||||
33848203|NCT06176807|||OTHER||OTHER|||||||
33848204|NCT06515132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is being conducted as a double-blind trial, wherein the surgeons, assessors and participants' family members are kept unaware of the assigned research groups. However, it is necessary to inform the physicians responsible for adjustment of stimulation parameters about the allocation of participants. Follow-up assessments of participants after stimulation will be conducted by an independent assessor using standardized evaluation criteria.||t|t|t|t
33848205|NCT03927573|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation scheme; Single patient cohorts on the first three dose levels, 3+3 afterwards.||||
33848206|NCT00678613|RANDOMIZED|||PREVENTION||DOUBLE||||||
33848207|NCT00839904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848208|NCT03803631|||COHORT||PROSPECTIVE|||||||
33953512|NCT03668613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161716|NCT00714415|||COHORT||PROSPECTIVE|||||||
34161717|NCT05858892|||OTHER||OTHER|||||||
34161718|NCT04649515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are assigned to either treatment or placebo|t|f|t|f
33848209|NCT02668601|||CASE_CONTROL||RETROSPECTIVE|||||||
33848210|NCT04428268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|investigator will not be aware of the treatments or outcomes until the end of the study|double blind randomized clinical trial|f|f|t|t
33953513|NCT02257931|||CASE_CONTROL||PROSPECTIVE|||||||
33953514|NCT04461912|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study includes participants with age-related cataract and healthy subjects as control group||||
33953515|NCT03752866|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This registry will include market released Portico™ valves (23mm, 25mm, 27mm and 29mm), delivery systems and loading systems. The registry will also allow future iterations of the Portico valve and delivery system along with expanded indications to be included as they receive approval for commercial use in the country where the subject is enrolled.||||
33953516|NCT05181553|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Subjects cannot be blinded to treatment allocation, but all laboratory analyses and outcomes will be assessed in a blinded fashion by research staff.|"The proposed research will combine a dietary RCT (objectives 1, 2) and a cohort investigation (objective 3). The dietary intervention will be undertaken as a crossover RCT at the INAF (Université Laval) in Quebec City. Men and women with genetically-defined HeFH will consume in a random order a fully-controlled diet low in red and processed meats and high in plant foods, reflecting Canada's Food Guide principles (CFG diet in further sections), and a standard North American diet (NAD diet; i.e. control diet), reflecting current dietary intakes of French-Canadians, for 4 weeks each, and separated by a 4-week washout period.~The first and second objective consist respectively to investigate the impact of a CFG diet in place of a standard NAD on LDL-C concentrations and plasma metabolome.~The third objective consist to evaluate the association between the plasma metabolomic signature of a diet low in red and processed meats and high in plant foods and cardiovascular disease risk."|f|f|t|t
33953517|NCT06411002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953518|NCT01514591|||COHORT||PROSPECTIVE|||||||
33953519|NCT04980066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33953520|NCT02797951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057656|NCT03431662|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34057657|NCT02253771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057658|NCT05512806|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study due to which blinding is not applicable.|||||
34057659|NCT06137287|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34057660|NCT05724459|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34057661|NCT01741792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057662|NCT00723190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057663|NCT00926458|||COHORT||PROSPECTIVE|||||||
34057664|NCT03861312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057665|NCT01820507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057666|NCT06073275|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||This study was a randomized, double-blind, crossover design|t|f|t|t
34057667|NCT05487378|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057668|NCT03195023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057669|NCT06461065|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057670|NCT01756781|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34057671|NCT02585271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057672|NCT00079586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161719|NCT05292716|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34161720|NCT05211427|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34161721|NCT01669772|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33848211|NCT00944073|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848212|NCT01159002|||COHORT||PROSPECTIVE|||||||
33848213|NCT06274372|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33744560|NCT02320604|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744561|NCT05032703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||t|f|f|f
33744562|NCT02407561|||COHORT||PROSPECTIVE|||||||
33744563|NCT01617421|NA|SINGLE_GROUP||OTHER||NONE||||||
33848214|NCT02280694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848215|NCT03510494|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group receiving 270 minutes of weekly physical education Control group receiving 90 minutes of weekly physical education Intervention group physical education teachers receiving physical education courses (ATK-concept)||||
33848216|NCT02912923|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33848217|NCT00269893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848218|NCT05857644|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||An open-label, single dose, parallel group, multicenter study to investigate the effect of varying degrees of hepatic function on the plasma PK of PF-07923568 after a single, oral 200 mg dose administered in the fed state (standard breakfast).||||
33848219|NCT02751541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848220|NCT00670631|NA|SINGLE_GROUP||TREATMENT||NONE||Induction- Tandem Transplants with VTD-MEL and gemcitabine, BCNU, melphalan, velcade and dexamethasone- Maintenance therapy||||
33848221|NCT05028907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848222|NCT04404127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The trial will be blinded with respect to Basiliximab induction allocation. The study will be blinded to subjects and site study investigators, with the following exceptions:~A single pharmacist A single biostatistician Patients with receive either basiliximab or an intravenous piggyback (IVPB) with normal saline depending on their allocation."||t|f|t|f
33848223|NCT04732598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848224|NCT01237275|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33848225|NCT01835418|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848226|NCT05321654|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective parallel randomized controlled trial with repeated measures||||
33848227|NCT06182943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848228|NCT04890119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848229|NCT01621568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848230|NCT03872024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848231|NCT01712659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848232|NCT02751775|||CASE_ONLY||PROSPECTIVE|||||||
33848233|NCT03443050|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34057673|NCT03128320|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34057674|NCT01759316|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34057675|NCT00731757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057676|NCT03203759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057677|NCT01609309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057678|NCT04385290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subtrials are not blinded.|"The phase I dose escalation trial (MODULE) will be conducted according to the 3+3 design.~The phase II trial in CBF AML (MAGNOLIA) will be conducted in a open label and randomized manner.~The phase II trial in FLT3 mutated AML (MAGMA) will be conducted in a open label and randomized manner."|t|t|t|t
34057679|NCT02083185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057680|NCT01293513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057681|NCT01646112|||||RETROSPECTIVE|||||||
34057682|NCT00307632|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34057683|NCT02236806|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both participants and Care Providers are not aware of intervention allocation.||t|t|f|f
34057684|NCT01112410|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34057685|NCT04848792|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The design of this experiment will be a randomized, double-blind, placebo-controlled, cross-over design, where each subject will serve as their own control. Randomization of order of trials (supplement/placebo) will be performed by a person that is otherwise not part of study personnel, and study personnel and subjects will be blinded to the order. The person doing the randomizing will keep a record of the order using study ID, and researchers will be unblinded upon completion of data collection.|Humans|t|f|t|f
34057686|NCT03641534|||CASE_CONTROL||PROSPECTIVE|||||||
34057687|NCT06406634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057688|NCT05443438|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to one of for conditions.||||
34057689|NCT02133794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057690|NCT06622265|||COHORT||PROSPECTIVE|||||||
34057691|NCT00100113||||TREATMENT||||||||
34057692|NCT06017817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The first assessments will be made before randomization.~After the randomization, there is no masking."|80 subjects in total are recruited to this study: 40 subjects in the non-surgical treatment (NST), of which 20 participants in the NST Study group (NST-1) and 20 participants in the NST Control group (NST-2), and 40 subjects in the surgical treatment (ST), of which 20 participants in the ST Study group (ST-1) and 20 participants in the ST Control group (ST-2).|t|f|t|f
34057693|NCT00774527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057694|NCT00004638||||DIAGNOSTIC||||||||
34057695|NCT05668143|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single Blinded|The patients will be divided into two as the experimental and control group.The study will be conducted as a randomized controlled trial. Patients in the experimental group will be informed about the using virtual reality glasses during total knee replacement surgery.|f|f|f|t
34057696|NCT02426749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057697|NCT01335880|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057698|NCT06042049|NA|SINGLE_GROUP||PREVENTION||NONE|No masking is used. All involved know the identity of the intervention assignment.|||||
34057699|NCT05447767|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057700|NCT03279796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057701|NCT00108511|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34161722|NCT04852718|||COHORT||PROSPECTIVE|||||||
34161723|NCT03084003|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34161724|NCT03838081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34161725|NCT00607087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161726|NCT01568710|||||PROSPECTIVE|||||||
34161727|NCT05984589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161728|NCT00048698||||TREATMENT||||||||
34161729|NCT00037492|RANDOMIZED|||PREVENTION||||||||
34161730|NCT05789394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161731|NCT03470090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants didn't know taking which exercise treatment methods.|Experimental, Randomized Controlled Study|t|f|f|f
34161732|NCT03935243|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161733|NCT05852912|||COHORT||CROSS_SECTIONAL|||||||
34161734|NCT04030572|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161735|NCT05242484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161736|NCT06029569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161737|NCT05906433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The PI standard of care is to offer patients who complain of knee pain a corticosteroids injection regardless of patient participation in a study. A consent will be obtained prior the injection by a trained/qualified team member. Subjects will be randomly allocated to groups by concealed allocation. Randomization sequence between three groups will be created using Excel and will be further stratified by sex within each block, to ensure even distribution. A set of numbered envelopes will be created, with each having one unique group assigned. A staff member will assign an envelope with group assignment upon consent and record envelope number ID. The ARNP will open an envelope, administer injection based on the group assigned. The ARNP will prepare the medication to maintain the double blinded aspect of the study. The ARNP is trained and experienced with injections and has giving injections for several years. She will not be involved in the evaluations of the patient pre/post injection.|"At screening/baseline, informed consent will be obtained, demographics and medical history will be collected, patient x-ray will be reviewed/KL grade confirmed, narcotic use in last 6 months will be screened using E-FORCSE (Florida Prescription Drug Monitoring Program) database, inclusion and exclusion criteria will be assessed, and patient will be randomized into one of the study groups. We will only include patients who are receiving unilateral knee injections. Further, patient's baseline information on VAS Pain and current medication (analgesic or NSAID) will be collected. VAS Pain will be also collected immediately after the intervention and 2 minutes after the intervention, in addition to global perceived improvement score and AEs.~The intervention in this study is intra-articular knee injection of synthetic corticosteroid (kenalog) and variable amount of anesthetic (0ml, 2ml or 4 ml of 0.25% bupivacaine)."|t|f|f|f
34161738|NCT04563195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848234|NCT03026985|||COHORT||PROSPECTIVE|||||||
34057702|NCT04909749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Primary study Investigator(s) and analyzers of samples with be masked. Only one co-I responsible for group randomization will be unmasked to study.|Approximately 100,000 patients are clinically managed by El Rio providers each year. A PHQ-2 is routinely completed by all visiting patients at El Rio health to screen for depression. Patients who screen positive on the PHQ-2 subsequently take the PHQ-9, a similar but more sensitive and specific depression assessment tool. For our study, a total of 350 patients will be recruited and randomized to PGx-guided antidepressant therapy (n= 175) or treatment as usual (n =175). Patients who are currently clinically managed for depression will be eligible for participation as well. Patients who are pregnant, have a history of major depressive disorder, or a concurrent diagnosis of other psychiatric issues will be excluded. Patients who will not be treated with antidepressants will be excluded|t|f|t|f
33848235|NCT05687357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848236|NCT04078243|||COHORT||PROSPECTIVE|||||||
33848237|NCT01060579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057703|NCT06394856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057704|NCT01325116|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34057705|NCT01565369|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34057706|NCT00312065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057707|NCT04754620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34057708|NCT01345110|||COHORT||PROSPECTIVE|||||||
34057709|NCT01513811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057710|NCT03812562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057711|NCT03763461|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057712|NCT03412188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be divided into 2 groups:~Group 1 (eltrombopag arm n=20 patients): Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy. patients will receive a total daily dose of eltrombopag of (25-50mg/d). Dose adjustments may be made based on platelets count.~Group 2 (n=20 patients) Patients who are currently receiving other lines of treatment (steroids, IVIG, azathioprine, and rituximab)."||||
34057713|NCT06619418|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34057714|NCT06619119|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34057715|NCT01696149|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34057716|NCT02619396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057717|NCT06619106|||COHORT||PROSPECTIVE|||||||
34057718|NCT06616714|||COHORT||PROSPECTIVE|||||||
34057719|NCT05657600|||CASE_CONTROL||PROSPECTIVE|||||||
34057720|NCT01533636|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057721|NCT03976167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34057722|NCT01500408|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34057723|NCT02634268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057724|NCT05426213|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057725|NCT05760742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34161739|NCT00122408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161740|NCT03565783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161741|NCT01908478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161742|NCT01985750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34161743|NCT06727266|||CASE_CONTROL||PROSPECTIVE|||||||
34161744|NCT04728607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161745|NCT05595642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057726|NCT06318052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057727|NCT01152359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057728|NCT00132938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057729|NCT02101372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057730|NCT00327743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057731|NCT04913727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057732|NCT06215469|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34057733|NCT04826887|||COHORT||PROSPECTIVE|||||||
34057734|NCT03566875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057735|NCT06304805|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This is a PK assessment study, hence only bio-sample analysis personnel were masked for the type of treatment received for each sample to avoid bias in analysis. Other study personnel, including participants, investigators and staffs were not masked for treatment types.||f|f|f|t
34057736|NCT02005913|||CASE_ONLY||PROSPECTIVE|||||||
34057737|NCT02932735|||COHORT||PROSPECTIVE|||||||
34057738|NCT02393924|||COHORT||PROSPECTIVE|||||||
33953521|NCT04186234|NA|SINGLE_GROUP||TREATMENT||NONE|Inapplicable|Stereotactic body radiation therapy as bridging therapy before liver transplantation for hepatocellular carcinoma||||
33953522|NCT04938102|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34161746|NCT05522257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This pilot study is a single centre, open-label, phase II study in patients with advanced soft tissue sarcoma (cohort 1) and advanced urothelial cell carcinoma (cohort 2). It is a non-randomized, non-blinded, prospective pilot study to assess the level of PSMA expression and the feasibility of PSMA-targeted theranostics in these patient groups. In all patients that are included in this pilot study, immunohistochemical PSMA staining will be performed on their biopsy material. In case of high PSMA expression, as defined by previous literature, a \[18F\]-JK-PSMA-7 PET/CT scan will be made to assess the level of tracer uptake in the malignant lesion(s). The expected duration of recruitment is 1 year and 9 months. An early stopping rule of 5 negative PSMA PET/CT scans is implemented in this study, for each cohort.||||
34161747|NCT02602522|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34161748|NCT04259125|||COHORT||PROSPECTIVE|||||||
34161749|NCT05586984|||COHORT||PROSPECTIVE|||||||
34161750|NCT05654168|||COHORT||CROSS_SECTIONAL|||||||
34161751|NCT05042076|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, Phase I, open label, non-randomized, non-placebo controlled||||
34161752|NCT06184750|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34161753|NCT06436404|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding (Participant)|Randomized controlled, single-blind parallel design experimental study.In the study, premature infants will be divided into three groups by randomization. Each group will be referred to as A, B or C for convenience. The type of intervention will be determined by drawing lots for A, B and C. For example, A= Hammock Position, B= Kangaroo Care c=Control Group. When applying the hammock position to a group; The other group will receive kangaroo care, while the other group will receive standard care. For randomization, blocks of 6 will be created for 36 infants and this process will be done by an independent statistician.|t|f|f|f
33744564|NCT03973190|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Group RET: Closure of the alveolus by first intention through palatal flap sliding according to the technique of Khoury et al. (2000).~SBC Group: Fill bone alveolus with Bone Ceramic® graft (Straumann AG, Basel, Switzerland) and cover it with palatal flap according to the technique of Khoury et al. (2000).~PRO Group: Alveolus sealing by a temporary ovoid pony of acrylic resin"||||
33744565|NCT03925636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744566|NCT03663751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744567|NCT04656158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33744568|NCT04691869|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33744569|NCT03980470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744570|NCT03873649|||COHORT||PROSPECTIVE|||||||
33744571|NCT02667158|||OTHER||RETROSPECTIVE|||||||
33744572|NCT02078284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953523|NCT05882656|||COHORT||PROSPECTIVE|||||||
33953524|NCT02504463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953525|NCT02944344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33953526|NCT04984499|||OTHER||CROSS_SECTIONAL|||||||
33953527|NCT05580432|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Waitlisted control||||
33953528|NCT01300741|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33953529|NCT04513665|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will be conducted in two stages. Stage 1 will accrue 16 patients and if two or greater responses are seen, Stage 2 will accrue an additional 9 patients.||||
33953530|NCT03759509|RANDOMIZED|PARALLEL||OTHER||NONE||The study will randomly sample from previously screen low sleep quality participants, then random assign to experimental (aerobic exercise) and control (routine activity) groups||||
33953531|NCT06330467|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||3 groups : borderline, early psychosis and FDC.||||
33744573|NCT01140191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848238|NCT01014143|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33848239|NCT00578461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848240|NCT06609733|||CASE_CONTROL||RETROSPECTIVE|||||||
33848241|NCT04128761|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33848242|NCT06609135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161754|NCT06241053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants of both groups will be informed about the possible risks and potential.~benefits but they won't know which group they are placed in. The participants must sign consent forms agreeing to the experiment."||t|f|f|f
34161755|NCT05929287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants won't be aware of which group they are randomized to.||t|f|f|f
34161756|NCT01049529|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34161757|NCT03025984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161758|NCT05163652|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34161759|NCT03549104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Principal Investigator and outcome assessors masked.|randomized controlled trial|f|f|t|t
34161760|NCT03124576|||COHORT||PROSPECTIVE|||||||
34161761|NCT03469102|||COHORT||RETROSPECTIVE|||||||
34161762|NCT03600740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161763|NCT03468361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161764|NCT03694717|||COHORT||PROSPECTIVE|||||||
34161765|NCT06421584|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Mentors and telementors performing the GOALS-assessment of the video records are blinded to the temporal order of the performed procedures by the residents in both groups.|This randomized controlled trial (RCT) was designed as a superiority trial to demonstrate the superiority of telementored resident skill learning in the operating room (OR) compared to standard training methods.|t|f|f|t
34161766|NCT01219985|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34161767|NCT03263572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161768|NCT06726876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34161769|NCT05331599|||COHORT||PROSPECTIVE|||||||
34161770|NCT05938075|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34161771|NCT04162522|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34161772|NCT03744767||SEQUENTIAL||TREATMENT||NONE||all participants receive fixed monthly intravitreal anti-VEGF injections for 6 months, plus adjuvant treatment during 4 months, followed by 2 months without adjuvant treatment.||||
34161773|NCT06292780|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Note: Participants enrolled in Phase 2 will be randomized 1:1||||
34161774|NCT06727357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34161775|NCT05565196|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|6801|||||
34161776|NCT03885024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This study proposes a two-arm, individual-level randomized trial in which those in the intervention condition refer a study buddy peer who will be trained to help retain the index participant in their follow-up visits."||||
34161777|NCT05897229|||COHORT||CROSS_SECTIONAL|||||||
34161778|NCT03127293|||CASE_CONTROL||PROSPECTIVE|||||||
34161779|NCT04702841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161780|NCT01069965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161781|NCT05313841|||CASE_ONLY||CROSS_SECTIONAL|||||||
34161782|NCT00273065|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34161783|NCT06579963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Trial participants will be aware of the intervention to which they have been allocated, and the research fieldworkers will be aware of the intervention allocation. The trial steering committee members and trial statistician will remain blinded until the end of trial period and data collection.||f|f|t|t
33848243|NCT05142488|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Only the laboratory technician will be blinded|||||
33848244|NCT00049920|||COHORT||PROSPECTIVE|||||||
33848245|NCT06308848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Randomized controlled trial (Proof of concept study)|t|t|t|t
33848246|NCT00577876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848247|NCT03675373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953532|NCT01738204|||CASE_CONTROL||PROSPECTIVE|||||||
33953533|NCT04360213|||COHORT||PROSPECTIVE|||||||
34161784|NCT05721521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34161785|NCT06456645|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34161786|NCT06726512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161787|NCT02087449|||CASE_ONLY||PROSPECTIVE|||||||
34161788|NCT04366440|RANDOMIZED|SEQUENTIAL||OTHER||NONE||A stepped-wedge study design will be utilized. All sites will begin in the control intervention, order set review and modification. Sequentially, clusters of 3 hospitals will begin in the experimental intervention, order set review and modification plus facilitation.||||
34161789|NCT04880655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161790|NCT04827888|||COHORT||OTHER|||||||
34161791|NCT01584739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34161792|NCT01454986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161793|NCT02668887|||COHORT||PROSPECTIVE|||||||
34161794|NCT04240574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744574|NCT01055366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744575|NCT04986657|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33744576|NCT00581529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744577|NCT02106026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744578|NCT06496893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, placebo-controlled study|t|t|t|t
33744579|NCT02855099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744580|NCT06626191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744581|NCT04108546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744582|NCT00724347|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744583|NCT06045962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744584|NCT05123365|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33744585|NCT00406575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744586|NCT02094703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744587|NCT02161744|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I open label study to assess safety and tolerability||||
33744588|NCT06483750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744589|NCT06668974|||OTHER||RETROSPECTIVE|||||||
33744590|NCT05207696|||OTHER||RETROSPECTIVE|||||||
33744591|NCT05440864|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a phase II, open label single arm, multicentre study of single dose Tremelimumab (T300) in combination with Durvalumab preoperatively in patients with upfront resectable HCC followed by adjuvant Durvalumab.~This study will enroll 28 patients at three academic institutions in Canada and Europe. Patients will receive 1 dose Tremelimumab (300 mg) with Durvalumab (1500mg) at cycle 1 (4W) and 1 further cycle of Durvalumab (1500mg) pre surgical resection. Post-surgical resection patients will begin adjuvant Durvalumab (1500mg Q4W) to complete 13 cycles of treatment (or 11 post operatively) in total."||||
33744592|NCT03321981|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2||||
33744593|NCT02387632|||COHORT||PROSPECTIVE|||||||
33744594|NCT00839072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744595|NCT04464187|||COHORT||PROSPECTIVE|||||||
33744596|NCT04595708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual who collected baseline and follow-up surveys was blinded to the status of the participant as part of control or intervention group.|Randomized controlled trial|f|f|f|t
33744597|NCT05308862|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744598|NCT01429259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744599|NCT03844763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744600|NCT01817049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33744601|NCT01138332|||CASE_ONLY||RETROSPECTIVE|||||||
33744602|NCT06040489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848248|NCT04129216|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Patients will start the hormone therapy before surgery; the investigators look for the genomic profiles of the tumor before and after chemotherapy||||
33848249|NCT03122132|||OTHER||PROSPECTIVE|||||||
33848250|NCT06355427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848251|NCT01182194|RANDOMIZED|CROSSOVER||||NONE||||||
33848252|NCT00071747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33848253|NCT05446467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848254|NCT04371198|NA|SINGLE_GROUP||OTHER||NONE||||||
33848255|NCT01141556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848256|NCT00471731|||||PROSPECTIVE|||||||
33848257|NCT06606483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848258|NCT03748992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848259|NCT03354585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Only the study physician, research coordinator, and intervention facilitators will be aware of group assignment.|This intervention study will utilize an unbiased randomized study design. Pain intensity and pain unpleasantness ratings will be assessed using before and after all sessions where low back pain is induced. Study volunteers will be randomized and subsequently participate in a six session mindfulness meditation, non-mindfulness meditation or book-listening control regimen. Study volunteers will be required to complete two MRI scans over the course of the study.|t|f|t|t
33848260|NCT04342052|||COHORT||PROSPECTIVE|||||||
33848261|NCT01124331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848262|NCT04333641|||OTHER||PROSPECTIVE|||||||
33848263|NCT01528553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33848264|NCT00461513|||OTHER||PROSPECTIVE|||||||
33848265|NCT03500159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953534|NCT05232643|||COHORT||CROSS_SECTIONAL|||||||
33953535|NCT06567574|||OTHER||RETROSPECTIVE|||||||
33848266|NCT04847206|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"Double-blind, placebo-controlled, 5-period cross-over design with four active substance conditions (equimolar doses of psychoactive substance) and placebo:~1. MDMA (100 mg MDMA-hydrochloride; 84.1 mg MDMA free base) 2) MDA (93.9 mg MDA-hydrochloride; 78.0 mg MDA free base) 3) lysMDMA (171.7mg lysMDMA dihydrochloride; 84.1 mg MDMA free base) 4) lysMDA (165.6 mg lysMDA dihydrochloride; 78.0 mg MDA free base) 5) Placebo"|t|t|t|f
33848267|NCT01518400|||COHORT||PROSPECTIVE|||||||
33848268|NCT01097122|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33848269|NCT01850732||||SCREENING||||||||
33848270|NCT06609746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34057739|NCT04973059|RANDOMIZED|CROSSOVER||OTHER||NONE||This study is not evaluating a clinical intervention. There is no anticipated clinical benefit from this study. It is assessing whether use of the SmartDrive increases participation and decreases solution isolation. Secondarily it is will provide information about the levels of exertion needed in comparing wheelchair propulsion using SmartDrive and usual wheelchair propulsion. We intend to determine if SmartDrive improves participation in the winter when it is difficult to propel manual wheelchair on snow covered sidewalks and parking lots. Participants will be randomly assigned to using either the SmartDrive or not in the first week of monitoring in the summer. They will then switch to either the intervention (SmartDrive) or control (no SmarDrive) for the next week. This will then be repeated in the winter. Activity information will be collected using the SmartDrive sensor and another sensor that will measure a wide range of activity data including for the control arm of the study.||||
33848271|NCT02505438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33848272|NCT00381615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848273|NCT05062759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the participant nor any of the investigators or sponsor staff who are involved in the treatment or clinical evaluation and monitoring of the participants will be aware of the treatment received. Since tezepelumab and placebo are not visually distinct, study intervention will be handled by a qualified person (eg, pharmacist or study nurse) at the site.||t|t|t|f
34057740|NCT00131365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057741|NCT01618851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057742|NCT01024556|||||PROSPECTIVE|||||||
34057743|NCT03843424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057744|NCT05272696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057745|NCT02440542|||COHORT||PROSPECTIVE|||||||
34057746|NCT05491525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34057747|NCT05620992|||CASE_CONTROL||RETROSPECTIVE|||||||
34161795|NCT06458452|RANDOMIZED|PARALLEL||OTHER||SINGLE|Fourth semester students of Vocational School of Anaesthesiology||t|f|f|f
34161796|NCT06543810|NA|SINGLE_GROUP||OTHER||NONE||Pilot feasibility study for Hula intervention in PD patients.||||
34161797|NCT00935311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34161798|NCT05487261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161799|NCT02273661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848274|NCT04199832|||OTHER||PROSPECTIVE|||||||
33848275|NCT02224690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848276|NCT00251901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33848277|NCT03674944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848278|NCT05398237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33848279|NCT00355459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848280|NCT03028727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848281|NCT03023761|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33848282|NCT03166410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848283|NCT00160238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33848284|NCT00530140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848285|NCT05399914|||COHORT||PROSPECTIVE|||||||
33953536|NCT02975882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953537|NCT06647966|||CASE_CONTROL||RETROSPECTIVE|||||||
33953538|NCT03495752|NA|SINGLE_GROUP||OTHER||NONE||||||
33953539|NCT05564533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33953540|NCT03725436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953541|NCT02471794|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953542|NCT06564961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo||t|f|f|f
33953543|NCT00301873|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33953544|NCT05072977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848286|NCT00809484|||CASE_ONLY||PROSPECTIVE|||||||
33953545|NCT05424939|||COHORT||PROSPECTIVE|||||||
33953546|NCT02299661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33953547|NCT06651801|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953548|NCT06442774|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will download an app that will randomise them on the intervention or control group.||f|f|t|t
33953549|NCT03868917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Each participant is randomized to one of two groups.|t|f|f|t
33953550|NCT04554225|||COHORT||PROSPECTIVE|||||||
33953551|NCT00993525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953552|NCT00258310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953553|NCT04272411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33953554|NCT04273659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33953555|NCT01940731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953556|NCT05694026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masked examiner for all clinical assessments will not involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the three groups.||f|t|t|t
33953557|NCT06653699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization assignments were placed into sequentially numbered opaque sealed envelopes, which Will be kept by a certificated research Physiotherapist. The envelope will be opened on the day of operation, and the corresponding drug and placebo will be handled by a researcher who will not involve in patient care. The patients, trial participants, anesthesiologists and data collectors will be blinded to allocation|All patients will randomize into two groups, Group A: 1 dose of IV Dexamethasone 10mg+ tranexamic acid (20 mg/kg); Group B: 2 doses of IV Dexamethasone 10mg+ tranexamic acid 20 mg/kg. In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered at 10 minutes before surgery. In group B, dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered at 10 minutes before surgery and then 10mg of intravenous dexamethasone will be again administered before incision closure.|t|t|t|t
33953558|NCT05275556|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Subjects, investigators, study site personnel, and pathologists will not be blinded to treatment assignments. All Verily personnel involved in the statistical analysis of this study will be blinded to treatment assignment. For the interim analysis, unblinded analysis will be performed by an independent statistician, the results of which will be communicated to a select group of Verily personnel not involved in the study management.||f|f|f|t
33953559|NCT04931875|||COHORT||PROSPECTIVE|||||||
33953560|NCT01175408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057748|NCT04933916|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33848287|NCT06110390|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be unaware of the intervention. Data analysis performed independently to assess outcome variables|Cohort study. Permuted-block randomization to one of three arms|t|f|f|t
33953561|NCT06182748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33848288|NCT05201391|NA|SINGLE_GROUP||TREATMENT||NONE||"Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete."||||
33848289|NCT04187807|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel Assignament|t|t|t|f
33953562|NCT06653829|NA|SINGLE_GROUP||TREATMENT||NONE||A group of participants will be introduced to the device and preliminary feasibility, acceptability, and initial target engagement will be assessed.||||
33953563|NCT00562874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33953564|NCT01530152|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33953565|NCT06650657|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33953566|NCT04754529|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33953567|NCT02058238|||CASE_CONTROL||PROSPECTIVE|||||||
33953568|NCT00464308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953569|NCT03814213|||OTHER||PROSPECTIVE|||||||
33953570|NCT02892435|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33953571|NCT04471766|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33848290|NCT03280589|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33953572|NCT01764776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057749|NCT05119868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848291|NCT04379362|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, interventional treatment, non-randomized, open label, single arm, phase II study with a medical device.||||
33848292|NCT02289573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848293|NCT00018278|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848294|NCT06071559|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848295|NCT00577577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33848296|NCT05033431|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33848297|NCT01942590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953573|NCT05054088|||COHORT||PROSPECTIVE|||||||
33953574|NCT03091478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057750|NCT04395092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057751|NCT00347919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057752|NCT05822362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled, parallel group study.|t|t|t|t
34057753|NCT01877356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057754|NCT02560324|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34057755|NCT05520970|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study is designed as observer-blinded.||t|t|t|t
34057756|NCT00920127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057757|NCT02951845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057758|NCT06494332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057759|NCT06649071|||COHORT||PROSPECTIVE|||||||
34057760|NCT03573219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The SWD applicators will be placed in the desired position, around the forearm for the upper limb experiments, or below the knee for the lower limb experiments. The distance between applicators will be adjusted until the desired pain sensation is obtained according to the subjective criterion of the volunteer. This sensation should be mild or moderate pain, but tolerable for the duration of the application. Once the first application is completed, the volunteer will be allowed to rest for a period of 10 minutes, and the assessment will be repeated to test for possible after effects. After it is verified that the muscles recovered their normal temperature and the pain sensation has completely disappeared, the variables related to changes in motor responses under rest conditions will be recorded. Then SWD will be applied a second time using the same parameters as in the first application. Once the registration is complete, the experiment will be finished.||||
34057761|NCT04347694|||OTHER||PROSPECTIVE|||||||
34057762|NCT02846038|||FAMILY_BASED||PROSPECTIVE|||||||
34057763|NCT01621451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057764|NCT00819780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057765|NCT00043667||||TREATMENT||||||||
34057766|NCT01835275|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34057767|NCT04574492|||COHORT||PROSPECTIVE|||||||
34057768|NCT05785013|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34057769|NCT03441607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057770|NCT05999422|||COHORT||CROSS_SECTIONAL|||||||
33953575|NCT05444114|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants in each condition do not know what other participants are doing, nor that there is another condition.|Participants are randomly assigned to one of two conditions before performing a picture description task from which we measure speech fluency in several ways|t|f|f|f
33953576|NCT04330677|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33848298|NCT04667832|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848299|NCT02533141|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33848300|NCT06395012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33848301|NCT01865968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848302|NCT02010853|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848303|NCT00412152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848304|NCT00598364|||COHORT||PROSPECTIVE|||||||
33848305|NCT02734134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848306|NCT06324799|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled clinical trial||||
33848307|NCT04465500|NA|SINGLE_GROUP||TREATMENT||NONE||Androgen Deprivation Therapy (ADT) High-dose-rate (HDR) Brachytherapy External Beam Radiation Therapy (EBRT)||||
33848308|NCT06357325|||CASE_ONLY||CROSS_SECTIONAL|||||||
33848309|NCT01587859|||CASE_ONLY||RETROSPECTIVE|||||||
33848310|NCT04222608|||COHORT||PROSPECTIVE|||||||
33848311|NCT04720248|||COHORT||PROSPECTIVE|||||||
33848312|NCT04864288|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848313|NCT02884310|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33848314|NCT03134794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33848315|NCT06416709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848316|NCT00476970|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33848317|NCT05462392|RANDOMIZED|PARALLEL||OTHER||SINGLE|single-blind|randomized controlled trial|t|f|f|f
33848318|NCT00914901|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33848319|NCT00406055|||||PROSPECTIVE|||||||
33848320|NCT02977273|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33848321|NCT01485146|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33848322|NCT05079451|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm, multi-step study||||
33848323|NCT05470192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848324|NCT03482830|||COHORT||PROSPECTIVE|||||||
33848325|NCT04179942|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33848326|NCT04048850|||COHORT||PROSPECTIVE|||||||
33848327|NCT00053560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33848328|NCT04997980|||CASE_CONTROL||RETROSPECTIVE|||||||
33848329|NCT01427595|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33953577|NCT04655365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953578|NCT02217397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057771|NCT06620367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057772|NCT01447927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34057773|NCT04695795|||CASE_ONLY||PROSPECTIVE|||||||
34057774|NCT01459718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057775|NCT02066818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34057776|NCT04246138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|randomisation done by software||t|f|t|f
34057777|NCT04206176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single, group crossover from clopidogrel to low dose ticagrelor.||||
34057778|NCT05108415|||OTHER||PROSPECTIVE|||||||
34057779|NCT03258970|||COHORT||PROSPECTIVE|||||||
34057780|NCT00093847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057781|NCT02718183|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34057782|NCT00971035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057783|NCT01004224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057784|NCT02775877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057785|NCT05190822|||COHORT||PROSPECTIVE|||||||
34057786|NCT02252900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057787|NCT04496505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|a. will provide randomized devices and give study staff a list of device ID numbers to assign in order. Study investigators will have no knowledge of which device is a sham device. will keep blinding information on a separate locked external hard drive that investigators will not have access to. Data attached to each device ID will sent to 's analytics team for statistical analysis.||t|t|t|t
34057788|NCT03211923|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057789|NCT04007107|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34057790|NCT03523624|||COHORT||PROSPECTIVE|||||||
34057791|NCT05710913|||COHORT||RETROSPECTIVE|||||||
34057792|NCT05954533|||COHORT||CROSS_SECTIONAL|||||||
34057793|NCT05176626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, study investigators and research staff, care providers, laboratory staff, and outcomes assessors will be blinded to treatment assignment.|Blinded, placebo-matched|t|t|t|t
34057794|NCT04306159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34057795|NCT00102141|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34057796|NCT06297993|||COHORT||OTHER|||||||
34057797|NCT00290459|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34057798|NCT01518231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057799|NCT02260869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34057800|NCT00769067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057801|NCT04868851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pilot, parallel group, randomised controlled trial||||
34057802|NCT02048917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057803|NCT00960349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057804|NCT00000592|RANDOMIZED|||PREVENTION||||||||
34057805|NCT03090724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057806|NCT03156179|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057807|NCT03276468|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a multicentric open-label phase II trial in 3 cohorts of patients||||
34057808|NCT02758444|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34057809|NCT04125784|||COHORT||PROSPECTIVE|||||||
33953579|NCT04690959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants as well as The assessor, who took the measurements for both the intervention and control groups, was blinded to the subject's group, while the treating therapist was not blinded to the treatment intervention.|A prospective, parallel-group, randomized clinical trial participants will be randomly assigned to the control group or one of the 2 intervention groups. One group received neural gliding mobilization and the other neural tensioning mobilization, both targeting the median nerve|t|f|f|t
33953580|NCT05621317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953581|NCT06171165|||COHORT||PROSPECTIVE|||||||
33744603|NCT03822299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research nurse, not involved in the trial, create the allocation sequence using a website. This was done in blocks of 21 patients.|Intervention. Dietary supplement: fecal suspension. Healthy donor or own faeces (placebo) administrated through working canal of a gastroscope.|f|f|f|t
33744604|NCT03535818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, controlled, prospective study|t|t|f|f
33744605|NCT00620308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33744606|NCT01735123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33744607|NCT00000744||||TREATMENT||DOUBLE||||||
33744608|NCT01686711||PARALLEL||TREATMENT||||||||
33744609|NCT00371891|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744610|NCT06276543|||COHORT||RETROSPECTIVE|||||||
33744611|NCT04651023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33744612|NCT04069975|||CASE_CONTROL||RETROSPECTIVE|||||||
33744613|NCT03119766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744614|NCT00928382|||||PROSPECTIVE|||||||
33744615|NCT05313854|||COHORT||PROSPECTIVE|||||||
33744616|NCT02880046|||COHORT||CROSS_SECTIONAL|||||||
33744617|NCT00519480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744618|NCT00254254|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33744619|NCT05424419|||COHORT||RETROSPECTIVE|||||||
33744620|NCT00966940|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33744621|NCT02323919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33744622|NCT06264440|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744623|NCT02224729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744624|NCT02568527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744625|NCT04171700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744626|NCT01357798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744627|NCT02179801|||COHORT||PROSPECTIVE|||||||
33744628|NCT06535750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744629|NCT01108653|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33744630|NCT00746837|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744631|NCT06137391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744632|NCT02008383|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744633|NCT03145116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744634|NCT01248884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33744635|NCT01761747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744636|NCT05978323|RANDOMIZED|PARALLEL||OTHER||DOUBLE|For each group, 21 blocks were created by generating random numbers in Excel by a person other than the researcher and assigned to groups A and B. The assignment of the intervention and control groups was made by drawing lots. Index cards prepared for two primary healthcare organizations by block randomization by the researcher who did not participate in the clinical part of the study will be placed in closed opaque envelopes and their sequence numbers will be written on the envelopes. The research data will be entered into the computer database by the researcher as coded as A and B. Statistical analyses will be performed by the researcher who did not participate in the data collection phase according to this code. The research report will also be written in coded form. Research participants and statistical evaluators were planned to be blind to group assignment, single-blind, and statistician blind.|Prospective, parallel randomized controlled clinical trial|t|f|f|t
33744637|NCT01097135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848330|NCT03031145|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848331|NCT01052467|||COHORT||PROSPECTIVE|||||||
34057810|NCT05754580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057811|NCT06648746|||COHORT||RETROSPECTIVE|||||||
34057812|NCT04908215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|INM-755 (cannabinol cream) and vehicle cream (control) are identical in appearance and texture and packaged in kits labelled with unique blinded kit numbers.|Within-patient randomized, double-blind comparisons of INM-755 (cannabinol cream) versus vehicle cream (control) in matched, paired index areas|t|t|t|t
34057813|NCT06162845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blinded to their group allocation and were not aware that another treatment existed until debriefing and unblinding.||t|f|f|f
34057814|NCT00279617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057815|NCT06624189|||COHORT||PROSPECTIVE|||||||
34057816|NCT02959684|||OTHER||PROSPECTIVE|||||||
34057817|NCT05561946|||COHORT||PROSPECTIVE|||||||
34057818|NCT05278338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057819|NCT04355429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057820|NCT02673801|||COHORT||PROSPECTIVE|||||||
34057821|NCT00801281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057822|NCT00108485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057823|NCT05685862|||CASE_ONLY||PROSPECTIVE|||||||
34057824|NCT02879994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057825|NCT05759429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057826|NCT04417972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057827|NCT04792671|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057828|NCT01837225|||COHORT||PROSPECTIVE|||||||
34057829|NCT02603068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057830|NCT02042300|||COHORT||PROSPECTIVE|||||||
34057831|NCT03170466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34057832|NCT03337581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848332|NCT05805228|RANDOMIZED|CROSSOVER||OTHER||NONE||This study was conducted with experimental and control group design.||||
33848333|NCT00536536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848334|NCT01240473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848335|NCT00701532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848336|NCT06331403|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848337|NCT04701892|||COHORT||PROSPECTIVE|||||||
33848338|NCT01001338|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34057833|NCT01283334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057834|NCT00336869|||COHORT||CROSS_SECTIONAL|||||||
34057835|NCT04428242|||OTHER||PROSPECTIVE|||||||
34057836|NCT06648330|||COHORT||PROSPECTIVE|||||||
34057837|NCT02407054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057838|NCT04678427|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34057839|NCT05795920|NA|SINGLE_GROUP||TREATMENT||NONE||Unresectable advanced pancreatic cancer||||
34057840|NCT04958148|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind|This is a randomized, double-blind, placebo-controlled trial. Half the participants will be in placebo arm, the other half will be in salt arm.|t|f|t|f
34057841|NCT02971475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057842|NCT02909829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057843|NCT05428202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Identical tubes with no indicative label, identical creams with similiar texture and odor|Randomized, double blind, placebo controlled|t|f|t|t
34057844|NCT03205735|||COHORT||PROSPECTIVE|||||||
34057845|NCT00276185|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34057846|NCT02564445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057847|NCT05601011|||COHORT||PROSPECTIVE|||||||
34057848|NCT00449228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34057849|NCT01004406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057850|NCT02004899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057851|NCT05002517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057852|NCT04655248|||COHORT||PROSPECTIVE|||||||
34057853|NCT01883947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34057854|NCT00231439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34057855|NCT01439022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057856|NCT00215527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057857|NCT03785509|||COHORT||RETROSPECTIVE|||||||
34057858|NCT06638385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848339|NCT01142232||SEQUENTIAL||TREATMENT||NONE||All patients will receive melphalan 100 milligrams (mg) per meters squared (m2) intravenously day -2 and day -1. Phase I patients will be enrolled sequentially into one of dose levels below and administered the corresponding lenalidomide dose. The recommended phase II dose based on dose limiting toxicities observed in the phase I portion will be used for lenalidomide dosing in the phase II portion of the trial Dose level -1 Lenalidomide 25 mg daily day -7 to day +2, Dose level 1 Lenalidomide 50 mg daily day -7 to day +2, Dose level 2 Lenalidomide 75 mg daily day -7 to day +2, Dose level 3 Lenalidomide 100 mg daily day -7 to day +2, Dose level 4 Lenalidomide 150 mg daily day -7 to day +2,||||
33848340|NCT04337892|||COHORT||CROSS_SECTIONAL|||||||
33953582|NCT05866159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A double-blinded design will be conducted to assess the effectiveness of kinesio versus sham tape, as patients cannot distinguish between the two.~The assessment of back-specific body perception, which is the primary outcome, will be conducted by an assessor unaware of the treatment allocation prior to treatment, as well as on days 3 and 7."|comparing the use of kinesiotape for the treatment of back-specific body image, pain, functional disability, and physical activity of individuals with non-specific CLBP to sham-taping|t|f|f|t
33953583|NCT03148873|||OTHER||PROSPECTIVE|||||||
33953584|NCT06019611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33953585|NCT01701180|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34057859|NCT03338543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant is allocated randomly by staff A, and grouping situation is concealed; Technician (stuff B) or chargeing docotor operates PENS or TENS, or administers oral analgesic medication; Related datas are collected according to perdetermined forms by stuff C; Outcomes are assessed by stuff D.|patients with liver cancer pain.|t|t|t|t
34057860|NCT05970016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848341|NCT02029872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848342|NCT04580082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848343|NCT00509691|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848344|NCT04240301|||OTHER||OTHER|||||||
33848345|NCT05333692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848346|NCT04513652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The Investigator(s), Sponsor, and the subject will be masked to treatment assignment throughout the conduct of the study. Exceptions to this are limited to one statistician at the Contract Research Organization (CRO) who will prepare the randomization code, and three people at the Sponsor who will review the batch records and release product. None of these unmasked persons will be involved in the day to day execution of the study. The masking will be broken after database lock.|Subjects who provide informed consent and fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to receive a single dose of AG-920 or identical looking placebo into one (study) eye (2 drops 30 seconds apart).|t|f|t|f
33848347|NCT05560438|NA|SINGLE_GROUP||TREATMENT||NONE||Single subject experimental design (SSED) study||||
33848348|NCT02286986|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33848349|NCT00371683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33848350|NCT01242735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848351|NCT02150343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848352|NCT01831479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848353|NCT05766085|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848354|NCT06543719|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33848355|NCT04670939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848356|NCT03502031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848357|NCT05687526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848358|NCT06443580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33848359|NCT01668329|||COHORT||PROSPECTIVE|||||||
33848360|NCT00817713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848361|NCT04428827|||COHORT||RETROSPECTIVE|||||||
33848362|NCT06487845|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33848363|NCT05641129|||COHORT||PROSPECTIVE|||||||
33848364|NCT01107821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848365|NCT02855697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848366|NCT02500810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848367|NCT04492800|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848368|NCT03367429|RANDOMIZED|PARALLEL||OTHER||NONE||"If the within-subject design is used, N=15 and subjects will be randomized 1:1 to receive the standard injection to either the LGM or MGM. The experimental injection will be delivered to the muscle not receiving the standard injection.~If the between-subject design must be used, N=25 and subjects will be randomized 2:3 to receive either the experimental or standard injection to the spastic LGM.~Please note the following:~Standard Injection: 25 units of onobotulinumtoxinA (Botox®) diluted in 0.25cc of saline.~Experimental Injection: 25 units of onobutilinumtoxinA (Botox®) diluted in 0.50cc of saline."||||
33848369|NCT06460584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848370|NCT05356299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848371|NCT03918499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953586|NCT02660489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953587|NCT05181176|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial, parallel group study comparing 3 weight loss interventions comprised of a similar dietary recommendation with either coffee (coffee group), tea (tea group) or placebo (herbal tea).||||
34057861|NCT01954134|||CASE_CONTROL||PROSPECTIVE|||||||
34057862|NCT02781428|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34057863|NCT05644431|||COHORT||PROSPECTIVE|||||||
33953588|NCT00944125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33953589|NCT05006313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953590|NCT05846152|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33953591|NCT00554788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953592|NCT03007615|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33744638|NCT06669247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1: non-randomized dose escalation Phase 2: randomized dose expansion||||
33744639|NCT05921461|||CASE_CONTROL||PROSPECTIVE|||||||
33744640|NCT03379025|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33744641|NCT00208754|||||RETROSPECTIVE|||||||
33744642|NCT05306327|||COHORT||PROSPECTIVE|||||||
33744643|NCT02188017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744644|NCT04133610|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33744645|NCT00000129|RANDOMIZED|||TREATMENT||||||||
33744646|NCT01556113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744647|NCT00652665|RANDOMIZED|CROSSOVER||||NONE||||||
33744648|NCT01907958|||CASE_ONLY||PROSPECTIVE|||||||
33744649|NCT02081300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744650|NCT01490346|||COHORT||PROSPECTIVE|||||||
33744651|NCT05160922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744652|NCT03448146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744653|NCT00646802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744654|NCT01127178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744655|NCT04614389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Eligible subjects who consent for this study will undergo a SWE and CEUS evaluation of their thyroid gland at the time of their standard of care scheduled thyroid biopsy||||
33744656|NCT05599529|||COHORT||RETROSPECTIVE|||||||
33848372|NCT05920460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848373|NCT06298240|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848374|NCT06572098|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"1. Study Group-Patient with Lymphedema~2. Control Group-Healthy Group"|"1. Working Group (Complex decongestive therapy)~2. Control Group"|t|f|f|f
33848375|NCT01967589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848376|NCT02926898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848377|NCT06039631|RANDOMIZED|PARALLEL||TREATMENT||NONE||the selection trial design||||
33848378|NCT01038622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848379|NCT04621513|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Randomized controlled trial||||
33848380|NCT03222102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848381|NCT03111511|NA|SINGLE_GROUP||OTHER||NONE||||||
33848382|NCT06574048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy will provide either saline or 10mg dexamethasone in saline in a masked fashion so that the clinical staff are blinded.||t|t|t|t
33848383|NCT02138708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848384|NCT02774421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848385|NCT02548845|||COHORT||RETROSPECTIVE|||||||
33848386|NCT00159692|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33848387|NCT03271034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848388|NCT05342064|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The study will be implemented within a non-randomized stepped-wedge pragmatic intervention study design with nested randomized screening, diagnostic and adherence studies.||||
33848389|NCT01153867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848390|NCT06578637|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33848391|NCT00109330|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33848392|NCT01278173|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848393|NCT03492944|||COHORT||PROSPECTIVE|||||||
33848394|NCT00672334|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848395|NCT02362659|||COHORT||PROSPECTIVE|||||||
33848396|NCT00488332|||CASE_ONLY||PROSPECTIVE|||||||
33848397|NCT02443454|||COHORT||CROSS_SECTIONAL|||||||
33848398|NCT02062593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848399|NCT04072068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848400|NCT03871673|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33848401|NCT01638351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848402|NCT04245228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848403|NCT04582136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848404|NCT01533597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848405|NCT00426699|||CASE_ONLY||PROSPECTIVE|||||||
33848406|NCT06505109|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomized to treatment or control.||||
33848407|NCT02540928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33848408|NCT05578131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848409|NCT00217308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848410|NCT03174587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848411|NCT05799651|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33848412|NCT04708730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848413|NCT02723331|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161800|NCT05319158|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The assessments for the main outcome will be performed by a blinded expert.|"The infants will be pre-stratified according to General Movement Optimality Score (GMOs). The Control group will receive standard care and the Intervention groups will begin the therapy at 34-36w. The intervention will be explained and guided by the principal researcher and experienced Pediatric Physical therapist. Parents will conduct the intervention until the 50-52 weeks PMA. General Movement Assessment (GMA) will be performed at term, 44w and 54w PMA.~Motor assessment will be carried out at 6 months Corrected Age (CA) and a global assessment at 12 months CA.~Those assessments will be performed by independent and blind professionals at their corresponding Hospitals."|f|f|f|t
34161801|NCT06364267|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34161802|NCT04829149|||COHORT||PROSPECTIVE|||||||
34161803|NCT06106958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator assessing laboratory-based outcome measures will be blinded to group allocation and will not be the member of the study team communicating with participants about their intervention protocols.|"There will be two groups:~1. Performing foot rehabilitation exercises and wearing minimalist shoes (intervention group)~2. Only performing foot rehabilitation exercises (control group)"|f|f|f|t
33848414|NCT03695939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1/2, Open-label, Multi-center, Clinical Trial to evaluate the safety, tolerability, and efficacy of realSKIN® to provide complete wound closure of severe and extensive deep-partial or full-thickness burn wounds. Approximately 25 total subjects will be enrolled. The designated realSKIN® product size will be placed on the burn wound following wound site preparation, including necessary debridement and tangential excision as determined by burn surgeon and secured in place via suturing or stapling. The remaining burn wound will be covered with human cadaver allograft and treated according to local standard of care with care to avoid any overlap or significant contact of the two temporary wound dressings. The Investigator will assess the wounds and identify the matched pair of burn sites then the treatments will be randomly assigned to the sites.||||
33953593|NCT04381117|||CASE_ONLY||PROSPECTIVE|||||||
33953594|NCT05117294|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33953595|NCT06335394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953596|NCT04162301|NA|SEQUENTIAL||TREATMENT||NONE||||||
33953597|NCT06539078|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33953598|NCT03145038|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33953599|NCT04402580|RANDOMIZED|PARALLEL||TREATMENT||NONE||The RTX4 trial is an open-label, two-parallel-arm, controlled and randomized clinical trial testing the superiority of RTX over MMF in maintaining steroid free disease remission in patients with SDNS||||
33953600|NCT01998659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057864|NCT00072436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057865|NCT05839106|NA|SEQUENTIAL||TREATMENT||NONE||"In dose escalation stage, three subjects will be enrolled at the protocol starting dose of PM1032 for 21 Days DLT observation, followed by same dose every 2 weeks (Q2W) until they meet the discontinuation criteria.~Dose escalation will proceed to the next dose level according to the 3+3 design.~Dose expansion stage of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose escalation stage."||||
34057866|NCT06618833|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057867|NCT03576534|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
34057868|NCT06623253|||OTHER||CROSS_SECTIONAL|||||||
34057869|NCT02455609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057870|NCT06623110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057871|NCT00688233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057872|NCT02381938|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34057873|NCT01942317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34057874|NCT01563367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057875|NCT02794701|||OTHER||CROSS_SECTIONAL|||||||
34057876|NCT06382441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34057877|NCT02021136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057878|NCT03161145|||CASE_ONLY||RETROSPECTIVE|||||||
34161804|NCT05379595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161805|NCT00002359||||TREATMENT||DOUBLE||||||
34161806|NCT04339829|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.||||
34161807|NCT02641470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848415|NCT04290559|||COHORT||PROSPECTIVE|||||||
33848416|NCT04645667|||COHORT||PROSPECTIVE|||||||
33848417|NCT01476098|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33848418|NCT02631824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848419|NCT02483026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33953601|NCT03253809|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Nonrandomized survey of different pacing sites in the coronary veins.||||
33953602|NCT00250965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953603|NCT04189536|NA|SINGLE_GROUP||OTHER||NONE||||||
33953604|NCT00997269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953605|NCT06224387|NA|SINGLE_GROUP||TREATMENT||NONE|QD and durg holiday,PO.|QD and durg holiday,PO.||||
33953606|NCT01111968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953607|NCT06362707|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33953608|NCT03582657|||COHORT||PROSPECTIVE|||||||
33953609|NCT03503552|||OTHER||OTHER|||||||
33953610|NCT02372786|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33953611|NCT02164084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34057879|NCT05410041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057880|NCT01588457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057881|NCT03289598|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single Blind||f|f|f|t
34057882|NCT05168878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161808|NCT04185675|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34161809|NCT04327947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Clinical trial, triple arm, randomized|t|f|f|f
34161810|NCT03484247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33848420|NCT02680990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848421|NCT03559231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057883|NCT02594189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057884|NCT06157112|||COHORT||PROSPECTIVE|||||||
34057885|NCT05849922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057886|NCT04291105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848422|NCT06236659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Before commencing each experimental intervention, a laboratory technician (independent to the study) made up the three doses of hydrolyzed collagen (HC) and randomly assigned the order of HC dose (Excel 2016, Microsoft, Washington, USA) for each participant. Also, for each intervention, the technician recorded the date, randomly allocated trial number (1, 2 or 3) and corresponding HC dose to blind the investigator.|Double-blind, randomized cross-over design|t|f|t|t
33953612|NCT03953391|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Person doing the statistical analyses will blinded to the treatments|Randomised, full cross-over study|f|f|f|t
33848423|NCT02104843|NA|SINGLE_GROUP||||NONE||||||
33848424|NCT01445301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33953613|NCT00399204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953614|NCT06493188|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33953615|NCT05270629|||CASE_CONTROL||RETROSPECTIVE|||||||
33953616|NCT06008470|||CASE_CONTROL||PROSPECTIVE|||||||
33953617|NCT00088504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953618|NCT03810027|||CASE_ONLY||RETROSPECTIVE|||||||
33953619|NCT04143477|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33953620|NCT03572049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057887|NCT02012465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057888|NCT06466876|NA|SINGLE_GROUP||TREATMENT||NONE||Within participant design.||||
34057889|NCT02620241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848425|NCT05084469|||CASE_ONLY||PROSPECTIVE|||||||
33848426|NCT00263341|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33848427|NCT05811962|||CASE_CONTROL||RETROSPECTIVE|||||||
33848428|NCT06118203|||OTHER||PROSPECTIVE|||||||
33848429|NCT01696669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953621|NCT00925509|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33953622|NCT04612712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953623|NCT00260949|||COHORT||PROSPECTIVE|||||||
33953624|NCT05283655|NA|SINGLE_GROUP||TREATMENT||NONE||pre-post intervention||||
33953625|NCT00406497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953626|NCT06622083|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33953627|NCT04926857|||COHORT||PROSPECTIVE|||||||
33953628|NCT05434949|||COHORT||PROSPECTIVE|||||||
33953629|NCT04495296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953630|NCT04773314|||OTHER||PROSPECTIVE|||||||
33953631|NCT02765958|||CASE_ONLY||PROSPECTIVE|||||||
33953632|NCT02989922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953633|NCT00326625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953634|NCT05552391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953635|NCT05855967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953636|NCT00456027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953637|NCT03199573|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953638|NCT05688527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953639|NCT04353401|||COHORT||OTHER|||||||
33953640|NCT05392920|||OTHER||PROSPECTIVE|||||||
33953641|NCT03323944|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953642|NCT02084329|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33953643|NCT06013462|||COHORT||PROSPECTIVE|||||||
34057890|NCT04799548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161811|NCT00392730|||||PROSPECTIVE|||||||
34161812|NCT04077853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953644|NCT01465594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953645|NCT03693235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33953646|NCT04587635|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double blind study||t|t|t|f
33953647|NCT06650813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33953648|NCT03280628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Plastic Surgeons who rate all scars at the end of the study are blinded to the closure method.||f|f|f|t
33953649|NCT04158739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953650|NCT01432600|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953651|NCT01997060|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33953652|NCT06371040|NA|SEQUENTIAL||TREATMENT||NONE||"CD19-BCMA Targeted CAR-T Dose 1 5.0 e5/ kg CD19-BCMA CAR-T positive T cells~CD19-BCMA Targeted CAR-T Dose 2 1.5 e6/ kg CD19-BCMA CAR-T positive T cells~CD19-BCMA Targeted CAR-T Dose 2 5 e6/ kg CD19-BCMA CAR-T positive T cells"||||
33953653|NCT05527288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.||||
33953654|NCT02936349|||OTHER||PROSPECTIVE|||||||
33953655|NCT03673137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953656|NCT02673827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953657|NCT04340739|||COHORT||PROSPECTIVE|||||||
33953658|NCT04103268|||CASE_CONTROL||PROSPECTIVE|||||||
33953659|NCT01810575|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33953660|NCT02392312|||CASE_ONLY||PROSPECTIVE|||||||
33953661|NCT00960648|||CASE_CONTROL||PROSPECTIVE|||||||
34057891|NCT03506568|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34057892|NCT06188702|NA|SEQUENTIAL||TREATMENT||NONE||||||
34057893|NCT03257878|||OTHER||PROSPECTIVE|||||||
34057894|NCT06118814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057895|NCT00274313|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34057896|NCT04982068|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34057897|NCT00643461|||COHORT||PROSPECTIVE|||||||
34057898|NCT03707119|||COHORT||PROSPECTIVE|||||||
34057899|NCT00212472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848430|NCT00278837|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848431|NCT02700347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848432|NCT00926627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848433|NCT01603823|||COHORT||PROSPECTIVE|||||||
33848434|NCT04075877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The care provider and the outcomes assessor will be blind to participants' study assignments.|Randomized controlled trial|f|t|f|t
33848435|NCT04849351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848436|NCT04616950|||COHORT||RETROSPECTIVE|||||||
33848437|NCT00044265|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33848438|NCT01540331|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33848439|NCT00421954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848440|NCT03282240|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|QHD00013 was a modified double-blind trial with an unblinded administrator used at each trial site. The administrator was not involved in any of the blinded study assessments (e.g., safety).|QHD00013 was a phase III, randomized, modified double-blind, active-controlled, multi-center trial.|t|f|f|t
33848441|NCT04831918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848442|NCT02313376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33848443|NCT05957432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848444|NCT04224298|||CASE_CONTROL||PROSPECTIVE|||||||
33848445|NCT06261801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848446|NCT04595851|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33848447|NCT02654301|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33848448|NCT01994655|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33848449|NCT06384560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848450|NCT05398744|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33848451|NCT05972928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848452|NCT02608723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848453|NCT04945889|||OTHER||PROSPECTIVE|||||||
33848454|NCT02767284|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33848455|NCT03498859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33848456|NCT05734352|||OTHER||PROSPECTIVE|||||||
33848457|NCT01979367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848458|NCT06610942|||CASE_CONTROL||PROSPECTIVE|||||||
33848459|NCT00606125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848460|NCT05563727|||COHORT||PROSPECTIVE|||||||
33848461|NCT01413464|||COHORT||PROSPECTIVE|||||||
33848462|NCT00684619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848463|NCT02774239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953662|NCT05867511|NA|SINGLE_GROUP||PREVENTION||NONE||The study is a one-armed pilot 8-week tailored intervention with a pre-post-design, as well as an intensive-longitudinal design with weekly measurements.||||
33953663|NCT02416505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953664|NCT04936009|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know whether they are receiving active or sham TMS until both sessions have been completed.|Participants will receive both active and sham TMS in a randomized crossover assignment involving two study sessions.|t|f|f|f
33848464|NCT03028753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848465|NCT02878577|||COHORT||PROSPECTIVE|||||||
33848466|NCT06602635|||COHORT||RETROSPECTIVE|||||||
33848467|NCT05033951|||COHORT||PROSPECTIVE|||||||
33848468|NCT00064233||||TREATMENT||NONE||||||
33848469|NCT02461784|||CASE_CONTROL||PROSPECTIVE|||||||
33848470|NCT01901341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848471|NCT05225194|||OTHER||PROSPECTIVE|||||||
33848472|NCT02874924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33848473|NCT06304610|NA|SINGLE_GROUP||PREVENTION||NONE||all participants receive the same tests||||
33848474|NCT04525053|||COHORT||RETROSPECTIVE|||||||
33848475|NCT02336295|NA|SINGLE_GROUP||||NONE||||||
33848476|NCT04719624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33953665|NCT02736669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953666|NCT05809999|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33848477|NCT02628639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848478|NCT06106620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33848479|NCT03653325|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled study||||
33848480|NCT02632435|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33848481|NCT02691117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848482|NCT05922293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848483|NCT05714345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848484|NCT05187143|||CASE_ONLY||PROSPECTIVE|||||||
33848485|NCT02148640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848486|NCT06019741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|simple randomization|randomized double blind of placebo and intervention group|t|t|t|t
33848487|NCT00474877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
33953667|NCT04092491|||COHORT||PROSPECTIVE|||||||
33953668|NCT05263024|||CASE_CONTROL||OTHER|||||||
33953669|NCT03251443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953670|NCT06537479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953671|NCT00247416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953672|NCT05069129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33953673|NCT00213486|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953674|NCT02901912|||COHORT|||||||||
33953675|NCT05898022|NA|SINGLE_GROUP||OTHER||NONE|Participant, care provider, investigator, outcomes assessor learn the order of furosemide and placebo administration at the end of their N-of-1 trial.|The proposed pilot, feasibility study will enroll patients in a series of N-of-1 trials. Each individual N-of-1 trial will have 2 blocks. In each block patients will crossover between furosemide (plus potassium chloride) for 1 week and placebo (plus placebo electrolyte solution) for 1 week. Each patient will have 14 days of total exposure to furosemide over the 28-day N-of-1 trial.||||
33953676|NCT04723329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|t|f|f|f
34057900|NCT03435224|NA|SINGLE_GROUP||OTHER||NONE||||||
34057901|NCT03203928|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two group randomized controlled study||||
34057902|NCT00528203|||COHORT||PROSPECTIVE|||||||
34057903|NCT06107946|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34057904|NCT05107791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057905|NCT02945397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057906|NCT02920541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057907|NCT06648941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057908|NCT02824016|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34057909|NCT06250907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057910|NCT04124159|||COHORT||PROSPECTIVE|||||||
34057911|NCT02607852|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Arm A: Patients 5-18 years old Arm B: Patients 0-4 years old||||
34057912|NCT00182598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057913|NCT06158815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744657|NCT05658172|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|This study will be performed as partially double-blinded. This means, all patients and doctors are blinded initially as blood sampling is done in all patients, irrespective of randomization to the Standard Surveillance arm or the Intensive Surveillance arm. If one of the biomarkers (CA27.29, CEA, CA125, CTC, ctDNA) is abnormal and requires a confirmatory blood sampling or triggers imaging, unblinding is the consequence as these patients will be asked to undergo further assessments and the responsible doctor will arrange these. Unblinding in this case is the ethical consequence of not letting all patients undergo a confirmatory blood sampling or even undergo additional imaging without elevated biomarkers. If no confirmatory blood sampling or imaging is necessary, patients in the Intensive Surveillance arm will not be unblinded as there is no purpose to serve. Patients in the Standard Surveillance arm will not be unblinded altogether.|This is a partially double-blinded, multi-center, randomized, controlled superiority study.|t|t|t|t
33744658|NCT01324492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744659|NCT05035901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744660|NCT04701021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744661|NCT01897584|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744662|NCT02532218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744663|NCT01477034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33744664|NCT00170118|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33744665|NCT03326999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial with two arms: one arm will receive adductor canal block and obturator nerve block with the local anesthetic bupivacaine; second arm will receive adductor canal block with bupivacaine and obturator nerve block with saline.|t|t|t|t
33744666|NCT03998527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744667|NCT05017740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Trial participants, research team collecting data outcome, and all study team members except the embryologists will be blinded to treatment allocation. It is not possible to conceal allocation to the embryologists, who will perform the intervention.|Participants will be randomised to undergo PICSI or standard ICSI in a 1:1 treatment ratio.|t|t|f|t
33744668|NCT06081660|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||2 x 2 mixed factorial design, pre-test/posttest variables to examine impact on ACP||||
33744669|NCT01169870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953677|NCT00988039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953678|NCT01204606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33953679|NCT06110338|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33953680|NCT01136616|||CASE_ONLY||PROSPECTIVE|||||||
33953681|NCT03863925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33953682|NCT01282879|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33953683|NCT05552183|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953684|NCT03334227|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with severe sepsis will be randomized to recieve conventional oxygenotherapy if needed or high flow nasal cannula.||||
33953685|NCT04912804|||COHORT||PROSPECTIVE|||||||
33953686|NCT05770362|||CASE_ONLY||PROSPECTIVE|||||||
33953687|NCT00018343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953688|NCT03933046|NA|SINGLE_GROUP||SCREENING||NONE||||||
33953689|NCT02992808|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953690|NCT01569074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953691|NCT04913311|||COHORT||PROSPECTIVE|||||||
33953692|NCT02873195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953693|NCT01991600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33953694|NCT05727865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953695|NCT06179186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"participants will receive both treatments in right and left axilla, and they won´t know which treatment will be performed at each side.~The outcome assessor won´t know which treatment was performed at the axilla."|Participants are assigned two groups in parallel for the duration of the study|t|f|f|t
33953696|NCT06609252|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trial||||
33953697|NCT06510114|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with active moderate-to-severe GO were randomized at a ratio of 1:1 to receive glucocorticoid therapy for 12 weeks on a weekly protocol or daily scheme.||||
34057914|NCT04990349|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with two arms||||
34057915|NCT00082017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057916|NCT05400733|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34057917|NCT02611505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057918|NCT00771251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057919|NCT01279070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057920|NCT01470781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|assessment staff, investigator, and participants blind to group membership.||t|f|t|t
34057921|NCT00022243||||TREATMENT||||||||
34057922|NCT04250350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057923|NCT01241877|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34057924|NCT00028899||||TREATMENT||||||||
34057925|NCT01122407|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33744670|NCT03221582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744671|NCT05114681|||CASE_ONLY||PROSPECTIVE|||||||
33744672|NCT01889537|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33953698|NCT03136978|||CASE_CONTROL||PROSPECTIVE|||||||
33953699|NCT00295919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953700|NCT03955016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded for the outcome|Randomized controlled trial|f|f|f|t
33953701|NCT04457323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953702|NCT05459012|||CASE_ONLY||PROSPECTIVE|||||||
33953703|NCT06650917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953704|NCT00877799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953705|NCT06173882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953706|NCT05309993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953707|NCT03676439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and independent evaluator|A comparision, Randomized and double blinded study|t|f|f|t
33953708|NCT05090046|||COHORT||CROSS_SECTIONAL|||||||
33953709|NCT04115800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953710|NCT00268775|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33953711|NCT03707145|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant is unaware of the other groups details. Assessor and investigator are not blinded due to the need for providing information to the participant about their group allocation in this pilot project|Randomised; Interventional; Design type: Treatment, Complex Intervention, Physical, Rehabilitation|t|f|f|f
33953712|NCT05427370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The STICH3C trial is a prospective, unblinded, international multi-center randomized trial of comparing revascularization by PCI vs. CABG in patients with multivessel/LM CAD and reduced LVEF.|f|f|f|t
33953713|NCT01076140|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744673|NCT05430529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants will be followed up via telephone by an allocation-blinded interviewer at 2-month after the random group allocation.|A 2-arm, parallel, single-blinded pilot randomized controlled trial to examine the feasibility, acceptability and potential efficacy of implementing the brief alcohol intervention in co-users of tobacco and alcohol.|f|f|f|t
33953714|NCT06326723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953715|NCT01308762|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33953716|NCT01828164|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33953717|NCT04964960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953718|NCT04883892|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||RCT, single-blind, allocation 1:1. After 12 months patients in the control group are allowed to cross-over in the treatment group|f|f|f|t
33953719|NCT06415305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953720|NCT05456321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and families will be blinded. The principal investigator will be blinded. The research staff member coordinating the visit will be blinded. The care provider is not involved in the research and is, therefore, blinded.|1:1 randomized allocation to active tDCS or placebo (sham tDCS).|t|t|t|t
33953721|NCT06652061|||OTHER||PROSPECTIVE|||||||
33953722|NCT02141373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33953723|NCT00953017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33953724|NCT03563716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953725|NCT02615652|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33953726|NCT05661071|||CASE_CONTROL||PROSPECTIVE|||||||
33953727|NCT00798902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953728|NCT06001736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953729|NCT00296192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953730|NCT06303024|NA|SEQUENTIAL||TREATMENT||NONE||This is a multicentric no-profit pilot study, composed by two phases. I phase: observational prospective study II phase: interventional study||||
33953731|NCT02399410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057926|NCT06619301|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not documented in the patient\&#39;s electronic medical record if they are in the study and were randomized or if they declined randomization.|Each patient will continue management of diabetes mellitus in pregnancy with whichever medication they randomize to, Glargine or NPH. Analysis will be intention-to-treat.||||
34057927|NCT02273271|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34057928|NCT06258928|||CASE_CONTROL||PROSPECTIVE|||||||
34057929|NCT05481528|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34057930|NCT01609166|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34057931|NCT02312869|||COHORT||PROSPECTIVE|||||||
34057932|NCT06620835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057933|NCT05320107|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34057934|NCT00902343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057935|NCT03147131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057936|NCT00493233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953732|NCT02820324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953733|NCT04185259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants in acupuncture group and sham acupuncture group, together with efficacy evaluators and data analysts will be blinded to the group assignments. Participants in the waitlist control group and acupuncturists will not be blinded.|Participants will be randomized to acupuncture group, sham acupuncture group, or waitlist (no acupuncture) group at a ratio of 2:1:1 using simple randomization.|f|f|t|t
33953734|NCT06108973|||COHORT||PROSPECTIVE|||||||
33953735|NCT00395265|||COHORT||RETROSPECTIVE|||||||
33953736|NCT06180993|||OTHER||PROSPECTIVE|||||||
34057937|NCT06255379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057938|NCT00373958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34057939|NCT01650545|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34057940|NCT06622473|NA|SINGLE_GROUP||OTHER||NONE||||||
34057941|NCT00240955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744674|NCT06288984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744675|NCT06631586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33744676|NCT03982394|||COHORT||PROSPECTIVE|||||||
33744677|NCT00005633||||TREATMENT||||||||
34057942|NCT01984489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161813|NCT03575728|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Based on self-report answers to screening questions, participants will be divided into two groups: (i) those who screen positive for a history of mood disorders and (ii) all other participants. All outcome measures apply only to the mood disorder group.||||
34161814|NCT03223116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161815|NCT01354717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161816|NCT01077401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161817|NCT05010980|||COHORT||OTHER|||||||
34161818|NCT05281198|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34161819|NCT00519051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161820|NCT06149208|||COHORT||PROSPECTIVE|||||||
34161821|NCT00116220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161822|NCT03639025|||COHORT||PROSPECTIVE|||||||
34161823|NCT05717400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057943|NCT02481271|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34161824|NCT00726635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161825|NCT04275973|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will perform testing inside the laboratory (lab testing), outside the laboratory (field testing) on the campus of University of Wisconsin, Madison, and/or extended testing in a home and community environment (take-home testing) to evaluate different aspects of device function.~Outcomes will generally be compared using a repeated-measures design, in which each participant acts as his/her own control. This design is chosen to minimize the statistical problems caused by heterogeneity in the participant population."||||
34057944|NCT01871402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744678|NCT01218152|||||PROSPECTIVE|||||||
33744679|NCT02984540|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33744680|NCT02759159|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33744681|NCT03609827|||OTHER||PROSPECTIVE|||||||
33744682|NCT03335553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744683|NCT04931511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744684|NCT00648076|RANDOMIZED|CROSSOVER||||NONE||||||
33744685|NCT03613857|||COHORT||PROSPECTIVE|||||||
33744686|NCT03066531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744687|NCT00198068|||CASE_CONTROL||PROSPECTIVE|||||||
34057945|NCT06622681|||COHORT||PROSPECTIVE|||||||
34057946|NCT01482962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057947|NCT01221714|||CASE_CONTROL||PROSPECTIVE|||||||
34057948|NCT01789580|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34057949|NCT04827966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34057950|NCT06618924|||CASE_ONLY||OTHER|||||||
34057951|NCT00355225|RANDOMIZED|PARALLEL||ECT||NONE||||||
33744688|NCT01502501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744689|NCT00724282|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34057952|NCT05742893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34057953|NCT03724500|||COHORT||PROSPECTIVE|||||||
34057954|NCT00003910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057955|NCT04028973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34057956|NCT05286359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"The staff conducting the trial assays will be blinded to any results already available from the investigational, comparator or reference test.~All RDTs will be read by two blinded operators, with a third operator for discrepant results"|||||
34057957|NCT05556850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057958|NCT04579445|||CASE_ONLY||PROSPECTIVE|||||||
34057959|NCT05490602|||COHORT||PROSPECTIVE|||||||
34057960|NCT06621420|||COHORT||PROSPECTIVE|||||||
34057961|NCT03796442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057962|NCT03419598|||CASE_CONTROL||PROSPECTIVE|||||||
34057963|NCT01573767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34057964|NCT04403256|||CASE_ONLY||CROSS_SECTIONAL|||||||
34057965|NCT03794661|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Outcomes assessor will be masked to subjects' deep brain stimulation programming.|||||
33744690|NCT04243876|||CASE_CONTROL||RETROSPECTIVE|||||||
33744691|NCT02597959|||COHORT||PROSPECTIVE|||||||
33744692|NCT05305144|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744693|NCT00423124|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744694|NCT04952545|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744695|NCT04625803|NA|SINGLE_GROUP||TREATMENT||NONE||"MSS/pMMR:Participants received 5 preoperative cycles of PD1 inhibitor and chemotherapy (mFOLFOX6), 2 months of apatinib, followed by surgery.~Apatinib,PD1 inhibitor and chemotherapy needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of mFOLFOX6 combined with PD-1 monoclonal antibody were performed as adjuvant therapy.~MSI/dMMR:Participants received 5 preoperative cycles of PD1 inhibitor and 2 months of apatinib, followed by surgery.~Apatinib,PD1 inhibitor needed to be stopped for 4-6 months before operation. 1 month after surgery, 7 cycles of PD-1 monoclonal antibody and apatinib were performed as adjuvant therapy."||||
33744696|NCT06486259|||CASE_ONLY||PROSPECTIVE|||||||
33744697|NCT03380442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Since the psilocybin is ingested orally in capsule form, whereas ketamine is administered intranasally, the participants will either receive a placebo capsule containing microcrystalline cellulose (if they belong to the group receiving ketamine), or intranasally administered saline solution (with added bitter flavoring which will mimic the taste of ketamine that is often detectable even when administered intranasally).|In a randomized, double-blind placebo-controlled design, 20 of the participants will receive ketamine, and 20 will receive psilocybin. 20 of the participants will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified. The no-treatment group will only attend the initial clinical interviews, and their depressive symptoms will be assessed remotely.|t|t|t|t
33744698|NCT01479660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744699|NCT02742727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744700|NCT06283979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744701|NCT02328326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33744702|NCT02574546|||COHORT||PROSPECTIVE|||||||
33744703|NCT02048384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744704|NCT03575923|||OTHER||PROSPECTIVE|||||||
33744705|NCT05028998|||CASE_CONTROL||RETROSPECTIVE|||||||
33744706|NCT02932618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744707|NCT00700687|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744708|NCT06296719|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33744709|NCT00679003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744710|NCT00875680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744711|NCT03431077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744712|NCT03563495|RANDOMIZED|PARALLEL||TREATMENT||||||||
33744713|NCT04834323|RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking|This study included patients who were admitted to our center to do laparoscopic sleeve gastrectomy . Cases were collected in the period from December 2019 to December 2020. Sample size was 84 patients divided into 2 equal groups . Group 1: included 42 patients who were subjected to distal mesogastric fixation after laparoscopic sleeve gastrectomy. Group 2: included 42 patients who were subjected to laparoscopic sleeve gastrectomy alone without distal mesogastric fixation.||||
33744714|NCT05818735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744715|NCT05450874|||COHORT||RETROSPECTIVE|||||||
33744716|NCT02794493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744717|NCT03649022|||COHORT||OTHER|||||||
33744718|NCT02246998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744719|NCT04613414|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33744720|NCT00005854||||TREATMENT||||||||
33744721|NCT03321019|||CASE_CONTROL||PROSPECTIVE|||||||
33744722|NCT01159938|RANDOMIZED|CROSSOVER||||NONE||||||
33744723|NCT00355082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744724|NCT03436979|||COHORT||PROSPECTIVE|||||||
33744725|NCT00280332|||CASE_CONTROL||PROSPECTIVE|||||||
33744726|NCT06413667|||OTHER||PROSPECTIVE|||||||
34057966|NCT02142361|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34057967|NCT05387681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34057968|NCT01829178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34057969|NCT01903785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34057970|NCT00801437|||CASE_ONLY||PROSPECTIVE|||||||
34057971|NCT06393153|||COHORT||RETROSPECTIVE|||||||
34057972|NCT00565916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34057973|NCT02522013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161826|NCT04931251|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|no masking|This is a multi-site, single arm, financial navigation intervention||||
34161827|NCT05958797|||COHORT||PROSPECTIVE|||||||
34161828|NCT02184858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161829|NCT03401255|||CASE_ONLY||PROSPECTIVE|||||||
34161830|NCT06373146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161831|NCT01288989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161832|NCT03377153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161833|NCT02161978|||CASE_ONLY||PROSPECTIVE|||||||
34161834|NCT02166502|||CASE_ONLY||PROSPECTIVE|||||||
34161835|NCT02877303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161836|NCT04843761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057974|NCT03246373|||COHORT||PROSPECTIVE|||||||
34057975|NCT05648175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure blinding, all participants will complete the intake assessment by the healthcare team (Arm 1) and the Triage Module (Arm 2). Only the relevant data (i.e., Arm 1: intake assessment vs. Arm 2: Triage Module) will be analyzed depending on the treatment arm that the participant is randomly assigned to.|If eligible for this randomized controlled trial, participants (n = 186) will be randomized to receive an e-CBT treatment recommended by a multi-professional healthcare team consisting of a psychiatrist, psychiatric medical resident, and a trained research assistant (Arm 1, control group; n = 93), or the AI machine learning algorithm (Arm 2, experimental group; n = 93).|f|t|t|f
34057976|NCT06272045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"cluster randomized at the home visiting supervisor level, stratified within home visiting agencies~Participants are masked throughout the study enrollment process (e.g., recruitment, consent, and baseline data collection). Participant may become unmasked to treatment arm after enrollment."||t|f|f|t
33744727|NCT05509829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||150 patients of the prospectively included cohort will undergo NPWT. 150 patients of the retrospective cohort are used as a control group.||||
33744728|NCT02308436|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33744729|NCT00822510|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33744730|NCT01782131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744731|NCT03617640|||COHORT||PROSPECTIVE|||||||
33744732|NCT06152120|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research staff will be blinded to the study arm when collecting data from family surrogates by telephone at follow up time-points. The study biostatistician will also be blinded to the allocation of the study arm.|"The investigators will use a sequential mixed-methods approach including a pilot randomized controlled trial using a quantitative study to evaluate the effects of a structured nurse-facilitated ACP intervention and a qualitative study to explore the perceptions of the family surrogates and the ACP nurse facilitator on the ACP intervention.~Each patient-family dyad will be randomized in a 1:1 ratio to ACP intervention vs. usual care before the baseline interview."|f|f|f|t
33744733|NCT06261151|||COHORT||RETROSPECTIVE|||||||
33744734|NCT04937374|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"Arm 1: Rehmannia Glutinosa leaf extract~Arm 2: Placebo"|t|t|t|f
33744735|NCT00390052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744736|NCT04586140|||COHORT||CROSS_SECTIONAL|||||||
33744737|NCT02239887|||COHORT||PROSPECTIVE|||||||
33744738|NCT05391282|||COHORT||PROSPECTIVE|||||||
33848488|NCT05971459|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will receive a standardized functional and cognitive evaluation, as well as gait, fine motor, and gross motor assessments. Functional status will be measured using the Short Physical Performance Battery and the Timed Up \& Go Test (TUG) for basic and instrumental activities of daily living. Global cognition will be assessed using the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), the Trail-Making Test (TMT) A \& B, the WAIS-R Digit Symbol Substitution Test (DSST), the Digit Span Test, and the Letter Number Sequencing test. Fine and gross motor skills will be assessed using the Action Research Arm Test, the Hydraulic Hand Dynamometer Test, the Box and Block Test (BBT), and the 9-Hole Pegboard Test (9HPT).|Mixed-method group comparative study, individuals with PD vs healthy individuals|t|f|f|f
33848489|NCT03674372|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848490|NCT05949294|NA|SEQUENTIAL||TREATMENT||NONE||||||
33848491|NCT06155227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848492|NCT00469573|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33848493|NCT01320059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848494|NCT04531644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848495|NCT05781100|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Video Coders and Investigators are masked to the condition the dyad is exposed to during video / data analysis.|"To assess effects of maternal technology use on infant feeding interactions at 2wk and 4mo, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days:~TV Use condition: Mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. The show will be stopped when the mother indicates she is done feeding her infant.~Mobile Device Use condition: Mothers will be asked to use their mobile device in a way they find relaxing and pleasurable during the feeding interaction.~Control condition: Mothers will be asked to feed their infant in a room free of all potential technological distractions."|f|f|t|t
33848496|NCT03382379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34057977|NCT05454540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34057978|NCT04516382|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Single group of subjects will sequentially receive PTG-300 as IV, subcutaneous, and intramuscular administration||||
34057979|NCT01595958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34057980|NCT03035435|||CASE_CONTROL||PROSPECTIVE|||||||
34057981|NCT03912818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057982|NCT00560287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34057983|NCT06648421|||OTHER||CROSS_SECTIONAL|||||||
33744739|NCT03913273|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study calls for an experimental group of eleven participants who underwent AMI transtibial amputations incorporating surgically constructed Agonist-antagonist Myoneural Interfaces (AMIs), and a control group of eleven participants who underwent standard transtibial amputations. Each participant in the control group is prospectively matched to a participant in the experimental group to the degree possible based on time since amputation, body habitus, age, and biological sex. Matching is conducted by methods that estimate causal effects by reducing imbalance in the matching variables; any differences in outcomes in the two groups should therefore be attributable to the AMIs. We anticipate that a planned number of thirty two enrolled, consented participants will allow us to account for participant attrition over time. The study protocol focuses on functional performance testing of a multi-degree of freedom prosthesis in fully healed participants.||||
33744740|NCT02106468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744741|NCT00566228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744742|NCT01211626|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33744743|NCT02758431|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33744744|NCT00741234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744745|NCT03744156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744746|NCT05106257|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33744747|NCT01332877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744748|NCT03749551|||COHORT||PROSPECTIVE|||||||
33744749|NCT03787368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients, investigators, and all other site staff will remain blinded for the administered BAY1213790 or placebo, with the exception of the unblinded pharmacist or specifically dedicated site personnel.The sponsor will be not be blinded. Bioanalysis of plasma concentrations and PD parameters, as well as the evaluation of results will be performed in a non-blinded fashion.||t|f|t|f
33744750|NCT04313634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744751|NCT06175689|||COHORT||PROSPECTIVE|||||||
33744752|NCT02360709|||COHORT||PROSPECTIVE|||||||
33744753|NCT00436059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744754|NCT02588391|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33744755|NCT00804947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744756|NCT03974880|||COHORT||PROSPECTIVE|||||||
34057984|NCT02044874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34057985|NCT00638742|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34057986|NCT02267135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076521|NCT05411835|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Sachets of the ketone or maltodextrin powder are coded and packaged identically. The bionutrition unit will prepare the beverage and maintain the randomization code and the code for the ketone and maltodextrin products.|Subjects with either CPT2, TFP, LCHAD or VLCAD deficiency will be randomized to receive a ketone beverage (see composition in Appendix A) or an isocaloric maltodextrin control beverage (see composition in Appendix A) before moderate intensity exercise. Twenty minutes after consuming the pre-exercise beverage, subjects will complete a moderate intensity treadmill exercise test for 45 minutes. After a washout period of 48 hours, subjects will repeat the exercise. During the 2nd exercise test subjects will crossover to the beverage not consumed during the 1st exercise study.|t|f|t|t
33953737|NCT05698693|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study uses qualitative interviews (Aim 1; n=10) to inform the adaptation of a sleep intervention for African American adults with overweight/obesity, short sleep, and physical inactivity. The feasibility, satisfaction, and preliminary efficacy will be tested (Aim 2) using a 2-armed randomized control trial (n=80).||||
33953738|NCT04129866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953739|NCT05101057|||COHORT||RETROSPECTIVE|||||||
33953740|NCT00845377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953741|NCT03985293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953742|NCT06519422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953743|NCT04706494|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33953744|NCT05257109|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind, both participant and investigator will be blind to e-liquid being administered|Within subject design, all participants will receive all e-liquid flavors/water concentrations|t|f|t|f
33953745|NCT01141569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744757|NCT05147818|||CASE_CONTROL||RETROSPECTIVE|||||||
34057987|NCT04709419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Active and Control samples will be prepared in sealed and labeled as A or B Randomization envelopes (A\&B) will be provided to the research staff and used to obtain randomization assignment. After run-in evaluation subjects who continue to meet all inclusion and no exclusion criteria will be randomized in a 1:1 ratio to be treated with either Control or Celliant therapies, stratified by wound size (greater than size of 4 cm2) and study center. Study staff will use the randomization number labels and sock assignment of socks A or B contained in the envelope. The number will become the subject ID. The research staff will note the randomization number and the treatment assignment letter (A or B) on the CRF. The key, indicating therapy assignments (Active or Control), will only be available to staff not directly involved in the study until after the subject has completed study activities.||t|t|t|f
34057988|NCT05912231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057989|NCT03114501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744758|NCT02563912|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34057990|NCT04875988|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34057991|NCT06315153|||COHORT||OTHER|||||||
34057992|NCT01596153|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34057993|NCT06623500|||COHORT||PROSPECTIVE|||||||
34057994|NCT06621485|||CASE_CONTROL||RETROSPECTIVE|||||||
34057995|NCT00228319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057996|NCT00435435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34057997|NCT00553397|||CASE_ONLY||RETROSPECTIVE|||||||
34057998|NCT06621056|||COHORT||PROSPECTIVE|||||||
33744759|NCT01230697|||COHORT||PROSPECTIVE|||||||
33744760|NCT06244784|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744761|NCT06218017|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33744762|NCT01503905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744763|NCT05462366|||FAMILY_BASED||PROSPECTIVE|||||||
33744764|NCT01793792|NA|SINGLE_GROUP||TREATMENT||NONE||Low Profile Visualized Intraluminal Support device||||
33744765|NCT05348629|||COHORT||PROSPECTIVE|||||||
33744766|NCT02624804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744767|NCT06495008|||CASE_CONTROL||PROSPECTIVE|||||||
33744768|NCT04242927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33744769|NCT01018901|NA|SINGLE_GROUP||OTHER||NONE||||||
33744770|NCT04680221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34057999|NCT02743390|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34058000|NCT00146653|||||PROSPECTIVE|||||||
34058001|NCT00006357||||TREATMENT||||||||
34076522|NCT02805296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076523|NCT00368303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34076524|NCT02214342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744771|NCT06226376|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33744772|NCT04269928|||COHORT||RETROSPECTIVE|||||||
33744773|NCT06634914|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single arm interventional.||||
33744774|NCT06670326|NA|SINGLE_GROUP||TREATMENT||NONE|The investigator will not have access to assignment of participants to waitlist length and the data until data collection is complete.|Multiple baseline case series design: by randomizing participants to different lengths of waitlist (baseline) and comparing means and slopes of weekly reported Pathological Affective Dependence severity and mental health measures, the effectiveness of the treatment is tested.||||
33744775|NCT01815177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744776|NCT03398538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers||||
33744777|NCT00061295|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33744778|NCT00774735|RANDOMIZED|PARALLEL||||NONE||||||
33744779|NCT05582434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744780|NCT06348394|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, parallel controlled, open-label, single center study||||
33744781|NCT02520765|||COHORT||PROSPECTIVE|||||||
33953746|NCT05765942|||CASE_CONTROL||PROSPECTIVE|||||||
33953747|NCT04637815|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33953748|NCT05948826|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953749|NCT00007332||||PREVENTION||DOUBLE||||||
33953750|NCT01584804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953751|NCT02010346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33953752|NCT03294382|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33953753|NCT05651373|||COHORT||PROSPECTIVE|||||||
33953754|NCT04940091|||COHORT||PROSPECTIVE|||||||
33953755|NCT01058226||||||NONE||||||
33953756|NCT05877456|||CASE_ONLY||PROSPECTIVE|||||||
33953757|NCT05362669|RANDOMIZED|PARALLEL||OTHER||NONE||Invitation to cervical cancer screening using SMS compared to telephone call invitation.||||
33953758|NCT05542212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953759|NCT04053933|||COHORT||PROSPECTIVE|||||||
33848497|NCT03226184|||CASE_CONTROL||PROSPECTIVE|||||||
33848498|NCT04403464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848499|NCT05741359|NA|SINGLE_GROUP||TREATMENT||NONE||Total target count of CD3+CAR+ viable cells||||
33848500|NCT01737827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848501|NCT06306131|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|The intervention will be masked to the laboratory preforming the analysis of the urinary metabolites. The statistician, clinicians, coordinators and participants will be aware of the medication being studied.|Placebo controlled in first cycle with levonorgestrel plus meloxicam in second menstrual cycle.|f|f|f|t
33848502|NCT05304052|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Study coordinators who will be consenting and responsible for the pre-treatment and post-treatment assessments will be masked so that they will not have any bias as to which students participated in the mindfulness meditation intervention and which were in the wait list control group. A research associate who will not be participating in the assessments will be the one to call subjects and inform them of their assigned study arm.|After completing the pre-intervention assessment (consisting of completing an online survey, a blood draw and brain scan while performing tasks in a fMRI machine), students will be randomized to one of the two study conditions. Study subjects will be informed of their assigned condition and those assigned to the mindfulness meditation class will be provided with specific details for the class, while those assigned to the wait list control group won't be expected to do anything during the six week class schedule, other than not to take any meditation classes.|f|f|f|t
33848503|NCT01529203|NA|SINGLE_GROUP||OTHER||NONE||||||
33848504|NCT06610318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848505|NCT02878889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848506|NCT01870908|||CASE_ONLY||PROSPECTIVE|||||||
33848507|NCT02177591|||COHORT||CROSS_SECTIONAL|||||||
33848508|NCT01293487|NA|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33848509|NCT04659941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33848510|NCT04404985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848511|NCT02842320|NA|SINGLE_GROUP||OTHER||NONE||||||
33848512|NCT03935802|||COHORT||RETROSPECTIVE|||||||
33848513|NCT04300075|||COHORT||PROSPECTIVE|||||||
33848514|NCT05834426|||COHORT||PROSPECTIVE|||||||
33848515|NCT02482168|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33848516|NCT02334982|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33848517|NCT02871531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848518|NCT06397677|||COHORT||PROSPECTIVE|||||||
33848519|NCT01414400|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848520|NCT05337085|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33848521|NCT05839795|NA|SINGLE_GROUP||OTHER||NONE||||||
33953760|NCT03014427|||OTHER||PROSPECTIVE|||||||
33953761|NCT02404181|||COHORT||PROSPECTIVE|||||||
33953762|NCT02073591|||||PROSPECTIVE|||||||
33953763|NCT04698252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953764|NCT00194116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953765|NCT00278473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33953766|NCT02048059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953767|NCT01410747|||COHORT||PROSPECTIVE|||||||
33953768|NCT01353586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953769|NCT00583427|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33953770|NCT05741788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953771|NCT04765501|||OTHER||PROSPECTIVE|||||||
33953772|NCT05885711|||COHORT||PROSPECTIVE|||||||
33953773|NCT01036594|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33953774|NCT01788969|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33953775|NCT01728935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076525|NCT01189877|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848522|NCT01679405|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||For Part A of the study a standard 3+3 design was used. The recruitment was carried out in cohorts. Subjects were not allowed to participate in both cohorts. If the maximum tolerated dose was found there should be additional patients recruited to confirm the maximum tolerated dose (part B)||||
33848523|NCT01266681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848524|NCT06520800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Series of n-of-1 trials||||
33848525|NCT05984082|||OTHER||PROSPECTIVE|||||||
33848526|NCT04686201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized||||
33953776|NCT04681001|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized placebo-controlled double blinded|t|t|t|t
33953777|NCT01448070|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33953778|NCT03752424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953779|NCT02942537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953780|NCT03626246|||COHORT||CROSS_SECTIONAL|||||||
33953781|NCT03788785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is an open, controlled, randomized, parallel-group, two-arm, multicenter clinical study||||
33953782|NCT02487459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953783|NCT04491188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33953784|NCT03642158|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|double blinded||t|f|t|t
33953785|NCT02204709|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33953786|NCT05391607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953787|NCT01771627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953788|NCT01764594|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33953789|NCT06566053|||COHORT||RETROSPECTIVE|||||||
33953790|NCT02020421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953791|NCT04163328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The proposed research study is a randomized, double-masked, controlled clinical trial to test the efficacy of HydroEye® nutraceutical in subjects with contact lens discomfort.||t|t|t|t
33953792|NCT03854799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953793|NCT04615338|||OTHER||OTHER|||||||
33953794|NCT05866614|||COHORT||PROSPECTIVE|||||||
33953795|NCT05666648|||CASE_CONTROL||OTHER|||||||
33953796|NCT01511562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953797|NCT05359146|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A randomized, cross-over, prospective, single-centre, open label phase 0 study, comparing the dosimetry of 177Lu-DOTATOC and 161Tb-DOTA-LM3 in the same patients.||||
33953798|NCT05070507|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33953799|NCT04212624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953800|NCT03611920|||CASE_CONTROL||RETROSPECTIVE|||||||
33953801|NCT05354999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33953802|NCT02264886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953803|NCT00923299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953804|NCT00389168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953805|NCT04639050|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33953806|NCT05412823|||COHORT||PROSPECTIVE|||||||
33953807|NCT06429891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953808|NCT03590691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A cluster-randomized trial design|t|f|f|f
33953809|NCT01157065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953810|NCT04575987|||COHORT||PROSPECTIVE|||||||
33953811|NCT05250609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician will be blinded throughout the whole procedures (double blind). Principle investigator will be responsible for all clinical procedures.||f|t|f|t
33953812|NCT03300804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953813|NCT01932515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953814|NCT00326118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953815|NCT06489197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953816|NCT04749173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953817|NCT02959398|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33953818|NCT03770481|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two-groups comparison study|t|t|f|f
33953819|NCT06060717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953820|NCT05558007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953821|NCT06068088|||COHORT||PROSPECTIVE|||||||
33953822|NCT02352116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34058002|NCT05663944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomised to sirolimus or placebo. To ensure reasonable costs at this early stage of study, the placebo will not be identically matched. The participants and their clinical care providers will be blinded. In this proof of concept study, sirolimus is not expected to have a recognisable health benefit to the participants and therefore unlikely to lead to unblinding of allocated treatment. Further, blinding will be maintained throughout the trial by having random titration schedules in the placebo arm. The Investigating team and pharmacy representative will not be blinded at this early stage of study. The final unblinding of all trial participants will be undertaken after the creation of a locked analysis data set.|Randomised, patient-blinded, placebo-controlled, proof of concept, parallel group, single centre trial|t|t|f|t
34058003|NCT01765777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058004|NCT01432561|NA|SINGLE_GROUP||||NONE||||||
34058005|NCT00828724||CROSSOVER||OTHER||NONE||||||
34058006|NCT04145375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058007|NCT02641886|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34058008|NCT05593536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34058009|NCT04852796|||COHORT||CROSS_SECTIONAL|||||||
33953823|NCT05056012|||COHORT||PROSPECTIVE|||||||
33953824|NCT04358822|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33953825|NCT02359409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953826|NCT03179488|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, crossover trial|t|f|f|t
33953827|NCT01768494|||COHORT||PROSPECTIVE|||||||
33953828|NCT05728359|||COHORT||PROSPECTIVE|||||||
33953829|NCT01139242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953830|NCT05032573|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33953831|NCT02730039|||COHORT||PROSPECTIVE|||||||
33953832|NCT06653738|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||Patients will be allocated to either empagliflozin 25 or placebo once daily, and to either personalized or generic dietary counseling (2x2 factorial design).|t|t|t|t
33953833|NCT03199924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind study|t|t|f|f
33953834|NCT05411848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953835|NCT00998231|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33953836|NCT05112263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161837|NCT04700540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Researchers will enroll 100 PWMC and their care partners to participate in initial, 3-month, and 6-month surveys. Half of the PWMCs will be randomly assigned to the intervention group (to receive the SR) and the other half randomly assigned to the attention control group.|f|f|f|t
33953837|NCT01338909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953838|NCT04220723|||COHORT||PROSPECTIVE|||||||
33953839|NCT00000459|RANDOMIZED|||PREVENTION||||||||
33953840|NCT06330480|RANDOMIZED|PARALLEL||SCREENING||NONE||Check@Home is a population-based screening with a phased assessment and implementation using an iterative design executed consecutively in four regions in the Netherlands.||||
33953841|NCT02220621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33953842|NCT02014194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33953843|NCT00825669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953844|NCT03916354|||COHORT||PROSPECTIVE|||||||
33953845|NCT04945226|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort 1 / Cohort 2 (Group 1, Group 2) / Cohort 3||||
33953846|NCT05168657|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Random-order cross over trial in a home-use setting with two 14-day study arms||||
33953847|NCT03746249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953848|NCT03296592|||COHORT||PROSPECTIVE|||||||
33953849|NCT04769830|||COHORT||PROSPECTIVE|||||||
33953850|NCT05151991|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33953851|NCT05190562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953852|NCT02916056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953853|NCT02237885|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33953854|NCT03166969|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33953855|NCT04138550|||OTHER||CROSS_SECTIONAL|||||||
33953856|NCT04952610|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a multicenter study to enable patients with PVST to have continued access of etripamil NS. The study will only include patients who have participated in a Milestone Pharmaceuticals Inc. approved clinical research trial (NODE-301 Part 1, RAPID Study (NODE-301 Part 2), NODE-302, or NODE-303) of etripamil NS for PSVT. Patients who experienced any significant safety issues during participation in a previous study, as per Investigator's assessment, are excluded.~This study is planned to continue until etripamil NS is commercially available for patients with PSVT or the study is terminated by the Sponsor for any reason."||||
33953857|NCT01346202|||COHORT||RETROSPECTIVE|||||||
33953858|NCT02709408|||COHORT||PROSPECTIVE|||||||
33953859|NCT06337344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953860|NCT05552898|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender and endorsement of problems with energy and/or focus reported during enrollment, then randomized to one of the study arms|t|f|t|f
33953861|NCT02988310|||||CROSS_SECTIONAL|||||||
33953862|NCT04992780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953863|NCT03239340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953864|NCT05476809|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Randomization to groups will follow a randomization table created by our university statistician. The project manager will create sequentially numbered sealed envelopes containing group assignment. Each consenting patient and their family caregiver will receive the envelope in the order in which they are enrolled. The project manager will have access to the spreadsheet that indicates the randomization order, but not the research nurses who assess outcomes. After randomization, patients and their family caregivers in the experimental group will receive the SCM, and those in the control group will receive usual care. Patients and families will not be aware of their group enrollment and will be masked to the care model they receive. Research nurses who collect data will be independent of those who deliver the interventions.|Current study plan to developed an advanced version of this smart-clothes care model based on prior study and the theory of Finding a Balance Point to further include monitoring for medication, abnormal life patter of the persons with dementia, and quality of hired care, and an interactive family caregiver app, and to examine this upgraded smart-clothes care system in a clinical trial.|t|f|f|t
33953865|NCT02284880|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34161838|NCT02489292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161839|NCT02923570|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase II randomized two-arm trial comparing proton-beam radiation therapy (PBRT) with photon- based intensity-modulated radiation therapy (IMRT) for cancers in the head and neck region requiring ipsilateral radiation.||||
34161840|NCT00755365|||CASE_ONLY||RETROSPECTIVE|||||||
34161841|NCT02905630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161842|NCT04208438|||COHORT||PROSPECTIVE|||||||
34161843|NCT06069414|||COHORT||PROSPECTIVE|||||||
34161844|NCT02950909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161845|NCT06216821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161846|NCT04131062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||One control arm (traditional, human-mediated consent) compared against one intervention arm (electronic-based consent using the Sage eConsent framework).||||
34161847|NCT00706420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34161848|NCT00223483|||OTHER||PROSPECTIVE|||||||
33953866|NCT03912883|||COHORT||RETROSPECTIVE|||||||
33953867|NCT03508466|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953868|NCT00116545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953869|NCT02886611|||OTHER||CROSS_SECTIONAL|||||||
33953870|NCT06537921|NA|SINGLE_GROUP||OTHER||NONE||Feasibility||||
33953871|NCT02150889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953872|NCT01790139|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34161849|NCT02312050|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34161850|NCT03494790|||COHORT||PROSPECTIVE|||||||
34161851|NCT00291018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34161852|NCT06362317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744782|NCT02278601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744783|NCT05469321|||COHORT||RETROSPECTIVE|||||||
33848527|NCT00572039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848528|NCT02466750|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848529|NCT01616745|||COHORT||PROSPECTIVE|||||||
34058010|NCT03438461|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34058011|NCT05152069|||CASE_ONLY||RETROSPECTIVE|||||||
34058012|NCT00762008|||CASE_CONTROL||PROSPECTIVE|||||||
34058013|NCT00224146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058014|NCT06618885|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|This trial will be conducted in a double-blinded manner. Namely, the participants, site staff, sponsor staff, the study monitor(s) and the trial statistician will be blinded to the treatment allocation. The independent statistician and the pharmacist are not blind throughout the study.||t|t|t|t
34058015|NCT00084318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058016|NCT00497770|||||PROSPECTIVE|||||||
34058017|NCT04416737|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will each come in for 3 visits separated by at least 1 week. During the first two visits they will be randomized to either upper or lower peritoneal injection followed by the other site. During the third visit a subcutaneous injection will be performed to provide comparative data to the standard of care.||||
34058018|NCT05930834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34076526|NCT00926757|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34076527|NCT05022277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34076528|NCT01261390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076529|NCT01468454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161853|NCT00674414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161854|NCT00255788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161855|NCT04961424|||CASE_CONTROL||RETROSPECTIVE|||||||
34161856|NCT00959179|||CASE_ONLY||PROSPECTIVE|||||||
34161857|NCT04556279|||COHORT||PROSPECTIVE|||||||
34161858|NCT02005588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161859|NCT05750576|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34161860|NCT03434158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161861|NCT01624116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161862|NCT03432169|RANDOMIZED|PARALLEL||OTHER||SINGLE|Will code data entered into database.|Group A receives Yoga (stretching with mindfulness) and Group B receives stretching (stretching without mindfulness)|f|f|f|t
33848530|NCT01119872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848531|NCT04717245|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In this study, 75 patients were included, divided into these three groups:~Group 1 - Treatment with topical vaginal promestriene - 25 patients were included in this group~Group 2 - Treatment with fractional CO2 LASER - 25 patients were included in this group~Group 3 - Treatment with microablative fractional radiofrequency - 25 patients were included in this group"||||
33848532|NCT04572308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848533|NCT03656510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848534|NCT00174343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848535|NCT05718466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848536|NCT01659788|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33848537|NCT01999140|||COHORT||PROSPECTIVE|||||||
33848538|NCT00909337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848539|NCT06155994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848540|NCT00005082||||DIAGNOSTIC||||||||
33848541|NCT03183726|||CASE_ONLY||PROSPECTIVE|||||||
33848542|NCT03316820|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848543|NCT00596479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33848544|NCT05439590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Smoothies containing 30 g CSO, 30 g OO, 60 g CSO, and 60 g OO were designed to be comparable in taste and appearance. The smoothies will be prepared and coded prior to receipt by the research team. Randomization is for order of coded meals.|The design is randomized parallel design, where the healthy adults will be randomized into 30 g CSO, 30 g OO, 60 g CSO, and 60 g OO.|t|f|t|f
33848545|NCT01768637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848546|NCT04247763|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Double-blind: The data manager assigned arbitrary names to each meal so that only the data manager and the kitchen staff were unblinded.|Randomized crossover trial: participants were randomized to sequence of meal type; they ate one high saturated fat meal and one high oleic sunflower oil meal with 1-4 weeks washout in between meals|t|t|t|t
33848547|NCT05805436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848548|NCT03131154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848549|NCT04428918|||COHORT||PROSPECTIVE|||||||
33848550|NCT00519519|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33848551|NCT04014491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848552|NCT00688558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848553|NCT00296673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33848554|NCT04701177|||COHORT||PROSPECTIVE|||||||
33848555|NCT00537654|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848556|NCT01222026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848557|NCT00046254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33848558|NCT00613665|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33848559|NCT06461702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848560|NCT02744911|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34161863|NCT05668286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients who are diagnosed with adhesive capsulitis in the orthopedic outpatient clinic will be included. Included patients will be randomly divided into two groups according to age, sex, concomitant diabetes mellitus (DM) disease and clinical stage of the disease. For randomization, stratified randomization will be applied according to the information obtained from the outpatient clinic. While patients in group 1 received an anterior extra-articular steroid injection under USG guidance, patients in group 2 received posterior intra-articular steroid injection under USG guidance.1 mL of triamcinolone acetonide and 1 mL of prilocaine hydrochloride (2%) will be injected to all patients. Patients will be first evaluated before injection, than randomized to groups and prospectively followed up by an orthopaedic surgeon who will be blinded to the groups. Evaluation will be done for pain VAS, functional status ;ASES and Quick DASH at 1,3 and 6 weeks after the injection.|t|t|t|f
34161864|NCT02669251|NA|SEQUENTIAL||TREATMENT||NONE||||||
34161865|NCT06507930|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34161866|NCT02899091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161867|NCT03648957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161868|NCT05877755|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161869|NCT05893381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161870|NCT05431855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34161871|NCT02023996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161872|NCT05257629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34161873|NCT03286452|||CASE_ONLY||PROSPECTIVE|||||||
34161874|NCT00369213|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34161875|NCT05181644|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized controlled study. It is a 1:1 randomization, stratified, with 3 blocks of patients distributed in the two groups (experimental and control).||||
34161876|NCT03674632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34161877|NCT03208634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161878|NCT06017726|||CASE_CONTROL||PROSPECTIVE|||||||
34161879|NCT00592904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161880|NCT03078894|||COHORT||RETROSPECTIVE|||||||
34161881|NCT01378442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848561|NCT05020327|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Patients will be screened by questionnaire to determine No risk, Low risk, or High Risk for penicillin allergic reaction. Those that are deemed Low Risk based on questionnaire, will be subsequently challenged with graded oral amoxicillin challenge.||||
33848562|NCT02830360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848563|NCT02129270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161882|NCT02497417|||CASE_ONLY||PROSPECTIVE|||||||
34161883|NCT03308708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34161884|NCT00780416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848564|NCT04368559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848565|NCT02437253|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33848566|NCT00125073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848567|NCT00477321|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848568|NCT02988518|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848569|NCT05240742|||COHORT||PROSPECTIVE|||||||
33848570|NCT00682851|||COHORT||CROSS_SECTIONAL|||||||
34161885|NCT02705196|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161886|NCT04741919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each participant will be randomized to a specific LPI placement (superior or temporal) for one eye, and will be given the other alternative placement for the second eye. This is paired-eye comparative clinical trial.|t|f|f|f
34161887|NCT04985318|||COHORT||RETROSPECTIVE|||||||
34161888|NCT06704724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161889|NCT05133765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Three period randomised cross-over clinical trial||||
33744784|NCT03223298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be carried out by the biostatistics team at Weill Cornell. This will provide assurance that there will be equal patient allocation to both study arms, at each participating site, in the event that the target sample size is not reached. The list will be maintained by the investigational pharmacy. A designated research assistant will be identified at each site to prepare the interventional medication (botulinum versus normal saline). The identity of the agent injected will be unknown to the surgeon as the agent will be drawn up by an assistant in a masked syringe immediately prior to each procedure and labeled with the patient's identifier. Only one assistant at each site will know the identity of the agents during the trial.|Study participants will be randomly allocated to one of two treatment arms (injection of botulinum versus placebo). Blocked randomization will be performed at each of the participating sites. They will be stratified based on study site.|t|t|t|f
33744785|NCT06636201|||COHORT||PROSPECTIVE|||||||
33744786|NCT05911854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744787|NCT05930093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744788|NCT01101737|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33744789|NCT04745676|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33744790|NCT05916508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744791|NCT04031222|||COHORT||PROSPECTIVE|||||||
33744792|NCT05639738|NA|SINGLE_GROUP||OTHER||NONE||||||
33744793|NCT04307186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is a one-way crossover study with blinded participants and blinded image readers|||||
33744794|NCT01367262|NA|SINGLE_GROUP||OTHER||NONE||||||
33744795|NCT02919579|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33744796|NCT03678948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study subject will not be made aware of the treatment received until after completion of the research study.||t|f|f|f
33744797|NCT04712526|||CASE_ONLY||PROSPECTIVE|||||||
33744798|NCT03277222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a prospective dose-ranging double-blinded pilot study over 4 months. At enrolment, participants and their physicians will be blinded to treatment.|"Arm 1: Drug: IN insulin Dose: Twice daily IN insulin R at 40 IU (n=10) twice daily using a nasal delivery device. IN insulin R will be administered twice daily.~Arm 2: Drug: Sterile Saline placebo Dose: Placebo (Sterile Saline placebo, matched volume; (n=10) twice daily using nasal delivery device."|t|t|t|t
33744799|NCT00538161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744800|NCT03931434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind Placebo Controlled|t|t|t|t
33744801|NCT00497380|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33744802|NCT05227287|||COHORT||OTHER|||||||
33744803|NCT06422741|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33744804|NCT02910258|||COHORT||PROSPECTIVE|||||||
33744805|NCT03631186|||COHORT||PROSPECTIVE|||||||
33744806|NCT03434119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744807|NCT03435393|||COHORT||OTHER|||||||
33744808|NCT05200923|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33744809|NCT03376321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744810|NCT05610553|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744811|NCT03002181|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33744812|NCT06635252|||COHORT||PROSPECTIVE|||||||
33744813|NCT02015897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744814|NCT02116634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744815|NCT05267041|NA|SINGLE_GROUP||OTHER||NONE||One questionnaire between diagnostic annoucement and first line treatement One 6 months later One before second line treatment One 6 months later after second line treatment Optionnal Veinous Blood Sample (28 mL) between the diagnostic annoucement and the first line of treatment||||
33744816|NCT03958903|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744817|NCT02358577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744818|NCT01415791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744819|NCT03607305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744820|NCT04298567|||COHORT||PROSPECTIVE|||||||
33744821|NCT06092996|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744822|NCT00607451|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33744823|NCT03606317|||CASE_ONLY||RETROSPECTIVE|||||||
33744824|NCT00464542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744825|NCT01021969|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33744826|NCT00884429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33744827|NCT03668145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be blinded to participant, care provider, investigator and outcome assessors.||t|t|t|t
33744828|NCT03043183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33744829|NCT04540107|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33744830|NCT04122417|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33744831|NCT04198129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744832|NCT00388414|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33744833|NCT02964845|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848571|NCT03203031|||CASE_ONLY||PROSPECTIVE|||||||
33848572|NCT04539080|||CASE_CONTROL||PROSPECTIVE|||||||
33848573|NCT00778960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33848574|NCT00540046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848575|NCT01151410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848576|NCT05220787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be assigned to 1 of 2 treatment groups.|t|t|t|t
33848577|NCT02942524|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848578|NCT03235557|||COHORT||PROSPECTIVE|||||||
33848579|NCT00804531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848580|NCT03584542|||OTHER||PROSPECTIVE|||||||
33848581|NCT00215137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848582|NCT03363672|||COHORT||PROSPECTIVE|||||||
33848583|NCT06252948|||CASE_CONTROL||PROSPECTIVE|||||||
33848584|NCT01064661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33744834|NCT06669000|||COHORT||PROSPECTIVE|||||||
33744835|NCT02854540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744836|NCT03988179|||COHORT||PROSPECTIVE|||||||
33744837|NCT03646513|||COHORT||PROSPECTIVE|||||||
33744838|NCT05354700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744839|NCT06273852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This substudy is not blinded.||||
33744840|NCT05255640|||COHORT||PROSPECTIVE|||||||
33744841|NCT04498650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744842|NCT01303289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33848585|NCT00795366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744843|NCT06007092|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|double blinded|"Within each group, patients will be randomized between poly-ICLC- adjuvanted CD40HVac or placebo in a 5:1 ratio.~12 patients will be treated at each dose level (10 with vaccine and 2 with placebo).~The patients will receive three subcutaneous injections of a poly-ICLC- adjuvanted CD40HVac or placebo:~* The first injection will occur at week 0~* The second injection will occur at week 4 (±7 days)~* The third injection will occur at week 24 (±7 days)"|t|f|t|f
33744844|NCT03788486|NA|SINGLE_GROUP||TREATMENT||NONE||Single site prospective study with no control group to assess the safety and clinical efficacy of a low power LED light device on the signs and symptoms of dry eye disease.||||
33848586|NCT01204398|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848587|NCT03014076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848588|NCT03303846|NA|SINGLE_GROUP||SCREENING||NONE||||||
33848589|NCT01574378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848590|NCT02630108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848591|NCT05134831|||COHORT||PROSPECTIVE|||||||
33848592|NCT04135768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded, since the study procedure will be performed via the incision for the main surgery. Thus no external (wound) evidence of the participant's allocation will be visible.|Pilot study, single center, parallel group design|t|f|f|f
33848593|NCT05368792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The principal investigator, clinic staff and outcome assessors of colon visibility and hydration will be blinded to the treatment allocation of participants||f|t|f|t
33848594|NCT01146782|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33848595|NCT03983603|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33848596|NCT04055532|||COHORT||PROSPECTIVE|||||||
33848597|NCT02914275|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848598|NCT06198322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded limited to the outcome assessment|split-mouth, prospective, single-center, single-blinded, two-arm randomized clinical trial with a 1:1 allocation ratio.|f|f|f|t
33848599|NCT01021215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848600|NCT01620476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848601|NCT00477360|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33848602|NCT05213494|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33953873|NCT05288621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33953874|NCT04792073|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase II Single-Arm Clinical Trial Assessing Comprehensive Ablative Radiation Therapy with Avelumab in Unresectable and Metastatic Merkel Cell Carcinoma (CARTA)||||
33953875|NCT03843905|||COHORT||PROSPECTIVE|||||||
33953876|NCT00836966|||COHORT||PROSPECTIVE|||||||
33953877|NCT00991146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953878|NCT03890159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33953879|NCT00586677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953880|NCT05355506|||CASE_CONTROL||PROSPECTIVE|||||||
33953881|NCT05849025|||COHORT||PROSPECTIVE|||||||
33953882|NCT03330275|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33953883|NCT00545493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953884|NCT02188667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953885|NCT01046201|||COHORT||PROSPECTIVE|||||||
33953886|NCT04187937|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, non-controlled, single-arm feasibility study of intraoperative ultrasound-based navigation for non-anatomical liver resections||||
33953887|NCT02057224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953888|NCT01495104|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33953889|NCT04034875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953890|NCT06650020|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33953891|NCT01884909|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33953892|NCT04349501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"A logistic regression model of biochemical recurrence within 3 years will be fit, using maximum likelihood, on the change in RSI cellularity index from MRI #1 to MRI #2 and relevant covariates such as demographics. Continuous variables will be splined; only main effects will be considered. The cross-validated AUC for this model will be reported with a 95% bootstrap confidence interval using Efron's bias-corrected and accelerated (bca) method. If the lower bound on the 95% confidence interval of the AUC excludes 0.55, RSI cellularity index will be declared viable for identifying participants who will recur within the three-year post treatment. If declared viable, a Cox model for predicting recurrence time will be fit, and the hazard ratios for RSI will be used to describe the adjusted associations supported by the data between RSI cellularity index and recurrence time."||||
33953893|NCT03730025|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33953894|NCT02168569|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953895|NCT01797809|||COHORT||PROSPECTIVE|||||||
33953896|NCT03677973|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33953897|NCT04762212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The care provider (Cathy Arnot) will not be blinded as she knew the groups of the participants. The Investigators and the Outcomes Assessors were blinded as they were not aware of the group each participant was placed in.|A parallel design, also called a parallel group study, compares two or more treatments. Participants are randomly assigned to either group, treatments are administered, and then results are compared.|f|f|t|t
33953898|NCT01856348|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34058019|NCT03618563|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|After the baseline evaluation, participants were randomly assigned to Intervention Group A or B by block randomization. For example, the first participant was allocated to Group A, the second to Group B, third to Group A, and so forth (Jadad 1998). Participants did not know to which group they belonged and had not contact with other participants during all study phases. Further, the OT who performed the participant evaluations was blinded to their treatment allocations.|The study was designed as a randomized controlled and crossover trial to evaluate the efficacy of the treatment among adolescents with EF deficits in their daily performance. The first Intervention Group (A) received the FITTED intervention. After a crossover switching trial, the second Intervention Group (B) received the FITTED intervention in order (Fig 1). An OT performed all four evaluations (Phases 1, 1a, 2, and 3) in similar environmental conditions. Another OT performed the intervention process according to the protocol. The Ethics Committee of the University of Haifa approved the study.|t|f|f|f
34161890|NCT04759157|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Investigators and outcomes assessors will not have knowledge of the randomization table. Participants will be reminded to not to tell the outcomes assessors their group. Only the statistician and interventionist will be aware of the group.|This is a dyadic study. Couples are randomly assigned as a dyad.|f|f|t|t
34161891|NCT03266406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161892|NCT05452733|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34161893|NCT01607944|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848603|NCT06127823|RANDOMIZED|PARALLEL||TREATMENT||NONE|The randomisation list will be made by a researcher/statistician not involved in the trial, who will be the only person to access the randomisation list during the trial.|The INTENSE-GDM trial is a randomised controlled parallel group open-label effectiveness trial. Participants will be randomised to either an intensive dietary counselling group or a usual dietary care group (control group) in a 1:1 ratio.||||
33848604|NCT03356782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161894|NCT01310764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161895|NCT02502942|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34161896|NCT00704704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161897|NCT02094092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161898|NCT05930496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161899|NCT05970991|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34161900|NCT02560272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161901|NCT00842855|||COHORT||PROSPECTIVE|||||||
34161902|NCT01481337|||COHORT||PROSPECTIVE|||||||
34161903|NCT02270112|||CASE_CONTROL||PROSPECTIVE|||||||
34161904|NCT04543227|||CASE_CONTROL||PROSPECTIVE|||||||
33848605|NCT04265820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848606|NCT04410640|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848607|NCT02900586|||COHORT||PROSPECTIVE|||||||
33848608|NCT05480930|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants who are consulted/examined by telephone only will be masked to which arm they are participating in. Participants who are consulted/examined in-person will not be explicitly informed of the study arm but will be able to observe if the provider is using paper forms or an electronic device.|This study is an interrupted time series trial where the pre-intervention period will employ existing paper clinical decision support tools and the intervention period will employ a new digital clinical decision support tool. A small fraction of participants will participate in both the pre-intervention and post-intervention periods but most will only participate in one.|t|f|f|f
33848609|NCT05206981|||COHORT||OTHER|||||||
33848610|NCT04642716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Saliva of periodontitis patients collected for analyzing free amino acids.||||
33848611|NCT00484289|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848612|NCT06031038|RANDOMIZED|PARALLEL||OTHER||NONE||To compare the time in remission of patients with complex IBD (require immunosuppressants and/or biologics to control their luminal inflammatory activity) controlled with the TECCU intervention (G_TECCU) with respect to usual clinical practice (G_Control) after 52 weeks of follow-up.||||
33848613|NCT00283088|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33848614|NCT05559476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848615|NCT04201054|NA|SINGLE_GROUP||OTHER||NONE||||||
33848616|NCT06239597|NON_RANDOMIZED|PARALLEL||OTHER||NONE|In the course setting, the students, the professor, and the intervention providers will not be masked.|an experimental group and a control group will be applied.||||
33848617|NCT03930862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848618|NCT01882205|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33848619|NCT02665767|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33848620|NCT04744168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Women will be distributed randomly in the experimental or the placebo arm. They won't know that the point 16 HM isn't effective on cervix maturation. They will believe that both techniques work.||t|f|f|t
33848621|NCT02734797|||COHORT||PROSPECTIVE|||||||
33848622|NCT00232544|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33848623|NCT04173351|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This randomized controlled study was conducted at Gulhane Training and Research Hospital, Obstetrics and Gynecology clinic between February 2016 and January 2017. The CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting randomised controlled trials (RCTs) has been used to describe the methods.|t|f|t|f
33848624|NCT05563285|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, the combination of Exercise and Mindfulness-Based Intervention method was used to intervene the smartphone addiction of female university students' emotion regulation and inhibitory control compared with the usual PE sessions method. Each parallel group has female separately.|t|f|t|t
33848625|NCT06182553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||A randomized controlled trial with four parallel groups will be used in the current study.|t|t|t|t
33848626|NCT06609785|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33848627|NCT03403218|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single group assignment. cross-sectional survey.||||
33848628|NCT01238900|||CASE_ONLY||PROSPECTIVE|||||||
33848629|NCT05778877|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34161905|NCT01332253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161906|NCT05785429|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33848630|NCT06295198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After evaluations, the groups determined as a result of randomization via a website were placed in opaque envelopes. The participant is randomized to one of the Mulligan or Maitland groups by selecting an envelope.|Participants with lateral ankle sprains will be randomized to the Mulligan and Maithland groups, and their evaluations and treatments will be completed.|f|f|f|t
33848631|NCT02374892|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33848632|NCT06610825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848633|NCT00682669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848634|NCT04083573|||CASE_ONLY||CROSS_SECTIONAL|||||||
33953899|NCT02577094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953900|NCT05086627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953901|NCT02325193|||COHORT||PROSPECTIVE|||||||
33953902|NCT06567210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers responsible for randomization and data-analysis will be blinded to the study arms.|experimental parallel two-arm repeated measures randomized controlled trial|f|f|f|t
33848635|NCT05676853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848636|NCT02981108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848637|NCT05948553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The overall 2-stage randomization scheme will be implemented by an unblinded statistician who is otherwise uninvolved in study operations. Participants will be assigned a study number at Screening (Subject ID). In the first stage of randomization, eligible participants who complete screening will be randomly assigned to an open platform cohort for which they are eligible (both site PIs and participants are aware of the cohort assignment) and, within that cohort, the second stage of randomization is to intervention vs placebo (double-blind) using Interactive Response Technology (IRT).~For this APT, participants assignment to a cohort will not be blinded. The tablets/capsules used in the cohorts may not be visually similar between cohorts and blinding to cohort assignment is not necessary to avoid bias. However, within each cohort, participants, site personnel, contract research personnel and the sponsor will be blind to treatment assignment (intervention vs. placebo)."|Fluoxetine is one of multiple interventions that will be tested in this adaptive platform trial (NCT05422612).|t|t|t|t
33848638|NCT05426928|||COHORT||PROSPECTIVE|||||||
33848639|NCT01822054|||CASE_CONTROL||PROSPECTIVE|||||||
33848640|NCT06410768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848641|NCT01775475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848642|NCT00413998|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33953903|NCT06649175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953904|NCT06002425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953905|NCT06437522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953906|NCT03179462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33953907|NCT05829252|||OTHER||CROSS_SECTIONAL|||||||
33953908|NCT06652659|||COHORT||PROSPECTIVE|||||||
33953909|NCT06649877|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33953910|NCT04846907|||COHORT||CROSS_SECTIONAL|||||||
33953911|NCT01977924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33953912|NCT06653868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33953913|NCT03372018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33953914|NCT02720796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953915|NCT05901376|||CASE_CONTROL||PROSPECTIVE|||||||
33953916|NCT05965232|||COHORT||PROSPECTIVE|||||||
33953917|NCT05863325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953918|NCT00457249|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953919|NCT03623217|||COHORT||PROSPECTIVE|||||||
33953920|NCT05980013|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33953921|NCT05549986|||COHORT||RETROSPECTIVE|||||||
33953922|NCT01504152|||COHORT||RETROSPECTIVE|||||||
33953923|NCT04717934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953924|NCT01301248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744845|NCT04273633|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33953925|NCT00023426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953926|NCT01320176|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848643|NCT05909852|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33953927|NCT01640964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058020|NCT02200237|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058021|NCT02944500|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34058022|NCT03600012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
34058023|NCT06621433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34058024|NCT06448533|||COHORT||RETROSPECTIVE|||||||
34161907|NCT04325828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161908|NCT06397573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161909|NCT00600210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161910|NCT01667653|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161911|NCT02501590|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34161912|NCT04630145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161913|NCT02777489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848644|NCT03391401|||COHORT||PROSPECTIVE|||||||
33848645|NCT00408720|||||OTHER|||||||
33848646|NCT04886622|NA|SEQUENTIAL||TREATMENT||NONE||||||
33848647|NCT04137159|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Study statistician is masked to intervention type|Randomized cross-over wait-list controlled|f|f|f|t
33848648|NCT03461536|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Patients, investigators, and outcome assessors will be blinded to study arm.||t|f|t|t
34058025|NCT05740176|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter, prospective, historically controlled||||
34058026|NCT06207240|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants will receive identical intervention protocols.||||
33848649|NCT02608957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848650|NCT06610669|||COHORT||RETROSPECTIVE|||||||
33848651|NCT05405439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848652|NCT02290730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953928|NCT03004430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33953929|NCT03330977|NA|SINGLE_GROUP||TREATMENT||NONE||Comparison before/after||||
34058027|NCT05249075|||COHORT||PROSPECTIVE|||||||
34058028|NCT06623331|||CASE_CONTROL||RETROSPECTIVE|||||||
34058029|NCT05632315|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label, comparative||||
34058030|NCT06554990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058031|NCT06160284|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be medically healthy females and males with OUD.||||
34058032|NCT05654428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Just Participants are unaware about which type of intervention they are being underwent.|A Randomized Control Trail with 2 Equal groups|t|f|f|f
34058033|NCT04181437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058034|NCT06575660|NA|SINGLE_GROUP||OTHER||NONE||||||
34058035|NCT02395237|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161914|NCT01870505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161915|NCT04381663|||COHORT||OTHER|||||||
34161916|NCT04784832|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34161917|NCT00987311|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34161918|NCT00610311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161919|NCT04475120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161920|NCT00274508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33744846|NCT00443248|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33953930|NCT01014754|||CASE_CONTROL|||||||||
33953931|NCT00798161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953932|NCT06207656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953933|NCT04760639|||COHORT||PROSPECTIVE|||||||
33953934|NCT00660855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744847|NCT04898153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848653|NCT04846673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848654|NCT06444412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848655|NCT05361187|||CASE_ONLY||PROSPECTIVE|||||||
33848656|NCT01195961|||||PROSPECTIVE|||||||
33848657|NCT06007521|||CASE_ONLY||PROSPECTIVE|||||||
33953935|NCT01443676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953936|NCT03930615|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058036|NCT00707902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058037|NCT06647680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161921|NCT05179148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161922|NCT04891380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|It is impossible to mask since the devices used must be put on and operated by the responsible crew.|All patients who meet the inclusion criterias will be eligiable.||||
34161923|NCT06059989|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous Infliximab with and without Immunomodulators during Induction treatment in Moderate to Severe Crohn's Disease.||||
34161924|NCT01621711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34161925|NCT01567111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34161926|NCT03982680|NA|SINGLE_GROUP||TREATMENT||NONE||All patients were given Toripalimab 3 mg/kg (day 1 and 15); Gem+5-FU (Gem 1250mg/m2+CF 200 mg/m2+5-FU400 mg/m2 intravenous drip+5-FU 2.4-3.6 g/m2 continuous intravenous drip for 48 hours), the first and fifteenth days, four weeks for a cycle, a total of four cycles. After 4 cycles, Toripalimab was maintained at 3 mg/kg Q3 w for a total of 1 year if the disease was not progressing or toxic side effects were tolerated.||||
34161927|NCT01633658|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34161928|NCT04678635|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind study to transcranial direct current stimulation|Prospective, randomized, double-blind, placebo-controlled study with application or not of chronic transcranial direct current stimulation sessions - associated with aerobic exercises - in patients with systemic autoimmune myopathies.|t|f|t|f
34161929|NCT02154919|||CASE_CONTROL||PROSPECTIVE|||||||
34161930|NCT01521858|||CASE_ONLY||RETROSPECTIVE|||||||
34161931|NCT00226486|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34161932|NCT01068574|||COHORT||PROSPECTIVE|||||||
34161933|NCT05432752|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will undergo clinical evaluation for concussion and will also be evaluated using the Concussion Pen. All subjects (both controls and concussion patients) will undergo all eye tracking measurements. Randomization to being evaluated using clinical care first then the Concussion Pen and vice versa will be utilized.||||
34161934|NCT05196022|||COHORT||PROSPECTIVE|||||||
34161935|NCT03336294|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34161936|NCT02289807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848658|NCT05253300|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The type of this study is a quasi-experimental clinical study.||||
33848659|NCT00079066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848660|NCT03189745|NA|PARALLEL||PREVENTION||NONE||||||
33848661|NCT01123876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848662|NCT05109754|NA|SEQUENTIAL||TREATMENT||NONE||||||
33848663|NCT00735631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848664|NCT00882687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33848665|NCT03407937|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Repeated measures on a single group of participants||||
33848666|NCT05207553|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33848667|NCT04312334|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The outcome assessor will be masked to treatment.|"To test the efficacy of the Supertowel under the different conditions, we will use a crossover controlled study based and adapted on the protocol of the European Committee for Standardization (EN 1499) which is designed to evaluate the ability of hand-wash agents to eliminate transient pathogens from volunteers' hands without regard to resident microorganisms. This procedure is based on the post-contamination treatment of hands and involves the placement of the test organism (E. coli \[ATCC 11229\]) on the hands of test subjects, followed by exposure of the test product.The study will be organized in two rounds of tests."|f|f|f|t
33848668|NCT01852253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848669|NCT00173654|||DEFINED_POPULATION||OTHER|||||||
33848670|NCT05741333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848671|NCT00583193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848672|NCT05567354|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blind treatment and randomization will be used to reduce potential bias during data collection and evaluation of clinical endpoints. A placebo control will be used to establish the frequency and magnitude of changes in clinical endpoints that may occur in the absence of active treatment, as well as to minimize subject and investigator bias.|This will be a 3 way crossover study to evaluate the abuse potential of PF614.|t|f|t|t
33848673|NCT05029232|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33848674|NCT05159791|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848675|NCT05914987|||COHORT||OTHER|||||||
33848676|NCT00625261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34161937|NCT01401517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848677|NCT06248099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33848678|NCT04328116|||COHORT||PROSPECTIVE|||||||
33848679|NCT03732560|||COHORT||RETROSPECTIVE|||||||
33848680|NCT02856477|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33848681|NCT01473004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848682|NCT01405365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33848683|NCT04328454|||COHORT||RETROSPECTIVE|||||||
33848684|NCT02777138|||OTHER||CROSS_SECTIONAL|||||||
33848685|NCT04498559|||OTHER||PROSPECTIVE|||||||
33848686|NCT04216901|||OTHER||PROSPECTIVE|||||||
33848687|NCT00978523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848688|NCT05471830|||COHORT||CROSS_SECTIONAL|||||||
33848689|NCT02316860|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34058038|NCT05152654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the practicing surgeon will know which group the patients will be in until the end of the study. will not share this information with researchers and patients.|Patients participating in the study will be divided into two groups. Patients with unilateral inguinal hernia will be determined according to the envelope selection method. Patients will not know which group are in. The patients in the first group will be fixed with 5 tackers while performing total extraperitoneal repair. While the patients in the second group are performing total extraperitoneal repair, no fixation will be made while placing the mesh.|f|t|f|f
33848690|NCT02832401|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33848691|NCT06446544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848692|NCT01472679|||COHORT||RETROSPECTIVE|||||||
33848693|NCT04521569|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All study team members and subjects will be blinded to treatment assignment with the exception of the statisticians and investigational pharmacist preparing the study treatment.|Randomization to the EVLP with placebo or EVLP with Regadenoson groups will be performed in a 1:2 ratio.|t|t|t|f
33848694|NCT03965689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058039|NCT01622270|||CASE_ONLY|||||||||
34058040|NCT02573831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161938|NCT00873600|||CASE_CONTROL||PROSPECTIVE|||||||
33744848|NCT00373789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33744849|NCT00299234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744850|NCT00235768|||DEFINED_POPULATION||OTHER|||||||
33744851|NCT01862744|||||PROSPECTIVE|||||||
33744852|NCT02493127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744853|NCT00655187|||CASE_CONTROL||PROSPECTIVE|||||||
33744854|NCT06497439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848695|NCT05090280|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33848696|NCT00287807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848697|NCT04271982|||COHORT||PROSPECTIVE|||||||
33848698|NCT01775124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848699|NCT04821687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848700|NCT05416541|||COHORT||PROSPECTIVE|||||||
33848701|NCT04410523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848702|NCT03459443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848703|NCT00871585|||CASE_ONLY||PROSPECTIVE|||||||
34161939|NCT05095259|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Experimental Observational Case-Control study. Two groups: One group of type 1 diabetes and one group of healthy controls.||||
34161940|NCT06083753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34161941|NCT05783414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researchers performing the assessments will be blinded to the intervention group allocation.||f|f|f|t
34161942|NCT03116685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161943|NCT05432492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848704|NCT01523132|||COHORT||PROSPECTIVE|||||||
33848705|NCT05364892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnosis and follow up of ANCA-associated vasculitis||||
33848706|NCT04308395|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive Patidegib Topical Gel, 2%,||||
33848707|NCT04006054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33848708|NCT03879369|||OTHER||OTHER|||||||
33848709|NCT03093077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33848710|NCT05404750|||OTHER||CROSS_SECTIONAL|||||||
33848711|NCT05412797|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33848712|NCT01863576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33848713|NCT01583231|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848714|NCT04441372|||COHORT||PROSPECTIVE|||||||
33848715|NCT06253182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single masking, participant|This is a two-arm randomized controlled trial|t|f|f|f
33848716|NCT02316002|NA|SINGLE_GROUP||TREATMENT||||||||
33848717|NCT00768794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848718|NCT01283204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848719|NCT02345187|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33848720|NCT05332431|||CASE_CONTROL||PROSPECTIVE|||||||
33848721|NCT05641181|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg|t|t|t|t
33848722|NCT05274152|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The study will take the form of feasibility and proof of concept trial using IVR as a physiotherapy rehabilitation tool following lower limb or knee surgery for children (aged 11 - 16). It will examine the feasibility, acceptability, usability, and efficacy of the IVR system from the perspectives of the children, parents and staff. The mixed-method approach (collecting quantitative and qualitative data)~Participants:~Child participants (n=15) will be patients of Sheffield Teaching Hospitals NHS Trust.~Inclusion criteria, aged 11-16.~This study also included parents who have child participating in the study and being able to speak and understand English.; and physiotherapists involved in the physical therapeutic. There are no exclusion criteria for parents or staff, so long as they meet the inclusion criteria."||||
33848723|NCT03789448|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848724|NCT06408480|||CASE_CONTROL||PROSPECTIVE|||||||
33848725|NCT02000193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848726|NCT01590082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848727|NCT00245921|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33848728|NCT01984073|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33848729|NCT05199415|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058041|NCT01322035|||COHORT||PROSPECTIVE|||||||
34058042|NCT06623552|||CASE_CONTROL||PROSPECTIVE|||||||
34058043|NCT06622551|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34058044|NCT01892709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744855|NCT03538535|NA|SINGLE_GROUP||TREATMENT||NONE||Adapted version of Behavioral Activation psychotherapy designed to optimize decision making and learning.||||
33744856|NCT02446132|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058045|NCT03191864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34058046|NCT06619678|NA|SEQUENTIAL||TREATMENT||NONE||||||
34058047|NCT06628778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Prospective Randomized Open, Blinded-Endpoint study design. There will be a blinded end-point adjudication committee.|PROBE study design, Randomized allocation 2:1 (Intervention:Standard of care) of dalteparin thromboprophylaxis versus standard-of-care (i.e., no pharmacological thromboprophylaxis). Analytic study populations will be modified intent-to-treat, per-protocol, and safety populations|f|f|f|t
34058048|NCT06234696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058049|NCT04285515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058050|NCT04324736|||COHORT||RETROSPECTIVE|||||||
34058051|NCT05328596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058052|NCT01647919|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34058053|NCT06493656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A final number of 50 patients were enrolled in the trial and randomly assigned to either the isolated corticosteroid injection group (Group CS) or the concomitant hydrodilatation group (Group CSHD). Double-blinded randomization was performed by an independent nurse using a computer-generated random sequence. A musculoskeletal radiologist, blinded to group allocation, performed the diagnostic ultrasound and MRI interpretations. A blinded orthopaedic nurse carried out the physical examination and clinical scoring.|"Study group underwent ultrasound-guided posterior approach of glenohumeral space injection for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline.~Control group underwent ultrasound-guided posterior approach of glenohumeral space HYDRODILATATION for adhesive capsulitis of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 15 mL normal saline."|t|f|f|t
34058054|NCT01671072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058055|NCT02742454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Board-certified radiologists interpreting head ultrasound findings are blinded to study arm. Consensus on maximum grade of IVH between two radiologists (some combination of site radiologist and one of three external readers blinded to each others' interpretation) is required.||f|f|f|t
34058056|NCT03664830|NA|SINGLE_GROUP||TREATMENT||NONE||Each SCD research participant will receive up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)||||
34058057|NCT06592755|||COHORT||RETROSPECTIVE|||||||
34058058|NCT06443801|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34058059|NCT03518970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the participants in this study won't know if they are in the intervention group or in the control group|This study proposes phase II in the development of randomized clinical trials for complex interventions, which refers to the development of an exploratory trial. This approach will be developed with participants randomly assigned to two groups (intervention and control) and pre-test and post-test measurements will be taken. The nursing intervention of this study is designed to be evaluated in terms of its viability, acceptability and preliminary effects in a health care institution with family caregivers of people with cancer in palliative care.|t|f|f|f
34058060|NCT00483106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34058061|NCT06483243|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058062|NCT06517901|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34058063|NCT04110561|NA|SINGLE_GROUP||OTHER||NONE||||||
34058064|NCT05985473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058065|NCT02180997|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058066|NCT05097547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161944|NCT06178107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This is a double blinded, randomised of parallel design pilot study will include 50 adults aged 18-65 with coeliac disease (CD). After an initial screening, potential subjects will be assessed for inclusion in the run-in trial.~Those subjects who meet the inclusion criteria will be then invited to the intervention study for a total duration of 9 weeks, followed by 3 weeks follow up."|t|f|t|t
34161945|NCT03080948|||CASE_CONTROL||PROSPECTIVE|||||||
34161946|NCT00731679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161947|NCT04277065|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34161948|NCT01400568|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34161949|NCT05844280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744857|NCT02443181|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744858|NCT03666039|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33744859|NCT04289857|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33848730|NCT01769651|||COHORT||CROSS_SECTIONAL|||||||
34058067|NCT06204406|||COHORT||PROSPECTIVE|||||||
34161950|NCT03944720|||COHORT||PROSPECTIVE|||||||
34161951|NCT03867448|||CASE_ONLY||PROSPECTIVE|||||||
34161952|NCT02474420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34161953|NCT03777761|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The study will be double-blind in regard to tucatinib and placebo study treatments and open-label for the positive control, moxifloxacin.||t|t|t|f
34161954|NCT00195039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161955|NCT02123849|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34161956|NCT00646360|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161957|NCT06110208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161958|NCT02942758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161959|NCT05971693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744860|NCT05653505|||COHORT||PROSPECTIVE|||||||
33744861|NCT05811338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33744862|NCT05641688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33744863|NCT00505739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744864|NCT01265329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33744865|NCT03701750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848731|NCT00993668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848732|NCT05762913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848733|NCT02663518|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open label|Phase 1a/1b trial of PF-07901800 (TTI-621) for relapsed or refractory hematologic malignancies and selected solid tumors were conducted in 4 parts. In the dose escalation phase (Part 1), advanced lymphomas were enrolled in sequential dose cohorts for safety, tolerability, PK, and MTD. In the expansion phase (Part 2), subjects with various hematologic malignancies and selected solid tumors were treated at recommended dose determined in phase 1a (Part 1) for safety and efficacy. In the expansion phase (Part 3), 2 cohorts (cutaneous T-cell lymphoma and peripheral T-cell lymphoma) were evaluated for potentially further studied using Simon 2-stage design. In the phase 1b dose optimization (Part 4), further dose escalation was investigated in patients with relapsed and/or refractory CTCL following a 3+3 escalation and revised DLT criteria.||||
33848734|NCT00248482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848735|NCT00544310|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33848736|NCT03601377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigators were blind with regards to which group participants were allocated.|Experiment 1: 2 groups (1 intervention and 1 placebo) receive treatment in parallel Experiment 2: 3 groups (2 types of intervention and 1 placebo) receive treatment in parallel|t|f|t|f
33848737|NCT00361010|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848738|NCT04561869|||OTHER||RETROSPECTIVE|||||||
33848739|NCT00697697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848740|NCT03896412|NA|SINGLE_GROUP||OTHER||NONE||||||
33848741|NCT03644953|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, open label study of combination hydroxyurea and simple chronic transfusion.||||
33848742|NCT01608763|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33848743|NCT00752557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848744|NCT06359834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33848745|NCT02656329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848746|NCT03929744|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||Part C is a crossover design.|t|f|t|f
33848747|NCT05843825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The selected patients were stratified according to age, gender, years of mandibular edentulism, number of old non-satisfactory dentures.~Patients were assigned to one of two groups using balanced randomization procedure to ensure comparability between groups."|Patients were randomly assigned into two equal groups . (BOS-G) Block out spacer group : patients who would be delivered mandibular implant overdenture retained by three locator attachments using block out spacer during pick up .(WBOS-G) Without block out spacer group : patients who would be delivered mandibular implant overdenture retained by three locator attachments without using block out spacer during pick up|t|f|f|t
33848748|NCT01193673|||CASE_ONLY||CROSS_SECTIONAL|||||||
33744866|NCT04642638|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33744867|NCT00986999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744868|NCT06280430|||CASE_CONTROL||RETROSPECTIVE|||||||
33744869|NCT01934218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744870|NCT05846724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744871|NCT02544906|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33848749|NCT01275950|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33848750|NCT03150173|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 1:1 to receive the O-BMT intervention or enhanced referral||||
33848751|NCT01184144|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33848752|NCT00437541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848753|NCT01497600|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33848754|NCT03018431|||COHORT||PROSPECTIVE|||||||
33848755|NCT01010334|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33848756|NCT03438500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848757|NCT00531700|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33744872|NCT00427050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744873|NCT03874364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33744874|NCT05637138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open label|only one group of healthy volunteers is planned in the study, for which measurements of skin permeability, subcutaneous microcirculation and TcpO2 / oxygen sensor will be performed.||||
33744875|NCT00513669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33744876|NCT06635447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744877|NCT04163302|NA|SINGLE_GROUP||TREATMENT||NONE||This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided in 3 groups by different infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.||||
33744878|NCT01525290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744879|NCT06636435|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33744880|NCT06282627|||COHORT||PROSPECTIVE|||||||
33744881|NCT05226208|||OTHER||PROSPECTIVE|||||||
33744882|NCT06361082|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33744883|NCT00725166|||CASE_CONTROL||PROSPECTIVE|||||||
33744884|NCT01294839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33744885|NCT00886158|||COHORT||PROSPECTIVE|||||||
33744886|NCT02256462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744887|NCT03261518|||CASE_ONLY||PROSPECTIVE|||||||
33744888|NCT04820764|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33848758|NCT02374684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953937|NCT06652087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The participants are divided into two parallel groups for the duration of the study. Forty patients with HFRS with a body mass index of more than 25 kg/m2 and a positive SIBO test will be randomly assigned in a 1:1 ratio to the experimental (rifaximin) and control groups. All patients will also receive standard HF treatment (diuretics, including an aldosterone antagonist; a sodium-glucose cotransporter-2 inhibitor).|t|f|f|f
33953938|NCT06167759|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33953939|NCT05704946|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33953940|NCT05921370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This prospective study will be conducted in patients prepared for RIRS presented to Ain Shams University Hospital.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."|t|f|f|f
33953941|NCT03635021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953942|NCT06455163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34161960|NCT03349125|||COHORT||CROSS_SECTIONAL|||||||
34161961|NCT03864302|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33744889|NCT01408160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744890|NCT05644548|||COHORT||PROSPECTIVE|||||||
33744891|NCT00524134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744892|NCT06634758|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Intervention Group Procedure 4 interviews were conducted with patients in this group and in each interview, patients were given MS Symptom Management and Relaxation Exercise training. Nursing care based on the Human Care Model was provided.~Control Group Procedure No intervention other than routine treatment and care was applied to the patients in the control group. Data Collection Form, MS Quality of Life Scale were applied to the patients. Face-to-face interviews were conducted with these patients two and a half months after the first interview and the MS Quality of Life Scale was applied again. After the study ended, between June and November 2023, Watson Human Care Model Based Nursing Care was applied to the patients in this group (1 patient could not attend the planned interviews due to a change of province and 1 patient could not take leave from work)."||||
33744893|NCT05300724|||CASE_ONLY||PROSPECTIVE|||||||
33744894|NCT01156753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848759|NCT01156792|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33848760|NCT04488718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848761|NCT01949038|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33848762|NCT06072040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848763|NCT05784831|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33848764|NCT00003601|RANDOMIZED|||PREVENTION||||||||
33848765|NCT00873431|RANDOMIZED|PARALLEL||||NONE||||||
33848766|NCT05435768|||COHORT||PROSPECTIVE|||||||
33848767|NCT06298929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848768|NCT02935725|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33848769|NCT03188913|||CASE_ONLY||PROSPECTIVE|||||||
33848770|NCT05831722|||CASE_ONLY||PROSPECTIVE|||||||
33848771|NCT02483000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953943|NCT06650670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33953944|NCT04007393|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"At baseline, each participant will be randomized 1:1 to either the 12-week (Arm 1) or 24-week (Arm 2) response assessment to LSMT. This randomization will be blinded to the participant, investigator, and outcomes assessor for the duration of the study; i.e. up until 48 weeks.~The second randomization includes only those participants who are non-responders to phentermine+LSMT. Each non-responder to phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Participants, investigators, and outcomes assessors will be blinded to phentermine/placebo. The topiramate will be open label."|2-staged sequential multiple assignment randomized trial|t|t|t|t
33953945|NCT03574818|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility and Biomaker Study||||
33953946|NCT06353217|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Pre/post pilot study||||
34161962|NCT03115905|||COHORT||PROSPECTIVE|||||||
34161963|NCT06725862|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34161964|NCT06725329|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will use a three-phase integrated sequential approach (Qual-Quant-Qual). The first stage is a qualitative phase to adapt and culturally-integrate the psychosocial intervention for KA. Focus group discussions (FGDs) with individuals with lived experience (n = 15) will be conducted in KA. Upon analysis of the FGDs with study participants, the findings will be used to adapt a previously developed psychosocial education intervention for KA (Aim 1). The second phase involves pilot testing the tailored intervention using a single-group, pre-posttest design (n = 30). The last stage will involve post intervention individual, semi-structured in-depth interviews that will focus on participants' reflections of the sessions in relevance to their culture and pain management (n = 10). The feasibility and acceptability of the tailored intervention will be assessed by integrating the qualitative and quantitative findings (Aim 2).||||
34161965|NCT00002357||||TREATMENT||DOUBLE||||||
34161966|NCT05553171|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34161967|NCT03167775|NA|SINGLE_GROUP||TREATMENT||NONE||the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment||||
34161968|NCT00931606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744895|NCT04780204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744896|NCT00137332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33744897|NCT03007823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744898|NCT03049046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744899|NCT01757769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744900|NCT00467870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744901|NCT04458948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744902|NCT03362554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33744903|NCT03375619|||COHORT||PROSPECTIVE|||||||
33744904|NCT02858739|||COHORT||PROSPECTIVE|||||||
33744905|NCT05955014|||COHORT||OTHER|||||||
33744906|NCT02896855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744907|NCT03848533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It will be done using a sealed envelope, which will contain a letter A, B or C, and will be given to choose an envelope to the participants. The letter obtained will indicate the group to which the subject will belong during the intervention. The intervention designated for each of the groups will be unknown by the researcher and participants.||t|f|t|f
33744908|NCT03334123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33744909|NCT03102398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744910|NCT05733988|||COHORT||CROSS_SECTIONAL|||||||
33744911|NCT02860728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744912|NCT00811863|||COHORT||PROSPECTIVE|||||||
33744913|NCT02715128|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33744914|NCT00006154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744915|NCT06534476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744916|NCT02287103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744917|NCT06670391|||CASE_CONTROL||RETROSPECTIVE|||||||
33744918|NCT04804358|NA|SINGLE_GROUP||OTHER||NONE||||||
33744919|NCT05282524|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744920|NCT05069441|||CASE_ONLY||PROSPECTIVE|||||||
33744921|NCT05194397|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"The participants and the investigator team will be blinded as to the group assignment: NR vs Placebo. All collected data (e.g., questionnaires) will be coded, so initial analysis will be conducted without knowledge of the participant's group status.~While the assignment of participants to the exercise groups will not be blinded to the participant or majority of the study team, a designated blinded technician will perform the follow-up Cardio Pulmonary Exercise Testing. Follow-Up Cardio Pulmonary Exercise Testing will be performed by a dedicated blinded study team member, an exercise technician, who will not know if the participant was assigned to an arm including the exercise intervention."|Randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise.|t|t|t|t
33744922|NCT06491004|||COHORT||PROSPECTIVE|||||||
33744923|NCT00936364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744924|NCT04573920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33744925|NCT05724797|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33744926|NCT03809182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded|Prospective, randomized, placebo-controlled trial|t|t|t|t
33744927|NCT00814372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744928|NCT00563784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848772|NCT01102010|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33848773|NCT03152903|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33848774|NCT03237546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848775|NCT03568487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848776|NCT05277220|||COHORT||PROSPECTIVE|||||||
33848777|NCT03299972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33848778|NCT01917721|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33848779|NCT01303029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848780|NCT02739867|||COHORT||PROSPECTIVE|||||||
33848781|NCT06125704|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33848782|NCT03751059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848783|NCT03142126|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will receive early ambulation.||||
33848784|NCT05842772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|An independant research assistant will type the answers into Excel. The study principal investigator will conduct the data analyses and will be blinded to the identity of the participants only knowing them by their unique number.|The DESIRE trial is designed as a pragmatic, pilot, randomized, controlled, non-blinded multicenter superiority trial with two parallel groups will test the acceptability and feasibility of the intervention on patients, relatives, and health professionals.|f|f|t|t
33953947|NCT01284413|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953948|NCT06565884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Three doctors set up a blind evaluation group to evaluate the photos of the subjects before and after receiving the device treatment|The method of randomized control and evaluator blindness is suitable for screening A total of 224 subjects were enrolled and randomly divided into control group and experiment according to 1:1 ratio Group)|f|f|f|t
33953949|NCT06522360|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33953950|NCT05049902|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a multi-center, open-label, non-inferiority, randomized controlled trial.||||
33953951|NCT02760849|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953952|NCT00514501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953953|NCT01696266|||COHORT||CROSS_SECTIONAL|||||||
33953954|NCT01687777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33953955|NCT06173674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953956|NCT05263804|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744929|NCT03729219|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Other parts will be blinded except unblinded person who prepares the doses.|A randomized, placebo-controlled phase IIb|t|t|t|f
33744930|NCT05794191|||COHORT||RETROSPECTIVE|||||||
33744931|NCT00818948|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33744932|NCT01773226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744933|NCT03085563|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33744934|NCT06496152|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33744935|NCT01800877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744936|NCT03401970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744937|NCT05197959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744938|NCT03183687|||COHORT||RETROSPECTIVE|||||||
33744939|NCT03449602|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33744940|NCT02964936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744941|NCT04651452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The participant and their care provider, who prescribes their aromatase inhibitor, will remain masked to which writing condition (self-affirmation or reflective journaling) the participant is randomized into. The outcomes assessor will remain masked to which condition the participants will complete. However, the experimenter will help set up the participant's online content and, therefore, will not be masked to the writing condition.||t|t|f|t
33744942|NCT06029907|NA|SINGLE_GROUP||OTHER||NONE||||||
33744943|NCT02484794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744944|NCT03391479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848785|NCT03724994|||COHORT||PROSPECTIVE|||||||
33848786|NCT06058312|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848787|NCT06611072|NON_RANDOMIZED|PARALLEL||OTHER||NONE||investigator-initiated, multi-center explorative cross-sectional study||||
33953957|NCT04527159|NA|SEQUENTIAL||TREATMENT||NONE||||||
33953958|NCT03609970|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34161969|NCT01103583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33953959|NCT00259311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33953960|NCT01868308|||COHORT||PROSPECTIVE|||||||
33953961|NCT01715675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953962|NCT02614352|RANDOMIZED|CROSSOVER||||NONE||||||
33953963|NCT00251680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33953964|NCT04045405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161970|NCT05477784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Only biostatistician will be unmasked.|2-group randomized control trial: experimental and alternative treatment control group|t|t|t|f
34161971|NCT06527781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|PD5K3 group and placebo control group are double-blinded, while the active comparator group is open-labeled.||t|t|t|f
34161972|NCT06308198|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34161973|NCT05761990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"POSTERIOR ISOMETRIC TECHNIQUES~* For 5 to 10 seconds, a submaximal (10-20%) hypertonic muscle contraction is carried out away from the barrier while resistance is supplied in the other side.~* The individual is told to relax while breathing after the isometric contraction. After then, until the next barrier is reached, a gentle stretch is employed to pick up the slack.~NOVEL STRETCHING TECHNIQUE The NS will be performed in a supine posture for Group B participants. Participants will be instructed to open their knees while wearing a resistance band around their knees. Participant will be instructed to bridge as high as he can while keeping his shoulders 90 ° abducted and his elbows 90 ° flexed. By lifting the body weight upward, the bridging motion pins the scapula's medial border against the thorax without immediately squeezing or constricting the posterior shoulder bones."|t|f|t|f
34161974|NCT01128244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161975|NCT05839808|NA|SINGLE_GROUP||OTHER||NONE||||||
34161976|NCT06041074|||COHORT||RETROSPECTIVE|||||||
34161977|NCT02124694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34161978|NCT04936815|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Three clusters representing the three administrative units of the Ob/Gyn department will be randomly allocated to an experimental or a control condition. During 18 months, each of the three clusters will undergo a randomly allocated experimental period of 6 months and two control periods of 6 months. Women seen at least once during the experimental period will be offered to undergo systematic echocardiographic screening for structural heart disease followed by guideline-directed peripartum management. Women only seen during the control periods will undergo routine antenatal care and receive echocardiography only if clinically indicated. After 15 months recruitment, the investigators will perform a conditional power analysis. If the conditional power is below 80% but above 50%, and an extension is considered feasible, the investigators will extend the recruitment duration to 36 months and allocate each administrative unit to another experimental recruitment period of 6 months duration.|f|f|f|t
33848788|NCT00030498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848789|NCT05281159|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Parallel Assignment~* Parallel-arm randomized controlled trial,~* Three arms~  * Arm 0: Standard of care control (standard text messaging)~ * Arm 1: Experimental, Risk Information group~ * Arm 2: Experimental, Risk Information + Action group~* Patient-level randomization stratified by arm assignment in CRC45+ Choice Evaluation. The investigators will also randomly assign patients into receiving the text message on one of ten workdays, stratifying by arm assignment in both the CRC45+ Choice Evaluation and CRC45+ Text Evaluation"||||
34161979|NCT06726395|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study personal assessing the side effects, are as fara as possible unaware of what study drug is given.|Observational||||
33848790|NCT00377442|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34161980|NCT05767112|RANDOMIZED|CROSSOVER||OTHER||NONE||Crossover Assignment The order of treatments was be randomized.||||
34161981|NCT00146536|||CASE_ONLY||PROSPECTIVE|||||||
34161982|NCT00596752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848791|NCT06406179|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a 18-months follow-up national, multicenter, prospective , randomized, biomarker strategy design trial, whereby kidney transplant patients will be randomized 1:1 at the time of transplantation in 2 study groups.~* Group I (routine group): during the first 18 months after transplantation, patients will follow a standard clinical follow-up based on kidney allograft function and a surveillance allograft biopsy performed at 3 and 12 months after transplantation and for clinical indication whenever considered necessary by the clinician (3 CI visits maximum expected per patient during the follow up .~* Group II (dd-cfDNA-guided): Patients will follow a dd-cfDNA-guided strategy based on dd-cfDNA levels in the blood associated with relevant clinical data on the basis of its detection and prediction capacities for rejection at M3, M12 and during visits for clinical indication (3 CI visits maximum) to decide whether a biopsy is performed within the first 18 months of follow-up."||||
34161983|NCT05500963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848792|NCT06609369|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who smoke randomly assigned and stratified by sex and severity of tobacco dependence||||
34161984|NCT01973998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848793|NCT02315846|||CASE_CONTROL||PROSPECTIVE|||||||
33848794|NCT06610955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessments will be performed by a doctor who will be blinded to exercise group allocation|Two groups without control group|f|f|t|t
33848795|NCT01129544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848796|NCT02231801|||COHORT||PROSPECTIVE|||||||
33953965|NCT04301401|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34161985|NCT00183625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34161986|NCT06019338|||COHORT||PROSPECTIVE|||||||
34161987|NCT01874080|RANDOMIZED|CROSSOVER||||NONE||||||
34161988|NCT06725589|||CASE_CONTROL||RETROSPECTIVE|||||||
34161989|NCT06171633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953966|NCT06286397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blinded, Placebo-Controlled Trial|t|t|t|t
33953967|NCT04047316|||OTHER||PROSPECTIVE|||||||
33953968|NCT01554917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33953969|NCT03681925|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patient participants will be unaware of which arm their dietitian has been randomized to.|6 dietitians will be randomized in a 2:1 intervention:control fashion. Each dietitian will recruit 19 patient participants, for 114 total patient participants.|t|f|f|f
33953970|NCT01623245|||COHORT||PROSPECTIVE|||||||
34161990|NCT05878847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Triple blinded|The study is split into three experimental sessions where you will be randomised to one of two supplements, Q-actin (2 x 10 mg gummies daily) or placebo (2 x 10 mg gummies daily) supplementation for 12 weeks|t|t|t|t
34161991|NCT06725940|||COHORT||PROSPECTIVE|||||||
34161992|NCT00001379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34161993|NCT02916901|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34161994|NCT01969955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34161995|NCT01336140|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34161996|NCT05490030|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will be divided into 2 parts. Participants in the hepatic impairment groups will be staged by their respective degree of hepatic impairment according to the Child Pugh classification score determined at the screening visit and confirmed unchanged at the baseline visit.~Healthy participants who were identified and enrolled as matching partners for a hepatic impairment group in Part I can serve as matching partners for participants in hepatic impairment group in Part II if they fulfilled the matching criteria. Otherwise, additional matched healthy participants will be enrolled.~Part I: will include participants with mild and moderate levels of hepatic impairment as well as healthy control participants assigned to the groups Part II: will include participants with severe hepatic impairment."||||
34161997|NCT00003967||||TREATMENT||||||||
34161998|NCT01617863|||CASE_CONTROL||PROSPECTIVE|||||||
34161999|NCT04200690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33744945|NCT02165150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744946|NCT02361853|||COHORT||PROSPECTIVE|||||||
33744947|NCT04198662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The randomization lists will be created by the UC San Diego Investigational Drug Service which will create the sealed, opaque randomization envelopes with treatment group assignments. The treating investigators doing the procedures will be the only other individuals aware of the treatment group assignments. The Investigational Drug Service will not provide the treatment group assignments to the investigators until the completion of data collection for all subjects; and will only provide Treatment A vs Treatment B assignments for the initial statistical analysis. Only at the completion of statistical analysis will each treatment be revealed to the investigators."|Multicenter, randomized, double-masked, sham-controlled, parallel design, clinical trial|t|t|f|t
33744948|NCT00246636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744949|NCT05619614|||COHORT||PROSPECTIVE|||||||
33744950|NCT01306162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744951|NCT01116817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744952|NCT03130582|||COHORT||PROSPECTIVE|||||||
33744953|NCT04271930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33744954|NCT05679492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744955|NCT06180564|RANDOMIZED|PARALLEL||PREVENTION||NONE||. In the test group after devascularisation of the bowel segment surgeon marked the resection line using their conventional method, then IRT was used to determine the resection line using infra- red camera in rainbow display mode. Resection line was determined by abrupt colour change (corresponds to decrease in temperature \>3 degree Celsius) over the visualised bowel wall. Margins were revised if difference between surgeon and IRT determined resection lines were more than 1cm apart.||||
33744956|NCT04326491|||CASE_CONTROL||PROSPECTIVE|||||||
33744957|NCT06322914|||CASE_CONTROL||RETROSPECTIVE|||||||
33744958|NCT02198573|||||PROSPECTIVE|||||||
33953971|NCT06145451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researchers have no direct contact with research participants as all data collection activities are carried out by care providers.||f|f|t|f
33953972|NCT03861689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953973|NCT03628846|||COHORT||PROSPECTIVE|||||||
33953974|NCT03638648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953975|NCT06172569|||COHORT||PROSPECTIVE|||||||
34162000|NCT02334293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162001|NCT06451991|RANDOMIZED|PARALLEL||OTHER||NONE|Within the scope of the research, students will be divided into control (n=33) and experimental (n=33) groups by simple randomisation method. Since the students and instructors should know and follow the material to be used in the data collection process, blinding was not performed.|||||
34162002|NCT00811681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162003|NCT01151566|||COHORT||PROSPECTIVE|||||||
34162004|NCT00193206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162005|NCT00837213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34162006|NCT00123123|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34162007|NCT02037516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34162008|NCT06277661|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162009|NCT03397342|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162010|NCT04294030|||COHORT||PROSPECTIVE|||||||
33953976|NCT04437927|||CASE_CONTROL||PROSPECTIVE|||||||
33953977|NCT00919932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953978|NCT05735717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953979|NCT01111032|||COHORT||PROSPECTIVE|||||||
33953980|NCT03974607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33953981|NCT02259166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33953982|NCT00301925|RANDOMIZED|FACTORIAL||TREATMENT||||||||
33953983|NCT01371981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953984|NCT06067191|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33953985|NCT04997369|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33953986|NCT05813730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33953987|NCT05377541|||COHORT||PROSPECTIVE|||||||
33953988|NCT02628821|||CASE_ONLY||PROSPECTIVE|||||||
33744959|NCT01443962|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33744960|NCT05273710|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33744961|NCT01944046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|Randomized, Double-blind, placebo-controlled clinical trial for 24 weeks. Followed by 24 week open label treatment period in which ALL participants receive Oxytocin|t|t|t|t
33744962|NCT01870271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744963|NCT02068989|||COHORT||PROSPECTIVE|||||||
33744964|NCT06365580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744965|NCT04731649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33744966|NCT00324623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744967|NCT03813329|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Opaque gelatin capsules||t|f|f|t
33744968|NCT02169674|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, single-center, parallel group study of residual HBV seroprotection rates and the capacity of seronegative individuals to respond to a challenge dose of HBV vaccine.||||
33744969|NCT00977262|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33744970|NCT06670690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33744971|NCT02907333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744972|NCT02359526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744973|NCT02520635|||COHORT||PROSPECTIVE|||||||
33744974|NCT02976766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744975|NCT04741568|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33744976|NCT00748436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33744977|NCT02648698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33744978|NCT05540236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33744979|NCT03850392|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|the cytokine level assessment was blinded regarding the treatment arm|first phase : randomization ice versus cold CO2 second phase : ice-treated knees versus contralateral non-treated knees|f|f|f|t
33744980|NCT03421925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33744981|NCT03296995|NA|SINGLE_GROUP||SCREENING||NONE||||||
33744982|NCT02576574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744983|NCT06010589|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33744984|NCT06499870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33744985|NCT01197079|||||PROSPECTIVE|||||||
33744986|NCT05909865|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be a non-controlled multicenter clinical trial with the main aim of developing a multivariable prediction model of the improvements after a physical therapy treatment based on exercise and education.||||
33744987|NCT04592367|||COHORT||PROSPECTIVE|||||||
33744988|NCT03694548|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Part A: Survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of yoga program in adolescent patients with SCD and chronic pain and their parents~Part B: Feasibility and safety of yoga program in adolescent patients with SCD and chronic pain from Part A"||||
33744989|NCT02796339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33744990|NCT03407638|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|"Statistical analysts (biostatisticians) who analyze trial results will be masked for objectives 1 and 2.~Main analyses of the primary outcome will be conducted by the National Drug Abuse Treatment Clinical Trials Network (NDAT CTN) Data and Statistics Center (DSC). The de-identified dataset provided to the DSC by the data management team at Kaiser Permanente Washington Health Research Institute will have the identity of the intervention and Usual Primary Care clinic at each site masked."|Pragmatic Trial: Six health systems are participating in a pragmatic, cluster-randomized, quality improvement trial (hybrid Type III implementation trial). Each of the 6 health systems provided 2 PC clinics willing to be in the randomized controlled trial. Each health system will implement collaborative care for OUD treatment in one randomly selected PC clinic. All data used to evaluate primary and secondary outcomes are secondary data from the EHR or insurance claims.||||
33744991|NCT01154166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33744992|NCT01545102|||COHORT||PROSPECTIVE|||||||
33848797|NCT06114316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Eighty individuals who alcohol use disorder were assessed for eligibility and 70 individuals (who completed their detoxification process, were able to understand the scales and forms and maintain individual interviews, were between 30 and 60 years of age, were diagnosed with alcohol addiction according to the DSM-5 diagnostic criteria, and voluntarily agreed to participate in the studywere) randomized. An experimental and a control group were formed by assigning persons to each group by using the stratified randomization technique in which a sex factor was involved, according to a random-number table. Four male participants in the experimental group (who were not involved in intervention) and two male participants in the control group (who were discharged) were excluded as they did not continue the study.|t|f|f|f
33848798|NCT02755051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848799|NCT06233344|RANDOMIZED|PARALLEL||OTHER||NONE||This is a randomized, open-label, parallel arm trial.||||
33848800|NCT02552368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848801|NCT02715349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848802|NCT03950050|NA|SINGLE_GROUP||TREATMENT||NONE||"The aim of this single arm, phase II study is to evaluate the efficacy and safety of adding ambroxol to patients with type 1 GD and suboptimal response to ERT.~HYPOTHESIS The addition of ambroxol will improve the disease related symptoms and disease impact of patients with GD with suboptimal response to ERT."||||
33848803|NCT03063333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled study with three arms: coping-oriented hypnosis, neutral hypnosis, no hypnosis|t|f|f|t
33953989|NCT00026312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33953990|NCT04221100|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33953991|NCT03345485|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In phase 1 (dose escalation phase) of the study, subjects were allocated sequentially.~In phase 2, subjects were allocated in parallel to the various arms (cohorts) based on their cancer specifics.~In the substudies 1 and 2, subjects were allocated into a single group in each substudy.~Overall, the study model is described as Sequential as the study proceeded in phases."||||
33953992|NCT04707833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33953993|NCT02459470|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33953994|NCT03363724|||COHORT||RETROSPECTIVE|||||||
33953995|NCT03375346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible patients were randomly assigned to one of the two groups in a 1:1 ratio using an odd or even random numbers table. Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm. The control group performed the same session without vibration.|f|f|t|f
33953996|NCT06651645|||COHORT||RETROSPECTIVE|||||||
33848804|NCT06245148|||COHORT||OTHER|||||||
33953997|NCT02018601|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33953998|NCT06413446|||CASE_ONLY||PROSPECTIVE|||||||
33953999|NCT00209235|NA|SINGLE_GROUP||OTHER||NONE||Natural history||||
33954000|NCT02618421|||COHORT||CROSS_SECTIONAL|||||||
33954001|NCT04038307|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33954002|NCT04827446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Blocked randomization will be used to limit bias and achieve an equal distribution of participants to the intervention and control arms of the study (69 control, 69 intervention; with 23 from each cancer population in each arm). This approach will recruit participants in small blocks to ensure that half of the participants within each block will be allocated to the treatment and the other half to the control.|t|f|f|f
34162011|NCT06645470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"2-part design:~(1) Randomized Pre-Post Parallel Design - 30 adults (18-\<59 years) will be recruited that are newly prescribed an anti-obesity medication and randomize 10 to each of the intervention conditions.~Randomized to:~1. Standard Medical Care only,~2. Standard Medical Care + aerobic training,~3. Standard Medical Care + resistance training~(2) Parallel longitudinal observational design - 10 older adults (\>= 60 years) will be recruited that are newly prescribed an anti-obesity medication for observation.~An additional subset of older adults taking an Anti-Obesity Medication (no exercise training)."|f|f|f|t
34162012|NCT05148806|||COHORT||PROSPECTIVE|||||||
34162013|NCT05575089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33848805|NCT06312527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33848806|NCT01624103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33848807|NCT03877419|||CASE_ONLY||CROSS_SECTIONAL|||||||
33848808|NCT04034446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848809|NCT05042908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848810|NCT04212273|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848811|NCT05111054|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848812|NCT00615745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848813|NCT01920854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848814|NCT05381415|||COHORT||PROSPECTIVE|||||||
33848815|NCT00119210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848816|NCT05586802|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two designs according to the presence of fertility desire (Design 1) or high metabolic risk (Design 2)||||
33848817|NCT03716700|||COHORT||PROSPECTIVE|||||||
33848818|NCT03914612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|On February 6, 2023, all patient treatment assignments were unblinded. Patients randomized to Arm I will not receive additional placebo infusions.||t|t|t|t
33848819|NCT06607939|NA|SINGLE_GROUP||TREATMENT||NONE||"Experimental: Dose Escalation ORB-021 ORB-021 Dose Escalation Participants will be administered study drug at dose levels corresponding to their Cohort. Cohort 1 will be treated with the lowest dose, and the dose will be escalated for future cohorts 5 dose cohorts have been pre-specified. Doses from the escalation arms will be selected as RP2D candidates.~Drug: ORB-021 is dosed via IV infusion"||||
33848820|NCT00361400|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33848821|NCT01578200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848822|NCT01948700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33848823|NCT01558401|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33848824|NCT02982395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954003|NCT03622775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954004|NCT00462241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954005|NCT02159651|||CASE_ONLY||PROSPECTIVE|||||||
34058068|NCT04481035|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will be randomly assigned to treatment I or II (double blind: NAC study drug or placebo) for 8 weeks then cross over to the other treatment option. Drug/placebo is formulated by the investigational pharmacy at Cincinnati Children's hospital. Encapsulated drug/placebo appear identical. If drug/placebo is administered as a powder, a flavor masking agent is applied to both to enforce the participant treatment blinding. Unmasking of the treatment blind will only occur after data is collected and analyzed.|This is a double-blind placebo controlled, prospective, Phase IIa study to explore safety, tolerability, and efficacy of NAC on learning and motor behavior in children with NF1 aged 8 through 16 years old.|t|t|t|t
34058069|NCT04409535|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34058070|NCT01067625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058071|NCT02079142|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058072|NCT02387528|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34058073|NCT06356974|NA|SINGLE_GROUP||TREATMENT||NONE||one-arm, open label, non-randomized, multicentre, phase IIIb study||||
34058074|NCT01341210|||CASE_ONLY||CROSS_SECTIONAL|||||||
34162014|NCT02545387|||COHORT||RETROSPECTIVE|||||||
34162015|NCT05820282|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33848825|NCT05467189|||COHORT||PROSPECTIVE|||||||
33848826|NCT05179382|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33848827|NCT00833833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848828|NCT06024759|||CASE_ONLY||OTHER|||||||
33848829|NCT02156739|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848830|NCT01604629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848831|NCT04397991|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33848832|NCT04559230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848833|NCT06610292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33848834|NCT02751411|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized between two treatment arms||||
33848835|NCT06352476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant will not know whether he or she is in the experimental or control group.|The research is an experimental study with a pre-test and post-test control group trial model.|t|f|f|f
34162016|NCT03430934|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Evaluation of a in-house developed Near Infrared Navigation System camera for Moh's tumor||||
33848836|NCT01745731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848837|NCT03795259|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33848838|NCT02516332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848839|NCT04506164|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||his stepped-wedge trial relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation and facilitation. The eight participating sites will be stratified by size (a combination of number of TCM staff and average number of post-9/11 Veterans enrolled per month) and block randomized to four step/crossover cohorts of two sites each. All sites receive the same intervention at different times.||||
33848840|NCT02807662|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33848841|NCT00614601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848842|NCT00848731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33848843|NCT00627263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33848844|NCT02235831|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33848845|NCT06609941|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive (interventional group) alternative nostril breathing along with pharmacological management and the other group (control group) will receive only pharmacological management.||||
33848846|NCT04485858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848847|NCT05032989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848848|NCT00226343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33954006|NCT06651814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954007|NCT05934305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954008|NCT00448929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954009|NCT06586658|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33954010|NCT04298008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162017|NCT02186665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162018|NCT05668598|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Interventional, prospective, Study case-control||||
34162019|NCT04903535|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy Volunteers||||
34162020|NCT05842252|NA|SINGLE_GROUP||TREATMENT||NONE||greater trochanter transfer and subtrochanteric valgus osteotomy||||
34162021|NCT00756418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162022|NCT01389492|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34162023|NCT04309474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162024|NCT03348839|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|no one|Multicentre study, in randomized mastered clusters, in stepped wedge||||
34162025|NCT03790059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162026|NCT03319823|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study Design and Procedures~Participants who meet the inclusion criteria will be contacted by the study team. The purpose of the study will be explained, and they will be asked to sign an informed consent form. Based on their nocturnal systolic blood pressure, the investigators will assign participants to one of two treatment groups:~* Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of \< 160 mm Hg.~* Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg."||||
34162027|NCT04044339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162028|NCT00749723|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162029|NCT02548338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162030|NCT03755882|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34162031|NCT03949608|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||We will randomize patients by block of 2 weeks of inclusion in intervention or controlled group. Each 2 weeks, all participants will be included in the intervention group, and the next 2 weeks the participants will be included in the control group||||
34162032|NCT00271102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162033|NCT04441489|||CASE_ONLY||PROSPECTIVE|||||||
34162034|NCT04804163|NA|SINGLE_GROUP||OTHER||NONE||||||
34162035|NCT02154841|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34162036|NCT00211328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162037|NCT00308854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162038|NCT03912779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34162039|NCT02360891|||COHORT||PROSPECTIVE|||||||
34162040|NCT03813264|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.~The study will take place in the clinic complex located at the Shalvata Mental Health Center campus (Shalva clinic, departmental follow-up clinics, day department), and will include 10 therapists (psychiatrists, psychologists, social workers) and 10 patients."||||
34162041|NCT01874886|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162042|NCT03850028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162043|NCT05350449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162044|NCT04522596|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Phase IV clinical trial, single-center, double-blind, randomized, two-period crossover, placebo-controlled.|t|t|t|t
34162045|NCT00321464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34162046|NCT04703426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162047|NCT04151433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162048|NCT04841616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162049|NCT06149871|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34162050|NCT01393249|||COHORT||PROSPECTIVE|||||||
34162051|NCT04311125|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162052|NCT01694056|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34162053|NCT02478099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162054|NCT03787550|||COHORT||PROSPECTIVE|||||||
34162055|NCT06284655|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded statistician|Parallel two-arms randomized control trial|f|f|f|t
34162056|NCT00640107|||CASE_ONLY||PROSPECTIVE|||||||
33848849|NCT03271567|||CASE_ONLY||PROSPECTIVE|||||||
33848850|NCT05268445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization between chemical angioplasty and chemical plus mechanical angioplasty using an adjustable remodeling mesh or a balloon||||
33848851|NCT06418945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848852|NCT06245993|||CASE_ONLY||PROSPECTIVE|||||||
33848853|NCT03191682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848854|NCT05566067|||COHORT||PROSPECTIVE|||||||
33848855|NCT04579289|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33848856|NCT02037464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33848857|NCT04535024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848858|NCT04279392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The research pharmacist will deliver the drug pr placebo to the treatment nurse in an unlabeled 100 ml saline bag for infusion.|In this randomized controlled trial each subject will be randomized (1:1, block randomization with a block size of 10) to one treatment group (Active or Inactive treatment) and will be considered part of the intent-to-treat (ITT) cohort. The research pharmacist will be responsible for completing the randomization process, and will hold the group assignment data. All other study personnel will be blinded to group assignment.|t|t|t|t
33848859|NCT02428062|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33848860|NCT04338659|NA|SEQUENTIAL||TREATMENT||NONE||||||
33848861|NCT01620021|||CASE_CONTROL||PROSPECTIVE|||||||
33848862|NCT01005459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848863|NCT00615121|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848864|NCT04775199|RANDOMIZED|PARALLEL||TREATMENT||NONE|Although it is impossible to mask the assessors of the proximal outcome measures, those assessing the distal outcomes can be masked. Specifically, the people scoring the science exposition (a distal measure of generalized scientific content) will be masked to the treatment arm assignments.|||||
33848865|NCT06540534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33848866|NCT05785169|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The intervention will be implemented across three steps with a total of 6 clinics (2 clinics per step). This stepped-wedge design will use stratified randomization to assign the timing of the intervention to one of 3 study sequences. Clinics would have been selected based on serving a majority of Black patients. Other characteristics (e.g., poverty level) will be assessed at selection to ensure equivalence across the groups of clusters; selection of clinics will restrict on these variables. The criterion used to randomize clinics (by strata) to one of the 3 study sequences will be urbanicity (rural/suburban vs urban), which accounts for clinic size (# patients/year). Within each of the 2 strata, 3 clinics will be randomized to one of the 3 groups of clusters. Stratified Randomization will be conducted in Statistical Analysis System (SAS).||||
33848867|NCT05449236|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33848868|NCT04667182|||COHORT||PROSPECTIVE|||||||
33848869|NCT04026659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848870|NCT03724773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33848871|NCT03797677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848872|NCT04675190|||CASE_CONTROL||PROSPECTIVE|||||||
33848873|NCT00632892|||CASE_ONLY||PROSPECTIVE|||||||
33848874|NCT01312636|||COHORT|||||||||
33848875|NCT00229437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848876|NCT00600678|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33848877|NCT01147601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848878|NCT00672191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848879|NCT03451682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33848880|NCT03178643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848881|NCT05869890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848882|NCT00476710|||CASE_CONTROL||RETROSPECTIVE|||||||
33848883|NCT04959643|||COHORT||PROSPECTIVE|||||||
33848884|NCT04713800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848885|NCT06610721|||OTHER||PROSPECTIVE|||||||
33848886|NCT03796962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848887|NCT05740423|||COHORT||PROSPECTIVE|||||||
33848888|NCT03358251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848889|NCT00920569|||||PROSPECTIVE|||||||
33848890|NCT03751046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954011|NCT04800159|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Participants will randomly receive one of the study products at each visit. All participants will receive all three of the study products. Allocation assignment of visits will be assigned using a randomization string provided by the statistician. The allocation schedule will be kept in the pharmacy and concealed from all other study personnel.|The interventional component of the project (Phase 2) will have a randomized cross-over design that randomly assigns the order of the administration of the three study products (placebo, cannabis with higher concentration of tetrahydrocannabinol (THC) and lower concentration of cannabidiol (CBD), or cannabis with higher CBD concentration and lower THC concentration). The cannabis administration phase of this study will compare the study products to: 1) ART concentrations in blood and CSF and 2) measures of uridine 5'-diphospho-glucuronosyltransferase (UGT) activity.|t|t|t|t
33954012|NCT04431960|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The extract and placebo will have the identical shape and color and will be packaged into coded containers.|"The study participants will be randomly assigned to three groups and asked to consume 1 tablet containing 392 mg blackcurrant (BC) extract per capsule (low-BC Group), 2 capsules containing 392 mg BC extract per tablet (total 784 mg/day; high-BC Group), or 1 placebo capsule (Control Group) daily with breakfast meals for 6 months.~To avoid bone deterioration related to calcium and vitamin D deficiency, all participants will take a calcium citrate caplet daily that includes 400 mg calcium and 500 IU vitamin D (Bayer AG, Germany) beginning 2 weeks before the study and lasting for the duration of the study."|t|t|t|t
33848891|NCT01843894|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33848892|NCT04639388|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Monocentric study with two parallel groups||||
33744993|NCT00455195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33744994|NCT01359800|||||CROSS_SECTIONAL|||||||
33848893|NCT02557529|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33744995|NCT03467659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33744996|NCT06669897|||OTHER||PROSPECTIVE|||||||
33744997|NCT02854098|||OTHER||CROSS_SECTIONAL|||||||
33744998|NCT04946201|||CASE_CONTROL||PROSPECTIVE|||||||
33744999|NCT00547560|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33745000|NCT05942508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745001|NCT06635733|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is a cluster randomized controlled trial (RCT) where healthcare providers are assigned to either the intervention group, which uses the Rhapsode Capable™ platform for in-person skills practice (ISP) scheduling, feedback, and assessment, or the control group, which follows paper-based ISP. Both groups receive the same Pediatric Acute Care Education (PACE) adaptive learning content, but the method of ISP differs between groups.||||
33745002|NCT00529828|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33745003|NCT01823718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745004|NCT03227770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745005|NCT02540200|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745006|NCT01174342|||COHORT||PROSPECTIVE|||||||
33745007|NCT00201383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745008|NCT00561223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745009|NCT03920917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745010|NCT03346629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745011|NCT06120543|||COHORT||OTHER|||||||
33745012|NCT05504460|RANDOMIZED|PARALLEL||TREATMENT||NONE||The test group will use the investigational device Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd.) + basic treatment (supportive treatment determined by the investigator based on the condition of the patients), and the control group will use basic treatment only||||
33745013|NCT06634927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745014|NCT03272438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are not aware of whether they are in an experimental or control condition.|Participants will be randomly assigned to one of three between-subjects conditions: consistent schedule, inconsistent schedule, no schedule. The study is a longitudinal study over 9 weeks, including a baseline week, a 4-week intervention and a follow-up assessment 4 weeks after the intervention.|t|f|f|f
33745015|NCT04867577|||COHORT||PROSPECTIVE|||||||
33745016|NCT01404312|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745017|NCT01412944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745018|NCT04799015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745019|NCT02167828|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33745020|NCT04744480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745021|NCT01998373|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745022|NCT02635815|||COHORT||PROSPECTIVE|||||||
33745023|NCT00417937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745024|NCT02699177|||COHORT||PROSPECTIVE|||||||
33745025|NCT03793881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745026|NCT01273727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745027|NCT06635798|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745028|NCT04586855|||OTHER||OTHER|||||||
33745029|NCT02345057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745030|NCT03956017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745031|NCT00216684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33848894|NCT02067559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745032|NCT02545673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33745033|NCT05245864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33745034|NCT01257295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33745035|NCT01580917|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745036|NCT01293708|||COHORT||PROSPECTIVE|||||||
33745037|NCT05843942|||OTHER||CROSS_SECTIONAL|||||||
33745038|NCT04122079|||OTHER||CROSS_SECTIONAL|||||||
33745039|NCT04544462|||COHORT||PROSPECTIVE|||||||
33848895|NCT00433940|||COHORT||PROSPECTIVE|||||||
33848896|NCT06609993|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33848897|NCT00998335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848898|NCT03912376|||COHORT||PROSPECTIVE|||||||
33848899|NCT01833845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848900|NCT02113345|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33848901|NCT04768374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745040|NCT03719456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745041|NCT01365494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848902|NCT03107832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848903|NCT03546764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient does not know the details of the treatment assignment|Two arms - Percutaneous catheter arm vs Chest tube arm|t|f|f|f
33848904|NCT02625051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848905|NCT00767416|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33848906|NCT06261580|||OTHER||PROSPECTIVE|||||||
33848907|NCT00744757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848908|NCT05568732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33848909|NCT04452565|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33848910|NCT06610006|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group(interventional group) will be doing High Intensity Training (HIIT) and Isometric Wall Squat and the other group (control group) will be doing High intensity Interval Training (HIIT).||||
33848911|NCT00749034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33848912|NCT00166712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848913|NCT02078843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848914|NCT04981171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848915|NCT05456802|||COHORT||PROSPECTIVE|||||||
33954013|NCT00967707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848916|NCT03123601|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All patients, with chronic neurologic diseases selected from a nursing home, will be invited to participate. At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.||||
33848917|NCT04531501|||COHORT||CROSS_SECTIONAL|||||||
33848918|NCT06127550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All participants will be told they are receiving active stimulation at a custom current level that may or may not be detectable to them. Half of the participants (randomly assigned) will not receive stimulation.|Participants will be randomly assigned to either active stimulation or sham stimulation groups.|t|f|f|f
33848919|NCT06020053|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33848920|NCT04602221|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||3-treatment period design|t|t|t|f
33848921|NCT06281899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848922|NCT03919604|||COHORT||RETROSPECTIVE|||||||
33848923|NCT04470453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848924|NCT04656704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848925|NCT01368289|||COHORT||PROSPECTIVE|||||||
33954014|NCT06509542|NA|SINGLE_GROUP||OTHER||NONE||While patients are in rehabilitation, upper limb movements will be recorded using wrist-worn accelerometers and video cameras, during dressing, meal preparation, and meal-taking activities.||||
33848926|NCT00585403|||COHORT||CROSS_SECTIONAL|||||||
33848927|NCT01345695|||CASE_CONTROL||PROSPECTIVE|||||||
33848928|NCT04084184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848929|NCT02093000|||CASE_ONLY||PROSPECTIVE|||||||
33848930|NCT03663491|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33848931|NCT06306547|||COHORT||OTHER|||||||
33848932|NCT05956639|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33848933|NCT06609954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinding|This is a randomized controlled trial having two groups. One group(interventional group) will be given Reduced Exertion High Intensity Training (REHIT) and the other group (control group) will be given High intensity Interval Training (HIIT).|t|f|f|f
33848934|NCT05558631|||COHORT||PROSPECTIVE|||||||
33848935|NCT05811390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954015|NCT06279468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954016|NCT01959984|RANDOMIZED|CROSSOVER||||NONE||||||
33954017|NCT01028274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954018|NCT01920698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954019|NCT06225401|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Teacher of nursing students and outcomes assessor||f|t|f|t
33954020|NCT02195921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954021|NCT06119737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33954022|NCT04715321|||COHORT||PROSPECTIVE|||||||
33954023|NCT02987114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954024|NCT00926809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954025|NCT04757402|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33954026|NCT03562923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058075|NCT05716854|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The study will be double-blind, and the blind will be maintained through a randomization schedule held by the dispensing pharmacist. Treatments will be over-encapsulated. The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.|This clinical study consists of 2 parts: a 3-arm, 22-subject crossover study (Part 1) and a 4-arm, 22-subject crossover study (Part 2). These parts are included in the same protocol and study due to the similarity of the inclusion and exclusion criteria, similar procedures, and similar primary goals.|t|t|t|t
34058076|NCT04128722|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Primary outcome is assessed on anonymised photographs by an adjudication committee blinded from treatment allocation|Individually randomized stepped wedge|f|f|f|t
34058077|NCT05866367|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34058078|NCT05296902|||COHORT||PROSPECTIVE|||||||
34058079|NCT00526019|||CASE_CONTROL||PROSPECTIVE|||||||
34058080|NCT05735314|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped wedge cluster-randomized trial. There will be 4 clusters, with 3-4 clinics per cluster. In a stepped wedge fashion, the 4 clusters will receive the control followed by the study intervention--that is, in the first step the first cluster will receive the intervention after 6 months of control, in the second step the second cluster will receive intervention after 12 months of control, in the third step the third cluster will receive the intervention after 18 months of control, and in the fourth step the fourth cluster will receive the intervention after 24 months of control.||||
34058081|NCT04181515|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|placebo for stressor, and sham figure of 8 coil for rTMS|mixed design, with 4 (2x2) within-subject conditions (placebo vs. stressor X sham vs. rTMS), each occurring in two parallel groups (10 Hz dorsolateral prefrontal cortex vs. sham rTMS in group 1, and 1 Hz medial prefrontal cortex vs. sham rTMS in group 2)|t|f|t|t
34058082|NCT03873415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058083|NCT06457360|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34058084|NCT02613429|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34058085|NCT04395391|||COHORT||PROSPECTIVE|||||||
34058086|NCT06649084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058087|NCT03310658|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34058088|NCT03772977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058089|NCT05328375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33848936|NCT05762289|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients were randomized using sealed envelope method where all the participants selected their envelopes which were opaque and placed in a container . All the patients who were willing after informing all the risk and procedures were then selected in two groups Group A (treatment group) or weight bearing group and Group B (Control group)non weight bearing group.|||||
33848937|NCT01843127|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33848938|NCT00928018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162057|NCT06726278|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|"Although this study is an observational study, masking was used to minimize bias in the assessment of outcomes. The participants were blinded to the group allocation (misoprostol or placebo). Additionally, the care providers performing the hysteroscopic procedures were also blinded to the group assignments to avoid any bias in procedural conduct or outcome reporting.~The investigators and outcomes assessors involved in the data analysis were also unaware of the group allocation, ensuring impartial evaluation of the results. This blinding process was maintained throughout the study to minimize bias and enhance the reliability of the observed outcomes.~Since this study does not involve random assignment or an investigational treatment, it is important to note that masking was implemented as part of the observational design to preserve the validity of the findings, despite the lack of intervention assignment typically seen in clinical trials."||t|t|t|t
33848939|NCT02708329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848940|NCT03935321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848941|NCT03503461|||CASE_CONTROL||PROSPECTIVE|||||||
33848942|NCT02096315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848943|NCT04580446|NA|SINGLE_GROUP||TREATMENT||NONE||Rolling 6 dose finding cohort followed by dose expansion cohort||||
33848944|NCT05101967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848945|NCT03469531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848946|NCT03611413|||COHORT||PROSPECTIVE|||||||
33848947|NCT05429905|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1 run-in will be conducted to determine the recommended phase II dose(s) (RP2D) for adult and paediatric patients in independent dose escalation cohorts.~Phase II will enrol patients in 2 concurrent cohorts at the R2PD."||||
33848948|NCT06445673|||COHORT||PROSPECTIVE|||||||
33848949|NCT02618642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A total of the 120 participants who agreed to fulfil the inclusion criteria throughout the study were randomly chosen by drawing marked squares from an opaque envelope. They were helped by an assistant researcher. The sixty individuals were selected in this way Next, those who were enrolled were further randomized into four groups, each including 15 individuals:||f|f|f|t
33848950|NCT06268548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848951|NCT02704793|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33848952|NCT02960750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848953|NCT00700427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848954|NCT02333305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo|coenzyme Q10|t|t|t|t
33848955|NCT02575001|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33848956|NCT04830423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33848957|NCT00002323||||TREATMENT||DOUBLE||||||
33848958|NCT04719975|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, blinded, counter-balanced, cross-over design|t|f|f|t
33848959|NCT06115629|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34162058|NCT00930930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162059|NCT03744949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|remifentanil will be given by a dosage of 0.5-1.0-1.5-2.0 µg/kg of adjusted body weight bolus according to randomization, by an infusion pump over 30 seconds|Four groups of patients. Randomization into the dose of remifentanil given according to a randomization list for a total number of patients of 80.|t|t|t|t
34162060|NCT06166966|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
34162061|NCT00994006|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34162062|NCT00640848|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34162063|NCT05117190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162064|NCT01758913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162065|NCT01582711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162066|NCT06119113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162067|NCT03472326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162068|NCT06010342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162069|NCT05160896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162070|NCT03910972|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34162071|NCT02825524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162072|NCT05695885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The main outcome measure is completed by a trained evaluator unaware of assigned treatment condition (i.e., the Independent Evaluator; IE).|Parallel RCT|f|f|f|t
34162073|NCT04930900|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162074|NCT06245733|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34162075|NCT06401863|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|No masking due to the nature of the intervention|Rolling implementation at the clinic level with control clinics not exposed to the tool.||||
34162076|NCT05363189|||CASE_CONTROL||PROSPECTIVE|||||||
33848960|NCT04114864|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The study is a prospective C-RCT, with a two (group) by three (time) repeated measures factorial design. Both the intervention and the wait-list control group will be assessed at baseline, immediately post-intervention for the intervention group or after 7 weeks for the wait-list control group - and at the 3MFU.|t|f|t|t
33848961|NCT01375088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848962|NCT00005130|||COHORT||PROSPECTIVE|||||||
33848963|NCT00952120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33848964|NCT06032832|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Test meals will be randomized and served to participants. Participants will not know or taste the differences of dephytinization in soy protein concentrate or in chickpea.|Randomized control trial, cross-over|t|f|f|f
33848965|NCT03026699|||CASE_CONTROL||RETROSPECTIVE|||||||
33848966|NCT06135428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33848967|NCT03212300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33848968|NCT02139761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954027|NCT05743244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization method will be stratified by TrialNet study site. The participants will not be informed regarding the intervention assignment until the end of the study. The investigator and clinic personnel will also be masked as to study assignment. Laboratories performing assays for this protocol will be masked as to the identity of biological material to be studied.|Participants aged 12-35 years will be randomized 1:1:1 to receive abrocitinib, ritlecitinib, and placebo. The planned design is to enroll 26 participants in each of the 3 arms: the abrocitinib arm, the ritlecitinib arm, and the shared placebo arm. Within the shared placebo arm, participants will be randomized 1:1 to receive placebo matched to abrocitinib or placebo matched to ritlecitinib. Randomization will be stratified by the following two age categories: 12-17 years old, and 18 years or above. Within each stratum, participants will be randomized to either the abrocitinib arm, ritlecitinib arm, or the shared placebo arm using random block sizes. The total number of enrolled participants from the older age stratum (18 years or above) will be limited to 33 to replicate the age distribution in previous new-onset trials. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo then enter a follow-up period of up to 12 months.|t|t|t|f
33848969|NCT01812434|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33848970|NCT05076084|||COHORT||RETROSPECTIVE|||||||
33848971|NCT03301896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848972|NCT04585854|NA|SINGLE_GROUP||OTHER||NONE|Blinded image analysis|Controlled before-after comparison||||
33848973|NCT05152420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Placebo controlled, single ascending dose.|t|t|t|t
33848974|NCT01052129|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33848975|NCT01249716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33954028|NCT04240665|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will complete a curriculum involving 2-hour weekly sessions for 6-weeks.||||
33954029|NCT06124001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954030|NCT06249438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954031|NCT01439776|RANDOMIZED|PARALLEL||TREATMENT||NONE|Vitamin D add|Control: Peg-ING + ribavirin Treatment: peg-INF+ ribavirin + Vitamin D||||
33954032|NCT00032825||||TREATMENT||||||||
33954033|NCT05019872|RANDOMIZED|CROSSOVER||OTHER||SINGLE||All participants receive twelve pasta samples differing in the hardness of carrots and penne, and the addition of sauce|t|f|f|f
33954034|NCT06650943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The psychometric scale evaluators will be blinded.||f|f|f|t
33954035|NCT05303844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954036|NCT04279002|||COHORT||PROSPECTIVE|||||||
33954037|NCT05631756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954038|NCT03099161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954039|NCT00609115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Single crossover for only the control group participants from the controlled part of the study.|t|f|f|t
33954040|NCT00608075|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954041|NCT01569594|||CASE_ONLY||PROSPECTIVE|||||||
33954042|NCT05844995|NA|SINGLE_GROUP||OTHER||NONE||||||
33954043|NCT05469776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954044|NCT06650631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954045|NCT04782258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954046|NCT03611595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954047|NCT02896621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954048|NCT04679649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Batch randomisation - computer generated|"Pragmatic randomised controlled clinical trial (RCT) with secondary element of observational cohort trial in line with the Trials within Cohort design (TwiCs). Trial A is Manual mobilisation of the spine."|t|f|f|t
33954049|NCT06653517|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33954050|NCT04513873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954051|NCT01016184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954052|NCT01873131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33954053|NCT03537625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954054|NCT06653881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954055|NCT06650605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954056|NCT00985127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954057|NCT00127296|RANDOMIZED|CROSSOVER||||NONE||||||
34058090|NCT05913635|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The researchers who conducted the biomarker measurements were not aware of the assignments of the trial.|A randomized, crossover study design uses two intervention days (a no-breakfast day and a no-dinner day) and a 6-day washout period.|f|f|f|t
34058091|NCT00894790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058092|NCT01793688|||CASE_CONTROL||PROSPECTIVE|||||||
34058093|NCT06244498|||CASE_CONTROL||RETROSPECTIVE|||||||
34058094|NCT05292417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058095|NCT06559189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058096|NCT01306045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058097|NCT01615211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058098|NCT00278005|||||RETROSPECTIVE|||||||
33848976|NCT06434909|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33848977|NCT03412747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33848978|NCT06096454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33848979|NCT06077253|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||One eye intervention (prophylactic iridotomy), one eye no intervention||||
33848980|NCT00294177|||DEFINED_POPULATION||OTHER|||||||
33848981|NCT04875559|||COHORT||PROSPECTIVE|||||||
33848982|NCT00254618|RANDOMIZED|PARALLEL||||NONE||||||
33848983|NCT04223817|NA|SINGLE_GROUP||SCREENING||NONE||SSc patients compared to control subjects without SSc matched on sex and age||||
33848984|NCT00564460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33848985|NCT01800552|||CASE_ONLY||CROSS_SECTIONAL|||||||
33848986|NCT02734576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848987|NCT03924440|||COHORT||PROSPECTIVE|||||||
33848988|NCT02908919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33848989|NCT02659800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participant is blinded and partially randomized in the Pilot study.|Dose Escalation - 3 levels - Group A Dexamethasone less/equal 0.75mg/day; Group B Dexamethasone greater/equal 4mg/day. At MTD Group A - w/outDexamethasone randomized Arm 1 placebo and Arm 2 MTD; Group B MTD w/ Dexamethasone single arm|t|t|f|f
33848990|NCT06373315|||OTHER||CROSS_SECTIONAL|||||||
33848991|NCT00464867|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33848992|NCT05125484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33848993|NCT00710177|||CASE_CONTROL||PROSPECTIVE|||||||
34058099|NCT01570634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848994|NCT02593721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33848995|NCT02039232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848996|NCT00979134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33848997|NCT05693701|RANDOMIZED|PARALLEL||PREVENTION||NONE||Treatment assignment will be via block randomization stratified on age category in a 1:1 allocation ratio.||||
33848998|NCT03520543|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33848999|NCT01762098|||CASE_ONLY||PROSPECTIVE|||||||
33954058|NCT03408327|RANDOMIZED|PARALLEL||OTHER||SINGLE||We will conduct a single-blinded, randomized controlled study. Ninety participants will be randomly assigned to experimental group or control group. The intervention for both groups will last for 12 weeks, with a 12-week of follow-up.|t|f|f|f
33954059|NCT05879315|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33954060|NCT05707156|||COHORT||PROSPECTIVE|||||||
34058100|NCT00094536|NA|SINGLE_GROUP||OTHER||NONE||||||
34162077|NCT03040674|||COHORT||PROSPECTIVE|||||||
34162078|NCT00043511||||PREVENTION||DOUBLE||||||
34162079|NCT03974724|||COHORT||PROSPECTIVE|||||||
34162080|NCT00828230|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162081|NCT04379206|||COHORT||CROSS_SECTIONAL|||||||
34162082|NCT04430504|NA|SINGLE_GROUP||TREATMENT||NONE||Case series of eligible patients||||
34162083|NCT03796117|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34162084|NCT03915314|||CASE_CONTROL||PROSPECTIVE|||||||
34162085|NCT02037334|||COHORT||PROSPECTIVE|||||||
34162086|NCT02823093|||CASE_CONTROL||PROSPECTIVE|||||||
34162087|NCT00351065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33849000|NCT06327178|||COHORT||RETROSPECTIVE|||||||
33849001|NCT02864667|||CASE_ONLY||RETROSPECTIVE|||||||
33849002|NCT00735475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33849003|NCT03711175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subject will not know which group they were randomized to until the completion of the study.|Two treatment arms. One group will have the subscapularis repaired during surgery, and one group will not have the subscapularis repaired during surgery. All subjects will receive the same device.|t|f|f|f
33849004|NCT04075994|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849005|NCT04725240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849006|NCT06209333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849007|NCT02083107|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33849008|NCT05339217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849009|NCT02560311|||COHORT||RETROSPECTIVE|||||||
33849010|NCT00611429|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33849011|NCT00905515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849012|NCT02615080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954061|NCT03506724|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who present to the hospitals in this study will be randomized to receive IV labetalol or oral nifedipine when presenting with persistent severe range blood pressures (2 readings or more within 15 minutes) of either 160mmHg systolic or 110mmHg diastolic. These anti-hypertensives are first line therapy for management of severe range blood pressures by the American Congress of Obstetricians and Gynecologists.||||
33954062|NCT01079169|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33954063|NCT00530621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954064|NCT04324957|||OTHER||OTHER|||||||
33954065|NCT05390086|||CASE_ONLY||OTHER|||||||
33954066|NCT06565702|||CASE_CROSSOVER||PROSPECTIVE|||||||
33954067|NCT01249625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33954068|NCT05773053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954069|NCT05966155|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate vs. delayed pharmacogenetic testing and genotype-guided pain or depression therapy||||
33954070|NCT03654495|RANDOMIZED|PARALLEL||TREATMENT||NONE|The aim is to focus on recruitment, attrition and adherence to the rehabilitation intervention. This trial is composed of a comparative cross-sectional part and a randomized conventional rehabilitation-controlled trial part with 1:1 allocation ratio.|This trial is a two-arm, parallel-group, randomized-controlled pilot trial with a cross-sectional comparison at baseline.||||
34058101|NCT05878821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double masking|Two groups,one group will be treated by shockwave therapy and postural correction exercise and other group will be treated by postural correction exercise|t|f|t|t
34058102|NCT04264117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058103|NCT05323994|||OTHER||PROSPECTIVE|||||||
34058104|NCT05787886|||OTHER||OTHER|||||||
34058105|NCT02763397|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34058106|NCT03407703|||COHORT||PROSPECTIVE|||||||
34058107|NCT03953482|||COHORT||PROSPECTIVE|||||||
34058108|NCT03370575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058109|NCT06572423|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34058110|NCT01471717|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34162088|NCT06099561|||CASE_ONLY||OTHER|||||||
34162089|NCT01159015|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34162090|NCT00003346||||TREATMENT||||||||
34162091|NCT01278992|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162092|NCT01942174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162093|NCT05581459|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34162094|NCT03051763|||COHORT||PROSPECTIVE|||||||
34162095|NCT05427240|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34162096|NCT04730791|||COHORT||CROSS_SECTIONAL|||||||
34162097|NCT06540794|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34162098|NCT06182969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162099|NCT00668837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162100|NCT02628561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162101|NCT04575571|||COHORT||PROSPECTIVE|||||||
34162102|NCT00950313|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33849013|NCT03257943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849014|NCT06445829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33849015|NCT02810574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33849016|NCT02730949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162103|NCT05022966|||COHORT||PROSPECTIVE|||||||
34162104|NCT01259180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34162105|NCT05044871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849017|NCT02518789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849018|NCT03631810|||COHORT||PROSPECTIVE|||||||
33849019|NCT06349811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849020|NCT00767975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849021|NCT03273296|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849022|NCT00923260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849023|NCT00057031|NON_RANDOMIZED|||TREATMENT||NONE||||||
33849024|NCT02627170|||CASE_ONLY||PROSPECTIVE|||||||
33849025|NCT03982589|||COHORT||PROSPECTIVE|||||||
34162106|NCT05357755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162107|NCT02343406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162108|NCT05478083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patient blinding is not possible, since leuprorelin will induce menopause related complaints.~Primary outcome is not reported to investigators until the study has finished. Outcome assessors are blinded for study subject and treatment allocation."|Randomized, controlled trial in which patients are randomized between either 1. Direct start with treatment or 2. Delayed start with treatment which will start after 18 months of standard care with the study medication|f|f|f|t
34162109|NCT04823442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34162110|NCT04207749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162111|NCT03433417|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34162112|NCT06042634|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessor was blinded to group allocation of participants|Parallel arm of 1:1 ratio|f|f|f|t
34162113|NCT03431350|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34162114|NCT00974623|||COHORT||PROSPECTIVE|||||||
33745042|NCT03131648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of the IMPs will contain no evidence of their identity.~Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded HCP at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments."||t|f|t|f
34162115|NCT03956966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double blind|t|f|t|t
34162116|NCT02870153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162117|NCT04891133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Corresponding placebo tablets||t|t|t|t
34162118|NCT03636126|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||The total study time will be 4 weeks. Participants will be asked to use the VR and tACS for two of these four weeks. Participants will be randomly assigned to one of two groups: A) a group that uses the tACS+VR for weeks 1 \& 2 or B) a group that uses the tACS+VR for weeks 3 \& 4.||||
34162119|NCT01483183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162120|NCT05809193|NA|SINGLE_GROUP||TREATMENT||NONE||"It is aimed to examine the effects of family-focused therapy, which will be applied in the early period to individuals who have been diagnosed with bipolar disorder and psychotic disorder and who have achieved remission, and their families. It will be carried out using the guide Family-Focused Therapy for High-Risk Adolescents and Young Adults for Bipolar Disorder or Psychosis revised by Miklowitz et al. in 2018. In terms of practical application, the sessions will be psychoeducational sessions that will be held in groups of 3 sessions, 3 sessions with the youth and the family. communication skills sessions to be held individually and 3 sessions as problem solving skills sessions to be held individually with the youth and family will be completed in 9 sessions. Sessions will be held once a week and all sessions will be completed in 9 weeks."||||
34162121|NCT01797055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162122|NCT03020927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162123|NCT03422952|||COHORT||PROSPECTIVE|||||||
34162124|NCT02683434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34162125|NCT03828331|||COHORT||CROSS_SECTIONAL|||||||
34162126|NCT06169982|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34162127|NCT05349786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162128|NCT03154996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162129|NCT03055520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162130|NCT03261219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745043|NCT00856583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745044|NCT01362621|||COHORT||PROSPECTIVE|||||||
33745045|NCT00389662|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33745046|NCT04634604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745047|NCT06626828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849026|NCT00249054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849027|NCT00723541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849028|NCT01844687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34162131|NCT00924768|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34162132|NCT03692702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162133|NCT02816801|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34162134|NCT01032720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162135|NCT05831488|||COHORT||PROSPECTIVE|||||||
34162136|NCT03113994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162137|NCT02233972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34162138|NCT01415141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162139|NCT00120965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162140|NCT03315039|NA|SEQUENTIAL||TREATMENT||NONE||||||
34162141|NCT05282771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33745048|NCT06636240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849029|NCT01911598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745049|NCT06111950|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33849030|NCT05481658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849031|NCT01827475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162142|NCT04206371|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34162143|NCT01255618|||CASE_ONLY||PROSPECTIVE|||||||
34162144|NCT05449691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind masking||t|f|f|f
33954071|NCT01237704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954072|NCT01554059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954073|NCT01073176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954074|NCT05280613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will know whether they have been randomized to receive the Family Check-Up or treatment as usual. Clinicians cannot be blinded because they will be providing the intervention. However, investigators and outcome assessors will be blinded to treatment status.|An intention-to-treat, parallel-arm randomized controlled trial of N=80 autistic children/youth (ages 6-17 years) with ASD and high levels of EBP and their caregivers.|f|f|t|t
33954075|NCT00962546|||COHORT||PROSPECTIVE|||||||
33954076|NCT04463992|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33954077|NCT06037148|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Double (Participant, Investigator)|3 sequential dose cohorts with ascending DM-101PX doses. In each cohort two treatment arms: placebo and active drug|t|f|t|f
33954078|NCT00608127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954079|NCT03777800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058111|NCT00985517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In the first part of the study (Phase 1), 2 escalating dose cohorts received CERE-120.~In the second part of the study (Phase 2), subjects were randomized 1:1 to receive CERE-120 or Sham Surgery."|t|t|t|t
34058112|NCT01286168|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34058113|NCT06621524|||COHORT||PROSPECTIVE|||||||
34058114|NCT00880581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058115|NCT06312111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058116|NCT00739505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058117|NCT05039567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058118|NCT06051474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058119|NCT02289846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058120|NCT03295552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058121|NCT06336837|||COHORT||RETROSPECTIVE|||||||
34058122|NCT01685957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058123|NCT03911986|RANDOMIZED|CROSSOVER||SCREENING||NONE|There is no masking.|A randomized controlled cross-over multi-centered clinical trial in General Practice, comparing; a) opportunistic pulse screening + immediate ELR device (R-Test) for 1 week; or, b) opportunistic pulse screening + delayed ELR device (R-Test) for 1 week, in patients with CHA2DS2-VASc score of 3 or greater, and without a contraindication to oral anticoagulation.||||
34076530|NCT03654729|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"This is a Phase 3, multicenter, double-blind, placebo-controlled study to establish the efficacious dose of PledOx in prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by oxaliplatin.~Patients with metastatic colorectal cancer (mCRC), who are indicated for first-line modified FOLFOX6 (mFOLFOX6) chemotherapy for at least 3 months, without any pre-planned treatment breaks, will be randomized in a 1:1:1 ratio, stratified by region (Asia, non-Asia) and PK sub-study (yes, no) to one of three treatment arms:~* Arm A: PledOx (2 µmol/kg) + mFOLFOX6 chemotherapy~* Arm B: PledOx (5 µmol/kg) + m~* Arm C: Placebo + mFOLFOX6 chemotherapy"|t|t|t|f
34076531|NCT00800111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162145|NCT05604027|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162146|NCT03532126|||COHORT||PROSPECTIVE|||||||
34162147|NCT02406911|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34162148|NCT04054141|NA|SINGLE_GROUP||TREATMENT||NONE||Open label rTMS treatment||||
34162149|NCT01511068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162150|NCT05109624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162151|NCT03643627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162152|NCT04398628|||COHORT||PROSPECTIVE|||||||
34162153|NCT03005132|||CASE_CONTROL||RETROSPECTIVE|||||||
34162154|NCT04612257|NA|SINGLE_GROUP||TREATMENT||NONE||The pilot study aims to enroll 20 children participants with type 1 diabetes mellitus using insulin pump therapy. Each participant will undergo a 40-hour intervention period, with the possibility of being invited to a second 40-hour intervention period using the same system.||||
34162155|NCT02923856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162156|NCT01937260|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34162157|NCT01224717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162158|NCT03827603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162159|NCT05503342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In both arms, patients will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record weekly three measurements of peak expiratory flow and fill out a questionnaire to assess the control on paper (control group) or fill out a risk score for exacerbation contemplated in the mobile application, which the pharmacist will have access through a web platform (intervention group). Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable.||||
34162160|NCT01980381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745050|NCT04848038|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Raters (psychometrician, exercise physiologist) who perform outcome assessments will be blinded to the participant's intervention group. The study medical monitor and investigators will be unblinded to assist with safety assessments and address safety concerns or adverse events.|"Participants will be randomized to 1 of 4 study arms. Intervention arm include:~1. core and fusion control condition;~2. 150 minutes of endurance training (ET) only;~3. 2 days a week of progressive weight training (WT) only;~4. 150 minutes of ET and 2 days a week of WT.~Participants exercise according to allocation for 1 year."|f|f|f|t
33745051|NCT06573398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745052|NCT05307549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745053|NCT06086223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random assignment of intervention will be done after subjects have been assessed for eligibility and recruited. The sealed opaque envelope method will be used for randomization.|"Based on determining outcome variable, the estimated minimum required sample size is 176 cases (88 cases in each group).~The sample size was calculated using G\*power software 3.1.9.7., based on the following assumptions: the patient satisfaction rate was higher in those patients who underwent arthroscopy compared with ORIF alone (93% vs 75%, P ¼ .05) (5).~Main statistical test is z test, Alpha = 0.05, Power = 0.95 Allocation ratio= 1."|f|f|f|t
33745054|NCT06291805|||COHORT||CROSS_SECTIONAL|||||||
33745055|NCT06442371|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33954080|NCT03889509|||OTHER||RETROSPECTIVE|||||||
33954081|NCT04973917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162161|NCT05447481|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects were blinded to the study treatment that they received|This was a randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of chicory inulin-type fructans in adults with functional constipation.|t|f|f|t
34162162|NCT00767806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162163|NCT02318966|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34162164|NCT04156035|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34162165|NCT04647968|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking because it is a surgical procedure|Randomized Controlled Trial||||
34162166|NCT04160858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Keeping outcome assessors and data analysts blinded to the allocation (i.e. participants and groups identifiable by number only). This ensures unbiased ascertainment and analysis of outcomes. When participants arrive at the lab for testing, they will be instructed not to reveal their allocated condition.|"The trial design is a two-arm, single-blinded ( i.e. assessors and analysts blinded to allocation), RCT with a 6-month intervention period and 6-month follow-up (Exercise condition only). After baseline assessments, participants will be randomly allocated to 6 mos of exercise (Exercise) or a wait-list (Control) using a 1:1 ratio. The trial is designed to be comparable to usual care and maximize PRECIS scores, while providing insight on mechanisms that may explain intervention effects."|f|f|t|t
34162167|NCT01382238|RANDOMIZED|CROSSOVER||||NONE||||||
34162168|NCT06304363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162169|NCT05662982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two independent groups will be assessed longitudinally over 40 weeks: one group will be assessed using only the standard of care ischial containment socket and the other group will receive the subischial socket.||||
34162170|NCT02270554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162171|NCT04477577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34162172|NCT03723772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162173|NCT01150708|||COHORT||PROSPECTIVE|||||||
34162174|NCT00797277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162175|NCT01885676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162176|NCT05527444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162177|NCT05785793|||COHORT||OTHER|||||||
34162178|NCT06726824|||COHORT||PROSPECTIVE|||||||
34162179|NCT06024603|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34162180|NCT01860313|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162181|NCT01071421|||CASE_CONTROL||PROSPECTIVE|||||||
34162182|NCT02598440|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162183|NCT04538417|NA|SINGLE_GROUP||TREATMENT||NONE||Participants who meet inclusion and exclusion criteria will be enrolled into the study after consenting to participate and before receiving residual limb neuroma C-RFA. This procedure is considered standard of care and are typically based on physician preference. Data will be collected by questionnaire at baseline and select follow up timelines.||||
34162184|NCT05904067|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162185|NCT02110667|||COHORT||PROSPECTIVE|||||||
34162186|NCT04055909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162187|NCT05336747|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33745056|NCT00497653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33745057|NCT00344682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745058|NCT01230476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745059|NCT04111081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745060|NCT06636617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33745061|NCT01201434|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33745062|NCT02830594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745063|NCT00120393|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745064|NCT01610323|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33745065|NCT06175494|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745066|NCT03905226|||COHORT||RETROSPECTIVE|||||||
33745067|NCT02393079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849032|NCT01246557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849033|NCT04085185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849034|NCT01004848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33849035|NCT05660343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In order to apply the principle of double-blind, we ensure that neither the laser therapist nor the patient knew whether the treatment was active or not, classical music was played in the background to mask the laser sound and the laser's programs were arranged by an assistant so that the treatment did not begin until a permission was taken from the assistant; in addition, labels on Oil bottles were removed by an assistant to ensure that no one knew the type of the Oil or its ingredients. For safety reasons, both the patient and the laser therapist wore protective goggles during the laser treatment. All patients were treated with ozonated olive oil and LLL by the same therapist.||t|t|t|t
33849036|NCT00496886|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849037|NCT03599531|||COHORT||PROSPECTIVE|||||||
33849038|NCT03403582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849039|NCT02197403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33849040|NCT06226103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162188|NCT02636530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33745068|NCT03931577|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Cluster randomised factorial controlled trial.||||
33745069|NCT06060171|||COHORT||PROSPECTIVE|||||||
33849041|NCT06485453|||CASE_CONTROL||RETROSPECTIVE|||||||
33849042|NCT04490967|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will use salicylic acid 30% peeling on the right side of the face and topical Silymarin 1.4% cream on the left side.||||
33954082|NCT00305331|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33954083|NCT04427618|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33954084|NCT00685763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954085|NCT06651489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954086|NCT01392469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954087|NCT04909177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954088|NCT06653374|||OTHER||CROSS_SECTIONAL|||||||
33954089|NCT05229783|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|The two endoscopists will be blinded to each other's findings when searching the lesions.|"Each patient will be his (her) own control and have the two procedures :~* Firsty : high-resolution endoscopy combined with virtual chromoendocopy (performed by endoscopist A)~* Secondly: white light endoscopy with Seattle protocol (performed by endoscopist B)"|f|t|f|f
33954090|NCT04151316|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33954091|NCT01589016|||CASE_CONTROL||PROSPECTIVE|||||||
33954092|NCT04286438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954093|NCT03039686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954094|NCT03907709|||CASE_CONTROL||RETROSPECTIVE|||||||
33954095|NCT06650956|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study population includes girls aged 10-13 years for HPV vaccination and boys and girls aged 10-13 years for other adolescent health services. The intervention district will receive an integrated service package comprising HPV vaccination and adolescent health services delivered through school-based, facility-based, and outreach approaches. The comparison district will continue with its standard HPV vaccination and routine adolescent health service delivery. The intervention will be for 7 months from 2024 November to 2025 May.|f|f|f|t
33954096|NCT05992207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954097|NCT01053169|||COHORT||CROSS_SECTIONAL|||||||
33954098|NCT03184402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954099|NCT03940742|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33954100|NCT05595863|||COHORT||PROSPECTIVE|||||||
33954101|NCT06516653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954102|NCT03541356|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind|"Thirty-Two (32) to Thirty-Six (36) subjects will be randomized to treatment or placebo. INP103 is a drug-device combination product containing a drug component, L-dopa, and device component, the I231 Precision Olfactory Delivery (POD) device. In Cohorts 1, 2, and 3, L-dopa will be administered intranasally in single doses of one (35 mg), two (70 mg) or four (140 mg) puffs of INP103, 60 minutes after oral benserazide hydrochloride 25 mg.~In Cohort 4 the INP103 formulation will contain L-dopa:carbidopa administered nasally. Dosing will take place once OFF episode is confirmed and will not include predosing with oral benserazide."|t|t|t|t
33954103|NCT00352664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954104|NCT00560573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954105|NCT05393635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954106|NCT00003652|RANDOMIZED|||TREATMENT||||||||
33954107|NCT01975129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954108|NCT03710759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954109|NCT01710007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954110|NCT04391686|||COHORT||OTHER|||||||
33954111|NCT06031922|||COHORT||PROSPECTIVE|||||||
33745070|NCT04898608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The lab tech will be blind to whether the sample under evaluation belongs to the intervention group or the control group. A research project collaborator who is not informed about grouping of participants will obtain outcome measurements of the functional test. Outcome adjudicators, and data analysts will be kept blinded to the allocation. Moreover, all investigators, staff, and participants will be kept masked to outcome measurements and trial results.|Participants will be randomly allocate to intervention group or control group and will be examined in the same way.|f|f|f|t
33745071|NCT04450615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33745072|NCT05959850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised controlled trial. Participants will be randomised at a 2:1 ratio to the drug solution or placebo respectively.|t|t|t|t
33745073|NCT03016871|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745074|NCT06316843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745075|NCT01194141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745076|NCT06387563|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33745077|NCT04873375|NA|SINGLE_GROUP||TREATMENT||NONE||All patients included in this interventional single arm study will be treated with cemiplimab||||
33745078|NCT01159496|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33745079|NCT00645398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745080|NCT00941187|||COHORT||PROSPECTIVE|||||||
33745081|NCT02978365|NA|SINGLE_GROUP||SCREENING||NONE||||||
33745082|NCT04862143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745083|NCT01244152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33745084|NCT00451854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745085|NCT01640691|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33745086|NCT06635668|||COHORT||PROSPECTIVE|||||||
33745087|NCT04247854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745088|NCT03089424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The mode of intervention (active or placebo photobiomodulation) will be coded by an independent researcher. The randomization schedule will contain only codes (not the actual intervention). The output from the laser device is exactly the same from either the active or the placebo interventions. These features will guarantee that participants, therapists and outcomes assessor will be blinded to the treatment arms.||t|t|t|t
33745089|NCT02878993|||COHORT||PROSPECTIVE|||||||
33745090|NCT01511952|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33745091|NCT05827367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33745092|NCT06043921|||COHORT||PROSPECTIVE|||||||
33745093|NCT02255175|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33745094|NCT01518205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745095|NCT02601313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745096|NCT05695859|||COHORT||PROSPECTIVE|||||||
33745097|NCT06205511|||COHORT||CROSS_SECTIONAL|||||||
33745098|NCT03571061|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33745099|NCT04093622|||CASE_ONLY||PROSPECTIVE|||||||
33745100|NCT03701724|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Sham rTMS will be used for the arm without rTMS"||t|f|t|t
33745101|NCT01788683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745102|NCT05512494|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33745103|NCT03057548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745104|NCT01276587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849043|NCT04385589|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The study will include 100 diabetic patients type 2 patients who will be admitted to care unit with decompensated heart failure.50 patient will receive Dapagliflozin plus insulin (if needed) and Diuretics plus conventional heart failure measures ,the other group will receive insulin for control of blood sugar plus diuretics and anti-failure measures.|t|f|t|f
33849044|NCT04435210|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants in the study will be randomized into two study groups in ratio 1:1. One of the study groups will receive 20mg of oral nifedipine while the other arm will receive 10mg of intravenous hydralazine. Each dose is to be repeated after 30 minutes if the blood pressure is equal to or greater than 160/110 mmHg.||||
33849045|NCT04558879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849046|NCT04369859|||COHORT||PROSPECTIVE|||||||
33849047|NCT03500601|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||2 x 4 week intervention with 4 week washout|t|f|t|t
34058124|NCT04964297|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Prospective pilot, single-center, single-arm, open-label, phase 1 investigator-initiated study to determine device ability to detect bowel gas during laparoscopic right colectomy with intracorporeal anastomosis using Perf-AlertTM gas detection system on 20 subjects into 2 Cohorts.~Cohort 1: 10 subjects with measurement of bowel gas at 8 predetermined time points during right laparoscopic colectomy as follow:~1. Initiation of surgery/laparoscopy start Insufflation~2. Abdominal exploration~3. Completion of colon mobilization~4. Colon transection~5. At Colotomy~6. At Enterotomy~7. Anastomosis completion~8. End of surgery- after re-insufflation before closure~Cohort 2: 10 subjects with continuous monitoring of bowel gases through the surgery. The level of H2 and CH4 gases will be noted at the 8 predetermined time points during the continuous monitoring as well."||||
34058125|NCT00475345|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34058126|NCT00291772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058127|NCT03186534|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34058128|NCT02813005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058129|NCT00570349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058130|NCT05928559|||COHORT||PROSPECTIVE|||||||
34058131|NCT06559852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058132|NCT02210286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058133|NCT03852927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058134|NCT00735137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058135|NCT00002063||||TREATMENT||||||||
34058136|NCT05102825|||COHORT||PROSPECTIVE|||||||
34058137|NCT05237284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058138|NCT00232596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058139|NCT06631482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058140|NCT03156907|NA|SINGLE_GROUP||TREATMENT||NONE|Open|||||
34058141|NCT06620055|||COHORT||PROSPECTIVE|||||||
33745105|NCT06035133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745106|NCT04148248|||CASE_ONLY||PROSPECTIVE|||||||
33745107|NCT00254982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745108|NCT05234944|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Non-randomized|Non-randomized pilot study, all participants will receive intervention||||
33745109|NCT05740462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33745110|NCT01926106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33745111|NCT06246877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33745112|NCT02528214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745113|NCT04090307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745114|NCT00970502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745115|NCT03404323|||COHORT||PROSPECTIVE|||||||
33745116|NCT01576601|||COHORT||PROSPECTIVE|||||||
33954112|NCT06650111|||COHORT||RETROSPECTIVE|||||||
33954113|NCT05356546|||COHORT||PROSPECTIVE|||||||
33745117|NCT03655158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"placebo applications were performed to mask participant~investigator who applied ozone, did not evaluate the healing~Investigator who evaluate the healing, did not know the control and test sides."|Split- mouth placebo controlled design (right quadrants of the surgical areas were assigned to receive ozone therapy in all patients. As placebo application, left quadrants received regular air from the ozone generator)|t|f|t|t
33745118|NCT06634472|||COHORT||PROSPECTIVE|||||||
33745119|NCT04867564|||COHORT||PROSPECTIVE|||||||
33745120|NCT05655793|||COHORT||PROSPECTIVE|||||||
33745121|NCT01868581|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33745122|NCT05493280|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745123|NCT02995603|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745124|NCT05154864|||COHORT||PROSPECTIVE|||||||
33849048|NCT06043752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849049|NCT01193426|||COHORT||PROSPECTIVE|||||||
33849050|NCT05427604|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33849051|NCT05918718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849052|NCT05721404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849053|NCT01015547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849054|NCT02926599|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33849055|NCT05689151|||COHORT||PROSPECTIVE|||||||
33849056|NCT05670873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849057|NCT01737554|||COHORT||PROSPECTIVE|||||||
33849058|NCT00272675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33849059|NCT02632422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849060|NCT02295553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849061|NCT04596189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A placebo-controlled, double blind, prospective, real-world trial in patients with CRSwNP undergoing revision surgery for CRSwNP|t|t|t|t
33849062|NCT01281969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849063|NCT03456739|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33954114|NCT05254015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded controlled trial|Randomized Controlled Trial|f|f|t|t
33954115|NCT06565923|||COHORT||PROSPECTIVE|||||||
33954116|NCT01153685|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954117|NCT00794222|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34162189|NCT04331470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All of the research team will be blind about the groups of study and position of patients in each group except of physician and main researcher. Files of patients which will be numbered using a random number table will be sent for analyzer of the study.Information about position of patients in the groups is masked from research team. Outcomes Assessor will receive the information of patients without any name in the file. Just when statistical analysis would be finished information of groups will be revealed.|Study is two armed , double blind, parallel, randomized clinical trial.|t|f|f|t
34162190|NCT05081232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Male patients undergoing Robot-Assisted Radical Prostectomy and eligible will receive Human Umbilical Cord (UC) allograft. It is hypothesized that patients receiving UC allograft placed around the neurovascular bundle will facilitate earlier return to potency and continence compared to those that do not receive UC allografts.||||
34162191|NCT05144139|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34162192|NCT00321451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162193|NCT04807335|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33849064|NCT03820674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded to their group assignment. Assessors and interventionists were not blinded to the group assignment.|Both groups received 6-week interventions.|t|f|f|f
33849065|NCT03421626|||CASE_ONLY||CROSS_SECTIONAL|||||||
34162194|NCT02378324|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
34162195|NCT05434390|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel model. Participants will be randomly assigned to either an intervention or control arm of the study.||||
34162196|NCT04197180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162197|NCT02292446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162198|NCT03902314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Anesthesia care providers will be acquiring the study solution from the institution's pharmacy (lidocaine or saline) to administer perioperatively. The pharmacy will prepare the study solutions per randomization and label the solution as the study solution without reference to lidocaine or saline. Per protocol, the care providers will then administer the study solution as a weight based infusion.|"Enrolled patients will be randomly assigned into one of two intervention groups:~Group 1: systemic lidocaine infusion Group 2: normal saline infusion"|t|t|t|t
34162199|NCT05681702|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized||||
34162200|NCT00513149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745125|NCT06299501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Three-armed study, two intervention groups and one control group|f|f|f|t
33745126|NCT01651429|NA|SINGLE_GROUP||SCREENING||NONE||||||
33745127|NCT06245785|||COHORT||RETROSPECTIVE|||||||
33745128|NCT05870280|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33745129|NCT06167681|NA|SEQUENTIAL||TREATMENT||NONE||||||
33849066|NCT01747993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849067|NCT04648644|||COHORT||PROSPECTIVE|||||||
33849068|NCT05736211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849069|NCT02158052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849070|NCT02512367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33849071|NCT04315259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|study is Single Blinded||t|f|f|f
33849072|NCT05717101|||COHORT||PROSPECTIVE|||||||
33849073|NCT00871299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849074|NCT01786980|||||PROSPECTIVE|||||||
33849075|NCT05529147|||CASE_ONLY||PROSPECTIVE|||||||
33954118|NCT03949764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745130|NCT01826591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33745131|NCT04025073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745132|NCT03451838|||COHORT||PROSPECTIVE|||||||
33745133|NCT03028168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33745134|NCT06532682|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745135|NCT05034003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33745136|NCT01197950|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33745137|NCT01311492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33745138|NCT06425354|||COHORT||PROSPECTIVE|||||||
33745139|NCT06635395|||OTHER||PROSPECTIVE|||||||
33745140|NCT01329601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745141|NCT05319691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will use a single-blinded (investigator) two-arm randomized control trial (RCT) design.|Investigators will use a single-blinded (investigator) two-arm randomized control trial (RCT) design. The trial will be 24 weeks long and divided into two distinct parts: an initial 12-week Treatment Phase followed by a 12-week Follow-up Phase. Participants will be randomized 1:1 into weekly virtual yoga classes (Yoga Now) or a wait-list control (Yoga Later) who will receive usual care. After the 24 week study period, participants in Yoga Later will be offered the yoga intervention in a non-study format.|f|f|t|f
33745142|NCT06023056|||COHORT||PROSPECTIVE|||||||
33745143|NCT01299246|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
33745144|NCT06534346|RANDOMIZED|CROSSOVER||OTHER||NONE||Single-dose clinical trial with healthy volunteers sequentially using a single dose of DA-302168S tablet under fasting and thereafter under fed conditions.||||
33745145|NCT04495673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745146|NCT02493361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745147|NCT04266028|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||4 sequential study cohorts with ascending DM-101 doses. In each cohort two treatment arms: placebo and active drug|t|f|t|f
33745148|NCT00506493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849076|NCT06610448|RANDOMIZED|CROSSOVER||OTHER||NONE||Each participant is randomly assigned a different blood pressure device each day over the course of 3 days. All participants will use each device, but the devices will be applied on different days and on different arms.||||
33849077|NCT00797251|||COHORT||PROSPECTIVE|||||||
33849078|NCT05212805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849079|NCT03488628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849080|NCT00692276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745149|NCT03793985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745150|NCT06635421|||COHORT||PROSPECTIVE|||||||
33745151|NCT03286023|||COHORT||PROSPECTIVE|||||||
33849081|NCT03685851|||COHORT||RETROSPECTIVE|||||||
33849082|NCT06332937|||COHORT||RETROSPECTIVE|||||||
33849083|NCT00544375|||CASE_ONLY||PROSPECTIVE|||||||
33849084|NCT05851053|||COHORT||CROSS_SECTIONAL|||||||
33849085|NCT01230567|||CASE_CONTROL||PROSPECTIVE|||||||
33849086|NCT02934256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849087|NCT03450837|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849088|NCT05243238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849089|NCT04716998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849090|NCT02502903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849091|NCT00414245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849092|NCT00903006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849093|NCT01350284|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33849094|NCT02856854|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33849095|NCT02001298|RANDOMIZED|PARALLEL||||NONE||||||
33849096|NCT03352648|||COHORT||PROSPECTIVE|||||||
33849097|NCT03104946|||COHORT||RETROSPECTIVE|||||||
33849098|NCT01400347|||COHORT||PROSPECTIVE|||||||
33849099|NCT03661203|||COHORT||PROSPECTIVE|||||||
33849100|NCT05786495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849101|NCT02534987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849102|NCT01417143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849103|NCT01324596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849104|NCT00132847|||COHORT||PROSPECTIVE|||||||
33849105|NCT05611632|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||Participants will be randomised to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.|t|f|t|t
33849106|NCT01466101|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33849107|NCT02555852|||COHORT||RETROSPECTIVE|||||||
33849108|NCT05867563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849109|NCT03753672|||COHORT||PROSPECTIVE|||||||
33849110|NCT02854787|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33849111|NCT02432508|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33849112|NCT04742127|||COHORT||RETROSPECTIVE|||||||
33849113|NCT02237443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849114|NCT04729413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Couples are randomized 1:1 to receive the intervention (couples counseling and health education) or control (enhanced standard of care) in parallel for the duration of the study||||
33849115|NCT01729351|||COHORT||RETROSPECTIVE|||||||
33849116|NCT03711331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33849117|NCT05366101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849118|NCT01335451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849119|NCT02062853|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849120|NCT00509431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849121|NCT02553967|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849122|NCT02233452|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33849123|NCT00895154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849124|NCT04247087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly assigned to receive intravenous vitamin K or placebo solution. Coronary tomography was performed and interpreted by Radiology staff, who had no knowledge about the study groups or their intervention|randomized clinical trial with double blinding compared to placebo|t|f|f|t
33849125|NCT02883127|||COHORT||PROSPECTIVE|||||||
33849126|NCT06086366|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849127|NCT02047903|||OTHER||PROSPECTIVE|||||||
33849128|NCT04488393|||COHORT||RETROSPECTIVE|||||||
33849129|NCT02055495|||COHORT||PROSPECTIVE|||||||
33849130|NCT02162797|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849131|NCT02223676|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849132|NCT03405051|||COHORT||PROSPECTIVE|||||||
33849133|NCT03594201|||COHORT||RETROSPECTIVE|||||||
33849134|NCT04083677|||COHORT||PROSPECTIVE|||||||
33954119|NCT02493023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954120|NCT01035229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954121|NCT00075101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954122|NCT05010915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954123|NCT06545019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The parturient will be randomly grouped into two groups which are Group V (Informative Video) and Group C (control group) using a computer-generated sequence in a permuted block of six. A research assistant/medical officer who is not involved in the conduct of study will perform the allocation concealment by placing the randomization sequence into sealed and opaque envelopes, which will be numbered accordingly. The next available envelope will be taken for the next recruited parturient and open by the investigator after the baseline anxiety level assessment is completed.||t|t|f|f
33954124|NCT05990946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954125|NCT06651762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954126|NCT05039931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954127|NCT04155775|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33954128|NCT05735938|||COHORT||PROSPECTIVE|||||||
33954129|NCT02355366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33954130|NCT04112927|||CASE_CONTROL||RETROSPECTIVE|||||||
33954131|NCT04028570|NA|SEQUENTIAL||TREATMENT||NONE||3+3 radiation dose escalation||||
33954132|NCT02072707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954133|NCT02243709|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33954134|NCT05053737|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||HPV unrelated head and neck cancer. Neoadjuvant Atezolizumab w/ SBRT followed by surgery then risk adjusted adjuvant therapy per NCCN guidelines (adjuvant RT or CRT)||||
34058142|NCT02957058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058143|NCT04420585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058144|NCT03835598|||COHORT||RETROSPECTIVE|||||||
34058145|NCT06618846|||COHORT||PROSPECTIVE|||||||
34058146|NCT04875390|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34058147|NCT05528913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|2:1 (Benralizumab : Placebo)|t|f|t|f
34058148|NCT04242446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058149|NCT00570297|||CASE_ONLY||PROSPECTIVE|||||||
34058150|NCT06582407|||COHORT||RETROSPECTIVE|||||||
34058151|NCT03366324|NA|SINGLE_GROUP||TREATMENT||NONE||The only one group of patients will receive the combination of CAR-T therapy and HSCT.||||
34058152|NCT04531618|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Study staff who deliver the intervention will not be blinded to participant group. Hospital staff will be blind to group status.||t|f|f|t
34058153|NCT02847923|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33849135|NCT03702231|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849136|NCT05379036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849137|NCT04208282|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849138|NCT01847677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849139|NCT05101031|||CASE_ONLY||PROSPECTIVE|||||||
33849140|NCT03375567|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.|f|f|f|t
33849141|NCT02630602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849142|NCT06240923|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A sample size of 24 maxillary dental distalizing sites were selected and divided into two groups twelve in each:~Group 1: Single coil spring. Group 2: Double coil spring."||||
33849143|NCT02968316|||COHORT||PROSPECTIVE|||||||
33849144|NCT03527550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849145|NCT02632526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33954135|NCT05782309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33954136|NCT01544465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058154|NCT04593095|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34058155|NCT04887636|||OTHER||CROSS_SECTIONAL|||||||
33745152|NCT05847218|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|This is a double-blind study|"The study is planned to be conducted in Two Phases (Cohort A and Cohort B). The first phase will be carried out in two Cohorts i.e., single oral dose of investigational drug 750 mg or placebo under fasting (Cohort A1) and single oral dose of investigational drug 750 mg or placebo under fed conditions (Cohort A2). The second phase of the study will also be carried out in two cohorts i.e., single oral dose of 1500 mg or placebo under fasting (Cohort B1) and single oral dose of 1500 mg or placebo under fed conditions (Cohort B2). The second phase of the study will be carried out after the safety assessments of period one.~Blood and urine samples will be collected from volunteers till 24 hours post dose in each Cohort for pharmacokinetic assessment of the drug and its active metabolites."|t|t|t|f
33745153|NCT04414670|||COHORT||RETROSPECTIVE|||||||
33745154|NCT02418325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745155|NCT03633383|||COHORT||RETROSPECTIVE|||||||
33745156|NCT00347074|||CASE_CONTROL||OTHER|||||||
33745157|NCT04223011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745158|NCT05614297|||OTHER||CROSS_SECTIONAL|||||||
33849146|NCT03426605|NA|SEQUENTIAL||TREATMENT||NONE||Open Label, Dose-Escalation||||
33849147|NCT01792336|||||PROSPECTIVE|||||||
33849148|NCT00710359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33849149|NCT01040039|||COHORT||PROSPECTIVE|||||||
33849150|NCT00002001||||TREATMENT||DOUBLE||||||
33849151|NCT03246776|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33849152|NCT05322252|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849153|NCT01191268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849154|NCT00698945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33849155|NCT04266418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849156|NCT01942785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849157|NCT00201786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849158|NCT01959477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849159|NCT00495105|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849160|NCT02567747|||OTHER||RETROSPECTIVE|||||||
33849161|NCT05408702|||COHORT||PROSPECTIVE|||||||
33849162|NCT00760968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849163|NCT03971903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Particpants are assigned to active ABM treatment or placebo training|t|f|t|t
33849164|NCT05538559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849165|NCT01449500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33849166|NCT06520254|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|a randomized, controlled, parallel, two-arm trial||||
33849167|NCT03090828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849168|NCT02792751|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33849169|NCT04574167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Following enrollment in the study, participants will be randomized to either active or sham tDCS. Random permuted blocks will be used to ensure equal treatment numbers at certain equally-spaced points in the sequence of participant assignment.|This study will be a double-blind, randomized, placebo (sham) controlled study of Veterans with AUD who will receive cognitive training and be randomized to either active or sham tDCS.|t|t|t|t
33849170|NCT04269291|||COHORT||PROSPECTIVE|||||||
33849171|NCT03182218|||OTHER||PROSPECTIVE|||||||
33849172|NCT05936294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849173|NCT03982901|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849174|NCT05534438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849175|NCT06149910|||COHORT||RETROSPECTIVE|||||||
33849176|NCT06027593|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33849177|NCT03871023|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||3 separate treatment arms|f|f|t|f
33849178|NCT03973281|RANDOMIZED|PARALLEL||OTHER||SINGLE|The physician reading all ultrasound images will be blinded to randomization|Randomized Control Study|f|f|f|t
33849179|NCT04992182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954137|NCT05639894|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Sentinel Cohort: single-blind~* Investigators, study staff who conduct the safety assessment, and the participant will not know which study intervention is administered~* Sponsor study staff and study staff preparing/administering the study interventions and not involved with the safety evaluation will know which study intervention is administered Main and Booster Cohorts in Stage 1 and Stage 2: Modified double-blind~* Investigators, study staff who conduct the safety assessment, and the participant will not know which study intervention is administered~* Only the study staff who prepare and administer the study intervention and are not involved with the safety evaluation will know which study intervention is administered"|Sequential (Phase I)/ parallel (Phase IIa)|t|t|t|t
33954138|NCT05149989|NA|SINGLE_GROUP||OTHER||NONE||||||
33849180|NCT05543187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954139|NCT00795210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954140|NCT05571618|||COHORT||RETROSPECTIVE|||||||
33954141|NCT01389804|||COHORT||PROSPECTIVE|||||||
33954142|NCT05062161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be randomized in a 1:1 ratio to each arm by a computer-generated random allocation sequence. All study investigators and outcome assessors will be blinded to group assignment and will not have access to the randomization sequence. The Educational Research Coordinator who will deliver the educational sessions will be unblinded to treatment arm but will not be involved in collecting study measures or data analyses.||f|f|t|t
33954143|NCT00249600|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058156|NCT00566956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058157|NCT06359314|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33745159|NCT06284811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745160|NCT05699434|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33745161|NCT06636513|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on IBS symptoms.||||
33745162|NCT06057350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745163|NCT06427785|||CASE_ONLY||PROSPECTIVE|||||||
33745164|NCT01610700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745165|NCT04847635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, randomized, longitudinal, interventional study|t|t|t|f
33745166|NCT05234294|||COHORT||PROSPECTIVE|||||||
34162201|NCT03822767|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34162202|NCT00941915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162203|NCT03151733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162204|NCT02639442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162205|NCT04042961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162206|NCT00413036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162207|NCT03350815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and Investigators will be blinded to the secukinumab dose during Treatment Period 2.|This was a randomized, double-blind, parallel-group, multicenter design which included an initial 16 week open-label period (Treatment Period 1) followed by a randomized, double-blind, parallel-group period (Treatment Period 2),|t|f|t|f
34162208|NCT00445185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162209|NCT05883644|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IIIb Non-randomised and non-blinded single arm study||||
34162210|NCT02100475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162211|NCT04832191|||CASE_ONLY||PROSPECTIVE|||||||
34162212|NCT04241484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162213|NCT01288001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162214|NCT02161835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162215|NCT04995211|||COHORT||PROSPECTIVE|||||||
34162216|NCT01374633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162217|NCT05112562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162218|NCT05380440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745167|NCT01509118|||CASE_ONLY||PROSPECTIVE|||||||
33745168|NCT05487508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator) Participants were not aware of the arms/treatment given as they were under general anesthesia during the administration of dexamethasone. Preoperatively, subjects were given explanation of the purpose, methods, benefits, and risks of the procedure including the randomization method. Investigators were kept unaware of the randomization of dexamethasone as they were restricted for assessing the patients' medical record and the patients' identity were coded in the primary database|A double-blind, single center, multi-arm phase 4 randomized controlled clinical trial was conducted with four intervention arms: placebo CCABG, dexamethasone CCABG, placebo OPCAB, and dexamethasone OPCAB arm. The recruitment of subjects were conducted simultaneously by means of a block randomization.|t|f|t|f
33745169|NCT05056649|||COHORT||RETROSPECTIVE|||||||
33745170|NCT05396586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Three randomized crossover trials (N-back, Span and Multisensory) will be conducted and in each trial, participants will be randomly assigned to 1 of 2 conditions: Condition 1 consists of training type 1 followed by training type 2, whereas Condition 2 consists of training type 2 followed by training type 1. In the N-back trial, participants will be assigned to Non-Gamified N-back training and Gamified N-back training. In the Span trial, they will be assigned to Non-Gamified Span training and Gamified Span training and in the Multisensory trial, they will be assigned to Non-gamified Unisensory N-back training and Non-gamified Multisensory N-back training.|t|f|f|t
33745171|NCT06415682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745172|NCT00628329|||COHORT||CROSS_SECTIONAL|||||||
33745173|NCT03447418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745174|NCT03506971|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745175|NCT00760864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745176|NCT05531396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745177|NCT06028269|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33745178|NCT04848025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745179|NCT01141192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33745180|NCT01592097|||COHORT||PROSPECTIVE|||||||
33745181|NCT06635408|||COHORT||PROSPECTIVE|||||||
33745182|NCT05812261|||COHORT||PROSPECTIVE|||||||
33745183|NCT01490632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745184|NCT04973137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849181|NCT04277182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the researcher who will analyze the primary outcome of the study will not know which group of animals the samples were taken from.|"* 1st. group: It will be considered as a control group and rats will not be treated.~* 2nd. group: Vehicle group, Propolis vehicle will be applied to rats for 21 days.~* 3rd. group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~* 4th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~* 5th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~* 6th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days."|f|f|f|t
33849182|NCT02567773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162219|NCT03130920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162220|NCT04951622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162221|NCT04850469|||COHORT||PROSPECTIVE|||||||
34162222|NCT01285934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162223|NCT00001212||||TREATMENT||||||||
34162224|NCT04996251|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34162225|NCT03910088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745185|NCT05053087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double-blinded study. Computer randomization will be used for patient grouping and the research pharmacy will dispense the medication to the anesthesia team, who will set the adductor catheter dosing based upon randomization. The surgical team and patient will remain blinded to the medication and dosing regimen.|A Three-Arm, Double-Blinded, Randomized Controlled Trial|t|f|t|f
33745186|NCT04246034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745187|NCT06459687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745188|NCT06633640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745189|NCT02959060|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745190|NCT06218329|||COHORT||RETROSPECTIVE|||||||
33745191|NCT04088097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745192|NCT00164437|RANDOMIZED|PARALLEL||ECT||NONE||||||
33745193|NCT02633878|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33745194|NCT06538090|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participants: While the families will not be told explicitly if they have been assigned to the intervention or control group, they may be able to determine their group based on the information regarding movement behaviours they receive/do not receive during their 2 month immunization appointment.~Research Coordinator: The research coordinator will be aware of the group allocations as they will be in charge of coordinating random assignment and have to schedule other measures based on their specific allocation."|All participants will be randomly assigned to group 1 (intervention) or group 2 (control), in a computer generated 1:1 sequence.|t|f|f|f
33745195|NCT02276300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745196|NCT01857544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745197|NCT05444920|||COHORT||OTHER|||||||
33745198|NCT04383912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Computer randomization software will be used to determine whether the right or left side will receive onabotulinum toxin injection. The contralateral side will receive a placebo injection of equal volume (normal saline).~The health care professional assisting with the procedure will not be masked to randomization. He/she will draw up the onabotulinum toxin A and placebo in two separate identical syringes marked A (right side) and B (left side). They will reference a form showing the results of the computer generated randomization, which will be kept in a study chart separate from the patient's normal oculoplastic visits. They will sign this form, as well as record the lot number of the onabotulinum toxin A and normal saline.~The oculoplastic surgeon will visually divide each incision in half, and inject half of the volume of syringe A at each side of the right direct brow lift incision, and half of the volume of syringe B at each side of the left direct brow lift incision."|This is a double masked, prospective, randomized controlled trial. Participants will function as their own internal control, with one side (i.e. brow) being randomized to the treatment arm, and the other to placebo.|t|t|t|t
33745199|NCT06568692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745200|NCT01840423|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33745201|NCT00604253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745202|NCT00251810|||||PROSPECTIVE|||||||
33745203|NCT04959045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This research is a randomized controlled experimental study. It was planned to divide the students into two groups as experimental and control groups. Simple random sampling method will be used to determine the experimental and control groups. To ensure randomization, each student will be numbered and data sets (experiment and control) will be created.||||
33745204|NCT02096653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745205|NCT02508480|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33745206|NCT04179032|NA|SINGLE_GROUP||TREATMENT||NONE||Cohorts 1, 2, and 3 will be recruited in parallel design. In Part A participants will receive 200 mg/mL belimumab via SC injection once a week (QW) in Cohort 1, every 10 days (Q10d) in Cohort 2, and every 2 weeks (Q2W) in Cohort 3. In Part B, dosing frequency may change according to pre-defined criteria based on changes in body weight of the participant.||||
33745207|NCT05403489|||OTHER||RETROSPECTIVE|||||||
33745208|NCT06042829|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33745209|NCT04627766|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monitoring of vital signs with VT-Patch and standard of care||||
33849183|NCT03274167|RANDOMIZED|PARALLEL||TREATMENT||||||||
33849184|NCT04065945|||COHORT||PROSPECTIVE|||||||
33849185|NCT05470049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33849186|NCT00844532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849187|NCT03299998|||COHORT||RETROSPECTIVE|||||||
33849188|NCT03046693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation of the subject is done by using block randomization. Randomization will be performed by a third party before the study began. Number randomization results will be incorporated into the white envelope sealed and classified into group A (got citcoline) or group B (placebo) in accordance with the results of randomization. Neither the participant, investigator nor the outcome assessor know whether the patient is classified into group A or B.|Sample of 20 people for each treatment group (Group A: citicoline and group B : placebo). Both group were given drug (whether citicoline or placebo) for 60 days.|t|f|t|t
33849189|NCT00956059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745210|NCT04897295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure the allocation concealment of participants, the sham group will receive a stimulation with a weak amperage for only the first and the last 20 seconds of the session, giving them a similar sensation experienced by the active tDCS. The assessors will never stimulate participants to ensure the blind condition.|double blind, randomized, sham-controlled with a 1:1 allocation into 2 parallel arms|t|f|f|t
33745211|NCT04543929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745212|NCT00649012|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33745213|NCT05491473|||CASE_CONTROL||RETROSPECTIVE|||||||
33745214|NCT01707602|RANDOMIZED|PARALLEL||||NONE||||||
33745215|NCT02535065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745216|NCT05044572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745217|NCT03507166|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: RC48-ADC||||
33745218|NCT06024928|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||This study is a randomized controlled parallel design trial where participants will be randomized 1:1 to either a control group or an experimental group.||||
33745219|NCT04431323|NA|SINGLE_GROUP||TREATMENT||NONE||"ESPRIMO is a feasibility study using a participatory design.~It is composed of a pre-phase and three main consequential phases:~* Pre-phase: Exploring the psychological impact of COVID-19 on young adults with MS using a cross-sectional web-based survey for patients with MS;~* Phase 1 (Co-creation of the intervention): initial co-creation phase aiming to develop a biopsychosocial intervention (the so-called ESPRIMO intervention) targeted at young adults with MS, using cross-sectional web-based surveys for young adults with MS and healthcare providers as well as focus groups with patients;~* Phase 2 (intervention): aiming to test preliminary effect, feasibility, and acceptability of the ESPRIMO intervention in a sample of young patients with MS; Phase 3 (Fine tuning of the intervention): evaluation of the results by the ESPRIMO Board (composed of four young adults with MS and three healthcare professionals) and subsequent fine-tuning of the ESPRIMO intervention."||||
33745220|NCT00783536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745221|NCT04393545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745222|NCT04450589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.|Subjects will be randomized into 1 of 2 parallel groups. There will be one (1) treatment group and one (1) placebo group. Subjects will receive either the ALRV5XR treatment regimen or placebo regimen.|t|t|t|t
33849190|NCT01072760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33849191|NCT02407392|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33849192|NCT06101043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33849193|NCT05023681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this study, patients are randomly assigned 1:1 to the r-SAK treatment group and the saline control group using a central randomization system.||t|t|t|t
33849194|NCT04107987|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33849195|NCT00852033|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33849196|NCT00766363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849197|NCT01905137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058158|NCT05265091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058159|NCT06647927|||COHORT||OTHER|||||||
34058160|NCT02779335|NA|SINGLE_GROUP||||NONE||||||
34058161|NCT03714646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34058162|NCT03048123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058163|NCT05212220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058164|NCT02925715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34058165|NCT00005072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058166|NCT03163394|||CASE_CONTROL||PROSPECTIVE|||||||
34058167|NCT02174913|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34058168|NCT01342250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058169|NCT02035748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849198|NCT00036023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849199|NCT05317845|||COHORT||CROSS_SECTIONAL|||||||
33849200|NCT00067262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33849201|NCT05939934|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33849202|NCT06377046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, single center, prospective, single blinded, parallel group, pilot-trial.|t|f|f|f
33849203|NCT04541498|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33849204|NCT00476073|RANDOMIZED|PARALLEL||||NONE||||||
33849205|NCT04018573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849206|NCT01498159|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33849207|NCT03242720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33849208|NCT04573829|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33849209|NCT02884908|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33849210|NCT04532554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849211|NCT05681689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849212|NCT01312051|||OTHER||CROSS_SECTIONAL|||||||
33849213|NCT05261919|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There were no masking in this study.|"All the participants were in one group and received acupuncture manipulation. The investigator used directional supplementation and draining manipulation. The investigator perform acupuncture with supplementation manipulation first, followed by a measurement of the electrical characteristics using Agilent B1500A. The investigator remove the acupuncture and then perform acupuncture with draining manipulation, followed by measurements. After one meridian measurements were completed, the investigator removed the needle and proceeded to the next meridian to repeat the same procedure.~The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.~The acupoints were HT7、HT3、SI5、SI8、BL57、BL40、KI3、KI10 in this study."||||
33849214|NCT01422421|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33849215|NCT04340791|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849216|NCT00070824|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849217|NCT02488538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849218|NCT02898935|||OTHER||CROSS_SECTIONAL|||||||
33954144|NCT05312801|NA|SEQUENTIAL||TREATMENT||NONE||"Open label, dose escalation study.~Dose Levels~1. 1 x 10 million BAFF+ CAR cells/kg~2. 2 x 10 million BAFF+ CAR cells/kg~3. 4 x 10 million BAFF+ CAR cells/kg~4. 8 x 10 million BAFF+ CAR cells/kg"||||
33954145|NCT05335759|||OTHER||PROSPECTIVE|||||||
33954146|NCT04404192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954147|NCT02980939|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33954148|NCT00374465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33954149|NCT05732012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954150|NCT06652282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954151|NCT02908191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33954152|NCT04688489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954153|NCT05656430|RANDOMIZED|PARALLEL||TREATMENT||NONE||After recruitment finished, participants will be randomized to either intervention condition (treatment group) or control condition (wait list). Participants in the control group will receive the same treatment once the intervention group has finished the treatment and outcome measures has been collected.||||
33954154|NCT04619134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954155|NCT03793309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058170|NCT03240523|RANDOMIZED|PARALLEL||TREATMENT||NONE|With protocol version 5.0 the blinded study arms A3 and B were converted to one open-label study arm called A3/B.|||||
34058171|NCT01189734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058172|NCT05413343|||COHORT||PROSPECTIVE|||||||
34058173|NCT05519137|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants will randomly be assigned to initially receive the active or control lighting intervention|t|f|f|t
34058174|NCT03043157|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participant receives hypnotic (propofol) before we use the drug|Dose-finding using Dixon's up-and-down adaptative clinical trial||||
34058175|NCT00385775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058176|NCT04695951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058177|NCT06649474|NA|SINGLE_GROUP||PREVENTION||NONE||50 patients with pancreatic adenocarcinoma and 50 patients with oesogastric adenocarcinoma||||
34058178|NCT05908331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"2:1 randomized trial (MagicTouchTM vs. plain old balloon angioplasty \[POBA\])"|t|f|f|t
34058179|NCT06648551|||OTHER||PROSPECTIVE|||||||
34058180|NCT06645912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized ıntervantıonal study||||
34058181|NCT05336942|||COHORT||PROSPECTIVE|||||||
34058182|NCT04808232|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34058183|NCT05470010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058184|NCT06612437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058185|NCT02982616|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34058186|NCT04546516|||CASE_CROSSOVER||PROSPECTIVE|||||||
34058187|NCT06293040|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double-blind (Participant, Outcomes Assessor), placebo controlled, and double-dummy|All participants will complete all dose conditions (study arms) in a randomized order|t|t|f|t
34058188|NCT04086589|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076532|NCT04999761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076533|NCT05044247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058189|NCT04612777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Participants will be randomized either to the intervention (Opening Doors to Recovery) or standard treatment (Intensive Case Management or Case Management)"||||
33745223|NCT01224262|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33745224|NCT00146952|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33745225|NCT04336254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745226|NCT03634774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Mealtime observations are completed by assessors who are blinded to the order in which sites receive the intervention|Step-wedge design; all three groups receive the intervention but two are wait list control for varied amounts of time|f|f|t|t
33745227|NCT04766619|||OTHER||OTHER|||||||
33745228|NCT05477134|NA|SINGLE_GROUP||OTHER||NONE||||||
33745229|NCT04387084|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33745230|NCT05419648|||COHORT||PROSPECTIVE|||||||
33745231|NCT05169359|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|No masking|Stepped wedge design||||
33745232|NCT04418804|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Women and / or men over the age of 18 who expressed their consent to participate in the study and signed a formal consent form, will be divided into 3 groups according to their medical condition:~1. Participants without an active diagnosis of pleural disease.~2. Participants diagnosed with pneumothorax.~3. Participants diagnosed with pleural effusion."||||
33745233|NCT05477355|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants in wait list control (WLC) are explained that they will be receiving the intervention at a later time.|The intervention is Group Problem Management Plus (PM+).||||
33745234|NCT02762526|||COHORT||PROSPECTIVE|||||||
33745235|NCT05082090|||COHORT||OTHER|||||||
33745236|NCT00692172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745237|NCT06471101|||COHORT||RETROSPECTIVE|||||||
33745238|NCT06530407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745239|NCT03094572|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33745240|NCT03574168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745241|NCT02568787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33745242|NCT06357728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be given a continuous glucose monitoring device to wear for 10 days before during and after the oral glucose tolerance test.||||
33745243|NCT01434758|||COHORT||PROSPECTIVE|||||||
33745244|NCT02997358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745245|NCT03177304|NA|SINGLE_GROUP||OTHER||NONE||||||
33745246|NCT06152536|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Monocentric, controlled and randomized trial in crossover.||||
33745247|NCT03985423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745248|NCT05360979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745249|NCT03859323|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33745250|NCT00125216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745251|NCT00326235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34058190|NCT04000698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058191|NCT05622045|||COHORT||PROSPECTIVE|||||||
34058192|NCT05538767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058193|NCT02829827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745252|NCT04320329|||COHORT||PROSPECTIVE|||||||
34058194|NCT03373539|||COHORT||PROSPECTIVE|||||||
34058195|NCT01768975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058196|NCT02079636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058197|NCT02823392|||COHORT||PROSPECTIVE|||||||
34058198|NCT04505384|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058199|NCT03228316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|prospective interventional||f|t|f|f
34058200|NCT04374682|||CASE_ONLY||PROSPECTIVE|||||||
34058201|NCT00000865||||TREATMENT||NONE||||||
33849219|NCT02318173|||CASE_ONLY||PROSPECTIVE|||||||
34058202|NCT01115556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058203|NCT01576276|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34058204|NCT04742660|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are blinded to allocated groups. Outcomes assessors are blinded to which group participants are assigned.|The anticipants are administered either ramosetron+placebo or ramosetron+glycyrrhizin|t|f|f|t
34058205|NCT00781170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058206|NCT06197503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058207|NCT02494375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058208|NCT02873572|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34058209|NCT03129282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34058210|NCT02719938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34058211|NCT04940611|||COHORT||PROSPECTIVE|||||||
34058212|NCT04935840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34058213|NCT03962231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058214|NCT03711149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This randomized controlled trial will involve two arms: (1) and intervention arm consisting of activity monitor feedback loop and art tours and (2) control group consisting of standard of care.||||
34058215|NCT01383473|||CASE_ONLY||PROSPECTIVE|||||||
34058216|NCT05959408|NA|SINGLE_GROUP||PREVENTION||NONE||It is a cross-sectional, without risk or constraint, monocentric study on the viability of the main bacterial STIs in MSM.||||
34058217|NCT03480698|||OTHER||PROSPECTIVE|||||||
34058218|NCT00771355|||CASE_ONLY||PROSPECTIVE|||||||
33849220|NCT04797650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849221|NCT02582112|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33849222|NCT04930731|||COHORT||PROSPECTIVE|||||||
33849223|NCT05245552|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33849224|NCT05947942|||COHORT||PROSPECTIVE|||||||
33849225|NCT04869293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849226|NCT01993927|||COHORT||PROSPECTIVE|||||||
33849227|NCT04545684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33849228|NCT00439803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33849229|NCT00989534|RANDOMIZED|PARALLEL||||NONE||||||
33849230|NCT04472559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849231|NCT04846309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849232|NCT03506685|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2x5 mixed model anova|f|f|f|t
33849233|NCT05922384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849234|NCT02589561|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33849235|NCT06013228|||COHORT||PROSPECTIVE|||||||
33849236|NCT06610435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To ensure blinding, baseline and final outcome measurements were performed by researchers other than the physiotherapist performing manual therapy.|Thirty patients with bruxism were randomly divided into as Manual Therapy Group (15) and Home Exercise Group (15).|f|f|f|t
33849237|NCT04222075|||COHORT||PROSPECTIVE|||||||
33849238|NCT02523599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954156|NCT04273763|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954157|NCT01950052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33954158|NCT05477368|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33954159|NCT03861533|||OTHER||PROSPECTIVE|||||||
33954160|NCT02033928|||CASE_ONLY||PROSPECTIVE|||||||
33954161|NCT03888651|||COHORT||PROSPECTIVE|||||||
33954162|NCT02861534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954163|NCT00940446|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954164|NCT04386512|||CASE_ONLY||RETROSPECTIVE|||||||
33954165|NCT01733160|||COHORT||PROSPECTIVE|||||||
33954166|NCT05375487|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33954167|NCT01856296|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33954168|NCT05146609|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33954169|NCT06566391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954170|NCT01937546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33954171|NCT01600612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954172|NCT04016909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058219|NCT05048212|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058220|NCT02351193|||COHORT||PROSPECTIVE|||||||
33849239|NCT03743454|||OTHER||CROSS_SECTIONAL|||||||
33849240|NCT06143969|||COHORT||PROSPECTIVE|||||||
33849241|NCT00752947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954173|NCT06538961|||COHORT||PROSPECTIVE|||||||
33954174|NCT02769832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954175|NCT02006901|||COHORT||PROSPECTIVE|||||||
33954176|NCT03908229|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954177|NCT04206072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954178|NCT03456401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954179|NCT01656850|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954180|NCT06651320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33954181|NCT03573843|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058221|NCT04329091|NA|SINGLE_GROUP||OTHER||NONE||||||
34076534|NCT06167889|||COHORT||RETROSPECTIVE|||||||
34058222|NCT05678244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|IV acetaminophen and saline appear identical in solution. They will be administered at identical rates. Care providers, participants' parents, investigators, outcomes assessors, and statisticians will remain blinded.|Patients will be randomized to the control or comparator group. There will be 60 patients enrolled, with 30 patients per arm.|t|t|t|t
34058223|NCT04282291|||CASE_CONTROL||PROSPECTIVE|||||||
34058224|NCT00260312|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34058225|NCT06100692|||COHORT||PROSPECTIVE|||||||
34162226|NCT04692519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The principal investigator and postdoctoral fellow on the project will both be blind. Only the coordinator will know who is the in intervention group and who is in the delayed access group.|"Participants who are selected to participate in the intervention will be given access to videos containing the Duet intervention modules. We will ask families to watch one Duet module a week, if possible. They will have up to 3 months to complete the 6 modules. Intervention participants will be scheduled for follow-up data collection at 3 months, 6 months, and pending funding, 1-year after baseline.~Participants who are in the delayed access control group will not have to complete the modules and will be scheduled for a 3-month, 6-month, and pending funding, a 1-year follow-up calls. They will have delayed access to the modules, which means that they will receive access to the module videos at their 6-month study session and will be offered the opportunity to contact the research team with any questions."|f|f|t|t
34058226|NCT03720145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058227|NCT00437827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058228|NCT00389298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34058229|NCT04250233|||COHORT||PROSPECTIVE|||||||
34162227|NCT02429830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162228|NCT05711134|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34162229|NCT00961363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162230|NCT02644343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162231|NCT03802474|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162232|NCT03986528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162233|NCT04524364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162234|NCT04625218|||OTHER||PROSPECTIVE|||||||
34162235|NCT00013741|RANDOMIZED|||||DOUBLE||||||
34162236|NCT05906836|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34162237|NCT03805919|||COHORT||PROSPECTIVE|||||||
34162238|NCT04078347|||CASE_CONTROL||PROSPECTIVE|||||||
34162239|NCT00493259|||COHORT||RETROSPECTIVE|||||||
33745253|NCT01873794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34162240|NCT03965741|||COHORT||RETROSPECTIVE|||||||
33745254|NCT00120172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745255|NCT05620758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745256|NCT03669029|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745257|NCT00601926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745258|NCT04613973|||COHORT||RETROSPECTIVE|||||||
34162241|NCT02709330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162242|NCT06310616|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34162243|NCT01435486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162244|NCT06075589|||COHORT||PROSPECTIVE|||||||
34162245|NCT04141423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34162246|NCT03738618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162247|NCT05722548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34162248|NCT01835158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162249|NCT01520961|||CASE_CONTROL||PROSPECTIVE|||||||
34162250|NCT00018967||||SUPPORTIVE_CARE||NONE||||||
33745259|NCT05851404|||CASE_CONTROL||RETROSPECTIVE|||||||
33745260|NCT03033303|NA|SINGLE_GROUP||TREATMENT||NONE||In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF.||||
33745261|NCT03912857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745262|NCT03721380|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33745263|NCT02609243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745264|NCT03674177|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Observer-blind In this study, the subject and study site personnel involved in the clinical evaluations of the subjects are blinded while other study personnel may be aware of the treatment assignments.||t|f|t|t
33745265|NCT05738395|||COHORT||CROSS_SECTIONAL|||||||
33745266|NCT01437592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745267|NCT02460991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162251|NCT05786508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33954182|NCT05802147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was carried out as a randomized controlled experimental study in order to examine the effect of early skin-to-skin contact on mother-infant attachment and traumatic birth perception and to provide new information to the literature. The sample of the study consisted of 350 women who applied to the Training and Research Hospital in the city center of Batman between December 2021 and May 2022, and who agreed to participate as the study group (n: 175) and the control group (n: 175), who had a normal delivery in the delivery room has created.||||
33849242|NCT04973501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study was designed as parallel group (outpatients) randomized comparison of two kinds of physiotherapeutic interventions.|t|f|t|t
33954183|NCT05789316|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954184|NCT04207359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study plans to enroll 30 breast cancer patients who have completed chemotherapy within 6 months prior to consenting for this study. Patients eligible to participate in this study will be allocated to either the creatine group or the control group (1:1) based on a pre-determined randomization list. Each arm will have 15 participants. One arm will receive creatine and the other will serve as the control group with no creatine.||||
33954185|NCT02871921|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study assessors will be blinded to the subject study arm assignment.||f|f|f|t
33954186|NCT02086734|||COHORT||PROSPECTIVE|||||||
33954187|NCT03217500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954188|NCT01092286|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954189|NCT05753592|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954190|NCT06650033|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised to Adaptive radiotherapy or standard radiotherapy, 2:1 randomisation||||
33954191|NCT06649630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33954192|NCT06649214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954193|NCT00887965|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954194|NCT02311400|||OTHER||PROSPECTIVE|||||||
33954195|NCT02254499|||COHORT||PROSPECTIVE|||||||
33954196|NCT06568523|NA|SINGLE_GROUP||SCREENING||NONE||||||
33954197|NCT06006416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954198|NCT01541410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954199|NCT06506669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Patients, clinicians (operating room nurses, ophthalmologists, and anesthesia staff), and research staff responsible for data collection and analysis will be blinded to the treatment group in order to minimize bias and maximize the validity of results.|A single-center, randomized, double-blinded, randomized pilot clinical trial|t|t|t|t
33954200|NCT01655784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954201|NCT01966185|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33954202|NCT01431807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954203|NCT01826617|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33954204|NCT00285363|||COHORT||PROSPECTIVE|||||||
33954205|NCT06056323|NA|SEQUENTIAL||TREATMENT||NONE||Phase I: Dose escalation with a conventional 3+3 design, including 1.5、5、15、30 and 40mg/kg dose group Phase II：Dose expansion phase. During the dose escalation process, expansion cohorts will be conducted based on the preliminary RP2D. A Simon 2-stage design will be utilized with a stopping rule to allow for early termination of a particular cohort at the end of Stage 1 if patients have insufficient responses to HB0045.||||
33954206|NCT02983773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33954207|NCT04035993|NA|SINGLE_GROUP||OTHER||NONE||||||
33849243|NCT01160289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849244|NCT06598605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849245|NCT00732589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849246|NCT00700258|||COHORT||PROSPECTIVE|||||||
33849247|NCT02724969|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Lactation consultant providing assistance has no knowledge of group assignment. Statistician completing final analysis of data will be blinded to group assignment.||f|t|f|t
33849248|NCT04356885|||COHORT||PROSPECTIVE|||||||
33849249|NCT05110768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849250|NCT06226675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33849251|NCT03256851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954208|NCT05167994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954209|NCT00293605|||CASE_ONLY||PROSPECTIVE|||||||
34058230|NCT05274542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33849252|NCT06243692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either lacosamide or topiramate from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included lacosamide, and Drug B included propranolol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.~Both groups received open-label 500-1000mg acetaminophen during acute attack."|We will assess The number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.|f|f|t|t
33849253|NCT02393027|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849254|NCT06471777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849255|NCT02424734||||TREATMENT||NONE||||||
33849256|NCT03229590|||COHORT||PROSPECTIVE|||||||
33849257|NCT01780181|||CASE_CONTROL||PROSPECTIVE|||||||
33849258|NCT03753737|||OTHER||CROSS_SECTIONAL|||||||
33849259|NCT05062603|||COHORT||PROSPECTIVE|||||||
33849260|NCT01459900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33849261|NCT01077271|||COHORT||PROSPECTIVE|||||||
33849262|NCT00042718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33849263|NCT01253109|||COHORT||PROSPECTIVE|||||||
33849264|NCT02338973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849265|NCT00607685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849266|NCT02828878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849267|NCT06055348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849268|NCT04491266|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33849269|NCT01407692|||OTHER||PROSPECTIVE|||||||
33849270|NCT04554524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849271|NCT01138059|||CASE_ONLY||PROSPECTIVE|||||||
33849272|NCT00124293|||COHORT||PROSPECTIVE|||||||
33849273|NCT04982835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be assigned a treatment group by enrolling site and will not be blinded to the treatment group assignment before their surgery. Investigator, and site will not be blinded to treatment assignment due to the need to prepare for the respective surgery associated with the treatment assignment.|||||
33849274|NCT04447196|||COHORT||PROSPECTIVE|||||||
33849275|NCT05197725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The intervention involves wearing a face mask so participants will know if they are in the intervention group. The investigators will be blinded as to intervention assignment.|This is a randomized controlled trial with an equal number of intervention and control villages enrolled each day.|f|f|t|f
34058231|NCT06623045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34058232|NCT05832918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058233|NCT04080674|||COHORT||PROSPECTIVE|||||||
33849276|NCT04955340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849277|NCT05112952|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849278|NCT06448273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849279|NCT06373523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo pills will be manufactured in identical appearance to the study drug (Dapagliflozin)|Eligible subjects will be randomly allocated to either the Dapagliflozin group or placebo group (i.e. control group)|t|t|t|t
33849280|NCT03589508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849281|NCT00417339|||COHORT||PROSPECTIVE|||||||
33849282|NCT05984004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849283|NCT02225210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849284|NCT00875927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849285|NCT06417528|||COHORT||PROSPECTIVE|||||||
33849286|NCT01806103|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745268|NCT04040803|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All people studied will have each of the five treatments separately over different days in random order.|t|f|f|f
33745269|NCT02917980|||COHORT||PROSPECTIVE|||||||
33745270|NCT02747342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745271|NCT06635967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745272|NCT04727866|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33745273|NCT00827034|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745274|NCT04936412|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745275|NCT02513017|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33745276|NCT04768010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849287|NCT04143958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849288|NCT00353522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849289|NCT02545933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058234|NCT05631106|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Control Trial||||
34058235|NCT03118141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058236|NCT06648616|NA|SINGLE_GROUP||OTHER||NONE||||||
34058237|NCT03667872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058238|NCT02170467|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058239|NCT04574934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible because of intervention therapy. We analyzed data by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (study group) and Group B (control group).|Thirty patients with muscular dystrophy were enrolled in this study and were assessed for eligibility. Their age ranged from four and forty years. They were assigned randomly into two equal groups. Group (A) study group received the traditional physical therapy program plus aquatic therapy. And the group (B) control group received traditional physical therapy program only. All patients will receive sessions two times/week for three successive months. Pulmonary function test was used to assess pulmonary functions pre and post-intervention. All patients were assisted before and after three months of intervention.|f|f|f|t
34058240|NCT01949441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058241|NCT04791540|||COHORT||PROSPECTIVE|||||||
34058242|NCT00821223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058243|NCT06361303|||COHORT||PROSPECTIVE|||||||
34058244|NCT00097994|||COHORT||PROSPECTIVE|||||||
34058245|NCT00876226|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34058246|NCT01721915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058247|NCT00383695|RANDOMIZED|||TREATMENT||NONE||||||
34058248|NCT03613883|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058249|NCT01947426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34162252|NCT06482541|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Participants will act as their own control. Each participant will get exosome treatment on one half of the treatment area and placebo on the other half of the treatment area. The treatment area will be two rectangles each measuring 4cm on the sagittal plane by 2cm on the coronal plane on the scalp vertex. One rectangle will be 2.0 mm left of the midline of the scalp and another will be 2.0 mm right of the midline of the scalp. Participants in the 5 billion exosome group will receive 5 billion WJMSC-exosome treatment on one side of the treatment area and an equivalent volume of saline on the other side of the treatment area. Participants in the 50 billion exosome group will receive 5 billion WJMSC-exosome treatment on one side of the treatment area and an equivalent volume of placebo on the other side of the treatment area.|t|t|t|t
34162253|NCT01833559|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162254|NCT02352623|||COHORT||PROSPECTIVE|||||||
34162255|NCT05391906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162256|NCT00337207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162257|NCT03226834|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|blindness concerns medical staff: nurses in charge of the blood parameters measurements as well as anxiety evaluation are not informed of the allocation of the patients|control randomized, single blind, monocentric|f|t|t|f
34162258|NCT04406649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162259|NCT01107665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162260|NCT00945256|RANDOMIZED|FACTORIAL||||NONE||||||
34162261|NCT05612256|||COHORT||PROSPECTIVE|||||||
34162262|NCT05783336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162263|NCT06025006|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34162264|NCT00010283||||SUPPORTIVE_CARE||||||||
34162265|NCT01085370|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34162266|NCT06675955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162267|NCT03070535|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subject is not told which meal, HIGH or LOW, they receive at each meal visit until after they have completed the study. At the conclusion of study participation for each subject (after their second meal), they are told which of their meals was HIGH and which one was LOW.|Subjects will be randomized to receive either the LOW or HIGH meal for their first meal and will cross-over and receive the alternate meal for their next meal. Meals are on separate days.|t|f|f|f
34162268|NCT05248659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162269|NCT06124378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849290|NCT06198205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment.|it is a randomized control trial, used to compare Effects of Fundamental Motor Skills Program on Motor and Cognitive Abilities in school going children. Subjects meeting the predetermined inclusion and exclusion criteria will be divided into two groups using simple random sampling technique.|t|f|f|f
33849291|NCT04391881|||OTHER||CROSS_SECTIONAL|||||||
33849292|NCT02766192|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058250|NCT05621005|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Study design: non inferiority prospective non randomized controlled trial~Study population and setting:~The study enrolled patients with chronic liver disease and ascites who were monitored at outpatient clinics or who were admitted to Ain Shams University hospitals.~Sample size: 104 patients with decompensated liver cirrhosis were enrolled in the study. The Control Group (n=52), to receive standard of care treatment \& Norfloxacin prophylaxis for the decompensated liver disease and a second Treatment Group (n=52) who will receive Rifaximin prophylaxis in addition to the original management."|f|f|f|t
33745277|NCT04578262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849293|NCT03450226|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized controlled trial|t|t|t|t
33849294|NCT01893021|||COHORT||PROSPECTIVE|||||||
33849295|NCT00706043|||COHORT||PROSPECTIVE|||||||
33849296|NCT04422444|||COHORT||PROSPECTIVE|||||||
33849297|NCT03446820||SEQUENTIAL||OTHER||NONE||Participants will be randomly assigned to sleep in the residential module of the Well Living Lab. One week will be with standard sheets, followed by one week of hygro cotton sheets.||||
33849298|NCT04334187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849299|NCT04642300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849300|NCT04650139|||COHORT||PROSPECTIVE|||||||
33849301|NCT05134701|||CASE_ONLY||PROSPECTIVE|||||||
33849302|NCT05534815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745278|NCT01343082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745279|NCT02909777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745280|NCT05601479|RANDOMIZED|PARALLEL||PREVENTION||NONE|This study was an open-label, unblinded study. Both participants were aware of their enrollment status.Scale evaluators, nerve conduction velocity measurement testers during the study did not know the grouping of subjects. The collected data were submitted to statistical experts who were unaware of the group assignments for statistical analysis.|||||
33745281|NCT05935345|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058251|NCT06648291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058252|NCT02062710|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33745282|NCT01732393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745283|NCT00769366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849303|NCT05564728|||CASE_ONLY||PROSPECTIVE|||||||
33849304|NCT00662090|||OTHER||PROSPECTIVE|||||||
33849305|NCT06188429|||COHORT||PROSPECTIVE|||||||
33849306|NCT05991284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded core echocardiography laboratory|Multicenter, Investigator-initiated, Prospective, Randomized trial with Open Blinded Endpoint|f|f|f|t
33849307|NCT01085968|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849308|NCT05998161|RANDOMIZED|PARALLEL||TREATMENT||NONE|All endpoints are patient-reported outcome measures (PROMs). Given that participants are aware of their study group (receiving reviga in addition to treatment as usual or only receiving treatment as usual), this trial is not blinded.|||||
33849309|NCT05911932|||COHORT||PROSPECTIVE|||||||
33849310|NCT00817973|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34058253|NCT01605032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058254|NCT02222597|||COHORT||PROSPECTIVE|||||||
34058255|NCT03633149|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058256|NCT04965441|||COHORT||RETROSPECTIVE|||||||
34058257|NCT00083941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058258|NCT05501327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058259|NCT02222675|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058260|NCT01837173|||COHORT||RETROSPECTIVE|||||||
34058261|NCT00295035|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34058262|NCT05295979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058263|NCT03147859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34058264|NCT02850016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058265|NCT04455698|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058266|NCT06463483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058267|NCT03679338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058268|NCT01293851|||||PROSPECTIVE|||||||
34058269|NCT03168737|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34058270|NCT04727034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058271|NCT06054334|||COHORT||RETROSPECTIVE|||||||
34058272|NCT04024267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058273|NCT00467961|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of selective depletion of alloreactive T cells to prevent graft vs host disease||||
34058274|NCT04869319|||COHORT||PROSPECTIVE|||||||
34058275|NCT04690725|NA|SINGLE_GROUP||TREATMENT||NONE||TQB3525 orally taken||||
34076535|NCT00493012|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34076536|NCT00052078|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34076537|NCT03868189|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33745284|NCT06635187|||CASE_CONTROL||PROSPECTIVE|||||||
33745285|NCT04507191|||OTHER||CROSS_SECTIONAL|||||||
33745286|NCT04994626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745287|NCT00548769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745288|NCT02478294|||COHORT||PROSPECTIVE|||||||
33745289|NCT03280992|||COHORT||PROSPECTIVE|||||||
33745290|NCT01262508|||CASE_ONLY||PROSPECTIVE|||||||
33745291|NCT04196400|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||comparative prospective clinical trial|t|f|f|t
33745292|NCT02860598|||COHORT||PROSPECTIVE|||||||
34076538|NCT01166750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076539|NCT01081782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954210|NCT06582680|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Neither the participants nor the researchers will know whether the participant received the placebo or one of the beta blocking drugs. Masking will be performed by the research nurse who will know which drug the participant received.|"We will first collect participant demographics, medical history, anthropometrics (body mass, height and composition). Individuals will be exposed to 3 hours in a hot environmental condition after receiving the placebo, propranolol, or metoprolol.~Prior to entering the environmental chamber, baseline data will be collected while resting in a thermoneutral environment. Drug or placebo will be administered. Participants will then enter the environmental chamber and will be seated in a semi-recumbent position on a chair with breathable fabric to minimize impediments to heat dissipation. Periodically throughout the simulated heat-wave participants will lightly exercise to simulate metabolic heat production associated with activities of daily living (\~3 metabolic equivalents; METS). Throughout the heat-wave simulation trials we comprehensively evaluate the thermoregulatory and cardiovascular responses."|t|f|t|f
33954211|NCT06048198|||CASE_ONLY||PROSPECTIVE|||||||
33954212|NCT04094402|||OTHER||CROSS_SECTIONAL|||||||
33954213|NCT05173922|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33954214|NCT00210925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33954215|NCT05810727|||COHORT||RETROSPECTIVE|||||||
33954216|NCT00488007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954217|NCT03461653|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised trial||||
33954218|NCT06651307|RANDOMIZED|CROSSOVER||OTHER||NONE||All subjects performed testing with and without elbow sleeves. The sequence of conditions was allocated by a randomized and counterbalanced crossover approach.||||
33954219|NCT06651424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33954220|NCT05507671|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants will not be informed if they received BCG or placebo. They will be informed that the injection may or may not give a local reaction regardless of what they receive.~Blood samples for serological and cytokine studies will be coded and the laboratory technician will not know which samples are from participants who received BCG or placebo."|Two-arm study, BCG vaccine versus placebo, to assess the effect of BCG in preventing severe form of covid19 and improving the efficacy of anti-SARS-CoV-2 vaccines|t|f|f|t
33954221|NCT05042128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33954222|NCT05879796|||COHORT||PROSPECTIVE|||||||
33954223|NCT06224504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34058276|NCT06620445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants (Children/Guaddians or Parents) are unaware of which group they are assigned (CBT group or usual care group). Researcher are aware of the group assignments.|"This single-blinded, two-arm randomized controlled trial will involve 80 children aged 8-16 with malignancies receiving chemotherapy.~Participants will be randomly assigned to either the experimental group, which will receive five weekly sessions of cognitive-behavioral intervention, or the control group, which will receive usual care. Each intervention session will last 30-35 minutes.~Outcomes will be measured at baseline and one-month post-intervention using the Revised Child Anxiety and Depression Scale and Pediatric Quality of Life Inventory Generic Core Score 4.0."|t|f|f|f
34058277|NCT02285543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058278|NCT02378415|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058279|NCT01633008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058280|NCT04651946|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible patients accept DNA methylation testing in serum and in ovarian tissues.||||
34058281|NCT04148638|||CASE_CONTROL||RETROSPECTIVE|||||||
34058282|NCT01971333|||COHORT||PROSPECTIVE|||||||
34058283|NCT01896947|||CASE_ONLY||PROSPECTIVE|||||||
34058284|NCT00955968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058285|NCT03508752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058286|NCT00919997|||CASE_ONLY||PROSPECTIVE|||||||
34058287|NCT01256749|||CASE_ONLY||PROSPECTIVE|||||||
34058288|NCT00900757|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34058289|NCT02284568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34058290|NCT00459004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058291|NCT06011356|||COHORT||PROSPECTIVE|||||||
34058292|NCT01647984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34058293|NCT03721042|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058294|NCT06002139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058295|NCT06590025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is randomized clinical trial comparing two psychological interventions: INCREM and psychoeducation, and no drugs or biological/vaccine or combination products are tested, regardless it is a phase 3 study. Included patients can be prescribed pharmacological treatments, but these are not investigated here-in.|f|f|f|t
34058296|NCT05222152|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058297|NCT04253782|NA|SINGLE_GROUP||TREATMENT||NONE||"Study personnel (recovery coaches + health educators) will form teams and meet (mostly remotely/electronically and/or by phone) with participants, who will select one of three options that may help with opioid misuse:~1. treatment with buprenorphine/naloxone (BUP),~2. methadone maintenance, intensive outpatient, or residential treatments, or~3. education only. Throughout the study, participants may switch to any other option."||||
34058298|NCT04512599|NA|SINGLE_GROUP||PREVENTION||NONE||The study is an open-label, non-randomized study in Parkinson's disease participants||||
34058299|NCT00197002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058300|NCT06079307|RANDOMIZED|PARALLEL||OTHER||SINGLE|due to ethical consideration participants cannot be blinded nor examiners as they will be providing oral hygiene instructions and information relative to using the mouth rinse and the mouth foam. everyone handling the data after examination will be blinded, they will be dealing with data obtained after identifying an identification code to each participant.|3 parallel arms running for 12 months and six-points data collection (examination - plaque index and gingival index)|f|f|f|t
34058301|NCT01282112|||||RETROSPECTIVE|||||||
34058302|NCT03160222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162270|NCT04417361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The following study procedures will be in place to ensure double-blind administration of study treatments. Access to the randomization code will be strictly controlled and this will reside with our pharmacist, who will not be blinded. All members of the clinical team and biostatistician will be blinded. Packaging and labeling of test and control treatments will be identical to maintain the blind. Each participant will be given an identical study packet, containing their assigned drug and study information. The study blind will be broken on completion of the clinical study and after the study database has been locked. Investigators will be made aware of their participants' treatment designations only after all the data has been collected and analyzed. During the study, the blind may be broken only in emergencies when knowledge of the participant's treatment group is necessary for further clinical management.|The study drug will be administered with a subcutaneous injection of galcanezumab or placebo. The first dose (at month 1) will be a loading dose of two injections, or 240 mg in total. After that, at month 2 and month 3, each participant will get either a subcutaneous injection of galcanezumab 120 mg or placebo. The injections will be with a pre-loaded syringe containing either galcanezumab or placebo.|t|t|t|t
34162271|NCT01365169|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34162272|NCT03274544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162273|NCT01591187|||CASE_ONLY||PROSPECTIVE|||||||
34162274|NCT04655573|||COHORT||PROSPECTIVE|||||||
34162275|NCT02041845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162276|NCT01316679|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162277|NCT00514384|||COHORT||PROSPECTIVE|||||||
34162278|NCT01330329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162279|NCT01970306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162280|NCT04538664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162281|NCT05528393|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162282|NCT06726343|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Pregnant women of ≥22 weeks gestation will undergo two 30-minute monitoring sessions (60 minutes total). One with currently approved Corometrics 259cx and one with the investigational device. During both monitoring sessions, maternal pulse rate will be monitored using SpO2 and the investigator shall be present to adjust the transducer placement as needed.||||
34162283|NCT02388334|||||PROSPECTIVE|||||||
34162284|NCT00819871|||CASE_CONTROL||PROSPECTIVE|||||||
33745293|NCT00407537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745294|NCT03836287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745295|NCT00958035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745296|NCT04797247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participants, study staff, investigator and sponsor blinded to treatment and lipid levels|Randomized, double blind, placebo controlled|t|t|t|t
33745297|NCT02958436|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33745298|NCT01060215|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33745299|NCT05864794|NA|SINGLE_GROUP||SCREENING||NONE||||||
33745300|NCT06669975|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745301|NCT03607448|||COHORT||PROSPECTIVE|||||||
33745302|NCT01218438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745303|NCT06634953|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745304|NCT02654080|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745305|NCT01485510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33745306|NCT06531655|||COHORT||PROSPECTIVE|||||||
33745307|NCT05164822|||COHORT||PROSPECTIVE|||||||
33745308|NCT06635096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745309|NCT03387852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745310|NCT00413153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745311|NCT00283504|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745312|NCT03675386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849311|NCT06268080|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Blinding of procedural anesthesiologist is not possible. Patients, surgeons, and all outcome assessors will be blinded. One unblinded research coordinator at each site will collect pEEG related data points. Other research coordinators will be blinded as to treatment allocation and will collect data relating to primary and secondary outcomes. Clinicians carrying out participant usual care will be able to unblind study allocation if necessary by viewing the patients anesthesia record via password protected, accessing clinician identity logged, Electronic Health Record (EHR). This record will be unavailable for access by other means.|Multicentre, prospective, randomized, active control, parallel group, intention to treat, safety and efficacy study.|t|f|t|t
34076540|NCT04424147|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with rrAML are treated with HVA regimen||||
34076541|NCT00810199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076542|NCT04370275|||COHORT||PROSPECTIVE|||||||
33954224|NCT02162381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33954225|NCT06075927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954226|NCT06390280|||CASE_ONLY||PROSPECTIVE|||||||
33954227|NCT04962815|||CASE_CONTROL||PROSPECTIVE|||||||
33954228|NCT03315325|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|There was no masking. Every individual was told about injecting the kisspeptin, however, they were not informed at the time when kisspeptin was injected.|Healthy men, 15 in number were selected. These individuals were classified on the basis of their ages in three groups: adult, middle age and advanced aged. Each group comprised of five participants.||||
33954229|NCT02139969|||COHORT||RETROSPECTIVE|||||||
34058303|NCT05487885|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study has a longitudinal design in which participants complete 2 sets of activities:~Phase 1: Phenotyping. This includes assessment with diagnostic interview, questionnaires, behavioral tasks, MRI, app-based digital assessment, and blood draw for inflammatory markers. This set of activities will occur at 4 time points over the course of 1 year/participant (study entry, approximately 4 months, approximately 5 months, and approximately 1 year), and all participants will complete them.~Phase 2: Therapeutic activities: (1) 10 theta burst stimulation (TBS) sessions (TBS 2 times/session) plus positive affect (PA) training for all participants; and (2) IV ketamine infusion for those who do not respond to TBS/PA activities."||||
34058304|NCT03714334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954230|NCT06400095|||COHORT||PROSPECTIVE|||||||
34058305|NCT05073029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058306|NCT04645602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058307|NCT06258551|||COHORT||PROSPECTIVE|||||||
34058308|NCT03940274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954231|NCT06334601|||COHORT||CROSS_SECTIONAL|||||||
34058309|NCT02150876|||CASE_CONTROL||RETROSPECTIVE|||||||
34058310|NCT02651805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34058311|NCT04647656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058312|NCT05080283|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective, pre-market, single-site, non-randomized.||||
34058313|NCT05129293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34058314|NCT02231281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058315|NCT01658592|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33954232|NCT05959824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized, double blind, placebo controlled clinical study.|t|f|t|f
34058316|NCT02054910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954233|NCT06289010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058317|NCT03359798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058318|NCT00932698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058319|NCT00318851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058320|NCT01930344|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34058321|NCT01819103|||COHORT||PROSPECTIVE|||||||
34058322|NCT01096589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058323|NCT04000737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058324|NCT00460265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058325|NCT00535847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058326|NCT06619665|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34058327|NCT00108342|RANDOMIZED|PARALLEL||||NONE||||||
33954234|NCT01850901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954235|NCT01995604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33954236|NCT00307138|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33954237|NCT06504407|NA|SINGLE_GROUP||SCREENING||NONE||Single arm interventional study||||
34058328|NCT05909813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34058329|NCT03409003|||COHORT||PROSPECTIVE|||||||
34058330|NCT00358956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058331|NCT02638675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34058332|NCT04008706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study in which participants will be enrolled into 3 cohorts. In the treatment-naive (TN) cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory (R/R) cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior ibrutinib cohort, up to 40 participants with Prior ibrutinib therapy will be enrolled.||||
34058333|NCT06618781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058334|NCT06619431|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34058335|NCT00668187|||COHORT||PROSPECTIVE|||||||
34058336|NCT06642311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34058337|NCT04437875|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||An open, prospective, two-stage, non-randomized, first-phase study involving healthy volunteers||||
34058338|NCT04558320|||COHORT||PROSPECTIVE|||||||
34058339|NCT02523235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058340|NCT00157911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058341|NCT04684758|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34058342|NCT05577910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unmasked trial coordinators will ensure masking by reminding and accompanying each patient before and during visits. Treatment related complications will be evaluated by all participants in a standard datasheet regardless of group assignment. Follow-up investigators will be asked if they know each participant's group assignment at each visit and why.|"This is a prospective, randomized, assessor-masked, 3-arm (1:1:1), active-controlled trial of 360 subjects with meibomian gland dysfunction contributing one study eye. For subjects with both eyes eligible, the eye with the most meibomian gland dropout (meiboscore), fewest expressible meibomian glands, thinnest lipid layer, or lowest TFBUT values (in this order) will be selected as the study eye.~Enrolled patients will be randomized into one of the following groups, 1 month after recruitment during the 15-month study period receiving bilateral treatment of:~Group A: 1-session VTP at month 0~Group B: 4-session IPL+MGX at month 0,1,2,3~Group C: twice daily EW for 15 months~Topical lubricating eye drops (Hypromellose, 3mg/ml) will be the monotherapy for all subjects."|f|f|f|t
34058343|NCT04231305|||COHORT||PROSPECTIVE|||||||
34058344|NCT05366309|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058345|NCT00034619||||TREATMENT||||||||
34058346|NCT03181503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058347|NCT04257162|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058348|NCT05262712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Assessment, motor training, data analyzes and group allocation are done by different persons. Participants as well as the assessor, the trainer and the investigator are blinded to the group allocation.||t|t|t|t
34058349|NCT05984264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058350|NCT04836364|||COHORT||CROSS_SECTIONAL|||||||
34058351|NCT06098703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Vaccine recipients will not be aware of whether they are in the intervention or control group or the objective of the trial. Care providers who are trained in the intervention are aware of the group allocation. They will not communicate with care providers not trained in the intervention. Care providers that are in the intervention pharmacies will not deliver care to participants in the control pharmacies and care providers in the control pharmacies will not deliver care in the intervention pharmacies. Vaccine recipients are rating the primary outcome.|Cluster trial involving at least 24 community pharmacies allocated to CARD or control (standard care) in a 1:1 ratio. Eligible pharmacies belonging to Wholehealth Pharmacy Partners from across Ontario, Canada, will be included.|t|f|f|t
34058352|NCT04182568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162285|NCT03887715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Central Rater and sponsor are blinded in the RCT phase. Sites will need to have an unblinded programmer who is only programming the device and not collecting outcomes data.|1:1 randomization of active stimulation vs. no stimulation for 12 months post randomization.|t|t|t|t
34162286|NCT05129540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Custom-made foot orthoses and placebo orthoses will have similar appearance for participants. The investigator who record data by means of questionnaires will not know which group the patients belong to.|Two groups of people with chronic sciatica caused by lumbar disc herniation will be included. Patients in group A will be given treatment with custom-made foot orthoses. Patients in group B will be given treatment with placebo orthoses.|t|f|t|f
34162287|NCT04253392|||CASE_ONLY||PROSPECTIVE|||||||
34162288|NCT05370131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34162289|NCT05189847|||COHORT||PROSPECTIVE|||||||
34162290|NCT05467384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Case with healthy control|t|t|f|f
34162291|NCT00297323|||||PROSPECTIVE|||||||
34162292|NCT00475566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745313|NCT00329277|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745314|NCT06067087|||OTHER||CROSS_SECTIONAL|||||||
33745315|NCT02891889|||COHORT||RETROSPECTIVE|||||||
33745316|NCT04956393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745317|NCT05133557|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Each volunteer was allocated xylitol-containing placebo gum or xylitol-containing BBE gum according to a predetermined randomization scheme. To ensure investigator blinding, test products were dispensed through other staff members who kept the assignment codes in sealed envelopes. Randomization resulted in half the participants receiving placebo gum (2 gram; 1 gram xylitol) first, and half receiving first the BBE gum (2 gram; 1 gram xylitol and 100 mg BBE) that were identical in size, shape, color and flavor.|This study was a randomized, crossover-washout design.|t|t|t|f
33849312|NCT05220709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single-centre pilot study to evaluate the feasibility of bio impedance measurements to determine fluid shifts in the pediatric population after a surgical procedure was performed.||||
33849313|NCT04227704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The ketamine and placebo study injectates (subcutaneous and intravenous) will be prepared, in way that does not allow differentiation, by pharmacy staff who are otherwise uninvolved in the study. Participants will be allocated to groups using a random sequence generator. The patients, investigators and outcome assessors will remain unaware of their group until data collection is complete for all participants.|Participants will be randomised to one of three groups (two interventional and one control).|t|t|t|t
33849314|NCT01767480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849315|NCT03661762|||COHORT||OTHER|||||||
33849316|NCT06124469|||COHORT||OTHER|||||||
33849317|NCT06611228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Pragmatic, randomized controlled (parallel-arm cluster), non-drug interventional clinical study|f|f|f|t
33849318|NCT01566253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745318|NCT03797534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33745319|NCT04698980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"150 participants selected according to their G6PD activity:~* 50 subjects with severe deficit G6PD activity (\<30% of the median in the general population, ie 3.6U / g Hb), adults or children two years and over.~* 50 subjects with intermediate G6PD activity (30-80%), adults.~* 50 subjects with normal G6PD activity (\> 80% ie\> 9.6U / g Hb), adults."||||
33745320|NCT04850534|||COHORT||OTHER|||||||
33745321|NCT03447769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745322|NCT02341716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745323|NCT04000906|NA|SEQUENTIAL||TREATMENT||NONE||||||
33745324|NCT00402753|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33745325|NCT00637221|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33745326|NCT00270543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745327|NCT03293823|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be informed whether it is an intervention or control group; instead they will be informed they will receive a computerized cognitive intervention.|6-week cognitive training group vs. an active control group|t|f|f|f
34058353|NCT02847143|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058354|NCT05288608|||COHORT||PROSPECTIVE|||||||
34058355|NCT04106089|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|actigraphy scoring will be conducted by study staff blind to patient study arm|Aggregated N of 1 design (ABA or AAB)|f|f|f|t
34058356|NCT01264666|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33745328|NCT03711981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which type of injection they have received for pain control.|Patients in one arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery. The patients in the control arm of the study would receive pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.|t|f|f|f
34058357|NCT06649188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058358|NCT00526903|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34058359|NCT02691429|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33745329|NCT05393232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors will not know randomization assignment. Investigators will not know randomization assignment. Participants and the nutritionist/dietitian interventionist will need to know randomization assignment in order to carry out the intervention.|Individual level, parallel, randomized trial|f|f|t|t
33745330|NCT02342067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745331|NCT03061994|||COHORT||PROSPECTIVE|||||||
33849319|NCT05408832|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Mixed between and within (Crossover) participant assignment. The study uses a between participant randomization; two arms have a multiple crossover design (with different intervention orders to the crossover) and one arm has no order prescribed.||||
34058360|NCT05475587|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34058361|NCT01886586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058362|NCT01179737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058363|NCT00431665|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34058364|NCT01794793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058365|NCT04108221|RANDOMIZED|PARALLEL||OTHER||SINGLE||two arms : arm A : c-TAP Block performed by surgeon arm B : us-TAP Block performed by anesthetist|f|f|t|f
34058366|NCT00972634|||COHORT||CROSS_SECTIONAL|||||||
34058367|NCT06459570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058368|NCT01917344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058369|NCT02954653|NON_RANDOMIZED|||TREATMENT||NONE||||||
34058370|NCT03250481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34058371|NCT05169112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058372|NCT03274557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||To evaluate improvement of VAS and functionality before and after treatment of Achilles tendinosis using radiofrequency-plasma based microtenotomy in comparison to traditional physical therapy.|t|f|t|f
34058373|NCT02681757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058374|NCT01843114|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34162293|NCT03783299|RANDOMIZED|FACTORIAL||SCREENING||NONE||The study is employing a split-plot community-randomized controlled trial design, with peer navigator test and treat randomized at the health center catchment level, and village-based test and treat randomized at the village level within health center catchment areas (HCCA).||||
34162294|NCT00653588||PARALLEL||TREATMENT||DOUBLE||||||
34162295|NCT05717192|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162296|NCT06022796|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not feasible to apply blinding to the study design due to the nature of the intervention|In this randomized controlled trial, participants in the HK-RTE group will be advised to follow a healthy ketogenic diet with RTE meals provided (n=25), with a maximum of 50g net carbohydrate intake daily. Those in the control group will be instructed to follow a healthy ketogenic diet (HKD) (n=25).||||
34162297|NCT04397744|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162298|NCT04774263|||CASE_ONLY||PROSPECTIVE|||||||
34162299|NCT02449161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34162300|NCT05881954|||COHORT||PROSPECTIVE|||||||
34162301|NCT03349788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162302|NCT03123926|||CASE_CONTROL||PROSPECTIVE|||||||
33849320|NCT03596866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058375|NCT05972291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Each person in this study will receive either glutamine or whey powder to mix in with water. This is done by a random assignment using a computer program for yes or no. All odd numbers of participants will undergo the random choice of the computer program. All even number participants will get the opposite treatment of the previous odd number participant."|In this study, the investigators will conduct a randomized, double-blind, placebo-controlled clinical trial studying glutamine 5 grams orally three times a day compared to a placebo 5 grams orally three times a day for 12 weeks in 80 Veterans with GWI and GI symptoms. This study will also look at Veterans that have chronic GI symptoms and do not have GWI. The Symptom Severity Scale and intestinal permeability will be measured at baseline, 4, 8, and 12 weeks.|t|f|f|f
34058376|NCT05565001|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34162303|NCT05620888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The baseline assessment, the intervention, and the post-intervention assessment are provided automatically via the mobile app. In addition, participants are randomly assigned to a specific experimental group before starting the study and do not know which experimental group they are assigned. These features of the study minimize observer bias.||t|f|f|f
34162304|NCT04488926|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34162305|NCT05097443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162306|NCT02538042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34162307|NCT05357222|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be grouped based on their daily vocal usage (i.e. vocal user (4+ hours of speaking per day) or low vocal user (less than 4 hours per day). Both groups will be given a series of vocal stretching exercises that will be completed through a 2mm diameter straw.||||
34162308|NCT06434181|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The lead researcher, data collectors, and participants were blinded to the conditions. The distribution of the supplements for each condition was performed by a member of the staff that was not involved with the study.||t|f|t|t
33849321|NCT03842254|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849322|NCT03996343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849323|NCT04523389|||COHORT||PROSPECTIVE|||||||
33849324|NCT01453868|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058377|NCT01537627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849325|NCT06048679|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33849326|NCT06610396|||COHORT||PROSPECTIVE|||||||
33849327|NCT01009151|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33849328|NCT01090479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33849329|NCT02610166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33849330|NCT04461054|||COHORT||RETROSPECTIVE|||||||
33849331|NCT03629327|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Three arms will be followed simultaneously||||
33849332|NCT00223873|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849333|NCT01820585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849334|NCT06417580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This double-blind study guarantees the confidentiality of the interventions, since both the research participant and the main researcher will not be able to differentiate the procedure applied. The placebo gel, the experimental desensitizing gel and the potassium nitrate gel will be inserted into a dappen jar delivered immediately before the clinical interventions by a research collaborator. The gels have a similar texture, color and odor to prevent identification. The evaluator will also not be aware of the group the participant belonged to, as they will not participate in the randomization process. The research will have a single operator to carry out the clinical part.|"This randomized clinical trial will be parallel, double-blind, placebo-controlled. Composed of three groups: a placebo control group with gel without any active ingredient (CG), a group with potassium nitrate gel (GNK) and an experimental group with 10% potassium pregabalin gel (GPG). Applications will be carried out in 3 sessions with an interval of 72 hours between each one. Sensitivity recording will be performed at T0 (baseline), T1 (after first session), T2 (after second session), T3 (after third session), T4 (7 days after the last session) and T5 (one month after the last session) and T6 (3 months after the last session).~A questionnaire (QEDH-15) will be applied to evaluate the impact of desensitizing treatment on improving the participants' oral health-related quality of life (HRQoL). The questionnaire will be applied at baseline (T0) and at the last sensitivity record (T6)."|t|f|t|f
33849335|NCT06253598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849336|NCT04244838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849337|NCT05443152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849338|NCT04535414|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849339|NCT01192464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849340|NCT01871350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33849341|NCT00558038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849342|NCT03647488|NA|SINGLE_GROUP||TREATMENT||NONE||Run-in part was single group. Randomized part (parallel design) was not opened.||||
33849343|NCT04242251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The person administering the patient reported outcome measures will be blinded to the participant's allocation to study arms.||f|f|f|t
34058378|NCT00854334|||COHORT||CROSS_SECTIONAL|||||||
34058379|NCT05814042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two groups: Control vs Intervention|t|t|t|t
34058380|NCT03499405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention group will have access to a culturally matched family navigator, control group will not have access to a culturally matched family navigator.||||
34058381|NCT03740321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Blocked randomized, single blind, prospective study|t|t|f|t
33849344|NCT00491569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33849345|NCT03281655|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort study||||
33849346|NCT03363243|RANDOMIZED|PARALLEL||TREATMENT||NONE||1 Treatment group with STOP therapy; 1 Treatment as usual group||||
33849347|NCT05023083|||OTHER||PROSPECTIVE|||||||
33849348|NCT02842801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849349|NCT01096823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849350|NCT05326815|||COHORT||PROSPECTIVE|||||||
33954238|NCT03305926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954239|NCT05963022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954240|NCT06232135|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33954241|NCT06436690|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped-wedge randomized controlled trial||||
33954242|NCT00474370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954243|NCT02269800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954244|NCT04943510|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"three randomizations will be used to determine the order of the tests that will be proposed to the subjects:~* on the one hand for the exercise modalities (match, anaerobic, aerobic)~* and, on the other hand, for the exercise modalities included in the anaerobic and aerobic exercise families: Anaerobic agility / anaerobic - linear sprints Aerobic - shuttle / aerobic - linear"||||
33954245|NCT06566573|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective cross-sectional study||||
33954246|NCT02712359|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33954247|NCT05859269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954248|NCT01019109|||CASE_ONLY||PROSPECTIVE|||||||
33954249|NCT01302288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954250|NCT04259307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954251|NCT06563661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomised, controlled (wait-list control), and two-armed trial.|f|f|t|t
33954252|NCT06567171|||OTHER||PROSPECTIVE|||||||
33954253|NCT03718221|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33954254|NCT05153629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954255|NCT04993287|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33954256|NCT05812131|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Providers will be randomly assigned to COPEWeb online training or in-person COPE training||||
33954257|NCT00761761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954258|NCT02716519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849351|NCT03218540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient is anesthetized, thus unaware type of treatment. The assessor is blinded of the monitor|Group SVV: fluid management guided by stroke volume variation (SVV) protocol Group CVP: fluid management guided by central venous pressure (CVP) protocol|t|f|f|t
33849352|NCT04641377|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33849353|NCT01290029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849354|NCT00386139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33849355|NCT04041011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954259|NCT03699956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"In this study, patients will be randomized to 1 of 2 groups or arms. Patients in Arm 1 will receive the study drug, RRx-001, once a week for 3 weeks followed by up to 4 cycles of platinum doublet (platinum plus etoposide) chemotherapy. Patients with stable disease or better will go on to the Platinum Stacking Phase and will receive RRx-001 once a week for 2 weeks followed by 2 cycles of single agent platinum chemotherapy in a repeating pattern until such time as their cancer gets worse.. Patients in Arm 2 will receive the standard of care platinum doublet (platinum plus etoposide) chemotherapy for up to 4 cycles. . Patients in arm 2 whose cancer gets worse (as determined by imaging scans), may cross-over to the Platinum Stacking Phase of Arm 1 (see study schema below)."||||
33954260|NCT04014413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954261|NCT03934242|||COHORT||PROSPECTIVE|||||||
33954262|NCT06135129|||COHORT||PROSPECTIVE|||||||
33849356|NCT04522687|||COHORT||PROSPECTIVE|||||||
33954263|NCT04937452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849357|NCT00669682|||COHORT||PROSPECTIVE|||||||
33954264|NCT04607265|||CASE_CONTROL||PROSPECTIVE|||||||
33954265|NCT01068093|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849358|NCT03475277|||OTHER||OTHER|||||||
33954266|NCT00232778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849359|NCT04322877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954267|NCT06063954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954268|NCT02792400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33954269|NCT06410586|||OTHER||OTHER|||||||
33954270|NCT02404675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954271|NCT06254131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954272|NCT04237831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954273|NCT03733418|||COHORT||PROSPECTIVE|||||||
33954274|NCT00096317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954275|NCT04716816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|treatment method and treatment group||t|f|f|t
33954276|NCT05695456|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|Nor the participant, nor the primary or secondary investigators involved in the study will know to which nutrients the patient reacted as assessed by CLE, nor will they know what the order of the diet is (sham or real). An investigator who did not participate in the CLE will give dietary instructions.|A double-blind cross-over dietary elimination study: Patients with a positive CLE reaction to one or two specific nutrients will then be randomized to a blinded exclusion diet for 6 weeks of those nutrients or to exclusion of another tested nutrient that yielded no change in CLE (=sham diet), in a cross-over fashion. Patients with no CLE reaction will undergo an empirical exclusion diet of gluten-containing grains for 6 weeks. To mirror the crossover character of the intervention, CLE negative patients will then undergo a milk exclusion diet for 6 weeks (order is interchangeable).|t|t|t|t
33954277|NCT02801149|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954278|NCT00822237|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33954279|NCT01438827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954280|NCT06651125|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954281|NCT06250972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954282|NCT02002299|||CASE_ONLY||PROSPECTIVE|||||||
33954283|NCT00403611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33954284|NCT03397576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor is blinded to treatment assignment|Randomized controlled trial|f|f|f|t
33954285|NCT05514496|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954286|NCT05381025|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will be aware of the contents of the active material but will not be informed as to whether they will begin or end the study with the active vs the placebo. Study Managers will also not be aware of what an individual participant is taking during the study.|Participants will be divided into two arms which will cross-over during a washout period such that each participant will take the active and the placebo in one phase of the two-phase study.|t|f|t|f
33954287|NCT01907516|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058382|NCT02788370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34058383|NCT04765995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058384|NCT01967641|NA|SINGLE_GROUP||TREATMENT||NONE|Following induction, patients were stabilized beginning on Day 2 on one of three blinded doses of buprenorphine/naloxone (2/0.5, 8/2, or 16/4 mg per day) for a week then underwent laboratory testing for a second week. Each blinded buprenorphine dose was administered in equal divided doses according to a QID dosing schedule, and each dose was maintained for a two-week period, with the second week including laboratory testing.|||||
33849360|NCT03898037|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33849361|NCT06609395|NA|SINGLE_GROUP||TREATMENT||NONE||Open pilot study||||
33849362|NCT01452373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849363|NCT00574873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849364|NCT06589960|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33849365|NCT05192668|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849366|NCT00852254|||CASE_ONLY||PROSPECTIVE|||||||
33849367|NCT05333952|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849368|NCT01757431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849369|NCT00002768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849370|NCT05970679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849371|NCT00547768|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33745332|NCT05321524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745333|NCT03524222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745334|NCT04933682|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This will be a 2-part, open-label, fixed-sequence study.||||
33745335|NCT02271386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745336|NCT02263300|||CASE_CROSSOVER||PROSPECTIVE|||||||
33745337|NCT04581941|||CASE_ONLY||RETROSPECTIVE|||||||
33745338|NCT01876173|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
33745339|NCT04112147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745340|NCT03869775|||COHORT||PROSPECTIVE|||||||
33954288|NCT04137926|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|In this study, the clinical researchers are responsible for the clinical diagnosis of the subjects and the diagnosis of senile plaques. The biological sample testing agency receives the blind coded samples. After the repeated testing, the data are handed over to the blind statistical experts for statistics. The statistical experts only obtain the grouping information and biological sample data, but do not know the specific diagnosis grouping, so as to ensure the accuracy of the statistical results. The results were analyzed by the researchers after the completion of the statistics.|AD, MCI due to AD and Normal Control|f|f|t|t
33849372|NCT00948766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849373|NCT06327581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849374|NCT02750280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954289|NCT04269031|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This study is single-blind (in which the study center staff remain blinded during the clinical conduct of a given cohort) with regard to treatment (AZD2373 or placebo) at each dose level. Study subjects will be blinded to treatment allocation throughout the study.||t|f|t|f
33954290|NCT03176927|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954291|NCT03962114|NA|SINGLE_GROUP||TREATMENT||NONE||Open label proof of concept study||||
33954292|NCT03788239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954293|NCT01827553|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33954294|NCT01035112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954295|NCT05629741|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33954296|NCT00490399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954297|NCT04838132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33954298|NCT01923207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954299|NCT00446134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849375|NCT00491166|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849376|NCT04831541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849377|NCT02247557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All participants, investigators and care providers do not know which regimen is given to patients of the three arms.|This is a double-blind, randomized, placebo-controlled physician initiated study enrolled patients with refractory IC/BPS. Patients were assigned to intravesical instillation of lipotoxin (onabotulinumtoxinA 200 U with 80mg sphingomyelin), onabotulinumtoxinA 200 U in normal saline, or normal saline.|t|t|t|f
33849378|NCT00377923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33849379|NCT02806648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849380|NCT00872677|||CASE_CONTROL||PROSPECTIVE|||||||
33954300|NCT01219270|||COHORT||PROSPECTIVE|||||||
33954301|NCT01321970|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954302|NCT06575348|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954303|NCT02304302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954304|NCT06566651|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33954305|NCT01861431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33954306|NCT00526929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954307|NCT02831478|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33954308|NCT04766970|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33954309|NCT06265376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954310|NCT00491218|||NATURAL_HISTORY||PROSPECTIVE|||||||
33954311|NCT00034593||||TREATMENT||||||||
33954312|NCT06123624|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058385|NCT03221140|||COHORT||PROSPECTIVE|||||||
34058386|NCT01889121|||COHORT||RETROSPECTIVE|||||||
34162309|NCT00497406|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34162310|NCT01377662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162311|NCT04090411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162312|NCT01849406|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058387|NCT00477997|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34058388|NCT00979524|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058389|NCT03229148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is an open label trial because it is not possible to maintain the anesthesiologist and patient blinded during the procedure. However, all subsequent evaluations will be conducted by clinical research staff blinded to the randomization group.|Multicentic, prospective, open, in parallel groups, stratified and randomised study.|f|f|f|t
34162313|NCT05671068|||CASE_CONTROL||PROSPECTIVE|||||||
34162314|NCT00002984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162315|NCT00080301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162316|NCT02291419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745341|NCT03124641|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33745342|NCT00822029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745343|NCT00325793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745344|NCT02159482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162317|NCT04975178|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|MTBVAC and BCG vaccine will be prepared, and allocation concealed by the site pharmacist. All other site staff will be blinded to vaccine allocation, throughout the follow-up period. Data pertaining to the MTBVAC vaccine and to BCG control will be collected in an observer-blinded manner. Blinding will be maintained throughout the vaccination and follow-up portions of the vaccine trial. No set of individual codes will be held at Biofabri's Headquarters. Biofabri's Headquarters will be able to access the individual randomization code from the SATVI Pharmacy randomization register. The code will be broken by the Site's Pharmacist (Study Contact for Emergency Code Break) only in the case of medical events that the investigator/physician in charge of the participant feels cannot be treated without knowing the identity of the study vaccine(s). The Site's Pharmacist is responsible for unblinding the treatment assignment in accordance with specified time frames for expedited reporting of SAEs.|"The study is designed to include the following:~1. Safety population (all study participants randomized to receive BCG or MTBVAC in a 1:1 fashion): All participants from the 4 South African sites (approx. 7000); all 120 participants from Madagascar \& Senegal.~2. Reactogenicity population:~   - First 1000 from the 4 South African sites and all 120 in Madagascar and Senegal.~3. Immunogenicity population (subset of the safety population - total 460):~   - First 60 HU and 25 HEU participants from the South African sites (total 340) and all 120 from Madagascar \& Senegal.~4. Efficacy population (subset of the safety population - all participants from the South African sites):~   * First 1000, including 240 HU and 100 HEU newborns.~  * Additional 6000 (not part of reactogenicity \& immunogenicity population). Senegal \& Madagascar participants are excluded from the efficacy population. DSMB will periodically review cumulative safety and reactogenicity data."|t|t|t|t
34162318|NCT00512876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162319|NCT02515734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162320|NCT04891523|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34162321|NCT06576050|||COHORT||PROSPECTIVE|||||||
33849381|NCT04835337|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33849382|NCT04048421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849383|NCT02810587|||CASE_ONLY||PROSPECTIVE|||||||
33849384|NCT03139669|NA|SINGLE_GROUP||SCREENING||NONE||||||
33849385|NCT02875886|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849386|NCT02923492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849387|NCT06418581|||OTHER||RETROSPECTIVE|||||||
33849388|NCT05192941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be randomized at the baseline visit (Day 1) to one of the following two double-blind treatment groups in a 1:1 ratio.~1. Inclisiran sodium 300 mg s.c.~2. Corresponding placebo Each participant will receive one injection of blinded inclisiran or placebo on Day 1, a second injection of blinded inclisiran or placebo on Day 90 and a subsequent injection of blinded inclisiran or placebo on Day 270, unless there is a need for discontinuing inclisiran/placebo in the course of the study"|"Double-blind investigational treatment inclisiran/placebo: subcutaneous injections of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) or placebo, in 1.5 mL solution.~Open label study treatment rosuvastatin: all participants will receive rosuvastatin, starting at the lowest indicated dose and titrating up until they reach their individual LDL-C target or MTD, whichever occurs first."|t|t|t|t
33849389|NCT02187627|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849390|NCT03484273|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be 4 compression conditions based on strap configuration of the Lifewrap garment: full abdominal and lower extremity compression, abdominal only compression, lower extremity only compression and no compression. The order of these interventions will be randomized.||||
33849391|NCT04230291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849392|NCT00734097|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849393|NCT05385432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849394|NCT00822523|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33849395|NCT04325243|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33849396|NCT06083597|||CASE_ONLY||CROSS_SECTIONAL|||||||
33849397|NCT06610071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849398|NCT01728168|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849399|NCT04907526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849400|NCT00471159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849401|NCT05710159|||COHORT||PROSPECTIVE|||||||
33849402|NCT02943811|||CASE_CONTROL||RETROSPECTIVE|||||||
33849403|NCT04705103|||COHORT||PROSPECTIVE|||||||
33849404|NCT04223739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745345|NCT04890002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33745346|NCT02487264|||CASE_ONLY||RETROSPECTIVE|||||||
33745347|NCT05643885|||COHORT||RETROSPECTIVE|||||||
33745348|NCT04378244|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential assignment||||
33745349|NCT03879798|NA|SEQUENTIAL||TREATMENT||NONE||This study is a non-randomized phase I/II trial assessing the safety and tolerability of DS-3201b in combination with irinotecan in patients with recurrent small cell lung cancer.||||
33745350|NCT00021762||||TREATMENT||||||||
33745351|NCT03786601|||CASE_CONTROL||PROSPECTIVE|||||||
33745352|NCT04182425|||COHORT||PROSPECTIVE|||||||
33849405|NCT04330352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849406|NCT01875549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849407|NCT02309073|||COHORT||PROSPECTIVE|||||||
33849408|NCT04542161|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33849409|NCT04357444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849410|NCT01668901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849411|NCT02209662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849412|NCT02093091|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849413|NCT00833261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849414|NCT02997943|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33849415|NCT05249868|||OTHER||OTHER|||||||
33954313|NCT03456986|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All data will be encrypted so participant's ID does not identify person. Two interventions, both improving motion discrimination will be investigated. Both have the potential of improving cognitive skills, so staff will not think one works better than the other. All data will be input by the senior research assistants who will not know what group a participant belonged to.|The feasibility of PATH neurotraining will be evaluated by comparing it with another cognitive training program, Brain HQ's Target Tracker, and ascertaining the relative advantage(s) of PATH neurotraining for enhancing cognition in older adults between 55 and 75 years of age whose cognition is either in the age-normative range or in the mild cognitive impairment (MCI) range of standardized psychometric measures.|t|t|f|t
33954314|NCT06561048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954315|NCT01208532|||CASE_ONLY||PROSPECTIVE|||||||
33954316|NCT05762588|||CASE_ONLY||PROSPECTIVE|||||||
33954317|NCT06650488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954318|NCT00815139|||CASE_ONLY||PROSPECTIVE|||||||
33954319|NCT00595946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954320|NCT03083457|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Each patient will be randomized to receive or not scheduled recruiting maneuvers every hour. In each of the two groups, patients will receive mechanical ventilation with 3 different levels of PEEP in a sequential, randomized, cross-over manner: each period will last 40 minutes.~A randomization sequence will be produced by a dedicated software and sealed envelopes will be used to allocate patients to study treatments."|t|f|f|f
33954321|NCT00502749|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954322|NCT00348049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33954323|NCT00179426|||||OTHER|||||||
33954324|NCT02273349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954325|NCT06537661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954326|NCT02772341|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34162322|NCT01679223|||CASE_ONLY||CROSS_SECTIONAL|||||||
34162323|NCT06392334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162324|NCT00328367|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34162325|NCT01731366|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34162326|NCT05395325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849416|NCT02890212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162327|NCT02919046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162328|NCT03372135|||COHORT||RETROSPECTIVE|||||||
34162329|NCT04014985|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34162330|NCT02255994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849417|NCT02625688|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849418|NCT00379028|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33849419|NCT01851499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849420|NCT00860847|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745353|NCT00511004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745354|NCT05742373|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomised control||||
33745355|NCT01891123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849421|NCT04871022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849422|NCT02888873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849423|NCT03534401|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The ARCHES Kenya study will take place in six IPPF-affiliated Family Health Options Kenya (FHOK) clinics in Nairobi, Kenya or surrounding smaller cities for all clients receiving voluntary FP counseling. The intervention study will involve a matched cluster control trial. Three clinics will serve as the intervention sites and three other clinics matched on client volume and demographics, clinic structure and staffing will serve as matched comparison sites and will not receive the intervention.||||
33849424|NCT05834881|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849425|NCT05205187|||CASE_CONTROL||PROSPECTIVE|||||||
34162331|NCT02862873|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34162332|NCT02722954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162333|NCT01584310|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849426|NCT04840199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849427|NCT01010191|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849428|NCT06097910|||COHORT||PROSPECTIVE|||||||
33849429|NCT00345527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849430|NCT00561782|||CASE_CONTROL||PROSPECTIVE|||||||
33849431|NCT00019552||||TREATMENT||||||||
33849432|NCT02259647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849433|NCT05303259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849434|NCT03698812|||COHORT||PROSPECTIVE|||||||
33849435|NCT05128383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849436|NCT03039101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33849437|NCT01873560|||COHORT||PROSPECTIVE|||||||
33849438|NCT05548140|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849439|NCT01656733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849440|NCT01045408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849441|NCT05614986|||COHORT||PROSPECTIVE|||||||
33849442|NCT02949804|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33849443|NCT04639271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849444|NCT03991702|||COHORT||PROSPECTIVE|||||||
33849445|NCT00003493||||TREATMENT||||||||
33849446|NCT02882529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33849447|NCT03596333|||CASE_ONLY||RETROSPECTIVE|||||||
33849448|NCT05080816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Persons responsible for genomic/transcriptomic/proteomics analyses are blinded. All samples are coded.||f|f|f|t
33849449|NCT00297232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849450|NCT05149053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849451|NCT01763801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33954327|NCT05870566|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, open randomized parallel-group trial||||
33954328|NCT01880918|||||RETROSPECTIVE|||||||
33954329|NCT06647446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954330|NCT06652321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954331|NCT00912327|||COHORT||PROSPECTIVE|||||||
33954332|NCT04540172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954333|NCT06566001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954334|NCT03960268|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open Label Single Arm Study||||
33849452|NCT04847193|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33849453|NCT01174732|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33849454|NCT03407560|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33954335|NCT03963960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954336|NCT00256841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954337|NCT04700813|||COHORT||PROSPECTIVE|||||||
33954338|NCT02930538|||COHORT||PROSPECTIVE|||||||
33954339|NCT06259760|||CASE_CONTROL||PROSPECTIVE|||||||
33954340|NCT02246855||||TREATMENT||||||||
33954341|NCT06288490|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of concept: treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL)||||
33954342|NCT05432739|||COHORT||PROSPECTIVE|||||||
33954343|NCT01815372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954344|NCT06548529|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954345|NCT00991211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954346|NCT00003452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954347|NCT03940898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058390|NCT04606823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058391|NCT00824876|||||PROSPECTIVE|||||||
34058392|NCT04300452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants will be unaware of the treatment they will receive as well as the care provider responsible for its administration|The parturients will be divided in two groups: the group to which carbetocin will be administered and the group to which ergometrin will be used as the main uterotonic drug. Randomization will be achieved with the help of a computer and the method ¨sealed envelope¨. In this method the investigator receives a sealed envelope either by mail or by computer, in which a random number will be placed. This number will correspond to one of the treatments. For greater relialibility in the results some exclusion criteria will be set.|t|t|f|f
34058393|NCT05451875|||CASE_ONLY||RETROSPECTIVE|||||||
34058394|NCT04216446|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058395|NCT04316442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849455|NCT00069108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849456|NCT01869127|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849457|NCT03573687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The supplements will be made by a third party person and premixed, taste-matched, and provided in opaque shaker bottles.|Randomized, crossover, double-blind, acute study with two conditions: nighttime PRO consumption (NP) and daytime PRO consumption (DP).|t|f|t|f
33849458|NCT04488627|||CASE_ONLY||PROSPECTIVE|||||||
33849459|NCT02433340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849460|NCT05748223|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33849461|NCT04679480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849462|NCT05565027|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Lung volume measurements using the test and reference devices were clearly different and could not be blinded to subjects and investigators, so an open trial design was used.|The subject stood on the turntable of the instrument and grasped the postural fixator with both hands up. The subjects pinched their nose and breathed through the disposable filter mouthpiece connected to the pneumotachograph, taking care not to leak air at the corners of the mouth. The subjects were instructed to perform tidal breathing, deep inhalation, deep exhalation, etc., and to perform dynamic DR photography and pneumotachograph monitoring simultaneously. At the end of the examination, assist the subjects to leave the examination equipment and re-measure their vital signs.||||
33849463|NCT04931082|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33849464|NCT01912677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849465|NCT04898439|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Children will know whether their school is having more nature|We have 2 groups: an intervention group that includes children from school that will have more nature in its environment and a control school||||
33849466|NCT00493298|||COHORT||PROSPECTIVE|||||||
33849467|NCT03955523|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Case series: intraindividual analyses comparing single exercise trial vs single diet trial vs control (doing nothing)||||
33849468|NCT03463161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of 2 study groups based on response to prior therapy.||||
33954348|NCT05109169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Lifestyle intervention: participants will not be told to what intervention group they have been assigned and outcome assessors will be blinded to the lifestyle intervention group allocation.~Metformin/placebo treatment within the FINGER 2.0 intervention group: double blind."|"Participants are initially randomized 1:1 to two parallel arms:~* self-guided multidomain lifestyle intervention~* FINGER 2.0 multidomain lifestyle-based intervention~Participants in the FINGER 2.0 intervention who are eligible for metformin treatment will be further randomized 1:1:1 to either:~* metformin 2000mg/day~* metformin 1000mg/day~* placebo"|t|t|t|t
33954349|NCT04723667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors were blinded|This study aims to evaluate the effects of a 13-week empowerment-based psycho-behavioral program to improve neuropsychiatric symptoms, cognitive functions, and health-related quality of life among persons with mild cognitive impairment. A feasibility pilot study will be first evaluated in a pilot study among 30 participants with MCI and subsequently a full-scale randomized controlled trial will be conducted.|f|f|f|t
33954350|NCT01065545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954351|NCT03458039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the trainings, masking of AYA participants is not possible. Outcomes assessors who evaluate counselor competency will be masked to the randomization scheme. Data analysts will be masked.|Adolescents and young adults (AYA) with indicated mental health or behavioral health problems will be randomized to either the in-person CETA (n = 150), T-CETA (n=150), or treatment as usual condition (n = 100), for a total of 400 AYA participants. Each counselor will be trained in both CETA and T-CETA delivery methods.|f|f|f|t
33745356|NCT06055296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will use a Hybrid 1 design that combines a randomized effectiveness trial and a mixed methods observational implementation evaluation. Hybrid designs assess both clinical effectiveness and implementation, thus bridging the gap between two research areas.||||
33745357|NCT06582615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel design with optional cross-over of the control group to the treatment group after 6-month follow-up.||||
33745358|NCT04001465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745359|NCT04144673|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel study|t|t|t|t
33745360|NCT04178551|NA|SINGLE_GROUP||TREATMENT||NONE||The VHA Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment (CONDUIT) will improve access to evidence-based MOUD and advance the science of implementation by providing an integrated, multidisciplinary approach to implementation of evidence-based MOUD across the continuum of care in VHA. CONDUIT implementation teams incorporate expertise from addiction medicine and addiction psychiatry, primary care and hospital medicine, implementation science and health economics. The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.||||
33745361|NCT02765932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745362|NCT04195503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745363|NCT04846504|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Hybrid type III effectiveness implementation model testing implementation strategies at the individual and OB clinical level. Individual level strategies involve randomizing participants to receive telephonic coaching by professional or peer coach. Clinic level strategies involve randomizing OB clinics to use printed materials and/or electronic medical record prompts to recommend/refer participants to the Mindful Mood Balance for Moms (MMB4M) program or to usual care with no recommendations/referrals to the MMBFM program.||||
33745364|NCT00274534|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33745365|NCT04469179|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33745366|NCT05807711|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, single-center, randomized controlled trial||||
33745367|NCT00744653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849469|NCT05860660|||COHORT||PROSPECTIVE|||||||
33849470|NCT04609306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will then be randomized 1:1 into Experimental or Control cohorts.|Two group parallel study|t|f|f|f
33849471|NCT02848287|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33849472|NCT05519098|||CASE_ONLY||PROSPECTIVE|||||||
33849473|NCT03261700|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|For the RCT (Aim 3), participants will be randomized to RISE or an information and referral condition.||||
33849474|NCT04849494|||COHORT||CROSS_SECTIONAL|||||||
33849475|NCT00113945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849476|NCT03870347|||COHORT||PROSPECTIVE|||||||
33745368|NCT04279795|||COHORT||PROSPECTIVE|||||||
33745369|NCT00360308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745370|NCT00918359|||CASE_ONLY||PROSPECTIVE|||||||
33745371|NCT03845348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745372|NCT04619641|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745373|NCT04880759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745374|NCT01056224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745375|NCT01367184|||COHORT||PROSPECTIVE|||||||
33745376|NCT05802459|||COHORT||PROSPECTIVE|||||||
33849477|NCT03981562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is double blinded, the investigators and the patients throughout the data collection and data analysis period will not be aware of the vitamin D dosage given.|Patients included in the study will be randomized. Block randomization will be utilized to ensure an equal number of experimental and control patients are in each arm. A closed envelope system will be used to randomize participants within each arm.|t|f|t|f
33849478|NCT04280302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849479|NCT04072692|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33849480|NCT05128461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups as exercise group and control group|t|f|f|t
33849481|NCT01990729|||COHORT||PROSPECTIVE|||||||
33849482|NCT05417022|||COHORT||PROSPECTIVE|||||||
33849483|NCT00600886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849484|NCT01094210|||CASE_CROSSOVER||PROSPECTIVE|||||||
33849485|NCT01694173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849486|NCT04191473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745377|NCT04071938|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33745378|NCT03887377|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|The injector, patient, and outcome assessor will be blinded to the treatment side and placebo side of injection.|Each patient will serve as their own control as one breast incision will be injected with botulinum toxin type A while the other will receive placebo.|t|t|f|t
33745379|NCT03894449|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33745380|NCT04172792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745381|NCT01968213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745382|NCT06636344|||CASE_ONLY||OTHER|||||||
33745383|NCT00003011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745384|NCT04733560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are surgeons are blinded to the contents of the injections (either local anesthetic or saline). Allocations will be revealed after all data is collected at the time of data analysis.|Randomized control trial|t|t|f|f
33745385|NCT01437449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745386|NCT03858400|||OTHER||OTHER|||||||
33745387|NCT02103439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745388|NCT06534268|||CASE_ONLY||PROSPECTIVE|||||||
33745389|NCT03262129|||COHORT||PROSPECTIVE|||||||
33745390|NCT05542355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A: None (Open-label). Part B: Double-blind.|Part A = Single Arm open label. Part B = Randomised, placebo-controlled, double-blind.|t|f|t|t
33745391|NCT05108337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745392|NCT00935025|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33745393|NCT06635655|||CASE_CROSSOVER||PROSPECTIVE|||||||
33849487|NCT05951985|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal with assessments occurring quarterly over the course of two years||||
33849488|NCT02679027|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33849489|NCT00641901|||CASE_ONLY||PROSPECTIVE|||||||
33849490|NCT03966768|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial||||
33849491|NCT02865837|NA|SINGLE_GROUP||OTHER||NONE||||||
33745394|NCT04977167|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745395|NCT04034433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33745396|NCT03478891|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745397|NCT04445818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The person recruiting participants and the participants enrolled are not blinded to the allocation status. Double blinding in cluster RCTs for psychosocial or behavioural interventions is often difficult to implement.|This study is a cluster randomised controlled trial with three arms: more appreciation arm (MA), less criticism arm (LC), and more fruit and vegetable arm (FV).||||
33745398|NCT04950699|||CASE_CONTROL||RETROSPECTIVE|||||||
33849492|NCT02168829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849493|NCT00602940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849494|NCT04638595|||COHORT||CROSS_SECTIONAL|||||||
33849495|NCT05462158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954352|NCT04244162|||COHORT||PROSPECTIVE|||||||
33745399|NCT03851653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745400|NCT04145752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective, randomized, controlled, open label trial||||
33745401|NCT04321720|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33745402|NCT02423473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745403|NCT03984669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745404|NCT06171113|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33745405|NCT04478279|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.||||
33745406|NCT05202561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745407|NCT04399629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745408|NCT04898335|||COHORT||PROSPECTIVE|||||||
33745409|NCT03348891|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33745410|NCT01343368|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745411|NCT06183801|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33745412|NCT00793416|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849496|NCT06324604|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"Part A will enroll Healthy Adult Volunteers will be randomized, double-blind, placebo-controlled, single ascending dose (SAD), randomized to MTX-101 or placebo in a 1:1 ratio for the first 2 participants (sentinel dosing) and a 3:1 ratio thereafter. Participants in the multiple ascending dose (MAD) will be randomized in a 3:1 ratio and be dosed on Days 1 and 22 for a total of 2 doses.~Part B of this study plans to enroll at least 24 (up to 40) participants with Celiac Disease or Type 1 Diabetes, randomized in a 1:1 ratio, in a crossover design, dosed with MTX-101 or placebo on Days 1 and 22 for a total of 2 doses"|t|t|t|f
33849497|NCT04673253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33849498|NCT03056027|||CASE_ONLY||PROSPECTIVE|||||||
33849499|NCT01886378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849500|NCT05834439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33849501|NCT00712673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849502|NCT05422404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849503|NCT03744104|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33849504|NCT06138314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849505|NCT04625387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849506|NCT00431080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849507|NCT00069485|||DEFINED_POPULATION||PROSPECTIVE|||||||
33849508|NCT06063018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849509|NCT03955796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849510|NCT02903264|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33954353|NCT05119556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded adjudication committee will evaluate all hospitalizations.|This is a 52 week, prospective, randomized controlled, phase 3, multi-center clinical trial.|f|f|f|t
33954354|NCT06647940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954355|NCT05560594|NA|SINGLE_GROUP||OTHER||NONE||"Explore the behavior of the urinary bladder and prostate during emptying the bladder with an intermittent catheter.~By use of 3D scanning techniques and dynamic MRI, the objective is to investigate behavior of bladder emptying using an intermittent catheter compared to the voluntary bladder emptying."||||
33954356|NCT06537505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954357|NCT06411782|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a cross-controlled study. Inspiratory muscle training (IMT) training will be performed on the subjects, and then FR will be applied to the Right SCM muscle. A 1 week purification period will be given. Later, after the IMT study, FR will be applied to the Left SCM muscle. All evaluation parameters will be repeated before and after the applications.||||
33954358|NCT01711034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954359|NCT03687580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The active and sham devices are externally identical and emit the same guiding light. The only difference is that the sham does not emit the therapeutic near infrared rays. However, since near infrared laser light is invisible to the human eye, the treatment allocation cannot be determined.|Single center, Prospective, Double Blind, Randomized, Sham-Controlled, Parallel Group, Superiority comparison|t|t|t|f
33954360|NCT00632138|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33954361|NCT06543251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954362|NCT01902992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954363|NCT03397940|||COHORT||PROSPECTIVE|||||||
33954364|NCT02288650|RANDOMIZED|PARALLEL||||NONE||||||
33954365|NCT03170271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954366|NCT05409157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954367|NCT02491086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849511|NCT05820165|||COHORT||PROSPECTIVE|||||||
33849512|NCT01644279|||COHORT||CROSS_SECTIONAL|||||||
33849513|NCT04989465|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849514|NCT00309959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849515|NCT02762149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849516|NCT04678999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33849517|NCT02407301|||COHORT||PROSPECTIVE|||||||
33849518|NCT03073954|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33849519|NCT04493502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849520|NCT01008319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954368|NCT04917406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954369|NCT06415669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058396|NCT02678585|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745413|NCT06106477|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33745414|NCT01465893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745415|NCT01829269|||COHORT||PROSPECTIVE|||||||
33849521|NCT02876159|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849522|NCT00510640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849523|NCT05697952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849524|NCT04147117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849525|NCT02415452|||COHORT||RETROSPECTIVE|||||||
33849526|NCT05241002|||COHORT||PROSPECTIVE|||||||
34162334|NCT03343834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|"1 population divided in 2 groups: Retrospective study (n=80): Patient who underwent HSCT, in Saint-Antoine hospital, between 2010-2015, treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).~Prospective study (n=58): Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière, in 2016-2017, treated by rituximab for high level EBV-DNAemia (above 10 000c/mL), And/or having post-transplant lymphoproliferative diseases(PTLD) Concerned population Allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients with a high Epstein-Barr virus (EBV) viral load"|||||
34162335|NCT05137028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954370|NCT06651372|||COHORT||RETROSPECTIVE|||||||
33745416|NCT06669988|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study will include students from both nutrition and non-nutrition departments. Participants will engage in one of three teaching modes: VR group, video group, or written materials group, all focusing on hygiene safety during food service and equipment operation. In the VR group, participants will wear virtual reality headsets for immersive learning in a 3D space with interactive scenarios, simulating a large-scale food service environment. In the video group, participants will watch a 2D video featuring similar scenarios to the VR experience but without interactive elements. The written materials group will receive content through static photos and text, lacking dynamic visuals or immersive experiences.||||
33954371|NCT03387423|||COHORT||PROSPECTIVE|||||||
33954372|NCT06065631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be given either glasses or a prescription. Hence, they could not be masked.~The Care Provider, in our case, screening and examination team will be providing either glasses or prescriptions to the participants. Hence, they could not masked.~Investigators and Outcome assessor will only analyse the data at the end of the trial and they will not be"|All eligible children will be randomized by school to receive at the start of the school year either: free ready-made or custom eyeglasses (Intervention), or an eyeglasses prescription and letter to parents, with free eyeglasses at endline (Control). The clusters (schools) will be stratified into groups based on the prevalence of refractive error and on the score on the baseline mathematics and reading exams. The division of the sample into schools in the two cities (Bo and Freetown) will be in the same proportion as the proportion of the number of public schools in those two cities.|f|f|t|t
33954373|NCT01950325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954374|NCT03434873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954375|NCT01655173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954376|NCT03922984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954377|NCT06651138|||COHORT||PROSPECTIVE|||||||
33954378|NCT05479734|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33954379|NCT06520735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954380|NCT06168201|||COHORT||OTHER|||||||
33954381|NCT00665613|||CASE_ONLY||RETROSPECTIVE|||||||
33954382|NCT02776215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954383|NCT06359093|||OTHER||CROSS_SECTIONAL|||||||
33954384|NCT00381667|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33954385|NCT05087173|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33954386|NCT03409328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954387|NCT01145573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954388|NCT05602025|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, multicenter, open-label study in healthy adult participants.||||
33954389|NCT03176628|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Placebo capsules are identical in appearance to active agent.|Randomized 5 subjects in active arm (Basis) : 1 subject in control (placebo)|t|t|t|f
33954390|NCT05753085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single-centre, prospective, non-randomized, open-label feasibility study of the Conavi Medical Novasight Hybrid System (IVUS and OCT) for stent optimization and atheroma assessment in patients who present with non-ST elevation myocardial infarction (NSTEMI).||||
33745417|NCT02171468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745418|NCT04589923|||COHORT||PROSPECTIVE|||||||
33745419|NCT00142480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954391|NCT05255861|||OTHER||RETROSPECTIVE|||||||
33954392|NCT00864604|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33954393|NCT06653322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954394|NCT04120701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954395|NCT03881605|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized controlled trial||||
33954396|NCT04048616|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||double blind randomized placebo controlled 2x2 factorial design|t|t|t|t
33954397|NCT00011999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954398|NCT05888818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There is an experimental and a control group.The distribution of the patients to the groups was made according to the random numbers table obtained by using the index formulas and randomly in the excel program in the web environment.|f|f|t|f
33954399|NCT03431285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study. The study solution will be prepared in identical 100-ml Normal Saline bags by the research nurse||t|t|f|t
34162336|NCT05484011|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 + 3 de-escalation design||||
34162337|NCT00149903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162338|NCT02682732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162339|NCT03553524|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34162340|NCT04571502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome Assessors will not be involved with the intervention implementation and study participants will be asked not to reveal their group assignment.||f|f|f|t
34162341|NCT06334887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"A parallel randomized controlled trial (RCT) with two arms: experimental group (use of esTOCma) and control group (untreated) will be carried out.~As participants enroll in the study, those that meet the inclusion criteria will be randomized into experimental or control group and into contamination or aggressive vignette (see Outcome Measures). Everyone will complete the baseline measures (T1). Then, those assigned to experimental group will use the app esTOCma until they finish it (they will be given a 10-days deadline), whereas control group will do nothing for 10 days. After that, all the participants will complete again the assessment instruments (T2)."|t|f|f|f
34162342|NCT04977401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A computer-based block randomization scheme will be created using block randomization and stratifying by center and by organ type (stomach/rectum). Data will be collected through a printed CRFs and then anonymized and entered into a central web based secured platform.|"A multicentric, randomized, open label prospective study:~* All subjects with indications of gastric and rectal ESD undergo screening and baseline visit~* Informed consent is obtained when scheduling the ESD procedure~* Randomization is made at the time of the ESD procedure after confirmation of the indication~* ESD is performed using a 25 G needle, a dual-knife-J with glycerol (standard solution) or ORISETM gel in order to remove the lesion en-bloc. Additional saline injection through the electrosurgical knife will be left at the discretion of the endoscopist~* A follow-up visit is scheduled at 2-4 weeks"|t|f|f|f
33849527|NCT04364243|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be informed, instructed and provide consent to the study assistant, while assessments will be taken by a measurement assistant, blinded to the group assignment. Data which is not collected in all groups (e.g. intervention adherence) will be collected and managed by the study assistant.|2 x 2. Stratified randomization are used to assign patients to groups A and B and participants not receiving treatment to groups C and D. Participants are stratified by an average height.|f|f|f|t
33849528|NCT05307601|||COHORT||PROSPECTIVE|||||||
33849529|NCT02571647|||COHORT||PROSPECTIVE|||||||
33849530|NCT01035073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849531|NCT01219868|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849532|NCT03727555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849533|NCT05734898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849534|NCT02622009|||CASE_CONTROL||PROSPECTIVE|||||||
33849535|NCT02140281|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33849536|NCT03867032|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849537|NCT02984202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954400|NCT01915498|NA|SEQUENTIAL||TREATMENT||NONE||||||
33954401|NCT06062758|NA|SINGLE_GROUP||OTHER||NONE||Simulation training will consist of three stages. The first stage is preliminary preparation. At this stage, students who review the resources identified and come prepared for the simulation scenario will be asked questions appropriate to the simulation objectives to help them remember the subject. In the second stage, the simulation will be realized. A high-fidelity mannequin/simulator will be used during the simulation, and the responsible faculty will give patient responses in the cabin. While the students taking roles during the simulation provide care to the patient, other group members will watch their teammates in the cabin or in a The simulation will be finalized by discussing the critical points of the case, the care to be given, communication skills and patient safety.||||
33954402|NCT01038700|||COHORT||PROSPECTIVE|||||||
33954403|NCT05935618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954404|NCT03664388|||COHORT||RETROSPECTIVE|||||||
33954405|NCT05966129|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate vs. delayed pharmacogenetic testing and genotype-guided pain or depression therapy||||
33954406|NCT01269671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954407|NCT06164886|||COHORT||PROSPECTIVE|||||||
33849538|NCT00542243|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33849539|NCT00688103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849540|NCT04271631|RANDOMIZED|PARALLEL||OTHER||NONE|Open label|||||
33849541|NCT00001750||||TREATMENT||||||||
33954408|NCT06487182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34058397|NCT00787098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058398|NCT03722940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34058399|NCT06344533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058400|NCT00984061|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058401|NCT04855617|||COHORT||PROSPECTIVE|||||||
34058402|NCT00366119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058403|NCT06371729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058404|NCT06245447|||COHORT||PROSPECTIVE|||||||
34058405|NCT06056804|NA|SINGLE_GROUP||TREATMENT||NONE||neoadjuvant chemoradiotherapy combined with PD-1 monoclonal antibody and thymalfasin||||
34058406|NCT02395263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058407|NCT03889470|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||NTG vs Placebo|t|f|f|f
34058408|NCT06400706|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34058409|NCT02550600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058410|NCT04185935|||FAMILY_BASED||PROSPECTIVE|||||||
34058411|NCT01623973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058412|NCT06619743|||COHORT||PROSPECTIVE|||||||
34058413|NCT03410732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058414|NCT04587349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058415|NCT01647191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058416|NCT06387706|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34058417|NCT04620590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058418|NCT01729520|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34162343|NCT01387841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34162344|NCT04359160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34162345|NCT02430857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162346|NCT03237715|||CASE_CONTROL||PROSPECTIVE|||||||
34162347|NCT05900544|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental||||
34162348|NCT02848534|||COHORT||RETROSPECTIVE|||||||
34162349|NCT05933460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|No participant or personnel knew the randomization process and the only knew did not had to do with participants or administration of supplement or collecting data. The company providing the supplement did not know either.|Double blind placebo controlled randomized trial|t|t|t|t
34162350|NCT06409143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34162351|NCT01036321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162352|NCT03629522|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|an anesthesia nurse ; not included in the analysis, verified the allocation and prepared the syringe fulled with ondansetron or saline solution|Ondansetron group (group O): 8mg(10 ml) of Ondansetron administrated 5 minutes before spinal anesthesia control group (group C): saline solution 0,9%(10ml)|t|t|f|t
34162353|NCT04648683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, nonrandomized, repeated measures design||||
34162354|NCT00818051|RANDOMIZED|||TREATMENT||||||||
34162355|NCT01441726|||||PROSPECTIVE|||||||
34162356|NCT05117762|||COHORT||PROSPECTIVE|||||||
33849542|NCT05712707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.|Throughout the 7-day inpatient study, participants will receive sublingual BXCL501 or placebo twice daily and lofexidine or placebo 4 times daily using a double-blind, triple-dummy design. This study will utilize a methadone taper in order to ensure that opioid withdrawal severity is not so severe that it results in discharge immediately after enrollment (before a medication effect can be observed). Throughout the 7-day inpatient study, participants will receive: Methadone QID at 9am, 2pm, 7pm, 11pm. Total daily methadone doses: Day 1= 30mg, Day 2= 25mg, Day 3= 20mg, Day 4= 15 mg, Day 5= 10mg, Day 6= 5mg, Day 7= 0mg. On each day a PRN methadone dose of 5mg x 2, will also be available (total daily dose will not exceed 40mg).|t|f|t|t
33849543|NCT05502367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33849544|NCT05535283|||CASE_CROSSOVER||PROSPECTIVE|||||||
33849545|NCT04447664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849546|NCT02814084|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849547|NCT04783831|||CASE_CONTROL||PROSPECTIVE|||||||
33849548|NCT00031876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954409|NCT06188923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized, double-blind, placebo-controlled trial. All roles will be masked with the exception of the research pharmacist.|Participants will be randomized to receive the active study medication (pregnenolone) or placebo.|t|t|t|t
33954410|NCT02122939|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954411|NCT04733807|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33954412|NCT06565871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954413|NCT06108297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954414|NCT03869905|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This pilot study includes individuals with mild ulcerative colitis / ulcerative colitis in remission, and is a randomized, double-blind, placebo-controlled trial with two parallel treatment groups for the first 90 days. Subjects on placebo will be crossed over to Aquamin® after the halfway visit at day 90. Subjects on Aquamin® will continue their treatment until the end.|t|f|t|t
34162357|NCT04131946|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Experimental and Standard of care arms||||
34162358|NCT02133781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34162359|NCT03027401|||CASE_ONLY||PROSPECTIVE|||||||
34162360|NCT06080633|||CASE_ONLY||RETROSPECTIVE|||||||
34162361|NCT01011140|||OTHER||PROSPECTIVE|||||||
34162362|NCT03859271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162363|NCT00007358|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34162364|NCT05330832|||COHORT||PROSPECTIVE|||||||
33849549|NCT04062487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849550|NCT01191502|||CASE_CONTROL||RETROSPECTIVE|||||||
34162365|NCT06727344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162366|NCT06275386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849551|NCT05803655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Only the head-nurse and the patient will not be masked, since one will randomize the patient to a group and give her instructions on how to use the medication, and the other will apply the injection herself.~However, allocation will be concealed from the the laboratory team, treating physicians, outcome assessors and investigators. They will not be given information about when the patient applied the injection, and the patient will be instructed not to reveal information regarding her use."|The patient will be randomized to either ''36 hour'' or ''38 hour'' group on the day of ovulation trigger. According to her allocation, she will apply the injection. Except for the difference in the interval between ovulation trigger and oocyte pick-up procedure, women in both arms will undergo exactly the same treatment steps.|f|t|t|t
33954415|NCT05465122|||COHORT||PROSPECTIVE|||||||
33954416|NCT00962013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849552|NCT04767139|||OTHER||PROSPECTIVE|||||||
33849553|NCT02819154|||COHORT||PROSPECTIVE|||||||
33954417|NCT04559776|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||cross-sectional study with 2 groups of toddlers (with typical developing and with unilateral cerebral palsy) recorded twice in gait analysis within 30 days interval||||
33954418|NCT03833934|||COHORT||PROSPECTIVE|||||||
33954419|NCT03191409|||COHORT||PROSPECTIVE|||||||
33954420|NCT06652126|||COHORT||PROSPECTIVE|||||||
33954421|NCT06568380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33954422|NCT00886873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954423|NCT02157181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954424|NCT06159699|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33954425|NCT02461147|||COHORT||PROSPECTIVE|||||||
33954426|NCT03024359|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||All subjects receive a dietary intervention with olive oil.||||
33954427|NCT00163371|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33954428|NCT04512105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954429|NCT03105076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33954430|NCT04755426|||COHORT||PROSPECTIVE|||||||
33954431|NCT04566094|||COHORT||RETROSPECTIVE|||||||
33954432|NCT05041868|NA|SINGLE_GROUP||TREATMENT||NONE||Women with Scleroderma will use a booklet-guided rehabilitation program that lasts three months (3 times per week with a duration of 60 minutes per session). Consisting of stretching, warm-up and cool-down exercises, muscle strengthening (flexion, extension, adduction, and abduction movements in exercises involving open and closed kinetic chains), endurance exercises, aerobic training, balance training and proprioception. The patient will be evaluated at 2 different timepoints (baseline and after 12 weeks of training). The physiotherapist contacts the patient by phone weekly to follow the progression of the treatment. Before and after the intervention, patients will be submitted to the following assessments: Cochin Hand Functional Scale (CHFS), Short-Form 36 Health Survey (SF-36); Scleroderma Health Assessment Questionnaire Disability Index (SHAQ-DI); lung function; lung ultrasound; handgrip; Glittre Activities of Daily Living test.||||
33954433|NCT03606109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954434|NCT05876039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33954435|NCT03888898|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954436|NCT01079572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33954437|NCT05666765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective controlled||||
33954438|NCT05601414|NA|SINGLE_GROUP||PREVENTION||NONE||Each visit will take at most 2 hours to complete study exercises. 15 Participants will have the option to complete study procedures twice more, spaced one week apart, for a total of three weeks of participation.||||
33954439|NCT04355767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954440|NCT02194959|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954441|NCT05494151|||COHORT||PROSPECTIVE|||||||
33954442|NCT06318975|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954443|NCT00682097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954444|NCT01773499|||COHORT||PROSPECTIVE|||||||
33954445|NCT06262581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954446|NCT05457829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954447|NCT00036556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33954448|NCT06201494|||COHORT||PROSPECTIVE|||||||
33954449|NCT04548336|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33954450|NCT01454167|||||PROSPECTIVE|||||||
33954451|NCT01736527|NA|SINGLE_GROUP||||NONE||||||
33954452|NCT00423501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954453|NCT06450522|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954454|NCT02353572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954455|NCT06653205|||COHORT||RETROSPECTIVE|||||||
33954456|NCT05046275|||COHORT||RETROSPECTIVE|||||||
33954457|NCT04406272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954458|NCT05940571|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954459|NCT02190968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33954460|NCT02185027|||COHORT||PROSPECTIVE|||||||
33954461|NCT05582655|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Independent evaluators as well as outcome coders will be blinded to time point and treatment condition||f|f|f|t
33954462|NCT06653673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is planned to be conducted as a Randomized Controlled Trial (RCT).|f|f|f|t
33954463|NCT05372211|||OTHER||CROSS_SECTIONAL|||||||
33954464|NCT03914209|||COHORT||PROSPECTIVE|||||||
33954465|NCT02943369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058419|NCT01433068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058420|NCT01038596|||CASE_CONTROL||PROSPECTIVE|||||||
34058421|NCT04890977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058422|NCT00713661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058423|NCT04489394|||COHORT||RETROSPECTIVE|||||||
34058424|NCT02994758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058425|NCT02308813|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058426|NCT00387010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058427|NCT02529904|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34162367|NCT04498143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Random assignment to condition will be conducted in a triple-masked manner. Participants will be masked to whether they received active treatment and investigators will be masked to which condition the participant is randomized to-as the randomization occurs automatically within the Qualtrics survey. Additionally, as the primary and secondary outcomes are self-report measures, we will not be utilizing an outcomes assessor (e.g. a clinical interviewer).|We will use a between-subjects design. Adolescents (13-16) recruited online via social media who report elevated self-hate and past month engagement in nonsuicidal self-injury will be randomized to the SAVE (active) or psychotherapy support (control)-SSI.|t|f|t|t
34162368|NCT01112787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33954466|NCT06454695|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Most questionnaires will be self-reported via Castor EDC. Only a screening interview will be administered by researchers online.|The design is a randomized, controlled, pragmatic, multicenter, pilot trial. Adult patients with major depressive disorder will be randomized (1:1) to either treatment as usual (TAU) only, or TAU with future-oriented imagery rescripting.|f|f|f|t
33954467|NCT00940329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954468|NCT06561945|||COHORT||PROSPECTIVE|||||||
33954469|NCT06538779|||CASE_ONLY||PROSPECTIVE|||||||
33954470|NCT00644527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33954471|NCT01915485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954472|NCT06653296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954473|NCT02504060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162369|NCT03801174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162370|NCT02255344|||COHORT||PROSPECTIVE|||||||
33954474|NCT05805293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162371|NCT04137731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34162372|NCT01631994|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34162373|NCT04057807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162374|NCT06295861|||COHORT||PROSPECTIVE|||||||
33745420|NCT04279249|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||"This study is a randomized crossover trial, in which study participants are randomly assigned (by computer) to different arms of the study in which they receive different interventions - in this case, either the HEPA air filter or the sham filter. The two arms will run concurrently, rather than sequentially.~Primary Outcome Measures will be measured concurrently, rather than at separate time points (i.e., blood pressure and blood samples will both be taken at study onset, 30 days, 60 days and 90 days) and therefore fall within the same time points."|t|f|f|t
33745421|NCT00206648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745422|NCT00982462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745423|NCT04608474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study model involves two groups. One group is for patients who are treated exclusively with Evolocumab while the second group involves patients who are treated using a combination of Evolocumab and a statin-based drug.||||
33745424|NCT02945085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745425|NCT06588491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745426|NCT03360461|NA|SINGLE_GROUP||TREATMENT||NONE||Single-centre stage IIa developmental study, Open label, single arm, non-randomised feasibility study.||||
33745427|NCT06052501|||CASE_ONLY||PROSPECTIVE|||||||
33745428|NCT02633384|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745429|NCT04939480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745430|NCT03738540|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33745431|NCT04377646|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Random blind allocation.|Double blind randomized clinical trial with 3 arms|t|t|t|f
33745432|NCT06163755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33745433|NCT01343511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745434|NCT01435577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745435|NCT04265755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954475|NCT05100277|||COHORT||PROSPECTIVE|||||||
33954476|NCT02418338|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954477|NCT00000868||||PREVENTION||DOUBLE||||||
34162375|NCT02089074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162376|NCT00645021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162377|NCT04674722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162378|NCT00346788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162379|NCT06360848|||COHORT||RETROSPECTIVE|||||||
34162380|NCT00330005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162381|NCT02125084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954478|NCT04962659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954479|NCT02780817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954480|NCT05439135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849554|NCT06088147|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954481|NCT04649151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part 1A is observer-blind. Participants will remain blinded until the initiation of Part 1B.||t|t|t|t
33954482|NCT02922231|||CASE_ONLY||PROSPECTIVE|||||||
33849555|NCT06347289|||OTHER||PROSPECTIVE|||||||
33954483|NCT03233659|||COHORT||PROSPECTIVE|||||||
33954484|NCT05227937|||CASE_ONLY||PROSPECTIVE|||||||
33954485|NCT01233349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954486|NCT06565975|||COHORT||RETROSPECTIVE|||||||
33954487|NCT05446116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954488|NCT00408135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954489|NCT06286813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Interventional research with two parallel groups (almond olive group and virgin olive oil group) and no control group.||||
33954490|NCT01924572|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33954491|NCT06343922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group 1 will receive exercises by using oral motor facilitation technique protocol three times a week Group 2 will receive traditional oral motor exercises three times per week|t|f|f|f
33954492|NCT02719639|||OTHER||PROSPECTIVE|||||||
33954493|NCT01917175|||COHORT||PROSPECTIVE|||||||
33954494|NCT02098434|NA|SINGLE_GROUP||OTHER||NONE||||||
33954495|NCT00310869|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33954496|NCT00075465||||TREATMENT||NONE||||||
33954497|NCT00448110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954498|NCT06540430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The intervention group will use a mobile application where patients input their stoma condition, allowing healthcare professionals to monitor and manage their care.~The control group consists of patients who received conventional outpatient-based stoma care without using the application service."||||
33954499|NCT01901393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954500|NCT03281005|||CASE_CONTROL||PROSPECTIVE|||||||
33849556|NCT05607537|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849557|NCT00555724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849558|NCT05514041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Change in Cassini surface qualifier image analysis from baseline (pre-administration) to post-administration of OC-01 (varenicline solution) nasal spray as measured by a masked evaluator||t|f|f|t
33849559|NCT05513157|||COHORT||PROSPECTIVE|||||||
33849560|NCT06440135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954501|NCT00245258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33954502|NCT06282250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954503|NCT05909007|||COHORT||RETROSPECTIVE|||||||
33954504|NCT00170898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33954505|NCT02894060|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954506|NCT04761523|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Doctors caring for the participants and assessors of all other outcomes (laboratory parameters, BMI, blood pressure, adverse events) as well as statisticians handling the data will be blinded to the participants' allocated group. Outcome assessors will be not avare of the allocated interventions.||f|t|f|t
33954507|NCT05773924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058428|NCT04221620|NA|SINGLE_GROUP||TREATMENT||NONE|Co-PI Catherine Young will be completing all evaluations and de-indentification of study participants. I (Lauren Hall) will be working with the de-identified data.|One single group of 30 pediatric participants will undergo 20 sessions of traditional occupational therapy services while receiving EEG neurofeedback within each session. Standardized assessment will be administered at the beginning of the session and at the end of 20 sessions to compare differences between executive functioning skills.||||
34058429|NCT00877955|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34058430|NCT00380666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058431|NCT02737228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058432|NCT05637970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058433|NCT02286648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058434|NCT05519488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This 3-week longitudinal study will include 200 patients from St. Elizabeth's Medical Center who have scheduled appointments for cancer restaging. Participants will be randomized into one of two groups: a) an intervention group, in which patients will listen to music using Rubato Life app, and b) a control group, in which patients listen to music of their own choice that they believe to be stress reducing. Patients in both groups will be asked to listen to at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study. Patients will be asked to complete assessments of anxiety (STAI-S) prior to randomization, on the day of their restaging, and following one hour of post-restaging music listening.|t|t|f|f
34058435|NCT00616980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058436|NCT02400567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058437|NCT03863704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be given two possible anatomic sites to apply nerve stimulation, one of which is known to induce vagal nerve stimulation and the other does not.||t|f|f|f
34058438|NCT02928770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058439|NCT05818241|||CASE_CONTROL||PROSPECTIVE|||||||
34058440|NCT04053985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058441|NCT06305312|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058442|NCT00509379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058443|NCT04801472|NA|SINGLE_GROUP||OTHER||NONE||||||
34058444|NCT05288296|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058445|NCT02122770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058446|NCT01382225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33436884|NCT05861024|||COHORT||RETROSPECTIVE|||||||
33849561|NCT03866473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Optical coherence tomography technicians and visual acuity testers, including refractionists, will be masked to treatment group at outcome visits. Study participants will be masked to their treatment group assignment. Every effort will be made to keep investigators masked. Study coordinators who will be involved with training and compliance assessment will not be masked to treatment group|Random assignment (1:1) to photobiomodulation (PBM) or sham|t|t|t|t
33849562|NCT01045343|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849563|NCT00598273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849564|NCT01058031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849565|NCT01986673|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849566|NCT02011373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849567|NCT05413109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849568|NCT05142852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849569|NCT01140698|||COHORT||PROSPECTIVE|||||||
33849570|NCT06074276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849571|NCT00638352|||COHORT||RETROSPECTIVE|||||||
33849572|NCT01981395|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33849573|NCT02538159|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33849574|NCT04466995|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Endotracheal tube pressure will be measured in the surgical technique using 2 different methods.(laparoscopic and laprotomic)|t|f|t|t
33849575|NCT02930031|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33849576|NCT05421247|||COHORT||OTHER|||||||
33849577|NCT01049217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849578|NCT04545229|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this pilot study, no masking was implemented.|Three-group RCT||||
33849579|NCT06181760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical placebo|Randomized, double-blind, placebo controlled|t|t|t|t
33849580|NCT01455805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849581|NCT03837210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849582|NCT01027182|NA|SINGLE_GROUP||||NONE||||||
33849583|NCT04259944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849584|NCT04903041|||COHORT||PROSPECTIVE|||||||
33849585|NCT02090036|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33849586|NCT01242826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849587|NCT03769662|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single dose study||||
33849588|NCT02938091|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33849589|NCT04072042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Radiological Assessment of tumor will be independently reviewed by outcome assessor, who is blinded to patient biomarker status|In each of the treatment arm, we recruit patients according to the biomarker status and hypothesize that the anti-angiogenic therapeutic efficay would be higher than historical control as a biomarker-driven approach.|f|f|f|t
33849590|NCT05002829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849591|NCT04984434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849592|NCT01164644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849593|NCT02055196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849594|NCT03700112|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33849595|NCT02842827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849596|NCT04565847|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|albutamol or placebo will be delivered following a mannitol cough challenge in a randomized, double-blind crossover design.|t|t|t|t
33849597|NCT04100031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33849598|NCT06610851|||COHORT||PROSPECTIVE|||||||
33849599|NCT03539887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
33849600|NCT01424449|NA|SINGLE_GROUP||||NONE||||||
33849601|NCT04788381|||COHORT||RETROSPECTIVE|||||||
33849602|NCT04001543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849603|NCT06337084|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33849604|NCT03812393|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm interventional clinical trial with an early check for futility using a surrogate endpoint||||
33849605|NCT05497401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849606|NCT02469272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849607|NCT00522873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849608|NCT05315765|||OTHER||PROSPECTIVE|||||||
33849609|NCT00461032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849610|NCT06212401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849611|NCT05995327|||COHORT||OTHER|||||||
33849612|NCT03192657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849613|NCT05921825|||COHORT||PROSPECTIVE|||||||
33849614|NCT01165931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849615|NCT00457912|||CASE_ONLY||PROSPECTIVE|||||||
33849616|NCT00231946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33849617|NCT01850277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849618|NCT03061071|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The technician scoring the polysomnograms will be unaware of previous PSG results from the patient to the best of their ability (ie: will not look back in their records for the purpose of reviewing their previous PSGs prior to scoring).|6 week crossover study, randomized to order of treatment|f|f|f|t
33849619|NCT03251391|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849620|NCT04369716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Conducted in 2 separate phases (1 phase/fruit) with 3 visits/phase||||
33849621|NCT01671254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33849622|NCT02197559|||COHORT||PROSPECTIVE|||||||
33849623|NCT02769403|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33849624|NCT05515003|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Nonrandomized Control Group, Pretest-Posttest Design||||
33849625|NCT01135537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849626|NCT02390245|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33849627|NCT05397834|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded study|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33849628|NCT06078865|||COHORT||PROSPECTIVE|||||||
33849629|NCT06121167|||CASE_CONTROL||PROSPECTIVE|||||||
33849630|NCT03876860|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control trial with two arms including control arm and experimental arm||||
33849631|NCT03590405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954508|NCT00745459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954509|NCT06467292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Healthy right-handed adults with normal hearing will be recruited in equal number from both sexes. All participants will be fluent English speakers.||||
33954510|NCT06652711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954511|NCT06243510|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954512|NCT02189200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954513|NCT06652009|||COHORT||PROSPECTIVE|||||||
33849632|NCT02699086|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33849633|NCT05675787|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups in parallel for the duration of the study: Control group and Experimental group;||||
33849634|NCT05342506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954514|NCT03075215|||OTHER||PROSPECTIVE|||||||
33954515|NCT02879552|||CASE_ONLY||PROSPECTIVE|||||||
33954516|NCT03232775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The medical examination teams (one chief medical resident and one nurse) will be blind to the study aim.||f|t|f|f
33954517|NCT05808907|||COHORT||PROSPECTIVE|||||||
33954518|NCT05384184|||CASE_ONLY||PROSPECTIVE|||||||
33954519|NCT01702545|||CASE_ONLY||PROSPECTIVE|||||||
33745436|NCT04974216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745437|NCT02244944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745438|NCT00189631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954520|NCT02301520|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33954521|NCT04429633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954522|NCT01354015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954523|NCT05041179|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Double-blind, randomized, Placebo-controlled|t|t|t|t
34058447|NCT06608186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|statistician|50 case in this novel trial. 25 in each group will be randomized after taking 5 days of ovarian stimulation to either drospirenone tablet/d or cetrorelix injection/d till the day of hCG.|f|f|f|t
34058448|NCT03750747|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954524|NCT04611152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For masking purposes, sham injections will be administered at every monthly visit if an active treatment is not administered. To preserve masking, two investigators are required for this study. The masked Investigator will be responsible for the examinations and safety assessments. The unmasked Investigator will perform the injections and post-treatment assessments.|Participants will be randomized 1:1 into one of two treatment arms: KSI-301 or aflibercept.|t|t|f|t
33954525|NCT01169194|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849635|NCT03599973|NA|SINGLE_GROUP||OTHER||NONE||||||
33849636|NCT01819259|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33849637|NCT00560066|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33849638|NCT01732159|RANDOMIZED|PARALLEL||||NONE||||||
33849639|NCT04132531|||CASE_CONTROL||PROSPECTIVE|||||||
33849640|NCT01245985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849641|NCT00194987|RANDOMIZED|PARALLEL||TREATMENT||NONE|participants and their physicians will know if they are receiving IVIG x 2 or IVIG x1 plus prednisone|randomization between 2 groups||||
33849642|NCT03787056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849643|NCT00081627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849644|NCT04829500|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This 4-year, stepped-wedge cluster randomized trial (SW-CRT) uses a hybrid implementation-effectiveness design, and primary and administrative data collection to pursue four aims. Randomization in this hybrid implementation-effectiveness design is at the system level (in our case the CLC) since existing staff provide the intervention. To address the research questions and corresponding aims, the study approach assesses both the clinical innovation (MAP-VA) and the implementation process itself (blended facilitation). Implementation process measures, fidelity, and outcome indicators will be tracked using a mixed methods evaluation approach.||||
33849645|NCT01029951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849646|NCT01970631|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33849647|NCT04550533|||OTHER||PROSPECTIVE|||||||
33849648|NCT02843893|NA|SINGLE_GROUP||||NONE||||||
33849649|NCT03028038|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33849650|NCT04672226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849651|NCT06609915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomised controlled trial|t|f|f|f
33849652|NCT02022189|||COHORT||RETROSPECTIVE|||||||
33849653|NCT00200993|RANDOMIZED|||PREVENTION||||||||
33849654|NCT01815138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849655|NCT04133051|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group (A): 17 cases will be subjected to bilateral Ultrasound-guided Quadratus lumborum block through bilateral catheter insertion for perioperative analgesia.~Group (B): 17 cases will be subjected to epidural catheter insertion for perioperative analgesia (as a control group).~This number is to be increased to 34 patients (17 patients in each group) to account for the necessity to use non-parametric test. Sample size was calculated using G\*Power program (University of Düsseldorf, Düsseldorf, Germany) 17, 20, 21."||||
33849656|NCT02980731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849657|NCT02866136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849658|NCT02689518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849659|NCT05900700|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33849660|NCT00795613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849661|NCT02073747|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33849662|NCT02677480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33849663|NCT05636423|||COHORT||CROSS_SECTIONAL|||||||
33849664|NCT04914299|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups: One receives a novel mobile-App based intervention and the other groups receives standard of care (psychoeducation about postpartum depression, referral and monitoring).||||
33849665|NCT00551265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954526|NCT04450316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized on a 1:1 ratio to either LDN or placebo. The randomization sequence will be logged by the study coordinator in a REDCap randomization log blinded to other research staff and clinical team and outcome assessors.|Randomized placebo-controlled pilot study|t|t|t|t
33954527|NCT06652516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33954528|NCT06064110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34162382|NCT03009474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162383|NCT01292187|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34162384|NCT04869865|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will be given the intervention||||
33849666|NCT00294203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849667|NCT00244816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849668|NCT03948165|||COHORT||PROSPECTIVE|||||||
33849669|NCT02954965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849670|NCT05378230|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The intervention trial consisted of a single-center, one-arm study with a total duration of 8 weeks, which includes 2-weeks run-in period, 4 week intervention period and 2-weeks post-intervention or wash-out period. The intervention period was divided in 4 periods of 7 days each and the treatment consisted of increasing dose of Lactobacillus plantarum AB-B (CECT 7527, CECT 7528, CECT 7529).||||
33849671|NCT04659577|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible people are enrolled to internet-based CBT for panic disorder or depression||||
33849672|NCT02133118|||COHORT||PROSPECTIVE|||||||
33849673|NCT04762121|||COHORT||PROSPECTIVE|||||||
33849674|NCT00243048|RANDOMIZED|||TREATMENT||||||||
33849675|NCT00226837|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33849676|NCT02760277|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33849677|NCT03620331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33849678|NCT04895137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849679|NCT00841555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849680|NCT04642872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849681|NCT01777451|||CASE_ONLY||PROSPECTIVE|||||||
33849682|NCT01262677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849683|NCT01249989|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33954529|NCT01505543|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33954530|NCT04753879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849684|NCT01976117|NA|SINGLE_GROUP||||NONE||||||
33849685|NCT00480376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954531|NCT05103683|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954532|NCT01939834|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33745439|NCT02594891|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745440|NCT00631423|||CASE_CONTROL||PROSPECTIVE|||||||
33745441|NCT05006625|||OTHER||CROSS_SECTIONAL|||||||
33849686|NCT03037073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33849687|NCT01613859|||||PROSPECTIVE|||||||
33849688|NCT02341131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849689|NCT01015859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849690|NCT00847925|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33849691|NCT03260218|||CASE_ONLY||PROSPECTIVE|||||||
33849692|NCT00376831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849693|NCT04049734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33849694|NCT02093559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849695|NCT04498338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849696|NCT00950326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849697|NCT00994682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849698|NCT00434213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849699|NCT02829164|||COHORT||RETROSPECTIVE|||||||
33849700|NCT00339456||||TREATMENT||||||||
33849701|NCT05664867|RANDOMIZED|PARALLEL||PREVENTION||NONE||clinical trial with a hybrid effectiveness-implementation design||||
33849702|NCT00005377|||FAMILY_BASED||RETROSPECTIVE|||||||
33849703|NCT00236093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954533|NCT03620201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954534|NCT03953157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954535|NCT03451474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954536|NCT03998852|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954537|NCT03951701|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954538|NCT00538473|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954539|NCT00663039|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33954540|NCT05762796|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The Aim 1 of the study uses a cross-sectional design. The behavioral and neuroimaging data will be collected in one or two separate visits.~The Aim 2 \& Aim 3 of the study use a cross-over design. The data will be collected in either twenty-three or twenty-four visits."||||
33954541|NCT06652568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"Though not masked, the study is double blinded. Double blinding will be ensured by the ThinkSono software, as it will not be giving any indication of diagnosis or image quality to the operator. The comparison scan will be done by a qualified imaging specialist as per the standard of care at the local institution, but they will also not know the results of the ThinkSono scan. There will also be remote qualified clinicians reviewing the ThinkSono data (separately from local staff) who also will not know the results of the local imaging specialist. Only at the final data assessment upon study completion will outcome assessors be aware of ThinkSono device results and local site imaging results."|Single arm comparison study between the ThinkSono device and standard of care venous duplex ultrasound.||||
33954542|NCT04905238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954543|NCT02902107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954544|NCT00171080|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954545|NCT05936788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be 2 groups i.e. group A will receive active cycle of breathing technique (ACBT) and group B will receive diaphragmatic breathing technique. Spirometer will be used to evaluate pulmonary functions and breathless, cough and sputum scale (BCSS) will be used to evaluate the improvement in sputum diary of patients. The trial will be completed in two days after patients admitted in the ICUs/CCUs and before and after each session, primary and secondary outcomes will be measured for both groups. A|There will be 2 groups i.e. group A will receive active cycle of breathing technique (ACBT) and group B will receive diaphragmatic breathing technique. Spirometer will be used to evaluate pulmonary functions and breathless, cough and sputum scale (BCSS) will be used to evaluate the improvement in sputum diary of patients. The trial will be completed in two days after patients admitted in the ICUs/CCUs and before and after each session, primary and secondary outcomes will be measured for both groups. A|t|f|f|f
33954546|NCT00529165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162385|NCT06531070|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34162386|NCT04200118|||COHORT||PROSPECTIVE|||||||
34162387|NCT00966615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162388|NCT05483075|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745442|NCT05353335|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33745443|NCT05688904|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33745444|NCT02590718|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33849704|NCT00903682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849705|NCT04535804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849706|NCT03368638|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series||||
33849707|NCT06459739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33849708|NCT00825825|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33849709|NCT02046889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849710|NCT05839392|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849711|NCT00191178|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849712|NCT05729971|||CASE_CONTROL||PROSPECTIVE|||||||
33849713|NCT02167737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849714|NCT05011773|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Evaluation of symptomatology on and off deep brain stimulation"||||
33849715|NCT01119105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849716|NCT01940185|||COHORT||PROSPECTIVE|||||||
33849717|NCT04925687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849718|NCT04458129|NA|SINGLE_GROUP||TREATMENT||NONE||Bi-centric, non-comparative, prospective, Phase II trial according to a Fleming scheme.||||
33849719|NCT05802225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849720|NCT02491515|||CASE_ONLY||PROSPECTIVE|||||||
33849721|NCT04715243|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre randomized trial of confirmed COVID-19 cases presenting to the emergency department, the ward, high dependency or intensive care unit (ICU) with ARDS requiring non-invasive mechanical ventilation. They will be assigned to one of the three arms; high flow nasal cannula (HFNC), Face-mask NIV or Helmet NIV.||||
33849722|NCT05144126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849723|NCT03568396|||COHORT||PROSPECTIVE|||||||
33849724|NCT03576170|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33849725|NCT05769569|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase I, randomized, open-label trial to investigate the safety of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-BN-HIV and A244d11 gp120/ALFQ vaccination, and the impact on time to sustained viral rebound of ≥1000 copies/mL for 4 consecutive weeks during ATI in PLWH who initiated ART during AHI. The study will involve 35 adults who initiated ART during Fiebig I-V acute HIV infection, with plasma HIV RNA \<50 copies/mL for ≥48 weeks, CD4 T-cell counts ≥450 cells/mm3, viruses susceptible to both VRC07-523LS and PGDM1400LS and the absence of known protective HLA allele.||||
33849726|NCT02728869|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33849727|NCT05479201|||COHORT||PROSPECTIVE|||||||
33849728|NCT04025346|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Double blind, randomized, placebo controlled|t|t|t|t
33849729|NCT00014807||||PREVENTION||||||||
33849730|NCT00351520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849731|NCT06079125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849732|NCT05800418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849733|NCT02641574|||||RETROSPECTIVE|||||||
33849734|NCT06609317|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33849735|NCT05163782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849736|NCT00729079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849737|NCT04835077|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Study||||
33849738|NCT06301425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849739|NCT00828477|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849740|NCT03694275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849741|NCT06610149|NA|SINGLE_GROUP||TREATMENT||NONE||Single-Arm, Open-Label Study||||
33849742|NCT05734469|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33849743|NCT05749484|||COHORT||PROSPECTIVE|||||||
33849744|NCT00760773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058449|NCT06451328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058450|NCT06027034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058451|NCT02402634|||CASE_CONTROL||PROSPECTIVE|||||||
33849745|NCT05817552|||OTHER||OTHER|||||||
33849746|NCT04073459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849747|NCT04918446|RANDOMIZED|PARALLEL||OTHER||NONE||A small pilot study using a randomized clinical trial of T-POSE compared to usual care.||||
33849748|NCT00876577|||COHORT||PROSPECTIVE|||||||
33849749|NCT03592810|||COHORT||PROSPECTIVE|||||||
33849750|NCT03831373|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33849751|NCT03308526|||COHORT||PROSPECTIVE|||||||
33849752|NCT05851287|||COHORT||PROSPECTIVE|||||||
33849753|NCT04988867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849754|NCT06083779|||CASE_CONTROL||PROSPECTIVE|||||||
33849755|NCT00808054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33849756|NCT02884895|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33849757|NCT00659178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849758|NCT04874285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058452|NCT05766345|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34058453|NCT00633776|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34058454|NCT05141643|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058455|NCT05451537|||COHORT||PROSPECTIVE|||||||
34058456|NCT03053648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All of the assessments in this study will be self-completed. The researchers who perform the assessment and analysis will be blinded to group allocation.||f|f|f|t
34058457|NCT06622967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058458|NCT05614180|||COHORT||PROSPECTIVE|||||||
34058459|NCT04473820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058460|NCT04447677|||COHORT||PROSPECTIVE|||||||
34058461|NCT04652401|||COHORT||CROSS_SECTIONAL|||||||
34058462|NCT00951834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058463|NCT01616849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058464|NCT03848806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954547|NCT00306124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33954548|NCT01615822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954549|NCT03361540|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33954550|NCT02658578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33954551|NCT06468007|||OTHER||RETROSPECTIVE|||||||
33954552|NCT03049774|||CASE_ONLY||RETROSPECTIVE|||||||
33954553|NCT01988337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Split-mouth design|t|t|f|f
33954554|NCT03554759|||COHORT||PROSPECTIVE|||||||
33954555|NCT06568757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954556|NCT04935866|||COHORT||PROSPECTIVE|||||||
33954557|NCT05745441|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33954558|NCT02423564|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33954559|NCT04456998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects, investigators, other site personnel, and Sponsor (and/or designee) personnel who are directly involved in the conduct of the study, collection of the data, and analysis of the final safety and efficacy results will remain blinded to treatment assignments until after the completion of the study and the database has been locked.||t|f|t|f
33954560|NCT00989365|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954561|NCT01903213|||COHORT||PROSPECTIVE|||||||
33954562|NCT05813392|RANDOMIZED|PARALLEL||TREATMENT||NONE||The enrolled breast cancer survivors were randomized into two groups: the intervention group was the dCBT-I treatment group and the control group was the wait-for-treatment group.||||
33954563|NCT02753608|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954564|NCT03236337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954565|NCT04824573|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals are randomly allocated into Inspiratory Muscle Training (IMT) and Manual Therapy groups.||||
33954566|NCT06631235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954567|NCT05518409|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954568|NCT05589701|||COHORT||PROSPECTIVE|||||||
33954569|NCT01843660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954570|NCT00568516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954571|NCT04998188|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"his is a double-blind randomized controlled trial with 1:1 allocation. Patients, healthcare professionals who assess clinical and functional outcomes (outcome assessors) and professionals who analyze the data will be blinded."|The study is a double-blinded RCT with possibility ,after 6 months, to cross-over from control arm (saline solution ) to the treatment arm (collagen). After 6 months, patients in the control arm have the possibility to cross-over into the treatment arm, in which case they will be followed for an additional 6 months|t|f|f|t
33954572|NCT04420000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954573|NCT01521429|||COHORT||PROSPECTIVE|||||||
33954574|NCT03302130|NA|SINGLE_GROUP||OTHER||NONE||||||
33954575|NCT00002767|RANDOMIZED|||TREATMENT||||||||
33954576|NCT03311386|||COHORT||PROSPECTIVE|||||||
33954577|NCT05878405|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745445|NCT04895267|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The investigators designed a single-blind, sham-controlled, crossover study, in which the COVID-19 participants were blinded for the real LF-ThMS or sham stimulation conditions.|"Arms:~The investigators designed a single-blind, sham-controlled, crossover study on COVID-19 participants who underwent two sessions of the study (real and sham Low-field thoracic magnetic stimulation, LF-ThMS), and other COVID-19 participants who underwent only the real LF-ThMS.~Sham comparator:~For sham exposure, the coils were positioned in the same coordinates in the same COVID-19 participants, but the LF-ThMS pulse generator was not turned on."|t|t|f|f
33745446|NCT00096135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954578|NCT01482442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954579|NCT04491773|||COHORT||PROSPECTIVE|||||||
33745447|NCT04464564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745448|NCT01660906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745449|NCT02345512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745450|NCT03919994|||COHORT||PROSPECTIVE|||||||
33745451|NCT02508311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745452|NCT06613347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745453|NCT00235794|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33745454|NCT06536114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will not be a physical therapist and thus not involved with the participant's medical treatment.|multi-site, single-blinded, randomized controlled trial|f|f|f|t
33745455|NCT06515912|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745456|NCT02002676|||CASE_ONLY||PROSPECTIVE|||||||
33745457|NCT00659633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745458|NCT06636552|NA|SINGLE_GROUP||TREATMENT||NONE||This is an investigator-initiated, prospective, multicenter, phase II, open-label, single-arm, non-randomized, single-stage clinical trial.||||
33745459|NCT02393495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745460|NCT00022568||||TREATMENT||||||||
33745461|NCT00518947|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33745462|NCT01941862|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33954580|NCT02473107|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33954581|NCT03111394|||COHORT||PROSPECTIVE|||||||
33954582|NCT06649357|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who are candidates according to standard medical practice for BPH surgery with a prostate volume ≤ 80 cc measured by urological ultrasound or magnetic resonance imaging (MRI). Surgery will be randomly assigned using MoLEP or Bi-TURP.||||
33954583|NCT00421486|||CASE_CONTROL||PROSPECTIVE|||||||
34058465|NCT00386425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058466|NCT05739591|||COHORT||PROSPECTIVE|||||||
34058467|NCT04864158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33954584|NCT05846503|RANDOMIZED|CROSSOVER||OTHER||NONE|There is no masking. This is an intervention study without drugs. Intervention comprises training and education, data and feedback, and task shifting.|Randomized cluster stepped-wedge study design where clinics will be assigned to a time at which they initiate the intervention. There are nine clinics which have been classification (low, medium and high) according to their volume. One clinic from each classification has been randomized to a cluster such that there are three clusters each with a low, medium and high volume clinic.||||
33954585|NCT06061328|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This hybrid type III trial will compare the effectiveness and implementation of the decision aid (DA) vs. Current Tool to improve liver cancer screening for Veterans with cirrhosis in 20 VA sites, as well as assess how users make decisions based on the source of the recommendation (e.g., expert opinion vs. machine-derived). VA clinicians in both arms will receive a one-time 1-hour webinar training on either the new DA or the Current Tool. Trainers will be available to provide technical assistance after the webinars during the 6-month implementation phase but will not provide additional implementation support. Participants will be encouraged to initiate the recommended strategies within 3 months of training.||||
33954586|NCT03669874|||COHORT||PROSPECTIVE|||||||
33954587|NCT06456749|||COHORT||PROSPECTIVE|||||||
33954588|NCT03666819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954589|NCT06551506|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954590|NCT01847625|||OTHER||OTHER|||||||
34162389|NCT04664374|||COHORT||PROSPECTIVE|||||||
34162390|NCT00651716|||COHORT||PROSPECTIVE|||||||
34058468|NCT02978391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162391|NCT02135510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058469|NCT04254107|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34162392|NCT03819361|||COHORT||PROSPECTIVE|||||||
34162393|NCT04732689|||COHORT||PROSPECTIVE|||||||
34162394|NCT01132313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162395|NCT04642391|||COHORT||PROSPECTIVE|||||||
34162396|NCT04175028|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34058470|NCT06646510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058471|NCT05015621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058472|NCT04430231|||COHORT||PROSPECTIVE|||||||
34058473|NCT02521779|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34058474|NCT02873637|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34058475|NCT03931317|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34058476|NCT05976308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076543|NCT00908414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34076544|NCT05969990|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076545|NCT05996939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34162397|NCT05799131|||CASE_ONLY||PROSPECTIVE|||||||
34162398|NCT04206488|NA|SINGLE_GROUP||OTHER||NONE||||||
34162399|NCT01375023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162400|NCT01442714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162401|NCT00930553|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162402|NCT06064071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162403|NCT05936073|||COHORT||RETROSPECTIVE|||||||
34162404|NCT02033746|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34162405|NCT01247961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162406|NCT01563263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745463|NCT04039113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.|t|t|t|t
33745464|NCT00990652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745465|NCT00052065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745466|NCT04480294|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34162407|NCT01761448|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34162408|NCT03602365|NA|SINGLE_GROUP||OTHER||NONE||Non randomized, single group study comparing the effects of GJ on resting oxygen consumption (VO2) measurements in seated and supine postures||||
34162409|NCT05257291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162410|NCT06154707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162411|NCT03053570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162412|NCT00119470|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34162413|NCT04486014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind (participant) study||t|f|f|f
34162414|NCT03798327|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blind control||f|f|f|t
34162415|NCT01505374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34162416|NCT00904488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162417|NCT00091091|||COHORT||PROSPECTIVE|||||||
34162418|NCT01076530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745467|NCT06438861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745468|NCT02777593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745469|NCT06065072|||COHORT||OTHER|||||||
33745470|NCT02221206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745471|NCT05481762|||CASE_CONTROL||RETROSPECTIVE|||||||
33745472|NCT01930773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745473|NCT02182193|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745474|NCT02980367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745475|NCT02415400|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33745476|NCT02951325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745477|NCT01458574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745478|NCT01093352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745479|NCT03353818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745480|NCT06152224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33745481|NCT05008679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745482|NCT06634628|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||People with Huntington's disease (PwHD) compared to healthy controls (HC)||||
33745483|NCT05499975|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-arm non-randomized study||||
34162419|NCT02362750|||COHORT||PROSPECTIVE|||||||
33954591|NCT03273257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33849759|NCT02790944|||COHORT||PROSPECTIVE|||||||
33954592|NCT00611780|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33954593|NCT01159717|||CASE_ONLY||RETROSPECTIVE|||||||
33954594|NCT06475105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This research is an experimental clinical study with a double blinded randomized controlled trial design. The study group consisted of patients with acute decompensated heart failure with volume overload who required intravenous diuretic therapy. The first group was patients who received intravenous furosemide plus acetazolamide 250 mg / 12 hours orally for up to 3 days (group A). Meanwhile, the second group was patients who received intravenous furosemide plus placebo for up to 3 days (group B).|t|t|t|f
33849760|NCT04571359|||CASE_ONLY||CROSS_SECTIONAL|||||||
33849761|NCT01157676|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non inferiority phase 3 randomized clinical trial comparing robotic to open radical cystectomy||||
33849762|NCT03517033|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849763|NCT02388854|||CASE_CONTROL||PROSPECTIVE|||||||
33849764|NCT05973695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849765|NCT02112747|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33849766|NCT03329274|||COHORT||PROSPECTIVE|||||||
33849767|NCT00286338|||||PROSPECTIVE|||||||
33849768|NCT06079541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33849769|NCT01900197|||COHORT||PROSPECTIVE|||||||
33849770|NCT00155974|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33849771|NCT01127893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849772|NCT00177801|||||PROSPECTIVE|||||||
33849773|NCT05823831|||CASE_CONTROL||PROSPECTIVE|||||||
33849774|NCT04417322|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849775|NCT01678105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849776|NCT01277900|||CASE_ONLY||PROSPECTIVE|||||||
33849777|NCT04729686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849778|NCT02145234|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33849779|NCT00712998|||CASE_CONTROL||PROSPECTIVE|||||||
33849780|NCT05131568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33849781|NCT03699826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849782|NCT06046950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849783|NCT04392401|||COHORT||PROSPECTIVE|||||||
33849784|NCT04635592|||COHORT||PROSPECTIVE|||||||
33849785|NCT03298243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Aims 1 and 2: Parallel-group longitudinal study. Participants will practice reaching to locations in front of them using vibrotactile feedback to guide the precision of the movements. For one group, the tasks will be organized to slowly become more difficult as practice continues. For the other group, the training will only involve the more difficult task. Subjects will be asked to perform simulated tasks of daily living at the beginning or end of practice to test transfer of the vibrotactile training/learning.||||
33954595|NCT05494723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954596|NCT00916617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954597|NCT06602297|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33954598|NCT05242406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954599|NCT01067339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954600|NCT06385873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954601|NCT03026894|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33954602|NCT06557473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An investigator not participating in the study was responsible for drug preparation and allocation according the computer generated random numbers.|comparison of lidocaine and fentanyl in hemodynamic stability after induction of general anesthesia in hypertensive patients.|t|t|t|t
33954603|NCT03063957|||COHORT||PROSPECTIVE|||||||
33954604|NCT01982045|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33954605|NCT04543539|||COHORT||PROSPECTIVE|||||||
33954606|NCT01427556|||||PROSPECTIVE|||||||
33954607|NCT05180994|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849786|NCT01263665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954608|NCT02723760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954609|NCT06110767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This research is a cross-sectional, prospective and experimental study.|f|f|f|t
33954610|NCT06652854|||COHORT||PROSPECTIVE|||||||
33849787|NCT05151705|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare the pharmacokinetics of HR17031 injection in subjects with mild and moderate liver impairment and normal liver function||||
33849788|NCT00803751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33849789|NCT02325479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849790|NCT05373823|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Type one hybrid effectiveness-implementation study consisting of three aims. Aim 1 (Months 1-15) focuses on MSS enhancement using stakeholder collaboration. Aim 2 (Months 16-60) involves the longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas. Aim 3 (Months 16-60) is a mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation. The figure below illustrates the integration of the PHM and implementation science frameworks with the study's aims.||||
33849791|NCT06487611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This study will employ a two-arm pilot randomized control trial with qualitative interviews.|f|f|t|t
33849792|NCT05421611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33849793|NCT00230087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954611|NCT04303065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the pharmacist, who masks the capsules and labels the containers, will know the assignement of the codes, and will keep them blind until the last phase of the study, after the main statistical analysis, or when unmasking is required.||t|t|t|t
33954612|NCT02111265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954613|NCT04195867|NA|SINGLE_GROUP||OTHER||NONE||||||
33954614|NCT06558799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954615|NCT01765504|||COHORT||PROSPECTIVE|||||||
34076546|NCT01650467|||COHORT||CROSS_SECTIONAL|||||||
34076547|NCT00992641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765222|NCT06481254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The principal investigator completed the consent and assent forms after explaining the purpose of the study to all participants. In the research planned as a single-blind randomized controlled clinical study, the other researcher who applied the data collection tools to reduce bias was not told who the experimental groups (hawthorn vinegar group, black mulberry syrup group, green tea group) and the patients with DM in the control group were.|The sample size of the study was calculated as 128 individuals in total (32 for each group) for 4 groups (hawthorn vinegar, black mulberry syrup, green tea, control group) with an effect size of 0.25 with α=0.05 and the power of the targeted test was 0.80 (80%) in the G\*Power 3.1.9.7 program, which could not be used as a reference since there was no previous four-group study on the subject. Each group was increased to account for drop-outs and deaths and a total of 140 individuals, 35 for each group, were included in the study|f|f|t|f
33765223|NCT00208585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33765224|NCT00659984|NA|SINGLE_GROUP||TREATMENT||NONE||Ultratrace™ Iobenguane I 131||||
33849794|NCT05332145|NA|SINGLE_GROUP||PREVENTION||NONE||"In Phase 1, the investigators will develop the MAP to Health web-based interview that will be used to explore what is particularly meaningful to participants, how physical activity is consistent with those goals, and what activities patients plan to engage in. Participants (N=12) will complete the interview and rate the ease of use, usefulness, intention to use, and theoretical fidelity of the intervention.~In Phase 2, the investigators will conduct a proof-of-concept pilot trial using a double-pretest single group design. Participants (N=35) will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks."||||
33849795|NCT01741896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849796|NCT02076438|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33849797|NCT02880384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849798|NCT04004936|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||In order to inform a Veterans Affairs (VA) system-wide approach to improve prescribing safety for older Veterans, the investigators will conduct a randomized study to determine best practices for influencing provider prescribing behavior in order to decrease PIMs prescribed for older Veterans at the time of ED discharge. The overall goal of this project is to determine which EQUIPPED implementation strategy (active or passive feedback) is most effective to reduce prescribing of PIMs for older Veterans discharged from the ED. Eight sites will be randomized to either active feedback with individual, in-person academic detailing or passive feedback delivered via an individualized electronic dashboard.||||
33849799|NCT04311528|NA|SINGLE_GROUP||PREVENTION||NONE||open label; all subjects will receive the 9-valent HPV vaccine||||
33954616|NCT06638866|NA|SINGLE_GROUP||SCREENING||NONE||All subjects underwent an abdominal or chest non-contrast CT scan, and their CT images were automatically interpreted by AI.||||
33954617|NCT00902265|||CASE_ONLY||PROSPECTIVE|||||||
33954618|NCT03879135|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954619|NCT03680924|||CASE_ONLY||OTHER|||||||
33954620|NCT01077167|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954621|NCT06149988|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954622|NCT03950817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954623|NCT01190202|NA|SINGLE_GROUP||OTHER||||||||
33954624|NCT06650280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954625|NCT03918980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954626|NCT05263869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954627|NCT01539707|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33954628|NCT02953873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954629|NCT03029104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Visual acuity will be evaluated by an observer who is masked as to the treatment protocol to which study subjects have been assigned.||f|f|f|t
33954630|NCT03978806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The PI will not know arm assignment.|This will be a pilot RCT (randomized controlled trial) of a 3 month intervention of Latino ESRD patients that will be randomized to one of two arms: 1) PN Arm, in which a bilingual PN provides support with social factors and support with adherence using motivational interviewing during 5 visits or 2) Control (standard care) Arm.|f|f|t|f
33954631|NCT04361006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954632|NCT00002680||||TREATMENT||||||||
33954633|NCT06652815|||CASE_ONLY||CROSS_SECTIONAL|||||||
33954634|NCT00157040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954635|NCT00556166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954636|NCT03681561|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954637|NCT01460394|||COHORT||PROSPECTIVE|||||||
33954638|NCT06650046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954639|NCT05611372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954640|NCT04980417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954641|NCT00463177|||||CROSS_SECTIONAL|||||||
33954642|NCT00104962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954643|NCT05242107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954644|NCT02903095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33954645|NCT01341067|||COHORT||PROSPECTIVE|||||||
33954646|NCT01004575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954647|NCT06160726|||COHORT||RETROSPECTIVE|||||||
33954648|NCT02911610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076548|NCT01587105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34076549|NCT04149717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"The three test solutions will be coded as A, B and C. Both the subject and the provider of the test solution to the subject will be blinded to the ingredients in the solution. The person who provides the test solution will be blind to the identity of the subject other than by subject number. The person who analyzes the data will be blinded to subject identity and which test solution was administered. The key for the test solutions and subject identity will be kept in a locked drawer in the office of the principal investigator."|repeated measures, crossover design|t|f|t|t
33954649|NCT05093647|||CASE_ONLY||CROSS_SECTIONAL|||||||
33745484|NCT06247306|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Next to the investigator and participants, research assistants as well as medical technical radiology assistants (MTRAs) will be blinded to the conditions. Only after the 6-week long ecological momentary assessment is completed are participants as well as investigators, MTRAs and research assistants debriefed concerning the participants group assignment (experimental or Yoke-control group).|Firstly,.all participants are assigned to either the experimental or the sham-control (Yoke-control) group through a fully automated, double-blind procedure. All participants undergo one neurofeedback (NFB) session with two runs à 9:30 mins. The NFB runs have a block structure with alternating periods/ blocks of self-regulation and rest. Participants of both groups receive the instruction to decrease their stress-response (thus, upregulating their ACC activity), through whichever strategy helps them to achieve this goal. The experimental group receives real-time fMRI feedback of their respective ACC activity. The sham-control group or Yoke-control group receives a previously acquired recording of the neurofeedback signal from a different participant instead of their own real-time ACC activity.|t|f|t|f
34162420|NCT05637788|||COHORT||RETROSPECTIVE|||||||
34162421|NCT01594619|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34162422|NCT05743088|||OTHER||CROSS_SECTIONAL|||||||
33954650|NCT03728257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There will be two groups. The research study that will compare two methods of self-managing exercise after receiving a lung transplant. These methods are a home-based exercise program plus self-monitoring or self-monitoring alone. The investigator would also like to collect information about the patients health and ability to exercise, and the amount of physical activity the participants do per day. The length of the study will be 6 months.|f|t|f|t
34162423|NCT01436786|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33954651|NCT01626209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954652|NCT05709275|||COHORT||PROSPECTIVE|||||||
33954653|NCT05123040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954654|NCT06566833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954655|NCT06566027|RANDOMIZED|PARALLEL||OTHER||NONE||We designed the study to treat patients, randomly assigning them by lottery to receive either an activator or the EF (Functional Education) class II standard. The activator versus the EF (Functional Education) class II standard group consisted of 30 subjects (17 girls, 13 boys) and 30 subjects (12 girls, 18 boys), respectively. The changes in skeletal, dental, and soft tissue were recorded before, at 6 months of treatment. Blinding was not performed. After six months of treatment, the study's endpoint was reached and then selected those who achieved the standards for sampling at Can Tho University of Medicine and Pharmacy. The Can Tho University of Medicine and Pharmacy Ethics Council in Biomedical Research No. 23. 340.HV/PCT-H signed the study on April 12, 2023.||||
33954656|NCT04395157|||OTHER||OTHER|||||||
33954657|NCT06304688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33954658|NCT05228990|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33954659|NCT03166670|||OTHER||CROSS_SECTIONAL|||||||
33954660|NCT04758715|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954661|NCT02626910|||COHORT||PROSPECTIVE|||||||
33954662|NCT03299088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954663|NCT00568464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954664|NCT03296904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954665|NCT00658086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162424|NCT05597696|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162425|NCT03517761|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are blind to treatment condition until 6 months post-procedure. Participants in sham control group can crossover to treatment group at that time.|Single-center, prospective, single-blinded, randomized, controlled study to include 80 subjects total, 40 treated with Bone Marrow Concentrate and 40 subjects treated with a Sham Procedure with cross-over from the sham to active group at 6 months|t|f|f|f
34162426|NCT06139744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162427|NCT05082246|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking. All participants will be getting interventions and measurements will be taken pre- and post- intervention.|"This study is a pilot designed to assess the quality of experience of patients measured through standardized assessment forms and objective parameters such as vital signs including blood pressure and heart rate. Participants will be compared with their own data for each intervention.~This will be a prospective pilot pre-post study for the duration of eight weeks, or as long as required to obtain 30 participants. If, prior to the study, measurements of blood pressure and heart rate; pain scale ratings; and anxiety, depression and stress scale scores in patients show an overall improvement when compared to the same information taken after the completion of eight week weeks, then it can be concluded that these CAM methods are feasible and beneficial in the rehab setting."||||
34162428|NCT03293030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162429|NCT03685227|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34162430|NCT05140460|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34162431|NCT01792037|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34162432|NCT05215834|RANDOMIZED|PARALLEL||SCREENING||NONE||Prospective randomized and cohort study||||
34162433|NCT01327677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162434|NCT01006759|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34162435|NCT01362894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162436|NCT00102128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162437|NCT06141447|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This will be a double blinded study.|Randomized controlled trial - randomized to either receive treatment (40 units IV oxytocin + 1000 mL normal saline) or placebo (1000 mL normal saline alone).|t|t|t|f
34162438|NCT02708810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162439|NCT05639140|||COHORT||PROSPECTIVE|||||||
34162440|NCT06407674|||COHORT||CROSS_SECTIONAL|||||||
34162441|NCT06308666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162442|NCT01057186|||COHORT|||||||||
34162443|NCT04323072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34162444|NCT04814121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162445|NCT03863431|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34162446|NCT03667469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|sealed non-transparent envelopes|"Participants are randomly allocated to one of three groups:~1. Surgical bariatric procedure in the first (A) group undergo the laparoscopic stapleless-separated mini-gastric bypass procedure: Gastric band (absorbable ligature) was introduced in the abdomen and retracted through the retrogastric tunnel. Mobilization and displacement of gastric fundus and create obstructive gastroplication. Hand-sewn gastrojejunostomy completes the intervention.~2. Surgical bariatric procedure in the second (B) group: Linear cutter stapler-separated mini-gastric bypass (MGB/OAGB): standard surgery.~3. Non-Surgical interventional in three (C) group including hypocaloric diet therapy."|t|t|t|t
34162447|NCT06078059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849800|NCT04326595|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"1. Full detailed history taking .~2. Through clinical examination .~3. pregnancy was confirmed by ultrasound examination or serum beta human chorionic gonadotropins (β-HCG) level for patients.~4. All patients had routine laboratory tests including blood group, Rh factor, complete blood count, and electrolytes.~5. Then the all tissues obtained at evacuation should be submitted for histopathological examination"||||
33849801|NCT02609347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849802|NCT02733055|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849803|NCT02234648|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33849804|NCT04307771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33849805|NCT05966597|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33849806|NCT01299870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33849807|NCT02786550|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33849808|NCT04109924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849809|NCT04334200|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Intervention group receiving support group program||||
33849810|NCT05378971|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects and researchers can know which treatment is being used.|Patients enrolled were divided into two categories: 1) patients suitable for Autologous Hematopoietic Stem Cell Transplantation(ASCT) started pomalidomide maintenance therapy 3 months after ASCT; 2) patients not suitable for ASCT started pomalidomide maintenance therapy after induction and consolidation therapy to achieve maximum efficacy. Dosing on days 1-21, 2 mg daily for 28 days as a cycle, for a total duration of 36 months or the onset of disease progression, intolerable adverse events.||||
33849811|NCT00979810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745485|NCT05938634|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|"Participants in the control group will be masked from the proposed intervention.~Participants in the study group (in each Stage of Change) will be masked from the type of intervention they are supposed to receive."||t|f|f|f
33745486|NCT01757964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745487|NCT04759820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745488|NCT00344123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745489|NCT06310161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33745490|NCT06670599|||COHORT||CROSS_SECTIONAL|||||||
33745491|NCT00345904|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33745492|NCT05773859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745493|NCT03305016|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants will receive TransCon hGH||||
33849812|NCT06392074|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33849813|NCT06016959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849814|NCT04021550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849815|NCT03972085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849816|NCT04495101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849817|NCT05146180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849818|NCT03394001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849819|NCT05110027|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33849820|NCT03042897|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33849821|NCT04897750|NA|SINGLE_GROUP||TREATMENT||NONE||The study population will receive a target dose of intranasal CT001 corresponding to sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg (and an additional dose 10 -15 minutes after, if needed) prior to an elective surgical, procedure.||||
33849822|NCT06476613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849823|NCT00687687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849824|NCT00218660|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33849825|NCT05294601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Three groups with nutritional interventions and recreational games and observation before and after of physiological variables needed in the outcomes.|t|t|f|t
33849826|NCT02478710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849827|NCT00117923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33849828|NCT05372952|||COHORT||PROSPECTIVE|||||||
33849829|NCT03750045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849830|NCT06610123|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Statistician||t|f|t|f
33849831|NCT03356626|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33849832|NCT04444544|||COHORT||PROSPECTIVE|||||||
33849833|NCT05688345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33849834|NCT00369473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849835|NCT03005769|||COHORT||RETROSPECTIVE|||||||
33849836|NCT01394822|||COHORT||PROSPECTIVE|||||||
33849837|NCT03271554|||COHORT||PROSPECTIVE|||||||
33849838|NCT04733521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745494|NCT01829412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849839|NCT02984293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33849840|NCT00146120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849841|NCT05690724|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomised, double-blinded, placebo-controlled, parallel proof of concept study|t|t|t|t
33849842|NCT02383056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849843|NCT02875808|||COHORT||PROSPECTIVE|||||||
33849844|NCT03350373|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33849845|NCT00556387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33849846|NCT04695912|RANDOMIZED|CROSSOVER||TREATMENT||NONE||crossover, open-label, randomized, controlled trial||||
33849847|NCT02781844|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849848|NCT04201782|||COHORT||PROSPECTIVE|||||||
33849849|NCT06434896|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial||||
33849850|NCT02592408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954666|NCT02626273|NON_RANDOMIZED|PARALLEL||||NONE||||||
33954667|NCT00027573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954668|NCT03427827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954669|NCT00980460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954670|NCT01102608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954671|NCT01038076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954672|NCT04185025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34076550|NCT03158168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745495|NCT06670066|RANDOMIZED|PARALLEL||PREVENTION||NONE||This research project will use a cluster-level randomized control trial design in which a participating health center is randomized to either the experimental condition (Let's Talk Birth Control) or the control condition (standard health services). All participants enrolled at health centers randomized to the experimental condition should receive the Let's Talk Birth Control intervention while all participants enrolled at health centers randomized to the control condition should receive health services as usual.||||
33745496|NCT03912259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745497|NCT03590301|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants will not know whether they are in the control or experimental group.||t|f|f|f
33745498|NCT06276855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental group Control group||||
33745499|NCT06031246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745500|NCT06464393|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745501|NCT03725982|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Subjects and experimenters will not be blinded, because it will be obvious which task will be performed by the subjects and measurements need to be tracked by the experimenter.|"1. Static sorting Six conditions as combination of exoskeleton (without vs. with) and trunk posture (forward flexion vs. flexion + rotation left vs. flexion + rotation right) are investigated in a randomized order.~2. Dynamic lifting Twelve conditions as combination of exoskeleton (without vs. with), work posture (forward flexion vs. flexion + rotation left vs. flexion + rotation right) and knee angle (extended/stoop vs. flexed/squat) are investigated in randomized order.~3. Functional tasks Three tests with two conditions in randomized order (exoskeleton: without vs. with) will be investigated in fixed order (stair-climbing; timed-up-and-go; course with various simulated industrial workstations).~4. Angle-force relation Twelve conditions as combination of exoskeleton (without vs. with), knee angle (extended/stoop vs. flexed/squat) and trunk flexion angle (0 vs. 30 vs. 60 degrees) are investigated in randmized order."||||
33745502|NCT04287374|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33745503|NCT00893932|||COHORT||PROSPECTIVE|||||||
33745504|NCT01753024|||COHORT||PROSPECTIVE|||||||
33745505|NCT01159691|||COHORT||PROSPECTIVE|||||||
33745506|NCT05627128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All staff collecting data (e.g., dietary assessment) or assaying samples (e.g., fecal calprotectin, cytokines, sequencing) including the PI's, will be blinded to diet group assignments.|Randomized intervention trial in adults with Crohn's disease.|f|f|t|t
33745507|NCT01788904|||COHORT||PROSPECTIVE|||||||
33745508|NCT05319327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator who will analyze data will be provided with blinded data regarding the groups. Control and intervention groups will be randomly designated as group A and B. Investigator responsible for the analyses of the effect of the intervention on primary outcomes will compared groups A and B in a blinded manner.|Controlled, randomized, parallel groups intervention|f|f|t|f
33745509|NCT01369342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745510|NCT00365859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745511|NCT06577532|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33745512|NCT04215029|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34076551|NCT03235037|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label study to assess the motor and cognitive and developmental effects of carbidopa/levodopa when administered orally in doses of 1 -10mg per kg per day. This study will recruit and monitor patients over a 2 year period.||||
34076552|NCT06179069|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076553|NCT00765531|||COHORT||PROSPECTIVE|||||||
33745513|NCT04032847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745514|NCT02353923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745515|NCT01631032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745516|NCT02575846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745517|NCT04593888|RANDOMIZED|PARALLEL||PREVENTION||NONE|"study participants will be randomized to either the gluten-reduced or no intervention arm on-going after enrolment."|||||
33849851|NCT00189488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849852|NCT00366002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849853|NCT01849627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849854|NCT06179784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be allocated to one out of ten treatment modules according to their most relevant pain process. The same module will be used for the whole therapy phase if no adverse effects or long lasting non-response is observed. Only then can the participant be allocated to another treatment module.||||
33849855|NCT00381277|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33849856|NCT05055557|||COHORT||PROSPECTIVE|||||||
34076554|NCT04752839|||OTHER||PROSPECTIVE|||||||
34162448|NCT02728401|||COHORT||PROSPECTIVE|||||||
34162449|NCT02755220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058477|NCT06264752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Statisticians performing the analysis will be blinded to the treatment allocation.~The investigators will randomize clusters to intervention and control within strata defined hospitals to adjust for inherent subgroup differences. The allocation sequence list will be maintained by the data management team (DMT) using a secure web-based system where assignments will be maintained and accessed by the CDSS. Pharmacists will only receive alerts for patients of physicians randomized to the intervention."|This is a prospective, randomized, interventional controlled trial at eight hospitals within the UPMC health-system. Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. Hospital service clusters will be allocated 1:1 to the intervention or usual care with a web-based system to maintain concealment using a randomized block design.|f|f|f|t
34058478|NCT03817957|RANDOMIZED|PARALLEL||TREATMENT||NONE||"2:2:1 distribution Polyglucoferron, Ferric Carboxymaltose i.v., or oral iron substitution with Ferrous sulfate. After safety assessment of first 35 patients treated with Polyglucoferron or Ferric Carboxymaltose i.v. respectively, Ferric Carboxymaltose arm will be closed.~Remaining patients will be distributed in an 2:1 mode to Polyglucoferron or oral iron"||||
34162450|NCT03605446|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Single blind white label||t|f|f|f
34058479|NCT00900731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34058480|NCT02895724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076555|NCT01476995|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162451|NCT01797263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849857|NCT04158232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162452|NCT04988529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162453|NCT03748641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162454|NCT01035619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162455|NCT02402582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"All patients had similar inpatient rehabilitation programs. Both groups exercised for 0-2h/day. Walking distance was measured using a Fitbit (Fitbit, San Francisco, USA). Routine care included education on smoking cessation and education on food selection.~FCEM: Daily exercise occurred between 8-10 AM and was supervised by designated family members. Investigators randomly attended sessions in an unannounced fashion. Physical therapy consultation was available on investigator request. Exercise data were independently collected from the patient and their designated family member on a weekly basis (κ statistic=0.9).~Control: Patients exercised daily, at any time. Sessions were supervised by family members. Investigators did not attend sessions. Exercise data were independently collected from the patient and their designated family member on a weekly basis (κ statistic=0.4)."|t|f|t|t
34162456|NCT05988879|||CASE_CONTROL||PROSPECTIVE|||||||
34162457|NCT03994666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162458|NCT01814124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162459|NCT02458053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162460|NCT03763019|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34162461|NCT02842164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745518|NCT00644722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745519|NCT04108091|||CASE_ONLY||OTHER|||||||
33745520|NCT04711564|||COHORT||PROSPECTIVE|||||||
33745521|NCT04325659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is of a device (the Bridge Device), not of a drug.|t|t|t|t
33745522|NCT05191576|||CASE_CONTROL||PROSPECTIVE|||||||
33745523|NCT02983734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745524|NCT01410448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745525|NCT02494791|NA|SINGLE_GROUP||SCREENING||NONE||||||
33745526|NCT04141306|||COHORT||RETROSPECTIVE|||||||
33745527|NCT06486740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745528|NCT05853913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Individuals will perform both rest and exercise conditions.||||
33745529|NCT01813799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745530|NCT03408912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745531|NCT03932565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745532|NCT05685108|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||After screening, eligible participants will be assigned to one of the two groups and randomized to order of treatments.||||
33745533|NCT00044382|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745534|NCT06669130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745535|NCT05735106|||COHORT||PROSPECTIVE|||||||
33745536|NCT05234892|||COHORT||PROSPECTIVE|||||||
33745537|NCT04078282|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Cluster randomized controlled trial where family physicians are to be randomized into interventional or control group||||
33849858|NCT00730275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849859|NCT04019223|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849860|NCT03690232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|outcomes assessor and participant do not know the treatment patient received.|The study in the first year is a prospective, randomized controlled, double-blind study. The enrolled patients were randomly divided into two groups: the intraarticular glucose group and the intraarticular HA group.|t|f|f|t
33849861|NCT05486962|||COHORT||PROSPECTIVE|||||||
33849862|NCT04695431|||COHORT||RETROSPECTIVE|||||||
33849863|NCT03995693|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Opaque bottles to administer beverages with similar sweet taste.||t|f|f|f
33849864|NCT02881580|||COHORT||RETROSPECTIVE|||||||
33849865|NCT00818532|||||PROSPECTIVE|||||||
33849866|NCT04054700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745538|NCT02282501|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33745539|NCT06393452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745540|NCT05251753|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Randomized controlled trial||||
33849867|NCT03623373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849868|NCT04096053|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33849869|NCT01756768|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849870|NCT05857982|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm trial with ORR as the main endpoint. Due to limited data on mitoxantrone hydrochloride liposome injection, no statistical hypothesis will be made in this study to ensure the accuracy of the estimate.||||
33849871|NCT03103451|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33849872|NCT00824447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745541|NCT01407185|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33745542|NCT05854381|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745543|NCT03538626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745544|NCT06307145|||COHORT||RETROSPECTIVE|||||||
33745545|NCT03165526|||COHORT||RETROSPECTIVE|||||||
33745546|NCT06669598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33745547|NCT02486224|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33745548|NCT06465420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|During the study, the vaccine recipient and those responsible for evaluating any study endpoint (e.g., safety, reactogenicity, and immunogenicity) will all be unaware to which subjects the vaccine was administered.|Phase I First-in-Human randomized, controlled study to assess the safety and immunogenicity of the candidate Hia vaccine.|t|t|t|t
33745549|NCT00243373|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33745550|NCT06636396|||COHORT||CROSS_SECTIONAL|||||||
33745551|NCT00748046|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745552|NCT06634550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745553|NCT06635031|||COHORT||PROSPECTIVE|||||||
33745554|NCT06457009|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33745555|NCT04612361|||COHORT||PROSPECTIVE|||||||
33745556|NCT00880932|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33745557|NCT05916742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment|f|f|t|t
33745558|NCT00784043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745559|NCT05156138|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745560|NCT03806985|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33745561|NCT02138591|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745562|NCT00936390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745563|NCT04065438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745564|NCT06074666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745565|NCT04617028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745566|NCT01899976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745567|NCT04015648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745568|NCT05383248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745569|NCT03188939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"For the 3 techniques , we will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib. In intra- cluster-injection technique using in plane method and lateral to medial direction , the local anesthetic is injected inside main and satellite neural cluster.~In double-injection technique using in plane method and lateral to medial direction half the volume of local anesthetic is injected at intersection of first rib and subclavian artery and another half is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus."|t|f|f|t
33745570|NCT04667117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded treatment|Parallel, prospective study||||
33745571|NCT04245891|||OTHER||RETROSPECTIVE|||||||
33745572|NCT03790176|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||group A - patients on automated peritoneal dialysis group B - critically ill patients with pneumonia||||
33745573|NCT00000893||||TREATMENT||||||||
33745574|NCT06627842|||COHORT||OTHER|||||||
33745575|NCT04667455|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participant and standard clinical care providers will be blinded to biomarker analyses and advanced cardiac imaging findings throughout the study|case-control cohort|t|t|f|f
33745576|NCT04635722|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after study design with one interventional group and no control or placebo group||||
33745577|NCT04294810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745578|NCT05867446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant) To Diet Therapy Attitude Towards Fluid Restriction Compliance|pecha kucha training|t|f|f|f
33745579|NCT06205524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745580|NCT01834417|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33745581|NCT01289912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745582|NCT01636882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745583|NCT04412395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, clinical trial.|t|t|t|t
33745584|NCT02116465|RANDOMIZED|CROSSOVER||||NONE||||||
33745585|NCT02579642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745586|NCT04481048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In order to preserve the double-masking of the trial, only the investigation pharmacy will be unmasked. Both treatments (NAC and placebo) will be distributed from the investigational pharmacy. Except for the pharmacist, all staff will be blinded to the treatment sequence.|This is a phase II, double blind, placebo-controlled clinical trial with the goal to explore safety, tolerability, and efficacy of N-acetylcysteine (NAC).|t|t|t|t
33849873|NCT05339984|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849874|NCT02619981|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33849875|NCT04064593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849876|NCT01234077|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849877|NCT05660460|NA|SINGLE_GROUP||SCREENING||NONE||||||
33849878|NCT06610916|NA|SINGLE_GROUP||OTHER||NONE||||||
34058481|NCT04624776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Investigator-initiated, 1:1 randomized, multicenter, double-blind, placebo-controlled clinical trial. A minimum of 120 unconscious OHCA patients will be randomized 1:1 after 5 minutes of sustained ROSC to an infusion of 250 mg (4 mL) methylprednisolone in the pre-hospital setting. The methylprednisolone will be given as a bolus infusion of 1 x 250 mg (1 x 4 mL) over a period of 5 minutes. Patients allocated to placebo will receive 4 mL of isotonic saline (NaCl 0.9%).|t|t|t|t
34058482|NCT03254212|NA|SEQUENTIAL||TREATMENT||NONE||Fixed nightime oxygen therapy throughout the study duration with oxygen flow determined according to the results of the home oxygen titration procedure.||||
34058483|NCT03303443|||OTHER||PROSPECTIVE|||||||
33745587|NCT00380068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745588|NCT00033254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745589|NCT03263377|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33745590|NCT01396538|||COHORT||PROSPECTIVE|||||||
33745591|NCT04601155|||CASE_CONTROL||PROSPECTIVE|||||||
33745592|NCT00611091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33745593|NCT01761435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745594|NCT00620477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745595|NCT03914157|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will study 30 patients with ARAS randomized to SWT or sham (n=15 each) twice a week over 3 weeks. We will measure before and again 3 months after a 3-wk regimen renal cortical and medullary perfusion and function (multi-detector computed tomography \[MDCT\]), oxygenation, and fibrosis (magnetic resonance imaging \[MRI\]), urinary and plasma levels of renal injury markers, systemic endothelial function, and heart rate variability, an index of sympathetic activation.||||
33745596|NCT00823082|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33745597|NCT02953626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745598|NCT01006044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745599|NCT06558318|||CASE_CONTROL||PROSPECTIVE|||||||
33745600|NCT06114823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745601|NCT03429426|||COHORT||PROSPECTIVE|||||||
33745602|NCT05889247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745603|NCT06081309|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label safety pilot study of EEG-based personalized TMS||||
33745604|NCT02044510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745605|NCT05935540|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A parallel, 2-armed RCT with follow-ups at 6 and 12 months|f|t|f|t
33745606|NCT04954339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745607|NCT01953926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745608|NCT01764984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745609|NCT00158379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745610|NCT02522533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745611|NCT05806801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33745612|NCT00354705|||CASE_ONLY||PROSPECTIVE|||||||
33745613|NCT04657146|||CASE_ONLY||PROSPECTIVE|||||||
33745614|NCT04536636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745615|NCT00891566|||CASE_CONTROL||PROSPECTIVE|||||||
33745616|NCT04225208|NA|SINGLE_GROUP||OTHER||NONE||||||
33745617|NCT01597544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745618|NCT06326606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a randomized, double-blind, placebo-controlled, single ascending and multiple dose study to assess the safety, tolerability, and pharmacokinetics of MLS101 in healthy participants.~Single Ascending Dose (SAD): 24 participants will be enrolled in 3 sequential dose cohorts and will be randomized to receive a single dose of MLS101 or placebo. Additional cohorts (comprising 8 participants in each cohort) may be enrolled to explore more doses."|t|t|t|t
33745619|NCT04058769|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33745620|NCT04465006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One group received hippotherapy exercise, while the other group received conventional exercise.|t|f|f|f
33745621|NCT02684422|||COHORT||PROSPECTIVE|||||||
34162462|NCT04498442|RANDOMIZED|PARALLEL||OTHER||NONE||"In this prospective randomized control trial, the effects of yoga practices are being compared between seasoned yoga practitioners with two controls who are age and gender matched and living in the same neighborhood.~One control group acts as active control who receives active intervention in the form of yoga activities during the study duration. The study provides its active control group an opportunity to learn and practice Simha-Kriya which involves deep breathing exercises and meditation. In contrast, the other control group acts as a placebo control and performs either reading activities or remains idle for 15 minutes throughout the study period.~The participants will be requested to complete a set of surveys as a part of the research activity. These surveys include validated scales on stress, resilience and well-being; and objective questions on COVID-19 infection and medical history."||||
33745622|NCT03989804|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33745623|NCT01792089|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33849879|NCT01963923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33849880|NCT04238273|||CASE_CONTROL||PROSPECTIVE|||||||
34162463|NCT04651868|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Day A, B, C and D will be conducted in a randomized and double-blinded order (blinded for the participant and the investigator). The infusion order will be unblinded after the last patient last visit.||t|f|t|f
34162464|NCT05125406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162465|NCT04402879|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, unblinded, randomized controlled trial at four (4) medical sites in Calgary, Alberta.||||
34162466|NCT05563272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162467|NCT05441267|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomised double-blind placebo-controlled trial|Randomised double-blind placebo-controlled trial|t|t|t|t
34162468|NCT00582374|||COHORT||PROSPECTIVE|||||||
33745624|NCT00475059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745625|NCT02511431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745626|NCT06669793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745627|NCT03037385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1 (Complete):~* Advanced MTC, NSCLC or other solid tumor~* 30-600mg (PO QD or BID)~Phase 2 (400mg QD):~* Group 1: RET fusion NSCLC previously treated with a platinum chemotherapy~* Group 2: RET fusion NSCLC not previously treated for metastatic disease~* Group 3: MTC previously treated with cabozantinib and/or vandetanib~* Group 4: MTC not previously treated with cabozantinib or vandetanib~* Group 5: Other solid tumors with a RET fusion not eligible for any of the other groups and previously treated with SOC or have no acceptable SOC for their tumor type as determined by the investigator~* Group 6: Any solid tumor with a RET alteration (fusion or mutation) previously treated with a selective RET Inhibitor~* Group 7: Other solid tumors with a RET mutation previously treated with SOC~* Group 8: RET fusion NSCLC previously treated with a platinum chemotherapy (China only)~* Group 9: MTC not previously treated with systemic therapy for advanced or metastatic disease (China only)"||||
33745628|NCT01803997|RANDOMIZED|CROSSOVER||||NONE||||||
33765225|NCT03046511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33765226|NCT04297618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765227|NCT04456335|||CASE_CONTROL||OTHER|||||||
33849881|NCT03638973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849882|NCT00192647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849883|NCT01405326|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33849884|NCT00820196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162469|NCT05314907|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34162470|NCT05355662|||CASE_CONTROL||RETROSPECTIVE|||||||
34162471|NCT04602117|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, 3+3 design, single-arm, phase I trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.||||
34162472|NCT03467711|||CASE_ONLY||PROSPECTIVE|||||||
34162473|NCT05200676|||COHORT||CROSS_SECTIONAL|||||||
34162474|NCT02292719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162475|NCT05922371|||COHORT||PROSPECTIVE|||||||
34162476|NCT04205682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162477|NCT04768621|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Questionnaire||||
34162478|NCT02969356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162479|NCT03335865|||COHORT||PROSPECTIVE|||||||
34162480|NCT04328220|||CASE_ONLY||PROSPECTIVE|||||||
34162481|NCT01969006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162482|NCT03160898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162483|NCT03089411|||OTHER||RETROSPECTIVE|||||||
34162484|NCT04879966|||COHORT||PROSPECTIVE|||||||
34162485|NCT04327570|||OTHER||PROSPECTIVE|||||||
34162486|NCT06262113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34162487|NCT00266045|||COHORT||PROSPECTIVE|||||||
34162488|NCT02057172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162489|NCT01959841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162490|NCT03737539|||COHORT||PROSPECTIVE|||||||
34162491|NCT00502554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162492|NCT00742417|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34162493|NCT05185999|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single-arm, Open Label, Phase 1 Interventional study||||
34162494|NCT00799903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162495|NCT05164627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954673|NCT06161038|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"1. Cohort A-Myofascial pain syndrome The eligible patients first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.~   Then, they are conveniently assigned into two groups (40 subjects in each group): A. therapeutic ultrasound group; B. prolotherapy group. The same physician (the principal investigator) injects all patients to avoid inter-physician variability.~   Rescue therapy (cross-over treatment): If the participant does not satisfy with their first round treatment and the improvement of VAS is less than 10, then they are eligible to receive the rescue therapy-the treatment in the other group.~2. Cohort B-idiopathic scoliosis:~The recruited patients receive evaluation for once only. The collected parameters include Cobb's angle, spine rotational angle, VAS-pain and VAS-sng (visual analogue scale), pain threshold, strength and tone of paraspinal muscle, and SF-36."||||
33954674|NCT03676816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954675|NCT06580041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954676|NCT00390091|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33954677|NCT06652789|NA|SINGLE_GROUP||TREATMENT||NONE||Proposed study design: Interventional study (Pre-post study design) Elderly Out-patient and in-patients of Psychiatry department, St. John's Medical College and Hospital, Bengaluru, and St. John's Community Health Centre, Mugalur||||
33954678|NCT05480488|NA|SEQUENTIAL||OTHER||NONE||This is a prospective, open-label, fixed-sequence Phase 1 study.||||
33954679|NCT01330407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954680|NCT01299428|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33954681|NCT00696059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954682|NCT01757418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954683|NCT06647576|||COHORT||PROSPECTIVE|||||||
33954684|NCT06215872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Knowledge that which exercises are structured for research will keep from participants.|Prospective Randomized Control Single-Blind Study|t|f|f|f
33954685|NCT03252756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, randomized proof-of-concept study|t|t|f|f
33954686|NCT06257459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058484|NCT04195555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058485|NCT03379844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058486|NCT02063178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058487|NCT03559868|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33765228|NCT04637165|||CASE_ONLY||PROSPECTIVE|||||||
34058488|NCT00760370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765229|NCT02964455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765230|NCT02177539|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34058489|NCT05845450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase II, multicentre, single-arm, open-label, multi-cohort trial||||
34058490|NCT02718248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058491|NCT03098056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058492|NCT03976947|||OTHER||RETROSPECTIVE|||||||
34058493|NCT00697541|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058494|NCT02120820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34058495|NCT04064021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058496|NCT05109897|||CASE_ONLY||CROSS_SECTIONAL|||||||
34058497|NCT05205148|||COHORT||OTHER|||||||
34058498|NCT03811327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058499|NCT04988477|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pre-post study with multiple baselines to account for change over time.||||
34058500|NCT01992315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058501|NCT01237249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058502|NCT06050720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will have been referred to the sleep clinic at Royal Stoke Hospital for a diagnosis of a possible sleep disorder, possibly sleep apnoea. If they enrol in the study the participants will be asked to wear the Apne-Scan DC1 device to changing pressures in the user's breathing whilst asleep.||||
34058503|NCT00976209|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34058504|NCT06649227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058505|NCT06498089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor is blinded to the intervention.|This study was a randomized, controlled study, including two arms.|f|f|f|t
34058506|NCT00274443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058507|NCT04912219|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34058508|NCT02472743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076556|NCT04226300|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants, their families, post-anesthesia care unit nurses and anesthesiologists reviewing images of the ultrasound will be blinded to the intervention.|Patients will be randomized to receive a TAP block either by the surgeon, laparoscopically, or by the anesthesia team via ultrasound guidance.|t|t|f|t
34076557|NCT00184938|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34076558|NCT00642226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076559|NCT03786315|||COHORT||CROSS_SECTIONAL|||||||
34076560|NCT00122291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954687|NCT06250660|RANDOMIZED|PARALLEL||TREATMENT||NONE|The assignment to each group will be blind. It will be done through a computer application, which assigns random numbers to each participant.|Women who meet the inclusion criteria will be divided into two groups. There will be an intervention group, corresponding to the intake of strawberry and a control group. Participants will be randomly assigned to each group, the randomization will be 1:1, so there will be the same number of participants in each of the two groups. The intervention group will receive the corresponding amount of strawberries and the control group will continue with their usual diet and treatment for dysmenorrhea.||||
33954688|NCT01265875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162496|NCT03201419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each subject will receive 2 medications (an oral solution and an orally disintegrating tablet (ODT) formulation) throughout the trial, in order to keep the treatment blinded.|The trial consisted of a 2 week period of screening/lifestyle changes during which no treatment was given, a 2 week enrichment period (including a 1 week single blind active run-in period \[FE 201836 500 µg\] and a 1 week washout period) followed by a 12 week randomized treatment period for each subject. Prior to the first interim analysis, the first 129 subjects were randomized to daily treatment with FE 201836 500 µg, placebo, or desmopressin (25 µg for females and 50 µg for males) in a 2:2:1 ratio. After the first interim analysis, subjects were randomized to daily treatment with FE 201836 (50 µg, 100 µg, 150 µg, 250 µg, 350 µg, or 500 µg), placebo, or desmopressin (25 µg for females and 50 µg for males) using response adaptive allocation probabilities.|t|f|t|f
33954689|NCT02140801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076561|NCT03850834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162497|NCT04763941|||COHORT||CROSS_SECTIONAL|||||||
33954690|NCT05727540|||COHORT||PROSPECTIVE|||||||
33954691|NCT04485026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954692|NCT00973167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162498|NCT03960112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Per patient analysis in a prospective, multicenter cohort, open study.||||
34162499|NCT00640965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954693|NCT01218386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34162500|NCT02925624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162501|NCT03097536|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076562|NCT02638779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076563|NCT00219947|||OTHER||PROSPECTIVE|||||||
34076564|NCT00369915|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34076565|NCT04361799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076566|NCT03161041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076567|NCT01836562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076568|NCT04525430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076569|NCT02248064|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34076570|NCT04232007|NA|SINGLE_GROUP||OTHER||NONE||Closed-loop system to titrate vasopressor||||
34076571|NCT02244047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34162502|NCT05325970|||COHORT||PROSPECTIVE|||||||
34162503|NCT05217394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34162504|NCT03088488|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162505|NCT04270799|||COHORT||RETROSPECTIVE|||||||
34162506|NCT02525588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162507|NCT01409876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162508|NCT05642520|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical monitor will hide the treatment to the clinical observer, the patient and the statistician.|"The study was a double-blind controlled clinical trial (RCT) comparing the oval section abutment of a 2.9mm (test group) to a circular section abutment in 3.3mm (control group) implants for the replacement of a single tooth.~The choice of the diameter to be used as recommended by the manufacter, was determined by the mesiodistal width between the two adjacent natural teeth, in order to maintain at least 1.5mm between the implant and the adjacent tooth. When said the distance was between 5.9 and 6.3 mm, a 2.9 mm implant was placed, while if the width ranged between 6.4 and 7.1 mm, a 3.3 mm implant was placed. Both implant designs are made of a titanium and zirconium alloy (Roxolid®) with a SLActive® surface (Institut Straumann AG, Basel, Switzerland)."|t|f|t|t
34162509|NCT05979519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162510|NCT03871244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel open-label pragmatic non-inferiority randomised controlled trial (RCT)|f|f|t|t
34162511|NCT02002741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162512|NCT05375227|RANDOMIZED|PARALLEL||OTHER||SINGLE||A randomized, monocentric, examiner-blind, two-arm, parallel, controlled clinical research study|f|f|f|t
34162513|NCT00110500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34162514|NCT01897948|RANDOMIZED|PARALLEL||||DOUBLE||||||
34162515|NCT03430960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34162516|NCT01458262|||COHORT||PROSPECTIVE|||||||
34162517|NCT02757144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34162518|NCT01277874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162519|NCT01008943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162520|NCT01493973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162521|NCT04161937|RANDOMIZED|PARALLEL||PREVENTION||NONE||We have intervention and control arm and at the same time parellel||||
34162522|NCT00003864||||TREATMENT||||||||
34162523|NCT02488005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162524|NCT01822418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162525|NCT01822197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162526|NCT04744922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162527|NCT02742545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34162528|NCT02551822|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34162529|NCT02303249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954694|NCT03715335|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||A comparative effectiveness pragmatic trial using a stepped wedge crossover design will be conducted. A stepped wedge design involves the sequential roll-out of an intervention or a sequence of interventions to individuals or sites over multiple time periods. At the end of the study, all sites will have received all interventions, but the order in which sites are enrolled is randomly assigned. Once the final intervention is implemented, that intervention will continue until the end of the study.||||
33954695|NCT06649617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954696|NCT04034524|||COHORT||RETROSPECTIVE|||||||
33954697|NCT04387227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954698|NCT06649812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954699|NCT01928095|||OTHER||PROSPECTIVE|||||||
33954700|NCT01638416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Two staff not involved in the direct care of each patient checked the red-cell units, and concealed the collection and expiry dates from clinical staff using a bag with opaque panels (Australia, Ireland and Saudi Arabia), or an obscuring sticker (NZ and Finland).||t|t|t|t
33954701|NCT04076982|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were told that the study investigated the impact of a dietary intervention on body composition and strength. The 'egg patty' and 'biscuit' were referred to as dietary supplements.|Qualifying participants will be stratified and randomly assigned to one of two treatment arms: mung bean protein or control biscuit. Participants will meet with study investigators on two occasions separated by 8 weeks for assessments.|t|f|f|f
33954702|NCT04655339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954703|NCT01152931|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058509|NCT05351541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This trial is testing various doses of psilocybin in combination with add-on medications. Participants, study staff and clinical assessors will be blinded to individual treatment conditions until study close-out. The clinician administered instruments will be administered by different clinical study staff than the facilitators who provide the preparation, psilocybin therapy, and integration sessions.|All patients will receive a dose of psilocybin between 1-30 mg, and one of the following: placebo, zolpidem, modafinial, or zolpidem and modafinil. All patients will receive two psilocybin preparation sessions , a single dose of psilocybin within a therapeutic environment (6-8 hours), three integration sessions and two follow up visits. All drugs will be orally administered during the dosing session. The study procedures will follow best practices for administering psilocybin in clinical trials.|t|t|t|t
34058510|NCT04527211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Simple randomization will be done with a random number generator and masking will be maintained by concealing the allocation with opaque envelopes. The active medicine as the control will have the same presentation, color and taste, it will be differentiated by a pre-established code from the maker. This will maintain the concealment of patients, caregivers and evaluators. At the central level, only an intervention safety coordinator will know the assignment of each patient in case serious adverse events occur and the concealment needs to be lifted. The outcomes of interest will be obtained from the clinical history of the patients and through direct measurement in the follow-up visits.|It will be performed a randomized, multicenter, triple-masked, placebo-controlled clinical experiment to determine the relative risk of SARS COV-2 infection, seroconversion, and clinically presenting disease.|t|t|t|t
34058511|NCT02211963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34058512|NCT06213740|||COHORT||RETROSPECTIVE|||||||
34058513|NCT05914038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058514|NCT03846115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34058515|NCT04094272|||COHORT||PROSPECTIVE|||||||
34058516|NCT06021756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058517|NCT06618612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162530|NCT00350688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162531|NCT05331586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34162532|NCT04463342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded (Participant and Outcome assessor)|Occlusal Caries in Posterior teeth|t|f|f|t
34162533|NCT03056742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162534|NCT02665572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162535|NCT05674058|||COHORT||PROSPECTIVE|||||||
34058518|NCT01873300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058519|NCT02763332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058520|NCT01870674|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34058521|NCT03266692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162536|NCT00858624|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34162537|NCT05314335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34162538|NCT04083430|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765231|NCT05975437|||OTHER||OTHER|||||||
33765232|NCT06461819|NA|SINGLE_GROUP||TREATMENT||NONE||"2) Clinical study design~-A single institution with a single group, a phase II study, Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase. We plan to evaluate grade 1 or higher rectal bleeding occurring within 3 years in patients who have received low -fractionation curative radiotherapy.~3) Primary endpoint NIH-NCI Common Terminology Criteria for Adverse Events (CTCAE) V 5.0 Frequency of rectal bleeding of grade 1 or higher within 3 years~4) Secondary endpoint~1. Radiation therapy-related side effects other than rectal bleeding~2. Side effects related to biodegradable material injection~3. 5-year biochemical recurrence-free survival~4. 5-year progression-free survival~5. 5-year overall survival~6. quality of life"||||
33765233|NCT05553847|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The patient will be blinded for the oxygen supply. An independent person will prepare the oxygen setup with usual fixed dose or automated titration. The setup i covered. The assessor conducting the tests is blinded.|multicentre double blinded randomized crossover trial|t|f|f|t
33849885|NCT03838887|||CASE_CONTROL||PROSPECTIVE|||||||
34162539|NCT04966260|RANDOMIZED|PARALLEL||OTHER||NONE||This is a small randomized controlled trial conducted in a study population of patients admitted to a geriatric palliative care unit. The clinical team will determine if the patient is eligible for the study. Patients and families/friends of patients who are randomized to the personalized VR will be consented over the telephone by the research assistant., Participants will then be randomly assigned into one of the three study arms: comparator, standardized VR or personalized VR, on a 1:1:1 basis using computer-generated random numbers and a block size of 3 without additional stratification.||||
34162540|NCT02159235|||||RETROSPECTIVE|||||||
34162541|NCT06383416|||COHORT||RETROSPECTIVE|||||||
34162542|NCT00406172|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34162543|NCT00314964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162544|NCT03418636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34162545|NCT04730856|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162546|NCT03216408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162547|NCT02652351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162548|NCT05682001|||CASE_CONTROL||PROSPECTIVE|||||||
34162549|NCT04660149|||COHORT||CROSS_SECTIONAL|||||||
34162550|NCT01744548|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34162551|NCT03825302|||CASE_CONTROL||PROSPECTIVE|||||||
34162552|NCT04589442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162553|NCT04311762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162554|NCT04736381|||COHORT||PROSPECTIVE|||||||
34162555|NCT01793766|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34162556|NCT03028610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162557|NCT05272475|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||Our study is a crossover trial with subjects randomized to one of two treatment sequences: (A) a single dose of chamomile extract capsule followed by a single dose of chamomile tea or (B) a single dose of chamomile tea followed by a single dose of chamomile extract capsule. The study requires two visit days where subjects will consume their assigned chamomile preparation at the research site. To minimize any carryover effects, the two visits must be at least 3 days apart, and no more than 8 weeks apart. Randomization will be computer-generated by the biostatistician using the SAS software, and implemented using REDCap software|f|f|t|f
34162558|NCT04492501|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||It will be an interventional retrospective case control, single centre based cohort study in Pak Emirates Military Hospital Rawalpindi (PEMH), Pakistan from 1st April to 31st July 2020. This study will be carried out at the Department of Pulmonology and Critical care. PEMH is the largest Covid-19 designated hospital in the country. Data of all hospitalized patients is maintained by PEMH Covid-19 Research and evaluation cell. The study was approved by Institutional Review Board.||||
34162559|NCT00648362|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34162560|NCT00965575|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34162561|NCT02798978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162562|NCT02094651|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34162563|NCT01199224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162564|NCT04394065|||COHORT||PROSPECTIVE|||||||
34162565|NCT05030168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162566|NCT03583970|||COHORT||RETROSPECTIVE|||||||
34162567|NCT01511016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162568|NCT00241345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162569|NCT05935371|||CASE_CONTROL||PROSPECTIVE|||||||
34162570|NCT01940835|||CASE_CONTROL||PROSPECTIVE|||||||
33745629|NCT04579263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two obese patients selected according to the inclusion criteria will undergo fecal microbiota transplantation from a healthy donor with a normal body mass index against the background of glucose-lowering therapy||||
33745630|NCT00492349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745631|NCT01689116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765234|NCT01222429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33765235|NCT02975284|||COHORT||PROSPECTIVE|||||||
33765236|NCT02543320|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33765237|NCT01736501|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765238|NCT04749927|||COHORT||PROSPECTIVE|||||||
33765239|NCT00984321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33765240|NCT05326763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765241|NCT01765595|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765242|NCT03233178|||COHORT||RETROSPECTIVE|||||||
33765243|NCT04803617|||CASE_CONTROL||PROSPECTIVE|||||||
33765244|NCT02553811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765245|NCT05008029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will analyze the database without knowing which treatment arm each participant was allocated. He does not work in the center where the study will be carried out, nor does he contact the participants.||f|f|f|t
34162571|NCT06023706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33954704|NCT04907994|||COHORT||RETROSPECTIVE|||||||
33954705|NCT03867500|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33954706|NCT00946556|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33954707|NCT00848666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162572|NCT01599013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162573|NCT03826238|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162574|NCT03410563|||COHORT||PROSPECTIVE|||||||
34162575|NCT00895115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162576|NCT01897363|||CASE_ONLY||PROSPECTIVE|||||||
33954708|NCT04308759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34162577|NCT05326646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162578|NCT05211206|||COHORT||PROSPECTIVE|||||||
34162579|NCT03920943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigators will conduct a prospective cohort study of patients undergoing emergent or urgent interfacility patient transport by Ornge in Ontario, Canada. The study will include all patients, regardless of age, who are intubated and mechanically ventilated, and transported for emergent or urgent indications.||||
34162580|NCT05509426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162581|NCT03654937|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33954709|NCT04724070|||COHORT||PROSPECTIVE|||||||
34162582|NCT00924248|||COHORT||PROSPECTIVE|||||||
34162583|NCT01789437||PARALLEL||DIAGNOSTIC||NONE||||||
34162584|NCT03592368|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34162585|NCT00713544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162586|NCT05546476|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind for 12-week double-blind treatment period followed by an up to 1 year optional open-label treatment period||t|t|t|t
34162587|NCT02398604|RANDOMIZED|PARALLEL||TREATMENT||NONE|HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio|20 patients and 10 patients will be controls with a total of 30 HLHS patients.||||
34162588|NCT02737475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162589|NCT02643238|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162590|NCT00991939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162591|NCT04279535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745632|NCT06534515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This will be a two-arm, randomized controlled trial exploring whether the Tomatis training could improve the components of auditory processing in children with NDDs referred to a Romanian Child and Adolescent Psychiatric Unit. Outcomes assessment will be conducted at baseline (T1), immediately after the training (T2).|t|t|t|t
33745633|NCT06530953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33745634|NCT00690521|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745635|NCT01985126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745636|NCT03822442|||COHORT||PROSPECTIVE|||||||
33745637|NCT03080129|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33954710|NCT00030849||||TREATMENT||||||||
33954711|NCT02609932|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33954712|NCT02066688|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33954713|NCT04839835|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33954714|NCT02663999|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954715|NCT00290511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954716|NCT01900925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954717|NCT03162276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954718|NCT06519500|||COHORT||PROSPECTIVE|||||||
33954719|NCT02263222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162592|NCT05421481|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34162593|NCT03374371|||CASE_CONTROL||RETROSPECTIVE|||||||
34162594|NCT01862913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162595|NCT04106518|||COHORT||PROSPECTIVE|||||||
34162596|NCT02451020|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745638|NCT02979535|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745639|NCT03140436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each group received treatment through a different operator (one operator per one group). Each patient was randomized using sealed envelopes according to treatment side (right or left) using powder grain size 65 µm or 40 µm. The patients and operators were blinded from the type of the powder.|This study was designed as a double-blind, randomized split-mouth design.|t|t|t|f
33745640|NCT06197893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745641|NCT02543346|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33745642|NCT00288587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745643|NCT01183377|||||CROSS_SECTIONAL|||||||
33745644|NCT06270823|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33745645|NCT03447782|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This group includes patients reviewed after 3 months of observational study with NDPH who have not improved clinically-they will take naltrexone, 4.5 mg, for 3 months. The other group includes healthy control patients||||
33745646|NCT04030416|||CASE_ONLY||CROSS_SECTIONAL|||||||
33745647|NCT04053764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745648|NCT05605119|NA|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation 3+3 dose escalation"||||
33745649|NCT04709536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162597|NCT03589261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162598|NCT04679974|NA|SINGLE_GROUP||TREATMENT||NONE||ABA design||||
34162599|NCT02440243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162600|NCT00943930|||CASE_ONLY||PROSPECTIVE|||||||
34162601|NCT05447208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162602|NCT03643458|||CASE_ONLY||PROSPECTIVE|||||||
34162603|NCT02473900|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162604|NCT01736670|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33745650|NCT01322516|||COHORT||PROSPECTIVE|||||||
33765246|NCT04508296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162605|NCT01750216|||COHORT||PROSPECTIVE|||||||
34162606|NCT06210048|||OTHER||PROSPECTIVE|||||||
34162607|NCT00832416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849886|NCT01164904|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33849887|NCT02870803|||COHORT||PROSPECTIVE|||||||
33849888|NCT05601154|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33849889|NCT03410368|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with small-cell lung cancer receive autologous NK cells adoptive cancer immunotherapy as a maintenance therapy in the presence of stable disease (SD), partial remission (PR) or complete remission (CR) after the first-line chemotherapy.||||
33954720|NCT04288739|||CASE_ONLY||CROSS_SECTIONAL|||||||
33954721|NCT01267227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954722|NCT00088400||||TREATMENT||||||||
34162608|NCT06280508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745651|NCT04304833|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||The provider-directed management model is the current care standard for patients with HF; care delivery consists of office and emergency visits, with telephone or in person communications. The mHealth care management model consists of real time bio-monitoring kits and telemedicine visits using a secure wireless gateway with a cloud-based clinician portal connected to a Bluetooth-paired Android Tablet. Daily readings are transmitted to a 24-hour RN call center and triaged per protocols.|t|f|f|f
33745652|NCT03176680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33745653|NCT06636097|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745654|NCT00438386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745655|NCT01664845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745656|NCT01311102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745657|NCT04125420|||COHORT||PROSPECTIVE|||||||
33745658|NCT06568302|NA|SEQUENTIAL||TREATMENT||NONE||||||
33745659|NCT04686448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745660|NCT03116594|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33849890|NCT00819390|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33849891|NCT06532370|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will all be assigned to the CM intervention group and will be asked to follow-up three times per week for a total of 12-weeks to engage in the intervention.||||
33849892|NCT03258684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The participants in treatment group receive intravenous vitamin C, hydrocortisone, and thiamine. The participants in control group receive normal saline.|t|f|f|t
33849893|NCT00061984|RANDOMIZED|||TREATMENT||NONE||||||
33954723|NCT06418932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham procedure. Blinded to treatment allocation. The investigator and the patients will be blinded to treatment assignments. For this purpose, a restraint system will be used which will be applied to the lower limbs and will mask the assignment.|Patients will be assigned to standard treatment (parenteral administration of furosemide) versus parenteral administration of furosemide plus lower limb compression therapy for a maximum of 72 hours. The dose of furosemide in all participants will be based on the clinical judgment of the responsible health professional.|t|f|t|f
33954724|NCT01261962|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34076572|NCT02198729|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076573|NCT02736448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076574|NCT06036394|||CASE_ONLY||RETROSPECTIVE|||||||
34162609|NCT02951494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162610|NCT02694302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162611|NCT02446717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162612|NCT02780284|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34162613|NCT03316144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162614|NCT01522300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162615|NCT05287828|||OTHER||RETROSPECTIVE|||||||
34162616|NCT02607943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162617|NCT04713163|||COHORT||PROSPECTIVE|||||||
34162618|NCT01709370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162619|NCT00881114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162620|NCT00398840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162621|NCT04226846|||COHORT||PROSPECTIVE|||||||
34162622|NCT05870488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162623|NCT01397461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162624|NCT03402035|||COHORT||PROSPECTIVE|||||||
33849894|NCT04324203|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076575|NCT06405178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076576|NCT01164150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076577|NCT01266824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34076578|NCT01884948|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34076579|NCT01779557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076580|NCT02574169|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076581|NCT04256980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076582|NCT06107647|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076583|NCT03251157|||OTHER||CROSS_SECTIONAL|||||||
34162625|NCT05702502|||CASE_ONLY||PROSPECTIVE|||||||
34162626|NCT05183438|||CASE_CONTROL||RETROSPECTIVE|||||||
34162627|NCT01743443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162628|NCT05836168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|placebo, outcome assessors are blinded to the group allocation|Randomized, placebo controlled study|t|f|t|t
34162629|NCT03772262|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34162630|NCT04034004|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Only the study physician, research coordinator, and research pharmacist will be aware of drug assignments. Research staff (nurses; research technicians) and the PI will be blinded to drug assignment.|The study will employ a double blinded crossover factorial design. Baseline pain ratings will be assessed using visual analog scales obtained during three sessions where low back pain is induced. Study volunteers will participate in a four session (20min/session) meditation intervention. After meditation training, subjects will report to the UCSD Altman Clinical and Translational Research Institute across two separate experimental sessions. Half of the volunteers will be administered naloxone (opioid antagonist; 0.15 mg/kg bolus+ 0.1 mg/kg/hour infusion) and the other in the subsequent session will be administered IV placebo-saline, vice versa.|t|f|t|t
34162631|NCT06298136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be informed that an intervention (program A or program B) will be assigned to them randomly. For research team who will be in contact with participants for outcome assessment, whether the participants have been allocated to arm 1 or arm 2 will be blinded.|This study will investigate the effects of an online mindfulness-based intervention (MBI) on outcomes in children with ADHD. The effects of the MBI (arm 1) will be investigated in comparison with the effects of psychoeducation (arm 2).|t|f|f|t
34162632|NCT03698227|NA|SINGLE_GROUP||TREATMENT||NONE||Olaratumab and doxorubicin rechallenge in anthracycline pretreated, advanced soft tissue sarcoma patients||||
34162633|NCT03580681|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34162634|NCT02586623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162635|NCT05980585|NA|SINGLE_GROUP||PREVENTION||NONE|The participant, the investigator, and the outcomes assessor will all be masked to the device data during the trial.|The study looks at a single group of patients that uses the CPM Device||||
34162636|NCT03724929|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34162637|NCT03309423|||CASE_ONLY||PROSPECTIVE|||||||
34162638|NCT02053636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162639|NCT06051903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162640|NCT03357562|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34162641|NCT06294730|||COHORT||PROSPECTIVE|||||||
34162642|NCT02521922|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34162643|NCT00005617||||TREATMENT||||||||
34162644|NCT04531241|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34162645|NCT05981482|||CASE_ONLY||CROSS_SECTIONAL|||||||
34162646|NCT05650281|||COHORT||RETROSPECTIVE|||||||
34162647|NCT01979952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162648|NCT04737018|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34162649|NCT06407050|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34162650|NCT04656457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34162651|NCT06090565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were randomised to cefixime 800 mg single oral dose plus doxycycline 100 mg twice a day orally for 7 days or the comparator ceftriaxone 1 g single intramuscular dose plus azithromycin 2 g single oral dose with a computer-generated pseudo-random code using permuted block randomisation in a 1:1 ratio|f|f|f|t
34162652|NCT02517697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162653|NCT02759250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162654|NCT02134717|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34162655|NCT00620724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162656|NCT02770924||PARALLEL||TREATMENT||NONE||||||
34162657|NCT04229641|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34162658|NCT00891228|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34162659|NCT01388907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162660|NCT00224588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162661|NCT00306085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34162662|NCT05431478|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34162663|NCT05651906|||COHORT||PROSPECTIVE|||||||
34162664|NCT03265236|||CASE_CONTROL||PROSPECTIVE|||||||
33765247|NCT02708433|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33765248|NCT05520385|||CASE_CONTROL||PROSPECTIVE|||||||
33765249|NCT01616576|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765250|NCT02385019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765251|NCT03342053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765252|NCT01876641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765253|NCT00167895|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33765254|NCT02601898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765255|NCT00199498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33765256|NCT05138159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765257|NCT06624618|||CASE_ONLY||RETROSPECTIVE|||||||
33765258|NCT05189054|||COHORT||PROSPECTIVE|||||||
33765259|NCT00951262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33765260|NCT00724139|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765261|NCT03107819|||COHORT||PROSPECTIVE|||||||
33765262|NCT05458596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765263|NCT01752088|||CASE_ONLY||PROSPECTIVE|||||||
34162665|NCT02083536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162666|NCT03054649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162667|NCT02837029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162668|NCT01420926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162669|NCT04714008|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34162670|NCT01440855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34162671|NCT05001204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162672|NCT05984043|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162673|NCT00646425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765264|NCT05876611|||COHORT||PROSPECTIVE|||||||
34058522|NCT06461221|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind sham-controlled|Each participant receives 4 stimulation conditions in a counterbalanced order across 4 visits (1 stimulation condition/visit)|t|f|t|f
34058523|NCT00044707|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34058524|NCT00276211|||COHORT||PROSPECTIVE|||||||
33954725|NCT04824612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The evaluator, analyst, and participants will be unaware of the group to which the participants are allocated. The operator will also be unaware of whether the blue light has a biological effect or is a placebo.|58 patients will be allocated in the experimental and control groups: sham (N = 29): intralesional administration of corticoid (IAC) and sham PBM in the preoperative and postoperative periods of keloid removal surgery; and experimental group with active PBM combined with IAC (N = 29) in the preoperative and postoperative periods of keloid removal surgery. Transcutaneous PBM will be performed on the keloid in the preoperative period and on the remaining scar in the postoperative period using blue LED (470 nm, 0,4 W, 24J per point on 10 linear points, total 240J).|t|t|f|t
33954726|NCT01356290|NA|SINGLE_GROUP||TREATMENT||NONE||3 Strata (medulloblastoma - 40 patients; ependymoma - 30 patients; ATRT - 30 patients)||||
33954727|NCT06565767|RANDOMIZED|PARALLEL||OTHER||NONE|open|||||
33954728|NCT06047964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954729|NCT04192747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-blind, 1:1 Randomized trial of parallel design|t|f|f|t
33954730|NCT02674568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954731|NCT01296269|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33954732|NCT02016027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954733|NCT06313697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058525|NCT00317200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058526|NCT04326868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The participants diagnosed positive for Soil Helminths Infection will be randomly assigned to one of the following treatment arms of the study.~Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study. These regimens consisted of treatment as follow: given as a single tablet once daily for 3 consecutive days~* A single tablet of ABZ (400mg), administered during 3 consecutive days;~* 1 tablet of ABZ 400mg + 1 tablet of MBZ (500mg) administered in 3 consecutive days,~* 1 tablet of ABZ (400mg) + Pyr (125 mg) administered in 3 consecutive days"|f|f|t|f
34058527|NCT06483061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058528|NCT01694342|||COHORT||PROSPECTIVE|||||||
34058529|NCT01502397|||COHORT||PROSPECTIVE|||||||
34058530|NCT02630849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058531|NCT02968667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34058532|NCT05483894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058533|NCT04197895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058534|NCT04167124|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34058535|NCT04349449|||COHORT||PROSPECTIVE|||||||
34058536|NCT06230666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058537|NCT00705458|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34058538|NCT04220333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The team, composed of five researchers, was divided in two groups: three researchers performed the interview before and after the intervention, two others applied the intervention, which divided participants in two groups: control and intervention, assuming the confidentiality of this classification, as expected in a randomized, case control, blind assessment of outcome study.~Both groups received the same initial recommendations: 'please, lie down, relax and pay attention to your breath'. The total procedure time was the same for both groups."|"The team, composed of five researchers, was divided in two groups: three researchers performed the interview before and after the intervention, two others applied the intervention, which divided participants in two groups: control and intervention, assuming the confidentiality of this classification, as expected in a randomized, case control, blind assessment of outcome study.~Both groups received the same initial recommendations: 'please, lie down, relax and pay attention to your breath'. The total procedure time was the same for both groups."|f|f|t|f
34058539|NCT00750412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058540|NCT06037694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058541|NCT04819503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Blinding is achieved by inserting a card into the rTMS stimulator which determines whether the patients receive active or sham stimulation. Thus, both experimenter and patients are blinded towards group allocation. Care providers are also blinded to the treatment allocation.~The main efficacy analyses will be performed blinded without identification of participants and group allocation."|All included patients participate in sub-study 1 and 2. Sub-study 1 is an observational study where patients undergo a spinal anaesthesia in an open label manner. In sub-study 2, patients are once randomly assigned in a 1:1 ratio to one of two counterbalanced arms: either they first receive active rTMS, and then after a 9 week washout period, sham rTMS, or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation|t|t|t|t
34058542|NCT05640284|||CASE_CONTROL||RETROSPECTIVE|||||||
34058543|NCT06556277|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Double-blind, randomized, placebo-controlled cross-over study|t|f|t|f
34058544|NCT03926390|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058545|NCT05587868|||COHORT||PROSPECTIVE|||||||
34058546|NCT02425722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058547|NCT03653949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Simple blind (investigador/outcomes aseessor)||f|f|t|t
34058548|NCT06389487|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058549|NCT01243502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058550|NCT06260046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33745661|NCT03652311|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not know if they are receiving therapeutic CVS or sham stimulation.~Participant survey responses will be blinded during analysis and only the use of non-informative catalogue will be used. This will eliminate bias in the analysis of the survey data."|This study is designed as a nonrandomized, single-blind, sham-controlled trail in which willing participants will receive a 5 day course of twice daily caloric vestibular stimulation (CVS) or sham treatment|t|f|f|t
33745662|NCT03273439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-institution, randomized controlled, double blinded trial. Participants were randomized to receive, over 4 weeks, 20 sessions of either active or sham rTMS. Clinical assessment was performed at baseline, 4 weeks and 8 weeks by 2 psychiatrists blinded to the treatment assigned. Inter-rater reliability was satisfactory (κa=0.86).|In this study, we assessed the therapeutic effects and safety of left dorsolateral prefrontal cortex (DLPFC) high-frequency repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia. We evaluated the efficacy of rTMS on cognition in patients with chronic schizophrenia.|t|f|f|f
33745663|NCT01737112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745664|NCT02504658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745665|NCT05316038|||COHORT||PROSPECTIVE|||||||
33745666|NCT04986553|||COHORT||PROSPECTIVE|||||||
33745667|NCT02794402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745668|NCT04941755|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33745669|NCT02630667|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33745670|NCT04139317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745671|NCT06457542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Model involves two groups having disease of shoulder impigement syndrome. First group recieves treatment active release technique and Second group recieves soft tissue mobilization.||||
33745672|NCT01529957|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33745673|NCT04972955|||COHORT||PROSPECTIVE|||||||
33745674|NCT06328647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and outcome assessor will be masked to the group allocation. Clinicians will be unmasked to group allocation.|Randomized Clinical Trial|t|f|f|t
33745675|NCT05659290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954734|NCT06247930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954735|NCT04170569|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Single|Randomized Controlled trial with a prospective pretest-posttest experimental model|t|f|f|f
33954736|NCT02252029|||COHORT||PROSPECTIVE|||||||
33954737|NCT03165253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954738|NCT03833531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments will be performed by allocation-blind assessors. Upon seeing a participant for an assessment, assessors are instructed to immediately state that participants are not allowed to discuss aspects of the treatment.|"A randomized controlled trial comparing PTSD-treatment ImRs) to integrated PTSD-PD treatment (SFT-ImRS)in patients with PTSD and comorbid CPD.~The PTSD treatment (ImRS) specifically address the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months. Integrated PTSD-PD treatment consist of a PTSD treatment (ImRS) interwoven in a PD treatment (SFT) that takes at least one group-session per week, for the duration of one year."|f|f|t|t
33954739|NCT04359888|||COHORT||PROSPECTIVE|||||||
33954740|NCT02618148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33954741|NCT04501809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954742|NCT05317923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954743|NCT00577031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954744|NCT00417820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33745676|NCT06467045|||COHORT||PROSPECTIVE|||||||
33745677|NCT04419493|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Part A: Open label Part B: Adaptive two-stage group-sequential design||||
33745678|NCT03778294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745679|NCT01673139|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33745680|NCT01847846|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33745681|NCT02599792|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33745682|NCT06635941|||OTHER||PROSPECTIVE|||||||
33745683|NCT02025777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745684|NCT06636058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33745685|NCT00936858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745686|NCT02395562|||COHORT||RETROSPECTIVE|||||||
33745687|NCT06513897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33745688|NCT00875836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745689|NCT05457946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745690|NCT05834608|||COHORT||PROSPECTIVE|||||||
33954745|NCT01320826|||COHORT||PROSPECTIVE|||||||
33954746|NCT03449277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954747|NCT03672201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and assessors will be blind to the group assignment.||t|f|f|t
33954748|NCT04942561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33954749|NCT05384119|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954750|NCT01246102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954751|NCT04566666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954752|NCT03296267|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
33954753|NCT03128775|RANDOMIZED|PARALLEL||PREVENTION||NONE||"PAAPPAS Nudge is a randomized community-based, school-based trial designed to promote healthful choices in a low-income scenario, with will be held in 2018 school-year in 18 municipal public schools in the municipality of Duque de Caxias, metropolitan area of Rio de Janeiro, Brazil (http://duquedecaxias.rj.gov.br/portal/). All students from the 5th and 6th grade from the 18 selected schools will be invited to participate to the study.~The study design will be of the factorial type, with 4 group arms:~A) Group 1: control (without any activity); B) Group 2: will receive educational activities in the classroom; C) Group 3: will receive changes in the school environment (nudge strategies); D) Group 4: will receive educational activities and changes in the school environment."||||
33954754|NCT03856632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745691|NCT00814203|||COHORT||PROSPECTIVE|||||||
33745692|NCT04291963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33745693|NCT01658787|||COHORT||PROSPECTIVE|||||||
33745694|NCT02079805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745695|NCT01316926|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33745696|NCT00823719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745697|NCT05617716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745698|NCT00742703|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33745699|NCT02541929|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33745700|NCT00628771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745701|NCT04236349|||COHORT||PROSPECTIVE|||||||
33745702|NCT04842955|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33745703|NCT05382416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data collection and analysis will occur without knowledge of participant intervention condition.|SHARE! will advertise the availability of their Peer Toolkit training via their website, email distribution list, and to individuals who previously expressed interest. Participants who enroll in the study will be clustered by worksite. The worksites will be randomized to receive the training either first in the Summer or after follow-up data collection in the Fall.|f|f|f|t
33765265|NCT00874432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058551|NCT00270231|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34058552|NCT02733341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058553|NCT05465616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded for this study.||t|f|f|f
33849895|NCT00768079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849896|NCT02461043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849897|NCT01809496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849898|NCT02782546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849899|NCT04858087|||COHORT||PROSPECTIVE|||||||
33849900|NCT04688502|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33849901|NCT03404687|||CASE_CROSSOVER||PROSPECTIVE|||||||
33849902|NCT02374671|RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-randomized arm was run in parallel with a randomized sub-study consisting of 2 arms; Immediate Treatment and Deferred Treatment. Upon completion of the 6 month observation period, the Deferred Treatment group then crosses over upon implantation to become part of the overall study group.||||
33849903|NCT00267904|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849904|NCT02730637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849905|NCT05320432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33849906|NCT02130921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849907|NCT02097901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849908|NCT06441500|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33849909|NCT02388243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849910|NCT02876276|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33849911|NCT05849831|||COHORT||PROSPECTIVE|||||||
33849912|NCT01261637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849913|NCT01810601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849914|NCT06208098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849915|NCT02547259|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33849916|NCT01330173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849917|NCT05841732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33849918|NCT02652923|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33849919|NCT04619940|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Measurements were conducted separately in different cabinets without seeing each other for each participant by 1 physical medicine and rehabilitation specialist and 1 physiotherapist. The measurements were recorded in separate locations until all participants were completed.|Measurements were conducted separately in different cabinets without seeing each other for each participant by 1 physical medicine and rehabilitation specialist and 1 physiotherapist. The measurements were recorded in separate locations until all participants were completed.|f|f|t|f
33849920|NCT06116864|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||This is a randomized controlled trial that compares Endocuff with Gi Genius (group A) to GI Genius alone (group B) for patients who are undergoing elective outpatient colonoscopy. Patients will be randomized by a secure online randomization software that will allocate patients in a 1:1 ratio to group A or group B.|t|f|f|t
33849921|NCT03068065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849922|NCT01830959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33849923|NCT06372873|||OTHER||RETROSPECTIVE|||||||
33849924|NCT00398554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849925|NCT00262951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849926|NCT01627977|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33849927|NCT02440451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849928|NCT06243393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849929|NCT01182467|||CASE_ONLY||PROSPECTIVE|||||||
33849930|NCT05277103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849931|NCT00946231|||CASE_ONLY||PROSPECTIVE|||||||
33849932|NCT01030406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Matching white tablets||t|f|t|f
33849933|NCT00468104|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33849934|NCT03058029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are assigned to one of two groups in parallel for the duration of the study|t|t|t|f
33849935|NCT03925545|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33849936|NCT03075410|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33849937|NCT01049932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33849938|NCT00497887|||COHORT||PROSPECTIVE|||||||
33849939|NCT00116883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849940|NCT06231654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849941|NCT02686684|||CASE_CONTROL|||||||||
33849942|NCT00003890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058554|NCT06622577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058555|NCT05906186|||COHORT||PROSPECTIVE|||||||
34058556|NCT02590874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34162674|NCT03734003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162675|NCT03237793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A unified stratified randomization, double blind controlled parallel designed was the type generated the allocation sequence. A skilled assistant enrolled the participants and assigned the participants to interventions.|The present study was designed as a randomised controlled clinical trial which was unicenter, double-blinded, parallel designed study, according to the Consolidated Standards of Reporting Trials (CONSORT) criteria, 2010.|t|f|f|t
34162676|NCT01049737|||COHORT||PROSPECTIVE|||||||
34162677|NCT06114186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized 1:1 to the intervention or control groups||||
34162678|NCT05961657|||COHORT||RETROSPECTIVE|||||||
34162679|NCT06532084|RANDOMIZED|PARALLEL||TREATMENT||NONE||In total 88 patients will be included in the study. After inclusion into the study patients will be randomized in 1:1 proportion in two arms (44 patients per arm): treatment with sorafenib or observation. Patients will be followed up for two years. The strata is a type of donor.||||
34162680|NCT00921791|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34162681|NCT03811314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||comparison of therapeutic effect between aerobic and strength training on dementia patient, and comparison of therapeutic effect between isokinetic and isotonic training on patients with mild cognitive impairment|f|f|t|t
34162682|NCT01902329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162683|NCT03948334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849943|NCT01417650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33849944|NCT06610552|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33849945|NCT03916939|RANDOMIZED|PARALLEL||OTHER||SINGLE|simulated osteopathy||t|f|f|f
33849946|NCT02570685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33849947|NCT03141723|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization at birth followed by randomization at 1 hour||||
33849948|NCT06068595|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849949|NCT04772482|||COHORT||PROSPECTIVE|||||||
33849950|NCT02262247|||CASE_ONLY||PROSPECTIVE|||||||
33849951|NCT01467726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849952|NCT02752737|||COHORT||PROSPECTIVE|||||||
33849953|NCT01018303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849954|NCT01744392|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33849955|NCT02850484|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33849956|NCT04664543|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
33849957|NCT02825862|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33849958|NCT00061139|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33849959|NCT04193124|||CASE_ONLY||PROSPECTIVE|||||||
33849960|NCT04029194|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33849961|NCT00619333|NA|SINGLE_GROUP||||NONE||||||
33849962|NCT01559779|||CASE_CONTROL||PROSPECTIVE|||||||
33849963|NCT02845362|NA|SINGLE_GROUP||SCREENING||NONE||||||
33849964|NCT06062290|||COHORT||PROSPECTIVE|||||||
33849965|NCT05939141|||COHORT||PROSPECTIVE|||||||
33849966|NCT04995939|||COHORT||PROSPECTIVE|||||||
33849967|NCT00184665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849968|NCT02192801|||COHORT||PROSPECTIVE|||||||
33849969|NCT03170349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849970|NCT00714545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849971|NCT05979350|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Paralleled 1:1 randomized trial||||
33849972|NCT05817227|||COHORT||OTHER|||||||
33849973|NCT06322979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954755|NCT06234969|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33954756|NCT03172715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954757|NCT05819411|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot Randomized Controlled Trial||||
33954758|NCT04478188|||OTHER||PROSPECTIVE|||||||
33954759|NCT05558046|||COHORT||PROSPECTIVE|||||||
34162684|NCT05692544|||COHORT||PROSPECTIVE|||||||
34162685|NCT04577469|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33849974|NCT01358487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849975|NCT05503472|||OTHER||CROSS_SECTIONAL|||||||
33849976|NCT01225419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33849977|NCT01119599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33849978|NCT03861208|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33849979|NCT02703051|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33849980|NCT02439047|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33849981|NCT03715179|||COHORT||PROSPECTIVE|||||||
33849982|NCT03188393|NA|SINGLE_GROUP||OTHER||NONE||||||
33849983|NCT01475279|NA|SINGLE_GROUP||||NONE||||||
33849984|NCT04504604|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33849985|NCT04463316|||COHORT||RETROSPECTIVE|||||||
33849986|NCT00950586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33849987|NCT04866251|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849988|NCT03268525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The surgeons, the pain assessing researchers, and the participating women will all be blinded to what the syringes contain.|Drug group versus placebo group|t|t|t|t
33849989|NCT03756129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a non-confirmatory, multi-center, 6-treatment arm in the EU countries and 5-treatment arm in the USA (no ketamine arm), randomized, subject and investigator blinded, parallel group, placebo controlled study in treatment-resistant depression patients. The study allows for the inclusion of subjects seeking treatment for their disease from both an 'inpatient' or 'outpatient' clinic setting.|t|f|t|f
33849990|NCT04463966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849991|NCT02355080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33849992|NCT02734927|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33849993|NCT04971681|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33849994|NCT06235944|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33849995|NCT04108052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33849996|NCT02849522|||COHORT||PROSPECTIVE|||||||
33849997|NCT03129139|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849998|NCT01375231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33849999|NCT06611319|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Investigator-initiated and academically sponsored multicenter randomized double blind active-control non-inferiority trial|t|t|t|t
33850000|NCT02476279|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850001|NCT05113329|||CASE_CONTROL||RETROSPECTIVE|||||||
33850002|NCT05216887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850003|NCT05330312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|HAM-A raters are blinded (HAM-A = Hamilton Anxiety Rating Scale).|The investigation consisted of a Part 1 (pilot phase) with a single arm (4 weeks of dCBT), and a Part 2 (pivotal phase) with a randomised, controlled, parallel-group design to either 9 weeks of dCBT or a control group with no intervention.|f|f|f|t
33850004|NCT04481152|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850005|NCT01498029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954760|NCT04705896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blood Banks at participating sites prepare intravenous hyperoncotic albumin and normal saline (control) in identical infusion mini-bags. Opaque bags and intravenous tubing covers will be used to maintain blinding as much as possible.~The packaging for normal saline and 25% albumin will be identical (mini-bags) and be covered. The intravenous tubing will have an opaque sleeve to mask any colour discrepancy in the 2 product"|A randomized controlled trial with two parallel arms 1:1|t|t|t|t
33954761|NCT06650319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954762|NCT00902486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058557|NCT05157620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research staff conducting assessments will not be informed as to which group each participant has been assigned. Additionally, investigators will be be masked to groups, except for Dr. Bramoweth. Dr. Bramoweth will be conducting qualitative interviews with participants enrolled in the YE group only. He will be masked to all other participants except those participating in the qualitative interviews.|This is a randomized controlled trial. Participants will be randomized to either a Yoga-based exercise intervention or a Wellness Lifestyle Program intervention. Both interventions will be conducted simultaneously.|f|f|t|t
34058558|NCT05408325|||CASE_CONTROL||PROSPECTIVE|||||||
34058559|NCT05581472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind. Outcome assessor online surveys.|Three groups are created through randomization to either intervention alone, intervention plus phone coaching or the control group. The intervention includes 8 online intervention modules that are administered weekly for 8 weeks. A 7-day sleep diary is administered one week prior to the intervention and one week after the intervention. The control group completes the online sleep diaries and all the same assessments as the treatment group. At the end of the 1 month follow-up they are given the opportunity to receive the intervention.|f|f|f|t
34058560|NCT02978859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058561|NCT02998476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058562|NCT03204487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058563|NCT03589339|NA|SEQUENTIAL||TREATMENT||NONE||||||
34058564|NCT02719301|||COHORT||RETROSPECTIVE|||||||
34058565|NCT00734331|||CASE_CONTROL||PROSPECTIVE|||||||
34058566|NCT04735770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34058567|NCT00115245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058568|NCT03668717|||CASE_ONLY||RETROSPECTIVE|||||||
34058569|NCT01876537|RANDOMIZED|PARALLEL||TREATMENT||||||||
34058570|NCT02002533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058571|NCT00192101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058572|NCT01103947|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34058573|NCT02346110|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058574|NCT00293371||||TREATMENT||NONE||||||
34058575|NCT06181305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058576|NCT05137535|||FAMILY_BASED||RETROSPECTIVE|||||||
34058577|NCT01825174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058578|NCT00150124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058579|NCT04649918|||COHORT||PROSPECTIVE|||||||
33765266|NCT02670252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765267|NCT05007561|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33850006|NCT00646633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33850007|NCT06202586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33850008|NCT00130624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850009|NCT00000145|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33850010|NCT00972205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850011|NCT02226627|||CASE_ONLY||CROSS_SECTIONAL|||||||
33850012|NCT04982237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058580|NCT05631522|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058581|NCT03785613|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3-way cross-over (three periods, three treatments and six sequence groups) with single application each. There will be a wash-out period between administrations, i.e., between removal of previous patch and application of new patch of at least 10 days.||||
34058582|NCT06623578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058583|NCT04045132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Video coders will be blinded to intervention assignment.||f|f|f|t
34058584|NCT03525028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058585|NCT06389292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058586|NCT03085238|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, non-blinded, single-arm study||||
34058587|NCT01378975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058588|NCT02895308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34058589|NCT04807504|||COHORT||PROSPECTIVE|||||||
34058590|NCT03376347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058591|NCT00148577|||||PROSPECTIVE|||||||
33745704|NCT04800029|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Three-phase interrupted time series design - Experimental Group (TIPS alone); Experimental (TIPS + ED-SAFE); Active Comparator - No intervention, monitoring of Treatment as Usual (TAU)||||
33745705|NCT04985591|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745706|NCT01318187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33745707|NCT01427075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058592|NCT02913365|||COHORT||RETROSPECTIVE|||||||
34058593|NCT02288078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058594|NCT06649448|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058595|NCT03219606|NA|SINGLE_GROUP||OTHER||NONE||||||
33745708|NCT01752192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33745709|NCT05132699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A compounding pharmacy will supply both the study drug and a matching strawberry flavored liquid.|A double-blind randomized controlled clinical trial. Permuted block randomization will ensure equal allocation of participants to either study drug or placebo. Randomization will be performed by a designated study team member.|t|f|t|f
33745710|NCT06279221|||COHORT||PROSPECTIVE|||||||
33745711|NCT03861962|||COHORT||RETROSPECTIVE|||||||
33745712|NCT05168241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|While taking informed consent, the purpose and content of the study were explained to the participants.|Power analysis was used to calculate the sample size of the study. The power of the test was calculated with the G\*Power 3.1 program. The effect size was calculated as 1.24 according to the study of Canga et al., which was a similar study that was taken as a reference during the calculation process (28). The sample consisted of a total of 30 patients, 15 of whom were control and 15 were song/melodica, determined by power analysis at 95% confidence interval, 5% significance level and 1.24 effect size (df=28; t=1.701).||||
33745713|NCT03411655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33745714|NCT04084808|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33745715|NCT01638923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745716|NCT02084966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745717|NCT00158743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745718|NCT01756625|||COHORT||PROSPECTIVE|||||||
33745719|NCT05062928|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33745720|NCT01130766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745721|NCT04740294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blinding will be done in the pharmacy using a pre-developed randomization table. Study medication, whether MgSO4 or placebo, will be prepared by a study pharmacist and sent to the nursing/clinical staff for administration labelled as study drug. Unblinding, if clinically indicated, can be provided to the treatment team but it is not anticipated that this will be required."|This is a randomized placebo-controlled pilot study with 1:1 randomization|t|t|t|t
33745722|NCT03885453|||CASE_ONLY||CROSS_SECTIONAL|||||||
33745723|NCT03619733|||COHORT||PROSPECTIVE|||||||
33745724|NCT04729855|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745725|NCT05524194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745726|NCT05641493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745727|NCT01470755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745728|NCT05591352|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33745729|NCT06669260|||COHORT||PROSPECTIVE|||||||
33745730|NCT05499741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745731|NCT02073331|||COHORT||PROSPECTIVE|||||||
33745732|NCT02194049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745733|NCT04287465|||COHORT||PROSPECTIVE|||||||
33745734|NCT02662842|||CASE_CROSSOVER||PROSPECTIVE|||||||
33745735|NCT03935386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745736|NCT00870805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850013|NCT06196632|||CASE_CONTROL||RETROSPECTIVE|||||||
34058596|NCT00278226|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058597|NCT06060106|||COHORT||RETROSPECTIVE|||||||
34058598|NCT06009016|||COHORT||PROSPECTIVE|||||||
34058599|NCT02468128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058600|NCT00239213|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34058601|NCT02231593|||COHORT||CROSS_SECTIONAL|||||||
34058602|NCT03521817|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a between-subjects parallel study design. All women will undergo a 30% energy restriction for 8-weeks and will be randomized to an ethanol-consuming group or a non-ethanol control group at the start of the study.||||
34058603|NCT02778724|||COHORT||PROSPECTIVE|||||||
34058604|NCT04395612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058605|NCT05487287|||CASE_CONTROL||PROSPECTIVE|||||||
34058606|NCT05373992|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33850014|NCT00790816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850015|NCT04130763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850016|NCT02617303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058607|NCT00810017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058608|NCT06439628|||COHORT||PROSPECTIVE|||||||
34058609|NCT05756127|||OTHER||OTHER|||||||
34058610|NCT01560533|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34058611|NCT03042871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058612|NCT04053010|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058613|NCT03336268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058614|NCT00962091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058615|NCT01440140|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058616|NCT04388904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058617|NCT04978441|||COHORT||PROSPECTIVE|||||||
34058618|NCT03703908|NA|SEQUENTIAL||TREATMENT||NONE||Open-Label, Intra-Subject, Dose Escalation||||
34058619|NCT01811862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162686|NCT00464503|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34162687|NCT02984917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162688|NCT02039284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162689|NCT01919229|RANDOMIZED|PARALLEL||||NONE||||||
34162690|NCT02097030|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34162691|NCT00036634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162692|NCT03499314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34162693|NCT03887273|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34162694|NCT03529968|||COHORT||RETROSPECTIVE|||||||
34162695|NCT05028335|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34162696|NCT04800601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162697|NCT02722200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34162698|NCT01456169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162699|NCT01199809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162700|NCT00756431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162701|NCT03782363|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose finding study for the determination of the MTD for the RP2D with cohort of 3 patients plus 3 other patients as scaling design||||
34162702|NCT03013920|||COHORT||PROSPECTIVE|||||||
34162703|NCT04875052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34162704|NCT00001393|||CASE_CONTROL||PROSPECTIVE|||||||
34162705|NCT00155181|||CASE_CONTROL||OTHER|||||||
34058620|NCT05107466|||OTHER||PROSPECTIVE|||||||
34058621|NCT00560586|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058622|NCT00526565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058623|NCT02567409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058624|NCT01027728|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34058625|NCT04982458|||OTHER||PROSPECTIVE|||||||
34058626|NCT02332239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058627|NCT03071731|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Randomization to decide on which visit the participant will receive the placebo will be generated by a software and managed by the main investigator. Bronchodilators and the placebo will be put in an aerosol of same shape and color so the participants and outcomes assessor won't be able to tell which one is which.|Participants receive one intervention (bronchodilation before performing a functional test) during the initial phase of the study and during the second phase of the study are evaluated in parallel after receiving a placebo or vice versa (random order)|t|t|f|t
34058628|NCT04231396|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||40 subjects will participate in total, including children and adults with HL aided with either Hearing Aids or Cochlear Implants||||
34162706|NCT05171673|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, controlled study in pediatric and adult participants with minor soft tissue injuries. One-hundred fifty (150) participants between 6 and 11years old; 12 and 16 years old; and 18 and 45 years old will be enrolled, with equal numbers in each of the three age groups. The 50 adults enrolled will serve as the control.||||
34162707|NCT03211975|||COHORT||PROSPECTIVE|||||||
34162708|NCT04472299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850017|NCT05180929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850018|NCT06399133|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|This was a single-center, randomized controlled trial of patients hospitalized in the Orthopedics and Traumatology Clinic of a state hospital between September 15, 2022, and April 30, 2023. Overall, 102 patients were randomly assigned to study and control groups. Routine clinical practice was maintained for patients in the control group, whereas a care package constituting postoperative warm water intake, abdominal massage, and a high-fiber diet was provided to those in the study group. Data was collected using the 'Constipation Risk Assessment Scale' and 'Visual Analog Scale'. Constipation severity was evaluated by administering the scales one day before surgery (T0) and one (T1), two (T2), three (T3), and four (T4) days postoperatively. Data were analyzed using SPSS software (version 20.0; IBM, Canada). Statistical significance was set at p \< 0.05.|This was a single-center, randomized controlled trial of patients hospitalized in the Orthopedics and Traumatology Clinic of a state hospital between September 15, 2022, and April 30, 2023. Overall, 102 patients were randomly assigned to study and control groups. Routine clinical practice was maintained for patients in the control group, whereas a care package constituting postoperative warm water intake, abdominal massage, and a high-fiber diet was provided to those in the study group. Data was collected using the 'Constipation Risk Assessment Scale' and 'Visual Analog Scale'. Constipation severity was evaluated by administering the scales one day before surgery (T0) and one (T1), two (T2), three (T3), and four (T4) days postoperatively. Data were analyzed using SPSS software (version 20.0; IBM, Canada). Statistical significance was set at p \< 0.05.||||
33850019|NCT04500795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients divided into two groups, embolization group and control (conventional) group. Patients remain in control group if they refuse embolization.||||
33850020|NCT00090077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850021|NCT05074797|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850022|NCT00106418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850023|NCT02170818|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33850024|NCT01659853|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33850025|NCT01451216|||CASE_ONLY||PROSPECTIVE|||||||
34162709|NCT03189160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850026|NCT03468205|||COHORT||PROSPECTIVE|||||||
33850027|NCT04490590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850028|NCT03312452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will blinded to group allocation by concealment of the IV fluid delivery device in the operating room. Analysts will be presented with data that has been coded to conceal each participants' allocation to either the intervention or control group.||t|f|f|t
33850029|NCT03471351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058629|NCT00735293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058630|NCT02834988|||COHORT||PROSPECTIVE|||||||
34058631|NCT06231602|||COHORT||PROSPECTIVE|||||||
34058632|NCT02900495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058633|NCT02255318|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34058634|NCT01655849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058635|NCT01534208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058636|NCT01443091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058637|NCT04341831|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34058638|NCT06619938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34058639|NCT01149421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058640|NCT05821972|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162710|NCT04701190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The hypotension will be recognized by the participants due to feeling unwell of theirselves. However they will not have any information about the dosage of the study drug. So they will be blinded to the study group which they will be included by the investigator of the study.~The investigator will collect the data coming from the monitors, patients and the newborn. Therefore, the investigator will not be aware of the intervention about the dosing of noradrenaline made by the anesthesiologist."||t|f|t|f
34162711|NCT06727383|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34162712|NCT02859103|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34162713|NCT02732964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162714|NCT06727435|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, single center, prospective clinical trial||||
34162715|NCT02866227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162716|NCT05195541|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34162717|NCT01587040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162718|NCT04376749|||CASE_CONTROL||PROSPECTIVE|||||||
34162719|NCT04968652|||OTHER||CROSS_SECTIONAL|||||||
34058641|NCT02956447|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33850030|NCT04727268|||OTHER||OTHER|||||||
33850031|NCT05299294|||CASE_ONLY||PROSPECTIVE|||||||
33850032|NCT01952353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850033|NCT02679508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850034|NCT01319084|||CASE_CONTROL||PROSPECTIVE|||||||
33850035|NCT01001559|||CASE_CONTROL||RETROSPECTIVE|||||||
33850036|NCT02947087|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850037|NCT01781507|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33850038|NCT03476707|||COHORT||PROSPECTIVE|||||||
33850039|NCT00492362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33850040|NCT06294808|||CASE_ONLY||RETROSPECTIVE|||||||
33850041|NCT01049295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33850042|NCT00195091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850043|NCT02289092|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33850044|NCT03998943|||COHORT||PROSPECTIVE|||||||
33850045|NCT00560118|NON_RANDOMIZED|||TREATMENT||||||||
33850046|NCT01683656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850047|NCT03012698|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will include 30 patients enrolled in 2 stages.~1. The first 15 patients are treated in the more severe dry eye conditioned eye.~2. The remaining 15 patients will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."||||
33850048|NCT01581138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850049|NCT03891693|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will be treated with SUPERA® stents and Passeo-18-Lux||||
33850050|NCT04826861|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33850051|NCT02059785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850052|NCT01611805|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33850053|NCT03009552|||COHORT||PROSPECTIVE|||||||
33850054|NCT01775150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850055|NCT05803031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the type of the intervention and the whole-time frame of the study will be 12 weeks.|This study was designed to be a Randomized, Controlled, Parallel design, Two arms clinical trial. The patients will be randomly allocated to one of the two groups; test and control group using computer generated random tables (www.randomizer.org ) .|t|f|f|f
33850056|NCT00518466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850057|NCT02838927|||COHORT||PROSPECTIVE|||||||
33850058|NCT00039312||||SCREENING||||||||
33850059|NCT04242953|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33850060|NCT04284215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33850061|NCT03603249|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The Outcomes Assessor will be independent of the Clinical Research Associates, i.e. he/she will be analyzing the VerifyNow samples without knowledge of the intervention the patient has received.|The study will be of a prospective, randomized, controlled, sequential trial design.||||
33850062|NCT04618445|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33850063|NCT02747641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850064|NCT04738227|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33850065|NCT00178126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850066|NCT03745261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850067|NCT04092361|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34058642|NCT06390007|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34058643|NCT00556634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34058644|NCT01881880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162720|NCT05737654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162721|NCT01327599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162722|NCT02629120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162723|NCT03570814|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomised trial. Approximately 40 clusters per study arm||||
33850068|NCT03254485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850069|NCT04748874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850070|NCT03695237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850071|NCT01681888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850072|NCT04157374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850073|NCT02004353|||COHORT||PROSPECTIVE|||||||
33850074|NCT01847300|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34058645|NCT00070018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058646|NCT00292110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058647|NCT02528890|||COHORT||PROSPECTIVE|||||||
34058648|NCT01695330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058649|NCT05950581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058650|NCT04340258|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, single-arm||||
34058651|NCT02013661|||||CROSS_SECTIONAL|||||||
34058652|NCT05575791|||COHORT||PROSPECTIVE|||||||
34058653|NCT01425970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850075|NCT06547281|||COHORT||RETROSPECTIVE|||||||
33850076|NCT06481644|||COHORT||PROSPECTIVE|||||||
33850077|NCT00667771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850078|NCT02414932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33850079|NCT04950829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850080|NCT03545503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850081|NCT02670759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850082|NCT04556721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850083|NCT04073251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind controlled clinical study .|t|t|f|f
33850084|NCT04610541|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, multi-center, interventional safety study||||
34162724|NCT04882436|||CASE_ONLY||PROSPECTIVE|||||||
34162725|NCT01965730|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
34162726|NCT02800499|||COHORT||PROSPECTIVE|||||||
34162727|NCT06299540|||COHORT||PROSPECTIVE|||||||
34162728|NCT00824473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162729|NCT03057015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745737|NCT03152552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850085|NCT04877730|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850086|NCT05576753|NA|SINGLE_GROUP||TREATMENT||NONE||One single group of 20 patients||||
33850087|NCT02244645|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33850088|NCT01271491|||CASE_CONTROL||PROSPECTIVE|||||||
33850089|NCT06262074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162730|NCT04597385|||OTHER||PROSPECTIVE|||||||
34162731|NCT06238778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Enrolled subjects randomized to either the treatment arm or the control arm. The patient, the study site personnel, the CRO, and the sponsor are blinded to which group the patient is randomized to. Only the site pharmacist, and one study monitor from the CRO are unblinded. The Medical Monitor is blinded unless there is a medical reason for unblinding.|Randomized, double blind interventional study|t|t|t|t
34162732|NCT05317663|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The investigators will conduct a 2x2x2x4 within-subject (2: HWL vs no-HWL x 2: pre- vs post- smoking) and between-subject (2: beginner vs established smokers x 4: HWLs) experimental study. Participant in each group (beginner, established smoker) will be randomly assigned to one of the 4 HWLs conditions, and undergo 2 WP smoking sessions that differ by HWL on the WP device (HWL vs. no-HWL), with pre-/post-smoking assessment of harm perception, intention to quit, puffing behavior, satisfaction, urge to smoke, and toxicant exposure. The investigators will use Latin Square crossover design balanced for carry-over effect (random order of 4 HWL condition), and to ensure equal distribution of study participants across gender.||||
34162733|NCT06727123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162734|NCT05293639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162735|NCT05304767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162736|NCT01361100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745738|NCT01184066|RANDOMIZED|PARALLEL||TREATMENT||NONE|There was no masking. This intervention was open.|||||
34162737|NCT05516732|||COHORT||CROSS_SECTIONAL|||||||
34162738|NCT00852943|||OTHER||PROSPECTIVE|||||||
34162739|NCT02960607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850090|NCT02442336|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33850091|NCT04218045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking cannot be applied as both patient and surgeons must be fully informed and consenting regarding the procedure of choice, and the possible outcomes and complications|Non-randomized controlled trial, where patients are assigned to one of two kinds of bariatric procedures, and results are compared between both groups||||
33850092|NCT00480129|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33850093|NCT05004571|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||3:1 treatment to placebo|t|t|t|t
33850094|NCT06179394|||CASE_CROSSOVER||PROSPECTIVE|||||||
33745739|NCT01032967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745740|NCT04587440|NA|SINGLE_GROUP||OTHER||NONE||Study of the variation of the dynamic of the pelvic bone in pre and post operative of a hip replacement||||
33745741|NCT00220194|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745742|NCT02411721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745743|NCT00002334||||TREATMENT||DOUBLE||||||
33745744|NCT04032899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745745|NCT02960529|||CASE_CONTROL||PROSPECTIVE|||||||
33745746|NCT00740545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765268|NCT01657630|||CASE_ONLY||PROSPECTIVE|||||||
33765269|NCT02186080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33765270|NCT02901145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765271|NCT02757924|NA|SINGLE_GROUP||OTHER||NONE||||||
33765272|NCT01547299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765273|NCT02413463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765274|NCT04268992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial|t|f|f|f
33765275|NCT03735563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators and medical staff are blinded to the fact which study medication is given. A pharmacist or a nurse not participating in treatment of the child in question prepares the drug. Preparation of the study drug is done in a different location than where the treatment takes place.||t|t|t|t
33765276|NCT02328131|||CASE_ONLY||PROSPECTIVE|||||||
33765277|NCT04399551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study hence no blinding is required|||||
33765278|NCT01078662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765279|NCT02578914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765280|NCT02006121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765281|NCT03495804|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Participants are randomly assigned to group A or B. Participants of group A are given isotonic mannitol as oral contrast agent, while participants of group B are given isotonic polyethylene glycol as oral contrast agent.|f|t|f|t
33765282|NCT06272305|||COHORT||RETROSPECTIVE|||||||
33765283|NCT06307119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34162740|NCT02779049|||COHORT||PROSPECTIVE|||||||
34162741|NCT06544616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850095|NCT04536545|||CASE_ONLY||PROSPECTIVE|||||||
33850096|NCT00977990|||||OTHER|||||||
33850097|NCT03581825|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33850098|NCT05576259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162742|NCT06446986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162743|NCT01094535|NA|SINGLE_GROUP||SCREENING||NONE||||||
33850099|NCT02575859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33850100|NCT03573583|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"To ensure concealment of the allocation, the randomization procedures will be performed by an investigator who are not involved in the assessments.~The team assessing study outcomes will be masked to intervention assignment."|The pilot study will be single-blind, parallel group, randomized controlled trial of 24 moderate to low functioning participants randomized in a 1:1 allocation ratio to a high-intensity Resistance Training group (RT) or a Successful Aging Health Education comparator group (HE) for 14 weeks.|f|f|f|t
33850101|NCT01588483|||CASE_ONLY||PROSPECTIVE|||||||
34162744|NCT04047251|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|None, open label|Open label, dose escalation||||
34162745|NCT03499093|||OTHER||PROSPECTIVE|||||||
34162746|NCT05802043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34162747|NCT00171171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162748|NCT00974649|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34162749|NCT06461832|||COHORT||PROSPECTIVE|||||||
34162750|NCT06725524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162751|NCT00755495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162752|NCT01680666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162753|NCT02489318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162754|NCT02318342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162755|NCT04985461|||CASE_ONLY||PROSPECTIVE|||||||
34162756|NCT00933322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34162757|NCT05516758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162758|NCT03353480|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This is an open-label, randomized, single-dose, 3-way crossover, reference scaled bioequivalence study under fasted and fed conditions in healthy Chinese subjects.~Under each condition, subjects will be randomized to one of the 3 treatment sequences. Each treatment sequence will consist of 3 periods, separated by a washout period of at least 14 days between each period. For sequence 1, first localized originator, then originator and finally originator will be administered. The order for sequence 2 is originator, localized originator and originator. The order for sequence 3 is originator, originator and localized originator."||||
34162759|NCT05291117|||CASE_ONLY||PROSPECTIVE|||||||
34162760|NCT05672706|||COHORT||PROSPECTIVE|||||||
34162761|NCT03954080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162762|NCT02489539|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850102|NCT05161728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850103|NCT02279628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850104|NCT00629733|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850105|NCT02585232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850106|NCT03756987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization sequence will be computer generated. Allocation concealment will be carried out via concealed assignments in opaque, sealed, and consecutively numbered envelopes.||t|t|t|t
33850107|NCT00574756|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33850108|NCT05102721|NA|SEQUENTIAL||TREATMENT||NONE||||||
33850109|NCT04336787|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33850110|NCT01638234|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33954763|NCT06568718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954764|NCT06652698|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954765|NCT00592007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162763|NCT00821496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162764|NCT01098227|||CASE_CONTROL||PROSPECTIVE|||||||
34162765|NCT06725420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blind||f|f|t|t
34162766|NCT04392154|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162767|NCT04407988|NA|SINGLE_GROUP||TREATMENT||NONE||Pyrotinib plus Letrozole||||
34162768|NCT04519502|||COHORT||RETROSPECTIVE|||||||
34162769|NCT03736941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162770|NCT06406023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850111|NCT05201118|NA|SINGLE_GROUP||TREATMENT||NONE||The efficacy and safety, as well as the pharmacokinetic and pharmacodynamic characteristics of CT103A combined with different doses of Selinexor will be assessed in patients with relapsed/refractory extramedullary multiple myeloma. In this study, CT103A will be infused at the dose of 1.0×10\^6 cells/Kg, while Selinexor was set as two dosage groups of 20 mg/week and 40 mg/week. Subjects in all dose groups received a single infusion of CT103A, and at least 1 month after the infusion of CT103A, Selinexor was administered orally once a week for one year when platelet count recovered to ≥50×10\^9 /L. 8 to 10 subjects were enrolled at each dose group level, with a total of 16 to 20 subjects expected to be enrolled.||||
33850112|NCT04896151|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33850113|NCT03118986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33850114|NCT00283218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850115|NCT03828253|||COHORT||PROSPECTIVE|||||||
33850116|NCT00551590|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33850117|NCT00543712|NA|SINGLE_GROUP||TREATMENT||||||||
33850118|NCT00982995|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33850119|NCT04441060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850120|NCT06037473|||COHORT||RETROSPECTIVE|||||||
33850121|NCT04902508|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|All assessors will be blinded to intervention assignments. To reduce assessor bias, after Phases 1 and 2, two different trained research assistants unfamiliar with the participant will administer the Grammatical Language Probe. These same examiners may administer the 1-, 6-, and 12-month assessments. The PIs and board of advisors will also be blinded to intervention assignments.|This study uses a sequential multiple assignment randomized trial (SMART) design with two phases of randomization.|f|f|t|t
33850122|NCT03361280|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33850123|NCT03318042|NA|SINGLE_GROUP||SCREENING||NONE||||||
33850124|NCT02978573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850125|NCT00785993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850126|NCT04837820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3-arm, parallel, randomized controlled trial comparing acupuncture vs. sham acupuncture vs. wait-list control.|t|f|f|t
33850127|NCT01026285|||||PROSPECTIVE|||||||
33850128|NCT04133506|||CASE_CONTROL||PROSPECTIVE|||||||
33954766|NCT03632798|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Study investigators will be kept blind to the schedule. All participants will be screened by the ChemoID drug response assay; however, the treating physician will receive the ChemoID results only for those participants who are randomized to receive ChemoID-guided treatment arm.|parallel group randomized controlled clinical trial|t|t|t|t
33954767|NCT00268385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954768|NCT00960232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954769|NCT00087763|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33954770|NCT06351501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation of the main criterion by the CGAS will be administered by a psychologist trained on this scale who will not have knowledge of the adolescent's attribution group and will not have participated in their care, based on elements keys to the patient's file which will be provided to him without any element that could indicate his group to which he belongs or his original sex, and a telephone interview with the adolescent and with his parents where they will have been previously informed not to not reveal the group to which they belong or the sex of origin.|multicentric, controlled, randomized, open trial with blinded assessment of the primary outcome measure (Prospective Open Blinding Endpoint PROBE study)|f|f|f|t
33954771|NCT06643975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954772|NCT04807881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954773|NCT04687358|||COHORT||OTHER|||||||
33954774|NCT00633009|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34058654|NCT03488849|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a two-arm, open-label study involving users - largely licensed paramedics or combat medics - identifying the cricothyroid membranes on healthy volunteers. The Control Group will perform cricothyroid membrane identification on healthy male and female volunteers of varying heights, weights, and BMI's with the standard, freehand approach. The Experimental Group will perform cricothyroid membrane identification on the volunteers with the help of the SureCRIC.||||
34058655|NCT00689559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34058656|NCT03925584|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"1. To explore the feasibility of implementing standardized nurse-led music therapy for neonates post congenital heart surgery who are admitted to the cardiac intensive care unit.~2. To describe the safety of implementing standardized nurse-led music therapy in the CICU.~3. To gather data regarding sedation requirements of subjects during music therapy.~4. To describe the parents perspective regarding nurse-led music therapy in the CICU."||||
34058657|NCT02255136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, single-blind (subject), randomized, placebo-controlled, parallel group, interventional clinical trial|t|f|f|f
34058658|NCT00621465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058659|NCT03375515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058660|NCT02455375|||CASE_CONTROL||PROSPECTIVE|||||||
34058661|NCT00784550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058662|NCT06623188|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34058663|NCT02685501|||COHORT||PROSPECTIVE|||||||
34058664|NCT00105287|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058665|NCT03546010|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34058666|NCT06211933|NA|SINGLE_GROUP||TREATMENT||NONE||HIFU intervention at day 0 for each patient included.||||
34058667|NCT04750733|||COHORT||PROSPECTIVE|||||||
33850129|NCT05026346|||OTHER||PROSPECTIVE|||||||
33850130|NCT06446622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850131|NCT00363870|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33850132|NCT04569643|||CASE_CONTROL||PROSPECTIVE|||||||
33850133|NCT01518933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850134|NCT00536302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850135|NCT04628351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162771|NCT05079828|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Independent read by masked investigators for assessment of the primary outcome.|Patients will be randomised to receive a PET/CT with either 18F-PSMA-1007 and a second exam with 68Ga-PSMA-11 or vice-versa, in the reverse order.|f|f|f|t
34162772|NCT01110356|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34162773|NCT01012258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162774|NCT02557737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162775|NCT01721226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162776|NCT02008344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162777|NCT04574401|NA|SEQUENTIAL||OTHER||NONE||||||
34162778|NCT01915173|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34162779|NCT06263478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162780|NCT03718767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162781|NCT03670563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Team members collecting outcomes data will not know participant allocation|Randomized controlled trial with two intervention arms and one control arm|f|f|f|t
34162782|NCT03874117|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34162783|NCT01404780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162784|NCT04466306|||COHORT||PROSPECTIVE|||||||
34162785|NCT00323648|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34162786|NCT05541679|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34162787|NCT02964000|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34162788|NCT02630472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34162789|NCT04724915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked investigators will be responsible for the data processing and analysis. Reporting will be done together with non-masked authors.|Arm 1: Robot-assisted total knee arthroplasty Arm 2: Conventional jig-based total knee arthroplasty|f|f|f|t
34162790|NCT02915263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162791|NCT06337669|||COHORT||PROSPECTIVE|||||||
34162792|NCT04770116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study helpers||t|t|t|t
34162793|NCT01284023|||OTHER||CROSS_SECTIONAL|||||||
34162794|NCT03760523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162795|NCT06499285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study in which treatment assignment will be blinded for the Investigators and any personnel (other than the selected unblinded personnel) involved with the study conduct or evaluation at the investigational sites, the CRO, and the Sponsor.|Participants will be randomly assigned in a 2:1 ratio to receive either KER-050 or placebo, respectively, subcutaneously every 4 weeks. Randomization will be stratified according to ring sideroblast status and baseline transfusion burden.|t|t|t|t
34162796|NCT02531893|||CASE_CONTROL||PROSPECTIVE|||||||
34162797|NCT00214539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162798|NCT02497729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850136|NCT05526079|NA|SINGLE_GROUP||TREATMENT||NONE||Induction FOLFOX Chemotherapy followed by concurrent chemoradiotherapy and nonoperative surveillance for complete responders||||
33850137|NCT03341689|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33850138|NCT03398213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850139|NCT01493232|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33850140|NCT04769349|||COHORT||PROSPECTIVE|||||||
33850141|NCT01975870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850142|NCT01244854|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33850143|NCT04298021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850144|NCT05202639|||OTHER||RETROSPECTIVE|||||||
33850145|NCT06284200|||COHORT||CROSS_SECTIONAL|||||||
33850146|NCT01474434|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33850147|NCT03254342|||OTHER||PROSPECTIVE|||||||
33850148|NCT00456677|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double blind, placebo-controlled. crossover study|t|t|f|f
33850149|NCT06067061|NA|SINGLE_GROUP||TREATMENT||NONE||An open-label, monocentric, single arm, phase II study with a safety run-in.||||
33850150|NCT02891408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850151|NCT03524053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Patients will undertake 3 separate conditions in a randomised order.||||
33850152|NCT04955444|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study consists of 2 groups: (1) the historical control group and (2) the post-implementation group. The historical control group includes 160 patients who underwent a thyroidectomy or a parathyroidectomy procedure from January 2018 to December 2019 (20 patients randomly sampled from each quarter prior to bundle implementation). The quality improvement bundle will be implemented at Houston Methodist Hospital in June 2021. The post-implementation group will include the first 80 eligible patients accrued over 4 to 6 months following bundle implementation. An estimated sample size of 80 patients in the post-implementation group and 160 patients in the historical control group will provide 80% power to detect an absolute decrease of 20% in the primary endpoint using a two-sided alpha of 0.05.||||
33850153|NCT03417895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850154|NCT05943899|||OTHER||RETROSPECTIVE|||||||
33850155|NCT00294918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850156|NCT02677454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850157|NCT02907645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33850158|NCT06137326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a parallel group randomized controlled trial with two arms receiving different interventions.|f|f|t|f
34162799|NCT05778981|||COHORT||PROSPECTIVE|||||||
34058668|NCT02719353|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33954775|NCT03713515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Stepped Wedge|f|f|f|t
33954776|NCT04092608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single center randomized controlled superiority study|t|f|f|t
33954777|NCT02959372|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33745747|NCT04838301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After 12 months participants and study personnel will be aware of the open label phase, but initial randomization will remain blind during the entire length of the study (placebo-controlled and open-label periods); that is, all participants and study personnel are blinded to each participant's randomization to initial treatment group.|Participants are assigned to the active intervention or placebo in parallel for 12 months. After 12 months, all participants in the placebo group will be crossed-over to receive Allo for the remainder of the study (6 month open-label phase).|t|t|t|t
33745748|NCT00490646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058669|NCT05400889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058670|NCT01527487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058671|NCT03132870|||COHORT||RETROSPECTIVE|||||||
34058672|NCT02197624|||CASE_ONLY||PROSPECTIVE|||||||
34058673|NCT02403349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058674|NCT06211738|||COHORT||PROSPECTIVE|||||||
34058675|NCT01885767|||CASE_ONLY||OTHER|||||||
34058676|NCT04495816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The healthcare providers interacting with the patients, as well as the participants themselves, will not know which arm they have been assigned to. Only the research fellows will have access to the randomization scheme.|Patients will be randomized into treatment and control groups. The treatment group will receive omega-3-fatty acid supplementation (1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid) to be taken twice daily for 6 weeks. The control arm will receive a placebo pill to be taken twice daily.|t|f|t|f
34058677|NCT02939027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058678|NCT06430502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058679|NCT01664949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058680|NCT02416050|||OTHER||PROSPECTIVE|||||||
34058681|NCT03149289|||COHORT||RETROSPECTIVE|||||||
34058682|NCT04072991|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058683|NCT01688778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058684|NCT03117894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058685|NCT04109937|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study is not blinded.|Participants will be randomized to receive 1 of the 2 treatment arms.||||
34058686|NCT02359812|||COHORT||PROSPECTIVE|||||||
34058687|NCT04318171|||COHORT||PROSPECTIVE|||||||
34058688|NCT01768845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058689|NCT00847782|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34058690|NCT01152216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058691|NCT03485937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058692|NCT02091375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058693|NCT00690300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058694|NCT06309420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Investigator-blinded, Randomized,Tested product versus comparator (benchmark product), In parallel groups, With multiple applications, Single centre.|f|f|t|f
34058695|NCT02061683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058696|NCT04681755|||CASE_ONLY||RETROSPECTIVE|||||||
34058697|NCT02250066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745749|NCT05222230|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective open label basic science study.||||
33745750|NCT04820673|||COHORT||PROSPECTIVE|||||||
33745751|NCT01220557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745752|NCT02000245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745753|NCT03882684|||CASE_CONTROL||RETROSPECTIVE|||||||
33745754|NCT04584112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745755|NCT06636032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745756|NCT03599804|||COHORT||PROSPECTIVE|||||||
34058698|NCT03634436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058699|NCT03795025|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34058700|NCT02679833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34058701|NCT04714632|||CASE_CONTROL||PROSPECTIVE|||||||
34058702|NCT01520142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162800|NCT05408390|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized, single-blind, crossover study|t|f|f|f
34162801|NCT00490958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162802|NCT04811846|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot trial with parallel group design and comparison of 2 established techniques (TURBT, PKVB)||||
34162803|NCT03712683|NA|SINGLE_GROUP||SCREENING||NONE||||||
33850159|NCT01660581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162804|NCT06196346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There was no assignment to different groups and as a result, no masking.|The study was designed to examine changes in inter-brain synchrony over the course of standard psychotherapy, and not treatment effectiveness. As such, a single group design was deemed adequate.||||
34162805|NCT06625905|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850160|NCT02486276|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34162806|NCT03692559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34162807|NCT05024734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162808|NCT04269213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850161|NCT03397732|||CASE_CONTROL||PROSPECTIVE|||||||
33850162|NCT06054282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The investigator enrolling patients will be blinded to group assignments when recruiting patients (until families have consented to participate).|||||
33850163|NCT04949347|||CASE_ONLY||RETROSPECTIVE|||||||
33850164|NCT02721667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850165|NCT04691089|||CASE_ONLY||PROSPECTIVE|||||||
33850166|NCT03386825|||OTHER||RETROSPECTIVE|||||||
33850167|NCT02341027|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850168|NCT04852367|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||prospective non-randomised safety cohort study||||
33850169|NCT02513719|||COHORT||PROSPECTIVE|||||||
33850170|NCT00559611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850171|NCT05251701|||COHORT||PROSPECTIVE|||||||
33850172|NCT00802698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850173|NCT05757284|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850174|NCT00811304|||COHORT||PROSPECTIVE|||||||
33850175|NCT01321385|||COHORT||RETROSPECTIVE|||||||
33850176|NCT00756691|||COHORT||PROSPECTIVE|||||||
33850177|NCT06074029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850178|NCT02859324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162809|NCT05179239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab)|t|t|t|t
34162810|NCT03758534|||COHORT||RETROSPECTIVE|||||||
34162811|NCT00785980|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850179|NCT06145191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Multiple arm randomized controlled trial|t|t|f|f
33850180|NCT06576661|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33850181|NCT02215382|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33850182|NCT01313247|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33850183|NCT01501682|||||RETROSPECTIVE|||||||
33850184|NCT04924842|||CASE_ONLY||PROSPECTIVE|||||||
33850185|NCT04889105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized to Smart MOVE! vs. usual care using block randomization. Randomization will be stratified by baseline 6MWT performance using computer-generated blocks of 2, 4, and 6 to reduce imbalance. A blinded assessor will perform baseline assessment before randomization with condition assignments concealed in prepared envelopes that will be opened after all assessments are completed. Based on the nature of the intervention, it is not feasible to blind participants to their allocation status following randomization or study staff measuring post-assessment outcomes as both the PI and study staff are involved in delivering the intervention.|f|f|t|f
33850186|NCT02250092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850187|NCT04002401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162812|NCT00307905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162813|NCT06727409|NA|SINGLE_GROUP||TREATMENT||NONE||in parallel fashion to optimise tolerated doses of Finerenone||||
33850188|NCT04028089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850189|NCT00485901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850190|NCT05619029|||COHORT||RETROSPECTIVE|||||||
33850191|NCT04011943|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"In total, 85 participants must be registered. 35 are healthy volunteers. Of these volunteers, 15 will receive autologous transplantation of fecal microbiota, 10 will receive both autologous and heterologous transplantation and 10 volunteers form a placebo-controlled group.~50 participants will form a treatment group."|t|f|f|f
33850192|NCT02819362|||COHORT||PROSPECTIVE|||||||
33850193|NCT03177499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850194|NCT00057629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850195|NCT00094354|||||PROSPECTIVE|||||||
34162814|NCT05463081|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34162815|NCT03295760|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34162816|NCT06600321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162817|NCT04704466|||COHORT||RETROSPECTIVE|||||||
34162818|NCT05699824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162819|NCT00625079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162820|NCT04115631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162821|NCT01391624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162822|NCT05007756|NA|SINGLE_GROUP||OTHER||NONE||||||
34162823|NCT06124963|NA|SEQUENTIAL||TREATMENT||NONE||WX390 continuous oral dosing (0.9 mg once a day) Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks)||||
34162824|NCT00242541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162825|NCT05693350|||COHORT||PROSPECTIVE|||||||
34162826|NCT05396911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162827|NCT00773513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162828|NCT00669604|||COHORT||PROSPECTIVE|||||||
34162829|NCT05755139|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignmen||||
34162830|NCT04895241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162831|NCT04869540|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34162832|NCT00855816|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34162833|NCT05973760|||CASE_CONTROL||OTHER|||||||
34162834|NCT01142882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162835|NCT05984680|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||"There are two aims to this trial. Arm A is for participants and providers with study intervention consisting of surveys/interviews and an assessment to design a COPD care pathway for implementation in community oncology clinics, evaluated in Arm B.~Aim B is for participants only to evaluate feasibility of COPD care pathway in oncology clinics."||||
33745757|NCT04712812|||COHORT||PROSPECTIVE|||||||
33745758|NCT04236557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745759|NCT05253625|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The participants will be assigned to three groups. Before, during and after a painful intervention the first group (Group A) will listen to a lullaby recorded with the mothers voice, the second group (Group B) will listen to a lullaby recorded with a unfamiliar female voice, and the third group (Group C) without and intervention (no lullaby).||||
33745760|NCT00991250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745761|NCT00650832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33745762|NCT06162520|||CASE_CONTROL||RETROSPECTIVE|||||||
33745763|NCT01947946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745764|NCT02078323|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33745765|NCT01308216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745766|NCT05427786|RANDOMIZED|PARALLEL||PREVENTION||NONE|A Multi-center, Open Label, Randomized, Parallel-group Study|||||
33745767|NCT00598689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33745768|NCT03579563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33745769|NCT05739747|||COHORT||PROSPECTIVE|||||||
33745770|NCT05169658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745771|NCT01714219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745772|NCT04381026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33745773|NCT05741125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745774|NCT04495374|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34162836|NCT05663203|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34162837|NCT00930384|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34162838|NCT04330963|||COHORT||PROSPECTIVE|||||||
34162839|NCT03974503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors at the post-treatment and follow-up assessment will not be aware of what treatment the participants received.|Participants will be randomly assigned to one of two cognitive-behavioral treatments for sleep and nightmares.|f|f|f|t
34162840|NCT06555809|||OTHER||PROSPECTIVE|||||||
34162841|NCT04439539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162842|NCT05871099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162843|NCT03376737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162844|NCT00971074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058703|NCT05200117|||COHORT||PROSPECTIVE|||||||
34058704|NCT06624254|||COHORT||PROSPECTIVE|||||||
34058705|NCT00454506|||COHORT||PROSPECTIVE|||||||
34058706|NCT05412225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745775|NCT03834064|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The dentist assessing the oral health status of the intervention and control participants will be masked to participant group assignment.|The primary objective of this study is to assess the direct effect of the OHPROM strategy on oral health status of persons with IDD at post intervention \[4-month\] and sustained \[12-month\] in comparison to the control group|f|f|f|t
34058707|NCT05402124|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a single arm, open-label, prospective cohort pilot study.||||
34058708|NCT01763723|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058709|NCT00369200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058710|NCT06200415|RANDOMIZED|PARALLEL||TREATMENT||NONE||supra and sub gingival scaling will be performed to all patients followed by application of local delivery drug within two groups to assess the effects after 1 month then 3 months.||||
34058711|NCT00390442|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058712|NCT01451632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058713|NCT01577849|RANDOMIZED|CROSSOVER||||NONE||||||
34058714|NCT06372275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058715|NCT03395717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind|f|f|f|t
34058716|NCT03817034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058717|NCT04038177|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34058718|NCT05964517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants dont know in which group enrolled.|"Control and study group~Facial distortion modeling was applied to the study group for 30 minutes, once a week, for 4 weeks. The control group was followed for 4 weeks and the same evaluations were made to the patients twice."|t|f|f|f
34058719|NCT01001598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058720|NCT02250261|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058721|NCT00103922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058722|NCT04146675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34058723|NCT04713436|||CASE_CONTROL||PROSPECTIVE|||||||
34058724|NCT00134641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058725|NCT02556619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058726|NCT02952989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058727|NCT06158568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058728|NCT02255552|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058729|NCT03903003|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34058730|NCT00583882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850196|NCT03117231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162845|NCT05939362|NA|SINGLE_GROUP||OTHER||NONE||||||
34162846|NCT02645292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162847|NCT06669117|NA|SEQUENTIAL||TREATMENT||NONE||||||
34162848|NCT06587490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162849|NCT05977842|||COHORT||RETROSPECTIVE|||||||
34162850|NCT06260800|||OTHER||CROSS_SECTIONAL|||||||
34162851|NCT02354014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162852|NCT04770038|||CASE_CONTROL||PROSPECTIVE|||||||
34162853|NCT06674525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162854|NCT03545438|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Within each dosing cohort randomization is performed according to a computer-generated randomization scheme. Other than the study drug prepared by an unblinded pharmacist and administered by unblinded nurses who will be instructed not to discuss randomized treatment assignments and have no other role in the study, all study staff and PI, along with the subjects are blinded as to treatment.|single ascending dose with placebo controll|t|t|t|f
33745776|NCT00832923|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33745777|NCT05881499|||OTHER||CROSS_SECTIONAL|||||||
33745778|NCT01602848|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33745779|NCT03821376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Imaging reviewers will be blinded to pathologic grade|Imaging findings for enrolled patients will be compared to pathologic grading||||
34058731|NCT01332279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058732|NCT03794102|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34058733|NCT01497886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34162855|NCT02246959|RANDOMIZED|PARALLEL||PREVENTION||NONE||In a 4-arm, randomized controlled trial, we propose to evaluate the relative effectiveness and cost-effectiveness of improving cholesterol levels among participants who are at high risk of CVD and who have elevated LDL cholesterol levels by testing process versus outcomes financial incentives. Participants will use electronic pill bottles that continuously monitor statin adherence.||||
33745780|NCT03473886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745781|NCT04166019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Outcome assessors and researchers (and center staff) are blind to the group assignment and intervention undertaken and concealed to the participant list.|Parallel Assignment; repeated-measures 3-arm randomized controlled trial|f|f|t|t
33850197|NCT02875899|||COHORT||PROSPECTIVE|||||||
34058734|NCT05953480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058735|NCT03260426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058736|NCT01494064|||COHORT|||||||||
34058737|NCT01241617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058738|NCT00945204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34058739|NCT01783821|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34058740|NCT02760030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162856|NCT01675518|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34162857|NCT03263624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162858|NCT05683834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162859|NCT04487080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only Arm B and C will be masked to all (Double-blind).||t|f|t|t
34162860|NCT05421013|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 cohorts. In the absence of DLT, subsequent cohorts will receive increasing dose of STP705||||
33850198|NCT01993173|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850199|NCT02807103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850200|NCT06259617|||COHORT||PROSPECTIVE|||||||
33850201|NCT00417105|||CASE_ONLY||PROSPECTIVE|||||||
33850202|NCT06419478|||OTHER||CROSS_SECTIONAL|||||||
33850203|NCT05902156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will be divided into groups according to the randomization list created to assign each patient to a group. Two independent researchers will assign participants to the DiaPaDeSS intervention and control groups and evaluate the outcome measurement data. Researchers will not be blinded because they will perform these interventions. However, the participants will be blinded because they do not know which group they are in.|Patients with type 2 diabetes will be pretested and randomized (intervention 36, control 36) to the DiaPaDeSS intervention and control groups. Both the DiaPaDeSS intervention and control groups will use the DiaPaDeSS for three months. While participants in the DiaPaDeSS intervention group can reach all contents of the DiaPaDeSS, others can reach only these fields: self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires.|t|f|f|f
33850204|NCT02190045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850205|NCT05288569|||COHORT||PROSPECTIVE|||||||
33850206|NCT01276938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850207|NCT04251507|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058741|NCT05520021|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33850208|NCT04812275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850209|NCT00911937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850210|NCT05631470|||COHORT||PROSPECTIVE|||||||
33850211|NCT03086577|||OTHER||CROSS_SECTIONAL|||||||
33850212|NCT05293483|||COHORT||PROSPECTIVE|||||||
33850213|NCT01546636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33850214|NCT01048554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850215|NCT01959997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850216|NCT00416832||||TREATMENT||||||||
33850217|NCT02217124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33850218|NCT04054518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850219|NCT06605495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850220|NCT05790577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850221|NCT05462886|NA|SINGLE_GROUP||OTHER||NONE||||||
33850222|NCT03420170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850223|NCT00670345|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850224|NCT05868902|||CASE_CONTROL||RETROSPECTIVE|||||||
33850225|NCT01800032|||COHORT||PROSPECTIVE|||||||
33850226|NCT00974376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850227|NCT01458431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850228|NCT03601767|||COHORT||PROSPECTIVE|||||||
33850229|NCT00950794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850230|NCT00159133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850231|NCT03732404|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which was used.|This is a randomized, placebo-controlled, study.|t|t|t|t
33850232|NCT01415362|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33850233|NCT00370682|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33850234|NCT06577285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33850235|NCT05670015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33850236|NCT06495372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850237|NCT00876382|||CASE_ONLY||RETROSPECTIVE|||||||
33850238|NCT02047331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34058742|NCT02918552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058743|NCT00732979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058744|NCT03611231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058745|NCT03495154|NA|SINGLE_GROUP||TREATMENT||NONE|All subjects enrolled will receive the Parietene DS Composite Mesh|||||
34058746|NCT04979182|||CASE_ONLY||RETROSPECTIVE|||||||
34058747|NCT00477607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34058748|NCT03438734|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||Prospective Randomized Clinical Study|f|f|t|f
34058749|NCT02039973|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33850239|NCT04181684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850240|NCT01962415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850241|NCT05916339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850242|NCT06609798|||COHORT||PROSPECTIVE|||||||
33850243|NCT04482686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850244|NCT04602273|||COHORT||PROSPECTIVE|||||||
33850245|NCT02614417|||COHORT||CROSS_SECTIONAL|||||||
33850246|NCT00297336|||||PROSPECTIVE|||||||
34058750|NCT03578016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34058751|NCT02991417|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34058752|NCT04991363|NA|SEQUENTIAL||SCREENING||NONE||||||
33850247|NCT05816265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be 1:1 between control group and iron group. Subjects randomized to the iron group will receive iron infusion 1 week after enrollment. The control group will not receive iron replacement infusion.||||
33850248|NCT00148512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850249|NCT05318547|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33850250|NCT02857569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850251|NCT05074927|NA|SINGLE_GROUP||SCREENING||NONE||||||
33850252|NCT00366808|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33850253|NCT02192125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058753|NCT02170896|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058754|NCT04840420|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label randomised control trial||||
34058755|NCT03542331|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34058756|NCT00001656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162861|NCT06577597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blinded study where participants and site staff will be blinded to the study intervention.||t|t|t|f
34162862|NCT05476783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162863|NCT02784171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162864|NCT04227093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled trial|t|t|f|f
34162865|NCT05590728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162866|NCT06590467|||COHORT||OTHER|||||||
34162867|NCT06114888|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants randomized to usual care or usual care + diagnostic intervention.||||
34162868|NCT06335784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745782|NCT05266911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|statistical analysis for secondary outcomes|A pilot randomized controlled trial and follow-up qualitative description study.|f|f|f|t
33745783|NCT04464304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745784|NCT04968938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745785|NCT00022464||||TREATMENT||||||||
33745786|NCT00562159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745787|NCT02828111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33745788|NCT04365946|||CASE_CONTROL||PROSPECTIVE|||||||
33745789|NCT00317239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745790|NCT00618475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745791|NCT03696121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745792|NCT00869232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745793|NCT06457750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745794|NCT03523533|NA|SINGLE_GROUP||OTHER||NONE||This is an observational study.||||
33745795|NCT04351438|||CASE_ONLY||RETROSPECTIVE|||||||
33745796|NCT02247505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745797|NCT01721018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850254|NCT06233825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind.|Randomized controlled feasibility pilot trial.Two-arm study. Half of participants are allocated to the nutritional intervention condition (5 g omega-3, 40 g essential amino acids \[EAA\] per day), and half to the placebo control condition (5 g safflower oil, 40 g non-essential amino acids \[NEAA\] per day).|t|t|t|t
33850255|NCT02802254|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850256|NCT01134120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850257|NCT03518827|||COHORT||PROSPECTIVE|||||||
34162869|NCT03466411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162870|NCT02968342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162871|NCT03081884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will have the same intervention||||
34162872|NCT02346461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162873|NCT03420547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162874|NCT06104904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162875|NCT04047628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34162876|NCT02855268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162877|NCT02883374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162878|NCT05639257|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34162879|NCT06725498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162880|NCT00402870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34162881|NCT02822898|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33745798|NCT05509972|||CASE_CONTROL||PROSPECTIVE|||||||
33745799|NCT03726346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745800|NCT05520905|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33745801|NCT04792346|||CASE_ONLY||PROSPECTIVE|||||||
34162882|NCT03918421|||COHORT||PROSPECTIVE|||||||
34162883|NCT00742183|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34162884|NCT00511134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162885|NCT03550274|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed method pilot cohort study||||
34162886|NCT05919888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a prospective clinical trial in which patients will be assigned a study arm in sequential fashion.|t|f|f|f
34162887|NCT06128369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162888|NCT00733915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34162889|NCT01770574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162890|NCT06727149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162891|NCT04714814|||COHORT||PROSPECTIVE|||||||
33745802|NCT02883725|||COHORT||PROSPECTIVE|||||||
33745803|NCT03080519|NA|SINGLE_GROUP||TREATMENT||NONE||Intervational Therapy||||
33745804|NCT00428454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745805|NCT04757753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be done to the assessors who analyzed radiographs to reduce bias to healing assessment.|Study subject (tooth) will be randomized in a 1:1 allocation ratio between the 2 treatment groups; the allocation will be stratified by the endodontic indication, i.e. primary or secondary root canal treatment, to enhance balance.|f|f|f|t
33745806|NCT06668948|||CASE_CONTROL||PROSPECTIVE|||||||
33745807|NCT04598477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745808|NCT06551519|||COHORT||OTHER|||||||
33745809|NCT01380483|RANDOMIZED|CROSSOVER||||NONE||||||
33745810|NCT02084953|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33745811|NCT06388577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and the person who will perform the statistical analysis will be blinded. Participants will be assigned to intervention and control groups coded as A and B. Afterwards, it will be determined which of the A and B groups belong to the control and intervention groups by drawing lots.It will not be explained to the parents which group they are in, and it will be stated that education about epilepsy will be given. While entering the data, the researcher will enter the data encrypted as A and B in order to prevent measurement bias, the statistical analysis of the data will be carried out according to this encryption and the report of the study will be written in encrypted form. After the statistical analyses of the research are carried out and the research report is written as a result of the data found, it will be explained which of the groups the individuals are included in.|Prospective, single-centre, randomised controlled, single-blind interventional study in parallel groups|t|f|f|t
33745812|NCT02938416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33745813|NCT00426504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745814|NCT01637012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745815|NCT05106231|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|For the blinding of researchers, they remain blinded towards the stage of publication. During the post-intervention follow up, the researchers still are blinded by the participants' allocation, as the Sarawak Pharmacy Service Division keeps the participant list with group allocation. None of the instruments distributed to the participants will disclose their name and group assignment to assure the blinding among researchers who do the data analyses. Only after this study's results are published, the blinding or the codes will be broken through the return of the participants' list to the principal investigator. The Sarawak Pharmacy Service Division will maintain the randomisation codes throughout the study without disclosing them to the researchers or the participants. No breaking code procedure is necessary for this study as the intervention of this study is educational and does not involve the investigation of medicinal products (IMP).|The study's design will be a prospective, multicenter and parallel-design single-blind randomised controlled with two treatment groups. The trial evaluates a PICC's effectiveness in improving HBA1C involving four-session structured group-based intervention (SGBI) of a two to three-hour pharmacist-led program with follow up evaluations. The control arm will have the same syllabus without SGBI.|f|f|f|t
33745816|NCT06310772|||COHORT||PROSPECTIVE|||||||
33745817|NCT02920905|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33745818|NCT04445805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745819|NCT05126797|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34162892|NCT05509803|RANDOMIZED|PARALLEL||PREVENTION||NONE|This will be an intervention delivered at the school-level to improve physical education; blinding is not possible in this study.|This will be a 2-group cluster-randomized clinical trial, with the school being the unit of assignment and randomization. 4 schools will receive an intervention and 4 schools will serve as controls.||||
34162893|NCT02771717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162894|NCT05759858|||COHORT||PROSPECTIVE|||||||
34162895|NCT04243993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162896|NCT05904574|||CASE_CONTROL||RETROSPECTIVE|||||||
34162897|NCT03234413|||CASE_ONLY||RETROSPECTIVE|||||||
34162898|NCT01908530|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34162899|NCT04844502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162900|NCT05727813|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162901|NCT05433155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of the device for clinicians and study staff is not feasible in this study. Participants will be blinded. The statisticians will be blinded at the time of generating the randomization schedule and remain blinded at the time of analysis.|Prospective, randomized, multi-center parallel group trial|t|f|f|f
34162902|NCT03605108|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34162903|NCT00988013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose escalation of total marrow irradiation prior to stem cell transplantation||||
34162904|NCT02837458|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33745820|NCT05369650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, the anesthesiologist, data collectors, the physicians performing the follow-up, and data analysts will be blinded to the group allocation. Blinding will maintain until the completion of the final analyses.|The experimental patients are randomly divided into three groups and received different doses of lidocaine and the control group received the same amount of saline.|t|t|t|t
33745821|NCT02521090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745822|NCT05207059|NA|SINGLE_GROUP||PREVENTION||NONE||HELMS is conceptualised as a single-arm implementation pilot trial, where lifestyle interventions are implemented in overweight or obese women from preconception to pregnancy and postpartum periods. We will follow both mother and child up to 18 months after delivery.||||
33745823|NCT05860322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745824|NCT01923727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745825|NCT03151265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is open label, meaning that no masking occurs|The two study groups (LBP group vs. Active in spot group), will receive the same intervention in the same order (i.e. Baseline day with no intervention, then intervention day with ThermaCare intervention).||||
33745826|NCT03676062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745827|NCT05558059|||COHORT||PROSPECTIVE|||||||
33745828|NCT05057533|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745829|NCT04055948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research Assistant (RA) will be blind to which group CG is assigned.|Randomization will be done using the minimization stratified randomization technique (QMinim). Stratification variables will be CG gender, CG age, and patient cancer type.|f|f|t|f
33745830|NCT00803647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745831|NCT02239718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745832|NCT02961140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745833|NCT00747799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745834|NCT06360835|||COHORT||RETROSPECTIVE|||||||
33745835|NCT01953796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745836|NCT05078944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33745837|NCT05094960|||CASE_CONTROL||PROSPECTIVE|||||||
33745838|NCT04305613|||COHORT||PROSPECTIVE|||||||
33745839|NCT03125304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The participants assigned to the treatment groups will receive acupuncture at Sanyinjiao (SP 6), Zhaohai (KI 6) ,Taichong (LR 3) ,Qichong (ST 30) and Guanyuan (CV4), while the control group will receive acupuncture at non-acupoint.|t|f|f|t
33850258|NCT03095001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33850259|NCT00095420|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33850260|NCT03196154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850261|NCT01134536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850262|NCT02121301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34162905|NCT02396212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162906|NCT06727097|||COHORT||PROSPECTIVE|||||||
34162907|NCT00398034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33745840|NCT04156308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A double masking is proposed. Three active interventions are compared. The patients will be blinded in relation to the study group they belong to, ensuring the masking of the participants.~The data that is intended to be obtained for its analysis are of a self-reported nature and will be collected and administered by an external investigator not linked to the interventions, ensuring the masking of the evaluator.~Due to the nature of the interventions, masking of therapists is not possible."|A pragmatic experimental comparative trial with three branches of study (osteopathic treatment with 2 different dosages versus active muscle exercise) is proposed.|t|f|f|t
33745841|NCT00778466|RANDOMIZED|CROSSOVER||||NONE||||||
33745842|NCT02075593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745843|NCT03285282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33745844|NCT01745861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745845|NCT04597320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Fentanyl group and Esketamine group|t|t|t|t
33745846|NCT03521635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745847|NCT02616094|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33745848|NCT03477448|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33745849|NCT04297540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33745850|NCT03727750|NA|SINGLE_GROUP||TREATMENT||NONE|open-label|Single arm, open-label, interventional||||
33745851|NCT00798798|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33745852|NCT00332748|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745853|NCT05459844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745854|NCT03682094|NA|SINGLE_GROUP||TREATMENT||NONE|No masking.|||||
33745855|NCT00113438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745856|NCT06578767|||COHORT||PROSPECTIVE|||||||
33745857|NCT05954351|||COHORT||RETROSPECTIVE|||||||
33745858|NCT06349161|||COHORT||RETROSPECTIVE|||||||
33745859|NCT02416791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33745860|NCT00448539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745861|NCT06138574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33745862|NCT04413890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745863|NCT06536348|||OTHER||OTHER|||||||
33850263|NCT00173121|||||OTHER|||||||
33850264|NCT01587391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850265|NCT05042232|||COHORT||PROSPECTIVE|||||||
33850266|NCT06475261|||COHORT||PROSPECTIVE|||||||
33850267|NCT04393753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850268|NCT00621361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850269|NCT05773144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33850270|NCT06124911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850271|NCT06414837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850272|NCT02717351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745864|NCT02875587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33745865|NCT03153280|NA|SINGLE_GROUP||TREATMENT||NONE||"Lithium: starting dose: 2x 400mg p.o. per day. Initial target blood concentration (Level 1 = 0.6mmol/L).~Oxaliplatin: 130 mg/m2 in 500 ml normal saline (NS) over 120 minutes on Day 1 of each 3 week cycle.~Capecitabine: 1000 mg/m2 b.i.d po on Days 1 to 14 of each 3 week cycle."||||
33745866|NCT01866410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745867|NCT02196246|||CASE_CONTROL||PROSPECTIVE|||||||
33745868|NCT06635473|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33745869|NCT02026700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745870|NCT02864082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745871|NCT02693873|NA|SINGLE_GROUP||TREATMENT||NONE||GLA:DCanada Program - Education and targeted, personalized exercise for people with hip and/or knee osteoarthritis||||
33745872|NCT02795442|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33745873|NCT03567538|||COHORT||RETROSPECTIVE|||||||
33850273|NCT03029221|||COHORT||PROSPECTIVE|||||||
33850274|NCT00440999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33745874|NCT03408158|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33745875|NCT00116805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745876|NCT02543359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745877|NCT03616951|||CASE_ONLY||PROSPECTIVE|||||||
33850275|NCT05812833|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomized Controlled|t|f|f|f
33850276|NCT03913780|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||920 high-risk patients in cardiac rehabilitation, who after the exclusion criteria, 764 individuals were organized into 3 groups. This research for the group number 1 was retrospective with medical record and for groups 2 and 3 it was a randomized controlled trial with a basic probabilistic sampling by means of a table of random numbers, whose order was randomized through the Microsoft Excel 16.0 program, being the group experimental 1 at the end with 253 participants (aerobic exercise without strength training), 256 participants in experimental group 2 (aerobic exercise + strength training in the upper extremities) and control group with 255 (aerobic exercise + strength training for the lower extremities).|t|t|t|f
33850277|NCT02805881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850278|NCT02116673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33850279|NCT01028027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34162908|NCT06088979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162909|NCT04795739|||COHORT||PROSPECTIVE|||||||
34162910|NCT00196664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34162911|NCT05006261|NA|SINGLE_GROUP||OTHER||NONE||||||
34162912|NCT05523817|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will receive active or sham stimulation and will be blinded as to the stimulation type.|Within-subject crossover study|t|f|f|t
33850280|NCT01957449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850281|NCT01390077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850282|NCT00653666|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33850283|NCT02381600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850284|NCT02847247|NA|SINGLE_GROUP||OTHER||NONE||||||
33850285|NCT02645227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850286|NCT06219369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique."|t|f|f|f
33850287|NCT01692899|||||RETROSPECTIVE|||||||
33850288|NCT02731183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850289|NCT05976893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||patients with very high risk of ASCVD and cancer|f|f|f|t
33850290|NCT02319759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850291|NCT04290936|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Part 1: NUC-naïve patients will be randomization into tenofovir alafenamide(TAF) or placebo arm in 1:1 ratio.~Part 2: NUCs-treated patients will be switched to tenofovir alafenamide(TAF) treatment."|t|t|t|t
33850292|NCT02793076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850293|NCT06231446|||COHORT||OTHER|||||||
33850294|NCT05722574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to either the intervention condition or the information-only control group.|t|f|f|f
33850295|NCT03562650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants are assigned to a condition and given a treatment justification, but are not told whether they are in the treatment or control condition.|Active treatment and active treatment control conditions.|t|f|f|f
33850296|NCT04100577|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A longitudinal, quasi-experimental design with two study arms will be used. Study arm 1 will consist of self-identified pregnant black women who are enrolled in the TNT-PISP intervention and Study arm 2 will consist of self-identified pregnant black women who are not enrolled in the TNT-PISP intervention. During the recruitment process, potential study participants will be able to self- select which study arm they would like to be in after each arm is described in detail. Although self-selection is traditionally discouraged in research, given the vulnerable population the investigator will be working with and historic distrust with medical community, investigator believe there is power in giving women of color choice in how they wish to navigate and engage with this study.||||
33850297|NCT00892073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850298|NCT00153881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850299|NCT03770533|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33850300|NCT02590705|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33850301|NCT03323073|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850302|NCT06327516|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850303|NCT01183234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850304|NCT03531385|||COHORT||PROSPECTIVE|||||||
33850305|NCT06476756|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Group A: combine effects of ACBT and Buteyko techniques will be performed first 3days of cardiac rehab phase 1.~Group B: effect of buteyko techniques will be performed first three days of cardiac rehab phase 1."|t|f|f|f
33850306|NCT05354765|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33850307|NCT03262324|||COHORT||CROSS_SECTIONAL|||||||
33850308|NCT05617482|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"All patients will be informed about the three tyoes of nerve blocks; the ultrasound guided ilioinguinal, iliohypogastric nerve blocks, TAP block and quadratus lumborum block. and will sign that they agree to have any one of them according to randomization.~Also the outcome assessor will be unaware about the type of nerve block given to the patient."||t|f|f|t
33850309|NCT05451914|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850310|NCT02891837|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33850311|NCT04595318|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850312|NCT03138772|||COHORT||PROSPECTIVE|||||||
34162913|NCT06725238|||OTHER||CROSS_SECTIONAL|||||||
34162914|NCT04466852|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Initial feasibility phase with patients discharged from hospital to a pilot Primary Clinic, followed by cluster randomization at Primary Clinic level, stratified by type: i. Family Clinic (with certified Family doctors) or ii. Basic Unit (mix of non-certified doctors)|t|f|f|t
34162915|NCT02470598|||COHORT||PROSPECTIVE|||||||
34162916|NCT00899756|||OTHER||PROSPECTIVE|||||||
34162917|NCT04953130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster randomised trial with 26 communities (13 per arm)|f|f|f|t
34162918|NCT04354324|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34162919|NCT05337800|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34162920|NCT03797846|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective randomized trial with a 6 month follow-up period||||
33745878|NCT04408755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745879|NCT05085600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745880|NCT01509170|||CASE_ONLY||PROSPECTIVE|||||||
33745881|NCT05501860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The study is double masked.|Subjects who provide informed consent and fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 2:1 ratio to receive a single dose of AG-920 or placebo into one (study) eye (2 drops 30 seconds apart).|t|t|t|f
33745882|NCT01703455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850313|NCT06610058|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33850314|NCT01453829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850315|NCT03606668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850316|NCT05612152|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33745883|NCT06635070|||OTHER||CROSS_SECTIONAL|||||||
33745884|NCT05939128|||COHORT||PROSPECTIVE|||||||
33745885|NCT06350903|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33745886|NCT02359396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745887|NCT06429020|||CASE_CONTROL||RETROSPECTIVE|||||||
33745888|NCT04596254|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745889|NCT02202473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850317|NCT03278093|||COHORT||CROSS_SECTIONAL|||||||
33850318|NCT02291081|||COHORT||PROSPECTIVE|||||||
33850319|NCT01981473|||||CROSS_SECTIONAL|||||||
33850320|NCT04658238|||CASE_CONTROL||PROSPECTIVE|||||||
34162921|NCT06108154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"1 SVD group divided into two sub groups. A) interventional.group and B)control group.2. LSCS group divided into two sub groups A)intervention, B)control group.~observation compare for final result."|f|f|f|t
34162922|NCT05867212|||COHORT||RETROSPECTIVE|||||||
34162923|NCT06468995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162924|NCT00318799|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34162925|NCT00856765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162926|NCT04848623|||OTHER||CROSS_SECTIONAL|||||||
34162927|NCT03818035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34162928|NCT04046900|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomized 2:1 to VMT vs. placebo. An initial pilot of 8 people will be enrolled and safety assessed (with unblinding and comparison of the arms) before proceeding with the larger study of 54 people, which will be analyzed separately.|t|t|t|t
34162929|NCT06490133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel groups double blind, 12-week nutritional intervention|t|t|t|t
34162930|NCT02891395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162931|NCT03728010|||COHORT||PROSPECTIVE|||||||
34162932|NCT06576076|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Following a shared two-week baseline assessment period (Arm 1) for all enrolled participants, participants will be split into 2 arms, randomly assigned to one of two interventions (Arms 2 or 3, CB-Abst or CB-Mon).|f|f|f|t
34162933|NCT05534399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162934|NCT04516109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|We will be utilizing anonymous staff surveys. After the staff within the operating room (scrub, circulator, PA, and fellow) completes the paper survey (following the procedure), the staff member (who did not use the device per specific surgery) will administer the survey and seal in an envelope, which will be sent to the PRA. Thus, these responses will be blinded to the PI.|All eligible patients undergoing hip arthroscopy by the principal investigator will be assigned to one of two groups for analysis, based on the appropriate SOC surgical treatment for FAI, hip dysplasia, or a combination of the two. All patients will undergo hip arthoscopy with the use of the modified hip capsule slotted cannula.|f|f|t|f
34162935|NCT06727045|RANDOMIZED|PARALLEL||OTHER||SINGLE|The minimization method was used to determine the patients in the intervention and control groups included in the research sample, and the random distribution of patients to the groups was made by a statistician other than the researcher using a computer program (www.randomizer.org) and taking into account age, gender, and scores from the comfort scale.|Groups (intervention-control) were determined by the minimization method by recording the scores obtained from age, gender and comfort performance.|f|f|t|f
34162936|NCT01708317|NA|SINGLE_GROUP||SCREENING||NONE||||||
33745890|NCT06030245|||COHORT||PROSPECTIVE|||||||
33893352|NCT04200612|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are informed that they will be randomly assigned to either a EAP horse interaction group or a EAP horse movie group. They are told that this study is meant to investigate the outcomes of two different types of EAP. In actuality, there are 3 groups in total - one intervention and two control groups. Participants in the intervention and active-control group will be told that they are in the EAP horse interaction group whereas participants in the placebo-control group are told that they are in the EAP horse movie group.|The design of the experiment will be a single-blind Randomized Controlled Trial. Participants are randomly assigned to either an intervention group, an active-control group or a placebo-control group. Participants in the intervention group will go through the 5-week EAP program consisting of the clinical processing following some activities found in EAP manuals. Participants in the active-control group will undergo a 5-week program that only involves interactions with horses without any clinical input (i.e. commonly coined as animal-assisted activities). Participants in the placebo-control group will undergo a 5-week movie screening of 1 hour each session that is related to horses in the lab.|t|f|f|f
33893353|NCT00597649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893354|NCT02209506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893355|NCT02765841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893356|NCT00396396|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33893357|NCT01737775|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893358|NCT03116880|||CASE_ONLY||PROSPECTIVE|||||||
33893359|NCT05660122|||CASE_ONLY||PROSPECTIVE|||||||
33893360|NCT00391599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34162937|NCT06402123|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This a double-blind study in which investigators, participants/caregivers, Sponsor, and all study personnel will be blinded.|"Randomized, double-blind, placebo-controlled, 3-treatment, 2-period, incomplete-block, 4-sequence, crossover study.~Eligible patients will be randomized to 1 of 4 crossover treatment sequences. Each treatment period will last 12 weeks, separated by a 4-week washout period."|t|t|t|t
34162938|NCT06123078|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Double blind control technique|Repeated measures design|t|t|t|t
34162939|NCT03894618|NA|SEQUENTIAL||TREATMENT||NONE||||||
34162940|NCT04293185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162941|NCT00730808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34162942|NCT06514885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, operators and investigators will not be informed of the group allocation|two-arm randomized controlled clinical trial|t|t|t|f
34162943|NCT05766826|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will conduct individual randomization, assigning half of the women to receive coupons and the other half to the control group as we enroll.||||
34162944|NCT01693536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162945|NCT06457867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34162946|NCT05838157|||COHORT||PROSPECTIVE|||||||
34162947|NCT02509923|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34162948|NCT02820454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162949|NCT04685265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is double-blind. Treatment assignment will not be known to the subjects, the sponsor or the staff who are involved in the clinical evaluation of the subjects and the analysis of data. The randomisation schedule and disclosure envelopes will be generated by an unblinded statistician at Quotient Sciences.||t|t|t|t
34162950|NCT06291480|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Analyses will be done after blinding to participant id and gender.|Intervention period compared to care as usual in cross-over design.|f|f|f|t
34162951|NCT05676112|||COHORT||PROSPECTIVE|||||||
34162952|NCT02667132|||CASE_CONTROL||RETROSPECTIVE|||||||
34162953|NCT02315313|||CASE_ONLY||RETROSPECTIVE|||||||
34162954|NCT05270837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162955|NCT02152709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34162956|NCT00915720|||CASE_ONLY||PROSPECTIVE|||||||
34162957|NCT01597336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162958|NCT06206161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162959|NCT02470520|||COHORT||PROSPECTIVE|||||||
34162960|NCT00446108|||CASE_CONTROL||RETROSPECTIVE|||||||
34162961|NCT00227409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34162962|NCT06727175|||COHORT||PROSPECTIVE|||||||
34162963|NCT04557813|||COHORT||OTHER|||||||
34162964|NCT05092945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups in parallel (with and without Type 2 diabetes). In each group, the protocol will be carried out as a within-subject, randomized, cross-over study in which each subject will serve as his/her own control.||||
34162965|NCT04131179|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34162966|NCT02362464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162967|NCT01462240|||CASE_ONLY||RETROSPECTIVE|||||||
34162968|NCT06088719|||COHORT||RETROSPECTIVE|||||||
34162969|NCT06279377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34162970|NCT01011543|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34162971|NCT03634163|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomization with stepped wedge||||
34162972|NCT04236752|NA|SINGLE_GROUP||TREATMENT||NONE||HDR Brachytherapy Boost of 15Gy to the prostate followed by Stereotactic Ablative Body Radiation (SBRT) 25 Gy in 5 fractions, once weekly to prostate, SVs and pelvic lymph nodes + 6-18 months of ADT||||
33893361|NCT01501487|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893362|NCT06573853|||OTHER||RETROSPECTIVE|||||||
33893363|NCT03693872|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|open|Interventional to minimal risks and constraints, non randomized, open|t|f|f|f
33893364|NCT05648474|||COHORT||PROSPECTIVE|||||||
34162973|NCT01174121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162974|NCT00125957|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34162975|NCT04788394|||OTHER||RETROSPECTIVE|||||||
34162976|NCT04561258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162977|NCT03507673|||COHORT||PROSPECTIVE|||||||
34162978|NCT05870423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose-escalation.||||
33745891|NCT05853250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Personnel who recruited and enrolled patients preoperatively were not involved in any other component of the study. Surgeons and medical providers did not receive any information about group assignment. Reiki/manual therapy personnel did not collect outcome survey data; those that did were not informed of group assignment. Data coming from a database was retrieved by a data analyst who did not receive group assignment information."|Patients were recruited and enrolled into the study preoperatively. After completing baseline information, they were randomized to the intervention or control group. After surgery they received the group assignment.|f|t|f|t
33745892|NCT03921268|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745893|NCT00407992|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745894|NCT05014165|||FAMILY_BASED||PROSPECTIVE|||||||
33745895|NCT05635123|||COHORT||PROSPECTIVE|||||||
33745896|NCT04391049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745897|NCT00122018|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33745898|NCT03137147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745899|NCT04842357|RANDOMIZED|CROSSOVER||OTHER||NONE|The participant cannot be masked because they realise if they are in group A or B|The investigators will recruit last year medical students and randomise them into two groups: Group A and Group B. Both groups will be video recorded during the performance of the two skills on simulators (i.s. Donati suture and intraosseous venous access) (timepoint: T0). Then group A will watch a standardised video about the skills, and group B will do self-study. Then, both groups will be again video recorded during the performance of the two skills on simulators (timepoint: T1). After 1 week group B will watch the same standardised video about the skills, and group A will do self-study. Then both groups will be again video recorded during the performance of the two skills on simulators (timepoint: T2).||||
33745900|NCT03483636|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33745901|NCT06583096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"After initial survey (screening) is received, participants that are eligible for the trial and complete the baseline assessments will be assigned (3:1) to the Assessment Only (n = 25) or the Intervention (n=75) condition.~The intervention arm contains two components: personalized feedback reports and supportive text messages. Each week participants are randomized, with a 2:1 probability to receive (versus not receive) a personalized feedback report, and a 2:1 probability to receive (versus not receive) supportive text messages during the week. For those randomized to receive text messages in a given week, there is a daily 50:50 randomization to receive (or not receive) a text message."||||
33745902|NCT04626791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745903|NCT05043649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745904|NCT03136614|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33745905|NCT03808506|||COHORT||PROSPECTIVE|||||||
33745906|NCT06374602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745907|NCT00648908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745908|NCT02585895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745909|NCT05230524|||COHORT||PROSPECTIVE|||||||
33745910|NCT02873611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745911|NCT01178151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893365|NCT05715216|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893366|NCT05065112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893367|NCT05133986|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33893368|NCT01936038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893369|NCT04724889|||CASE_CONTROL||PROSPECTIVE|||||||
33954778|NCT06341270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of participants will be maintained throughout the observation period. The sham group will receive electrode attachment but without stimulation,Throughout the study, for adequate blinding, an opaque tape will be applied to the patient's skin above the electrodes, and the patient's target acupoints will be wrapped in a blanket. All patients will be informed that they might or might not feel a tingling sensation around the acupoints when the TEAS device is working. The patients should not be unblinded until the statistical analysis of the study data is completed.|Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS）or the sham groups using a computer-generated random number table. After the randomization, use the opaque envelope, hide each group envelope into an opaque envelope, the envelope outside the code, will be sealed to the researcher, when the study, if the inclusion criteria, then open the corresponding numbered envelope, and intervene according to the group scheme in the envelope.|t|f|f|t
33954779|NCT00711165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33954780|NCT05064098|||COHORT||PROSPECTIVE|||||||
33954781|NCT05056740|||COHORT||RETROSPECTIVE|||||||
33954782|NCT00183170|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33954783|NCT00299546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954784|NCT05925764|||COHORT||PROSPECTIVE|||||||
33954785|NCT03635970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the evaluator of the treatment goals does not know the treatment that each patient received|Treatment for peripheral arterial disease plus diabetes with 2 arms of study.|f|f|f|t
33954786|NCT00440193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954787|NCT02705664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954788|NCT01829659|||COHORT||PROSPECTIVE|||||||
33954789|NCT05649787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded only for the evaluator of primary and secondary endpoints|This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out in a single centre.|f|f|t|f
33954790|NCT02768935|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33954791|NCT05032183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954792|NCT05454488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954793|NCT03731325|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-concurrent multiple baseline design;participants will be randomized to a 7 week, or 10 week group with staggered baseline periods followed by 4-8 weeks of the intervention consisting of FBT and EFT. Enrollment is for parent-child dyads.||||
33954794|NCT06138041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33954795|NCT05163548|NA|SINGLE_GROUP||TREATMENT||NONE||Early Feasibility Study||||
33954796|NCT05219032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33954797|NCT03478813|RANDOMIZED|PARALLEL||TREATMENT||NONE||A parallel randomized trial conducted in 9 Child welfare clinics in one City in southern Finland. The study subjects are randomly allocated into intervention and control groups.||||
33954798|NCT06568276|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre Randomized Controlled Trial||||
33954799|NCT04973748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33954800|NCT06043102|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study evaluating the efficacy and safety|Open label study evaluating the efficacy and safety||||
34058757|NCT01659346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058758|NCT04620954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058759|NCT04824755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058760|NCT06301581|||COHORT||RETROSPECTIVE|||||||
34058761|NCT05725408|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either an in-person group or a telehealth group. Both will receive the same intervention but using different formats for delivery.||||
34058762|NCT05473741|||COHORT||PROSPECTIVE|||||||
34162979|NCT04979676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator is unaware of which participants are allocated to which condition; she is only aware of the inclusion criteria all participants must fulfill. The investigator and outcome assessor/data analyst are also unaware of treatment outcome and blind to the allocation condition.|"This work uses a randomized and parallel clinical trial methodology (although the different parallel conditions are collected sequentially over the duration of the trial) to assess the effectiveness of three therapeutic approaches (i.e., CT, CFT and ACT) with adolescents with SAD, compared to a waiting-list control group.~Originally, participants were to be sequentially and over time recruited and allocated to the different parallel conditions (i.e., assignment to CT or to a wait-list control condition in the first year; assignment to CFT or to a wait-list control condition in the second year, and assignment to ACT in the third year). However, the Covid-19 pandemic forced us to adapt the interventions to an online individual format thus delaying the assignment to the experimental conditions. So, all participants recruited in the first year were assigned to the wait-list control group and later randomly allocated to an experimental condition by the responsible investigator."|f|f|t|t
34162980|NCT00813189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162981|NCT01180686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058763|NCT00813670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34162982|NCT04585841|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Control group will enter this study if not wanting to participate in cannabidiol study. Due to this masking is not possible.|Cancer patients entering a phase 2 trial on cannabis for prevention on chemotherapy-induced peripheral neuropathy are asked to enter this study monitoring cannabidiols effect on lean body mass during chemotherapy. 40 participants are expected to enter intervention group, 20 participants in control group.||||
34162983|NCT05037474|||COHORT||RETROSPECTIVE|||||||
34058764|NCT05062330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058765|NCT03308318|||CASE_ONLY||PROSPECTIVE|||||||
34058766|NCT06648525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058767|NCT00026429||||TREATMENT||||||||
33893370|NCT05745662|||CASE_ONLY||PROSPECTIVE|||||||
33745912|NCT05260710|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label)||||
33745913|NCT04818346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded||t|f|t|t
33745914|NCT01432366|||COHORT||PROSPECTIVE|||||||
33745915|NCT05067491|RANDOMIZED|PARALLEL||TREATMENT||NONE||15 Intervention vs 15 non-intervention control group for cynophobia (fear of dogs)||||
33745916|NCT03389802|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stratum 1: Recurrent or refractory primary malignant CNS tumor patients; Stratum 2: Newly diagnosed DIPG patients||||
33745917|NCT01495767|||COHORT|||||||||
33745918|NCT02129738|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33745919|NCT04323436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Run-in part: single arm, open-label.~Randomized part: two-arms parallel assignment, double-blinded, placebo control"|t|t|t|t
33745920|NCT06465147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745921|NCT06040866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745922|NCT02977624|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This exploratory study was a partially randomized controlled trial with a waitlist control crossover design.||||
33745923|NCT02243033|||COHORT||PROSPECTIVE|||||||
33745924|NCT04558710|||COHORT||PROSPECTIVE|||||||
33745925|NCT06543979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745926|NCT00006127||||TREATMENT||||||||
33745927|NCT03916003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745928|NCT01823848|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33745929|NCT03290144|||COHORT||OTHER|||||||
33745930|NCT04331600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745931|NCT03972488|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745932|NCT04073043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The intervention is a secure psychoeducational e-health platform. Participants will be randomized into two groups - Intervention and Control and will be provided with access to self-guided learning modules such as emotional health, healthy living, mental fitness tools and parenting. The Intervention group will also be given telephone coaching by a trained lay coach who will guide participants through the materials, provide positive reinforcement and help to answer questions. The coach will schedule 7 contacts over the 12 week intervention period with an average of 10 - 15 minutes for each call. A suggested script with specific objectives is provided as well as training based on the drafted coach manual. Coach supervision meetings will take place where difficulties/questions will be reviewed including coach logs, recorded contacts periodically and feedback to the coach. The control group will be provided with the intervention materials but will not receive telephone support.|f|f|t|f
33745933|NCT05997004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Patients were randomly assigned to two groups having 31 in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesiologist who were not involved in the study.|t|t|t|t
33745934|NCT02811029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33745935|NCT06287359|||COHORT||PROSPECTIVE|||||||
33745936|NCT00599326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745937|NCT04955639|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant blinded to arm assignment but not to the smoking cessation program he/she is using.|1:1 randomization|t|f|f|f
33745938|NCT03840460|||COHORT||PROSPECTIVE|||||||
33745939|NCT00320658|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33745940|NCT06293235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33745941|NCT05827978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33745942|NCT00633321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893371|NCT00257036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893372|NCT05638321|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33745943|NCT02602808|||COHORT||PROSPECTIVE|||||||
33745944|NCT00153049|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33745945|NCT00384228|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745946|NCT03517774|NA|SINGLE_GROUP||OTHER||NONE||||||
33745947|NCT03293940|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745948|NCT01659723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745949|NCT05808725|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A Randomized, Open Label, Balanced, Three Treatment, Three period, Three Sequence, Single Dose, Crossover design.||||
33893373|NCT06282692|NA|SINGLE_GROUP||PREVENTION||NONE|"This is an open label, phase III trial - immunobridging study. There will be only 1 group in the study. All subjects (12 to 17 years old) will receive INAVAC 5 µg dose.~The vaccine will be administered with 2-dose schedule, intramuscularly, with 28 day interval."|||||
33893374|NCT03230994|||COHORT||PROSPECTIVE|||||||
33893375|NCT05718401|||COHORT||PROSPECTIVE|||||||
33893376|NCT02522819|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33893377|NCT05800691|||COHORT||RETROSPECTIVE|||||||
33893378|NCT00646893|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33893379|NCT04755556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Home Based Intensive Bimanual training|f|f|f|t
33893380|NCT05107180|||COHORT||PROSPECTIVE|||||||
33893381|NCT00022932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893382|NCT05385562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893383|NCT05416892|||COHORT||PROSPECTIVE|||||||
33893384|NCT05274750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double-blind study.|Participants will receive either depemokimab (GSK3511294) or placebo during the study.|t|t|t|f
33893385|NCT04152759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162984|NCT05952557|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised in a 1:1 ratio to one of the following arms: • Arm A: Standard ET of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen) ± abemaciclib • Arm B: Camizestrant ± abemaciclib||||
34162985|NCT02316496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34162986|NCT03319004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34162987|NCT02682667|||COHORT||PROSPECTIVE|||||||
34162988|NCT05899400|||COHORT||RETROSPECTIVE|||||||
34162989|NCT00215033|||||RETROSPECTIVE|||||||
34162990|NCT06726408|||CASE_ONLY||PROSPECTIVE|||||||
34162991|NCT03407755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeon and patient masked to choice of intraocular gas. Study coordinator not masked.|Patients randomized to either air or sulfur hexafluoride (SF6)|t|f|t|f
34162992|NCT06725550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162993|NCT05730413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34162994|NCT05721170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be assigned randomly in 1:1 ratio to either continue or withdraw the already receiving beta-blockers medication||||
34162995|NCT01540357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34162996|NCT05712720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34162997|NCT01950403|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34162998|NCT06113211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34162999|NCT01637155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163000|NCT04344249|||COHORT||PROSPECTIVE|||||||
34163001|NCT06547450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients (participants) will know the treatment they have been assigned to. Healthcare professionals and researchers will know the condition each patient has been assigned to (mandatory to provide a given type of intervention).|All consecutive patients with emotional disorders attending any of the collaborating centers will be asked to participate in the present study. Once inclusion criteria are met, each patient will be randomly assigned to one of the two experimental groups: the 8-session UP group or the 5-session UP group. Randomization will be performed by a researcher unrelated to the study using a computer-generated sequence (Randomizer). Randomization will be stratified according to the severity of the primary measures of depression and anxiety, using the recommended cutoff in the manuals. Stratification will be made to ensure a comparable proportion of severely depressed and anxious individuals in each group. For each subgroup (i.e., severe or less severe depression and/or anxiety), participants will be randomly assigned to the 8-session UP group or the 5-session UP group.|f|f|f|t
34163002|NCT00913419|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33745950|NCT01106144|||CASE_ONLY||RETROSPECTIVE|||||||
33745951|NCT02869217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745952|NCT00110617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745953|NCT02295423|||COHORT||PROSPECTIVE|||||||
33745954|NCT05463562|||CASE_ONLY||PROSPECTIVE|||||||
33745955|NCT05997693|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33745956|NCT03425149|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|only dedicated site staff responsible for handling including preparation and administration of the vaccine will be unblinded||t|f|t|t
33745957|NCT06130059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745958|NCT00035438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33745959|NCT06635265|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Electrode arrays placed adjacent to nerves are connected to an external pulse generator to evaluate the effect of short-term stimulation on airflow and/or AHI||||
33745960|NCT04942106|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33745961|NCT00093769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745962|NCT06322472|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Descriptive research||||
33745963|NCT01413451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33745964|NCT05797285|RANDOMIZED|PARALLEL||TREATMENT||NONE|The treatments in this study will not be masked. Assessment of the primary study objective (wound closure) will be overseen by an adjudication panel of at least two wound care experts to reduce bias.|"In this trial, two groups of subjects with diabetic foot ulcers (DFUs), will receive standard of care (SOC) treatment for their condition. The study has two phases: a 14-day screening phase to determine eligibility, and a 13-week treatment phase. Half of the patients will be randomized to a 510K FDA cleared ProgenaMatrix applied weekly and the other half will be randomized to a 510K FDA cleared ProgenaMatrix applied bi-weekly (i.e., once every two weeks).~SOC includes offloading the DFU with controlled ankle movement (CAM) boots or total contact casting, appropriate sharp or surgical debridement, and wound care covering with ProgenaMatrix followed by a padded 3-layer dressing of 4x4 gauze, soft roll, and compressive wrap."||||
33745965|NCT04980053|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|In this context, individuals included in the study will be assigned to the control and intervention groups respectively, randomized by an expert statistician and received in closed envelopes.|20 for intervention 1 (back massage) group, 20 for intervention 2 (breast massage) group and 20 for control group|t|f|f|t
33745966|NCT06220448|||COHORT||RETROSPECTIVE|||||||
33745967|NCT03722160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745968|NCT04471818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33745969|NCT01793064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33893386|NCT06069791|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Both bupivacaine concentration and order of administration will be unknown except to Research Pharmacy|incomplete block assignment|t|t|t|t
33893387|NCT02580734|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33893388|NCT00603005|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33893389|NCT03714893|||COHORT||RETROSPECTIVE|||||||
33893390|NCT05902728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850321|NCT06248333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One day before the first programming, the grouper and the programmer will release the cover independently. Only the grouper and the programmer will know the group information of each patient, in which the programmer does not communicate with the patient about the programming parameters. After each programming, the results are uniformly placed in the programmer to keep the others (patients, neurologists) blind about grouping and parameters. The evaluation will be finished by neurologists, who do not participate in the surgical treatment and programmer. So that the participants, care providers, investigators, and outcomes assessors will not know which group are assigned to from randomization (Month 2) to Month 5. The statistical team is independent of other researchers.|After completion of DBS surgery (Month 0), participants will undergo an 8-day parameter exploration period after 1-month postoperative recovery (month 1), and DBS off after individual parameters have been determined. At Month 2, participants will be randomly assigned to one of two groups: Group A or Group B. Group A (Activate Stimulation) will have their stimulator turned on after randomization. Group B (Sham Stimulation) will receive sham stimulation, meaning the stimulator will remain off until Study Month 5. At Month 5, Group A will continue to receive stimulation and not have the stimulator turned off, and the stimulator in Group B will be turned on and left on for the remainder of the study (Month 11).|t|t|t|t
33850322|NCT00670839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850323|NCT03062579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850324|NCT02351518|||COHORT||PROSPECTIVE|||||||
33850325|NCT04814641|||CASE_CONTROL||RETROSPECTIVE|||||||
33850326|NCT01052103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850327|NCT01391039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850328|NCT02632162|||CASE_CONTROL||PROSPECTIVE|||||||
33850329|NCT03801473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Initial assessments will be performed by first clinician (EA). Then, patients will be randomly grouped. The outcome assessor, second clinician (TOU) will be blinded.||f|f|t|t
33850330|NCT02743026|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33850331|NCT03444350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The clinician who performed the therapy (S.D.) was not informed about the modality of the treatment till the first session of each patient (right at this moment, a sealed envelope was opened and the clinician was then able to see the treatment modality). The results of the study were evaluated in a blinded manner (both before treatment and after treatment).~The ozone was applied in the gingival sulcus of all teeth with a fine-tipped tool placed in the periodontal pocket. It was moved in the apical-coronal direction in a sweeping motion. Within 30 seconds, this application was applied in mesial, distal, buccal, and lingual manner. No ozone application was used in the Control Group, and they received only placebo."|RANDOMIZED CONTROLLED TRIAL|t|f|t|f
33850332|NCT01675479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850333|NCT02084173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33954801|NCT03624049|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post study||||
33954802|NCT06000007|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control feasibility study with two arms: intervention arm vs. control arm||||
33954803|NCT02530801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954804|NCT01958502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954805|NCT06651736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The 6 and 12-month post-LVR assessments will be administered by a study team member that is masked to Arm assignment.|Participants with IRD will be recruited and will be allocated into one of three study arms, depending on self-reported anxiety. Participants (N \~ 60) without vision-related anxiety will be designated to Arm 1 and receive LVR. Participants (N \~ 120) with vision-related anxiety will be randomly assigned to either Arm 2 or 3, in which participants will receive LVR with adjunctive ERT.|f|t|f|f
33954806|NCT06455475|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patient will be randomized to standard of care (SOC) or Derm-Maxx as an addition to SOC||||
33954807|NCT04275830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33954808|NCT06340750|NA|SEQUENTIAL||TREATMENT||NONE||||||
33954809|NCT05218096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking of treatment allocation will be observed until at least Week 34.||t|t|t|f
33954810|NCT00329758|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33954811|NCT05677763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954812|NCT06308107|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33954813|NCT01165424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954814|NCT05939401|||COHORT||PROSPECTIVE|||||||
33954815|NCT02175472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33954816|NCT03035500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33954817|NCT04139642|||CASE_CROSSOVER||PROSPECTIVE|||||||
33954818|NCT01421524|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954819|NCT01040468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954820|NCT05965323|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34058768|NCT00382876|||DEFINED_POPULATION||OTHER|||||||
34058769|NCT01318213|||OTHER||PROSPECTIVE|||||||
34058770|NCT05136144|NA|SEQUENTIAL||TREATMENT||NONE||Adaptive design||||
34058771|NCT04777669|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058772|NCT00777322|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058773|NCT05769621|||COHORT||RETROSPECTIVE|||||||
34058774|NCT05742568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058775|NCT02422810|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34058776|NCT01067261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058777|NCT02549976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058778|NCT04312620|||COHORT||PROSPECTIVE|||||||
34058779|NCT00549913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058780|NCT04761991|||COHORT||PROSPECTIVE|||||||
34163003|NCT06137976|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"* Patient will masked to group assignment and will be under anesthesia during intervention.~* Surgeon will be masked to group assignment. Placement of the nasogastric or orogastric tube will occur while the surgeon is scrubbing and out of the room. There will be a drape over the face until the surgical drapes are covering the patient to maintain surgeon blinding. Removal of tube will take place prior to undraping the patient to maintain blinding.~* All documents noted group assignment will be in an opaque envelope."|"* Block randomization in groups of 10 to either receive nasogastric or orogastric intubation after endotracheal intubation prior to abdominal entry for the duration of the surgery or no gastric decompression at all.~* Sequentially numbered, opaque, sealed envelope (SNOSE) technique"|t|t|f|f
34163004|NCT04305366|||CASE_CONTROL||RETROSPECTIVE|||||||
34163005|NCT06726746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163006|NCT00584519|||COHORT||PROSPECTIVE|||||||
34163007|NCT03502447|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33745970|NCT00974857|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33745971|NCT05585424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||nonranzomized controlled trial study||||
33745972|NCT00550225|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33745973|NCT02014857|||CASE_CONTROL||PROSPECTIVE|||||||
33745974|NCT04618354|||OTHER||RETROSPECTIVE|||||||
34163008|NCT03146546|||COHORT||PROSPECTIVE|||||||
34163009|NCT01740804|||CASE_ONLY||PROSPECTIVE|||||||
34163010|NCT04721210|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34163011|NCT00181662|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163012|NCT04661007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34163013|NCT04046146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163014|NCT04220554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34163015|NCT04249817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
34163016|NCT04208555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33745975|NCT06097598|||OTHER||CROSS_SECTIONAL|||||||
33745976|NCT06046573|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33745977|NCT03537924|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745978|NCT04287049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33745979|NCT01634698|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33745980|NCT04433767|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33745981|NCT00706121|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33745982|NCT03727191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33745983|NCT01330797|||CASE_CROSSOVER||PROSPECTIVE|||||||
33745984|NCT05700682|||CASE_ONLY||PROSPECTIVE|||||||
33745985|NCT06534242|||CASE_CONTROL||RETROSPECTIVE|||||||
33745986|NCT03400540|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups randomly divided. Both groups will be given three different verbal instructions to contract pelvic floor muscles.||||
33745987|NCT04661995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in all three groups will be blinded to the randomization of tinnitus treatment. Three treatment groups are identified: Amplification + Notched Noise Therapy; Amplification + Broadband Noise (white noise); and Amplification Only. Participants will be blinded to the treatment they are receiving so that results of perceptual change of subjective tinnitus can be truly measured with validated, evidence-based outcome measures.|A formal randomized controlled trial assessing Amplification + Notched-Noise Therapy (NNT), Amplification + Broadband Noise (BBN), or Amplification-Only (A-O) as treatments for tinnitus will be conducted. 108 participants will be tested on four occasions: baseline, and 4, 8, and 12 weeks post-baseline. Sound delivery for all participants will be accomplished using hearing aids to stream the custom notched noise filter software to the device. These participants will use the devices during most/all waking hours for 8 weeks and will be blinded to the type of stimulus they are receiving. Participants in all three groups will complete outcome measures at week 0 (baseline), week 4 (first in-course assessment), and week 8 (final in-course assessment). Treatment will be discontinued after 8 weeks, with a follow-up assessment at 12 weeks.|t|f|f|f
33745988|NCT01040104|||||PROSPECTIVE|||||||
33745989|NCT04477980|||COHORT||RETROSPECTIVE|||||||
33745990|NCT04743908|RANDOMIZED|PARALLEL||PREVENTION||NONE||Using a two-arm randomized controlled trial design, participants will be enrolled into the SNS arm (involves social networking referrals only) or the SNS+messaging arm. The latter includes affirmation/misinformation correction messaging (discussion tools and coaching).||||
33745991|NCT04411108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745992|NCT00758953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33745993|NCT03126838|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33745994|NCT05958342|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||permuted block design|t|t|t|t
33745995|NCT02005471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745996|NCT02649868|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33745997|NCT03179839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33850334|NCT01075802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850335|NCT00559390|||FAMILY_BASED||PROSPECTIVE|||||||
33850336|NCT01367977|||CASE_ONLY||RETROSPECTIVE|||||||
33954821|NCT06541561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of participants will be maintained throughout the observation period. The sham group will receive electrode attachment but without stimulation, Throughout the study, for adequate blinding, an opaque tape will be applied to the patient's skin above the electrodes, and the patient's target acupoints will be wrapped in a blanket. All patients will be informed that they might or might not feel a tingling sensation around the acupoints when the TEAS device is working. The patients should not be unblinded until the statistical analysis of the study data is completed.|Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS) or the sham groups using a computer-generated random number table. After the randomization, use the opaque envelope, hide each group envelope into an opaque envelope, the envelope outside the code, will be sealed to the researcher, when the study, if the inclusion criteria, then open the corresponding numbered envelope, and intervene according to the group scheme in the envelope.|t|f|f|t
33954822|NCT06650644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954823|NCT04481399|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33954824|NCT03412448|||COHORT||PROSPECTIVE|||||||
33954825|NCT04534296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes assessor and statistical analyst will be masked to randomization results||f|f|f|t
33954826|NCT06567834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Eligible subjects were randomly assigned 1:1 to bilateral implantation with either Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric (ZXR00V/ZXW150) or Tecnis Symfony/Tecnis Symfony Toric (ZXR00/ZXT150).|t|t|f|f
33850337|NCT02369640|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33850338|NCT05569772|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||multi-centric double blind RCT|t|t|t|f
33850339|NCT03618368|RANDOMIZED|PARALLEL||OTHER||SINGLE|blinded group: as dialyzers are almost identical except for their labels, blinding is achieved by masking dialyzer labels.|"1 blinded group on THERANOVA-500 dialyzer (Expanded Hemodialysis (HDx))~1 blinded group on REVACLEAR-400 dialyzer (conventional hemodialysis (HD))~1 non-blinded group on THERANOVA-500 dialyzer (Expanded Hemodialysis (HDx))~1 non-blinded group on REVACLEAR-400 dialyzer (conventional hemodialysis (HD))"|t|f|f|f
33850340|NCT06610877|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will be unaware of which focused ultrasound protocols are being applied when or whether the applied protocol is considered to be a candidate active stimulation or sham protocol.|This is a within-subject repeated-measures interventional study to test which of a set of LIFU stimulation parameters are most effective at producing temporary tremor reduction when applied to the DRTT - the white matter circuit involved in essential tremor. During a single session up to 25 different stimulation protocols will be tested in each participant in a shuffled manner including sham stimulation protocols.||||
33850341|NCT04973904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850342|NCT00538200|RANDOMIZED|PARALLEL||||NONE||||||
33893391|NCT04212000|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33954827|NCT06303687|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Participants will be randomly assigned to either the intervention (fNIRS and VR-PAT) or the control (fNIRS and standard of care) at the first research dressing change and will then crossover to the alternative group for the second laser procedure.||||
33954828|NCT03936946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told what the intervention is until they are assigned (i.e. each group will not know what they will be listening to ahead of time or what other groups are listening to).|Participants will be randomly assigned to Group 1, Group 2, or Group 3. Group 1 begins the 28 day challenge in October (while group 2 acts as a passive control) and Group 2 begins the 28 day challenge 1 months late (while Group 1 receives no further intervention). Group 3 will begin the 28 day challenge concurrent with Group 1, but will listen to different audio clips than Group 1 (blinded).|t|f|f|f
33954829|NCT01469845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954830|NCT01264328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954831|NCT03415412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954832|NCT05560802|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, stepped-wedge cluster randomized trial||||
33954833|NCT05645562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33954834|NCT01140815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954835|NCT03813966|||CASE_ONLY||PROSPECTIVE|||||||
33954836|NCT03515681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33954837|NCT02558335|||COHORT||PROSPECTIVE|||||||
33954838|NCT01526707|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33954839|NCT05884866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, double-dummy|4-arm, double-blind, double-dummy, parallel-group|t|t|t|f
33954840|NCT01778309|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33954841|NCT01650142|||COHORT||PROSPECTIVE|||||||
33954842|NCT03868176|||COHORT||PROSPECTIVE|||||||
33954843|NCT02309541|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33954844|NCT02525380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954845|NCT02539329|||CASE_CONTROL||PROSPECTIVE|||||||
33954846|NCT02825979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954847|NCT05109403|||COHORT||PROSPECTIVE|||||||
33954848|NCT03892902|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||4-way cross-over study|t|t|t|t
33954849|NCT02181634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954850|NCT04335916|||OTHER||CROSS_SECTIONAL|||||||
33954851|NCT06005740|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954852|NCT04765345|||COHORT||PROSPECTIVE|||||||
33954853|NCT04234516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind, double dummy||t|f|f|t
33954854|NCT03131466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954855|NCT04274101|||COHORT||RETROSPECTIVE|||||||
33954856|NCT06519799|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|As the intervention is the use of a menstrual product, no masking is possible.|Each participant will wear all 5 menstrual products in a randomized order.||||
33954857|NCT04639570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954858|NCT00322530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954859|NCT00359073|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893392|NCT06269848|||OTHER||CROSS_SECTIONAL|||||||
33893393|NCT00961532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893394|NCT02379858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850343|NCT05574491|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Participants who met the inclusion criteria and underwent thorough the baseline assessment will be randomly assigned to the conditions of the intervention groups (traditional and computerized versions of SSL).~Children allocated to the traditional and multimedia versions of the SSL program will receive the eight-week intervention.~Participants in WLC group will receive no psychological intervention during the eight-week duration of the program.~Children and parents in the three groups will complete the same series of measures at about the same time (pre-test and after eight weeks). Children in WLC group will receive the intervention once the follow-up visit is completed."|f|f|f|t
34163017|NCT00636285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163018|NCT00779493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163019|NCT01383226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163020|NCT04747899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163021|NCT00016328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850344|NCT05511961|RANDOMIZED|PARALLEL||PREVENTION||NONE||A two-arm randomised waitlist-control superiority trial (1:1 allocation ratio) will be conducted to evaluate the effectiveness of the HWF model in improving the financial situation of families who have self-reported economic difficulties. The intervention arm will be referred to budget and debt counselling immediately after randomisation and the waitlist-control arm around 3 months later. Both arms will be offered a financial guidance book at randomisation. Randomised controlled trial (RCT) assessments will take place at two points: pre-intervention (T1) and post-intervention (T2; around 3 months after randomisation). Longitudinal cohort assessment (both arms) will take place around 12 months after randomisation.||||
33850345|NCT04042493|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The Connect for Health program is a package of practice-level care enhancements to systematically improve the quality of clinical care provided for childhood obesity and offer support directly to parents to improve the children's growth trajectories.||||
33850346|NCT01039792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850347|NCT01414504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850348|NCT04884412|RANDOMIZED|PARALLEL||TREATMENT||NONE||National multicentre, prospective, randomised, non-inferiority, open label, comparative clinical trial in 2 parallel groups.||||
33850349|NCT01767532|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33850350|NCT02372136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the statistician and the formula technicians know the patients' allocation.||t|t|t|t
33850351|NCT02317133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850352|NCT04262752|NA|SINGLE_GROUP||TREATMENT||NONE||"Each subject in the study will be his/her own control in a BEFORE-AFTER Study, with one group assessed before intervention, during intervention and after intervention.~Additionally, in order to discuss and analyse the results, further subgroups could be made on the basis of aetiology of the chronic constipation to compare results, i.e.: subjects with constipation derived from Neurogenic Bowel Disease (NBD) vs Idiopathic (No NBD) subjects whose constipation is from unknown origin"||||
33850353|NCT04230603|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850354|NCT04204603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850355|NCT00525382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33850356|NCT01854853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850357|NCT01079663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850358|NCT05368467|||COHORT||PROSPECTIVE|||||||
33850359|NCT02876822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850360|NCT05470673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850361|NCT02368678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33850362|NCT04401501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850363|NCT05410431|||CASE_ONLY||CROSS_SECTIONAL|||||||
33850364|NCT03404453|||COHORT||PROSPECTIVE|||||||
33850365|NCT03294148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers will not know which treatment the participants will be receiving (placebo or psychotherapy).|Participants will be randomized to one of two different studies: a placebo vs. waitlist study or a psychotherapy vs. waitlist study, with randomization stratified on pain intensity, age, gender, and opioid use. After an eligibility session, eligible participants will be randomized to the treatment group or the waitlist group (with a ratio of 2:1 treatment:waitlist), using a computer-generated random sequence. This scheme will result in three equally sized groups-placebo, psychotherapy, and waitlist-as the investigators will collapse data from the waitlist arms in the two studies for analyses. The investigators do not use a standard three-way randomization because the investigators do not want placebo participants to think they are in a control condition. Thus, the investigators constrain participant's expectations to either injection vs. waitlist or to psychotherapy vs. waitlist.|f|f|f|t
33850366|NCT06033768|||CASE_ONLY||CROSS_SECTIONAL|||||||
33850367|NCT01946438|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850368|NCT00566878|||OTHER||PROSPECTIVE|||||||
33850369|NCT02436590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850370|NCT04292184|RANDOMIZED|PARALLEL||TREATMENT||NONE||For the purposes of this study we will flush the deceased donor kidney with UW (perfusion solution) or UW + sodium thiosulfate (STS). There will be two groups in the study - UW with or without STS and patients will be randomly assigned to a group in a 1:1 ratio (i.e. 50 in one group and 50 in the other).||||
33850371|NCT03367390|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33850372|NCT02418676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33850373|NCT05319301|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33850374|NCT03402815|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34163022|NCT05661604|||COHORT||PROSPECTIVE|||||||
34163023|NCT02613585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163024|NCT03539718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||comparative|f|f|f|t
34163025|NCT06425991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163026|NCT05059509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163027|NCT04515901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163028|NCT06726720|||COHORT||OTHER|||||||
34163029|NCT03792256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163030|NCT02031263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163031|NCT05350644|||COHORT||PROSPECTIVE|||||||
34163032|NCT02345473|||COHORT||PROSPECTIVE|||||||
34163033|NCT04683848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850375|NCT05370001|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient is not being informed what ETT-size is being used.|Patients planned for liver tumour ablation will be randomised to one of two sizes of ETT, size 8 or size 9.|t|f|f|f
33850376|NCT02143752|||CASE_ONLY||PROSPECTIVE|||||||
33850377|NCT03316300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects and all personnel at the image reading center remained masked to the treatment assignment throughout the study. In addition, the refractionist, VA examiner, and photographers/imagers were masked to treatment assignment (NT-501 implantation or sham procedure) at all follow-up visits. The ophthalmologist, surgeon, and clinic coordinator were instructed not to discuss the assigned treatment with the subject.|After confirming eligibility in conjunction with the reading center, the study eye of each subject was randomized (1:1) to either have NT-501 implanted or to undergo the sham procedure.|t|f|f|t
33850378|NCT04910607|||OTHER||PROSPECTIVE|||||||
33954860|NCT06568874|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33954861|NCT02985515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective cohort, pre- and post-intervention study||||
34163034|NCT06725576|||COHORT||OTHER|||||||
34163035|NCT02353715|||COHORT||PROSPECTIVE|||||||
34163036|NCT02728453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163037|NCT05233033|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163038|NCT04936633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163039|NCT01855659|||||PROSPECTIVE|||||||
34163040|NCT04440748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcome Assessor will be blinded for the allocation of participants.||f|f|f|t
34163041|NCT03565536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163042|NCT00856063|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34163043|NCT06025539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33765284|NCT04596137|NA|SINGLE_GROUP||PREVENTION||NONE|Researchers and family of infants knew about all the details of the study. Verbal and written permission was obtained from families.|The study was conducted between May -September 2016 in FHC. As 1-month-old infants were enrolled for the study, the total number of infants enrolled in FHCs each month was determined. Post-natal infants numbers were recorded in May-June, June-July, July-August, and August-September, for 48, 52, 59, and 57 infants, respectively. A pilot study was conducted on 20 infants born in May. Following the pilot study, monthly randomization was performed by an investigator. Accordingly, the study and control groups were determined monthly. There was no blinding in this study.||||
33850379|NCT05244915|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33850380|NCT04705207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|placebo is a traditional massage instead of a intervention reflexology massage|a group has intervention, a group has placebo intervention|t|f|f|t
33850381|NCT00936741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850382|NCT01633918|RANDOMIZED|PARALLEL||||NONE||||||
33850383|NCT01739816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33850384|NCT04735380|||COHORT||PROSPECTIVE|||||||
33850385|NCT05900362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850386|NCT03611296|||COHORT||PROSPECTIVE|||||||
33850387|NCT02272088|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33954862|NCT03657576|NA|SEQUENTIAL||TREATMENT||NONE||Modified continuous reassessment model (mCRM). Using this statistical method, dose changes occur based upon toxicities (or lack thereof) observed after a 24 day observation period for the initial dose level. If toxicities occurring at any dose were acceptable, doses for subsequent cohorts can be increased by up to 1 log until a maximum tolerated dose is reached. If toxicities are unacceptable then dose de-escalation occurs until a safe acceptable maximum tolerated dosage is defined. However, it should be noted that the dose alterations are not predictable and cannot be predefined, they are statistically determined after each patient using mCRM software.||||
33850388|NCT05871567|||COHORT||PROSPECTIVE|||||||
33850389|NCT03671694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|only the care provider (who is not involved with recruitment or evaluation of patients' outcomes) will be aware of the treatment assignments|RCT|t|f|t|t
33850390|NCT03482401|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomised, parallel-controlled dietary intervention||||
33850391|NCT04317677|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850392|NCT06611124|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||reduction with axial traction to disimpact the fracture with dorsal pressure for metacarpals shfat and head fractures pinng of the fracture with k-wire for fixation|f|t|f|f
33850393|NCT03898232|||COHORT||RETROSPECTIVE|||||||
33850394|NCT06205537|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33850395|NCT03888989|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850396|NCT06302517|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33850397|NCT06387368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850398|NCT00327496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850399|NCT00893984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850400|NCT02704468|||||CROSS_SECTIONAL|||||||
33850401|NCT01220193|||COHORT||PROSPECTIVE|||||||
33850402|NCT00743301|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33850403|NCT01981772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850404|NCT00294515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850405|NCT06180018|NA|SINGLE_GROUP||SCREENING||NONE||||||
33850406|NCT03910686|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33850407|NCT03354091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking is performed through sealed envelopes. The investigator has no knowledge of which patients who is randomized to intervention or control|Cluster-Randomized controlled trial|f|f|t|f
33850408|NCT02873091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850409|NCT01128816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850410|NCT06378268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850411|NCT02824081|NA|SINGLE_GROUP||||NONE||||||
33850412|NCT04587076|||OTHER||CROSS_SECTIONAL|||||||
33850413|NCT03191500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850414|NCT00568438|||COHORT||RETROSPECTIVE|||||||
33850415|NCT00190749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850416|NCT05609110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850417|NCT02238054|||COHORT||PROSPECTIVE|||||||
33850418|NCT02938026|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850419|NCT00446992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850420|NCT03666091|||COHORT||PROSPECTIVE|||||||
33850421|NCT03216421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850422|NCT02799901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954863|NCT05887102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Pharmacists and women will not be blind to the intervention but analyses of data self-reported by the participants (questionnaires) will be conducted in a blinded fashion.|This is a cluster randomized controlled pilot trial using mixed methods (quantitative and qualitative). A cluster consists of a pharmacy, its pharmacists and its patients with adjuvant endocrine therapy (AET) prescription who have agreed to participate. Participating pharmacies will be randomly assigned to two groups. In the first group, pharmacists will provide usual services to women (control group). In the second group, pharmacist and women will have access to the PACHA program in addition to the usual services (intervention group).|f|f|f|t
33954864|NCT05898009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954865|NCT01913769|||CASE_CONTROL||PROSPECTIVE|||||||
33954866|NCT03855930|||COHORT||PROSPECTIVE|||||||
33954867|NCT03880955|||COHORT||PROSPECTIVE|||||||
33954868|NCT02152631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954869|NCT06385821|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33954870|NCT03916055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducting post- and follow-up assessments will be blind to treatment allocation, for the full duration of the trial. At each follow-up assessment, participants will be reminded by their assessor to not reveal their arm allocation. To measure blinding integrity, all assessors will record whether the participating families inadvertently reveal their group allocation, and subsequently guess each participant's treatment allocation at each assessment point, and motivate their choice. If the treatment allocation is accidently revealed, that very part will be cut out of the video recording, and a new blind assessor will watch the video and conduct the assessment that will be used in the trial. Subsequent assessments for that participant will then be conducted by a different assessor (than the first one; blind to treatment allocation), where possible. The blinding will be broken after the trial's final participant has finished her/his 3-month follow-up assessment (primary endpoint).|Single-blind parallel-group randomised controlled superiority trial.|f|f|f|t
33954871|NCT04247503|||COHORT||PROSPECTIVE|||||||
33954872|NCT05863351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954873|NCT02461407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954874|NCT05570214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33954875|NCT06099886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954876|NCT02771340|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954877|NCT00759226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058781|NCT04608344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34058782|NCT00814944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058783|NCT03193879|||COHORT||PROSPECTIVE|||||||
34058784|NCT04476121|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first medicine was applied, if dry socket was diagnosed following a tooth extraction. In case of subsequent extraction of homonymous tooth in the same patient and reoccurrence of dry socket, patients were treated with PRF application.||||
34058785|NCT00136435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058786|NCT02790359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33850423|NCT02328339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34058787|NCT06623370|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
34058788|NCT01732471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058789|NCT01404208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058790|NCT05186038|||OTHER||CROSS_SECTIONAL|||||||
33850424|NCT03834038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850425|NCT02700477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33850426|NCT00350480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850427|NCT00725933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850428|NCT01724073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850429|NCT06216873|||CASE_ONLY||OTHER|||||||
34058791|NCT04117074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058792|NCT01537068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058793|NCT02691728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058794|NCT03026530|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34058795|NCT05432323|||COHORT||PROSPECTIVE|||||||
34058796|NCT02152553|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34058797|NCT06437275|||OTHER||CROSS_SECTIONAL|||||||
34058798|NCT00956631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850430|NCT05765162|||COHORT||PROSPECTIVE|||||||
33850431|NCT00805181|||COHORT||PROSPECTIVE|||||||
33850432|NCT02108990|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850433|NCT04593927|||COHORT||PROSPECTIVE|||||||
33850434|NCT01177982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850435|NCT05907109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors blinded to the allocation of participants|Prospective Multicentric single-blinded, Two-arm Randomized Clinical Trial|f|f|f|t
33850436|NCT02030301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850437|NCT00851838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850438|NCT03770910|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33850439|NCT01535560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850440|NCT00002987||||TREATMENT||||||||
33850441|NCT00618982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850442|NCT02948023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850443|NCT03727438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850444|NCT03122600|||OTHER||PROSPECTIVE|||||||
33850445|NCT06246266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33850446|NCT01915472|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850447|NCT01621737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850448|NCT03954795|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33850449|NCT04694443|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The rater will be blind to the patient status (study vs. control).|Single blind, randomized, case-control study|f|f|f|t
33850450|NCT00539565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850451|NCT03887078|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two successive randomizations based on patterned response to primary intervention. Pre-surgical participants (n=200) will be randomized to groups in Noom Coach for Bariatric Health or standard care pre-surgery. Post-surgery, optimal and suboptimal responders will be randomized to Noom Bariatric or standard care. This design allows for comparisons between all 8 conditions. Contrasts allow us to answer the critical question about main effects of Noom Pre-surgery and Noom augmentation and whether this augmentation effect differs based on empirically derived classification of early response.||||
33850452|NCT03614637|||OTHER||PROSPECTIVE|||||||
33850453|NCT02261259|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33850454|NCT01337583|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163044|NCT04515758|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants are told that there are two intervention groups (regular exercise group and an augmented exercise group). They are not told how the two group interventions differ (i.e. they are unaware of which group they were assigned to, as they do not know what intervention is being delivered to the other group). Assessors of the outcomes are not aware of which group the participant's have been assigned to."|Participants are randomly assigned to either the exercise only group or the cognitive training and exercise group.|t|f|f|t
34163045|NCT06385483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163046|NCT06548100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850455|NCT04406090|||COHORT||RETROSPECTIVE|||||||
33850456|NCT03217682|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||After the patient has been registered into the study, they will be assigned to either the music therapy or massage therapy cohort. The music therapy cohort will be available to the first 30 patients and 30 caregivers accrued. Upon reaching 60 subjects enrolled, the music therapy cohort will close to accrual and the massage therapy cohort will open to accrual. Once the massage therapy cohort has enrolled 30 patients and 30 caregivers, the massage therapy cohort will close to accrual and the study will be closed to all further accrual.||||
33850457|NCT02869854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33850458|NCT05233332|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33850459|NCT04288609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
33850460|NCT04467528|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850461|NCT00345293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850462|NCT02533531|NA|SINGLE_GROUP||OTHER||NONE||||||
33850463|NCT01254240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850464|NCT06611371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Subjects randomized 1:1:1:1, placebo-controlled, observer blinded|Single dose of low, mid or high concentrations of IVT GBS-06, or a placebo (saline control) at Day 1 (Randomized 1:1:1:1). The four study groups will be enrolled simultaneously to allow for parallel assessments of participants.|t|t|t|t
33954878|NCT05326997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participants involved in the study, nor the outcomes assessor will be aware of the groups formed, as well as the treatments received.|All participants will receive a skin preparation with enzymatic peeling, for homogeneity in the thickness of the stratum corneum among the participants and to reduce the unwanted reflection of photons. One week after the application of the peeling, the pre-treatment evaluation will be carried out and the participants will receive the intervention related to their treatment group, according to the allocation given by randomization. The area to be treated will be sanitized with Rennova® Beauté Micellar Water for makeup/sunscreen removal. Then, a cleaning foam based on 10% urea from Vivence laboratory will be used and also removed with gauze. After randomization, the study population will be divided into two groups (n=28 per group), wich are: (1) Group A - PBM with yellow LED application + placebo cosmetic treatment Home Care 2x per day, (2) Group B - PBM sham + treatment with 5% liposomal tranexamic acid Home Care cosmetic cream 2x per day.|t|f|f|t
33954879|NCT05087576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33954880|NCT06134687|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial||||
33765285|NCT00997737|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33765286|NCT01160484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765287|NCT03548116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The study participants will be blinded to their group assignment for the entire duration of the study. The study investigators will also be blinded to participant assignments on this study, except for the investigators performing the ultrasound procedure, co-investigators randomizing the participants, and co-investigators involved in the study's monitoring.|After a screened individual is deemed eligible for continued participation, a study investigator will enter the participant's information into a randomization portal in order to receive the group assignment.|t|f|t|f
34163047|NCT03335774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954881|NCT03151707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954882|NCT03467373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33745998|NCT06635174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Randomization will be generated at the local pharmacy by a computer program in blocks of two and the randomization allotment only will be known by a pharmacist not involved in the care of the children.~after that the pharmacist will prepper the syringe than contain the 2ml 50% dextrose or the placebo 2ml normal water. each syringe will have code. the code key will be only with the pharmacist."|Total of 90 patient divided randomly in 2 groups, one group will receive 2ml of 50% oral dextrose and control group will receive 2ml of normal water as placebo. The Neonatal Infant Pain Scale (NIPS) will be used to measure the pain score among the infants. It was designed and validated in Canada by Lawrence J Alcock D et al. It uses the behaviors that nurses have described as being indicative of infant pain or distress. It is composed of six (6) Parameters Facial expression Cry Breathing patterns Arms Legs State of arousal|t|t|t|f
33745999|NCT01352598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746000|NCT03422003|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746001|NCT03719105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort 1 and 2 will be based on initial diagnosis.||||
33746002|NCT06636214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746003|NCT05684965|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33746004|NCT03088384|||CASE_ONLY||PROSPECTIVE|||||||
33746005|NCT05028660|||COHORT||PROSPECTIVE|||||||
33746006|NCT06636448|||COHORT||PROSPECTIVE|||||||
33746007|NCT01073618|||CASE_ONLY||PROSPECTIVE|||||||
33765288|NCT01336959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765289|NCT01291316|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33765290|NCT05600725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be unaware of their group assignment. Investigators delivering the intervention vs. sham will be aware. Analysts processing primary data (serum testing, echocardiographic dimensions, 6-min walk distance, CPEX) will not be aware of group assignments.|Subjects will be randomized in a single-blinded fashion to intervention vs. sham treatment|t|f|f|t
33765291|NCT03177889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954883|NCT00885937|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33765292|NCT02322814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163048|NCT06500988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34163049|NCT06726161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163050|NCT04014465|||COHORT||PROSPECTIVE|||||||
34163051|NCT03477396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163052|NCT05090891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163053|NCT01156103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163054|NCT01645254|NA|SINGLE_GROUP||||NONE||||||
34163055|NCT04994756|||COHORT||PROSPECTIVE|||||||
34163056|NCT05730036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163057|NCT06097663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163058|NCT02021643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163059|NCT06007820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163060|NCT01458483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163061|NCT03655561|||COHORT||PROSPECTIVE|||||||
34163062|NCT06264011|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|This study uses a cross-sectional, repeated measures, crossover design. All participants will complete both conditions of the study but will be randomized to start in either the salaat or counting conditions.|There is one intervention (i.e., the prayer condition) and one control condition (i.e., the counting condition).|f|f|t|f
34163063|NCT02442440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163064|NCT03342534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34163065|NCT04218409|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a within-participant study so that each participant receives all conditions.|t|f|f|t
34058799|NCT00162994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34058800|NCT05418972|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm clinical trial||||
34058801|NCT00174226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34058802|NCT04003545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In the placebo group, the laser application will be simulated in the same way as the active group, but the device will be turned off.~The outcome assessor will not know to which group the patients belong."||t|f|f|t
34058803|NCT05221268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058804|NCT02574702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058805|NCT06465134|||CASE_CONTROL||PROSPECTIVE|||||||
34058806|NCT05528198|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058807|NCT01472965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058808|NCT04829331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058809|NCT01058486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058810|NCT05040620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850465|NCT05253820|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single-center parallel randomized controlled study||||
33850466|NCT03946579|NA|SINGLE_GROUP||OTHER||NONE||||||
33850467|NCT03035201|||COHORT||PROSPECTIVE|||||||
33850468|NCT02267473|||COHORT||PROSPECTIVE|||||||
33850469|NCT05087979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058811|NCT00389051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058812|NCT01374932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850470|NCT06147050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850471|NCT01939665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850472|NCT00682773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33850473|NCT05145309|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study supplement will be dispensed in a blinded manner.||t|f|t|f
33850474|NCT03553680|RANDOMIZED|PARALLEL||TREATMENT||NONE||Emotion-Focused CBT||||
33850475|NCT05416190|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|Patients are recruited according to their LA status (LA- or LA+).|Citrated whole blood was collected from all participants and lupus anticoagulant testing was performed before and after spiking in vitro injectable anticoagulants. No distinction between the groups LA+ and LA-.||||
33893395|NCT04193683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893396|NCT04644718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For blinding purposes, a masked set of randomization procedures designed to keep both participants and experimenters unaware of the administered intervention (real or sham; mode of stimulation) in addition to group allocation concealment (Alonzo et al., 2016; Fonteneau et al., 2019). The randomization sequence will be encrypted and stored on a secure server to confirm blinding process. Independent Endpoint committee blinded to group assignment and time of assessment will evaluate the collected data to further enhance blinding integrity.|Patients will be randomly assigned to one of the two groups in a ratio of 1:1 with the use of permuted-block randomization design. The first intervention group will receive real tDCS with SLT, while the second group (control group) will receive sham tDCS with same SLT protocol.|t|t|f|t
34058813|NCT03367559|NA|SINGLE_GROUP||PREVENTION||NONE|An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live attenuated rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks and 8 weeks in Vietnam|||||
34058814|NCT04566133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058815|NCT00553852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058816|NCT04111718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058817|NCT02103335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058818|NCT00038623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058819|NCT03298256|||COHORT||PROSPECTIVE|||||||
34058820|NCT02741791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058821|NCT01789671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058822|NCT00411073|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34058823|NCT06621082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058824|NCT05057897|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"Previously unvaccinated immunocompromised adults will be enrolled in 5 disease cohorts of approximately 60 participants each:~1. Solid organ transplant~2. Hematopoietic stem cell transplant~3. Solid organ cancer patients receiving cytotoxic chemotherapy~4. Chronic inflammatory disorders~5. Primary immunodeficiency A sixth cohort of immunocompetent individuals will also be recruited. Participants will be allocated to the immunocompromised cohorts according to the underlying aetiology of their immunocompromised status.~Immunocompromised participants will receive a third dose (primary vaccination series) 4 weeks or more after dose 2 with AZD1222 and will continue to be followed to the end of the study. Immunocompetent participants will be eligible to receive a third dose booster 6 months after dose 1 and will continue to be followed to the end of the study."||||
34058825|NCT00155766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058826|NCT00203944|||CASE_ONLY||PROSPECTIVE|||||||
34058827|NCT06617351|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34058828|NCT01528657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34058829|NCT03944369|RANDOMIZED|PARALLEL||OTHER||NONE||A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Study||||
34058830|NCT03936335|||COHORT||RETROSPECTIVE|||||||
34058831|NCT06649500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34058832|NCT05269212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34058833|NCT00063479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058834|NCT05236231|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33954884|NCT01895829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33954885|NCT04319965|||COHORT||PROSPECTIVE|||||||
33954886|NCT01170767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954887|NCT06652373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33954888|NCT04896697|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33954889|NCT01243307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33954890|NCT03867825|||COHORT||PROSPECTIVE|||||||
33954891|NCT03913429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33954892|NCT02999646|NA|SINGLE_GROUP||TREATMENT||NONE||antitumor immunization MVX-ONCO-1||||
33954893|NCT03875716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058835|NCT03301740|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The study will be double-blinded in that participants will not be informed of the treatment paradigm. Investigators, including those performing transthoracic echocardiography (TTE) interpretation, will be blinded to treatment paradigm. Ultrasonographers performing intra-HD TTEs will be blinded to treatment paradigm.|The study is a 4-phase crossover trial in which participants are successively alternated between conventional HD and conventional HD + linear UF profiling across 4 phases with intervening wash-out periods. The study compares conventional HD (the participant's standard HD prescription with no UF profiling) to conventional HD + linear UF profiling. Participants will be randomly allocated to conventional HD or conventional HD + linear UF profiling for phase 1. Participants will undergo 9 treatments during each phase for a total of 18 conventional HD treatments and 18 UF profiled treatments. Participants will undergo 3 wash-out HD treatments between phases.|t|f|t|t
34076270|NCT04472546|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Subject group :~Exploratory study, monocentric and comparative performed at:~* control subject group, divided in 5 subgroups :~  * A': associated to acne of the face subgroup~ * B' : associated to atopic dermatitis of the upper limb subgroup~ * C' : associated to vulgar plaque psoriasis subgroup~ * D' : associated to telangiectasic erythrocouperosis papule of the face (rosacea) subgroup~ * E' : associated to seborrheic dermatitis of scalp subgroup~* subject group with dermatitis, divided in 5 subgroups :~  * A: acne of the face subgroup~ * B : atopic dermatitis of the upper limb subgroup~ * C : vulgar plaque psoriasis subgroup~ * D : telangiectasic erythrocouperosis papule of the face (rosacea) subgroup~ * E : seborrheic dermatitis of scalp subgroup~Visit number :~It includes 1 unique visit to the Skin Research Center, Toulouse, France. The maximum duration of participation for a subject is 1 day (around 2 hours)."||||
33850476|NCT06479642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician performing the evaluation will be blind to which procedure is performed|"Our study was designed as a prospective, single-blind randomized controlled study. Patients who applied to our hospital's PMR outpatient clinic and were diagnosed with advanced stage gonarthrosis with anterior knee pain after physical examination and imaging evaluation will be included in our study. Patients were selected for the first group with the Research Randomizer computer program. The patients will be randomized into two groups of 36 people: the three-nerve RF Group (3RFG), the second group will be the four-nerve RF Group (4RFG). The physician performing the evaluation will be blind to which procedure is performed. The demographic and clinical characteristics of the patients will be recorded. Patients will be evaluated using the Visual Analogue Scale (VAS),Patella Femoral Pain Severity Scale and Kujala Patellofemoral Scoring System and WOMAC. These evaluations will be made and recorded at the beginning, at the 4th and 12th weeks after the procedure."|f|f|f|t
33850477|NCT01893294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850478|NCT05600296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850479|NCT02711969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850480|NCT06293703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be a prospective, randomized controlled trial with a 1:1 recruitment allocation ratio coordinated at the Cleveland Clinic Foundation (CCF)|t|f|f|f
33850481|NCT04362384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Symptoms will be assessed by a nurse blinded to the prescribed treatment||f|f|f|t
33850482|NCT05073666|||COHORT||PROSPECTIVE|||||||
33850483|NCT04897906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pregnant women included in the research sample will be divided into two groups as experimental and control groups. Experimental group; is the group to be trained. Control group; It is the group in which no intervention will be made other than data collection.||||
33850484|NCT02109315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850485|NCT01975181|||COHORT||PROSPECTIVE|||||||
33850486|NCT02391779|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33850487|NCT00514891|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850488|NCT02866500|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33850489|NCT02647567|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33850490|NCT03592901|||CASE_ONLY||PROSPECTIVE|||||||
33850491|NCT02343874|||COHORT||CROSS_SECTIONAL|||||||
33954894|NCT03753893|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33954895|NCT02508649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954896|NCT05744219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The attending nurse at the postoperative ward will do the final preparation of study drug and thus be aware of which patient receives placebo or iv iron. As the Ferric Carboxymaltose solution is opaque, the study drug is kept concealed behind the patient. Most patients have amnesia of the first hours after general anaesthesia. This effect is more pronounced after long and complex surgery which is the case for all patients included in this trial. Blinding from the patent's perspective is therefore not expected to be a major concern. The personnel preparing the study drug and nurse at the postoperative ward does not participate in care beyond this point, ensuring blinding is maintained.|At end of surgery, peri-operative blood loss is determined and if 400-4000 ml, the patient is randomised to iv Ferric Carboxymaltose 1000 mg or placebo.|t|t|t|t
33954897|NCT06149351|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33954898|NCT05919771|||COHORT||PROSPECTIVE|||||||
33954899|NCT02633462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954900|NCT01565655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33954901|NCT05935930|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33954902|NCT06035094|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34058836|NCT04298450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will not be notified of treatment assignment, but based on the nature of the intervention, they cannot be fully masked. Their care provider may know treatment assignment if disclosed by the participant, or if they get notified that the participant is in distress. Treatment assignment will be known by the research personnel involved in managing the intervention and the database linking participant information to study identification numbers. Treatment assignment may be known by a co-principal investigator providing clinical supervision for adverse or serious events. Research personnel involved in qualitative interviews will also be aware of treatment assignment since only individuals receiving the active treatment participate. The lead principal investigator and research personnel involved in the chart review (where the primary outcome will be extracted) and other analyses will be masked to treatment assignment.|Immediately after study enrollment, participants will be randomized using an electronic data management system to the active or sham intervention. Randomization will be stratified by sex and referral source (main emergency department vs. Bridging Clinic vs. inpatient unit), using a computer algorithm to perform a blocked randomization assignment within strata.|f|f|t|t
34058837|NCT01707251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058838|NCT03540303||SEQUENTIAL||TREATMENT||NONE||CAR19 T cell therapy improves the clinical efficacy of refractory/relapsed B-cell lymphoma, and the combined PDL1 inhibitors may further improve the efficacy of CD19 CART in the treatment of lymphomas. The clinical efficacy of KITE's CAR19 T cells and PD-L1 inhibition was reported. This phase 1 study was conducted in 9 patients with DLBCL, 8 patients got remission and during which 5 got complete remission. However, this type of treatment requires more data and observation in a larger sample of patients. In addition, Kite Pharmaceuticals' CD19 CART is priced at 370,000 US dollars. The cost of immune checkpoint inhibitors is also very expensive. Only very small proportion of patients could afford for that expenses. In this study, genetically engineered CAR T cells, which carry cytoplasmic activated PD1, are not inhibited by PDL1 molecules, will avoid the simultaneous application of immune checkpoint antibodies and the according adverse events.||||
34058839|NCT05738876|||OTHER||PROSPECTIVE|||||||
34058840|NCT03149120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058841|NCT05455190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058842|NCT00122122|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058843|NCT01185509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The analysis was performed for 2 separate cohorts due to a change in study conduct during the trial (see arm description).||||
34058844|NCT04944810|||COHORT||PROSPECTIVE|||||||
34058845|NCT06273475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data will be analysed by the PhD student blinded towards group allocation. The test leader responsible for RCT outcome assessment will be blinded towards group allocation.|Multicentre randomised (1:1) parallel-group intervention study with assessor-blinding.|f|f|t|t
34058846|NCT03426436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The cardiologist will be blinded to the type of waveform they are analyzing (synthesized versus actual).|||||
34058847|NCT03547362|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The study is designed as a randomized, single-blinded within-subject (cross-over) trial in which a group of 12 subjects receive 6 different dairy products.|f|f|t|t
34058848|NCT01350648|||COHORT||PROSPECTIVE|||||||
34058849|NCT05561153|||COHORT||PROSPECTIVE|||||||
34058850|NCT05541744|||COHORT||PROSPECTIVE|||||||
34058851|NCT03595813|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058852|NCT03141775|||COHORT||OTHER|||||||
34058853|NCT05750732|||COHORT||PROSPECTIVE|||||||
34058854|NCT02579343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058855|NCT01841567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058856|NCT01914575|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058857|NCT02429310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058858|NCT01908933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058859|NCT04794413|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, proof-of-principle, 8-week treatment, pilot study for male and female patients aged 18 years and older with Tourette Syndrome. There were no control groups nor randomization.||||
34058860|NCT00900640|||CASE_ONLY||PROSPECTIVE|||||||
34058861|NCT05609942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34058862|NCT00157820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058863|NCT04972370|||COHORT||RETROSPECTIVE|||||||
34058864|NCT02744482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163066|NCT04142294|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Histidine supplementation trial, non-randomized, sequential delivery of graded doses of the amino acid histidine. All participants serve as their own controls. Following baseline measurements, subjects ingest encapsulated high quality histidine for four continuous weeks at graded doses of 4, 8 and 12 g/day. A forth dose at 16 g/day is assessed if no adverse outcomes are observed for the three graded doses. Histidine doses are suggested based on experience with other amino acids (relative difference of average intake and metabolic limits). Each dose is followed by a 3-week minimum recovery period. During the recovery period, subjects will continue to be monitored (vitals and weight) but no supplementation is consumed. At the conclusion of each washout period, before the start of the next dose, subjects provide a blood sample, vitals (blood pressure and heart rate), weight, 4-day diet record, sleep log, hunger and satiety VAS, mood VAS, and physical activity monitoring.||||
34163067|NCT03378830|||COHORT||PROSPECTIVE|||||||
34163068|NCT06029049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850492|NCT03677765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163069|NCT01565681|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34163070|NCT00627250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163071|NCT05054426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850493|NCT03517202|||COHORT||RETROSPECTIVE|||||||
33850494|NCT01545323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893397|NCT05929495|NA|SINGLE_GROUP||TREATMENT||NONE||Metformin dose of 1 g/day orally in two administrations (500 mg tablets) during the first two weeks of treatment, increasing to 2 g/day in two 1 g tablets thereafter||||
33893398|NCT01053312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893399|NCT00476086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893400|NCT03728049|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter open-label randomized controlled clinical trial||||
33893401|NCT01682044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058865|NCT02789956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058866|NCT00373009|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34058867|NCT00416689|||CASE_ONLY||PROSPECTIVE|||||||
34058868|NCT04234295|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34058869|NCT02762552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058870|NCT03780803|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34058871|NCT01491750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34058872|NCT06128291|||CASE_ONLY||RETROSPECTIVE|||||||
34058873|NCT02634372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058874|NCT01236781|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34058875|NCT00093418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058876|NCT03332628|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34058877|NCT00481260|||CASE_ONLY||RETROSPECTIVE|||||||
34058878|NCT00264160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058879|NCT05940129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34058880|NCT05869279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058881|NCT00923663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058882|NCT04642677|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Single institution, Open-label, Randomized, Phase 2||||
34058883|NCT00715728|||COHORT||PROSPECTIVE|||||||
34058884|NCT06205173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34058885|NCT05680831|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|TRC Environmental Corporation, who is on-site contractor responsible for the exposure operation will randomize the subjects into either air or ozone arms, neither subjects nor staff involved in conduct of experiments will be informed of exposure conditions.|This is a randomized, double-blind, cross-over study with two arms.|t|t|t|t
34058886|NCT00714753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058887|NCT05213013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Children and their parents|Children and their parents|t|t|f|f
34058888|NCT05228925|||COHORT||PROSPECTIVE|||||||
34058889|NCT00857597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058890|NCT04323865|||COHORT||PROSPECTIVE|||||||
34058891|NCT05062824|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Weight and length are being collected by the nurse in Borinquen Health Center, they are blinded to the study groups.||f|f|f|t
34058892|NCT02237209|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34058893|NCT06620211|||CASE_ONLY||RETROSPECTIVE|||||||
34058894|NCT02013856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34058895|NCT00259974|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34058896|NCT01028430|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34058897|NCT05405894|||COHORT||PROSPECTIVE|||||||
34058898|NCT01228110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058899|NCT03984227|||CASE_CONTROL||RETROSPECTIVE|||||||
34058900|NCT04930510|||CASE_CONTROL||PROSPECTIVE|||||||
34058901|NCT05542797|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34058902|NCT03399903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058903|NCT01957618|||COHORT||PROSPECTIVE|||||||
34058904|NCT02784522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058905|NCT02170961|||COHORT||PROSPECTIVE|||||||
34058906|NCT01338961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34058907|NCT02571920|||COHORT||PROSPECTIVE|||||||
34058908|NCT00383175|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34058909|NCT06237413|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34058910|NCT05992259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1 randomization of active stimulation vs. sham stimulation|f|f|f|t
34058911|NCT05737017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058912|NCT01443351|||CASE_ONLY||PROSPECTIVE|||||||
34058913|NCT03462459|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34058914|NCT03102697|||COHORT||PROSPECTIVE|||||||
34058915|NCT00860249|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34058916|NCT04777448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058917|NCT03112668|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34058918|NCT01297166|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34058919|NCT06077552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058920|NCT01194934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058921|NCT06623279|NA|SEQUENTIAL||TREATMENT||NONE||"Three dosing cohort:~Low dose : 3 subjects Middle dose: 6 subjects High dose: 6 subjects"||||
34058922|NCT05628896|||COHORT||PROSPECTIVE|||||||
34058923|NCT06621953|RANDOMIZED|PARALLEL||TREATMENT||NONE||The overall study is a two phase RCT. Phase one will investigate two different BFR-RT protocols (high- vs low-pressure) for 1-week (7x BFR-RT sessions in 5 days). Phase two will take the BFR-RT protocol that elicited the greatest improvement in symptoms (high- or low-pressure) and compare that to conventional UK Defence Rehabilitation practices over a 3 week period (21x BFR-RT sessions over 15 days). Due to the nature of the intervention, it is not possible to blind participants or outcome assessors to the treatment allocation. There is also no effective sham condition available. This is a common limitation within all blood flow restriction training research.||||
34058924|NCT05569928|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34058925|NCT00213772|||CASE_CONTROL||PROSPECTIVE|||||||
34058926|NCT04376333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither patient nor therapists can be blinded to treatment condition. The outcomes assessors and the investigators will be blinded.|2-group randomized clinical trail|f|f|t|t
34058927|NCT01231295|||COHORT||PROSPECTIVE|||||||
34058928|NCT03333902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34058929|NCT06055244|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Pilot randomized clinical trial|t|t|t|t
34058930|NCT02119832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058931|NCT01334580|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34058932|NCT00175032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058933|NCT01292343|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34058934|NCT04351906|NA|SINGLE_GROUP||TREATMENT||NONE||ECCO2R||||
34058935|NCT03179293|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34163072|NCT06726187|||COHORT||CROSS_SECTIONAL|||||||
34163073|NCT02132819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34163074|NCT01440088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163075|NCT03818191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163076|NCT00505557||PARALLEL||TREATMENT||SINGLE||||||
34163077|NCT06345547|||COHORT||PROSPECTIVE|||||||
34163078|NCT04140630|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33893402|NCT06657404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893403|NCT02956655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893404|NCT02494141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893405|NCT05893134|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33893406|NCT05418712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893407|NCT03959644|||OTHER||PROSPECTIVE|||||||
33893408|NCT02187393|||||PROSPECTIVE|||||||
34163079|NCT02293798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163080|NCT00546546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163081|NCT02392572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163082|NCT01887132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34163083|NCT04881617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163084|NCT02756676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163085|NCT01464177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163086|NCT01025063|||COHORT||PROSPECTIVE|||||||
34163087|NCT04303572|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase III open-label, randomized controlled trial comparing immune tolerance induction with one drug, with or without a second drug in the eradication of hemophilia inhibitors.||||
34163088|NCT04789915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Placebo-controlled, randomized clinical trial|t|t|t|t
34163089|NCT00288678|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34163090|NCT06230224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163091|NCT02600221|||COHORT||CROSS_SECTIONAL|||||||
34163092|NCT05479240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163093|NCT00687804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34163094|NCT06176768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163095|NCT03257033|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects with stable or responding disease after approximately four months of induction therapy, and who are not surgical candidates will then be randomized to be in either the test group or control group. Crossovers are not allowed.||||
34163096|NCT00795236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163097|NCT06725316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163098|NCT03261609|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163099|NCT01187628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163100|NCT03610191|||CASE_CONTROL||PROSPECTIVE|||||||
34163101|NCT05307692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163102|NCT04223713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163103|NCT00676013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163104|NCT01496469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163105|NCT05121948|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163106|NCT04187495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163107|NCT00871338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163108|NCT05993923|||CASE_ONLY||PROSPECTIVE|||||||
34163109|NCT05809843|||COHORT||PROSPECTIVE|||||||
34163110|NCT06165042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163111|NCT02641028|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34163112|NCT00934219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163113|NCT05263557|RANDOMIZED|PARALLEL||OTHER||NONE||Interventional||||
34163114|NCT04107532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163115|NCT00226811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163116|NCT04418258|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34163117|NCT02347839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163118|NCT03259087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163119|NCT06284772|||COHORT||PROSPECTIVE|||||||
34163120|NCT00604630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163121|NCT06531252|||OTHER||CROSS_SECTIONAL|||||||
34163122|NCT01220739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163123|NCT04266132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation, perform the block, and administer bupivacaine solution.|Prospective, randomized, double blind study|t|f|f|t
34163124|NCT00002043||||TREATMENT||||||||
33954903|NCT06653127|||COHORT||PROSPECTIVE|||||||
33954904|NCT02423746|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33954905|NCT05188274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33954906|NCT01892813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33954907|NCT00641810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954908|NCT04275375|||COHORT||PROSPECTIVE|||||||
33954909|NCT03150433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be masked to treatment condition||f|f|f|t
33954910|NCT06652217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the statistatian||f|f|f|t
33954911|NCT00320801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954912|NCT04477473|||OTHER||PROSPECTIVE|||||||
33954913|NCT06315530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954914|NCT06652334|||CASE_CONTROL||PROSPECTIVE|||||||
33954915|NCT02151565|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33954916|NCT00142961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33954917|NCT05491018|||COHORT||PROSPECTIVE|||||||
33954918|NCT03273816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The primary endpoint is taken by a nurse who does not know the randomization arm.|Randomized, controlled, bi-centric (national), superiority, open-label, blind-blind (evaluator) trial comparing sophrology to routine care in preparation for deep brain stimulation. The distribution of patients will be balanced between the two groups.|f|f|f|t
33850495|NCT04393337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinding of the clinicians, nurses, and patient caregivers are impractical. However, to minimize the bias, we will neither mention the method used to estimate the endotracheal tube insertion depth to the patient caregivers explicitly and nor record in the patient charts. We will blind the primary outcome assessment by masking the consultant pediatric radiologist to the group assignment. Similarly, the consultant pediatric radiologist will determine the following secondary outcomes-endotracheal tube tip above the upper border of T1 vertebra, endotracheal tube tip below the lower border of T2 vertebra, and pneumothorax. The other secondary outcomes (endotracheal tube repositioning after the X-ray, oxygen therapy at 28 days, oxygen therapy, or positive pressure support at 36 weeks post-menstrual age, duration of invasive ventilation, and death before discharge) will be determined by the trained research assistant.|Eligible infants will be randomly assigned (1:1) to the 'gestational age chart' or 'nasal-tragus length' method We will stratify the randomization by gestational age at birth (\<28 weeks and \>28 weeks) and participating center. An independent researcher will generate the randomization sequence with a computer at the website www.sealedenvelope.com hosted by King Abdullah bin Abdulaziz University Hospital, Saudi Arabia. The researcher will upload the sequence to the in-built randomization module within the Research Electronic Data Capture (REDCap) system. The sequence is inaccessible to the trial investigators. We will conceal the allocation by incorporating the random permuted blocks of size 2 and 4 sequences within the REDCap system.|f|f|f|t
33850496|NCT01778257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33850497|NCT06283368|||CASE_CONTROL||RETROSPECTIVE|||||||
33850498|NCT00419510|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33850499|NCT02164123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33850500|NCT03561831|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33850501|NCT02536443|||COHORT||PROSPECTIVE|||||||
33850502|NCT02865980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850503|NCT01946763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33850504|NCT02372500|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33850505|NCT03383926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the evaluator of the research and the participant do not know the lenght of the Longo's intervention that is performed.|In the surgery, Longo's intervention would be done by two ways differing in the distance of the suture from the tobacco pouch to the anal margin (4.5 cm in the first group and 6 cm in the second group).|t|f|f|t
33850506|NCT01893125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33850507|NCT02341859|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33850508|NCT01315587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850509|NCT05249439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of patients will be recruited from our specialist obesity clinic. One group will take part in the new I-SatPro weight loss programme One group will follow a standard NHS Tier 3 weight loss programme||||
33850510|NCT05712473|||COHORT||PROSPECTIVE|||||||
33850511|NCT03929172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850512|NCT02447172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33954919|NCT02823782|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33954920|NCT02439801|||CASE_CROSSOVER||PROSPECTIVE|||||||
33954921|NCT05007652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954922|NCT03073642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor will not know in which group volunteers are allocated; Care provider will not know outcome measures for any volunteers before study completion.|Double blind randomized controlled trial with 1:1 allocation|f|t|t|f
33954923|NCT06621511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33954924|NCT06055894|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized, non blinded, telehealth based, national pilot study with 100 patients (25 per arm). Randomization will be stratified based on BMI (normal/elevated) and Mayo risk SMM criteria.||||
33954925|NCT04571164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954926|NCT05978570|||COHORT||CROSS_SECTIONAL|||||||
33954927|NCT06541756|RANDOMIZED|PARALLEL||TREATMENT||NONE|not possible|Prospective Randomized Controlled Study||||
33954928|NCT00563706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954929|NCT00871806|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33954930|NCT04911075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954931|NCT03196960|||COHORT||PROSPECTIVE|||||||
33954932|NCT04013373|||COHORT||PROSPECTIVE|||||||
33954933|NCT03895827|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcome assessor is blind to the condition of the participant.|Participants randomly assigned to experiment group getting Recovery Initiation and Management after Overdose (RIMO) intervention or control group getting a passive referral to medication assisted treatment.|f|f|f|t
33954934|NCT06338280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33954935|NCT06226064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954936|NCT01279265|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33954937|NCT06417749|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a single-blind design, where the outcome assessors will be masked from the assignment of the participants.|This is a two-arm parallel design, with one arm being the control arm and the other being the intervention arm (MIND diet education and food supply).|f|f|f|t
34058936|NCT03410082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The person who surveys the patient's satisfaction in the post anesthesia care unit does not know which group the patient was assigned to.|Randomized controlled trial|f|f|f|t
34058937|NCT01979471|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34058938|NCT01041976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34058939|NCT01319851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058940|NCT01489124|RANDOMIZED|CROSSOVER||||NONE||||||
34058941|NCT05625191|||CASE_CONTROL||PROSPECTIVE|||||||
34163125|NCT03370718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163126|NCT03567876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163127|NCT01766180|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34163128|NCT02053090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163129|NCT00068757||||TREATMENT||NONE||||||
34163130|NCT02526628|||CASE_CONTROL||OTHER|||||||
34163131|NCT05271214|||CASE_ONLY||PROSPECTIVE|||||||
34163132|NCT05733156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058942|NCT04519788|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"8 participants per cohort (randomised AT-301A/Placebo : AT-301B, 2:6). Part 1: (SAD) Participants will receive: Cohort 1 - AT- 301A/Placebo or AT-301B 0.1mL per nostril (0.2mL total); or, Cohort 2 - AT-301A/Placebo or AT-301B 0.2mL per nostril (0.4mL total).~Part 2: (MAD) Cohort 3 - AT-301A/Placebo or AT-301B 0.1mL per nostril (0.2mL total), three times/day for 14 days; or, Cohort 4 - AT- 301A/Placebo or AT-301B) 0.2mL per nostril (0.4mL total), three times/day for 14 days."|t|t|t|t
34058943|NCT06624111|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34058944|NCT05908435|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Teen survey participants will not know whether the park where the free sunscreen dispenser is located is an intervention or control site.||t|f|f|f
34163133|NCT02134444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163134|NCT00079560|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34163135|NCT01588561|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34163136|NCT05971069|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Enrolled patients will be divided into three groups according to the real time near-infrared fluorescence imaging during surgery.|||||
34163137|NCT04659616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163138|NCT05987696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163139|NCT00033488||||SCREENING||||||||
33850513|NCT00434005|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33850514|NCT03273361|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects were randomly assigned to a pedaling sequence based on the Graeco Latin squares design. They were blinded regarding which pedaling sequence they were assigned to.||t|f|f|f
33850515|NCT05924308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850516|NCT02143297|||CASE_CONTROL||PROSPECTIVE|||||||
33850517|NCT00712946|||CASE_CONTROL||PROSPECTIVE|||||||
33850518|NCT00188786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850519|NCT04839874|||COHORT||RETROSPECTIVE|||||||
33850520|NCT03362047|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, randomized, prospective, open pilot study||||
33850521|NCT00081497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850522|NCT04353973|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33850523|NCT02257567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850524|NCT00699894|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850525|NCT02170480|||COHORT||PROSPECTIVE|||||||
33850526|NCT02232607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850527|NCT04806217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850528|NCT06609564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33850529|NCT00628576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850530|NCT03368339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Masked||t|f|t|f
33850531|NCT01880528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33850532|NCT06116955|||COHORT||PROSPECTIVE|||||||
33850533|NCT02394301|||COHORT||PROSPECTIVE|||||||
33850534|NCT03860285|||COHORT||PROSPECTIVE|||||||
33850535|NCT04232059|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE||The aim of this study is to evaluate the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.|t|t|t|t
33850536|NCT01096654|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33850537|NCT03989661|||COHORT||RETROSPECTIVE|||||||
33850538|NCT04899141|||COHORT||PROSPECTIVE|||||||
33850539|NCT02335931|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850540|NCT03226951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163140|NCT02442024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163141|NCT02491983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163142|NCT00612755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163143|NCT03441061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850541|NCT02704663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850542|NCT00910689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850543|NCT02220231|NA|SINGLE_GROUP||||NONE||||||
33850544|NCT01759576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850545|NCT05198011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850546|NCT02349373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33850547|NCT01321320|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33850548|NCT05391737|||CASE_CONTROL||PROSPECTIVE|||||||
33850549|NCT02863497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850550|NCT05560347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, controlled, experimental, clinical trial||||
33850551|NCT05468359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850552|NCT00329511|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850553|NCT04703738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind (Outcomes Examiner)|parallel, randomized, controlled, single-blind, multi-centre clinical trial|f|f|f|t
33850554|NCT00913237|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850555|NCT00159276|||CASE_CONTROL||PROSPECTIVE|||||||
33850556|NCT00201721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850557|NCT01347801|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33850558|NCT00577265|||||PROSPECTIVE|||||||
33850559|NCT01181323|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33850560|NCT03594604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be randomized to receive oral contraceptive pills or norethindrone|Patients will be randomized to receive oral contraceptive pills or norethindrone|f|f|t|f
33850561|NCT06610422|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850562|NCT05594953|||COHORT||RETROSPECTIVE|||||||
33893409|NCT05139030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only study drug administrators (anesthesiologists) will be unblinded to perform the block procedures||t|f|t|t
34163144|NCT00910780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163145|NCT05142605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163146|NCT03009422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163147|NCT05832879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163148|NCT03786536|NA|SINGLE_GROUP||TREATMENT||NONE||Healthy volunteer study||||
34163149|NCT05648292|||CASE_CONTROL||PROSPECTIVE|||||||
34163150|NCT04728386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33850563|NCT06609447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Multicenter, Randomized, Double-blind, Placebo-controlled trial in adult subjects with moderate active ulcerative colitis|t|f|t|f
34163151|NCT05303623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment Randomized Healthy participants|t|f|f|f
34163152|NCT02240641|||COHORT||PROSPECTIVE|||||||
34163153|NCT06393972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163154|NCT03874572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163155|NCT06160011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163156|NCT04976686|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||First phase will be purely observational, second phase involves diet modification||||
34163157|NCT03310814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163158|NCT05175586|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||30 divided into two groups: Group 1 (n=15) percutaneous neuromodulation together with orthopaedic manual therapy (Maitland and Mulligan) Group 2 (n=15) orthopaedic manual therapy (Maitland and Mulligan).|t|f|t|t
34163159|NCT06172647|||CASE_CONTROL||PROSPECTIVE|||||||
34163160|NCT04987502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163161|NCT06722677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The device can be set as active VNS or sham VNS (the actual intensity is 0 mA). An unmasking programmer not involved in treatments or assessments will be messaged the group of the participant and set appropriate stimulation setting at baseline follow-up timepoint. Other masking researchers, including therapists and assessors, as well as the participant will not know the stimulation setting.||t|t|t|t
34163162|NCT03805789|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34163163|NCT06046729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase 2b|t|f|t|f
34163164|NCT04601896|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163165|NCT04403451|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental design with a randomized controlled trial for the impact evaluation.||||
34163166|NCT04688749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163167|NCT06009094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163168|NCT06091735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34163169|NCT03329092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"An independent adjudication committee (central blinded assessor) will be convened at regular intervals during the study. The adjudication committee will be blinded to study treatment and will review the clinical response assessments at each visit. In case of a discrepancy with the Investigator's assignment of clinical response, the adjudication committee's assessment will prevail.~In addition, for cIAI subjects classified as a clinical failure, and all cIAI subjects classified as a cure who undergo another procedure (eg, another surgical procedure) subsequent to randomization, the expert panel will review the adequacy of the surgical source control."|Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study|f|f|f|t
34163170|NCT06725849|||CASE_ONLY||CROSS_SECTIONAL|||||||
34163171|NCT02298400|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34163172|NCT05989880|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163173|NCT05314998|RANDOMIZED|PARALLEL||TREATMENT||NONE||Therapeutic intervention of standard adjuvant chemotherapy comprising oxaliplatin- or gemcitabine-based regimens based on standard clinical criteria, compared to selection using a treatment specific signature and prediction model.||||
34163174|NCT02259465|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34163175|NCT01070173|||COHORT||PROSPECTIVE|||||||
34163176|NCT05142826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Observers are masked to group assignment of the participants||f|f|f|t
34163177|NCT00534859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163178|NCT05649800|||CASE_CONTROL||PROSPECTIVE|||||||
34163179|NCT03970941|||COHORT||PROSPECTIVE|||||||
34163180|NCT03148041|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163181|NCT00940901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163182|NCT02588404|||CASE_ONLY||PROSPECTIVE|||||||
34163183|NCT01518374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163184|NCT06654752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163185|NCT01824550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163186|NCT00955396|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34163187|NCT02595424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163188|NCT06141863|||CASE_ONLY||CROSS_SECTIONAL|||||||
34163189|NCT06340945|NA|SEQUENTIAL||TREATMENT||NONE||||||
34163190|NCT01009684|||COHORT||PROSPECTIVE|||||||
34163191|NCT05943249|||OTHER||OTHER|||||||
34163192|NCT01015781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163193|NCT04184297|||COHORT||RETROSPECTIVE|||||||
34163194|NCT03018691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163195|NCT03928795|||COHORT||PROSPECTIVE|||||||
33850564|NCT01912560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850565|NCT04750785|||COHORT||PROSPECTIVE|||||||
33850566|NCT06078137|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33850567|NCT00134745|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33850568|NCT03102645|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Packaging, randomization and masking of investigational drugs (imipramine and placebo) by Region Hovedstadens Apothecary before delivery to investigator. Sealed envelope with participant ID and drug data will be opened after data analysis.|16 healthy female subjects. Double-blinded, crossover study on two days with 1 week washout. Either placebo or imipramine 50 mg single dose before and after measurement of UOP and AOP.|t|f|t|t
33850569|NCT05223777|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will undergo primary total hip athroplasties through a direct anterior surgical approach using press fit implants. Anesthesia will be either general anesthesia or spinal anesthesia.Multimodal analgesia and rapid recovery techniques are used for all procedures. Twenty-five (25) of these procedures will be performed using the KINCISE and 25 will be performed using traditional handheld mallets.||||
33850570|NCT02946190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850571|NCT04802616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163196|NCT03077919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be centrally randomized to 2:1 active:sham SGB and will be evaluated at Womack Army Medical Center in North Carolina, Tripler Army Medical Center in Hawaii, and Landstuhl Regional Medical Center in Germany. Randomization will be stratified by site so that each will have a 2:1 active:sham ratio. The target population includes active-duty service members and study duration is 10 weeks in the clinical effectiveness trial for which an enrollment of 240 participants is planned.|t|t|t|t
34163197|NCT06726629|||COHORT||PROSPECTIVE|||||||
34163198|NCT04678752|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Effectiveness-Implementation Hybrid Type 1 Study using a Stepped Wedge Cluster Randomized Trial design||||
33850572|NCT03212989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850573|NCT05367115|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33850574|NCT05999695|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33850575|NCT02851641|||COHORT||PROSPECTIVE|||||||
34163199|NCT06726655|||CASE_CONTROL||RETROSPECTIVE|||||||
34163200|NCT04523207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163201|NCT06726915|||COHORT||CROSS_SECTIONAL|||||||
34163202|NCT00112372|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163203|NCT05880381|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of the two groups.||||
34163204|NCT01281826|||COHORT||PROSPECTIVE|||||||
34163205|NCT04067258|||OTHER||PROSPECTIVE|||||||
34163206|NCT00200720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163207|NCT04995523|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study includes 5 parts: Part A: Dose escalation; B \& C \& E: Dose expansion non-randomized; D: Randomized RP2D \& alternative dose.||||
34163208|NCT05574010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A is open label Part B and Part C are a double-blinded study. Study participants and their caregivers, investigators and other site staff, and sponsor staff involved in the study team will be blinded.|"Part A: This part of the study is an open label with up to 6 participants in each dose cohort. There will be 2 dose cohorts.~Part B and Part C: These parts of the study have a randomized, double- blinded, placebo-controlled, parallel study design."|t|f|t|t
34163209|NCT00109824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163210|NCT05865470|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.|t|f|t|f
34163211|NCT00550407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163212|NCT00669708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163213|NCT00946790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163214|NCT06630117|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34163215|NCT01844336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163216|NCT05708495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34163217|NCT02171442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163218|NCT03415945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163219|NCT06706219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163220|NCT03206801|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The assessor of the primary outcome will be masked. As the intervention involves a study biopsy, based on an elevated urine CXCL10, it is not possible to blind the participant, care provider or investigator.|This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients. Patients with elevated urine CXCL10 will be randomized 1:1 to the intervention and control arms, stratified by center (\~ 420 enrolled to urine CXCL10 screening for n=250 randomized participants).|f|f|f|t
34163221|NCT03354273|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163222|NCT01933490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850576|NCT00201890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850577|NCT00618618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850578|NCT05002764|||COHORT||OTHER|||||||
33850579|NCT00136981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850580|NCT01791036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850581|NCT00513604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850582|NCT01771640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850583|NCT00196001|||COHORT||PROSPECTIVE|||||||
33850584|NCT03429231|||COHORT||PROSPECTIVE|||||||
33850585|NCT02510209|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893410|NCT02693977|||COHORT||PROSPECTIVE|||||||
33893411|NCT05742386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized design in which clinics will be randomized||||
33893412|NCT04700267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893413|NCT00909272|||||PROSPECTIVE|||||||
33893414|NCT02590393|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33893415|NCT04269551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163223|NCT02791230|NA|PARALLEL||TREATMENT||NONE||||||
34163224|NCT06508463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163225|NCT05865522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34163226|NCT01908452|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34163227|NCT00096434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163228|NCT00988988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163229|NCT05286502|||COHORT||PROSPECTIVE|||||||
34163230|NCT04094857|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label||||
34163231|NCT04331717|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163232|NCT04513912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163233|NCT04970654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163234|NCT00018889|||CASE_ONLY||PROSPECTIVE|||||||
34163235|NCT02436616|||COHORT||PROSPECTIVE|||||||
34163236|NCT04041154|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163237|NCT06474637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746008|NCT04105023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The interventions with genistein and placebo were identically encapsulated in appearance, both the researcher and the participant did not know what type of maneuver was assigned. The bottle with the capsules was distributed by a person outside the study who was the same one who performed the randomization.~Study staff and participants were blinded during the assignment and execution of the interventions in the study. the capsules delivered to the participants were 2 per day, the capsules had the same color and appearance"|These individuals were advised to consume the recommended diet for subjects with MetS according to the guidelines of the ATPIII. Patients were randomly distributed to consume a) placebo treatment or b) genistein capsules (50 mg/day). The participants were followed for 2 months|t|f|t|f
33746009|NCT03205995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746010|NCT03239379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blind, placebo-controlled||t|t|f|t
33746011|NCT01999504|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33746012|NCT03551938|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33746013|NCT01989650|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33746014|NCT06451068|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be assigned to a group based on ocular history/diagnosis. Each participant will receive the same intervention.||||
33746015|NCT00647712|RANDOMIZED|CROSSOVER||||NONE||||||
33746016|NCT01093794|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746017|NCT05472714|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Comparison between year 1 and year 2 cohorts, with year 2 cohort receiving intervention||||
33746018|NCT04191057|NA|SINGLE_GROUP||SCREENING||NONE|The participant will not be given the results of the free light chain result|||||
33746019|NCT05343702|||CASE_CONTROL||PROSPECTIVE|||||||
33746020|NCT04962464|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||prospective, randomized trial|f|f|f|t
33746021|NCT02096900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746022|NCT05556408|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746023|NCT06469320|||COHORT||PROSPECTIVE|||||||
33746024|NCT04104581|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33746025|NCT01571362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746026|NCT06054724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746027|NCT03044067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746028|NCT06088654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746029|NCT02132611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746030|NCT06516757|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163238|NCT04122508|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34163239|NCT01385657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34163240|NCT01804881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163241|NCT04146545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cases will receive the CRx-D Intervention. Controls will not receive the intervention but will receive the usual standard of care.|t|f|f|f
34163242|NCT05073926|||COHORT||PROSPECTIVE|||||||
33746031|NCT02152267|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33746032|NCT06634693|||CASE_ONLY||PROSPECTIVE|||||||
34163243|NCT05043753|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"To compare the diagnostic accuracy of symphysis fundal height (SFH) as opposed to SFH combined with point of care ultrasound to measure the fetal abdominal circumference (POC-US-AC) in identifying small and large for gestational age infants (SGA and LGA infants) among low-risk pregnant women cared for by midwives after 35 weeks' gestation.~Low risk pregnancies will be evaluated at 35-38, 40, 41, and 41+ weeks' gestation by midwives trained in SFH measurement and POC-US. Formal obstetric US performed by a perinatologist (i.e high risk obstetrician) will be performed in case SFH and/or POC-US suspect fetal growth or amniotic fluid abnormalities. Prenatal evaluations will be compared to actual birthweights"||||
34163244|NCT04190901|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||"This is a 2x2 experimental design. Subjects were randomly assigned to one of four possible conditions: Black Female, Black Male, White Female, White Male. Within each condition, subjects were randomly assigned 1 of 10 possible putative doctors from a total of 40 putative doctors, 10 for each condition. For example, 10 Black Female doctors, etc. The images of putative physicians were selected from actors in the Chicago Face Database and altered to wear a white coat. Given that the vast majority of Emergency Physicians in the United States are white men, the White Males condition served as the control."||||
34163245|NCT03052244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163246|NCT06511102|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34163247|NCT03718026|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163248|NCT00581581|||CASE_CONTROL||PROSPECTIVE|||||||
34163249|NCT04981379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial|t|t|t|f
34163250|NCT05289986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163251|NCT06169449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163252|NCT01639053|||COHORT||PROSPECTIVE|||||||
34163253|NCT06419712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34163254|NCT05975645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163255|NCT01543074|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34163256|NCT06259669|||COHORT||PROSPECTIVE|||||||
34163257|NCT02529163|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34163258|NCT04171297|||COHORT||PROSPECTIVE|||||||
34163259|NCT06726811|||CASE_CONTROL||PROSPECTIVE|||||||
34163260|NCT05335876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163261|NCT02068794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163262|NCT03660761|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label (Subject)|single arm||||
34163263|NCT04254484|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34163264|NCT06727006|||COHORT||PROSPECTIVE|||||||
34163265|NCT03282890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163266|NCT02920749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163267|NCT06419088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34163268|NCT05233618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163269|NCT04070989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163270|NCT01308697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163271|NCT04927065|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Parts A-H: non-randomized Part J: randomized|Parts A-H: Sequential Part J: Parallel (participants were randomized to receive either mRNA-1273.815 or mRNA-1273.231)||||
34163272|NCT06465004|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized cross-over design|t|f|f|t
34163273|NCT04503265|NA|SEQUENTIAL||TREATMENT||NONE||||||
34163274|NCT06727279|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Chicken-flavoured plant-based meat analogs will be used in this study||t|t|t|f
34163275|NCT02968368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163276|NCT06493058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33746033|NCT02264067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746034|NCT05023252|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants in the trial are enrolled in an intervention group for 9 months||||
33746035|NCT02709954|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33746036|NCT04697758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33746037|NCT05309161|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33746038|NCT02808455|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33746039|NCT04156607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Half of the children with DS (Sham taping group) took sham taping application.|The study was carried out with the participation of 3 groups as kinesio taping application group with Down Sydnrome children (KT) (n=12, DS), sham taping application group with Down Syndrome children (ST) (n=12, DS) and healthy control with healty children (HC) (n=12). Healty children took no taping applications. KT group took Kinesio tape, ST group took sham taping evaluated 2 times after the tapings (immediately and 45 minutes later).|t|f|f|f
34163277|NCT01416948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163278|NCT04142801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization for the allocation of the patient in each group|regular use of a web application at home to train cognition and behavior|t|f|t|f
34163279|NCT00410956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163280|NCT02175017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163281|NCT06344299|||CASE_CONTROL||RETROSPECTIVE|||||||
34163282|NCT05171192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163283|NCT06367348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Couples will be randomized 1:1 to intervention or control arm||||
34163284|NCT04367831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163285|NCT00921349|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163286|NCT01062152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163287|NCT02566317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163288|NCT04628429|||COHORT||PROSPECTIVE|||||||
34163289|NCT02579967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163290|NCT06725303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163291|NCT02673463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163292|NCT00005650|||NATURAL_HISTORY|||||||||
33746040|NCT01627249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746041|NCT03178357|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746042|NCT03969069|||COHORT||PROSPECTIVE|||||||
33746043|NCT04837482|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746044|NCT03820661|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746045|NCT04725721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746046|NCT04947111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"* Estimate the specific serotype prevalence for DENGUE Virus in groups from 5 to 35 years old in areas of low and high dengue endemicity.~* Determine the general prevalence of antibodies (IgG) against DENGUE Virus in groups aged 5 to 35 years in areas of high and low incidence of dengue."||||
33746047|NCT02126293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746048|NCT06491121|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A double blind (outcome assessor \& statistical analysis) three-armed multicentre RCT will be conducted. This RCT will adhere to Good Clinical Practice (GCP) regulations.|f|f|t|t
33746049|NCT04883671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746050|NCT03689010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746051|NCT06507566|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33746052|NCT00193700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746053|NCT02612402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33746054|NCT00050310|||COHORT||PROSPECTIVE|||||||
33850586|NCT04845243|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants will receive six sessions (duration approx. 1h/session) of the software-based training program Emotionen Verstehen und Ausdrücken (EVA; Moebert \& Lucke, 2019). Sessions will be administered 2-3 times/week depending on the participants' time availability. In order to objectively identify the potential benefit of the training for each participant, they will perform two separate tasks before and after the emotion recognition training, the Geneva Emotion Recognition test (GERT; Schlegel, Grandjean,\& Scherer, 2014) and a social decision-making task. A comparison of their performance pre- and post-training is taken as an indicator of improvement in emotion recognition skills."||||
33850587|NCT01493843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850588|NCT02262091|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34163293|NCT00981461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163294|NCT00776854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163295|NCT01632020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163296|NCT05042583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Neither the experimenters nor the participants knew whether they were getting an experimental drug or a placebo. In this way, the description of the therapeutic effects and adverse reactions of the subjects, as well as the record of the various reactions of the experimenters, can be as objective as possible.|Sixty patients with liver lobectomy were selected and divided into two groups according to random number table method: experimental group and control group., with 30 cases in each group. All enrolled patients signed informed consent. Control group: The control group was injected with physiological saline 6ml for stellate ganglion block.Experimental group: The experimental group was injected with 0.5% ropivacaine 6ml for stellate ganglion block.|t|t|t|t
34163297|NCT03097965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163298|NCT00622505|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163299|NCT01111435|||COHORT||PROSPECTIVE|||||||
34163300|NCT06725758|NA|SEQUENTIAL||TREATMENT||NONE||||||
34163301|NCT03275285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163302|NCT01815827|RANDOMIZED|PARALLEL||||NONE||||||
34163303|NCT03636789|NA|SINGLE_GROUP||OTHER||NONE||||||
34163304|NCT04966507|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34163305|NCT06725381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163306|NCT04837573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163307|NCT03291717|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163308|NCT05565703|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial including an intervention and attention control group||||
34163309|NCT04789876|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were allocated to the intervention and control group. The intervention group received a phosphate mobile app for 12 weeks and the control group received one-off dietary counselling delivered by a dietitian with a phosphate booklet.||||
34163310|NCT02956694|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We evaluated the effectiveness of the intervention, here a training program, using a pre-post design, and also assessed the barriers and facilitators to completing the training program.||||
34163311|NCT06439277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163312|NCT05956899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||After taking informed consent and recruitment of eligible participants, they will be randomized using a sequentially numbered, opaque sealed envelope (SNOSE) method. 74 radio-opaque envelopes will be prepared according to two groups: 37 participants for each Group A, Palonosetron and Group B, Ondansetron. Group A will receive IV palonosetron 1.5mcg/kg prior to commencement of general anaesthesia; while Group B will receive IV ondansetron 0.15mg/kg at the start of wound closure.|t|f|t|f
34163313|NCT00585520|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34163314|NCT01186991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163315|NCT05813964|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase III, international, multicenter, open-label, parallel-group, randomized, controlled trial among cis men who have sex with men.||||
34163316|NCT01581398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163317|NCT06108219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded||t|t|t|t
34163318|NCT01034930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163319|NCT05898126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind trial. Participants will be blinded to treatment allocation.|Clinical trial in which patients affected by shock, randomly receive either renin-guided hemodynamic management or usual care.|t|f|f|f
34163320|NCT01646281|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34163321|NCT04726722|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2 x 2||||
34163322|NCT05594719|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants were randomly divided into three groups without knowing the type of light|"The participants were randomly divided into the following three groups:~1. Sun-like spectrum, color temperature of 5000K, shorter-wavelength dominant;~2. Sun-like spectrum, color temperature of 5000K, wavelength proportion similar to the sunlight;~3. Sun-like spectrum, color temperature of 5000K, longer-wavelength dominant."|t|f|f|f
34163323|NCT02021669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163324|NCT02545218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163325|NCT01432392|||COHORT||PROSPECTIVE|||||||
34163326|NCT05173896|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163327|NCT01880658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163328|NCT04890470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34163329|NCT06280716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Randomized, double-blind, parallel group, placebo controlled|t|f|t|f
34163330|NCT02795585|||COHORT||PROSPECTIVE|||||||
34163331|NCT04385186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||MULTICENTER, CONTROLLED, RANDOMIZED, SIMPLE BLIND, CLINICAL TRIAL|f|f|t|f
34163332|NCT06411574|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be recruited into one of two groups: standard of care (GES only) or BSGM-guided care (GES + BSGM). Each group will undergo treatment based on their respective management plan.||||
34163333|NCT03243136|||COHORT||PROSPECTIVE|||||||
34163334|NCT03811171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163335|NCT00655616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163336|NCT04030975|||CASE_ONLY||PROSPECTIVE|||||||
34163337|NCT06725134|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163338|NCT00369577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850589|NCT05164029|||COHORT||PROSPECTIVE|||||||
33850590|NCT04310098|||COHORT||PROSPECTIVE|||||||
34163339|NCT04457063|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective non-comparative non-randomized clinical study which was conducted on 12 eyes of 8 patients 4 males and 4 females who underwent PKP for keratoconus, and then toric ICL was implanted after minimum of one year with stable refraction||||
34163340|NCT03030118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163341|NCT06143267|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The randomized order of infusions is blinded to both participant and investigator|Randomized, double-blinded, single-arm study. Each participant goes through six experimental days in a randomized order - acting as their own controls||||
34163342|NCT06125509|||COHORT||PROSPECTIVE|||||||
34163343|NCT05564455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, interventional study||||
34163344|NCT03231007|||OTHER||CROSS_SECTIONAL|||||||
34163345|NCT06039995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163346|NCT05026359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
33850591|NCT03947190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850592|NCT01296789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850593|NCT05342025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor will be blind to the randomization and the investigator will be blind to the results of the assessments.||f|f|t|t
33850594|NCT06406842|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator of control group||t|f|f|t
33850595|NCT01460173|NON_RANDOMIZED|PARALLEL||||NONE||||||
33850596|NCT01380015|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34058945|NCT00441818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058946|NCT02815813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34058947|NCT05946577|||COHORT||PROSPECTIVE|||||||
34058948|NCT00691899|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34058949|NCT06090097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers conducting functional outcomes on study completion will be blinded from the intervention group.|randomized control trial|f|f|f|t
34058950|NCT05862883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Main group consisting of 201 children of 6-18 years old with mild and moderate COVID-19 form who were treated at the specialized clinic Zangiota 1 and were taking Rutan. Control group consisting of 100 children of 6-18 years old with mild and moderate COVID-19 form who were treated at the specialized clinic Zangiota 1 and were not taking Rutan."|t|f|f|t
34058951|NCT05900089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058952|NCT03357575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058953|NCT00648934|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34058954|NCT00379808|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34058955|NCT01834716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34058956|NCT02071810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34058957|NCT03684226|||COHORT||PROSPECTIVE|||||||
34058958|NCT05375344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058959|NCT04814316|||CASE_CONTROL||PROSPECTIVE|||||||
34058960|NCT03124121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058961|NCT05680506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a another person who will be unaware of the group the particpant belong to|This study is a randomized controlled trial which will consist of two groups. One will recieve conventional physcial therapy only and the second will recieve conventional physcial therapy with pain neuroscience education.Both groups will be recruited concurrently.|f|f|f|t
34058962|NCT05210101|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34058963|NCT03409900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34058964|NCT01491126|||COHORT||PROSPECTIVE|||||||
34058965|NCT03840148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34058966|NCT03265548|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
34058967|NCT00980174|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33850597|NCT06093776|||CASE_ONLY||PROSPECTIVE|||||||
33850598|NCT01418989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954938|NCT03378310|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33954939|NCT05285527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954940|NCT01733641|||COHORT||PROSPECTIVE|||||||
33954941|NCT06653725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients are randomized 1:1 to 1,3-butanediol or matching placebo treatment for 30 days.|t|t|t|t
33954942|NCT02064374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954943|NCT06468449|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Assistant coaches implementing the intervention plan.|In this study, the experimental group performed optimal load strength training aimed at developing the maximum power output of long jumpers, while the control group performed traditional strength training aimed at developing the fast strength of long jumpers.|t|f|f|f
34163347|NCT06713330|RANDOMIZED|PARALLEL||TREATMENT||NONE||The purpose of this 36-month prospective, randomized controlled, split-mouth pilot study, is to compare a new prefabricated resin crown material against the gold standard stainless steel crown in primary molars that require full coverage restorations. The results of this study can help determine if resin polymer crowns clinically perform like stainless steel crowns, and if they are an acceptable esthetic alternative treatment option for a full coverage restoration of a primary molar.||||
34163348|NCT04236388|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33850599|NCT02501915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850600|NCT00300521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746055|NCT06531954|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The 88 volunteer cases were divided into two groups by randomization. By randomization, according to the order of participation in the study, odd-numbered people (such as first, third, fifth) were included in the breathing exercises group (Group BE); even-numbered people (such as second, fourth, sixth) were included in the vagus nerve stimulation group (Group VNS). After randomization, 44 cases in Group BE and 44 cases in Group VNS were evaluated. All participants completed the study.|Our study was conducted as a randomized prospective study. In both groups, the interventions were performed for ten sessions for two weeks, five days a week. In both groups, heart rate variability, heart rate, and blood tension were measured before and after each session, and the pulmonary function test was evaluated the day before and the day after the ten sessions of applications.|t|f|f|f
33850601|NCT03435354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Those conducting the post-intervention assessments will be blind to study group allocation.|Cluster-randomized trial, with randomization by within each site by week (i.e., site-week)|f|f|f|t
33850602|NCT01051830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33850603|NCT01575028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33850604|NCT01841931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850605|NCT04952454|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33850606|NCT02300441|||COHORT||PROSPECTIVE|||||||
33850607|NCT05415943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850608|NCT05813639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sealed envelope, random software|Prospectively randomized patients with positive facet joint syndrome|f|t|f|f
33850609|NCT00658684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850610|NCT02822144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954944|NCT04936334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Two separate radiologists (one from Nuclear Medicine and one from MRI) will read images in a blinded fashion and provide their findings for the surgeons to use in treatment planning.|68Ga-PSMA-11 PET will be performed and we will study how the knowledge of the results informs treatment decisions versus the treatment decisions with only MRI knowledge.||||
33954945|NCT04400175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954946|NCT04014972|||COHORT||RETROSPECTIVE|||||||
33954947|NCT00297063|RANDOMIZED|PARALLEL||TREATMENT||||||||
34058968|NCT05596500|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Investigators and study participants will be blind to treatment allocation.|Randomized treatment, double blinded procedures, crossover|t|f|t|f
34058969|NCT04932746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Triple masking:~Anesthesiologists, graduate students, anesthesiologists, patients and their families will not know if a child is taking the drug or not.~Also, the person who will conduct the survey will not know either, all will be hidden.~Depending on the volume in ml, to mask the medical team from the substance of the drug..."||t|t|t|t
34058970|NCT00497848|NON_RANDOMIZED|PARALLEL||||NONE||||||
34058971|NCT02319720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746056|NCT06486168|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746057|NCT00765193|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746058|NCT06670352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746059|NCT02848417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33746060|NCT00386906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746061|NCT02727101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746062|NCT06030726|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746063|NCT03551015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746064|NCT05956340|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33746065|NCT04402177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746066|NCT04833647|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants performed CPET on an electronically braked cycle ergometer . During the exercise testing, serial saturation, heart rate and blood pressure measurements were obtained. The peak oxygen consumption (VO2max) was measured and served as the primary endpoint of the study. A CPET technician and a senior pediatrician were present and monitored the participants' condition during the study.||||
33850611|NCT01524601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850612|NCT02570932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058972|NCT05449938|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34058973|NCT01200732|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34058974|NCT01966419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While the study was double-blind (participant and investigator blinded), the care provider and outcomes assessor were also blinded.||t|f|t|f
34058975|NCT01103102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058976|NCT06402591|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||randomized controled trial||||
34058977|NCT00718380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954948|NCT06634407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954949|NCT05371236|||CASE_ONLY||CROSS_SECTIONAL|||||||
33954950|NCT01069458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746067|NCT04777565|NA|SINGLE_GROUP||OTHER||NONE||||||
34058978|NCT01819753|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34058979|NCT06119334|RANDOMIZED|PARALLEL||TREATMENT||NONE||Paralell group design with intervention participants compared to wait-list control subjects. 16 weeks intervention.||||
34058980|NCT03344965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058981|NCT00751257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058982|NCT01942499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34058983|NCT01343667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058984|NCT06622096|||COHORT||PROSPECTIVE|||||||
34058985|NCT00334191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34058986|NCT01060605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058987|NCT06293027|||CASE_CONTROL||PROSPECTIVE|||||||
34058988|NCT04810247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34058989|NCT01367600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34058990|NCT06166537|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessor blinded|Assessor-blinded randomised controlled trial with a non-inferiority comparison|f|f|f|t
34058991|NCT04530591|||CASE_ONLY||PROSPECTIVE|||||||
34058992|NCT02542241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34058993|NCT04605393|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34058994|NCT01007734|||COHORT||CROSS_SECTIONAL|||||||
34058995|NCT02895646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34058996|NCT01848743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34058997|NCT04144036|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34058998|NCT03482076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34058999|NCT06649032|||COHORT||PROSPECTIVE|||||||
34059000|NCT04443621|||CASE_CONTROL||PROSPECTIVE|||||||
34059001|NCT06477835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059002|NCT00628849|||COHORT||PROSPECTIVE|||||||
34059003|NCT04875312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059004|NCT06648954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059005|NCT01756963|||COHORT||PROSPECTIVE|||||||
34059006|NCT00284427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059007|NCT05863091|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34059008|NCT04211974|||CASE_ONLY||PROSPECTIVE|||||||
34059009|NCT00655473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059010|NCT03273400|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The study will be a cross-over design. A pre-test post-test design will be used to evaluate the sEMG activity of the Erector Spinae muscle group and the Hamstring muscle (Biceps Femoris). Lumbar flexion range of motion and hamstring length will be tested prior too mobilisations and post intervention immediate and at intervals of 5, 10, 15, 20, 30, 60 minutes. Participants will be receive non-intervention one week and mobilisations the following week.|t|f|f|f
34059011|NCT05250687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163349|NCT04345562|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163350|NCT01890837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163351|NCT05616481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163352|NCT05700877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The participants are masked for screening results if they are randomized to standard treatment, but all participants will obtain information on which arm they are randomized."|The Steno Inten-CT study is an investigator-initiated pragmatic open-label event-driven randomized controlled trial.|t|f|f|t
34163353|NCT06081387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163354|NCT06727071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163355|NCT04587050|||COHORT||CROSS_SECTIONAL|||||||
33746068|NCT06262529|NA|SINGLE_GROUP||OTHER||NONE||||||
33746069|NCT05283174|||COHORT||PROSPECTIVE|||||||
34163356|NCT06122506|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163357|NCT03194126|RANDOMIZED|PARALLEL||OTHER||SINGLE|The primary outcome will be evaluated by a blinded evaluator: the laminaria placement is performed by the on-call team at Day-1, whilst the delivery is performed by a different team at Day 0, with the laminaria removed in the morning.||f|f|f|t
34163358|NCT03777059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163359|NCT06098937|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34163360|NCT06726967|||CASE_ONLY||RETROSPECTIVE|||||||
34163361|NCT03384368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163362|NCT05283421|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|A randomization code will be made and given to the hospital pharmacy who will be packing and blind the tablets for the study. The study medicine will be sent to the women with the same/equal etiquette. At the gynecological examination, the colposcopist will not know which study arm the woman is in.|Randomized controlled double blind multicenter study|f|t|f|f
34163363|NCT02564458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954951|NCT00421369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33954952|NCT04993339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954953|NCT05793060|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33954954|NCT04843891|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Eligible subjects, including healthy volunteers and patients with sarcoidosis, cardiovascular disease and cancer, will be enrolled to undergo imaging with the PET Probe \[64\]Cu Macrin||||
33954955|NCT03189199|||COHORT||PROSPECTIVE|||||||
33954956|NCT03099265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746070|NCT05064969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33746071|NCT05282381|||COHORT||PROSPECTIVE|||||||
33746072|NCT06328361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850613|NCT03383315|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study drugs were prepared under sterile conditions by a pharmacist independent to the study and kept in packs.The patients recruited were randomized to receive one of the study packs. The study pack were numbered by the pharmacist, who used a computer-generated random number sequence to assign treatment allocations. The allocation list was kept by the pharmacist. Treatment allocations were revealed only after study completion, when all outcome measurements had been performed and recorded by the investigator in the study database.|Patients are randomized into two groups. One group receives tramadol and metoclopramide, while another group receives tramadol and placebo (normal saline).|t|t|t|f
33746073|NCT01248650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746074|NCT02785406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850614|NCT00539773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850615|NCT03207009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850616|NCT02112032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850617|NCT00057174|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33850618|NCT01474928|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33850619|NCT01435733|||CASE_ONLY||RETROSPECTIVE|||||||
33850620|NCT00885040|||||PROSPECTIVE|||||||
33850621|NCT05564416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850622|NCT03085615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only our lab technicians will be truly blinding to group allocation.|Subjects will be randomized to receive either 25-30 kcals/kg or 12-14 kcals/kg. They will be followed for a maximum of 7 days or until ICU discharge. Blood draws will occur twice daily.|f|f|f|t
33954957|NCT03979586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954958|NCT06260358|||OTHER||PROSPECTIVE|||||||
33954959|NCT00054275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954960|NCT01649999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33954961|NCT04483570|||COHORT||RETROSPECTIVE|||||||
33746075|NCT05014594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746076|NCT00026533||||TREATMENT||||||||
33746077|NCT05680103|||COHORT||CROSS_SECTIONAL|||||||
33746078|NCT02253693|||COHORT||PROSPECTIVE|||||||
33746079|NCT02529774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746080|NCT04790981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746081|NCT04201548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746082|NCT06670274|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33746083|NCT05209282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental, Randomized Controlled Study|t|f|f|f
33746084|NCT06630871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746085|NCT00549926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954962|NCT03125564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954963|NCT06650332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954964|NCT04190056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954965|NCT05137639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33954966|NCT05273554|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059012|NCT06505161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|40 sealed opaque envelopes will be prepared. 20 of the envelopes will contain ballots corresponding to the DN control group and 20 to the PE group. Only the examiner who will carry out the intervention will know the group of each participant. The main examiner will be the one who monitors the intervention without knowing which group each participant belongs to.|The subjects will be divided into two groups. The control group will receive DN treatment, and the experimental group will receive PE, both in the lumbar multifidus muscles.|t|f|f|t
34059013|NCT05952804|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants and study staff (except for site pharmacists) will be blinded to treatment arm assignments.||t|t|t|t
34059014|NCT03565263|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34059015|NCT05591612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059016|NCT05307185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator, but not the patients will know the real identity of the treatment assignment (food preparation and packaging will be unlabelled and not recognizable).|Multi-disciplinary, single-blind, parallel-group randomized controlled trial design|t|f|f|f
34059017|NCT02812134|||COHORT||PROSPECTIVE|||||||
34059018|NCT03164434|||CASE_ONLY||PROSPECTIVE|||||||
34059019|NCT03701698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163364|NCT06726356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects were blinded. Study personnel responsible for assessing patients' symptom scores and recording information on acute exacerbations were blinded whenever possible. The bronchoscopy operator responsible for giving bronchoalveolar lavage treatment and the person in charge of the patient's bed were not blinded. To avoid subjective bias on the part of the assessor, non-blind people should not disclose blinded information to the assessor.|Control group A (conventional clinical treatment), Control group B (application of saline bronchoalveolar lavage based on conventional clinical treatment), and group C (application of bronchoscopic acetylcysteine combined with saline alveolar lavage based on conventional clinical treatment), were randomly selected into the groups according to a predefined sequence of randomisation tables prior to the operation due to the nature of the intervention.|t|f|f|f
34163365|NCT01687296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163366|NCT02618902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163367|NCT00028704|RANDOMIZED|||TREATMENT||||||||
33746086|NCT04506970|||CASE_CONTROL||PROSPECTIVE|||||||
33746087|NCT02091999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954967|NCT05621681|||CASE_CONTROL||PROSPECTIVE|||||||
33954968|NCT01728376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954969|NCT03970252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163368|NCT02459444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33850623|NCT04617977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850624|NCT04447846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850625|NCT00968227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850626|NCT05727345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After surgery, all patients will be followed by the same orthopaedist who is blind to the patient groups. Also, the patients themselves cannot know their groups as well. Only the investigator opens the opaque closed envelope and the same anesthesiologist, the investigator will perform blocks and will be the only one knowing study groups.|Once the investigator chose from the opaque envelopes which group the patient will be included, interscalene brachial plexus block will be applied for Group A and shoulder anterior capsular block will be applied for Group B. All other interventions will be standardized.|t|f|f|t
33850627|NCT00346671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850628|NCT05126082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||40 community-based, primary care clinics with the largest number of visits among youth 6-17 years will be balanced and randomly allocated in a 1:1:1 allocation ratio to usual care, low-intensity implementation, or high-intensity implementation of the PedsBP CDS.||||
33850629|NCT02105922|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33850630|NCT00731809|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850631|NCT06335277|||CASE_ONLY||PROSPECTIVE|||||||
33954970|NCT03738293|||CASE_CONTROL||RETROSPECTIVE|||||||
33954971|NCT03531684|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34163369|NCT06121089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"All patients will be randomly divided into two groups in a 1:1 ratio.~1. Research group (ICR) - Laparoscopy ileocecal resection with extended D3 lymphadenectomy (including 201, 202, 203 and 213 groups of lymph nodes). The minimum distance from the tumor is 10 cm, along the line of adequate blood supply. Next step - formation of a manual double-row ileo-ascendo-anastomosis.~2. Control group (RHC) - Laparoscopy right hemicolectomy with D3 lymphadenectomy (including 211, 212, 221, 222-rt groups of lymph nodes). Next step - formation of a manual double-row ileo-transverse-anastomosis."|t|f|t|f
34163370|NCT06725277|||COHORT||PROSPECTIVE|||||||
34163371|NCT01217463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163372|NCT00389493|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34163373|NCT03171337|RANDOMIZED|PARALLEL||OTHER||TRIPLE||The parallel group includes the positive and negative controls, the positive control is Fu's Subcutaneous Needling group and the negative is Sham acupuncture group. And the other parallel control is the fMRI of patients with CTTH VS fMRI of healthy people.|t|t|t|f
34163374|NCT01695434|||CASE_CONTROL||PROSPECTIVE|||||||
34163375|NCT02363621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163376|NCT05189119|||COHORT||PROSPECTIVE|||||||
34163377|NCT04428229|||CASE_ONLY||PROSPECTIVE|||||||
34163378|NCT00287508|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34163379|NCT05123599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163380|NCT04182841|NA|SINGLE_GROUP||TREATMENT||NONE||RheOx Treatment||||
34163381|NCT04212598|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase II study.||||
34163382|NCT01698502|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34163383|NCT01557088|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163384|NCT00684775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163385|NCT02475278|NA|SINGLE_GROUP||OTHER||NONE||||||
34163386|NCT02418052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163387|NCT02678351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163388|NCT01154777||CROSSOVER||TREATMENT||NONE||||||
34163389|NCT00082407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163390|NCT06139406|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163391|NCT01363089|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163392|NCT00123318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163393|NCT00747084|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34163394|NCT04353739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|There are four data collection points: week 1 (before intervention for immediate treatment (IT) group), week 4 (right after intervention for the IT group, but before intervention for delayed treatment (DT) group), week 7 (after intervention for the DT group), and week 10. Therefore, in this data collection schedule, the IT group will have one-baseline (week 1), two-post-intervention evaluation (week 4), and three and four- follow-ups with 3-week intervals (week 7 and week 10), while the DT group will have 2 baselines (week 1 \& week 4), 1 post-intervention evaluation (week 7), and 1 follow-up with a 3-week interval (week 10). Assessment consists of surveying at two times and a dried blood spot test at week 1 and 4.|Intervention Core Modules: Developed upon the results of the prior studies involving familial relations among APA HIV+ populations, the family-informed self-management intervention has been fully manualized, and has eight modules: (1) psycho-education, (2) cognitive-behavioral management skills training, (3) preparation for disclosure, (4) family relations and support management, (5) anxiety and depressive symptom management, (6) brief mindfulness training, (7) symptom reduction, and (8) the Life-Steps program. The intervention will be delivered via four face-to-face, one-on-one counseling sessions to the participants over 4 weeks. Each module will take on 30 minutes for delivery and each session will deliver two modules in sequence. The primary desired outcome is improved quality of life and diminished viral load.|t|f|f|f
34163395|NCT06471218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163396|NCT05039957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163397|NCT04661982|||COHORT||PROSPECTIVE|||||||
34163398|NCT06222580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163399|NCT02379169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163400|NCT04880096|||COHORT||PROSPECTIVE|||||||
34163401|NCT06087224|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stepped wedge cluster randomized trial||||
34163402|NCT00532688|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34163403|NCT02851706|||COHORT||PROSPECTIVE|||||||
34163404|NCT06725875|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental study|t|f|f|f
34163405|NCT06538116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163406|NCT00398099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163407|NCT01866358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34163408|NCT06322888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746088|NCT05553691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Test Cohort of patients already taking an SSRI for their depression, compared to the Control Cohort who are not already taking an SSRI. All patients will receive SPL026||||
33746089|NCT02870790|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746090|NCT00997165|||COHORT||PROSPECTIVE|||||||
33746091|NCT01107574|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33746092|NCT04763122|||CASE_CONTROL||RETROSPECTIVE|||||||
33746093|NCT06352853|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746094|NCT02487563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746095|NCT00959517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33746096|NCT04514315|||COHORT||PROSPECTIVE|||||||
33746097|NCT03266250|||OTHER||PROSPECTIVE|||||||
33746098|NCT00311272|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33746099|NCT04821596|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33746100|NCT01693432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746101|NCT03539562|||COHORT||PROSPECTIVE|||||||
33746102|NCT00372463|RANDOMIZED|FACTORIAL||||NONE||||||
33746103|NCT05982522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746104|NCT00000974||||TREATMENT||NONE||||||
33746105|NCT04482751|||COHORT||PROSPECTIVE|||||||
33746106|NCT01193803|||CASE_CONTROL||PROSPECTIVE|||||||
33746107|NCT00672048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746108|NCT01206244|||CASE_CONTROL||PROSPECTIVE|||||||
33746109|NCT06495801|RANDOMIZED|PARALLEL||TREATMENT||NONE|The baseline data collection is conducted before randomization. No masking will be used after the randomization.|Participants of the intervention group are given access and encouraged to use Frendie PRO mobile application||||
33746110|NCT00889213|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33746111|NCT05623150|||COHORT||CROSS_SECTIONAL|||||||
33746112|NCT00967850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746113|NCT01434602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33746114|NCT04353869|||COHORT||CROSS_SECTIONAL|||||||
33850632|NCT00112047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850633|NCT01175954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850634|NCT06401239|||COHORT||PROSPECTIVE|||||||
33850635|NCT01149109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850636|NCT00577356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850637|NCT00767468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850638|NCT04939961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Placebo and experimental capsules (A and B) were prepared by collaborator-investigator (MycoMedica). Both experimental and placebo capsules appear similar to each other in terms of colour, flavour, size, and shape to make sure that they cannot be distinguished. Information about capsules will be provided to participants and investigators at the end of the trial.|Randomized placebo controlled|t|f|t|f
33850639|NCT05681923|||COHORT||PROSPECTIVE|||||||
33954972|NCT03389776|||COHORT||PROSPECTIVE|||||||
33954973|NCT06566846|||CASE_CONTROL||RETROSPECTIVE|||||||
33954974|NCT04561973|||COHORT||PROSPECTIVE|||||||
33954975|NCT02519582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954976|NCT02784002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163409|NCT03856216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163410|NCT05184634|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34163411|NCT02152306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163412|NCT04291859|NA|SEQUENTIAL||TREATMENT||NONE||||||
34163413|NCT01737125|||CASE_ONLY|||||||||
34163414|NCT05948631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33746115|NCT03318575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33746116|NCT03140748|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33746117|NCT04481347|||COHORT||PROSPECTIVE|||||||
33746118|NCT03621384|||OTHER||CROSS_SECTIONAL|||||||
34163415|NCT05582993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163416|NCT00458120|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33746119|NCT01962493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34163417|NCT03545074|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pretest and immediate postest design with an active control condition.||||
34163418|NCT06069336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomization will occur within 24 hours of admission|t|t|t|t
34163419|NCT00001595|||COHORT||PROSPECTIVE|||||||
34163420|NCT02370420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163421|NCT02114606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163422|NCT00940758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163423|NCT00592488|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34163424|NCT02530008|||COHORT||PROSPECTIVE|||||||
34163425|NCT04541030|||COHORT||RETROSPECTIVE|||||||
34163426|NCT03316638|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||2 Cohorts||||
34163427|NCT06312202|||COHORT||RETROSPECTIVE|||||||
34163428|NCT05566028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746120|NCT05794464|NA|SINGLE_GROUP||OTHER||NONE|No masking will be used in the study.|The study subjects will be enrolled in one group.||||
33746121|NCT00305058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746122|NCT06634706|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33746123|NCT00586105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746124|NCT03432624|||CASE_CONTROL||PROSPECTIVE|||||||
33954977|NCT03176953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study. Only pharmacist will have access to randomization table.|Participants randomly assigned to one of two conditions.|t|t|t|t
33954978|NCT04176354|||COHORT||RETROSPECTIVE|||||||
33954979|NCT02286284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059020|NCT04622423|||COHORT||PROSPECTIVE|||||||
34059021|NCT02624388|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34059022|NCT01971762|||COHORT||PROSPECTIVE|||||||
34059023|NCT03194711|||CASE_ONLY||RETROSPECTIVE|||||||
34059024|NCT04380012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059025|NCT04789928|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot phase, non-comparative, non-randomized, multicentric study on 35 patients with uncomplicated LTIVC-related BSI and eligible for a conservative treatment||||
34059026|NCT04104217|||OTHER||PROSPECTIVE|||||||
34059027|NCT05493813|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients who meet the enrollment criteria and who provide written informed consent will be randomly assigned to either of the intubated Sev-GA or non-intubated TIVA-propofol groups according to either the discretion of anesthesiologist in charge or random allocation. If the patient was in critical situation, uncooperative, or with uncontrolled movement, the anesthesiologist would choose the intubated Sev-GA instead of the scheduled randomization. However, if patient is cooperative and not critical, the patient would be randomly assigned according to the randomization list created with the use of computer-generated, permuted-block sequences. Only the anesthesiologist and physicians involved in EVT are aware of the anesthesia assignment. On the contrary, patients, personnel who collect data, fill out questionnaire and scale measurement, and personnel who assess outcomes are unaware of the group assignments.|This study is a prospective, single-centered, double-blind, randomized control trial at Taipei Veterans General Hospital. Patients who are scheduled to undergo emergent EVT for acute ischemic stroke with large vessel occlusion will be randomly assigned to either of the two intra-procedural general anesthetic regimens that include a volatile anesthesia with sevoflurane (Sev-GA) or to a total intravenous anesthesia with propofol (TIVA-propofol).|t|f|f|t
34059028|NCT05621369|||COHORT||PROSPECTIVE|||||||
34163429|NCT03502473|RANDOMIZED|PARALLEL||TREATMENT||NONE||Flanks will be randomized in accordance with randomization list. One flank will receive a single treatment pass or no treatment. The other side will receive multiple passes (up to 5 passes) during the same treatment session.||||
34163430|NCT04950530|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will be randomised to start on Biktarvy tablet once daily OR no treatment for the first 28 day dosing phase of the study then will cross over to the alternative for the second dosing phase, following a 2 week washout period (equivalent to 5+ B/F/TAF elimination half-lives).||||
34163431|NCT06726369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163432|NCT00801216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163433|NCT06726759|||OTHER||OTHER|||||||
34163434|NCT06628219|NA|SINGLE_GROUP||OTHER||NONE||||||
34163435|NCT06529913|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163436|NCT06141707|||OTHER||PROSPECTIVE|||||||
34163437|NCT01078610|||CASE_ONLY||PROSPECTIVE|||||||
34163438|NCT05896527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Sponsor, participants, Investigators, and study staff responsible for any study procedures will be blinded.||t|f|t|f
34163439|NCT05583916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163440|NCT04302220|||COHORT||PROSPECTIVE|||||||
34163441|NCT05818683|NA|SEQUENTIAL||TREATMENT||NONE||||||
34163442|NCT06680817|||COHORT||PROSPECTIVE|||||||
34163443|NCT06726733|||CASE_CONTROL||RETROSPECTIVE|||||||
34163444|NCT03045523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163445|NCT05340738|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Type 2 hybrid implementation-effectiveness, randomized stepped-wedge study comparing LyssnCBT-supported psychotherapy to services as usual (SAU)||||
34163446|NCT06727448|||COHORT||PROSPECTIVE|||||||
34163447|NCT02858310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163448|NCT04914533|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm trial||||
33746125|NCT06528119|||COHORT||OTHER|||||||
33746126|NCT03498248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||neutropenia after cytotoxic chemotherapy||||
33746127|NCT06143215|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking is possible to be performed in the planned RCT due to the nature of the intervention (time dependent).|Three arms parallel randomized clinical trial||||
33746128|NCT04371900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746129|NCT06038721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746130|NCT00144339||PARALLEL||TREATMENT||||||||
33954980|NCT05563142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33954981|NCT05894668|||CASE_ONLY||PROSPECTIVE|||||||
33954982|NCT05393830|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Independent Groups Comparison||||
33954983|NCT00000254|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33954984|NCT00792142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954985|NCT02676518|||CASE_ONLY||CROSS_SECTIONAL|||||||
33954986|NCT05418517|||COHORT||RETROSPECTIVE|||||||
33954987|NCT00240786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33954988|NCT06397001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33954989|NCT06652204|||COHORT||PROSPECTIVE|||||||
34059029|NCT01838434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059030|NCT03293082|||COHORT||CROSS_SECTIONAL|||||||
34059031|NCT00454818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059032|NCT03738800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059033|NCT03356899|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34163449|NCT06127589|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34163450|NCT02098798|||COHORT||PROSPECTIVE|||||||
33746131|NCT03829904|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Placebo is manufactured to have the same appearance with VGH-BPH1, after that VGH-BPH1 and placebo will be coded as package A and B by the manufacturer and the codes will only be revealed after the study ends. Therefore, patients and investigators will not know which package is VGH-BPH1 or placebo.|40 participants will be recruited from Division of Urology in a Medical Center. They will be randomizedly allocated into treatment and control groups, each including 20 participants. After eight weeks of taking, there is a two weeks of drug wash-out period. And then two groups will be switched for another eight weeks. The study duration is totally 18 weeks.|t|f|t|f
33746132|NCT03020420|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746133|NCT04349787|||COHORT||RETROSPECTIVE|||||||
33746134|NCT04644354|||OTHER||RETROSPECTIVE|||||||
33746135|NCT05300308|||COHORT||PROSPECTIVE|||||||
33746136|NCT01517698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33954990|NCT06630858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Sealed opaque envelopes containing study participation numbers will be used to assign each patient. A researcher not involved in patient follow-up will use the web-based;Research Randomizer; (Urbaniak and Plous 2013) tool to give each participation number to a random group with a 1:1 ratio.~A nurse not an active investigator in the study will have each participant choose an envelope containing the study participation number. They will inform the anesthetist who will administer the block/blocks about which group the patient is in immediately before administration. Researchers, patients, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program;Research Randomizer (Urbaniak and Plous 2013).|f|t|t|t
33746137|NCT04216108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746138|NCT02706158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33954991|NCT04051658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a four-arm parallel assignment involves four groups of participants which consists of anodal-, cathodal-, dual- and sham tDCS.|t|f|t|t
33954992|NCT01143610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746139|NCT00098124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746140|NCT05741736|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746141|NCT01431677|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34059034|NCT03870776|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"There are 3 groups :~* Placebo group will receive placebo during 42 days with antidepressant treatment in add-on.~* Dose 1 during 42 days with antidepressant treatment in add-on. Upon IDMC recommendation after the first futility analysis (IDMC#5 13-Jun-2022), Dose 1 was stopped from the 17-Jun-2022.~* Dose 2 during 42 days with antidepressant treatment in add-on."|t|t|t|t
33746142|NCT02575092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746143|NCT02462876|||COHORT||RETROSPECTIVE|||||||
33746144|NCT02446561|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34059035|NCT04659629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059036|NCT01712893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059037|NCT01734252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059038|NCT01193075|||COHORT||PROSPECTIVE|||||||
34059039|NCT04134065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34059040|NCT04403659|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34059041|NCT00492882|||DEFINED_POPULATION||PROSPECTIVE|||||||
34059042|NCT02941796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059043|NCT06547242|RANDOMIZED|CROSSOVER||OTHER||NONE||Single centre, open-label, randomised (order of treatments), balanced, 2-period, 2-sequence, single dose cross-over trial with administrations under fasting conditions separated by a washout period of at least 45 treatment-free days||||
34059044|NCT01582659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059045|NCT05056792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomized|Randomized controlled trial|t|t|f|f
34059046|NCT05583500|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059047|NCT06618521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059048|NCT00503451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059049|NCT01394068|||COHORT||PROSPECTIVE|||||||
34059050|NCT02062996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746145|NCT05893654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746146|NCT06635993|||COHORT||PROSPECTIVE|||||||
33746147|NCT05934734|||OTHER||CROSS_SECTIONAL|||||||
33746148|NCT03516318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746149|NCT06436053|||COHORT||PROSPECTIVE|||||||
33746150|NCT05497284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746151|NCT06635499|||COHORT||RETROSPECTIVE|||||||
33746152|NCT06669065|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33746153|NCT01972516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746154|NCT04458584|||OTHER||PROSPECTIVE|||||||
33746155|NCT06316986|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746156|NCT01023100|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33746157|NCT01361412|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33954993|NCT03490175|||COHORT||PROSPECTIVE|||||||
33954994|NCT05878600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33954995|NCT01853969|||COHORT||PROSPECTIVE|||||||
33954996|NCT05997316|NA|SINGLE_GROUP||TREATMENT||NONE|Assessors will be blinded to the participant's intervention fidelity and engagement.|||||
33954997|NCT02503800|||COHORT||PROSPECTIVE|||||||
33954998|NCT06563440|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized trial||||
33954999|NCT04865887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955000|NCT04854421|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33955001|NCT03016416|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34059051|NCT06451289|||CASE_CONTROL||RETROSPECTIVE|||||||
34059052|NCT01523210|||CASE_CROSSOVER||PROSPECTIVE|||||||
34059053|NCT02651519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163451|NCT05287646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The statistician will be masked to the intervention order.|A randomized, block, cross-over design will be used to evaluate the residual limb-socket fit. A group of 11 (Group 1) and a group of 10 (Group 2) participants will be formed. Participants in Group 1 will first be tested with the elevated vacuum system active and then repeat all procedures with the elevated vacuum system inactive. Participants in Group 2 will first be tested with the elevated vacuum system inactive and then repeat the tasks with the elevated vacuum system active.||||
34163452|NCT01484535|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34163453|NCT06518161|NA|SINGLE_GROUP||OTHER||NONE||||||
34163454|NCT00799435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163455|NCT02305212|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34163456|NCT05100914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The block randomization allocation sequence was computer-generated random numbers with a 1:1 ratio by Microsoft Excel. Participants were randomly allocated using sequentially numbered sealed envelopes. The envelopes were opened just before the operation, the research nurse who was involved in the data collection was blinded to the group allocation, and participants were not informed of their group allocation status. Given the nature of the interventions, it was not allowed to blind the participates and the research nurse.|The Institute for Patient and Family-Centered Care promotes four core concepts: dignity and respect, information sharing, participation, and collaboration. Health care practitioners listen to and respect patients and families' perspectives and choices as well as incorporate the knowledge, values, beliefs, and cultural backgrounds of patients and families into the care plan. Affirmative and useful methods are employed for communicating data that are complete, accurate, and unbiased with patients and families, so that they receive data expediently, participate effectively, and make decisions in care. Health care practitioners encourage and support the families of patients for participation in caring and making decisions that align with families' preferences. Health care practitioners collaborate with patients and families in program development, implementation, and evaluation.|f|f|t|t
34163457|NCT06726980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163458|NCT04071769|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163459|NCT05999266|||CASE_ONLY||CROSS_SECTIONAL|||||||
34163460|NCT02468726|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|t|f|f
34163461|NCT05246800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial (RCT) was performed, comparing the experimental group that made use of a structured 8-week mHealth mindfulness program and a control group after 8 weeks, with follow-up after six months.|t|f|f|f
34163462|NCT06140173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163463|NCT06472115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163464|NCT05677282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, active-controlled, treatment trial of Travelers Diarrhea (TD) in an outpatient setting enrolling deployed United States (US) service members assigned to Joint Task Force (JTF)-Bravo, Soto Cano Air Base, Honduras and Camp Lemonnier, Djibouti (CLDJ) and United Kingdom (UK) military personnel to British Army Training Unit, Kenya (BATUK) who present for medical care with acute TD.|t|t|t|t
34163465|NCT04366661|NA|SINGLE_GROUP||SCREENING||NONE||||||
34163466|NCT02995317|||COHORT||PROSPECTIVE|||||||
34163467|NCT02598297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163468|NCT05455476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcomes assessors will not know what condition that the participant was allocated to, nor will the statistician who is one of the co-investigators.|Participants are randomized to one of two interventions.|f|f|t|t
34163469|NCT05461391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163470|NCT01136408|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163471|NCT06262100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163472|NCT02772744|||COHORT||PROSPECTIVE|||||||
34163473|NCT03084692|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single group before and after intervention study design will be used for this pilot feasibility trial.||||
34163474|NCT06236919|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34163475|NCT06725966|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental, multicenter, open-label, randomized study (using balanced block randomization) with two parallel arms||||
34163476|NCT04699383|||COHORT||PROSPECTIVE|||||||
33893416|NCT03384992|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE||FoRtitude includes three CSMs: (1) diaphragmatic breathing and relaxation, (2) cognitive restructuring, and (3) scheduled worry practice. The fourth intervention component is (4) telephone coaching. We assigned two levels (yes, no) to each component. Evaluating individual and combined intervention components, each with two levels, results in a classic full factorial design with 16 (2 x 2 x 2 x 2) experimental conditions|t|t|t|f
33746158|NCT06635304|||CASE_CONTROL||RETROSPECTIVE|||||||
33746159|NCT01739829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746160|NCT05734846|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746161|NCT04773015|||COHORT||OTHER|||||||
33746162|NCT04331366|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33746163|NCT00114374|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33746164|NCT00290940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746165|NCT03671603|||OTHER||PROSPECTIVE|||||||
33746166|NCT05709743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive each level of visual information (target or distractor)||||
33746167|NCT01260233|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33746168|NCT05577429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants will be required to complete 3 exercise interventions.|t|f|f|f
33746169|NCT02268838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746170|NCT06442553|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33746171|NCT03589456|||CASE_ONLY||OTHER|||||||
33955002|NCT06346080|NA|SINGLE_GROUP||OTHER||NONE||A survey will be conducted in a single group of participants from different geographical regions and backgrounds||||
33955003|NCT06170632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955004|NCT01338701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955005|NCT00381186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955006|NCT00243672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33955007|NCT03046966|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33955008|NCT05916963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will not be blinded except for the outcome assessment: radiologists in charge of interpreting CT-Scans will be blinded.||f|f|f|t
33955009|NCT05881863|||COHORT||PROSPECTIVE|||||||
33955010|NCT00506558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955011|NCT05550259|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A stepped wedge cluster randomized trial||||
33955012|NCT06652802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is designed as single-blind, meaning the outcome assessors and the data analysts will be blinded to the group allocations to reduce bias in the evaluation of the outcomes|"The study design is a randomized controlled trial. In this type of study, participants are randomly assigned to two different groups, i.e Group A and Group B.~Group A participants receive only Nurse-Conducted Brief Intervention (NCBI). Whereas's Group B receives Nurse-Conducted Brief Intervention (NCBI). supplemented with mobile based application.~The study is designed as single-blind, meaning the outcome assessors and the data analysts will be blinded to the group allocations to reduce bias in the evaluation of the outcomes"|f|f|f|t
33955013|NCT05327803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind||t|t|t|f
33955014|NCT04703647|||OTHER||PROSPECTIVE|||||||
33955015|NCT05060913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059054|NCT00461760|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34059055|NCT02669082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059056|NCT04660708|NA|SINGLE_GROUP||TREATMENT||NONE||single-cohort quasi-experimental longitudinal interventions study||||
34059057|NCT03447652|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor is blinded to which group the subjects were in.|4 independent groups|f|f|f|t
34059058|NCT05659511|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34059059|NCT06649279|||COHORT||PROSPECTIVE|||||||
34059060|NCT01238718|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34059061|NCT02781181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955016|NCT01466907|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955017|NCT05864287|NA|SINGLE_GROUP||TREATMENT||NONE|"This is an open trial of Bodies In Motion (BIM) Intervention. The study will primarily examine results pre-post treatment within these athletes. However, athletes who do not sign up to participate in the BIM may be used as no treatment controls, utilizing data collected during their bi-annual mental health screens and propensity matching. However, this does not typically qualify as an Arm."|No treatment control||||
34059062|NCT03283059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059063|NCT02839564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059064|NCT00622336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059065|NCT05695105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163477|NCT06444581|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Participants who meet the inclusion criteria and undergo the full baseline assessment will be assigned to the intervention group condition or to the wait-list control (WLC) group. Children assigned to the intervention condition will receive the twelve-week intervention. Participants in the WLC group will not receive any psychological intervention during the twelve-week program. Children and parents in all groups will complete the same set of measures at approximately the same time (pre-test and post-twelve weeks). Children in the WLC group will receive the intervention after the follow-up visit is completed.|f|f|f|t
34163478|NCT01366482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163479|NCT05733442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163480|NCT04198792|||COHORT||PROSPECTIVE|||||||
34163481|NCT05030207|NA|SINGLE_GROUP||OTHER||NONE||Single site, 1 arm unblinded, pilot feasibility clinical trial to investigate the feasibility of acquiring Real-Time Gated 4DCT scans for lung cancer patients undergoing radiation therapy and to determine the incidence of imaging artifacts in comparison to conventional 4DCT||||
34163482|NCT03739710|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will be open-label.|||||
33746172|NCT04240821|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label extension study||||
33850640|NCT04614454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized to either the intervention or the control group, fitted and trained to use the home TENS device to self-administer treatment for at least one hour each day. The subjects will not know to which arm they are randomized. Neither will the study coordinator or the investigator. Only a 3rd party collaborator will know the assignment scheme and this will be revealed in blocks every time 4 subjects complete the trial.|Patients will be randomized 1:1 to receive treatment daily for 4 consecutive weeks versus sham, followed by an open-label phase for additional 4 consecutive weeks.|t|t|t|t
33746173|NCT00916864|||CASE_ONLY||PROSPECTIVE|||||||
33746174|NCT04210687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163483|NCT04915729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850641|NCT01776801|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850642|NCT01853774|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33850643|NCT01413854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850644|NCT01481298|||COHORT||RETROSPECTIVE|||||||
33850645|NCT00735020|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33850646|NCT03733041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects and the study team (staff responsible for administering treatment or rating outcomes and study physicians) will not know the coil assignment since coils are labeled 'X' or 'Y' and are identical.|Participants will be randomized to parallel groups to receive either the rTMS or sham treatment with allocation ratio of 1:1. The stratified randomization scheme will be generated by a statistician using a random block design with random block sizes, and assignments (X or Y) will be placed in sealed envelopes for sequential opening.|t|t|t|t
33850647|NCT03805620|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33850648|NCT05747300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850649|NCT04621773|||COHORT||PROSPECTIVE|||||||
33850650|NCT00632437|||CASE_ONLY||PROSPECTIVE|||||||
33850651|NCT04771754|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will be randomised to start on dolutegravir 50 mg once daily OR no treatment for the first 28 day dosing phase of the study then will cross over to the alternative for the second dosing phase, following a 2 week washout period (equivalent to 5+ dolutegravir elimination half-lives).||||
33850652|NCT01723254|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33850653|NCT02691533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850654|NCT04007341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850655|NCT05396482|||COHORT||CROSS_SECTIONAL|||||||
33850656|NCT02764216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850657|NCT02951364|||COHORT||PROSPECTIVE|||||||
33850658|NCT03074890|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33850659|NCT04793841|||COHORT||PROSPECTIVE|||||||
33850660|NCT04095481|||CASE_ONLY||PROSPECTIVE|||||||
33850661|NCT06610409|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850662|NCT01274845||CROSSOVER||TREATMENT||NONE||||||
33850663|NCT04630392|NA|SINGLE_GROUP||TREATMENT||NONE||Self-controlled study||||
33850664|NCT05522621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850665|NCT01736865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955018|NCT04259905|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33955019|NCT00811031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955020|NCT04069507|||COHORT||PROSPECTIVE|||||||
33955021|NCT05440175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant were blinded about the treatment group in which they are enrolled.|This is an randomized control trail in which the stroke patients are divided into three different treatment group.|t|f|f|f
33955022|NCT06415279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955023|NCT05329155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33955024|NCT01114386|||COHORT||PROSPECTIVE|||||||
33955025|NCT05525429|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33955026|NCT01266642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955027|NCT06560255|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33955028|NCT05196230|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33955029|NCT05234619|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955030|NCT05929040|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Waitlist control. An experimental group and a delayed group over 8 weeks Waitlist controlled RCT (N= 16 immediate group, N=15)||||
33955031|NCT00247845|||CASE_CONTROL||PROSPECTIVE|||||||
33955032|NCT00432367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955033|NCT05417009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham settings for neuromodulation device.|RCT|t|f|f|t
33955034|NCT01101269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955035|NCT05378269|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33955036|NCT02395536|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The site of the Reveal LINQ insertion was randomized. Therefore it was not possible to blind the subject or the investigator.|||||
33955037|NCT04860752|||COHORT||PROSPECTIVE|||||||
34163484|NCT02957734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746175|NCT05408494|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Outcomes assessors will be blind to condition.|Utilizing a 2 x 2 factorial design, participants will be randomized to a mobile weight loss program that includes digital self-monitoring, simplified and self-selected dietary targets program alone or to a fully-gamified version of the program, comprised of a mobile behavior change program featuring team-based competition and digital reinforcers for attainment of streaks and milestones. Participants are also randomized to receive sham or active neurotraining, which will be integrated into the program they receive.|f|f|f|t
33746176|NCT04797858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33850666|NCT01864954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850667|NCT05615493|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The closed envelop method will be used for the randomization of the patients who will be blinded to group allocation. The assessments will be done by the first physiatrist (A), who will not involved in patients' sessions. The randomization will be performed by the second physiatrist (B ) who will not be involved in patients' assessment and ESWT sessions . ESWT Sessions for both groups will be will be carried out by the third physiatrist (C ) who will not take part in the assessments or patients' randomization . Both (C) and (A) were blinded to group allocation.|adult ischemic or hemorrhagic hemiplegic stroke patients with unilateral spastic equinus foot for at least 6 months before enrollment to reduce the confounding effect of natural recovery|t|t|t|f
33746177|NCT01949480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33746178|NCT03116139|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746179|NCT05218005|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Two sequential groups of patients will be recruited. The first cohort will consist of a control group of patients presenting with acute coronary syndrome who will be treated according to usual standard-of-care. The second cohort will consist of patients presenting with acute coronary syndrome in whom research-based genetic testing for FH will be performed during hospitalization and the results returned to the treating physicians.||||
33746180|NCT05035719|||COHORT||RETROSPECTIVE|||||||
33746181|NCT05518929|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Randomized, Open-label, Propofol-controlled||||
33746182|NCT01173445|||COHORT||PROSPECTIVE|||||||
33746183|NCT03564379|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33746184|NCT02824913|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33746185|NCT02872259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746186|NCT05625906|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33746187|NCT05881668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746188|NCT03421691|NA|SINGLE_GROUP||OTHER||NONE||||||
33746189|NCT00583726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746190|NCT06636539|NA|SINGLE_GROUP||SCREENING||NONE||||||
33746191|NCT03146169|NA|SINGLE_GROUP||PREVENTION||NONE||A four-session training workshop is provided to the trainees in order to enhance their competence and performance for conducing and/or assisting the implementation of community -based interventions and activities.||||
33746192|NCT06634940|||CASE_ONLY||CROSS_SECTIONAL|||||||
33746193|NCT02053350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746194|NCT04972513|||COHORT||PROSPECTIVE|||||||
33746195|NCT02431039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746196|NCT06668987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850668|NCT00472160|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850669|NCT00558259|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33850670|NCT05442996|NA|SEQUENTIAL||TREATMENT||NONE||||||
33850671|NCT02013960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850672|NCT06545838|||COHORT||PROSPECTIVE|||||||
33850673|NCT00371332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33850674|NCT01015560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850675|NCT03915704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850676|NCT03450187|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|"Up to 5 cohorts of 8 subjects each will be enrolled. Subjects in each cohort will be randomized 6:2 to receive multiple oral doses of TP 271 at 1 of 5 ascending doses of TP-271 or placebo once or twice daily for 7 days, as shown in the table below. Every effort will be made to dose all subjects in a cohort on the same day.~Proposed Oral Doses of Study Drug by Dose Cohort Cohort Dose Regimen Proposed Oral Dose A Once daily 50 mg TP-271 q24 (n = 6) or matching placebo (n = 2) B Once daily 100 mg TP-271 q24 (n = 6) or matching placebo (n = 2) C Once daily 200 mg TP-271 q24 (n = 6) or matching placebo (n = 2) D Once daily 300 mg TP-271 q24 (n = 6) or matching placebo (n = 2) E Once daily 400 mg TP-271 q24 (n = 6) or matching placebo (n = 2) Abbreviations: q24 = every 24 hours."|t|t|t|t
33850677|NCT04463368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850678|NCT02713282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850679|NCT01532895|||COHORT||PROSPECTIVE|||||||
33850680|NCT01625585|||COHORT|||||||||
33850681|NCT01078220|||COHORT||PROSPECTIVE|||||||
33850682|NCT00232674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850683|NCT02638077|||COHORT||PROSPECTIVE|||||||
33850684|NCT00002291||||TREATMENT||DOUBLE||||||
33850685|NCT01993043|||COHORT||PROSPECTIVE|||||||
33850686|NCT03283072|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants can't see the device and therefore the settings. The assessment of sensory function is done by a separate investigator who did not participate in the set up of the hypoxicator|Within subjects design with randomization of presentation of four different hypoxia/normoxia intervals.|t|f|f|t
33850687|NCT05325801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850688|NCT00688454|||||PROSPECTIVE|||||||
33850689|NCT03289429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850690|NCT03108456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850691|NCT04663724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850692|NCT06140654|||CASE_CONTROL||PROSPECTIVE|||||||
33850693|NCT03422523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850694|NCT03191773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850695|NCT06441929|||COHORT||CROSS_SECTIONAL|||||||
33850696|NCT05264389|||COHORT||PROSPECTIVE|||||||
33850697|NCT04091048|||COHORT||PROSPECTIVE|||||||
33850698|NCT03302351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33850699|NCT02194673|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33955038|NCT02729350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163485|NCT00278733|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34163486|NCT06018948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163487|NCT04438317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Since the study is based on two different techniques, the masking of participants, care providers and local investigator is impossible.|"* Prospective clinical trial, randomized, controlled, open-label~* Two parallel groups, comparing two strategy involving different medical devices"|f|f|f|t
34163488|NCT02828475|||COHORT||PROSPECTIVE|||||||
34163489|NCT03357536|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33955039|NCT04182386|||COHORT||RETROSPECTIVE|||||||
33955040|NCT03858998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33955041|NCT06126770|RANDOMIZED|PARALLEL||PREVENTION||NONE||Mixed method 2-arm cluster randomized controlled trial||||
33955042|NCT01030055|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955043|NCT03030638|||COHORT||CROSS_SECTIONAL|||||||
33955044|NCT01430832|||COHORT||PROSPECTIVE|||||||
33955045|NCT06264141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A blinded participant number will be assigned to each randomized participant. Site staff/ physician will then dispense a kit labelled with the authorization number generated during randomization to the individual participant. No study investigators, associates performing assessments or participants will be aware of the study medication in the assigned treatments.|A two-week therapy of NONS vs Placebo (saline nasal spray) initiated immediately after the onset of a new RARS episode to assess the acceleration to clinical success (cured/much-improved symptoms), lack of use of INCS (Day 5, or thereafter) and rescue oral antibiotics (ATBs) (Day 8, or thereafter) after initiation of nitric oxide-releasing solution (NORS) platform therapy.|t|t|t|t
33955046|NCT01096862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955047|NCT05518565|||COHORT||CROSS_SECTIONAL|||||||
33955048|NCT02801201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955049|NCT04598815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955050|NCT01708252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163490|NCT01107314|||OTHER||PROSPECTIVE|||||||
34163491|NCT06474884|||COHORT||PROSPECTIVE|||||||
34163492|NCT02246907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34163493|NCT01441804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163494|NCT01574235|||COHORT||PROSPECTIVE|||||||
34163495|NCT06513169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163496|NCT03877211|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34163497|NCT00217217|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34163498|NCT04533529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163499|NCT03676868|||CASE_ONLY||PROSPECTIVE|||||||
34163500|NCT06553495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34163501|NCT01922271|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34163502|NCT05176236|NA|SINGLE_GROUP||OTHER||NONE||||||
34163503|NCT01041313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163504|NCT04400565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34163505|NCT04270708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34163506|NCT06364228|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33850700|NCT03933904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850701|NCT01789736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850702|NCT05331677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850703|NCT04326517|||COHORT||OTHER|||||||
33850704|NCT02033161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850705|NCT01297881|||COHORT||PROSPECTIVE|||||||
33850706|NCT01681173|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33850707|NCT04370548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Eligible patients will be randomly assigned to one of the following treatment groups (2:1): DARE- BV1 clindamycin phosphate vaginal gel, 2% (1 dose is 5 g gel = 100 mg clindamycin) QD × 1 day, or placebo vaginal gel (Universal HEC Placebo Gel), 5g, QD × 1 day. Study drug will be applied intravaginally within 1 day of randomization.|t|t|t|t
33850708|NCT00474643|||CASE_CONTROL||OTHER|||||||
33850709|NCT02245737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850710|NCT00324675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850711|NCT01081054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850712|NCT01080833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850713|NCT03837418|||COHORT||PROSPECTIVE|||||||
33850714|NCT05961904|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33955051|NCT06700460|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"All LASIK procedures in this study are to be Wavefront Optimized treatments. To ensure standardization of treatments within the LASIK cohort, Wavefront-Guided and Topography-Guided treatments are prohibited. The EX500 laser, an excimer laser, employes a 1050 Hz multidimensional active tracker, online optical pachymetry, an onboard nitrogen generator and a 500 Hz laser pulse frequency that enables the treatment of each D of myopia in 1.4 seconds. The EX500 laser will perform the wavefront refraction according to the user manual and MOP instructions.~Refer to current approved EVO+ ICL Directions for Use (DFU) for surgical instructions.6 Study surgeons will use 2% HPMC OVD for EVO+ ICL surgery as recommended in the DFU."||||
33955052|NCT02879630|||CASE_CONTROL||PROSPECTIVE|||||||
33955053|NCT01350609|RANDOMIZED|CROSSOVER||||NONE||||||
33955054|NCT05193578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The un-blinding will occur after the data analysis have ended and two blinded conclusions have been uploaded to clinicaltrials.gov based on the results of the primary and secondary outcomes defined in the SAP. The two blinded conclusions are added to the SAP.||t|t|t|t
33955055|NCT06156046|||COHORT||OTHER|||||||
33955056|NCT04485624|||CASE_ONLY||CROSS_SECTIONAL|||||||
33955057|NCT04317547|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We propose a hybrid, RCT to test the effectiveness and implementation of an evidence-based, parent-focused intervention among teen drivers with a moving violation. We aim to recruit 90 dyads (45 per group, totaling 180 study participants), comprised of one teen driver ages 16 or 17 who has committed a moving violation (e.g., speeding, failure to obey traffic signal) and the parent/legal guardian ('parent') who is most involved with the teen's driving. Recruitment will occur at the Franklin County Juvenile Traffic Court in Ohio following the parent-teen dyad's mandatory court appearance. After completing informed consent/assent and the baseline assessment, enrolled parent-teen dyads will be randomly assigned into either the Control or Intervention Group using a stratified block randomization. All enrolled dyads will be followed for a 6-month period.|t|f|f|f
34163507|NCT01453010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163508|NCT02326597|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34163509|NCT02306798|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163510|NCT00491127|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163511|NCT02880098|||COHORT||PROSPECTIVE|||||||
33850715|NCT01226095|||||PROSPECTIVE|||||||
33850716|NCT00140985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850717|NCT00204204|||DEFINED_POPULATION||OTHER|||||||
33850718|NCT02822313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850719|NCT00740987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850720|NCT02923687|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850721|NCT01425424|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33850722|NCT01788787|||COHORT||PROSPECTIVE|||||||
34163512|NCT06725784|NA|SINGLE_GROUP||OTHER||NONE||||||
34163513|NCT06726096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163514|NCT03943641|||COHORT||RETROSPECTIVE|||||||
33850723|NCT01735851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850724|NCT05375851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As we are going to use a digital tool as an adjunct to the treatment and as the clinician also needs to guide the patient during this intervention and discuss with him about the content of the videos and the results of the scales, there is no possibility of blinding these parts, however, we opted for blind the evaluator who will carry out the baseline, mid-term and end-of-study evaluations. The study coordinator will talk to each patient to advise them not to reveal which group they participated during the interview with the blinded evaluator.||f|f|f|t
33850725|NCT05270174|||COHORT||PROSPECTIVE|||||||
33850726|NCT03110185|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33850727|NCT05774743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33850728|NCT03862001|RANDOMIZED|PARALLEL||SCREENING||NONE||The intervention will involve a randomized control trial (RCT) with an intervention group that receives LungCARE and a comparison group that does not receive LungCARE.||||
33850729|NCT00211185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850730|NCT04307420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850731|NCT00464009|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850732|NCT04020354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33850733|NCT06228118|||OTHER||PROSPECTIVE|||||||
33850734|NCT03034538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850735|NCT03699085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals on the study team designated to conduct follow up interviews will be blinded to which arm participants belong to.||f|f|f|t
33850736|NCT02867878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850737|NCT01372098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163515|NCT01810003|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33850738|NCT02047864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850739|NCT01842490|||CASE_CONTROL||PROSPECTIVE|||||||
33850740|NCT04702542|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Comparison of 2 mutually comparable patient groups.||||
33850741|NCT02366468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850742|NCT01764685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850743|NCT01258413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850744|NCT03861325|||COHORT||PROSPECTIVE|||||||
33850745|NCT00987454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850746|NCT05425628|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, unblinded, single arm first in human/feasibility clinical study.||||
33850747|NCT00705861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850748|NCT02926404|||COHORT||OTHER|||||||
33850749|NCT00316160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33850750|NCT01632982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850751|NCT04967560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization of DBS are blinded to evaluators, participants, and programming doctors. The programming doctors used the specific software to allocated the participants, that software was preset random coding program to randomized allocate the subjects. The DBS interface of all patients is displayed as a true stimulus, but the true impulse was running in the background controlled by the software, so that even the programming doctors could not know the grouping.|All eligible patients who consent to participation and met all inclusion and exclusion criteria will be randomized to active and sham-stimulation group at post-operative.|t|f|f|t
33850752|NCT05130047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|30 participants with diarrhea and laboratory confirmed BAM will be randomized 1:1 to either aldafermin (NGM282), 1 mg, or placebo given daily by subcutaneous injection. Participants and investigators are blinded to the treatment.||t|f|t|f
33850753|NCT04418570|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34059066|NCT00046917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059067|NCT05807997|||CASE_ONLY||RETROSPECTIVE|||||||
34059068|NCT03788668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the pulmonologist or the phoniatracian or the surgeon who will befrom post operative sleep study, post operative nasopharyngoscopy and post operative sleep endoscopy will know the type of operation performed to the patients.||f|t|t|f
34059069|NCT00199329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059070|NCT03466125|||COHORT||RETROSPECTIVE|||||||
34059071|NCT01481584|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
34059072|NCT01718834|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34059073|NCT01801358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163516|NCT01428908|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34163517|NCT01438658|||COHORT||PROSPECTIVE|||||||
34163518|NCT03742973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163519|NCT00554450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163520|NCT05314465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163521|NCT06725602|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"It is a cross-sectional and self-controlled trial, aimed at collecting primary data, with randomization of the application order regarding device, laterality, segment, and blinding of the statistical analyst regarding the applied tourniquet model.~All participants will take part in all three arms of the study (3 device models) in a randomized manner by drawing lots, so that the devices will be compared within the same participant (self-controlled). The subjects will participate on 3 non-consecutive days, during which they will draw lots to determine which device will be used, thereby distributing their participation across the three study arms in a randomized manner."|f|f|f|t
34163522|NCT01870115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Melatonin (5mg), strontium (citrate; 450mg) vitamin D3 (2000IU)and vitamin K2 (MK7; 60mcg)|t|t|t|t
34163523|NCT02563236|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163524|NCT00380731|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163525|NCT06514547|NA|SINGLE_GROUP||SCREENING||NONE||1) Some participants will receive this vaccine as part of routine clinical care, and we will coordinate our study visits based on the receipt of that vaccine. 2) Some participants will receive this vaccine outside of the Centers for Disease Control and Prevention recommended schedule, but as in accordance with FDA approved use and 3) Some participant who are receiving this vaccination outside of current FDA approval for a single dose in those above 18 by receiving a second dose.||||
34163526|NCT00583687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163527|NCT03275324|||COHORT||PROSPECTIVE|||||||
33850754|NCT02502123|||COHORT||PROSPECTIVE|||||||
33850755|NCT05865015|||COHORT||CROSS_SECTIONAL|||||||
33850756|NCT05712122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059074|NCT01305005|||COHORT||PROSPECTIVE|||||||
34059075|NCT03552224|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34059076|NCT02611128|||OTHER||CROSS_SECTIONAL|||||||
34059077|NCT02068170|||COHORT||PROSPECTIVE|||||||
34163528|NCT03271502|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34059078|NCT02638259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850757|NCT01047293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850758|NCT03768583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850759|NCT05235230|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, partial replicate crossover, three-phase, three-sequence, two treatments bioequivalence study||||
33850760|NCT01959334|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33850761|NCT01157273|||COHORT||CROSS_SECTIONAL|||||||
33850762|NCT02830971|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33850763|NCT05060978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850764|NCT02977637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850765|NCT00588653|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||f|t|t|t
33850766|NCT02369146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850767|NCT04867928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850768|NCT04452760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33850769|NCT01442896|||COHORT||PROSPECTIVE|||||||
33850770|NCT05246280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850771|NCT04027192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Open-label crossover in bridging part; double-blind, parallel group in multiple dose escalation part|"The study will be performed in 2 study parts. Each participant will take part in one study part only.~* Bridging part: This will be a single-center, randomized, open-label cross-over part with 3 study interventions, 3 intervention periods and 2 intervention sequences.~* Multiple dose escalation part: This will be a single-center, randomized, placebo-controlled, double-blind, parallel group multiple dose escalation part."|t|t|t|t
33850772|NCT00801931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850773|NCT05334251|||COHORT||PROSPECTIVE|||||||
33850774|NCT00616057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33850775|NCT02455154|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850776|NCT02901782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850777|NCT06602089|||COHORT||PROSPECTIVE|||||||
33850778|NCT05764941|||COHORT||RETROSPECTIVE|||||||
33850779|NCT02950064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850780|NCT04866446|||COHORT||PROSPECTIVE|||||||
34059079|NCT01157650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059080|NCT01461252|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34059081|NCT02115074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059082|NCT06295887|RANDOMIZED|PARALLEL||OTHER||NONE||control group vs. test group, 1:1||||
34059083|NCT05267925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059084|NCT05137340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized, clinical, parallel-group study|f|f|f|t
34059085|NCT02203851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059086|NCT00874328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059087|NCT05939115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850781|NCT05769283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33850782|NCT05610332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893417|NCT00204087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893418|NCT05863247|||OTHER||RETROSPECTIVE|||||||
34059088|NCT00001047||||TREATMENT||||||||
34059089|NCT06143254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All tests and recordings will be performed by two SLPs of the research group with experience in the diagnosis and treatment of speech and language disorders in children with CP±L. The annotation, analysis and scoring will be performed by the same SLPs. Both raters will analyze 100% of the video-recordings to calculate inter-rater reliability. To calculate intra-rater reliability, both raters will re-assess 20% of the recordings. The raters will not provide intervention to any of the included children and caregivers. They will be blinded for group allocation of the child and caregivers.|The trial is a two-centre, randomized, parallel-group, longitudinal, controlled trial. Treatment allocation is in a 1:1:1:ratio. Children are randomized to either an infant sign training group (IST group), a verbal training group (VT group) or no intervention control group (C group). The aim is to demonstrate superiority of the active intervention (IST group) compared with control (VT group and C group).|f|f|t|t
34059090|NCT04100915|||CASE_ONLY||PROSPECTIVE|||||||
34059091|NCT01902758|NON_RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34059092|NCT05999838|||COHORT||CROSS_SECTIONAL|||||||
34059093|NCT00733083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059094|NCT05729542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059095|NCT01905501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059096|NCT04462523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked Sub-investigators to exam subjects at each visit after clinical evaluation for cell and/or flare.||f|f|f|t
34059097|NCT00421824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059098|NCT03866733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059099|NCT06440733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059100|NCT00027677||||TREATMENT||||||||
34059101|NCT05207852|||OTHER||PROSPECTIVE|||||||
34059102|NCT02687906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850783|NCT04735328|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participating clinics will be grouped in four groups - two groups will start the intervention in 2021, two groups will start in 2022. All participants receive the same intervention.||||
34163529|NCT06726304|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Behavioural intervention with rolling recruitment|t|t|t|t
34163530|NCT02934165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163531|NCT05413408|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163532|NCT06395038|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163533|NCT02664506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163534|NCT06726460|||OTHER||CROSS_SECTIONAL|||||||
34163535|NCT03664232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163536|NCT05556668|||COHORT||RETROSPECTIVE|||||||
34163537|NCT04977713|RANDOMIZED|PARALLEL||PREVENTION||NONE||The randomized controlled trial||||
34163538|NCT06467916|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34163539|NCT06726031|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163540|NCT06725407|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163541|NCT01609114|||CASE_CONTROL||PROSPECTIVE|||||||
34163542|NCT01854580|||COHORT||PROSPECTIVE|||||||
34163543|NCT04314986|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34163544|NCT05185726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Videos of speech will be scores for %SS by assessors who are blinded for the treatment arm in which the child belongs.|A three arm 1:1:1 randomised, multicentre, open-label non-inferiority parallel group pragmatic trial|f|f|f|t
34163545|NCT05376631|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34163546|NCT05773638|||COHORT||RETROSPECTIVE|||||||
34163547|NCT05563415|NA|SEQUENTIAL||PREVENTION||NONE||Stepped Wedge||||
33850784|NCT03070951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850785|NCT05559931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850786|NCT00269347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33850787|NCT00602563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850788|NCT05653570|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33850789|NCT01227382|NA|SINGLE_GROUP||||NONE||||||
33850790|NCT00432666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850791|NCT03774485|||CASE_CONTROL||PROSPECTIVE|||||||
33850792|NCT02939612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33850793|NCT03650309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850794|NCT04696380|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33850795|NCT01220427|||||RETROSPECTIVE|||||||
33850796|NCT06474728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850797|NCT02413333|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33850798|NCT02196870|||CASE_CONTROL||PROSPECTIVE|||||||
33850799|NCT05918237|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
33850800|NCT02211885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850801|NCT02173847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850802|NCT01322802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850803|NCT02376374|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33850804|NCT04973644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850805|NCT04954404|NA|SINGLE_GROUP||TREATMENT||NONE||Transcatheter mitral valve repair/Transcatheter mitral valve replacement||||
33850806|NCT04465747|||COHORT||RETROSPECTIVE|||||||
33955058|NCT02237768|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955059|NCT05150197|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33955060|NCT04925531|||OTHER||OTHER|||||||
33955061|NCT02564172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955062|NCT03224234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||At midpoint (week 12), patients will be converted to the alternate arm (cross-over design).||||
33955063|NCT03192631|RANDOMIZED|CROSSOVER||OTHER||NONE||Cross-over study of 20 patients randomized to two arms, 9 month before cross-over.||||
33955064|NCT00007735|RANDOMIZED|PARALLEL||||DOUBLE||||||
33955065|NCT05879692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955066|NCT05355194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955067|NCT05035706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955068|NCT00758225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955069|NCT01016925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33955070|NCT05661825|||COHORT||RETROSPECTIVE|||||||
33955071|NCT00925184|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33955072|NCT00058045||||TREATMENT||||||||
33955073|NCT04645732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study investigators, outcome assessors and the statistician will be blinded to randomization. Furthermore, a blinded interpretation of the study results will be conducted|The RCT is a pragmatic, parallel-group, superiority RCT (1:1 ratio)|f|f|t|t
33955074|NCT04121169|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be randomized 1:1 to receive IM-01 treatment dosage at 20g or 10g twice a day|Twenty four patients in each group will receive IM-01 treatment at 20g or 10g twice daily:for 10-14 days.||||
33955075|NCT03824483|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be enrolled in a single-stage phase 2 design.||||
33955076|NCT02427425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955077|NCT02566460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33850807|NCT01423032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746197|NCT03077724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo control with medications dispensed by the Investigational Drug Service|Randomized, double-blinded, placebo controlled trial|t|t|t|t
33850808|NCT04479215|||OTHER||PROSPECTIVE|||||||
33850809|NCT00326833|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746198|NCT00971048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33746199|NCT04639453|||OTHER||PROSPECTIVE|||||||
33850810|NCT00092352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746200|NCT02169687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955078|NCT01456598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955079|NCT02234427|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33746201|NCT06670547|||COHORT||PROSPECTIVE|||||||
33746202|NCT06380231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33746203|NCT03625193|||COHORT||PROSPECTIVE|||||||
33746204|NCT04458350|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746205|NCT04271709|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33746206|NCT03149783|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Study drug label of drug"|Randomized Controlled Double Blind Trial|t|t|t|t
33746207|NCT04643444|||COHORT||PROSPECTIVE|||||||
33746208|NCT01335243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746209|NCT01872169|NA|SINGLE_GROUP||SCREENING||NONE||||||
33955080|NCT01750528|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955081|NCT04014296|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33955082|NCT05097066|||COHORT||RETROSPECTIVE|||||||
33955083|NCT04222218|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The patient and the examiner who administered the clinical scales were blind to the type of rTMS delivered, which was applied by another blinded experimenter.|Each patient received both rTMS and sham cerebellar stimulation in randomized order in two different sessions, separated by at least 2 weeks. In each session, motor tasks, clinical scales and wearing sensor assessments were tested twice in all patients: at baseline (pre-stimulation) and after rTMS (post-stimulation)|t|f|t|f
33955084|NCT05770778|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33955085|NCT02296671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955086|NCT01130805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955087|NCT00669110|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746210|NCT03380962|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty enrolled study patients will receive study medication Clazakizumab (Vitaeris Inc; Vancouver Canada, BC)||||
33746211|NCT05219240|||COHORT||RETROSPECTIVE|||||||
33746212|NCT00346060|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33746213|NCT01257867|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33746214|NCT01381328|||CASE_ONLY||PROSPECTIVE|||||||
33746215|NCT01917526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746216|NCT02357628|||COHORT||PROSPECTIVE|||||||
33746217|NCT03904472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746218|NCT06164262|||OTHER||PROSPECTIVE|||||||
33746219|NCT01495065|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33746220|NCT04785404|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients will be randomly distributed to two groups. Group A patients will have skin wounds stithed after stoma reversal while in secondary closure group B, wound will be allowed to heal by secondary intention||||
33746221|NCT02458105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746222|NCT03712917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746223|NCT04151914|||COHORT||PROSPECTIVE|||||||
33746224|NCT05935501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746225|NCT02797925|||CASE_CONTROL||PROSPECTIVE|||||||
33746226|NCT05924919|NA|SINGLE_GROUP||OTHER||NONE||||||
33746227|NCT04488536|||COHORT||PROSPECTIVE|||||||
33850811|NCT01116102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850812|NCT00591370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850813|NCT03857074|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, open label, pilot feasibility study.||||
33850814|NCT03620370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955088|NCT06539585|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33955089|NCT05744635|||COHORT||PROSPECTIVE|||||||
33955090|NCT06651983|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955091|NCT02559778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955092|NCT04625907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955093|NCT02396238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955094|NCT03244904|||COHORT||PROSPECTIVE|||||||
33955095|NCT03616704|||OTHER||PROSPECTIVE|||||||
33955096|NCT05134545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955097|NCT04423315|||COHORT||RETROSPECTIVE|||||||
33955098|NCT02844088|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33850815|NCT02043964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850816|NCT00016939||||TREATMENT||||||||
33850817|NCT06448832|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33850818|NCT01466933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850819|NCT00832182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850820|NCT00686569|||CASE_CONTROL||PROSPECTIVE|||||||
33850821|NCT05004896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850822|NCT04059653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33850823|NCT00423930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850824|NCT02199704|NA|SINGLE_GROUP||||NONE||||||
33850825|NCT05963139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33955099|NCT02191969|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33955100|NCT05477940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955101|NCT05774782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955102|NCT02831686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059103|NCT02322502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059104|NCT00602433|||CASE_ONLY||PROSPECTIVE|||||||
34059105|NCT02823834|||COHORT||PROSPECTIVE|||||||
33746228|NCT04897893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A prospective, single-arm, phase IV pilot study where all participants receive the same treatment for a similar duration. Their pre-treatment baseline condition will serve as a comparator for the effects observed following MAG-EPA treatment. There is no control group in this study.||||
33746229|NCT06196762|NA|SEQUENTIAL||TREATMENT||NONE||0.3mg/kg, 1.0mg/kg, 3.0mg/kg,10mg/kg，20mg/kg.||||
33746230|NCT04826354|RANDOMIZED|PARALLEL||TREATMENT||NONE||Effects of high-dose Statin Versus low-dose statin plus ezetimibe on statin-associated Muscle Symptoms||||
33746231|NCT00064727||||TREATMENT||||||||
33746232|NCT01325948|||||CROSS_SECTIONAL|||||||
33746233|NCT03397212|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33746234|NCT01714128|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746235|NCT03351374|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33746236|NCT02194426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746237|NCT03577002|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33746238|NCT03006250|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33746239|NCT02516618|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33746240|NCT04094454|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746241|NCT05544994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33746242|NCT01316133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746243|NCT04719793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746244|NCT04691765|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The trial will involve 12 patients in a standard dose escalation design. The first cohort of 4 patients will start at 100 mg SC daily, the dose approved for rheumatoid arthritis. If no dose limiting toxicities are experienced by these patients during the first cycle of treatment, then the next cohort of up to 4 patients will be treated at 100 mg SC twice daily (BID). The third cohort of up to 4 patients will be treated at 200 mg BID SC daily, to approximate doses used to treat inflammopathies such as Cryopyrin-Associated Periodic Syndromes.||||
33746245|NCT02269293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746246|NCT00124527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746247|NCT05975190|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomized design of the study will test R\&R interventions compared to current conventional DIBH instruction.||||
33746248|NCT06635512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746249|NCT06031701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental pretest-posttest design with a non-equivalent wait list control group||||
33746250|NCT02180646|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33746251|NCT05088213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746252|NCT02105363|||COHORT||PROSPECTIVE|||||||
33746253|NCT01719952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746254|NCT04789421|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Randomisation of patients to Arm 1 (with RCM evaluation) or Arm 2 (without RCM evaluations) was performed following clinical and dermoscopy evaluation, and was only revealed to the clinician at presentation of RCM evaluation request.|A two-arm prospective, multi-center study of the triage of patients with equivocal skin lesions suspicious for melanoma, compared with the standard of care (i.e. clinical and dermoscopic examination). A 1:1 randomization into the interventional or control arms occurred at the time of enrolment. Arm 1 (interventional) included lesions that were evaluated with RCM with management decisions taken according with overall information (2 possible outcomes: excision or digital monitoring. Arm 2 (control) included lesions that were not evaluated with RCM, with management decisions taken according to clinical and dermoscopy evaluations only (2 possible outcomes: excision or follow-up).|f|t|f|f
33746255|NCT06315218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33746256|NCT03534752|||COHORT||RETROSPECTIVE|||||||
33746257|NCT01314118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746258|NCT03453606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746259|NCT05515159|||CASE_CONTROL||PROSPECTIVE|||||||
33746260|NCT05408039|||COHORT||PROSPECTIVE|||||||
33746261|NCT05204355|||COHORT||PROSPECTIVE|||||||
33746262|NCT00593372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746263|NCT04254900|||COHORT||PROSPECTIVE|||||||
33746264|NCT05624242|||COHORT||PROSPECTIVE|||||||
33746265|NCT02059694|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33746266|NCT00919243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746267|NCT04452708|||COHORT||PROSPECTIVE|||||||
33746268|NCT05672992|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746269|NCT03862404|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Blinded drug preparation|RCT with one active group and a control (placebo) group|t|f|f|t
33746270|NCT01752946|||||PROSPECTIVE|||||||
33746271|NCT00782340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746272|NCT01704092|||CASE_CONTROL||PROSPECTIVE|||||||
33746273|NCT03631979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746274|NCT05445427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746275|NCT00321919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746276|NCT05399953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized single blind controlled clinical trial|f|f|f|t
33955103|NCT03653637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual who evaluates the outcomes of interest will not know the assigned condition of the participants.|Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33955104|NCT04662424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955105|NCT05570058|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34059106|NCT01771601|||CASE_ONLY||PROSPECTIVE|||||||
34059107|NCT06197412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746277|NCT04230408|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm study||||
33746278|NCT02626715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746279|NCT00252759|||||PROSPECTIVE|||||||
33746280|NCT06034405|||COHORT||PROSPECTIVE|||||||
33746281|NCT05996159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746282|NCT00062933||||TREATMENT||||||||
33746283|NCT00175682|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33746284|NCT01965834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746285|NCT00250887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850826|NCT00625248|||||PROSPECTIVE|||||||
33850827|NCT01885520|RANDOMIZED|CROSSOVER||||NONE||||||
33850828|NCT05599503|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33850829|NCT05444959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850830|NCT03494478|NA|SINGLE_GROUP||OTHER||NONE||||||
33850831|NCT02877329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850832|NCT05344781|||COHORT||PROSPECTIVE|||||||
33850833|NCT03977415|||COHORT||PROSPECTIVE|||||||
33850834|NCT03064659|||COHORT||PROSPECTIVE|||||||
33850835|NCT01832285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850836|NCT00969709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850837|NCT02415673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33850838|NCT03516929|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34059108|NCT05733039|||COHORT||PROSPECTIVE|||||||
34059109|NCT02189018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059110|NCT06532136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059111|NCT00595114|||COHORT||RETROSPECTIVE|||||||
34059112|NCT02811588|||COHORT||PROSPECTIVE|||||||
34059113|NCT03470428|||COHORT||PROSPECTIVE|||||||
34059114|NCT00489515|||COHORT||PROSPECTIVE|||||||
34059115|NCT02428374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059116|NCT05217511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059117|NCT04303754|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34059118|NCT01350440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059119|NCT05509764|||COHORT||PROSPECTIVE|||||||
34059120|NCT04469673|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34059121|NCT02014220||||PREVENTION||||||||
34059122|NCT04482244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059123|NCT06228079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059124|NCT02026336|NA|SINGLE_GROUP||SCREENING||NONE||||||
34059125|NCT04198285|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34059126|NCT03362164|||COHORT||PROSPECTIVE|||||||
34059127|NCT03229629|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Cluster randomised controlled trial Clustered at the village level, 5 treatment arms and one control group Within three treatment arms, voucher will be individually randomised||||
34059128|NCT04907331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33850839|NCT00623402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850840|NCT03912246|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33850841|NCT03718130|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||6 groups of 12 subjects each will receive varying vaccine dosages and vaccine canditdate combinations||||
34059129|NCT00671775|||CASE_CONTROL||PROSPECTIVE|||||||
34059130|NCT03509870|NA|SINGLE_GROUP||TREATMENT||NONE|open|unblinded single arm intervention||||
33850842|NCT03801915|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34059131|NCT02747797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059132|NCT04682262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator diagnosed primary dysmenorrhea with clinical history and anamnesis. Investigator refers the patient to the surgical nurse and nurse performs the randomization process and prepare the patient (control group) for the cervical dilatation and hysteroscopy and schedule the control group for follow-up (expectant). The outcomes assessor is also blind to the assigned group.||f|f|t|t
34059133|NCT03408249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059134|NCT06621498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059135|NCT02407132|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34059136|NCT04429204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059137|NCT00426140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059138|NCT04738136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059139|NCT01726036|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34059140|NCT03251794|||COHORT||PROSPECTIVE|||||||
34059141|NCT04463732|||COHORT||CROSS_SECTIONAL|||||||
34059142|NCT01928797|RANDOMIZED|PARALLEL||TREATMENT||NONE|The investigator assigned the subject to one of the groups. Care provided followed the protocol for the group and the investigator analyzed the outcome results.|Investigator randomly assigns the subjects into one of the two groups. Control group and Interventional group||||
34059143|NCT01980810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059144|NCT00393263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059145|NCT06619028|NA|SEQUENTIAL||TREATMENT||NONE||A prospective longitudinal controlled design on the use of external body weight (where patients are their own control: intrasubject controlled study) for 4 weeks, with a 4-week pre-control period and a 4-week follow-up.||||
34059146|NCT04948554|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34059147|NCT01602432|||COHORT||PROSPECTIVE|||||||
34059148|NCT00204503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850843|NCT02104050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850844|NCT00462332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850845|NCT04540250|||OTHER||CROSS_SECTIONAL|||||||
33850846|NCT01340638|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33850847|NCT05557227|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The participants will receive either dextrose, water, lactose, galactose in a randomized order (computer generated block randomization) prior to a one-hour exercise bout. Participants, but not investigators, are masked to nutrition allocation.|The study is a single-blinded, randomized crossover study, consisting of 4 study days of 1-hour fixed intensity cycling, after consumption of either galactose, lactose, glucose or water.|t|f|f|f
34059149|NCT01846221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Group assignment will be performed by opening a previously prepared numbered opaque envelope containing the assignment CLO or FENT. The investigator preparing the study drug will not reveal the group assignment. The investigator administering the drug (different from the investigator preparing the drug) and assessing the outcomes will be blinded to the group assignment. The participant will also be blinded to the group assignment."|"Subjects will randomly receive either a mixture of 100 mcg of clonidine and 12.5 mg of bupivacaine for a total volume of 10 ml (CLON group) and the other group will receive 100 mcg of fentanyl and 12.5 mg of bupivacaine for a total volume of 10 ml (FENT group). If the treatment is declared a failure, the patient will receive the alternative of the initial treatment."|t|t|t|t
34059150|NCT01168310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059151|NCT06404060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of the primary outcome, Endurance Shuttle Walk Test (ESWT), is blinded.|This platform protocol is designed to allocate participants into an appropriate intervention appendix based on their symptoms of exercise intolerance. Once assigned to an appendix, eligible participants are randomized in a 1:1 ratio to either the study intervention group or a control group.|f|f|f|t
34059152|NCT03688958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|two randomized clinical groups including women with early (stage II) and advanced (stage III) breast cancer. In the Early group, women were treated with I2 (5 mg/day) or placebo (colored water) for 7 to 35 days. In the Advanced group, patients received treatment (I2 or placebo) along with 4 to 6 cycles of FEC/TE treatment.|t|t|t|f
34059153|NCT01656278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059154|NCT06623773|||COHORT||PROSPECTIVE|||||||
34059155|NCT01653860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059156|NCT03101722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The studies were divided into 2 groups: Control subgroup and huperzine A group.The study is a single-center, randomized, basic treatment and health education controlled trial, with minimized allocation of patients to one of the two groups.~For the study of tinnitus intervention, there is a 3 to 12 month follow-up."|f|t|f|f
34059157|NCT05755386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163548|NCT04662359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All patients will receive the ultrasound assessment, so there is no need for masking|This single-arm pilot interventional study will evaluate the potential for ultrasound to improve disease activity assessments for patients with rheumatoid arthritis with clinical scores indicating moderate or high disease activity. Patient facing measures including the Routine Assessment of Patient Index Data (RAPID)3 and the Clinical Disease Activity (CDAI) will be used to determine patient disease activity, as well as whether patients are eligible for the study. The investigators will also collect inflammatory marker levels (including C-reactive protein) and ultrasound assessment to determine severity of illness and for physicians to determine treatment recommendations. Additional patient information will be obtained via chart reviews, and providers will complete pre- and post-ultrasound assessments of the patients.||||
34163549|NCT05271916|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, open-label, Phase I/IIB clinical study of Dacomitinib+Anlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) patients with EGFR 21L858R mutation.||||
34163550|NCT04119180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163551|NCT01200368|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34163552|NCT05575362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163553|NCT04311255|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
34163554|NCT03988764|||CASE_ONLY||PROSPECTIVE|||||||
34163555|NCT05830370|||CASE_CONTROL||OTHER|||||||
33746286|NCT00484705|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33746287|NCT06635746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746288|NCT02816671|||CASE_ONLY||PROSPECTIVE|||||||
33746289|NCT02658643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746290|NCT00252642|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746291|NCT03034577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746292|NCT06634979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746293|NCT02365467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746294|NCT06286631|||COHORT||OTHER|||||||
33746295|NCT04023695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33746296|NCT04050293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo-controlled, 2-arm, parallel group study|t|t|t|t
33746297|NCT00867711|||COHORT||RETROSPECTIVE|||||||
33746298|NCT03181360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746299|NCT01659021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746300|NCT01404572|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33746301|NCT05850403|||OTHER||CROSS_SECTIONAL|||||||
33746302|NCT02254447|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33746303|NCT03024073|||COHORT||PROSPECTIVE|||||||
33746304|NCT02848508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746305|NCT04672304|||OTHER||RETROSPECTIVE|||||||
33746306|NCT02722746|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33746307|NCT03667053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850848|NCT05347043|NA|SINGLE_GROUP||SCREENING||NONE||||||
33850849|NCT04971278|||COHORT||PROSPECTIVE|||||||
33850850|NCT05497973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Non-inferiority randomized trial testing two experimental conditions: 1) ehealth ecosystem, 2) usual psychosocial care. Assessment of main outcomes are conducted at recruitment (T0), 3 months from T0 (T1), 6 months from T0 (T2), and 9 months from T0 (T3). Hence, the design is 2 (treatment conditions) X 4 (assessments). The whole project's methodology adheres to the principles of Responsible Research and Innovation (RRI).~The sample size has been estimated with the support of the R software (R Core Team, 2020), setting a non-inferiority margin of 5 points in the Hospital Anxiety and Depression Scale (Vaganian et al., 2020), with power at 80% and one-tailed α of 2.5%. A dropout rate of 25% was assumed. It was anticipated that 152 participants were necessary (n = 76 per arm) to ensure that a two-sided 95% confidence interval would exclude the non-inferiority threshold."||||
33850851|NCT01280162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850852|NCT06433960|||OTHER||PROSPECTIVE|||||||
33850853|NCT00919347|||CASE_CONTROL||PROSPECTIVE|||||||
33850854|NCT00986973|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33850855|NCT03009760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850856|NCT06126731|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with histologically or cytologically confirmed mCRPC who have previously progressed on at least one line of taxane chemotherapy (or not fit or not willing to receive a taxane) and a next generation antiandrogen (e.g. enzalutamide, apalutamide, darolutamide, abiraterone acetate)||||
33893419|NCT00393822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33893420|NCT04141696|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33893421|NCT04224623|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33893422|NCT00124306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893423|NCT02993978|||CASE_CONTROL||PROSPECTIVE|||||||
33893424|NCT03500744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham block will be performed||t|t|f|f
34059158|NCT06620068|||OTHER||RETROSPECTIVE|||||||
34059159|NCT04891211|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Patients will be examined without knowing their vitamin D level. The OCT evaluations will be performed by a highly trained ophthalmic technician, and the compatibility of the results will be confirmed by two experienced retinal specialists.|Group 1: 1) age \<18 years old; 2) serum vitamin D \[(25(OH) D), calcitriol\] level \<20 ngr/mL in previous two weeks Group 2: 1) age \<18 years old; 2) serum vitamin D \[(25(OH) D), calcitriol\] level \>20 ngr/mL in previous two weeks|f|f|t|t
34059160|NCT00160225|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34059161|NCT00101075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059162|NCT00663897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059163|NCT00245076||||PREVENTION||NONE||||||
34059164|NCT02657577|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34059165|NCT01312714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059166|NCT05057403|||COHORT||PROSPECTIVE|||||||
34059167|NCT05545020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059168|NCT02090621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059169|NCT06647082|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34059170|NCT03444051|||COHORT||RETROSPECTIVE|||||||
34059171|NCT03449992|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Twelve participants were randomly assigned to either an intervention group or a placebo group, and a 4 digits code based on their Spanish ID card were used to code their names.~Then, an independent researcher prepared individual bags with either a 15-days worth of placebo drinks or beetroot drinks, and gave it to the athletes. Then, this person was withdrawn for the research procedures.~Finally, another group of researchers, without knowing what athlete was on each group (intervention or placebo), conducted the performance tests pre and post 15 days of supplementation, and another group analyzed the data once collected."|Twelve elite distance runners were randomly assigned to either an intervention group or a placebo group. Participants in each group consumed beetroot juice or a placebo drink for 15 consecutive days.|t|f|t|t
34059172|NCT05148403|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label, result blind method|Patients in the case group were treated with glibenclamide within 10 hours after onset, orally or through nasogastric tube, 1.25 mg each time, once every 8 hours, for 7 consecutive days. The control group was blank control.||||
34059173|NCT00091637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059174|NCT02953106|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34059175|NCT00928031|||COHORT||RETROSPECTIVE|||||||
34059176|NCT02610829|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059177|NCT04045184|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34059178|NCT01044511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34059179|NCT00126100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059180|NCT00734695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059181|NCT06355167|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group A (n=10): 400mg/d of Bacopa monnieri Broup B (n=10): 800 mg/d of Bacopa monnieri||||
34059182|NCT00196339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059183|NCT03104426|RANDOMIZED|PARALLEL||TREATMENT||NONE||"RCT with unblinded treatment allocation 1:1 ratio. Either treatment with darbepoetin alfa or standard care. No placebo."||||
34059184|NCT04318119|||COHORT||PROSPECTIVE|||||||
34059185|NCT05356962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be blind whether the patients were operated by a surgeon in the control or in the intervention group.||f|f|f|t
34059186|NCT02342548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059187|NCT02232854|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33850857|NCT05216432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Single Agent Arm:~Part 1(multiple ascending doses, QD or BID):unresectable or metastatic solid tumors with PIK3CA mutation per local assessment; Part 2 (RP2D determined in Part 1) Patients with unresectable or metastatic solid tumors with ≥1 PIK3CA mutation per local assessment will be enrolled protocol defined groups~Double Combination Arm Part 1(multiple ascending doses, QD or BID): HR+, HER2- advanced or metastatic breast cancer with PIK3CA mutation per local assessment Part 2 (RP2D determined in Part 1) Group 1: patients who have not received prior PI3Kα inhibitor Group 2: patients who are intolerant to PI3Kα inhibitor~Triple Combination Arms Part 1(multiple ascending doses, QD or BID): HR+, HER2- advanced or metastatic breast cancer with PIK3CA mutation per local assessment Part 2 (RP2D determined in Part 1) Patients with HR+, HER2- advanced or metastatic breast cancer with PIK3CA mutation per local assessment will be enrolled protocol defined groups"||||
33850858|NCT05018221|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Blinding of all parties will not be possible for all domains. The default position of the BEAT-Calci platform is that treatments determined by randomization will be blinded to as high a level is feasible.~Within practical domains, a blind will be adopted, whereby participants, site personnel, trial investigators and outcome assessors will remain blinded to the treatment from the time of randomization until database lock of the comparisons to which that participant is contributing data. In blinded domains, randomization data will not be accessible by anyone else involved in the trial with the following exceptions: (1) data managers who work on the randomization and drug management system, (2) unblinded statistician(s) involved with the response adaptive randomization, and (3) the unblinded biostatistician who prepares reports for the IDMC. Information on the blind, or lack thereof, per domain will be described in the respective Domain-Specific Appendix."|Adaptive, platform, randomized controlled trial, involving multiple interventions spanning several domains of therapeutic care.|t|t|t|t
33850859|NCT06300359|||OTHER||CROSS_SECTIONAL|||||||
33850860|NCT04431700|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized, single-blind, controlled trial. All eligible participants will be randomly assigned to one of two diets.||||
33850861|NCT05303220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850862|NCT04025567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163556|NCT02426840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850863|NCT05366790|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Investigators will be blinded to the participants' group allocation. In this pragmatic trial, pediatricians may decide to discuss smoking and/or vaping with families as part of their usual care, and participants may mention the CEASE/CEASE-A intervention during the encounter with the provider. As such, participants and physicians will not be blinded.|Participants will be randomized to received either the CEASE intervention (supportive smoking cessation services) or care as usual.|f|f|t|f
33850864|NCT02598024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850865|NCT02957526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34163557|NCT03741582|||OTHER||PROSPECTIVE|||||||
34163558|NCT01571752|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34163559|NCT06654440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163560|NCT02289638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163561|NCT02527590|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163562|NCT05494606|||COHORT||PROSPECTIVE|||||||
34163563|NCT06411873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects were recruited through consecutive sampling until the required number of participants was reached. They were then randomly assigned into study groups using block randomization. The randomization process was conducted online via https://www.sealedenvelope.com/, overseen by the methodology team. Results were stored securely, inaccessible to researchers. Allocation concealment was ensured with sequentially numbered sealed opaque envelopes, indicating standard or high-protein enteral nutrition. These were handed to a designated nutritionist coordinator, independent of the research team, responsible for storage, preparation, and distribution. Research assistants informed the coordinator of subjects, who then prepared the assigned nutrition accordingly. High-protein enteral nutrition resembled standard nutrition to maintain blindness. Researchers, patients, families, nurses, and physicians remained unaware of the nutrition type.|This trial is an interventional study with two arms. Participants will be randomised to high enteral protein or standard enteral protein. For both trial arms, participants will be provided with enteral nutrition (EN) as per standard of care.|t|t|t|t
34163564|NCT06150482|||COHORT||RETROSPECTIVE|||||||
34163565|NCT03386721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163566|NCT06726005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163567|NCT00602420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34163568|NCT04104607|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multicenter dose escalation and dose expansion phase I trial, designed to gain evidence of maximally tolerated and recommended phase-II dose of CC-1 in adult patients with CRPC.||||
34163569|NCT05609435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized, trial of REASSURE vs usual care within UW Health oncology clinics||||
34163570|NCT03117855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163571|NCT06709443|||OTHER||PROSPECTIVE|||||||
34163572|NCT05178199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34163573|NCT01002651|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34163574|NCT05120414|RANDOMIZED|PARALLEL||TREATMENT||NONE||The control and experimental groups were compared with each other.||||
33955106|NCT05419687|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Only the statistician and the PI will be aware of the allocation order sequence, while the country co-investigators will be blinded to the allocation sequence and only the next health facility/secondary hospital randomized for roll out will be revealed at each crossover intervention implementation time point. The outcome assessors will also be blinded.|The SW-RCTs will consist of 11 sequences (11 different possibilities of timing and sequencing the introduction of the intervention components), and a maximum of four intervention periods, combining an individual de-escalating training intervention followed by a refreshment training in the form of a collaborative learning and a code of conduct board level intervention with an overall study duration of 24 months.|f|f|t|t
33850866|NCT02097082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955107|NCT03254407|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33955108|NCT01232387|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34059188|NCT03541954|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"2 types of patients will be included:~* 30 patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria \> 5)~* 30 patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria \< 5)"|f|t|t|t
34059189|NCT01632150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059190|NCT04909268|||CASE_ONLY||PROSPECTIVE|||||||
34059191|NCT00139100|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34059192|NCT02603562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059193|NCT05738122|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34059194|NCT05249283|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33850867|NCT06169683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059195|NCT05836857|||COHORT||PROSPECTIVE|||||||
34059196|NCT03254823|||OTHER||OTHER|||||||
34059197|NCT02660606|||CASE_ONLY||PROSPECTIVE|||||||
34059198|NCT01484093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059199|NCT00558896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059200|NCT02132975|RANDOMIZED|PARALLEL||||NONE||||||
34059201|NCT01570881|||COHORT||PROSPECTIVE|||||||
34059202|NCT05731869|||CASE_CONTROL||PROSPECTIVE|||||||
33850868|NCT02673515|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33850869|NCT04702529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059203|NCT04064164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Six nursing homes will be randomly assigned to treatment and control conditions. All NHs will received the CHATO training. The treatment NHs will received immediate feedback from the Speeko App after each recording sessions whereas the Control NHs will not receive feedback until all recording sessions are complete.||||
34059204|NCT03067675|||COHORT||CROSS_SECTIONAL|||||||
33850870|NCT02992821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955109|NCT05604209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind|t|f|t|f
33850871|NCT06334484|||COHORT||RETROSPECTIVE|||||||
33850872|NCT04331496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind randomized controlled trial|f|f|f|t
33850873|NCT06187194|NA|SINGLE_GROUP||TREATMENT||NONE||Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy||||
33850874|NCT01697215|||CASE_ONLY||PROSPECTIVE|||||||
33850875|NCT06277310|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a before and after stepped wedge study design||||
33850876|NCT02686047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850877|NCT02015182|||CASE_ONLY||PROSPECTIVE|||||||
33850878|NCT06437587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Due to the nature of the intervention, it is impossible to blind the researcher of the intervention who will deliver the intervention. Therefore, the participants and the outcome assessor will be blinded. The outcome assessor will be blinded to the allocation throughout the study and will independently assess all outcomes at T0, T1, and T2 for both groups.||t|f|f|t
33955110|NCT00000847||||PREVENTION||DOUBLE||||||
33955111|NCT04365127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059205|NCT05308602|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34059206|NCT02913027|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33850879|NCT01002066|||COHORT|||||||||
33850880|NCT00227474||||TREATMENT||NONE||||||
33955112|NCT01137643|||OTHER||PROSPECTIVE|||||||
34059207|NCT01222377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059208|NCT04160572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059209|NCT02361554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059210|NCT00985959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059211|NCT05968027|||CASE_CONTROL||RETROSPECTIVE|||||||
33955113|NCT06701526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059212|NCT03994614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850881|NCT01607632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850882|NCT04771728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850883|NCT03657654|||COHORT||PROSPECTIVE|||||||
33850884|NCT02029846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850885|NCT03780075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850886|NCT04577547|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33850887|NCT03031860|||OTHER||PROSPECTIVE|||||||
33850888|NCT00417261|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33955114|NCT06253520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955115|NCT05490160|||CASE_ONLY||RETROSPECTIVE|||||||
33955116|NCT02712736|NA|SINGLE_GROUP||OTHER||NONE||||||
34059213|NCT02872857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059214|NCT03619759|||COHORT||RETROSPECTIVE|||||||
34059215|NCT02835950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059216|NCT04543318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059217|NCT02203318|||CASE_CONTROL||PROSPECTIVE|||||||
34059218|NCT04104932|||COHORT||PROSPECTIVE|||||||
34059219|NCT05135884|||COHORT||OTHER|||||||
34059220|NCT00150397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34163575|NCT02486536|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34163576|NCT05784545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163577|NCT00180388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955117|NCT00444665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955118|NCT00238108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955119|NCT01199510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33955120|NCT02085798|||COHORT||PROSPECTIVE|||||||
33955121|NCT06652672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, prospective, non-inferior, partially randomized patient-preference trial||||
33955122|NCT00219362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955123|NCT03269877|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33955124|NCT06555952|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blind|randomized, double-blinded, 2-arm parallel, 6-week study|t|f|t|f
33955125|NCT04649892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Participants will be randomly allocated to two groups:~1. Naltrexone and brief psychoeducational intervention~2. Placebo and brief psychoeducational intervention This will be double-blind controlled study."|t|t|t|f
33955126|NCT01977560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955127|NCT00557830|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955128|NCT06703515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955129|NCT02253199|NON_RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
33955130|NCT04278872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059221|NCT02980510|RANDOMIZED|PARALLEL||TREATMENT||NONE|The primary endpoint is the complete response rate where complete response is defined as complete disappearance of metastatic lesions after a maximum of 12 cycles of chemotherapy and tumor marker level normalization (CEA).|National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.||||
34059222|NCT00655681|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33850889|NCT01410123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850890|NCT00235482|NA|SINGLE_GROUP||TREATMENT||NONE||CAVATAK||||
33850891|NCT02253901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850892|NCT04039477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850893|NCT04428073|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33850894|NCT01666457|||OTHER||PROSPECTIVE|||||||
33850895|NCT01015339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850896|NCT02437071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850897|NCT00645866||||TREATMENT||NONE||||||
33850898|NCT03866161|||COHORT||PROSPECTIVE|||||||
33850899|NCT06056167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850900|NCT05045508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33955131|NCT06271226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|participant and statistical analysis expert is blind.|Since there will be variability in patient admissions to intensive care units, block randomization will be used. Three different groups will be coded with different letters (A,B,C) and blocks will be created. Then randomization will be performed by assigning random numbers on the computer. The letters determined in the randomization will be written in closed envelopes and stored, and the randomization process will be carried out by an independent researcher. After the patient who meets the inclusion criteria is identified, the independent researcher will be contacted to find out which group the patient is in.|t|f|f|t
33955132|NCT04857879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955133|NCT02212834|||COHORT||RETROSPECTIVE|||||||
33955134|NCT03906929|NA|SINGLE_GROUP||SCREENING||NONE||Using of buried and exposed intramedullary k-wire in pediatric forearm fixation.||||
33955135|NCT01436942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33955136|NCT04402944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955137|NCT06567054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparative, single-cohort, interventional study model: investigational device vs. comparator device. Measurements are performed on the same cohort of participants: Part 1 - cross-sectional study; Part 2 - prospective study.||||
33955138|NCT06454955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955139|NCT02181673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955140|NCT06542172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955141|NCT05449314|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33955142|NCT04210882|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33955143|NCT02786810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955144|NCT06039956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955145|NCT03258515|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33955146|NCT04362761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059223|NCT00691873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059224|NCT06648148|||COHORT||PROSPECTIVE|||||||
34059225|NCT05744037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850901|NCT03210584|||COHORT||PROSPECTIVE|||||||
33850902|NCT03104491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850903|NCT01332773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850904|NCT05449561|||CASE_ONLY||CROSS_SECTIONAL|||||||
33850905|NCT00183066|||||PROSPECTIVE|||||||
33850906|NCT02682745|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33850907|NCT02183844|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33850908|NCT01567904|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34059226|NCT04481191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850909|NCT02867579|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33850910|NCT04834453|||COHORT||PROSPECTIVE|||||||
33850911|NCT03543657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850912|NCT00269360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33850913|NCT06300450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators and outcomes assessors will be blinded to the assignment of the clinician to the computer alert or control (non-alert) group.|400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this patient- and provider-facing alert-based CDS (EPIC BPA)|t|f|t|t
33850914|NCT03616977|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33850915|NCT06354231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850916|NCT02907515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850917|NCT03629639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33850918|NCT00660543|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850919|NCT06609382|||COHORT||RETROSPECTIVE|||||||
33850920|NCT01733173|||COHORT||PROSPECTIVE|||||||
33850921|NCT04646954|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible participants accept DNA methylation testing, with cytology and/or hrHPV assay in a hospital-based community。||||
33850922|NCT04641871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850923|NCT05879549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850924|NCT02539147|||OTHER||OTHER|||||||
33955147|NCT04512976|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No masking is required as each subject will be exposed to each cooling modality (e.g., fan only, skin wetting, and a combination of a fan and skin wetting).|"The investigators will conduct a randomized crossover design study. Burn survivors (20-40% burn surface area), burn survivors (\>40% burn surface area), and non-burned individuals will each perform four bouts of 60-min of exercise trials with the following cooling strategies: A) a control trial, B) skin wetting only trial, C) fan only trial, and D) a combination of skin wetting with a fan trial. Subjects will perform these four bouts under one of the following environmental conditions (30 deg C and 38 deg C).~A subject will only be required to perform exercise across all four cooling modalities for a given environmental temperature (i.e., four exercise bouts); each will not be required to perform exercise across all combinations of environmental temperatures and cooling modalities (i.e., 12 exercise bouts)."||||
33955148|NCT04707014|RANDOMIZED|PARALLEL||OTHER||SINGLE|Different investigators are assigned to each phase of the study, with one designated as responsible for recruitment (MQD), another for intervention and control (JMPP), and another for subsequent evaluation in the post-anaesthesia recovery unit (URPA) and at 24 hours (responsible nursing staff).|"Patients are randomly distributed to one of the following groups:~Intervention group: Technique of rapid conversational hypnosis, with focus on therapeutic suggestion (guiding the patient into a hypnotic trance), adapted to child's cognitive development. Induction with hypnotic suggestion focuses and accompanies the child's body sensations and allows their active participation. After standard sedation, therapeutic suggestion is maintained throughout the surgery and in the post-hypnotic period before awakening.~Control group: High-tech distraction technique (Apple®), passive and chosen by the child, either an animated video or his or her favourite music. After standard intravenous sedation, the child is taken to the operating theatre to watch his or her favourite video or music and this is maintained throughout the procedure."|f|f|f|t
33955149|NCT03480165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955150|NCT06033963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955151|NCT04047459|||OTHER||PROSPECTIVE|||||||
33955152|NCT03192917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955153|NCT02384200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955154|NCT01603927|||COHORT||PROSPECTIVE|||||||
33955155|NCT02250157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059227|NCT06622707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746308|NCT04117932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746309|NCT01910129|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33746310|NCT04060394|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Dose Escalation to determine Recommended Phase II Dose (RP2D) of LAE001/Prednisone plus Afuresertib in m-CRPC patients. Once RP2D is determined, Phase II will evaluate LAE001/Prednisone plus Afuresertib vs and Docetaxel/Prednisone plus Afuresertib in m-CRPC patients.||||
33746311|NCT02457221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746312|NCT01710072|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33746313|NCT03460223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746314|NCT05981443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746315|NCT03185975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33746316|NCT05568888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746317|NCT03238937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746318|NCT03879720|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization to standard endotracheal intubation or endoscopist-facilitated endotracheal intubation.||||
33746319|NCT03955393|||CASE_ONLY||PROSPECTIVE|||||||
33746320|NCT02000284|||CASE_CONTROL||PROSPECTIVE|||||||
33746321|NCT00354523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746322|NCT00709280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746323|NCT00655980|RANDOMIZED|FACTORIAL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33746324|NCT00249951|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33746325|NCT03009526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746326|NCT06329180|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746327|NCT02790853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746328|NCT01494402|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33746329|NCT04880304|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator who administers the semi-structured diagnostic interview for both groups using the Adult ADHD Investigator Symptom Rating Scale (AISRS), which is a robust, valid efficacy measure of ADHD symptoms in adult patients will be blinded to the study participants' diagnosis status. Additionally, the statistician will be blinded from group assignment. These processes will ensure single blind method.||f|f|t|t
33746330|NCT01713218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746331|NCT02832323|NA|SINGLE_GROUP||OTHER||NONE||||||
33746332|NCT02638662|||COHORT||PROSPECTIVE|||||||
33746333|NCT03419169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of all outcome measures will be masked as to which group patients have been assigned. Patient information will be coded using a numerical system by and independent member of the research team during the course of the study and data analysis.|Patients will be assigned to one of two groups: 1) Light load BFR resistance training; or 2) Heavy load resistance training. An independent member of the research team will carry out block randomisation using opaque envelopes containing slips of paper. Each envelope will contain four slips (Two x BFR group and two x heavy load group), thus patients will be randomised in groups of four.|f|f|f|t
33746334|NCT00833989|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33850925|NCT05887115|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Research assistants will not collect any NFP program data - only equivalent research data in both control and NFP groups. Research assistants will remind participants not to tell the researchers which group they are in prior to each research data collection. We will also record in our participant tracking database if a researcher is ever unmasked (e.g., saw the NFP folder/ materials/participant mentioned their NFP nurse during an interview). Similarly, the nurses providing NFP will not be aware of which of their clients are involved in the study."||f|f|t|f
33746335|NCT04571619|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sequential multiple assignment design with a randomized component followed by a non-randomized component||||
33746336|NCT03057119|RANDOMIZED|PARALLEL||SCREENING||SINGLE||A repeated measures randomized control trial design to compare patient outcomes at baseline as well as 3 and 6 months post-intervention|t|f|f|f
33746337|NCT00783744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746338|NCT02417038|||COHORT||PROSPECTIVE|||||||
33746339|NCT02486926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33746340|NCT05603273|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33746341|NCT04679467|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Open-label.|Open-label, single group interventional study.||||
33746342|NCT01853592|||||PROSPECTIVE|||||||
33746343|NCT01090804|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33746344|NCT02529319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746345|NCT04284800|||COHORT||PROSPECTIVE|||||||
33746346|NCT03248739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746347|NCT06188364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study is a single center, randomized clinical trial (RCT). We will use a block-randomization design with two arms:~1. Usual Care Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge and~2. Experimental USS supplemented with community health services delivered by a certified CHW (CHW+USS) for care partners:~   1. beginning within one week of inpatient rehabilitation discharge,~  2. active services (initiated by CHW or Care Partner) extending over 1- 12 weeks post-discharge, and~  3. passive services (initiated by care partner request only) 13-24 weeks post-discharge."||||
33850926|NCT02055781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850927|NCT01805401|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33850928|NCT00386373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850929|NCT01859273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163578|NCT04992663|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-blinded, starting as single centre, randomised controlled trial (RCT). After implementation of the DELIVR trial in the Zuyderland MC, the study will be expanded as a multi centre trial.||||
33850930|NCT01201265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850931|NCT03341767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Parallel assignment, placebo-controlled with later arm for pharmacokinetics|t|t|t|t
33850932|NCT03306459|||CASE_CONTROL||PROSPECTIVE|||||||
33850933|NCT00267839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33850934|NCT04682444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) Matching placebo tablet.||t|f|f|t
33850935|NCT00292032|||COHORT||PROSPECTIVE|||||||
33850936|NCT02436473|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33850937|NCT02252380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850938|NCT02747199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850939|NCT01796015|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33850940|NCT02234687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33850941|NCT02884076|||COHORT||PROSPECTIVE|||||||
33850942|NCT05216497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850943|NCT00178100|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33850944|NCT01536015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33850945|NCT05909111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850946|NCT04361682|||COHORT||RETROSPECTIVE|||||||
33850947|NCT00002674||||TREATMENT||||||||
33850948|NCT00157560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33850949|NCT02996331|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33850950|NCT04838951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Endoscopist wil not be blinded to treatment. Treatment arm allocation will be concealed to patients, data collector and data analysts.||t|f|f|t
33955156|NCT05028881|||COHORT||PROSPECTIVE|||||||
34163579|NCT05949268|||COHORT||PROSPECTIVE|||||||
33850951|NCT03654872|||CASE_ONLY||PROSPECTIVE|||||||
33850952|NCT02498431|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33850953|NCT01996189|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33850954|NCT03383120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment group will be concealed at all time points from both clinical examiners (N.C., A.Z.) and the biostatistician (D.C.). Only the operator (D.H.) will be aware of the type of treatment to be performed based on the computer-generated allocation table. The un-blinded operator will perform the first follow-up visit one week post-operatively to ensure blinding of the examiners.|Prospective, single-centre, superiority, randomized, controlled clinical trial|f|f|f|t
33850955|NCT05420844|NA|SINGLE_GROUP||OTHER||NONE||||||
33955157|NCT02326337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Group Sequential Design of a maximum of 220 subjects with two predetermined interim analyses at 73 and 146 subjects|t|t|t|t
33955158|NCT04274426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955159|NCT03105232|||COHORT||PROSPECTIVE|||||||
33955160|NCT02829229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955161|NCT05517746|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33955162|NCT01056185|||COHORT||PROSPECTIVE|||||||
34163580|NCT06333665|||COHORT||RETROSPECTIVE|||||||
33850956|NCT03221673|||COHORT||CROSS_SECTIONAL|||||||
33850957|NCT03374527|||COHORT||CROSS_SECTIONAL|||||||
33955163|NCT02290782|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study: IORT +/- EBRT (risk adapted approach).||||
33955164|NCT04190251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746348|NCT02951104|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746349|NCT02365051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746350|NCT02494284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746351|NCT00851214|||COHORT||PROSPECTIVE|||||||
33850958|NCT05174455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850959|NCT02818959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850960|NCT03402490|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group of participants received motivational counseling to enhance physical activity; the other group received usual care||||
33850961|NCT03723616|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33850962|NCT04596943|||COHORT||PROSPECTIVE|||||||
33850963|NCT01534377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33850964|NCT01383460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33850965|NCT02648490|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, dose-escalation study of HLX07 ,3+3 design||||
33955165|NCT04914559|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Site pharmacy will not be blinded to product assignment, study staff and participants will be blinded to product assignment. Product will be provided in unlabeled cups.|This will be a randomized crossover design. The subjects will be randomized to one of two interventions on two separate study days, one week apart.|t|f|f|f
33955166|NCT04813653|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, prospective study||||
33955167|NCT01503502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955168|NCT06515665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"A online site named randomizer.org  gave us a random queue. Participant do not know their queue."|There are 3 groups. Fisrt group has therapeutic foot orthosis. Second group has orthosis and exercises with artificial intelligence. Third group is control group.|t|f|f|f
33955169|NCT03597620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||15 eligible patients will be enrolled. Patient will be treated for 12 weeks. There will be a total of five visits: screening, baseline, w4, w8 and w12. Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp. Patients will be provided with metaderm cleanser, can be use daily. For scalp psoriasis, patient will also use the shampoo Head \& Shoulders formula with 1% Pyrithione Zinc as the active ingredient||||
33955170|NCT04141085|||CASE_CONTROL||PROSPECTIVE|||||||
33955171|NCT01045759|||||PROSPECTIVE|||||||
33955172|NCT06023758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955173|NCT03780101|||OTHER||PROSPECTIVE|||||||
33955174|NCT02371642|||COHORT||PROSPECTIVE|||||||
33955175|NCT04928599|||COHORT||PROSPECTIVE|||||||
33955176|NCT04975113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955177|NCT03514173|||OTHER||OTHER|||||||
33955178|NCT04182412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization process will be initiated after general anesthesia is induced and the group affiliation will be determined by opening of a sealed envelope specifying the group assignment. The information of group allocation is stored in a closed envelope kept in a locked archive until the study is completed.|two different laparoscopic to one of techniques for abdominal wall reconstruction: narrowing of linea alba with continuous suture, with and without mesh|t|f|t|f
33955179|NCT05415618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955180|NCT04045834|||CASE_CONTROL||PROSPECTIVE|||||||
33955181|NCT05672225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33850966|NCT00697333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955182|NCT00477620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955183|NCT04074122|||CASE_CONTROL||PROSPECTIVE|||||||
33955184|NCT00147472|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955185|NCT02769182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33955186|NCT05784311|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized with a 1:1 allocation before surgery into the intervention or control group:~* Patients in the intervention group will receive perioperative prophylaxis (similar to the control group) followed by five days of 1500mg IV cefuroxime and 500mg IV metronidazole thrice daily.~* Patients in the control group will only receive perioperative prophylaxis (a single dose of 5-7mg/kg gentamicin followed by 2gr IV cefazolin and 500mg IV metronidazole every 4h of surgery), which will be discontinued after surgery."||||
33955187|NCT06562582|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This prospective, 2x2x2 factorial, randomized, controlled,||||
33955188|NCT03205163|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33955189|NCT03373825|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|"Participants in ARM1 were only aware of the use of the Take home rapid drug test as a urine test. Participants in ARM2, while instructed to test their drug residue, were aware of the ability to use the take home rapid drug test as a urine test."|Participants will be assigned to either ARM1 or ARM2 depending on when they enrolled in the study.|t|f|f|f
33955190|NCT00891527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955191|NCT05794555|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Participants will be randomized in stage 1 to enhanced usual care or enhanced usual care plus lactulose. After 12 weeks participants will be re-randomized to TeleTai-Chi (at-home, via Zoom, supervised by a study team instructor) vs. continued enhanced usual care. The participants that took lactulose in Stage 1 will continue to take lactulose through Stage 2 until their participation is complete.~The observational sub-study will include enrollment of approximately 215 participants."||||
33955192|NCT05279807|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients with uncontrolled BP on treatment with any Ace-i or any CCB, if eligible, will enter a 4-week run-in period.~Patients will then be all assigned to mono-therapy with ZOF 30mg or AML 5mg for 4 weeks if in treatment with Ace-i or CCB respectively.~At Visit 2 patients with uncontrolled BP, tolerating treatment and with adherence within 80%/120% ranges, will receive extemporaneous combination ZOF 30mg+AML 5mg, while patients with controlled BP, tolerating treatment or with adherence out of 80%/120% range, will be withdrawn from the study together with patients with SBP/DBP ≥ 180/100 mmHg.~At Visit 3 (Visit 2 + 4 weeks ± 2 days) controlled patients will continue extemporaneous combination for additional 4 weeks ± 2 days, while uncontrolled patients will be up-titrated to ZOF 30mg/AML 10mg for the same time. Patients with SBP/DBP ≥ 180/100 mmHg or not tolerating extemporaneous combination or with adherence out of 80%/120% range, will be withdrawn from the study."||||
33955193|NCT02546180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955194|NCT00003861|||CASE_ONLY||RETROSPECTIVE|||||||
33955195|NCT06558526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment will be blinded to the participants and research team.||t|f|t|t
33850967|NCT04709315|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"that the anesthetist who prepared the experimented drugs was different from the one who was responsible for administration of all medications during induction and maintenance and was responsible for the patient throughout the surgery till patient was ready to transfer to PACU. An independent third anesthetist blinded to the experimental drug administration, carried out intubation and scored intubating conditions. This independent anesthetist, was summoned to enter the operating room 45 seconds after neuromuscular relaxant was administered, when the patient was ready for intubation.~Moreover,All drugs administered in control group (saline 0.9%- succinyl; 1mg/kg) and experimental group (Dex; 1 µg/kg- rocuronium; 0.6mg/kg), were prepared in 10 mL syringe and were given via infusion pump. Saline and Dex were given over 10 minutes immediately prior to induction."||t|t|t|t
33955196|NCT02902757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955197|NCT04444401|||CASE_ONLY||OTHER|||||||
33955198|NCT04484805|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33955199|NCT06650774|||OTHER||RETROSPECTIVE|||||||
33955200|NCT01125358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33955201|NCT06565611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955202|NCT02788955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850968|NCT05983224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33850969|NCT00455949|||DEFINED_POPULATION||PROSPECTIVE|||||||
33850970|NCT00691327|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33850971|NCT05300347|||OTHER||PROSPECTIVE|||||||
33850972|NCT00710853|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33850973|NCT03143621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will not be told what group they are assigned to, however, complete masking will be difficult to achieve. The patient's treatment assignment is part of the medical record.|Randomized, parallel-group, controlled clinical trial|t|f|f|t
33850974|NCT01236534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850975|NCT05629754|||COHORT||OTHER|||||||
33955203|NCT06651021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955204|NCT02271100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized blinded comparison of two methods to identify landmarks for a procedure|t|f|f|t
33955205|NCT03464110|RANDOMIZED|PARALLEL||OTHER||NONE||Interventional: To determine the effect of a clinician communication coaching intervention versus control on an objective measure of the quality of communication (primary outcome) and patients' perceptions of the quality of patient-centered care (secondary outcome), both overall and within Black and White patients.||||
33955206|NCT01326611|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|t|f
33955207|NCT04341727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746352|NCT01951430|||CASE_ONLY||PROSPECTIVE|||||||
34059228|NCT03769675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163581|NCT06693089|NA|SINGLE_GROUP||TREATMENT||NONE|"Treatment-seeking participants will first receive an assessment screening visit. Once evaluated for inclusion/exclusion criteria, and informed written consent has been obtained, baseline measures about primary and secondary outcomes will be completed. Participants will then be proposed for inclusion in the study.~Recruitment will stop once 64 participants have met inclusion criteria and have accepted to participate to the study."|The study is a single arm study to evaluate MIT-ED effectiveness on a larger sample of adults with transdiagnostic ED presentations which include underweight participants. They will receive up to 40 individual sessions of MIT-ED. The study is run in an private outpatient clinic specialized in eating disorder treatment. Therapies will be delivered both in person or through videoconferencing. Three therapists will be involved in the trial, all trained in MIT.||||
34163582|NCT01191671|||CASE_ONLY||PROSPECTIVE|||||||
34163583|NCT06727318|||CASE_ONLY||PROSPECTIVE|||||||
34163584|NCT02511002|||COHORT||PROSPECTIVE|||||||
34163585|NCT05066386|||COHORT||OTHER|||||||
34163586|NCT06457789|NA|SINGLE_GROUP||OTHER||NONE||||||
34163587|NCT03261388|||OTHER||PROSPECTIVE|||||||
34163588|NCT05767840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163589|NCT05833438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746353|NCT05268666|NA|SEQUENTIAL||TREATMENT||NONE||||||
33746354|NCT04070573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is an open label randomized controlled trial.|Arm 1: 81mg oral ASA daily. Arm 2: 162mg oral ASA daily. Patients will obtain their prescriptions from their respective pharmacies. Women in Arm 1, will be instructed to take one table of 81mg aspirin per day; those in Arm 2, will be asked to take two tablets simultaneously orally once per day. Therapy will be initiated at the baseline visit and continued until 1 week before planned delivery or upon admission for unplanned/imminent delivery as per clinical routine.|f|f|f|t
33746355|NCT03297840|||OTHER||OTHER|||||||
33746356|NCT05190393|||COHORT||RETROSPECTIVE|||||||
33746357|NCT00413504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746358|NCT01278277|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746359|NCT05175963|||COHORT||PROSPECTIVE|||||||
33746360|NCT05302466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer-assisted block randomisation (stratification according to pain intensity) is carried out by an independent statistician. The blinding of the study refers to the measurement assistants who do not know/are not allowed to ask about the respective status of the participant.|This is a monocentric, partially blinded, randomised clinical intervention study (RCT) in a parallel group design with participants from the Erlangen-Nuremberg area.|f|f|f|t
33746361|NCT03088657|||COHORT||PROSPECTIVE|||||||
34163590|NCT04530253|||COHORT||PROSPECTIVE|||||||
34163591|NCT01066728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746362|NCT03958344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized parallel double arm|f|f|t|t
33746363|NCT02086357|||COHORT||PROSPECTIVE|||||||
33746364|NCT06479629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746365|NCT06059196|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster-randomized controlled trial; stratified randomization based on facility type and urban/rural location.||||
33746366|NCT06389604|NA|SINGLE_GROUP||PREVENTION||NONE|No blinding due to nature of intervention|Non-randomized, within subject experiemental trial||||
33746367|NCT06529679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746368|NCT05711524|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention and randomization are not made at the level of the individual patient, but rather on clusters of patients by month. The clusters will include all patients at NYP/WC for whom pooled cryo is ordered during a single month.||||
33746369|NCT05307055|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746370|NCT01906294|||CASE_ONLY||PROSPECTIVE|||||||
33746371|NCT01063257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746372|NCT03806829|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33746373|NCT00803465|||COHORT||PROSPECTIVE|||||||
33746374|NCT06529588|||CASE_CONTROL||RETROSPECTIVE|||||||
33746375|NCT00605241|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746376|NCT06636045|||COHORT||PROSPECTIVE|||||||
33850976|NCT03468231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In the OXA group, saline replace the fluorouracil and leucovorin solution and patients are treated the same time as the FOLFOX group.||t|t|f|t
33850977|NCT01710891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850978|NCT01220518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850979|NCT00497185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163592|NCT05081895|||CASE_ONLY||PROSPECTIVE|||||||
33850980|NCT04678115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33850981|NCT01581359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33850982|NCT04869228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33850983|NCT04433702|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34059229|NCT01170637|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059230|NCT04398654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059231|NCT00800813|||COHORT||PROSPECTIVE|||||||
34059232|NCT02707471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059233|NCT00846703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059234|NCT00250458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059235|NCT04494763|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label Randomized controlled trial - Block randomization||||
34059236|NCT03639805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059237|NCT06011460|||CASE_ONLY||PROSPECTIVE|||||||
34059238|NCT04303936|NA|SINGLE_GROUP||OTHER||NONE||||||
34163593|NCT00853866|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34163594|NCT00997802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163595|NCT05548946|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34163596|NCT00398567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163597|NCT06726083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to study participant group assignment.|Randomized controlled trial with an intervention group compared to a control group|f|f|f|t
34163598|NCT01871519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746377|NCT06502171|NA|SINGLE_GROUP||TREATMENT||NONE||"This will be an open label, single arm, prospective, multicenter study to assess the tolerability and efficacy of selumetinib and cabozantinib in combination in patients with NF1 ≥16 years old with progressive or symptomatic PN.~The primary goal of the phase 1 is to determine the feasibility of combination therapy with cabozantinib and selumetinib to treat plexiform neurofibromas in people with NF1 based on toxicity and tolerability.~If the results of Phase 1 show it is feasible to combine the study drugs, the plan is to submit amendments for phases 1b and 2 to evaluate the efficacy of these agents at a reduced dose compared with the prior monotherapy clinical trials and determine if these biologically active agents are effective at lower doses in combination; specifically, if that they have improved rates of response, improved depth of response and tolerability profiles that could translate into long term use to support durability of response."||||
33746378|NCT01517451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746379|NCT03347500|||OTHER||PROSPECTIVE|||||||
33746380|NCT02233829|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
33746381|NCT01629355|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746382|NCT01204151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33746383|NCT03916965|||COHORT||PROSPECTIVE|||||||
33746384|NCT00153764|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33746385|NCT06218667|NA|SEQUENTIAL||TREATMENT||NONE||||||
33746386|NCT03910257|NON_RANDOMIZED|PARALLEL||OTHER||NONE||a quasi-experimental research design with pre-and post-test control group design||||
33746387|NCT03722251|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Repeated measures cross-over design.|t|f|f|f
33746388|NCT01351285|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33746389|NCT06104215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746390|NCT02038673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746391|NCT03216876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746392|NCT04233099|||CASE_CONTROL||PROSPECTIVE|||||||
33746393|NCT03689322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33850984|NCT02594605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33850985|NCT00704379|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33850986|NCT05466409|||COHORT||PROSPECTIVE|||||||
33850987|NCT05324397|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single-arm, multicenter clinical study||||
33850988|NCT01322997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746394|NCT00360529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746395|NCT04992260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33746396|NCT04034641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746397|NCT00821418|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746398|NCT01258114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746399|NCT02740127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33850989|NCT03768804|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double blind, randomised crossover study|t|f|t|t
33850990|NCT02982460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33850991|NCT03723876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850992|NCT00996476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33850993|NCT02706899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746400|NCT06636474|NA|SINGLE_GROUP||OTHER||NONE||All patients benefiting from a DLAI and suffering from psychiatric disorders, monitored in sector 75G08-09 of the Saint-Maurice hospitals, and sectors 75G19, 75G20-21, 75G25, 75G26 of the GHU Paris.||||
33955208|NCT01666067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955209|NCT03003858|||COHORT||RETROSPECTIVE|||||||
33955210|NCT00870714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955211|NCT05967767|RANDOMIZED|PARALLEL||OTHER||SINGLE|In this study, blinding was provided in practice by using the simulation device for the normoxia condition.|single-blind placebo-controlled design|t|f|f|f
33955212|NCT02850783|NA|SINGLE_GROUP||||||||||
33955213|NCT04458428|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955214|NCT01816334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955215|NCT02766959|||COHORT||PROSPECTIVE|||||||
33955216|NCT00879762|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33955217|NCT06653335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33955218|NCT00823680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955219|NCT03715816|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The study is not blinded, because the subject(s) will know which of the three experimental conditions they are exposed to (control without breaks; intervention with passive or active breaks). The same applies to the experimenter(s).|||||
33955220|NCT04587856|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33955221|NCT00004123|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955222|NCT05116566|||COHORT||PROSPECTIVE|||||||
33955223|NCT04197882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955224|NCT05538663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955225|NCT05475535|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33955226|NCT01411475|||COHORT||PROSPECTIVE|||||||
33955227|NCT02416089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955228|NCT05444361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators, participants, and clinical staff will be masked to treatment group assignment, with the only exception being the unmasked individual who performs the procedure (and will not have subsequent contact with the participant).|Pragmatic, multicenter, randomized, triple-masked, sham-controlled clinical trial|t|t|t|t
33955229|NCT03242707|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will know which group they have been assigned to|Participants will be randomly assigned to receive either a single autologous fat injection or a single hyaluronic acid injection.||||
33955230|NCT00061958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955231|NCT01679691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33955232|NCT06500026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955233|NCT05256940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to treatment received by participants.|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help participants at high-risk for suicide resolve their ambivalence about living by increasing their motivation to live, and is delivered in three sessions in-person, virtually, or by telephone.|f|f|f|t
33955234|NCT01912391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955235|NCT00558831|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955236|NCT01139086|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955237|NCT04060979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955238|NCT01419405|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33955239|NCT05268003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955240|NCT06550440|||CASE_CONTROL||RETROSPECTIVE|||||||
33955241|NCT06653270|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33955242|NCT06023511|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33955243|NCT01534390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955244|NCT05832242|||COHORT||PROSPECTIVE|||||||
33955245|NCT06651671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955246|NCT06564272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955247|NCT05560217|||OTHER||CROSS_SECTIONAL|||||||
33955248|NCT06152653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955249|NCT05645263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The outcome assessor don't know which group the patient is in.|All patients were divided into 3 groups according to bezoar formation time combined with the willing of the patients. Patients whose phytobezoar formation time was less than a week in Group 1 , phytobezoar formation time between 1week and 2 weeks in Group2 , phytobezoar formation time longer than 2 weeks in Group 3. Every group was subdivided into intervention and control group according to whether Coco-cola was dieted.|f|f|f|t
33746401|NCT04295733|||COHORT||PROSPECTIVE|||||||
33746402|NCT02412930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955250|NCT04342390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955251|NCT00276458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955252|NCT04061655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33955253|NCT01581086|||COHORT||RETROSPECTIVE|||||||
33955254|NCT05672394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955255|NCT00910065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059239|NCT06526650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059240|NCT05997823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059241|NCT06620822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076271|NCT05282368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This small pilot study is designed as a mixed methods randomized controlled trial to estimate and test the effect of a nurse-guided PHM™ intervention on psychological distress and perceived caregiving competencies using longitudinal, repeated measures. Qualitative and quantitative data are expected to provide crucial insights regarding app usage patterns, interactions with the nurse interventionist, and impacts of the intervention on the individual/dyad.||||
34076272|NCT01589419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076273|NCT00490971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076274|NCT04401332|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34076275|NCT02504320|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34076276|NCT01725633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076277|NCT05238688|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076278|NCT05292261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059242|NCT05884424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The technician in charge of assessing users participating in the study must be blinded throughout the intervention, i.e., he/she will not be able to know whether the assessed users belong to the experimental group or to the control group.~The person from CREA - Imserso in charge of randomization and data analysis will also be blinded.~The participants and the technician implementing the intervention cannot be blinded, due to the inherent nature of the intervention.~Data analysis will also be performed blinded."|The investigators propose the conduct of a randomized and controlled multicenter pragmatic clinical trial to compare 12 weeks of robot therapy sessions with the PARO robot versus 12 weeks of standard care. Participants who meet the inclusion criteria will be allocated by block randomization to either the PARO robot intervention group or the standard care control group. Participants allocated to the PARO group will undergo three intervention sessions per week for 12 weeks, in addition to continuing their standard care. Participants in the control group will maintain their standard care, participating in those activities previously assigned in their individual care plan. In addition, follow-up will be performed 12 weeks after the end of the intervention to assess the duration of the effects.|f|f|t|t
34163599|NCT05841875|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33955256|NCT06565065|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants will not be directly told of the order of their treatment or workout sessions in an attempt to blind between OMT and sham treatment. Investigators will be blinded to the order in which participants receive their treatment besides the direct treater and the research assistant. Outcome assessors and statisticians will only analyze coded participant data.||f|f|t|t
33850994|NCT00911287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850995|NCT02274974|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33850996|NCT05952687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955257|NCT01600755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955258|NCT06277466|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33850997|NCT00832234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746403|NCT05618353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo at the same time points as the intervention|One day before surgery: Colchicine 1.2 mg with 0.6 mg PO one hour later. This load will be followed by colchicine 0.6 mg twice daily for a total of 14 days. If a patient is unable to take oral medications (by mouth or nasogastric tube) post-operatively (e.g., post abdominal surgery), colchicine will be held until the clinically treating physician allows resumption of oral medications if still within 14 days post-operation.|t|t|t|t
33850998|NCT01206036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33850999|NCT00940732|RANDOMIZED|PARALLEL||||NONE||||||
33851000|NCT02675127|RANDOMIZED|CROSSOVER||||NONE||||||
33851001|NCT00267631|||COHORT||PROSPECTIVE|||||||
33955259|NCT02875340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955260|NCT06539962|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955261|NCT01145872|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33851002|NCT05358106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind study where participants are blinded.|Single-blind, partially randomized, placebo-controlled study in healthy volunteers. Approximately 40 to 56 healthy adult participants are planned to be enrolled in 7 cohorts of 4 to 8 participants, randomized in a 3:1 ratio to receive AntiBKV or placebo|t|f|f|f
34059243|NCT03243344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34059244|NCT02495194|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34076279|NCT05136417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076280|NCT06600412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851003|NCT03047304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851004|NCT02412839|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851005|NCT00352911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33851006|NCT04780477|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33851007|NCT03500913|||COHORT||PROSPECTIVE|||||||
33851008|NCT02032979|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34076281|NCT05989932|||COHORT||OTHER|||||||
34163600|NCT04843436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163601|NCT01668225|||CASE_ONLY||PROSPECTIVE|||||||
34163602|NCT00431015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851009|NCT02213341|||CASE_CONTROL||PROSPECTIVE|||||||
33851010|NCT06408974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33851011|NCT00023894||||TREATMENT||||||||
33851012|NCT00918580|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33851013|NCT03816267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851014|NCT05307211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
33851015|NCT05866731|||COHORT||PROSPECTIVE|||||||
33851016|NCT00842985||SEQUENTIAL||TREATMENT||NONE||||||
33955262|NCT03370627|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33955263|NCT04102514|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34163603|NCT06727370|||CASE_CONTROL||PROSPECTIVE|||||||
34163604|NCT05428631|NA|SINGLE_GROUP||PREVENTION||NONE||Patients will be pre-selected (pre-inclusion visit) during hospitalizations in the cardiology and nephrology departments of the Nîmes University Hospital. The study will be offered to any patient with class NYHA III heart failure who has been hospitalized in the previous 12 months for cardiac decompensation (current indication for the CARDIOMEMS™ system) and with advanced chronic renal failure with GFR (CKD-EPI) \< 30 ml/min/1.73m2 persisting for more than 3 months and confirmed by Iohexol clearance.||||
33955264|NCT06695910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||"The study is divided in two phases. Phase 1: Single arm. 8 subjects treated with MAG-EPA over a period of 56 days followed by a 28 days wash-out period.~Phase 2: Two arms, placebo controlled, double-blind study. 40 subjects are assigned either to MAG-EPA or Placebo (sunflower oil) and are treated over a 56 days period followed by a 28 days wash-out period."|t|t|t|t
33955265|NCT04028297|||COHORT||PROSPECTIVE|||||||
33955266|NCT05455593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blind to the intervention recieved by the participants||f|f|f|t
33955267|NCT04092257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851017|NCT01480219|||COHORT||RETROSPECTIVE|||||||
33851018|NCT02244021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851019|NCT00636311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851020|NCT00206661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851021|NCT02434068|||COHORT||PROSPECTIVE|||||||
33955268|NCT06563128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Five groups with a control goup|t|f|t|t
33955269|NCT04677894|||CASE_ONLY||PROSPECTIVE|||||||
33955270|NCT00308230|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33955271|NCT00897507|||CASE_ONLY||RETROSPECTIVE|||||||
33955272|NCT01513759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955273|NCT05238909|||COHORT||PROSPECTIVE|||||||
33955274|NCT01965015|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33955275|NCT05850260|||COHORT||PROSPECTIVE|||||||
33955276|NCT06219954|||CASE_ONLY||PROSPECTIVE|||||||
33955277|NCT03976817|||COHORT||RETROSPECTIVE|||||||
33955278|NCT00888472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955279|NCT04785027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955280|NCT06105697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955281|NCT06412380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33851022|NCT00590096|||CASE_ONLY|||||||||
33955282|NCT06540807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955283|NCT01819467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33955284|NCT04223622|||COHORT||CROSS_SECTIONAL|||||||
33955285|NCT02587117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955286|NCT04024254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955287|NCT06651398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The endoscopist who performs the colonoscopy and the investigator who acts as second observer are blinded to objectively assess the BBPS.||f|t|t|f
33955288|NCT05063149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study subjects, all study investigators including the principal investigator and treating physicians will be blinded for the allocation during the complete study period. A sealed envelope with the treatment allocation per code is present at the pharmacy to be used only when 1) crucial for a medical emergency, 2) the participant will continue with Protea-2 and the database concerning year 1 is locked for this specific participant, and 3) at trial completion after the last patient last visit.|Half of the participants (250) will receive treatment (Broncho-Vaxom) and the other half will receive placebo. Randomization will be stratified for gestational age (moderate (30+0-32+6) vs. late (33+0-35+6) prematurity). In the follow-up study Protea-2, infants from the treatment arm in year 1 will be randomised to receive Broncho-Vaxom or placebo in year 2. Randomisation will stratified for gestational age again, but also for the amount of lower respiratory episodes in year 1 (\<2 vs. \>/=2) Infants from the control arm in year 1 will not receive treatment in year 2.|t|t|t|t
33955289|NCT01582074|||CASE_CONTROL||PROSPECTIVE|||||||
33955290|NCT05021315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955291|NCT03162120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955292|NCT06049004|||OTHER||CROSS_SECTIONAL|||||||
34059245|NCT03916731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized Assignment of Investigational and Control devices by Sponsor. Participants and Dialysis Clinics providing routine maintenance hemodialysis care are masked.|Equal numbers of Participants are randomly assigned investigational or control grafts for implant. Study follow up examinations and routine dialysis procedures over the study period are identical for both groups.|t|t|f|f
34059246|NCT04692766|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34059247|NCT01346540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33851023|NCT03411447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955293|NCT01302639|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33955294|NCT05927532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955295|NCT05451849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059248|NCT05850390|||COHORT||PROSPECTIVE|||||||
34059249|NCT06416020|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multisite hybrid Type 1 effectiveness-implementation randomized clinical trial||||
34059250|NCT02224326|||COHORT||PROSPECTIVE|||||||
34059251|NCT00000207|RANDOMIZED|||TREATMENT||DOUBLE||||||
33851024|NCT02819830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955296|NCT04482231|||OTHER||CROSS_SECTIONAL|||||||
33955297|NCT03840031|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participant is blinded, meal option A --\> B or B --\> A based on investigator randomisation.|Each woman consumes both Orange Fleshed Sweet Potato varieties|t|f|f|f
33955298|NCT02435615|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33955299|NCT01527942|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34059252|NCT03633799|NA|SINGLE_GROUP||TREATMENT||NONE||VeraCept Intrauterine Device (IUD)||||
33851025|NCT03562143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients that agree to participate will be randomized to receive either 1 tablet of 325mg ferrous sulfate (65 mg of elemental iron) on consecutive days for 6 weeks or 2 tablets together (130 mg of elemental iron ) every other day for 6 weeks. Both groups will be receiving the same total amount of iron over the study period (2730 mg of elemental iron over 6 weeks).||||
34059253|NCT02559726|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34059254|NCT02134548|||CASE_ONLY|||||||||
34059255|NCT01131884|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34059256|NCT01232530|||COHORT||PROSPECTIVE|||||||
34059257|NCT00250536|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34076282|NCT03338764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851026|NCT01632670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851027|NCT02412410|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33851028|NCT02918227|NA|SINGLE_GROUP||OTHER||NONE||||||
33851029|NCT05097222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Study participants will be blinded to the PBMT treatment regimen they will receive. Participants will wear opaque goggles to blind them from seeing any light emitted from the LED arrays.~A trained laser technician will provide treatment to the study participants. The laser clinician will be unblinded to the participant's treatment allocation. Assessments will be performed by an independent blinded assessor."||t|f|f|t
33955300|NCT01905813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955301|NCT01734421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851030|NCT00950274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851031|NCT02708264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes assessor and data analyst||f|f|f|t
34163605|NCT06227234|RANDOMIZED|CROSSOVER||OTHER||NONE|Nil, however, Outcomes Assessor will be blinded to study hypothesis.|Investigators will conduct an open-label, crossover, mannequin, randomized controlled trial to compare two airway clearance devices (LifeVac© and Dechoker©) with traditional abdominal thrusts as choking interventions. Participants will complete all through interventions in one of 6 randomized orders.||||
33746404|NCT04829344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The Investigator(s), Sponsor, and the subject will be masked to treatment assignment throughout the conduct of the study. Exceptions to this are limited to one statistician at the Contract Research Organization (CRO) who will prepare the randomization code, and three people at the Sponsor who will review the batch records and release product. None of these unmasked persons will be involved in the day to day execution of the study. The masking will be broken after database lock.|Subjects who provide informed consent and fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to receive a single dose of AG-920 or identical looking placebo into one (study) eye (2 drops 30 seconds apart).|t|f|t|f
33746405|NCT02277782|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33746406|NCT03550313|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851032|NCT05550701|||COHORT||RETROSPECTIVE|||||||
33955302|NCT06703177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955303|NCT06530706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746407|NCT02020954|||COHORT||PROSPECTIVE|||||||
33746408|NCT04226924|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The Treatment Period of the study is double-blind. The Extension Period is open label.|The study includes a 24-week blinded treatment period during which patients will receive weekly infusions of trehalose or placebo, followed by a 24-week open-label extension period during which all patients will receive weekly infusions of trehalose.|t|t|t|t
33746409|NCT03272633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746410|NCT05677334|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, controlled study||||
33746411|NCT04183322|||COHORT||PROSPECTIVE|||||||
33746412|NCT06360692|||OTHER||PROSPECTIVE|||||||
33746413|NCT00004129||||TREATMENT||||||||
33746414|NCT05320822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746415|NCT01436903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746416|NCT05859100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to one of the two parallel arms (i.e., egg intervention arm and no intervention arm) for the first 4 weeks. Starting from week 5, the participants in the egg intervention arm will continue with the intervention till week 8 and the participants in the control arm will crossover to the intervention arm for weeks 5 to 8.||||
33746417|NCT03230916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746418|NCT00650741|||||CROSS_SECTIONAL|||||||
33746419|NCT03456908|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746420|NCT05435612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746421|NCT05548803|||COHORT||PROSPECTIVE|||||||
33746422|NCT01600157|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33746423|NCT05904847|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33955304|NCT02845037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955305|NCT06652945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955306|NCT03501017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33955307|NCT01826032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33955308|NCT03843723|||CASE_ONLY||PROSPECTIVE|||||||
33955309|NCT02105207|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33955310|NCT03003793|||CASE_CONTROL||PROSPECTIVE|||||||
33955311|NCT04177472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Primary - BMI percentile at 12 months of age, and 24 months of age~Secondary- Proportion of infants with BMI percentile \>85th at 12 months of age, and 24 months of age~Anthropometrics measured directly by trained study staff~Infant dietary intake of fruits and vegetables, animal source foods, whole grains, desserts and sweets, and salty snacks at 10 to 11 months.~Measured at 10 months using an Infant Diet History questionnaire adapted from the Infant Feeding Practices Study II. Measured at 10 months using the Nutrition Data System for Research (NDSR)~Responsive feeding measured using the Infant Feeding Styles Questionnaire (IFSQ) full scale and Chatoor's feeding scale at 10 to 11 months."||f|f|f|t
33955312|NCT01683331|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955313|NCT00004199|RANDOMIZED|||TREATMENT||||||||
33955314|NCT05859893|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The current 4-week randomized, single-blind factorial trial was conducted with a control group and one intervention group.||||
33955315|NCT03930901|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups; intervention group that involved schools where HELP will be administered and control group that involved schools that will not receive health education.||||
33955316|NCT00618800|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33955317|NCT01592968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955318|NCT04509596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955319|NCT05752396|||CASE_CONTROL||PROSPECTIVE|||||||
33955320|NCT02256202|||COHORT||PROSPECTIVE|||||||
33955321|NCT04311723|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Image reviewers||f|f|f|t
33955322|NCT04172727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33955323|NCT00017797|||CASE_CONTROL|||||||||
33955324|NCT01041807|||OTHER||PROSPECTIVE|||||||
33955325|NCT06652685|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subjects receive IA regimen as the initial induction. On day five of induction, D5-PBCR will be tested according to protocol. Patients will be assigned to different arms according to the result of D5-PBCR.~For FLT3 mutate patients, a combination of gilteritinib will be recommended in this study. Induction and consolidation phase: gilteritinib 80mg on D8-14."||||
34163606|NCT05206812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163607|NCT05901636|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34059258|NCT06287866|RANDOMIZED|PARALLEL||OTHER||SINGLE|Two blinded observers will record their scores independently using the POSAS instrument.||f|f|f|t
34059259|NCT01455246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059260|NCT05020405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059261|NCT01626625|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059262|NCT05409079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059263|NCT02948010|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34059264|NCT04518969|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomized controlled study||||
33851033|NCT06414707|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This randomized controlled trial included two groups of Egyptian patients diagnosed with dyspepsia related to Clarithromycin-resistant strains of H.pylori.~* Group (1) ( Vonoprazan Group) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for two weeks.~* Group (2)(Pantoprazole Group) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.~All cases were diagnosed with H. Pylori resistant infection after clarithromycin based treatment regimen for H. pylori confirmed with persistent positive test of fecal H. pylori Ag before the starting of the study.~All patients of the two groups were followed up for persistence of infection 8-weeks following the end of therapy by testing fecal H. pylori Ag."||||
34059265|NCT01981343|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33851034|NCT05239637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851035|NCT02617680|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851036|NCT05744752|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|"It is an animal model study and the investigator will mask the groups as A, B, C, D, E, F so the outcome assessor will be blinded."|A total of 90 male rabbits of average weight 1-2 kg will be obtained from the animal house of COMSATS University, Lahore. These rabbits will be segregated into 06 groups, each group consisting of 15 rabbits. All rabbits will be kept safe in iron cages under controlled temperature (25±2 C), humidity (55 ± 5%), and 12-hour dark-light cycle. One week after their acclimatization into a new environment the trial will begin. All experimental protocols will be performed following the guidelines for the human use of laboratory animals established at COMSATS University, Lahore.|t|f|f|t
33851037|NCT01593332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851038|NCT06470061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33955326|NCT01803464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059266|NCT05591924|||COHORT||PROSPECTIVE|||||||
33955327|NCT05095896|||CASE_ONLY||RETROSPECTIVE|||||||
33955328|NCT06011902|||COHORT||RETROSPECTIVE|||||||
33955329|NCT04130594|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This clinical trial is designed as a double blind randomized placebo-controlled study|Parallel Assignment|t|f|f|f
33955330|NCT03519152|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|patient were masked for which tablet they were reciving during the study.||t|f|f|f
33955331|NCT05390853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After selection, enrollment and basal assessments, patients are randomized just before the first tDCS session by the professional who will apply the tDCS and will thus be the only one knowing the assigned intervention during the study||t|f|t|t
33955332|NCT04881448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955333|NCT00878735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33955334|NCT01136629|||CASE_ONLY||PROSPECTIVE|||||||
33955335|NCT00000423|RANDOMIZED|FACTORIAL||||NONE||||||
33955336|NCT04730973|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single blinded study|randomized controlled study|f|f|t|t
33955337|NCT05943158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955338|NCT01550354|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33955339|NCT05174273|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study is a phase 2/3 open-label controlled trial (CT) in which adults with MDD with and without IBS who are being treated with an approved antidepressant medication will be assigned to additionally receive either FMT or to continue with their current treatment in a treatment as usual (TAU) arm. An IBS alone group receiving TAU will be recruited as a clinical control group.||||
33955340|NCT06401317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned in a 1:1 ratio to receive either the saline injection or the corticosteroid injection. Opaque syringes will be used to mask the content to both participants and clinicians. The study will use computer-generated randomization to prepare and distribute sealed, opaque envelopes. These envelopes, indicating whether saline or corticosteroids should be injected, will be randomly sent to the healthcare facilities of the doctors involved in the study.|2-arm pragmatic randomized controlled trial|t|t|f|f
33955341|NCT03388528|NA|SINGLE_GROUP||TREATMENT||NONE||Forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial Clinics for Research and Service in Themed Assessments (CRESTA) clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle||||
33955342|NCT00096473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33955343|NCT01029769|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33955344|NCT06650306|||CASE_CONTROL||RETROSPECTIVE|||||||
33955345|NCT04089150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955346|NCT04551027|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955347|NCT06652997|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design||||
34059267|NCT01907061|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059268|NCT01976468|||CASE_ONLY||PROSPECTIVE|||||||
34059269|NCT02827643|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34059270|NCT02544295|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34059271|NCT03714854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34059272|NCT03058224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059273|NCT04492605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059274|NCT00843037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059275|NCT01546168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34059276|NCT06532604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||MESANTIDEP is a pilot, longitudinal, prospective and multicenter cohort study.||||
34163608|NCT03892746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomly assigned by the Cleveland Clinic biostatistician to receive either active or sham tDCS. The tDCS will be pre-programmed with codes for active and sham stimulation. The code will be given to the intervention team by the biostatistician. Investigators analyzing functional outcome data and neurophysiology data will receive coded data that conceals the identity of the subject.|In this phase I/II clinical trial, an anticipated 49(up to 54) subjects will receive 15 sessions of upper limb training while receiving either active tDCS or sham tDCS to the target in the brain devoted to the weaker triceps of the weaker upper limb.|t|t|t|t
34163609|NCT01688375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33955348|NCT04185207|||COHORT||PROSPECTIVE|||||||
33955349|NCT04995302|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this study, one scar in one subject, will be divided into two areas, one-half of the scar will receive an intervention of microneedling, and the other half will receive microneedling+amnion bilayer. Hence, one subject will receive both interventions at the same time|f|f|t|t
33955350|NCT04352621|NA|SINGLE_GROUP||TREATMENT||NONE||To assess the effects of 0.5 mg/kg intranasal ketamine on response to rTMS treatment as measured by the Inventory for Depressive Symptomatology, Self-Rated Version (IDS-SR) in patients with treatment resistant depression (\< 25% response to between 1 and 4 adequate antidepressant trials in the current episode).||||
34163610|NCT06558838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Efficacy assessments will be done by a qualified trained blinded assessor.|This will be a randomized, efficacy assessor-blinded, parallel group, pilot study.|f|f|f|t
33955351|NCT05945849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163611|NCT01082692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163612|NCT02068625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34163613|NCT02071199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163614|NCT02871635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163615|NCT06725992|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, multiple-dose, crossover phase 1 clinical trial||||
34163616|NCT05974098|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33746424|NCT00604981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34059277|NCT01877382|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33746425|NCT01781572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059278|NCT00176436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059279|NCT06622954|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups, 1 control group and 1 intervention group.||||
34059280|NCT02143791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059281|NCT03604770|||COHORT||PROSPECTIVE|||||||
34059282|NCT00993759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059283|NCT01528943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34059284|NCT01252862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163617|NCT00476827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163618|NCT06349382|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants will be randomized to receive preoperative OCHL (the experimental group) or no intervention (the control group) in a 1:1 ratio. Randomization will be performed using computer-generated randomization codes, which will be held in sealed envelopes. Patients in the experimental group (OCHL group) will receive a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL on the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL 2 hours before the induction of anesthesia. Participants in the no-intervention (control) group will be fasted from midnight until surgery. All other aspects of perioperative patient care will be the same for all participants, as per the standardized Institutional protocol for the treatment of abdominal aortic aneurysms and Leriche Syndrome.|f|t|t|f
34163619|NCT05635513|||OTHER||PROSPECTIVE|||||||
34163620|NCT01434849|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33746426|NCT00826891|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746427|NCT03859843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746428|NCT03877523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746429|NCT00321854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746430|NCT01012869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746431|NCT06087367|||CASE_ONLY||RETROSPECTIVE|||||||
33746432|NCT03297268|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33746433|NCT06383975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746434|NCT06370598|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746435|NCT02336464|||COHORT||PROSPECTIVE|||||||
33746436|NCT04604587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746437|NCT03690869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746438|NCT06635902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746439|NCT00933231|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33746440|NCT04002934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a randomized, placebo controlled, double-blind, delayed-start trial of BZA in 50 women with MS to be given as follows:~Group A will receive 3 months of BZA + 3 months of BZA; Group B will receive 3 months of placebo + 3 months of BZA"|t|t|t|t
33746441|NCT04885829|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33746442|NCT00393926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746443|NCT03849755|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||PEPPER study is a randomized cross-over clinical trial with 50 participants. After 4 weeks of ruin-in period all subjects will be randomized to either control group or intervention group in 1:1 ratio. The groups will be stratified by pump or MDI. After 3 months, each group will revert to their standard therapy for 4 weeks (wash-out period) and then crossover to the other group. All participants will be using CGM during whole study.|t|f|f|f
33746444|NCT05131100|||CASE_ONLY||PROSPECTIVE|||||||
33746445|NCT02401191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746446|NCT00244504|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33746447|NCT04208022|||OTHER||OTHER|||||||
33746448|NCT00863096|||COHORT||PROSPECTIVE|||||||
33746449|NCT06395350|NA|SINGLE_GROUP||OTHER||NONE||17 adults for whom remote monitoring has been indicated by a health professional. At least 15 usable data points will be collected.||||
34059285|NCT01886742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059286|NCT04139837|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34059287|NCT02678000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059288|NCT01648088|||OTHER||CROSS_SECTIONAL|||||||
34059289|NCT04132089|RANDOMIZED|SEQUENTIAL||OTHER||NONE||A three factor cross-over design was utilized.||||
34059290|NCT03931408|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Before the intervention, you will be randomly assigned to one of three groups.||t|t|t|t
34059291|NCT05146063|||OTHER||PROSPECTIVE|||||||
33746450|NCT03753165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a single blinded randomised clinical trial|t|f|f|f
33746451|NCT03385018|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm randomized controlled study||||
33746452|NCT04724655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746453|NCT05131750|||COHORT||PROSPECTIVE|||||||
33851039|NCT04261998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851040|NCT03552432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746454|NCT03726034|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A trained research assistant will be responsible to collect demographic data and assessing the outcomes at T0, T1, T2. The research assistant will be blinded to the grouping of participants.|Two-arm single-blinded randomized controlled feasibility trial.|f|f|f|t
33746455|NCT05295498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor). Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.|Parallel Assignment. Patients will be randomly assigned to active or to sham stimulation.|t|f|t|t
33746456|NCT02291614|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33746457|NCT04388020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851041|NCT04579822|||COHORT||RETROSPECTIVE|||||||
33851042|NCT05338489|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33851043|NCT02638480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851044|NCT04694209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851045|NCT02428361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851046|NCT00005829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851047|NCT03988920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851048|NCT00080132||||TREATMENT||NONE||||||
33851049|NCT01323647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851050|NCT00379041|RANDOMIZED|||TREATMENT||||||||
33851051|NCT00004204||||TREATMENT||||||||
33851052|NCT04805229|||COHORT||RETROSPECTIVE|||||||
33851053|NCT06095700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851054|NCT03180177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851055|NCT03439423|||CASE_ONLY||PROSPECTIVE|||||||
33851056|NCT03686631|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The outcomes assessor / statistician will be blinded to which group each patient is in.|Patients will be enrolled randomly into either the passive arm or the smartphone arm prior to their surgery.|f|t|f|t
33851057|NCT02666469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851058|NCT01473446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851059|NCT00527592|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33851060|NCT02772419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851061|NCT02128542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851062|NCT03689400|||COHORT||RETROSPECTIVE|||||||
33851063|NCT06312228|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33851064|NCT06265870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059292|NCT01432821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34059293|NCT04489381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059294|NCT00688311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34059295|NCT06619470|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34059296|NCT04787796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059297|NCT06647875|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|participants do not know which group they are in|After being informed about the study and giving written consent, the parents of the infants included in the study were stratified according to the father's education level, birth order of the child, and self-efficacy scale scores, and then in order of admission to hospital assigned to the study and control groups.|t|f|f|f
34059298|NCT04323267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34059299|NCT06391593|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The study will consist of two treatment periods. The initial Single-Dose Treatment Period is a randomized, double-blind, placebo-controlled 3-way crossover design with oral administration of a single dose of ALTO-203 25 μg, ALTO-203 75 μg, and matching placebo. In the subsequent Multi-Dose Parallel-Group Treatment Period, participants will receive ALTO-203 25 μg, ALTO-203 75 μg, or matching placebo randomized 1:1:1 for a total of 28 days.|t|t|t|t
34059300|NCT01572467|||CASE_ONLY||RETROSPECTIVE|||||||
34059301|NCT03460171|||COHORT||PROSPECTIVE|||||||
34059302|NCT01763138|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34059303|NCT05273775|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-center, single arm, open-label, fixed sequence, self-control||||
34059304|NCT02570139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059305|NCT02292186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059306|NCT03145662|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomization to either high pressure balloon or cutting balloon||||
34059307|NCT00659698|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34059308|NCT06619795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059309|NCT01777295|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33955352|NCT06049355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33955353|NCT00391092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955354|NCT01637064|||CASE_ONLY|||||||||
33955355|NCT06006819|||COHORT||PROSPECTIVE|||||||
33955356|NCT06004700|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|A matched control group will be enrolled from medical records. The data analyst will be blinded to the treatment assignment (i.e., app intervention or matched controls)|||||
33955357|NCT05281328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955358|NCT00249327|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34059310|NCT02847182|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33955359|NCT00646282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059311|NCT01764997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059312|NCT01100892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746458|NCT03339050|NA|SINGLE_GROUP||PREVENTION||NONE||Health for Hearts United is a longitudinal church-based intervention to reduce cardiovascular disease (CVD) risk in mid-life and older African Americans. Using community-based participatory research (CBPR) approaches and undergirded by both the Transtheoretical Model of Behavior Change and Socio-ecological theory, the 18-month intervention was developed in six North Florida churches (three treatment, three comparison).||||
33955360|NCT04639310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746459|NCT06635720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955361|NCT00170456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33955362|NCT05104450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators will randomly assign participants to one of two groups.|f|f|f|t
33955363|NCT03683121|||COHORT||PROSPECTIVE|||||||
33746460|NCT06670443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955364|NCT01598740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746461|NCT01621217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955365|NCT00006014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746462|NCT02501304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955366|NCT06283485|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746463|NCT05403723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955367|NCT05205824|NA|SINGLE_GROUP||OTHER||NONE||||||
33955368|NCT03300726|||CASE_CONTROL||PROSPECTIVE|||||||
33955369|NCT02918318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955370|NCT02424799|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33955371|NCT03144115|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33955372|NCT02866409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33955373|NCT04379102|||CASE_CONTROL||RETROSPECTIVE|||||||
33955374|NCT02799485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955375|NCT05725473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955376|NCT05917314|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both participant groups and the study coordinators will be blinded to the allocation.|Randomized Controlled Trial. Participants will be randomized into the intervention group (SlimBiotics Probiotic) or into a placebo product control group.|t|f|t|f
34059313|NCT06623786|||OTHER||PROSPECTIVE|||||||
34059314|NCT06623305|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective - Retrospective Longitudinal Study||||
34059315|NCT00767039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059316|NCT05194267|NA|SINGLE_GROUP||TREATMENT||NONE||Open label feasibility study||||
34059317|NCT03816644|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34059318|NCT06449443|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059319|NCT03968224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized single-blind controlled clinical trial|t|f|f|f
34059320|NCT04533191|||COHORT||PROSPECTIVE|||||||
33746464|NCT03719872|||COHORT||PROSPECTIVE|||||||
33746465|NCT06186648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746466|NCT02319499|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33746467|NCT06636643|||CASE_CONTROL||PROSPECTIVE|||||||
33746468|NCT02039050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746469|NCT04442217|||OTHER||PROSPECTIVE|||||||
33746470|NCT00838110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746471|NCT01741220|||COHORT||PROSPECTIVE|||||||
33746472|NCT02935062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746473|NCT06632197|||CASE_ONLY||PROSPECTIVE|||||||
33746474|NCT06435871|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33746475|NCT02628054|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33746476|NCT01308749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746477|NCT06478147|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Out of three treatments, one of the investigators is blinded for all treatments while the other is not blinded.~The participant is fully blinded, i.e. treatments will be served in generic containers for Oral Nutritional Supplement (unlabelled) and vanilla-flavoured."|"Crossover Assignment~All participants undertake all three experimental conditions in a random order."|t|f|t|f
33746478|NCT02738177|RANDOMIZED|||TREATMENT||SINGLE|||t|f|f|f
33746479|NCT00157326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746480|NCT05116163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators plan to enroll 20 rheumatologists and a maximum of 200 patients randomized into two different control arms. The providers will observe the outcomes in each separate arm as well as evaluate the results of both arms to each other.||||
34059321|NCT01729533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059322|NCT04268498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059323|NCT05821790|||COHORT||PROSPECTIVE|||||||
34059324|NCT00743938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076283|NCT04004312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746481|NCT01713413|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746482|NCT06395480|||COHORT||PROSPECTIVE|||||||
33746483|NCT06204549|NA|SINGLE_GROUP||OTHER||NONE||||||
33746484|NCT06000046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746485|NCT03733054|||COHORT||CROSS_SECTIONAL|||||||
33746486|NCT04485962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746487|NCT00328419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746488|NCT00495482|||COHORT||PROSPECTIVE|||||||
34163621|NCT06418594|NA|SINGLE_GROUP||TREATMENT||NONE||This study adopts a single-arm, open-label design, planning to enroll 30 patients with HER2-negative breast cancer brain metastasis.||||
34163622|NCT04328740|NA|SEQUENTIAL||TREATMENT||NONE||Open label||||
34163623|NCT05274958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention and data collection will take place before the patient sees the psychiatry clinician. The outcomes assessor will not be involved in the patient care.|Patients on a waitlist to see psychiatry will be enrolled then randomized to usual care or an intervention with monthly PROMs and an educational video|f|f|f|t
33746489|NCT03065894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, longitudinal, pragmatic, non-randomized clustered, non-blinded, controlled trial||||
33746490|NCT06503276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955377|NCT03725267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Melatonin and placebo pills will be manipulated in identical format. The pharmacist will provide similar packets of 7 pills each numbered from 1 to 100. Each packet will have placebo or melatonin according to a randomization list previously sent from a researcher responsible (not involved with intervention). Patients will be consecutively enrolled and receive the packet following the order of one to 100.|Randomized, double blind, placebo-controlled, 2-arm parallel trial|t|t|t|f
33955378|NCT03121560|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"Prospective cross-over study (each woman will be her own control) on women with peri-menopausal menorrhagia. Each woman, after signing the informed consent, will come into the bleeding clinic where she will undergo both examinations in a random order, in two days time."||||
33955379|NCT06651996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955380|NCT01995058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059325|NCT04612413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Up to Protocol Version 10.0, eligible patients were randomized to one of the 4 treatment groups in a 1:1:1:1 ratio between the 4 Cohorts:~1. Placebo~2. Single Intravenous (IV) dose of Allocetra-OTS, 5x10\^9 cells~3. Single IV dose of Allocetra-OTS, 10x10\^9 cells~4. Single or two IV doses of Allocetra-OTS, 10x10\^9 cells in each dose~Starting from Protocol Version 10.0, patient will be randomized to either Cohort 1 (Placebo) or Cohort 4 (Single or two IV doses of Allocetra-OTS, 10x10\^9 cells in each dose)."|t|f|t|f
34059326|NCT03108937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059327|NCT06225154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059328|NCT02938949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059329|NCT05599672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessor is blinded to the intervention condition.|This study will test the Adapt/manualize an Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention compared to standard medication counseling|f|f|f|t
34059330|NCT03071640|||COHORT||PROSPECTIVE|||||||
34059331|NCT02153658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059332|NCT00320437|||DEFINED_POPULATION||PROSPECTIVE|||||||
34059333|NCT03705000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059334|NCT06376591|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059335|NCT00146900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059336|NCT00371644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059337|NCT01733043|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34059338|NCT00005817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059339|NCT01455181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059340|NCT02060266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059341|NCT03212066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059342|NCT03321461|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34059343|NCT01498705|||COHORT||PROSPECTIVE|||||||
34059344|NCT03011983|||CASE_CONTROL||PROSPECTIVE|||||||
34059345|NCT00946894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746491|NCT05889988|||COHORT||PROSPECTIVE|||||||
33746492|NCT01304836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746493|NCT04045392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33746494|NCT03217513|||COHORT||PROSPECTIVE|||||||
33746495|NCT02374827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746496|NCT02539264|||COHORT||RETROSPECTIVE|||||||
33746497|NCT01664078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746498|NCT04219748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163624|NCT05205291|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163625|NCT06060067|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163626|NCT06726473|||OTHER||CROSS_SECTIONAL|||||||
34163627|NCT03862339|||COHORT||PROSPECTIVE|||||||
34163628|NCT01450761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746499|NCT02037347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746500|NCT03529604|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746501|NCT04956718|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|participants do not know its a placebo|Single centered; national ,randomized, crossover, pilot study|t|f|f|f
33746502|NCT02080026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33746503|NCT01544868||PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746504|NCT03832127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746505|NCT02076152|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746506|NCT00662051|||COHORT||PROSPECTIVE|||||||
33851065|NCT02910739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851066|NCT06306339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851067|NCT00662233|NA|SINGLE_GROUP||TREATMENT||||||||
33851068|NCT01585987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851069|NCT03254446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study|t|t|t|t
33851070|NCT04172103|||COHORT||RETROSPECTIVE|||||||
33851071|NCT01680484|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33851072|NCT04059003|||COHORT||PROSPECTIVE|||||||
33851073|NCT04496492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851074|NCT03854773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|there are three models for this study. the first group is erector spinae plane block group. the second one is thoracal paravertebral block group. the third one is the control group.|t|f|f|t
33851075|NCT04687280|||COHORT||RETROSPECTIVE|||||||
33851076|NCT00596193|||CASE_CONTROL||PROSPECTIVE|||||||
33955381|NCT06703827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The chief investigator will be responsible for administering baseline outcome measures but not facilitating the MCT group sessions to minimize the potential for bias. Consequently, the assessment after the intervention will be performed in a fully blind manner. Participants will be reminded not to reveal their group status to the post-intervention assessor in order to maintain the blinding.|The proposed study is an experimental, multi-centre trial aiming to investigate the impact of online MCT group on participants' persecutory delusions and cognitive biases in Early Intervention for Psychosis Service in Kent. Participants will be allocated randomly to either MCT group or Treatment as Usual Group (TAU) and these two groups will be compared to each other. This study will use an online survey called Qualtrics (Qualtrics, Provo, UT) that will include quantitative measures that participants will be asked to complete.|f|f|t|t
33955382|NCT02215434|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955383|NCT01351194|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33955384|NCT04546737|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33955385|NCT02317523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955386|NCT00679094|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33955387|NCT02163278|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33955388|NCT00056537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955389|NCT04419701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33955390|NCT06651723|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||The study will be blind randomized crossover clinical trial of 2 months' duration. The randomization will occur at day 0, followed by the 1st phase (30 days), a washout period of 21 days, and finally the 2nd phase (30 days).|f|f|f|t
33955391|NCT00216424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955392|NCT03374566|||COHORT||PROSPECTIVE|||||||
33955393|NCT02414490|||COHORT||PROSPECTIVE|||||||
33955394|NCT06079437|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33955395|NCT05272267|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33955396|NCT00080925||||TREATMENT||||||||
33955397|NCT00391118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955398|NCT02539472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059346|NCT04147624|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34059347|NCT03362138|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059348|NCT06507631|||CASE_ONLY||PROSPECTIVE|||||||
34059349|NCT00868491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059350|NCT04561024|||COHORT||RETROSPECTIVE|||||||
34059351|NCT01619540|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34059352|NCT05415371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059353|NCT06452745|||COHORT||CROSS_SECTIONAL|||||||
34059354|NCT06441760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All participants will be blinded to the simulated transport scenarios.|Single blind, parallel arm, multicenter simulation RCT of prehospital teams from 9 Pediatric Emergency Care Applied Research Network (PECARN) and non-PECARN sites|f|f|f|t
34059355|NCT03035006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059356|NCT06504771|||COHORT||CROSS_SECTIONAL|||||||
34059357|NCT00241124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34059358|NCT02059434|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34059359|NCT04584190|||CASE_ONLY||RETROSPECTIVE|||||||
34059360|NCT03407183|||COHORT||PROSPECTIVE|||||||
34059361|NCT04467190|||CASE_CROSSOVER||PROSPECTIVE|||||||
34163629|NCT06725745|||COHORT||PROSPECTIVE|||||||
34163630|NCT05698277|||COHORT||PROSPECTIVE|||||||
34163631|NCT01181466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163632|NCT06540144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163633|NCT06533579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059362|NCT06079762|NA|SINGLE_GROUP||TREATMENT||NONE||single-group feasibility/acceptability, stage I (NIH stage model for behavioral intervention development)||||
34059363|NCT01503398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163634|NCT04967196|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163635|NCT05088057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163636|NCT02203994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163637|NCT03387865|||CASE_ONLY||PROSPECTIVE|||||||
34163638|NCT00280527|||CASE_CONTROL||PROSPECTIVE|||||||
34163639|NCT05763576|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34163640|NCT04320355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||An exploratory descriptive design with before and after measurements.||||
33851077|NCT03373201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851078|NCT00827320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851079|NCT01614431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851080|NCT05015933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851081|NCT01619397|NA|SINGLE_GROUP||OTHER||NONE||||||
33851082|NCT00002332||||TREATMENT||DOUBLE||||||
33851083|NCT03284047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851084|NCT04320706|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|t
34163641|NCT03372967|||COHORT||PROSPECTIVE|||||||
34163642|NCT02591108|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163643|NCT05659927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subcutaneous injections were 52.5 mg, 105 mg, 210 mg and 420 mg, respectively. Four patients were included in the 52.5 mg dose group (2 in the drug group and 2 in the placebo group). There were 10 cases in the other 3 dose groups (8 cases in the drug group and 2 cases in the placebo group). In accordance with the principle of dose increment, from low dose to high dose.|t|t|t|t
34163644|NCT06727162|||CASE_ONLY||RETROSPECTIVE|||||||
34059364|NCT06521580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059365|NCT00000710||||TREATMENT||NONE||||||
34163645|NCT06726863|RANDOMIZED|SEQUENTIAL||OTHER||NONE||This is a 4-treatment period study that uses three different models: Treatment Period 1 will be a single-arm model, Treatment Period 2 will be a parallel-group model, and Treatment Periods 3 and 4 will be crossover models.||||
34163646|NCT02277444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163647|NCT01569620|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34163648|NCT05958849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163649|NCT05054998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163650|NCT04198480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163651|NCT05596604|||OTHER||CROSS_SECTIONAL|||||||
33746507|NCT01810588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746508|NCT03776136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746509|NCT04480112|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|Trial investigators and outcome assessors will be blind to the treatment randomization and allocation..|"The investigators will employ an AB/BA crossover design (2-sequence, 2-period, 2-treatment design) where A will be the intervention phase and B will be the passive control phase. Each period will have a duration of 1 month. Assessment of the primary outcome will be done at the end of each period. Since this is a study of a behavioral intervention, 4-week washout period will suffice to observe an acute change in cognitive performance without significant carryover effects.~To avoid imbalance among groups, randomization will be stratified by cognitive syndrome diagnosis (healthy older adult, mild cognitive impairment and mild dementia). Participants will be randomized to the treatment sequences using a 1:1 allocation ratio."|f|f|f|t
33746510|NCT01865591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746511|NCT05734508|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746512|NCT01765634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746513|NCT03750318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients recruited will be wearing the Aingeal device as part of an integrated monitoring with opioid delivery system at ward setting.||||
33746514|NCT04211714|NA|SEQUENTIAL||TREATMENT||NONE||||||
33746515|NCT02356380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746516|NCT03950765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746517|NCT01026974|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746518|NCT03152747|||OTHER||PROSPECTIVE|||||||
33746519|NCT00059800|NON_RANDOMIZED|||TREATMENT||||||||
33746520|NCT06630299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746521|NCT02188433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33746522|NCT00611143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746523|NCT03540927|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only outcome assessors will be blind to allocation status of the participants.||f|f|f|t
33746524|NCT05930327|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746525|NCT05225818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746526|NCT05754450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746527|NCT06028230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746528|NCT00264615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33746529|NCT04479618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|off-site wound experts and the local physicians verifying wound closure and/or complications will be blinded to the randomization group|A targeted-blinded, randomized controlled trial|f|f|f|t
33746530|NCT05832437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patient participants, data collectors, and the statistician will be blinded to assignment. Consent materials will inform patient participants that the focus of the trial is on the communication they have with their clinician about asthma management and control. Immediately after the intervention, patient participants will be asked to guess the condition to which their clinician had been randomized. At the end of participants' final data collection visit, data collectors will be asked to guess whether participants had received the active or control intervention at the visit. These data will provide some measurement of the success of masking.||t|f|f|t
33746531|NCT01734681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746532|NCT04831736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746533|NCT06108622|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33851085|NCT00359216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851086|NCT05528029|||COHORT||RETROSPECTIVE|||||||
33851087|NCT04068766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851088|NCT03704246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059366|NCT06623799|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34059367|NCT05125952|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059368|NCT06623669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059369|NCT03168919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||One arm study||||
34059370|NCT05131087|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
34059371|NCT03803228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059372|NCT04502355|||COHORT||PROSPECTIVE|||||||
34059373|NCT00497978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34059374|NCT00339196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059375|NCT01818206|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059376|NCT03425357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076284|NCT02017275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163652|NCT04519463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both Xylocaine spray and Placebo (saline) will be in similar containers with serial numbers, Both clinician and patient are blinded to the content.|Double-Blind Randomized Controlled Trial|t|f|t|f
34163653|NCT01726582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163654|NCT06272708|||COHORT||CROSS_SECTIONAL|||||||
34163655|NCT02949999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851089|NCT01065844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851090|NCT02322164|||COHORT||CROSS_SECTIONAL|||||||
33851091|NCT00662506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851092|NCT00203762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851093|NCT00518492|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851094|NCT01183260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851095|NCT02668484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851096|NCT00901823|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851097|NCT01376427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851098|NCT02516020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851099|NCT06140706|NA|SINGLE_GROUP||OTHER||NONE||||||
33851100|NCT04138693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851101|NCT03580005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851102|NCT05258045|||COHORT||OTHER|||||||
33851103|NCT00757341|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851104|NCT06072508|NA|SINGLE_GROUP||OTHER||NONE||||||
33851105|NCT06444230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851106|NCT00500773|||COHORT||PROSPECTIVE|||||||
33851107|NCT06292962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|a randomized, double-blinded, sham-controlled, parallel group clinical trial||t|t|t|t
33955399|NCT04218175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The researcher who performed shear wave elastography did not know which group the case was evaluated during the measurement.|f|f|f|t
33955400|NCT00397904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955401|NCT05968924|NA|SINGLE_GROUP||SCREENING||NONE||||||
33955402|NCT00359359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955403|NCT03083639|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33955404|NCT04837274|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33955405|NCT05649423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955406|NCT05397119|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All IN study vaccines are milky white in appearance. Vaccinators will be unblinded to vaccine allocation, but they will have no role in assessment of vaccine safety or immunogenicity. Only the vaccine compounding personnel, the unblinded vaccinator, and the study statistician will have access to the randomization code prior to study completion. Unblinding procedures are described in the Manual of Operations.|"Participants will be randomized to receive BW-1014 in 3 different dose levels (25 µg, 50 µg or 100 µg rH5 in NE adjuvant), using a pipette dropper. Control arms include rH5 alone (without NE adjuvant) or placebo (saline) control.~Since this is first in humans, a dose escalation assessment will take place. A sentinel group of 2 participants from the lowest dose (25 µg rH5 in NE) with 2 rH5 control and 2 placebo control will be dosed first before proceeding to the next dose level. Each escalation of dose will take place after safety clearance of the prior lower dose level. Dosing of the remainder of subjects per dose arm will take place after safety clearance of the corresponding dose sentinel participants."|t|t|t|t
33955407|NCT00606996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955408|NCT02453282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955409|NCT05134740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059377|NCT04237558|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparison between laparoscopic hysterectomy versus non-descent vaginal hysterectomy using bipolar vessel sealers in patients with abnormal uterine bleeding||||
34059378|NCT01045083|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34059379|NCT05105828|||CASE_CONTROL||RETROSPECTIVE|||||||
34059380|NCT04489875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851108|NCT02383004|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33851109|NCT04684407|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33851110|NCT06178081|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Our study will include 50 people with periodontitis and 50 healthy periodontal patients (100 individuals in total), and these two groups will be divided into two as smokers and non-smokers. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and gingival cerevicular fluid will be taken from all individuals at the beginning of the study. Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and gingival crevicular fluid will be repeated 12 weeks after the treatment. IL-39 analysis will be performed by ELISA in saliva and gingival crevicular fluid of individuals. IL-39 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis.|f|f|t|f
33851111|NCT03605173|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33851112|NCT01277393|||CASE_ONLY||PROSPECTIVE|||||||
33851113|NCT00484458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851114|NCT05105451|||COHORT||PROSPECTIVE|||||||
33851115|NCT06594783|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Carvedilol plus EVL group:~Participants will take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.~Carvedilol alone group:~Patients will take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable)."||||
33851116|NCT06609811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851117|NCT01553773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851118|NCT02592993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851119|NCT04268290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851120|NCT03866291|||COHORT||PROSPECTIVE|||||||
33851121|NCT02641496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The Outcomes Assessor will be masked so as to not influence the 12 month outcome variables.||f|f|f|t
33851122|NCT04637854|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851123|NCT03219515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851124|NCT01198756|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33851125|NCT03143946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851126|NCT01085266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851127|NCT03510585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851128|NCT01893931|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33955410|NCT02133911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955411|NCT01396499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851129|NCT00196976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33851130|NCT04206033|||CASE_ONLY||PROSPECTIVE|||||||
33851131|NCT05977504|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851132|NCT05893628|||OTHER||PROSPECTIVE|||||||
33851133|NCT00641329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851134|NCT01074216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851135|NCT00605215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851136|NCT05357430|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33955412|NCT02861729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||split-mouth design|t|f|f|t
33955413|NCT00646607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955414|NCT03466060|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33955415|NCT05838352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955416|NCT05260307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|While participants will not be informed about the specific experimental condition being tested, certain acoustical changes may be perceptible to them and thus strict masking is impossible.|All participants will be tested under a number of experimental conditions that simulate different hearing aid conditions. They will act as their own control.||||
33955417|NCT05517707|||COHORT||PROSPECTIVE|||||||
33955418|NCT06396247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization|We hypothesize that patients assigned to FAST will improve these outcomes significantly more than those assigned to DTC and that FAST participants with higher levels of perceived exertion and adherence will improve these measures the most.|t|f|t|f
33955419|NCT00941681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955420|NCT04969263|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label, non-randomized.||||
33955421|NCT04942964|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33955422|NCT05535842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|non-blinded|open-label, two-armed, randomized controlled trial||||
33955423|NCT03114527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955424|NCT05217901|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059381|NCT01272401|||CASE_ONLY||PROSPECTIVE|||||||
34059382|NCT01157000|NA|SINGLE_GROUP||||NONE||||||
34059383|NCT06385691|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective, single-center, single-arm Phase II study.||||
34059384|NCT04116723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851137|NCT01870232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851138|NCT01039623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851139|NCT02274532|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33851140|NCT00574613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33851141|NCT04893265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial||||
33851142|NCT02932566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851143|NCT02947893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851144|NCT00000241||||TREATMENT||||||||
33851145|NCT00351663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851146|NCT06417567|||COHORT||PROSPECTIVE|||||||
33851147|NCT01683734|||COHORT||PROSPECTIVE|||||||
33955425|NCT02723786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059385|NCT02262598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059386|NCT04543097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants, their treating clinicians and VSWs cannot be blinded to allocation due to the nature of the intervention. The data will be analysed independently by two statisticians one of whom will be blinded to intervention allocation the other statistician will be unblinded to allow intervention delivery details to be reported to the Trial Steering Committee (TSC) / Data Monitoring Committee (DMC) if required.||f|f|t|t
34059387|NCT06649487|||OTHER||PROSPECTIVE|||||||
34059388|NCT06230029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059389|NCT06083688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Students will be randomized to three arms Arm 1: intermittent preventive treatment with dihydroartemisinin-piperaquine (IPTsc-DP); Arm 2: intermittent preventive treatment with sulfadoxine-pyrimethamine plus amodiaquine (IPTsc-SPAQ); Arm 3 the control arm. Females 13 years and older (likely post-menarche) in Arms 1 and 2 will receive chloroquine alone.|f|f|f|t
34059390|NCT05519059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059391|NCT01846884|||COHORT||PROSPECTIVE|||||||
34059392|NCT03717051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059393|NCT02535351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059394|NCT06270017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluation of patients derived colon cancer tumour cell growth in zebra fish embryos and response evaluation of combinations of chemotherpy||||
34059395|NCT00825526|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34059396|NCT04622761|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two arm, phase II randomised multi-centre trial. 120 patients will be recruited to the trial. Patients will be randomised to a control arm of immediate surgery or a treatment arm in a ratio of 1:2 (control 40pts: treatment 80pts). Patients in the treatment arm will receive hormonal treatment and Cabazitaxel 25 mg/m2 day 1 intravenously over one hour every 21 days. Treatment will be continued for 4 cycles (3 months) unless disease progression, unacceptable toxicity or patient request.||||
34059397|NCT00648505|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34059398|NCT02018354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34059399|NCT02696447|||COHORT||PROSPECTIVE|||||||
34059400|NCT02106702|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34059401|NCT00357838|||||OTHER|||||||
34059402|NCT04908904|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34076285|NCT05915273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076286|NCT05183334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34076287|NCT02683980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076288|NCT02351401|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34076289|NCT03258801|||COHORT||PROSPECTIVE|||||||
34076290|NCT04245592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Patients were blinded to the kind of olive oil consumed using unlabeled bottles.~A coding number in the blood samples of the patients were used to blind the Investigators."||t|f|t|f
34076291|NCT01683604|||COHORT||PROSPECTIVE|||||||
34059403|NCT06128785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both groups will use adhesive pads, and the sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group.~All study patients will be treated independently and separately, ensuring that patients will not come into contact with each other. To test the effectiveness of blinding of participants, two hospitals will be selected from for blinded success assessment."|"Needles: Huatuo brand disposable acupuncture needles φ0.25×40mm (1.5 inch); needles are purchased from Suzhou Medical Supplies Factory Co.~Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37), lasting 30 min each time.~Postoperative electroacupuncture stimulation method: all acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to the electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation will be given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal discharge or until the fourth day."|t|f|f|t
34059404|NCT03256292|||COHORT||CROSS_SECTIONAL|||||||
34059405|NCT02848274|||COHORT||PROSPECTIVE|||||||
34059406|NCT00081731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059407|NCT02631746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059408|NCT01904318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059409|NCT03207074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163656|NCT02914405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163657|NCT00363636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163658|NCT04201106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34163659|NCT04708834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163660|NCT04524234|||COHORT||PROSPECTIVE|||||||
34163661|NCT06177600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to an Immediate Arm (access to a digital platform, plus usual care) or a Deferred Arm (usual care; access to the digital platform at 6 mo). Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline. For each Arm, the intervention period will last 6 months, followed by 9 months of observation, during which access to the intervention is maintained. Assessments will be performed every 3 months over the 15 month period to document changes in mental health outcomes and the two groups will be compared.||||
34163662|NCT04862247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163663|NCT05706571|RANDOMIZED|FACTORIAL||OTHER||SINGLE||Nicel ve nitel verilerin oluşturulmasında ikisi deney ve biri kontrol grubu olmak üzere üç grupta oluşacaktır. Araştırmanın deney ve kontrol grupları oluşturulurken seçkisiz, yansız seçim yapılarak gruplar arasında homojenlik sağlanması planlanmaktadır. Arttırılmış gerçeklik ve Benner modeli ile öğretimin hemşirelik öğrencilerinin çocuk hasta yaşam sonu bakım modülünü deney ve kontrol gruplarına herhangi bir uygulama yapmadan önce ön test yapılması planlanmaktadır. Son testler ise kontrol grubuna; klasik öğrenme, deney 1 grubuna; Benner'n Acemilikte Uzmanlığa Modeline göre simülasyon sonrası, deney2 grubuna ise mobil arttırılmış gerçeklik uygulaması sonrası son testlerin yapılması planlanmaktadır.|t|f|f|f
34163664|NCT06652958|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163665|NCT01818596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163666|NCT05864326|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, randomized, two-arm, controlled trial, including women requiring cervical ripening during the process IOL using Balloon catheter||||
34163667|NCT02506634|||COHORT||PROSPECTIVE|||||||
34163668|NCT02458573|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34163669|NCT03725384|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163670|NCT05234957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746534|NCT04134442|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33746535|NCT06184984|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33746536|NCT02156674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746537|NCT00392561|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33746538|NCT06634589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746539|NCT01562756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746540|NCT02451800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746541|NCT01126593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33746542|NCT02501343|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33746543|NCT01899846|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33746544|NCT04781153|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The preventive intervention - professional tooth cleaning - cannot be blinded, but the outcome measure (lung function tests) are blinded for the operator/investigator.|"This is a single-blinded longitudinal intervention study with two study groups. The participants will act as their own control as they enter the study with the same periodontal diagnose and receive the same periodontal treatment during the study period. The study does not aim to explore the effect of the periodontal treatment itself, but how removal of oral bacteria affects lung function. After randomization the participants in the first study arm will be moved directly into an active periodontal treatment phase including a scaling and rootplaning with adjunctive chlorhexidine. The second study arm will receive the intervention 3-4 weeks after the first study group - as a delayed intervention group. At the first appointment they will receive prophylactic periodontal treatment and oral hygiene instructions. This will enable comparison between the immediate intervention group with the delayed intervention (oral hygiene motivation), which serves as the control group."|f|t|t|f
33746545|NCT03579745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746546|NCT00547391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746547|NCT04302857|||COHORT||PROSPECTIVE|||||||
33955426|NCT03187899|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patient will be blinded as to which block they receive to prevent bias. The Attending performing/overseeing the block will not be blinded to which block is being performed.|"Participants will be randomized to receive either an interscalene brachial plexus block plus sham superficial cervical plexus block or an interscalene brachial plexus block plus a superficial cervical plexus block. The patient will be blinded as to which block they receive to prevent bias. The Attending performing/overseeing the block will not be blinded to which block is being performed. Patients receiving a traditional interscalene block and a sham superficial plexus block with 5-10cc of normal saline N = 20. Patients group receiving both an interscalene and a superficial plexus block N = 20."|t|f|f|f
34059410|NCT04660318|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34059411|NCT01272141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059412|NCT05542667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059413|NCT05044949|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The study is double-blind and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.|Double-blind, randomised, placebo-controlled, parallel-group study|t|t|t|t
34059414|NCT03191136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, single dose, cross-over clincial trial||||
34059415|NCT03273725|||OTHER||PROSPECTIVE|||||||
34059416|NCT02386930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059417|NCT06240533|||COHORT||OTHER|||||||
34059418|NCT01619306|||COHORT||CROSS_SECTIONAL|||||||
34059419|NCT02622841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059420|NCT01058759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059421|NCT02340611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059422|NCT01454843|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163671|NCT03214354|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II pilot, non-randomized, prospective study to evaluate the safety and efficacy of a nonmyeloablative conditioning allogeneic stem cell transplantation for patients with sickle cell disease who have a matched related major ABO-incompatible donor.||||
34163672|NCT04494620|RANDOMIZED|PARALLEL||SCREENING||NONE||The control group received standard of care while the intervention group received 3 rounds of screening with visual inspection, each 3 years apart. At the 9th year of the study, once significant oral cancer mortality reduction following 3 rounds of screening among the high-risk subjects in the intervention arm was confirmed, the control arm was offered 1 round of screening with visual inspection while the intervention group was offered a 4th round of screening.||||
34163673|NCT06357039|||OTHER||CROSS_SECTIONAL|||||||
34163674|NCT03335410|||COHORT||PROSPECTIVE|||||||
33851148|NCT02891317|||COHORT||PROSPECTIVE|||||||
33851149|NCT02641860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851150|NCT02740374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059423|NCT03161249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blind evaluators|This is an experimental, randomized and longitudinal study of repeated measures with independent groups (Treatment group or experimental group: EG and control group: CG) which includes pre and post treatment and 6 months follow-up. This randomized clinical trial includes blind evaluators.|f|f|t|f
34059424|NCT01192113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059425|NCT01060878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059426|NCT01952080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059427|NCT01200459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059428|NCT02124759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163675|NCT03343626|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33746548|NCT02544243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746549|NCT06161844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851151|NCT02706132|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851152|NCT05834777|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|For the procedure of the cross-over main study, both participating sites will recruit patients that will be randomized through a centralized randomization key to ensuring an equally balanced allocation of patients to the respective cross-over groups (icatibant or placebo). All study personnel will be blinded except the IDS pharmacy.|"Randomized, placebo-controlled, cross-over study, with a pharmocokinetics evaluation phase.~Study duration for main cross-over study: Approximately 60 days including screening evaluation activities."|t|t|t|t
34059429|NCT01018381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059430|NCT02278367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059431|NCT04875026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study is investigator-blinded||f|f|t|f
34059432|NCT01135069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059433|NCT00756600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059434|NCT05882695|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blinded|Phase 1 randomized, double-blind, placebo-controlled, single, and multiple ascending dose study in HV and a repeat dose expansion in ALS cohort(s)|t|t|t|t
34059435|NCT01472757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059436|NCT02934087|RANDOMIZED|CROSSOVER||||NONE||||||
34059437|NCT00703287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059438|NCT03141450|||COHORT||PROSPECTIVE|||||||
34059439|NCT03417024|||COHORT||PROSPECTIVE|||||||
34059440|NCT04747951|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34059441|NCT00759889|||OTHER||PROSPECTIVE|||||||
34059442|NCT01942031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059443|NCT04568525|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Randomized clinical trials|t|f|f|f
34059444|NCT05382195|||CASE_ONLY||RETROSPECTIVE|||||||
34076292|NCT01747499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076293|NCT01624480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163676|NCT03590314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind RCT with two parallel group|f|f|t|f
34163677|NCT06723665|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34163678|NCT05919511|||COHORT||PROSPECTIVE|||||||
34163679|NCT01131910|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163680|NCT03420872|||COHORT||PROSPECTIVE|||||||
34163681|NCT01940757|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163682|NCT06385366|||COHORT||PROSPECTIVE|||||||
33851153|NCT05932745|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants will be given a nicotine containing e-cigarette that could have various levels of cooling flavoring. Participants will not be told the nicotine concentration of the product or the type or concentration of the added coolant or what order it is presented in. Investigator and research assistant (i.e. care provider) will know the doses of nicotine and coolant, but will not know what order coolants are presented to participants.|All participants receive all 15 study conditions.|t|t|t|f
33746550|NCT04976738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851154|NCT00589589|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33746551|NCT03506516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33746552|NCT05983601|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Parallel controlled randomized double blind study|t|f|t|f
33851155|NCT01928251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851156|NCT04085965|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851157|NCT04442880|||COHORT||RETROSPECTIVE|||||||
33851158|NCT00283127|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33746553|NCT06448871|||CASE_ONLY||CROSS_SECTIONAL|||||||
33746554|NCT05932069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746555|NCT01863277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33746556|NCT04348604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955427|NCT03423914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|random allocation of the mother to the control or intervention group|Mixed study, where the quantitative and qualitative. From the quantitative is an experimental study type controlled clinical trial. From the qualitative it will be interpretive phenomenological|t|t|f|f
33955428|NCT04776135|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33955429|NCT00489684|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33955430|NCT04132102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746557|NCT05135910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851159|NCT03168607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851160|NCT06234878|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851161|NCT05839015|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955431|NCT00367601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955432|NCT05104268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects will then be randomized into two groups. Group 1 will continue standard therapy with oral topical agents for oral mucositis. Group 2 will additionally receive Bocaliner™ devices along with cleaning materials with instructions about device use and cleaning. Subjects in the Group 2 will use Bocaliner™ with each topical treatment for oral mucositis up to 5 times per day for 2 weeks or shorter if not tolerated.||||
33955433|NCT05187507|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33955434|NCT05196802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955435|NCT01922635|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33955436|NCT01544374|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33955437|NCT01900353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33955438|NCT04898790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor completing primary outcome testing during the RCT in Aim 3 will be blinded.|"Aim 1 will seek feedback from 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members for preliminary adaptation of the evidence-based physical activity intervention (CHAMPS-II) manual, and development of study materials.~Aim 2 will iteratively adapt and implement CHAMPS-II for adults 60 years and older undergoing HCT with feedback from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.~Aim 3 will take the final CHAMPS-II adaptation from Aim 2 and pilot test it, using a Type 1 hybrid effectiveness-implementation design to determine its preliminary effectiveness to improve cognitive function compared to a wait-list control condition. Feedback will be obtained on the intervention and control condition from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members."|f|f|f|t
33955439|NCT05420636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955440|NCT04187469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955441|NCT05243810|NA|SINGLE_GROUP||TREATMENT||NONE|Patients will be assigned an internal ID number|A prospective, single-arm, repeated measures study feasibility study will be coordinated by the Lawson Health Research Institute on the use of EPC Silver Wound Gel (EPC-123) in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study.||||
33955442|NCT00317031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33955443|NCT03915041|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33955444|NCT05883527|||OTHER||RETROSPECTIVE|||||||
33955445|NCT00803530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955446|NCT05581797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955447|NCT05859126|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33955448|NCT04950673|||COHORT||PROSPECTIVE|||||||
33955449|NCT03965026|||COHORT||RETROSPECTIVE|||||||
33955450|NCT06650267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163683|NCT00986843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163684|NCT05697341|RANDOMIZED|PARALLEL||TREATMENT||NONE||90 Patients were enrolled from the outpatient urology clinic of Ain Shams University hospital (Demredash Hospital) randomized to either Group A Ultra-Mini-Percutaneous nephrolithotomy group or Group B stented SWL group via the closed envelope method.||||
34163685|NCT05373862|NA|SINGLE_GROUP||OTHER||NONE||||||
34163686|NCT06627283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163687|NCT00312026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34163688|NCT04486378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163689|NCT06726252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163690|NCT05608538|||COHORT||PROSPECTIVE|||||||
34163691|NCT05658588|NA|SINGLE_GROUP||TREATMENT||NONE||a two-stage plan by Simon||||
33746558|NCT05078190|||COHORT||PROSPECTIVE|||||||
33746559|NCT06182787|||OTHER||PROSPECTIVE|||||||
33746560|NCT03892772|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34059445|NCT03757637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study was not fully blinded; however, the group allocation was concealed from the patient and primary researcher until after baseline assessments were completed. A primary researcher obtained patient consent, collected selfreported assessments, and if the patients were randomized to intervention group, the intervention trainer explained the exercise program to participants. The study statistician and data managers remained blinded at all times.|There are various models of SCP, in general, the primary care physician model or nurse-led model are generally being recognized for effective detecting patients' distress and recurrences, effective coordination and communication, and taking SCP as standard cancer care. In Taiwan, we take a large number of advanced DTC patients, it is important to integrate the SCP but also need to concern about the limited time in busy OPD clinics and patients' differences because of various physical or psychological conditions and needs. We will build up the contents and operable programs for two interventions groups: NLSCP and ICT supported HAP.|f|t|t|t
34059446|NCT06618807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To ensure balanced allocation across trial groups, the trial will employ a block randomization method with a block size of 4. This method generates balanced combinations (TTCC, TCTC, TCCT, CTTC, CTCT, CCTT), from which blocks will be randomly selected to assign the 60 participants evenly, with 30 participants per group. Randomization will be performed using a computer-generated process, and an independent Research Assistant will manage this to maintain blinding for participants, study investigators, and data analysts. Unblinding will occur only in the case of patient emergencies or at the end of the trial. This approach ensures that each participant is assigned to either the sham or active treatment group in a 1:1 ratio, while maintaining the integrity of the trial and reducing potential biases.|The trial is a randomized, double-blind, sham-controlled trial designed to evaluate the efficacy of transcranial photobiomodulation (tPBM) in improving cognitive function among patients with MCI. Participants will be randomly assigned in a 1:1 ratio to receive either active tPBM treatment or a sham treatment. The trial will evaluate the effects of home-based tPBM sessions daily 6 days/week over 8 weeks on mitochondrial function via Blood-based and Neuroimaging biomarkers in patients with MCI.|t|t|t|t
34059447|NCT00329641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059448|NCT04437472|||COHORT||PROSPECTIVE|||||||
34059449|NCT06424600|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059450|NCT03024528|||COHORT||PROSPECTIVE|||||||
34059451|NCT02744027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059452|NCT01784341|||CASE_CONTROL||PROSPECTIVE|||||||
34059453|NCT00653302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059454|NCT03111199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059455|NCT01465633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34059456|NCT00606840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059457|NCT06130124|||CASE_ONLY||PROSPECTIVE|||||||
34059458|NCT01550016|||COHORT||PROSPECTIVE|||||||
34059459|NCT04448600|||CASE_ONLY||PROSPECTIVE|||||||
34059460|NCT06648161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34059461|NCT00929474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059462|NCT06500923|||COHORT||PROSPECTIVE|||||||
34059463|NCT04561297|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Measurements are made prior to the biopsy determination of whether tumor is benign or malignant|Patients scheduled for biopsy of the breast||||
34059464|NCT01897610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059465|NCT01617772|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34059466|NCT01117675|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34059467|NCT03248518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34059468|NCT05500482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The control arm will not receive a vaccine, however the investigator and the outcome assessors will be trained not to seek history of vaccination. The clusters selected for vaccination and their boundaries will not be accessible to the investigators and outcome assessors.||f|f|t|t
34059469|NCT04676685|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34059470|NCT03157739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059471|NCT00585715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851162|NCT02290132|||CASE_ONLY||PROSPECTIVE|||||||
33851163|NCT03231631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851164|NCT03053154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33851165|NCT01383499|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33851166|NCT02275832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851167|NCT03454698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851168|NCT03825926|||COHORT||PROSPECTIVE|||||||
33851169|NCT04351737|NA|SINGLE_GROUP||TREATMENT||NONE||In patients who undergo bilateral pterygium surgery, eyes will be randomized to receive either DEXTENZA at baseline, Month 1 and Month 2 or prednisolone x 3 months. Both eyes will receive antibiotic drops four times per day for two weeks and Maxitrol ointment at bedtime for two weeks following surgery.||||
33851170|NCT04793659|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Periods 1 and 2 of the open-label phase will be unblinded.~Periods 3 and 4 are double-blind crossover phases."|Combined Open-Label and Double-Blind, Placebo-Controlled Crossover|t|t|t|t
33851171|NCT04486326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851172|NCT00353769|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33851173|NCT04041674|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33955451|NCT04179578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization process is initiated after general anesthesia is induced and the group affiliation will be determined by opening of a sealed envelope specifying the group assignment. The information of group allocation is stored in a closed envelope kept in a locked archive until the study is completed.|"Crura plastic or crura plastic with the addition of lateral release"|t|f|t|t
34059472|NCT05447676|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants will not know if they receive 4-AP or placebo over the course of the study and the investigators are also blinded except for PI (Dr. Monica Perez).|Arm 1 and 2 will be studied with randomized crossover design; Participants for Arm 3 will be recruited after finishing the sessions for Arms 1 and 2. Participants who were finished the Arms 1 and 2 study procedures can also participate in Arm 3 study procedures.|t|t|f|t
34059473|NCT01087580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955452|NCT03885648|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955453|NCT05237674|RANDOMIZED|PARALLEL||PREVENTION||NONE||Fifteen of thirty municipal primary and lower secondary schools with one or more classes in grade 4-10 will be randomly assigned to the TEACHOUT intervention. Classes within the other 15 schools will act as controls and continue their teaching as usual. Teachers of the participating classes in the waitlisted control schools will be offered the intervention once the trial is finished.||||
33955454|NCT05156164|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Parallel Assignment|t|f|f|t
33955455|NCT02866695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955456|NCT03855462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955457|NCT02466776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955458|NCT03312881|||COHORT||PROSPECTIVE|||||||
33955459|NCT06061848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059474|NCT00322361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059475|NCT03449394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059476|NCT03556293|RANDOMIZED|FACTORIAL||PREVENTION||NONE||2x2 factorial cluster randomized trial||||
34059477|NCT06461351|||OTHER||PROSPECTIVE|||||||
33746561|NCT05409014|NA|SINGLE_GROUP||TREATMENT||NONE||This was a single-group clinical trial evaluating the effect of pelvic floor muscle training in incontinent women who exercise.||||
33746562|NCT02535208|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33746563|NCT03487835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746564|NCT04728243|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33746565|NCT00982358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746566|NCT05892354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746567|NCT04223193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746568|NCT06312839|||COHORT||RETROSPECTIVE|||||||
33746569|NCT03222518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"study medications consists of identical shape pills of each study medication randomization is made by sealed envelops and a randomly sequence generated numbers.~patients and the research associate who collected the outcome data are blinded from the study group"|"Subjects are randomized in 3 arms:~* paracetamol group~* NSAID group~* paracetamol + NSAID group"|t|f|f|t
33746570|NCT04006977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746571|NCT01417312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33746572|NCT04846608|||CASE_CONTROL||RETROSPECTIVE|||||||
33746573|NCT00546728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955460|NCT01626794|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33955461|NCT01591499|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33955462|NCT04394572|||OTHER||CROSS_SECTIONAL|||||||
33746574|NCT04561479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33955463|NCT01615757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955464|NCT02689986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955465|NCT03503201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33955466|NCT02791607|||COHORT||PROSPECTIVE|||||||
33955467|NCT02610842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955468|NCT01753973|||COHORT||PROSPECTIVE|||||||
33955469|NCT01851343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955470|NCT05125822|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single group study that will consist of two interventions: an 8-week meal replacement therapy period in which participants are asked to reduce their body mass index (BMI) by \>/= 5% by following a prescribed eating regimen and standardized lifestyle/behavior modification counseling which will occur every 2 weeks throughout the study.||||
33955471|NCT04206436|||CASE_ONLY||PROSPECTIVE|||||||
33955472|NCT05351437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind study where participants are blinded.|"Single-blind, placebo-controlled study in healthy volunteers. The trial will comprise four dose cohorts, each composed of 6 participants receiving MTx-COVAB36 and 2 participants receiving placebo, with pre-defined dose levels.~The predefined investigational medicinal product (IMP) doses are: 100 mg, 500 mg, 1,000 mg and 2,000 mg, respectively. Participants will be randomized into study arms (MTx-COVAB36 or placebo)."|t|f|f|f
33955473|NCT05552430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955474|NCT02545868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33955475|NCT03979339|NA|SINGLE_GROUP||OTHER||NONE||||||
33955476|NCT02139930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33955477|NCT04043052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955478|NCT05080218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955479|NCT00000705||||TREATMENT||NONE||||||
33955480|NCT06436469|NA|SINGLE_GROUP||TREATMENT||NONE||The model for this study is a single-group pretest-posttest design.||||
33955481|NCT03130777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single arm, prospective, multi-center study||||
33955482|NCT00738244|||CASE_CROSSOVER||PROSPECTIVE|||||||
33746575|NCT03929146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059478|NCT00148213|||||OTHER|||||||
34059479|NCT05595564|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33955483|NCT02379650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955484|NCT06653595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will be use the random.org program to randomize families into two groups: experimental group (which will receive the intervention) and control group (which will receive usual care).The experimental group intervention will include: 1 pre-discharge face-to-face session, 8 home sessions until 4 months, and 3 telephone sessions until the baby is 6 months old. All sessions will be conducted by an Advanced Practice Nurse and IBCLC Expert in breastfeeding issues.||||
33955485|NCT00120380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955486|NCT05755399|NA|SINGLE_GROUP||OTHER||NONE||||||
33955487|NCT05474794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment A non-blinded, single center, non-randomized prospective, case control study||||
33955488|NCT06247579|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The exposure group will use disposable plastic tableware (DPT) made of polystyrene, provided by the hospital canteens for two months||||
33955489|NCT04928794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059480|NCT01627301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059481|NCT00115037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059482|NCT02163616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059483|NCT02268747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059484|NCT06223321|||COHORT||RETROSPECTIVE|||||||
34059485|NCT03125187|RANDOMIZED|CROSSOVER||OTHER||NONE||Hospitalizations for intravenous administration of study medications will occur in two periods (visits 1 and 2) for administration of the drugs, and participants who receive the test medication at visit 1 will receive the comparator medication at Visit 2 and vice versa||||
34059486|NCT02212548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059487|NCT00334802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059488|NCT04893356|||COHORT||RETROSPECTIVE|||||||
34059489|NCT02870842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34059490|NCT06090617|||CASE_CONTROL||PROSPECTIVE|||||||
34059491|NCT02903524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059492|NCT00969956|||CASE_ONLY||PROSPECTIVE|||||||
34059493|NCT03008993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34059494|NCT03415659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059495|NCT05636007|||COHORT||PROSPECTIVE|||||||
34059496|NCT03838406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059497|NCT05463900|||CASE_CONTROL||PROSPECTIVE|||||||
34059498|NCT03957811|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two parallel groups. One will receive the standard treatment for diabetes, and the other will receive standard treatment plus sessions of vibration exercise therapy.||||
34059499|NCT04954716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059500|NCT00847392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059501|NCT01498224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059502|NCT05192408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and study team members who carry out intervention(nurses) will not be masked. Outcome assessors will be study team members from different clinics as participants or study team members who were not involved in intervention, and will thus be unaware of participants' allocated group.||f|f|f|t
34059503|NCT05081557|||COHORT||PROSPECTIVE|||||||
34059504|NCT02707588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059505|NCT06098963|||COHORT||CROSS_SECTIONAL|||||||
34059506|NCT00319033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059507|NCT05074446|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||It will be a 2x2 between-subject factorial design. Simulation CPR scores will be the dependent variable. Being an intensivist or non-intensivist and stereotype threat will be the independent variables of the study. There will be four groups to be compared: intensivist in the experimental group (1), intensivist in the control group (2), non-intensivist in the experimental group (3), non-intensivist in the control group (4).|t|t|t|f
33746576|NCT04050995|||OTHER||PROSPECTIVE|||||||
33746577|NCT01774565|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised parallel (phase 1-3) and randomised crossover (phase 4)||||
33746578|NCT00848679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746579|NCT05969067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746580|NCT00407446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746581|NCT00845572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746582|NCT04695834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"All participants will be asked to wear long trousers to cover a potential scar at the level of the knee.~All patients will be asked to apply a bandage at the site of the operation (or the site of entrapment if there was no operation) Participants are not allowed to discuss their treatment with the outcome assessor."|Prospective Multi-center Randomized Parallel-group|f|f|f|t
33746583|NCT04005183|||OTHER||PROSPECTIVE|||||||
33746584|NCT00749151|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33746585|NCT02700282|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33746586|NCT06636305|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One groups will be assigned to a physical activity intervention, the other group will serve as a control group.||||
34059508|NCT03675295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Investigate if, and to what extent, hydro-dissection using Hyalase versus saline, under ultrasound guidance, can improve the clinical condition, change in nerve conduction parameters of patients with CTS and delay or avoid the surgical intervention.|t|f|f|t
34059509|NCT05572177|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34059510|NCT04709705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, parallel group, active comparator-controlled trial to evaluate the noninferiority or superiority of CPP with LSP in controlling blood loss in patients undergoing CPB surgery.|t|t|t|t
33955490|NCT03914469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research staff conducting outcomes assessments will be blinded to whether the subject is in active or waitlist group|Investigators will assess the feasibility of a tele-delivered behavioral change intervention among older adults (aged 50 and older) with cLBP and depression. Fifty participants will be randomly assigned to one of two groups, behavioral intervention arm (n=25) versus the waitlist control arm (n=25).|f|f|f|t
33851174|NCT05569031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851175|NCT04374357|||COHORT||PROSPECTIVE|||||||
33851176|NCT06203015|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33851177|NCT02516475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851178|NCT05720845|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851179|NCT02072915|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33851180|NCT05402930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955491|NCT04686968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851181|NCT02593266|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851182|NCT06427564|||COHORT||PROSPECTIVE|||||||
33851183|NCT02304146|||COHORT||PROSPECTIVE|||||||
33851184|NCT04375761|||FAMILY_BASED||PROSPECTIVE|||||||
33851185|NCT04253080|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33851186|NCT02632032|NA|SINGLE_GROUP||||NONE||||||
33851187|NCT02944591|||CASE_ONLY||OTHER|||||||
33955492|NCT00816166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955493|NCT00755573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955494|NCT03958877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955495|NCT01939470|||COHORT||PROSPECTIVE|||||||
33955496|NCT01761617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059511|NCT06107270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All the patients will be blinded to group allocation by ensuring that they were unaware of the exercise performed by the other group. To maintain the blinding, the intervention sessions will be delivered separately to members of each treatment group, The allocation will be conducted by another researcher before the baseline.|"Group A (n=15) will be treated by Post Isometric Relaxation, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks).~Group B (n=15) will be treated by DNF training, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks) Group C (n=15) will be treated by Post Isometric Relaxation combined DNF training, infrared radiation and continuous ultrasound for 12 sessions (3 sessions per week for four weeks)"|t|f|f|t
34059512|NCT04543721|||COHORT||PROSPECTIVE|||||||
34059513|NCT03089671|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"Patient packages will be created and assigned a kit number. For those randomized to the vitamin B2 group, the package will consist of a pill of vitamin B2 (100mg riboflavin) inside an opaque gelatin capsule that is matched to a litre bag of normal saline wrapped in an opaque covering. For those randomized to the D5W group, the package will consist of a pill that is a placebo pill (opaque gelatin capsule of microcrystalline cellulose powder) matched to a litre bag of D5W wrapped in an opaque covering. These packages will be coupled with the patient according to her randomization group in the preoperative area.~In the preoperative area, all patients will be given the pill in their package by mouth 60 to 120 minutes before the start of surgery. The covered bag will then accompany the patient to the operating room and will be set up as the instillation fluid for cystoscopy. This way, the patient and operating team will be blinded to the agent used for ureteric visualization."|Double-blinded, randomized controlled trial|t|t|f|f
34059514|NCT00715104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851188|NCT00201227|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851189|NCT06108960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851190|NCT01545154|||COHORT||PROSPECTIVE|||||||
33851191|NCT05442905|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The 3 analgesic twchniques were described to the parents preoperatively and they will agree to give their child either of them and To maintain blinding, postoperative evaluation of pain scores will be done by an anesthesiologist, who will be not involved in administering block.|"Group Q: will receive quadratus lumborum block the patient will be placed in lateral positionGroup T: will receive TAP block with 0.7mL/kg of 0.25% bupivacaine under US guidance. A linear high frequency ultrasound probe (6-13 MHz) will be placed transversely in the mid axillary line between the iliac crest and the costal margin.~Group C: will receive caudal block with 1mL/kg of 0.25% bupivacaine, with children in left lateral position."|t|f|f|t
33851192|NCT05422664|||CASE_ONLY||OTHER|||||||
34059515|NCT00779688|||||PROSPECTIVE|||||||
33851193|NCT04665999|||OTHER||PROSPECTIVE|||||||
33851194|NCT03143166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851195|NCT03674593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind masking (Participant)|Single-center, prospective, semi-open, randomized study|t|f|f|f
33851196|NCT04470232|||COHORT||PROSPECTIVE|||||||
33851197|NCT01571401|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33955497|NCT04268394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955498|NCT06576752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851198|NCT06526013|RANDOMIZED|PARALLEL||PREVENTION||NONE||After randomization into the intervention arm versus control, patients in the intervention group will receive a device for self-measurement and will be trained in its use. Subsequently, these patients will independently measure their cholesterol levels monthly using capillary blood tests and report the results to the study physicians, who will then adjust the therapy accordingly. The control group will attend scheduled visits at months 6 and 12, where medication adjustments can be made, as has been done in the outpatient clinic up to now||||
33851199|NCT00350116|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33851200|NCT06243861|||COHORT||PROSPECTIVE|||||||
33955499|NCT06402890|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Before the intervention commenced, a laboratory technician (independent to the study) made up the dry ingestions all the 30 g doses of hydrolyzed collagen (HC), and calorie matched placebo and stored in sachets. These sachets were labelled as with the participants name. The technician randomly assigned either HC or placebo to participants who were pair matched (Excel 2016, Microsoft, Washington, USA). The groupings and contents of the sachets were unknown to the researcher and the participants, who all remained blinded until data collection and analysis were complete.|Double-blind, placebo-controlled trial|t|f|t|t
33955500|NCT04071457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955501|NCT02766686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955502|NCT05393765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized controlled trial with a two-group pre-test and post-test design|f|f|f|t
33955503|NCT03980561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955504|NCT06649864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955505|NCT00199095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955506|NCT05286931|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort||||
33955507|NCT03763539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33955508|NCT06651203|||COHORT||PROSPECTIVE|||||||
33955509|NCT06650618|||CASE_ONLY||PROSPECTIVE|||||||
33955510|NCT06474351|||CASE_CONTROL||PROSPECTIVE|||||||
33955511|NCT05665712|||COHORT||RETROSPECTIVE|||||||
33955512|NCT00661960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955513|NCT06163209|||CASE_ONLY||PROSPECTIVE|||||||
33955514|NCT06650683|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33955515|NCT02187939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33955516|NCT05427214|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33955517|NCT04650178|||COHORT||OTHER|||||||
33955518|NCT05652491|||COHORT||PROSPECTIVE|||||||
33955519|NCT04469868|NA|SINGLE_GROUP||PREVENTION||NONE||All patients who undergo major urologic oncology surgery will be eligible to be enrolled.||||
33955520|NCT01187615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955521|NCT06257511|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Investigators will record videos of the participants during simulation sessions, before and after the interventions. The people assessing the non-technical skills of the cardiac surgical teams will be masked if the videos were recorded before or after the intervention.|"The goal of this project is to develop and test an intervention to improve the non-technical skills of cardiac surgical teams. The Investigators will develop, pilot test, refine, and assess the preliminary effectiveness of Non-Technical Skills for cardiac Surgery (NOTSCS) intervention on the non-technical skills of participants, operating room (OR) time, and patient post-operative complications (intraoperative bleeding, and unplanned return to the OR.~Investigators will compare the outcomes between the intervention and control groups, before and after the intervention."|f|f|f|t
33955522|NCT03252015|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33955523|NCT03465982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955524|NCT05266131|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955525|NCT00444873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955526|NCT06282029|NA|SINGLE_GROUP||OTHER||NONE||This pilot study includes a pre-/post test of a small intervention sample without control group.||||
33955527|NCT05014139|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955528|NCT03790020|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||3 types of local anesthetic applying method will be compared||||
33955529|NCT04971174|||COHORT||OTHER|||||||
33955530|NCT02218515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955531|NCT03253159|RANDOMIZED|PARALLEL||PREVENTION||NONE||Hypnosis before intravenous anesthesia versus no preparation before intravenous anesthesia||||
33955532|NCT01502267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955533|NCT02159534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33955534|NCT06702267|||OTHER||PROSPECTIVE|||||||
33955535|NCT06271798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955536|NCT06538402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955537|NCT04511975|NA|SEQUENTIAL||TREATMENT||NONE||||||
33955538|NCT04757896|RANDOMIZED|PARALLEL||TREATMENT||NONE|blind surgeon and investigator|Assignment||||
33955539|NCT03244722|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33955540|NCT02666768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955541|NCT00350818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955542|NCT04462354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955543|NCT05053750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059516|NCT00210600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163692|NCT04273893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants, clinical research staff, and treating clinicians will be aware of arm assignment. The labels on research blood will not include the treatment arm on which the participant is assigned and this information will not be provided to lab investigators and staff.||f|f|f|t
34163693|NCT02223338|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33955544|NCT06568406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955545|NCT01518296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955546|NCT00795379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955547|NCT06126523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955548|NCT06379139|||COHORT||PROSPECTIVE|||||||
33955549|NCT04981782|||COHORT||PROSPECTIVE|||||||
34059517|NCT03247764|||COHORT||PROSPECTIVE|||||||
34059518|NCT02089100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851201|NCT05306405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851202|NCT06151223|||COHORT||PROSPECTIVE|||||||
33851203|NCT03606434|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will undergo same 30 minute intermittent hypoxia protocol.||||
33851204|NCT00681460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851205|NCT03266705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33851206|NCT02146326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851207|NCT01477554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33851208|NCT06315504|||COHORT||PROSPECTIVE|||||||
33851209|NCT05100082|||COHORT||PROSPECTIVE|||||||
33851210|NCT01692028|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33955550|NCT02701049|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33955551|NCT06464536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All patients will wear surgical gloves, patients in the control group will wear gloves of the correct size with a pressure less than 3 mmHg||t|t|t|t
33955552|NCT01578018|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33955553|NCT03313401|||CASE_ONLY||PROSPECTIVE|||||||
33955554|NCT06467305|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Healthy right-handed adults with normal hearing will be recruited in equal number from both sexes. All participants will be fluent English speakers.||||
33955555|NCT00110084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851211|NCT04297449|||OTHER||PROSPECTIVE|||||||
33955556|NCT03338907|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The sequence whether the IMP or the comparator is applied first will be randomly assigned using the web-based randomizer.|Controlled, randomized, single blind, crossover|t|f|f|f
33955557|NCT05874518|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33955558|NCT06652594|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34059519|NCT01366859|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34059520|NCT02666898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059521|NCT00642109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059522|NCT03244618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059523|NCT01625208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059524|NCT04331067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059525|NCT00415597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059526|NCT03522233|||COHORT||PROSPECTIVE|||||||
34059527|NCT05661630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34059528|NCT02169206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059529|NCT02191176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34059530|NCT01323153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059531|NCT00353548|||CASE_CONTROL||PROSPECTIVE|||||||
34059532|NCT06621264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059533|NCT05656703|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|group blinding for all of the above except for staff anesthesiologist of the light anesthesia group|Randomised-controlled, double blind study, monocentric|t|f|t|t
34059534|NCT05749068|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34059535|NCT06154642|||COHORT||PROSPECTIVE|||||||
34059536|NCT00783224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34059537|NCT01914159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851212|NCT03496831|||COHORT||RETROSPECTIVE|||||||
33851213|NCT03237637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33851214|NCT01853644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851215|NCT02657512|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
33851216|NCT00177034|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955559|NCT02332655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955560|NCT06648499|||COHORT||CROSS_SECTIONAL|||||||
34059538|NCT06052540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059539|NCT02930161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059540|NCT03305900|||COHORT||CROSS_SECTIONAL|||||||
34059541|NCT05548998|||COHORT||PROSPECTIVE|||||||
34059542|NCT00147784|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163694|NCT01151371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163695|NCT06725485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163696|NCT02781220|||CASE_ONLY||PROSPECTIVE|||||||
34163697|NCT06040099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163698|NCT06462183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, ascending dose escalation followed by dose expansion||||
33746587|NCT06223828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Children will be enrolled into either a single interventional arm or a parallel standard care arm.||||
33955561|NCT05007106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with locally recurrent unresectable or metastatic cervical cancer whose tumors express programmed cell death 1 ligand 1 (PD-LI) and have a combined positive score (CPS) ≥1 will be randomly assigned to treatment with either pembrolizumab/vibostolimab co-formulation or pembrolizumab only. The other study intervention arms will be assigned to participants depending on the selected cancer type.||||
33746588|NCT06470529|||COHORT||CROSS_SECTIONAL|||||||
33746589|NCT06530017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955562|NCT05428059|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33746590|NCT05493553|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Baseline (no supplements or intermittent fasting requirements) and two interventional phases (Phase 1: supplements only; Phase 2: supplements and intermittent fasting)|t|f|f|f
33746591|NCT04993326|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33955563|NCT03323359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746592|NCT05061264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A study group submitted to abdominal wall repair with PVDF mesh in the infected setting compared to a control group submitted to abdominal wall repair with PVDF mesh in the clean setting.||||
33955564|NCT01836094|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33955565|NCT05744388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized prospective study||||
33746593|NCT01412723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33746594|NCT06535594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955566|NCT06455774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746595|NCT03081455|||COHORT||PROSPECTIVE|||||||
33746596|NCT05253898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746597|NCT04274608|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33955567|NCT06539689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746598|NCT02352948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746599|NCT06646341|||CASE_ONLY||RETROSPECTIVE|||||||
33955568|NCT06569017|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33955569|NCT04401709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955570|NCT02890966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955571|NCT00513578||||TREATMENT||NONE||||||
33955572|NCT02696304|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33955573|NCT03965507|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955574|NCT04501159|||COHORT||CROSS_SECTIONAL|||||||
33955575|NCT00544349|NON_RANDOMIZED|||TREATMENT||NONE||||||
34163699|NCT05681065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Design: randomised, open-label, multicentre, parallel-group clinical trial with 2-month follow-up.~Patients in the intervention group will be fitted with the TeNDER system device best suited to the patient's needs, in addition to routine clinical practice. Patients in the control group will be treated according to standard clinical practice."||||
33746600|NCT00060450|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33746601|NCT04724317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746602|NCT00626522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746603|NCT05424068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746604|NCT01606449|||COHORT||RETROSPECTIVE|||||||
33746605|NCT06316362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746606|NCT01310036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163700|NCT02534363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163701|NCT02327676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163702|NCT02782286|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34163703|NCT03374579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Fluid challenge with assessment of change of co2 gap||||
34163704|NCT03162822|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Within-subject design over 2 visits||||
34163705|NCT05685745|||COHORT||PROSPECTIVE|||||||
34163706|NCT02035527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163707|NCT00924196|||COHORT||PROSPECTIVE|||||||
33765293|NCT05707611|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Fifteen patients with allergic rhinitis aged 18 - 45 years old. The experiment was a crossover design in which each participant was given three types of exercise: running, cycling, and swimming. The participant perform moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise. The dependent variables between pre-test and post-test were analyzed by a paired t-test. The dependent variables between groups were analyzed by independent t-test. One way repeated measures ANOVA was used to compare the variables among exercise. Differences were considered to be significant at p \< 0.05.||||
33765294|NCT01716143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765295|NCT03462134|||OTHER||CROSS_SECTIONAL|||||||
33765296|NCT01069575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955576|NCT02384837|||COHORT||PROSPECTIVE|||||||
33955577|NCT03607552|||COHORT||PROSPECTIVE|||||||
33955578|NCT02773641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955579|NCT05925309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33955580|NCT01585896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955581|NCT04243655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with standard medical treatment (SMT) as per patients requirement.||||
33955582|NCT06650241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163708|NCT06708559|||OTHER||PROSPECTIVE|||||||
34163709|NCT04182815|||COHORT||PROSPECTIVE|||||||
34163710|NCT06655155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163711|NCT05720390|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|In order to blind both investigator and participant, the treatments will be prepared on the morning of each study day, and filled in covered syringes, by a research officer who will have no involvement in data analysis.||t|f|t|t
33746607|NCT06670014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study includes three blinded speech-language pathologists (SLPs) who will evaluate the speech intelligibility, the primary outcome measure. These SLPs will be blinded to the group assignments (treatment or control) of the participants. Each SLP will independentlry assess the speech intelligibility of participants at three times points: baseline, post-treatment, and follow-up.|"This is a two-arm interventional study comparing the efficacy of \&#39;repeech\&#39; application to a workbook-based treatment for post-stroke dyasarthria.~* Treatment group: Participants in the treatment group will use the \&#39;repeech\&#39; application for 4 weeks, with recommended usage of 5 days per week, for 30 to 60 minutes per session.~* Control Group: Participants in the control group will use a workbook provided by the sponsor, due the lack of a standarized care protocol for dysarthria. The control group will be instructed to use the workbook with the same frequency and duration as the treatment group (5 days per week, 30 to 60 minutes per session)."|f|f|f|t
33746608|NCT05584215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746609|NCT03082963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746610|NCT04965844|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33746611|NCT02599194|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Intra-patient comparison of 2 different radiolabels||||
33746612|NCT01573845|RANDOMIZED|PARALLEL||||NONE||||||
33746613|NCT05665777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746614|NCT05642390|||CASE_ONLY||PROSPECTIVE|||||||
33746615|NCT05985486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33746616|NCT06239168|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33746617|NCT05116267|||COHORT||RETROSPECTIVE|||||||
33746618|NCT00364962|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33746619|NCT02370602|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746620|NCT01718769|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746621|NCT04099069|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746622|NCT03249922|||CASE_ONLY||PROSPECTIVE|||||||
33746623|NCT01028573|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33746624|NCT02032511|||COHORT||PROSPECTIVE|||||||
33765297|NCT03133104|||COHORT||RETROSPECTIVE|||||||
33765298|NCT05244811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851217|NCT05955794|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"participants: 500 (400 syndromic patients plus 100 non-syndromic controls matched for gender and age).~400 patients suffering from different syndromes will be recruited, although the investigators will focus in particular on Down syndrome, Noonan, Costello, Smith-Magenis, Cri du Chat, 22q11 deletion, Williams, Crisponi, Rubinstein Taybi and CHARGE to analyse their vocal pattern characteristics. The choice of the listed conditions is guided by their prevalence in the population and previously reported peculiar vocal patterns. The patients recruited are those regularly followed by the Centre for Rare Diseases and Congenital Defects of the Agostino Gemelli IRCCS University Polyclinic Foundation, Rome. Voice recordings collected in the laboratory from syndromic patients will be analysed both perceptually and objectively and compared with a control group of non-syndromic patients, matched for age and gender."||||
33851218|NCT05209763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomised, 2x2 factorial design, angle centre interventional study with randomisation 1:1:1:1||||
33851219|NCT02956785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765299|NCT01811979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33765300|NCT05451238|||COHORT||RETROSPECTIVE|||||||
33765301|NCT00069602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765302|NCT00179530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765303|NCT03579290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765304|NCT06104514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765305|NCT05489939|||COHORT||PROSPECTIVE|||||||
33765306|NCT05106114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765307|NCT05480670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765308|NCT05768724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All cases were assigned codes. The codes were sealed in opaque envelops and kept in statistician ofce until the last patient completed the study.Study personnel involved in the analysis of the results (endocrinologist, radiologist, nurse, and laboratory technicians) were blinded to group assignments.|single-blind, randomized, two-arm, parallel six-month dietary intervention.|t|t|t|t
33765309|NCT01622543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765310|NCT02601937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were enrolled either to the dose escalation or the dose expansion portion of the study. Participants in the dose expansion portion of the study were separated into cohorts based on their disease-type.||||
33765311|NCT05131958|||COHORT||PROSPECTIVE|||||||
33955583|NCT03184376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blinded to the treatment allocation. Oligofructose and maltodextrin taste and look the same (white powder) and both were placed in identical foil packaging.|Single-blind, placebo controlled, randomized trial|t|f|f|f
34059543|NCT06010420|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||use of insoles|f|f|f|t
33955584|NCT04692103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955585|NCT05978817|RANDOMIZED|PARALLEL||TREATMENT||NONE|Double (open label)|Parallel Assignment||||
33955586|NCT04338256|||COHORT||PROSPECTIVE|||||||
33955587|NCT06358157|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized||||
33955588|NCT03527407|||CASE_ONLY||PROSPECTIVE|||||||
33955589|NCT06150872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each subject will have at least 2 saphenous vein grafts. One graft will be randomized to treatment and one graft will be randomized to control. The outcomes assessor will be blinded to which graft has been treated.||f|f|f|t
33955590|NCT04677907|RANDOMIZED|PARALLEL||OTHER||DOUBLE|all blind except surgeon, who will not take part in study or analysis after surgery|A Double Blinded Randomised Controlled Trial|t|t|f|f
33955591|NCT05958979|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants will be randomly assigned to use a varying number of e-liquids with differing marketing strategies.|t|f|f|t
33955592|NCT05413395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-center, randomized, blinded, controlled trial|t|f|f|f
33955593|NCT04466436|||OTHER||PROSPECTIVE|||||||
33955594|NCT05345418|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33955595|NCT06466057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is a psychiatrist who was not involved in the randomization and treatment process.||f|f|f|t
33955596|NCT00244881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955597|NCT01293682|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33955598|NCT05804123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo Navax® and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax® suspension is unrecognizable to investigators except the PI and analyzer, nurses, patient's parents, and patients due to opaque plastic container.|Blind randomized controlled trial|t|t|t|f
33955599|NCT01583400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955600|NCT04955210|||OTHER||PROSPECTIVE|||||||
33955601|NCT05669924|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33955602|NCT03998774|||CASE_ONLY||PROSPECTIVE|||||||
33955603|NCT06652425|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33955604|NCT03107416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059544|NCT04571801|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Arm 1: Standard diagnostics (Microbial diagnostics by means of standard culture methods + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis~Arm 2: Standard diagnostics + NGS (Microbial diagnostics using standard culture methods + Next Generation Sequencing + optional consultation of experts in the field of infectious diseases) within the first 72 h after diagnosis"||||
34059545|NCT01524783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059546|NCT03160001|RANDOMIZED|PARALLEL||OTHER||DOUBLE||1 patient group and 1 placebo group|t|f|t|f
34059547|NCT06623877|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34059548|NCT05177900|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The patient will be allocated to the both arms in a cross-over design (no interphase gap and interphase gaps of different lenghts). The order of the pulses will be delivered in a random order, and with a double-blind design. Of all pulses, the therapeutic window will be assessed acutely (3 times per pulse shape).|t|f|f|t
34059549|NCT03083769|||COHORT||OTHER|||||||
34059550|NCT05726942|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33746625|NCT03822013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Although randomized control trial is the gold standard for clinical trial studies; there are ethical concerns about placebo control group in rare diseases such as Sandhoff and Tay sachs diseases.||||
33765312|NCT04374396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Sham ESP block will be administrated in the control group Measurements will be obtained by anesthetist not participating in the study and blinded to its group|Parallel Assignment Prospective study|t|f|t|t
33765313|NCT04764292|NA|SINGLE_GROUP||SCREENING||NONE||||||
33765314|NCT04318730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765315|NCT04481126|||COHORT||RETROSPECTIVE|||||||
33955605|NCT05317169|||COHORT||PROSPECTIVE|||||||
33955606|NCT02591173|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746626|NCT03405870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because this is a pilot study, and because the lipid emulsion appears white and will be visible to the treatment team, the study will not be blinded. Data abstractors will, however, be blinded to the treatment effect. As the treatment effects are objective measurements (lipid levels, SOFA score, etc.) the likelihood of bias is low.|The study has a Phase I/II design. For the Phase I, which has been completed, 10 patients were enrolled in the study to evaluate for dose limiting toxicity (DLT). For patients enrolled in the Phase I dose-escalation study, there was no control group, with doses starting at 1.0g/kg and increasing incrementally based on weight by 0.2g/kg to a maximum dose of 1.6g/kg. Dose escalation or de-escalation occurred based on whether DLTs were observed at a specific dose, with the threshold for toxicity set at 10%. After evaluating for DLT, the two highest and safest doses will be used to randomize the remaining 48 patients into the Phase II study to either Smoflipid or control (no active treatment) using a Bayesian Optimal Interval Design. Thus, the Phase II arm will include 24 patients per arm randomized to one of the two most efficacious doses of the study drug based on body weight, while the control group will receive no drug.|f|f|f|t
33955607|NCT01205373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955608|NCT02238639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955609|NCT03779282|||CASE_CONTROL||PROSPECTIVE|||||||
33955610|NCT03311217|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized trial with four communities assigned to intervention and four communities assigned to control||||
33955611|NCT06111131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a double-blind randomized 1:1 controlled post-market study; the investigator and the subject will be blind to the device. A qualified staff member will assist the endoscopist by performing the preparation, insertion, and removal of the device the subject was randomized to, to ensure the investigator is blinded. The shaft and handle end of the Ancora-SB overtube will be the same as the Olympus ST-SB1 overtube.|t|f|t|f
33955612|NCT06271109|||COHORT||OTHER|||||||
34059551|NCT04208321|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34059552|NCT00850096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33851220|NCT04415723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|single-blinded|one intervention group one control group|f|f|t|t
34059553|NCT04319081|||COHORT||PROSPECTIVE|||||||
34059554|NCT04927871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163712|NCT04502563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|All subjects will wear non-invasive sensors. The subjects and the investigators will not know whether subjects are randomized to active arm (remote monitoring data shared with treatment team and used for clinical decisions per algorithm) or to control arm (data collected but not shared with treatment team).|Prospective randomized study|t|t|t|t
34163713|NCT06726239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||experiment-control|t|f|f|f
33851221|NCT01990118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851222|NCT01560468|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851223|NCT01629602|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33851224|NCT06279026|NA|SINGLE_GROUP||TREATMENT||NONE||UTAA17 injection||||
33851225|NCT05414487|||COHORT||PROSPECTIVE|||||||
33851226|NCT01543932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851227|NCT03044925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851228|NCT03580668|||COHORT||PROSPECTIVE|||||||
33851229|NCT04281446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The randomization and allocation of participants will be performed by a researcher who will not have access to evaluations and data collection. The interventions will be carried out by the researcher who made the allocation, and data collection by a second researcher, who is blinded to the allocation of the participants.~Participants will not know about their allocation during the collection process and during the intervention they will wear a mask covering their eyes."|"The randomization and allocation of participants will be performed at beginning of the project, allocating the participants in 2 groups:~* Endogenous ovarian cycle Photobiomodulation Group(G-FBM-CEN);~* Endogenous ovarian cycle Sham Group (G - Sham - CEN)."|t|f|t|t
33851230|NCT02210143|||||PROSPECTIVE|||||||
33851231|NCT04303767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851232|NCT06610383|||CASE_CROSSOVER||PROSPECTIVE|||||||
33851233|NCT05820477|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The investigators use mail-in A1c kits for the primary outcome-hemoglobin A1c-and the lab analyzing these samples is masked to participants' assigned condition.||f|f|f|t
33851234|NCT03598010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851235|NCT03147404|NA|SINGLE_GROUP||TREATMENT||NONE||Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)||||
33851236|NCT03460691|||COHORT||PROSPECTIVE|||||||
33851237|NCT03536143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intrasubject treatment assignment/randomization||||
33851238|NCT03997084|||COHORT||RETROSPECTIVE|||||||
33851239|NCT00822211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851240|NCT00513513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851241|NCT05505331|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851242|NCT02854969|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33851243|NCT06223854|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The salts will be packaged in 500-gram plastic containers (canisters) labeled with the participants' study identification number. Two containers of salt will be delivered to the participants' homes every two weeks, at which time the previously delivered canisters will be collected..|This study is a community-based, three-arm, randomized, dose-response intervention trial with randomization at the level of the household of non-pregnant women of reproductive age.|t|t|t|t
33851244|NCT00790751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851245|NCT01046773|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33851246|NCT00080457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33851247|NCT03029351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851248|NCT01326754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851249|NCT02040584|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A multicentre, randomized, open-label, controlled, exploratory clinical trial with 12-months (52 weeks) of follow-up."||||
33851250|NCT03100643|||COHORT||CROSS_SECTIONAL|||||||
33851251|NCT01283477|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33851252|NCT03099746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33851253|NCT04968808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851254|NCT01152632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851255|NCT00212160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33955613|NCT05324254|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Partial masking: Although blanket heaviness will be perceived, blanket weights tested in the study will not be disclosed to participants. Wait-list control group will know they are not receiving active intervention.||t|f|t|t
33955614|NCT02765139|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059555|NCT01916161|||COHORT||PROSPECTIVE|||||||
34059556|NCT05450926|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34059557|NCT02050568|||CASE_ONLY||PROSPECTIVE|||||||
34163714|NCT06727227|||COHORT||OTHER|||||||
33851256|NCT00597246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851257|NCT02434497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851258|NCT02174042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851259|NCT03309462|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851260|NCT01495832|RANDOMIZED|PARALLEL||||NONE||||||
33851261|NCT05615545|||OTHER||RETROSPECTIVE|||||||
33851262|NCT03952325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955615|NCT05951478|||COHORT||OTHER|||||||
34059558|NCT05359770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059559|NCT00123617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059560|NCT05471570|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34059561|NCT04529512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059562|NCT05290480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Treatment and evaluation were performed by two different physiotherapists. The assessing physiotherapist was blind to group allocation.||f|f|t|f
34163715|NCT05947864|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163716|NCT04249843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955616|NCT03668379|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Medical providers of the patients enrolled in the study will be notified that their patient is in a study for depression but not told what intervention arm. At all follow-up outcome points, the assessor will be blind to all intervention arms the patient were randomized to.|"The study utilizes a Sequential Multiple Assignment Randomized Trial (SMART) design in order to guide a series of adaptive behavioral interventions. In a SMART, eligible participants will be randomized at baseline and assigned to 1st-stage treatments consisting of either 1. Behavioral Activation Therapy (BAT) or 2. BAT \& mHealth. During the first stage treatment, Patient Health Questionnaire-9 (PHQ-9) scores will be collected. At the follow-up period, the PHQ-9 will provide a cutoff score to determine whether a participant showed a clinically meaningful response (responder/non-responder) to the 1st stage treatment. Responder indicates that patients successfully responded to the 1st stage treatment and will continue the treatment in maintenance mode. Non-responder indicates that the patient did not respond to the 1st-stage treatment and are re-randomized to either an augmented or switched intervention."|f|t|f|t
33955617|NCT03092115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955618|NCT01389700|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33955619|NCT06222502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059563|NCT02482064|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34059564|NCT01690910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059565|NCT03047096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059566|NCT02909881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059567|NCT00624559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34059568|NCT06620341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the nature of the intervention, masking of doctors and participants was not possible, but telephone follow-up staff and data analysts were masked to allocation group until after the definitive analysis was done.||f|f|f|t
34059569|NCT03376217|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled trial||||
34059570|NCT05818410|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059571|NCT03258008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746627|NCT00071487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746628|NCT01360151|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746629|NCT06202378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746630|NCT05972720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746631|NCT00243724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746632|NCT00694317|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746633|NCT01060761|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33746634|NCT00295750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746635|NCT03099850|||COHORT||PROSPECTIVE|||||||
33746636|NCT05161858|||COHORT||PROSPECTIVE|||||||
33746637|NCT04942171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746638|NCT06560970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will be blind to their assigned condition.||t|f|f|f
33746639|NCT05580991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746640|NCT02763527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059572|NCT05468749|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34059573|NCT01537016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059574|NCT00600405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059575|NCT03176615|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will consume a high-fat meal and a low-fat meal served seperately in a randomized order on two seperate days (two-seven days apart)||||
34163717|NCT05276817|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Split mouth study. For each patient, each quadrant is assigned to a randomized treatment. 4 treatment arms.||||
34163718|NCT06019455|||COHORT||PROSPECTIVE|||||||
34163719|NCT00746863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163720|NCT06725043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34163721|NCT03496675|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Blinding of assessors will be ensured by using assessors who do not participate in the daily care of each unit. Assessors will also remind participants not to reveal the unit's allocation to them. At the time of the last assessment, success of blinding will be verified by asking assessors whether they inadvertently discovered the unit's allocation. Intervention providers and study participants (PLWD and staff) cannot be blinded due to the nature of the interventions. However, efforts will be made to ensure that no differential expectations are created and equipoise is maintained (e.g., by careful wording of the patient information and consent form).||f|f|f|t
34163722|NCT06526988|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster-randomization will occur at the clinician level, where the clinician is randomized to 1 of 4 study arms (usual care, EPIC-HF only, PROMPT-HF only, both). Randomization will be stratified at the site level. Patient assignment follows clinician randomization.|t|f|f|f
34163723|NCT05838768|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"This is an open label study. Treatment will be open to patients, Investigator staff, persons performing the assessments and the Sponsor clinical trial team.~For the dose escalation and dose expansion, no randomization will be performed. For the dose optimization (HRO761 single agent arm only), patients will be equally randomized to the two selected HRO761 single agent treatment dose levels."|||||
34163724|NCT02118974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163725|NCT03828617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163726|NCT05432401|NA|SINGLE_GROUP||TREATMENT||NONE||TAA05 Injection||||
34163727|NCT06410014|||COHORT||CROSS_SECTIONAL|||||||
34163728|NCT06725056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163729|NCT06337695|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A Randomized, Double-Blinded, Placebo Controlled Trial|t|t|t|t
34163730|NCT05408715|||COHORT||PROSPECTIVE|||||||
34163731|NCT06137586|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The randomized order of infusions is blinded to both participant and investigator|Randomized, double-blinded, single-arm study. Each participant goes through five experimental days in a randomized order - acting as their own controls||||
34163732|NCT04899336|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163733|NCT02999906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163734|NCT00004561|RANDOMIZED|||TREATMENT||||||||
34059576|NCT04520334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059577|NCT03264378|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|None of participants, care providers, or outcome assessor knows whether which participants have been assigned to intervention or control condition.|The experimental group will receive physical exercise intervention (PEI) that is supported by standardized administrative procedures plus the GTO-ThAI implementation support system designed to improve the quality of implementation of the PEI program. The active comparator group will receive PEI that is supported only by standardized administrative procedures that the Thai government typically uses to promote policy-driven initiatives.|t|t|f|t
34059578|NCT00104065|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34059579|NCT01294371|||||PROSPECTIVE|||||||
34059580|NCT05084365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059581|NCT00772122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059582|NCT05548868|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, parallel groups, pilot randomized controlled trial||||
34059583|NCT06499012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34059584|NCT00526331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059585|NCT02750605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059586|NCT02680184|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34059587|NCT06648980|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34059588|NCT04588727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Staff will remain blinded. For this single-blind study (in which the study center staff have remained blinded during the dosing phase of the study), the randomization code will be available at the SRC meeting and the data will be reviewed unblinded.~The pharmacokineticist will remain unblinded during the study conduct, unless otherwise required based on study findings.~The following personnel will have access to the randomization list:~1. The AstraZeneca personnel carrying out the labeling and packaging of subject specific treatments~2. The pharmacy personnel preparing study drug at the site~3. The personnel performing the bioanalyses of the plasma/urine samples. The randomization list should be kept in a secure location until the end of the study.~In the event of a medical emergency, the treatment received may be revealed by personnel authorized by the principal investigator (PI), after discussing with AstraZeneca."||t|t|t|f
34076294|NCT05150665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors will be blind. The patients name will be sealed from pre and post photographs and cephalometric radiographs. Then two assessors will carry out, blindly and independently, the measurements and analysis of the study||f|f|f|t
34163735|NCT06726551|||CASE_ONLY||OTHER|||||||
34163736|NCT03368586|||CASE_ONLY||PROSPECTIVE|||||||
34163737|NCT03791970|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163738|NCT00001350|||CASE_ONLY||PROSPECTIVE|||||||
34163739|NCT01127815|||CASE_CONTROL|||||||||
33851263|NCT00824031|||||CROSS_SECTIONAL|||||||
34163740|NCT04322188|||COHORT||RETROSPECTIVE|||||||
34163741|NCT03494296|||CASE_CONTROL||PROSPECTIVE|||||||
34163742|NCT01646086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163743|NCT06091150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163744|NCT06492187|||COHORT||PROSPECTIVE|||||||
34163745|NCT06106802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163746|NCT01264406|||CASE_CONTROL||OTHER|||||||
34163747|NCT04083365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163748|NCT01954095|||COHORT||PROSPECTIVE|||||||
34163749|NCT04783909|||CASE_CONTROL||PROSPECTIVE|||||||
34163750|NCT03010033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163751|NCT03029910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34163752|NCT00237497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163753|NCT05392309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163754|NCT05569447|||CASE_ONLY||RETROSPECTIVE|||||||
33955620|NCT04929834|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33746641|NCT04327466|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955621|NCT06653452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955622|NCT03140527|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33955623|NCT04116359|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955624|NCT03700515|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33955625|NCT02536625|||CASE_CONTROL||PROSPECTIVE|||||||
33955626|NCT02080273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33955627|NCT06620016|||COHORT||PROSPECTIVE|||||||
33955628|NCT06567977|||COHORT||PROSPECTIVE|||||||
33955629|NCT06651528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955630|NCT06542523|||CASE_ONLY||PROSPECTIVE|||||||
33955631|NCT06565741|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP.||||
33955632|NCT02939118|||COHORT||PROSPECTIVE|||||||
33955633|NCT03522155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This randomized controlled trial will involve two arms: (1) an intervention arm consisting of a patient-centered communication strategy for life expectancy and (2) standard of care treatment counseling. The intervention will be randomized at the level of the patient to balance study arms in terms of measured and unmeasured patient characteristics.||||
33955634|NCT03074357|||OTHER||RETROSPECTIVE|||||||
33955635|NCT01003470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746642|NCT05887193|||CASE_CONTROL||PROSPECTIVE|||||||
33746643|NCT05369585|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label, single center, single arm||||
33955636|NCT00002949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955637|NCT01854125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955638|NCT00185107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33955639|NCT00662974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34059589|NCT04586335|NA|SEQUENTIAL||TREATMENT||NONE||Open-label, multicenter study which is composed of 2 parts: 1.) dose escalation and 2.) dose expansion. Bayesian optimal interval (BOIN) design will be used to determine the MTD and/or RP2D. Safety, tolerability, PK, PD, and clinical activity will also be evaluated. The CYH33 starting dose of this trial is 20 mg QD in combination with olaparib 300 mg BID. Two additional dose levels of CYH33 at 30 mg QD and 40 mg QD in combination with olaparib 200 mg BID will be evaluated. In the initial dose cohort of 20 mg CYH33 as well as in subsequent dose cohorts 20 and 30 mg QD and 40 mg QD in combination with olaparib 200 mg BID, 3 patients will be initially enrolled at each dose level of CYH33. These evaluable patients will be included into this dose level for decision making on dose selection for the next cohort. 10 mg QD of CYH33 will be evaluated in the combination with olaparib 200 mg BID, according to the BOIN design.||||
34059590|NCT02360475|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34059591|NCT06074887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34059592|NCT00112281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34059593|NCT06527222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059594|NCT05400031|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34059595|NCT03996590|||COHORT||PROSPECTIVE|||||||
34059596|NCT00719914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059597|NCT02271711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059598|NCT06077149|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory testing will be blinded to vaccine and study cohort||f|f|f|t
33746644|NCT00710047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33746645|NCT03341390|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33746646|NCT02635958|||COHORT||OTHER|||||||
33746647|NCT02864433|||CASE_CONTROL||PROSPECTIVE|||||||
33746648|NCT03812796|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomised||||
33746649|NCT03332862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746650|NCT00566267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33746651|NCT03105362|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open label single center pilot study||||
33746652|NCT06109038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746653|NCT01109992|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746654|NCT05465889|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33746655|NCT01015989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The CARE Kenya counseling tool software randomizes the participant automatically to the control or intervention arms when the user first logs into the program, using a quasi-random number algorithm.||t|f|f|f
33746656|NCT06454357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955640|NCT02102217|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33955641|NCT06689917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059599|NCT06447259|||COHORT||RETROSPECTIVE|||||||
34059600|NCT04295057|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059601|NCT05602129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076295|NCT04474262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076296|NCT02896764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765316|NCT06002191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study design is a randomized controlled trial.|f|f|f|t
33955642|NCT03683719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955643|NCT05219513|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955644|NCT01638260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955645|NCT04515940|||OTHER||PROSPECTIVE|||||||
33955646|NCT01940276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955647|NCT00752388|||COHORT||PROSPECTIVE|||||||
33955648|NCT00136565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955649|NCT00637598|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33955650|NCT00337155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955651|NCT05193435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955652|NCT06537583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not know either they include in treatment or control group||t|f|f|f
33955653|NCT02823587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076297|NCT02952690|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34163755|NCT02052752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163756|NCT03434548|||CASE_CONTROL||PROSPECTIVE|||||||
34163757|NCT01615016|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Intervention team whose members are not part of the patients' care team. Blinded for type of intervention|Randomized, double blind|t|t|t|t
33955654|NCT06445725|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||single arm, pre-post, mixed-methods pilot study||||
33955655|NCT01689922|||OTHER||PROSPECTIVE|||||||
33955656|NCT04846075|||COHORT||PROSPECTIVE|||||||
33955657|NCT03972709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955658|NCT05910580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33955659|NCT00668369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955660|NCT06653790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The care provider and investigators will be blided|The severely acute malnourished children in intervention group will be sent to development pediatrician who will do a developmental assessment of the child and stimulation. A sensory therapist, an occupational and a physiotherapist will also be available for sessions. The psychosocial stimulation will be offered in two phases: in-patient (at stabilization unit) and after discharge, patient will be referred to outpatient (at outpatient therapeutic center) and developmental outpatient. The sessions with development pediatrician and team will be held every week lasting for about 20-40 min in the presence of the caregiver. The intervention includes auditory, tactile and visual stimulation, hand-eye coordination, and different types of sensory-motor training that include fine and gross motor activities. The guiding principle will be to enhance a child's holistic development-cognitive, language, physical, and social-in an integrated manner by using age-appropriate play materials, cultural t|f|t|t|f
33955661|NCT02677337|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955662|NCT05373017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955663|NCT02952300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33955664|NCT02245997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955665|NCT05567562|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|All participants, investigators and care providers will be blinded as to dual-anti platelet therapy or placebo treatment|Double-blind crossover study is a Phase 2 interventional study to assess whether dual-anti platelet therapy improves pulmonary blood flow compared to placebo|t|t|t|t
33955666|NCT05164562|||CASE_ONLY||CROSS_SECTIONAL|||||||
33955667|NCT03335839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33955668|NCT06379984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955669|NCT00665366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955670|NCT05496634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled study||||
33955671|NCT06649695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163758|NCT04803526|||OTHER||CROSS_SECTIONAL|||||||
34163759|NCT00807352|||COHORT||PROSPECTIVE|||||||
34163760|NCT04859088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163761|NCT00352924|||COHORT||PROSPECTIVE|||||||
34163762|NCT01324661|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34163763|NCT05143034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163764|NCT00250159|||COHORT||PROSPECTIVE|||||||
34163765|NCT06706141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A single-blind, randomized, controlled pretest-posttest experimental design was used for this research.|t|f|f|f
34163766|NCT01578681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163767|NCT00311506|||||PROSPECTIVE|||||||
34163768|NCT04758065|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of investigators at study inclusion to randomization sequence, using sealed envelopes|It is a randomized controlled clinical trial with parallel groups.||||
34163769|NCT03038295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163770|NCT01488526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34163771|NCT01115673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163772|NCT05562323|||COHORT||PROSPECTIVE|||||||
34163773|NCT05305560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163774|NCT06726564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163775|NCT03334032|||COHORT||PROSPECTIVE|||||||
34163776|NCT01880177|||||CROSS_SECTIONAL|||||||
34163777|NCT06726213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34163778|NCT02588261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163779|NCT05919953|NA|SINGLE_GROUP||OTHER||NONE||||||
34163780|NCT00413218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163781|NCT04968912|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34163782|NCT04992871|||COHORT||PROSPECTIVE|||||||
34163783|NCT00203489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34163784|NCT01994616|||||PROSPECTIVE|||||||
34163785|NCT02426736|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34163786|NCT04112966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34163787|NCT03833024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind placebo-controlled trial with oral placebo|Multicentre, randomized, placebo-controlled trial|t|f|t|t
34076298|NCT04192240|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33746657|NCT06042647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Investigator will not know which product is applied to the right and left psoriasis target plaque.|One product applied to psoriasis on the right side of the body and a second product applied to the left side of the body. The right and left side product applications will be randomized.|f|f|t|f
34076299|NCT03003442|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34076300|NCT00036283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33746658|NCT03322865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746659|NCT04230473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851264|NCT03027453|||COHORT||PROSPECTIVE|||||||
34076301|NCT05694806|||COHORT||RETROSPECTIVE|||||||
34076302|NCT01815658|||CASE_ONLY||RETROSPECTIVE|||||||
33746660|NCT05918094|RANDOMIZED|PARALLEL||TREATMENT||NONE||540 subjects will be randomized in a 1:1 ratio into either the modified XELOX plus sintilimab group or the standard XELOX plus sintilimab group.||||
33746661|NCT01438047|||COHORT||PROSPECTIVE|||||||
33851265|NCT03971630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746662|NCT05403762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33746663|NCT06177340|||CASE_ONLY||RETROSPECTIVE|||||||
33746664|NCT06308159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746665|NCT00820768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746666|NCT02442661|||OTHER||PROSPECTIVE|||||||
33955672|NCT05026879|||COHORT||CROSS_SECTIONAL|||||||
33955673|NCT03332394|||COHORT||PROSPECTIVE|||||||
33955674|NCT05471518|||OTHER||CROSS_SECTIONAL|||||||
33955675|NCT06420726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two-arm Randomized Controlled Trial|f|f|t|t
33955676|NCT02108132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955677|NCT05419635|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33955678|NCT04962958|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33955679|NCT02008552|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746667|NCT06230757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746668|NCT00208793|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33765317|NCT03503539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765318|NCT04100512|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765319|NCT01616875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765320|NCT00439829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765321|NCT00056758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765322|NCT04953338|||COHORT||RETROSPECTIVE|||||||
33955680|NCT00857922|||OTHER||PROSPECTIVE|||||||
33955681|NCT06568588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Children diagnosed with ASD will be randomly organized into 2 groups. Group A (n=33) will receive Sb supplements at a dose of 250 mg 3 times a day for a period of 4 months. While Group B (n=33) will not receive supplementation for 4 months. This will be followed by a 30-day washout period, during which time neither group consumes probiotics. After this time, the children's groups will change treatment for another four months."||||
33955682|NCT00605397|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33955683|NCT05359341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955684|NCT04868877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955685|NCT00242567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076303|NCT02517957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34076304|NCT05734820|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Blinded, single center, controlled, prospective trial|f|t|f|f
34076305|NCT01726075|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076306|NCT05896397|||COHORT||PROSPECTIVE|||||||
34076307|NCT02962310|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765323|NCT00054925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33765324|NCT03179813|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33765325|NCT02640391|||CASE_ONLY||CROSS_SECTIONAL|||||||
33765326|NCT04204213|||COHORT||PROSPECTIVE|||||||
33765327|NCT06273358|||COHORT||PROSPECTIVE|||||||
33765328|NCT04045210|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a tho arm single-center, prospective, randomized, controlled trial comparing the effect of PSBPS vs. no PSBPS on psychological and clinical outcomes in the critically ill population. PSBPS will be administered by trained ICU doulas to eligible patients||||
33765329|NCT06320925|||OTHER||RETROSPECTIVE|||||||
33765330|NCT03881319|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765331|NCT06624917|RANDOMIZED|PARALLEL||TREATMENT||NONE|Once enrolled patients were randomized to receive|Once enrolled in the study population, patients will be divided prior to admission into the two study groups (Green Breast Surgery Group and Conventional Care Group).||||
33955686|NCT06537778|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33746669|NCT06578234|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The subject will be blinded to the order of adenosine doses.|The subjects will be randomized to start with one of the two adenosine doses, followed by the other dose 10 minutes later during the same examination.|t|f|f|f
33746670|NCT06252129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746671|NCT03953027|||COHORT||PROSPECTIVE|||||||
33746672|NCT01821664|||COHORT||PROSPECTIVE|||||||
33851266|NCT04822493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The investigators plan to use block randomization with stratification. The randomization schedule will have 1:1 allocation with a fixed block size of 4. To ensure equivalent numbers for planned cesarean and planned vaginal deliveries, patients will be stratified based on expected mode of delivery.~Randomization will occur at the time of enrollment. A computer-generated randomization scheme has been developed within the mobile application. When the participant is assigned a study number, the application with randomly assign them to the study or control group, based on the scheme described above."||||
33851267|NCT03619070|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851268|NCT02373943|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33851269|NCT00626132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851270|NCT04669353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The invesigators randomized participants in a 1:1 ratio to two equal groups containing one hundred patients each (intervention and control groups). A statistician not directly involved in the study prepared a computer generated randomization list and placed the allocation information in sequentially numbered sealed envelopes that were opened according to the attendance of the patients after signing the informed consent. The study authors were unaware of the envelope allocation sequence. Participants and outcome assessors did not know which group had been assigned to for the duration of the study.||t|f|f|t
33851271|NCT03451760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, placebo-controlled study. The placebos will be matched to the active supplement in both sensory and physical characteristics. The participants, study investigators, research associates, and study coordinators will have no knowledge of study assignment. Data analysis will be performed blinded to treatment status. The OHSU Research Pharmacy will be responsible for establishing a randomization scheme for newly enrolled participants. Additionally, the Research Pharmacy will ensure blinding of all study medications. The investigators will also evaluate the effectiveness of our blinding by giving study evaluators, participants, study partners, and investigators a short questionnaire asking about knowledge of group assignment. The randomization code will be broken only after data analysis or if there are numerous serious adverse events before the end of the study.|Randomized, double-blind, placebo-controlled clinical trial with a 12 week intervention period.|t|t|t|t
33851272|NCT04850794|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||Therapists will answer clinical questions about a case study (A or B, randomized order of presentation) without using the tool. They will then be presented with the tool and will answer the same clinical questions about a second case study (A or B, randomized order of presentation)|f|t|f|f
33851273|NCT01207297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851274|NCT05384405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial testing iTBS versus sham|t|f|t|t
33851275|NCT06271460|||COHORT||PROSPECTIVE|||||||
33851276|NCT01683929|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33851277|NCT03878251|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851278|NCT05271552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blinded|Randomized|f|f|t|t
33851279|NCT00531102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851280|NCT00737373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851281|NCT01442831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851282|NCT02877966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33955687|NCT05800327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The study design assumes two sequential stages corresponding to Phase I and Phase III studies.~Stage 1 This is an open-label, single-center, non-randomized cohort study of the safety and tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single intravenous or subcutaneous levilimab injections administered to healthy subjects at ascending doses (modified 3+3 design).~Stage 2 This is a randomized, comparative, double-blind, controlled clinical study to assess efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of levilimab when administered at repeated intravenous or subcutaneous doses in combination with methotrexate in subjects with active rheumatoid arthritis resistant to methotrexate monotherapy."|t|t|t|t
33955688|NCT00402207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955689|NCT02069145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955690|NCT06535828|||COHORT||PROSPECTIVE|||||||
33955691|NCT02860039|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33955692|NCT03587740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955693|NCT01444469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955694|NCT03264001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955695|NCT05923320|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single paticipant|A repetitive measure design with a pretest-posttest control group|t|f|f|f
33746673|NCT01875926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746674|NCT06170008|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The second-degree burn wounds were covered with clear silicone film and decellularized pig skin after conventional clinical treatment.~After skin grafting, the wounds were covered with transparent silicone film and petroleum jelly gauze with physical microstructure modification."||||
33746675|NCT02934373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746676|NCT04153266|||COHORT||PROSPECTIVE|||||||
33746677|NCT00352729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746678|NCT06199921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746679|NCT04590703|||CASE_CONTROL||RETROSPECTIVE|||||||
33746680|NCT05846594|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746681|NCT06305572|||COHORT||PROSPECTIVE|||||||
33746682|NCT03449030|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33746683|NCT05520229|||CASE_CONTROL||RETROSPECTIVE|||||||
33746684|NCT00675740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059602|NCT05582369|NA|SINGLE_GROUP||TREATMENT||NONE||At each decision point-operationalized as the beginning of the time window during which a participant planned to exercise-each participant will be randomized to receive one of three intervention options: active intervention (text messages aimed to prime expectations of emotional rewards of exercise), a control message (a reminder that they will receive a study questionnaire later in the day), or no intervention.||||
34059603|NCT00001043||||PREVENTION||||||||
34059604|NCT00001783||||TREATMENT||||||||
34059605|NCT01479192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059606|NCT02110940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059607|NCT01519297|NA|SINGLE_GROUP||SCREENING||NONE||||||
34059608|NCT03685292|||CASE_ONLY||PROSPECTIVE|||||||
34059609|NCT03909854|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Before-and-after trial design of adaptive pressure control and assist volume control||||
34059610|NCT05600283|NA|SINGLE_GROUP||SCREENING||NONE||||||
34059611|NCT02028403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059612|NCT03929250|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE||Randomization will use an arm equivalence design to promote equal numbers of participants for each order schema.|t|f|f|t
34059613|NCT01736605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059614|NCT06620627|||COHORT||PROSPECTIVE|||||||
34059615|NCT02660879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059616|NCT01752153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059617|NCT05781594|||COHORT||PROSPECTIVE|||||||
34059618|NCT00574795|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34059619|NCT02223156|||CASE_CONTROL||PROSPECTIVE|||||||
34059620|NCT03679286|||COHORT||PROSPECTIVE|||||||
34059621|NCT05524220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059622|NCT05366413|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34059623|NCT00005604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059624|NCT03897933|||COHORT||RETROSPECTIVE|||||||
34059625|NCT01667939|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059626|NCT00943670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059627|NCT06454422|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34059628|NCT00038896||||TREATMENT||||||||
34163788|NCT03191266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A double-blind randomized clinical trial with two groups: Active rTMS Treatment Group (Active rTMS) - will receive four to five treatments (two treatments per day) each week for 2 weeks. Sham Control Treatment group (i.e., identical rTMS experimental procedure, but no active stimulation) will receive the same frequency and duration of rTMS sessions.|A double-blind randomized clinical trial with two groups: Active rTMS Treatment Group (Active rTMS) - will receive four to five treatments (two treatments per day) each week for 2 weeks. Sham Control Treatment group (i.e., identical rTMS experimental procedure, but no active stimulation) will receive the same frequency and duration of rTMS sessions. The proposed rTMS protocol is consistent with the FDA approved treatment regimen employed for major depressive disorders.|t|t|t|t
34163789|NCT01486966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163790|NCT05401136|||COHORT||PROSPECTIVE|||||||
34163791|NCT03591562|||COHORT||PROSPECTIVE|||||||
33746685|NCT03179228|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Single Center||||
33746686|NCT05660265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study will be a double blinded study where the sponsor may be unblinded.|This is a placebo controlled multi-center study.|t|t|t|f
33765332|NCT06134323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||medication-combined transcutaneous vagus nerve stimulation group or the medication-combined sham stimulation group|t|f|f|t
33765333|NCT06091462|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33765334|NCT01222923|RANDOMIZED|CROSSOVER||||NONE||||||
33765335|NCT02579018|NON_RANDOMIZED|PARALLEL||||NONE||||||
33765336|NCT05996952|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851283|NCT02120742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33851284|NCT02566343|||COHORT||PROSPECTIVE|||||||
34059629|NCT02670733|||COHORT||PROSPECTIVE|||||||
34059630|NCT02865603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059631|NCT02898324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059632|NCT03147300|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are blinded to assignment to the control or intervention grouping|A cluster randomised trial with dog leg design|t|f|f|f
34059633|NCT00727090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059634|NCT00335959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059635|NCT04576065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||usual care group compared to intervention group||||
34059636|NCT01044953|||COHORT||PROSPECTIVE|||||||
34059637|NCT05646615|||COHORT||PROSPECTIVE|||||||
34059638|NCT02806544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059639|NCT02210169|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059640|NCT05236894|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34059641|NCT05123469|||COHORT||PROSPECTIVE|||||||
34059642|NCT05730153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34059643|NCT06507904|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34059644|NCT00126269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059645|NCT03410810|||COHORT||CROSS_SECTIONAL|||||||
34163792|NCT02102997|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33851285|NCT02697994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163793|NCT00250237|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34163794|NCT03832335|||COHORT||PROSPECTIVE|||||||
34163795|NCT00063778|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163796|NCT05937061|||CASE_CONTROL||RETROSPECTIVE|||||||
34163797|NCT04094974|||COHORT||PROSPECTIVE|||||||
34163798|NCT04508426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163799|NCT01385709|||CASE_ONLY||PROSPECTIVE|||||||
34163800|NCT06719804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163801|NCT01450865|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34163802|NCT00660465|||CASE_ONLY||CROSS_SECTIONAL|||||||
34163803|NCT01800097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163804|NCT03222687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163805|NCT03415282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163806|NCT04017091|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed design study with quasi-experimental Intervention group||||
34163807|NCT06527521|||COHORT||CROSS_SECTIONAL|||||||
34163808|NCT01553019|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163809|NCT02650180|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163810|NCT02691559|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34163811|NCT06342518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851286|NCT02898415|||COHORT||RETROSPECTIVE|||||||
33851287|NCT03231501|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open label study with fixed dose.||||
33851288|NCT00964587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851289|NCT06271629|||COHORT||PROSPECTIVE|||||||
33851290|NCT06015828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double-blinded randomized controlled trial Neonates will be randomized using closed envelopes into two groups||t|t|t|t
33851291|NCT00363909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34163812|NCT06654895|||CASE_ONLY||PROSPECTIVE|||||||
34163813|NCT02950480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163814|NCT05187078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Physician participants were aware of assignment to utilize the single-toothed tenaculum clamp or allis clamp directly prior to IUD placement procedure. Participants were blinded to the clamp assigned.||t|f|f|f
34163815|NCT06328673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163816|NCT01623544|||COHORT||RETROSPECTIVE|||||||
34163817|NCT04303559|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a phase III open-label, randomized controlled trial comparing two drugs in the prevention of hemophilia inhibitor formation.||||
34163818|NCT04671264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851292|NCT01078454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955696|NCT06568471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study consists of the preceding 12-week double-blind, placebo-controlled treatment period and the subsequent 40-week (incluing 36-week HST101 treatment and 4-week follow-up) open-label treatment period.|All participants will be in-parallel randomized in a 2:1 ratio to HST101 or Placebo|t|f|t|t
33955697|NCT05839379|||OTHER||PROSPECTIVE|||||||
33851293|NCT05031663|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcome assessor will not be aware which participant is in what arm. The participant and the care provider will know about the treatment allocation|this will be a parallel, free-living, randomized controlled trial, where 54 middle-aged men will be randomized to receive either the almonds or a placebo snack|f|f|t|t
33955698|NCT00890409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955699|NCT05736809|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Planter fascia is a fibrous connective tissue originate from the medial calcaneal tubercle and help support the arch of the foot repetitive tensile overload from standing for long periods of time or running causes changes in the aponeurosis. Patient mostly present with pain on first step in the morning or after long non-weight bearing, Tenderness to anterior medial head. Its can first be treated conservatively where 90 % cases treated greater then 6 months of duration. Baseline treatment is given as Rest , Ice , compression and Elevation , with this NSAID ,shoe inset ,Taping, orthotics, deep friction massage and precautions are advised to the patients. Arch taping is most probably used and orthotics in acute treatment is commonly preferred due to its cost.|The study would be a RCT (Randomized control trial) at Pakistan sports board in which convenience sampling technique would be used .This study include total 21 participants and for this purpose lotare method would be used to select the participants on comparison of calcaneal taping , planter fascia stretching and sham taping for one week for acute treatment . Each groups contain 7 participants with heel pain with baseline treatment will be given to each of the groups .||||
33955700|NCT06567431|||COHORT||PROSPECTIVE|||||||
33955701|NCT02032446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163819|NCT02275663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163820|NCT01314001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163821|NCT03841422|||COHORT||PROSPECTIVE|||||||
34163822|NCT04713956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163823|NCT06009835|||CASE_ONLY||PROSPECTIVE|||||||
34163824|NCT01862523|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34163825|NCT06466460|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163826|NCT05552963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851294|NCT00650351|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33851295|NCT04940026|NA|SINGLE_GROUP||OTHER||NONE||||||
33851296|NCT00798915|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33851297|NCT05790330|||COHORT||PROSPECTIVE|||||||
33851298|NCT01921010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851299|NCT03813420|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163827|NCT04851054|||CASE_ONLY||PROSPECTIVE|||||||
33851300|NCT05500443|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The tablets have identical appearance, including taste, color, and size. The randomization-list is available to the data- and safety monitoring board, but patients, nurses, physicians and other data collectors are blinded to the allocation during the study.|Patients are randomly assigned in a 1:1 ratio to either daily oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) (720 μg/day, K2VITAL®Delta) and D (25 μg/day) or placebo for 24 months. Treatment of both groups will last for at least 24 months. To evaluate progression in CAC score, a non-contrast CT-scan is performed at baseline and after 12 and 24 months of follow-up.|t|t|t|t
33851301|NCT00029133|RANDOMIZED|||TREATMENT||||||||
33851302|NCT00188760|||CASE_CONTROL||PROSPECTIVE|||||||
34163828|NCT04444466|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|This is an investigator- and participant-blind study.|Cohort design|t|t|t|t
33955702|NCT03870061|RANDOMIZED|PARALLEL||PREVENTION||NONE|Potential participants in treatment communities likely interact with implementing staff (either to receive the program, or in passing). Potential participants in control communities usually only interact with data collection staff. They are informed about the studies' general goals.|"The study will be structured as a two-arm cluster RCT. One arm (83 clinics) will serve as the control and will operate as the status quo, while the other arm (84 clinics) will receive New Incentives full program. This design will measure the causal effect of New Incentives' program on the likelihood of an infant receiving a vaccine.~New Incentives, an international non-governmental organization (NGO), is addressing the apparent shortfall in demand for immunization by offering cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. To be eligible, the child must reside in the catchment area of the clinic and fall within the age range targeted for the vaccination in question. Infants do not need to have received the previous vaccine in the schedule to be eligible. Incentives are paid in cash by a New Incentives staff member who also ensures the infant meets the eligibility criteria outlined above."||||
33955703|NCT02960724|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163829|NCT03625284|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163830|NCT06727396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163831|NCT04104737|NA|SINGLE_GROUP||OTHER||NONE||||||
34163832|NCT05367791|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163833|NCT01691157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163834|NCT04276233|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
34163835|NCT06514001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34163836|NCT02842294|||COHORT||PROSPECTIVE|||||||
34163837|NCT00195533|||COHORT||PROSPECTIVE|||||||
34163838|NCT02044055|||COHORT||RETROSPECTIVE|||||||
34163839|NCT06169553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163840|NCT04451941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163841|NCT04724863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163842|NCT05062135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective open-label clinical trial||||
34163843|NCT02472301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34163844|NCT02034877||||PREVENTION||NONE||||||
34163845|NCT01111617|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163846|NCT05529693|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163847|NCT06149078|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163848|NCT04522167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163849|NCT00782717|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34163850|NCT04423055|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163851|NCT03128242|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34163852|NCT06726434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163853|NCT04372420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and outcome assessor are masked from the study|Group A- RhBMP-2 absorbable sponge is placed in grade II furcation and Group B- PRF is placed in the grade II furcation|t|f|f|t
34163854|NCT06227897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163855|NCT03133507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34163856|NCT05941234|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163857|NCT02928575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163858|NCT05180383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163859|NCT06147141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Online Peer Companion Intervention group (OPCI) and Wait-List Group (WLG)|f|f|t|t
34163860|NCT04781686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163861|NCT06503666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study, masking of AGYW-MF participants is not possible. Our research assistants will be masked to the randomization scheme.|AGYW-MF will be randomized to either ZAIMARA or Health Promotion.|f|f|f|t
34163862|NCT05171088|||OTHER||PROSPECTIVE|||||||
34163863|NCT02668458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163864|NCT03826069|RANDOMIZED|PARALLEL||OTHER||SINGLE|Expert endoscopists will assess the performance of the participants during simulated colonoscopy, simulated polypectomies, simulated scenarios, and two live colonoscopy procedures. Assessors will have no knowledge of the group assignments and assessments will be done by viewing video recordings of the participants. The videos will be edited to remove the faces and other identifiable characteristics of the participants and patients.|Parallel group, single-blinded, randomized controlled trial|f|f|f|t
34163865|NCT01362829|||COHORT||PROSPECTIVE|||||||
33851303|NCT02176213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955704|NCT00670527|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33955705|NCT02263846|||CASE_ONLY||PROSPECTIVE|||||||
33955706|NCT06422949|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33955707|NCT01884194|||COHORT||RETROSPECTIVE|||||||
33955708|NCT01607398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955709|NCT04551859|NA|SINGLE_GROUP||OTHER||NONE||||||
33955710|NCT05610098|||COHORT||PROSPECTIVE|||||||
33851304|NCT04025112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851305|NCT05730062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double (Participant, Outcomes Assessor)|This is a placebo controlled (oxycodone vs placebo) crossover study in patients initiating one of the following SSRIs (Paroxetine, Sertraline, Citalopram, Escitalopram)|t|f|t|t
33851306|NCT06610708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851307|NCT04906408|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Patient will not know what they received until randomization after consent process, surgeon will find out the day of surgery|Partially blinded prospective, randomized-controlled trial|f|f|t|f
33851308|NCT00411853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955711|NCT03287908|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955712|NCT05406310|||CASE_CONTROL||PROSPECTIVE|||||||
33955713|NCT05217537|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955714|NCT00143416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955715|NCT05138614|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices along with MOUD: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery|f|f|f|t
33955716|NCT00580931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163866|NCT04975776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study staff entering data will be blinded to the condition. The researchers will provide some supervision to the health care professional who deliver the treatment. The researchers will therefore know the identities of the health care professionals they supervise. However, outcome data will be pseudonymized, so researchers will be blinded during outcome assessment. It is not possible to blind the health care professionals delivering the treatment or patients receiving it.|A multi-center randomized controlled trial in primary health care with two parallel study arms: (1) sleep restriction group therapy (experimental condition) and (2) sleep hygiene (control condition).|f|f|t|f
34163867|NCT01359345|NA|SINGLE_GROUP||SCREENING||NONE||||||
34163868|NCT04015206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will aply the scales being blind for the arm the participant was assigned|Study Type: Interventional Enrollment: 104 participants Allocation: Randomized Intervention Model: Parallel|f|f|f|t
34163869|NCT03468244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163870|NCT02085694|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163871|NCT04998955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor was blinded with regards to which intervention group the participants had been assigned.|Randomized controlled trial|f|f|f|t
33746687|NCT06356610|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Study participants will know when they are using their UBCC (usual brand combustible cigarette) and the nicotine gum. However, participants will not be informed of which Ploom® HTS (heated tobacco stick) product they are using. Participants will not see the stick or device packaging.|This is a randomized, controlled, six-way crossover clinical study to characterize the nicotine PK and subjective effects of HTPs (2 menthol varieties, Products A and B; 2 tobacco flavor varieties, Products C and D). The study will include participants' UBCC (Product F) and a nicotine gum (Product E) as high and low abuse liability reference products. Sponsor will prepare the randomization schedule. On Day -1 participants will be randomized at 1:1:1:1:1:1 ratio into 1 of 6 sequences as listed below. At least 60 participants will be randomized to ensure approximately 48 completed participants, with approximately 24 menthol and 24 non-menthol cigarette smokers. Participants will be stratified by sex and cigarette type for each of the sequences. A 6x6 Latin Square with the following sequences will be used for the randomization: Sequence 1 = ABFCED Sequence 2 = BCADFE Sequence 3 = CDBEAF Sequence 4 = DECFBA Sequence 5 = EFDACB Sequence 6 = FAEBDC.|t|f|f|f
34163872|NCT00249509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34163873|NCT05759494|||COHORT||CROSS_SECTIONAL|||||||
34163874|NCT00971334|||||PROSPECTIVE|||||||
33746688|NCT03149094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163875|NCT04329910|||COHORT||CROSS_SECTIONAL|||||||
33746689|NCT06006520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||oropharyngeal exercises and aerobic exercises|f|f|f|t
33746690|NCT01726192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746691|NCT06670898|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163876|NCT00226382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163877|NCT03263273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163878|NCT01922141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163879|NCT06725511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34163880|NCT05192993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163881|NCT03524014|||CASE_CONTROL||PROSPECTIVE|||||||
34163882|NCT03123666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163883|NCT00860171|NA|SINGLE_GROUP||TREATMENT||NONE||A single site, open label clinical trial.||||
34163884|NCT06725888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163885|NCT03884790|NA|SINGLE_GROUP||OTHER||NONE||||||
34163886|NCT05152108|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33746692|NCT00277264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746693|NCT00493766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746694|NCT02313142|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33746695|NCT06670495|||CASE_ONLY||CROSS_SECTIONAL|||||||
33746696|NCT06636162|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Ten patients will be enrolled and treated with DSP-0390, and if the patients tolerate dosing well, another ten patients will be enrolled and treated with a higher dose of DSP-0390.||||
33746697|NCT04607967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746698|NCT00001048||||TREATMENT||||||||
33746699|NCT00653809|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746700|NCT06417099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746701|NCT03399734|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33746702|NCT02053948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746703|NCT02866253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746704|NCT05712291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746705|NCT02334800|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33746706|NCT02610062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746707|NCT06019468|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking|||||
33746708|NCT02378168|||||RETROSPECTIVE|||||||
33851309|NCT06414473|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All participants, investigators, and study personnel will be blinded to treatment order assignments throughout the study.|Randomized, double-blind, placebo-controlled, clinical trial|t|f|t|t
33851310|NCT01714531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851311|NCT02518737|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33851312|NCT01303731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851313|NCT06610695|||OTHER||OTHER|||||||
33851314|NCT04037267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851315|NCT00249002|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851316|NCT02142140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851317|NCT02727062|||COHORT||PROSPECTIVE|||||||
33851318|NCT03170037|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Comparison of 2 two-handed mask ventilation techniques' ease to anesthesia providers||||
33851319|NCT04675151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851320|NCT03228602|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34163887|NCT03174366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059646|NCT00958607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059647|NCT06184139|||COHORT||RETROSPECTIVE|||||||
34163888|NCT03109639|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The pathologist will be blinded to the needle used for specimen collection.|The participants will be randomised to one of the two groups. The first group will undergo tissue acquisition using the conventional EUS needle. After this, the lesion will be punctured again using the experimental Acquire EUS FNB needle to obtain tissue. In the second group, the experimental Acquire EUS FNB needle will be used first followed by the conventional needle to acquire tissue.|f|f|f|t
34163889|NCT03066193|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive two active medications and will be followed-up bi-weekly for 12 weeks.||||
34163890|NCT03837145|||CASE_ONLY||PROSPECTIVE|||||||
34163891|NCT01460134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163892|NCT03306940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163893|NCT06725095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sealed envelopes||t|t|t|t
34163894|NCT05028452|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group posttest only design||||
34059648|NCT02515994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059649|NCT01549041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059650|NCT05787366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, multicenter, controlled, randomized open-labelled study||||
34059651|NCT01384019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059652|NCT02745912|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059653|NCT01280682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059654|NCT06519409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059655|NCT06214702|||CASE_CONTROL||PROSPECTIVE|||||||
34059656|NCT04441476|||COHORT||PROSPECTIVE|||||||
34059657|NCT03647774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"A multicenter, open-label treatment study. Extended-release naltrexone hydrochloride injectable suspension (Vivitrol®) (later referred to as XR-NTX) 380 mg/4 weeks One control group enrolled in the national ART program receives treatment as usual; flexible dose of daily oral buprenorphine or buprenorphine-naloxone in line with the clinical guidelines in Norway"||||
34059658|NCT06451796|||COHORT||PROSPECTIVE|||||||
34059659|NCT05514210|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34059660|NCT05734950|||OTHER||RETROSPECTIVE|||||||
34059661|NCT05827575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059662|NCT01807416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059663|NCT03034473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746709|NCT05771753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746710|NCT03743038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Eligible subjects will be randomized (1:1) to treatment with Test Article A to one side of the face versus Test Article B on the contralateral side.|t|f|f|t
33746711|NCT02534857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746712|NCT02874482|||CASE_CONTROL||PROSPECTIVE|||||||
33746713|NCT01820676|||COHORT||PROSPECTIVE|||||||
33746714|NCT05004623|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is an early feasibility study.||||
33851321|NCT04326166|||OTHER||PROSPECTIVE|||||||
33851322|NCT04221399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851323|NCT04137094|RANDOMIZED|PARALLEL||OTHER||NONE||Adult ED patients who decline rapid HIV/HCV screening will be randomly assigned to the ED medical staff arm or the HIV/HCV counselor arm. Within each arm, participants further will be randomly assigned to receive the persuasive health communication intervention or watch the CDC HIV/HCV testing brochures-based video.||||
34059664|NCT01801280|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059665|NCT02680613|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The participants were not aware of which group they were randomized to. The care provider providing the screening service was not aware of the group of the participant.||t|t|f|f
34059666|NCT03721588|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059667|NCT05563402|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163895|NCT01673997|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163896|NCT04999995|||COHORT||PROSPECTIVE|||||||
34163897|NCT03078556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163898|NCT02743013|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163899|NCT03308006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163900|NCT00114855|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34163901|NCT06162780|||OTHER||PROSPECTIVE|||||||
34163902|NCT00819936|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34163903|NCT03158194|NA|SINGLE_GROUP||TREATMENT||NONE||Single-subject multiple baseline design.||||
34163904|NCT01243723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163905|NCT01851629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34163906|NCT03068702|||CASE_ONLY||RETROSPECTIVE|||||||
34163907|NCT05187039|||COHORT||PROSPECTIVE|||||||
34163908|NCT02245945|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163909|NCT01698814|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34163910|NCT02294058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34163911|NCT06056661|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163912|NCT05330208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||SHR-1816 injection compared with placebo|t|t|t|t
34163913|NCT06348446|||COHORT||RETROSPECTIVE|||||||
34059668|NCT01573416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059669|NCT05715047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746715|NCT01873365|||COHORT||PROSPECTIVE|||||||
34059670|NCT02557373|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34059671|NCT02608255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059672|NCT01314105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059673|NCT03605940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059674|NCT01939626|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|To minimize the possible bias for the primary outcome, the embryologist performing the morphologic evaluation on day 3 and 5-6 was blinded to the treatments. The physician, the embryologist, and the couple were also blinded to the culture group from which the embryo had been selected for transfer.|"This study was a two-arm, prospective, randomized, controlled clinical trial performed at four independent IVF clinics. Ovarian stimulation and oocyte collection and fertilization were performed as per each clinic's practice. If \>6 oocytes from the patient were fertilized, the resulting zygotes underwent stratified randomization into the two different media.~Allocation was performed in a 1:1 ratio according to a computer-generated randomization list for each couple, which was provided in sealed and numbered envelopes to each clinic.~Zygotes randomized into G-1/G-2 underwent a media change from G-1 to G-2 on day 3 and subsequent culture until days 5-6. The zygotes randomized to G-TL were cultured continuously without any media change until days 5-6."|t|t|t|f
34059675|NCT05783024|||COHORT||RETROSPECTIVE|||||||
34059676|NCT04836481|||OTHER||PROSPECTIVE|||||||
34059677|NCT00771511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059678|NCT06623903|||COHORT||PROSPECTIVE|||||||
34059679|NCT02172586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059680|NCT04764084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059681|NCT05299372|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34059682|NCT02195427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059683|NCT05814692|||OTHER||CROSS_SECTIONAL|||||||
33746716|NCT05956964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Subjects will be randomized to different arms via a matched-pairs design using the following criteria: age, sex, and race. Within each arm, the loaded limb will serve as an internal control to assess effects of unloading.||||
34163914|NCT06277063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746717|NCT03808675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to nature of the intervention (exercise), the participant cannot be blinded. However, assessors for various outcomes will be blinded to the group status.|One-year, single-blind, parallel group, randomized controlled trial (RCT) that compares the effects of moderate aerobic exercise vs. usual care + health education|f|f|f|t
33746718|NCT06191926|||CASE_CONTROL||RETROSPECTIVE|||||||
33746719|NCT00553267||PARALLEL||TREATMENT||||||||
33746720|NCT04817280|||CASE_CONTROL||RETROSPECTIVE|||||||
33746721|NCT04433169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746722|NCT05772793|||COHORT||PROSPECTIVE|||||||
34163915|NCT04526626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163916|NCT03406637|||CASE_ONLY||OTHER|||||||
34163917|NCT04484818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34163918|NCT04007263|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34163919|NCT06172179|||COHORT||RETROSPECTIVE|||||||
34163920|NCT00233766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746723|NCT01265069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746724|NCT04320069|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, multi-center, prospective clinical study.||||
33746725|NCT00485485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746726|NCT01091311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746727|NCT02047019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746728|NCT06039020|||COHORT||PROSPECTIVE|||||||
33746729|NCT05897099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746730|NCT02107521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33746731|NCT04616625|||COHORT||PROSPECTIVE|||||||
33746732|NCT01674036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746733|NCT03385876|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Assignment||||
33765337|NCT03597035|NA|SINGLE_GROUP||TREATMENT||NONE||An open label proof-of-concept clinical trial in 50 patients with Type II diabetes evaluating the effects of MRA + Patiromer on LV mass and plaque regression over 12 months of treatment by magnetic resonance imaging (MRI).||||
33765338|NCT01261715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765339|NCT02912468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Dupilumab and placebo were provided in matching 2 milliliter (mL) pre-filled syringes. To protect the blind, each treatment kit was prepared such that the dupilumab dose and its corresponding placebo volume were identical and indistinguishable and were labelled with a treatment kit number.||t|f|t|f
33765340|NCT04848883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Evaluators of secondary outcomes will be blind related to the intervention.|"Six primary care centres will be randomised by conglomerates in 3 parallel groups. First group with three randomised centres will receive a conventional AMS, meanwhile the three other parallel randomised centres will include an infectious diseases specialist in the AMS group and a biweekly meetings.~List of study sites: El Castells from Castelldefels, Prat de Llobregat 2, Gava 1, Viladecans 2, Hospitalet de Llobregat 2 Sant Josep and Santa Eulàlia Nord."|f|f|f|t
33765341|NCT01358838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765342|NCT02218840|||COHORT||PROSPECTIVE|||||||
33765343|NCT04062708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765344|NCT03906305|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"In this study patients will receive dry needling intervention in shoulder muscles. The following muscles will be addressed: upper trapezius, supraspinatus, deltoid anterior fibers and infraspinatus.~They will also receive physical therapy based on Bobath concept. All the subjects belong to Madrid Polibea Sur neurorehabilitation clinic. The sample of the study is estimated to consist of twenty patients, with a washout period of forty five days after the intervention.~The data will be collected by an external physical therapist. All the therapists belong to Polibea Sur neurological clinic and Madrid Rey Juan Carlos University departments of physical therapy, occupational therapy, rehabilitation and physical medicine, experts in neurological treatment and trained in dry needling."|t|f|t|t
34059684|NCT04375904|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II non-randomised, multi-centre, single arm trial assessing the safety of patients receiving image guided SABR in 8 fractions of 7.5Gy. The treatment will adhere to organ at risk dose-volume histogram constraints allowing a minimum dose coverage of 75% to 95% of the planning target volume (PTV) coverage, and a minimum dose of 75% to 99% of the gross tumour volume (GTV), using dose intensity modulation. These minimums are chosen to represent at least an equivalent BED to the RT standard fractionation of 55 Gy in 20 fractions based on actual treatment dose of 7.5 Gy in 8 fractions. The safety of the regimen will be based on the rate of ≥ Grade 3 treatment related toxicities per CTCAE V5 occurring between start of treatment and one-year from the end of treatment, which are possibly, probably or definitely related to radiotherapy.||||
34059685|NCT02697565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059686|NCT00672841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059687|NCT01502137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059688|NCT04077138|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059689|NCT03486002|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059690|NCT01572311|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059691|NCT02333383|||CASE_ONLY||PROSPECTIVE|||||||
34059692|NCT01959698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059693|NCT06288269|||COHORT||RETROSPECTIVE|||||||
34059694|NCT03391804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163921|NCT01365364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34163922|NCT00740584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163923|NCT06538155|||COHORT||RETROSPECTIVE|||||||
34163924|NCT00240461|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34163925|NCT05423314|||OTHER||RETROSPECTIVE|||||||
34163926|NCT01373658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34163927|NCT03226743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163928|NCT04459507|||COHORT||OTHER|||||||
34163929|NCT04637295|||COHORT||CROSS_SECTIONAL|||||||
34163930|NCT04236362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163931|NCT03959059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163932|NCT01558947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163933|NCT02768779|||COHORT||PROSPECTIVE|||||||
33746734|NCT05829902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A copy of the randomization list will be provided to those packing the product kits. The randomization list is a document that consists of randomization numbers, which uniquely assign each study patient to one of the treatments. The sponsor and all staff directly involved in the trial will thus be blinded to the product allocated to the participants. The randomization number will be documented.|This study is a randomized, placebo-controlled, parallel intervention with two arms. The study is divided into three phases: the run-in period (14 days), the intervention period (14 days) and the follow-up period (14 days). Eligible participants will be randomized in a 1:1 ratio to receive either lemon balm extract or a placebo. Randomization will be stratified by ISI-value and age at baseline. Treatment assignments will be pre-planned according to a computer-generated randomization scheme prepared by a vendor.|t|t|t|t
33746735|NCT03821311|NA|SINGLE_GROUP||TREATMENT||NONE||It's a prospective, single-center, pilot, pathophysiological study.||||
33746736|NCT06669052|||COHORT||PROSPECTIVE|||||||
33746737|NCT03843918|NA|SEQUENTIAL||TREATMENT||NONE|Phase I: Open label; Phase II: Open label;|Phase I: 3+3 design for dose escalation Phase II: designed as a single arm, multicenter trial||||
33746738|NCT03278665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746739|NCT03266588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746740|NCT00000216||||TREATMENT||||||||
33746741|NCT05850689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33746742|NCT01763567|||||PROSPECTIVE|||||||
33746743|NCT04152733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33765345|NCT04822740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765346|NCT03230383|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33765347|NCT02687321|||COHORT||PROSPECTIVE|||||||
33765348|NCT06422455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765349|NCT01985828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765350|NCT05190484|||CASE_ONLY||PROSPECTIVE|||||||
33765351|NCT02710786|||COHORT||PROSPECTIVE|||||||
33765352|NCT03035305|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765353|NCT00603265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765354|NCT00944658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765355|NCT01674621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Since the abaloparatide injection arm was administered subcutaneously (SC), it was not possible to blind this arm of the study. Therefore, abaloparatide-SC was considered a reference drug, but the centralized BMD assessments and bone marker evaluations remained blinded to all treatment assignments.||t|f|t|t
33765356|NCT00276107|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33765357|NCT06031597|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33765358|NCT05963152|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||1:1:1 parallel group design||||
33765359|NCT02410967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33765360|NCT01788696|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33765361|NCT01161472|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33765362|NCT06230458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765363|NCT00056940|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33765364|NCT02842944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34163934|NCT02733523|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34163935|NCT03306992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163936|NCT06727136|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study involves 2 parts (A and B) and 3 cohorts (Cohort 1, 2 and 3) of which Cohort 2 has a crossover design.||||
34163937|NCT06243640|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34163938|NCT05102864|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34163939|NCT04751318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34163940|NCT01054456|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163941|NCT05848895|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34163942|NCT05711732|||COHORT||PROSPECTIVE|||||||
33851324|NCT00647491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059695|NCT04407429|||COHORT||PROSPECTIVE|||||||
33851325|NCT02674815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851326|NCT06594744|RANDOMIZED|PARALLEL||TREATMENT||NONE||"EVL group:~EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.~Carvedilol group:~The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&amp;amp;lt; 90 mmHg), bradycardia (resting heart rate \&amp;amp;lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial."||||
33851327|NCT01009580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851328|NCT02878902|||COHORT||CROSS_SECTIONAL|||||||
33851329|NCT00998998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851330|NCT03809559|||COHORT||CROSS_SECTIONAL|||||||
33851331|NCT00912301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851332|NCT05941728|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33851333|NCT02508246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851334|NCT06132243|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851335|NCT04538690|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851336|NCT02814539|||COHORT||PROSPECTIVE|||||||
33851337|NCT06596447|||COHORT||PROSPECTIVE|||||||
33851338|NCT04613349|||CASE_ONLY||PROSPECTIVE|||||||
33851339|NCT04684394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851340|NCT06023563|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups, intervention and the control, will be compared within and between longitudinally 3 times. Before-, after- and 4 weeks after the intervention.||||
33851341|NCT00936273|||COHORT||CROSS_SECTIONAL|||||||
33851342|NCT06420622|||COHORT||CROSS_SECTIONAL|||||||
33851343|NCT02279394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851344|NCT06335602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851345|NCT00689585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851346|NCT00432146|||||PROSPECTIVE|||||||
33955717|NCT03682211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All clinical and research staff, patients and parents are blinded to the treatment allocation. All study drugs will be packaged in blinded trial packs by a clinical trial pharmacist who is blinded to interventions and outcomes.The matched size and shape of the placebo ampoule is necessary to maintain blinding of intervention by the investigators.|randomised, double-blind, double-dummy active control trial|t|t|t|f
33955718|NCT00421811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059696|NCT04122664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients randomised into one of two groups||t|f|f|f
34059697|NCT04453800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be conducted in a double-blind form. The clinical research team participating in the study will be divided into two groups: blind and non-blind members, strictly ensuring that researchers and subjects are blind||t|f|t|f
34059698|NCT03309826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analysis of all outcome measures will be conducted on a blinded basis.||f|f|f|t
34059699|NCT02617719|||CASE_ONLY||PROSPECTIVE|||||||
34059700|NCT00840242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059701|NCT01704001|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059702|NCT06499974|||COHORT||PROSPECTIVE|||||||
34059703|NCT05961475|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34059704|NCT02898558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059705|NCT04390763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059706|NCT01944670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851347|NCT04078633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||N/A - the study does not involve drug or biologic products. The study looks at the impact of behavioural interventions|t|f|f|f
33851348|NCT04498091|||COHORT||PROSPECTIVE|||||||
33851349|NCT05014646|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851350|NCT04234854|||COHORT||PROSPECTIVE|||||||
33851351|NCT02588300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851352|NCT03439254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851353|NCT00007449||||TREATMENT||||||||
33851354|NCT04836065|||COHORT||PROSPECTIVE|||||||
34059707|NCT03774225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessments where conducting by a blind examiner (investigator) in different days of the training. The examinator wasn't know which group the participant would be performing|Prospective, single-blind, parallel-group, randomised trial|f|f|t|f
34059708|NCT00803205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059709|NCT03423966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059710|NCT05248334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059711|NCT05583279|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The proposed project consists of a mixed-methods cross-over design involving a three-phase clinical trial aimed at assessing the feasibility, acceptability, and preliminary effectiveness of comprehensive DBT-A adapted for youth in the GAJJS. DBT-A/outcomes will be assessed across two different levels of care (i.e., at short- vs. long-term facilities) and service delivery methods (i.e., in-person vs. telehealth).||||
34059712|NCT00623597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059713|NCT00344591|RANDOMIZED|PARALLEL||||NONE||||||
34059714|NCT00018291|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33746744|NCT03664713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluators will be blind to treatment. Participants cannot be blind to treatment due to the impossibility of creating a sham alternative to EMDR therapy, due to its use of bilateral stimulation.|The project will be carried out in the sub-acute and long-stay inpatient wards of Parc de Salut Mar, Institute of Neuropsychiatry and Addiction (INAD), located in the Centre Forum. It consists of a single-blind RCT with two parallel branches, 1) individual therapy with EMDR and TAU, and 2) TAU only, with patients matched by age, sex, psychiatric diagnosis and premorbid IQ. Once the patient has been stabilized with psychotropic medication and has begun taking part in the psychosocial activities proposed by the unit, they will be offered the chance to receive 25 individual EMDR therapy sessions, each lasting 60 minutes. The patients will be evaluated at the beginning of their hospital stay, again when discharged from the unit and then at 6 and 12 month follow up.|f|f|f|t
33746745|NCT04181554|||CASE_ONLY||PROSPECTIVE|||||||
33746746|NCT02007577|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33746747|NCT02221934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746748|NCT05905952|||OTHER||CROSS_SECTIONAL|||||||
33746749|NCT02367911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746750|NCT02220972|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33746751|NCT05289804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The investigators have opted to use a parallel-group design as it is unclear what the carry-over effect and/or wash-out period will be for NITESGON. Patients will be randomized after the baseline evaluation and will be assigned to receive one of the four possible types of NITESGON. To eliminate subjective bias, all patients and the investigator testing the endpoint measures will be blinded to the type of intervention.|t|f|t|f
33746752|NCT01730937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746753|NCT03832010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746754|NCT02091726|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746755|NCT06227585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746756|NCT05054790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746757|NCT06489613|||COHORT||PROSPECTIVE|||||||
33746758|NCT05522803|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33746759|NCT02703883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746760|NCT03497923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|quadruple|2 arms, randomized, double blind trial|t|t|t|t
33746761|NCT03811067|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33746762|NCT02011438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33746763|NCT02734342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746764|NCT06635707|||COHORT||PROSPECTIVE|||||||
33746765|NCT01657422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955719|NCT03305159|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients will be randomized to the control or intervention and not be told which antiseptic they received for the surgical preparation of the vagina.|Eligible patients will be randomized to either the control (povidone iodine) or intervention (chlorhexidine gluconate).|t|f|f|f
33955720|NCT03352804|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33955721|NCT00596973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955722|NCT04145973|||COHORT||PROSPECTIVE|||||||
33955723|NCT03365869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955724|NCT03901352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the Double-blind Phase, masking will be triple (as shown above). During the Open Extension Phase, there will be no masking - the allocation is not applicable.|"During the Double-blind Phase, participants will be randomized into parallel treatment arms.~During the Open Extension Phase, all participants will be assigned to a single group."|t|t|t|f
33955725|NCT00517868|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33955726|NCT04438980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746766|NCT06295562|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955727|NCT05910840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data analysts|"Active arm: Participants randomized to the active arm will have access to the Support-t online training and peer support platform in addition to their usual diabetes care, over the 18 month intervention period. Support-t contains 3 components: 1) Educational material, 2) News blog and 3) Patients' discussion forum.~Control arm: Participants randomized to usual care only will attend their usual diabetes clinic visits, over the 18-month intervention period, which consists of visits with their health care provider and ad-hoc diabetes education with nurses and dietitians."|f|f|f|t
33955728|NCT00265460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955729|NCT01570439|||COHORT||PROSPECTIVE|||||||
33955730|NCT05262894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33955731|NCT03394404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955732|NCT03902249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33955733|NCT06501131|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34059715|NCT04759859|||CASE_CONTROL||PROSPECTIVE|||||||
34059716|NCT01300208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059717|NCT02014922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746767|NCT05734118|NA|SINGLE_GROUP||OTHER||NONE||||||
33746768|NCT01592032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746769|NCT01415830|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33746770|NCT02429336|||CASE_CONTROL||PROSPECTIVE|||||||
33746771|NCT02653482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746772|NCT02778607|||CASE_CONTROL||PROSPECTIVE|||||||
33746773|NCT03812146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open clinical trial|f|f|f|t
33765365|NCT05529784|||COHORT||RETROSPECTIVE|||||||
33765366|NCT02872298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765367|NCT06257368|||COHORT||PROSPECTIVE|||||||
33765368|NCT01216163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765369|NCT04652830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors performing the follow-up ultrasound and clinical examination are blinded to the allocation|Single-blinded parallel randomized controlled trial|f|f|f|t
33765370|NCT02218528|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34059718|NCT02252471|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163943|NCT04733053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The components of each treatment arm will be disclosed to participants as we wish to test the interventions under real world conditions whereby consumers are fully informed about the nature of the components before choosing whether or not they wish to participate. The research staff collecting non-self-reported outcome measures (including the primary outcome) will be blinded to group allocation. The staff member collecting laboratory measures at 6 months will be different to the staff member who collects the baseline data. It is not possible to blind physiotherapists as they are providing interventions to both trial arms (in order to ensure physiotherapist-related factors such as personality, clinical practice experience etc are similar across groups and cannot confound results). The person performing the statistical analyses will be blinded.||f|f|t|t
34163944|NCT01223729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34163945|NCT03491514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34163946|NCT05751837|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label, comparative, phase I safety and feasibility study, with correlative translational studies||||
34163947|NCT02766868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163948|NCT00482625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163949|NCT02404818|||COHORT||PROSPECTIVE|||||||
34163950|NCT06725264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Male and female subjects at least 18 years of age with moderate to severe granuloma annulare or cutaneous sarcoidosis affecting at least 5%body surface area.||||
34163951|NCT01552135|||CASE_ONLY||PROSPECTIVE|||||||
34059719|NCT03786692|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The design of this study will be an open label, randomized, phase 2 study in adult (≥ 18 years) male and female subjects with stage IV disease who have never smoked, irrespective of their driver mutation status, as well as subjects who have tumors that possess a driver mutation.~The study will be comparing the four agent treatment group (Arm A) that includes carboplatin + pemetrexed + bevacizumab + atezolizumab versus a three agent control group (Arm B) that includes carboplatin + pemetrexed + bevacizumab for 4 cycles, each cycle lasting for 3 weeks. Treatment will be followed by maintenance in both arms that will include all agents except carboplatin. There is no crossover in this study.~1. Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab~2. Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab"||||
34163952|NCT03618420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All study participants will receive the same intervention.||||
34163953|NCT03191630|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants in the intervention group will receive the combination of the SystemCHANGE and activity tracker intervention while participants in the control group will use activity trackers only. Intervention and control groups will receive the same instruction on use of the activity tracker, and have the same number of study contacts.||||
34059720|NCT03799406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059721|NCT03347344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Treatments will be presented in numbered boxes, labeled for this study according to the Good Manufacturing Practices by the General Agency of Equipment and Health Products (AGEPS).~Each numbered box will consist of 6 months of treatment: 20 blister packs of 20 active or placebo tablets"|Multi-centric, double-blind randomized, two-arm controlled study (one group with 50 mg riluzole twice a day versus one group with placebo), during one year|t|t|t|f
34059722|NCT05990959|||COHORT||RETROSPECTIVE|||||||
34059723|NCT00550862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059724|NCT03479593|||CASE_ONLY||PROSPECTIVE|||||||
34059725|NCT05173818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|f|t
34059726|NCT06620588|||COHORT||PROSPECTIVE|||||||
34059727|NCT05922527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059728|NCT01671566|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34059729|NCT00699231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059730|NCT00140530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059731|NCT04723563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059732|NCT04791605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Cemented femur stem Non-cemented femur stem|Gait of cemented femur stem of acute cervical collum femoris stem. Gait of non-cemented femur stem of acute cervical collum femoris stem.|f|f|f|t
34059733|NCT02663752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34163954|NCT02544659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163955|NCT03782701|RANDOMIZED|PARALLEL||TREATMENT||NONE||The left and right eye of each subject will be randomized to receive either Lumify or balanced saline placebo.||||
34163956|NCT03708978|||COHORT||OTHER|||||||
34059734|NCT05890430|||COHORT||PROSPECTIVE|||||||
34059735|NCT04481113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059736|NCT02205905|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059737|NCT04240860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059738|NCT04191941|NA|SINGLE_GROUP||TREATMENT||NONE||Novel CAR-T Cell Therapy||||
34059739|NCT05356975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851355|NCT05959954|||COHORT||PROSPECTIVE|||||||
33746774|NCT05720806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Physician performing surgical intervention will be blinded from surgery until first follow up. Also, physician performing ultrasound evaluation of hip capsule will remain blinded to weight bearing designation.|Subjects will be enrolled into either Weight bearing as tolerated group immediately or Flat foot weight bearing group for 2 weeks. Currently, flat foot weight bearing for the first 2 weeks is standard of care.|f|t|f|t
33746775|NCT01612403|||CASE_CONTROL||RETROSPECTIVE|||||||
33746776|NCT06532708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746777|NCT06082050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746778|NCT04154124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851356|NCT03224351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746779|NCT01844804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33746780|NCT06171945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33746781|NCT01494051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746782|NCT02624973|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33746783|NCT00153777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33746784|NCT06669078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746785|NCT02647658|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment of clusters (clinics). Cluster randomized trial.||||
33746786|NCT05072912|||OTHER||PROSPECTIVE|||||||
33746787|NCT04401579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746788|NCT02812810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746789|NCT06198569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851357|NCT03112564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851358|NCT02813629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851359|NCT00825916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33851360|NCT06143436|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851361|NCT04374851|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The subjects will not know which device they are using in each period (new or current) because they look exactly the same. The PI will also not know which device is used as they will be prepared for the PI before the Appointments.|Subjects will randomly wear the new device or the current device for the first period and then switch to the other device for the second period.|t|f|t|f
33851362|NCT02258308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851363|NCT02003573||SEQUENTIAL||TREATMENT||NONE||||||
33851364|NCT03339700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059740|NCT05220059|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double-blinded|Double-blind placebo controlled dose-response crossover study|t|f|t|t
34059741|NCT02947542|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34059742|NCT00698074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34059743|NCT03245697|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34059744|NCT02382796||||TREATMENT||NONE||||||
34059745|NCT00401544|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34059746|NCT01833936|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059747|NCT03619551|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be performed after eligibility is confirmed. Randomization between the two busulfan dose levels will be done separately in each genotype stratum, using permuted blocks. Randomization will be stratified further by donor type (Haploidentical related vs. Matched Unrelated Donor).||||
34059748|NCT01777568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The designated operating-room suite alternated between using either 30% oxygen as tolerated or 80% oxygen for periods of 2 weeks. For example, the first period used 30% oxygen, the second 80% oxygen, and so on. The oxygen concentration during the initial period was randomly designated by the study statistician. But, thereafter, oxygen delivery was not randomized on a per-patient or even per-period basis.|t|f|f|f
34059749|NCT00324142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059750|NCT01471509|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34059751|NCT02713438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34059752|NCT02637713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059753|NCT02222831|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34059754|NCT02581228|||COHORT||RETROSPECTIVE|||||||
34059755|NCT06619002|||COHORT||PROSPECTIVE|||||||
34059756|NCT01871766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059757|NCT01765829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059758|NCT03364517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled cluster study.|t|f|f|f
34059759|NCT05838950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34059760|NCT06226792|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34059761|NCT03001505|||COHORT||OTHER|||||||
34059762|NCT01289249|||COHORT||PROSPECTIVE|||||||
34059763|NCT04423627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, placebo controlled, parallel design|t|t|t|f
34059764|NCT03787303|NA|SINGLE_GROUP||TREATMENT||NONE|N/A (not applicable)|Triiodothyronine (T3) - IND Exempt||||
34059765|NCT06253741|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34163957|NCT05825326|||COHORT||RETROSPECTIVE|||||||
34163958|NCT01751100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34163959|NCT06725615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomised controlled intervention study|t|f|t|t
34163960|NCT01004289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163961|NCT01019070|NON_RANDOMIZED|PARALLEL||||NONE||||||
34163962|NCT02669459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34163963|NCT05605106|||CASE_CONTROL||PROSPECTIVE|||||||
34163964|NCT00089037||||SUPPORTIVE_CARE||NONE||||||
34163965|NCT01988714|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34163966|NCT04282668|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34163967|NCT00829842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34163968|NCT02595957|||COHORT||CROSS_SECTIONAL|||||||
34163969|NCT06342908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163970|NCT01051336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163971|NCT01961271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163972|NCT04062591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34163973|NCT03170661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746790|NCT02999776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746791|NCT04420325|||COHORT||PROSPECTIVE|||||||
33746792|NCT01503034|||CASE_CONTROL||RETROSPECTIVE|||||||
33746793|NCT04082065|RANDOMIZED|PARALLEL||OTHER||SINGLE|single|interventional|f|f|t|f
33746794|NCT03301051|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind||t|t|t|t
33746795|NCT06535451|||COHORT||PROSPECTIVE|||||||
33746796|NCT01278329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33746797|NCT01192906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059766|NCT01741506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059767|NCT04861116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059768|NCT06521255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059769|NCT06298513|||COHORT||PROSPECTIVE|||||||
34059770|NCT02167815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059771|NCT00291161|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059772|NCT02553434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059773|NCT00331513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059774|NCT04385875|RANDOMIZED|PARALLEL||OTHER||DOUBLE|AELIX-002 was a double-blind clinical trial. During ATI_extension, AELIX-002 will be unblinded and allocation will be disclosed to both participants and investigators.|"Participants of the AELIX-002 clinical trial were randomly allocated to one of the following arms:~* Vaccine: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20.~* Placebo: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration.~ATI_extension will keep allocation from AELIX-002 for a separate description of the results."|t|f|t|f
34059775|NCT04948034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059776|NCT04291456|NA|SINGLE_GROUP||TREATMENT||NONE|A blinded physician will complete the neurologic exam and determine the EDSS (and be blinded as to which trial the patient is participating in) and the radiologists reading the MRI scans will be blinded that the MRI scans are part of a clinical trial.|Non-inferiority Design||||
34059777|NCT02602613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059778|NCT05776316|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34059779|NCT06595459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059780|NCT05872100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34059781|NCT04794829|||COHORT||PROSPECTIVE|||||||
34059782|NCT01758978|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059783|NCT00420277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059784|NCT00326781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059785|NCT02703506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059786|NCT05809024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059787|NCT02653170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059788|NCT00556205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059789|NCT02672007|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34059790|NCT01577615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059791|NCT04288336|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34059792|NCT00326170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059793|NCT00241293|||DEFINED_POPULATION||OTHER|||||||
34059794|NCT05939791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059795|NCT03078413|||COHORT||CROSS_SECTIONAL|||||||
34059796|NCT00347594|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34059797|NCT00947024|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059798|NCT02768441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059799|NCT00454467|||COHORT||PROSPECTIVE|||||||
34059800|NCT05259410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059801|NCT02101359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059802|NCT02387775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059803|NCT01223066|||COHORT||PROSPECTIVE|||||||
34059804|NCT00800956|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34059805|NCT01043562|||COHORT||PROSPECTIVE|||||||
34059806|NCT01786824|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34059807|NCT02526875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059808|NCT00977704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059809|NCT00657306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059810|NCT01758198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059811|NCT01505738|||COHORT||PROSPECTIVE|||||||
34059812|NCT03326284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The protein doses provided will be masked. As all participants will receive the same amount and the drinks will taste similarly.|: Forty women (\~ 50 years) will be randomized to four groups. Following a five day hypocaloric diet (three groups) or an energy balanced diet (one group). The women will report to the laboratory to ingest one of three different protein doses.|t|f|f|f
34059813|NCT00771329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059814|NCT03216148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All pediatric patients with brain Tumor receive a FET-PET Investigation in Addition to conventional MRI at the end of the first-line therapy. In case of Progression or Relapse patients may receive a second FET-PET Investigation in Addition to Routine surveillance MRI.||||
34059815|NCT03981965|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three groups were designed for a 24 week duration of the study. Two groups performed physical activity in two 12-week periods. A health professional acted as a supervisor during the first period. The second period was autonomous, with women providing mutual support through whatsapp, a mobile phone based social network. The first group followed the guidelines emanated from the FOCUS European project. The third group was an inactive control.||||
34059816|NCT05112289|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34059817|NCT01090154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059818|NCT05304689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||two groups of patients||||
33746798|NCT02124967|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746799|NCT06670534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059819|NCT05754658|||COHORT||PROSPECTIVE|||||||
34059820|NCT00785434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059821|NCT00435019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163974|NCT04555460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163975|NCT02432417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163976|NCT06727201|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34163977|NCT03233113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre-determined condition allocation was listed in an Excel spreadsheet and concealed with black cell masking color. Interested individuals who met initial eligibility criteria during a pre-enrollment phone screening were entered in the order of screening in the assignment Excel spreadsheet (that was already masked to conceal condition assignment). Only the participant's therapist viewed the allocated condition immediately prior to the first treatment session by temporarily lifting the cell mask.|The current study follows a two-arm, parallel group RCT study design. Participants are randomized to either the active control arm (Exposure and Response Prevention) or the experimental arm (Exposure with Judicious Safety Behaviors). Participants are not offered the opportunity to choose their study condition, nor are they provided with an explanation of the difference between their assigned treatment arm and the alternative treatment arm. Randomization was achieved prior to initial participant recruitment via a random number generator with the condition that an equal number of participants be randomized to each condition.|f|f|f|t
34163978|NCT01702025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34163979|NCT03462719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163980|NCT02167802|||COHORT||PROSPECTIVE|||||||
33851365|NCT04802798|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double blinded|cross-over study|t|f|t|t
34163981|NCT06726590|||CASE_ONLY||OTHER|||||||
33851366|NCT05829356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study will be blinded to participants and sites (except for those preparing/administering study interventions. The sponsor will be unblinded.||t|f|t|f
33851367|NCT06183957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled trial|t|f|f|t
33851368|NCT03058835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33955734|NCT03819465|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatment arms for MEDI5752 (Arms A4 and B4) will enroll 42 and 60 patients, respectively. Arm B5 (AZD2936+chemotherapy) will enroll 60 patients.~For all other treatment arms, 30 patients will be enrolled into each arm; additional patients may be enrolled in order to have 30 evaluable patients per arm (ie, dosed)."||||
33955735|NCT03447470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open label design|"Module 1 monotherapy Dose escalation in those patients with advanced solid tumors while being monitored for safety and dose-limiting toxicity. This module will provide information on dosing and schedules for further module(s).~Module 2 will commence by enrolling patients with advanced solid tumors into a monotherapy dose escalation, in combination with a fixed dose of nivolumab (a known anti-cancer treatment). This module will provide information and safety and tolerability of the study drug or in combination with the anti-cancer treatment.~Module 3 will investigate the pharmacokinetic, Wnt pathway inhibition, incidence/severity of Wnt pathway related adverse events and anti-tumour activity of RXC004 when given at 2 different intermittent dosing schedules in selected patients with Wnt ligand dependent advanced tumours."||||
33955736|NCT02173132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059822|NCT03616561|||COHORT||PROSPECTIVE|||||||
34059823|NCT00835679|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34059824|NCT03825068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851369|NCT05900687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851370|NCT03710031|||COHORT||PROSPECTIVE|||||||
33851371|NCT04399070|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33851372|NCT01178385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851373|NCT01449136|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33851374|NCT04580342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851375|NCT06610812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trail|t|f|f|f
33851376|NCT03116737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851377|NCT00309296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059825|NCT04611737|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34059826|NCT02187575|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34059827|NCT00527644|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34059828|NCT03586479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre- and post-outcome assessments will be performed by an individual blind to arm assignment.|Children will be randomly assigned to one of three treatment arms|f|f|f|t
34059829|NCT03541330|NA|SINGLE_GROUP||OTHER||NONE||||||
34059830|NCT03133091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059831|NCT00842075|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34059832|NCT02777944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059833|NCT04984317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059834|NCT02425761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Adjudication committee reviews blinded notes, data collection forms, and films to determine shunt failure.|1 to 1 randomized trial comparing two commonly used shunt insertion entry sites.|f|f|f|t
34059835|NCT01258075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059836|NCT04104113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059837|NCT03909113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059838|NCT03059706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34059839|NCT02795520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059840|NCT02811497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059841|NCT05467618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial with non-probability consecutive sampling.||||
34059842|NCT04721704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059843|NCT01825083|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34059844|NCT02604550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34059845|NCT02910570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059846|NCT03416634|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||90 participants will use a wearable device and 90 will use a smartphone app to track activity. These groups will be further randomized to receive an automated motivational intervention, or a personalized motivational intervention or no additional intervention; each study arm will have 30 participants.||||
34059847|NCT01971697|||||PROSPECTIVE|||||||
34163982|NCT01684202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851378|NCT00212420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851379|NCT04903587|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851380|NCT03896204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955737|NCT05671991|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||"Randomized, placebo controlled, acute crossover study of empagliflozin in 30 chronic PD patients, with an 8 week pre post open label extension in all 30 patients where they will receive empagliflozin daily."|t|t|t|f
34163983|NCT06399289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34163984|NCT02197702|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|identical placebo||t|t|t|t
34163985|NCT04428151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34163986|NCT06554379|||COHORT||CROSS_SECTIONAL|||||||
34163987|NCT01837277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34163988|NCT05524779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163989|NCT06727058|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|"Modified double blind (participants; sites, except for those preparing/administering study intervention; and Sponsor will be blinded). Sponsor's internal safety monitoring team will be unblinded if necessary. Evaluation of the Safety of the sentinel cohorts will be unmasked for the Sponsor's safety Team."||t|f|t|t
34163990|NCT04627363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34163991|NCT03713281|NA|SINGLE_GROUP||TREATMENT||NONE|Although study includes one arm, Participant is masked to the identity of the investigational product.|||||
34163992|NCT02290015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34163993|NCT06420271|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||A randomized cross-over design will be used. A 3-weeks wash-out period will be observed between the two conditions (real and sham).|t|t|f|t
34163994|NCT04041271|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34163995|NCT03958357|||CASE_ONLY||PROSPECTIVE|||||||
34163996|NCT05223868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851381|NCT06610500|||COHORT||OTHER|||||||
33851382|NCT04974242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851383|NCT04881552|||COHORT||PROSPECTIVE|||||||
33851384|NCT00653445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851385|NCT05057845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851386|NCT03725085|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851387|NCT00271518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851388|NCT04894110|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Group 1: Open-Label, Dose-Escalation Study Group 2: Randomized, double masked|t|t|t|t
33851389|NCT02892786|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851390|NCT01877473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955738|NCT01901939|NA|SINGLE_GROUP||PREVENTION||NONE||observational||||
33851391|NCT02439073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33851392|NCT05010837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851393|NCT00000739||PARALLEL||TREATMENT||||||||
33851394|NCT04357197|NA|SINGLE_GROUP||TREATMENT||NONE||Single prospective single center study||||
33851395|NCT00297596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851396|NCT02844725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33851397|NCT02596438|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33851398|NCT01873066|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851399|NCT06225193|||COHORT||RETROSPECTIVE|||||||
33851400|NCT01455493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851401|NCT00086333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851402|NCT06012253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single Blind (Participant, Outcomes Assessor)|This is a randomized controlled trial consisting of two groups: experimental and control|t|f|f|t
33955739|NCT00952432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851403|NCT05104281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851404|NCT02359682|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851405|NCT03624348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will be blind to condition throughout data accrual.|Randomization to either digital meditation condition or wait-list control.|f|f|t|f
33893425|NCT06653621|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Double (Participant, Outcomes Assessor) . Given the distinct visual appearance of the liposomal bupivacaine (milky white) and bupivacaine (transparent), a double-blind study design is not feasible. Consequently, this study employs a single-blind approach where neither participants nor outcome assessors will be aware of treatment allocation. Healthcare providers administering the study drug will be aware of the treatment group assignment. Rigorous procedures will be implemented to minimize potential bias, including standardized outcome assessment tools, blinded data entry, and independent data analysis.|This study utilizes a factorial interventional design, where participants undergoing total knee arthroplasty surgery will be allocated into four separate groups. Group one will receive liposomal bupivacaine plus bupivacaine as a regional anesthetic for adductor block, the group two will receive bupivacaine for adductor block; the group three will receive liposomal bupivacaine plus bupivacaine as a regional anesthetic for femoral nerve block ; Group four will receive bupivacaine as a regional anesthetic for femoral nerve block .Two types of interventions are involved, namely, choice of anesthesia mode (2 levels: adductor block, femoral triangle block) and anesthetic administration (2 levels: bupivacaine liposomes and bupivacaine mixture, bupivacaine).The study aims to compare the analgesic efficacy, duration of pain relief, opioid consumption, between the four groups .|f|f|f|t
33955740|NCT04109768|NA|SINGLE_GROUP||PREVENTION||NONE||pre post intervention||||
33955741|NCT02756169|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33955742|NCT02591602|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33955743|NCT04831502|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33955744|NCT00769132|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33955745|NCT03094949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955746|NCT00573118|||CASE_CONTROL||RETROSPECTIVE|||||||
34163997|NCT03523767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The study clinician/ nurse will be aware of the nature of the injection. The study subjects and researcher collecting/analyzing the data will remain blinded to the intervention due to the possible confounding effects of the participant expectations and researcher analyzing the data.|In this double blind crossover design, each participant will receive saline injection or typhoid vaccine injection at the first study visit, and will then receive the other injection at the second study visit.|t|f|f|t
34163998|NCT03513276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34163999|NCT01130363|||CASE_CONTROL||PROSPECTIVE|||||||
34164000|NCT02750488|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34164001|NCT01369784|||CASE_ONLY||CROSS_SECTIONAL|||||||
34164002|NCT04891289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a multi-center, prospective randomized controlled phase II study.||||
34164003|NCT01311336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34164004|NCT00183326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164005|NCT02220829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164006|NCT02878317|||COHORT||PROSPECTIVE|||||||
34164007|NCT01124279|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34164008|NCT05159466|||COHORT||PROSPECTIVE|||||||
34164009|NCT04515212|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34164010|NCT00003411||||TREATMENT||||||||
34164011|NCT06725810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164012|NCT05440734|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The nature of the treatment (melatonin vs placebo) will only be unrevealed when the key parameters have been determined (e.g, PSG sleep scoring, alertness levels, vasomotor symptoms, adverse effects, hormone levels).|Randomized crossover placebo-controlled study|t|f|t|t
34164013|NCT02962661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164014|NCT00985868||||TREATMENT||NONE||||||
34164015|NCT04146350|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34164016|NCT05899140|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an exploratory study and will not use a placebo|2-arm randomized controlled trial||||
34164017|NCT06618118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164018|NCT01907464|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164019|NCT01359904|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
34164020|NCT05614037|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Test preparation (T) : Felodipine Controlled Release Tablets Specification: 5 mg Batch number: 22090301 Content: 100.8% Valid until: September 2024 Storage conditions: sealed, room temperature (10\~30℃) Manufacturer: Overseas Pharmaceuticals, Ltd. Supplier: Overseas Pharmaceuticals, Ltd. Reference preparation (R) :Felodipine Modified-release tablets(trade name: plendil ®) Specification: 5 mg Batch number: 2204 a11 Content: 99.1% Valid until March 2025 Storage conditions: below 25℃ Manufacturer: AstraZeneca AB Supplier: Overseas Pharmaceuticals, Ltd.||||
34164021|NCT05213702|RANDOMIZED|PARALLEL||TREATMENT||NONE||Male/non-pregnant female subjects between age 18-75 years, both inclusive, who will undergo Percutaneous Nephrolithotomy (PCNL).||||
34164022|NCT03738488|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Study model: Longitudinal, prospective, experimental, multi centric on a cohort of patients diagnosed of Renal Cell Carcinoma with Vascular Involvement from 2018 in either the HUVR or the HURC||||
34164023|NCT02363595|||COHORT||PROSPECTIVE|||||||
34164024|NCT06135974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study product is labeled in a blinded manner with a code. Only pharmacy will have the link to the code and treatment assignment. However, the one arm starting study product during antibiotic treatment will be unblinded for both participants and investigators. However, the laboratory staff conducting the analyses for the primary and secondary outcomes will remain masked.|This is a randomized trial with 5 arms|t|t|t|t
33955747|NCT06124846|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This parallel intervention study will collect fMRI data in adolescents ages 15-18 years old with and without CUD at three different timepoints over the course of their intervention. abstinence. Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol.||||
33955748|NCT00024271||||TREATMENT||||||||
33955749|NCT06453707|||OTHER||PROSPECTIVE|||||||
33955750|NCT01371006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955751|NCT05941845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164025|NCT01987102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164026|NCT05894447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164027|NCT04683029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164028|NCT05488457|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their cesarean delivery.||||
34164029|NCT06260163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164030|NCT06440005|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A mTPI-2 design (Guo et al, 2017) with a target DLT rate of at most 30% will be applied for dose-escalation and expansion to determine the AGX101 RP2D.||||
34164031|NCT02552134|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164032|NCT01391663|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34164033|NCT03919357|||COHORT||PROSPECTIVE|||||||
34164034|NCT01559571|||COHORT||PROSPECTIVE|||||||
34164035|NCT05590585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164036|NCT02019511|||COHORT||PROSPECTIVE|||||||
34164037|NCT01905878|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study was open label-single arm trial, which was done at Pharmacology and Therapeutic Department and Clinical Pathologic Department of Faculty Medicine of University of Indonesia Cipto Mangunkusumo Hospital. The study drug was enteric coated DLBS1033 tablet, which contained 490 mg bioactive protein fraction; and produced by PT Dexa Medica, Tangerang, Indonesia.||||
34164038|NCT05580081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The RCT is a parallel group design, in which those in Control will be offered i-CAN after the 18 week waiting period.||||
34164039|NCT02416739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164040|NCT00200603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164041|NCT03507205|||COHORT||PROSPECTIVE|||||||
34164042|NCT03500640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||An initial 16-session Diabetes Prevention Program (DPP), called Group Lifestyle Balance (GLB) and aligned with current Medicare guidelines, will be administered to all enrolled participants primarily through group telephone contact, videos, and workbooks. Subsequently one-half of those enrolled will be randomly assigned to either (1) 30-minute DPP behavior intervention group telephone contact, or (2) 15-minute support group telephone contact for a total of 18 additional follow up months.|f|f|t|t
34164043|NCT04585789|NON_RANDOMIZED|PARALLEL||OTHER||NONE||As per protocol amendment-5, JNJ-56136379 has been removed as study intervention and all participants are counted as single arm in each panel.||||
34164044|NCT03897673|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34164045|NCT06725563|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive lumen-apposing metal stents (LAMS) as a treatment for IBD-related strictures. The size of the stent used will depend on the length of the stricture. All LAMS placements are part of a single arm.||||
34164046|NCT00377858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164047|NCT02059798|||COHORT||PROSPECTIVE|||||||
34164048|NCT04204707|||COHORT||PROSPECTIVE|||||||
34164049|NCT05067387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.|t|f|t|f
33955752|NCT06650202|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 20 spinal cord injured participants who were previously implanted with a spinal cord epidural stimulation (scES) unit will be enrolled and split into two groups with 10 participants in each. All participants will undergo a physical examination and classification of their spinal cord injury to determine eligibility criteria, which are the same for both groups. Participants will then be placed into one of the two groups based on their availability and preference. Group 1 will consist of individuals with SCI and an scES implant that will receive TPAD training with stimulation and assessments with and without stimulation. Group 2 will consist of individuals with SCI and an scES implant that will only receive assessments with and without stimulation. Each participant will serve as their own control.||||
34164050|NCT06725901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The data analyst will be masked to trial results.|This is a before and after study.||||
34164051|NCT06128304|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34164052|NCT03766126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164053|NCT06204250|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34164054|NCT06725693|||COHORT||PROSPECTIVE|||||||
34164055|NCT06726798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164056|NCT05841537|||COHORT||PROSPECTIVE|||||||
33955753|NCT03073291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be unaware of the psuedo-underage assessment of their retail recreational marijuana store. Pseudo-patron assessment teams will be unaware of the experimental condition to which each retail recreational marijuana store is assigned.||t|f|f|t
33955754|NCT06536595|||OTHER||PROSPECTIVE|||||||
33955755|NCT06213441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||prospective randomized controlled clinical trial|t|f|f|t
33955756|NCT03549143|||COHORT||PROSPECTIVE|||||||
33955757|NCT03731117|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-comparative, multicenter, study||||
33955758|NCT05054621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34164057|NCT06447415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multi-center, randomized, double-blind and double simulated, placebo controlled, single dose escalation|t|t|t|t
33955759|NCT02395601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164058|NCT05877534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164059|NCT06020781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164060|NCT05810155|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34164061|NCT06647069|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164062|NCT05013359|||COHORT||CROSS_SECTIONAL|||||||
34164063|NCT02009488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34164064|NCT01345188|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34164065|NCT04372823|||OTHER||PROSPECTIVE|||||||
34164066|NCT02551263|||COHORT||PROSPECTIVE|||||||
34164067|NCT05027867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164068|NCT00451022|||CASE_ONLY||PROSPECTIVE|||||||
33955760|NCT00836979|||COHORT||CROSS_SECTIONAL|||||||
33955761|NCT06389825|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33955762|NCT06568627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded|A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study.|t|t|t|t
33955763|NCT03141346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33955764|NCT05353816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955765|NCT06651710|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33955766|NCT01232075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955767|NCT06380101|NA|SINGLE_GROUP||OTHER||NONE||||||
33955768|NCT04984161|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33955769|NCT06561698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955770|NCT00489008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955771|NCT01607580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955772|NCT02555254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955773|NCT04253028|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33955774|NCT00864084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955775|NCT01845194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33955776|NCT04995510|||OTHER||PROSPECTIVE|||||||
33955777|NCT00631709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955778|NCT00581178|||COHORT||PROSPECTIVE|||||||
33955779|NCT00860054|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33955780|NCT03729830|||CASE_ONLY||PROSPECTIVE|||||||
33955781|NCT04795973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adults aged between 18 to 75 years old||||
33955782|NCT01407107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955783|NCT06019533|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33955784|NCT01231880|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33955785|NCT02707718|||COHORT||PROSPECTIVE|||||||
33955786|NCT03973723|||COHORT||RETROSPECTIVE|||||||
33955787|NCT03372772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind|Control Group- Patients with only levothyroxine therapy Interventional Group- Patients with Levocarnitine supplementation in addition to levothyroxine therapy|t|f|f|f
33955788|NCT00055159||||TREATMENT||||||||
33955789|NCT00703261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955790|NCT06292728|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33955791|NCT05591404|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955792|NCT06702098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955793|NCT03328286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955794|NCT04285983|||COHORT||PROSPECTIVE|||||||
33955795|NCT06105008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955796|NCT00764127|||CASE_CONTROL||PROSPECTIVE|||||||
33955797|NCT01394120|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955798|NCT04935931|NA|SINGLE_GROUP||OTHER||NONE||||||
33955799|NCT05927194|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955800|NCT05880537|||CASE_ONLY||PROSPECTIVE|||||||
33955801|NCT05636475|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized controlled experimental study||||
33955802|NCT03157934|||OTHER||PROSPECTIVE|||||||
33955803|NCT01759056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955804|NCT01814917|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164069|NCT03785704|RANDOMIZED|PARALLEL||TREATMENT||NONE||Totally 60 subjects will be included in the study.Random assignment was 1:1 to Xinmailong injection group and control group.||||
34164070|NCT00287716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955805|NCT03635060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955806|NCT03144219|||CASE_CONTROL||PROSPECTIVE|||||||
33955807|NCT05555745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955808|NCT06566976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955809|NCT04220073|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33955810|NCT04257773|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34164071|NCT03819049|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34164072|NCT06221839|||COHORT||CROSS_SECTIONAL|||||||
34164073|NCT06311578|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164074|NCT02780492|||COHORT||PROSPECTIVE|||||||
34164075|NCT00649506|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34164076|NCT03337334|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33746800|NCT06670807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893426|NCT05370911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the independent rater for each participant will be blinded to their condition; blind will be broken at the end of week 7 (i.e., 4 weeks post-second dosing), after which participants in the waitlist/delayed treatment group will begin their treatment phase.|In the study, participants will be randomized to receive either immediate treatment with two doses of oral psilocybin separated by one week (n = 15) or enter a waitlist control/delayed treatment group and receive the same treatment 7 weeks post-randomization (n = 15).|f|f|f|t
33893427|NCT06586489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893428|NCT04756934|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33893429|NCT04147949|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33893430|NCT04285918|||COHORT||PROSPECTIVE|||||||
33893431|NCT05078814|||CASE_ONLY||PROSPECTIVE|||||||
34059848|NCT05900817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, outcome assessors and data analyst will be blinded to the interventions during the clinical trial. After complete data entry of the trial, they will be unblinded to avoid any bias to either two groups. Outcome assessor chart was examined and filled up by two experts. Two principal Investigators and operators) will be blinded until generation of the allocation sequence. Later on, two invistigators will be unblinded within the treatment session due to different treatments packing and steps. Both investigators won't be involved in assessing the outcome. Informed Consent: both Investigators will be introduced the trial to patients regarding the main aspects of the trial.||t|f|f|t
34059849|NCT02851056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059850|NCT00416676||||TREATMENT||NONE||||||
34059851|NCT01569750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059852|NCT03956615|NA|SINGLE_GROUP||OTHER||NONE||||||
34059853|NCT00745511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059854|NCT05189496|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34059855|NCT04428203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059856|NCT04844905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent statistician will randomize the clusters to DP+IVM or DP+Placebo. The Placebo is identical in size, shape and colour and packaging. An independent pharmacist at Medical Research Council Unit The Gambia @ London School of Hygiene and Tropical Medicine will label the IVM and Placebo according to the statistician's designation and maintain the masking from all other investigators. Specifically generated masking codes will be generated and saved in three separate encrypted locations securely. Only the statistician and the pharmacist will have access to the encryption key.|Two arms with clusters randomized to DP+IVM or DP+Placebo with a 1:1 ratio|t|t|t|t
34059857|NCT01623037|NA|SINGLE_GROUP||OTHER||NONE||||||
34059858|NCT00189852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059859|NCT03672448|||COHORT||PROSPECTIVE|||||||
34059860|NCT05673161|||OTHER||RETROSPECTIVE|||||||
34059861|NCT01058902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059862|NCT03652948|NA|SINGLE_GROUP||TREATMENT||NONE||Study 1: 8 week mobile app based intervention using cognitive behavioral and mindfulness skills Study 2: 12 week mobile app based intervention (8 week intervention+4 weeks focused on sleep and nutrition)||||
34059863|NCT04907227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059864|NCT05578105|||CASE_ONLY||RETROSPECTIVE|||||||
34059865|NCT04210375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, single-ascending dose with single active sentinel subject per cohort|t|t|t|t
34059866|NCT04489849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059867|NCT03871816|||COHORT||PROSPECTIVE|||||||
34059868|NCT05409313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34059869|NCT04198584|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants (n=32) were assigned by 3:1 randomization to VC-CBCS or SC. Participants were recruited in 4 cohorts (Wave 1: n=7, Wave 2: n=9, Waves 3, 4: n=8 each). In Wave 1, 5 participants were randomized to VC-CBCS and 2 to SC. In Wave 2, 7 participants were randomized to VC-CBCS and 2 to SC. In Waves 3 and 4, 6 participants were randomized to VC-CBCS and 2 to SC.||||
34059870|NCT00711828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059871|NCT06510387|||COHORT||CROSS_SECTIONAL|||||||
34059872|NCT00600990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34059873|NCT01329718||PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34059874|NCT05523141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059875|NCT00871442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059876|NCT03211143|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34059877|NCT01789372|||CASE_CONTROL||PROSPECTIVE|||||||
34059878|NCT03621540|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Use of NeuroConn Stimulator study mode||t|t|t|f
34059879|NCT05448287|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm quasi-experimental design with baseline and end-line. The baseline and end-line were collected on different households but in the same clusters.||||
34059880|NCT05207618|NA|SINGLE_GROUP||TREATMENT||NONE||before- after study||||
33893432|NCT02228499|||CASE_CONTROL||PROSPECTIVE|||||||
34059881|NCT05907161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Before initial treatment the care provider will randomly pick an envelope with one of the three treatment modalities. At follow-up visits the investigator will perform the periodontal examination without having access to the patients data.||f|t|t|f
34164077|NCT04320784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Outcome assessor treated anonymus data|It is a single blind, parallel arms study|f|f|f|t
34164078|NCT00963586|||COHORT||CROSS_SECTIONAL|||||||
34164079|NCT04661046|NA|SINGLE_GROUP||SCREENING||NONE||||||
34164080|NCT01550757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34164081|NCT06191393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Some participants will know their SOC diagnosis before completing testing on our device.|||||
34164082|NCT05049798|||COHORT||PROSPECTIVE|||||||
34164083|NCT05666141|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
34164084|NCT01011374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164085|NCT06726200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164086|NCT06725368|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, prospective, multicenter, open-label phase II study.||||
33893433|NCT02922764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893434|NCT02830165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164087|NCT05319353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Three dosing cohorts based on participant's age.||||
34164088|NCT01372566|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34164089|NCT04528719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|For older adult Cohorts 7, 8, 9, 10, and 11, the second booster injection on Day 730 (Month 24) will be open-label.||t|t|t|t
34164090|NCT03325959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|randomization by computer, the patient and her primary care physician will know the treatment received. Any side effects during therapy will be reported to the care providers and nurses and physicians unrelated to the study. Investigators and outcome assessors will not know the patient's arm.|randomized controlled trial using conventional pharmacotherapy treatment compared to hyperbaric oxygen therapy|f|f|t|t
34164091|NCT02754726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164092|NCT04514822|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164093|NCT03267004|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|The project staffs who will be analyzing the digital images taken by Sony Smarteyeglass during meal sessions will be masked including the types of foods and volume provided to the participants.|A 2x2x2x2x3 mixed factorial design will be used, with a between-subject factor of the order of meals (Order 1 and 2) and within-subject factors of food shapes (Regular and Irregular), food complexities (Single food and Mixed food), meals (Meal A and B), and methods of measurement (DietCam, weighed food intake, and 24-hour dietary recall).|f|f|t|f
34164094|NCT04579471|||COHORT||PROSPECTIVE|||||||
34164095|NCT05481775|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164096|NCT02548208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164097|NCT02639299|||OTHER||CROSS_SECTIONAL|||||||
34164098|NCT05404048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164099|NCT01424501|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34164100|NCT01301313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164101|NCT06280092|NA|SINGLE_GROUP||OTHER||NONE|This is an unmasked study|A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery||||
34164102|NCT00391144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34164103|NCT04358692|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164104|NCT01128426|||CASE_ONLY||PROSPECTIVE|||||||
33893435|NCT01973283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893436|NCT02240862|||COHORT||PROSPECTIVE|||||||
33893437|NCT05239689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893438|NCT06620107|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33893439|NCT05607134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955811|NCT03353415|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The proposed study is designed to assess the efficacy of unmasked personal CGM to reduce the frequency of hypoglycemia after gastric surgery. Participants themselves will not be masked to study design. The only masking will be of the device sensor glucose data during the first 2 weeks (Dexcom G4) or 10 days (Dexcom G6) of the study.|The proposed study is designed to assess the efficacy of unmasked personal CGM to reduce the frequency of hypoglycemia after gastric surgery. Specifically, we will analyze glycemic patterns during a phase of baseline masked CGM wear (2 weeks for the Dexcom G4 or 10 days for the Dexcom G6), in comparison to a sequential, second phase of unmasked CGM wear (2 weeks for the Dexcom G4 or 10 days for the Dexcom G6). Please note that we have chosen to have a consistent masked monitoring first, as providing unmasked data to participants first could alter their dietary or other patterns and reduce ability of the study to independently assess efficacy of the CGM intervention.||||
33955812|NCT04736316|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33955813|NCT01360021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33955814|NCT06554678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33955815|NCT03052374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955816|NCT01382680|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33955817|NCT04874701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955818|NCT05246150|||CASE_ONLY||CROSS_SECTIONAL|||||||
33955819|NCT00822601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34164105|NCT05597033|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34164106|NCT02331186|||CASE_ONLY||PROSPECTIVE|||||||
33893440|NCT03808155|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind.||t|t|t|t
33893441|NCT05546489|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893442|NCT00862602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893443|NCT06203002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893444|NCT00001189||||TREATMENT||||||||
33893445|NCT01117376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893446|NCT02353949|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893447|NCT06165588|||COHORT||PROSPECTIVE|||||||
33893448|NCT01876589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893449|NCT00443521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893450|NCT02012010|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33893451|NCT04447547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893452|NCT00566306||PARALLEL||PREVENTION||NONE||||||
33893453|NCT03746730|||COHORT||PROSPECTIVE|||||||
34164107|NCT06725797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Microbiological and microbiome assessors are blinded to subjects' treatment or arm randomization list.~Epidemiological and statistic assessors are blinded to arm randomization list as well."|The study is an interventional pilot trial assessing the efficacy of hypothermal sulphurous thermal water (STW) in the wound hygiene of patients affected by hard to heal, chronic, infected wounds. The eligible subjects will be 1:1 randomized in two arms and treated with pure sulfurous spa water, already authorized for medical drinking therapy, on soaked gauzes (GROUP A) or for full limb immersion (GROUP B) for 20 minutes. Ph, Trans epidermal water loss (TEWL), healing rate (Bates-Jensen Wound Assessment Tool) wound fluorescence imaging for bacterial colonization and wound microbiome will be tested at 3 timepoints: T0 (prior treatment), T1 (just after treatment) , Tf (complete wound re-epithelization).|f|f|f|t
33851406|NCT06519487|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant and the outcomes assessor will be blinded to the conditions to reduce bias. Participants will not be informed about the specific conditions (race-based exclusion or non-race-based exclusion) they are experiencing during Cyberball game and will be instructed not to discuss their experiences with the investigator or the outcomes assessor. All participant's questionnaire responses, blood, and saliva samples are labeled with anonymized codes (computer-generated ID numbers) to prevent identification of the condition order and Cyberball randomizes sequences automatically. The outcomes assessor, who will analyze the blood and saliva samples for immune cell function and genomic and epigenetic markers and the questionnaire, will be unaware of the participants' assigned conditions. Data analysis will be performed on de-identified datasets and randomization managed by a separate team member not involved in data collection or analysis.|"A crossover model is used to investigate whether geography, race, and ethnicity, interacting with laboratory discrimination conditions, affect immune cell function through genomic and epigenetic mechanisms, with perceived discrimination moderating the immune outcomes. Participants from each geographic region and belonging to one of three race or ethnic groups will experience race-based and non-race-based social exclusion and washout phases to mitigate carryover effects. For instance, participants might first experience race-based social exclusion, followed by an inclusion period (washout), and then non-race-based social exclusion, followed by another washout. Blood samples will be collected after each social exclusion to measure immune responses. Each participant will serve as their own control, facilitating within-subject comparisons to reduce variability due to individual differences, except on the variables of interest."|t|f|f|t
33851407|NCT01837784|||COHORT||PROSPECTIVE|||||||
33851408|NCT05908045|||COHORT||CROSS_SECTIONAL|||||||
33851409|NCT06380855|||CASE_ONLY||RETROSPECTIVE|||||||
33851410|NCT02757027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34164108|NCT06360393|||COHORT||PROSPECTIVE|||||||
34164109|NCT05633472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164110|NCT05859074|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164111|NCT04647240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164112|NCT01964963|||COHORT||PROSPECTIVE|||||||
34164113|NCT06319534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164114|NCT01594229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164115|NCT06726070|||OTHER||PROSPECTIVE|||||||
34164116|NCT05443256|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two separate arms of study|t|f|f|f
34164117|NCT00889512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164118|NCT03030417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164119|NCT06727422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164120|NCT01930942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164121|NCT04705246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164122|NCT01299181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164123|NCT00041379||||TREATMENT||||||||
34164124|NCT02306538|||COHORT||PROSPECTIVE|||||||
34164125|NCT04458909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164126|NCT06726538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164127|NCT05826067|||COHORT||PROSPECTIVE|||||||
34164128|NCT03458949|NA|SINGLE_GROUP||SCREENING||NONE||||||
34164129|NCT05902598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164130|NCT05684068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164131|NCT03896321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34164132|NCT06465433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164133|NCT03784677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164134|NCT02509845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34164135|NCT06577987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851411|NCT05727969|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The group's allocations will be only blinded to assessors, data collectors, and parents of children|The randomization will be computer generated random number and the randomization sequence will be kept hidden in sealed opaque envelopes just opened after recruitment and admittance to the operating room.|t|f|t|t
33851412|NCT02769559|||COHORT||RETROSPECTIVE|||||||
33851413|NCT05597462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||A multi-center, randomized, double-blind, placebo-controlled, parallel group trial with a treatment period of 16 weeks.|t|f|t|t
33851414|NCT02775695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851415|NCT04647643|||COHORT||RETROSPECTIVE|||||||
33851416|NCT01851954|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851417|NCT03071367|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33851418|NCT05616520|||COHORT||PROSPECTIVE|||||||
33851419|NCT00149760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851420|NCT01564628|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851421|NCT05731453|NA|SINGLE_GROUP||SCREENING||NONE||||||
33851422|NCT00541398|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851423|NCT00585195|NA|PARALLEL||TREATMENT||NONE||||||
33851424|NCT01389427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851425|NCT03051243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851426|NCT04182945|NA|SINGLE_GROUP||OTHER||NONE||||||
33851427|NCT01742104|||COHORT|||||||||
33851428|NCT04987736|||OTHER||RETROSPECTIVE|||||||
33851429|NCT00504621|||||CROSS_SECTIONAL|||||||
33851430|NCT02561065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851431|NCT01953653|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33851432|NCT01478139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851433|NCT02013518|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33851434|NCT00816400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851435|NCT02863471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851436|NCT01489891|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33851437|NCT04940000|NA|SINGLE_GROUP||OTHER||NONE||||||
33851438|NCT01022268|||CASE_CONTROL||PROSPECTIVE|||||||
33851439|NCT00240136|||COHORT||OTHER|||||||
33851440|NCT01668667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059882|NCT05660824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This study is triple-blinded concerning (i) the participants during the intervention and throughout the study duration, (ii) the outcome assessor, and (iii) the statistician. The investigator in charge of the injections will be unblinded and therefore will not be assigned to outcomes assessment.~Follow-up and outcome assessment will be identical for both arms."|Multicentric randomized. Randomization will be performed at a 1:1 ratio to either the intervention arm or the active comparator. Each block of 4 patients will be assigned to specific strata according to age (over or under 40), presence of either partial, full cartilage defects or full cartilage defects with bone deformation.|t|f|t|t
34059883|NCT00065767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34059884|NCT02431117|||COHORT||PROSPECTIVE|||||||
34059885|NCT04339179|||COHORT||PROSPECTIVE|||||||
34059886|NCT04820712|||COHORT||RETROSPECTIVE|||||||
34059887|NCT05771818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059888|NCT03469180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059889|NCT00058084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059890|NCT00248976|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34059891|NCT04445506|||CASE_CONTROL||RETROSPECTIVE|||||||
34059892|NCT05525234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, randomized, placebo-controlled|t|t|t|t
34059893|NCT01658449|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34059894|NCT02268370|NA|SINGLE_GROUP||OTHER||NONE||||||
34059895|NCT03398863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34059896|NCT04237129|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34059897|NCT02848989|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34059898|NCT00272870|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059899|NCT02833935|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34059900|NCT05046431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059901|NCT04169438|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This pilot study is double-blinded, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study team member will administer the treatment as well as answer questions and discuss any problems throughout the study.|The study consists of two (2) Treatments, both of which are administered in combination with petrolatum. The Treatments consist of either a restorative wound care cream (FS2 ingredient) or a vehicle wound care cream (without the FS2 ingredient).|t|f|t|f
33851441|NCT00883701|||CASE_CONTROL||PROSPECTIVE|||||||
33851442|NCT00038909||||TREATMENT||||||||
33851443|NCT05127252|||COHORT||PROSPECTIVE|||||||
34059902|NCT01428687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059903|NCT02370667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34059904|NCT01279564|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34059905|NCT02519634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059906|NCT04218292|||COHORT||PROSPECTIVE|||||||
33851444|NCT06261164|||COHORT||PROSPECTIVE|||||||
33851445|NCT01492465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851446|NCT01468467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851447|NCT06227143|||COHORT||PROSPECTIVE|||||||
33851448|NCT06025760|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Critically ill mechanically ventilated patients will receive protein of 2 gm/kg/day in the interventional group. Critically ill mechanically ventilated patients will receive protein of 1.2 gm/kg/day in the control group.|f|t|f|t
33851449|NCT03751566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851450|NCT05551533|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851451|NCT05054153|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33851452|NCT06163911|||COHORT||RETROSPECTIVE|||||||
33851453|NCT01648686|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33851454|NCT03010176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851455|NCT02768311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851456|NCT02503878|||COHORT||PROSPECTIVE|||||||
33851457|NCT05156684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955820|NCT05887752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After selection and enrollment, just before the beginning of the 4-week rehabilitation period, baseline assessments are carried out and patients are randomized. Due to the nature of the Hunova® treatment, blinding of patients and researchers involved in treatment administration will not be possible. Blinding is thus forecast for outcomes' assessors and statisticians only.|Randomized Controlled Trial (add-on in the first half of the study period)|f|f|f|t
33955821|NCT02192307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955822|NCT01020695|||CASE_CONTROL||RETROSPECTIVE|||||||
33955823|NCT03253666|||COHORT||PROSPECTIVE|||||||
33955824|NCT02534467|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33746801|NCT01914926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851458|NCT02322801|||COHORT||PROSPECTIVE|||||||
33955825|NCT06650072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34059907|NCT02353884|||CASE_CONTROL||PROSPECTIVE|||||||
34059908|NCT01844206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059909|NCT02237924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059910|NCT00357136|||||RETROSPECTIVE|||||||
34059911|NCT02186847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059912|NCT00004809||||TREATMENT||||||||
34059913|NCT06339216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059914|NCT03055468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Random sequence generation will be done by an independent biostatistician|We will have an intervention and a control group.|t|t|t|t
34059915|NCT01738841|||COHORT||PROSPECTIVE|||||||
34059916|NCT05574933|||CASE_ONLY||CROSS_SECTIONAL|||||||
34059917|NCT03635905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059918|NCT00438802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059919|NCT04507893|||CASE_ONLY||RETROSPECTIVE|||||||
34059920|NCT00928941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34059921|NCT05347875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A four-site single-masked randomized controlled trial|t|f|f|f
34059922|NCT06533852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34059923|NCT01264354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059924|NCT00001569||||TREATMENT||||||||
34059925|NCT05998434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059926|NCT00936130|||COHORT||PROSPECTIVE|||||||
34059927|NCT05112094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34059928|NCT02503072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059929|NCT05612802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059930|NCT00576810||PARALLEL||TREATMENT||||||||
34059931|NCT01907217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34059932|NCT00460707|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34059933|NCT03494972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059934|NCT03284645|||COHORT||PROSPECTIVE|||||||
34059935|NCT05565144|||COHORT||RETROSPECTIVE|||||||
34059936|NCT02432859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34059937|NCT04339803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059938|NCT06408064|RANDOMIZED|PARALLEL||OTHER||NONE||Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded music. Group A will be that of patients exposed to live music, which will be carried out by a music therapist using the guitar as the only musical instrument. Instrumental lullabies will be used, which will be selected by the patients' legal guardians. Group B corresponds to patients who will be exposed to pre-recorded music, of the genre of lullabies, instrumental type, using a speaker that will be placed inside the patient's incubator. Group C will be those patients in whom no musical intervention will be performed.||||
33851459|NCT06307899|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33851460|NCT01954966|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33851461|NCT05323760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851462|NCT03782077|||COHORT||PROSPECTIVE|||||||
33851463|NCT02335528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851464|NCT01232179|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33851465|NCT06301984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851466|NCT00553072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33851467|NCT02880891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33851468|NCT02988622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851469|NCT01762319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851470|NCT04985968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851471|NCT03260257|NA|PARALLEL||TREATMENT||NONE||||||
34059939|NCT06298357|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be 2 parallel groups, immediate start group and waitlist control group. Once control participants finish the wait period (8 weeks), they will start the intervention (8 weeks). Participants in the immediate start group will start exercise and mindfulness in the hospital and continue the program for 8 weeks outside of the hospital.||||
34059940|NCT01255410|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34059941|NCT02870205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059942|NCT02570672|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34059943|NCT05995405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059944|NCT06486649|||CASE_CROSSOVER||PROSPECTIVE|||||||
34059945|NCT02105714|||CASE_CONTROL||PROSPECTIVE|||||||
34059946|NCT01686698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059947|NCT01825161|||COHORT||PROSPECTIVE|||||||
34059948|NCT01447875|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746802|NCT03257462|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34059949|NCT02897427|||OTHER||OTHER|||||||
34059950|NCT04984759|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is a prospective open-label study in which both participants and investigators know the identity of the treatment and its dosage.|"Arms 1 and 2 will enroll first as preliminary data from Arms 1 and 2 is needed before Arm 3 can begin enrolment.~All eligible and consenting women who are immediately postpartum will be enrolled in Arm 1 until it is completed.~Arm 2 will enroll eligible women breastfeeding older infants and young children. If there are no safety concerns after 2-4 mother-child dyads have been enrolled in Arm 2, successively younger infants will be enrolled to a minimum of 14 days old.~If there are no safety concerns with Arms 1 and 2, Arm 3 will begin enrolment."||||
34059951|NCT01860742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059952|NCT05940896|NA|SINGLE_GROUP||TREATMENT||NONE||"DV is given intravenously once every 2 weeks, (dose escalation plan: 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg). DV will be administered at least 2 times during the treatment, and the final DV dose needs to be completed before the last radiotherapy.~Concurrent standard radiotherapy for solid tumors is given for 5-7 weeks, 5 times per week."||||
34059953|NCT04477044|RANDOMIZED|PARALLEL||OTHER||NONE||The participants will be randomised to 2 groups, either in the study group having a GoPro Hero4 camera mounted on their head or control group with no GoPro Hero4 camera mounted on their head||||
34059954|NCT00597506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34059955|NCT04857918|RANDOMIZED|PARALLEL||OTHER||NONE||The study will utilize a two-arm, parallel group, unblinded randomized controlled pilot trial design. UBC undergraduate students (N = 60) will be equally randomized to either an eight-week social identity building virtual running group (n = 30) or an eight-week control group (n = 30).||||
34164136|NCT05734755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent assessor who is blinded to the group allocations will assess the participants' outcomes.|A four-arm RCT to evaluate the effects of an individualized dietary behavioural change (IDBC) programme and exercise training, in combination (COMB group) and separately (EXER-only and IDBC-only groups), to counteract sarcopenic obesity when compared with a control group receiving only health talks.|f|f|f|t
34164137|NCT02538601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164138|NCT06725173|||COHORT||PROSPECTIVE|||||||
34164139|NCT00700713|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164140|NCT01647841|||COHORT||PROSPECTIVE|||||||
34164141|NCT01255891|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164142|NCT03986203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the clinical site staff member who trains the subject will know the group assignment. All subsequent interactions with each subject will not be carried out by the trainer.||t|f|t|t
34164143|NCT05050097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164144|NCT05173883|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164145|NCT06714214|||COHORT||PROSPECTIVE|||||||
34164146|NCT04520971|RANDOMIZED|PARALLEL||TREATMENT||NONE||1/1 randomization to 780G or continue with standard of care||||
34164147|NCT00570310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164148|NCT05065788|||CASE_CONTROL||RETROSPECTIVE|||||||
33765371|NCT04826328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Part I - Double-Blind, placebo-controlled, three-step, Single Ascending Dose Part II - Double Blind, placebo-controlled, Expansion Phase to enroll additional patients to an SMC-cleared dose/volume level|t|f|t|f
34164149|NCT01232322|||COHORT||PROSPECTIVE|||||||
33765372|NCT05854030|||COHORT||PROSPECTIVE|||||||
33765373|NCT04902820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Participants are randomly assigned and will be made aware of the condition to which they are assigned.|This is a two-arm randomized controlled trial with a one-to-one allocation ratio. Randomization will be stratified by sub-group (adult men who have sex with men ages 18-27 \[n = 320\], adult transgender women ages 18-27 \[n = 40\], and adolescent men who have sex with men ages 15-17 \[n = 40\]).||||
33765374|NCT00894634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765375|NCT02118337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765376|NCT02081222|||COHORT||RETROSPECTIVE|||||||
33765377|NCT03515057|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33765378|NCT00480896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765379|NCT05912478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33765380|NCT02093676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765381|NCT06624852|||CASE_CONTROL||RETROSPECTIVE|||||||
33765382|NCT04757818|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Double-blind, randomized, parallel, placebo-controlled clinical study|t|f|t|f
33765383|NCT00536822|||||PROSPECTIVE|||||||
33765384|NCT01017978|NA|SINGLE_GROUP||||NONE||||||
33765385|NCT05973318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765386|NCT06390514|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33765387|NCT02026232|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33765388|NCT05147727|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Fluconazole and famitinib interaction||||
33765389|NCT02932839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765390|NCT00303563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765391|NCT05172895|||COHORT||RETROSPECTIVE|||||||
33765392|NCT04789902|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped-wedge cluster randomized trial (SW-CRT) design, where the sequential crossover will occur in one direction. SW-CRT is a flexible CRT design progressively being used in trial arms with varying delays in switching from the control condition to the active intervention condition state. This study will include the implementation of the intervention in four different rural and urban hospitals. Therefore, one hospital will be randomly allocated using a stratified sampling technique to each of four sequences, which will determine the order in which the intervention is implemented across participating hospitals or clusters. This allocation of one cluster to each sequence maximizes the statistical power||||
33765393|NCT02766816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33765394|NCT00694382|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33765395|NCT06505694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Participant, Investigator)|Parallel Assignment|t|f|t|f
33765396|NCT03810222|||COHORT||PROSPECTIVE|||||||
33955826|NCT03724591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33955827|NCT05598619|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel trial|t|t|t|t
33955828|NCT04794049|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33955829|NCT05366725|||COHORT||OTHER|||||||
33955830|NCT06531343|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33955831|NCT00576849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955832|NCT01845181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955833|NCT06701916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The nature of the intervention means that neither participants nor the health care professionals in the SHARE intervention can be blinded to allocation in the RCT.|Parallel Assignment An RCT: Heart failure patients who consent to participate and meet the inclusion criteria will be randomized. Randomization will be conducted by research nurses. Participants will be randomly assigned to either the control or intervention group with a 1:1 allocation, according to computer-generated randomization. The control group will receive usual care, while the intervention group will receive a person-centered care intervention for three months in addition to usual care.||||
33955834|NCT00685711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955835|NCT06565585|||CASE_CONTROL||RETROSPECTIVE|||||||
33955836|NCT02973178|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33955837|NCT01131208|||OTHER||RETROSPECTIVE|||||||
33955838|NCT03828344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955839|NCT04819932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955840|NCT05692739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a randomized controlled trial for the treatment of dry eye disease with three arms: topical insulin, topical cyclosporin (gold standard) and artificial tears (placebo)|t|f|f|t
33955841|NCT03896373|||CASE_CONTROL||PROSPECTIVE|||||||
33955842|NCT01260194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955843|NCT06335511|||COHORT||PROSPECTIVE|||||||
33955844|NCT00924573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164150|NCT01598909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765397|NCT01809041|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33765398|NCT04381221|||COHORT||PROSPECTIVE|||||||
33765399|NCT01610154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765400|NCT03522077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765401|NCT02500914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765402|NCT05988970|NA|SINGLE_GROUP||OTHER||NONE||||||
33765403|NCT04395183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized, double-blind||t|f|t|f
33765404|NCT02232841|||CASE_ONLY||CROSS_SECTIONAL|||||||
33765405|NCT04125524|||OTHER||CROSS_SECTIONAL|||||||
33765406|NCT05030259|||COHORT||PROSPECTIVE|||||||
33765407|NCT03733743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Standardized living protocol||||
33765408|NCT04836117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|All participants will know what group they are placed in. For Group 1 (Informed), clinicians and participants will receive their test results immediately. Those in Group 2 (Uninformed) will not receive their test results until study conclusion.|||||
33765409|NCT01134601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765410|NCT02034305|||COHORT||CROSS_SECTIONAL|||||||
33765411|NCT05244148|RANDOMIZED|PARALLEL||TREATMENT||NONE||"3 Arms:~1. Group A: IP1 - Stérimar BLOCKED NOSE Baby nasal spray + standard of care~2. Group B: IP2 - Stérimar Stop \& Protect Cold Baby + standard of care~3. Group C: Standard of Care alone"||||
33765412|NCT05891626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cluster randomized controlled trial, mixed methods||||
33765413|NCT05822921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Parents of children who meet criteria for a diagnosis of autism spectrum disorder (ASD) will be randomized into one of three groups (i.e., in-person psychoeducation, telehealth psychoeducation, or psychoeducation as usual with paper psychoeducation materials)."||||
33765414|NCT02384525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765415|NCT02991443|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33765416|NCT05559853|||CASE_CONTROL||PROSPECTIVE|||||||
33765417|NCT03716674|NA|SINGLE_GROUP||OTHER||NONE|This was a cross-sectional study|A single group of 9 patients completed the 4 conditions presented in the Methods section.||||
33765418|NCT05341102|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|All the participants will be double blinded except for LY3556050 (Part 1) - Cohort 7 which will be open label.||t|f|t|f
33765419|NCT00133939|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765420|NCT00826163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765421|NCT05561777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765422|NCT00347581|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33765423|NCT01800695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765424|NCT00011830||||TREATMENT||||||||
33765425|NCT00001565||||TREATMENT||||||||
33765426|NCT03108495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765427|NCT02986061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765428|NCT00675155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765429|NCT06326710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33765430|NCT03157206|||COHORT||PROSPECTIVE|||||||
33765431|NCT02378532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765432|NCT00248196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765433|NCT04838834|||COHORT||PROSPECTIVE|||||||
33765434|NCT01402596|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
33765435|NCT00515437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765436|NCT00181038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33765437|NCT03158389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765438|NCT01121484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765439|NCT02048748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33765440|NCT02086552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765441|NCT05905497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765442|NCT05583214|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33746803|NCT06313762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The intervention group will use the Pico G2 VR goggles (Pico Interactive Inc) during the administration of the two vaccines, together with an Android AOYODKG tablet, which will be connected to the goggles as a controller.~The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home."||||
33851472|NCT05644860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The two materials being compared look similar and according to the manufacturers' instructions they are applied using a similar protocol i.e. enamel conditioning, application of unfilled resin, placement of brackets and light curing. Hence the patient will not be able to identify as to which experimental group they are placed in.|"The patients meeting the slection criteria chall be randomly allocated in two groups (A and B)/ Brackets in the group A shall be bonded with the conventional composite (Transbond XT, 3M Unitek, USA) with appreciably good shear bond strength. In patients belonging to group B, brackets shall be bonded with nanohybrid composite (Filtek Z250).~Long term succes shall be evaluated by comparing the bracket failute rate between the two groups."|t|f|f|f
33746804|NCT00925158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33851473|NCT03452579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851474|NCT05596058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients do not know other type of intervention; who have to do the assessment do not know the type of interventions|We are going to use a simple randomization scheme 1:1:1 with excel and assign subjects into three groups respectively: 15 patients in physical-cognitive tasks groups, 15 patients in active exercise Only and 15 patients in Cognitive training.|t|f|f|t
33851475|NCT05589948|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
33851476|NCT06384573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851477|NCT04714476|NA|SINGLE_GROUP||OTHER||NONE||Healthy subjects will test made-to-measure compression garments. No comparator group due to explorative design.||||
33851478|NCT02379104|||COHORT||PROSPECTIVE|||||||
33851479|NCT02999126|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33746805|NCT03772080|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746806|NCT00810134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746807|NCT03196648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33851480|NCT06608173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851481|NCT05923671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33851482|NCT03860701|||CASE_ONLY||PROSPECTIVE|||||||
33851483|NCT00002331||||TREATMENT||||||||
33851484|NCT01084837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955845|NCT06278532|||CASE_ONLY||CROSS_SECTIONAL|||||||
33955846|NCT06652152|||COHORT||RETROSPECTIVE|||||||
33955847|NCT04966117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|There are no other parties who will be masked in the clinical trial.|Single site, open, parallel-group randomized controlled trial of a disease management program (intervention group) to reduce hospital readmissions or death compared to usual care (control group)|f|f|f|t
33955848|NCT00559975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33955849|NCT00049010|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33955850|NCT01906931|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33955851|NCT06653348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study designed to be blind to the outcome assessors, meaning that the neurologist evaluating the patients' outcomes was unaware of the treatment assignments.||f|f|f|t
33955852|NCT01023815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955853|NCT06225674|||OTHER||OTHER|||||||
33955854|NCT06367998|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33955855|NCT00274807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059956|NCT05021289|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|care provider|Designed as a prospective randomized single-blind trial, the research was performed with the participation of a total of 128 women who had high-risk pregnancies and received inpatient treatment on 1 February - 1 May 2021 at the perinatology service of a maternity and children's hospital located in the Anatolian side of Istanbul province of Turkey (64 pregnant women in the experimental group, 64 pregnant women in the control group).|t|f|f|f
34059957|NCT02149316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34059958|NCT02749864|||OTHER||CROSS_SECTIONAL|||||||
34059959|NCT01151774|||CASE_ONLY||PROSPECTIVE|||||||
34059960|NCT03657940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059961|NCT04220749|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 Arm study randomized in a 1:1 ratio||||
34059962|NCT00567749|||CASE_ONLY||PROSPECTIVE|||||||
34059963|NCT06618053|||COHORT||RETROSPECTIVE|||||||
34059964|NCT06501495|NA|SINGLE_GROUP||OTHER||NONE||||||
34059965|NCT06515392|||COHORT||PROSPECTIVE|||||||
34059966|NCT00742508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059967|NCT00888602|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34059968|NCT00598611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059969|NCT02071082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059970|NCT03863327|||CASE_CONTROL||RETROSPECTIVE|||||||
34059971|NCT01238562|RANDOMIZED|CROSSOVER||||NONE||||||
34059972|NCT00006033||||TREATMENT||||||||
34059973|NCT00361920|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059974|NCT03161002|||COHORT||PROSPECTIVE|||||||
34059975|NCT00990665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059976|NCT01702194|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164151|NCT00674674|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164152|NCT05549830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking will not be used. Participants meeting the inclusion criteria will be assigned to one of the two groups by randomization.|In this trial, a two-group design will be used, with an equal number of random participants assigned to each group||||
34164153|NCT05120362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164154|NCT00970437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164155|NCT03202563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059977|NCT01376466|||COHORT||PROSPECTIVE|||||||
34059978|NCT05992961|||COHORT||RETROSPECTIVE|||||||
34059979|NCT02554318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34059980|NCT04382144|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A nurse at the outpatient clinic will choose an envelope with the randomization information and assign the patient into their groups. The same nurse will prepare the injection, mask the syringe with a tape and give it to the doctor who will administer the injection. The same injection technique will be used for both drugs.|"The trial will be a crossover study. During the pilot phase, we will recruit up to 6 patients, after which we will do a power analysis. In the main study, up to 25 patients will be randomized into 2 groups. Group 1 will receive an injection af levobupivacaine (Chirocaine) into the lateral epicondylitis. The outcomes are assessed over the next month and then they are given the injection of liposomal bupivacaine (Exparel).~Normal distribution of data will be tested by Shapiro-Wilks test. The mean and Standard Deviation will be reported for normally distributed data. For data not distributed normally, the median and inter quartile ranges of the data will be reported.~Independent samples t-test will be used for between-group comparison (normal distribution). The Mann-Whitney test will be used for non-normal data."|f|t|f|f
34059981|NCT03040427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34059982|NCT05098067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34059983|NCT04681898|||CASE_ONLY||RETROSPECTIVE|||||||
34059984|NCT03808025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients who consent to the study will be prospectively randomized to one of two arms: one will receive educational intervention, the other will not. Investigators will be masked to patient intervention when assessing and collecting outcomes.||f|f|f|t
34164156|NCT05850520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164157|NCT03035604|||COHORT||PROSPECTIVE|||||||
34164158|NCT05184582|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization to supervised high-intensity interval training during neoadjuvant chemotherapy or usual information about physical activity.||||
33851485|NCT00001573||||TREATMENT||||||||
34164159|NCT00806039|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851486|NCT03307759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851487|NCT06609967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851488|NCT00444171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851489|NCT02364843|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851490|NCT02776384|||COHORT||PROSPECTIVE|||||||
33851491|NCT00939666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955856|NCT04798027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"In the FEC: blinding for vaccine group assignment (formulation) of participants, outcome assessors, Investigators, laboratory personnel, and Sponsor study staff. Only study site staff who prepare and administer the vaccine and were not involved with the safety evaluations were unblinded to vaccine group assignment. There was no blinding for injection schedule.~The Sentinel Cohort was open-label (no blinding)."|This was a sequential group prevention study consisting of a sentinel cohort followed by the Full Enrollment Cohort. There were 3 dose levels (up to 25 participants 18-49 years of age for each dose level) in the Sentinel Cohort, which were done in an open-label fashion with stepwise safety evaluation for each dose level and each vaccination. All sentinel participants received 2 vaccinations, 21 days apart. For the Full Enrollment Cohort (FEC), which was done in a double-blind design participants were stratified into 2 groups based on age at enrollment: the younger adult age group (140 planned participants 18-49 years of age) and the older adult age group (168 planned participants greater than or equal to \[\>=\] 50 years of age). The FEC Cohort 1 (Groups 1 to 3) received a single injection of study intervention while participants in Cohort 2 (Groups 4 to 6) received 2 vaccinations (to be given 21 days apart).|t|t|t|t
34059985|NCT02225327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164160|NCT00855244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164161|NCT00277771|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34164162|NCT00765180|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34164163|NCT05963906|||CASE_ONLY||PROSPECTIVE|||||||
34059986|NCT04486170|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34059987|NCT06730906|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34059988|NCT02782299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059989|NCT05766618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a split-mouth randomized, controlled single-center superiority trial, with two parallel groups with a 1:1 allocation ratio.|f|f|f|t
34059990|NCT01914211|||COHORT||PROSPECTIVE|||||||
34164164|NCT02097693|||COHORT||PROSPECTIVE|||||||
34164165|NCT06039709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164166|NCT00965250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164167|NCT02934724|||COHORT||CROSS_SECTIONAL|||||||
34164168|NCT02396706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164169|NCT04742452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164170|NCT03827525|||COHORT||PROSPECTIVE|||||||
34164171|NCT02096549|||COHORT||PROSPECTIVE|||||||
34164172|NCT05112939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851492|NCT02849717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33851493|NCT01236365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851494|NCT05925361|NA|SINGLE_GROUP||TREATMENT||NONE||Single center prospective intervention study||||
33851495|NCT02115516|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33851496|NCT00252577|||OTHER||PROSPECTIVE|||||||
33851497|NCT02634489|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34164173|NCT06725914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, statistician blinding was used for the implementation of randomization and data analysis.|The study was a single-blind, parallel group, randomized controlled experimental design.Randomization was performed by an independent investigator to avoid bias. Preterm infants were randomly assigned to the experimental and control groups (1:1) by simple randomization method. Using the permutation block randomization method, 6 permutations were formed as a block of 4 using the letters A and B. The number of samples was divided by the number of permutations (40/6=7) and sorted 7 times from 1 to 6 using a table of random numbers (www.randomizer.org). The combinations generated according to this order (e.g. BBAA (3) ABBA (2)) were prepared in sealed envelopes (40 pieces) by an independent statistician. Which letter represented which group was determined by lottery. To ensure confidentiality, each preterm infant was randomly assigned a numerical code and the results were reported to the researcher collectively in sealed opaque envelopes.|f|f|f|t
34164174|NCT06004986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33851498|NCT03241225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Standardized assessments will be conducted by trained raters blind to participant assignment.|The investigators will compare the effectiveness and target engagement of EM/PROTECT with EM enriched with training of EM staff in linking EM victims to mental health services (EM/MH) in order to position us for a fully powered R01. To ensure rigor and reproducibility, EM/PROTECT or EM/MH will be offered to randomly assigned depressed EM victims, and standard assessments will be conducted by trained raters blind to participant assignment and our hypotheses.|f|f|f|t
33851499|NCT05336812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851500|NCT02002650|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33851501|NCT01956292|||CASE_ONLY||PROSPECTIVE|||||||
33851502|NCT05352568|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-test/post-test pre-experimental design with convenience and snowball sampling.||||
33851503|NCT05379504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be masked to study participant assignment. Baseline assessments will be completed prior to enrollment.|Individuals will be randomized to one of two study arms in blocks of 4.|f|f|f|t
33851504|NCT01336803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851505|NCT01014533|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33851506|NCT06374173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851507|NCT00000201||||TREATMENT||||||||
33851508|NCT02952378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851509|NCT02708914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851510|NCT04162613|||COHORT||PROSPECTIVE|||||||
33851511|NCT01129466|RANDOMIZED|CROSSOVER||||NONE||||||
33851512|NCT05885087|NA|SINGLE_GROUP||TREATMENT||NONE||single group prospective trial||||
33851513|NCT03107234|||COHORT||PROSPECTIVE|||||||
33851514|NCT02792673|RANDOMIZED|PARALLEL||||NONE||||||
33851515|NCT04580576|||COHORT||RETROSPECTIVE|||||||
33851516|NCT00901433|||CASE_ONLY||PROSPECTIVE|||||||
33851517|NCT00357851|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33851518|NCT02371213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851519|NCT03471260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851520|NCT01295762|NA|SINGLE_GROUP||SCREENING||NONE||||||
33851521|NCT02293304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851522|NCT02924064||PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851523|NCT02724059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851524|NCT02851485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164175|NCT06069427|NA|SINGLE_GROUP||PREVENTION||NONE|Due to the nature of the interventions (exercise), masking is not possible.|Participants will each undergo 3 trials in a randomised order.||||
34164176|NCT00835250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164177|NCT03644875|||COHORT||PROSPECTIVE|||||||
34164178|NCT04106609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164179|NCT00059345|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34164180|NCT04346329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Phase III double-blind, randomized, placebo-controlled clinical study|t|t|f|f
34164181|NCT02041416|||COHORT||PROSPECTIVE|||||||
33851525|NCT05015907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164182|NCT03535129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34164183|NCT05639296|||COHORT||PROSPECTIVE|||||||
34164184|NCT04590560|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Eligible women signing the written informed consent will be randomized with a 1:1:1 ratio to:~Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C)."||||
34164185|NCT03468868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Evaluators who assess clinical reported outcomes will be blinded to arm assignment.|Two-stage randomized choice design aimed at noninferiority.|f|f|f|t
34164186|NCT06672549|NA|SINGLE_GROUP||SCREENING||NONE||The PWMP protocol includes screening assessments plus a framework for the subsequent intervention, which is the primary purpose of the protocol.||||
34164187|NCT05244746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33851526|NCT03017300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34164188|NCT04656743|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34164189|NCT01156766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164190|NCT06355453|||COHORT||PROSPECTIVE|||||||
34164191|NCT04245839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164192|NCT02073994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164193|NCT04818970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|1:1 Randomized Placebo Control Trial|t|t|t|t
34164194|NCT00034294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164195|NCT04170543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blinded study in which MEDI3506 and placebo. Neither the subject nor any of the investigator or sponsor staff who are involved in the treatment or clinical evaluation of the subjects will be aware of the treatment received.|"Eligible subjects will be randomized to receive MEDI3506 or placebo as follows:~Group 1: MEDI3506 Dose 1. Group 2: MEDI3506 Dose 2. Group 3: MEDI3506 Dose 3 Group 4: MEDI3506 Dose 4 Group 5: Placebo (volume matched) All subjects will receive Dapa from Day 85 to Day 168."|t|t|t|t
34164196|NCT06725836|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164197|NCT04809285|NA|SINGLE_GROUP||OTHER||NONE||||||
34164198|NCT01387035|||COHORT||PROSPECTIVE|||||||
34164199|NCT04391114|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective comparative randomized controlled trial comparing two standard of care treatments|f|f|f|t
34164200|NCT00356967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164201|NCT00342589|||CASE_CONTROL||PROSPECTIVE|||||||
34164202|NCT00060632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164203|NCT04234867|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33851527|NCT01719354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851528|NCT00702351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851529|NCT01465347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851530|NCT05094505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851531|NCT03063801|||COHORT||RETROSPECTIVE|||||||
33851532|NCT01103362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851533|NCT00289497|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33851534|NCT05696301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955857|NCT00636922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955858|NCT02871336|||COHORT||PROSPECTIVE|||||||
33955859|NCT02297724|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33955860|NCT05925049|||COHORT||OTHER|||||||
33955861|NCT00331929|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33955862|NCT00869700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955863|NCT05761522|||CASE_ONLY||PROSPECTIVE|||||||
33955864|NCT04611555|||COHORT||PROSPECTIVE|||||||
33955865|NCT01148628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955866|NCT06653660|||COHORT||PROSPECTIVE|||||||
33955867|NCT04695210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Parallel group single blinded (outcome assessor) randomised controlled trial|f|f|t|t
34164204|NCT06725394|||OTHER||CROSS_SECTIONAL|||||||
34164205|NCT04583917|||COHORT||CROSS_SECTIONAL|||||||
34164206|NCT01788449|||||PROSPECTIVE|||||||
34164207|NCT01568840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164208|NCT06433323|||COHORT||PROSPECTIVE|||||||
34164209|NCT03451851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164210|NCT03668002|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will provide preliminary data and possibly demonstrate feasibility of a large scale randomized controlled trial comparing AVF and AVG in elderly patients (defined as patients over 65 years of age) receiving hemodialysis through a TDC.||||
34164211|NCT06017180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||intervention group and sham group|f|f|t|t
33851535|NCT06609772|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Power analysis was performed to calculate the sample size of this study. According to the calculation made using the G\*power 3.1 program; the sample size was determined as 110 (55 experimental, 55 control) with an effect size of 0.22, a margin of error of 0.05, a confidence level of 0.95, and a universe representation power of 0.95. Considering the possible losses that may occur for any reason, it was planned to include 120 individuals (60 experimental, 60 control) who are living liver donors in the study. In this study, the randomization method will be used in assigning the participants to the control and experimental groups. Thus, it was aimed to protect the randomization in case of data loss. Computer-assisted randomization will be used for randomization.|t|f|f|f
33851536|NCT02422862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851537|NCT01696838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33851538|NCT02709213|||COHORT||PROSPECTIVE|||||||
33851539|NCT04334954|||CASE_ONLY||CROSS_SECTIONAL|||||||
33851540|NCT06336733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851541|NCT04377750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851542|NCT04322591|||COHORT||RETROSPECTIVE|||||||
33851543|NCT04959448|||COHORT||PROSPECTIVE|||||||
33851544|NCT02698085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851545|NCT00096343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851546|NCT02367820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851547|NCT05077085|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter open label randomized controlled trial||||
33851548|NCT04591431|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, prospective, multicenter, Proof of Concept, Phase II clinical trial||||
33851549|NCT00837798|||CASE_ONLY||PROSPECTIVE|||||||
33851550|NCT00391131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851551|NCT02110719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851552|NCT05490719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851553|NCT04369482|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination, fibrosis, posterior capsule opacification (PCO) score and YAG capsulotomy rate.|t|f|t|f
33851554|NCT03154073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851555|NCT00713089|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33851556|NCT05189873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization list will be prepared by a statistician using the block randomization method (using the site:www.sealedenvelope.com). Treatments are placed in sealed envelopes and will be kept by the out-of-study nurse. After identification of the eligibility of the patient, the procedure is explained to her and informed consent is obtained. Then the treatment is performed based on the kind of treatment in the envelope.||f|f|t|t
33851557|NCT03557580|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851558|NCT01642251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851559|NCT01947972|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851560|NCT05692479|||CASE_CONTROL||PROSPECTIVE|||||||
33851561|NCT05308238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled feasibility study|f|f|f|t
33851562|NCT01076426|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33851563|NCT01856777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851564|NCT06453785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851565|NCT06130761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851566|NCT05288153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851567|NCT01457989|||||PROSPECTIVE|||||||
33851568|NCT01485081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851569|NCT01704638|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33851570|NCT01181388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851571|NCT02647216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851572|NCT03078426|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33955868|NCT05121688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Principal Investigator and the assessor will be blinded to the randomization and allocation. The assessor will have not access to patients' medical record. Patients will be also asked to do not explain about their procedure to the assessor.|The participants will be randomly allocated to Tele-physiotherapy or control groups.|f|f|t|t
33955869|NCT03690206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164212|NCT06726317|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This was a Quasi Experimental study with a parallel control group||||
34164213|NCT06059404|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Outcomes assessor will be blinded to participant group assignment||f|f|f|t
34164214|NCT05821244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164215|NCT00419107|||CASE_CONTROL||PROSPECTIVE|||||||
34164216|NCT02112617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164217|NCT06725927|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164218|NCT03472950|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164219|NCT06054607|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34164220|NCT06281535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851573|NCT04556292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851574|NCT00408252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851575|NCT00879866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851576|NCT05639660|||CASE_ONLY||CROSS_SECTIONAL|||||||
33955870|NCT05738083|||COHORT||PROSPECTIVE|||||||
33955871|NCT06279273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164221|NCT03251937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34059991|NCT04978805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Progressive Relaxation Exercise and control group|This study is an experimental study with pre-test and post-test contro|t|f|f|f
34059992|NCT04398186|||CASE_CONTROL||PROSPECTIVE|||||||
34164222|NCT01118832|||CASE_ONLY||OTHER|||||||
34059993|NCT05654272|||COHORT||PROSPECTIVE|||||||
34059994|NCT05168384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059995|NCT02635542|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Open label drug administration. Outcomes assessor and care providers are otherwise masked.||t|t|f|t
34059996|NCT05353972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059997|NCT02607306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34059998|NCT06384456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34059999|NCT00835627|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34164223|NCT00932906|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34164224|NCT04951752|||CASE_CONTROL||RETROSPECTIVE|||||||
34164225|NCT06404138|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study nurse, who assesses the outcomes during home visits (baseline, after six weeks, after one year) will be blinded|Patients are randomized 1:1 in one of the two intervention groups|f|f|f|t
33851577|NCT05069103|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Similar to the original TWIST trial, patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~1. A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~2. At least one image of their surgical wound(s).~Patients will receive automated requests via notifications asking to complete the online tool over the 30-day period (every 3 days +/- 1 day), however they may also complete the online form whenever wished."||||
33851578|NCT04754204|||CASE_ONLY||PROSPECTIVE|||||||
33851579|NCT01582685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33955872|NCT04945980|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were blinded to treatments.|A 2-period, randomized cross-over design was used. Each participant completed two 5-wk diet interventions in a randomly assigned order with a 4-wk washout period between the test diet interventions.|t|f|f|f
33955873|NCT05691218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955874|NCT03088280|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955875|NCT04285736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955876|NCT04637217|||CASE_CONTROL||PROSPECTIVE|||||||
33955877|NCT06651879|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"both care providers are blinded: the ultrasound examiner will be blinded regarding the clinical evaluation of the airway.~the anesthesiologist will be blinded regarding the ultrasound airway assessment"|The trial is a pilot of randomized clinical, two parallel groups, 1:1 allocation, superiority study.|f|t|f|f
33955878|NCT05801094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955879|NCT05591547|NA|SINGLE_GROUP||TREATMENT||NONE||Single group non-randomized interventional prospective cohort study||||
33955880|NCT01510587|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955881|NCT05472363|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33955882|NCT03835312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955883|NCT00103155||||TREATMENT||||||||
33955884|NCT04800822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955885|NCT01262391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955886|NCT05923333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955887|NCT06039007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955888|NCT01033513|||CASE_CONTROL||PROSPECTIVE|||||||
33955889|NCT01833897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955890|NCT04951817|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955891|NCT03797378|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33955892|NCT02099929|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33955893|NCT04842448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be randomized to either active treatment or sham treatment. Assessors will be blinded to treatment group.|Randomized, placebo-controlled, double-blind, phase II|t|f|t|t
33955894|NCT03074916|||CASE_CONTROL||PROSPECTIVE|||||||
33955895|NCT00463385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955896|NCT00491322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33955897|NCT06136676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blinded data analysis. The researcher who analyzes the data will be kept unaware of the information about the groups.|"The study consists of 3 arms, including:~Arm 1 - experimental groups: Heart-Centred Spiritual Meditation. Within this arm, the interventions encompass Islamic heart-centred contemplation and Christian heart-centred contemplation. Participants allocated to the spiritual meditation groups will receive either Islamic or Christian heart-centred contemplation intervention, depending on their respective religious affiliations.~Arm 2 - active control group: Mindfulness-based Stress Reduction. Participants assigned to the active control group will receive mindfulness intervention. This arm mirrors the time commitment and level of engagement of the contemplation interventions.~Arm 3 - passive control group: Waitlist control. Participants assigned to the waitlist control group will not receive any intervention."|f|f|f|t
33955898|NCT00006092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955899|NCT02392559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33955900|NCT02578043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955901|NCT00390572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955902|NCT05644899|||COHORT||RETROSPECTIVE|||||||
34060000|NCT00311103|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33955903|NCT06584097|||OTHER||PROSPECTIVE|||||||
33955904|NCT05288452|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||We used the multiphase optimization strategy (MOST) as the ideal approach for the proposed study as, with the three proposed intervention components, identifying an optimal intervention through a single randomized controlled trial (RCT) with multiple arms or through multiple RCTs would be methodologically inefficient and resource-intensive. Given this, we rely on the eloquent and rigorous MOST-based optimization design, which leverages factorial experimentation to identify an optimal set of intervention component(s). In a factorial experiment, the goal is not to compare individual experimental conditions (in this case, eight conditions), but to use combinations of conditions to estimate the main and interaction effects of the intervention components. Thus, numerous intervention components can be evaluated simultaneously while utilizing the entire randomized sample.|f|f|t|f
33955905|NCT02384239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955906|NCT00405496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060001|NCT01099774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851580|NCT06608316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessors and participants were blinded to the participants' group allocation.|Parallel Assignment: After stratification according to gender and age, the participants will be randomly allocated to one of three groups: (1) Left DLPFC stimulation group, (2) Bilateral DLPFC stimulation group, and (3) Sham stimulation group, using a 1:1:1 allocation ratio.|t|f|f|t
33851581|NCT06112990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, the investigators, and all members of the study team will be blinded to the treatment assignment.|Double-blind, placebo-controlled, randomized, controlled trial|t|t|t|f
34060002|NCT03054064|NA|SINGLE_GROUP||OTHER||NONE||||||
34060003|NCT06455124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060004|NCT00480493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060005|NCT02990351|||COHORT||RETROSPECTIVE|||||||
34060006|NCT02454075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060007|NCT03819959|||COHORT||PROSPECTIVE|||||||
34060008|NCT00501059|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34060009|NCT05810506|||COHORT||CROSS_SECTIONAL|||||||
34060010|NCT05721677|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized, open labeled study||||
34060011|NCT01031745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060012|NCT00785213|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060013|NCT04355806|||COHORT||PROSPECTIVE|||||||
34060014|NCT02174705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060015|NCT02134353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060016|NCT06339203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060017|NCT02464891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060018|NCT02456038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060019|NCT06215300|||COHORT||PROSPECTIVE|||||||
34060020|NCT00130429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060021|NCT00994695||PARALLEL||PREVENTION||NONE||||||
34060022|NCT06172348|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34060023|NCT05308784|||OTHER||OTHER|||||||
34060024|NCT01284387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060025|NCT01397786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060026|NCT03119623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060027|NCT03806231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060028|NCT06620523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Blinded: study team, including principal investigator, sub-investigators, study coordinators, hospital pharmacy and medical students. Patient is also blinded.~Unblinded: investigational drug pharmacists, investigational drug pharmacy technicians, nurses administering medication"||t|t|t|f
34060029|NCT04007224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060030|NCT05678400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060031|NCT06441032|||COHORT||RETROSPECTIVE|||||||
34060032|NCT02970019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060033|NCT05651308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060034|NCT01944891|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34060035|NCT05901350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34060036|NCT03499275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This is a study that comprises:~* A parallel group, randomised placebo-controlled, assessor-blinded trial with participants randomised (1:1) to usual care (home based exercise programme) with either placebo or active NMES for six weeks, with a 12 week follow-up.~* Qualitative interviews with participants and staff."|t|f|f|t
34060037|NCT01629823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060038|NCT05049928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060039|NCT02787733|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34060040|NCT03399682|||COHORT||PROSPECTIVE|||||||
34060041|NCT03762928|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33851582|NCT06154109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851583|NCT01823692|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33851584|NCT04448704|||COHORT||CROSS_SECTIONAL|||||||
33851585|NCT01076192|||COHORT||PROSPECTIVE|||||||
33851586|NCT02536807|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33851587|NCT02335177|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851588|NCT00978627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851589|NCT02279225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33851590|NCT05416060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a three-arm, non-blinded, randomized, controlled, parallel-groups, comparative effectiveness trial with N=150 participants.|"This is a three-arm, non-blinded, randomized, controlled, parallel-groups, comparative effectiveness trial with N=150 participants.~The protocol was developed in accordance with Good Clinical Practice, SPIRIT, and CONSORT 2013 guidelines."|f|f|f|t
33851591|NCT04541784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researchers and the statistician will be blinded to treatment assignment to prevent ascertainment bias.||f|f|f|t
33851592|NCT02220673|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33851593|NCT00742053|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060042|NCT03964467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|PI is only doing the testing, while the trainers are training all the participants|randomized controlled trial|t|f|t|t
34060043|NCT01029171|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34060044|NCT01501773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060045|NCT00072540||||TREATMENT||||||||
34060046|NCT02835417|||COHORT||PROSPECTIVE|||||||
33746808|NCT03721991|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|randomised controlled with placebo tablets matching active capsules with investigational product|randomised controlled study with active compared to placebo for 12 weeks|t|t|t|t
33746809|NCT01178853|RANDOMIZED|CROSSOVER||||NONE||||||
33746810|NCT06534151|||COHORT||PROSPECTIVE|||||||
33851594|NCT00095732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851595|NCT01003678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851596|NCT05939531|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851597|NCT01096485|RANDOMIZED|CROSSOVER||||NONE||||||
33851598|NCT02729285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33851599|NCT00836420|||CASE_ONLY||PROSPECTIVE|||||||
33851600|NCT04578197|||COHORT||PROSPECTIVE|||||||
33851601|NCT02163564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851602|NCT01439152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746811|NCT02105948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33746812|NCT06100497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746813|NCT02682264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746814|NCT04134819|||COHORT||PROSPECTIVE|||||||
33746815|NCT00040222|||FAMILY_BASED||OTHER|||||||
33746816|NCT02264795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765443|NCT05971823|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to device nicotine concentration and flavor used during ECIG sessions. No blinding will occur for the own brand condition.|Participants will complete 4, within-subject, laboratory sessions that differ by the product used: 1) own brand cigarette, 2) NJOY Ace 2.4% nicotine ECIG (Menthol and Classic Tobacco flavor), 3) NJOY Ace 5.0% nicotine ECIG (Menthol and Classic Tobacco flavor), and 4) NJOY Daily ECIG 6% nicotine (Menthol and Extra Rich Tobacco). The first condition for all participants will be their own brand cigarette. The subsequent three sessions will be assigned using a Latin-square following enrollment, and within each session participants will sample and evaluate two flavors of each session's product (session flavor order is incorporated into the Latin-square condition order assignment).|t|f|f|f
33765444|NCT05974995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765445|NCT05020262|||OTHER||RETROSPECTIVE|||||||
33955907|NCT00419965|||COHORT||PROSPECTIVE|||||||
33955908|NCT04591327|||COHORT||OTHER|||||||
33955909|NCT04794725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955910|NCT01017731|NA|SINGLE_GROUP||||NONE||||||
33955911|NCT06566248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955912|NCT00171899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955913|NCT06622824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955914|NCT06651177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955915|NCT06414655|||COHORT||PROSPECTIVE|||||||
33955916|NCT03099655|NA|SINGLE_GROUP||TREATMENT||NONE||The Medtronic Attain Stability Quad MRI SureScan (Model 4798) is a steroid-eluting, quadripolar electrode, transvenous, over-the-wire (OTW), IS4-LLLL compatible, active fixation, cardiac vein pacing LV lead. This lead is similar to the Attain Performa family of quadripolar leads (Models 4298, 4398, and 4598) but also has a side helix for active fixation which is similar to the Attain Stability bipolar lead (Model 20066/4796) (available outside of the United States).||||
33955917|NCT02704988|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33955918|NCT02217657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955919|NCT02437175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955920|NCT02772003|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33955921|NCT04145804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955922|NCT06541691|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|The quadruple masking (Participant, Treating Clinician, Investigator, Outcomes Assessor) is used for the first randomization, and the second randomization is open-label with blinded adjudication|2×2 full factorial design|t|t|t|t
33955923|NCT05990608|||OTHER||OTHER|||||||
33955924|NCT01830712|||COHORT||RETROSPECTIVE|||||||
33955925|NCT06357208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33955926|NCT04747912|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33955927|NCT02002949|RANDOMIZED|PARALLEL||||NONE||||||
33955928|NCT01708694|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33955929|NCT06111794|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This study uses a treatment/waitlist-control crossover repeated-measures design.|f|f|f|t
33955930|NCT02751372|NA|SINGLE_GROUP||OTHER||NONE||||||
33955931|NCT04856488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955932|NCT02972086|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33955933|NCT03530007|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33955934|NCT05428267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955935|NCT00119080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955936|NCT01009073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851603|NCT05293951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Experimental participants will perform resisted task-specific upper limb exercises while in a seated position at their kitchen table. During the exercises, participants will pull a resistance cord with their non-affected arm, while looking at its reflection in a mirror covering their affected arm.~Control participants will perform non-resisted task-specific upper limb exercises while in a seated position at their kitchen table. During the exercises, participants will be watching their non-affected arm reflected in a mirror covering their affected arm.~The outcome assessor was blinded to treatment allocation. They evaluated participants in a separate lab and were asked not to discuss the treatment given to patients. Even if the the patient mentioned the trials they would discuss the fact that they were using Mirrors."|Pilot Randomised Controlled Trial|t|f|f|t
33851604|NCT02879474|||COHORT||PROSPECTIVE|||||||
33851605|NCT05353946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851606|NCT00003849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851607|NCT04161625|NA|SINGLE_GROUP||PREVENTION||NONE|Information on the numbers reached will not be masked. All health outcomes are self-reports and self-assessments by the participants and reported in digital surveys. Outcomes will not be influenced by any other outcome assessors.|This is a pragmatic clinical trial evaluating reach, effects and cost effectiveness of a mobile health application. The intervention will last for 12 months with follow-up assessments at 3, 6, 9 and 12 months.||||
33851608|NCT02973711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851609|NCT06359691|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Three-armed crossover trial design to test effectiveness and sustainment of our implementation strategies across LAC DHS clinics and the communities they serve.|f|f|f|t
33851610|NCT01426867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060047|NCT01254851|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060048|NCT02356666|||CASE_ONLY||RETROSPECTIVE|||||||
34060049|NCT05309473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34060050|NCT03873909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||randomized 2-way cross-over||||
34060051|NCT00129181|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34060052|NCT05964114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060053|NCT06730087|||OTHER||CROSS_SECTIONAL|||||||
34164226|NCT04807933|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants won't be informed of the condition to which they belong. A debriefing will be done at the end of the last session (T3) for each participant.|The study requires 3 sessions (T1 / T2 / T3) with at least 24 days between each. The period (24 days) between the first session and the second session (T1-T2) will be considered as the control period. During the period, the participants will practice none exercise. The period (24 days) between the second session and the third session (T2-T3) will be considered as the intervention period. At the end of the second session (T2), the participants will be separated into two inter-subject groups: an experimental group performing BFB technique (3X5 min per day) in the intervention period (T2-T3) and a control group not performing a specific exercise in the intervention period (T2-T3).|t|f|f|f
34060054|NCT03640481|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2, open label, randomized, multicenter study in subjects with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy||||
34060055|NCT01925235|||COHORT||RETROSPECTIVE|||||||
34060056|NCT00628095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060057|NCT02307084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060058|NCT04554212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060059|NCT05103839|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060060|NCT01194635|||OTHER||RETROSPECTIVE|||||||
34060061|NCT02105389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060062|NCT06448858|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34060063|NCT04616105|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34060064|NCT01210495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060065|NCT03343249|NA|SINGLE_GROUP||OTHER||NONE||||||
34060066|NCT01746797|||COHORT||PROSPECTIVE|||||||
34060067|NCT04470284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060068|NCT01273740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060069|NCT06302088|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||All participating clinics will take part in baseline surveys of unit staff (n=240-360) and safety stakeholders will be identified. Following surveys, hospitals will be randomized to the control arm (n=3) or the intervention arm (n=3). Both groups will engage in key informant interviews on safety culture (n=30-60). Control group hospitals will continue standard operating procedures. Intervention group hospitals will engage in social network analysis of surveys, have peer leaders identified, and engage in safety leadership training and quality improvement cycles. All hospitals regardless of arm will take part in 6-and-12-month surveys and 24-month interviews.||||
34060070|NCT03013296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34060071|NCT03199612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo controlled randomized trial with 1:1 enrollment in each study arm.|t|t|t|t
34060072|NCT02458430|||COHORT||PROSPECTIVE|||||||
34060073|NCT05956353|NA|SINGLE_GROUP||SCREENING||NONE||||||
34060074|NCT00047216||||TREATMENT||NONE||||||
34060075|NCT05167175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060076|NCT06258187|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The quasi-randomization scheme will be determined by a randomizer for each month. This will be revealed at the beginning of each month on whether to use Pedi-Cap or not during delivery room resuscitation.|f|f|f|t
34060077|NCT00581542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34164227|NCT05349357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164228|NCT03374787|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34164229|NCT04949594|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34164230|NCT05813457|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164231|NCT00352677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060078|NCT01406184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34060079|NCT03796338|||COHORT||PROSPECTIVE|||||||
34060080|NCT03066245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164232|NCT06472245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164233|NCT00657163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851611|NCT01630746||||TREATMENT||||||||
33851612|NCT01703650|||COHORT||PROSPECTIVE|||||||
33851613|NCT02902874|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851614|NCT01170611|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851615|NCT06258226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851616|NCT05148143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851617|NCT04910789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851618|NCT04303611|||COHORT||RETROSPECTIVE|||||||
33851619|NCT05367154|||OTHER||OTHER|||||||
33851620|NCT04304573|||COHORT||PROSPECTIVE|||||||
33851621|NCT04913454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851622|NCT05361525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851623|NCT00666146|||FAMILY_BASED||OTHER|||||||
33851624|NCT02861547|||COHORT||RETROSPECTIVE|||||||
33851625|NCT02255214|||COHORT||PROSPECTIVE|||||||
33851626|NCT01096277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851627|NCT03573726|NA|SINGLE_GROUP||OTHER||NONE||||||
33851628|NCT05450094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851629|NCT00950222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851630|NCT06021171|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Volunteers will be asked to mix the powder packet (e.g. supplemental functional fiber source or placebo), with any food or beverage once daily. All 3 powders are identically packaged and only visible as white powder, and all 3 powders are colorless, odorless and tasteless when mixed in a liquid or semi-solid food. Instructions and education to both groups will be identical. Packets were sent to the Researcher pre-packaged and pre-labeled as A, B, C by the product company.~Subject randomization to treatment order was completed using random number generator by a Research Assistant not involved in direct contact with subjects."|This is a double-blind, randomized, placebo-controlled crossover trial.|t|t|t|t
33851631|NCT00334854|NON_RANDOMIZED|||TREATMENT||||||||
33851632|NCT05480410|NA|SINGLE_GROUP||TREATMENT||NONE||A single group including patients with neuropathic oncological pain.||||
33851633|NCT03787927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060081|NCT04417140|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"5.1 General Design Description A double-blinded RCT with two arms: treatment (dHACM) and control. Patients will be recruited from 8 LSUHSC-NO surgeons' practices (Drs. Boudreaux, Stuke, Orangio, Moore, tMarr, Hunt, Greiffenstein, and Barton).~Subjects will be randomized to treatment or control at a rate of 1:1, stratified by surgeon. Subjects, nursing staff, and surgeons not present at the time of fascial closure will be kept blinded to the subjects' treatment arm. Computer-generated randomization will be performed in permutated blocks of 20 patients, using SAS version 9.4."|"5.1 General Design Description A double-blinded RCT with two arms: treatment (dHACM) and control. Patients will be recruited from LSUHSC-NO surgeons' practices .~Subjects will be randomized to treatment or control at a rate of 1:1, stratified by surgeon. Subjects, nursing staff, and surgeons not present at the time of fascial closure will be kept blinded to the subjects' treatment arm. Computer-generated randomization will be performed in permutated blocks of 20 patients, using SAS version 9.4."|t|f|t|t
34060082|NCT03533881|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1: following minimal nutritional changes Group 2: following minimal nutritional changes and taking Arom Digest Slim||||
34060083|NCT01813513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060084|NCT02750007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060085|NCT03794505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060086|NCT05294991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34060087|NCT01485445|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33851634|NCT03519906|||CASE_ONLY||PROSPECTIVE|||||||
33851635|NCT06609694|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||The aim of this study is to examine whether clinically important indices during sleep are comparable between oxygen delivery by portable and by continuous flow. This aim will be accomplished by a randomized crossover study design.|t|f|f|f
33851636|NCT04200976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851637|NCT03212560|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33851638|NCT03106597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded-endpoint|"1. Manidipine 20mg/day, Amlodipine 10mg/day~2. Sealed envelope method randomization according to gender and age~   * 25 males under 55 years old~  * 25 males more than 55 years old~  * 25 females under 55 years old~  * 25 females more than 55 years old"|t|f|f|f
33851639|NCT02054611|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33851640|NCT04224571|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective and Non-randomized controlled trial||||
33851641|NCT00662935|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33851642|NCT01164254|||COHORT||PROSPECTIVE|||||||
33851643|NCT02531347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851644|NCT00207610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851645|NCT01845909|||COHORT||PROSPECTIVE|||||||
33851646|NCT05083000|NA|SEQUENTIAL||TREATMENT||NONE||The dose escalation will be in a standard 3+3 dose escalation design with 0.25mg increments of Topotecan; it will begin with a single dose 0.25mg for 3 patients-expanded to another 3 if no toxicities are seen. Subsequent dose levels will be 2 doses of 0.25mg, a single dose of 0.5mg and then 2 doses of 0.5mg (maximum of 24 patients).||||
33851647|NCT01153958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851648|NCT00414037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851649|NCT05448612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851650|NCT03542461|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized in a 1:1 ratio to 2 treatment arms and stratified by centre and response to first-line induction therapy (minimization method)||||
33851651|NCT03735212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851652|NCT02409069|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33851653|NCT05399420|||COHORT||PROSPECTIVE|||||||
33851654|NCT01738425|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33851655|NCT00004404||||TREATMENT||||||||
34060088|NCT02156375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060089|NCT02326298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060090|NCT04773652|||COHORT||PROSPECTIVE|||||||
34060091|NCT04505605|||OTHER||PROSPECTIVE|||||||
34060092|NCT02134002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060093|NCT02521532|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34060094|NCT06366139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765446|NCT01338922|RANDOMIZED|PARALLEL||TREATMENT||NONE||open multicentre parallel randomised controlled intervention trial with waiting-list-control-group||||
33765447|NCT04102930|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33765448|NCT00023647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060095|NCT02971540|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34060096|NCT06731582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060097|NCT04303533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060098|NCT00588614|||COHORT||PROSPECTIVE|||||||
34060099|NCT01458717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060100|NCT01637766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060101|NCT01670838|||COHORT||PROSPECTIVE|||||||
34060102|NCT06287775|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34060103|NCT04803591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060104|NCT01585324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060105|NCT03652116|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to local infiltration of cesarean section wound with either bupivacaine or pethidine; with follow up of postoperative pain relief.||||
34060106|NCT02877719|||COHORT||CROSS_SECTIONAL|||||||
34060107|NCT03176667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060108|NCT00313365|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060109|NCT02595281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060110|NCT02035774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060111|NCT04601103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Assessors did not know what toothpaste subjects used.|The study was designed as an imbalanced 2 Period Crossover Study. However, the study was terminated during the washout period and the results reported here reflect only the period 1 results.|f|f|f|t
34060112|NCT04550351|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34060113|NCT01130155|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34060114|NCT01985139|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34060115|NCT03014713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34060116|NCT05276622|||COHORT||PROSPECTIVE|||||||
34060117|NCT06269016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060118|NCT01289756|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060119|NCT03269084|||COHORT||PROSPECTIVE|||||||
34060120|NCT04205149|||COHORT||PROSPECTIVE|||||||
34060121|NCT04005144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060122|NCT01757730|||CASE_CONTROL||PROSPECTIVE|||||||
34060123|NCT02160847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060124|NCT02106663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060125|NCT01593280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060126|NCT01013623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060127|NCT05697250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Stone free status is assessed on low dose CT 3 months post endoscopically by an outcome assessor blinded to the randomisation.|The patients are randomised to ureteroscopic stone treatment with Thulium Fiber Laser with either low or high laser settings. The ureteroscopic procedures are performed in a standardised manner irrespective of the laser settings, and follow-up is similar in both groups.|f|f|f|t
34060128|NCT05285722|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34060129|NCT04747873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told if they are in a stepped care approach or not. They will all be participating in the same e-CBT modules.|Participants will be randomized into 2 groups. One group will be given 12 weeks of e-CBT for depression. The other group will be given the same 12 weeks of e-CBT modules along with the possibility of additional attention if deemed necessary by the therapist.|t|f|f|f
34060130|NCT01701297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060131|NCT03041103|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Single arm not blind||||
34060132|NCT06245967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060133|NCT03141983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060134|NCT05311566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060135|NCT04113408|||CASE_ONLY||PROSPECTIVE|||||||
34060136|NCT01211483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765449|NCT02328703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851656|NCT02350608|||COHORT||PROSPECTIVE|||||||
33851657|NCT05178667|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33851658|NCT00729872|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34060137|NCT03713840|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060138|NCT05220345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||International multicenter prospective interventional cohort, compared with a cohort from the Discovery II study (NL73127.091.20, trial code NL9135).||||
33851659|NCT01657851|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851660|NCT00921596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851661|NCT05657717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33851662|NCT04129697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851663|NCT03170999|||COHORT||PROSPECTIVE|||||||
33851664|NCT00638781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33851665|NCT04580329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851666|NCT03929757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33851667|NCT02778854|||COHORT||PROSPECTIVE|||||||
33955937|NCT02024386|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851668|NCT01066520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33955938|NCT06632990|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851669|NCT00840151|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33851670|NCT06605664|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm of hyperpolarized 13C pyruvate MRI||||
33851671|NCT02791074|||CASE_CONTROL||PROSPECTIVE|||||||
33851672|NCT05514782|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization occurred by assignment to either Cell 1 or Cell 2 using a randomization list, prepared by KGL Skin prior to the start of the study.|Randomized, double-blinded, placebo-controlled, single-center|t|f|t|f
33851673|NCT05657015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The phytochemicals were prepared by the pharmacist and coded so that the patients, researcher, and outcomes assessor were blinded to the type of intervention.|This study was designed to be a Randomized, Controlled, Triple-blinded, Phase (IV) clinical trial; the eligible participants were randomly allocated to one of the two comparative parallel groups; test and control group using computer-generated random tables (www.randomizer.org).|t|f|t|t
33851674|NCT06226740|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33851675|NCT03099499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851676|NCT04004247|NA|SINGLE_GROUP||OTHER||NONE||12 volunteers||||
33851677|NCT04991532|||CASE_CONTROL||PROSPECTIVE|||||||
33851678|NCT01588431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851679|NCT03187574|||CASE_CONTROL||PROSPECTIVE|||||||
33851680|NCT01688687|||COHORT||PROSPECTIVE|||||||
33851681|NCT06477822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants don't know what intervention are they receiving The outcomes assessor don't know the intervention that the participant is receiving|Treatment group: receive a manual therapy secuence of techniques focus on the autonomic nervous system Simulated group: receive a sequence of simulated manual therapy techniques|t|f|f|t
33851682|NCT02865525|||OTHER||PROSPECTIVE|||||||
33851683|NCT02021097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955939|NCT06646003|||CASE_ONLY||CROSS_SECTIONAL|||||||
33955940|NCT00638339|||CASE_CONTROL||PROSPECTIVE|||||||
33955941|NCT01525407|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33955942|NCT02496442|RANDOMIZED|PARALLEL||||NONE||||||
33955943|NCT05459077|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Aim 3B group will participate in an adapted intervention related to blood pressure management.||||
33955944|NCT02148835|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33955945|NCT06652139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955946|NCT06700538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851684|NCT03476213|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Group A will be anesthetized using TIVA, group B using TCI|t|t|f|t
33851685|NCT03235284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Outcomes Assessor)||f|f|f|t
33851686|NCT00306670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851687|NCT05420285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955947|NCT05550025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955948|NCT06540820|||COHORT||CROSS_SECTIONAL|||||||
33955949|NCT06652776|||COHORT||OTHER|||||||
33955950|NCT06344858|||COHORT||PROSPECTIVE|||||||
33955951|NCT00567086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060139|NCT05432050|||COHORT||PROSPECTIVE|||||||
33851688|NCT03801122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Arm 1 : Tranexamic acid 3g/day Arm 2 : Tranexamic acid 1.5g/day Arm 3 : No tranexamic acid|t|f|f|t
34060140|NCT03635385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060141|NCT05263765|||CASE_ONLY||OTHER|||||||
34060142|NCT05615610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060143|NCT01113138|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34060144|NCT06622525|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open-label clinical trial at the General Hospital of Mexicali; central tendency measures will be obtained for variables.||||
34060145|NCT02505451|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34060146|NCT05149378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060147|NCT01551719|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060148|NCT00948506|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34060149|NCT03284372|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34060150|NCT03754634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060151|NCT04837599|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34060152|NCT01885715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060153|NCT00463216|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34060154|NCT01601457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060155|NCT03075202|||COHORT||PROSPECTIVE|||||||
34060156|NCT04812340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060157|NCT03968250|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The design of this pilot web-based CBT Fatigue therapy will be a non-randomised prospective non-controlled before-and-after study, in which observations will be made only in a patient group that receives the intervention (IG). No control group will be recruited. Assessments will be conducted at three measurement points: T0 (before the intervention), T1 (at the end of the intervention), T2 (3 months after T1).||||
34060158|NCT02063048|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060159|NCT05440474|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34060160|NCT03118791|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double blind randomized controlled crossover|t|t|t|t
34060161|NCT00664794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060162|NCT00876148|||COHORT||RETROSPECTIVE|||||||
34060163|NCT01436331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060164|NCT04251962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34060165|NCT00407927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060166|NCT02075775|||COHORT||PROSPECTIVE|||||||
34060167|NCT05199896|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34060168|NCT02939976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060169|NCT03042416|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060170|NCT02306694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955952|NCT03312764|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All study investigators that collect data or analyze the data are prevented from knowing the interventions assigned to individual participants.|Participants are randomly allocated to one of two groups for the duration of the study.|f|f|t|t
33955953|NCT05950828|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851689|NCT00541021|RANDOMIZED|||TREATMENT||DOUBLE||||||
33851690|NCT02305836|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33851691|NCT00339222|||FAMILY_BASED||OTHER|||||||
33851692|NCT05033873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851693|NCT03322072|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm prospective cohort study||||
33851694|NCT04822597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data will be analyzed with intervention arms masked.|There will be four separate treatment arms. Participants have equal chances of being assigned to any of the four arms.|f|f|f|t
33955954|NCT04999592|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The clinical team responsible for the participant (physicians, nurses and others) and involved with direct patient care will be blinded. Investigators will be blinded and the placebo will match the study drug. Outcomes Assessors will be blinded to treatment assignment during assessments of pneumonia and functional outcome.||t|t|t|t
33851695|NCT01583153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851696|NCT00181064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33955955|NCT02511873|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33955956|NCT06244095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955957|NCT01097759|||||PROSPECTIVE|||||||
33955958|NCT01965431|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33851697|NCT04355247|NA|SINGLE_GROUP||PREVENTION||NONE||"This is a pilot Phase II exploratory study. It is a non-randomized study which will be carried out at Auxilio Mutuo Hospital and possibly at other institutions to be recruited.~The investigator plans to enter a total of 20 patients in order to determine whether the risk of progressing to respiratory failure can be reduced by administering corticosteroids.~The investigator assume that virtually all patients who met the criteria for entry into this trial will develop respiratory insufficiency if left untreated.~If \</= 50% of patients with high risk develop respiratory failure the investigator will consider the treatment as successful."||||
33851698|NCT00588185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851699|NCT02644486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851700|NCT03096704|||CASE_CONTROL||PROSPECTIVE|||||||
33851701|NCT06238518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, 1:1 randomized, controlled, multicenter trial to assess effectiveness and safety of adding IVL to Conventional Therapy compared to Conventional Therapy only in calcified coronary lesions.|f|f|f|t
33851702|NCT06159153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33851703|NCT02388685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851704|NCT02909530|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33851705|NCT02703090|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33955959|NCT02472431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955960|NCT03231423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955961|NCT01948011|RANDOMIZED|CROSSOVER||||NONE||||||
33955962|NCT02662556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955963|NCT00863239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955964|NCT04764669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955965|NCT01410565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955966|NCT06576830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851706|NCT03999996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be double-blinded, randomized, and placebo-controlled from Month 15 onwards for participants from parent trial DEN-304 (US) and from Month 42 onwards for participants from parent trial DEN-315 (Mexico).||t|t|t|t
33851707|NCT03239613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851708|NCT04275089|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33851709|NCT04280341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851710|NCT04307251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851711|NCT01351831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851712|NCT04806542|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Study.||||
33851713|NCT01248546|||COHORT||PROSPECTIVE|||||||
33851714|NCT06379464|||OTHER||CROSS_SECTIONAL|||||||
33851715|NCT03367650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Bi-centric epidemiological prospective, cross-sectional descriptive study coupled with a longitudinal study.||||
33851716|NCT06463561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851717|NCT05963373|||OTHER||OTHER|||||||
33955967|NCT06648473|NA|SINGLE_GROUP||OTHER||NONE||||||
33955968|NCT06698406|||COHORT||CROSS_SECTIONAL|||||||
34060171|NCT04984681|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34060172|NCT04151238|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34060173|NCT00079300|RANDOMIZED|||TREATMENT||DOUBLE||||||
33851718|NCT00297687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33851719|NCT00520169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851720|NCT02283073|||CASE_CONTROL||PROSPECTIVE|||||||
33851721|NCT00095498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851722|NCT03983629|||COHORT||PROSPECTIVE|||||||
33851723|NCT05421507|||COHORT||PROSPECTIVE|||||||
33851724|NCT04533568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851725|NCT03639467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060174|NCT01540136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060175|NCT01778699|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34060176|NCT02258334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060177|NCT06478602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060178|NCT02277158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060179|NCT02440321|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34060180|NCT02490748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060181|NCT01131065|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34060182|NCT00018369|||||PROSPECTIVE|||||||
34060183|NCT01960894|||COHORT||PROSPECTIVE|||||||
34060184|NCT00360815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060185|NCT03526926|||COHORT||PROSPECTIVE|||||||
34060186|NCT04447495|||CASE_CONTROL||PROSPECTIVE|||||||
34060187|NCT02538692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060188|NCT06266156|||COHORT||RETROSPECTIVE|||||||
34060189|NCT04497350|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a single-site, randomized, blinded, clinical trial comparing the efficacy of transcranial magnetic stimulation (TMS) and intermittent theta burst stimulation (iTBS) in subjects with treatment refractory depression (trMDD). The study will recruit 30 subjects, all suffering from treatment refractory depression (trMDD). Half of the subjects (15) will be randomized to the TMS treatment group, while the other half will be assigned to the iTBS treatment group. The randomization ratio will be 1:1.|t|f|f|f
34060190|NCT00103493|RANDOMIZED|PARALLEL||||SINGLE||||||
34060191|NCT04978428|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label treatment study||||
34060192|NCT06496022|||COHORT||PROSPECTIVE|||||||
34060193|NCT06472102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060194|NCT03934957|||COHORT||PROSPECTIVE|||||||
34060195|NCT00013637|||DEFINED_POPULATION||PROSPECTIVE|||||||
34060196|NCT05421052|||OTHER||CROSS_SECTIONAL|||||||
34060197|NCT06620250|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34060198|NCT05864053|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind|Randomized double blind three way (1:1:1) cross over clinical trial|t|t|t|t
34060199|NCT05479591|||COHORT||PROSPECTIVE|||||||
34060200|NCT01116713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34060201|NCT03873441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060202|NCT06071182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060203|NCT03553420|||CASE_ONLY||PROSPECTIVE|||||||
34060204|NCT03126565|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34060205|NCT03134716|||CASE_CONTROL||PROSPECTIVE|||||||
34060206|NCT00508937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34060207|NCT03330067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Before surgery patients will be assigned to one of two types of CO2 gas (conventional-room temperature and dry, or conditioned-95°F and 95% humidity) by a method similar to the flip of a coin.||||
34060208|NCT04236167|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One part of the outcomes will be assessment of clinical photographs of the scars. The assessor will be blinded to which part of the scar received the laser treatment.|Prospective split scar study|f|f|f|t
34060209|NCT01139099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060210|NCT03079037|||COHORT||PROSPECTIVE|||||||
34060211|NCT02167048|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33851726|NCT06255327|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Participants in the control group were not given any information or training before or after the operation, and they were on routine hospital care.|The sample of the study (n=60) consisted of patients underwent major abdominal surgery required general anesthesia and hospital stay who got diagnosed by consultant general and bariatric surgery, being between 30-60 years old (39.9±8.82 years old; 47 F/ 13 M) volunteered to attend this study. The participants were randomly divided into two groups.|t|f|f|f
33851727|NCT05614154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Patients who met the criteria for participation in the study 2nd group patients dressed with antiseptic with hypochlorous active substance|Patients meeting the inclusion criteria Patients dressed with 1st group Povidone-iodine antiseptic (routinely applied antiseptic in the clinic)||||
33851728|NCT05621577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851729|NCT05166187|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33851730|NCT00781287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851731|NCT00521066|||COHORT||PROSPECTIVE|||||||
33851732|NCT03856554|NA|SINGLE_GROUP||TREATMENT||NONE||"Transforminal lumbar interbody fusion~: unilateral versus bilateral facetectomy"||||
33851733|NCT01885754|||COHORT||PROSPECTIVE|||||||
33851734|NCT03786523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060212|NCT04989972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|The research design has a parallel design for the first 8 weeks and a open label single group study for the last 8 weeks|t|f|t|f
34060213|NCT04546113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34060214|NCT03801824|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33746817|NCT04044677|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The device DS-Stimulator, Neuroconn Mobile tDCS allows the blindness of the researcher and the participant, so the participants, researchers, and outcome assessors will remain blind to group allocation during the study. To ensure proper blinding, participants will receive codes and will be concealed from the allocation process by one different researcher. The researchers responsible for applying the intervention and the outcome assessors will not know the study design, allocation, objectives, and expected outcomes. In addition, for the blinding of the experimenter (responsible for applying the intervention), one assessor (responsible for randomization) will be in charge of giving the active device to the experimenter.|Group 1 will start with ten sessions of tDSC-active combined to VR tasks. After one-month washout, this group will be reallocated to another 10 sessions with tDCS-sham combined to VR tasks. In contrast, Group 2 will do the opposite protocol (participants will start allocated to ten sessions of TDCS-sham and VR tasks, and after one-month washout period will be reallocated to ten sessions of tDCS-active and VR tasks).|t|t|t|t
33746818|NCT02057822|||||PROSPECTIVE|||||||
33746819|NCT06630455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33746820|NCT05734794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746821|NCT00907673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851735|NCT04665570|||COHORT||PROSPECTIVE|||||||
33851736|NCT03193359|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851737|NCT04140019|||CASE_ONLY||PROSPECTIVE|||||||
33851738|NCT00001396||||TREATMENT||||||||
33851739|NCT01793467|||COHORT||PROSPECTIVE|||||||
33851740|NCT03447808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851741|NCT02337751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851742|NCT03857620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851743|NCT03451617|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33851744|NCT05381610|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33851745|NCT05782023|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060215|NCT00758147|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34060216|NCT00757029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851746|NCT04634929|||CASE_CONTROL||PROSPECTIVE|||||||
33851747|NCT04496531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Therapists and other personnel (MR technicians, SOT and DGI administrators, Neuropsychologists etc.) were not informed as to which group a subject belonged. In order to maintain this blinding, both subjects and therapists were instructed not to discuss any details of the stimulus sensation with each other. Additionally, all subjects were instructed not to adjust the stimulus intensity in the presence of therapists. All questions about device use or the stimulation were to be addressed only to the PI|"Fourteen MS patients, seven each in an active and a sham stimulation group, participated.~Participants received intensive physical therapy and working memory training for 14 weeks. Functional magnetic resonance imaging (fMRI) using motor imagery and working-memory tasks were completed prior to and following therapy, as were sensory organization tests (SOT), motor performance measures, and neuropsychological assessment."|t|t|f|t
33851748|NCT01465529|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33851749|NCT03471156|||COHORT||PROSPECTIVE|||||||
33851750|NCT03970070|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34060217|NCT05437588|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34060218|NCT04101032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060219|NCT00503997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060220|NCT03944733|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|A study staff not involved with data analyses or outcome assessment will provide the intervention to participants.|Iron deficient anemic (IDA) mothers will be given an iron supplement versus iron sufficient (control; CN) mothers will be given a placebo (gelatin pill) daily.|t|t|t|t
34060221|NCT04743323|||CASE_CROSSOVER||PROSPECTIVE|||||||
34060222|NCT02405975|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34060223|NCT04402281|||CASE_CONTROL||OTHER|||||||
34060224|NCT05733026|||COHORT||PROSPECTIVE|||||||
34060225|NCT02906033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34060226|NCT06328504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060227|NCT05362240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups with the first intervention four corner fusion , and the second with three corner fusion without triquetrum excision||||
34060228|NCT00940680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060229|NCT03567512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34060230|NCT05062252|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060231|NCT06331195|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34060232|NCT00142259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060233|NCT02427438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060234|NCT02300350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060235|NCT03890627|||COHORT||PROSPECTIVE|||||||
34060236|NCT00362713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060237|NCT02422550|||COHORT||PROSPECTIVE|||||||
34060238|NCT01397539|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34060239|NCT03978013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Pomegranate and control juice will be provided by Primor Company, Hadera, Israel. Control juice has similar color and test but do not include pomegranate.|RCT|t|t|t|t
34060240|NCT03784118|NA|SINGLE_GROUP||SCREENING||NONE||||||
34060241|NCT01361269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060242|NCT00256321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851751|NCT01315353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851752|NCT05830045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33851753|NCT03736473|NA|SINGLE_GROUP||OTHER||NONE||||||
33851754|NCT01685671|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33851755|NCT00284817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851756|NCT05025046|||COHORT||PROSPECTIVE|||||||
33851757|NCT04524325|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There is 1 group of trans men (n=20) and 1 group of cisgender women (n=20). Study procedures, protocols, and measurements will be the same for both groups and performed and/or taken in a similar time period.||||
33851758|NCT04460885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851759|NCT04041531|NA|FACTORIAL||BASIC_SCIENCE||SINGLE||16 combinations of 4 levels of pCO2 and 4 levels of temperature will be assessed for each participant|f|f|t|f
33851760|NCT02375178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851761|NCT05124743|||CASE_ONLY||PROSPECTIVE|||||||
33851762|NCT05778669|||COHORT||PROSPECTIVE|||||||
33851763|NCT05184023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is doubled blinded, a subject 's specific ID card will be provided for each of the enrolled subject and the investigators don't know whether it is PEMF or Sham treatment for that subject's specific ID card. And the investigator will ask the manufactory about the number of grouping at the end of the study.|Participants will be assigned into either treatment group or sham group.|t|t|t|f
33851764|NCT03299868|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Single institution, Open-label, Randomized, Phase 2||||
33851765|NCT03125720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33851766|NCT05682391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851767|NCT03639831|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33851768|NCT00700973|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851769|NCT02611791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851770|NCT04979650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851771|NCT00277576|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33851772|NCT04980443|NA|SINGLE_GROUP||SCREENING||NONE|Endoscopy staff will be blinded to the result of the CELTiC test. Additionally, laboratory staff that assesses the CELTiC test will be blinded to the result of the colonoscopy.|We will cross-sectionally assess the CELTiC test in a group of FIT-positive individuals.||||
33851773|NCT03623854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851774|NCT06087926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will be blinded as to which site is being stimulated, experimental site or control site.||t|f|f|f
33851775|NCT03389906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pilot study||||
33851776|NCT02667197|||OTHER||RETROSPECTIVE|||||||
33851777|NCT06168552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851778|NCT00978796|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33851779|NCT06422468|NA|SINGLE_GROUP||OTHER||NONE||||||
33851780|NCT05055505|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design.||||
33851781|NCT01666379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33851782|NCT03824639|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33851783|NCT04908397|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a single-center, prospective study enrolling 10 PAH patients. All eligible participants will be given carnitine supplements for 2 weeks.||||
33851784|NCT02844647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955969|NCT05146700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Open-label, primary outcome assessor- and analyst-blinded, randomized, controlled clinical trial with regards to treatment: treating staff will be aware of the trial participants' randomization group.~While including patients for the study, the research team and treating staff will be aware of the trial participants' oxygen allocation strategy. However, at least two allocation blinded primary outcome assessors (specialists in anesthesiology, intensive care, emergency medicine or similar) will be appointed at each center to assess in-hospital major lung complications (pneumonia and acute respiratory distress syndrome). Blinding will be ensured by concealing all information indicative of the allocation prior to assessment. The statistician and manuscript writers will be blinded towards the allocation of treatment once the trial ends when data is being analysed and the manuscript is drafted."|"Trial participants are randomized pre-hospital or in the trauma bay to a restrictive or liberal oxygen treatment for eight hours.~Experimental (restrictive oxygen): The restrictive group will receive the lowest dosage of oxygen (≥21%) ensuring an SpO2 target = 94%~Active comparator (liberal oxygen): The liberal group will receive a flow of 15 L O2/min for non-intubated trial participants or an FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation; later in the operating room (OR), intensive care unit (ICU), post-anesthesia care unit (PACU) and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation (SpO2) is ≥98%"|f|f|f|t
33955970|NCT00187174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060243|NCT03524352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060244|NCT02466217|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34060245|NCT01915654|||CASE_CONTROL||RETROSPECTIVE|||||||
34060246|NCT05864573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060247|NCT04108988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851785|NCT05810454|RANDOMIZED|PARALLEL||TREATMENT||NONE||"participants are randomly assigned to either iPACES (pedal-to-play) or PACE (pedal-while-play) exergaming interventions to be completed 3-5x/wk for 3 months, then PACE crosses over to iPACES for 3 months, and all followed a final month"||||
33851786|NCT01945060|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33851787|NCT06257524|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33851788|NCT04338087|||CASE_CONTROL||PROSPECTIVE|||||||
33851789|NCT02621320|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851790|NCT02020382|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33851791|NCT04304521|||CASE_ONLY||PROSPECTIVE|||||||
33851792|NCT03045068|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective Randomized trial in neonates comparing platelet apheresis transfusion prior to termination of CPB versus standard transfusion of platelet apheresis after modified ultrafiltration and protamine administration||||
33851793|NCT02117947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060248|NCT03165474|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Participants will be randomized into intervention or control arm and will be provided with different orientations.||t|f|f|f
34060249|NCT06618040|NA|SINGLE_GROUP||OTHER||NONE||||||
34060250|NCT04491305|||COHORT||PROSPECTIVE|||||||
34060251|NCT02505334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060252|NCT05919914|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34076308|NCT03506438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The electronic study data system login/password arrangement will not allow any investigator to ascertain treatment group.~The study data system will automatically send links to study surveys for participant self-completion, and therefore outcomes assessors will be blinded to the majority of post-randomization data collection."|Unit of randomization is the ICU attending physician. We anticipate 15-25 ICU physicians for intervention and 15-25 for control. Therefore each clinician will likely have 5-12 family members each.|f|f|t|t
34076309|NCT02090504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076310|NCT01852123|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34076311|NCT05793281|||COHORT||RETROSPECTIVE|||||||
33746822|NCT03720704|||COHORT||PROSPECTIVE|||||||
33746823|NCT06019312|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33746824|NCT03302962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33746825|NCT01748929|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33746826|NCT06670833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33746827|NCT02399579|NA|SINGLE_GROUP||||NONE||||||
33746828|NCT02032472|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060253|NCT06263270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is double-blind, placebo-controlled. Neither the investigator, care providers, patients, nor study sponsor have knowledge of the interventions assigned to each participant.|The Phase 1a trial will be a multicenter, double-blind, randomized, placebo-controlled clinical study to evaluate the safety of two doses of CYT-108 (given at Day 1 and Day 85) in participants with mild to moderate primary OA of the knee, followed out to 26 weeks. A Screening Visit will be performed between twenty-eight days to two days before the first dose, (i.e., Days -28 to -2), and if eligible, participants will attend baseline evaluation on Day 1 to confirm eligibility before randomisation to treatment. The first and second doses will be administered on Day 1 and Day 85 (12 weeks post-first dose, with six follow-up visits on Days 8, 29, 57, 85, 113, and 183; Weeks 1, 4, 8, 12, 16, and 26 weeks post-first dose respectively).|t|t|t|t
34060254|NCT05395897|||COHORT||RETROSPECTIVE|||||||
34060255|NCT04587739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060256|NCT02712021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164234|NCT03544255|||COHORT||PROSPECTIVE|||||||
34164235|NCT06085599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants did not know which group they were in.|This study was conducted as a randomised controlled study with experimental and control groups.|t|f|t|f
34164236|NCT03439735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164237|NCT02649556|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34164238|NCT01967563|||COHORT||PROSPECTIVE|||||||
34060257|NCT04051099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060258|NCT04599933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060259|NCT04940520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060260|NCT04788225|||CASE_CONTROL||PROSPECTIVE|||||||
34060261|NCT06277154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060262|NCT02332564|||COHORT||PROSPECTIVE|||||||
34060263|NCT05988905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Robot assisted gait training enables training of automatically programmed normal gait pattern. Patients underwent 30 min of RAGT using SUBAR® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 8 weeks. The CON group focused on gait training such as active range of motion (ROM) exercise, weight bearing training, manual lymphatic drainage, and hypertrophic scar care for 60 min once a day for 5 days a week for 8 weeks.|robot assisted gait training|f|f|f|t
34060264|NCT04120454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060265|NCT05265156|NA|SINGLE_GROUP||OTHER||NONE||Single arm, prospective, open-label, longitudinal, interventional study||||
34060266|NCT01511718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076312|NCT03789097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076313|NCT03692637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164239|NCT06726109|||COHORT||PROSPECTIVE|||||||
34076314|NCT00733278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076315|NCT02900248|||COHORT||PROSPECTIVE|||||||
34164240|NCT01643382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746829|NCT04945174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33746830|NCT02459574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060267|NCT04251728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be assigned to Exercise plus AMPS group or Exercise plus Placebo. The placebo consist in replicating the same experimental setting and procedure, but the intensity of the stimulus is not sufficient to elicit an effect.~The outcomes assessor will be in charge only of the evaluations with no information about the group participants belong to."|A randomized, double-blind, two-arm, parallel-group study|t|f|f|t
34060268|NCT06621667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060269|NCT04586634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060270|NCT05615805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34060271|NCT00880386|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060272|NCT01890226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060273|NCT05876793|NA|SEQUENTIAL||TREATMENT||NONE||We will use the Dixon's up and down method.||||
34060274|NCT03138694|||COHORT||PROSPECTIVE|||||||
34060275|NCT02986841|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34060276|NCT06250634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060277|NCT05236101|NA|SINGLE_GROUP||OTHER||NONE||||||
34060278|NCT03112733|||COHORT||PROSPECTIVE|||||||
34060279|NCT02209805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060280|NCT00104819||||TREATMENT||NONE||||||
34060281|NCT06228872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In this trial, masking will ensure blinding of interventions:~Participant: They will be unaware of receiving active tDCS therapy or sham intervention. A remote-controlled mobile app will facilitate this.~Investigator: They will be masked, not knowing the assigned interventions. This minimizes bias in data collection and analysis.~Outcomes Assessor: They will be masked to assigned interventions, ensuring objective and unbiased outcome assessment.~Implementing masking ensures that participants, care providers, investigators, and outcomes assessors remain unaware of the intervention received, maintaining trial integrity and validity."|The study is a prospective, controlled, double-blind, randomized clinical trial in collaboration with the University of Chile. It includes patients with moderate cognitive impairment due to moderate-to-severe traumatic brain injury lasting over 6 months. Participants will be randomly assigned to the experimental or control group. The intervention involves computerized cognitive training (CCT) through a mobile app and daily self-administered transcranial direct current stimulation (tDCS) therapy to the prefrontal dorsolateral cortex (PFDL) for one month. Prior to the intervention, a training session will instruct patients on device use and adverse effects monitoring. Neuropsychological evaluations will be conducted at baseline (T0), immediately after the last session (T1), and one month later (T2). This trial aims to assess the efficacy of combined CCT and tDCS for cognitive impairment in TBI patients.|t|t|t|t
34060282|NCT03461016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060283|NCT01844505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060284|NCT00574223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060285|NCT04498416|||COHORT||PROSPECTIVE|||||||
34060286|NCT05914675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060287|NCT00866333|NA|SINGLE_GROUP||TREATMENT||NONE||The Single Group Assignment is one of three regimens based on the protocol version at the time of enrollment.||||
34060288|NCT03294291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All Children will be randomly assigned to one of 2 groups of 25 patients each using a computer-generated number table.|t|f|f|t
34060289|NCT00391157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060290|NCT03138746|||COHORT||PROSPECTIVE|||||||
34060291|NCT03564080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomised control trial assessing feasibilty of new treatment method - combined supervised exercise programme||||
34060292|NCT01643733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060293|NCT00117624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060294|NCT01934075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060295|NCT01642485|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34060296|NCT01143064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060297|NCT05150782|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm intervention||||
34060298|NCT04744259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060299|NCT05109871|NA|SINGLE_GROUP||OTHER||NONE||||||
34060300|NCT04270227|||OTHER||CROSS_SECTIONAL|||||||
34060301|NCT01232621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060302|NCT02330757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060303|NCT06142695|||COHORT||RETROSPECTIVE|||||||
34060304|NCT01920867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060305|NCT04240275|||OTHER||PROSPECTIVE|||||||
34060306|NCT01432964|||COHORT||PROSPECTIVE|||||||
34060307|NCT00431873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060308|NCT03543397|||COHORT||RETROSPECTIVE|||||||
34164241|NCT05128578|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||LEAP is a modular 12-week pain self-management intervention with 6 individual sessions and 6 optional group sessions. Individual sessions serve the purpose of individualizing the program to the needs of the patients. Group sessions allow participants to practice skills, set goals with the group, seek social support, and learn together. The purpose of the LEAP program is to make pain better, help patients reach their personal goals (things that may be hard to do because of pain), and add to the care patients' medical team is providing.||||
34164242|NCT06487091|||CASE_ONLY||PROSPECTIVE|||||||
34164243|NCT05639985|||OTHER||PROSPECTIVE|||||||
34164244|NCT03551626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164245|NCT00934765|||CASE_ONLY||PROSPECTIVE|||||||
34164246|NCT06725342|||OTHER||RETROSPECTIVE|||||||
34164247|NCT06725979|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34164248|NCT02944279|||COHORT||PROSPECTIVE|||||||
34164249|NCT01317251|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34076316|NCT03801642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076317|NCT03155555|||COHORT||PROSPECTIVE|||||||
34076318|NCT01859182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164250|NCT03826186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Thoracic epidurals are administered. After randomization, one group will receive thoracic epidurals in the traditional way (control group) and the other with CompuFlo assistance (study group).|t|f|f|f
34164251|NCT00854880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746831|NCT00077025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851794|NCT01319630|||CASE_CONTROL||PROSPECTIVE|||||||
33851795|NCT00652210|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851796|NCT02853747|||COHORT||CROSS_SECTIONAL|||||||
33851797|NCT04555980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The assessor did not know the grouping of the pain scores in memory, nor did he know the purpose of the warming patch.|Group W : the injection site was covered with warm patch. Group C: the injection site was covered with Cotton patch.|f|f|t|t
33851798|NCT05986747|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants who met inclusion criteria will be randomly allocated to one of the groups, i.e. CBT video plus TAU (intervention group) or waitlist plus TAU (control group) in a 1:1 ratio.||||
33851799|NCT02293564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851800|NCT02744378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851801|NCT01246739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851802|NCT05475652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33851803|NCT03375528|NA|SINGLE_GROUP||PREVENTION||NONE||Patients derived from a population of patients referred to 12 months follow-up coronary angiography for ischemic heart disease who are enable to be performed IVUS will be enrolled in the present trial, between December 2017 and December 2018. The study was an all comers design involving consecutive enrollment of patients with stable angina or acute coronary syndrome who had at least 1 coronary lesion (defined as a stenosis of \>50%) suitable for stent implantation 12 months before. The follow-up coronary angiography was performed according to standard techniques by experienced interventionalists only. Instent restenosis was defined as a diameter stenosis ≥50% of the vessel reference diameter by visual assessment. Detailed demographic details including anthropometric measurements, cardiovascular risk factors and medication use were recorded for the participants.||||
33851804|NCT00807287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851805|NCT03701529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33851806|NCT00292721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851807|NCT02006953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851808|NCT02472197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851809|NCT03810131|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34164252|NCT00671489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164253|NCT02255227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164254|NCT02506192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, placebo-controlled||t|f|t|t
34164255|NCT02177188|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164256|NCT03740659|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single|A randomized, assessor-blinded, parallel-group study.|f|f|f|t
34164257|NCT00801229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164258|NCT02682368|||COHORT||PROSPECTIVE|||||||
34164259|NCT00414141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164260|NCT06726499|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164261|NCT06726330|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a non-randomized controlled preference trial. Participants decide their surgical approach based on counseling. The study accommodates real-world clinical practices, empowering patients in the decision-making process.||||
34164262|NCT05693363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164263|NCT02641431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164264|NCT02414685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164265|NCT06609057|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164266|NCT05663580|||COHORT||PROSPECTIVE|||||||
34164267|NCT01466127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34164268|NCT01008072|||CASE_CONTROL||RETROSPECTIVE|||||||
34164269|NCT06725355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164270|NCT01405300|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34164271|NCT05849168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164272|NCT00798525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164273|NCT06646289|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164274|NCT02226718|||COHORT||PROSPECTIVE|||||||
34164275|NCT01013194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164276|NCT04963400|||COHORT||PROSPECTIVE|||||||
34164277|NCT02155777|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164278|NCT06443190|NA|SINGLE_GROUP||OTHER||NONE||||||
34164279|NCT01038830|||COHORT||PROSPECTIVE|||||||
34164280|NCT00242723|||COHORT||PROSPECTIVE|||||||
34164281|NCT01153737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164282|NCT01470456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164283|NCT05661851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34164284|NCT04537026|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Participants, study investigators, and research personnel collecting data will remain blinded to patient treatment allocation.~participants will be randomized to group #1 or #2 based on a random computer-generated schedule. Participants will be blinded to the group to which they are randomized. The physician preforming the injection will also be blinded to group. Research personnel will prepare the study drug and SOC medication such that the physician and patient cannot distinguish between groups. Identical syringes will be used in both groups, and both dexamethasone and hAF are colorless, translucent, odorless liquids, which are indistinguishable in a syringe. However, unblinded research personnel will prepare the study drug injection and maintain the blind by placing a blank label over the syringe to ensure that the treatment is blinded to the patient and treating physician."|A Double-blinded, randomized, prospective study to evaluate the standard of care (Corticosteriod) vs. Sterile Amniotic Fluid Filtrate Epidural Injection for the treatment of Lumbosacral Radicular Pain due to Spinal Stenosis.|t|t|t|f
34164285|NCT02695251|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34164286|NCT04258826|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34164287|NCT06074562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164288|NCT04338308|||COHORT||RETROSPECTIVE|||||||
34164289|NCT06725199|||CASE_CONTROL||OTHER|||||||
34164290|NCT06465511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The investigator and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to the intervention or the control arm.~The participants are masked in terms of not knowing that the intervention are hypothesized to yield larger effects than the others (i.e. controls)."|This is a 2-arm feasibility trial study with an intervention group and a control group. Computer-generated block randomization sequences will be generated by a statistician who is blinded to the identity of participants prior to the start of the trial. A block randomisation structure with randomly permuted block sizes of 2 and 4 will be used to reduce selection bias and ensure close balance of the numbers in each arm. The serially labelled opaque sealed envelope method will be used for randomisation.|t|f|t|t
34164291|NCT06105840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851810|NCT06181331|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"he investigator, care provider, investigator and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to intervention or control arms.~The participants are masked in terms of not knowing that one intervention is hypothesized to yield larger effects than the other."|"First stage intervention: We will use a block randomization with randomly permuted block sizes of 2,4, and 6 to ensure close balance of the numbers in each arm. Participants will be randomised to the eConquerFear or eHealthMaintenance~Second stage intervention for non-respondents: We will use a block randomization with randomly permuted block sizes of 2,4, and 6 to ensure close balance of the numbers in each arm. Participants will be randomised to the augment eConquerFear with eHealthMaintenance (or vice versa) versus switch to supervised, face-to-face ConquerFear intervention."|t|t|t|t
34164292|NCT03461146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164293|NCT02466932|||||CROSS_SECTIONAL|||||||
34164294|NCT04066478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, double-blind, placebo controlled study|t|t|t|f
33851811|NCT05403112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This trial is considered a randomized double blind clinical trial due to the following:~1. The participant will be blinded to the technique that will be used during the surgical operation.~2. The outcome assessor will be blinded~3. The operator (DR.O.S.) will not be blinded for both techniques during the surgical operation, as the two techniques are different. (Dr. M.O.).~The purpose of double blinding procedure is to reduce assessment bias and to increase accuracy and objectivity of clinical outcomes."|randomization clinical trial|f|t|f|f
33851812|NCT03324191|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and Researchers will be blinded to the interventions.|Double-blind, single-centre randomised controlled trial using a cross-over experimental design.|t|f|t|f
33851813|NCT01435616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851814|NCT02811731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851815|NCT02732652|||COHORT||PROSPECTIVE|||||||
33851816|NCT01854723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851817|NCT02814929|||COHORT||PROSPECTIVE|||||||
33851818|NCT05551312|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33851819|NCT04405349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851820|NCT00719082|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33851821|NCT05838144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33955971|NCT06647693|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Investigator and research assistant will not be blind. A second blinded research assistant will complete reliability.|Sequential is the best match for the intervention study model. The primary intervention model is a single case experimental design called a multiple baseline design. The investigators randomized participants into one of three start dates for the beginning of the intervention. Data is taken on a twice weekly basis during the baseline phase and intervention phase. The investigators also will add formal testing upon initial contact, right before intervention, upon completion of intervention procedures, and a follow-up without intervention.|f|f|f|t
34164295|NCT00439296|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33746832|NCT03183427|||CASE_CONTROL||RETROSPECTIVE|||||||
33746833|NCT00866840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746834|NCT06627933|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33746835|NCT01201629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33746836|NCT06636565|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746837|NCT02166008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746838|NCT01616264|||||PROSPECTIVE|||||||
33746839|NCT01237002|||COHORT||RETROSPECTIVE|||||||
33746840|NCT01786967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746841|NCT04732403|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746842|NCT01798953|||CASE_CONTROL||RETROSPECTIVE|||||||
33746843|NCT03981458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Atrophic vaginitis and recurrent urinary tract infection are often found concurrently in post-menopausal women. The argument over which condition appeared first, or if one is caused by the other, is prevalent in clinical settings and there is no official guidance as to which should be treated first. We propose two arms to this study - one treating the atrophic vaginitis via use of Hyalofemme cream (hyaluronate cream), and the other treating recurrent UTI by use of Ialuril (hyaluronate bladder instillation). We intend to investigate the effect on the incidence of UTI in the patients with both treatments, as well as focusing on some markers of the immune response in the urine and vaginal douche samples from these participants.|f|f|f|t
33746844|NCT02012491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33746845|NCT04654416|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33746846|NCT05437380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746847|NCT04207723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851822|NCT03805347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded randomized|Treatment group and Control group|t|t|t|f
33851823|NCT01992393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851824|NCT02199743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851825|NCT04235179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851826|NCT04199897|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Computerized randomization followed by pseudo anonymication|The study will employ a randomized triple-blind, placebo controlled design.|t|t|t|t
33851827|NCT01404195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851828|NCT03505541|||COHORT||PROSPECTIVE|||||||
33851829|NCT02031692|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851830|NCT03481192|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"To groups of patients :~A group of patients admitted for IMV exclusively using amnesic substances.~A control group admitted for IMV and ingested exclusively non-amnesic~Two visits, the first one for the first evaluation of cognitive functions directly following the psychiatric interview (E1), and the second one at 24h-48h after the psychiatric evaluation (E2)"||||
33851831|NCT03507660|NA|SINGLE_GROUP||TREATMENT||NONE||all participants will receive the same six verbal instruction given in a random order.||||
33851832|NCT03884140|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33851833|NCT03484845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851834|NCT00976612|||COHORT||PROSPECTIVE|||||||
33851835|NCT03588286|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33851836|NCT03558373|||COHORT||PROSPECTIVE|||||||
33851837|NCT04314804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33851838|NCT02831387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851839|NCT06472193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851840|NCT03081052|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33851841|NCT02761876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851842|NCT02515877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851843|NCT01143779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851844|NCT06171347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data will be collected and coded by the nurse researcher. Data will be analyzed by an independent statistician. The study groups will be disguised as A and B. The statistician will not know the groups. In addition, the statistical expert will not see the data of the experimental group regarding satisfaction.|"Patients in the experimental group will receive oral cold spray in the postoperative period.~Patients in the control group will receive standard care in the postoperative period."|f|f|f|t
33851845|NCT02438501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851846|NCT04172194|||COHORT||RETROSPECTIVE|||||||
33851847|NCT04032054|||COHORT||PROSPECTIVE|||||||
33955972|NCT06179290|RANDOMIZED|PARALLEL||OTHER||NONE||This is a multi-site, open-label, two-group (menthol and non-menthol), six-arm (HTP, Continue Smoking, and Smoking Abstinence arms within each group) randomized, clinical study to evaluate changes in BoEs in adult smokers who remain smoking, switch to the Ploom HTP, or abstain from smoking, for 60 days (5 days in clinic followed by 55-day ambulatory phase). This study follows the recommendations of the FDA's final Premarket Tobacco Product Application guidance (FDA, 2023).||||
33955973|NCT04292756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955974|NCT03889197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data entered as group A and B.||f|f|f|t
34060309|NCT03094676|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigator and the assessor will not receive information about the participant, not knowing, from which group the participant has just arrived for intervention in the investigator's case and the assessor will not receive group information in the HRV data packet.||f|f|t|t
34060310|NCT04439305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060311|NCT05267990|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||a prospective cohort study||||
34060312|NCT06363526|NA|SINGLE_GROUP||TREATMENT||NONE||12 participants were randomized to follow a digital respiratory physiotherapy program for 5 weeks. The participants were evaluated at the beginning and at the end of the study, and the results will be measured before and after each intervention during the study.||||
34060313|NCT00992134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060314|NCT01904903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060315|NCT03286933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060316|NCT06482177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060317|NCT01195844|||COHORT||PROSPECTIVE|||||||
34060318|NCT01005888|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33851848|NCT02276183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33851849|NCT01171443|||CASE_ONLY||PROSPECTIVE|||||||
33851850|NCT04114630|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33851851|NCT03002753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851852|NCT00291850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851853|NCT05867628|||CASE_ONLY||PROSPECTIVE|||||||
33851854|NCT05309915|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Initially, for each cohort subjects will be randomized 1:1 to STP707 or placebo. After safety evaluation up to 8 additional subjects will be enrolled randomized 7:1 to STP707 or placebo within the same cohort.||||
34060319|NCT02243046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851855|NCT01280110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33851856|NCT00731120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851857|NCT03206762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||255 subjects are planned for enrollment (with a block 2:1 randomization)|t|f|f|f
33851858|NCT03969381|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33851859|NCT05998473|||COHORT||RETROSPECTIVE|||||||
33851860|NCT02729753|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851861|NCT04110977|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized, active-controlled, parallel-group trial||||
33851862|NCT01091077|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851863|NCT05724589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851864|NCT02729662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851865|NCT05688982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851866|NCT02400294|||||CROSS_SECTIONAL|||||||
33851867|NCT00311727|NON_RANDOMIZED|||PREVENTION||||||||
33851868|NCT02730598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851869|NCT04998760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851870|NCT01742611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164296|NCT05560685|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33851871|NCT04452942|||COHORT||PROSPECTIVE|||||||
34060320|NCT04554992|NA|SINGLE_GROUP||TREATMENT||NONE||Given that this is a pilot study to evaluate the safety of treatment with convalescent COVID-19 plasma versus standard care in subjects with severe and/or critical COVID-19 between the cases and historical controls without predetermined data, a convenient sample size of 700 patients (350 per group) has been proposed.||||
34060321|NCT05963828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34060322|NCT02733198|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34164297|NCT01526213|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34164298|NCT02109991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851872|NCT00757588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851873|NCT02580643|||OTHER||PROSPECTIVE|||||||
33851874|NCT01387685|||CASE_CONTROL||RETROSPECTIVE|||||||
33851875|NCT03531944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851876|NCT05601687|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients shall be randomly assigned in a 1:1 ratio to either the step-up or the accelerated approach. Block randomization shall be performed with a concealed, fixed block size using a web-based randomization program. Random block sizes of 4 or 6 shall be used for preparation of the randomization sequence. The computer-generated block randomization assignments shall be placed in opaque sealed envelopes. Randomization shall be performed by a study coordinator when patients meet the inclusion criteria.||||
33851877|NCT06323512|||CASE_ONLY||PROSPECTIVE|||||||
33851878|NCT01304433|||COHORT||PROSPECTIVE|||||||
33851879|NCT01455857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851880|NCT00208780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851881|NCT05806307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Intervention~All women will be randomly assigned to either:~Group A (misoprostol): who will receive 800 microgram misoprostol rectally one and half hour before operation.~Group B (Tourniquet): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus.~Group C (Carbetocin): intramural; preparation of 100 μg of carbetocin diluted within 10 cm of saline (0.9%) Group D (Oxytocin): who will receive oxytocin 40 I.U. intramyometrially Group E (combined TXA and ethamsylate): will receive 1 g tranexamic acid and 500 mg ethamsylate IV 10 minutes before skin incision Group F receive terlipressin intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline.~Group G: infiltration of the serosa and / or myometrium with a solution composed of 50 ml Bupivacaine 0.25% and 0.5 mg of epinephrine"|t|f|f|t
33851882|NCT02457559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851883|NCT00926497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851884|NCT04750525|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33851885|NCT01448187|||COHORT||PROSPECTIVE|||||||
33851886|NCT00305240|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060323|NCT00948415|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34060324|NCT03558841|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, active-controlled||||
34060325|NCT03101852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060326|NCT06528795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Quasi-experimental randomized controlled trial|t|f|f|f
34060327|NCT02553707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060328|NCT02114541|||OTHER||PROSPECTIVE|||||||
34060329|NCT00516334|||COHORT||PROSPECTIVE|||||||
34060330|NCT05105906|||CASE_CONTROL||OTHER|||||||
34060331|NCT01671150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34164299|NCT04295525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164300|NCT05379465|||OTHER||CROSS_SECTIONAL|||||||
34164301|NCT06002945|||COHORT||PROSPECTIVE|||||||
34164302|NCT06671782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized controlled pilot study.||||
34164303|NCT02221674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164304|NCT06726421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164305|NCT00044772||||TREATMENT||||||||
34164306|NCT05695599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will only have codes but in the database but will not know which code corresponds to which group.||f|f|f|t
34164307|NCT03516422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34164308|NCT03789916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164309|NCT06523894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase Ia/Ib||||
33851887|NCT02868385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33851888|NCT02633579|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33851889|NCT05057299|||COHORT||RETROSPECTIVE|||||||
33955975|NCT02352207|||COHORT||PROSPECTIVE|||||||
33955976|NCT00576875|||COHORT||CROSS_SECTIONAL|||||||
33955977|NCT04376073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955978|NCT06701903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33955979|NCT00232245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955980|NCT00124579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060332|NCT04318639|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single group design||||
33955981|NCT00672308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33955982|NCT00551473|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33955983|NCT00552812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955984|NCT01285388|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33851890|NCT03394729|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|"In the study, the principal investigator will be blind to the order of the tablets consumed by adolescents. The propolis tablets and control tablets will have a similar appearance, taste, texture and sizes, will be coded as A and B by an independent investigator and will be delivered to participants in an opaque and closed bottle. Individuals will be instructed to consume each type of tablet (propolis and propolis) twice a day (10 a.m. and 5 p.m.) for 7 days, giving a 30 day interval between test and control. Volunteers will be followed at the beginning and end of each intervention."|Clinical trial of prevention, cross, blind, randomized controlled with two arms in the study phase 2-3.|f|t|t|t
33851891|NCT01531010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851892|NCT00001522|||COHORT||PROSPECTIVE|||||||
33851893|NCT03366623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851894|NCT00722527|||COHORT||PROSPECTIVE|||||||
33851895|NCT03922646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851896|NCT03737474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851897|NCT04323631|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33851898|NCT05483634|||COHORT||PROSPECTIVE|||||||
33851899|NCT00287495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851900|NCT03643393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851901|NCT04552977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851902|NCT02469389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33955985|NCT05516498|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33955986|NCT03874910|||OTHER||CROSS_SECTIONAL|||||||
33955987|NCT06224764|NA|SINGLE_GROUP||OTHER||NONE||Mother and Father questionnaires (on paper or by phone).||||
33955988|NCT06499935|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Phase 1:Observational study. Phase 2: Double-blinded randomized control trial study. An explanation of the procedure and a written consent form will be provided. Then the CAIT will be used followed by assigning the participants into a healthy group and an injured group for the observational part and collecting the data on the injured foot. Then further randomly divided the injured group into a rigid taping group, a sham taping group, and a control group. Application of the interventions will be done to the affected foot and sham tape will be applied to the control group then the effects will be observed and the measurements will be noted and compared to the previous data. The CAIT will be used again to observe the differences that may result. The study will take place at Mousawat Institution.|t|f|f|t
33955989|NCT04166877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Single center, investigator-initiated, randomized, double-blinded, placebo controlled study|t|t|t|t
33955990|NCT06197698|NA|SINGLE_GROUP||OTHER||NONE||||||
33851903|NCT00557934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851904|NCT00730457|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33851905|NCT02912676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955991|NCT06281522|||CASE_CONTROL||RETROSPECTIVE|||||||
33955992|NCT05648097|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33955993|NCT02186470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33955994|NCT03662711|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33955995|NCT05338671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two different arms each receiving an inferior alveolar nerve block with two different local anesthetics|t|f|f|f
33955996|NCT05458895|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33955997|NCT04037683|||OTHER||OTHER|||||||
33851906|NCT02533570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33955998|NCT03489239|NA|SINGLE_GROUP||OTHER||NONE||||||
33955999|NCT03724422|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either a treatment or control group.||||
33956000|NCT00511329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956001|NCT02933216|||COHORT||PROSPECTIVE|||||||
33956002|NCT04678700|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental study composed of an intervention group and a control group The control group will receive the intervention after finishing the intervention with the experimental group.||||
33956003|NCT02919033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33851907|NCT00158860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33956004|NCT00633295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956005|NCT06701747|||COHORT||RETROSPECTIVE|||||||
33956006|NCT04642131|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Participants will be given a bottle with either caffeine and carbohydrates or just carbohydrates.|Participants will be given a bottle with either caffeine and carbohydrates or just carbohydrates, and personalized insoles or standard insoles. All participants will complete athletic and biomechanics tests before and after completing a 43 minute fatigue protocol.|t|f|t|f
33956007|NCT06167798|||COHORT||CROSS_SECTIONAL|||||||
33956008|NCT03387267|NA|SEQUENTIAL||SCREENING||NONE|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.|The clinical trial will initially start as a 3-look group sequential design (GSD). Alpha-spending will be calculated using Lan-DeMets spending function (with O'Brien-Fleming parameter). At the first interim analysis (IA-1) the threshold on the ROC curve may be re-computed using the ROC curve generated using the IA-1 data, in which case, the validation trial would start afresh following IA-1 using a 2-look GSD. Data included in the IA-1 would no longer be used for the validation phase.||||
33956009|NCT05722275|||COHORT||PROSPECTIVE|||||||
33956010|NCT06644729|||COHORT||PROSPECTIVE|||||||
33851908|NCT04000360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS III) will be conducted by a consistent rater, blinded as to participant randomization group.|256 mild to moderate PD patients will be randomized into a high-intensity home exercise group or a Usual and Customary Care group (no exercise control group).|f|f|t|f
33956011|NCT00915980|||CASE_ONLY||PROSPECTIVE|||||||
34060333|NCT03218319|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34060334|NCT02739308|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33851909|NCT01372423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851910|NCT01290315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851911|NCT00408239|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851912|NCT01090427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851913|NCT03782220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851914|NCT04217629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851915|NCT02977585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33851916|NCT01869582|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33851917|NCT05665465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||All participants will sample the three doses of nicotine spray in a counter-balanced crossover design.|t|f|t|f
33851918|NCT02087709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851919|NCT01241175|RANDOMIZED|||PREVENTION||DOUBLE|||f|t|f|t
33851920|NCT04161495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956012|NCT05286580|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33956013|NCT06260007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956014|NCT06130839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and outcome assessors will be kept blinded about the intervention which the patients will be going to recieve.|Assignment|t|f|f|t
33851921|NCT00622258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851922|NCT03525431|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851923|NCT01559753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851924|NCT05808881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956015|NCT05336318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Comprehensive cohort studies (CCS) are characterized by incorporating patient preferences into the study by using a parallel preference group. The procedure is to ask patients' preferences at the beginning of the study before randomization. Those who do not consent to randomization will be retained in the study, but group assignment will be made according to their preferences. Patients who agree to randomization are randomized to one of the two groups (intervention vs. control)."||||
33956016|NCT05511805|||CASE_ONLY||PROSPECTIVE|||||||
33956017|NCT03763708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956018|NCT05025774|||CASE_CONTROL||PROSPECTIVE|||||||
33956019|NCT02463058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956020|NCT01806259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956021|NCT06128278|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33956022|NCT04443231|||COHORT||PROSPECTIVE|||||||
34060335|NCT03240224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060336|NCT01902212|NA|SINGLE_GROUP||||NONE||||||
34060337|NCT00842998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076319|NCT05130827|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot trial investigating a single dose of plinabulin on day of stem cell infusion (Day 0) in conjunction with pegfilgrastim on Day +1 after autologous hematopoietic cell transplant (AHCT).||||
33851925|NCT02518321|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33851926|NCT00946101|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33851927|NCT01786473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851928|NCT02551406|||COHORT||RETROSPECTIVE|||||||
33851929|NCT04331145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060338|NCT03456999|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a patient, investigator and sponsor-blinded study. Patients and investigators will remain blinded to study treatment throughout the study,|This is a non-confirmatory, randomized, placebo-controlled, blinded, proof-of-concept study in kidney transplant recipients. Approximately 96 eligible patients are planned to be randomized 2:1 to receive MAU868 or placebo.|t|f|t|t
33851930|NCT01576250|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060339|NCT05735990|||COHORT||RETROSPECTIVE|||||||
34060340|NCT02933905|||COHORT||PROSPECTIVE|||||||
33851931|NCT05557357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060341|NCT03183934|||CASE_ONLY||PROSPECTIVE|||||||
34060342|NCT01885494|||COHORT||PROSPECTIVE|||||||
34060343|NCT00237471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851932|NCT05618834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34060344|NCT01079754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060345|NCT03180515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060346|NCT00001076||||PREVENTION||DOUBLE||||||
34060347|NCT04590677|||COHORT||PROSPECTIVE|||||||
34060348|NCT06648694|||COHORT||PROSPECTIVE|||||||
34060349|NCT03973333|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential from arm monotherapy IV dose escalation is opened first; then monotherapy SC dose escalation, monotherapy expansion and combination dose escalation may run||||
34060350|NCT05215912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
34060351|NCT01876979|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34060352|NCT04761406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, placebo controlled, double-blind, parallel arm intervention trial.|t|t|t|t
34060353|NCT02566603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060354|NCT04272827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random assignment of patients to one of the two treatment groups (experimental or controlled) is provided centrally via a 24/7 Internet service in ratio 2:1 (experimental: controlled) based on permuted blocks. The assignment is stratified to stage and centre.|After a run in phase, randomization is performed in the intervention and control arm (2:1).|f|f|f|t
34060355|NCT00328159|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34060356|NCT04308980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060357|NCT00162175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060358|NCT05302024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060359|NCT03066219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060360|NCT01685853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34060361|NCT00432315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164310|NCT05880303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single-blinded parallel arm study|Randomized controlled clinical trial with two parallel groups (intervention versus delayed treatment), with a balanced 1:1 treatment allocation and with 6 months follow-up for both groups.|f|f|t|t
34164311|NCT00066677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164312|NCT05855772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34164313|NCT06726291|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase IV, multicentric, single arm study, using a fixed dose combination of netupitant and palonsetron in the treatment of chemo-naive patients ≥18 years of age with histologically or cytologically confirmed diagnosis of endometrial cancer who will receive a single line of taxane-platinum combination with or without immunotherapy.||||
34164314|NCT06389578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164315|NCT01858363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34164316|NCT00091234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164317|NCT02688686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164318|NCT03641170|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34164319|NCT02416596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164320|NCT06422884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060362|NCT03994744|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients fulfilling Eligibility Criteria will be included in our study. Participants will be given intravenous administration of Sintilimab (1200mg/3w).~Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~Treatments will be administrated for one year or until disease progression, death, or unacceptable toxicity.~Regular follow-up and safety assessment: Patients were assessed for drug safety and treatment efficacy every 2 cycles (6 weeks) in the first 3 months after enrollment, and then evaluated every 4 cycles (12 weeks). Assessment of tumor response, adverse events. Follow-up until disease progression and patient death."||||
34060363|NCT03990935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164321|NCT00834665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164322|NCT01946152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164323|NCT02734745|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164324|NCT06721234|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34164325|NCT01436578|||COHORT||PROSPECTIVE|||||||
34164326|NCT00672919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164327|NCT00376792|RANDOMIZED|||TREATMENT||NONE||||||
34164328|NCT06500117|NA|SINGLE_GROUP||OTHER||NONE||||||
33851933|NCT04800432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Aim 2 includes randomization to a comparison group - 48 parent-child dyads (96 individuals) anticipated for enrollment.~Aim 2 was the small pilot RCT"|f|f|f|t
33851934|NCT05537831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33851935|NCT03082404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851936|NCT01472094|||COHORT||PROSPECTIVE|||||||
33851937|NCT00090129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851938|NCT06043583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060364|NCT02086825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060365|NCT06137534|NA|SINGLE_GROUP||OTHER||NONE|The researcher who performed the evaluation did not participate in the exercise sessions applied in the study. He/she does not have information about the application.|It includes a single-group exercise application with volunteer healthy university students.||||
34076320|NCT01889368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34076321|NCT02402946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060366|NCT05011890|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This is a single site non-randomized feasibility study. Participants on treatment and/or surveillance for new or existing diagnoses of lung cancer were assigned to monitor their patient-reported outcomes using a mobile medical application. The study population includes patients with a diagnosis of lung cancer undergoing outpatient treatment or surveillance at UNC. Patients were recruited from the Multidisciplinary Thoracic Oncology Program clinics at the University of North Carolina over 10-12 months and undergo ePRO monitoring for 6 months or until criteria for coming off study are met, whichever comes first.|This is a single site nonrandomized feasibility study, participants on treatment and/or surveillance for new or existing diagnoses of lung cancer were assigned to a single arm involving monitoring of their patient-reported outcomes using a mobile medical application. The study population will include patients with a diagnosis of lung cancer undergoing outpatient treatment or surveillance at UNC. Patients will be recruited from the Multidisciplinary Thoracic Oncology Program (MTOP) clinics at the University of North Carolina over 10-12 months and undergo ePRO monitoring for 6 months or until criteria for coming off study are met, whichever comes first.||||
34060367|NCT06107907|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34060368|NCT01236950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851939|NCT03592550|||COHORT||PROSPECTIVE|||||||
33851940|NCT04603638|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33851941|NCT02716818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851942|NCT00599911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851943|NCT02656823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851944|NCT00025103||||TREATMENT||||||||
33851945|NCT06308003|||COHORT||PROSPECTIVE|||||||
33851946|NCT01130961|||COHORT||RETROSPECTIVE|||||||
33851947|NCT05963490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851948|NCT02119845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851949|NCT00679393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851950|NCT01462123|||||PROSPECTIVE|||||||
33851951|NCT00307502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851952|NCT01690598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851953|NCT03998982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33851954|NCT04725786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33851955|NCT04201964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851956|NCT00065377||||TREATMENT||||||||
33851957|NCT01237587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851958|NCT04637178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants/investigators will be blinded to muscle biological charateristics until after clean-up of main outcome variables. Participants/investigators will be aware of intervention arm affiliation.||t|f|t|f
33851959|NCT00349674|RANDOMIZED|PARALLEL||||NONE||||||
33851960|NCT01251250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851961|NCT00320125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851962|NCT06058754|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants are informed that they will be allocated to one of two occupational therapy intervention programs that both aims to improve ADL ability, but overall primarily differ in terms of their format i.e. a group-based versus a one-to-one intervention program format. Participants are not informed, which of the two types of formats that are the new experimental intervention format (ADAPT) nor control (UOT). Baseline assessments are conducted prior to randomization by a local employed occupational therapists, who is instructed not to reveal which intervention that is the new experimental intervention. The post and follow-up assessors, a research occupational therapy assistant employed at the Parker Institute, is also instructed not to disclose which intervention that is the new experimental one. Finally, all participants are reminded not to disclose any details, that may provide the outcome assessors with insights regarding their allocated study arm.|A single-center, double-blinded, randomized, parallel-group, equivalence 6-months follow-up study with external pilot, effect, process and economic evaluations|t|f|f|t
33851963|NCT06211881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851964|NCT06152809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||One group of patients, two dose levels (arms)||||
33851965|NCT00066313|RANDOMIZED|||TREATMENT||DOUBLE||||||
33851966|NCT00233298|||||PROSPECTIVE|||||||
33851967|NCT00152880|||DEFINED_POPULATION||OTHER|||||||
33851968|NCT02816242|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33851969|NCT03272126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33851970|NCT00804089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33851971|NCT01406964|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33851972|NCT04185454|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study will be performed as an open, randomised two-dimensional single-centre trial with 3-level between-patient Response Surface Pathway (RSP) design in the first dimension and 3-level within-patient RSP design in the secondary dimension.||||
33956023|NCT06395584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants assigned to the light therapy treatment group will use two different colours of light (white and green). One colour is a treatment light and the other is a placebo. Participants will not be told which is the treatment colour and which is the placebo.|Participants will be randomly assigned to two groups: one group will receive daily light therapy treatments and the second group will not.|t|f|f|f
33956024|NCT06317870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|quadruple|single centered, prospective, double blinded non inferiority trial|t|t|t|t
33956025|NCT01438346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956026|NCT02780115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956027|NCT05784363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956028|NCT03359473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Study treatment will consist of two dosing cohorts: Cohort 1 will comprise of male subjects randomized to receive either placebo or 2 milligrams (mg) of GSK2881078 and Cohort 2 will comprise of post-menopausal female subjects randomized to receive either placebo or 1 mg of GSK2881078.|t|f|t|f
33956029|NCT01502800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060369|NCT02034812|||COHORT||RETROSPECTIVE|||||||
34060370|NCT03515629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060371|NCT02553785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164329|NCT03349658|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34164330|NCT05594862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060372|NCT05767242|||COHORT||PROSPECTIVE|||||||
34060373|NCT04234269|||CASE_ONLY||PROSPECTIVE|||||||
34060374|NCT02222441|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34060375|NCT00669552|||COHORT||PROSPECTIVE|||||||
34060376|NCT05814705|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34060377|NCT00516932|||CASE_CONTROL||PROSPECTIVE|||||||
34060378|NCT00650416|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34060379|NCT00111371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060380|NCT01186913|||COHORT||PROSPECTIVE|||||||
34164331|NCT01449006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164332|NCT01580982|||OTHER||PROSPECTIVE|||||||
34164333|NCT03147352|||COHORT||PROSPECTIVE|||||||
34164334|NCT04713306|||COHORT||OTHER|||||||
34164335|NCT05467748|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase IB: Determine RP2D of tulmimetostat by using BOIN design with 2 dose levels, 200 and 300 mg once daily in combination of standard pembrolizumab 200 mg IV every 3 weeks. Tulmimetostat is currently under evaluation as single agent for patients with various solid tumors.~Phase II: Based on Simon Optimum two stage design, our total number of patients for phase II is 54 patients (patients treated with RP2D from phase IB will be included in the analysis). We will enroll 15 patients at first stage to determine futility of the trial and complete the remaining 39 patients during stage II."||||
34164336|NCT05917613|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot||||
34164337|NCT04311684|||COHORT||CROSS_SECTIONAL|||||||
34164338|NCT04339517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164339|NCT03980730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164340|NCT01633424|||COHORT||RETROSPECTIVE|||||||
34164341|NCT05924945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization table will be kept with the sponsor. Subjects and study site staff (investigators, researchers, care providers) will be blinded to the group assignment.||t|t|t|t
34164342|NCT03897556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a three-arm study.||||
34164343|NCT02908906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164344|NCT01653639|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164345|NCT01684319|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34164346|NCT02341820|||COHORT||PROSPECTIVE|||||||
33746848|NCT02564575|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746849|NCT05952141|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||"Pragmatic Sequential Multiple Assignment Randomized Trial (SMART).~This study uses a sequential randomization design in which all eligible participants will be randomized into one of two interventions at Stage 1 and then participants that do not respond to Stage 1 interventions will be randomized to receive Stage 2 interventions"|f|f|f|t
33746850|NCT00762125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746851|NCT03837652|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after Study||||
33746852|NCT05495854|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746853|NCT04386681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|t|f
33746854|NCT04669704|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33746855|NCT01360606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746856|NCT00463190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746857|NCT01915134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746858|NCT04315389|||CASE_ONLY||PROSPECTIVE|||||||
33746859|NCT03520634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746860|NCT01134029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746861|NCT00873795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746862|NCT00986167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746863|NCT01899079|||COHORT||PROSPECTIVE|||||||
33746864|NCT06669377|||COHORT||RETROSPECTIVE|||||||
33746865|NCT02629510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34060381|NCT02119975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060382|NCT01055405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060383|NCT01162148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34060384|NCT04615806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076322|NCT02712957|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33851973|NCT03636282|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Trained assessors conducting measurements are not blinded to study allocation in all instances. When a trained assessor is not blinded, potential bias related to measurement of the primary outcome (weight) is being addressed by the requirement of photos of weight (measured via an electronic scale) being taken alongside the study measurement form (including study ID), at all follow-up time points. Furthermore, a study team member will verify that all weights recorded on the study measurement form match what is shown in the photo.|Pragmatic cluster randomized controlled trial with 2 arms: intervention (immediate delivery of Hockey FIT program) and comparator (wait-list control/delayed delivery of Hockey FIT program)|f|f|f|t
34164347|NCT04219241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164348|NCT02133898|NA|SINGLE_GROUP||OTHER||NONE||||||
34164349|NCT06725251|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164350|NCT02115295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164351|NCT04184570|||OTHER||PROSPECTIVE|||||||
34164352|NCT03047577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unlike other team members, the investigator interviewing the patients will be unaware of the treatment group. The patient will be encouraged not to reveal the treatment group to the investigator.|Patients are randomly assigned to a standard care or an intervention arm|f|f|f|t
34164353|NCT02872246|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164354|NCT04583527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164355|NCT03953469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There are two arms. One arm involves consuming a placebo. The second arm involves taking the Passionflower. Neither the primary investigator nor the participant will know which treatment they are taking.||t|f|t|t
34164356|NCT01101789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34164357|NCT00699608|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33851974|NCT01013454|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851975|NCT02324647|||COHORT||PROSPECTIVE|||||||
33851976|NCT02443974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33851977|NCT00603226|||COHORT||PROSPECTIVE|||||||
33851978|NCT00883051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33851979|NCT04557943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A sealed envelope of the randomized sequence was given to the investigator and care provider, and participants were recruited consecutively according to the sequence. Participants were masked from the therapy by receiving treatment individually in different rooms and occasions. On the day of the assessment, the physician and laboratory technicians were blinded from group allocation|This study involves two arms assigned randomly for receiving different treatment. One arm for Prolotherapy and Sodium Hyaluronate in the comparison group.|t|f|f|t
33851980|NCT00484133|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851981|NCT06327308|||CASE_ONLY||PROSPECTIVE|||||||
33851982|NCT02732977|NA|SINGLE_GROUP||||NONE||||||
33851983|NCT02125747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33851984|NCT05982132|||CASE_ONLY||PROSPECTIVE|||||||
33851985|NCT05296018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant) Mandala and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
34164358|NCT01928927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33851986|NCT02825030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956030|NCT03334942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the study coordinator and VIP staff members will be aware of a participant's randomization assignment. The study research assistants (RAs), who will be responsible for administering baseline, 4-month, and 10-month assessments will be blinded to the participant's study condition throughout the duration of the study.|Research assistants (RAs) will perform eligibility screening in the CHOP ED or Trauma Unit on potentially eligible youth and their caregivers who present for care following an assault-related injury. For individuals discharged before being screened, RAs will phone them within 14 days of discharge for screening. Consented youth and caregivers will complete baseline study assessments followed by random assignment to either the intervention \[Violence Intervention Program (VIP) with Child and Family Traumatic Stress Intervention (CFTSI)\] or control (VIP-only) conditions. VIP is the standard of care provided to assault injured youth treated in the CHOP ED or Trauma Unit. The study coordinator or VIP staff member will notify youth of their assigned condition. CFTSI clinicians will schedule intervention sessions with the families in community-based mental health centers. RAs will be blinded to participant condition and administer baseline and follow-up assessments to all participants.|f|f|f|t
33956031|NCT01224769|||COHORT||RETROSPECTIVE|||||||
33956032|NCT06542224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956033|NCT04138173|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33956034|NCT04471792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized, single-blind research design.||t|f|f|f
33956035|NCT02342574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956036|NCT04639635|||CASE_ONLY||PROSPECTIVE|||||||
34060385|NCT06088251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34060386|NCT06287710|||OTHER||PROSPECTIVE|||||||
34060387|NCT06095635|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34060388|NCT00181129|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34060389|NCT00922142|||CASE_CONTROL||PROSPECTIVE|||||||
34060390|NCT04734275|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060391|NCT02568618|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34060392|NCT03879057|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060393|NCT04939675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060394|NCT01848236|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060395|NCT05717764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060396|NCT06219330|||CASE_CONTROL||RETROSPECTIVE|||||||
34060397|NCT00615979|||OTHER||CROSS_SECTIONAL|||||||
34060398|NCT01022775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060399|NCT01546597|NA|SINGLE_GROUP||||NONE||||||
34060400|NCT02294175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060401|NCT05619406|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcome assessor will be blinded|The relational data model is adopted in the Model component of the system|f|f|t|t
34060402|NCT05670275|||COHORT||OTHER|||||||
34164359|NCT00687739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164360|NCT03353805|||COHORT||PROSPECTIVE|||||||
33851987|NCT04568694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33851988|NCT04226885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33851989|NCT00479492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33851990|NCT01871701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33851991|NCT03211754|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33851992|NCT04345757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33851993|NCT05443646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851994|NCT05703997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33851995|NCT04824053|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33851996|NCT05441241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33851997|NCT00081042||||TREATMENT||NONE||||||
33851998|NCT04497922|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33851999|NCT02457169|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852000|NCT02962960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852001|NCT04098757|||OTHER||PROSPECTIVE|||||||
33852002|NCT03117322|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|pediatric neurologist and laboratory staff.|Three interventions in parallel against a control group|t|t|t|f
33852003|NCT00445354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33852004|NCT05363371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33852005|NCT02914977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852006|NCT03235960|||CASE_ONLY||PROSPECTIVE|||||||
33852007|NCT00545051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852008|NCT04901260|||CASE_ONLY||PROSPECTIVE|||||||
33852009|NCT00267085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852010|NCT04640077|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33852011|NCT05405452|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852012|NCT05195502|||COHORT||PROSPECTIVE|||||||
33852013|NCT05428930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Active-controlled|t|f|t|f
33852014|NCT04192903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852015|NCT03467776|||COHORT||OTHER|||||||
33852016|NCT03821753|||CASE_CONTROL||RETROSPECTIVE|||||||
33956037|NCT03632837|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are regularily going to be unconsciuos during the differential treatment phase due to the nature and severity of their condition, yet exceptions to this are not going to be suppressed for obvious ethical reasons.|||||
33956038|NCT01281176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956039|NCT01254357|||COHORT||PROSPECTIVE|||||||
33956040|NCT01912547|||COHORT||PROSPECTIVE|||||||
33956041|NCT00081978|RANDOMIZED|||TREATMENT||||||||
33956042|NCT01311505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956043|NCT06412666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956044|NCT03360721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956045|NCT01555242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956046|NCT06106282|||COHORT||PROSPECTIVE|||||||
33956047|NCT04873830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956048|NCT05210400|||CASE_ONLY||PROSPECTIVE|||||||
33956049|NCT04027907|||CASE_CONTROL||RETROSPECTIVE|||||||
33956050|NCT04387487|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|participant and investigators will be masked|Intervention name- multimedia video information Intervention details- multimedia video information of 4.5 mins regarding procedure, indication and complications related to spinal anesthesia will be shown to patients in intervention group , patient will be allowed to ask questions.|t|f|t|f
33956051|NCT06699290|||COHORT||PROSPECTIVE|||||||
33956052|NCT00557700|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33956053|NCT06701123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956054|NCT02030509|||CASE_ONLY|||||||||
33956055|NCT06653712|||COHORT||CROSS_SECTIONAL|||||||
33956056|NCT03529045|||COHORT||PROSPECTIVE|||||||
33956057|NCT01876082|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956058|NCT00648583|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33956059|NCT05058027|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33956060|NCT03813160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060403|NCT04912388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060404|NCT06072404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060405|NCT02097797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060406|NCT02631278|NA|SINGLE_GROUP||||NONE||||||
34060407|NCT00040235||||TREATMENT||||||||
34060408|NCT02274064|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34060409|NCT02939716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34060410|NCT01779167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060411|NCT04094831|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34060412|NCT00365209|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34060413|NCT00002369||PARALLEL||TREATMENT||||||||
34164361|NCT06725446|||OTHER||CROSS_SECTIONAL|||||||
34164362|NCT06726603|||COHORT||OTHER|||||||
34164363|NCT06161129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not meet each other. Outcome assessors and participants will not know which type of filters are used.|"Four arms will be used:~1: Control. 2. BlueCut filter. 3. FL-41 filter. 4. Below 500 nm filter."|t|f|f|t
34164364|NCT03311165|||COHORT||PROSPECTIVE|||||||
34164365|NCT01337336|||COHORT||RETROSPECTIVE|||||||
34164366|NCT00184314|||CASE_ONLY||RETROSPECTIVE|||||||
34164367|NCT05491382|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33852017|NCT02922309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852018|NCT04552483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly allocated into one of the two groups: A or B. Patients received labelled medication: A or B, by the pharmacist. Patients received an identification number, so care providers, outcomes assessors and investigators did not know anything regarding the patients' groups.|"Patients diagnosed with COVID-19 will be randomly divided into 2 groups: experimental and control groups.~Experimental group: 196 patients diagnosed with COVID-19 confirmed by RT-PCR will receive nitazoxanide 500mg 8/8 hs for 5 days. Control group: 196 patients diagnosed with COVID-19 confirmed by RT-PCR will receive placebo 8/8 hs for 5 days."|t|t|f|f
33852019|NCT04459013|||COHORT||PROSPECTIVE|||||||
33852020|NCT02542774|||COHORT||RETROSPECTIVE|||||||
33852021|NCT00901654|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33852022|NCT00406523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852023|NCT02839759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852024|NCT00118651|||CASE_CONTROL||PROSPECTIVE|||||||
33852025|NCT03842722|||COHORT||PROSPECTIVE|||||||
33852026|NCT00424385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852027|NCT01825928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852028|NCT03390647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33852029|NCT00827866|RANDOMIZED|PARALLEL||||NONE||||||
33852030|NCT03866707|||CASE_CONTROL||PROSPECTIVE|||||||
33852031|NCT05467423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852032|NCT00000473|RANDOMIZED|||PREVENTION||DOUBLE||||||
33852033|NCT01240226|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852034|NCT01211288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852035|NCT03337451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852036|NCT04288999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852037|NCT02826915|||CASE_ONLY||PROSPECTIVE|||||||
33852038|NCT01522469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852039|NCT05042596|||CASE_ONLY||PROSPECTIVE|||||||
33852040|NCT03720873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852041|NCT03028220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852042|NCT00003382||||TREATMENT||||||||
33852043|NCT01771107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852044|NCT01184261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852045|NCT05896878|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, open-label, non randomized evaluation of daily supplementation with Root.Health, a plant-based anti-inflammatory dietary supplement, on Foundation Pain Index (FPI) scores in a chronic opiate patient population. The daily supplement is offered without charge to study participants. All patients are counseled and consented per established protocol as per established IRB requirements. This study will enroll 20 total patients. The details of the study design, patient demographics, description of the intervention method, and statistical tests performed are described.||||
33852046|NCT01122160|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33852047|NCT02635568|||COHORT||PROSPECTIVE|||||||
33852048|NCT00561132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852049|NCT05653765|||COHORT||RETROSPECTIVE|||||||
33852050|NCT03932669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852051|NCT02822586|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956061|NCT05924464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956062|NCT05335096|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33852052|NCT06244420|||COHORT||RETROSPECTIVE|||||||
33852053|NCT04775771|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33852054|NCT05985421|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852055|NCT00709852|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33852056|NCT02537821|||COHORT||PROSPECTIVE|||||||
33852057|NCT03107338|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The patients and the evaluator of the VAS (MMV) were unaware of the results of the randomization and the treatment received.|This study was conducted as a prospective randomized double-blind study with a placebo. The present study considered the checklist items proposed in the CONSORT statement.|t|f|t|t
33956063|NCT02216214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956064|NCT06531109|||COHORT||PROSPECTIVE|||||||
33852058|NCT02937233|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33852059|NCT01849159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852060|NCT05023421|||FAMILY_BASED||PROSPECTIVE|||||||
33852061|NCT03795597|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Busulfan IV over 3 hours every 24 hours for a total of 4 doses from D-6 to D-3. First two daily infusions will be given at a fixed dose of 3.2 mg/kg over 3 hours from D-6 to D-5. The 3rd and 4th daily doses will be adjusted to an AUC of approximately 5,000 mMol-min per dose.~Melphalan 140 mg/ m2 IV over 15-30 minutes for one dose on day -3.~Carfilzomib administration will follow a Phase I dose escalation design.~Each cohort will start with a goal of accruing three patients to determine the dose limiting toxicities.~Once the Maximum Tolerated Dose is established an expansion cohort will be treated to include a total of 10 additional patients."||||
33852062|NCT06006559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852063|NCT00154765|RANDOMIZED|PARALLEL||ECT||NONE||||||
33852064|NCT06124781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060414|NCT02073565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060415|NCT00367484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060416|NCT03374670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060417|NCT01206413|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34060418|NCT03161626|||CASE_CONTROL||RETROSPECTIVE|||||||
34060419|NCT03070405|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34060420|NCT03005431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060421|NCT02900417|NA|SINGLE_GROUP||||NONE||||||
34060422|NCT06509971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060423|NCT04363918|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34060424|NCT04861194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060425|NCT02057913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164368|NCT05519514|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The randomization schedule was not be available to the bio-analytical operations team to keep them blinded on the treatment assignment.|Cross Over||||
34164369|NCT05338034|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|During this study, subjects, investigators, the Sponsor, and the clinical research organization (CRO) (except specific vendors whose role in study conduct requires their unblinding, eg, personnel operationally associated with the interactive response technology \[IRT\]) will be blinded to the study intervention assignment. Study team personnel will remain blinded throughout the study with the exception of a Sponsor Committee who will review interim analysis results and make decisions regarding dropping and/or adding a treatment cohort and an unblinded study team member assigned to monitor that at least 6 subjects in each dose cohort had serial PK measurements taken.||t|t|t|t
34164370|NCT01396213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|randomized, double-blind, placebo-controlled|t|f|t|f
34164371|NCT05062447|||CASE_CONTROL||PROSPECTIVE|||||||
34164372|NCT04171050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The providers will know what intervention the patients underwent, but the patients and the care team obtaining pain scores in the hospital will be blinded to the intervention|"This will be a prospective blinded randomized controlled trial. We will recruit women who are undergoing vaginal prolapse repair surgery with a Female Pelvic Medicine and Reconstructive Surgery fellowship-trained provider within the University of California, Los Angeles (UCLA) Health System.~Women will be recruited prior to undergoing vaginal reconstructive surgery. They will then be randomized to control group with standard of care with local anesthesia used during surgery (Group 1) or PNB in addition to use of local anesthesia typically used during surgery (Group 2)."|t|t|f|f
34164373|NCT06725433|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective open label randomized trial||||
34164374|NCT04958889|||COHORT||PROSPECTIVE|||||||
34164375|NCT01669317|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34164376|NCT06129136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants are randomized to groups by external statistician. Test lotions are looking the same so participants and investigators don't know in which group they are.||t|f|t|t
34164377|NCT02784847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164378|NCT06727084|||COHORT||PROSPECTIVE|||||||
34164379|NCT03923634|NA|SINGLE_GROUP||OTHER||NONE||||||
34164380|NCT03812536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164381|NCT02555176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164382|NCT06726265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164383|NCT04883866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|At the time of discharge, the participants will not know that they are in the intervention and control group. Participants will be blinded. In the evaluation of the data, the groups will not be coded as intervention and control groups, they will be coded as group A and group B, and their analysis will be evaluated and reported by an independent statistician. In addition, the statistician will be blind.|This is a pretest-posttest designed randomized controlled trial using the stratified block randomization method.|t|f|f|t
34164384|NCT01650194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164385|NCT01367834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164386|NCT01225094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34164387|NCT01949974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164388|NCT04577378|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Single (Participant)|"Patients and method :~13- This study will performed on 45 patients tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection will randomly divided into 3 equal groups"|t|f|f|f
34164389|NCT01814475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164390|NCT05167565|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164391|NCT01150097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164392|NCT06369974|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study|Single participant interventional study||||
34164393|NCT03965494|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164394|NCT02495129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164395|NCT05349630|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||All participants will complete resting echocardiography and exercise testing as part of parent study prior to oral iron supplementation. Participants who enroll in this study will complete 30 days of oral iron supplementation and then repeat resting echocardiography and exercise testing.||||
33852065|NCT03186131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852066|NCT04487912|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33852067|NCT05064683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34164396|NCT03932695|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|first phase of the study is RCT double blind placebo cross-over. The second phase is open during 6 weeks of supplementation|double blind cross over and open for the phase II of the study|t|t|t|t
33852068|NCT00568035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852069|NCT01670955|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33852070|NCT03461276|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33852071|NCT06206057|||CASE_ONLY||CROSS_SECTIONAL|||||||
33852072|NCT02860611|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852073|NCT06014840|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33852074|NCT00335647||||TREATMENT||NONE||||||
33852075|NCT06372678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852076|NCT04837898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Supplement will be pre-weighed by an individual (independent of the study) and provided to participants in sealed packets||t|f|t|t
33852077|NCT03429829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Children in the reception grade and grade 1 of two schools in a township in South Africa are class-wise cluster-randomized to the fluoride varnish or control groups.|f|f|f|t
33852078|NCT00985153|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33852079|NCT04280068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to arms assignments.|Participants will be randomized to an evidenced-based brief behavioral intervention.|f|f|f|t
33852080|NCT00677326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852081|NCT05569720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852082|NCT04725474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to a dose level of CTL-002 (Part A) or an expansion cohort (Part B) at the time of their enrollment||||
33852083|NCT01398995|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33852084|NCT02188420|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33852085|NCT02576301|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852086|NCT00058760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33852087|NCT04383808|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956065|NCT00835133|||FAMILY_BASED||PROSPECTIVE|||||||
33956066|NCT01807910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33956067|NCT05433376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956068|NCT04692753|||COHORT||PROSPECTIVE|||||||
33956069|NCT06177886|||COHORT||PROSPECTIVE|||||||
33956070|NCT06650475|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33956071|NCT03029559|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"We will use a Latin square, repeated measures design which will consist of 12 subjects participating in the following four experimental conditions: There will be an interval of 1 week between each of the four conditions, which will serve as a washout period.~1. IH+ITL: Subjects will be exposed to a session of IH (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of ITL at 80%MIP (10 breaths per set).~2. IH: Subjects will only be exposed to a session of intermittent hypoxia.~3. Sham IH +ITL: Subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).~4. Sham IH: Subjects will be exposed to a single 45-minute session of sham IH (normoxia) alone."|Latin square, repeated measures design to study the effects of IH administered alone and in combination with inspiratory threshold loading on the above stated respiratory parameters.|t|f|f|f
33956072|NCT06653062|||COHORT||PROSPECTIVE|||||||
34164397|NCT02303093|||COHORT||PROSPECTIVE|||||||
34164398|NCT03655041|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34164399|NCT01372969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164400|NCT01564563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164401|NCT04907474|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34164402|NCT06725537|||OTHER||RETROSPECTIVE|||||||
34164403|NCT04406675|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852088|NCT03763773|||COHORT||PROSPECTIVE|||||||
33852089|NCT04258501|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Randomization was generated by the bio-statistician CRO. Subjects and key study team personnel were blinded as much as possible with regard to the identification of specific treatments but their distinctive colors, flavors or tastes could not be masked.~To ensure the study team was not apparently aware of the treatments being administered to subjects, persons who were involved in the preparation of test products were not involved in rest of the study.~The sponsors team was blinded."|Randomized, balanced, incomplete block design exploratory study of efficacy, with 8 active treatments (4 treatments per subject; 35 or 37 subjects per treatment) compared to a reference treatment (all 72 subjects).|t|f|f|t
33852090|NCT00452426|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33852091|NCT05217498|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33852092|NCT01877772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852093|NCT05934786|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33852094|NCT01449149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852095|NCT06122480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956073|NCT00005504|||COHORT||PROSPECTIVE|||||||
33852096|NCT02785471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852097|NCT05356104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors for TCD and Cognition and behavior assessments will be blinded to the randomization assignment|"110 patients with cSVD of Age-Related White Matter Changes Scale of 2 or 3 will be randomized into treatment arm with GLP-1R agonist and standard medical therapy, and control arm with standard medical therapy alone in a 1:1 ratio. In this 78 weeks pilot study, investigators shall evaluate the tolerability and safety profile of exenatide, a GLP-1R agonist in SVD patients, together with changes in clinical, imaging and sonographic parameters."|f|f|f|t
33852098|NCT00202384|||CASE_ONLY||PROSPECTIVE|||||||
33852099|NCT04621318|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33852100|NCT02824419|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33852101|NCT04318067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852102|NCT02784054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852103|NCT05606731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants who will collect surveys and measurement data will be blinded to participation condition.|A prospective randomized 2-arm clinical trial|f|f|f|t
33852104|NCT00577837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852105|NCT02717572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852106|NCT04600492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A double-blind, placebo-controlled study|A double-blind, placebo-controlled study|t|f|t|f
33852107|NCT01209780|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33852108|NCT04602416|||COHORT||PROSPECTIVE|||||||
33852109|NCT00666601|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852110|NCT03252847|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Biological||||
33852111|NCT00055601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852112|NCT05598671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852113|NCT02112331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852114|NCT05576038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Interventions will be blinded by McMaster University Central Pharmacy|Prospective randomized controlled trial: double-blinded, placebo controlled exploratory study|t|t|t|t
33852115|NCT00848926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852116|NCT03273556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852117|NCT02224976|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852118|NCT02596165|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852119|NCT01775280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852120|NCT02463110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852121|NCT04714385|||COHORT||PROSPECTIVE|||||||
33852122|NCT05877313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852123|NCT05753371|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33852124|NCT06106529|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852125|NCT03169101|||CASE_CONTROL||PROSPECTIVE|||||||
33852126|NCT01773291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852127|NCT01530828|||CASE_ONLY||PROSPECTIVE|||||||
33852128|NCT00460226|||||PROSPECTIVE|||||||
33852129|NCT03488641|||COHORT||PROSPECTIVE|||||||
33852130|NCT04097392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852131|NCT04688073|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33852132|NCT02292654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852133|NCT04937803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852134|NCT03017534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852135|NCT02844426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852136|NCT03573349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852137|NCT00348023|RANDOMIZED|PARALLEL||||SINGLE||||||
33956074|NCT04000997|||COHORT||PROSPECTIVE|||||||
33956075|NCT05292339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956076|NCT05358795|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Cluster Randomized Controlled Trial||||
33956077|NCT02230228|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956078|NCT05937230|||COHORT||PROSPECTIVE|||||||
33956079|NCT02206100|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33956080|NCT06541002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956081|NCT01212926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956082|NCT02406937|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33956083|NCT02251431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956084|NCT01717521|||COHORT||PROSPECTIVE|||||||
33956085|NCT00005009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956086|NCT02843529|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Adults at high risk of developing ALZ within 18-40 months (MCI) or cognitively normal for their age sex matching group. Risk factors include parents with a history of ALZ, and/or positive APOE4 alleles.|t|f|t|f
33956087|NCT06568848|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33956088|NCT05292781|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33956089|NCT05029167|RANDOMIZED|PARALLEL||TREATMENT||NONE||The RELIEPH trial is a substudy of the BOX trial, which is a multicenter, randomised clinical trial with a 2x2 factorial design. Patients are allocated 1:1:1:1 to two interventions, respectively high- or low mean arterial pressures (double blinded) and restrictive- or liberal oxygenation (open label). The RELIEPH trial focuses on the oxygen intervention and only has access to data from one trial site. This makes the RELIEPH trial a single-center, parallel-group randomised controlled trial with patients allocated 1:1 to the oxygen target interventions.||||
33956090|NCT02886494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33956091|NCT03640234|||OTHER||PROSPECTIVE|||||||
33956092|NCT01414062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956093|NCT04461431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956094|NCT04622540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956095|NCT04426552|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33956096|NCT05752344|||COHORT||CROSS_SECTIONAL|||||||
33956097|NCT05808699|||CASE_ONLY||PROSPECTIVE|||||||
33956098|NCT00626574|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34060426|NCT06363032|||COHORT||PROSPECTIVE|||||||
34060427|NCT02690519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852138|NCT03224754|||CASE_ONLY||CROSS_SECTIONAL|||||||
33852139|NCT03188406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852140|NCT00653601|||CASE_CONTROL||PROSPECTIVE|||||||
33852141|NCT00520325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852142|NCT05130853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33852143|NCT04051736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33852144|NCT06194526|||CASE_CONTROL||PROSPECTIVE|||||||
33852145|NCT03562247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33852146|NCT02139293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852147|NCT06329778|||COHORT||OTHER|||||||
33852148|NCT06115447|||CASE_CONTROL||PROSPECTIVE|||||||
33852149|NCT00502086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852150|NCT03587051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852151|NCT02708654|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33852152|NCT00000731||||TREATMENT||NONE||||||
33852153|NCT03019731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852154|NCT03743467|||CASE_CONTROL||OTHER|||||||
34060428|NCT05256875|||COHORT||PROSPECTIVE|||||||
34060429|NCT04685668|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Intervention implementation and evaluation~The overall implementation design will be a pragmatic stepped wedge cluster-randomized trial where each of the five maternity units (hospital) represents a cluster receiving the intervention at the cluster-level. In a random order, the maternity units will receive the intervention with three-month intervals. Informed by the logical pathway, the evaluation levels follow the Kirkpatrick model, including birth attendants' perceptions and reactions, their changes in learning and clinical care practices, and resulting changes in birth outcomes. The cost of co-creation and implementation will be collected alongside the entire study to analyze the incremental cost-effectiveness."||||
33852155|NCT03897764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients were randomly allocated in two groups. The allocation sequence was generated by a random number table, and group allocation was concealed in sealed, opaque envelopes that were not opened until operation. During the operation the envelope was opened by a nurse outside the operating theatre. The nurse prepared a blind syringe with the study drug, which was then transferred to a sterile bowl in the operating room and injected. Both bupivacaine and saline are colourless and not possible to identify the solution by its visual appearance, or by smell. The envelope was then sealed again and not opened until the study was concluded. The patients, anesthesiologists, and nurses providing postoperative care were blinded to group assignment|prospective double-blinded randomized placebo controlled study|t|t|t|t
33852156|NCT00636077|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060430|NCT02849392|RANDOMIZED|CROSSOVER||||NONE||||||
33852157|NCT03106909|||COHORT||PROSPECTIVE|||||||
34060431|NCT05270915|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852158|NCT04801810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060432|NCT04936698|||COHORT||PROSPECTIVE|||||||
33852159|NCT03865264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33852160|NCT06203366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852161|NCT05613374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060433|NCT02433067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060434|NCT00766467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34060435|NCT06729892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060436|NCT04493151|NA|SINGLE_GROUP||OTHER||NONE||||||
34060437|NCT05411003|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34060438|NCT04511195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both treatments present an identical appearance and are packed in white collapsible tubes, which are introduced in cardboard boxes and identified through a folio number.|Participants will be randomly assigned to one of the two groups: the experimental group receiving a phytopharmaceutical elaborated with the standardized extract from Sphaeralcea angustifolia, and a control group receiving an identical formulation containing Diclofenac|t|t|t|t
34060439|NCT02927106|||COHORT||PROSPECTIVE|||||||
34060440|NCT01398189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060441|NCT06511323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060442|NCT03646305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This was a single-center, parallel-group study with balanced randomization of participants into four conditions; two experimental and two control \[1:1:1:1\]. This is a non-inferiority study to examine whether singing is as effective as verbal repetition as a cognitive defusion strategy for body image distress.||||
34060443|NCT05313282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164404|NCT02766712|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34164405|NCT04909866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164406|NCT01083823|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164407|NCT00437424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164408|NCT05984706|||OTHER||PROSPECTIVE|||||||
34164409|NCT04112303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852162|NCT00140751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852163|NCT01033045|||||PROSPECTIVE|||||||
33852164|NCT04506788|||CASE_ONLY||PROSPECTIVE|||||||
33852165|NCT00964093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852166|NCT00014651||||SUPPORTIVE_CARE||||||||
33852167|NCT02217332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852168|NCT05062187|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852169|NCT02377115|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852170|NCT02105584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164410|NCT06725654|||OTHER||CROSS_SECTIONAL|||||||
34164411|NCT03121365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Eligible participants will be stratified by site and randomized 1:1|f|f|f|t
34164412|NCT05114408|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164413|NCT06530199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746866|NCT03745664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Doctors, staff and any primary care provider/s involved in the participant's non-trial management will be blinded to the group allocations. Individual participants will be not told their group allocation until the end of their involvement in the trial and after the completion of the trial|Phase 3, multicenter, double-blind, placebo-controlled, randomized, intervention trial|t|t|t|t
33746867|NCT05820724|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33746868|NCT05430139|||CASE_ONLY||PROSPECTIVE|||||||
33852171|NCT01293305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33852172|NCT01170559|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33852173|NCT01877837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164414|NCT04359914|||CASE_CONTROL||PROSPECTIVE|||||||
34164415|NCT05922189|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33956099|NCT06702150|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||In the hospital where the study was carried out, each nurse is responsible for the whole care of a group of people on one working day and may or may not be given responsibility for the same people on subsequent days (individualized care model). An intervention was proposed in an inpatient unit consisting of implementing the model of organizing care by primary nursing in which a nurse is responsible for the care plan for a group of people from admission to discharge from the unit.||||
33746869|NCT02252211|NA|SEQUENTIAL||TREATMENT||NONE||Patients were enrolled in sequential cohorts following a 3+3 dose-escalation scheme.||||
33746870|NCT06156930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double-blind study design|three-armed|t|f|f|t
33746871|NCT06670430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746872|NCT03171298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746873|NCT00981591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33746874|NCT00864448|RANDOMIZED|CROSSOVER||||NONE||||||
33746875|NCT03418454|||CASE_CONTROL||PROSPECTIVE|||||||
33852174|NCT03470246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The PACO trial is based on randomized clinical trial. Besides the standard post-operative care, the cardiac operation patients of the intervention groups will receive activity guidance during a 90-day intervention after elective coronary artery bypass grafting, aortic valve replacement or mitral valve repair. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.||||
33852175|NCT06425874|||COHORT||PROSPECTIVE|||||||
33852176|NCT00470340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852177|NCT05451498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blinded research team that will not be involved in any other aspect of the study will be responsible for mixing and packaging the supplements for each participant. A blinded code will be established that represents all three supplement conditions and will be revealed after data has been analyzed.|randomized, double-blind, placebo-controlled, parallel design|t|f|t|f
33852178|NCT01813929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33852179|NCT02865486|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33852180|NCT04360317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956100|NCT06642350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are unaware of participant status (WB-EMS or MTT) and were not allowed to ask participants correspondingly||f|f|f|t
33956101|NCT06652191|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33956102|NCT06566443|NA|SEQUENTIAL||PREVENTION||NONE||||||
33956103|NCT03759301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33956104|NCT02380716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956105|NCT06538571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060444|NCT05422209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060445|NCT04687748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be selected through purposive sampling technique per inclusion \& exclusion criteria. Further, Randomization will be done by sealed envelope method.|There will be two groups of participants, Experimental group will receive pelvic floor strengthening with EMGBF (Electromyographic Biofeedback ) and control group receive excercises without EMGBF.|t|f|f|f
34060446|NCT03974841|||COHORT||RETROSPECTIVE|||||||
34060447|NCT06731218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060448|NCT02917824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060449|NCT03860714|||CASE_CONTROL||PROSPECTIVE|||||||
34060450|NCT04823793|||CASE_CONTROL||PROSPECTIVE|||||||
34060451|NCT03767556|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34060452|NCT03672461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060453|NCT06730009|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34060454|NCT05541094|||CASE_CONTROL||PROSPECTIVE|||||||
34060455|NCT06016439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060456|NCT01028248|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060457|NCT00933582|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34060458|NCT02865590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060459|NCT02357667|||CASE_CONTROL||PROSPECTIVE|||||||
34060460|NCT00289406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060461|NCT00844480|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34060462|NCT00725101|||COHORT||PROSPECTIVE|||||||
34060463|NCT03325894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060464|NCT04687020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060465|NCT02174003|||||PROSPECTIVE|||||||
34060466|NCT03625310|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34060467|NCT06109376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060468|NCT05489640|||COHORT||PROSPECTIVE|||||||
34060469|NCT06708949|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060470|NCT02984267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765450|NCT03908073|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double blind placebo controlled|Proof of concept prospective randomized double-blind crossover study evaluating the use of transcutaneous vagal nerve stimulation in a model of acute psychological stress in participants with quiescent Ulcerative colitis|t|t|t|t
33765451|NCT06053554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33765452|NCT05680961|||COHORT||CROSS_SECTIONAL|||||||
33765453|NCT02885493|||COHORT||PROSPECTIVE|||||||
33765454|NCT04723043|RANDOMIZED|PARALLEL||SCREENING||NONE||"The first group was labelled as Group V as they are applied with mechanical ventilation under controlled volume, and the second group was labelled as Group P as they are applied with mechanical"||||
33746876|NCT06634745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants: The participants in this study were blinded to their treatment allocation. They did not know whether they were receiving antimicrobial photodynamic therapy (aPDT) with standard needle irrigation, EDDY sonic activation system, passive ultrasonic irrigation, or Endoactivator sonic activation system.|This study is a randomized, parallel-group clinical trial evaluating the effectiveness of antimicrobial photodynamic therapy (aPDT) using different irrigation activation techniques in teeth with apical periodontitis. Sixty patients with single-rooted, single-canal teeth were included. Participants were randomly assigned to four groups: aPDT with standard needle irrigation (SII), aPDT with Endoactivator, aPDT with passive ultrasonic irrigation (PUI), and aPDT with EDDY. All groups received aPDT using methylene blue, following standard endodontic procedures. The primary outcome was the efficacy of microbial reduction in the root canal system. Secondary outcomes included lesion healing, postoperative pain, and discoloration potential. Data were analyzed to compare the effectiveness of different techniques. The null hypothesis was that there would be no significant difference among the groups in terms of lesion healing, postoperative pain, and discoloration potential.|t|f|f|f
33746877|NCT00005776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746878|NCT05916690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746879|NCT03750201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Intra-ocular pressure (IOP) measurements by masked investigator or masked technique (masked reading).||f|f|f|t
33746880|NCT06299397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After randomization was performed by a researcher independent of the study, it was decided by lottery method which group would be the experiment and which group would be the control group.|Participants determined by the researchers before starting the study were divided into experimental and control groups by randomization method. Humor-based breastfeeding education was given to women in the experimental group for 35-45 minutes once a week for 2 weeks on specified days and hours. Breastfeeding education was given in practice. Then, humor was practiced with songs and clown costumes. An interim test was administered one month after this application and a final test was administered three months later.|t|f|t|f
34164416|NCT00783614|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34164417|NCT00718510|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34164418|NCT05149534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants deemed eligible after the baseline assessments will be randomized using a computerized block randomization with a 1:1 allocation ratio of active rTMS/WET and sham rTMS/WET conditions. The investigators will be utilizing permuted block design with randomized blocks of 4 and 2. This will be conducted by an independent study coordinator who will be uninvolved in the research beyond randomization and blinding with assistance from a data analyst in addition to statistics consultant.|Double blind, randomized clinical trial|t|t|t|t
34164419|NCT00488540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164420|NCT05940701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34164421|NCT05309902|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34164422|NCT05547126|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34164423|NCT04236674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164424|NCT03348280|||OTHER||CROSS_SECTIONAL|||||||
34164425|NCT06543888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34164426|NCT04684069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164427|NCT01757106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164428|NCT00550017|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164429|NCT04448977|||CASE_CONTROL||PROSPECTIVE|||||||
34164430|NCT05924347|||COHORT||PROSPECTIVE|||||||
34164431|NCT03203252|||CASE_ONLY||RETROSPECTIVE|||||||
34164432|NCT03232346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164433|NCT06100679|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Trained enumerators will be blinded to the treatment conditions from the beginning of the study (i.e., at baseline data collection) and before entering clusters (i.e., villages/communities) at mid-term and endline.|Stepped-wedge cluster randomized controlled trial-sequential transition of clusters from control to intervention conditions in randomized order, until all clusters are exposed.|f|f|f|t
34164434|NCT05038865|||COHORT||PROSPECTIVE|||||||
34164435|NCT04483726|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34164436|NCT03400826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164437|NCT03255317|NA|SINGLE_GROUP||OTHER||NONE||"At each time point at which a participant is eligible to receive an engagement strategy, the participant is randomized to either receive the strategy or not receive the strategy. Participants are only eligible to potentially receive some engagement strategies after completing their self-report survey questions and/or active tasks that day (see intervention section for more information)."||||
34164438|NCT05065359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multiple Ascending Dose|t|t|t|t
34164439|NCT01504022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164440|NCT04427865|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164441|NCT04990258|||COHORT||PROSPECTIVE|||||||
34164442|NCT03776799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164443|NCT04363879|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel treatment arms for two types of endometrial scratch||||
34164444|NCT05897606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intervention group received multivitamin and minerral|t|t|t|t
34164445|NCT05789628|||CASE_CROSSOVER||PROSPECTIVE|||||||
34164446|NCT04947241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164447|NCT02996526|||COHORT||PROSPECTIVE|||||||
34164448|NCT04132310|||COHORT||PROSPECTIVE|||||||
34164449|NCT00191308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164450|NCT06178614|NA|SEQUENTIAL||TREATMENT||NONE||||||
34164451|NCT04616859|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind||t|f|t|f
34164452|NCT00298974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164453|NCT06500884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164454|NCT05585840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Study|f|f|f|t
34164455|NCT06419725|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34164456|NCT00990743|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34164457|NCT01852838|||CASE_CONTROL||PROSPECTIVE|||||||
34164458|NCT00189839|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34164459|NCT00203229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956106|NCT06298487|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956107|NCT05888649|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33956108|NCT05258500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34076323|NCT01005862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076324|NCT01534117|NON_RANDOMIZED|PARALLEL||||NONE||||||
34076325|NCT03291821|RANDOMIZED|PARALLEL||OTHER||NONE||Unicentric, prospective, randomized, non-blind, parallel-group controlled phase IV clinical study.||||
33746881|NCT06235216|NA|SINGLE_GROUP||TREATMENT||NONE||two cohorts of patients||||
33746882|NCT02123693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33746883|NCT03355079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956109|NCT04607772|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33956110|NCT06371911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956111|NCT02758509|||COHORT||PROSPECTIVE|||||||
33956112|NCT01166074|||COHORT||RETROSPECTIVE|||||||
33956113|NCT00519948||CROSSOVER||||NONE||||||
33956114|NCT02208934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33956115|NCT04969991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, investigators, and study personnel involved in the conduct of the study, including data management, will be blinded to treatment assignment with the exception of a specified unblinded statistician, an unblinded pharmacist at each clinical site, a programmer from the contract research organization (CRO) who will have access to the randomization code, and the DSMB.|"The study will be conducted in 2 parts. Both parts will be randomized and double-blind. Part 1 will be dose-finding in 4 parallel treatment groups randomized to treatment with varespladib (at 250 mg once daily \[QD\], twice daily \[BID\], or three times daily \[TID\] \[total doses of 250, 500, or 750 mg/day\]) or placebo in a 5:5:5:3 ratio. After all participants in Part 1 have completed Day 28, a data safety monitoring board (DSMB) will review the safety results from Part 1 and will recommend the dose regimen to be used in Part 2. Part 2 will randomize an additional 72 participants to the dose regimen selected from Part 1 or placebo in a 1:1 ratio.~In both parts of the study, eligible participants will be enrolled and randomized to receive either varespladib or placebo in addition to institutional standard of care for 7 days."|t|t|t|t
33956116|NCT06566352|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956117|NCT04556877|||CASE_CROSSOVER||PROSPECTIVE|||||||
33956118|NCT04875637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956119|NCT03829527||SEQUENTIAL||PREVENTION||NONE||||||
33956120|NCT00003786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956121|NCT00602927|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33956122|NCT05297149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33956123|NCT03545360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076326|NCT03075267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076327|NCT03146741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076328|NCT02627456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34076329|NCT00785161|||COHORT||PROSPECTIVE|||||||
33746884|NCT05411965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-way crossover||||
33746885|NCT05834504|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746886|NCT04278144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multiple ascending dose and dose-expansion of BDC-1001 administered as a single agent or in combination with nivolumab.||||
33746887|NCT00497302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746888|NCT06670742|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33746889|NCT06304233|||COHORT||PROSPECTIVE|||||||
33746890|NCT03553589|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33746891|NCT05291208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33746892|NCT01244048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746893|NCT03782155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized clinical trial study|t|f|t|t
33746894|NCT00634608|NON_RANDOMIZED|PARALLEL||||NONE||||||
33746895|NCT01007591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746896|NCT02828657|||COHORT||PROSPECTIVE|||||||
33746897|NCT00201006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746898|NCT00896168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746899|NCT01477827|||COHORT||PROSPECTIVE|||||||
33746900|NCT03114254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746901|NCT06484244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746902|NCT01155947|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33746903|NCT00388843|||COHORT||PROSPECTIVE|||||||
33746904|NCT01182753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765455|NCT02715817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765456|NCT05733975|NA|SINGLE_GROUP||OTHER||NONE||||||
33765457|NCT04866004|NA|SINGLE_GROUP||OTHER||NONE||||||
33956124|NCT03494673|||CASE_CONTROL||PROSPECTIVE|||||||
33956125|NCT03780452|||CASE_ONLY||PROSPECTIVE|||||||
33956126|NCT01615900|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956127|NCT05244109|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33956128|NCT02779686|||CASE_CONTROL||PROSPECTIVE|||||||
33956129|NCT00532779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956130|NCT01074853|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33956131|NCT02991651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852181|NCT00284687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164460|NCT01658007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852182|NCT03046654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852183|NCT00705679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852184|NCT03687541|||COHORT||RETROSPECTIVE|||||||
33852185|NCT05027997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852186|NCT05506579|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"This is an assessor blinded cluster randomized controlled trial with rhythmic gymnastics clubs as the unit of randomization. Two different interventions (preventive exercises for the knees, lower back and hip/groin and PFMT) for two different conditions (overuse injuries and UI) are combined in this design.~After inclusion, all rhythmic gymnastics clubs will be randomly allocated 1:1 to preventive exercises for knee, lower back and hip/groin and PFMT or a control group with no intervention."|f|f|f|t
33852187|NCT04479631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852188|NCT00486629|RANDOMIZED|PARALLEL||PREVENTION||NONE||Lifestyle questionnaire on mothers and offspring. Tests on glucose tolerance and epigenetic analysis in offspring.||||
33852189|NCT05937334|||COHORT||PROSPECTIVE|||||||
33852190|NCT01354561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852191|NCT06000137|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852192|NCT00485498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164461|NCT06703034|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a single-center, comparative, prospective, interventional study with minimal risk and constraints, RIPH category 2 outside of healthcare product||||
34164462|NCT06263894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In order to reduce selection bias in determining the experimental and control groups, a computer-assisted randomization program (https://www.randomizer.org) will be used for pregnant women who meet the inclusion criteria.|One experimental group and one conventional (control) group|t|f|f|t
34164463|NCT06206525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164464|NCT02196155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852193|NCT02880345|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33852194|NCT06226090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852195|NCT02407990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164465|NCT02929602|||CASE_ONLY||PROSPECTIVE|||||||
34164466|NCT05177497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164467|NCT05801666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34164468|NCT02532465|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164469|NCT04726683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34164470|NCT05058222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765458|NCT04091724|||COHORT||PROSPECTIVE|||||||
33765459|NCT06625502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765460|NCT05291221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765461|NCT03028402|||CASE_CONTROL||PROSPECTIVE|||||||
33765462|NCT05923112|||CASE_ONLY||PROSPECTIVE|||||||
33765463|NCT02294188|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33765464|NCT02693301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765465|NCT03169634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to study arm allocation. The physiotherapists performing the functional assessments will be blinded to study arm allocation. T|This is a 3 armed study in which participants are randomised to receive 1 of 3 types of revision total knee arthroplasty|t|f|f|t
33765466|NCT05508906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatment Group 1: OP-1250 in combination with ribociclib~Treatment Group 2: OP-1250 in combination with alpelisib~Treatment Group 3: OP-1250 in combination with everolimus"||||
33765467|NCT02626858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765468|NCT01996215|||COHORT||PROSPECTIVE|||||||
33765469|NCT04321265|||COHORT||PROSPECTIVE|||||||
34164471|NCT01988675|||COHORT||PROSPECTIVE|||||||
33765470|NCT03606122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765471|NCT06233643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765472|NCT02566798|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33765473|NCT03779139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765474|NCT02821624|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33765475|NCT01550172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765476|NCT01492491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852196|NCT00661479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33852197|NCT06124287|||COHORT||PROSPECTIVE|||||||
33852198|NCT05416801|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852199|NCT00990977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33852200|NCT04310384|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33852201|NCT03218345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852202|NCT00569556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852203|NCT04962243|||CASE_CONTROL||RETROSPECTIVE|||||||
33852204|NCT02288247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852205|NCT04442997|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33852206|NCT02627729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33852207|NCT05878301|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33852208|NCT00482560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852209|NCT02750982|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33852210|NCT00318071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852211|NCT05416073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852212|NCT03635593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852213|NCT03730480|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33852214|NCT03436251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852215|NCT06610786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852216|NCT01765166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852217|NCT05587439|||COHORT||OTHER|||||||
33852218|NCT05132192|||COHORT||RETROSPECTIVE|||||||
33852219|NCT01124773|||COHORT||PROSPECTIVE|||||||
33852220|NCT01274832|||CASE_CONTROL||PROSPECTIVE|||||||
33852221|NCT00475397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852222|NCT02896049|||COHORT||PROSPECTIVE|||||||
33956132|NCT00572468|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33956133|NCT00713830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852223|NCT05919862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956134|NCT01578603|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34164472|NCT00941408|||CASE_ONLY||CROSS_SECTIONAL|||||||
34164473|NCT04163575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164474|NCT03754517|||CASE_CONTROL||PROSPECTIVE|||||||
34164475|NCT04757116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164476|NCT02504489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|placebo||t|f|f|f
34164477|NCT03869554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164478|NCT00704886|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164479|NCT05276258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164480|NCT00727623|||COHORT||PROSPECTIVE|||||||
34164481|NCT00128310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956135|NCT04431622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956136|NCT05610813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956137|NCT05301894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956138|NCT06649799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33956139|NCT01064869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34164482|NCT03676972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164483|NCT01059734|||||RETROSPECTIVE|||||||
34164484|NCT01926834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164485|NCT06276426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164486|NCT05248581|||COHORT||PROSPECTIVE|||||||
34164487|NCT03470480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This preliminary study aims to consent and enroll 20 individuals with Methamphetamine Use Disorder. Participants will be randomized into two rTMS conditions (real versus sham) and two picture cues conditions (METH versus neutral). Randomization provides the following four groups: real METH (RM), real neutral (RN), sham METH (SM) and sham neutral (SN). The randomizations can be performed with a web-based randomization generator (www.randomization.com) (47). Subjects and rTMS administrators will be blinded to the treatment.|t|f|t|t
34164488|NCT03172312|||CASE_ONLY||PROSPECTIVE|||||||
34164489|NCT02460809|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34164490|NCT04030026|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Matching Placebo|Randomized, double-blinded, placebo-controlled, 2-Treatment, 2-Period Crossover Study|t|t|t|t
34164491|NCT04914026|||COHORT||PROSPECTIVE|||||||
33852224|NCT06300385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 parallel groups randomized controlled study|f|f|f|t
33852225|NCT04838600|||CASE_ONLY||PROSPECTIVE|||||||
33852226|NCT05462301|||COHORT||PROSPECTIVE|||||||
33852227|NCT04213950|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study consists of 2 groups: (1) the historical control group and (2) the post-implementation group. The historical control group includes patients who received rabies PEP from January 2015 to June 2018. The quality improvement bundle will be implemented across the Houston Methodist health system in December 2019. The post-implementation group includes patients who receive rabies PEP within 12 months following bundle implementation. An estimated sample size of 70 patients in the post-implementation group and 254 patients in the historical control group will provide 80% power to detect an absolute increase of 20% in the primary endpoint using a two-sided alpha of 0.05.||||
33956140|NCT02001038|||CASE_ONLY|||||||||
33956141|NCT02815189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956142|NCT03920527|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956143|NCT03916692|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Randomized Cross-over trial|t|f|f|f
33956144|NCT00527709|||OTHER||RETROSPECTIVE|||||||
33956145|NCT00345969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956146|NCT06701084|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33956147|NCT05742607|NA|SINGLE_GROUP||TREATMENT||NONE|"Experimental: IPH5201 + durvalumab + chemotherapy~Patients will receive Neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy.~Following surgery, patients will receive adjuvant treatment with IPH5201 and durvalumab"|||||
33956148|NCT01135316|||COHORT||PROSPECTIVE|||||||
33956149|NCT06566625|||COHORT||PROSPECTIVE|||||||
33956150|NCT04040738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The labour analyst, the investigator, the statistician is unaware of group allocation.|Study participants n=25 in the S-GA, n=25 in the S-RA, n=25 in the H-GA, and n=25 in the H-RA Groups.|f|f|t|t
33956151|NCT05887518|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A total of 70 patients in the sample group determined by randomisation will be divided according to the A and B groups formed by the same statistician in the computer environment. The information that the patients included in the research sample were assigned to group A and B according to the randomisation table will be kept by the consultant, and the socks with and without heating feature will be numbered from 1 to 70 according to the randomisation table and given to the practitioner so that the practitioner will be blinded when he/she does not know which sock has heating feature and which one does not. Thus, patients will be blinded as they do not know which group they are in.|Prospective, two-arm (1:1), randomised controlled, double-blind clinical trial|t|t|t|f
33956152|NCT05635760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956153|NCT01742390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956154|NCT04602208|||COHORT||RETROSPECTIVE|||||||
33956155|NCT00447265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33956156|NCT04793152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956157|NCT04095975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956158|NCT06566430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956159|NCT05276869|||CASE_CROSSOVER||OTHER|||||||
33956160|NCT00337727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33956161|NCT06701773|||CASE_CONTROL||RETROSPECTIVE|||||||
33956162|NCT02143479|||COHORT||PROSPECTIVE|||||||
34164492|NCT02481297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164493|NCT04628780|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33852228|NCT03085030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both the antioxidant and the placebo will be put in sealed envelops with a number on it. the number denotes its order in the randomization process. The investigator, care providers and the outcome assessors will not know the allocated group of the participants. The bio-statistician will prepare the table of random numbers. the pharmacist will prepare the sealed envelopes according to the table of randomization. Independent nurse will bring the sealed envelope of the participant from the pharmacy without knowing whether the envelope contains drug or the placebo.|"The first group will take antioxidant drug orally once daily for one month before IVF/ICSI cycle.~The second group will take placebo with a same regimen as the antioxidant group"|t|t|t|t
33852229|NCT01173133|||COHORT||PROSPECTIVE|||||||
33956163|NCT05718505|RANDOMIZED|PARALLEL||OTHER||SINGLE||All participants will ingest the investigational and predicate device in a tandem ingestion. The order of device ingestion will be randomized, controlled centrally via an Electronic Data Capture system.|f|f|f|t
33852230|NCT01296347|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33852231|NCT03990831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients with lower extremity burn : 15 patients patients with upper extremity burn : 10 patients healthy controls : 11||||
33852232|NCT04367012|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33852233|NCT03002831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852234|NCT02816944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852235|NCT02010528|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852236|NCT03866499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852237|NCT03897686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A patient, study investigator and Sponsor representative (monitoring specialist) will not know to which group a patient is included. to preserve blinding of any patient and study team, an independent unblended physician is to be engaged, he/she will receive the product per randomization code and perform the procedure of intra-articular injection of the study MD and placebo.|multicenter double-blind randomized comparative placebo-controlled|t|f|t|f
33852238|NCT05577884|||COHORT||PROSPECTIVE|||||||
33852239|NCT00806572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852240|NCT03933527|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||factorial assignment|f|t|f|t
33852241|NCT04924933|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852242|NCT00036959||||TREATMENT||NONE||||||
33852243|NCT03625895|||COHORT||PROSPECTIVE|||||||
33956164|NCT02670356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956165|NCT02708940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956166|NCT00005886|RANDOMIZED|||TREATMENT||DOUBLE||||||
33956167|NCT04624256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956168|NCT03574623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956169|NCT03032575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956170|NCT01177735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956171|NCT06701513|||COHORT||PROSPECTIVE|||||||
33956172|NCT00213629|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956173|NCT04625634|NA|SINGLE_GROUP||OTHER||NONE||Repeated measures study||||
33956174|NCT03259646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||cluster randomized trial|t|f|f|f
33956175|NCT03190707|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study population will be stratified randomized on an individual level, thus half of the women, who agree to participate, is being randomized to the intervention group and the other half is being randomized to the control group. The trial participants will be allocated within each municipality to either control- or intervention group. The project personnel visiting the families to collect baseline data carry out the randomization. The project personnel bring a sealed envelope when visiting the families. In the envelope, the randomization group is stated together with a randomization number. The envelope is packed by a third party individual who receives a computer generated allocation list from another researcher. The envelopes get the numbers from this random sequence. The researcher generates the allocation list by block randomization with random block sizes of 2. The random allocation list is generated once and will be destroyed after the sealed envelopes are packed.|f|f|t|t
33956176|NCT04874311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956177|NCT03584035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will do all assessments (pre and post intervention) without group allocation.|Randomized Control Trial|f|f|f|t
33956178|NCT06115707|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33956179|NCT03356834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956180|NCT01518465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956181|NCT04918095|||COHORT||PROSPECTIVE|||||||
33956182|NCT02705417|||COHORT||RETROSPECTIVE|||||||
33956183|NCT04779242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164494|NCT02233634|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34164495|NCT02552030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164496|NCT02731495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164497|NCT06465329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164498|NCT04479332|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164499|NCT02936388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164500|NCT02466282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164501|NCT05647590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164502|NCT03930602|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34164503|NCT06307626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956184|NCT05438199|NA|SINGLE_GROUP||OTHER||NONE||||||
33956185|NCT02141438|||COHORT||PROSPECTIVE|||||||
33956186|NCT03191435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Randomized clinical trial|t|f|f|t
33956187|NCT03125707|||CASE_ONLY||PROSPECTIVE|||||||
33956188|NCT05891496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956189|NCT00157573|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164504|NCT06726226|||COHORT||PROSPECTIVE|||||||
34164505|NCT02771236|||COHORT||CROSS_SECTIONAL|||||||
34164506|NCT04764513|NA|SINGLE_GROUP||TREATMENT||NONE||This dose escalation study will be conducted in two phases. The first phase will have 3 cohorts(Dose escalation, x5 dose increments between cohorts, 2×10\^6、 1×10\^7/kg and 5×10\^7 of cells per kg of body weight). The second phase is an expansion cohort at the maximum tolerated dose determined in the first phase.||||
34164507|NCT01407510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956190|NCT04243005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be masked until postoperative period. Outcome assessor will be masked until all predefined outcomes have been analysed||t|f|f|t
33956191|NCT04469322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patient blinded to condition|randomized, single blind, multi-center, prospective|t|f|f|f
33956192|NCT06516133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956193|NCT02033382|||CASE_CONTROL||PROSPECTIVE|||||||
33956194|NCT05230160|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956195|NCT04507646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Two blinded researchers indenpendent performered auricular acupuncture for experimental or control group, respectively.~Experimental group receive true auricular acupuncture and control group receive sham auricular acupuncture."||t|t|f|t
33956196|NCT03785652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956197|NCT00903409|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33956198|NCT06402513|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956199|NCT03465072|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956200|NCT02484131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|data analyst||f|f|t|f
33956201|NCT04356196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33956202|NCT06565377|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33956203|NCT00518011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956204|NCT02601326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956205|NCT01481961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956206|NCT06034301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The recruitment material and informed consent will make it appear that the effectiveness between an electronic medication cap and a medication adherence app are being compared and that some participants will get the app while others will get the electronic medication bottle. The reality is that all participants will receive an electronic medication bottle.|Feasibility randomized controlled trial|t|f|f|f
33956207|NCT06098131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33956208|NCT04574037|||COHORT||RETROSPECTIVE|||||||
33956209|NCT03889925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the type of injection that they receive.||t|f|f|f
33956210|NCT04522271|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Unblinding will occur only if necessary to ensure study participants safety, interim analysis at 5 ± 1 months, or eligibility for our associated open label trial (OARS trial). Only Dr. Mack (Co-PI) can request to break the blind for safety reasons or eligibility for the OARS Trial; only Dr Stintzi (Co-PI) will request to break the blind for interim analysis. Once the blind is broken, the patient will be discontinued from study product.|A single center, randomized, placebo-controlled, double-blinded, parallel, pilot clinical trial|t|t|t|t
34060471|NCT02510313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Our study works with Laterite to oversee data collection in the field. Laterite enumerators are blind to study condition and therefore do not know which study arm, apart from their VUP status (class or expanded), participants have been randomized into.|"The proposed study design consists of a four-arm cluster randomized control trial (CRT), which will span approximately 52 cells in 3 districts of Rwanda to compare outcomes among VUP eligible households with at least one child 6-36 months in the following study arms:~* Classic VUP public works (control)~* Expanded VUP public works (control)~* Combined Classic VUP public works with Sugira Muryango (treatment)~* Combined Expanded VUP public works with Sugira Muryango (treatment)"|f|f|f|t
34060472|NCT02991716|||COHORT||PROSPECTIVE|||||||
34060473|NCT04529304|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Patient is blinded to intervention. Outcome assessoring done by patient/IPAD-solution from CANTAB, patient status assessed by blinded care-provider (nurse)|Two groups with 50 participants in each group. We want to compare one group with visible EEG-monitor with a group where the EEG monitor is invisible to the anesthetic team.|t|t|f|t
34060474|NCT01327313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060475|NCT06022354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060476|NCT00034346|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060477|NCT01371877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060478|NCT05391581|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Single blind, placebo controlled, randomized, crossover study|t|f|f|f
33956211|NCT04640701|||OTHER||RETROSPECTIVE|||||||
34060479|NCT03725501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060480|NCT00160134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060481|NCT01801241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060482|NCT03679169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060483|NCT00191425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060484|NCT00112021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060485|NCT04655040|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060486|NCT00439088|||DEFINED_POPULATION||OTHER|||||||
34060487|NCT03673501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060488|NCT06147960|||COHORT||RETROSPECTIVE|||||||
34060489|NCT00541008||||TREATMENT||NONE||||||
34060490|NCT00759057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060491|NCT03408444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060492|NCT04536870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34060493|NCT02826265|||COHORT||PROSPECTIVE|||||||
34060494|NCT02887222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956212|NCT05451407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956213|NCT06561334|||OTHER||PROSPECTIVE|||||||
33956214|NCT06124534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956215|NCT06537531|||OTHER||PROSPECTIVE|||||||
33956216|NCT03992261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956217|NCT04330521|||COHORT||RETROSPECTIVE|||||||
34060495|NCT01507402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956218|NCT06351540|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|placebo controlled, double-blind|double-blind, placebo-controlled, within-subjects crossover design|t|f|t|f
34060496|NCT02982044|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164508|NCT05779020|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34060497|NCT04578093|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||case-control||||
34060498|NCT05007041|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Subjects, study coordinators, and investigators will be blinded to the type of influenza vaccine administered in conjunction with the Recombinant Zoster Vaccine, Adjuvanted.||t|f|t|t
34164509|NCT00823563|||CASE_ONLY||PROSPECTIVE|||||||
34164510|NCT05159999|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164511|NCT02935530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060499|NCT02397824|||COHORT||PROSPECTIVE|||||||
34060500|NCT05616429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Double blind randomized clinical trial (RCT) comparing Alcat based personal diet for the treatment of IBS versus sham standard balanced diet"|t|f|t|f
34060501|NCT00094549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060502|NCT04102865|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34060503|NCT05510076|||COHORT||PROSPECTIVE|||||||
34060504|NCT04820231|NA|SINGLE_GROUP||TREATMENT||NONE||The patients with mono-lateral hip pain , grade 1 or 2 hip osteoarthritis according to the Kellgren-Lawrence classification||||
34060505|NCT01592292|||COHORT||PROSPECTIVE|||||||
34060506|NCT01299415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060507|NCT00911209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164512|NCT05852691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164513|NCT05172726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164514|NCT06166680|||OTHER||OTHER|||||||
34164515|NCT03217708|||COHORT||PROSPECTIVE|||||||
34164516|NCT05944679|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34164517|NCT03178604|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34164518|NCT03642652|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants were not aware of the trial. Only Intervention arm participants received text reminders|Randomisation into Intervention and control groups. Text message sent to Intervention group. No intervention in control group|t|t|f|f
34164519|NCT04033055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will be blinded to the randomisation arm. As the procedure is conducted under general anaesthesia, the patient will not be informed whether the procedure which was performed on him/her did or did not result in the implantation of the CycloMesh™ device. Also, the surgeon such as the outcome assessor will be blinded to the randomisation arm||t|f|t|t
34164520|NCT04372251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators that will conduct the follow-up examinations 2 and 5 years after surgery will be blinded for the operative treatment.|Two-arm parallel assignment. Patients er randomized to operative treatment with either the sinus tarsi approach or percutaneous and arthroscopically assisted osteosynthesis.|f|f|t|f
34164521|NCT03534102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Testing 3 sequential standards of care; each of 3 arms lasts 4 months, and all patients recruited within an arm are assigned to the same treatment.||||
34164522|NCT01668849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765477|NCT02040558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765478|NCT03729102|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The serum samples from all participants would be labelled as the codes, of which the laboratory technicians could not access to the groups or other details of the participants.|"There would be two study groups. Those who had received primary immunization would be the control group. While persons who had received primary immunization and later received booster vaccination for at least 3 times would be the study group.~All participants would be given one dose of rabies vaccine and monitored the immunological cells and cytokines before and after the rabies booster injection."|f|f|f|t
33765479|NCT00499850|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765480|NCT03260127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33765481|NCT04409548|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765482|NCT01341977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33765483|NCT05053243|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765484|NCT05635292|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765485|NCT04402164|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|another person than the investigators|Group 1: Dentally anchored Herbst appliance Group 2: Skeletally anchored Herbst appliance|f|f|f|t
33765486|NCT02698683|||COHORT||PROSPECTIVE|||||||
33765487|NCT05712746|||COHORT||PROSPECTIVE|||||||
33765488|NCT06023901|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33765489|NCT03497507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Once an obstetrician determines that a patient laboring with an epidural catheter should have a non-emergent cesarean section instead of continuing labor, the clinical anesthesiologist will contact the research team. A member of the research team will contact the patient while she is still in the labor and delivery room, at which time informed consent would be obtained.|t|f|f|t
33765490|NCT04061720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33765491|NCT00755014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33765492|NCT03517618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765493|NCT00669903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33765494|NCT04570774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765495|NCT04662463|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33765496|NCT00494533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765497|NCT01257659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765498|NCT02354963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765499|NCT02067390|||COHORT||PROSPECTIVE|||||||
33765500|NCT00831363|||COHORT||PROSPECTIVE|||||||
33765501|NCT03511417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765502|NCT02698449|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765503|NCT02611050|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33765504|NCT01057030|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33765505|NCT00004935|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33852244|NCT01830725|||CASE_CONTROL||PROSPECTIVE|||||||
34164523|NCT00002963|RANDOMIZED|||TREATMENT||||||||
34164524|NCT03360643|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164525|NCT04414163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164526|NCT00787631|||CASE_ONLY||PROSPECTIVE|||||||
34164527|NCT04775563|||OTHER||CROSS_SECTIONAL|||||||
34164528|NCT01300312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33852245|NCT02783664|||COHORT||PROSPECTIVE|||||||
33852246|NCT01168323|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852247|NCT04956185|||CASE_ONLY||PROSPECTIVE|||||||
33852248|NCT01094860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852249|NCT04160520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and study team (i.e. investigators responsible for collecting pain scores) will be blinded as to treatment arm for the duration of the study (2 hours after initiation or until ED discharge/hospital admission). Treatment team (physicians and nurses involved in ED care of the patient) will be unblinded to maintain participant safety and proper medication administration. While the treating physician may be aware of what drugs have been ordered, the need for rescue medications is based on patient pain score at the 30-minute point.||t|f|t|f
34164529|NCT05326711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164530|NCT03779698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two full-time pediatric dentistry faculty members (other than the operator) from KAU blindly evaluated all the teeth clinically and radiographically.|A double-blinded, split-mouth, randomized, controlled clinical study design was used with a sample of 37 healthy children aged 4- to 8-year-old. A total of 56 pairs (112 teeth) of carious primary teeth, 1 pair per child, were selected for treatment. One tooth from each pair was randomly assigned to either the BiodentineTM pulpotomy group or the formocresol pulpotomy group.|t|f|t|t
34164531|NCT05133154|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The subjects will be included in the 3 following groups :~* Group 1 : Low-grade glioma group: n=30~* Group 2 : High-grade glioma group: n=10~* Group 3 : Control (patients undergoing brain surgery for a non-tumor disease) group: n=10"||||
34164532|NCT01776840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164533|NCT06725082|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33852250|NCT02317315|||COHORT||PROSPECTIVE|||||||
34164534|NCT04079595|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34164535|NCT00655629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164536|NCT05747742|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34164537|NCT06579950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Trial participants will be aware of the intervention to which they have been allocated, and the research fieldworkers will be aware of the intervention allocation. The trial steering committee members and trial statistician will remain blinded until the end of trial period and data collection.||f|f|t|t
34164538|NCT05168033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34164539|NCT02618265|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164540|NCT05341726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patient participants, data collectors, and the statistician will be blinded to assignment. Consent materials will inform patient participants that the focus of the trial is on the communication they have with their clinician about asthma management and control. Immediately after the intervention, patient participants will be asked to guess the condition to which their clinician had been randomized. At the end of participants' final data collection visit, data collectors will be asked to guess whether participants had received the active or control intervention at the visit. These data will provide some measurement of the success of masking.||t|f|f|t
34164541|NCT02219334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164542|NCT04085588|||CASE_CONTROL||PROSPECTIVE|||||||
34164543|NCT00704366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852251|NCT04209959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33852252|NCT02715791|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33956219|NCT06627894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The unblinded study coordinator is aware of randomization. The investigator and study team members responsible for the delivery of the intervention will be unblinded.~The study team staff performing outcomes assessments and the investigators overseeing this process will be blinded."|Internet based CBT-D vs Active Control|f|f|t|t
33956220|NCT03026842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956221|NCT05026749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956222|NCT06409325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both clinical staff and participants were blinded to the treatment assignment.|The present clinical protocol is designed as a double-blind, parallel, non-inferiority, randomized clinical trial.|t|f|f|t
33956223|NCT02714140|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33956224|NCT00740532|||COHORT||RETROSPECTIVE|||||||
33956225|NCT01301378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956226|NCT06566599|||COHORT||RETROSPECTIVE|||||||
34164544|NCT04917484|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, non blinded||||
34164545|NCT03712787|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852253|NCT02754986|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33852254|NCT02756273|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852255|NCT00654199|||CASE_ONLY||PROSPECTIVE|||||||
33852256|NCT00657202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852257|NCT02270918|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33956227|NCT03925116|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized||||
33956228|NCT02815540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956229|NCT01915238|||||PROSPECTIVE|||||||
33956230|NCT02694393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956231|NCT01953731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956232|NCT03479515|||COHORT||PROSPECTIVE|||||||
33956233|NCT01002118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33956234|NCT04062643|||CASE_ONLY||PROSPECTIVE|||||||
33956235|NCT01923961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956236|NCT06652633|NA|SINGLE_GROUP||OTHER||NONE||||||
33956237|NCT01445236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956238|NCT04410627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33852258|NCT03525951|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research team members doing the language sample analysis and behavioral coding will be blind to group membership (Study 1 and 2) and whether the session was recorded pre-test vs. posttest (Study 2).|"Study 1 (Remote) : Participants in the TD and DLD groups will receive no treatment; observational data only.~Study 2 (Remote): Participants in the DLD and ASD+DLD groups will receive the Enhanced Milieu Teaching intervention. Participants in the TD will serve as the no-treatment comparison group."|f|f|f|t
33852259|NCT06253091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852260|NCT00045513||||TREATMENT||||||||
33852261|NCT05678751|||CASE_CONTROL||PROSPECTIVE|||||||
33852262|NCT04328883|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852263|NCT06206252|||CASE_CONTROL||PROSPECTIVE|||||||
33852264|NCT05700773|||CASE_ONLY||PROSPECTIVE|||||||
33852265|NCT04379726|||CASE_CONTROL||PROSPECTIVE|||||||
33852266|NCT05444049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956239|NCT02152930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956240|NCT01248000|||COHORT||RETROSPECTIVE|||||||
33956241|NCT06649734|||COHORT||PROSPECTIVE|||||||
33956242|NCT05927207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised wait-list controlled trial||||
33956243|NCT04048473|||OTHER||CROSS_SECTIONAL|||||||
33956244|NCT04469465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956245|NCT06653283|||COHORT||PROSPECTIVE|||||||
33956246|NCT06650293|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33956247|NCT06523400|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A multicenter, randomized, double-blind, parallel-group, placebo-controlled study intended to evaluate the efficacy and the safety of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2). The study will consist of a 4-week screening period and a 26-week treatment phase with patient visits at screening, baseline, Weeks 1, 2, 14, and 26. Eligible patients will be randomized to mexiletine or placebo in a 1:1 ratio. Approximately 80 DM1 patients (40 active: 40 placebo) are planned to be enrolled. For the purpose of sample size re-estimation, an interim analysis will be conducted when a total of 40 patients complete/early terminate the study. In addition, 16 DM2 patients are planned to be enrolled (sub-group - 8 active: 8 placebo).||||
33956248|NCT06652347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956249|NCT03004963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852267|NCT06347887|||COHORT||PROSPECTIVE|||||||
33956250|NCT03956901|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33956251|NCT06346197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956252|NCT06650969|||COHORT||PROSPECTIVE|||||||
34060508|NCT06525636|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34060509|NCT06504667|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34060510|NCT04026035|||OTHER||PROSPECTIVE|||||||
33852268|NCT02794753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852269|NCT01526031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852270|NCT03390218|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33852271|NCT00591721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852272|NCT06342271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852273|NCT00379743|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34060511|NCT04970017|||CASE_ONLY||CROSS_SECTIONAL|||||||
34060512|NCT05052216|||CASE_CONTROL||PROSPECTIVE|||||||
34060513|NCT06514378|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060514|NCT02865811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060515|NCT06135025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the outcome assessor was blinded to allocation.|This is a randomized controlled trial. Potentially eligible participants are identified using available records from the emergency department of Fattouma Bourguiba Monastir Hospital.|f|f|f|t
34060516|NCT00013000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34060517|NCT06731634|||CASE_ONLY||CROSS_SECTIONAL|||||||
34060518|NCT00266591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060519|NCT05245734|NA|SINGLE_GROUP||PREVENTION||NONE||uncontrolled, open-label, multicenter, international (From the total number of patients a subgroup for studying some pharmacokinetics parameters is formed )||||
34060520|NCT04446351|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will receive treatment in different dose escalation arms of the study.||||
34060521|NCT01237093|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34060522|NCT00736567|||||CROSS_SECTIONAL|||||||
34060523|NCT05940025|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060524|NCT02672358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060525|NCT02311556|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060526|NCT03851146|NA|SEQUENTIAL||TREATMENT||NONE||"The study will employ dose level cohorts of three patients that will be treated at each level described in Table 1, based on the number of T cells to be infused using the 3 + 3 dose-escalation strategy. If the proposed number of T cells is unable to be obtained due to technical production reasons, the available number will be infused. However, the cohort will only be escalated when a minimum of three patients have been safely treated at the planned level.~The fourth cohort dose level has been set according to the maximum level considered to be feasible taking into account technical constraints. The study will be expanded to accrue additional patients at the MTD (expansion phase cohort) with an expansion cohort of upto 20 patients. For technical and logistic reasons the maximum number of patients to be enrolled on the study will be 30."||||
34060527|NCT05564650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060528|NCT00958373|||COHORT||PROSPECTIVE|||||||
33852274|NCT00836095|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852275|NCT02610127|||COHORT||OTHER|||||||
33852276|NCT04555031|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33852277|NCT02887170|||COHORT||RETROSPECTIVE|||||||
33852278|NCT04810143|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33852279|NCT05396677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind placebo study||t|f|t|f
33852280|NCT06609720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups with 2 subgroups, each subgroup receive either ADG or DFDBA|f|f|f|t
33852281|NCT05029180|||OTHER||CROSS_SECTIONAL|||||||
33852282|NCT06442033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|A historical control group will be utilized for analysis from a previous project. All participants in this study will be exercising in the community setting.|Single Group||||
33852283|NCT05998538|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33852284|NCT02299154|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33852285|NCT00626301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852286|NCT06266715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852287|NCT04901767|||OTHER||PROSPECTIVE|||||||
33956253|NCT05786794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Approximately 500 patients from 10 rural clinics will be recruited to participate in the trial. All participants will complete baseline surveys and eligible candidates will engage with a Patient Navigator who will assist them in overcoming specific barriers to obtain a diagnostic audiogram with an audiologist.||||
33956254|NCT01700907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33956255|NCT02350439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956256|NCT05553028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956257|NCT06696534|NA|SINGLE_GROUP||SCREENING||NONE||||||
33956258|NCT01984970|||||PROSPECTIVE|||||||
33956259|NCT01487018|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33956260|NCT04751786|NA|SEQUENTIAL||TREATMENT||NONE||Eligible subjects will receive three i.v. infusions of PRECIOUS-01 at a 3-weekly interval in three dose-finding cohorts (low: 0.4 mg/kg, intermediate: 0.8 mg/kg, and high: 1.6 mg/kg fixed doses). Subjects will be monitored for safety and the occurrence of Dose-Limiting Toxicities (DLTs). A 3+3 design is used for the dose escalation steps. Three subjects will be enrolled sequentially per cohort. If the maximum tolerated dose (MTD) is not reached in the planned dose escalation cohorts, the RP2D will be based on the observed safety and immune modulatory activity as pharmacodynamic parameter supporting the RP2D. The sample size is based on the determination of the MTD/RP2D. In order to collect sufficient information regarding changes in immune related parameters as readout for pharmacodynamics of the particles, it is planned to extend the two highest dosing cohorts to a total of six subjects or to extend the highest dosing cohort to a total of nine subjects, depending on observed toxicity.||||
33956261|NCT02554331|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33956262|NCT02989259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956263|NCT03449420|||COHORT||RETROSPECTIVE|||||||
33956264|NCT00632476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33956265|NCT03701516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33956266|NCT00958698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956267|NCT03347786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956268|NCT05071235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956269|NCT04167839|NA|SINGLE_GROUP||TREATMENT||SINGLE|Second observers were masked from participants' evaluation data and treatment phase||f|f|f|t
33956270|NCT06000839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956271|NCT00288106|||COHORT||PROSPECTIVE|||||||
33956272|NCT06566222|||COHORT||RETROSPECTIVE|||||||
33956273|NCT05343247|||CASE_CONTROL||RETROSPECTIVE|||||||
33956274|NCT00396318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956275|NCT04382599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956276|NCT06347549|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33956277|NCT06242977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon and patient are both blinded to which cream is being utilized, whether it be EMLA, or a control cream. Investigators and study personelle are not blinded to this.|Double blinded, placebo controlled, randomized trial. Two arms, one is the intervention arm which will receive EMLA cream and local anesthesia infiltration while the control arm will receive local anesthesia infiltration and a control, lotion cream.|t|t|f|f
33956278|NCT00742859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956279|NCT04762771|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an unblinded randomized study to treat hospitalized covid-19 patients with colchicine plus current care per institution treating physicians vs. current care per institution treating physicians alone (the control arm)||||
33956280|NCT02566967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956281|NCT06540833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956282|NCT01570998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956283|NCT03778190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956284|NCT00090337|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33956285|NCT06218030|NA|SINGLE_GROUP||OTHER||NONE||||||
33956286|NCT00447694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956287|NCT06652048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956288|NCT04803773|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33956289|NCT06346756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956290|NCT05161884|||COHORT||PROSPECTIVE|||||||
33852288|NCT04169230|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Following the screening, eligible participants will be randomised to receive either a single 20mg oral dose of citalopram or a matched lactose placebo tablet using an online randomisation tool. Note that the study is not assessing the safety or efficacy of citalopram, but rather using it as a probe to understand the role of serotonin in self-referential emotional processing biases.|t|f|t|t
33852289|NCT03864822|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Stimulation type will be randomized by a colleague not involved in the study. A single investigator will assess all outcomes on all participants before and after each phase of stimulation, but participants not the investigator will be aware of Active/Sham assignment until after study completion||t|f|t|t
33852290|NCT03902925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852291|NCT03567434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34164546|NCT03635749|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Two nearly identical tablet forms of Clopidogrel (75mg Clopidogrel and matching placebo) with almost the same size, color and smell will be used in this research.~Two nearly identical tablet forms of Aspirin (100mg Aspirin and matching placebo) with almost the same size, color and smell will be used in this research.~Two nearly identical tablet forms of Atorvastatin (20mg Atorvastatin and matching placebo) with almost the same size, color and smell will be used in this research.~Centers are not able to apply unblinding with biological experiment in this study. Researchers shall never unblind the code unless special situations occur such as Serious Adverse Events (SAE), which is essential for treatment. Clinical outcomes of efficacy and safety are submitted to Adjudication Committee, who should be blinded to randomization, for final determination."|"The subjects are randomly assigned to the following four groups:~1. Intensive antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin)~2. Intensive antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin)~3. Standard antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin)~4. Standard antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin)"|t|t|t|t
34164547|NCT04658004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164548|NCT04794270|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34164549|NCT04323059|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study participants will be randomized into three different intervention groups. Based on the group of assignment, the participants will receive either the standardized milk-based formulation, the standardized non-milk based formulation or the hospital-based formulation.||||
34164550|NCT00412893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164551|NCT00508326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164552|NCT02559739|||COHORT||PROSPECTIVE|||||||
34164553|NCT05990634|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33852292|NCT06064175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34164554|NCT02071134|||COHORT||PROSPECTIVE|||||||
34164555|NCT04438395|||CASE_ONLY||OTHER|||||||
34164556|NCT06726668|||COHORT||PROSPECTIVE|||||||
34164557|NCT01862536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164558|NCT03211494|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33852293|NCT02192879|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852294|NCT06066450|||CASE_ONLY||PROSPECTIVE|||||||
33852295|NCT04589949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852296|NCT06507202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852297|NCT05464797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34164559|NCT06019078|||COHORT||PROSPECTIVE|||||||
33852298|NCT01022060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852299|NCT00986674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852300|NCT04574050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|"A feasibility RCT comprising two groups:~1. Intervention (SELF-BREATHE in addition to standard NHS care)~2. Control group (standard / currently available NHS care)"|f|f|f|t
33852301|NCT05590884|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33852302|NCT04308161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852303|NCT01041131|||COHORT||RETROSPECTIVE|||||||
33852304|NCT03635073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852305|NCT03707197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will be blind to condition throughout data accrual.|Randomization to either digital meditation condition or waitlist-control condition|f|f|t|f
33956291|NCT06236334|NA|SINGLE_GROUP||PREVENTION||NONE|All subjects will participate in a blended/hybrid intervention of live and online lifestyle support|People at risk for diabetes will be selected. Screening at HbA1c level will be a selection criterion||||
33956292|NCT06576167|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||stepped wedge clustered-randomized trial||||
33956293|NCT02556528|NA|SINGLE_GROUP||||NONE||||||
33956294|NCT02079389|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164560|NCT03089580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34164561|NCT03120130|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Study with dose escalation regime, done according to the classic scheme known as 3 + 3"||||
34164562|NCT06726447|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The masking is single-blind and patient-centered, which is appropriate for this type of intervention where it is not feasible to blind healthcare professionals. This helps to reduce bias in measurements related to patient satisfaction and experience.|Clusters|t|f|t|t
34164563|NCT03329846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164564|NCT01809522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164565|NCT00647504|||CASE_CONTROL||PROSPECTIVE|||||||
33852306|NCT05208177|NA|SINGLE_GROUP||TREATMENT||NONE||"Dose-escalation: Traditional 3+3 dose-escalation design. Dose-expansion: 10 to 12 subjects (included subjects of the dose-escalation part) will be enrolled in each tolerable dose level.~Efficacy-expansion: After determination of the recommended dose for Phase II (RP2D), selected cohorts with different tumor types will be expanded."||||
33852307|NCT05173740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Before data extraction and data analysis all data will be anonymized, and group allocation will be blinded as (group X and Y).~Participants will be randomly assigned to either the intervention or the usual care group using a computer random generator, with a 1:1 allocation. The randomisation will be conducted by a blinded investigator."||f|f|t|f
33852308|NCT01485055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852309|NCT00898183|||COHORT||PROSPECTIVE|||||||
33852310|NCT02684851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852311|NCT00537693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852312|NCT05380037|||COHORT||CROSS_SECTIONAL|||||||
33852313|NCT04538443|||COHORT||CROSS_SECTIONAL|||||||
33852314|NCT05196568|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852315|NCT04456569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852316|NCT03520946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852317|NCT05599763|||COHORT||PROSPECTIVE|||||||
33852318|NCT02486744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852319|NCT02687893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852320|NCT02479048|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33852321|NCT03069001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852322|NCT06084091|||COHORT||PROSPECTIVE|||||||
33852323|NCT00645554|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852324|NCT02637570|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33852325|NCT05518682|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One arm with the same device protocol, except that there are two subgroups with different hearing/audiogram profiles.||||
33852326|NCT01794637|||COHORT||PROSPECTIVE|||||||
33852327|NCT04816331|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852328|NCT04878354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852329|NCT05182697|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852330|NCT06081504|RANDOMIZED|PARALLEL||TREATMENT||NONE||Forty-five patients of both sexes with healed LL burns will be allocated randomly into three groups: the Wii fit exercises group, the pilates exercises group, and the standard physical therapy group.||||
33852331|NCT04229992|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33852332|NCT01457547|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33852333|NCT03083353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study capsules will be prepared containing: (a) 15 mg immediate release isradipine or (b) pill placebo consisting of Avicel microcrystalline cellulose powder (non-digestible pass-through). Isradipine and placebo capsules will be identical in appearance to maintain the double-blind. Individual doses will be dispensed to participants by blinded personnel 75 m prior to the first cue exposure session and patients will be asked to remain in the clinic until session time.|Participants will be randomized to receive isradipine (ISR) or placebo (PBO).|t|t|t|t
33852334|NCT05172427|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two active conditions or a waitlist control condition. Participants assigned to the EMA/EMI condition will receive the intervention, following by two weeks of EMA with personalized EMI prompts sent to them based on their responses to the EMA questions. Participants assigned to the EMA condition will receive the intervention, followed by two weeks of EMA only (with no EMI prompts based on their responses). The waitlist control will not receive the intervention prior to completing two weeks of EMA, and will not receive EMI prompts based on their responses. Those in the waitlist control will be given the opportunity to receive the intervention at their one-month follow up appointment.||||
33852335|NCT04394208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1 (Control): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + placebo Group 2 (Intervention): Includes 25 patients with COVID-19 pneumonia receiving standard of care as per Ministry of Health Protocol of Treatment + Silymarin Oral at a dose of 420 mg/day in 3 divided doses.|t|t|f|f
33852336|NCT02389608|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33852337|NCT04463173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852338|NCT01481220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852339|NCT06132126|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33852340|NCT04684251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852341|NCT02173431|||COHORT||PROSPECTIVE|||||||
33852342|NCT00550082|||COHORT||PROSPECTIVE|||||||
33852343|NCT04722939|||COHORT||PROSPECTIVE|||||||
33746905|NCT03998618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Metastatic breast cancer patients (N = 250) will be randomly assigned in equal numbers to Acceptance and Commitment Therapy (ACT) or education/support using a stratified block randomization scheme to balance the groups by age (\<65 yrs. vs. 65+ yrs.) and performance status (patient-reported Eastern Cooperative Oncology Group \[ECOG\] scores 0 or 1 vs. 2).|f|f|f|t
33746906|NCT00890955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746907|NCT02469194|||COHORT||PROSPECTIVE|||||||
33746908|NCT00121238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852344|NCT00444899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852345|NCT05714748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852346|NCT03486847|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852347|NCT01452659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852348|NCT05187468|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33852349|NCT05234229|||COHORT||PROSPECTIVE|||||||
33852350|NCT05342909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors are blinded to group allocation.||f|f|f|t
33956295|NCT06248671|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple blind (blinded to patients, study personnel, and statistician).|Parallel group study with three arms, comparing Atorvastatin 20 mg and 40 mg against placebo. Each participant will receive 84 encapsulated tablets. The participant will take one capsule orally each day, preferably at the same time of the day.|t|t|f|t
33956296|NCT06410859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956297|NCT05681104|||OTHER||CROSS_SECTIONAL|||||||
33956298|NCT03154268|||COHORT||RETROSPECTIVE|||||||
33956299|NCT03348501|||COHORT||PROSPECTIVE|||||||
33956300|NCT06567665|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33956301|NCT06214780|||COHORT||RETROSPECTIVE|||||||
33746909|NCT05566301|||CASE_CONTROL||PROSPECTIVE|||||||
33956302|NCT01527786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746910|NCT05758064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060529|NCT04629924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The dental surgeon cannot, of course, be blind to the type of anesthesia. The subject may be kept blind to the type of anesthesia administered. This is the most important since the main criterion of judgment is a criterion reported by the patient (his or her pain during anesthesia). Similarly, the evaluator will be kept blind to the type of anesthesia administered.|"This is a multicentre, randomized, split-mouth, randomized controlled trial in which the experimental and control anesthetic systems will be randomly assigned to the teeth (randomization unit) of the tooth pair. controlerals considered in the same patient. This design allows a gain in power, each subject being its own witness without any carry-across effect, the two treatments being separated by one to two weeks (split-mouth cross-over)."|t|f|f|t
34060530|NCT06730997|||OTHER||RETROSPECTIVE|||||||
34060531|NCT05910060|||CASE_CONTROL||RETROSPECTIVE|||||||
33852351|NCT05505110|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Participants, the principal investigator, co-investigators, data manager, and the lead biostatistician will be blinded to the actual group assignment until all statistical analyses of the data required to meet the primary and co-primary endpoints have occurred. The Data and Safety Monitoring Board will remain unmasked to actual group allocation throughout the pre-specified blinding period.|This is a single-center, parallel-arm, blind, sham-controlled, feasibility RCT to be conducted in healthy cesarean-born infants.|t|t|t|t
33852352|NCT00289432|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33956303|NCT06566547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956304|NCT01327989|||COHORT||PROSPECTIVE|||||||
33956305|NCT04051840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956306|NCT03246321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956307|NCT03883789|||OTHER||PROSPECTIVE|||||||
33956308|NCT03107442|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33956309|NCT05501002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956310|NCT03310606|NA|SINGLE_GROUP||OTHER||NONE||||||
33956311|NCT03112707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956312|NCT01224418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956313|NCT00265239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956314|NCT06389240|||COHORT||PROSPECTIVE|||||||
33956315|NCT00638118|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33956316|NCT04256135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||It is an experimental, prospective, parallel and longitudinal double-blind study with elderly patients with knee osteoarthritis|t|f|t|t
33956317|NCT02964910|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956318|NCT01591902|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33956319|NCT05559242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956320|NCT06162117|||CASE_ONLY||CROSS_SECTIONAL|||||||
33956321|NCT01807780|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956322|NCT00363428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956323|NCT00241319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33956324|NCT02007512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956325|NCT03540446|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33956326|NCT06369792|||COHORT||PROSPECTIVE|||||||
33956327|NCT06030947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956328|NCT05271526|||CASE_CONTROL||PROSPECTIVE|||||||
33956329|NCT04166851|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33956330|NCT03872622|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956331|NCT03507608|RANDOMIZED|PARALLEL||TREATMENT||NONE||The initial phase is a 6-patient single-arm run-in phase to test feasibility and rule out futility of the intervention. All patients within the run-in phase will receive 50mg flutamide prior to brachytherapy and prostatic biopsy. If futility is ruled out (\>1 patients with DSBs on biopsy), then accrual will continue in the randomized in a 2:1 ratio (12:6 patients), for an all-trial total of 18 patients receiving flutamide vs 6 patients receiving placebo.||||
33956332|NCT04361552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956333|NCT03878056|||COHORT||PROSPECTIVE|||||||
33956334|NCT06565520|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33956335|NCT04736576|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33956336|NCT02393066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956337|NCT06562075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746911|NCT00846664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746912|NCT03157986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33746913|NCT06635330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746914|NCT05695183|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33746915|NCT02001480|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33746916|NCT06518577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746917|NCT00987467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956338|NCT02015286|||COHORT||OTHER|||||||
34060532|NCT00629876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060533|NCT00248833|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|The first 2 cohorts were double blind, and the third cohort was not blinded. The investigator preparing the vaccine did not participate in making subsequent study assessments or subject evaluability decisions. After the vaccine was prepared, the subject's identification number was placed onto the drawn syringe. All information, vaccine dose, adjuvant dose (if applicable), and subject identification number, was recorded on the Vaccine Administration Code Form. The form was placed in an envelope. The envelope was sealed and placed in a secured location. The medical personnel who vaccinated the subjects witnessed the dilution and placement of the subject identification number on the syringe. This staff member vaccinated the subject but did not participate in subsequent study visits or the evaluation. The blind was broken after verification that all serology testing was completed.|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). Two dosage levels were investigated: 25 µg with and without adjuvant and 50 µg of protein without adjuvant. Each dose was given intramuscularly at 0, 6, and 24 weeks.|t|t|t|t
34060534|NCT00002266||||TREATMENT||NONE||||||
34060535|NCT02460523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060536|NCT05983172|||COHORT||OTHER|||||||
34060537|NCT05735912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060538|NCT05307796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060539|NCT03180424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060540|NCT02707315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060541|NCT00568139|||COHORT||OTHER|||||||
34060542|NCT03678896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060543|NCT05941741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060544|NCT04604405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060545|NCT06133946|||COHORT||PROSPECTIVE|||||||
34060546|NCT03897114|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Cocoa and maltodextrin (placebo) are provided in identical sachets which are identified just with the letters A and B.|Double blind placebo controlled study|t|f|t|f
34060547|NCT00564044|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34060548|NCT01821209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060549|NCT04850573|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be randomly assigned to an equine assisted activities intervention or wait-listed control for eight weeks. At the end of the eight week period, participants assigned to the wait-listed control will be offered the opportunity to participate in the equine assisted activities intervention.||||
34060550|NCT00432796|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34060551|NCT05526222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852353|NCT05077644|NA|SINGLE_GROUP||TREATMENT||NONE||Data from 65 participants (n=50 in this extended study of a piloted user study) will be collected and analyzed to assess the user experience of the Stella (TM) App. Participants will be selected if they have given birth in the four months prior to the study start date, meet eligibility criteria and and have mild-to moderate postpartum depression or have experienced depressive||||
33746918|NCT03652753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852354|NCT02181387|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33852355|NCT00383136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852356|NCT03656237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Cluster Randomized Trial (Clusters are the community health units - CSCOMs)|f|f|t|t
33852357|NCT00265421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852358|NCT02464150|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852359|NCT00050037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852360|NCT03944473|RANDOMIZED|PARALLEL||OTHER||DOUBLE|On the day of surgery, an envelope containing the randomization code will be given to an anesthesiology physician or nurse anesthetist responsible for the clinical care of the study patient. Patients will be randomly allocated to receive neostigmine or sugammadex using a 1:1 allocation ratio. Patients will be stratified based on their ASA physical score. A research associate who is not directly involved with the study procedures will maintain the randomization codes. All others will be blinded||t|f|t|f
33746919|NCT01585103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746920|NCT01277965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33746921|NCT02504294|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746922|NCT03019536|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33852361|NCT04684602|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, prospective, open label clinical trial. It will include 5000 patients suffering acute and chronic conditions under 10 different categories. Patients will undergo a single treatment with a biological tissue allograft and will be followed for 12 months.||||
33852362|NCT04643522|||COHORT||RETROSPECTIVE|||||||
33765506|NCT03129529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33765507|NCT04999371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765508|NCT02773680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765509|NCT02055937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765510|NCT02266602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765511|NCT01187329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852363|NCT00006260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852364|NCT00509808|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33852365|NCT01457326|||CASE_CONTROL||PROSPECTIVE|||||||
33852366|NCT01201733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852367|NCT05333679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852368|NCT02572882|NA|SEQUENTIAL||OTHER||NONE||This is a sequential trial that included three sequential phases: 1. Pre-treatment phase: 8 weeks during which no treatment was administered 2. p-Inulin phase: 12 weeks during which p-inulin was administered 8g orally twice daily 3. Post-treatment phase: 8 weeks during which no treatment was administered. Eleven of the 13 participants in the p-inulin phase entered the post-treatment phase. The other two withdrew prior to the post-treatment phase.||||
33852369|NCT00711932|||COHORT||CROSS_SECTIONAL|||||||
33852370|NCT00613119|||||PROSPECTIVE|||||||
33852371|NCT05182281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852372|NCT02534454|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33852373|NCT05536752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060552|NCT03662113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33852374|NCT04537559|||COHORT||RETROSPECTIVE|||||||
33852375|NCT03197779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852376|NCT05026333|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blind to which stress/anxiety group they belong to. Researchers will not be blind to the group assignment as group assignment is part of the eligibility criteria for inclusion/enrollment in the study.|2 groups (high stress/anxiety compared to low stress/anxiety) will be compared on their performance on within laboratory stress and cognitive tasks (4 different tests).|t|f|f|f
33852377|NCT02277002|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33852378|NCT04267302|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852379|NCT02761161|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33852380|NCT02315352|RANDOMIZED|CROSSOVER||||NONE||||||
33852381|NCT03541174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Study with multiple periods and parts.~Once eligibility is confirmed during screening and the run-in period, the individuals entered the randomized treatment period consisting of 3 parts: Part 1: double-blind (DB), randomized to aprocitentan 12.5 mg, aprocitentan 25 mg or placebo; Part 2 single-blind (SB) aprocitentan 25 mg; Part 3: double-blind withdrawal (DB-WD) re-randomized to aprocitentan 25 mg or placebo."|t|t|t|f
33852382|NCT00056485|RANDOMIZED|PARALLEL||OTHER||NONE||This was a pilot feasibility study; the first part was a single group; the second part was a two-group randomized design.||||
33852383|NCT00585416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852384|NCT02560714|||COHORT||PROSPECTIVE|||||||
33852385|NCT05801744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852386|NCT04283331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The laser vision technician will be the only member aware of which eye received the control vs intervention treatment.||t|t|t|t
33852387|NCT01530451|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33852388|NCT00549783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852389|NCT01067560|||||PROSPECTIVE|||||||
34060553|NCT04934176|||CASE_ONLY||PROSPECTIVE|||||||
33852390|NCT02690922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852391|NCT02721173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852392|NCT00003232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852393|NCT01321151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852394|NCT04002193|||CASE_ONLY||PROSPECTIVE|||||||
33852395|NCT05839496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852396|NCT03876132|||OTHER||PROSPECTIVE|||||||
33852397|NCT00003424|RANDOMIZED|||TREATMENT||||||||
33852398|NCT03566654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852399|NCT06109025|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33852400|NCT05315882|||COHORT||RETROSPECTIVE|||||||
33852401|NCT00126373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852402|NCT02679573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852403|NCT03575988|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33852404|NCT01195051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852405|NCT00321373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33852406|NCT05811923|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|All supplements provided to all research participants containing Caffeine, Paraxanthine, 1-Methylxanthine, or Placebo will be procured and prepared in a similar manner. All supplements are in identical capsules.|Using a randomized, double-blind, placebo-controlled, crossover study design. to ingest one of seven supplement conditions. One condition will be a non-energetic placebo (maltodextrin) while the other six supplemental conditions will be a 200 mg dose of caffeine, 100 mg paraxanthine, 200 mg paraxanthine, 300 mg paraxanthine, a combination of caffeine (200 mg) + paraxanthine (200 mg), and a 200 mg dose of 1-methylxanthine. All supplements will be orally ingested with 8 fluid ounces of cold tap water.|t|f|t|f
34164566|NCT02644317|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34164567|NCT03871426|||COHORT||PROSPECTIVE|||||||
34164568|NCT04663503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164569|NCT00234923|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33852407|NCT00142077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33852408|NCT02323282|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33852409|NCT04061447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852410|NCT01762501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852411|NCT05492461|||OTHER||PROSPECTIVE|||||||
33852412|NCT00038168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852413|NCT01795027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852414|NCT01567579|||CASE_ONLY||PROSPECTIVE|||||||
33852415|NCT02729831|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852416|NCT01513577|RANDOMIZED|PARALLEL||||NONE||||||
33852417|NCT04729998|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33852418|NCT04706767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852419|NCT00640133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852420|NCT00563888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852421|NCT00411060|||OTHER||PROSPECTIVE|||||||
33852422|NCT02877238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33852423|NCT00407576||||TREATMENT||||||||
34060554|NCT04673656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34060555|NCT02569086|||CASE_ONLY||PROSPECTIVE|||||||
34060556|NCT00970099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060557|NCT03729414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|long term outcome will be evaluated by a third observer unaware of the type of surgery performed|Prospective, multi-centre, parallel-arm randomized controlled equivalence trial. Eligible patients will be randomized to either mucopexy without Doppler guided artery ligation or mucopexy with doppler guided hemorroidal artery ligation.|f|f|f|t
34164570|NCT00790192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164571|NCT02089594|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Neuropsychological testers and neuropsychologist blinded to treatment group.|Randomized prospective controlled|f|f|t|f
34164572|NCT04416048|RANDOMIZED|PARALLEL||PREVENTION||NONE|Central randomization will be implemented in this study. Subjects will be randomly assigned to 1 of 2 treatment groups based on a computer-generated randomization schedule prepared before the study under the supervision of the sponsor. The randomization will be stratified by site, gender, age, kidney function (subjects with eGFR ≥30 mL/min/1.73m2 and \<50 mL/min/1.73m2 versus subjects with eGFR ≥50 mL/min/1.73m2), history of CAD or heart failure and oxygen demand on admission to the hospital. The computer system will assign a unique treatment code, which will dictate the treatment assignment and study drug kits for the subject. The requestor must use his or her own user identification and personal identification number when contacting the system and will then give the relevant subject details to uniquely identify the subject.|A multicenter, prospective, randomized, event-driven study.||||
34164573|NCT03593057|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34164574|NCT03153475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164575|NCT05350163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The model is both parallel and sequential, in that Matched and Mismatched strata run in parallel and independently. Within each stratum, Cohorts I-III are filled sequentially. In addition, Cohort I of each stratum has three groups (A-C) that are filled sequentially.||||
34164576|NCT00746616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164577|NCT05911269|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Explanatory-Sequential Mixed Methods Study||||
34164578|NCT03971565|||OTHER||PROSPECTIVE|||||||
34164579|NCT01398826|||CASE_CONTROL||PROSPECTIVE|||||||
34164580|NCT04854551|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|capsule, double blind|Participants will be counterbalanced for the order they undergo placebo and medication.|t|f|t|t
34164581|NCT06723444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164582|NCT01929382|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34164583|NCT04984486|||OTHER||CROSS_SECTIONAL|||||||
34164584|NCT00004936||||DIAGNOSTIC||||||||
34164585|NCT00108771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164586|NCT04661436|||COHORT||PROSPECTIVE|||||||
34164587|NCT03169335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164588|NCT03863665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers undertaking the neuroimaging analysis are masked to the treatment allocation.|Patients will be randomised in a 1:1 ratio to intervention or control arms of the study. Participants and their physicians will not be blinded to study arm allocation|f|f|t|t
34164589|NCT00561288|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34164590|NCT00936806|||CASE_CONTROL||PROSPECTIVE|||||||
34164591|NCT00991653|||COHORT||CROSS_SECTIONAL|||||||
34164592|NCT04496856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34164593|NCT05729932|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34164594|NCT05863884|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164595|NCT03044366|||CASE_CONTROL||RETROSPECTIVE|||||||
34164596|NCT03648294|||CASE_ONLY||RETROSPECTIVE|||||||
34164597|NCT01633541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164598|NCT00575965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164599|NCT04583995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34164600|NCT06278766|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164601|NCT03728543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34164602|NCT02743455|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34164603|NCT02766634|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34164604|NCT05203952|||COHORT||PROSPECTIVE|||||||
34164605|NCT05775016|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Intervention will be blinded to both participant and investigators|This study will be conducted using a double-blind, placebo-controlled, parallel group design.|t|f|t|f
34164606|NCT04034303|||COHORT||PROSPECTIVE|||||||
34164607|NCT03510442|||COHORT||PROSPECTIVE|||||||
34164608|NCT01126723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164609|NCT05094648|||COHORT||PROSPECTIVE|||||||
34164610|NCT03398707|||COHORT||PROSPECTIVE|||||||
34164611|NCT04339621|||CASE_CONTROL||PROSPECTIVE|||||||
34164612|NCT01135615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34164613|NCT03093337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164614|NCT01189474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164615|NCT06540963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164616|NCT02011100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34164617|NCT03115762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164618|NCT00172211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164619|NCT06264999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34164620|NCT03554928|||COHORT||PROSPECTIVE|||||||
34164621|NCT00277550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164622|NCT05947617|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study follows a dose-escalation design where participants are enrolled in sequential cohorts receiving escalating doses of VIX001 (1 ml, 3 ml, or 10 ml). This suggests a sequential approach in terms of dose administration within the study.||||
34164623|NCT01559272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164624|NCT06709898|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized clinical trial||||
34164625|NCT02058446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164626|NCT06525779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34164627|NCT03981679|NA|SINGLE_GROUP||SCREENING||NONE||||||
34164628|NCT02905500|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34164629|NCT06725628|||COHORT||PROSPECTIVE|||||||
34164630|NCT06725732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34164631|NCT02278926|||CASE_CONTROL||RETROSPECTIVE|||||||
34164632|NCT02938208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164633|NCT03273335|||COHORT||PROSPECTIVE|||||||
34164634|NCT05263414|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34164635|NCT03571555|||COHORT||PROSPECTIVE|||||||
34164636|NCT02351765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164637|NCT00099138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34164638|NCT02386982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164639|NCT00679835|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852424|NCT00954486|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164640|NCT06368791|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164641|NCT00797849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34164642|NCT02482116|||COHORT||PROSPECTIVE|||||||
34164643|NCT02517541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164644|NCT01398371|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34164645|NCT04487314|||COHORT||PROSPECTIVE|||||||
33852425|NCT02857166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852426|NCT06370533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33852427|NCT04001231|NA|SINGLE_GROUP||OTHER||NONE|Open-label Study|Single group||||
33852428|NCT04184739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33852429|NCT06415565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852430|NCT01717092|||COHORT||PROSPECTIVE|||||||
33852431|NCT01000285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852432|NCT02938260|||COHORT||RETROSPECTIVE|||||||
33852433|NCT06106932|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||This was a prospective randomized follow up study with analysis of ovarian samples derived from GnRH agonists-treated and non-treated women before surgery. The randomization was performed by accessing a central internet-based randomization program. The random allocation sequence and the assignment of the participants to interventions were made by 2 of the authors \[A.K. and S.K\].|t|f|f|f
33852434|NCT04020627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852435|NCT00109382|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33852436|NCT05143983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects masked from the study hypothesis.|Two groups of participants will be recruited: depressed patients and healthy controls. Each of these groups will be divided in two arms: one group listening to positive music at the first testing visit and neutral music at the second one, and the other group being exposed to positive and neutral conditions in the reverse order.|t|f|f|f
33852437|NCT05088018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852438|NCT01798251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852439|NCT03773315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852440|NCT01036763|||||PROSPECTIVE|||||||
33852441|NCT04727892|||CASE_ONLY||RETROSPECTIVE|||||||
33852442|NCT05235204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852443|NCT05690113|||OTHER||PROSPECTIVE|||||||
33852444|NCT03607422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852445|NCT02785510|||CASE_ONLY||CROSS_SECTIONAL|||||||
33852446|NCT05319782|NA|SINGLE_GROUP||OTHER||NONE||||||
33852447|NCT01159587|||COHORT||PROSPECTIVE|||||||
33852448|NCT03765099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33852449|NCT00122915|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33852450|NCT04705129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852451|NCT01365832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852452|NCT04049799|||COHORT||PROSPECTIVE|||||||
33852453|NCT03910751|||COHORT||PROSPECTIVE|||||||
33852454|NCT02903173|||COHORT||PROSPECTIVE|||||||
34060558|NCT06254508|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33852455|NCT04147078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852456|NCT01598311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852457|NCT01874431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852458|NCT00672893|||||PROSPECTIVE|||||||
33852459|NCT02330146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852460|NCT05129553|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33852461|NCT03293641|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Pilot Trial in which children aged 6 months to less than 13 years were randomized on a ration of 1:1 to receive the Zinc plus Standard of Care versus Standard of Care Management for Sickle Cell Disease||||
33852462|NCT01998087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33852463|NCT04886895|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort||||
33852464|NCT02797574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852465|NCT01970345|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852466|NCT00467168|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33852467|NCT01503853|||||PROSPECTIVE|||||||
33852468|NCT06153927|||COHORT||RETROSPECTIVE|||||||
33852469|NCT01561404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060559|NCT00866567|||COHORT||PROSPECTIVE|||||||
34060560|NCT01786538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060561|NCT06730477|||COHORT||OTHER|||||||
34060562|NCT05900336|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34060563|NCT01956461|||CASE_ONLY||PROSPECTIVE|||||||
34060564|NCT06173804|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A pre-post-test study to assess the implementation outcomes and preliminary health responses||||
34060565|NCT00505661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060566|NCT03724851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060567|NCT06057714|||CASE_ONLY||CROSS_SECTIONAL|||||||
34060568|NCT04093791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly divided in three groups: the one that will follow the collective intervention (G); the one that will follow the Individual Intervention (I) and the control group, that will receive no intervention (C)||||
34060569|NCT05240469|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
34060570|NCT05267223|||OTHER||PROSPECTIVE|||||||
34060571|NCT06620185|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34060572|NCT00969670|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34060573|NCT00061373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060574|NCT03667417|||COHORT||PROSPECTIVE|||||||
34060575|NCT00311636|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34060576|NCT01663194|||COHORT||PROSPECTIVE|||||||
34060577|NCT05415332|||COHORT||OTHER|||||||
34060578|NCT04973241|||COHORT||CROSS_SECTIONAL|||||||
34060579|NCT04779606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060580|NCT01474031|||COHORT||PROSPECTIVE|||||||
33852470|NCT00201994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852471|NCT01345773|||COHORT||PROSPECTIVE|||||||
33852472|NCT03868605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852473|NCT06502912|||COHORT||RETROSPECTIVE|||||||
33852474|NCT02504515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852475|NCT03224923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33852476|NCT05636605|||COHORT||OTHER|||||||
33852477|NCT05071196|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled, prospective clinical trial||||
33852478|NCT05191992|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33852479|NCT01934361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852480|NCT00626678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33852481|NCT00372229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852482|NCT06056232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33852483|NCT04694430|||CASE_ONLY||CROSS_SECTIONAL|||||||
33852484|NCT00067509|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33852485|NCT00140192|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33852486|NCT04600154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852487|NCT06376123|||CASE_ONLY||PROSPECTIVE|||||||
33852488|NCT04558749|||OTHER||CROSS_SECTIONAL|||||||
33852489|NCT02390050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852490|NCT05025202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the sham intervention group were not aware they they were not performing the IET intervention.||t|f|f|f
33852491|NCT01207037|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852492|NCT03533985|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Parents of infants will be unaware of the interventions' effects. Outcomes Assessor will be unfamiliar with desired outcomes.|Counterbalancing will be achieved by assigning a different order of presentation of conditions for each group. Participants will remain in the study for two weeks, but continue to receive music therapy for the duration of their stay in the NICU.|t|f|f|t
33852493|NCT04578782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852494|NCT05180188|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The crossover trial has a two-period design. In the first study period, participants will not be exposed to any intervention and will be advised to not start any new medications, diets or participate in any activities which could influence their health. In the second period, participants will perform regular moderate-intensity exercise 3 times/week. Both study periods will last 8 weeks.||||
33956339|NCT06700902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 60 students will be enrolled in the study per semester, 30 of whom will be randomized to Taking Action and 30 to the control condition. Enrollment will occur over a period of 5 semesters, with two Taking Action groups running concurrently each semester. Randomization will occur at the participant-level and will be facilitated by using an HIPAA-compliant, Internet-based randomization service (studyrandomizer.com). The research assistant, who will be blind to the random allocation sequence, will enter participants into the randomization service after completion of the baseline interview and notify them of the condition to which they are assigned.||||
33956340|NCT01033175|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33956341|NCT02682069|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33956342|NCT03829020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956343|NCT03022799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33956344|NCT03853980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956345|NCT00836238|||COHORT||PROSPECTIVE|||||||
33956346|NCT03823859|||COHORT||PROSPECTIVE|||||||
33956347|NCT06703437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956348|NCT06529250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956349|NCT02599350|||COHORT||PROSPECTIVE|||||||
33956350|NCT02539979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956351|NCT04078893|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33956352|NCT05566730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956353|NCT04708782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956354|NCT03911882|||COHORT||PROSPECTIVE|||||||
33956355|NCT03303820|||COHORT||RETROSPECTIVE|||||||
33956356|NCT06565533|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 45 students were randomly selected from South China Normal University. Of these selected students, 15 were randomly assigned to Intervention Group 1 (RETI), 15 to Intervention Group 2 (VR), and the remaining 15 to the control group.||||
34060581|NCT05110521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060582|NCT01071239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060583|NCT02893904|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34060584|NCT04457947|||OTHER||PROSPECTIVE|||||||
34060585|NCT03013764|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34060586|NCT03849963|||CASE_ONLY||PROSPECTIVE|||||||
34060587|NCT00631085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34060588|NCT01298141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060589|NCT02961062|NA|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34060590|NCT06354907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To minimize the possibility of a breach in confidentiality, each child's and parent's information is protected with a code number that will be associated with all of their study materials instead of their name. All identifying information is stored in a separate locked cabinet in the office of Dr. Graham-Bermann. All other study materials (without names) will be kept in a locked cabinet in the research laboratory of Dr. Graham-Bermann to maintain privacy.|Two groups of children and their parent will be compared and evaluated twice (twelve weeks apart). The first group (approximately half of the sample) will participate in the Kids' Empowerment Program in their classroom and their parent will complete assessments online. The second group will complete both assessments and then receive the program in their classroom after the 12 week interval.|t|f|f|f
34060591|NCT04605432|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34060592|NCT05024981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060593|NCT00081796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060594|NCT02290600|||COHORT||PROSPECTIVE|||||||
34060595|NCT00421265|||DEFINED_POPULATION||PROSPECTIVE|||||||
34060596|NCT00299559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060597|NCT02824536|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34060598|NCT02406300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060599|NCT00426777|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34060600|NCT02223325|||CASE_CONTROL||PROSPECTIVE|||||||
34060601|NCT02096068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060602|NCT06730867|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060603|NCT03152825|||COHORT||PROSPECTIVE|||||||
34060604|NCT04096794|||CASE_ONLY||PROSPECTIVE|||||||
34060605|NCT06121882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor) Sponsor, Investigator, Participant are blinded. Unblinded operator will perform procedure.||t|f|t|t
34060606|NCT02386345|||CASE_ONLY||OTHER|||||||
34060607|NCT00067769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060608|NCT00481767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34060609|NCT03600246|||COHORT||PROSPECTIVE|||||||
34164646|NCT04799249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind Trial||t|f|t|f
34164647|NCT00187252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34164648|NCT05943886|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34164649|NCT06514781|||COHORT||RETROSPECTIVE|||||||
34164650|NCT03007914|||COHORT||PROSPECTIVE|||||||
34164651|NCT01459445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164652|NCT03362749|||CASE_ONLY||PROSPECTIVE|||||||
34164653|NCT02665182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34164654|NCT01361646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164655|NCT01748838|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34164656|NCT03166241|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164657|NCT03221686|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164658|NCT01362881|||COHORT||PROSPECTIVE|||||||
34164659|NCT04892082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind - the investigator is unaware of the intervention assignment|Parallel Assignment - Participants are being randomized to intervention or control groups at a 1:1 ratio|f|f|t|f
34164660|NCT06725641|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34164661|NCT01727596|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
34164662|NCT05066165|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164663|NCT02801565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164664|NCT06346574|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be educators at Head Start centers where either the intervention is offered at the onset of the study (intervention group) or after six months (comparison condition).||||
34164665|NCT04950465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164666|NCT05184517|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blinded, participant and Outcome Assessors are blinded to the intervention||t|f|f|t
34164667|NCT05864144|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164668|NCT04775953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164669|NCT00193817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164670|NCT00587678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164671|NCT00061893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164672|NCT04653285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164673|NCT06343727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This trial is an open-label randomized controlled parallel arm feasibility tria|f|f|f|t
34164674|NCT01789684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34164675|NCT02466984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164676|NCT06170853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164677|NCT04887324|||COHORT||RETROSPECTIVE|||||||
34164678|NCT01054482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164679|NCT03650088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164680|NCT04555564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm, prospective, single-center||||
34164681|NCT00984308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164682|NCT00557999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164683|NCT00002306||||TREATMENT||||||||
34164684|NCT04120415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164685|NCT05959460|||COHORT||PROSPECTIVE|||||||
34164686|NCT02737579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164687|NCT00836992|||CASE_CONTROL||PROSPECTIVE|||||||
33956357|NCT05673915|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956358|NCT06406894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852495|NCT05589168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956359|NCT04671329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956360|NCT01169831|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33956361|NCT01501071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852496|NCT04695743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956362|NCT06702020|||COHORT||RETROSPECTIVE|||||||
33956363|NCT06470087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956364|NCT03862807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956365|NCT03296059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956366|NCT05907044|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956367|NCT06567730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956368|NCT04785651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956369|NCT01155258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956370|NCT05682352|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33956371|NCT03538314|NA|SINGLE_GROUP||TREATMENT||NONE||UV1/GM-CSF||||
33956372|NCT04388085|||COHORT||PROSPECTIVE|||||||
33956373|NCT01637207|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33956374|NCT04708626|||COHORT||RETROSPECTIVE|||||||
34060610|NCT04375813|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Once the list is generated, a non-study staff member will deliver the list to the designated pharmacist. The pharmacist will follow the generated list in consecutive order of enrollment to determine which group the subject will be assigned. The pharmacist will prepare the correct study drug (Placebo or eRapa (encapsulated rapamycin) 0.5 mg) and label the drug with subject information. Research staff will transport drug from pharmacy to clinic and provide for subject. Randomization will remain double blinded for study staff and subject. Patients will be given a once-daily oral eRapa (encapsulated rapamycin) at 0.5 mg or placebo MF for 1 year. Once the primary objectives have been met (i.e., all participants have completed follow up), the study staff and PI will be unblinded to the randomized study treatment arms. The above mentioned generated randomization list with subject assignments will be provided to the study staff and PI by the designated pharmacist.|This is a multi-site phase II double-blind randomized trial. Subjects will be randomized into placebo arm or intervention arm with low dose (0.5 mg) eRapa (encapsulated rapamycin) Monday-Friday for one year or until disease recurrence. Patients will undergo endoscopic evaluation of the bladder every 3 months for 2 years, then every 6 months for 2 years, and at year 5. Some patients may also concurrently receive BCG immune therapy maintenance (weekly for 6 weeks for induction period, weekly for 3 weeks at 3 months, 6 months, and then every 6 months for a total of 7 maintenance cycles following tumor removal) per standard of care. Patient-reported outcome assessments, cognitive assessments, and physical assessments will be completed according to the study calendar. Research blood to assess safety, immune response and rapamycin level will be collected regularly throughout the study period. Participants will be followed for up to 5 years following enrollment.|t|f|t|f
34060611|NCT03242187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060612|NCT00273468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060613|NCT01589107|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34060614|NCT05576441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852497|NCT03384901|||CASE_ONLY||RETROSPECTIVE|||||||
33852498|NCT02482077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852499|NCT00002448||PARALLEL||TREATMENT||||||||
33852500|NCT01148914|||CASE_CONTROL||PROSPECTIVE|||||||
33852501|NCT00174096|||NATURAL_HISTORY||RETROSPECTIVE|||||||
33852502|NCT03939091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852503|NCT02269332|||CASE_CONTROL||PROSPECTIVE|||||||
33852504|NCT06118996|NA|SINGLE_GROUP||OTHER||NONE||||||
33852505|NCT04196101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852506|NCT05346133|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852507|NCT00504660|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852508|NCT00126893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852509|NCT02034370|||CASE_CONTROL||PROSPECTIVE|||||||
33852510|NCT05778344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852511|NCT05367232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852512|NCT01783847|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33852513|NCT00584649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852514|NCT03141385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33852515|NCT01775267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852516|NCT02630693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956375|NCT06219135|||COHORT||PROSPECTIVE|||||||
33956376|NCT02191930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956377|NCT04924738|||COHORT||PROSPECTIVE|||||||
33956378|NCT06058598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33956379|NCT01692470|||CASE_ONLY||PROSPECTIVE|||||||
33956380|NCT03037918|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Participants will be given a unique identifier, which will not disclose the treatment group. All biological samples will be labelled with only the unique identifier.|Open label, control trial||||
33956381|NCT01419028|||COHORT||RETROSPECTIVE|||||||
33956382|NCT04496765|||COHORT||RETROSPECTIVE|||||||
33956383|NCT05918952|||COHORT||PROSPECTIVE|||||||
33956384|NCT05655494|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study Team will recruit an ethnically diverse sample of eligible patients N = 350 (approximately 88 White/non-Hispanic participants, 88 White/Hispanic participants, 88 Black/non-Hispanic participants, and 88 Black/Hispanic participants), evenly distributed across Black/African-American, Hispanic/Latino, and white to complete the intervention.||t|f|f|f
34164688|NCT02421796|||CASE_CONTROL||PROSPECTIVE|||||||
34164689|NCT00286494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164690|NCT03679728|||OTHER||CROSS_SECTIONAL|||||||
34164691|NCT02650089|RANDOMIZED|CROSSOVER||||NONE||||||
34164692|NCT04557540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164693|NCT04991675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were randomized into two groups: pelvic floor muscle exercises (Group PFM n=20) and diaphragmatic breathing exercises (Group DB n=20). Exercise programs consisted of 1 set of contractions per day and each set included 30 repetitions for 6 weeks. Women were asked to complete forms of Incontinence Impact Questionnaire (IIQ-7) and the Urogenital Distress Inventory (UDI-6), Incontinence Quality of Life (I-QOL), and Overactive Bladder (OAB-V3) before starting the program and again at the end of the 6-week program. Changes from baseline were compared in both groups and between the two groups.||||
34164694|NCT03288571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164695|NCT00998140|||COHORT||OTHER|||||||
33746923|NCT05645588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Therapists (Care Provider) could not be blinded according to the nature of the intervention. However, therapists will be blinded to allocation concealment as they do not be aware of the patients' group assignment at baseline assessment until they open the opaque randomization envelope, which contains the patient randomization number and group assignment. The random sequence generation and the envelopes were prepared by the study coordinator who is not involved patient recruitment. Patients received post intervention questionnaires from a study assistant/nurse of the respective outpatient department (outcome assessor) who is also blinded to the patients' group assignment. After completing the questionnaires, the study assistant will sent them to study coordinator so that the therapist could not influence the patients' answers.||f|f|t|t
33746924|NCT01561248|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33746925|NCT02837341|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746926|NCT05553808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746927|NCT02987413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746928|NCT06669858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33746929|NCT05713318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746930|NCT04969250|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33746931|NCT04019847|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|t|f|f
33746932|NCT01758692|||CASE_CONTROL||PROSPECTIVE|||||||
33746933|NCT02288780|||COHORT||PROSPECTIVE|||||||
33765512|NCT06626178|NON_RANDOMIZED|PARALLEL||SCREENING||NONE|No blinding in this study|In the study are considered 4 different cohorts. Lung cancer patients diagnosed outside screening and treated at San Raffaele Hospital; smokers and former smokers aged over 50 years old at high risk for lung cancer, cardiovascular diseases and chronic obstructive pulmonary disease (COPD); subjects enrolled in previous screening cohorts in this Institute, which presented a computed tomography (CT) with the presence of lung nodules \>4 mm and to conclude, subjects enrolled in previous screening cohorts in this Institute, which presented a negative computed tomography (CT).||||
33765513|NCT06321978|||CASE_ONLY||OTHER|||||||
33765514|NCT04315025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765515|NCT01479413|||CASE_ONLY||PROSPECTIVE|||||||
33852517|NCT01871753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852518|NCT04619901|||COHORT||PROSPECTIVE|||||||
33852519|NCT06290674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masking (Investigator and Participant)|Clinical randomized controlled study|t|f|t|f
34164696|NCT06530212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34164697|NCT01233063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34164698|NCT04192955|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34164699|NCT00022802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34164700|NCT04626375|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34164701|NCT02756572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164702|NCT01120106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164703|NCT05154110|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34164704|NCT04459377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164705|NCT04037865|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164706|NCT00786318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164707|NCT04274868|||COHORT||OTHER|||||||
33852520|NCT03265938|||CASE_ONLY||PROSPECTIVE|||||||
33852521|NCT00538915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852522|NCT00219804|RANDOMIZED|PARALLEL||||DOUBLE||||||
33852523|NCT06357013|||COHORT||PROSPECTIVE|||||||
33852524|NCT02990312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852525|NCT00506987|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33852526|NCT04018599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33852527|NCT00081107||||TREATMENT||NONE||||||
33852528|NCT02977481|||OTHER||CROSS_SECTIONAL|||||||
33852529|NCT06227078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852530|NCT01018147|NA|SINGLE_GROUP||||NONE||||||
33852531|NCT04123574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852532|NCT03207100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study uses a single-blinded design in which only the investigators and not the subjects know the method of intervention.|Subjects are grouped into the analgesia-first minimal sedation group (experimental group) or antihypertensive drug treatment group (control group) using the central randomization system upon enrollment. Antihypertensive intervention is performed on the subjects in accordance to the protocol of each group.|t|f|f|f
33852533|NCT00851448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33852534|NCT00547820|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33852535|NCT00220467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33852536|NCT01739491|||COHORT||PROSPECTIVE|||||||
33852537|NCT00111215|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33852538|NCT03966807|||COHORT||PROSPECTIVE|||||||
33852539|NCT04728412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852540|NCT06270472|||COHORT||PROSPECTIVE|||||||
33852541|NCT00486460|RANDOMIZED|PARALLEL||||DOUBLE||||||
33852542|NCT03190447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852543|NCT05096585|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All subjects will complete 3 study conditions with a minimum of one week between each condition.||||
33852544|NCT06046963|NA|SINGLE_GROUP||TREATMENT||NONE|oepn label|||||
33852545|NCT00183001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852546|NCT00897312|||CASE_ONLY||PROSPECTIVE|||||||
33852547|NCT01011387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852548|NCT03310905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852549|NCT05584787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852550|NCT04539782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33852551|NCT00234767|||||PROSPECTIVE|||||||
33852552|NCT02202382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852553|NCT01377753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852554|NCT03705377|||OTHER||CROSS_SECTIONAL|||||||
33852555|NCT00834145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852556|NCT01088828|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33956385|NCT03361527|||OTHER||PROSPECTIVE|||||||
34164708|NCT03741504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34164709|NCT03425825|||COHORT||RETROSPECTIVE|||||||
34164710|NCT00260884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164711|NCT00592124|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34164712|NCT05607524|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34164713|NCT02588235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164714|NCT00002164||||TREATMENT||||||||
33852557|NCT05680038|||COHORT||PROSPECTIVE|||||||
33852558|NCT04870684|||CASE_ONLY||PROSPECTIVE|||||||
33852559|NCT01653067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852560|NCT00398645|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33852561|NCT03924908|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33852562|NCT02667587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852563|NCT04592042|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|A single group of patients will be enrolled in the study.||||
33852564|NCT00153062|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33852565|NCT02810548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852566|NCT00505284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852567|NCT01731509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852568|NCT02335710|||COHORT||RETROSPECTIVE|||||||
33852569|NCT05849987|||CASE_CROSSOVER||PROSPECTIVE|||||||
33852570|NCT06006689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852571|NCT02501798|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852572|NCT01248780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852573|NCT06171581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized control study|f|f|t|f
33852574|NCT04170673|||COHORT||PROSPECTIVE|||||||
33852575|NCT02112838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852576|NCT04690868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852577|NCT00933855|||COHORT||PROSPECTIVE|||||||
33852578|NCT05023603|||OTHER||CROSS_SECTIONAL|||||||
33852579|NCT00999674|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||||||||
33852580|NCT04171882|||COHORT||PROSPECTIVE|||||||
33852581|NCT02671370|||OTHER||CROSS_SECTIONAL|||||||
33852582|NCT00901186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852583|NCT01506609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852584|NCT02789046|||COHORT||PROSPECTIVE|||||||
33852585|NCT04961658|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A dose-escalation study evaluating GEM00220 cell therapy in 4 cohorts with 3 subjects per cohort. Study will proceed from lower dose to next higher dose if no safety concerns are observed in each cohort. If no safety issues are identified, we will continue to the Phase 1b trial.~Phase 1b: A single-arm, open-label extension of the Phase 1a trial to assess early signs of efficacy (major morbidity and mortality). The Phase 1b trial will enroll up to 9 participants."||||
33852586|NCT01828788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852587|NCT01869101|||CASE_CONTROL||PROSPECTIVE|||||||
33852588|NCT04932668|NA|SINGLE_GROUP||OTHER||NONE||To evaluate the feasibility and acceptability of a home-based NMES program on lower limb spasticity in patient with post-stroke||||
34164715|NCT01640782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164716|NCT02328248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164717|NCT06312735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164718|NCT04538976|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a multicenter controlled, randomized, open-lapel trial.||||
34164719|NCT03444493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Stabilizastion (exercise group) and control group||||
34164720|NCT01262859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164721|NCT02558855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164722|NCT05315479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164723|NCT01103765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164724|NCT06408571|||COHORT||RETROSPECTIVE|||||||
34164725|NCT03067246|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34164726|NCT01035671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164727|NCT03692039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the operator find an eligible participant, a phone call is made to the assistant supervisor to confirm the patient eligibility then to assign the participant to either group according to the generated random sequence.|Blocks of 4 are generated on a Microsoft Excel sheet where the intervention and control are denoted A \& B and randomly distributed. The table is kept with the assistant supervisor.|t|f|f|f
34164728|NCT05308979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel study with 2 arms, 1:1 randomization|t|f|f|f
34164729|NCT00980356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164730|NCT02727907|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34164731|NCT04713488|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956386|NCT02783508|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956387|NCT05460377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956388|NCT05043779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956389|NCT03273010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956390|NCT05131282|||CASE_CONTROL||PROSPECTIVE|||||||
33956391|NCT03761121|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33956392|NCT03286595|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33956393|NCT04907916|||OTHER||OTHER|||||||
33956394|NCT00537056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956395|NCT06567405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956396|NCT00880867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956397|NCT01870921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956398|NCT04479943|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||This study uses an incomplete stepped wedge cluster randomized controlled trial. In the incomplete stepped wedge design, inpatient units are randomly sequenced into the intervention. A baseline (control period) and 2 follow up data collection periods (intervention and post intervention period) occur for each unit. Incomplete stepped wedge cluster randomized trials are novel study designs that are particularly beneficial for evaluating service delivery interventions using a pragmatic design, when evaluations need to be completed at a system or population level, or it is impractical or cost prohibitive to roll out an intervention across multiple units simultaneously.|t|f|f|f
33956399|NCT03413722|||COHORT||PROSPECTIVE|||||||
33956400|NCT04117048|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients included benefit from at home INR measure||||
33956401|NCT06701552|||OTHER||CROSS_SECTIONAL|||||||
33956402|NCT06623006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956403|NCT06567197|||COHORT||PROSPECTIVE|||||||
33956404|NCT03505606|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33956405|NCT05193331|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective study||||
33956406|NCT04229758|RANDOMIZED|PARALLEL||PREVENTION||NONE||The trial will employ an innovative adaptive design using time as a dose (1, 2 and 4 weeks) and adapting randomization probabilities to the better performing doses with a PROBE model to minimize surveillance bias.||||
33956407|NCT06538714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33956408|NCT05416125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060615|NCT04438499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||There will be no control arm or blinding in this trial or inclusion of a sham or placebo, as it is not applicable to the study design.||||
34060616|NCT06531772|||CASE_CONTROL||PROSPECTIVE|||||||
34060617|NCT01890616|||CASE_ONLY||PROSPECTIVE|||||||
34060618|NCT06726837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will blinded to the group to which they will assigned, but the operator will aware of it. Outcome assessments will be performed by a investigator who was blinded to group allocation.||t|f|f|t
34060619|NCT06619886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060620|NCT06730256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060621|NCT05873335|NA|SINGLE_GROUP||OTHER||NONE||||||
34060622|NCT06451549|NA|SINGLE_GROUP||TREATMENT||NONE|As this is a single arm study, all participants will receive the intervention and no masking is required.|All participants will be given access to Syndi immediately||||
34060623|NCT06026176|||OTHER||CROSS_SECTIONAL|||||||
34060624|NCT00558051|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33765516|NCT01138930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956409|NCT06460298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study includes a dose escalation arm, followed by an expansion arm at the ideal dose for participants To estimate the objective response rate (ORR) of ProAgio in combination with gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.||||
33956410|NCT01523301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956411|NCT02093650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956412|NCT05649059|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33956413|NCT03544567|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33956414|NCT00869726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956415|NCT02428491|NA|SINGLE_GROUP||PREVENTION||NONE||Participants in this trial were randomized in a 1:1 ratio in 2 cohorts. All participants in both cohorts received Sanofi Pasteur's DTaP-IPV-HB-PRP\~T combined vaccine in a 3-dose Infant Series. Participants from Cohort 1 provided blood samples for immunogenicity assessment and were evaluated for safety and immunogenicity. Participants in Cohort 2 did not provide any blood samples for immunogenicity analysis and were evaluated for safety only.||||
33956416|NCT06567184|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956417|NCT02962115|NA|SINGLE_GROUP||SCREENING||NONE||||||
33956418|NCT04499391|RANDOMIZED|PARALLEL||PREVENTION||NONE||stratified cluster randomized design||||
33956419|NCT04784858|||COHORT||PROSPECTIVE|||||||
33956420|NCT02397083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956421|NCT03427788|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33956422|NCT03992612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956423|NCT05036447|RANDOMIZED|FACTORIAL||OTHER||SINGLE||Participants in both groups (patients and control) perform unilateral leg resistance exercise, contralateral leg serves as control|f|f|f|t
33956424|NCT05157529|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm investigational clinical trial assessing the efficacy and safety of the new generation of the AQUABEAM Robotic System (P1G3) and the Apogee 2300 Ultrasound System.||||
33956425|NCT06568445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956426|NCT01184781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060625|NCT06022042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study takes a single-blind method. During research process, the researchers cannot avoid knowing the type of abutment used by the subjects during the clinical examination and operation, so the subjects can only be single-blinded.The clinical examination data were measured and averaged by two independent clinicians. The data was analysed by a third person.|The researchers prospectively and continuously recruited subjects who underwent implant therapy in the Oral Implantation Center of the Stomatology Hospital Affiliated to Zhejiang University School of Medicine, and all subjects who signed written informed consent were divided into 8 groups by random number table method: ① On1 abutment + Nobel Replace Conical Connection PMC implant group (hereinafter referred to as Nobel PMC), ②On1 abutment + Nobel Parallel™ Conical Connection implant group (hereinafter referred to as Nobel PCC), ③On1 abutment + Nobel Replace Conical Connection implant group (Hereinafter referred to as Nobel CC), ④ One-stage abutment + Nobel PMC implant set, ⑤ One-stage abutment + Nobel PCC implant set, ⑥ One-stage abutment + Nobel CC implant set.|t|t|f|t
34060626|NCT00269100|||DEFINED_POPULATION||PROSPECTIVE|||||||
34060627|NCT00004759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060628|NCT02180802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34060629|NCT01432275|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34060630|NCT05795205|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34060631|NCT02818621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34060632|NCT02535234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060633|NCT00561470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060634|NCT00322127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060635|NCT04012281|||COHORT||PROSPECTIVE|||||||
34060636|NCT02671734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060637|NCT04405284|||COHORT||RETROSPECTIVE|||||||
34060638|NCT03182634|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34060639|NCT00877149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060640|NCT01764724|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34060641|NCT03525782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060642|NCT00000298||||TREATMENT||DOUBLE||||||
34060643|NCT05069311|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34060644|NCT04098445|||COHORT||PROSPECTIVE|||||||
34060645|NCT02882880|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34060646|NCT06509893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34060647|NCT00070213|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34060648|NCT05207904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060649|NCT02470819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164732|NCT00997282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164733|NCT04800848|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34164734|NCT05874284|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34164735|NCT01597635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164736|NCT04341714|||COHORT||PROSPECTIVE|||||||
34164737|NCT02320461|||COHORT||PROSPECTIVE|||||||
34164738|NCT02464618|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34164739|NCT02045095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060650|NCT02747849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060651|NCT06006013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060652|NCT04587401|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Patients with mental retardation, with brain tumor, head trauma, cerebral aneurysm, cerebrovascular accident, dementia, psychiatric disease, and carotid stenosis were excluded from the study.|Patients, aged between 18 and 85, who were scheduled for lumbar surgery under general anesthesia by neurosurgery department and were classified as Class I, II, and III according to the ASA (American Association of Anesthesiologists) classification, were included in the study.|t|t|f|f
34060653|NCT01004601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164740|NCT04693975|||OTHER||PROSPECTIVE|||||||
34164741|NCT04693559|RANDOMIZED|PARALLEL||OTHER||NONE||Patient will be randomized into to groups according to the surgical procedures performed as follow||||
34164742|NCT02041325|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34164743|NCT03158324|NA|SINGLE_GROUP||TREATMENT||NONE||Two parallel cohorts will be implemented: i. patients with tumors predicted to be dependent on oxidative phosphorylation metabolism or oncogene addicted tumors which have developed resistance to primary TKI therapy, or ii. patients with nasopharyngeal carcinoma||||
34164744|NCT04502641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164745|NCT01505517|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34164746|NCT01042925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164747|NCT02111330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164748|NCT03197584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164749|NCT00356681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164750|NCT05375448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164751|NCT04553900|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164752|NCT04393168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164753|NCT06106048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164754|NCT01403155|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164755|NCT01362348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164756|NCT06188026|NA|SEQUENTIAL||TREATMENT||NONE||single-centre, one-sequence cross-over, open-label study||||
34164757|NCT05394688|||COHORT||PROSPECTIVE|||||||
34164758|NCT05178277|||COHORT||PROSPECTIVE|||||||
34164759|NCT00692666|||||RETROSPECTIVE|||||||
34164760|NCT03571204|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34164761|NCT02238119|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34164762|NCT05188664|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study includes two stages, Phase I (Dose escalation) which includes LM-302 monotherapy dose escalation (part Ia) and LM-302 in combination with Toripalimab therapy dose escalation (part Ib) and Phase II (Dose expansion).||||
34164763|NCT04534686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164764|NCT05567250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34164765|NCT02038335|||COHORT||PROSPECTIVE|||||||
34164766|NCT06180044|||COHORT||PROSPECTIVE|||||||
34164767|NCT05878535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164768|NCT00006591||||TREATMENT||||||||
34164769|NCT00741975|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164770|NCT00567450|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34164771|NCT04354662|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, non-randomized, phase II clinical trial||||
34164772|NCT03800121|||COHORT||PROSPECTIVE|||||||
34164773|NCT02946034|NA|SINGLE_GROUP||TREATMENT||NONE||This a single-arm study. Initially, Viekira Pak was available through Abbvie. However, once Mavyret became available, it supplanted Viekira Pak as the study medication.||||
34164774|NCT01358825|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164775|NCT04830579|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34164776|NCT00725049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164777|NCT02634333|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34164778|NCT05993663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|Single intervention will be carried out for the 60 people who are part of the intervention groups, which will be 4 in total||||
34164779|NCT03079063|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blinding is performed by an independent third party operator (nurse/pharmacist, unblinded), who will prepare undistinguishable syringes with patient's dosing and labeling. Central lab operators will be blinded.|Randomized, single dose, double blinded, two-way cross-over study.|t|f|t|t
33765517|NCT00802555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765518|NCT04315532|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34060654|NCT00083668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060655|NCT01473394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060656|NCT06730750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060657|NCT00787917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164780|NCT06270485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164781|NCT04526912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164782|NCT04344275|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single (Participant)||t|f|f|f
34164783|NCT03315520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164784|NCT00808119|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34164785|NCT02442349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164786|NCT05367570|||CASE_CONTROL||PROSPECTIVE|||||||
34164787|NCT05193162|||OTHER||RETROSPECTIVE|||||||
34164788|NCT02742220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164789|NCT02485561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956427|NCT05860049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956428|NCT03576794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized, double-blind, placebo controlled treatment study during 12 months (part I) and an additional open-label follow-up of 12 months (part II).|t|t|f|f
33956429|NCT01757873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956430|NCT06006169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956431|NCT03902600|||CASE_ONLY||PROSPECTIVE|||||||
33956432|NCT05013749|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study as it is not possible to conceal the surgical procedure for each arm from the operator (Treating Physician) or from the participant|"Eligible women will receive complete information about the study. If they agree to participate in it, they will sign the informed consent for both interventions: hysterectomy and partial myometrial resection. The final modality of intervention will be decided at randomization prior to the start of the surgical procedure.~If the diagnosis of PAS is confirmed by observing the clinical criteria endorsed by the International Federation of Gynecology and Obstetrics (FIGO), the patient's participation in the study is confirmed and the surgical procedure defined by randomization is continued, that is, one of the two arms of the study: Primary hysterectomy or Partial myometrial resection."||||
33956433|NCT02392975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956434|NCT02866370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956435|NCT05917938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956436|NCT06362369|NA|SEQUENTIAL||TREATMENT||NONE|Phase 1b - Open Label|||||
33956437|NCT05760924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956438|NCT03026868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956439|NCT01388101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956440|NCT04574531|||OTHER||OTHER|||||||
33956441|NCT01396980|||COHORT||PROSPECTIVE|||||||
33956442|NCT06599047|||COHORT||CROSS_SECTIONAL|||||||
33956443|NCT05339542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||the study will include two groups. Group I (study group) will be injected PRP. Group II (control group) will be injected methylprednisolone|t|f|f|t
34060658|NCT03502018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, Investigator(s), outcome assessors will all be blinded throughout the duration of the trial. Care providers pre- and post- op will be blinded as well, the operative team will not be blinded.|There will be a total of 50 patients enrolled in this randomized blinded prospective two arm study. The participants will be randomized into either the control or the EXPAREL treatment group, with 25 patients in each cohort.|t|f|t|t
34060659|NCT04940715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment. Randomized, longitudinal, experimental, prospective, parallel and double-blind study with chronic low back pain adults.|t|f|f|t
34164790|NCT04485949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164791|NCT02896283|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34164792|NCT02747186|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34164793|NCT04110912|||COHORT||PROSPECTIVE|||||||
34164794|NCT06197386|||CASE_ONLY||CROSS_SECTIONAL|||||||
33746934|NCT04298541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery.~Visit 1 Patients will undergo a 68-Ga-DOTATATE PET/CT or PET/MR scan as standard of care, or as part of a separate research study.~Visit 2 At least 24h and up to 4 weeks apart from Visit 1, patients will undergo 68Ga-DOTATOC PET/CT scan.~Follow-up Phase Patients enrolled in the study are planned for surgery as part of SOC. After the two scans, patients will undergo surgery and a histopathologic analysis of the resected tumor will be performed. The histopathology results will be used to correlate molecular biomarkers with imaging parameters. During the follow up period a review of clinical and imaging records related to the diagnosis will be conducted by the research team as part of the study during the follow- up period."||||
33746935|NCT03400891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33746936|NCT05328531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase II is double-blind, participants and investigators are blind.|Group A : 50mg by single subcutaneous injection; Group B : 100mg by single subcutaneous injection Group C : 195mg by single subcutaneous injection;Group D : 100mg by single subcutaneous injection Group E : 195mg by single subcutaneous injection; Group F: 1ML Compound Betamethasone Injection by single intramuscular injection|t|f|t|f
33746937|NCT00906672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746938|NCT00048516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746939|NCT06233318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PIFB will be administered to the patient after anesthesia induction and before surgical incision according to the randomization regimen. The unblinded researcher will randomize and inform to the unblinded anesthesia care provider who will perform the PIFB procedure. The rest of clinicians, research personnel and patients will be blinded to the group assignment.|This is a single-center, prospective, randomized, placebo-controlled, double-blinded trial in patients undergoing open-heart surgery at Richard M. Ross Hospital - The Ohio State University Medical Center. All study procedures will be done in accordance with institutional and ORRP-IRB guidelines.|t|f|f|t
33746940|NCT01098006|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33746941|NCT02315157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746942|NCT05978765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746943|NCT01666002|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33746944|NCT06201182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Patients will be randomized into 3 groups:~* In placebo group, patients will receive placebo capsules and placebo via enema.~* In enema group, patients will receive placebo capsules and FMT via rectal enema.~* In capsule group, patients will receive FMT capsules and placebo via rectal enema."|t|t|t|f
33746945|NCT05921877|||COHORT||PROSPECTIVE|||||||
33746946|NCT02307929|||COHORT||PROSPECTIVE|||||||
33746947|NCT02938000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746948|NCT02127801|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33746949|NCT05268146|||OTHER||CROSS_SECTIONAL|||||||
33746950|NCT06146348|||COHORT||PROSPECTIVE|||||||
33746951|NCT01597687|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33746952|NCT01669122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956444|NCT06253585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746953|NCT05542576|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Dose escalating via Cohorts total 1-4 cohorts||||
33746954|NCT04695171|||COHORT||PROSPECTIVE|||||||
33765519|NCT06075563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765520|NCT06613126|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33765521|NCT06423053|RANDOMIZED|PARALLEL||TREATMENT||NONE||Students who attempted to enroll in Biology 3: Mindful Physiology at Dartmouth College during the course selection period were randomly assigned to the class or waitlist by the college registrar. The intervention is participation in Biology 3, a college biology course with integrated mindfulness practices along with usual access to the College's wellness offerings. The control condition is the waitlist for Biology 3 along with usual access to the College's wellness offerings.||||
33765522|NCT05936632|||OTHER||PROSPECTIVE|||||||
33765523|NCT05826015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852589|NCT02550470|||OTHER||OTHER|||||||
33852590|NCT00459615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33852591|NCT00528645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852592|NCT00435591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852593|NCT02561754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852594|NCT02951767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852595|NCT06328751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be carried out using a specific application called Randomizer ® for Clinical Trial Lite, which is a secure and validated application that works with encrypted network traffic using Transport Layer Security (TLS), a strong encryption. There will be 3 groups which will be divided into the Case Group, the Active Control Group and the Passive Control Group. Each patient will be seen individually wearing a Samsung® smartwatch and will not know about the other patients' meditation. The case group will watch a 7-minute immersive virtual reality video of mindfulness meditation with image and sound in the Oncology Control Center Foundation (FCECON) office, using Samsung® gear VR virtual reality glasses. The active control group will watch a 7-minute mindfulness meditation video presented via cell phone with image and sound at the office. The passive control group will perform breathing exercises based on the healthcare professional's instructions for 4 minutes in the office.|This is a prospective, experimental, longitudinal, randomized controlled trial (RCT), carried out in three stages.|t|f|f|f
33852596|NCT00559702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852597|NCT05316415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33852598|NCT02075541|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33852599|NCT01948726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852600|NCT05502549|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33956445|NCT06702475|||COHORT||PROSPECTIVE|||||||
33956446|NCT06319573|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33956447|NCT02046239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956448|NCT05560230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization and study medication will be handled by the hospital pharmacy. All research team members, caregiving clinicians and enrolled patients will be blinded to the study allocation arms and the randomisation list will be concealed until all statistical analyses are made.|120 patients undergoing surgical treatment for endometriosis will be included in this prospective, randomized, double-blind, controlled trial with two arms: Intervention arm (clonidine 150 microgram). Control arm (isotonic saline).|t|t|t|t
33956449|NCT01016158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956450|NCT04294290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956451|NCT05774769|||COHORT||CROSS_SECTIONAL|||||||
33956452|NCT00564486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956453|NCT05589649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956454|NCT05141045|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33956455|NCT06702280|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060660|NCT06126094|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The test subjects receive capsules of probiotics and palceb in marked bags and take one or the other arbitrarily without being told what is in which bag. Likewise, the researchers do not know whether the subjects took the probiotic or the placebo|The test subjects receive capsules of probiotics and palcebo in marked bags and take one or the other arbitrarily without being told what is in which bag. Likewise, the researchers do not know whether the subjects took the probiotic or the placebo.|t|f|t|f
34060661|NCT04472026|NA|SINGLE_GROUP||OTHER||NONE||||||
34060662|NCT01477294|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34060663|NCT05425680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060664|NCT04658576|||COHORT||PROSPECTIVE|||||||
34060665|NCT05608278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060666|NCT05556564|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34060667|NCT02432391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765524|NCT03427190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765525|NCT05201911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765526|NCT00616564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765527|NCT05341323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33765528|NCT02916797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765529|NCT04713787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is masked only to the laboratory personnel. All stool samples, labelled only with a barcode and the date of sample collection by the study team will be evaluated by blinded laboratory staff and will remain blinded until locked.||f|f|f|t
33765530|NCT05024422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765531|NCT03815084|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33765532|NCT03357367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765533|NCT04644640|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765534|NCT03373864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765535|NCT01040650|||COHORT||PROSPECTIVE|||||||
33852601|NCT06258460|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data will be blinded to intervention assignment by the trial statistician using R software|This study will be a two-arm randomized controlled trial (RCT). The intervention group will receive a two-day multimodal-based intensive educational intervention with 8 weeks follow-up (supervision based online teaching). The wait-list control group will not receive the intervention until the end of the study. Both groups will be followed up to 8 weeks.|f|f|f|t
33852602|NCT04878653|||CASE_CONTROL||PROSPECTIVE|||||||
33852603|NCT01650246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852604|NCT01586637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852605|NCT04842097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|It is not possible to blind the participants to group allocation due to the nature of the mindfulness-based stress reduction intervention; however, the outcome assessor, who will administer the outcome questionnaires to the participants will be blinded to the participants' group allocation as well the investigator and the data analyst who will conduct the analysis ensuring neutrality of the outcome assessment.|A two group parallel single blind pilot RCT|f|f|t|t
33956456|NCT03827460|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|The intervention is 2 weeks of monitored abstinence from alcohol compared to usual drinking. Thus, it is not possible to mask conditions for participants or investigators.|"Arms 1 and 2: 2 session parallel, random order, no blind.~Arm 3: Sequential, includes all subjects who complete Arm1 or Arm 2"||||
33956457|NCT06184373|||COHORT||PROSPECTIVE|||||||
33956458|NCT05775341|||COHORT||PROSPECTIVE|||||||
33746955|NCT03992755|NA|SINGLE_GROUP||TREATMENT||NONE||The study will evaluate the long-term safety of LIQ861 in PAH (WHO Group 1) patients who have completed a Liquidia LIQ861 clinical study. All patients will be treated on an outpatient basis until regulatory approval of LIQ861 or study is terminated by sponsor. Study enrollment will occur after final assessments from a prior study have been completed.||||
33746956|NCT01059760|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956459|NCT04473339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956460|NCT03843307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956461|NCT02926053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956462|NCT06568497|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33956463|NCT04645927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33956464|NCT05267639|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will take home two interventional devices for data collection and feedback. One of the interventions will be their usual microprocessor knee to collect as a baseline, and the other will be the commercially available Ossur Power Knee. Participants will be trained on the interventional knees during the first month of at-home use. Functional outcome measures and self-report surveys will also be completed in-lab before and after each take-home intervention, as well as at the last training visit, in order to form a detailed comparison between the two interventions.||||
33956465|NCT04527549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956466|NCT04082533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33956467|NCT02258386|||OTHER||PROSPECTIVE|||||||
33956468|NCT01425515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956469|NCT03803514|||COHORT||PROSPECTIVE|||||||
33956470|NCT02560207|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33956471|NCT03009591|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33956472|NCT04645342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060668|NCT04305106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060669|NCT04326439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060670|NCT02660021|||COHORT||PROSPECTIVE|||||||
34060671|NCT05714475|||CASE_ONLY||RETROSPECTIVE|||||||
34060672|NCT00987402|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34060673|NCT00146913|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34060674|NCT02484638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060675|NCT00287391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060676|NCT03669718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060677|NCT06013202|RANDOMIZED|PARALLEL||OTHER||SINGLE|single|This study is designed as a parallel randomized control clinical trial|t|f|f|f
34060678|NCT01869569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060679|NCT01313494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060680|NCT00894244|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34060681|NCT01683422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060682|NCT00410618|||CASE_ONLY||PROSPECTIVE|||||||
34060683|NCT04028622|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34060684|NCT01348113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060685|NCT03978247|NA|SINGLE_GROUP||SCREENING||NONE||The study is aimed at patients suffering from severe or morbid obesity and engaged in a bariatric surgery course. An additional blood sample will be taken upstream of the surgical procedure in the fasted subject. During the surgical procedure, a liver biopsy will be performed. The two diagnosis determined by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).||||
34060686|NCT04888715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060687|NCT06292793|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34060688|NCT01085136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060689|NCT00328094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060690|NCT00674856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060691|NCT02921750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060692|NCT05123547|||COHORT||PROSPECTIVE|||||||
34060693|NCT05212415|||CASE_ONLY||CROSS_SECTIONAL|||||||
34060694|NCT06160310|||COHORT||PROSPECTIVE|||||||
34060695|NCT01920256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060696|NCT05247892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34060697|NCT06308757|RANDOMIZED|PARALLEL||TREATMENT||NONE|Two-arms, 2: 1 randomization stratified by type 2 diabetes mellitus and gender|Multicentric, Prospective, Open, Randomized, Controlled, and Interventional, with no medicinal use||||
34060698|NCT04045080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34060699|NCT04021875|||CASE_ONLY||PROSPECTIVE|||||||
33852606|NCT02936128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852607|NCT00371228|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852608|NCT02584803|||CASE_ONLY||CROSS_SECTIONAL|||||||
33852609|NCT06096987|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852610|NCT01800084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852611|NCT03120247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pharmacokinetic and pharmacodynamic study of three different doses of oral transmucosal dexmedetomidine|t|f|f|t
33852612|NCT00612469|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34060700|NCT04217005|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060701|NCT01319240|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34060702|NCT03578146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This study has four modules with a total of 21 cohorts, each module was reported and submitted separately.~Module 1, NCT01758432 (54 subjects with 7 cohorts including placebo); Module 2, NCT03578146 (48 subjects with 6 cohorts including placebo); Module 3, NCT03551730 (27 subjects with 4 cohorts including placebo); Module 4, NCT03551743 (28 subjects with 4 cohorts including placebo)"|t|t|t|t
34060703|NCT02621658|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34060704|NCT04885894|||OTHER||PROSPECTIVE|||||||
34060705|NCT00394771|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34060706|NCT00919906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060707|NCT03215719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060708|NCT00316862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060709|NCT04486469|NA|SINGLE_GROUP||TREATMENT||NONE|The patients were cited for individual sessions in a close space so they did not know if they all received the same treatment.|24 patients diagnosed with Irritable Bowel Syndrome||||
34060710|NCT01291134|||COHORT||PROSPECTIVE|||||||
34060711|NCT05883059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|assessor was blinded. The assessor, who not participated in the study, was experienced, and well qualified in the use of the tests.||f|f|f|t
34060712|NCT06730386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060713|NCT00637806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060714|NCT01416155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060715|NCT02682875|||CASE_ONLY||PROSPECTIVE|||||||
33956473|NCT04024852|RANDOMIZED|PARALLEL||OTHER||NONE||Participants with implanted cardioverter defibrillator (ICD) were randomly divided into the control and intervention group. Both groups did daily 30-minute walked outdoors for maximum 70 days, and their data on blood pressure, pulse rate and blood oxygen saturation pre- and post-exercise were collected. Hourly ambient concentrations of PM2.5, O3, NO2, sulphur dioxide (SO2) and carbon monoxide (CO) were collected, and AQHI calculated. On days forecast with AQHI ≥5, the intervention group was advised to exercise indoors. Mixed-effects models were applied to analyze the associations between air pollution and cardiovascular measures.||||
33956474|NCT06321042|||COHORT||PROSPECTIVE|||||||
33956475|NCT02657746|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33956476|NCT03049371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956477|NCT05572814|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956478|NCT04335292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060716|NCT01329588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060717|NCT00000213||||TREATMENT||||||||
34060718|NCT06108739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060719|NCT03098017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Personnel involved in randomization, in the analyses of the samples collected, and who were involved in the data processing were blinded.||f|f|f|t
34060720|NCT04336813|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34060721|NCT06731478|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study.|||||
34060722|NCT02636556|NA|SINGLE_GROUP||TREATMENT||NONE||Intensity modulated radiotherapy with VP-16/Cisplatin||||
34060723|NCT04650906|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants are partly masked. The control group will be masked; however, the intervention group will not be masked. Other parties will not be masked.|"Participants are assigned to one of two or more groups in parallel for the duration of the study.~Young people will be recruited through Facebook.dk and instragram, and block randomized to either use of Mindhelper (intervention group) or no information on Mindhelper (control group).~At baseline participants will respond to a questionnaire on sociodemographic characteristics, and validated items related to well-being (primary outcome), psychological distress and daily functioning (secondary outcomes), and intentions and barriers to help-seeking (explorative outcomes). One week later participants will be asked to respond to a similar questionnaire. We will use 1:1 propensity score to increase comparability between the two groups and report the standardized difference on all baseline variables between high- and low-level users to evaluate whether the matching."|t|f|f|f
34060724|NCT04564924|||COHORT||PROSPECTIVE|||||||
34060725|NCT00247988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060726|NCT06731426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060727|NCT06018506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060728|NCT00002615|RANDOMIZED|||TREATMENT||||||||
34060729|NCT01664832|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34060730|NCT06012955|||COHORT||RETROSPECTIVE|||||||
34060731|NCT06061172|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to intervention group and control group, respectively, in parallel for the duration of the study||||
34060732|NCT00180427|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34060733|NCT01023841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060734|NCT05706038|||CASE_ONLY||RETROSPECTIVE|||||||
34060735|NCT05159102|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34164795|NCT03852017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following implementation pre-testing, we will use a pilot randomized-controlled design to compare 2 groups: Group A: Mindfulness (n=25), a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life; and Group B: Relaxing Music (n=25) - a daily audio session of peaceful and relaxing music. Participants will be assessed at baseline just prior to randomization to the two study arms (T1), followed by assessments at the end of the intervention period (T2), and 1 month (T3) and 3 months (T4) after the 4-week intervention period.||||
33852613|NCT05191277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|In case of assignment to one of the hidden arms, both participants and investigators (i.e. physicians, psychologists, and research assistants) will be blinded to group assignment. Accordingly, in case of assignment to one of the open trial arms, participants and investigators will be aware of group assignment. The primary outcome is a self-report measure assessed via an online-survey by the participants; the outcome assessor (= participant) will therefore only be blinded to group assignment in the hidden arms. The person responsible for randomization and preparation of the medication is not blinded, but has no contact with the study participants.|The PHEA-study is a randomized, balanced open-hidden discontinuation trial with a 2x2-factorial design (treatment: continuation versus discontinuation; expectation: high versus moderate). A stratified block-randomization will be applied, with participants receiving either open discontinuation (OD), hidden discontinuation (HD), open continuation (OC), or hidden continuation (HC) of their antidepressant medication. Participants will have a 1:1:1:1 chance of being allocated to one of the four experimental groups. With an anticipated dropout rate of 20 % our recruitment target is N=196 (n=49 per group). Randomization will be stratified by i) intake duration of antidepressant medication with 24 months as a marker for long-term intake (\<24 months intake vs. ≥ 24 months intake, 3:7); and ii) risk of developing discontinuation symptoms associated with the antidepressant medication (moderate vs. higher or unknown risk, 1:1).|t|f|t|t
34164796|NCT03887013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34164797|NCT00890747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164798|NCT03691597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852614|NCT05736822|||COHORT||RETROSPECTIVE|||||||
33956479|NCT01789515|||COHORT||RETROSPECTIVE|||||||
33956480|NCT04205292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956481|NCT02242331|||COHORT||PROSPECTIVE|||||||
33956482|NCT00138658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956483|NCT04679233|NA|SINGLE_GROUP||OTHER||NONE||Single group pre-test, post-test feasibility and safety study||||
33956484|NCT04849858|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a prospective cohort study with retrospective data analysis. Patients will be assigned to treatment groups on a consecutive basis. We will be recruiting 45 eligible patients from our University of California Irvine (UCI) gynecologic oncology clinic. Each clinic patient who is scheduled for surgery will be screened for eligibility. The first 15 patients enrolled will receive perioperative plain bupivacaine transversus abdominis plane (TAP) blocks. The next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine (LB) TAP blocks. The final 15 patients enrolled will receive perioperative LB TAP blocks followed by redosing of the TAP blocks in 48-60 hours.||||
33956485|NCT03586986|||CASE_CONTROL||PROSPECTIVE|||||||
33956486|NCT02976389|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956487|NCT05051384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956488|NCT06568770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1 will receive S-FICB and Group 2 will receive PENG|t|f|f|t
33956489|NCT06670105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956490|NCT04004780|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33956491|NCT01618201|||CASE_CONTROL||PROSPECTIVE|||||||
33956492|NCT01144988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956493|NCT04181697|||COHORT||PROSPECTIVE|||||||
33956494|NCT03800134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33956495|NCT02790619|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33956496|NCT06306573|||COHORT||PROSPECTIVE|||||||
33956497|NCT03278639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both investigators taking care of patients and outcomes assessors will be blinded.|randomized, prospective, blind, controlled clinical trial|f|f|t|t
33956498|NCT00068770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956499|NCT02550509|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956500|NCT03033069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956501|NCT00132600|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33956502|NCT06146543|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Control group|t|f|f|f
33956503|NCT06599658|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33956504|NCT00868816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164799|NCT02882594|||COHORT||PROSPECTIVE|||||||
34164800|NCT04080102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164801|NCT06398938|||COHORT||PROSPECTIVE|||||||
34164802|NCT03506997|NA|SINGLE_GROUP||TREATMENT||NONE||Two stage Simon Minimax design phase II trial, with 90% power and 5% type I error to discard treatment if \<20% responses are observed and detect activity \>40%||||
34164803|NCT00006107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164804|NCT02591940|||||PROSPECTIVE|||||||
33956505|NCT01537809|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33956506|NCT06204848|NA|SINGLE_GROUP||OTHER||NONE||||||
33956507|NCT03455530|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Data collection will be conducted by research staff blinded to the intervention condition. CHWs will only be present at the first baseline-assessment prior to data collection.|Both groups will receive a baseline exposure assessment and health screenings from El Rio Community Health Center. Then, the intervention group will receive the industrial hygiene (IH)-enhanced community health worker (CHW) intervention. After the second exposure assessment, the delayed group will receive the intervention. A third exposure assessment will be obtained to determine if exposure levels and controls are maintained in the intervention group, and to assess the intervention in the delayed group. This will help us assess sustainability of the intervention. CHWs will accompany evaluators during the first assessment but leave before data collection begins. We anticipate that the CHW intervention will be completed over a 60-day time period (range: 30-90 days).|t|t|t|t
33956508|NCT04475731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956509|NCT02446496|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33956510|NCT03639584|||COHORT||PROSPECTIVE|||||||
33956511|NCT04372810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The volunteers were randomized by means of sealed matte envelopes in the following groups: sham group (GS), evaluated on day 1 and day 7, and received preventive diabetes guidance at the end of the experiment (follow-up) and intervention group (GI), assessed on day 1, then underwent manual manipulation intervention and were reevaluated post-intervention. They were again evaluated on the 7th post-treatment day and received preventive guidance at the end of the experiment (follow-up).|t|t|f|t
33956512|NCT00919165|||CASE_CONTROL||PROSPECTIVE|||||||
33956513|NCT06439316|||COHORT||RETROSPECTIVE|||||||
33956514|NCT05166369|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Multicenter, cluster, randomized, factorial, controlled trial.||||
33956515|NCT06701877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33956516|NCT06313294|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The research patients will be blind to the proposed intervention.|Participants will are assigned to one of two groups in parallel for the duration of the study|t|f|f|f
33956517|NCT05823194|NA|SINGLE_GROUP||TREATMENT||NONE||The study included a comprehensive evaluation of the participants' medical history, surgical procedures, oncological treatment, and fertility preservation methods.||||
33956518|NCT02611531|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33956519|NCT05984329|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33956520|NCT02341872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956521|NCT05645016|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The design is a two-arm cluster randomized trial with randomization at the level of the church (4 Churches), and analyses at the level of the individual participants (i.e., church members).||||
33956522|NCT06606314|||COHORT||OTHER|||||||
33956523|NCT03387735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33956524|NCT01735864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956525|NCT06015711|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33956526|NCT00107809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33956527|NCT01959659|||COHORT||RETROSPECTIVE|||||||
33956528|NCT06539208|NA|SEQUENTIAL||TREATMENT||NONE||||||
33956529|NCT06649825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956530|NCT05287802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, the outcome assessor, care provider physicians, and the statistician were blinded to allocation. The supervising physician was not blinded.|This study was planned to compare the effects of isometric strengthening exercises plus balance and proprioception exercises performed by two different methods with isometric strengthening exercises alone. This was a single-center randomized trial with 3 parallel arms|t|t|f|t
33956531|NCT05814510|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33956532|NCT03187873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956533|NCT04959708|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the therapist will remain unblinded, however, the rest of group researcher will be blinded during the whole study|A clinical pilot study will be conducted with two controlled and parallel groups.|f|f|t|t
33956534|NCT01607866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956535|NCT06496711|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||explorative, open, non-randomised mixed-methods study||||
34164805|NCT03257124|NA|SINGLE_GROUP||TREATMENT||NONE||"1. Brain Metastasis cohort (BM cohort)~2. Leptomeningeal Metastasis cohort (LM cohort)"||||
34164806|NCT06440941|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164807|NCT06085508|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Digital patient education to reduce kinesiophobia||||
34164808|NCT01922713|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34164809|NCT02286921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164810|NCT06725953|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Social Cognitive Theory-based, Technology-delivered Physical Activity Program||||
34164811|NCT03874702|||CASE_ONLY||PROSPECTIVE|||||||
33746957|NCT06609239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956536|NCT06213961|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||prospective randomized controlled clinical trial|t|f|f|t
33956537|NCT04839133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164812|NCT01313260|||CASE_CONTROL||PROSPECTIVE|||||||
34164813|NCT01362608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746958|NCT05593835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster Randomised Trial||||
33746959|NCT04189562|NA|SINGLE_GROUP||OTHER||NONE||||||
33746960|NCT04479150|||COHORT||CROSS_SECTIONAL|||||||
33746961|NCT02721238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746962|NCT00058838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33746963|NCT01319448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33746964|NCT06634992|||COHORT||RETROSPECTIVE|||||||
33746965|NCT00175851|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33746966|NCT01518543|||CASE_ONLY||PROSPECTIVE|||||||
33852615|NCT02157922|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852616|NCT01617304|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33852617|NCT05780320|||COHORT||RETROSPECTIVE|||||||
33852618|NCT01656382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852619|NCT04048954|||COHORT||PROSPECTIVE|||||||
33852620|NCT00151151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852621|NCT05902312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the study's design, blinding participants and TMS operators will not be possible. Still, staff responsible for participant assessments and data analysis will be blinded to treatment conditions and external to the clinic staff. Patients will be instructed not to reveal their group assignment to the raters. Patients will not be given the specifics of the treatment parameters and will be instructed not to talk to each other during the study period. Both treatments will be presented as effective to them. Lastly, the data management center will strictly control access to the randomization code.|randomized, single-center, two-arm, parallel-group superiority trial|f|f|f|t
33852622|NCT02641678|||COHORT||PROSPECTIVE|||||||
33852623|NCT02843477|||OTHER||PROSPECTIVE|||||||
33852624|NCT03871842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852625|NCT02780154|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33852626|NCT00857272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852627|NCT00666393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852628|NCT04433546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852629|NCT02079454|||COHORT||PROSPECTIVE|||||||
33852630|NCT03549533|||OTHER||PROSPECTIVE|||||||
33956538|NCT06519266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956539|NCT00000227||CROSSOVER||TREATMENT||||||||
33956540|NCT04921384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956541|NCT03372395|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Pilot study||||
33956542|NCT03911817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Prospective randomized controlled clinical trial|t|f|f|f
33956543|NCT03001427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956544|NCT05922592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956545|NCT03463759|||CASE_CONTROL||PROSPECTIVE|||||||
33956546|NCT06537323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956547|NCT02414165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164814|NCT01521026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164815|NCT04260789|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open randomized post-market trial||||
34164816|NCT06503809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164817|NCT02610582|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|open label|||||
34164818|NCT05757804|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34164819|NCT00451971|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34164820|NCT05913830|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34164821|NCT06528236|||OTHER||OTHER|||||||
34164822|NCT01380769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164823|NCT03399630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and treating physician are both blinded, being that neither are aware of which knee received the autologous adipose tissue injection and which knee received the placebo lactated ringers injection|Double blind parallel groups assignment|t|t|f|f
34164824|NCT02979652|||COHORT||PROSPECTIVE|||||||
34164825|NCT06461338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34164826|NCT02106871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34164827|NCT01257516|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34164828|NCT02332174|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34164829|NCT00273273|||||OTHER|||||||
34164830|NCT05155813|||COHORT||PROSPECTIVE|||||||
34164831|NCT01525615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164832|NCT00130169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164833|NCT02680665|||COHORT||PROSPECTIVE|||||||
34164834|NCT04526223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164835|NCT00644150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164836|NCT00836186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective study designed to analyze tumor markers and pathologic data in order to examine the prediction of tumor response to radiation therapy.||||
34164837|NCT01708863|||COHORT||PROSPECTIVE|||||||
34164838|NCT00442728|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34164839|NCT04618289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and researcher will be double-blinded as to which groups participants will be assigned. The researcher will administer the numbered supplement pot (i.e; 001) to the participants based on the sequence that participants attend their baseline clinic (Week 0). The blinding will be maintained throughout the study period of 8 weeks and allocation will not be unlocked until the end of the data analysis or during any adverse event.|A total of 120 participants who are eligible to continue with the study will be randomised to receive either 4000 IU (100 mcg) of vitamin D3-fortified fruit juice or placebo-fruit juice. The participants will be instructed to consume the vitamin D3-fortified fruit juice or placebo-fruit juice in the morning by diluting the powder in 150 ml of water, daily, for the 8-week duration of the study. All the participants will be reminded to not alter their dietary habits and physical activity, in addition, to abstaining from donating blood during the course of the study which may interfere with interpretation of study findings.|t|f|t|f
34164840|NCT00783809|||COHORT||PROSPECTIVE|||||||
34164841|NCT03646708|||COHORT||PROSPECTIVE|||||||
34164842|NCT01416402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164843|NCT05060770|||CASE_ONLY||OTHER|||||||
34164844|NCT04422808|||OTHER||PROSPECTIVE|||||||
34164845|NCT02724449|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164846|NCT03363516|||OTHER||PROSPECTIVE|||||||
34164847|NCT06304207|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All baseline and follow up outcomes assessment will be conducted by a study team member blinded to the subject group allocation.|The study design will be a pilot randomized controlled, assessor-blinded trial with three groups: 1) Tele-rehab where patient will be at home but will receive supervised intervention remotely, 2) Onsite outpatient physical therapy, 3) Control group.|f|f|f|t
34164848|NCT01109355|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34164849|NCT02518386|||COHORT||PROSPECTIVE|||||||
34164850|NCT05701020|NA|SINGLE_GROUP||OTHER||NONE||||||
34164851|NCT00152893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33956548|NCT06567275|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33956549|NCT01658215|RANDOMIZED|CROSSOVER||||NONE||||||
34164852|NCT00165880|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164853|NCT01200303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164854|NCT02289313|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34164855|NCT05527665|||CASE_CONTROL||RETROSPECTIVE|||||||
34164856|NCT06359613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The product will be provided to intervention group (n=50) in polyethylene bags containing 28 cupcakes (35gm by weight/cupcake, 2/day) providing approximately 20%DV of energy. Cupcakes of equal weight and size made with rice flour (mostly used recipe) will be provided to the control group (n=50)||||
34164857|NCT06309563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164858|NCT03501225|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34164859|NCT01217762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164860|NCT05782062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164861|NCT04715529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SAD and MAD: 6 cohorts, 8 subjects take FZJ-003 and 2 subjects take placebo; Food Effect on Phamocokinetics: 14 subjects, crossover designing|t|t|t|t
34164862|NCT06720857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164863|NCT04423094|||COHORT||RETROSPECTIVE|||||||
34164864|NCT01289093|||COHORT||PROSPECTIVE|||||||
34164865|NCT02236468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164866|NCT01157247||||TREATMENT||||||||
34164867|NCT04005157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164868|NCT05819593|||CASE_CROSSOVER||PROSPECTIVE|||||||
34164869|NCT01841723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893454|NCT04691258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Physical Exercises Treatment - The participants performed the squat exercise with the maximum range of motion, even if the participant was unable to perform the movement with a neutral vertebral posture, especially in the lumbar region, which, in most cases, rounding occurs when the range of motion is imposed. The positioning of the feet in this group was also carefully controlled, for this group, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the antero-superior iliac spines (ISIS). The direction of the knees was oriented pointing in the direction of the toes parallel during the whole cycle of the movement.|t|f|f|f
34164870|NCT02018081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956550|NCT05872451|NA|SINGLE_GROUP||OTHER||NONE||Patients undergoing TURP procedure under general anesthesia||||
33956551|NCT00896038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164871|NCT05031793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164872|NCT04965246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34164873|NCT00356707|||COHORT||PROSPECTIVE|||||||
34164874|NCT03895333|||CASE_CONTROL||PROSPECTIVE|||||||
34164875|NCT03464747|||COHORT||PROSPECTIVE|||||||
34164876|NCT04148495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34164877|NCT06726681|||COHORT||PROSPECTIVE|||||||
34164878|NCT02191371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164879|NCT02952599|||COHORT||PROSPECTIVE|||||||
33852631|NCT05496946|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|For randomization, a randomization table was created using the http://stattrek.com/statistics/random-numbergenerator.aspx site. As a result, the sample of the research; The purpose of the study was explained, and after the briefing, a total of 80 students, 40 students in both groups, who were allowed to participate in the research and who met the criteria for inclusion in the sample, formed.|The sample size of the study; Using the G\* Power 3.1.9.2 program, the mean and standard deviation of a similar study in the literature (İlaslan, 2019) (Spielberger State Anxiety Scale total score mean=28.8; SD=5.4 and Spielberger State Anxiety Scale total score mean=39, 5; SD=10.4). For the calculated effect size=0.91, α=0.05 and power=0.95, it was determined that there should be at least 33 students in both groups, for a total of 66 students. Students in the sample group were randomly assigned by the researcher to the Low-Reality Model (Experimental-1 Group) and Standardized Patient (Experimental-2 Group) groups.|f|f|t|f
33852632|NCT00475930|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34164880|NCT03015324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852633|NCT05951296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852634|NCT01013597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852635|NCT04540393|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852636|NCT03819738|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||For each subject, condition effects will be estimated using the general linear model||||
33852637|NCT04281550|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study was a three-phase multi-method design consisting of analysis of the empirical grounds for the hydration intervention, development of a multi-component hydration intervention and a feasibility cluster trial of the intervention. The first phase constituted of a survey of care homes, a systematic review-informed review of previous literature and collection of professional perspectives. Second phase was the development the intervention through five workshop events. Finally, the feasibility phase compared 6 intervention homes and 5 control homes in North East England, over a 3-month period.||||
33852638|NCT01844947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852639|NCT02582567|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33852640|NCT01822301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852641|NCT01012713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852642|NCT02364791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852643|NCT01958307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852644|NCT01006473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852645|NCT06299085|NA|SINGLE_GROUP||SCREENING||NONE||"The minimum sample size was determined by considering the circulating levels of gastro-entero hormones (PYY, ghrelin, GLP-1, GIP), adipokines (leptin and adiponectin) and hormones associated with the anabolism of muscle and bone tissue (insulin). as primary endpoints; the highest calculated sample size obtained for ghrelin levels was used for the purposes of this study.~The calculation was performed using G\*Power software (v3.1.9.7) assuming a type I error (α error) of 0.05, a Power (1-β error) of 0.8, an effect size of 0.44.~The resulting minimum sample size is 42 patients. Taking into account the presence of any drop-outs, 20% more patients will be considered, for a total of 50 patients to be enrolled."||||
33852646|NCT04388397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33852647|NCT03536299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852648|NCT03337854|||CASE_ONLY||RETROSPECTIVE|||||||
33852649|NCT04537182|RANDOMIZED|PARALLEL||TREATMENT||NONE||International, multi-center, open label, morphology- and site-stratified, 1:1 randomized, actively controlled||||
33852650|NCT03810352|||COHORT||CROSS_SECTIONAL|||||||
33852651|NCT01613560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852652|NCT02768870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852653|NCT05788211|||OTHER||RETROSPECTIVE|||||||
33956552|NCT02822612|||CASE_ONLY||CROSS_SECTIONAL|||||||
33956553|NCT03533335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Group 1: Oral spray (chlorhexidine) Group 2: Oral spray (chlorine dioxide) Group 3: Oral spray (water)|t|t|t|t
33956554|NCT01164137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956555|NCT00986609|NA|SINGLE_GROUP||OTHER||NONE||||||
33956556|NCT02136615|||COHORT||PROSPECTIVE|||||||
34164881|NCT05301010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two group: study drug and reference|t|t|t|t
34164882|NCT03863509|||CASE_CONTROL||PROSPECTIVE|||||||
34164883|NCT00398658|RANDOMIZED|PARALLEL||||DOUBLE||||||
34164884|NCT03058926|||CASE_CONTROL||PROSPECTIVE|||||||
34164885|NCT04233177|||COHORT||PROSPECTIVE|||||||
34164886|NCT02954614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164887|NCT01176058|RANDOMIZED|PARALLEL||||NONE||||||
33956557|NCT04520711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956558|NCT02334839|||COHORT||PROSPECTIVE|||||||
34060736|NCT02670382|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34060737|NCT03005457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060738|NCT02787018|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34060739|NCT00476892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34060740|NCT03877757|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34060741|NCT01681316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060742|NCT00898599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34060743|NCT02940093|||COHORT||PROSPECTIVE|||||||
34060744|NCT00034944||||TREATMENT||DOUBLE|||t|f|t|f
34060745|NCT00456508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060746|NCT01625689|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34060747|NCT00757185|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34060748|NCT02344797|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34060749|NCT00533052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060750|NCT02958358|NA|SINGLE_GROUP||||NONE||||||
34060751|NCT02973113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060752|NCT04703361|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34060753|NCT02908074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060754|NCT04258540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomisation by a simple online program.||f|f|t|t
34060755|NCT00002048||||TREATMENT||||||||
33956559|NCT06704139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be allocated in 1: 1 ratio into the two study groups using a web-based randomiser (https://www.randomizer.org/) to generate codes placed within sealed, opaque, sequentially numbered envelopes by a research assistant who will not be involved in patient care or assessment. This assistant also will prepare the study solutions in identical syringes that will be labelled ''study drug'' according to the assigned group||t|t|t|t
33956560|NCT00806416|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956561|NCT01294709|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33956562|NCT05724875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956563|NCT05905809|RANDOMIZED|PARALLEL||TREATMENT||NONE||An interventional, prospective, monocentric, randomized, open and controlled study||||
33956564|NCT04425642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956565|NCT03054168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||To achieve our aims we will recruit 16 young healthy males (Age: 18-30 y; BMI: 18-30kg/m2) and 16 older healthy males (Age: 65-75 y; BMI: 18-30kg/m2). Volunteers will then be randomly assigned to a testing group; 1) Young placebo trained (N=10), 2) Young gonadotropin releasing hormone analogue trained (3.6mg Zoladex subcutaneous injection (every 4 weeks) N=10), 3) Old placebo trained (N=10) and 4) Old Testosterone trained (Sustanon 250: 250 mg every 2-3wks intramuscular injection, N=10). All participants will receive whole body resistance exercise training for six weeks.|t|f|t|t
33956566|NCT02131831|||CASE_ONLY||PROSPECTIVE|||||||
33956567|NCT05520060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33956568|NCT04041063|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcomes assessor will not have knowledge of the time point at which they are assessing the participant.|All participants will receive nerve transfer surgery. Half of the participants will receive 6 weeks of robotic training starting one year after the surgery. The other half of the participants will receive 6 weeks of robotic training starting one year plus 6 weeks after the nerve transfer surgery.|f|f|f|t
33956569|NCT00002066||||TREATMENT||DOUBLE||||||
33956570|NCT02107768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164888|NCT00904735|RANDOMIZED|||TREATMENT||NONE||||||
34164889|NCT04022863|||COHORT||PROSPECTIVE|||||||
34164890|NCT00358007|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34164891|NCT00732875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164892|NCT03477045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34164893|NCT02741596|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34164894|NCT05069051|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, two-armed controlled, multicenter phase II study analyzing the efficacy and safety of belimumab in combination with venetoclax plus rituximab in patients with refractory or relapsed CLL.||||
34164895|NCT06726642|||CASE_CONTROL||PROSPECTIVE|||||||
34164896|NCT00851617|RANDOMIZED|PARALLEL||||NONE||||||
34164897|NCT00378781|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34164898|NCT04803149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is a participant-blinded trial and deliberate action, utilizing a physical barrier, will be taken to ensure the blind remains intact.||t|f|f|f
34164899|NCT02151669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164900|NCT04965480|||CASE_ONLY||RETROSPECTIVE|||||||
34164901|NCT02464046|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33852654|NCT00104663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164902|NCT03591718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164903|NCT04523857|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164904|NCT04755036|||OTHER||PROSPECTIVE|||||||
34164905|NCT04756804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164906|NCT05590975|RANDOMIZED|PARALLEL||PREVENTION||NONE||The assessment will be carried out parallel in the intervention and the control arm.||||
34164907|NCT02466763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852655|NCT00705354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852656|NCT04694404|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Eledrly Patients with Untreated Advanced or Recurrent Gastric Cancer||||
33852657|NCT06199674|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34164908|NCT02195570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164909|NCT03547310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164910|NCT04043559|||COHORT||RETROSPECTIVE|||||||
34164911|NCT04800458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164912|NCT00217932|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34164913|NCT03573310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34164914|NCT01459588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164915|NCT02677194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164916|NCT02342223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164917|NCT04617067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164918|NCT05206721|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164919|NCT04718623|||COHORT||PROSPECTIVE|||||||
33852658|NCT05162989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator cannot see both the test device and reference device measurement results.|||||
33852659|NCT00903630|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852660|NCT06244485|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33893455|NCT01931865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893456|NCT04008017|||OTHER||CROSS_SECTIONAL|||||||
34164920|NCT02825381|||COHORT||RETROSPECTIVE|||||||
34164921|NCT04485559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746967|NCT06634641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746968|NCT04313803|||COHORT||PROSPECTIVE|||||||
34164922|NCT00310089|RANDOMIZED|||TREATMENT||||||||
34164923|NCT05206760|||COHORT||PROSPECTIVE|||||||
34164924|NCT00361556|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34164925|NCT06458543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852661|NCT03213860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|While it is not possible to blind participants and clinical staff to the assigned interventions, the assessments will be undertaken by a researcher blinded to group allocation.||f|f|f|t
34164926|NCT06165328|||COHORT||PROSPECTIVE|||||||
33852662|NCT03869151|||COHORT||PROSPECTIVE|||||||
33956571|NCT06196970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956572|NCT05813275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164927|NCT02420704|||COHORT||PROSPECTIVE|||||||
34164928|NCT00306553|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34164929|NCT05239858|||COHORT||PROSPECTIVE|||||||
34164930|NCT04039958|RANDOMIZED|CROSSOVER||OTHER||NONE||Partial replicate crossover study||||
34164931|NCT01366599|||COHORT||RETROSPECTIVE|||||||
34164932|NCT00462306|||COHORT||PROSPECTIVE|||||||
34164933|NCT06726772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164934|NCT02330055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746969|NCT01060228|NA|SINGLE_GROUP||||NONE||||||
33852663|NCT01670760|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852664|NCT02036879|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852665|NCT04690530|||COHORT||PROSPECTIVE|||||||
33852666|NCT02628782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852667|NCT04789772|NA|SINGLE_GROUP||TREATMENT||NONE||Because of uncertainty of effectiveness of laser acupuncture and drop out rate of MA users, investigators make an observational single group of pilot study.||||
33852668|NCT01206543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852669|NCT01362257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852670|NCT00724438|||COHORT||PROSPECTIVE|||||||
33852671|NCT02926144|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33852672|NCT03868072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852673|NCT00784693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852674|NCT05846347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956573|NCT06650553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956574|NCT05508321|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective interventional study||||
34164935|NCT02425696|||COHORT||PROSPECTIVE|||||||
34164936|NCT05083533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Evaluation was made before the exercise application, after the eight-week application, and at the sixth month after the exercise program.|f|f|t|f
34164937|NCT04354376|||COHORT||RETROSPECTIVE|||||||
34164938|NCT05505344|||OTHER||OTHER|||||||
34164939|NCT00771888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164940|NCT01822457|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34164941|NCT05295875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164942|NCT00893061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164943|NCT00918099|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34164944|NCT00664885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164945|NCT00631904|||COHORT||PROSPECTIVE|||||||
34164946|NCT02497183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33746970|NCT02907346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746971|NCT00089440||||TREATMENT||||||||
33746972|NCT01699243|||CASE_ONLY||PROSPECTIVE|||||||
33746973|NCT03220191||SEQUENTIAL||BASIC_SCIENCE||NONE||the subjects will receive palbociclib alone in period 1, and receive palbociclib with rabeprazol in period 2||||
33746974|NCT05608629|NA|SINGLE_GROUP||TREATMENT||NONE||Application of electrode to left tragus with stimulus intensity at that which is just below pain threshold for 35 min a day for 6 weeks||||
33746975|NCT03649828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both Kefir and curd had been prepared to have the same consistency, color and flavor. Therefore, participants did not know if they were actually receiving kefir or curd. The care provider was a nutritionist that did not from each group the participants came from. There was two major investigators. The investigator responsible for the analysis of the data was also blind to the experimental groups, and he was also the outcome assessor.|There were two experimental groups. The kefir group (KG), that received orally probiotic milk fermented with the kefir grains, and the control group (CG), that received curd|t|t|t|t
33746976|NCT04158375|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33852675|NCT01821287|||CASE_CONTROL||PROSPECTIVE|||||||
33852676|NCT02896920|||COHORT||PROSPECTIVE|||||||
33852677|NCT00168623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852678|NCT02502799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852679|NCT01997307|||CASE_CONTROL||PROSPECTIVE|||||||
33852680|NCT05259020|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852681|NCT02725801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852682|NCT06284720|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33852683|NCT03877666|||COHORT||PROSPECTIVE|||||||
33852684|NCT01523925|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33852685|NCT00447811|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33852686|NCT05660486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33852687|NCT04908462|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33852688|NCT02650882|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33852689|NCT03139110|||COHORT||PROSPECTIVE|||||||
33852690|NCT02111187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852691|NCT03561012|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33852692|NCT06063811|||COHORT||RETROSPECTIVE|||||||
33852693|NCT03759951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33852694|NCT01639781|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33852695|NCT06610136|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Statistician|Randomized controlled trial|t|f|t|f
33852696|NCT05994404|||COHORT||PROSPECTIVE|||||||
33852697|NCT04074863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent hand therapist, who is not involved in the rehabilitation of the participants, will carry out the measurements.|Participants randomized to one of the group and receive the group specific surgery. Postoperative treatment is identical between the groups.|f|f|f|t
33852698|NCT01502020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852699|NCT02301260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852700|NCT04949360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants cannot be blinded considering the type of intervention being tested. The allocation codes will be concealed and only three members of the research team will have access to the codes and randomization table. All the outcomes will be either collected automatically (via software) or by hired professionals unaware of the objectives of this trial.|Participants will be randomized and distributed in four parallel and independent groups.|f|t|f|t
33852701|NCT04296253|||COHORT||PROSPECTIVE|||||||
33852702|NCT05221671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The demographic data of the children and parents who agreed to participate in the study will be recorded by the anesthetist in the polyclinic, and an information leaflet will be given to those who will be included in the group that receives the information leaflet. Anesthesia knowledge level and anxiety level determination questionnaire and m-YPAS will be done by the researchers. Researchers applying these scales will not know which patients are included in the group receiving the information leaflet and which patients are in the control group. Conversion and evaluation of the survey results into study data will be done by other researchers. The principal researcher will supply the communication between these researchers.|Patients and parents participating in the study will be divided into two groups by randomization. An information leaflets will be given to one group, but not to other group. Anesthesia knowledge level and anxiety level assessment questionnaires will be administered to both groups. These survey results will be compared between the two groups.|f|f|t|f
33852703|NCT01300962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852704|NCT04918667|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33956575|NCT05144958|||CASE_ONLY||PROSPECTIVE|||||||
33956576|NCT00457431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956577|NCT06393907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be randomized for each intervention using sequentially numbered, opaque sealed envelopes after recruitment in the study. The care provider who uses the devices cannot be blinded.|Hemostatic Forceps versus Bipolar Electrocautery Probes|t|f|f|f
33956578|NCT01267968|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956579|NCT03299218|RANDOMIZED|FACTORIAL||PREVENTION||NONE||"1. Control Group~2. Cash-based transfers only by BISP~3. Cash-based transfers and Social \& behaviour change communication (SBCC)~4. Cash-based transfer and SNF~5. Cash-based transfers, SNF and SBCC"||||
33956580|NCT05958238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34164947|NCT01534000|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164948|NCT00165932|||CASE_CONTROL||PROSPECTIVE|||||||
34164949|NCT04108611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will not be masked as hemodiafiltration with endogenous re infusion must be observed|Role of online hemodiafiltration with endogenous re infusion in treatment of systemic lupus erythematosus activity resistant to conventional therapy||||
34164950|NCT02361333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34164951|NCT05273320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164952|NCT04138641|||COHORT||PROSPECTIVE|||||||
34164953|NCT02707146|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34164954|NCT00293657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164955|NCT01951651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164956|NCT01270178|||CASE_ONLY||PROSPECTIVE|||||||
34164957|NCT06504810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34164958|NCT02996630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34164959|NCT00269919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164960|NCT02609061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164961|NCT03754348|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34164962|NCT01091779|||CASE_ONLY||PROSPECTIVE|||||||
34164963|NCT00977626|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34164964|NCT01974830|||COHORT||PROSPECTIVE|||||||
34164965|NCT01934491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34164966|NCT06185582|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Participant will be blinded about application of pruritogens.|The sub-project takes place over three sessions on three consecutive days. The participants will randomly receive two pruritogens and two pain stimulations (heat or capsaicin) in the same and in the opposite arm.|t|f|f|f
34164967|NCT04600713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled multicenter study|f|f|f|t
34164968|NCT03202407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded|parallel group|t|f|f|f
34164969|NCT02687464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164970|NCT04095182|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34164971|NCT03318380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164972|NCT01749878|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34164973|NCT03761186|RANDOMIZED|PARALLEL||OTHER||SINGLE|Nurses that will take lab samples as well as laboratory personal that analyses the samples will be masked. Due to the nature of the study, it is not possible to mask the participants or the care providers/investigators.||f|f|f|t
34164974|NCT00410930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34164975|NCT05964075|||COHORT||PROSPECTIVE|||||||
34164976|NCT05346575|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|All study team members will be blinded to the block randomization sizes except the biostatisticians. Outcome assessors will be masked to a participants randomization assignment. Interventionists (Study team member administering the TOTAL intervention) will notify participants randomized to the TOTAL intervention. The outcomes assessor will administer assessment surveys to all participants and will remain blinded from each participants intervention status.|A multi-site, two-arm, parallel randomized control trial to test the effectiveness of the TOTAL intervention vs. usual care on initiation if obesity treatment among Veterans with overweight/obesity.|f|f|t|t
34164977|NCT01575431|||OTHER||PROSPECTIVE|||||||
34164978|NCT02307058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164979|NCT04078555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164980|NCT02825615|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34164981|NCT03836768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164982|NCT05711121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and the investigator assessing the treatment results were blinded to the injection technique.|Patients having radicular pain were randomized to either caudal or transforaminal epidural injection group|t|f|t|f
34164983|NCT05923814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34164984|NCT02441023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34164985|NCT01002001|||CASE_ONLY||PROSPECTIVE|||||||
34164986|NCT00172263|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34164987|NCT01951560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34164988|NCT05864417|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34164989|NCT02735668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34164990|NCT02085018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34164991|NCT04755608|RANDOMIZED|PARALLEL||OTHER||NONE||Self Controlled Randomised Trial||||
34164992|NCT01997424|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34164993|NCT01800383|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34164994|NCT00962637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164995|NCT02883803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34164996|NCT00252070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164997|NCT05822882|||CASE_CONTROL||RETROSPECTIVE|||||||
33956581|NCT04651673|||OTHER||OTHER|||||||
33956582|NCT06060496|NA|SINGLE_GROUP||TREATMENT||NONE|Using the MagVenture A/P coil|||||
33956583|NCT04413357|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Site pharmacy will not be blinded to product assignment, study staff and participants will be blinded to product assignment. Product will be provided in unlabeled cups.|This will be a randomized crossover design. The subjects will be randomized to one of three interventions on three separate study days, one week apart.|t|f|f|f
33956584|NCT02086968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956585|NCT01347983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956586|NCT02998645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956587|NCT03969979|||CASE_ONLY||CROSS_SECTIONAL|||||||
33956588|NCT01829490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956589|NCT03086642|NA|SEQUENTIAL||TREATMENT||NONE||||||
33956590|NCT01291186|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33956591|NCT03285152|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, MSK investigator-initiated, multi-center, randomized, pilot study of KD vs SD consumption in treatment naïve endometrial cancer patients during the presurgical window period between diagnosis and surgical staging.||||
33956592|NCT02135276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956593|NCT06316960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956594|NCT04559373|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Intervention study involving a single group, multiple-pre, multiple-post, sequential design.||||
33956595|NCT01964391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956596|NCT01211873|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33956597|NCT00397293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956598|NCT05939713|||COHORT||RETROSPECTIVE|||||||
33956599|NCT05748431|||CASE_CROSSOVER||PROSPECTIVE|||||||
33956600|NCT01243866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956601|NCT05589246|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33956602|NCT01493583|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33956603|NCT05589571|||COHORT||PROSPECTIVE|||||||
33956604|NCT03474952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||RIPC group and control (sham-RIPC) group|t|t|t|t
33956605|NCT04682977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The statistician conducting data analysis will be blinded to group assignment of study participants. A numerical code will be used to identify the study arm for each participant in the outcome database. Outcome measurement will be carried out by blinded assessors at baseline and immediately post-intervention.|Participants will be randomized to receive the IPROACTIF intervention or usual primary care services. Stratified randomization will be carried out with each diagnostic category (diabetes and heart disease) serving as a stratum.|f|f|t|t
33746977|NCT00715429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746978|NCT03699943|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Caverstem 1.0 - Low dose - 30 cc - 20 patients Caverstem 1.0 - High dose - 60 cc - 20 patients Caverstem 2.0 - 20 cc - 100 patients|f|f|f|t
33956606|NCT00518531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956607|NCT00197561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33956608|NCT02263118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33956609|NCT06341413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956610|NCT01570127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956611|NCT00002373||PARALLEL||TREATMENT||||||||
33956612|NCT04426188|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33956613|NCT06109402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956614|NCT06373978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This study is a double-blind, randomized controlled trial comparing the effectiveness of oral acetaminophen, diclofenac, and tramadol in reducing the consumption of narcotic doses (primary outcome) and minimizing patients' exposure to narcotics (secondary outcome) following an ultrasound-guided percutaneous needle tenotomy procedure on the lateral elbow.|t|t|t|t
33956615|NCT02648763|||CASE_ONLY||PROSPECTIVE|||||||
33956616|NCT03101215|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33746979|NCT05831332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956617|NCT06702826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956618|NCT02830724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33956619|NCT00544713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33746980|NCT01432119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765536|NCT01400230|||COHORT||PROSPECTIVE|||||||
33765537|NCT03644069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765538|NCT01676948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34164998|NCT05375591|||COHORT||RETROSPECTIVE|||||||
34164999|NCT03457376|||CASE_CONTROL||RETROSPECTIVE|||||||
34165000|NCT05413161|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This will be double blind study. The order of receiving the Test (T) or Reference product (R1 or R2) for each subject during the study will be based on randomization schedule generated by SAS® version 9.4 or higher, The randomization will be balanced. The randomization code will be kept under controlled access. The study drug will be blinded by the CRO.|This will be parallel group design having single study period|t|f|t|t
34165001|NCT00571974|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165002|NCT00952029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165003|NCT00673335|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165004|NCT03730532|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient Preference Trial||||
34165005|NCT00941759|||COHORT||PROSPECTIVE|||||||
34165006|NCT05884008|||COHORT||RETROSPECTIVE|||||||
34165007|NCT04597593|||COHORT||PROSPECTIVE|||||||
34165008|NCT01586949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165009|NCT03351647|||COHORT||PROSPECTIVE|||||||
33852705|NCT01248065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165010|NCT00574535|||COHORT||RETROSPECTIVE|||||||
34165011|NCT01699230|RANDOMIZED|PARALLEL||||NONE||||||
33852706|NCT00511901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852707|NCT06407596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852708|NCT00150865|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34165012|NCT04824469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||randomized controlled experimental study|t|f|f|t
33852709|NCT05813977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Group 1: Tritube (FCV) Group 2: Conventional endotracheal tube|t|f|t|f
33852710|NCT03903016|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852711|NCT01553331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852712|NCT00386269|RANDOMIZED|PARALLEL||||DOUBLE||||||
33852713|NCT02331251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852714|NCT06598722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852715|NCT02389920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852716|NCT01991054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852717|NCT02022267|||COHORT||RETROSPECTIVE|||||||
33852718|NCT01323634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852719|NCT02882139|||CASE_ONLY||OTHER|||||||
33852720|NCT04788511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|f|t|f
33852721|NCT01807013|||COHORT||PROSPECTIVE|||||||
33852722|NCT06183749|||CASE_ONLY||RETROSPECTIVE|||||||
33852723|NCT03362866|||COHORT||PROSPECTIVE|||||||
33852724|NCT01618604|||CASE_ONLY||PROSPECTIVE|||||||
33852725|NCT04543487|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852726|NCT04681599|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33852727|NCT05601947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165013|NCT06006195|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34165014|NCT01278563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165015|NCT06375213|||COHORT||PROSPECTIVE|||||||
33852728|NCT04803331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852729|NCT04293445|||COHORT||PROSPECTIVE|||||||
33852730|NCT04150601|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852731|NCT00287066|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165016|NCT03025646|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34165017|NCT05957965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33746981|NCT04440553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were unaware of their group membership. Investigators were not blinded to group membership.|Participants were randomized to a uniform random group, or a reinforcement learning group. Within these groups, participants received the same types of text-messages, but the delivery schedule differed.|t|f|f|f
33746982|NCT00048282|||||PROSPECTIVE|||||||
33746983|NCT06569056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33746984|NCT01200667|||COHORT||CROSS_SECTIONAL|||||||
33746985|NCT04625543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746986|NCT03900260|NA|SINGLE_GROUP||OTHER||NONE||||||
33746987|NCT05457608|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All participants received Lens A and then Lens B in fixed-sequence order.|t|f|f|f
33746988|NCT06486753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746989|NCT02421614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33746990|NCT02352558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746991|NCT04207190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746992|NCT05804877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33746993|NCT00498329|||||PROSPECTIVE|||||||
33746994|NCT01270451|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33746995|NCT03830034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746996|NCT01054820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852732|NCT00346632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746997|NCT01333124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33746998|NCT03546244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33746999|NCT05805397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized group assignment|f|f|t|t
33747000|NCT06298539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33747001|NCT01895387|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747002|NCT02573519|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33747003|NCT04494152|||CASE_ONLY||PROSPECTIVE|||||||
33747004|NCT02040402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747005|NCT00737087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747006|NCT00433069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765539|NCT00002159||||TREATMENT||||||||
33956620|NCT05268718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165018|NCT03214575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956621|NCT02880722|||OTHER||PROSPECTIVE|||||||
33956622|NCT04395040|||COHORT||PROSPECTIVE|||||||
34165019|NCT05622565|||OTHER||OTHER|||||||
34165020|NCT01912196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165021|NCT02373488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165022|NCT06390683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165023|NCT04051853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165024|NCT00239928|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165025|NCT03810196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165026|NCT01402817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165027|NCT03568344|||OTHER||PROSPECTIVE|||||||
34165028|NCT00748670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165029|NCT03004911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165030|NCT03133247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165031|NCT02445872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165032|NCT00419731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165033|NCT03401775|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165034|NCT01806142|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34165035|NCT01300806|||COHORT||PROSPECTIVE|||||||
34165036|NCT05236608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165037|NCT02893241|||COHORT||PROSPECTIVE|||||||
34165038|NCT00597688|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34165039|NCT04477161|NA|SINGLE_GROUP||OTHER||NONE||pilot, prospective, single-arm, single-center study||||
34165040|NCT00638495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165041|NCT04886908|||COHORT||RETROSPECTIVE|||||||
34165042|NCT04004910|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Multicenter, Open-Label, Three-Part Study||||
34165043|NCT05545072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded, placebo-controlled, parallel-group||t|t|t|f
34165044|NCT00641004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747007|NCT06670911|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, Simon 2-stage study. The null hypothesis is that the response rate with chemotherapy alone is 0.35 (35% according to published data from the INCA (10)), and the alternative hypothesis is that the true response rate is 0.55 (20% increase in response with the addition of pembrolizumab, as per the KEYNOTE-826 study. In stage I, a total of 14 patients will be treated. If there are 5 or fewer responses among these 14 patients, the study will be terminated early. Otherwise, an additional 30 patients will be treated in stage II, resulting in a total sample size of 44. If there are 21 or more responses among these 44 patients, we reject the null hypothesis and conclude that the treatment is promising. The type I error is 0.05 and the power is 0.8.||||
33747008|NCT06669182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33747009|NCT00651508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747010|NCT04564833|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Subjects will be randomized 1:1:1 to low dose RBT-1, high dose RBT-1, and placebo|t|t|t|f
33747011|NCT03215446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33747012|NCT06077227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pre- and post-intervention surveys will be used to assess the effects of virtual reality (VR) therapy on the phantom limb experience in the intervention group. Matched controls from the registry will be surveyed on their phantom limb symptoms at matching time intervals to the intervention group for comparison.||||
33747013|NCT05544799|||COHORT||PROSPECTIVE|||||||
33747014|NCT04405700|||COHORT||PROSPECTIVE|||||||
33747015|NCT03800823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852733|NCT00956748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852734|NCT04329507|||CASE_CONTROL||PROSPECTIVE|||||||
33852735|NCT05748691|||COHORT||OTHER|||||||
33852736|NCT04555382|||COHORT||PROSPECTIVE|||||||
33852737|NCT04026880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33852738|NCT00862147|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33852739|NCT00005597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852740|NCT02165254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852741|NCT01054170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852742|NCT03173677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33852743|NCT02183051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852744|NCT03845569|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover trial.||||
33852745|NCT04987086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165045|NCT01304602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165046|NCT01669486|||COHORT||PROSPECTIVE|||||||
34165047|NCT03018613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165048|NCT03905928|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34165049|NCT05038150|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will employ a standard 3 + 3 escalating dose design to explore dose limiting toxicities (DLTs). Currently plans to evaluate 5 cohorts with 3- 6 patients to determine the Maximum Tolerated Dose (MTD). Patients who had no dose-limiting toxicities observed in Part 1 proceeded to Part 2.~Alternatively, if a DLT occurs in only 1/3 patients at any dose, then 3 more patients should be enrolled at this dose level. If this is the highest dose and there have been no DLTs-then 3 more patients must be evaluated at the same dose level to confirm the MTD. The MTD is defined as the highest dose at which no more than one (1) DLT is observed among 6 patients.~Part 3 is an open-label, dose expansion phase. There will be at least 2 tumor types selected , expand between second to four dose level in each tumor type."||||
34165050|NCT03633110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165051|NCT04924517|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study design is a randomised, controlled, crossover design in which participants undertake two conditions in a randomised order with at least four weeks in between trials.||||
34165052|NCT06726382|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34165053|NCT03976388|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Outcome assessors, analysts and investigators will be masked in this trial. Due to the intervention's characteristics, it has been deemed impossible to mask participants.||f|f|t|t
34165054|NCT04254224|||COHORT||PROSPECTIVE|||||||
34165055|NCT01340924|||COHORT||PROSPECTIVE|||||||
33747016|NCT04837248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will assess patients at baseline, 6 weeks, 12 weeks, and 6 months and will not know which arm of the study each patient belongs to.|"Group 1. Conventional treatment. Patients will be treated by means of a physiotherapy programme without digital support. They will be given a written document with exercises and recommendations on the first day.~Group 2. Experimental treatment. Patients will be treated with a digitally supported physiotherapy programme."|f|f|f|t
33747017|NCT01893242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747018|NCT03446443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747019|NCT01409967|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33747020|NCT05051566|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33747021|NCT00938873|||CASE_ONLY||RETROSPECTIVE|||||||
33747022|NCT05727605|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747023|NCT06264050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||pre post study on a single cohort||||
33747024|NCT05083247|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparative randomised phase II||||
33747025|NCT00124904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33747026|NCT04788667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747027|NCT01694537|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747028|NCT00433784|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33747029|NCT05947344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747030|NCT00293839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33747031|NCT02937545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33747032|NCT06058156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747033|NCT03166618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747034|NCT01445899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747035|NCT04490746|||COHORT||PROSPECTIVE|||||||
33852746|NCT03655821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852747|NCT00757783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852748|NCT02736305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852749|NCT04454554|||OTHER||CROSS_SECTIONAL|||||||
33852750|NCT01177579|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33747036|NCT00354874|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747037|NCT04885374|||OTHER||PROSPECTIVE|||||||
33747038|NCT02898974|||CASE_ONLY||PROSPECTIVE|||||||
33747039|NCT04885686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The color of the two powders are not the same. The dentist will not be blinded to the treatment, but the patient will. The study is simple-blinded.|Study subject will be randomized in a 1:1 allocation ratio between the 2 treatment groups; the allocation will be stratified by pre-operative pain (3 classes) and center (12 classes).|t|f|f|f
33747040|NCT00122512|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33747041|NCT00158938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747042|NCT03643952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747043|NCT03744507|||COHORT||PROSPECTIVE|||||||
33747044|NCT05317468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33747045|NCT05558657|RANDOMIZED|PARALLEL||TREATMENT||NONE||We aim to have two study group, including the intervention group that receive acupressure combined with nursing interventions, and the control group that receive acupressure on sham acupoints combined with nursing interventions||||
33852751|NCT04532203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852752|NCT02953860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852753|NCT01633983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852754|NCT00073866||||TREATMENT||||||||
33852755|NCT04703231|||CASE_CONTROL||PROSPECTIVE|||||||
33852756|NCT01688830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852757|NCT01762891|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33852758|NCT01414140|||CASE_ONLY||PROSPECTIVE|||||||
33852759|NCT02558504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852760|NCT03418831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956623|NCT04770194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Subjects will be screened for inclusion in the study up to 28 days prior to dosing. Subjects will be admitted to the clinical unit on the morning of Day -1, and will be dosed in a randomised, double-blind manner on the morning of Day 1 following an overnight fast (approximately 10 h).~Drug administration will be performed with an appropriate interval (approximately 10 min) between subjects based on logistical requirements. Subjects will remain resident in the clinical unit until up to 48 h after dosing (up to Day 3). Subjects with AEs that represent a cause for concern will be asked to remain resident in the clinical unit until the AE resolves or stabilises. The minimum interval between dose administrations will be 14 days to allow for interim review of PK and safety data from the previous regimen. A follow-up visit will take place 5 to 7 days post-dose for assessment of safety and tolerability."|t|f|t|f
33956624|NCT04843501|RANDOMIZED|PARALLEL||PREVENTION||NONE||10 schools will receive the experimental CATCH My Breath program and 10 schools will receive the usual care Texas Education Agency required tobacco prevention program. Each school will include 70 students.||||
33956625|NCT06181136|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33956626|NCT00527527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956627|NCT00380575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33956628|NCT04853888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956629|NCT06593366|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All parties will be blinded to the participant's treatment arm.||t|t|t|t
33956630|NCT03348319|||CASE_ONLY||PROSPECTIVE|||||||
33956631|NCT06160583|||COHORT||OTHER|||||||
33956632|NCT02594384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956633|NCT00326339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956634|NCT02619370|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33956635|NCT06184659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956636|NCT03337776|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34165056|NCT06725823|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|patients will not be aware about which type of intervention they will recieve also the care provider and outcome assessor will be not aware about type of intervention patients will recieve|The study will include 50 patients with frozen shoulder with no healthy volunteer, Patients in this study will be randomized into two groups according to the treatment performed Shoulder anterior capsular block group and Suprascapular nerve block group|t|t|f|t
34165057|NCT02266355|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165058|NCT03061435|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34165059|NCT00411671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165060|NCT00042705|||||PROSPECTIVE|||||||
34165061|NCT01855737|||||PROSPECTIVE|||||||
34165062|NCT04974801|RANDOMIZED|CROSSOVER||OTHER||NONE||Single center, randomized, prospective crossover study||||
34165063|NCT05685342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"An investigator who is not involved in this study randomly allocates the group and another investigator who dose not evaluate clinical endpoints keeps the result of allocation in a sealed envelope.~On the day of study, the second investigator opens the envelope to check allocation and sends a drug and normal saline in identical looking bottles with label only indicating the order of administration."|A prospective randomized double-blinded study|t|t|t|t
34165064|NCT00977171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165065|NCT03766659|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||International multicenter prospective randomized comparative study.|t|f|f|f
34165066|NCT02023957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165067|NCT06467903|NA|SINGLE_GROUP||SCREENING||NONE||specific screening exhamination||||
34165068|NCT00004893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165069|NCT04415814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165070|NCT02818972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165071|NCT06149455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165072|NCT04517032|||COHORT||PROSPECTIVE|||||||
34165073|NCT02362724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165074|NCT03721341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165075|NCT01965704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165076|NCT04005599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The anesthesiologist in charge of randomization will number 40 opaque envelopes and insert a card in each with the corresponding information of the group (according to the lottery) and the medication to be administered. Another anesthesiologist in charge of preparing the blind solution alone will open the envelope. Both of these investigators, as well as the anesthesiologist providing anesthesia and the anesthesiologist in charge of data evaluation will not participate in any of the other steps of the trial. The patients will be blinded to their own treatment group.|Prospective, controlled, randomized and double-blind clinical trial.|t|t|t|t
34165077|NCT05676307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852761|NCT00693797|||CASE_CONTROL||PROSPECTIVE|||||||
34165078|NCT02686385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165079|NCT01380795|NA|SINGLE_GROUP||SCREENING||NONE||||||
34165080|NCT06429449|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165081|NCT05052190|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Pragmatic comparative effectiveness trial with a standard-of-care control group|t|f|f|f
34165082|NCT01582139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165083|NCT03385226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852762|NCT00818649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852763|NCT01895283|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852764|NCT01408615|||COHORT||PROSPECTIVE|||||||
33852765|NCT01648881|||COHORT||PROSPECTIVE|||||||
33852766|NCT01948908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165084|NCT01844453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34165085|NCT03229109|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33852767|NCT02791828|||COHORT||PROSPECTIVE|||||||
33852768|NCT02830945|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial||||
33852769|NCT00655291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852770|NCT04572113|||CASE_ONLY||CROSS_SECTIONAL|||||||
33852771|NCT02032277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852772|NCT00784355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852773|NCT03715439|||COHORT||PROSPECTIVE|||||||
33852774|NCT04680754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled experimental study to determine the effect of post-thyroidectomy head-neck stretching exercises on postoperative pain level and wound healing||||
33852775|NCT00841880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852776|NCT00482573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852777|NCT03700073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852778|NCT03794687|||COHORT||PROSPECTIVE|||||||
33852779|NCT05137015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two teams will work on injury data collection. Teams are not informed for which group (intervention or control) they are recording the datas.|Cluster randomised controlled trial|f|f|f|t
33852780|NCT05141812|||COHORT||CROSS_SECTIONAL|||||||
33852781|NCT05379660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33852782|NCT06476145|||COHORT||PROSPECTIVE|||||||
33956637|NCT00057330|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33956638|NCT02010307|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33956639|NCT02071446|||CASE_ONLY||CROSS_SECTIONAL|||||||
34165086|NCT04861935|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups were formed as those with and without dimples in the sacral region.||||
34165087|NCT03652935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747046|NCT05554237|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Participant and investigator-blinded and sponsor-open design for Part-1 and Part-2.||t|f|t|f
33747047|NCT01092208|||||RETROSPECTIVE|||||||
33852783|NCT01657513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852784|NCT05958576|||COHORT||RETROSPECTIVE|||||||
33852785|NCT05351684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852786|NCT05074485|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33852787|NCT05134441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852788|NCT05358028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852789|NCT04854668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852790|NCT01789645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852791|NCT04666402|||COHORT||PROSPECTIVE|||||||
33852792|NCT04617561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165088|NCT00127023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33893457|NCT01306981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893458|NCT01501643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893459|NCT02561156|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33893460|NCT03534648|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34165089|NCT02463279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165090|NCT02340065|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34165091|NCT01435213|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34165092|NCT02397304|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34165093|NCT04712370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34165094|NCT05362929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Images of deidentified participants before and after treatment will be presented by two independent, non biased, blinded, board certified dermatologists for rating of improvement and outcome scores.|This is a single-institution, baseline-controlled, prospective comparative study||||
34165095|NCT03997669|||CASE_CONTROL||PROSPECTIVE|||||||
34165096|NCT01370265|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34165097|NCT02392806|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165098|NCT06302946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34165099|NCT03612336|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation.|||||
34165100|NCT04924595|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34165101|NCT04708093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective study|t|f|f|f
34165102|NCT05397769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165103|NCT06726486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A single-blind parallel Randomized Controlled Clinical Trial.|f|f|t|f
34165104|NCT05514054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165105|NCT01426958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165106|NCT05463107|||COHORT||PROSPECTIVE|||||||
34165107|NCT03596203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165108|NCT03546556|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165109|NCT03136016|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34165110|NCT01559675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165111|NCT00051376|RANDOMIZED|||TREATMENT||DOUBLE||||||
34165112|NCT00402467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34165113|NCT02068326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165114|NCT02915042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165115|NCT04440826|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34165116|NCT06495021|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into a control group and treatment group for their duration of the study upon informed consent. Control patients will not receive lymphatic pump OMT, while treatment patients will receive lymphatic pump therapy.||||
34165117|NCT01943812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165118|NCT01968330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956640|NCT06423937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956641|NCT02949219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852793|NCT04219397|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Following patient enrollment, only the unblinded study coordinators will provide information and education to the patients/families about which arm they are randomized to. The investigator and other collaborators will conduct follow-up phone calls and data input and analysis in a blinded fashion.|"1. Usual care (control)~2. Intervention #1: provision of formal education on medication take back~3. Intervention #2: provision of formal education on medication home disposal of residual opioids, and provision of a medication home disposal kit."|f|t|t|t
33956642|NCT06594289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Complete random grouping method was used in this study. Patients meeting the inclusion criteria were assigned to group A and Group B in a 1:1 ratio with 110 cases in each group by random number table method. The results are hidden in an opaque sealed envelope, which is then stored by the clinical study designer (i.e., a random code sheet). The researcher opened the envelope on the morning of the operation to obtain the group of patients and informed the operating physician and anesthesiologist to intervene accordingly according to the study protocol.||t|t|t|f
33956643|NCT04125160|||CASE_CONTROL||PROSPECTIVE|||||||
33956644|NCT04344782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956645|NCT04056091|RANDOMIZED|PARALLEL||TREATMENT||NONE|Only statistician will be masked to tretament|||||
33956646|NCT02394379|||COHORT||PROSPECTIVE|||||||
33956647|NCT06326112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of the health care team will not be feasible as they must administer the intervention|RADAR-Canada is a parallel group CT in which study participants are randomized in a 1:1 ratio to protocolized deresuscitation or usual care|f|f|f|t
33956648|NCT04059861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The ultrasound examiner should not be aware of the results of the MRI.|Clinical trial||||
33956649|NCT05266807|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Controlled, Open-label, Multicenter||||
33956650|NCT06653478|||COHORT||PROSPECTIVE|||||||
33747048|NCT03570294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060756|NCT03760328|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Neither the subject nor the investigator or Outcomes Assessor (double-blinded) will know the outcome of the randomization until after the subject has fulfilled and completed all study requirements at the end of the visit 3.|This study is a prospective, multi-center, randomized, crossover study, conducted under a common protocol. Subjects will be enrolled after they have been implanted and using the Inspire therapy (Inspire II/IV, Inspire Medical Systems, Maple Grove, USA) for at least six months. Participants will be randomized to one of two groups: therapeutic stimulation or sham stimulation. During the second phase of the study therapy settings of the stimulation system will be adjusted to crossover.|t|f|t|t
33747049|NCT00003269|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060757|NCT00771264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060758|NCT06267521|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not know whether they are in a group receiving active stimulation (groups 2, 3, and 4) or sham stimulation (group 1). However, participants will know whether they are performing meditation (groups 1, 3, and 4) or listening to only the didactic meditation material (group 2), and participants will be aware of how many nights they are undergoing stimulation (1 night per week for group 3, 2 nights per week for groups 1, 2, and 4). Thus, participants will be only partially blind to condition. Investigators will not be blind to condition.||t|f|f|f
33747050|NCT05748405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956651|NCT02297958|||CASE_ONLY||PROSPECTIVE|||||||
33956652|NCT06039293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956653|NCT02263677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060759|NCT05125913|||COHORT||PROSPECTIVE|||||||
34060760|NCT06428721|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060761|NCT03589963|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34060762|NCT04960852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060763|NCT04377464|||COHORT||PROSPECTIVE|||||||
34060764|NCT04895813|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|NO MASKING|Open label posttest controlled parallel group randomized controlled study||||
34060765|NCT05604794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060766|NCT00741091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060767|NCT04981093|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34060768|NCT06394466|||COHORT||OTHER|||||||
34060769|NCT02506127|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34060770|NCT01069419|||COHORT||PROSPECTIVE|||||||
34060771|NCT02436031|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34060772|NCT00745524|||CASE_CONTROL|||||||||
34060773|NCT00557414|||COHORT||PROSPECTIVE|||||||
34060774|NCT06293105|||OTHER||OTHER|||||||
33956654|NCT05844826|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060775|NCT02333552|||COHORT||PROSPECTIVE|||||||
34060776|NCT03383575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060777|NCT01622725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060778|NCT05521841|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||hospital based randomized, prospective, interventional study|t|f|t|t
34060779|NCT00207727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060780|NCT02647879|||COHORT||PROSPECTIVE|||||||
34060781|NCT04512313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060782|NCT00430352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060783|NCT06343376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060784|NCT03790449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Statistician is blinded|Randomized Controlled Trial (1:1)||||
34060785|NCT05297929|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060786|NCT01197170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060787|NCT03403946|NA|SINGLE_GROUP||TREATMENT||||||||
34060788|NCT06094101|NA|SINGLE_GROUP||TREATMENT||NONE||interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study||||
34060789|NCT00223964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34060790|NCT01046032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34060791|NCT01124292|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060792|NCT01510535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852794|NCT05234112|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"In Uganda, India and Bangladesh eligible women in geographic areas are invited to perform self-test for hrHPV. hrHPV-positive women are invited for further examination of the cervix using VIA. In case of cervical dysplasia local treatment is performed.~Women in vulnerable populations in Slovakia are invited to self-test for hrHPV. hrHPV positive women are seen by gynaecologist for Pap-smear cytology. Based on classification further therapy is offered"||||
33852795|NCT00619203|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33852796|NCT04067375|||COHORT||PROSPECTIVE|||||||
33852797|NCT00850603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852798|NCT02796625|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852799|NCT00032526|RANDOMIZED|||ECT||SINGLE||||||
33852800|NCT03881618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two group . a group and b group. the intervention of a group is electroacupuncture + auricular pressure and b group is auricular pressure ,after intervention for 1 month and crossover.||||
33852801|NCT00239343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852802|NCT04650308|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33852803|NCT00414284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852804|NCT04419883|||COHORT||PROSPECTIVE|||||||
33852805|NCT01721460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852806|NCT04563286|||COHORT||PROSPECTIVE|||||||
33852807|NCT04015999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33852808|NCT00320827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852809|NCT06138054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants will be randomized by recruiters who are blind to condition assignment.|Participants will be randomly assigned using block randomization (sequence pairs of MI-CBTech and mindfulness control in random order) to assign participants 1:1 to the two treatment conditions to ensure the treatment arms remain balanced across the course of the study.|t|f|t|t
33852810|NCT04451174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852811|NCT02218294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852812|NCT02377141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852813|NCT01651442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852814|NCT05463692|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852815|NCT02197767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956655|NCT00216073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956656|NCT05165173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will receive a coded sample that either contains 4000 IUs microparticles of vitamin D or 4000 IUs nanoparticles of vitamin D|randomized comparator-controlled trial|t|f|t|f
33956657|NCT01125007|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33956658|NCT06652308|||COHORT||RETROSPECTIVE|||||||
33956659|NCT06173713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956660|NCT04475536|||COHORT||PROSPECTIVE|||||||
33956661|NCT00178763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852816|NCT05985941|||COHORT||PROSPECTIVE|||||||
33956662|NCT06425601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956663|NCT02183701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956664|NCT02934568|NA|PARALLEL||TREATMENT||NONE||||||
33956665|NCT05804201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956666|NCT05015803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind study design. The therapeutic care for insomnia is synonymous with the study intervention, therefore blinding of the CBT care provider is impossible.|CBTi with Application, Standard TeleHealth CBTi, and Sleep Hygiene Education study groups run in parallel after randomization.|t|f|f|f
33956667|NCT06405087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956668|NCT00030602||||TREATMENT||||||||
33852817|NCT02571049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||DFN-11 injection and placebo injection administered in one treatment period and two DFN-11 injections administered in another treatment period|t|f|t|f
33852818|NCT01304238|||COHORT||RETROSPECTIVE|||||||
33852819|NCT03341208|||CASE_ONLY||PROSPECTIVE|||||||
33852820|NCT00552877|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33852821|NCT04125732|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33852822|NCT02424903|||COHORT||PROSPECTIVE|||||||
33852823|NCT01176279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33852824|NCT05933421|||COHORT||RETROSPECTIVE|||||||
33956669|NCT05643118|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33852825|NCT03664089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956670|NCT05634629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956671|NCT03015207|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33852826|NCT01662726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956672|NCT06653400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An assistant will be in charge of mixing either the intervention or control paracervical block. The physician performing the procedure and the patient will be blinded to the intervention.|To study the effect of a combined ketorolac and lidocaine paracervical block on procedure related pain with office hysteroscopy. The standard of care is currently just a lidocaine paracervical block.|t|t|f|f
33852827|NCT04100668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956673|NCT06013683|||COHORT||CROSS_SECTIONAL|||||||
33852828|NCT01879215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165119|NCT04248127|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The honey intervention or isocaloric amounts of sugar will be provided in yogurt. The study participant will not be told what sweetener they will be receiving.|Randomized single-blind 2-arm crossover trial. Each arm will be 4 weeks in length, with a 4 week washout between arms.|t|f|f|f
34165120|NCT00056979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165121|NCT00776971||CROSSOVER||||NONE||||||
34165122|NCT00014079|||CASE_ONLY||PROSPECTIVE|||||||
33956674|NCT00834288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165123|NCT04720521|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34165124|NCT02432586|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165125|NCT01515631|||CASE_ONLY||RETROSPECTIVE|||||||
34165126|NCT06409910|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1: External beam radiotherapy 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily.~Arm 2: External beam radiotherapy 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days."||||
34165127|NCT01160536|||||RETROSPECTIVE|||||||
34165128|NCT02494986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165129|NCT05939999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluations will be conducted blindly, that is, by an evaluator who will not be directly involved in the intervention.||f|f|t|t
34165130|NCT04633382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165131|NCT04053166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two experienced observers will blindly read the MRI scans.||f|f|f|t
34165132|NCT01854970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852829|NCT03824782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A dual-centre, prospective parallel group trial with balanced randomization (1:1) will be conducted.|f|f|t|t
33852830|NCT02171416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852831|NCT00513773|||COHORT||PROSPECTIVE|||||||
33852832|NCT05453123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33852833|NCT01244321|||CASE_CONTROL||PROSPECTIVE|||||||
33852834|NCT01795482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852835|NCT01793532|||CASE_CONTROL||PROSPECTIVE|||||||
33852836|NCT05886556|||COHORT||RETROSPECTIVE|||||||
33852837|NCT00225966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852838|NCT03377309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956675|NCT01097369|||COHORT||PROSPECTIVE|||||||
33956676|NCT05855473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33956677|NCT06452797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33956678|NCT06091527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956679|NCT01268683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165133|NCT00930085|NA|SINGLE_GROUP||||NONE||||||
34165134|NCT06073652|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|There are two masked, randomized formula-fed intervention groups, Control Formula (CF) and experimental Formula (EF)||t|t|t|t
34165135|NCT05092529|||COHORT||PROSPECTIVE|||||||
34165136|NCT06415461|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label study with nine subjects, who will all receive an intra-articular injection of the CFL test agent, at either of three dose levels (30 x 106 TNC, 60 x 106 TNC, and 90 x 106 TNC). The administration will be performed under ultrasound image guidance. The first three subjects will receive the 30 x 106 TNC dose; provided that the adverse event profile is acceptable, the next three subjects will receive the 60 x 106 TNC dose; provided that the adverse event profile remains acceptable, the next three subjects will receive the 90 x 106 TNC dose.|Dose ranging study of increasing doses of cell product||||
34165137|NCT06363734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165138|NCT00859560|||COHORT||RETROSPECTIVE|||||||
34165139|NCT00992355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165140|NCT00016679||||TREATMENT||||||||
34165141|NCT05161923|||CASE_ONLY||PROSPECTIVE|||||||
34165142|NCT03842033|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will conduct a randomized, controlled trial of 372 adolescents with uncontrolled mild-severe persistent asthma to examine the effectiveness of a personalized, interactive PEAKmAAP application with and without PCP data sharing in reducing asthma morbidity. The trial includes 3 groups: 1) a group utilizing the PEAKmAAP alone, 2) a group utilizing the PEAKmAAP with PCP data sharing (PEAKmAAP-DS), and 3) a usual care NutriMapgroup utilizing an application with daily non-asthma related reminders for attention control.||||
34165143|NCT05072938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165144|NCT02875379|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956680|NCT04881331|||CASE_ONLY||PROSPECTIVE|||||||
33956681|NCT04384731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956682|NCT01910701|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956683|NCT01609127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956684|NCT04476459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956685|NCT00683046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956686|NCT06566859|||CASE_CROSSOVER||PROSPECTIVE|||||||
33956687|NCT01889927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852839|NCT01748877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956688|NCT02502084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956689|NCT03682016|||COHORT||CROSS_SECTIONAL|||||||
33956690|NCT00684437|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33956691|NCT06652074|||OTHER||CROSS_SECTIONAL|||||||
33956692|NCT01972607|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33956693|NCT06124326|NA|SINGLE_GROUP||OTHER||NONE||||||
33956694|NCT06565598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956695|NCT04228081|||COHORT||CROSS_SECTIONAL|||||||
33852840|NCT04466046|||COHORT||PROSPECTIVE|||||||
33852841|NCT00370331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852842|NCT02035644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33852843|NCT00361660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33852844|NCT03715582|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33852845|NCT01025401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852846|NCT00416143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852847|NCT05946057|||CASE_ONLY||OTHER|||||||
33852848|NCT02041520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33852849|NCT03775889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852850|NCT04881981|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 phase one trial||||
33852851|NCT04951154|||COHORT||PROSPECTIVE|||||||
33956696|NCT06469736|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956697|NCT01277107|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33852852|NCT04828200|||CASE_CONTROL||PROSPECTIVE|||||||
33852853|NCT05276297|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Open-label for Treatment 1 and single-blinded for Treatment 2.||t|f|f|f
33852854|NCT00010985|RANDOMIZED|||TREATMENT||||||||
33956698|NCT06653088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956699|NCT05186727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956700|NCT02995928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956701|NCT06567782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956702|NCT01054716|||CASE_CONTROL||PROSPECTIVE|||||||
33956703|NCT06665776|||OTHER||PROSPECTIVE|||||||
33956704|NCT00123110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956705|NCT05434767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956706|NCT02325401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956707|NCT01198990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956708|NCT04476654|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel Assignment||||
33956709|NCT01827085|||||PROSPECTIVE|||||||
33956710|NCT06652386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be randomly assigned to either the telemedicine or in-person support group using a computer-generated randomization sequence with block sizes of varying lengths to ensure allocation concealment and they are unaware of which group they have been assigned to as well as the outcome assessor is unaware|"* Telemedicine Group:~  * Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~ * Scheduled sessions at postpartum days 1, 3, 7, and 14.~ * Additional support available upon request.~* In-Person Group:~  * Nursing-led lactation support at the hospital bedside and during follow-up clinic visits.~ * Scheduled sessions at postpartum days 1, 3, 7, and 14.~ * Additional support available upon request."|t|f|f|t
33956711|NCT06269965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956712|NCT02206256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956713|NCT06318091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33956714|NCT04317664|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956715|NCT03458910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants will be randomly assigned to either the HRV-increase group or the HRV-decrease group.|t|f|f|f
33956716|NCT03840473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852855|NCT05611437|||COHORT||PROSPECTIVE|||||||
33852856|NCT00250939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852857|NCT02423928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852858|NCT01639495|NA|SINGLE_GROUP||TREATMENT||NONE||This study had a single arm: catheter ablation for PAF||||
33852859|NCT01664598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852860|NCT05630482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Control Trial|f|f|f|t
33852861|NCT04248660|||COHORT||RETROSPECTIVE|||||||
33852862|NCT02654756|||COHORT||RETROSPECTIVE|||||||
33852863|NCT04421183|||COHORT||PROSPECTIVE|||||||
33852864|NCT05361876|||CASE_CONTROL||PROSPECTIVE|||||||
33852865|NCT05114239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165145|NCT03342417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Non-Randomization Phase 2 clinical trial with Safety Run-In (3 parts): Part 1 in 20 newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy and intend to undergo surgery after completion of investigational neoadjuvant therapy. Parts 2 and 3 in 20 PRROC and gastric cancer patients, respectively. Enrollment of patients in each of the 3 parts will begin with 3 patients. If no dose-limiting toxicities (DLTs, defined as toxicity ≥Grade 3) are observed during the first cycle, enrollment can continue for the remaining 17 patients. If 1 of the first 3 patients experiences a DLT, the enrollment will be expanded to a total of 6 subjects. If no more than 1 of 6 subjects experiences a DLT, enrollment can continue for the remaining 14 patients. If 2 or more of the first 2-6 subjects experience a DLT, enrollment may be paused and the study data will be reviewed.||||
34165146|NCT00852865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165147|NCT03292068|RANDOMIZED|PARALLEL||TREATMENT||NONE||Triangulation design will be used including both qualitative and quantitative methods. All the intervention groups will receive usual care in combination with a special intervention. The control group will only receive usual care. In the study the three interventions will be performed at one hospital each.||||
34165148|NCT05099796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165149|NCT04174690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Biaxial rotation force platform combined with electromyography||||
34165150|NCT02839850|NA|SINGLE_GROUP||TREATMENT||NONE|An independent radiographic reviewer will be assessing all radiographs from the study.|||||
34165151|NCT06727461|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"This is a single-blinded multicenter randomized controlled trial to evaluate the effects of the FEED@home intervention.~Each patient-family dyad will be randomized in a 1:1 ratio to FEED@home program vs. usual care after completing the baseline interview. Allocation sequence will be generated by a computer program using random block sizes of 4, 8 and 12. The sequence will be put in sequentially numbered opaque sealed envelopes to ensure concealment."|f|f|f|t
34165152|NCT01764711|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34165153|NCT03871062|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34165154|NCT03811444|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34165155|NCT05503186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34165156|NCT02147756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852866|NCT03843931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852867|NCT00798330|||COHORT||PROSPECTIVE|||||||
33852868|NCT00563485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852869|NCT04398407|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study in a randomized control trial, with an enhanced control condition. Prior to the randomized trial, the investigators will conduct a small pilot study. Findings from the pilot study will inform revisions of the intervention prior to the randomized trial.||||
33852870|NCT05323396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"The participants and the study team will know the results of the tests, and thus will know the groups that the participants are in, since only the parasite-positive participants will receive treatment."|"This trial is closest to a parallel trial, but different from most clinical trials in that the participants will not be randomized by the study team. The two groups will be determined based on the results of the initial sample collection. Those with a result positive for intestinal parasitic infection (by either stool microscopy, stool PCR, or Strongyloides IgG) will be in the parasite-positive group for the remainder of the study. Those negative for all of these will be in the parasite-negative group. The markers sCD14, sCD163, and I-FABP will be compared between the two groups. Additionally a comparison will be made between the pre-treatment and post-treatment levels of the parasite-positive participants."||||
33852871|NCT00557180|||COHORT||PROSPECTIVE|||||||
33852872|NCT05337358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852873|NCT01941719|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33956717|NCT05782140|||COHORT||PROSPECTIVE|||||||
33956718|NCT04365907|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956719|NCT05136859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956720|NCT03745560|||CASE_ONLY||PROSPECTIVE|||||||
33956721|NCT00935415|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34060793|NCT06463418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060794|NCT02951572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060795|NCT02594774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165157|NCT02534415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165158|NCT01900795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34165159|NCT04168229|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Masking is not possible as the differences in hardware between the devices is obvious. The subjects and Investigator will recognize which device is the new one and which is the comparator.|The study is a controlled, open-label, comparative trial using a cross-over design. The subjects first wore the BTE Hearing aids and then the ITE.|f|f|f|t
34165160|NCT03294590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcome Assessors and Oral Health Examiners will be blind to treatment condition.||f|t|f|t
34165161|NCT01492790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165162|NCT02219854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165163|NCT03116711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165164|NCT02083835|||COHORT||PROSPECTIVE|||||||
34165165|NCT00267995|||||RETROSPECTIVE|||||||
34165166|NCT02949726|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34165167|NCT01398007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165168|NCT04507607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165169|NCT02741635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060796|NCT06730503|||CASE_ONLY||PROSPECTIVE|||||||
34060797|NCT00920179|||CASE_CONTROL||PROSPECTIVE|||||||
34060798|NCT00055861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060799|NCT00955981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060800|NCT02870127|||FAMILY_BASED||PROSPECTIVE|||||||
34060801|NCT05171244|RANDOMIZED|PARALLEL||OTHER||NONE||Single-center Randomized Pilot Study in Parallel Groups||||
34060802|NCT01677481|||COHORT||PROSPECTIVE|||||||
33852874|NCT00477334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852875|NCT01873222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33852876|NCT01242137|||CASE_CONTROL||PROSPECTIVE|||||||
33852877|NCT05444569|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||The study has two parts. Part A is parallel model and part B is crossover.|t|f|t|f
33852878|NCT04183309|||COHORT||PROSPECTIVE|||||||
33852879|NCT01598623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852880|NCT05915650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33852881|NCT04080921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852882|NCT03133052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852883|NCT00006342|||CASE_ONLY||PROSPECTIVE|||||||
33852884|NCT03080012|||COHORT||PROSPECTIVE|||||||
33852885|NCT01528176|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33852886|NCT01173406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852887|NCT00226031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956722|NCT06702137|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"It is a randomized, controlled, double-blind, and cross-over study. Phase 1 is a randomized, controlled, double-blind, and cross-over study. In this phase, each participant will be randomly assigned to receive one session of active stimulation and one session of sham stimulation using the EXOPULSE Mollii suit (phase 1).~The crossover design is appropriate for assessing symptomatic treatment of this chronic and relatively stable disease. Furthermore, the sessions will be separated by a wash-out interval of two weeks. Thus, a 2-week washout period should be enough to prevent a potential carry-over effect.~At the end of phase 1 (two weeks after the second session of active or sham), an open-label phase (phase 2) will be proposed for all patients and will consist of 4 weeks of active stimulation (every other day stimulations for a total of 14 sessions).~In total, each participant will be included in the study for 8 weeks (4 weeks for phase 1 and 4 weeks for phase 2)."|t|t|f|t
33956723|NCT03486327|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Up to 24 subjects will be enrolled into 3 dose groups starting with the lowest dose group as follows: Dose group 0.03mL/kg, dose group 0.05mL/kg and dose group 0.08mL/kg/, with a maximum of 8 patients in each dose group.||||
33956724|NCT06014359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956725|NCT04854707|||COHORT||RETROSPECTIVE|||||||
33956726|NCT05061459|||CASE_CONTROL||PROSPECTIVE|||||||
33956727|NCT06111781|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will undergo baseline tests at the beginning of the study and will be randomized to receive Stereotactic body radiotherapy (SBRT) + Ultrashort GNRH Antagonist Relugolix (SUGAR) vs. Stereotactic body radiotherapy (SBRT) alone.||||
33956728|NCT02552329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956729|NCT06193044|RANDOMIZED|CROSSOVER||OTHER||NONE||(Reference Replicate)||||
33956730|NCT05565105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956731|NCT03255226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956732|NCT03278483|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Arm Isoniacid Diabetic patients with a positive TST of \>10mm, who wil be randomly assigned to receive treatment with isoniazid tablets 300mg daily plus pyridoxine 50mg daily~* Arm B Diabetic patients with a positive TST of \>10mm, who wil be randomly assigned to receive treatment with rifampin capsules 600mg daily"||||
33956733|NCT02516917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956734|NCT02031874|||COHORT||PROSPECTIVE|||||||
33956735|NCT00730067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956736|NCT06636682|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956737|NCT04718727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||All patients will receive oral 10, 5 mg Olanzapine or placebo one hour preoperative|t|t|t|t
33956738|NCT06700577|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33956739|NCT04332874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956740|NCT05759988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor will be blinded to the group allocation||f|f|f|t
33956741|NCT00160446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956742|NCT00461396|||COHORT||PROSPECTIVE|||||||
33956743|NCT02651974|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33956744|NCT01402193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956745|NCT01071083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852888|NCT02519400|NA|SINGLE_GROUP||||NONE||||||
33852889|NCT00944567|||COHORT||PROSPECTIVE|||||||
33852890|NCT02485782|||COHORT||CROSS_SECTIONAL|||||||
33852891|NCT02853838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852892|NCT01413776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852893|NCT04646538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852894|NCT03259360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852895|NCT02873143|||COHORT||PROSPECTIVE|||||||
33852896|NCT03019796|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33852897|NCT06392347|||OTHER||PROSPECTIVE|||||||
33852898|NCT01942265|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33852899|NCT06056193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852900|NCT00777946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852901|NCT02935933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33956746|NCT00572169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956747|NCT05954611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956748|NCT00677170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956749|NCT04668326|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Device Trial||||
33956750|NCT01743664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33956751|NCT05264623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956752|NCT05285943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33956753|NCT02741609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852902|NCT03221192|||COHORT||CROSS_SECTIONAL|||||||
33852903|NCT03087019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852904|NCT04407585|||COHORT||PROSPECTIVE|||||||
33852905|NCT04315051|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Observer Blinded|A Double-Blind, Randomized, Placebo Controlled trial of the Safety and Efficacy of DBI-001 Gel in patients with interdigital T. pedis. Test articles will be applied by subjects once daily at bedtime for a period of four (4) weeks.|t|t|t|t
33852906|NCT06524206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33852907|NCT05939973|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open-label, cross-over arm from the 2-group randomized pilot study evaluating a treatment for obesity.||||
33852908|NCT04412291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852909|NCT05469750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852910|NCT05795244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956754|NCT02011581|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33956755|NCT04204135|||COHORT||PROSPECTIVE|||||||
33956756|NCT06007378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33956757|NCT03401762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded as to sham vs. intervention, but not as to which interventional arm.||t|f|f|t
33956758|NCT05949658|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The Bayesian Optimal Interval Design (BOIN) will be used to perform a phase I, dose finding trial in healthy older men and women (55-89yrs) for the mTOR inhibitors sirolimus and everolimus. Middle-aged to older adults will be treated with either sirolimus or everolimus for 6 weeks. All participants will take one capsule weekly. This dose escalation trial will begin with two cohorts, each consisting of 3 male and 3 female participants. The first two cohorts will take a weekly 5mg dose of sirolimus or a weekly 5mg dose of everolimus. The first arm of the study will be with everolimus. The second arm of the study will be with sirolimus. The dose can be escalated/de-escalated from the current dose based on the rate of dose limited toxicity (DLT) at the end of the 6-week intervention for each cohort. The 15mg dose will be the highest dose possible in this trial.||||
33956759|NCT01098058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956760|NCT05482438|||COHORT||RETROSPECTIVE|||||||
33956761|NCT05354336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956762|NCT04203758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956763|NCT01230502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956764|NCT02204527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study was a randomized, double-blind, placebo-controlled clinical trial on 40 outpatients with hypertension and type 2 diabetes were recruited.~Patients were allocated into two equal groups of 20 by computer-generated randomly permutated codes. the subjects were randomly assigned to 1 of 2 groups: Group 1 received a single dose (100.000 IU) of oral supplementation with cholecalciferol (vitamin D3). Group 2 received matching placebo capsules containing microcrystalline cellulose."|t|f|t|f
33956765|NCT03265483|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33956766|NCT04070534|NA|SINGLE_GROUP||OTHER||NONE||||||
33956767|NCT06514586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Double-Blinded Randomized Controlled Trial The study includes 2 arms. The subjects will be randomized to receive (apply) either oxytocin topical gel (intervention arm) or placebo gel (control arm).|t|t|t|t
33956768|NCT05959668|||OTHER||OTHER|||||||
34060803|NCT05532176|NA|SINGLE_GROUP||OTHER||NONE||seven sub-groups of 40 persons each according to their age: 20-29/30-39/40-49/50-59/60-69/70-79/80-89years old||||
34060804|NCT01935700|NA|SINGLE_GROUP||TREATMENT||NONE||opeo labeled||||
34060805|NCT06320041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852911|NCT06156618|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||this study will be a double blind, randomised design, crossover trial||||
33852912|NCT03012607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33852913|NCT03945682|RANDOMIZED|PARALLEL||TREATMENT||NONE|No study drug as part of this RCT|Participants will be randomised to one of 2 groups 1. Intervention arm 2. Usual standard of care.||||
33852914|NCT05910099|||CASE_CROSSOVER||PROSPECTIVE|||||||
33852915|NCT01822509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060806|NCT03334318|||COHORT||PROSPECTIVE|||||||
34060807|NCT04475354|||COHORT||PROSPECTIVE|||||||
34060808|NCT06069921|||COHORT||RETROSPECTIVE|||||||
34060809|NCT05029193|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All outcome measures are self-reported measures administered via online surveys, except for one. The person performing the data analysis will be blinded to group allocation.|Participants will be randomly assigned to a mindfulness intervention or a waitlist control. Participants in the waitlist control group will receive the intervention after a 2-month waiting period.|f|f|f|t
34060810|NCT03039491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060811|NCT01700738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060812|NCT02293759|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060813|NCT01084395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060814|NCT01863498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060815|NCT06505551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060816|NCT05363163|NA|SINGLE_GROUP||TREATMENT||NONE|Participants and investigators assessors will know which filler was used.|All participants will receive the same medical device (Gana X)||||
33852916|NCT04218149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852917|NCT00983931|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852918|NCT01520220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852919|NCT02518490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852920|NCT00394082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852921|NCT02881905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852922|NCT03060460|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||historical control cohort (Group A) and then a randomized prospective study (Group B and C).||||
33852923|NCT04395027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852924|NCT06272071|||COHORT||PROSPECTIVE|||||||
33852925|NCT03187691|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-randomized, open uncontrolled||||
33852926|NCT01411839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33852927|NCT03080428|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients will be identified prior to surgery based on biopsy results. During the post-operative multidisciplinary decision-making meeting, a first therapeutic decision to prescribe or not an adjuvant chemotherapy will be taken according to usual clinical and histopathological markers and official guidelines in use in the center. After the patient has signed the inform consent form, the surgical sample will be sent by the investigator site to a selected genomic platform according to the randomization result.||||
33852928|NCT01676181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33852929|NCT05521945|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33852930|NCT00617253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852931|NCT04397848|||COHORT||PROSPECTIVE|||||||
33852932|NCT01420315|||COHORT||CROSS_SECTIONAL|||||||
33852933|NCT01074515|||COHORT||PROSPECTIVE|||||||
33852934|NCT05714098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852935|NCT03407664|||COHORT||RETROSPECTIVE|||||||
34060817|NCT06375096|||COHORT||PROSPECTIVE|||||||
33852936|NCT02783768|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33852937|NCT03840915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852938|NCT02114710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852939|NCT00114413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852940|NCT06119672|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33852941|NCT01970722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852942|NCT01999270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852943|NCT01886612|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33852944|NCT02979392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852945|NCT01288521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33852946|NCT00050115|||COHORT||OTHER|||||||
33852947|NCT00593294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852948|NCT03465098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852949|NCT05566977|NA|SINGLE_GROUP||TREATMENT||NONE||refractory lupus nephritis type one diabetes in adults||||
34060818|NCT04872556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigators would put eye masking over participants. The care providers would not know the laser acupuncture device or pseudo-laser acupuncture device with randomization. The investigator did not know which group the participants belonged with.|Participants would be 90 cancer patients accepted Taxanes treatment who are suffered from myalgia and Arthralgia. The investigators would put 45 participants in experimental groups and the other 45 participants in control group with randomization.|t|t|t|f
33852950|NCT02688907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852951|NCT03128008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852952|NCT02534298|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33852953|NCT04059419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852954|NCT02817022|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33852955|NCT03587077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852956|NCT05833633|||COHORT||PROSPECTIVE|||||||
33747051|NCT05369052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852957|NCT04894760|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33852958|NCT02009761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852959|NCT02907164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33852960|NCT01878214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33852961|NCT03742284|NA|SINGLE_GROUP||OTHER||NONE||||||
34060819|NCT05646758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060820|NCT02716493|NA|SINGLE_GROUP||||NONE||||||
34060821|NCT05008809|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, randomized, controlled, multicenter, phase III study with two parallel arms||||
34060822|NCT01859052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060823|NCT06037525|||COHORT||PROSPECTIVE|||||||
34060824|NCT04170907|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Vaping of high and low concentration nicotine salt and free-base nicotine will be double-blinded.|Participants will be switched in a within-subject crossover design among the three product types.|t|f|t|f
34060825|NCT02147405|||COHORT||PROSPECTIVE|||||||
34060826|NCT01523288|||CASE_CONTROL|||||||||
34060827|NCT05481918|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinding of the patients is not possible, due to the nature of the study and the obviosity of group allocation. The principal investigator will be blinded to the allocation and will only get access to the coding list in special cases (e.g. harm). Furthermore, the principal investigator is not involved in the statistical analysis of data.||f|f|t|f
34060828|NCT04858594|||COHORT||PROSPECTIVE|||||||
34060829|NCT00937248|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060830|NCT06430775|||COHORT||PROSPECTIVE|||||||
34060831|NCT06726902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060832|NCT05068492|||COHORT||CROSS_SECTIONAL|||||||
34060833|NCT03457805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165170|NCT01030835|||||OTHER|||||||
33852962|NCT05085236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852963|NCT00580645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34165171|NCT01079975|||COHORT||PROSPECTIVE|||||||
34165172|NCT02028533|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34165173|NCT05660148|||CASE_ONLY||PROSPECTIVE|||||||
34165174|NCT04334304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Arm 1: Posterior Stabilized TKA without robot Arm 2: Posterior Stabilized TKA with robot Arm 3: Bicruciate retaining TKA without robot Arm 4: Bicruciate retaining TKA with robot|f|t|f|t
34165175|NCT03769259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34165176|NCT04593524|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165177|NCT02742831|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34165178|NCT02028442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165179|NCT05201794|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34165180|NCT05810363|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165181|NCT00842218|||COHORT||PROSPECTIVE|||||||
34165182|NCT00226057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165183|NCT00494585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165184|NCT01073449|||COHORT||PROSPECTIVE|||||||
34165185|NCT05497089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165186|NCT04872192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34165187|NCT00867165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165188|NCT03987477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165189|NCT06725459|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Prevena Restor Bella Form™ wound vacuum will be applied to the reduction mammaplasty incision as directed for up to 7 days postoperatively. Prevena Restor Bella Form™ is a ciNPWT management system. ciNPWT management systems apply negative pressure to the incision and structurally stabilize the surrounding tissues.||||
34165190|NCT02046707|NON_RANDOMIZED|PARALLEL||||NONE||||||
34165191|NCT00195949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165192|NCT05396053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study (2 groups) and control|f|f|f|t
34165193|NCT06726707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Adaptative Design, Randomized, Multicenter, Controlled, Double-Blinded Exploratory trial|t|t|t|f
34165194|NCT00950846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165195|NCT04203836|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||Single dose, cross-over with food effect|t|t|t|f
34165196|NCT06151444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165197|NCT03335735|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will be blinded to their random assignment into the control, loss-framed messaging, or gain-framed messaging group.||t|f|f|f
34165198|NCT02297386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165199|NCT05630950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165200|NCT01218581|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165201|NCT01433796|||COHORT||PROSPECTIVE|||||||
34165202|NCT01706523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852964|NCT05344040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852965|NCT01340651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852966|NCT01380574|||COHORT||RETROSPECTIVE|||||||
34165203|NCT00806910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165204|NCT03789240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165205|NCT02016651|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34165206|NCT04184284|||COHORT||PROSPECTIVE|||||||
34165207|NCT00398697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165208|NCT05035940|||OTHER||CROSS_SECTIONAL|||||||
34165209|NCT04929678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165210|NCT05689255|||COHORT||PROSPECTIVE|||||||
34165211|NCT05366569|||OTHER||PROSPECTIVE|||||||
34165212|NCT01412528|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165213|NCT00456404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165214|NCT05669859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The exercise intervention planned in the study includes physical movements and is carried out by connecting to the participant via remote online communication tools.|f|f|f|t
34165215|NCT06609083|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34165216|NCT02733445|||COHORT||RETROSPECTIVE|||||||
34165217|NCT01946217|||COHORT||PROSPECTIVE|||||||
34165218|NCT05928403|||COHORT||OTHER|||||||
34165219|NCT00854230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956769|NCT06236126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blinded observer (positioned in front of the patient and unable to see the procedure) will record data during the epidural procedure|A single center, prospective, randomized, double blind pilot study for the evaluation of pain due to epidural Tuohy needle insertion with prior administration of subcutaneous or intradermal administration of lidocaine in parturient women requesting epidural analgesia for laboring pain at The Ohio State University Wexner Medical Center - Obstetric Anesthesia Division.|t|f|f|t
34165220|NCT06630806|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study is non-randomized for part A but randomized for part B. Study drug will be assigned in sequential manner in Part A but parallel assignment in Part B.||||
34165221|NCT00509470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747052|NCT01895166|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33747053|NCT01625429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747054|NCT05661331|||COHORT||PROSPECTIVE|||||||
34165222|NCT00183105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165223|NCT01016600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165224|NCT04851626|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking not feasible for pilot design.|Pilot randomised controlled trial with 2 parallel study arms.||||
34165225|NCT03605966|||COHORT||PROSPECTIVE|||||||
33747055|NCT06453226|||COHORT||CROSS_SECTIONAL|||||||
34165226|NCT05624307|||COHORT||PROSPECTIVE|||||||
34165227|NCT06690905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165228|NCT03686904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165229|NCT02493686|||COHORT||RETROSPECTIVE|||||||
34165230|NCT05682339|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|In order to blind both investigator and participant, the treatments will be prepared on the morning of each study day, and filled in covered syringes, by a research officer who will have no involvement in data analysis.||t|f|t|t
33747056|NCT06393465|||COHORT||RETROSPECTIVE|||||||
33747057|NCT06259253|||CASE_ONLY||CROSS_SECTIONAL|||||||
33747058|NCT01576562|||CASE_CONTROL||PROSPECTIVE|||||||
33747059|NCT02804542|||COHORT||OTHER|||||||
33747060|NCT03839953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747061|NCT00439907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747062|NCT06476717|||COHORT||PROSPECTIVE|||||||
33747063|NCT02179112|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33747064|NCT06058832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33747065|NCT01024322|||COHORT||PROSPECTIVE|||||||
33747066|NCT05888701|||COHORT||RETROSPECTIVE|||||||
33747067|NCT03797404|||COHORT||PROSPECTIVE|||||||
33747068|NCT03895424|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33747069|NCT06326801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747070|NCT02040480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747071|NCT02388386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747072|NCT02368353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747073|NCT06516588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747074|NCT05358444|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33747075|NCT05616533|||CASE_ONLY||PROSPECTIVE|||||||
33747076|NCT05062239|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Discontinuous of statin Intervention: Discontinuous of statin, n = 50 Length of preoperative discontinuous: 7 to 14 days prior to surgery Length of postoperative discontinuous: 30 days Control group: continuing medication, n = 50~No withdrawal study could be found in the literature. We therefore estimate that 100 patients with 50 patients in each group will be enough to observe significant differences, if withdrawal statin should be a clinically manifested issue for the risk of POAF from 36% to 66%.~Sample size Continuance of statins: 50 Discontinuance of statins: 50"||||
33747077|NCT03020147|||COHORT||RETROSPECTIVE|||||||
33747078|NCT05264753|||OTHER||PROSPECTIVE|||||||
33747079|NCT01508403|||||PROSPECTIVE|||||||
33747080|NCT06669403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747081|NCT05008354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747082|NCT03069222|||CASE_CONTROL||PROSPECTIVE|||||||
33747083|NCT06557265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747084|NCT02479412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747085|NCT03392311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747086|NCT02921997|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33956770|NCT02672488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852967|NCT00819962|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33956771|NCT00798707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956772|NCT02507271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956773|NCT06059547|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be assigned to a treatment group based on tumor tissue and tumor size.|t|f|f|f
33956774|NCT05959564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956775|NCT04222478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33852968|NCT02487732|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33956776|NCT02603536|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Repeated measures study. All participants acted as their own controls with data from year prior to intervention serving as control data and data from intervention year as intervention data.||||
33852969|NCT02850367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33852970|NCT01401582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33852971|NCT04782401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33852972|NCT00294853|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852973|NCT06336720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852974|NCT05444153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852975|NCT02743156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852976|NCT01285609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956777|NCT01652482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956778|NCT06566560|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33956779|NCT00832286|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33956780|NCT04509440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956781|NCT03706209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Three-arm randomized, double-blind, placebo-controlled, parallel group phase II multi-center trial|t|t|t|t
33956782|NCT05131893|||COHORT||PROSPECTIVE|||||||
33956783|NCT05308654|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33956784|NCT04749121|NA|SEQUENTIAL||PREVENTION||NONE|The participants will be tested for fit test before and after UVC determination of the respirators.The other tests were in vitro and based on the survival of bacteria and virus on the masks together with the tensile strength|Before and after intervention in one group||||
33956785|NCT01307488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956786|NCT03601923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956787|NCT01506986|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33956788|NCT03356769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, investigators, site personnel, and the sponsor's study team were masked to treatment allocation, but allocation was not concealed from personnel in charge of drug supply, and implementation of the randomisation list. The Data Safety Monitoring Board (DSMB) independent statistician and programmer were semi-blind to treatment allocation at the time of DSMB meetings.||t|t|t|t
33956789|NCT06540040|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|his study is an open-label trial, meaning that there is no masking. All parties involved in the study, including participants, care providers, investigators, and outcome assessors, are aware of the type of dressing each participant receives.|"### Model Description~\*\*Parallel Assignment\*\*: This study employs a parallel assignment model, where participants are randomly allocated to one of four intervention groups. Each group receives a distinct type of wound dressing post-operatively. The outcomes are measured and compared across these groups to evaluate the efficacy of each dressing type. The interventions include Aquacel Ag, OPSITE, MEPILEX POST OP BORDER, and traditional gauze-based dressings. This model allows for a direct comparison of the different interventions in a controlled manner."||||
33956790|NCT00203892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956791|NCT05570175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher who collected the data and the researcher who applied the intervention program was never the same.|Participants were randomly assigned to experimental group who received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks, and a control group receiving standard rheumatology care only.|f|f|f|t
33956792|NCT06446193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956793|NCT05037409|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33852977|NCT05142384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to participant condition.|Head Start (HS) agencies will be randomized to offer Mom-Net with either high- or low- intensity coaching. Subsequently, participants will be randomized to either the Mom-Net condition offered by their child's HS agency or to Treatment as Usual within the community/Waitlist (TAU/WL). Assessments will be conducted at T1- prior to participant randomization, at T2- subsequent to the conclusion of the intervention period, and at T3 1 year after T1. Subsequent to the T2 assessments, participants in the TAU/WL condition will be offered the opportunity to participate in the Mom-Net version offered by their HS agency. The T3 assessment will thus enable us to examine Maintenance of effects for those in the Mom-Net condition, and Replication of Mom-Net within group effects for those in the TAU/WL condition.|f|f|f|t
33852978|NCT05364749|||COHORT||PROSPECTIVE|||||||
33956794|NCT06649643|||COHORT||CROSS_SECTIONAL|||||||
33956795|NCT02449109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956796|NCT06048718|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, two-stage optimal Simon's design, phase II clinical trial.||||
33956797|NCT06073873|||COHORT||PROSPECTIVE|||||||
33956798|NCT05972954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956799|NCT04432129|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33956800|NCT04631055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060834|NCT00011180|||CASE_CONTROL||RETROSPECTIVE|||||||
33852979|NCT06191653|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This project will use a longitudinal design. Caregivers recruited from 4 (out of 6) YDC, selected based the number of available caregivers, will be allocated to two conditions: 2 to the treatment group and the other 2 to the wait-list control group. The criteria of this allocation is the number of caregivers available in each institution: the treatment group will be composed of the two YDC with the larger number of caregivers in order to increase the chance of having a greater number of participants and dealing with natural dropout levels. A sample of youth will be recruited in all 4 YDC to assess the indirect impact of the intervention program. This trial will include a Treatment group (N=25), a Waiting list Control group (N=25), and a sample of youth (20 recruited from the Treatment YDC and 20 recruited from the Control YDC).|This project will use a longitudinal design. Caregivers recruited from 4 (out of 6) YDC, selected based the number of available caregivers, were allocated to two conditions: 2 to the treatment group and the other 2 to the wait-list control group. The criteria of this allocation was the number of caregivers available in each institution: the treatment group was composed of the two YDC with the larger number of caregivers in order to increase the chance of having a greater number of participants and dealing with natural dropout levels. A sample of youth was all recruited in all 4 YDC to assess the indirect impact of the intervention program. This trial included a Treatment group (N=34), a Waiting list Control group (N=36), and a sample of youth (45 recruited from the Treatment YDC and 31 recruited from the Control YDC).|f|f|f|t
33852980|NCT05309343|||COHORT||PROSPECTIVE|||||||
33852981|NCT01295177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33852982|NCT04020705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33852983|NCT01724853|NON_RANDOMIZED|PARALLEL||||NONE||||||
33852984|NCT00690560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33852985|NCT02869100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33852986|NCT01182701|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33852987|NCT02940405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33852988|NCT02927600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33852989|NCT02238574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852990|NCT01893437|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33852991|NCT04771949|||COHORT||CROSS_SECTIONAL|||||||
33852992|NCT03814187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852993|NCT04463212|||CASE_ONLY||PROSPECTIVE|||||||
33956801|NCT05367934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The nurses in the intervention group were given therapeutic touch for 15 minutes once a week for two weeks, and the patients in the control group did not receive any treatment other than their routine care.|This study is a randomized controlled experimental study.|t|f|f|f
33956802|NCT04124900|||CASE_ONLY||PROSPECTIVE|||||||
33956803|NCT05063318|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors.||||
33956804|NCT02025400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956805|NCT01500434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956806|NCT06333041|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, cross-over study|t|t|t|t
33956807|NCT05385276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956808|NCT01596088||||TREATMENT||NONE||||||
33956809|NCT01974869|||COHORT||PROSPECTIVE|||||||
33956810|NCT06702449|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Data will be collected in an observer-blind manner||t|f|t|t
33956811|NCT05044637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165231|NCT05432284|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|placebo controlled, double blind|All participants will complete all dose conditions (study arms) in a randomized order|t|f|f|t
34165232|NCT01187485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165233|NCT06727019|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165234|NCT04491968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm randomized controlled trial.|f|f|t|t
34165235|NCT04050618|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subjects will be masked to lens type. Investigators will be unmasked.||t|f|f|f
34165236|NCT02660853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165237|NCT05781074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165238|NCT05539001|||COHORT||PROSPECTIVE|||||||
34165239|NCT04050449|||COHORT||PROSPECTIVE|||||||
34165240|NCT02320929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34165241|NCT06726148|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165242|NCT06727253|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34165243|NCT06726694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956812|NCT04925479|NA|SEQUENTIAL||TREATMENT||NONE||||||
33956813|NCT06697483|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956814|NCT03356366|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33956815|NCT01341158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956816|NCT04946474|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956817|NCT04375735|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to either receive exogenous surfactant daily for 3 days, or receive standard treatment.||||
33956818|NCT04188678|NA|SINGLE_GROUP||OTHER||NONE||Age ≥60 years who are undergoing allogeneic bone marrow transplant at Johns Hopkins Hospital to treat a hematologic malignancy||||
33956819|NCT02096796|||COHORT||PROSPECTIVE|||||||
33956820|NCT02058368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956821|NCT02512991|||COHORT||PROSPECTIVE|||||||
33956822|NCT02800278|||COHORT||PROSPECTIVE|||||||
34165244|NCT04871425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165245|NCT03741972|||COHORT||PROSPECTIVE|||||||
34165246|NCT02636205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165247|NCT04110782|||CASE_CONTROL||RETROSPECTIVE|||||||
34165248|NCT04472234|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060835|NCT06625593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165249|NCT05440812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Efficacy of STAIRS will be assessed by conducting a randomized controlled trial (N=140). In this trial, participants will be randomly assigned either to the experimental group receiving care as usual complemented with the STAIRS-training or the control group receiving care as usual. Measurement points are at T0 (baseline), T1 (post-treatment) and T2 (6 months after end of treatment). Qualitative semi-structured interviews will be held in the experimental group at T1 about the value that participants assign to the elements of the training, as well as the experienced acceptability, and perceived usefulness of the training.||||
34165250|NCT02316561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165251|NCT06468098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165252|NCT06345625|||CASE_CONTROL||PROSPECTIVE|||||||
34165253|NCT04803851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165254|NCT05682742|NA|SINGLE_GROUP||OTHER||NONE||||||
34165255|NCT02847559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165256|NCT01821339|||CASE_ONLY||PROSPECTIVE|||||||
34165257|NCT02922998|||COHORT||PROSPECTIVE|||||||
34165258|NCT02729441|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165259|NCT04265807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and investigators will be masked to treatment assignment up to the point of randomization.||t|f|t|f
34165260|NCT00844376|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34165261|NCT04485546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165262|NCT00139230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165263|NCT03762031|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34165264|NCT01108913|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33747087|NCT04287023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33852994|NCT04310891|||COHORT||PROSPECTIVE|||||||
34165265|NCT06692140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165266|NCT01603589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33852995|NCT03327337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33852996|NCT03830749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33852997|NCT03298711|||CASE_ONLY||PROSPECTIVE|||||||
33852998|NCT00251823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33852999|NCT06214299|||OTHER||PROSPECTIVE|||||||
33853000|NCT00559858|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33853001|NCT02058654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34060836|NCT04268654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060837|NCT04962828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060838|NCT03603977|||CASE_ONLY||PROSPECTIVE|||||||
34060839|NCT04502238|||CASE_CROSSOVER||PROSPECTIVE|||||||
34060840|NCT02457832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060841|NCT01071863|||COHORT||PROSPECTIVE|||||||
34060842|NCT02352987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060843|NCT03570554|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34060844|NCT06342583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060845|NCT05021458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060846|NCT00525902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060847|NCT01040936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165267|NCT04034784|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34165268|NCT02392130|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34165269|NCT00366951|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34165270|NCT00491491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165271|NCT04846322|||COHORT||PROSPECTIVE|||||||
34165272|NCT00106327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165273|NCT04566601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165274|NCT00241722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853002|NCT04633798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853003|NCT04178044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853004|NCT04585776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853005|NCT03717129|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33853006|NCT04708925|||OTHER||RETROSPECTIVE|||||||
33853007|NCT01116882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853008|NCT03270397|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33853009|NCT00416234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853010|NCT02749240|NA|SINGLE_GROUP||OTHER||NONE||||||
33853011|NCT04149730|||CASE_ONLY||PROSPECTIVE|||||||
33853012|NCT02020759|||COHORT||PROSPECTIVE|||||||
33853013|NCT02041234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853014|NCT01904123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853015|NCT04985760|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Randomized, double-blind, dose escalation|t|t|t|t
33853016|NCT00715962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853017|NCT03585413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||prospective, randomized, placebo-controlled, double-blind interventional study|t|t|t|t
33853018|NCT03531970|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33853019|NCT05128994|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33853020|NCT03508037|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33853021|NCT04719884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853022|NCT05909995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33853023|NCT06318715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853024|NCT04176146|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33956823|NCT06538428|||CASE_CONTROL||RETROSPECTIVE|||||||
33956824|NCT06505213|||COHORT||RETROSPECTIVE|||||||
33956825|NCT05562713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33956826|NCT03231709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956827|NCT01777191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956828|NCT06195267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956829|NCT05920031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956830|NCT05647694|NA|SINGLE_GROUP||OTHER||NONE|The use of the app will not be masked.|Participants will compare the value of the prototype app to their previous navigational experience without the app.||||
33956831|NCT04196699|NA|SINGLE_GROUP||OTHER||NONE||||||
33956832|NCT02145000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33956833|NCT05162326|NA|SEQUENTIAL||TREATMENT||NONE||||||
33956834|NCT05573646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33956835|NCT05008419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||40 participants with TBI will be randomized to receive the discourse treatment with a telehealth component or Treatment as Usual (TAU).|f|f|f|t
34060848|NCT04585620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060849|NCT02271399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33747088|NCT03021226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747089|NCT06670976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747090|NCT02978274|||CASE_CONTROL||PROSPECTIVE|||||||
33747091|NCT00149058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33853025|NCT04708210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853026|NCT02905071|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33853027|NCT03018951|||COHORT||CROSS_SECTIONAL|||||||
33853028|NCT06108882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853029|NCT05827432|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33853030|NCT02143557|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853031|NCT02798965|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34060850|NCT04748172|||CASE_CONTROL||PROSPECTIVE|||||||
33853032|NCT01335087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060851|NCT00782600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060852|NCT05718323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060853|NCT01214252|||||RETROSPECTIVE|||||||
33853033|NCT04070443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853034|NCT03312283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853035|NCT00737971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853036|NCT01550445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853037|NCT00989131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853038|NCT02850120|||COHORT||RETROSPECTIVE|||||||
33853039|NCT03741452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853040|NCT02050711|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33853041|NCT00687973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853042|NCT00913315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853043|NCT01094379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853044|NCT06398977|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33853045|NCT05007808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853046|NCT00508703|||CASE_ONLY||PROSPECTIVE|||||||
33853047|NCT01820013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853048|NCT05222724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853049|NCT05275725|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib open-label single-arm dose-finding clinical trial||||
33853050|NCT04058366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853051|NCT01007643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33853052|NCT01210664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853053|NCT02440009|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853054|NCT02311868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853055|NCT02304796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853056|NCT04622774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853057|NCT01227577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853058|NCT03271021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853059|NCT04782466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|All participants will receive both the intervention and the attention-control condition and will not be informed of which of the procedures is the active intervention condition. The statistician, PI, and fitness testers, and physical activity data analysts will be blinded to the group assignment.|At baseline, participants will be randomized using online research randomizer software, in blocks of 2 each, balanced for the clinical site, sex, and pubertal status (using self-selected Tanner staging), which may independently predict physical fitness level and has also been associated with physical activity level especially in adolescent girls to either a 6-month PA intervention or waitlist attention-control condition. The research coordinator will request the randomization of the participant as provided by the online research randomizer at the completion of the baseline test and will inform the study participant of their assigned study arm.|t|t|t|t
33853060|NCT00763737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853061|NCT02662101|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33853062|NCT01601886|||COHORT||RETROSPECTIVE|||||||
33853063|NCT01882933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853064|NCT02445001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853065|NCT00405691|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33853066|NCT05373160|||OTHER||PROSPECTIVE|||||||
33853067|NCT03810612|||COHORT||PROSPECTIVE|||||||
33853068|NCT01105754|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33853069|NCT01508715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853070|NCT01243632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853071|NCT01952054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853072|NCT00279786|||COHORT||OTHER|||||||
33853073|NCT01677897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853074|NCT00760006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853075|NCT02589860|||COHORT||PROSPECTIVE|||||||
33853076|NCT03277573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind study. Only investigational pharmacist will be unblinded.|Randomized, Double-Blind, Placebo-Controlled|t|t|t|f
33853077|NCT03787082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will receive open label nitrate and be randomly assigned to either chlorhexidine mouthwash or placebo mouthwash. The participant and investigator will be blinded to which mouthwash the participant is randomized.||t|f|t|f
33853078|NCT01115751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853079|NCT04260880|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33853080|NCT01944371|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33853081|NCT03534323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853082|NCT02649946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853083|NCT03946150|||CASE_CONTROL||RETROSPECTIVE|||||||
33853084|NCT03059069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853085|NCT01452321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853086|NCT04928430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a phase II/III, multicenter, international, randomized (1:1), placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of XAV-19 in patients with moderate-to-severe COVID-19.|t|t|t|f
33853087|NCT02970474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853088|NCT02091648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853089|NCT02872831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33853090|NCT01312012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853091|NCT03466801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853092|NCT01827618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853093|NCT01667211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853094|NCT00987246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853095|NCT02639598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853096|NCT02594761|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34060854|NCT03150394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060855|NCT02720900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747092|NCT05975268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study uses a double-blind design in which subjects, investigators, and other researchers will remain blind to the allocation of the study drug and placebo.~If serious adverse events occur to subjects during the study, the investigator must be informed of the treatment received by the subjects before appropriate treatment can be given. For safety reasons, the investigator may unblind the subjects urgently after obtaining the consent of the sponsor's medical monitor."|Parallel|t|t|t|t
33747093|NCT05625048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33747094|NCT06635382|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33747095|NCT04913363|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study was designed in a single group, where participants will be complete the interventions (green space activities) in this order: Citizen Science, Walking, Planting. However, participants may or may not show up on the day of an activity. i.e. participants may skip one or more interventions, even though that was not the intent of the study design.||||
33747096|NCT02279758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747097|NCT03089086|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A cluster randomised controlled trial to assess the impact of meningococcal B vaccine 4CMenB on nasopharyngeal carriage of N. Meningitidis|f|f|t|t
33747098|NCT06369350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33747099|NCT00868023|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747100|NCT05005975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747101|NCT01742767||PARALLEL||TREATMENT||||||||
33747102|NCT05102487|||COHORT||PROSPECTIVE|||||||
33747103|NCT04137380|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33747104|NCT05892679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The researcher cannot be blinded due to the nature of the research. However, participants will be blinded without knowing whether they are in the study group or the placebo group. Thus, the research will be carried out as a single-blind randomized controlled trial. When the research is completed, the data of the study and control groups (coded as A or B) will be transferred to the computer environment by an independent researcher, and the data will be analyzed by a statistician and the findings will be reported.|Prospective, randomized controlled study|t|f|f|t
34060856|NCT05442606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060857|NCT05481268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34060858|NCT06529172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747105|NCT05475418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747106|NCT05795595|NA|SEQUENTIAL||TREATMENT||NONE||||||
33747107|NCT03752229|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33747108|NCT02644460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747109|NCT01939028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747110|NCT06635603|||COHORT||PROSPECTIVE|||||||
33747111|NCT06114446|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33747112|NCT01042457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747113|NCT06433180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747114|NCT00578994|||COHORT||PROSPECTIVE|||||||
33747115|NCT05637021|||COHORT||PROSPECTIVE|||||||
33747116|NCT03337529|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33747117|NCT03135951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747118|NCT01436994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747119|NCT01613248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747120|NCT03671330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747121|NCT06099613|NA|SEQUENTIAL||PREVENTION||NONE||||||
33747122|NCT01169467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747123|NCT04894604|NA|SINGLE_GROUP||TREATMENT||NONE||Single group of Subjects (with a low to moderate exuding surgically closed incision) in use of the Avance® Solo NPWT System.||||
33747124|NCT04696731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747125|NCT04775680|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33747126|NCT02495753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747127|NCT00074035|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747128|NCT03675022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747129|NCT04838574|||COHORT||PROSPECTIVE|||||||
33853097|NCT00326404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747130|NCT03932643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060859|NCT05547061|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34060860|NCT05344690|||CASE_CONTROL||RETROSPECTIVE|||||||
34060861|NCT03906292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||5 parallel cohorts||||
34060862|NCT02540681|||COHORT||PROSPECTIVE|||||||
34060863|NCT06517173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This trial is designed as a multicenter, randomized, double-blind, placebo-parallel controlled trial using a multicenter, randomized, double-blind, placebo-parallel controlled trial design. Subjects are randomly assigned in a 1:1 ratio and random number tables are generated using SAS（Statistics Analysis System）software.|t|t|t|f
34060864|NCT02713854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060865|NCT06126016|||COHORT||PROSPECTIVE|||||||
34060866|NCT01668953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34060867|NCT02935582|||COHORT||PROSPECTIVE|||||||
34060868|NCT03782974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, on-site care-providers and investigators, and the outcome assessors will be informed that this study is placebo controlled, and that each participant has a 50/50 chance of receiving treatment or placebo. The test material will include treatment and placebo, both coated by the same coating. The code will be kept by the sponsor and disclosed after the analyses are completed.|Individuals with Protective Qi Insufficiency|t|t|t|t
34060869|NCT06011304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060870|NCT02470403|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34060871|NCT04840459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060872|NCT04655144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060873|NCT03042754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34060874|NCT00189319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060875|NCT04508114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34060876|NCT05474118|||COHORT||RETROSPECTIVE|||||||
34060877|NCT02962323|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060878|NCT00079872|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34060879|NCT03589118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome (VAS scale) will be presented to the patient and reported by a study nurse blinded of the randomization arm of the patient.|"Patients are randomized in two groups :~* usual medical and psychological support in the control group~* qi gong sessions added in the experimental group~Allocation between groups qi and control is 1 : 1"|f|f|f|t
33747131|NCT03975348|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747132|NCT02310750|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33747133|NCT04786444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33747134|NCT06285812|||COHORT||OTHER|||||||
33747135|NCT01572727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747136|NCT02590354|NA|SINGLE_GROUP||OTHER||NONE||||||
33747137|NCT03759873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33747138|NCT01764945|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060880|NCT05099107|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34060881|NCT01078506|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34060882|NCT04568291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060883|NCT02368743|||COHORT||PROSPECTIVE|||||||
34060884|NCT01072513|NA|SINGLE_GROUP||||NONE||||||
34060885|NCT03437876|NA|SINGLE_GROUP||TREATMENT||NONE||a open-label, self-control study||||
34060886|NCT02147522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34060887|NCT03534115|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|the investigators, clinical staff and patients were blinded. The main solution containing NAC or the placebo was marked by A and B.||t|t|t|f
34060888|NCT04936659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060889|NCT02201095|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34060890|NCT02698644|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34060891|NCT05100498|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060892|NCT04205461|||COHORT||PROSPECTIVE|||||||
34060893|NCT05051800|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Recruitment and randomization of participants into an online support program vs. usual care. Participants in the usual care condition offered the program after 6 months.||||
34060894|NCT03764228|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34060895|NCT05117398|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, pragmatic, open-label, non-inferiority, randomized (1:1), multicenter trial, in patients with non-complicated CR-BSI due to S. aureus, with two parallel groups receiving 14 days of active antimicrobial therapy.||||
34060896|NCT00718796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060897|NCT06327685|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33747139|NCT01325168|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747140|NCT01973127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747141|NCT00579917|||COHORT||PROSPECTIVE|||||||
33853098|NCT03536754|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-blind|Randomized, placebo-controlled, Phase 2|t|t|t|f
33853099|NCT00377091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853100|NCT06164392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853101|NCT05522790|||COHORT||RETROSPECTIVE|||||||
33853102|NCT02245906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33853103|NCT05345808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853104|NCT00002301||||TREATMENT||||||||
33853105|NCT01955889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853106|NCT04447690|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33853107|NCT01149356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853108|NCT05374161|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 2-arm RCT will be conducted (brief ACT-based intervention vs waitlist control group).||||
33853109|NCT00414687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853110|NCT04257591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind||f|f|f|t
33853111|NCT05187182|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The dose escalation phase will occur first. In the dose expansion phase, participants will be assigned to either Cohort A or Cohort B and treated in parallel.||||
33853112|NCT00413972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853113|NCT02789254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853114|NCT05523999|||COHORT||PROSPECTIVE|||||||
33853115|NCT05040984|||COHORT||RETROSPECTIVE|||||||
33853116|NCT05609201|||CASE_CONTROL||PROSPECTIVE|||||||
33853117|NCT02118558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853118|NCT03430531|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm, pilot study||||
33853119|NCT04033185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853120|NCT04822831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.|This study used repeated experimental measurements and purpose sampling, and we invited patients in respiratory care ward (RCW) in northern Taiwan. They were randomly assigned to the experimental group and the control group. The experimental group was given 45 degree Semi-sitting for 2hrs and upper-limb exercise training 10mins once a day. The control group was just continue the routine treatment. After 4 weeks, we measure the respiratory parameters such as maximum inspiratory pressure (MIP), tidal volume (VT), minute ventilation (MV), and rapid shallow breathing index(RSBI) of these two groups, and used GEE to compare with them. To find the differences in respiratory parameters, ventilator detachment rate,|t|f|f|f
33853121|NCT02723526|||||PROSPECTIVE|||||||
33853122|NCT00004051||||TREATMENT||||||||
33853123|NCT02684253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853124|NCT04900987|RANDOMIZED|PARALLEL||PREVENTION||NONE||patients will be randomly assigned in a 1:1 manner to radial arterial compression with conventional pneumatic TR band alone and radial arterial compression with pneumatic TR band mechanical compression with use of clean sterile steri-strips.||||
33853125|NCT01478529|RANDOMIZED|CROSSOVER||||NONE||||||
33853126|NCT02450799|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33853127|NCT00427895|RANDOMIZED|||PREVENTION||QUADRUPLE|||t|t|t|t
33956836|NCT05113277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be randomly assigned to the active or control condition. The participant will not be informed of which condition they are receiving until after completion of the study, at which point individuals in the control condition will be given access to the active intervention.|Participants will be randomly assigned to complete 1 of 2 interventions - active or control.|t|f|f|f
33956837|NCT01062022|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33956838|NCT06172361|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatment group: Prednisone (or equivalent dose of methylprednisolone) + Tofacitinib~Positive control group: prednisone (or equivalent dose of methylprednisolone)"||||
33956839|NCT06566287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956840|NCT06082609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||h. According to the functional impression techniques, all patients will be classified into two equal groups: Group A: Functional relining of processed RPD base at insertion Group B : Digitally obtained altered cast|t|f|f|f
33956841|NCT05439291|RANDOMIZED|PARALLEL||PREVENTION||NONE||The research will consist of randomized 1:1 controlled trial comparing regular epilation regimen only vs. regular epilation regimen with surgical excision||||
33956842|NCT06156761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956843|NCT02179385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956844|NCT05537246|||CASE_CROSSOVER||PROSPECTIVE|||||||
33956845|NCT05871853|||COHORT||PROSPECTIVE|||||||
33956846|NCT01247753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956847|NCT02425358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956848|NCT06568315|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Counseling messages and supplement packaging do not enable masking of participants or study staff with direct participant contact. Laboratory staff measuring the trial's outcomes and investigators will be masked.||f|f|t|t
33956849|NCT01064830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34060898|NCT03356119|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All recruited subjects will be assigned to implant removal using the RemovAid IMD. There is no formal comparator in this study. The investigators are investigating design functionality and safety.||||
34060899|NCT01706575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060900|NCT04982016|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34060901|NCT01619020|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34060902|NCT00073892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060903|NCT02645552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34060904|NCT05405660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060905|NCT06408311|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34060906|NCT00088959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060907|NCT01582763|||COHORT||PROSPECTIVE|||||||
34060908|NCT03477994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34060909|NCT01676506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060910|NCT03650725|||COHORT||PROSPECTIVE|||||||
34060911|NCT01712334|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060912|NCT00924391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060913|NCT01886781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060914|NCT01591551|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165275|NCT03921034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the regional anesthesiologist performing the block will know the randomization status. The study participants, outcome assessors/researchers, other anesthesia personnel, surgeons, physician assistants, and nurses will be blinded to the treatment arm.||t|t|f|f
34165276|NCT01839058|||COHORT||PROSPECTIVE|||||||
33747142|NCT04805125|RANDOMIZED|PARALLEL||OTHER||NONE||Cohort embedded platform with a first sub-study pilot trial of two arms comparing licensed vaccines against SARS-CoV-2. The platform design allows to expand the pilot trial into a larger trial by sub-protocols to add or drop vaccine arms or to add further sub-protocols for re-randomization of patients with no immune response to a vaccine booster or new vaccines A parallel two-arm open-label randomized controlled exploratory pilot trial comparing the first in Switzerland approved SARS-CoV-2 vaccines (based on a trial platform that is integrated into the ongoing routine prospective data collection of two national cohorts, the SHCS and STCS). Within substudy-2 and substudy-3 observational studies were added to the platform trial.||||
34165277|NCT06344728|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165278|NCT01086774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165279|NCT05356832|||COHORT||CROSS_SECTIONAL|||||||
34165280|NCT02735148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165281|NCT02583919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747143|NCT03349450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747144|NCT01237639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747145|NCT00352365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165282|NCT03953833|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is divided into the dose escalation group and the dose expansion group. Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is from day 1 to day 21 of the first treatment cycle.~Dose expansion stage: treatment cycle is administered every 21days and could be administered continuously until the disease progresses or is intolerable.DLT is not accessed during this stage.~Blind method: open Test range: Domestic test"||||
34165283|NCT04257890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34165284|NCT00750724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34165285|NCT05456880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165286|NCT02322437|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165287|NCT05946941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165288|NCT05219682|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participant started with EEG measurements at rest followed by 3 EEG measurements in mirror therapy and 3 EEG measurements with mirror therapy in virtual reality. The order of measurement was randomized.||||
34165289|NCT05768412|||COHORT||PROSPECTIVE|||||||
34165290|NCT01201720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165291|NCT06176742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165292|NCT00026702|||COHORT||CROSS_SECTIONAL|||||||
34165293|NCT04692675|NA|SINGLE_GROUP||OTHER||NONE||||||
34165294|NCT00882232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165295|NCT04579341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165296|NCT02910466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165297|NCT00733629|||COHORT||PROSPECTIVE|||||||
34165298|NCT04197349|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34165299|NCT02423057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165300|NCT03140397|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34165301|NCT05946603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34165302|NCT03623763|||COHORT||PROSPECTIVE|||||||
34165303|NCT02412228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165304|NCT01231919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165305|NCT03764644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, sham-controlled, randomized trial|t|t|t|t
34165306|NCT05252949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||We will administer either OEA or placebo to the study participants over a blinded period of 10 weeks, followed by an open label phase with all participants receiving OEA for 5 weeks.|t|t|t|t
34165307|NCT01493401|NA|SINGLE_GROUP||OTHER||NONE||||||
34165308|NCT00638534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165309|NCT01395901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165310|NCT03413124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165311|NCT01731054|||COHORT||PROSPECTIVE|||||||
34165312|NCT03776747|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33747146|NCT02345031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747147|NCT00006325||||TREATMENT||||||||
33747148|NCT04749420|||OTHER||PROSPECTIVE|||||||
33747149|NCT01309620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747150|NCT02034578|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33747151|NCT03560427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747152|NCT01943201|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33747153|NCT03872349|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33747154|NCT06668311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33747155|NCT05331352|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||First group : women following a psychotherapy Second group : women unfollowing a psychotherapy||||
33747156|NCT01168817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747157|NCT05003791|||OTHER||CROSS_SECTIONAL|||||||
33747158|NCT03966976|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33747159|NCT01305967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853128|NCT01365949|||CASE_ONLY||RETROSPECTIVE|||||||
33853129|NCT04097301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853130|NCT02996565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165313|NCT03087513|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|"This is a randomized blinded study where the administering anesthetist, surgeon and neurophysiologists will be blinded to the intervention.~Further, a blinded research assistant will perform assessment, data collection, and analysis of neurophysiology data attained."|Randomized controlled crossover trial comparing the change in MEP amplitudes with administration of sugammadex or placebo.|t|t|t|t
34165314|NCT06725108|||COHORT||PROSPECTIVE|||||||
34165315|NCT00001186|||COHORT||PROSPECTIVE|||||||
34165316|NCT01826656|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165317|NCT06396819|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|single-blind|A therapeutic intervention using povidone collagen vs. placebo was carried out, and the patients were recruited after meeting the inclusion criteria and divided into two randomized groups (Case vs Control). Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group.|t|f|f|f
34165318|NCT01889225|||COHORT||PROSPECTIVE|||||||
34165319|NCT03610841|||CASE_CONTROL||PROSPECTIVE|||||||
34165320|NCT06437262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165321|NCT03800238|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be collected via survey and data analysis will be conducted blinded to study group assignment.||f|f|f|t
33747160|NCT01221597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747161|NCT04729803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747162|NCT04936022|RANDOMIZED|PARALLEL||OTHER||NONE||Multi-centre randomized controlled feasibility study||||
33747163|NCT06216847|||COHORT||PROSPECTIVE|||||||
33747164|NCT03525353|||CASE_ONLY||RETROSPECTIVE|||||||
33853131|NCT01043393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853132|NCT05314790|||COHORT||RETROSPECTIVE|||||||
33853133|NCT05003440|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||The study consists of two parts. Part 1 consists of three sequential dose ascension cohorts each with 4 healthy Japanese participants, randomised 3:1. The purpose of Part 1 is to provide safety clearance for initiating Part 2 and the randomisation of Japanese participants into the phase 2 study NN6435-4697. Part 2 will randomise the remaining Japanese participants into three parallel dose groups. (3:1:3:1:3:1).|t|t|t|t
33853134|NCT05117164|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33853135|NCT03305731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853136|NCT00390585|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853137|NCT01873820|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33956850|NCT00318409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956851|NCT01898624|||CASE_ONLY||PROSPECTIVE|||||||
33956852|NCT05694169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956853|NCT00281827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956854|NCT06561711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956855|NCT02312752|NA|SINGLE_GROUP||OTHER||NONE||||||
33956856|NCT02490215|||COHORT||PROSPECTIVE|||||||
33956857|NCT05204849|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial, 1:1 fashion||||
33956858|NCT06652230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747165|NCT05764850|||CASE_CONTROL||PROSPECTIVE|||||||
33747166|NCT00035126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747167|NCT02186119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747168|NCT01572584|||CASE_ONLY||PROSPECTIVE|||||||
33853138|NCT02475239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853139|NCT02084056|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853140|NCT00291590|RANDOMIZED|PARALLEL||ECT||NONE||||||
33853141|NCT01554774|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853142|NCT05866874|||COHORT||PROSPECTIVE|||||||
33853143|NCT04584775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Traditional Chinese Medicine plus Standard Care versus Standard Care||||
33853144|NCT02483585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853145|NCT03938545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956859|NCT02244086|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33956860|NCT06550180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747169|NCT04747977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study|t|f|t|f
33747170|NCT05893342|||COHORT||PROSPECTIVE|||||||
33747171|NCT06532175|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34060915|NCT03442166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the suture is completed, the researcher responsible for applying the LED will remove and open the envelope containing the information from the experimental group in which the patient will be inserted and proceed to the experiment. A single examiner will run the daily application of the LED and will not perform any type of evaluation. Surgical procedures will be performed by the same surgeon. The preoperative and postoperative evaluations (1, 2, 5 and 7 days postoperatively) will be done by an examiner who will not be aware of the group in which each patient is allocated. Patients will not be aware of whether or not they received LED irradiation, because the person in charge of the LED application will position the plate in place for intra and extraoral irradiation in all patients and only trigger the light when and where predicted in the specific experimental group. The characteristic sound of the device will be triggered by recording in the sham group.||t|f|t|f
34060916|NCT02223819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060917|NCT03482791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060918|NCT06047132|||OTHER||CROSS_SECTIONAL|||||||
34060919|NCT06598371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34060920|NCT03896672|NA|SINGLE_GROUP||OTHER||NONE||||||
34060921|NCT03458923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853146|NCT02924428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853147|NCT05973435|||COHORT||PROSPECTIVE|||||||
33853148|NCT00373477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853149|NCT03634020|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, consecutive enrollment, single-arm study||||
33853150|NCT02216474|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33853151|NCT01347762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853152|NCT05968404|||COHORT||OTHER|||||||
33853153|NCT04248231|||COHORT||RETROSPECTIVE|||||||
33853154|NCT02482337|NA|SINGLE_GROUP||OTHER||NONE||||||
33853155|NCT02090959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853156|NCT01130233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853157|NCT03620916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomized in a 1:1 ratio into experimental and control group|f|f|t|t
33853158|NCT00950950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853159|NCT00006373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853160|NCT00783900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853161|NCT05706753|NA|SINGLE_GROUP||OTHER||NONE||||||
33853162|NCT02819466|||COHORT||PROSPECTIVE|||||||
33853163|NCT03279445|||COHORT||RETROSPECTIVE|||||||
33853164|NCT01620112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33853165|NCT03211312|||OTHER||RETROSPECTIVE|||||||
33853166|NCT03020654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853167|NCT02536599|||COHORT||PROSPECTIVE|||||||
33853168|NCT05247554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853169|NCT00038974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853170|NCT02344563|RANDOMIZED|CROSSOVER||||NONE||||||
33853171|NCT02482051|||OTHER||PROSPECTIVE|||||||
33853172|NCT03687047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853173|NCT04664439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853174|NCT04322838|||CASE_CONTROL||PROSPECTIVE|||||||
33853175|NCT04937712|||COHORT||PROSPECTIVE|||||||
34060922|NCT06027502|NA|SINGLE_GROUP||TREATMENT||NONE||Two groups, those with a cervical level SCI and a control group of non-disabled healthy individuals||||
34060923|NCT06181630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060924|NCT03860116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34060925|NCT02428738|||CASE_CONTROL||PROSPECTIVE|||||||
34060926|NCT03025568|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34060927|NCT03824821|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853176|NCT01990560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853177|NCT05907278|NA|SINGLE_GROUP||PREVENTION||NONE||All participants receive the intervention||||
33853178|NCT03597074|||COHORT||PROSPECTIVE|||||||
33853179|NCT06037629|||OTHER||PROSPECTIVE|||||||
33853180|NCT01350310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853181|NCT01154010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33853182|NCT01932567|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33853183|NCT00758277|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33853184|NCT00994084|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33853185|NCT04443101|||CASE_ONLY||PROSPECTIVE|||||||
33853186|NCT05298072|||COHORT||OTHER|||||||
33853187|NCT01362777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853188|NCT02720367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33853189|NCT05158998|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33853190|NCT00079989||||TREATMENT||NONE||||||
33853191|NCT03810469|||COHORT||PROSPECTIVE|||||||
33853192|NCT04960189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853193|NCT02292927|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open label|||||
33853194|NCT04361994|||COHORT||PROSPECTIVE|||||||
33853195|NCT01572753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853196|NCT02608593|||CASE_CONTROL||OTHER|||||||
33853197|NCT02870335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853198|NCT03622619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853199|NCT00003657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060928|NCT00100191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060929|NCT02938624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060930|NCT01007292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060931|NCT03376191|||COHORT||PROSPECTIVE|||||||
33956861|NCT02198209|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956862|NCT03490539|||COHORT||PROSPECTIVE|||||||
33956863|NCT03032237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33956864|NCT05613855|||COHORT||PROSPECTIVE|||||||
33956865|NCT00357708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956866|NCT06395389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33956867|NCT06280066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33853200|NCT04249154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853201|NCT05365048|RANDOMIZED|PARALLEL||OTHER||NONE||This prospective study will utilize a cluster randomization design to compare three implementation strategies with outcome measures at the patient, provider and system level. Prior to randomization, clinics will be matched in triads on key attributes that may be associated with implementation success (e.g. geographic location, CFIR constructs, membership, race/ethnicity and baseline HPV vaccine converge) using a SAS algorithm. The 3 clinics matched in a triad will be most like each other in these attributes. The matched triads will be first randomized to determine the timing of their implementation (phase 1 will include 10 triads of 30 clinics) or phase 2 (10 triads of 30 clinics). Within each triad, the 3 clinics will then be randomized to determine which receives the local-tailored strategy ( 20 clinics) vs prescribed ( 20 clinics) vs usual care (20 clinics).||||
33853202|NCT04661956|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||a prospective multicenter random control trial||||
33853203|NCT04401852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853204|NCT04061538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853205|NCT05163171|||COHORT||PROSPECTIVE|||||||
33853206|NCT00642772|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33853207|NCT01092741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853208|NCT02492022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33956868|NCT02725840|||COHORT||PROSPECTIVE|||||||
33853209|NCT06265064|||COHORT||PROSPECTIVE|||||||
33853210|NCT00728585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33853211|NCT02725346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853212|NCT06492122|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation and dose expansion||||
33853213|NCT02542111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853214|NCT04103060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853215|NCT01471496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853216|NCT05945797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33956869|NCT06652555|||CASE_ONLY||PROSPECTIVE|||||||
33956870|NCT05375968|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The randomization schedule will be generated by a statistician who is not related to the study. The blinded study intervention will be infused, which medication one receives will be decided by chance, like the toss of a coin .The subjects who received saline at visit 2, will get the study drug GIP(3-30)NH2 at visit 3, and vice versa||t|f|f|t
33956871|NCT01834391|||CASE_CONTROL||PROSPECTIVE|||||||
33956872|NCT04294498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747172|NCT06171685|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33747173|NCT04802733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747174|NCT02087410|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34060932|NCT05072275|||COHORT||PROSPECTIVE|||||||
34060933|NCT05846217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34060934|NCT03870529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060935|NCT02453854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060936|NCT00693602|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34060937|NCT00975858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060938|NCT05409430|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Acute Ischemic Stroke (AIS), indicated for treatment with ANA 5F device in combination with Solitaire stent retriever, whose stroke is attributable to an occlusion of a large artery in the neurovasculature.||||
34060939|NCT02900846|||CASE_ONLY||RETROSPECTIVE|||||||
34060940|NCT00583375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060941|NCT03847415|||COHORT||PROSPECTIVE|||||||
34060942|NCT05365269|NA|SINGLE_GROUP||PREVENTION||NONE|By nature, the participants, investigators and outcomes assessors of the single arm study are informed that an intervention is being (or has been) delivered.|||||
33956873|NCT05998031|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|A blinding code will be entered into the stimulation device to initiate the randomized stimulation condition.|Participants will enroll in a randomized double-blinded crossover within subject study. Each participant will undergo two MRI sessions. Each MRI session will include either one active tDCS or one sham tDCS. The order of delivering active or sham tDCS first will be randomized. A washout period between active and sham tDCS will be set for at least two-weeks to ensure no after-effect from the first stimulation session will be carried over to the second session.|t|f|f|t
33956874|NCT06461897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956875|NCT04461626|||OTHER||PROSPECTIVE|||||||
33956876|NCT00327652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956877|NCT06701500|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33956878|NCT06567223|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956879|NCT06398561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We randomized the participants across the informatic program named RedCap. Only was masking the outcome assessor.|"A two-branch randomized clinical trial will be carried out, in which one branch will receive the intervention based on a peer support program (Active Patient Program) and the other branch will receive information and exercises aimed at improving their mental health through a validated App, free and in its Spanish version, called COGITO, which consists of planning exercises based on cognitive-behavioral therapy. The App to be used can be found for free by accessing the following link: https://apps.apple.com/us/app/cogito-mct/id1557322291 (for Apple devices) https://play.google.com/store/apps/details?id=de.uke.cogitoapp\&hl=en_US\&pli=1 (for Android devices).~A measurement of the study variables will be carried out through validated instruments at the beginning of the program, another one at the end of the six sessions (6 weeks), 6 and 12 months after the last session."|f|f|f|t
33956880|NCT05469854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33956881|NCT01309152|||CASE_CONTROL||PROSPECTIVE|||||||
33956882|NCT04381468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized to one of two treatment arms and will receive one dose of study drug every 4 weeks during the 44-week dosing period for a total of 12 doses of study drug|t|t|t|t
33956883|NCT06565845|||CASE_CONTROL||RETROSPECTIVE|||||||
33956884|NCT00297882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956885|NCT05145023|||COHORT||PROSPECTIVE|||||||
33956886|NCT06700408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33956887|NCT01977625|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33956888|NCT04280939|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33956889|NCT06543056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956890|NCT03773393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956891|NCT05310578|||COHORT||PROSPECTIVE|||||||
33956892|NCT01104935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956893|NCT05910450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Pivotal, Double-Blind - Part 1: multicenter, prospective, randomized, Double Blind, vehicle-controlled interventional study.~Extension, Single-Blind - Part 2: subjects who will have completed Pivotal, Double-Blind - Part I of the trial and have been defined as Part 1 responders, will be randomized to be treated, in Single-Blind, for additional 6 months with IMP or vehicle solution."|t|f|t|f
33956894|NCT04846920|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The Belzutifan 160 mg BID, Belzutifan 160 mg TID and Belzutifan 200 mg TID study arms will be enrolled sequentially; the Belzutifan 120 mg QD study arm will be enrolled in parallel to the Belzutifan 160 mg BID, Belzutifan 160 mg TID and Belzutifan 200 mg TID arms."||||
33956895|NCT03775577|||COHORT||PROSPECTIVE|||||||
33956896|NCT04746456|||COHORT||PROSPECTIVE|||||||
33956897|NCT05519527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956898|NCT05557968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33956899|NCT05484830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment group allocation cannot be concealed for the operating team, but participants, other members of the treatment team, laboratory personnel and other practitioners administering postoperative care as well as outcome assessors will be blinded regarding the allocation.|Investigator-initiated single-site paralle-group (1:1) prospective, randomized, partially double-blinded trial|t|t|f|t
33956900|NCT00722007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956901|NCT06700382|||COHORT||OTHER|||||||
33956902|NCT05638607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33956903|NCT00131573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956904|NCT04661163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent assessors blinded to the treatment will evaluate outcome.|A randomised, assessor-blinded parallel-groups superiority clinical trial|f|f|f|t
33956905|NCT01876628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956906|NCT05149807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multi-center phase II/III clinical study consisting of two stages: Stage I is a single-arm open-label phase II study to preliminarily explore the efficacy and safety of SHR-1701 plus S-1 and oxaliplatin; Stage II is a randomized, double-blind, multi-center phase III study of SHR-1701 plus S-1 and oxaliplatin versus placebo plus S-1 and oxaliplatin as perioperative treatment in subjects with resectable GC or GEJC.|t|t|t|t
33956907|NCT02827188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33956908|NCT03113201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165322|NCT03066063|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Amblyopia arm enrollees will be randomized to one of two groups. A standard of care group will be prescribed patching for two or six hours per day, seven days per week. Standard of care group participants with best-corrected vision worse than 20/200 in their amblyopic eye will be prescribed six hours of patching daily, while participants whose best-corrected visual acuity is 20/200 or better will be prescribed two hours of patching daily. Participants assigned to an experimental group will play iCare vision therapy games for approximately 20 minutes per day, five days per week.~Convergence insufficiency arm enrollees will be assigned to one of two groups: (1) the iCare experimental group, in which participants will be prescribed vision therapy gameplay for approximately 20 minutes per day, five days per week; and (2) a dosage-matched control group, which will be prescribed pencil pushups for 20 minutes per day, five days per week."||||
34165323|NCT00148148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747175|NCT04992767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747176|NCT04566029|||CASE_CONTROL||PROSPECTIVE|||||||
34165324|NCT06235567|RANDOMIZED|PARALLEL||TREATMENT||NONE||"For group A, the study drug, DEXTNZA, is administered during the surgical procedure and the patient does not need to do any additional steps. For group B, the patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.~The fellow eye will receive the alternate treatment when undergoing the procedure at a subsequent date at least 3 weeks following the first eye, and both within 45 days of the screening visit. Day 0 to Day 30 surgery and assessment schedule will be followed twice, once for each eye."||||
34165325|NCT01125800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165326|NCT00427284|||CASE_CONTROL||PROSPECTIVE|||||||
34165327|NCT00786799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165328|NCT04222296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study||||
34165329|NCT02342964|NA|SINGLE_GROUP||SCREENING||NONE||||||
34165330|NCT04601012|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34165331|NCT05078372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Prior to being included in the study, the patient will be mentioned the times when he will receive the medication as well as the dosage of administration. The patient will not know what medication is being administered to him / her. The drug will be given to the anesthesist in unlabeled syringes without access to any information legend. In the same way, the study group only will be know by a doctor outside the research protocol and will not participate in any other phase of the study so that no member of the research team will know what medication was administered.|Two study groups will be generated, each consisting of 54 research subjects, randomly each recipient will receive epidural anesthesia with or without intraarticular ropivacaine. The group to which the patient belongs will be assigned through a computer program, the patient will not know to which group he belongs or what medication he will receive. The patients will be extracted from the external traumatology clinic|t|f|t|f
34165332|NCT04780165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747177|NCT00911872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853217|NCT01795573|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33853218|NCT03843138|||COHORT||PROSPECTIVE|||||||
33853219|NCT03329560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853220|NCT05176769|||COHORT||RETROSPECTIVE|||||||
33853221|NCT03834051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853222|NCT03855423|NA|SINGLE_GROUP||OTHER||NONE||Single arm intervention study 3+3 step up design||||
33853223|NCT03060668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853224|NCT01401907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||early palliative care|f|f|f|t
33853225|NCT00928447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853226|NCT02042222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956909|NCT06566924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956910|NCT05179434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853227|NCT03432715|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|All data collectors are masked.|A portion of participating schools will receive a Student Wellness Champion curriculum, training for their wellness team, as well as technical assistance provided by a Wellness Specialist (WCC-S Group). Other participating schools will only receive the training and technical assistance (WCC Group) and some will solely receive resources (Control Group). The process to determine which school receives which intervention is completely random, and will not be decided until after baseline data collection.|f|f|f|t
34165333|NCT02401165|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34165334|NCT05443724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165335|NCT06361758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165336|NCT04359199|||OTHER||CROSS_SECTIONAL|||||||
34165337|NCT05561582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165338|NCT01860833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165339|NCT03373929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, single-center, observational study||||
34165340|NCT01381393|||COHORT||PROSPECTIVE|||||||
33747178|NCT03923959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All OR pharmacists are un-blinded to subject randomization.|A prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.|t|t|t|t
33747179|NCT05947474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165341|NCT06538922|NA|SINGLE_GROUP||PREVENTION||NONE||Fifteen adolescents (aged 12-14) who are at high risk for or experimenting with substance use and their primary caregivers will complete a single appointment involving a baseline assessment, 2-hour single session evidence-based family skills training intervention, and follow-up assessment, followed by a weeklong daily diary, and semi-structured interview to guide the development of an mHealth app delivering a just-in-time adaptive intervention (JITAI).||||
34165342|NCT03148366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165343|NCT00811603|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165344|NCT00047515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34165345|NCT02166619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165346|NCT06109064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165347|NCT05268510|NA|SINGLE_GROUP||TREATMENT||NONE||"Eligible subjects will receive 2 six-week (q42d) cycles of mod. FOLFOX-6 plus 400 mg pembrolizumab. Alternatively, subjects may receive 2 six-week (q42d) cycles of CAPOX plus 400 mg pembrolizumab. The decision for either mod. FOLFOX-6 or CAPOX is made at the sole discretion of the investigator taking into account the best interest of the patient.~Following the chemotherapy induction phase, the subjects are scheduled to receive up to 16 six-week (q42d) cycles of pembrolizumab (400 mg) plus olaparib (300 mg bid.)."||||
34165348|NCT04668768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165349|NCT00670904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165350|NCT01722019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165351|NCT04355403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165352|NCT05900037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to randomized treatment and treatment used.|Randomization 1:1|t|f|f|f
34165353|NCT01469273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165354|NCT03853135|||CASE_CONTROL||PROSPECTIVE|||||||
34165355|NCT06627335|||COHORT||RETROSPECTIVE|||||||
34165356|NCT05812365|||COHORT||PROSPECTIVE|||||||
34165357|NCT03122210|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165358|NCT04121702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165359|NCT04157803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165360|NCT00778115|RANDOMIZED|CROSSOVER||||NONE||||||
34165361|NCT02447614|||COHORT||PROSPECTIVE|||||||
34165362|NCT00970918|NA|SINGLE_GROUP||SCREENING||||||||
34165363|NCT03737136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34165364|NCT03667157|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165365|NCT04410718|||COHORT||PROSPECTIVE|||||||
34165366|NCT05915299|||OTHER||OTHER|||||||
34165367|NCT06727214|||COHORT||RETROSPECTIVE|||||||
34165368|NCT00268918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165369|NCT04033744|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|One clinician, not involved in patient treatment and not aware of what therapeutic approach was used for the different sites of treatment, performed all clinical measurements (PD, CAL, gingival recession, plaque index and gingival bleeding index) before and after 12 and 18 weeks of surgery.||f|f|t|t
34165370|NCT02173106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165371|NCT06489145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165372|NCT06190041|||CASE_ONLY||CROSS_SECTIONAL|||||||
34165373|NCT04707495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165374|NCT06344429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165375|NCT02072265|||CASE_CONTROL||PROSPECTIVE|||||||
33853228|NCT05607394|||CASE_ONLY||PROSPECTIVE|||||||
33893461|NCT03354845|RANDOMIZED|PARALLEL||OTHER||SINGLE|Group assignment was made known to the pharmacists and doctors involved in the deprescribing study intervention. However, patients were not aware of which group they had been assigned to.|The study was conducted as an open trial with two parallel groups. A total of 200 patients were randomized to an intervention (deprescribing) or control (usual care) group in a 1:1 ratio. Randomization of patients was performed after recruitment by an independent administrator using GraphPad randomization sequence software ©2017. Doctors were free to make any changes to patients' medication regimens as they wished in both groups.|t|f|f|f
34165376|NCT01522326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165377|NCT02249936|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34165378|NCT01692977|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34165379|NCT04608604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165380|NCT04268108|||COHORT||PROSPECTIVE|||||||
34165381|NCT05935020|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Investigator and Outcomes Assessor are blinded to participant group allocation. Further, the personnel administering the intervention after discharge from the surgical ward (Care Provider) is masked.|Two group, parallel, randomized, controlled feasibility trial|f|t|t|t
34165382|NCT05096065|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165383|NCT06568042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165384|NCT01080807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165385|NCT06703567|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34165386|NCT06456827|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34165387|NCT06200753|||COHORT||PROSPECTIVE|||||||
34165388|NCT03400852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind (Investigator/Participant) The Care Provider and Outcomes Assessor were also blinded, but it is a double-blind trial, followed by an open-label period.|In the double-blind period, participants are randomized to receive study drug or placebo. It is followed by an open label period wherein all participants receive study drug.|t|f|t|f
34165389|NCT04809571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165390|NCT06707337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients with colorectal cancer in the experimental and control groups will be masked.|The study was planned as a prospective, two-armed (1:1), randomized controlled experimental study. This randomized controlled trial will be reported according to the CONSORT guidelines.|t|f|f|f
34165391|NCT00970112|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34165392|NCT02487095|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165393|NCT04522453|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Assessors will not be informed whether primary care providers or patients are in the paper of digital arm of the mental health Gap Action Program.|Feasibility cluster randomized controlled trial|f|f|f|t
34165394|NCT04235348|||COHORT||PROSPECTIVE|||||||
34165395|NCT03539965|||COHORT||RETROSPECTIVE|||||||
34165396|NCT06726057|RANDOMIZED|PARALLEL||PREVENTION||NONE||Hybrid type III implementation-effectiveness cluster randomized controlled trial||||
34165397|NCT00488735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165398|NCT02924493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747180|NCT01811550|||COHORT||PROSPECTIVE|||||||
33747181|NCT01725646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747182|NCT05359523|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33747183|NCT01792011|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33956911|NCT04840628|NA|SINGLE_GROUP||OTHER||NONE||the chronic obstructive pulmonary disease patients with respiratory failure||||
33956912|NCT06701162|RANDOMIZED|PARALLEL||OTHER||NONE||The patients were randomly assigned into two groups to receive after a standardized induction of general anesthesia either an ultrasound-guided TAP block or IIIH block with bupivacaine 0.3 ml/kg.||||
33956913|NCT01048411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747184|NCT05042219|||OTHER||PROSPECTIVE|||||||
33747185|NCT00377819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747186|NCT06316427|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigator Initiate Trial||||
33747187|NCT03434925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747188|NCT04851613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase I: Single-arm, open-label study to evaluate efficacy, safety, tolerability, PK of the therapy with afuresertib plus fulvestrant. Phase III: A multi-center, randomized, double-blind, placebo-controlled study to assess efficacy and safety of afuresertib/placebo plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic BC who have failed 1 to 2 prior lines of ET with/without a CDK4/6 inhibitor (up to 1 therapy), or chemotherapy (up to 1 chemotherapy).|t|t|t|t
33747189|NCT04256551|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33956914|NCT03847428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956915|NCT01856257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956916|NCT04980391|RANDOMIZED|PARALLEL||PREVENTION||NONE|The study was unblinded to ensure the participant's safety.|||||
34060943|NCT04064541|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Subjects in this study will serve as their own control in order to assess their ability to perform functional, cognitive and QOL assessments in the virtual/ distance health environment.||||
34060944|NCT03121924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34060945|NCT00035295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060946|NCT01538992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060947|NCT00776802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060948|NCT02036671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060949|NCT01552148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165399|NCT02261363|||COHORT||PROSPECTIVE|||||||
34165400|NCT02598284|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165401|NCT05617144|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165402|NCT03148613|NON_RANDOMIZED|PARALLEL||OTHER||NONE||All subjects experience device use compared to a control device (predicate).||||
34165403|NCT02050009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165404|NCT02171507|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165405|NCT02314325|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33893462|NCT05301244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experiment and control groups were not clearly stated in the outcome evaluation. Coded as A-B.The person making the assessment was not informed about this.||f|f|f|t
34165406|NCT02274792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165407|NCT04232033|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34165408|NCT02036125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34165409|NCT04299685|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34165410|NCT04064749|RANDOMIZED|PARALLEL||SCREENING||NONE||The Screening, Brief Intervention and Referral to Treatment (SBIRT) model provides the underlying structure for the proposed brief intervention. SBIRT interventions utilize a combination of brief educational approaches (i.e., information about risks of use) combined with motivational interviewing techniques designed to enhance motivation to make a change in a target behavior.||||
34165411|NCT04494074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165412|NCT01450059|||COHORT||PROSPECTIVE|||||||
34165413|NCT06084936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165414|NCT03659799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34165415|NCT00226928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165416|NCT03699917|||CASE_ONLY||RETROSPECTIVE|||||||
34165417|NCT01293825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165418|NCT06727305|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who will be randomized in 1:1:1:1:1:1 ratios to receive oral tablet doses of sirolimus and everolimus with concentrations of 0.5mg, 1mg, 2mg each||||
34165419|NCT06725472|||CASE_CONTROL||PROSPECTIVE|||||||
34165420|NCT04533321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165421|NCT01333293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893463|NCT00233311|||COHORT||PROSPECTIVE|||||||
33893464|NCT00455637|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33893465|NCT03815175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893466|NCT00975091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893467|NCT00643513|||CASE_ONLY||PROSPECTIVE|||||||
33893468|NCT05581043|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||We will use a randomized cross-over design to investigate 10 volunteers with T2DM on six different occasions separated with at least one week.|t|f|f|f
34165422|NCT06726525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165423|NCT00593762|||COHORT||PROSPECTIVE|||||||
34165424|NCT02795117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165425|NCT00181766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165426|NCT00000424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34165427|NCT00673582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165428|NCT03796065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Research Assistants (RAs) who will collect both qualitative and quantitative data will be blind to the condition in which study participants are randomized.|The investigators will conduct a Randomized Controlled Trial among Somali Bantu and Bhutanese families (N=300; 150 per group). Half of the families will be randomized to receive the FSI-R and half will be randomized to the control condition where the participants will receive Treatment as Usual (TAU).|f|t|f|f
34165429|NCT04909489|||OTHER||CROSS_SECTIONAL|||||||
34165430|NCT04585204|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34165431|NCT04792021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants are assigned to one of two groups in parallel for the duration of the study.~One arm is the intervention arm: those receiving N-acetylcysteine (NAC). One arm is the control group : those not receiving N-acetylcysteine (NAC)."|t|t|f|f
34165432|NCT01242592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165433|NCT06722872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In order to prevent selection bias in the study, the assignment to the experimental and control groups will be made on a computer by a person who is unfamiliar with the research process. Individuals included in the study will not be told whether they are in the experimental or control group. The analysis of the data will be done by a statistics expert who is outside the research process.|Two groups with experimental and control groups|t|f|f|t
34165434|NCT06727188|||COHORT||PROSPECTIVE|||||||
34165435|NCT01591941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34165436|NCT05653661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165437|NCT02485132|||COHORT||PROSPECTIVE|||||||
34165438|NCT04320017|||COHORT||PROSPECTIVE|||||||
34165439|NCT02637765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165440|NCT03622736|||OTHER||PROSPECTIVE|||||||
34165441|NCT00896298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165442|NCT06375174|||CASE_ONLY||PROSPECTIVE|||||||
34165443|NCT01649934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165444|NCT00172835|||NATURAL_HISTORY||OTHER|||||||
34165445|NCT04254666|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34165446|NCT04557800|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34165447|NCT06421038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the care provider and the outcomes assessor will not know which treatment will be given to the patients.|Thyme honey on recurrent aphthous stomatitis|f|t|f|t
34165448|NCT01340586|NON_RANDOMIZED|PARALLEL||||NONE||||||
34165449|NCT06351150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165450|NCT04544358|RANDOMIZED|PARALLEL||PREVENTION||NONE||Random assignment to intervention (BAILAMOS program) or control||||
34165451|NCT00711672|||COHORT||PROSPECTIVE|||||||
34165452|NCT02539901|||COHORT||PROSPECTIVE|||||||
34165453|NCT05089643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165454|NCT05364463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165455|NCT01007357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165456|NCT00530738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34165457|NCT02382445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34165458|NCT04014283|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The selected randomization method is block randomization with randomly chosen blocks sizes.~Randomization must take place before 120 days after the Screening Visit (Day 0). After confirmation that the patient meets all eligibility criteria for the study, the patient will be randomly assigned (1:1) to either placebo or supplementation group. Patients with selenium deficiency can choose between diet modification and supplementation group.~The last step of randomisation is the blinding/assigning procedure - connecting randomization numbers with placebo or supplement packages numbers and assigning them to the subjects. All SELINA personnel, participants and clinicians will be blinded to the treatment allocation; only the Statistical Center will have the possibility to unblind the data."|"Supplementation of selenium or diet modification will be effective in reducing the risk of developing breast cancer in women with high risk, as compared to placebo.~The null hypothesis assumes no significant differences between the supplementation and placebo groups. The alternative hypothesis assumes that patients with high risk of breast cancer in supplementation or diet modification group with optimal selenium level will have significantly reduced risk of developing cancer in relation to the placebo group with selenium deficiency. The comparison of disease-free survival time intervals is best covered by Cox Regression and is represented by a Kaplan-Meier survival curve tested by log- rank test.~The comparison of proportions of diseased and healthy subjects in the supplementation arm with respect to the placebo arm is best attempted using the Fisher Exact Test. Graphical representation should be based on bar plots for percentages and/or raw numbers, or a similar representation."|f|f|t|f
34165459|NCT04093713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165460|NCT00965380|||CASE_ONLY||PROSPECTIVE|||||||
34165461|NCT00876161|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34165462|NCT00005961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165463|NCT05306587|||OTHER||PROSPECTIVE|||||||
34165464|NCT02180399|||OTHER||OTHER|||||||
34165465|NCT02532608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33893469|NCT04748029|||CASE_CONTROL||RETROSPECTIVE|||||||
33893470|NCT03949673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165466|NCT01076959|||COHORT||PROSPECTIVE|||||||
34165467|NCT01409447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165468|NCT01523418|||COHORT||PROSPECTIVE|||||||
34165469|NCT06279455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pelvic Floor Muscle Exercise Group||||
34165470|NCT03626961|||COHORT||PROSPECTIVE|||||||
34165471|NCT06190626|||COHORT||PROSPECTIVE|||||||
34165472|NCT01463241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165473|NCT00268840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165474|NCT00557635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165475|NCT03368365|NA|SINGLE_GROUP||PREVENTION||NONE|The occurrence of unplanned hospitalizations is independent of the spirometer used.|All transplanted subjects will be equiped with the Ventilotel (r) after their inclusion in the study.||||
34165476|NCT06359717|||COHORT||PROSPECTIVE|||||||
34165477|NCT03956550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747190|NCT05210192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind placebo-controlled study|Injection into the sphenopalatine ganglion of the patients in both groups will be made by entering the arcus zygomaticum and oriented at a 45 degree angle towards the opposite tooth. Injections will be made with a dental injector. The first group will be injected with 4ml of 1% lidocaine, and the second group will be injected with 4ml of 0.9% saline. Injections will be repeated weekly for the first 4 weeks, then monthly. At the end of the 1st and 3rd months of the treatment, the patients will be evaluated in the routine outpatient clinic control, and the two groups will be compared statistically by questioning the frequency of pain, the number of attacks, the severity of pain (VAS), and the duration of pain.|t|f|t|f
34165478|NCT06531486|NA|SEQUENTIAL||TREATMENT||NONE||||||
34165479|NCT05104307|||CASE_ONLY||PROSPECTIVE|||||||
34165480|NCT01333384|||OTHER||OTHER|||||||
34165481|NCT05357716|||COHORT||PROSPECTIVE|||||||
33747191|NCT01750268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747192|NCT02363738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165482|NCT00536237|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34165483|NCT05771766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165484|NCT03603301|||COHORT||PROSPECTIVE|||||||
34165485|NCT02631980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34165486|NCT05217940|NA|SINGLE_GROUP||SCREENING||NONE||||||
34165487|NCT00663013|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165488|NCT04090333|||COHORT||PROSPECTIVE|||||||
34165489|NCT00393211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747193|NCT03646786|NA|SINGLE_GROUP||OTHER||NONE||||||
33747194|NCT00572234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765540|NCT01461330|RANDOMIZED|PARALLEL||PREVENTION||NONE||"intervention: DASH diet plus exercise DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat Exercises: the recommended physical activity will consist of using a pedometer during the experimental period.~active comparator = ADA diet = Adoption of ADA diet."||||
33765541|NCT04404478|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants will be randomized into groups. Group sessions held online on different dates and times. Participants are asked not to share details about the study. Data collectors are blinded to participant grouping. Facilitators are blinded to the groups they are not facilitating.|Randomized control trial comparing intervention group (B-SWELL) with an attention control group (WE) to assess the following outcomes: healthy lifestyle scores, perceived stress scores, self efficacy, unhealthy days, and depressive symptoms.|t|f|f|t
33765542|NCT04394845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165490|NCT01867736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165491|NCT03359174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165492|NCT04100382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165493|NCT04162067|||COHORT||RETROSPECTIVE|||||||
34165494|NCT01001117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165495|NCT04311489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled clinical trial|t|t|t|f
34165496|NCT03824002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34165497|NCT04608565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165498|NCT05897034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|t|f|f
34165499|NCT01249066|||||RETROSPECTIVE|||||||
34165500|NCT04542954|||COHORT||OTHER|||||||
33765543|NCT01971190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33765544|NCT04632732|||COHORT||PROSPECTIVE|||||||
33765545|NCT04511416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomised placebo controlled trial|t|t|t|t
33765546|NCT03317028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165501|NCT04593758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165502|NCT02484755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165503|NCT00349817|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33853229|NCT02731573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Phase Ib/II, Prospective, Multicenter, Two part study; Part 1 Open Label, Single arm \& Part 2 Randomized, Single-blinded, D-PLEX Concomitantly with Standard Of Care vs. Standard of Care alone.~Study population include subjects above the age of 18 years, that undergoing cardiac surgery through mid-sternotomy, including patients with high risk of infection, such as diabetes (Insulin and/or non-insulin dependent), patients with Peripheral Vascular Disease (PVD), Chronic Obstructive Pulmonary Disease (COPD), heavy smokers, Bilateral Mammary artery harvesting, and subjects administered chronic steroid treatment.~Subjects who meet the eligibility criteria and provide signed informed consent, will be enrolled into the study and will be treated with D-PLEX concomitantly with standard of care (part 1) or randomized 2:1 to D-PLEX concomitantly with standard of care vs. standard of care only (part 2)."|t|f|f|f
33853230|NCT02860494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853231|NCT05636722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853232|NCT02539953|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853233|NCT01711723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853234|NCT00861523|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165504|NCT00604565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34165505|NCT00806988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165506|NCT06261593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34165507|NCT02279667|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165508|NCT03930693|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Beetroot juice intervention given to all participants (1 dose only)||||
34165509|NCT01593631|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34165510|NCT00478842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853235|NCT03743285|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34165511|NCT01479868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165512|NCT04178629|||COHORT||PROSPECTIVE|||||||
34165513|NCT02693041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165514|NCT05336578|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34165515|NCT04205526|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The only individual that will be unblinded is the person administering the rTMS.||t|t|t|t
33853236|NCT06004011|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34165516|NCT00500188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165517|NCT06202963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34165518|NCT02638324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853237|NCT02039453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33853238|NCT00008073||||TREATMENT||||||||
33853239|NCT03241303|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33853240|NCT05972031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cluster randomized controlled trial|f|f|f|t
34165519|NCT01286519|||CASE_ONLY||PROSPECTIVE|||||||
34165520|NCT02042521|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34165521|NCT00879385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165522|NCT00005857||||TREATMENT||||||||
34165523|NCT04390243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165524|NCT02656355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165525|NCT05842759|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single center, clinical interventional proof-of-concept study in 120 patients scheduled for elective major non-cardiac surgery at the University Medical Center Hamburg-Eppendorf.||||
33853241|NCT02875977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking is used in this study|Participants are randomized to standard counseling for pelvic floor physical therapy (PFPT) or to an experimental counseling group that comprises both standard counseling and a 4-minute PFPT educational video using a 1:1 allocation||||
33853242|NCT01439360|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33853243|NCT01466621|||||RETROSPECTIVE|||||||
33853244|NCT01827293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853245|NCT02277041|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34060950|NCT02753387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165526|NCT04863391|||COHORT||PROSPECTIVE|||||||
34165527|NCT00491413|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165528|NCT04386460|||COHORT||PROSPECTIVE|||||||
34165529|NCT03098862|||CASE_CONTROL||OTHER|||||||
34165530|NCT01964417|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34165531|NCT05687721|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm study||||
34165532|NCT01153126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165533|NCT00972335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165534|NCT06504316|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison two groups: intervention group (oXiris filter) and control group (ST 150 filter)||||
34165535|NCT02378688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165536|NCT01209351|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34165537|NCT00605124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34165538|NCT02218645|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165539|NCT02364141|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33853246|NCT04340323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060951|NCT05805085|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34060952|NCT00805077|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34060953|NCT06731205|||COHORT||PROSPECTIVE|||||||
34060954|NCT04826133|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34060955|NCT05674877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34060956|NCT05531448|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||patients eligible for 2wT who consent will be randomized 1:1 into routine retention care an 2wT-based retention care. At 6 months, control arm participants will receive also receive 2wT and continue in 2wT as part of routine Lighthouse retention activities under the umbrella R33 NIH-funded quasi-experimental study.||||
34060957|NCT00290381|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Nasal Allergen Challenge Study|t|f|t|f
34060958|NCT06496204|||COHORT||PROSPECTIVE|||||||
34060959|NCT05837728|||CASE_ONLY||PROSPECTIVE|||||||
34165540|NCT01729299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34165541|NCT03242629|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33853247|NCT02814201|||CASE_CONTROL||PROSPECTIVE|||||||
33853248|NCT02533596|||COHORT||PROSPECTIVE|||||||
33853249|NCT03068533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|similar empty tubes filled by the control and intervention toothpaste then sealed and given a number only.The patients,care provider,outcome assessor and investigator are blinded to the intervention and control toothpaste.||t|t|t|t
33853250|NCT00728611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853251|NCT05999097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Prospective study, randomized single blind clinical trial|t|f|f|f
33853252|NCT04601701|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853253|NCT03336567|||COHORT||CROSS_SECTIONAL|||||||
33853254|NCT02319577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853255|NCT05341596|||COHORT||RETROSPECTIVE|||||||
33853256|NCT02394951|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33853257|NCT04869631|||OTHER||PROSPECTIVE|||||||
33853258|NCT00583934|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853259|NCT02179450|||CASE_CONTROL||PROSPECTIVE|||||||
33853260|NCT02968082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853261|NCT02877914|||OTHER||RETROSPECTIVE|||||||
33853262|NCT03343301|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33853263|NCT05974215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|each patient was not informed about type of received restoration|group 1 mandibular implant supported overdenture group 2 mandibular implant supported fixed overdenture|t|f|f|f
33853264|NCT02162589|||COHORT||PROSPECTIVE|||||||
33853265|NCT00898898|||COHORT||RETROSPECTIVE|||||||
33853266|NCT00995969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853267|NCT04500431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853268|NCT00812331|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060960|NCT02098616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853269|NCT03430206|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients are randomized at time of enrollment to either the control or intervention arms.||||
33853270|NCT01162317|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33853271|NCT02915302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853272|NCT04510831|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33853273|NCT02670031|||COHORT||PROSPECTIVE|||||||
33853274|NCT05897450|||CASE_CONTROL||PROSPECTIVE|||||||
33853275|NCT02481947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853276|NCT04999098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, 3-armed, parallel, active-treatment controlled|f|f|f|t
33853277|NCT01834677|||COHORT||PROSPECTIVE|||||||
33853278|NCT01028937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853279|NCT03948555|||COHORT||PROSPECTIVE|||||||
33853280|NCT02666846|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33853281|NCT02442492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060961|NCT05850897|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060962|NCT01821950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34060963|NCT01416714|||COHORT||PROSPECTIVE|||||||
34060964|NCT00033657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060965|NCT06583447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34060966|NCT02109016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853282|NCT00628264|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853283|NCT00257062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33853284|NCT00024986||||TREATMENT||||||||
33853285|NCT05035784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33853286|NCT06139016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853287|NCT02628496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853288|NCT02293148|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33853289|NCT02303015|||COHORT||RETROSPECTIVE|||||||
33853290|NCT03644407|||OTHER||PROSPECTIVE|||||||
34060967|NCT02418585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060968|NCT04286477|||CASE_CROSSOVER||PROSPECTIVE|||||||
33853291|NCT01003574|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33853292|NCT01548378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853293|NCT02075268|NA|SINGLE_GROUP||||NONE||||||
34165542|NCT05716061|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33853294|NCT00648154|RANDOMIZED|CROSSOVER||||NONE||||||
33956917|NCT03857945|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking not feasible for this study.|"Working in conjunction with UAB Foot and Ankle Division of the Orthopaedic department, volunteers meeting inclusion criteria will be identified in the outpatient clinic setting. After thorough discussion of risks and benefits, potential volunteers will be consented for participation in the study. The volunteer's demographic data will be obtained including gender, age, and race. The patient will then undergo the pre-operative mobility device(s) training during the pre-operative physical therapy visit, if they are randomized to Group 1. Patients in Group 2 will not receive this training. The preoperative training will not incur any additional cost to the patient. Patients in both groups will then undergo standard operative care. During routine 2-week and 6-week follow-up visits, they will be asked questions from a questionnaire that will assess the number and details of any fall(s) they may have experienced."||||
34060969|NCT00687583|||COHORT||PROSPECTIVE|||||||
34060970|NCT05915676|||CASE_CONTROL||PROSPECTIVE|||||||
34060971|NCT01010958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060972|NCT02355769|||CASE_CONTROL||PROSPECTIVE|||||||
34060973|NCT05234931|||OTHER||CROSS_SECTIONAL|||||||
34060974|NCT03318679|||COHORT||PROSPECTIVE|||||||
34165543|NCT03035799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165544|NCT00483405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165545|NCT03787121|||COHORT||RETROSPECTIVE|||||||
34165546|NCT05565937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34165547|NCT02222558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060975|NCT05642624|||COHORT||PROSPECTIVE|||||||
34060976|NCT04281316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060977|NCT06173739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34060978|NCT02107287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060979|NCT03196375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34060980|NCT06278727|||COHORT||PROSPECTIVE|||||||
34060981|NCT03933722|||CASE_ONLY||PROSPECTIVE|||||||
34060982|NCT04747444|RANDOMIZED|CROSSOVER||OTHER||NONE||Individuals with knee osteoarthritis will walk 45 minutes on a treadmill at 100% full body weight loading||||
34060983|NCT02889250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060984|NCT04706806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Both groups received vinegar, either liquid form (active) or pill form (placebo)|randomized, controlled trial|t|f|f|f
34165548|NCT04767893|||OTHER||CROSS_SECTIONAL|||||||
34165549|NCT01556451|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34165550|NCT05960981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165551|NCT04480268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165552|NCT00381758|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34165553|NCT04977284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165554|NCT05265208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853295|NCT01124032|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33853296|NCT01638494||FACTORIAL||TREATMENT||NONE||||||
33853297|NCT01774487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853298|NCT04262817|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33853299|NCT03660800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33853300|NCT02344004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853301|NCT02274818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853302|NCT00669994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956918|NCT06562673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956919|NCT06535347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients will be aware of their own messages but will not be aware of other messages.|||||
33956920|NCT03159000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956921|NCT03208218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34060985|NCT04276610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060986|NCT00003418|RANDOMIZED|||TREATMENT||||||||
34060987|NCT02484300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34060988|NCT03768700|||COHORT||PROSPECTIVE|||||||
34060989|NCT04733716|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The pain sensitivity of all measurement patients was taken on the day before the surgery by the same author, and these values were blinded from another author who recorded the repetitive postoperative VAS and knee scores.||t|f|t|f
34060990|NCT00270283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34060991|NCT02358980|||||PROSPECTIVE|||||||
34060992|NCT05489991|NA|SEQUENTIAL||TREATMENT||NONE||||||
34060993|NCT00616603|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34060994|NCT05530200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34060995|NCT05426824|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34060996|NCT02672332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34060997|NCT05848882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060998|NCT01420679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34060999|NCT04018040|NA|SINGLE_GROUP||TREATMENT||NONE|Due to the nature of this type of dietary intervention it is not possible to blind the participant nor treating gastroenterolgist|Phase 1: Open labelled, single centre trial in mild to moderate UC ( n=14) Phase 2:Open labelled, single centre trial in mild to moderate CD (n-12)||||
34061000|NCT06420375|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blinded study.|This is a crossover study in which each participant will receive active medication for a period of time and placebo for a period of time.|t|t|t|t
34061001|NCT01236326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061002|NCT06019403|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34165555|NCT05892601|RANDOMIZED|PARALLEL||OTHER||SINGLE|Stratified block randomisation method was used to assign the participants to the intervention and control groups. To prevent bias, randomisation was performed by an unbiased nurse who was not involved in the study. In order to control the imbalances that may arise between the intervention and control groups, stratification (2X2) was made according to gender (girls, boys) and age (5,6,7) and an equal number of children were assigned to each group (blocking). Assignments were made according to a list generated by an online randomisation tool. All participants completed the study process and there was no case loss. The parents of the children who participated in the study were unaware of which group their children were in. Since the applications were carried out by the researcher, researcher blinding could not be performed. Therefore, the study is single blind.|The design of this study is a randomized controlled experimental study with a single-blind pretest-posttest control group.|f|t|f|f
34165556|NCT04729725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165557|NCT00586859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165558|NCT05282069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165559|NCT00936702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165560|NCT02296567|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34165561|NCT03027622|||COHORT||PROSPECTIVE|||||||
34165562|NCT05152459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165563|NCT05620082|||CASE_CROSSOVER||PROSPECTIVE|||||||
34165564|NCT01784731|||CASE_ONLY||CROSS_SECTIONAL|||||||
34165565|NCT00174902|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34165566|NCT01265381|||CASE_CONTROL||RETROSPECTIVE|||||||
34165567|NCT02640547|||COHORT||PROSPECTIVE|||||||
34165568|NCT00909506|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34165569|NCT00466440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853303|NCT03898401|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34165570|NCT01308086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165571|NCT01867749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165572|NCT00900666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165573|NCT03958058|||COHORT||RETROSPECTIVE|||||||
34165574|NCT02936817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165575|NCT03108794|||COHORT||PROSPECTIVE|||||||
34165576|NCT04201665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165577|NCT02947646|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
34165578|NCT06134570|||OTHER||RETROSPECTIVE|||||||
34165579|NCT04233203|||COHORT||RETROSPECTIVE|||||||
34165580|NCT05041283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165581|NCT00644020|||CASE_CONTROL||PROSPECTIVE|||||||
34165582|NCT02305771|NA|SINGLE_GROUP||OTHER||NONE||||||
34165583|NCT03904121|||COHORT||PROSPECTIVE|||||||
34165584|NCT01156558|||COHORT||RETROSPECTIVE|||||||
34165585|NCT01239966|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165586|NCT06095219|||OTHER||PROSPECTIVE|||||||
33853304|NCT04330131|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Treatment group participants will consist of all the families who enroll in the TMW interventions in the hospitals and clinics of the treated community (the target zip codes for intervention delivery). The comparison group will consist of families enrolled from hospitals and pediatric clinics with similar characteristics to the treatment group sites.Then within this comparison group, the researchers will define a sample of comparison families who have similar individual characteristics as the treated families.|t|f|f|f
33893471|NCT04516681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165587|NCT01941329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165588|NCT05460611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165589|NCT03709004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34165590|NCT03647657|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No masking|Group 1 patients will receive first 177Lu-PP-F11N alone, second 177Lu-PP-F11N in combination with Sacuitril. Group 2 patients will first receive 177Lu-PP-F11N in combination with Sacuitril, second 177Lu-PP-F11N alone. Affiliation of patients to Groups 1 and 2 will be randomised.||||
34165591|NCT02838758|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34165592|NCT02184923|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34165593|NCT05979337|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34165594|NCT06270953|||COHORT||PROSPECTIVE|||||||
34165595|NCT00139048|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34165596|NCT02620592|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34165597|NCT03604211|||COHORT||RETROSPECTIVE|||||||
34165598|NCT05200715|||COHORT||OTHER|||||||
34165599|NCT01186302|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165600|NCT02114463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165601|NCT02536027|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33893472|NCT02468193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165602|NCT03686735|||COHORT||PROSPECTIVE|||||||
34165603|NCT00137514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165604|NCT03030001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165605|NCT03072264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165606|NCT01574508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165607|NCT02750670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165608|NCT00775996|RANDOMIZED|CROSSOVER||||NONE||||||
34165609|NCT00496080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165610|NCT05072106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165611|NCT04189705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165612|NCT02868411|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165613|NCT00241787|||COHORT||PROSPECTIVE|||||||
34165614|NCT00614679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165615|NCT02927392|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747195|NCT06565507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a double-blind trial in regards to dose regime of OXF. Neither the investigators nor the subjects know which dose of OXF a given subject is receiving, although subjects and clinical study staff will know whether they are receiving one of the OXF regimes or active ABZ+PZQ.|The intervention administered orally will be done randomly, in three groups or arms; arms 1 and 2, receiving oxfendazole (OXF) in a single dose or oxfendazole in three-days regimen (days 1, 4 and 7), respectively; arm 3, receiving a ten days albendazole (ABZ) + praziquantel (PZQ) regimen.|t|f|t|f
33956922|NCT06581250|RANDOMIZED|FACTORIAL||OTHER||NONE||The study uses a 2x2x2 factorial cluster-randomized design The unit of intervention and randomization will be dental clinic sites (clusters). Forty clinics will be randomized between eight possible combinations of receiving or not receiving the three study interventions. The factorial structure of the design ensures that 20 clinic sites receive each intervention, and 20 do not. Five clinic sites will receive none of the interventions, five clinics will receive all three interventions, and 30 clinic sites will receive a different combination of 2 of the 3 interventions.||||
33956923|NCT06180174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956924|NCT02272972|||OTHER||OTHER|||||||
33956925|NCT06565403|||COHORT||RETROSPECTIVE|||||||
33956926|NCT05410769|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33956927|NCT05714150|NA|SINGLE_GROUP||OTHER||NONE||The intervention will consist of a single session of practicing complex (cognitively engaging) balance tasks using an exergaming balance platform. The session will include 30 minutes of practice. Participants with TBI history and without TBI history will both complete the same intervention.||||
33956928|NCT03257774|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956929|NCT06150001|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956930|NCT03039517|RANDOMIZED|PARALLEL||TREATMENT||NONE||subjects who meet the study entrance criteria will be randomly assigned into one of two groups using block randomization technique in a 1:1 ratio. The control group will receive care using elastic compression stocking and the intervention group will use the ACTitouch device. Stratified randomization will occur based on whether the DVT has iliac or non-iliac involvement.||||
33956931|NCT04208165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33956932|NCT01909752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956933|NCT05425823|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||parallel randomized controlled trial|f|f|f|t
33956934|NCT00795483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956935|NCT06569030|NA|SINGLE_GROUP||OTHER||NONE||||||
34165616|NCT05932797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intervention model based on a clinical trial, in which the effectiveness of multimodal treatment will be evaluated in a research group through an ex ante, ex post measurement and then another follow-up measurement compared to a control group. In the first stage, focused on diagnosis, physical, neurological and mental health evaluations will be carried out, to then begin an interdisciplinary treatment process for 6 months, the second stage will be a retest evaluation using the same parameters used at the beginning, applied at the end of the intervention, and finally in the third stage, to evaluate the results with respect to a follow-up carried out 3 months after the end of the study.|t|f|f|f
34165617|NCT05548517|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized Controlled Trial~Enroll 48 to achieve sample size of 40 (20/group)"||||
34165618|NCT01366989|||CASE_ONLY||RETROSPECTIVE|||||||
34165619|NCT00358930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165620|NCT01541046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165621|NCT04253613|||CASE_CONTROL||PROSPECTIVE|||||||
34165622|NCT00814450|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747196|NCT01749644|||COHORT||PROSPECTIVE|||||||
33747197|NCT00615966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33747198|NCT01605617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747199|NCT04333394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both patients and researchers won't be aware of the treatments patients receiving in this study (unaware of the quiddity of A and B capsules), so the study has a double-blind design. Only one of the staff of the company that supplied the Probiotic supplement is aware of the type of assigned intervention for each patient. After collecting the data, he will unseal the codes for researchers, the statistical analyst, participants and those who prepare the manuscript.|The present study will be conducted as a phase 3, randomized double-blind placebo-controlled trial on 40 attention deficit hyperactivity disorder patients allocated in 2 parallel groups each consisted of 20 patients who will receive Probiotic or placebo. From the beginning of the study, A and B codes are available to researchers to recruit the patients using ten 4-Block Randomization.|t|t|t|t
33747200|NCT05859204|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
34165623|NCT00474448|||CASE_ONLY||OTHER|||||||
34165624|NCT04226508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The CHOiCE includes different substudies, with different study designs, i.e., RCT, single arm.||||
34165625|NCT04210674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the treatment was distributed with sequentially numbered, sealed, and randomized envelope. The pediatrician, participant, children's caregiver and outcome assessor were not informed about the treatment code.|All children were randomly divided into two groups to receive either topical steroid ointment or the traditional medicinal product of Argan spinosa oil|t|t|t|t
34165626|NCT01820286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165627|NCT01179581|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33956936|NCT05088382|||COHORT||PROSPECTIVE|||||||
34165628|NCT02794766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956937|NCT04184882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956938|NCT03712046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33956939|NCT05492877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomised to receive either Mitiperstat (AZD4831) or placebo.|t|t|t|t
33956940|NCT02292407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956941|NCT01271426|||CASE_ONLY||RETROSPECTIVE|||||||
33956942|NCT02502565|||COHORT||PROSPECTIVE|||||||
33956943|NCT02204449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33956944|NCT00480363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956945|NCT05631652|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33956946|NCT01244516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956947|NCT05083559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33956948|NCT06701032|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33956949|NCT05065957|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In phase IIa, a modified 3+3 dose-finding design trial will be conducted to identify the selected dose of the combination of D07001-softgel capsules plus Xeloda (or TS-1). After the dose-finding stage will be completed, a phase IIb/III adaptive design, open label, multicenter, active controlled, parallel-group trial will be implemented and incorporated into a dose-expansion stage to evaluate the efficacy and safety of D07001-softgel capsules plus Xeloda.||||
34165629|NCT02135055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165630|NCT00391482|RANDOMIZED|PARALLEL||||NONE||||||
33747201|NCT06129669|||COHORT||PROSPECTIVE|||||||
33747202|NCT05372458|||COHORT||PROSPECTIVE|||||||
33747203|NCT05246423|||COHORT||PROSPECTIVE|||||||
33747204|NCT04447404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||3:1 randomization DUR-928:placebo|t|t|t|t
33747205|NCT04701398|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial||||
33747206|NCT02501460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33747207|NCT05240014|NA|SINGLE_GROUP||OTHER||NONE||||||
33747208|NCT04154787|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study for treatment (LNP023 or rituximab).|||||
33747209|NCT03103555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747210|NCT01715805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747211|NCT01845610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747212|NCT06073574|||COHORT||PROSPECTIVE|||||||
33747213|NCT02157194|||CASE_ONLY||PROSPECTIVE|||||||
33747214|NCT04020991|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33747215|NCT01479920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747216|NCT00540280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747217|NCT00249080|||COHORT||PROSPECTIVE|||||||
33747218|NCT06589648|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The research statistician will be blinded.|||||
33747219|NCT00607425|||CASE_CONTROL|||||||||
33747220|NCT00922493|RANDOMIZED|PARALLEL||||||||||
33765547|NCT02803060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956950|NCT05302037|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33956951|NCT00819091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33956952|NCT06146517|NA|SINGLE_GROUP||OTHER||NONE||||||
33956953|NCT04044365|||COHORT||PROSPECTIVE|||||||
33956954|NCT06536868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765548|NCT03068546|||COHORT||PROSPECTIVE|||||||
33765549|NCT04046835|||COHORT||RETROSPECTIVE|||||||
33765550|NCT00920530|||COHORT||PROSPECTIVE|||||||
33765551|NCT00462722|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33765552|NCT02231229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765553|NCT05250713|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765554|NCT04505436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765555|NCT05918562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33765556|NCT03417921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765557|NCT01686165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765558|NCT01928680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956955|NCT06701942|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33956956|NCT04666012|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33956957|NCT06290622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956958|NCT05595161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956959|NCT06411470|||CASE_CONTROL||PROSPECTIVE|||||||
34165631|NCT02354274|RANDOMIZED|PARALLEL||TREATMENT||NONE|Two independent radiation plans are made before randomization to ensure best available plans for both arms and trial.|||||
34165632|NCT04379063|||COHORT||PROSPECTIVE|||||||
34165633|NCT04115384|NA|SINGLE_GROUP||OTHER||NONE||||||
34165634|NCT02987751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165635|NCT04639544|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165636|NCT02498288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165637|NCT01242878|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34165638|NCT02544503|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34165639|NCT00068341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165640|NCT01336517|||CASE_CONTROL||PROSPECTIVE|||||||
34165641|NCT01634776|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34165642|NCT00376129|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747221|NCT04568538|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician will be blind in evaluating the results. The intervention and control group will be defined as group 1 and group 2 for statistical analysis. Scales will be evaluated by the researcher who cannot be blinded due to the nature of the study.|Single-blind randomized controlled study|t|f|f|f
33747222|NCT03457532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747223|NCT05118854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747224|NCT00127075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747225|NCT03858205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747226|NCT06635018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional prospective single-arm study||||
33747227|NCT02656797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747228|NCT02952924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747229|NCT05967572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Behavioral responses and physiological measurements of premature babies will be evaluated by using these video recordings by the nurse responsible for ROP, a lecturer who specializes in newborns and pain, and the researcher (3 experts), who are experienced in the ROP examination who do not know the groups, and who waive all rights of the research.|The research is a stratified randomized controlled experimental type study.|f|t|t|t
33747230|NCT01227681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747231|NCT06270901|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33747232|NCT00168025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747233|NCT02907021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747234|NCT03339986|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33747235|NCT05308251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33747236|NCT00052468|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33747237|NCT03408717|||OTHER||PROSPECTIVE|||||||
33747238|NCT03395418|||OTHER||PROSPECTIVE|||||||
33747239|NCT04003649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747240|NCT01251003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747241|NCT03926091|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1：6 cycles of TC (Docetaxel 75 mg/m\^2 ivgtt d1+Cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle).~Arm 2：4 cycles of TC (Docetaxel 75 mg/m\^2 ivgtt d1+Cyclophosphamide 600 mg/m\^2 iv d1, 21 days per cycle)."||||
33747242|NCT04066114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747243|NCT00728819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747244|NCT03013114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747245|NCT04732962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747246|NCT05685615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747247|NCT02615223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747248|NCT06634966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747249|NCT06669546|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33747250|NCT04980833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747251|NCT01015742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747252|NCT01138904|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747253|NCT05735951|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33747254|NCT01973933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747255|NCT02242747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747256|NCT06424249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747257|NCT03200938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blind study, the patient is masked|Comparative study with same series for the two groups|t|f|t|t
33747258|NCT02273141|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33747259|NCT03386123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747260|NCT02243553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747261|NCT04214132|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33747262|NCT04535401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747263|NCT00472095|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33747264|NCT05366322|||COHORT||RETROSPECTIVE|||||||
33747265|NCT06636604|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747266|NCT06412120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747267|NCT01142557|||COHORT||PROSPECTIVE|||||||
33747268|NCT05516797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747269|NCT06155968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33747270|NCT05110196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747271|NCT02268552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747272|NCT05146674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747273|NCT02509221|||COHORT||PROSPECTIVE|||||||
33747274|NCT06669273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33956960|NCT06703008|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33956961|NCT06567418|||COHORT||RETROSPECTIVE|||||||
33956962|NCT02030327|||COHORT||PROSPECTIVE|||||||
33956963|NCT04311359|||CASE_ONLY||CROSS_SECTIONAL|||||||
33956964|NCT04546126|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33956965|NCT06653686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165643|NCT05287386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165644|NCT02574273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165645|NCT05462249|||CASE_CONTROL||PROSPECTIVE|||||||
34165646|NCT02726412|||COHORT||PROSPECTIVE|||||||
34165647|NCT02587520|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165648|NCT03038126|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34165649|NCT05414890|||COHORT||PROSPECTIVE|||||||
34165650|NCT06473220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34165651|NCT03410524|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Endoscopist and patient blinded study.||t|t|t|f
34165652|NCT00598936|||CASE_ONLY||PROSPECTIVE|||||||
34165653|NCT04494906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165654|NCT02929030|||CASE_ONLY||PROSPECTIVE|||||||
34165655|NCT03029468|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Three-arm feasibility trial||||
34165656|NCT03384940|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165657|NCT02186574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33956966|NCT06070701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Propensity score matching||||
34165658|NCT00165178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165659|NCT00462007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165660|NCT02564393|||CASE_CONTROL||PROSPECTIVE|||||||
34165661|NCT01982123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165662|NCT02564133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165663|NCT02959359|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34165664|NCT02341352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34165665|NCT00671034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165666|NCT06527586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165667|NCT00655538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165668|NCT03708718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Double-blind. The trial management team are blind to treatment allocation for the duration of the trial. The site research teams and patients are blind to treatment until code-break. At this point the on-site team and patient are unblind to allocation for continuing care. The site pharmacy personnel, PRedSS trial monitor and supervising statistician are unblind throughout.~From August 2020: Open-Label - The patient, site research team and site pharmacy are unblind. The trial management team are unblind for patients recruited from August 2020 onwards but remain blind to patients randomised to trial under the double-blind design. The trial monitor and trial statistician continue to be unblind for all patients randomised to trial."|"Patients are allocated to received either prednisolone or matched placebo for the duration of the trial. The allocation is randomised 1:1.~From August 2020: Under the open-label design, patients are allocated to receive prednisolone or no additional treatment. The randomisation allocation is 1:1."|t|t|t|f
34165669|NCT02922335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165670|NCT02857673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34165671|NCT05846360|||COHORT||RETROSPECTIVE|||||||
34165672|NCT05138029|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747275|NCT01602536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33956967|NCT00136500|||OTHER||PROSPECTIVE|||||||
33956968|NCT06701214|||COHORT||PROSPECTIVE|||||||
33956969|NCT03943407|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33956970|NCT06703580|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33956971|NCT04419428|||CASE_ONLY||PROSPECTIVE|||||||
33956972|NCT02159573|||COHORT||RETROSPECTIVE|||||||
33956973|NCT04669756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33956974|NCT05576597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956975|NCT06702397|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized multi-center controlled trial comparing microsurgical-assisted testicular sperm extraction (m-TeSE - Group A) and testicular sperm extraction performed with surgical loupes (l-TeSE - Group B) in adult males with non-obstructive azoospermia (NOA) in terms of surgical outcomes and sperm retrieval rates||||
33956976|NCT00228878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956977|NCT05072145|||COHORT||RETROSPECTIVE|||||||
33956978|NCT06023680|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33956979|NCT04797637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in a 1:1 ratio using permutated blocks of 6. REDCap will be used for randomization, using an uploaded randomization sequence. A member of the study team will access REDCap to complete randomization.||||
33956980|NCT00903942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33956981|NCT01348659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33956982|NCT04782687|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, phase II, open-label, non-blinded, trial to investigate the effects of S-DRd for first line treatment of multiple myeloma in patients who are ineligible for stem cell transplant.||||
33956983|NCT04390100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||3 groups each receiving a different type of intervention|t|f|t|t
33956984|NCT02944097|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34165673|NCT05616468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165674|NCT04479826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165675|NCT04005261|||CASE_ONLY||PROSPECTIVE|||||||
34165676|NCT04157777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34165677|NCT00017511||||SUPPORTIVE_CARE||||||||
34165678|NCT05692063|||COHORT||PROSPECTIVE|||||||
34165679|NCT03688815|||COHORT||RETROSPECTIVE|||||||
34165680|NCT01152528|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34165681|NCT02426463|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165682|NCT05317065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165683|NCT00300755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165684|NCT00993408|RANDOMIZED|PARALLEL||OTHER||||||||
34165685|NCT02562716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165686|NCT05661279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34165687|NCT01056939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853305|NCT04697771|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The person making the first and last outcome assessor does not know which group the participants are from.|Participants will be randomly divided into two groups. The same intervention will be applied to the second group after the first group has received intervention for 8 weeks.|f|f|f|t
33853306|NCT06610110|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33853307|NCT04137965|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33747276|NCT05436236|||CASE_CONTROL||PROSPECTIVE|||||||
33853308|NCT02563639|||CASE_ONLY||PROSPECTIVE|||||||
33853309|NCT02757391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33956985|NCT06388265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33956986|NCT02704130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33956987|NCT06384898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is an individually randomized group-treatment (IRGT) trial. Individuals randomly allocated to remote Tai Chi receive the intervention with other participants through an instructor.|f|f|t|f
33956988|NCT03020966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33956989|NCT03284515|||COHORT||PROSPECTIVE|||||||
33956990|NCT06703047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33956991|NCT06596382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized double-blinded placebo-controlled trial was performed toward patients diagnosed with NALFD with several established inclusion and exclusion criteria of study. Two main groups were formed to separate the patient into metabolic syndrome and non-metabolic group. In these groups, it will further divided into two groups where the administration of tocotrienol rich-vitamin E and placebo were given in random manner. Each participant will consume the vitamin/placebo daily for one capsule in the duration of six months. Various assessments was conducted before and after taking the vitamin E/placebo.|t|f|f|f
33956992|NCT02267759|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33956993|NCT02820818|||COHORT||CROSS_SECTIONAL|||||||
33956994|NCT06116994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Impossibility to blind the participant and operator to the intervention. The statistician was blinded to the groups.|Case Control|f|f|f|t
33956995|NCT04457518|||CASE_ONLY||OTHER|||||||
33956996|NCT06056063|NA|SINGLE_GROUP||OTHER||NONE||||||
33956997|NCT05354141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|Multicenter, randomized, double-blinded, placebo-controlled trial|t|t|t|f
33956998|NCT06543498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33956999|NCT00939965||||TREATMENT||NONE||||||
33957000|NCT03920488|||CASE_ONLY||PROSPECTIVE|||||||
33957001|NCT03315871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957002|NCT05889533|||COHORT||PROSPECTIVE|||||||
33957003|NCT00380458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33957004|NCT01246297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957005|NCT03059940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957006|NCT03121664||CROSSOVER||BASIC_SCIENCE||NONE||||||
33957007|NCT01458860|||CASE_CROSSOVER||PROSPECTIVE|||||||
33957008|NCT02618772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957009|NCT02553005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957010|NCT06701448|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33957011|NCT00571909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957012|NCT03444909|RANDOMIZED|PARALLEL||OTHER||NONE||"35 women will be divided into 3 test groups. results will be analyse in fonction of the repartition of the gestationnal age~10 women between 24-29 Week of amenorrhea (WA); 15 women between 30-35 WA; 10 women between 36-41 WA will be included."||||
33957013|NCT03076502|||COHORT||PROSPECTIVE|||||||
33957014|NCT06569004|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33957015|NCT04141670|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33747277|NCT06634576|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|In research protocol, all neck postures were randomized, and did eye tracker recalibration before each task.|"All for health populations.~Inclusion criterias following:~1. Age between 20 and 60 years.~2. No history of significant neck surgeries.~3. No history of corrective eye surgery.~4. No skeletal muscle injuries or pain in the upper or lower limbs.~5. Free from vestibular system-related disorders and neurological symptoms.~6. Participants must avoid food and drink for 3 hours before the experiment.~7. Participants should have 8 hours of sleep the night before the experiment.~Exclusion criterias following:~1. Any participant who has undergone vision correction surgery in the last year.~2. Any participant who has experienced significant head or neck trauma in the past year.~3. Any participant with a history of vestibular system disorders or neurological symptoms.~4. Participants who have used medications or alcohol for an extended period.~5. Participants with abnormal pain in any part of the torso.~6. Individuals suffering from claustrophobia."||||
33957016|NCT04983095|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomised to control (standard care)1:1 intervention (SBRT+standard care)||||
33957017|NCT06471738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957018|NCT04437407|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||A consecutive, six-night, in-home, controlled, cross-over sleep study in third-trimester pregnant women to validate the ability of the PB2 and Ajuvia devices to reduce the amount of time pregnant women spend sleeping on their backs at night in the home setting in the third trimester of pregnancy|f|f|t|t
33957019|NCT04686500|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective study with retrospective data analysis||||
33747278|NCT02877290|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33747279|NCT05178082|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Statistical analysis of data will be blinded.|Randomized controlled trial for application and assessment of the two interventions. Patients waiting for multidisciplinary pain treatment at Rigshospitalet and Herlev/Gentofte Hospital will be invited to participate and randomly assigned to one of three arms (1:1:1): VP group, ER group or control group (no intervention). Assessments will occur at baseline, 2 months, 6 months, and 12 months after the intervention.||||
33747280|NCT06026293|||COHORT||OTHER|||||||
33747281|NCT04674358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747282|NCT05996003|NA|SEQUENTIAL||TREATMENT||NONE||||||
33853310|NCT03038230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853311|NCT02876198|||COHORT||PROSPECTIVE|||||||
33853312|NCT00558194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853313|NCT04471623|NA|SINGLE_GROUP||OTHER||NONE||||||
34165688|NCT00657982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747283|NCT06470217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747284|NCT04357028|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33747285|NCT03274843|NA|SINGLE_GROUP||OTHER||NONE||||||
33747286|NCT02818881|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33747287|NCT00108225|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747288|NCT00416013|||CASE_ONLY||PROSPECTIVE|||||||
33747289|NCT02921243|||CASE_ONLY||PROSPECTIVE|||||||
33853314|NCT04046718|RANDOMIZED|PARALLEL||TREATMENT||NONE||two group study, one is the study group and the other is a control group||||
33853315|NCT04762823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blind to the different stimulation intensities (sham, 4 mA) and the test administrators will also be blind to the subject's assigned stimulation condition.||t|f|t|f
33853316|NCT01636960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853317|NCT02037633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853318|NCT02866084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853319|NCT02618915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853320|NCT05513924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853321|NCT01398722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853322|NCT00570050|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33853323|NCT06391060|||COHORT||RETROSPECTIVE|||||||
33853324|NCT02601664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853325|NCT04574752|||COHORT||PROSPECTIVE|||||||
33853326|NCT04171453|||OTHER||PROSPECTIVE|||||||
33853327|NCT01196273|||COHORT||PROSPECTIVE|||||||
33853328|NCT02769377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853329|NCT02679352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853330|NCT01626300|||CASE_CONTROL||RETROSPECTIVE|||||||
33853331|NCT05208671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853332|NCT03291587|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853333|NCT00716508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853334|NCT00753051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061003|NCT02745691|||COHORT||PROSPECTIVE|||||||
34061004|NCT04621838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165689|NCT03246789|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Investigators will randomly assign four senior centers to offer either Engage-M (N=40), the treatment offered by REDS (1 individual and 8 weekly group sessions) or 8 group sessions Wellness in Mind and Body plus mental health referral (W-MH; N=20). Participants will have clinically significant depressive symptoms (PHQ-9\>10) and will be older and middle-aged adults (55+). Clients will be identified by senior center staff trained in SMART-MH strategies. Investigators will offer additional training to staff of all centers on SMART-MH outreach, depression screening, and treatment engagement. Investigators will train and provide weekly supervision to 2 or more LCSWs per center of the two centers assigned to Engage-M. Investigators will not offer training or supervision to senior center staff leading the groups of W-MH but will provide oversight so that clients receive mental health referrals and are encouraged to attend weekly Wellness group meetings."||||
34165690|NCT03088527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165691|NCT01449435|||CASE_CROSSOVER||PROSPECTIVE|||||||
33747290|NCT02943148|||OTHER||CROSS_SECTIONAL|||||||
33747291|NCT04586101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747292|NCT04376021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747293|NCT05086367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|f|t
33747294|NCT03618238|NA|SINGLE_GROUP||TREATMENT||NONE||drug||||
33747295|NCT06439563|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33747296|NCT05970861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747297|NCT05073133|NA|SINGLE_GROUP||TREATMENT||NONE||OAV101 will be administered as a single IV infusion at 1.1e14 vg/kg over approximately 60 minutes||||
33747298|NCT02485470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747299|NCT02010060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747300|NCT03604081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747301|NCT04717596|||OTHER||CROSS_SECTIONAL|||||||
33853335|NCT00451542|||OTHER||RETROSPECTIVE|||||||
33853336|NCT02545023|||CASE_ONLY||PROSPECTIVE|||||||
33853337|NCT02954068|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33853338|NCT05455515|||OTHER||PROSPECTIVE|||||||
33853339|NCT02729428|||CASE_CONTROL||PROSPECTIVE|||||||
33853340|NCT03523429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853341|NCT03038438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853342|NCT03719846|||OTHER||PROSPECTIVE|||||||
33853343|NCT05365217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853344|NCT02624310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33853345|NCT04984525|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Part 1:~Triple (Participant, Care Provider, Investigator) Double-blind (Sponsor-open)~Part 2:~Open-label"||t|t|t|f
33853346|NCT00454454|||COHORT||PROSPECTIVE|||||||
33853347|NCT02314845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061005|NCT00691639|||CASE_ONLY||RETROSPECTIVE|||||||
34061006|NCT02491801|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34061007|NCT02041650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061008|NCT03153267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061009|NCT06618144|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165692|NCT01366326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957020|NCT04965896|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will complete 2 study sessions at night, consuming plain white rice (corresponding to 75g of available carbohydrate) alongside each test meal (either the nuts or control meal) on two separate occasions. The order of scheduling of the sessions will be randomised.||||
33957021|NCT04225416|||COHORT||CROSS_SECTIONAL|||||||
33957022|NCT06332209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957023|NCT01849029|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33957024|NCT06565754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33957025|NCT01551329|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33957026|NCT01188759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957027|NCT06023953|||COHORT||PROSPECTIVE|||||||
33957028|NCT04269746|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33957029|NCT02487979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957030|NCT05471063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957031|NCT06564155|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957032|NCT02232685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957033|NCT04482101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957034|NCT04764825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation and study medication will be handled by the hospital pharmacy. All research team members, caregiving clinicians and enrolled patients will be blinded to the study allocation arms and the randomisation list will be concealed until all statistical analyses are made.|Randomized controlled trial|t|t|t|t
33957035|NCT03491800|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Given the nature of the intervention and it's intended purpose (i.e., to enhance communication with participants and health care providers), it is not possible to blind participants, care providers, or the investigators.|Individual patients and dyads (i.e., a HF patient and family member) will receive the question/topic prompt list immediately before their clinic visit||||
33957036|NCT03417674|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
33957037|NCT01881178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33957038|NCT03686124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957039|NCT01238523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957040|NCT04032522|||OTHER||OTHER|||||||
33957041|NCT03176511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"As with any active intervention, participants will know their group assignment and double-blinding is not possible. Of note, our primary outcome measures are objective and require post-processing, thus study staff collecting the data will be blinded to participant results. Further, our bio-engineer post-processor will be blinded to study assignment."|The proposed pilot study will employ a single-blind, two-group randomized clinical trial. We will randomly assign 24 community-dwelling older adults (≥ 60 years) from an underserved population who are at high fall risk to either: A.) 4-week MOB+DTBC intervention, or B.) 4-week MOB only intervention (n=12/group).|f|f|f|t
33957042|NCT06542354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33957043|NCT05517005|NA|SINGLE_GROUP||OTHER||NONE||||||
33957044|NCT04095546|||COHORT||PROSPECTIVE|||||||
33957045|NCT04036786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was a single-center, single-blinded, prospective randomized controlled trial (RCT), parallel-group RCT comparing the effects of a preeclampsia education and counseling program during pregnancy with standard antenatal care. Participants were 132 pregnant women with risk of preeclampsia.||||
33957046|NCT00901420|||CASE_CONTROL||PROSPECTIVE|||||||
33957047|NCT04598009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957048|NCT05760638|||COHORT||PROSPECTIVE|||||||
33957049|NCT03065517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957050|NCT02989467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957051|NCT02755727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957052|NCT05819645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957053|NCT06496360|||OTHER||CROSS_SECTIONAL|||||||
33957054|NCT04925622|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957055|NCT06597006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked (Year 1) to No Masking (Year 2)|Parallel (Year 1) to single-group (Year 2)|t|f|t|f
33957056|NCT04578548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957057|NCT01273584|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33957058|NCT00698607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957059|NCT05503160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33957060|NCT00552682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957061|NCT00535873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957062|NCT01904084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957063|NCT04635631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957064|NCT01162993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957065|NCT05144477|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957066|NCT02341794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165693|NCT03094117|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis|Two arms, parallel group, randomized controlled trial|t|f|f|f
34165694|NCT01865227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165695|NCT00207311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165696|NCT02174991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33957067|NCT05237687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165697|NCT05371925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants will be randomly distributed to received either IMP or placebo at the Research site pharmacy under the same blister format and capsule appearance.|This is a Prospective, multicenter, randomized (1:1, placebo use) trial with a parallel-group designed|t|t|t|f
34165698|NCT01561235|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34165699|NCT00348985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957068|NCT03789162|||COHORT||PROSPECTIVE|||||||
33957069|NCT03300882|||COHORT||PROSPECTIVE|||||||
33957070|NCT01387672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957071|NCT06511167|||COHORT||PROSPECTIVE|||||||
33957072|NCT06446154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Fruquintinib||||
33957073|NCT03104673|||COHORT||PROSPECTIVE|||||||
33957074|NCT05437718|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957075|NCT05678101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Fifteen of the patients will be randomized to the intervention and 15 will receive placebo (non-active TENS treatment).|This study will be a prospective, randomized, single-blinded, placebo-controlled repeated measures design.|t|f|f|f
33957076|NCT01021696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33957077|NCT06416930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957078|NCT06488417|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33957079|NCT04094818|||CASE_CONTROL||PROSPECTIVE|||||||
33957080|NCT01376856|||CASE_CROSSOVER||PROSPECTIVE|||||||
33957081|NCT00142324|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33957082|NCT06375122|||COHORT||PROSPECTIVE|||||||
33957083|NCT00460421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33957084|NCT06556914|||OTHER||PROSPECTIVE|||||||
33957085|NCT00335985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957086|NCT06700655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957087|NCT04177173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957088|NCT05801107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957089|NCT01314859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957090|NCT00825799|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34165700|NCT05617781|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34165701|NCT06138769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165702|NCT05210491|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34165703|NCT05910216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial with two groups|f|f|f|t
34165704|NCT01588444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747302|NCT05480566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33957091|NCT05243134|||COHORT||PROSPECTIVE|||||||
33957092|NCT04311411|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Tirzepatide and placebo dosing are double-blind. Liraglutide dosing is open label.||t|f|t|f
33957093|NCT02405494|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33957094|NCT02390037|||COHORT||PROSPECTIVE|||||||
33957095|NCT04543578|||CASE_ONLY||PROSPECTIVE|||||||
33957096|NCT06702527|||CASE_ONLY||PROSPECTIVE|||||||
33957097|NCT04731909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957098|NCT04923607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957099|NCT03770182|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33957100|NCT05362955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957101|NCT04672824|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33957102|NCT00713765|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33957103|NCT04992897|||COHORT||RETROSPECTIVE|||||||
33957104|NCT06703775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957105|NCT05641246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Principle investigator and the Researcher are aware of the intervention taken for each participant. The participant will be blinded ( Single blinded)|The study consists of 2 Arms, A control arm which will only receive standard of care (CARBAMIDE) and an intervention arm which will receive (CARBAMIDE and VOLTAREN)|t|f|f|f
33957106|NCT04992689|||COHORT||RETROSPECTIVE|||||||
34165705|NCT01197599|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34165706|NCT04567641|||COHORT||PROSPECTIVE|||||||
33853348|NCT06341036|||OTHER||CROSS_SECTIONAL|||||||
34165707|NCT05817838|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Adult-child pairs will be randomized to: (1) financial incentive only arm that will receive weekly $15 financial incentive coupons to subsidize purchase of healthy foods at a local SEA grocery store; or (2) financial incentive plus twice-monthly, family-based group nutrition education at the Center for SEA led by SEA community health workers; three motivational interviewing (MI) calls by trained community health workers; dietary norms messaging for adults (via weekly text messages) and for children (via Infographics at nutrition education sessions); and weekly $15 financial incentive coupons to subsidize purchase of healthy foods at SEA grocery stores; or (3) an Academic Engagement attention control arm that will follow the structure of the financial incentive plus nutrition education, MI and text messages and infographics arm.|f|f|f|t
34165708|NCT04214340|||COHORT||PROSPECTIVE|||||||
34165709|NCT03779659|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165710|NCT03631342|RANDOMIZED|CROSSOVER||OTHER||NONE||"In order to perform both interventions, the patients were placed in dorsal decubitus with a head elevated at 45 ° and submitted to closed tracheal aspiration, according to the recommendations of the American Association for Respiratory Care. In addition, the bacteriological filter was changed, the cuff pressure was increased and the presence of leaks in the mechanical fan circuits was verified.~All patients underwent five hyperinflation maneuvers, the order being determined by randomization. Controlled volume ventilation (VCV) at a constant flow rate of 20 Lpm (VCV-20) and 40 Lpm (VCV-40), controlled pressure ventilation (VCV-40) was performed for 2 minutes at 10 minute intervals. PCV), pressure-controlled ventilation associated with inspiratory time adjustment (PCV + Tins) and pressure-supported ventilation (PSV). PEEP and FiO2 were maintained throughout the study."||||
34165711|NCT04502537|||COHORT||PROSPECTIVE|||||||
34165712|NCT06051669|||COHORT||CROSS_SECTIONAL|||||||
34165713|NCT05055024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165714|NCT00135317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165715|NCT02420379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165716|NCT04280055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165717|NCT01235013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165718|NCT03109184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165719|NCT05568628|||CASE_ONLY||PROSPECTIVE|||||||
33853349|NCT05056987|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34165720|NCT00855621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853350|NCT01822288|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853351|NCT02918578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853352|NCT02819206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853353|NCT03297723|||COHORT||PROSPECTIVE|||||||
33853354|NCT06191497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33853355|NCT00125502|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853356|NCT04831294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Investigators and participants are blind to material assignment.|"Single-site, randomized, placebo-controlled, cross-over, within-subjects design.~Study sessions are 72 hours apart. Visits included pre-post assessments following ingestion of either placebo or CBD."|t|f|t|t
33853357|NCT02701140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|PROBE|PROBE|t|f|t|t
33853358|NCT06215027|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Single group|||||
33853359|NCT05138367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853360|NCT03293693|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Intervention With cross-over design. Three test meals will be tested.|t|f|t|t
33853361|NCT01853137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853362|NCT00565539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853363|NCT03217643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853364|NCT03676231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853365|NCT02202954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853366|NCT01424904|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33853367|NCT00062998|||||PROSPECTIVE|||||||
33853368|NCT05130242|||CASE_ONLY||RETROSPECTIVE|||||||
33853369|NCT01771120|||||CROSS_SECTIONAL|||||||
33853370|NCT01251731|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34165721|NCT00724672|||||PROSPECTIVE|||||||
34165722|NCT03168828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165723|NCT05599737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165724|NCT04484870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853371|NCT05203354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33853372|NCT01178554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33853373|NCT06025162|||COHORT||RETROSPECTIVE|||||||
33853374|NCT04308343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853375|NCT05000073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853376|NCT03054402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34165725|NCT01664182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165726|NCT03806621|||COHORT||PROSPECTIVE|||||||
34165727|NCT02486016|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34165728|NCT03337971|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single blind (participant only)|A block randomised, cross-over design receiving either a milk-based protein supplement (MBPS) or isoenergetic (corn starch) placebo control (PLACEBO).|t|f|f|f
34165729|NCT03512301|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34165730|NCT06456255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||We propose a double-blind, parallel arm, randomized controlled trial evaluating whether injecting 0.25% bupivacaine with 1:200,000 epinephrine is superior to no injection (sham procedure) during ESS.|t|f|t|f
33853377|NCT03990493|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment with Dose Modification||||
33853378|NCT02825784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853379|NCT03457363|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Comparison of level oxygenation between classical oxygenation with nasal canulae with or without adjunctive of a double trunk mask||||
33853380|NCT01682382|||COHORT||PROSPECTIVE|||||||
33853381|NCT00744523|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33853382|NCT02110615|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33853383|NCT06184074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957107|NCT06095362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853384|NCT04667078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||experimental group will be treated by P2Y12 inhibitor (cangrelor) in addition to MT and BMM|t|f|f|f
33853385|NCT02879422|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33853386|NCT01783041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165731|NCT00419939|||||PROSPECTIVE|||||||
34165732|NCT05935332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853387|NCT04882995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061010|NCT06579404|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre, multinational, open-label, randomised single period, parallel design study contrasting fully closed-loop insulin delivery and standard insulin therapy with CGM over 26 weeks in adults with type 2 diabetes.||||
34165733|NCT04643626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multi-center prospective pilot trial study||||
34165734|NCT05684458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients and the investigators know which group they are assigned to. Only the outcome assessor doesn't know which patient is assigned to which group.||f|f|f|t
34165735|NCT01130753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165736|NCT01877512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165737|NCT00093210|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34165738|NCT02921581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165739|NCT01214005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34165740|NCT01512095|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165741|NCT01910402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165742|NCT03564613|||COHORT||PROSPECTIVE|||||||
34165743|NCT01729286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165744|NCT03062020|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34165745|NCT03106064|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34165746|NCT05745311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165747|NCT01053494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165748|NCT02151188|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165749|NCT00441246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853388|NCT03509454|||COHORT||CROSS_SECTIONAL|||||||
33853389|NCT00759915|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33853390|NCT05485467|||COHORT||PROSPECTIVE|||||||
33853391|NCT03994289|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34061011|NCT04731025|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be double-blind so that the patients, site investigators and data monitors will be blinded to the allocation. Only the designated nurses and the members of the trial coordinating unit (who provide the randomization number and treatment allocation) are not blinded to the allocation. The unblinded persons will not in any way be part of the treatment, clinical evaluation of outcomes or data assessment.||t|t|t|t
34061012|NCT00109876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061013|NCT05949541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061014|NCT03393429|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34061015|NCT05014581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061016|NCT03057223|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is an open-label, prospective, single-arm, and single-center interventional clinical study.||||
34061017|NCT03473613|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061018|NCT03493750|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Dentists are masked of the patient group|Impact of an oral evaluation realized by a nurse combined with a questionnaire (the healthplan guide)|f|t|f|f
34061019|NCT05201040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061020|NCT04392167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061021|NCT01866267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061022|NCT02596217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061023|NCT01270386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061024|NCT02580864|||OTHER||PROSPECTIVE|||||||
34061025|NCT01539395|||COHORT||CROSS_SECTIONAL|||||||
34061026|NCT03698968|NA|SINGLE_GROUP||PREVENTION||NONE|Open|||||
34061027|NCT00908076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061028|NCT02537834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061029|NCT02235441|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34061030|NCT04919876|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|capsules for 2 supplement have the same color and shape|randomized, double blind, placebo-controlled, parallel design, controlled feeding trial|t|t|t|t
34061031|NCT05650346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061032|NCT03901053|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be cast, fit, and tested with each device in question (Reaktiv and PhatBrace AFO). Participants will be randomized to one of two arms (AB or BA) to maximize the likelihood of similarity between groups with respect to a range of anthropometric, demographic and injury related factors. We will use block randomization in groups of 4 to achieve equal randomization between groups over time.||||
34061033|NCT02335749|NA|SINGLE_GROUP||OTHER||NONE||||||
34061034|NCT06625398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized to one of the three study arms.|Participants will be randomized to one of the three study arms.|t|f|t|t
33957108|NCT04916067|NA|SINGLE_GROUP||PREVENTION||NONE||Modified Simon-Two Step. An initial cohort of 5 patients will be enrolled and treated sequentially with 30 day follow-up. If stopping criteria are not met, the cohort will be expanded to an additional 15 patients followed concurrently for the duration of the study period||||
33957109|NCT05986565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957110|NCT05161546|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The BiMAR study is an open-label and non-randomized comparative monocentric study applied in psychiatry and neuroscience.~This research included two groups of adult subjects: a group of patients with BD in the euthymic phase and a group of healthy control subjects."||||
33957111|NCT02924584|||COHORT||RETROSPECTIVE|||||||
33957112|NCT03069365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957113|NCT01054469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33957114|NCT02871466|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957115|NCT06539949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957116|NCT06260683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957117|NCT04846049|||COHORT||PROSPECTIVE|||||||
34165750|NCT03525691|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33957118|NCT04141839|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants use code numbers to submit their data.|A cluster-randomized trial design with crossover to randomize participants at the bar level into intervention and delayed intervention arms.|t|f|f|f
33957119|NCT05873075|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957120|NCT04425954|||COHORT||RETROSPECTIVE|||||||
33957121|NCT00503035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957122|NCT06349408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957123|NCT04719728|||COHORT||PROSPECTIVE|||||||
33957124|NCT03415139|||COHORT||PROSPECTIVE|||||||
33957125|NCT06568952|||COHORT||PROSPECTIVE|||||||
33957126|NCT03558607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957127|NCT03327532|NA|SINGLE_GROUP||OTHER||NONE||||||
33957128|NCT00826865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33957129|NCT02306174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957130|NCT05573555|NA|SEQUENTIAL||TREATMENT||NONE||"Phase 1b will use an escalation/de-escalation approach to determine the RP2D of ARV-471 when administered in combination with ribociclib. The decision to escalate the starting dose level of ARV-471 will be using mTPI-2 decision criteria based on the number of DLT-evaluable participants and the number of DLTs in those participants during the DLT observation period (Cycle 1).~During Phase 1b, a 7 days lead-in period will be conducted with ARV-471 as monotherapy.~Phase 2 will further evaluate the preliminary antitumor activity and safety of the combination RP2D.~In addition, the potential drug-drug interaction (DDI) between ARV-471 and ribociclib will be evaluated, at the doses selected for the ph2 portion, in a DDI Assessment Cohort(s)"||||
34165751|NCT05806320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34165752|NCT00035490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165753|NCT05076201|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34165754|NCT01139632|||||PROSPECTIVE|||||||
34165755|NCT01333228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165756|NCT02285335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747303|NCT03340051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747304|NCT05070091|||OTHER||PROSPECTIVE|||||||
33747305|NCT06669923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747306|NCT02241967|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33765559|NCT03675451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765560|NCT00610064|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33765561|NCT00803101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957131|NCT05968482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33957132|NCT06704048|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed method||||
34165757|NCT01952236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165758|NCT02025179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165759|NCT01395576|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165760|NCT03154385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165761|NCT05274386|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Subjects will be switched between 3 averaging times (4to6s-10s-16s) every 12 hours. The sequence will be assigned in random order. Each enrolled subject will continue in the study with regular changes in averaging time through the course of their need for A-FiO2.|t|f|f|f
33747307|NCT03835377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study was a double-blind, cluster-randomized controlled trial (with randomization at the school level) of: (1) iron-biofortified black beans, compared to (2) a commercial variety of beans, with the intervention randomized at the school level. School administrators, children, research staff (i.e. managing the intervention, food weighing, assessment of outcomes), and laboratory staff were blinded to the intervention group.||t|f|t|t
33747308|NCT02967302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747309|NCT00328081|||DEFINED_POPULATION||PROSPECTIVE|||||||
33747310|NCT04398524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747311|NCT02562755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747312|NCT02723838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747313|NCT05709730|||COHORT||RETROSPECTIVE|||||||
33747314|NCT05530135|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Three arm pilot feasibility study||||
33747315|NCT06495775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747316|NCT05503108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747317|NCT01904812|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33747318|NCT05981274|||OTHER||OTHER|||||||
33747319|NCT04501315|||COHORT||PROSPECTIVE|||||||
33747320|NCT04523545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747321|NCT01720355|||||PROSPECTIVE|||||||
33747322|NCT04533425|||COHORT||PROSPECTIVE|||||||
33747323|NCT02206503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747324|NCT00717509|||COHORT||CROSS_SECTIONAL|||||||
33747325|NCT02715921|NA|SINGLE_GROUP||OTHER||NONE||||||
33747326|NCT06669780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747327|NCT01692535|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33747328|NCT03562000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747329|NCT01328574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747330|NCT01662882|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747331|NCT05221164|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33747332|NCT06216691|NA|SINGLE_GROUP||OTHER||NONE||||||
33853392|NCT01927926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33853393|NCT03173573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part 1,3,4: Double blind; Part 2, 5: open label.|5-part study. Part 1,3,4: parallel assignment; Part 2: cross over assignment; Part 5: single assignment|t|t|t|f
33853394|NCT03261245|||CASE_CONTROL||RETROSPECTIVE|||||||
33853395|NCT05717231|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33853396|NCT04200521|||CASE_CONTROL||PROSPECTIVE|||||||
33853397|NCT01257425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853398|NCT01574209|||CASE_CONTROL||PROSPECTIVE|||||||
33853399|NCT05314920|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessors will be blinded during pre- and post-treatment. Participants will be blinded during pretreatment assessment; however, it cannot be guaranteed that they will keep blinded in post-treatment.|Multicenter randomized controlled trial with pre-post measures and 12-month follow-up.|t|f|f|f
34165762|NCT06147999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The 14 inactive Biophoton Generators packed with the same 32-Oz metal can as the active Treatment device will be labeled with a code and placed under a hotel bed for use. The shape, weight and overall looking is identical between the active and placebo devices.|This study is a randomized, triple-blinded, placebo-controlled prospective intervention clinical research in two groups. About 80 patients with brain disorder will participate in the clinical interventional study at the hotel-like Tesla MedBed Center in Butler, PA, USA.|t|t|t|t
34165763|NCT06423456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Intraoperative lidocaine infusion is a frequently preferred method in surgical procedures due to its reducing the need for opioids, providing better postoperative pain control, reducing postoperative nausea and vomiting and increasing rapid recovery. Our aim in this study is to show the effect of intraoperative lidocaine infusion on reducing complications such as pain, nausea, vomiting, and the need for opioid analgesia that occur after hysteroscopy operations, which are often performed in gynecology clinics.|t|t|f|t
34165764|NCT02551341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165765|NCT05701293|||COHORT||PROSPECTIVE|||||||
34165766|NCT05029869|||COHORT||PROSPECTIVE|||||||
34165767|NCT00549315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165768|NCT02348593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165769|NCT06175481|||OTHER||PROSPECTIVE|||||||
34165770|NCT04317040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165771|NCT04188938|||CASE_ONLY||OTHER|||||||
34165772|NCT05201508|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective open label randomized trial||||
34165773|NCT02336230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165774|NCT01574274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165775|NCT01186185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165776|NCT04947696|||COHORT||PROSPECTIVE|||||||
34165777|NCT00490269|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34165778|NCT00502671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165779|NCT01459484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747333|NCT05913622|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is possible as the device is visible after placement.|Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains||||
33747334|NCT00628732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747335|NCT03332524|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Multi-centers double-blinded clinical trial with one intervention arm with SP160412 (Ibuprofen and Chlorpheniramine combined) with one arm with Active control (Ibuprofen with placebo) and a third arm (Chlorpheniramine with Placebo)|t|t|t|t
33747336|NCT01367327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747337|NCT04372966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded|Randomaised controlled trial|t|f|f|t
33747338|NCT05570526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective, randomized, double-blinded, placebo-controlled trial.|t|f|t|f
33747339|NCT05462626|NA|SINGLE_GROUP||TREATMENT||NONE||This quantitative pilot study will use a quasi-experimental approach with a single-group, pretest-posttest design to evaluate the effects of the Holistic Occupational Performance Empowerment (HOPE) lifestyle program on health-related quality of life and occupational performance of community-dwelling older adults.||||
34165780|NCT03371693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853400|NCT04881604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the characteristics of the study, it will be blind only to the researcher responsible for analyzing the collected data.|Randomization will be by lot when the patient enters the study. Envelopes will be made available that will contain a code that determines the allocation of patients in the intervention group experimental or standard.|f|f|f|t
33853401|NCT05008861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853402|NCT04375020|||COHORT||PROSPECTIVE|||||||
33853403|NCT00776126|||CASE_ONLY||PROSPECTIVE|||||||
33853404|NCT00648817|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33853405|NCT03259451|||COHORT||RETROSPECTIVE|||||||
34165781|NCT03071887|NA|SINGLE_GROUP||OTHER||NONE||This is an open pilot of the adapted Relaxation Response Resiliency Program (3RP).||||
33853406|NCT00088686||||TREATMENT||||||||
33853407|NCT01108107|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33853408|NCT06178393|||COHORT||RETROSPECTIVE|||||||
33853409|NCT03263286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853410|NCT03339570|||COHORT||PROSPECTIVE|||||||
33853411|NCT04943367|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33853412|NCT03198182|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33853413|NCT03069612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853414|NCT05488015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor responsible for collecting the results was blinded, without commenting on the group from which the patient came.||f|f|f|t
33853415|NCT02175251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853416|NCT01516242|||COHORT||PROSPECTIVE|||||||
33853417|NCT02669511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853418|NCT02870166|||FAMILY_BASED||PROSPECTIVE|||||||
33853419|NCT00129597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33853420|NCT00164931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33853421|NCT05493215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853422|NCT00463528|||||OTHER|||||||
33853423|NCT06355193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853424|NCT04847726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Study participants underwent contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride. The diagnostic performance will be compared intra-individually.||||
33957133|NCT06363591|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients with thin (≤1.0 mm) invasive melanomas excised with a histopathological margin ≥1.5 mm will be offered to participate following informed consent and randomization (1:1) to either:~1. Standard treatment with a WLE of the diagnostic excision scar with a lateral clinical surgical margin of 10 mm and a deep clinical surgical margin down to the muscular fascia as recommended by the Swedish national guidelines.~   or~2. Experimental treatment with no WLE."||||
33957134|NCT03378999|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34165782|NCT01055561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165783|NCT02807207|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34165784|NCT04832932|||OTHER||OTHER|||||||
34165785|NCT04291573|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34165786|NCT00003461||||TREATMENT||||||||
34165787|NCT00199121|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853425|NCT02878681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853426|NCT02675504|||OTHER||PROSPECTIVE|||||||
33853427|NCT00230893|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34165788|NCT04304612|||OTHER||OTHER|||||||
34165789|NCT02172638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34165790|NCT00354679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165791|NCT02093793|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165792|NCT01817023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|central investigator organization digital randomize||f|f|t|f
33853428|NCT01240031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33853429|NCT04843553|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Research Pharmacists used list provided by biostatistician to fill unidentified (except for patient name) pill bottles.||t|t|t|f
33853430|NCT01315496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853431|NCT00557648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853432|NCT02761941|||COHORT|||||||||
33853433|NCT06483529|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE||prospective equivalence study with a two-arm crossover design - explorative pilot study|t|t|t|t
33853434|NCT04925973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853435|NCT06084156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853436|NCT02518126|||CASE_CONTROL||PROSPECTIVE|||||||
33853437|NCT02942238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853438|NCT04710160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957135|NCT06700967|||COHORT||PROSPECTIVE|||||||
33957136|NCT05429632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||prospective, multicenter, randomized, double-blind, placebo-controlled, and 3-arm parallel group study|t|t|t|t
33957137|NCT04497571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trials.|t|f|t|t
34165793|NCT03168412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165794|NCT01579227|||COHORT||PROSPECTIVE|||||||
34165795|NCT05976802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165796|NCT06032169|||CASE_CONTROL||PROSPECTIVE|||||||
34165797|NCT01619839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165798|NCT04734717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165799|NCT03941496|NA|SEQUENTIAL||TREATMENT||NONE||This study is a Phase Ib/IIa single-institution, open-label, non-randomized clinical trial of using azacitidine in pulmonary TB patients during the continuation phase of ATT.||||
34165800|NCT01168726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33747340|NCT00496665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747341|NCT04317820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors will be blinded to which condition the participant was assigned.|Participants will be randomized to either the DBR treatment or wait-list conditions.|f|f|f|t
33747342|NCT05403008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors and statistician||t|f|f|t
33747343|NCT01850680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747344|NCT04477603|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33747345|NCT02003001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747346|NCT01629004|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
34165801|NCT00774293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747347|NCT06636136|NA|SEQUENTIAL||TREATMENT||NONE||||||
33747348|NCT06113627|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding of the researchers in charge of the evaluations and data analysis will be implemented, so that they are unaware of the assignment of each patient to the groups. It is not possible to blind participants and the physiotherapist (care provider) due to the very nature of the intervention|Randomized Controlled Trial|f|f|t|t
33747349|NCT02267382|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33747350|NCT03411967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747351|NCT03591341|||OTHER||PROSPECTIVE|||||||
33853439|NCT03993821|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open-label, 52-week study designed to assess the efficacy, safety and pharmacodynamics (PD) of burosumab in a single subject with cutaneous skeletal hypophosphatemia syndrome (CSHS). Burosumab (formerly KRN23) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. It is hypothesized that burosumab may provide clinical benefit in this patient due to the common underlying feature in this patient and in patients with X-linked hypophosphatemia (in whom burosumab is FDA-approved) - abnormally elevated FGF23, in the context of low age-adjusted serum phosphorous levels. Patient will be seen at Screening, Baseline and every 2-4 wks, as described in Schedule of Activities"||||
33853440|NCT01814202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853441|NCT04564651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853442|NCT02873247|||COHORT||PROSPECTIVE|||||||
33853443|NCT00173160|||DEFINED_POPULATION||OTHER|||||||
33853444|NCT01590017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853445|NCT00732225|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853446|NCT00285220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853447|NCT00541060|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33853448|NCT00831337|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853449|NCT04384315|||COHORT||PROSPECTIVE|||||||
33957138|NCT06650254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind (researchers are not blinded) randomization is recorded as the mothers will be supported by the researchers face to face and via the Web application. The statistician is also blinded for data analysis purposes.|Randomized Controlled Trial|f|f|f|t
33957139|NCT06650397|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33957140|NCT01644461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957141|NCT02922036|NA|SEQUENTIAL||TREATMENT||NONE|One part of the study was randomized. The final part of the study was single-arm, open label.|||||
33957142|NCT04757675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957143|NCT01132170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33957144|NCT01887366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957145|NCT00625118|||COHORT||PROSPECTIVE|||||||
33957146|NCT02623530|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34165802|NCT01475435|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34165803|NCT01521507|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165804|NCT04441411|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
34165805|NCT01626924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165806|NCT00626275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34165807|NCT03637777|||COHORT||PROSPECTIVE|||||||
34165808|NCT02079038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34165809|NCT05668910|||CASE_CONTROL||PROSPECTIVE|||||||
34165810|NCT04504981|NA|SINGLE_GROUP||PREVENTION||NONE|This is a pilot study with no comparison/control group so masking is not relevant.|In Phase 3, we will pilot test Y2Prevent with three groups of African American young men who have sex with men (AAYMSM) in Los Angeles. Each group will have up to 10 members (n=30). The intervention will be delivered to the three groups in a sequential order so that the experiences from the first group can be used to adapt and/or further refine the intervention before it is pilot tested with the second group. Feedback from the first group will be used to further adapt and refine the intervention. It will be pilot tested again with a second group of 10 participants. Y2Prevent will be further refined as needed, and it will then be pilot tested with a third and final group of up to ten participants.||||
34165811|NCT01451489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165812|NCT02707068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165813|NCT02300259|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34165814|NCT05032482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The first 24 weeks will be the randomized controlled portion of the study; the remaining 24 weeks will be an open label extension.||t|t|t|t
34165815|NCT00920855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747352|NCT02313012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747353|NCT03516331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165816|NCT03004729|NA|SINGLE_GROUP||SCREENING||NONE||||||
34165817|NCT04814966|||OTHER||OTHER|||||||
34165818|NCT06063863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747354|NCT04454411|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747355|NCT01279889|||COHORT||PROSPECTIVE|||||||
33747356|NCT05802238|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center randomized controlled trial, parallel two-arm design allocation 1:1 exposed-control design||||
33747357|NCT06388525|||CASE_CONTROL||RETROSPECTIVE|||||||
33747358|NCT03496038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33747359|NCT05406687|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33747360|NCT05499429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomly assigned to the active stimulation group and sham stimulation group, Patients，Care Provider and Outcomes Assessor did not know the patient grouping.|Patients were randomly assigned to the active stimulation group and sham stimulation group.|t|t|f|t
33747361|NCT05752123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747362|NCT06574867|||COHORT||PROSPECTIVE|||||||
34165819|NCT04249856|||OTHER||PROSPECTIVE|||||||
33853450|NCT05396469|||COHORT||CROSS_SECTIONAL|||||||
33853451|NCT03536260|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33853452|NCT00680784|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33853453|NCT02334501|NA|SINGLE_GROUP||||NONE||||||
33853454|NCT01515397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165820|NCT04892264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165821|NCT00915863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165822|NCT06419075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The attending anesthesiologist will receive the randomized assignment from the lead research team at UTMB and prepare the diluted study agents. The OR staff, attending surgeon, and learners including fellows and residents are blinded.|The enrolled subjects will be randomized into one of the 3 arms including tranexamic acid (2 mg/dL), vasopressin (0.1 U/dL), and normal saline.|t|t|t|t
34165823|NCT02227004|||COHORT||PROSPECTIVE|||||||
34165824|NCT05590052|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34165825|NCT03483896|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34165826|NCT01115868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853455|NCT01558011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165827|NCT03601260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165828|NCT00346125|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165829|NCT01102036|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33853456|NCT03275129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients over the age of 18 who arrive to the hospital requiring surgery for hip fracture repair.||||
33853457|NCT01744223|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33853458|NCT03634696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853459|NCT04483505|NA|SINGLE_GROUP||OTHER||NONE||Open label, prospective, multicenter, single-arm, phase I dose-escalation study.||||
33853460|NCT06524713|||OTHER||RETROSPECTIVE|||||||
33853461|NCT03446729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853462|NCT05566496|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33853463|NCT00465920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33853464|NCT02574156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853465|NCT03422588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853466|NCT05213897|||COHORT||PROSPECTIVE|||||||
33957147|NCT06013423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957148|NCT00003769||||TREATMENT||||||||
34165830|NCT02346175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165831|NCT05478642|||COHORT||OTHER|||||||
34165832|NCT06278792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All physicians were blinded for the spot urinary sodium measurements. Additionally, while urine was collected for the first 48 h in both groups, the analysis was only performed afterwards.|The EASY-HF study was a single-centre, randomized, open-label study comparing standard of care (SOC) diuretic management at the treating physician's discretion with a nurse-led natriuresis-guided protocol in patients with ADHF.|t|t|f|f
33853467|NCT04252768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853468|NCT02314182|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33853469|NCT04633486|||COHORT||OTHER|||||||
33853470|NCT04200885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Among the patients randomized because of severe postoperative sequelae expected as a result of radiological examination prior to surgical extraction of lower third molar teeth; postoperatively nonsteroid antiinflammatory drug prescribed group compared with preoperative single dose intraoral submucosal corticosteroid administration and postoperative therapeutic elastic bandage application.||||
33853471|NCT04560829|||COHORT||PROSPECTIVE|||||||
33853472|NCT01528501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853473|NCT03404141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165833|NCT03241082|||COHORT||PROSPECTIVE|||||||
34165834|NCT04486651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165835|NCT00671424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34165836|NCT00238979|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34165837|NCT01677325|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33747363|NCT03564912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165838|NCT03138421|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33747364|NCT06087601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Group 1: sham blocks Group 2: genicular nerve neurolysis|t|t|f|t
33747365|NCT03001648|||COHORT||RETROSPECTIVE|||||||
33747366|NCT06060691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747367|NCT00957502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747368|NCT03669848|||OTHER||PROSPECTIVE|||||||
34165839|NCT02679755|NON_RANDOMIZED|||TREATMENT||NONE||||||
33853474|NCT04732494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165840|NCT04230915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165841|NCT01864343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165842|NCT04437381|||COHORT||PROSPECTIVE|||||||
34165843|NCT00947271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34165844|NCT01787630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165845|NCT00670371|||||CROSS_SECTIONAL|||||||
34165846|NCT05246371|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165847|NCT04052308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165848|NCT03604029|||COHORT||PROSPECTIVE|||||||
34165849|NCT05173909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|None of the participants，care providers and outcomes assessors knew the grouping, and only the experimenter had to adjust BIS. In this way, the description of the treatment effects and adverse reactions of the subjects, as well as the recording of the experimenter's various reactions, can be as objective as possible.|A total of 73 patients were selected and divided into two groups according to random number table method: BIS closed loop target controlled infusion group with BIS value of 55 (group H) and BIS closed loop-target controlled infusion group with BIS value of 45 (group L), The final grouping results were 36 cases in group H and 37 cases in group L. All enrolled patients signed informed consent forms.|t|t|f|t
33747369|NCT01785238||PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33747370|NCT00920426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747371|NCT02534909|NA|SINGLE_GROUP||TREATMENT||NONE||"All patients were on active treatment.~In treatment periods 1 to 3, patients received the following:~• LFG316 20 mg/kg as i.v. infusion every 2 weeks~Patients participating in treatment period 4 received the following:~* LFG316 20 mg/kg as i.v. infusion every 2 weeks for 4 weeks (total 2 infusions)~* LNP023 200 mg b.i.d. for approximately 20 weeks. Four capsules (each 50 mg) were administered each time study medication was taken.~Down-titration was permitted only in case of LNP023 treatment discontinuation:~* LNP023 30 mg taken in the evening (once daily) for 7 days (3 capsules of 10 mg each time study medication was taken).~* Followed by LNP023 10 mg taken in the evening (once daily) for 7 days (1 capsule of 10 mg each time study medication was taken).~* LFG316 was administered via i.v. infusion by the investigator or designated study staff over approximately 2 hours in Period 1 and between 40 minutes and 2 hours from Period 2 onwards."||||
33747372|NCT03775239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747373|NCT06670950|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747374|NCT06364189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33747375|NCT06636461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33747376|NCT05373394|||CASE_CONTROL||PROSPECTIVE|||||||
33747377|NCT00233493|||FAMILY_BASED||PROSPECTIVE|||||||
33747378|NCT02732925|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33747379|NCT06180824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial|t|f|f|f
33747380|NCT01944501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747381|NCT01380327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747382|NCT02081092|||CASE_ONLY||PROSPECTIVE|||||||
33747383|NCT01633710|||CASE_ONLY||CROSS_SECTIONAL|||||||
33747384|NCT03600337|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|f|t
33747385|NCT06308939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747386|NCT06030609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853475|NCT00932113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34165850|NCT00556894|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853476|NCT05273697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957149|NCT06212375|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33957150|NCT01875419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957151|NCT01178567|||COHORT||RETROSPECTIVE|||||||
34165851|NCT02380287|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165852|NCT04871659|||COHORT||CROSS_SECTIONAL|||||||
34165853|NCT00410878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165854|NCT04041934|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|double blind|Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions|t|f|t|f
34165855|NCT04676295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165856|NCT04321044|NA|SINGLE_GROUP||OTHER||NONE||||||
34165857|NCT02849119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165858|NCT00074334||||TREATMENT||||||||
34165859|NCT00497757|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34165860|NCT01687608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747387|NCT06482372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34165861|NCT00545090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165862|NCT02939534|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33747388|NCT04482647|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33853477|NCT03080831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Study fluids blinded using opaque bags||t|t|t|t
33893473|NCT05649176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a feeding study. All participants will receive a diet designed to moderate the blood glucose response. The diets will be similar except that in the experimental group soybean flour (soy) will be incorporated into the foods|Randomized controlled two-arm parallel trial|t|f|t|t
33893474|NCT00986349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893475|NCT06071312|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open-label, single-center trial.||||
34165863|NCT02134860|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747389|NCT01821469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747390|NCT03911492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853478|NCT04778241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding to treatment allocation was possible only for the investigator and data analyst because the clinicians could know the intervention as osteo-perforation can be obviously seen clearly. Masking the intervention for the participants were not possible because micro-osteoperforation is a surgical procedure. All the trial documents were labeled with the study ID number, which was used for participant identification and data collection without unmasking the allocation group. This allowed the investigator to complete data collection and measurements blindly.||f|f|t|t
34061035|NCT03643367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be informed about their group assignments, technicians, processing the samples, will not have any access to ICU or patient charts (= double blind trial)|Patients with septic shock are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time (4 hours) to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.|t|f|f|t
34061036|NCT03536949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853479|NCT05248074|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853480|NCT02869360|||COHORT||PROSPECTIVE|||||||
33853481|NCT01011426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853482|NCT02088437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33853483|NCT00437723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853484|NCT01095107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33853485|NCT02368496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853486|NCT03865303|||COHORT||PROSPECTIVE|||||||
33853487|NCT00414713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061037|NCT04813913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061038|NCT01306435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34061039|NCT00705185|||CASE_CONTROL||PROSPECTIVE|||||||
34061040|NCT06051331|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34061041|NCT01187667|||CASE_CONTROL|||||||||
34061042|NCT04679051|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This project will be a randomized crossover study. Each week will consist of a different time in bed schedule of either 8 or 11 hours time in bed (TIB). The investigators estimated that about 11 hours in bed will result in at least 9 hours of total sleep time (i.e., long duration sleep). Laboratory testing will occur after five consecutive nights of either 8h or 11h TIB to assess the effect of sleep duration on vascular function, and after the sixth consecutive night of TIB to assess the effect of exercise on vascular function under different sleep conditions.||||
34061043|NCT00495599|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061044|NCT02359799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061045|NCT04785040|||OTHER||CROSS_SECTIONAL|||||||
34061046|NCT00731718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061047|NCT00032422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34061048|NCT00756197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061049|NCT05583643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061050|NCT00365001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061051|NCT05111392|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Beverages will have similar color, flavoring, and taste.|Mixed model.|t|f|f|f
34061052|NCT03211442|||COHORT||RETROSPECTIVE|||||||
34061053|NCT01464801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061054|NCT02946814|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34061055|NCT00337324|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34061056|NCT05531305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061057|NCT04805359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061058|NCT00772824|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Case Control|t|f|f|f
34061059|NCT04192058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165864|NCT00397384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165865|NCT02469350|NA|SINGLE_GROUP||OTHER||NONE||||||
34165866|NCT05701007|||OTHER||RETROSPECTIVE|||||||
34165867|NCT05759689|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34165868|NCT01757314|||COHORT||PROSPECTIVE|||||||
34165869|NCT00918177|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165870|NCT05098730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study is a single site, two-group quasi-experimental design comparing the effects of strategy training on rehabilitation engagement, cognitive performance, and community participation of home-dwelling stroke survivors living with and without pets. The investigators will also conduct qualitative interviews with participants who have pets.||||
34165871|NCT00209352|RANDOMIZED|PARALLEL||||DOUBLE||||||
33853488|NCT03751579|||COHORT||PROSPECTIVE|||||||
33853489|NCT04302441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853490|NCT01971710|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853491|NCT01203280|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853492|NCT02212210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853493|NCT01835938|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33853494|NCT00390910|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853495|NCT02463565|||COHORT||CROSS_SECTIONAL|||||||
33853496|NCT04508361|||CASE_ONLY||PROSPECTIVE|||||||
33853497|NCT00691405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853498|NCT02567500|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33853499|NCT00526721|||CASE_CONTROL||PROSPECTIVE|||||||
34061060|NCT02356133|||COHORT||PROSPECTIVE|||||||
34061061|NCT02314754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061062|NCT04969380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061063|NCT04026412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061064|NCT02727426|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34061065|NCT05821075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34061066|NCT03744845|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34061067|NCT03974022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061068|NCT05368415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34061069|NCT01752894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853500|NCT03253965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165872|NCT05577923|NA|SINGLE_GROUP||TREATMENT||NONE||Depending on the DFI, the subjects will be divided into four groups, namely T0, TS(≤2 years), TM(2-5 years), and TL(≥5 years). All subjects will receive the same treatment regimen.||||
34165873|NCT01613677|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165874|NCT03391934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both of the drugs used in the study are indistinguishable for patients and their respective curative staff because they are similar in size and shape of the vials, caps, aluminum sealing and paints, and it is not possible to distinguish the type of brand from the appearance of the vials. Additionally, people who are evaluating the results and analyzing data are not aware of the type of patient grouping.||t|f|t|f
34165875|NCT00652795|RANDOMIZED|CROSSOVER||||NONE||||||
33853501|NCT03542370|||OTHER||PROSPECTIVE|||||||
34165876|NCT00335400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165877|NCT00642590|||COHORT||PROSPECTIVE|||||||
34165878|NCT06223685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A prospective randomized, placebo-controlled, double-blinded study of 100 patients with hydrogen-methane breath test-confirmed small intestinal bacterial overgrowth (SIBO) and symptoms, to evaluate the efficacy of a dietary intervention using probiotic bacterial strains as adjunctive therapy to rifaximin.~All patients included in the study according to the standard of therapeutic management of SIBO will receive a prescription for rifaximin at a dose of 1200 mg/d for 14 days (Xifaxan 200 mg, 3 op. of 28 tablets, DS. 3 x 400mg).~50 patients will be randomly assigned to an arm receiving a 4enteric probotic, while 50 patients will receive capsules that will have an identical shell to the probiotic, but will contain only potato starch."|f|f|t|f
33853502|NCT02288533|NA|SINGLE_GROUP||OTHER||NONE||||||
33853503|NCT01223586|||COHORT||RETROSPECTIVE|||||||
33853504|NCT02742636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853505|NCT00690118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853506|NCT01270971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165879|NCT02057861|||CASE_CONTROL||PROSPECTIVE|||||||
34165880|NCT00675909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34165881|NCT04932239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study will be study will be a two-arms pre-post intervention study with a follow-up survey after 4 months|t|f|f|f
34165882|NCT01749306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165883|NCT02607618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165884|NCT05727735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165885|NCT04521322|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Multicenter, randomized, double blind compared vs placebo|t|f|t|f
34165886|NCT04995536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165887|NCT02164201|||COHORT||PROSPECTIVE|||||||
34165888|NCT04803695|||COHORT||PROSPECTIVE|||||||
33853507|NCT00515632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853508|NCT02925013|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33853509|NCT05526066|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blinded|"On Day 1, participants will receive a single dose of Study Drug via intravenous infusion.~If the safety observations are considered acceptable, that participant will enter the multiple-dose portion of the study in which they will receive a further 5 doses of Study Drug on Days 15, 29, 43, 57 and 71."|t|t|t|t
33957152|NCT03515889|RANDOMIZED|PARALLEL||OTHER||SINGLE|Throughout the study every effort will be made to ensure objective and blinded assessments of outcomes. Although participants will be told of their treatment assignment they will not be provided details about the intervention techniques of the other treatment groups. Focus will instead be maintained on the group to which they are assigned. Staff who obtain and record participant assessments at the clinical assessments will not be informed of the participant's treatment assignment and will not participate in the delivery of the study interventions.|Participants (n=192) with BMI ≥30 and ≤49 will be randomized to one of two parallel study arms: Group A: Ideal Protein Weight Loss Intervention; Group B: Standard Low-Fat, Low-Calorie, Guideline-based Weight Loss Intervention. Participants will undergo baseline testing, and if eligible, will be randomly assigned to study group, undergo three months of their assigned study intervention, and clinical testing at baseline, 6, and 12 weeks.|f|f|f|t
33957153|NCT02547779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165889|NCT02851303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165890|NCT00012103||||SCREENING||||||||
34165891|NCT04816214|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was terminated early based on Sponsor's decision unrelated to any safety concerns and the randomized part of the study was not initiated||||
34165892|NCT02820675|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34165893|NCT00825188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165894|NCT01769859|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33957154|NCT04592731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957155|NCT03109613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957156|NCT04285892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective randomized control trial|t|f|f|f
33957157|NCT04250818|||CASE_CONTROL||PROSPECTIVE|||||||
34165895|NCT02754531|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34165896|NCT02976935|||COHORT||PROSPECTIVE|||||||
34165897|NCT06192849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165898|NCT03594773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165899|NCT00483691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34165900|NCT02660164|||CASE_CONTROL||PROSPECTIVE|||||||
34165901|NCT03355846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165902|NCT03015636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165903|NCT00203164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165904|NCT03385148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165905|NCT02839863|||COHORT||PROSPECTIVE|||||||
34165906|NCT00760656|||COHORT||PROSPECTIVE|||||||
34165907|NCT01344902|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165908|NCT06367439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single - Primary Investigator|The study will utilize a 10-week, two-arm, single-blinded, waitlist control, randomized controlled trial (RCT). Healthy adults (19-64 years) from the Victoria community participating in less than 75 minutes of vigorous physical activity per week will be randomized to either the Supernatural (SN) condition or the wait-list control (WLC) condition for a 10-week period.|f|f|t|f
34165909|NCT03165370|||OTHER||CROSS_SECTIONAL|||||||
34165910|NCT02804126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165911|NCT02987465|||CASE_CONTROL||PROSPECTIVE|||||||
34165912|NCT02987946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165913|NCT02418039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34165914|NCT02935647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165915|NCT01636635|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34165916|NCT03094741|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34165917|NCT02747966|||COHORT||CROSS_SECTIONAL|||||||
34165918|NCT05920317|||OTHER||RETROSPECTIVE|||||||
34165919|NCT04303481|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34165920|NCT00258492|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165921|NCT03607942|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34165922|NCT05047861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165923|NCT03026881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165924|NCT02698826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165925|NCT03087136|||COHORT||PROSPECTIVE|||||||
34165926|NCT04578951|||COHORT||PROSPECTIVE|||||||
34165927|NCT02944214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165928|NCT02719626|||CASE_ONLY||CROSS_SECTIONAL|||||||
34165929|NCT04485897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165930|NCT04769570|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34165931|NCT01721863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34165932|NCT05947318|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Neither the participant or the professionals that will make the training and the assessments will know to which group the participants was assigned.|"Three experimental groups:~1. tACS-70 Hz group~2. tACS-7Hz group~3. tACS-sham group"|t|t|f|t
34165933|NCT04870502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165934|NCT06435377|||OTHER||PROSPECTIVE|||||||
34165935|NCT03678311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165936|NCT03488966|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747391|NCT03620942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The first phase recruited 76 parturients. The second phase recruited 97 parturients. Parturients recruited from this phase will be randomized into either ADIVA group or DIVA group.|t|f|t|f
33747392|NCT00414700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747393|NCT05767944|RANDOMIZED|PARALLEL||OTHER||SINGLE|For those assessing \& providing postoperative analgesia (secondary outcome)they are blind to the used anaesthetic technique .|patients were allocated to one of two groups. one received WALANT (with no tourniqut) \& the other (control) group received supra-clavicular block (with tourniquet). Groups were compared for anaesthesia efficiency|f|f|f|t
33747394|NCT01650259|||COHORT||PROSPECTIVE|||||||
33747395|NCT05101538|||CASE_CONTROL||PROSPECTIVE|||||||
33747396|NCT06668935|||COHORT||PROSPECTIVE|||||||
33747397|NCT01483001|NA|SINGLE_GROUP||||NONE||||||
33747398|NCT04492735|||CASE_ONLY||PROSPECTIVE|||||||
33747399|NCT02625623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747400|NCT04028700|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Patients will not be told which type of blood they are receiving first. There is no way to tell if blood has enzyme deficiencies by looking at it.||t|f|f|f
34165937|NCT02753426|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34165938|NCT02021942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165939|NCT03104179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34165940|NCT06009367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||One investigated group with intervention and one control group without intervention|f|t|f|f
34165941|NCT04965324|||COHORT||PROSPECTIVE|||||||
34165942|NCT02185066|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34165943|NCT03407417|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Study Team will recruit an ethnically diverse sample of eligible patients (N = 3,000, 1,500 men, 1,500 women, evenly distributed across White, African-American, Hispanic/Latino) to complete the intervention||t|f|f|f
34165944|NCT06130241|NA|SINGLE_GROUP||TREATMENT||NONE||female with breast cancer and malignant axillary lymphnodes who underwent neoadjuvant chemotherapy||||
34165945|NCT00330759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34165946|NCT05575388|||CASE_CONTROL||PROSPECTIVE|||||||
34165947|NCT05456789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165948|NCT04085276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165949|NCT02134535|||COHORT||CROSS_SECTIONAL|||||||
34165950|NCT03945461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34165951|NCT06144879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34165952|NCT05115968|||CASE_CONTROL||PROSPECTIVE|||||||
34165953|NCT04713852|||COHORT||RETROSPECTIVE|||||||
34165954|NCT05854355|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Four schools allocated to receive the intervention; four schools allocated to the control group|t|f|f|f
34165955|NCT05189912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were not informed about their randomization allocation in order to increase reliability during follow-up.||t|f|f|f
34165956|NCT03707301|||COHORT||PROSPECTIVE|||||||
33957158|NCT06425419|RANDOMIZED|PARALLEL||TREATMENT||NONE||Half of the patients will receive intravitreal topotecan at the time of surgery. Randomization will be done based on a computer-generated list that would randomly allocate each of the 50 participants to being either in the treatment arm or in the control arm, in a particular order. Results will be printed on a card put in sealed envelopes that would be given to each research subject based on the allocation order given by that computer-generated list.||||
33957159|NCT02374008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957160|NCT04365829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957161|NCT06696170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957162|NCT06319339|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blinded study|There will be a peripheral artery disease (PAD) group and an age-matched healthy control group. Within each of these groups will be a 1:1 randomized, crossover, double-blinded study.|t|f|t|f
33957163|NCT04305184|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33957164|NCT04987307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957165|NCT04619472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957166|NCT03717298|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957167|NCT04203888|RANDOMIZED|CROSSOVER||OTHER||NONE||This study utilizes a multiple crossover design to conduct N-of-1 trials in individuals.||||
33957168|NCT04774172|||COHORT||RETROSPECTIVE|||||||
33957169|NCT02297607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33957170|NCT06565910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Given the distinct visual appearance of the liposomal bupivacaine (milky white) and ropivacaine (transparent), a double-blind study design is not feasible.~Consequently, this study employs a single-blind approach where neither participants nor outcome assessors will be aware of treatment allocation. Healthcare providers administering the study drug will be aware of the treatment group assignment. Rigorous procedures will be implemented to minimize potential bias, including standardized outcome assessment tools, blinded data entry, and independent data analysis."|This study utilizes a parallel interventional design, where participants undergoing hip arthroplasty surgery will be allocated into two separate groups. One group will receive liposomal bupivacaine plus bupivacaine as a regional anesthetic for Pericapsular Nerve Group (PENG) block, while the other group will receive ropivacaine for the same purpose. Both interventions will be administered under ultrasound guidance. The study aims to compare the analgesic efficacy, duration of pain relief, opioid consumption, and patient satisfaction between the two groups, with assessments conducted at multiple time points within 72 hours post-surgery. The parallel design allows for the direct comparison of the two interventions and their respective outcomes in managing postoperative pain following hip arthroplasty.|t|f|f|t
33957171|NCT04093479|||COHORT||PROSPECTIVE|||||||
33957172|NCT04835207|||COHORT||PROSPECTIVE|||||||
33957173|NCT06567366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957174|NCT05347407|||CASE_CONTROL||PROSPECTIVE|||||||
33957175|NCT01830257|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33957176|NCT04754425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957177|NCT00138879|||CASE_CONTROL||PROSPECTIVE|||||||
33957178|NCT03165630|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The 4th month assessor is unaware of the arm participants are assigned to.||f|f|f|t
33747401|NCT04440735|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1 will involve sequential enrollment of patient cohorts to investigate the safety of up to 7 potential dose levels. Dose escalation will commence with up to 3 single subject cohorts before moving to a 3 + 3 dose escalation scheme to determine the maximum tolerated dose and/or recommended phase II dose.~Up to 3 additional dose finding cohorts will be enrolled in parallel to the monotherapy dose escalation to establish a safe dose of DSP107 when given in combination with atezolizumab. These dose-finding combination arms will start at least one dose level below a DSP107 monotherapy dose that has already been deemed safe.~Part 2 will comprise 2 expansion cohorts:~Expansion cohort A will involve enrollment of patients in a single arm receiving DSP107 in combination with atezolizumab.~Expansion cohort B will involve enrollment of patients randomized to receive either DSP107 monotherapy or DSP107 in combination with atezolizumab."||||
33747402|NCT01195012|RANDOMIZED|PARALLEL||OTHER||||||||
33747403|NCT01858168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747404|NCT04717804|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33747405|NCT04952324|||COHORT||PROSPECTIVE|||||||
33957179|NCT05957237|||CASE_CONTROL||OTHER|||||||
33957180|NCT03642886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In adjudication of arrhythmia events the adjudicators would not know if the participants have been randomized to the detraining or control group||f|f|t|t
33957181|NCT03747094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957182|NCT02388659|||CASE_CONTROL||PROSPECTIVE|||||||
33957183|NCT04075656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061070|NCT05461456|NA|SINGLE_GROUP||TREATMENT||NONE||The study is an 'Open Label, Single-Dose, Single-Treatment, Single-Period Safety and Bioavailability Study in Healthy, Adult, Male Human Subjects, where the subjects will be housed in the clinical facility from not less than 11 hours pre-dose till at least 72 hours post-dose. Altogether, the subject will stay for consecutive 03 days and 04 nights in the facility.||||
34061071|NCT02144636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061072|NCT05233384|||COHORT||CROSS_SECTIONAL|||||||
33747406|NCT05323526|||COHORT||PROSPECTIVE|||||||
33747407|NCT00421499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33747408|NCT01416792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33747409|NCT02808962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747410|NCT00000457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747411|NCT06525623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747412|NCT01517802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747413|NCT01142674|||COHORT||PROSPECTIVE|||||||
33747414|NCT04213196|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33747415|NCT01007487|||||PROSPECTIVE|||||||
33747416|NCT04756518|||COHORT||RETROSPECTIVE|||||||
33747417|NCT04637204|||COHORT||RETROSPECTIVE|||||||
33747418|NCT02046980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747419|NCT02049073|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747420|NCT00989651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165957|NCT06271044|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No masking.|Patients with low risk papillary thyroid cancer either received a radioiodine treatment according to the normal Finnish treatment schedule or were schedulded for only follow-up .||||
34165958|NCT00360633|||COHORT||PROSPECTIVE|||||||
34165959|NCT04787107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34165960|NCT05831592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective interventional study||||
34165961|NCT02172144|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34165962|NCT00056693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165963|NCT04424667|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel assignment|t|t|f|t
34165964|NCT01606969|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34165965|NCT04358302|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open-label, direct-to-family, adherence and exposure-response study of hydroxychloroquine (HCQ) self-administration in pediatric lupus participants with the use of an electronic pill bottle cap that provides automatic dosing reminders||||
34165966|NCT04380389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34165967|NCT02228317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165968|NCT01127243|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34165969|NCT05797402|||COHORT||CROSS_SECTIONAL|||||||
34165970|NCT02089919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34165971|NCT00040170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165972|NCT06550219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165973|NCT04480944|||COHORT||RETROSPECTIVE|||||||
33747421|NCT06668064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747422|NCT05804565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patient-blinded, assessor-blinded|1:1 parallel randomised controlled trial|t|f|t|t
33747423|NCT05481879|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33747424|NCT03682718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747425|NCT05663515|||COHORT||RETROSPECTIVE|||||||
33747426|NCT04551170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747427|NCT02222779|||ECOLOGIC_OR_COMMUNITY|||||||||
33747428|NCT03002350|||COHORT||PROSPECTIVE|||||||
33747429|NCT03801239|||COHORT||RETROSPECTIVE|||||||
33747430|NCT02820779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747431|NCT01925079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747432|NCT05725538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind method will be carried out on the persons collecting and analysing the data.||f|f|f|t
33747433|NCT04554875|||CASE_CONTROL||RETROSPECTIVE|||||||
33747434|NCT03961165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747435|NCT00159211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747436|NCT05917405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747437|NCT00095264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747438|NCT05699759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747439|NCT06636279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747440|NCT00450086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747441|NCT03861598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747442|NCT01393379|||||PROSPECTIVE|||||||
33747443|NCT03755505|||OTHER||CROSS_SECTIONAL|||||||
33747444|NCT02283866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33747445|NCT06257758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will be a modular design conducted in two phases. Each module will consist of a dose escalation and dose expansion portion. The study will initially begin with Module A evaluating VIO-01 as a monotherapy. Based on emerging PK and PD data, a protocol amendment implementing additional modules evaluating combination therapies with VIO-01 may be added. After the completion the Module A dose escalation, additional enrollment into expansion cohorts or other modules may proceed in parallel.||||
33747446|NCT00022256||||TREATMENT||||||||
33747447|NCT03336619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747448|NCT00383448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747449|NCT04969081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to randomization status.|Two branch study: one branch for Vets not interested in competitive employment, and one for Vets interested in competitive employment. Within each branch, Veterans will be randomized to either treatment as usual, or treatment as usual plus referral to competitive or non-competitive work-focused program.|f|f|f|t
33747450|NCT01408368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747451|NCT00847262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747452|NCT04052672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747453|NCT01587664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747454|NCT05996276|||COHORT||RETROSPECTIVE|||||||
33747455|NCT06255223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747456|NCT01556438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747457|NCT00017381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165974|NCT01343030|||CASE_ONLY||RETROSPECTIVE|||||||
34165975|NCT00410761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165976|NCT02412098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165977|NCT05809609|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All members of the study team will be blinded to the condition a participant is allocated to with the exception of the team member responsible for administering the drug/placebo.|Participants will be assigned to receive ketamine or placebo. Ketamine is not being administered for treatment purposes, the purpose is to understand the mechanisms underpinning its effects.|t|f|t|f
34165978|NCT05053659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165979|NCT04699656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34165980|NCT04868617|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34165981|NCT06048159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34165982|NCT00200330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165983|NCT05072730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165984|NCT01635595|||COHORT||RETROSPECTIVE|||||||
34165985|NCT03847935|||COHORT||PROSPECTIVE|||||||
34165986|NCT05366634|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34165987|NCT01387126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165988|NCT04973072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34165989|NCT03379285|||COHORT||RETROSPECTIVE|||||||
33747458|NCT06668246|||COHORT||RETROSPECTIVE|||||||
33747459|NCT04333667|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated either to the intervention or control groups. The control group is a waiting list. The control group will participate in the intervention after it will be completed for the intervention group.||||
33747460|NCT00781625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33747461|NCT00781300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747462|NCT02156713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747463|NCT04978493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Ustekinumab treatment is open-label for the Sponsor, patients and investigator/site staff.|t|t|t|f
33747464|NCT06038305|||OTHER||CROSS_SECTIONAL|||||||
33747465|NCT06476405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33747466|NCT04514848|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33747467|NCT06552741|||COHORT||PROSPECTIVE|||||||
33747468|NCT00921492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747469|NCT00263666|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study was conducted in a double-blind manner. The parents/guardians of the subjects and the study personnel were unaware of the administered treatment (HRV vaccine or placebo).||t|t|t|t
33747470|NCT00460889|||||RETROSPECTIVE|||||||
33747471|NCT05427669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747472|NCT01293448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747473|NCT02289300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747474|NCT02571569|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747475|NCT01212367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747476|NCT05607693|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple dose of SHR3680 will be administered||||
33853510|NCT01802567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853511|NCT02134977|||COHORT||PROSPECTIVE|||||||
33853512|NCT03956485|||COHORT||PROSPECTIVE|||||||
33747477|NCT05924152|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||One-sequence Crossover Study||||
33747478|NCT02979262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747479|NCT00605800|||CASE_CONTROL||PROSPECTIVE|||||||
33747480|NCT04328844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a two-part FIH dose study, where Part A is a dose-escalation group treatment study with IOA-244 and Part B is a parallel cohort study||||
33747481|NCT06373094|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33747482|NCT04251000|NA|SINGLE_GROUP||PREVENTION||NONE|This is a single arm unblineded effort.|Single arm pilot study||||
33747483|NCT01987869|||CASE_ONLY||CROSS_SECTIONAL|||||||
33747484|NCT01874223|||CASE_ONLY||PROSPECTIVE|||||||
33747485|NCT05222191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747486|NCT06185660|||COHORT||PROSPECTIVE|||||||
33747487|NCT00275795|||||OTHER|||||||
33747488|NCT00783991|||||CROSS_SECTIONAL|||||||
33747489|NCT03443960|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33747490|NCT05170373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747491|NCT05006781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747492|NCT02786082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747493|NCT01310439|||CASE_CROSSOVER||PROSPECTIVE|||||||
33747494|NCT00093054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747495|NCT04947800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told which weeks they are receiving the active acupuncture versus the control.||t|f|f|f
33747496|NCT01076569|||CASE_CONTROL||RETROSPECTIVE|||||||
33747497|NCT02302079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747498|NCT04997174|||CASE_CONTROL||RETROSPECTIVE|||||||
33747499|NCT03441425|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33747500|NCT02384954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747501|NCT00629187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747502|NCT05562440|NA|SINGLE_GROUP||OTHER||NONE||Focus Group Discussion||||
33747503|NCT03826667|||CASE_ONLY||RETROSPECTIVE|||||||
33747504|NCT06670703|||COHORT||RETROSPECTIVE|||||||
33747505|NCT02114242|||CASE_CONTROL||PROSPECTIVE|||||||
33747506|NCT05878639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747507|NCT05934344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747508|NCT06258174|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33747509|NCT05680025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33747510|NCT02043210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747511|NCT03487250|||COHORT||PROSPECTIVE|||||||
33747512|NCT01818323|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|"In this dose escalation study, the intervention consists of intratumoral delivery of panErbB-specific CAR T cells, administered alone or following lymphodepleting chemotherapy with fludarabine and cyclophosphamide. In cohort 7, patients will also receive 3 doses of Nivolumab, the first of which is administered 24h before CAR T-cells~This note has been added in response to the warning  WARNING: Phase 1/Phase 2 studies typically have at least one Intervention Type of Drug, Biological/Vaccine or Combination Product."||||
33747513|NCT06373757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747514|NCT02468024|RANDOMIZED|PARALLEL||TREATMENT||NONE||Surgery versus SAbR||||
33747515|NCT01605838|||COHORT||PROSPECTIVE|||||||
33747516|NCT04537962|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33853513|NCT02050152|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33747517|NCT01785329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747518|NCT04424381|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study was designed as a four-period complete and replicate crossover||||
33747519|NCT06151197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747520|NCT01935817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747521|NCT00802568|NON_RANDOMIZED|||TREATMENT||NONE||||||
33747522|NCT06462326|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33853514|NCT01242358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33853515|NCT00153504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853516|NCT00122460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853517|NCT01546350|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34165990|NCT04885335|||OTHER||PROSPECTIVE|||||||
34165991|NCT02366312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747523|NCT06507267|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33747524|NCT04160819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33747525|NCT06669026|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"Group 1: vitamin D3-loaded Poly lactic-co-glycolic acid (PLGA) nanoparticles gel as an adjunct to mechanical debridement.~* Group 2: vitamin D3 gel (regular non-nanoparticle form) as an adjunct to mechanical debridement.~* Group 3: placebo gel as an adjunct to mechanical debridement.~* Group 4: only mechanical debridement."|t|f|f|f
33747526|NCT03335033|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747527|NCT02289131|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747528|NCT02777151|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33747529|NCT05695365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747530|NCT04396067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853518|NCT00156819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853519|NCT02426346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061073|NCT03861871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061074|NCT05597579|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34061075|NCT01899807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061076|NCT03324828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Clowns: outcomes assesor Hidroxicine: participant, care provider, investigator and outcomes assessor||t|t|t|t
34061077|NCT01538004|||CASE_CROSSOVER||PROSPECTIVE|||||||
34061078|NCT02408224|||OTHER||PROSPECTIVE|||||||
34061079|NCT04611230|||COHORT||PROSPECTIVE|||||||
34061080|NCT01467154|||CASE_CONTROL||PROSPECTIVE|||||||
34061081|NCT02616315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061082|NCT03644056|NA|SINGLE_GROUP||OTHER||NONE||||||
33747531|NCT02853968|||COHORT||PROSPECTIVE|||||||
33747532|NCT01559298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747533|NCT06670209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747534|NCT06276192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Non-Inferiority Randomised Controlled Trial|f|f|f|t
33747535|NCT05450965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747536|NCT04616157|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive treatment||||
33747537|NCT05985187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747538|NCT03589898|NA|SINGLE_GROUP||OTHER||NONE||||||
33747539|NCT01510847|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747540|NCT05041673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747541|NCT01914796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33747542|NCT06529952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||the study include three groups group 1: hysterostopic resection of the upper and lower edges of the CSD then endocoagulation group2: hysteroscopic endocoagulation group3: hormonal treatment by 3rd generation contraceptive pills for 6 months|t|f|f|f
33747543|NCT01535404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747544|NCT02370212|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33747545|NCT04830449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747546|NCT06666400|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This randomized type 1 Hybrid Effectiveness-Implementation Trial will enroll 600 birthing individuals post-delivery, while they are still in the hospital, pre-discharge. These individuals will be randomized to one of two groups: the LHM arm (N=300) will receive a CBT+ Cardiovascular Health (CVH) Intervention to reduce CV risk, and the attention control arm (N=300) will receive standard doula care and the same number of telephone or video call-delivered sessions on general health education topics not related to CV health or depression.|f|t|t|t
33747547|NCT02868060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747548|NCT02476513|||COHORT||PROSPECTIVE|||||||
33747549|NCT06369298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747550|NCT05880992|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33747551|NCT00450827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747552|NCT04347681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental arm receiving convalescent plasma and parallel arm is control.||||
33747553|NCT02136277|||||PROSPECTIVE|||||||
33747554|NCT04740515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747555|NCT03713593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747556|NCT02959437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747557|NCT01240174|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33747558|NCT03405987|||COHORT||PROSPECTIVE|||||||
33747559|NCT06669845|NA|SINGLE_GROUP||OTHER||NONE||||||
33747560|NCT01452269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747561|NCT03601832|NA|SINGLE_GROUP||TREATMENT||NONE|No masking in this study.|All patients enroled in the study are allocated to one group with 4-D navigated stereotactic radiosurgical ablation.||||
33747562|NCT04237662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Opaque envelopes|Single-centre randomized, parallel design, clinical trial with a 3-month follow-up|f|t|t|t
33853520|NCT05134077|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||We present a cohort study of patients with renal cysts (the first group - kidneys with cysts, the second group - kidneys without cysts in the studied patients). All patients will undergo contrast-enhanced CT of the urinary system (volume of atrophic parenchyma will be calculated), as well as nephroscintigraphy.||||
33853521|NCT04330703|||CASE_CONTROL||PROSPECTIVE|||||||
33853522|NCT04600193|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34061083|NCT05571202|||CASE_CONTROL||RETROSPECTIVE|||||||
34061084|NCT04506398|||COHORT||OTHER|||||||
34061085|NCT00191659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061086|NCT03274258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061087|NCT01122940|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34061088|NCT01240928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061089|NCT06461416|RANDOMIZED|PARALLEL||OTHER||NONE||The study will utilize the randomized study design with two groups of 15 participants in each arm. The intervention group will receive telehealth occupational therapy services for 12 weeks. The control group will meet three times via zoom but not receive an intervention. All participants will have three assessments completed before and after the intervention.||||
34061090|NCT02320227|NA|SINGLE_GROUP||OTHER||NONE||||||
34165992|NCT02178761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34165993|NCT04640233|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34165994|NCT05021770|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34165995|NCT04081779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Personnel other than the statisticians and lay health educators||f|t|t|f
34165996|NCT01390922|||||PROSPECTIVE|||||||
34165997|NCT03827655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34165998|NCT03573323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34165999|NCT05471544|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166000|NCT00584415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166001|NCT06164665|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Treatment type (PIO/PLA) will be coded to de-identify treatment (Example: treatment A and treatment B or similar) to blinded staff. Assigned unblinded staff, responsible for administering the treatment to volunteers, will be responsible for creating treatment codes to match treatment. They will maintain record of randomization scheme and treatment.|randomized crossover placebo controlled double blinded study|t|f|t|f
34166002|NCT01167374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166003|NCT04450940|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|Clinic staff, study authors|Participants were randomized to receive 1 of 2 surveys at enrollment - either the PACV (a survey that identifies vaccine hesitant parents) or a placebo survey on general childhood health topics. 6 months following enrollment, all participants received the PACV, regardless of baseline randomization group.|f|t|t|t
34166004|NCT03393494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166005|NCT04014062|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The study staff taking care of subject's safety and the laboratory personnel doing the sample analysis of pharmacokinetic, pharmacodynamic and immunogenicity data are blinded.||f|f|f|t
34166006|NCT02611817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166007|NCT00754377|||COHORT||RETROSPECTIVE|||||||
34166008|NCT02257229|||COHORT||PROSPECTIVE|||||||
34166009|NCT00311935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166010|NCT01220167|RANDOMIZED|CROSSOVER||OTHER||NONE||Open label, balanced, randomized three period, three treatment, three sequence, three-way crossover bioavailability study .||||
34166011|NCT04915443|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients attending Qassim University dental clinics with teeth indicated for simple extraction will be assigned randomly to one of the two study groups either (Periotome Group) or (Piezotome Group) after insuring that they fit the inclusion criteria.||||
34166012|NCT05458206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||EFFECT OF MULLIGAN SNAG MOBILISATION AND DIAPHRAGMATIC RELEASE|t|f|f|t
34166013|NCT04399395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166014|NCT03501732|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34166015|NCT04134481|||COHORT||PROSPECTIVE|||||||
34166016|NCT00075621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166017|NCT03515824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166018|NCT03455738|||COHORT||PROSPECTIVE|||||||
34166019|NCT06024486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166020|NCT02718729|NA|SINGLE_GROUP||OTHER||NONE||||||
34166021|NCT05705466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166022|NCT03178383|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34166023|NCT05425329|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34166024|NCT04098809|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34166025|NCT05279859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34166026|NCT00452790|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34166027|NCT04375917|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled parallel study||||
34166028|NCT02741245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166029|NCT01022658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166030|NCT04935073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853523|NCT06241768|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33893476|NCT01215084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893477|NCT05018286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893478|NCT05297565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893479|NCT05270603|||OTHER||PROSPECTIVE|||||||
33893480|NCT05227729|||CASE_ONLY||PROSPECTIVE|||||||
33893481|NCT00618150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34166031|NCT02158871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34166032|NCT00631332|||OTHER||OTHER|||||||
34166033|NCT06316349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher responsible for conducting the ultrasonographic measurements will be blinded regarding the randomization and allocation groups.|Rondomized controlled trial|f|f|f|t
34166034|NCT02625805|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166035|NCT02721602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166036|NCT03641040|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34166037|NCT02137824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166038|NCT03544021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166039|NCT02444949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166040|NCT04068246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166041|NCT03573141|||COHORT||PROSPECTIVE|||||||
34166042|NCT01836640|||||PROSPECTIVE|||||||
34166043|NCT01817426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166044|NCT03637660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166045|NCT00428948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166046|NCT02083692|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166047|NCT05753488|||COHORT||RETROSPECTIVE|||||||
33853524|NCT05384444|RANDOMIZED|PARALLEL||TREATMENT||NONE|Allocation concealment：an independent researcher implements the randomized allocation scheme to ensure that the subjects and the researchers who screen the subjects are unable to know the subsequent subjects in advance|Concealed allocation: the statisticians formulate the randomization scheme and generates the random number.||||
33853525|NCT00723021|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33853526|NCT01730781|||OTHER||OTHER|||||||
33853527|NCT03995667|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33853528|NCT06486038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166048|NCT05531981|||COHORT||PROSPECTIVE|||||||
34166049|NCT02754921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166050|NCT04698603|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 (Part A): Two dose levels of GH001 investigated in single doses. Phase 2 (Part B): GH001 investigated in an individualized dosing regimen.||||
34166051|NCT00024180||||TREATMENT||||||||
34166052|NCT02300363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166053|NCT02505659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747563|NCT05721859|||CASE_ONLY||PROSPECTIVE|||||||
33747564|NCT00688636|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33853529|NCT03272581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853530|NCT00550875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853531|NCT02963610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853532|NCT06288646|||CASE_CONTROL||PROSPECTIVE|||||||
33853533|NCT05030545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853534|NCT01994668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33853535|NCT01776541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853536|NCT01964885|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853537|NCT02782689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853538|NCT06276907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957184|NCT04369885|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|This is an open-label study.|All participants will receive the intervention consisting of a home telemedicine tablet platform (GoHome) that will collect multiple spirometry tests each week (including both forced and slow spirometry measurements), pulse oximetry, and quality of life (QoL) Questionnaire responses. The platform will remind patients to take their medications remind patients to perform measurements, send patients helpful information, and execute a University of North Carolina (UNC) clinic established COPD Action Plan.The backend of the platform is a remote server (Monitored Therapeutics Incorporated CarePortal) that collects the data, send out alerts to the Principal Investigator and can track and trend the data for them.||||
33957185|NCT03877848|||COHORT||PROSPECTIVE|||||||
33957186|NCT01968174|||CASE_ONLY||PROSPECTIVE|||||||
33957187|NCT04794595|||COHORT||PROSPECTIVE|||||||
33957188|NCT05657964|||OTHER||PROSPECTIVE|||||||
34061091|NCT04600362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|This is an investigator-initiated, multi-center, prospective, randomized, double-blind, interventional phase II study.|t|t|t|t
34061092|NCT06066541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33853539|NCT02349646|||COHORT||PROSPECTIVE|||||||
34061093|NCT04327661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061094|NCT03479944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853540|NCT05012891|||COHORT||PROSPECTIVE|||||||
33853541|NCT01600820|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33853542|NCT02608320|RANDOMIZED|CROSSOVER||OTHER||||||||
33853543|NCT02966951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853544|NCT05185583|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34061095|NCT03921359|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061096|NCT05896683|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34061097|NCT01590732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061098|NCT06730854|||COHORT||RETROSPECTIVE|||||||
34061099|NCT05347134|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly divided into the experiment group and control group in a 1:1 ratio, stratified by: number of previous treatment lines (2-3 vs. \>3); Presence of liver metastases (yes vs. No)||||
34061100|NCT02614131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061101|NCT04527913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Center will enroll probands, assigning a unique study subject number and allocating an opaque randomization envelope.|Single-centre randomized, parallel design, clinical trial with a five-week follow-up|f|f|t|t
34061102|NCT00692107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061103|NCT00779532|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34166054|NCT00479336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166055|NCT05523544|NA|SINGLE_GROUP||TREATMENT||NONE||In this study a non-concurrent multiple baseline Single Case Experimental Design (SCED) (Kazdin, 1982) will be done. A SCED is specific for small sample sizes. No control group is needed with this design. Each participant starts at its own date, in this way we create a within-subject design.||||
34166056|NCT01001247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166057|NCT05322434|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34166058|NCT02056795|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34166059|NCT01505959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166060|NCT01284517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166061|NCT02114138|||COHORT||PROSPECTIVE|||||||
34166062|NCT02510001|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34166063|NCT02148523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34166064|NCT04184219|||COHORT||CROSS_SECTIONAL|||||||
34166065|NCT00659074|RANDOMIZED|FACTORIAL||||NONE||||||
34166066|NCT05533996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166067|NCT03173404|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Randomized open-label clinical trial. Women scheduled for their first or second IVF/ICSI cycle and with no abnormality detected in transvaginal ultrasound examination, were randomized to two groups.~In the first group (group I): 31 patients underwent hysteroscopy examination before IVF cycle.~The second group (group II): 37 patients underwent direct cycle without previous hysteroscopy."||||
33853545|NCT06109675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061104|NCT04865939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed of group allocation. Blinding treating clinicians is impractical due to the techniques used.|randomized, single-blinded controlled noninferiority trial|t|f|f|f
34061105|NCT05553470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166068|NCT04569292|||CASE_ONLY||OTHER|||||||
34166069|NCT00539994|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34166070|NCT04533724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166071|NCT03710122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853546|NCT06208319|||COHORT||CROSS_SECTIONAL|||||||
33853547|NCT03905161|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853548|NCT01080495|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853549|NCT02401867|||OTHER||CROSS_SECTIONAL|||||||
33853550|NCT02684357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853551|NCT02291497|||||PROSPECTIVE|||||||
33853552|NCT03975595|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34166072|NCT05492240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will not be blinded to the arms due to facility/clinician training required for this study design. Study sites \[i.e., skilled nursing facilities (SNFs)\] will be the unit of randomization. SNF study sites will be made broadly aware of the study initiative during the site recruitment process; however, the site will not be provided with detailed information about the intervention unless randomized to the Intervention arm. As such, clinicians, or rehabilitation care providers, at usual care sites will remain blinded to the intervention for the duration of the study. Clinicians will collect patient-level functional outcomes as part of their standard of care and all patients who are subjects of the intervention will not be aware of the group allocation in the study.||t|f|f|f
34166073|NCT01227980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166074|NCT05737251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166075|NCT04579640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166076|NCT04840082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166077|NCT06206993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166078|NCT04806074|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34166079|NCT01954641|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34166080|NCT02780466|||COHORT||PROSPECTIVE|||||||
34166081|NCT05159518|NA|SEQUENTIAL||TREATMENT||NONE||||||
34166082|NCT03392220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166083|NCT01123616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34166084|NCT01999296|||COHORT||PROSPECTIVE|||||||
33853553|NCT02868866|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853554|NCT02354508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853555|NCT00004145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853556|NCT01730794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853557|NCT04912271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166085|NCT02939586|RANDOMIZED|CROSSOVER||TREATMENT||NONE||eligible participants from stage 1 screening will be invited to participate in stage 2 RCT. participants will be randomly assigned to either HD or HDF for 2 months, 1 month wash-our period and cross-over to the other treatment for another 2 months. The total trial period will be 5 months.||||
33853558|NCT00241852|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853559|NCT02350777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853560|NCT02739295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853561|NCT05386797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853562|NCT02418221|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33853563|NCT06328907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853564|NCT00969527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853565|NCT05729607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel-arm|f|f|f|t
33853566|NCT01848561|||COHORT||PROSPECTIVE|||||||
33853567|NCT02706912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853568|NCT03433053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853569|NCT01060540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853570|NCT01218893|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33853571|NCT06231342|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Subjects and research personnel assessing subjects during follow-ups will be blinded throughout the study. Only the clinicians inside the operative room will be unblinded.|A prospective double-blinded randomized trial|t|f|f|t
33853572|NCT00557297|||||CROSS_SECTIONAL|||||||
33853573|NCT01506453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33853574|NCT05658237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853575|NCT02479321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853576|NCT04723420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853577|NCT06367673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853578|NCT00002209||||TREATMENT||DOUBLE||||||
33853579|NCT02511912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853580|NCT05874154|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33853581|NCT00250926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853582|NCT01704768|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853583|NCT02435758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853584|NCT06168097|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||case control study 100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis and 100 women undergoing surgery for gynaecological disorders||||
33853585|NCT05730010|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853586|NCT04566926|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33853587|NCT05786430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853588|NCT01453803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853589|NCT05276609|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33853590|NCT01477320|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33853591|NCT04103385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|We will attempt to mask care provider. The Investigators will be completely blind to condition assignment. Outcomes will be assessed via computer and thus will also be masked.||f|f|t|t
33853592|NCT02564874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853593|NCT05638997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|t|f|f|t
33853594|NCT06347406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853595|NCT05344482|||COHORT||RETROSPECTIVE|||||||
33853596|NCT05232994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853597|NCT01432717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853598|NCT06164080|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33853599|NCT03244085|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33853600|NCT06098456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients decide wheter to receive the experimental treatment or to undergo routine clinical practice.||||
33853601|NCT02198079|||CASE_ONLY||PROSPECTIVE|||||||
33853602|NCT02731794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853603|NCT01864057|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33853604|NCT02070003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853605|NCT01115660|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853606|NCT01621113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853607|NCT00173069|||DEFINED_POPULATION||OTHER|||||||
33853608|NCT01498367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33853609|NCT02625727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853610|NCT03154060|NA|SINGLE_GROUP||OTHER||NONE||open-label, prospective, single-arm study||||
33853611|NCT03566446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893482|NCT02038062|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33957189|NCT06651788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study will be double-blinded to minimize bias. After selection into either spray group the cans will be disguised only showing a number 1 or number 2.~Given that the freeze spray is a skin refrigerant, the saline placebo will be refrigerated to mimic the temperature on the skin. The freeze spray is odorless, as is saline, so should not pose a different in smell experience. Neither the participants or physicians will be unblinded at any point; the unblinded investigator will be the only person with access to unblinded data.."|the freeze spray group (receiving freeze spray before the injection)|t|t|f|f
33957190|NCT00001001||||TREATMENT||NONE||||||
33957191|NCT03079739|||COHORT||PROSPECTIVE|||||||
33957192|NCT05529641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061106|NCT06525662|RANDOMIZED|PARALLEL||OTHER||SINGLE|The instructors teaching students how to use the different stylet shapes will be masked regarding the study hypothesis and participant group allocation. It will be emphasised to instructors that each participant has an equal amount of time to learn to use both shapes.|"Design: Randomised controlled trial with 2 parallel groups Population: Final year medical students in NUS Medicine learning endotracheal intubation (ETI) with direct laryngoscopy using a Macintosh blade via simulation. These students have limited exposure to ETI and are novices in this procedure.~Intervention: 30-degree STC styleted endotracheal tube (ETT) Comparator: Arcuate styleted ETT"|f|t|f|f
33893483|NCT00544739|||CASE_CONTROL||PROSPECTIVE|||||||
34166086|NCT04252131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants are randomized into treatment or placebo group. Investigator also did not know who are in which group.|Total of 92 schizophrenia patients with obesity was divided randomly into: 1) control group, received oral administration of Cassia seed placebo (3.0g), once/day for 12 weeks continuously; 2) treatment group, received oral administration of Cassia seed (3.0g), once/day for 12 weeks continuously.|t|f|t|f
34061107|NCT01925157|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34061108|NCT04511949|NA|SINGLE_GROUP||OTHER||NONE||This is a cross-sectional, single-center study carried out on the cohort of index patients followed on an outpatient basis||||
34166087|NCT06193642|NA|SINGLE_GROUP||OTHER||NONE||||||
34061109|NCT03557268|||COHORT||PROSPECTIVE|||||||
34166088|NCT02436018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34166089|NCT00498693|||CASE_CONTROL||PROSPECTIVE|||||||
34166090|NCT03009851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166091|NCT02042768|||COHORT||PROSPECTIVE|||||||
33853612|NCT05491304|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|"The patients will be divide into different risk groups according to cytokine concentration, clinical manifestation and laboratory findings. For low/intermediate risk and not severe patients, steroid or ruxolitinib will be used initially; while those with high risk or severe disease, DXM+VP16±ruxolitinib will be administered."||||
33853613|NCT02385968|||COHORT||PROSPECTIVE|||||||
33853614|NCT02470910|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853615|NCT00815620|||COHORT||PROSPECTIVE|||||||
33853616|NCT01668511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853617|NCT01048671|||COHORT||PROSPECTIVE|||||||
33853618|NCT03972254|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a mixed methods feasibility study using a single-subject research design and qualitative description.||||
33853619|NCT04219579|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33853620|NCT06159322|||COHORT||CROSS_SECTIONAL|||||||
33853621|NCT05101408|||COHORT||PROSPECTIVE|||||||
33853622|NCT03672656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853623|NCT02766166|||COHORT||PROSPECTIVE|||||||
33853624|NCT02541123|||COHORT||PROSPECTIVE|||||||
33853625|NCT05229731|||CASE_CONTROL||PROSPECTIVE|||||||
33853626|NCT06336954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853627|NCT04511182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853628|NCT00546130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853629|NCT01088373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853630|NCT00617474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853631|NCT03226210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33853632|NCT03733639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients won't know if his anastomoses has been reinforced with Tisseel®.||t|f|f|f
33853633|NCT02442154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853634|NCT02926274|||COHORT||PROSPECTIVE|||||||
34061110|NCT00800605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34166092|NCT02414035|||COHORT||PROSPECTIVE|||||||
34166093|NCT02537717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166094|NCT00669214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166095|NCT02195375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166096|NCT01857427|||COHORT||PROSPECTIVE|||||||
34166097|NCT04603261|||COHORT||PROSPECTIVE|||||||
34166098|NCT01865760|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34166099|NCT01100320|RANDOMIZED|CROSSOVER||||NONE||||||
34166100|NCT03938896|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34166101|NCT03292224|||CASE_ONLY||PROSPECTIVE|||||||
34166102|NCT02917239|||COHORT||CROSS_SECTIONAL|||||||
33853635|NCT03802084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853636|NCT00682890|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853637|NCT04417296|||COHORT||PROSPECTIVE|||||||
33853638|NCT03456284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853639|NCT06153225|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34061111|NCT04469959|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double Blinded||t|t|t|t
34061112|NCT00909714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061113|NCT03070041|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34061114|NCT05262868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061115|NCT01463410|||CASE_ONLY|||||||||
34061116|NCT00101036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061117|NCT00684749|||||PROSPECTIVE|||||||
34061118|NCT02783456|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|t|f|f
34061119|NCT00774007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061120|NCT02479971|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34061121|NCT06027632|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34061122|NCT05324280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled clinical study with waiting list control group||||
33853640|NCT00703768|||CASE_ONLY||PROSPECTIVE|||||||
33853641|NCT04734093|||COHORT||CROSS_SECTIONAL|||||||
33853642|NCT01645293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853643|NCT06467149|||OTHER||PROSPECTIVE|||||||
33853644|NCT04754308|NA|SINGLE_GROUP||SCREENING||NONE||||||
33853645|NCT03037931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853646|NCT04166123|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33853647|NCT00648830|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853648|NCT00410085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||||||
33853649|NCT02088164|||COHORT||RETROSPECTIVE|||||||
33853650|NCT05321147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957193|NCT06568835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Active exercise group: patients were asked to choose walking (no less than 8000 steps per day) or low-intensity aerobic exercise such as jogging, swimming, Tai Chi, etc., according to their own conditions, for no less than 30 minutes each time, at least 3 times per week, and the intensity of the exercise was determined by the need to increase the frequency and depth of breathing during the exercise, and it was appropriate to feel slightly tired but not exhausted (RPE score 12-16).~Exercise intensity should be at least 3 times a week, and the exercise intensity should be at a level that requires an increase in breathing rate and depth, allowing for dialogue and communication, slight sweating, and a feeling of being slightly tired but not exhausted (RPE score of 12 to 16).~Control group: only receive conventional MHD treatment, no requirement for exercise."|f|f|f|t
33957194|NCT06138548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747565|NCT04479813|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33747566|NCT02491008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747567|NCT00182754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747568|NCT02486328|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33747569|NCT02882568|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747570|NCT04525391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747571|NCT01990469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957195|NCT05996601|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957196|NCT01906801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957197|NCT03586778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment will be performed by an individual blind to group assignment.||f|f|f|t
33957198|NCT06700551|RANDOMIZED|PARALLEL||OTHER||SINGLE||Psychoeducation|f|f|f|t
33957199|NCT05911763|||COHORT||PROSPECTIVE|||||||
34061123|NCT00219570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34061124|NCT03504306|||COHORT||CROSS_SECTIONAL|||||||
34061125|NCT04989634|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061126|NCT01718145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166103|NCT00475748|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061127|NCT00769535|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33747572|NCT03771482|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34061128|NCT02013570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061129|NCT06304558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Placebo group will mimic the Intervention group, but the device will not be connected. With this non-invasive neuromodulation, patiens do not experiment any sensation when the device is connected.||t|f|f|t
34166104|NCT04362995|||COHORT||PROSPECTIVE|||||||
34166105|NCT03579706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants anonymously complete all online measures and the intervention without contact with study personnel. Participants are randomized to the active or control condition without being told which condition they are participating in.||t|f|f|t
34166106|NCT02817126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166107|NCT04161742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166108|NCT01216683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061130|NCT02253121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747573|NCT06634485|||CASE_CONTROL||PROSPECTIVE|||||||
33747574|NCT01049425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747575|NCT06585969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747576|NCT06635291|||COHORT||PROSPECTIVE|||||||
34061131|NCT00834730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061132|NCT04917562|||COHORT||RETROSPECTIVE|||||||
34061133|NCT05581433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33747577|NCT05884060|||COHORT||RETROSPECTIVE|||||||
33747578|NCT01697293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747579|NCT06038123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747580|NCT00519181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747581|NCT00777725|||COHORT||PROSPECTIVE|||||||
33747582|NCT02958969|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33765562|NCT00744328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765563|NCT01347385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765564|NCT01012570|||CASE_CONTROL||PROSPECTIVE|||||||
33765565|NCT00810758|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33765566|NCT01025622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765567|NCT00280826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765568|NCT03383003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33765569|NCT02392611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765570|NCT02542839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33765571|NCT03554993|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33765572|NCT04240990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||TB-Speed SAM is a multicentric, prospective diagnostic cohort study assessing several diagnostic tests that could result in the development of a score and algorithm for TB treatment decision in hospitalised children with SAM.||||
33765573|NCT02597790|||COHORT||PROSPECTIVE|||||||
33765574|NCT05637411|||COHORT||PROSPECTIVE|||||||
33765575|NCT02734108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765576|NCT00001444||||TREATMENT||||||||
33765577|NCT02166957|||COHORT||RETROSPECTIVE|||||||
33765578|NCT01279733|||COHORT||PROSPECTIVE|||||||
33765579|NCT04031521|||CASE_CONTROL||PROSPECTIVE|||||||
33765580|NCT04712201|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33765581|NCT04626973|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"At the time of enrollment, we will stratify all patients according to LDL-cholesterol \<100mg/dL, DM, and acute coronary syndrome, and randomly assign them in two groups according to LDL-cholesterol targeting level with a 1:1 ratio: Intensive-targeting group vs. Conventional-targeting group. In addition, patients in each group will be randomly assigned to receive two lipid-lowering therapy regimen with a 1:1 ratio: Ezetimibe/Statin combination therapy vs. Statin monotherapy."||||
33957200|NCT03890835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be participant-blind where the participant will not know the intervention done.|Type: Two arm, parallel, randomized clinical trial. Allocation ratio: 1:1 Framework: Superiority.|t|f|f|f
33957201|NCT02204839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957202|NCT06703255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957203|NCT03089931|||COHORT||PROSPECTIVE|||||||
33957204|NCT03791255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957205|NCT04889794|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33957206|NCT02980029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957207|NCT00291356|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33957208|NCT05167396|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a cross-sectional, open, monocentric, non-randomized study applied in psychiatry and neuroscience.~This study will include three groups of adults subject (\>18 years)~* Patients with clinical high risk of psychosis (CHRP ; n=30)~* Patients having experienced a first psychotic episode (FEP ; n=30)~* Healthy Controls (HC ; n=30)"||||
33957209|NCT06353113|NA|SINGLE_GROUP||OTHER||NONE||||||
33957210|NCT06063291|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33957211|NCT05643625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each healthy woman will be interviewed and evaluated alone, and it will be ensured that they do not coincide with other woman who may be included in the study.|randomized prospective clinical trial|t|f|f|f
33957212|NCT05198349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957213|NCT06702228|||COHORT||PROSPECTIVE|||||||
33957214|NCT06429033|NA|SEQUENTIAL||OTHER||NONE||||||
33957215|NCT06569160|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33957216|NCT06426186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33957217|NCT05632757|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957218|NCT00424632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957219|NCT06700642|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||In the design of the study, in order to fix the effect of possible confounding variables for the research and control arms, 36 groups formed according to the distribution of gender, age groups and education levels of the research arm were matched to the control arm in terms of these characteristics.||||
33957220|NCT02618252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957221|NCT02525627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957222|NCT04751435|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957223|NCT02255773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957224|NCT05794386|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a 1:1 randomized controlled trial.||||
33957225|NCT04934969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||feasibility of using essential oils post joint replacement surgery and trends toward relief of symptoms||||
33957226|NCT06703684|||CASE_ONLY||CROSS_SECTIONAL|||||||
33957227|NCT05031286|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957228|NCT05484622|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential design for safety lead-in and randomized perioperative phases, parallel design within randomized perioperative phase.||||
33957229|NCT03847532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957230|NCT02277548|RANDOMIZED|PARALLEL||TREATMENT||||||||
33957231|NCT05564494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a pilot multi-center, double-blinded, RCT of a minimum of 100 patients, performed in five cities at seven sites (Calgary (2 sites), Winnipeg (2 sites), Montreal, Halifax, and Ottawa).|t|t|t|t
33957232|NCT01661153|||COHORT||PROSPECTIVE|||||||
33957233|NCT05782478|||COHORT||PROSPECTIVE|||||||
33957234|NCT05388201|||OTHER||CROSS_SECTIONAL|||||||
33957235|NCT04613310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||4 components Nasopharyngeal swab by PCR Nasopharyngeal swab by RDT Saliva by PCR Saliva by RDT||||
33957236|NCT03899545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34061134|NCT03203460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor will be blinded to group assignment for the primary outcome of natural killer cell cytotoxic activity and the secondary outcomes of other circulating biomarkers.||f|f|f|t
34061135|NCT02061449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061136|NCT06431685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061137|NCT03794934|RANDOMIZED|PARALLEL||TREATMENT||NONE||CGM apply followed by structured education of CGM||||
34061138|NCT02827435|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34061139|NCT03058367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061140|NCT04766255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||controlled randomized prospective clinical study.|t|f|t|t
34061141|NCT02710344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34061142|NCT03704948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We enrolled 55 participants. For the first 45, the study model was parallel. Group 1 received Listening Visits and Group 2 received usual mental health care from a NICU social worker. After study modification design due to the pandemic, the study model was changed to singe group and they received Listening Visits over zoom from a NICU nurse.||||
34061143|NCT02258269|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33957237|NCT03747939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957238|NCT05853237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|he patientsdidnt know the different types of laser which procedure they received \& the outcomes assessor done by my supervisors and didn't know which result related to specific group|group A receive laser therapy class IV+traditional wound care and group (B): Laser therapy class IIIb + traditional wound care and group C receive only traditional wound care|t|f|f|t
33957239|NCT05894382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957240|NCT06694857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957241|NCT06566950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33957242|NCT01922973|||||PROSPECTIVE|||||||
33957243|NCT00016783|||||PROSPECTIVE|||||||
33957244|NCT05916378|||COHORT||PROSPECTIVE|||||||
33957245|NCT03288649|||OTHER||PROSPECTIVE|||||||
33765582|NCT00988221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765583|NCT01038258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765584|NCT06559943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765585|NCT04859439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765586|NCT01639105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33957246|NCT02501655|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33957247|NCT02085369|||COHORT||PROSPECTIVE|||||||
33765587|NCT02256644|||CASE_CONTROL||OTHER|||||||
33765588|NCT00345163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765589|NCT04011332|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||monocentric parallel cluster design with a baseline period||||
33765590|NCT01047644|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33765591|NCT03349268|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|All healthcare personnel (including device operators and environmental services staff) will be blinded to the intervention/sham status of the devices. In addition, the study personel including the PI and individuals performing data analysis, will be blinded to the intervention/sham status of the devices. The device status will be written on a piece of paper by the manufacturer with the serial numbers of each device indicated, sealed in an envelope and kept in a secure location by the study statistician for later retrieval when trial data analysis has been completed.|Two-armed crossover with an initial intervention period of 12 months, followed by a 6 month washout period and a second intervention period of 12 months. The 6 month washout period will be necessary because of the long-term survivability of eiHAIs, such as C. difficile, on environmental services.|t|t|t|t
33765592|NCT03626350|||OTHER||PROSPECTIVE|||||||
33765593|NCT01462162|||COHORT||PROSPECTIVE|||||||
33765594|NCT06000982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765595|NCT02205801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33765596|NCT04247399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33765597|NCT00105586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765598|NCT05134662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765599|NCT04966780|||COHORT||PROSPECTIVE|||||||
33765600|NCT06624943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765601|NCT06283797|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control study in parallel groups, followed by a non randomized extension||||
33765602|NCT05025501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33765603|NCT00518934|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33765604|NCT00930943|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33765605|NCT05829291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765606|NCT05741905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765607|NCT04989985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765608|NCT03899961|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|The study is a parallel, randomized, blinded phase 4 study (safety)|t|t|t|t
33957248|NCT06422832|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"Patients will not know whether the algorithms was activated or not at the beginning of the study. However, if a contact with the patient is made due to the algorithm, the patient will then understand they are not on the control group.~The person responsible for contacts will also know if an individual patient is on the control or intervention group."||t|f|t|t
33957249|NCT00555399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957250|NCT00274664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957251|NCT03981315|||CASE_CONTROL||PROSPECTIVE|||||||
33957252|NCT03332212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957253|NCT01215955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957254|NCT03566173|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957255|NCT06702865|||OTHER||PROSPECTIVE|||||||
33957256|NCT04511923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957257|NCT02641730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957258|NCT04732728|||OTHER||PROSPECTIVE|||||||
33957259|NCT06566807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957260|NCT06322355|||CASE_ONLY||RETROSPECTIVE|||||||
33957261|NCT05584839|||OTHER||CROSS_SECTIONAL|||||||
33957262|NCT02878239|||CASE_CONTROL||PROSPECTIVE|||||||
33957263|NCT06399276|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957264|NCT06542718|||COHORT||PROSPECTIVE|||||||
33957265|NCT06442826|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33957266|NCT00595127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957267|NCT03230695|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33957268|NCT05311215|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33957269|NCT05510856|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blind||t|f|t|f
33957270|NCT06701968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|f|f|t|t
33957271|NCT06121661|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33957272|NCT01995409||||PREVENTION||||||||
33957273|NCT03384407|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33957274|NCT05093374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Cohort 1: Quantitative assessment: Treatment decision with support of artificial intelligence software. (n=145) Cohort 2: Qualitative assessment: Treatment decision without support of artificial intelligence software. (n=145)|t|t|f|f
33957275|NCT04221204|NA|SEQUENTIAL||TREATMENT||NONE||sequential assignment The starting dose in this dose-escalation study is 50 mg, and the preset 6 dose-escalation cohorts are 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg, respectively.||||
33957276|NCT04839003|||COHORT||PROSPECTIVE|||||||
33957277|NCT04727580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061144|NCT02258542|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33765609|NCT02834195|||||CROSS_SECTIONAL|||||||
33957278|NCT02023723|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33957279|NCT04657978|||CASE_ONLY||PROSPECTIVE|||||||
33957280|NCT02475161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957281|NCT01293786|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957282|NCT05958862|||COHORT||PROSPECTIVE|||||||
33957283|NCT06696274|||CASE_ONLY||CROSS_SECTIONAL|||||||
33957284|NCT05519605|||COHORT||PROSPECTIVE|||||||
33957285|NCT05665530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957286|NCT04439097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|will perform all evaluations without knowing the group to which the patients have been assigned, and they will not have a relationship with the physiotherapist who applies the intervention.|This study is a randomized parallel-group, single blinded controlled clinical trial|f|f|f|t
33957287|NCT02060227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957288|NCT05303727|NA|SINGLE_GROUP||TREATMENT||NONE||There are 3 groups according to different sources of donor: (1) Cord blood HSCT: Flu+Bu+CTX+Topotecan (without ATG); (2) Peripheral blood HSCT or haploid bone marrow combined with peripheral stem cell transplantation: Flu+Bu+Melphalan+Antithymocyte globulin (ATG)+ Thiotepa (TT) or (3) Flu+Bu+Melphalan+ATG (applicable to peripheral stem cells or haploid bone marrow combined with peripheral stem cell transplantation for which TT cannot be used).||||
33957289|NCT04533165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, single-arm pilot interventional trial||||
33957290|NCT03056716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957291|NCT02061709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957292|NCT05066347|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33957293|NCT06497101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957294|NCT05307588|||COHORT||CROSS_SECTIONAL|||||||
33957295|NCT00152386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33957296|NCT03162016|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765610|NCT01472562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957297|NCT01135901|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33957298|NCT04383769|||COHORT||PROSPECTIVE|||||||
33957299|NCT05991492|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33957300|NCT02561728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957301|NCT02032823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061145|NCT00634595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061146|NCT06016881|||COHORT||PROSPECTIVE|||||||
34061147|NCT06237816|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33747583|NCT05903144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Forty females were randomly assigned to two groups. Group A received manual diaphragm release with conventional breathing exercises and prone positioning. Group B received conventional breathing exercises and prone positioning. Both groups took their prescribed medications. Their ages ranged from 35 to 45 years and with moderate COVID-19 illness. Any cases with mild and severe COVID-19 illness, ICU admission, and chest diseases were excluded.|t|t|t|f
33747584|NCT03708679|||OTHER||PROSPECTIVE|||||||
33747585|NCT04051229|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be compared to their individual pre-intervention states. All 20 subjects will be placed in the same group and asked to follow the same exercise protocol.||||
33747586|NCT06669507|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized single-arm treatment study with treatment as usual||||
34166109|NCT02493036|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects from the study SB-2-010-001 (NCT02495623) were given either SYN-010 21 mg, SYN-010 42 mg, or Placebo. The subjects were offered the opportunity to roll over into SB-2-010-002 and receive SYN-010 42 mg. Some of the analyses were done from day one of SYN-010-001.||||
34166110|NCT01560286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747587|NCT02468765|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33747588|NCT03317977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747589|NCT03690505|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747590|NCT00288158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747591|NCT01994330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747592|NCT01064739|NA|SINGLE_GROUP||||NONE||||||
33747593|NCT05872633|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants and practitioners is not possible due to the nature of the study. However, the statistician who creates the randomization schedule and performs statistical analyses is blinded to group allocation.|||||
33747594|NCT01371344|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33747595|NCT01276964|||COHORT||PROSPECTIVE|||||||
33747596|NCT00507377|||COHORT||PROSPECTIVE|||||||
33747597|NCT02603653|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166111|NCT02739399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747598|NCT05984953|||COHORT||RETROSPECTIVE|||||||
34166112|NCT03032263|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34166113|NCT03149172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon and the subject will not be blinded. The evaluation of the core histology will be done by a blinded investigator.||f|f|f|t
34166114|NCT02867735|NA|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34166115|NCT00202007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34166116|NCT05332847|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166117|NCT05242393|||COHORT||OTHER|||||||
33747599|NCT04494750|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33747600|NCT03798860|||COHORT||PROSPECTIVE|||||||
33747601|NCT00274053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33747602|NCT04130646|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33747603|NCT06291272|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Opaque plastic bags containing test meals prepared by some one not involved in analysis pf results|3 way cross -over|t|f|t|t
33747604|NCT06670040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||It's a randomized controlled trial with active accelerated Theta Burst Stimulation (aTBS) treatment and sham controlled group|t|t|t|f
33747605|NCT00089726|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747606|NCT02142049|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33747607|NCT06477900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747608|NCT03369600|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33747609|NCT06002373|||COHORT||RETROSPECTIVE|||||||
33765611|NCT01391325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765612|NCT02088203|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33765613|NCT03372837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765614|NCT01247714|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166118|NCT01799226|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34166119|NCT02472574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765615|NCT01789996|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33765616|NCT02861144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33765617|NCT04596826|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33765618|NCT06054971|||COHORT||PROSPECTIVE|||||||
33765619|NCT05508386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|pseudonymized interrater|||||
33765620|NCT05072184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study will be conducted as a prospective, randomized, double-blind, parallel-group clinical trial.|t|t|t|t
34166120|NCT02311114|||OTHER||OTHER|||||||
34166121|NCT04055779|||CASE_CONTROL||PROSPECTIVE|||||||
34166122|NCT00703924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166123|NCT02722226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34166124|NCT00681889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166125|NCT03771651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166126|NCT03647826|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Mind Power Intervention Group 1 starts in the beginning of the school semester, and Mind Power Intervention Group 2 functions as a Control Group until it starts six months after Group 1.||||
34166127|NCT00135889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33957302|NCT06703151|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|"Structured and semi-structured questionnaires:~Basic social demographics and health history: age, gender, education level, occupational profile, living status, height, weight, and whether there are chronic diseases diagnosed by a physician, stroke, cancer or immune system-related diseases, etc., current treatment status (treatment method, home implementation overview, treatment institution), how effective the treatment is (biochemical indicators: such as blood pressure, blood sugar, blood lipids); whether there are professionals from medical institutions Provide health information related to personal diseases, such as drug precautions (time, dosage, usage), basic simple home instrument measurements (such as blood pressure monitors, blood glucose machines, weight scales), and self-care related information obtained by patients from medical institutions, weight loss methods and other information (such as diet, calories, exercise, drugs)."|The 1st year will involve a cross-sectional descriptive study targeting farmers and fishermen in the southwest coastal regions. Collaborating with the local health bureau and regional hospitals. It will investigate their self-care abilities, chronic dehydration, and associated influencing factors. The estimated samples are approximately 338 individuals. The research methods for the 2nd and 3rd years involve: (1) Developing a tabletop game educational tool tailored to the socioeconomic and cultural needs of farmers and fishermen, and training designated educators; (2) Employing a community-based quasi-experimental research design. Eligible participants will be cluster-randomized into intervention and control groups. Both groups will receive educational materials. The intervention group will additionally engage with the \[SC-8 Monopoly-style board game\] intervention, while the control group will only follow the regular community care model.||||
33957303|NCT04452097|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In phase 1, eligible subjects will be divided into low, medium and high-dose groups with 3 patients/group. If there is no safety concerns for each group, the dose will be escalated from lower dose to the next higher dose. In phase 2a, a total of 30 subjects will be randomized into the treatment and control groups with a ratio of 3:2.||||
33957304|NCT06137339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants cannot be blinded to their allocation in order to follow the study protocol. Investigator and Outcomes Assessor will be blinded.|Study participants will be randomly assigned equally to either the intervention or the control group.|f|f|t|t
34166128|NCT05295186|||CASE_ONLY||PROSPECTIVE|||||||
33853651|NCT04210869|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Crossover Assignment Participants will receive, in random order, daily 60 g of mixed nuts (mixed nut treatment) or no food products (control treatment) for sixteen weeks, separated by a washout period of at least 8 weeks.|f|f|t|t
33853652|NCT00169871|||||PROSPECTIVE|||||||
33853653|NCT03781999|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33853654|NCT06385431|||COHORT||PROSPECTIVE|||||||
33853655|NCT02116101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33853656|NCT00054054||||TREATMENT||||||||
33853657|NCT01328717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853658|NCT04112121|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||parallel, randomized, open-labeled, controlled clinical trial||||
33853659|NCT02738736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853660|NCT01509287|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853661|NCT04389736|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33853662|NCT06254768|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33957305|NCT06251024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"* Investigators, laboratory personnel, sponsor and participants will be blinded~* Study staff preparing/administering the study interventions will be unblinded"|Parallel, multi-center, case driven|t|t|t|t
33957306|NCT00353782|||CASE_ONLY||PROSPECTIVE|||||||
33957307|NCT06703801|||COHORT||PROSPECTIVE|||||||
33957308|NCT04579367|||COHORT||PROSPECTIVE|||||||
33957309|NCT06703203|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33957310|NCT02810496|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957311|NCT00364416|||COHORT||PROSPECTIVE|||||||
33957312|NCT05455411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957313|NCT05314413|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33957314|NCT03664024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957315|NCT04007406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957316|NCT06041516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061148|NCT00000774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061149|NCT03989934|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34061150|NCT01047332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34061151|NCT03356535|||CASE_CONTROL||PROSPECTIVE|||||||
34061152|NCT04336462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061153|NCT05899075|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34166129|NCT00746278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166130|NCT03292380|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34166131|NCT01236521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166132|NCT02471014|||COHORT||PROSPECTIVE|||||||
34166133|NCT02194595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166134|NCT04373226|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Monocentric study with two parallel groups||||
34166135|NCT00347217|||CASE_ONLY||PROSPECTIVE|||||||
34166136|NCT05853822|||COHORT||PROSPECTIVE|||||||
34166137|NCT06097065|||CASE_CONTROL||OTHER|||||||
33893484|NCT04547257|RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary objective is to demonstrate the safety and effectiveness of the Exthera Medical Seraph 100 Microbind Affinity Blood Filter in the clinical improvement of SARS-CoV-2 infected patients, measured by the reduction of established and suspected prognostic parameters.||||
33893485|NCT04695977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747610|NCT04199091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator who will perform the group assignment will have no contact to the study participants. The outcome assessors will be blinded to group allocation. Patients will partly be blinded to the group intervention: The will be told that they will receive one of two self-help therapies - one that focus on the relaxation of fasciae and the other that focus on the relaxation of muscles. The statistician who will perform the analyses will kept blind to the group intervention by renaming groups with numbers.||f|f|t|t
33747611|NCT00916565|||COHORT||PROSPECTIVE|||||||
33747612|NCT03058679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853663|NCT04956172|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants are not informed the order or type (standard Tone A, standard Tone B) of the sequences|"This is a within-subject repeated-measures, randomly counterbalanced, single blind study.~All participants will be asked to attend two study visits, one week (6-8 days) apart. At each study visit, participants will complete two NeuroCatch Platform 2 assessments with different auditory sequences. One sequence will include the Standard Tone A (80dB), and another will include Standard Tone B (93dB) while keeping the deviant tone volume consistent (105dB). The order of presentation of the two sequences will be randomly counterbalanced (i.e Session 1: AB \& Session 2: BA, or Session 1: BA \& Session 2: AB)."|t|f|f|f
33957317|NCT04777591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Control group: TAP block with plain bupivacaine Intervention group: TAP block with plain bupivacaine + liposomal bupivacaine|t|f|f|f
33957318|NCT02132936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33957319|NCT03286426|NA|SINGLE_GROUP||SCREENING||NONE||All patients will have images taken of the back of the eye with a portable fundus camera. If able, visual acuity and color vision will be checked.||||
33957320|NCT06632509|||CASE_ONLY||PROSPECTIVE|||||||
33853664|NCT05629403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33853665|NCT05918250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061154|NCT03309696|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This prospective, experimental design includes a block randomized, blinded, sham controlled, mixed effects model with sequential assignment to treatment arms (1 or 10 Hz rTMS) and random assignment to the tDCS conditions within each arm. The order of the three experimental conditions within each arm is randomized.|t|f|f|t
33853666|NCT03987178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A provider is assigned to perform conjunctival swabs; this person is completely masked to exposure. The culture plates, which are randomized, are sent to a microbiology lab and the technicians are completely masked to exposures when reading the plates.||f|f|t|t
33853667|NCT00906945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853668|NCT04017676|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter, randomized, controlled study with a group comparison and a program trial, in which the subjects are recruited according to a systematic allocation by order.||||
33853669|NCT01786187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853670|NCT01108679|||COHORT||PROSPECTIVE|||||||
33853671|NCT02216305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853672|NCT00596427|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33853673|NCT04714931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, Controlled, not randomized||||
33853674|NCT03452358|||COHORT||RETROSPECTIVE|||||||
33853675|NCT05359497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, observational study||||
33853676|NCT01440712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853677|NCT00592254|||CASE_ONLY||PROSPECTIVE|||||||
33853678|NCT00369720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853679|NCT00645307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853680|NCT01696942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061155|NCT02283736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061156|NCT00737893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061157|NCT04926922|||COHORT||PROSPECTIVE|||||||
34061158|NCT00671827|||CASE_ONLY||OTHER|||||||
34061159|NCT04560621|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||f|f|f|t
34061160|NCT03186859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061161|NCT03259672|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34061162|NCT06355648|||CASE_CONTROL||PROSPECTIVE|||||||
34061163|NCT06730802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061164|NCT01746238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061165|NCT01094652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34076584|NCT05609396|NON_RANDOMIZED|FACTORIAL||SCREENING||SINGLE||"This study is a 2x2 factorial design non-randomised control trial. This design will test main effects of each intervention and investigate whether the two interventions interact (25). Individuals between the ages of 60-62 (new invitees) will be sampled from invitees who do not respond to the initial screening invitation and allocated to one of four trial arms using batch randomisation. The four trial arms will be:~1. Usual care - Standard reminder and no test kit~2. Standard reminder plus test kit~3. Theoretically informed behavioural intervention (modified reminder letter) at reminder and no test kit~4. Theoretically informed behavioural intervention at reminder with test kit The main effect of the test kit is estimated by comparing 2+4 vs 1+3; main effect of behavioural intervention is estimated from 3+4 vs 1+2."|t|f|f|f
34166138|NCT05307354|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34166139|NCT03862183|||COHORT||PROSPECTIVE|||||||
34166140|NCT04402424|||COHORT||PROSPECTIVE|||||||
34166141|NCT03062514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166142|NCT02472717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166143|NCT05880966|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34166144|NCT00837200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166145|NCT01178268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166146|NCT00842556|RANDOMIZED|CROSSOVER||||NONE||||||
34166147|NCT06166381|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34166148|NCT01635231|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34166149|NCT04723017|||COHORT||CROSS_SECTIONAL|||||||
34166150|NCT02686918|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34166151|NCT02168907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747613|NCT06481917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33747614|NCT03977220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853681|NCT04253067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind, participant and biostatistician will be blinded to treatment group. Subjects will be randomized 1:1 to active fCO2 laser treatment group or sham treatment group. Randomization will be performed using a table of random numbers. Randomization envelopes will be provided by the biostatistician and will be securely stored in a locked cabinet. The research coordinator(s) will be responsible for maintaining the confidentiality and security of the randomization envelopes. An enrollment and randomization log will be stored securely. The biostatistician will prepare more envelopes, if necessary.|Subjects will be randomized 1:1 to active fCO2 laser therapy or sham. Study will be performed in a single-blind manner. (Participant and biostatistician)|t|f|f|t
34076585|NCT02842476|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076586|NCT00002029||||TREATMENT||||||||
34166152|NCT01773486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166153|NCT02747810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166154|NCT02478463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166155|NCT05974930|||COHORT||PROSPECTIVE|||||||
34166156|NCT02248805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166157|NCT02908126|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166158|NCT00290173|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166159|NCT04609631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853682|NCT03174912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853683|NCT04413773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled trial||||
33853684|NCT05677152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In this trial, zoledronic acid or placebo will be administered once immediately before arthroscopic rotator cuff repair.~Randomization will take place. immediately before surgery by the anesthesiologist using sealed envelopes. To simplify the study procedure, zoledronic acid 5 mg (Aclasta®), administered as single intravenous infusion (verum) or sodium chloride (physiological saline solution 0.9%), administered as single intravenous infusion (placebo) will be administered preoperatively by the anesthesiologist after induction of anesthesia. Thereby, patients and surgeons are blinded to the randomization process."|"placebo controlled trial (Zoledronic acid versus Placebo), randomized,~2 Teams: unblinded and blinded"|t|f|t|f
33853685|NCT05034302|||OTHER||CROSS_SECTIONAL|||||||
33853686|NCT04262947|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33853687|NCT01279512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853688|NCT00640081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853689|NCT03172676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853690|NCT00368160|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33853691|NCT00155792|||DEFINED_POPULATION||OTHER|||||||
33853692|NCT02703493|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation of radiation therapy for high risk oropharyngeal cancer||||
33853693|NCT03006731|RANDOMIZED|PARALLEL||TREATMENT||NONE|Only the outcome assessor is blinded for the cardiopulmonary exercise stress test but not for the 6-minute walk test.|||||
33853694|NCT03825653|||OTHER||PROSPECTIVE|||||||
33853695|NCT03296033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||After consenting to the study, patients will be randomized to one of two groups.||||
33853696|NCT02072161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853697|NCT05347420|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33853698|NCT03182452|||COHORT||PROSPECTIVE|||||||
33853699|NCT03862846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853700|NCT05140941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853701|NCT03234985|||OTHER||PROSPECTIVE|||||||
33853702|NCT00746213|||COHORT||RETROSPECTIVE|||||||
33853703|NCT06218147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853704|NCT02953405|||COHORT||PROSPECTIVE|||||||
33853705|NCT00889018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853706|NCT00665158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853707|NCT00966277|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853708|NCT00604266|||CASE_ONLY||PROSPECTIVE|||||||
33853709|NCT02126696|||COHORT||CROSS_SECTIONAL|||||||
33853710|NCT04323774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853711|NCT06446960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|It is a randomised, double-blind study|Patients will be randomised to receive one of 3 study treatments (lidocaine 20 mg/ml, levobupivacaine 1.25 mg/ml, or saline).|t|t|t|t
33853712|NCT03650517|||COHORT||PROSPECTIVE|||||||
34166160|NCT02139072|||CASE_CONTROL||PROSPECTIVE|||||||
34166161|NCT02802566|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34166162|NCT01412164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166163|NCT01587144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166164|NCT03703544|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34166165|NCT05441631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166166|NCT03870295|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33853713|NCT06112561|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33853714|NCT00603720|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33853715|NCT03214094|||COHORT||PROSPECTIVE|||||||
33853716|NCT04647812|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Consecutive cohort study||||
33853717|NCT00259584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853718|NCT04076748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853719|NCT06020742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853720|NCT01978522|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|f|t
34076587|NCT05039697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076588|NCT01275144|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34076589|NCT02668965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34076590|NCT05214469|||CASE_CONTROL||PROSPECTIVE|||||||
34076591|NCT05418439|NA|SINGLE_GROUP||OTHER||NONE||||||
34076592|NCT02675764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076593|NCT05436561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076594|NCT00749593|||COHORT||CROSS_SECTIONAL|||||||
34076595|NCT04907214|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34076596|NCT00475254|||COHORT||PROSPECTIVE|||||||
33957321|NCT05346939|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|In this study, the athletic trainer will intervene with a dynamic tape (spiral dynamic technique) using a dynamic tape for the first test and a sham dynamic tape for the second test.|The first year, the investigators would verify the relation between wearable device and motion analysis and its validity and reliability (n=15). And the investigators are going to observe the effect of dynamic taping in lower limb biomechanics of high-school soccer and basketball athletes (n=50). In the second year, the investigators would recruit high school soccer and basketball athletes to examine the effect of dynamic taping in lower limb biomechanics under fatigue (n=50). In order to exclude the influence of sequence and learning effect, a cross-over study was used, and the interval between the two tests was about 2 weeks.||||
33957322|NCT01548573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957323|NCT01788163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061166|NCT05865275|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* an investigator was employed for patient recruitment and to perform preliminary sensitivity tests at baseline for all selected patients (baseline)~* a non-clinical investigator was used to divide the patients into two study groups using random distribution software.~The laser procedure and the whitening procedure were performed by two different clinical operators who were not aware of the organization of the two study groups.~Subsequently, the first operator, already employed to collect scores in baseline, and who was unaware of the assigned clinical protocols, underwent again all participants of the study to sensitivity Test asking them to record the degree of dental sensitivity, for each bleached tooth, perceived from immediately, to 1 h, to 24 h, and 48 h after the end of bleaching treatment using the score."|A randomized double-blind and placebo-controlled clinical trial study|t|f|t|t
34061167|NCT01585610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061168|NCT01569256|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34061169|NCT03572400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061170|NCT00041665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34061171|NCT04151485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants, statisticians and medical staff will be blinded for intervention allocation. Since, to control the therapist variable, the two types of interventions will be done by the same person, blinding on the Care Provider's part is not possible.|Mind/Body and Fertility Support Groups will be running in a parallel manner, with continuous enrollment on the basis of pre-generated random number tables. Each group will consist of 10-16 members, and run for 10 weeks. Every 11th week two new groups (one Mind/Body and one Fertility Support) will be scheduled, and so on, until the desired number of participants will be collected.|t|f|t|t
34061172|NCT01600274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166167|NCT06219096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study utilizes a double-blind design to ensure impartiality among operators, outcome assessors, and patients. The randomization assignment is only known to the research nurse, who administers the two different ICG administration protocols during surgery based on the assigned randomization number and group allocation. To maintain blinding, an opaque curtain is placed over the anesthesia operation area on the patient's head side, preventing the surgical operator from knowing the randomization assignment. The entire process of grouping and drug delivery is observed solely by the dedicated research nurse. In order to minimize assessment bias, the evaluators and data collectors are also blinded and have no knowledge of the patient's grouping information, thus reducing the potential impact of bias on the results. The efficacy of fluorescence imaging will be evaluated and scored independently by three experts in the field of fluorescence.||t|f|t|t
34166168|NCT03004365|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34166169|NCT06101706|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34166170|NCT03697642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166171|NCT04308941|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE|Subjects will be enrolled in each cohort sequentially there is no masking of procedures|The first 10 subjects will be randomly chosen for the first cohort (scleral TonoPen), the second 10 subjects will be randomly chosen for the second cohort (scleral pneumatonometry), and the third 10 subjects will be randomly chosen for the third cohort (Diaton).||||
34166172|NCT00202761|NA|SINGLE_GROUP||OTHER||NONE||||||
34166173|NCT05206175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747615|NCT05229692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed at Piazza Surgical Center. Assessors will be blinded to which intervention participant has received.|Study will be divided into two randomly assigned groups - control and interventional. Control group will receive current standard of care for recovery (rest and minimal activity for 6 weeks post-operative). Interventional group will receive neuromuscular electrical stimulation treatments 2 times a week for 6 weeks post-operative.|f|f|f|t
34166174|NCT05577338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747616|NCT03046212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747617|NCT00282620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34166175|NCT05010096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166176|NCT02338544|||COHORT||PROSPECTIVE|||||||
33853721|NCT04983641|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33957324|NCT06489847|||COHORT||PROSPECTIVE|||||||
33957325|NCT00006397||||TREATMENT||NONE||||||
33957326|NCT02636166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957327|NCT03475186|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34166177|NCT03187119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166178|NCT06385119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34166179|NCT06139341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747618|NCT06356064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747619|NCT01900990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747620|NCT04019938|||COHORT||CROSS_SECTIONAL|||||||
33747621|NCT03150056|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a two-arm, open-label dose escalation and dose expansion cohort study.||||
33747622|NCT00868439|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33747623|NCT01576926|||||PROSPECTIVE|||||||
33747624|NCT06027229|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33747625|NCT05155826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective monocentric study, randomized in 2 parallel groups, evaluating the effectiveness of the use of a virtual reality headset on the reduction of pain during intra-cervical balloon insertion for induction versus standard care.||||
33853722|NCT05419453|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853723|NCT05320549|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853724|NCT04310033|||CASE_CONTROL||PROSPECTIVE|||||||
33853725|NCT04869943|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. Subjects in the Control Treatment Group will receive a ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus or selective estrogen receptor modulator(SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization.||||
33853726|NCT03487354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853727|NCT06476470|||COHORT||PROSPECTIVE|||||||
33853728|NCT02529631|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853729|NCT04439682|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853730|NCT03475615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853731|NCT05273593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Feasibility study||||
33853732|NCT01084629|||COHORT||PROSPECTIVE|||||||
33853733|NCT04539678|||COHORT||RETROSPECTIVE|||||||
33853734|NCT00975767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853735|NCT00000823||||TREATMENT||||||||
33853736|NCT02579499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853737|NCT03464799|||CASE_ONLY||PROSPECTIVE|||||||
33853738|NCT05175638|||CASE_CONTROL||PROSPECTIVE|||||||
33853739|NCT02032914|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853740|NCT01959022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853741|NCT04953325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957328|NCT01139801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061173|NCT02919267|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34061174|NCT06613360|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061175|NCT01870804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34061176|NCT05588245|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061177|NCT00979420|||||RETROSPECTIVE|||||||
34061178|NCT01201174|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34061179|NCT01267201|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34061180|NCT00571571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061181|NCT01420562|||COHORT||PROSPECTIVE|||||||
34061182|NCT05284734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061183|NCT02437032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061184|NCT05123391|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061185|NCT00128804|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34166180|NCT03700801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||According to two different therapies, patients were divided into the study group (triple combination therapy group) and control group (premixed insulin treatment group). Each group included 65 cases.||||
34166181|NCT03361293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and families will be blinded. The principal investigator will be blinded. The research staff member coordinating the visit will be blinded. The care provider is not involved in the research and is, therefore, blinded.|1:1 randomized allocation to active tDCS or placebo (sham tDCS).|t|t|t|t
34166182|NCT02241148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853742|NCT05067465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Standardized diet over five days (n = 4x40) and test meal on day 6 with postprandial profiling (n = 4x12):~Four groups characterized by defined intake of:~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)"||||
33853743|NCT03668184|||COHORT||RETROSPECTIVE|||||||
34166183|NCT03170700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessments will be conducted by staff blind to group membership.|Participants will be randomly assigned to one of three conditions: 1) Nutrition Program (Eating Smart • Being Active) alone (control); 2) Nutrition program with parental feeding content (In-person); or 3) Nutrition program with parental feeding content (online).|f|f|f|t
34166184|NCT03550612|||COHORT||RETROSPECTIVE|||||||
34166185|NCT00506870|RANDOMIZED|PARALLEL||||NONE||||||
33853744|NCT05199194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853745|NCT05764928|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I: A 3+3 design with dose escalation to determine the dose-limiting toxicity (DLT) and recommended dose level (RDL) in the first cycle of combination use with Pemetrexed + Cisplatin Therapy.~Phase II: A following study to determine the efficacy while using the RDL of BLEX 404 Oral Liquid combined with Pemetrexed + Cisplatin Therapy in a total of 20 stage-IV or recurrent non-small cell lung cancer patients."||||
33853746|NCT03796260|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853747|NCT02749435|||OTHER||OTHER|||||||
33853748|NCT00118755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853749|NCT04384185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trial|t|f|t|t
33853750|NCT01210261|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33853751|NCT01685164|||CASE_ONLY||PROSPECTIVE|||||||
33853752|NCT01853982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853753|NCT00343252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853754|NCT00519038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33853755|NCT06069674|||COHORT||PROSPECTIVE|||||||
33853756|NCT04157231|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|The clinical outcome will be assessed by a blinded assessor|A before and after, effectiveness-implementation hybrid study design with blinded outcome assessment will be conducted. This type 1 effectiveness-implementation hybrid design will test the essential acute stroke care management plan and secondarily gather data to inform subsequent research trials|f|f|f|t
33853757|NCT01468831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853758|NCT04236115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||double blinded randomised trial|t|f|f|f
33853759|NCT03887390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients will be randomly assigned to one of two groups (intervention or usual care) using a computer-generated sequence. Due to the nature of the study, patients, health professionals, and members of the research team cannot be masked to the allocation.|This is a mixed-method feasibility study centered on a pilot clinical trial in family medicine groups in Quebec, Canada, accompanied by a realistic qualitative evaluation of process.||||
33853760|NCT00636753|||COHORT||PROSPECTIVE|||||||
33853761|NCT02871856|NA|SINGLE_GROUP||SCREENING||NONE||||||
33853762|NCT00601419|||CASE_ONLY||PROSPECTIVE|||||||
33853763|NCT01386073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33853764|NCT02084745|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized with a 1:1 allocation into two groups. Group 1 will comprise 20 patients undergoing KPro and simultaneous GDD while group 2 will include 20 patients undergoing KPro and then GDD 6 months later. Randomization schedule will be computer generated.||||
33853765|NCT05103293|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33853766|NCT03800615|||CASE_ONLY||RETROSPECTIVE|||||||
33853767|NCT02429674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853768|NCT04312893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Our study goal is the measure the effectiveness of press tack needles (acupuncture group) in reducing delirium severity in critically ill patients in the ICU. In order to ensure a double bind procedure, we will implement the use of press tack placebos (control group) as a competitor. In addition to the mentioned above interventions, patients in both groups will receive routine ICU care as per individual patient's needs.|two groups, randomized, pre-post intervention study|t|t|t|t
33853769|NCT05657886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33957329|NCT05409664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a randomized controlled trial. Participants will be randomly assigned to a intervention group or a control group. The study duration will be 3-months for both groups; assessments will be completed pre- and post-intervention.|f|f|f|t
33957330|NCT06703957|||COHORT||RETROSPECTIVE|||||||
33957331|NCT06542887|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Controlled Open labeled||||
33957332|NCT06702605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957333|NCT06262490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853770|NCT01580969|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957334|NCT06701487|||CASE_CONTROL||PROSPECTIVE|||||||
33957335|NCT00306137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957336|NCT06567483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||After a run-in period, the patients were randomly allocated to receive either 8-week of predilution hemodiafiltration using super-high flux, ELISIO-21HX, or hemodialysis using super-high flux as the control treatment. After a wash-out period of hemodiafiltration using high flux dialyzer, they were assigned to receive the other treatment for 8 weeks.||||
33957337|NCT06101719|||COHORT||PROSPECTIVE|||||||
33957338|NCT05305079|||COHORT||PROSPECTIVE|||||||
33957339|NCT00761566|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33957340|NCT06538935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957341|NCT05968300|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Non-randomized trial (Preference trial)||||
33957342|NCT03925025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061186|NCT00473785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34061187|NCT03631719|||CASE_CONTROL||PROSPECTIVE|||||||
34061188|NCT00334295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061189|NCT06034925|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061190|NCT02491125|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34061191|NCT03218267|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34061192|NCT02240069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061193|NCT06021366|||COHORT||RETROSPECTIVE|||||||
34061194|NCT02380495|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34061195|NCT00376272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061196|NCT01895348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061197|NCT03838237|||COHORT||PROSPECTIVE|||||||
34166186|NCT02783196|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34166187|NCT01224119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893486|NCT04957173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061198|NCT02947906|||||PROSPECTIVE|||||||
34061199|NCT06540417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061200|NCT00676572|||OTHER||PROSPECTIVE|||||||
34061201|NCT05901584|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34061202|NCT01366794|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34061203|NCT01541839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166188|NCT02256566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166189|NCT03652181|||COHORT||PROSPECTIVE|||||||
34166190|NCT02055287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166191|NCT00706446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166192|NCT00426920|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166193|NCT04404231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient and the investigator are blinded||t|t|t|t
34166194|NCT00191334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166195|NCT04612166|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization done at the hospital level in the MercyOneSM Health Network. Patients that are attributed to clinics that report to the participating intervention hospitals, will be screened and recruited as intervention patients. Patients that are attributed to clinics that report to participating control hospitals, will be screened and recruited as control patients.||||
34166196|NCT04549545|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participant will be blinded to the study arm they are assigned to.|2:1 site-stratified randomization will be used to allocate participants to either the active treatment arm (Vivaer procedure) or the control arm (sham procedure). Crossover within 30 days after 3 month follow-up visit.|t|f|f|f
34166197|NCT03654794|||COHORT||PROSPECTIVE|||||||
34166198|NCT00010036||||TREATMENT||||||||
34166199|NCT04671433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|No intervention - deferred treatment group (Bilateral, subretinal administration of AAV5-RPGR to be administered in the follow-up study)|Bilateral, subretinal administration of AAV5-RPGR - immediate treatment group|f|f|f|t
33747626|NCT04525404|||COHORT||PROSPECTIVE|||||||
33747627|NCT05788549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747628|NCT05508282|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Parents will be advised of the purpose of the study in general terms (how parents and babies interact at home) yet not the behaviors or outcomes of interest.|Single-blind randomized trial with two arms: intervention (enhanced reading \& screen time guidance using a new mobile app) and control (usual guidance).|t|f|f|f
33747629|NCT00481429|||CASE_ONLY||PROSPECTIVE|||||||
33747630|NCT06370767|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomly assigned to either start the intervention program immediately, or be placed on an 8-week waitlist. Once randomized, the participant will again be randomized into a treatment condition: 1) peer-mediated bikeshare training intervention; or 2) peer-mediated public travel training intervention. 20 participants from each condition who have not opted out of being in the GPS subsample will be randomly assigned to be invited to a GPS subgroup.||||
33747631|NCT06043050|||COHORT||RETROSPECTIVE|||||||
33747632|NCT05099848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747633|NCT01552213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747634|NCT03913585|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||To test the acceptability, feasibility and short-term effect of a selective preventive program that systematically helps citizens evaluate individual risk of lifestyle related disease and, if needed, offers targeted and coordinated preventive services in the primary health care sector.||||
33747635|NCT02630264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747636|NCT00444782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747637|NCT02931734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747638|NCT00734227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33747639|NCT04935502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as accessor of the study would be kept blind of the treatment group to which patient would be allocated.After the complete initial screening process, every recruited patient will be accessed by an independent assessor, expert will use outcome measuring tools. his will be recorded as baseline measurement assessment||f|f|f|t
33747640|NCT01704417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747641|NCT01558622|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33747642|NCT06170827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747643|NCT04938895|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33747644|NCT00102895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747645|NCT01262066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747646|NCT00421252|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33765621|NCT04476420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765622|NCT05228002|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34061204|NCT06431113|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34061205|NCT04220086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061206|NCT00005005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34061207|NCT00874562|RANDOMIZED|PARALLEL||||NONE||||||
34061208|NCT06016985|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34061209|NCT02165475||||TREATMENT||||||||
34061210|NCT01291576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061211|NCT06558188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061212|NCT00709007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061213|NCT00077441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061214|NCT05248724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants were not informed about what group (intervention or placebo) they were assigned.|This study was a prospective single-blind, two arms, parallel-group|t|f|f|f
34061215|NCT05212324|||COHORT||PROSPECTIVE|||||||
34061216|NCT03123796|||CASE_CONTROL||RETROSPECTIVE|||||||
34061217|NCT01651338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34061218|NCT00778102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061219|NCT05329051|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34061220|NCT05679817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind protocol was adopted. The researcher who collected the data was blind to the allocation of treatment.|A prospective, dual-arm, randomized controlled trial|f|f|f|t
34061221|NCT00551161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061222|NCT04898972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166200|NCT00685165|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34166201|NCT03083366|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized non-blinded study of sacral neuromodulation plus standard neurogenic bladder care versus standard neurogenic bladder care in patients with spinal cord injury||||
33747647|NCT06150027|RANDOMIZED|PARALLEL||OTHER||NONE||Randomization (ratio 1:1) will be stratified according to the investigation center and pre-existing follow-up by pain management team.||||
34166202|NCT06483724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166203|NCT00808093|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166204|NCT02869633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166205|NCT02356172|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166206|NCT04995432|||COHORT||RETROSPECTIVE|||||||
34166207|NCT03074708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747648|NCT03708198|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33747649|NCT06413108|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|This is a double-blind randomised controlled trial. The treating physician and staff involved with assessing all laboratory outcomes of the study are blinded. The study pharmacist will be unblinded and responsible for randomisation and treatment preparation. Entomology staff involved in the mosquito feeding assays will be blinded for the parasitology results.|We will perform two sequential stages of clinical research, each recruiting a distinct cohort of participants to confirm: 1. TB31F safety and 2. TB31F efficacy. The safety cohort will be composed of the three dose groups in adults (groups 1, 2 and 3) and two dose groups in children (groups 4 and 5). The efficacy cohort will be composed of two dose groups in adults and children (group 6). Participants will be randomised within each treatment group to receive a single sub-cutaneous dose of TB31F or placebo.|t|t|t|t
33747650|NCT04681638|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, phase IV, multicenter, randomized controlled prospective clinical trial in patients with burns. The study model is parallel (between-patient). The intervention to be tested is Pathogen-Reduced Plasma for burn shock resuscitation vs. standard-of-care resuscitation.||||
34166208|NCT03552497|||COHORT||RETROSPECTIVE|||||||
34166209|NCT06062979|||COHORT||PROSPECTIVE|||||||
34166210|NCT03360903|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34166211|NCT04149249|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34166212|NCT00689923|||CASE_ONLY||PROSPECTIVE|||||||
33747651|NCT01682460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747652|NCT01486160|||CASE_ONLY||PROSPECTIVE|||||||
33747653|NCT00003135||||TREATMENT||||||||
33747654|NCT02950246|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33747655|NCT01940042|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33747656|NCT06430450|||CASE_CONTROL||PROSPECTIVE|||||||
33747657|NCT03624504|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34166213|NCT01202266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33747658|NCT03404128|||COHORT||PROSPECTIVE|||||||
33747659|NCT03786679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors are not involved in the treatment and the radiological assessment of images will be assessed with anonymyized images.|Parallel assignment|f|f|f|t
33853771|NCT05068245|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention being tested is music. Patients will receive either routine pain control measures only (control group) or routine pain control measures and music (treatment group). Routine pain control will include instructions to take ibuprofen 600 mg 30 minutes prior to the procedure. These instructions will be given to all participants. It will be noted whether patients actually take ibuprofen or not by the study staff. Patients randomized to receive music in addition to routine pain control measures, will listen to preselected classical music.||||
33853772|NCT06147284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of this trial, neither the staff, participants nor care provider can be masked to allocation. The data analyst will be blinded after study completion by having the intervention group information coded. All outcome assessors will be blinded to subject allocation.||f|f|t|f
33853773|NCT02775799|||COHORT||PROSPECTIVE|||||||
34166214|NCT04543773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166215|NCT01968148|||COHORT||PROSPECTIVE|||||||
34166216|NCT00566423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166217|NCT00003663||||TREATMENT||||||||
34166218|NCT05532358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Drug drug interaction study||||
34166219|NCT04714164|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility and acceptability study||||
34166220|NCT02938195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166221|NCT05065905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747660|NCT06670885|||COHORT||PROSPECTIVE|||||||
33765623|NCT04318028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765624|NCT02520648|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33765625|NCT01334944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765626|NCT01380886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765627|NCT03019003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765628|NCT01115985|RANDOMIZED|CROSSOVER||||NONE||||||
33765629|NCT05580159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study uses a double blinded design, and the investigators and participants will all remain blinded before unblinding and do not know which group the participant belongs to.|a randomized observer-blinded parallel controlled trial：Experimental group（mRNA vaccine） and positive control group（inactive vaccine）|t|t|t|t
33765630|NCT04279301|||COHORT||PROSPECTIVE|||||||
33957343|NCT03681769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Data for this randomized, double-blind, sham-controlled study (behavioral assessments, functional MRI measurements) will be acquired by the members of the Dr. Hanlon's lab, including graduate students and research specialists. These individuals will also perform data under the guidance of the PI. Manuscript composition will be led by the PI, with the assistance of the research team.|"This randomized, double-blind, sham-controlled study will parametrically evaluate the longitudinal effects of 16 days of rTMS to the DLPFC (Aim 1) or the MPFC (Aim 2) on self-reported pain and the brain's response to pain. This will be done in a cohort of patients recruited from Medical University of South Carolina clinics and the outer community with chronic lower back pain that have been using prescription opiates for 3 or more months without adequate pain relief. Participants will be randomized to receive TMS to the DLPFC, MPFC, or sham (50% at each site), using a Latin square randomization. Resting state connectivity will be collected along with data from a standardized thermal pain paradigm wherein individuals are exposed to pain and instructed to try to control' the pain. Quantitative Pain Testing will be collected 12 times. MRI data will be collected 3 times: before the 1st visit of TMS, before the 12th visit of TMS, and before the 16th visit of TMS."|t|t|t|t
33957344|NCT05328167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957345|NCT03420573|||COHORT||PROSPECTIVE|||||||
33957346|NCT00185731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957347|NCT06652724|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will be fully aware of the purposes of the research and written informed consent will be obtained from all subjects. All recruited participants will undergo a baseline assessment (T0) using the tests listed in the next section. Patients who meet the inclusion criteria will be enrolled and randomized sequentially into one of three groups: brief psychodynamic therapy (DIT), Expressive Writing Therapy (EST) and controls (TAU). The group selected for the DIT intervention will conduct 16 sessions (one per week) and the group for TSE 8 meetings (one every fortnight) (see description of interventions) for a total intervention time of 4 months.||||
33957348|NCT05443659|||COHORT||PROSPECTIVE|||||||
33957349|NCT03667742|||COHORT||PROSPECTIVE|||||||
33957350|NCT06703814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||intraoperative Flow-controlled ventilation versus intraoperative pressure-controlled ventilation during general anesthesia|t|f|f|t
33957351|NCT00018174|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33957352|NCT01306968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957353|NCT06701045|||CASE_ONLY||CROSS_SECTIONAL|||||||
33957354|NCT02935946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957355|NCT06282523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957356|NCT06024785|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no blinding.|"* Stratification: Indication for decompression (study arm 1) or fusion (study arm 2)~* Randomization within study arm 1 and study arm 2 between study intervention and control intervention"||||
33957357|NCT06567821|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The procedure will be recorded for subsequent blinded review.|This is a prospective randomized single blinded study. A block randomization will be performed to randomize each candidate to determine which side will receive a balloon sinusotomy without navigation and which side will receive balloon sinusotomy with the assistance of navigation. Each person has a set of sinuses on the right side and a set of sinuses on the left side. One side will be randomized to the balloon dilation with navigation while the other side will be performed with balloon dilation without navigation.|f|f|f|t
33957358|NCT01817764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957359|NCT02531698|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33957360|NCT06702423|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33957361|NCT00759668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957362|NCT06267781|||COHORT||PROSPECTIVE|||||||
33957363|NCT02487407|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33957364|NCT05918055|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957365|NCT06381401|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33957366|NCT06594445|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957367|NCT04032444|||COHORT||OTHER|||||||
33957368|NCT06372834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957369|NCT06480383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957370|NCT05134727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957371|NCT06317337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957372|NCT06277778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957373|NCT06703710|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33957374|NCT06701344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957375|NCT00975338|||COHORT||PROSPECTIVE|||||||
33957376|NCT00716027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957377|NCT03801395|||FAMILY_BASED||PROSPECTIVE|||||||
33957378|NCT02790372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957379|NCT00720304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957380|NCT05780515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957381|NCT05700942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Stratified randomization will be used to allocate participants to their treatment group (higher or lower dose of tsDCS)||t|f|t|f
33957382|NCT04986488|||COHORT||PROSPECTIVE|||||||
33957383|NCT05341583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957384|NCT05552092|NA|SINGLE_GROUP||OTHER||NONE||||||
34061223|NCT02033200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061224|NCT01108419|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34061225|NCT03197870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061226|NCT03345888|||COHORT||RETROSPECTIVE|||||||
33957385|NCT03858920|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957386|NCT06125886|NA|SINGLE_GROUP||SCREENING||NONE||||||
33957387|NCT04818060|||CASE_CONTROL||PROSPECTIVE|||||||
33957388|NCT02001285|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957389|NCT04800913|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective randomized one-centre trial||||
33957390|NCT04477785|||CASE_CONTROL||OTHER|||||||
33747661|NCT05613660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Subjects will be randomly assigned in as 1:1:1:1 ratio to receive either treatment A or B or C or D and three different dosages i.e. 2.5g, 5g, and 10g. The randomization code will be generated by NovoBliss Research. Single-blind will be followed for the evaluators.~Subjects will be randomly allocated to one of the treatment groups and one of treatment dose, as per the randomization code. This is single-blind study and blinding will be kept wherein neither the evaluator staff nor the Investigator shall be aware of the test treatment or test treatment dose allocation (except for osteoarthritis patients for Bovine Test Treatment). To maintain blinding, the study staff who involves in treatment dispensing and distribution will not be involved in any other study-related activities."|Proof of Science, Randomized, Four-arm, Comparative, Single-Blind, Evaluator-Blinded, Dose Response, Safety and Efficacy Study|f|f|t|t
33957391|NCT05680727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will put on a swim cap and undergo treatment site-marking according to standard protocols. All individuals will get two treatment sites marked: 1) Their individualized target based on resting state functional connectivity data, and 2) Beam F3 target based on head measurements. One group will be treated at target #1, and the other group will be treated at target #2.~Neither group will be able to see the computer screen that shows the neuronavigation in real-time, although they will be able to see their MRI scan on a monitor."|Parallel-group double-blind randomized controlled trial|t|f|t|t
33957392|NCT04441203|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a single center, prospective, randomized, open-label blinded-endpoint (PROBE) trial in which the treatment group will be implanted with a CardioMEMS HF sensor and managed using remote access to hemodynamics compared to a non-implanted control group.||||
33957393|NCT01819389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957394|NCT06542003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Because participants are either actively receiving facilitated participatory arts sessions or not, it is not possible to mask the intervention.|Participants are randomly assigned to two primary groups: an intervention group and a control group. Within the intervention group, participants are further divided into two subgroups due to logistical reasons, allowing for separate sessions for music and dance activities. This division is not to provide different interventions, but rather to manage the logistics of hosting the sessions, e.g. where only so many students may participate in group drumming at a time.||||
33957395|NCT05188287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957396|NCT06649591|||COHORT||PROSPECTIVE|||||||
33957397|NCT02469675|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957398|NCT05681039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957399|NCT05521958|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33957400|NCT06123897|||COHORT||PROSPECTIVE|||||||
33957401|NCT06359964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957402|NCT03308123|||OTHER||RETROSPECTIVE|||||||
33957403|NCT06117111|||CASE_ONLY||PROSPECTIVE|||||||
33957404|NCT04484987|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two diet interventions: TRE group (eating all their food for the day in 9 hours) or the control group (eating all their food for the day in 15 hours) for 12 weeks. Tests to asses changes in metabolism will be performed before and after the intervention.||||
33957405|NCT05438524|||COHORT||PROSPECTIVE|||||||
33957406|NCT04449354|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957407|NCT04265209|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33957408|NCT06520358|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and assessors will be blinded to group allocation.|The pilot study will utilize a double-blind, placebo-controlled, randomized-order, repeated-measures, cross-over experimental design|t|f|f|t
33957409|NCT06354959|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33957410|NCT01991184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747662|NCT04109248|||COHORT||PROSPECTIVE|||||||
33957411|NCT01861717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061227|NCT05510219|NA|SINGLE_GROUP||TREATMENT||NONE||This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital . All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.||||
34061228|NCT04796883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061229|NCT04694768|||COHORT||PROSPECTIVE|||||||
34166222|NCT00662207|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166223|NCT04067934|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot/feasibility design||||
34166224|NCT01468740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166225|NCT00871871|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34166226|NCT01544426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166227|NCT05651100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166228|NCT04494035|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A prospective, single-arm, non-blinded study, intending to treat and collect and evaluate data in up to ten (10) human subjects who are currently being treated with hemodialysis and who present with acute thrombosis in their arteriovenous (AV) grafts, treated with the CAPERE® Thrombectomy System.||||
33747663|NCT06078332|||CASE_CROSSOVER||PROSPECTIVE|||||||
33747664|NCT03887468|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747665|NCT00317772|NA|SEQUENTIAL||TREATMENT||NONE||||||
33747666|NCT01535716|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33957412|NCT03506776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957413|NCT06539143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a clinical equivalence randomized controlled trial comparing the efficacy of conscious sedation and paracervical block among women selected for manual vacuum aspiration following incomplete miscarriages in first trimester in Alex Ekwueme Federal University Teaching Hospital, Abakaliki (AEFUTHA), Ebonyi State.||||
33853774|NCT01635920|RANDOMIZED|PARALLEL||||NONE||||||
33957414|NCT05643027|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957415|NCT02788383|||CASE_ONLY||RETROSPECTIVE|||||||
33957416|NCT03881722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled cross-over trial||||
34061230|NCT01678885|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061231|NCT03530813|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective Randomised Parallel Study||||
34061232|NCT05919095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061233|NCT01043705|||CASE_CONTROL||PROSPECTIVE|||||||
34061234|NCT01264848|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34061235|NCT02315872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061236|NCT00618709|NON_RANDOMIZED|PARALLEL||||NONE||||||
34166229|NCT04452019|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"All together each included patient will attend five sessions. First session includes an orthostatic test and other baseline measurements. In order to describe test-to-test variation (reliability) when using the devices, two sessions are held in standard standing frame (A) and two sessions in Innowalk Pro (B), preferably within the same week. If, for practical reasons, this is not feasible, training is allowed in the following week. The order of the workouts is block randomized to ABAB or BABA at inclusion. The orthostic test and the training session are estimated to last approx. 1 hour including all measurements."||||
34166230|NCT06306209|||COHORT||PROSPECTIVE|||||||
33853775|NCT05150951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are never told which manipulation that is expected to affect the threat memory processes.||t|f|f|f
33853776|NCT05660239|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study participants and researchers both know which community change intervention they are receiving or implementing respectively.|Study participants together with the relevant community stakeholders will co-design feasible communication and activity-based change projects that are based on both cultural and scientific norms, to reduce epilepsy stigma in the community Researchers will then compare the Quality of Life, Attitudes and Beliefs about Living with Epilepsy scores and the Kilifi Stigma Scale scores, pre and post the implementation of the community change projects in two parishes (urban and rural) to see if there is improvement in these assessments scores.|f|f|f|t
33853777|NCT03720860|||COHORT||PROSPECTIVE|||||||
33853778|NCT01104116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853779|NCT01526252|||OTHER||PROSPECTIVE|||||||
33853780|NCT05066737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853781|NCT01683903|||COHORT||PROSPECTIVE|||||||
33853782|NCT05532982|||OTHER||CROSS_SECTIONAL|||||||
33853783|NCT04646915|||COHORT||PROSPECTIVE|||||||
33853784|NCT05636956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|t|f|f|f
34061237|NCT02107573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957417|NCT05790200|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957418|NCT04464382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33957419|NCT03406611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957420|NCT05948917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061238|NCT02956057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061239|NCT05160194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061240|NCT04800874|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects must have been enrolled in the MLB-01-001 study to participate in this trial. Three ascending dose cohorts of 4-6 subjects each are planned.||||
33853785|NCT05316701|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Phase III is a randomized, open-label, multicenter study comparing outcomes between patients receiving Orca-T followed by single-agent tacrolimus or standard-of-care (SOC) control followed by dual agent, tacrolimus-based Graft-versus-Host-Disease (GVHD) prophylaxis regimen||||
33853786|NCT02927860|||CASE_ONLY||PROSPECTIVE|||||||
33957421|NCT06372145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957422|NCT00003892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957423|NCT04560452|||COHORT||PROSPECTIVE|||||||
34061241|NCT04614103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061242|NCT04580537|RANDOMIZED|PARALLEL||TREATMENT||NONE||a proof-of-concept, single-center, prospective, open-label, randomized, clinical trial with an intra-individual comparison of treatments||||
34061243|NCT06386692|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061244|NCT01542034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061245|NCT01851187|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061246|NCT04523870|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34061247|NCT03452241|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33957424|NCT06081946|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participant will be blinded about application of pruritogens.|The participants will be instructed to wake up at three designated timepoints for three consecutive nights at home.||||
33957425|NCT04519294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957426|NCT03534635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957427|NCT01905007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061248|NCT01884012|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34061249|NCT05479838|||OTHER||PROSPECTIVE|||||||
34061250|NCT01286194|||COHORT||PROSPECTIVE|||||||
34061251|NCT03340233|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34061252|NCT03532815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061253|NCT00607100|||COHORT||PROSPECTIVE|||||||
34061254|NCT01570569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061255|NCT02358785|||COHORT||PROSPECTIVE|||||||
33853787|NCT01195285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853788|NCT00062049||||TREATMENT||||||||
33853789|NCT05969743|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33853790|NCT02067117|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33853791|NCT03829293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853792|NCT03234101|||COHORT||PROSPECTIVE|||||||
33853793|NCT00458887|||COHORT||PROSPECTIVE|||||||
33853794|NCT00457808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853795|NCT03297931|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33853796|NCT00601094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853797|NCT02391454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853798|NCT01377597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853799|NCT03435523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853800|NCT05540288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853801|NCT03815786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853802|NCT04839757|||COHORT||CROSS_SECTIONAL|||||||
33853803|NCT01206374|||COHORT||PROSPECTIVE|||||||
33853804|NCT00400348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853805|NCT02860780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853806|NCT04497454|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, single-center, open-label, superiority, controlled trial||||
33853807|NCT01580423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33853808|NCT06195254|||COHORT||RETROSPECTIVE|||||||
33853809|NCT05318677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33853810|NCT05780554|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853811|NCT00238524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33853812|NCT02889003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853813|NCT04420715|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33853814|NCT00323336|||||PROSPECTIVE|||||||
33853815|NCT00451880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853816|NCT04454827|||COHORT||PROSPECTIVE|||||||
33853817|NCT05586074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853818|NCT02107053|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33853819|NCT01236339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853820|NCT05171023|||CASE_ONLY||PROSPECTIVE|||||||
33853821|NCT00425984|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853822|NCT02304601|||COHORT||PROSPECTIVE|||||||
33853823|NCT02880631|||COHORT||PROSPECTIVE|||||||
33853824|NCT00336895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853825|NCT03368469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853826|NCT05933408|||OTHER||RETROSPECTIVE|||||||
33853827|NCT00162357|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853828|NCT05958641|||OTHER||CROSS_SECTIONAL|||||||
33853829|NCT00873314|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33853830|NCT05353933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The investigator who examine GERD-related symptoms and outcome assessor will be blinded.~However, the investigator who examine the side effects of thread embedding acupuncture will not be blinded."||f|f|t|t
33853831|NCT04825483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed about the study hypotheses, until the study is completed, at which time they will be provided a lay summary of study findings. However, the components of each treatment arm will be disclosed during recruitment, allowing us to test the interventions in a way whereby potential participants are fully informed about the nature of the components before deciding whether to participate. As the primary and some of the secondary outcomes are participant-reported, participants are also the outcome assessors and are unblinded. Physiotherapists and dietitians will not be blinded to group allocation or study hypothesis. Staff collecting the secondary outcome body composition data will be blinded to group allocation. Research staff administering and entering the participant-reported data will be blinded. Statistical analyses will be performed blinded.|A superiority, 2-group, parallel randomised controlled trial|f|f|t|f
33853832|NCT03468738|||OTHER||PROSPECTIVE|||||||
33853833|NCT01248091|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853834|NCT03392545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853835|NCT00833131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957428|NCT06682949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957429|NCT00038467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957430|NCT02957461|||COHORT||PROSPECTIVE|||||||
33957431|NCT02115373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853836|NCT03344653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomized at a 1:1 ratio to treatment with Resolute Onyx stent or the BioFreedom stent (control).|Prospective, multi-center, blinded, randomized, controlled study enrolling eligible subjects at global centers. The enrollment period is anticipated to be approximately 14 months.|t|f|f|f
33853837|NCT03876782|||COHORT||PROSPECTIVE|||||||
33853838|NCT04662541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853839|NCT01813331|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853840|NCT00568802|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33853841|NCT00342875|||CASE_CONTROL||RETROSPECTIVE|||||||
33853842|NCT05699954|||COHORT||PROSPECTIVE|||||||
33853843|NCT03378505|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to two conditions. Half of the participants will be required to use a daily check-in mobile app that promotes alignment of daily behaviors with their individualized life purpose. The other half of participants will complete brief bi-weekly reflections. Alternative assignment provided for non-participating students.||||
33853844|NCT00008489||||TREATMENT||||||||
33853845|NCT05169138|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||The research was planned to define the superiority of inhalation and massage methods applied with lavender oil compared to the control group and each other.|f|t|f|f
33957432|NCT01652872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957433|NCT00262184|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33957434|NCT02306018|||CASE_ONLY||PROSPECTIVE|||||||
33957435|NCT05905874|||COHORT||OTHER|||||||
33957436|NCT00499252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957437|NCT00433771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957438|NCT05419336|||COHORT||PROSPECTIVE|||||||
33957439|NCT05831787|||COHORT||PROSPECTIVE|||||||
33747667|NCT02198027|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33957440|NCT00693056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957441|NCT03138135|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957442|NCT06703749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957443|NCT01491737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957444|NCT03143205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957445|NCT06651047|||COHORT||PROSPECTIVE|||||||
33957446|NCT06651255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957447|NCT04720885|||COHORT||RETROSPECTIVE|||||||
33957448|NCT06703606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957449|NCT02621021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957450|NCT06362304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957451|NCT05597514|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33957452|NCT01729624|||||PROSPECTIVE|||||||
34166231|NCT06270914|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This study utilizes quasi-experimental non-randomized design, including two waves of participant recruitment. Two waves of recruitment are used. In the first wave of recruitment, intervention and active control group are used and outcomes will be measured at three time points. In addition to quantitative data, qualitative observations and interviews are conducted to get a deeper understanding of the process of implementation of SWPIS. In the second wave of data recruitment, intervention and wait-list control group are used and outcomes will be measured at two time points (pre- and post).||||
34166232|NCT05229484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166233|NCT00178568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166234|NCT00001114||||TREATMENT||||||||
34166235|NCT05862909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The group allocation variable will be masked during the data analyses to minimize possible bias concerning the statistical procedure. For this purpose, an independent researcher will delete all information in the dataset indicating the group allocation. Therefore, the evaluator does not know which expression of the group variable represents the CHD-specific intervention, the general intervention, or the waitlist control group.|Randomized controlled trial with two intervention groups and a waiting list control group|f|f|t|t
33957453|NCT06159686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747668|NCT04367753|||COHORT||RETROSPECTIVE|||||||
33765631|NCT02350920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33957454|NCT01473589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957455|NCT02405351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957456|NCT06470737|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||we apply one of three experimental methods in your hand: either an injection of salt water (7% NaCl) or we apply small needles from the plant mucuna pruriens or histamine (1%) Histamine is an itch-provoking substance formed in the human body. For 10 minutes after this, you are to assess the itch and pain you perceive on a scale from 0 to 10, in which 0 is no itch/pain and 10 is worst itch/pain imaginable. We will also apply non-invasive magnetic stimulations to your brain.||||
33957457|NCT00137462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33957458|NCT00003273||||TREATMENT||||||||
33957459|NCT06025786|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957460|NCT06703502|||CASE_ONLY||CROSS_SECTIONAL|||||||
33957461|NCT01016431|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33957462|NCT03637270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957463|NCT03695042|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33957464|NCT05795062|||COHORT||RETROSPECTIVE|||||||
33957465|NCT06701851|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957466|NCT04904588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765632|NCT02269761|||COHORT||PROSPECTIVE|||||||
33765633|NCT06303544|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Wedge design using repeated cross sectional samples of Head Start preschool students||||
33765634|NCT03653832|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- effectiveness trial with internal pilot||||
33765635|NCT01462461|||COHORT||PROSPECTIVE|||||||
33765636|NCT02820584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765637|NCT01719601|||CASE_ONLY||PROSPECTIVE|||||||
33957467|NCT06047249|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|t|f|f
33957468|NCT03361332|||OTHER||PROSPECTIVE|||||||
33957469|NCT06319963|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1/2a, open label, multicenter, dose-escalation and dose expansion trial to assess the safety, tolerability, and preliminary efficacy of Lenti-HPV-07 to participants with HPV associated oropharyngeal squamous cell cancer or cervical cancer. Three dose strengths will be investigated: a low, midlevel, and high dose. Lenti HPV-07 will be administered as either 2 × intramuscular (IM) injections to participants in arm A (recurrent or metastatic stage, refractory to previous treatments) or as a single IM injection to participants in Arm B (newly diagnosed with locally advanced HPV+ cancer never treated). Eligible participants in Arm B will receive only 1 injection of Lenti-HPV-07 prior to the initiation of their standard of care (SoC) therapy. After 18 participants in either arm have been treated in the escalation phase and have completed the 14 day DLT period, the Safety Review Committee and Sponsor will determine the OBD for use in the dose expansion phase.||||
33765638|NCT02471859|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33747669|NCT05966441|RANDOMIZED|PARALLEL||PREVENTION||NONE||"* Details of the research steps that the subscriber will be exposed to:~* Base line evaluation then alignment in either intervention or control group either for taking the interventional drug or standard of care in control group.~* Blood samples will be collected at baseline.~* Patient will be given a weekly supply of the medication and will be asked to take his prescribed dose daily.~* Every week all patients will be asked about their symptoms and if they experience any adverse drug reaction.~* Patients will receive the interventional drug until the last paclitaxel dose will be taken.~* After 3 months, another full clinical examination and blood sample will be obtained."||||
33747670|NCT01426191|||CASE_ONLY||PROSPECTIVE|||||||
33747671|NCT01672801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747672|NCT05133596|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Adult subjects up to 55 years of age with persistent olfaction disorder after a symptomatic episode of COVID-19.||||
33957470|NCT00960687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33853846|NCT00715260|||COHORT||PROSPECTIVE|||||||
33957471|NCT05824975|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957472|NCT05042453|||COHORT||PROSPECTIVE|||||||
33853847|NCT02947269|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853848|NCT01436851|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The participants were challenged on two occasions, one with placebo extract, and the other with storage mite extract, but in random order, and without the participants knowing when they received allergen or placebo|Participants with storage mite sensitization were challenged with placebo extract and storage mite extract in the nose.||||
33853849|NCT01927029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33853850|NCT01055379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853851|NCT03990181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33853852|NCT04844801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853853|NCT00753272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33853854|NCT01635400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853855|NCT04270201|||CASE_CONTROL||PROSPECTIVE|||||||
33853856|NCT01183078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853857|NCT03133754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853858|NCT00437736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853859|NCT00160043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957473|NCT05775237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|This Study is Open-label|An Open-Label, Three-Arm, Parallel, Investigator-Initiated Trial of clinical study||||
33957474|NCT06687434|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33957475|NCT02420366|||CASE_ONLY||RETROSPECTIVE|||||||
33957476|NCT06565832|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34061256|NCT03619824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853860|NCT04916080|NA|SINGLE_GROUP||TREATMENT||NONE||50 children with chronic kidney disease will be assessed for iron profile, oxidative stress status and left ventricular functions before and after treatment with N-acetyl cysteine for 3 months||||
34061257|NCT00574249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061258|NCT02846870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061259|NCT01451242|||COHORT|||||||||
33853861|NCT01411215|||CASE_CONTROL||PROSPECTIVE|||||||
33853862|NCT05787028|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A single-center, randomized, placebo-controlled, double-blind, dose-increasing study|t|t|t|t
33853863|NCT02708719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061260|NCT04182438|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||This study will enroll 40 End-Stage Renal Disease on chronic hemodialysis patients. We will perform a randomized, double-blind, cross over study. In one group, low potassium content vegetables use as study intervention for two weeks (study phase), then shift to placebo (ordinary vegetables) for two weeks. In another group, ordinary vegetables will use firstly, then change to low potassium content vegetable use. Serum potassium, blood pressure, and biochemistries will analyze at the end of the study.|f|f|f|t
34061261|NCT01470014|||COHORT||PROSPECTIVE|||||||
34061262|NCT05571176|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blind study. Study participants, investigators, care providers and personnel collecting samples are blinded. Personnel preparing study drugs will not participate on conducting the study. On the first phase of the study, study participants will be administered one of the study drug infusions (either S-ketamine or placebo). The order of the study drug is random. On the second phase, study participants will be administered the other study drug (S- ketamine or placebo) that she/he did not receive on the first phase.|This is a cross-over study with two phases on 12 healthy volunteers. Study participants will be administered S-ketamine 0.29mg/kg/h intravenously or placebo (NaCl 0.9%) for 4 hours. 30 minutes after the initiation of the study drug infusion, each subject will be given single boluses of morphine 0.01mg/kg, hydromorphone 0.002mg/kg and buprenorphine 0.003mg/kg IV. We will analyze pharmacokinetic parameters (Cmax, tmax, AUC, t1/2) for morphine, hydromorphone, and buprenorphine. The aim of the study is to evaluate whether S-ketamine has a pharmacokinetic interaction with the opioids (morphine, hydromorphone, buprenorphine) known to be metabolized via liver UGT2B7 enzyme.|t|t|t|t
34061263|NCT04068740|||CASE_CONTROL||RETROSPECTIVE|||||||
34061264|NCT05814822|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34061265|NCT05280899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and surgeons will not be blinded to group allocation (weight-bearing status). The study Research Coordinator will perform randomization therefore they will also not be blinded to group allocation. The assessor for the functional and return to sport outcomes will be blinded to group allocation. To protect blinding, before each functional testing appointment, the blinded tester will remind patients not to reveal their group (weightbearing status).|A randomized, single-blinded trial will be completed with patients receiving one of two differing post-operative weightbearing recommendations|f|f|f|t
34061266|NCT00110916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076597|NCT05304845|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076598|NCT02232204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076599|NCT04678843|NA|SINGLE_GROUP||TREATMENT||NONE||We study a blended implementation approach for Family-Based Treatment delivered via videoconferencing (FBT-V)||||
34076600|NCT03972215|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34076601|NCT00379561|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747673|NCT04039672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747674|NCT03312556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747675|NCT00872144||CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747676|NCT03641482|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||split mouth design|t|t|f|f
33747677|NCT05795725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The patients will be blinded to the microbiome results for the study period. The gastroenterologists will be blinded to microbiome results. The microbiome researchers will be blinded to colonoscopy results The statisticians will be blinded to both intervention results until the end of patient enrollment|Fecal samples will be obtained from patients who are enrolled for colonoscopy for the clinical suspicion of colon cancer||||
33747678|NCT05184725|RANDOMIZED|PARALLEL||TREATMENT||NONE||The SaMD CARINAE embeds the I-Change Model, which claims that behavioral changes depend on the inner motivation to perform a specific behavior and the self-perception of personal abilities, or self-efficacy perception, to carry out the behavioral change.||||
33747679|NCT05549037|RANDOMIZED|PARALLEL||TREATMENT||NONE||One for morning group, the patients in this group were treated with chemotherapy plus pembrolizumab or sintilimab before 15:00. One for afternoon group, the patients in this group were treated with chemotherapy plus pembrolizumab or sintilimab after 15:00.||||
33853864|NCT01538927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853865|NCT00971243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853866|NCT02949466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853867|NCT02752074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166236|NCT03464409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166237|NCT02657889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166238|NCT00574717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166239|NCT04008875|||COHORT||PROSPECTIVE|||||||
34166240|NCT02719613|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34166241|NCT02610686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166242|NCT02917135|||CASE_ONLY|||||||||
34166243|NCT06173583|||COHORT||PROSPECTIVE|||||||
34166244|NCT03461107|||COHORT||PROSPECTIVE|||||||
34166245|NCT01061970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34166246|NCT02037139|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34166247|NCT02792478|||OTHER||PROSPECTIVE|||||||
34166248|NCT04838535|NA|SINGLE_GROUP||SCREENING||NONE||||||
34166249|NCT05788055|||COHORT||PROSPECTIVE|||||||
34166250|NCT01388569|||OTHER||RETROSPECTIVE|||||||
34166251|NCT06198387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166252|NCT02316418|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34166253|NCT06457061|||COHORT||CROSS_SECTIONAL|||||||
34166254|NCT06423469|||COHORT||PROSPECTIVE|||||||
34166255|NCT06000748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is single blind. The participants will be blinded to their intervention arm. The treating providers will not be blinded as they will receive either the low or high MAP-target treatment algorithm.|This is a single-blind, randomized control, parallel-group, pragmatic trial.|t|f|f|t
34166256|NCT06444035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166257|NCT00600951|||COHORT||PROSPECTIVE|||||||
34166258|NCT04950361|||CASE_ONLY||RETROSPECTIVE|||||||
33747680|NCT02325765|||COHORT||RETROSPECTIVE|||||||
33747681|NCT04779801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747682|NCT01206738|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33747683|NCT04844164|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747684|NCT03223363|RANDOMIZED|FACTORIAL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33747685|NCT01060982|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33747686|NCT00293735|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765639|NCT03484338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765640|NCT00485654|||||RETROSPECTIVE|||||||
33765641|NCT02903134|||COHORT||PROSPECTIVE|||||||
33765642|NCT02419092|||CASE_CONTROL||PROSPECTIVE|||||||
33765643|NCT05011825|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33765644|NCT05624866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Investigate if, and to what extent,carapl tunnel hydro-dissection using DEX or triamcinolone (TM) along with saline, under ultrasound guidance, can improve the clinical condition, change in nerve conduction parameters of patients with CTS and delay or avoid the surgical intervention.|t|f|f|t
33765645|NCT02331355|||CASE_ONLY||PROSPECTIVE|||||||
33765646|NCT03596021|||COHORT||PROSPECTIVE|||||||
33765647|NCT00582530|||CASE_CONTROL||PROSPECTIVE|||||||
33765648|NCT01705808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765649|NCT06315803|RANDOMIZED|PARALLEL||OTHER||NONE|There are practical differences in operation and blind methods cannot be achieved.|||||
33765650|NCT03617159|||CASE_CROSSOVER||PROSPECTIVE|||||||
33765651|NCT02329301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765652|NCT01139190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33765653|NCT01557621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33765654|NCT04530539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33765655|NCT03097861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765656|NCT01860586|NA|SINGLE_GROUP||TREATMENT||NONE||Outcomes were compared to a retrospective, historical control group.||||
33853868|NCT00183365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853869|NCT00859612|||OTHER||PROSPECTIVE|||||||
33853870|NCT06225011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166259|NCT03309748|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33853871|NCT01277367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747687|NCT06537453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will be randomized in either arm, will be coded such that the outcome assessor is blinded to the arm assignment of the participant.|One group will receive the Virtual Care Intervention through Virtual Home Hospitals and other group will receive Usual Care.|f|f|f|t
33853872|NCT05780892|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial of 3 interventions for clinician well-being as compared to controls.||||
33853873|NCT00004468||||TREATMENT||||||||
33747688|NCT06467838|||OTHER||OTHER|||||||
33747689|NCT06102941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747690|NCT01846130|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33747691|NCT04247620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be aware of their assignment to intervention or control, as will the investigators. However, the person collecting HbA1c (primary outcome) at baseline and follow-up (12 mo) will not be aware of the participant's assignment in the intervention.|"A parallel two-group design will be used to evaluate the intervention among n=150 young adults randomly assigned to the peer support intervention or usual care (1:1). All young adults are randomized to either an intervention group, in which they all receive the same treatment in addition to usual diabetes care, or a control group, in which they receive usual diabetes care without the additional intervention. Young adult participants will be in the study for 12 months.~Peer Mentor participants (up to n=36) will deliver the intervention to young adults randomized to the intervention group, and their outcomes related to being a Peer Mentor will also be evaluated pre-post."|f|f|f|t
33747692|NCT05247151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33747693|NCT04916470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33747694|NCT05499923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients were blinded for the technique used in each quadrant and also the outcome assessors were blinded about the technique used for debonding brackets.|Split mouth design|t|f|f|t
33747695|NCT03070613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747696|NCT04288843|||CASE_ONLY||OTHER|||||||
33747697|NCT01924650|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33747698|NCT06495736|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33747699|NCT01842854|||COHORT||CROSS_SECTIONAL|||||||
33747700|NCT02509533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747701|NCT03975283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33747702|NCT01592643|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747703|NCT00395876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747704|NCT04423068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747705|NCT00010491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33747706|NCT06219239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747707|NCT02395120|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33747708|NCT03910153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853874|NCT00971932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166260|NCT01695135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166261|NCT02720341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166262|NCT02048449|||||PROSPECTIVE|||||||
34166263|NCT03469648|||COHORT||PROSPECTIVE|||||||
34166264|NCT04835779|||CASE_CONTROL||PROSPECTIVE|||||||
34166265|NCT00725595|||CASE_ONLY|||||||||
34166266|NCT03835299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Investigators are masked because the participants are randomized and the intervention is delivered by a computer tablet. The outcome assessor is masked because donation-related data is recorded by blood collection staff who are unaware that donors may be participants in a study.||f|f|t|t
34166267|NCT01473732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166268|NCT04012580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166269|NCT01744249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166270|NCT02664662|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34166271|NCT06436534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853875|NCT01459419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853876|NCT05620368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853877|NCT05788393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||this study is to compare the effects of continuous intraoperative infusion of dexmedetomidine versus lidocaine as opioid sparing analgesia on patients undergoing laparoscopic cholecystectomy.||||
34166272|NCT06117436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166273|NCT05177614|RANDOMIZED|PARALLEL||OTHER||TRIPLE||All participants will participate in sensory testing (acceptability, preference and discrimination testing) of three uncooked fortified bouillon cubes (upper-level, lower-level and control), as well as cooked foods containing the three different bouillon cubes. Participants will then be randomized to one of three groups (upper-level, lower-level or control), and receive a 14 day supply of study-provided bouillon cubes to use at home.|t|f|t|t
34166274|NCT00068614||||TREATMENT||NONE||||||
34166275|NCT04258930|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized comparative open trial comparing occlusive therapy with hydrocolloid dressings versus a silicone gel vs a drying solution (standard care) to treat the rash of herpes zoster.||||
34166276|NCT06333379|||COHORT||RETROSPECTIVE|||||||
34166277|NCT06144463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166278|NCT01018277|||COHORT||PROSPECTIVE|||||||
34166279|NCT04806971|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166280|NCT05064371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166281|NCT01861626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166282|NCT01909999|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34166283|NCT00721448|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166284|NCT03645733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|One nurse, that gives the patients their cognitive questionnaire battery, is masked from knowing which dialysis fluid temperature the patient is receiving.|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months. In the intervention group, patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study. The intervention group is split into 3 brackets, stratified by age group (patients under 55 years of age, 55-75 and above 75). A third group will also be recruited, but not randomised, consisting of the primary carers (family, friends, etc) of the patients in the other two group to measure the burden they feel in caring for a patient with renal problems.|f|f|f|t
34166285|NCT00585117|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166286|NCT03155724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166287|NCT03528226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34166288|NCT06500637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166289|NCT00183131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34166290|NCT05113446|||COHORT||PROSPECTIVE|||||||
34166291|NCT06129279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34166292|NCT04796363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34166293|NCT05201404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel group, double-blinded, randomization in a 1:1 ratio to active versus placebo|t|t|t|t
34166294|NCT04480840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166295|NCT02003534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166296|NCT05246774|||COHORT||PROSPECTIVE|||||||
34166297|NCT00387296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166298|NCT02335307|||COHORT||PROSPECTIVE|||||||
34166299|NCT00507013|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166300|NCT05156788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166301|NCT05071170|||COHORT||CROSS_SECTIONAL|||||||
34166302|NCT04893434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This will be a prospective, single center non-randomized study. This study has two parts: Part 1 (volunteers) and Part 2 (women with gynecologic cancer).||||
34166303|NCT04038541|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a randomized, interventional trial with a crossover design, in which participants will be taking either probiotic (commercially available Visbiome) or prebiotic (prebiotin prebiotic) for 6 weeks as the first agent. Then, participants enter a 6-week washout period. After the washout period, participants take the second agent for 6 weeks. After taking the second agent, participants again have a 6-week wash-out period.||||
34166304|NCT02611726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34166305|NCT04260646|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34166306|NCT03487991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166307|NCT01158911|||COHORT||RETROSPECTIVE|||||||
34166308|NCT05831358|NA|SINGLE_GROUP||SCREENING||NONE||Not a randomized trial; use of convenience sampling.||||
34166309|NCT01000623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34166310|NCT04378270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166311|NCT00732823|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166312|NCT00956371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166313|NCT03018899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166314|NCT05622604|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of three conditions. Condition 1 is the control condition (i.e., no intervention condition). In Condition 2, participants will be given a free subscription to the Pray.com app and will be directed to use the app five days per week (i.e., autonomous use condition). In Condition 3, participants will be given a free subscription to the Pray.com app and will be directed to listen to a meditation prayer five days per week (i.e., meditative prayer condition).||||
34166315|NCT06461663|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will undergo breast conserving surgery with the BCL.||||
34166316|NCT06268652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166317|NCT04864249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166318|NCT00394199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166319|NCT05294315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166320|NCT00877461|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853878|NCT05821439|||OTHER||PROSPECTIVE|||||||
33893487|NCT03834948|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Each dose escalation cohort will initially recruit 3 patients to receive AO-176 or AO-176 + paclitaxel or AO-176 + pembrolizumab in a standard 3+3 design; the cohort will be expanded in the event of a DLT.~Once the MTD/RP2D has been established for monotherapy, AO-176 + paclitaxel or AO-176 + pembrolizumab, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy."||||
33957477|NCT06358859|RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary objective is to test whether a multi-level, community-engaged intervention with a food-is-medicine program in the Mississippi Delta can improve metabolic disease in specific minority groups. The basic study design is a cluster randomized controlled trial (RCT), with equal numbers of participants randomized to intervention and control groups. Each participant will be enrolled in the study for 12 months. The intervention involves regularly distributed fruit and vegetable produce boxes as well as nutrition education materials to the intervention group during their 12-month study period. The control group will receive produce boxes later, after their 12-month study participation has ended. Participants will be patients at participating Delta Health Center (DHC) clinics in Mississippi.||||
34166321|NCT04348266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The endoscopist who do the final endoscopy for assessing the efficacy of RFA will be blinded to the previous assigned location of RFA treatment.|Study in only GIM patients but will divide the stomach into 2 sites (left and right) to random for RFA treatment.|f|f|f|t
33957478|NCT05658731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stratum A: patients with new diagnosis of brain or head and neck cancer who will be undergoing radiation therapy with substructure informed planning~Stratum B: patients ≥ 2 years from radiation therapy for brain tumor who underwent standard planning radiation therapy~Stratum C: healthy controls matched to Stratum A patients"||||
33957479|NCT06699771|NA|SEQUENTIAL||TREATMENT||NONE||"The dose-escalation part of the study (Phase 1a) employs a 3+3 design to determine the DLT of GCC2005.~The dose-expansion part of the study (Phase 1b) will enroll patients in two cohorts to determine MTD and RP2D."||||
33957480|NCT06463886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957481|NCT05465044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors blinded to the study intervention will interview patients using computer-adapted telephone interviewing for the main outcome measure (SF36 PCS)|Pragmatic randomized controlled trial (RCT)|f|f|f|t
33957482|NCT06149624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33957483|NCT05109416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33957484|NCT03370393|RANDOMIZED|PARALLEL||PREVENTION||NONE||The families will be randomized to Pathways for African Americans' Success (PAAS) intervention program or a wait-list condition (1:1 ratio) for 6 weeks. The wait-list group has the option to participate in the PAAS program at the end of the study.||||
33957485|NCT03212443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166322|NCT02424617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34166323|NCT02532517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747709|NCT04288570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957486|NCT02803138|||CASE_ONLY||PROSPECTIVE|||||||
33957487|NCT06416527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be conducted by a team of researchers, including one researcher who will supervise the interventions, i.e., the application of pompages associated or not with PBM using LED clusters. This researcher will be the only one to know the intervention performed on each participant. Another researcher will conduct the initial assessment of outcomes and reevaluations (blinded to the experimental and control groups). The statistical analysis will also be performed blindly by a statistician who will receive the data without identification of the group. The patient will be blinded to the treatment with PBM (or its simulation).|"The participants will be divided into 2 groups:~1. Pompage Group (Control): Patients will receive treatment through the application of the pompage technique in the cervical region during 10 sessions performed 3 times per week, excluding weekends.~2. Pompage + FBM Group (Experimental): Treatment will consist of 10 sessions in which the pompage technique will be applied associated with photobiomodulation in the form of LED cluster in the cervical region, performed 3 times per week, excluding weekends."|t|f|f|t
33957488|NCT05659264|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The single ascending dose (SAD) stage of this study is open-label and the multiple ascending dose (MAD) stage of this study is single-blind and placebo-controlled.|t|f|f|f
33957489|NCT02922439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957490|NCT06521138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinding of the outcome assessors in this study was planned. The data obtained from the research will be coded as A and B by an independent researcher and transferred to the SPSS program. The data will be analyzed by an independent statistical expert.||f|f|f|t
33957491|NCT05166512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957492|NCT06563492|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33957493|NCT04877535|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be allocated in a single cluster in two time periods.||||
33957494|NCT01947257|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957495|NCT00983255|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33957496|NCT06565637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957497|NCT01480882|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166324|NCT02912715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166325|NCT00821808|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166326|NCT02917785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166327|NCT01284998|||COHORT||PROSPECTIVE|||||||
34166328|NCT01980095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166329|NCT01975363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166330|NCT02229188|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34166331|NCT05523336|||CASE_CONTROL||PROSPECTIVE|||||||
34166332|NCT05759897|RANDOMIZED|PARALLEL||OTHER||DOUBLE||HRS-7535 tablet compared with placebo|t|f|t|f
34166333|NCT04560933|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33893488|NCT05167201|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pre and post intervention study||||
33893489|NCT04265391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893490|NCT02478684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166334|NCT05570266|||CASE_CONTROL||PROSPECTIVE|||||||
34166335|NCT01620229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166336|NCT00302341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166337|NCT06262386|NA|SINGLE_GROUP||OTHER||NONE||||||
33853879|NCT06161168|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|Assessors will be trained on practice videos prior to establish consistent scoring practices. Additionally, assessors will be blinded to the time point at which the video recording was collected. Lastly, blinded therapists will observe gameplay videos collected at the beginning and towards the end of the intervention to identify movements made, any compensatory movements observed, repetition counts, fatigue level, as well the child's overall coordination (i.e. the smooth and controlled use of movements in motor performance with consideration of timing, velocity, targeting accuracy, motor planning, directions, force and endurance).|This is a 17 week mixed methods study with a non-blinded, randomized, multiple baseline single-case experimental design (SCED) to answer the secondary research question. The research design has two phases: a baseline phase (A) wherein a representative baseline will be established through repeated measurements of the PQRS, followed by the Bootle Blast intervention phase (B). In a randomized, multiple baseline SCED, the start of the B phase is randomized to mitigate threats to internal validity. A minimum of 3 measurements is required in each phase. In this study, participants will be randomly allocated to a baseline A phase ranging from 10 to 21 days. The B Phase will be 8 weeks followed by a second 3 week A phase. Families will retain Bootle Blast at home and will have the option to continue use of Bootle Blast in weeks 15 to 17 as desired.||||
33853880|NCT01213160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853881|NCT05431985|||COHORT||CROSS_SECTIONAL|||||||
33853882|NCT02866539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853883|NCT01856556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853884|NCT03738345|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be masked by the flow setting||t|f|f|f
33853885|NCT04043689|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33853886|NCT01589237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853887|NCT02838771|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33853888|NCT01513980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33853889|NCT00770341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853890|NCT05077657|||CASE_ONLY||PROSPECTIVE|||||||
33853891|NCT04719325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853892|NCT04538651|||COHORT||CROSS_SECTIONAL|||||||
33853893|NCT06067568|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33853894|NCT01548560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853895|NCT00888004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853896|NCT05202548|||CASE_ONLY||OTHER|||||||
33853897|NCT00000301|RANDOMIZED|||TREATMENT||DOUBLE||||||
33853898|NCT02285465|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33853899|NCT04499820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853900|NCT05448781|NA|SINGLE_GROUP||TREATMENT||NONE||endostatin combined with PD-1 antibody and platinum-containing two-drug chemotherapy||||
33853901|NCT05350631|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33853902|NCT00001092|||COHORT||PROSPECTIVE|||||||
34061267|NCT03077659|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose rising, Phase IIa trial. The study will include a dose escalation phase and a dose confirmation phase. In the dose escalation phase, NanoPac® concentrations of 6, 10, and 15 mg/mL in an injection volume of 20% of the lobe of the prostate containing the dominant lesion will be studied in cohorts of 3, with cohorts enrolled sequentially starting at the lowest concentration. Following DSMB review of the cohort data the next cohort may begin enrolling, or an additional 3 at the current dose may be enrolled, or if the first dose does not provide adequate safety and tolerability the study may be halted. The dose determined to be the most suitable for further evaluation, defined as the highest dose with an acceptable safety and tolerability profile as determined by the DSMB, will enroll additional subjects (dose confirmation phase) to provide a cohort of 12 subjects at that dose level.||||
34076602|NCT01945944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076603|NCT05255094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076604|NCT03513666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076605|NCT00678015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076606|NCT04635397|||COHORT||PROSPECTIVE|||||||
34076607|NCT02576262|||OTHER||PROSPECTIVE|||||||
34076608|NCT01131559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166338|NCT03353844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166339|NCT02621307|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34166340|NCT05128201|NA|SINGLE_GROUP||TREATMENT||NONE||System chemotherapy (Camrelizumab , Gemcitabine and cisplatin or nedaplatin) And local consolidative radiotherapy for all metastatic lesion, and Maintenance of Camrelizumab||||
34166341|NCT06284850|||COHORT||PROSPECTIVE|||||||
34166342|NCT03212118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166343|NCT00431626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33853903|NCT06414187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Given the nature of percutaneous IABP support a double-blind trial design is not feasible. Therefore, this trial is an open-label randomized clinical trial indicating both the patient, treating physicians as well as researchers are aware of the allocated treatment (i.e. with or without IABP). The Clinical Event Committee (CEC), responsible for adjudicating events belonging to e.g. the primary outcome, are blinded for the allocated treatment.|Patients enrolled in this trial will be 1:1 randomized to IABP support or standard of care (i.e. inotropes and/or vasopressors, but no IABP insertion). Patients will be stratified for ACS/non-ischemic etiology and stage B/stage C cardiogenic shock following stratification according to center.|t|t|t|f
33893491|NCT06422182|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893492|NCT00972608|||CASE_ONLY||PROSPECTIVE|||||||
33893493|NCT01617044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893494|NCT03599661|||COHORT||CROSS_SECTIONAL|||||||
34166344|NCT03225235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853904|NCT04950504|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||This study was designed as a multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects in Part B. However, the study was terminated for administrative reasons prior to the completion of the first Cohort in Part A.|t|t|t|t
33957498|NCT02417207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33957499|NCT03542253|||OTHER||OTHER|||||||
33853905|NCT04390022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.|t|f|t|f
34166345|NCT02241564|||CASE_ONLY||PROSPECTIVE|||||||
34166346|NCT05717816|||CASE_ONLY||PROSPECTIVE|||||||
34166347|NCT05206149|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34166348|NCT05546775|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166349|NCT00051493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853906|NCT02637973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166350|NCT00949507|||COHORT||PROSPECTIVE|||||||
33853907|NCT06050187|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33853908|NCT06382025|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33853909|NCT02443090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853910|NCT03371381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853911|NCT00023296||||TREATMENT||||||||
33957500|NCT04160416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957501|NCT04059484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957502|NCT05992285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853912|NCT02011087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853913|NCT00536783|||||PROSPECTIVE|||||||
33853914|NCT02667977|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|t|f|f
33853915|NCT02770456|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33853916|NCT04954261|||COHORT||PROSPECTIVE|||||||
33957503|NCT04526379|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study consists of 2 parts. The first part compares 30 children with PWS compared to 30 control children without PWS. The second part will be based on 12 children with PWS who have undergone part 1.||||
34076609|NCT03049228|||COHORT||CROSS_SECTIONAL|||||||
34076610|NCT02415153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076611|NCT00576862|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076612|NCT03744637|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"In Part 1 (Panel A) of this study, a double-blinding technique will be used. MK-5475 and placebo will be packaged identically so that blind is maintained. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the intervention assignments.~Part 2 of this study is conducted as open label; therefore, the Sponsor, investigator, and participant will know the intervention administered."|Part 1 of the study will evaluate safety, tolerability, and pharmacokinetics in this population using a sequential study design. Review of available safety data up to 24 hours post dose of at least the first 4 participants must occur prior to escalating to the next dose level. A break to review PK data from Periods 1 and 2 will occur after completion of Period 2. Review of safety will occur after completion of Period 3 in all participants from Panel A, prior to initiation of Part 2. An optional break to review rolling PK data from Panel A Period 3 will be dependent upon exposures observed in Periods 1 and 2.|t|f|t|f
34076613|NCT01528410|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a single center, open-label trial.||||
34076614|NCT01747096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076615|NCT03113370|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind, placebo controlled|Parallel arm randomized, double-blind, placebo controlled trial|t|t|t|t
34076616|NCT03256019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076617|NCT06282094|||COHORT||PROSPECTIVE|||||||
34076618|NCT02364687|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076619|NCT00593450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34076620|NCT05438979|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding information will be held by the study sponsor, VDF FutureCeuticals, Inc. The study will be conducted in a double-blind fashion such that both the investigators and the participants are unaware of their assignment. Unblinding will only occur once the study has been completed.|Participants will be randomly assigned to one of two groups - calcium fructoborate (CFB) or placebo.|t|f|t|f
34076621|NCT00509899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076622|NCT00234026||||TREATMENT||NONE||||||
34076623|NCT04559477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076624|NCT04501484|NA|SINGLE_GROUP||TREATMENT||NONE|All assessments filmed on video and scored by a blinded evaluator.|||||
34076625|NCT00002314||||TREATMENT||NONE||||||
34076626|NCT01570140|||COHORT||PROSPECTIVE|||||||
34076627|NCT00929994|||COHORT||PROSPECTIVE|||||||
34076628|NCT00000887||||TREATMENT||||||||
34076629|NCT05231889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34076630|NCT01724177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076631|NCT03461458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076632|NCT06133140|||COHORT||OTHER|||||||
34076633|NCT06314217|NA|SINGLE_GROUP||OTHER||NONE||Everads Injector: For targeted suprachoroidal delivery of therapy||||
34076634|NCT06392464|||CASE_CONTROL||RETROSPECTIVE|||||||
34076635|NCT01999647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34076636|NCT03327389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|participants, investicator, outcome assessors will be blinded for group allocation.|"1. Dexmedetomidine group~2. Control group"|t|f|t|t
34076637|NCT03361241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded (outcomes assessor)|Parallel Assignment|f|f|f|t
34076638|NCT01820247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076639|NCT04997876|||OTHER||RETROSPECTIVE|||||||
34166351|NCT05639231|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Complete blinding is difficult due to the nature of the intervention and the design (cluster randomization).~To preserve blinding as much as possible, several strategies have been set.~At the cluster level (healthcare professional intervention): Since rotation across wards happens at the physician level, but is rare at the level of the nursing staff, the healthcare professional intervention targets mostly nurses. The healthcare professionals will be informed to avoid speaking about the intervention with colleagues of other wards.~At the patient level, differential information for candidates for the intervention or for the control group (the randomization group is known when first approaching candidates for participation because of the cluster design) will be provided. Candidates for the control group will receive only partial information without explaining the intervention. They will be informed orally at the end of the study about all aspects of the study."|"In a first phase, the intervention will be pilot-tested in one ward of each hospital (no comparison group).~In a second phase, it will be tested in a parallel design (cluster randomized controlled trial)."|t|t|f|t
34166352|NCT01900158||SEQUENTIAL||TREATMENT||NONE||Phase I Dose escalation study With 4 cohorts of different doses of light and fimaporfin (Dose Escalation) plus and additional cohort With one repeated treatment of the dose selected for one treatment (Extended).||||
34166353|NCT06528158|||OTHER||PROSPECTIVE|||||||
34166354|NCT01128049|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166355|NCT03008161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166356|NCT05083429|||COHORT||RETROSPECTIVE|||||||
34166357|NCT01751009|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34166358|NCT00527176|||DEFINED_POPULATION||PROSPECTIVE|||||||
34166359|NCT01648634|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34166360|NCT05845086|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34166361|NCT04097366|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166362|NCT02374151|||CASE_ONLY||PROSPECTIVE|||||||
34166363|NCT06005181|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Parents/participants will be masked to which condition is active/passive. The outcomes assessor will be masked to condition.|This randomized cross-over design will employ two arms: music listening and piano training. Participants and outcomes assessor will be masked to which arm is active/passive.|t|f|f|t
33747710|NCT03174223|||CASE_CONTROL||RETROSPECTIVE|||||||
33747711|NCT05854472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|there is no masking in the study|||||
33747712|NCT01182220|||||PROSPECTIVE|||||||
33747713|NCT04723875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747714|NCT05660746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients newly diagnosed with Crohn's disease (ages 6-22 years inclusive) within the last 90 days AND starting infliximab||||
33747715|NCT06670820|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33747716|NCT03034148|NA|SINGLE_GROUP||SCREENING||NONE||||||
33747717|NCT01579708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747718|NCT04295564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747719|NCT02827877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166364|NCT02304523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747720|NCT05290558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. The randomization master list will be kept with the investigator and both patients and physician will be blinded to the treatment received.|This is a double-blinded randomised control trial. Participants will be randomised using block randomization by a pre-determined randomisation schedule generated by a biostatistician in block size of 4. Enrolment and assignment of intervention will be carried out by an investigator. The investigators will perform block randomization of the subjects in blocks of 4 in the ratio of 1:1 such that 2 will be assigned to treatment and 2 will be assigned to placebo.|t|t|f|f
33747721|NCT03704376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747722|NCT06669832|||COHORT||PROSPECTIVE|||||||
33747723|NCT05484674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747724|NCT06191913|||CASE_CONTROL||PROSPECTIVE|||||||
33747725|NCT02899208|||COHORT||PROSPECTIVE|||||||
33747726|NCT05294068|||COHORT||OTHER|||||||
33747727|NCT03497325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33747728|NCT03463902|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|participants, outcome assessors and raters are blinded. tDCS application is performed by an unblinded investigator|randomized, double-blind, cross-over trial of 5 tDCS protocols|t|t|f|t
33747729|NCT04728295|NA|SEQUENTIAL||TREATMENT||NONE||This is a bilateral study. Subjects will be treated on one side of the brain and will be allowed to receive treatment on the other side if eligible.||||
33747730|NCT00509847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747731|NCT02637297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33747732|NCT03310151|RANDOMIZED|PARALLEL||TREATMENT||NONE|As this is a small, education, non-funded project masking has not been possible|Randomised controlled trial with one control and one interventional group||||
33747733|NCT04989348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747734|NCT00690703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747735|NCT00991354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33747736|NCT04866316|||OTHER||PROSPECTIVE|||||||
33747737|NCT04926038|||CASE_CONTROL||PROSPECTIVE|||||||
33747738|NCT01507870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166365|NCT03416699|||CASE_ONLY||PROSPECTIVE|||||||
34166366|NCT01992588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33747739|NCT04390438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Clinical trial with 3 parallel groups; 2 experimental groups and 1 control group|t|f|t|t
33765657|NCT03748602|RANDOMIZED|PARALLEL||TREATMENT||NONE||"All patients diagnosed with NTOS refractory to conservative physiotherapy treatment (based on criteria produced by the reporting standards) and considered to benefit from TOD in a multidisciplinary TOS-consensus group are considered candidates for this study.~Patients will be randomized into surgery (TOD) versus conservative physiotherapy. The group randomised for conservative physiotherapy will be offered surgical therapy after 3 months if complaints persist."||||
33765658|NCT06339554|||COHORT||PROSPECTIVE|||||||
34166367|NCT03846050|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||"Participants are randomly assigned to 3 conditions, 2 active and one control condition. In the active conditions, participants will receive warning messages when their BAC reaches a set threshold that it is not safe for them to drive.~The two Active conditions differ in the timing of their onset of the intervention.~The control condition will not receive warning and will not report on their driving decision in the moment."|t|f|t|f
34166368|NCT01754974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166369|NCT02959593|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34166370|NCT01219309|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34166371|NCT03599791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding device|Multicentre, randomized, double-blind, active controlled, parallel group study|t|t|t|t
34166372|NCT02734693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166373|NCT00820469|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34166374|NCT01507688|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34166375|NCT04499937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166376|NCT03287999|||COHORT||PROSPECTIVE|||||||
34166377|NCT00210782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34166378|NCT06502496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"In order to limit biases linked to the absence of blinding and to potential patient preferences for one or other of the interventions, a consent to postponed information type of consent (Boter et al. 2003) will be used."|||||
34166379|NCT02768493|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34166380|NCT00900055|||COHORT||PROSPECTIVE|||||||
34166381|NCT03157375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166382|NCT00415285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166383|NCT01230463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166384|NCT02435004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166385|NCT04186767|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, unicentre, single group||||
34166386|NCT05802589|RANDOMIZED|PARALLEL||OTHER||SINGLE|Before surgery, patients were given a random number and all data were collected using this number. Group assignments were determined using simple randomization using the closed envelope technique. All data were collected blindly. The blocks were performed by the authors who did not play any role in data collection or analysis.|This study was designed as a randomized, double-blind, prospective efficacy study.|t|f|f|f
34166387|NCT06371105|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34166388|NCT01855412|||COHORT||PROSPECTIVE|||||||
34166389|NCT01835821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166390|NCT03471312|||CASE_ONLY||PROSPECTIVE|||||||
34166391|NCT01662323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34166392|NCT01657175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34166393|NCT02240966|||COHORT||CROSS_SECTIONAL|||||||
34166394|NCT01253291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166395|NCT02869399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166396|NCT05598281|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166397|NCT06110013|||COHORT||PROSPECTIVE|||||||
34166398|NCT00752193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34166399|NCT04325893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166400|NCT05293067|||COHORT||PROSPECTIVE|||||||
34166401|NCT02081157|||COHORT||PROSPECTIVE|||||||
34166402|NCT02864589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166403|NCT06152510|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166404|NCT05979675|||COHORT||PROSPECTIVE|||||||
34166405|NCT03553758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166406|NCT03202342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34166407|NCT01365286|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33765659|NCT01835600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33765660|NCT03381222|||COHORT||PROSPECTIVE|||||||
33765661|NCT03716544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765662|NCT02088632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33765663|NCT06160752|NA|SEQUENTIAL||TREATMENT||NONE||||||
33765664|NCT06625853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765665|NCT02641457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765666|NCT06009640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765667|NCT06006923|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33765668|NCT06196125|||COHORT||PROSPECTIVE|||||||
33765669|NCT06619652|||OTHER||CROSS_SECTIONAL|||||||
33765670|NCT02970513|NA|SINGLE_GROUP||SCREENING||NONE||||||
33765671|NCT05396092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765672|NCT03055611|||COHORT||PROSPECTIVE|||||||
33765673|NCT04093921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those providing care at the PPRC will not know which study arm their patients were in.||f|t|f|f
33765674|NCT05120648|||CASE_ONLY||PROSPECTIVE|||||||
33765675|NCT04601714|||COHORT||PROSPECTIVE|||||||
33765676|NCT02579356|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765677|NCT06625281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be kept unaware of which group they will be allocated and type of the intervention they will receive, whereas the investigator will be aware regarding the allocation and type of the intervention given to the participants. Single blinding is used in this study.||t|f|f|f
33765678|NCT02122341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765679|NCT06400966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The population of the research consisted of 173 3rd grade students who participated in the Child Health and Disease Nursing practice in the 2022-2023 academic year.||||
33765680|NCT02176421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765681|NCT00896428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765682|NCT00633932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765683|NCT01041664|||COHORT||CROSS_SECTIONAL|||||||
33957504|NCT03542500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Under the supervision of Innovations for Poverty Action (IPA) Sierra Leone, local research assistants (blind to site and youth condition assignments) will conduct all screening, baseline, and follow up quantitative assessments. Ongoing data collection at all sites will include youth attendance and satisfaction with YRI content, counselor satisfaction with content and delivery via scales and qualitative exit interviews, as well as monitored audio-recording of all sessions for fidelity by an independent expert rater hired by CARITAS. The expert fidelity monitor will be a skilled YRI trainer and supervisor from our prior RCT and will not be a part of the CTA Seed Team, thus allowing them to provide impartial and blinded fidelity ratings of all audio-transcripts.|Hybrid Type 2 Effectiveness-Implementation Cluster Randomized three-arm trial|f|f|f|t
33957505|NCT04682210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957506|NCT04856917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957507|NCT03949283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study investigators will be kept blind to the schedule. All participants will be screened by the ChemoID drug response assay; however, the treating physician will receive the ChemoID results only for those participants who are randomized to receive ChemoID-guided treatment arm.|Parallel group randomized controlled clinical trial|t|t|t|t
33957508|NCT00263393|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34166408|NCT00759161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166409|NCT04437485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166410|NCT00143910|||COHORT||PROSPECTIVE|||||||
34166411|NCT04258878|||COHORT||PROSPECTIVE|||||||
34166412|NCT03218384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166413|NCT04918706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomisation (2:1) will allocate 30 patients to two treatment groups. The first group will receive either 2 x 10\^6/kg body weight MSC in a range of 1.5 x 10\^6 MSC/ kg to 2.5 x 10\^6 MSC/kg (at a maximum of 200 x10\^6 MSC per study participant) with 5% DMSO iv or placebo (consisting of a 5% DMSO-solution in isotonic solution) at week 4 and 3 before the second LVRS. The second group will receive either the same dose of 2 x 10\^6/kg body weight MSC iv or placebo at week 12 and 11 before the second LVRS.|t|t|t|t
34166414|NCT04050059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34166415|NCT03523494|||COHORT||CROSS_SECTIONAL|||||||
34166416|NCT02750852|||COHORT||CROSS_SECTIONAL|||||||
34166417|NCT00003815|RANDOMIZED|||TREATMENT||||||||
34166418|NCT05757648|NA|SINGLE_GROUP||TREATMENT||NONE|Participant and Care provider is blinded as to which side is buffered and which is non-buffered|Patients serve as their own control. One side of the mouth is buffered, one side is non-buffered||||
34166419|NCT06451627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765684|NCT03501043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765685|NCT02358798|NA|SINGLE_GROUP||OTHER||NONE||||||
33765686|NCT01052402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33765687|NCT06275425|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||a single-blinded randomized controlled trial|t|f|f|t
33765688|NCT01633151|||||PROSPECTIVE|||||||
33765689|NCT03417037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765690|NCT01077479|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33765691|NCT02074722|||OTHER||PROSPECTIVE|||||||
33765692|NCT03368157|||COHORT||PROSPECTIVE|||||||
33765693|NCT05401435|NA|SINGLE_GROUP||OTHER||NONE||Two measuring devices are active simultaneously during single measurement of blood pressure and heart rate on each participant. Measurements are repeated 2 times a day for 28 days. The functioning of two measuring devices is compared.||||
33765694|NCT01108458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765695|NCT01433640|||COHORT||PROSPECTIVE|||||||
33765696|NCT02810067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765697|NCT01110083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765698|NCT00345384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33765699|NCT04398615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.|||||
33765700|NCT06081335|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33765701|NCT04317014|||CASE_CONTROL||RETROSPECTIVE|||||||
33765702|NCT03207646|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized 1:1 to either the experimental arm or the 'no intervention' (control) arm.||||
33765703|NCT04779905|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33765704|NCT03607201|||OTHER||RETROSPECTIVE|||||||
33765705|NCT05344963|||COHORT||PROSPECTIVE|||||||
33765706|NCT05915728|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE||The site staff in charge of the preparation and administration of study intervention will be unblinded and will not be involved in any evaluation of safety and efficacy. The site staff in charge of conducting all other study procedures as per the schedule of activities (SoA) will remain blinded to the study intervention administered.|t|t|t|t
33765707|NCT01349894|||COHORT||OTHER|||||||
33765708|NCT05959421|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized non-blinded interventional trial Type of control: Randomized - Booster or no booster at 6 months||||
33765709|NCT01913158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765710|NCT06266663|||CASE_ONLY||CROSS_SECTIONAL|||||||
33765711|NCT03148977|||CASE_CONTROL||PROSPECTIVE|||||||
33765712|NCT06624904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double-blind|Parallel randomised experimental medicine trial.|t|f|t|t
33765713|NCT04426344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this study, the physicians will not be blinded to the randomization assignment, however participants will be blinded. Once a subject is randomized, the research team will receive the randomization assignment (core warming or standard of care) and proceed with the procedures per the assignment.|Randomized, single center pilot study|t|f|f|f
33765714|NCT00668499|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765715|NCT06311656|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33765716|NCT02539836|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33765717|NCT06493136|||COHORT||PROSPECTIVE|||||||
33765718|NCT04596033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166420|NCT01453140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853917|NCT00513643|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34166421|NCT01082250|RANDOMIZED|CROSSOVER||||NONE||||||
34166422|NCT06166940|||OTHER||RETROSPECTIVE|||||||
34166423|NCT05923840|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The investigators will compare results from female POTS patients, free of known pulmonary or sleep disorders aged 15 to 39 years with, and without orthostatic hyperpneic hypocapnia, to healthy female volunteers.||||
34166424|NCT00684996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166425|NCT03746327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166426|NCT02956343|||CASE_CONTROL||PROSPECTIVE|||||||
34166427|NCT00590187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765719|NCT03282279|||CASE_ONLY||RETROSPECTIVE|||||||
33765720|NCT02287350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853918|NCT05960617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853919|NCT00890487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33853920|NCT02192021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853921|NCT04878666|||COHORT||PROSPECTIVE|||||||
33853922|NCT05302388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the study period, the subjects and all personnel involved in the evaluation and analysis of the results were unaware of the actual grouping.|This is a phase I randomized, double-blind, placebo-controlled and dose-increasing single dosing study.|t|t|t|t
33853923|NCT03160508|||CASE_ONLY||PROSPECTIVE|||||||
33853924|NCT06319456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853925|NCT04320394|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Monocentric, Open-Label prospective study||||
33853926|NCT01597453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853927|NCT02637960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33853928|NCT05441709|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 1:1 to either standard lactation care or to standard lactation care plus clinically-integrated breastfeeding peer counseling||||
33853929|NCT02305537|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853930|NCT00207701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33853931|NCT01919814|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33853932|NCT02293915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166428|NCT00209859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33853933|NCT00810394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853934|NCT01251185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33853935|NCT05469984|RANDOMIZED|PARALLEL||PREVENTION||NONE||women with prolonged premature rupture of membrane\>18 h or women in preterm delivery will be randomized to receive one of two prophylactic antibiotic treatment||||
33853936|NCT01111747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33853937|NCT04644562|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33853938|NCT05004051|||COHORT||PROSPECTIVE|||||||
33957509|NCT06689592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957510|NCT00039572||||TREATMENT||||||||
33957511|NCT06133907|NA|SINGLE_GROUP||OTHER||NONE||||||
34166429|NCT03101566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166430|NCT00226824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166431|NCT05258136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166432|NCT01028417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166433|NCT05882812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853939|NCT05507905|RANDOMIZED|PARALLEL||PREVENTION||NONE||IGROOVE will randomize 160 participants meeting enrollment criteria in a 1:1:1:1 fashion to attend a music appreciation class or dance classes either 1x/week, 2x/week or 3x/week for 24 weeks.||||
33853940|NCT04773197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a three-arm, prospective randomized controlled trial with participants being randomly assigned into one of the three groups: (1) coach-assisted BtB intervention (treatment condition 1), (2) coach-assisted animated EMW (treatment condition 2), and (3) standard BtB (control group).||||
33853941|NCT01443715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33853942|NCT02695303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853943|NCT02345785|||COHORT||PROSPECTIVE|||||||
33853944|NCT00681785|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33853945|NCT03334136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized to high dose vitamin D (20.000 IU/week) versus placebo for 4 months.|t|t|t|t
33957512|NCT02310815|||CASE_ONLY||PROSPECTIVE|||||||
33957513|NCT01590537|||CASE_ONLY||PROSPECTIVE|||||||
33957514|NCT06650540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957515|NCT04454957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Nonrandomized controlled interventional study||||
33765721|NCT00266760|||COHORT||PROSPECTIVE|||||||
33765722|NCT02359643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765723|NCT02998021|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765724|NCT02784223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33853946|NCT00886496|NON_RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33853947|NCT06248385|||COHORT||PROSPECTIVE|||||||
34166434|NCT03433963|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34166435|NCT01867762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166436|NCT03159559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166437|NCT06301451|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is estimated that 180 subjects will be enrolled and randomly divided into the experimental group and the control group according to 2:1. During the observation period, the experimental group drink the hydrogen water prepared by the experimental equipment on the basis of the general dietary guidance, while the control group adopted the general dietary guidance. Every subject's diet and lifestyle remains largely unchanged during the treatment period.||||
34166438|NCT00351754|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34166439|NCT04807686|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34166440|NCT05200065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prospective randomized study comparing the two techniques with patient allocation using computer generated randomization.|Prospective randomized study comparing two techniques of endoscopic enucleation of the prostate.|t|f|f|f
34166441|NCT03160339|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34166442|NCT02383875|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33853948|NCT03527368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33853949|NCT05810987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment||||
34166443|NCT04528641|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Phase I, open-label, dose escalation, clinical trial to assess the safety and immunogenicity of the candidate GRAd-COV2 vaccine in 90 healthy volunteers aged 18-55 years and elderly volunteers aged 65-85 years. The vaccine will be administered intramuscularly once in time.||||
33853950|NCT05220384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853951|NCT04463017|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The study will be conducted in one phase: a single dose, dose escalation phase in up to 7 cohorts|t|t|t|t
33957516|NCT03750916|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib and Docetaxel||||
33957517|NCT00295529|RANDOMIZED|PARALLEL||||NONE||||||
34166444|NCT06268535|||COHORT||RETROSPECTIVE|||||||
34166445|NCT00883961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34166446|NCT01594320|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34166447|NCT02620982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166448|NCT05499377|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34166449|NCT00580723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166450|NCT04145882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166451|NCT04688359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants is informed of two groups but not which group he is allocated in.|2 groups one intervention group and one control group|t|f|f|f
34166452|NCT05712070|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34166453|NCT01156714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166454|NCT00966511|||COHORT||PROSPECTIVE|||||||
33853952|NCT05125666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853953|NCT02645955|||COHORT||PROSPECTIVE|||||||
33957518|NCT01319747|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957519|NCT03354416|||COHORT||OTHER|||||||
33957520|NCT02628418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957521|NCT00604734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957522|NCT06698614|||COHORT||PROSPECTIVE|||||||
33957523|NCT05290805|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33957524|NCT06354439|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the outcome and the interventions, blinding was not considered an issue.|Randomized clinical trial||||
33957525|NCT01776060|||COHORT||OTHER|||||||
33957526|NCT04180371|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957527|NCT04541433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957528|NCT03548454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33957529|NCT01257100|||CASE_CONTROL||OTHER|||||||
33957530|NCT06568614|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ⅰ clinical study in subjects with advanced malignancies and the trial includes two stages: dose-escalation stage and dose-expansion stage. The trial aim at evaluating the safety, tolerability, PK profile and preliminary anti-tumor activity of SYH2039 which could provide a basis of treatment for the subsequent study design.||||
33957531|NCT02791581|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957532|NCT01823250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957533|NCT06700889|||COHORT||PROSPECTIVE|||||||
33957534|NCT06474130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166455|NCT01787461|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34166456|NCT02354235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166457|NCT00463255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957535|NCT06489028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957536|NCT00771654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957537|NCT02558179|||COHORT||PROSPECTIVE|||||||
33957538|NCT04681807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the nature of the intervention, treatment administrators will not be able to remain blind to group assignment; however, assessment staff, investigators, and participants will be blind to group assignment. Assessment staff and investigators will never be involved in the randomization or treatment procedures.|Patients will be randomized to either 7 visits over a period of 1 month of an emotion recognition training condition or 7 visits over a period of one month of active control training condition.|t|f|t|t
33957539|NCT06701799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Clinical Trial|t|f|t|t
33853954|NCT04407871|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33853955|NCT03546322|||COHORT||PROSPECTIVE|||||||
33853956|NCT00552240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853957|NCT03433079|||CASE_ONLY||PROSPECTIVE|||||||
33853958|NCT03243877|||COHORT||PROSPECTIVE|||||||
33853959|NCT00561054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853960|NCT00190411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853961|NCT01952223|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33957540|NCT02937285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957541|NCT01398449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957542|NCT06123975|||COHORT||PROSPECTIVE|||||||
33957543|NCT01248130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166458|NCT00328341|||COHORT||PROSPECTIVE|||||||
34166459|NCT04709042|NA|SINGLE_GROUP||OTHER||NONE||||||
34166460|NCT03345329|||CASE_CONTROL||PROSPECTIVE|||||||
34166461|NCT01011673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166462|NCT05435664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|There was no blinding due to the nature of the progressive relaxation exercise.|Randomized controlled||||
34166463|NCT02282280|||COHORT||PROSPECTIVE|||||||
34166464|NCT02582645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166465|NCT03380897|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE|Open Label|Factorial assignment||||
34166466|NCT04140396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166467|NCT03166696|||COHORT||PROSPECTIVE|||||||
34166468|NCT01425034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747740|NCT06038565|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Given the nature of CPAP, it is not possible to mask which CPAP device the subject is supported by, but the participant, care provider, and outcomes assessor will be masked to whether the subject was randomized to arm A (the device the lung physiology assessment deemed superior for that subject) or arm B (random assignment to the CPAP device, not taking into account the subject's lung physiology).|Lung physiology measurements with electrical impedance tomography and esophageal manometry will be collected while the participant is supported with RAM cannula ventilator CPAP followed by occlusive interface ventilator CPAP followed by occlusive interface bubble CPAP. A 1:1 block randomization of either A) physiology-based CPAP or B) one size fits all CPAP of either RAM cannula ventilator CPAP or occlusive interface bubble CPAP will be assigned to the participant. Arm B is further randomized 1:1 to either RAM cannula ventilator CPAP or occlusive interface bubble CPAP. The duration of CPAP treatment will be compared between the two arms (precision medicine approach vs standard of care) as well as compare each device and whether the physiology data would have predicted the CPAP device would have resulted in a shorter treatment period.|t|t|f|t
33747741|NCT06647095|||COHORT||RETROSPECTIVE|||||||
33747742|NCT05149274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747743|NCT06669429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747744|NCT06139731|||COHORT||PROSPECTIVE|||||||
33747745|NCT04363801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747746|NCT02041195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747747|NCT03455972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853962|NCT02851927|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33853963|NCT00110110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853964|NCT04265313|||OTHER||PROSPECTIVE|||||||
33853965|NCT00815685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853966|NCT01372865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166469|NCT05189470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Healing is assessed on digital ulcer images by assessors that are blinded to treatment allocation. The digital images will be blinded by the primary investigator before delivery to the assessors. Data analysts will also be blinded to treatment allocation. It is not possible to blind participants or the staff that perform wound care and clinical assessment of healing because inforatios are visible in the wound bed after application.|Randomized clinical trial|f|f|f|t
34166470|NCT01328704|||COHORT||PROSPECTIVE|||||||
34166471|NCT04073186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166472|NCT02611479|||COHORT||PROSPECTIVE|||||||
34166473|NCT03636217|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34166474|NCT04564170|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166475|NCT02289677|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166476|NCT05266417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166477|NCT03064646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166478|NCT00251459||||TREATMENT||||||||
34166479|NCT04528160|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34166480|NCT00714844|||CASE_ONLY||RETROSPECTIVE|||||||
34166481|NCT01276262|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34166482|NCT01395732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166483|NCT02181114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34166484|NCT02545608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166485|NCT06097026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166486|NCT02907762|||COHORT||PROSPECTIVE|||||||
33747748|NCT03936686|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There were five participant groups evaluated based on age groupings. These groups were compared within group and against each other.||||
33747749|NCT01349569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853967|NCT04830397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853968|NCT03945825|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33853969|NCT00969410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853970|NCT02936167|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33853971|NCT00452062|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33853972|NCT04451538|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166487|NCT05315492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33957544|NCT06702189|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"We designed a randomized, sham-controlled, double-blind trial to demonstrate the improvement of pain, pain-related disability, quality of life, fatigue and mood in adult patients with chronic low back pain following a 2-week intervention of active versus sham EXOPULSE Mollii suit. A 2-week washout period should be enough to prevent a potential carry-over effect. After this phase (phase 1), a second open-label phase (phase 2) will be proposed for patients to understand the effects of the EXOPULSE Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.~Summary:~* Phase 1: randomized sham-controlled crossover study (active versus sham condition)~* Phase 2: Open-label study (active condition)"|t|f|t|t
33957545|NCT03568630|||COHORT||PROSPECTIVE|||||||
33957546|NCT04338646|||COHORT||PROSPECTIVE|||||||
34166488|NCT02688244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166489|NCT05247086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166490|NCT03725631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166491|NCT02627872|||COHORT||CROSS_SECTIONAL|||||||
33747750|NCT03131518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All participants in the intervention group (n=18) will complete the following intervention arms in random order: (i) 3 months access to an e-bicycle with trailer (n=6), (ii) 3 months access to a longtail bicycle (n=6), and (iii) 3 months access to a regular bicycle with trailer (n=6), in total 9 months. Also, a control group (n=18) maintaining usual transportation and PA habits will be included.||||
33747751|NCT03137511|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomization of MGs corresponding to their exercise sites||||
33747752|NCT03565445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747753|NCT03796988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747754|NCT05975281|||COHORT||CROSS_SECTIONAL|||||||
33853973|NCT06057675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Patient participants will be blinded to the study arm to which they belong. Additionally, the independent reviewer of postoperative photos will be blinded to the study arm to which patients belong. Participation will end at the 7-day follow up appointment, at which time data collection will cease and treatment group will be disclosed to participants.~Provisions for breaking blinding would include a rare thromboembolic event or anaphylactic event of unknown cause in the immediate postoperative period, or patient desire to terminate involvement in the study."|In this study, patients undergoing Mohs reconstruction of the nose with local flap techniques will be randomized to receive either standard of care (subcutaneous injection of local anesthetic, 1% lidocaine with 1:100,000 epinephrine) or TXA treatment (subcutaneous injection of local anesthetic, 1% lidocaine with 1:100,000 epinephrine and TXA 1g/10mL, in 9:1 volume ratio) pre-operatively. Outcomes will include intraoperative bleeding and postoperative swelling and bruising.|t|f|f|t
33957547|NCT04308382|||OTHER||PROSPECTIVE|||||||
34166492|NCT00150267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166493|NCT04538638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|There is no blinding to the treatment allocation for the treating surgeon. The treatment will be blinded for the treating gastroenterologist, the endoscopist and the participants.|Patients with Crohn's disease will be randomised in a 1:1 ratio for mesenteric sparing versus central mesenterectomy when performing an ileocolic resection for Crohn's disease|t|t|f|f
34166494|NCT04105049|||COHORT||PROSPECTIVE|||||||
34166495|NCT04618003|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166496|NCT01901406|||CASE_ONLY||PROSPECTIVE|||||||
34166497|NCT03485066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34166498|NCT02870283|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166499|NCT01101035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166500|NCT04113317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166501|NCT06173414|||OTHER||PROSPECTIVE|||||||
34166502|NCT01485159|||CASE_ONLY||CROSS_SECTIONAL|||||||
34166503|NCT03324243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166504|NCT00988884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166505|NCT01528930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166506|NCT03868033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957548|NCT05854745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The content of each arm of the study is the same and will be taught live by the same HBB instructors; the only difference is the teaching method.||||
34166507|NCT06393075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33957549|NCT04440631|||COHORT||PROSPECTIVE|||||||
34166508|NCT02023307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957550|NCT06362252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957551|NCT05828667|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled non-blinded prospective single-center study||||
33957552|NCT06418074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33957553|NCT05718557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957554|NCT04011111|||CASE_CONTROL||PROSPECTIVE|||||||
33957555|NCT01721200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33957556|NCT02049580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747755|NCT01478568||CROSSOVER||||NONE||||||
33747756|NCT00273117|||NATURAL_HISTORY||PROSPECTIVE|||||||
33747757|NCT02351557|||COHORT||PROSPECTIVE|||||||
33747758|NCT03108924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747759|NCT06634602|||OTHER||CROSS_SECTIONAL|||||||
33747760|NCT06465849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Two blinded, experienced, and calibrated dentists (who specialized in esthetic dentistry with more than 15 years of clinical practice), will perform the clinical evaluation. Patients will be also blinded to group assignment. An inter-examiner and inter-examiner agreement of at least 85% will be necessary before beginning the evaluation|"This is a four-arm, double-blind, randomized controlled clinical trial. Experimental group 1: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations using an universal adhesive (3M) on dentin etched for 5 seconds.~Experimental group 2: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations using an universal adhesive (Kulzer) on dentin etched for 5 seconds.~Control group 1: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations using an universal adhesive (3M) on dentin etched for 15 seconds.~Control group 2: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations using an universal adhesive (Kulzer) on dentin etched for 15 seconds.~LCNCs will be randomized to universal adhesive usage and etching time."|t|f|f|t
33747761|NCT05094323|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33747762|NCT04100746|||COHORT||PROSPECTIVE|||||||
33747763|NCT00375687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747764|NCT05134454|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||multicenter, national, investigator-initiated, randomized, parallel-group, register based superiority study||||
33747765|NCT03578874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747766|NCT01097967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747767|NCT00373594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747768|NCT05827068|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747769|NCT01047839|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747770|NCT01808157|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33747771|NCT04429490|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747772|NCT05330962|||OTHER||CROSS_SECTIONAL|||||||
33747773|NCT06670196|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a 1:1 ratio to one of two intervention groups.||||
33747774|NCT00197977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33747775|NCT06349369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33747776|NCT05967520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747777|NCT06667921|||COHORT||PROSPECTIVE|||||||
33747778|NCT06133894|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinded study|Randomized controlled trial of volunteers over 70 years of age|f|f|f|t
33957557|NCT06543095|||COHORT||PROSPECTIVE|||||||
33957558|NCT04668131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957559|NCT01405209|||COHORT||OTHER|||||||
34166509|NCT06206460|||COHORT||PROSPECTIVE|||||||
34166510|NCT04801758|NA|SINGLE_GROUP||OTHER||NONE||||||
34166511|NCT02483780|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34166512|NCT00503269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166513|NCT04220346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34166514|NCT04400058|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34166515|NCT01582620|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34166516|NCT02124213|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34166517|NCT05417737|||CASE_ONLY||PROSPECTIVE|||||||
34166518|NCT06156280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166519|NCT00295542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166520|NCT05627635|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34166521|NCT04862065|NA|SINGLE_GROUP||SCREENING||NONE||Evaluation of assay performance characteristics.||||
34166522|NCT02518971|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34166523|NCT03997526|||OTHER||PROSPECTIVE|||||||
34166524|NCT06023940|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Treatment group: 2 week high fiber diet Control group: no diet provided, subjects eat whatever they want|f|f|f|t
34166525|NCT06482151|||COHORT||CROSS_SECTIONAL|||||||
33853974|NCT04361942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both experimental and placebo groups will receive a similar endovenous injection with either cells or placebo, respectively. Blind to participant, investigator and care providers.||t|t|t|f
33853975|NCT01517646|NA|SINGLE_GROUP||OTHER||NONE||||||
33853976|NCT02238353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957560|NCT02660775|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33957561|NCT03603925|||CASE_CROSSOVER||PROSPECTIVE|||||||
33957562|NCT06568991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33853977|NCT03970460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957563|NCT00993629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33957564|NCT03649607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166526|NCT00624273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853978|NCT02268474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853979|NCT01548079|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33853980|NCT02526147|RANDOMIZED|PARALLEL||||NONE||||||
33853981|NCT02394392|||||PROSPECTIVE|||||||
33957565|NCT02417259|||COHORT||PROSPECTIVE|||||||
33957566|NCT03923907|RANDOMIZED|PARALLEL||TREATMENT||NONE|The statistician will be masked|||||
33957567|NCT06703762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957568|NCT00541944|||COHORT||PROSPECTIVE|||||||
33957569|NCT06702514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33957570|NCT06283290|||OTHER||CROSS_SECTIONAL|||||||
33957571|NCT05004181|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957572|NCT05996523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957573|NCT04393831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial comparing Retzius sparing robot-assisted radical prostatectomy versus conventional robot-assisted radical prostatectomy|f|f|f|t
33957574|NCT04074356|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33957575|NCT06702462|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Click here to enter text.||t|f|t|f
33957576|NCT00700037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957577|NCT06216080|||COHORT||PROSPECTIVE|||||||
33957578|NCT04130009|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is comparative study between two groups one treated by Total knee with tourniquet and other group without tourniquet||||
33957579|NCT03666299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957580|NCT04038255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957581|NCT04798274|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33957582|NCT06653244|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The patients will be randomized in a 1:1:1 ratio, (group Mi) midazolam (administered intravenously at a dosage of 1 mg, up to a maximum dose of 3 mg) \[14\], \[15\],(group Mo) morphine (administered intravenously at a dosage of 2-4 mg, up to a maximum dose of 8 mg \[14\], \[15\],(group Dex.) dexmedetomidine ( administered intravenously, Load: 0.25 mcg/kg IV over 10 minutes , Maintenance 0.2-0.7 mcg/kg/hr continuous IV 7 infusion according to haemodynamics and sedation score of patient ; not to exceed 24 hr|t|f|t|f
33957583|NCT05531799|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33957584|NCT01504789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33957585|NCT00717158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33957586|NCT00230217|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957587|NCT01825499|||COHORT||PROSPECTIVE|||||||
33957588|NCT03787771|||COHORT||OTHER|||||||
33957589|NCT01261650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957590|NCT04188860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957591|NCT01062100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957592|NCT03147040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957593|NCT04826952|||CASE_ONLY||RETROSPECTIVE|||||||
33957594|NCT06701786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Clinical Trial|t|f|t|f
33957595|NCT06702891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957596|NCT01365741|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166527|NCT00998465|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166528|NCT01740713|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34166529|NCT01802008|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166530|NCT01963195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166531|NCT02348125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166532|NCT01955993|||COHORT||PROSPECTIVE|||||||
34166533|NCT00894140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166534|NCT03530943|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants remained unaware of their treatment allocation until after completing the baseline (pretest) assessments and the onset of their intervention||t|f|f|f
34166535|NCT00583336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166536|NCT02662972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166537|NCT02690350|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single arm, three cohorts||||
33853982|NCT03742921|||COHORT||RETROSPECTIVE|||||||
33853983|NCT02790268|||CASE_ONLY||CROSS_SECTIONAL|||||||
33853984|NCT04885452|||COHORT||PROSPECTIVE|||||||
33853985|NCT04698642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33853986|NCT01466634|||||RETROSPECTIVE|||||||
33853987|NCT02154204|||COHORT||PROSPECTIVE|||||||
33853988|NCT01052922|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33853989|NCT02202005|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33853990|NCT01822236|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33957597|NCT06544265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957598|NCT05810961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957599|NCT02202902|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33957600|NCT06702787|||COHORT||PROSPECTIVE|||||||
33957601|NCT06242327|||CASE_ONLY||OTHER|||||||
33957602|NCT05836194|||OTHER||PROSPECTIVE|||||||
34166538|NCT04619615|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patient participants will be blind to which training modality their resident therapist has been randomized to.|This is a mixed-methods feasibility and acceptability study, with a single blind randomized controlled design comparing asynchronous self-directed digital IPT training to a synchronous large group online IPT workshop.|t|f|f|f
34166539|NCT06073613|||COHORT||CROSS_SECTIONAL|||||||
33853991|NCT05285930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33853992|NCT02594683|||COHORT||PROSPECTIVE|||||||
33853993|NCT00936546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853994|NCT05943223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Internal pilot study|t|t|t|t
33853995|NCT00775463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33853996|NCT01707225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33853997|NCT04433273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33853998|NCT00233870|||COHORT||PROSPECTIVE|||||||
33853999|NCT00596778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854000|NCT03407443|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33854001|NCT02764918|||COHORT||PROSPECTIVE|||||||
33957603|NCT00413465|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33957604|NCT03425331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957605|NCT04083274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, the investigator and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is erector spinae plane block group. The second one is sham block group|t|f|t|t
33957606|NCT01987843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957607|NCT06703294|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957608|NCT04064931|||COHORT||PROSPECTIVE|||||||
33957609|NCT04926467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957610|NCT01935557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957611|NCT01345058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957612|NCT06566183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957613|NCT04227769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Randomized, double-blinded and open-label, placebo-controlled, partly cross-over clinical trial||t|f|t|f
33957614|NCT05405478|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33957615|NCT01700335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957616|NCT05778227|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In this study the participants are coded and the outcome assessor is blinded|Four group assigned with interventions and one control group.|t|f|f|t
33957617|NCT05021120|NA|SINGLE_GROUP||TREATMENT||NONE|None (open Label)|Sequential Assignment||||
33957618|NCT03123120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061268|NCT05745467|RANDOMIZED|PARALLEL||PREVENTION||NONE||Sixty-two adult patients with acute SARS-CoV-2 infection undergoing surgery (elective, urgent or emergent) at the University of Iowa will be randomized 1:1 to each of two groups, 3M 5% povidone iodine (treatment) or usual care. Vaccination status will be recorded. Patients randomized to treatment will receive 2 doses of 3M 5% nasal povidone iodine preoperatively given that this dose is commonly used to prevent surgical site infections.7 The first dose will occur prior to induction of anesthesia and the second dose will occur after induction of anesthesia and patient stabilization (in preoperative holding for elective patients or in the operating room for urgent/emergent surgery) but before incision and will involve application to each nares using 2 swabs per nares, 4 swabs per patient.||||
34061269|NCT01436864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061270|NCT03579628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061271|NCT02860117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061272|NCT06731465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The interventional study model used in this study is a two-arm, parallel-group, randomized controlled trial (RCT) with a 1:1 allocation ratio between two treatment arms: clear aligners and fixed braces. The study is structured to evaluate the treatment efficiency, efficacy and periodontal as well as occlusal parameters in participants treated with fixed labial braces or clear aligners for alignment of moderately crowded lower incisors. Block randomization is used to ensure an equal number of participants in each group, reducing potential imbalances in group size and baseline characteristics. Both groups will have regular progress checks every 4-6weeks, with adjustments or new aligners provided based on treatment progression.|f|f|f|t
34061273|NCT05057572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061274|NCT03724266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants should be blinded|postoperative pain after intervention|t|f|f|t
34061275|NCT03677934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061276|NCT04460534|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective monocentric, open-label, prospective study of male patients with CoV-2-SARS.||||
34061277|NCT04459598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061278|NCT01987232||SEQUENTIAL||TREATMENT||NONE||||||
34061279|NCT06611397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061280|NCT05005689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061281|NCT06339359|||COHORT||PROSPECTIVE|||||||
34061282|NCT02363985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34166540|NCT04208308|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Healthy and obese people in different age categories.|t|f|t|f
34166541|NCT03291483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166542|NCT02738749|NA|SINGLE_GROUP||OTHER||NONE||||||
34166543|NCT05561023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166544|NCT02586870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166545|NCT02781675|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34166546|NCT03276429|||COHORT||RETROSPECTIVE|||||||
34166547|NCT05077930|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized study design (1: 1), controlled trial, in hospitalized patients with COVID-19.||||
34166548|NCT05983471|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Interactive web response system (IWRS)||t|t|t|t
34166549|NCT03955614|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Surgical teams in participating departments will be observed whilst performing 25 cases as per their standard, in order to establish baseline measurements. Subsequently, the Gosurgery software will be introduced and 25 cases utilising the new technology will be assessed.||||
34166550|NCT02756338|||CASE_ONLY||PROSPECTIVE|||||||
34166551|NCT00086047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34166552|NCT06725771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166553|NCT05628142|NA|SINGLE_GROUP||OTHER||NONE||||||
34166554|NCT03240887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957619|NCT03253601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957620|NCT02804191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957621|NCT04699721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957622|NCT05264818|||CASE_CONTROL||PROSPECTIVE|||||||
33957623|NCT05851612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation and set up the ventilator as specified in the envelope. The study subjects and the resident assessing the outcome will be blinded to the study group.|Prospective, randomized, double blind study|t|f|f|t
33957624|NCT06700837|||COHORT||RETROSPECTIVE|||||||
33957625|NCT05552235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957626|NCT06153667|||COHORT||PROSPECTIVE|||||||
33957627|NCT03911739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957628|NCT06516549|RANDOMIZED|PARALLEL||OTHER||SINGLE|The analyst, or outcome assessor, will be masked in this clinical trial and will not know allocation status until analysis is complete.||f|f|f|t
33957629|NCT01426828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957630|NCT04219956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anesthetist is blinded to the arm of attribution||f|t|f|f
33957631|NCT00876109|NON_RANDOMIZED|||TREATMENT||NONE||||||
33957632|NCT03267316|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part I of the study is designed to define the Maximum Tolerated Dose/ Recommended Phase 2 Dose (MTD/RP2D) of CAN04 in subjects with relapsed or refractory Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Triple Negative Breast Cancer (TNBC) or Colorectal Cancer (CRC). \[Completed December 2018\]~Part II consists of seven treatment arms and aims to establish the safety and tolerability of CAN04 as monotherapy and in combination with the standard of care in subjects with NSCLC or PDAC, as well as to investigate early signs of efficacy \[Enrollment to all arms completed\]."||||
33957633|NCT06270537|||COHORT||PROSPECTIVE|||||||
33957634|NCT02095210|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957635|NCT05676164|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||A Multicenter, Prospective, Randomized Controlled Clinical Study|t|t|t|t
33957636|NCT02395094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33957637|NCT01906827|||CASE_CONTROL||PROSPECTIVE|||||||
33957638|NCT06703086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase three clinical trial with three intervention groups||||
33957639|NCT02444741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957640|NCT06540677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957641|NCT00605839|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33957642|NCT05500235|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparative effectiveness trial||||
33957643|NCT04278833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the type of corticosteroid (particulate or non-particulate) that they receive.|Single center, prospective, single blind, randomized controlled trial of hip, glenohumeral joint, biceps tendon, and subacromial bursa injections comparing the efficacy of particulate (triamcinolone, betamethasone) vs non-particulate (dexamethasone) steroids. Participants will be recruited at Stanford orthopedic and PM\&R clinics only after they have already opted for steroid injection as a part of their medical care. They will be randomized to receive either a particulate or non-particulate corticosteroid, then image-guided injection will be completed as per current clinic practice. Patients will follow up in clinic or via phone at 2 weeks, 3 months, and 6 months and will be asked their NRS score, functional questionnaires, other treatments they have tried, and for any side effects experienced. The treating physician may order repeat injections, medications, or refer to surgery, at their discretion. Up to three injections to the same structure are allowed during the study period.|t|f|f|f
33957644|NCT04918927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Phase IIA randomised, double-blind, placebo-controlled, interventional trial.|t|t|t|f
33957645|NCT06652269|||CASE_CONTROL||PROSPECTIVE|||||||
33957646|NCT00745680|||CASE_ONLY||PROSPECTIVE|||||||
33957647|NCT06494059|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33957648|NCT00865306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957649|NCT02467972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33957650|NCT06371079|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957651|NCT04518475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957652|NCT03943199|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33957653|NCT02549885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33957654|NCT00122148|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33957655|NCT06476171|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33957656|NCT06065514|||CASE_CONTROL||PROSPECTIVE|||||||
33957657|NCT06113783|RANDOMIZED|PARALLEL||TREATMENT||NONE||post-market, monocentre, randomized, controlled clinical investigation||||
34061283|NCT04911335|NA|SINGLE_GROUP||TREATMENT||NONE||Two-step design according to Simon's Optimum approach (1989). Overall sample = 77 evaluable cases (step1_26 cases; step2_51 cases). Parameters: P0 (minimum probability of response): 0.45; P1 (probability of optimal response): 0.60; Alpha: 5%; Power: 80%.||||
34061284|NCT06083844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061285|NCT05030675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061286|NCT06355089|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34061287|NCT05165199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061288|NCT03473327|||COHORT||PROSPECTIVE|||||||
34061289|NCT01448603|||COHORT||PROSPECTIVE|||||||
34061290|NCT05639010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061291|NCT01559376|||CASE_CONTROL||PROSPECTIVE|||||||
34061292|NCT06011954|||COHORT||PROSPECTIVE|||||||
34061293|NCT04992013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061294|NCT04684589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Half of participants to get tadalafil and half to get placebo.|t|f|t|f
34166555|NCT03067428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||double blind, randomized controlled trial|t|f|t|t
34166556|NCT06375070|||CASE_CONTROL||PROSPECTIVE|||||||
34166557|NCT01051687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166558|NCT01174771|||COHORT||CROSS_SECTIONAL|||||||
34166559|NCT00531258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166560|NCT02225093|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33854002|NCT06044974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data assessors: oral medicine co-worker and biochemist specialist, and statistician will all be blinded to the treatment of each patient; a triple-blinded clinical trial. Patients and primary clinician will not be blinded|Two groups suffering from myogenic Tempromandibular disorders. Each group will receive either photobiomodulation using ND-YAG laser or injection of epidermal growth factor intramuscular.|f|f|f|t
33854003|NCT06415006|||CASE_CONTROL||RETROSPECTIVE|||||||
33854004|NCT04466826|NA|SEQUENTIAL||TREATMENT||NONE||Open label, pre/post-treatment pilot study||||
33854005|NCT06001931|||CASE_ONLY||CROSS_SECTIONAL|||||||
33854006|NCT01719926|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33854007|NCT01767805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33854008|NCT06071260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854009|NCT02921308|||OTHER||CROSS_SECTIONAL|||||||
33747779|NCT02727894|||COHORT||PROSPECTIVE|||||||
33747780|NCT02485210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747781|NCT03033823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747782|NCT02669823|||CASE_ONLY||PROSPECTIVE|||||||
33747783|NCT01752504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33747784|NCT01478867|||COHORT||RETROSPECTIVE|||||||
33747785|NCT00808808|||||PROSPECTIVE|||||||
33747786|NCT03518177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel groups will be formed from patients with hospital-based pulmonary rehabilitation (Group 1) and those with home-based pulmonary rehabilitation(Group 2).||||
33747787|NCT06059716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747788|NCT04096079|||COHORT||RETROSPECTIVE|||||||
33747789|NCT03360253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Children allocated on different arms will receive drops of probiotics or placebo. Both product are identical in appearence and flavor|Randomized controlled trial, double blind allocation concealment|t|t|t|t
33854010|NCT00669526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854011|NCT02763787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854012|NCT02636179|||CASE_CONTROL||PROSPECTIVE|||||||
34061295|NCT03422159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized to receive either vitamin C/hydrocortisone/thiamine or triple placebo using a random number table provided to the dispensing pharmacists. Each patient will be allocated a unique subject ID which will be linked to the randomization sequence. Only the dispensing pharmacists will have a record of the subject ID and randomization sequence.|This is a double-blind placebo controlled study. Only the dispensing pharmacist will be aware of the treatment allocation. Patients will be randomized to receive either vitamin C/hydrocortisone/thiamine or triple placebo using a random number table provided to the dispensing pharmacists. Each patient will be allocated a unique subject ID which will be linked to the randomization sequence. Only the dispensing pharmacists will have a record of the subject ID and randomization sequence.|t|t|t|f
34061296|NCT05980143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061297|NCT02889120|||CASE_ONLY||PROSPECTIVE|||||||
34061298|NCT05854615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061299|NCT03380104|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects enrolled in this study will undergo Intradural Spinal Cord Stimulation.||||
34061300|NCT03003000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34061301|NCT02735707|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains||||
34061302|NCT03740776|||COHORT||PROSPECTIVE|||||||
34061303|NCT04089345|NA|SINGLE_GROUP||TREATMENT||NONE||open label pilot study||||
34166561|NCT00000526|RANDOMIZED|||PREVENTION||DOUBLE||||||
34166562|NCT02601404|||OTHER||PROSPECTIVE|||||||
34166563|NCT02053831|||CASE_ONLY||PROSPECTIVE|||||||
34166564|NCT03633851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166565|NCT00836589|||COHORT||PROSPECTIVE|||||||
34166566|NCT05336786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166567|NCT05402670|||CASE_CONTROL||PROSPECTIVE|||||||
34166568|NCT06089278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166569|NCT04540965|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Famotidine or Placebo for famotidine||t|t|t|t
34166570|NCT01683708|||CASE_CONTROL||PROSPECTIVE|||||||
34166571|NCT05549011|||COHORT||PROSPECTIVE|||||||
34166572|NCT02590731|||COHORT||PROSPECTIVE|||||||
34166573|NCT00756366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34166574|NCT02826343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166575|NCT00700440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166576|NCT03591926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166577|NCT02784795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854013|NCT04623970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854014|NCT04040504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, investigator and outcomes assessors will be blinded to the intervention. The endoscopist will not be blinded, since the type of scope and cap being used can be detected during the procedure.||t|f|t|t
33854015|NCT06204874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participant-blinded, placebo-controlled, single center prospective randomized clinical pilot trial.|t|f|f|f
33854016|NCT01189084|||COHORT||PROSPECTIVE|||||||
33854017|NCT01543126|||COHORT||PROSPECTIVE|||||||
33854018|NCT01210118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061304|NCT00881907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061305|NCT05537623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061306|NCT05180370|||COHORT||PROSPECTIVE|||||||
34061307|NCT02110030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061308|NCT01996657|||COHORT||PROSPECTIVE|||||||
34061309|NCT03837119|||COHORT||RETROSPECTIVE|||||||
34061310|NCT00980018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061311|NCT02980354|||CASE_CONTROL||PROSPECTIVE|||||||
34061312|NCT05026047|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34061313|NCT06300476|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34166578|NCT03984539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the beginning of client's appointments with the staff psychometrist, patients will be reminded of the study, provided information about the study and asked if to participate in the study. If interest is indicated, then the psychometrist will thoroughly review the letter of information with patients. If patients agree to participate and sign the consent form, study measures will be given. The psychometrist will then inform their assigned therapist that the client wishes to participate in the study. To ensure the psychometrist is not aware of randomization, Philip Masson (study PI) will randomize the client to one of the two interventions using the website random.org. Philip Masson will inform the therapist of the randomization, and the therapist will then proceed with the appropriate treatment intervention. The PI will then keep track of randomization assignment in a separate excel file that the psychometrist does not have access to.|This study is a randomized controlled trial comparing the efficacy of two outpatient psychological treatments for eating disorders that primarily differ in length. Investigators will use a longitudinal design that includes both interview and questionnaire measures to assess eating disorder symptoms and other mental health-related outcomes.|f|f|f|t
34166579|NCT02030522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061314|NCT03557476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061315|NCT01273714|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061316|NCT05032742|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061317|NCT00310076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061318|NCT06187961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061319|NCT06596317|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34061320|NCT04364113|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34061321|NCT03235115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34061322|NCT01122784|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34061323|NCT06385197|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A controlled-randomization dosing regimen administered to patients with MS and provided by a designated app. The treatment limitations of time interval is pre-defined according to approved therapeutic windows.||||
34061324|NCT04757233|NA|SINGLE_GROUP||OTHER||NONE||Pre-post pilot study||||
34061325|NCT03059121|||COHORT||PROSPECTIVE|||||||
34061326|NCT04572711|||COHORT||PROSPECTIVE|||||||
34061327|NCT03884816|||COHORT||PROSPECTIVE|||||||
34061328|NCT01036659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061329|NCT02771600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061330|NCT06182046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34061331|NCT04958902|NA|SINGLE_GROUP||OTHER||NONE||||||
34061332|NCT04306250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061333|NCT03684824|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061334|NCT05794009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor(s) will be blinded to the allocation of participants throughout the study. The name of the participants and the allocation will be removed from the assessment sheet.|Recruited participants from community centers will be randomly allocated into either an IVRE program or a home-based exercise program that is identical to the intervention group (control group) using computer-generated random numbers. This will be a single-blinded randomized controlled trial (RCT), where outcome assessor(s) will be blinded to the allocation of participants throughout the study. Participants will be informed of their allocated exercise protocols, and they will be advised not to disclose their allocated intervention to the assessor(s) or other participants.|f|f|f|t
34061335|NCT04705519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061336|NCT04068688|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Note the autism group will be the only group to receive intervention. The typically developing and developmental delay group will receive one baseline assessment, and no intervention. COVID-19 necessitated a pivot from in-person to telehealth coaching.||||
34061337|NCT05191667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061338|NCT04505449|||COHORT||RETROSPECTIVE|||||||
34061339|NCT04063657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061340|NCT01751581|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34061341|NCT01800019|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34061342|NCT05923411|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747790|NCT05449106|||COHORT||PROSPECTIVE|||||||
34061343|NCT03802565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957658|NCT04417127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Aim 1: Cluster randomized trial where 40 existing microfinance (MF) groups with n=900 members are randomized in a 1:1 ratio to receive either integrated community-based care (ICB) (Study Arm A) or standard care (Study Arm B). The ICB intervention will be delivered during regular MF group meetings monthly during trial months 1-6 and quarterly during months 7-18. The intervention will include (1) clinical teams visits with vital signs screening, consultations, medication distribution (ART and other chronic/acute medications), POC laboratory testing (creatinine, blood glucose, hemoglobin A1C, viral load); (2) peer support; (3) referrals to facilities as needed. Members of MF groups randomized to Study Arm B will continue to receive care at an AMPATH facility. Study Arm C will include n=300 participants who receive standard care at an AMPATH facility and are not involved in MF. Aim 2: Mediation analyses with n=50 trial participants. Aim 3: Cost-effectiveness analyses with n=5 budget staff.||||
33957659|NCT06439511|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"All participants will have heart rate measurement~1. by pulse oxymetry~2. by a smartphone application"||||
33957660|NCT01861730|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33957661|NCT05483673|||CASE_CROSSOVER||PROSPECTIVE|||||||
34166580|NCT00567853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166581|NCT04796597|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
34166582|NCT05864222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166583|NCT01966523|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34166584|NCT02982564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34166585|NCT02577692|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34166586|NCT05068258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166587|NCT03833869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166588|NCT05839171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166589|NCT02798939|||COHORT||PROSPECTIVE|||||||
34166590|NCT06499493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166591|NCT00002092||||TREATMENT||||||||
34166592|NCT04985721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166593|NCT00867516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166594|NCT06527118|RANDOMIZED|PARALLEL||OTHER||NONE||pretest-posttest, follow-up control group||||
34166595|NCT01681160|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34166596|NCT04681105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166597|NCT05991258|||COHORT||PROSPECTIVE|||||||
34166598|NCT03920254|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Long Term Safety (LTS)|t|t|t|t
34166599|NCT05775770|||COHORT||PROSPECTIVE|||||||
34166600|NCT00741052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166601|NCT03391661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166602|NCT04392817|NA|SINGLE_GROUP||TREATMENT||NONE||a quasi experimental study comparing pre to post therapy intervention in one group||||
34166603|NCT02420093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166604|NCT00003505||||TREATMENT||||||||
34166605|NCT05184530|||COHORT||RETROSPECTIVE|||||||
34166606|NCT00407186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166607|NCT02239159|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34166608|NCT02777775|||COHORT||PROSPECTIVE|||||||
34166609|NCT00498459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166610|NCT01721161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166611|NCT03333707|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34166612|NCT02848222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166613|NCT02447016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166614|NCT04958499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166615|NCT03784989|||OTHER||RETROSPECTIVE|||||||
34166616|NCT00880698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747791|NCT00574080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747792|NCT01367873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747793|NCT06143618|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33747794|NCT05013450|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33747795|NCT01615731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747796|NCT01515670|||COHORT||PROSPECTIVE|||||||
33747797|NCT03364205|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|There was no intervention in the control group which was in parallel.|Randomized Controlled Trials|f|f|t|f
33747798|NCT02988973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747799|NCT04531046|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, multicenter study||||
33747800|NCT06387901|||COHORT||PROSPECTIVE|||||||
33747801|NCT02698072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33747802|NCT00843167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747803|NCT02414893|||CASE_CONTROL||PROSPECTIVE|||||||
33747804|NCT01349075|||COHORT||PROSPECTIVE|||||||
33747805|NCT02814318|||CASE_CONTROL||PROSPECTIVE|||||||
33747806|NCT02215226|||CASE_CONTROL||PROSPECTIVE|||||||
33747807|NCT02815553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747808|NCT03780764|RANDOMIZED|PARALLEL||TREATMENT||NONE||A split mouth study design was applied for each patient. Two different fixed appliance brackets were used in the lower arch (self-ligating brackets on one side and conventional brackets on the other side of the same patients).||||
33747809|NCT06628921|||COHORT||PROSPECTIVE|||||||
34166617|NCT03041948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34166618|NCT06129643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166619|NCT01914640|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34166620|NCT01952886|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34166621|NCT02931019|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34166622|NCT05109780|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Patients will be informed of the condition they have been assigned to.|One condition||||
34166623|NCT04318769|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Participants are not blinded as they know which arm they are allocated too. Care providers and outcome assessors are blinded as the investigator runs the allocation sequence and outcomes are administered via survey weblink|Participants are allocated in a 2:1 fashion to arm 1: AFFIRM intervention; or arm 2: waitlisted control.|f|t|f|t
34166624|NCT05852080|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34166625|NCT05897008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Biological: CMAB007 Biological: Xolair #Omalizumab#|t|t|t|f
34166626|NCT00957879|RANDOMIZED|PARALLEL||||NONE||||||
33854019|NCT00738582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854020|NCT00418626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854021|NCT04278157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854022|NCT03300115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854023|NCT02777723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854024|NCT00900744|||COHORT||PROSPECTIVE|||||||
33854025|NCT02027220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854026|NCT02049164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854027|NCT00074971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854028|NCT03131583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854029|NCT03790319|||COHORT||PROSPECTIVE|||||||
33854030|NCT01990209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854031|NCT04256577|||CASE_CROSSOVER||PROSPECTIVE|||||||
33854032|NCT05127629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957662|NCT02629627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166627|NCT06466694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166628|NCT05557344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166629|NCT00067184|||COHORT||PROSPECTIVE|||||||
34166630|NCT02711124|||COHORT||PROSPECTIVE|||||||
34166631|NCT05456737|||COHORT||OTHER|||||||
34166632|NCT01290757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166633|NCT04983277|||CASE_ONLY||CROSS_SECTIONAL|||||||
34166634|NCT01078441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166635|NCT00141674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166636|NCT00497445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166637|NCT01775774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166638|NCT01569841|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166639|NCT01494792|||||PROSPECTIVE|||||||
34166640|NCT03415204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34166641|NCT00556998|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34166642|NCT03493295|||COHORT||PROSPECTIVE|||||||
34166643|NCT00991991|||||PROSPECTIVE|||||||
34166644|NCT00952458|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34166645|NCT00420862|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34166646|NCT05373446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747810|NCT06153173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061344|NCT00050817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747811|NCT03796624|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747812|NCT02975167|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33747813|NCT05461625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33747814|NCT05745077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747815|NCT01357967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747816|NCT02483169|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33747817|NCT06556927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33747818|NCT01643694|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33747819|NCT05707637|||COHORT||PROSPECTIVE|||||||
33747820|NCT00249236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33747821|NCT06485310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747822|NCT02496013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747823|NCT05266118|||COHORT||PROSPECTIVE|||||||
33747824|NCT01064037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747825|NCT02302729|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33747826|NCT03627481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747827|NCT05093231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747828|NCT01155544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747829|NCT03147248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 was open label.||t|t|t|t
33747830|NCT06015854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747831|NCT06209710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Intervention Group: Patients assigned to this group undergo a combination of Balloon Pulmonary Angioplasty (BPA) and Pulmonary Artery Denervation (PADN) alongside standard drug therapy.~Control Group: Patients in this group receive Balloon Pulmonary Angioplasty (BPA), Sham Pulmonary Denervation and standard drug therapy."|t|f|f|t
33747832|NCT04036175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747833|NCT04286373|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33747834|NCT05018611|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747835|NCT02532660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747836|NCT05411458|RANDOMIZED|PARALLEL||TREATMENT||NONE|An experimental study with a randomized controlled crossover design|||||
33747837|NCT05108233|||COHORT||PROSPECTIVE|||||||
33747838|NCT06034860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747839|NCT02462746|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747840|NCT06293729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747841|NCT01840540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747842|NCT06027268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747843|NCT06019234|||CASE_ONLY||RETROSPECTIVE|||||||
33747844|NCT06656299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and outcomes assessor wil be blinded|There are two groups for this study|t|f|f|t
33747845|NCT03987308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747846|NCT02605954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061345|NCT03542591|||OTHER||CROSS_SECTIONAL|||||||
34061346|NCT06190756|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Comparison of two groups : Control vs. Diabetes||||
34061347|NCT04505202|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061348|NCT00696202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061349|NCT01649310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34061350|NCT05040334|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"138 identical envelops, half of them filled with a label(Group 1) who are the Prophylactic antibiotic group with all instruction details, while the other half are labelled (group 2) who are the Placebo group with all instruction details. All envelops will be prepared by the investigator and sealed before starting enrollment. After enrollment, each participant will be allowed to choose one envelop to determine to which group she will be assigned."|Group 1;receiving antibiotic prophylaxis Group 2; Not receiving antibiotics|t|f|f|f
34061351|NCT03653091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34061352|NCT05243420|||OTHER||RETROSPECTIVE|||||||
34061353|NCT06731140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166647|NCT05508022|NA|SINGLE_GROUP||PREVENTION||NONE|"Blinding of the participants and the nursing researcher who delivered the intervention was not possible due to the nature of the intervention. Veri toplama sürecinde yanlılığı önlemek için; lavman işleminden önce ve sonra klinkte çalışan bağımsız bir gözlemci hemşire tarafından ölçekler uygulandı. Before data collection, randomization was performed by the statistician by coding the intervention and control groups as A and B. Analysis of the data was performed by a statistician to avoid bias in the evaluation of the data. After analyzing and interpreting the data during the statistical process, the codes of the intervention and control groups of the study were revealed. The statistician was blinded during the analysis of study data."|The research groups consisted of 106 (per group: 53) children who met the sample selection criteria. Children were randomly assigned to intervention and control groups. Assignment of children to groups was done by an independent statistician to ensure confidentiality and avoid bias. In this study, stratified randomization method was used to assign children to groups. In randomized controlled experimental studies, the number of cases in each group is required to be balanced and similar in terms of prognostic factors (such as age and gender). With the stratified randomization method, differences and undesirable situations between study groups are tried to be minimized. The permutation method is used to achieve this balance (Kahan ve ark., 2015). In this study, children were stratified according to age (6-9 and 10-12) and gender (female, male) variables.||||
34166648|NCT00108862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166649|NCT02186275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166650|NCT01726894|NA|SINGLE_GROUP||||NONE||||||
34166651|NCT00458380|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34166652|NCT00305435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166653|NCT02372578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166654|NCT00902681|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34166655|NCT01717872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166656|NCT04581226|||COHORT||PROSPECTIVE|||||||
34166657|NCT01172626|||CASE_ONLY||PROSPECTIVE|||||||
34166658|NCT05092672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover Assignment||||
34166659|NCT01064934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166660|NCT01683539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166661|NCT06527326|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34166662|NCT00421798|||CASE_CONTROL||PROSPECTIVE|||||||
34166663|NCT01105208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166664|NCT02911974|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34166665|NCT05084430|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Recurrent Newly Diagnosed||||
34166666|NCT00003279|RANDOMIZED|||TREATMENT||||||||
34166667|NCT01713959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166668|NCT02792231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166669|NCT02646631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166670|NCT00005952||||TREATMENT||||||||
34166671|NCT05424016|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, randomized, controlled trial with 2 parallel arms||||
34166672|NCT03883581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166673|NCT00704938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166674|NCT05094726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants|participants will divided into two equal groups , group A will receive photobiomodulation sessions and group B will receive placebo photobiomodulation|t|f|f|f
34166675|NCT01149928|||COHORT||CROSS_SECTIONAL|||||||
34166676|NCT03501472|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34166677|NCT02727218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33747847|NCT02765529|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747848|NCT06101693|||COHORT||PROSPECTIVE|||||||
33747849|NCT00001651|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||\[6,6-2H2\]-glucose will be administered as a continuous IV infusion for one to five days. Blood (approximately 30-50 ml) will be drawn every one to three days during the infusion to obtain cells for analysis. In addition, serum glucose will be checked every two to three days. Following completion of the infusion, blood may be drawn daily for the first week, and then twice weekly for an additional 3 weeks, and then weekly to monthly.||||
33747850|NCT05579860|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33747851|NCT04863066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747852|NCT06189417|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All clusters of study participants will be geographically isolated, and ensuring that intervention and control groups are not exposed to each other. Study participants, HEW and HDA, will be blinded to the outcome interest of the study to avoid the hawthorn effect.|Upon completion of the baseline data collection for both groups, a total of 28 clusters/villages will be selected, each involving a maximum of 20 study participants. These clusters will be evenly distributed, with 14 clusters assigned to the intervention group and 14 clusters allocated to the control group. The HEW-led club-based intervention will be integrated into the health extension package. The intervention will take place once a week during club meetings, lasting approximately 50 minutes for six months. Across all clusters or villages, the intervention group will receive 14 educational sessions within a week.|t|t|f|t
33747853|NCT03736434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data collectors masked as to the hypotheses of the study.|Three aim randomized controlled trial|t|t|f|f
33747854|NCT06426641|||COHORT||PROSPECTIVE|||||||
33747855|NCT05601973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747856|NCT02393794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747857|NCT02322957|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747858|NCT01754831|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33747859|NCT06100042|||COHORT||PROSPECTIVE|||||||
34166678|NCT03217955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomisation is coordinated a staff member of the psychosis department who is not involved in the research team and not familiar with both the assessments or intervention procedure. The results of the randomization is concealed from the assessors. Every effort has been made to keep assessors blind to treatment condition, using the following strategies: research workers were not involved in the randomization process, therapists and research workers made use of different (secured) agendas, and work locations / rooms in order tot minimize the chance of potential blind breaks; patients will be frequently reminded by assessors not to talk about treatment allocation.|"The present study entails a single-blind two-level RCT directed at patients with recent onset schizophrenia. Participants are randomly assigned to intervention condition (Cognitive Behavioral Therapy- Social Activation (CBTsa) plus Standard Treatment (ST)), or to the control condition (ST alone).~A baseline test battery is employed to examine causes of social withdrawal and interaction with treatment outcome. Follow-up assessments (repetition test battery) will take place directly after the intervention period and 6 months post-treatment."|t|f|t|t
34166679|NCT04374461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-institution study that will be open at MSKCC's Manhattan campus. Patients will be enrolled into 2 separate arms. The mechanically ventilated \&/or managed in a critical-care arm is closed to accrual as of September 2020.||||
34166680|NCT01061359|||||PROSPECTIVE|||||||
34166681|NCT03351517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166682|NCT06061822|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33747860|NCT05312775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33854033|NCT05423886|RANDOMIZED|PARALLEL||SCREENING||NONE||The intervention arm receives their screening invitation within 1,2 or 3 years, depending on their previous fecal Hemoglobin concentration. The control arm receives their screening invitation in 2 years (current practice).||||
33854034|NCT00722930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854035|NCT05249829|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Phase A of this study will be observer-blinded. Phase B of the study will be open-label and blinding is not applicable|t|t|t|t
33854036|NCT02256137|||COHORT||PROSPECTIVE|||||||
33854037|NCT02995577|||CASE_CONTROL||PROSPECTIVE|||||||
33854038|NCT01768117|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33854039|NCT01097382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854040|NCT05764993|RANDOMIZED|PARALLEL||PREVENTION||NONE||non-blinded, randomized study. Patients with COPD will be referred for evaluation by outpatient pulmonary clinics at Rochester Regional health. Following informed consent all patients will be evaluated by checking serum IgG, IgM, and IgA, as well as baseline and post-vaccine IgG to peptides antigens (diphtheria and tetanus) with Td as well as polysaccharide antigens (streptococcus pneumoniae) with pneumococcus polyvalent vaccine-23 (PPV23). Patients with COPD and pre-defined humoral dysfunction (please see below) will be randomized in 1:1 ratio to one of two groups until approximately 20 patients per group are accrued for a total of 40 patients||||
33854041|NCT02120131|||CASE_CONTROL||RETROSPECTIVE|||||||
33854042|NCT00002570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854043|NCT02619149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854044|NCT02976701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854045|NCT06107725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Outcome assessors will contact and obtain primary outcome measures of mRS without the knowledge of participants group assignment/treatment received.|Randomized, open label study|t|t|t|t
33854046|NCT01362660|||||PROSPECTIVE|||||||
33854047|NCT01007448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854048|NCT03720743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854049|NCT00912691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854050|NCT02520284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854051|NCT06382454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854052|NCT02717403|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854053|NCT01847469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854054|NCT06352164|NA|SINGLE_GROUP||SCREENING||NONE||||||
33854055|NCT05898256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854056|NCT03963531|||COHORT||PROSPECTIVE|||||||
33854057|NCT03720054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854058|NCT00680680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854059|NCT01597141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854060|NCT00666523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854061|NCT05039528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A 2-month pre-post pilot study will be conducted. Two worksites will be selected at random then randomized to either the tailored (intervention) or non-tailored (control) groups. Participants who fit the eligibility criteria will be recruited from each worksite and assigned to the study arm corresponding to their worksite (20 per worksite for a total of 40 participants).|t|f|f|f
33747861|NCT03069482|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned to one of two smoking cessation apps for the duration of the study: Learn to Quit or NCI QuitGuide. One app was designed to address the needs of people with serious mental illness (Learn to Quit) and the other was designed for the general population (NCI QuitGuide).||||
33957663|NCT00159367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747862|NCT05583591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957664|NCT01870752|NA|SINGLE_GROUP||TREATMENT||NONE||Thaw and surgical transplantation of previously collected cryopreserved ovarian cortical tissue||||
33747863|NCT03495050|||COHORT||PROSPECTIVE|||||||
33957665|NCT02181049|||COHORT||OTHER|||||||
34166683|NCT01592071|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34166684|NCT04590807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166685|NCT04851912|||COHORT||PROSPECTIVE|||||||
34166686|NCT03530397|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34166687|NCT05134558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166688|NCT03781661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental randomized controlled trial||||
34166689|NCT01603303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166690|NCT03642418|||COHORT||PROSPECTIVE|||||||
34166691|NCT04669808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Participants in the first cohort will attend the study center once weekly for an injection of STP705 into the BCC lesion. The participants will receive injections of STP705 once a week for 6 weeks. The clinician will evaluate the change in tumor size at each treatment visit. At the End of Treatment visit, the residual tumor, or former tumor location, will be excised for analysis.~In the absence of dose limiting toxicities (DLT), the subsequent cohorts will receive increasing doses of STP705, following the same schedule of administration as the first cohort."||||
34166692|NCT01618669|RANDOMIZED|PARALLEL||||NONE||||||
33747864|NCT02742168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The participants were underwent the 99mTc-3PRGD2 imaging and 18F-FDG imaging within one week.||||
33747865|NCT04158947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957666|NCT05932407|||COHORT||RETROSPECTIVE|||||||
34166693|NCT02921659|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34166694|NCT00003425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166695|NCT01555372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166696|NCT06409065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166697|NCT00327106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166698|NCT04079426|||OTHER||PROSPECTIVE|||||||
33747866|NCT03291574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747867|NCT05250596|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to Colchicine plus standard treatment with Atorvastatin or only standard treatment with Atorvastatin||||
33854062|NCT02301715|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33854063|NCT03854045|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Nonequivalent pre-post||||
33854064|NCT01605292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854065|NCT02939170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854066|NCT04513184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multicenter, randomized, controlled trial adult patients with confirmed COVID-19 infection|t|t|f|f
33957667|NCT05027425|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, Phase II, multicenter clinical trial||||
33957668|NCT06291857|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33957669|NCT06702436|||COHORT||RETROSPECTIVE|||||||
34166699|NCT03111836|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34166700|NCT05437523|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Toilet-trained children aged four years and older were enrolled if they were evaluated in our institution's pediatric gastroenterology clinic and were diagnosed with functional constipation based on the ROME IV criteria.~Children were excluded if they were expected to have alternative ROME IV diagnoses (e.g., irritable bowel syndrome), or if an alternative etiology was suspected to be a cause of their constipation.~Subjects were then block randomized to either receive a constipation action plan or the standard of care (control)"||||
34166701|NCT05665894|||OTHER||RETROSPECTIVE|||||||
34166702|NCT04802772|||COHORT||RETROSPECTIVE|||||||
34166703|NCT04899622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166704|NCT05491408|||COHORT||PROSPECTIVE|||||||
34166705|NCT03178435|RANDOMIZED|PARALLEL||PREVENTION||NONE||interventional cluster randomised trial -pilot /feasibility study||||
34166706|NCT02398240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166707|NCT04674007|||COHORT||CROSS_SECTIONAL|||||||
34166708|NCT02316080|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34166709|NCT00028847||||TREATMENT||||||||
34166710|NCT01242917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166711|NCT06330740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166712|NCT00254137|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166713|NCT05586919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166714|NCT00800566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166715|NCT04948047|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166716|NCT06362096|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34166717|NCT02490449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166718|NCT04934566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166719|NCT02029911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166720|NCT03997461|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166721|NCT04339816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Visually unrecognisable IP or placebo will be prepared by dedicated unblinded study pharmacist and handed over to care provider immediately before administration|Prospective, multi-centre, randomised, pragmatic, double blind trial|t|t|f|t
34166722|NCT02167529|||COHORT||PROSPECTIVE|||||||
34166723|NCT03715803|||COHORT||RETROSPECTIVE|||||||
34166724|NCT01220804|||CASE_CONTROL||PROSPECTIVE|||||||
34166725|NCT05513339|||COHORT||PROSPECTIVE|||||||
34166726|NCT03679065|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34166727|NCT04410094|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34166728|NCT05520632|||CASE_CONTROL||PROSPECTIVE|||||||
34166729|NCT02146794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166730|NCT03469466|||OTHER||PROSPECTIVE|||||||
34166731|NCT05771649|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Blinding of trial participants and care providers is not possible because of obvious differences between the interventions.|A non-randomized controlled trial of three groups is proposed, with pretest, posttest and two follow-ups at 1 and 3 months.|f|f|t|t
34166732|NCT02049099|||||RETROSPECTIVE|||||||
33747868|NCT06181162|NA|SINGLE_GROUP||PREVENTION||NONE||YoPA introduces teen-centred, evidence-informed co-creation to tackle the complex real-world challenge of unhealthy lifestyles and health inequalities. In urban environments in 'Minority World' countries (i.e., Denmark, the Netherlands) and 'Majority World' countries (i.e., Nigeria, South Africa), academic researchers will engage adolescents and other key stakeholders in local co-creation communities. Together with academic researchers and local stakeholders, adolescents will be central in 1) mapping the local system, including needs and opportunities; 2) tailoring interventions to the local context; 3) implementing, and 4) evaluating interventions guided by our novel SUPER-AIM framework assessing local Systems, User perspective, Participatory co-creation process, Reach, Effects, Adoption, Implementation, and Maintenance of interventions in an integrated manner.||||
34166733|NCT00547651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166734|NCT04924816|||COHORT||PROSPECTIVE|||||||
33747869|NCT01842139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166735|NCT05926934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166736|NCT02205671|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34166737|NCT01775371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166738|NCT05191693|||COHORT||RETROSPECTIVE|||||||
34166739|NCT04979364|||COHORT||PROSPECTIVE|||||||
34166740|NCT02346045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166741|NCT03479086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166742|NCT05377853|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple regression analyses with life history and vision-related clinical factors as covariates||||
34166743|NCT01828008|||CASE_CONTROL||PROSPECTIVE|||||||
34166744|NCT04001348|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33747870|NCT05989308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||JDAT will access EHR visit data for these offices to establish the child patient pool and identify guardians.||||
33747871|NCT06532214|||COHORT||RETROSPECTIVE|||||||
33747872|NCT03948776|||COHORT||PROSPECTIVE|||||||
33957670|NCT03350880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Clinical Trial|f|f|t|t
33957671|NCT03347929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166745|NCT01933308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34166746|NCT00965666|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34166747|NCT01425801|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34166748|NCT06410898|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34166749|NCT01272232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166750|NCT04645446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Allocation Ratio = 1:1:1|t|t|t|t
34166751|NCT05649007|||CASE_ONLY||PROSPECTIVE|||||||
34166752|NCT05716074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166753|NCT06313164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34166754|NCT04874935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34166755|NCT00931931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166756|NCT05672290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166757|NCT00825201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747873|NCT05440110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a prospective, randomized controlled clinical trial for the first two weeks, followed by an open-label trial for the next two weeks, and combined functional neuroimaging study of 18F-FDG-PET to further explore the potential mechanisms. A total of 20 SNAP dementia patients will be recruited for consecutive two years, and be subjected to iTBS for 5 daily interventions per week for four consecutive weeks. Cognitive evaluation will be performed before and immediately after TBS intervention, and 8 weeks after TBS. Data on functional neuroimaging will be also collected before and after TBS protocol.|t|t|t|t
33747874|NCT04250649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A standard block randomization strategy will be used. The ratio between intervention and control will be set at 2: 1. This will facilitate recruitment and provide more information on the effectiveness of the intervention. The randomization sequence will be created using the STATA program.|This is a single center, category A randomized clinical trial.|t|f|f|t
33747875|NCT04323852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|With the exception of the pharmacists, all the investigators, patients and the medical team were blinded to the group allocation.||t|t|t|t
34166758|NCT00154570|||DEFINED_POPULATION||OTHER|||||||
33747876|NCT06138977|NA|SINGLE_GROUP||OTHER||NONE||||||
33747877|NCT06401148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747878|NCT04899349|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747879|NCT00167544|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33747880|NCT06368245|||COHORT||RETROSPECTIVE|||||||
34166759|NCT00775099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33747881|NCT06635317|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"All patients who underwent a preoperative Doppler ultrasound of the lower extremities to screen for VTE and received antibiotic prophylaxis with cephalothin 1 gram intravenously.~At six hours post-surgery, patients in the aspirin group received enoxaparin, 40 mg/day subcutaneously for 3 days, and aspirin, 100 mg/day orally for 25 days. Patients in the enoxaparin group received enoxaparin, 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².~Additionally, all patients received pneumatic compression stockings postoperatively for at least 21 days as standard care.~Physical therapy was initiated on the day of surgery or postoperative day 1 and continued daily throughout the hospital stay.~Postoperative wound care and Doppler ultrasound evaluations were performed at two and four weeks postoperatively to detect any evidence of VTE."|t|f|f|f
33747882|NCT06372730|NA|SINGLE_GROUP||PREVENTION||NONE||Cohort study||||
33747883|NCT05205265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747884|NCT01560390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33747885|NCT04111445|NA|SEQUENTIAL||TREATMENT||NONE||||||
33747886|NCT06119633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747887|NCT00238823|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33747888|NCT04110808|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33747889|NCT02352311|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33747890|NCT00281541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747891|NCT01243138|||OTHER||CROSS_SECTIONAL|||||||
33747892|NCT01763931|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33747893|NCT05345015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Since each group is assigned into a different intervention, masking is not possible. Outcome measures will be recorded and they will be provided codes, to ensure masking of the outcomes assessors.|Participants are assigned to an electrical energy transfer (TECAR), a Transcutaneous Electrical Stimulation (TENS) or a control (CON) group in parallel for the duration of the study|f|f|f|t
33747894|NCT06351813|||COHORT||PROSPECTIVE|||||||
33747895|NCT06193876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747896|NCT00915642|||COHORT||PROSPECTIVE|||||||
34166760|NCT00469703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166761|NCT06060795|||COHORT||PROSPECTIVE|||||||
34166762|NCT04816084|NA|SINGLE_GROUP||SCREENING||NONE||||||
34166763|NCT05888675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166764|NCT01521130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166765|NCT04858828|||COHORT||PROSPECTIVE|||||||
33747897|NCT04706832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747898|NCT02576067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747899|NCT06434038|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blind|Participants will be randomized into one of 3 groups: 40 IU insulin, 80 IU insulin, or saline control.|t|f|f|f
33747900|NCT00303524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747901|NCT04704063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166766|NCT04724408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|device for intubation may not be blinded for provider or investigator|randomized 1:1|t|f|f|f
33747902|NCT02816580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061354|NCT00478114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061355|NCT02646384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061356|NCT02841566|||COHORT||PROSPECTIVE|||||||
34061357|NCT04668170|||COHORT||RETROSPECTIVE|||||||
34061358|NCT01186380|||CASE_ONLY||PROSPECTIVE|||||||
34061359|NCT02686658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Reading Center team and Sponsor were also masked.||t|f|t|f
34061360|NCT03295123|||CASE_ONLY||PROSPECTIVE|||||||
34061361|NCT06045442|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment in 1:1 ratio to either the intervention group (intradialytic exercise; twice a week for 30 min per dialysis session) or control group (Usual care)||||
34061362|NCT03219151|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34061363|NCT06019962|||COHORT||RETROSPECTIVE|||||||
34061364|NCT01542905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061365|NCT06242418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061366|NCT00722566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061367|NCT04800614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Three Period Crossover||||
34061368|NCT06133413|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparative, controlled, randomized 1:1, open, in two parallel arms study||||
34061369|NCT06536088|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34061370|NCT01463267|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34061371|NCT05106920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34166767|NCT00615017|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34166768|NCT05381363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166769|NCT05774639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be double blind study|This will be parallel study to compare efficacy, safety and immunogenicity of ADL-018 150 and 300 mg doses in comparison with US-licensed XOLAIR 150 and 300 mg|t|t|t|t
34166770|NCT02995980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166771|NCT00006474||||TREATMENT||||||||
34166772|NCT00037414|||COHORT||CROSS_SECTIONAL|||||||
34166773|NCT00506350|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166774|NCT01410513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166775|NCT05311735|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Test group I (mineralized tooth graft): extracted teeth will undergo the mineralization process according to the manufacture's guidelines. Procedure will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines)~* Test group II (partial-demineralized tooth graft): extracted teeth will be undergone to partial-demineralized process, according to the manufacture's guidelines. Procedures will be done in a specialized equipment for tooth graft preparation (Smart Dentin Grinder® (SDG) (KometaBio), and then sites will be grafted. Remaining graft will be stored appropriately for future grafting in the same patient (according to the guidelines).~* Control group (FDBA): extracted teeth will be discarded and sites will be grafted with FDBA."||||
34166776|NCT03609996|||OTHER||RETROSPECTIVE|||||||
34166777|NCT02043938|NA|SINGLE_GROUP||OTHER||NONE||||||
34166778|NCT06063044|||COHORT||RETROSPECTIVE|||||||
34166779|NCT05760859|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single-blind trial; participants not aware of the goal of the study|Participants were randomized (computer-generated numbers) to six versions of a simulated scenario of pulmonary embolism. The six versions differed only in the initial cues, i.e. in the reply of the patient to the initial question about the reason for his visit.|t|f|f|f
34166780|NCT02650765|||COHORT||PROSPECTIVE|||||||
34166781|NCT06194214|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34166782|NCT03951272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166783|NCT00021749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747903|NCT04327414|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Controlled trial:~December-January 2020: Recruitment of six secondary schools with immediate allocation to the intervention or control condition and collecting informed consents.~February 2020: Pre-test data collection, installing standing desks in intervention schools.~March 2020: Interruption of the study due to COVID-19 pandemic. September-October 2020: Recruitment of six new classes and collecting informed consents, pre-test data collection.~November-December 2020: Post-test data collection."||||
33747904|NCT02734212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors were blind with regards to participants condition||f|f|f|t
33747905|NCT01134900|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33747906|NCT02587351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747907|NCT03853629|||COHORT||PROSPECTIVE|||||||
33747908|NCT02477618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33747909|NCT00458328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33747910|NCT02742844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957672|NCT03451227|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Patients will be randomly allocated (computer generated) to receive either a dexmedetomidine infusion or a remifentanil infusion.~The patient, interventional cardiologist and data analyser will be blinded to the drugs given. The anaesthesia care provider will not be blinded"|This is a prospective, single blind, randomised controlled study looking at the feasibility of dexmedetomidine for sedation during ablation procedures at Toronto General Hospital.|t|t|f|f
33747911|NCT03881735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957673|NCT04954625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166784|NCT00027170|||COHORT||PROSPECTIVE|||||||
34166785|NCT01122602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166786|NCT03300557|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34166787|NCT01685567|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34166788|NCT02103491|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34166789|NCT02588326|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
34166790|NCT00155779|||NATURAL_HISTORY||OTHER|||||||
34166791|NCT00330603|||COHORT||PROSPECTIVE|||||||
34166792|NCT00182039|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34166793|NCT03919539|||CASE_ONLY||PROSPECTIVE|||||||
34166794|NCT06216067|||COHORT||PROSPECTIVE|||||||
34166795|NCT01125982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166796|NCT04623788|||COHORT||PROSPECTIVE|||||||
34166797|NCT04820244|||COHORT||PROSPECTIVE|||||||
34166798|NCT02810613|||OTHER||OTHER|||||||
34166799|NCT03354117|NA|SINGLE_GROUP||PREVENTION||NONE||Single, open-label trial of one-time dosing of ulipristal acetate and meloxicam at a peak fertility time point.||||
34166800|NCT05718856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166801|NCT00354380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957674|NCT03070327|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, dose escalating, nonrandomized, single-center, phase I study of EGFRt/BCMA-41BBz CAR T cells in patients with a diagnosis of MM. Dose escalation will follow a standard 3-by-3 escalation design. Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/BCMA-41BBz CAR T cells to establish the maximum tolerated dose (MTD). After a dose level has been determined safe to escalate (DLT in 0/3 or 1/6 patients), a parallel cohort at that dose level will be conducted while patients are taking Lenalidomide.||||
34166802|NCT05391035|||COHORT||PROSPECTIVE|||||||
34166803|NCT03512171|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant and the research analyst running their session are both blind, however a PET tech is unmasked who monitors the participant for any adverse reactions.|All subjects receive the same diagnositc intervention, with counterbalanced order|t|f|t|f
34166804|NCT02696265|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166805|NCT03113032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The chief investigator who will deliver the exercise protocol will be blinded as to which leg is the intended leg for surgery. This will be done by another member of the medical team allocating the patients in block randomisation as they come in from the waiting list. This list with the respective surgical leg will be kept safely away from the chief investigator until all data is recorded."|Randomised Controlled Feasibility Study|f|t|t|t
34166806|NCT04183374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166807|NCT04410172|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33747912|NCT05278273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Twenty adults (10 female, 10 male) will serve as the at-home training group. The cognitive health status for participants will be assessed using a self-report questionnaire and the Mini-Mental State Examination (MMSE), and all participants were deemed cognitively healthy (MMSE \> 26). At-home participants loaned the necessary equipment (e.g., 3D-glasses, computer equipment) from the research facilities and engaged in 10 training sessions over five weeks (2x per week). Participant recruitment, retention, adherence and experience will be used as markers of feasibility. For program validation, twenty participants above 50 years old, who had previously completed at least eight sessions of the in-lab 3D-MOT program, were randomly selected as the control group. Individual session scores, overall improvement and learning rates between groups will be compared.||||
33747913|NCT03664076|||CASE_ONLY||CROSS_SECTIONAL|||||||
33747914|NCT05602805|||CASE_ONLY||PROSPECTIVE|||||||
33747915|NCT00470951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747916|NCT05759273|||COHORT||RETROSPECTIVE|||||||
33747917|NCT04901429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747918|NCT03386370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747919|NCT04272281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747920|NCT06273072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747921|NCT06669299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747922|NCT04675138|||CASE_ONLY||OTHER|||||||
33747923|NCT05189730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747924|NCT05860699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo and CBD pills are looking alike and made on purpose for the study by the same manufacturer(Echo Pharmaceutical, BV)|Double Blind Randomized clinical trial with 3 arms :|f|f|f|t
33957675|NCT04232696|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, seamless two-phased pivotal study design.||||
33957676|NCT05619809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957677|NCT02257411|NA|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33957678|NCT05804240|||COHORT||PROSPECTIVE|||||||
33957679|NCT06076538|||CASE_ONLY||PROSPECTIVE|||||||
34166808|NCT03982641|||COHORT||PROSPECTIVE|||||||
34166809|NCT01139710|||COHORT||PROSPECTIVE|||||||
34166810|NCT03854838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166811|NCT03076762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigator and outcome assessor are blinded to the treatment arm.|Eligible patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA) into the trigone (the treatment group) or suburothelium (the comparative group) immediately followed by cystoscopic hydrodistention under intravenous general anesthesia in the operation room.|t|f|t|t
34166812|NCT05579977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166813|NCT01722539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166814|NCT01336933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166815|NCT04035252|||COHORT||PROSPECTIVE|||||||
34166816|NCT00329368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166817|NCT01239069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34166818|NCT01527968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166819|NCT04282252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166820|NCT04001634|||COHORT||RETROSPECTIVE|||||||
34166821|NCT00996463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166822|NCT05057481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166823|NCT06332066|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
34166824|NCT06270069|||COHORT||PROSPECTIVE|||||||
34166825|NCT06096649|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Zinc Di-(dibutyryl lisinate) vs Vehicle|t|f|t|t
34166826|NCT00304174|||CASE_CONTROL||PROSPECTIVE|||||||
34166827|NCT03703778|||CASE_CROSSOVER||PROSPECTIVE|||||||
34166828|NCT04791436|||COHORT||PROSPECTIVE|||||||
34166829|NCT04272346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166830|NCT00395356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166831|NCT06217848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166832|NCT05890768|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34166833|NCT05691894|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166834|NCT03445884|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166835|NCT04587375|||COHORT||PROSPECTIVE|||||||
34166836|NCT03973359|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34166837|NCT01914263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166838|NCT00844012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166839|NCT00999544|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Within subject crossover designed that examined 15 experimental conditions within a single group of participants|t|f|t|t
34166840|NCT06033066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34166841|NCT02897648|||COHORT||PROSPECTIVE|||||||
34166842|NCT02581306|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166843|NCT03592316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166844|NCT01978496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166845|NCT03488836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166846|NCT01550536|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34166847|NCT02794649|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166848|NCT06124365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166849|NCT01759420|||COHORT||PROSPECTIVE|||||||
34166850|NCT00563030|||CASE_CONTROL||PROSPECTIVE|||||||
34166851|NCT03929107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166852|NCT02774980|||CASE_ONLY||PROSPECTIVE|||||||
34166853|NCT01185015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166854|NCT02098746|||COHORT||PROSPECTIVE|||||||
33747925|NCT03372226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The study is a randomly controlled study with 2 conditions: Condition 1: Online Intervention Program (treatment of emotional and gambling-related symptoms), condition 2: Wait-list control group (access to the online program after the post-assessment).~Two assessments-points, the intervention period (pre-post) is eight weeks. At both measuring points sociodemographic and pathological data are obtained with an internet survey on Unipark®."|f|f|t|t
33747926|NCT00854451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33747927|NCT02362490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166855|NCT02893709|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166856|NCT01155336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166857|NCT00748345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166858|NCT05770817|||COHORT||PROSPECTIVE|||||||
33747928|NCT06025526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166859|NCT03818750|NA|SINGLE_GROUP||OTHER||NONE||||||
34166860|NCT00763646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166861|NCT03714724|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Intraabdominal pressure of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.||||
34166862|NCT00869752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166863|NCT05927766|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34166864|NCT02041481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166865|NCT05378321|NA|SINGLE_GROUP||SCREENING||NONE||||||
34166866|NCT04036981|||CASE_ONLY||PROSPECTIVE|||||||
34166867|NCT00425646||||TREATMENT||NONE||||||
33747929|NCT06669481|||COHORT||RETROSPECTIVE|||||||
33747930|NCT05084196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33747931|NCT04519918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747932|NCT01235468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747933|NCT06111716|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Mindfulness-Based Childbirth Education was implemented in the intervention group~Information-Based Birth Education was applied to the control group."|t|f|f|f
34166868|NCT06376578|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166869|NCT05191394|NA|SINGLE_GROUP||OTHER||NONE||||||
34166870|NCT01576432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34166871|NCT00100789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166872|NCT01774799|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34166873|NCT01708512|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34166874|NCT01535807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166875|NCT01043211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34166876|NCT03890588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Clinic level cluster randomized study||||
34166877|NCT05415358|||COHORT||PROSPECTIVE|||||||
34166878|NCT00076414||||TREATMENT||||||||
34166879|NCT06157866|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34166880|NCT04410185|NA|SINGLE_GROUP||OTHER||NONE||3 separate populations will be recruited: Patients (n=10), caregivers (n=10), and control subjects (n=10)||||
34166881|NCT02544568|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33957680|NCT06195072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There will be multiple interventional regimens, each consisting of the study participants receiving either the active IP or its matching placebo. Study participants, Investigators, and site staff will not be blinded to the regimen assignment, but they will be blinded to active product or matching placebo assignment. Enrollment to regimens may start at different time points during the study.|"Participants who have given informed consent for the Master Protocol and all available Regimen-specific Subprotocols for which they are eligible will be randomly assigned to a regimen. Within each regimen, participants will be assigned to active treatment or matching placebo in a ratio detailed in the randomization scheme.~Eligibility for the Regimen will be based on the inclusion and exclusion criteria in the Master Protocol and on the inclusion and exclusion criteria in the Regimen-specific Subprotocol.~Importantly, to preserve the integrity of randomization, participants will be consented to all possible Regimen-specific Subprotocols open at that time, for which they qualify. Eligible participants will then be randomized to only one Regimen-specific Subprotocol, followed by randomization to the active IP treatment or to the corresponding placebo within a Regimen-specific Subprotocol."|t|t|t|t
33957681|NCT03907540|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Single center, non-randomized, open-label, 2-part study||||
33957682|NCT00736138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957683|NCT02092584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957684|NCT03256526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33957685|NCT06315413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957686|NCT04661124|||CASE_CONTROL||PROSPECTIVE|||||||
33957687|NCT01129518|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957688|NCT01391910|||COHORT||PROSPECTIVE|||||||
33957689|NCT06646536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957690|NCT05084937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Structured transition form is used with 50% of the study patients||||
33957691|NCT01610284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957692|NCT00233376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957693|NCT01353794|||COHORT||PROSPECTIVE|||||||
34166882|NCT06376630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|envelopes|300 pts with MI are to be enrolled. Among them 100 pts with STEMI will be included into the substudy evaluating cardioprotective effects of early iv administration of esmolol. They will be randomized 1:1 by in arms receiving esmolol or no IV beta-blockers. In the esmolol arm the infusion will begin immediately on admission. 200 pts with MI and multivessel disease with non-IRA lesions of 50-85% diameter stenosis will be included into another substudy investigating coronary physiology. All patients will undergo PCI with IRA stenting. 50 stable patients will undergo invasive measurements of coronary physiology. Those will also undergo cardiac MRI. Other 150 pts will not undergo invasive measurements of coronary physiology during initial hospitalization. Pts in both groups will be hospitalized again in 30-40 days after MI. They will undergo stress SPECT or stress echocardiography. All patients will undergo a follow-up coronary angiography with invasive measurement of coronary physiology.|f|f|t|f
34166883|NCT00488488|||COHORT||PROSPECTIVE|||||||
34166884|NCT05147376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This clinical trial is a double-blind study that participants and examiner will be blinded to group assignment.||t|f|t|f
34166885|NCT04138992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854067|NCT04062968|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be randomized to video education or usual care. Randomization will be completed using a random number table. Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit.~Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing)."||||
33957694|NCT02118818|||CASE_CONTROL||PROSPECTIVE|||||||
33957695|NCT05851976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957696|NCT01462188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957697|NCT02107807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33957698|NCT02181842|||COHORT||PROSPECTIVE|||||||
33957699|NCT02653469|||COHORT||PROSPECTIVE|||||||
33957700|NCT06700486|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33957701|NCT05601193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957702|NCT02642991|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33957703|NCT03856879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study staff conducting patient surveys and evaluating quality of COPD care will be blinded to intervention/control assignment of the patient's provider.|Providers will be randomly assigned to the intervention or control group, stratified by site, provider type and panel size.|f|f|f|t
33957704|NCT05145660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957705|NCT06701409|||COHORT||PROSPECTIVE|||||||
33957706|NCT04166526|||COHORT||PROSPECTIVE|||||||
33957707|NCT03985800|RANDOMIZED|PARALLEL||OTHER||NONE||Comparison between technology interventions and in-person interventions.||||
33957708|NCT05005000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957709|NCT00650637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957710|NCT02292732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957711|NCT04991116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957712|NCT01889641|||COHORT||PROSPECTIVE|||||||
33957713|NCT00591526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957714|NCT06567353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854068|NCT04503343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957715|NCT04059900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33854069|NCT02941250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854070|NCT03200015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957716|NCT05392712|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33957717|NCT04560920|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will be informed that they are participating in a study of patient information and that this information will be discussed when available at the visit.|During aim 3, participants will be randomized to experimental or control group. Both groups will contribute PGHD, but the availability of PGHD at the visit will be the basis on which groups are compared. Earlier aims are not randomized but total anticipated enrollment is listed below.|t|f|f|f
33957718|NCT02572427|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33957719|NCT04556773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will initially consist of 5 treatment modules, each of which includes T-DXd in combination with other anti-cancer agents. Each module will have 2 parts: a dose-finding phase (Part 1) and a dose-expansion phase (Part 2). The Part 2 dose-expansion phase will use the recommended Phase 2 dose (RP2D) for the combination, either as determined in Part 1 or from another clinical study if appropriate. For each module, patients will be centrally assigned to one of the open modules, as per the module specific criteria.~In addition to safety and tolerability, this study will also assess ORR, PFS, DoR, and OS for each treatment combination."||||
33957720|NCT00973531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166886|NCT03833726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant will be randomly divided between LED group or LED Sham procedure that will consist of turned off device and heated gel and both patients and physiotherapists of kinesiotherapy phase wont be aware with group the participant is allocated.|The study will be conducted women diagnosed with Genitourinary Syndrome of Menopause treated with kinesiotherapy, divided in two groups: LED treatment or LED Sham.|t|t|f|f
34166887|NCT02405156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166888|NCT01678378|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166889|NCT02071966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34166890|NCT03010527|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166891|NCT04393129|||COHORT||PROSPECTIVE|||||||
34166892|NCT01998022|||||PROSPECTIVE|||||||
34166893|NCT04762732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747934|NCT02676869||SEQUENTIAL||TREATMENT||NONE||Study is an open label, dose finding study consisting of 2 parts. In part A, the dose is escalated following the protocol-defined safety observation period of the previous cohort. Patients will receive 9 cycles Pembrolizumab in combination with IMP321. In part B, the dose was defined based on the dose escalation. The treatment duration will be expanded to 19 cycles in the combined treatment.||||
33747935|NCT00563199|RANDOMIZED|PARALLEL||||DOUBLE||||||
33747936|NCT06669650|RANDOMIZED|PARALLEL||PREVENTION||NONE||Standard of Care (oxycodone) versus intervention group (hydromorphone)||||
33747937|NCT02239783|||COHORT||PROSPECTIVE|||||||
33747938|NCT04663152|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747939|NCT01564966|||COHORT||PROSPECTIVE|||||||
33747940|NCT04628689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33747941|NCT04016597|||OTHER||CROSS_SECTIONAL|||||||
33957721|NCT06698263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957722|NCT01070407|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957723|NCT04853849|||COHORT||PROSPECTIVE|||||||
33957724|NCT04729634|NA|SINGLE_GROUP||OTHER||NONE|The patients will not be aware of the study activities|A cohort of patients followed over time||||
34166894|NCT01165983|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34166895|NCT02953600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747942|NCT04082949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All subgingival procedures were performed by the same periodontology expert, who was blinded to the placebo or AFG application.|Randomised paralleled clinical trial|f|f|t|f
33747943|NCT01235208|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33747944|NCT00457262|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33747945|NCT01614548|||COHORT||RETROSPECTIVE|||||||
33747946|NCT05084872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747947|NCT06281548|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33747948|NCT00996996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747949|NCT02804854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33747950|NCT04556708|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33747951|NCT06343766|||CASE_CONTROL||PROSPECTIVE|||||||
33747952|NCT01626768|||||PROSPECTIVE|||||||
33747953|NCT03762395|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33747954|NCT02199236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747955|NCT02440958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747956|NCT02409173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747957|NCT01507220|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854071|NCT06158685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854072|NCT05812287|||CASE_CONTROL||OTHER|||||||
33854073|NCT04220697|NA|SINGLE_GROUP||SCREENING||NONE||||||
33854074|NCT06443554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854075|NCT02680002|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33854076|NCT04208945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854077|NCT01202214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33854078|NCT05559008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854079|NCT05125705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patients and the outcome assessor will be blinded in this trial.||t|f|f|t
33854080|NCT05631431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Double-blind for 3 months, after 3 months - open-label|t|t|t|f
33854081|NCT04121195|NA|SEQUENTIAL||TREATMENT||NONE||This is a dose-escalation study where pharmacokinetic assessments will be undertaken after dose-adjustments. In this type of study, each participant will serve as their own control, allowing the changes brought about by each dose change to be understood.||||
33854082|NCT04639141|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be recruited and randomised (1:1) to one of two 12-week treatment intervention groups: 1) synbiotic or 2) synbiotic + gut-directed hypnotherapy. Follow-up will occur at week 24.||||
33854083|NCT01543529|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33747958|NCT04484467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Using a random number generator, 56 patients with IBS or IBS/FD were randomly assigned to either the intervention group (28 individuals) or control group (28 individuals).~Researchers and patients were not informed who received a supplement or placebo."|"At Visit 1, all patients were randomly assigned into two groups. In the intervention group (Group 1), the supplement Standart Zdorovya GASTRO (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days. In the control group (Group 2), placebo (1 capsule, 730 mg, once a day) was added to the standard treatment regimen for 30 days (Table 1). During the 30 days of the study, three outpatient visits were conducted (Visit 1 - Day 1, Visit 2 - Day 15 + 2 days, and Visit 3 - Day 30 + 2 days)."|t|f|t|f
34166896|NCT06000124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All subjects were randomly assigned to either the control or experimental group to receive their respective exercise programs. The outcomes assessor was blinded to the group allocation of each participant during baseline and post-intervention assessments. No group assignment information was provided to the care providers.|The experimental group underwent plyometric training three times a week, performing three rounds each session, for a total intervention period of 10 weeks. The control group, on the other hand, engaged in regular exercises during the same intervention period. Before and after the training program, both groups underwent assessments to evaluate their balance abilities, which included the 30-second sit-to-stand test, time up and go test (TUG), functional reach test (FRT), and lower extremity explosiveness test.|f|t|f|t
34166897|NCT06106113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166898|NCT03077542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747959|NCT00793468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747960|NCT01715987|||CASE_CONTROL||PROSPECTIVE|||||||
33854084|NCT05822219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Participants are unblinded but study has non-disclosure component of keeping the difference between the two training arms as non-disclosed until the conclusion of the study.|Two different group training arms related to COVID-19 vaccine uptake||||
33747961|NCT05706805|||COHORT||PROSPECTIVE|||||||
33747962|NCT06634810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Research Coordinators conducting interviews, and all investigators will be blinded to treatment allocation.|This project will conduct a randomized controlled trial to evaluate a self-management support intervention for predominantly minoritized, low-income adults with COPD.|f|t|t|t
33747963|NCT02445612|||COHORT||PROSPECTIVE|||||||
33747964|NCT02773615|||COHORT||PROSPECTIVE|||||||
33747965|NCT00567125|||||PROSPECTIVE|||||||
33747966|NCT04522401|||COHORT||PROSPECTIVE|||||||
33854085|NCT01874301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854086|NCT05807737|||CASE_ONLY||PROSPECTIVE|||||||
33854087|NCT03542773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854088|NCT04967534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||parallel-group (1:1) randomized controlled trial|f|f|f|t
33854089|NCT00001032||||TREATMENT||||||||
33854090|NCT05727787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854091|NCT00645047|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854092|NCT05149911|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854093|NCT01275131|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33854094|NCT03372707|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Patients, Research Coordinators, study investigators, adjudicators, and data analysts will be blinded to the results of CLT in the control group.||t|f|t|t
33854095|NCT04685057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854096|NCT04805190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be randomized to either a single session cognitive-behavioral intervention to reduce pain catastrophizing or a pain education control group|t|f|f|f
33854097|NCT00839657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854098|NCT01070030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854099|NCT06337526|||CASE_ONLY||PROSPECTIVE|||||||
33854100|NCT02504944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854101|NCT02748720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854102|NCT06280625|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be given the food product without information on whether it is prepared 100% with wheat flour or with different soy flour %.|People will be evaluated with a food product prepared with different % of replacement of wheat flour for soy flour. Each person will be their own control. In other words, in randomized order, they will all be assessed with the food product prepared with the regular wheat flour (either bread, tortillas or arepas) and on two other visits with different percentages of soy flour.|t|f|f|f
33957725|NCT00181974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747967|NCT05519254|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33747968|NCT05033288|||COHORT||PROSPECTIVE|||||||
33747969|NCT02228668|||COHORT||OTHER|||||||
33747970|NCT00400010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34166899|NCT02041507|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34166900|NCT02214641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166901|NCT04648319|NA|SINGLE_GROUP||TREATMENT||NONE||single group assignment||||
34166902|NCT02526602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166903|NCT01271725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166904|NCT03214861|||COHORT||PROSPECTIVE|||||||
34166905|NCT03518294|RANDOMIZED|PARALLEL||TREATMENT||NONE||Standard of care Aerobic exercise||||
34166906|NCT00020917||||TREATMENT||||||||
33747971|NCT05595304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33747972|NCT01509573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33747973|NCT02235493|||OTHER||RETROSPECTIVE|||||||
33747974|NCT03570177|||COHORT||RETROSPECTIVE|||||||
33747975|NCT00179465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747976|NCT02223234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33747977|NCT05668754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Open-Label Titration Period with a Double-Blind Withdrawal Period|Phase 2, placebo-controlled, double-blind, randomized withdrawal study to determine the safety and efficacy of oral SDX in patients with Idiopathic Hypersomnia (IH).|t|f|t|f
33747978|NCT03006523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33747979|NCT00885404|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33747980|NCT03732209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants assigned to both groups will be masked to experimental hypotheses. Research personnel who will be conducting assessment sessions, including weight measurements, will not be informed of participants' group assignments.|Participants will engage in episodic future or control thinking in the natural environment. All participants will also receive case management regarding the Traffic Light Diet, modified for type 2 diabetes to include glycemic index of foods, as well as the Traffic Light Activity Plan and other techniques to aid in weight loss (e.g., self-monitoring).|t|f|f|t
33747981|NCT01280487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747982|NCT00319215|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33747983|NCT02672111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33747984|NCT06667115|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33747985|NCT00712842|||COHORT||PROSPECTIVE|||||||
33747986|NCT03588208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747987|NCT03910127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33747988|NCT06012760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33747989|NCT01618838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747990|NCT03214497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33747991|NCT06060457|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33747992|NCT02101892|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33747993|NCT06041724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747994|NCT00232804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33747995|NCT06670079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33747996|NCT04282135|||CASE_CONTROL||PROSPECTIVE|||||||
33747997|NCT04706468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging|t|t|t|t
33747998|NCT04820387|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33747999|NCT01292603||PARALLEL||TREATMENT||NONE||||||
33748000|NCT01349634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748001|NCT06139874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748002|NCT06669910|||OTHER||PROSPECTIVE|||||||
33748003|NCT02127164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748004|NCT02768896|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748005|NCT03500874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748006|NCT03580265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748007|NCT01288482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748008|NCT02097472|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748009|NCT06669286|||COHORT||RETROSPECTIVE|||||||
33748010|NCT01680328|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33748011|NCT03151434|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients randomized to epidural, single shot paravertebral block, and paravertebral catheter||||
33748012|NCT02285816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748013|NCT06053567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748014|NCT00530361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748015|NCT02676479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748016|NCT04241861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748017|NCT01369862|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748018|NCT03019211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748019|NCT02680054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748020|NCT01815268|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854103|NCT00865969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854104|NCT00831285|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33854105|NCT02445950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854106|NCT04928001|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||multiple baseline pre-post design||||
33854107|NCT05227105|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854108|NCT03522480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two study groups: A or B. Participants assigned to study group A will be taught by a respiratory therapist how to perform the autogenic drainage technique in week 0, and will be asked to perform the technique regularly on their own for secretion clearance for the first 8 weeks of the study. Beginning in week 8, they will be taught to use autogenic draining technique guided by a videogame through the Jamboxx respiratory therapy device and will be advised to perform the technique regularly using the game for guidance through week 16 Participants in group B will be taught to perform the autogenic draining technique using the Jamboxx respiratory therapy guided by a videogame in week 0, and will be instructed to perform the technique regularly for the next 16 weeks using the game for guidance||||
33957726|NCT04718272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957727|NCT03022318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957728|NCT06702917|||COHORT||PROSPECTIVE|||||||
33957729|NCT01962727|||||CROSS_SECTIONAL|||||||
33957730|NCT01741259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957731|NCT05260658|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33854109|NCT01729143|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33957732|NCT06703593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957733|NCT00956709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166907|NCT02019732|||||RETROSPECTIVE|||||||
34166908|NCT04531761|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34166909|NCT00694655|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33854110|NCT00978653|NA|SINGLE_GROUP||SCREENING||NONE||||||
34166910|NCT03666871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Randomized, double-blind|t|f|t|f
34166911|NCT03247257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34166912|NCT02553057|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166913|NCT05137964|||COHORT||RETROSPECTIVE|||||||
33854111|NCT01596621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854112|NCT00495586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854113|NCT00898027|||CASE_ONLY||PROSPECTIVE|||||||
33854114|NCT01793311|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33854115|NCT04758689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854116|NCT02523001|||COHORT||PROSPECTIVE|||||||
33854117|NCT04634825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrollment into each cohort will occur independently in a non-randomized fashion, based on PD-L1 expression results. Patients may not crossover between cohorts.||||
33854118|NCT05576194|||CASE_CONTROL||PROSPECTIVE|||||||
33854119|NCT03276325|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind||f|t|f|t
33854120|NCT00657670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854121|NCT03013660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33854122|NCT03076333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854123|NCT01374373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854124|NCT05037877|RANDOMIZED|PARALLEL||OTHER||SINGLE||This will be a 2-arm randomized, double-blinded, placebo-controlled study|t|f|f|f
33854125|NCT00551941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854126|NCT05751772|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Single-center randomized controlled trial||||
33854127|NCT02667847|||COHORT||PROSPECTIVE|||||||
33854128|NCT03513588|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33854129|NCT03523104|||COHORT||PROSPECTIVE|||||||
33854130|NCT01442818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854131|NCT02621125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854132|NCT05949112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854133|NCT01947985|||COHORT||PROSPECTIVE|||||||
33854134|NCT04206930|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33957734|NCT03290976|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient-preference, randomized controlled study||||
33957735|NCT06700434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Inclusion criteria: Females and males (least 18 years old), good oral and general health, no periodontal disease, no caries, and teeth colored A3 or darker according to the VITA Easy Shade Guide (VITA Zanhnfabrik, BadSckingrn, Germany).|A 6-month a double-blinded randomized controlled trial|t|f|t|t
33957736|NCT05569421|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33957737|NCT03660007|||COHORT||OTHER|||||||
33957738|NCT06660407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957739|NCT05987527|||CASE_CONTROL||PROSPECTIVE|||||||
33957740|NCT02525146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957741|NCT05845671|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33854135|NCT00552487||PARALLEL||DIAGNOSTIC||NONE||||||
33854136|NCT03322748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854137|NCT02299492|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854138|NCT04923074|||COHORT||PROSPECTIVE|||||||
33854139|NCT00611312|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33854140|NCT04438577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957742|NCT01447628|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33957743|NCT06700941|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33957744|NCT03213769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|controlled randimized clinical trial|t|f|t|f
33957745|NCT03544606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To insure that everyone has the chance of participation, Randomization will be done using computer generated randomization sheet using statsdirect version 3. Double blinding will be done by one of the supervisors who will be the only one to know the key, thus the care provider and the patient will not know is it the drug or the placebo.|"The patients will be divided into 2 groups.~Group 1:~80 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)~Group 2:~80 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix."|t|t|f|f
34166914|NCT00613496|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34166915|NCT05301517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166916|NCT03331900|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34166917|NCT01929226|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33854141|NCT03948724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854142|NCT03568331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854143|NCT01436188|RANDOMIZED|PARALLEL||||NONE||||||
33854144|NCT06207331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854145|NCT00253994|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33854146|NCT00680589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166918|NCT01798966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34166919|NCT01559181|||CASE_CONTROL||PROSPECTIVE|||||||
33748021|NCT05997238|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|An independent researcher, who would not meet or interact with patients before recruiting them, compiled a computer-generated randomised list using 1:1 assignments and random blocks of 8, 6 or 4 to ensure the invisibility of assignments. The groups corresponding to the numbers generated by the random number generator were placed in opaque envelopes and sealed, and the enrolled patients were assigned envelopes in the chronological order in which they were enrolled. On the day of surgery, the anesthesiologist prepares to mix the drug preparation after opening the sealed envelope, which is then handed to the operating room nurse. The patient, the rehabilitation physician, and the ward nurse did not know the type of drug mixture the patient was injected with.|An independent researcher, who would not meet or interact with patients before recruiting them, compiled a computer-generated randomised list using a 1:1:1:1 assignment and random blocks of 12, 8 or 4 to ensure the concealability of the assignment. The groups corresponding to the numbers generated by the random number generator were placed in opaque envelopes and sealed, and the enrolled patients were assigned envelopes in the chronological order in which they were enrolled.|t|t|t|t
33748022|NCT00704457|||CASE_CONTROL||PROSPECTIVE|||||||
33748023|NCT00490191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748024|NCT00860587|||CASE_ONLY||PROSPECTIVE|||||||
33748025|NCT04897958|||COHORT||RETROSPECTIVE|||||||
33748026|NCT05737810|||COHORT||CROSS_SECTIONAL|||||||
33748027|NCT03640260|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748028|NCT02111057|||COHORT||PROSPECTIVE|||||||
33748029|NCT05427279|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|A randomized double-blind crossover design with neither the subjects nor the investigators knowing who is on which treatment. The interventions will be coded using a blinded alphabetical letter code (A, B, C, D). A delegate researcher (independent party not further involved in the study) will randomize all interventions using a computer-generated randomization list. The delegate will hand in the code-breaker to the principal investigator in a sealed envelope. The envelope will be stored in a locked filing cabinet in the principal investigator's office, which will also be locked when unoccupied. The envelope will be opened by the principal investigator after completing the analysis of blood samples.|Participants will consume a supplemental dose of hydrolyzed collagen (20g with 50mg vitamin C), PrimaColl (20g with 50mg vitamin C), whey protein (20g whey isolate with 50mg vitamin C) or a placebo (20g maltodextrin with 50mg vitamin C) 1hr prior to exercise bouts (6 minutes of jump rope). The type of consumed supplementation will be randomized where neither the participant nor investigator will know which supplement is being consumed. Each participant will repeat the protocol four times.|t|f|t|t
33748030|NCT05404542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748031|NCT06636409|||COHORT||RETROSPECTIVE|||||||
33748032|NCT03787394|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||A two-step, randomised controlled intervention study|t|f|f|f
33748033|NCT06530914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748034|NCT01820728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854147|NCT01574391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854148|NCT00665912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33854149|NCT02293382|||CASE_ONLY||RETROSPECTIVE|||||||
33854150|NCT02678247|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33854151|NCT01976351|||COHORT||PROSPECTIVE|||||||
33854152|NCT00202293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33854153|NCT01140711|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
33854154|NCT05279001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854155|NCT02270515|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33854156|NCT04871854|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparative study two Covid-19 infected groups selected according to preexisting sever Covid -19 patients receiving Tocilizumab versus traditional thherapy||||
33854157|NCT02309255|||COHORT||RETROSPECTIVE|||||||
33854158|NCT01689337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854159|NCT04991792|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33854160|NCT01758770|||FAMILY_BASED||PROSPECTIVE|||||||
33854161|NCT02080741|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33957746|NCT03779165|||COHORT||PROSPECTIVE|||||||
33748035|NCT00755989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854162|NCT05742022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|two or more parties are unaware of the intervention assignment.|"At clinical centers, patients will be equally randomized by the envelope method into two groups to receive Phospholipovit or placebo.~The drugs will be administered after the signed informed consent. Phospholipovit will be administered 500 mg orally 2 times a day, for 12 weeks. Placebo will be administered orally 2 times a day, for 12 weeks. All patients will be examined after 12 weeks."|t|t|f|f
33854163|NCT05049954|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not feasible to apply blinding to the study design due to the nature of the intervention.|In this randomized controlled trial, participants in the HKD group will be advised to follow a calorie-restricted healthy ketogenic diet (n=35), with a maximum of 50g net carbohydrate intake daily. Those in the control group will be instructed to follow a calorie-restricted low fat diet (LFD) (n=35).||||
33854164|NCT00411346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33957747|NCT02441959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957748|NCT05981365|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33957749|NCT00976859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748036|NCT06205745|||COHORT||RETROSPECTIVE|||||||
33748037|NCT05796570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748038|NCT06635928|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748039|NCT02175433|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33748040|NCT04493398|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Two operators performed the clinical aspects of this study. Author TS, masked to treatment assignments, performed all clinical recordings and sampling, author IU performed all treatments. All analyses were performed by a statistician (SAL) who had not taken part in data collection or treatments.|Randomized, single-masked controlled trial (RCT). A split-mouth study design where each of the furcation in the lower jaw molars was randomized to the two specific treatments. Hence, each patient received both interventions randomly allocated to each side of the lower jaw.|f|f|t|t
33748041|NCT03131076|||COHORT||PROSPECTIVE|||||||
34166920|NCT05662098|NA|SINGLE_GROUP||TREATMENT||NONE||ADAPT is a prospective cohort study at Jinja Regional Referral Hospital (JRRH) primarily to assess the effect of hydroxyurea on blood transfusion utilization and secondarily to determine the feasibility of PK-guided hydroxyurea dosing.||||
34166921|NCT01315171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166922|NCT04266808|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes Assessors for both skin integrity and psychosocial measures will be blinded to participants' group allocation|Randomized trial with one intervention arm and one control arm.|f|f|f|t
33957750|NCT06554665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166923|NCT00112632||||TREATMENT||NONE||||||
34166924|NCT05113511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166925|NCT04676620|||COHORT||PROSPECTIVE|||||||
34166926|NCT04175730|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||50 men with clinical suspicion of PCa (elevated Prostate specific antigen (PSA) and/or abnormal DRE) will be enrolled into a prospective protocol and will undergo detection protocol MRI||||
34166927|NCT05374239|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Due to the nature of intervention, blinding may not be possible. However, occupational therapists at all 4 hospitals will be blinded to the allocation sequence, with only the next hospital randomised for rollout being revealed at each intervention implementation time point. This will allow for blinding to the intervention partially possible. The investigators will also remind occupational therapists at all 4 hospitals not disclose details about the intervention to other healthcare professionals until the end of the trial.|Hospital will be the unit of randomisation.|t|f|f|f
34166928|NCT02884024|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166929|NCT03560336|||COHORT||PROSPECTIVE|||||||
34166930|NCT03168620|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34166931|NCT01745367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34166932|NCT01111695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166933|NCT00239733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166934|NCT03847844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34166935|NCT00893958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34166936|NCT00726648|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33957751|NCT06638619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166937|NCT06065618|||COHORT||RETROSPECTIVE|||||||
33957752|NCT02813785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957753|NCT01722188|||CASE_ONLY||PROSPECTIVE|||||||
33957754|NCT04233788|||OTHER||PROSPECTIVE|||||||
33957755|NCT03367949|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Each patient will be given a code by the researcher (A.A) and the observers will be blind to which group this case belong.~Patients, evaluators and data analyst will be blinded"||t|t|t|t
34166938|NCT03722121|||COHORT||RETROSPECTIVE|||||||
34166939|NCT02714569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Part A is a crossover. Part B is a parallel assignment.|t|f|t|f
34166940|NCT04262726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166941|NCT03121508|NA|SINGLE_GROUP||PREVENTION||NONE||The investigators will utilize an evidence-based self-management program, and all individuals will be assigned to the prevention group to promote healthy lifestyles.||||
34166942|NCT04758702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34166943|NCT06396234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will have agreed to the study and randomized device or technique will be used.|Single-centered, Randomized, Pilot Study|t|f|f|f
34166944|NCT00587158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957756|NCT06701890|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33957757|NCT00270179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33957758|NCT06540222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, stepped-wedge cluster randomized trial||||
33957759|NCT03626207|||CASE_ONLY||PROSPECTIVE|||||||
33957760|NCT05789303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957761|NCT05830123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957762|NCT00191256|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957763|NCT05489068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Effectiveness-Implementation Hybrid Type 1 Design|t|f|t|t
33957764|NCT06458023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957765|NCT04904978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957766|NCT03906565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854165|NCT04256629|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This study is double-blind with regards to treatment (verinurad and allopurinol or the matching placebos) at each dose level. Placebo will be matched with verinurad and allopurinol for appearance and amount. Subjects randomized to placebo will receive the same volume of oral suspension as subjects on active drug.||t|f|t|t
33854166|NCT00182299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33854167|NCT00334035|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33854168|NCT02831803|NA|SINGLE_GROUP||OTHER||NONE||||||
33854169|NCT03991819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33854170|NCT02823366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893495|NCT05832762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"As the therapeutic arm is interventional in the experimental arm, the physicians in charge of the patient and the patients cannot be blinded.~The mRS score will be evaluated by qualified assessors blinded to the initial treatment"|The protocol is a national, multi-center, prospectively randomized into two parallel (1:1) arms, open to treatment with blinded endpoint trial (PROBE)|f|f|f|t
33957767|NCT03469141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Following the training/goal setting session, participants will be randomly assigned into either the intervention group that will receive biofeedback via the smartphone app for 4 weeks, or the control group that will continue to have the WC sensor system for measurement only and will not receive biofeedback.|All participants will complete two weeks of recording PR behavior by the monitoring system without feedback. Following baseline assessment, participants will be randomized into one of two groups: an intervention group that will receive an education session on PU prevention with goal setting for PR frequency and duration followed by four weeks of biofeedback via the smartphone app component of the monitoring system, or a control group that will receive only the education and goal setting session, but will not receive biofeedback and will have the WC sensor system for measurement only. After four weeks, the biofeedback feature in the intervention group will be turned off. The system will continue to monitor activities for another two weeks. We will assess whether improvements in PR adherence are retained after the 4-week bout of biofeedback (washout). Participants will return one year following the 8-week intervention to assess whether they have developed a PU.|t|f|f|f
33957768|NCT03841903|||COHORT||PROSPECTIVE|||||||
34061372|NCT03914027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomisation will allocate patients to either the intervention or control group. This will be performed electronically by using a randomization plan generator (Randomization Plans: Never the Same Thing Twice! n.d.) that has already given a randomization plan and code to generate the same plan obtained. To reproduce this study randomization plan, enter at http://www.jerrydallal.com/random/permute.htm :~24 subjects randomized into 2 blocks (intervention, control) Seed number 10180. Block randomization will be used to ensure that the numbers of participants assigned to each group is equally distributed during the different seasons."|Prospective randomized controlled trial. 24 patients with PS will be randomized in two groups, trained by tele-rehabilitation for 12 weeks and afterwards followed for 6 months. The control group will follow the usual control program for PS patients that only involves outpatient visits approximately every 3rd month. No specific PS rehabilitation program exists. The intervention group will receive TR in the form of video consultations- and chat sessions with a real physiotherapist and workout sessions with a virtual physiotherapist agent. They will also train with virtual reality glasses or tablets that show the actual exercises in the training program.|t|f|t|f
34061373|NCT02418741|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34061374|NCT00198575|||DEFINED_POPULATION||PROSPECTIVE|||||||
34061375|NCT03702712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33893496|NCT02603523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166945|NCT01522716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166946|NCT05743803|||OTHER||PROSPECTIVE|||||||
34166947|NCT02610777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854171|NCT01614197|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This study follows a standard 3+3 patient cohort escalation design, as described below:~1. Three patients are entered at the first dose level~2. If 0/3 experiences DLT at a given dose level, then the dose is escalated to the next higher level, if a higher dose level exists, and three patients are enrolled. If a higher dose level does not exists, up to three more patients are accrued at the same dose level.~3. If 1/3 experiences DLT at current dose, then up to three more patients are accrued at the same dose level.~4. If 2 or more DLTs are observed in a three-patient or six-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to three additional patients will be enrolled at the next lower dose level, if a lower dose level exists (unless six patients have already been treated at that prior dose)."||||
33854172|NCT06016673|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will receive stimulation to two brain areas (right dorsolateral prefrontal cortex and vertex) in a counterbalanced order.||||
33854173|NCT05325580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166948|NCT00106314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33854174|NCT04984954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||1:1 stratified block random grouping according to the center|t|t|t|t
34166949|NCT05617508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both participants and all investigators are blinded during the trial and during data analysis.|Randomized double-blinded placebo-controlled study. 80 participants randomized in 1:1:2 ratio to either: 1. Placebo (n=20), 2. NR 1000mg for 3 months (n=20), 3. Dose escalation group: NR 1000mg 1st month, NR 2000mg 2nd month, NR 3000mg 3rd month (n=40).|t|t|t|f
34166950|NCT00329888|||DEFINED_POPULATION||OTHER|||||||
33854175|NCT01798121|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34166951|NCT00510159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34166952|NCT04701333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166953|NCT00166829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166954|NCT00555880|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34166955|NCT02535143|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34166956|NCT00436995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34166957|NCT00487357|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34166958|NCT04627155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34166959|NCT00985465|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34166960|NCT00872599|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34166961|NCT05874024|||CASE_CONTROL||PROSPECTIVE|||||||
34166962|NCT01463462|||CASE_ONLY||PROSPECTIVE|||||||
34166963|NCT01303939|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Magnetic resonance images (MRI) of the brain were obtained from glaucoma patients to look at structures and volume. Age, gender, ethnic healthy matches for each glaucoma patient received MRIs of the brain for comparison.||||
34166964|NCT02059226|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748042|NCT05234164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects requiring treatment of the SFA will undergo a calcification review based on the Fanelli classification. Subjects graded with Fanelli 1 or 2, and subjects requiring treatment of the P1 segment of the proximal popliteal artery will be treated with the Exist 6F NiTi Stent type FLEX.~Subject graded with Fanelli 3 and 4 will be treated with the Exist 6F NiTi Stent PULL."||||
33748043|NCT04602325|||COHORT||PROSPECTIVE|||||||
33957769|NCT04461080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||parallel, two-arm 1:1 individual participant allocation randomized controlled trial|f|f|f|t
33957770|NCT05080088|||COHORT||RETROSPECTIVE|||||||
33957771|NCT02801838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061376|NCT03919500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061377|NCT01561599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061378|NCT01217125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061379|NCT00475514|RANDOMIZED|PARALLEL||||DOUBLE||||||
34061380|NCT04600063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166965|NCT02507388|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34166966|NCT05912764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166967|NCT02673918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was conducted in two parts and thereby had two groups of participants. Part 1 participants were newly operated for breast cancer. Part 2 participants had completed surgery and radiation therapy for breast cancer. Both groups received the same intervention, namely a home-based rehabilitation program.||||
34166968|NCT00002781||||TREATMENT||||||||
34166969|NCT00818792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166970|NCT02726620|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||It is an interrupted time-series of a decision support package intervention that aims to study the the effect of the decision support package on patient outcome. The effects of the individual decision support components of the package on healthcare provider behavior will be studied in a nested cluster-randomized trial: in the first month the attending anesthesiologists will be randomized to near-realtime notifications or feedback emails; in the second month in-room providers will be randomized to near-realtime notifications or feedback emails. Starting month four all providers will receive both near-realtime notifications and feedback emails.||||
34166971|NCT01226225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957772|NCT06702566|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE). A total of 1500 patients with definitive diagnosis of malignant solid tumor or acute leukemia will be enrolled in this study. Patients are divided into 3 groups according to the anti-tumor therapy they are to receive. Three groups will be set up, namely group A: immunotherapy group (patients will be treated with immunotherapy, or immuno- plus targeted therapy, or immuno- plus chemotherapy); group B: targeted therapy group (patients will be treated with targeted monotherapy, targeted plus chemotherapy); group C: chemotherapy group (patients will be treated with chemotherapy).||||
33957773|NCT03533608|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will engage in 12, 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.||||
33957774|NCT04324112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957775|NCT00339066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957776|NCT04434235|||COHORT||CROSS_SECTIONAL|||||||
33957777|NCT05105737|||CASE_CONTROL||RETROSPECTIVE|||||||
33957778|NCT02525354|||COHORT||CROSS_SECTIONAL|||||||
33957779|NCT00228332|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33854176|NCT04141969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33957780|NCT06676241|||COHORT||RETROSPECTIVE|||||||
33854177|NCT02513277|||COHORT||CROSS_SECTIONAL|||||||
33854178|NCT00003025||||TREATMENT||||||||
33854179|NCT02077569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33854180|NCT06414694|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854181|NCT01809002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854182|NCT02913417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854183|NCT03257020|||CASE_CONTROL||RETROSPECTIVE|||||||
33957781|NCT00686231|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33957782|NCT06703840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957783|NCT00334477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33957784|NCT04806958|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants, EMS providers, dispatch providers, treating physicians will be blinded||t|t|f|t
33854184|NCT05493241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In Aim 3, a research coordinator masked to group assignment will conduct the 6- and 12-week assessments.|Participants in Aim 2 (open trial, single arm) will all receive the ACTIVaTE intervention. Participants in Aim 3 (randomized controlled trial) will be randomly assigned to the ACTIVaTE intervention or an attention control arm.|f|f|f|t
33957785|NCT06703125|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061381|NCT05106751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061382|NCT04517045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34061383|NCT03725033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061384|NCT02163642|||COHORT||PROSPECTIVE|||||||
34061385|NCT05244434|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34061386|NCT01679912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061387|NCT01680653|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34061388|NCT04663425|||COHORT||RETROSPECTIVE|||||||
34061389|NCT04128891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061390|NCT02930525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061391|NCT04787328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061392|NCT00162149|NON_RANDOMIZED|PARALLEL||||NONE||||||
34061393|NCT05708183|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34061394|NCT00005601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075957|NCT06257056|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"The investigators propose a clinical trial involving 12-months open-label bilateral DBS in subjects with treatment refractory schizophrenia. The open label period is intended to ensure that maximal benefit can be achieved with the current proposed protocol.~Following open label optimization, to control for possible placebo, each subject will enter a double blinded randomized discontinuation, intended to confirm clinical benefit of DBS among responders (4 months)."|"Participants will undergo a maximum of two experimental sessions with ketamine and at least one with placebo. No participant will undergo more than two ketamine administration sessions.~This is an overall 12-month feasibility and safety study. The first 8-months will be open-label bilateral DBS that targets a brain region within brain networks implicated in schizophrenia, which will be followed by a 4-month double-blind randomized discontinuation study. After 8 months, participants will enter a double blind (participant and rater) discontinuation study for 4-months to confirm the clinical benefit of DBS among responders. Final Go-No Go checkpoint occurs after final participants reaches the end of the 12-month study period. Participants will be randomized to either the ON or OFF stimulation phase for 2 months each. If randomization is initially in the ON phase, for the first 2 months, there will be no change in the stimulation settings."||||
34075958|NCT00461825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748044|NCT04310826|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33854185|NCT04987437|||COHORT||PROSPECTIVE|||||||
33854186|NCT01729325|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33854187|NCT03149718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854188|NCT02166125|||CASE_ONLY||PROSPECTIVE|||||||
33854189|NCT00549614|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33854190|NCT03059225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854191|NCT04061395|NA|SINGLE_GROUP||OTHER||NONE||||||
33854192|NCT03251781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854193|NCT04606043|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Split-mouth design|t|f|f|f
33854194|NCT03543501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind study where the assessor will be taking measurement before and after the intervention, albeit without knowing which intervention was given.||f|f|f|t
33854195|NCT06115681|||COHORT||RETROSPECTIVE|||||||
33854196|NCT05737537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854197|NCT00775320|||CASE_CONTROL||PROSPECTIVE|||||||
33854198|NCT04618328|NA|SINGLE_GROUP||TREATMENT||NONE||ATRA is used to treat ITP patients.||||
33748045|NCT03761602|||COHORT||PROSPECTIVE|||||||
34166972|NCT01116401|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34166973|NCT00896766|||CASE_ONLY||RETROSPECTIVE|||||||
34166974|NCT03208140|||CASE_ONLY||PROSPECTIVE|||||||
34166975|NCT04797039|||COHORT||PROSPECTIVE|||||||
34166976|NCT03823183|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE||"This study includes 4 intervention conditions: (1) Multi-modal Cognitive intervention + Physical intervention, (2) Cognitive intervention + Physical control, (3) Physical intervention + Cognitive control, and (4) Active Control group, Cognitive control + Physical control) x 3 (Time: Pretest, Post-test, 3-month follow-up) mixed factorial design, with Type of training as between-subject factors and Time as within-subject factor. The dependent variables will be behavioral and/or electrophysiological measures of executive functions (inhibition, shifting, working memory), memory functions (short term, episodic memory), and emotional well-being, quality of live and motivation."|t|f|f|f
34166977|NCT04929535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34166978|NCT01685775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34166979|NCT00005992||||TREATMENT||||||||
34166980|NCT02677935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34166981|NCT00631605|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34166982|NCT01347528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34166983|NCT04936061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34166984|NCT06365996|||COHORT||CROSS_SECTIONAL|||||||
34166985|NCT04911894|NA|SEQUENTIAL||TREATMENT||NONE||||||
34166986|NCT03195816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Comparison between experimental group and control group.|t|f|f|t
34166987|NCT02299726|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34166988|NCT01088334|||||PROSPECTIVE|||||||
34166989|NCT00263874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34166990|NCT04470635|||CASE_CONTROL||PROSPECTIVE|||||||
34166991|NCT02232217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34166992|NCT01345760|||CASE_ONLY||RETROSPECTIVE|||||||
34166993|NCT05625659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Two independent readers at each institution participating in the trial will be assigned the task of either interpreting the results of the DBT images or the CESM images: one reader will read only the DBT images, while the other will read only the CESM images. Both individuals will be blinded to the results of the other modality, and the readers may not discuss their findings before both finalize their interpretations and complete the requisite CRFs.|All participants who meet eligibility criteria will be offered Contrast Enhanced Spectral Mammography (CESM) in addition to their routine annual screening Digital Breast Tomosynthesis (DBT) at both the year 0 and year 1 visits.||||
34166994|NCT01290614|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33748046|NCT02466022|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748047|NCT00622167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748048|NCT03079752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors were not given access to the participants' original treatment assignments||f|f|f|t
33748049|NCT01197222|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33748050|NCT02566031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075959|NCT02872025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075960|NCT01442012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34075961|NCT00988000|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075962|NCT05036798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075963|NCT05201612|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive pembrolizumab 200 mg IV every 3 weeks and olaparib 300 mg, po, bid continuously until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.||||
34075964|NCT02721615|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075965|NCT01870986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34075966|NCT05852314|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34075967|NCT00351689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34075968|NCT05155748|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster randomized trial||||
34075969|NCT00121719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075970|NCT03036371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075971|NCT04677114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075972|NCT03746925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a 2 group, parallel study where they will be randomized into one of the two groups. One will receive SuperPATH approach and the other will receive DAA.|f|f|f|t
34075973|NCT00001577||||TREATMENT||||||||
34075974|NCT04292067|||CASE_CONTROL||PROSPECTIVE|||||||
34075975|NCT05311826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|it will be masking also data analyzer||f|f|f|t
34075976|NCT02277275|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34075977|NCT01693913|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34075978|NCT03683836|||COHORT||RETROSPECTIVE|||||||
34075979|NCT01476267|NA|SINGLE_GROUP||OTHER||NONE||||||
34075980|NCT01985100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075981|NCT03200561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075982|NCT03889249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|90 day outcomes are assessed in a blinded manner|The proposed trial is a pragmatic, registry linked, prospective, randomized (1:1) controlled, open-label parallel group clinical trial with blinded endpoint assessment of 1600 patients to test if intravenous tenecteplase (0.25 mg/kg body weight, max dose 25 mg) is non-inferior to intravenous alteplase (0.9 mg/kg body weight) in patients with acute ischemic stroke otherwise eligible for intravenous thrombolysis as per standard care.|f|f|f|t
34075983|NCT05198856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075984|NCT02430571|||CASE_ONLY||PROSPECTIVE|||||||
34075985|NCT03784157|||OTHER||PROSPECTIVE|||||||
34075986|NCT03825991|||COHORT||PROSPECTIVE|||||||
34075987|NCT04770506|||COHORT||PROSPECTIVE|||||||
34075988|NCT04708080|||COHORT||RETROSPECTIVE|||||||
34075989|NCT03844425|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Investigator will be masked with the randomization sequance \& allocation.||f|f|t|f
34075990|NCT04475471|||COHORT||PROSPECTIVE|||||||
34075991|NCT05270980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075992|NCT04685252|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Individually unique coding for each stickpack||t|t|t|t
33748051|NCT04458610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748052|NCT03455426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748053|NCT02911948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748054|NCT00007189|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33748055|NCT02176135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748056|NCT02345148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748057|NCT01116570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748058|NCT01694862|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748059|NCT04029922|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||MT-5111 (active drug)||||
33748060|NCT06237972|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study employs a primary two-arm randomized, controlled design to examine effects of a 4- weeks perturbation-based balance training with and without targeted NMES on reactive balance control and early gait fall risk predictors in stroke population. Forty participants will be randomly assigned (1:1) to the NMES (n=20) or No-NMES group (N=20). Participants will be assigned using blocked randomization to one of the two groups. The random allocation sequence will be computer generated. Additionally, a third group of age-matched healthy participants (n=20) will conduct the baseline 5-minutes walking test to collect baseline lower limb EMG patterns that will be used for the Altered muscle activation patterns (AMAP) analysis.||||
33748061|NCT05585723|||OTHER||CROSS_SECTIONAL|||||||
33748062|NCT02910648|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|We have adopted a randomized placebo control experimental design which requires the subjects to be blind to the subject's group assignment to minimize expectancy effects and the testing technician to be partially blind (blind to the sound cue group assignment and not blind to the go/no-go task) to minimize technician bias that could comprise the causal conclusions from being drawn.||t|t|t|f
33748063|NCT05290350|||COHORT||PROSPECTIVE|||||||
34166995|NCT02474563|||COHORT||PROSPECTIVE|||||||
34166996|NCT06263374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A randomization list will be centrally generated by an independent methodologist for each center and integrated into the electronic case report form. The physiotherapist will disclose the allocation to the participant during the inclusion visit, following clear, transparent, and appropriate information, and obtaining the participant's consent to participate in the study. This disclosure occurs after all measurements have been completed. The inclusion visit is scheduled 30 days ± 8 before the surgery.|Multi-centric randomized controlled trial|f|f|t|t
34166997|NCT01168349|||COHORT||PROSPECTIVE|||||||
34166998|NCT05404087|||COHORT||PROSPECTIVE|||||||
34166999|NCT02403999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34167000|NCT04449627|||COHORT||RETROSPECTIVE|||||||
34167001|NCT03360435|||COHORT||PROSPECTIVE|||||||
34167002|NCT00415129|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34167003|NCT03329768|||COHORT||PROSPECTIVE|||||||
34167004|NCT04184830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34167005|NCT03940729|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167006|NCT03579940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33748064|NCT02191982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748065|NCT01972841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748066|NCT06242626|||COHORT||PROSPECTIVE|||||||
33748067|NCT00224224|||||RETROSPECTIVE|||||||
33748068|NCT02201927|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33893497|NCT02617914|||OTHER||PROSPECTIVE|||||||
33893498|NCT06483477|RANDOMIZED|PARALLEL||PREVENTION||NONE||multinational, randomized, active-controlled, parallel-group, multicenter trial||||
33893499|NCT06378827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33893500|NCT01530490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893501|NCT00245232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33893502|NCT00303550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33893503|NCT03115450|||CASE_ONLY||PROSPECTIVE|||||||
33893504|NCT01104220|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33893505|NCT02506530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893506|NCT02833025|||COHORT||PROSPECTIVE|||||||
33893507|NCT01322828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893508|NCT04341571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized double-blind|Double-blind, controlled clinical trial|t|f|t|f
33893509|NCT01561287|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167007|NCT04171531|RANDOMIZED|PARALLEL||TREATMENT||NONE||At 6 months, the effect of treatment with Botox A or mid-urethral sling will be evaluated within a classic RCT model. The analysis will determine the effect of treatment on the primary outcome, change in Urogenital Distress Inventory (UDI) score at 6 months.||||
33748069|NCT05467553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167008|NCT00218504|||CASE_ONLY||PROSPECTIVE|||||||
33748070|NCT02806180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167009|NCT02181309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748071|NCT02980159|||COHORT||RETROSPECTIVE|||||||
33748072|NCT05944419|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Clinical Trial||||
33748073|NCT04139395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748074|NCT03716713|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33748075|NCT04250272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167010|NCT02892526|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34167011|NCT04006093|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two groups of participants will receive one single-dose of 5 mg of apixaban: the first group of participants with a normal renal function, the second group contains participants with end-stage renal disease treated with peritoneal dialysis.||||
34167012|NCT01593124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34167013|NCT00973453|NON_RANDOMIZED|PARALLEL||||NONE||||||
34167014|NCT00651339|||CASE_ONLY||PROSPECTIVE|||||||
34167015|NCT05217160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care givers and the investigators will be blinded to which treatment group the participants are randomized to receive.|Participants will be randomized to receive either treatment with Kerastat or treatment with Kerastat with Morphine.|t|t|t|f
34167016|NCT04926649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34167017|NCT01378988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854199|NCT05623722|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to two groups in parallel. All patients in both groups receive the same administration of acute gastrointestinal injury and enteral nutrition strategy according to the guidelines, and the routine practice of the ICU.For patients in the erector spinae plane block group, ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The interventions end on day 7 or cease when the patients are discharged from the ICU, died, or withdrew their consent.||||
34167018|NCT00479713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167019|NCT02040740|||COHORT||CROSS_SECTIONAL|||||||
33854200|NCT00685633|RANDOMIZED|||TREATMENT||||||||
34167020|NCT00795535|||COHORT||PROSPECTIVE|||||||
34167021|NCT00402168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167022|NCT00795704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167023|NCT01276639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167024|NCT00175786|||||PROSPECTIVE|||||||
34167025|NCT05362968|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34167026|NCT04538937|||OTHER||PROSPECTIVE|||||||
34167027|NCT02052804|||COHORT||PROSPECTIVE|||||||
34167028|NCT01508169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167029|NCT01620086|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34167030|NCT05661786|||COHORT||PROSPECTIVE|||||||
33748076|NCT02732366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854201|NCT05060068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The syringes and infusions will be identical for all of the groups and will run at the same rate in all subjects to enable blinding of the investigators. Outcomes will be evaluated by anesthesiologists who are blinded to the treatment allocation. Patients, nurses, observers, and the statistician will be blinded to patient allocation throughout the study period.||t|t|t|t
33854202|NCT00433459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854203|NCT00116337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854204|NCT02076178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167031|NCT03087695|||COHORT||PROSPECTIVE|||||||
34167032|NCT06117865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34167033|NCT02855034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167034|NCT01492205|||COHORT||PROSPECTIVE|||||||
34167035|NCT01671033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167036|NCT03242694|||COHORT||PROSPECTIVE|||||||
34167037|NCT03852134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167038|NCT02864121|NA|SINGLE_GROUP||SCREENING||NONE||||||
34167039|NCT05254106|||COHORT||RETROSPECTIVE|||||||
34167040|NCT02116881|||COHORT||PROSPECTIVE|||||||
34167041|NCT01976052|||CASE_CONTROL||PROSPECTIVE|||||||
34167042|NCT05889715|NA|SINGLE_GROUP||OTHER||NONE||The study will use a single-arm with participants to be enrolled in three groups of 15 each (n=45) into the Green Wellness Program: Plants-2-Plate||||
34167043|NCT04353245|||CASE_CONTROL||PROSPECTIVE|||||||
34167044|NCT05951946|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167045|NCT04370158|||COHORT||PROSPECTIVE|||||||
34167046|NCT02535325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167047|NCT03382990|||COHORT||RETROSPECTIVE|||||||
34167048|NCT03214107|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167049|NCT01633788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167050|NCT02268734|||CASE_ONLY||RETROSPECTIVE|||||||
34167051|NCT05676502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167052|NCT06206538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34167053|NCT02744365|||OTHER||PROSPECTIVE|||||||
34167054|NCT00027625||||TREATMENT||||||||
34167055|NCT02471235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34167056|NCT05659823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Current treatment: Patients receive elective or emergency CS. Guideline recommended treatment: Only elective CS included.||||
33854205|NCT02892084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33957786|NCT05476276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization assignment within an ISA will be blinded from study participants, staff from clinical sites, investigators, asset owners, IND sponsors, and/or designees. This blinding will be accomplished by providing identical investigational product and packaging for each asset and its corresponding control treatment. The use of IXRS will ensure the blinding is accomplished.|The Platform Protocol is intended to potentially accommodate different design plans for different assets. In addition, it is anticipated that the protocol may evolve over time, as lessons learned from earlier assets are used to fine tune the study design for later assets in an adaptive approach. For reasons of generalizability (including consideration of minimizing participant burden and being attractive to asset holders), a parallel-group design will typically be employed, and it is the current intention that designs should provide 80% power to detect an effect size of 0.35 on the primary efficacy outcome|t|t|t|f
33957787|NCT05052879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957788|NCT06694974|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33854206|NCT03095690|NA|SINGLE_GROUP||OTHER||NONE||||||
33854207|NCT03022279|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33854208|NCT06386718|||OTHER||CROSS_SECTIONAL|||||||
33854209|NCT05406076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854210|NCT00589680|||OTHER||RETROSPECTIVE|||||||
33854211|NCT00176397|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854212|NCT04331223|||COHORT||RETROSPECTIVE|||||||
33854213|NCT01839487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854214|NCT06065969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957789|NCT06234930|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will undergo sequential exposure to various stimulation conditions in a random order. The nature of each condition will not be disclosed to participants. The experimenter is unmasked to ensure protocol adherence.|Parallel, non-comparative Study Model: Sham-controlled study where participants from two groups (Cognitively Impaired due to AD and Cognitively Healthy participants) are exposed to both active and sham conditions.|t|f|f|f
33957790|NCT02658500|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33957791|NCT03280563|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957792|NCT06080503|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957793|NCT06264271|||CASE_CONTROL||RETROSPECTIVE|||||||
33957794|NCT00267579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957795|NCT06697756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data and statistical analysis will be performed by a researcher blinded to groups and participants' identities.|Participants will undergo anthropometrics, familiarization, and strength test, and will be randomized to a high-effort, or a low-effort resistance training protocol, that will be carried out 2 days/week, for 16 weeks, and will be composed of 7 exercises (hex bar squat, seated chest press, leg press, lat pulldown, leg extension, shoulder press, leg curl, always in this order). Load will be set at 10-RM load (75% 1-RM). Participants will be instructed to perform the concentric (lifting) phase of the repetition as fast as they can (\~0.5 seconds), and to perform the eccentric phase in 2 seconds. Psychological responses (perceived exertion, enjoyment, feeling scale, discomfort, and self-efficacy) will be assessed. Anthropometrics will be repeated after training, and before and after the training period, glycemic control will be assessed via a continuous glucose monitoring device. The main outcomes will be compared between training interventions, pre-training data will used as comparator.|f|f|f|t
33957796|NCT05482893|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957797|NCT04136626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957798|NCT02817269|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33957799|NCT04573244|||CASE_ONLY||PROSPECTIVE|||||||
33957800|NCT02122744|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33957801|NCT06454058|||COHORT||RETROSPECTIVE|||||||
33957802|NCT06704074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957803|NCT02528734|||COHORT||PROSPECTIVE|||||||
33957804|NCT00000784|||CASE_ONLY||PROSPECTIVE|||||||
33957805|NCT01149083|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957806|NCT06702800|||OTHER||PROSPECTIVE|||||||
33957807|NCT03311828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957808|NCT06137729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33957809|NCT06702748|||COHORT||RETROSPECTIVE|||||||
33957810|NCT05995964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957811|NCT03963739|||CASE_ONLY||PROSPECTIVE|||||||
33957812|NCT05489380|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|the endoscopist will remain blinded to the AccuMeasure measurement outcomes, to avoid a learning effect that could influence subsequent measurements. Even so, all pathologist assessments will be done independent of the study allocation.|As optical assessment of polyps has a high interobserver variability, the order of polyps' size measurement using biopsy forceps or AM will be randomized per patient. Therefore, this study consists of two arms: Optical polyp size assessment, followed by biopsy forceps and then AM measurement (1), and optical assessment, followed by AM measurement and then biopsy forceps assisted assessment (2) (Figure 1).|f|f|f|t
33957813|NCT05043324|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957814|NCT06702709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33854215|NCT03453320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854216|NCT02070887|||CASE_CONTROL||PROSPECTIVE|||||||
33854217|NCT06015178|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33854218|NCT01319188|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33854219|NCT01135407|||||PROSPECTIVE|||||||
33854220|NCT05610293|||COHORT||RETROSPECTIVE|||||||
33854221|NCT05685927|||COHORT||PROSPECTIVE|||||||
33854222|NCT04175626|||COHORT||PROSPECTIVE|||||||
33854223|NCT02622815|||CASE_CONTROL||PROSPECTIVE|||||||
33854224|NCT03030170|RANDOMIZED|PARALLEL||OTHER||NONE||intervention with reinforced medical device, or not||||
34061395|NCT03104218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A randomisation list will be established prior to the initiation of the study using a random number generator. The randomisation list will be generated by an independent research assistant not involved in data collection. Allocation will be concealed in sealed and opaque envelopes that will be sequentially numbered. Randomisation will be stratified to ensure balance of the treatment groups with respect to sex. A blocked randomisation will also be used to make sure that two equal groups of 20 participants are obtained. Given that it is possible to blind the treating PT, the participants and the evaluators, a triple-blind design will be used. An independent research assistant from the CIRRIS will open the randomisation envelope indicating the participant's assignment. The research assistant will be blind to the baseline evaluation results. The research assistant will be the one who will set-up the parameters on the tDCS before treatment sessions with tDCS (real or sham tDCS).|This triple-blind (patients, therapist \& evaluator), parallel-group RCT will include four evaluation sessions over 3 months (baseline, week 3, week 6, 3-month) and 8 supervised physiotherapy treatments during a 6-week rehabilitation program (3 sessions the 1st week, 2 sessions the 2nd weeks, 3 session in the last 4 weeks). Thereafter, participants will be randomly assigned to one of two intervention groups, and then take part in their assigned 6-week intervention. At week 3, 6, and 12, the self-administered questionnaires will be re-administered, while US measurements will only be re-evaluated at week 6.|t|t|f|t
34061396|NCT00423397||||TREATMENT||NONE||||||
34061397|NCT04302480|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061398|NCT02633566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061399|NCT06301009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34061400|NCT01500967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061401|NCT02673268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061402|NCT00630084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854225|NCT04421833|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33854226|NCT01393860|||COHORT||RETROSPECTIVE|||||||
33893510|NCT00779168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061403|NCT01982838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061404|NCT04202315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061405|NCT00475631|||CASE_ONLY||RETROSPECTIVE|||||||
34061406|NCT03955965|||COHORT||RETROSPECTIVE|||||||
34061407|NCT06429137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061408|NCT06326684|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34061409|NCT02507843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061410|NCT02394236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061411|NCT02671019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061412|NCT02334176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061413|NCT00756665|||COHORT||PROSPECTIVE|||||||
34061414|NCT00971061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167057|NCT04821258|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"CRC candidates for surgery with curative intent will be considered to include in the study. Patients who fulfill criteria will be screened and randomly allocated to be treated with MICODIGEST 2.0 or placebo previous to the admission. Patients will be also stratified based on tumor location (distal or proximal to splenic flexure).~Patients will be followed for 4-6 weeks until surgery intervention."|t|t|t|f
34167058|NCT03612778|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial with two parallel groups.||||
34167059|NCT01673828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167060|NCT03314701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167061|NCT02333357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167062|NCT03482531|||OTHER||PROSPECTIVE|||||||
34167063|NCT05543902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167064|NCT02857608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167065|NCT01145846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167066|NCT03563820|||COHORT||PROSPECTIVE|||||||
34167067|NCT01496235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167068|NCT04006951|NA|SINGLE_GROUP||OTHER||NONE||||||
34167069|NCT03583853|||CASE_CROSSOVER||PROSPECTIVE|||||||
34167070|NCT01769963|NA|SINGLE_GROUP||||NONE||||||
34167071|NCT05931926|||COHORT||PROSPECTIVE|||||||
34167072|NCT02510625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893511|NCT01771783|RANDOMIZED|CROSSOVER||||NONE||||||
34167073|NCT06007183|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, care providers, and investigator will not be blinded for the timing of when the participant will receive the vaccine booster or placebo booster. They will be blinded to all booster treatment assignments (vaccine booster or placebo booster).|All eligible participants in the youngest (12 to \<18 years) and oldest 2 (≥65 years) age groups will be assigned to a booster at Year 3 (Group 1). All other participants will be randomized 1:1:1 to a booster at Year 3 (Group 1), 4 (Group 2), or 5 (Group 3). Prior to booster dose administration participants will be randomized 1:1 to CHIKV VLP vaccine booster or placebo booster.|t|t|t|f
34167074|NCT00359996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167075|NCT02343393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167076|NCT03326778|||CASE_ONLY||PROSPECTIVE|||||||
34167077|NCT02489071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33854227|NCT04815967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|No other parties are masked in the clinical trial.|A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment in Safety Study of MYOBLOC|t|t|t|t
33854228|NCT01556477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854229|NCT00819520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854230|NCT02178670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33854231|NCT00240344|||CASE_ONLY||PROSPECTIVE|||||||
33854232|NCT05389085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This prospective non-blinded clinical study will include 75 patients with suspicious pigmented skin tumours (i.e. malignant melanomas, lentigo maligna, pigmented nevi, and pigmented basal cell carcinomas) referred to or diagnosed at Dept. of Dermatology, BFH. All tumours are histologically verified by skin biopsy or surgical excision. Patients who meet the inclusion criteria will be enrolled if they consent. If patients demonstrate more than one skin tumour within the same anatomical location, only one lesions will be included and scanned.||||
33854233|NCT02240693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854234|NCT02796157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854235|NCT00201747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854236|NCT03482583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854237|NCT05368051|||COHORT||PROSPECTIVE|||||||
33854238|NCT05169320|||COHORT||PROSPECTIVE|||||||
33854239|NCT04037904|||COHORT||PROSPECTIVE|||||||
33854240|NCT02862834|||CASE_ONLY||PROSPECTIVE|||||||
33854241|NCT03784560|||COHORT||PROSPECTIVE|||||||
33854242|NCT05880615|||COHORT||RETROSPECTIVE|||||||
33854243|NCT04960735|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A single group intervention that will collect health-related Quality of Life evidence from patients with cancer from 13 hospitals for six months. The multicentre study combines an implementation research component and effectiveness, using quantitative and qualitative methods for data collection and analysis. Outcomes will be analysed not only at individual level but also at health organisation level.||||
33854244|NCT02943226|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33854245|NCT03809429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854246|NCT02038491|||COHORT||PROSPECTIVE|||||||
33854247|NCT03008707|||CASE_CONTROL||PROSPECTIVE|||||||
33854248|NCT04461483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854249|NCT04153123|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The preparation of the syringes was performed by one of the researchers not involved in the execution of the blockades. The same anesthesiologist performed all the blocks, while the same ophthalmologist did the ocular monitoring measures.|"Group 1: Peribulbar anesthesia with 2% lidocaine with epinephrine 1/200,000.~Group 2: Peribulbar anesthesia with 2% lidocaine without epinephrine."|t|t|t|t
33854250|NCT02207881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854251|NCT04818333|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of SHR-A1811||||
33854252|NCT06409520|||CASE_CONTROL||PROSPECTIVE|||||||
33854253|NCT05555056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham stimulation mode will be used in the HD-tES machine. For sham stimulation, the current will be applied for 30 seconds ramp-up followed by 30 seconds ramp-down, and thus no active stimulation will be administered except for the initial and last 1 minutes.|Thirty participants among those who are enrolled in the parent clinical trial will be recruited. Participants will receive 5-week CBTm treatment and a battery of psychological assessment as part of the parent clinical trial. Individuals enrolled in the current study will receive daily HD-tDCS during the period of CBTm treatment (5-week). Half of the individuals will receive real stimulation and the other half will receive sham stimulation. Participants will be scanned with MRI before and after the 5-week treatment. EEG data will be collected before (10 minutes), during (20 minutes) and after (20 minutes) each HD-tDCS session .|t|f|f|t
33854254|NCT02937064|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33854255|NCT06524752|||COHORT||PROSPECTIVE|||||||
33854256|NCT04883437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854257|NCT05979454|||CASE_ONLY||PROSPECTIVE|||||||
33854258|NCT03111251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854259|NCT04160767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854260|NCT05882097|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will not know which group they belong to. Due to procedures to implement the study, it is inevitable that the operations team will know who will belong to the control and treatment arms (control participants will not receive the Transform program). This study will be a single masked study.|"This study is a cluster-randomised controlled trial. A total of 4,800 participants from 160 communities will be randomly assigned to one of the two treatment arms: Transform and Control. The treatment will be assigned at the community level, so all participating households in a community will be in the same treatment arm. This will prevent dissemination of information and mixing of control and treatment groups among the participants.~The RCT will be rolled out in two batches. For each batch (i.e. 40 communities), a list of eligible communities will be drawn up and randomised into one of the treatment arms. To reduce the risk of bias, communities and participants will be recruited before the clusters have been randomly allocated."|t|f|f|f
33748077|NCT04576169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Operating surgeon, operating theatre staff, coordinating research assistant (CRA), and research assistants (RA) cannot be blinded to the allocation. In central or radial tear randomization cohort, outcome assessors will be blinded and they will not participate in the care at any other point in the trial, except during follow-up visits. The participants are also blinded, resulting in a triple-blinded randomization cohort since also trialist are blinded in data analysis phase as in foveal tear randomization cohort. In the ulnar tear cohort, randomization cannot be blinded due to differing postoperative treatment.||t|f|t|t
33748078|NCT02372409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748079|NCT03375944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854261|NCT03794167|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33854262|NCT00420433|||CASE_ONLY||PROSPECTIVE|||||||
33854263|NCT03363763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Subjects will be randomly assigned in a 1:1:1 ratio to receive 1 of 2 treatments or placebo. The randomization is stratified by site.~Subjects who complete the double-blind phase of the study with an overall compliance rate \>80% and \<120%, as determined by weight of returned study medication, will be offered entry into an open-label period for an additional 12 weeks."|t|t|t|t
33854264|NCT04464954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854265|NCT04398953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854266|NCT00582686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854267|NCT04261491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854268|NCT05165797|||CASE_ONLY||PROSPECTIVE|||||||
33854269|NCT06090877|||COHORT||PROSPECTIVE|||||||
33854270|NCT02057523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854271|NCT02683005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854272|NCT05065333|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Emergency Department sites (unit of randomization) cannot be blinded; however patients who are subjects of the intervention are not aware of the arm of the site in the clinical trial.|This will be a stepped wedge cluster randomized trial, with the site as the unit of randomization. There will be five study periods and four sites. In the first period no sites will receive the intervention. During each subsequent period, one site will crossover to receive the intervention.|t|f|f|f
33854273|NCT00284986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854274|NCT00235547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33854275|NCT03200379|||COHORT||PROSPECTIVE|||||||
33854276|NCT05102604|RANDOMIZED|PARALLEL||PREVENTION||NONE|Both groups will be instructed to continue to follow their habitual diet but the intervention group will receive one avocado per day|Participants will be randomly assigned to one of two equally sized groups.||||
33854277|NCT00947557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854278|NCT02801968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854279|NCT03457038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Major patients admitted to the Resuscitation Department of the CHU Toulouse-Rangueil for severe sepsis, or development of sepsis during the stay resuscitation; sepsis defined by a SOFA score ≥ 2||||
33854280|NCT05872360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33854281|NCT04876677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854282|NCT02874339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854283|NCT01401192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854284|NCT00627211|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33854285|NCT02466633|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957815|NCT03469882|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinded outcomes assessment|Randomized controlled trial|f|f|f|t
33957816|NCT01474148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957817|NCT05650658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33957818|NCT03618680|||COHORT||PROSPECTIVE|||||||
33957819|NCT05394831|NA|SEQUENTIAL||TREATMENT||NONE||||||
33957820|NCT00501800|||CASE_CONTROL||PROSPECTIVE|||||||
33957821|NCT06694168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"To calculate the sample size, statistically significant EVA values were taken from a previous series of cases in the same line of research. The values were analyzed using STATA software, resulting in an N of 26 patients (26 defects). Finally, a final N of 30 defects to be treated was established (1 defect per patient), overestimating the initial N in case of possible losses during the follow-up period. If there is more than one site per patient that needs to be treated, it will be decided randomly which site will be included in the study, treating all sites with the same technique.~The sample was randomized using the digital STATA software, separating the sample into sites to be treated using the EPP technique with defect filling using LPRF (15 defects) and sites to be treated with the same technique but without LPRF (15 defects)."|f|t|f|f
33957822|NCT04024280|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33957823|NCT06084481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957824|NCT05480956|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33957825|NCT03296215|||COHORT||PROSPECTIVE|||||||
33957826|NCT06038916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957827|NCT04794582|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"For observer masking, the observer (outcomes assessor) will belong to the General Surgery team that is not directly involved with the transplantation procedure and agrees not to verify the assignment in the transplantation surgical protocol.~Finally, the masking of the analyst (investigator) is achieved through collaboration with the Clinical Biostatistics Unit in the data analysis of the study (independent analyst) using a pseudo-anonymized database."|Blinded parallel randomized clinical trial. A stratified allocation by the variable obesity will be performed using permuted blocks of variable size in each stratum. To guarantee the concealment of the randomization sequence, the randomization codes will be kept in opaque envelopes with correlative numerical identification that will be opened once it has been verified that the patient meets the inclusion criteria and has signed the informed consent form.|t|f|t|t
33957828|NCT00667134|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957829|NCT04637282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, within-subject, dose-titration design|t|t|t|t
33957830|NCT02362646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957831|NCT01072318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957832|NCT06700876|||CASE_CONTROL||PROSPECTIVE|||||||
33957833|NCT03533829|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34061415|NCT03514706|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Lung ultrasound will be done by an investigator blinded to group allocation|"Adult patients scheduled for elective thoracic surgery with one lung ventilation will be included in the study. Patients will be randomly allocated into one of two groups:~Group V: will receive volume controlled mechanical ventilation. Group P: will receive pressure controlled mechanical ventilation."|f|f|t|f
34061416|NCT06029153|NA|SINGLE_GROUP||TREATMENT||NONE||Self-control||||
34061417|NCT00565669|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061418|NCT02707042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34061419|NCT06717802|||COHORT||PROSPECTIVE|||||||
34061420|NCT00909415|||||RETROSPECTIVE|||||||
34061421|NCT06289686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061422|NCT03632226|||COHORT||PROSPECTIVE|||||||
34061423|NCT03390985|||COHORT||PROSPECTIVE|||||||
34061424|NCT03528057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The surgical team and the patient will be blinded as to which arm the patient will be assigned both at the time of recruitment in the clinic and at the start of surgery. The patient and surgeon will both be blinded at the start of the surgery (RALPN). The surgeon will be informed intra-operatively during the renorrhaphy portion of the procedure as to which arm the patient will be assigned, at which point he will be un-blinded. Following completion of the entire surgery, the patient will also be informed as to which arm he/she was randomized upon request.||t|t|t|f
34061425|NCT00546455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061426|NCT03987100|||OTHER||PROSPECTIVE|||||||
34167078|NCT05876507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Outcomes Assessor)|This is a single blind, randomized controlled study. The intervention group will receive an audio record explaining progressive relaxation exercise. Then participants will undergo training about the exercises. After training, the intervention group will perform the exercises at home by their own. The exercises will be performed everyday for 4 weeks about 25-30 minutes. Principal investigator will check the participants weekly about implementation of exercises.|t|f|f|t
34167079|NCT05482828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167080|NCT00043043|RANDOMIZED|||PREVENTION||DOUBLE||||||
34167081|NCT01881516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167082|NCT01599000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167083|NCT00743249|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34167084|NCT00390767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167085|NCT01432405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061427|NCT02842229|||CASE_ONLY||RETROSPECTIVE|||||||
34061428|NCT01848509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061429|NCT00114738|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167086|NCT05162677|||COHORT||PROSPECTIVE|||||||
34167087|NCT04820348|||COHORT||CROSS_SECTIONAL|||||||
34167088|NCT02524171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research Assistants conducting the 6- and 12- month outcome assessments are blinded to condition assignment.||f|f|f|t
34167089|NCT04632771|||COHORT||CROSS_SECTIONAL|||||||
34167090|NCT04657874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple blind randomization and computer-based random allocation||t|t|t|f
34167091|NCT06154564|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34061430|NCT05127824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061431|NCT04775576|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34061432|NCT05878665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061433|NCT02086448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167092|NCT04011657|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|A parallel-group, 1:1 block-cluster randomized, cross-over study|||||
34167093|NCT04335617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this double blinded study Daflon and placebo are packed in the same manner, the blind is also protected by randomization. Only the principal investigator can break the blind in case of ethical or threatening patterns by contacting the sponsor and clinical research item.|This is a multicenter, randomized, double-blind, placebo-controlled Phase III study.|t|f|t|f
34167094|NCT02864563|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33854286|NCT02874274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854287|NCT05132283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854288|NCT00887432|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33854289|NCT00002996||||SUPPORTIVE_CARE||||||||
33854290|NCT01576653|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33854291|NCT06301282|||COHORT||PROSPECTIVE|||||||
33854292|NCT00304525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33854293|NCT04156854|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33854294|NCT02995954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854295|NCT00679237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854296|NCT06063785|||COHORT||PROSPECTIVE|||||||
33854297|NCT00106145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854298|NCT02920619|||CASE_ONLY||CROSS_SECTIONAL|||||||
33854299|NCT01122095|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33854300|NCT01131234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854301|NCT04780347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854302|NCT06223204|NA|SINGLE_GROUP||OTHER||NONE||||||
33854303|NCT02607696|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854304|NCT01788098|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33854305|NCT02932007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854306|NCT01209143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854307|NCT05663853|||OTHER||PROSPECTIVE|||||||
33854308|NCT03890718|NA|SEQUENTIAL||TREATMENT||NONE||||||
33854309|NCT00502021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33854310|NCT06137014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854311|NCT05384782|||COHORT||RETROSPECTIVE|||||||
33854312|NCT04617210|||COHORT||PROSPECTIVE|||||||
33854313|NCT04997759|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854314|NCT05740735|||COHORT||PROSPECTIVE|||||||
33854315|NCT01684332|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33957834|NCT01216319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957835|NCT06700694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34167095|NCT04995575|||COHORT||CROSS_SECTIONAL|||||||
34167096|NCT00643968|RANDOMIZED|PARALLEL||||NONE||||||
34167097|NCT00972101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748080|NCT03580876|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label study|two strategies||||
33854316|NCT03797261|NA|SEQUENTIAL||TREATMENT||NONE||||||
33854317|NCT01079741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854318|NCT02890433|||COHORT||RETROSPECTIVE|||||||
33854319|NCT04107376|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33854320|NCT03701815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854321|NCT03309306|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A subset of subjects will complete Phase I, which is the lab-based portion of the study, prior to the RCT.|f|f|t|t
33854322|NCT04188691|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33854323|NCT04448197|||OTHER||PROSPECTIVE|||||||
33854324|NCT04491669|||CASE_ONLY||RETROSPECTIVE|||||||
33854325|NCT01676909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33854326|NCT05517837|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33854327|NCT00095654|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33854328|NCT02480153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854329|NCT04989413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854330|NCT00447304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854331|NCT05681858|||COHORT||PROSPECTIVE|||||||
33854332|NCT03426254|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intent of this study was to assess the safety and efficacy of two forms of Talazoparib therapy for the treatment of advanced solid tumors . After an enrollment period, patients will randomized to receive oral Talazoparib (1 mg, one times a day ) or subcutaneously Talazoparib (1 mg subcutaneous injection by pen-syringe / mechanical dispenser) .||||
33854333|NCT03775070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854334|NCT00252733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854335|NCT03314597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854336|NCT01166867|||CASE_ONLY||PROSPECTIVE|||||||
33854337|NCT01680068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854338|NCT03450967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854339|NCT03489473|||CASE_ONLY||PROSPECTIVE|||||||
33854340|NCT00187967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33854341|NCT00167960|||CASE_CONTROL||PROSPECTIVE|||||||
33854342|NCT02739373|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33854343|NCT02312388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854344|NCT04386187|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"This is a partial controlled-feeding trial in which participants will be initially randomized to a food intervention or education control and then will be crossed-over after 12 weeks."|f|f|t|f
33854345|NCT03691246|||COHORT||RETROSPECTIVE|||||||
33854346|NCT00006165||||PREVENTION||||||||
33854347|NCT03626519|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33854348|NCT03450512|||CASE_ONLY||PROSPECTIVE|||||||
33854349|NCT05925179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33854350|NCT04361188|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33854351|NCT00061529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33854352|NCT05397184|NA|SINGLE_GROUP||OTHER||NONE|Not applicable (Open Label)|Phase 1, open label, non randomised||||
33854353|NCT02647294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854354|NCT02754817|||COHORT||RETROSPECTIVE|||||||
34167098|NCT04221724|NA|SINGLE_GROUP||PREVENTION||NONE||Multicenter single group interventional study||||
33854355|NCT03819374|||COHORT||PROSPECTIVE|||||||
34061434|NCT05083676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We propose an interventional prospective study with hybrid design that evaluates both implementation of Acceset platform (e.g., fidelity, adoption, and utility), as well as clinical outcomes (e.g., anxiety and depressive symptoms) using randomized controlled trials. The intervention comprises of two components: (1) digital peer support training and (2) digital intervention involving three features, specifically emotionality, motivations and functional improvement serving as digital markers of psychological well-being, the peer emotional disclosure process, as well as community engagement.||||
34167099|NCT01165541|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167100|NCT01749969||PARALLEL||TREATMENT||NONE||||||
34167101|NCT02339311|||COHORT||PROSPECTIVE|||||||
34167102|NCT03558919|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controled clinical trial||||
34167103|NCT04644211|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167104|NCT03264365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data analyses|Pragmatic, non-blinded, multicenter, parallel-group randomized controlled trial|f|f|f|t
34167105|NCT05154084|||COHORT||OTHER|||||||
34167106|NCT00165672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167107|NCT00603330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167108|NCT03145311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34167109|NCT05626101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167110|NCT01793623|||CASE_ONLY||PROSPECTIVE|||||||
34167111|NCT00481702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167112|NCT06473415|||COHORT||PROSPECTIVE|||||||
34167113|NCT05887921|RANDOMIZED|PARALLEL||TREATMENT||NONE||Surgical, observational, prospective, monocentric study.||||
34167114|NCT05724992|NA|SINGLE_GROUP||OTHER||NONE||||||
34167115|NCT06184607|||COHORT||PROSPECTIVE|||||||
34167116|NCT04839016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167117|NCT00004092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167118|NCT01966822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167119|NCT04648813|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34167120|NCT06054100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Electrocardiography parameters assessors and clinical laboratory technicians were masked to the study patient group allocation||f|f|f|t
34167121|NCT05003466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167122|NCT00880620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167123|NCT02401347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167124|NCT02682147|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34167125|NCT00257699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167126|NCT04117204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34167127|NCT04818619|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34167128|NCT02199366|||COHORT||PROSPECTIVE|||||||
34167129|NCT00175513|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167130|NCT05100615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34167131|NCT03536585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Independent reviewer to identify the one-month and four-month post-treatment photograph of the mons pubis and labia.||f|f|f|t
34167132|NCT00584012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854356|NCT01718353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854357|NCT02409368|NA|SINGLE_GROUP||OTHER||NONE||||||
33854358|NCT02303522|||COHORT||RETROSPECTIVE|||||||
33854359|NCT03753659|NA|SINGLE_GROUP||TREATMENT||NONE||Immunotherapy with pembrolizumab in combination with local ablation||||
33854360|NCT04291820|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will be blinded by the arm inclusion. The outcomes will be measured by the blinded nurse in the PACU|A prospective interventional single-blind randomized trial|f|f|f|t
33854361|NCT01907360|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, single-treatment||||
33854362|NCT03897244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854363|NCT05353673|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators are undertaking a parallel group, multicenter, randomized controlled trial of 100 adults with steroid-resistant/ relapse ITP in China. Patients were randomized to Sitagliptin plus danazol and danazol monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.||||
33854364|NCT00605644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854365|NCT05219474|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33854366|NCT00065286|||DEFINED_POPULATION||PROSPECTIVE|||||||
33854367|NCT06294054|||COHORT||PROSPECTIVE|||||||
33854368|NCT05172349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854369|NCT03686748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participant in the Chronic Pain Group are initially blinded to the intervention they will be receiving in the study.~Healthy participants under go all assessments in the study."|Two group, single blind for chronic pain patients receiving intervention, additional basic science component with baseline comparisons between patients and healthy controls.|t|f|f|f
33854370|NCT02569203|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33854371|NCT01669876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854372|NCT01995851|||CASE_CONTROL||PROSPECTIVE|||||||
33854373|NCT06340399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|this is a open label use study|patients receiving BCAA|f|t|t|t
33854374|NCT03215810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854375|NCT00407277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33854376|NCT05021094|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|blind experiment|Subclinical POI and POI patients|t|t|t|t
33854377|NCT00920049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33854378|NCT04009915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33854379|NCT01911065|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854380|NCT00883077|||CASE_CONTROL||PROSPECTIVE|||||||
33854381|NCT02641223|||COHORT||PROSPECTIVE|||||||
33854382|NCT06043167|||COHORT||PROSPECTIVE|||||||
33854383|NCT02835326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33854384|NCT01313689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854385|NCT00330265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854386|NCT06333262|NA|SEQUENTIAL||TREATMENT||NONE||||||
34061435|NCT04888845|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34061436|NCT03084068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061437|NCT05112042|||COHORT||CROSS_SECTIONAL|||||||
34061438|NCT00792506|NA|SEQUENTIAL||TREATMENT||NONE|This was an open label|||||
34061439|NCT03285659|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34167133|NCT04457765|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34167134|NCT01854359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167135|NCT03667755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167136|NCT05668832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167137|NCT05792813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167138|NCT04889508|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking will be used since both participants and staff need to be aware which condition the participant belongs to in order to be able to attain and provide the appropriate training and practice prior to starting the actual interventions.|||||
34167139|NCT00940940|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34167140|NCT04332107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167141|NCT05122728|||CASE_CONTROL||PROSPECTIVE|||||||
33748081|NCT03772301|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33854387|NCT00186394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854388|NCT05725629|||COHORT||CROSS_SECTIONAL|||||||
33854389|NCT06086925|NA|SEQUENTIAL||TREATMENT||NONE||All subjects will be a part of the same treatment group and receive the same dosage.||||
33854390|NCT03975738|||OTHER||PROSPECTIVE|||||||
33854391|NCT05536011|||COHORT||PROSPECTIVE|||||||
33748082|NCT03557164|||COHORT||PROSPECTIVE|||||||
34061440|NCT01315041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061441|NCT01007760|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34061442|NCT04384770|||COHORT||PROSPECTIVE|||||||
34061443|NCT05559424|RANDOMIZED|PARALLEL||TREATMENT||NONE||Before enrollment start, the plausibility of the study hypothesis will be verified in an experimental pilot randomized investigation conducted n an ex-vivo beating heart animal model||||
34061444|NCT06731595|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061445|NCT00424021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061446|NCT02259634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061447|NCT02093390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061448|NCT05061017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061449|NCT02467894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061450|NCT04498000|||COHORT||PROSPECTIVE|||||||
33854392|NCT01197482|||CASE_CONTROL||PROSPECTIVE|||||||
33854393|NCT02661087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854394|NCT03543293|||COHORT||RETROSPECTIVE|||||||
33854395|NCT02675868|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33854396|NCT00286260|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33854397|NCT02054988|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33854398|NCT05251467|||OTHER||PROSPECTIVE|||||||
33854399|NCT00323856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854400|NCT01937156|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893512|NCT01374698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893513|NCT04619407|||COHORT||PROSPECTIVE|||||||
33893514|NCT02120417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893515|NCT02532231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893516|NCT01492010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893517|NCT05149196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33893518|NCT05587881|||COHORT||PROSPECTIVE|||||||
33893519|NCT05990803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893520|NCT04919629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893521|NCT04083495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893522|NCT01612234|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33893523|NCT04407169|||COHORT||RETROSPECTIVE|||||||
33893524|NCT03525873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893525|NCT01287663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893526|NCT05363917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Arm 1: Natrunix with MTX placebo (+folate) Arm 2: Natrunix placebo with MTX (+folate)|t|f|t|f
33893527|NCT02145130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893528|NCT03006211|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33893529|NCT05886361|||CASE_CONTROL||RETROSPECTIVE|||||||
33893530|NCT00041314||||TREATMENT||||||||
33893531|NCT02469246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893532|NCT06651411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893533|NCT05930860|||CASE_ONLY||PROSPECTIVE|||||||
33893534|NCT00885911|||COHORT||PROSPECTIVE|||||||
33893535|NCT05014178|||COHORT||CROSS_SECTIONAL|||||||
33893536|NCT03315429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893537|NCT02490657|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33893538|NCT05240261|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33893539|NCT05363007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893540|NCT06172101|||OTHER||PROSPECTIVE|||||||
33893541|NCT04960358|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33893542|NCT00762346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893543|NCT04708587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893544|NCT01209858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893545|NCT06498921|||COHORT||RETROSPECTIVE|||||||
33893546|NCT01365221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893547|NCT03818269|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33893548|NCT06528431|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomization comparing 2 therapeutic strategies||||
33893549|NCT01012661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167142|NCT05259735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Final outcome assessment will be conducted after 6 month for both arms by blind assessor.||f|f|f|t
33854401|NCT03326453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Principal investigator ,main supervisor and co-supervisor cannot be blinded as the implant placement technique for both groups will be different. In addition during assessment of 2ry outcome (bone height change) the x-ray will reveal the difference in the shape of both types of implants thus assessor couldn't be blind.||t|f|f|f
33854402|NCT04832282|NA|SINGLE_GROUP||OTHER||NONE||||||
33854403|NCT04480125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854404|NCT03466996|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854405|NCT00319839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854406|NCT00580346|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|t|f
33854407|NCT02216045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854408|NCT01355653|RANDOMIZED|CROSSOVER||||NONE||||||
33854409|NCT01234753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33854410|NCT00234806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854411|NCT05252650|||CASE_CONTROL||PROSPECTIVE|||||||
33854412|NCT01130584|||COHORT||PROSPECTIVE|||||||
33854413|NCT00014326|RANDOMIZED|||TREATMENT||||||||
33854414|NCT00530907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854415|NCT02501070|||COHORT||RETROSPECTIVE|||||||
33854416|NCT01127269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854417|NCT05938374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Preoperative moderately fractionated RT with Fluzoparib Preoperative moderately fractionated RT without Fluzoparib||||
33854418|NCT03172182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33854419|NCT04514666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854420|NCT05871177|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, single-arm, multicentric, pilot clinical study||||
33854421|NCT05241457|||COHORT||PROSPECTIVE|||||||
33854422|NCT02121834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33854423|NCT01672723|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33854424|NCT00014131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854425|NCT04707651|NA|SINGLE_GROUP||TREATMENT||NONE||Lifestyle intervention including formula diet||||
33854426|NCT03706313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33854427|NCT06011174|||CASE_ONLY||PROSPECTIVE|||||||
33854428|NCT01945541|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33854429|NCT02680327|||COHORT||PROSPECTIVE|||||||
33854430|NCT02372656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854431|NCT04890925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is an experimental design. A comparison with control group is made to evaluate time related changes. The intervention (Community Support Network) group will be compared with a group receiving usual care to investigate 6 months intervention-induced effect.|t|f|f|t
33854432|NCT05236478|||CASE_CONTROL||PROSPECTIVE|||||||
33854433|NCT05635981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The operator who performed the composite restorations is not blinded. Two evaluators who are responsible for the assessment of the clinical performance of restorations according to FDI criteria and the participants are blinded to the study groups.||t|f|f|t
33854434|NCT05629481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854435|NCT03866304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854436|NCT03050255|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33957836|NCT04762316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The number of post-recruiting people who have fibroids is divided into 2 groups~* The group of pregnancy uterine fibroids uses drugs under study.~* The group of pregnancy uterine fibroids uses a placebo"|Selection of women ages 18 to 40, with pregnancy uterine fibroids and pregnancy in the 8th week of pregnancy.|t|f|t|f
34167143|NCT01370902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854437|NCT05432726|||COHORT||PROSPECTIVE|||||||
33854438|NCT02086123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854439|NCT02631512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167144|NCT05395637|||CASE_ONLY||CROSS_SECTIONAL|||||||
34167145|NCT01360320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167146|NCT03194906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, double-blind, placebo-controlled trial design.|t|t|t|t
34167147|NCT00757237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167148|NCT05829954|||OTHER||PROSPECTIVE|||||||
34167149|NCT04630665|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34167150|NCT01796717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33854440|NCT00390182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854441|NCT05745831|NA|SINGLE_GROUP||OTHER||NONE||Prospective mulicentric study||||
33957837|NCT05887973|||COHORT||PROSPECTIVE|||||||
33957838|NCT03368872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel assignment|t|t|t|t
33957839|NCT01861600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957840|NCT03509688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854442|NCT03107104|||COHORT||PROSPECTIVE|||||||
33854443|NCT03785171|||CASE_ONLY||PROSPECTIVE|||||||
33854444|NCT02224677|||CASE_CONTROL||PROSPECTIVE|||||||
33854445|NCT04595383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854446|NCT04288765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with newly diagnosed and previously untreated multiple myeloma living in Mexico that are fit for a quadruple therapy for multiple myeloma. Those patients that aren't fit or unavailable for transplant will go to the continuous treatment arm. The stratification of the study will be done by age and by cytogenetic risk.||||
33854447|NCT00889668|NA|SINGLE_GROUP||SCREENING||NONE||||||
33854448|NCT06327932|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957841|NCT01542879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957842|NCT00327899|||||RETROSPECTIVE|||||||
34061451|NCT03140605|||OTHER||PROSPECTIVE|||||||
33748083|NCT06119100|||COHORT||PROSPECTIVE|||||||
33748084|NCT00446316|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748085|NCT01601574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748086|NCT03330665|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748087|NCT00108095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748088|NCT03160027|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants randomized to the Immediate PBM treatment group will receive 12 weeks of PBM, delivered with the Vielight Neuro device, for 12 weeks, once every other day (e.g., Mon, Wed, Fri), undergo behavioral assessments at baseline, weeks 6 and 12, and undergo 3 Tesla MRI at baseline and week 12.~Participants randomized to the Delayed PBM treatment group will maintain their usual activities for 12 weeks, undergo behavioral assessments at baseline, weeks 6 and 12, and undergo 3 Tesla MRI at baseline and week 12. After the week 12 behavioral and MRI assessments, participants in this group will receive 12 weeks of PBM, delivered with the Vielight Neuro device, for 12 weeks, once every other day (e.g., Mon, Wed, Fri), undergo behavioral assessments at weeks 18 and 24."||||
33748089|NCT00202163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748090|NCT01782989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748091|NCT06624969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748092|NCT01019876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748093|NCT01176539|||CASE_ONLY||CROSS_SECTIONAL|||||||
33854449|NCT01848951|||OTHER||PROSPECTIVE|||||||
33854450|NCT03178539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33854451|NCT00348855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33854452|NCT02068209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33854453|NCT00139191|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957843|NCT06702982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957844|NCT00331604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957845|NCT01802762|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957846|NCT04165317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957847|NCT03473145|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33957848|NCT06420323|||OTHER||PROSPECTIVE|||||||
33957849|NCT05430308|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open labelled parallel study||||
33957850|NCT04332835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blinded||f|f|f|t
33957851|NCT06009159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||4-week of clinical study with a total of 60 subjects, randomized into 2 groups (30 subjects in tVNS and 30 subjects in control group )|t|f|t|f
33957852|NCT01317069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957853|NCT03366155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957854|NCT05269615|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be randomly allocated in a 1:1 ratio to valsartan or placebo. Valsartan and placebo tablets will be indistinguishable in taste, smell, appearance and dosage. The protocol will be developed in a double-blind manner in that both participants and investigators will be blinded toward the intervention condition.||t|f|t|f
33957855|NCT05179486|||CASE_CONTROL||PROSPECTIVE|||||||
33957856|NCT05540535|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33957857|NCT05550675|||CASE_CONTROL||PROSPECTIVE|||||||
33957858|NCT05181709|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Random and Sequential Assignment||||
33957859|NCT00345826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957860|NCT05361798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957861|NCT06701097|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33957862|NCT03681275|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33957863|NCT04035694|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957864|NCT01299272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33957865|NCT06567951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"Detaile design was described in Study Description section. In brief: MPH and MSPH will be (or not) daily supplemented with 36 ml of EVOO from gestational week 28 to the end of pregnancy."|f|f|t|f
33957866|NCT06681896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957867|NCT06697821|||CASE_ONLY||RETROSPECTIVE|||||||
33957868|NCT03926728|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33957869|NCT03751124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized withdrawal following an open-label extension to a randomized controlled parent study|t|t|t|t
33957870|NCT06498817|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957871|NCT06528938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957872|NCT06430385|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33957873|NCT02548039|||COHORT||PROSPECTIVE|||||||
34061452|NCT05196906|||COHORT||PROSPECTIVE|||||||
34061453|NCT01549262|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33748094|NCT04422379|||COHORT||OTHER|||||||
33957874|NCT06702384|||COHORT||PROSPECTIVE|||||||
33957875|NCT05709054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957876|NCT05237934|||COHORT||PROSPECTIVE|||||||
33957877|NCT06625047|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957878|NCT06567080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957879|NCT02703779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957880|NCT06448910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748095|NCT04372771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33854454|NCT00063154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854455|NCT02314767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33854456|NCT05466773|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||quasi-experimental design with 4 groups||||
33854457|NCT01193920|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33854458|NCT00562133|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854459|NCT01544660|||COHORT||PROSPECTIVE|||||||
33854460|NCT04342793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854461|NCT06349928|||COHORT||CROSS_SECTIONAL|||||||
33893550|NCT01744561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748096|NCT04367675|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748097|NCT00476476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748098|NCT00477191|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33748099|NCT06595108|NA|SINGLE_GROUP||TREATMENT||NONE|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination chemotherapy should begin stereotactic body radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions.|Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination chemotherapy should begin stereotactic body radiotherapy to one or more but not more than five sites for primary cancer and/or metastatic lesions.||||
33748100|NCT01343407|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33748101|NCT06273917|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33748102|NCT04090424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748103|NCT00002026||||TREATMENT||||||||
33748104|NCT04100772|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748105|NCT04957966|NA|SINGLE_GROUP||TREATMENT||NONE||Intra-individually randomized design: Random assignment (50:50) to either the intervention condition or the control condition||||
33854462|NCT03160651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind randomized trial Investigator, patients, and care providers will be masking Only statisticians and pharmacist will not be masking||t|t|t|f
33854463|NCT05052554|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||QR-504a will be administered per intravitreal (IVT) injection, as a single dose. The starting dose is 30 µg. Guided by the dose (de-)escalation plan, doses in a range of below 30 µg and up to 60 µg may be evaluated following pre-specified criteria for opening additional dose cohorts.||||
33854464|NCT02091453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854465|NCT05954520|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33854466|NCT04784260|||COHORT||PROSPECTIVE|||||||
33854467|NCT02970877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854468|NCT04268524|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised control trial||||
33854469|NCT04275401|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33854470|NCT01385813|||CASE_CONTROL||RETROSPECTIVE|||||||
33854471|NCT02960854|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33854472|NCT05611008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33854473|NCT04409353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33854474|NCT00828880|||COHORT||RETROSPECTIVE|||||||
33854475|NCT02727127|||COHORT||PROSPECTIVE|||||||
33854476|NCT04345835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33854477|NCT01414374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854478|NCT04879771|||CASE_CONTROL||PROSPECTIVE|||||||
33854479|NCT03868488|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33854480|NCT04217733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854481|NCT03574298|||COHORT||PROSPECTIVE|||||||
33854482|NCT01588496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854483|NCT03747198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|MSM tablets will be packaged and labelled (intervention A or B) by Bergstrom nutrition off-site.|double blinded randomized parallel design|t|f|t|t
33854484|NCT02952287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854485|NCT05884151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854486|NCT05323201|NA|SEQUENTIAL||TREATMENT||NONE||||||
33854487|NCT00456950|||COHORT||PROSPECTIVE|||||||
33854488|NCT02714387|||COHORT||PROSPECTIVE|||||||
33854489|NCT02325427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854490|NCT02705287|||COHORT||PROSPECTIVE|||||||
33854491|NCT03109145|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854492|NCT03618654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854493|NCT04509115|||COHORT||PROSPECTIVE|||||||
33854494|NCT03741231|||COHORT||RETROSPECTIVE|||||||
33854495|NCT03437343|||CASE_ONLY||RETROSPECTIVE|||||||
33854496|NCT00606957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854497|NCT02941562|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854498|NCT03188757|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33854499|NCT00002521|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854500|NCT05134350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33854501|NCT02707237|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33854502|NCT01706887|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33854503|NCT00645801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinding was done to ensure minimum bias. The clinicians attending to the patients were not involved in the randomization process, and all were blinded to the identity of the drug received as the placebo was identical to the active drug in packaging, appearance, and schedule of administration. Separate individuals generated the allocation sequence, enrolled participants, and assigned participants to their groups. The blind was maintained until all decisions regarding data evaluability were made. Only the research assistant who assigned participants to their treatment groups was permitted access to the randomization list, which was maintained in a locked filing cabinet during the trial. The patients were blinded to their medication status.||t|t|t|t
33854504|NCT04054791|||COHORT||PROSPECTIVE|||||||
33854505|NCT00562705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854506|NCT01768520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854507|NCT01658722|||||PROSPECTIVE|||||||
33854508|NCT03327428|||COHORT||PROSPECTIVE|||||||
33854509|NCT02787889|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33854510|NCT01944150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854511|NCT04176302|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33854512|NCT05063825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33854513|NCT03879837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854514|NCT03753620|NA|SINGLE_GROUP||OTHER||NONE||||||
33748106|NCT03370887|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33748107|NCT06397469|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double blind||t|f|t|t
33748108|NCT04553757|||COHORT||PROSPECTIVE|||||||
33748109|NCT01828242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33748110|NCT06467006|||COHORT||PROSPECTIVE|||||||
33748111|NCT02580097|||CASE_ONLY||PROSPECTIVE|||||||
33748112|NCT01048528|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748113|NCT06505200|||COHORT||PROSPECTIVE|||||||
33748114|NCT00733317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167151|NCT03969095|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinding procedures will be taken to minimize bias - Raters extracting data from VFSS studies will also be blinded to participant allocation, VFSS time-point (pre vs post treatment), time post stroke, and bolus consistency. Each VFSS will be de-identified and converted so that all audio collected during the study will be removed to avoid revealing information to the blinded raters.|Randomized crossover trial|f|f|f|t
34167152|NCT05289843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant , Investigator, Outcomes assessor||t|f|t|t
34167153|NCT00967317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167154|NCT02304744|||COHORT||PROSPECTIVE|||||||
34167155|NCT03015766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34167156|NCT02768766|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167157|NCT01494948|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34167158|NCT01825187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167159|NCT05262257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748115|NCT05472428|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33748116|NCT03118960|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748117|NCT06344312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748118|NCT02978794|||COHORT||PROSPECTIVE|||||||
33748119|NCT04499794|||COHORT||PROSPECTIVE|||||||
33748120|NCT01519713|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748121|NCT05319431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748122|NCT06634446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33748123|NCT01358968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748124|NCT06670118|||COHORT||PROSPECTIVE|||||||
33748125|NCT01302119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167160|NCT00738335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167161|NCT00799266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167162|NCT03103126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The conditions/treatments cannot be masked but the outcome assessors will be masked as to the arm that the participants are allocated to.|Randomised controlled trial: control group vs. one intervention arm|f|f|f|t
34167163|NCT00569140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167164|NCT03865082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167165|NCT00316537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34167166|NCT00623324|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34167167|NCT04689516|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33957881|NCT00209430|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33957882|NCT01818219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957883|NCT01186744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957884|NCT04309760|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Comparison between Mtf and control subjects.||||
33957885|NCT05717166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957886|NCT01126359|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33957887|NCT06696261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957888|NCT02174549|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, dose escalation 3+3 design completed; now only for expansion cohort in neuroendocrine tumor.||||
33957889|NCT04049448|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, follow-up study||||
33854515|NCT02687022|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33957890|NCT06172127|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-comparative, phase 2 short induction treatment phase followed by maintenance treatment phase clinical trial||||
33748126|NCT05239039|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748127|NCT02507895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748128|NCT05974527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748129|NCT03680599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854516|NCT03501641|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Blinding to the purpose of the study during recruitment is maintained to minimize preparation bias. After randomization, the participants are unblinded and use image-based virtual reality model or conventional video-based model on a virtual reality eyeglass in an ordinary office environment for 10 minutes. Heart rate variation will be monitored during learning and cognitive load will be assessed by the participants. Subsequently, each participant will perform history taking and physical examination for a real patient in a teaching clinic. The competence will be evaluated using the mini-clinical evaluation exercise, direct observation of procedural skills (DOPS), and milestone assessments. Investigators and outcome assessors are blinded to their randomization and learning models.|This randomized controlled trial will recruit 64 subjects who are novices in otolaryngology at an academic teaching hospital. The cognitive style of the participants is assessed using the Group Embedded Figures Test. The subjects are randomly assigned (1:1) to a novel image-based virtual reality group and conventional video-based group matched by age, sex, and cognitive style.|f|f|t|t
33854517|NCT02835833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854518|NCT01988766|||COHORT||RETROSPECTIVE|||||||
33854519|NCT00852540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854520|NCT02856828|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854521|NCT02206594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854522|NCT05304468|RANDOMIZED|PARALLEL||TREATMENT||NONE||phase III non-inferiority||||
33854523|NCT00194519|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33854524|NCT04374344|||COHORT||PROSPECTIVE|||||||
33854525|NCT01124409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854526|NCT05916573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854527|NCT06322953|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33854528|NCT03942809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854529|NCT05624320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854530|NCT04115085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854531|NCT00824356|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33854532|NCT04833699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854533|NCT00591045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854534|NCT06525909|||COHORT||PROSPECTIVE|||||||
33854535|NCT03290209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854536|NCT04236505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomised into two intervention groups and a waitlist controlled group|t|f|f|f
33854537|NCT00584597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854538|NCT00923533|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33854539|NCT03034304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854540|NCT01303523|||COHORT||PROSPECTIVE|||||||
33854541|NCT01001832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854542|NCT05438017|NA|SINGLE_GROUP||OTHER||NONE||||||
33854543|NCT05703386|||COHORT||PROSPECTIVE|||||||
33854544|NCT05534256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor and statistician will be blinded.||f|f|f|t
33854545|NCT05441254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854546|NCT00515320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854547|NCT04429997|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33854548|NCT01924520|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33854549|NCT06164067|||COHORT||PROSPECTIVE|||||||
33854550|NCT04552756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854551|NCT03410615|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-comparative, randomized, phase II study of cisplatin plus radiotherapy or durvalumab plus radiotherapy followed by adjuvant durvalumab or durvalumab plus radiotherapy followed by adjuvant tremelimumab and durvalumab in intermediate risk, HPV-positive, locoregionally advanced oropharyngeal squamous cell cancer (LA-OSCC) of the head and neck.||||
33854552|NCT04115553|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33854553|NCT04553198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is blinded to the intervention type.|stratified randomization|f|f|f|t
33854554|NCT02035592|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33957891|NCT04808960|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|All assessors will be blinded to previous assessments (micro-CT) as well as the clinical and demographic data of the cadavers||f|f|f|t
33957892|NCT06602037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957893|NCT04352907|||COHORT||PROSPECTIVE|||||||
33957894|NCT03594175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957895|NCT06652646|||COHORT||PROSPECTIVE|||||||
33957896|NCT06210516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind|A Randomised-controlled Trial|f|f|f|t
33957897|NCT04359186|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33957898|NCT00884455|||OTHER||PROSPECTIVE|||||||
33957899|NCT03834961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957900|NCT06356831|||COHORT||PROSPECTIVE|||||||
33957901|NCT06702579|||CASE_ONLY||CROSS_SECTIONAL|||||||
34167168|NCT00392392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167169|NCT01272570|||COHORT||PROSPECTIVE|||||||
33854555|NCT04054752|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33854556|NCT04025580|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33854557|NCT02009254||||PREVENTION||||||||
33854558|NCT04119258|||CASE_ONLY||CROSS_SECTIONAL|||||||
33854559|NCT00842270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854560|NCT03073265|||COHORT||PROSPECTIVE|||||||
33854561|NCT03231930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will receive the same intervention, which is rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid , followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV RNA viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at ths clinic and referred to appropriate practitioners for HCV treatment. All results will be confirmed with standard laboratory testing as these devices are not yet approved for diagnostic use in Australia.||||
33854562|NCT01217957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854563|NCT01813370|||COHORT||PROSPECTIVE|||||||
33854564|NCT02105623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854565|NCT04822285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33854566|NCT00000263|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|t|f|f
33854567|NCT05465772|||COHORT||PROSPECTIVE|||||||
33854568|NCT04213157|||COHORT||RETROSPECTIVE|||||||
33854569|NCT05258838|||CASE_ONLY||CROSS_SECTIONAL|||||||
33854570|NCT02436785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|open label||f|f|f|t
33748130|NCT01504594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854571|NCT04834349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854572|NCT05204745|||CASE_CONTROL||PROSPECTIVE|||||||
33854573|NCT00333385|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854574|NCT03129880|RANDOMIZED|PARALLEL||TREATMENT||NONE||"For purposes of this study participants will be randomized into one of the following two groups:~4-6 weekly standard of care therapy sessions, once a week, for a maximum of six weeks 4-6 standard of care therapy sessions in one day Standard of care treatment may continue past patient enrollment in this study."||||
33854575|NCT01190137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854576|NCT05663437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854577|NCT01341756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854578|NCT03365128|||CASE_ONLY||PROSPECTIVE|||||||
33854579|NCT01111474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854580|NCT03422354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients were randomized to two groups using a computer-generated list and kept in a sealed envelope into two groups:|"after approval of the ethical committee (N-73-2017)Which approval date was 12/2/2018 74 patients scheduled for elective hip surgery were included in the study after detailed description and signing a detailed informative consent (figure1). The patients were randomized to two groups using a computer-generated list and kept in a sealed envelope into two groups:~* Group P: 37 patients were received single shot L1-L2 paravertebral block before undergoing general anesthesia (GA).~* Group G: 37 patients were received GA. The target of the mean blood pressure was to be more than 50mm Hg while the systolic pressure to be between 80 and 100 mm Hg and the diastolic blood pressure targeted to be 50 to 70 mmHg."|f|t|t|f
33854581|NCT04894487|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled two groups ( control group and experiment group)||||
33854582|NCT06436027|||COHORT||RETROSPECTIVE|||||||
33748131|NCT05338788|||COHORT||CROSS_SECTIONAL|||||||
33854583|NCT01801735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854584|NCT02052830|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854585|NCT06004947|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748132|NCT03586648|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33854586|NCT02391272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854587|NCT05272956|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854588|NCT06181474|||CASE_ONLY||PROSPECTIVE|||||||
33854589|NCT05532943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854590|NCT04080908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854591|NCT04022551|||OTHER||PROSPECTIVE|||||||
33854592|NCT04840641|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33854593|NCT00367887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167170|NCT04509791|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||the trial design consists of 7 cohorts, each recruited sequentially, with between 3 and 5 treatment arms ( there will be fewer arms for later cohorts)|t|f|t|f
34167171|NCT03626792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Group 1 - Hypertensive: Composed of hypertensive women who participated in a training program with Pilates exercises in the soil associated to the daily antihypertensive of each one.~* Group 2 - Normotensives: Composed of normotensive women who participated in a training program with solo Pilates exercises without antihypertensive presence.~Both groups underwent 12 weeks of Pilates training."||||
34167172|NCT02399709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167173|NCT03617952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167174|NCT00548600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167175|NCT00250341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167176|NCT06288048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation and data assessor were blinded.||f|f|t|t
34167177|NCT05753839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167178|NCT05631561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167179|NCT00148759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167180|NCT05982990|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
34167181|NCT00858026|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34167182|NCT04506541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167183|NCT03563209|||CASE_ONLY||CROSS_SECTIONAL|||||||
34167184|NCT06002217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167185|NCT01338818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167186|NCT05170451|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized controlled trial with crossover|t|t|t|t
33854594|NCT01704131|||COHORT||PROSPECTIVE|||||||
33854595|NCT03788083|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Subjects will not know whether an active or non-active substance is being injected. The choice for TriMix or placebo will take place according to the predefined schedule and can not be influenced by the patient or the investigator. Only after the comparison of the tumour tissue before (the initial biopsy where the diagnosis was made) and after (obtained at second biopsy or surgery) the intratumoral injection, it will be known whether mRNA or non-active product was used for the injection.||t|f|f|f
33854596|NCT02919904|||COHORT||PROSPECTIVE|||||||
33854597|NCT03356457|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Once stable hypoglycemia is reached, a cognitive testing battery will be administered by a study co-investigator who will be blinded to the treatment assignment.|"This will be a single center, placebo-controlled, cross-over, randomized clinical pilot study.~At the screening visit informed consent will be obtained. Medical history and documents will be reviewed to screen potential subjects by inclusion and exclusion criteria. Subjects will receive a physical examination and laboratory blood work (BUN/creatinine, electrolytes, lipid profile, liver function, and HbA1c) as well as urine toxicology screens (to confirm self-report of alcohol, and drug information) to ensure good physical health."|t|f|f|f
33854598|NCT02772406|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33854599|NCT04651517|NA|SINGLE_GROUP||OTHER||NONE||Subjects 18 years of age or older who are undergoing CT guided, minimally invasive percutaneous procedures of the lung.||||
33854600|NCT00272922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854601|NCT01491672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854602|NCT00960531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854603|NCT05486650|||COHORT||PROSPECTIVE|||||||
33854604|NCT03722147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854605|NCT00610467|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33854606|NCT00441753|||COHORT||PROSPECTIVE|||||||
33854607|NCT05333770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854608|NCT03107897|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparing individuals who have prehabilitation prior to their TAVR procedure with those that do not.||||
33854609|NCT02054741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854610|NCT00220753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854611|NCT02966301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854612|NCT01063660|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33854613|NCT04250441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854614|NCT04593316|||CASE_CONTROL||PROSPECTIVE|||||||
33854615|NCT00346268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854616|NCT01501760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854617|NCT02943486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854618|NCT04721028|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34167187|NCT03790722|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33854619|NCT05515380|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854620|NCT03275844|||OTHER||CROSS_SECTIONAL|||||||
33854621|NCT04229251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854622|NCT00315900|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33854623|NCT03527173|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind The subject, the site and sponsor personnel involved in the clinical evaluation of the subjects are blinded while other study personnel may be aware of the treatment assignment.||t|t|t|t
33854624|NCT02499770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167188|NCT04440878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167189|NCT03231852|||COHORT||PROSPECTIVE|||||||
34167190|NCT00700596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34167191|NCT00961155|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34167192|NCT04582786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Step 1 of the study is single blinded for participants only.||t|t|t|t
34167193|NCT03857100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34167194|NCT02185703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167195|NCT05605236|||CASE_ONLY||RETROSPECTIVE|||||||
34167196|NCT02859714|||COHORT||RETROSPECTIVE|||||||
34167197|NCT04974424|||CASE_CONTROL||RETROSPECTIVE|||||||
34167198|NCT04437901|||COHORT||OTHER|||||||
34167199|NCT00205335|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34167200|NCT02186613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167201|NCT00732212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34167202|NCT00358397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167203|NCT01253642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167204|NCT00644696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167205|NCT03244917|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The research assistants collecting outcome data through chart reviews and follow-up proxy interviews will be blinded to nursing home randomization. The Principal Investigator, data programmers, and statistician will be blinded to treatment assignment|Cluster Randomized Clinical Trial|t|t|t|t
34167206|NCT03195283|||COHORT||PROSPECTIVE|||||||
34167207|NCT04183114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The masking uses observer blind with some unmasked staff to prepare the vaccine to be administered by masked investigator.|healthy infants aged 9 - 12 months|f|t|t|t
33854625|NCT02094755|||COHORT||PROSPECTIVE|||||||
33854626|NCT01122862|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34061454|NCT06424587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||a parallel group, randomized, controlled experimental study.|t|f|t|f
34061455|NCT03161886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061456|NCT00901472|||COHORT||CROSS_SECTIONAL|||||||
34061457|NCT03598582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061458|NCT06730139|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34061459|NCT02920814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061460|NCT02182466|||COHORT||PROSPECTIVE|||||||
34061461|NCT02974205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061462|NCT03623542|||COHORT||PROSPECTIVE|||||||
34061463|NCT04066777|NA|SINGLE_GROUP||TREATMENT||NONE||prospective controlled study||||
34061464|NCT01926938|||||CROSS_SECTIONAL|||||||
34061465|NCT05655468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061466|NCT02764567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061467|NCT05904080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061468|NCT06066528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061469|NCT04309565|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Hybrid type I effectiveness-implementation trial|t|f|f|f
33854627|NCT03086525|||COHORT||PROSPECTIVE|||||||
34061470|NCT02999724|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34061471|NCT03654131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061472|NCT00737607|||CASE_ONLY||PROSPECTIVE|||||||
34061473|NCT02923245|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34061474|NCT01472939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061475|NCT05958745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34061476|NCT00603382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061477|NCT05769634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061478|NCT03080480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061479|NCT02060864|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34061480|NCT06459869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061481|NCT06731361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Not possible due to the type of intervention|Cluster randomised controlled trial with 2 arms: intervention and control. Ratio 1:1. 2 clusters start in september, 2 clusters start in october and 2 clusters start in november.||||
34061482|NCT06229405|||COHORT||PROSPECTIVE|||||||
34061483|NCT01861873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061484|NCT03724240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34061485|NCT06730945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061486|NCT04246645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061487|NCT01239836|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061488|NCT01811836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061489|NCT03348098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061490|NCT00989859|||CASE_ONLY||PROSPECTIVE|||||||
34061491|NCT00236275|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061492|NCT01311934|||CASE_ONLY||PROSPECTIVE|||||||
34167208|NCT04406896|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Moderate hepatic impaired participants will be dosed after an interim analysis of at least 6 participants with mild hepatic impairment. Healthy participants will be matched to hepatic impaired participants.||||
33854628|NCT02154789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854629|NCT00569595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854630|NCT04371653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854631|NCT04612374|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854632|NCT02434939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854633|NCT00355199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854634|NCT01795664|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33854635|NCT02648165|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33854636|NCT06107608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893551|NCT00428168|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34061493|NCT05530980|NA|SINGLE_GROUP||OTHER||NONE||||||
34061494|NCT00314132|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34061495|NCT04130048|||COHORT||RETROSPECTIVE|||||||
34061496|NCT05885633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||While the study group consisted of PCOS patients, the control group was selected from non-PCOS patients with male factor infertility.||||
34061497|NCT01878734|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061498|NCT05076747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893552|NCT06187506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061499|NCT04577534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061500|NCT02861417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061501|NCT02631070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167209|NCT05062005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061502|NCT06553768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061503|NCT03628248|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34061504|NCT00672399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34061505|NCT04515641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061506|NCT02532114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061507|NCT06730620|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34061508|NCT00423189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061509|NCT02185287|||CASE_CONTROL||PROSPECTIVE|||||||
34061510|NCT05581992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34061511|NCT05451615|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061512|NCT05768191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061513|NCT05648240|||COHORT||PROSPECTIVE|||||||
34061514|NCT01430624|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34061515|NCT03526198|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34061516|NCT05828212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061517|NCT06125067|||OTHER||RETROSPECTIVE|||||||
34061518|NCT04240457|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Randomized at outset|Treatment of patients with disease|f|f|f|t
34167210|NCT05084313|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are three groups in the study, two of which includes interventions, and one group constitutes the control group. The participants will be randomized into groups with a sealed envelope. There is only one session of the allocated intervention for the particular participant, since the study aims to measure acute effects of cranial and visceral manual therapy on autonomic nervous system parameters.||||
34167211|NCT05380063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167212|NCT02356445|||COHORT||RETROSPECTIVE|||||||
34167213|NCT02354534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167214|NCT01788917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167215|NCT02179411|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34167216|NCT03726957|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The investigators adopted a cluster randomized controlled trial with village as the unit of randomization. Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove (control group) or to an improved cookstove (intervention group). A household that was willing to participate was considered eligible: 1) if it had a traditional wood burning cookstove; and 2) if the household included at least one child between the ages of 8-15. If a household had more than one child within the target age range, the oldest child within the age range was selected for study. Study participants within each household were the mother and the selected child.||||
34167217|NCT03393234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be assigned to two different groups and receive intraoperative radiation randomly. The care provider and investigator also don't know the concrete situation of the patients.||t|t|t|f
33854637|NCT04752982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The outcome assessor, stroke survivor, carer, research team and clinical care staff (e.g. GP) will be blinded to group allocation. Participants will not be told if they are in the active or attentional control c-SIGHT group. The set-up and equipment is the same between the two arms and only the instructions differ.|Participants are randomly allocated (using minimisation) to either the active intervention or attentional control group. Minimisation will use the following parameters: age, days since stroke, side of hemisphere damaged, and neglect severity (measured using the star cancellation test).|t|t|t|t
33854638|NCT04700020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854639|NCT03418948|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Participants will be blinded for the allocation. Physicians can not be blinded for the use of Endocuff, but during the first procedure they will be blinded for the second procedure method to limit observer related bias.||t|f|t|f
33957902|NCT06541925|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33957903|NCT02787785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957904|NCT04074798|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patients with low back pain are compared to patients without low back pain (healthy controls).|t|f|f|f
33957905|NCT03671135|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33957906|NCT05620706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957907|NCT06283745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||PRP injections will be given to one arm while sham saline injections will be given to the other arm.|t|f|f|f
33957908|NCT06041269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957909|NCT06585202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957910|NCT06348823|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33957911|NCT05631769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957912|NCT06703450|||COHORT||PROSPECTIVE|||||||
33957913|NCT01339468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957914|NCT06646991|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33957915|NCT06703879|||OTHER||PROSPECTIVE|||||||
33957916|NCT05297734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster Randomized Controlled Trial among 24 clinics|f|f|f|t
33957917|NCT04117958|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957918|NCT04959175|NA|SEQUENTIAL||TREATMENT||NONE||||||
33957919|NCT05886413|||COHORT||RETROSPECTIVE|||||||
33957920|NCT01514643|||CASE_CONTROL||PROSPECTIVE|||||||
33957921|NCT06537609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957922|NCT04601831|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label, seamless phase I/II study||||
33957923|NCT00334269|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33957924|NCT06700681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33957925|NCT05505851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2|t|f|f|t
33957926|NCT02854189|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957927|NCT06584708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33957928|NCT03891732|||COHORT||PROSPECTIVE|||||||
33957929|NCT01080911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957930|NCT02810639|||COHORT||PROSPECTIVE|||||||
34061519|NCT00588081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061520|NCT04414085|||CASE_ONLY||RETROSPECTIVE|||||||
34061521|NCT05215379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061522|NCT01836991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061523|NCT05995457|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Advanced practice nurses (APNs) will carry out clinical examinations before and after the treatment. They will not be present during the treatment, and the patient will not know the technique used, in order to ensure a double-blind evaluation. Only the nurses performing the injection will be aware of the technique used (experimental or control).||t|f|t|f
34061524|NCT03484221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167218|NCT03522792|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants will not be informed of the nature of the infusion they are administered on any of the study days. The investigator will be provided with an infusion (either isotonic saline with HSA or isotonic salin with HSA + neurotensin) prepared by a designated colleague|Participants will be studied on multiple occasions (5 days) in a randomised and double blinded fashion. One day will serve as an acclimatization day.|t|f|t|t
34167219|NCT01623479|||CASE_ONLY||CROSS_SECTIONAL|||||||
34167220|NCT00430716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167221|NCT02637583|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34167222|NCT03187132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167223|NCT04384159|||COHORT||RETROSPECTIVE|||||||
34167224|NCT04395846|||COHORT||PROSPECTIVE|||||||
34167225|NCT03058692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33854640|NCT02273817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34167226|NCT05994508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167227|NCT05291793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients were not aware of the ingredient of the injection they had received Care providers were not aware of the ingredient of injection during application|Identical work scheme applied in 4 different centers by 4 Physicians. Both patient selection, randomization, and blind injection applications have been implemented in same order.|t|t|f|f
34167228|NCT00406601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167229|NCT04811040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical pharmacologist and sponsor are not masked to treatment assignment.||t|f|t|f
34167230|NCT04327102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34167231|NCT00689312|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34167232|NCT00228358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748133|NCT01566045|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167233|NCT01735266|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34167234|NCT01518556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167235|NCT03649074|NA|SINGLE_GROUP||TREATMENT||NONE||The study will enroll participants into one of two cohorts according to stimulant status. Both cohorts will be assigned to AKL-T01 (with AKL-X01 symptom tracking).||||
34167236|NCT05048316|NA|SINGLE_GROUP||OTHER||NONE||||||
34167237|NCT01495286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167238|NCT02417883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167239|NCT00352001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167240|NCT02936635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167241|NCT04548466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167242|NCT03152695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167243|NCT03073421|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34167244|NCT00187863|||CASE_ONLY||PROSPECTIVE|||||||
34167245|NCT05237817|||COHORT||OTHER|||||||
34167246|NCT02366351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167247|NCT02643459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748134|NCT01772433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748135|NCT04365634|||CASE_CONTROL||RETROSPECTIVE|||||||
33748136|NCT00187018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748137|NCT01676168|||CASE_CONTROL||PROSPECTIVE|||||||
33748138|NCT02474927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748139|NCT04844476|||OTHER||CROSS_SECTIONAL|||||||
33748140|NCT05574127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33748141|NCT03913611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The therapist assessing patients' range of movement and the radiologist assessing integrity of the repair will be blinded to the arm of the trial that the patient entered.|Patients will be randomised to two groups, with balanced numbers entering each group.|f|f|f|t
33748142|NCT05046795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, double-blind, placebo-control, parallel group study|t|t|t|t
34167248|NCT01682733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748143|NCT02336334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748144|NCT04339231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||XXXXX|t|t|f|f
33748145|NCT02730494|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748146|NCT02775526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748147|NCT02571504|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33854641|NCT03503344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854642|NCT00446667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854643|NCT05186194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33854644|NCT05674331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854645|NCT03373695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854646|NCT05810337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33893553|NCT06656767|||OTHER||RETROSPECTIVE|||||||
34167249|NCT03188107|||CASE_CONTROL||PROSPECTIVE|||||||
34167250|NCT06320639|||COHORT||CROSS_SECTIONAL|||||||
34167251|NCT03068494|||COHORT||CROSS_SECTIONAL|||||||
34167252|NCT05438719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167253|NCT03639363|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34167254|NCT05724407|||OTHER||CROSS_SECTIONAL|||||||
34167255|NCT01771978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167256|NCT04163029|||COHORT||PROSPECTIVE|||||||
34167257|NCT02028481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167258|NCT02385851|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34167259|NCT04945759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Posttest and control grouped randomized controlled clinical trial.|f|t|f|f
34167260|NCT01946139|NA|SINGLE_GROUP||SCREENING||NONE||||||
34167261|NCT06420089|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label||||
34167262|NCT03075618|||COHORT||PROSPECTIVE|||||||
34167263|NCT04581486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34167264|NCT00549640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167265|NCT01329627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167266|NCT02936674|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34167267|NCT03370042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167268|NCT03594682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854647|NCT03714425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||High frequency device vs. Low frequency device|t|f|t|f
33854648|NCT03324451|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients with T2DM at a clinic in southern Taiwan are assigned to the intervention arm, whereas patients with T2DM at the endocrinology department of a hospital in northern Taiwan are placed in the control arm. Eligible patients that match the inclusion criteria are recommended by doctors to initiate insulin treatment. Research assistants will explain the objectives of this study to eligible participants. Subsequently, baseline data will be collected from participants by research assistants after the participants sign the consent forms. Afterwards, the participants in the intervention arm will receive the intervention. For the control arm, the participants will receive regular patient education originally administered at the hospital.||||
33854649|NCT01558895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167269|NCT05502913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167270|NCT02996149|||CASE_ONLY||PROSPECTIVE|||||||
34167271|NCT04045327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167272|NCT03962179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167273|NCT04071197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study group will be subjected to gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril||||
34167274|NCT01544920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167275|NCT05219331|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34167276|NCT04347863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167277|NCT06134219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167278|NCT05354908|||CASE_ONLY||CROSS_SECTIONAL|||||||
34167279|NCT05051579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167280|NCT00490464|||DEFINED_POPULATION||PROSPECTIVE|||||||
34167281|NCT00974753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34167282|NCT03946748|NA|SEQUENTIAL||TREATMENT||NONE||||||
34167283|NCT02836652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167284|NCT02098330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167285|NCT02459119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167286|NCT02848963|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34167287|NCT04388683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167288|NCT02018341|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34167289|NCT05399563|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34167290|NCT00350571|RANDOMIZED|PARALLEL||||NONE||||||
34167291|NCT04759781|||COHORT||PROSPECTIVE|||||||
34167292|NCT01454596|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167293|NCT04207242|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34167294|NCT01429493|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34167295|NCT03169166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167296|NCT00128895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167297|NCT06027203|||CASE_ONLY||RETROSPECTIVE|||||||
34167298|NCT04376216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167299|NCT01594931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167300|NCT00088140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167301|NCT03018444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33854650|NCT00879112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748148|NCT02265900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854651|NCT02710903|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854652|NCT00512317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854653|NCT03434782|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33854654|NCT05508620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854655|NCT03507465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854656|NCT03390374|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants is randomly allocated into 2 study groups (nystatin group and control group) during study period||||
33854657|NCT00655863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854658|NCT02791945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854659|NCT05748496|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854660|NCT04975477|||COHORT||RETROSPECTIVE|||||||
33854661|NCT04869423|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two groups: one control and one experimental group|f|f|t|f
33854662|NCT03170453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854663|NCT03550820|||CASE_ONLY||PROSPECTIVE|||||||
33854664|NCT02937454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854665|NCT04581954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854666|NCT02730741|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33854667|NCT02574754|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33854668|NCT00271960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854669|NCT01614743|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33854670|NCT03617341|||COHORT||PROSPECTIVE|||||||
33854671|NCT00577473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854672|NCT05837494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893554|NCT04046861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33893555|NCT02262403|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34061525|NCT05259384|RANDOMIZED|PARALLEL||TREATMENT||NONE||The enrolled candidates will be split into two subgroups(PD group or DP group) based on the location of their neoplasms. Every subgroups will be divided into two parallel groups by the randomization of intervention plan(lap surgery or robotic surgery)||||
34061526|NCT00234338|||||PROSPECTIVE|||||||
34061527|NCT00624650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061528|NCT02583867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061529|NCT01744002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061530|NCT06385522|NA|SEQUENTIAL||TREATMENT||NONE||||||
33748149|NCT02207920|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748150|NCT06066060|NA|SINGLE_GROUP||OTHER||NONE||||||
33748151|NCT04522518|||CASE_CONTROL||PROSPECTIVE|||||||
33748152|NCT06669559|NA|SINGLE_GROUP||OTHER||NONE||||||
33748153|NCT02856464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748154|NCT00325611|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33748155|NCT04417959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects randomized to either phaco-DSAEK or phaco-DMEK will be blinded in the study.|Study subjects with the requirement for endothelial keratoplasty and a concomitant need for cataract extraction will be randomized 1:1 to either phaco-DSAEK or phaco-DMEK. Further, a third group consisting of sujects with a solely need for cataract extraction will be included as a control group in our study. The three groups will be prospectively followed.|t|f|f|f
34061531|NCT06730542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061532|NCT03881891|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061533|NCT02665494|||COHORT||PROSPECTIVE|||||||
34061534|NCT06712186|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34061535|NCT06283641|||COHORT||PROSPECTIVE|||||||
34061536|NCT03404349|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34061537|NCT06631326|||COHORT||RETROSPECTIVE|||||||
34061538|NCT02100137|||COHORT||PROSPECTIVE|||||||
34061539|NCT01303640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061540|NCT04427137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061541|NCT05473689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061542|NCT05191368|||OTHER||OTHER|||||||
34061543|NCT04022239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061544|NCT04742309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesia teams in the operating rooms and recovery room nurses will be masked to treatment group assignment (therefore, the primary outcome measure collection). Outcomes assessor for the questionnaire involving secondary outcomes on the day following surgery will not be masked to treatment group, although subjects will remain masked.||t|f|f|t
34061545|NCT02065414|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34061546|NCT03976414|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34061547|NCT00388297|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34061548|NCT04815499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34061549|NCT04294433|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised 1:1 for 2 study groups. Non-randomised for comparator group.||||
34061550|NCT00798018|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34061551|NCT01174810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061552|NCT06272006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study implements single-blind masking where outcomes assessors are unaware of participants' group assignments to minimize bias. While blinding participants and care providers is not feasible due to the nature of surgical interventions, strict protocols ensure assessors remain blinded to treatment allocation throughout the study, enhancing outcome evaluation objectivity.|This randomized controlled trial compares two gingival recession treatments: Coronally Advanced Flap (CAF) with Connective Tissue Graft (CTG) versus Modified Coronally Advanced Tunnel (MCAT) with CTG. Participants are randomized 1:1 to either intervention. Outcomes assessors are blinded to allocation, ensuring unbiased evaluation of the primary outcome, Anatomical Recession Rate (ARR), and secondary clinical outcomes over a 12-month follow-up.|f|f|t|t
34061553|NCT01720329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34061554|NCT01361113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167302|NCT02750774|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167303|NCT00061737|||||RETROSPECTIVE|||||||
34167304|NCT05915845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167305|NCT03923894|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167306|NCT04387513|||COHORT||RETROSPECTIVE|||||||
34167307|NCT05355064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167308|NCT04765514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167309|NCT05361694|||COHORT||PROSPECTIVE|||||||
33748156|NCT05475054|||COHORT||RETROSPECTIVE|||||||
33854673|NCT04581668|RANDOMIZED|CROSSOVER||OTHER||NONE||Cross over physiological study with 2 different phases with a 30 minute Wash out period: 30 minutes. Order will be randomized.||||
33854674|NCT02664727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854675|NCT05237661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854676|NCT02593409|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167310|NCT00481819|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167311|NCT01384123|||COHORT||PROSPECTIVE|||||||
33748157|NCT00670774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748158|NCT02034747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748159|NCT00708513|||CASE_ONLY||PROSPECTIVE|||||||
33748160|NCT01446458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748161|NCT03818139|||COHORT||PROSPECTIVE|||||||
33748162|NCT03512665|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748163|NCT05879887|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Data collectors and principal investigator will be blind to participant condition; participants will be instructed NOT to discuss their assignment with data collectors. Trials participants will know their intervention condition as will the palliative care coach involved in delivering the intervention.|2x2x2x2 full factorial pilot randomized trial|f|f|t|t
34167312|NCT05551858|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Part-2 First 12- weeks includes 1:1 drug versus placebo|Part-1 Single group Part-2 crossover|t|t|t|f
34167313|NCT02931032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167314|NCT00580736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167315|NCT00878956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167316|NCT00521287|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34167317|NCT01012986|||COHORT||CROSS_SECTIONAL|||||||
34167318|NCT02108249|||COHORT||OTHER|||||||
34167319|NCT03915171|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34167320|NCT01250366|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34167321|NCT05220878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|Parallel assignment|t|f|t|f
34167322|NCT02501252|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||CORN were assigned into three arms namely: HP, HC and control arms||||
34167323|NCT01384734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167324|NCT05659771|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|cover story - different aim|"The 5 conditions of this study are:~1. low energy density, hard texture (slow eating rate)~2. low energy density, soft texture (fast eating rate)~3. High energy density, hard texture (slow eating rate)~4. High energy density, soft texture (fast eating rate)~5. Average energy density and medium hard texture (control)"|t|f|f|f
34167325|NCT02257034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34167326|NCT00716963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34167327|NCT04273477|||OTHER||PROSPECTIVE|||||||
34167328|NCT00821652|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34167329|NCT04283071|||CASE_CONTROL||PROSPECTIVE|||||||
34167330|NCT00514358|||COHORT||PROSPECTIVE|||||||
34167331|NCT02870998|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167332|NCT06472492|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study is a Randomized controlled trial. The eligible and consenting participants will be screened for the severity of depression using Hamilton Depression Rating Scale. Participants scoring \<8 will be considered for the study. They will be assessed for their level of cognitive functioning (Baseline) using digit span test (forward and backward), Trail making test Part A and B, Stroop color word test. The baseline scores will be noted Each person will be randomly assigned to either yoga group or treatment-as-usual group. The yoga group will attend the yoga under the guidance of a therapist for 6 weeks (6 days a week). The treatment-as-usual group will continue with usual treatment. The assessments will be repeated after 6 weeks of supervised yoga and after 4 weeks of discontinuation of supervised yoga for both participants of yoga group and treatment-as-usual group.||||
34167333|NCT05498168|||COHORT||PROSPECTIVE|||||||
34167334|NCT05152758|RANDOMIZED|PARALLEL||PREVENTION||NONE||This trial will randomize up to 196 ACL-reconstruction patients to receive either the standard of care or a physical activity prescription (PARx) at 7 years post-reconstruction in a 1:1 ratio.||||
34167335|NCT03741686|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34167336|NCT00717249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167337|NCT02568514|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34167338|NCT05663021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167339|NCT04354792|||COHORT||CROSS_SECTIONAL|||||||
33957931|NCT05722340|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"To assure the blinding of non-surgical study staff (MDA participants, histologists, etc), allocation results in the electronic case report (eCRF) form are made available to designated surgical staff only. Patients, investigators / outcome assessors / care givers and study staff are blinded to allocation results in as much as possible.~Only designated surgical staff (identified prior to centre initiation and kept to a strict necessary minimum) not otherwise involved in outcome assessment or patient care have access to allocation results on the eCRF and are summoned to maintain secrecy.~Data analysts will not be involved in trial field logistics and will be blinded. During analyses, when group assignments are first required, they will only be revealed as group A or group B. Only when analyses have been completed will the exact nature of groups be revealed."|In this prospective, parallel group, randomized (1:1), controlled, pilot trial, screening will take place during routine multidisciplinary assessment (MDA) meetings. The study is then presented to eligible patients during their next pre-surgical visits; if the patients are interested in participating, informed consent procedures are completed (again during routine visits) and the patients are randomized to two arms. In the experimental arm, patients will undergo NIVATS for lung biopsy, and in the standard arm, patients will undergo traditional IGAVATS for lung biopsy. Histology is then performed as usual, before entering a centralized pathway for a second analysis by an expert external to the study, and a second routine MDA convened (both blinded to study arms). Patients are followed-up for 12 months.|t|t|f|t
33957932|NCT01493609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957933|NCT06133348|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957934|NCT06032767|||COHORT||PROSPECTIVE|||||||
33957935|NCT04101721|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-Label|||||
34167340|NCT03022396|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34167341|NCT03826719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167342|NCT04215536|||COHORT||RETROSPECTIVE|||||||
33748164|NCT04484285|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34167343|NCT00472901|||||PROSPECTIVE|||||||
34167344|NCT03112265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34167345|NCT02763644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167346|NCT01529073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167347|NCT04879693|NA|SINGLE_GROUP||OTHER||NONE|All systems worn will be blinded. All sensor insertions will be performed at the clinic by subjects and/or caregivers.|||||
34167348|NCT00052585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167349|NCT04429191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167350|NCT01379716|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34167351|NCT00096421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167352|NCT03228771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3 Groups: Group 1: statin loaded in PRGF Group 2: statin loaded in methylcellulose gel Group 3: control|f|f|f|t
34167353|NCT06049329|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34061555|NCT06515210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is double-blinded. The fibre supplements are provided in individual daily sachets, packaged and code-labelled by researchers not involved in data analysis or patient care to ensure double-blinding.|Randomized, double-blinded, parallel-arm, placebo-controlled, six-week clinical trial, with optional 6-week extension for participants in whom the primary outcome is achieved.|t|f|t|f
34061556|NCT02991014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061557|NCT05690165|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061558|NCT03328494|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061559|NCT00401960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061560|NCT06514456|||COHORT||PROSPECTIVE|||||||
33854677|NCT02258165|||COHORT||PROSPECTIVE|||||||
34167354|NCT02169986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34061561|NCT06731686|||COHORT||RETROSPECTIVE|||||||
34061562|NCT01945294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061563|NCT04533243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061564|NCT03927027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061565|NCT02623842|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34061566|NCT03690973|RANDOMIZED|PARALLEL||TREATMENT||NONE|single blinded|Randomized clinical trial||||
34061567|NCT03349905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061568|NCT03969264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator and research assistant are blinded to study intervention.|Randomized parallel two-arm study.|f|f|t|t
34061569|NCT04115410|||COHORT||RETROSPECTIVE|||||||
33854678|NCT04485182|||COHORT||PROSPECTIVE|||||||
33854679|NCT03756246|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Both healthy and depressed arms will receive the influenza vaccine.||||
33854680|NCT06105268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single (Investigator)|The sample of the study will consist of two groups: experimental and control. The number of students in each group is the difference between the experimental and control groups in order to determine the effectiveness of shoulder dystocia management given using the flipped learning technique; With 95% confidence (1-α), 95% test power (1-β), d = 1.3000000 effect size and two-sided t test, the number of samples to be taken in each group will be 17 and the study should be conducted with a total of 34 students (16). . Since there is no case of data loss and there is no sample study where the flipped learning technique and shoulder dystocia are used together, a total of 68 students will be studied, 34 students in each group.|f|f|t|f
33854681|NCT05709015|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33854682|NCT05997368|||OTHER||PROSPECTIVE|||||||
33854683|NCT00763867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854684|NCT03295110|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854685|NCT00190567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33854686|NCT05160792|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single group comparison of comfort between legs - both with identical compression bandages but the index leg with a GraduCheck device under the bandage and the control leg without.||||
34061570|NCT00081926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061571|NCT02570334|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34167355|NCT02568540|||COHORT||PROSPECTIVE|||||||
34167356|NCT00230646|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33854687|NCT00292162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854688|NCT04759664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854689|NCT03325920|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Participants, as well as the investigating dentist are blind to the result obtained from the polysomnographic recording. The statistican is also unaware of the sleep bruxism diagnosis.|Single-center, national, double-blind, controlled clinical trial with parallel group design|t|f|t|t
33854690|NCT02097641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854691|NCT03401229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854692|NCT03435757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854693|NCT06305377|||CASE_ONLY||RETROSPECTIVE|||||||
33854694|NCT00882154|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893556|NCT02926339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33748165|NCT01693120|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with Phased RF Ablation System||||
33893557|NCT00742781|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893558|NCT05142241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061572|NCT01905033|||COHORT||PROSPECTIVE|||||||
34061573|NCT05153668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061574|NCT05921149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061575|NCT05615233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061576|NCT06426160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, placebo-controlled, double-blinded investigator-initiated trial|t|f|t|f
34061577|NCT03257241|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of the efficacy of two standard induction treatment protocols (DA-90 and DAC) in patients with newly-diagnosed AML (with the exception of acute promyelocytic leukemia). Comparison of the efficacy of two standard reinduction treatment protocols (CLAG-M and FLAG-IDA) in patients with refractory and relapsed AML.||||
34061578|NCT01342172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061579|NCT00607633|||COHORT||PROSPECTIVE|||||||
34061580|NCT02046772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061581|NCT01606748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061582|NCT02117713|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34061583|NCT02388412|||CASE_CONTROL||PROSPECTIVE|||||||
34061584|NCT00851773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061585|NCT00732680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061586|NCT00032721|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34061587|NCT00483210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061588|NCT03040505|||OTHER||PROSPECTIVE|||||||
34061589|NCT03387345|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Otherwise healthy male and female adults||||
34061590|NCT04312841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061591|NCT06731153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167357|NCT00134303|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34167358|NCT06109363|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic stepped wedge design - over 4 months, 18 sites enter trial at 1 month intervals. 2||||
33854695|NCT04290169|NA|SINGLE_GROUP||TREATMENT||NONE||The single subject design was chosen due to its sensitivity to individual differences which is a relevant feature when studying heterogenous population as adults with spastic CP. The study is a multiple-treatment design with two intervention phases, an ABACAA design. The study include a baseline assessment phase (A1), a three-month intervention phase with motion controlled video game training (B), post-intervention assessment (A2), a second three-month intervention phase with Motion Controlled Video Game (MCVG) treatment and BoNT-A treatment (C) including an assessment in the middle when BoNT-A usually have its peak (6 weeks after application) (A3), post-intervention assessment three months after application of BoNT-A (A4) and a follow-up assessment 9 months after beginning of first intervention (A5). All participants will be medically examined and assessed with functional measures in all assessment phases. The timeframe from baseline to follow-up is approximately 9 months.||||
33854696|NCT02635360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854697|NCT02617849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854698|NCT06153953|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854699|NCT01313637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854700|NCT06244446|||COHORT||PROSPECTIVE|||||||
33854701|NCT00044031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854702|NCT02991131|||COHORT||PROSPECTIVE|||||||
33854703|NCT03511313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854704|NCT04040816|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33854705|NCT03769012|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|A randomization schedule will be created and provided to the Investigator indicating the order of randomization. Each participant will be assigned a randomization code according to the order of the randomization list generated using www.randomization.com. Enrolled participants will be randomized to the different treatment arms at day -14. Concealment of the allocation of treatment will be employed through the use of opaque sealed envelopes, each labeled with a randomization number. Each envelope will contain information regarding the treatment associated with each randomization number.|Single-center, randomized, double-blind, placebo-controlled, parallel study|t|t|t|t
33854706|NCT02541760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33854707|NCT02132013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854708|NCT02026310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854709|NCT00116727|||COHORT||PROSPECTIVE|||||||
33854710|NCT02237313|NA|SINGLE_GROUP||OTHER||NONE||||||
33854711|NCT04312217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Children and their parents entering day surgery are pre-operatively exposed to medical clowning (N=38) or normal pre-operative care (N=32)||||
33854712|NCT01098097|||COHORT||PROSPECTIVE|||||||
33854713|NCT01722110|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854714|NCT01777269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854715|NCT04781088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854716|NCT02968732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854717|NCT00580268|||COHORT||PROSPECTIVE|||||||
33854718|NCT06266884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The contact numbers of the prospective fathers will be taken and a training video and presentation on kangaroo care will be sent via WhatsApp. Kangaroo care will be applied to the fathers in the experimental group during birth.||||
33854719|NCT04790019|RANDOMIZED|CROSSOVER||PREVENTION||NONE||All participants will complete the control condition and one of two experimental conditions in a randomized and counterbalanced crossover design.||||
33854720|NCT03453437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854721|NCT01600521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33854722|NCT02132546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33748166|NCT00645697|||COHORT||RETROSPECTIVE|||||||
33854723|NCT02897960|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33854724|NCT02066285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854725|NCT02225951|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33854726|NCT05535933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854727|NCT00005652||||TREATMENT||||||||
33854728|NCT05506657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854729|NCT00585377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854730|NCT00433524||||DIAGNOSTIC||||||||
33854731|NCT05663879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33854732|NCT03637985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The allocation was concealed in sequentially numbered opaque envelopes by a blinded and an independent research assistant and selected 69 individuals randomly into the study.||f|f|t|t
33957936|NCT05611710|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blinded|This is a randomized, double blinded, placebo controlled trial of anakinra in patients with dengue with warning signs or severe dengue|t|f|t|f
33957937|NCT06560463|||COHORT||PROSPECTIVE|||||||
33957938|NCT05828095|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167359|NCT02614729|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34167360|NCT05487521|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34167361|NCT06307418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Informal caregivers of patients with Head and neck cancer will be randomized to internet-based support or to support as usual.||||
34167362|NCT05266612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854733|NCT00187668|||COHORT||PROSPECTIVE|||||||
33854734|NCT03237351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854735|NCT00894153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893559|NCT06657807|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled feasibility study using pretest-posttest design with 2 mo FU as primiary endpoint.||||
33893560|NCT03158402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893561|NCT01209715|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33957939|NCT06700850|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33957940|NCT02390973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957941|NCT01398813|||||CROSS_SECTIONAL|||||||
33957942|NCT05524207|||CASE_CONTROL||PROSPECTIVE|||||||
34061592|NCT00522704|||COHORT||PROSPECTIVE|||||||
33748167|NCT04564183|||COHORT||PROSPECTIVE|||||||
33893562|NCT04846114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants on OAT allocated to one of the three different local hemostatic strategies, were not informed wich agent was used. Time of compression was equal in all groups.|80 surgical procedures (pr) in 71 patients (18 not OAT/53 on OAT) were assigned to one of four groups: control group (Cg n=20 pr not OAT) and 3 experimental groups of patients on OAT with local hemostatic management were randomized: tranexamic acid group (TXAg n=20 pr), bismuth subgallate group (BSg n=20 pr) and dry gauze group (DGg n=20 pr).|t|f|f|f
33893563|NCT02601417|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33893564|NCT02339948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893565|NCT01734343|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34167363|NCT03006380|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34167364|NCT01028105|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167365|NCT03584165|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34167366|NCT06434883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34167367|NCT00116012|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167368|NCT00887549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167369|NCT01425684|||OTHER||PROSPECTIVE|||||||
34167370|NCT04955457|||OTHER||CROSS_SECTIONAL|||||||
34167371|NCT05343858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167372|NCT06289933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167373|NCT03275740|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind (investigator and subject), sponsor open in healthy male participants. Masking will not be applied for participants with ITP (all ITP participants will receive PF-06755347).|single ascending dose study|t|f|t|f
34167374|NCT00619515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167375|NCT02986126|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34167376|NCT00540072|RANDOMIZED|PARALLEL||||DOUBLE||||||
34167377|NCT02180581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167378|NCT01434173|||COHORT||RETROSPECTIVE|||||||
34167379|NCT05460455|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34167380|NCT03914417|NA|SINGLE_GROUP||TREATMENT||NONE||Application of imiquimod 3.75% cream to treat actinic keratosis||||
34167381|NCT00002503||||TREATMENT||||||||
34167382|NCT00874146|||COHORT||RETROSPECTIVE|||||||
34167383|NCT02928315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167384|NCT05289115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|f|t
34167385|NCT03053947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167386|NCT01080040|||COHORT||PROSPECTIVE|||||||
34167387|NCT03049761|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a examiner-masked, 3-treatment, randomized clinical trial comparing the safety of different oral hygiene regimens.|f|f|t|f
34167388|NCT00375271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167389|NCT02551068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167390|NCT02542501|||CASE_ONLY||PROSPECTIVE|||||||
34167391|NCT05596136|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33957943|NCT05183230|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research assistants administering the assessments will be blind to participant randomization in the R33 phase.||f|f|f|t
33957944|NCT01684306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34167392|NCT00954993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167393|NCT02535455|NA|SINGLE_GROUP||OTHER||NONE||||||
33854736|NCT04246567|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The investigators divided the patients to two groups. Patients were divided into two groups with a lottery. Surgeons did not know which hypotensive anesthesia technique were used. And surgeons evaluated surgical satisfaction and bleeding scores|A total of 60 ASA 1 patients aged between 18-55 who underwent elective rhinoplasty surgery were included the study.The patients were divided into two groups. One group received hypotensive anesthesia with total intravenous anesthesia technique according to MBP and the other group received hypotensive anesthesia with inhalation anesthesia technique. Blood samples were taken from all patients before anesthesia induction and 30. ,60. ,120. second of intraoperative period for TAS, TOS, HIF 1a. At the and of the operation patients were fallowed in the post anesthesia care unit for 30 minutes and pain and nause vomiting scores were evaluated. İn addition, surgical satisfaction and bleeding scores and anesthetic consumption of both groups were recorded|t|f|f|f
33957945|NCT03382457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854737|NCT00816348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854738|NCT00338156|||COHORT||RETROSPECTIVE|||||||
33854739|NCT02647229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33854740|NCT01577745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957946|NCT05138900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957947|NCT06562972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33957948|NCT06686602|||COHORT||RETROSPECTIVE|||||||
33957949|NCT06626594|||OTHER||CROSS_SECTIONAL|||||||
33854741|NCT02738944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854742|NCT01845051|||CASE_CONTROL||PROSPECTIVE|||||||
33854743|NCT02911415|||COHORT||PROSPECTIVE|||||||
33854744|NCT02893930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854745|NCT05401760|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Inclusion criteria:~1. Patients with pediatric congenital cataract Aged less than two years associated with other ocular anomalies which is high risk for developing PCSG as microcornea and aniridia.~2. Patient with pediatric cataract with other eye had post cataract surgery glaucoma"||||
33957950|NCT00061646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33957951|NCT06087198|||CASE_ONLY||PROSPECTIVE|||||||
33957952|NCT00134472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957953|NCT04557982|||COHORT||PROSPECTIVE|||||||
33957954|NCT05967624|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33957955|NCT01843439|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33957956|NCT06703541|||COHORT||PROSPECTIVE|||||||
33957957|NCT06642610|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33957958|NCT06700863|||COHORT||PROSPECTIVE|||||||
33957959|NCT04720573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator assessing the ECGs, and rhythm holter recordings was blinded to randomization.|1:1 randomization|f|f|t|f
33957960|NCT00109278|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33957961|NCT02795780|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957962|NCT06084572|||CASE_ONLY||PROSPECTIVE|||||||
33957963|NCT03889405|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957964|NCT06080191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957965|NCT06700785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33957966|NCT04137770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167394|NCT04932928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167395|NCT01059409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167396|NCT02760966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167397|NCT01759797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167398|NCT04301466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167399|NCT00154297|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167400|NCT00255190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167401|NCT00423839|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34167402|NCT05022459|||COHORT||PROSPECTIVE|||||||
34167403|NCT02058953|||COHORT||PROSPECTIVE|||||||
34167404|NCT03469063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34167405|NCT01316874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957967|NCT06272318|||COHORT||PROSPECTIVE|||||||
34167406|NCT01262079|||COHORT||PROSPECTIVE|||||||
33957968|NCT06243016|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33957969|NCT05224141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33957970|NCT00996918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957971|NCT05043220|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33957972|NCT04851470|||COHORT||CROSS_SECTIONAL|||||||
33957973|NCT06523309|||COHORT||PROSPECTIVE|||||||
33957974|NCT00308100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167407|NCT04340635|||CASE_ONLY||OTHER|||||||
33748168|NCT04094311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748169|NCT00511576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748170|NCT06669819|||COHORT||CROSS_SECTIONAL|||||||
33748171|NCT01661374|||CASE_CONTROL||PROSPECTIVE|||||||
33748172|NCT01168492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748173|NCT06568705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748174|NCT05809037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748175|NCT02358603|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Case group subjects will complete study required protocol testing while wearing an experimental device, the ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. Results will be compared to a Control Group.||||
33748176|NCT05659602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748177|NCT00781976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748178|NCT02992262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748179|NCT01029223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33748180|NCT04302350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33748181|NCT01673932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748182|NCT05780203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748183|NCT00071669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33748184|NCT05186623|||CASE_ONLY||PROSPECTIVE|||||||
33748185|NCT05831319|||COHORT||PROSPECTIVE|||||||
33748186|NCT00492284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748187|NCT05638867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open-label study. But while the study is in progress, the grouping information is masked from outcome assessors (CEC).|Open-label, Two-arm, Randomized Superiority Trial|f|f|f|t
33748188|NCT01594073|||COHORT||PROSPECTIVE|||||||
33748189|NCT01275625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748190|NCT03346876|||COHORT||PROSPECTIVE|||||||
33748191|NCT02062632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33748192|NCT00639717|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33748193|NCT05880095|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intervention groups will be randomly assessed letters A, B or C. Data analists will used masked groups in the analysis.|Open, controlled, randomized, parallel groups trial|f|f|f|t
33748194|NCT02943603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748195|NCT04542343|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33748196|NCT03212105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748197|NCT00857324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748198|NCT06120764|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant will be randomly assigned to groups. An independent statistician will analyze the data.|"The children in the experimental group will listen to the Guided Imagery CD prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion started and during the chemotherapy infusion. In the meantime, patients will be encouraged to think of various images, such as imagining that the treatment is over, returning to their old life quickly, etc."|t|f|f|t
33748199|NCT04946591|||COHORT||PROSPECTIVE|||||||
33748200|NCT02065531|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33748201|NCT03796546|||OTHER||PROSPECTIVE|||||||
33748202|NCT04169737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748203|NCT03710915|NA|SEQUENTIAL||TREATMENT||NONE||"Drug: HG146 capsule HG146 capsule is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.~Other Name: HG280146, HG0146, HG280146, HG280146-P1"||||
33748204|NCT05281380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748205|NCT03397264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Ph 1b open label; Ph 2a quadruple masked|Phase 1b - sequential dose followed by Phase 2a - parallel arm|t|t|t|t
33748206|NCT02125526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748207|NCT03122418|NA|SINGLE_GROUP||OTHER||NONE||Subjects will receive a personal fitness device and asked to develop an individual exercise program.||||
33748208|NCT03453398|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants are divided in three different groups on the bases of their actual shift work modalities. Thus no allocation process is possible within this project.||||
33854746|NCT01014260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33854747|NCT01759368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893566|NCT04782622|||CASE_CONTROL||PROSPECTIVE|||||||
33893567|NCT04424576|||COHORT||PROSPECTIVE|||||||
33893568|NCT03830281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061593|NCT03647605|NA|SINGLE_GROUP||OTHER||NONE||||||
34061594|NCT00179205|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34061595|NCT06215755|NA|SINGLE_GROUP||TREATMENT||NONE||"Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks."||||
34167408|NCT01014130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167409|NCT03371472|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||In a group of patients with PVL there are defined two arms: one where PVL is located in mitral position (10 patients) and the second one where PVL is located in aortic position (10 patients).||||
33957975|NCT06702215|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Both patients with BPD and healthy controls will undergo two experimental conditions, in counterbalanced order.|t|f|f|f
33957976|NCT01873235|||COHORT||PROSPECTIVE|||||||
33957977|NCT06567522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Pragmatic randomized low interventional single-centre parallel non blinded design with blinded assessment of the objectives.|Pragmatic single-centre parallel group randomized clinical trial|f|t|f|f
33957978|NCT04067856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33957979|NCT06285955|||CASE_ONLY||PROSPECTIVE|||||||
33957980|NCT06214793|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, prospective phase II study of taletrectinib in participants with CDH1-mutated breast metastatic ILC||||
33957981|NCT04816877|||CASE_CONTROL||PROSPECTIVE|||||||
33957982|NCT06701383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957983|NCT03126682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding to be done - Outcome assessor and care provider will be blinded to randomization arm of subject|2 Arms of randomization - one wherein patients get Wellbutrin in first ECT and another arm wherein patients get it with second ECT. Counterbalanced randomization|f|t|f|t
33957984|NCT05581004|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957985|NCT02953418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33957986|NCT06569134|||COHORT||RETROSPECTIVE|||||||
33957987|NCT05425277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33957988|NCT00764244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33957989|NCT01364766|||||CROSS_SECTIONAL|||||||
33957990|NCT05838508|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33957991|NCT05042687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33957992|NCT03506646|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||1:1 randomized, cross-over, double-blinded|t|f|t|f
33957993|NCT03983850|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33957994|NCT06701266|||OTHER||CROSS_SECTIONAL|||||||
33957995|NCT05259696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1: The study uses a modified 3+3 design with 5 planned dose levels of E-602 as monotherapy and 2 planned dose levels of E-602 in combination with cemiplimab. Phase 2: Consists of dose-expansion and will use the recommended Phase 2 dose level for E-602 as monotherapy and in combination with cemiplimab.||||
33957996|NCT03443180|NA|SINGLE_GROUP||OTHER||NONE||All subjects will receive a dietary intervention. They will be instructed and asked to follow a diet free of gluten and the protein amylase trypsin inhibitors (ATI), which is frequently found in gluten-containing foods, for four weeks. They will then be asked to resume their normal diet.||||
33957997|NCT01087333|||CASE_CONTROL||PROSPECTIVE|||||||
33957998|NCT05910320|NA|SINGLE_GROUP||OTHER||NONE||||||
33957999|NCT06036173|||OTHER||PROSPECTIVE|||||||
33958000|NCT04758611|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, open-label, single-arm pilot study||||
34061596|NCT05414266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061597|NCT02539654|NA|SINGLE_GROUP||OTHER||NONE||||||
34061598|NCT02949908|||COHORT||PROSPECTIVE|||||||
34061599|NCT02241265|||CASE_ONLY||RETROSPECTIVE|||||||
34061600|NCT04076371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167410|NCT06378034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167411|NCT06050746|||COHORT||PROSPECTIVE|||||||
34167412|NCT00257426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167413|NCT01935635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167414|NCT03266133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748209|NCT04383496|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention uses Graded Exercise Therapy to increase perceived behavioral control by enhancing knowledge about appropriate activities and helping participants set appropriate and attainable daily goals for physical activity. We will also incorporate motivational interviewing techniques and mHealth to enhance positive personal attitudes about physical activity.||||
34061601|NCT06047600|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||cross-sectional stepped wedge cluster randomized controlled trial||||
34061602|NCT05104879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34061603|NCT02376296|||COHORT||PROSPECTIVE|||||||
34061604|NCT06373159|||COHORT||RETROSPECTIVE|||||||
34061605|NCT04609241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061606|NCT05470075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, double-blind, dose finding, parallel controlled with active drug and placebo, phase II clinical trial|t|t|t|t
34061607|NCT04105894|||CASE_ONLY||RETROSPECTIVE|||||||
34061608|NCT00849134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167415|NCT04524858|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm study||||
34167416|NCT01517932|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167417|NCT05268640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167418|NCT00381004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748210|NCT05557942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748211|NCT01815164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748212|NCT02148250|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33748213|NCT05440526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748214|NCT05075928|||CASE_ONLY||RETROSPECTIVE|||||||
33748215|NCT01327326|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33748216|NCT00887497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748217|NCT06670937|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study aims at collecting airway mucus from individuals with non cystic fibrosis bronchiectasis.||||
33748218|NCT05136573|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33748219|NCT03353935|||CASE_ONLY||PROSPECTIVE|||||||
33748220|NCT01334801|||CASE_ONLY||PROSPECTIVE|||||||
33748221|NCT04024618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be 1:1, both EN and PN arms. The patients will be randomized in permutated blocks independently by Statistician.||||
33748222|NCT00228020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33748223|NCT06196268|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33748224|NCT06378346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748225|NCT03282448|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748226|NCT01427868|RANDOMIZED|CROSSOVER||||NONE||||||
33748227|NCT03727633|NA|SINGLE_GROUP||TREATMENT||NONE|No masking is used. All involved know the identity of the intervention assignment.|The purpose of this study is to assess efficacy and tolerance of hepatic intra-arterial injection of an emulsion of Idarubicine and Lipiodol for treatment of non-metastatic, unresectable hepatocellular carcinoma on cirrhosis with Child-Pugh A/B7.||||
33748228|NCT06415656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854748|NCT06294132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant: the participants will not know whether they received the lumbar manipulation or sham lumbar manipulation.~Care Provider: the care providers (those who perform the lumbar manipulation and sham lumbar manipulation) will not be involved in collecting any outcome data.~Investigator: all investigators collecting outcome measures will not know which subjects received the lumbar manipulation or sham lumbar manipulation.~Outcome assessor: the outcome assessors will not be involved in collecting data."|Participants will be randomly assigned to either receive lumbar manipulation or a sham lumbar manipulation.|t|t|t|t
33854749|NCT02175004|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854750|NCT01444573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854751|NCT05694104|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33854752|NCT06284148|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||This is a stepped wedge cluster randomized trial which has 3 sequences starting intervention in randomized order.||||
33854753|NCT00174512|RANDOMIZED|CROSSOVER||ECT||NONE||||||
33854754|NCT05134870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854755|NCT02700763|NA|SINGLE_GROUP||OTHER||NONE||||||
33854756|NCT05469399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33854757|NCT00169052|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33854758|NCT00512460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854759|NCT02973048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854760|NCT02958267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854761|NCT02464033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854762|NCT03306836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854763|NCT02673840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854764|NCT00597961|||CASE_ONLY||PROSPECTIVE|||||||
33854765|NCT02012764|||COHORT||PROSPECTIVE|||||||
33854766|NCT03572478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854767|NCT04235933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061609|NCT00568360|||COHORT||PROSPECTIVE|||||||
34061610|NCT00914706|||COHORT||PROSPECTIVE|||||||
34061611|NCT04155021|||OTHER||PROSPECTIVE|||||||
34061612|NCT02683148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061613|NCT03956342|||COHORT||PROSPECTIVE|||||||
34061614|NCT04724577|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation study for carbon ion radiotherapy in prostate cancer||||
33748229|NCT02995772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748230|NCT01044004|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33854768|NCT00164645|RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
33854769|NCT01201317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893569|NCT02211365|||COHORT||PROSPECTIVE|||||||
33893570|NCT02951052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893571|NCT02562729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893572|NCT04073550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061615|NCT01523015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061616|NCT00908427|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061617|NCT05610800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748231|NCT02232893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748232|NCT04537923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061618|NCT01021488|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893573|NCT05045040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33893574|NCT01552343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893575|NCT01390740|||COHORT||PROSPECTIVE|||||||
33893576|NCT01905956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893577|NCT00982566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893578|NCT05344547|||CASE_ONLY||PROSPECTIVE|||||||
34061619|NCT04308915|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34061620|NCT00259285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061621|NCT06002776|||OTHER||RETROSPECTIVE|||||||
34061622|NCT01343992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061623|NCT04424511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators will utilize a matching placebo to mask study arm allocation. All children aged 1-11 months in all study communities will be offered biannual or quarterly azithromycin or placebo distribution in an identical fashion. Placebo will be identical to azithromycin in appearance, taste, odor, and packaging. The interventions will be coded only with a letter code.|LAKANA is a cluster-randomized, placebo-controlled, double-blinded, parallel-group, three-arm clinical trial, with adaptive design.|t|t|t|t
34061624|NCT04764786|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34061625|NCT00199576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34061626|NCT04167930|||OTHER||OTHER|||||||
34061627|NCT03759366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061628|NCT00807391|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061629|NCT04990401|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible participants will receive the behavioral activation teletherapy intervention in this single-arm study.||||
34061630|NCT00568256|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34167419|NCT03494920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded core laboratory adjudications of the primary outcome. NIHSS and mRS (secondary outcomes) performed by blinded assessor.|Patients will be randomised to either direct endovascular clot retrieval or to bridging intravenous thrombolysis with endovascular clot retrieval.|f|f|f|t
33854770|NCT05391477|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients will be blinded to group allocation. The endoscopist in group 2 will be blinded to the AIOD. However, the endoscopist in group 1 will not be blinded to the CADx diagnosis because the output helps the endoscopist to focus the lesion properly for a AIOD diagnosis. In group 2, the person in charge of handling the GI-Genius output will communicate with the endoscopist when the AIOD of a particular lesion has been obtained. There is no need to mask personnel who enters HOD or AIOD data on the CRD because at that point results of pathology are not available.|The ODDITY trial is a European multicenter randomized, parallel-group superiority trial comparing GI-Genius artificial intelligence optical diagnosis (AIOD) to human optical diagnosis (HOD) of colon lesions ≤ 5 mm performed by endoscopists, using histopathology as the gold standard. A total of 643 patients attending a colonoscopy within a CRC screening program (either FIT- or colonoscopy-based) or because of post-polypectomy surveillance will be randomized to the ADI group (group 1) or the HOD (control, group 2) group. A computer-generated 1:1 blocking randomization scheme stratified for center and endoscopist will be used.|t|f|f|f
34167420|NCT04533386|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167421|NCT01774201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34167422|NCT06170554|||OTHER||PROSPECTIVE|||||||
34167423|NCT01329237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167424|NCT02423655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167425|NCT01501266|||COHORT||PROSPECTIVE|||||||
34167426|NCT00931034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167427|NCT03843086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167428|NCT01067274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167429|NCT04143685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167430|NCT00452283|||CASE_ONLY||PROSPECTIVE|||||||
34167431|NCT04803643|||OTHER||CROSS_SECTIONAL|||||||
34167432|NCT03200834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167433|NCT02430090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167434|NCT06403462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34167435|NCT00631358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167436|NCT01748097|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34167437|NCT00363532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34167438|NCT05045261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167439|NCT01929590|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34167440|NCT00599066|||CASE_ONLY||PROSPECTIVE|||||||
33854771|NCT04067648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Observers and patients were double-blind. Sufentanil was assigned by a specialist. Different doses of sufentanil were allocated in the same volume according to the weight of the child.||f|f|t|f
33854772|NCT01532726|||CASE_CONTROL||PROSPECTIVE|||||||
33854773|NCT06250556|NA|SINGLE_GROUP||OTHER||NONE||pre-to-post design for experiment 2.||||
33854774|NCT00959647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854775|NCT04568460|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33854776|NCT00947674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854777|NCT00001267||||TREATMENT||||||||
33854778|NCT01187472|||OTHER||PROSPECTIVE|||||||
33854779|NCT05969925|||COHORT||PROSPECTIVE|||||||
33854780|NCT05052346|||COHORT||CROSS_SECTIONAL|||||||
33854781|NCT03133546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854782|NCT03584568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854783|NCT04354896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893579|NCT00986531|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34061631|NCT02284763|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34061632|NCT00770133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061633|NCT05583292|||COHORT||PROSPECTIVE|||||||
34061634|NCT04324866|||COHORT||PROSPECTIVE|||||||
34061635|NCT05209841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34167441|NCT06392724|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm unblinded, single-center study||||
34167442|NCT01841905|||COHORT||PROSPECTIVE|||||||
34167443|NCT01779232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167444|NCT03196804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33748233|NCT05921968|RANDOMIZED|PARALLEL||TREATMENT||NONE|100 opaque envelopes will be numbered serially and the corresponding letter which denotes the allocation will be put according to the electronic randomization table. Then all envelopes will be closed and put in one box. When the first patient arrives, the envelope will be opened and the patient will be allocated according to the letter inside|prospective,randomized,open-label,parallel-group study||||
33748234|NCT06158750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167445|NCT06232265|||COHORT||PROSPECTIVE|||||||
34167446|NCT03375034|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34167447|NCT03556163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167448|NCT05977400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748235|NCT01865370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33748236|NCT00193934|||COHORT||PROSPECTIVE|||||||
34167449|NCT00062179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34167450|NCT02585362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167451|NCT02576639|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33854784|NCT04076839|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either: 1) a 9-week GMT program or 2) a 9-week wait-list control (WLC) condition. Participants will be tested at baseline prior to group commencement. Once the testing session is complete, the participants will be assigned to (GMT or WLC). Participants enrolled in the GMT program will attend 9-weeks of GMT sessions (2 hours/week for 9 weeks) and a post-intervention testing session date. Participants enrolled in the WLC group will be given a testing session date after 9 weeks has past. Participants will attend a final testing session (in 3 months' time; approximately 3 hours in duration). WLC will be offered a complimentary 9-week GMT program once the final testing session is complete. Following the completion of the complimentary 9-week GMT program, individuals in the WLC will complete post-intervention testing (1-2 weeks following the completion of GMT and again at 3 months, post GMT completion).||||
33854785|NCT00000550||||TREATMENT||||||||
33854786|NCT01759407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34061636|NCT00553982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061637|NCT03013608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061638|NCT02176460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061639|NCT06441617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded with respect to Program A and Program B. However, the third arm of the trial, Treatment as Usual, will not be blinded. Since outcome assessments are collected online via surveys, the outcome assessor is a blinded entity.||t|f|f|t
34061640|NCT04027075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will recruit 400 adolescents to test an app designed to increase mindfulness skills and reduce substance use. Participants will be randomly assigned in equal numbers to the intervention group (and will use the app) or the control group.|f|f|f|t
34061641|NCT04846816|NA|SINGLE_GROUP||TREATMENT||NONE||The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.||||
34061642|NCT06730425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34061643|NCT00504959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061644|NCT00552032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061645|NCT06223555|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34061646|NCT03785899|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061647|NCT05705115|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open-label using blinded randomization. The intervention to be taken by a participant will be assigned using randomization envelopes, opened at visit 1.|"* Block randomized~* Placebo controlled~* Single center~* Crossover~* Factorial 2x2"||||
34061648|NCT06710899|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061649|NCT06336148|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|This is an Open label Single dose study.||||
34061650|NCT01733485|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34075993|NCT03821987|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX(cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."||||
34075994|NCT06255080|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34167452|NCT01514019|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167453|NCT00878163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167454|NCT04395807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167455|NCT02905266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167456|NCT05385666|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34167457|NCT04804917|||OTHER||PROSPECTIVE|||||||
34167458|NCT02602886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748237|NCT03989947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075995|NCT00791219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34075996|NCT04749095|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34075997|NCT01737307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34075998|NCT06132334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.|Parallel Assignment|t|f|t|t
34075999|NCT05897749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076000|NCT00625456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076001|NCT01161576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We chose an initial dose two fold lower of 9.0x10\^11 genome copies/subject (Group A). Initially, the study plan was to proceed to Group B, which would receive a higher dose of 1.8x10\^12 genome copies if the initial dose was well tolerated. However, after assessing the MRI images of the first 6 children who received the dose of 9.0x10\^11 gc, we discovered that 4 of the 6 subjects at 6 months and 1 of the 6 subjects at 12 months exhibited varying degrees of T2 hyperintensities related to diffusion restriction at the sites of vector deposition. Although there are no clinical correlates to these MRI findings, we have decided to lower the dose by ½ log to 2.85x10\^11 gc for the remaining subjects to be enrolled in protocol #0810010013. The volume of the drug solution will be the same as in Group A, but the concentration of the vector will be ½ log less.||||
34076002|NCT01158742|||COHORT||CROSS_SECTIONAL|||||||
34076003|NCT02256839|||CASE_CONTROL||PROSPECTIVE|||||||
34076004|NCT04610710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trail (RCT)||||
34076005|NCT01845597|||CASE_ONLY||RETROSPECTIVE|||||||
34076006|NCT00078403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076007|NCT03060226|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34076008|NCT06235710|||COHORT||CROSS_SECTIONAL|||||||
34076009|NCT06203249|||COHORT||OTHER|||||||
34076010|NCT05814315|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34076011|NCT00809445|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076012|NCT02607501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076013|NCT00230334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076014|NCT06128018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076015|NCT01829698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076016|NCT02990013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34167459|NCT05527041|||OTHER||PROSPECTIVE|||||||
34167460|NCT02579213|||CASE_CONTROL||PROSPECTIVE|||||||
34061651|NCT04753268|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"This is a prospective, single-arm pilot study evaluating preliminary efficacy and acceptability of a Noom breast cancer survivor weight loss program.~The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."||||
34167461|NCT04675333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167462|NCT04781166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interview-based assessments will be conducted by personnel who are unaware of treatment condition.|Adult participants will be enrolled in the intervention, and we will use pre-, post-data to evaluate whether the program appears to be helpful. Adolescent participants will be randomly assigned to a waitlist control or intervention; those in the waitlist will be offered the intervention after they complete the waitlist period.|f|f|f|t
34167463|NCT03232996|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34167464|NCT05316025|||COHORT||PROSPECTIVE|||||||
34061652|NCT06425445|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061653|NCT05009407|||COHORT||PROSPECTIVE|||||||
34061654|NCT06318819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061655|NCT00563160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061656|NCT04291677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061657|NCT06644222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two intervention groups|t|f|f|f
34061658|NCT05503875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061659|NCT03196037|NA|SINGLE_GROUP||OTHER||NONE||A single-arm pre-/post-test non-randomized study design.||||
34061660|NCT00325624|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34061661|NCT01382316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061662|NCT04272606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 2B randomized, single-center, double-blinded, placebo vs treatment clinical trial with 1:1 randomization|t|t|t|t
34061663|NCT00345878|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167465|NCT06340308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061664|NCT03755518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061665|NCT03085667|||CASE_ONLY||PROSPECTIVE|||||||
34061666|NCT02983916|||COHORT||PROSPECTIVE|||||||
33748238|NCT04323618|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33854787|NCT04460274|||COHORT||RETROSPECTIVE|||||||
33854788|NCT02709096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854789|NCT02236104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854790|NCT05218187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research coordinator, not involved in subject testing, will be responsible for identification and management of subject group allocation. The research investigation team will conduct all testing and will remain mask to group allocation throughout the duration of the study.|A convenience sample of 30 persons with Parkinson's Disease will be enrolled for this clinical trial. If found eligible for the study and agree to consent to participate, subjects will be randomized to either conventional physical therapy (CPT) group or CPT with G-EO training using a random numbers generator and concealed allocation.|f|f|t|f
33854791|NCT03958786|NA|SINGLE_GROUP||OTHER||NONE||Multicenter, prospective study||||
33854792|NCT00343447|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854793|NCT04612959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The women which participated in the study will not know which group she was in. The data from the groups will be collected by an online survey and the participants will fill form themselves. And data will retreated from the online database by the person who will nt know groups of participants.|Randomized controlled double-blind trial|t|f|f|t
33854794|NCT01163916|||||PROSPECTIVE|||||||
33854795|NCT06088212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061667|NCT04351126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061668|NCT06731348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061669|NCT02077413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061670|NCT00436098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061671|NCT04828603|||OTHER||PROSPECTIVE|||||||
34061672|NCT06731543|||OTHER||OTHER|||||||
34061673|NCT04524585|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167466|NCT03369418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|devices were masked at supplier and unblinded at end of the study.||t|f|t|f
34167467|NCT01051674|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34167468|NCT02668497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748239|NCT00428350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061674|NCT06422936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group design with same treatment and study procedures||||
33958001|NCT06590987|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Fully blinded two-armed pragmatic Randomized Controlled Trial (RCT).~In this particular pragmatic RCT all participants follow the same T0-control-T1-intervention-T2 procedure, suitable for both between-groups and within-subjects comparisons of the Strolll AR intervention effects as well as for evaluating its clinical feasibility. With regard to the between-groups comparison, participants will be allocated to control (using T0-T1 change data) or intervention (using T1-T2 change data) groups using multiple (n=20) two-armed randomizations. The randomization will be predefined by an independent person using a Matlab script, locked with a date and timestamp, and kept concealed from participants, therapists and researchers. After the final T2 assessment of the last participant, the 20 randomizations of participants over control and intervention groups will be revealed to the researchers and applied in the data analysis."||||
33958002|NCT06539702|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34061675|NCT05710679|NA|SINGLE_GROUP||OTHER||NONE||"Biological samples of patients included in the study (i.e., patients treated with potentiated radiotherapy for a locally advanced head and neck cancer) will be analysed (Next generation sequencing (NGS)):~* At inclusion : a FFPE block + a blood sample to identify tumor specific variants (tcDNA and cvDNA)~* 3 months after radiotherapy in case of incomplete response (PET-CT) : a blood sample to search if the tumor specific variants identified before the treatment are found~Patients with incomplete response after 3 months potentiated radiotherapy will undergone a salvage adenectomy.~The main objective is to assess the ability of circulating DNA to predict residual disease during salvage adenectomy."||||
34167469|NCT01694381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded study.|The trial consists of two study parts in which healthy male volunteers will randomly and in a double-blinded manner receive a single dose of M5 or M5-placebo intravenously, with (part II) or without (part I) a preceding single dose of C1-inhibitor.|t|t|t|t
34167470|NCT03449966|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||All procedures were performed with both WLE and pCLE. One patient underwent both WLE and pCLE. Target biopsy under pCLE and random biopsy at cancer lesion under WLE will be done for one patient. The proportion of remnant cancer cells in biopsy samples will be compared.||||
33854796|NCT06035679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854797|NCT05914441|||COHORT||PROSPECTIVE|||||||
34061676|NCT02689882|NA|SINGLE_GROUP||OTHER||NONE||||||
33854798|NCT04446533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The products will be packaged in such a way that they are not recognizable either by the operator or by the patient. Each package will be assigned a number that in turn will refer to the type of the product. The association between the number and type of the product will be collected by another operator on the basis of the association carried out by a dedicated software. The operator who will deliver the product will be informed about the type only at the end of the treatment.~The data will be collected in pseudonymised form and inserted into a dedicated database in order to carry out the statistical analysis provided."|"Following a professional oral hygiene session, subjects will be divided into three groups: BMG0703, active comparator a nd placebo.~First application of products will be applied clinically, and subsequently, one bottle of the product (test, comparative or placebo) will be given to the patient to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."|t|f|t|f
33854799|NCT04084470|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double-blind randomized cross-over study|t|f|t|f
33854800|NCT00639353|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33854801|NCT01592500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061677|NCT01712308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061678|NCT05292976|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double Dummy||t|f|t|f
34061679|NCT00693342|RANDOMIZED|||TREATMENT||||||||
34061680|NCT05996536|||COHORT||CROSS_SECTIONAL|||||||
34061681|NCT01863524|||||PROSPECTIVE|||||||
34061682|NCT00842400|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34061683|NCT03017027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061684|NCT03489941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061685|NCT06381154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061686|NCT00943176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061687|NCT04202289|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients were blinded to the hypothesized effects of either treatment, but neither the patients nor the consultant were blinded to the treatment administered, due to the necessity of visualizing the treatments in order to conduct them properly (i.e., both types of dressing need to be seen to be applied, evaluated, replaced and removed adequately).|Prospective, randomized, monocentric, open-label, controlled phase III clinical study||||
34061688|NCT06730633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, propensity-matched-controlled trial||||
34061689|NCT04965103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and research assistant collecting outcomes were blinded.||t|f|f|t
34061690|NCT02844907|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34061691|NCT06234111|||CASE_ONLY||PROSPECTIVE|||||||
34167471|NCT01611038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34167472|NCT05737914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167473|NCT01493193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167474|NCT03567031|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Patient is under general anesthesia|Cerebral blood flow is measured in each patient at 3 different, controlled levels of end-tidal CO2||||
34167475|NCT04604041|||COHORT||PROSPECTIVE|||||||
33958003|NCT01582828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958004|NCT04977830|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34061692|NCT00982852|||CASE_CONTROL||PROSPECTIVE|||||||
34061693|NCT06325670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958005|NCT05043168|||COHORT||OTHER|||||||
33958006|NCT04793815|NA|SINGLE_GROUP||TREATMENT||NONE||Cryo-activation therapy will be performed in patients with advanced NSCLC (PD-L1≥50%) prior to ICB monotherapy in order to transform 'cold' tumors into 'warm' tumors, with the intent to improve ICB efficacy.||||
33958007|NCT05218083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958008|NCT05558605|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|PROBE design|Multicentre RCT comparing AI-TTE with usual care|f|f|f|t
33958009|NCT04338581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 2a, double blind, placebo-controlled, multi-center, proof of concept trial of AMG 714 for the treatment of vitiligo. Participants will be randomized 2:1 to receive AMG 714 or placebo for AMG714. Random assignment will be stratified by active versus stable vitiligo.|t|t|t|t
33958010|NCT00181831|||COHORT||PROSPECTIVE|||||||
33958011|NCT05533112|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33958012|NCT06623526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-way crossover||||
33958013|NCT03491020|||COHORT||PROSPECTIVE|||||||
33958014|NCT01508923|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33958015|NCT04445194|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33958016|NCT03813394|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized 1:1 into either Treatment Arm A or Arm B. Treatment will continue until tumor progression, intolerance to treatment, or up to 2 years (32 doses of pembrolizumab/bevacizumab). For patients who have progressed on pembrolizumab alone, cross over to Arm B is allowed, with repeat biopsy of the lesions before and 1 week after starting bevacizumab. Patients who discontinue from the trial will not be replaced.||||
33958017|NCT03330847|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the study treatment design (monotherapy and 2 different combination therapies will be employed) neither patients nor Investigators will be blinded to study treatment.|||||
33958018|NCT02412696|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33958019|NCT03688503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958020|NCT03724292|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33958021|NCT06366204|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single day interventions; Repeated measures design.||||
33958022|NCT02763007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958023|NCT04328311|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33958024|NCT05282810|||COHORT||PROSPECTIVE|||||||
33958025|NCT06628323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958026|NCT00062036||||TREATMENT||NONE||||||
33854802|NCT05380778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958027|NCT04112667|||COHORT||PROSPECTIVE|||||||
33958028|NCT02548117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958029|NCT06102824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061694|NCT03813134|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open, multicentre, randomised strategy trial in Cardiogenic Shock (CGS)||||
33854803|NCT01847053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33854804|NCT05782452|||CASE_ONLY||PROSPECTIVE|||||||
33958030|NCT06617858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958031|NCT03927989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33958032|NCT00774722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061695|NCT01934127|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34061696|NCT00061022|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34061697|NCT03660150|||COHORT||RETROSPECTIVE|||||||
33854805|NCT02683876|||CASE_CONTROL||PROSPECTIVE|||||||
33854806|NCT05466565|||COHORT||PROSPECTIVE|||||||
33854807|NCT03821441|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33854808|NCT04969978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854809|NCT05435365|||CASE_CROSSOVER||PROSPECTIVE|||||||
33854810|NCT00610103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958033|NCT03603405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958034|NCT04382560|RANDOMIZED|PARALLEL||OTHER||DOUBLE||wait-list control design|f|f|t|t
33958035|NCT03457727|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This will be an open-label study and blinding will not be performed.|Subjects will receive danirixin reference and test formulations in a cross-over manner.||||
33958036|NCT03526679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958037|NCT05317000|RANDOMIZED|PARALLEL||TREATMENT||NONE||This Phase 2 study is a 3-arm window trial, randomizing patients to pre-operative treatment with 5-azacytidine alone, to nivolumab alone, or the combination of 5-azacytidine and nivolumab.||||
33958038|NCT06045195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958039|NCT06537440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the specific nature of acupuncture clinical research, it is difficult to accomplish double blinding of subjects and operators, so this trial was blinded to subjects and statisticians only. The statistical analyst was a non-subject and was not aware of the patient treatment or the trial protocol. For all patients who participated in acupuncture, blinded evaluation questions were asked at the 2nd week after acupuncture.||t|f|t|f
34061698|NCT00998348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061699|NCT03035734|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061700|NCT05171634|NON_RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||f|f|t|t
34061701|NCT00392470||||TREATMENT||||||||
34061702|NCT00002644|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind||t|t|t|f
34061703|NCT02696954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061704|NCT01167634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061705|NCT03536052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061706|NCT01192035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061707|NCT05289687|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study of daratumumab-hyaluronidase in T-ALL patients in morphologic CR with persistent or relapsed MRD. MRD will be assessed centrally for eligibility and response by flow cytometry. All patients will receive daratumumab-hyaluronidase once weekly for up to 4 doses during Course 1. .||||
34061708|NCT01224652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167476|NCT06265181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|When the researcher evaluates the participant according to the inclusion criteria, written consent will be obtained from the participant and pre-evaluation forms will be applied when compliance with the criteria is achieved. Afterwards, the participant's group will be notified to the researcher by the independent researcher and randomization will be carried out. With this; Data entries will be made by an independent researcher as group A and group B, without writing the group names. Until the data analysis and reporting is completed, the statistician will be blinded to which group is the intervention and which group is the control.|Experimental and control group.|t|f|f|t
34167477|NCT01406457|||CASE_ONLY||PROSPECTIVE|||||||
34167478|NCT02066766|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34167479|NCT00395655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167480|NCT01163526|||COHORT||PROSPECTIVE|||||||
34167481|NCT03524482|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will conduct a 2-arm semi-pragmatic randomized design among current tobacco users (N=100). CMHA residents will be randomly assigned to receive (1) the newly translated Path2Quit or (2) SmokeFreeText (NCI's publicly available, standard text messaging program) combined with brief behavioral counseling session plus 2 weeks of nicotine replacement therapy (NRT).||||
34167482|NCT03782233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167483|NCT04442542|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||850 hospitalized patients, who, after the exclusion criteria, 708 hospitalized patients with different diseases (mainly cancer, heart failure, COPD, postoperative gastrointestinal, fractures, pneumonia, high blood pressure, diabetes mellitus) finally began the investigation and organized into 2 groups. The present one was distributed with a basic probability sampling using a table of random numbers, the order of which was randomized through the Microsoft Excel 16.0 program, with the experimental group being 337 participants (Respiratory exercises plus new method of intervention with respiratory incentive - JaPer Method -) and the control group with 371 (Respiratory exercises plus conventional use of the respiratory incentive).|t|f|t|t
34167484|NCT01601535||SEQUENTIAL||TREATMENT||NONE||||||
34167485|NCT02913482|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167486|NCT05597774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167487|NCT03356275|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34167488|NCT00411749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167489|NCT02147743|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34167490|NCT03259555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants received a dose of brexpiprazole or placebo for a maximum of 21 days and were evaluated throughout the duration of the study.|t|t|t|t
34167491|NCT04520607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Note: The first 48 weeks will be single-blind and placebo-controlled while the remainder of the study will be open-label and uncontrolled.||t|f|f|f
34167492|NCT03406273|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167493|NCT04125043|||COHORT||PROSPECTIVE|||||||
34167494|NCT03881111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167495|NCT00930891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167496|NCT02341235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34167497|NCT05768100|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34167498|NCT03479229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167499|NCT05090735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33854811|NCT04660604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants do not have the knowledge about what we are investigated and group types.|Randomized controlled study|t|f|f|f
33854812|NCT02534038|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33854813|NCT03377426|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A blinded evaluator will perform the safety and efficacy assessments||f|f|f|t
33854814|NCT02102477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854815|NCT03601988|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients randomized to receive chemotherapy or chemo-radiotherapy after D2 surgery||||
33854816|NCT01966471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854817|NCT04088487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854818|NCT01442779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854819|NCT04295876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel intervention and control groups.||||
33854820|NCT00669448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854821|NCT02665637|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33854822|NCT04300686|RANDOMIZED|CROSSOVER||TREATMENT||NONE|None. Open-label.|Severe TAK patients were divided into two groups, with 20 cases for each group at the randomized ratio 1:1, prescribed with adalimumab (40mg.bim.IH) and tocilizumab (8mg/kg.qm.ivgtt) respectively, in the presence of prednisone. After the 24 weeks of treatment, the disease remission is evaluated (primary endpoint). If the disease activity is alleviated (remission), the strategy would be maintained for another 24weeks, otherwise (resistant), the treatment strategy would be shifted to the opposite for 24weeks. After 48 weeks, the disease remission would be evaluated once again (secondary endpoint).||||
33854823|NCT02939547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33854824|NCT00633724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854825|NCT00040677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854826|NCT02145247|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34167500|NCT05144100|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two groups/arms in the study to evaluate the efficacy of primary surgery versus primary chemoradiation. Participants will be assigned to one of two or more groups for the duration of the study||||
34167501|NCT02140515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34167502|NCT01178463|||COHORT||RETROSPECTIVE|||||||
34167503|NCT01913951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167504|NCT03850366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854827|NCT01740141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854828|NCT00132782|||CASE_CROSSOVER||PROSPECTIVE|||||||
33854829|NCT04924543|RANDOMIZED|PARALLEL||OTHER||NONE|No masking planned|"All enrolled participants are allocated to the same intervention, with pre-course and post-course assessments.~Participants will then be randomized 1:1 to one of two arms: (1) to receive short refresher training on optical diagnosis, or (2) no additional intervention.~All participants will complete a final late post-course assessment to test knowledge retention from the training module and the impact of refresher training."||||
34167505|NCT02260934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167506|NCT05067517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854830|NCT00343954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167507|NCT02635607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167508|NCT03917797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking for patients, physicians providing patient care and outcome assessors.|Superiority trial comparing MSCs versus Placebo in SLE patients with severe renal disease receiving Standard of Care treatment.|t|t|t|t
33854831|NCT01419457|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33854832|NCT00862628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854833|NCT00428623|||||PROSPECTIVE|||||||
33854834|NCT02416804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33854835|NCT00123552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33854836|NCT00549133|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854837|NCT05493670|||COHORT||PROSPECTIVE|||||||
33854838|NCT01145755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854839|NCT03336996|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854840|NCT00171600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854841|NCT05354180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854842|NCT05300360|||OTHER||PROSPECTIVE|||||||
34167509|NCT00354146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167510|NCT01368250|||COHORT||PROSPECTIVE|||||||
34167511|NCT04742907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators, study staff, sponsor designees, and subjects will be blinded to randomized study treatment for the duration of the study. The pharmacist or designee performing the preparation and administration will also be blinded.|Randomized, Double-Blind, Placebo-Controlled|t|f|t|f
34167512|NCT01034514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167513|NCT05944406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34167514|NCT02230748|||CASE_ONLY||PROSPECTIVE|||||||
34167515|NCT03226002|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34167516|NCT02919761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part 1: Open Label ; Part 2: Double-blind|Part 1: Single Group; Part 2: Parallel|t|f|t|f
34167517|NCT03863288|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Subjects are randomly assigned to one of 4 doses of OXT or placebo. Investigators and subjects and parents/guardians are blinded to assignment.|Randomized, double-blind, placebo-controlled|t|t|t|f
34167518|NCT04393493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind clinical trial|Its a randomized, controlled, phase II, 2-arm, double-blind clinical trial|t|f|t|f
34167519|NCT05011812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Open to Sponsor||t|t|t|f
34167520|NCT03627871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167521|NCT03654183|||COHORT||PROSPECTIVE|||||||
34167522|NCT00449124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34167523|NCT01839435|NA|SINGLE_GROUP||||NONE||||||
34167524|NCT02398305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167525|NCT05787665|||COHORT||PROSPECTIVE|||||||
34167526|NCT03395899|RANDOMIZED|PARALLEL||OTHER||NONE|No masking - open label|||||
33854843|NCT02867319|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33854844|NCT04810754|NA|SINGLE_GROUP||TREATMENT||NONE||open label, unblinded||||
33854845|NCT04891432|||COHORT||PROSPECTIVE|||||||
33854846|NCT02722733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854847|NCT04305938|||CASE_ONLY||PROSPECTIVE|||||||
34167527|NCT05448339|||COHORT||RETROSPECTIVE|||||||
34167528|NCT01433016|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167529|NCT01696370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167530|NCT02210000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167531|NCT00235586|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34167532|NCT02960516|||COHORT||PROSPECTIVE|||||||
34167533|NCT05839574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167534|NCT01402401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167535|NCT03929796|||OTHER||PROSPECTIVE|||||||
34167536|NCT04670341|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||In the first week of the experiment, subject chewing tapioca pearl inthe bubble tea. In the second week, the same subjects drink tea without chewing tapioca pearl||||
34167537|NCT01307436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854848|NCT05152043|||COHORT||PROSPECTIVE|||||||
33854849|NCT02486133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854850|NCT06222385|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Visit type was masked to neuroimaging assessors and blood biomarker analysis laboratory|Cross-over randomized study|f|f|f|t
33854851|NCT05261048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcome Assessor) Study will be single blinded. The assessor will be unaware of the treatment given to both groups.||f|f|f|t
33854852|NCT00104559|RANDOMIZED|PARALLEL||||NONE||||||
33854853|NCT03525288|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomly selected from a standard-care cohort.||||
33854854|NCT05981599|||COHORT||RETROSPECTIVE|||||||
33854855|NCT01360931|||CASE_CONTROL||PROSPECTIVE|||||||
33854856|NCT04538456|||COHORT||PROSPECTIVE|||||||
33854857|NCT03618121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167538|NCT03833739|RANDOMIZED|PARALLEL||TREATMENT||||Randomized clinical trial||||
34167539|NCT01661049|||COHORT||RETROSPECTIVE|||||||
34167540|NCT04057066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167541|NCT01676987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167542|NCT04730765|||COHORT||PROSPECTIVE|||||||
34167543|NCT03476148|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167544|NCT06256588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167545|NCT00421057|||CASE_ONLY||PROSPECTIVE|||||||
34167546|NCT06063694|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: transmetatarsal amputation without augmentation Group 2: transmetatarsal amputation augmentation with synthetic electrospun fiber matrix||||
33958040|NCT00016835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and examiners were unaware of the type of medication and examiners were also unaware of the type of periodontal therapy the participants receive|Study participants were randomized into 3 groups for the initial non-surgical treatment appointment. One group received supra-gingival scaling and placebo, one group received non-surgical periodontal supra- and sub-gingival scaling plus metronidazole and one group received non-surgical periodontal supra- and sub-gingival scaling plus doxycycline. All three groups received 3-month follow-up visits for 15 months and the group receiving supra-gingival scaling and placebo at the initial visit received supra- and sub-gingival scaling at the 9-month follow-up visit.|t|t|f|f
34167547|NCT05153577|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Potential subjects will initially be recruited from a list of 30 parents who participated in the previous IRB-exempt, qualitative study (IRB 20-017497 - Fresh Start) and consented to be re-contacted for future studies. The remaining subjects will be recruited from a list of families who received a WIC prescription for their child(ren) from a provider at the Children's Hospital of Philadelphia (CHOP) Cobbs Creek between 2019-2020; this list was obtained via IT query of Epic for our prior study. No medical records will be accessed for screening for this study. Potential subjects will be screened using the protocol inclusion and exclusion criteria during the initial recruitment call.||||
34167548|NCT03820882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, randomized, open-label, parallel assignment|f|f|t|t
34167549|NCT03899298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking.|The study will be ongoing for patient inclusion and data acquisition. Patients will be separated into one of seven categories including: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The treatments will not be randomized or blinded. This is a partially patient funded study. The study has been approved by an Alion accredited Institutional Review Board, Solutions IRB as of March 2019.||||
34167550|NCT06059235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34167551|NCT03527472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo-controlled|t|t|t|t
34167552|NCT05510089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167553|NCT04589871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm parallel groups randomized control trial|t|f|f|t
34167554|NCT05981508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167555|NCT03782519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167556|NCT00360412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167557|NCT03471247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167558|NCT00055835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167559|NCT01029184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167560|NCT03136471|||COHORT||PROSPECTIVE|||||||
34167561|NCT01768507|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34167562|NCT03854058|||COHORT||PROSPECTIVE|||||||
34167563|NCT02816697|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34167564|NCT03650491|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Following completion of the dose escalation phase of the study and determination of a recommended phase 2 dose, patients will be enrolled into a dose expansion cohort.||||
34167565|NCT02043353|||COHORT||RETROSPECTIVE|||||||
34167566|NCT03073239|||COHORT||PROSPECTIVE|||||||
34167567|NCT00670280|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
34167568|NCT04452630|||COHORT||PROSPECTIVE|||||||
34167569|NCT01135134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167570|NCT01527123|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34167571|NCT03181607|||CASE_CONTROL||PROSPECTIVE|||||||
33854858|NCT03730857|RANDOMIZED|FACTORIAL||TREATMENT||NONE||One hundred eleven inpatients with acutely exacerbated schizophrenia were randomized to give optimal therapy of olanzapine, risperidone, and paliperidone in one-week run-in period and 12 weeks' intervention.||||
33854859|NCT02457208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854860|NCT02952807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854861|NCT01786733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854862|NCT02295657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854863|NCT04265833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, three-arm parallel, two-blinded clinical trial|f|f|f|t
33854864|NCT03426267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33854865|NCT01059123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854866|NCT01892826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854867|NCT06282614|NA|SINGLE_GROUP||OTHER||NONE||Prospective, multicenter (France), open label without comparator study||||
33854868|NCT04565379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854869|NCT06328803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33854870|NCT01249274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854871|NCT01079338||||BASIC_SCIENCE||||||||
33854872|NCT05767307|||COHORT||PROSPECTIVE|||||||
33854873|NCT01498679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854874|NCT01586000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33854875|NCT00229411|NON_RANDOMIZED|CROSSOVER||ECT||NONE||||||
33854876|NCT02833532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854877|NCT05971667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854878|NCT04330885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator does not take part in data collection. All data collected via web based surveys.|Randomized controlled study with two treatment arms; one with care as usual and the intervention group with prehab before surgery. This is a feasibility study to determine how many subjects who need to be included to be able to a obtain an estimate of variance in an outcome when an important difference between groups|f|f|t|t
33854879|NCT02737839|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958041|NCT05979688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are masked to participant group assignment.|Randomized controlled trial|f|f|f|t
33958042|NCT02265640|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958043|NCT03501407|||COHORT||PROSPECTIVE|||||||
34167572|NCT03458312|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|a sample of patients with HGG (n=30) and their caregivers (n=30) recruited for intervention group (IG) with 'Nurse-led Family and Network Consultations' using pretest and posttest measures.|"To explore the feasibility of a 'Nurse-led Family and Network Consultation' (FNC) that seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~To explore the impact of these nurse consultations on the nurses' perception of autonomy, self-esteem, and confidence, representing their professional identity"||||
34167573|NCT02724098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167574|NCT05898217|RANDOMIZED|PARALLEL||PREVENTION||NONE||4 groups, each are assigned to one week of drinking fluid milk, almond milk, soy milk, or oat milk.||||
34167575|NCT02541812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167576|NCT05339022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167577|NCT02201680|||COHORT||PROSPECTIVE|||||||
34167578|NCT05583123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167579|NCT03071263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167580|NCT04641845|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Experimental repeated measures study||||
34167581|NCT03501563|||OTHER||PROSPECTIVE|||||||
34167582|NCT01082835|||CASE_CONTROL||PROSPECTIVE|||||||
34167583|NCT00016497|RANDOMIZED|PARALLEL||TREATMENT||||||||
34167584|NCT01111708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167585|NCT06155422|||CASE_ONLY||PROSPECTIVE|||||||
34167586|NCT00325715|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34167587|NCT02336607|RANDOMIZED|PARALLEL||||NONE||||||
34167588|NCT00363844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854880|NCT04223427|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The order of the five STN-DBS stimulation conditions will be randomized and assessments will be performed blinded from the stimulation condition. The effects of STN DBS on gait recordings will be assessed in 5 different conditions: with single ring DBS (1), and with current shaping for DBS of the gait 'hot spot' (2), of the dorsal STN (3) of the ventral STN (4) and of the DBS of narrow fiber tracts (5). The first condition will always be the single ring DBS.|t|f|t|f
34167589|NCT02961959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167590|NCT05711043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958044|NCT01842516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167591|NCT03626259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind (subject, investigator)|assignment|t|f|t|f
34167592|NCT03959163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167593|NCT00362648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167594|NCT02572323|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34167595|NCT00726414|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33958045|NCT06451679|||COHORT||PROSPECTIVE|||||||
33854881|NCT05539274|||CASE_ONLY||PROSPECTIVE|||||||
33958046|NCT03955718|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33958047|NCT03494816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958048|NCT06354764|||COHORT||RETROSPECTIVE|||||||
33958049|NCT05640908|||COHORT||PROSPECTIVE|||||||
33958050|NCT05256563|||COHORT||PROSPECTIVE|||||||
33958051|NCT05278949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958052|NCT06588660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958053|NCT02404272|||OTHER||PROSPECTIVE|||||||
33958054|NCT05923541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958055|NCT02437981|||COHORT||PROSPECTIVE|||||||
34061709|NCT03906721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized single-blind open-label placebo clinical trial. 60 inpatients will be included from SRH, both men and women aged 18 or older with traumatic and non-traumatic SCI (ASIA A-D), polytrauma and burn injury patients from the Comprehensive Rehabilitation Program at Spaulding Rehabilitation Hospital who have; above, at, or sub-lesional neuropathic pain and/or nociceptive pain (musculoskeletal or visceral) that is moderate or severe in nature (average VAS scale score of 4 or greater at time of enrollment). All subjects must meet clinical criteria for the use of opioids as a treatment for pain management.|f|f|f|t
33854882|NCT03353831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061710|NCT06081959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061711|NCT04876976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients and their relatives were blinded to the type of the intervention|"Cases of group (I) underwent multilayered closure using dartos facial flap and cyanoacrylate glue as an interposition layer.~Cases of the control group (II) underwent the same procedure without using cyanoacrylate."|t|f|f|f
34167596|NCT03653858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicenter, randomized, sham-controlled, double blind (patient and observer blinded)|t|f|f|t
33854883|NCT00407212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33854884|NCT00690443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854885|NCT06185361|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33854886|NCT04113083|||OTHER||OTHER|||||||
33854887|NCT06001086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854888|NCT03089151|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33854889|NCT00807261|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958056|NCT00757198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958057|NCT06550362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958058|NCT00442338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958059|NCT06229262|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcome assessor will not be aware of which participant is in which arm|this will be a12 week, parallel study , free living with college going young adults aged 18-30 years|f|f|t|t
33958060|NCT06345183|||COHORT||OTHER|||||||
33958061|NCT00568100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061712|NCT06731673|||COHORT||PROSPECTIVE|||||||
34167597|NCT00988598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167598|NCT04190914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and outcomes assessor will be blind to which group they belong or assess respectively||t|f|f|t
34167599|NCT00429559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167600|NCT02753803|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34061713|NCT03907020|NA|SINGLE_GROUP||OTHER||NONE||||||
34061714|NCT04786093|RANDOMIZED|PARALLEL||TREATMENT||NONE||We hypothesize that Durvalumab and stereotactic radiotherapy, in the form of PULSAR and SAbR, and durvalumab will confer a 60% increase in improvement in quality of life over the historical control rate of 33%, for an absolute improvement of 27%. Using a two-sided exact binomial test with a two-sided significance level of 0.1 and 80% power, we estimate that we will need to enroll 23 patients per arm do detect a difference. Accounting for 10% attrition, we will plan to enroll 52 patients.||||
34061715|NCT02655419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061716|NCT01323816|||COHORT||RETROSPECTIVE|||||||
34061717|NCT03490396|RANDOMIZED|PARALLEL||OTHER||SINGLE|OM grading via the WHO oral toxicity grading scale will be performed by the trained blinded evaluator at least 3X/week (e.g., M, W and F), with ≤ 48h (±24h) in between each assessment.|The initial design is a prospective, randomized, single-blind (evaluator), parallel, three arm, controlled clinical study.|f|f|f|t
34061718|NCT05590117|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061719|NCT02954185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061720|NCT05725213|||COHORT||PROSPECTIVE|||||||
34167601|NCT02414308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167602|NCT00247403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167603|NCT05694039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34167604|NCT00644046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167605|NCT00890825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167606|NCT02252146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167607|NCT04529967|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34167608|NCT04033367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167609|NCT03036410|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167610|NCT01458639|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34167611|NCT06024070|NA|SINGLE_GROUP||TREATMENT||NONE||pre post study design||||
33748240|NCT05772546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748241|NCT01541228|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33748242|NCT04898101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748243|NCT04974164|||CASE_CONTROL||PROSPECTIVE|||||||
33748244|NCT00342316|RANDOMIZED|PARALLEL||TREATMENT||NONE||Formally, this is not Phase III study, since there are no new drugs or interventions. Rather - a prospective, controlled study where we include pts aimed for alloSCT before any donor search. Both groups of pts (with or without a matched donor) are followed ≥2yrs. The hypothesis is that pts with a donor do better than those without a donor (sib and/or unrelated).||||
33854890|NCT01379391|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854891|NCT00589238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854892|NCT02424188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854893|NCT06036303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854894|NCT05437185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants were distributed between 2 arms using an aperiodic, nondeterministic, atmospheric random noise randomization algorithm. The stimulation type was unblinded upon completing all the follow-ups or dropping out. The blinding was ensured by a dedicated team member with no direct access to the participants or their data.|Participants were randomly allocated either to the active or sham (placebo) group.|t|t|t|t
33854895|NCT02949258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854896|NCT00521560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854897|NCT03226821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854898|NCT03287531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061721|NCT00941694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34061722|NCT01894659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33748245|NCT01586143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33854899|NCT00136539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854900|NCT04094246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33854901|NCT05406830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061723|NCT05524480|RANDOMIZED|PARALLEL||PREVENTION||NONE||Twenty community health centers (CHCs) will be recruited and randomized to either the SEMM-Dissemination and Implementation Assistance arm or the SEMM-Usual Implementation Practice arm.||||
34061724|NCT06698900|||COHORT||RETROSPECTIVE|||||||
34061725|NCT03652649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061726|NCT00860041|||COHORT||PROSPECTIVE|||||||
34167612|NCT03576326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|An independent outcomes assessor and PIs will be blinded to participants' group assignment, and participants will be told that the examiner and PIs cannot answer any incentive questions and they should not mention the incentive program to them. (Due to the nature of the intervention, the staff explaining the study arms after randomization and providing the incentive gift cards at follow-up visits cannot be blinded.)|Eligible consenting parent-child participant dyads, within strata and permuted blocks, will be randomized in equal allocation to one of two arms. Strata will be based on site and smartphone operating system (iOS or Android).|f|f|t|t
34167613|NCT02735967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34167614|NCT02987725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167615|NCT05258604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167616|NCT00483470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167617|NCT00760955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167618|NCT00988078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167619|NCT04881916|||COHORT||OTHER|||||||
34167620|NCT02887092|||COHORT||PROSPECTIVE|||||||
34167621|NCT03868254|||OTHER||RETROSPECTIVE|||||||
34167622|NCT03435185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854902|NCT04651075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the participant did not know which group he was in.|There are 3 groups as intervention and control|t|f|f|f
33854903|NCT03369990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854904|NCT04017039|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33854905|NCT03965611|||CASE_CONTROL||PROSPECTIVE|||||||
33854906|NCT00075647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958062|NCT06060314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients presented with symptoms of numbness at night, pain, or tingling sensation in the fingers particularly at night diagnosed by consultant orthopedic surgeon on physical examination. To ensure randomization, the lottery method was used to allocate the patients to study groups. Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred while patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR). Patients were assessed during a follow up visit at 3rd month measured using functional status by consultant orthopedic surgeon. Data was recorded by the principle investigator under the supervision of consultant orthopedic surgeon.|This was a randomized control trial. To ensure randomization, the lottery method was used to allocate the patients to study groups. Patients in Group A were treated conservatively i.e Splinting in neutral position of wrist for 6 wks min at night and during the day as preferred while patients in Group B were managed through surgical intervention i.e open carpal tunnel release (OCTR). Patients were assessed during a follow up visit at 3rd month measured using functional status scale of the Boston questionnaire (BQ).|t|f|t|t
34061727|NCT02191436|||COHORT||CROSS_SECTIONAL|||||||
34061728|NCT05764746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A health facility-based, three-arm partially blinded randomized clinical trial will be conducted to assess efficacy and safety of a sequential administration of artemether-lumefantrine followed immediately by artesunate-amodiaquine (AL+ASAQ) or artemether-lumefantrine with by amodiaquine (AL+AQ) compared to artemether-lumefantrine plus placebo (AL+PBO).|t|f|t|f
34061729|NCT04016181|||COHORT||PROSPECTIVE|||||||
34061730|NCT00398437|RANDOMIZED|||DIAGNOSTIC||||||||
34061731|NCT03310294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"As a double blind study neither the researchers nor the participants knew which treatment each participant received. The treatment was randomly allocated to the subjects according to the procedure for treatment assignment described above.~To maintain the blind (see also paragraph 4.4.1) no differences between the active treatment and the placebo were evident on the package, and the carton boxes containing the study products were identified by a number corresponding to the randomization (the products will be labelled with a batch number, Investigator/center, subject ID number and expiry date)."|"This is a phase IV, parallel, placebo-controlled, double-blind, multicenter, randomized study to evaluate the effect of a combination of probiotics and prebiotics in subjects with recurrent Herpes labialis.~This specific design has been chosen as the most suitable to achieve the objectives of the trial, mainly the demonstration of the clinical efficacy of the combination of probiotics and prebiotics in subjects with recurrent Herpes labialis in terms of reduction of the number of HL recurrences at day 49 vs baseline."|t|f|t|f
34061732|NCT05669469|||COHORT||PROSPECTIVE|||||||
34061733|NCT04602572|||COHORT||PROSPECTIVE|||||||
34061734|NCT03872258|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061735|NCT01433744|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061736|NCT04295343|||CASE_ONLY||PROSPECTIVE|||||||
33854907|NCT03501160|||FAMILY_BASED||RETROSPECTIVE|||||||
34061737|NCT06730763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33854908|NCT06486207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33854909|NCT05318079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854910|NCT00001457||||TREATMENT||||||||
33854911|NCT02447367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061738|NCT00766285|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34061739|NCT05158686|||COHORT||RETROSPECTIVE|||||||
34061740|NCT00113191|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34061741|NCT03217019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061742|NCT05724485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants will be randomized to receive BCAA or placebo. The BCAA and placebo were prepared by pharmacists who contained both 12.45 grams of BCAA and placebo in the same quantity, the same containing sachet, and labeled enveloped from No.1 to No.50. The sequence of labels was randomized by computer generator block of 4 randomizations with conceal allocation to investigators, participants, care providers, and outcomes assessor.||t|t|t|t
34061743|NCT00394433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061744|NCT06032520|||CASE_ONLY||PROSPECTIVE|||||||
34061745|NCT01428115|||COHORT||PROSPECTIVE|||||||
34061746|NCT06354205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061747|NCT05489419|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34061748|NCT01110668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061749|NCT03597022|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061750|NCT00796744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061751|NCT05156710|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization for Cohort B only|||||
34061752|NCT03781583|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Testing will be done in three conditions: baseline (no HMD), sham (smartHMD worn but not active), and smartHMD (smartHMD worn and active)||||
34061753|NCT05937607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34061754|NCT00097305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061755|NCT00263055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076017|NCT05048043|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible families will be randomly assigned to either the CABI or traditional consultation condition. The investigators will use a two-wave cohort design, so that one-half of the sample will be randomly assigned to participate in the first semester (September to December) and the second half in the second semester (January to May), assuring that the proportion of students in each condition do not exceed a 5:4 ratio each semester. Participation will end with a post-intervention evaluation in December or May (depending on wave), thereby providing three total measurement occasions.||||
34076018|NCT05701358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076019|NCT03659123|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34076020|NCT05862051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854912|NCT04259515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33854913|NCT03905954|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33854914|NCT04227964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent examiner|Single center RCT|f|f|f|t
33854915|NCT04679688|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33854916|NCT03401151|||COHORT||PROSPECTIVE|||||||
33854917|NCT02054520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854918|NCT02926079|||COHORT||CROSS_SECTIONAL|||||||
33854919|NCT00519311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33748246|NCT06580574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748247|NCT01986257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748248|NCT06125314|||COHORT||RETROSPECTIVE|||||||
33748249|NCT00596440|||CASE_CONTROL||PROSPECTIVE|||||||
33748250|NCT00725296|||COHORT||PROSPECTIVE|||||||
33748251|NCT04850833|||COHORT||PROSPECTIVE|||||||
33748252|NCT00047879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748253|NCT02216123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748254|NCT03584698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748255|NCT00465413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854920|NCT01313117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061756|NCT05738837|RANDOMIZED|PARALLEL||PREVENTION||NONE|All participants are blind to allocation at baseline assessment. Randomization occurs after in-person survey completion and is initially masked (using colour coded room assignments). Allocation is revealed to participants by intervention staff once they arrive at their assigned intervention room. All data analysis is done by a Co-I who has no contact with participants.|Approximately 900 self-identified girls/young women age 14-18 (who have not already graduated high school) will be recruited from 3 communities in Ontario over two years. Participants will be randomly assigned to either receive the A-EAAA program immediately (treatment group) or 6 months later (waitlist control group). Control group participants will attend a brief 'usual care' session providing them with basic information on SV and consent in parallel with the treatment group's first session. All participants will complete surveys at 4 timepoints: baseline, 1-week post-intervention (control group matched to treatment group timing), and 6 and 12 months after baseline. The control group will take the A-EAAA program following the 6-month post-survey and complete one additional survey, 1-week after their final program session.||||
34061757|NCT03761173|||COHORT||PROSPECTIVE|||||||
34061758|NCT06354790|||COHORT||PROSPECTIVE|||||||
34061759|NCT04312594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061760|NCT05031637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061761|NCT06490172|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Mixed Methods Explanatory Sequential Design||||
34061762|NCT03728998|NA|SINGLE_GROUP||SCREENING||NONE||||||
34061763|NCT03304795|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33748256|NCT04854291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748257|NCT04757623|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomised control trial of two arms|t|t|t|t
33854921|NCT02913729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854922|NCT03745482|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33854923|NCT02737709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854924|NCT01190514|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33854925|NCT00448123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33854926|NCT05729178|||COHORT||PROSPECTIVE|||||||
33854927|NCT02705560|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33854928|NCT00867282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33854929|NCT03728777|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||double-blind, randomized, placebo-controlled, cross-over study.|t|f|t|f
33854930|NCT00690820|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33854931|NCT02926625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854932|NCT02802826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33854933|NCT03794362|||COHORT||PROSPECTIVE|||||||
33854934|NCT02697292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33854935|NCT06046768|NA|SINGLE_GROUP||OTHER||NONE||To evaluate the impact of psychological treatment on the improvement of oral disorders perceived by parents in their child.||||
33854936|NCT03253874|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33854937|NCT05898243|||COHORT||PROSPECTIVE|||||||
33854938|NCT02824666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854939|NCT02926976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854940|NCT02343055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854941|NCT01458223|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854942|NCT04628819|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The patients, their parents and the investigators will not know the treatment taken by the patient. Unblinding will be performed at the end of the study.|Patients will be randomized in one of the two parallel groups. The first group will be supplemented with Lactobacillus Rhamnosus and the second group will intake a placebo.|t|t|t|f
33854943|NCT01324440|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34061764|NCT00939471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854944|NCT00007345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854945|NCT01214265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854946|NCT02709915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854947|NCT04078412|||COHORT||PROSPECTIVE|||||||
33854948|NCT01045395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33854949|NCT00264927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33854950|NCT01137968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854951|NCT04361877|||COHORT||PROSPECTIVE|||||||
33854952|NCT04211428|||CASE_ONLY||PROSPECTIVE|||||||
33854953|NCT03230526|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854954|NCT00907790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854955|NCT04733742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854956|NCT00004815|NON_RANDOMIZED|||TREATMENT||||||||
33854957|NCT03554954|||COHORT||CROSS_SECTIONAL|||||||
33854958|NCT01959516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33854959|NCT00406653|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33854960|NCT03183700|RANDOMIZED|PARALLEL||SCREENING||||||||
33854961|NCT02578862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33854962|NCT02733393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061765|NCT02014051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061766|NCT06236724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061767|NCT06730893|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061768|NCT03081143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061769|NCT04343053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Technicians performing assays will be blinded to stage of the infection and outcomes|||||
34061770|NCT03696485|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061771|NCT04832750|||COHORT||PROSPECTIVE|||||||
34061772|NCT01484860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854963|NCT02912325|NA|SINGLE_GROUP||OTHER||NONE||||||
33854964|NCT05001594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854965|NCT01520493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854966|NCT04641494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33854967|NCT02057978|||CASE_CONTROL||PROSPECTIVE|||||||
33854968|NCT02660463|||CASE_CONTROL||PROSPECTIVE|||||||
33854969|NCT03682549|||CASE_CONTROL||PROSPECTIVE|||||||
33854970|NCT04100642|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33854971|NCT00594360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854972|NCT01047423|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33854973|NCT05560971|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and study staff both blinded.|Interventional double-blinded study with participants randomized to either POA or placebo|t|f|t|f
33854974|NCT04990479|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Treatment Cohorts of the study.~Part 1:~• Cohort 1a: 3 patients (expandable to 9) with unresectable stage III / IV Cutaneous Melanoma.~Part 2~* Cohort 2a: 13 patients with unresectable stage III / IV Cutaneous Melanoma.~* Cohort 2b:12 patients with stage IV NSCLC (PDL1≥ 50%). In all cohorts, the treatment consists of four Nous-PEV vaccine administrations in combination with pembrolizumab as SoC."||||
33854975|NCT00322673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33854976|NCT04309136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854977|NCT00980993|||CASE_ONLY||PROSPECTIVE|||||||
34061773|NCT06036784|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Double Blind||t|f|t|f
34061774|NCT03600155|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061775|NCT05949424|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group: standard SmPC dosing. Intervention group: lower starting dose with dose-escalation inversely following the dosing steps from the SmPC every 2 weeks in case of good tolerability.||||
34061776|NCT03859791|||COHORT||RETROSPECTIVE|||||||
34061777|NCT02452840|||COHORT||PROSPECTIVE|||||||
34061778|NCT04633603|||COHORT||PROSPECTIVE|||||||
33854978|NCT02417402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33854979|NCT00282204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33854980|NCT05695937|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33854981|NCT04385420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Between each cohort, a blinded interim analysis of PK, safety and tolerability had to be performed. The available data was evaluated by the Investigator and sponsor in a Safety Review Committee (SRC) meeting.~Once a dose level was judged to be safe, the SRC determined the dose level for the next cohort considering a maximal increment of 400 mg compared to the previous cohort, and the next dose level could be administered to the next cohort."|"This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor.~Subjects were to be enrolled in 3 different cohorts in the SAD and 3 different cohorts in the MAD and were to be randomly (blinded) allocated to active treatment or placebo (each cohort consisted of 8 subjects receiving active treatment and 2 subjects receiving placebo)."|t|t|t|t
33854982|NCT01393327|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33854983|NCT01406951|||CASE_CONTROL||PROSPECTIVE|||||||
33854984|NCT00091169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33854985|NCT02618954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33854986|NCT02070588|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33854987|NCT04196153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33854988|NCT02522351|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33958063|NCT05447559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Participants, treating clinicians, all members of the research team including the study statistician will be blinded to treatment arm allocation.~Active treatment will consist of 2-grams cefazolin powder for injection. Placebo will consist of an identical empty vial. The commercial labels will be removed and a sheath placed over the vial. Amber-tinted syringes will be provided for drawing up and administration of cefazolin/placebo to mask study arm.~The vial containing cefazolin or placebo will be reconstituted in a minimum of 10 mL of sterile water for injections and administered in keeping with product information for cefazolin and / or local guidelines."|Adaptive, double-blind, three-arm, placebo-controlled, phase IV, noninferiority trial|t|t|t|t
33958064|NCT04638829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958065|NCT06215313|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will use a single-case experimental design (SCED). In this study, there are three groups (PTSD, depression, and PTSD with comorbid depression) and two interventions (EMDR and IR), that is 3 x 2 = 6 simultaneous SCEDs. Seven patients per SCED will be included, i.e., a total of 42 patients. Patients will be randomly assigned to one of the two interventions.||||
33958066|NCT02041000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958067|NCT06702501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958068|NCT06542445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All blinded except dispensing pharmacist.|Each participant will be randomly assigned to receive either the terpene-enriched CBD oil or a placebo for 5 weeks.|t|t|t|t
33958069|NCT03993288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958070|NCT04668300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958071|NCT05690464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958072|NCT04443673|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled, randomized, two branches, clinical trial.||||
33958073|NCT03992456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958074|NCT04960254|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33958075|NCT04104490|||COHORT||CROSS_SECTIONAL|||||||
33958076|NCT06087991|||OTHER||PROSPECTIVE|||||||
33958077|NCT03684473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958078|NCT01305486|||COHORT||PROSPECTIVE|||||||
33958079|NCT06704152|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958080|NCT00929201|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958081|NCT04400253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33958082|NCT06156631|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A single-blind method will be used for the main outcome measure (BP) in this study. Blood pressure and the anthropometric measurements (height, weight, and waist circumference) will be assessed by a research assistant who doesn't know which group a participant belongs to. However, an open-label method will be applied for the other outcome measures: dietary habits, physical activity, and medication adherence.|A Quasi-experimental design will be used to test the efficacy of the intervention (DASH-ExMAMI) on participants. The participants will be allocated into experimental and control groups. The experimental group will complete dietary, physical activity, medication adherence, and anthropometric assessments before and after the intended intervention. Similarly, the control group will be subjected to dietary, physical activity, medication adherence, and anthropometric assessments before and after the intervention, as in the experimental group but receiving only a usual care (UC) as provided by the PHC. The intervention (DASH-ExMAMI) will last ten weeks (ten sessions) and will include DASH dietary instruction and meal planning, self-monitored brisk walking exercise, and a medication adherence intervention based on an individual MI counselling approach.|f|f|f|t
33958083|NCT03665246|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The present study is a cluster randomized trial (CRT) of 32 program groups with 16 groups randomly assigned to receive the intervention program (iMBC/ECD + C-PrES) and 16 groups randomly assigned to receive the control program (C-PrES only).The main reason for including randomization is to reduce the risk of selection bias. The unit of inference for this CRT is at the individual level but the unit of randomization is the C-PrES group (cluster) level due to issues of program feasibility.||||
33958084|NCT06704022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958085|NCT00398632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958086|NCT00424515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061779|NCT03114657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061780|NCT00630747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061781|NCT06718387|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061782|NCT06717854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061783|NCT01325259|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34061784|NCT05801900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061785|NCT04886206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Continual Reassessment Method for MTD||||
33854989|NCT05155163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized clinical trial|f|f|f|t
33854990|NCT04465760|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33854991|NCT05306769|||OTHER||CROSS_SECTIONAL|||||||
33854992|NCT01525719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33854993|NCT05227885|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33854994|NCT04681547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33854995|NCT00461136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33854996|NCT00505817|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33854997|NCT04984733|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|An open-label, single arm, A'Hern single stage phase II design. Patients will receive TMZ priming followed by nivolumab to establish disease control rates.||||
33854998|NCT02743377|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33854999|NCT04986995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855000|NCT01491893|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33855001|NCT01600573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061786|NCT05555316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061787|NCT06104280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Aim 1 will test the hypothesis that MOUD differentially impacts function of ipRGC responses. Aim 2 will examine whether MOUD differentially impacts daytime sleepiness, daily sleep-wake behavior, sleep architecture, and sleep-disordered breathing. Finally, Aim 3 will determine if ipRGC function predicts opioid relapse among MOUD groups at 1-, 3- and 6- month follow-up.||||
34061788|NCT00429845|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34061789|NCT05691491|NA|SEQUENTIAL||TREATMENT||NONE||||||
34061790|NCT06380803|||COHORT||PROSPECTIVE|||||||
34061791|NCT02508571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Allocation is concealed from all investigators, nurses, doctors, and parents, with the sole exception of the occupational therapists, who provided the interventions.||f|t|t|t
34061792|NCT02129634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061793|NCT06210373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061794|NCT06436755|||COHORT||CROSS_SECTIONAL|||||||
34061795|NCT02951039|||COHORT||PROSPECTIVE|||||||
34061796|NCT00622596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061797|NCT04106362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061798|NCT00848978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34061799|NCT00662558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061800|NCT06719219|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34061801|NCT04397471|||CASE_ONLY||PROSPECTIVE|||||||
34061802|NCT03299894|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Patients will be prospectively included at Emergency Department triage during 2 consecutive 6-month periods (1-month wash-out interlude between the 2 inclusion periods):~* First inclusion period: usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection.~* Second inclusion period: usual procedure for patient triage at Emergency Department admission PLUS routine calculation of qSOFA in all patients admitted to the Emergency Department with a suspected or proven bacterial infection. Patients with a qSOFA value ≥2 will be directly and immediately notified to Emergency Department physicians by triage nurses."||||
34061803|NCT04967365|||COHORT||PROSPECTIVE|||||||
34061804|NCT00100841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061805|NCT06071221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34061806|NCT06189313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061807|NCT05849584|||COHORT||PROSPECTIVE|||||||
34061808|NCT06705959|||COHORT||PROSPECTIVE|||||||
34061809|NCT05230615|||COHORT||PROSPECTIVE|||||||
34061810|NCT06631846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061811|NCT03337594|||COHORT||PROSPECTIVE|||||||
34061812|NCT06027307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061813|NCT03223311|||OTHER||OTHER|||||||
34061814|NCT02153229|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061815|NCT05241600|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomly assigned to either the MBCP condition (intervention under study) or treatment as usual condition (non-mindfulness-based childbirth class of participant's choice from a list provided).||||
34061816|NCT01744171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061817|NCT06338215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34061818|NCT06469385|NA|SINGLE_GROUP||TREATMENT||NONE||3 participants will be included in each of three cohorts of ENS-002.||||
34061819|NCT04038619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061820|NCT03700203|||CASE_CONTROL||PROSPECTIVE|||||||
34061821|NCT04399603|||OTHER||PROSPECTIVE|||||||
34061822|NCT06155513|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||This exploratory study includes two groups of eight (8) subjects. Subjects of group A will receive treatment A (serum A and cream A). Subjects of group B will receive treatment B (serum B and cream B). A skin area with eczema lesions will be identified during the screening visit. Subjects will be asked to apply the serum, then the cream to the targeted area at least once a day for a period of forty-two (42) days. The pre-treatment baseline state will serve as a control for the effects observed following treatment on the targeted area.||||
34061823|NCT05198154|||COHORT||PROSPECTIVE|||||||
34061824|NCT04662294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061825|NCT05320068|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Proportion 2:1 in favour to the intervention arm|t|t|t|f
34061826|NCT06730204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34061827|NCT05600062|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34061828|NCT01259375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061829|NCT01969084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061830|NCT00737334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061831|NCT05210153|||COHORT||PROSPECTIVE|||||||
33855002|NCT04328636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each neonate was assigned a unique identification number. Pharmacy filled the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, nurses, echocardiographers, and data collectors were unaware of group assignment and drug/placebo therapy.|"Two groups of neonates with PPHN~1. NebMag group: receive nebulized magnesium sulfate and intravenous placebo.~2. IVMag group: receive intravenous magnesium sulfate and nebulized placebo."|t|t|f|t
33958087|NCT06701695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the trial, patients were kept unaware of their group assignments, ensuring they remained blinded to the study parameters. While the surgeon possessed knowledge of the group allocations, he was not directly involved in patient data analysis.|Two groups were established, one serving as the control group receiving standard hemiarthroplasty treatment.|t|f|f|t
33958088|NCT06700811|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will receive treatment with ketogenic diet.||||
33855003|NCT02182557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33958089|NCT04729504|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855004|NCT00012623|||||RETROSPECTIVE|||||||
33855005|NCT05050994|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective observational pilot trial||||
33855006|NCT06081023|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||Two groups i-e control and experimental. The experimental group was provided with treatment while the control group was only provided with behavioral relaxing techniques.|t|f|f|f
33855007|NCT02618031|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The participants and investigators evaluating 90 day outcomes will be blinded to the group.|Patients will be assigned to one of two groups based on the outcome of diagnostic evaluation. Treatment will be identical for the two groups.|t|f|t|t
34061832|NCT05411250|||CASE_CONTROL||PROSPECTIVE|||||||
33855008|NCT00332189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855009|NCT04778423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061833|NCT05605639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33855010|NCT03686319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33855011|NCT04671134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855012|NCT00938860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855013|NCT03399487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855014|NCT04187989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855015|NCT05436080|||COHORT||PROSPECTIVE|||||||
33855016|NCT03005964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855017|NCT02470156|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33855018|NCT05311891|||CASE_ONLY||OTHER|||||||
33855019|NCT02584582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855020|NCT03130803|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33855021|NCT00640887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855022|NCT00221741|||||PROSPECTIVE|||||||
33958090|NCT00185718|||||PROSPECTIVE|||||||
33958091|NCT04690660|||COHORT||PROSPECTIVE|||||||
33958092|NCT03970278|||COHORT||PROSPECTIVE|||||||
34061834|NCT05988710|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||randomized, double blind, double-dummy, placebo-controlled, crossover|t|f|t|f
34061835|NCT01131039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855023|NCT02963103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855024|NCT01296685|||CASE_CONTROL||PROSPECTIVE|||||||
33855025|NCT05880394|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855026|NCT02788903|||COHORT||OTHER|||||||
33855027|NCT01800981|||||PROSPECTIVE|||||||
33855028|NCT00098852||||TREATMENT||||||||
33855029|NCT04589429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958093|NCT00780156|||||PROSPECTIVE|||||||
33958094|NCT06567457|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958095|NCT02287142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33958096|NCT01193829|||COHORT||PROSPECTIVE|||||||
33958097|NCT06542068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33958098|NCT05630235|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33958099|NCT02050373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34061836|NCT02897388|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34061837|NCT05122533|||COHORT||PROSPECTIVE|||||||
34061838|NCT01420016|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34061839|NCT04030260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061840|NCT03032601|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34061841|NCT03005613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061842|NCT01537978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061843|NCT06726785|||COHORT||PROSPECTIVE|||||||
33855030|NCT04871100|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive the intervention or a control intervention.||||
33855031|NCT02183597|||COHORT||RETROSPECTIVE|||||||
33855032|NCT02709824|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33855033|NCT03940053|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855034|NCT04986085|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33855035|NCT00268021|||COHORT||RETROSPECTIVE|||||||
33855036|NCT00507364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855037|NCT01414985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855038|NCT02325167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855039|NCT03748407|NA|SINGLE_GROUP||SCREENING||NONE||||||
33855040|NCT05864261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061844|NCT04427488|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748258|NCT05131295|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients were randomly assigned using a computer-derived table to receive from admission to the 15th-day post-ictus an oral dose of 2.5 ml/24 hours of placebo (aluminum hydroxide suspension) or a dapsone suspension containing 100 mg (2.5 ml/24 hours). In patients with unpaired consciousness a nasogastric tube was used. Treatment was initiated during the first five days post-ictus and continued until day 15. All patients underwent aneurysm clipping by microsurgery or obliteration employing endovascular coils; postoperatively, both groups received the usual prophylaxis (which included oral nimodipine from admission until day 21 post-ictus, normovolemia, and dextran) and/or treatment (which included the use of vasogenic amines and, in refractory cases, cerebral intra-arterial administration of nimodipine) of cerebral vasospasm.|t|t|t|f
33748259|NCT00297752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748260|NCT01964170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748261|NCT02935335|||COHORT||PROSPECTIVE|||||||
33748262|NCT03846700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|non inferiority, blinded, prospective, randomized clinical trial.|t|f|f|t
33748263|NCT06245083|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|Participants are randomized to receive either pyrroloquinoline quinone (PQQ) or placebo|t|f|t|f
33748264|NCT04425564|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748265|NCT06415955|||COHORT||RETROSPECTIVE|||||||
33748266|NCT05918926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748267|NCT04636255|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33748268|NCT06511232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a single-blind randomized controlled trial with two arms, 1) Intervention and 2) control. The intervention group will receive an intraosseous (IO) injection of 10mg of morphine mixed with up to 100mg of saline into the tibial tubercle. The control group will receive the standard of care treatment, which is no IO injection. The subjects' post-operative pain levels, pain medication consumption, side effects to pain medications, and range of motion will be recorded for 14 days following surgery. Additionally, patient reported outcomes will be tracked via surveys prior to surgery and 2, 6, and 12-weeks following surgery.|t|f|f|f
33748269|NCT04014660|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33748270|NCT03684629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748271|NCT05321420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748272|NCT05388253|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748273|NCT01220011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748274|NCT06670248|||COHORT||PROSPECTIVE|||||||
33748275|NCT03969654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748276|NCT02130193|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748277|NCT06139523|||COHORT||PROSPECTIVE|||||||
33748278|NCT01681589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748279|NCT05354050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748280|NCT00207272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748281|NCT06283550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748282|NCT06507293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33855041|NCT02789527|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33855042|NCT06254547|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33855043|NCT01531647|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33855044|NCT04191018|||COHORT||PROSPECTIVE|||||||
33855045|NCT00290108|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33855046|NCT01747525|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33855047|NCT04525872|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855048|NCT02010008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33855049|NCT00953407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958100|NCT05358392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|: Women who applied to Etlik Zübeyde Hanım Gynecology Training and Research Hospital IVF/ICSI unit for IVF/ICSI treatment. who meet the criteria for inclusion in the study will be informed about the study, and the women who accept the study will be assigned to the groups determined by randomization.After participating in the study, the participants will know which group they are in.|"Since there is no reference study on this subject, the effect width will be calculated for the main research question by making a preliminary application (9 cases, 9 controls) and the sample will be calculated with 90 power and 0.05 margin of error in the effect width obtained. Block randomization (3 blocks as male infertility, female infertility and unexplained infertility) for the pre-application intervention and control groups was performed through the Randomization Sofcare Allocation program. In the main application, this program will be made according to the number of samples and the intervention and control groups will be assigned. Pre-application data will be included in the research analysis.~The Patient Follow-up Form consists of 3 parts. In the first part, there are data on socio-demographic and obstetric characteristics. The second part includes the infertility stress scale (pre-test) and the third part includes the infertility stress scale (post-test)."|t|f|f|f
33958101|NCT05919069|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be enrolled within the following groups based on their CP classification score as determined at screening: Group 1: Participants with mild hepatic impairment (CP Class A, score of 5 or 6).~Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).~Group 3: Participants with severe hepatic impairment (CP Class C, score of 10 to 15).~Group 4: Participants with normal hepatic function matched on a group level regarding age, body weight, and sex to the impaired groups"||||
33958102|NCT05461248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The experimental group collected stoma exudates and used an enema bag to infuse them from the anus.~The control group was not reinfused."||||
33958103|NCT02709759|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33958104|NCT06662435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958105|NCT06702735|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study is a prospective, non-blinded randomized controlled trial with three parallel arms. After a selection phase of 2 weeks, eligible participants were equally allocated to the study arms (ratio 1:1:1). The intervention phase consists of three weeks, followed by a follow-up of two weeks.||||
33958106|NCT06581848|||COHORT||OTHER|||||||
33958107|NCT00514709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076021|NCT03362177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076022|NCT01664676|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34076023|NCT04156126|||COHORT||PROSPECTIVE|||||||
33855050|NCT04490187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to sham vs active stimulation groups. The outcomes assessor will be blinded to group allocation.|Children with DCD with be recruited and randomized to receive active stimulation or sham tDCS|t|f|f|t
33855051|NCT05504863|||COHORT||PROSPECTIVE|||||||
33855052|NCT04970030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855053|NCT00172627|||||OTHER|||||||
33855054|NCT01599715|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33855055|NCT02806388|||COHORT||OTHER|||||||
33855056|NCT05784220|NA|SINGLE_GROUP||PREVENTION||NONE|No masking|||||
34061845|NCT06436391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blinded for mothers|The study will be conducted with infants of mothers who meet the inclusion criteria and agree to participate in the study. After explaining the study to the parents, the study will start after obtaining their verbal and written consent. Randomization will be random assignment to a control group or two intervention groups (1:1:1) with sequentially numbered, sealed, opaque envelopes containing randomly generated numbers after mothers have obtained informed consent. Randomization will be carried out via www.random.org using a table of random numbers. This will be done by an independent statistician and envelopes will be given to the researchers|t|f|f|f
34061846|NCT06119243|||CASE_ONLY||PROSPECTIVE|||||||
34061847|NCT01534364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061848|NCT06406387|||COHORT||PROSPECTIVE|||||||
34061849|NCT06518278|||COHORT||PROSPECTIVE|||||||
34061850|NCT06720077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061851|NCT00071968|RANDOMIZED|||TREATMENT||NONE||||||
34061852|NCT00822575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34061853|NCT02732327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061854|NCT04296786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061855|NCT06028334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This project will use masked outcome assessment, with special precautions taken to prevent inadvertent unmasking. These include a script reminding participants not to discuss any of their experiences in the trial. Any instances of inadvertent unmasking will be recorded for later analysis of their influence."|This is a waitlist controlled randomized trial. All participants will receive the GetUp\&Go treatment program. Participants will be randomly assigned with a 50% chance of either receiving immediate treatment (IT) with the 10-week program, or going on a 10-week waitlist, after which they will start the GetUp\&Go program.|f|f|f|t
34061856|NCT01534806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061857|NCT02232152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061858|NCT01859962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34061859|NCT06730490|||COHORT||PROSPECTIVE|||||||
34061860|NCT05027048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The patient, obstetrician, anesthesiologist, and clinical research staff will be blinded to the intervention. Drugs will be labeled only as study drug"|Double blind, placebo controlled randomized clinical trial with 1:1 allocation|t|t|t|t
34061861|NCT06181786|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34061862|NCT02929966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061863|NCT04944303|RANDOMIZED|PARALLEL||TREATMENT||NONE|This randomized, prospective, controlled, double-blind trial was conducted at the second affiliated hospital of Guangzhou Medical University,China|All of the patients were randomized divided into normal saline group (Group C, n =20) and sugammadex group (Group S, n =2). Group C did not receive any neuromuscular block antagonist（NMBA)||||
34061864|NCT06254235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061865|NCT03219905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061866|NCT06433505|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34061867|NCT06264674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind multicentre, randomised, active-controlled, 2-arm, parallel-group|Double-blind multicentre, randomised, active-controlled, 2-arm, parallel-group|t|t|t|t
34061868|NCT05264103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061869|NCT05570370|||OTHER||CROSS_SECTIONAL|||||||
34061870|NCT05315154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061871|NCT04364464|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34061872|NCT03383900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized into two groups: experimental (G-IMT) and sham (Gn-IMT). The two groups will perform a protocol of 8 weeks of training (6 days / week) with the PowerBreath|t|f|f|t
34061873|NCT03158636|||COHORT||PROSPECTIVE|||||||
34061874|NCT06061055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061875|NCT02978885|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34061876|NCT04036097|||COHORT||PROSPECTIVE|||||||
34061877|NCT02977676|||COHORT||RETROSPECTIVE|||||||
34061878|NCT01523704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061879|NCT01101659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
34061880|NCT01279174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061881|NCT05763368|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34061882|NCT02847338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061883|NCT02636101|||COHORT||PROSPECTIVE|||||||
34061884|NCT03878875|||COHORT||PROSPECTIVE|||||||
34061885|NCT01973335|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||f|t|t|t
34061886|NCT00003045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061887|NCT06469918|||CASE_ONLY||PROSPECTIVE|||||||
34061888|NCT00990067|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33855057|NCT04848870|||COHORT||PROSPECTIVE|||||||
33855058|NCT04259645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"An envelope will contain the randomized concentration and volume of ropivacaine to be administered to the patient. Once the anesthesiologist knows which volume he is going to administer, he will reseal the envelope and return it to the research team. This process will allow only the anesthesiologist performing the block to have knowledge of the volume he is administering, keeping both the patients and outcome assessor of the research team blinded.~The anesthesiologist will fill the syringe with the appropriate volume of medication. Immediately after, he will cover the numbers on the syringe with a piece of opaque tape, preventing any others from visualizing the volume to be administered."|The study will be conducted as a prospective, randomized, double blinded, parallel trial at the University of Pittsburgh Medical Center (UPMC) Shadyside Hospital.|t|f|f|t
34061889|NCT06545344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061890|NCT05078749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061891|NCT03434249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a prospective randomized double blind placebo controlled clinical trial|t|t|t|t
34061892|NCT05524844|||COHORT||PROSPECTIVE|||||||
34061893|NCT04701918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061894|NCT01389336|||CASE_CONTROL||PROSPECTIVE|||||||
34061895|NCT06368804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061896|NCT03053427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061897|NCT04565899|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pilot trial of an implementation strategy within one primary care clinic where all providers will be invited to participate||||
33855059|NCT03165929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33855060|NCT00282282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855061|NCT01403610|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33855062|NCT02731053|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33855063|NCT03936582|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33855064|NCT03435497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855065|NCT00547365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855066|NCT03975205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A Phase 1, single-blind, randomized, two-way, crossover Bio-equivalence study of Intravenously administered Doxorubicin in Patients With lymphomas, leukemia's and carcinoma That Has Progressed or Recurred After Platinum-based Chemotherapy||||
33855067|NCT04891822|||CASE_CONTROL||PROSPECTIVE|||||||
33855068|NCT04862871|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be evaluated in three independent groups (healthy controls, participants who have completed an exercise program, participants who are waiting to complete an exercise program).||||
33855069|NCT04253574|||CASE_ONLY||RETROSPECTIVE|||||||
33855070|NCT00095069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855071|NCT01222273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855072|NCT04398420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855073|NCT02668185|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855074|NCT01530165|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Intervention versus Control||||
33855075|NCT05919160|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33855076|NCT01542931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855077|NCT02012114|NA|SINGLE_GROUP||OTHER||NONE||||||
33855078|NCT04450160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855079|NCT02935452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33855080|NCT01284686|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33855081|NCT05955287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In the intervention group, patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners. Patients with OSA and their bed partners will be contacted in their preferred manner (text messages, email, or phone call) periodically (no more than 4 per week) to determine how well they slept, to encourage them to use their CPAP, or to remind them to contact study staff if they are having difficulty using their CPAP.|t|t|t|t
33855082|NCT01898923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855083|NCT05190718|||COHORT||PROSPECTIVE|||||||
33855084|NCT02652871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855085|NCT00454129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33855086|NCT04459247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33855087|NCT04594447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855088|NCT03849001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855089|NCT06445426|||CASE_ONLY||PROSPECTIVE|||||||
33855090|NCT02764294|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855091|NCT03841682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33855092|NCT02859363|||COHORT||RETROSPECTIVE|||||||
33855093|NCT00678184|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855094|NCT06353893|||CASE_ONLY||PROSPECTIVE|||||||
33855095|NCT02411357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855096|NCT01659619|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33855097|NCT03111121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|SINGLE BLIND: The nurses in PACU will be the only evaluators of the subject who will be blinded to the two groups. The PACU nurses will evaluate ALDRETE discharge criteria and make a note in the electronic medical records for the subject discharge time from PACU.|"Group 1: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)~Group 2: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6 -1.2 mg/kg (vitals maintained within 20% of baseline). Group 2 will receive reversal with sugammadex 4mg/kg"|f|t|f|f
33855098|NCT01619150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33855099|NCT03203395|NA|SINGLE_GROUP||SCREENING||NONE||||||
33855100|NCT01242553|||COHORT||PROSPECTIVE|||||||
33855101|NCT01012739|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855102|NCT05612763|NA|SEQUENTIAL||TREATMENT||NONE|participant is not told which fitting method they have been assigned to|The participants will have three lab sessions and two field trials. In the first session, every participant will receive PD and CD fittings. The wearing schedule orders for all the participants will be counterbalanced. For the first field trial, half of the participants will wear the hearing aids with PD and the other half of the participants will wear the hearing aids with CD. In session two, outcomes for the first hearing aid condition will be measured. Then, the participants will wear hearing aids with the other type of fitting strategy for the second field trial. After that, they will return to the lab for session 3, in which outcomes for the second hearing aid condition will be measured. Outcome measures include a self-report field evaluation (Abbreviated Profile of Hearing Aid Benefit, or APHAB) and a lab-based speech recognition test (Quick Speech-in-Noise Test, Quick-SIN).||||
33855103|NCT06375707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855104|NCT00368992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748283|NCT06068413|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34061898|NCT04306887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167623|NCT06342817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Responders will be randomly randomized 1:1 and subsequently communicated whether they will participate in the intervention group or the control group.|Those students interested in participating in the study will leave their contact details (telephone and email) to the research coordinator, to whom it will be sent an online questionnaire containing the inclusion and exclusion criteria, and the free consent form through the Google forms platform. Collection instruments will only be made available after fulfilling the inclusion criteria and absence of exclusion criteria and agreement with the consent form. Responders will be randomly randomized 1:1 and subsequently communicated whether they will participate in the intervention group or the control group.||||
34061899|NCT04097197|NA|SINGLE_GROUP||PREVENTION||NONE||Before-after study||||
34167624|NCT00934635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167625|NCT04012541|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participating patients and dentists are not able to blind information about random allocation. However, in order to reduce the bias, the cardiologist who treats the patient and prescribes the medicines performs an investigator-masked design that masks information about the treatment group.|This study is randomized controlled trial. Patients who agreed to the study were randomly assigned to the intervention group and control group at a 1: 1 ratio.|f|f|t|f
33855105|NCT03982615|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective randomized split mouth designed study intended to evaluate the healing and health of peri-implant mucosa following placement of titanium abutments with or without laser-etching.~Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment. The other implant will receive a standard healing abutment (not laser-etched)."||||
34167626|NCT02894671|||COHORT||PROSPECTIVE|||||||
34061900|NCT02073656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061901|NCT03634683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061902|NCT05496608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* The clinical data (Gingival index, Plaque index, PPD, CAL) were collected by a blinded single operator at the university outpatient clinic.~* The biochemical analysis: The biochemist received the filter papers with a label for group letter and patient number. She was didn't know which intervention was carried out for any of the samples."||f|f|f|t
34061903|NCT05048589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061904|NCT06730776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34061905|NCT05866549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34061906|NCT03499288|||COHORT||CROSS_SECTIONAL|||||||
34167627|NCT06262789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167628|NCT02289495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855106|NCT04278040|NA|SINGLE_GROUP||TREATMENT||NONE|The trial was open label|||||
34061907|NCT04352218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"To prospective collect and assess safety and efficacy data on the Petalo trial in the treatment of patients with non-thrombotic internal jugular vein stenosis and chronic headache poor responder to best medical therapy."|f|f|t|f
34061908|NCT04722952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061909|NCT02957045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748284|NCT06670573|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748285|NCT01892072|||CASE_CONTROL||PROSPECTIVE|||||||
33748286|NCT04359927|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748287|NCT03119454|||CASE_ONLY||PROSPECTIVE|||||||
33748288|NCT04184063|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33855107|NCT04293380|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33855108|NCT02619487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33855109|NCT01552525|||COHORT||PROSPECTIVE|||||||
33855110|NCT01426763|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33855111|NCT04988815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855112|NCT06378489|||COHORT||PROSPECTIVE|||||||
33855113|NCT02348762|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34061910|NCT00265525|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34061911|NCT04742166|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167629|NCT01467544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958108|NCT05357261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||To evaluate the effectiveness of receiving daily-delivered meals with a wellness check and socialization versus frozen, drop-shipped meals on food insecure, homebound older adults' ability to remain in the community and out of institutional settings.|f|f|f|t
33958109|NCT03650179|||COHORT||PROSPECTIVE|||||||
33958110|NCT05705544|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"It is not possible to blind the bronchoscopist or the patient to the platform used for each procedure, as they are both large distinctive-appearing pieces of equipment.~However, thoracic pathologists (the outcomes assessor) and bronchoscopy schedulers (the care provider team) will remain blinded, such that allocations should be unable to influence their histopathological interpretation or scheduling of procedures in a given OR, respectively."|This study will be performed as a pragmatic, cluster randomized controlled trial with parallel group assignment.|f|t|f|t
33958111|NCT04491942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958112|NCT03493945|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33748289|NCT03234426|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33748290|NCT03814889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748291|NCT06233968|||COHORT||PROSPECTIVE|||||||
33748292|NCT03882476|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34167630|NCT05626166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This proof of concept study will be designed to be a randomized, double-blind, placebo controlled parallel study, The blindness will be maintained by the similarity in appearance, color and shape between placebo and diosmin tablets.|"This proof of concept study will be designed to be a randomized, double-blind, placebo controlled parallel study. The study will be conducted on 60 patients with mild to moderate ulcerative colitis receiving mesalamine. Patients will be recruited from Tropical Medicine Department, Tanta University Hospital, Tanta, Egypt. The patient will be followed for 3 months. The blindness will be maintained by the similarity in appearance, color and shape between placebo and diosmin tablets. The patients will be randomized in a 1:1 ratio by neutral researcher using sealed envelopes methods with assignment codes into the following two groups: Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.~Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months"|t|f|t|f
33748293|NCT05432193|NA|SEQUENTIAL||TREATMENT||NONE||||||
33958113|NCT04519203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are randomized using sealed envelopes. The ramdomization will be kept blinded to the study subjects||t|f|f|f
33958114|NCT05862714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958115|NCT06374147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958116|NCT06337968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748294|NCT06118372|NA|SINGLE_GROUP||TREATMENT||NONE||Open label non-randomized phase I trial.||||
33958117|NCT03178474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researchers involved in laboratory tests will be blinded to the group status||f|f|f|t
33958118|NCT03848000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958119|NCT05991778|||COHORT||PROSPECTIVE|||||||
33958120|NCT06290609|NA|SINGLE_GROUP||TREATMENT||NONE||A single group of participants who will receive active treatment with the experimental stimulation device will be studied.||||
33958121|NCT05556031|||CASE_ONLY||PROSPECTIVE|||||||
33958122|NCT01251874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958123|NCT05302700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33958124|NCT06702488|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958125|NCT04241185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All Sponsor personnel will be blinded to treatment assignments, with the exception of designated unblinded team members. Chemoradiotherapy will be administered to all participants and will be open-label.||t|t|t|t
33958126|NCT03735238|||CASE_ONLY||OTHER|||||||
33958127|NCT06702293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33958128|NCT06700512|NA|SINGLE_GROUP||OTHER||NONE||||||
34167631|NCT04394923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, prospective, randomized pilot study||||
34167632|NCT00451256|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34167633|NCT02232022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167634|NCT01356537|||COHORT||PROSPECTIVE|||||||
34167635|NCT02124733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator assesses photographs without prior knowledge of intervention|Patients with actinic keratosis of the face/scalp were enrolled for an intrapatient comparative study of two different regimens for delivering ALA-based PDT treatment. In this contralateral/bilateral study design, each patient served as his/her own control. One side of the face or scalp (Side B), the traditional control regimen of PDT was given (1 h topical drug then 16 min 40 sec of blue light). On the test side (Side A), we administered a new regimen; topical drug was applied and then the blue light immediately started. Three groups of patients (Study arms) had different times of exposure (either 30 min, 45 min, or 60 min). For all patients, the post-treatment course was compared for Sides A vs. B. The primary endpoints were pain during illumination, and lesion clearance at 3 months post-therapy.|f|f|f|t
34167636|NCT05182788|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34167637|NCT02052544|||||PROSPECTIVE|||||||
34167638|NCT05648266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34167639|NCT03864939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients are blinded during the study period.||t|f|f|f
34167640|NCT04636281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167641|NCT00314639|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34167642|NCT00890734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167643|NCT02560883|||COHORT||PROSPECTIVE|||||||
34167644|NCT02477124|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34167645|NCT04890379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167646|NCT03880292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167647|NCT03242486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167648|NCT03010319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748295|NCT03930472|RANDOMIZED|PARALLEL||PREVENTION||NONE||With delayed intervention for control group, but those outcomes not assessed.||||
33855114|NCT06424626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958129|NCT05524714|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33958130|NCT04631406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958131|NCT06656390|NA|SEQUENTIAL||TREATMENT||NONE||||||
33958132|NCT05774431|||COHORT||RETROSPECTIVE|||||||
33958133|NCT00719758|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958134|NCT01342367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958135|NCT06567626|||CASE_ONLY||PROSPECTIVE|||||||
33958136|NCT02076139|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33958137|NCT05470140|NA|SINGLE_GROUP||TREATMENT||NONE||This study will determine the safety and tolerability of WU-NK-101 and define the RP2D.||||
33958138|NCT06427954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33958139|NCT01150409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958140|NCT00481585|||COHORT||PROSPECTIVE|||||||
33958141|NCT05103410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33958142|NCT01731431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958143|NCT06442384|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958144|NCT06703723|||CASE_CONTROL||PROSPECTIVE|||||||
33958145|NCT01470352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958146|NCT04365842|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33958147|NCT01205542|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33958148|NCT06701734|||CASE_CONTROL||PROSPECTIVE|||||||
33958149|NCT01612780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958150|NCT05005130|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33958151|NCT05863078|||COHORT||CROSS_SECTIONAL|||||||
33958152|NCT02856620|||COHORT||PROSPECTIVE|||||||
33958153|NCT05723042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958154|NCT03737760|||COHORT||PROSPECTIVE|||||||
33958155|NCT06266975|||COHORT||CROSS_SECTIONAL|||||||
33958156|NCT06229379|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33958157|NCT06195358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958158|NCT06280794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958159|NCT05150340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958160|NCT03745326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958161|NCT04730544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958162|NCT01556165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958163|NCT05134493|||COHORT||PROSPECTIVE|||||||
33958164|NCT06666426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33958165|NCT03768388|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33958166|NCT00289939|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33958167|NCT06154772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33958168|NCT05418387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958169|NCT06700525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will not have access to study arm assignment and participants will be encouraged not to divulge their study arm assignment during assessments.||f|f|f|t
33958170|NCT04540315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33958171|NCT03911466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061912|NCT01554176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34061913|NCT02960555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855115|NCT00549809||PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855116|NCT03884205|||CASE_CONTROL||PROSPECTIVE|||||||
33855117|NCT04997473|NA|SINGLE_GROUP||OTHER||NONE||Evaluate the effectiveness of an addiction model based mobile health (mHealth) weight loss intervention with coaching in obese pediatric patients after hematopoietic stem cell transplant||||
33855118|NCT01800825|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855119|NCT04283721|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||f|t|f|t
33855120|NCT04025086|||COHORT||PROSPECTIVE|||||||
33855121|NCT00914264|||COHORT||PROSPECTIVE|||||||
33855122|NCT04927182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855123|NCT03846141|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33958172|NCT06271941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33958173|NCT01005407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958174|NCT02102529|||COHORT||PROSPECTIVE|||||||
33958175|NCT03347474|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive bilateral surgical implantation of DBS system||||
33958176|NCT04183660|||CASE_ONLY||PROSPECTIVE|||||||
33958177|NCT06704126|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33958178|NCT01102972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958179|NCT06653504|||COHORT||PROSPECTIVE|||||||
33958180|NCT05548543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958181|NCT02617446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|"Cohort I: Participants enrolled in a 2:1 ratio to istaroxime 0.5 µg/kg/min or placebo.~Cohort II: Participants enrolled in a 2:1 ratio to istaroxime 1.0 µg/kg/min or placebo.~Cohort I was enrolled first, followed by Cohort II."|t|t|t|t
33958182|NCT01812577|||OTHER||PROSPECTIVE|||||||
33958183|NCT01262274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958184|NCT04793828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958185|NCT06396091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958186|NCT06019286|||CASE_CONTROL||PROSPECTIVE|||||||
33958187|NCT06234124|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Trained study staff including licensed physical therapists|Randomized controlled clinical trial with a crossover design|f|f|f|t
33958188|NCT06700746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958189|NCT06275893|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label treatment with IC14. Participant outcomes will be compared to baseline. Pharmacokinetics will be measured.||||
33958190|NCT00923013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958191|NCT04950413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34061914|NCT05191459|||COHORT||PROSPECTIVE|||||||
33958192|NCT04049695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958193|NCT05960773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958194|NCT02454413|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33958195|NCT06495268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|By default, hearing rehabilitators will be aware of which group of participants they are assigned to, since those assigned to the intervention group will need to implement a HA fitting protocol different from standard care. Participants will not be actively told which group they are assigned to following randomisation, although complete masking may not be feasible based on the differences between HA fitting protocols. Outcome assessors, the PI, co-PI, and other key project team members will be blinded to group allocation.|"Participants are randomly assigned to either intervention (individualised data-driven hearing rehabilitation) or control group (standard care hearing rehabilitation) by computer-generated allocation in blocks of four (two individuals randomly allocated to each group).~The intervention group will receive individually fitted HAs with immediate SPIN-based benefit validation. HA selection and individual tailoring will also be based on hearing questionnaires data. Participants are invited to intervention-related monitoring appointments at 3, 6 and 12 months.~The control group will receive the same HAs fitted according to the standard care protocol. Standard care follow-up includes a phone call check 3 months after the primary fitting. Additional monitoring/re-fitting may be offered based on the participant's feedback and hearing rehabilitator's clinical judgement.~12-month and 24-months follow-up appointments are arranged for both groups."|t|f|f|t
33958196|NCT02099331|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33958197|NCT06462469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061915|NCT01185262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958198|NCT06702592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958199|NCT06228469|||CASE_ONLY||PROSPECTIVE|||||||
33958200|NCT03818867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958201|NCT00639158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958202|NCT06538844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958203|NCT06568367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958204|NCT06703554|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|same bottles dark in color was used|Sage Extract Natural product|t|f|t|t
33958205|NCT03398161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958206|NCT06703996|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33958207|NCT06667076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958208|NCT02339428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958209|NCT05529992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958210|NCT06701175|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients indicated for knee arthroscopy||||
33958211|NCT04930536|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|A Prospective, Multicentre, Phase-IV study and Clinical trials with a single arm.||||
33958212|NCT06312761|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958213|NCT03884608|||COHORT||PROSPECTIVE|||||||
33958214|NCT06701240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Condition is masked for researchers, including those administering and evaluating outcome measures.||f|f|t|t
33958215|NCT03939728|||COHORT||PROSPECTIVE|||||||
33958216|NCT04986605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061916|NCT05143008|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will be provided with counseling sessions throughout the course of their pregnancy.||||
34061917|NCT04939753|||COHORT||RETROSPECTIVE|||||||
34061918|NCT06658886|||OTHER||CROSS_SECTIONAL|||||||
34167649|NCT01022281|||COHORT||PROSPECTIVE|||||||
34167650|NCT05416866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Except the regional anesthesiologist who performed the blocks, patients, surgeons, theatre anesthesiologists, ward staff, caregivers, and the outcome assessor were unaware of group allocation. The regional anesthesiologist was not involved in the other parts of the study. All data was collected by personnel blinded to the patient group allocation.|A randomized, double-blind, controlled trial|t|t|t|t
34167651|NCT04306614|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34167652|NCT00002868|RANDOMIZED|||TREATMENT||||||||
34167653|NCT02494960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34167654|NCT03049917|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34167655|NCT03830359|NA|SINGLE_GROUP||OTHER||NONE||||||
34167656|NCT00515151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167657|NCT03167333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167658|NCT05730296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34167659|NCT04984967|RANDOMIZED|PARALLEL||OTHER||SINGLE|Peripheral venous catheterization is perform by a nurse. The placement characteristics are evaluated by the investigator, blind of the condition of placement if possible.||f|f|t|f
34167660|NCT03065322|||OTHER||PROSPECTIVE|||||||
34167661|NCT02950740|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34167662|NCT05699850|||OTHER||OTHER|||||||
34167663|NCT05101434|||COHORT||PROSPECTIVE|||||||
34061919|NCT00198913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061920|NCT04809948|||OTHER||PROSPECTIVE|||||||
34061921|NCT02959515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061922|NCT06671587|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study comparing iGlarLixi to Gla-100.||||
34061923|NCT04662255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061924|NCT00324389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958217|NCT05147350|NA|SEQUENTIAL||TREATMENT||NONE||Dose Escalation and expansion||||
33958218|NCT03495700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is designed as a randomized controlled clinical trial.|f|f|t|t
33855124|NCT04895683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher conducting the data analysis will do so using a trial arm code. They will not have the key to unlock which trial arm is which.|3-armed parallel randomised controlled trial|f|f|f|t
33958219|NCT06473961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958220|NCT00068003|||COHORT||PROSPECTIVE|||||||
33958221|NCT06330545|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective phase II trial where patients diagnosed with late/advanced stage Dupuytren's Contracture (DC) who undergo successful CCH injection and release will receive a standardized regimen of radiotherapy (RT). The study will be powered to assess the outcome in patients undergoing the combination of successful release followed by RT. Patients will be monitored for acute and late toxicities while we evaluate disease recurrence defined as a \> 20 degree worsening of contracture in the presence of a palpable cord, or the need for medical/surgical intervention to correct the new or worsening contracture.||||
33958222|NCT06635577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34167664|NCT05931757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167665|NCT01718457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855125|NCT05822778|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34167666|NCT00659113||||TREATMENT||NONE||||||
34167667|NCT01931423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167668|NCT02800863|||COHORT||PROSPECTIVE|||||||
34167669|NCT04535635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent party (Dr. Lesley Bainbridge, Associate Professor at the University of British Columbia Department of Physical Therapy, Faculty of Medicine) will perform a two-group block randomization prior to the start of the trial. The PI will record clinical notes as per standards and include the group (ART or sham) in these notes. These notes are kept on a password-protected laptop that only he has access to. The assessors, Mike Edgar and Frank Astri, will be blinded to the randomization scheme and allocation. The participants will also be blinded to which group they are part of.|"This study will consist of two groups - one receiving ART® and the other receiving a sham. Prior to the start of the study, an independent party (Dr. Lesley Bainbridge, Associate Professor at the University of British Columbia Department of Physical Therapy, Faculty of Medicine) will perform a two-group block randomization to determine which participants will receive the sham and which will receive ART®. The assessors, Mike Edgar and Frank Astri, will be blinded to the randomization and treatment allocation. The PI, Jason Pajaczkowski, will be blinded to the randomization process but as the treating clinician, he will know into which group each new participant has been allocated only at the time of presentation when he is required to open the next allocation sequence.~The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique."|t|f|f|t
34167670|NCT04467086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to intervention versus control group allocation. Care providers (including investigators) cannot be masked due to the need to titrate propranolol and sedative doses according to patient condition in the intervention arm. Similarly, outcomes assessors will be recording the daily and total doses of propranolol received by each participant, and thus cannot be blinded.|Randomized Controlled Trial with 1:1 allocation (intervention and control group)|t|f|f|f
34167671|NCT02758717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855126|NCT04945915|||COHORT||PROSPECTIVE|||||||
33855127|NCT05319275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855128|NCT02645188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855129|NCT00421044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855130|NCT04553250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855131|NCT06093854|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Decompression surgery + IORT (15-20 Gy, 20-50min）~2. Decomression surgery + postoperative SBRT ( 30Gy, 5 fractions, 3 weeks)"||||
33855132|NCT00100581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855133|NCT04721535|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33855134|NCT05584267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855135|NCT01090531|||COHORT||PROSPECTIVE|||||||
33855136|NCT04822974|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855137|NCT00502957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855138|NCT06310174|||CASE_ONLY||PROSPECTIVE|||||||
33855139|NCT04207502|||COHORT||CROSS_SECTIONAL|||||||
33855140|NCT06463925|NA|SINGLE_GROUP||OTHER||NONE||||||
33958223|NCT05940467|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective study whereby participants undergo periods of sleep loss||||
33958224|NCT05232565|||COHORT||PROSPECTIVE|||||||
33958225|NCT01107834|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33958226|NCT03220893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958227|NCT02084888|||COHORT|||||||||
33958228|NCT05778591|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33958229|NCT04925453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The tDCS unit software has a double-blind selection, blinding all study members, care providers, and participants until blinds are broken.|This is a double-blind, randomized, placebo (sham) controlled pilot study.|t|t|t|f
33958230|NCT05981573|||COHORT||PROSPECTIVE|||||||
33958231|NCT05785299|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33855141|NCT03013582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855142|NCT00290043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855143|NCT02679131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855144|NCT03931031|||COHORT||PROSPECTIVE|||||||
33855145|NCT02074553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855146|NCT05552885|||COHORT||PROSPECTIVE|||||||
33855147|NCT02927717|||COHORT||RETROSPECTIVE|||||||
33855148|NCT00448279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855149|NCT02767128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958232|NCT06272448|NA|SINGLE_GROUP||TREATMENT||NONE||Before-after study with one follow-up at 3 months of treatment end||||
33958233|NCT02364414|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958234|NCT02285452|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33958235|NCT06607692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958236|NCT00458016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958237|NCT02765542|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958238|NCT06009432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958239|NCT05769322|||COHORT||PROSPECTIVE|||||||
33958240|NCT06182852|||COHORT||RETROSPECTIVE|||||||
33958241|NCT02118896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958242|NCT06236711|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33958243|NCT05604521|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855150|NCT00277706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855151|NCT00445900||||TREATMENT||NONE||||||
33855152|NCT00831831|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33855153|NCT00658099|||COHORT||PROSPECTIVE|||||||
33855154|NCT02294227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855155|NCT02325557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958244|NCT03080272|||COHORT||PROSPECTIVE|||||||
33958245|NCT05981118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958246|NCT06446973|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33958247|NCT03436407|||CASE_CONTROL||PROSPECTIVE|||||||
33958248|NCT03626857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061925|NCT01890213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061926|NCT01941836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855156|NCT04841356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855157|NCT02395874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855158|NCT00639210|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33855159|NCT05772494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The participants are consecutively assigned to either intervention or control group depending on the time for the next prolonged sick leave period. Participants in the intervention group are invited to an assessment session with an occupational therapist focusing on limitations and enablers in activities related to pre-requisites for returning to work. Participants in the control group receive assessments for sickness certificate according to ordinary routines.||||
33855160|NCT04716491|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|The main researcher will not participate in the recruitment, application of the intervention and data collection steps. There will be interventional nurses who have been trained by them and who will do these actions.The outcomes defined at the beginning of the study will be analyzed by a statistician who will not participate in the randomization process and in any step prior to data analysis|The sample will be divided into two groups: intervention group (formed by participants who will wear eye masks and hearing protectors) and control group (formed by participants who will not use any device, that is, they will receive the usual care of the unit that does not include any sleep hygiene approach)|f|f|t|t
33855161|NCT04036864|||OTHER||RETROSPECTIVE|||||||
33855162|NCT02872883|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33855163|NCT02490202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855164|NCT02238665|||||PROSPECTIVE|||||||
33855165|NCT00409214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855166|NCT02525757|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855167|NCT03495570|||COHORT||PROSPECTIVE|||||||
33855168|NCT04432246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855169|NCT00180570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855170|NCT04281004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855171|NCT06148051|||CASE_CONTROL||PROSPECTIVE|||||||
33855172|NCT01553123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855173|NCT03720197|||COHORT||PROSPECTIVE|||||||
33855174|NCT06436157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This pilot study will randomize patients who are starting or switching their systemic therapies for solid cancers, eligible for GCT, and have not undergone prior genetic testing into two groups: enhanced education intervention and usual care education."||||
33855175|NCT01944241|||COHORT||RETROSPECTIVE|||||||
34061927|NCT05385224|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958249|NCT04590417|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33958250|NCT05410457|||COHORT||PROSPECTIVE|||||||
33958251|NCT01130207|||CASE_ONLY||PROSPECTIVE|||||||
33958252|NCT05268341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958253|NCT06652113|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-labeled multicenter randomized clinical trial||||
33958254|NCT05013827|||CASE_ONLY||CROSS_SECTIONAL|||||||
34061928|NCT06073743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061929|NCT00087126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061930|NCT03903367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33748296|NCT03876652|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Prospective, multi-institutional, randomized, double-blind intervention study. Patients with a diagnosis of cardioinhibitory syncope will be included. They have implanted a pacemaker with a closed loop sensor. Pacemakers are left in CLS mode during the first month, the month in the implant is cited patients and the random form is left reprogrammed in DDD-R or DDD-CLS mode as randomization is established. After 4 months of this last visit, the reprogramming mode will be exchanged and left for another 4 months. During this time, a clinical and electrophysiological evaluation will be performed. At the end of these 8 months, the patient will be rescheduled in the same electrophysiologist's mode as the patient has felt better. The clinical follow-up will continue for 12 more months. At the end of the study, the results of the quality of life scales will be analyzed, the occurrence of episodes of syncope, the reduction of pre-syncopal symptoms, mode and programming will be evaluated.|t|f|t|f
33958255|NCT06222879|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three parallel arms||||
33958256|NCT05136664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2-part, single-blind, randomised withdrawal, placebo-controlled (Part B), parallel group study that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part B).|t|f|f|f
33958257|NCT06274853|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33958258|NCT06702670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958259|NCT05811260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748297|NCT05188846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748298|NCT06110923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748299|NCT00580632|||CASE_ONLY||RETROSPECTIVE|||||||
33855176|NCT04016467|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomized intervention, blinding of pain measure to intervention PT, and blinding of intervention assignment pain assessment PT|Controlled clinical trial|t|f|t|t
33855177|NCT03674567|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33855178|NCT00581815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855179|NCT06459466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855180|NCT01824160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855181|NCT00561951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855182|NCT05560100|||OTHER||PROSPECTIVE|||||||
33855183|NCT03714932|||OTHER||PROSPECTIVE|||||||
33855184|NCT01610141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855185|NCT02279069|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855186|NCT05260515|NA|SINGLE_GROUP||PREVENTION||NONE||PROACTS is a Phase I/II study to assess the efficacy of AARP Staying Sharp online health program, focusing on the health of non-professional home-based caregivers of persons with Alzheimer's disease and related dementias (ADRD). PROACTS has three aims. Aim 1 \& 2 is an one-time survey study to evaluate the current uptake and utilization of Staying Sharp among caregivers. Aim 3 is a single-group intervention to assess how Staying Sharp may maintain health and function for caregivers of persons with ADRD. Participants will participate in a 4-month program with a 4-month follow-up.||||
33855187|NCT01304459|||CASE_ONLY||PROSPECTIVE|||||||
33855188|NCT01405586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855189|NCT00661804|||||PROSPECTIVE|||||||
33855190|NCT04343638|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The subject will be randomly allocated to 2 groups using computer-generated randomization method. Anesthesiologists will not be blinded to the groups because of organizational reasons.||t|f|f|t
33855191|NCT04690842|||COHORT||PROSPECTIVE|||||||
33855192|NCT04470167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855193|NCT00027781||||TREATMENT||||||||
33855194|NCT02832154|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855195|NCT01340820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855196|NCT05316194|||COHORT||RETROSPECTIVE|||||||
33855197|NCT01551212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958260|NCT04824560|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958261|NCT06703632|NA|SINGLE_GROUP||SCREENING||NONE|Laboratory Technicians|Low-risk interventional study||||
33958262|NCT06061302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061931|NCT04963959|NA|SINGLE_GROUP||OTHER||NONE||||||
34061932|NCT01827215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076024|NCT03485534|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, Parallel||||
34076025|NCT05643989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076026|NCT01785537|||COHORT||PROSPECTIVE|||||||
34076027|NCT00297700|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34076028|NCT04968093|NA|SINGLE_GROUP||TREATMENT||NONE||To assess the impact of a mindfulness-based group treatment for adolescents with CM and HFEM on headache frequency reduction over 12 months.||||
34076029|NCT04001192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076030|NCT01016145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076031|NCT00901043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076032|NCT04195724|NA|SINGLE_GROUP||OTHER||NONE||||||
34076033|NCT03404388|NA|SINGLE_GROUP||SCREENING||NONE|All participants will receive the same testing and training. A assessor blinded to whether the participant has received training will assess the Berg Balance Scale.|||||
34076034|NCT04794751|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34076035|NCT00090909||||TREATMENT||NONE||||||
34076036|NCT00920959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076037|NCT05139355|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34076038|NCT03847961|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients are stratified by site and randomly assigned in a 1:1 ratio to either CA330 hemoperfusion plus conventional medical therapy group or conventional medical therapy group.||||
34076039|NCT03176719|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34076040|NCT00715299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076041|NCT01676246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34076042|NCT05146323|||COHORT||RETROSPECTIVE|||||||
34076043|NCT04422171|||COHORT||PROSPECTIVE|||||||
34076044|NCT02140177|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076045|NCT06259214|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34076046|NCT02390089|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33958263|NCT06700772|RANDOMIZED|PARALLEL||TREATMENT||NONE|None. Because the two interventions used in this trial are clearly different and can be easily recognized by the participant and investigator|A Randomized clinical trial A trial will be conducted in hospital of oral and maxillofacial surgery department.faculty of oral and dental medicine Cairo university Equal randomization of participant Both groups receiving treatment Each group of patient receiving a single treatment simultaneously||||
33855198|NCT04520360|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center, open-label, randomized, 5-period, 10-sequence study designed to assess each treatment in all subjects enrolled in the study. The five treatments tested using a single oral administration will be: (1) Oral Suspension Type 1, 300 mg Oral Tablet, Oral Suspension Type 2 all under fasted conditions and (2) Oral Suspension Type 2, 300 mg Oral Tablet under fed conditions. Each dose is followed by at least a seven-day washout period. The sequence and period arrangement will be constructed based on the Williams design to ensure the study is balanced with respect to first-order carry-over effects.||||
33958264|NCT06703021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855199|NCT01604707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958265|NCT06562439|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||We will randomize children to receive developmental screening alone or developmental screening with a home-based intervention.||||
33958266|NCT04057898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958267|NCT05726318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958268|NCT02316743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958269|NCT04923906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958270|NCT06180577|||COHORT||RETROSPECTIVE|||||||
33958271|NCT06481995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The analysis of the primary outcome will be performed using blinded treatment arms.|multi- center, randomized, controlled|f|f|f|t
33958272|NCT01772394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958273|NCT00390507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33958274|NCT03528967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061933|NCT03078127|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All subjects will undergo baseline testing, followed by study procedures for three separate interventions, with subjects randomized into three arms in which a different sequence in which to complete the studies.||||
34061934|NCT02555124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34061935|NCT02721303|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34061936|NCT05765253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061937|NCT01546038|RANDOMIZED|||TREATMENT||NONE||||||
34061938|NCT06588634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855200|NCT00062894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855201|NCT03558594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Behavioral: Self-Hypnosis Training~Behavioral: Mindfulness Meditation"||||
33855202|NCT03680404|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject has one control site and three experimental sites concurrently tested within the same study using intradermal microdialysis on the dorsal forearm.||||
33855203|NCT05787431|||COHORT||CROSS_SECTIONAL|||||||
33855204|NCT00899548|||COHORT||PROSPECTIVE|||||||
33855205|NCT02201589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958275|NCT03576547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958276|NCT03612713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33958277|NCT04331392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded to whether they are completing the experimental or active control intervention.|Participants are randomly assigned to either the experimental intervention (allocentric navigation training) or the active control intervention (educational videos).|t|f|t|t
33958278|NCT05670496|||COHORT||PROSPECTIVE|||||||
33958279|NCT00266461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061939|NCT04736173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061940|NCT06033833|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study will have a double-blind treatment period and an open-label treatment period after week 24|This study will have a double-blind treatment period and an open-label treatment period|t|t|t|f
34061941|NCT03051516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34076047|NCT02815033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076048|NCT04805138|||OTHER||CROSS_SECTIONAL|||||||
34076049|NCT02619097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076050|NCT04328909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748300|NCT05997043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For Parkinson's disease patients with overactive bladder, participants were assigned to an experimental or control group in a 1:1 ratio at the end of the baseline visit.Assignment will be concealed (sealed envelopes) and randomized to either the experimental or control group using an independent online computerized randomization system. Once randomized into the study, all patients will be included in the ITT analysis|The intervention group was given oral anti-Parkinson's drugs and Botox injection, while the control group was given only anti-Parkinson's drugs.|f|f|f|t
33855206|NCT00504881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855207|NCT01966380|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855208|NCT02179320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855209|NCT06033651|||COHORT||PROSPECTIVE|||||||
34076051|NCT01387178|||COHORT||RETROSPECTIVE|||||||
34076052|NCT02501746|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076053|NCT04453761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076054|NCT03446092|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34076055|NCT01520207|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34076056|NCT05922644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076057|NCT00472732|||COHORT||PROSPECTIVE|||||||
34076058|NCT03950453|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|participant and outcomes assessor|cohort study|t|f|f|t
34076059|NCT00798941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076060|NCT01614015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076061|NCT04407676|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomised||||
34061942|NCT06176313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes Assessor will be performed by an investigator who was blinded to group allocation.|The research employs a pre-test post-test control group design with a randomized controlled semi-experimental approach to determine the impact of education provided for coping with premenstrual syndrome and Mandala activity on premenstrual symptoms.|f|f|f|t
34061943|NCT04267185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be collected objectively by researchers who are blinded to treatment allocation. Researchers who are involved with delivery of the intervention will be aware of treatment allocation, but will not be involved with data collection, entry or analysis.|This pilot study will use a two-arm, parallel group, single-blinded RCT design that examines the feasibility and preliminary efficacy of a twelve-week physical activity intervention in persons with moderate-to-severe MS disability and their family caregivers compared with a delayed control condition.|f|f|f|t
34061944|NCT05760222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061945|NCT01459341|||CASE_ONLY||PROSPECTIVE|||||||
34061946|NCT05758272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34061947|NCT04432116|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||All interventions are applied to each participant|f|f|f|t
34061948|NCT06002438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention and control powders will be packaged such that investigators and outcomes assessors will not know their identity. Participants and care providers are likely to be able to distinguish them, however.||f|f|t|t
34061949|NCT02009059|||COHORT||PROSPECTIVE|||||||
34061950|NCT06448195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061951|NCT03738449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061952|NCT03938649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061953|NCT05801419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34061954|NCT00930631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061955|NCT01229033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061956|NCT06425666|RANDOMIZED|PARALLEL||TREATMENT||NONE|After screening and enrollement subjects will be randomly allocated to the trial groups (cataract surgery versus triple-DMEK, allocation rate 1:1)|"The trial will be a prospective, randomised, controlled, European, multicentre, open clinical trial in which patients with FECD and cataract will receive either cataract surgery without DMEK (intervention goup/arm 1) or triple-DMEK (DMEK in combination with cataract surgery; control group/arm 2).~(Protocol V02_0_TC page 37)"||||
34061957|NCT06247553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinding||f|f|f|t
33855210|NCT02318797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33855211|NCT01097785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33855212|NCT04260425|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33855213|NCT06373029|||OTHER||PROSPECTIVE|||||||
33855214|NCT00160784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748301|NCT01093729|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33855215|NCT02148549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855216|NCT01975974|||CASE_ONLY||PROSPECTIVE|||||||
33855217|NCT04748900|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855218|NCT02652403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061958|NCT01362517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34061959|NCT06408142|||COHORT||PROSPECTIVE|||||||
34061960|NCT03630913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061961|NCT02561741|NA|SINGLE_GROUP||||NONE||||||
34061962|NCT00006994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34061963|NCT06729970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel A \& B cohorts and then Parallel C \& D cohorts.||||
34076062|NCT04371055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomised, parallel, multicenter interventional trial with blinded assessment of the primary endpoint|f|f|f|t
34076063|NCT01715948|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076064|NCT06080542|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE||Two interventions will be carried out in a single group, one aerobic session and HIIT session.|f|f|f|t
34076065|NCT01579513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748302|NCT06377241|||COHORT||PROSPECTIVE|||||||
33748303|NCT02363946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748304|NCT04582630|||COHORT||PROSPECTIVE|||||||
33748305|NCT03104634|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Matched placebo.||t|t|t|t
33748306|NCT06204627|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The study will be controlled, randomized and double-blind.|"The study will be controlled, randomized, double-blind and will include patients with chronic neck pain, divided into four groups:~1. active TDCS associated with laterality recognition stimuli (n = 25);~2. active TDCS associated with landscape recognition stimuli (n = 25);~3. TDCS sham associated with laterality recognition stimuli (n = 25);~4. TDCS sham associated with landscape recognition stimuli (n = 25)."|t|f|t|t
33748307|NCT01015391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748308|NCT02437591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748309|NCT01983293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748310|NCT02836418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748311|NCT06190301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748312|NCT00364429|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958280|NCT00093067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748313|NCT04207099|||COHORT||PROSPECTIVE|||||||
33748314|NCT03585244|||COHORT||PROSPECTIVE|||||||
33748315|NCT02412137|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748316|NCT06670300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Melanoma and kidney cancer||||
33748317|NCT06670781|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||A blinded comparative crossover diagnostic accuracy study|f|f|f|t
33748318|NCT06309693|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a randomized control trial in which patients undergoing robotic-assisted sacrocolpopexy with concurrent robotic assisted hysterectomy or robotic assisted sacrocolpopexy after previous hysterectomy will be randomized to one of two standard of care approaches for postoperative pain management: the enhanced recovery after surgery (ERAS) protocol and the quadratus lumborum truncal nerve block. Subjects will undergo one of two standard of care approaches to postoperative pain management and be asked about their pain postoperatively.||||
33958281|NCT04372563|||OTHER||PROSPECTIVE|||||||
33748319|NCT00481806|||CASE_ONLY||PROSPECTIVE|||||||
34061964|NCT06665971|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a single arm clinical trial with subgroup analysis comparing responder's vs non-responders. Methods used to minimize bias:~All participants will be treated with medications. There is no placebo arm of the study. Based on the available data the response to the drug is approximately 60%, i.e., eosinophil count of \< 6/HPF on esophageal mucosal biopsy (Responders). The remaining 40% participants are expected to have eosinophil count of \> 6/HPF on esophageal mucosal biopsy after treatments (Non-responders). The study design is to compare the responder vs non-responders."||||
34061965|NCT02151435|||COHORT||PROSPECTIVE|||||||
34061966|NCT01255462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061967|NCT03572361|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single arm, open label Phase II study in volunteers with breast cancer receiving daily dose of one pill of vaccine V3-MOMMO||||
34061968|NCT03059199|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34061969|NCT01038414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061970|NCT05148845|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Open-label, single-arm phase 3B vaccine implementation study||||
34061971|NCT01772680|NA|SINGLE_GROUP||OTHER||NONE||||||
33748320|NCT00411567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748321|NCT02931279|||COHORT||PROSPECTIVE|||||||
33748322|NCT03268876|||COHORT||PROSPECTIVE|||||||
33748323|NCT02208180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748324|NCT04396613|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33748325|NCT00687037|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33748326|NCT05598333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The IWRS will be programmed with blind-breaking instructions. In case of an emergency, the investigator has the responsibility for determining if unblinding of a subject's intervention assignment is warranted. If the investigator is unavailable, and a treating physician not associated with the study requests emergency unblinding, the emergency unblinding requests are forwarded to the emergency medical advice 24 hours/7 day service.|Adaptive, double blinded, placebo controlled, randomized|t|t|t|t
33748327|NCT02123654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748328|NCT01326364|||COHORT||PROSPECTIVE|||||||
33748329|NCT03569280|NA|SEQUENTIAL||TREATMENT||NONE||KPG-121 Plus Enzalutamide or Abiraterone or Apalutamid||||
33748330|NCT00489970|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748331|NCT05427799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a parallel, single-blind, randomized trial|f|f|t|f
33958282|NCT06704061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958283|NCT01950572|||CASE_ONLY||PROSPECTIVE|||||||
33958284|NCT00001238|||COHORT||PROSPECTIVE|||||||
34061972|NCT03406000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061973|NCT01577719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34061974|NCT03215407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34076066|NCT02855489|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34167672|NCT04365712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The patient did not know with which instrument the osteotomy had been performed.~The radiologist who certifies the osteotomy radiographic healing did not know with which instrument the osteotomy had been performed.~The clinical investigator who collected the evaluation questionnaires was not aware of the type of instruments used during the surgery."|"40 patients affected by hallux valgus were recruited, based on the listed inclusion and exclusion criteria; 20 underwent 1st metatarsal osteotomy treated with a piezoelectric tool (experimental group) and 20 underwent 1st metatarsal osteotomy with a traditional oscillating saw (control group). The patients were randomly allocated (1:1) in a Piezoelectric Group (PG) and in a Control Group (CG) utilizing sealed envelopes. The envelopes were prepared and shuffled by the same senior surgeon involved in the surgical procedures and drawn by a researcher not involved in the surgical procedures or the clinical and radiographic assessment.~3 patients in PG (1 did not comply with the post-operative management and 2 missed the scheduled follow-up appointments) and 3 patients in CG (all patients discontinued from the evaluations) were lost to follow-up.~Thus, 17 patients in each group were evaluated in the 1-year analysis, all treated according to their original assignment."|t|f|t|t
33022786|NCT05858658|||COHORT||RETROSPECTIVE|||||||
33855219|NCT06421610|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Cohort study||||
33855220|NCT00905112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855221|NCT04044274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33855222|NCT04032587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855223|NCT02711111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855224|NCT04455438|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is designed to determine the Maximum Tolerated Dose (MTD) that could be safely delivered in the lung reirradiation setting. The MTD was defined as the highest dose level in which a proportion of 1 out of 5 or fewer patients experienced DLT. Due to the late onset nature of DLT, in order to allow for continuous accrual without sacrificing patient safety or the accuracy of identifying the MTD, the Time-To-Event Bayesian Optimal Interval (TITE-BOIN) design will be used.||||
33855225|NCT05033171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855226|NCT05782998|||COHORT||PROSPECTIVE|||||||
33855227|NCT01175447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855228|NCT05382078|||COHORT||PROSPECTIVE|||||||
33958285|NCT05092802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958286|NCT04218344|||COHORT||PROSPECTIVE|||||||
33958287|NCT05900531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958288|NCT06201598|||CASE_ONLY||PROSPECTIVE|||||||
33958289|NCT01171131|||COHORT||OTHER|||||||
33958290|NCT03130855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167673|NCT04891016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167674|NCT02166892|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855229|NCT00518661|||COHORT||RETROSPECTIVE|||||||
33855230|NCT06143306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This will be double blinded. The surgeon performing the surgery and the research team member collecting follow-up pain and opioid data will be blinded to the randomization assigned to the patient. The anesthesiologist performing the block and the medical assistant preparing the drugs for the anesthesiologist will be unblinded.||t|t|t|t
33855231|NCT00494481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855232|NCT05126433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855233|NCT00824161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748332|NCT05602376|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Aim 1: Site-testing-days will be randomised 1:1 to implement either U=U (intervention) or SoC (Control) messaging scripts for both invitation-to-test and ART initiation.~Aim 2: Randomization will be stratified by the 6 study clinics, to account for possible differences in the baseline viral loads of the catchment area populations initiating ART within each clinic with individual-level randomization will be used with random block sizes."|Two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2)|f|f|t|t
33855234|NCT00647725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958291|NCT00002560||||TREATMENT||||||||
33958292|NCT06466187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958293|NCT00414011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958294|NCT00874042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958295|NCT06452316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958296|NCT05636501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958297|NCT06458712|NA|SEQUENTIAL||TREATMENT||NONE||||||
33958298|NCT06702878|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study employs a group-randomized crossover design, comparing outcomes from the treatment group with that of a standard-of-care control group from the same hospitals.||||
34167675|NCT03669614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a standard double-blind randomized controlled trial.|"This study is a dose-escalation, placebo-controlled study where subjects are randomized to receive study drug or placebo.~SAD and MAD HV Phases: The HV SAD and MAD will each include up to 24 adult subjects in 3 groups (8 per dose group) in each the SAD and MAD phase . All subjects will be randomly assigned in a 3:1 ratio to receive a single administration of active drug (12 HVs) or placebo (4 HVs).~The CF MAD will evaluate 4 different dose levels in a total of 54 adult CF subjects (10 per dose level). The first 3 subjects (sentinel subjects) in the low, medium and high dose level will be randomly assigned at a 2:1 ratio to receive either AR-501 or placebo, for a total of 9 CF subjects. An expanded cohort will randomize 30 adult subjects at a 2:3:3:2 ratio to three doses of inhaled AR-501 or placebo. Subsequently an 80mg Ga dose (top dose) cohort will randomize subjects at a 2:1 ratio to receive either AR 501 or placebo for a total of 15 subjects , including 6 sentinel subjects."|t|t|t|t
34167676|NCT06106126|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167677|NCT02428101|||COHORT||PROSPECTIVE|||||||
34167678|NCT02088450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167679|NCT05806437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167680|NCT00648635|||CASE_ONLY||PROSPECTIVE|||||||
34167681|NCT02539771|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167682|NCT05833529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167683|NCT02366195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167684|NCT04941495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random allocation will be done through toss coin method into two groups; Conventional Physiotherapy Control group (n=22) and Proprioceptive training Experimental group (n=22).||||
34167685|NCT03498807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During this period, all patients were total sedation using continuous infusion, to prevent any spontaneous breathing .All patients were ventilated using a ventilator|Moderate to severe ARDS patient on mechanical ventilation from ER or word transfer ICU.(P/F≦200+PEEP≧ 5cmH20)|t|f|f|f
34167686|NCT00617175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167687|NCT04640649|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167688|NCT04295317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167689|NCT00434681|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34167690|NCT01482026|NON_RANDOMIZED|PARALLEL||||NONE||||||
34167691|NCT05923879|||OTHER||RETROSPECTIVE|||||||
34167692|NCT03523884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855235|NCT01502631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167693|NCT04179006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855236|NCT04310423|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The study team, medical personnel, and participants will be blind to drug condition.|Randomized, triple-blind, placebo-controlled, parallel-group study of low dose endotoxin (0.8 ng/kg)|t|t|t|f
34167694|NCT00911248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167695|NCT05914948|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Subjects meeting study eligibility criteria will be implanted with a Medtronic 8-contact Vectris subcompact or compact electrode.||||
34167696|NCT00154440|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167697|NCT00409539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167698|NCT02507323|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34167699|NCT02926989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167700|NCT06233188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167701|NCT00730977|NA|SINGLE_GROUP||||NONE||||||
34167702|NCT00003239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167703|NCT00938678|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34167704|NCT05009277|||COHORT||PROSPECTIVE|||||||
34167705|NCT02975050|||COHORT||PROSPECTIVE|||||||
34167706|NCT02434822|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167707|NCT01112397|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167708|NCT03215316|||COHORT||PROSPECTIVE|||||||
34167709|NCT01730521|||CASE_ONLY||PROSPECTIVE|||||||
34167710|NCT02783365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167711|NCT05432713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167712|NCT05170022|||CASE_CONTROL||PROSPECTIVE|||||||
34167713|NCT02962167|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167714|NCT03324802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167715|NCT02182934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34167716|NCT06015386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34167717|NCT03923257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167718|NCT02685306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167719|NCT01674088|||CASE_CONTROL||PROSPECTIVE|||||||
33958299|NCT03030482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33958300|NCT06297616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958301|NCT00996008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958302|NCT04242784|||COHORT||RETROSPECTIVE|||||||
33958303|NCT06701279|||COHORT||PROSPECTIVE|||||||
33958304|NCT04950803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33958305|NCT06695832|||OTHER||RETROSPECTIVE|||||||
33958306|NCT06079801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958307|NCT02530320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958308|NCT00088023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958309|NCT03287102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958310|NCT05350969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy staff is unblinded. They will hand-over prepared investigational medicinal product (IMP) in light-protected syringe.||t|t|t|t
33958311|NCT05702827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958312|NCT04920162|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33958313|NCT01417208|||COHORT||PROSPECTIVE|||||||
33958314|NCT05728918|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33958315|NCT05664841|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33958316|NCT03262519|||COHORT||PROSPECTIVE|||||||
33958317|NCT06701071|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to the two treatment arms||||
33958318|NCT06213389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33958319|NCT06703918|||COHORT||RETROSPECTIVE|||||||
33855237|NCT06186570|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial with a parallel group design is used. The intervention group will receive the online-based self-help intervention immediately after the baseline assessment (T0), while the waitlist-control group will receive the online-based self-help intervention after study completion at T1. Both study conditions are allowed to continue standard scheduled treatment.||||
33748333|NCT04609254|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33855238|NCT02766894|||COHORT||PROSPECTIVE|||||||
33958320|NCT01025388|||CASE_ONLY||CROSS_SECTIONAL|||||||
33958321|NCT05924672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958322|NCT01467674|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33958323|NCT05209139|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33958324|NCT06568107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group - all participants enrolled in the study will receive the non-pharmacological intervention||||
33958325|NCT06264362|NA|SINGLE_GROUP||TREATMENT||NONE||In Phase 1 (not a clinical trial), 15 dyads and 15 clinicians will be interviewed (a dyad equals one person living with mild to very mild dementia and their care partner) to inform design of the intervention. In Phase 2 (a clinical trial), 20 people living with mild to very mild dementia will be treated with the new intervention. Their care partners may be involved in treatment.||||
33958326|NCT01258231|||COHORT||PROSPECTIVE|||||||
33958327|NCT04994249|||COHORT||PROSPECTIVE|||||||
33958328|NCT02264509|||COHORT||PROSPECTIVE|||||||
33958329|NCT04943913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061975|NCT06534086|RANDOMIZED|PARALLEL||OTHER||NONE||Other = feasibility (primary) + clinical pilot outcomes (secondary)||||
34061976|NCT06244459|NA|SINGLE_GROUP||TREATMENT||NONE||Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.||||
34061977|NCT05958654|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34061978|NCT03424629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061979|NCT03654105|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34061980|NCT03349281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061981|NCT03894215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061982|NCT03674697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34061983|NCT06695247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34061984|NCT05331781|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34061985|NCT03391232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34061986|NCT00383682|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34061987|NCT03410212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34061988|NCT05673096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Due to the nature of the intervention, blinding of parents and therapists is impossible. The primary outcome measure, Autism Diagnostic Observation Schedule, Calibrated Severity Score (ADOS-CSS), and further outcomes (Brief Observation of Social Communication Change (BOSCC), Dyadic Communication Measure for Autism (DCMA) and Measure of Naturalistic Developmental Behavioral Intervention Strategy Implementation - Caregiver Change (MONSI-CC)) are videotaped, leaving raters blinded to treatment allocation. At the clinical follow-up assessment, families are asked not to reveal group allocation.~Data from the DAN-PACT trial will be kept separate from research data and will not be accessible to the research team. We will follow the rule that statistical analyses are conducted with the intervention groups coded. The steering committee will write two abstracts while the blinding is intact assuming either group as intervention group and control, respectively. After this, the code will be broken"||f|f|t|t
34061989|NCT01578226|||COHORT||PROSPECTIVE|||||||
34061990|NCT03050112|NA|SINGLE_GROUP||OTHER||NONE||||||
34061991|NCT00572052|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34061992|NCT06557733|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34061993|NCT06588166|||COHORT||CROSS_SECTIONAL|||||||
34061994|NCT01861418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34061995|NCT06271278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants will be blinded to their group assignment. The subjects will be selected in a randomized order using software. Data collection will be conducted without involvement from research analysts.|This study was conducted as a randomised controlled study with experimental and control groups.|t|f|t|t
34061996|NCT03595358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34061997|NCT03768024|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Qualified participants for the treatment phase will be randomized to 1 of 7 treatment-sequences based on a computer generated randomization schedule. Participants will receive all 7 treatments in the order specified by the treatment sequence according to a 7-sequence, 7-period balanced design.|t|t|t|t
34167720|NCT06136364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167721|NCT00724178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167722|NCT03840863|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167723|NCT00961181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748334|NCT06127667|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33748335|NCT06216457|||COHORT||PROSPECTIVE|||||||
33748336|NCT02173977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748337|NCT02699333|||CASE_CONTROL||PROSPECTIVE|||||||
33748338|NCT05403580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33748339|NCT03252587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748340|NCT02048943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748341|NCT00363818|||COHORT||PROSPECTIVE|||||||
33855239|NCT03875846|||COHORT||PROSPECTIVE|||||||
33855240|NCT03616197|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Determination of graft area measurements and shrinkage ratio of all photographs was performed by a periodontologist , an independent specialist who had not performed any surgical procedures.||f|f|f|t
33855241|NCT02765061|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33855242|NCT03105622|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33855243|NCT01943409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33855244|NCT06085001|||CASE_ONLY||PROSPECTIVE|||||||
33855245|NCT05034120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855246|NCT00464607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748342|NCT00607334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958330|NCT01213004|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33748343|NCT05194774|||COHORT||PROSPECTIVE|||||||
33855247|NCT06189560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855248|NCT05163587|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||two arm parallel assignment|t|t|t|t
33855249|NCT02634957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33855250|NCT03048643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855251|NCT00940108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855252|NCT03774966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855253|NCT05647915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855254|NCT03169504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855255|NCT01244776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855256|NCT00067587|||CASE_CONTROL||PROSPECTIVE|||||||
33855257|NCT04634656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855258|NCT06432608|NA|SINGLE_GROUP||TREATMENT||NONE||Original longitudinal, analytical, and prospective quasi-experimental study in adults diagnosed with functional chronic constipation under the ROME IV criteria. The study will provide a product based on fermented milk with the probiotic Lacticaseibacillus paracasei strain Shirota for 4 weeks.||||
33855259|NCT06429475|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Clinical Trial||||
33855260|NCT03802942|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized open label||||
33855261|NCT06423209|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE||The study consisted of a 4-arm non-randomized controlled clinical trial, with measurements at the beginning and end of a 16-week intervention.|f|f|t|t
33855262|NCT01470313|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33748344|NCT01837381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855263|NCT05493085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855264|NCT05430360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855265|NCT04094792|RANDOMIZED|PARALLEL||TREATMENT||NONE||two-group randomized controlled efficacy trial||||
33855266|NCT05057923|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"two parallel experimental groups were designed.~1. the vaccinated volunteers and 2. unvaccinated groups."||||
33958331|NCT05754749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958332|NCT00713713|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33958333|NCT01823237|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33748345|NCT05987683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748346|NCT02657226|||OTHER||RETROSPECTIVE|||||||
33748347|NCT02671435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748348|NCT02526264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748349|NCT01909310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748350|NCT06447857|||COHORT||RETROSPECTIVE|||||||
33748351|NCT06352710|||OTHER||PROSPECTIVE|||||||
33748352|NCT00576069|||CASE_CONTROL||PROSPECTIVE|||||||
33748353|NCT01716312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33748354|NCT01971372|||CASE_ONLY||PROSPECTIVE|||||||
33748355|NCT00897364|||OTHER||PROSPECTIVE|||||||
33748356|NCT01463748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33748357|NCT02201069|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33748358|NCT03809481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open-label, randomized, active-controlled|f|f|f|t
33748359|NCT05013333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748360|NCT03588533|NA|SINGLE_GROUP||TREATMENT||NONE||"* Herzuma 8mg/kg loading over 90min (1st cycle)~* Herzuma 6mg/kg maintenance over 30min (2nd cycle\~ ) every 3 weeks~* Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~* Cisplatin 60\~100mg/m2 i.v. D1 every 3 weeks"||||
33748361|NCT05152238|||COHORT||PROSPECTIVE|||||||
33748362|NCT00278434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748363|NCT04443023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748364|NCT03139487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748365|NCT01776918|||CASE_ONLY||CROSS_SECTIONAL|||||||
33748366|NCT04242199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of 2 parts. Part 1 is a dose-escalation design to identify the maximum tolerant dose and/or pharmacologically active dose for INCB099280. Part 2 is an expansion at 1 or more dose levels to further explore safety, preliminary efficacy, pharmacokinetic, and pharmacodynamic effects.||||
33748367|NCT05394870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748368|NCT01936064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33748369|NCT01274091|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33748370|NCT00384553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748371|NCT00272168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855267|NCT01119482|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33855268|NCT00419133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855269|NCT00959166|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33855270|NCT04200157|||OTHER||CROSS_SECTIONAL|||||||
33855271|NCT01146626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855272|NCT03701867|NA|SINGLE_GROUP||OTHER||NONE||||||
33958334|NCT03356431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958335|NCT03891979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958336|NCT05019638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958337|NCT06518993|||COHORT||RETROSPECTIVE|||||||
33958338|NCT04682639|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33958339|NCT05877859|||COHORT||PROSPECTIVE|||||||
33958340|NCT05874479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34061998|NCT01772849|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34061999|NCT03511716|||COHORT||PROSPECTIVE|||||||
34062000|NCT02993354|||CASE_CROSSOVER||PROSPECTIVE|||||||
34062001|NCT05651438|||COHORT||PROSPECTIVE|||||||
34062002|NCT05019885|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental clinical treatment||||
33855273|NCT02892188|||COHORT||PROSPECTIVE|||||||
34076067|NCT05763914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A cluster-randomized clinical trial, including three different hospitals. At each hospital, 78 cleaners will be included.|t|f|f|f
34062003|NCT04977362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All scientists and statisticans involved in the analysis of the study will be blinded to the allocation of participants and will receive only pseudomized data from the study coordinator, who organises data collection.|Randomized Controlled Trial|f|f|t|f
33748372|NCT00000602||||TREATMENT||||||||
34062004|NCT03293953|||COHORT||PROSPECTIVE|||||||
34062005|NCT04686266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and all staff involved in collecting assessment data will be blinded to group assignment until after the data are locked. The Health Coaches providing the intervention and the caregiver participants will not be blinded.||f|t|t|t
34062006|NCT06302023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062007|NCT00215371|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34062008|NCT06446336|||COHORT||PROSPECTIVE|||||||
34062009|NCT04045899|RANDOMIZED|PARALLEL||OTHER||SINGLE||Methods:This prospective, randomised, single-blind study was conducted on 150 American Society of Anesthesiologists physical status I-II, randomly allocated into 3 groups, undergoing elective surgical procedures under general anaesthesia.PLMATM, Air-Q® and Ambu AuraGainTM appropriate for weight or/and height was inserted.Primary outcome measure was insertion time.Airway sealing pressure,ease of insertion, number of attempts,overall success rate, glottis view,number of attempts of gastric tube placement , hemodynamic parameters and complications were also recorded.|t|f|f|f
34062010|NCT04996511|NA|SINGLE_GROUP||OTHER||NONE||||||
34062011|NCT06255717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34062012|NCT05413122|RANDOMIZED|FACTORIAL||TREATMENT||NONE|This will be an open-label trial; neither the participants nor study personnel will be blinded to treatment assignment post randomization, but randomization block assignment will be concealed from the study personnel who will be enrolling participants.|The investigators will conduct a 4-factor, balanced full factorial randomized controlled trial to evaluate the main and interaction effects of these 2-level interventions in one peri-urban and one urban setting in South Africa. The investigators will randomize adults with HIV who are current smokers into 1 of 16 possible combinations of the four intervention components.||||
34062013|NCT05601297|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062014|NCT02927041|||COHORT||CROSS_SECTIONAL|||||||
34062015|NCT03233204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062016|NCT02567864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34062017|NCT06526078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062018|NCT06494306|||CASE_CONTROL||PROSPECTIVE|||||||
34062019|NCT01826370|||COHORT||PROSPECTIVE|||||||
34062020|NCT03237780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062021|NCT01398410|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062022|NCT06629584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062023|NCT04240964|||CASE_CONTROL||PROSPECTIVE|||||||
34062024|NCT02360202|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34062025|NCT05348031|||CASE_ONLY||RETROSPECTIVE|||||||
34062026|NCT06731764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062027|NCT05688254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated either to the intervention or control groups. The intervention group will use the intervention and the control will take care as usual.||||
34062028|NCT01676818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062029|NCT05704777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessment of the outcomes will be performed by researchers blinded to the group allocation of each participant.||f|t|t|f
34062030|NCT03491631|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34062031|NCT02987569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748373|NCT01919008|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33748374|NCT02271126|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855274|NCT02019927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855275|NCT00599885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855276|NCT00555178|||COHORT||PROSPECTIVE|||||||
33855277|NCT01657955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062032|NCT03541109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062033|NCT06276244|||CASE_ONLY||PROSPECTIVE|||||||
34062034|NCT02400866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958341|NCT03837340|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are two study arms- groups - both consisting of patients with SMI (severe mental illness). One group will be receiving care as usual, which in the actual setting means mostly medical treatment, without home care and assertive treatment through community based outreach teams. Another, intervention group, will be receiving assertive treatment care, with mobile assertive teams, consisting of at least three team members.||||
34062035|NCT00622804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062036|NCT01562249|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34062037|NCT04233671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Interventional Study Model: Parallel Assignment|t|t|f|t
33855278|NCT03587974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Cluster randomized controlled trial|f|f|f|t
33855279|NCT01745848|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33855280|NCT05159869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The third phase of the study will be a pilot randomized controlled trial exploring the design and feasibility of a novel approach to dementia intervention development. Using a two-group randomized, parallel design, 60 persons with dementia will be assigned to treatment (the collaborative creation of a tailored activity plan) or wait-list control. Treatment group participants will receive the activity plan intervention, and will be reassessed at six months from baseline as well as 12 months. There will also be a check-in after three months' time. After four months, wait-list controls will receive the same intervention and will be reassessed at six and 12 months from baseline. This design allows for estimation of effect sizes using a randomized two-group design at four months, confirmation of treatment gains for wait-listed participants from four to 12 months, and evaluation of intervention acceptability for all 60 participants."|f|f|f|t
33855281|NCT06082583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855282|NCT02770573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855283|NCT05540054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855284|NCT06081582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855285|NCT01235104|||COHORT||RETROSPECTIVE|||||||
33855286|NCT03883425|||CASE_CONTROL||PROSPECTIVE|||||||
33855287|NCT00066989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33855288|NCT05960253|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855289|NCT02587468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33958342|NCT05681026|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958343|NCT04427956|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized interventional clinical trial||||
33958344|NCT06626568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958345|NCT06579469|||COHORT||PROSPECTIVE|||||||
33958346|NCT06502730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958347|NCT05531591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062038|NCT04242992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|As the intervention is a behavioral intervention, it will not be possible to blind women to their intervention, but outcome assessors will be blinded.|Women will be randomized 1:1 to either CETA or an active attention control arm.|f|f|f|t
34062039|NCT01855282|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34062040|NCT04060459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062041|NCT03451110|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34062042|NCT04074382|||COHORT||OTHER|||||||
34062043|NCT05029804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Study|t|f|f|f
34062044|NCT05020418|NA|SINGLE_GROUP||PREVENTION||NONE||Cardiac device procedures performed within the national VA healthcare system during the period from Fiscal Year (FY) 16-24 will be identified using a list of relevant Current Procedural Terminology (CPT) codes. Based on our preliminary results, we anticipate that the VA Corporate Data Warehouse (CDW) EP Procedures Cohort (electronic surveillance cohort) will include approximately 100,000 cardiac device cases. Because this cohort is based in CDW, once a Veteran undergoing a device procedure is identified using CPT codes, the orders, procedures, and consults that occurred during the 90-day window following the procedure can be extracted from the VA Electronic Health Record (EHR) In addition to the full cohort, the implementation bundle will be tested at the three high-volume intervention sites (\~1500 cases per year). Roll out of the interventions will occur in a stepped manner, such that pre- and post- intervention data will be collected at all sites.||||
34062045|NCT06432309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomised blinded End-point study|f|f|f|t
34062046|NCT01500213|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34062047|NCT03840551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34062048|NCT06347445|||COHORT||CROSS_SECTIONAL|||||||
34062049|NCT04134520|||COHORT||PROSPECTIVE|||||||
34062050|NCT02160522|||COHORT||PROSPECTIVE|||||||
34062051|NCT00641875|||COHORT||PROSPECTIVE|||||||
34062052|NCT04015518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062053|NCT03871725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062054|NCT05450185|||COHORT||PROSPECTIVE|||||||
34062055|NCT00829816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062056|NCT05037539|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34062057|NCT05622721|||COHORT||PROSPECTIVE|||||||
34062058|NCT03448939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062059|NCT02798120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062060|NCT03910530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062061|NCT01576003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062062|NCT01440569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062063|NCT06078722|||COHORT||PROSPECTIVE|||||||
34062064|NCT01323036|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34062065|NCT01839305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062066|NCT03289806|||CASE_CONTROL||PROSPECTIVE|||||||
34062067|NCT03858894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076068|NCT00218478|||CASE_ONLY||PROSPECTIVE|||||||
34076069|NCT03404986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076070|NCT03890458|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855290|NCT05399043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, parallel, non-randomized prospective quasi-experimental study design||||
33855291|NCT00000837||||PREVENTION||||||||
33855292|NCT06432894|||CASE_ONLY||PROSPECTIVE|||||||
33855293|NCT03063112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33855294|NCT01098565|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34062068|NCT04332731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical staff (Nephrologist and Nurse) will be blinded to which patients are allocated to the randomized treatment and control groups. Only the interventional radiologist will know at the time of the procedure which group the patient has been assigned to. The radiologist will not be involved with patient follow up following the procedure. This way, the clinical follow-up will not be affected by clinician or patient knowledge of specific patient treatment. Unblinding will occur after the six-month follow-up assessment. The patient will be told the type of treatment received and, if they were allocated to the sham arm, will be offered the opportunity to undergo the RDN procedure. The patient treatment allocation will not be revealed until after the patient's six month follow-up period is complete.|Patients will be randomly allocated to one of two arms: 1) renal denervation (treatment group) or 2) sham (control group). The experimental group patients will receive a single treatment with radiofrequency ablation applied bilaterally. Similar to the treatment arm, sham patients will be given general anesthesia. The steps will be similar in the sham arm.|t|t|t|f
34062069|NCT01914354|||CASE_CONTROL|||||||||
33855295|NCT05786989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855296|NCT03589092|||COHORT||CROSS_SECTIONAL|||||||
33855297|NCT05603130|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855298|NCT06284980|||OTHER||PROSPECTIVE|||||||
33855299|NCT06351527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855300|NCT00440258|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33855301|NCT05581667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062070|NCT02811380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34062071|NCT03317457|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment Arm A: Combination of Durvalumab and Tremelimumab Treatment Arm B: Doxorubicin||||
34062072|NCT01923844|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34062073|NCT05268354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062074|NCT05677776|||COHORT||RETROSPECTIVE|||||||
34062075|NCT05135689|||CASE_ONLY||RETROSPECTIVE|||||||
34062076|NCT06539533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062077|NCT01770067|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34062078|NCT04549376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062079|NCT02176083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062080|NCT04833231|||COHORT||PROSPECTIVE|||||||
34062081|NCT03433313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062082|NCT03761225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062083|NCT04150302|||OTHER||OTHER|||||||
34062084|NCT01100216|RANDOMIZED|CROSSOVER||||NONE||||||
34062085|NCT03597828|||COHORT||PROSPECTIVE|||||||
34062086|NCT02248974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34062087|NCT05279768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34062088|NCT03083431|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind Placebo-controlled||t|t|t|t
34062089|NCT02791438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062090|NCT01759836|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062091|NCT05958719|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062092|NCT03488225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062093|NCT05073354|||CASE_ONLY||PROSPECTIVE|||||||
34062094|NCT06730516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group. Nine patients, five in group (1) and four in group (2) were excluded due to poor quality OCTA images or non-compliance). Group (1) included 23 patients (46 eyes) treated with Latanoprost 0.005 % while 24 patients (48 eyes) received treatment with Brimonidin tartrate 0.2% in group (2).|t|t|t|t
34167724|NCT02246595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167725|NCT02254473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167726|NCT04738981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167727|NCT00003464||||TREATMENT||||||||
34167728|NCT05835765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167729|NCT05289063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Active drug and placebo will be made identical in appearance and given to participants in a blinded fashion.|Randomized double blind design|t|t|t|t
34167730|NCT03585478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167731|NCT06081543|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33855302|NCT05511792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Outcomes Assessors all remain unaware of the intervention assignments throughout the trial.||t|f|f|t
34062095|NCT01797159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062096|NCT05502991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062097|NCT05505318|||CASE_ONLY||RETROSPECTIVE|||||||
34062098|NCT03447600|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34062099|NCT05858164|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34062100|NCT01830998|||CASE_CONTROL||PROSPECTIVE|||||||
34062101|NCT05547607|||COHORT||PROSPECTIVE|||||||
34062102|NCT00022880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062103|NCT00367419|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34076071|NCT03414190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34076072|NCT00446017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076073|NCT01817075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34076074|NCT02622243|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34076075|NCT02573259|NON_RANDOMIZED|||TREATMENT||NONE||||||
34076076|NCT04260997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076077|NCT03756948|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167732|NCT05824130|||COHORT||PROSPECTIVE|||||||
34167733|NCT03318588|||CASE_CONTROL||PROSPECTIVE|||||||
34167734|NCT02513121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855303|NCT05782426|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.||||
33855304|NCT03952494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855305|NCT02440230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855306|NCT01030198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33855307|NCT02301598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855308|NCT04271501|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||DOUBLE|Repigmentation will be evaluated via measurement of the area repigmented and will be rated by the patient and a Blinded Evaluator (blinded to treatment allocation) using standardized photographs.|Each subject serves as their own control.|t|f|f|t
33855309|NCT04927117|||CASE_CONTROL||PROSPECTIVE|||||||
33855310|NCT00140309|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33855311|NCT03346161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855312|NCT01730170|||COHORT||PROSPECTIVE|||||||
33855313|NCT06074965|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 1-center, prospective, open label, 2-arm study of ≥16 subjects who use the insulin pumps. These subjects will be using 2 types of infusion sets for two periods of 3 months each type that will serve as an exploratory pilot study to assess the impact of infusion sets on lipohypertrophy||||
33855314|NCT04789278|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33855315|NCT04483245|||COHORT||PROSPECTIVE|||||||
33855316|NCT01046890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855317|NCT06033014|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076078|NCT04784130|RANDOMIZED|PARALLEL||OTHER||NONE||RCT||||
33855318|NCT00500162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33855319|NCT03609684|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33855320|NCT04094025|NA|SINGLE_GROUP||OTHER||NONE||||||
33855321|NCT00799513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855322|NCT00282191|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33855323|NCT04125030|||COHORT||PROSPECTIVE|||||||
33855324|NCT00703898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855325|NCT01852474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855326|NCT04805775|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33855327|NCT00855023|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855328|NCT05293210|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Patients who meet all inclusion criteria and none of the exclusion criteria will be randomized to receive a daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of oral or intravenous dexamethasone 6 mg for 7 more days versus the center's standard treatment which includes the use of oral or intravenous dexamethasone 6 mg for 10 days with escalation to a daily dose of oral or intravenous dexamethasone 20 mg for 3 days if clinical criteria of respiratory distress develop despite treatment with dexamethasone 6 mg daily.~Randomization will be performed in a centralized manner. Randomization will be done directly in the database itself by including the patient in the CRD-e (Redcap). When the investigator registers a patient in the CRD-e, the system will directly assign him/her to which group he/she has been randomized."|"The study consists of 2 phases:~* Hospitalization phase: Day 1 of IC signature to day of hospital discharge. In case of not having completed 10 days of hospitalization since inclusion, patients will have to complete the 10 days of treatment on an outpatient basis. This medication will be provided by the Hospital Pharmacy. In case of discharge, the information will be obtained from the patients in person or by telephone contact, according to their needs, with the patient himself or his caregivers and/or cohabitants.~* Follow-up phase: outpatient visits at 30, 60 and 90 days. The information is obtained from the patients, from the medical records or by telephone contact with the patient himself or his caregivers and/or cohabitants according to availability and need of the patient."||||
33855329|NCT01190982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855330|NCT00200434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855331|NCT03488433|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be randomly assigned to either neutral rotation brace, or antirotation sling following reverse total shoulder arthroplasty. The patients, PI and co-investigators all will be blinded to patient assignments until the day of surgery when an envelope with their assignments are given to surgeon at day of surgery.|Patients undergoing reverse total shoulder arthroplasty or rotator cuff repair will be randomly assigned to two groups of immobilization method groups, namely abduction brace group and antirotation sling group.||||
33855332|NCT04168216|||CASE_ONLY||PROSPECTIVE|||||||
33855333|NCT00622349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855334|NCT02303691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Completer analyses focused on prediction of active ABM outcomes using neural measures. Control arm used for effect size comparisons.|t|f|f|t
33855335|NCT05776212|||CASE_CONTROL||PROSPECTIVE|||||||
33855336|NCT02528383|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33855337|NCT05857631|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label phase II trial investigating the cumulative incidence of late grade ≥2 gastro-intestinal or genito-urinary toxicities in patients receiving adjuvant hypofractionated external beam radiotherapy to the pelvis for post-operative cervical or endometrial cancer.||||
33855338|NCT00078611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855339|NCT02573220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855340|NCT05390411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pragmatic randomized controlled cluster trial|f|f|f|t
33855341|NCT00180323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855342|NCT01535755|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34167735|NCT01671761|||COHORT||PROSPECTIVE|||||||
34167736|NCT06094322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167737|NCT03796637|NA|SINGLE_GROUP||OTHER||NONE||||||
34167738|NCT05269160|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33855343|NCT02877563|||COHORT||PROSPECTIVE|||||||
33855344|NCT05963529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be informed of the study interventions before providing informed consent but will be masked to the order the fixed-condition exposures (i.e., participants will not know whether the humidity is above or below their identified inflection point). Data processing and statistical analysis for the fixed-condition exposures will be performed with the analyst blinded to participant and trial conditions.|"Each participant will complete four trial conditions including one humidity-ramp protocol and three fixed-condition exposures. The humidity ramp protocol will always be completed first. Ambient temperature will remain constant at 42°C. After a 1-hour equilibrium period, relative humidity will be increased by 3% in 10-min increments, from 28% to 70%. The inflection point for core (esophageal) temperature will be subsequently determined.~On three separate days following the humidity ramp protocol, participants will complete three fixed-condition exposures in random order: 1) 42°C with relative humidity \>5% below the estimate compensability limit (below-threshold condition); 2) 42°C with relative humidity \>5% above the estimated compensability limit (above-threshold condition) and 3) 28°C with 35% relative humidity (control condition). Exposure will be terminated early if core temperature exceeds 39.2°C or if the participant requests to withdraw."|t|f|f|t
33855345|NCT04151797|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855346|NCT04698941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855347|NCT00251420|RANDOMIZED|PARALLEL||||NONE||||||
33855348|NCT03386890|||COHORT||PROSPECTIVE|||||||
33855349|NCT06262685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will remain blinded to arm assigned because pharmacogenetic phenotype and statin/dose-guidance will only be exclusively accesible to the attending physician|Phase IV, multicentre, controlled, randomized, parallel and single-blind adaptive clinical trial nested within the iPHARMGx master protocol study|t|f|f|f
33958348|NCT04967989|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are randomized twice: the first, at study entry, to low energy or standard SLT; and the second, at Month 12, to annual or as-needed repeat SLT. There are 2 arms in the first 12 months of the study and 2 different arms in Months 13-48.||||
33958349|NCT06334354|||CASE_CONTROL||PROSPECTIVE|||||||
33958350|NCT00852072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958351|NCT06701201|||COHORT||PROSPECTIVE|||||||
33958352|NCT06702904|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958353|NCT01827072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958354|NCT06384989|||COHORT||PROSPECTIVE|||||||
33958355|NCT05572658|||COHORT||PROSPECTIVE|||||||
33958356|NCT00256217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958357|NCT05596227|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33958358|NCT05408533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33958359|NCT06526390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and surgeons cannot be blinded to the allocated trial arm due to the differing nature of the interventions. However, the radiologists assessing the post-operative imaging (CT scans) will be blinded to the intervention. The postoperative clinical assessment will be performed by investigators who are blinded to the surgical procedures and had not been involved in the surgeries. We will perform blinded statistical analyses, in which the individual performing the analyses in unaware the group belonging. The code for group assignment will not be broken until the analyses and interpretation have been completed.||f|t|t|t
33958360|NCT01713478|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958361|NCT06587100|||COHORT||PROSPECTIVE|||||||
33958362|NCT04011904|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33958363|NCT01898117|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34062104|NCT06030830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention given to the intervention group will be hidden from participants in the control group, and they will not be asked to refrain from using their smartphones for a week. Participants in the control group will be given information about the intervention week after the second lab visit and allowed to undergo the same intervention the following week.|The SMaRT Mom intervention plan will be administered for one week during which mothers will be instructed not using their smartphone while breastfeeding. Before and after the intervention week, two lab sessions will be take place in which mothers in both intervention and control groups will be asked to take a screen shot of their smart digital use of the past week, and will be connected to the electrophysiological monitoring systems to assess their biobehavioral responses during: baseline, the smartphone cue-reactivity task, breastfeeding and face-to-face interaction while using or not using the smartphone. Following the first lab visit, mothers will be instructed to follow the intervention program. The participants will be asked to complete three daily reports of any distractions while breastfeeding. During the intervention week, two remote sessions (20 minutes each) will be performed by a research assistance to support the implementation of the intervention plan.|t|f|f|f
34062105|NCT04047849|RANDOMIZED|PARALLEL||TREATMENT||NONE||The treatment group will include those subjects randomized to the antibiotic arm versus the control arm, no antibiotics. The antibiotic arm will receive a single, 500mg dose of Azithromycin given prior to discharge to home, followed by 250mg daily for 4 more days, and Amoxicillin 500mg orally TID for 7 days (first dose also being given prior to discharge home). Both arms will receive patient pamphlets with study contacts, precautions, and graphs for daily temperature/symptom tracking. Weekly follow up with Maternal-Fetal Medicine, for both arms, will include history and physical exam, vital signs, and ultrasound for fetal well-being and measurement of AFI. Both arms will be re-admitted to the hospital either at 1) viability (23 0/7 weeks) or 2) clinical signs of placental abruption, preterm labor, chorioamnionitis or fetal demise. Re-admission of both arms at viability will include latency antibiotics, neuroprotective magnesium sulfate, and corticosteroids for fetal lung maturity.||||
34062106|NCT06729983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062107|NCT01267084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062108|NCT06697093|||COHORT||PROSPECTIVE|||||||
34062109|NCT01810705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062110|NCT03219086|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The spinal solution will be prepared by an independent anaesthetist, anaesthetist trainee or research nurse on a sterile table after opening the sealed envelope with the appointed study group. The patient, the anaesthetist performing the CSE and the observer are not aware of the local anaesthetic solution administered.|prospective double blind randomised|t|f|t|t
34062111|NCT03922204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062112|NCT06062953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167739|NCT06032910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167740|NCT02619474|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34167741|NCT04104386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators were unfamiliar with who was categorized to which arm, and laboratory technicians were unfamiliar as well.||f|f|t|t
34167742|NCT02552914|||COHORT||PROSPECTIVE|||||||
34167743|NCT01606709|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33855350|NCT00260663|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33855351|NCT00589654|||COHORT||PROSPECTIVE|||||||
33855352|NCT01005433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33855353|NCT00484731|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33855354|NCT05602831|||COHORT||PROSPECTIVE|||||||
33855355|NCT02210234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33855356|NCT06178406|||COHORT||PROSPECTIVE|||||||
33855357|NCT06176677|||CASE_CROSSOVER||PROSPECTIVE|||||||
33855358|NCT02736773|NA|SINGLE_GROUP||OTHER||NONE||||||
33855359|NCT01306097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33855360|NCT05752539|||COHORT||PROSPECTIVE|||||||
33958364|NCT05354206|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"After baseline evaluations of the effect of transcutaneous SCS on single pulse responses, motor function, and a familiarization phase on a body-machine interface, participants will be randomly assigned to one of two arms in the study.~Arm 1: Participants will receive interventions A and B and transcranial magnetic stimulation is used to evaluate the excitability of the corticospinal tract.~Arm 2: Participants will receive interventions A and B and a loud auditory stimuli is used to evaluate the excitability of the reticulospinal tract.~Arms 1 and 2 will run in parallel. Participants will perform interventions A and B in a randomized cross-over design. In both interventions A and B, participants will use their legs to control a computer cursor as transcutaneous spinal cord stimulation is delivered. Intervention A, participants perform a range-of-motion task, while in intervention B, participants perform a precision-control task."||||
33958365|NCT02426294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958366|NCT06694571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33958367|NCT05880485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958368|NCT01211613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958369|NCT06509815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958370|NCT03216798|||COHORT||PROSPECTIVE|||||||
33958371|NCT06314074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33958372|NCT02291172|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33958373|NCT05887674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34062113|NCT05929079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062114|NCT02849067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062115|NCT03693469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855361|NCT03328403|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to use either the Aspiration System or one of the stent-retreivers (Trevo / Solitaire) first. Other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.||||
33855362|NCT02853357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855363|NCT03267160|||COHORT||PROSPECTIVE|||||||
33855364|NCT00421707|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855365|NCT01710332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855366|NCT06207513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855367|NCT02159430|||COHORT||CROSS_SECTIONAL|||||||
33855368|NCT03032393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855369|NCT04977141|||COHORT||PROSPECTIVE|||||||
33855370|NCT03280667|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, multicentre, phase 2 trial||||
33855371|NCT02156128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855372|NCT00122694|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33855373|NCT00160862|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33855374|NCT02042612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855375|NCT02767713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34062116|NCT06676735|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34167744|NCT00498914|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167745|NCT00040443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167746|NCT00372268|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167747|NCT03476135|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167748|NCT00941317|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34167749|NCT01702558|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167750|NCT05703750|||COHORT||RETROSPECTIVE|||||||
34167751|NCT05279287|||COHORT||PROSPECTIVE|||||||
34167752|NCT04725253|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The physician in charge will kept the randomization code, and no rater became aware of treatment allocations until requesting unmasking. Nurses were blinded except those who managed the study medication. All clinical staff, including nurses, physiotherapists or occupational therapist, will blinded. Patient and Family will be blind as well.|This randomized placebo-controlled trial.|t|t|f|f
34167753|NCT02339753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167754|NCT02394535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167755|NCT04001413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167756|NCT03367728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167757|NCT03378817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study, case matched (1:2)||||
34167758|NCT06426953|||OTHER||PROSPECTIVE|||||||
34167759|NCT04946890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167760|NCT02736201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167761|NCT00000346||||TREATMENT||||||||
33958374|NCT03463824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The principal investigators, the statistician, and members of the data collection team will remain blinded to intervention assignment throughout the duration of the study. They will be given the identifying codes only at the end of the study when it is necessary to interpret the results. The un-blinded study coordinator, who is responsible for scheduling testing and treatment sessions, will serve to receive the study patients and escort them to the various testing and treatments sites to minimize the interaction between patients; however, the study coordinator will not participate in the assessments.|Participants will be randomly assigned to one of two intervention arms. Both intervention arms involve immersive video games that encourage participants to produce progressively larger lumbar flexion excursions at each game level and across treatment sessions. The two groups are distinguished by the amount of lumbar flexion needed to achieve game objectives.|t|t|t|t
33958375|NCT02407405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958376|NCT05270512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958377|NCT00630994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958378|NCT01556646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958379|NCT01970696|||OTHER||OTHER|||||||
33958380|NCT02733861|||COHORT||PROSPECTIVE|||||||
33958381|NCT04629300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34062117|NCT04159168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An assessment-naïve independent evaluator not involved in intervention implementation will function will provide Clinical Global Impression (CGI) evaluations.|"This study utilizes a randomized controlled trial design to test whether a new neurocognitive intervention (Facial Affect Sensitivity Training: FAST) can improve facial affect sensitivity (FAS) in children with elevated CU traits. In FAST, which uses exogenous incentives to train FAS, a series of emotional facial expressions are presented on a computer monitor. Child participants are instructed to look at the eyes of the emotional expressions they view, and must select from a list of emotions the one that matches the facial expression they saw on each trial, which results in reinforcement of correct responses via auditory reward tone. Correct responses also earn points toward incrementally priced small toys given at the end of each session. The objective is to make appropriate eye gaze more automatic during FER (thus improving facial affect sensitivity) by repeatedly pairing correct responses with a reward."|f|f|f|t
34062118|NCT05904119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062119|NCT00514787|||CASE_ONLY||PROSPECTIVE|||||||
34062120|NCT02804906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34062121|NCT02303990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062122|NCT06194292|||COHORT||RETROSPECTIVE|||||||
34062123|NCT03337035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|this study will be double blinded for both participants/guardians and medication administrator|Phase 1: a. oral placebo, and b. oral probiotics; Phase 2: a. intranasal OXT + oral placebo, and b. intranasal OXT + oral probiotics|t|t|t|f
34062124|NCT00237250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062125|NCT01889355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062126|NCT05580328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062127|NCT06680076|||CASE_CONTROL||PROSPECTIVE|||||||
33855376|NCT03268122|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Multiple-crossover, cluster-randomized, controlled trial|f|f|f|t
33855377|NCT01377051|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855378|NCT00790608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855379|NCT04819984|NA|SINGLE_GROUP||PREVENTION||NONE|The measured values of continuous PtC02 will not be disclosed to care provider or participant during the ventilatory weaning test|All patients meeting the inclusion criteria will be included in the trial||||
33855380|NCT01544829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33855381|NCT04771468|||COHORT||PROSPECTIVE|||||||
33855382|NCT03718533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855383|NCT01720745|||COHORT||PROSPECTIVE|||||||
33855384|NCT02271477|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33855385|NCT03439176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33855386|NCT01988623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855387|NCT05634525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855388|NCT05029479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855389|NCT04292678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33855390|NCT03054896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855391|NCT01166321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855392|NCT03194100|||CASE_CONTROL||PROSPECTIVE|||||||
33748375|NCT05525494|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Pragmatic comparative effectiveness trial with a standard-of-care control group|t|f|f|f
33748376|NCT04233268|||COHORT||PROSPECTIVE|||||||
33748377|NCT02167074|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33748378|NCT06653439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Researchers, surgeons and nurses, and those involved in study outcome analysis will not be aware of the randomization of the group. Block quality and standardization will be performed by an anesthetist experienced in regional anesthesia for S-QLB block.|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program.|f|t|t|t
33748379|NCT06635213|RANDOMIZED|PARALLEL||OTHER||DOUBLE||After determining the predominant pain phenotype in patients with CTS, patients with mixed type (neuropathic and nosiplastic pain phenotype) will be randomly divided into two groups. One group (Group 1) will receive desensitisation and the other group (Group 2) will receive desensitisation and pain neuroscience education.|t|f|f|t
33748380|NCT06490484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748381|NCT00700401|||COHORT||PROSPECTIVE|||||||
34062128|NCT05942924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Centres will be randomised for the fortnight at which they will switch their tactile stimulation practice from selective stimulation to repetitive stimulation. The analysing researcher will be blinded for the allocation of treatment switch.|This is a stepped-wedge cluster randomised controlled trial. The participating centre, rather than the individual infant, will be the unit of randomisation.|f|f|f|t
33748382|NCT00113568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748383|NCT02774057|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748384|NCT05426551|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748385|NCT01275573|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33748386|NCT00101855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33748387|NCT06669390|NA|SINGLE_GROUP||PREVENTION||NONE||This is an unblinded, single-arm study||||
33748388|NCT05637606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial intervention is not blinded for investigators, clinical staff, and patients, as blinding intraoperative MAP target is not feasible. The physicians of each center assessing all postoperative outcomes will be masked for the allocation.|"The study will be a multicentric, randomized, non-blinded clinical trial. Eligible patients will be assigned in a 1:1 ratio to either a to control or treatment group. Randomization list will be created by a computer with the use of a permuted block design and embedded in the Electronic Case Report Form. Randomization will be performed using a 'block of 6 and stratified according to predefined baseline characteristics:~1. Age ≥ 75 years~2. Preoperative systolic pressure~   1. \< 140 mmHg~  2. ≥ 140 mmHg"|f|f|f|t
33748389|NCT01398488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748390|NCT01882322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748391|NCT02057146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748392|NCT02239679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748393|NCT06633263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In condition 1 : CBT-I precede BATD In condition 2 : BATD precede CBT-I Condition 1 is starting in Novembre Condition 2 is starting in February||||
33748394|NCT03057795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748395|NCT06284876|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748396|NCT04520984|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748397|NCT01898338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748398|NCT02959073|||CASE_ONLY||PROSPECTIVE|||||||
33748399|NCT01043666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748400|NCT03986853|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33748401|NCT01128413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062129|NCT02707406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062130|NCT03563664|NA|SINGLE_GROUP||TREATMENT||NONE||38 ovulatory patients with unexplained recurrent implantation failure were recruited. Endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was compared before and after treatment with danazol.||||
34062131|NCT04541602|||CASE_CONTROL||PROSPECTIVE|||||||
34062132|NCT05861102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062133|NCT02454374|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062134|NCT04895995|RANDOMIZED|PARALLEL||TREATMENT||NONE||The allocation scheme below refers to Phase 2.||||
34062135|NCT00950560|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062136|NCT06368882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062137|NCT00003734|RANDOMIZED|||TREATMENT||||||||
34062138|NCT04020081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062139|NCT05143216|||CASE_CONTROL||PROSPECTIVE|||||||
34062140|NCT06372418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Fieldworkers collecting endpoint data at 6 months of age will be blinded to group allocation to avoid any bias subject to knowledge of group allocation.|"Randomized Control Trial:~Participants will be randomized to either receive Breastfeeding support intervention (BFSI) or standard of care."|f|f|f|t
33958382|NCT06703736|||CASE_CONTROL||PROSPECTIVE|||||||
33958383|NCT06704035|RANDOMIZED|PARALLEL||SCREENING||NONE||"Classic two parallel arm study in a 1:1 ratio. Participants will be assigned at random using a computerised database to either an experimental group (early OGTT Results Revealed), or a control group (early OGTT Results Concealed). The investigators, healthcare providers and participants will know which study arm they are allocated to, but the early OGTT results will only be made known for the OGTT Results Revealed group."||||
33958384|NCT04377516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167762|NCT03847766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The randomization will be done by the AmbuFlex-system (a generic on-line system for self-recorded patient reported outcomes) as a part of the inclusion process.~Patients in the intervention arms will receive diagnosis specific questionnaires through a safe internet connection every third month. The responses are seen by the clinicians in the Electronic Health Record.~Patients will receive 2 reminders if they do not answer the questionnaires and clinicians will call the patient"||||
33958385|NCT04974593|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|Results from H2 and CH4 excretion, as well as symptom scores during the breath test will remain unknown to the participants and the study personnel until the end of the study to guarantee study blinding. However, because of the imbalance in the proportion of lactose H2BT-positive vs. -negative subjects, results of the H2BT will be analyzed by a trained physician with no contact with study subjects or investigators in order to guarantee that sufficient subjects are recruited in both groups.||t|t|t|f
33958386|NCT06501989|NA|SINGLE_GROUP||TREATMENT||NONE||Each cycle of chemotherapy is 2 weeks long, so you will be receiving treatment on the study for a total of 8 weeks. You will also need additional imaging (CT scans) after you complete the first four cycles of chemotherapy, which brings your total time in the study to about 3 months including treatment and follow-up.||||
33958387|NCT02552394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958388|NCT02981667|||CASE_CROSSOVER||PROSPECTIVE|||||||
33958389|NCT01176578|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958390|NCT06192264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958391|NCT04652635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|6 month appearance will be assessed by a blinded individual||f|f|f|t
33958392|NCT05188807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958393|NCT06680089|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958394|NCT02856282|||CASE_ONLY||RETROSPECTIVE|||||||
33958395|NCT04921189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958396|NCT05697835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study staff responsible for administering ratings and collecting outcomes throughout the study are blinded. The investigator(s) are also blinded. This blinding is kept throughout the study until data collection is complete. At the end of the follow-up, the study coordinator will complete a blinding question to try to guess the arm to which each participant was allocated.|Hybrid Type 1 effectiveness-implementation randomized controlled trial design|f|f|t|t
33958397|NCT06703658|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34062141|NCT00556738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062142|NCT05075993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062143|NCT02904551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34062144|NCT05903313|||CASE_CONTROL||RETROSPECTIVE|||||||
34062145|NCT00717275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062146|NCT05693545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167763|NCT01957878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167764|NCT03101254|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167765|NCT03491826|||COHORT||RETROSPECTIVE|||||||
34167766|NCT00657644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167767|NCT06142539|||OTHER||PROSPECTIVE|||||||
34167768|NCT06427408|||COHORT||PROSPECTIVE|||||||
34167769|NCT00828971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167770|NCT02864693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167771|NCT01094678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167772|NCT04459689|||CASE_ONLY||PROSPECTIVE|||||||
34167773|NCT00443417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167774|NCT02096016|||COHORT||PROSPECTIVE|||||||
34167775|NCT00738907|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748402|NCT03437005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Investigator and subject will be blinded.|The patient will be randomized to one of two groups, with one group receiving ketoconazole cream and the other receiving desonide ointment.|t|f|t|f
34062147|NCT04947995|||CASE_CONTROL||PROSPECTIVE|||||||
34062148|NCT03438526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062149|NCT02298413|||COHORT||PROSPECTIVE|||||||
34062150|NCT03193658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized controlled double blinded study|t|t|t|t
34062151|NCT01399970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34167776|NCT01916382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167777|NCT06008392|||COHORT||PROSPECTIVE|||||||
34167778|NCT03526744|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||A simple open step-up design will be employed with no placebo control, but the sequence will be randomized. Both participant and investigator are blinded for the dose.|t|f|t|f
34167779|NCT00764361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167780|NCT00031473|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34167781|NCT06262308|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a pilot study where a small cohort of women will give given personalised psychological intervention||||
34167782|NCT05230628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Model: 1:1 randomization of active stimulation vs. no stimulation for 6 months post randomization.|t|t|t|f
34167783|NCT06122623|NA|SINGLE_GROUP||OTHER||NONE||||||
34062152|NCT00240825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855393|NCT02334774|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-and post- intervention||||
33855394|NCT01616056|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855395|NCT01704924|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958398|NCT04650984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958399|NCT06220513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|- Patients will be allocated in two groups using computer-generated table by a person who has access to the computer-generated table but is not involved in data collection or patient management perioperatively. BLock will be given by Anesthesiologist who is not involved in the study.Data collection will be carried out by a person who is completely blinded to the randomization. The person who analyzed the data statistically will not be involved in randomization or data collection.|: a double -blinded randomized clinical study.|t|t|f|t
33958400|NCT04537052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958401|NCT00029042||||TREATMENT||||||||
33958402|NCT00987571|||CASE_CONTROL||PROSPECTIVE|||||||
33958403|NCT00410839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748403|NCT00534196|||COHORT||PROSPECTIVE|||||||
33748404|NCT05308173|||COHORT||RETROSPECTIVE|||||||
33748405|NCT03797768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33748406|NCT05845229|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33855396|NCT04690179|||COHORT||RETROSPECTIVE|||||||
33855397|NCT04018235|||COHORT||CROSS_SECTIONAL|||||||
33855398|NCT00666809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855399|NCT06042010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855400|NCT05365477|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855401|NCT04333927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855402|NCT00947739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855403|NCT02640157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958404|NCT05395702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958405|NCT02143401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958406|NCT06701136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062153|NCT04395274|||COHORT||PROSPECTIVE|||||||
34062154|NCT05792995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062155|NCT00623051|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34062156|NCT05264519|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34062157|NCT01805973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34062158|NCT01606202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062159|NCT06730295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062160|NCT02340312|||COHORT||PROSPECTIVE|||||||
34062161|NCT03242642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062162|NCT03241537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062163|NCT03862768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062164|NCT04666844|||COHORT||PROSPECTIVE|||||||
34062165|NCT06505083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||"This prospective randomized controlled trial design was conducted in thirty-two community-dwelling older participants who completed a modified stepping exercises program for 50 minutes/day, three days/week over six weeks. They were assessed for their functional mobility relating to levels of independence and prospectively followed up periods one month.~RESULTS: The participants in our study demonstrated significant improvements in their functional mobility after within 4 weeks of training, and these improvements continued to increase by week 6 (p\<0.01). Notably, the participants showed significant improvements in all functional outcomes at week 4, week 6, and one-month follow-up (p\<0.05). The most significant improvements were observed in the FTSST, TUGT, and lower limb muscle strength, and these outcomes were significantly different from the pre-test and intermediate tests (p\<0.01)."|t|f|f|t
34062166|NCT00410059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062167|NCT06608693|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34062168|NCT06523439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Raters will be blinded as to whether the adolescent participants received Standard SAINT® (10 TMS treatments per day for 5 days) or Truncated SAINT® (5 TMS treatments per day for 5 days).|Single-blinded|f|f|f|t
34062169|NCT01541670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062170|NCT04312282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062171|NCT02322450|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34062172|NCT03933020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062173|NCT06238713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062174|NCT06167642|||COHORT||PROSPECTIVE|||||||
34062175|NCT02858180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062176|NCT06731322|||CASE_CONTROL||PROSPECTIVE|||||||
34062177|NCT03099772|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial||||
34062178|NCT00001863||||TREATMENT||||||||
34062179|NCT06344325|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34062180|NCT03697564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062181|NCT04103957|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062182|NCT02613715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34062183|NCT04263636|||COHORT||PROSPECTIVE|||||||
34062184|NCT01281267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062185|NCT05621304|||COHORT||PROSPECTIVE|||||||
34062186|NCT03327961|||COHORT||PROSPECTIVE|||||||
34062187|NCT05892016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. spontaneous healing (control) Alveolar ridge preservation grafted with bone particle and~2. covered with a free palatal graft~3. covered with pedical palatal graft~4. covered with a collagen membrane~5. covered with a non-resorbable high-density polytetrafluoroethylene membrane."|t|f|f|t
34062188|NCT03811210|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34062189|NCT02397291|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062190|NCT00619164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062191|NCT00051441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855404|NCT03127254|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855405|NCT04773496|||COHORT||PROSPECTIVE|||||||
33855406|NCT01146054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855407|NCT05350579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855408|NCT03726710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062192|NCT05848596|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||"Preliminary information will be given to the experimental group before the application of the simulation. After the preliminary information, training will be given to the experimental group. In addition, how to provide hand washing will be shown with a demonstration method. After the training, the simulation application will be carried out. After the simulation application is completed, the attendants will be asked to make their self-evaluations. Then, a second feedback will be given by the trainer and the analysis session will be terminated. A handwashing brochure will be provided after the study data has been collected.~No intervention will be applied to the control group after the pre-test. A handwashing brochure will be provided after the study data has been collected."|f|f|t|t
34062193|NCT02888353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062194|NCT00287677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062195|NCT04769505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34062196|NCT06730971|||COHORT||PROSPECTIVE|||||||
34062197|NCT04477733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062198|NCT05079776|||COHORT||PROSPECTIVE|||||||
34062199|NCT05815485|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Azeliragon and placebo will be dispensed and labeled by the unblinded research pharmacist at each site in a blinded manner that will not reveal if the product dispensed is active or placebo.||t|t|t|t
34062200|NCT04786249|||COHORT||RETROSPECTIVE|||||||
34062201|NCT05155449|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076640|NCT05965596|RANDOMIZED|PARALLEL||PREVENTION||NONE||a randomly selected sample of gynecological cancer women attending the study setting, fulfilling the inclusion criteria and consented to participate in the study will be recruited into the study sample. Then they will be randomly assigned into either the intervention group or the control group using computer-generated random codes in serially numbered opaque sealed envelopes. Creation and concealment of the allocation sequence will be done by the supervisor. While the researcher will enroll the participants, assess eligibility, discuss the trial, obtain consent, ascertain intervention assignment (such as opening next envelope) and carry out the intervention. Participants in the intervention group will receive a psycho educational intervention program and those in the control group will receive the routine care provided for all gynecological cancer patients in the study setting.||||
33748407|NCT01702753|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748408|NCT02235948|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33748409|NCT03193164|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The blood samples will be mask analyses|This study will be randomized crossover clinical trial.|f|f|t|f
33855409|NCT06018181|||COHORT||PROSPECTIVE|||||||
33855410|NCT02336750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855411|NCT03322787|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33855412|NCT05768633|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748410|NCT03081845|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33855413|NCT05992402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855414|NCT05003960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855415|NCT00952172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855416|NCT03068663|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"2 groups of patients will be follow :~* Pchir : Non small cell lung carcinoma patients with an indication of immediate surgery.~* Pct-chir : Non small cell lung carcinoma patients with an indication of neoadjuvant chemotherapy before the surgery."||||
33855417|NCT03170154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855418|NCT02245672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855419|NCT01493011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855420|NCT02774161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855421|NCT03467503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33958407|NCT06103864|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised either 1:1 to Arm 1 (Dato-DXd + durvalumab) and Arm 2 (ICC + pembrolizumab), or in selected countries, 1:1:1 to Arms 1, 2 and 3 (Dato-DXd monotherapy). Once approximately 75 participants are randomised to Arm 3, this cohort will close, and all countries will continue with a 1:1 randomisation strategy for Arms 1 and 2.||||
33958408|NCT06043518|||CASE_CONTROL||PROSPECTIVE|||||||
33958409|NCT03694483|||COHORT||PROSPECTIVE|||||||
33748411|NCT02246517|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33748412|NCT03491644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study will be an open-label randomized clinical trial with regards to treatment: treating staff will be aware of the patient's randomization group.~Outcome assessors (attending anesthesiologist for pneumonia and research assistant for long term outcomes (GOSE after 30 days, ARDS\* within 30 days, pneumonia diagnosed after discharge within 30 days)) will be blinded to the patients' randomization.~To ensure blinding, prior to assessing the outcomes, all information indicative of the allocation will be censured by the PI.~To validate the blinding, the attending anesthesiologist and research assistant assessing outcome variables will be asked to guess which group of randomization the patient is in.~ARDS: PaO2/FiO2 will be calculated for the assessor in order to maintain blinding."|"Intervention: restrictive oxygen treatment for the first 24 hours. This implies administration of the lowest dosage of oxygen possible in order to achieve a saturation of 94%, using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing. A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.~Control: liberal oxygen treatment for the first 24 hours. In the trauma bay and during intrahospital transportation this implies an FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the OR, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."|f|f|f|t
33748413|NCT01871038|||CASE_CONTROL||PROSPECTIVE|||||||
33748414|NCT03378167|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"COLONOSCOPY:~1. Microbial enemas are drawn up in a 500cc syringe that is concealed with an opaque bag, used to infuse contents through the colonoscope. This will insure contents are blinded to non-study personnel in the room~2. Patients randomized to the control study arm will have identical concealment of the 500cc syringe used to infuse contents through the colonoscope. For the NS infusion, study personnel will add an additional 0.75 ml of commercially available (Club House® brand), food-grade food coloring (2 drops red, 3 drops green, 7 drops yellow) to confer a brown color to the clear normal saline solution. This step will maintain blinding for the patient and non-study personnel in the room, as the contents of the liquid will be visible endoscopically, but will still retain a similarly-colored brown appearance akin to human stool.~ORAL CAPSULAR THERAPY:~a), b) The opaque color of both the OMC and OPC will insure that blinding is preserved to the study patient."|"Patients will be randomized 2:1 to one of two groups upon consent: intervention or control. 30 patients will be randomized to receive an FMT via colonoscopy + oral microbiota capsular (OMC) therapy (INTERVENTION), and 15 patients will be randomized to receive normal saline (NS) via colonoscopy + dextrose-containing oral capsules (oral placebo capsule, OPC) (CONTROL). Randomization will occur through a computer-generated block-randomization pattern (block size = 6 participants).~Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."|t|t|f|t
33958410|NCT03425786|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33958411|NCT06650800|NA|SINGLE_GROUP||OTHER||NONE||||||
33958412|NCT05388136|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958413|NCT01766141|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958414|NCT04532489|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958415|NCT05982158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors involved in completing the assessments will be masked to treatment condition. Due to the type of intervention, it will not be possible to blind therapists delivering the interventions to participant's treatment condition. Clinicians providing routine care will also be aware of the condition. Participants will be instructed not to discuss treatment with their outcomes assessor. When an interview leads to unblinding, the outcomes assessor will be replaced.|AMETHYST is a pragmatic, parallel group, randomised controlled superiority trial, comparing avatar therapy to CBT for persisting AVHs, with the primary outcome of post-intervention hallucination severity. In both arms, therapy will be delivered within a three-month period, with assessor-blinded assessments completed at baseline, post-intervention (3 months), and follow-ups (6 months and 9 months).|f|f|f|t
33958416|NCT06320080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958417|NCT02998710|||CASE_ONLY||PROSPECTIVE|||||||
33958418|NCT03080402|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||24 female athletes (12 with high KAM; 12 with normal KAM) will be recruited into the intervention/ testing phase of this study. Female athletes with KAM \> 25.25 Nm will be classified as high KAM and will receive 12 sessions of mechanically-driven perturbation training and female athletes with KAM \< 25.25 Nm will be classified as normal KAM and only participate in baseline performance testing, followed 6 weeks later by another session of drop jump motion analysis and performance testing.||||
33958419|NCT03430037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958420|NCT02416167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958421|NCT06696066|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958422|NCT05729711|||COHORT||PROSPECTIVE|||||||
33958423|NCT03325062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are only informed that they will participate in one of two post-operative rehabilitation programs (without specific details). Outcome assessors are also blinded to group assignment.||t|f|f|t
34076641|NCT01655225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076642|NCT05528172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076643|NCT00613821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34076644|NCT05562245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was planned in a randomized controlled experimental design to evaluate the effect of motivational interviewing-based breastfeeding education on breastfeeding motivation, breastfeeding success and breastfeeding self-efficacy perception of primiparous mothers after cesarean section.|f|f|f|t
33855422|NCT01386788|||COHORT||PROSPECTIVE|||||||
33855423|NCT05901662|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33958424|NCT04983823|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Outcomes assessor will receive study data based on pooled de identified dataset.|Randomization to CC-DMP or usual care|f|f|f|t
34062202|NCT05255250|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participants: While the families will not be told explicitly if they have been assigned to the intervention or control group, they may be able to determine their group based on when their workshop is scheduled (i.e., immediately versus after completion of all study measures).~Research Coordinator: The research coordinator will be aware of the group allocations as they will be in charge of coordinating random assignment and have to schedule participants into workshops and other measures based on their specific allocation.~Outcomes Assessors: Research assistants who score children's fundamental movement skills based on recorded videos will not be told explicitly if a participant is part of the intervention or control group. Though there is a possibility that they may recall group assignment from previous data collection sessions they led."|All participants will complete baseline measures and then be randomly assigned to group 1 (intervention) or group 2 (control), in a computer generated1:1 sequence.|t|f|f|f
33958425|NCT06700603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort 1: Patients with imaging-confirmed progression during or within 3 months of completion of irinotecan treatment Cohort 2: Patients with imaging-proven disease progression 3 months after completion of irinotecan treatment||||
33855424|NCT01133951|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855425|NCT04242563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062203|NCT04970472|||COHORT||PROSPECTIVE|||||||
34062204|NCT04407416|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33855426|NCT02841930|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855427|NCT00495287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062205|NCT03827902|||CASE_CONTROL||PROSPECTIVE|||||||
34062206|NCT05843201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062207|NCT02073318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062208|NCT03890614|||COHORT||PROSPECTIVE|||||||
33855428|NCT03731507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062209|NCT00962936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062210|NCT04930614|||OTHER||CROSS_SECTIONAL|||||||
34062211|NCT05242133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062212|NCT00957749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062213|NCT01963650|||COHORT||PROSPECTIVE|||||||
33855429|NCT02370082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855430|NCT04875676|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33855431|NCT02688959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958426|NCT06283069|||OTHER||OTHER|||||||
33958427|NCT04651582|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33958428|NCT01588678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958429|NCT03784612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34062214|NCT04756128|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This will be a four arm, prospective, randomized, open label trial in patients hospitalized with moderate COVID-19. Randomization will be stratified by baseline severity score (2 or 3) to ensure balanced baseline severities between the four arms. Block randomization will be used to ensure equal group sizes. As the final sample size is unknown, study staff will use small blocks of eight for randomization. This is being done in an effort to ensure evenly distributed treatment arms.||||
34062215|NCT02261324|||COHORT||PROSPECTIVE|||||||
34062216|NCT00169624|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34062217|NCT05659069|||CASE_ONLY||PROSPECTIVE|||||||
34062218|NCT05842564|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34062219|NCT03027206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062220|NCT04982172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062221|NCT03704116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|Two groups run in parallel (active and control)|t|f|f|t
34062222|NCT06523543|||COHORT||PROSPECTIVE|||||||
33855432|NCT00629330|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33855433|NCT03730636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855434|NCT04708756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855435|NCT03742167|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Live and video raters of paramedic performance are blinded to group allocation.||f|f|f|t
33855436|NCT01079130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855437|NCT02727465|||COHORT||OTHER|||||||
33855438|NCT04789512|||CASE_CONTROL||PROSPECTIVE|||||||
33855439|NCT02875093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855440|NCT04851340|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33855441|NCT01516593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855442|NCT05392153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958430|NCT03797339|||COHORT||PROSPECTIVE|||||||
33748415|NCT05088928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958431|NCT05965401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, their prescribing physician, and the investigator will all be blinded to study arm. The study coordinator will be the only one unblinded to study arm allocation.|This is a parallel arm randomized controlled trial.|t|t|t|t
33958432|NCT06702085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167784|NCT02318563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167785|NCT04924985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167786|NCT05616923|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Allocation of drug to cheek side for each bottle set is known only to an investigator not involved in patient assessment and will be unmasked only at the end of the trial.|"Each patient will receive two creams labeled right cheek or left cheek, one containing the active ingredient and the other serving as vehicle control. The labels of each bottle were randomized and the contents of each remains blinded to both the subject and the investigator."|t|t|t|t
34167787|NCT02136966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167788|NCT01365728|||CASE_CONTROL||PROSPECTIVE|||||||
34167789|NCT03254199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33855443|NCT03497754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167790|NCT00596986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34167791|NCT06346834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855444|NCT04270630|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855445|NCT02066428|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33855446|NCT02641600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855447|NCT00602394|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855448|NCT03818685|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is an open-label, randomised, multicentric, comparative, Phase II study||||
33855449|NCT04223869|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855450|NCT05831930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855451|NCT04756388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be informed that they will be randomized to one of three types of cognitive training, however, will have no idea what the conditions or the hypotheses. Outcome assessors will be blind to condition.|Participants will be randomized to receive Computerized Cognitive Training only, Strategy Development only, or both (Executive Functioning Training; ET).|t|f|f|t
33855452|NCT01816854|||CASE_ONLY||PROSPECTIVE|||||||
33855453|NCT05418023|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33855454|NCT01720173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855455|NCT05407922|||COHORT||PROSPECTIVE|||||||
33855456|NCT03171077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855457|NCT00168974|||||PROSPECTIVE|||||||
33855458|NCT00888446|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958433|NCT03259867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||One arm for advanced HCC, and one for second line metastatic gastro-esophageal cancer . All enrolled patients will receive the same treatment with TATE and a PD-1 inhibitor (nivolumab) until disease progression||||
33958434|NCT05808894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062223|NCT05674318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34167792|NCT06400914|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34167793|NCT06474078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167794|NCT06273150|||COHORT||PROSPECTIVE|||||||
34167795|NCT02537249|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34167796|NCT00067886|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34167797|NCT00102765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062224|NCT00310466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855459|NCT03695666|||OTHER||RETROSPECTIVE|||||||
33855460|NCT04010825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33855461|NCT05830838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855462|NCT04929548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855463|NCT05916118|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855464|NCT02925637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855465|NCT00295594|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855466|NCT06109974|||COHORT||PROSPECTIVE|||||||
33855467|NCT03904355|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33855468|NCT00927160|||COHORT||PROSPECTIVE|||||||
34167798|NCT03680820|||COHORT||PROSPECTIVE|||||||
34167799|NCT00485017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167800|NCT02966808|||COHORT||RETROSPECTIVE|||||||
34167801|NCT02763839|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34167802|NCT02599363|NA|SEQUENTIAL||TREATMENT||NONE||||||
34167803|NCT04075344|RANDOMIZED|PARALLEL||OTHER||SINGLE|This study is single-blinded research, wherein the outcome assessors will be blinded to the assignment of the intervention or control groups.|Cluster randomized control trials|f|f|f|t
34167804|NCT03992352|||COHORT||PROSPECTIVE|||||||
34167805|NCT05402514|||COHORT||RETROSPECTIVE|||||||
34167806|NCT04537793|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33855469|NCT04704011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855470|NCT04686526|||COHORT||PROSPECTIVE|||||||
33855471|NCT04751656|NA|SINGLE_GROUP||OTHER||NONE||Single-arm trial||||
33748416|NCT04694274|||CASE_CONTROL||PROSPECTIVE|||||||
33748417|NCT01063400|||COHORT||PROSPECTIVE|||||||
33748418|NCT05551949|NA|SINGLE_GROUP||PREVENTION||NONE||Open label, single group clinical trial||||
33748419|NCT05157191|||COHORT||PROSPECTIVE|||||||
33748420|NCT05973526|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33748421|NCT02930239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748422|NCT00236548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748423|NCT01087853|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33748424|NCT03901066|||COHORT||CROSS_SECTIONAL|||||||
33748425|NCT05538624|NA|SEQUENTIAL||TREATMENT||NONE|Not applicable in this open-label trial.|In this two-part study, Part 1 is the Dose Escalation Phase; Part 2 is the Dose Expansion Phase.||||
33855472|NCT00567710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855473|NCT03556241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855474|NCT00061451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855475|NCT05337852|RANDOMIZED|PARALLEL||PREVENTION||NONE||The randomized experiment was designed as a control study.||||
33855476|NCT00015041||||TREATMENT||||||||
33855477|NCT00972452|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33855478|NCT06324565|||OTHER||CROSS_SECTIONAL|||||||
33855479|NCT05874115|||COHORT||PROSPECTIVE|||||||
33855480|NCT00709696|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33958435|NCT05758246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will initially be equally randomized between placebo, 20 mg/kg (once), and 20 mg/kg (once daily for 2 days). After 60 participants have been enrolled, the randomization ratio will be adapted so that a higher proportion of participants will be randomized to the optimal dosing regimen. The proportion randomized to the control will be held constant throughout the trial.|t|f|t|t
33958436|NCT03060252|||COHORT||PROSPECTIVE|||||||
33958437|NCT02690532|||CASE_CONTROL||PROSPECTIVE|||||||
33958438|NCT03287141|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33958439|NCT06274385|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33958440|NCT04843332|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||This will be a parallel two-arm randomized controlled trial with the following two arms: (1) usual oncology care or (2) usual oncology care + supplemental community health worker intervention. All participants who consent to the study will be randomized 1:1 into the usual oncology care arm versus the intervention arm. Patients randomized into the intervention arm will be assigned a community health worker who will begin the intervention. Each arm will include 55 participants (total for the study n=110).|f|t|t|t
34062225|NCT02920177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062226|NCT00659542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062227|NCT01785849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062228|NCT03046992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062229|NCT05071716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34062230|NCT04633239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062231|NCT03146871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167807|NCT01693549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167808|NCT05661344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167809|NCT03586713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Screening of patients that come to the conservative dentistry department seeking dental care will continue until the target population is achieved. The patients' teeth will be subjected to visual examination and diagnosis using dental charts. Once the patients that are potentially eligible for this study are identified, they will be contacted by the research investigator who will explain the study and ascertains the patient's interest. If interested, more detailed evaluations and preparations are made||||
34167810|NCT01207258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34167811|NCT01450501|||COHORT||PROSPECTIVE|||||||
34167812|NCT05612308|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|There were two groups; Vertical Oscillatory and Sustained Natural Apophyseal group. Participants were allocated to each group randomly. Each group received intervention accordingly||||
34167813|NCT01794000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167814|NCT01204177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167815|NCT05555875|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||2x2 factorial trial with micro-randomization in automated motivational messaging arms||||
34167816|NCT03669367|RANDOMIZED|PARALLEL||TREATMENT||NONE||National multi-center study, open, controlled and randomized||||
34167817|NCT03189537|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34167818|NCT01182155|||COHORT||PROSPECTIVE|||||||
33748426|NCT04099810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748427|NCT05003089|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind for BAY1834845, BAY1830839 and placebo (participant and investigator) with unblinded active control (prednisolone), rater-blinded for skin reaction assessments (all 4 study interventions).||t|t|t|t
33748428|NCT03776981|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748429|NCT01937676|||COHORT||PROSPECTIVE|||||||
33748430|NCT04290026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748431|NCT01632605|NA|SINGLE_GROUP||||NONE||||||
33855481|NCT03211910|RANDOMIZED|PARALLEL||PREVENTION||NONE||Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's • Intervention:: medical device: Bubble wrap mattress has been successful in enhancing wound healing. Wound healing is greater than 20% healing within two weeks documented by measurement of the wound bed or wound healing to less than the dermal layer documented by photography and agreement of healing between research associate and physician . The bubble wrap mattress will be place underneath the participant. Follow-up will occur weekly for 6 weeks.||||
33855482|NCT00258063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855483|NCT04621591|NA|SINGLE_GROUP||OTHER||NONE||||||
33855484|NCT00945126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855485|NCT00609765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062232|NCT04775550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062233|NCT06520514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062234|NCT06511362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062235|NCT05654090|RANDOMIZED|CROSSOVER||OTHER||NONE||An open-label, randomized, balanced, two-treatment, two-period, twosequence, single dose, two-way crossover study||||
34167819|NCT00176774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855486|NCT03924739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34062236|NCT02444975|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062237|NCT05155722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062238|NCT02379273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167820|NCT01906333|RANDOMIZED|CROSSOVER||||NONE||||||
34167821|NCT01473290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34167822|NCT05033119|||OTHER||CROSS_SECTIONAL|||||||
34062239|NCT01076751|||COHORT||PROSPECTIVE|||||||
34167823|NCT02602093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855487|NCT06249373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855488|NCT04589208|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE|"The study will be subject and rater blind, i.e. subjects and raters, will be blinded to the treatment (ketamine dose) group.~The study physician will be aware of the ketamine dose, and ketamine dose will be the same for both sessions.~Subjects will not be told what the exact ketamine dose they will receive, but it will be based on their weight and will be no higher than 0.08 mg/kg."|Single blind (rater, participant will be unaware of dose). Subjects will be assigned ketamine doses in 10 subject cohorts||||
33855489|NCT05331963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855490|NCT00675090|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34062240|NCT00901784|RANDOMIZED|CROSSOVER||||NONE||||||
34167824|NCT04337424|||CASE_CONTROL||PROSPECTIVE|||||||
34167825|NCT00082498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167826|NCT05772819|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167827|NCT02109640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167828|NCT05084586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167829|NCT06344403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167830|NCT04007497|||OTHER||CROSS_SECTIONAL|||||||
34062241|NCT05541900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062242|NCT04746261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062243|NCT01276691|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34062244|NCT05136534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062245|NCT02938234|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34062246|NCT03172364|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34062247|NCT00772005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062248|NCT02832141|||CASE_CROSSOVER||PROSPECTIVE|||||||
34062249|NCT06241924|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34062250|NCT01578954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062251|NCT05366218|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy||||
34062252|NCT01921738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167831|NCT04665271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Active control with cross-over at post-treatment and three month follow-up||||
34167832|NCT06392958|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34167833|NCT02006004|||CASE_ONLY||RETROSPECTIVE|||||||
33855491|NCT05695625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855492|NCT00925431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855493|NCT03029312|RANDOMIZED|PARALLEL||TREATMENT||NONE||Paired randomized controlled study||||
33855494|NCT03644030|||CASE_ONLY||PROSPECTIVE|||||||
33855495|NCT04633551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855496|NCT01093521|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33855497|NCT02113930|||COHORT||PROSPECTIVE|||||||
33855498|NCT04095741|||COHORT||CROSS_SECTIONAL|||||||
33958441|NCT06057233|||CASE_CONTROL||PROSPECTIVE|||||||
34167834|NCT02506712|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34167835|NCT01841879|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167836|NCT02428192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167837|NCT01262807|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34167838|NCT05187819|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|"The results of the blood tests will be hidden for all involved until the investigation at the outpatients clinic is finished. Only the researchers will get the answers for the blood tests.~The researchers will also get the results from investigation at the outpatient clinic, including test results of biomarkers in CSF."|A blood test will be taken from patients included. All included patients will have possible early dementia symptoms. A random sample of patients with negative and with positive blood-test results for actual biomarkers for Alzheimer's disease will be referred for further investigation at the memory outpatient clinic in Stavanger. The diagnosis from the memory clinic will be compared with the test results for the biomarkers, in order to calculate the positive and negative predictive value for these biomarkers in general practice.|t|t|t|t
34167839|NCT04550637|||COHORT||PROSPECTIVE|||||||
34167840|NCT00424944|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34167841|NCT04194268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167842|NCT02677168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167843|NCT01191723|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34167844|NCT03564717|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34167845|NCT05893095|||OTHER||RETROSPECTIVE|||||||
34167846|NCT01896024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34167847|NCT01860287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34167848|NCT01576289|||COHORT||PROSPECTIVE|||||||
34167849|NCT04593108|||CASE_CONTROL||PROSPECTIVE|||||||
34167850|NCT03282383|||CASE_CROSSOVER||PROSPECTIVE|||||||
34167851|NCT00550953||PARALLEL||TREATMENT||||||||
34167852|NCT05006235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34167853|NCT04662008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167854|NCT03306667|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34167855|NCT03832348|NA|SINGLE_GROUP||OTHER||NONE||||||
34167856|NCT01934257|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34167857|NCT04062110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomised trial|two-arm, parallel-group, prospective randomised trial|t|f|f|f
34167858|NCT02360826|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34167859|NCT03487731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167860|NCT01495208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167861|NCT00622037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167862|NCT00720590|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34167863|NCT04073121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167864|NCT01667289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167865|NCT04468581|||COHORT||RETROSPECTIVE|||||||
33748432|NCT03819660|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, extension study , long term safety and tolerability||||
33748433|NCT06618326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748434|NCT04679168|||COHORT||PROSPECTIVE|||||||
33748435|NCT05568992|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958442|NCT06298318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33958443|NCT02864953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958444|NCT05148455|||COHORT||PROSPECTIVE|||||||
33958445|NCT06700564|||COHORT||PROSPECTIVE|||||||
33958446|NCT02917876|||COHORT||PROSPECTIVE|||||||
33958447|NCT06543511|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958448|NCT02517346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34167866|NCT02911870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34167867|NCT02163824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167868|NCT03767621|||CASE_ONLY||PROSPECTIVE|||||||
34167869|NCT06061939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34167870|NCT03385655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167871|NCT01271556|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34167872|NCT00371592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34167873|NCT03129867|||COHORT||PROSPECTIVE|||||||
34167874|NCT04830930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover Assignment||||
34167875|NCT04766463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34167876|NCT04168658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34167877|NCT04344808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patient will be unaware of which group since during the surgical procedure patient eyes' will be covered.~Outcome assessor won't take part of the clinical process and will be blinded regarding which group is allocated each patient."||t|f|t|t
34167878|NCT04474678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167879|NCT04234620|||OTHER||PROSPECTIVE|||||||
34167880|NCT01180465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167881|NCT04908085|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Waitlist control trial|f|f|f|t
34167882|NCT05245201|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention will be implemented in 2-3 clinics, with 2-3 control clinics receiving standard of care. Eligible community health centers will be those with at least 500 patients and a minimum of 10 HIV diagnoses. Clinics located in counties identified as HIV hotspots will be prioritized. Clinics specializing in HIV or sexual health care, where providers may have less need for PrEP decision support, will be excluded. Overall, 26 clinics are expected to meet these eligibility criteria, with a total of 831 incident HIV diagnoses in 2018. Of eligible clinics, 2-3 will be recruited to receive the intervention. Using a covariate-constrained matching procedure with EHR data on important covariates (e.g., urbanity and the sex, race, and age distributions of the patient population), 2-3matched control clinics will be selected.||||
33855499|NCT03274960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator will not be aware of study group at analysis stage of results. The assessors of outcome will be blinded to study arm as they analyse data to reduce risk of bias.|The control group shall be receiving the usual current antenatal services which do not include any screening at all for asymptomatic bacteriuria. Control group participants will however be treated as routinely being done when a woman presents with symptoms of a UTI. Control group will therefore continue to get the routine antenatal care service as currently being done at the clinics. Participants in the intervention group will each be screened for asymptomatic bacteriuria once in each trimester using the Griess test. A culture test will be done which will confirm diagnosis of bacteriuria. participants in intervention group who will present with symptoms and who will test positive for bacteriuria with the Griess and culture test will be treated with antibiotics as per usual treatment protocol. A comparison about number of preterm births for intervention group and control group will be done to reveal the effect of the study intervention.|f|f|t|t
33855500|NCT00430261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855501|NCT00210470|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Open Label Single Arm Phase 2a trial of Safety of IRX-2 in Patients with Operable Head and Neck Cancer||||
34167883|NCT02898363|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33855502|NCT04397341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855503|NCT01203748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855504|NCT04670354|||COHORT||PROSPECTIVE|||||||
33855505|NCT03646201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33855506|NCT02430688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33855507|NCT01258335|RANDOMIZED|||PREVENTION||TRIPLE|||t|t|t|f
33855508|NCT01640275|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33855509|NCT00889317|||COHORT||PROSPECTIVE|||||||
33855510|NCT05061784|||CASE_ONLY||RETROSPECTIVE|||||||
33855511|NCT05507931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855512|NCT02150603|||||CROSS_SECTIONAL|||||||
33855513|NCT04528927|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33855514|NCT03434678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|(surgical staff) blinded|Prospective randomized controlled single institution trial.|f|f|t|f
33855515|NCT03481023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to which condition they were assigned; the Outcomes Assessor will be blinded to the hypotheses of the study as well as the condition to which the participant was assigned.||t|f|f|t
33855516|NCT04395898|||COHORT||RETROSPECTIVE|||||||
33855517|NCT05657483|||COHORT||PROSPECTIVE|||||||
33855518|NCT03548246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855519|NCT05344729|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855520|NCT01614535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33855521|NCT00517582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855522|NCT02408276|||COHORT||PROSPECTIVE|||||||
33855523|NCT04481477|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855524|NCT00917605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855525|NCT06476886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to treatment assignment. It is not possible for clinicians or families to be blind to treatment.|"The Pilot Phase will consist of 20 youth admitted to YCSU and their parents receiving ICI.~In the RCT, 60 youth will be randomized in a 1:1 ratio to YCSU (n=30) or APIU (n=30)."|f|f|f|t
33855526|NCT02673424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855527|NCT03490526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855528|NCT04776785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was performed by a computer-generated random sorting sequence (sealed in opaque envelopes that sequentially numbered randomly selected through).|randomized controlled, three-arm parallel, double-blinded, split-mouth clinical trial|t|f|f|t
33855529|NCT04961723|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||"5 arm randomized control trial evaluating models of care by population group. For MSM group 3 arms; a postal delivery model of HCV antibody self-test, a peer delivery model of HCV antibody self-test compared the standard or care (participant going to clinic for HCV antibody RDT).~For PWID 2 arms; a peer delivery model of HCV antibody self-test compared the standard or care (participant going to clinic for HCV antibody RDT)."||||
33855530|NCT05837715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855531|NCT03407820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patient and surgeon will be blinded until just before the start of the procedure.||t|t|f|f
34167884|NCT01835717|||COHORT||CROSS_SECTIONAL|||||||
34167885|NCT03813888|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167886|NCT04039126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|DOUBLE BLINDED, PARTIPANT ASIIGNED USING WINPEPI||t|t|t|f
34167887|NCT01766453|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34167888|NCT06079333|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, non-randomized, single center, open-label phase II study||||
33748436|NCT01705054|||CASE_ONLY||PROSPECTIVE|||||||
33748437|NCT01848873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855532|NCT05621603|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will employ a matched waitlist control comparison design. Schools (6) will be randomly assigned to either the training arm or the control arm. Schools assigned to the control arm will eventually receive the training.||||
33855533|NCT00240045|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855534|NCT03728413|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33958449|NCT06262347|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an intent-to-treat, two-arm, open-label, randomized controlled trial.||||
34167889|NCT04333368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34167890|NCT03635463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double blinded( participant and outcome assessor)||t|f|f|f
34167891|NCT06368258|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34167892|NCT02401685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958450|NCT05902767|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants will be randomly assigned to one of the two study groups: Nuts of Control.||||
34167893|NCT02730728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167894|NCT05694455|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Patients diagnosed with septic shock in the emergency department admitted to the hospital will be enrolled within 4 hours of the emergency physician's decision to admit the patient to the hospital.~On enrollment, On enrollment and at hours 10-14, 22-26, and 44-48, the research team will assess micro hemodynamic incoherence and Macro hemodynamic incoherence as well as the total amount of IV fluids and vasoactive medications administered, demographics, Charlson morbidity scale and Sofa score.~Healthy controls will have sublingual microscopy and urine collection performed at time of intubation for elective procedure."||||
34167895|NCT05004831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167896|NCT06543901|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study employs a parallel-group randomized controlled trial (RCT) design. In this model, participants are randomly assigned to one of two groups: the intervention group or the control group. Each participant remains in their assigned group for the duration of the study, receiving either the intervention being tested (MIPO submuscular plate fixation) or the control treatment (conservative management with Thomas splint). This design allows for a direct comparison of the outcomes between the two groups, minimizing bias and ensuring the reliability of the results.||||
34167897|NCT01735448|||COHORT||PROSPECTIVE|||||||
34167898|NCT05011227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167899|NCT04839939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167900|NCT04390126|||COHORT||PROSPECTIVE|||||||
33958451|NCT02368119|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34167901|NCT04406766|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34167902|NCT02367417|||COHORT||PROSPECTIVE|||||||
33958452|NCT05840497|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33958453|NCT00455923|RANDOMIZED|PARALLEL||TREATMENT||||||||
33958454|NCT04318041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator, hospital pharmacists and monitors are blind to the treatment. The analysis of the results will be performed blind.||t|t|t|t
33958455|NCT05779046|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Twelve patients with allergic rhinitis aged between 19 and 31 years who had a positive skin prick test to house dust mite (D. pteronyssinus). The experiment was a crossover design in which each participant was given two types of high-intensity interval training exercise (HIT): HIT 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute) and HIT 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 2 minutes). Rhinitis symptoms, nasal blood flow, peak nasal inspiratory flow, pulmonary functions, respiratory muscle strength, and fractional exhaled nitric oxide were measured before and immediately, 15 minutes, 30 minutes, 45 minutes, and 60 minutes after exercise for each exercise program.||||
33958456|NCT05519267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33958457|NCT05798923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958458|NCT00561093|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33958459|NCT01778452|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33958460|NCT05349890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958461|NCT03976076|NA|SINGLE_GROUP||TREATMENT||NONE||Patients received the investigational product at a dose of 6 milligram per kg orally twice daily; once in the morning and 12 hours following the morning dose during the first 7 days of Treatment Period 1. Starting from the PM dose on the day of Visit 3, the dose was escalated and patients received the investigational product at a dose of 9 mg/kg orally twice daily. Starting on Day 15, the dose was escalated again and patients received the investigational product at a dose of 15 mg/kg orally twice daily until the end of Treatment Period 1 (Day 28).||||
33958462|NCT03981614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062253|NCT05482165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062254|NCT05209711|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34062255|NCT05470816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|TxA blinded for the TRIGS Trial|Multicentre, randomised, triple-blind, placebo-controlled, clinical trial (a substudy of the TRIGS trial).|t|t|t|t
34062256|NCT03318926|||COHORT||RETROSPECTIVE|||||||
34062257|NCT00684632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34062258|NCT00847431|||CASE_CONTROL||PROSPECTIVE|||||||
34062259|NCT03368404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34062260|NCT05114057|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34167903|NCT06028997|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective cohort-study||||
34167904|NCT03097185|||CASE_ONLY||PROSPECTIVE|||||||
34167905|NCT02329470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167906|NCT01225614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167907|NCT03250637|||OTHER||PROSPECTIVE|||||||
34167908|NCT01879683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167909|NCT03143530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care providers, investigators, and observers who record central measurements will be blinded to group allocation.|"Participants will be assigned to one of two of the following groups for the duration of the study.~1. General anesthesia + pectoralis block with Ropivacaine 30ml of 0.25% (75mg)~2. General anesthesia + sham block with 30ml of normal saline"|t|t|t|t
34167910|NCT01644305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34167911|NCT01023711|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34167912|NCT06518044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167913|NCT04445142|||CASE_ONLY||RETROSPECTIVE|||||||
34167914|NCT00731419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34167915|NCT01751984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167916|NCT00001716||||TREATMENT||||||||
34167917|NCT02202239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167918|NCT04421170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855535|NCT05268874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant will be blinded to the study|38 patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for clavicle surgery will be included in the study. Patients will be randomly divided into two groups (Group Clavipectoral and Group Control) including 19 patients each, before entering the operating room.|t|f|f|t
33855536|NCT01906554|NA|SINGLE_GROUP||||TRIPLE|||t|f|t|t
34167919|NCT01335139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855537|NCT03166826|||COHORT||PROSPECTIVE|||||||
34167920|NCT03011788|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34167921|NCT05406011|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants are subdivided in parallel groups by their age and according to the toothbrush change (to change or not to change the toothbrush) after scaling.||||
34167922|NCT04585425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167923|NCT00006326||||TREATMENT||||||||
34167924|NCT04325334|NA|SINGLE_GROUP||TREATMENT||NONE||Both runners with and without knee osteoarthritis will be recruited. They will all receive the same intervention.||||
34167925|NCT01392131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167926|NCT05162183|||COHORT||RETROSPECTIVE|||||||
34167927|NCT04281615|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167928|NCT02601157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167929|NCT02960386|NA|SINGLE_GROUP||OTHER||NONE||||||
34167930|NCT05202678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167931|NCT01104896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34167932|NCT06006650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167933|NCT04435483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167934|NCT00611689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167935|NCT01546558|NA|SINGLE_GROUP||||NONE||||||
34167936|NCT02802839|RANDOMIZED|PARALLEL||||NONE||||||
33855538|NCT04780022|||COHORT||RETROSPECTIVE|||||||
33855539|NCT00207805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855540|NCT02719587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855541|NCT04085406|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33855542|NCT01757808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855543|NCT04436939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This was a split mouth study design in which both test and control group were the same patient||||
33855544|NCT04168684|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Parents received an intervention but did not know whether it was experimental or control. All participants had an identification number that did not indicate group.|Families randomized to Attachment and Biobehavioral Catch-up (ABC) or to a control intervention (DEF)|t|t|t|t
33855545|NCT06164509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33855546|NCT00196404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855547|NCT00985946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855548|NCT04121494|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Masking for Arms D,E Non-masking for Arms A,B,C,F|Stage I - dose escalation study (Arms A,B,C) Stage II - experimental arms: randomized (Arms D,E), parallel (Arm F)|t|t|t|t
33855549|NCT05927857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855550|NCT04309344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855551|NCT05253677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855552|NCT04556461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33855553|NCT00671944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855554|NCT00163306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855555|NCT03565120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855556|NCT03034629|NA|SINGLE_GROUP||OTHER||NONE||||||
33855557|NCT01751074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855558|NCT03752918|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This study will be a double-blind, placebo-controlled, within-subjects, crossover-dose neuroimaging study in which participants will initially receive either a single dose of MDMA 1.5mg/kg or a placebo (niacin 250mg), with a crossover dose to follow. Doses will be separated by 2 weeks.|t|t|t|t
33855559|NCT01385878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855560|NCT01435330|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33855561|NCT00837551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855562|NCT03364712|||COHORT||PROSPECTIVE|||||||
33855563|NCT05199220|||COHORT||PROSPECTIVE|||||||
33855564|NCT05494177|||COHORT||PROSPECTIVE|||||||
33855565|NCT00722267|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855566|NCT04258436|RANDOMIZED|PARALLEL||OTHER||SINGLE|Pediatric Cardiovascular ICU personnel will be blinded to the randomization assignment||f|t|f|f
33855567|NCT04832425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855568|NCT00866853|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855569|NCT01765465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34062261|NCT02509975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062262|NCT06068283|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized 2:1 to either the LOTUS mHealth intervention or an informational control. Participants randomized to the treatment arm will receive access to the LOTUS intervention for 6-months. Participants in the control arm will, in parallel, receive access to an information-only website for 6-months.||||
34062263|NCT05118061|||COHORT||PROSPECTIVE|||||||
34062264|NCT01675154|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This trial is adaptive design/flexible design. The participants were randomized from the start of the study|t|t|t|t
34167937|NCT05005663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958463|NCT06702345|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This will be a first in human, open-label, adaptive design, escalating clinical trial, investigating the oral exposure of toxigenic C. difficile in healthy volunteers. The adaptive design is aimed at a stepwise escalation to ensure safety of trial participants and gear towards the optimal balance between endpoints and tolerability. The study will start with one cohort of volunteers, cohort A, with an option to escalate to a second cohort, cohort B, and a third cohort, cohort C, if needed. Escalation to the subsequent cohort will be performed by adding antibiotic pretreatment. Escalation will be based upon safety first and secondly upon microbiological and clinical endpoints (ideally aiming for an attack rate of 70% in both). In every cohort small pilot groups (of five volunteers each) will be used to flag safety signals and determine the escalation schedule, having the option to include 15 more participants to the same cohort or escalate to the pilot group of the subsequent cohort.||||
33958464|NCT03146507|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958465|NCT03394274|||OTHER||RETROSPECTIVE|||||||
33958466|NCT04676607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958467|NCT00097084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958468|NCT03047031|||COHORT||OTHER|||||||
34062265|NCT06401343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062266|NCT00409851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748438|NCT04509947|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33748439|NCT04928950|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||15 adults undergoing TEMLA enrolled in a 12-month period.||||
33958469|NCT05968703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All participants will receive the interventional treatment. Two different surgical trajectories will be used for placing the leads in the NBM. Half the cohort will be randomized to each trajectory.|t|f|f|t
33958470|NCT03466788|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|open label||t|f|f|f
33958471|NCT00447291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33958472|NCT06703905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958473|NCT05268523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-Centre, multi-arm, pragmatic RCT|f|f|f|t
33958474|NCT00001729||||TREATMENT||||||||
33958475|NCT05839119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958476|NCT04489888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958477|NCT02341976|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958478|NCT02507115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958479|NCT02936479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958480|NCT04534088|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33958481|NCT03574194|NA|SINGLE_GROUP||TREATMENT||NONE||6-10 weeks methionine-restricted diet (MRD) with standard of care curative-intent radiation therapy (6 week course or less), without concurrent chemotherapy||||
33958482|NCT05340023|||COHORT||PROSPECTIVE|||||||
33958483|NCT02515981|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958484|NCT05445778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958485|NCT00953927|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958486|NCT03273712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958487|NCT06567990|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Prospective, multi-site, not randomized, national study||||
33958488|NCT03891875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958489|NCT03953768|NA|SINGLE_GROUP||OTHER||NONE||Prospective single-arm with internal control group||||
33958490|NCT01890486|||OTHER||PROSPECTIVE|||||||
33958491|NCT05197881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062267|NCT06435806|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||We will select 10 binary distinctions of medical illustration design elements and test each in a two-arm between-subjects evaluation.|t|f|f|f
34062268|NCT06528145|||COHORT||PROSPECTIVE|||||||
34062269|NCT02667626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34062270|NCT01962545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062271|NCT06730698|||CASE_ONLY||CROSS_SECTIONAL|||||||
34062272|NCT04531982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062273|NCT04205344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|You do not know the dose of bupivacaine you receive|Clinical trial open controlled parallel randomized simple|t|f|t|f
34062274|NCT04940416|||COHORT||PROSPECTIVE|||||||
34062275|NCT03213197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility of a Standardized Video for Patient Education and as a Decision Aid on Code Status for Patients in the Emergency Department pending Admission to the Hospital||||
34062276|NCT00673426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34062277|NCT03277716|NA|SINGLE_GROUP||TREATMENT||NONE||Microwave Ablation Combined With TACE in the Treatment of Non-resectable Huge Hepatocellular Carcinoma||||
34062278|NCT06052306|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062279|NCT04408508|NA|SINGLE_GROUP||OTHER||NONE||Patients reporting penicillin allergy will be enrolled based on eligibility criteria for direct oral amoxicillin challenge. There will be one treatment group of patients assigned low risk for penicillin allergy.||||
34062280|NCT06091592|||CASE_CONTROL||RETROSPECTIVE|||||||
34062281|NCT03195972|||COHORT||PROSPECTIVE|||||||
34062282|NCT04575259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062283|NCT04122755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062284|NCT00382902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33958492|NCT06224673|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958493|NCT02842086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855570|NCT03772444|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patients undergoing colorectal surgery will be randomized (n=10) to receive one week daily 70 ml of beetroot juice (\~ 7 mmol inorganic nitrate) or (n=10) an equivalent volume of nitrate-depleted beetroot juice (control group 1). An additional control group (n=10) is added to the pilot study, in which patients will receive an equivalent volume of water (control group 2); this allows us to investigate whether the antioxidants present in beetroot juice contribute to the protective effect of beetroot juice in POI. Beetroot juice and nitrate-depleted beetroot juice cause discoloration of urine (beeturia) and feces from the purple betacyanin pigments in beetroot; for the control group that receives water, this will not be the case and blinding for this group is thus not possible.|||||
33958494|NCT06483711|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958495|NCT00219752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958496|NCT02574507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958497|NCT03913767|||COHORT||PROSPECTIVE|||||||
33958498|NCT06703372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958499|NCT05654623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958500|NCT04008121|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958501|NCT04840901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33855571|NCT00354458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958502|NCT02830646|NA|SINGLE_GROUP||||NONE||||||
33958503|NCT05229562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958504|NCT05152004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Interventional Study Model|f|f|t|f
33958505|NCT05020730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to receive PTM-001 (400 mg) or matching placebo every day for 12 weeks after which all patients will receive open-label PTM-001 400 mg daily for an additional 12 weeks|t|t|t|t
33958506|NCT06472050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958507|NCT06700499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958508|NCT05255354|||OTHER||PROSPECTIVE|||||||
33855572|NCT02314910|||CASE_ONLY||PROSPECTIVE|||||||
33958509|NCT00732784|RANDOMIZED|CROSSOVER||||NONE||||||
33958510|NCT05088525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958511|NCT03455114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958512|NCT02752451|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34062285|NCT06109272|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062286|NCT05729828|||CASE_ONLY||PROSPECTIVE|||||||
33855573|NCT03279263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062287|NCT02461797|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34062288|NCT04010864|||COHORT||PROSPECTIVE|||||||
34062289|NCT03383692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34167938|NCT05120427|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessors and investigators will be blinded to the treatment assignment.|The study used a 2x2 factorial design testing growth charts and supplements.|f|f|t|t
34167939|NCT04118465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167940|NCT01187940|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167941|NCT05054140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958513|NCT04950322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958514|NCT06568666|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||The study involved 45 professional soccer players, divided into three groups: lumbar manipulation group (n=15), sacroiliac joint manipulation group (n=15), and control group (n=15). The manipulations were performed in a side-lying position, and tests (V - Sit Reach Test, horizontal and vertical jump tests) were performed 5 minute before manipulation techniques and after the manipulation techniques. Normal distribution parameters were determined using Kolmogorov-Smirnov and Shapiro Wilks tests. Quantitative data comparisons were made using Oneway Anova test, Tukey HDS test, Kruskal Wallis test, Dunn's test, Paired Sample T test, and Wilcoxon sign test. The p\<0.05 level was used to determine statistically significant differences. The study used various tests to compare parameters, with the p\<0.05 level being considered significant for statistically significant differences.|t|f|f|t
33958515|NCT05629117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958516|NCT06160674|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062290|NCT05123976|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34167942|NCT01819155|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167943|NCT01546857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062291|NCT02446262|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33958517|NCT03172390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort||||
33958518|NCT02740660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958519|NCT05365594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958520|NCT04608656|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Data collection enumerators will not be aware which intervention arm the households belong to.|"The study households will be assigned one of three study arms:~i) Intervention arm 1: Livestock feed only.~Households in villages assigned to intervention arm 1 will receive a pre-defined amount of livestock feed to maintain two tropical livestock units for a total of 60 days during the dry season (when animals would be moved away in search of pastures).~ii) Intervention arm 2: 1.Provision of Livestock feed, 2. Nutritional counselling~Households recruited into intervention arm two will receive livestock feeds and will be enrolled in a nutritional education and counselling program.~iii) Control arm~The households recruited under this arm will receive none of the two study interventions. These households will receive identical assessment and data collection like other study households in the study."|t|f|t|f
34062292|NCT02879708|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34062293|NCT05860959|||COHORT||PROSPECTIVE|||||||
34167944|NCT01908686|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34062294|NCT05668104|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34062295|NCT05189522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062296|NCT01916902|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34062297|NCT06534385|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34062298|NCT03605849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062299|NCT06731517|||COHORT||PROSPECTIVE|||||||
34062300|NCT03802435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062301|NCT00471757|||COHORT||RETROSPECTIVE|||||||
34062302|NCT05893069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Randomized||t|t|t|f
34062303|NCT03232164|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center, open label, single-arm, pilot study||||
34062304|NCT01641705|||||CROSS_SECTIONAL|||||||
34062305|NCT04431076|||COHORT||PROSPECTIVE|||||||
33855574|NCT05220254|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33855575|NCT00340691||||TREATMENT||||||||
33855576|NCT06001489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Prior to visiting the outpatient clinic, patients are unaware about their allocation. Only after their outpatient clinic visit, patients are informed about whether they belong to the control or intervention group. The surgeon, nurses OR assistants, however, are not informed about the treatment allocation. This is only known to the investigators and outcomes assessors.|"This prospective, single-center, randomized controlled trial (RCT) includes patients awaiting elective open heart surgery via a sternotomy. Patients who met the inclusion criteria were invited to participate in the study. Patients were allocated randomly to either the control or intervention group. The control group received oral information from the treating cardiothoracic surgeon. The intervention group received additional information through an educational 360-degree semi-immersive Virtual Reality (VR) Tour. The VR Tour provided patients a comprehensive visual experience of the entire clinical pathway of the scheduled surgical procedure,~Patients complete two validated questionnaires immediately following their outpatient clinic visit to assess pre-procedural anxiety. This data was considered the 'baseline'. One day prior to the surgery, during the hospital admission, patients are asked to complete the same questionnaires again. This data will be referred to as 'follow-up (FU)'."|f|t|f|f
33855577|NCT00598143|||COHORT||PROSPECTIVE|||||||
33855578|NCT04681027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855579|NCT02148614|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958521|NCT06074159|RANDOMIZED|PARALLEL||OTHER||NONE||All study participants in two pregnancy cohorts will get a personal exposure report for chemicals measured during their pregnancy. 200 participants from each cohort (N Total= 400) are randomly selected and assigned equally to one of two groups: 1) those who only receive their personal results online and 2)those who receive in-clinic to measure differences in participants' environmental health literacy. Pre-and post-tests are administered before and after report-back.||||
33958522|NCT06703645|||OTHER||PROSPECTIVE|||||||
33958523|NCT01179256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958524|NCT06417723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|for patients - closed envelope system for investigator - Maxillary nerve block performer will not participate pain and results assesment|"two groups designed from septoplasty patintes for study.~1. only general anesthesia~2. General anesthesia + maxillary nerve block"|t|f|t|f
33958525|NCT06704009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958526|NCT01801618|||||CROSS_SECTIONAL|||||||
34062306|NCT03908216|||COHORT||PROSPECTIVE|||||||
34062307|NCT06349005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062308|NCT00925652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062309|NCT00078949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062310|NCT04761159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, controlled|t|t|f|f
34062311|NCT03362801|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34062312|NCT05920135|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33855580|NCT04307810|||OTHER||CROSS_SECTIONAL|||||||
33855581|NCT00458991|||COHORT||PROSPECTIVE|||||||
33855582|NCT03532087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33958527|NCT03016988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062313|NCT06235697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062314|NCT03988673|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Parallel three group (1:1:1): (i) decision aid with information only (Control), (ii) decision aid with information plus an implicit VCM, (iii) decision aid with information plus an explicit VCM.|t|t|t|t
34062315|NCT01864213|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34062316|NCT00572975|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062317|NCT04877444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome measure will be assessed by a blinded rater to improve scientific rigor.|Study participants will be randomized to one of two groups. One group will receive 24 sessions of aerobic exercise and upper extremity rehabilitation. The second group will receive 24 sessions of stretching exercise and upper extremity rehabilitation.|f|f|f|t
34062318|NCT04304118|||CASE_ONLY||PROSPECTIVE|||||||
34062319|NCT04878458|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, parallel, open, non-inferior randomized controlled trial||||
34062320|NCT04032951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062321|NCT03025347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34062322|NCT01078298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062323|NCT06255028|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062324|NCT02370069|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34062325|NCT00194194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855583|NCT02208999|||COHORT||PROSPECTIVE|||||||
33855584|NCT03240874|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Two phases of study:~1. Usability testing - focus groups followed by individual usability testing (single arm)~2. Feasibility testing - pilot randomized controlled trial of SweetMama care versus usual care"||||
33855585|NCT00949208|||COHORT||PROSPECTIVE|||||||
33855586|NCT00101881|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33855587|NCT02970331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855588|NCT05106829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|By random generator|Physical therapy and ankle weights.|t|f|f|t
33855589|NCT03709420|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33855590|NCT01012115|||COHORT||PROSPECTIVE|||||||
33855591|NCT05603091|||COHORT||PROSPECTIVE|||||||
33855592|NCT02238522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855593|NCT06450938|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33855594|NCT05144633|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855595|NCT02283554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855596|NCT04953715|||COHORT||PROSPECTIVE|||||||
33855597|NCT05724160|RANDOMIZED|PARALLEL||OTHER||NONE|No groups will be masked|"32 patients with non-specific low back pain will be allocated to the physiotherapy group.~32 patients with non-specific low back pain will be allocated to the physiotherapy + sitting elliptical group. They will be receive routine physiotherapy care based on the protocols for non-specific low back pain and using the ellipticals will not affect the process of the treatment."||||
33958528|NCT02432521|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33958529|NCT04318002|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33855598|NCT03467243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research assistants administering the outcomes measures will be blinded to the Veteran's treatment condition.|"Cognitive Behavioral Social Skills Training for Peer Specialists (CBSST-Peer). At each site, two PSs will co-lead a series of 20 weekly, 60-minute CBSST-Peer classes, grouped into two 10-class modules: the Cognitive Skills Module and the Social Skills Module. The treatment manual includes a patient workbook and includes homework assignments.~Social Skills Training-Peer. These groups will run according to the Bellack et al. model used in VA's SST rollout. Groups will use behavioral rehearsal role play to improve communication and interaction skills Treatment as usual group. Participants will continue to receive treatment as they normally would."|f|f|f|t
33855599|NCT00896051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855600|NCT02216357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34167945|NCT05184192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded, both participants and investigators will be blinded. Intervention will be packaged in blinded fashion by pharmacist before being shipped to participants by research assistant|Double-blinded, randomized, placebo-controlled trial|t|f|t|t
33855601|NCT05682157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855602|NCT04428125|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33855603|NCT01008293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855604|NCT05271292|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be enrolled sequentially in 3 dose-escalating cohorts (Chiauranib capsules 35mg, 50 mg and 65 mg once daily)||||
33855605|NCT05008835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855606|NCT02940821|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33855607|NCT03794570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and outcomes assessors will be blinded to treatment group. Physical therapy providers will not be masked.|Double blinded randomized control trial|t|f|t|t
33855608|NCT04977726|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33855609|NCT00699920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855610|NCT03333239|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33855611|NCT02739360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855612|NCT02669420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855613|NCT00449553|||COHORT||PROSPECTIVE|||||||
33855614|NCT02796560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855615|NCT04647630|||CASE_ONLY||PROSPECTIVE|||||||
33855616|NCT00518791|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33855617|NCT03153137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855618|NCT05428761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33855619|NCT03692260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33855620|NCT04506268|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33855621|NCT04787250|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, open-label, parallel-group design||||
33855622|NCT00790764|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855623|NCT06494891|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive intravenous alcohol.||||
33855624|NCT04168853|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||The IPITA (Impact of Pumps on Internal Thoracic Arteries) study consisted of two parallel prospective, monocenter, randomized, active-treatment-controlled clinical trials|t|f|f|t
33855625|NCT00460200|||||PROSPECTIVE|||||||
33855626|NCT00055523|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33855627|NCT00141726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062326|NCT04798872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessor will be blinded to participants allocation.|The study consist of two groups: intervention and control group. Mothers and fathers in intervention group will be provided web-based educational program and mothers and fathers in control group will be provided usual care.|f|f|f|t
34062327|NCT04645134|||COHORT||CROSS_SECTIONAL|||||||
34062328|NCT05147701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167946|NCT06076148|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||All participants will test both multiplayer and individual games. Order of testing is reversed in between arms.||||
34167947|NCT03070080|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34167948|NCT00665665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167949|NCT03430778|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34167950|NCT02631551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34167951|NCT00421681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167952|NCT02136017|||CASE_ONLY||RETROSPECTIVE|||||||
34167953|NCT03471273|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167954|NCT04099966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167955|NCT03043885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167956|NCT04867551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748440|NCT05974969|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33855628|NCT04386811|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34167957|NCT03200119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855629|NCT03390920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855630|NCT03159533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Step wedge design, whereby 5 groups of 3 practices will implement the intervention in phases.||||
33855631|NCT02139787|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33855632|NCT01049971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855633|NCT00615329|||CASE_ONLY||PROSPECTIVE|||||||
33855634|NCT02826330|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33855635|NCT05877378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855636|NCT00526487|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33958530|NCT06583538|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958531|NCT04564287|||COHORT||PROSPECTIVE|||||||
33958532|NCT00729703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958533|NCT06701253|||COHORT||PROSPECTIVE|||||||
34167958|NCT03373149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167959|NCT01794988|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34167960|NCT01553903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167961|NCT05013424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167962|NCT03621657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a phase 2, double-blind, randomized, placebo-controlled trial assessing the effects of either daily (group 1) or one-time (group 2) oral FMT on the composition and function of gut microbiome compared to placebo (group 3) in a population of patients with a history of Clostridium difficile infection (CDI).|t|f|t|t
34167963|NCT05724745|NA|SINGLE_GROUP||OTHER||NONE||||||
34167964|NCT05706948|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34167965|NCT02777658|||COHORT||PROSPECTIVE|||||||
33855637|NCT05198908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized controlled clinical trial|t|t|f|t
34167966|NCT03980899|||COHORT||PROSPECTIVE|||||||
34167967|NCT04592588|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34167968|NCT03965013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|The study consists of 2 parts each with 2 arms. Part 1 is NNC0268-0965 vs. placebo in healthy volunteers. Part 2 is NNC0268-0965 vs. insulin glargine in subjects with type 1 diabetes mellitus.|t|t|t|t
34167969|NCT02385747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167970|NCT02624440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167971|NCT01964794|||CASE_ONLY||CROSS_SECTIONAL|||||||
34167972|NCT02884648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855638|NCT00796120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855639|NCT03444753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855640|NCT00006177|||COHORT||OTHER|||||||
33748441|NCT04169139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiners are blinded|randomized, blinded, parallel arm trial, non-inferiority comparison of REPaiR therapy (experimental treatment) versus MIST (control therapy)|f|f|f|t
33855641|NCT02915393|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33855642|NCT01454518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33855643|NCT04778956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748442|NCT02444455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958534|NCT04022759|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participant will not explicitly be told which condition they are in by the researcher or the clinician working directly with them. However, they are likely to be able to infer this from the treatment being delivered, having read the information sheet regarding the study. The clinician working with the participant will be aware what condition they are in so that they are able to deliver the appropriate intervention.|"The feasibility element of the study will aim to explore service users' willingness to participate in the study; clinician's willingness to recruit participants; whether the recruitment method is effective in recruiting participants; and to assess attrition rates.~The pilot study aims to look at the processes involved in the study as outlined in the protocol, and whether any of these require changes to inform a larger scale RCT; this includes whether the recruitment, randomisation and treatment processes can be carried out effectively. Moreover, the study aims to determine whether the attachment security priming intervention appears to be effective in reducing therapy drop-out; increasing attendance to therapy; and decreasing rates of clients' being stepped-up to step 3 high-intensity services. Secondary to this, the study aims to assess whether priming attachment security appears to have an impact upon levels of depression, anxiety and impaired functioning."||||
33958535|NCT05623449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958536|NCT06224192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958537|NCT06254963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised into one of 2 groups, either supplemental sand jump training or land jump training.||||
34167973|NCT02719496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167974|NCT03255135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167975|NCT04934501|||COHORT||PROSPECTIVE|||||||
34167976|NCT03015168|||CASE_ONLY||RETROSPECTIVE|||||||
34167977|NCT05851196|||OTHER||OTHER|||||||
34167978|NCT02426515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167979|NCT00128739|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34167980|NCT02856048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167981|NCT03568240|||COHORT||PROSPECTIVE|||||||
34167982|NCT00186225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34167983|NCT00740207|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34167984|NCT01509235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34167985|NCT01437280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167986|NCT05229185|NA|SINGLE_GROUP||TREATMENT||NONE||This study has a pre-post intervention design, recruiting 20 patients in the chronic phase after stroke. Pre- and post-intervention assessments are administered on day 1 and 7.The 5 days in between, all patients receive the same training with the robot, there is no control group.||||
34167987|NCT05014672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo-controlled 1:1:1 in double blind treatment period.|t|f|t|f
34167988|NCT02631096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Subject) in cohort 1-3, Open label in Cohort 4||t|f|f|f
34167989|NCT04034823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167990|NCT02838108|||COHORT||PROSPECTIVE|||||||
33855644|NCT00884494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33855645|NCT03316625|NA|SINGLE_GROUP||OTHER||NONE||||||
33855646|NCT00821574|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33855647|NCT01594307|||||PROSPECTIVE|||||||
33855648|NCT02349360|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33855649|NCT06193460|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"Group I (20 teeth): the anaesthesia will be reversed by the photobiomodulation mode of diode laser therapy (low-level laser therapy).~Group II (controlled group) :( 20 teeth) anaesthesia will be withdraw without intervention."|t|f|f|f
33855650|NCT05510752|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33855651|NCT00977054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855652|NCT03541382|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33855653|NCT00690235|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33855654|NCT01647269|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33855655|NCT01003197|||COHORT||RETROSPECTIVE|||||||
33855656|NCT01560689|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855657|NCT02471833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33855658|NCT03294746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34167991|NCT00721396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34167992|NCT03974386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167993|NCT02843906|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34167994|NCT05222828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34167995|NCT02807623|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34167996|NCT04082234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34167997|NCT01013051|||CASE_CONTROL||PROSPECTIVE|||||||
33855659|NCT04320797|||CASE_CONTROL||PROSPECTIVE|||||||
33855660|NCT04047589|||COHORT||CROSS_SECTIONAL|||||||
33855661|NCT05350384|||CASE_ONLY||PROSPECTIVE|||||||
33855662|NCT05053438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The allocation pattern is concealed to the investigators and therapists providing intervention.|Participants will be randomized 1:1 to intensive feeding intervention (standard care) or intensive feeding intervention (standard care) + rapid tube weaning study groups using permuted blocks of size 2 or 4.|f|f|t|f
33855663|NCT02784197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855664|NCT05680064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|At the beginning of this study, all participants are informed about in which group they will participate.|experimental research||||
33855665|NCT01828073|||COHORT||PROSPECTIVE|||||||
33855666|NCT02795429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855667|NCT05859932|||CASE_CROSSOVER||PROSPECTIVE|||||||
33855668|NCT00901277|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855669|NCT05334745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855670|NCT01832233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855671|NCT01416415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33855672|NCT01169246|||COHORT||PROSPECTIVE|||||||
33855673|NCT03187340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33855674|NCT05555407|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33855675|NCT06161935|||COHORT||RETROSPECTIVE|||||||
33855676|NCT01487408|||COHORT||PROSPECTIVE|||||||
33855677|NCT04725396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855678|NCT02527343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855679|NCT00722852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855680|NCT03353350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855681|NCT01137526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855682|NCT00509678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855683|NCT04751708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34167998|NCT02488837|||COHORT||PROSPECTIVE|||||||
34167999|NCT06027866|||COHORT||PROSPECTIVE|||||||
34168000|NCT01156480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168001|NCT01654926|||COHORT||PROSPECTIVE|||||||
34168002|NCT02843269|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34168003|NCT05720910|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34168004|NCT00945282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855684|NCT02960841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855685|NCT06135675|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33855686|NCT02699983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855687|NCT05242185|||COHORT||PROSPECTIVE|||||||
33855688|NCT01943032|||CASE_CONTROL||PROSPECTIVE|||||||
33855689|NCT00517907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855690|NCT03931720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855691|NCT04942834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855692|NCT03482154|||COHORT||RETROSPECTIVE|||||||
33855693|NCT04166890|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|"Both anesthetics will be masked so that no differences are observed between them at the time of their application by the surgeon, clinical monitor and patient. Therefore, they will be covered with adhesive paper marked with the letter A or B. Each pair of anesthetics will be stored in an envelope and inside it will say the side that would apply each anesthetic (right or left) and each envelope will have a consecutive number from 1 to 196, and will be delivered to each patient in order of arrival at the study.~Being a double blind study, it must be guaranteed that neither the patient, nor the surgeon, nor the clinical monitor knows about the allocation of treatments at the time of intervention."|Open, randomized, double blind, controlled, phase 4 crossover, randomized clinical trial will be conducted to compare the efficacy and clinical safety of two homologous active principles, articaine HCl with 1: 100,000 epinephrine (test) against the reference formulation 4% articaine HCl with 1: 100,000 of epinephrine, used intraorally in extraction of retained third molars (18), and will be carried out in the Faculty of Dentistry of the University of Antioquia|t|t|t|f
33855694|NCT01174160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168005|NCT05938621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855695|NCT04626492|||OTHER||PROSPECTIVE|||||||
33958538|NCT05996549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Our study design will be quasi-experimental. We will run an influenza vaccination campaign before the influenza season, where the vaccine will be offered free of cost to high-risk patients (intervention arm). In the second hospital, vaccination will not be offered (control arm).|f|f|t|f
34168006|NCT00928902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168007|NCT04365621|NA|SINGLE_GROUP||OTHER||NONE||It is a prospective study with a single group assignement.||||
34168008|NCT06526416|||OTHER||PROSPECTIVE|||||||
34168009|NCT00872235|RANDOMIZED|CROSSOVER||||NONE||||||
34168010|NCT05331560|NA|SINGLE_GROUP||TREATMENT||NONE|Since TPS is a new NIBS technology, no studies have been done on older adults with mild NCD, which is a golden period for intervention before the pathology involved the whole brain and leading to irreversible damage. We would like to perform an open-label self-controlled study to assess the effectiveness and tolerability of TPS with neuro-navigation on cognition in older adults with mild NCD.|||||
34168011|NCT02347397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168012|NCT03767946|||COHORT||PROSPECTIVE|||||||
34168013|NCT03569904|||OTHER||PROSPECTIVE|||||||
34168014|NCT03412396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168015|NCT00935740|||CASE_CONTROL||PROSPECTIVE|||||||
34168016|NCT04277559|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33958539|NCT03390452|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168017|NCT01423968|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34168018|NCT00571155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168019|NCT04469972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168020|NCT01623115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168021|NCT05757635|||CASE_ONLY||PROSPECTIVE|||||||
34168022|NCT05703321|||OTHER||PROSPECTIVE|||||||
34168023|NCT05430958|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168024|NCT01119469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748443|NCT06269926|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The investigators will randomize 40 adults with cerebral palsy and pain-related impairment in daily activities into two study arms: Group 1 (Education-CBT) will receive enhanced usual care (a pain education booklet in addition to usual medical care) followed by Cognitive Behavioral Therapy for Chronic Pain (CBT-CP; the primary intervention-a once weekly, 12-week group therapy course). Group 2 (CBT-Education) will instead receive CBT-CP first. To maintain reasonable therapy cohort sizes (n=10 per cohort), each group (n=20 participants) will consist of two separate therapy cohorts (n=10 each). Participants will be evaluated at the beginning of the study, and then once every 3 months during the 12-month duration of the study.|f|f|f|t
33748444|NCT03347253|||CASE_ONLY||PROSPECTIVE|||||||
33958540|NCT06702176|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The investigators designed a trial that includes two phases: (i) phase 1 which consists of a 2-week intervention of Exopulse Mollii suit active versus sham, separated by a 2-week washout period to prevent any carry-over effects; (ii) phase 2 that will be carried out two weeks following the end of phase 1. Phase 2 will last 6 months (24 weeks: 7 sessions per week) with a monthly assessment aiming to explore the long-term effects of this method on fibromyalgia.~Summary:~* Phase 1: randomized sham-controlled crossover study (active vs. sham condition/ assessment every two weeks )~* Phase 2: Open-label (active condition, 6 months/monthly assessment)"|t|f|t|t
34168025|NCT03515525|||COHORT||RETROSPECTIVE|||||||
34168026|NCT01474941|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34168027|NCT05851833|||COHORT||RETROSPECTIVE|||||||
34168028|NCT00997958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168029|NCT02310412|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168030|NCT03117816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A randomized, open-label assessor blinded, multi-center, controlled phase III trial||f|f|f|t
34168031|NCT04493996|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34168032|NCT03572452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34168033|NCT04729075|||COHORT||OTHER|||||||
34168034|NCT01149317|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34168035|NCT00296816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748445|NCT05371184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748446|NCT01298128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748447|NCT05790733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomized, bicentric, interventional study||||
33748448|NCT03939468|||COHORT||PROSPECTIVE|||||||
33748449|NCT01696422|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33748450|NCT03315000|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33748451|NCT03555396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748452|NCT04811027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748453|NCT00240318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748454|NCT00345241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748455|NCT03181880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748456|NCT05876065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748457|NCT01817179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958541|NCT04415177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958542|NCT03125915|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Assignment to video condition is masked with respect to the care provider. The person conducting the CHTC session is unaware of whether couples have viewed the communication skills training video prior to the session.|The study tests two independent variables in a fully-crossed factorial design. Half of the couples complete a substance use module during their CHTC session (half do not); half view communication skills training videos (half do not).|f|t|f|f
33958543|NCT02445222|NA|SINGLE_GROUP||OTHER||NONE||||||
33958544|NCT04593589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958545|NCT04464200|NA|SINGLE_GROUP||TREATMENT||NONE||This is a standard phase I open-label dose-escalation trial. Cohorts of 3-6 patients will be infused with escalating doses of 19(T2)28z1XX CAR T cells to establish the MTD. There are 4 planned dose levels with one additional de-escalation dose level. A 3+3 design will be used to establish the RP2D. Once the RP2D is determined, the study will open to Dose Expansion phase and up to 12 patients with B-cell non-Hodgkin lymphoma (same eligibility criteria as the dose-escalation phase).||||
33958546|NCT01220037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33958547|NCT04632563|||OTHER||CROSS_SECTIONAL|||||||
33958548|NCT04297254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958549|NCT06303622|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958550|NCT02587325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958551|NCT04454619|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The samples will be sent to the laboratory with numbers|Crossover Assignment Crossover design is used|f|f|f|t
33958552|NCT06696001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistants and personnel will be aware of the randomized intervention for each participant since this will be stored on an encrypted spreadsheet with a password. The participants will be made aware that they will be randomized to a group, however, they will not know what intervention they have been assigned to.|There are two interventions that the participants will randomly be assigned to. Each participant will only complete one of these two interventions during their duration in the study.|t|f|f|f
33958553|NCT01275521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958554|NCT06340087|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34062329|NCT06730308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062330|NCT03662815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168036|NCT01936675|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34168037|NCT01218763|||COHORT||PROSPECTIVE|||||||
34168038|NCT01169948|||CASE_ONLY||CROSS_SECTIONAL|||||||
34168039|NCT00687180||||TREATMENT||||||||
33855696|NCT06266819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study protocol in the research will be created using SPIRIT as a guide. Reporting of the trial will be structured according to the CONSORT checklist. Random distribution of pregnant women included in the study to the intervention and control groups will be made at www.randomizer.org. Which group will be the intervention or control group will be determined by drawing lots at the beginning of the study. Pregnant women in the intervention group will be given the practice of chewing mint-flavored gum.~Since the researcher knows which group the pregnant women are included in, the data collection phase of the study is single blind. To avoid selection bias in this study, pregnant women will be randomly assigned to the intervention and control groups by randomization method. To prevent reporting bias, the analysis of the research data will be carried out by an expert statistician."|two groups with chewing mint gum experimental group and a control group|f|f|f|t
33855697|NCT02284451|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33855698|NCT05077865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo is matching in appearance to the 150mg MYMD1 capsules|Double-blind, randomized, placebo-controlled study|t|f|t|f
33855699|NCT01280812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33958555|NCT05003739|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is open-label, not randomized, retrospective and longitudinal cohort clinical study. The follow up outcomes of each patient are compared with the baseline measurements of the same subject (preoperative assessment for clinician-based evaluations and patient-reported outcomes; immediate postoperative assessment for the radiographical evaluation)||||
33958556|NCT06523465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958557|NCT01284231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958558|NCT06543134|||COHORT||PROSPECTIVE|||||||
33958559|NCT00826176|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958560|NCT01111084|||COHORT||PROSPECTIVE|||||||
33958561|NCT06580782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data Analyst will be masked to the interventions assigned to participants.||f|f|f|t
33958562|NCT04450979|RANDOMIZED|PARALLEL||PREVENTION||||||||
33958563|NCT06564467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Drug: JMT202 Other: Placebo|t|t|t|t
33958564|NCT06537947|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33958565|NCT04911127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958566|NCT03923816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33958567|NCT02900300|||COHORT||RETROSPECTIVE|||||||
33958568|NCT03978897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treating therapists and patient will be aware of treatment. The outcome assessor will have access to outcome data only, without knowledge of which treatment patient received.||f|f|f|t
34168040|NCT03904212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168041|NCT00771199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168042|NCT03560310|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel treatment arms.||||
33958569|NCT00006385|RANDOMIZED|||TREATMENT||||||||
33958570|NCT05077774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958571|NCT00718978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958572|NCT03225820|||COHORT||OTHER|||||||
33958573|NCT05446376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958574|NCT05947799|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33958575|NCT01346501|||COHORT||PROSPECTIVE|||||||
33958576|NCT04528992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958577|NCT01902524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958578|NCT03974217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958579|NCT06384365|||COHORT||CROSS_SECTIONAL|||||||
33958580|NCT06658275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958581|NCT03930056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958582|NCT06702683|||COHORT||PROSPECTIVE|||||||
34062331|NCT01126866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062332|NCT01512459|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062333|NCT05770336|||COHORT||CROSS_SECTIONAL|||||||
34062334|NCT04128124|||COHORT||PROSPECTIVE|||||||
34062335|NCT01630356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34062336|NCT03667027|||CASE_CONTROL||PROSPECTIVE|||||||
34168043|NCT06522789|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34168044|NCT05980728|||COHORT||PROSPECTIVE|||||||
34168045|NCT06317753|RANDOMIZED|PARALLEL||PREVENTION||NONE||The protocol includes a randomized controlled trial with a follow-up at three months involving three groups of adolescents (18-24 Y) -experimental group 1, will be enrolled in the Aerobic program, experimental group 2 will be involved in the agility program, and an active control group that will be participating in a stretching program. Participants will be randomly assigned to each group.||||
34168046|NCT02431988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958583|NCT04504097|RANDOMIZED|PARALLEL||SCREENING||NONE||This cluster randomized controlled trial (cRCT) will evaluate the effectivness of HIVST delivery approaches on HIV testing uptake among refugee youth in Kampala. Clusters include 3 sites, informal settlements. Sites will be randomized in a 1:1:1 method to one of 3 study arms: Arm 1-HIVST, Arm 2- HIVST+ m-health, and Arm 3-standard of care (control). We propose a cRCT design of randomizing by slums to reduce the possibility of experimental contamination due to the shared social and physical environment in slums. Data collectors will administer tablet-based surveys (baseline, t1: 8 months, t2: 12 months). Arms 1 \& 2 will receive HIVST kits at each time-point.||||
33958584|NCT04493099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168047|NCT03192826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients are masked to their assignment by covering the labels on the bottles of the drugs administered The investigator responsible for the measurement of the intraocular pressure is also masked to the intervention administered to each patient.|This is a prospective, randomized, double masked comparative study|t|f|t|f
34168048|NCT02324283|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34168049|NCT01739036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34168050|NCT03537846|||COHORT||CROSS_SECTIONAL|||||||
34168051|NCT03857919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168052|NCT04154046|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients WHO meet all inclusion and non of the exclusion criteria are randomly allocated to two arms in the study. The allocation is stratified by treatment center.||||
34168053|NCT00496015|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168054|NCT04551118|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34168055|NCT00001002||||TREATMENT||NONE||||||
34168056|NCT04561895|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34168057|NCT01070589|||CASE_CONTROL||PROSPECTIVE|||||||
34168058|NCT03287817|NA|SINGLE_GROUP||TREATMENT||NONE||A dose escalation and expansion phase (Phase I) followed by Phase II||||
34168059|NCT01513408|NA|SINGLE_GROUP||OTHER||NONE||||||
34168060|NCT00990106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168061|NCT01467505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168062|NCT01658748|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34168063|NCT02371824|||CASE_ONLY||CROSS_SECTIONAL|||||||
34168064|NCT00295191|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33958585|NCT06672458|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33958586|NCT02087826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958587|NCT06700421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958588|NCT00797316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958589|NCT05512286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958590|NCT06542692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958591|NCT06055959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958592|NCT04434209|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34168065|NCT02456155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168066|NCT00293917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168067|NCT03326804|||CASE_ONLY||PROSPECTIVE|||||||
33748458|NCT03288662|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors||||
33748459|NCT01097538|RANDOMIZED|PARALLEL||||NONE||||||
33748460|NCT00656591|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34062337|NCT03818776|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm 1: 60 CGyE in 20 fractions (3+3 participants, 3-6 total) Arm 2: 69 CGyE in 23 fractions (3+3 participants, 3-6 total) Followed by expansion cohort at identified RP2 dose (12 participants)||||
33855700|NCT04254302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded data collection specialists will conduct pre-intervention COPM and PEDI-CAT interviews, as well as post-intervention PEDI-CAT interviews. All other measures are self-completed online. The researchers and data analyst will also be blinded to participant allocation. Participants will be made aware of their allocation group following goals selection.|The family will be the unit of randomization. A web-based randomization service will allocate participants to either usual care or the WECARE intervention (1:1). To ensure equal distribution of participants between arms, permutated blocks of variable (2:4:6) size will be generated. No stratification or minimization strategies will be used. Participants will be invited to set their motor-performance goals before allocation to avoid the influence of the allocation group on goals selection.|f|f|t|t
33855701|NCT00448409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855702|NCT05786833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855703|NCT06267586|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be unaware of arm allocation however as each arm contains a different number of capsules to be consumed, the investigator will be aware of the arm allocation|Randomized, single-blind, placebo-controlled, parallel dose response study conducted over 70 days|t|f|f|f
33855704|NCT03642951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855705|NCT04267783|||COHORT||PROSPECTIVE|||||||
33855706|NCT00182403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855707|NCT02159560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|patient, evaluator, statistician all blinded to assignment|Randomized, double-blinded comparison of two epidural catheter designs|t|t|t|t
34062338|NCT04935008|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||all patients in mechanical ventilation||||
34062339|NCT02869841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062340|NCT05212480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After initial medical evaluation, every patient who meet the inclusion criteria, will receive randomly either Zinc or Placebo as detailed above according to the predetermined randomization. Patients enrolled in the zinc group received 25 mg of zinc twice a day for 15 days. Patients enrolled in the placebo group received 1 capsule twice a day for 15 days.||t|t|f|t
34062341|NCT06333405|NA|SINGLE_GROUP||PREVENTION||NONE||single group, open label, observational study with intervention (FMT)||||
34062342|NCT02214862|NA|SINGLE_GROUP||||NONE||||||
34062343|NCT06193148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062344|NCT04532411|||OTHER||OTHER|||||||
34062345|NCT00005762||||TREATMENT||||||||
34062346|NCT03268018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062347|NCT00146666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062348|NCT01967095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062349|NCT05637112|||COHORT||PROSPECTIVE|||||||
34062350|NCT06482333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062351|NCT04189133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062352|NCT06285734|||OTHER||CROSS_SECTIONAL|||||||
34062353|NCT06731387|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study focuses on analyzing 50 medication dispensation processes on hospital wards, evenly distributed across two distinct periods: a control period without the involvement of Pharmaceutical Technical Assistants (PTAs) (medication dispensation by the night nurses) and an intervention period where PTAs actively participate in medication dispensation. Nurses and PTAs observed during the dispensation processes will be included in the study based on the selected medication dispensation moments during which they are on duty.||||
34062354|NCT00399295|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076645|NCT06415019|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The treatments (IPs and control) will not be blinded to investigative personnel involved in the preparation/application and removal of treatments. However, the Investigator and trained evaluator involved in the evaluation of responses, will remain blinded during the course of the study until Database Lock and finalization of the Statistical Analysis Plan.||t|f|t|t
34076646|NCT01153217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076647|NCT05044429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076648|NCT01617239|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855708|NCT01241097|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33855709|NCT05050916|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33855710|NCT00241605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855711|NCT05455138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855712|NCT03082742|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33855713|NCT05849948|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33855714|NCT02808637|RANDOMIZED|||PREVENTION||DOUBLE|||t|f|f|t
33855715|NCT01809223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855716|NCT04779372|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be random allocation into two groups named Group dCBT-I and Group Sleep Education.||||
33855717|NCT03016689|||CASE_ONLY||PROSPECTIVE|||||||
33855718|NCT01337115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33855719|NCT00655694|||COHORT||PROSPECTIVE|||||||
33855720|NCT02396043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958593|NCT04500054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958594|NCT04207892|||COHORT||PROSPECTIVE|||||||
33958595|NCT00013273|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958596|NCT06354972|||CASE_ONLY||RETROSPECTIVE|||||||
33855721|NCT00029172|RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
33855722|NCT05694572|||COHORT||PROSPECTIVE|||||||
33855723|NCT02948374|||COHORT||PROSPECTIVE|||||||
33855724|NCT05344820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33234822|NCT06692907|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Study staff including Outcomes Assessor, Study Statistician, Study Regulatory, QC coordinators and lab staff.||t|f|t|f
33855725|NCT03902223|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34168068|NCT04426318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There is no outcome assessor - all assessments will be conducted online by participants. Investigators will be blind to group assignment during data analysis. Analysis of hypotheses related to baseline characteristics, adherence and dosage cannot be blinded.|Random parallel assignment|f|f|t|f
34168069|NCT04524416|||OTHER||PROSPECTIVE|||||||
34168070|NCT05921435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855726|NCT03498482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855727|NCT04364009|RANDOMIZED|PARALLEL||TREATMENT||NONE||ANACONDA study is a French multicentre, open-label, randomized, controlled superiority trial comparing the administration of optimized standard of care and Anakinra versus optimized standard of care alone in patients hospitalized in a medical unit with COVID-19.||||
33855728|NCT01553305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855729|NCT02577731|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33855730|NCT02822638|||COHORT||PROSPECTIVE|||||||
34076649|NCT03900208|||COHORT||PROSPECTIVE|||||||
34076650|NCT06531902|||CASE_CONTROL||RETROSPECTIVE|||||||
34076651|NCT04745741|||COHORT||RETROSPECTIVE|||||||
34076652|NCT02403011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076653|NCT03227159|||COHORT||PROSPECTIVE|||||||
34076654|NCT02928796|||COHORT||PROSPECTIVE|||||||
34076655|NCT05537311|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor will be blinded to treatment group|pilot-randomized trial|f|f|f|t
34076656|NCT00473057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076657|NCT04892732|||COHORT||RETROSPECTIVE|||||||
34076658|NCT05883735|||COHORT||RETROSPECTIVE|||||||
34076659|NCT02146040|||COHORT||RETROSPECTIVE|||||||
34076660|NCT05332041|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34076661|NCT04974229|||COHORT||CROSS_SECTIONAL|||||||
34076662|NCT00447668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076663|NCT02768168|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34076664|NCT00058071|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34076665|NCT01976793|||COHORT||RETROSPECTIVE|||||||
34076666|NCT05550636|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076667|NCT06131450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076668|NCT02434874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076669|NCT03066232|||COHORT||PROSPECTIVE|||||||
34076670|NCT00000694||||TREATMENT||||||||
34076671|NCT04557735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076672|NCT06354218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076673|NCT00675987|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34076674|NCT01557478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076675|NCT00983645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076676|NCT04058639|RANDOMIZED|PARALLEL||TREATMENT||NONE||block randomization||||
34076677|NCT01240096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076678|NCT01516138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34076679|NCT02485483|||||PROSPECTIVE|||||||
34076680|NCT06320210|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34076681|NCT02248467|||COHORT||PROSPECTIVE|||||||
34076682|NCT02708550|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34076683|NCT02620683|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34076684|NCT03562078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34076685|NCT03718715|||COHORT||PROSPECTIVE|||||||
34076686|NCT05467852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076687|NCT00000363|RANDOMIZED|||TREATMENT||DOUBLE||||||
34076688|NCT00090896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076689|NCT06085521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076690|NCT01607593|||COHORT||RETROSPECTIVE|||||||
34076691|NCT02174224|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34076692|NCT02915159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076693|NCT01774383|||CASE_ONLY||PROSPECTIVE|||||||
34076694|NCT04758013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34076695|NCT03722082|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Primary outcome||f|f|f|t
34076696|NCT01040949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076697|NCT01119521|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076698|NCT05646927|||COHORT||PROSPECTIVE|||||||
34076699|NCT05074953|||COHORT||RETROSPECTIVE|||||||
34076700|NCT00543114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076701|NCT02057263|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33855731|NCT02794168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855732|NCT02017951|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33855733|NCT03413657|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE||"Subjects will be randomized to either undergo the PEEP challenge or tidal volume challenge first. After the initial challenge, subjects will cross over to whichever challenge has not yet been performed.~Subjects will be separated into the following categories: fluid responders and non-responders and analyzed in those categories."|t|t|t|t
33855734|NCT01018121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855735|NCT02621671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855736|NCT02293031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855737|NCT05939466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855738|NCT02044211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Blended intervention: Blended, centralized, nurse-provided, telephone-delivered collaborative care for both heart failure and depression;~Collaborative care for heart failure: Blended, centralized, nurse-provided, telephone-delivered collaborative care for heart failure alone~Usual Care: PCPs usual care for heart failure and depression; and~Non-Depressed comparison cohort (randomly sampled, not randomized)."|f|f|f|t
33855739|NCT03126708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855740|NCT00259987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855741|NCT02253108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958597|NCT04978194|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"During the first academic semester of the academic year 2021/2022, baseline assessments were carried out using an online questionnaire (made on qualtrics secure software) in three groups (online group, hybrid group, control group): measures of mental health (e.g., academic burnout, anxiety and depression), psychological processes (e.g., intolerance of uncertainty, coping, learned helplessness), learning (e.g., cognitive and metacognitive strategies, motivational strategies and beliefs about learning), situational factors (e.g., levels of concern about their health, the health of their loved ones) and socio-demographic factors (e.g., age, level of education, gender, field of study) These assessments were performed in October 2021 (First Time - T1) and December 2021 (Second time - T2).~During the first academic semester, a university-based intervention to promote better management of emotions and learning was realised in two Experimental group (online group and hybrid group)."||||
33958598|NCT04580511|||CASE_ONLY||PROSPECTIVE|||||||
33958599|NCT06263387|||COHORT||CROSS_SECTIONAL|||||||
33958600|NCT04301089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958601|NCT06515080|||COHORT||PROSPECTIVE|||||||
33958602|NCT06153979|||COHORT||PROSPECTIVE|||||||
33958603|NCT05176301|||COHORT||RETROSPECTIVE|||||||
33958604|NCT05454579|||COHORT||PROSPECTIVE|||||||
33958605|NCT00712907|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33958606|NCT04149288|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33958607|NCT06222398|||COHORT||PROSPECTIVE|||||||
33958608|NCT01059942|||COHORT||CROSS_SECTIONAL|||||||
33958609|NCT00003607|RANDOMIZED|||TREATMENT||||||||
33958610|NCT06390111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958611|NCT06700954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33958612|NCT06703671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, outcome assessors, and statisticians were blinded.|"In the electroacupuncture group, electroacupuncture was applied to selected acupoints for 30 min per treatment, and the treatment was performed 3 times per week (1-2 days between each treatment), receiving a total of 12 treatments in 4 weeks. Considering the possibility of uncontrollable factors such as temporary outings and overtime work during the treatment period, we will allow subjects to miss a maximum of 3 treatments, including 2 consecutive treatments.~In the sham acupuncture group, placebo-needle treatment was performed on nonacupoints for 30 min per treatment, and the treatment was performed 3 times per week (with an interval of 1-2 days between treatments), with a total of 12 treatments received in 4 weeks. Considering the possibility of uncontrollable factors such as temporary outings, overtime work, etc. during the treatment period, we will allow subjects to miss a maximum of 3 treatments, including 2 consecutive treatments."|t|f|t|t
33958613|NCT03303807|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33958614|NCT05689034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, Double-blind, Placebo-controlled Study||t|t|t|t
33958615|NCT06700798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958616|NCT03113175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958617|NCT05133843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, single center, open-label||||
33958618|NCT00130663|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958619|NCT02280915|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33958620|NCT05647733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the anesthesiology team will know the allocation received since they must implement the intervention, limiting differential outcome classification bias since they will not assess outcomes. Patients, surgeons, and non-anesthesia health professionals will be blinded to allocation.|Participants will be allocated to either group in a 1:1 ratio. A research assistant will randomize the patient once a viable graft is confirmed, and then share allocation with the anesthesiology team.|t|f|t|t
33958621|NCT04768218|||COHORT||CROSS_SECTIONAL|||||||
33958622|NCT03739996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062355|NCT05691244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this double-blind study, the subject and all relevant personnel involved with the conduct and interpretation of the study (including investigator, investigational site personnel, and the sponsor or designee's staff) will remain blinded to the identity of the Investigational Product (IP) assigned and the randomization codes. The final randomization list will be kept strictly confidential, filed securely by the independent biostatistician, and accessible only to authorized persons as per the sponsor's standard operating procedures until the completion of the study.|This is a multi-centric, randomized, double-blind, placebo-controlled phase-III clinical study to assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke.|t|t|t|t
34062356|NCT05495217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062357|NCT00655603|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34062358|NCT00597012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062359|NCT04842591|||COHORT||PROSPECTIVE|||||||
34062360|NCT06433934|NA|SINGLE_GROUP||TREATMENT||NONE||Each patient will receive mask #1, then receive mask #2. The flowrate to maintain same desired oxygen saturations will be documented.||||
33855742|NCT05635539|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||27 patients with COVID and 35 patients with Influenza||||
33855743|NCT01506141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062361|NCT03832504|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33855744|NCT02038543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855745|NCT02934425|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34062362|NCT03523780|||COHORT||RETROSPECTIVE|||||||
33855746|NCT02783521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855747|NCT02498496|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33855748|NCT05139433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A trained clinical psychologist, blinded to which group the subject was allocated, will clinically assess the child/adolescent at T0, T1 and T2|Participants will be randomized to be either in the intervention group (internet-based therapy) or the active control group (educational videos)|f|f|f|t
33855749|NCT00208923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855750|NCT03341351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessor performing the objective structured assessment of technical skills will be masked to the intervention of the participant.||f|f|f|t
33855751|NCT05433753|||COHORT||PROSPECTIVE|||||||
33855752|NCT02261051|||||PROSPECTIVE|||||||
33958623|NCT06155149|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A co-researcher in the project will sort the families alphabetically according to their surnames. The same co-researcher will write the number opposite each family in the list of families. An independent biostatistician, who is not involved in the study, and 30 families for each group will be determined from these numbers. Families living in container houses and tent cities were assigned to group A (control group) and group B (experimental group) by drawing lots. As a result of the draw of lots, group A will form the control group and group B will form the study group where the mobile application will be used. The data obtained from the research will be transferred to the computer environment by the other co-researcher who does not know which of the study and control groups are A and B groups. A biostatistician independent of the research will analyze the data and report the findings without knowing which of the A and B groups is the study group and which is the control group.|The study was planned as a prospective, two-arm (1:1), randomized controlled trial|f|f|t|t
33958624|NCT06073041|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Adopting and non Adopting clinics will be followed in a parallel fashion over the course of the study. Number of participants listed below is equivalent to clinics being invited to adopt.||||
33958625|NCT05037812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958626|NCT02737072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062363|NCT02450552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062364|NCT05691764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34062365|NCT01524822|||COHORT||PROSPECTIVE|||||||
34062366|NCT01634659|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34062367|NCT03727295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062368|NCT04594941|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34062369|NCT02381769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34062370|NCT05548491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-masked||f|f|f|t
34062371|NCT06697730|||COHORT||RETROSPECTIVE|||||||
34062372|NCT05629091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062373|NCT05437237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062374|NCT02603926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062375|NCT03066856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||BRCA mutation carriers, with or without breast cancer, aged 18-70 years and without metastases are eligible. After the baseline examinations, women are randomized to an active dietary intervention or to a control group. The intervention group should attend six full days of activities over the next six months.||||
34062376|NCT05225571|||OTHER||CROSS_SECTIONAL|||||||
34062377|NCT05460234|||COHORT||RETROSPECTIVE|||||||
34062378|NCT03091075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation will be performed using computer software and will occur at the pharmacy to ensure that all investigators are blinded.|Men and women aged 40 - 75 scheduled for rotator cuff repair, who have failed nonoperative management of chronic, full thickness rotator cuff tears confirmed by MRI, will be randomized into one of two groups, a control group (receiving placebo medication) and an experimental group receiving oral Oxandrolone for 12 weeks postoperative.|t|t|t|t
34062379|NCT01492725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062380|NCT03386617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062381|NCT05721638|||COHORT||PROSPECTIVE|||||||
34062382|NCT03175471|||COHORT||PROSPECTIVE|||||||
34062383|NCT04504175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855753|NCT05708404|||COHORT||RETROSPECTIVE|||||||
33855754|NCT04035174|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Results from LTS-2 patch will be immediately known by both participant and investigators ; but results from skin snips will be masked both for participant and investigators.|Each participant will have both a LTS-2 patch applied on the skin and a skin snip performed.|f|f|f|t
33855755|NCT03343457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855756|NCT00326469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855757|NCT06027164|||COHORT||PROSPECTIVE|||||||
33855758|NCT04454177|||COHORT||PROSPECTIVE|||||||
33855759|NCT00454766|||CASE_ONLY||PROSPECTIVE|||||||
33855760|NCT00491777|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855761|NCT04431401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33855762|NCT01944813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33855763|NCT04053530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysts, statistician and outcome assessor (A.O.) will be blinded after assignment to interventions while the operator will not due to the difference in restorative material presentation and its application protocol.|3 parallel groups|f|f|f|t
33855764|NCT03861117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855765|NCT02949505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855766|NCT04499274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062384|NCT05842005|NA|SINGLE_GROUP||TREATMENT||NONE||This study is designed as a prospective case series. Our hypothesis is that the mesh-reduced sling will improve stress urinary incontinence (SUI) symptoms in women with SUI and normal urethral closure pressure at 2 months and 12 months after surgery.||||
33855767|NCT00491829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855768|NCT00837408|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33855769|NCT00461487|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33855770|NCT01422226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855771|NCT05692297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855772|NCT05749289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855773|NCT00001563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855774|NCT04599608|||CASE_ONLY||PROSPECTIVE|||||||
33855775|NCT05251662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855776|NCT05624294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855777|NCT04012996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient is blinded to their treatment randomization until after surgery.|multi-center, prospective, randomized, controlled comparison|t|f|f|f
33855778|NCT04144504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855779|NCT01096134|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33748461|NCT05020639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855780|NCT01216033|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855781|NCT01321346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855782|NCT05490394|||COHORT||OTHER|||||||
33855783|NCT02898844|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33855784|NCT03503253|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm study with consecutive, eligible subject enrollment. All subjects will undergo percutaneous LAA leak closure procedure with detachable coils.||||
33958627|NCT03500887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33958628|NCT06144931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33958629|NCT05110625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958630|NCT05353491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33958631|NCT05368714|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of three study conditions: 1) economic empowerment (EE) only, 2) multiple family group-based family strengthening (MFG-based FS), 3) combined EE+MFG-based FS.||||
33958632|NCT00005160|||COHORT||PROSPECTIVE|||||||
33958633|NCT00294931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748462|NCT00479011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33748463|NCT02969889|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33748464|NCT02300220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748465|NCT06104410|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is designed as binary outcome parallel group non-inferiority trial||||
33748466|NCT00179023|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958634|NCT03716804|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Parallel assignment Intervention group: Educational intervention to prescribers and Medicine-Tab Nitrofurantoin (100 mg, 2 times daily for 7 days) to the patients.~Control group: No educational intervention to the prescribers and Medicine- of personal choice of physician(Tablet Ciprofloxacin, 500 mg/Tablet Cef 3, 200 mg/Tab Cefuroxime, 250 mg) to the patients."||||
33958635|NCT06353087|||OTHER||PROSPECTIVE|||||||
33958636|NCT06536946|||CASE_ONLY||RETROSPECTIVE|||||||
34062385|NCT06294665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062386|NCT01903681|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34062387|NCT04484155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062388|NCT04717388|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34062389|NCT02384109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062390|NCT00087425||||TREATMENT||NONE||||||
34062391|NCT02356510|||COHORT||RETROSPECTIVE|||||||
34062392|NCT00098566|||COHORT||PROSPECTIVE|||||||
34062393|NCT06624020|||COHORT||RETROSPECTIVE|||||||
34062394|NCT06283680|||COHORT||RETROSPECTIVE|||||||
34062395|NCT05299619|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, prospective, non-masked, pilot study, to assess the safety and efficacy of the Tixel treatment.||||
34062396|NCT02758873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062397|NCT00214734|||CASE_ONLY||PROSPECTIVE|||||||
34062398|NCT05538091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062399|NCT03117881|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34062400|NCT06304922|||COHORT||PROSPECTIVE|||||||
34062401|NCT05433480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062402|NCT02199639|||COHORT||PROSPECTIVE|||||||
34062403|NCT00507351|||CASE_ONLY||PROSPECTIVE|||||||
34062404|NCT03084757|NA|SINGLE_GROUP||SCREENING||NONE||||||
34062405|NCT05149573|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The participant and study investigator will not know whether the study participant has received PEMF (treatment) or Sham (control) therapy. Only the study coordinator, who will distribute the devices to study participants, will be unmasked to the therapies.|"This study is designed as a double-blind, sham-controlled clinical trial separated into two Aims. Aim 1 will include 60 female adults with IC/BPS, divided into two groups: 1) 30 participants with an anesthetic bladder capacity (BC) ≤ 400cc and 2) 30 participants with BC \> 400cc. Patients within each of the two groups will be randomly assigned in a 1:1 ratio to either the PEMF (treatment) or Sham (control) group. The Sham device is identical to the treatment device but does not deliver PEMF. All participants will be instructed to use their device every day, morning and evening, for 8-minute sessions over a 4-week period.~Aim 2 will include an additional cohort of 15 female adults with IC/BPS. These participants will undergo the standard 4-week regimen of PEMF therapy, followed by a one-week-per-month maintenance period of twice daily PEMF therapy for an additional 3 months post-enrollment (the fourth week in months 2, 3, and 4)."|t|f|t|f
34062406|NCT05957224|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The participants will be blinded to the intervention as the shakes will be given in unmarked containers - however as the flavours are very different it is likely that participants will be able to tell them apart. Data analysts will be blinded.|There is a one-week washout period between intake of the two shakes.|t|f|f|t
34062407|NCT00361166|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34062408|NCT04529850|NA|SINGLE_GROUP||PREVENTION||NONE||To evaluate the effects of GC4419 in subjects with head and neck cancer, who are at high risk for Severe Oral Mucositis (SOM)||||
33748467|NCT03282227|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Single dose, open-label treatment||||
33958637|NCT06703112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study will develop a multimodal public dataset incorporating ultrasound, MRI images, and clinical data, which will be used to train convolutional neural networks (CNNs) for the intelligent classification of ovarian tumors. The dataset will be constructed using retrospective multicenter data and validated prospectively in clinical settings. To ensure privacy and data security, federated learning will be employed to facilitate collaborative model training across multiple centers without sharing raw patient data. The primary outcome will be the accuracy of AI in predicting common pathological types of ovarian tumors, compared to traditional diagnostic methods.||||
33958638|NCT05204628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958639|NCT06445738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm, non-randomised study using MRI and pathological findings to select patients for omission of post-operative radiotherapy.||||
33958640|NCT03022019|RANDOMIZED|PARALLEL||TREATMENT||||||||
33958641|NCT05534191|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33958642|NCT06703528|||COHORT||PROSPECTIVE|||||||
33958643|NCT05900739|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33958644|NCT03430557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958645|NCT06701188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958646|NCT04216537|||COHORT||OTHER|||||||
33958647|NCT05867173|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33958648|NCT05713916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized pragmatic clinical trial|t|t|f|f
33958649|NCT01576731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958650|NCT00002634||||TREATMENT||||||||
33958651|NCT01845090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958652|NCT06598540|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants would not know the difference between the two arms of the study other than there are two different behavioral nutrition interventions. The biostatistician analyzing the data would not know which arm of the study participants were assigned to.|We will conduct a randomized controlled trial to compare the impact on physician well-being outcomes of a brief mindset intervention that frames daily food choices as an opportunity for demonstrating self-kindness to a brief nutrition education intervention (control) among physicians on burnout, self-compassion, self-kindness, and diet quality in physician during 6-weeks. Surveys will be completed at baseline and in weeks 2, 4, and 6 after the start of the intervention.|t|f|f|t
33958653|NCT03102138|||COHORT||PROSPECTIVE|||||||
33958654|NCT00182273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33958655|NCT02656875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958656|NCT03660514|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The Jovenes Sanos study will take place in two urban clinics in Tijuana, Mexico for all clients receiving voluntary FP counseling. The intervention study will involve a matched cluster control trial. Two clinics will serve as the intervention sites.||||
33958657|NCT01467401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958658|NCT00257088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958659|NCT04427930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958660|NCT06526923|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single ascending dose||||
33958661|NCT06499896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958662|NCT05907902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded-endpoint, PROBE design|Participants are assigned to two groups in parallel for the duration of the study.|f|f|f|t
33958663|NCT05558189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062409|NCT00412594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062410|NCT02476370|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34062411|NCT04353388|||CASE_CONTROL||PROSPECTIVE|||||||
34062412|NCT04643964|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are told they may or may not be asked to watch videos and fill out worksheets. More detailed descriptions of the interventions being tested are not provided.|Participants will be randomly assigned to one of three conditions: (1) a brief intervention focused on one domain of coping skills (the entrée condition), (2) a brief intervention focused on three domains of coping skills (the sampler condition), or (3) a no-intervention control condition. If participants are randomly assigned to the first condition, they will be further randomized into one of three brief interventions: (1) a focus on cognitive coping skills, (2) a focus on behavioral coping skills, or (3) a focus on interpersonal coping skills. The sampler condition will involve limited coverage of each of these same three types of skills.||||
34062413|NCT05490134|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||All participants will be randomized to one of four stimulation groups in a 1:1:1:1 fashion such that each group will have 34 participants. Within each group, participants will be randomized to either receive naloxone or saline on their first visit, and the opposite on their second visit. The drug visit will be counterbalanced within each group to avoid a potential order confound.|t|t|t|t
34062414|NCT03304184|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will be treated with a tooth colored filling that will be placed near the gum line. The second group will be treated with a white colored filling that will be placed near the gum line.||||
34062415|NCT01063985|||||PROSPECTIVE|||||||
34062416|NCT03745040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded and will not be informed if they received the study drug or not.|This is a prospective randomized clinical trial with two cohorts: one experimental and one control.|t|f|f|f
34076702|NCT04670120|RANDOMIZED|PARALLEL||TREATMENT||NONE||First group: Pyfazimine 100mg group, 12 cases. Second group: Pyfazimine 200mg group, 12 cases. Third group: Pyfazimine 300mg group, 12 cases. Forth gourp: Pyrazinamide 1500mg group, 10 cases. Fifth group: Pyfazimine 200mg + Pyrazinamide 1500mg group, 10 cases.||||
34076703|NCT05105347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076704|NCT03775083|||COHORT||PROSPECTIVE|||||||
34076705|NCT00387322|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748468|NCT01870141|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748469|NCT03823118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748470|NCT05239234|||COHORT||PROSPECTIVE|||||||
33855785|NCT05808504|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Sham and real tACS will be applied with the same equipment (StarStim, Neuroelectrics). The stimulation will consist in applying a current (max 2 mA) at frontal sites (F8 and Cz) for 12-15 minutes during the task. A 10 s ramp (fade-in/fade-out) will be used to avoid current perception of the stimulation and optimize blinding. Sham stimulation will be done using the same protocol, but with no stimulation in between onset and offset. According to the most recent literature (Russo et al., 2013), tACS does not usually cause other sensations, allowing to distinguish it from sham. EEGs will be performed with the same chronology and monitoring. As a whole V2 and V3 will consist of this pattern : task+EEG before stimulation, then task+stimulation, then task+EEG. Blinding of the experimenter will be made possible because it is the PI who will start the stimulation program and he will not be involved in the analysis of the raw data and a random number will be given to the participant.|The experimental phase will consist of 3 visits. A first one will consist of a neuropsychological exam with the MoCA, STAI, MADRS and LARS scales. Participants will also perform the Stop Task with an EEG recording. V1 has several purposes: check for inclusion criteria, define subject-specific frequency used for the stimulation, based on EEG analysis. With V1 we will also make sure that PD patients (recruited after controls), have an impaired performance at the task compared to controls. After V1, two other visits will be carried out with a 3 month interval. At V2, participants will be offered in a pseudo-randomized order either the real stimulation or the sham stimulation, with inhibition and EEG assessment (total time 45 min) before and after stimulation. The stimulation condition will be reversed during V3. V2 or V3 will also be accompanied by a brief neurological exam using the Hoehn and Yahr, and Schwab and England evaluations, and a measure of the levodopa equivalent daily dose.|t|t|f|f
33855786|NCT00179049|||CASE_ONLY||PROSPECTIVE|||||||
33855787|NCT00188175|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33855788|NCT02475902|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33855789|NCT03433911|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855790|NCT03019185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855791|NCT06341348|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|A trained interviewer, who was blind with the study design and participants, was assigned to collect the participants' information on demographic and disease characteristics.|||||
33855792|NCT02388867|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33855793|NCT03021954|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33855794|NCT02846753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855795|NCT00413296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855796|NCT00629460|||COHORT||CROSS_SECTIONAL|||||||
33855797|NCT02270086|||COHORT||PROSPECTIVE|||||||
33855798|NCT04693494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded: spontaneous behavior of babies is evaluated, that doesn't depend of having knowledge of the intervention. Outcomes assessor doesn't know the evaluated baby group.|Intervention and control group.|t|f|f|t
33855799|NCT00081406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855800|NCT03718910|||COHORT||CROSS_SECTIONAL|||||||
33855801|NCT01492530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855802|NCT05205915|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33855803|NCT03628898|NA|SINGLE_GROUP||OTHER||NONE||||||
33855804|NCT01620255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33855805|NCT04648735|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|the participant and the outcome assessor were both blind to the design.|an observational, cross-sectional research design|t|f|f|t
33855806|NCT06335043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855807|NCT00250679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33855808|NCT00312143|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33855809|NCT01048580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855810|NCT05714631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855811|NCT02787837|||COHORT||PROSPECTIVE|||||||
33855812|NCT01395979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33855813|NCT01246934|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33855814|NCT02799953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33855815|NCT01821716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855816|NCT05423626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open lable randomized clinical trial|t|f|f|f
33958664|NCT05755724|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blinded|The study will be designed as a single-centre, prospective, double blinded, randomized (1:1) trial|t|f|f|t
33958665|NCT06567288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958666|NCT06103838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855817|NCT05048433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855818|NCT03991104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855819|NCT01327859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855820|NCT00717067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855821|NCT05720988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855822|NCT01935180|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33855823|NCT02307760|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33855824|NCT00134433|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33855825|NCT03523260|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33855826|NCT03143816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855827|NCT02688673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855828|NCT03438786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"patients will be randomized into two groups according to the surgical technique performed as follows :-~* Group A: Patients undergoing TIPP hernioplasty~* Group B: Patients undergoing lichtnestein's technique hernioplasty"|t|f|f|f
33855829|NCT04997733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855830|NCT00396500|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33855831|NCT04541537|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||TRIPLE||Experimental, interventional, prospective, open, monocentric study with risks and minimal constraints|t|f|t|t
33958667|NCT06235125|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958668|NCT00567996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958669|NCT03934437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958670|NCT03654807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958671|NCT00403923|||CASE_CROSSOVER||PROSPECTIVE|||||||
33958672|NCT01232062|||COHORT||RETROSPECTIVE|||||||
33958673|NCT06675695|||COHORT||RETROSPECTIVE|||||||
33958674|NCT03441958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958675|NCT00418756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958676|NCT04834297|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958677|NCT00637793|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33958678|NCT06701305|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33958679|NCT06651931|||COHORT||RETROSPECTIVE|||||||
33958680|NCT06263543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958681|NCT02362243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958682|NCT03962218|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34168071|NCT04934371|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"All audiological evaluations and tinnitus questionnaires performed before and after treatment will be carried out by trained personnel blind to the treatment condition. The neuroConn DC stimulator has a study mode where input codes will be used (the researcher and the participants will be blinded to these codes) and the settings generated will be either a sham or actual stimulation"|Each patient will undergo tDCS and active listening therapy. This will be double-blinded randomized-sham controlled intervention during which excitatory/anodal tDCS or sham will be administered alongside active listening therapy 5 times a week for 2 weeks. After 2-month follow up participants will be crossed-over to the other treatment type. (Model AB- BA|t|t|t|f
33855832|NCT01139060|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855833|NCT05030987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168072|NCT00495729|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33855834|NCT01490671|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33855835|NCT02232412|||CASE_ONLY||PROSPECTIVE|||||||
33855836|NCT00562211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855837|NCT01110876|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855838|NCT03286322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855839|NCT01431222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855840|NCT03728322||SEQUENTIAL||TREATMENT||NONE||||||
33855841|NCT03425071|||CASE_ONLY||CROSS_SECTIONAL|||||||
33855842|NCT05428423|||COHORT||PROSPECTIVE|||||||
33855843|NCT03251196|||COHORT||PROSPECTIVE|||||||
33855844|NCT03030703|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33855845|NCT04942730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855846|NCT04424797|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prone vs. Supine positioning||||
33855847|NCT01485354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855848|NCT00666679|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33855849|NCT02037841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33855850|NCT00676377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33855851|NCT03412305|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The tablets corresponding to each patient is packed in a container by the manufacturer of the trial drug. Each drug container is labeled by a code number (1-1000) and the contents of the containers are distributed according to a randomization list with block size 6. Randomization is thus carried out by the manufacturer, independent of investigator and participating clinicians.|Randomized, placebo-controlled trial|t|t|t|t
33855852|NCT02125708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855853|NCT04278001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|When evaluating data quality from either device, PI will be blinded to corresponding BP of the other device.|||||
33855854|NCT04012138|RANDOMIZED|PARALLEL||TREATMENT||NONE||InSaKa trial is a therapeutic, controlled, open label, with parallel groups of treatment in a 1:1:1 ratio, multi-centre, national and randomized clinical trial to compare insulin/dextrose intravenous infusion, nebulized salbutamol or combination of salbutamol and insulin/dextrose to reduce serum potassium levels at 60 minutes.||||
34168073|NCT04353128|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168074|NCT00153036||||TREATMENT||||||||
33855855|NCT05703074|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|For the NR vs placebo comparison, participants, care providers, investigators and outcome assessors are blinded. For the MBRT vs. usual care comparison, due to the nature of the intervention, only outcome assessors are blinded|A 2 x 2 factorial randomized controlled trial, where Mind-Body Reprocessing Therapy (MBRT) is compared with care as usual and Nicotinamide Riboside (NR) is compared with placebo.|t|t|t|t
33855856|NCT03613285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855857|NCT03933930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855858|NCT04388774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168075|NCT04092153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34168076|NCT03767647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168077|NCT02980471|||CASE_ONLY||PROSPECTIVE|||||||
34168078|NCT01175863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168079|NCT01777074|||COHORT||CROSS_SECTIONAL|||||||
34168080|NCT03746626|||COHORT||PROSPECTIVE|||||||
34062417|NCT05347290|RANDOMIZED|PARALLEL||OTHER||NONE||This single center randomized 1-3 month clinical study compares conventional lead aprons and ancillary shields to the Rampart IC, M1128 fully configurable, portable, floor supported system that provides radiation protection and orthopedic safety for operators and the scrubbed interventional team members. There will be three study arms, each arm requiring 21 procedures for a total of 63 total procedures. Each enrolled subject may be involved in more than one procedure/case. For all arms, subjects will wear real-time dosimeters on their right temple, shoulder, and hip, and values will be collected post-procedure.||||
34062418|NCT01374477|||CASE_CONTROL||PROSPECTIVE|||||||
33855859|NCT06485362|||CASE_CONTROL||PROSPECTIVE|||||||
33855860|NCT03139357|||OTHER||PROSPECTIVE|||||||
33855861|NCT02485054|||CASE_ONLY||PROSPECTIVE|||||||
33855862|NCT03968120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33855863|NCT01894633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855864|NCT04507126|NA|SINGLE_GROUP||OTHER||NONE||||||
33855865|NCT01143974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855866|NCT00225693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33855867|NCT03674463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855868|NCT04175821|||CASE_ONLY||RETROSPECTIVE|||||||
34062419|NCT00904839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062420|NCT05657457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062421|NCT06249178|||CASE_ONLY||PROSPECTIVE|||||||
34062422|NCT00003028||||TREATMENT||||||||
34062423|NCT03138200|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34062424|NCT00540904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062425|NCT05353634|||COHORT||RETROSPECTIVE|||||||
34062426|NCT03102307|||COHORT||PROSPECTIVE|||||||
34062427|NCT06712615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
34062428|NCT02679989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062429|NCT06472999|||COHORT||PROSPECTIVE|||||||
34062430|NCT04373798|||COHORT||PROSPECTIVE|||||||
34062431|NCT05359510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062432|NCT05947227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group A will be treated with manual chest physical therapy and Buteyko breathing technique Group-B will be treated with manual chest physical therapy and Diaphragmatic breathing technique. Patients will perform the technique 5 times a weeks for 8weeks and treatment evaluation will be done after 8 weeks.|t|f|f|f
34062433|NCT05272826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062434|NCT04226495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062435|NCT05104424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062436|NCT06625411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, Investigator, Outcomes Assessor and Sponsor will be masked.|Participants will be randomized to one of the three study arms.|t|f|t|t
34062437|NCT05260424|||CASE_CROSSOVER||PROSPECTIVE|||||||
34062438|NCT01238094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062439|NCT04181268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062440|NCT04840524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34062441|NCT01792323|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34062442|NCT01230684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062443|NCT05830669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34062444|NCT03329248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062445|NCT03407547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062446|NCT00825656|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34062447|NCT05537649|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34062448|NCT04411147|||COHORT||PROSPECTIVE|||||||
34062449|NCT05652400|||COHORT||PROSPECTIVE|||||||
34062450|NCT02647255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062451|NCT00649233|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34062452|NCT00303212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062453|NCT02564406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062454|NCT01032070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062455|NCT03844594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168081|NCT00809263|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34168082|NCT02447965|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34168083|NCT03111563|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33855869|NCT02536391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855870|NCT03286257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855871|NCT04154176|||COHORT||PROSPECTIVE|||||||
33855872|NCT02019043|RANDOMIZED|CROSSOVER||SCREENING||NONE||Note: Although the trial period and recruitment is complete, data entry is ongoing. Completion of data entry is anticipated for August 2018.||||
33855873|NCT03074760|||COHORT||RETROSPECTIVE|||||||
33855874|NCT02838693|||COHORT||PROSPECTIVE|||||||
33855875|NCT04256382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34062456|NCT02966119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062457|NCT01195181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062458|NCT01395173|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34062459|NCT02339155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062460|NCT06731712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34062461|NCT04394793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062462|NCT03127813|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34062463|NCT06703619|||COHORT||PROSPECTIVE|||||||
34062464|NCT01857700|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34062465|NCT00346736|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33855876|NCT00172484|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34062466|NCT02631902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062467|NCT06731075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Contract Reserarch Organization and Medical Laboratories.|In this randomized, double-blind, double dummy, placebo-controlled study, approximately 300 eligible subjects with T2DM and inadequate control on at least one to three glucose-lowering agents will undergo an initial 4-week Screening Period. This will be followed by a 26-week Double-Blind Treatment Period, commencing with a safety Follow-up Visit four weeks after the completion of the trial.|t|t|t|t
34168084|NCT04753684|||COHORT||RETROSPECTIVE|||||||
34062468|NCT06730178|NA|SINGLE_GROUP||TREATMENT||NONE|Of 47 qualified subjects, 24 volunteers took part in this study after the researchers had explained the study process. All subjects had been diagnosed as having primary insomnia or insomnia related to medical and psychiatric comorbid diagnoses using the D Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) diagnostic criteria.|All insomnia patients were asked to complete the insomnia scales. The goals and processes of relaxation training were explained by therapists. The patients were asked to record data before relaxation training, inclusive of all sleep durations, the frequency of night waking, the time needed to fall asleep, and medication history. The insomnia scales were completed again one week later, and the relaxation training started in the second week. The patients recorded their sleep conditions every day and underwent relaxation training intervention for 4 weeks. They were treated similarly, four times in total.||||
34062469|NCT05605509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062470|NCT06285084|||COHORT||PROSPECTIVE|||||||
33855877|NCT03719170|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A cluster-randomized (by Veterans Integrated Service Networks or VISN) pragmatic trial of the provider-centered intervention versus pragmatic control.||||
34062471|NCT01249833|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34062472|NCT02007044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062473|NCT06731114|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups.one group will recieve conventional physical therapy including hot pack and tens for 10mins and suboccipital muscle release ( 3mins 3 reps) 9 mins .12 sessions in total where as group B will receive Sternocleidomastoid release for 5 mins along with suboccipital muscle release and conventional physical therapy.||||
34062474|NCT01440387|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062475|NCT05161078|||COHORT||OTHER|||||||
34062476|NCT00156000|||COHORT||PROSPECTIVE|||||||
34062477|NCT04747990|||COHORT||RETROSPECTIVE|||||||
34062478|NCT05245045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062479|NCT03062995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062480|NCT01451554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062481|NCT03907930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blinded study|group of patients will be submitted for conventional PCNL other group will be submitted to tubeless PCNL|t|t|t|f
33855878|NCT05821231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855879|NCT02614573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855880|NCT01200420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855881|NCT02164383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855882|NCT00012298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958683|NCT03111407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study patients will not know if their knee prosthesis will be implanted with iAssist or with conventional instrumentation|2 groups of patients: 1 will have the knee prosthesis implanted with iAssist and the other with conventional instrumentation.|t|f|f|f
33958684|NCT00928785|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958685|NCT06702956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized double blinded clinical trial|t|f|t|t
33958686|NCT05150821|||CASE_CONTROL||RETROSPECTIVE|||||||
33958687|NCT01955473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958688|NCT00000394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33958689|NCT00435240|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062482|NCT03986554|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants will include healthy adults, between the ages of 18 and 45 years with no major medical history.||||
34062483|NCT05740345|||OTHER||OTHER|||||||
34062484|NCT03386604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34062485|NCT02219776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34062486|NCT03568032|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062487|NCT03226678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062488|NCT06378632|||CASE_ONLY||PROSPECTIVE|||||||
34062489|NCT04767854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062490|NCT06730347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062491|NCT02539134|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34062492|NCT01159288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062493|NCT06710457|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33855883|NCT00264953|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33855884|NCT04647045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||A randomized single-blind case controlled trial was performed in patients who were diagnosed with constipation-predominant irritable bowel syndrome. Each recruited participant was given three bottles of 125 ml cultured milk drink containing 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01 consumed daily for 30 days. At pre- and post-30-day consumption, fecal pH, ITT, clinical symptoms, IL-6, IL-8 and TNF-α levels were assessed.|t|f|f|f
33855885|NCT04127890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855886|NCT00573495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855887|NCT00715481|||COHORT||PROSPECTIVE|||||||
33855888|NCT05412849|||CASE_CONTROL||RETROSPECTIVE|||||||
33855889|NCT05570123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33855890|NCT05900882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855891|NCT04664673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Allocation|f|t|f|t
33855892|NCT05254574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855893|NCT01895153|||COHORT||PROSPECTIVE|||||||
33958690|NCT02704299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958691|NCT02246231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958692|NCT03935451|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34062494|NCT06055998|||CASE_CROSSOVER||PROSPECTIVE|||||||
33855894|NCT05710861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicentric pragmatic clinical trial, comparative, with no insu, randomized in two parallel groups with a 1:1 allocation ratio|t|f|f|f
33855895|NCT02855970|NA|SINGLE_GROUP||||NONE||||||
33855896|NCT04753320|||COHORT||PROSPECTIVE|||||||
34062495|NCT01323504|RANDOMIZED|PARALLEL||||NONE||||||
33855897|NCT02683941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855898|NCT02202668|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33855899|NCT02418273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855900|NCT04299438|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33855901|NCT05231031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33958693|NCT01413685|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062496|NCT06718036|||COHORT||OTHER|||||||
34062497|NCT04512365|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|THC or placebo will be prescribed to participants by a licensed psychiatrist, and dispensed by the University of Illinois at Chicago's Investigational Drug Service (IDS). Staff at the Clinical Research Center will give the drug or placebo to participants with the PI or a physician designate, present on-site and/or available by pager.|Half of the participants will receive placebo during the first laboratory visit and THC during the second laboratory visit. The other half of participants will receive THC during the first laboratory visit and placebo during the second laboratory visit.|t|f|t|f
33958694|NCT01995773|||COHORT||CROSS_SECTIONAL|||||||
33958695|NCT06630936|||COHORT||PROSPECTIVE|||||||
33958696|NCT06604299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958697|NCT06538207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062498|NCT05922813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062499|NCT03043911|||CASE_ONLY||PROSPECTIVE|||||||
34062500|NCT04544943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062501|NCT05604326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33958698|NCT05292079|||COHORT||PROSPECTIVE|||||||
33958699|NCT04127994|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33958700|NCT01038531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062502|NCT04072731|||COHORT||RETROSPECTIVE|||||||
34062503|NCT01643798|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33855902|NCT00027495||||PREVENTION||||||||
34062504|NCT06132113|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A: Dose escalation, Part B: Dose expansion||||
34062505|NCT06291740|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial (RCT)||||
33855903|NCT00701779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855904|NCT03405441|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34062506|NCT03693794|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34062507|NCT02607280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062508|NCT05703464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062509|NCT04693468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062510|NCT01584401|||COHORT||PROSPECTIVE|||||||
34062511|NCT06512883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062512|NCT01656187|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34062513|NCT03743480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|centralized randomization|||||
34062514|NCT00694720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062515|NCT03398239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062516|NCT03284112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076706|NCT05337865|||COHORT||PROSPECTIVE|||||||
34076707|NCT04786691|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The investigators performing the gastric ultrasound will be blinded to which arm of the study the participant is currently in.|Randomized Controlled Crossover|f|f|t|t
34076708|NCT05988762|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will not be told whether they are performing the supramaximal or submaximal walkout. Black trash bags will be used to cover the weights during the walkout set so that the participant cannot see which condition they are in.||t|f|f|f
34076709|NCT01807533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34076710|NCT05041556|||CASE_CONTROL||PROSPECTIVE|||||||
34076711|NCT03119948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076712|NCT00956839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076713|NCT00148044|||||PROSPECTIVE|||||||
34076714|NCT02408198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076715|NCT03358550|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Sequence of tests was randomized. It is no multi-arm study.|||||
34076716|NCT05388981|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Placebo-controlled, sequential escalating dose cohorts|t|t|t|t
34076717|NCT03225287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076718|NCT01834339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076719|NCT03167554|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Randomized controlled clinical trial.|t|t|f|t
34076720|NCT01921517|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34076721|NCT02558842|RANDOMIZED|PARALLEL||||NONE||||||
34076722|NCT04633681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind study. Neither the participant nor the investigator will be aware of the coding of food products used in the study.|Double-blind, within-subjects, cross-over trial|t|f|t|f
34076723|NCT01419314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076724|NCT00523770|||COHORT||PROSPECTIVE|||||||
34076725|NCT05856253|||COHORT||RETROSPECTIVE|||||||
34076726|NCT04862260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076727|NCT02574663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855905|NCT03271203|||COHORT||CROSS_SECTIONAL|||||||
33855906|NCT03218241|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33855907|NCT00121277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855908|NCT00275262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855909|NCT03126045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither patients know the needle used during the spinal punction, nor the person collecting the information.|Arm 1: standard needle Arm 2: Atraumatic needle|t|f|f|t
33855910|NCT00167817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855911|NCT05631301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The M\&C-Youth \& M\&C-Caregiver intervention will both run for six weeks in one of three groups (Two treatments: direct, virtual; One control: waitlist). The treatment sessions run once a week and last approximately one hour. Individuals initially enrolled in the waitlist control arm will be subsequently be invited to participate in the intervention arm of the study.||||
33855912|NCT01095263|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33855913|NCT00593957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855914|NCT02911493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33855915|NCT02707731|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33855916|NCT05802641|||COHORT||OTHER|||||||
33855917|NCT06215677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855918|NCT01314820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33855919|NCT04524884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855920|NCT03869723|||COHORT||RETROSPECTIVE|||||||
33855921|NCT05458557|||OTHER||CROSS_SECTIONAL|||||||
33855922|NCT05888051|||OTHER||OTHER|||||||
33855923|NCT03369561|||COHORT||PROSPECTIVE|||||||
33855924|NCT05084443|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33855925|NCT00575029|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33855926|NCT04433585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855927|NCT03027154|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33855928|NCT00652860||||TREATMENT||NONE||||||
33855929|NCT05637385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-way mixed (one within, one between) factor study. Same training, applied to central vision loss group and normal vision control group viewing with simulated central scotomas.||||
33855930|NCT00621387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33855931|NCT04289766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855932|NCT06367010|||COHORT||RETROSPECTIVE|||||||
33855933|NCT04921137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855934|NCT01812551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855935|NCT06076603|||COHORT||PROSPECTIVE|||||||
34062517|NCT04267159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The AFFECT trial is a randomized clinical trial with a non-inferioirity setting studying the applicability of delayed rhythm control in the management of acute paroxysmal or persistent atrial fibrillation or flutter.~Patients are randomized to two treatment protocols in 2:3 ratio. For every two patients randomized to conventional treatment, three patients are randomized to experimental treatment. The randomization ratio is designed to allow for maximally one third of the patients in the experimental treatment group to drop-out without compromising the power of the study.~Overall five hundred patients are required to show non-inferiority with a one-sided alpha value 0.025 and 90% power expecting a maximal drop out rate of 33% (n=100) from the experimental treatment arm."|f|f|f|t
34076728|NCT01101750|NA|SINGLE_GROUP||OTHER||NONE|No masking.|Prospective study to evaluate immune response to the Gardisil vaccine in patients with a history of liver transplant and patients with a history of kidney transplant.||||
33855936|NCT05955313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855937|NCT00525187|||DEFINED_POPULATION||OTHER|||||||
33855938|NCT00311285|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33855939|NCT02985320|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33855940|NCT04417946|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33855941|NCT00721669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855942|NCT01197859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855943|NCT03616925|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients for this study were selected from the outpatient section of the Department of Periodontics, KLE Society's institute of Dental Sciences, Bangalore, Karnataka. Fifteen patients, aged between 30-55 years (10 males and 5 females) diagnosed with chronic periodontitis, contributing to 30 sites were enrolled for the study by convenience sampling method. It was made clear to the potential subjects that participation was voluntary. Written informed consent was obtained from patients, and ethical clearance for the study was received from the Institutional Ethics Committee (IEC), KLE Society's institute of Dental Sciences, Bangalore. This Randomized controlled trial was carried out from November 2013 to October 2014.||||
33855944|NCT05400980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All subjects will be blinded to the treatment assignment up to the primary efficacy endpoint (3 months post-procedure).|Randomization in a ratio 2:1 Urocross Expander implant using the Urocross Expander System vs. Sham control (cystoscopy only)|t|f|f|t
33855945|NCT04658082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33855946|NCT06020807|||COHORT||PROSPECTIVE|||||||
33855947|NCT00280943|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
33855948|NCT00790465|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33855949|NCT04327076|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33855950|NCT01445067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855951|NCT06447077|||COHORT||PROSPECTIVE|||||||
33855952|NCT04823221|||CASE_ONLY||RETROSPECTIVE|||||||
33855953|NCT00752310|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33855954|NCT05369273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33855955|NCT00436033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855956|NCT04457167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase III, non-randomized, monocentric, observational, prospective trial.||||
33855957|NCT01179425|NON_RANDOMIZED|PARALLEL||||NONE||||||
33855958|NCT05488574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Investigators doing data collection will not know which subjects are interventional and which are controls. Outcomes assessor will not be aware of which group of subjects were interventional and which did not participate in intervention.|A randomized control group, investigator blinded, repeated measure interventional program.|f|f|t|t
33855959|NCT06310057|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose escalation study, all the patients will recieve 10mg tofacitinib at the beginning. Then at 3rd month, one group will continue at 10mg, if they fulfill the ASDAS major improvement criteria and other group will escalate to 15mg.||||
34076729|NCT02524340|||COHORT||RETROSPECTIVE|||||||
33855960|NCT05379582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855961|NCT02585479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855962|NCT00743275|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33855963|NCT00102609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855964|NCT02083874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855965|NCT01556295|||||CROSS_SECTIONAL|||||||
33855966|NCT01139021|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33855967|NCT01896154|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33855968|NCT00945308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33855969|NCT01296373|||COHORT||PROSPECTIVE|||||||
33855970|NCT03258164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33855971|NCT00838929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33855972|NCT02296970|||OTHER||PROSPECTIVE|||||||
34076730|NCT00411450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748471|NCT06291168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||The 60 participants will be divided into three groups. These groups will be randomly divided into three groups as chiropractic manipulation group (n=20), yoga-based exercise group (n=20) and conventional exercise group (control group) (n=20). Exercise programs will be performed under the supervision of a physiotherapist. Chiropractic manipulation will be applied to the lumbar region and sacroiliac joint in the side lying position. Data will be analyzed in SPSS 29.0 IBM program. Kruskal-Wallis H test will be used for difference analysis between groups, Kruskal-Wallis H test will be used for comparisons between groups by taking the differences between measurement times and the significance level will be determined as p\<0.05.|t|f|f|t
33748472|NCT05040451|||COHORT||PROSPECTIVE|||||||
33855973|NCT00372385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33855974|NCT06444685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855975|NCT02200692|||COHORT||PROSPECTIVE|||||||
33855976|NCT00988520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855977|NCT00138671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855978|NCT04131400|||COHORT||PROSPECTIVE|||||||
33958701|NCT05167227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation will be concealed from all investigators and staff until the study group is assigned. Only the study manager and research assistants involved in the delivery of the intervention components will subsequently be made aware of allocation. It is not possible to mask participating clinicians, however, patients of participating clinicians will not have knowledge of their clinicians potential participation in weekly teleECHO sessions, monthly interactive webinars, and quarterly short courses. All staff that are involved in the collection of data and investigators that conduct analyses will remain blinded to allocation throughout the study.|20 consenting clinicians across primary care clinics at FHCSD will be randomized at a ratio of 1:1 to either participate in 1) weekly teleECHO sessions with monthly interactive webinars and quarterly short courses or 2) monthly interactive webinars and quarterly short courses alone (a control group). Throughout participation, the investigators expect that the clinicians will provide care for approximately 856 FHCSD patients diagnosed with PASC, ME/CFS, or OPIFI (approximately 42 patients per clinician). The clinicians will be consented and will receive exposure to intervention components (i.e., a professional cluster). Therefore, patient outcomes derived from routine clinical care will be evaluated according to the study arm of their respective clinicians.|f|f|t|t
33958702|NCT02630004|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33958703|NCT01136044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958704|NCT00695604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958705|NCT05652686|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will consist of 3 parts: Dose Escalation (Part A), Dose Expansion (Part B), Chemo Combination Therapy (Part C) and ICI combination Therapy (Part D).||||
33958706|NCT04070469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958707|NCT05607719|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33958708|NCT02758951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958709|NCT05226013|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33958710|NCT06701708|||CASE_CROSSOVER||PROSPECTIVE|||||||
33958711|NCT00065793|||COHORT||PROSPECTIVE|||||||
33958712|NCT00928135|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33855979|NCT04130386|RANDOMIZED|PARALLEL||TREATMENT||NONE||Assigned to either motivational interviewing or e-education.||||
33958713|NCT00045396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076731|NCT02056418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076732|NCT03529253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076733|NCT03646968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855980|NCT01131871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33855981|NCT03375216|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33855982|NCT02513745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855983|NCT03244735|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
33855984|NCT05184088|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible patients will receive a single administration of the imaging agent \[18F\]florbetaben at a radioactive dose of 300 MBq.||||
33958714|NCT04760847|RANDOMIZED|PARALLEL||TREATMENT||NONE||The control group will have 32 patients and the group undergoing IF will have 32 patients (for both recurrent acute and chronic pancreatitis); the randomization is 1:1; IF versus control. Sixty four subjects will be enrolled at UH for a total of 64 subjects.||||
34076734|NCT04979091|||COHORT||RETROSPECTIVE|||||||
33855985|NCT03226236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855986|NCT06304974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33855987|NCT03103763|||COHORT||PROSPECTIVE|||||||
33855988|NCT04647916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855989|NCT02726685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33855990|NCT03697577|||OTHER||PROSPECTIVE|||||||
33855991|NCT00871780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855992|NCT00003193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855993|NCT05468346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168085|NCT03729648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this trial, neither the staff, participants nor care provider can be masked to allocation. The data analyst will be blinded after study completion by having the intervention group information coded.|Parallel Randomized Controlled Trial|f|f|t|f
34168086|NCT00075712|RANDOMIZED|||TREATMENT||||||||
34168087|NCT01544725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168088|NCT02732457|||COHORT||PROSPECTIVE|||||||
34168089|NCT03882892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168090|NCT02055898|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34168091|NCT05083689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34168092|NCT04690140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients were randomly assigned into modified coronally advanced tunnel (n=25) and epithelialized free gingival graft (n=25) groups by one of the authors with an allocation ratio of 1:1 by using a computer-generated program after successful completion of phase I periodontal treatment. One calibrated author masked to the applied surgical technique recorded all clinical variables. The labeled envelope containing the intervention name was opened by the surgeon.||t|t|t|t
34168093|NCT04021095|NA|SINGLE_GROUP||OTHER||NONE||Customised head protection prototype device.||||
34168094|NCT00276510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168095|NCT03932877|||CASE_CONTROL||PROSPECTIVE|||||||
33855994|NCT03111693|||OTHER||CROSS_SECTIONAL|||||||
33855995|NCT02540057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168096|NCT01618032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168097|NCT00556907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168098|NCT00992758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168099|NCT01107951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168100|NCT02828761|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33855996|NCT02072447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168101|NCT03065777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168102|NCT05738265|||CASE_CROSSOVER||PROSPECTIVE|||||||
34168103|NCT05505448|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34168104|NCT01476007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168105|NCT03104296|||COHORT||PROSPECTIVE|||||||
34168106|NCT06156371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Individuals to be sampled will be assigned to groups according to the permutated block randomization method. Block size will be taken as 6. Random numbers will be generated in Excel by a researcher other than the researcher who collected the data, and a suitable number of blocks will be created for the sample. Assignment to groups will be made using the blocks of 6 corresponding to this number in the table. Index cards prepared in accordance with the assignment list will be placed in closed opaque envelopes and serial numbers will be written on them. The envelopes will be kept by a person who does not participate in the study and the assignment order will be learned from this person. The data will be recorded as coded as A, B and C, statistical analyzes will be carried out by the researcher who did not participate in the data collection phase according to this code, and the research report will be written in coded form.|prospective, randomized controlled clinical trial|t|t|f|t
34168107|NCT05971550|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168108|NCT06107140|||COHORT||RETROSPECTIVE|||||||
34168109|NCT06317571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups with intervention group and control group||||
34168110|NCT06042959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34168111|NCT04058041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34168112|NCT00408850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168113|NCT03564652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168114|NCT04969029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168115|NCT00232063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168116|NCT00230126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168117|NCT00374439|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33855997|NCT00924261|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33958715|NCT06576375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168118|NCT04143867|NA|SEQUENTIAL||TREATMENT||NONE||A prospective, one-arm study with subjects serving as their own control.||||
34168119|NCT05695807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168120|NCT01038141|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168121|NCT06212297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168122|NCT04377217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168123|NCT01606072|NA|SINGLE_GROUP||||NONE||||||
34168124|NCT01067677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168125|NCT03279029|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168126|NCT05418296|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34168127|NCT04154475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168128|NCT01430897|||COHORT||RETROSPECTIVE|||||||
34168129|NCT06533007|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748473|NCT02100982|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants in both arms use iPad to complete assessments, Customized Care (intervention arm) receives intervention on iPad, care as usual completes assessments only|Customized Care (intervention) vs. care as usual|t|f|f|f
33748474|NCT05715294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33748475|NCT01027000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748476|NCT00003951||||TREATMENT||||||||
33855998|NCT02179099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33855999|NCT00978666|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856000|NCT02568865|||COHORT||PROSPECTIVE|||||||
33856001|NCT04308772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958716|NCT03199898|||CASE_ONLY||CROSS_SECTIONAL|||||||
33958717|NCT06026124|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Within-participant design in which each child learns words under two conditions||||
34168130|NCT04787224|||COHORT||PROSPECTIVE|||||||
34168131|NCT05041231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34168132|NCT02451917|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168133|NCT01050634|||CASE_ONLY||PROSPECTIVE|||||||
34168134|NCT03678701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168135|NCT00317993|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33856002|NCT06089889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"a staff nurse will be nominated for recording the child's pain intensity on video for objectively assessing the child's pain score.~video recorder will be blinded of intervention. The staff nurse responsible for videotaping will be kept uninformed about the intervention and control group"|Children will be allocated in two groups by randomization (lottery method). one group will be intervention group and other group would be control group|f|f|f|t
33856003|NCT03646500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective randomized controlled non-inferiority trial, with retrobulbar block being the gold standard. Patients will be randomized to receive conscious sedation or retrobulbar injection prior to trans-scleral diode laser (TSD).|t|t|t|t
33958718|NCT04196439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958719|NCT05430009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856004|NCT04335812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856005|NCT03022032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856006|NCT05047471|||COHORT||PROSPECTIVE|||||||
33856007|NCT04753970|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958720|NCT03100786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33958721|NCT05748483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958722|NCT06201962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Because of the nature of the intervention, double-blinding was not possible in this study.|This study used a randomized controlled trial. A parallel trial design was used describing two different experimental groups (Massage and Foot Reflexology) and a control group|t|f|f|f
33958723|NCT06394830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958724|NCT01961635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33958725|NCT06700720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958726|NCT04539236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958727|NCT03845855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958728|NCT02428959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958729|NCT02606864|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958730|NCT05025241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062518|NCT06628388|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||A stepped-wedge cluster randomized waitlist-controlled trial will be conducted. Stepped-wedge design is considered as a unidirectional crossover RCT. Current trial will consist of four consecutive phases with each lasting for four months. The three social service organizations will be the three clusters to be randomized. In the first phase, all participants in all three clusters will be allocated to the waitlist-control treatment. In the second phase, newly joined participants in cluster 1, randomly determined, will be exposed to the intervention condition, while the other two clusters remain in the waitlist-control. In the third phase, newly joined participants in cluster 1 and 2, will be allocated to the intervention condition, while cluster 3 remain receiving the waitlist-control condition. In the fourth phase, all newly recruited participants in the three clusters will be allocated to intervention condition.|f|f|f|t
34062519|NCT06721637|||OTHER||CROSS_SECTIONAL|||||||
34062520|NCT06446349|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Brief motivational intervention in community pharmacy||||
34062521|NCT00829829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062522|NCT03734900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062523|NCT05844150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062524|NCT05961345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the experimental group was conducted early by the researcher and the outcome evaluations were performed by the researcher who blinded the group allocation|two groups, a control and an experimental group.|t|f|f|t
34062525|NCT06111872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Care provider is blinded from knowing the group of the study. However patients are informed regarding the drugs received|Patients will be randomized into the intervention or control group (Intervention group will receive Ketamine - Midazolam and control group will receive Midazolam- Pethidine as a sedative agent in ERCP|f|t|f|f
34062526|NCT00370097|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062527|NCT01756508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062528|NCT04623697|||CASE_CONTROL||PROSPECTIVE|||||||
34062529|NCT04291495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062530|NCT06147089|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||There are three study arms: control group, personalised sleep intervention, and personalised nutritional intervention||||
34062531|NCT03174288|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34062532|NCT01349933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062533|NCT00792116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062534|NCT04108949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded to treatment condition and receive no information about which treatment the participant will receive or have received.|A randomized controlled trial with two arms.|f|f|f|t
34062535|NCT05629767|||CASE_ONLY||PROSPECTIVE|||||||
34062536|NCT01160835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062537|NCT02634710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062538|NCT00524173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062539|NCT06444425|||COHORT||PROSPECTIVE|||||||
34062540|NCT04156945|RANDOMIZED|PARALLEL||PREVENTION||NONE||A 3-arm multicenter randomized trial. The trial will start with a 6 month run-in period (standard care) to determine at-risk behaviour under no intervention.||||
33856008|NCT00686725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856009|NCT03496584|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33856010|NCT02444481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856011|NCT04001985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168136|NCT04453865|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Participants will be randomized via Qualtrics (1:1 allocation ratio) to either the Online Resources and Referrals (ORR) and the Parent Accommodation SSI or ORR alone and delayed SSI access. Those in the experimental condition (ORR+immediate SSI) will also complete immediate post-SSI questionnaires. Two weeks later, all parents-regardless of condition-will complete the 2-week follow up questionnaires. Parents in the ORR+delayed SSI condition will then be invited to complete the accommodation SSI and immediate post-SSI questionnaires. Thus, all participants will receive the accommodation SSI and complete immediate post-SSI questionnaires, either immediately or at 2-week follow-up.||||
34168137|NCT03960216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856012|NCT03448120|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33856013|NCT02744326|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34168138|NCT01176032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168139|NCT03780335|||CASE_CONTROL||RETROSPECTIVE|||||||
34168140|NCT01662167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168141|NCT04920955|||CASE_CONTROL||PROSPECTIVE|||||||
34168142|NCT04916574|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168143|NCT02788344|||COHORT||RETROSPECTIVE|||||||
34168144|NCT03535974|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34168145|NCT01003847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168146|NCT01102088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168147|NCT03006146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168148|NCT02710656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168149|NCT01400698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168150|NCT03550378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, Double-Blind, Placebo-Controlled|t|f|t|f
34168151|NCT05196607|||COHORT||PROSPECTIVE|||||||
34168152|NCT02060435|||CASE_CONTROL||RETROSPECTIVE|||||||
34168153|NCT05384340|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34168154|NCT02763423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168155|NCT01454791|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34168156|NCT02632292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168157|NCT01338337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168158|NCT05627271|||COHORT||CROSS_SECTIONAL|||||||
34168159|NCT04508166|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34168160|NCT03933813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Unblinded, window of opportunity trial||||
33748477|NCT06085170|||CASE_CONTROL||PROSPECTIVE|||||||
33856014|NCT04213430|||OTHER||OTHER|||||||
33856015|NCT02924142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856016|NCT01147237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856017|NCT06071026|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Multiple N of one trial|t|f|f|t
33856018|NCT00690040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856019|NCT01092000|||COHORT||PROSPECTIVE|||||||
33856020|NCT00003998|RANDOMIZED|||TREATMENT||||||||
33856021|NCT02186223|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33856022|NCT01607554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748478|NCT00607555|||CASE_CROSSOVER||PROSPECTIVE|||||||
33856023|NCT02286778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856024|NCT06245720|||COHORT||CROSS_SECTIONAL|||||||
33856025|NCT01406340|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33856026|NCT00697879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856027|NCT05831813|NA|SINGLE_GROUP||TREATMENT||NONE||Before the intervention starts, participants will first follow a baseline period, ranging between 1 and 7 weeks. The length of the baseline period is based on the date of enrolment and therefore not random. Following the baseline period, all participants will start in the group intervention. Data are collected at screening, pre-intervention, post-intervention, one-month follow-up and three-month follow-up, as well as during weekly measurements during the waiting list period and the course.||||
34168161|NCT05932108|||COHORT||PROSPECTIVE|||||||
34168162|NCT02986646|||CASE_ONLY||PROSPECTIVE|||||||
34168163|NCT05777044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research personnel who administer heart rate variability and EEG were blinded to group assignment.|Participants will be randomized to one of three groups: waitlist control (usual routine), Hatha yoga (experimental group), and meditation (active comparative group).|f|f|f|t
34168164|NCT03520985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168165|NCT03228108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168166|NCT03236441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168167|NCT03901144|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Every patient use three different creams (1 test cream, 2 reference creams) and one untreated area. They are their own controls|t|f|t|f
34168168|NCT06383832|NA|SINGLE_GROUP||TREATMENT||NONE||This study included a total sample size of 36 subjects and underwent a 12 week intervention with dapagliflozin. Then, subgroup analysis was conducted. According to the 24-hour dietary review method on the 3rd day of each week during the introduction period, the low carbohydrate group accounted for 10-25% of the total energy intake due to carbohydrates, while the non low carbohydrate group accounted for 26% or more of the total energy intake due to carbohydrates.||||
34168169|NCT02183857|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34168170|NCT04718207|||COHORT||RETROSPECTIVE|||||||
34168171|NCT03318835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168172|NCT01467011|||CASE_ONLY||PROSPECTIVE|||||||
34168173|NCT02692937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856028|NCT01216384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748479|NCT00008853||||PREVENTION||DOUBLE||||||
33856029|NCT01295034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856030|NCT01548157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856031|NCT06370260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This trial is designed as a prospective, randomized, placebo-controlled, triple blinded, with two parallel groups and an equal allocation ratio in all groups. In this study, the intervention consists of delivery of a hydrogen carbamide/peroxide gel or placebo gel, made by the same manufacturer.|t|f|t|t
33856032|NCT02890394|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33856033|NCT02317081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856034|NCT03486457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856035|NCT04568720|||CASE_CROSSOVER||PROSPECTIVE|||||||
33856036|NCT02550717|||COHORT||RETROSPECTIVE|||||||
33856037|NCT02207348|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958731|NCT00902278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33958732|NCT05350748|||COHORT||PROSPECTIVE|||||||
33958733|NCT02875431|||COHORT||PROSPECTIVE|||||||
33958734|NCT06538909|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33958735|NCT06604949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33958736|NCT06408454|||OTHER||RETROSPECTIVE|||||||
33958737|NCT01262729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958738|NCT06172933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|While participants and study trainers will be aware of group assignment, a blinded study team member will perform outcome assessments.|Randomized, wait-list controlled, blinded intervention trial|f|f|f|t
33958739|NCT06702124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958740|NCT05674864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blindness will be maintained by the similarity in shape and the appearance of both the Linex ® capsule and placebo.|"92 patients with persistent H. pylori infection will be recruited randomly to one of the following groups:~* Group 1 (Control Group): consists of 46 patients who will receive Amoxicillin 1 gm T.I.D + Lansoprazole 30 mg T.I.D. + Placebo 1 capsule T.I.D for 14 days.~* Group 2 (Linex ® group): consists of 46 patients who will receive Amoxicillin 1 gm T.I.D + Lansoprazole 30 mg T.I.D + Linex ® capsule (which contains Bifidobacterium Infants, Enterococcus Feacium and Lactobacillus Acidophilus) 1 capsule T.I.D for 14 days."|t|f|t|f
33958741|NCT05179980|||COHORT||PROSPECTIVE|||||||
33958742|NCT01366365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958743|NCT05145647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958744|NCT05899218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958745|NCT06213974|||COHORT||OTHER|||||||
33958746|NCT00014859|||CASE_CONTROL||PROSPECTIVE|||||||
33958747|NCT05155956|||COHORT||PROSPECTIVE|||||||
33958748|NCT06090500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||submucosal injection of cold saline 2 to 5 degrees celsius for cryotherapy|t|t|t|t
33958749|NCT06520371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958750|NCT03004417|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33958751|NCT05388032|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Clinical and laboratory staff members who assess the study outcomes will be blinded to participant intervention assignment. Study participants, investigators, and study staff members who conduct the intervention cannot be blinded to intervention assignment because this is a dietary behavioral intervention trial.|Eligible participants will be randomized 1:1 into the dietitian-led behavioral intervention and usual diet.|f|f|f|t
33958752|NCT05105035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Active study drug and placebo will appear the same to study staff and patients. Bottles will be blinded to study staff and patients.||t|f|t|f
33958753|NCT06470841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958754|NCT02437929|||||PROSPECTIVE|||||||
33958755|NCT06543238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Since the application will be performed by the researcher, patients will be blinded in this study. The statistician will be blinded in the evaluation of the data.|The study consists of two groups: control and experimental group.|t|f|f|t
33958756|NCT00969267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958757|NCT05044832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062541|NCT05008393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo used in this study will consist of the diluent solution used in the interventional drug preparation, which has the same physical characteristics as the interventional drug preparation. All the solutions will be prepared at a central pharmacy and will be sent to each site center in specific boxes containing the necessary regulatory information. The solutions for each study arm will be identified by a random letter from A to I (three letters each arm).|Patients will be randomized at a 1: 1: 1 ratio to each of the treatment groups.|t|t|t|t
34062542|NCT00235781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062543|NCT04230356|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34062544|NCT02893111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062545|NCT02706171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748480|NCT01412008|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33748481|NCT02368249|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33748482|NCT05224050|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open trial with all participants receiving the experimental intervention (HRVB) in addition to smoking cessation therapy and nicotine replacement therapy patch.|All participants will receive individualized smoking cessation therapy (SCT), nicotine replacement therapy patch (NRT) and heart rate variability biofeedback (HRVB)||||
33748483|NCT06446843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748484|NCT00265369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856038|NCT05228041|||COHORT||PROSPECTIVE|||||||
33856039|NCT04822623|||COHORT||PROSPECTIVE|||||||
33856040|NCT04246320|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33856041|NCT04269330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062546|NCT06533631|||COHORT||PROSPECTIVE|||||||
34062547|NCT00394134|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34062548|NCT01881087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34062549|NCT00555126|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34062550|NCT03601572|||CASE_ONLY||PROSPECTIVE|||||||
34062551|NCT00711607|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34062552|NCT06075810|NA|SEQUENTIAL||TREATMENT||NONE||Open-label dose escalation following a standard 3+3 cohort design with a 21 day Dose Limiting Toxicity (DLT) evaluation||||
33856042|NCT01324115||||TREATMENT||||||||
34062553|NCT01724801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062554|NCT03006068|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062555|NCT00667186|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33748485|NCT05001100|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized||||
33748486|NCT04622579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748487|NCT00949351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33748488|NCT05229289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856043|NCT03487926|||OTHER||PROSPECTIVE|||||||
33856044|NCT06251453|||OTHER||RETROSPECTIVE|||||||
33856045|NCT01282177|||COHORT||PROSPECTIVE|||||||
33856046|NCT00003263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856047|NCT04700722|||COHORT||CROSS_SECTIONAL|||||||
33856048|NCT03538249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All evaluations were performed by investigators who were unaware of the allocation of patients to different interventions.|"Interventions Aerobic exercise training Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.~Inspiratory muscle training The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.~Resistance training The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training."|t|f|f|t
33856049|NCT02842606|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33856050|NCT05353348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856051|NCT00103051||||TREATMENT||NONE||||||
33856052|NCT04068623|||COHORT||PROSPECTIVE|||||||
33856053|NCT02742259|||COHORT||PROSPECTIVE|||||||
33856054|NCT05020431|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33856055|NCT00031551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856056|NCT03875677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856057|NCT05937087|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33856058|NCT06353438|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33856059|NCT00475033|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856060|NCT01749904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856061|NCT04214600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of patients and all members of the research team (except for the researcher conducting the CBT intervention) will be carried out throughout the trial.|A prospective, randomized, parallel-group, two-arm controlled trial|t|f|f|f
33856062|NCT01090622|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33856063|NCT00992433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856064|NCT04026087|||COHORT||OTHER|||||||
33856065|NCT05923268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856066|NCT06215430|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33856067|NCT04947423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33856068|NCT00609882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856069|NCT03313921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||cross-sectional open-label non-inferiority assessment of a novel diagnostic entity compared to current gold-standard in two seperate groups of patients (healthy and diseased)||||
33856070|NCT05393284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-masked study in which participants, care providers, central reading center and investigators are masked to study intervention.|This study is a randomized, double-masked, placebo-controlled, multicenter study to investigate the efficacy and safety of OPL-0401 in patients with diabetes mellitus (DM) with non-proliferative diabetic retinopathy (NPDR) or mild PDR with or without diabetic macular edema (DME). Data from an interim analysis may be used to consider additional arms in the study.|t|t|t|t
33856071|NCT00006098||||TREATMENT||||||||
34062556|NCT00752869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062557|NCT06731166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34062558|NCT04652700|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"In Study Part 1, double-blind with in-house blinding is used.~In Study Part 2, sponsor personnel not directly involved with blinded safety monitoring will be unblinded to participants' randomized study intervention in Part 1 (personnel involved with Part 2 will remain blinded).~In Study Part 3, al participants, investigators, and Sponsor personnel are unblinded as to the participant's original randomized intervention group."||t|f|t|f
34062559|NCT00077116|RANDOMIZED|||TREATMENT||NONE||||||
34062560|NCT01594398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062561|NCT05853211|||OTHER||RETROSPECTIVE|||||||
34062562|NCT05216458|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34062563|NCT04853108|||CASE_ONLY||RETROSPECTIVE|||||||
34062564|NCT00112255|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34062565|NCT01630460|||CASE_CONTROL||PROSPECTIVE|||||||
34062566|NCT00893906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34062567|NCT06731621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062568|NCT06221813|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062569|NCT00535327|||COHORT||PROSPECTIVE|||||||
34062570|NCT06358430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062571|NCT03383952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076735|NCT03590574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076736|NCT02953288|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34076737|NCT06422169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856072|NCT05696431|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Each patient will receive the three universal adhesives with the same restorative material randomly in three posterior teeth. All the materials will be used according to their manufacturers' instructions.|t|t|t|f
33856073|NCT03177278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856074|NCT01451125|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33856075|NCT05750537|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Stepped-wedge cluster randomized controlled trial||||
33856076|NCT04667897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856077|NCT04470466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856078|NCT01652599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856079|NCT00948051|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33856080|NCT02590809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856081|NCT02377804|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33856082|NCT00784953|||||PROSPECTIVE|||||||
33856083|NCT04208776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062572|NCT03790605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study design follows a double blinded design where the participant and the outcome assessor are unaware of the intervention to the subject|"Total subjects = 40 INCLUSION CRITERION~1. Systemically healthy individuals both males and females of 20-60 years~2. Presence of a minimum of 20 teeth in the oral cavity~3. Localised periodontal pockets with probing depths greater than 4mm i.e., Periodontitis in its stages 2 and 3, as described by the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and published by the American Academy of Periodontology (AAP) EXCLUSION CRITERION~1 Known allergy to curcumin and/ or hydroxyl propyl methyl cellulose 2 Systemic diseases and/or Inflammatory conditions, Obesity 3 Former or current tobacco users 4 Chronic consumption of alcohol 5 Use of anti-inflammatory drugs and antibiotics over the past 3 months 6 Periodontal therapy in any form, surgical or non surgical in the past 6 months 7 Pregnant and lactating mothers"|t|f|f|t
33856084|NCT00729768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856085|NCT02043678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856086|NCT01808482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856087|NCT04173637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856088|NCT03609853|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|placebo controlled, double-blind||t|f|f|t
33856089|NCT00434915|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33856090|NCT00502827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856091|NCT05691556|||COHORT||RETROSPECTIVE|||||||
33856092|NCT00892931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856093|NCT05112107|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33856094|NCT05715866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluators of all the results and the main caregivers of the participating patients will be masked.|Random intervention model|f|f|f|t
33856095|NCT03608540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856096|NCT01516177|||COHORT||PROSPECTIVE|||||||
33856097|NCT01871311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856098|NCT04926220|||COHORT||PROSPECTIVE|||||||
33856099|NCT02001610|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33856100|NCT03090230|NA|SINGLE_GROUP||TREATMENT||NONE||Subject must have a traumatic injury of the descending thoracic aorta that occurred no more than 30 days prior to the planned stent implant procedure. All subjects enrolled, will be included in the patient population for the primary analysis. All subjects implanted with the RelayPro Thoracic Stent-Graft will be included in the patient population for the secondary analyses.||||
33856101|NCT01450254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856102|NCT01208493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856103|NCT02694939|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33856104|NCT02522455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062573|NCT02181569|||COHORT||PROSPECTIVE|||||||
34062574|NCT06730464|||COHORT||OTHER|||||||
34062575|NCT05677230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856105|NCT05868343|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||First, the centers are randomized to begin the trial period by offering all their patients either hybrid CR or traditional CR. After recruiting half of the target patient population to be included in the study, centers will switch to offering the other type of CR to their new patients admitted from that point on.|f|f|t|f
33856106|NCT02774031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856107|NCT04528251|||CASE_CONTROL||PROSPECTIVE|||||||
33856108|NCT02957721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958758|NCT06096181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The following persons are masked:~1. Participant and parents~2. Pediatric Intensive Care Unit (PICU) staff taking care of patient postoperatively~3. Surgeon"||t|t|f|f
33958759|NCT01257737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958760|NCT06099327|||COHORT||PROSPECTIVE|||||||
34062576|NCT03715231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062577|NCT02671825|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062578|NCT03442374|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Stratified by fatty infiltration severity (n=20/group x 2 groups + non exercise controls n=20)|f|f|f|t
34062579|NCT01093651|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34062580|NCT06241066|||COHORT||RETROSPECTIVE|||||||
34062581|NCT06731296|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34062582|NCT01507714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062583|NCT03946228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062584|NCT04266704|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062585|NCT06274710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34076738|NCT06230731|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34076739|NCT01715701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34076740|NCT02167438|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34076741|NCT01488617|||COHORT||PROSPECTIVE|||||||
34076742|NCT02874612|||COHORT||PROSPECTIVE|||||||
34076743|NCT05558319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076744|NCT05944185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076745|NCT00892463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076746|NCT03679559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168174|NCT06413485|||COHORT||PROSPECTIVE|||||||
34168175|NCT04084717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be assigned to one of the following:~Cohort 1 - ROS1 rearrangement Cohort 2 - MET-activating mutation (exon 14) Cohort 3 - MET-amplification"||||
34168176|NCT03222700|||CASE_ONLY||PROSPECTIVE|||||||
34168177|NCT02663011|||CASE_ONLY||RETROSPECTIVE|||||||
34168178|NCT04215926|||CASE_ONLY||CROSS_SECTIONAL|||||||
34168179|NCT05467241|NA|SINGLE_GROUP||TREATMENT||NONE||Combined Alternative Therapy: The novel combined alternative therapy that will be studied consists of self-induced therapeutic tremors (SITT) plus mindfulness. SITT is the intentional induction of the body's innate tremor mechanism to treat hyperarousal and muscle tension, which is characteristic of CPP. SITTs are thought to restore somatic and autonomic nervous system homeostasis, by discharging sympathetic arousal and down-regulating the autonomic nervous system. Previous work has shown that mindfulness training may improve symptoms of CPP, however there are no studies investigating the impact that the combination of mindfulness coupled with SITTs may have on the symptoms of CPP.||||
34168180|NCT03462108|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study for the neonates is double-blind, randomized study. While, the study for the adults and childrens is open-labeled study|"* Adults and Children Group: Experimental, open labeled, prospective intervention study~* Neonates Group: Experimental, randomized, double blind, prospective intervention study"|t|f|t|f
34168181|NCT01490775|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33856109|NCT04712331|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: groups (A) \& (B) \& (C) ( three study groups ) and group (D) ( control group )|Sixty patients will undergo abdominoplasty, their age ranged from 20 to 45 years, they were randomly distributed into four equal groups. The ultrasonography was used to evaluate abdominal muscle thickness as indicator for muscle strength at 4 occasions, initial assessment, pre-operative assessment, 2 months post-operative assessment, and finally 4 months post-operative assessment). For study group (A); received graduated abdominal exercises, group (B); received Russian stimulation on abdominal muscles, group (c); received combination between graduated abdominal exercises and Russian stimulation on abdominal muscles, the study groups received the treatment protocol for 30 min., 3 times per week for 6 weeks preoperatively for control group (D); were instructed to presume in normal activities of daily living preoperatively|f|f|f|t
34168182|NCT01156220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168183|NCT04715672|||COHORT||PROSPECTIVE|||||||
34168184|NCT02991638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168185|NCT00017602|RANDOMIZED|||TREATMENT||NONE||||||
33856110|NCT00215085|||||RETROSPECTIVE|||||||
33856111|NCT05142137|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||3x3|t|f|t|f
33856112|NCT03226275|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33856113|NCT01838122|||COHORT||PROSPECTIVE|||||||
33856114|NCT00344474|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33856115|NCT01476774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856116|NCT01115296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856117|NCT06189586|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Description for medicine or protocol of treatment in detail:~Dosing regimen:~1. Intravenous hormone group: 40mg sodium methylprednisolone succinate for injection(dissolved in 0.9% saline or5% glucose injection 50ml), intravenous infusion for 30 minutes, once a day for 5 consecutive days.~2. Nebulized inhalation group: 2 mg budesonide suspension for inhalation, nebulized inhalation for minutes,administered 4 times a day for 5 consecutive days."||||
33856118|NCT00400985|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33856119|NCT00419666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856120|NCT03253926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33856121|NCT06248970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33856122|NCT03360838|||COHORT||PROSPECTIVE|||||||
33856123|NCT04137900|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076747|NCT06278948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34076748|NCT01059773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076749|NCT01358292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076750|NCT01161810|||COHORT||PROSPECTIVE|||||||
34076751|NCT01514383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076752|NCT00660712|||COHORT||PROSPECTIVE|||||||
33856124|NCT01054846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168186|NCT04714567|||COHORT||CROSS_SECTIONAL|||||||
34168187|NCT03880058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168188|NCT03061357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants in both intervention and control arms were not disclosed to the specific purpose of the study in order to prevent the subject-expectancy effects on study outcomes.||t|f|f|f
34168189|NCT01827150|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168190|NCT05823402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076753|NCT02021292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168191|NCT04591938|NA|SINGLE_GROUP||OTHER||NONE||Prospective, multicentre, non-randomized, investigator-initiated study||||
34168192|NCT00628030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856125|NCT00155935|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856126|NCT03081754|||CASE_ONLY||PROSPECTIVE|||||||
33856127|NCT00911482|||||CROSS_SECTIONAL|||||||
33856128|NCT02330874|||COHORT||RETROSPECTIVE|||||||
33856129|NCT04007185|||COHORT||PROSPECTIVE|||||||
33856130|NCT06391502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33856131|NCT01648335||PARALLEL||TREATMENT||||||||
33856132|NCT00761046|||COHORT||RETROSPECTIVE|||||||
33856133|NCT00679627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856134|NCT03872570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33856135|NCT00858884|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33856136|NCT04975438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study||t|f|t|f
34076754|NCT03943914|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076755|NCT01912950|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076756|NCT03050177|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33748489|NCT05579327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Patients having demonstrated stable maintenance treatment with tiratricol will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total T3 \> ULN of the participant's normal range, for a sample collected during the 30-day Randomized Treatment Period). In other words, the patients will be randomized to complete withdrawal of tiratricol treatment (placebo) for 30 days or to continue with the stable tiratricol maintenance treatment for 30 days. If during the 30 days, a rescue criterion (serum total T3 \> ULN of the participant's normal range) is reached, the randomized treatment will be stopped, and the patient will go back on unblinded tiratricol treatment.~Serum total T3 concentrations measured during the Randomized Treatment Period that are below the LLN of the normal range will not lead to any modifications to the blinded study drug administration schedule of daily tiratricol dosing."|t|t|t|t
33748490|NCT01518868|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33748491|NCT06143748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748492|NCT03295188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062586|NCT05654545|NA|SINGLE_GROUP||PREVENTION||NONE|The intervention conditions are randomized, so the participant does not know which intervention condition is presented when.|A repeated measures within-subjects design will be employed. Conditions (the type of dialog) will be counterbalanced to minimize carryover effects. Baseline questionnaires measuring demographic characteristics, previous experience with VR, and smoking-specific characteristics will be administered at the start of the experiment. In addition, questionnaires measuring abstinence self-efficacy (i.e., the endpoint for the primary objective), phasic (state) tobacco craving, positive and negative affect, and sense of presence will be administered after every VR session (four times in total) to investigate the study objectives. Positive and negative affect will also be assessed before the VR sessions as a baseline measure. Finally, questionnaires measuring acceptance of the conversational agent and user-experiences will be administered after the last VR session.||||
34062587|NCT04151745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||To investigate the effects of atrial pacing on right ventricular function and hemodynamics after open heart surgery.||||
33748493|NCT04762680|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"In the original Phase 2 part, participants, outcome assessors, Investigators, laboratory personnel, and sponsor study staff are blinded to intervention group; and those preparing the study interventions are unblinded to vaccine assignment group.~The supplemental Cohort 1 intervention group and Supplemental Cohorts Comparator Group will be open-label. Supplemental Cohort 2 will involve sequential randomization to main arms then exploratory arms, and the intervention will be modified double-blind (observer-blinded, as described)."|To address the emergence of variant strains, Sanofi Pasteur is developing monovalent and bivalent vaccines for use as universal late booster vaccines which will be studied in additional Phase 3 study cohorts that are added to the initial Phase 2 protocol cohorts. Supplemental Cohorts 1 and 2 will evaluate booster vaccine candidates.|t|t|t|t
33748494|NCT01217073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748495|NCT01183676|RANDOMIZED|CROSSOVER||||NONE||||||
33748496|NCT05558033|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel group randomized controlled trial||||
34062588|NCT06221098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856137|NCT02306486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856138|NCT02180022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33856139|NCT01992042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856140|NCT01912456|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33856141|NCT02577757|NON_RANDOMIZED|PARALLEL||||NONE||||||
33856142|NCT02255266|||COHORT||RETROSPECTIVE|||||||
33856143|NCT00133146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind with a single-blind component||t|f|t|t
34062589|NCT06657170|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-arm, single-center, randomized controlled trial||||
34062590|NCT06099431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062591|NCT02616718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062592|NCT04794010|||COHORT||PROSPECTIVE|||||||
34062593|NCT06362031|||COHORT||RETROSPECTIVE|||||||
34062594|NCT02736591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062595|NCT02612350|||COHORT||PROSPECTIVE|||||||
34062596|NCT04145024|||COHORT||PROSPECTIVE|||||||
34062597|NCT04550845|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34062598|NCT06390761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062599|NCT05920785|||CASE_CONTROL||PROSPECTIVE|||||||
34062600|NCT03784859|||CASE_ONLY||PROSPECTIVE|||||||
34062601|NCT05909761|||OTHER||OTHER|||||||
34062602|NCT06602167|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34062603|NCT00738062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062604|NCT03342131|||CASE_CONTROL||PROSPECTIVE|||||||
34062605|NCT05936541|RANDOMIZED|PARALLEL||TREATMENT||NONE||Probiotic Bifidobacterium Bifidum PRL2010||||
34062606|NCT02817698|NA|SINGLE_GROUP||OTHER||NONE||||||
34062607|NCT00005624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062608|NCT06061211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34062609|NCT06514521|||COHORT||PROSPECTIVE|||||||
34062610|NCT05094544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062611|NCT02035397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34062612|NCT02002416|||CASE_CONTROL||RETROSPECTIVE|||||||
34062613|NCT00532272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062614|NCT02425033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062615|NCT03009383|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062616|NCT04724031|||OTHER||OTHER|||||||
34062617|NCT06725667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34062618|NCT04583358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748497|NCT00241254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856144|NCT00004253||||TREATMENT||||||||
33856145|NCT02373254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856146|NCT00604812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856147|NCT02080312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856148|NCT04413123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856149|NCT03752099|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33856150|NCT00572390|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34168193|NCT02102789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168194|NCT02203695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168195|NCT01998425|||COHORT||PROSPECTIVE|||||||
34168196|NCT03258307|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34168197|NCT00005674||||TREATMENT||||||||
33856151|NCT00875654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856152|NCT05969054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856153|NCT04290442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the office of acute pain management, one member of the research team will be responsible for providing the anesthesiologist in charge of performing the block with a sealed envelope. Each envelope will be labeled with a number corresponding to a matching number labeled on each patient binder. This envelope will contain the information regarding the block type based on randomization to be administered to the patient. Once the anesthesiologist knows which block he is going to administer, he will reseal the envelope and return it to the research team member. This process will allow only the anesthesiologist performing the block to have knowledge of the block type he or she is administering, keeping research team members blinded. The envelopes and binders will be kept by the principal investigator in a safe place and only reopened to be analyzed at the end of the study.|The study will be conducted as prospective, randomized, single blinded, parallel trial at the University of Pittsburgh Medical Center (UPMC) Shadyside Hospital.|f|f|f|t
33856154|NCT05902234|||COHORT||PROSPECTIVE|||||||
34062619|NCT00902980|||CASE_CONTROL||RETROSPECTIVE|||||||
34062620|NCT00235066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062621|NCT00584714|||CASE_ONLY||PROSPECTIVE|||||||
34062622|NCT04698421|||COHORT||PROSPECTIVE|||||||
34062623|NCT01380691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34062624|NCT01948583|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062625|NCT03291470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34062626|NCT05777941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168198|NCT04475952|||COHORT||PROSPECTIVE|||||||
34168199|NCT01204749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168200|NCT00236353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168201|NCT03345251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||640 were enrolled but 608 were analyzed|t|f|f|t
34168202|NCT00920751|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34168203|NCT01475877|||||PROSPECTIVE|||||||
34062627|NCT01442727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062628|NCT05141006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062629|NCT05753501|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062630|NCT04245202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062631|NCT03023540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients who completed the pivotal phase III study CLN-PXT3003-02 are allowed to continue in this open-label study. In Period 1, patients who were randomly assigned to placebo or low-dose PXT3003 in pivotal phase III study were assigned to receive low-dose PXT3003 (5 mL), whereas patients assigned to high-dose PXT3003 continued on that dose (receiving the high-dose PXT3003 (5 mL) or twice the low-dose for each administration (i.e. 10 mL)). The primary objective was to assess safety and tolerability for prolonged exposure to PXT3003, and to evaluate the effect on disability in patients with mild to moderate CMT1A.~In Period 2, all patients are allowed to continue in an open-label fashion to receive high-dose PXT3003 (receiving twice the low-dose for each administration (i.e. 10 mL). The objective is to mainly assess the safety and tolerability in the aforementioned patient population."||||
34062632|NCT01053520|RANDOMIZED|CROSSOVER||||NONE||||||
34062633|NCT06718673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the intervention, it was not possible to blind participants or care providers.|||||
34062634|NCT04907500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062635|NCT00379431|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062636|NCT02799173|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062637|NCT06531629|||COHORT||RETROSPECTIVE|||||||
34168204|NCT05195229|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168205|NCT03596827|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The MIRRE pilot study is a randomized, double-blind dose-response, parallel human infection study in 30 healthy adults|t|t|t|t
34168206|NCT02724358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168207|NCT04324671|||COHORT||CROSS_SECTIONAL|||||||
33748498|NCT01253434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748499|NCT06173401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748500|NCT01143948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168208|NCT01460056|||COHORT||RETROSPECTIVE|||||||
34168209|NCT06118437|||OTHER||PROSPECTIVE|||||||
34168210|NCT00917475|||COHORT||PROSPECTIVE|||||||
34168211|NCT00763386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168212|NCT04140968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168213|NCT03153696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34168214|NCT00495768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168215|NCT00184223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34168216|NCT02344654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34168217|NCT01691794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168218|NCT02304939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168219|NCT02312349|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34168220|NCT03684174|||CASE_CONTROL||PROSPECTIVE|||||||
34168221|NCT01487135|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34168222|NCT02277600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168223|NCT01733875|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33748501|NCT00695903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748502|NCT03206346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748503|NCT04301336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Four experimental groups, one control group|t|t|f|f
34168224|NCT02684773|||COHORT||PROSPECTIVE|||||||
34168225|NCT00487019|||COHORT||PROSPECTIVE|||||||
34168226|NCT04827264|||COHORT||PROSPECTIVE|||||||
34168227|NCT02197117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958761|NCT05074602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Randomized, Double-Blind, active controlled, parallel groups, Multicenter Phase III Clinical Study|t|t|t|t
33856155|NCT01749605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856156|NCT03260231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind|"This study is a parallel, randomized, single blind, controlled, 5-months nutritional intervention, investigating health effects of dietary intake of milled mix of flax/sesame pumpkin seeds in sour milk, in patients with NHL undergoing chemotherapy.~At the beginning of the study, all patients received nutritional counselling, where half of the study subjects are randomly assigned to a treatment arm with milled seed mix consumption, or control arm without seed mix. Treatment arm is provided with 450g of milled seed mix and instructed to consume 30g of the mix daily (18g flax seed, 6g pumpkin seeds, and 6 g sesame) in 180 mL of sour milk. Control arm is instructed to consume180 mL of sour milk."|f|t|t|f
33856157|NCT00969878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856158|NCT02361151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856159|NCT05602948|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33748504|NCT03298126|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomization was carried out after written informed consent through SNOSE (Sequentially Numbered Opaque Sealed Envelopes) method to ensure allocation concealment. Patients were randomized into two groups for TR band removal i.e. Group 1 received protocol A which is currently in practice at AKUH and group 2 underwent protocol B developed by Cohen and Alfonso which is supported by literature. The techniques for protocol A and protocol B. Radial artery patency was determined at 24 hours by a trained resident doctor who was blinded to the protocol administered.|The parallel group, non-inferiority trial|f|f|f|t
33958762|NCT03392415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized registry with option of crossover after 6months||||
33958763|NCT02214004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958764|NCT06533891|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33958765|NCT01080209|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33958766|NCT06301568|||COHORT||RETROSPECTIVE|||||||
33748505|NCT05999955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856160|NCT06375421|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The order of conditions and the order of word list presentation will be counterbalanced. The order of condition/word list combination will be pre-determined, and participants will be assigned to the next available combination based on when they join the study (i.e., a counterbalanced within-person crossover design).||||
33958767|NCT05073276|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33958768|NCT04688814|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blinded||t|f|t|f
33958769|NCT04007744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958770|NCT06017856|||COHORT||PROSPECTIVE|||||||
33958771|NCT03554473|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958772|NCT06068842|||COHORT||RETROSPECTIVE|||||||
33958773|NCT04296071|||COHORT||PROSPECTIVE|||||||
33958774|NCT03203746|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Total subjects selected were allocated into three study groups, Group I (Test group), Group II (Positive control group) and Group III (Negative control group). Group I: Included 8 patients with severe chronic periodontitis managed by Scaling and root planing (SRP) and local delivery of lycopene loaded in solid lipid microparticles. Group II: Included 8 patients with severe chronic periodontitis managed by Scaling and root planing (SRP) only. Group III: Included 8 patients with clinically healthy periodontium.||||
33958775|NCT04968743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958776|NCT05128487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958777|NCT02748616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958778|NCT01421602|||COHORT||PROSPECTIVE|||||||
33958779|NCT06343142|RANDOMIZED|CROSSOVER||PREVENTION||NONE||2 x 2-factor crossover design study||||
34062638|NCT05260216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|After the data is entered, the analyst is analyzed under the premise of uninformed, and the packet is performed after all analyzes are completed.||f|f|f|t
33748506|NCT02102308|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856161|NCT05804266|RANDOMIZED|PARALLEL||TREATMENT||NONE||Considering a mean number of treated vessel of 4 per each patient, with standard technique we expect that 36% of patients need will have at least on vessel bleeding and requiring an adjunctive hemostasis, versus 6% of patients with underwater coagulation technique. With an alpha error of 5%, a power of 80% we need a total of 70 patients (35 in each arm), to detect this difference.||||
33856162|NCT00473135|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33856163|NCT04143074|NA|SINGLE_GROUP||TREATMENT||NONE||single multidisciplinary intervention||||
33856164|NCT01127139|||||PROSPECTIVE|||||||
33856165|NCT04581889|||COHORT||PROSPECTIVE|||||||
33856166|NCT03365713|||COHORT||PROSPECTIVE|||||||
33856167|NCT00510679|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33856168|NCT02009995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856169|NCT00565474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33958780|NCT06516510|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33958781|NCT02076113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958782|NCT06553131|||COHORT||PROSPECTIVE|||||||
33958783|NCT03821142|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded POP-Q Examination: The POP-Q examination will be performed by a physician different to the corresponding surgeon|Calistar S Single Incision POP System||||
33958784|NCT06096870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958785|NCT03599843|NA|SINGLE_GROUP||OTHER||NONE||Type 2, hybrid implementation-effectiveness study||||
33958786|NCT02670980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958787|NCT04542902|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33958788|NCT06423768|||COHORT||PROSPECTIVE|||||||
33958789|NCT05736432|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34062639|NCT01538849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062640|NCT03280225|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34062641|NCT03725774|NA|SINGLE_GROUP||PREVENTION||NONE||Uncontrolled before-and-after study||||
34062642|NCT00986986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062643|NCT03707834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062644|NCT04848259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168228|NCT01269866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168229|NCT01380223|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168230|NCT00872963|||COHORT||PROSPECTIVE|||||||
34168231|NCT04401540|||COHORT||PROSPECTIVE|||||||
34168232|NCT03264274|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single arm study||||
34168233|NCT01064115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168234|NCT06524128|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||This is a randomized, bicentric, single-blind, cross-over study.|f|f|f|t
34168235|NCT04361370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168236|NCT05022186|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34168237|NCT00219063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34168238|NCT03055117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34168239|NCT04649814|||COHORT||PROSPECTIVE|||||||
34168240|NCT03412344|||OTHER||CROSS_SECTIONAL|||||||
34168241|NCT03642977|||COHORT||PROSPECTIVE|||||||
34168242|NCT02563314|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34168243|NCT03155126|||COHORT||RETROSPECTIVE|||||||
34168244|NCT01307384|||COHORT||PROSPECTIVE|||||||
34168245|NCT00380055|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34168246|NCT05952232|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, double-blind, Placebo-controlled|t|t|t|f
34168247|NCT04002076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168248|NCT01329159|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34168249|NCT01033539|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34168250|NCT04218617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168251|NCT05774301|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||pre- and post-test||||
34168252|NCT03776682|||COHORT||PROSPECTIVE|||||||
34168253|NCT02568761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168254|NCT05893394|||COHORT||PROSPECTIVE|||||||
34168255|NCT01167803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748507|NCT05960500|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748508|NCT02324439|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168256|NCT00905450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168257|NCT02984488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168258|NCT04130607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are not aware of the other arms in the trial|Randomized trial of teaching methods with 3 arms.|t|f|f|f
34168259|NCT05772624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168260|NCT02539641|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34168261|NCT02271698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168262|NCT06379165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168263|NCT01960140|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168264|NCT04107714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168265|NCT05757986|||COHORT||PROSPECTIVE|||||||
34168266|NCT02995356|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748509|NCT04764058|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748510|NCT00215267|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748511|NCT02512575|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33748512|NCT01558154|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33748513|NCT00784810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748514|NCT06458322|||COHORT||PROSPECTIVE|||||||
33748515|NCT02523313|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33748516|NCT01161316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748517|NCT00137033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34168267|NCT02484066|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34168268|NCT02579200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168269|NCT02947386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168270|NCT03008694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168271|NCT00395746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168272|NCT03689023|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168273|NCT02845817|NA|SINGLE_GROUP||||NONE||||||
33748518|NCT02962713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748519|NCT03377491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748520|NCT06167668|||COHORT||PROSPECTIVE|||||||
33748521|NCT01306773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748522|NCT06669728|||OTHER||CROSS_SECTIONAL|||||||
34168274|NCT05223270|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||semi-experimental study with post test, control group|t|f|f|f
34168275|NCT04324502|||COHORT||PROSPECTIVE|||||||
34168276|NCT03563066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168277|NCT03003052|||COHORT||PROSPECTIVE|||||||
34168278|NCT04907981|||CASE_CONTROL||OTHER|||||||
34168279|NCT04954508|||OTHER||PROSPECTIVE|||||||
34168280|NCT04236102|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34168281|NCT05347836|||CASE_CONTROL||RETROSPECTIVE|||||||
34168282|NCT05624476|||CASE_CONTROL||PROSPECTIVE|||||||
34168283|NCT04811066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168284|NCT00688259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168285|NCT00314743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168286|NCT00472459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168287|NCT03326388|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Study of Intermittent Schedule of Drug Dosing||||
34168288|NCT01293279|||||PROSPECTIVE|||||||
34168289|NCT00905463|||COHORT||PROSPECTIVE|||||||
34168290|NCT02604446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168291|NCT03710746|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Participants will be masked to their response training condition. Outcomes assessors will be masked to both participant conditions.||t|f|f|t
34168292|NCT04369313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34168293|NCT00215358|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34168294|NCT01003041|||CASE_CROSSOVER||PROSPECTIVE|||||||
33856170|NCT05125263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856171|NCT05255367|NA|SINGLE_GROUP||PREVENTION||NONE||Single group||||
33856172|NCT00351130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856173|NCT05596838|||COHORT||RETROSPECTIVE|||||||
33856174|NCT03754413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856175|NCT01315951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856176|NCT06237686|NA|SINGLE_GROUP||OTHER||NONE||||||
34168295|NCT04748666|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The investigators will compare a) care partner emotional symptom (depression) change and b) caregiver burden change from baseline to 6-months post-baseline, to assessed long-term effects of PST and booster sessions several months beyond completion of the training. The investigators will also measure secondary care partner outcomes, including caregiver self-efficacy, positive aspects of caregiving, and alcohol use. Finally, the investigators will assess care partners' satisfaction, confidence using the PST strategy, and engagement across all conditions.||||
34168296|NCT06019221|||CASE_ONLY||RETROSPECTIVE|||||||
34168297|NCT00264199|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168298|NCT04581265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168299|NCT00005608||||TREATMENT||||||||
34168300|NCT05356416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168301|NCT02338635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168302|NCT00194805|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168303|NCT02314663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168304|NCT01982734|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34168305|NCT02374164|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168306|NCT04019353|||COHORT||PROSPECTIVE|||||||
34168307|NCT00773162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168308|NCT01095432|||COHORT||PROSPECTIVE|||||||
34168309|NCT04703088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Studied medication will be administered to the patient after randomization by the investigators (two anesthesia residents or two staff anesthesiologists) who will not be involved in subsequent anesthetic management of the patients. The investigators will also program the infusion rate of norepinephrine at the start of each case and will be the only persons aware of the assigned infusion rate. The investigators will hide the infusion rate with an opaque paper cover over the infusion display during the case.~The investigators will also collect all the data during each procedures. To summarize, the anesthesiologist in charge of the patient will not know which treatment will be injected and the rate of the pump infusion"|Randomized blinded parallel assignment|t|t|f|f
34168310|NCT06465940|||COHORT||CROSS_SECTIONAL|||||||
34168311|NCT00443040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168312|NCT06271434|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Triple|"All competitors will be randomly divided into two groups (double-blind):~A. supplemented (n = 15), who will receive one capsule of a supplement called THYROX (Atlantic krill oil) four times a day.~B. control (n = 15) receiving placebo. The supplementation period will be six weeks."|t|f|t|t
34168313|NCT03923790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168314|NCT05255575|||COHORT||PROSPECTIVE|||||||
34168315|NCT04914065|||COHORT||PROSPECTIVE|||||||
34168316|NCT01584141|||CASE_CONTROL||RETROSPECTIVE|||||||
34168317|NCT05637008|||COHORT||PROSPECTIVE|||||||
34168318|NCT04548739|||CASE_ONLY||PROSPECTIVE|||||||
34168319|NCT00106847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34168320|NCT00184795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168321|NCT04438694|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, single-institution, single-arm, study using a historical control group for comparison. Open label, 2 arms: SOC and SOC+CP||||
34168322|NCT00639470|RANDOMIZED|PARALLEL||||NONE||||||
34168323|NCT00429949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168324|NCT03760991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168325|NCT05937763|||COHORT||CROSS_SECTIONAL|||||||
34168326|NCT02264158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748523|NCT03722368|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33748524|NCT04647526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748525|NCT00229125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748526|NCT02179437|||OTHER||RETROSPECTIVE|||||||
34062645|NCT00104468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856177|NCT02472769|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856178|NCT02654873|||CASE_ONLY||PROSPECTIVE|||||||
33856179|NCT00516243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856180|NCT06053723|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856181|NCT04017286|||COHORT||PROSPECTIVE|||||||
33856182|NCT03151096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Field nurse measuring blood pressure, laboratory and data entry staff will be blinded as to the genotype of the study participants and to the identity of the treatment arm to which a participant is assigned from the time of randomization to the time of unblinding. The placebos are designed to be indistinguishable from the active drugs||f|f|t|f
33856183|NCT03569657|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are assigned to the group intervention, which is not part of routine medical care, to evaluate the group's effectiveness on participants' psychological well-being and their healthcare utilization.||||
33748527|NCT06355986|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Assignment to a particular cluster (ALERT or NO ALERT) will be masked to the patient participant, investigator, and outcomes assessor. Since the intervention is a computer alert to the provider of record, he/she will be aware of whether or not a notification is provided.|2500-patient U.S. multicenter, community-based Quality Improvement Initiative in the form of a cluster-randomized controlled trial.|t|f|t|t
33748528|NCT01118208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33748529|NCT05214040|||OTHER||RETROSPECTIVE|||||||
33856184|NCT00081770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856185|NCT02938533|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33856186|NCT04182594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856187|NCT02583139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856188|NCT00849277|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062646|NCT04946552|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748530|NCT02097108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856189|NCT04329832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856190|NCT01551160|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33856191|NCT04105309|RANDOMIZED|PARALLEL||TREATMENT||NONE||three-group parallel randomized-controlled trial||||
34062647|NCT00001502||||TREATMENT||||||||
34062648|NCT06730880|||CASE_CONTROL||PROSPECTIVE|||||||
34062649|NCT06545942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062650|NCT04808518|||COHORT||PROSPECTIVE|||||||
34062651|NCT03410901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062652|NCT04728373|||COHORT||RETROSPECTIVE|||||||
34062653|NCT04172428|||COHORT||PROSPECTIVE|||||||
34062654|NCT03227536|||COHORT||RETROSPECTIVE|||||||
34062655|NCT01199822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062656|NCT04297475|||COHORT||PROSPECTIVE|||||||
34062657|NCT00051181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062658|NCT02600767|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of the efficacy of artemether and lumefantrine for uncomplicated P. falciparum malaria.||||
34062659|NCT01324570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062660|NCT01573754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062661|NCT06304740|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34062662|NCT02430103|||COHORT||PROSPECTIVE|||||||
34062663|NCT01167556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34062664|NCT06498687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062665|NCT02230540|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062666|NCT06731738|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34062667|NCT00634049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062668|NCT04108780|||COHORT||RETROSPECTIVE|||||||
34062669|NCT05903612|||COHORT||PROSPECTIVE|||||||
34062670|NCT04056000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062671|NCT04927494|NA|SINGLE_GROUP||SCREENING||NONE||||||
34062672|NCT00392522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062673|NCT05367882|||COHORT||PROSPECTIVE|||||||
34062674|NCT06239779|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In this study, both participant and investigator masking have been implemented to minimize potential bias and maintain objectivity. Participants in the education group are unaware of the existence of the control group, and conversely, participants in the control group are unaware of the education group. Additionally, to further ensure objectivity, after data collection, a secretary anonymizes patients into groups A and B using stickers. This comprehensive masking approach prevents both participants and the investigator from being influenced by knowledge of group assignments during data analysis and interpretation, thereby enhancing research integrity.|This study is a randomized controlled trial with a pre-post intervention (education) evaluation.|t|f|t|f
34062675|NCT04592627|||COHORT||PROSPECTIVE|||||||
34062676|NCT06731088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062677|NCT03663348|||COHORT||PROSPECTIVE|||||||
34062678|NCT00655512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34062679|NCT01635907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062680|NCT06464926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Assigned to ON or OFF group. ON group receives active therapy immediately after treatment assignment; OFF group receives active therapy after four months of treatment assignment.|t|t|t|t
34062681|NCT05572372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062682|NCT04140240|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Parallel Assignment a experimental design with pre test and post test|Parallel Assignment a experimental design with pre test and post test|f|f|f|t
34062683|NCT00677573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062684|NCT02608008|||OTHER||RETROSPECTIVE|||||||
34062685|NCT01110213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062686|NCT00092339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062687|NCT01931241|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34062688|NCT05166720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34062689|NCT00678470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062690|NCT02535169|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34062691|NCT03650296|||OTHER||PROSPECTIVE|||||||
34062692|NCT05854043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062693|NCT01891318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062694|NCT04910672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The investigator does not participate in the randomization process. Participants will be blinded as to which treatment group they belong to. The experimental group will not know the treatment time, the type of treatment or the sessions received by the control group, or vice versa.~The researcher who will carry out the pre- and post-measurements will be blinded in relation to the type of intervention.~The investigator who will perform the statistical analysis will be blinded with respect to the type of intervention."|This is a double-blind prospective, longitudinal, randomized, controlled clinical trial.|t|f|f|t
34062695|NCT06220409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34062696|NCT05342428|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34062697|NCT04736732|||COHORT||PROSPECTIVE|||||||
34062698|NCT05800496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Subjects were randomly assigned in a 1:1 ratio to receive either treatment A or Placebo. The randomization code was generated by NovoBliss Research.~Subjects were randomly allocated to one of the treatment groups, as per the randomization code. Complete double-blinding was kept wherein neither the subjects nor the investigator was aware of the test treatment allocation. To maintain double blinding, the study staff who involves in treatment dispensing and distribution was not involved in any other study-related activities."|A Proof-of-Concept, Placebo-Controlled, Safety, and Efficacy|t|f|t|f
34062699|NCT04260269|||COHORT||RETROSPECTIVE|||||||
34062700|NCT03769597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062701|NCT03418194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856192|NCT02976454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856193|NCT04388241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856194|NCT06115551|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33856195|NCT02490553|||||CROSS_SECTIONAL|||||||
33856196|NCT02485535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856197|NCT02904486|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34168327|NCT04737278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigational product bottles were labeled according to the requirements of ICH--GCP guidelines and applicable local regulatory guidelines. Investigational products were coded by the unblinded personnel at KGK Synergize who were not involved in the collecting or analyzing of study data. Each package contained a similar label differing only in randomization number.|randomized, double--blind, placebo controlled, parallel study|t|f|t|f
34168328|NCT02356913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168329|NCT02654548|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34168330|NCT02776111|||COHORT||PROSPECTIVE|||||||
34168331|NCT05296434|||CASE_CONTROL||PROSPECTIVE|||||||
34168332|NCT04137913|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to limited funding, the research team is unable to conduct a truly randomized clinical trial. Research staff assessing baseline assessment (pre-intervention) and follow-up assessments (post-intervention) will not be intentionally masked. Participants also will not be masked. During the screening process, participants are told that they are randomized into a certain group.They are informed which group they have been assigned to at their baseline visit. However, in actuality they are not completely randomized because participants will be recruited in cohorts: all experimental participants will be recruited first, followed by the recruitment of non-waitlist controls. When all experimental participants have been recruited, control participants will be recruited thereafter. Because control participants will not receive the music intervention after the study, the recruitment method will change when controls are recruited for the study. Hence, the non-randomized design of this study.|Half the participants will be placed in the experimental group while the other half will be placed in the non wait-list control group. Individuals in the control group will not be given the music intervention during their enrollment in the study. Due to the lack of funds, the research team is unable to provide individuals in the control group with the intervention after the study.||||
34168333|NCT00043719|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34168334|NCT05238766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168335|NCT01693029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168336|NCT02803736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168337|NCT03897959|NA|SINGLE_GROUP||PREVENTION||NONE||Patients will utilize existing urinary drainage catheter for 30 days and then switch to alternative for 30 days. Patient will repeat this cycle once more.||||
34168338|NCT02302365|||CASE_ONLY||RETROSPECTIVE|||||||
34168339|NCT00701610|||COHORT||PROSPECTIVE|||||||
34168340|NCT03045874|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34168341|NCT02813889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168342|NCT05288647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168343|NCT01806220|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168344|NCT00007592|||||PROSPECTIVE|||||||
34168345|NCT05927844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|open, single-arm||||
34168346|NCT02210728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168347|NCT05072392|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The patient will be blinded to group allocation as they are anesthetised during the intervention procedure.~The outcome assessor for the primary outcome (incidence of nasal bleeding) will also be blinded by inspecting the gauze swab for blood outside the patient's operating theatre.~The care provider and investigator are unable to be blinded due to the nature of the intervention."|"Two parallel study groups allocated by randomization to either the intervention group (Foley-assisted nasal endotracheal intubation) or control (standard nasal endotracheal intubation).~Randomisation is via sealed opaque numbered envelopes that are only opened to reveal group allocation once the patient has been recruited."|t|f|f|t
34168348|NCT01638663|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34168349|NCT00356044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168350|NCT01157910|||CASE_CONTROL||PROSPECTIVE|||||||
34168351|NCT05077800|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168352|NCT02531217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168353|NCT04477499|||OTHER||PROSPECTIVE|||||||
34168354|NCT04513548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Part 1 is not masked Part 2 is masked||t|f|t|f
34168355|NCT00006252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958790|NCT03644459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958791|NCT03910010|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958792|NCT05975216|||OTHER||OTHER|||||||
34168356|NCT01246427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168357|NCT02952885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168358|NCT00796666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168359|NCT01919528|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958793|NCT02414867|||COHORT||PROSPECTIVE|||||||
34168360|NCT02525653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168361|NCT01441843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168362|NCT06468956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168363|NCT02181465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168364|NCT04862325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34168365|NCT02517034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168366|NCT03898726|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|neither the paticipant nor the investigator knew type of vaginal cuff closure||t|f|t|f
34168367|NCT00483613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33958794|NCT00131326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33958795|NCT06565559|||COHORT||PROSPECTIVE|||||||
34168368|NCT01143571|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34168369|NCT01725490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168370|NCT04152226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"A single center open label dose escalating study design will be used in a population of patients with interdigital Tinea pedis. Each subject will have a single application of the test article applied to each foot. The three test articles will be a low dose, medium and a high dose of J. lividum. Each of the three groups will have 4 subjects. After the first cohort has completed their day 7 visits and if no significant tolerability of safety issues is identified the second cohort will be enrolled. After the second cohort has completed the day 7 visits and if no significant tolerability or safety issues are identified the third cohort will be enrolled.~At all evaluations, signs and symptoms of application site reactions will be recorded at baseline, as well as days 2, 3, 7, 14, and 28."||||
34168371|NCT01177007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168372|NCT01043055|||COHORT||PROSPECTIVE|||||||
34168373|NCT02828735|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168374|NCT01579435|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34168375|NCT01176734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168376|NCT04899843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Newly diagnosed Acne vulgaris patients|t|f|t|f
33856198|NCT03952429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Participants will be notified there are 2 versions of the app and they will randomly be assigned to one of the 2 conditions, but will not know which one. Therapists giving the users input on how to use the app do not know in which condition the patient is either. Outcome (relapse rates) are assessed by interns and admin staff of the clinic who are independent from the study. The study investigators do not know the patients and only receive anonymized data on group and outcome variables.|This is a parallel study, participants will be randomised into 2 groups: one will be given the App with cognitive bias modification, whilst the other one will receive the app without the modification|t|t|t|t
34168377|NCT05055544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, controlled, double-blinded, two-armed multicentre trial.|t|t|t|t
34168378|NCT00013520||||TREATMENT||||||||
34168379|NCT01876355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168380|NCT03115944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168381|NCT02609958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168382|NCT03980249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168383|NCT04933071|RANDOMIZED|PARALLEL||OTHER||SINGLE|Those that are grading residents (ie. attending physicians) will not be aware which arm the residents are randomized to.|Residents in PGY-1 or PGY-2 group will be randomized to podcast learning (intervention) or usual teaching (no intervention)|f|f|f|t
34168384|NCT03190395|RANDOMIZED|PARALLEL||TREATMENT||NONE||Contorol Group:Pure Circumferential pulmonary vein isolation(CPVI) Experimental Group:Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA)||||
34168385|NCT05175092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"single-center, open-label, two-stage recruitment~* pilot study of 5 recipients to determine if LDLT is a suitable treatment for patients with non-resectable LM with 3 years of follow-up, if Overall Survival greater than 60%, then~* stage two recruitment focusing on accruing additional recipients will commence.~* control group of participants that sign the informed consent and are enrolled in the study but do not undergo LDLT due to a lack of an eligible donor"||||
33856199|NCT03221517|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34168386|NCT04836585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The RA randomizing the participant will be not be blinded to the treatment allocation because they have to inform the provider of the treatment allocation. This RA will not be collecting outcome measures. The RA collecting outcome measures will be blinded to the treatment allocation.||f|f|t|t
34168387|NCT04803266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168388|NCT01460108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168389|NCT03687788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33856200|NCT05822167|RANDOMIZED|CROSSOVER||PREVENTION||NONE||3 interventional Studies 9 arms||||
33856201|NCT01717690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856202|NCT01658826|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33856203|NCT00914160|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856204|NCT03252275|RANDOMIZED|PARALLEL||OTHER||NONE||We will conduct a parallel comparison of intervention and control arms to measure study endpoints||||
33856205|NCT05742737|||COHORT||RETROSPECTIVE|||||||
33856206|NCT00607022|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This is a phase IV Post-Market evaluation of three 510K cleared implant products. One type of dental implant was used but clinically loaded with a dental crown at one of three time points, immediate at implant placement, at 6weeks or 12 weeks following implant placement. There are therefore 3 interventions being evaluated.|t|f|f|t
33856207|NCT04101604|||CASE_CONTROL||PROSPECTIVE|||||||
33856208|NCT05925556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856209|NCT00913653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168390|NCT04130321|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34168391|NCT03321084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The one who assess the patients in the beginning and in the final moment (investigator) not know in what group the patient is. As the investigator that will do the statistic (outcome assessor).|Two groups: a MatPilates group (MG) and a Control group (CG).|f|f|t|t
34168392|NCT04982939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168393|NCT05553795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled multicentric trial||||
34168394|NCT02907424|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34168395|NCT01885221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168396|NCT03324490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Using computer \& sealed envelope randomization, patients are assigned to receive either thoracic spinal anesthesia \[TSA group: n=30\] or thoracic epidural anesthesia \[TEA group: n=30\].|t|f|f|t
34168397|NCT02907151|||COHORT||PROSPECTIVE|||||||
34168398|NCT02762695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168399|NCT03706443|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigator instills known eye drop; masked to participant|Single masked; randomized|t|f|f|f
33856210|NCT00000193||||TREATMENT||DOUBLE||||||
33856211|NCT00322205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856212|NCT00127777|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33856213|NCT00238147||||TREATMENT||NONE||||||
33856214|NCT00606567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856215|NCT05997927|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33856216|NCT01498653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856217|NCT05273853|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33856218|NCT01174654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33856219|NCT00069238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856220|NCT02127918|||COHORT||PROSPECTIVE|||||||
33856221|NCT00203476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856222|NCT02920333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856223|NCT03075007|||COHORT||PROSPECTIVE|||||||
33856224|NCT06384638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33856225|NCT03741569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958796|NCT05630703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator will be blinded for the duration of the study. The study psychologist and the dietician will be blinded to the study results for the duration of the study.|"The randomization scheme used will be a random number generator using the Research Randomizer website (https://www.randomizer.org/) where the subjects will be randomized in one (1) of two (2) arms:~Mindfulness-based Awareness Training in IBS (MB-IBS-EAT) Intervention OR Low FODMAP Diet Intervention"|f|f|t|f
33856226|NCT03120767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856227|NCT02275494|||COHORT||PROSPECTIVE|||||||
33856228|NCT03163485|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33856229|NCT04262973|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33856230|NCT02457767|||COHORT||PROSPECTIVE|||||||
33856231|NCT02416817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856232|NCT01718782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856233|NCT03453931|||CASE_ONLY||PROSPECTIVE|||||||
33856234|NCT02457312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856235|NCT00687817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856236|NCT02867293|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33856237|NCT04399590|||COHORT||PROSPECTIVE|||||||
33856238|NCT06247644|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel model - two treatment arms: Device with adhesive vs. Device with adhesive + additional adhesive ring||||
33958797|NCT02460861|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33856239|NCT04568746|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33856240|NCT05647239|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|no masking done|The study was conducted in a randomized controlled study design in order to determine the effect of Shotblocker on pain and injection satisfaction in patients who were using DMAH and received subcutaneous injection after arthroplasty surgery in orthopedics training clinic.|t|f|f|f
34076757|NCT05208996|NA|SEQUENTIAL||TREATMENT||NONE||"This is a dose-escalation trial, all participants will receive single or multiple treatment with siCoV/KK46 via an inhaled route. Participants enrolled in this trial may receive one of the following doses:~Cohort 1: 3.7 mg; Cohort 2: 11.1 mg; Cohort 3: 22.2 mg"||||
33856241|NCT01038063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856242|NCT06418828|||COHORT||PROSPECTIVE|||||||
33856243|NCT02757859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856244|NCT03436108|||CASE_CONTROL||PROSPECTIVE|||||||
33958798|NCT05001763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958799|NCT02996461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958800|NCT06117566|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||WX390 continuous oral dosing (0.5 mg once a day) WX390 continuous oral dosing (0.7 mg once a day) WX390 continuous oral dosing (0.9 mg once a day) Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks)||||
33958801|NCT06473558|NA|SINGLE_GROUP||SCREENING||NONE||||||
33958802|NCT06362616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958803|NCT06228053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958804|NCT00016406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958805|NCT04024722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958806|NCT06355583|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33958807|NCT05789420|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33958808|NCT04446117|RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 580 eligible subjects will be randomized in a 1:1 fashion to the experimental arm receiving cabozantinib and atezolizumab in combination (290) or to the control arm receiving a second NHT (290).||||
34076758|NCT00173628|||DEFINED_POPULATION||OTHER|||||||
33856245|NCT01344512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856246|NCT04998370|||COHORT||PROSPECTIVE|||||||
33958809|NCT05588128|||COHORT||PROSPECTIVE|||||||
33958810|NCT05945147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958811|NCT04282733|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants are staff on two hospital units tending to the same patient population with the same policies and protocols - postpartum patients. One unit will have the Mindfulness Rounds Initiative as the intervention, the other will not. Both units will be evaluated against each other, and against themselves in a pre-/post- design.||||
33958812|NCT01604148|||COHORT||RETROSPECTIVE|||||||
33958813|NCT04440163|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33958814|NCT05165277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33958815|NCT00146003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856247|NCT02873507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856248|NCT00227890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33856249|NCT05330637|||COHORT||PROSPECTIVE|||||||
33856250|NCT02977117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856251|NCT03125525|||CASE_ONLY||PROSPECTIVE|||||||
33856252|NCT00194857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856253|NCT04168333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856254|NCT05363423|||CASE_ONLY||RETROSPECTIVE|||||||
33958816|NCT05220904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33958817|NCT05088980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958818|NCT05420818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856255|NCT03408054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856256|NCT05822453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856257|NCT05402748|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33856258|NCT01138579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856259|NCT02031315|||COHORT||PROSPECTIVE|||||||
33856260|NCT06485440|||COHORT||PROSPECTIVE|||||||
33856261|NCT05792969|||CASE_CONTROL||PROSPECTIVE|||||||
33958819|NCT04215952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Administration and scoring of all primary and secondary outcome measures will be carried out by a speech pathologist on study staff who (1) is not the treating clinician for the participant being assessed, and (2) is blind to the group assignment of the participant being assessed. Because SFA is a behavioral intervention, it will not be possible to blind the treating clinician to group assignment. It will also be impossible to definitively blind participants to their group assignment. However, we will not formally disclose to participants the group to which they have been assigned, and in the informed consent process, we will describe the conditions only in relative terms.|Study participants will be randomly assigned to one of two treatment conditions.|t|t|t|t
33958820|NCT06702358|NA|SINGLE_GROUP||TREATMENT||NONE||"Laser pointer instruments Product Details Infrared laser diode made in Italy, it must be perpendicular with direct contact to each point.~Each point will stimulate bilaterally by a laser beam of the following parameters wave length 904 nm; strength, 24 mW; energy, 0.1 J; stimulation time, 30 s/point; and two sessions per week for 8 weeks."||||
33856262|NCT05632445|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33856263|NCT02558309|||CASE_ONLY||PROSPECTIVE|||||||
33958821|NCT04289584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33856264|NCT00338533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856265|NCT00681330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958822|NCT01933932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168400|NCT05714826|RANDOMIZED|PARALLEL||PREVENTION||NONE||It is a prospective randomized study that implements a multi-modal digitally based comprehensive health optimization program in the pre and post-operative setting in patients undergoing radical cystectomy for muscle invasive bladder cancer. Two patient groups will be enrolled and randomized where one group will go through the peri-operative optimization programs and the other group will receive the usual pre-op care followed by post-op care via standard follow-up protocol.||||
34168401|NCT04879056|||CASE_CROSSOVER||PROSPECTIVE|||||||
34168402|NCT00997919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856266|NCT00351143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168403|NCT02038153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168404|NCT00256061|||||RETROSPECTIVE|||||||
33856267|NCT05617352|||OTHER||RETROSPECTIVE|||||||
33856268|NCT00446628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856269|NCT02181712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856270|NCT00597441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856271|NCT02241954|||COHORT||PROSPECTIVE|||||||
33856272|NCT03560089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessment of video||f|f|f|t
33856273|NCT05788523|||COHORT||RETROSPECTIVE|||||||
33856274|NCT00616369|||COHORT||PROSPECTIVE|||||||
33856275|NCT01813708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33856276|NCT04578613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856277|NCT05052866|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33856278|NCT06144177|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856279|NCT03275753|||COHORT||CROSS_SECTIONAL|||||||
33856280|NCT02931825|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33856281|NCT06058169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856282|NCT04692935|||OTHER||RETROSPECTIVE|||||||
33856283|NCT01803568|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33856284|NCT04596696|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33856285|NCT05276115|||COHORT||PROSPECTIVE|||||||
33856286|NCT05647850|||CASE_CONTROL||PROSPECTIVE|||||||
33856287|NCT05024994|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II study exploring the efficacy of E7820 in patients with relapsed and refractory myeloid malignancies with mutations in splicing factors.||||
33856288|NCT00104312|||COHORT||CROSS_SECTIONAL|||||||
33856289|NCT05097027|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33958823|NCT06132100|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator and outcomes assessor did not know the allocation of participant.|The purpose of this clinical trial is to use a digital recording device integrated with an incentive spirometer to record a patient's deep breathing lung training following abdominal surgery. Through this digital recording, it will be possible to effectively assess the daily frequency, duration, depth of deep breaths, and the volume of inhalation performed by the patient during their breathing exercises. This will transform the previously difficult-to-describe deep breathing training into a digital record, allowing healthcare professionals to quickly evaluate the patient's condition. Patients can also monitor their own respiratory function changes, leading to positive health promotion benefits, accelerating their postoperative recovery, and simultaneously reducing healthcare costs and improving medical quality.|f|f|t|t
33958824|NCT01363518|||COHORT||PROSPECTIVE|||||||
33958825|NCT00005129|||COHORT||PROSPECTIVE|||||||
33958826|NCT04583384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958827|NCT05370781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958828|NCT06700629|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33958829|NCT02837263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958830|NCT03760926|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33958831|NCT00792818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958832|NCT01066039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958833|NCT03830229|||COHORT||PROSPECTIVE|||||||
33958834|NCT03148327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958835|NCT03541668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856290|NCT04440982|RANDOMIZED|PARALLEL||OTHER||SINGLE|Masking will only be applied until main lumpectomy is removed. At time of randomization, the study arm will be revealed to the study team.|Subjects will be randomized to receive the device intervention. All subjects will receive the study drug.|f|f|t|f
33856291|NCT04597528|||COHORT||PROSPECTIVE|||||||
33856292|NCT05998356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects will be blinded to the treatment arm, while surgeons cannot be blinded for obvious reasons. The data collection from post-operative visits will be performed by assessors blinded to the inclusion arm to minimize possible biases.|Subjects randomly assigned to the intervention (experimental) group will benefit from BET, and subjects in the control group will undergo a Eustachian tube catheter insertion for probing and flushing the Eustachian tube but without dilation.|t|f|f|t
33856293|NCT04316208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Care provider will adjust the PEEP level, make measurements and record arterial blood gas analysis results. Biostatistician will compare data set at each PEEP to each other. Investigator will analyze the data|After craniotomy, PEEP will be adjusted to 0 cmH2O, 5 cmH2O and 10 cmH2O for 5 minutes each to collect the data||||
33856294|NCT05430893|||COHORT||RETROSPECTIVE|||||||
33856295|NCT02982915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062702|NCT06528509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Care Providers: The clinicians responsible for confirming consent on the day of surgery will be blinded to the group assignments of the patients. They will not know whether a patient received the AI-generated video or the standard written information brochure.~Outcomes Assessors: The individuals assessing the outcomes, including patient understanding and satisfaction, as well as preoperative anxiety levels, will also be blinded to the group assignments. This includes the personnel administering and analyzing the multiple-choice questionnaires and anxiety scales.~Participants: Participants will not be blinded as they will be aware of the type of information they received (AI-generated video or written brochure)."|The study is designed as a parallel, randomized controlled trial. Participants scheduled for cataract surgery are randomly allocated into two groups: the intervention group and the control group. The intervention group receives AI-generated informative videos, while the control group receives standard written information brochures. The study will run in two cohorts, with Cohort A including English speaking patients and Cohort B Bengali speakers.|f|t|f|t
33856296|NCT01556893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856297|NCT00210977|||COHORT||PROSPECTIVE|||||||
33856298|NCT04206579|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both packages of intervention have a similar dimension to ensure the participants are not recognizing the formula. The pharmacists are responsible for preparing the formula and given to the nurse prior to the intervention. Investigators are being masked during the whole intervention.|the study involves two different groups with a cross-over design. Each participant will be given an oral formula according to the group allocation followed by outcome measurement. After the wash-out period, the formula will be switched and given to the participants, followed by outcome measurement|t|f|t|f
34062703|NCT03745105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062704|NCT05729581|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Our study has 2 phases: 1) observational and 2) interventional (with educational programme):~1. st group - CG (control group) - mothers without intervention~2. nd group - EG (experimental group) - mothers with applied educational intervention on sustainable diet and breastfeeding"|t|f|f|f
34062705|NCT06048575|||OTHER||RETROSPECTIVE|||||||
34062706|NCT01074723|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34062707|NCT05438966|||COHORT||CROSS_SECTIONAL|||||||
33856299|NCT02564926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856300|NCT03626428|||CASE_ONLY||RETROSPECTIVE|||||||
33856301|NCT00340977|||CASE_CONTROL||RETROSPECTIVE|||||||
33958836|NCT00358670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958837|NCT01260168|||CASE_ONLY|||||||||
33958838|NCT03443973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958839|NCT00317967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958840|NCT03852407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958841|NCT03337763|||COHORT||PROSPECTIVE|||||||
33958842|NCT06430307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958843|NCT06568120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled study|f|f|f|t
34062708|NCT03194347|||COHORT||PROSPECTIVE|||||||
34168405|NCT03649217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168406|NCT02343146|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34168407|NCT00286585|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34168408|NCT01545726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168409|NCT01260714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168410|NCT00117637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168411|NCT01847963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168412|NCT05661812|||CASE_CONTROL||RETROSPECTIVE|||||||
34168413|NCT04034706|||COHORT||PROSPECTIVE|||||||
33958844|NCT04717869|||COHORT||PROSPECTIVE|||||||
33958845|NCT04141761|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Single-blind, placebo-controlled, 2:1 randomly assigned|t|f|t|t
33958846|NCT03811366|NA|SINGLE_GROUP||OTHER||NONE||All patients were treated with a standard high-dose corticosteroid||||
33958847|NCT02587000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33958848|NCT02757261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33958849|NCT00002879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958850|NCT04057352|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33958851|NCT01585064|||COHORT||PROSPECTIVE|||||||
33958852|NCT03821688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958853|NCT03693157|||COHORT||PROSPECTIVE|||||||
33958854|NCT01097850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958855|NCT05660837|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Baseline survey, follow-up survey, and anthropometry measurement will be collected through assessor masked to assignment details.|"The investigators are providing informational and emotional social support (nutrition, mental health, baking classes) through two different communication modalities (online vs. mixed mode) whose effects will be contrasted against each other and a third, control, condition.~Treatment 1: Mixed-mode social support group Treatment 2: Online social support group Control: No intervention"|f|f|f|t
33958856|NCT05724576|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||10 anterior wall STEMI patients without cardiogenic shock will be enrolled into group 1 (i.e., will receive 1.5 x 107 OmniMSC-AMI, n=5) and then group 2 (3.0 x 107 OmniMSC-AMI, n=5).||||
33958857|NCT06551948|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Test meals in opaque plastic bags|3 way cross over|t|f|t|t
33958858|NCT05873959|||CASE_ONLY||RETROSPECTIVE|||||||
33856302|NCT00515983|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33856303|NCT01941797|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33856304|NCT06422780|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomised controlled trial with follow-up||||
33856305|NCT04364854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856306|NCT05119309|||COHORT||RETROSPECTIVE|||||||
33856307|NCT03169322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856308|NCT00771563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856309|NCT03588728|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants were not informed of their randomization group until debreifing.|2 (CR, Control CR) x 2 (tDCS xSham tDCS)|t|f|f|f
33856310|NCT02313233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856311|NCT01348360|||COHORT||PROSPECTIVE|||||||
33856312|NCT02580695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856313|NCT05121987|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856314|NCT00511472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856315|NCT03045601|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33856316|NCT06367920|||COHORT||RETROSPECTIVE|||||||
33856317|NCT03553368|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33856318|NCT01399333|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33856319|NCT05269810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856320|NCT04126772|||CASE_CONTROL||PROSPECTIVE|||||||
33856321|NCT03728556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856322|NCT00512954|||CASE_ONLY||PROSPECTIVE|||||||
33856323|NCT06526351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is designed as a single center, double-blinded, randomized, patient-oriented, controlled clinical trial.|t|t|f|t
33856324|NCT02228655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856325|NCT02136160|NA|||PREVENTION||NONE||||||
33856326|NCT01096303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856327|NCT02512757|||CASE_CONTROL||PROSPECTIVE|||||||
33856328|NCT05291000|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
33856329|NCT03090815|||COHORT||PROSPECTIVE|||||||
34062709|NCT02065063|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34062710|NCT03938688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34076759|NCT04891302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856330|NCT03622554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856331|NCT01293929|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856332|NCT03656523|||COHORT||PROSPECTIVE|||||||
33856333|NCT00000577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856334|NCT04732533|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group, open-label intervention.||||
33856335|NCT03318705|||CASE_CONTROL||PROSPECTIVE|||||||
33856336|NCT01210066|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33856337|NCT00002023||||TREATMENT||||||||
33856338|NCT02446886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856339|NCT02838433|NA|SINGLE_GROUP||||NONE||||||
33856340|NCT02849288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856341|NCT02674789|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33856342|NCT04446325|||COHORT||RETROSPECTIVE|||||||
33856343|NCT01578759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33856344|NCT00624143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856345|NCT02582723|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33856346|NCT04744285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856347|NCT05150496|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33856348|NCT00589082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856349|NCT04217928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor and biostatistician will be blinded||f|f|f|t
33856350|NCT02778932|||OTHER||PROSPECTIVE|||||||
33856351|NCT01462838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856352|NCT06078839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Nafamostat mesilate treatment group (experimental group) : Basic treatment + Nafamostat mesilate 2.0 mg/kg/d Placebo control group: Basic treatment + 5% glucose with Nafamostat mesilate equal volume|t|t|t|t
33856353|NCT02179723|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33856354|NCT01350336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856355|NCT00634660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856356|NCT02237651|||COHORT||PROSPECTIVE|||||||
33856357|NCT06323018|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization and intervention is done by a dedicated study nurse. Patient, orthopedic surgeon, investigator and outcomes assessor and statistician are all blinded to the study intervention.||t|t|t|t
33958859|NCT04442763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958860|NCT04700215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33958861|NCT06702033|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Highest risk pathology (pT4) = remove from trial.~* High-risk pathology = Arm 1~* Intermediate-risk pathology will be randomized to Arm 2A, Arm 2B, or Arm 2C.~* Low-risk pathology = remove from trial."||||
33958862|NCT03461029|||CASE_ONLY||CROSS_SECTIONAL|||||||
33958863|NCT01754480|RANDOMIZED|PARALLEL||TREATMENT||||||||
33958864|NCT06565572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958865|NCT00739622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958866|NCT03003728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958867|NCT03640442|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34076760|NCT00715559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076761|NCT03227393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33748531|NCT05309265|NA|SINGLE_GROUP||OTHER||NONE||||||
33856358|NCT06311604|NA|SINGLE_GROUP||OTHER||NONE||Prospective, open-label, single-centre, interventional dose escalation study||||
33856359|NCT06236282|||COHORT||RETROSPECTIVE|||||||
33856360|NCT04743167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856361|NCT02263937|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33856362|NCT03282812|||CASE_CONTROL||PROSPECTIVE|||||||
33856363|NCT01444456|||COHORT||PROSPECTIVE|||||||
33856364|NCT02501538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856365|NCT05328323|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856366|NCT00465946|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33856367|NCT04876742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33856368|NCT00002565|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856369|NCT04934488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33856370|NCT03298685|||OTHER||PROSPECTIVE|||||||
33856371|NCT05208866|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open-label study||||
33856372|NCT03458065|||CASE_CONTROL||PROSPECTIVE|||||||
33856373|NCT00165087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856374|NCT03760705|||COHORT||OTHER|||||||
33856375|NCT02137720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856376|NCT00603148|||COHORT||PROSPECTIVE|||||||
33856377|NCT00713115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856378|NCT01247571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856379|NCT05999968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856380|NCT03207685|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33856381|NCT03186196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33856382|NCT02920931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856383|NCT02254525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856384|NCT00094042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856385|NCT06128993|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised placebo controlled||||
33856386|NCT00676819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33856387|NCT01400555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856388|NCT03782025|||COHORT||PROSPECTIVE|||||||
33856389|NCT05137353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856390|NCT06350578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind|A binary outcome non-inferiority randomized trial.|f|t|f|f
33856391|NCT03433248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856392|NCT06117098|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT feasibility study, non-inferiority and superiority trial||||
33856393|NCT00544388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856394|NCT01284660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33958868|NCT04085263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"The participants will be kept blind through the use of sham block in the control group.~Outcome assessors will be blinded as they will be anesthesia resident and nurse not participating in the study.~The investigators will be blinded"|Prospective study|t|f|t|t
33958869|NCT03850262|||CASE_ONLY||PROSPECTIVE|||||||
33958870|NCT06323343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33958871|NCT04462224|||COHORT||PROSPECTIVE|||||||
33958872|NCT02167100|||||RETROSPECTIVE|||||||
33958873|NCT03638102|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33958874|NCT03328468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33958875|NCT06247254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33958876|NCT04976335|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33958877|NCT06539130|||CASE_ONLY||PROSPECTIVE|||||||
33958878|NCT04757831|||COHORT||PROSPECTIVE|||||||
33958879|NCT06498557|||COHORT||PROSPECTIVE|||||||
33958880|NCT04804293|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Central hypothesis is that SWE provides quantitative information about the physical properties of the MN and surrounding tissue that help to identify carpal tunnel syndrome, its severity and response to treatment.||||
33958881|NCT06138626|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33958882|NCT06154122|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33856395|NCT03739177|||COHORT||PROSPECTIVE|||||||
33856396|NCT05615090|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The waitlist group receives usual care for the first 8 weeks. After 8 weeks, the waitlist group begins the intervention and the immediate intervention group begins a maintenance phase||||
33856397|NCT03404830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Groups were assigned during the months of July and August through the sports centers where these elderly people performed some kind of physical activity.|Randomized controlled trial|f|t|t|t
33856398|NCT05826574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856399|NCT04697303|||OTHER||OTHER|||||||
33856400|NCT02617056|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33856401|NCT06151054|||COHORT||OTHER|||||||
33856402|NCT05031403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856403|NCT02843971|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856404|NCT02902003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856405|NCT01207726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856406|NCT03800641|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33856407|NCT02260882|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856408|NCT02778711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856409|NCT00004252|RANDOMIZED|||TREATMENT||||||||
33856410|NCT00081874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856411|NCT01391585|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33856412|NCT02373553|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33856413|NCT00006380||||TREATMENT||||||||
33856414|NCT06022562|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856415|NCT04834206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856416|NCT04357860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856417|NCT06389253|||COHORT||CROSS_SECTIONAL|||||||
33856418|NCT03201705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958883|NCT03899506|||COHORT||PROSPECTIVE|||||||
33958884|NCT00033137|||COHORT||PROSPECTIVE|||||||
34168414|NCT04734886|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33958885|NCT05208944|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part A - Safety lead-in, modified 3+3 design~Part B - Simon's 2-stage design, randomized, dose-finding, 3-arm (or 2 arm, based on Part A emerging data) with optional extension cohort(s)~Part C (optional to open) - high dose arm, 3+3 design potentially followed by Simon's 2-stage design"||||
33958886|NCT04114578|||COHORT||PROSPECTIVE|||||||
33856419|NCT02793479|||COHORT||PROSPECTIVE|||||||
33958887|NCT02627885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958888|NCT05069168|||CASE_ONLY||PROSPECTIVE|||||||
33958889|NCT03464045|||COHORT||PROSPECTIVE|||||||
33958890|NCT05204888|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients assigned to the HFNT group will be provided a myAirvo 3 device. The myAirvo 3 is a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. The interface used in this trial is the Optiflow™ + Duet nasal cannula sized for patient comfort. Patients will also be provided with a pulse oximetry device that connects to the myAirvo 3 to record pulse oximetry and heart rate once daily after wearing the device for two minutes.~Patients assigned to the control group will be provided with a pulse oximetry device to record pulse oximetry and heart rate once daily after using the pulse oximeter for two minutes as well as answering a respiratory questionnaire and input data into a smartphone adapted to be used as an electronic diary."||||
34062711|NCT03240406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research clinician who assesses cognitive status needs to be blinded to assignment.|This is a pilot randomized clinical trial to the effects of an anti-inflammatory diet on cognition in a middle-aged cohort. The comparison arm will receive information on self-care matters such as aches and pains of aging.|f|f|f|t
33856420|NCT05090748|||OTHER||PROSPECTIVE|||||||
34062712|NCT05133414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062713|NCT03875976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study aims to evaluate the effectiveness of a fast track protocol , which consists of an innovative analgesic therapy scheme and a rapid rehabilitation protocol, and a standard care protocol.||||
34062714|NCT01393132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856421|NCT04129853|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856422|NCT05244889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|While the study will be single-blinded (researchers analysing data will be blind to allocation), randomisation will be concealed to the RA and participant until the individual's eligibility has been established.|Individuals will be randomly assigned to a dCBT-I or the sleep hygiene education control group.|f|f|f|t
33856423|NCT00293631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856424|NCT00624923|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062715|NCT03643913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the surgeon are blinded for the intervention. The anesthesist knows the allocation.||t|f|t|f
33856425|NCT00434473|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856426|NCT00642382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856427|NCT02020629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33856428|NCT01144767|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33856429|NCT00265447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856430|NCT00921960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856431|NCT01543724|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33856432|NCT05332405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856433|NCT00000274||||TREATMENT||||||||
33856434|NCT02170935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856435|NCT05843188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062716|NCT02795845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062717|NCT05297110|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34062718|NCT02922257|||COHORT||PROSPECTIVE|||||||
34062719|NCT01287000|||COHORT||PROSPECTIVE|||||||
34062720|NCT02320682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062721|NCT06553885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062722|NCT06712901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34062723|NCT03606694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Assignment|t|f|t|f
33856436|NCT03583177|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856437|NCT03451162|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33856438|NCT01483664|||COHORT||PROSPECTIVE|||||||
33856439|NCT00000198||||TREATMENT||||||||
34062724|NCT04339010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This was a single-blind randomized controlled trial comparing the effect of AHT versus AHT associated with PFM contraction in incontinent women.|f|f|f|t
34062725|NCT05628298|||CASE_ONLY||PROSPECTIVE|||||||
34076762|NCT05269368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Three experts, independent of the study, will examine the photos three months after the intervention using a standardized evaluation grid based on 10 criteria.|"* Experimental group: No Wicking~* Control groupe: Wicking after intervention"|f|f|f|t
34076763|NCT04924634|||COHORT||RETROSPECTIVE|||||||
33856440|NCT01668108|||OTHER||PROSPECTIVE|||||||
33856441|NCT00302627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856442|NCT00073112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856443|NCT04878731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33856444|NCT02768051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856445|NCT05868174|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation/de-escalations will be supported by the guidance given by outputs of the Bayesian model-based dose-escalation design.||||
33856446|NCT04242589|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856447|NCT01640054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856448|NCT02882828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856449|NCT04902833|||COHORT||PROSPECTIVE|||||||
33856450|NCT03999320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856451|NCT02234245|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33856452|NCT04011618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|randomized double-blind|Double-blind, placebo-controlled clinical trial|t|t|t|f
33856453|NCT04402398|||COHORT||RETROSPECTIVE|||||||
33856454|NCT01561209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33856455|NCT03917680|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958891|NCT00998582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958892|NCT02263586|||COHORT||RETROSPECTIVE|||||||
33958893|NCT01990079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958894|NCT00463814|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958895|NCT06239792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958896|NCT06702371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Allocation concealment is ensured through the use of Sealed Envelope, which maintains the randomisation schedule securely and prevents members of the research team responsible for enrolling participants from accessing the allocation sequence. The research team involved in data collection will not be blinded to group allocation. Members of the research team who will analyse the data will be blinded to the randomisation schedule and group allocation.|Participants will be randomly allocated (1:1) to the EMBody intervention group or the waitlist attention control group. Those in the intervention group will complete the EMBody intervention content as well as online surveys. Those in the control group will complete the online surveys at the same time points and will receive the EMBody intervention content after their study involvement.|f|f|t|t
33958897|NCT05968664|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33958898|NCT06315569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748532|NCT03370653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo|"Preliminary safety assessment (N=2): an open-label, escalating dose (2 doses) study.~Core study: conducted on 2 populations in parallel:~* A first cohort (N=18): MPS VI patients receiving ERT assigned in 3 arms:~  * Placebo (N=6)~ * Odiparcil 500 mg per day (250 mg BID) (N=6)~ * Odiparcil 1000 mg per day (500 mg BID) (N=6).~* A second cohort (N=6): MPS VI patients not receiving ERT (odiparcil 1000 mg per day (500 mg BID))."|t|t|t|t
33748533|NCT00314197|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33748534|NCT05130658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748535|NCT00844038|||CASE_ONLY||PROSPECTIVE|||||||
33748536|NCT04647149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748537|NCT05477602|||COHORT||PROSPECTIVE|||||||
33748538|NCT05710601|||COHORT||PROSPECTIVE|||||||
33856456|NCT02583035|NA|SINGLE_GROUP||OTHER||NONE||||||
33958899|NCT01039402|||COHORT||CROSS_SECTIONAL|||||||
33958900|NCT02380248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958901|NCT06702007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062726|NCT06469697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Care providers will not be able to know whether the children referred are from intervention not comparator group as they will only receive a generic referral form from the project.|This is pilot will be conducted in 9 schools where radio broadcasts and community broadcasts will be implemented (intervention) and 9 schools where only community broadcasts will be implemented (comparator).|f|t|f|f
34062727|NCT02562235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062728|NCT00268034|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34168415|NCT03074565|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|An investigator, not involved in providing the treatment, will be responsible for randomizing each subject to an initial treatment modality and to which side of the mouth they will receive each treatment. The patient will be masked as to which modality has been used. The care provider cannot be masked as they must use different instrumentation for each treatment type. When assessing outcomes, the investigator will be masked as to the treatment modality and the side of the mouth.|Subjects will be randomized to receive one of two treatment modalities on either the left or right side of the mouth on their first treatment visit. During the second treatment visit, subjects will receive the other treatment modality on the other side of the mouth.|t|f|f|t
34168416|NCT01418430||||TREATMENT||||||||
34168417|NCT00318084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168418|NCT01962441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168419|NCT05734599|||COHORT||CROSS_SECTIONAL|||||||
33856457|NCT06409780|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33856458|NCT06346860|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33856459|NCT03975166|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33856460|NCT03113903|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|open||t|f|f|f
33748539|NCT01736813|||CASE_ONLY||PROSPECTIVE|||||||
33748540|NCT05142267|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The participant and investigator will be blinded to the drug order across the 3 laboratory drug administration sessions.|The study will be a mixed between/within-subjects design with double-blind counterbalanced placebo-controlled administration of both an opioid antagonist and an opioid agonist. Both drugs are being administered solely to probe mechanisms linking stress with individual differences in opioid analgesic responses (this is not an efficacy trial).||||
33856461|NCT00321113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856462|NCT00234546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856463|NCT06419829|||COHORT||OTHER|||||||
33856464|NCT00096720|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33856465|NCT02800577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856466|NCT04294563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33856467|NCT03549312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062729|NCT05679180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856468|NCT02289612|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33856469|NCT02463643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958902|NCT03843034|||CASE_CONTROL||PROSPECTIVE|||||||
33958903|NCT00272623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34062730|NCT06531499|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be assigned to a treatment arm based on their PSMA expressed target per PET images (based on central read).||||
34062731|NCT06098716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||3 arm parallel design single blinded randomized control trial|t|f|f|f
34062732|NCT04310475|NA|SINGLE_GROUP||TREATMENT||NONE||Case series, feasibility study||||
34062733|NCT02722161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062734|NCT03279354|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33856470|NCT04019548|RANDOMIZED|PARALLEL||OTHER||NONE||Open-label, randomized study.||||
33856471|NCT01484730|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856472|NCT00755703|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33856473|NCT04130529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33856474|NCT02018835|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168420|NCT05719649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|With the random assignment system of Taipei Medical University, 6 Blocks, double-blind|Test group: NTU 101 Lactobacillus Vegetable Capsules Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gellan gum.|t|t|f|f
34168421|NCT00120016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168422|NCT01046981|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34168423|NCT04960969|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168424|NCT01698385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168425|NCT04273334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168426|NCT04044469|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The investigator randomly assigns participants to one of the experimental conditions. Participants are not aware which experimental condition they are allocated to.|Participants are randomly assigned to one of three experimental groups in parallel for the duration of the study|t|f|f|f
34168427|NCT02104453|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34168428|NCT05448040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168429|NCT00667888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856475|NCT01570036|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33856476|NCT01469208|||COHORT||PROSPECTIVE|||||||
33856477|NCT02718937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856478|NCT05046366|||COHORT||PROSPECTIVE|||||||
33856479|NCT04002609|||CASE_CONTROL||PROSPECTIVE|||||||
33856480|NCT05889065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be aware of which group the participant belongs to.|This is a randomized controlled trial having two groups. One group will receive conventional physical therapy and the other group will receive scapular PNF with conventional physical therapy. Both groups will be recruited concurrently.|f|f|f|t
33856481|NCT04616703|||COHORT||PROSPECTIVE|||||||
33856482|NCT01637623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856483|NCT02855424|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33856484|NCT00828841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856485|NCT02749656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856486|NCT02804776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856487|NCT05895565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856488|NCT01778023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856489|NCT02723643|||CASE_ONLY||PROSPECTIVE|||||||
33748541|NCT05815524|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33856490|NCT02184650|||COHORT||PROSPECTIVE|||||||
33856491|NCT02071667|||CASE_ONLY||PROSPECTIVE|||||||
33856492|NCT01487031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33856493|NCT00459160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856494|NCT05798533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856495|NCT02552641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856496|NCT00824811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856497|NCT01770457|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856498|NCT01958970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958904|NCT06393673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958905|NCT04066192|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Participants will be blind to medication assignment, as will all care providers and investigators.|Double-blind placebo controlled clinical trial.|t|t|t|t
33748542|NCT05328401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748543|NCT04939129|||COHORT||PROSPECTIVE|||||||
33856499|NCT05019378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856500|NCT00359151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856501|NCT05000502|RANDOMIZED|PARALLEL||OTHER||SINGLE|Staff doing assessments will be masked to study group allocation|40 breast cancer survivors will be randomized (like flipping a coin) to one of two study conditions: 1) home-based aerobic exercise training (with aerobic exercise progression targeting improved cardiorespiratory fitness) or 2) standard attention control (stretching exercises). All participants will be asked to maintain their usual diet and avoid change in body weight during the study.|f|f|f|t
33856502|NCT04910854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856503|NCT00724308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33856504|NCT01383772|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33856505|NCT02154009|||CASE_ONLY||PROSPECTIVE|||||||
33856506|NCT06135077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856507|NCT00315432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856508|NCT02982733|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856509|NCT03082222|||COHORT||PROSPECTIVE|||||||
33856510|NCT06473545|||COHORT||RETROSPECTIVE|||||||
33856511|NCT01522313|||COHORT||RETROSPECTIVE|||||||
33856512|NCT04536987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Staff performing clinical evaluations was unaware of the study design.|Random assignment to two study groups|f|f|f|t
33856513|NCT00454441|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33856514|NCT05525611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, placebo-controlled parallel study with a 12 weeks duration.|t|f|t|t
33856515|NCT02169453|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33856516|NCT04259073|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33856517|NCT04775589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856518|NCT05679856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856519|NCT05185557|||OTHER||PROSPECTIVE|||||||
33856520|NCT00706433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856521|NCT00622453|||OTHER||OTHER|||||||
33856522|NCT00701077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856523|NCT06202235|||COHORT||PROSPECTIVE|||||||
33856524|NCT00261768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856525|NCT00718354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856526|NCT00988871|||CASE_ONLY||PROSPECTIVE|||||||
33856527|NCT02405026|||COHORT||PROSPECTIVE|||||||
33856528|NCT00199940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856529|NCT00597298|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33856530|NCT04923152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Group A, group B|double blind randomized|t|t|t|t
34062735|NCT05615636|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748544|NCT05994235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748545|NCT06669949|||OTHER||PROSPECTIVE|||||||
33856531|NCT00037128|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33856532|NCT02422056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33856533|NCT05690100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33856534|NCT02839642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856535|NCT05201014|||CASE_ONLY||OTHER|||||||
33856536|NCT04502628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856537|NCT02086266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856538|NCT01074619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856539|NCT02660307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856540|NCT01832441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856541|NCT03005860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33856542|NCT03690648|||CASE_CONTROL||PROSPECTIVE|||||||
33856543|NCT03740997|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856544|NCT00710281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856545|NCT01266733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856546|NCT05634980|||CASE_ONLY||PROSPECTIVE|||||||
33856547|NCT02502097|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33856548|NCT01386060|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33856549|NCT02853253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856550|NCT00370409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34062736|NCT01449513|RANDOMIZED|PARALLEL||||NONE||||||
34062737|NCT00090584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748546|NCT03228511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856551|NCT00760903|||CASE_CONTROL|||||||||
33856552|NCT00388557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958906|NCT06238128|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33958907|NCT06236074|NA|SINGLE_GROUP||OTHER||NONE||||||
33958908|NCT03469362|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33958909|NCT01793285|||COHORT||RETROSPECTIVE|||||||
33958910|NCT03424382|||COHORT||PROSPECTIVE|||||||
34168430|NCT05715164|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The baseline survey will help to evaluate the smoking status, smoking behavior, socio-demographic characteristics, health status, etc. The three-arm study design would randomize 600 participants into three groups. Of the 600 participants, 200 each will receive e-cigarettes, nicotine pouches, and basic care counseling respectively. Four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches or e-cigarettes. All participants will complete a follow-up survey at 60 weeks. The provision of e-cigarettes and nicotine pouches will be stopped after the first 48 weeks. The remaining 12 weeks will be without the provision of any intervention and the participants must buy these items on their own.||||
34168431|NCT06361563|||COHORT||RETROSPECTIVE|||||||
34168432|NCT03494270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168433|NCT01274481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168434|NCT05035758|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||In this study, we will separate the patients into three groups; the control group (A) receives the standard exercise therapy that is part of the rehabilitation at the center. The intervention group B additionally to this standard therapy receives transcendental meditation sessions. Intervention group C also receives the standard rehabilitation exercise training and in addition yoga sessions.|f|f|f|t
34168435|NCT05164081|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Register-based cluster-randomized cross-over controlled trial||||
34168436|NCT05580822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168437|NCT01288755|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168438|NCT05345353|||COHORT||RETROSPECTIVE|||||||
34168439|NCT01212562|||CASE_ONLY||PROSPECTIVE|||||||
34168440|NCT00001118||||TREATMENT||||||||
34168441|NCT02374749|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168442|NCT05272371|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment group compared to historical group.||||
34168443|NCT02719171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168444|NCT05751746|||CASE_CONTROL||PROSPECTIVE|||||||
34168445|NCT05448495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34168446|NCT03866655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168447|NCT00893035|||COHORT||PROSPECTIVE|||||||
34168448|NCT02736058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168449|NCT05940194|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34168450|NCT00276263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168451|NCT03515759|||COHORT||CROSS_SECTIONAL|||||||
34168452|NCT00114816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168453|NCT03827135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168454|NCT01949935|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168455|NCT02461381|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34168456|NCT01707836|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34168457|NCT04562181|NA|SINGLE_GROUP||OTHER||NONE||||||
34168458|NCT04325971|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|anonymisation of all data|||||
34168459|NCT04585282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blind method of this study is evaluator blindness, that is, the evaluator does not know the grouping of subjects.|In this study, patients were randomly assigned to study group and control group by random number table.|f|f|t|f
34168460|NCT00744926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168461|NCT01843036|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34168462|NCT01244841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168463|NCT00523757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168464|NCT01983228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intervention participants will receive a pedometer-mediated walking intervention that will incorporate Action Planning and the use of MI and CBT techniques. The intervention will be delivered in 6 telephone counseling sessions over three months.|f|f|t|t
34168465|NCT00292942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168466|NCT00002009||||TREATMENT||||||||
34168467|NCT02669342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients are not told which catheter is inserted at which time point until after they exit the study.||t|f|f|f
33748547|NCT02999165|||CASE_CONTROL||PROSPECTIVE|||||||
33748548|NCT02125175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748549|NCT04083248|NA|SINGLE_GROUP||OTHER||NONE||||||
33748550|NCT05949762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856553|NCT04012229|||COHORT||RETROSPECTIVE|||||||
33856554|NCT05869630|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Cohort Study||||
33856555|NCT05997498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"A statistician prepared a computer-generated random tableand placed the group allocation in serially numbered closed opaque envelopes in a 1:1 ratio. Packing, sealing and numbering will be performed by two independent doctors other than the investigator.~Patients are allocated to either study group (cervical dilatation) or control group (no cervical dilatation). Allocation will be never changed after opening the envelopes. All patients are blinded to the allocation to avoid bias.~Neither the investigator nor the outcome assessor following up the patient postoperatively are aware whether the patient had undergone cervical dilation during the cesarean section or not (double-blinding). Randomization coding tables will be hidden from the investigator till the end of the study."||t|f|t|f
33856556|NCT00478868|||||CROSS_SECTIONAL|||||||
33748551|NCT04827511|||CASE_CONTROL||PROSPECTIVE|||||||
33748552|NCT00679939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856557|NCT01259843|||COHORT||PROSPECTIVE|||||||
33856558|NCT02004548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856559|NCT04248985|||COHORT||PROSPECTIVE|||||||
33748553|NCT01158131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33748554|NCT04195009|||OTHER||PROSPECTIVE|||||||
33958911|NCT03772548|||CASE_CONTROL||PROSPECTIVE|||||||
33958912|NCT05769192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958913|NCT03260491|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33958914|NCT02912884|||COHORT||PROSPECTIVE|||||||
33958915|NCT04711824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958916|NCT06420427|||COHORT||PROSPECTIVE|||||||
33958917|NCT03608072|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33958918|NCT06566755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958919|NCT04335565|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single (participant)||t|f|f|f
33958920|NCT00850837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958921|NCT06567132|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person performing the biochemical analysis did not know the owner of the samples.|Participants included in the study were divided into four groups according to whether they had polycystic ovary syndrome and gingivitis.|f|f|f|t
33958922|NCT01138852|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33958923|NCT00003166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958924|NCT01361698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958925|NCT06254859|||COHORT||PROSPECTIVE|||||||
33958926|NCT05179655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the intervention, a blinding of participants and therapists is not possible. Blinded outcome assessment will be performed by a trained researcher. Statistical analyses will be performed by two blinded statisticians presenting independent reports and with the intervention groups coded as A and B.|An investigator-initiated, multi-site randomised, parallel group, clinical superiority trial with blinded outcome assessment investigating the internet-based intervention ERITA as add-on to TAU compared to TAU alone in NSSI engaging psychiatric, outpatient youth. Participants will be randomised at the allocation ratio 1:1. Randomisation will be handled centrally at the Copenhagen Trial Unit (CTU) using a computer-generated allocation sequence with a varying block size concealed from the investigators. The allocation sequence will be stratified NSSI at baseline 1-10 versus 11≤ episodes in the past month, and trial site. CTU will generate the allocation sequence and investigators at the clinical trial sites will assign participants to the intervention groups using an OpenClinica web-based system developed by the CTU|f|f|t|t
33958927|NCT02599610|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33958928|NCT06414265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958929|NCT05242146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958930|NCT06404931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33958931|NCT04456764|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33958932|NCT06433765|||COHORT||PROSPECTIVE|||||||
33958933|NCT00858611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33958934|NCT04711850|||COHORT||PROSPECTIVE|||||||
33958935|NCT02552420|||COHORT|||||||||
33958936|NCT06702943|||COHORT||PROSPECTIVE|||||||
33958937|NCT06703268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958938|NCT00197366|||||RETROSPECTIVE|||||||
33958939|NCT05116761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
33958940|NCT01278446|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33958941|NCT01534429|||COHORT||PROSPECTIVE|||||||
33958942|NCT02091388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958943|NCT06702657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33958944|NCT03237481|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33958945|NCT06666517|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33958946|NCT06700707|||OTHER||PROSPECTIVE|||||||
33748555|NCT02754648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748556|NCT03947918|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Three-week study includes:~Week 1 - all children get usual sleep Tuesday-Friday.~Week 2 - children are randomized to getting no more than 8 hours or at least 10 hours of sleep (Tuesday-Friday).~Week 3 - children crossover to the opposite sleep condition (Tuesday-Friday)."||||
33958947|NCT05961319|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33958948|NCT06701370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958949|NCT00739206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33958950|NCT05330611|RANDOMIZED|PARALLEL||TREATMENT||NONE||"We are proposing a prospective, randomized trial evaluating efficacy of ultrasound-guided cryoneurolysis for pain control after traumatic rib fractures in patients 18-64 years of age.~Eligible patients would be enrolled by the trauma service after consent is obtained."||||
33958951|NCT01516684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34062738|NCT02972749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34062739|NCT06276452|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34062740|NCT04129528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062741|NCT03759145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062742|NCT00213577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062743|NCT05477628|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|To reduce the risk of bias, all research assistants who collect baseline and outcome data will be blinded. All other study personnel, including data analysts, will also be blinded to group allocation. Due to the nature of the intervention, children and parents cannot be blinded, but they will be blinded to trial hypotheses. Healthcare providers who provide the interventions also cannot be blinded.|This will be a pragmatic, randomized, longitudinal factorial Trials within Cohorts (TwiCs) clinical trial. This study will be a direct comparison of two HCP prescriptions provided randomly at the individual level: 1) Optimal breastfeeding with mobile lactation consultant support vs. usual care and 2) High-quality childcare starting at 1 year of age vs. usual care. We will combine TwiCs methods with a longitudinal factorial design to enhance the integration of cohort study and factorial trial designs.|f|f|f|t
34062744|NCT05497232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062745|NCT03379792|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062746|NCT06621576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062747|NCT04659135|||CASE_ONLY||PROSPECTIVE|||||||
34062748|NCT01733459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062749|NCT03918278|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062750|NCT01261845|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34168468|NCT01574586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958952|NCT06336538|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Investigator will first conduct focus groups with older (≥65 years old) African American/Black (AA/B) breast cancer survivors (BCS) with elevated depressive symptoms. They will collect participant perspectives on barriers and facilitators to participation in MBI clinical trials, as well as how to adapt this intervention, called Mindfulness-Based Cognitive Therapy-Brief (MBCT-Brief), to increase cultural relevancy for older AA/B BCS with elevated depressive symptoms. They will then conduct a single arm clinical trial that incorporates the results of the qualitative data analysis to establish feasibility and acceptability of MBCT-Brief.||||
33958953|NCT01874015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33958954|NCT04498806|NA|SINGLE_GROUP||OTHER||NONE||||||
34168469|NCT04499495|||COHORT||RETROSPECTIVE|||||||
33958955|NCT02235415|||COHORT||PROSPECTIVE|||||||
33958956|NCT01556464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958957|NCT03173807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pilot study that will employ a randomized, 2-arm wait-control design||||
33958958|NCT01679418|RANDOMIZED|PARALLEL||||NONE||||||
33958959|NCT03682731|||COHORT||PROSPECTIVE|||||||
33958960|NCT06568263|||OTHER||OTHER|||||||
33958961|NCT00788008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958962|NCT05443503|NA|SINGLE_GROUP||OTHER||NONE||||||
33958963|NCT04327609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958964|NCT00830271|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33958965|NCT04897334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33958966|NCT06145880|||COHORT||RETROSPECTIVE|||||||
33958967|NCT01217567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33748557|NCT01381692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748558|NCT05626400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748559|NCT06651515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748560|NCT05991752|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33748561|NCT00791024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33748562|NCT02564523|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33748563|NCT03886103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748564|NCT06213766|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748565|NCT06449833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958968|NCT03259763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomly allocated with a 1:1 ratio to one of the study arms (EUS-GE or ES)|t|f|f|f
33958969|NCT01783860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33958970|NCT03428217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care providers, investigators and outcomes assessors are blinded to treatment. Progression free survival (PFS) will be assessed by a blinded Independent Radiology Committee for the primary endpoint of the study.|This is a double blinded placebo-controlled study where patients will be randomized 1:1 to either CB-839 (telaglenastat) plus cabozantinib or placebo plus cabozantinib|t|t|t|t
33958971|NCT01721824|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33958972|NCT06696729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33958973|NCT04322383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958974|NCT02184169|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33958975|NCT01518985|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33958976|NCT01810393|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168470|NCT02334930|||COHORT||PROSPECTIVE|||||||
34168471|NCT03188146|||COHORT||PROSPECTIVE|||||||
34168472|NCT01203735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168473|NCT06172686|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two antimalarial drugs will be used to induce gametocytes. The first arm will receive Piperaquine tablets (Piramal Pharma Solutions, India), that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg). The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.||||
34168474|NCT02383381|||CASE_CONTROL||PROSPECTIVE|||||||
34168475|NCT02832934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168476|NCT00269308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168477|NCT02394314|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34168478|NCT05355103|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34168479|NCT02036047|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34168480|NCT03264859|||COHORT||PROSPECTIVE|||||||
34168481|NCT04864639|NA|SINGLE_GROUP||OTHER||NONE||||||
34168482|NCT04539600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168483|NCT03901131|||COHORT||PROSPECTIVE|||||||
34168484|NCT01655758|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34168485|NCT06264726|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168486|NCT02884388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168487|NCT01780116|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34168488|NCT04972786|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Magventure rTMS device enables double blinding. Participant group assignment will be blind to the participant, investigator, and outcomes assessor until all subject data has been collected, at which point the group assignment will be unblinded.|Sham versus active rTMS to dACC|t|f|t|t
34168489|NCT05546151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168490|NCT01001975|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34168491|NCT04816474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34168492|NCT04247230|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Von Frey hair (monofilaments) was used to assess the changes in touch sensitivity on the glans penis after the application of IMP.||||
34168493|NCT03098641|||COHORT||RETROSPECTIVE|||||||
34168494|NCT03416296|||OTHER||PROSPECTIVE|||||||
34168495|NCT02426333|||CASE_ONLY||PROSPECTIVE|||||||
34168496|NCT03584750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168497|NCT03379220|||COHORT||PROSPECTIVE|||||||
34168498|NCT04930523|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group will be treated by decompression session while experimental group will be treated with ELDOA along with decompression.||||
34168499|NCT03671941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168500|NCT06217107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34168501|NCT01332123|NA|SINGLE_GROUP||||NONE||||||
34168502|NCT00549692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168503|NCT03546621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Open-label, Randomized||||
34168504|NCT04360746|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748566|NCT02172508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748567|NCT06670859|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33748568|NCT03568318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748569|NCT01848080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748570|NCT03850769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748571|NCT03877042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748572|NCT01002326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748573|NCT01864564|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34168505|NCT04228263|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168506|NCT04903782|||COHORT||PROSPECTIVE|||||||
34168507|NCT00024336||||TREATMENT||||||||
34168508|NCT05103826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168509|NCT03007966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168510|NCT03145740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The patient´s primary physician in the clinic, the primary occupational therapist, physiotherapist and the nurses were kept blinded for the whole period of the intervention.~The patient´s relatives did know into what group the patient was randomized. The patient himself did not know. The occupational therapists associated to the project were not blinded.~The otolaryngologist, who scored the video recorded FEES examinations was blinded. The colleagues from Germany, who analyse data are blinded."||t|t|f|t
34168511|NCT00286442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168512|NCT03529058|||COHORT||RETROSPECTIVE|||||||
34168513|NCT04148534|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34168514|NCT02072863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168515|NCT04872361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind (Participant, Outcomes Assessor).||t|f|f|t
34168516|NCT04984239|NA|SEQUENTIAL||TREATMENT||NONE||||||
34168517|NCT02255916|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34168518|NCT01138423|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168519|NCT02572544|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168520|NCT00139074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168521|NCT01753622|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168522|NCT06069258|||COHORT||CROSS_SECTIONAL|||||||
34168523|NCT03530826|||OTHER||PROSPECTIVE|||||||
34168524|NCT02433886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168525|NCT03705052|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34168526|NCT06512350|||CASE_CONTROL||PROSPECTIVE|||||||
34168527|NCT02729220|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34168528|NCT05488639|||COHORT||PROSPECTIVE|||||||
34168529|NCT03038321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168530|NCT01484210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168531|NCT01724866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168532|NCT05869435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168533|NCT04267510|||COHORT||OTHER|||||||
34168534|NCT04852861|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|The research nurse administrating the vaccine is the only one who is not blinded.||t|t|t|t
34168535|NCT01668303|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34168536|NCT02727829|||OTHER||PROSPECTIVE|||||||
34168537|NCT00367939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168538|NCT02972203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168539|NCT00803283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168540|NCT00216671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168541|NCT05068635|||CASE_ONLY||RETROSPECTIVE|||||||
34168542|NCT02840682|||OTHER||RETROSPECTIVE|||||||
34168543|NCT05237648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168544|NCT04072913|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34168545|NCT01536717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168546|NCT04472949|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multicenter, open-label, single-arm, phase II trial||||
34168547|NCT04314908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant and Outcomes Assessor) The patients and outcome assessor were unaware as to which study group they had been allocated.|Parallel Assignment The patients were assigned to 4 medication groups randomly with an equal allocation rate between groups.The patients in the groups had same characteristics.|t|f|f|t
34168548|NCT02223780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168549|NCT05195567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168550|NCT03480152|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34168551|NCT03531671|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Assessing age related cataract, all 200 subjects will have whole eye OCT scan performed during their pre-operative cataract assessment and 50 subjects (all subjects requested to participate until 50 subject criteria met) will have these assessments reassessed during their post-operative assessment.||||
34168552|NCT02372526|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34168553|NCT03735836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized study with two parallel treatment arms.||||
34168554|NCT01573546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168555|NCT05646134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168556|NCT03546946|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34168557|NCT02121379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168558|NCT00867230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168559|NCT02488941|||||PROSPECTIVE|||||||
34168560|NCT05528055|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34168561|NCT05281666|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking. Both participant and care providers will know group assignment|Participants will be randomly assigned to either absorbable versus non-absorbable sutures and compared||||
34168562|NCT05686785|||COHORT||CROSS_SECTIONAL|||||||
34168563|NCT06079385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168564|NCT00202514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34168565|NCT06077045|||COHORT||RETROSPECTIVE|||||||
34168566|NCT01406301|||COHORT||RETROSPECTIVE|||||||
34168567|NCT02889588|||OTHER||PROSPECTIVE|||||||
34168568|NCT02949609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168569|NCT05046223|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34168570|NCT00942565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168571|NCT02775188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168572|NCT03689582|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168573|NCT02723812|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168574|NCT05932277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168575|NCT01300728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168576|NCT05608746|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34168577|NCT02691039|||FAMILY_BASED||OTHER|||||||
34168578|NCT01849601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168579|NCT05754853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168580|NCT01778790||||TREATMENT||DOUBLE||Deep Brain Stimulation|t|f|f|t
34168581|NCT03841110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168582|NCT01311882|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34168583|NCT02106000|||COHORT||PROSPECTIVE|||||||
34168584|NCT05003479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34168585|NCT00925262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168586|NCT03795116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a single-blind study. Participants and clinicians involved in subjective efficacy assessments will be blind to the study intervention (LED-RL phototherapy versus mock therapy). The principal investigator, along with the research coordinator who administers the LED-RL phototherapy, will be aware of each participant's treatment assignment.||t|f|f|t
34168587|NCT02939365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168588|NCT04757207|||COHORT||CROSS_SECTIONAL|||||||
34168589|NCT04585724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168590|NCT05189548|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168591|NCT05850949|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Repeated single arm||||
34168592|NCT03210207|||CASE_ONLY||RETROSPECTIVE|||||||
34168593|NCT00004858||||TREATMENT||||||||
34168594|NCT02419365|||COHORT||PROSPECTIVE|||||||
34168595|NCT06039553|||COHORT||PROSPECTIVE|||||||
34168596|NCT05016466|||COHORT||PROSPECTIVE|||||||
34168597|NCT01421017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168598|NCT00737776|||COHORT||PROSPECTIVE|||||||
34168599|NCT01548274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168600|NCT06261177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|f|t|t
34168601|NCT02483806|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34168602|NCT04507243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Active and Sham controlled|t|f|f|t
33748574|NCT00933569|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33748575|NCT06241404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33748576|NCT06446804|||COHORT||PROSPECTIVE|||||||
33748577|NCT03356925|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33748578|NCT06296368|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34168603|NCT01046565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34168604|NCT06164574|||COHORT||RETROSPECTIVE|||||||
34168605|NCT06071949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168606|NCT03308916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single intervention group selected for screening with a historical control group||||
33748579|NCT05646953|NA|SINGLE_GROUP||OTHER||NONE|Open Label|Single Center, Open Label, Safety and Efficacy||||
33748580|NCT04144842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748581|NCT03053050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33748582|NCT06670222|NA|SINGLE_GROUP||TREATMENT||NONE||"Dose escalation cohort to determine the dose limiting toxicity according to a BOIN (Bayesian optimal interval) scheme. Three doses of oral Arsenic will be tested, and 9 patients will be treated at each dose.~An expansion cohort at the selected dose will be conducted with 6 patients, for a maximum of 15 patients included at this dose level."||||
33748583|NCT03414138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Subjects will be randomly assigned to two groups by the research coordinator. Investigators, study staff and MRI technicians will be blind as to the participant's group assignment.|Healthy research participants, trained to psychophysically rate their experience in response to a range of thermal stimuli, will be randomly assigned to one of two experimental groups (mindfulness meditation n=20 or deep-breathing meditation n=20). After receiving four twenty-minute meditation training sessions, participants will return for a final session of thermal testing while lying in the MRI scanner. Participants will be exposed to 4 blocks of testing, using thermal stimuli cycled between painful (49°C) and non-painful (35°C) temperatures for 6 minutes. Blood oxygen-level dependent imaging will be used to map the functional connectivity of brain regions in response to the thermal fluctuations. In the first two blocks participants will lie quietly with eyes closed. After a 10 minute rest, subjects will begin meditating and the thermal testing will resume.|t|f|t|t
33748584|NCT05942313|||COHORT||PROSPECTIVE|||||||
33748585|NCT01771198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748586|NCT05774964|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748587|NCT01880424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748588|NCT00325468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856560|NCT02170792|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748589|NCT01920230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748590|NCT06086730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748591|NCT06670729|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The dentist who provides dental care was blinded to the assignment||f|t|f|t
33856561|NCT02340767|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33856562|NCT01029652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856563|NCT00573885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856564|NCT05880550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856565|NCT03252171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856566|NCT05724823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062751|NCT04002778|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34062752|NCT00853515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062753|NCT06731413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062754|NCT01935245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062755|NCT03050541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34062756|NCT04400981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinicians assessing NIHSS at 24 hours, 48 hours and 72 hours and modified Rankin scale at 3 months will be blinded to treatment allocation.|Phase II, prospective, multicenter, block randomized, parallel, open-label, clinical trial|f|f|f|t
34062757|NCT06070753|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34062758|NCT00933114|||CASE_ONLY||PROSPECTIVE|||||||
34062759|NCT03108872|||CASE_CONTROL||PROSPECTIVE|||||||
34062760|NCT03152994|||COHORT||PROSPECTIVE|||||||
34062761|NCT04877158|NA|SINGLE_GROUP||TREATMENT||NONE||Self-concept measures (Attribution Biases, Self-Esteem) and psychological symptoms (Eating, depression, anxiety) will be assessed before and after completion of the group.||||
34062762|NCT02368210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062763|NCT06392386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062764|NCT06308588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062765|NCT05822206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization is known to the study investigator, study clinician, project coordinator, and participant. The outcomes assessor is privy to randomization information.|Participants are randomized into one of two conditions: treatment (Cognitive Behavioral Therapy for Trauma and Self-Care; CBT-TSC) or control. The CBT-TSC condition consists of 10 therapy sessions and 3 follow-up visits. The control condition consists of 2 therapy sessions and 3 follow-up visits. The first two therapy sessions, which are received by all participants regardless of condition, employ LifeSteps and sexual decision making techniques. The remaining eight therapy sessions, which only those in the CBT-TSC condition receive, address thoughts and behaviors associated with trauma distress and poor engagement in HIV care.|f|f|f|t
34062766|NCT06719232|||COHORT||PROSPECTIVE|||||||
34062767|NCT03722407|NA|SEQUENTIAL||TREATMENT||NONE||||||
34062768|NCT05203991|||CASE_ONLY||PROSPECTIVE|||||||
34062769|NCT03538067|||OTHER||PROSPECTIVE|||||||
34062770|NCT06651476|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34062771|NCT03592498|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical study Phase II, pilot, open, monocentric and randomized.||||
34062772|NCT02397434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062773|NCT06021184|||COHORT||OTHER|||||||
34062774|NCT05886998|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34062775|NCT00463294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062776|NCT03947931|||OTHER||PROSPECTIVE|||||||
34062777|NCT04673435|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes assessors (healing time and scar assessments) are blinded.|Randomized matched design with application of both study dressings symmetrical or adjacent body sites at the same time.|f|f|f|t
34062778|NCT02954822|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34076764|NCT02336867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34076765|NCT06111768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076766|NCT03163407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34076767|NCT04607902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized to the Behavioral Activation SSI (BA-SSI), Growth Mindset SSI (GM-SSI), or the Supportive Therapy SSI (ST-SSI; each 30 minutes in length).|Participants will be randomized (via a random number generator in Qualtrics, double-masking the randomization procedure) to one of the conditions.|t|f|t|t
33748592|NCT02955511|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|||t|f|f|t
34168607|NCT02625792|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33748593|NCT02904304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062779|NCT03535532|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since one of the intervention is invasive surgical operation, the other is conservative medical treatment, the difference between these two intervention is too obvious to mask, no masking are designed in this study.|resistant hypertensive patients diagnosed with adrenal diseases based on imaging tools will be randomly allocated into unilateral laparoscopic adrenalectomy group and standard medical treatment group.||||
33748594|NCT03943732|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Open Randomized study, consecutive 2 weeks-period for observation group and study group||||
33748595|NCT00373334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748596|NCT05883813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant does not know about the group in which he is included.|This study is randomized controlled trial which consist of 2 groups. One group will be given suboccipital muscle release. Second group will be given SNAGS along with sub-occipital muscle release. All the groups were recruited concurrently.|t|f|f|f
33748597|NCT01387412|||COHORT||PROSPECTIVE|||||||
33748598|NCT06610617|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Those who receive tDCS on Visit 1 will receive sham stimulation on Visit 2, and those who receive sham on Visit 21and will receive tDCS stimulation on Visit 2. The order of tDCS and sham stimulation is randomized so half of the participants will receive active tDCS first and half will receive tDCS sham. The study member will also be blinded to delivering active or sham tDCS to the participant.|The interventional study model is a randomized, double-blinded, crossover trial in older taxane treated breast cancer survivors comparing effects of balance between active and sham treatments of a single exposure of transcranial direct current stimulation to the left dorsolateral prefrontal cortex.|t|t|t|f
33748599|NCT02081846|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33748600|NCT03959865|||COHORT||RETROSPECTIVE|||||||
33748601|NCT04294368|RANDOMIZED|PARALLEL||PREVENTION||NONE||Control group to receive standard fortification of donor breast milk. Experimental group to receive targeted fortification of donor breast milk.||||
33748602|NCT04641143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748603|NCT05854511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748604|NCT04445610|||CASE_ONLY||PROSPECTIVE|||||||
33748605|NCT02741960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748606|NCT03898206|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33748607|NCT06459609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33748608|NCT02428868|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33748609|NCT06125392|||COHORT||OTHER|||||||
33748610|NCT06100627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748611|NCT04460742|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33748612|NCT02283060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748613|NCT05224791|||COHORT||RETROSPECTIVE|||||||
33748614|NCT01744028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748615|NCT05855044|NA|SINGLE_GROUP||OTHER||NONE||||||
33748616|NCT05463328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748617|NCT02854774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748618|NCT00466518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748619|NCT01759589|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33856567|NCT01708993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856568|NCT02425930|||COHORT||PROSPECTIVE|||||||
33856569|NCT06327750|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross-over trial||||
33856570|NCT00256451|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33856571|NCT04656925|NA|SINGLE_GROUP||TREATMENT||NONE||A-B-A, or a return to baseline design.||||
34076768|NCT06143046|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind study||t|t|t|t
34076769|NCT04893551|NA|SEQUENTIAL||TREATMENT||NONE||||||
34076770|NCT02047279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076771|NCT06435767|||COHORT||RETROSPECTIVE|||||||
34076772|NCT01441973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076773|NCT03836157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076774|NCT04187833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076775|NCT06336317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076776|NCT00459810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076777|NCT04797988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076778|NCT04007328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34076779|NCT05354518|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34076780|NCT01448252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076781|NCT03808233|||COHORT||PROSPECTIVE|||||||
34076782|NCT01898169|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34076783|NCT03063736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076784|NCT00121706|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34076785|NCT04821661|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076786|NCT00817622|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34076787|NCT03086629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076788|NCT01776970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34076789|NCT04221919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34076790|NCT01726296|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34076791|NCT04001088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34076792|NCT05928039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This trial is a prospective, randomized, open-label, blinded-endpoint (PROBE) trial. The primary endpoint will be evaluated by a blinded, external central reviewer.|f|f|f|t
34076793|NCT04609657|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Same packaging for all (cans). Color and flavor matched.||t|t|t|t
34076794|NCT06612567|||OTHER||CROSS_SECTIONAL|||||||
34076795|NCT05962112|||COHORT||PROSPECTIVE|||||||
34076796|NCT00166868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076797|NCT04263246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34076798|NCT03193632|||COHORT||PROSPECTIVE|||||||
33856572|NCT03616041|||COHORT||PROSPECTIVE|||||||
33856573|NCT05755360|||COHORT||PROSPECTIVE|||||||
34168608|NCT01349517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856574|NCT06450678|||OTHER||PROSPECTIVE|||||||
33856575|NCT04740554|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856576|NCT00862355|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33856577|NCT06110325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor-blind randomized control trial. A masked assessor conducted the measurements.|A one-month assessor-blind randomized controlled trial will be conducted involving 30 seniors with balance deficits. Participants will be divided equally into two groups (intervention and control), each comprising 15 individuals. The intervention group will receive a Cawthorne and Cooksey-based exercise program, while the control group will receive counseling on fall prevention and guidance for maintaining an active and healthy lifestyle through informational leaflets.|f|f|f|t
33958977|NCT03860987|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33958978|NCT05685199|||CASE_CONTROL||PROSPECTIVE|||||||
33958979|NCT02449967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958980|NCT03549845|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Pragmatic cluster randomized controlled trial with parallel intervention and control groups.~Randomization will occur at the building level (clusters) and the intervention is open to all building residents."||||
33958981|NCT01093365|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33958982|NCT05543863|||COHORT||PROSPECTIVE|||||||
33958983|NCT05443009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will not know to which group the child belongs (anesthetic to be used), nor will he or she see the label of the anesthetic. He or she will be in the room during the initial anesthetic infiltration. All children will be considered participants in the control group, to conceal the anesthetic to be used. The evaluator will be asked to leave the room for as long as necessary to prevent learning whether or not the child receives an additional anesthetic.|A blind, controlled, randomized, non-inferiority clinical trial with two parallel groups with allocation ratio will be 1:1|f|f|f|t
33958984|NCT06233058|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33958985|NCT05346237|||COHORT||PROSPECTIVE|||||||
33958986|NCT04595565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958987|NCT05469815|NA|SINGLE_GROUP||OTHER||NONE||||||
33958988|NCT04977388|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blind Placebo-controlled Randomized Crossover Clinical Trial|t|f|t|f
33958989|NCT03022929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958990|NCT00068653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958991|NCT04129515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958992|NCT04406129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33958993|NCT05964361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958994|NCT05225428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33958995|NCT02969473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33958996|NCT04512391|||COHORT||RETROSPECTIVE|||||||
33958997|NCT00872573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33958998|NCT05674721|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33958999|NCT03187288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168609|NCT01169129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168610|NCT04804683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study is interventional because it requires blood/urine sampling.||||
34168611|NCT01247324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168612|NCT03243617|RANDOMIZED|PARALLEL||OTHER||DOUBLE|AO+ Mist (or placebo) are supplied in white 100mL metered spray bottles. Test products are blinded and labeled for application to the LEFT or RIGHT side of the body.|Bi-Lateral study|t|t|f|f
34168613|NCT00651781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168614|NCT01121796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34168615|NCT06202222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748620|NCT04288908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Only participants will be masked to the assigned condition. The researcher has to be aware of the assigned condition to prepare the experimental task accordingly.|The two conditions, based on the experimental task called Cyberball, will be: social inclusion and social exclusion.|t|f|f|f
33959000|NCT04656782|||OTHER||PROSPECTIVE|||||||
33959001|NCT05040035|||COHORT||PROSPECTIVE|||||||
33959002|NCT04177745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168616|NCT01712126|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168617|NCT01480960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168618|NCT02741622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168619|NCT02967146|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33748621|NCT06395064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748622|NCT06578923|||CASE_CONTROL||OTHER|||||||
33856578|NCT03203720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors blind to treatment group of participants.|Randomized trial comparing Brief Motivational Intervention + Standard Care versus Standard Care Alone|f|f|f|t
33856579|NCT00711893|||COHORT||PROSPECTIVE|||||||
33856580|NCT01041352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856581|NCT03929315|||COHORT||PROSPECTIVE|||||||
33856582|NCT06023082|NA|SINGLE_GROUP||OTHER||NONE|Participants will be blinded to the brand and name of the supplement they are taking.|||||
33856583|NCT01683487|||CASE_ONLY||RETROSPECTIVE|||||||
33856584|NCT03417336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856585|NCT00547131||||TREATMENT||||||||
33959003|NCT01247207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168620|NCT00086866|RANDOMIZED|||TREATMENT||NONE||||||
34168621|NCT00333021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168622|NCT06034288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168623|NCT00403871|||DEFINED_POPULATION||OTHER|||||||
34168624|NCT05404152|||OTHER||CROSS_SECTIONAL|||||||
34168625|NCT03890068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168626|NCT04400188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Fluzoparib (SHR-3162) combined with temozolomide or Fluzoparib (SHR-3162) and temozolomide with SHR-1316||||
34168627|NCT02994563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168628|NCT03245125|||COHORT||PROSPECTIVE|||||||
34168629|NCT00271375|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34168630|NCT01057849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168631|NCT03490825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The study is designed as a randomized controlled trial where each participant will receive one of four intervention types. Subjects will be randomized at baseline visit to one of four arms using a randomized block design to achieve balanced groups. Randomization will be stratified by sex. The allocation will be created using an online randomization tool. This study will include a 6 week four arm field intervention to evaluate the independent effect of meal timing or melatonin as well as their combined effects|t|t|t|t
34168632|NCT01889875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34168633|NCT05625984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168634|NCT03201588|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized intervention study of 105+105 (number based on power analysis regarding up to date ROP frequency, see 5.1 and 11.1) infants without major malformations born with a gestational age less than 28 weeks + 0 days will be performed.||||
34168635|NCT00809016|NON_RANDOMIZED|||DIAGNOSTIC||NONE||||||
34168636|NCT03422029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168637|NCT05181358|||COHORT||PROSPECTIVE|||||||
34168638|NCT06189326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168639|NCT04392726|||COHORT||CROSS_SECTIONAL|||||||
34168640|NCT05298202|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each Subject acts as their own control in a repeated measures design||||
34168641|NCT05131425|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A blinded clinical evaluator will assess outcome|The main objective of the current proposal is to conduct an RCT (i.e., treatment group and treatment-as-usual (TAU) control group) to examine the impact of a cognitive behavioral treatment for anxiety in an adolescent sample of Autistic youth with intellectual disability. This clinical trial incorporates random assignment, a control group, and a treatment group. All participants in the TAU control group can crossover and complete the intervention.|f|f|f|t
34168642|NCT00466063|||COHORT||PROSPECTIVE|||||||
34168643|NCT05199051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168644|NCT06136780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168645|NCT03304561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168646|NCT04912778|||CASE_ONLY||CROSS_SECTIONAL|||||||
34168647|NCT06275555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168648|NCT06374953|||OTHER||PROSPECTIVE|||||||
33748623|NCT01808690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748624|NCT00727272|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33748625|NCT02015117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748626|NCT01736228|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748627|NCT04700293|NA|SINGLE_GROUP||OTHER||NONE||||||
33748628|NCT03760237|||COHORT||PROSPECTIVE|||||||
33748629|NCT06320860|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33748630|NCT03925376|||COHORT||PROSPECTIVE|||||||
33748631|NCT06581549|||OTHER||OTHER|||||||
33748632|NCT04695223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748633|NCT00526123|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856586|NCT02414737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856587|NCT01211522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, placebo controlled||t|t|t|t
33856588|NCT04065178|||COHORT||PROSPECTIVE|||||||
33856589|NCT00234520|||||PROSPECTIVE|||||||
33856590|NCT02024763|RANDOMIZED|PARALLEL||||NONE||||||
33856591|NCT02852473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33856592|NCT01173198|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33856593|NCT05854550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856594|NCT04355910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is represented in code||f|f|f|t
33856595|NCT05477459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study drug or placebo will be provided in 1-ml ampoules and are similar in appearance, taste and smell||t|f|t|t
33856596|NCT00200460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856597|NCT03015818|NA|SINGLE_GROUP||OTHER||NONE||||||
33856598|NCT00313001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856599|NCT06062732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Baseline and post-treatment assessment will be conducted by researchers who are blind to treatment allocation. Young people, teachers and families are not blind to treatment allocation.|Randomised controlled trial|f|f|t|t
33856600|NCT02686060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856601|NCT05225350|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible children where randomized to 1 of 2 interventional arms.||||
33856602|NCT02946970|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33856603|NCT01810120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856604|NCT01932554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856605|NCT04654065|NA|SINGLE_GROUP||OTHER||NONE||||||
33856606|NCT04637880|||COHORT||PROSPECTIVE|||||||
33856607|NCT01115790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856608|NCT02411500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856609|NCT04705636|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33856610|NCT01690611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856611|NCT02916680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856612|NCT03448133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33856613|NCT00125281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33856614|NCT03610165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Single-center randomized comparison of invasive arterial pressure monitoring vs. arterial pressure monitoring combined with Acumen Hypotension Prediction Index (HPI) software guidance on intraoperative hypotension duration and severity.|t|f|t|f
33856615|NCT02539537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856616|NCT04191044|||OTHER||PROSPECTIVE|||||||
33856617|NCT05478551|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The injector, assessor, patient, and outcome assessor will be blinded to the treatment side and placebo side of injection.|We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control.|t|t|t|f
33856618|NCT02736604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33856619|NCT02791373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856620|NCT03885830|||COHORT||PROSPECTIVE|||||||
33959004|NCT05504408|||COHORT||PROSPECTIVE|||||||
33959005|NCT02379338|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959006|NCT04486807|||COHORT||PROSPECTIVE|||||||
33959007|NCT06083883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959008|NCT05338437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959009|NCT00006096|RANDOMIZED|||TREATMENT||||||||
33959010|NCT03851107|NA|SINGLE_GROUP||TREATMENT||NONE||An 18-week individual-based interrupted time series design with multiple baselines across 8 participants will be employed.||||
33959011|NCT06107127|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959012|NCT01531062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959013|NCT05408910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a parallel-designed multicenter randomized controlled trial of rifaximin versus placebo done in 100 patients with CF age 12 and up and over 30 kg of weight recruited based on bloating and distension symptoms.|t|t|t|f
33959014|NCT05600868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959015|NCT01226615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959016|NCT06574217|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959017|NCT04303117|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959018|NCT03667586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study design will be randomized prospective with a control group. More specifically, all patients will be randomly assigned either to the psychotherapy or the control group. Randomization will be 1:1 and will be performed through the method of sealed envelopes. A group of participants will receive weekly group cognitive behavioral therapy sessions, while another group will receive care as usual with regular weekly brief follow-ups by the gastroenterologists and the nurse of the research team. In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months. All patients will be re-evaluated at 6 months (treatment completion), 12 months and 18 months after study initiation.|f|f|f|t
33959019|NCT06414954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959020|NCT04824040|||COHORT||PROSPECTIVE|||||||
33959021|NCT05523310|||COHORT||PROSPECTIVE|||||||
33959022|NCT02094573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959023|NCT03514121|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm trial with multiple cohorts||||
34062780|NCT05575336|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A quasi-experimental trial following a multicentre, non-randomized, non-concurrent, unblinded and controlled design. Patients belonging to the intervention group will be under the ADLIFE intervention, while patients on the control group will follow the standard of care (SoC). The mixed-method approach will provide scientific evidence based on the effectiveness, socio-economic, implementation and technology acceptance assessment of ADLIFE intervention compared to the SoC when applied in real-life settings. The quantitative outcomes will be analysed not only at the individual level but also at the health organisation level.||||
34062781|NCT04946019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062782|NCT04016246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062783|NCT02774005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062784|NCT01120132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062785|NCT03148717|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062786|NCT04320953|NA|SINGLE_GROUP||OTHER||NONE||||||
34062787|NCT06505278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062788|NCT05096572|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34062789|NCT06314451|||OTHER||CROSS_SECTIONAL|||||||
34062790|NCT04311281|||CASE_CONTROL||PROSPECTIVE|||||||
34062791|NCT02664922|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34062792|NCT05040100|RANDOMIZED|PARALLEL||OTHER||SINGLE|A blinded grader scored all tests.||f|f|f|t
34062793|NCT02064465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062794|NCT02433145|||CASE_CONTROL||PROSPECTIVE|||||||
34062795|NCT05201066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34062796|NCT05075044|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects infected with HIV receive three doses inactivated COVID-19 vaccine||||
34062797|NCT04636294|||CASE_CONTROL||RETROSPECTIVE|||||||
34062798|NCT03093051|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Patients undergoing a routine clinically indicated procedure will have the investigational therapy delivered during the clinically indicated procedure.||||
34062799|NCT01037816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062800|NCT04777656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062801|NCT00348036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062802|NCT02772276|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34062803|NCT06055023|NON_RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34062804|NCT01500044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34062805|NCT03742856|||CASE_CONTROL||PROSPECTIVE|||||||
34062806|NCT00154401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062807|NCT04280458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34062808|NCT03858283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34168649|NCT06179576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Families will be randomly assigned to the treatment or control condition upon enrollment in the study. Because it is an intervention, administered by facilitators, the facilitators and parents will be aware of the treatment families status. The investigators will know which families are receiving the treatment or not because they will need to manage the progress of the intervention and the progress of data collection. Those blind to treatment status will be the data collectors, who will administer all parent surveys and objective measures, including the videotaped parent-child interactions. The coders of the videotaped parent-child interactions will also be blind to treatment status.|Dyads in the EHS-CTB hybrid condition will receive 6 individual sessions of CTB conducted by trained facilitators. The first session would be at the center, the 2nd through 5th would be remote, and 6th would be at the EHS center as a group session with other families. Sessions will occur approximately one to two weeks apart, allowing for program completion within 10 weeks. During the first in-person session, families will receive tablets with data plans and with the Zoom. They will receive a welcome pack that includes baby gifts that are used to support each session. Dyads in the EHS-CTB digital only group will receive EHS early education, as well as EHS home visitation, and will have access to the CTB content via the CTB App, but will receive no CTB sessions. Content includes videos of baby Elmo and his father and suggested activities.|f|f|f|t
34168650|NCT04256824|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized-controlled study|t|f|f|t
34168651|NCT06264739|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blindness patients and those who follow up after surgery will not know which group is in the study.|randomized double blinding|t|t|f|f
34168652|NCT06290596|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168653|NCT04364828|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34168654|NCT04646408|||OTHER||CROSS_SECTIONAL|||||||
33748634|NCT03155607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33748635|NCT06103136|||COHORT||PROSPECTIVE|||||||
33748636|NCT00385931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748637|NCT04873570|RANDOMIZED|CROSSOVER||OTHER||NONE||A single center, open label, randomized, single-dose, two-period, two-way cross-over study||||
33748638|NCT03626948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748639|NCT06497478|||COHORT||PROSPECTIVE|||||||
33748640|NCT01750047|||||CROSS_SECTIONAL|||||||
33748641|NCT03214913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748642|NCT00749138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856621|NCT06434454|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The young individuals in the control group will be informed about the study, including its purpose and methodology, and their consent will be obtained. The control group will receive sleep education, consisting of two educational presentations provided 15 days apart. The questionnaires of the scales used for analysis will be administered to assess their sleep problems. The content of the education will be prepared based on the literature and will be reviewed by at least three experts.~The young individuals in the experimental group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis"||||
33856622|NCT05438368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856623|NCT05735795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
34168655|NCT02954107|||CASE_CONTROL||PROSPECTIVE|||||||
34168656|NCT02519608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168657|NCT03366181|||COHORT||PROSPECTIVE|||||||
34168658|NCT06366178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168659|NCT00688584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168660|NCT02316990|||CASE_ONLY||RETROSPECTIVE|||||||
34168661|NCT00614380||||TREATMENT||||||||
34168662|NCT00367250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168663|NCT06491602|||CASE_ONLY||CROSS_SECTIONAL|||||||
34168664|NCT06322563|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34168665|NCT00423657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168666|NCT06524687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168667|NCT03367858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168668|NCT05007522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be provided identical appearing pills||t|t|t|t
34168669|NCT05541146|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy. After treatment, patients will be reassessed and if there is a peritoneal response, they will undergo gastrectomy.||||
33748643|NCT06223620|||OTHER||RETROSPECTIVE|||||||
33748644|NCT01904448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748645|NCT00866151|||COHORT||PROSPECTIVE|||||||
33748646|NCT03341910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748647|NCT06409026|NA|SINGLE_GROUP||OTHER||NONE||||||
33748648|NCT04240405|||OTHER||PROSPECTIVE|||||||
33748649|NCT03754296|||COHORT||PROSPECTIVE|||||||
33748650|NCT05475951|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748651|NCT00622128|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33748652|NCT02436148|||OTHER||CROSS_SECTIONAL|||||||
33765725|NCT06358911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This clinical trail was a double blinded trail in which the participant and outcome assessor were blinded to allocation, thus the participant was unaware of which experimental material had been assigned to him/her. Also outcome assessors were blinded to the treatment that each participant had received|"This clinical study will be conducted to evaluate the effect of using 4th generation Poly amido amine dendrimer (PAMAM-COOH) as a desensitizing agent and compared with three different commercially available desensitizing materials: 3% potassium nitrate and 0.11% fluoride (Ultra EZ), as described by manufacturer, Casein-phosphopeptide-amorphous calcium phosphate with F, (MI paste plusTm), and Hydroxyapatite, Fluoride and Xylitol, Hydroxyapatite and F (ReminPro), on:~1. Long-term Post-bleaching hypersensitivity.~2. Long-term Post-bleaching shade stability. For Patients treated with 40% hydrogen-peroxide bleaching agent."|t|f|f|t
33765726|NCT00687336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765727|NCT03847038|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168670|NCT02576223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168671|NCT05682755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168672|NCT02988778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34168673|NCT00080665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168674|NCT01564069|||COHORT||CROSS_SECTIONAL|||||||
33748653|NCT06266767|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|This is a randomized double-blinded design. Patients and their attending physicians / clinical anaesthetists / data collection study member / midwives / nurses will be blinded to patient group allocation|"We aim to use a pragmatic sequential optimization method as described by Sveticic et al. 2003. For the first round of recruitment, the research team will randomize women into 8 different groups of PIEB/PCEA regimens with six (n=6) women per group and set up the epidural pump for the maintenance of labor analgesia. This first round of recruitment will be called Complex #1. The PCEA bolus volume and lockout interval will stay the same for all groups.~There will be 8 combinations of PIEB/PCEA using an epidural mixture of 0.1% levobupivacaine + 2mcg/ml Fentanyl (n=48). We will exclude the 2 worst performing groups (as assessed by our composite primary outcome). Using sequential optimization, 2 new groups with different combinations of PIEB volume / interval will be added to the remaining 6 groups. Complex 2 therefore will consist of 8 groups of 48 patients (n=6 per group). We anticipate 3 to 4 rounds of recruitment until our statistician determines the 2 best performing groups."|t|t|f|t
33748654|NCT03152253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168675|NCT01480622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748655|NCT02159833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748656|NCT06667583|||CASE_ONLY||CROSS_SECTIONAL|||||||
33748657|NCT06191848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168676|NCT03260179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168677|NCT04694690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168678|NCT00804466|NA|SINGLE_GROUP||SCREENING||NONE||||||
34168679|NCT05532865|||CASE_ONLY||PROSPECTIVE|||||||
34168680|NCT02719821|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34168681|NCT05733858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168682|NCT01792700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168683|NCT03498950|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The patients will be randomized and distributed into two groups: Placebo Group (n=40) - submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae; Test Group (n= 40) - submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.|"The study sample will be composed of 80 patients selected at the Hematopoietic Stem Cell Transplantation Center of the Hospital Israelita Albert Einstein. The patients will be randomized and distributed into two groups."|t|f|f|f
34168684|NCT04562454|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168685|NCT00348439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168686|NCT00888017|||CASE_CONTROL|||||||||
34168687|NCT04951830|||COHORT||RETROSPECTIVE|||||||
33748658|NCT05081544|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33748659|NCT05655312|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I/IIa First-in-Human Study of \[212Pb\]VMT01 Targeted Alpha-Particle Therapy for MC1R Positive Advanced Malignant Melanoma Dose||||
33748660|NCT02105116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748661|NCT04973280|||COHORT||CROSS_SECTIONAL|||||||
33748662|NCT05271617|||COHORT||PROSPECTIVE|||||||
33748663|NCT01938755|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34168688|NCT03327623|||COHORT||PROSPECTIVE|||||||
34168689|NCT05117736|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|A randomization sequence list will be performed by the statistical department. Patients will be randomized according to a computer-generated randomization sequence with 1:1 distribution using randomly permuted blocks of 4 and 6.|This study is a prospective monocentric, randomized, double-blind, placebo-controlled, crossover clinical trial.|t|t|t|t
34168690|NCT04053608|||COHORT||PROSPECTIVE|||||||
34168691|NCT02534545|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168692|NCT02408588|||COHORT||PROSPECTIVE|||||||
34168693|NCT00569712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168694|NCT03421067|||COHORT||RETROSPECTIVE|||||||
34168695|NCT01173016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168696|NCT06357117|||CASE_CONTROL||PROSPECTIVE|||||||
34168697|NCT00876616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168698|NCT00963352|||CASE_CONTROL||PROSPECTIVE|||||||
34168699|NCT01556386|||||RETROSPECTIVE|||||||
34168700|NCT06472674|||COHORT||PROSPECTIVE|||||||
34168701|NCT04439461|||OTHER||OTHER|||||||
34168702|NCT00627588|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168703|NCT04067323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The list of participants will be randomly coded and divided two group will be sealed. This envelop will stored by the head of National Institute of Nutrition, Vietnam. The investigators will be not known who the participants consume test product or placebo product during the recruiting stage and whole intervention period. The oil product will be packed in the same bottles (only different from coloring the label bottles), manufactured by Nortalic, Vietnam.|The study is a randomized, double-blind, community-controlled intervention trial. A screening survey will be used to recruit women aged from 20 to 45 considered overweight and obese within a city of Bac Giang province, Viet Nam, during which subjects will conduct nutritional status and determine whether overweight or obesity and eligible criteria. Subjects then will be randomly allocated to receive 1 of 2 treatment sequences, with a balanced number of subjects assigned to each dietary treatment (either MCT oil or Soya bean oil/soy oil mixed in yogurt together with their standard meals (lunch) daily) over a period of 4 months and their blood lipid and nutritional profiles checked.|t|f|t|f
34168704|NCT05929521|NA|SINGLE_GROUP||PREVENTION||NONE||1 arm pilot to determine feasibility, acceptability and effectiveness of group care for those who are engaged in transactional sex and taking PrEP for HIV prevention.||||
34168705|NCT04552769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168706|NCT03011281|||COHORT||PROSPECTIVE|||||||
33748664|NCT04304144|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a multicenter, open-label, sequential cohort, dose-selection study of CAEL-101 in Mayo Stage I, II and IIIa AL amyloidosis patients.~The study is divided into two parts:~* Part A defines the safety and tolerability of CAEL-101 in combination with SoC CyBorD and determines the RP3D~* Part B evaluates the safety and tolerability of CAEL-101 in combination with SoC CyBorD and daratumumab~Part A will employ a 3+3 dose escalation design. At least 3 patients will be enrolled in each dose cohort unless adverse events (AE) preventing further dosing are observed. Part B will enroll a minimum of 6 patients.~Patients will be seen in the clinic weekly for 4 weeks to receive study drug infusions. Study drug infusions will be bi-weekly thereafter or every 4 weeks after 50 weeks, if participants switch to an alternative dosing schedule. Patients are treated until death, toxicity, symptomatic deterioration, Investigator, patient, or Sponsor decision to terminate."||||
33748665|NCT00722761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748666|NCT01314651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748667|NCT04560257|NA|SINGLE_GROUP||TREATMENT||NONE||quasi- experimental||||
33748668|NCT03131388|||COHORT||CROSS_SECTIONAL|||||||
34062809|NCT05039320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34062810|NCT06517550|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34062811|NCT01853696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34062812|NCT06292013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062813|NCT01254721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062814|NCT05840328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33856624|NCT03668353|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation||||
33856625|NCT01016977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33856626|NCT01507818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856627|NCT05419362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856628|NCT04746443|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856629|NCT02370810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856630|NCT03248154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959024|NCT03983369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Multicenter randomized double blind placebo-controlled trial stratified according to the type of chemotherapy (Stratum A and B) and by center. Patients will be randomized in two parallel groups: preventive treatment with LLLT (Laser group) or a control group with a placebo intervention (Placebo group)."|This is a superiority trial, multicenter, prospective, randomized in two parallel groups (containing a placebo control group) and a double-blind assessment|t|t|t|f
33959025|NCT06351657|||CASE_ONLY||PROSPECTIVE|||||||
33959026|NCT00486213|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34062815|NCT01490697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062816|NCT00921011|||COHORT||PROSPECTIVE|||||||
33959027|NCT06111313|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Miami UAdapt Trial is a non-comparative phase II study that includes two parallel randomized cohorts that will prospectively assign men radiotherapy (RT) treatment. Patients with relatively favorable risk prostate cancer (PCa) will be eligible for focal therapy LEAD (FTLEAD) RT (n=40), and randomized to receive Lattice Extreme Ablative Dose (LEAD) single high dose RT (SDRT, 12-16 Gy) vs. the same overall plan with the addition of ultrashort-term ADT (uSTADT, 1 month duration) concurrent with SDRT. Higher risk patients are assigned to the HypoLEAD cohort (n=90) and randomized 1:1 to receive Lattice Extreme Ablative Dose (LEAD) single high dose RT (SDRT, 16-20 Gy) followed by moderately hypofractionated (HypoFx) RT for 25 additional fractions vs. the same overall plan with the addition of ultrashort-term ADT (uSTADT, 1 month duration) concurrent with SDRT. In HypoLEAD additional ADT will be assigned at physician discretion per standard of care.||||
33959028|NCT02088294|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34062817|NCT01288092|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062818|NCT03322943|||COHORT||OTHER|||||||
34062819|NCT06044272|||OTHER||RETROSPECTIVE|||||||
34168707|NCT04837937|RANDOMIZED|FACTORIAL||OTHER||NONE||"The randomized controlled clinical trial has a full factorial testing 3 components at 2 levels each (on and off).~Individuals will be randomized to 1 of 8 experimental conditions. Participants can be assigned to intervention (Yes) or control (No) conditions for each component. All participants will receive a caregiver-patient negotiation exercise so that no participant gets an inactive placebo."||||
34168708|NCT03779542|||CASE_CONTROL||PROSPECTIVE|||||||
34168709|NCT03656029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This will be a within-subjects, counterbalanced, placebo-controlled study of placebo or 3 doses of cannabis|t|f|t|f
33959029|NCT03933826|||COHORT||PROSPECTIVE|||||||
33959030|NCT02618707|||CASE_ONLY||PROSPECTIVE|||||||
33959031|NCT05123586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959032|NCT03837067|||OTHER||RETROSPECTIVE|||||||
33959033|NCT04113564|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34062820|NCT03684551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34062821|NCT05306236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34062822|NCT03233594|||OTHER||PROSPECTIVE|||||||
34062823|NCT06246149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062824|NCT05796648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168710|NCT01092728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168711|NCT00034775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168712|NCT02320006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168713|NCT05655663|NA|SINGLE_GROUP||OTHER||NONE||||||
34168714|NCT04974255|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34168715|NCT02469623|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168716|NCT05057663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168717|NCT01801566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168718|NCT02421978|||CASE_CONTROL||PROSPECTIVE|||||||
34168719|NCT06528951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes assessor)||f|f|f|t
34168720|NCT01087827|||CASE_ONLY||PROSPECTIVE|||||||
33856631|NCT03283306|||COHORT||PROSPECTIVE|||||||
33856632|NCT03098420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesia team that performs the block, along with the supervising PI or sub-investigator, will be blinded to the medication in the injectate.|Patients will be randomly assigned to 1 of 3 groups. They will be assigned to a group prior to being brought back to the operating room. The anesthesia team in the OR will take an envelope that has which group the patient will be randomly assigned to and they will perform the TAP block with the respective dose of dexamethasone. The anesthesia team that performs the block, along with the supervising PI or sub-investigator, will be blinded to the medication in the injectate|t|f|t|f
33856633|NCT06003946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33856634|NCT02424513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856635|NCT02123433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33856636|NCT06385756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856637|NCT02142660|||||PROSPECTIVE|||||||
33856638|NCT04932317|||COHORT||PROSPECTIVE|||||||
33856639|NCT00373815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856640|NCT01749020|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33856641|NCT02919657|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33856642|NCT04379141|||COHORT||PROSPECTIVE|||||||
33856643|NCT00822172|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33856644|NCT02733796|||CASE_ONLY||PROSPECTIVE|||||||
33856645|NCT02483182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856646|NCT02972866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33856647|NCT04190329|||COHORT||PROSPECTIVE|||||||
33856648|NCT04187053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856649|NCT01366586|||||PROSPECTIVE|||||||
34168721|NCT03431441|NA|SINGLE_GROUP||TREATMENT||NONE|Due to visible print differences, subjects and investigators will be aware of the patterns/variants of the investigational product. However, subjects will be masked to the lens brand to prevent bias during the lens discussions.|||||
34168722|NCT02230566|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168723|NCT05740488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168724|NCT00557921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168725|NCT02977000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168726|NCT04958369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856650|NCT00692978|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE||Two groups (asthma and healthy) go through different particle size of monodisperse aerosol treatments|t|f|f|t
33856651|NCT04866498|||COHORT||PROSPECTIVE|||||||
33856652|NCT02888704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856653|NCT01122251|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33856654|NCT05866926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856655|NCT00172588|||DEFINED_POPULATION||OTHER|||||||
33856656|NCT00146354|NON_RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33856657|NCT06181565|||COHORT||PROSPECTIVE|||||||
33856658|NCT03815032|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856659|NCT06323577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856660|NCT00402363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856661|NCT01411644|||COHORT||PROSPECTIVE|||||||
33856662|NCT03155256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856663|NCT01725542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856664|NCT02521220|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33856665|NCT05158582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856666|NCT02182570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856667|NCT04123392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856668|NCT01424150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33856669|NCT00191867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856670|NCT06060093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"1 session with both training and sleep in normoxia, supplemented with placebo (NPL)~1 session with training in normoxia, sleep in hypoxia, supplemented with placebo (HPL)~1 session with training in normoxia, sleep in hypoxia, supplemented with ketones (HKE)"|t|f|t|f
33856671|NCT03133520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856672|NCT06450431|||CASE_CONTROL||PROSPECTIVE|||||||
33856673|NCT00133887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959034|NCT03944798|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|"The local clinical team, site study personnel and participants cannot be blinded to the treatment allocation as the imaging modalities are visually distinguishable and these individuals will be required to arrange the booking of surveillance visits and imaging at their respective clinical site.~The Central Adjudication Committee (CAC) will be blinded to surveillance frequency; however, because the imaging modalities are visually distinguishable, the CAC cannot be blinded to imaging modality. The data analysts will, however, remain blinded throughout the trial and all interpretation of study results will be conducted in a blinded manner. Since the primary outcome is objective, a lack of blinding of study personnel and patients, and the incomplete blinding of outcome assessors, introduces minimal threats to validity."|2 x 2 factorial superiority randomized controlled trial|f|f|f|t
33959035|NCT03079869|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective non-randomized cohort study of 6-9 months duration (active study period 6 months).||||
33959036|NCT01238172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062825|NCT04520139|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|"Phase 1 will be open label.~Phase 2 will be be double-blinded."|"Phase 1 will be a dose-escalating design.~Phase 2 will be a randomized, double-blinded, placebo-controlled study design"|t|f|t|f
34062826|NCT06730581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062827|NCT05320198|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062828|NCT05345769|NA|SINGLE_GROUP||TREATMENT||NONE|The Phase 1 study is comprised of open-label multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).|||||
34062829|NCT01429064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062830|NCT00583102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062831|NCT05416645|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients with morbid obesity who had LSG between January 2017 to January 2022were included in the trial, which was a multicenter cohort study.|Patients with morbid obesity who had LSG between January 2017 to January 2022were included in the trial, which was a multicenter cohort study.|t|f|t|f
34062832|NCT06401044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062833|NCT05841914|||CASE_ONLY||PROSPECTIVE|||||||
34168727|NCT03863951|||CASE_CONTROL||PROSPECTIVE|||||||
34168728|NCT04230317|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
34168729|NCT01665469|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168730|NCT01918124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168731|NCT04294017|||CASE_CONTROL||PROSPECTIVE|||||||
34168732|NCT03142529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168733|NCT05048173|||CASE_CONTROL||RETROSPECTIVE|||||||
34168734|NCT02528825|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34168735|NCT00088530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168736|NCT02832544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168737|NCT04632888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective, randomised, parallel trial design|t|f|f|f
34168738|NCT05256680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34168739|NCT01936714|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34168740|NCT04683835|||CASE_ONLY||PROSPECTIVE|||||||
34168741|NCT03936608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168742|NCT06011408|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Open-label, observational study with two groups taking antipsychotic with or without Tardive Dyskinesia||||
34168743|NCT05299398|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33856674|NCT00430443|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856675|NCT01703663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856676|NCT01804062|||COHORT||PROSPECTIVE|||||||
33856677|NCT04660266|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||liver evaluation by US before, 14 days and 21 days after bone marrow transplantation, in the purpose to predict the appearance of Veno occlusive disease.||||
33856678|NCT00812149|||||PROSPECTIVE|||||||
33856679|NCT05183854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856680|NCT01305525|||OTHER||PROSPECTIVE|||||||
33856681|NCT00588484|||COHORT||PROSPECTIVE|||||||
33856682|NCT00084578|RANDOMIZED|||TREATMENT||||||||
33856683|NCT02550665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959037|NCT06568913|NA|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||follow up of platelets count and The outcome of the thrombopoietin receptor agonists in pediatric patient with persistent or chronic ITP unresponsive to steroids||||
33959038|NCT06536907|||CASE_CONTROL||RETROSPECTIVE|||||||
33959039|NCT00179218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959040|NCT02093468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33959041|NCT05095766|||COHORT||PROSPECTIVE|||||||
33959042|NCT04262024|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Hyperprolactinemic women receiving cabergoline therapy will be divided into 2 groups: with health education and without health education.|Prospective study ( randomized controlled trial)|t|f|f|f
33959043|NCT06606106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33959044|NCT04329013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will randomize the patients who need EGD into 2 groups; left lateral and prone position by block of 4.||||
33959045|NCT03307902|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind||t|f|t|t
33959046|NCT05454618|||COHORT||PROSPECTIVE|||||||
33959047|NCT03910101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959048|NCT04681495|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33959049|NCT04760574|||COHORT||CROSS_SECTIONAL|||||||
33959050|NCT06459401|NA|SINGLE_GROUP||TREATMENT||NONE||All participants with stroke will complete study procedures that include walking with and without the intervention.||||
33959051|NCT02993016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168744|NCT05555966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168745|NCT01875159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168746|NCT06268054|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168747|NCT00524277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34168748|NCT05579015|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34168749|NCT05277376|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||This is an open-label, randomized, 3-arm study in 162 healthy adult subjects with the following objective: Primary: To assess the systemic absorption and pharmacokinetics of BEMT from 3 different market image sunscreen drug formulations containing 6% BEMT under maximal-use conditions.||||
34168750|NCT01732744|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34168751|NCT02986711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34168752|NCT05697783|||COHORT||RETROSPECTIVE|||||||
34168753|NCT00226590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168754|NCT02120066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168755|NCT03549975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168756|NCT02306681|||COHORT||PROSPECTIVE|||||||
34168757|NCT01152892|||COHORT||PROSPECTIVE|||||||
34168758|NCT01096836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168759|NCT03056677|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34168760|NCT06339151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168761|NCT04612725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856684|NCT02146651|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33856685|NCT04412915|||COHORT||RETROSPECTIVE|||||||
33856686|NCT01978860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856687|NCT03732313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856688|NCT02910661|||COHORT||CROSS_SECTIONAL|||||||
33856689|NCT01662115|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33856690|NCT02456077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34168762|NCT04456634|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Randomised (single blinded; treatment allocation concealed to participants but not Investigator)|2 groups each to be enrolled sequentially. Group 1a will be a sentinel group of 2 participants, and Group 1b will be composed of 6 participants; to be administered either AL + Ruxolitinib or AL + placebo.|t|f|f|f
34168763|NCT02155634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168764|NCT03990896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168765|NCT04076540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168766|NCT06394986|||COHORT||PROSPECTIVE|||||||
34168767|NCT01775956|||CASE_ONLY||RETROSPECTIVE|||||||
34168768|NCT03284606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168769|NCT05489341|||COHORT||RETROSPECTIVE|||||||
33856691|NCT02737917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856692|NCT05368987|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33856693|NCT00100386|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856694|NCT02294916|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856695|NCT02084641|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33856696|NCT02866110|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33856697|NCT03064035|RANDOMIZED|PARALLEL||TREATMENT||NONE||For adults on long-term warfarin therapy who present to the ED with emergent bleeding, or who are in need of urgent invasive surgical procedures: the exposure of interest will be fixed vs. variable dose 4FPCC, to which eligible patients will be randomly assigned in a 1:1 ratio.||||
33856698|NCT04089969|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Single-Blind decision-making study.||||
33856699|NCT00156884|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856700|NCT05397860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856701|NCT05296720|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33856702|NCT04834856|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33856703|NCT04938024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856704|NCT06044402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double-blind, controlled trial|t|f|f|t
33856705|NCT05525884|||OTHER||CROSS_SECTIONAL|||||||
33856706|NCT00223522|||||PROSPECTIVE|||||||
33856707|NCT00219453|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33856708|NCT05988255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blinded to which treatment they would receive.|Prospective single-blinded randomized controlled trial (therapy, level 1B)|t|f|f|f
33856709|NCT03765320|||COHORT||RETROSPECTIVE|||||||
33856710|NCT03688607|||COHORT||PROSPECTIVE|||||||
33856711|NCT04261023|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33856712|NCT02905994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856713|NCT01584856|||COHORT||PROSPECTIVE|||||||
33856714|NCT04923802|||COHORT||PROSPECTIVE|||||||
33856715|NCT05321888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856716|NCT02049151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856717|NCT04362605|NA|SINGLE_GROUP||TREATMENT||NONE||Patients after gastrectomy who suffer from anastomotic leak||||
33856718|NCT02564354|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856719|NCT01588834|||COHORT||PROSPECTIVE|||||||
33856720|NCT01703351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856721|NCT00938470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856722|NCT00381303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856723|NCT04295980|||CASE_CONTROL||PROSPECTIVE|||||||
33856724|NCT06148974|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Due to the character of the test products, the masking is partial||t|f|f|f
33959052|NCT06568887|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33959053|NCT00402779|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33959054|NCT05924555|||CASE_CONTROL||PROSPECTIVE|||||||
33959055|NCT05759182|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A Single-Arm, Open-label, Pre-Post Comparison Study Design||||
33959056|NCT03467919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Micro Fragmented Adipose Tissue (MFAT) on Knee Osteoarthritis|t|f|f|f
33959057|NCT00583128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856725|NCT04811209|||OTHER||PROSPECTIVE|||||||
33959058|NCT02622607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959059|NCT03286400|||COHORT||PROSPECTIVE|||||||
33959060|NCT01811121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959061|NCT06697977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33959062|NCT05255783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959063|NCT04247646|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856726|NCT02647866|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"Double-blind Induction Therapy was separated into Part A for administration of multiple ascending IV doses of KHK4083 (or placebo) to subjects in Cohorts 1-3 and Part B for administration of the maximally tolerated dose (as determined in cohorts 1-3) in expansion cohort 4. Subjects in Part A were prohibited from participating in Part B.~Subjects in each cohort were randomly assigned in a 3:1 ratio to receive KHK4083 or placebo by IV infusion over 60 minutes (± 10 min.). Each subject received a total of 6 treatments (1 IV infusion per treatment) every 2 weeks from Week 0 (Day 1) to Week 10.~Subjects who completed double-blind Induction Therapy (i.e., at least 5 of 6 treatments) and had a clinical response or mucosal healing, as defined above, were eligible to continue in double-blind Long Term Extension Therapy (Weeks 12-52) \& after protocol amendment all subjects who received at least 5 of 6 treatments were eligible for Open Label Extension Therapy (Weeks 12-52)."|t|t|t|t
33959064|NCT03192566|NA|SINGLE_GROUP||TREATMENT||NONE||Determine the single dose pharmacokinetics of acetaminophen and its metabolites (glucuronide, sulphate, cystein and mercapturic acid) in obese children and adolescents||||
33959065|NCT05633901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34062834|NCT00323037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076799|NCT03088319|||COHORT||PROSPECTIVE|||||||
34076800|NCT02751112|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34076801|NCT05238636|||COHORT||PROSPECTIVE|||||||
34076802|NCT02541331|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34076803|NCT05051046|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34076804|NCT06018805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34076805|NCT02843464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076806|NCT06418113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076807|NCT05468541|||COHORT||PROSPECTIVE|||||||
34076808|NCT02761590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34076809|NCT05667662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076810|NCT02871141|||COHORT||PROSPECTIVE|||||||
34076811|NCT00404859|||||PROSPECTIVE|||||||
34076812|NCT00965237|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959066|NCT06538246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The investigators will be blinded to group assignment and survey results. Survey results will be reported by the participants via their mobile apps, and so will not be visible to anyone.||t|f|t|t
33959067|NCT04985357|||COHORT||PROSPECTIVE|||||||
33959068|NCT05012098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959069|NCT02083770|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33959070|NCT04335994|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33959071|NCT05038410|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959072|NCT01364246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959073|NCT03416153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959074|NCT04547478|||CASE_ONLY||RETROSPECTIVE|||||||
33959075|NCT06700759|||CASE_CONTROL||PROSPECTIVE|||||||
33856727|NCT06416553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A two parallel group, randomized, placebo controlled design will be used. Twenty PD patients will be stimulated for 4 weeks (20 sessions), stimulation will be combined with speech therapy . Other twenty PD patients will be stimulated with the same protocol using sham stimulation, sham stimulation will be combined with speech therapy.|t|t|f|t
33856728|NCT05390983|RANDOMIZED|PARALLEL||TREATMENT||NONE||case-control study||||
34062835|NCT05797155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will recruit 500 daily adult smokers through social media to test the CoQuit app for smoking cessation. Participants will be randomly assigned in equal numbers to either the CoQuit app or an app that has similar content but no tasks for inducing cognitive dissonance among participants.|f|f|f|t
34062836|NCT00425893|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34062837|NCT05611996|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A cohort of 20 older adults will be assigned to the Peer plus program for 8 weeks, without a comparison group.||||
34062838|NCT05035225|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34062839|NCT05995249|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34062840|NCT05070468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.|Subjects are assigned to two groups by randomization block balanced method allocation and using quadruple blocks. In this case, there are 6 modes And in each case, 2 people will be in the control group and 2 people will be in the intervention group. Thus, by using the table of random numbers and assigning the numbers 1 to 6 to groups of 4 people, people are finally assigned to two groups of intervention and control.|t|t|t|t
34168770|NCT04811742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A power analysis was performed to determine the sample size, which was calculated to include 31 newborns for each study group under the conditions of 0.05 significance level, 0.95 confidence interval and 0.95 power. Due to possible missing data, the sample size was increased by 10%, and the study was completed with a total of 69 newborns, including 35 in the immersion bathing group and 34 in the showering group.In this study, randomization by throwing a dice was used to allocate newborns into study groups. A dice was rolled for each newborn who met the study inclusion criteria, whereby the newborn was assigned to the immersion bathing group when an even number was observed, and to the showering group when an odd number was observed.||||
34168771|NCT04967976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34168772|NCT00416624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856729|NCT02939248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856730|NCT01972711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856731|NCT01276431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856732|NCT02386709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062841|NCT03514979|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a phase IIb, open label study to evaluate the responses of patients with ANCA associated vasculitis (AAV) to pneumococcal vaccination. It has been designed primarily to assess the immunogenicity of pneumococcal vaccines in patients with AAV treated with rituximab compared to disease controls, but also to provide mechanistic information on vaccine response by comparing AAV patients and healthy controls.||||
34062842|NCT01190111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062843|NCT00437372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062844|NCT05760300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168773|NCT05979948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168774|NCT02291146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856733|NCT01264822|||COHORT||PROSPECTIVE|||||||
33856734|NCT04291599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This will be a phase 2, single-center, unblinded randomized controlled pilot trial of two arms comparing opioid-sparing analgesia to the current BCH institutional practice which has been reported to predominantly include administration of opioids as a first-line analgesic to pediatric patients who present to the emergency department with a diagnosis of acute pancreatitis.||||
33856735|NCT02790580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856736|NCT01306487|||CASE_CONTROL||RETROSPECTIVE|||||||
33856737|NCT05384353|||COHORT||PROSPECTIVE|||||||
33856738|NCT06328426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33856739|NCT02648750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33748669|NCT02989155|||OTHER||RETROSPECTIVE|||||||
33856740|NCT00830648|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33959076|NCT01966107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959077|NCT03297801|||COHORT||PROSPECTIVE|||||||
33959078|NCT05836571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959079|NCT03925922|||COHORT||PROSPECTIVE|||||||
33959080|NCT05182008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959081|NCT06188689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959082|NCT05078632|||COHORT||PROSPECTIVE|||||||
33856741|NCT03861377|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 03Remi). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.|Randomized, controlled, double blind.|t|t|t|t
33959083|NCT04175691|||CASE_CONTROL||PROSPECTIVE|||||||
34168775|NCT05418322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The interventions and collection of data will be conducted by the same clinician. Therefore, both clinician and participants will not be blinded in this study given the nature of the interventions. However, as the participants will be randomized and allocated by an independent individual, blinding the clinician to the allocated interventions at the beginning of the trial, during baseline assessment, is possible.|||||
34168776|NCT00646646|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34168777|NCT04164134|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34168778|NCT05549817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168779|NCT04809012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168780|NCT03089021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168781|NCT03291938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168782|NCT05976516|||COHORT||PROSPECTIVE|||||||
34168783|NCT06401369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168784|NCT00154856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168785|NCT03947710|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Open label, randomized, cross-over clinical study.||||
34168786|NCT01894607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168787|NCT03395483|||COHORT||PROSPECTIVE|||||||
34168788|NCT02090426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168789|NCT01788566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168790|NCT01068522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168791|NCT01250106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34168792|NCT03016572|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34168793|NCT02462148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168794|NCT01233596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168795|NCT00760682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168796|NCT04064658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34168797|NCT04496739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748670|NCT03435133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748671|NCT03899883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856742|NCT04916522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856743|NCT00334555|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33856744|NCT05021523|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Repeated measure design (pre/post intervention) with an intervention group and a sham group|t|f|t|f
33856745|NCT02681133|||||CROSS_SECTIONAL|||||||
33856746|NCT05082129|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33856747|NCT00351949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856748|NCT00571831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856749|NCT02638935|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33856750|NCT00144651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856751|NCT04822012|||COHORT||PROSPECTIVE|||||||
33856752|NCT00905138|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33856753|NCT03774251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized prospective study|f|f|f|t
33856754|NCT02361138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856755|NCT00782522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856756|NCT02882087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856757|NCT05622851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects are blinded to treatment assignment to each side of their faces.|Randomized, split-face, subject-blinded, comparative|t|f|f|f
33959084|NCT04376918|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Prospective, randomized (sequence randomization), controlled (cross over)||||
33959085|NCT04885816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized treatment will not be revealed to patient at any time during procedure or afterwards until follow-up is done.|"Randomized, single-blind, non-inferiority clinical trial enrolling high bleeding risk patients and coronary artery disease to be treated by percutaneous coronary intervention at the National Institute of Cardiology Ignacio Chávez in México. Included patients will have follow-up at the outpatient clinic through 1 year, until death or study exit, whichever comes first."|t|f|f|f
33959086|NCT00399919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959087|NCT06696313|NA|SINGLE_GROUP||OTHER||NONE||||||
33959088|NCT04883411|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, first-in-human, multi-center, non-randomized, single arm study.||||
34168798|NCT02152826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168799|NCT03952013|||COHORT||PROSPECTIVE|||||||
34168800|NCT04268082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168801|NCT04098523|NA|SINGLE_GROUP||SCREENING||NONE||||||
34168802|NCT02384863|||COHORT||PROSPECTIVE|||||||
34168803|NCT01917747|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168804|NCT01993992|||CASE_ONLY||PROSPECTIVE|||||||
33856758|NCT02562495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856759|NCT00852046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856760|NCT03658668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856761|NCT02802098|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33856762|NCT00440700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856763|NCT04604548|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33856764|NCT00271427|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33856765|NCT00077220|RANDOMIZED|||TREATMENT||||||||
33856766|NCT03124095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856767|NCT04785235|||CASE_CONTROL||PROSPECTIVE|||||||
33856768|NCT01687530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062845|NCT06731439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062846|NCT04935086|||CASE_CONTROL||RETROSPECTIVE|||||||
33748672|NCT02605980|||COHORT||CROSS_SECTIONAL|||||||
34062847|NCT05671419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study investigator will be masked to treatment assignment.||f|f|t|f
33748673|NCT04545541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33856769|NCT01844245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856770|NCT04651907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856771|NCT01298037|||OTHER||PROSPECTIVE|||||||
33856772|NCT02918123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062848|NCT04480567|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062849|NCT01097070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062850|NCT05666921|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34062851|NCT05563506|NA|SINGLE_GROUP||OTHER||NONE||||||
34062852|NCT00673725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062853|NCT03493022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34062854|NCT06731660|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||2x2 factorial design comparing effect of Wispr digital otoscope, education with performance feedback, both, or neither on diagnosis and antibiotic treatment of otitis media in young children.||||
34062855|NCT00096993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062856|NCT03330366|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34062857|NCT00507650|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34062858|NCT06465914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34062859|NCT03634241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062860|NCT06729541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34062861|NCT02155075|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33856773|NCT01003990|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33856774|NCT04929743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856775|NCT00835120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856776|NCT03371030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856777|NCT04677868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062862|NCT01329432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062863|NCT04365478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856778|NCT02829788|||COHORT||PROSPECTIVE|||||||
33856779|NCT02370043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33856780|NCT05889481|||COHORT||OTHER|||||||
33856781|NCT04768270|||OTHER||PROSPECTIVE|||||||
33856782|NCT05895838|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"The pharmacological interventions will be placebo controlled, and participants, care providers, investigators, and outcome assessors are blinded.~The physiological interventions of early wakeup and extubation as well as the back-rest position are open label."|Patients will be randomized in a 1:1 fashion to receive either the experimental intervention or placebo/control intervention for each of the four interventions with an assumption of no interaction.|t|t|t|t
33856783|NCT03614910|||COHORT||PROSPECTIVE|||||||
33856784|NCT01838252|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33856785|NCT00211497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856786|NCT00010712|RANDOMIZED|||TREATMENT||||||||
33856787|NCT06225934|||CASE_CROSSOVER||PROSPECTIVE|||||||
33856788|NCT03717831|||COHORT||PROSPECTIVE|||||||
33856789|NCT02196454|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33856790|NCT06475443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856791|NCT01020448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856792|NCT03798093|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Cardiac research sonographers that obtained study measurements were blinded to the study intervention|Cluster Randomized Crossover|f|f|f|t
33856793|NCT02778243|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856794|NCT00180921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856795|NCT06455150|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856796|NCT03539692|||OTHER||OTHER|||||||
33856797|NCT02871310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33856798|NCT03489174|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants will not know if they are assigned to the intervention or control group. Their weekly urine test that is collected by the opioid substitution therapy clinic will be tested monthly for pregnancy. Pregnancy will then be reported to the patient's attending physician on the day of testing, who would then communicate the result to the patient. The physician will continue with standard pregnancy care. The investigators will remain blind throughout data analysis and will not know if the pregnancy was discovered via monthly testing or standard practice.|Participants will be randomly assigned to either standard practice or monthly pregnancy screening.|t|f|t|f
33856799|NCT00395148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33856800|NCT04760054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be masked to group allocation. Participants will not be masked from knowledge of other group's activities, but will only receive the training from one specific training group.|Three groups: One intervention, One Exercise Comparison, One Attentional Control|f|f|f|t
33856801|NCT05401279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856802|NCT06178926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34168805|NCT03748966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Adults or children (age 3-17) with X-linked hypophosphatemia (XLH) will be enrolled the study. All research subjects will be treated with optimized doses of calcitriol alone (without phosphate supplementation) for one year.||||
34168806|NCT06239740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In the sham acupuncture control group (CG), participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study.|"In the electroacupuncture group (EG), participants received acupuncture at 10 scalp points (Baihui \[GV20\], Ex-hn 1, 3 points of intelligence \[Shenting \[GV24\], Benshen \[GB13\] on both sides, Touwei \[ST8\] on both sides). Electroacupuncture was applied for 20 minutes at Benshen \[GB13\] and Touwei \[ST8\] on both sides. They also received acupuncture at Tai chong \[LV3\], Tai Yuan \[LU9\], and Tai Xi \[KI3\] on both sides, as shown in picture 1. Acupuncture sessions were weekly for 10 weeks.~In the sham acupuncture control group (CG), participants received acupress or a brief needle insertion at He gu on both hands during the first and 10th weeks, marking the endpoint of the study."|t|t|f|t
34168807|NCT06443372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34168808|NCT03693521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34168809|NCT00141102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168810|NCT02840708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168811|NCT03991845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34168812|NCT04844736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856803|NCT01947192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34168813|NCT00900510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168814|NCT00833040|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168815|NCT00420576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168816|NCT00314730|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34168817|NCT02122679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168818|NCT03402802|||COHORT||PROSPECTIVE|||||||
34168819|NCT00730158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168820|NCT01915160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168821|NCT05754723|RANDOMIZED|PARALLEL||TREATMENT||NONE||Aim 1 will assess post-secondary students' current mental health needs, through surveys and focus groups. Aims 2 and 3 will use the findings from the surveys and focus groups to inform the development of 6-week psychoeducation and 12-week diagnosis-specific e-CBT programs. The psychoeducation program will be followed by 6-months of AI-assisted journaling exercises to monitor the student's mental health and determine whether they would benefit from stepping up their care to receive the diagnosis-specific e-CBT program. Aims 4 and 5 will determine the efficacy and cost-effectiveness of the online psychoeducation and diagnosis-specific e-CBT programs by comparing them to treatment as usual. Aims 6 and 7 will use the data to monitor the success and fidelity of the programs using surveys and focus groups.||||
34168822|NCT02798393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168823|NCT05353322|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||f|f|t|t
34168824|NCT05787340|NA|SINGLE_GROUP||TREATMENT||NONE||case series||||
34168825|NCT02899936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168826|NCT05157295|RANDOMIZED|PARALLEL||TREATMENT||NONE||"One group of participants will receive the experimental treatment, which is 4 injections, and the other group of participants will receive the standard treatment, which is 20 injections."||||
34168827|NCT01412177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168828|NCT05817565|||OTHER||PROSPECTIVE|||||||
33856804|NCT04685226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168829|NCT01758809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168830|NCT02754570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168831|NCT06402097|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34168832|NCT03066869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748674|NCT00081367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856805|NCT01605266|||COHORT||PROSPECTIVE|||||||
33856806|NCT00874341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856807|NCT00350896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959089|NCT06627244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959090|NCT03888131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959091|NCT02944682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748675|NCT00396903|||||PROSPECTIVE|||||||
33856808|NCT04431817|||CASE_CONTROL||PROSPECTIVE|||||||
33856809|NCT05773989|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, parallel, randomized trial||||
33856810|NCT01142596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856811|NCT05977114|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33748676|NCT04858269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748677|NCT04357574|||OTHER||PROSPECTIVE|||||||
33748678|NCT00152776|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33748679|NCT06395597|||COHORT||PROSPECTIVE|||||||
33748680|NCT02580604|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33748681|NCT01043081|||CASE_ONLY||CROSS_SECTIONAL|||||||
33748682|NCT05509413|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization into a control arm (wait-and-see) and a treatment arm (vaginal gel)||||
33748683|NCT06188065|||COHORT||PROSPECTIVE|||||||
33748684|NCT00572949|||COHORT||PROSPECTIVE|||||||
33748685|NCT02500992|||CASE_CONTROL||PROSPECTIVE|||||||
33748686|NCT03191318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748687|NCT03319277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748688|NCT01673802|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study, with dose adjustment.||||
33748689|NCT05019339|RANDOMIZED|PARALLEL||PREVENTION||NONE||experimental group and attention control group||||
33748690|NCT02263404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748691|NCT04305925|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label early feasibility/pilot study to evaluate the safety and feasibility of the focal laser ablation (FLA) Orion System. Men with histologically confirmed, non-metastatic, prostate adenocarcinoma, clinical stage ≤ T2b, with Gleason score 7 by MRI-ultrasound fusion targeted biopsy, without history of prior treatment and without neoadjuvant radiation or hormone therapy, who desire focal treatment with laser ablation will be enrolled.||||
33748692|NCT06147102|||COHORT||PROSPECTIVE|||||||
33856812|NCT02319525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856813|NCT01259726|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33856814|NCT01946841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856815|NCT00482950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856816|NCT05503654|RANDOMIZED|PARALLEL||PREVENTION||NONE||A two-arm parallel cluster randomized community trial||||
33856817|NCT04692415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856818|NCT05975151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856819|NCT00334724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33856820|NCT04870853|||COHORT||RETROSPECTIVE|||||||
33856821|NCT05605587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856822|NCT02170389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856823|NCT04502966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856824|NCT00866723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856825|NCT02088307|RANDOMIZED|PARALLEL||||NONE||||||
33856826|NCT02650245|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856827|NCT01200823|||||OTHER|||||||
33856828|NCT04162340|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation phase: CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells with an escalation approach, 2e6 to 5e6 CAR-T cells/kg||||
33856829|NCT02158520|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856830|NCT05760053|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, prospective, open label, single-arm, phase II study||||
33856831|NCT05709795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient won´t know what strategy has been followed to achieve CTI block|Prospective randomized multicentric|t|f|f|f
33856832|NCT02928107|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33856833|NCT01061957|||COHORT||PROSPECTIVE|||||||
33959092|NCT02600910|||COHORT||PROSPECTIVE|||||||
33959093|NCT06555133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959094|NCT05565872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959095|NCT06702306|RANDOMIZED|PARALLEL||SCREENING||NONE||Feasibility Randomised Control Trial||||
33959096|NCT05327790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To maintain blinding, LFMT and placebo capsules will appear identical.||t|t|t|t
33748693|NCT01194960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748694|NCT00440050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748695|NCT05080400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant blind to cooking process|randomised 2-way crossover study|t|f|f|f
33748696|NCT01186627|||COHORT||PROSPECTIVE|||||||
33748697|NCT04195464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Doble-blinded||t|f|f|t
33748698|NCT04517266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748699|NCT02766751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748700|NCT00924885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748701|NCT06435234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33748702|NCT04179487|||COHORT||PROSPECTIVE|||||||
33748703|NCT05102890|RANDOMIZED|PARALLEL||SCREENING||NONE||Telemedicine tool as a pre-consultation assessment for older patients in the primary care setting||||
33748704|NCT06579573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748705|NCT00524290|||COHORT||RETROSPECTIVE|||||||
33856834|NCT04386707|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33856835|NCT02373410|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33856836|NCT01418196|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33748706|NCT03913741|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group assignment||||
33748707|NCT04104867|RANDOMIZED|PARALLEL||OTHER||SINGLE||"The participants will be randomly selected into one of the three arms (1:1:1 ratio) of a sealed, opaque envelope by one of the surgical residents or by the attending surgeon. The participants in each group will receive an envelope containing pills of identical appearance, each of Domperidone 10 mg, Itopride 50 mg or placebo. Both the attending physicians and the participants are blinded to the kind of study medication contained in the envelope.~They are also informed to begin consuming the 3 liters of PEG-EL at 5.00 PM and complete it within 3 hours. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy. At the colonoscopy unit, the patients will be interviewed regarding the severity of abdominal discomfort during the preparation period after consuming the 3 liters of PEG-EL using a numeric pain rating scale."|t|f|f|f
33748708|NCT01604330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748709|NCT01587651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748710|NCT03358225|||COHORT||RETROSPECTIVE|||||||
33748711|NCT01396967|NA|SINGLE_GROUP||||NONE||||||
33748712|NCT06670612|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33856837|NCT03237182|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients randomized to the intervention receive a individualized tuberculosis treatment based on whole genome sequencing and the patients randomized to the control receive the standard of care tuberculosis treatment||||
33856838|NCT05003726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856839|NCT03272425|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856840|NCT02091050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062864|NCT01618110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34062865|NCT06083792|||COHORT||PROSPECTIVE|||||||
34062866|NCT03370523|||CASE_ONLY||PROSPECTIVE|||||||
34062867|NCT03557684|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34062868|NCT01443325|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34062869|NCT01900431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062870|NCT01192724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062871|NCT06020196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study will be a prospective, single-blinded, randomized controlled trial (RCT) that include 182 patients scheduled for an elective lower segment Cesarean section at the Obstetrics and Gynecology department of Kasr Alainy University Hospital from April 2023 to August 2023.~After obtaining approval from the hospital's institutional review board, we assessed 182 young women scheduled for an elective lower segment Cesarean section to determine their eligibility for the study.~The182 patients admitted to be enrolled in our study, in which they're randomized into 2 groups, Group 1(n= 91) received bilateral surgical rectus sheath block and Group 2 (n =91) received subdermal infiltration of local anaesthetics."|t|f|f|t
34062872|NCT01917357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062873|NCT06199349|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This clinical study is a double-blind study, in which participants such as clinical researchers, project managers, and project monitors are unaware of the random coding and drug administration groups of the subjects. Non-blind monitoring during the clinical study will be conducted by non-blind monitors. In addition, drug preparation will be carried out by non-blind researchers independent of this study. Analysis and testing personnel will also adopt blind analysis.||t|t|t|t
34062874|NCT00001736||||TREATMENT||||||||
34062875|NCT04423978|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34062876|NCT01618019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34062877|NCT04247568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34062878|NCT03427268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856841|NCT04100551|||COHORT||PROSPECTIVE|||||||
33856842|NCT01222260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856843|NCT04664231|||OTHER||PROSPECTIVE|||||||
33856844|NCT05566613|||COHORT||PROSPECTIVE|||||||
33856845|NCT01690364|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33856846|NCT04827745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Cohort A: Subjects with R/R CD19-positive MPAL~CohortB: Subjects with CD19-positive MPAL in complete remission and detectable MRD"||||
33856847|NCT00613262|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33856848|NCT03809741|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33856849|NCT01716117|NA|SINGLE_GROUP||TREATMENT||NONE||The SCENT Trial is a multi-center, prospective, non-randomized trial.||||
33856850|NCT04547153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856851|NCT03718078|NA|SINGLE_GROUP||OTHER||NONE||||||
33856852|NCT04354844|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856853|NCT00360256|||||RETROSPECTIVE|||||||
33856854|NCT05588687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is an experimental, parallel-group (intervention-control), randomized controlled design||||
33856855|NCT03266757|||COHORT||PROSPECTIVE|||||||
33856856|NCT02369770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062879|NCT02348359|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34062880|NCT01831323|||||PROSPECTIVE|||||||
34062881|NCT04026932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34062882|NCT03248414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
34062883|NCT04369235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062884|NCT02921633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062885|NCT05343104|||COHORT||PROSPECTIVE|||||||
34062886|NCT05705271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062887|NCT04592289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062888|NCT00257205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062889|NCT06623448|||OTHER||CROSS_SECTIONAL|||||||
34062890|NCT06731101|RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare tow groups of Palmar hyperhidrosis one with injection Local anesthetic at stellate ganglion, the other will take medication||||
34062891|NCT03889119|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"SBRT for the management of localized prostate cancer is a Phase II non-randomized clinical trial open to patients with biopsy proven localized prostate cancer. Patients will be deemed eligible for SBRT in any risk group categorization based upon the standard D'Amico stratification:~* Low-risk: initial PSA \<10 and clinical stage T1c-T2a/b and biopsy Gleason grade 3+3~* Intermediate-risk: initial PSA \>10 but \<20 or clinical stage T2c or biopsy Gleason grade 3+4 or 4+3~* High-risk: initial PSA \>20 or clinical stage T3 or biopsy Gleason grade 4+4 or higher)."||||
34062892|NCT06718270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062893|NCT01752634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062894|NCT05167279|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33856857|NCT04579133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062895|NCT01587469|||COHORT||PROSPECTIVE|||||||
33856858|NCT04098315|||COHORT||PROSPECTIVE|||||||
34062896|NCT03959696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Physician participants will not be blinded to the study arm. Patients will not be given any information on their physician's assigned arm. Statistician will be blinded to the assignment when analyzing the results.|Two-arm, multi-site cluster randomized controlled trial.|f|f|f|t
34062897|NCT03950141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062898|NCT06379568|||CASE_CONTROL||RETROSPECTIVE|||||||
34062899|NCT03796715|||COHORT||RETROSPECTIVE|||||||
34062900|NCT06426134|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34062901|NCT00083720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34062902|NCT01068626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168833|NCT05167435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor involved in the clinical trial will be prevented from having knowledge of the interventions assigned to individual participants.|It is a randomized controlled trial. Total 80 patients will be recruited, 40 in each group that includes 4 patients as a dropout in both groups. There will be one interventional group and one control group. Treatment will be allocated using a random number sheet generated by SPSS software version 21. Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
34168834|NCT00697307|||||PROSPECTIVE|||||||
33748713|NCT00126516|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33748714|NCT04753840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856859|NCT05209750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional study without concurrent controls||||
33856860|NCT04567290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062903|NCT01897766|||COHORT||RETROSPECTIVE|||||||
34168835|NCT03153514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168836|NCT00841490|||CASE_CONTROL||PROSPECTIVE|||||||
34168837|NCT02855281|||CASE_ONLY||PROSPECTIVE|||||||
34168838|NCT05899439|||OTHER||CROSS_SECTIONAL|||||||
34168839|NCT01059097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168840|NCT02579460|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168841|NCT01679496|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34168842|NCT02522247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168843|NCT00694616|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34168844|NCT03188159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168845|NCT05450367|||COHORT||RETROSPECTIVE|||||||
34168846|NCT06073808|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Each patient will serve as their own control: one breast will receive the control device, and the other will receive the study device.|t|f|f|f
34168847|NCT00877136|||CASE_ONLY||PROSPECTIVE|||||||
34168848|NCT00697931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33748715|NCT04092218|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33748716|NCT01348451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748717|NCT02089672|||CASE_ONLY||RETROSPECTIVE|||||||
33748718|NCT00070590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748719|NCT03577600|NA|SINGLE_GROUP||TREATMENT||NONE||A case-study study. The controls will be historical and 2 controls will be taken that will be matched to the age range (preschool, school age, early adolescent, late adolescent), type of tumor and location (infra or supratentorial). This study is expected to last for approximately 12 months, comprised of 4-8 weeks of enrollment period, 28 days of treatment and 6 months of follow up. The enrollment will be completed prior to the beginning of initial treatment. The recruitment will be carried out with a sample at convenience in patients with brain tumors in terminal phase that are outside conventional treatment. The therapy with quantum magnetic resonance (Cytotron®) will be administered as a compassionate treatment with the authorization signed by the parents and with the respective informed consent (depending on age).||||
33748720|NCT01311999|||COHORT||PROSPECTIVE|||||||
33748721|NCT00105326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748722|NCT00333463|||||RETROSPECTIVE|||||||
33748723|NCT05153980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33748724|NCT06665945|||CASE_CONTROL||PROSPECTIVE|||||||
33748725|NCT06627920|||OTHER||OTHER|||||||
33748726|NCT02367261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856861|NCT02803892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33856862|NCT02730364|RANDOMIZED|PARALLEL||TREATMENT||NONE|This was an open label study.|||||
33856863|NCT04534556|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||TRIPLE||Prospective, double blind, randomized placebo controlled, plus open-label extension|t|t|t|f
34168849|NCT01647165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168850|NCT04983966|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34168851|NCT02292108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168852|NCT02103309|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34168853|NCT03633344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856864|NCT03138928|||CASE_ONLY||RETROSPECTIVE|||||||
34168854|NCT03421522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible participants will be randomized to one of two treatment groups: 1) ICBN preservation, or 2) usual surgical technique (ICBN sacrifice). Due to the nature of the intervention, it will not be feasible to blind the treating surgeons or the study personnel. The patients, data analysts, and those interpreting the study results will be blinded to treatment allocation.To ensure concealed allocation, eligible patients will be randomized using the randomization function within the REDCap Cloud electronic data capture system. Treatment allocation will be stratified by clinical site to account for systematic differences in surgeons and peri-operative care. To avoid crossover between treatment allocation, randomization will take place in the operating room after the surgeon has confirmed that the participant is a candidate for ICBN preservation.|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved|t|f|f|f
34168855|NCT03788174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168856|NCT03071068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168857|NCT02981368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168858|NCT00904813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856865|NCT02698969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34168859|NCT03274908|||CASE_ONLY||OTHER|||||||
34168860|NCT02454023|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34168861|NCT02967653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168862|NCT06035731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||open label, randomized, controlled, multicenter intervention study||||
34168863|NCT04024358|||OTHER||OTHER|||||||
34168864|NCT03540108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Single-centre, prospective, randomised, placebo-controlled, parallel-group design to determine the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 (LPLDL® in hypercholesterolaemic adults (\>6mmol).|t|t|t|t
34168865|NCT06185517|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Comprehension phase:~After an initial translation of the questionnaires into French, the aim of this of this phase is to ensure the level of understanding of each and potential suggestions, during a personal or telephone interview.~Validation phase:~The aim is to validate the French translation of the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ), and in particular to assess: internal validity, construct validity, acceptability, reliability, sensitivity, specificity."||||
34168866|NCT02567981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168867|NCT04178798|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Arm A (65 patients): Patients assigned to arm A, will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos schedule until disease progression, unacceptable toxicity or early withdrawal.~* Arm B (65 patients): Patients assigned to arm B, will remain on the w\&w approach until disease progression or early withdrawal."||||
34168868|NCT04763395|||CASE_ONLY||RETROSPECTIVE|||||||
34168869|NCT00955214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168870|NCT05417750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168871|NCT02875535|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34168872|NCT04731285|||COHORT||PROSPECTIVE|||||||
34168873|NCT05237349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168874|NCT03624673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Mask to participant and outcomes assessor.|This is a non-inferiority, randomized controlled trial to compare the peri-operative, renal functional and oncologic outcomes of endoscopic robot-assisted simple enucleation(ERASE) and standard robot-assisted partial nephrectomy(RAPN) in the treatment of T1 renal cell carcinoma.|t|f|f|t
34168875|NCT05225129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168876|NCT01205100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168877|NCT03262896|||COHORT||PROSPECTIVE|||||||
34168878|NCT02416843|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34168879|NCT00217425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168880|NCT01622959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168881|NCT05697198|||COHORT||PROSPECTIVE|||||||
34168882|NCT01813916|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34168883|NCT00357630||||TREATMENT||NONE||||||
33856866|NCT04727853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856867|NCT03791671|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be a intervention group and a control group. Both groups do active treatment. In the intervention group they will have individual balance training and in the control group they will have balance training in a group from 3-6 persons. But both groups will do the same balance program.||||
33856868|NCT03349320|||OTHER||PROSPECTIVE|||||||
33856869|NCT01661478|||COHORT||CROSS_SECTIONAL|||||||
33856870|NCT05147961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959097|NCT06702813|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional study evaluating the beneficial impact of continuous high frequency oscillatory ventilation in ICU patients.||||
34062904|NCT03168490|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|(Participant, Investigator, Outcomes Assessor)|A single-centre, prospective, randomised, placebo-controlled, parallel-group trial|t|f|t|t
34062905|NCT02778841|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34168884|NCT01392547|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34168885|NCT03382886|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, phase I study to test for maximum tolerated dose (MTD) or recommended phase II dose (RP2D)||||
34168886|NCT05569239|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind|A total number of 1,500 subjects are planned to be randomized (in a 1:1 ratio) into 2 groups to receive a single intramuscular injection of either OVX836 (480μg) or placebo.|t|f|t|f
34168887|NCT04125446|||COHORT||PROSPECTIVE|||||||
34168888|NCT03336463|||CASE_CONTROL||RETROSPECTIVE|||||||
34168889|NCT02867267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168890|NCT05759507|||COHORT||OTHER|||||||
34168891|NCT06104085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34168892|NCT05961163|||COHORT||PROSPECTIVE|||||||
34168893|NCT00951366|||CASE_ONLY||PROSPECTIVE|||||||
34168894|NCT03096340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168895|NCT01239511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168896|NCT00830544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856871|NCT02391857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856872|NCT03634514|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33856873|NCT05685589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856874|NCT02369445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856875|NCT03881553|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Within-subjects design. Each subject will serve as own control and receive periods of intervention and no intervention within a study session.||||
33856876|NCT00044538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856877|NCT01769235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856878|NCT01520298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856879|NCT00174018|||DEFINED_POPULATION||OTHER|||||||
33856880|NCT05427903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33856881|NCT00104676|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 3 trial with direct individual benefit, randomized, open-label, multicenter, parallel groups||||
33856882|NCT01438268|||COHORT||PROSPECTIVE|||||||
33856883|NCT04317703|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856884|NCT02569957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856885|NCT00903656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856886|NCT04473430|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Patients with type 2 DM treated with insulin and receiving hemodialysis will use a real-time/personal CGM for 4 weeks (Intervention-Control Group), then 2 weeks of wash-out period, and cross over to use POC BG for 4 weeks; and vice versa (Control-Intervention Group).|f|f|f|t
33856887|NCT03960307|||COHORT||PROSPECTIVE|||||||
33856888|NCT05134051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The MARVEL Pilot STUDY is an investigator-initiated, multicenter, single-arm, open-label, assessing the microcirculation after IVL and PCI in severe calcific stenoses.||||
33856889|NCT00850785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856890|NCT00960895|||CASE_ONLY||RETROSPECTIVE|||||||
33959098|NCT03393312|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|A study mode on the tDCS device is used, which requires the researcher to enter a code determining whether active or sham stimulation is applied. The codes have been assigned to the participants in a randomised manner by a researcher not involved in the stimulation sessions or assessment of the outcomes. All participants receive active tDCS in one session and sham tDCS in the other session in a randomised order.|Repeated-measures double-blinded research study comparing the effects of bifrontal tDCS to sham tDCS. Participants will take part in two testing sessions and will receive real and sham tDCS in counter-balanced order. Stimulation time (before vs. during task performance) will be included as a between-subject factor.|t|f|t|t
33959099|NCT02168205|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33959100|NCT00954694|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33959101|NCT02125734||CROSSOVER||TREATMENT||NONE||||||
33959102|NCT05359640|||CASE_CONTROL||PROSPECTIVE|||||||
33959103|NCT06702696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959104|NCT06279481|RANDOMIZED|PARALLEL||TREATMENT||NONE||a single-centered, prospective, randomized controlled study||||
33959105|NCT03476837|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The recruiter will not know the client allocation. The CHW will not know who the women are in the control group.|Participants will be randomized into two groups based on the baseline assessment of CS policy (no policy/partial policy). WCGs in the treatment group will receive a three-session dose at 1, 3, and 6 months. During each treatment group session, the CHW will provide the tobacco biofeedback, motivational interviewing and educational materials at the end of the session. WCGs in the control group will receive by mail the same series of educational materials received by the treatment group at 1, 3 and 6 months. Survey and other assessments will be collected at baseline, 1, 3, 6, and 12 months.|f|t|f|f
33959106|NCT02494583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is partially blinded. The participant, study site personnel, and the sponsor will be blinded in the pembrolizumab plus SOC chemotherapy (pembro combo) arm and the placebo plus SOC chemotherapy (SOC) arm, but not in the pembro monotherapy (mono arm) since only one type of study medication will be administered.||t|t|t|t
34062906|NCT03601273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168897|NCT01776658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168898|NCT00100035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168899|NCT02448277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168900|NCT00870181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168901|NCT05742477|||COHORT||PROSPECTIVE|||||||
34168902|NCT03636581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168903|NCT05572866|||COHORT||RETROSPECTIVE|||||||
34168904|NCT00377793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168905|NCT06020898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34168906|NCT00681629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168907|NCT00895284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168908|NCT00160186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34168909|NCT02972060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168910|NCT04248699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168911|NCT03951077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168912|NCT01971541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34168913|NCT05762497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168914|NCT05229393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the outcome assessor will be blind only for those outcomes that are not self-reported|Parallel Assignment|f|f|t|t
34168915|NCT01377584|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34168916|NCT02719548|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34168917|NCT03133611|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34168918|NCT05125159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||150 patients will be randomized in a 1:1, single-blinded fashion to 1 of 2 transseptal groups.|t|f|f|f
34168919|NCT00000928|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168920|NCT05258240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single-blinded as assessor of the study would be kept blind of the treatment group to which the patient will be allocated.||f|f|f|t
34168921|NCT05892614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34168922|NCT04864171|||COHORT||PROSPECTIVE|||||||
34168923|NCT05546034|||COHORT||PROSPECTIVE|||||||
33856891|NCT05402397|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients already treated with enalapril will be randomized to receive losartan or enalapril in a cross-over designed study. Those who recruit the inclusion criteria will receive enalapril and/or losartan during a one month period, followed by a 15 days of wash out (under enalapril treatment). On day 46, the second period of 30 days of treatment starts (enalapril or losartan, whichever was not received initially).||||
33856892|NCT05166980|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study salts will be packaged in color-coded, polyethylene bags.|3-armed, double-blind, community-based efficacy trial|t|t|t|t
33856893|NCT00265746|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33856894|NCT02493543|||COHORT||PROSPECTIVE|||||||
34062907|NCT05103436|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either receive 2 months of TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using a EMS 7500 TENS unit) upon entry to the study (Intervention group) or not (Control; but offered the same TENS following a 2-month delay for equipoise).||||
34062908|NCT05032456|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||42 laboring women allocated to intervention group and control group randomly||||
34062909|NCT05459194|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34062910|NCT01275703|||CASE_ONLY||PROSPECTIVE|||||||
34062911|NCT03945994|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The control group will continue to receive their standard care. A natural experiment in the form of a non-randomised wait-list controlled pre-post study to evaluate the outcomes of the CP programme, when implemented in CMHTs, in contrast to standard care; and|"This study will use multiple methods to answer our research questions. It will consist of:~1. a natural experiment in the form of a non-randomised wait-list controlled pre-post study to evaluate the outcomes of the CP programme, when implemented in CMHTs, in contrast to standard care; and~2. an evaluation of the implementation tools using a standardised tool and qualitative approaches to understand the barriers and facilitators of implementation in the different sites."|t|t|f|f
34062912|NCT04202328|||CASE_ONLY||RETROSPECTIVE|||||||
34062913|NCT06467994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062914|NCT02939482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34062915|NCT02732405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062916|NCT02466607|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34062917|NCT05289024|||COHORT||PROSPECTIVE|||||||
34062918|NCT01902355|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34062919|NCT04291326|||COHORT||PROSPECTIVE|||||||
34062920|NCT00775853|||OTHER||PROSPECTIVE|||||||
34062921|NCT00306787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062922|NCT06509672|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trial|f|f|f|t
33856895|NCT02088346|||COHORT||PROSPECTIVE|||||||
33856896|NCT05782686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed by another investigator outside the operating room after lumpectomy.|Randomized clinical trial|t|f|t|f
33856897|NCT00762970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33856898|NCT01444833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856899|NCT03018054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856900|NCT00558337|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33856901|NCT03118674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856902|NCT01078311|||COHORT||PROSPECTIVE|||||||
33856903|NCT02957864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856904|NCT01519466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33856905|NCT02489123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856906|NCT03821389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856907|NCT04842656|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of Active Release Technique and Post Isometric Relaxation in patients with Piriformis Syndrome||||
34062923|NCT01623024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062924|NCT00416429|RANDOMIZED|||TREATMENT||NONE||||||
34062925|NCT00405743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062926|NCT03350308|||CASE_ONLY||CROSS_SECTIONAL|||||||
34062927|NCT06519097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All eligible patients will be allocated randomly to one of 2 groups, the DT3 group and the Placebo group. Surgeons, medical oncologists, advanced practice professionals (APPs) (nurse practitioners and physician assistants) at the follow-up outpatient clinics, and patients will be blinded to the allocation. Patients in the DT3 group shall receive oral DT3 400 mg twice per day, and those in the placebo group shall receive oral placebo twice per day.||t|t|f|f
34062928|NCT05454254|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062929|NCT00089700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062930|NCT05635097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062931|NCT06730568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34062932|NCT03218605|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34062933|NCT00670605|||COHORT||PROSPECTIVE|||||||
34062934|NCT00539032|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062935|NCT05590533|||OTHER||PROSPECTIVE|||||||
34062936|NCT04003454|RANDOMIZED|PARALLEL||SCREENING||NONE||Patients presenting to the emergency department will be randomized to targeted HCV screening or nontargeted HCV screening||||
33856908|NCT04795882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Rolling 6 trial design||||
33856909|NCT00111527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856910|NCT02951741|||CASE_ONLY||PROSPECTIVE|||||||
33856911|NCT04919239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856912|NCT04008602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856913|NCT02853656|||COHORT||PROSPECTIVE|||||||
34062937|NCT03946670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062938|NCT00864136|||COHORT||PROSPECTIVE|||||||
34062939|NCT01822951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062940|NCT04760379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062941|NCT03776071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062942|NCT05948839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856914|NCT01489410|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856915|NCT04889547|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33856916|NCT03832413|||COHORT||PROSPECTIVE|||||||
33856917|NCT02686905|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33856918|NCT03049176|||COHORT||PROSPECTIVE|||||||
33856919|NCT02745743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856920|NCT04643288|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33856921|NCT04459403|||CASE_ONLY||CROSS_SECTIONAL|||||||
33856922|NCT02274194|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33856923|NCT01510496|||COHORT||PROSPECTIVE|||||||
33856924|NCT05257031|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33856925|NCT03200600|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33856926|NCT01453530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33856927|NCT05621031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33856928|NCT05417633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33856929|NCT02934321|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33856930|NCT03495128|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||longitudinal assessment||||
33856931|NCT04494581|||OTHER||PROSPECTIVE|||||||
33959107|NCT03591107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Recruitment Coordinators/Data Collectors will only recruit at one of the two sites. The baseline assessment will be conducted prior to random assignment. After the assessment, they will be aware of study assignment which is necessary for connecting patients assigned to the PCM arm to connect patients to the Care Manager. However, they will only conduct 6-month assessments with patients from the other site and therefore will not be aware of the assignments for those patients."||f|f|f|t
34062943|NCT06729931|||CASE_CONTROL||PROSPECTIVE|||||||
34062944|NCT00586287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062945|NCT01237327||PARALLEL||TREATMENT||NONE||||||
34062946|NCT05362695|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The investigator and all other clinical research unit staff, sponsor study personnel, and the participant will remain blinded to individual participant treatment assignments throughout the study. Treatment assignments of individual participants will only be unblinded to a sponsor representative for regulatory reporting purposes or if warranted by emerging safety or tolerability issues.||t|t|t|f
34062947|NCT02189655|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34062948|NCT04603794|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double Blinded. All mouthwash vials are masked.|This randomized, cross-sectional, double blinded, negative controlled, four armed, prospective, interventional study compared Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in 60 subjects being treated for Covid 19 at the The Ohio State University Medical Center. Real time reverse transcriptase quantitative PCR measured viral loads.|t|t|t|f
34062949|NCT03202069|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33856932|NCT02612753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33856933|NCT06023277|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional||||
33856934|NCT01610011|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959108|NCT03315910|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The investigators have chosen to conduct a full factorial experimental design.||||
34062950|NCT05400395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062951|NCT01438372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062952|NCT01534780|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34062953|NCT03059251|||COHORT||OTHER|||||||
34062954|NCT05055934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062955|NCT05876871|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062956|NCT01836809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062957|NCT00932451|NON_RANDOMIZED|||TREATMENT||NONE||||||
34062958|NCT01057797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34062959|NCT04703777|||CASE_ONLY||RETROSPECTIVE|||||||
34062960|NCT06258317|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34062961|NCT02612610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34062962|NCT04684875|||COHORT||PROSPECTIVE|||||||
34062963|NCT03493581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062964|NCT03441282|||COHORT||PROSPECTIVE|||||||
34062965|NCT05017025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062966|NCT04482166|NA|SINGLE_GROUP||OTHER||NONE||||||
34062967|NCT03031041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856935|NCT01800422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856936|NCT03339128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33856937|NCT03509233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The examiner performing the measurement of all clinical periodontal parameters is not aware of the type of treatment provided to the patient.|multicenter randomized controlled intervention trial|f|f|t|f
33856938|NCT01565954|||COHORT||PROSPECTIVE|||||||
33856939|NCT00520520|||CASE_CONTROL||PROSPECTIVE|||||||
33856940|NCT05664386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062968|NCT05370508|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34062969|NCT05716217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anaesthesia nurses inserting PVCs and registering data are blinded to the participants' study allocation.|One group is randomly assigned to an 8-week daily arm training program. The other group receives normal care|f|t|f|f
34062970|NCT01880567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062971|NCT01923337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062972|NCT05428384|||COHORT||PROSPECTIVE|||||||
34062973|NCT05735275|NA|SINGLE_GROUP||TREATMENT||NONE||open, multicenter, Single Group||||
34062974|NCT02380118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34062975|NCT05812092|||COHORT||PROSPECTIVE|||||||
34062976|NCT03105921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168924|NCT04498078|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34168925|NCT01020786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168926|NCT00677404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168927|NCT00764439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168928|NCT00003619||||TREATMENT||||||||
34168929|NCT05854680|||CASE_CONTROL||RETROSPECTIVE|||||||
33856941|NCT00830557|||CASE_ONLY||PROSPECTIVE|||||||
33959109|NCT06582888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.|t|t|t|t
33959110|NCT04534127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959111|NCT06538805|||OTHER||CROSS_SECTIONAL|||||||
33959112|NCT03145558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Central radiology reviewers are blinded.|1:1 randomization, open label with central radiological review|f|f|f|t
33959113|NCT06274697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959114|NCT06565689|NA|SEQUENTIAL||TREATMENT||NONE||||||
33959115|NCT02296047|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33959116|NCT03810742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959117|NCT06400329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to study hypotheses and the two treatment groups. As both arms of the study are providing education-based interventions, participants will be provided limited details of each intervention arm so as to blind them from knowing which is the intervention and which is the control. This will help minimize any bias that occurs by knowledge of group assignment and perception of treatment effects.||t|f|f|f
33959118|NCT02437539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34062977|NCT05191589|RANDOMIZED|PARALLEL||OTHER||NONE||Trainees/participants are randomized to either control or interventional group. After reaching proficiency participants must come back after 3-6 weeks to perform a retention test.||||
33959119|NCT05622799|NA|SINGLE_GROUP||OTHER||NONE||Non-controlled repeated measures||||
33959120|NCT06094543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959121|NCT06654960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959122|NCT00728988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959123|NCT01950195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062978|NCT05375084|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33856942|NCT02622958|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33856943|NCT06531161|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participants, care providers, investigators, and outcome assessors will be blinded throughout the clinical trial. To ensure blindness, the experimental drug and placebo will be similar in dosage, odor, and taste. Suxiao Jiuxin Pill and placebo will be repackaged and distributed according to standardized procedures.||t|t|t|t
33856944|NCT06473129|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm pilot||||
33856945|NCT03603028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856946|NCT00285987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856947|NCT00002123||||TREATMENT||DOUBLE||||||
33959124|NCT06205953|||COHORT||PROSPECTIVE|||||||
33959125|NCT03474640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Part A: sequential dose escalation followed by activity estimation in disease specific cohorts at the RP2D.||||
33959126|NCT00500656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34062979|NCT05993026|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34062980|NCT06481488|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Part A is double-blind and Part B is open-label.|Part A is a parallel design and Part B is a crossover design.|t|t|t|t
34062981|NCT04392830|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34062982|NCT05439928|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34168930|NCT01980329|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168931|NCT05642585|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34168932|NCT01180335|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34168933|NCT05330013|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33959127|NCT04350073|||COHORT||PROSPECTIVE|||||||
33959128|NCT04870307|NA|SINGLE_GROUP||OTHER||NONE||Dissemination and Implementation Research (D\&I): Involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.||||
33959129|NCT06703346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959130|NCT06586255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959131|NCT04615286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959132|NCT01658982|||COHORT||PROSPECTIVE|||||||
33959133|NCT05941299|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33959134|NCT02269501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959135|NCT06699940|||OTHER||RETROSPECTIVE|||||||
34062983|NCT01075399|NA|SINGLE_GROUP||||NONE||||||
34062984|NCT03065036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168934|NCT00259714|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34168935|NCT04117113|||COHORT||PROSPECTIVE|||||||
34168936|NCT00637429|||COHORT||PROSPECTIVE|||||||
33748727|NCT02277106|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33856948|NCT03898947|||COHORT||RETROSPECTIVE|||||||
33856949|NCT04326504|||COHORT||PROSPECTIVE|||||||
33856950|NCT03832634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33856951|NCT05053425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856952|NCT00381368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856953|NCT05968547|||COHORT||PROSPECTIVE|||||||
33856954|NCT02095951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856955|NCT00882427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856956|NCT02358382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33856957|NCT00182390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856958|NCT06298253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34062985|NCT02000063|||COHORT||PROSPECTIVE|||||||
34062986|NCT05746078|||OTHER||PROSPECTIVE|||||||
34168937|NCT06218563|NA|SINGLE_GROUP||OTHER||NONE||"The protocol consists of 4 or 2 different conditions (repeated 2 times) of vibration-induced illusion of movement in healthy and stroke participants respectively, resulting in 8 or 4 vibration blocks with 3 vibrations per block.~Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same."||||
33748728|NCT01345006|NA|SINGLE_GROUP||OTHER||NONE||||||
34168938|NCT03976258|||COHORT||PROSPECTIVE|||||||
33748729|NCT05534581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748730|NCT02771951|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33856959|NCT00948142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33856960|NCT04774770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Care providers (dialysis nurses) and outcomes assessors (research staff conducting the baseline and follow-up questionnaires) will be blinded to participant allocation.||f|t|f|t
33748731|NCT02322671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748732|NCT06635837|||COHORT||PROSPECTIVE|||||||
33748733|NCT04443738|||OTHER||PROSPECTIVE|||||||
33748734|NCT01817413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748735|NCT05947877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Preterm infants and their mothers were masked from the nature of the administered intervention.||t|f|f|t
34062987|NCT01172964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34062988|NCT01060709|||COHORT||PROSPECTIVE|||||||
34062989|NCT02200991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062990|NCT06711133|||CASE_CONTROL||PROSPECTIVE|||||||
34062991|NCT04688398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34168939|NCT04959396|NA|SINGLE_GROUP||TREATMENT||NONE||Endometrium ablation with the IUB SEAD device||||
34168940|NCT04945083|NA|SINGLE_GROUP||OTHER||NONE||||||
34168941|NCT03164811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168942|NCT03787186|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33748736|NCT03298139|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
33748737|NCT01854827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748738|NCT06347172|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33748739|NCT02107118|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33748740|NCT05184231|||COHORT||CROSS_SECTIONAL|||||||
33748741|NCT00127244|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33748742|NCT04390737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748743|NCT05198765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748744|NCT00001430||||TREATMENT||||||||
33748745|NCT00518115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748746|NCT00185185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748747|NCT02697253|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33748748|NCT06670183|||COHORT||PROSPECTIVE|||||||
33748749|NCT00245895|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33748750|NCT05802810|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33748751|NCT05415735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33748752|NCT05606120|||CASE_ONLY||RETROSPECTIVE|||||||
33748753|NCT00149253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748754|NCT04981587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748755|NCT04050826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856961|NCT04578769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856962|NCT06154486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856963|NCT01180998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856964|NCT00450060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33856965|NCT03555474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor was blinded to the type of intervention.|Single blind randomized controlled trial|f|f|f|t
33748756|NCT00679120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748757|NCT05556863|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
33748758|NCT00235976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33748759|NCT01576536|||COHORT||PROSPECTIVE|||||||
33748760|NCT05894876|||COHORT||RETROSPECTIVE|||||||
33748761|NCT03422874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748762|NCT01290835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748763|NCT05411887|||COHORT||PROSPECTIVE|||||||
33856966|NCT05793918|RANDOMIZED|PARALLEL||TREATMENT||NONE|Single (Outcomes Assessor)|A specialist physician will be diagnosed the supraspinatus tendinopathy.||||
33856967|NCT01240668|||CASE_ONLY||PROSPECTIVE|||||||
33856968|NCT01522105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168943|NCT01863459|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168944|NCT02375035|||||PROSPECTIVE|||||||
34168945|NCT01422161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34168946|NCT00151385|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34168947|NCT04722523|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Six patients can be enrolled once the study has opened to the starting dose level. If 0-1 of the first 6 patients treated on study experience a DLT, then an additional 4 patients will be accrued to the study. If 0-2 of the 10 patients experience a DLT, then the combination will be deemed to be safe. If \>2 of the first 6 patients accrued or \>3 of 10 patients accrued experience a DLT, then patients will be treated at one dose level reduction.||||
34168948|NCT00601497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168949|NCT00155493|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34168950|NCT05470335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168951|NCT03267550|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34168952|NCT04802811|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34168953|NCT02859259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34168954|NCT00629044|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34168955|NCT00622557|||CASE_ONLY||PROSPECTIVE|||||||
34168956|NCT01207375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168957|NCT05942144|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34168958|NCT01118546|||CASE_CONTROL||PROSPECTIVE|||||||
34168959|NCT04434417|||COHORT||PROSPECTIVE|||||||
34168960|NCT02752880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34168961|NCT03658122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized controlled trial with waitlist control. The waitlist control group will receive the study treatment after a two-month wait.|f|f|f|t
34168962|NCT05963620|||COHORT||PROSPECTIVE|||||||
34168963|NCT03062735|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34168964|NCT05487222|||CASE_CONTROL||PROSPECTIVE|||||||
34168965|NCT00389844|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34168966|NCT05072158|||COHORT||PROSPECTIVE|||||||
34168967|NCT05172609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34168968|NCT02643108|RANDOMIZED|PARALLEL||PREVENTION||NONE|The allocation will be masked during statistical analyses.|||||
34168969|NCT01324817|||CASE_ONLY||CROSS_SECTIONAL|||||||
34168970|NCT03499184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168971|NCT05183945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168972|NCT05932615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168973|NCT03685955|||COHORT||PROSPECTIVE|||||||
34168974|NCT04435444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2-group randomized controlled trial (RCT). Using a consecutive patient sampling scheme, we will randomize Muslim patients with stage III or IV cancer.||||
34168975|NCT00690729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168976|NCT04023526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168977|NCT03174353|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34168978|NCT03056417|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34168979|NCT00960063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168980|NCT01715168|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34168981|NCT04257201|RANDOMIZED|CROSSOVER||OTHER||SINGLE||"For this randomized crossover study, subjects will consume 5 test meals varying in mushroom content, each separated by a minimum of 10 days (Figure 1). For 3 days prior to each testing day participants will be provided with and instructed to exclusively consume a low-antioxidant run-in diet (low fruit, vegetable, and spice diet) to minimize background concentrations of potential test food-derived compounds of interest. On test days, participants will consume a standardized mixed-macronutrient meal (500 kcal, 75g CHO, 15g Protein, 15g Fat) containing 1) no mushrooms (control), 2) 84 g of raw white button mushrooms served cooked; 3) 168 g of raw white button mushrooms served cooked; 4) 84 g of raw yellow oyster mushrooms served cooked; or 5) 168 g of raw yellow oyster mushrooms served cooked. Between each run-in diet/testing period, participants will consume their usual, unrestricted self-selected diets for a minimum of 7 days."|f|f|t|f
34168982|NCT05058807|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34168983|NCT04744961|||CASE_CONTROL||PROSPECTIVE|||||||
34168984|NCT01683799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33856969|NCT01562457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856970|NCT02473666|||OTHER||RETROSPECTIVE|||||||
33856971|NCT01535950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34168985|NCT01054664|||COHORT||PROSPECTIVE|||||||
33856972|NCT02222051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168986|NCT00953667|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34168987|NCT04376307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospectice randomized||||
34168988|NCT02749539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33856973|NCT06485609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856974|NCT03025386|NA|SINGLE_GROUP||OTHER||NONE||||||
33856975|NCT04497142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856976|NCT00320541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856977|NCT03278106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34168989|NCT03347123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062992|NCT01277809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34062993|NCT01702532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34062994|NCT02766452|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34062995|NCT04952207|||COHORT||PROSPECTIVE|||||||
34062996|NCT00150306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34062997|NCT02604355|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34062998|NCT03318081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34062999|NCT00431067|NON_RANDOMIZED|||TREATMENT||NONE||||||
34063000|NCT04320134|||COHORT||PROSPECTIVE|||||||
34063001|NCT04148963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063002|NCT02262156|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063003|NCT06050330|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063004|NCT06406413|||COHORT||CROSS_SECTIONAL|||||||
34063005|NCT03765424|||COHORT||PROSPECTIVE|||||||
34063006|NCT05627752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063007|NCT06710860|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34063008|NCT03765112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063009|NCT00387049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063010|NCT06731816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel group comparison|f|f|f|t
34063011|NCT04261127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063012|NCT06720246|||CASE_CONTROL||PROSPECTIVE|||||||
34063013|NCT06504888|||COHORT||RETROSPECTIVE|||||||
34063014|NCT01116076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34063015|NCT01522235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To prevent unblinding because of observed efficacy, adverse events or changes in laboratory values, each site will have both a treating investigator and an examining investigator. The treating investigator will assess the participant's clinical response and laboratory findings. The treating investigator will make all clinical treatment decisions. The examining investigator will monitor only the clinical autonomic symptoms and quality of life scores, and autonomic tests. Both the treating and examining investigators should be physicians. To prevent infusion unblinding, infusions of IVIG and placebo will occur in opaque bags.||t|t|t|t
34063016|NCT03358316|||OTHER||CROSS_SECTIONAL|||||||
34063017|NCT05775328|||COHORT||PROSPECTIVE|||||||
34063018|NCT02716766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063019|NCT05808816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063020|NCT02370030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748764|NCT00144703|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34063021|NCT06730243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063022|NCT04331548|||COHORT||CROSS_SECTIONAL|||||||
34063023|NCT05859022|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients assigned for one of 2 arms: Roux-en-Y gastric By-pass (RYGB),bariatric arterial embolization (BAE).|t|t|t|t
34063024|NCT02920346|||CASE_ONLY||PROSPECTIVE|||||||
34063025|NCT02175381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34168990|NCT02960217|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34168991|NCT05220085|||COHORT||RETROSPECTIVE|||||||
34168992|NCT02675907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34168993|NCT00035789||||TREATMENT||||||||
34168994|NCT05003037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34168995|NCT05030181|RANDOMIZED|CROSSOVER||TREATMENT||NONE||single blinded randomized controlled trial||||
33748765|NCT00729833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748766|NCT05579353|||COHORT||RETROSPECTIVE|||||||
33748767|NCT00606372|||COHORT||PROSPECTIVE|||||||
33748768|NCT05489783|||COHORT||PROSPECTIVE|||||||
33748769|NCT01353014|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33765728|NCT01396577|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765729|NCT02724722|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33856978|NCT03711851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765730|NCT03254953|RANDOMIZED|PARALLEL||TREATMENT||NONE||12-week randomized controlled trial to compare 3 self-monitoring approaches for weight loss in a digital health intervention for adults who are overweight or obese||||
33856979|NCT02814682|||||RETROSPECTIVE|||||||
34063026|NCT05627726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063027|NCT02140983|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34063028|NCT01901861|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34063029|NCT06107153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Inclusion criteria:~1. New diagnosed T2DM with an age of 18 years and above.~2. HbA1c of equal to or more than 9% and or random serum glucose equal to or more than 300 mg/dl.~The study will compare the effect of two strategies for glucose control over one year. First, two-week basal insulin and combination glucose-lowering drugs. Second, combination glucose-lowering drugs"||||
34063030|NCT01860144|||COHORT||PROSPECTIVE|||||||
34063031|NCT03026933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063032|NCT03979183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34063033|NCT00311454|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063034|NCT04953507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063035|NCT05114980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063036|NCT03197194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063037|NCT06731283|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063038|NCT01180556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063039|NCT03865589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients undergoing myeloblative conditioning regimen as part of hematopoietic cell transplant will be consecutively studied||||
34063040|NCT04663087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063041|NCT00441532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063042|NCT05527847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34168996|NCT04309110|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||A prospective, non-blinded service evaluation of two sequential groups of patients carried out in two phases.||||
34168997|NCT06275334|||CASE_ONLY||RETROSPECTIVE|||||||
34063043|NCT01036633|||CASE_CONTROL||PROSPECTIVE|||||||
34168998|NCT03803189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The sequence will be concealed to primary care providers and study staff other than the research coordinator who will apply the allocation. Study staff, including analysts, will also be blind to treatment allocation. Patients and healthcare professionals who may interact with study participants cannot be blinded due to the nature of the intervention, but outcome assessment will be blind.|An independent statistician following a 2:1 ratio to increase opportunities to learn about the intervention processes during this pilot trial will randomly allocate consenting patients at each site following the completion of their baseline survey to intervention or usual care using a computer-generated sequence.|f|f|t|t
34168999|NCT01372059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169000|NCT03244852|||COHORT||RETROSPECTIVE|||||||
34169001|NCT02644759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169002|NCT03495830|||COHORT||PROSPECTIVE|||||||
34169003|NCT00503750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169004|NCT01227798|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34169005|NCT02748863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169006|NCT00752050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169007|NCT00884546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169008|NCT02068924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169009|NCT02946281|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169010|NCT06440421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34169011|NCT00551759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765731|NCT04396080|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who require it, will be treated with posterior partial restorations. That will be the intervention.||||
33765732|NCT01294501|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33765733|NCT01586312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765734|NCT00002757|RANDOMIZED|||TREATMENT||||||||
33765735|NCT00114634|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34169012|NCT01599156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169013|NCT03282058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Histology of the healing tissues will be examined by a pathologist who is blinded to whether the patient received or did not receive stenting.|Participants will be randomly assigned in one of two groups (stent vs no stent).|f|f|f|t
34169014|NCT04750291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169015|NCT00802516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33765736|NCT03265990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765737|NCT05822427|||COHORT||PROSPECTIVE|||||||
34169016|NCT05822934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind study||t|f|f|f
34169017|NCT03357107|||COHORT||RETROSPECTIVE|||||||
34169018|NCT03495466|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169019|NCT06136429|NA|SINGLE_GROUP||TREATMENT||NONE||The transcatheter aortic valve system consists of 7 parts, namely the valve, the delivery system, the catheter sheath, the exchange system, the recovery system, the development exchange solution, and the curing agent.||||
34169020|NCT05665010|||COHORT||CROSS_SECTIONAL|||||||
33765738|NCT02038686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765739|NCT01759069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765740|NCT00792558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765741|NCT02493049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765742|NCT06018909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were randomized into the experimental and control groups using a block randomization method. The variables of age (7-9 and 10-12 years), gender (girls and boys), and fear of procedure (yes and no) were used for block randomization.|f|f|t|f
33765743|NCT01456234|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765744|NCT01042743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33765745|NCT03453827|||CASE_CONTROL||RETROSPECTIVE|||||||
33765746|NCT02152501|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959136|NCT03166709|RANDOMIZED|PARALLEL||PREVENTION||NONE||Stepped wedge - 15 sites randomly divided into 5 groups which are then randomly ordered into 5 steps. Step 1 is all control. During steps 2-6 one group implements the experimental condition in assigned order until all groups are doing experimental condition.||||
33959137|NCT01747239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169021|NCT04088006|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Subjects and injectors will be unblinded. All investigators in charge of clinical examination and assessment of local tolerance, as well as all technicians in charge of measurements of moisturization, elasticity, roughness and management of subject questionnaire will be blinded.|"Intra-individual study with treatment of one cheek and one side of neckline area per subject in a randomly fashion.~Variation of moisturization, elasticity and roughness between treated areas and non-treated areas of each subject measured at different study timepoints."|f|f|t|t
33959138|NCT03613194|NA|SINGLE_GROUP||OTHER||NONE||||||
33959139|NCT03425773|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration||||
33765747|NCT04535336|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33765748|NCT03794258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765749|NCT05108207|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The enrollers, evaluators and healthcare personnel (nurses, physical therapists, physicians, occupational therapists) do not know the assigned group. Both groups receive a tablet of the same dimensions and with the same basic applications. However, blinding the patient is not possible, since when exploring the tablet, he or she will recognize whether or not it has the PREVEDEL program included. To reduce this bias, the staff that delivers the tablet encourages both groups to use its different basic applications (access the Internet) and that any doubts may have participants about its use should be made to the tablet coordinator, so that the evaluators or healthcare personnel remain masked.~The time between assignment and delivery of the tablet is between 4 to 12 hours in all participating centers. This variable will be measured for later analysis."|Multi-center, parallel-group, randomized controlled trial (RCT). CONSORT methodological recommendations are used for reporting non-pharmacological trials, in addition to TIDieR and SPIRIT recommendations.|f|f|f|t
33765750|NCT04688593|||CASE_ONLY||PROSPECTIVE|||||||
33765751|NCT00925496|||COHORT||PROSPECTIVE|||||||
33959140|NCT05664451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959141|NCT04192799|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||stepped-wedge cluster randomized controlled trial||||
33959142|NCT05552456|||OTHER||CROSS_SECTIONAL|||||||
33959143|NCT05617898|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33959144|NCT05648968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959145|NCT06347003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959146|NCT06404281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063044|NCT03336723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34063045|NCT04547231|||COHORT||PROSPECTIVE|||||||
34063046|NCT02211092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34063047|NCT04916314|RANDOMIZED|PARALLEL||TREATMENT||NONE|The nature of the intervention means it is not possible to mask providers or patients|||||
34063048|NCT05490537|||COHORT||PROSPECTIVE|||||||
34063049|NCT05202275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063050|NCT04312945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34063051|NCT01819948|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063052|NCT06412458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169022|NCT01999452|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169023|NCT04519736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169024|NCT04338282|NA|SINGLE_GROUP||TREATMENT||NONE||For patients with positive plasma EBV-DNA at the end of treatments, anti-PD-1 antibody (toripalimab 240mg, every 3 weeks for up to one year)is given as maintenance therapy for 1 year.||||
34169025|NCT02589054|||CASE_CONTROL||PROSPECTIVE|||||||
34169026|NCT02485691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169027|NCT05256485|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Standard cognitive behavioral therapy comprises approaches directed toward modifying dysfunctional thinking and behavior discussed through 8 sessions.~mindfulness based relapse prevention is an 8-week therapy program based on:~1. Attention to present moment experience, even if it includes craving or negative emotion.~2. An accepting attitude towards this experience letting it be exactly as it is, without judging it or reacting to it.~This group therapy was facilitated by an ex-addict working in El Maamora hospital.~12-step therapy was based on strengthening conscious contact with God and awakening spirituality through prayer and meditation."||||
34169028|NCT01379183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33765752|NCT00101660|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765753|NCT01374802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765754|NCT04844918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765755|NCT01097252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765756|NCT02254083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33765757|NCT04200313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765758|NCT04488003|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33765759|NCT03042286|||COHORT||OTHER|||||||
33765760|NCT02853266|||COHORT||PROSPECTIVE|||||||
33765761|NCT02914184|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33765762|NCT06010290|||CASE_CONTROL||RETROSPECTIVE|||||||
33765763|NCT03002038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765764|NCT03941613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33765765|NCT05157516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765766|NCT03101241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled, parallel-group study.|t|t|t|t
33765767|NCT05514574|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients and their relatives, clinical staff, will be blinded to the group assignment. Evaluation of the data will be done by a blinded technique by a biostatistician not involved in the study and blinded to group assignment.|Parallel Assignment Prospective Non-Randomized Controlled Clinical Trial|f|f|f|t
33765768|NCT02189993|||COHORT||RETROSPECTIVE|||||||
34169029|NCT04049487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be matched and sorted by a non clinical research staff member. The participant will not know which group they are in, nor will the outcomes assessor. The people who are leading the 2 exercise groups will know which the groups are, but will take care not to mention to participants which group they are in.|Participants will be matched and randomly assigned to two groups: a general exercise group and a diastasis specific group. Each group will participate in a 4 week long exercise program.|t|f|t|t
34169030|NCT04292535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, placebo controlled trial|Random allocation to a dose of intranasal insulin (0, 20, 40, 60, 80, 100, 120) Within each dose, random allocation to exercise or control activity.|t|f|t|f
34169031|NCT02054585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169032|NCT01332994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169033|NCT02091817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34169034|NCT00391300||||DIAGNOSTIC||||||||
34169035|NCT02790996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169036|NCT02222610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169037|NCT04608721|||COHORT||PROSPECTIVE|||||||
34169038|NCT00004249||||TREATMENT||||||||
34169039|NCT00646685|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169040|NCT00956917|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33856980|NCT00216697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169041|NCT05161416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The children and their parents were blinded to the groups. The principal researchers (R2, R3) were blinded to the research hypotheses. Data entry researchers (R4, R5, R6) were blinded (masked) to both research hypotheses and intervention groups. Data entries (R4, R5) were performed using the codes A and B, and shared with the researchers (R1, R7, R8) after statistical analyses were conducted and the research report was written.||t|f|f|t
34169042|NCT05852067|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34169043|NCT05940116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169044|NCT01095393|||COHORT||PROSPECTIVE|||||||
34169045|NCT02885688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169046|NCT04528914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research investigators, outcome assessor, and independent statistician (data analyst) will be blinded until the completion of the data analysis.The dietitian will remain unblinded. Success of blinding will be assessed after completion of the follow-up period.||t|t|t|t
34169047|NCT03571126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169048|NCT02638766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169049|NCT05620316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169050|NCT00301626|RANDOMIZED|PARALLEL||||NONE||||||
34169051|NCT03620266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169052|NCT02670577|||COHORT||PROSPECTIVE|||||||
34169053|NCT02539004|||CASE_ONLY||PROSPECTIVE|||||||
34169054|NCT01859923|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856981|NCT01340196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33856982|NCT03947437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. Participants, investigators, study personnel performing any study-related assessments following study injection, and laboratory personnel performing immunology assays will be blinded to treatment assignment.|A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy|t|f|t|f
33856983|NCT00742482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856984|NCT00683748|||CASE_ONLY||PROSPECTIVE|||||||
33856985|NCT00534573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33856986|NCT02895451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856987|NCT05694754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple blind study||t|t|t|t
33856988|NCT02851082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856989|NCT03174548|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33856990|NCT00292877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33856991|NCT01477333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33856992|NCT04483986|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Radiologist is blind.||t|f|t|f
34063053|NCT06154174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The intervention and control RUTFs will be packaged in identical opaque sachets aside from colored stickers which will indicate randomization group. The intervention and control RUTFs will be identical in appearance, consistency, and smell. Efforts have been made to mask possible taste differences resulting from choline, including by the addition of a small amount (5mg) of choline to the control food. Participant masking cannot be guaranteed, however.||f|t|t|t
34063054|NCT03751436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063055|NCT06038929|NA|SINGLE_GROUP||OTHER||NONE||Single cohort, open label study in 16 Vagus Nerve Stimulant-implanted subjects with drug-resistant epilepsy with seizures or depression, aged 18 years or older||||
34063056|NCT06712849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063057|NCT02519816|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34063058|NCT06731010|||COHORT||PROSPECTIVE|||||||
34169055|NCT01361555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169056|NCT03411616|||OTHER||CROSS_SECTIONAL|||||||
34169057|NCT05449184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169058|NCT05490862|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Match pairs Parallel group Double-control design||||
34169059|NCT03641937|NA|SINGLE_GROUP||OTHER||NONE||||||
34169060|NCT04868955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169061|NCT01815944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169062|NCT01769313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34169063|NCT03507036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169064|NCT06353594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169065|NCT00064285|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34169066|NCT01742195|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169067|NCT06424444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169068|NCT04024943|||COHORT||PROSPECTIVE|||||||
34169069|NCT00486369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169070|NCT02649140|RANDOMIZED|PARALLEL||||NONE||||||
33959147|NCT05788237|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Substudy A: This is an observer-blinded study. Participants will be blinded to their assigned study intervention. The study staff receiving, storing, dispensing, preparing, and administering the study interventions will be unblinded. All other study and site personnel, including the investigator and investigator staff, will be blinded to assignment of study intervention.~With the exception of the staff conducting the immunogenicity assays, the sponsor will be unblinded.~Substudy B: This is an observer-blinded study. Participants will be blinded to their assigned study intervention. The study staff receiving, storing, dispensing, preparing, and administering the study interventions will be unblinded. All other study and site personnel, including the investigator and investigator staff, will be blinded to assignment of study intervention.~With the exception of the staff conducting the immunogenicity assays, the sponsor will be unblinded."|"Substudy A: Approximately 250 healthy adults ≥60 years of age will be randomized 1:1 to either Group 1: combination (RSVpreF + qIRV) (Visit 1) followed by placebo (Visit 2); or Group 2: sequential administration of qIRV (Visit 1) followed by RSVpreF (Visit 2) administered 1 month apart. Randomization will be stratified by 3 age groups (60-64, 65-79, and ≥80 years) within each study site.~Substudy B: Approximately 200 healthy adults ≥50 years of age will be randomized 1:1 to either Group 1: combination (RSVpreF + qIRV) 1.0-mL formulation; or Group 2: combination (RSVpreF + qIRV) 0.5 mL formulation. Randomization will be stratified by 6 age/sex groups (female 50-64, female 65-79, and female ≥80 years; male 50-64, male 65-79, and male ≥80 years) within the study site."|t|t|t|t
34063059|NCT05710094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Blinding and unblinding procedures applied only to the single-dose groups, i.e., Groups 1-4, randomized to receive SBE (active) or sterile saline (placebo).~The computer-generated randomisation list was kept strictly confidential, accessible only to authorised persons, until the time of unblinding of the study.~The following procedures were implemented in the single-dose groups to minimise the risk of unintended unblinding:~i. Blinded staff prepared the patient's leg wound for the administration of IMP.~ii. Both patient and blinded staff applied a nose clip, prior to and during IMP administration, until all materials used for the treatment (plastic wrapping, gauze, gallipot, etc.) had been removed and the room had been vented for a couple of minutes by opening a window."|Randomised, double-blinded, placebo-controlled ascending single dose groups (Groups 1 to 4); followed by open-label multiple ascending dose groups (Groups 5 to 7)|t|f|t|t
34063060|NCT04984278|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34063061|NCT06731855|||COHORT||PROSPECTIVE|||||||
34063062|NCT01344317|||COHORT||PROSPECTIVE|||||||
34063063|NCT06731127|||CASE_CONTROL||PROSPECTIVE|||||||
34063064|NCT05577130|||CASE_ONLY||OTHER|||||||
34063065|NCT02172040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34063066|NCT03729323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind. The person responsible for randomizing and allocating research subjects, outcome assessors and those responsible for data analysis will be blinded.|Clinical-behavioral|t|f|f|t
34063067|NCT05665140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063068|NCT05065736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169071|NCT05459467|RANDOMIZED|PARALLEL||OTHER||SINGLE|Masking for randomisation and analysis||f|f|t|f
34169072|NCT01599975|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959148|NCT06350266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients will be aware of their own messages but not of messages sent to other patients or in other arms.|||||
33959149|NCT05125302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33959150|NCT05199545|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33959151|NCT05747261|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"3+3 design"||||
33959152|NCT06540924|||CASE_CONTROL||PROSPECTIVE|||||||
33959153|NCT06701292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33959154|NCT06061601|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||A pilot intervention feasibility study||||
33959155|NCT06558630|||COHORT||PROSPECTIVE|||||||
33959156|NCT06702046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959157|NCT01146886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063069|NCT06731244|RANDOMIZED|SEQUENTIAL||OTHER||NONE||ETHER is a stepped wedge cluster randomized trial||||
33765769|NCT06625203|||COHORT||RETROSPECTIVE|||||||
34063070|NCT00002756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063071|NCT02160028|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34063072|NCT03774134|||COHORT||PROSPECTIVE|||||||
34063073|NCT01877551|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34063074|NCT00465400|||CASE_ONLY||PROSPECTIVE|||||||
33765770|NCT04822480|||CASE_CONTROL||PROSPECTIVE|||||||
33765771|NCT01090310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33765772|NCT00238381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765773|NCT04885114|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33765774|NCT06336980|NA|SINGLE_GROUP||OTHER||NONE||||||
33765775|NCT01380301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765776|NCT00759044|||COHORT||PROSPECTIVE|||||||
33765777|NCT05079815|||COHORT||PROSPECTIVE|||||||
33765778|NCT03491345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765779|NCT01072123|NA|SINGLE_GROUP||OTHER||DOUBLE|||f|t|t|f
33765780|NCT04922996|||OTHER||PROSPECTIVE|||||||
33765781|NCT01729962|||CASE_ONLY||PROSPECTIVE|||||||
33765782|NCT02965755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765783|NCT04094337|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Eligible patients will be consecutively included and randomized to two groups, intervention group or control group. The investigators will use a web-based randomisation procedure, conducted at a place remote from where the study takes place.||||
33765784|NCT01005485|||COHORT||OTHER|||||||
33765785|NCT01206556|||COHORT||PROSPECTIVE|||||||
33765786|NCT00602680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765787|NCT05881876|||OTHER||PROSPECTIVE|||||||
33765788|NCT01305746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765789|NCT02435472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33765790|NCT05903716|||CASE_CONTROL||PROSPECTIVE|||||||
33765791|NCT06037174|||COHORT||PROSPECTIVE|||||||
33765792|NCT02310451|NA|SINGLE_GROUP||SCREENING||NONE||||||
33959158|NCT05192954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be under anesthesia and will not know which surgical method is being utilized.|Single-blinded randomized controlled trial|t|f|f|f
33959159|NCT00759759|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33959160|NCT05421715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Monocentric longitudinal prospective cohort study||||
33959161|NCT04886232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765793|NCT02354716|||CASE_ONLY||PROSPECTIVE|||||||
33959162|NCT06702995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959163|NCT03112096|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33765794|NCT01458184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959164|NCT05526924|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959165|NCT01968837|NA|SINGLE_GROUP||SCREENING||NONE||||||
33959166|NCT06568211|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34063075|NCT01178814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063076|NCT06201455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063077|NCT04405622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063078|NCT01714609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063079|NCT05633277|RANDOMIZED|CROSSOVER||TREATMENT||NONE|After randomization is selected, no masking is required for this study.|Arm 1 will be patients receiving sclerotherapy and ablation at the start of treatment along with compression therapy. The patients in arm 1 will not receive any further treatment during the duration of the study. Arm 2 will be patients who receive sclerotherapy at the start of treatment along with compression therapy, and ablation 3 months later. All patients in arm 2 will receive ablation at their 3 month appointment. After ablation, the patients in arm 2 will not receive any further treatment for the remainder of the study.||||
34063080|NCT01483989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169073|NCT00769886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765795|NCT05486442|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33765796|NCT05479604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765797|NCT01534884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765798|NCT04483934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765799|NCT01356992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765800|NCT00310323|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765801|NCT02714868|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765802|NCT01735396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765803|NCT02803567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33765804|NCT01422369|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33765805|NCT04106843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765806|NCT00737425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765807|NCT05872529|NON_RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE||Before and After model|f|f|f|t
33765808|NCT04463121|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765809|NCT05012150|||COHORT||PROSPECTIVE|||||||
33765810|NCT05064111|||COHORT||PROSPECTIVE|||||||
33765811|NCT05516017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765812|NCT06035614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765813|NCT04340908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765814|NCT03122730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765815|NCT02557490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765816|NCT04672096|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33765817|NCT03881501|||CASE_ONLY||PROSPECTIVE|||||||
33765818|NCT03963661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765819|NCT00402337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765820|NCT04105530|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||Enrollment is on hold per institutional COVID-19 guidelines|t|t|t|t
33765821|NCT04940013|NA|SINGLE_GROUP||OTHER||NONE||||||
33765822|NCT01283321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765823|NCT02664701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765824|NCT03486925|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33765825|NCT06109233|||COHORT||PROSPECTIVE|||||||
33765826|NCT00426322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765827|NCT04875364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765828|NCT00429689|||COHORT||PROSPECTIVE|||||||
33765829|NCT00957164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33765830|NCT04633161|||COHORT||CROSS_SECTIONAL|||||||
33765831|NCT04138199|||COHORT||OTHER|||||||
33765832|NCT01659398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765833|NCT00230139|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765834|NCT05168917|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Basal visit and follow up visits at 3,9,and 18 months in which stool specimens wil be collected.||||
33765835|NCT02204137|||COHORT||PROSPECTIVE|||||||
33765836|NCT00032045||||TREATMENT||NONE||||||
33765837|NCT02815787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765838|NCT05164432|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Two groups of women will be recruited those at high risk of preterm birth and those who have uncomplicated pregnancies||||
33765839|NCT04731233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765840|NCT03505450|||OTHER||PROSPECTIVE|||||||
33765841|NCT01250964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765842|NCT02973555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765843|NCT00640796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765844|NCT01805817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765845|NCT06191614|||CASE_ONLY||PROSPECTIVE|||||||
33765846|NCT05336201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33765847|NCT02876172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765848|NCT01496716|||COHORT||PROSPECTIVE|||||||
33765849|NCT04309929|||COHORT||PROSPECTIVE|||||||
33765850|NCT04612855|||COHORT||RETROSPECTIVE|||||||
33765851|NCT04495582|||OTHER||PROSPECTIVE|||||||
34063081|NCT04862663|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase Ib: Open, Parallel groups allowed, recruiting up to approx. 222 participants.~Phase III: open-label, randomised, recruiting approx. 794 participants."||||
34063082|NCT00833118|||||PROSPECTIVE|||||||
34063083|NCT03707366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants who conduct the interviews are masked to condition.|Randomized controlled trial with 2 groups|f|f|f|t
34063084|NCT04164823|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34063085|NCT05705258|||COHORT||PROSPECTIVE|||||||
34063086|NCT01909726|||COHORT||CROSS_SECTIONAL|||||||
34169074|NCT02102035|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34169075|NCT02147886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169076|NCT05042700|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34169077|NCT05627973|||OTHER||RETROSPECTIVE|||||||
34169078|NCT04356495|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multicenter, randomized, controlled clinical trial with for each drug :~* A safety study pilot phase.~* An efficacy study phase. The data collected during the pilot phase, combined with new external data that emerged during the period, will be used to position treatments for the efficacy phase."||||
34169079|NCT03102554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Longitudinal cohort||||
34169080|NCT03827408|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The researcher, statistician and participants will be blinded to the intervention group. Only the supervisor and the anesthesiologist will be aware of the allocation group. After data collection is completed, the randomization code will be broken to reveal the allocation group.|The participants will be randomly allocated into 3 groups that will undergo a procedural sedation session via a nebulizer. Children of group I will receive nebulized solution of 0.5 mg/kg Midazolam, Group II will receive nebulized solution of 5µg/kg Dexmedetomidine, and Group III will receive a nebulized solution of 0.3 mg/kg Midazolam and 3µg/kg Dexmedetomidine respectively.|t|t|t|t
34169081|NCT03992079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be conducted by means of a secure website (Sealed Envelope), with block randomization to help balance the groups by the procedures performed within each arm. The patients, post-anesthesia care unit (PACU) staff, and study investigators performing follow up assessments, collecting, and analyzing the data will be unaware of the treatment assignments. It is not feasible to blind the operating team or site enrolment personnel as different preoperative and discharge information, medication and patient education will be given to the experimental and control groups. A numbered, sealed envelope, corresponding to the patient's assigned study number, will be opened, and the research coordinator will alert the surgeon to the patient's group assignment. Using the assumption that patients do not know the difference between enhanced recovery and usual care, the patient will not be informed of which arm they are assigned to.|After providing written informed consent, patients will be randomly assigned in a 1:1 ratio to either the control group, which uses physician preference for pain control, and generally relies on extended opioids or the experimental group, which includes preemptive pain control, targeted education, and multimodal opioid-sparing pain management during the intraoperative and postoperative periods.|f|t|t|f
34169082|NCT01775644|||COHORT||PROSPECTIVE|||||||
34063087|NCT05587426|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34063088|NCT05984693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34063089|NCT02779660|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169083|NCT02800616|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34169084|NCT01353404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169085|NCT04735874|||COHORT||PROSPECTIVE|||||||
34169086|NCT02653326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34169087|NCT01948609|||COHORT||PROSPECTIVE|||||||
34169088|NCT04970875|||COHORT||RETROSPECTIVE|||||||
34169089|NCT01137032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169090|NCT01307319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169091|NCT04906122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Allocation: Randomized Intervention Model: Parallel Assignment~Intervention Model Description:~Prospective, randomised, parallel trial design Masking: Single (Participant) Primary Purpose: Supportive Care"|The research was planned as a randomized controlled study. Voluntary postpartum primiparous mothers who have recently given birth and their accompanying grandmothers will be randomly assigned to the intervention and control group.|t|f|f|f
34169092|NCT05362123|||OTHER||PROSPECTIVE|||||||
34169093|NCT02611180|||CASE_ONLY||PROSPECTIVE|||||||
34169094|NCT02742961|||COHORT||RETROSPECTIVE|||||||
34169095|NCT00416208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169096|NCT04968158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169097|NCT02416999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169098|NCT05515835|||OTHER||PROSPECTIVE|||||||
34169099|NCT02222571|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169100|NCT06493201|||COHORT||RETROSPECTIVE|||||||
34169101|NCT05927038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33765852|NCT00675194|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765853|NCT00720902|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765854|NCT02578511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765855|NCT03885011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765856|NCT03241290|||COHORT||PROSPECTIVE|||||||
33765857|NCT06577766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|f|t|f
33765858|NCT01659658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765859|NCT04268901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33765860|NCT00458913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765861|NCT01567865|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33765862|NCT02337712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765863|NCT05762614|||COHORT||PROSPECTIVE|||||||
33765864|NCT03068806|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33765865|NCT05266014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765866|NCT00960921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765867|NCT03127189|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765868|NCT01152294|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33765869|NCT00926003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063090|NCT04288817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063091|NCT02598011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063092|NCT06731790|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Controlled, pathophysiological, exploratory interventional pilot study||||
34063093|NCT05352919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748770|NCT04477252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The therapist responsible for the conventional treatment of the patient and the therapist who performs the assessment will not have access to information about the study group the patient encounters. Since the randomization of patients, access to the intervention of the Experimental Group will be facilitated by the researcher on an occasion other than the initial assessment.|In this simple blind randomized controlled pilot study, participants will be recruited from users of the rehabilitation center where the study will be carried out (Neurorehabilitation Clinic - Sant Cugat del Vallés). 30 participants will be recruited. In the recruitment process, patients will be informed about the study, they will be asked to sign an informed consent and the randomization between the experimental group and the control group will be done by computerized program and with the following interventions|f|t|f|t
33748771|NCT02515136|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33856993|NCT03631160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects who have signed informed consent were assigned to either TEAS group or control group on the basis of digital random numbers generated by SPSS.23.0 software. The acupuncturist(Z.-Y.) was informed of the randomization allocation each subject by a concealed envelope, just before the onset of TEAS. And during the treatment, the screen of all acupuncture treatment instruments was covered from to ensure the anesthesiologist and surgeon blinded. The acupuncturist, statistician, and data collectors work independently and only perform assigned tasks, besides after the agreement is initiated, all researchers will not have any private communication with the study.|patients undergoing elective laparoscopy cholecystectomy surgery were recruited and allocated into TEAS（transcutaneous electrical acupoint stimulation）group or control group|t|t|f|t
33856994|NCT03650257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856995|NCT04578574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33856996|NCT04555538|||CASE_CONTROL||PROSPECTIVE|||||||
33856997|NCT01498289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33856998|NCT02261597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33856999|NCT00526032|||CASE_ONLY||PROSPECTIVE|||||||
33857000|NCT05872815|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33857001|NCT01652950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33857002|NCT04782843|||COHORT||RETROSPECTIVE|||||||
33857003|NCT01285271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857004|NCT01273077|||COHORT||PROSPECTIVE|||||||
33857005|NCT02271997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857006|NCT00734383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857007|NCT01980550|NA|SINGLE_GROUP||||DOUBLE|||f|f|t|t
33857008|NCT01078675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857009|NCT00507676|||CASE_CONTROL||PROSPECTIVE|||||||
33857010|NCT04856020|||OTHER||PROSPECTIVE|||||||
33857011|NCT00001521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857012|NCT00409773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857013|NCT02296866|||COHORT||PROSPECTIVE|||||||
33857014|NCT02152657|NA|SINGLE_GROUP||TREATMENT||NONE||Tomography-guided mesenchymal stem cells injection.||||
33857015|NCT02751567|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33857016|NCT05115604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857017|NCT04507061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857018|NCT03770637|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The sponsor, investigators/staff and subjects will be blinded to treatment assignment. Active study drug and placebo have the identical appearance (i.e., clear, colorless liquid), and both will be provided in identical vials with blinded labeling that does not reveal the contents of the vial.|A randomized, placebo-controlled, double-blind, two-treatment, 2-period, crossover in-patient phase followed by a placebo-controlled, double-blind, parallel two-treatment outpatient stage..|t|f|t|f
33857019|NCT01006928|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857020|NCT00108147|RANDOMIZED|PARALLEL||||SINGLE||||||
33857021|NCT06528886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857022|NCT02782403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study did not go on to the Phase II portion of the study due to low accrual and competing studies.||||
33857023|NCT05751863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"We will enroll patients admitted into the MemorialCare Long Beach Medical Center Intensive Care Unit. Only patients admitted to the Trauma service and are mechanically ventilated, requiring continuous intravenous administration of sedatives and/or analgesics, and are anticipated to require MV for ≥ 48 hours will be screened.~Each month of the trial, the Trauma patients were assigned to use either protocol-directed sedation (PDS) plus daily sedation interruption (DSI) protocol (even numbered months) or Analgesia First Sedation (AFS) protocol (odd-numbered months). This is a pragmatic, unblinded, cluster-randomized, multiple-crossover study to evaluate the efficacy and safety of AFS versus PDS-DSI."||||
34063094|NCT03973255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063095|NCT06247072|||COHORT||PROSPECTIVE|||||||
33857024|NCT03969147|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857025|NCT01602562|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33857026|NCT02652013|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33857027|NCT01882751|||CASE_CONTROL||PROSPECTIVE|||||||
33857028|NCT04476225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33857029|NCT02882724|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063096|NCT05007574|||CASE_ONLY||PROSPECTIVE|||||||
34063097|NCT03212391|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric unblinded two parallel-group randomized controlled trial||||
34063098|NCT06034379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34063099|NCT06098144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cluster-randomized clinical trial|t|f|f|f
34063100|NCT03134885|||COHORT||PROSPECTIVE|||||||
34063101|NCT00455520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063102|NCT03178630|||COHORT||PROSPECTIVE|||||||
34063103|NCT06730646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33857030|NCT00395460|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34169102|NCT03675503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34169103|NCT02053012|||COHORT||PROSPECTIVE|||||||
34169104|NCT02464436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169105|NCT02302768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169106|NCT03273673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To reduce the possibility of bias, the biofeedback intervention will be completed by a single individual (clinician - Athletic trainer) and the biomechanical assessments will be completed by a second individual who will be blinded to the subject's group assignment (research technician).|This study involves one active intervention group and an attention control group|f|t|f|t
33857031|NCT05323006|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169107|NCT03125226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169108|NCT01145742|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
34169109|NCT05955846|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single arm, Four centers study||||
34169110|NCT03515577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169111|NCT01814527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33857032|NCT04152460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33857033|NCT00473681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33857034|NCT05863858|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients were randomized into two regimens:~1. Levofloxacin 500mg BID, Amoxicillin 1 gm BID, Omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mg BID, Tinidazole 500mg BID, Omeprazole 20 mg BID, or~2. Moxifloxacin 400 mg OD, Amoxicillin 1 gm BID, Omeprazole 20 mg BID."||||
33857035|NCT00064610|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959167|NCT06613412|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33959168|NCT00092235|||COHORT||PROSPECTIVE|||||||
33959169|NCT00418509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169112|NCT00153296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169113|NCT00451672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169114|NCT02454738|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169115|NCT00972192|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34169116|NCT01290523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169117|NCT03918616|||CASE_CONTROL||PROSPECTIVE|||||||
34169118|NCT04393415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34169119|NCT00878241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748772|NCT02438618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748773|NCT03541759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748774|NCT01672775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748775|NCT00786604|||CASE_CONTROL||PROSPECTIVE|||||||
34169120|NCT03018236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748776|NCT03878810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169121|NCT03708107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher who did the algometry was masked. The researcher who did the statistical analysis was masked.||f|f|f|t
34169122|NCT00025597||||TREATMENT||||||||
34169123|NCT02337868|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169124|NCT01263964|||CASE_CONTROL||PROSPECTIVE|||||||
33748777|NCT03106818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||pain control in the early postoperative period|t|f|t|f
34169125|NCT05930652|||COHORT||RETROSPECTIVE|||||||
33748778|NCT05991154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of this trial, it will not be possible to blind participants to their allocation. As measures are self-report, blinding of outcome measures is also not possible. Protect against bias will occur by blinding investigators to condition (i.e., only staff directly managing participants will be unblinded).|A pragmatic, parallel arm randomized controlled superiority trial will be used. Participants will be randomly allocated in a 1:1 ratio to the control (usual practice; UP) or intervention (UP + JoyPop) condition. Stratified block randomization (block size of 10) will be used to randomly assign participants to each condition.|f|f|t|f
33748779|NCT03705091|||COHORT||PROSPECTIVE|||||||
33748780|NCT01867151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748781|NCT00778674|RANDOMIZED|CROSSOVER||||NONE||||||
33748782|NCT02390284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748783|NCT01970826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33748784|NCT04224155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748785|NCT00522275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748786|NCT04862793|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A randomized controlled cluster trial following a stepped-wedge randomization.||||
33748787|NCT02366338|||COHORT||PROSPECTIVE|||||||
33748788|NCT05785780|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study uses a pilot, pre-post, hybrid effectiveness-implementation design to compare the adapted implementation strategy to usual care on: (1) effectiveness and (2) implementation outcomes.||||
33748789|NCT02362698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748790|NCT00833638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33748791|NCT05079620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748792|NCT00233558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748793|NCT01383915|||COHORT||PROSPECTIVE|||||||
33748794|NCT04878562|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||We will conduct a nonhybrid pragmatic implementation-effectiveness stepped wedge cluster-randomized study in which clinics will be the randomized clusters.||||
33748795|NCT04829370|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||A prospective, single-blind, parallel study at a single health care center.|t|f|f|f
33857036|NCT00389233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857037|NCT03739541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34169126|NCT04675385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants from 18 years old with a minimum number of 20 teeth who came for periodontitis treatment, were recruited at the Department of Periodontology, Faculty of Odonto-Stomalogy, the University of Medicine and Pharmacy at Ho Chi Minh City (FOS-UMPH.|t|f|f|t
34169127|NCT02016976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169128|NCT05917912|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34169129|NCT05997446|||COHORT||PROSPECTIVE|||||||
34169130|NCT05107895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the researcher who made the initial and final evaluations was blinded.|Randomized controlled trial|f|f|f|t
34169131|NCT01832077|||CASE_CONTROL||PROSPECTIVE|||||||
34169132|NCT01141712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169133|NCT01934959|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33765870|NCT00728117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765871|NCT04424875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33765872|NCT00612222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765873|NCT00431535|||||PROSPECTIVE|||||||
33765874|NCT04732429|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33765875|NCT00494260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765876|NCT01422135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33765877|NCT06316219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765878|NCT05739435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765879|NCT00581633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765880|NCT03669653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765881|NCT01720381|||CASE_CONTROL||PROSPECTIVE|||||||
33765882|NCT02592200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765883|NCT05763953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765884|NCT01860014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765885|NCT01413230|||||PROSPECTIVE|||||||
33765886|NCT00319059|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33765887|NCT04379037|NA|SINGLE_GROUP||TREATMENT||NONE||The objective of this study is to determine the therapeutic effect of transcutaneous vagus nerve stimulation in patients with moderate, severe or critical pneumonia associated with Coronavirus Disease 2019 (COVID-19).||||
33765888|NCT00642135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765889|NCT06102486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33765890|NCT01982877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33765891|NCT02760758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765892|NCT06163053|||COHORT||PROSPECTIVE|||||||
33765893|NCT01988363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765894|NCT00920621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33765895|NCT00467064|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34063104|NCT01768091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063105|NCT06730100|NA|SEQUENTIAL||TREATMENT||NONE||||||
34169134|NCT01792310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169135|NCT01619371|||CASE_ONLY||PROSPECTIVE|||||||
34169136|NCT05297877|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34169137|NCT02914639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857038|NCT01894061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169138|NCT02970981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169139|NCT04217382|||COHORT||PROSPECTIVE|||||||
34169140|NCT05783206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169141|NCT01169025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33857039|NCT04085315|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33857040|NCT03133325|NA|SINGLE_GROUP||OTHER||NONE||||||
34063106|NCT03617861|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinded||t|f|t|f
34063107|NCT06286475|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This is a 2-part study that includes both an open-label (Part 1) and a double-blind, placebo-controlled (Part 2) design. In Part 1, participants will be randomly assigned to receive open-label VRG50635 in 1 of 2 treatment sequences. In Part 2, participants will receive VRG50635 or placebo in a double-blind manner.|t|f|t|f
34063108|NCT00831909|||COHORT||PROSPECTIVE|||||||
34063109|NCT04893200|||CASE_ONLY||PROSPECTIVE|||||||
34063110|NCT06152744|||COHORT||PROSPECTIVE|||||||
34063111|NCT02638129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063112|NCT03924505|RANDOMIZED|PARALLEL||PREVENTION||NONE|Study statistician was masked to which participants were in the intervention arm and which participants were in the control arm.|||||
34063113|NCT04896437|||CASE_ONLY||RETROSPECTIVE|||||||
34063114|NCT01537276|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|t|t|f
34063115|NCT06080906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|300 toddlers (aged 7-71 months) and 300 infants (aged 2-6 months) will be eligible for parallel enrollment|t|f|t|f
34063116|NCT00382395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063117|NCT02918643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34063118|NCT04279782|||COHORT||PROSPECTIVE|||||||
34063119|NCT04022356|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34063120|NCT06040502|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063121|NCT03211429|RANDOMIZED|PARALLEL||OTHER||NONE|No Masking|||||
34063122|NCT06093867|||CASE_ONLY||PROSPECTIVE|||||||
34063123|NCT02071602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063124|NCT00001300||||TREATMENT||||||||
34063125|NCT00217737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063126|NCT06709014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study partner will also be masked.||t|t|t|t
34063127|NCT04909424|||COHORT||PROSPECTIVE|||||||
34063128|NCT02380391|||CASE_CONTROL||PROSPECTIVE|||||||
34063129|NCT01731769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063130|NCT05702411|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34063131|NCT03404258|||COHORT||PROSPECTIVE|||||||
34063132|NCT04559035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Hospitalization records were confirmed by study personnel blinded to participant status.|randomized clinical trial of two nasal irrigation protocols in outpatients PCR positive for SARS-CoV-2, nested in a prospective case:cohort using laboratory-confirmed cases in the CDC COVID-19 Case Surveillance dataset|f|f|f|t
34063133|NCT04812795|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomly assigned to the tailored or non-tailored arms using random assignment function within survey software.|t|f|f|f
34063134|NCT01902875|||CASE_CONTROL||PROSPECTIVE|||||||
34063135|NCT02295761|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34063136|NCT05273489|||COHORT||OTHER|||||||
34169142|NCT00472225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169143|NCT01742273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169144|NCT02107833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169145|NCT02376634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169146|NCT06014346|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063137|NCT06730529|||OTHER||PROSPECTIVE|||||||
34063138|NCT02195726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857041|NCT02981654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857042|NCT02779478|||CASE_CONTROL||PROSPECTIVE|||||||
33857043|NCT04079803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sponsor, participant, care provider, investigator including sub-investigators and outcomes assessors will be blinded to throughout the study which includes using an Integrated Web Response System (IWRS) and electronic data capture (EDC) to ensure blinding during the study.|Approximately sixty (60) patients will be enrolled into the study and randomized to one of three cohorts. Cohorts will receive placebo or PTI-125 at 50 or 100 mg b.i.d. (n=20 per group)|t|t|t|t
33857044|NCT00713726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063139|NCT04128488|||COHORT||PROSPECTIVE|||||||
34063140|NCT05903040|||CASE_ONLY||PROSPECTIVE|||||||
34169147|NCT00626444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169148|NCT00985673|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34169149|NCT01302717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169150|NCT03301883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169151|NCT00817726|||CASE_CONTROL||PROSPECTIVE|||||||
34169152|NCT05569902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169153|NCT00285896|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33857045|NCT03141008|||COHORT||PROSPECTIVE|||||||
33857046|NCT02308020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063141|NCT05595408|||COHORT||PROSPECTIVE|||||||
33857047|NCT03591302|NA|SINGLE_GROUP||TREATMENT||NONE||Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T Cell Transfusion in previous HLA Matched Living Donor Kidney Transplantation||||
34063142|NCT06018545|||COHORT||RETROSPECTIVE|||||||
34063143|NCT05808790|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, parallel-arm, phase III randomized controlled trial Patients will be randomized in a 1:1 manner to SABR or minimally invasive metastasectomy for the local treatment of three or less colorectal pulmonary metastases||||
33857048|NCT02016456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857049|NCT01224795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857050|NCT05176535|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857051|NCT04372407|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34063144|NCT01179789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857052|NCT04532138|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857053|NCT06080893|||COHORT||PROSPECTIVE|||||||
33857054|NCT05748054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857055|NCT02171325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857056|NCT02070796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857057|NCT06101849|NA|SINGLE_GROUP||TREATMENT||NONE||A pre-post study design.||||
33857058|NCT05612165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857059|NCT02843204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857060|NCT02133053|||CASE_ONLY||PROSPECTIVE|||||||
33857061|NCT00629434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857062|NCT01164124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063145|NCT03266575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized to pulmonary rehab vs home based exercise rpogram||||
33748796|NCT05909631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Statical analyser|The participants were split into four groups: control, Mediterranean diet with beet juice (BJ+MeD), Mediterranean diet alone (MeD) and beetroot juice (BJ). The Mediterranean diet included fruits, vegetables, fish, poultry, and other lean meats (without skin), sources of omega-3 fatty acids, nuts, and legumes. Beetroot juice had 250 mg of beetroot.|t|t|t|t
34063146|NCT05616325|||COHORT||PROSPECTIVE|||||||
34063147|NCT06004492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||blended learning program (8 hours of workshops and four months of practical learning on technology platforms); control group received conventional education|f|f|f|t
34169154|NCT03361085||SEQUENTIAL||PREVENTION||NONE||quasi experimental intervention study||||
34169155|NCT01512134|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34169156|NCT06350188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34169157|NCT04294121|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34169158|NCT00637065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169159|NCT04206735|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Hospitals that agree to participate are offered 3 dates at approximately 6-month intervals. They sign up for a date depending on their readiness to participate. A team of champions: nurses, respiratory therapists (RTs), and physicians from each hospital will attend a virtual one-day training which will include NIV knowledge, skills, and the principles of teamwork. The clinicians in the participating institutions will be then on how to appropriately deliver NIV know and the principles of teamwork by an online course and by the champions teams.||||
34169160|NCT00170508|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34169161|NCT00003316||||TREATMENT||||||||
34169162|NCT02005016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169163|NCT00791388|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33748797|NCT06265363|||COHORT||PROSPECTIVE|||||||
33857063|NCT02918760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857064|NCT02647320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857065|NCT04003220|||CASE_CONTROL||PROSPECTIVE|||||||
33857066|NCT04225221|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33857067|NCT03645954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857068|NCT00247377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857069|NCT04099017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After confirming eligibility, the physiotherapist performing intervention obtained treatment assignment (S.S. Ali). The subject will not be aware of the group allocation and different time slot will be given for the intervention. Another physiotherapist who will not be aware of allocation concealment, record the reading of outcomes at the baseline, after three and six weeks||t|f|f|t
33857070|NCT00892723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33857071|NCT00158899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857072|NCT06204354|||CASE_ONLY||PROSPECTIVE|||||||
33857073|NCT02147353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33857074|NCT01864837|||||PROSPECTIVE|||||||
33857075|NCT02146456|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33857076|NCT00533260|||CASE_ONLY||PROSPECTIVE|||||||
33857077|NCT02777385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857078|NCT00718640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857079|NCT02061098|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34063148|NCT01823172|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34169164|NCT00405080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857080|NCT03027492|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857081|NCT06475872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857082|NCT02823535|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33857083|NCT01267877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33857084|NCT04341766|||COHORT||PROSPECTIVE|||||||
33857085|NCT01346436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857086|NCT01925287|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33857087|NCT05206019|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857088|NCT01593306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857089|NCT03017274|||CASE_CONTROL||PROSPECTIVE|||||||
33857090|NCT05902923|||COHORT||PROSPECTIVE|||||||
33857091|NCT03681197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each of the consecutive women numbers will be written on sequentially numbered opaque sealed envelope that contains the assignment code.At the time of procedure,the responsible investigator will open the envelope to reveal the assignment,and she will introduce the planned method. Monitoring and follow up will be done. After enrollment,the cases will be randomly allocated into two groups.||t|f|f|f
33857092|NCT03270423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857093|NCT04534504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857094|NCT02877979|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33857095|NCT06096896|||COHORT||PROSPECTIVE|||||||
33857096|NCT03646656|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||single group assignment||||
33857097|NCT02961296|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857098|NCT03107650|||COHORT||PROSPECTIVE|||||||
33857099|NCT03123809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and clinical investigators are going to be blinded in regards to the status of GES (if it is ON or OFF) for 3 months after surgery. One non-clinical investigator is assigned to serve as un-blind person , who is going to generate a master list of participants by dividing them into two groups based on their etiologies (diabetic or idiopathic). All effort would be to include similar numbers of idiopathic and diabetic patients in each intervention group based on a block randomization method, allowing for GES to be turned ON at the surgery, or it will stay OFF for the 3 month during the blind portion of the study.|Based on confidential code set up for this study, there will be a randomized assigment for patients to have their GES devices turn ON or OFF. Half of these patients will be in each arm.|t|f|t|f
33857100|NCT00108212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857101|NCT00189033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857102|NCT02482870|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||Patients scheduled for general anesthesia with endotracheal intubation will be randomized to either intubation with Macintosh laryngoscope first or King Vision videolaryngoscope first. All patients will be intubated with both laryngoscopes.|t|f|f|t
33857103|NCT01924728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857104|NCT02913235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857105|NCT02498470|||COHORT||PROSPECTIVE|||||||
33857106|NCT04496063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857107|NCT02116985|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857108|NCT00364026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857109|NCT04742322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33857110|NCT02701348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857111|NCT02050230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857112|NCT04580485|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33857113|NCT05767671|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The population to be studied are patients identified to have ARDS, admitted to the intensive care unit, and placed on a mechanical ventilator. Control subjects will be individuals on mechanical ventilation for non-pulmonary reasons (i.e. following surgery, sepsis without lung involvement). A total of 56 subjects will be enrolled. As described below (in Research Methods and Enrollment) a 2:1 ratio of ARDS to control subjects will be targeted.||||
33857114|NCT00244231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857115|NCT05371782|||COHORT||RETROSPECTIVE|||||||
33857116|NCT02426879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959170|NCT02418559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959171|NCT05619484|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33959172|NCT05912153|||COHORT||PROSPECTIVE|||||||
33959173|NCT05165368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and outcomes assessor will be blinded to interventional group assignment.|Using the block randomization method, patients will be randomly assigned to the INF® Therapy only group or the INF® Therapy+ group. Ten participants will be recruited at a time with 5 randomly assigned to each group.|f|f|t|t
33959174|NCT02720094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33959175|NCT06703788|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with compatible with diagnosis of metabolic syndrome are the target of this study||||
33959176|NCT05174559|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized controlled trials in individual patients (interventional N-of-1 RCTs) offer an alternative research design to parallel group randomized controlled trials. The N-of-1 study attempts to determine the more effective treatment for one patient using multiple crossovers, with repetition providing statistical power.|t|f|t|t
33959177|NCT02532023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33959178|NCT05587686|||COHORT||RETROSPECTIVE|||||||
33959179|NCT05016310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959180|NCT05500456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959181|NCT04018937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169165|NCT02738814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34169166|NCT01599663|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169167|NCT01445717|||COHORT||PROSPECTIVE|||||||
34169168|NCT02304900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169169|NCT03568981|||COHORT||PROSPECTIVE|||||||
34169170|NCT05507307|RANDOMIZED|PARALLEL||PREVENTION||NONE|Randomized|Randomized||||
34169171|NCT03714178|NA|SINGLE_GROUP||TREATMENT||NONE||Patients undergoing catheter ablation of paroxysmal atrial fibrillation and meeting all protocol inclusion/exclusion criteria will be treated with the FARAPULSE Endocardial Ablation System.||||
34169172|NCT00632216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959182|NCT06096116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor) The patients, care provider administering IMP, and outcomes assessors will be blinded from treatment allocations. Delegated study personnel preparing the IMP will be unblinded.||t|t|f|t
33857117|NCT01998009|NA|SINGLE_GROUP||SCREENING||NONE||||||
33857118|NCT03759860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participant must be masked from the information on the treatment group assignment.~The BCVA and image (OCT, Color Fundus Photography (CFP), Fundus Autofluorescence (FAF), Fluorescence Angiography (FAG)) investigator of the institution must be blinded on the participants' treatment group assignment to eliminate bias in evaluation.~Based on the images (OCT, CFP, FAF) and quantified measurement results (BCVA, OCT), the blinded principal investigator (independent evaluator) evaluates efficacy and adverse events and determines whether ranibizumab should be administered again.~An investigator not blinded performs SRT and ranibizumab administration."||t|f|f|t
33857119|NCT05263479|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34063149|NCT05517434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A research nurse/staff will prepare the minimally manipulated cellular preparations and injection syringe(s), as well as deliver the corresponding syringe(s) based on group allocation to the clinician to administer the injection into the patient's knee joint. The syringe(s) containing the active treatment or saline solution will be obscured by a non-transparent, adhesive label hiding its content in order to maintain the blind for both the patient and clinician.|"STUDY 1 (N=74): All patients will undergo a bone marrow aspiration. A BMA injection \[Arm A, n=37\] will be compared to a saline injection \[Arm C, n=37\].~STUDY 2 (N=74): All patients will undergo a blood collection and lipoaspiration. A LAM injection followed by LP-PRP injection \[Arm B, n=37\] will be compared to two consecutive saline injections \[Arm D, n=37\]."|t|t|t|t
33857120|NCT05614895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063150|NCT00095589|||COHORT||CROSS_SECTIONAL|||||||
33857121|NCT01347346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063151|NCT00206089|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33857122|NCT00688831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857123|NCT04821518|||CASE_ONLY||PROSPECTIVE|||||||
34063152|NCT03255252|NA|SINGLE_GROUP||TREATMENT||NONE||radiothérapy with concomittant chemotherapy||||
34063153|NCT05289167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857124|NCT00185679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857125|NCT02052089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857126|NCT04239716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857127|NCT02857998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063154|NCT06368323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be measured by blinded assessors where possible, using blinded video or audio recordings.|A parallel group randomized trial design with a secondary crossover extension|f|f|f|t
33857128|NCT05029960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857129|NCT05735821|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Trial model with randomized control, pretest-posttest control group|t|t|t|t
34169173|NCT05020509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169174|NCT06086821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor does not know when Step 1 and 2 of periodontal treatment have been performed.||f|f|f|t
34169175|NCT02307708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169176|NCT03947177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169177|NCT00471692|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34169178|NCT05677893|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33857130|NCT02011815|||COHORT||PROSPECTIVE|||||||
33959183|NCT03072329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959184|NCT03722849|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The experiment will consist of two sessions. The first session will involve questionnaires, followed by measures of sensitivity and behavioural responses to tussive (cough evoking) stimulation. The second session will involve functional brain imaging measures of responses to tussive stimulation.||||
33959185|NCT06102707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169179|NCT01231958|||COHORT||PROSPECTIVE|||||||
34169180|NCT03980015|||CASE_ONLY||RETROSPECTIVE|||||||
33959186|NCT01413152|NA|SINGLE_GROUP||||NONE||||||
33959187|NCT03354962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959188|NCT01691261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959189|NCT06043219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Groups will be allocated by an academic researcher not involved in the study. The outcome assessor will be blinded to group allocation|Randomised control trial|f|f|t|t
33959190|NCT05224297|||COHORT||PROSPECTIVE|||||||
33959191|NCT03614065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959192|NCT04934332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959193|NCT06567899|||COHORT||PROSPECTIVE|||||||
33959194|NCT00122031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959195|NCT04792281|||COHORT||PROSPECTIVE|||||||
34169181|NCT04048486|||COHORT||PROSPECTIVE|||||||
34169182|NCT01990521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169183|NCT00793195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169184|NCT00361881|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169185|NCT01845935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169186|NCT06527170|||COHORT||PROSPECTIVE|||||||
34169187|NCT00420485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169188|NCT05887986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized controlled experimental study|t|t|t|t
34169189|NCT04900012|||COHORT||PROSPECTIVE|||||||
33959196|NCT06684613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We will use the Health Equity Implementation Framework (HEIF) to develop a semi-structured interview guide for the formative work in Aim 1. The HEIF addresses disparities in access to care and implicit bias, and domains will be measured in Aim 2 to examine health equity and implementation determinants. In Aim 2, we will randomize participants 1:1 to receive either a) the enhanced decision aid developed in Aim 1, or b) generic information on PrEP provided by a CDC-produced video, PrEP (Pre-Exposure Prophylaxis).|f|f|t|f
33857131|NCT04687228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will remain unaware of what group they have been randomized to as both groups will be actively be participating in groups focused on male body image.|Participants will briefly be screened for eligibility criteria by phone. Eligible participants will be assessed using two structured clinical interviews (SCID-5 \& EPSI-CRV) and complete a set of self-report measures at baseline. Following assessment participants will be randomized into one of two groups. One group will receive a dissonance-based intervention known as the More than Muscles (MTM), while other participants will engage in a Media Advocacy (MA) active control. Participants will complete the same set of self-report measures from baseline, after their final group, at 1-month follow-up and at 6-month follow-up. During the 6-month follow-up participants will also be reassessed using the same structured clinical interviews at baseline.|f|f|t|t
33959197|NCT04444362|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Due to the nature of this research, we could not keep the participants blind to group assignment, but the study staff and statistical analyses were all blind to patient allocation during datacollection.||f|t|t|t
33959198|NCT05837130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Analysis is done ex-vivo and arm assignment is based on if the participant is symptomatic or not.|||||
33959199|NCT02487368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959200|NCT06639854|||OTHER||PROSPECTIVE|||||||
33959201|NCT03901027|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The effectiveness of the intervention was tested within a quasi-experimental study with one group pre- and-posttest design.||||
33959202|NCT03081195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Schools will be randomly assigned to 3 study conditions: 1) MFG-delivered by trained family peers; 2) MFG-delivered by community health workers; or, 3) Comparison: Mental health and school support materials (books).|t|f|f|f
33959203|NCT05404568|||COHORT||PROSPECTIVE|||||||
33959204|NCT06703216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063155|NCT04775498|RANDOMIZED|PARALLEL||OTHER||NONE|"Eligible patients after obtaining their consent will be randomized:~* either in the face-to-face psychoeducation group and will benefit from a programme of psychoeducation sessions available at the participating center.~* or in the SIMPLe application group and will have access to the application (personal access)."|"* Standard group : patients will participate at all sessions of face-to-face psychoeducation (sessions labeled and controlled by their Regional Health Agency).~* Experimental group: patients will use SIMPLe application during 12 months."||||
34063156|NCT04201678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and healthcare providers will not know which patient is in which group.|Patients will be divided into three randomized groups according to anesthetic method with conventional local anesthesia infiltration (CLIA) method and extrapedicular infiltration anesthesia (EPIAA) and US guided erector spina group (ESP).|t|t|f|f
34063157|NCT00478699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063158|NCT04350814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|No research assistants involved in participant assessment, nor is the primary investigator, aware of which condition participants are assigned to. This masking will be monitored and conducted by a lab staff member not directly involved in the study.|The investigators will randomly assign participants to one of two conditions, and monitor their symptoms for 12 months. After the 12-months assessment period is complete, the investigators will offer the intervention to participants assigned to the active control condition to use at their own discretion.|f|f|t|f
34063159|NCT00055679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063160|NCT03283917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063161|NCT05585125|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34063162|NCT03345628|||CASE_CONTROL||OTHER|||||||
34063163|NCT05220748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857132|NCT04066790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169190|NCT05106881|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34169191|NCT01746303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169192|NCT00857285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169193|NCT05272618|||COHORT||PROSPECTIVE|||||||
34169194|NCT00798616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169195|NCT02305030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169196|NCT02961608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169197|NCT05565287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|prematurity (NICU)|"1. group: Intervention Parental advise based on the combination of neonatal neurobehaviourism and motor behaviour~2. group: Basic hospital guidelines"|t|t|t|t
34169198|NCT05101447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169199|NCT04721678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169200|NCT00597402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169201|NCT01972581|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34169202|NCT06543667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169203|NCT06112483|||COHORT||PROSPECTIVE|||||||
34169204|NCT01809821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169205|NCT01489319|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169206|NCT02921672|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169207|NCT01248195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857133|NCT01211743|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33857134|NCT03345134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857135|NCT04875741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study would be double-blind as the identity of the patient's group will not be revealed to the assessor and the patient will also be un-aware of the group to which they will be allocated.||t|f|f|t
34169208|NCT01030029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748798|NCT04797338|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomization list will be generated by a computer by 1:1 ratio. Sealed envelopes containing treatment allocation instructions will be attached to the consent forms.~At the day of triggering for final oocyte maturation, patients will sign an informed consent and will be allocated to one of the study arms according to the instructions in the envelop attached to the consent form."||||
33748799|NCT05256173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748800|NCT05222919|RANDOMIZED|PARALLEL||OTHER||SINGLE||single-blinded observational randomized-control trial|t|f|f|f
33748801|NCT03362905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study will include 123 patients who are candidates for IUD contraception. The aim of the study will be explained to all patients and an informed written consent will be taken. After recruitment, patients will be randomized to the 3 study arms using computer generated randomization sheet using MedCalcc version 13 to receive any of: lidocaine spray, cream and injection|t|f|t|f
34063164|NCT06730217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants randomized to the intervention group will benefit from a mechanical insufflator during airway clearance sessions (EOVE-70®, Air Liquide Medical Systems France). In this group, patients will also be assessed before and after each session, in order to compare the 2 chosen airway clearance techniques on variation in peak expiratory flow.|f|t|f|f
33748802|NCT00487162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748803|NCT01031810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748804|NCT03581305|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748805|NCT03796455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33748806|NCT05301751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33748807|NCT01260350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748808|NCT05969093|||OTHER||CROSS_SECTIONAL|||||||
33748809|NCT06580132|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blinded study|Controlled intervention|t|f|f|f
33748810|NCT05403541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor Staff is also masked, so the study is Quadruple-blind.||t|f|t|t
33748811|NCT01089972|||CASE_CONTROL||PROSPECTIVE|||||||
33748812|NCT02068573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748813|NCT03813654|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The interventional study design describes the Field Trial only.||||
33857136|NCT01461239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857137|NCT04823715|||COHORT||RETROSPECTIVE|||||||
33748814|NCT02558010|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33748815|NCT00248729|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33748816|NCT04879862|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The first 8 participants will be assigned to a group. Once technology is developed the last 8 participants will be randomized to a group.||||
33748817|NCT03671096|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33748818|NCT06373822|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748819|NCT03297580|||COHORT||PROSPECTIVE|||||||
33748820|NCT01921569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748821|NCT05928598|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Enrollment for the trial will include 76 participants for the standard care arm and will include 76 participants for the intervention arm (who will receive the Epilepsy Visit Planner). The study team will enroll for the standard arm and then for the intervention arm. Additionally, approximately 10 providers will be enrolled for an approximate total of 162 participants.||||
33748822|NCT01032577|||COHORT||PROSPECTIVE|||||||
33857138|NCT03559478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the intervention as they will be under anaesthetic whilst the procedure is being carried out.|A total of 70 participants will be randomized in a 1:1 ratio to either Treatment Group 1 (sharp dissection with scalpel plus electrocautery to obvious vessels) or Treatment Group 2 (electrocautery for all dissection) using the sealed opaque envelope randomization technique.|t|f|f|f
33857139|NCT04547673|||OTHER||PROSPECTIVE|||||||
33857140|NCT04531215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857141|NCT05373589|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33857142|NCT03171831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857143|NCT03463967|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33857144|NCT05974774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857145|NCT02489903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857146|NCT05738031|||COHORT||PROSPECTIVE|||||||
33857147|NCT03726814||SEQUENTIAL||TREATMENT||NONE||||||
34063165|NCT06730841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063166|NCT05676476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063167|NCT05983575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857148|NCT02667717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857149|NCT00793000|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33857150|NCT04040400|NA|SEQUENTIAL||TREATMENT||NONE||"The resection procedure should be performed with image guidance (neuronavigation) with standard surgical technique.~Optimal balloon applicator size will be selected with accordance to tumor bed/cavity geometry and adjacent normal brain parenchyma by the team of surgeons and radiation oncologists.~The radiation oncologist will place the miniature x-ray source inside the balloon shaped catheter placed inside the tumor cavity. Radiotherapy will be initiated by the treating radiation oncologist for a defined time interval calculated by the machine planning software.~After IORT has been delivered, the surgeon will remove the balloon applicator. Surgery will be continued in the regular fashion without additional requirements."||||
33857151|NCT01545570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857152|NCT06243419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857153|NCT00091585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857154|NCT03993912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857155|NCT00994500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857156|NCT05902182|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063168|NCT05467670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063169|NCT05119569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor will also be blinded.||t|f|t|f
34169209|NCT04959747|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subjects of both groups will be randomly assigned into 2 groups, the acupuncture group or the control (sham) acupuncture group with 1:1 ratio. For randomization, simple, complete non-sequential random numbers will be generated in advance by a computer program in a block of four, and kept by the principal investigator. After a patient's eligibility is confirmed, a randomization number which corresponds to the group allocation will be provided to the acupuncturist by the PI. This arrangement will ensure that the clinical assessor and participants are blinded to the allocation.|single blinded, randomized sham controlled, cross-over clinical trial|t|f|f|f
34169210|NCT00064363||||TREATMENT||NONE||||||
34169211|NCT05259345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34169212|NCT01645072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748823|NCT04386096|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34169213|NCT06352541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind.|Phase I, controlled, comparative, parallel groups, double blind, one center.|t|t|t|t
34169214|NCT02168114|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169215|NCT04510649|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34169216|NCT06115616|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169217|NCT00389948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169218|NCT04014179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748824|NCT03960190|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The Investigational Device used for this study, is an electric breast pump, intended to express and collect milk from the breast of a lactating woman. Both the 1K and 2K expression kit will be tested in single and double pumping regime.||||
33748825|NCT04295226|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33857157|NCT02609854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857158|NCT01019512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33857159|NCT02601196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857160|NCT01740323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857161|NCT02877160|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857162|NCT05404308|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective randomized trial||||
33857163|NCT05573087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857164|NCT02513888|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33857165|NCT01538797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33857166|NCT01249430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857167|NCT04266665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857168|NCT02027623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33857169|NCT03546933|||COHORT||PROSPECTIVE|||||||
33857170|NCT01769066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857171|NCT01222507|||||PROSPECTIVE|||||||
33857172|NCT02065141|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857173|NCT00221247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169219|NCT04357535|||COHORT||PROSPECTIVE|||||||
34169220|NCT02634385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169221|NCT05028192|||COHORT||PROSPECTIVE|||||||
34169222|NCT02641847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748826|NCT00786929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857174|NCT04692870|||CASE_ONLY||PROSPECTIVE|||||||
33857175|NCT02715154|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857176|NCT02673957|||COHORT||CROSS_SECTIONAL|||||||
33857177|NCT03565731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857178|NCT00202566|RANDOMIZED|PARALLEL||||DOUBLE||||||
33857179|NCT05521802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857180|NCT00707512|||COHORT||PROSPECTIVE|||||||
33857181|NCT03595839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857182|NCT03372356|||COHORT||PROSPECTIVE|||||||
33857183|NCT02762253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857184|NCT05610176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857185|NCT03541096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33857186|NCT00014313||||TREATMENT||NONE||||||
33857187|NCT04028882|||COHORT||PROSPECTIVE|||||||
34169223|NCT04921566|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34169224|NCT03728465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169225|NCT05811780|||COHORT||PROSPECTIVE|||||||
34169226|NCT00527735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857188|NCT02092220|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857189|NCT00221169|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857190|NCT04674670|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded randomized placebo-controlled between-within-subject cross-over design with repeated measures; Participants and experimenter will be blinded through out the complete data collection. In addition, participants are not fully instructed about the purpose of the specific tests during the test session, but will be debriefed after final testing session.|The drugs that will be used in this study will not be utilised as therapeutic clinical interventions, but as modulators of endogenous process and to assess psychobiological mechanisms in pain processing. Healthy controls will be administered with placebo or a dopamine agonist (bromocriptine) or a dopamine antagonist (amisulpride) on separate days to investigate the role of dopamine and fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational component of pain. Fibromyalgia patients receive only placebo or a dopamine agonist to see the effects of normalization of dopamine on fronto-striatal connectivity and BOLD response, because a lowered dopamine level is assumed to decrease the emotional-motivational component of pain.|t|f|t|f
33857191|NCT05131620|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant)|3 Group randomized|t|f|f|f
34169227|NCT04702412|NA|SINGLE_GROUP||SCREENING||NONE||Pilot study with a mixed method type 3 implementation-effectiveness hybrid design||||
34169228|NCT06440473|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34169229|NCT03358277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169230|NCT00225901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169231|NCT05918796|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33748827|NCT03185611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33748828|NCT02504073|||OTHER||OTHER|||||||
33748829|NCT04981665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748830|NCT03989466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748831|NCT02493998|||CASE_ONLY||PROSPECTIVE|||||||
33748832|NCT06636357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748833|NCT00389558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33748834|NCT02967185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748835|NCT04672551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who ascertain the primary outcome variable, i.e. CAPS scores, will be blind to the subject's treatment condition. Randomization will be conducted by a person outside of the study team.|Randomized controlled trial. The efficacy of the standardized trauma-focused procedure in terms of a reduced PTSD symptom level will be tested against a passive waitlist control group.|f|f|f|t
33748836|NCT00788996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748837|NCT04567537|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will be performing a prospective cohort study, where the entire lesion will receive laser treatment.||||
33748838|NCT04916223|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33748839|NCT01253993|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33748840|NCT02299362|||COHORT||PROSPECTIVE|||||||
33748841|NCT06267053|||CASE_ONLY||CROSS_SECTIONAL|||||||
33748842|NCT04223180|||COHORT||PROSPECTIVE|||||||
33748843|NCT02293629|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33857192|NCT06445283|||CASE_ONLY||OTHER|||||||
34169232|NCT00963391|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169233|NCT04291612|||COHORT||PROSPECTIVE|||||||
34169234|NCT05221411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169235|NCT02316730|RANDOMIZED|CROSSOVER||||NONE||||||
34169236|NCT02863614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33857193|NCT05924685|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be 1:1 randomised to:~1. Continue immunosuppressive therapy with MMF/MPA~2. Replace immunosuppressive therapy with MMF/MPA by everolimus"||||
34169237|NCT04666285|||COHORT||PROSPECTIVE|||||||
34169238|NCT01885156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169239|NCT03824041|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34169240|NCT04503746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169241|NCT06154811|||COHORT||PROSPECTIVE|||||||
34169242|NCT04019899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169243|NCT01357226|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169244|NCT06372626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169245|NCT01747512|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169246|NCT05583487|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|All teams will be asked to progressively mobilize the ventilated neurosurgery patient they are assigned to during the shift. Each team will be blinded to whether or not they will be utilizing the nurse-led mobility protocol or standard mobility procedures until arrival at the patient's room during the assigned mobility time.|This study will consist of a quasi-experimental research design to examine causality between two or more variables by comparing groups following an intervention. Although the intervention itself will be randomly assigned/administered to each of the multidisciplinary groups for this proposed research study, true randomization of participants cannot be achieved. This is primarily due to each patient having a pre-assigned multidisciplinary care team for each shift. Changing this patient assignment would compromise patient safety while interfering with continuity of care and workflow, which hospital units strive to achieve. By applying the purpose and elements of a quasi-experimental approach to this proposed research study, researchers can determine if an intervention/active independent variable consisting of a nurse-led mobility protocol, has an effect on the outcome measure of teamwork perceptions , which will serve as dependent variables.|f|t|f|f
34169247|NCT04616755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study casts will be scanned without name just with a number and assessor do not know which group they belong to.|Three groups with different retention devices|f|f|f|t
34169248|NCT02789059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169249|NCT00949429|||COHORT||PROSPECTIVE|||||||
34169250|NCT04147689|NA|SINGLE_GROUP||TREATMENT||NONE||One group of patient treated with DESIRIAL® PLUS (injection in labia majora)||||
34169251|NCT06227871|||COHORT||RETROSPECTIVE|||||||
34169252|NCT04400357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169253|NCT03614117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is an interventional, randomized, double-blind, placebo-controlled, parallel-group study.|t|t|t|t
34169254|NCT01637415|||COHORT||PROSPECTIVE|||||||
34169255|NCT06056492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169256|NCT02314052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169257|NCT00343265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169258|NCT00507169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169259|NCT02798250|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34169260|NCT06360822|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34169261|NCT05904561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169262|NCT00072007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169263|NCT01664910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169264|NCT01773317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34169265|NCT00210717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169266|NCT03894488|||CASE_ONLY||PROSPECTIVE|||||||
34169267|NCT02028923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169268|NCT02584179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169269|NCT06236971|||COHORT||PROSPECTIVE|||||||
34169270|NCT03798613|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34169271|NCT04807998|||COHORT||PROSPECTIVE|||||||
33857194|NCT00232141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857195|NCT00846547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857196|NCT00219648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857197|NCT02442323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857198|NCT06200831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857199|NCT04098965|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33857200|NCT01874860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169272|NCT05005481|||COHORT||PROSPECTIVE|||||||
34169273|NCT06002269|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Dietitians will be masked to study group.|BOOST Box intervention compared with usual care.|f|t|f|f
34169274|NCT02626585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169275|NCT04274816|NA|SINGLE_GROUP||TREATMENT||NONE||Seven days before undergoing a SNB, clinical stage I/II melanoma patients will be treated with an intradermal injection of tremelimumab, around the excision site of the primary tumor. Escalating doses of 2, 5, 10, or 20 mg of tremelimumab will be given (3 patients per dose level with an expansion at the optimal dose level with an additional 5 patients).||||
34169276|NCT04235517|||COHORT||PROSPECTIVE|||||||
34169277|NCT06276998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063170|NCT04140916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistical analyses of the outcomes will be performed by a statistician being blinded.|Patients will be randomized to either the control Group (PICC-line catheter) or the intervention Group (Midline catheter) using an online Tool (Research Electronic Data Capture (REDCap), Aarhus University, Denmark).|f|f|f|t
34063171|NCT00919542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063172|NCT03934359|NA|SINGLE_GROUP||TREATMENT||NONE||A phase Ⅰ,multi-center, open-label||||
34063173|NCT02984514|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959205|NCT05414019|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|"Observation:~Each patient will be followed up on periodic base for progress evaluation and integrity checks, as well as root resorption will be evaluated using CBCT images taken before and after the intrusion.~Ethical considerations:~An informed consent form (attached copy) that explains every step in the research will be given and discussed carefully with the patient and his/her parents before participation in the study and should be signed freely. The objectives of the study will be discussed and explained with the patients and / or their guardians and they will receive a copy of the consent form as well.~Data management and analysis:~The data will be collected, tabulated, and statistically analyzed using Statistical Package for Social Sciences (SPSS program, version 18, Inc., Chicago, III)."|The total sample of patients will be randomly divided into three equal groups: Miniscrew: 7 patients will receive an intrusive force delivered by elastics from 2 miniscrews between mandibular lateral incisor and mandibular canine. Utility arch: 7 patients will receive an intrusive force delivered by intrusive utility arch. Nitinol reverse curve wire: 7 patients will receive an intrusive force delivered by Nitinol reverse curve wire.||||
33893580|NCT05391438|NA|SINGLE_GROUP||OTHER||NONE||proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose. The primary endpoints will be glucose, insulin, and C-peptide area under the curve, insulinogenic index, and glucose variability as captured by percent time in range on CGM following the test meal.||||
33893581|NCT01076179|||COHORT||PROSPECTIVE|||||||
33959206|NCT06702540|||COHORT||RETROSPECTIVE|||||||
33959207|NCT05262023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959208|NCT02344914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959209|NCT06146504|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study will be double-blinded in that the study participants and the Citruslabs team will be blinded to the intervention or product allocation. Only the sponsor will know which product contains the active ingredients. After the study analysis is complete, the allocation will be unblinded.|Group A = the intervention group Group B = the placebo group|t|t|t|f
33959210|NCT04418115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician is not involved in any other aspect of the study, hence we can secure that the evaluation of the outcomes are done blinded to group allocation.|The study is a pragmatic, mixed-method, randomized controlled trial|f|f|f|t
33959211|NCT06703476|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study will use a cluster randomized trial design with crossover wherein surgeons will be cluster randomized for periods of 3 months to use or not use stents and to administer or not administer alvimopan. In addition, a factorial design will be used wherein the 2 study interventions (use of stents and use of alvimopan) will be investigated in the same group of patients.||||
33959212|NCT06419803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959213|NCT03327142|||COHORT||RETROSPECTIVE|||||||
34063174|NCT06730191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063175|NCT03385369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34063176|NCT00688922|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063177|NCT03365453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063178|NCT05366010|NA|SINGLE_GROUP||PREVENTION||NONE||Study subjects will serve as their own control. Medical records will be reviewed for each study subject for the twelve-month period prior to initiation of OLE therapy. The study will compare the frequency of exacerbations experienced prior to treatment with OLE to the frequency of exacerbations experienced in the active treatment period, during which study subjects receive treatment with The Volara® System. In addition, specific healthcare utilization indicators including hospitalizations, antibiotic use, and emergency department (ED) visits for pulmonary complications will be documented for each study period.||||
34063179|NCT04856631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063180|NCT02818426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063181|NCT04588597|||CASE_ONLY||RETROSPECTIVE|||||||
34063182|NCT03661216|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double (participant and investigator) and outcomes assessor|Double-blind, randomized, placebo-controlled, cross-over study.|t|t|t|t
34063183|NCT00858715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063184|NCT05276011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34169278|NCT05853341|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34169279|NCT02860585|||COHORT||RETROSPECTIVE|||||||
34169280|NCT04107246|||COHORT||PROSPECTIVE|||||||
34063185|NCT04667533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063186|NCT03953625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063187|NCT02604173|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34063188|NCT02755441|||COHORT||PROSPECTIVE|||||||
34063189|NCT06731270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063190|NCT05170230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This study is a prospective, comparative, double-blinded randomized placebo-controlled trial and multi-center study that will be conducted at Wael ElBanna Clinic and the NRC site~The study materials that will be used will include blood tests and ultrasound. The study will involve three study arms:~* Arm 1: intracapsular myomectomy Terlipressin injection in women undergoing laparoscopic myomectomy procedure~* Arm 2: intracapsular myomectomy Carbetocin injection in women undergoing laparoscopic myomectomy procedure~* Arm 3: intracapsular myomectomy saline injection in women undergoing laparoscopic myomectomy procedure Subjects who meet diagnostic requirements as listed in the inclusion and exclusion criteria will be included in the study. Women will be randomized to one of the three arms using a computer-generated randomization table with a 1:1:1 group allocation."|t|t|t|f
34063191|NCT04343365|||CASE_ONLY||PROSPECTIVE|||||||
34063192|NCT05582187|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is an open label, single dose, parallel cohort study||||
34063193|NCT04893460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063194|NCT04126642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169281|NCT04792736|||COHORT||PROSPECTIVE|||||||
34169282|NCT01548027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169283|NCT06387823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169284|NCT02703298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169285|NCT05822557|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, longitudinal, 28-day intervention study with a 7-day baseline period.||||
34169286|NCT01331603|||CASE_ONLY||PROSPECTIVE|||||||
34169287|NCT03481335|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a parallel 26-community cluster randomized controlled trial. A community cluster design was chosen as CHAP-P is intended as a community-level intervention. Thirteen communities (barangays) will receive the CHAP-P sessions and will be considered intervention, while the other 13 communities will receive care as usual and will be considered control. Measures of individual participants will be taken as a repeated cross-sectional sample at baseline and at six months. A community process evaluation and cost-effectiveness evaluation will also be undertaken.||||
34169288|NCT04954755|||CASE_CONTROL||OTHER|||||||
34169289|NCT03295435|||COHORT||CROSS_SECTIONAL|||||||
33748844|NCT04396834|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33748845|NCT05629351|||CASE_CROSSOVER||PROSPECTIVE|||||||
33748846|NCT06052449|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33748847|NCT00342862|||COHORT||PROSPECTIVE|||||||
33748848|NCT03182868|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33748849|NCT01475136|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33748850|NCT05634395|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33748851|NCT05244473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748852|NCT01022437|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33748853|NCT02271958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748854|NCT04714125|||COHORT||PROSPECTIVE|||||||
33748855|NCT03398005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748856|NCT04051372|||COHORT||PROSPECTIVE|||||||
33748857|NCT00000392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33893582|NCT05212051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Priticipant,Care provider and investigators are masked in this study|Parallel|t|t|t|f
33893583|NCT04168086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to what group they are assigned to||t|f|f|f
34169290|NCT02388581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169291|NCT05369663|||COHORT||PROSPECTIVE|||||||
34169292|NCT01942096|||COHORT||PROSPECTIVE|||||||
33748858|NCT06219759|||COHORT||PROSPECTIVE|||||||
33748859|NCT01766557|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748860|NCT01512225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748861|NCT06185803|||COHORT||OTHER|||||||
33748862|NCT03886818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748863|NCT05046353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748864|NCT04475913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33748865|NCT00990158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748866|NCT02270450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893584|NCT02083276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169293|NCT02313259|||OTHER||PROSPECTIVE|||||||
34169294|NCT03408197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34169295|NCT06018844|||COHORT||PROSPECTIVE|||||||
34169296|NCT01745926|||COHORT||PROSPECTIVE|||||||
34169297|NCT03309566|RANDOMIZED|CROSSOVER||OTHER||NONE||Single-dose, two-way crossover.||||
33959214|NCT03408236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959215|NCT06401603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959216|NCT02406365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959217|NCT06424704|||COHORT||PROSPECTIVE|||||||
33959218|NCT03290911|||COHORT||RETROSPECTIVE|||||||
33959219|NCT05092451|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959220|NCT06203340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Posttest and control grouped randomized controlled clinical trial|t|f|f|t
33959221|NCT03035981|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33959222|NCT05211037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959223|NCT02499406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959224|NCT04741945|NA|SINGLE_GROUP||OTHER||NONE||||||
34169298|NCT04674891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959225|NCT06704113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959226|NCT00424931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169299|NCT00633971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959227|NCT05218317|||CASE_CONTROL||PROSPECTIVE|||||||
33959228|NCT05077904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959229|NCT03567330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors and analysts will be blinded to treatment condition. Participants and providers cannot be effectively blinded to treatment condition.|Group (cluster) randomized trial. Total number of participants is 200, including 100 men and 100 women.|f|f|f|t
33959230|NCT05121779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063195|NCT05393934|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non randomized and controlled study design||||
34169300|NCT04664153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169301|NCT00181363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169302|NCT04957797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Nine matched-paired fresh frozen human cadaveric knees were randomly distributed into two groups: Flat-tunnel (FLT) group and round-tunnel (ROT) group. One knee from each pair was reamed with flat tunnel, while the contralateral knee was reamed with round tunnel.|f|f|t|t
34169303|NCT01317758|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169304|NCT04462835|||CASE_ONLY||RETROSPECTIVE|||||||
34169305|NCT05936112|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34169306|NCT06347198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169307|NCT04716426|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A participating researcher not involved in the recruitment and evaluation of the volunteers will carry out the randomization process. This researcher will be instructed not to disclose the randomization codes in the intervention groups to any of the volunteers and to the other researchers involved in the study, until its completion. The intervention bottles will be exactly the same regardless of whether it is APT™ T3X or placebo.||t|t|t|t
33748867|NCT05714189|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Women were able to choose themselves whether to adhere to a diet, and to which diet, or to adhere to the control group.|Women could chose to adhere to a diet or the control group. there was no cross-over.||||
33748868|NCT00806312|||CASE_CONTROL||PROSPECTIVE|||||||
33748869|NCT06004310|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study will be a quasi-experimental study and carried out at Bangabandhu Sheikh Mujib Medical University. A consecutive sampling method will be used. The participants will engage in a comprehensive 06-weeks outpatient multimodal and multidisciplinary pulmonary rehabilitation program.||||
33748870|NCT05477745|||CASE_ONLY||RETROSPECTIVE|||||||
33748871|NCT02137369|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33748872|NCT04871490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748873|NCT05373251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748874|NCT00146835|||COHORT||PROSPECTIVE|||||||
33748875|NCT01303666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33748876|NCT06093113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention group and active control group.||||
33748877|NCT05230238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748878|NCT01297062|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33748879|NCT04764396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The pathologist will be blinded to the allocation|After the amendment (Ame00126774) 98 more participants will be randomized.|t|f|f|t
33748880|NCT01454583|||CASE_ONLY||PROSPECTIVE|||||||
33748881|NCT06300008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748882|NCT05989633|||COHORT||PROSPECTIVE|||||||
33748883|NCT01319396|||CASE_ONLY||CROSS_SECTIONAL|||||||
33748884|NCT06670716|||CASE_CONTROL||PROSPECTIVE|||||||
33748885|NCT00735046|||||PROSPECTIVE|||||||
33748886|NCT04669496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959231|NCT00046020||||TREATMENT||||||||
33959232|NCT06701643|||COHORT||PROSPECTIVE|||||||
33959233|NCT06580184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34063196|NCT05807672|||OTHER||PROSPECTIVE|||||||
34063197|NCT05976035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator administering the treatment and the investigator performing the assessment will be different. The assessor will not know about the interventions that the participants received.|Participants will be divided into two groups with equal numbers by computer randomization method.|f|f|f|t
33959234|NCT04380701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959235|NCT05151822|NA|SINGLE_GROUP||OTHER||NONE||||||
33959236|NCT03740828|||COHORT||PROSPECTIVE|||||||
33959237|NCT06585943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to group allocation|prospective, single-center, parallel group, rater-blind, pragmatic randomized clinical trial|f|f|f|t
33959238|NCT06311565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled ( experimental and control group)|t|f|f|f
33959239|NCT03275168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single blind||f|f|t|t
33959240|NCT06206421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959241|NCT01785472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959242|NCT00050752|||CASE_ONLY||PROSPECTIVE|||||||
33959243|NCT01822964|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959244|NCT00099320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959245|NCT05048342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959246|NCT00479739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063198|NCT06146049|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169308|NCT01774032|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34169309|NCT00809900|||COHORT|||||||||
33748887|NCT03385837|||COHORT||PROSPECTIVE|||||||
33748888|NCT01780922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33748889|NCT04486352|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748890|NCT03019068|||OTHER||RETROSPECTIVE|||||||
33748891|NCT05852951|||COHORT||PROSPECTIVE|||||||
33748892|NCT00357864|||||PROSPECTIVE|||||||
33748893|NCT04152018|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33748894|NCT02266069|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748895|NCT06147895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33748896|NCT05789433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33748897|NCT01956526||||TREATMENT||NONE||||||
33748898|NCT03775850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to one of three cohorts based on disease condition: Cohort A (microsatellite stable colorectal cancer); Cohort B (Triple negative breast cancer); Cohort C (PD-1 relapsed tumors: non small cell lung cancer, gastroesophageal cancer, or any microsatellite unstable or renal cell carcinoma). Patients will receive monotherapy with EDP1503 for a period of 2 weeks, following which they will be dosed with a combination of EDP1503 and pembrolizumab.||||
33748899|NCT03007927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33748900|NCT06495879|||CASE_ONLY||CROSS_SECTIONAL|||||||
33748901|NCT00680212|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33748902|NCT00801775|||COHORT||PROSPECTIVE|||||||
33748903|NCT06187467|||COHORT||PROSPECTIVE|||||||
33748904|NCT06009341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748905|NCT01703364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748906|NCT02232113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748907|NCT05932134|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will randomly stratify into four groups: (1) Usual care (UC), (2) UC + high protein diet (HP), (3) UC + HP + core muscle rehabilitation, (4) UC + HP + core muscle rehabilitation + neuromuscular electric stimulation (NMES).~Researchers will compare group 2,3,4 to control group (1, usual care) to see if high protein diet, core muscle rehabilitation, neuromuscular electric stimulation works."||||
33748908|NCT02147548|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33748909|NCT06669195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748910|NCT03472079|||COHORT||RETROSPECTIVE|||||||
33748911|NCT02747134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748912|NCT03326687|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will receive both the isolated and combined treatments in an ABAB or BABA order of phases.||||
33748913|NCT03526250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748914|NCT01913600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748915|NCT03942250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748916|NCT05677087|NA|SINGLE_GROUP||OTHER||NONE||||||
33748917|NCT06108167|||CASE_ONLY||RETROSPECTIVE|||||||
33748918|NCT00242112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748919|NCT06104475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748920|NCT01460329|||COHORT||PROSPECTIVE|||||||
33748921|NCT05674422|||COHORT||PROSPECTIVE|||||||
33748922|NCT05719454|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||All subjects will undergo in visits 4 and 5 two sessions to test two different setup CNT Algorithms. One version will favor atrial pacing. The order of the setup versions will alternate, whereby subjects will start with setup version 1 or setup version 2 Subjects will be sequentially assigned to Version 1 or 2 on alternating basis: first subject to Version 1, second to Version 2, third to Version 1, etc. hey will also undergo setup without the use of an algorithm, similar to the method used in the MODERATO II study.||||
33748923|NCT05328518|||COHORT||PROSPECTIVE|||||||
33748924|NCT04514159|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the same treatment but ZN-c5 will be given at different doses in this dose escalation study.||||
33748925|NCT00738777|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33748926|NCT06390241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748927|NCT01603576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748928|NCT06451172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748929|NCT04805723|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33748930|NCT01055769|RANDOMIZED|CROSSOVER||||NONE||||||
33748931|NCT04020770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748932|NCT06669234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748933|NCT05073016|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33748934|NCT06204731|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33765896|NCT03380663|RANDOMIZED|PARALLEL||PREVENTION||NONE||A multi-center randomized control study, including single-treatment and repeated treatment trials on individuals suffering from heart failure and healthy control subjects.||||
33765897|NCT04457713|||COHORT||PROSPECTIVE|||||||
33765898|NCT00058227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959247|NCT04404530|||CASE_ONLY||PROSPECTIVE|||||||
33959248|NCT01266915|||COHORT||PROSPECTIVE|||||||
34169310|NCT04101071|RANDOMIZED|PARALLEL||OTHER||DOUBLE||SIngle blinded, randomised, controlled feasibility study|t|f|f|t
34169311|NCT01239849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169312|NCT01166841|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34169313|NCT04800250|RANDOMIZED|PARALLEL||TREATMENT||NONE||Case-control||||
34169314|NCT05283551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34169315|NCT02110563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893585|NCT00303810||||TREATMENT||NONE||||||
34169316|NCT01844388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169317|NCT00815217|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34169318|NCT05342558|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34169319|NCT02932137|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34169320|NCT04404868|||COHORT||CROSS_SECTIONAL|||||||
34169321|NCT01113359|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34169322|NCT03656939|||COHORT||OTHER|||||||
33748935|NCT04091139|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is to examine the effect of transdiagnostic cognitive behavioural therapy (Unified Protocol for adolescents, UP-A), in comparison with treatment-as-usual, in the reduction of depressive and anxiety symptoms among adolescents with common mental disorders.~All participants would be randomized into one of the two treatment arms, namely UP-A treatment condition (UP-A) and treatment-as-usual (TAU) condition. Following randomization, participants in UP-A condition would attend individual psychological treatment based on UP-A, which last for 10 to 12 weeks. Participants in the TAU condition would be provided with usual clinical psychological service (i.e. treatment as usual) in the first 12 weeks before they start attending the same individual treatment program based on UP-A."||||
33748936|NCT02959996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748937|NCT05361031|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, repeat dose, open label, phase I/IIA clinical study||||
33893586|NCT03323749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893587|NCT03404362|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893588|NCT00499551|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893589|NCT05912023|||COHORT||PROSPECTIVE|||||||
33893590|NCT00005487|||COHORT||PROSPECTIVE|||||||
33893591|NCT00896961|NA|SINGLE_GROUP||||NONE||||||
33893592|NCT01312194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893593|NCT04288245|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||TRIPLE||Double blind, randomized placebo controlled, optional open-label extension design|t|t|t|f
33748938|NCT02341417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748939|NCT06609005|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33748940|NCT04880564|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748941|NCT02073084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33748942|NCT02936557|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33748943|NCT05465226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a single-center, prospective, case-controlled trial. Intervention arm patients will be randomly matched 2:1 to a historical comparator, based on age, TBSA, number of surgeries, and opioid and illicit drug use histories||||
33748944|NCT00058123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748945|NCT03592212|||CASE_ONLY||OTHER|||||||
33748946|NCT03695172|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to one of three treatment groups, TAP, QL, or ESP blocks||||
33748947|NCT05233228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33748948|NCT03946943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748949|NCT03137303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33748950|NCT01564550|||CASE_CONTROL||PROSPECTIVE|||||||
33748951|NCT06669806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748952|NCT04790318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33748953|NCT00297154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748954|NCT02298192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765899|NCT01282671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893594|NCT05634603|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33893595|NCT04964258|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33959249|NCT00364273|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33959250|NCT06383143|||CASE_ONLY||PROSPECTIVE|||||||
34169323|NCT06260566|NA|SINGLE_GROUP||OTHER||NONE|N/A. No Masking|"The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication."||||
34169324|NCT05588349|RANDOMIZED|PARALLEL||TREATMENT||NONE||Dry needling plus stretching exercise versus stretching exercise alone||||
34169325|NCT03416855|||COHORT||PROSPECTIVE|||||||
34169326|NCT02702466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169327|NCT03430791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, phase II trial with two parallel arms, two-stage design and appropriate stopping rules for poor efficacy. Arm A will enroll participants without prior PD1/PDL1 checkpoint inhibitor, while Arm B will enroll participants with prior PD1/PDL1 checkpoint inhibitor. The investigator expect to enroll at least 30 (15 in each Arm) and a maximum of 60 (30 in each Arm) evaluable subjects. All subjects will receive tumor treating field (TTF) therapy plus nivolumab infusions for a maximum of 24 months, plus/minus concurrent ipilimumab for a maximum of 4 doses.||||
34169328|NCT02724332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169329|NCT02162550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169330|NCT02461654|||COHORT||PROSPECTIVE|||||||
34169331|NCT01842802|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34169332|NCT05439044|||COHORT||RETROSPECTIVE|||||||
34169333|NCT02216708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857201|NCT05488223|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|"Preparation of the intervention products, to blind the study. ω-3 PUFAs (Triple Strength Fish Oil®) were purchased in advance, each capsule contained 540 mg of eicosapentaenoic acid (20:5 n-3) and 360 mg of docosahexaenoic acid (22:6 n-3), for a 0.9g total. Likewise, a commercial brand of avocado oil (AcAg) was purchased in advance, putting the same amount in each capsule. The appearance of the ω-3 PUFA capsules and the AcAg capsules were the same. Then we worked with the company that prepared the blinding of the treatments, packaging bottles of 30 capsules each, labeling them as bottles A and B. The design contemplated giving each child two bottles, one marked to take it for breakfast and another marked to take it with food.~The content of each of the capsules was saved as a code that was unknown to the participants, the care provider, or the researchers. The codes were opened until the end of the study."|Subject to written informed consent, children who agreed to participate were randomly assigned to the following treatment groups. Group 1. Two daily capsules of ω-3FAs; Group 2. Two daily capsules, one of ω-3FAs of 0.9 g + 1 capsule of avocado oil (AcAg) of 0.9 g and; Group 3. Two daily capsules of 0.9 g of AcAg.|t|t|t|f
33857202|NCT00714597|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33857203|NCT05380492|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The Phase 1 cohorts will be open-label, the Phase 2a cohort will be masked.|The Phase 1 will enroll in a dose escalation study model (three sequential cohorts), followed by a Phase 2a cohort that will be randomized among a maximum tolerated dose arm, a lower dose arm, and a control arm.|t|t|t|t
33959251|NCT04805658|||COHORT||PROSPECTIVE|||||||
33959252|NCT05359003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized, controlled trial with a two-arm, parallel group design with a wait-list education||||
33959253|NCT06290739|||COHORT||RETROSPECTIVE|||||||
34063199|NCT06730230|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"With the stepped-wedge design, each clinic will function as a control or usual care group prior to the implementation of the intervention. During this period, the clinic will prescribe and treat patients enrolled in the RPM hypertension program using usual protocols."||||
34063200|NCT04116541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063201|NCT06308536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063202|NCT01531595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063203|NCT02658383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063204|NCT04492072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063205|NCT06124586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063206|NCT05833828|||COHORT||PROSPECTIVE|||||||
33857204|NCT00093808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857205|NCT00916825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857206|NCT03401541|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each arm will first receive 25(OH)D and then vitamin D or vitamin D and then 25(OH)D|t|f|t|f
33959254|NCT01031134|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34063207|NCT01649908|||||PROSPECTIVE|||||||
34063208|NCT06721312|||COHORT||PROSPECTIVE|||||||
34063209|NCT06083480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, randomized, controlled, mixed between/within-subject longitudinal trial|t|t|t|t
34063210|NCT03409445|||COHORT||RETROSPECTIVE|||||||
34063211|NCT00877708|||CASE_CONTROL||PROSPECTIVE|||||||
34063212|NCT02826577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34063213|NCT06731335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Feasibility trial|t|f|t|t
34063214|NCT04057664|||COHORT||PROSPECTIVE|||||||
34063215|NCT00550667|||CASE_CONTROL||OTHER|||||||
34063216|NCT00763516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063217|NCT02777281|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959255|NCT03402945|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Blinded adjudication of the s-SSIs will be performed by a committee consisting of three members.|1) cefazolin prophylaxis plus Prevena\*(\*diabetic and/or obese patients (BMI \>30kg/m2)) 2) cefazolin and vancomycin prophylaxis plus Prevena\*(\*diabetic and/or obese patients (BMI \>30kg/m2)), 3) cefazolin prophylaxis plus standard wound dressing, 4) cefazolin and vancomycin prophylaxis plus standard wound dressing.|f|f|f|t
33959256|NCT01596049|||COHORT||PROSPECTIVE|||||||
33959257|NCT05218031|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm randomised trial will be conducted (brief ACT-based intervention vs. waiting-list control group)||||
34063218|NCT06729957|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|All study outcomes are extracted from electronic health records and healthcare claims data that cannot be manipulated by the study team.|Care coordinators will be randomized to care navigation arm or services as usual arm at study outset and switch to the opposite arm halfway through the study.|f|f|f|t
34063219|NCT02472626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063220|NCT06719765|||OTHER||CROSS_SECTIONAL|||||||
34063221|NCT00167401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169334|NCT03255902|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This feasibility study will be a mixed methods non-randomized trial to examine the feasibility of combining a parent skill training intervention with a family evening routine intervention. Evidence of feasibility will include attendance, activities completed, and interviews.||||
34169335|NCT05308992|NA|SINGLE_GROUP||OTHER||NONE||||||
34169336|NCT01836588|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169337|NCT02326064|||COHORT||PROSPECTIVE|||||||
34169338|NCT00675402|||COHORT||PROSPECTIVE|||||||
33857207|NCT02262143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857208|NCT02972125|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857209|NCT00681746|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857210|NCT00219622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857211|NCT05310487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857212|NCT00455338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857213|NCT01504880|||COHORT||PROSPECTIVE|||||||
33959258|NCT02802007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959259|NCT02377687|||COHORT||PROSPECTIVE|||||||
33959260|NCT06386185|||CASE_CONTROL||RETROSPECTIVE|||||||
33959261|NCT06220838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959262|NCT03470896|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participant and care provider know the allocation group teleconsultation or traditional consultation."|One group : preanesthesia teleconsultation / One group : preanesthesia traditional teleconsultation / One sub-group : bis preanesthesia traditional teleconsultation|f|f|f|t
34063222|NCT02245113|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34063223|NCT03023384|||OTHER||PROSPECTIVE|||||||
34063224|NCT06654297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063225|NCT06035939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34063226|NCT03913104|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective Cohort||||
34063227|NCT06663163|||COHORT||RETROSPECTIVE|||||||
34063228|NCT02615392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169339|NCT04696263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169340|NCT04080180|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||In stage 1, participants are individually randomized (1:1) to BSM or CM. At the end of stage 1, adherent buprenorphine-naloxone participants remain in their respective intervention group during phase 2 (maintenance phase of same approach), whereas non-adherent participants are randomized (individually and 1:1) to either switch or add the respective other intervention in this part-factorial SMART. Our primary outcome is buprenorphine-naloxone adherence by the end of stage 2. This sequential randomization based on past treatment success assures that the assigned treatment option at any point in time is independent of future potential outcomes and only conditional on the subject's history, i.e., the sequential ignorable treatment assumption is satisfied by design,108 in sharp distinction to observational data where patients chose to switch/add or not to switch/add and where this assumption remains untestable.|f|f|f|t
34169341|NCT02229058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169342|NCT01562080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169343|NCT04428346|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomised with a computerised random number generator (or random number table) with block randomisation to assist with keeping participant balance between study arms with a small sample size.||f|f|t|f
34169344|NCT03453905|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized to two arms and followed prospectively||||
34169345|NCT00138749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857214|NCT06525961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857215|NCT04136665|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33857216|NCT01091753|RANDOMIZED|||TREATMENT||NONE||||||
33857217|NCT05417867|||CASE_ONLY||PROSPECTIVE|||||||
33857218|NCT01607112|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857219|NCT01100034|||COHORT||PROSPECTIVE|||||||
33857220|NCT00816686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857221|NCT06137222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, multicenter, randomized controlled clinical trial.|f|f|f|t
33857222|NCT00802009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857223|NCT00051363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857224|NCT02390830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857225|NCT02318823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33857226|NCT04987723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857227|NCT01893892|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33857228|NCT04849936|||COHORT||PROSPECTIVE|||||||
33857229|NCT01954381|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857230|NCT03188926|||CASE_ONLY||PROSPECTIVE|||||||
34063229|NCT04129840|RANDOMIZED|PARALLEL||OTHER||NONE||The intervention is a treatment algorithm (comparing two combination treatment strategies with the World Health Organization (WHO) standard and not an individual drug.||||
34063230|NCT01915524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063231|NCT04612972|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Researchers and participants are masked to Intervention group. Individual syringes are coded with a consecutive number only|"Arm 1:Investigational vaccine 1:~Inactivated SARS-CoV-2 vaccine (Vero cell) Manufacturer: Wuhan Institute of Biological Products Co., Ltd. Wuhan Institute of Virology, Chinese Academy of Sciences Specification: 200WU/dose for per human use, 0.5 mL/ dose~Arm 2: Investigational vaccine 2:~Inactivated SARS-CoV-2 vaccine (Vero cell) Manufacturer: Beijing Institute of Biological Products Co., Ltd. Specification: 4μg/dose for per human use, 0.5 mL/ dose~Arm 3: Placebo Product name: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine Active Ingredient: None; Virus Contents: None Adjuvant: aluminum hydroxide Manufacturer: Wuhan Institute of Biological Products Co., Ltd. Specification: 0.5 mL/ dose, 0.5mL for per human use"|t|t|t|t
34169346|NCT06133322|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinical research coordinators and laboratory technicians who assess health-related outcomes will be blinded to intervention assignment. Study physicians who review serious adverse events and unanticipated problems will also be blinded to intervention assignment.|Cluster randomization of 42 churches in New Orleans, Louisiana to 2 arms|f|f|f|t
33748955|NCT06667960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation phase will use a 3+3 design with enrollment of 3 patients per cohort and expansion to 6 patients in the event of a DLT. The Dose Escalation phase will determine the MTD/recommended phase 2 dose (RP2D) for Cohort Expansion.~In the Cohort Expansion phase of the study, up to 3 parallel cohorts of patients with specific tumor types, and a cohort of mixed solid tumors will simultaneously enroll and be treated to further characterize the safety, tolerability, PK, pharmacodynamics, and anti-tumor activity of JK06"||||
33748956|NCT02679690|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33748957|NCT05111236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be kept blind about group allocation and identification of the participants before assessments at baseline, after 06 weeks and 12 weeks of intervention|It is a RCT with two groups, RPT and Massage. Both groups will receive routine physical therapy (with addition of traditional massage in Massage group only) five days a week for a period of 12 weeks.|f|f|f|t
33748958|NCT01390454|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33748959|NCT01046305|||CASE_CONTROL||PROSPECTIVE|||||||
33857231|NCT05959694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169347|NCT05716555|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34169348|NCT05361369|NA|SINGLE_GROUP||OTHER||NONE||||||
33857232|NCT02940938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857233|NCT01658150|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857234|NCT03177551|||COHORT||PROSPECTIVE|||||||
33857235|NCT01274585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169349|NCT04782063|RANDOMIZED|PARALLEL||PREVENTION||NONE||Calibration of infant breast milk and formula intake: We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.||||
34169350|NCT02205996|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169351|NCT06360146|RANDOMIZED|PARALLEL||TREATMENT||NONE|Single|Randomized controlled trial||||
33857236|NCT04563338|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel with potential crossover from Arm C to Arm B.||||
33857237|NCT01205256|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33857238|NCT02960347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857239|NCT06402422|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33857240|NCT01281150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857241|NCT01143038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857242|NCT03806387|||COHORT||PROSPECTIVE|||||||
33857243|NCT04371861|||COHORT||PROSPECTIVE|||||||
33857244|NCT00005825||||TREATMENT||||||||
33857245|NCT01272804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857246|NCT04589754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857247|NCT00298090|||COHORT||PROSPECTIVE|||||||
33857248|NCT03891576|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a study built up by a randomized and a no-randomized part.~Randomized part:~Patients who either have a baseline body weight ≥58 and \<77kg, or have a baseline body weight ≥77kg and baseline platelet count \<150,000/µL (named as restricted population) will be randomly assigned to receive RADAR dosing or the SmPC dosing.~Randomization ratio will be 1:1 and will be based on a minimization procedure accounting for the following factors: i. platinum sensitivity; ii. use of bevacizumab in conjunction with the penultimate platinum based therapy; iii. best response (complete or partial) during the last platinum regimen.~No-randomized part:~Patients with weight \<58 or ≥77kg and baseline platelet count ≥150,000/µL will be enrolled into the study but not randomized."||||
33857249|NCT03048799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857250|NCT03216057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Masking intervention had made for investigation subjects and researchers|Randomized, double-blind, placebo-controlled clinical trial|t|f|t|f
33857251|NCT03939455|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33857252|NCT02330783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857253|NCT05847725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study included a three parallel group of blinded evaluators. These cases were followed up with a planned follow-up program between preoperative and postoperative three months.|f|f|f|t
33857254|NCT00369304|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857255|NCT02216643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857256|NCT06248346|||COHORT||RETROSPECTIVE|||||||
33857257|NCT04896112|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002||||
33857258|NCT04643860|||COHORT||CROSS_SECTIONAL|||||||
33857259|NCT00679653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857260|NCT04174144|||COHORT||PROSPECTIVE|||||||
33857261|NCT02880033|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33857262|NCT05303350|||COHORT||PROSPECTIVE|||||||
33857263|NCT05291767|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33857264|NCT01444209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857265|NCT02700945|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Subjects will be randomized 1:1 to the continuous monitoring arm or the control arm. Subjects randomized to the continuous monitoring arm will have a Reveal LINQ ICM inserted within 10 days of the qualifying stroke and undergo continuous remote monitoring. Subjects randomized to the control arm will be followed per site specific standard of care.||||
33857266|NCT01136811|NA|SINGLE_GROUP||OTHER||NONE||||||
33857267|NCT01474499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857268|NCT05128734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857269|NCT03993860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During grinding of sorghum powder, roasted small fish (3g/100g of sorghum) was added to the sorghum to provide a similar fish aroma as the fish product. The fish powder (12g)/ sorghum powder (12g) was then pre-packed in small plastic sachets. The participant and the field workers (research assistants and health workers) are blinded while the principal investigator (PI) is not blinded.|An independent statistician not be part of the study prepared the randomisation schedule. All eligible infants were randomly assigned to either the intervention (Chisense fish powder) or the control (placebo in the form of sorghum powder) group at 6 months. A 1:1 ratio using a computerised random number generator and block randomisation in Microsoft Excel was used to randomise the infants to two groups of equal size. The schedule was stratified by the gender of infants (boy or girl) to enable gender balance in both groups. Allocation of concealment was done using a central randomisation service through a computer algorithm to protect the randomisation schedule. If there two infants from the same household or in case of twins, they were treated as a single baby during randomisation to avoid contamination. However, each child had his or her own code and will be assessed as an individual throughout the study.|t|t|f|t
33857270|NCT00002428||||PREVENTION||DOUBLE||||||
33857271|NCT00193999|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857272|NCT01037244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857273|NCT00402597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857274|NCT01378923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33857275|NCT04086433|||COHORT||PROSPECTIVE|||||||
33857276|NCT01592864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33857277|NCT04530331|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857278|NCT03217305|NA|SINGLE_GROUP||TREATMENT||NONE|The investigator works as physician at the Department of Intensive Care. The participants are patients.|Control-Intervention-Control||||
33857279|NCT01684267|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857280|NCT05222607|||CASE_ONLY||PROSPECTIVE|||||||
33857281|NCT03765411|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857282|NCT01414777|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33857283|NCT04829929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857284|NCT02404207|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33857285|NCT03011502|NA|SINGLE_GROUP||SCREENING||NONE||||||
33857286|NCT06099847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only participants are blinded for the intervention. Care provider (physiotherapist), investigator (medical doctor, physiatrist) and outcomes assessor (medical doctor, physiatrist) are not blinded and they are know which intervention (TENS or sham stimulation) is provided to the patients.|We aim to compare sacral TENS in patients with chronic pelvic pain and compare it with sham stimulation therapy.|t|f|f|f
33857287|NCT00213291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857288|NCT02630888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857289|NCT02910154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33857290|NCT03289377|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33857291|NCT02800239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857292|NCT02225496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959263|NCT05988411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind|Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial.|t|f|f|f
33959264|NCT01258452|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169352|NCT02591810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169353|NCT01017185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748960|NCT01741623|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748961|NCT02640768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33748962|NCT05110859|||OTHER||PROSPECTIVE|||||||
33748963|NCT04543110|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm Phase II Fleming||||
33748964|NCT03842657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33748965|NCT04290754|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Cluster randomization of clinic sites|Comparative Effectiveness Study|t|t|t|f
33748966|NCT03413436|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33748967|NCT03815721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33748968|NCT00958269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33748969|NCT02647112|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33748970|NCT02007850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748971|NCT04219033|||COHORT||PROSPECTIVE|||||||
33748972|NCT01178086|||COHORT||PROSPECTIVE|||||||
33748973|NCT05005832|||COHORT||PROSPECTIVE|||||||
33857293|NCT00744185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857294|NCT05239351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, open-label, non-randomized clinical investigation||||
33857295|NCT05535465|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized - Step-wedged design||||
33857296|NCT02583087|||COHORT||PROSPECTIVE|||||||
33959265|NCT06540482|||OTHER||PROSPECTIVE|||||||
33748974|NCT00373776|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748975|NCT01181050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959266|NCT00438295|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959267|NCT03596086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959268|NCT02786186|||COHORT||PROSPECTIVE|||||||
33959269|NCT06245369|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33959270|NCT06540898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959271|NCT01938742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169354|NCT00881738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857297|NCT02907138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857298|NCT04905147|RANDOMIZED|PARALLEL||OTHER||SINGLE||The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.|f|f|t|f
33857299|NCT02397811|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33857300|NCT04799483|||COHORT||PROSPECTIVE|||||||
33857301|NCT01244451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063232|NCT05675514|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants did not know which group they were in.|"Participants will be randomized with the randomization program called Calculator Soup® (Ashland Global, USA) and divided into 2 groups as intervention and control groups.~The intervention group; (n=30) at the beginning of the study, after the initial evaluations (demographic information, functional movement screening test (FMS), t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test) were made, twice a week for 6 weeks, pre-training myofascial release technique will be applied. Final evaluations will be made when the intervention period is over.~The control group; (n=30) will do their routine training for 6 weeks after the first evaluations (demographic information, FMS, t agility test, vertical jump test, muscle strength test, muscle viscoelasticity and star balance test) and no application will be made. Final evaluations will be made at the end of 6 weeks."|t|f|f|f
34063233|NCT05410379|||CASE_ONLY||PROSPECTIVE|||||||
34063234|NCT03486119|||OTHER||PROSPECTIVE|||||||
34169355|NCT02408133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169356|NCT01436526|RANDOMIZED|CROSSOVER||||NONE||||||
34169357|NCT04997499|NA|SINGLE_GROUP||OTHER||NONE||Subjects will be current users of depot-medroxyprogesterone via intramuscular injection and will be asked to watch a video to instruct them on how to self administer a subcutaneous injection of the same medication||||
34169358|NCT04711785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Cohort study no masking presented.|Cohort study||||
34169359|NCT06158334|||COHORT||CROSS_SECTIONAL|||||||
34169360|NCT04326920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169361|NCT02944851|||COHORT||PROSPECTIVE|||||||
34169362|NCT04864990|||COHORT||PROSPECTIVE|||||||
34169363|NCT01808859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169364|NCT03082248|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34169365|NCT01903460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169366|NCT03450863|||COHORT||PROSPECTIVE|||||||
34169367|NCT04658329|||COHORT||PROSPECTIVE|||||||
34169368|NCT01865266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169369|NCT00983307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169370|NCT02512549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169371|NCT04350281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857302|NCT05240352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33857303|NCT01453426|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33857304|NCT01440374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33857305|NCT01171105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857306|NCT03057808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857307|NCT05809817|||COHORT||PROSPECTIVE|||||||
34063235|NCT00776620|RANDOMIZED|CROSSOVER||||NONE||||||
34063236|NCT04587024|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
34063237|NCT03381963|||COHORT||PROSPECTIVE|||||||
34063238|NCT03963180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063239|NCT05731167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34063240|NCT05640661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063241|NCT02226926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063242|NCT03069456|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Combined sigmoidal Emax models from anesthetic depth monitoring for sedation (ADMS) and combined sigmoidal Emax models from bispectral index (BIS) via population pharmacodynamic approach.||||
34063243|NCT04412642|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|||||
34063244|NCT00865267|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34063245|NCT06729996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063246|NCT02428894|||COHORT||PROSPECTIVE|||||||
34063247|NCT00417638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063248|NCT01564641|||COHORT||PROSPECTIVE|||||||
34063249|NCT00931827|||COHORT||PROSPECTIVE|||||||
34063250|NCT05857670|||OTHER||CROSS_SECTIONAL|||||||
34063251|NCT02914041|||OTHER||CROSS_SECTIONAL|||||||
34063252|NCT05681871|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective interventional quasi-experimental pre-post study South African multi-centre||||
34063253|NCT04477694|||COHORT||PROSPECTIVE|||||||
34063254|NCT06721221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063255|NCT03121573||SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34063256|NCT00958412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063257|NCT04978077|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34063258|NCT06232434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063259|NCT04498598|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34063260|NCT04474613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063261|NCT01075906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34063262|NCT06319872|NA|SEQUENTIAL||TREATMENT||NONE||||||
34063263|NCT03357900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063264|NCT01846806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063265|NCT06725680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063266|NCT03205098|||OTHER||PROSPECTIVE|||||||
34063267|NCT01687387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063268|NCT02897063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34063269|NCT05764681|||COHORT||PROSPECTIVE|||||||
34063270|NCT02599428|||COHORT||PROSPECTIVE|||||||
34169372|NCT03122041|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169373|NCT03656055|||COHORT||PROSPECTIVE|||||||
33857308|NCT03741647|||CASE_ONLY||PROSPECTIVE|||||||
33857309|NCT00759291|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33857310|NCT01679574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857311|NCT06240091|NA|SINGLE_GROUP||OTHER||NONE||||||
33857312|NCT00592085|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857313|NCT03227796|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind|First-in-human, phase 1, placebo-controlled, double-blind, single ascending dose study in heathy volunteers and osteoarthritis patients|t|t|t|t
33857314|NCT02682641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857315|NCT05727254|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the study (exercise intervention) no masking of participants and intervention providers is possible.|Randomized controlled trial with an intervention and a control arm.||||
33857316|NCT01313650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857317|NCT03438851|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will self-select into one of two treatment conditions: a full-time intensive program or a part-time program. Participants in the full-time program will be asked to complete 4 experimental sessions with the NeuroCatch PlatformTM over the course of 3 months (i.e. one session/ month); whereas, participants in the part-time program will be asked to complete 3 scans over 3 months (i.e. one session/1.5 months).||||
33857318|NCT03032471|||COHORT||PROSPECTIVE|||||||
33857319|NCT01059136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857320|NCT04279938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959272|NCT04586569|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The research team member handing out surveys and observing children for anxiety are masked. The PACU nurse observing for emergence agitation post-op is also masked.||f|t|f|t
33959273|NCT05037292|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Onboarding, training, and implementation of surgical subspecialties into a standardized frailty screening index and the utilization of a frailty review board by surgical specialty.||||
33959274|NCT06701058|||COHORT||PROSPECTIVE|||||||
33959275|NCT06700447|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33959276|NCT03739684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959277|NCT06533904|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Patients will be randomized to standard multi-modal pain regimen with percutaneous cryoablation versus standard multi-modal pain regimen alone.|t|f|t|f
33959278|NCT03568929|||COHORT||OTHER|||||||
33959279|NCT05077683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959280|NCT05600933|||CASE_ONLY||PROSPECTIVE|||||||
33959281|NCT03782688|||COHORT||PROSPECTIVE|||||||
34169374|NCT06236100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34169375|NCT03805802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigator receives reference product and the test product in boxes labelled stratus nimbus and cumulus. first 6 weeks participants are randomly assigned to stratus or nimbus and the second 6 weeks participants all receive cumulus."|First 6 weeks double blinded vs. a reference product and second 6 weeks open label both groups receive the test product in the second 6 weeks.|t|t|t|t
34169376|NCT02198365|||CASE_CONTROL||PROSPECTIVE|||||||
34169377|NCT02221869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169378|NCT06447558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169379|NCT05212558|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The outcome assessor was blinded to the treatment allocation|A randomized, placebo-controlled, assessor-blinded clinical trial|f|f|f|t
33857321|NCT00743054|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857322|NCT00186641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857323|NCT01279096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857324|NCT00004660|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857325|NCT03358966|||COHORT||PROSPECTIVE|||||||
33959282|NCT05337514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33959283|NCT05070169|||COHORT||PROSPECTIVE|||||||
33959284|NCT06213311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959285|NCT06299631|||CASE_ONLY||PROSPECTIVE|||||||
33959286|NCT06678191|||COHORT||PROSPECTIVE|||||||
34169380|NCT00447720|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34169381|NCT04945187|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A prospective, sequential cohort study with comparisons between non-equivalent groups.||||
34169382|NCT04122326|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be asked to work at an office workstation in a sequence of different workstation setups.||||
34169383|NCT03902691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857326|NCT00465556|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857327|NCT05024227|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33857328|NCT00767273|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857329|NCT01412463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857330|NCT05210218|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959287|NCT05308576|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33959288|NCT03974516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959289|NCT05166421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959290|NCT06033703|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
33959291|NCT01308073|||COHORT||PROSPECTIVE|||||||
33959292|NCT03029000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959293|NCT00000510|RANDOMIZED|||PREVENTION||DOUBLE||||||
33959294|NCT05286983|||COHORT||PROSPECTIVE|||||||
33959295|NCT04774809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959296|NCT05506800|||COHORT||PROSPECTIVE|||||||
33959297|NCT06537102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959298|NCT06695923|||CASE_CONTROL||PROSPECTIVE|||||||
33959299|NCT05587517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Mixed methods randomized controlled trial (RCT) to further evaluate the efficacy of EMPOWER for reducing surrogate symptoms of PTSD and PGD.|f|f|f|t
34169384|NCT04081922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169385|NCT04409197|||COHORT||PROSPECTIVE|||||||
33748976|NCT01454648|||CASE_CONTROL||RETROSPECTIVE|||||||
34063271|NCT03623633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063272|NCT05292482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063273|NCT05328388|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33748977|NCT01300130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33748978|NCT03273946|||COHORT||PROSPECTIVE|||||||
33748979|NCT02048228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063274|NCT03535194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063275|NCT02295267|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34063276|NCT06731309|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT with two intervention groups, one of which is gold standard intervention||||
34063277|NCT06730048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|experimental group will use augmented reality sension and outcome assessments will be performend by a investigator who was blinded to group allocation.|two-group study, experimental and control group|t|f|f|t
34063278|NCT01094782|RANDOMIZED|FACTORIAL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34063279|NCT02393105|||||CROSS_SECTIONAL|||||||
34063280|NCT04454710|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33748980|NCT05498376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748981|NCT02510495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748982|NCT02768961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748983|NCT06413524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33748984|NCT04885023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|All participants in two groups in addition to the formetric measurements and Biodex body balance assessors were not aware of the purpose of the study|A total of 52 patients (15 males and 37 females) participated in the current study, assigned to 2 groups, which were the group A who received hippotherapy combined with Schroth exercises and group B who received only Schroth exercises|t|f|f|t
33748985|NCT05893758|||COHORT||RETROSPECTIVE|||||||
33748986|NCT06292455|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34063281|NCT06323317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The post-intervention data collector (research assistant) will be blinded to the group allocation to avoid performance and detection biases.||f|f|f|t
34063282|NCT06219018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||In this pilot study, we will include 60 patients with newly diagnosed CIN II. Patients will be counseled according to standardguidelines between a LLETZ, imiquimod or expectant management. Patients choosing for expectant management will be asked toparticipate in the study and treatment with medical grade honey. Patients choosing imiquimod or LLETZ will be asked for the controlarm. Follow-up assessment takes place in accordance with the national guideline (first check-up is after 6 months). In addition,swabs for vaginal microbiota analysis will be taken at 0 and 6 months. Immunohistochemical stainings for the local immune infiltratewill be performed on biopsies taken during regular colposcopy at t=0. This exploratory study assesses the potential effect of honey,the optimal dosage and provides insight into its mechanisms of action.||||
34063283|NCT04670380|||OTHER||PROSPECTIVE|||||||
34063284|NCT00758654|||COHORT||PROSPECTIVE|||||||
34063285|NCT05499078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063286|NCT01678703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063287|NCT01580176|NA|SINGLE_GROUP||||NONE||||||
34063288|NCT04517578|||OTHER||PROSPECTIVE|||||||
34063289|NCT06731829|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34063290|NCT02415062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063291|NCT02636439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063292|NCT05490433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"RNSM and CNSM procedures are systematic at 1:1 ratio after obtaining consent forms for research participation and checking criteria for exclusion from selection It is randomly assigned from the award. The patient is subjected to a single blind examination so that the surgical method is unknown before surgery.~Reconstruction methods after resection are discussed with breast and/or plastic surgeons"|t|f|f|f
34063293|NCT04910243|||COHORT||CROSS_SECTIONAL|||||||
34063294|NCT04607980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigators, study personnel with the exception of the clinical research organization's unblinded biostatistician and unblinded programmers; and the data monitoring committee, and the study participants will remain blinded to treatment allocation.||t|t|t|t
34063295|NCT06150768|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group (1) will receive a CoCr removable partial denture; in the other two groups (2) and (3), implants will be inserted to restore missed posterior teeth (second mandibular premolar and second mandibular molar) in the span area using a two-stage surgical technique with the help of a radiographic and surgical stent. After a three-month osseointegration period, implants will be loaded with three units of anatomical PFM fixed partial dentures in group (2), while in group (3), implants will be loaded with three units of anatomical Zirconia fixed partial dentures. Biting force will be measured using a biting force sensor for both the intact and restored sides at the time of delivery of the removable partial denture and at loading of implants, after 2, 4, and 6 months. Patient satisfaction will be assessed through a quality-of-life questionnaire at the recall appointments.||||
34063296|NCT04613466|||COHORT||PROSPECTIVE|||||||
34063297|NCT02945254|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34063298|NCT06397989|RANDOMIZED|PARALLEL||OTHER||SINGLE|Neither participants nor outcomes assessors (who perform biometric attendance tracking) will be blinded to allocation to PM-RUF vs. rice/millet flour. The trial statistician responsible for final analyses will remain blinded by use of letter assignment to each school. The code linking letter/school to intervention vs. control will remain locked and inaccessible to the trial statistician.|Cluster-randomized, controlled, investigator-blinded superiority trial. Schools will be randomized to receive PM-RUF or local flour for porridge. Randomization will be stratified / covariate-constrained by primary vs. junior secondary school, school size, and distance from a main road.|f|f|t|f
34063299|NCT02223364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063300|NCT04373850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34063301|NCT03871959|NA|SINGLE_GROUP||TREATMENT||NONE||The dose escalation part will follow a classical 3+3 design. 3 to 6 patients will be enrolled at each Dose Level depending of the number of Dose Limiting Toxicities observed.||||
34063302|NCT06707441|||COHORT||PROSPECTIVE|||||||
34063303|NCT02851979|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063304|NCT02638051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063305|NCT00019630||||TREATMENT||||||||
33959300|NCT04424407|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-armed trial. All participants will receive Cognitive Behavioral Therapy for Insomnia||||
33959301|NCT00000135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33959302|NCT06636721|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33959303|NCT03634007|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959304|NCT05047237|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959305|NCT06307678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessments have performed by a investigator who was blinded to groups.|two groups: group 1 calcium hydroxide based medicament (control group) group 2: calcium silicate based medicament|f|f|f|t
33959306|NCT04275388|||COHORT||RETROSPECTIVE|||||||
33959307|NCT00264082|||||OTHER|||||||
33959308|NCT05903924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959309|NCT00981019|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33959310|NCT06700369|||COHORT||OTHER|||||||
33959311|NCT03647280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959312|NCT03777839|||COHORT||PROSPECTIVE|||||||
34063306|NCT01520194|||CASE_ONLY||RETROSPECTIVE|||||||
33959313|NCT01053078|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34063307|NCT02453997|||COHORT||PROSPECTIVE|||||||
33748987|NCT00093301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857331|NCT00283257|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33857332|NCT04734327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857333|NCT00418925|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33857334|NCT00860613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857335|NCT03764956|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized non inferiority trial with two parallel arms||||
33857336|NCT02876666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33857337|NCT00334347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857338|NCT05217654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|double-blind|Prospective, randomized, placebo-controlled, double-blind, parallel group, phase 1 trial. Subjects in study group A will receive a daily oral dose of 10 mg dapagliflozin for 14 days (until study day 15) Subjects in study group B will receive a 14 day treatment with placebo-dapagliflozin.|t|f|t|t
33857339|NCT00098384|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33857340|NCT00006332||||TREATMENT||NONE||||||
33857341|NCT02168842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857342|NCT00001024||||TREATMENT||||||||
33857343|NCT00503659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857344|NCT01800214|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33857345|NCT02963181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857346|NCT01222065|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33857347|NCT03943225|||OTHER||PROSPECTIVE|||||||
33857348|NCT01847118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857349|NCT00747825|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857350|NCT04363684|||COHORT||PROSPECTIVE|||||||
33857351|NCT04251260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the principal investigator who is not an assessor will know the allocation of the neonates to the 2 groups. The assessors will be blind to the allocation of the neonates.||f|f|f|t
33959314|NCT06033183|NA|SINGLE_GROUP||SCREENING||NONE||||||
33959315|NCT05343793|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959316|NCT00585039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063308|NCT05015543|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063309|NCT01731470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063310|NCT02706353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063311|NCT06622291|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Single-center prospective, randomized, placebo-controlled study|t|f|t|t
34063312|NCT01574677|||CASE_ONLY||PROSPECTIVE|||||||
34063313|NCT05524246|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063314|NCT03729622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857352|NCT03259022|||COHORT||PROSPECTIVE|||||||
33959317|NCT05919329|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33959318|NCT01984619|||COHORT||PROSPECTIVE|||||||
33959319|NCT04917029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33959320|NCT03438474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959321|NCT03797573|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959322|NCT05495425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959323|NCT05847569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959324|NCT05619627|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective Pilot Study, Single-site, open-label, phase I dose escalation trial||||
33959325|NCT06396533|||CASE_CONTROL||PROSPECTIVE|||||||
34063315|NCT06721559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding interventionalists and participants is not possible, given the nature of the intervention. However, assessment staff will be blinded when possible.||f|f|f|t
34063316|NCT06719869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063317|NCT03138941|||COHORT||PROSPECTIVE|||||||
34063318|NCT04885400|NA|SINGLE_GROUP||OTHER||NONE||Open-label pilot study||||
34063319|NCT03012763|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34063320|NCT05330468|||OTHER||PROSPECTIVE|||||||
34063321|NCT05207722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This Phase I/IIa study will utilize a 3+3 open label design, and will evaluate two escalating dosing Cohort levels of CYNK-101 in combination with rhIL2 following and initial induction and lymphodepletion regimen. Once the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is determined in Phase I, the Phase IIa portion of the study will commence.||||
34063322|NCT02103257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063323|NCT03366454|||COHORT||PROSPECTIVE|||||||
34063324|NCT05869110|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Study participants will not be informed which substances are investigated|Randomized, placebo-controlled, single-blind, cross-over, single-centre trial|t|f|f|f
34063325|NCT06444828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|non information of the type of implant used is given to the patient|RCT, single blinded|t|f|f|f
34063326|NCT03004924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169386|NCT03381521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063327|NCT04302740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||10 Housing First sites will be optimally matched and block randomized on a rolling basis to either LEAP or services-as-usual control conditions.||||
34063328|NCT02371564|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063329|NCT05228886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Services to which participants are referred will not be aware of the participant's inclusion in the research study or their study arm.||f|t|f|f
34063330|NCT04616001|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single group, pilot study||||
34063331|NCT00701480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34063332|NCT05989776|RANDOMIZED|PARALLEL||OTHER||SINGLE||The investigators will conduct a randomized stepped-wedge trial multi-site evaluating access to fertility preservation counseling over a 30-month period.|f|f|f|t
34063333|NCT03513900|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34063334|NCT04698174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063335|NCT00190372|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34063336|NCT06730165|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
34063337|NCT00312572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063338|NCT05039801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063339|NCT06436833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34063340|NCT00618241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063341|NCT01069315|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34063342|NCT05156645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063343|NCT04154514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169387|NCT00373581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169388|NCT05774535|||COHORT||PROSPECTIVE|||||||
34169389|NCT06237959|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169390|NCT03845127|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 Randomized Study Design. Crossover permitted after 6 months.||||
34169391|NCT04563377|NA|SINGLE_GROUP||OTHER||NONE||||||
34169392|NCT05204446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169393|NCT01373463|NON_RANDOMIZED|||TREATMENT||NONE||||||
34169394|NCT00922623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169395|NCT03689036|||COHORT||PROSPECTIVE|||||||
34169396|NCT00565734|||COHORT||PROSPECTIVE|||||||
34169397|NCT00804700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063344|NCT02722837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169398|NCT00823251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169399|NCT06477159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169400|NCT02304510|||COHORT||CROSS_SECTIONAL|||||||
34169401|NCT05797012|NA|SINGLE_GROUP||OTHER||NONE||||||
34169402|NCT06249685|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||ABA Repeated Reversal design||||
34169403|NCT05089799|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857353|NCT03674125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169404|NCT01089686|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34169405|NCT03775798|||COHORT||PROSPECTIVE|||||||
34169406|NCT04688658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169407|NCT00303355|||||PROSPECTIVE|||||||
34169408|NCT01911611|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34169409|NCT03116516|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, single dose, crossover clinical trial||||
34169410|NCT01210716|RANDOMIZED|CROSSOVER||||NONE||||||
34169411|NCT04486235|RANDOMIZED|PARALLEL||OTHER||NONE|The condition of the participant is revealed after the participant completes the consent form and screening questionnaire and is deemed eligible.|Randomization is stratified. On the screening form, participants indicate whether or not they plan to speak with their physician about their weight in their appointment. Randomization is stratified by if if the participant indicates that they plan to speak about weight or not.||||
34169412|NCT05515731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857354|NCT00473941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33857355|NCT03681951|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 dose escalation will administer escalating doses of GSK3145095 as monotherapy only. Part 2 will combine escalating doses of GSK3145095 with 200 mg pembrolizumab. Dose escalation of GSK3145095 will begin at least one level below the highest dose shown to have an acceptable toxicity profile in at least 3 subjects in Part 1. Part 3 will enroll subjects treated with one or more dose levels of GSK3145095 in combination with 200 mg pembrolizumab. Part 4 will investigate the combination of additional anticancer agents with one or more doses of GSK3145095 identified as safe in Part 1.||||
33857356|NCT01928498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33857357|NCT00052182|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33857358|NCT04993612|||COHORT||PROSPECTIVE|||||||
33857359|NCT04902469|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be informed about whether they are in the odor blank (control) or pleasant odor (experimental) group. However, the odor blank group is intended to control for the act of sniffing rather than the belief that one has sniffed a pleasant odor.|This is a between-subjects design in which 250 nicotine-deprived smokers, who vary in whether they smoke daily and in motivation to quit, will be exposed to smoking cues to induce peak cravings and then receive either a pleasant (n = 125) or neutral (n = 125) olfactory cue.|t|f|f|f
33857360|NCT00891345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857361|NCT05552209|||CASE_CONTROL||PROSPECTIVE|||||||
33857362|NCT04922489|||CASE_ONLY||RETROSPECTIVE|||||||
33857363|NCT01058408|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857364|NCT02474160|||OTHER||OTHER|||||||
33857365|NCT01894373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857366|NCT01995877|||CASE_ONLY||PROSPECTIVE|||||||
33857367|NCT00892684|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33857368|NCT00701220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857369|NCT00676065|||COHORT||PROSPECTIVE|||||||
33857370|NCT04631172|||OTHER||CROSS_SECTIONAL|||||||
33857371|NCT02053038|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33857372|NCT00705523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857373|NCT04607525|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34169413|NCT05416216|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Stepped Wedge Cluster Randomized Trial. To evaluate the effectiveness of the WELL intervention the researchers will implement a stepped wedge cluster randomized trial. In this design, ECE centers (steps 1-3) start the trial at the same point in time and act as controls until they are randomized to crossover from control to intervention conditions. This design has been used for pragmatic public health trials conducted as part of routine practice where phased implementation is preferable for feasibility and when the interventions are expected to provide more good than harm.||||
34169414|NCT05640440|||CASE_CONTROL||OTHER|||||||
34169415|NCT01622621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169416|NCT02191592|||CASE_ONLY||PROSPECTIVE|||||||
34169417|NCT02764463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169418|NCT02075112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169419|NCT02498301|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33857374|NCT00913666|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34169420|NCT06055179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will be randomly assigned to XCHT/placebo groups, at a 1:1 ratio, using a central randomization system provided by the TCM clinical study methodology group of Guangdong Provincial Hospital of Chinese Medicine. This group is also responsible for blinding, including keeping the blinding codes, supervision, and quality control of blinding, by allocating drug codes for each patient. Investigators will dispense the drug according to the drug codes. The investigators, the study subjects, the care givers, and the outcome assessors will be blinded to the assigned group of subjects.||t|t|t|t
34169421|NCT01454193|||COHORT||RETROSPECTIVE|||||||
34169422|NCT01485094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169423|NCT00532662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34169424|NCT04427319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169425|NCT04024891|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
34169426|NCT06159452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34169427|NCT02737007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169428|NCT00079040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169429|NCT03799796|NA|SINGLE_GROUP||OTHER||NONE||||||
34169430|NCT01682408|RANDOMIZED|||BASIC_SCIENCE||NONE||||||
34169431|NCT04443634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34169432|NCT01364584|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34169433|NCT03016312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169434|NCT06125834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169435|NCT01072188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169436|NCT02812836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857375|NCT00223678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857376|NCT02080221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169437|NCT06349694|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34169438|NCT02201524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169439|NCT02528708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169440|NCT00310011||||TREATMENT||NONE||||||
33748988|NCT04136951|NA|SINGLE_GROUP||SCREENING||NONE||To examine the study aims, the researchers are using an embedded mixed methods study design. The researchers will conduct pre- and post intervention trial of clinical decision support tool PREVENT's integration into clinical practice using homecare admissions from two New York City urban hospitals serving diverse racial and ethnic population. Quantitative methods, including logistic regression and survival analysis with propensity score matching, will be used to evaluate the effects of the tool on process and patient outcomes. Qualitative methods will be used to match the quantitative questions and provide an in depth insight into homecare admission processes using think-aloud simulations and interviews with homecare admission staff.||||
33748989|NCT06670469|||OTHER||OTHER|||||||
33748990|NCT03955432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748991|NCT02596815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33748992|NCT04539574|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33748993|NCT06013644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33748994|NCT03505632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This study is double blind study|Mechanical ventilation with either recruitment maneuver and low PEEP versus conventional mechanical ventilation and high PEEP|t|f|f|t
33748995|NCT00536003|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33748996|NCT02090101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33748997|NCT02859857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33748998|NCT04236791|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation.|||||
33748999|NCT03923413|||COHORT||PROSPECTIVE|||||||
33749000|NCT01247129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749001|NCT00726752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749002|NCT03963726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-randomized trial||||
33749003|NCT04656847|||OTHER||OTHER|||||||
33857377|NCT01670123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857378|NCT04497194|||COHORT||OTHER|||||||
33857379|NCT05210296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized controlled|f|f|t|f
33857380|NCT04201509|||CASE_CONTROL||PROSPECTIVE|||||||
33857381|NCT05141123|||COHORT||OTHER|||||||
33857382|NCT03639233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857383|NCT00582868|||CASE_ONLY||PROSPECTIVE|||||||
33857384|NCT02722720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857385|NCT05323799|||COHORT||PROSPECTIVE|||||||
33857386|NCT00108654||||TREATMENT||||||||
33857387|NCT03463148|||COHORT||RETROSPECTIVE|||||||
33857388|NCT02839837|NA|SINGLE_GROUP||OTHER||NONE||||||
33959326|NCT04929522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation concealment mechanism: The sequentially generated numbers were placed in opaque envelopes until the intervention was conducted, and each participant was asked to select an envelope that determines which group of intervention was assumed.|This study was a prospective, randomized, parallel, triple blinded, clinical trial.|t|f|t|t
33857389|NCT05395910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959327|NCT06072131|RANDOMIZED|PARALLEL||TREATMENT||NONE|None - Open Label|A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma||||
33959328|NCT00547209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857390|NCT04652167|||COHORT||PROSPECTIVE|||||||
33959329|NCT04230785|||COHORT||PROSPECTIVE|||||||
33857391|NCT04519112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959330|NCT06568809|||COHORT||PROSPECTIVE|||||||
33959331|NCT00756652|||COHORT||PROSPECTIVE|||||||
33959332|NCT03933982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959333|NCT04288323|NA|SINGLE_GROUP||SCREENING||NONE||||||
33959334|NCT06392048|||COHORT||RETROSPECTIVE|||||||
33959335|NCT06419855|||COHORT||PROSPECTIVE|||||||
33959336|NCT04272255|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33749004|NCT05641168|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33959337|NCT01705561|||CASE_ONLY||RETROSPECTIVE|||||||
33959338|NCT02629380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33959339|NCT05706311|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a type-1 cluster 2-arm randomized trial. Randomization will take place at the pharmacy level and will be stratified by zip code level of poverty and pharmacy patient volume.||||
33959340|NCT06132412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33959341|NCT06245694|||COHORT||RETROSPECTIVE|||||||
33959342|NCT04640909|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959343|NCT06566040|||COHORT||RETROSPECTIVE|||||||
33959344|NCT01910597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959345|NCT06438159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959346|NCT00808015|||CASE_ONLY||PROSPECTIVE|||||||
33959347|NCT05120752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857392|NCT02966392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33857393|NCT04200131|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857394|NCT02374021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857395|NCT04513704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857396|NCT03474068|||COHORT||RETROSPECTIVE|||||||
33857397|NCT05078320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857398|NCT00802425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857399|NCT04662762|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The random assignment was made to the nursing intervention group and the usual care group, generating a list using the EPIDAT ® programme. This list contained the patient number and the assignment group. The randomization procedure was performed during hospitalization for AMI. The researcher did not know the assignment list, calling the research unit at the time of each patient inclusion by phone, when they were told to which group they would belong to once the first interview was over.~The main outcome measured was therapeutic adherence 12 months after admission. This assessment was performed by trained nurses blinded to the group assignment."|"Patients were randomly assigned to a nursing intervention group or a usual care group (1:1).~Nonprobabilistic, consecutive sampling was carried out with random assignment of the study groups."|f|t|t|t
33857400|NCT02343731|NA|SINGLE_GROUP||||NONE||||||
33857401|NCT01351753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857402|NCT05997888|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857403|NCT06155448|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention arm will comprise PMC-plus: A 6-scheduled dose regimen administered to eligible children at 10 weeks, 14 weeks, 6 months, 9 months, 12 months and 15 months of age concurrently with EPI vaccinations DTP2/Penta2, DTP3/Penta3, vitamin A, and measles immunisation where appropriate. Eligible children attending the participating health facilities for other reasons beyond EPI would be invited to receive additional monthly doses between scheduled EPI-linked visits up until the child reaches 18 months of age||||
33959348|NCT01623882|||CASE_CONTROL||PROSPECTIVE|||||||
33959349|NCT06111417|||COHORT||PROSPECTIVE|||||||
33959350|NCT03394794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959351|NCT04832984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Cluster randomisation with blinding of statisticians||t|f|f|t
33959352|NCT05777369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959353|NCT05976867|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959354|NCT06514118|||COHORT||PROSPECTIVE|||||||
33959355|NCT05231161|||COHORT||PROSPECTIVE|||||||
33959356|NCT04706520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded as to which group they are randomized since both the vinegar and placebo beverages are the same in appearance and taste. The Investigators, clinic staff, and intervention staff are also all blinded. The only unblinded group is the Metabolic Kitchen who facilitates randomization and distribution of study product.|VAnish is a randomized, placebo-controlled, parallel study model with 3 groups consisting of 20 participants who will all consume 2 bottles of study product per day. Group 1 will receive 400mL/day of vinegar; Group 2 will receive 200mL/day of vinegar and 200mL/day of the placebo drink; Group 3 will receive 400mL/day of the placebo drink.|t|f|t|f
33959357|NCT06525155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959358|NCT02913651|||COHORT||RETROSPECTIVE|||||||
33959359|NCT05551000|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33749005|NCT06192888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749006|NCT01565707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749007|NCT06550791|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857404|NCT00330486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857405|NCT04238065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Research centers are used as a stratification factor. The researchers include subjects in the trial group or control group based on randomized envelopes.|One arm receive VR treatment while the other arm does not. Both arms get best optical correction and 2 hours (for mild and moderate amblyopia）patch or 6 hours (for severe amblyopia) patch their non-amblyopia eyes.|f|t|t|t
33857406|NCT05516550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blind will be performed by using Placebo equivalent to Treamid tablets without active substance and the corresponding labeling of the study drug.||t|f|t|f
33857407|NCT05423782|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33857408|NCT04761302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33857409|NCT02720536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857410|NCT02645695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33857411|NCT02046824|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
33857412|NCT00343135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063345|NCT00073502||||TREATMENT||||||||
33959360|NCT06567535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959361|NCT04520594|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Unblinding will occur only if necessary to ensure study participants safety, interim analysis at 5 ± 1 months, or eligibility for our associated open label trail (OARS trial). Only Dr. Mack (Co-PI) can request to break the blind for safety reasons or eligibility for the OARS Trial; only Dr. Stintzi (Co-PI) will request to break the blind for interim analysis. Once the blind is broken, the patient will be discontinued from study product.|A single center, randomized, placebo-controlled, double-blinded, parallel, pilot clinical trial|t|t|t|t
33959362|NCT04992169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant families will be randomly assigned by the smartphone app to one arm or the other. While caregivers are not directly notified of their group/arm assignment, their participation in arm-specific app-tasks may help them determine which arm they are assigned to. Investigators and outcomes assessors remain masked to condition until data collection and analysis is completed.|Randomized Clinical Trial with two arms.|t|f|t|t
33959363|NCT05394428|||COHORT||PROSPECTIVE|||||||
33959364|NCT04289467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959365|NCT05800743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063346|NCT03623971|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063347|NCT00934856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063348|NCT05269589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063349|NCT05529316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169441|NCT03538418|RANDOMIZED|PARALLEL||OTHER||SINGLE|An independent assessor who is blinded to the group allocations will assess the participants' outcomes.|"A two-arm parallel (single-blinded) cluster randomized controlled trial involves two groups of participants (the WAT group and the control group). Six community centres, which provide similar types of community care and social support services for community-dwelling older people, will be invited by a convenience method to work as collaborators in this study. Using computer-generated random numbers, a biostatistician not affiliated with this study will randomize the centres into either: the control or the experimental groups. Therefore, duing the trial, participants in one group receive intervention in parallel to participants in the other group (control group)."|f|f|f|t
34169442|NCT05646498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063350|NCT05226286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169443|NCT04243694|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34169444|NCT02047955|||COHORT||PROSPECTIVE|||||||
34169445|NCT00752700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169446|NCT02818868|||COHORT||PROSPECTIVE|||||||
34169447|NCT02182323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169448|NCT02179008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169449|NCT00629226||||TREATMENT||||||||
34169450|NCT03360331|||COHORT||RETROSPECTIVE|||||||
34169451|NCT02997501|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34169452|NCT00896714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169453|NCT04139655|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-Blinded|Randomized Control Pilot Study|t|t|t|f
33857413|NCT02193646|||CASE_ONLY||RETROSPECTIVE|||||||
33857414|NCT03675178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857415|NCT01712022|||COHORT||PROSPECTIVE|||||||
33857416|NCT01413100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857417|NCT05080998|||COHORT||PROSPECTIVE|||||||
34063351|NCT05641662|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34169454|NCT03572179|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants Patients can detect the transfer tray so blinding is not possible Operator The main operator is responsible for the bonding so the blinding is not possible Assessor The assessor (different from main operator will carry out the measurement blindly|all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method|f|f|f|t
34169455|NCT06451302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169456|NCT05024435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169457|NCT00786617|||COHORT||PROSPECTIVE|||||||
34169458|NCT03063463|||CASE_ONLY||PROSPECTIVE|||||||
34169459|NCT00215111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169460|NCT04781010|||CASE_ONLY||PROSPECTIVE|||||||
34169461|NCT05513326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34169462|NCT04085549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study has two parts. In part 1 the participants, care provider and outcome assessor know which treatment is given to each skin area. In part 2 participant, care provider, investigator and outcome assessor do not know which treatment is given to each skin area. Masking is done by identical cream tubes.||t|t|t|t
34169463|NCT03800849|||COHORT||PROSPECTIVE|||||||
34169464|NCT05644314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169465|NCT02767271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169466|NCT03694405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Group 1 = 3 prior doses of MenC vaccine (Alberta), Group 2 = 2 prior doses of MenC vaccine (British Columbia), Group 3 = 1 prior dose of MenC vaccine (Nova Scotia). Group A = Menveo (MenACWY-CRM), Group B = Menactra (MenACWY-DT), Group C = Nimenrix (MenACWY-TT)|t|f|f|t
34169467|NCT05605626|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169468|NCT04614896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169469|NCT00962208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34169470|NCT04043117|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857418|NCT01562951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857419|NCT05712733|||CASE_CONTROL||PROSPECTIVE|||||||
33857420|NCT01942720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857421|NCT06176339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857422|NCT04939922|||COHORT||PROSPECTIVE|||||||
33857423|NCT03167931|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Each participant is included for 2 neuromodulation sessions: one session where neurostimulation is effective, one session where neurostimulation is simulated. Sessions are performed blind for the participant and the outcome assessor.~Sessions order is randomized for each participant (no arm randomization)."|outcoume measure comparison is done between both age groups (18-49 years and 50-85 years).|t|f|f|t
33857424|NCT02756923|||COHORT||PROSPECTIVE|||||||
33857425|NCT04793802|||CASE_CONTROL||RETROSPECTIVE|||||||
33857426|NCT04637308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857427|NCT04579627|||COHORT||CROSS_SECTIONAL|||||||
33857428|NCT01688674|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34169471|NCT01879917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169472|NCT02253615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169473|NCT00414856|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34169474|NCT03685630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169475|NCT05863897|NA|SINGLE_GROUP||TREATMENT||NONE||A single-case experimental design with AB and follow-up phases across participants.||||
34169476|NCT00683111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34169477|NCT00499681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169478|NCT00879021|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34169479|NCT04197830|||COHORT||RETROSPECTIVE|||||||
34169480|NCT02196961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169481|NCT02178995|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34169482|NCT05853146|||CASE_ONLY||PROSPECTIVE|||||||
34169483|NCT00971802|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34169484|NCT03967145|||CASE_ONLY||PROSPECTIVE|||||||
34169485|NCT04092686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose, multicenter study|t|t|t|t
34169486|NCT03179566|RANDOMIZED|PARALLEL||OTHER||NONE||A run-in period will precede the randomization sequence. Individuals will be randomized to one of two groups based on the day of their surgery.||||
34169487|NCT04498715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169488|NCT04283864|||COHORT||PROSPECTIVE|||||||
34169489|NCT00851357|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34169490|NCT01320358|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857429|NCT01594008|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33857430|NCT02575820|||COHORT||RETROSPECTIVE|||||||
33857431|NCT02924974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857432|NCT06435130|NA|SINGLE_GROUP||PREVENTION||NONE||102 people (67 women and 35 men) with metabolic disorders were included in the interventional study||||
33857433|NCT05243030|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-arm RCT with 2:1 randomization to MES-PrEP+MTM or standard PrEP Counseling||||
34169491|NCT06139549|||OTHER||PROSPECTIVE|||||||
33857434|NCT03072277|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, double blinded, parallel arm hospital based trial.|t|t|t|f
33857435|NCT04620226|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33857436|NCT04080791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857437|NCT05079256|NA|SEQUENTIAL||TREATMENT||NONE|tissue samples are described using random pre-assigned codes.|single blinded intra-patient comparison||||
33857438|NCT02529813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857439|NCT05895409|||COHORT||PROSPECTIVE|||||||
33857440|NCT04551625|||COHORT||PROSPECTIVE|||||||
33857441|NCT00426153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169492|NCT02793336|||COHORT||PROSPECTIVE|||||||
34169493|NCT00917930|||CASE_CONTROL||PROSPECTIVE|||||||
34169494|NCT04247217|||CASE_ONLY||PROSPECTIVE|||||||
34169495|NCT02428777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169496|NCT03074071|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects will be offered participation in workshops where techniques are taught for enhancing hopefulness. Validated questionnaires will be administered before and after this intervention to assess efficacy.||||
34169497|NCT02010268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169498|NCT03976765|||CASE_ONLY||PROSPECTIVE|||||||
34169499|NCT02837900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169500|NCT02111447|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34169501|NCT03306966|||CASE_ONLY||PROSPECTIVE|||||||
34169502|NCT03310723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169503|NCT01788995|||COHORT||PROSPECTIVE|||||||
34169504|NCT01212861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169505|NCT02095470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169506|NCT02320916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33857442|NCT04823520|RANDOMIZED|PARALLEL||TREATMENT||NONE||"(Group 1): 30 patients MDA will be done to one half of the face then TCA 15% will be applied to the whole face.~(Group 2): 30 patients will receive MDA to one side of the face , TCA 20% will then be applied to the whole face."||||
33857443|NCT05078216|||COHORT||PROSPECTIVE|||||||
33857444|NCT04951401|||OTHER||OTHER|||||||
33959366|NCT05653349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959367|NCT00081835||||TREATMENT||||||||
33959368|NCT05348018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||"Participants were allocated either to a test group which accessed Serious games during a four-week test period in addition to conventional lectures or to a control group which benefited solely from conventional lectures"|t|f|f|t
33959369|NCT06702241|RANDOMIZED|PARALLEL||TREATMENT||NONE||All infants will receive 12 hours double therapy with a biliblanket and overhead light providing an intensity of either 40-, 55- or 70 µW/cm2/nm. Three groups will be treated with continuous phototherapy while a fourth group will receive intermittent phototherapy of 1,5 hours cycled intervals with an intensity of 70 µW/cm2/nm.||||
33959370|NCT04738552|||OTHER||PROSPECTIVE|||||||
33959371|NCT05329129|||COHORT||PROSPECTIVE|||||||
33959372|NCT05459545|||COHORT||PROSPECTIVE|||||||
33959373|NCT00086931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959374|NCT06560996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33959375|NCT02480855|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33959376|NCT01408407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959377|NCT05580588|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33959378|NCT06513988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959379|NCT01614808|||CASE_CONTROL||RETROSPECTIVE|||||||
33959380|NCT03025659|||COHORT||PROSPECTIVE|||||||
33959381|NCT01466959|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33959382|NCT00619671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959383|NCT06568978|||CASE_CONTROL||RETROSPECTIVE|||||||
33959384|NCT06579196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are enrolled into the Phase I arm until the recommended phase 2 dose (RP2D) is determined. Participants who receive the RP2D in Phase I are reassigned to the Phase II arm.||||
33959385|NCT04241068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959386|NCT05875623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959387|NCT03771768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double - blinded trial:~Outcome assessor (CS) and Statistician. Participants couldn't be blinded because of the difference in the nature of interventions method of application."|1:1|f|t|t|f
33959388|NCT01643928|RANDOMIZED|||TREATMENT||TRIPLE|||t|f|t|t
34063352|NCT02681159|||COHORT||PROSPECTIVE|||||||
34063353|NCT06474650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959389|NCT06568068|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33959390|NCT00566969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33959391|NCT00590239|||COHORT||PROSPECTIVE|||||||
33959392|NCT03593356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Researchers know about amount of cash payment subjects receive at the point of enrollment because they assist subjects with credit card activation and instructions. For follow-up assessments at age 1, 2, 3, 4, 6, 8 interviewers will be blind to the extent possible.|Parallel assignment|t|f|f|f
33959393|NCT01563029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959394|NCT03006822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063354|NCT01153620|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063355|NCT05638516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063356|NCT05441891|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants not received any intervention. The researchers in charge of outcome assessment and statistical analysis are blinded to the allocation of participants|Randomized, parallel, pre-post study design|f|f|t|t
34063357|NCT01499641|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34063358|NCT04709341|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34063359|NCT05322356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169507|NCT05329844|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34169508|NCT03078322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169509|NCT06462053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169510|NCT02949349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857445|NCT05110274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857446|NCT03620409|||COHORT||PROSPECTIVE|||||||
33857447|NCT04644458|||COHORT||PROSPECTIVE|||||||
33857448|NCT06101433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and investigator were blinded to study groups (double blinded study)|Patients were randomly classified into placebo or soy isoflavone groups using block randomization stratified by menopause status and gender for 12 weeks|t|f|t|f
33857449|NCT01395316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857450|NCT03376945|||COHORT||RETROSPECTIVE|||||||
33959395|NCT02077660|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33959396|NCT05171127|||COHORT||CROSS_SECTIONAL|||||||
33959397|NCT06573697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959398|NCT06701955|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33959399|NCT05153590|||COHORT||RETROSPECTIVE|||||||
33959400|NCT02812368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959401|NCT06025500|||COHORT||PROSPECTIVE|||||||
33959402|NCT04331418|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959403|NCT03890861|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959404|NCT03735095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959405|NCT06144827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959406|NCT03944538|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33959407|NCT05809986|||COHORT||PROSPECTIVE|||||||
34169511|NCT02003326|NA|SINGLE_GROUP||OTHER||NONE||||||
34169512|NCT03571139|||COHORT||PROSPECTIVE|||||||
34169513|NCT00425724|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169514|NCT00746070|||CASE_CONTROL||PROSPECTIVE|||||||
34169515|NCT01425502|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34169516|NCT02794207|||COHORT||PROSPECTIVE|||||||
34169517|NCT03566342|||CASE_CONTROL||PROSPECTIVE|||||||
33959408|NCT05385744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33959409|NCT01933139|RANDOMIZED|PARALLEL||||NONE||||||
33959410|NCT00423228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959411|NCT02717624|NA|PARALLEL||TREATMENT||NONE||||||
33959412|NCT03338673|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be randomized to receive either dual therapy (cognitive exercises plus brain stimulation) or monotherapy (cognitive exercises alone) first; after 3 weeks participants will switch to the other condition||||
34063360|NCT05030636|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Testing for each participant will comprise of 5 visits (1 preliminary and 4 experimental) conducted over a 5-8 week period at the LAPS-UdeM laboratory \[Laboratoire activité physique et santé (LAPS), Université de Montréal (UdeM), Montreal, Canada\]. Each participant will be assigned to the 3 different conditions in a random order. Each session will begin with 1 standard validated meal (breakfast) at 8:00 am, followed by 1 EX session (warm-up + 30 min @ 70% VO2 max + cool-down), performed at 9:30 am or 11:00 am, or no EX (30 min sedentary; Control).||||
34169518|NCT04412577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169519|NCT05043350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169520|NCT00227721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169521|NCT03268785|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34169522|NCT03287921|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169523|NCT00037167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169524|NCT02898454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169525|NCT02539797|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34169526|NCT00791063|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169527|NCT04831645|||COHORT||PROSPECTIVE|||||||
34169528|NCT02530346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34169529|NCT06063174|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169530|NCT04508881|RANDOMIZED|PARALLEL||TREATMENT||NONE||: This randomized clinical trial included 30 eyes of 25 patients (age range: 44-56 y) with refractory glaucoma. This study was conducted during the period from September 2018 to January 2020. The study included two groups, AGV with intraluminal stenting group (n=15) and AGV with external ligation group (n=15). Follow up continued to a year post operation. The primary outcome was Intraocular pressure (IOP) and its association with the number of postoperative glaucoma medications. IOP ≤ 21 mmHg without medications announced complete success while IOP ≤ 21 mmHg with medications indicated qualified success. IOP of \<6 mmHg defined hypotony.||||
34169531|NCT02123134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169532|NCT00492245|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857451|NCT01128465|||CASE_ONLY||PROSPECTIVE|||||||
33857452|NCT00995020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857453|NCT00190125|||||PROSPECTIVE|||||||
33857454|NCT04743154|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857455|NCT04964414|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33857456|NCT04261335|NA|SINGLE_GROUP||TREATMENT||NONE||3 + 3 dose escalation study design||||
33959413|NCT01850108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959414|NCT02619344|||COHORT||PROSPECTIVE|||||||
33857457|NCT04015856|RANDOMIZED|PARALLEL||PREVENTION||NONE||Wards (the lowest government administrative units in Nepal) will be treated as clusters or the primary sampling units in this study. Each cluster will be randomly assigned to one of the three arms. Adolescents residing in the study wards will be recruited.||||
33857458|NCT01775254|||COHORT||PROSPECTIVE|||||||
33857459|NCT06220903|NA|SINGLE_GROUP||TREATMENT||NONE||A study group that received treatment and was monitored for a total of 20 sessions every day.||||
33857460|NCT06372028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33857461|NCT05923957|||CASE_ONLY||PROSPECTIVE|||||||
33857462|NCT01749449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857463|NCT05055986|||OTHER||PROSPECTIVE|||||||
33857464|NCT03514212|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study||||
33857465|NCT05576818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857466|NCT05199974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857467|NCT03328533|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33857468|NCT00002566|RANDOMIZED|||TREATMENT||||||||
33857469|NCT02727166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857470|NCT01771328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857471|NCT04421521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959415|NCT05431348|||COHORT||PROSPECTIVE|||||||
33959416|NCT05526443|||COHORT||PROSPECTIVE|||||||
33959417|NCT06644755|NA|SEQUENTIAL||TREATMENT||NONE||This is an open-label study.||||
33959418|NCT00161109|||DEFINED_POPULATION||PROSPECTIVE|||||||
33857472|NCT04559880|NA|SINGLE_GROUP||OTHER||NONE||25 consecutive patients treated with tranexamic acid after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (LNPCP's) to prevent post-polypectomy delayed bleeding (PPDB).||||
33857473|NCT05584969|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The settlements that were assigned to the different study arms were at least 6 kilometers apart to reduce the possibility of spillover effects of the intervention. The participants in each study arm were blinded from 1) which other settlements were involved in the activities they were engaging in and 2) what activities were and who was involved in those activities within the other study arms. Data collectors/enumerators were blinded from the study arm assignment.|The intervention in Moms-only arm was run concurrently with a similar intervention in the Moms and Dads treatment arm. At the same time, the Control arm did not receive any intervention. Data were collected from all study arms at the same time during the study in order to compare the effect of the intervention in the treatment arms against the control.|t|f|f|t
34063361|NCT06419010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063362|NCT06191302|||COHORT||PROSPECTIVE|||||||
34169533|NCT05313035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Vaccine candidate and placebo are masking, lot number is masking||t|f|t|f
34169534|NCT00860808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169535|NCT01739166|RANDOMIZED|CROSSOVER||||NONE||||||
34169536|NCT03850860|||CASE_CONTROL||RETROSPECTIVE|||||||
34169537|NCT01442480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34169538|NCT06453408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169539|NCT01316016|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34169540|NCT04897217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169541|NCT03876717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects and all investigators are blinded. As effect and side effects of the active drug may demask the blinding, a central study nurse is the primary contact for the subjects during the intervention periode regarding everything except suspected/possible serious events.|Parallel arms, randomized 1:1 allocation.|t|t|t|t
34169542|NCT01155492|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34169543|NCT00471055|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34169544|NCT03691909|NA|SINGLE_GROUP||TREATMENT||NONE||A single IV infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in subjects with clinical diagnosis of RA.||||
34169545|NCT01259206|||CASE_CONTROL||PROSPECTIVE|||||||
34169546|NCT03558542|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34169547|NCT06202495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169548|NCT00428038|||CASE_CONTROL||PROSPECTIVE|||||||
34169549|NCT00269672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169550|NCT06436118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169551|NCT05052034|||OTHER||PROSPECTIVE|||||||
34169552|NCT05979740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169553|NCT06217939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169554|NCT05563129|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34169555|NCT00788307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169556|NCT00006053||||TREATMENT||||||||
34169557|NCT05224115|||COHORT||PROSPECTIVE|||||||
34169558|NCT03944928|||CASE_ONLY||PROSPECTIVE|||||||
34169559|NCT03543761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169560|NCT00723307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169561|NCT01420861|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34169562|NCT03938935|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34169563|NCT04204265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169564|NCT00649844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169565|NCT02964221|||COHORT||PROSPECTIVE|||||||
34169566|NCT02208102|||COHORT||PROSPECTIVE|||||||
33749008|NCT02491671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169567|NCT06256172|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34169568|NCT05655884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The research will be structured according to the CONSORT 2010 checklist of information to include when reporting a randomised trial (Schulz et al., 2010) to facilitate clarity, integrity, and transparency. The assignment of children to groups will be made using the simple randomization method. Children will not be informed about which group they are in (playing music, foot reflexology, control). The data collection tools of the study will be filled by the child, the parent, and an experienced university graduate nurse working in the day surgery clinic independent of the research. The nurse will be informed by the researcher about the scales to be used in the research. The researcher will not be involved in the data collection process, he will only observe the process. In addition, the database of the research will be created by a university graduate statistician working in a statistical center independent of the research, apart from the researcher."|This research was planned as randomized controlled, experimental.|t|f|f|t
34169569|NCT00982735|||COHORT||PROSPECTIVE|||||||
34169570|NCT03180385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169571|NCT04368260|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The primary objective of this study is to determine whether the newly designed nasopharyngeal swabs perform acceptably compared to standard swabs.||||
34169572|NCT02982902|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34169573|NCT03110471|||CASE_ONLY||PROSPECTIVE|||||||
34169574|NCT00213863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063363|NCT04714762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data will be anonomized (ID coded)||f|f|t|t
34169575|NCT03770312|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169576|NCT04565626|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34169577|NCT03210935|||COHORT||PROSPECTIVE|||||||
34169578|NCT02915666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857474|NCT04754477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857475|NCT02811185|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857476|NCT04523766|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33857477|NCT01692691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857478|NCT02773875|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857479|NCT04911556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant ,care provider,investigator and outcomes Assessor are all blind.|One group served as a control group, while the other three groups are treated with different strains of bifidobacterium longum|t|t|t|t
33857480|NCT03330353|||COHORT||PROSPECTIVE|||||||
33857481|NCT03398226|||COHORT||PROSPECTIVE|||||||
33857482|NCT05572333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the study, study participants, investigators, the sponsor, and all other persons involved in the conduct of the study will be blinded to treatment.|The study is double-blind, placebo-controlled and parallel-group in design.|t|f|t|f
34063364|NCT01505179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857483|NCT03545659|||COHORT||RETROSPECTIVE|||||||
33857484|NCT04531553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959419|NCT05109273|||COHORT||PROSPECTIVE|||||||
33959420|NCT02625961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959421|NCT02446197|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33959422|NCT00394992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959423|NCT02543229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959424|NCT02643810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959425|NCT02411110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169579|NCT05979844|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, single site study assessing the preliminary effectiveness, safety, and acceptability of an intervention consisting of MDMA-assisted bCBCT||||
33749009|NCT06294301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857485|NCT06494202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Different collaborators will be care providers and outcomes assessors.||f|t|f|t
33857486|NCT02253303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857487|NCT05925166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857488|NCT02489513|NA|SINGLE_GROUP||||NONE||||||
33857489|NCT02824263|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33857490|NCT05441917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857491|NCT00692302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857492|NCT01121835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857493|NCT02105350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857494|NCT03000361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857495|NCT01275001|||COHORT||PROSPECTIVE|||||||
33857496|NCT05105789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959426|NCT06702254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959427|NCT04289571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959428|NCT02223598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857497|NCT04293315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Pragmatic Cluster Randomized Controlled Trial. Implementation Hybrid Type 2 Study. It will be used:~Process Model: CFIR Theory of Change: COM-B Evaluation Framework: RE-AIM"||||
33857498|NCT01779687|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33959429|NCT05020197|||COHORT||PROSPECTIVE|||||||
33959430|NCT03214705|||COHORT||PROSPECTIVE|||||||
33959431|NCT06127979|NA|SINGLE_GROUP||OTHER||NONE||||||
33959432|NCT06118086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959433|NCT05329558|||CASE_CONTROL||PROSPECTIVE|||||||
33959434|NCT01506817|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33959435|NCT03285412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959436|NCT02228369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169580|NCT05936008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded to the participant's intervention group. Participants will not be given detailed information about the exercise groups.|"The Investigator will use an adaptive randomization design called minimization to ensure balance across groups. Intervention arms include:~1. Moderate intensity, continuous training exercise~2. High intensity, interval training exercise"|t|f|f|t
34169581|NCT04415203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169582|NCT01300234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169583|NCT00877240|NON_RANDOMIZED|PARALLEL||||NONE||||||
33857499|NCT03207555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857500|NCT02765607|||COHORT||PROSPECTIVE|||||||
33857501|NCT01783587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857502|NCT02083666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857503|NCT05779397|NA|SINGLE_GROUP||OTHER||NONE||||||
33857504|NCT00216879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857505|NCT03916848|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857506|NCT01466426|||CASE_CONTROL||PROSPECTIVE|||||||
33857507|NCT04317950|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33857508|NCT05381779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Triple (Participant, Investigator, Outcomes Assessor)Triple-blind study; the patients will not be informed about their groups (training group or the control group) and they will be evaluated and trained at different places and times.~Evaluations and interventions will be performed different physiotherapist. In addition, before statistical analysis patients' groups will be coded."||t|f|t|t
33857509|NCT00654472|||CASE_ONLY||PROSPECTIVE|||||||
33857510|NCT00537485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857511|NCT03442049|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33959437|NCT02233465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959438|NCT02258399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33959439|NCT04556500|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33959440|NCT00296582|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959441|NCT05705531|||COHORT||PROSPECTIVE|||||||
33959442|NCT06702969|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33959443|NCT04982718|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||Participants will be randomized to the intervention or control group in a 2:1 ratio. In the intervention group, participants will receive a HCV self-test (ST) kit delivered in non-identifiable packaging to their home or a preferred mailing address. In order to evaluate two sampling methods for HCV self-testing, the first 250 participants in the intervention group will receive an oral fluid-based HCV ST, and the next 250 participants will receive a blood-based fingerstick HCV ST. In the control group, participants will receive information about standard of care HCV antibody testing available at local testing sites in their community and information about additional supporting materials, such as access to live chat and a call center for questions about testing||||
33959444|NCT02314949|||COHORT||RETROSPECTIVE|||||||
33959445|NCT06257966|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized in a 1:1:1 ratio to the 1.2 mg JY09 injection group (n=200 cases), the 2.4 mg JY09 injection group (n=200 cases), and the dulaglutide injection group (n=200 cases).||||
33959446|NCT06356038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959447|NCT06673550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959448|NCT06701981|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959449|NCT05413850|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959450|NCT06236165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959451|NCT05312255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959452|NCT03713294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959453|NCT03403712|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063365|NCT05786612|RANDOMIZED|PARALLEL||TREATMENT||NONE||The clinical investigation is a two-arms, open-labelled, stratified, randomized, controlled, multicentre investigation comparing the clinical performance of Biatain® Silicone with standard of care in chron-ic wounds with wound depth down to 20 mm.||||
34063366|NCT06204120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169584|NCT03958175|||CASE_CONTROL||PROSPECTIVE|||||||
34169585|NCT04335643|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will either be randomly assigned to the intervention or to a wait-list period.||||
34169586|NCT03300401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169587|NCT03009786|||COHORT||PROSPECTIVE|||||||
33857512|NCT00825617|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169588|NCT02005367|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857513|NCT04314141|||COHORT||RETROSPECTIVE|||||||
33857514|NCT02151422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857515|NCT00696761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857516|NCT05941767|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33857517|NCT06434376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857518|NCT00688181|||CASE_ONLY||PROSPECTIVE|||||||
33857519|NCT05432778|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857520|NCT00926211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857521|NCT03800459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Blindness in the study was done by data collectors and statisticians. The data were collected by the nurse who did not know who is in the experiment and control group.~To reduce selection bias and to control the variables that may have an effect on outcome variables, random assignment was made to the experimental and the control group by a statistician who did not know the names and characteristics of the parents of and children with CF. The analysis of the data coded according to the groups was made by a statistician. After the statistical analyses were completed and the research report was written, the researcher explained the coding for the experimental and control group."||f|f|f|t
34169589|NCT05353595|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|protein and placebo are matched for flavour and provided in dark bottle. Independent person is responsible for drink randomization and preparation. Final blood and muscle analyses are performed by research personnel that was unaware of treatment allocation.|randomized, counter-balanced, cross-over design|t|f|t|t
34169590|NCT04759235|||COHORT||PROSPECTIVE|||||||
33857522|NCT01520896|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33857523|NCT03832296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Each eligible participant will be randomized to one of the two arms of the clinical trial (weight-loss maintenance, control) according to a variable block-length algorithm that will be controlled by the Data Management Group. Randomization will be stratified by intervention site to ensure nearly equal sample sizes for the two interventions to balance local population characteristics. Randomization uses a web-based system that is part of the study data management system. Intervention visits will not include any assessments and outcome assessors will remain blinded to group assignment. The lead biostatistician of the Data Management Group will develop the randomization table.|Participants will include 212 older adults aged ≥ 51 yrs. with knee OA who achieved a weight loss ≥ 5% in the D+E intervention arm of the WE-CAN trial. Eligible WE-CAN D+E participants will be randomized to either the weight-loss maintenance or health education attention control groups.|f|f|f|t
33857524|NCT00881608|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857525|NCT04300101|||COHORT||PROSPECTIVE|||||||
33857526|NCT01630122|||CASE_ONLY||PROSPECTIVE|||||||
33857527|NCT04577196|||OTHER||PROSPECTIVE|||||||
33857528|NCT01840787|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33857529|NCT05033418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857530|NCT02605421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857531|NCT00491543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857532|NCT00645541|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33857533|NCT01792193|||COHORT||PROSPECTIVE|||||||
33857534|NCT00189566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857535|NCT03421093|||COHORT||RETROSPECTIVE|||||||
33857536|NCT02244996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857537|NCT05048030|||COHORT||CROSS_SECTIONAL|||||||
33857538|NCT04792957|||CASE_ONLY||PROSPECTIVE|||||||
33857539|NCT01115972|RANDOMIZED|CROSSOVER||||NONE||||||
33857540|NCT02582125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857541|NCT00553423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34169591|NCT06075979|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34169592|NCT03609086|||CASE_ONLY||PROSPECTIVE|||||||
34169593|NCT00526292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169594|NCT00170872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169595|NCT00273338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169596|NCT04479085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||pretest-posttest, parallel group, randomized controlled study|f|f|f|t
34169597|NCT02495701|||COHORT||PROSPECTIVE|||||||
34169598|NCT05809921|||COHORT||RETROSPECTIVE|||||||
34169599|NCT01414894|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34169600|NCT04699890|||CASE_CONTROL||PROSPECTIVE|||||||
34169601|NCT03050801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169602|NCT02744092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749010|NCT03047668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749011|NCT02559674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749012|NCT02099838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749013|NCT02157038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857542|NCT00637923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857543|NCT05384262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be a randomized, single-blind (study center staff including the PI to remain blinded during the dosing phase of each cohort), placebo-controlled, SAD/MAD, sequential group design study in healthy male and/or female subjects, performed at multiple study centers.|This study will be a randomized, single-blind (study center staff including the Principal Investigator \[PI\] to remain blinded during the dosing phase of each cohort), placebo-controlled, Single Ascending Dose (SAD)/MAD, parallel type design in healthy male and/or female subjects, performed at multiple study centers.|t|f|f|f
33857544|NCT02388646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857545|NCT05363462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients involved in the protocol will be blinded|"Two groups of treatment with a surgical ankle fracture~1. Surgical treatment~2. Surgical treatment plus 1 g of topical vancomycin"|t|f|f|f
33857546|NCT06401460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169603|NCT03477734|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Males and females, 50 of them diagnosed with atrial fibrillation (AF), and 50 healthy participants, at least 30% of each gender in each group.||||
34169604|NCT02859246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169605|NCT04290039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169606|NCT02213835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169607|NCT04629755|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34169608|NCT05408962|||OTHER||OTHER|||||||
33749014|NCT02766530|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857547|NCT01941134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857548|NCT06058260|||CASE_CONTROL||PROSPECTIVE|||||||
33857549|NCT02742337|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33857550|NCT02802709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857551|NCT03849950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857552|NCT01937325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33857553|NCT01971203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857554|NCT04181151|||OTHER||PROSPECTIVE|||||||
33857555|NCT06200064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes were measured by separate physiotherapist, who did not provide prescribed intervention|This study is a four week, single blinded randomized controlled trial with pre-post design comparing self-stretching exercise group with post-isometric relaxation exercise group.|f|f|f|t
33857556|NCT04255069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857557|NCT05467397|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857558|NCT02598817|||COHORT||PROSPECTIVE|||||||
33857559|NCT00482508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857560|NCT00893646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857561|NCT04527120|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The examiners, examinees and statistician would be blinded to the nature of the model.~The model would be matched in colour shape and size with the commercially available model. The models would be covered by a plastic surgical drape, with a label on top that said model A or model B.~The models identity would be known only to the team leader. One the coin toss is complete and model allocated, the allocation would be marked unto a sealed envelope which would be opened only after data entry and analysis.~Any untoward event needing unmasking of the models like damage to the model, warranting replacement was also carried out by the team leader."||t|f|t|t
33959454|NCT05904769|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959455|NCT06410118|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will be compared to a waitlist control group.||||
33959456|NCT02564952|NA|SINGLE_GROUP||OTHER||NONE||||||
33959457|NCT06119373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959458|NCT01022177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959459|NCT02739074|||COHORT||PROSPECTIVE|||||||
34063367|NCT03403621|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization will done by the Research Pharmacy|"All participants will receive two treatments: drug and vehicle. Drug will be applied to one of two treatment sites. Vehicle will be applied to the other site. Treatment sites are distal and proximal end of the incision. Drug will be randomized to treatment site distal or proximal and masking will be as indicated. A 1-2 cm border zone will remain untreated in the middle of the scar."|t|t|t|f
34063368|NCT02589834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063369|NCT02358772|||COHORT||PROSPECTIVE|||||||
34063370|NCT06645821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063371|NCT04236375|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34063372|NCT01526876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063373|NCT03602833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063374|NCT00231283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857562|NCT03245970|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to treatment or non treatment group||||
33857563|NCT02079610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857564|NCT00832637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857565|NCT02752321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857566|NCT03041922|||CASE_ONLY||PROSPECTIVE|||||||
33857567|NCT01155375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857568|NCT04906447|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33857569|NCT00294554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063375|NCT02925377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063376|NCT01701505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063377|NCT03641313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063378|NCT05556265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34063379|NCT05839184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||randomised controlled|t|t|t|t
34063380|NCT05226234|||COHORT||RETROSPECTIVE|||||||
34063381|NCT02710916|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34063382|NCT00659516|||CASE_ONLY||PROSPECTIVE|||||||
34063383|NCT05159349|||COHORT||PROSPECTIVE|||||||
34063384|NCT05654675|||CASE_ONLY||PROSPECTIVE|||||||
33857570|NCT02497625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857571|NCT02116751|||COHORT||RETROSPECTIVE|||||||
33857572|NCT00003600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33857573|NCT03394430|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33857574|NCT03305354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857575|NCT03267940|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33857576|NCT05429333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857577|NCT04624685|||COHORT||PROSPECTIVE|||||||
33857578|NCT02308826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857579|NCT04308525|||COHORT||PROSPECTIVE|||||||
33857580|NCT05062083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857581|NCT04221386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33857582|NCT03411460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857583|NCT04612387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857584|NCT04942093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959460|NCT01465074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33959461|NCT00685048|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33959462|NCT02543515|||COHORT||PROSPECTIVE|||||||
33959463|NCT01770639|||CASE_ONLY||RETROSPECTIVE|||||||
33959464|NCT01879709|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33959465|NCT05166655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959466|NCT04433832|||COHORT||PROSPECTIVE|||||||
33959467|NCT06393738|NA|SEQUENTIAL||TREATMENT||NONE||The study will be initiated with the starting dose. The dose may be escalated to higher dose cohorts or de-escalated to lower dose cohorts based upon the safety and tolerability and as per a Cohort Review Committee recommendation. Backfill cohorts may be initiated at a previously cleared dose with select NHL subtypes||||
34169609|NCT06314334|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants were stratified according to the NRI prognostic index obtained from the baseline assessment (NRI \<2, NRI ≥2) and randomly assigned to three groups receiving different experimental treatments.~Group A (synchronous treatment group) received 4 cycles of Sintilimab combined with pegaspargase therapy. Concurrently, they received radiotherapy treatment. Group B (sequential treatment group) received 4 cycles of the PGEMOX regimen chemotherapy with sequential radiotherapy.~Group C (sandwiched radiotherapy group) received 2 cycles of the GELAD regimen chemotherapy initially, followed by radiotherapy and another two cycles GELAD chemotherapy."||||
34169610|NCT02113917|||COHORT||PROSPECTIVE|||||||
34169611|NCT06201260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959468|NCT00833976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959469|NCT03127943|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|double blind||t|t|f|f
33749015|NCT06385938|||CASE_CONTROL||OTHER|||||||
33749016|NCT04571398|||COHORT||PROSPECTIVE|||||||
33749017|NCT06134544|NA|SINGLE_GROUP||PREVENTION||NONE||Acutely decompensated cirrhosis ( with ascites).||||
33749018|NCT00572780|||COHORT||RETROSPECTIVE|||||||
33749019|NCT00303966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749020|NCT01839929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749021|NCT05496881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Participants will not be informed of the different study arms. Interventions will be scheduled to avoid contact between study arms. Participants will be asked to not describe their activities to those outside of their exercise group. Although it will not be possible to blind program instructors from the intervention that they deliver, instructors will not be aware of the expected results. Assessors and data analysts will be fully blinded to study arm allocation.|All interventions will involve 60-minute sessions delivered three times per week for 12 weeks. All interventions will involve the whole body but differ in content.|t|t|t|t
33749022|NCT04748744|||COHORT||PROSPECTIVE|||||||
33749023|NCT05674695|||COHORT||PROSPECTIVE|||||||
33749024|NCT02635633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749025|NCT03061253|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33749026|NCT06570863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749027|NCT04827212|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33959470|NCT04250896|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomized unit is the health center|Control group will receive standard child care in health units plus exposure to EsIAN (Strategy of Integral Attention to Nutrition of Mexico). At the same time as the intervention group, in addition to the control group, will receive SMS through a cell pone on practices related to the prevention of infant malnutrition (in primary caregivers) and the strengthening of counseling for the prevention of infant malnutrition with health providers.|t|t|f|t
33959471|NCT06083220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959472|NCT05617625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063385|NCT02278887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063386|NCT06174753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a single center, randomized, double-blind, parallel group study|t|t|t|f
34063387|NCT05935033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063388|NCT02810015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063389|NCT06608602|||CASE_CONTROL||PROSPECTIVE|||||||
33749028|NCT05654350|||CASE_CONTROL||RETROSPECTIVE|||||||
33857585|NCT02742623|||COHORT||PROSPECTIVE|||||||
33857586|NCT03956823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857587|NCT04409886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857588|NCT03077360|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33857589|NCT03240757|RANDOMIZED|PARALLEL||OTHER||NONE||randomized-crossover in healthy subjects||||
33857590|NCT04532372|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Phase I single-arm dose-escalation design followed by a phase II randomized two-arm design|t|f|t|f
33857591|NCT03442985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, double-blind, placebo-controlled|t|t|t|t
33857592|NCT00286520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959473|NCT06204536|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The PI will not be aware of cohort assignments.|Subsequent to conducting 2 non-interventional aims, the investigators will employ technology-based tools interventionally for the BCBAs for developing and managing an ABA treatment plan. The investigators divide the BCBAs into two interventional cohorts: one BCBA Tech cohort and one BCBA non-Tech cohort. The BCBA Tech cohort will have access to the full tech package from the start of this interventional aim; the BCBA non-Tech cohort will not have access to any tools from the tech package for the first 6 months. In the subsequent 18 months, they will receive one tool every 6 months until gaining access to the entire tech package.|f|f|t|f
33959474|NCT05963360|||COHORT||RETROSPECTIVE|||||||
33959475|NCT05221476|||COHORT||RETROSPECTIVE|||||||
33959476|NCT00378482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169612|NCT04694235|RANDOMIZED|PARALLEL||PREVENTION||NONE||A total of 653 pregnant women will be recruited from 40 villages in three sub-districts. Pregnant women will be randomly allocated into the intervention or control groups. Pregnant women in the intervention group will receive boiled eggs three times per week from 2nd trimester (16-20 weeks) until delivery.||||
34169613|NCT01360671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169614|NCT04610047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169615|NCT05723224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169616|NCT01071057|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169617|NCT05772741|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34169618|NCT00737646|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34169619|NCT00450970|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169620|NCT03826121|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169621|NCT00085163|RANDOMIZED|||TREATMENT||DOUBLE||||||
34169622|NCT03028298|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to either low dose sildenafil (20mg oral and 10mg intravenous) or high dose sildenafil (60mg oral and 30 mg intravenous)||||
34169623|NCT01121146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169624|NCT01096316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169625|NCT00601835|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33857593|NCT05090215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Randomization will occur using www.sealedenvelope.com. This will be performed by a member of the research team on the patient's first visit. Patients will not be blinded due to the active nature of the intervention. Any independent review performed of data will be done by a researcher who has been blinded to group allocation.~All possible analysis will be done in a single blinded manner (e.g., analysis of ultrasound scans, CPET, blood samples etc)."|Single centre randomised controlled trial|f|f|f|t
33857594|NCT02401360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857595|NCT04861025|||OTHER||PROSPECTIVE|||||||
33857596|NCT02740972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857597|NCT06312280|||CASE_ONLY||PROSPECTIVE|||||||
33857598|NCT03136328|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857599|NCT02688283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33857600|NCT02271425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857601|NCT00171704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857602|NCT02820337|||CASE_ONLY||PROSPECTIVE|||||||
34169626|NCT00973752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169627|NCT04458506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169628|NCT06084832|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34169629|NCT05254665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169630|NCT02519023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169631|NCT06502665|||COHORT||RETROSPECTIVE|||||||
34169632|NCT06555185|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169633|NCT05478941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169634|NCT02584946|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34169635|NCT01811888|||COHORT||PROSPECTIVE|||||||
34169636|NCT02536898|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34169637|NCT00361192|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169638|NCT06340022|RANDOMIZED|CROSSOVER||OTHER||NONE||The study was a single-center randomized controlled trial using a split mouth design with a 1:1 split ratio.||||
34169639|NCT00333008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169640|NCT03999515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169641|NCT04598022|||COHORT||PROSPECTIVE|||||||
34169642|NCT03651037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169643|NCT02793726|||COHORT||RETROSPECTIVE|||||||
34169644|NCT05800223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169645|NCT03652012|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169646|NCT04722874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169647|NCT02009319|||CASE_ONLY||PROSPECTIVE|||||||
34169648|NCT02008123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169649|NCT02640638|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34169650|NCT06304116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169651|NCT01192997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169652|NCT02161796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34169653|NCT01687361|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34169654|NCT02526277|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
34169655|NCT05339360|||COHORT||PROSPECTIVE|||||||
34169656|NCT01451723|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169657|NCT02475538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749029|NCT01814371|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749030|NCT02499874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749031|NCT01930370||CROSSOVER||TREATMENT||NONE||||||
33749032|NCT00105638|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33749033|NCT06105073|||COHORT||PROSPECTIVE|||||||
33749034|NCT01331473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749035|NCT01053208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33857603|NCT01236651|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33857604|NCT02902627|NA|SINGLE_GROUP||OTHER||NONE||||||
33857605|NCT04358900|||COHORT||PROSPECTIVE|||||||
33857606|NCT06503562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857607|NCT00551460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857608|NCT00353379|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33857609|NCT01136772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857610|NCT04893954|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33857611|NCT04615247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34063390|NCT05732558|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|all sensitive data regarding enrolled patients will be transmitted to the Outcomes Assessor anonymously (code assigned to the patient)|The study is designed to compare a prospective arm composed of 8 patients who were prescribed a CT-Guided bone biopsy (with the aid of endosight navigation system) with a retrospective arm with a bone lesion for which a percutaneous biopsy has been performed from January 2011 to May 2022 (without endosight navigation system)|f|f|f|t
34063391|NCT06174818|||OTHER||RETROSPECTIVE|||||||
34169658|NCT04363203|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Eligible, consented patients will be randomized to a 1:1:1 treatment allocation, stratifying by age (\<65, 65 or more) and region, and using randomly permutated blocks (block size of 3) within study site. Pharmacy is unblinded to study drugs.|A 3-arm RCT to determine the efficacy of hydroxychloroquine or azithromycin compared to placebo in treating mild to moderate COVID-19 among Veterans in the outpatient setting.|t|t|t|t
34169659|NCT03168113|||CASE_CONTROL||PROSPECTIVE|||||||
34169660|NCT00981097|||COHORT||PROSPECTIVE|||||||
34169661|NCT00008008||||TREATMENT||NONE||||||
34063392|NCT03996564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063393|NCT02812251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063394|NCT05164341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169662|NCT00504088|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169663|NCT05581017|||COHORT||RETROSPECTIVE|||||||
33857612|NCT04127149|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063395|NCT02388711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34169664|NCT03973216|NA|SINGLE_GROUP||TREATMENT||NONE||This study evaluates the effect of the intervention using a single group, before-after study model. The subjects will be evaluated at baseline and followed longitudinally, until study completion and a long-term followup.||||
34169665|NCT01831167|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34169666|NCT02872116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169667|NCT02107066|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34169668|NCT05299476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169669|NCT04169165|||COHORT||PROSPECTIVE|||||||
33749036|NCT05167864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinding of participant and provider administering the treatment|randomized controlled trial in which patients will be randomly assigned into one of four groups|t|t|f|f
33857613|NCT02586922|||COHORT||PROSPECTIVE|||||||
33857614|NCT04367987|||COHORT||PROSPECTIVE|||||||
34063396|NCT04811664|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34169670|NCT03634085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind, placebo-controlled|In Sessions I to VI, 6 single, orally administered ascending doses of BDM-2 or placebo will be investigated, alternately dosed in 2 cohorts of 8 healthy male subjects each (Cohorts A and B). For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo. In Sessions I to VI, doses are planned to be administered under fasted conditions.|t|f|t|f
34169671|NCT01799707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063397|NCT05061602|||COHORT||CROSS_SECTIONAL|||||||
34169672|NCT04992117|||COHORT||PROSPECTIVE|||||||
34169673|NCT05238389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169674|NCT02968264|||COHORT||PROSPECTIVE|||||||
34169675|NCT04198025|||COHORT||RETROSPECTIVE|||||||
34169676|NCT03418155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169677|NCT03844399|||COHORT||PROSPECTIVE|||||||
34169678|NCT03881839|||COHORT||PROSPECTIVE|||||||
34169679|NCT03360266|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator is masked in application of fluoride varnish and during all followup visits|The study model involves three groups|f|f|t|f
34169680|NCT04044768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169681|NCT02579668|NA|SINGLE_GROUP||||NONE||||||
34169682|NCT06083649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34169683|NCT06036277|||CASE_CONTROL||RETROSPECTIVE|||||||
34169684|NCT00702858|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34063398|NCT01732445|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34169685|NCT02602535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169686|NCT00004164||||TREATMENT||||||||
34169687|NCT05147181|||COHORT||PROSPECTIVE|||||||
34169688|NCT06021639|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Randomization will be planned 1 to 1 according to the order of application. Randomization will be planned by the endoscopy nurse in the endoscopy unit and will not be known to the endoscopist who will perform the procedure.|"Clear diet group (72 patients) 250 ml Sennozit A+B calcium (half dose is taken orally at 17.00 on the day before the procedure and the other half at 19.00 will be consumed. Enema 210 cc (Monobasic sodium phosphate 28.5 g. Dibasic sodium phosphate 10.5 g.) The procedure is rectal at 07.00 in the morning. will be used as Routine feeding of the patient up to the last 24 hours before the procedure. The last 24 hours will consume clear diet.~Low fiber diet group (72 patients) 250 ml Sennozit A+B calcium (half dose is taken orally at 17.00 on the day before the procedure and the other half at 19.00 will be consumed. Enema 210 cc (Monobasic sodium phosphate 28.5 g. Dibasic sodium phosphate 10.5 g.) The procedure is rectal at 07.00 in the morning. will be used as Routine feeding of the patient up to the last 24 hours before the procedure. He/she will consume low fiber food in the last 24 hours."|f|f|t|f
34169689|NCT03148535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169690|NCT02486575|RANDOMIZED|PARALLEL||||NONE||||||
34169691|NCT02906423|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34169692|NCT01217944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169693|NCT04061850|||COHORT||RETROSPECTIVE|||||||
34169694|NCT00467740||PARALLEL||TREATMENT||||||||
34169695|NCT03573934|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34169696|NCT01285817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169697|NCT04925349|||CASE_CONTROL||PROSPECTIVE|||||||
34169698|NCT00364676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169699|NCT05020132|||COHORT||PROSPECTIVE|||||||
34169700|NCT02868554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34169701|NCT03752047|||COHORT||RETROSPECTIVE|||||||
34169702|NCT03298802|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization will be performed by a person not involved in the clinical trial using a computer random list of numbers generated using STATA (StataCorp 14.0, Dallas, TX). This list of random number assignments will be kept secure and sent directly to the investigational drug service (IDS), who will be responsible for the allocation and dispensing of the medications|double-blind randomized placebo controlled clinical trial|t|t|t|f
34169703|NCT01173601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169704|NCT01631435|NA|SINGLE_GROUP||OTHER||NONE||||||
34169705|NCT02195908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169706|NCT02828371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34169707|NCT03253042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34169708|NCT03282461|NA|SINGLE_GROUP||TREATMENT||NONE|none - open label|open label||||
34169709|NCT02743273|||CASE_CONTROL||PROSPECTIVE|||||||
34169710|NCT05148364|||CASE_ONLY||PROSPECTIVE|||||||
34169711|NCT05241379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169712|NCT01009658|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34169713|NCT04977440|||COHORT||PROSPECTIVE|||||||
34169714|NCT06020157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169715|NCT00182169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169716|NCT03389022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169717|NCT00138593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749037|NCT02087163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749038|NCT06670794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749039|NCT03755453|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||All participants will receive a hearing aid fitted with fitting method A and afterwards fitted with fitting method B.|t|f|f|f
34063399|NCT05477992|NA|SINGLE_GROUP||OTHER||NONE||Non-randomised interventional feasibility study at a single institution||||
34063400|NCT05718141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel groups (1:1 allocation) Randomised controlled trial (RCT) design, with a waiting list control group who will have the opportunity to access the intervention at the end of the follow-up period (i.e. 4 weeks after randomisation).|f|f|t|t
34063401|NCT06260475|||COHORT||RETROSPECTIVE|||||||
34063402|NCT02589353|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749040|NCT03156049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063403|NCT05451394|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"The preventive program will be deployed in the first unit selection camp, then in the second the active control program will be deployed."||||
33857615|NCT06406556|NA|SINGLE_GROUP||TREATMENT||NONE||Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks) followed by 4 courses of pegaspargase.||||
33857616|NCT00050388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857617|NCT01919710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169718|NCT00887302|||COHORT||PROSPECTIVE|||||||
34169719|NCT02478008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169720|NCT04344223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Data and statistical analyses||f|f|f|t
34169721|NCT05361616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169722|NCT03022877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169723|NCT05865626|RANDOMIZED|CROSSOVER||OTHER||NONE||In the intervention group, 20 subjects will receive a smartphone and one of the two incentives (close-follow-up or a financial incentive) over a 12 weeks period. After this period, the participant will receive the second incentive. The order is determined randomly with 10 participants receiving the incentives. Participants may receive a third incentive (social feedback) the earliest 6 weeks after the beginning of the treatment, in addition to the basic incentive. The 10 participants in the control group will not receive a smartphone but will be followed-up monthly.||||
34169724|NCT04107662|||COHORT||PROSPECTIVE|||||||
34169725|NCT03975322|||CASE_ONLY||PROSPECTIVE|||||||
34169726|NCT04684264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169727|NCT01418638|||COHORT||PROSPECTIVE|||||||
34169728|NCT06112574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34169729|NCT01027715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169730|NCT05327179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Individual with cerebral palsy will be assigned to group 1 or group 2 by simple randomization using the Research Randomiser program (http://www.randomizer.org/) prior to treatment."|f|f|f|t
34169731|NCT01256268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857618|NCT00086034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857619|NCT00822588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857620|NCT00184821|||DEFINED_POPULATION||OTHER|||||||
33857621|NCT00639912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959477|NCT06283771|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|An independent biostatistician, who is not involved in the study, will select 70 individuals from the list of students enrolled between 1-250 by computer-generated randomization. The information that the volunteers included in the research sample were assigned to group A (experimental) and B (control) according to the randomization table will be kept by the researcher and the socks with the same appearance, with and without heating feature will be numbered from 1 to 70 according to the randomization table and given to the researcher. Thus, the practitioner will be blinded as he/she does not know which sock has a heating feature and which one does not. Healthy volunteers will be blinded because they do not know which group they are in. The data will be analyzed by a statistician independent of the research and the findings will be reported. Thus, the data analysis and statistics phase will also be blinded to group assignment.|The research was planned as a prospective, two-arm (1:1), randomized controlled, double-blind study|t|f|t|t
34169732|NCT01388517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169733|NCT04955171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169734|NCT03908333|NA|SINGLE_GROUP||TREATMENT||NONE||Ascorbic Acid Paclitaxel Protein Bound Cisplatin Gemcitabine||||
34169735|NCT04403412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers will participate in the operation to record operative parameters such as LA pressure. Other researchers including follow-up personnel and the ultrasonic data analyst are uninformed about the random situation of the patients (patient information is recorded according to the random number. Random numbers corresponding to the random allocation list are stored in the research center. After follow-up of the last patient is completed, the random allocation list is published by the random number designer; and the designer does not participate in the data collection and statistics.)|A total of 105 patients with persistent atrial fibrillation(AF), who are persistented more than one year and planned to undergo surgical treatment, will be allocated into two groups. These patients will receive left atrial appendage closure, radiofrequency ablation under the guidance of 3D mapping and left atrial appendage closure combined with radiofrequency ablation, respectively (allocation ratio, 1:1:1).|t|f|f|t
34169736|NCT06187259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
34169737|NCT00925834|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34169738|NCT01790594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169739|NCT01364714|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33857622|NCT01074671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857623|NCT01177787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857624|NCT04777526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857625|NCT00649090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857626|NCT03225495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857627|NCT06411483|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomized to receive active or placebo (inactive) bands.|An active device arm will be compared to an inactive device (placebo) arm|t|f|f|f
33857628|NCT02732054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959478|NCT03967418|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959479|NCT05137262|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959480|NCT04920565|RANDOMIZED|PARALLEL||PREVENTION||NONE|Using the matching method, a control group of 10 patients (historical randomization without endotoxemia assessment) with multiple organ dysfunction (SOFA ≥5, use of vasopressors) will be formed using the Oxyris universal set for renal replacement therapy for 72 hours.|"In 10 patients meeting three of the following criteria: SOFA ≥5 points, PCT\> 2 ng / ml; CRP\> 150 ng / ml, vasopressor use, intestinal paresis and / or positive blood culture data - as well as with an EAA level above 0.6, a hemoperfusion procedure with polymyxin B will be performed for 12 hours.~- with an initial EAA level of more than 0.9, 2 hemoperfusion procedures will be performed with a difference of 12 hours"||||
34063404|NCT01810783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063405|NCT00899704|||CASE_ONLY||RETROSPECTIVE|||||||
34169740|NCT00716235|||CASE_CONTROL||PROSPECTIVE|||||||
33857629|NCT01243697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857630|NCT04598204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857631|NCT05031208|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33959481|NCT06233175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|I will assess the patient before and after end of intervention programme||t|f|f|t
34169741|NCT03360123|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34169742|NCT05318261|||COHORT||PROSPECTIVE|||||||
34169743|NCT05036174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169744|NCT01378559|||CASE_ONLY||RETROSPECTIVE|||||||
34169745|NCT05238077|NA|SINGLE_GROUP||TREATMENT||NONE||The subject serves as their own control.||||
34169746|NCT05376384|||CASE_CONTROL||PROSPECTIVE|||||||
34169747|NCT00660192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169748|NCT00556075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857632|NCT00807235|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169749|NCT05664321|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34169750|NCT05754216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All patients who meet eligibility will undergo a planned resection of parapharyngeal space (PPS) mass for management of head and neck cancer and will have measurements and photos/videos of the common trunks taken. Fine-wire electrodes will be placed on these nerve branches. For each patient, if the target nerve branches can be identified and electrodes successfully placed, they will additionally undergo drug-induced sleep endoscopy (DISE) immediately following PPS surgery.||||
34169751|NCT06185465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169752|NCT03965975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959482|NCT01635127|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959483|NCT04864847|||COHORT||PROSPECTIVE|||||||
34169753|NCT04507022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169754|NCT03555461|||COHORT||PROSPECTIVE|||||||
34169755|NCT03041571|||COHORT||PROSPECTIVE|||||||
34169756|NCT00439257|||||PROSPECTIVE|||||||
34169757|NCT01129622|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169758|NCT00780117|||COHORT||PROSPECTIVE|||||||
34169759|NCT01410890|NA|SINGLE_GROUP||OTHER||NONE||||||
34169760|NCT00837915|RANDOMIZED|CROSSOVER||||NONE||||||
34169761|NCT00790426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169762|NCT05987358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749041|NCT04210453|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither participants, all care providers, investigators nor outcomes assessors know the treatment allocations.|Patients are divided into 2 groups, who are administered IV Vitamin C or who are administered IV normal saline.|t|t|t|t
33749042|NCT06414434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857633|NCT04888325|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33857634|NCT01762722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857635|NCT02455219|||CASE_ONLY||PROSPECTIVE|||||||
33857636|NCT00815672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33857637|NCT02917278|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857638|NCT03797079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation, perform the block, and administer bupivacaine solution.|Prospective, randomized, double blind study|t|f|f|t
33857639|NCT02782130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857640|NCT01679353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959484|NCT06012175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959485|NCT05090722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959486|NCT06056531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Because of the nature of the device and the procedure of venipuncture, blinding could not be performed|This is a prospective, randomized controlled experimental study.||||
33959487|NCT05442515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959488|NCT01093482|||COHORT||PROSPECTIVE|||||||
33959489|NCT05802342|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"This study was randomly divided into 3 groups at 1:1:1 with 50 subjects in each group. The treatment plan was as follows.~Group A: GM1 (100 mg) + albumin paclitaxel; Group B: GM1 (400 mg) + albumin paclitaxel; Group C: placebo + albumin paclitaxel;"|t|t|t|t
33959490|NCT01057160|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959491|NCT03105089|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33959492|NCT00704990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959493|NCT03105882|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33959494|NCT06701110|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study involves a single cohort of healthy male volunteers receiving a single oral dose of \[U-14C\] WX-081 to evaluate pharmacokinetics, metabolism, and mass balance.||||
33959495|NCT04199104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169763|NCT02787395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169764|NCT06001346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34169765|NCT02754973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34169766|NCT03836625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34169767|NCT04745585|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169768|NCT04948853|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized control trial||||
34169769|NCT05313789|||CASE_ONLY||PROSPECTIVE|||||||
34169770|NCT01389882|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34169771|NCT04855344|||COHORT||PROSPECTIVE|||||||
34169772|NCT00860730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169773|NCT05313113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169774|NCT00301795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169775|NCT01329302|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34169776|NCT05242029|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants, care providers, investigators, and outcomes assessors will be blinded for the duration of the trial.|Participants will be randomized to an active group or control group (46 per group). Participants will undergo a total of 2 dosing sessions (whether psilocybin or placebo). The active group will receive 40mg psilocybin first. All participants will receive a second dosing session at three months. The active group will be further randomized, with half receiving 40mg psilocybin, and half receiving placebo at three months.|t|t|t|t
33749043|NCT04250194|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749044|NCT04654338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857641|NCT05090553|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|Neither the patient nor the surgeons will have access to the results of microbiological cultures or molecular analysis. The radiologist who will review the exams will also be blinded to patient data and laboratory results. The researcher who will analyze the pain and function scores will also be blinded.||t|t|t|t
33857642|NCT01612624|||CASE_CONTROL||PROSPECTIVE|||||||
33857643|NCT00454389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857644|NCT03181750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Principal Investigator and outcomes assessor blinded to group allocation.|Multi-site Randomized Controlled Trial|f|f|t|t
33857645|NCT02047292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857646|NCT01866618|||COHORT||PROSPECTIVE|||||||
33857647|NCT01008215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857648|NCT02709421|||||RETROSPECTIVE|||||||
34169777|NCT06391099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857649|NCT05578144|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33857650|NCT00214838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857651|NCT02931799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33857652|NCT00157144|||||RETROSPECTIVE|||||||
33959496|NCT00689273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33959497|NCT04060927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169778|NCT06461988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169779|NCT05878834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33857653|NCT02225353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169780|NCT00322881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169781|NCT05973734|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients are planned to receive an islet transplantation. The patients will also receive either Arm 1) recipient T regulatory cell infusion or arm 2) same donor vertebral body derived bone marrow cell infusion. Attribution to either arm will be based on the availability of either cell product in specific cases.||||
34169782|NCT00004458|||||OTHER|||||||
34169783|NCT04053257|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Quasiexperimental, before and after study||||
34169784|NCT02376764|||COHORT||PROSPECTIVE|||||||
34169785|NCT00778778|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34169786|NCT03369821|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34169787|NCT01390896|||||PROSPECTIVE|||||||
34169788|NCT06037915|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169789|NCT02549547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169790|NCT00953602|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33959498|NCT03904498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33959499|NCT00028938|RANDOMIZED|||TREATMENT||||||||
33959500|NCT02858167|NA|SINGLE_GROUP||||NONE||||||
34169791|NCT04133870|||COHORT||PROSPECTIVE|||||||
34169792|NCT05513352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|single-blind|"Experiment 1:~* between-subject design~* 3x4 = 3(hearing group) x 4(condition)~* Masking: Single (Participant)~* Masking Description: single-blind~Experiment 2:~* between-subject design~* 3x4 = 3(hearing group) x 4(condition)~* Masking: Single (Participant)~* Masking Description: single-blind~Experiment 3:~* between-subject design~* 3x2x2x4 = 3(hearing group) x 2 (stimulation) x 2(timepoint) x 4(condition)~* Masking: Double (Participant, investigator)~* Masking Description: double-blind~Experiment 4:~* between-subject design~* 3x2x2x4 = 3(hearing group) x 2 (stimulation) x 2(timepoint) x 4(condition)~* Masking: Double (Participant, investigator)~* Masking Description: double-blind~Experiment 5:~* within-subject design~* 2x2x4 = 2 (training) x 2(timepoint) x 4(condition)~* Masking: Double (Participant, investigator)~* Masking Description: double-blind~Primary Purpose: Basic Science"|t|t|f|t
34169793|NCT01582815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169794|NCT02444429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34169795|NCT00923858|||CASE_CONTROL||PROSPECTIVE|||||||
34169796|NCT04955717|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Clinic randomized trial evaluating the effectiveness of antenatal CT and NG screening and treatment compared to the standard of care (treatment based on signs and symptoms) on pregnancy and neonatal outcomes.||||
34169797|NCT04825301|||COHORT||RETROSPECTIVE|||||||
34169798|NCT03137992|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind|Double-blind, double-dummy, placebo controlled|t|f|t|t
34169799|NCT05936489|RANDOMIZED|PARALLEL||TREATMENT||NONE|this is an open label study.|A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics||||
34169800|NCT02055326|RANDOMIZED|PARALLEL||||NONE||||||
34169801|NCT06352580|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33857654|NCT04557111|||CASE_ONLY||PROSPECTIVE|||||||
33959501|NCT00883259|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33959502|NCT03633773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857655|NCT04300088|||COHORT||PROSPECTIVE|||||||
33857656|NCT03911011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A field study designed as a crossover clinical trial.||||
33857657|NCT03607539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857658|NCT02230553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857659|NCT02805608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857660|NCT01972256|||COHORT||RETROSPECTIVE|||||||
33857661|NCT00461838|||COHORT||RETROSPECTIVE|||||||
33857662|NCT02844881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857663|NCT03969550|||COHORT||RETROSPECTIVE|||||||
33857664|NCT01541553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857665|NCT00751842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169802|NCT02721875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169803|NCT03826108|||CASE_CONTROL||RETROSPECTIVE|||||||
34169804|NCT01105910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34169805|NCT03749759|NA|SINGLE_GROUP||OTHER||NONE||||||
34169806|NCT04018053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169807|NCT02051452|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34169808|NCT02870777|NA|SINGLE_GROUP||TREATMENT||NONE||MRD-directed therapy||||
34169809|NCT02375659|||COHORT||PROSPECTIVE|||||||
34169810|NCT03892616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34169811|NCT00099372|||COHORT||PROSPECTIVE|||||||
34169812|NCT02349633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749045|NCT03955653|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||Patients will be randomized equally to the right anterior oblique view using fluoroscopy and the access to the femoral artery will be compared to that in the anterior-posterior projection|t|t|f|t
33857666|NCT03445351|NA|SINGLE_GROUP||PREVENTION||NONE||Intervention study, prospective, a cohort with 17 PLHA participants of the exercise program||||
33857667|NCT01829399|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33857668|NCT02642731|||COHORT||PROSPECTIVE|||||||
33857669|NCT00001984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857670|NCT02453360|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33857671|NCT00992251|||CASE_ONLY||PROSPECTIVE|||||||
33857672|NCT02092779|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33857673|NCT06370468|||OTHER||CROSS_SECTIONAL|||||||
33857674|NCT05604638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857675|NCT03867058|||COHORT||PROSPECTIVE|||||||
33857676|NCT00675805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33959503|NCT04808427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959504|NCT00950378|||CASE_CONTROL||PROSPECTIVE|||||||
33959505|NCT01612052|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33959506|NCT06360523|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|AI review (index) and radiologist review (standard) will be blinded to each other, while biopsy urologists will be well-informed of the findings of both AI review and radiologist review and make personalized biopsy plan by combining both findings.||f|t|f|f
33959507|NCT04586023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor will also be blinded.||t|f|t|f
33959508|NCT00597727|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"For the initial 12 months of the study, subjects were blinded to receive either peanut SLIT or placebo. After unblinding, subjects on placebo are crossed over to receive open-label peanut SLIT. They underwent an identical dosing protocol as those that were initially randomized to active treatment.~After 12 months of peanut SLIT dosing, whether initially randomized to active or crossed over from placebo, all subjects remained part of an open-label extended maintenance phase for the duration of the study (total peanut SLIT dosing 36-60 months)~2 additional cohorts were included in the protocol. One cohort, called the Early Unblinded Peanut SLIT cohort, was unblinded prior to the scheduled 12 month time point for pharmacy safety concerns. The second cohort, called the Pilot Peanut SLIT Rollover cohort involved subjects from the prior pilot study (NCT00429429) who were added to the study through an amendment and received open-label peanut SLIT."|t|t|t|f
33959509|NCT06442137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug. An independent researcher (not involved in the trial operations or evaluations) is responsible for managing the randomization sequence and drug coding, and will distribute the appropriate drugs to participants at the right times. This ensures that the trial operators and evaluators are unaware of the treatment type; only the independent researcher has this knowledge. During the experiment, the assessment of treatment effects and the recording of adverse events are carried out by independent evaluators who are unaware of the treatment groups. Both the trial operators and the evaluators do not have access to the drug coding and randomization sequence.|Participants are assigned to one of two groups in parallel for the duration of the study|t|t|t|t
33959510|NCT02987504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959511|NCT05485571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959512|NCT06234605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959513|NCT02367781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959514|NCT06410573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33959515|NCT05295641|||COHORT||PROSPECTIVE|||||||
33959516|NCT01766973|||CASE_CONTROL||PROSPECTIVE|||||||
33959517|NCT04323449|RANDOMIZED|CROSSOVER||OTHER||NONE||After baseline, participants will be asked to complete the tasks with two control methods (the new vision-guided control vs the default control). The tasks will be randomly presented to each participant and the sequence of the two control methods will be counterbalanced.||||
33959518|NCT04541992|||COHORT||PROSPECTIVE|||||||
33959519|NCT05327023|NA|SEQUENTIAL||TREATMENT||NONE||||||
33959520|NCT04820335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959521|NCT00786656|||OTHER||CROSS_SECTIONAL|||||||
33959522|NCT01365676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33959523|NCT01869595|||COHORT||PROSPECTIVE|||||||
33959524|NCT04000529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959525|NCT06562335|NA|SINGLE_GROUP||PREVENTION||NONE||multiple baseline single case experimental AB-phase design||||
34063406|NCT01388504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063407|NCT06404840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063408|NCT04836208|||COHORT||PROSPECTIVE|||||||
34063409|NCT05817812|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063410|NCT04353154|||COHORT||PROSPECTIVE|||||||
34063411|NCT02862925|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063412|NCT04293835|||CASE_CONTROL||RETROSPECTIVE|||||||
34063413|NCT04559425|||COHORT||PROSPECTIVE|||||||
34063414|NCT05247021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063415|NCT05350345|||COHORT||CROSS_SECTIONAL|||||||
34063416|NCT05585554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063417|NCT04696653|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34063418|NCT06655701|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063419|NCT04129775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34063420|NCT03030885|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1, open-label, single-arm, dose ascending, out-patient study to evaluate the radiopharmaceutical 131I-MIP-1095 in men with mCRPC. The study consists of three phases: Screening, Treatment, and a Follow-up Phase. The Screening Phase consists of subject evaluation for study eligibility and dosimetry assessment. The Treatment Phase consists of two parts: Part 1, dose escalation (Cohorts 1-5), and Part 2, an additional cohort at a selected optimized dose based on safety and efficacy.||||
34169813|NCT04736914|NA|SINGLE_GROUP||TREATMENT||NONE||Zanubrutinib Combined with R-CHOP，R-DHAOx||||
34169814|NCT01862289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169815|NCT03707353|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169816|NCT06116734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959526|NCT06568354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857677|NCT00581490|||CASE_CONTROL||PROSPECTIVE|||||||
33857678|NCT05912582|||COHORT||PROSPECTIVE|||||||
33857679|NCT05545657|||COHORT||CROSS_SECTIONAL|||||||
33857680|NCT06385405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||To test the hypothesis that repetitive transcranial magnetic stimulation based on individualized EEG modulation may be more effective in promoting symptomatic relief of major depressive disorder (MDD), patients were tested in a parallel controlled trial.During the treatment period, patients will be randomly grouped into the precision group, which will be treated with rTMS based on personalized modulation of EEG data, and the conventional group, which will be treated with TMS at a frequency of 10 Hz to stimulate the left dorsolateral prefrontal cortex (DLPFC).|t|f|f|t
33857681|NCT05937139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and the health care provider will not know which group the participants are assigned to.|The research is planned to be carried out as an experimental design with four groups of solomon. The randomization of the participants will be made using a computer program and the participants will be assigned to the experimental and control groups in this way|t|t|f|f
33857682|NCT01386281|||CASE_ONLY||PROSPECTIVE|||||||
33857683|NCT03416998|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33857684|NCT04512300|||OTHER||CROSS_SECTIONAL|||||||
34169817|NCT01947036|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34169818|NCT01917383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169819|NCT02138890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169820|NCT01091675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169821|NCT06238440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective. A randomized controlled double-blind study.|t|f|f|t
34169822|NCT03107260|NA|SINGLE_GROUP||OTHER||NONE||||||
34169823|NCT05452889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169824|NCT02326038|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34169825|NCT02677298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857685|NCT06502431|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34169826|NCT06411717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34169827|NCT05123534|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Drug/energy dose escalation to identify the RP2D as guided by BOIN for the combination of SONALA-001 and Exablate 4000 Type 2.0 MRgFUS.~The primary focus of the proposed study is safety, tolerability and determination of the MTD and RP2D; therefore, statistical modeling and inferential statistics are not planned."||||
34169828|NCT04699565|||COHORT||PROSPECTIVE|||||||
34169829|NCT01344915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169830|NCT02159066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857686|NCT01326533|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33857687|NCT05741151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959527|NCT03539939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959528|NCT03086980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33959529|NCT04715737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design|t|f|t|t
33959530|NCT03622086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959531|NCT06588413|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33959532|NCT05807217|||OTHER||PROSPECTIVE|||||||
33959533|NCT01327807|||||CROSS_SECTIONAL|||||||
33959534|NCT04190966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959535|NCT02360124|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33959536|NCT01406769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33959537|NCT04723173|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33959538|NCT06520722|||CASE_CONTROL||PROSPECTIVE|||||||
33959539|NCT05340517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959540|NCT06544473|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The patients with TS will be randomized to receive either oral (tablet) or transdermal (gel) estrogen replacement therapy. The study is not blinded, as both investigator and study participants know which medication, they are receiving.|A randomized crossover study||||
33959541|NCT05478499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959542|NCT00951899|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33959543|NCT06540183|||COHORT||RETROSPECTIVE|||||||
33959544|NCT05267184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|telephone interview at 3 and 12 months by clinical outcomes assessor blinded to treatment.||f|f|f|t
34063421|NCT06643637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a randomized, double-blind, placebo-controlled multiple dose study to assess the safety, tolerability, and pharmacokinetics of MLS101 in healthy participants.~Multiple Dose (MD): 16 participants will be enrolled in two dose cohorts and will be randomized to receive multiple doses of MLS101 or placebo. An additional cohort (8 participants) may enrolled to explore more doses."|t|t|t|t
34169831|NCT06356402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34169832|NCT00048412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169833|NCT05279352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169834|NCT04950244|||COHORT||PROSPECTIVE|||||||
33857688|NCT05566314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33857689|NCT05758311|||OTHER||CROSS_SECTIONAL|||||||
33857690|NCT04196608|||COHORT||PROSPECTIVE|||||||
34063422|NCT04260386|||COHORT||CROSS_SECTIONAL|||||||
34063423|NCT01315652|RANDOMIZED|PARALLEL||||NONE||||||
34169835|NCT01259141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169836|NCT00468026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169837|NCT00359463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169838|NCT05361824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|100ml infusion bottles identical in every aspect, except a unique label on them which was only known to investigator.|Computer generated, randomized selection of patients with 50% probability of assignment into either group Treatment group : Ketorolac group Control Group: Paracetamol|t|f|f|f
34169839|NCT00324207|||COHORT||PROSPECTIVE|||||||
34169840|NCT03753685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169841|NCT06148207|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063424|NCT03796676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063425|NCT05337917|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34169842|NCT04055675|||COHORT||PROSPECTIVE|||||||
34169843|NCT02525471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169844|NCT03410628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169845|NCT02232035|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34169846|NCT04622111|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Only PART B will be double-blind||t|f|t|f
34169847|NCT02016196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34169848|NCT01856699|||CASE_CONTROL||PROSPECTIVE|||||||
34169849|NCT04647201|||COHORT||RETROSPECTIVE|||||||
34169850|NCT03788057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Clinician takes decision about possible change in treatment basing on clinical data only - is not aware of the results of the inflammatory parameters measurements|A prospective, observational, interventional, single blind study. Clinician takes decision about possible reduction of ICS dose basing on clinical data only - is not aware of the results of the inflammatory parameters measurement.||||
34169851|NCT05150184|||COHORT||PROSPECTIVE|||||||
34169852|NCT00883363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169853|NCT04649112|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34169854|NCT03473236|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34169855|NCT00115505|||CASE_ONLY||PROSPECTIVE|||||||
34169856|NCT03239834|||COHORT||PROSPECTIVE|||||||
34169857|NCT02963454|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34169858|NCT03865446|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34169859|NCT02268149|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34169860|NCT06515587|NA|SINGLE_GROUP||SCREENING||NONE||||||
34169861|NCT05706779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169862|NCT01222845|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34169863|NCT03522298|NA|SINGLE_GROUP||TREATMENT||NONE||This phase 2 study comprises an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, RP2D, PK and clinical activity of paxalisib in patients with newly-diagnosed GBM with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with TMZ.||||
34169864|NCT01132807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169865|NCT05218369|||COHORT||PROSPECTIVE|||||||
34169866|NCT00267215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169867|NCT01780857|||COHORT||PROSPECTIVE|||||||
34169868|NCT03921827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome will be assessed by independent assessors for stroke/TIA recurrence within 6 months as well as change in cerebral vasodilatory reserve on acetazolamide challenged HMPAO- SPECT of brain.|Randomized clinical trial with 1:1 allocation to EECP therapy and best medical therapy|f|f|f|t
34169869|NCT03147846|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|closed envelop method||t|f|f|t
34169870|NCT03910504|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33857691|NCT03559998|||COHORT||PROSPECTIVE|||||||
33857692|NCT02832661|||COHORT|||||||||
34169871|NCT03416140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169872|NCT04712955|RANDOMIZED|PARALLEL||OTHER||NONE||Single center randomised controlled trial.||||
34169873|NCT01488045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34169874|NCT02093507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169875|NCT05086497|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33959545|NCT03203265|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||Prospective study to evaluate the first-time HIV testing, successful referral to HIV treatment, retention HIV testing among 3 different study groups. A participants will receive offline HIV testing,counseling and conventional retention strategies. HIV-positive result in A can choose to have either online or offline to HIV treatment. B1 participants will be guided to access services at the 'Adam's Love Clinic, that set up specifically to provide private, fast HIV testing and post-test counseling. B2 participants will be mailed a rapid HIV test kit. Counselor will guide the participant through an online HIV testing process. Post-test counseling will provided HIV test result online. Participants can choose one of two HIV testing and post-test counseling options. HIV-positive participants in B1 and B2 can choose again to refer to HIV treatment either online or offline. All participants in B1 and B2 will receive an online retention strategy.|t|f|f|f
33959546|NCT00713622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959547|NCT06568900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33959548|NCT03610646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masked study drug kits will be supplied to sites as necessary during the study. The outside label of the box will not reveal the identity of the product inside (whether it is Eylea or MYL-1701P) and will be assigned in a masked fashion through the Interactive Response Technology (IRT) system. An un-masked team will identified at site, to be responsible for preparation and administration of the study drug.|Participants are assigned to either MYL-1701P or Eylea groups in parallel for the duration of the study|t|f|t|t
34169876|NCT00859547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169877|NCT03090308|||COHORT||PROSPECTIVE|||||||
34169878|NCT03093896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34169879|NCT01557426|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169880|NCT02604381|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34169881|NCT00647296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo during Part 1 and Part 2 placebo washout.||t|t|t|t
34169882|NCT05275816|||COHORT||RETROSPECTIVE|||||||
34169883|NCT00822614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169884|NCT00364585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857693|NCT03294109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33857694|NCT04768257|||COHORT||PROSPECTIVE|||||||
33857695|NCT02100397|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857696|NCT04237766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857697|NCT05446688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857698|NCT01216228|||COHORT||PROSPECTIVE|||||||
33857699|NCT01794923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857700|NCT04503226|||CASE_ONLY||RETROSPECTIVE|||||||
33857701|NCT00169520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857702|NCT00712309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857703|NCT02359877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857704|NCT02623881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169885|NCT00898963|||OTHER||RETROSPECTIVE|||||||
34169886|NCT02728180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169887|NCT05103007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857705|NCT00542529|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34169888|NCT03292835|||CASE_CROSSOVER||PROSPECTIVE|||||||
34169889|NCT03867422|||COHORT||PROSPECTIVE|||||||
34169890|NCT01600885|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34169891|NCT03955835|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional treatment, single-arm, open-label, multi-centre trial||||
34169892|NCT01057953|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169893|NCT04418778|||COHORT||PROSPECTIVE|||||||
34169894|NCT05514769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34169895|NCT04706962|NA|SINGLE_GROUP||TREATMENT||NONE||"This first-in-human study is designed as a multi-center, open-label, with 4 sequential parts:~Part 1 (dose escalation), Part 2 (dose expansion), Part 3 (dose optimization), Part 4 (basket expansion)."||||
34169896|NCT04123522|||CASE_CONTROL||PROSPECTIVE|||||||
33857706|NCT05213910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857707|NCT01349725|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33857708|NCT05420883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Acupressure group One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.~Halojen ışık group One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.~Kontrol Group No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined."|"Akupresür One minute after the start of the Nonstress test recording, an application will be made to the Zhi yin (BL67) acupuncture point with a depth of 0.1-0.2 cm, on the outer edge of the little toe of both feet, at the nail end point. The application will be applied to both points simultaneously for 2 minutes consecutively and then repeated 2 times with a 3-minute rest period.~Halojen ışık One minute after the start of the Nonstress Test recording, halogen light stimulation will be given from the mother's abdomen to the fetal head for 10 seconds with a flashlight device worth 1,000,000 candles. The procedure will be repeated on the same spot 10 minutes after the first halogen light stimulation.~Kontrol No action will be taken against this group."|t|f|f|f
33857709|NCT05617651|RANDOMIZED|CROSSOVER||TREATMENT||NONE|In order to prevent distortion (bias) affecting test results during sample analysis, this clinical trial shall not be disclosed to analysis manager and analyst until the specimen analysis is completed.|||||
33857710|NCT00427336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857711|NCT00388453|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857712|NCT03708822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169897|NCT04757493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, care provider and primary outcome assessor will unaware about the allocated treatment.|"Its a randomized placebo controlled parallel group clinical trial. Prucalopride group is designated as A and placebo group is designated as group B."|t|t|f|t
34169898|NCT01475591|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34169899|NCT02063204|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169900|NCT05806463|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not be fully blinded to whether participants are in an intervention or control cluster. However, the use of a cluster-randomized approach reduces the risk of contamination among women from different clusters because it reduces the risk of communication between individuals in intervention and control arms. As HEWs will be responsible for assisting with recruitment of participants, HEWs will be aware of these eligibility criteria and who has been recruited for the study in both the control and intervention arms. As a result, HEWs will not be fully blinded to the study. Outcome assessors and statisticians will be blinded.|"This is a cluster-randomized parallel intervention study model.~Following random assignment of clusters to either the intervention or control arm and subsequent recruitment of participants, individuals will be enrolled in the study.~Intervention arm: Mother's Time intervention Control arm: Standard of care~Clusters will be randomly assigned using a random number generator to either the intervention arm or the control arm. Then, all individuals recruited within a given cluster will be assigned to the same intervention condition.~Anticipating that the Mother's Time intervention will be superior to the standard care with respect to reducing symptoms of stress, depression, and anxiety and increasing modern contraceptive use, women in the control group will have opportunity to receive the full intervention upon completion of the intervention to the intervention group."|f|f|f|t
34169901|NCT02919228|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34169902|NCT02383563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169903|NCT06110663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169904|NCT02714192|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169905|NCT03844555|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33959549|NCT03582059|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Single blind, randomized cross over study at a single centre|t|f|f|f
33959550|NCT04012008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33959551|NCT00696631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959552|NCT01732666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33959553|NCT02816749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959554|NCT03216681|||COHORT||PROSPECTIVE|||||||
33959555|NCT02594137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959556|NCT02719015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959557|NCT04253379|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33959558|NCT05494580|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: Pamiparib Drug: Surufatinib||||
33959559|NCT02275039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749046|NCT02042235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749047|NCT02347761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857713|NCT04123834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective cohort study design was used. Between March 2013 and March 2014, 12 patients underwent implantless ACL reconstruction using press-fit femoral technique, while 24 patients underwent implant ACL reconstruction. Objective functional outcome were measured using rolimeter, and subjective functional outcome were measured according to IKDC, Tegner-Lysholm and KOOS.||||
33857714|NCT06079684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857715|NCT00876928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33857716|NCT06524336|||OTHER||PROSPECTIVE|||||||
33749048|NCT01069029|||COHORT||RETROSPECTIVE|||||||
33857717|NCT05606835|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be selected from healthy individuals aged 18-40 years. According to the foot posture index, participants who has a value between 6 and 9 will be added to pronation group and participants who has a value between 10 and 12 will be added to hyper pronation group. Then measurement will be done by the same physiotherapist. Only one measurement will be done.||||
33857718|NCT01271803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857719|NCT05830409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33857720|NCT03836989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessors are blinded to the intervention. The physical therapist that teaches the research subjects how to perform the interventions are not blinded and patients are told they are assigned to either sensory or subsensory protocols.||f|f|t|t
33857721|NCT06068010|||COHORT||PROSPECTIVE|||||||
33857722|NCT02931071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857723|NCT04046133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857724|NCT05891912|NA|SINGLE_GROUP||TREATMENT||NONE|The assessors will be independent to the study and will be blinded to the treatment received by the patients.|This is a pre-test post-test study.||||
33959560|NCT06536582|||COHORT||PROSPECTIVE|||||||
33959561|NCT05302414|RANDOMIZED|PARALLEL||OTHER||SINGLE|two assessors using video to evaluate outcomes.|three arms|f|f|f|t
33959562|NCT04895696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959563|NCT05810974|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33959564|NCT05207176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857725|NCT01438684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959565|NCT06701474|||COHORT||PROSPECTIVE|||||||
33959566|NCT01336218|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34169906|NCT02760615|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169907|NCT02846129|||CASE_ONLY||RETROSPECTIVE|||||||
34169908|NCT06171958|||COHORT||PROSPECTIVE|||||||
34169909|NCT01706172|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34169910|NCT02611973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169911|NCT01830374|||COHORT||OTHER|||||||
34169912|NCT01863381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169913|NCT02497924|NA|SINGLE_GROUP||OTHER||NONE||||||
34169914|NCT01677689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959567|NCT06399263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959568|NCT06393816|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, open-label, phase II study with an external control arm (ESME AMLC database).||||
33959569|NCT01528046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959570|NCT02484404|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34063426|NCT03559803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063427|NCT03737279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169915|NCT01650558|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34169916|NCT05185388|||COHORT||RETROSPECTIVE|||||||
34169917|NCT05315349|NA|SINGLE_GROUP||OTHER||NONE||||||
34169918|NCT04513756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34169919|NCT02372877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169920|NCT01261988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169921|NCT00130858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169922|NCT01329263|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169923|NCT03470688|||COHORT||PROSPECTIVE|||||||
33749049|NCT04074642|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749050|NCT04365660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749051|NCT04177758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749052|NCT04987515|||COHORT||RETROSPECTIVE|||||||
33749053|NCT03776513|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33959571|NCT05864235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959572|NCT00547807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959573|NCT00557687|||COHORT||PROSPECTIVE|||||||
33959574|NCT06515496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959575|NCT01432782|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959576|NCT06492018|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33959577|NCT03291847|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A group of n=40 study participants will receive buprenorphine-naloxone medication assisted therapy for the treatment of opioid use disorder during pregnancy. This group will undergo fetal monitoring at 24, 28, 32 and 36 weeks of gestation.||||
34063428|NCT03092934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-Label|||||
34063429|NCT03118479|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34063430|NCT04087616|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34169924|NCT05445895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169925|NCT04895449|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169926|NCT04310111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169927|NCT00446979|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749054|NCT00454558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169928|NCT03630796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169929|NCT04752267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169930|NCT02040649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34169931|NCT00354016|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34169932|NCT00516113|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34169933|NCT05925777|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized prospective||||
34169934|NCT04477408|NA|SINGLE_GROUP||TREATMENT||NONE||self controlled prospective study||||
33959578|NCT05884333|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II study of optimized cord blood transplantation (CBT) in adults with high risk or advanced hematologic malignancies.||||
33959579|NCT04201834|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assessor will be masked to the visit.|||||
33959580|NCT00357565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959581|NCT05951959|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II, open-label, multicentre, international study assessing the efficacy of acalabrutinib in combination with venetoclax and rituximab in adult participants with treatment naïve MCL. Approximately 100 participants with treatment naïve MCL will be treated. The primary objective is to estimate the efficacy of AVR by assessment of CR rate with MRD negativity in participants with treatment naïve MCL.||||
33959582|NCT06352840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and outcome assessors will be blinded to study group assignment.||t|f|f|t
33959583|NCT02557568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33959584|NCT00279149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169935|NCT00914186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169936|NCT05214326|||COHORT||PROSPECTIVE|||||||
34169937|NCT06285487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169938|NCT01232868|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169939|NCT04312308|||COHORT||PROSPECTIVE|||||||
34169940|NCT01503008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857726|NCT01363167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857727|NCT05507918|RANDOMIZED|PARALLEL||PREVENTION||NONE||3 group parallel comparison, non-blinded, interventional||||
33857728|NCT04285801|||CASE_ONLY||RETROSPECTIVE|||||||
33857729|NCT02113384|||COHORT||PROSPECTIVE|||||||
33857730|NCT02558686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857731|NCT00790322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857732|NCT03601533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857733|NCT00703144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857734|NCT04603950|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857735|NCT05245565|||COHORT||PROSPECTIVE|||||||
33959585|NCT06235645|||CASE_ONLY||PROSPECTIVE|||||||
33959586|NCT06703099|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33959587|NCT06438354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33959588|NCT00590785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959589|NCT00981409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959590|NCT04933903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959591|NCT00759174|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34169941|NCT01379417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34169942|NCT02324517|||COHORT||PROSPECTIVE|||||||
34169943|NCT00404651|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34169944|NCT04041583|||CASE_ONLY||PROSPECTIVE|||||||
34169945|NCT03144739|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research assistants contacting families by telephone for be partially masked - they will not know information about the index child's provider or any baseline characteristics - it will not be possible to completely mask the study phase and thus the control/intervention status of the families.|stepped wedge design, hybrid implementation effectiveness|f|f|f|t
34169946|NCT05998122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169947|NCT02146417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749055|NCT03681028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749056|NCT04675788|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33749057|NCT00620841|||COHORT||RETROSPECTIVE|||||||
33749058|NCT06635590|||COHORT||PROSPECTIVE|||||||
33857736|NCT02074163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33857737|NCT03728374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857738|NCT06507995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33857739|NCT02795221|||||PROSPECTIVE|||||||
33857740|NCT04350554|||COHORT||OTHER|||||||
33857741|NCT02038920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857742|NCT02902705|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33857743|NCT03285178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169948|NCT04875013|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal cohort; single group assignment; interventional||||
34169949|NCT02172963|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34169950|NCT00370123|||COHORT||PROSPECTIVE|||||||
34169951|NCT01944007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34169952|NCT00054392|RANDOMIZED|||TREATMENT||||||||
34169953|NCT03215017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749059|NCT05034705|RANDOMIZED|PARALLEL||PREVENTION||NONE||Control - conventional suction system Interventional - dental aerosol box with modified high volume evacuation suction system||||
33857744|NCT03086213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857745|NCT01538329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857746|NCT02858830|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857747|NCT00683176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857748|NCT06360562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857749|NCT01172509|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33857750|NCT05873426|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857751|NCT05367180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857752|NCT00728715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857753|NCT03039257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857754|NCT00193687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857755|NCT00420251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857756|NCT05877625|||COHORT||PROSPECTIVE|||||||
33857757|NCT04382274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34169954|NCT04903561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169955|NCT02575755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169956|NCT04842708|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34169957|NCT00965081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169958|NCT01436591|||||PROSPECTIVE|||||||
34169959|NCT05925946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34169960|NCT05841368|||COHORT||PROSPECTIVE|||||||
34169961|NCT05470387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169962|NCT02204930|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34169963|NCT00602212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857758|NCT05114577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33857759|NCT03681704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857760|NCT03056911|||OTHER||RETROSPECTIVE|||||||
33959592|NCT05875064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a non-inferiority randomized clinical trial with parallel arms, with an allocation ratio of 1:1|f|f|f|t
33959593|NCT00593099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959594|NCT03785600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blinded to the intervention by way of study personnel's description. Subjects will be told that both devices may or may not be active and thus, will be unaware that all light boxes are active and all negative ion generators are inactivated.|Subjects will be randomized to receive MBLT or a sham/no-light control. Subjects randomized to receive MBLT will be given a light box (LightPad, Aurora Light Solutions) to take home. Subjects randomized to receive the sham/no-light control will be given a modified negative ion generator.|t|f|f|f
33857761|NCT03564639|||COHORT||PROSPECTIVE|||||||
33857762|NCT05730270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33959595|NCT00174473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857763|NCT03134157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857764|NCT06093126|NA|SINGLE_GROUP||TREATMENT||NONE|The subject will not be aware what the treatment is.|"The study will be an N of 1 trial over 8 weeks were treatment with lemborexant given alternated with a placebo in an ABBABAAB format."||||
33857765|NCT01800266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33959596|NCT06173128|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33959597|NCT03405389|||CASE_ONLY||PROSPECTIVE|||||||
33959598|NCT01468974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959599|NCT03128047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959600|NCT02793375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959601|NCT06568328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959602|NCT05756413|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Principal investigator and clinical examiner will be blinded to group allocation||t|t|f|f
33959603|NCT05847504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959604|NCT04961112|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|All study staff are blinded to active and sham brain stimulation devices until the completion of data collection.||t|f|t|t
33959605|NCT01931501|RANDOMIZED|||||||||||
33959606|NCT06267118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator will make all the protocol and research Performa. Drugs will already be prepared for nebulization and labelled by investigator. Researcher /care provider will nebulize the patients of both groups randomly and record the results accordingly.|Patients with acute bronchiolitis after informed written consent will be divided into two groups randomly. Group I will be nebulized with adrenaline every 6 hours and group II will nebulized with hypertonic saline every 6 hours. After 24 hours and 48 hours of nebulization, WDF score will be recorded by measuring respiratory rate, heart rate, chest retractions, chest auscultation findings and SPO₂ levels. Researcher will record all data on a specified Performa.|t|t|f|f
34169964|NCT02313220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169965|NCT01893801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169966|NCT04283305|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are randomly assigned to one of three conditions:~1. = virtual reality approach avoidance training~2. = computer-based approach avoidance training~3. = treatment as usual"||||
34169967|NCT06419985|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 Cohorts of 3+3||||
34169968|NCT01719796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169969|NCT01799096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34169970|NCT03707795|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants remain blinded as to their genotype.||t|f|f|f
34169971|NCT04960449|||OTHER||RETROSPECTIVE|||||||
34169972|NCT04959734|||COHORT||PROSPECTIVE|||||||
34169973|NCT00687401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959607|NCT06547814|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Study staff who are rating fidelity will be blinded to whether the observation is from the standard implementation or virtual facilitation condition.|"The investigators will use an incomplete stepped wedge cluster randomized design, where units (pharmacies) begin in one condition (standard implementation approach) and crossover to the other condition (virtual facilitation)."|f|f|f|t
33959608|NCT01986400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33959609|NCT00060489||||TREATMENT||||||||
33959610|NCT04862650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959611|NCT06350331|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33959612|NCT01579292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959613|NCT05290272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959614|NCT06251154|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33959615|NCT01687400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169974|NCT00583635|||CASE_CONTROL||PROSPECTIVE|||||||
34169975|NCT02922725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34169976|NCT02785185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169977|NCT05870514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34169978|NCT00004380|NON_RANDOMIZED|||TREATMENT||||||||
34169979|NCT02451059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169980|NCT01411826|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34169981|NCT01878019|||||PROSPECTIVE|||||||
33959616|NCT05076617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959617|NCT00445458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959618|NCT03078166|||COHORT||PROSPECTIVE|||||||
33959619|NCT03742245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959620|NCT05293743|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|The clinician assessing foot shape for recurrence will be blinded to the brace type. Clinicians involved in fitting the brace will not be.|Experimental arm with new device, control arm with standard device.|f|f|f|t
34169982|NCT00941941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34169983|NCT03140514|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34169984|NCT01689142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169985|NCT00433641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34169986|NCT05670522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169987|NCT02933788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34169988|NCT01686334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169989|NCT02619760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34169990|NCT05404243|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical trial||||
34169991|NCT04440267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169992|NCT03683173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857766|NCT03182725|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||20 patients with POTS will receive Ivabradine treatment vs placebo for one month. Then there will be a one-month wash out period prior to the cross over in which patients who received Ivabradine will receive the placebo, and patients who initially were on placebo will now receive Ivabradine.|t|t|t|t
33857767|NCT06190678|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33857768|NCT05965661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|VR upper limb hand training or VR control training|Randomized pilot study|f|f|f|t
33857769|NCT06065865|NA|SINGLE_GROUP||TREATMENT||NONE||The current study has a single case experimental design (SCED), more specifically, a non-concurrent multiple baseline design.||||
33857770|NCT04311060|||COHORT||PROSPECTIVE|||||||
33857771|NCT05095701|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857772|NCT03558360|||COHORT||CROSS_SECTIONAL|||||||
33857773|NCT03195738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34169993|NCT02494232|||COHORT||PROSPECTIVE|||||||
33857774|NCT02214433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33857775|NCT01978262|NA|SINGLE_GROUP||OTHER||NONE||||||
33959621|NCT04425369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33959622|NCT05399186|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||A prospective non-randomized quality control study before and after an intervention regarding preoperative preparation for total joint arthroplasty||||
33959623|NCT05083091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The participant and their care provider, who treats their IBS, will remain masked to the intervention condition (Monitor+Accept, MA-MBI; Monitor Only, MO-MBI; Coping Control, CC) to which the participant is randomly assigned. The outcomes assessor will remain masked to which condition the participants will complete. However, the experimenter will help set up the participant's intervention activities, and therefore will not be masked to the condition.||t|t|f|t
33959624|NCT04033549|||CASE_ONLY||PROSPECTIVE|||||||
34169994|NCT03467347|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34169995|NCT01785888|||COHORT||PROSPECTIVE|||||||
34169996|NCT04103359|NA|SINGLE_GROUP||OTHER||NONE||||||
34169997|NCT02028377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34169998|NCT00120926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34169999|NCT04713280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170000|NCT01320475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170001|NCT05968677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34170002|NCT04052490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857776|NCT03260595|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33857777|NCT00002863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857778|NCT04780295|||COHORT||RETROSPECTIVE|||||||
33857779|NCT03784651|||COHORT||PROSPECTIVE|||||||
33857780|NCT02454179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857781|NCT04501913|||COHORT||PROSPECTIVE|||||||
34170003|NCT00028483||||TREATMENT||||||||
34170004|NCT02033434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170005|NCT03324373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170006|NCT03285802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170007|NCT05180695|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The dose escalation will be conducted according to a sequential and adaptive Bayesian scheme, using the method of TITE-CRM to determine the MTD of pazopanib in combination with HDM201. This method allows continual accrual (i.e. the study will be opened to accrual continually) throughout the trial while using the 6-week toxicity endpoint as basis of dose escalation.~Dose allocation will be centrally defined, before each inclusion considering the DLT observed in all patients previously evaluated, and the current toxicity status of patients who have not received a full 2-cycle treatment (i.e. DLT period is still ongoing).~* A cumulative experience of 4 cycles at a given DL is required before allowing dose escalation to the next DL. Cumulative experience is defined as the addition of observation periods of all included and treated patients.~* A maximum of 6 patients can be included and treated at a same dose level before reassessment occurred."||||
34170008|NCT05620095|||COHORT||OTHER|||||||
33749060|NCT02230072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749061|NCT01084876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749062|NCT01988246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749063|NCT02388633|||COHORT||PROSPECTIVE|||||||
33749064|NCT06575218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749065|NCT01816594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749066|NCT05129826|NA|SINGLE_GROUP||SCREENING||NONE|The questionnaire is completed through by the 1st researcher and all clinical data collection will be recorded by the 2nd researcher.|Subjects who has aged ≥ 60 years old, not receive periodontal treatment within the previous 6 months, able to read Thai and express verbal communication, functional independent older adults (get ≥ 12 points from Barthel Index for Activities of Daily Living) and cognitive functional independent older adults (get \> 23 points from Thai Mental State Examination).||||
33749067|NCT05123508|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment arm and control arm||||
33749068|NCT01356017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33749069|NCT04226430|||CASE_CONTROL||PROSPECTIVE|||||||
33749070|NCT02791724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749071|NCT01540851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33749072|NCT02952638|||COHORT||PROSPECTIVE|||||||
33749073|NCT04663048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are not aware which eye will receive the reduced treatment and which eye will receive the ordinary treatment time.||t|f|f|f
33749074|NCT03311438|NA|SINGLE_GROUP||PREVENTION||NONE||Longitudinal study design, promoting oral health among children with congenital heart defects. Oral examination and intervention at baseline (below three years), at first follow-up (three years) and at second follow-up (five years).||||
33959625|NCT05350358|||CASE_ONLY||RETROSPECTIVE|||||||
33749075|NCT05378399|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33857782|NCT03168789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959626|NCT06612255|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33857783|NCT01247233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959627|NCT06703073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The overall 2-step randomization scheme will be implemented.~* Randomization Level 1 will be open-label, assigning an eligible patient to one of the available treatment cohorts.~* Randomization Level 2 will be double-blinded and will randomize participants at a 1:1 ratio to receive either IP or placebo within a specific cohort. Thus, the PPD blinded team, site blinded staff members, and participants/legal authorized representative will be considered blinded to study treatment assignment (either IP or placebo) throughout the course of the study.~To preserve the integrity of the study blind, an unblinded pharmacist at each site will be responsible for the reconstitution and dispensation of all study drugs and placebos and will endeavor to ensure that there are no observable differences between the treatment groups (IP or placebo) when dispensing the study materials."||t|t|t|f
33749076|NCT03491865|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749077|NCT02999555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857784|NCT02271516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857785|NCT05064189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857786|NCT00939679|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857787|NCT00416104|||DEFINED_POPULATION||OTHER|||||||
33857788|NCT00248846|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749078|NCT05010148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749079|NCT03962387|||CASE_ONLY||PROSPECTIVE|||||||
33749080|NCT00251745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749081|NCT02647398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749082|NCT06386523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749083|NCT00331981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749084|NCT04543123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749085|NCT03461068|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo masked with flavouring and participants consume in opaque containers||t|f|f|t
33749086|NCT03094026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749087|NCT05430490|||COHORT||CROSS_SECTIONAL|||||||
33857789|NCT02518022|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893596|NCT03731793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Full randomization and full blind study. Intervention was named by integratore A and integratore B"|Double-blind randomized placebo controlled study. 90 days of treatment with 600 mg/d of non-animal Chondroitin Sulphate or placebo|t|t|t|t
33893597|NCT01455350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857790|NCT06268769|RANDOMIZED|PARALLEL||PREVENTION||NONE||A dynamic allocation technique assigns participants in a 1:1 ratio to one of two treatment arms: Envarsus tablets (test IMP) or Advagraf capsules (comparator IMP). Randomisation is stratified by two factors: a) trial site, in order to minimise systematic treatment bias at the level of the trial centre and reduce the influence of inter-centre variability, and b) participation in the optional pharmacokinetic sub-study, in order to ensure an equal representation of Envarsus- and Advagraf-treated patients in the sub-study.||||
33857791|NCT04023825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959628|NCT06297941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959629|NCT06123494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959630|NCT06701396|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959631|NCT06038149|||COHORT||PROSPECTIVE|||||||
33857792|NCT05648526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33857793|NCT05283486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind clinical trial.||t|t|t|t
33857794|NCT04605887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857795|NCT02888145|||COHORT||OTHER|||||||
33857796|NCT02204176|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857797|NCT03604523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomized to procedure, but if participant fails the first procedure they are given the opportunity to crossover to the other arm for a follow up procedure.|t|f|f|f
33857798|NCT02122263|||||PROSPECTIVE|||||||
33857799|NCT06475781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug will be provided in wallet cards. The wallet cards will have unique numbering and will be assigned by an interactive web response system (IWRS). The capsules containing active drug and the placebo capsules will have the same appearance.|Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study|t|t|t|t
33857800|NCT01350453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857801|NCT01326234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857802|NCT03265834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857803|NCT05049278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959632|NCT04264273|||COHORT||PROSPECTIVE|||||||
33959633|NCT00005879|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33959634|NCT05292313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959635|NCT00128518|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33959636|NCT06463756|||COHORT||RETROSPECTIVE|||||||
33959637|NCT06610279|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34063431|NCT01831505|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170009|NCT03416088|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"1. Influence of beverage consumption 30 participants drink coffee, red wine, and water respectively on three mornings interval with a one-week washout period. Each period lasts 2 hours. OCTA and MRI scanning are taken every 30 minutes, and venous blood was collected before MRI scanning.~2. Influence of daily reading 30 participants read paper books, play video games with mobile phones, and non-read respectively on three mornings interval with a one-week washout period. Each period lasts 8 hours. OCTA and MRI scanning are taken every 2 hours.~3. Influence of body motion (exercise and body postural changes) Exercise: 30 participants will be enrolled. Participants undergo to jogging for 10 minutes, 30 minutes, and 1 hour respectively on three mornings interval with a 3-day washout period. OCTA and MRI scanning are taken before and after jogging.~Body postural changes: 30 participants will be enrolled. OCTA and MRI scanning are taken before and after body postural changes."||||
34170010|NCT00068159|||CASE_CONTROL||OTHER|||||||
34170011|NCT02620969|||COHORT||CROSS_SECTIONAL|||||||
34170012|NCT01919944|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33857804|NCT02601651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749088|NCT05278000|||COHORT||PROSPECTIVE|||||||
33749089|NCT00000985||PARALLEL||TREATMENT||||||||
33749090|NCT03701568|||CASE_ONLY||RETROSPECTIVE|||||||
33749091|NCT03884751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857805|NCT01567982|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33857806|NCT03437278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigator staff and personnel performing the study assessments remained blinded to the identity of the treatment from the time of randomization until final database lock. Data managers, programmers, statisticians, pharmacometricians and clinical experts of the Novartis trial team also remained blinded until final database lock. The study drug was prepared by an independent unblinded pharmacist (or authorized delegate) and administered by an independent unblinded administrator.|This was a Phase 2b dose-finding, randomized, double-blind, parallel group, placebo controlled multicenter study in adolescent patients|t|t|t|t
33857807|NCT00133692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857808|NCT00184977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857809|NCT01208610|||||PROSPECTIVE|||||||
33857810|NCT05954403|||COHORT||OTHER|||||||
33857811|NCT06108037|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be aware of the arm they are assigned to. There is no care provider or outcomes assessor in this study, as the patients will report their own perceptions in a survey.|"* Participants will be randomly allocated to one of six arms.~* Over the course of the study period, there will be multiple rounds of surveys, which will consist of a clinical scenario, a response (human or AI generated), and a disclosure statement (none, human, or AI).~* All respondents within an arm will be assigned to a sequence of response-disclosure pairs prior to the first round of surveys."|t|f|f|f
33857812|NCT03331016|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized stepped wedge design with waitlist controls||||
33857813|NCT04103697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857814|NCT06130748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33857815|NCT05785234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33857816|NCT04586582|||CASE_ONLY||PROSPECTIVE|||||||
33857817|NCT05256576|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||multi-center, controlled, open-ended intervention study||||
33857818|NCT00928174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959638|NCT04451109|||CASE_ONLY||RETROSPECTIVE|||||||
33959639|NCT04057118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959640|NCT06575270|||COHORT||PROSPECTIVE|||||||
33959641|NCT06693336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959642|NCT01838863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959643|NCT02470962|||COHORT||PROSPECTIVE|||||||
33959644|NCT06143683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170013|NCT03790111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170014|NCT01216202|||COHORT||PROSPECTIVE|||||||
34170015|NCT03630835|NA|SINGLE_GROUP||SCREENING||NONE||||||
34170016|NCT01612975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170017|NCT01103167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170018|NCT04471350|||COHORT||PROSPECTIVE|||||||
33857819|NCT03093987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857820|NCT02980237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33857821|NCT00117845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857822|NCT05938231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857823|NCT00302419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33893598|NCT03607227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893599|NCT06656195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893600|NCT01475955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33959645|NCT00664417|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959646|NCT03932838|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959647|NCT05769153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Stage 1 is open label. Stage 2 is double-masked.|Stage 1 will enroll 2 cohorts. Stage 2 will enroll 3 treatment arms.|t|f|t|f
33959648|NCT05503797|RANDOMIZED|PARALLEL||TREATMENT||NONE||All four open-label subprotocols will enroll patients independently of one another, in parallel. Subprotocol D is a 2-arm, randomized study. The other subprotocols are single-arm.||||
33959649|NCT01929148|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959650|NCT03973086|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33959651|NCT06461234|||COHORT||PROSPECTIVE|||||||
33959652|NCT05557487|||COHORT||PROSPECTIVE|||||||
33959653|NCT00221052|RANDOMIZED|PARALLEL||||DOUBLE||||||
34170019|NCT04835844|||COHORT||PROSPECTIVE|||||||
33959654|NCT01261429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063432|NCT02166749|||COHORT||RETROSPECTIVE|||||||
34170020|NCT01091064|RANDOMIZED|CROSSOVER||||NONE||||||
34170021|NCT00316667|||COHORT||PROSPECTIVE|||||||
34170022|NCT03170726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170023|NCT02085759|||CASE_CONTROL||PROSPECTIVE|||||||
33857824|NCT00153517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Investigational Drug Service at the University of Washington performed the randomization and provided the treatment assignments in opaque, sealed envelopes. Neither the subjects nor the study personnel assessing treatment effect were aware of which active agent had been assigned.|study participants were randomized to treatment with oral metronidazole (Centers for Disease Control and Prevention \[CDC\] recommended regimen: 250mg three times daily for 7 days) plus intravaginal placebo or intravaginal metronidazole (5 g of 0.75% gel twice daily for 5 days) plus oral placebo. The oral and vaginal placebos were indistinguishable from active therapy. Randomization to study group used random number tables, with a 1:1 ratio between study groups.|t|f|t|t
33857825|NCT04174456|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959655|NCT03574571|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.||||
33857826|NCT03507374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857827|NCT04138797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959656|NCT05274568|NA|SINGLE_GROUP||OTHER||NONE||||||
33959657|NCT03692078|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959658|NCT03257137|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will undergo both diet pattern conditions but not be informed of their differences. The technologist scoring the sleep studies and actiwatches will be blinded to the condition||t|f|f|t
33959659|NCT03875131|||COHORT||PROSPECTIVE|||||||
33959660|NCT05872503|||COHORT||PROSPECTIVE|||||||
33959661|NCT04735406|||COHORT||PROSPECTIVE|||||||
33959662|NCT01921725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959663|NCT03543046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063433|NCT06731491|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Non-Randomized and Blinded Parallel Cross-Sectional Clinical Study|f|f|t|t
34063434|NCT00002131||||TREATMENT||NONE||||||
33857828|NCT05139290|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||20 dyads (PLWDs and their adult daughter caregivers) will be enrolled to participate in the behavioral intervention together.||||
33959664|NCT00945971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063435|NCT01633099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063436|NCT04104087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double|it is randomized control trial|t|f|f|t
34063437|NCT04517773|||COHORT||CROSS_SECTIONAL|||||||
33857829|NCT06007274|||CASE_CONTROL||RETROSPECTIVE|||||||
34063438|NCT00190658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063439|NCT01000181|||CASE_ONLY||PROSPECTIVE|||||||
34170024|NCT03783507|RANDOMIZED|FACTORIAL||SCREENING||SINGLE||In order to examine if low-ED foods and high-ED foods substitute for each other, a 4 X 4 mixed-factor design with a between-subjects factor of order and a within-subjects factor of meal will be used. For the within-subjects factor of meal, four meal conditions will be implemented. Participants will be randomized to one of 4 orders to reduce the possibility of an order effect. During all sessions, participants will be provided with 12 ounces of water.|t|f|f|f
34170025|NCT00248495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170026|NCT06052228|||CASE_ONLY||PROSPECTIVE|||||||
33857830|NCT01206777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857831|NCT05639335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857832|NCT02953171|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33857833|NCT00166426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33857834|NCT01191931|||COHORT||PROSPECTIVE|||||||
33857835|NCT01642173|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33893601|NCT03311126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893602|NCT01596491|||COHORT||PROSPECTIVE|||||||
33893603|NCT05135364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893604|NCT01650805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063440|NCT01825239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063441|NCT05963451|||OTHER||RETROSPECTIVE|||||||
34063442|NCT06415175|||COHORT||PROSPECTIVE|||||||
34063443|NCT04790097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063444|NCT00189527|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34063445|NCT02700698|||COHORT||CROSS_SECTIONAL|||||||
34063446|NCT03681184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063447|NCT00671125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063448|NCT05645432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063449|NCT00295516|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063450|NCT04958759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063451|NCT02101333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063452|NCT04171817|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a multicenter, parallel-arm randomized controlled trial, with 1:1 allocation for intervention versus control. Among those randomized to intervention, dog-handler teams will be additionally randomized to Intervention A first, with crossover to Intervention B, or to Intervention B first, with crossover to Intervention A.||||
34063453|NCT05140616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063454|NCT01630954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063455|NCT03654391|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34063456|NCT05133583|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34063457|NCT01544192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34063458|NCT04262804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063459|NCT01942005|||COHORT||PROSPECTIVE|||||||
34063460|NCT01173419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063461|NCT00148655|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34063462|NCT03090451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|No masking for this study.|Two main arms: 1) moderate aerobic exercise, 2) intense aerobic exercise. In each arm, subjects will undergo three separate studies, i) at low insulin levels, ii) at medium insulin levels, and iii) at high insulin levels.||||
34063463|NCT03631654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063464|NCT03219229|||COHORT||PROSPECTIVE|||||||
34063465|NCT02183909|NA|SINGLE_GROUP||OTHER||NONE||||||
34063466|NCT04061733|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter||||
34170027|NCT04781335|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33857836|NCT03230656|RANDOMIZED|FACTORIAL||SCREENING||NONE||Each participant diagnosed with concussion/mild traumatic brain injury will be screened for cognitive and communication abilities at two weeks post-injury and then four weeks post-injury. Standardized scores of the screening measures will identify subjects that are below one standard deviation below the mean. Subjects that continue to exhibit deficits after one month will be randomly placed into an early cognitive-communication therapy group (one month post-injury) or waitlist control group who receive therapy two month post-injury.||||
34170028|NCT04692623|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|Proper care shall be taken while taking blood samples for checking blood glucose and serum insulin levels as per ICH good clinical practices guidelines.|Single group for Moxifloxacin having 30 healthy euglycemic volunteers, another group for Gemifloxacin having 30 healthy euglycemic volunteers|t|f|t|f
33857837|NCT05089136|||COHORT||PROSPECTIVE|||||||
33959665|NCT03190018|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Intervention study, pilot/feasibility for proof of concept of peritoneal dialysis with the Carry Life System for Peritoneal Dialysis (CLS PD)||||
33959666|NCT03300232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959667|NCT05606159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, double-blind, placebo-controlled multicenter clinical trial|t|t|t|t
34063467|NCT00429611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170029|NCT03998540|||CASE_ONLY||PROSPECTIVE|||||||
34170030|NCT01419795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170031|NCT03571230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|f|f|t|t
34170032|NCT03658005|||COHORT||PROSPECTIVE|||||||
34170033|NCT03383861|||CASE_CONTROL||RETROSPECTIVE|||||||
34170034|NCT03564288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170035|NCT03059316|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34170036|NCT02458716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170037|NCT00591682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170038|NCT03775460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170039|NCT05603117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857838|NCT05622617|||CASE_ONLY||PROSPECTIVE|||||||
34170040|NCT01102114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857839|NCT01114061|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33857840|NCT03897881|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33857841|NCT01118611||||TREATMENT||||||||
33857842|NCT00440804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857843|NCT04727918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857844|NCT01694355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857845|NCT00808353|||COHORT||PROSPECTIVE|||||||
33857846|NCT06125223|||COHORT||PROSPECTIVE|||||||
33857847|NCT04762953|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical trial is a non-randomized, open label, single arm clinical trial.||||
33857848|NCT00377247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857849|NCT06121908|||OTHER||PROSPECTIVE|||||||
33857850|NCT03234790|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|f|t|t
33857851|NCT03384654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857852|NCT03702556|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857853|NCT04250987|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm - open-label study||||
33857854|NCT01488487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857855|NCT00619762|||COHORT||PROSPECTIVE|||||||
34063468|NCT00780624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34170041|NCT05383573|||CASE_ONLY||RETROSPECTIVE|||||||
34170042|NCT02521506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170043|NCT01905098|RANDOMIZED|FACTORIAL||||NONE||||||
34170044|NCT02981147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170045|NCT04471519|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170046|NCT05443412|||COHORT||PROSPECTIVE|||||||
34170047|NCT01301807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170048|NCT02681198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170049|NCT04607044|||OTHER||PROSPECTIVE|||||||
34170050|NCT02027012|NA|SINGLE_GROUP||TREATMENT||NONE||Vessix device||||
34170051|NCT05510063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170052|NCT01174407|||CASE_CONTROL||PROSPECTIVE|||||||
34170053|NCT02753166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170054|NCT01591356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170055|NCT05970575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857856|NCT03379922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857857|NCT02302404|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33857858|NCT06015425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857859|NCT00911794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857860|NCT03084224|||CASE_ONLY||OTHER|||||||
33959668|NCT05801991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959669|NCT00710086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959670|NCT06222411|NA|SINGLE_GROUP||OTHER||NONE||||||
33959671|NCT01552005|||COHORT|||||||||
33959672|NCT05633095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959673|NCT03456973|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33959674|NCT03377387|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ib/II study of capecitabine 7/7 with neratinib in patients with HER2-positive metastatic breast cancer.||||
33959675|NCT01614158|||CASE_CONTROL||PROSPECTIVE|||||||
33959676|NCT01785043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959677|NCT04169425|||COHORT||RETROSPECTIVE|||||||
34170056|NCT05182723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170057|NCT00628017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170058|NCT03014739|||COHORT||PROSPECTIVE|||||||
34170059|NCT06464354|||CASE_ONLY||PROSPECTIVE|||||||
34170060|NCT01429675|RANDOMIZED|CROSSOVER||||NONE||||||
34170061|NCT00564681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170062|NCT03271424|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Qualitative focus group discussions (FGDs) with male and female community members aged 18 - 24~In-clinic observation of HIV self-testing and completion of a brief CAPI/ACASI interview with male and female community members aged 18 - 24"||||
33857861|NCT02634346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857862|NCT05854433|||COHORT||PROSPECTIVE|||||||
33857863|NCT06168188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857864|NCT02750150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857865|NCT03061630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857866|NCT02775825|||COHORT||RETROSPECTIVE|||||||
33857867|NCT00447382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857868|NCT01589666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857869|NCT02844049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857870|NCT03418337|RANDOMIZED|PARALLEL||TREATMENT||NONE||a prospective, randomized, open-level clinical study to evaluate 8 weeks PPI response rate for atypical GERD||||
33857871|NCT01849822|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857872|NCT00336752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857873|NCT04572412|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33857874|NCT05721820|||CASE_ONLY||RETROSPECTIVE|||||||
33857875|NCT06294522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857876|NCT04854629|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessor were unaware of participant status (i.e. spinomed active or control) and were not allowed to ask correspondingly|Randomized controlled trial with two study groups in parallel: (1) Spinomed active orthosis or 16 weeks (2) non spinomed active orthosis control|f|f|f|t
33857877|NCT02640885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857878|NCT01581151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857879|NCT03400332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857880|NCT00480584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170063|NCT00169663|||COHORT||RETROSPECTIVE|||||||
33857881|NCT02480257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857882|NCT05474599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857883|NCT00973362|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33857884|NCT04508023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857885|NCT04572087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The participants as well as the experimenters are blinded to the treatment group by using a unique 5-digit code for each participant which activates either verum or sham stimulation. The participants and experimenters are blinded to the randomisation condition as current in the sham condition is applied for 40 seconds at the beginning of each training session and during this time, no training of the cognitive control task is done. As participants perceive typical sensations of tDCS (e.g. tingling) and tDCS electrodes are actually mounted, this is considered as a valid placebo control.~The PIs and the biostatistician from the external ICEAB who is doing the statistical analysis are blinded as well until the end of the analysis."|"After the baseline measure (T0) without tDCS, participants are randomized to either the group that receives 6 training sessions (T1-T6) with 2 milliampere (ma) anodal tDCS to the right dlPFC or the group that receives 6 training sessions and sham tDCS.~After the six training sessions within 2 weeks a post measurement concerning task performance (T7) without tDCS takes place. 4 Weeks after treatment, the diagnostic post measurement (T8) will be executed. 3 months later, a follow-up via phone (T9) will be done."|t|t|t|t
33857886|NCT03641612|RANDOMIZED|PARALLEL||OTHER||TRIPLE||The trial design of this study will be a prospective, parallel, Randomized clinical trial (RCT).|t|f|t|t
33857887|NCT00632398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33857888|NCT01139658|||COHORT||PROSPECTIVE|||||||
33857889|NCT02423239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857890|NCT02259907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33857891|NCT05336331|||CASE_CONTROL||RETROSPECTIVE|||||||
33857892|NCT01218776|||COHORT||PROSPECTIVE|||||||
34170064|NCT03744728|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34170065|NCT06327698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857893|NCT04312321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Low urgency emergency calls are randomised by call-taker of dispatching center to 3 groups: routine prehospital emergency care without optional phone call consultation (1), with mandatory phone call consultation with base physician (2), with mandatory audivisual consultation with base physician (3). Power analysis. Based on available data prior to the initiation of the study, 10% of patients after low acuity calls were treated on site. The hypothesis that the video consult would lead to doubling this percentage will be investigated. In order to have 80% probability to confirm this at p \< 0.05, we would need 200 subjects per group. Planned interim analysis will be after 4 weeks of study (aprox. after 600 eligible cases) .||||
33857894|NCT04265560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857895|NCT01690312|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33857896|NCT05252156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857897|NCT03143660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063469|NCT06014125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single-centered randomised controlled trial||||
34063470|NCT02628509|||COHORT||PROSPECTIVE|||||||
34063471|NCT03516006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857898|NCT02973074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857899|NCT04395703|||COHORT||PROSPECTIVE|||||||
33857900|NCT03913975|NA|SINGLE_GROUP||PREVENTION||NONE||The purpose of the current project is to determine the effects of augmented neuromuscular training on brain neuroplasticity. Specifically we aim to evaluate the potential of standard augmented NMT (aNMT) to alter brain neural performance as evidenced by EEG and functional brain magnetic resonance imaging (MRI).||||
33857901|NCT02216617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857902|NCT05087485|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33857903|NCT00028743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857904|NCT00512200|||COHORT||PROSPECTIVE|||||||
33857905|NCT00247338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857906|NCT02147665|NA|SINGLE_GROUP||OTHER||NONE||||||
33857907|NCT04487834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857908|NCT02883283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170066|NCT03402334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded study. Participants are blinded to their designation in the study arms. Investigators cannot be blinded since the intervention they are providing is patient counseling.|This is a two-arm study. Group A will receive the intervention in addition to standard of care counseling while Group B will receive only standard of care counseling.|t|f|f|f
34170067|NCT05543954|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857909|NCT03840239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857910|NCT01756612|||COHORT||PROSPECTIVE|||||||
33857911|NCT00756470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857912|NCT02151838|||COHORT||PROSPECTIVE|||||||
33857913|NCT05300269|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, open, single-arm, two-stage phase II clinical study||||
33857914|NCT04017325|||COHORT||PROSPECTIVE|||||||
33857915|NCT00674869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857916|NCT05633602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857917|NCT01259284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33857918|NCT00568945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33857919|NCT00447759|RANDOMIZED|PARALLEL||TREATMENT||NONE|NSAID|Prospective Randomised Open Blinded-Endpoint Study (PROBE)||||
33857920|NCT02521311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893605|NCT06310369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893606|NCT06189443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959678|NCT04156282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||we will analyze 400 candidate for elective cesarean sections, divided into two groups ,each of 200 patients according to the rectus sheath closure:|t|f|f|t
33959679|NCT05698524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959680|NCT03909971|NA|PARALLEL||TREATMENT||NONE||||||
34170068|NCT02986217|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34170069|NCT04214223|||CASE_CROSSOVER||PROSPECTIVE|||||||
34170070|NCT05389098|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Pilot Study, Open-label and Parallel Groups||||
34170071|NCT04585698|||COHORT||PROSPECTIVE|||||||
34170072|NCT00528957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170073|NCT05800600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170074|NCT02076607|||||RETROSPECTIVE|||||||
34170075|NCT01366001|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34170076|NCT01207635|||CASE_ONLY||PROSPECTIVE|||||||
34170077|NCT05107544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170078|NCT04772014|||CASE_CONTROL||PROSPECTIVE|||||||
34170079|NCT05919407|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34170080|NCT02050477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170081|NCT01969708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170082|NCT06333249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Phase 2 study is a masked study; therefore, neither the investigator nor the subject will know the dose assignment. Both the subject and the investigator will know which eye received treatment.~Masking will continue until the Month 12 data analysis is performed."|"The purpose of the Phase 2 study is to evaluate the efficacy, safety, and tolerability of two doses of AGTC-501 in male subjects between 8 - 50 years of age (inclusive) with XLRP genetically confirmed by at least one pathogenic variant in the RPGR gene.~Approximately 12 subjects who meet the inclusion criteria, will be randomized in a 1:1 ratio to 1 of 2 treatment groups. Each subject will receive the assigned dose of AGTC-501 in the study eye; no treatment will be administered in the fellow eye. As treatment outcomes in pediatric vs. adult subjects may differ, randomization to dose groups will be stratified by age.~Each subject will receive a central subretinal injection of AGTC-501 at the assigned dose in the central macula of the study eye."|t|t|t|t
34170083|NCT01730300|||COHORT||PROSPECTIVE|||||||
34170084|NCT00786227|||COHORT||PROSPECTIVE|||||||
34170085|NCT01263626|||CASE_CONTROL||PROSPECTIVE|||||||
34170086|NCT05239481|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170087|NCT05638165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Single-center, Randomized, Double-blinded, Placebo-controlled|t|t|t|t
33857921|NCT04124393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The second endoscopist will perform tandem right colon examination and is blinded to the insertion method used by the first endoscopist.||f|f|f|t
33857922|NCT00002184||||TREATMENT||DOUBLE||||||
33857923|NCT04134676|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental clinical trial with open label||||
33857924|NCT04112901|||COHORT||RETROSPECTIVE|||||||
33857925|NCT01831856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857926|NCT02807792|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33857927|NCT01343485|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33857928|NCT01625572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959681|NCT03976843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959682|NCT04318249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be conducted as a parallel group, single-blinded pilot study for reducing insomnia among lung cancer patients. All subjects will participate in some form of insomnia treatment over a fourteen-day period. Participants eligible and enrolled in the study will be randomized into one of the two arms, which consist of the two different ART. Randomization and survey baseline measurements from eligible participants will occur on day -1 and the intervention period will last until day fourteen. On day thirty, two weeks post intervention(s), surveys will be emailed to participants to track any change in sleep quality, respiratory quality, and perception of sleep.|t|f|f|f
33959683|NCT03235973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959684|NCT06102499|||COHORT||PROSPECTIVE|||||||
34063472|NCT01458951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063473|NCT06114498|||COHORT||PROSPECTIVE|||||||
34063474|NCT05610072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||This study will use a double-blind, placebo-controlled design with all subjects receiving all hydromorphone (i.e., hydromorphone dose is a within subject factors). Half of the subjects will receive placebo and half of the subjects will receive 2.4mg/day NAC.|t|t|f|t
34063475|NCT05376280|||COHORT||PROSPECTIVE|||||||
34063476|NCT00416793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063477|NCT03338569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063478|NCT05403528|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to one of for conditions.||||
34063479|NCT05370404|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749092|NCT01741753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749093|NCT03772067|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel assignment||||
33749094|NCT04192994|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1: Intravitreal Antibiotic: Group 1a: intravitreal antibiotic isolated; group 1b: intravitreal antibiotic isolated + oral moxifloxacin.~Group 2: PPV: Group 2a: PPV + intraoperative intravitreal antibiotic ; group 2b: PPV + oral moxifloxacin."||||
33749095|NCT04969523|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33749096|NCT02457572|||COHORT||PROSPECTIVE|||||||
33857929|NCT00541723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33857930|NCT03650478|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective single center crossover study with two different arms, one conducted in the Neonatal Intensive Care Unit and the other in the Pediatric Intensive Care Unit.||||
33857931|NCT04395430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857932|NCT01087931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33857933|NCT00002060||||TREATMENT||DOUBLE||||||
33857934|NCT00606073||PARALLEL||TREATMENT||NONE||||||
33959685|NCT06538441|||COHORT||RETROSPECTIVE|||||||
34063480|NCT05020899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063481|NCT05343091|||COHORT||PROSPECTIVE|||||||
34063482|NCT05260775|||OTHER||RETROSPECTIVE|||||||
34170088|NCT00101686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170089|NCT02429635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170090|NCT04315155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open-label Phase I trial designed to determine the phase 2 recommended dose (RP2D) of belinostat in combination with nivolumab with or without ipilimumab. Overall, the trial will assess dosing and safety of two regimens in the study population:~* The double regimen: belinostat in combination with nivolumab;~* The triplet regimen: belinostat in combination with nivolumab and ipilimumab."||||
34170091|NCT05986370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170092|NCT05691881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170093|NCT05261386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170094|NCT04139226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170095|NCT01904409|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170096|NCT06389630|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34170097|NCT04369378|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial: adults randomly assigned to daily use of a meditation app for 30 days or control group (no usage of meditation app).||||
33857935|NCT01917513|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857936|NCT00358553|RANDOMIZED|CROSSOVER||||NONE||||||
33857937|NCT05040477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857938|NCT03289897|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857939|NCT05760391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857940|NCT00092495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33857941|NCT04350944|||COHORT||PROSPECTIVE|||||||
33857942|NCT05717608|RANDOMIZED|PARALLEL||OTHER||DOUBLE|supplementation with either fructose or dextrose|high versus low fructose diet for 4 weeks in either caucasian or surinamese asian type 2 diabetes patients|t|f|t|f
33857943|NCT02784405|||COHORT||PROSPECTIVE|||||||
33857944|NCT02347033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959686|NCT05155046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959687|NCT05189860|NA|SINGLE_GROUP||TREATMENT||NONE||Study objective is to assess the safety of the C-MIC System in case of system extended use or abandonment or explantation in patients having received a C-MIC System in the context of a prior study.||||
33959688|NCT05489523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959689|NCT04106947|||COHORT||CROSS_SECTIONAL|||||||
33959690|NCT00295308|RANDOMIZED|PARALLEL||TREATMENT||||||||
33959691|NCT00609063|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33959692|NCT06566417|||COHORT||PROSPECTIVE|||||||
33959693|NCT06368778|||COHORT||PROSPECTIVE|||||||
33857945|NCT03035968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor for the secondary outcome (Barthel Index and mRS after 90 days) is blinded. All other outcome assessors have knowledge of the interventions assigned to individual participants.||f|f|f|t
33857946|NCT04173065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857947|NCT02170454|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33857948|NCT06236464|||OTHER||PROSPECTIVE|||||||
33857949|NCT04427501|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Some treatment arms are open label.||t|f|t|f
33857950|NCT04675021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959694|NCT05330143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959695|NCT03939403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959696|NCT06563050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study subjects will not be blinded; the bronchoscopist and the assessor of outcomes will be blinded to the group allocation.|"Subjects in group A underwent nebulization with 5 mL of 2% lidocaine for 15 minutes by using a jet nebulizer.~In group B will underwent 10% lidocaine spray solution will be sprayed 10 times at the oropharynx at 5 s interval.~Group C: both nebulization and spray will be performed in the same manner except the number of spray will be 2 instead 10."|f|f|t|t
33959697|NCT02105597|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959698|NCT00156273|||OTHER||PROSPECTIVE|||||||
33857951|NCT06111677|||OTHER||RETROSPECTIVE|||||||
33857952|NCT01394653|RANDOMIZED|CROSSOVER||||NONE||||||
33857953|NCT02880202|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33857954|NCT05428137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3 arm parallel design|t|t|f|f
33857955|NCT02101034|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33857956|NCT01679795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857957|NCT02699034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857958|NCT02530853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33857959|NCT00978692|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33857960|NCT05718310|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33857961|NCT05048420|RANDOMIZED|FACTORIAL||TREATMENT||NONE||randomised controlled trial||||
33857962|NCT00954525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959699|NCT03794999|||COHORT||PROSPECTIVE|||||||
34063483|NCT05054699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be anaesthetised before the procedure, therefore will not be able to tell whether they received ECT ou MST. The preparation procedures before seizure will be identical for all participants regardless of the intervention. All monitoring and other procedures will be exactly the same for both groups. Investigator and rater will not have access to which procedure subjects received. To blind the staff, the MST sound will performed during all study interventions.|Subjects will be randomly and blindly allocated to either of two interventions, namely, MST or ECT. Clinical and cognitive parameters will be assessedat baseline, weeks 6, 12 and 18.|t|t|t|t
34063484|NCT01711775|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34063485|NCT02436902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063486|NCT01065064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34063487|NCT06281626|||CASE_ONLY||CROSS_SECTIONAL|||||||
34063488|NCT02261103|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34063489|NCT06241313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063490|NCT00441155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063491|NCT05313802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34063492|NCT04691206|NA|SINGLE_GROUP||OTHER||NONE||||||
34063493|NCT01715402|||COHORT||PROSPECTIVE|||||||
34063494|NCT02503254|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34063495|NCT05006846|||COHORT||PROSPECTIVE|||||||
34063496|NCT00135902|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34063497|NCT06516640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063498|NCT00586508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063499|NCT03994757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063500|NCT02742675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063501|NCT00986947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063502|NCT04924023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization was done using the closed-envelope method. A total of 60 cards, equally divided between the kaleidoscope and control groups (30 of each), were placed in sealed envelopes. The children were asked to choose one of these envelopes, which determined their placement in the kaleidoscope group or the control group.||||
34063503|NCT02267213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063504|NCT05666479|||CASE_ONLY||PROSPECTIVE|||||||
34063505|NCT05310318|||COHORT||RETROSPECTIVE|||||||
34063506|NCT05598710|||COHORT||PROSPECTIVE|||||||
34063507|NCT06228833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063508|NCT06572943|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33857963|NCT03252951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33857964|NCT03368911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Primary outcome is assessed by other investigator who do not know which endotrachdeal tube is used.||f|f|f|t
33959700|NCT06701227|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959701|NCT05098444|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Wait list control group||||
33959702|NCT02650609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959703|NCT06568640|NA|SINGLE_GROUP||TREATMENT||NONE||The study design is a single-center, open-label, self-controlled, single-arm, prospective study.||||
33959704|NCT03380182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063509|NCT05480865|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34063510|NCT05042830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34063511|NCT03747302|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are not aware of which arm of social messaging they are receiving and whether they are receiving the control message or not||t|f|f|f
34063512|NCT04110717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34063513|NCT01615978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063514|NCT04653623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34063515|NCT06417866|||COHORT||PROSPECTIVE|||||||
34063516|NCT06016348|||COHORT||PROSPECTIVE|||||||
33749097|NCT04850300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study participants, researchers who perform the functional assessments, and data analyst are unaware of the type of prosthetic stabilization used. They will not have access to the hospital medical history where the surgical procedure will be specified. The two surgeons in the study know the type of prosthesis used in each patient, and if the patient requests it, the technical specifications of the stabilization used are disclosed.|This study describes a prospective triple-blinded, randomized, controlled trial.|t|f|t|t
33749098|NCT06393049|NA|SINGLE_GROUP||TREATMENT||NONE||14 patients, all will have an hyperglycaemic clamp performed during admission while measuring cerebral microdialysis||||
33749099|NCT05374421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749100|NCT05735873|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study. Case series.||||
33749101|NCT03658174|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double blind placebo controlled crossover study|t|t|t|t
33749102|NCT04810598|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33749103|NCT03595904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will be blinded to the participants' assigned study group.|Participants are randomly assigned to one of two groups (1:1).|f|f|f|t
33749104|NCT00489606|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33749105|NCT05261178|||CASE_ONLY||CROSS_SECTIONAL|||||||
33857965|NCT00638131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857966|NCT03325998|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33857967|NCT05156632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33857968|NCT01633814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33857969|NCT04579965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33857970|NCT00935194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857971|NCT04014725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33857972|NCT01727622|||CASE_CONTROL||PROSPECTIVE|||||||
33857973|NCT04894123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857974|NCT03456271|||COHORT||PROSPECTIVE|||||||
33857975|NCT02986334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857976|NCT02925026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959705|NCT05673018|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||The parallel arm is a passively-enrolled contemporaneous comparator cohort of Medicare beneficiaries who receive usual care without MCED screening.||||
33959706|NCT05777174|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33959707|NCT04616079|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33959708|NCT03756207|NA|SINGLE_GROUP||TREATMENT||NONE||In this study, the investigators plan to prospectively recruit 80 muscle-invasive bladder cancer patients, who don't want to receive radical cystectomy or are not candidates for radical cystectomy, treated with multidisciplinary bladder-preservation therapy from Nov 2018 to Dec 2020 in Peking University Third Hospital.||||
33959709|NCT06328543|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Participant will be blinded about application of pruritogens|The participants will randomly receive applications of cowhage and histamine|t|f|f|f
33959710|NCT02270840|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959711|NCT06692166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959712|NCT05785754|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959713|NCT02865642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33959714|NCT06555562|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33959715|NCT05957913|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study design will be an open-label single arm study.||||
33959716|NCT01992770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959717|NCT06541977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Groups will be followed and assessed concurrently but separately, ensuring that the comparison between interventions is clear and not influenced by crossover effects.||||
33959718|NCT06315725|||CASE_CROSSOVER||OTHER|||||||
33959719|NCT06375837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959720|NCT03569566|||COHORT||CROSS_SECTIONAL|||||||
33959721|NCT04844931|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients will be randomized to one of the two groups in a 1:1 ratio stratified by center||||
33857977|NCT02718313|||CASE_ONLY||PROSPECTIVE|||||||
33857978|NCT00460551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959722|NCT06122649|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34170098|NCT01853826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170099|NCT00118183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170100|NCT05228665|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort||||
34170101|NCT03007550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170102|NCT02159586|||CASE_ONLY||PROSPECTIVE|||||||
34170103|NCT01043172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170104|NCT02796677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170105|NCT05114824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170106|NCT03349723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170107|NCT04790175|||COHORT||PROSPECTIVE|||||||
34170108|NCT03454295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749106|NCT01337453|||COHORT||PROSPECTIVE|||||||
33857979|NCT04835701|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857980|NCT04632433|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive cemiplimab at a dosage of 350 mg every 3 weeks for two cycles prior surgery. Stage III stage must be documented at screening and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan (if clinically indicated) and Positron emission tomography (PET). Postoperatively, adjuvant immunotherapy with cemiplimab will be administered at a dosage of 350 mg every 3 weeks for one year.||||
33857981|NCT05729880|||COHORT||CROSS_SECTIONAL|||||||
33857982|NCT03459274|||COHORT||PROSPECTIVE|||||||
34170109|NCT04516720|||COHORT||OTHER|||||||
34170110|NCT01892670|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33857983|NCT00005951||||TREATMENT||||||||
33857984|NCT00300898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170111|NCT00415948|||COHORT||PROSPECTIVE|||||||
34170112|NCT04006418|||COHORT||OTHER|||||||
34170113|NCT05117541|||CASE_ONLY||OTHER|||||||
34170114|NCT05826483|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Almonertinib monotherapy||||
34063517|NCT04187040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||All participating wards will be randomly assigned with a 1:1 allocation to either the intervention (3-step hand hygiene technique) or the control group (6-step hand hygiene technique). Randomization will be stratified by participating institution for balanced allocation. Within each stratum, block randomization will be applied to assign wards to the two study groups. Blocking will be used to ensure close balance of the number of wards assigned to each group at any time during the study. Stratified randomization will be performed to ensure balance of the two groups within each institution.|f|f|f|t
34063518|NCT05211141|||COHORT||OTHER|||||||
34063519|NCT01715519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170115|NCT03659318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170116|NCT04739826|||COHORT||PROSPECTIVE|||||||
34170117|NCT02996201|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170118|NCT04985526|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34170119|NCT02633670|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34170120|NCT06021925|||COHORT||PROSPECTIVE|||||||
34170121|NCT00278577|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170122|NCT03072446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170123|NCT00849940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170124|NCT03444610|NA|SINGLE_GROUP||OTHER||NONE||||||
34170125|NCT03668795|||COHORT||RETROSPECTIVE|||||||
34170126|NCT02843230|||COHORT||PROSPECTIVE|||||||
34170127|NCT04388761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170128|NCT00002044||||TREATMENT||||||||
34170129|NCT00792012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170130|NCT01665196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170131|NCT03899714|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Participants will be randomly assigned into one of two locations of the cryotherapy application. Some began the session with cryotherapy being applied on their ankle evertors, while others began the session with the cryotherapy being applied on their hip adductors.|f|f|f|t
34170132|NCT00018148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170133|NCT00528112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170134|NCT02735239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170135|NCT01643668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170136|NCT00738998|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170137|NCT02153268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170138|NCT01350999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170139|NCT01228279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170140|NCT03829085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857985|NCT02070133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33857986|NCT00348231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857987|NCT00884338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33857988|NCT05409482|||CASE_ONLY||PROSPECTIVE|||||||
34063520|NCT04292639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.||||
34063521|NCT00279006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33857989|NCT05270785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857990|NCT04508231|||COHORT||RETROSPECTIVE|||||||
33857991|NCT02594163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857992|NCT03758287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749107|NCT04959370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857993|NCT05280756|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33749108|NCT00922454||CROSSOVER||||NONE||||||
33749109|NCT02526693|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33857994|NCT03303716|||COHORT||PROSPECTIVE|||||||
33857995|NCT05751291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857996|NCT00695253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33857997|NCT04305080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857998|NCT06248554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33857999|NCT00437580|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33858000|NCT04780750|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33858001|NCT04580966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858002|NCT01667861|||||CROSS_SECTIONAL|||||||
33858003|NCT00306696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858004|NCT03861819|NA|SINGLE_GROUP||OTHER||NONE||||||
33858005|NCT00151957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858006|NCT01142856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858007|NCT05645835|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33858008|NCT03618823|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Experimental, open-label randomized control trial.||||
33858009|NCT00195507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858010|NCT06124872|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33858011|NCT00276029|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33858012|NCT05537688|||CASE_CONTROL||PROSPECTIVE|||||||
33858013|NCT02088918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33858014|NCT04778774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33858015|NCT02808143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858016|NCT00885651|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33858017|NCT01743625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858018|NCT02652273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858019|NCT04362410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded|48 healthy subjects will be randomly assigned to one of the three treatment cohorts (i.e. 1:1:1 to Low dose, Medium dose and High dose). 16 subjects will participate in each treatment cohort. Within each cohort, subjects will be randomized in a 3:1 ratio to receive a single dose of tezepelumab or placebo. Each subject will only participate in one cohort.|t|t|t|f
33858020|NCT02930356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858021|NCT04787497|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858022|NCT03811353|||COHORT||PROSPECTIVE|||||||
33858023|NCT03336151|NA|SINGLE_GROUP||OTHER||NONE||After a control period with no specific front-of-pack labeling, the intervention consists in the apposition of a front-of-pack labeling (Nutri-Score) to individual foods in a campus cafeteria. All foods are individually labeled.||||
33858024|NCT06441084|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33858025|NCT01709747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858026|NCT00050726||||TREATMENT||||||||
33858027|NCT02772705|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858028|NCT02623153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858029|NCT04818138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858030|NCT06231966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858031|NCT04610437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858032|NCT06185647|||OTHER||RETROSPECTIVE|||||||
33858033|NCT05302349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The radiologist evaluating the MR images will not know which participant is on which arm.|Randomized controlled|f|f|f|t
33858034|NCT00210730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858035|NCT01849484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858036|NCT04017728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858037|NCT04600232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858038|NCT01987141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858039|NCT05569226|||COHORT||CROSS_SECTIONAL|||||||
33858040|NCT02719678|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858041|NCT02265367|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33858042|NCT00442065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858043|NCT04742647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858044|NCT01148966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858045|NCT04344600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blinded study|Prospective, randomized, single-blind, controlled trial|t|f|f|f
33858046|NCT02882113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858047|NCT01329965|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33858048|NCT06320613|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33858049|NCT05105308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals who conduct the diagnostic interview will not be informed of the intervention arm to which a child is randomized.|The design is a two-group (n=70 per group) randomized controlled trial. Primary outcomes including ARFID symptoms and secondary outcomes (e.g., responder status of weight gain) will be assessed at baseline, posttreatment, and 3-month follow-up, while abbreviated measures will be assessed every session.|f|f|f|t
33858050|NCT01333163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33893607|NCT02086227|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33893608|NCT05153382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893609|NCT06218901|||CASE_ONLY||PROSPECTIVE|||||||
34063522|NCT06614777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Interventional study, exploratory, prospective, descriptive, bicentric.||||
34063523|NCT06415396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063524|NCT05556642|||OTHER||PROSPECTIVE|||||||
34170141|NCT05967598|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|"Before the experiment the stimulation threshold (i.e. current) for each stimulation (taVNS25 and taVNS100) will be assessed by a third person.~The participant will be told, that the investigators are comparing the effect of 3 different stimulation types and that each will be delivered at a different intensity.~The order of stimulation will be randomised across the 3 fMRI slots by a third person and the stimulation type will be noted in a separate log file.~The outcomes assessor will be blinded to the stimulation type until the end of the analysis process."|"40 participants with the diagnosis of PD patients aged \> 45 years will be included. Patients will be recruited from the outpatient and inpatient clinics. PD will be diagnosed according to the UK PD Society Brain Bank criteria: the investigators aim to include 20 patients with early-stage and 20 patients with late-stage PD. Each participant will complete 1 visit at the MRI scanning facility, during which they will complete 3 blocks of 8min block design fMRI. During each block they will receive a different kind of stimulation (taVNS25, taVNS100, xVNS; see detailed description).~The effect will be compared within each group (early and advanced patients) and between groups (early vs advanced PD patients)."|t|f|t|t
34170142|NCT03262220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893610|NCT05215522|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34170143|NCT05572008|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170144|NCT04678583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, controlled, patient and observer-blinded, confirmatory trial|t|f|f|t
34170145|NCT00071227||||TREATMENT||||||||
34170146|NCT02738008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170147|NCT00637078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170148|NCT02608944|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34170149|NCT00282139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893611|NCT02207907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33893612|NCT00519077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893613|NCT03486314|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33893614|NCT06475404|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33893615|NCT00382837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063525|NCT05105516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893616|NCT00372918|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063526|NCT03652584|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34063527|NCT03370458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking will be subjected to Participant, Care Provider, Investigator|Placebo and DR7 will be administered via a parallel design|t|t|t|f
34170150|NCT00647179|||COHORT||PROSPECTIVE|||||||
34170151|NCT03759834|NA|SINGLE_GROUP||TREATMENT||NONE|"The electrode will be placed in the middle ear. The patient and investigator will be blinded to the on-off status of the device. The patient will report if they have improvement of their tinnitus while both the patient and investigator are blinded to the on-off status."|||||
34170152|NCT02451085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170153|NCT01525836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170154|NCT03662958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170155|NCT00844844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170156|NCT04816448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170157|NCT00115440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170158|NCT03146611|||CASE_CONTROL||PROSPECTIVE|||||||
34170159|NCT03091725|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33893617|NCT01363843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893618|NCT03474367|||COHORT||PROSPECTIVE|||||||
33893619|NCT05038761|||COHORT||PROSPECTIVE|||||||
33893620|NCT02114190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893621|NCT03542682|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|single blinded|This study will be a cross-over, randomized order, single blinded clinical study in subjects with Type 1 Diabetes.|t|f|f|f
34063528|NCT03988972|RANDOMIZED|PARALLEL||OTHER||DOUBLE|allocation done by a person not involved in the study.|"The 180 patients who will be included in our study will be randomized through computer generated system in to 2 groups. Group D (diathermy) and group S (scalpel). Each group will include 90 patients.~Allocation and concealment will be done by sequentially sealed opaque envelopes. 180 envelopes will be numbered serially from 1 to 180, 90 envelopes will contain the letter D and the other 90 will contain the letter S.~In each envelope, the corresponding letter which donates the allocated group will be put according to the randomization table and them all envelopes will be closed and put in one box. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside, whom will be allocated by a person not involved in the study."|f|t|t|f
33749110|NCT03007667|||CASE_CONTROL||PROSPECTIVE|||||||
33749111|NCT00989287|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34063529|NCT02272933|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749112|NCT05080166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749113|NCT00983073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749114|NCT03464227|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34063530|NCT04192656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063531|NCT01651000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063532|NCT04387799|||CASE_CONTROL||PROSPECTIVE|||||||
34063533|NCT03277612|||COHORT||PROSPECTIVE|||||||
34063534|NCT06150469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind randomised controlled trial|t|t|t|t
34063535|NCT03376373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|independent evaluators are masked to condition assignment||f|f|f|t
34063536|NCT06351397|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063537|NCT06400407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To ensure the blind method, the sham stimulation coil will be used, which has the same parameters (including stimulation frequency, time, etc.) as the cTBS group, and has the same stimulation sound to ensure no effective stimulation, to ensure the blind state is maintained during the test. Investigators and patients who participate in the study treatment or are involved in the clinical evaluation of patients will be blinded to treatment grouping.||t|f|t|t
34063538|NCT05281900|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will complete each stage in a randomized order.||||
34063539|NCT02644330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063540|NCT00475878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749115|NCT02430194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063541|NCT05952362|||COHORT||PROSPECTIVE|||||||
34063542|NCT03080584|NA|SINGLE_GROUP||TREATMENT||NONE||comparison of AMH and ovarian response before and after acupuncture||||
33749116|NCT01318343|||COHORT||CROSS_SECTIONAL|||||||
34063543|NCT05024526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063544|NCT00380718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063545|NCT04291742|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063546|NCT03941197|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063547|NCT00318175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063548|NCT01738191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749117|NCT05829161|||COHORT||PROSPECTIVE|||||||
33765900|NCT03912623|RANDOMIZED|PARALLEL||TREATMENT||NONE|We wil use the zelen randomisation to minimize patient disappointment. The patient will be advice of only one group (3 weeks SPA treatment or only a week end access to the SPA)|Multicenter, Controlled, Randomized, Open Group Therapeutic Trial||||
33765901|NCT05844930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765902|NCT05038852|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33765903|NCT02825901|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33765904|NCT04319601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765905|NCT05995431|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765906|NCT03065114|||COHORT||RETROSPECTIVE|||||||
33765907|NCT04220814|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765908|NCT04564950|||CASE_CONTROL||RETROSPECTIVE|||||||
33765909|NCT03820323|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Investigators and those conducting the analysis will be blinded to arm allocation|Randomized control trial of two study arms|f|f|t|t
33765910|NCT01302561|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33765911|NCT02459093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765912|NCT05651360|||COHORT||PROSPECTIVE|||||||
33765913|NCT04069260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765914|NCT02044458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765915|NCT05330416|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized, open-label, single-center, controlled, superiority study comparing quality of life in two groups of patients operated on for ano-perineal suppuration in Crohn's disease:~* Flattening of the suppuration and drainage with a suture (reference strategy)~* Flattening of the suppuration without drainage with a nipple (evaluated strategy)"||||
33765916|NCT04995237|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33765917|NCT01803295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765918|NCT04520555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33765919|NCT00829686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33765920|NCT03983993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765921|NCT00172120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765922|NCT04277455|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective||||
33765923|NCT04133103|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33765924|NCT02733705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765925|NCT03762902|||COHORT||PROSPECTIVE|||||||
33765926|NCT05469542|||COHORT||CROSS_SECTIONAL|||||||
33765927|NCT05268575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858051|NCT04409249|||OTHER||RETROSPECTIVE|||||||
33858052|NCT00991263|||CASE_ONLY||RETROSPECTIVE|||||||
33858053|NCT01998412|||CASE_ONLY||PROSPECTIVE|||||||
33858054|NCT02859532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858055|NCT05312788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33858056|NCT01214187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33959723|NCT04138602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients who meet all the eligibility criteria will be enrolled in the study and randomized (1:1) to receive Emsella Chair or sham treatments. Randomization will be performed using a table of random numbers. Randomization envelopes will be provided by the study's biostatistician and will be securely stored in a locked cabinet. The study coordinator(s) will solely be responsible for opening the randomization envelopes and delivering the study treatments, according to the group assignment. Ultimately, they will be responsible for maintaining the confidentiality and security of the randomization envelopes. After the participant is randomized, the study coordinator(s) will complete the Subject Enrollment and Randomization Log. The log will be stored in the regulatory binder. The biostatistician will prepare more envelopes, if necessary.~The sham Emsella treatment will provide sensation without active HIFEM technology."|"Patients who meet all the eligibility criteria will be enrolled in the study and randomized (1:1) to receive Emsella Chair or sham treatments. Randomization will be performed using a table of random numbers. Randomization envelopes will be provided by the study's biostatistician and will be securely stored in a locked cabinet. The study coordinator(s) will solely be responsible for opening the randomization envelopes and delivering the study treatments, according to the group assignment. Ultimately, they will be responsible for maintaining the confidentiality and security of the randomization envelopes. After the participant is randomized, the study coordinator(s) will complete the Subject Enrollment and Randomization Log. The log will be stored in the regulatory binder. The biostatistician will prepare more envelopes, if necessary.~The patient will be given active Emsella treatment at the therapeutic level."|t|f|f|f
33959724|NCT06606899|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33959725|NCT06065475|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33959726|NCT05612178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33959727|NCT06083051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959728|NCT06703411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959729|NCT02836704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959730|NCT05681520|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm pilot study; intervention includes six 30-minute sessions with a peer specialist||||
33959731|NCT01010230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959732|NCT01283373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959733|NCT01929837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959734|NCT02833493|||CASE_ONLY||PROSPECTIVE|||||||
33959735|NCT02845973|||COHORT||CROSS_SECTIONAL|||||||
33959736|NCT06541743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"* (Regular Toothbrush): Oral-B Chhota Bheem Toothbrush.~* (Musical Toothbrush): Aqua White Musical Chhota Bheem Toothbrush.~* (Electric Toothbrush): Oral-B Star Wars Kids Electric Toothbrush"|f|f|t|f
33959737|NCT06541093|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33959738|NCT01019278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959739|NCT06173765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a 3 arm, randomized, controlled parallel design using the control arm from the USDA parallel study.|t|t|f|t
33959740|NCT05917093|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33959741|NCT00534521|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33959742|NCT04217915|||CASE_ONLY||PROSPECTIVE|||||||
33959743|NCT04676386|||COHORT||PROSPECTIVE|||||||
33959744|NCT06007209|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Sonographer will be masked from the pressure technique used with a fabric blind and noise-cancelling headphones.||f|f|f|t
33959745|NCT03715660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33959746|NCT03254537|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33959747|NCT03932474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858057|NCT03501186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The treatment given by investigator unaware of allocation of patients and outcome variables measured by different investigator||t|t|t|t
33858058|NCT06191770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind Clinical Trial, CTU prepare the Medications, and Patient, investigator and Data Collector was completely blind to the Stuidy|Two groups|t|t|t|t
33858059|NCT02027701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858060|NCT03211650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858061|NCT00447252|||DEFINED_POPULATION||OTHER|||||||
33858062|NCT06389019|||OTHER||RETROSPECTIVE|||||||
33858063|NCT00007917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765928|NCT05439239|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single blind, parallel, gender-comparative, randomized controlled study|t|f|f|f
33765929|NCT03528980|||CASE_CONTROL||PROSPECTIVE|||||||
33765930|NCT05168605|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study includes prospective intervention arm and historical control arm (data will be collected via retrospective chart review).||||
33765931|NCT06342427|||CASE_CONTROL||RETROSPECTIVE|||||||
33765932|NCT01031875|NON_RANDOMIZED|||TREATMENT||NONE||||||
33959748|NCT03519360|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33959749|NCT06536647|||COHORT||CROSS_SECTIONAL|||||||
33959750|NCT04315831|||OTHER||PROSPECTIVE|||||||
33959751|NCT06594094|NA|SEQUENTIAL||TREATMENT||NONE||"Two dosing cohort:~Low dose :2\~3 subjects High dose: 2\~3 subjects"||||
33959752|NCT01976637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959753|NCT02924337|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959754|NCT02155231|||COHORT||PROSPECTIVE|||||||
33959755|NCT03371680|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959756|NCT06200259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959757|NCT03686137|||COHORT||PROSPECTIVE|||||||
33959758|NCT02805673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959759|NCT05027945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959760|NCT06454630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959761|NCT04681781|||CASE_ONLY||PROSPECTIVE|||||||
33959762|NCT03464786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959763|NCT05246111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33959764|NCT04905927|||OTHER||PROSPECTIVE|||||||
33959765|NCT05653518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959766|NCT04460521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will undergo permutated block randomization to either the placebo controlled or experimental group in a 1:1 ratio. This method will be computer-generated. The allocation sequence will be concealed to research staff. The participants, clinic nurses, research assistants, and physician investigators as well as outcome assessors will be masked to participant group allocation. Unblinding will be permissible in extenuating circumstances only, such as if a participant experiences a severe adverse reaction secondary to the tablet and requires confirmation of the contents.|Randomized, double-blind, placebo-controlled trial|t|t|t|t
33959767|NCT05452642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment and data analysis will be masked||f|f|f|t
34063549|NCT06640881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959768|NCT04941274|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959769|NCT02964078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959770|NCT01148927|||CASE_ONLY||PROSPECTIVE|||||||
33959771|NCT03284424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959772|NCT02163629|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959773|NCT03906773|||COHORT||PROSPECTIVE|||||||
33959774|NCT00342797|||COHORT||RETROSPECTIVE|||||||
33959775|NCT04137406|||COHORT||RETROSPECTIVE|||||||
33959776|NCT03987737|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, single center, comparative study between two rectal emptying strategies. Patients will be randomized into one of two arms. In both arms the subjects will be asked to evacuate the rectum as much as possible prior to the MRI exam. In the study arm, a small catheter will be placed in the rectum by the MRI technician and the examination will be executed with the small catheter in situ. In the control arm, subjects will be scanned immediately after rectal evacuation on the toilet. If the DWI sequence is non-interpretable due to susceptibility artefacts, excessive air will be removed with small catheter placement eventually and the scan will be repeated.||||
33959777|NCT01226654|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33959778|NCT02462239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959779|NCT04577456|RANDOMIZED|PARALLEL||TREATMENT||NONE||Global multi center prospective randomized controlled study||||
33959780|NCT03648385|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959781|NCT04671303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959782|NCT06216301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959783|NCT01669759|||||CROSS_SECTIONAL|||||||
33959784|NCT03173521|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33959785|NCT05511129|||COHORT||RETROSPECTIVE|||||||
33959786|NCT05809115|||COHORT||PROSPECTIVE|||||||
33959787|NCT04503707|||COHORT||PROSPECTIVE|||||||
33959788|NCT05725577|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959789|NCT02591316|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33959790|NCT00523887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170160|NCT04673214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the conformation of the groups, random numbers generated by lottery will be used in which the patient will take a piece of paper as he arrives and will have the number of the group to which he will be assigned. With a type of block randomization, A (Azithromycin, paracetamol, Ivermectin, and Ribaroxaban) and B (paracetamol, Azithromycin, and Ribaroxaban).|Two groups of patients with COVID-19 will be integrated, a Group A taking the following medications: Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin tablets of 500 mg will take 1 single dose tablet the first day and then half a tablet (250 mg) orally every 24 for 4 days, Ivermectin tablets of 200mcg which will be calculated according to your weight and dose, it will be every 24 hours for 2 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days and a Group B will take Paracetamol 500 mg orally 1 tablet every 8 hours for 3 days in case of fever equal to or greater than 38.3 ° C, Azithromycin tablets of 500 mg will take 1 single dose tablet on the first day and then half a tablet orally every 24 hours for 4 days and Rivaroxaban 10 mg tablets will take 1 every 24 hours for 10 days.|t|f|f|f
34170161|NCT05305352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765933|NCT00860067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858064|NCT04581616|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34170162|NCT05653414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765934|NCT03842553|||COHORT||CROSS_SECTIONAL|||||||
33765935|NCT02523521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33858065|NCT03740594|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858066|NCT05394376|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33858067|NCT00413738|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858068|NCT03588507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the records of the study participants will be assigned code numbers and the results will be assessed by a third party . coding will not be broken until all assessment and statistics will be completed||f|f|f|t
33858069|NCT04147650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masked|"Subjects will be randomized to one of the following treatment groups:~Investigational product (IP): one drop 0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks, one drop 0.10% VOS OU BID over 12 weeks, or one drop 0.20% VOS OU BID over 12 weeks.~Comparator: one drop VOS vehicle OU BID over 12 weeks."|t|f|t|f
33858070|NCT01080677|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33765936|NCT05835882|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33765937|NCT01350895|||||RETROSPECTIVE|||||||
33765938|NCT04289701|||COHORT||PROSPECTIVE|||||||
33765939|NCT01589562|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33765940|NCT03066622|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label, not blinded, randomized 2-arm trial|This is a prospective, randomized, convenience sample, feasibility trial to test for non-inferiority of oral rapidly dissolving olanzapine versus current emergency department standard of care in providing symptomatic relief to patients presenting with primary headache.||||
33765941|NCT04738721|||OTHER||PROSPECTIVE|||||||
33858071|NCT00457704|||DEFINED_POPULATION||PROSPECTIVE|||||||
33858072|NCT04931186|||COHORT||RETROSPECTIVE|||||||
33858073|NCT01950026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858074|NCT05593679|||CASE_ONLY||OTHER|||||||
33858075|NCT04762654|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33858076|NCT05824260|||CASE_ONLY||RETROSPECTIVE|||||||
33858077|NCT01959048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858078|NCT00509574|||CASE_ONLY||PROSPECTIVE|||||||
33858079|NCT03267693|||OTHER||CROSS_SECTIONAL|||||||
33858080|NCT05551585|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858081|NCT01688856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858082|NCT04038593|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33858083|NCT05193682|||CASE_ONLY||PROSPECTIVE|||||||
33858084|NCT00617032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858085|NCT05658874|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, randomized pre-post intervention/prospective cohort study of usual Urogynecology care vs. multimodal, multidisciplinary care bundle (MMCB).||||
33858086|NCT02257879|||CASE_CROSSOVER||PROSPECTIVE|||||||
33858087|NCT00261001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858088|NCT05138913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858089|NCT02899013|||COHORT||PROSPECTIVE|||||||
33858090|NCT00450905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33858091|NCT01701596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858092|NCT02430974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858093|NCT05594823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858094|NCT04517552|||OTHER||PROSPECTIVE|||||||
33858095|NCT06382922|||COHORT||PROSPECTIVE|||||||
33858096|NCT03575754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858097|NCT02873273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858098|NCT01201655|||CASE_CONTROL||RETROSPECTIVE|||||||
33858099|NCT04553042|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33858100|NCT04616976|||CASE_CONTROL||RETROSPECTIVE|||||||
33858101|NCT04495231|||CASE_ONLY||CROSS_SECTIONAL|||||||
33858102|NCT02947776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858103|NCT01230788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858104|NCT05058625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858105|NCT04709380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858106|NCT05666388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858107|NCT00539890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858108|NCT00002765||||TREATMENT||||||||
33858109|NCT05381987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomisation allocation sequence will be based on computer-generated random sequence using permuted block size of 4 and concealed random allocation using sealed opaque envelopes.|This study will make use a pragmatic, two-arm, parallel, doubled-blind, randomised controlled as the study design.|t|f|f|t
33858110|NCT01389765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33858111|NCT00000730|RANDOMIZED|||TREATMENT||||||||
33858112|NCT04826211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858113|NCT02702726|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33858114|NCT04262531|||COHORT||PROSPECTIVE|||||||
33858115|NCT02576379|||COHORT||PROSPECTIVE|||||||
33858116|NCT02954640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858117|NCT02159196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858118|NCT00246402|RANDOMIZED|||PREVENTION||DOUBLE||||||
33858119|NCT03046784|||COHORT||PROSPECTIVE|||||||
33858120|NCT00555490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959791|NCT05399407|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Experimental group: health e-coaching Control group: standard care||||
33959792|NCT01615640|||CASE_ONLY||PROSPECTIVE|||||||
34170163|NCT02230735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34170164|NCT00961311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170165|NCT03597815|||CASE_CONTROL||PROSPECTIVE|||||||
34170166|NCT02050061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34170167|NCT03398304|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34170168|NCT05089006|||CASE_CONTROL||RETROSPECTIVE|||||||
34170169|NCT00000214||||TREATMENT||||||||
34170170|NCT01074775|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170171|NCT05805423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||single center, prospective, double-blinded randomized controlled trial|t|t|t|f
34170172|NCT00105911||PARALLEL||TREATMENT||SINGLE||||||
34170173|NCT02167308|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34170174|NCT00002643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170175|NCT01357174|||COHORT||RETROSPECTIVE|||||||
34170176|NCT04261686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170177|NCT05866666|||CASE_ONLY||PROSPECTIVE|||||||
34170178|NCT00103168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170179|NCT01602224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170180|NCT06215534|RANDOMIZED|CROSSOVER||OTHER||NONE||"12 products will be tested (2 x 6 products + each 3 contls) that means 18 ärmsin total"||||
34170181|NCT02511379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170182|NCT06296017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170183|NCT02422706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinding was applied by using consecutively numbered envelopes that contained the treatment assignments||t|t|f|f
34170184|NCT00596414|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33765942|NCT05031676|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant does not know the protocol which receive but i|The patients were randomized during the pre-anesthetic visit in two groups 1 and 2. They were randomized in blocks of four so that, in each block of four patients, there were two patients for the protocol 1 and two patients for the protocol 2.|t|f|f|f
33765943|NCT01540565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765944|NCT06299969|||CASE_ONLY||PROSPECTIVE|||||||
33959793|NCT05685693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063550|NCT03806023|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34063551|NCT01354548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063552|NCT03984968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063553|NCT00901979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063554|NCT02179749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063555|NCT04222140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170185|NCT06474624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34170186|NCT01329978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170187|NCT00539981|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34170188|NCT05235126|NA|SINGLE_GROUP||OTHER||NONE||All subjects will receive open treatment with Decoria intense for correction of nasolabial folds at Visit 1 with optional touch-up at Visit 2.||||
34170189|NCT00069446||||TREATMENT||||||||
34170190|NCT00792844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170191|NCT04752163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170192|NCT01054105|||CASE_CONTROL||PROSPECTIVE|||||||
34170193|NCT05072626|||COHORT||PROSPECTIVE|||||||
34170194|NCT06412510|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170195|NCT02978417|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170196|NCT05084040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170197|NCT03838185|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Subjects will receive a single dose of J147 or placebo in a fasted state. The dose levels are planned to be administered in ascending order. Progression to the next dose level, and dose selection, will be based on all available safety and tolerability data up to at least 48 hours post-dose and available PK data (up to at least 24 hours post-dose) from a minimum of 6 subjects (J147 n ≥4) in the preceding dose cohort. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.|t|t|t|t
34170198|NCT02926872|||OTHER||OTHER|||||||
34170199|NCT06430996|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33765945|NCT02783222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765946|NCT06287684|||CASE_ONLY||PROSPECTIVE|||||||
33765947|NCT00032344|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765948|NCT05263999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765949|NCT01788345|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33765950|NCT05068739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765951|NCT04522180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765952|NCT00977769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765953|NCT01566929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765954|NCT00639821|||COHORT||PROSPECTIVE|||||||
33765955|NCT06463821|||OTHER||PROSPECTIVE|||||||
33765956|NCT04107584|||COHORT||PROSPECTIVE|||||||
33765957|NCT02768948|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33765958|NCT04695340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765959|NCT04501133|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The purpose of this study is to understand how motor activation can be reduced. For this purpose, it will be examined how some muscles of the arm respond to electric and magnetic stimulation. The effects of the electric and/or magnetic stimulation will be recorded non-invasively with HD-EMG.||||
33765960|NCT02826369|NA|SINGLE_GROUP||OTHER||NONE||||||
33765961|NCT01735838|||||PROSPECTIVE|||||||
33765962|NCT02748694|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33765963|NCT00713674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765964|NCT03996941|||COHORT||PROSPECTIVE|||||||
33765965|NCT04780698|NA|SINGLE_GROUP||SCREENING||NONE||||||
33765966|NCT03278301|||COHORT||PROSPECTIVE|||||||
33765967|NCT04988425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random grouping||t|f|f|f
33765968|NCT03070509|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33765969|NCT05799937|||COHORT||PROSPECTIVE|||||||
33765970|NCT04770753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33765971|NCT03739775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765972|NCT03072225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33765973|NCT02133482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33765974|NCT04306939|||CASE_CONTROL||PROSPECTIVE|||||||
33765975|NCT03241602|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33765976|NCT03798834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33765977|NCT02172703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765978|NCT02932969|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33765979|NCT04022005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765980|NCT03533634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient and the outcomes analyzer were masked|randomized clinical trial|t|f|f|t
33765981|NCT04154865|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33765982|NCT04566588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765983|NCT00166686|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33765984|NCT01238549|||COHORT||PROSPECTIVE|||||||
33765985|NCT00316030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765986|NCT04235634|||COHORT||PROSPECTIVE|||||||
33765987|NCT01922323|||CASE_ONLY||PROSPECTIVE|||||||
33765988|NCT04535323|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33765989|NCT03976453|||CASE_CONTROL||PROSPECTIVE|||||||
33765990|NCT03592277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All parties involved, except for pharmacy personnel will be blinded.||t|t|t|t
33765991|NCT03018301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33765992|NCT02917941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858121|NCT04500756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|randomized (which means assigned by chance, like flipping a coin) into one of two groups. You will either be assigned to take metformin 500 mg tablet(s) daily or identical tablet(s) that contain no active drug, also taken every day.|Prospective, randomized, controlled trial comparing the ability of metformin to prevent AAA disease progression vs. placebo.|t|t|t|f
34170200|NCT01255423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170201|NCT04430322|||OTHER||RETROSPECTIVE|||||||
34170202|NCT03549221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170203|NCT00841334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170204|NCT02309944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170205|NCT02461667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170206|NCT01303211|||CASE_CONTROL||PROSPECTIVE|||||||
34170207|NCT04971460|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34170208|NCT03636555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|UNC Hospitals Investigational Drug Service blind labels intranasal spray bottles containing oxytocin or placebo spray and dispenses bottles based on a randomization scheme provided by the study Biostatistician|Double blind, placebo-controlled trial|t|t|t|f
34170209|NCT06514872|||CASE_ONLY||CROSS_SECTIONAL|||||||
34170210|NCT01889823|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170211|NCT02246049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170212|NCT00254917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170213|NCT06293521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170214|NCT02697266|||COHORT||PROSPECTIVE|||||||
34170215|NCT04687657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170216|NCT00000235||CROSSOVER||TREATMENT||||||||
34170217|NCT03084796|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34170218|NCT01916135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170219|NCT00964496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170220|NCT06059365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170221|NCT00659061|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34170222|NCT01120366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170223|NCT06058975|||COHORT||RETROSPECTIVE|||||||
34170224|NCT04265196|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Subjects will be assigned to the different treatment groups randomly and without receiving information about the different treatment options included in the study.||t|f|f|f
34170225|NCT04731389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170226|NCT00707785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170227|NCT04559854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170228|NCT02647307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170229|NCT00725777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170230|NCT03166514|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, cross-over administration of supplements with approximately 5-10 days between testing sessions.||||
34170231|NCT05817656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170232|NCT05709860|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34170233|NCT02102295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33765993|NCT02712593|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34063556|NCT00402610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170234|NCT02971423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170235|NCT03942289|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170236|NCT03979898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170237|NCT04511481|||COHORT||RETROSPECTIVE|||||||
34170238|NCT04070365|||OTHER||PROSPECTIVE|||||||
34170239|NCT02558517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170240|NCT02849977|||CASE_ONLY||PROSPECTIVE|||||||
34170241|NCT00006000||||TREATMENT||||||||
34170242|NCT01663870|||COHORT||PROSPECTIVE|||||||
34170243|NCT05860088|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34170244|NCT00213616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170245|NCT03986996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator will be blinded to the study group|2 groups with 1:1 randomization|f|f|t|f
34170246|NCT05665439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170247|NCT00110539|RANDOMIZED|PARALLEL||||DOUBLE||||||
34170248|NCT03149055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170249|NCT00669890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170250|NCT01840007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170251|NCT01222013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170252|NCT05296265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Forty individuals with above (AKA) or below (BKA) knee amputation suffering from chronic phantom limb pain (PLP) will be recruited and will be quasi-randomly assigned to Active VR versus Distractor VR treatments in 50:50 ratio.||||
34170253|NCT01911715|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170254|NCT04396535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170255|NCT00952991|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34170256|NCT03826940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34170257|NCT01290107|||COHORT||PROSPECTIVE|||||||
34170258|NCT00588926|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170259|NCT00475670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170260|NCT06045312|RANDOMIZED|PARALLEL||PREVENTION||NONE||In this study, there is an intervention and a control group.||||
34170261|NCT05413668|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34170262|NCT05568446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34170263|NCT04258423|RANDOMIZED|PARALLEL||PREVENTION||NONE||Tacrolimus as maintenance immunosuppression, then randomized to Everolimus plus Mycophenolate Mofetil, discontinuing Tacrolimus once Everolimus level within goal range OR randomized to continued maintenance with Tacrolimus plus Mycophenolate Mofetil.||||
34170264|NCT03793348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170265|NCT00733785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170266|NCT02519439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765994|NCT01351532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959794|NCT06702163|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"We designed a randomized crossover, sham-controlled, double blind trial to demonstrate the improvement of motor functions and stroke related symptoms following a single session of active versus sham EXOPULSE Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect.~Two weeks after the end of this phase (phase 1), a second phase of this trial, an open label phase, will be proposed for all patients to understand the effects of EXOPULSE Mollii suit employed over 4 weeks (a session every other day for a total of 14 sessions) on stroke related symptoms.~Summary:~* Phase 1: randomized sham-controlled crossover study (active versus sham condition)~* Phase 2: Open-label study (active condition)"|t|f|t|t
33959795|NCT01256398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959796|NCT02420665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063557|NCT04341558|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Single-centre stepped-wedge cluster randomised trial conducted in four surgical wards over a six-month period||||
33959797|NCT06503523|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||we apply one of three experimental methods in your hand: either an injection of salt water (7% NaCl) or we apply small needles from the plant mucuna pruriens or histamine (1%)||||
34170267|NCT04320004|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will use a cluster-randomized stepped-wedge design, using clinics as clusters (i.e., all clinics participate in all arms, but not all at the same time) to compare two main interventions (education only vs. education + mail-back bag) to baseline/usual care. In addition, the investigators will randomize patients in both intervention arms to receive or not to receive an added telephone reminder call through interactive voice response (IVR). The primary outcome of the study, medication disposal actions taken by the patient, will be assessed by a telephone survey.||||
34170268|NCT01577017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170269|NCT02730481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170270|NCT00660725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170271|NCT01269112|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749118|NCT05916651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The PRYME study is a Randomized Controlled Trial (RCT) that compares care-as-usual (e.g., supportive counseling by a student psychologist or mental health nurse-practitioner) with care -as-usual + mindfulness training. Participants are randomized to either of these conditions. Data is collected at baseline, after the mindfulness training (approximately 3 months after baseline), and at 2 and 6 months follow-up. Multiple measurements will be conducted using questionnaires, experimental tasks in and out of the MRI scanner, MRI scans, and clinical interviews.|f|f|f|t
33749119|NCT06636526|||COHORT||PROSPECTIVE|||||||
33749120|NCT04087148|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749121|NCT01695967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749122|NCT06164626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749123|NCT02891187|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749124|NCT03725644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749125|NCT02267395|||CASE_CONTROL||RETROSPECTIVE|||||||
33749126|NCT02530307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749127|NCT05496127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749128|NCT04455672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749129|NCT03347968|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33749130|NCT03996473|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749131|NCT01453816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749132|NCT03973619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749133|NCT05258825|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study without masking of participant, care provider, investigator or outcomes assessor.|This is a single arm study with all study patients receiving intravenous iron infusion.||||
33749134|NCT04769167|NON_RANDOMIZED|FACTORIAL||SCREENING||SINGLE|All participant's will not know whether they had evidence of recent viremia as this analysis is conducted in the future and the diagnosis of enteroviral viremia does not impact clinical treatment.|All participants will provide the same biologic specimens (stool \& blood) during their study arm's designated timeframe. All collected specimens will be analyzed per the study protocol.|t|f|f|f
33749135|NCT04575467|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749136|NCT03860857|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||All participants will complete the same study procedures, including the tau PET scans with investigational radio tracer 18F-MK6240. The arms define the age range and APOE status of the participants, with each having their own enrollment target.||||
33749137|NCT06247839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749138|NCT03117738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749139|NCT05225493|||COHORT||PROSPECTIVE|||||||
34063558|NCT04977414|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|"Participants cannot be blinded as this is a behavioural intervention.~Some of the researchers can be blinded. Specifically, it is not possible to blind reviewers R1 and R2 to the board papers group or time-period, as those researchers are extracting charts from the published board papers. R3 and R4 will be blinded and will be instructed to inform R1 if those researchers are unblinded at any point, and whether/how often those researchers are unblinded will be reported in the final manuscript."|||||
34063559|NCT05342493|||COHORT||PROSPECTIVE|||||||
33749140|NCT04020900|||CASE_CONTROL||PROSPECTIVE|||||||
33749141|NCT04879186|||COHORT||RETROSPECTIVE|||||||
33749142|NCT00043420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749143|NCT05709834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749144|NCT06015321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749145|NCT00443976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749146|NCT01374256|||CASE_CONTROL||RETROSPECTIVE|||||||
34063560|NCT00840593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063561|NCT04977492|||CASE_CONTROL||RETROSPECTIVE|||||||
34063562|NCT03689101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749147|NCT06532630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749148|NCT02804594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959798|NCT01356186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959799|NCT04861415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959800|NCT00817869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959801|NCT05480384|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959802|NCT01031225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959803|NCT03313154|||CASE_CONTROL||PROSPECTIVE|||||||
33959804|NCT05113862|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"* This trial is double-blinded (blinded to investigators and participants)~* Blinding will be maintained for the duration of the study~* All allocations will remain coded to all volunteers and investigators. An independent pharmacy team at CHUV will label the vaccine and comparator doses with coded participant numbers but will not have access to the identifier list linking the code to the participant identity. All vaccine and comparator doses will be prepared and labelled away from investigators and stored in identical conditions.~* The appearance of the comparators and doses will be identical. The solutions of both are indistinguishable within the dosage group and thus no shielding of the solution colour is needed."||t|t|t|t
34170272|NCT03976479|||COHORT||CROSS_SECTIONAL|||||||
34170273|NCT00921271|||COHORT||PROSPECTIVE|||||||
33749149|NCT03133975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|Randomized clinical trial VITAMIN D for treatment of dyslipedemia|t|f|t|f
33959805|NCT01040546|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959806|NCT00115466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959807|NCT02604186|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33959808|NCT06465706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and family will be blinded to which device they received.||t|f|f|f
33959809|NCT02680730|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959810|NCT01305265|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33959811|NCT01491373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959812|NCT05602974|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: adjuvant stereotactic body radiation therapy after hepatectomy with narrow margin Control: regular follow-up after hepatectomy with narrow margin||||
33959813|NCT06376773|||COHORT||RETROSPECTIVE|||||||
33959814|NCT06336174|||COHORT||PROSPECTIVE|||||||
33959815|NCT01115699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959816|NCT00227734|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959817|NCT01485588|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959818|NCT06457204|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959819|NCT00668109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959820|NCT05406427|||OTHER||PROSPECTIVE|||||||
33959821|NCT02665026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959822|NCT04668118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959823|NCT01466673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33959824|NCT04704817|||COHORT||PROSPECTIVE|||||||
33959825|NCT01618903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959826|NCT04721327|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959827|NCT05323409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959828|NCT03402126|||COHORT||PROSPECTIVE|||||||
33959829|NCT04947059|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Bladder cancer patients, who are treated with a transurethral resection of the bladder tumor, receive postoperatively an immediate single intravesical instillation with either gemcitabine hydrochloride or epirubicine hydrochloride|t|f|t|t
33959830|NCT06564337|NA|SINGLE_GROUP||TREATMENT||NONE||Research data on the survival of zirconia crowns as RPD abutments is limited although anecdotally these are being used regularly by dentists in clinical practice. To our knowledge a clinical trial evaluating the outcomes of surveyed monolithic zirconia crowns as RPD abutments has not been investigated previously. We propose to evaluate the outcomes of surveyed zirconia crowns as RPD abutments in a prospective trial and compare the survival, biological and technical complications with alternative materials historically used for surveyed crowns.||||
33959831|NCT06398080|||COHORT||PROSPECTIVE|||||||
34063563|NCT04967859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will be allocated to two groups randomly (draw), according to the prescribed topical treatment (gentamicin or placebo). The randomization protocol will be generated by an individual other than the patients' clinical follow-up using specific software (randomization). . The randomization list as well as the identification of the bottles and the uniformity of the packages will remain under the care of the researchers who are not familiar with the patients' clinical follow-up|Group 1 (control): Patients using placebo ointment in ES Group 2 (intervention): Patient using 0.1% gentamicin ointment in ES|t|t|t|t
34063564|NCT00403741|RANDOMIZED|PARALLEL||||NONE||||||
34063565|NCT02431806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063566|NCT06093971|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063567|NCT05086341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel-group, randomized controlled pilot- and feasibility trial, 2:1 (I:C) randomization.|f|f|t|t
34063568|NCT01675375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063569|NCT06441422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063570|NCT02143830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063571|NCT02561663|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34063572|NCT04268940|||COHORT||PROSPECTIVE|||||||
34063573|NCT01743118|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34063574|NCT00223730|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063575|NCT02732236|||COHORT||PROSPECTIVE|||||||
34063576|NCT02636803|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34063577|NCT03130140|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34170274|NCT05474352|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170275|NCT03083925|||CASE_CONTROL||PROSPECTIVE|||||||
33959832|NCT04691739|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959833|NCT03091218|||COHORT||PROSPECTIVE|||||||
33959834|NCT06248073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063578|NCT06179732|RANDOMIZED|PARALLEL||PREVENTION||NONE|Neither the deliverers of the intervention nor the outcome assessors are blinded to the group allocations.|||||
34063579|NCT05721690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063580|NCT00382109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749150|NCT05798195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749151|NCT02439229|||COHORT||PROSPECTIVE|||||||
33858122|NCT04990492|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This study will be a repeated measure, mixed methods design (i.e., it will contain both qualitative and quantitative components). Newly admitted patients will be asked to complete the questionnaires (i.e., GAD 7 and the UEQ) at two different time points (i.e., Baseline and 1-month follow-up). In order to reduce or control for order effects, the procedure will be counterbalanced.||||
34063581|NCT04006509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34063582|NCT00004866||||TREATMENT||||||||
34063583|NCT02548923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063584|NCT01164917|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34063585|NCT00865241|RANDOMIZED|CROSSOVER||||NONE||||||
34063586|NCT05907187|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063587|NCT02464644|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34063588|NCT01592461|||COHORT||PROSPECTIVE|||||||
34063589|NCT02944435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063590|NCT03584516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||In Part 2 of the study, participants in the placebo group will be allowed to cross over to the experimental group after completion of the primary analysis.|t|f|t|f
34063591|NCT06250179|NON_RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE|||t|f|f|f
34063592|NCT05391919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open lable randomized clinical trial|t|f|f|f
34063593|NCT05954936|||OTHER||RETROSPECTIVE|||||||
34063594|NCT00374218|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34063595|NCT00851019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063596|NCT03099694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063597|NCT06199271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063598|NCT01368107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063599|NCT02748408|||COHORT||PROSPECTIVE|||||||
34063600|NCT00000448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34063601|NCT03278782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063602|NCT02003963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33749152|NCT04112004|||COHORT||RETROSPECTIVE|||||||
33749153|NCT03189017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749154|NCT01160523|||||PROSPECTIVE|||||||
33749155|NCT06201338|||COHORT||PROSPECTIVE|||||||
33749156|NCT02119351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749157|NCT04300738|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749158|NCT04013815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and investigator checking the pain are not aware of which block has been performed|"60 patients will be enrolled to undergo thoracotomy lung resection surgery.~The population will be divided into two groups based on the type of block made:~Group E: ESP block (n = 30)~Group I: Intercostal block (n = 30)"|t|f|f|t
33749159|NCT03477435|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Type 1 hybrid effectiveness/implementation study to evaluate two population-based approaches||||
33749160|NCT05602363|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749161|NCT01738048|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749162|NCT03456193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749163|NCT00205348|||CASE_ONLY||PROSPECTIVE|||||||
33749164|NCT02183818|||CASE_CONTROL||PROSPECTIVE|||||||
33749165|NCT05322616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matched placebo-solution|Randomized, Double-Blind, Placebo-Controlled, Single- Ascending Dose|t|t|t|t
33749166|NCT05461872|||COHORT||RETROSPECTIVE|||||||
33749167|NCT00307827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063603|NCT01933178|NA|SINGLE_GROUP||||NONE||||||
34063604|NCT05935995|NA|SINGLE_GROUP||OTHER||NONE||||||
34063605|NCT00192348|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34063606|NCT06083701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063607|NCT03762005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063608|NCT05038566|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||A functional test will be used to evaluate the feasibility of the device design as compared with a baseline condition.||||
34063609|NCT05168072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063610|NCT04657367|||CASE_CONTROL||PROSPECTIVE|||||||
34063611|NCT05092204|||CASE_CONTROL||PROSPECTIVE|||||||
34063612|NCT03932929|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34063613|NCT06009809|||COHORT||PROSPECTIVE|||||||
34170276|NCT02883231|||CASE_ONLY||PROSPECTIVE|||||||
34170277|NCT01154868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170278|NCT04546035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants (including parents of patients), physiatrists who conducted ESWT and physiatrists who examined the patients' ASAS score are all blinded.||t|t|f|t
34170279|NCT00681044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170280|NCT00558246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749168|NCT05285813|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749169|NCT05020223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749170|NCT01678170|||CASE_ONLY||PROSPECTIVE|||||||
33749171|NCT05535816|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749172|NCT04988308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749173|NCT06544733|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Phase 2 (Treatment Group 1, Treatment Group 2, and Extension Phase) arms and Phase 3 Extension Phase arm are open-label; Phase 3 Treatment Group 1 and Phase 3 Treatment Group 2 arms are blinded.||t|f|t|f
33749174|NCT05663294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749175|NCT04401384|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Two by two factorial design|t|t|t|t
33749176|NCT00389714|NON_RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33749177|NCT02862106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063614|NCT04889599|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34063615|NCT01039805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063616|NCT06271759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34063617|NCT03130283|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||quasi experimental study design with propensity score matching||||
34063618|NCT00994409|||COHORT||PROSPECTIVE|||||||
33749178|NCT06319807|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33749179|NCT00562887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749180|NCT04769076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749181|NCT03137134|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open-label|||||
33749182|NCT06304259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749183|NCT00249925|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33749184|NCT01476254|||CASE_CONTROL||PROSPECTIVE|||||||
33858123|NCT00754143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858124|NCT00245934|||||PROSPECTIVE|||||||
33858125|NCT04415463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858126|NCT03097133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858127|NCT05085223|||COHORT||PROSPECTIVE|||||||
33858128|NCT06485752|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33858129|NCT03586687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858130|NCT02767401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858131|NCT00301275|||||PROSPECTIVE|||||||
33749185|NCT01373528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858132|NCT03931733|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients are assigned to either the intervention or control group based on flipping a coin.||t|t|f|f
33858133|NCT00639223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858134|NCT01526070|||COHORT||PROSPECTIVE|||||||
33858135|NCT01688414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170281|NCT02624271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170282|NCT01439516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170283|NCT02778646|||COHORT||CROSS_SECTIONAL|||||||
34170284|NCT00274248|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170285|NCT02222935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170286|NCT05532826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170287|NCT03121859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34170288|NCT02888106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Open-label, Randomized, Comparative, parallel-arm phase II study||||
34170289|NCT01099371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170290|NCT04761978|||COHORT||RETROSPECTIVE|||||||
34170291|NCT00361673|||||CROSS_SECTIONAL|||||||
34170292|NCT02362321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170293|NCT01964508|||COHORT||PROSPECTIVE|||||||
34170294|NCT05378685|RANDOMIZED|PARALLEL||PREVENTION||NONE|The intubation route (oral or nasal) is obvious and visible to everyone who interacts with the infant postoperatively.|Using a random number generator, infants are randomized to oral or nasal intubation by a pediatric cardiac anesthesiologist at the time of surgery. The anesthesiologist may elect to diverge from the randomization based on their clinical judgement and patient safety. Infants are analyzed as treated.||||
34170295|NCT02752594|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34170296|NCT00956735|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34170297|NCT02621112|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34170298|NCT02004730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170299|NCT03642873|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34170300|NCT01404039|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||There are 5 experiments: motor learning (3 groups, crossover), sensory learning (4 groups, parallel), observational task (2 groups, parallel), mental imagery (2 groups, parallel), and tDCS over the motor cortex (2 groups, crossover). Please note that the tDCS experiment has never been conducted.|f|f|t|t
34170301|NCT04389359|RANDOMIZED|PARALLEL||PREVENTION||NONE||PROTECT will use an innovative basket design to conduct a series of prospective, randomised comparisons in multiple vulnerable patient groups in the United Kingdom with the capabilities of assessing effects within specific patients groups, and across the pooled PROTECT cohort. Additional interventions may be added as these become available. Basket Trial design brings greater efficiency, due to running multiple comparisons within one master protocol. It also allows application of innovative Bayesian analysis methods that allow adaptive borrowing of information across populations. This will mean in the case that there is a consistent effect across populations, the trial will have greater power to find significant differences for individual patient groups.||||
34170302|NCT01668459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749186|NCT03905200|||CASE_CONTROL||PROSPECTIVE|||||||
33749187|NCT01614665|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749188|NCT05870800|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Phase II open-label trial of neoadjuvant CAPEOX chemotherapy with Atezolizumab followed by surgery and adjuvant chemotherapy for patients with localized resectable pMMR adenocarcinoma of the colon||||
33749189|NCT03671668|RANDOMIZED|PARALLEL||TREATMENT||NONE||Completely edentulous patients||||
33749190|NCT06374485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858136|NCT00861224|||COHORT||PROSPECTIVE|||||||
33858137|NCT00846391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858138|NCT05023343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Each participant serves as their own control i.e. each participant will receive both an active and placebo block TQL block. Left/right side are randomized.|t|t|t|t
33858139|NCT02921204|||COHORT||CROSS_SECTIONAL|||||||
33858140|NCT04824521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858141|NCT02705144|||COHORT||PROSPECTIVE|||||||
33858142|NCT02092974|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33858143|NCT02435966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858144|NCT01722149||SEQUENTIAL||TREATMENT||NONE||Adoptive Transfer of re-directed FAP-specific T cells||||
33858145|NCT04549233|||CASE_ONLY||CROSS_SECTIONAL|||||||
33858146|NCT02377791|||COHORT||RETROSPECTIVE|||||||
33858147|NCT04495803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858148|NCT03894254|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33858149|NCT02721745|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858150|NCT04086654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858151|NCT02475486|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858152|NCT03660553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858153|NCT04530409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893622|NCT04697563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The person who performs the laser treatment is unaware of the treatment given The laser devices can be used as a placebo laser by blocking the laser beam with a plug|Randomized double-blinded placebo- controlled clinical study|t|f|t|f
34063619|NCT04892992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Intervention group I were delivered DFG immediately, and Intervention group II were delivered DFG after three months.|Intervention group I were delivered DFG immediately and Intervention group II were delivered DFG after three months.|t|f|f|f
33893623|NCT04332237|||OTHER||RETROSPECTIVE|||||||
33893624|NCT00363415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893625|NCT02284724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063620|NCT01080729|||COHORT||PROSPECTIVE|||||||
34063621|NCT03933878|||COHORT||PROSPECTIVE|||||||
34063622|NCT02650622|||COHORT||PROSPECTIVE|||||||
34063623|NCT05555602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34063624|NCT03545269|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection along with a fibrin adhesive through minimal arthrotomy.~Active comparator: Microfracture The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate."||||
34063625|NCT02393430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063626|NCT03786185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant is not aware of the group (intervention or control) in which s/he belongs.|This is a 2x2x2 mixed model design with between subjects factors condition (congruent and incongruent) and age group (adolescent, adults, elderlies) and within subjects factor time (pre, post).|t|f|f|f
34063627|NCT06317116|||OTHER||CROSS_SECTIONAL|||||||
34063628|NCT06336278|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063629|NCT01752868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063630|NCT03738761|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Treatment is started at Visit 1 with Amlessa® 4mg/5mg (Amlessa® Arm) or Co-Amlessa® 4mg/1,25mg/5mg (Co-Amlessa® Arm) for 4 weeks.~At each of the three follow-up visits (at week 4, week 8 and week 12) patient BP is assessed and if normal office blood pressure was achieved, the treatment with the study medication prescribed for the previous treatment period is continued. If normal office blood pressure was not achieved at any of the follow-up visits (week 4, week 8 and week 12), Amlessa® or Co-Amlessa® strength is increased in accordance with the below sequence.~Amlessa® Arm Amlessa® 4mg/5mg (initial therapy) - Amlessa® 8mg/5mg - Amlessa® 8mg/10mg - Co-Amlessa® 8mg/2,5mg/10mg~Co-Amlessa® Arm Co-Amlessa® 4mg/1,25mg/5mg - Co-Amlessa® 8mg/2,5mg/5mg - Co-Amlessa® 8mg/2,5mg/10mg - end of study no further escalation of study medication dosage~Normal office BP is defined as SBP \< 140 mmHg and DBP \< 90 mmHg; patients with type 2 diabetes mellitus: SBP \< 140 mmHg and DBP \< 85 mmHg."||||
34063631|NCT03718754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063632|NCT01880905|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34063633|NCT02150070|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34063634|NCT03296020|RANDOMIZED|PARALLEL||OTHER||NONE||randomized clinical trials that included 2 armes: the control group and the case group||||
34063635|NCT05121740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Follow up Multicentric extension study of APLICOV-PC clinical trial.||||
34063636|NCT06730789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063637|NCT01794598|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34063638|NCT00743288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063639|NCT03702491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063640|NCT05871671|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34063641|NCT03394417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34063642|NCT01413074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063643|NCT04542434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063644|NCT03758105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063645|NCT06428032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34063646|NCT04492917|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34063647|NCT00985426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34063648|NCT05952713|||COHORT||RETROSPECTIVE|||||||
34063649|NCT06290804|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
34063650|NCT00718484|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063651|NCT06055920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063652|NCT03140956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063653|NCT05277350|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|double-blind|Dose escalation|t|t|t|t
34063654|NCT06059157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063655|NCT04136275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063656|NCT00003178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063657|NCT00701844|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34063658|NCT03793374|||CASE_ONLY||RETROSPECTIVE|||||||
34063659|NCT05974956|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Medical researcher N assessed the prognosis of mastitis using tool IV mastitis prognosis sheet for all patients control - study at follow up without knowing the study group who received the nursing teaching protocol"|"Quasi experimental research design that test for change through manipulation of the independent variable. However, in this study, it lacks one of the three key properties of an experimental design randomization.~The dependent variables (mastitis knowledge, self -care practice, pain level, and complications associated with mastitis) were measured and compared at base line for both control and study groups, then intervention was introduced to the study group. After three weeks; the dependent variables for both groups were evaluated to test the difference."|f|f|f|t
34063660|NCT00811993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063661|NCT03564795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled within-subject trial of 30 patients, each of whom will have a minimum of one burn treated with the KeraStat Gel device and one burn treated with the standard of care dressing||||
34063662|NCT06056362|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The images of patients will be reviewed by 2 experienced nuclear medicine physicians and they will be masked to all patients' clinical information.||t|f|f|t
34063663|NCT04409015|||CASE_ONLY||PROSPECTIVE|||||||
34063664|NCT00486707|||CASE_ONLY||PROSPECTIVE|||||||
34063665|NCT06731868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063666|NCT05369689|||COHORT||PROSPECTIVE|||||||
34063667|NCT04420819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34063668|NCT06082882|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34063669|NCT05691621|||CASE_ONLY||PROSPECTIVE|||||||
34063670|NCT02979080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063671|NCT04317924|RANDOMIZED|PARALLEL||PREVENTION||NONE||Stratified block randomization will be done using known predictors of prolonged air leak: 1) surgical procedure (wedge vs lobectomy) and 2) presence of pulmonary comorbidities (chronic obstructive pulmonary disease and emphysema).||||
34063672|NCT01686516|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34063673|NCT00006486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063674|NCT00625404|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063675|NCT05539261|||COHORT||PROSPECTIVE|||||||
34063676|NCT03968055|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34063677|NCT04038554|||CASE_CONTROL||PROSPECTIVE|||||||
34063678|NCT04908111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063679|NCT02694458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063680|NCT01010399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063681|NCT03436199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063682|NCT00410462|RANDOMIZED|||TREATMENT||||||||
34063683|NCT00822224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063684|NCT03646149|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34063685|NCT05543031|NON_RANDOMIZED|PARALLEL||OTHER||NONE|no masking|This study was designed to determine the benefit of music integrated phonological awareness programs for children using cochlear implants. In addition, the phonological skills and language skills of children using cochlear implants and children with normal hearing were compared in the pre and post-training results.||||
34063686|NCT06513156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063687|NCT03959904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||2 groups randomised to different suturing techniques following surgery|f|f|t|t
34063688|NCT05194956|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Single-centre prospective randomised controlled two-period crossover study|f|f|f|t
34063689|NCT05932849|||COHORT||RETROSPECTIVE|||||||
34063690|NCT00006305|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34063691|NCT06731192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063692|NCT01325194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063693|NCT02494401|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34063694|NCT03217968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063695|NCT03777111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749191|NCT06052410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Sensory development is targeted in activity-based education based on the principles of the Goal, Activity and Motor Enrichment (GAME) approach, which is an evidence-based early intervention approach for children between 24-36 months at risk of developmental delay. The program was implemented in the pediatric unit for 45 minutes a day, twice a week for 12 weeks. For the control group, evaluation tests were first applied to babies selected by simple random sampling method. According to the evaluation results, a personalized home program was given. Post-evaluations were repeated for both groups after 12 weeks. The basic principles of the GAME approach are examined in 3 parts: goal-oriented intensive motor training, parent training, environmental enrichment. In our study, activities were also implemented based on the sensory integration approach and cognitive rehabilitation intervention principles to present sensory and cognitive strategies within the activity.|t|f|f|f
33749192|NCT04313231|||COHORT||PROSPECTIVE|||||||
33749193|NCT06285682|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Volume of nutritional supplement is provided in a double-blinded manner. Both participants and research testers will be masked from knowing the specifics of the volume allocation.|Participants are randomly assigned a dose of olive-derived hydroxytyrosol in a double-blind manner. Following a ≥3 day wash out participants then cross-over to an alternate dose. This process is then repeated for the third and final dose.|t|f|t|f
33749194|NCT04734210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749195|NCT00551785|||COHORT||PROSPECTIVE|||||||
33749196|NCT03857659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858154|NCT03608982|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants will be informed about participating in a study, evaluating the performance of basic first aid courses taught by the Belgian Red Cross, but will be blinded from the actual goal of the research, i.e. testing the added value of simulated patients.~The outcome assessors will not be aware of the allocation status of participants whose practical skills they judge."|This is a cluster-randomized trial, in which allocation is done at the level of the companies that request a first aid course for their employees.|t|f|f|t
33858155|NCT01262703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858156|NCT01246752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858157|NCT00316134|||COHORT||PROSPECTIVE|||||||
33858158|NCT05151315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170303|NCT04986202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170304|NCT01139814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170305|NCT05824364|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel and cross over designs will be adopted according to the specific purposes of that given clinical study||||
34170306|NCT02492178|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34170307|NCT06061952|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170308|NCT03771755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34170309|NCT03984110|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170310|NCT02903160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170311|NCT00793858|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34170312|NCT01813396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170313|NCT03776695|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34170314|NCT01538069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34170315|NCT03186300|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34170316|NCT03295396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170317|NCT01548547|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34170318|NCT02418572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170319|NCT03520881|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||There is one group (intervention arm only) in this proof of concept study.||||
34170320|NCT00466544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34170321|NCT00644358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170322|NCT06256978|||CASE_ONLY||PROSPECTIVE|||||||
34170323|NCT01571102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170324|NCT06394037|||COHORT||PROSPECTIVE|||||||
34170325|NCT00003574||||TREATMENT||||||||
34170326|NCT03833492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170327|NCT06143358|RANDOMIZED|PARALLEL||TREATMENT||NONE||Qingkepingchuan Granules||||
34170328|NCT02950363|||OTHER||OTHER|||||||
34170329|NCT01366872|||CASE_ONLY||RETROSPECTIVE|||||||
34170330|NCT04551040|NA|SINGLE_GROUP||OTHER||NONE||Single group of healthy older adults||||
34170331|NCT04484558|||CASE_ONLY||CROSS_SECTIONAL|||||||
34170332|NCT02971917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170333|NCT01882673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858159|NCT03613987|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858160|NCT01493648|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33858161|NCT01973946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858162|NCT00730171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170334|NCT03400618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170335|NCT05599308|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Prospective, parallel-cohort, open label, non-randomized study||||
34170336|NCT03167385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170337|NCT00657540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170338|NCT02756481|||CASE_ONLY||RETROSPECTIVE|||||||
34170339|NCT06423365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34170340|NCT01383603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170341|NCT03710148|||COHORT||PROSPECTIVE|||||||
34170342|NCT05454774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170343|NCT00756249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170344|NCT06473922|||COHORT||PROSPECTIVE|||||||
33858163|NCT02604433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858164|NCT00699452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858165|NCT01285050|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170345|NCT00587717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170346|NCT02655848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749197|NCT01781728|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, controlled Phase 2 trial||||
34063696|NCT01371929|||CASE_CONTROL||PROSPECTIVE|||||||
34063697|NCT00065195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34063698|NCT00231309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063699|NCT05304494|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063700|NCT05338866|||COHORT||PROSPECTIVE|||||||
34063701|NCT00296127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33749198|NCT06153095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749199|NCT01846338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749200|NCT06669962|||COHORT||PROSPECTIVE|||||||
33858166|NCT00132223|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33858167|NCT01610362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858168|NCT01099423|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858169|NCT01365143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858170|NCT03095430|||CASE_CONTROL||PROSPECTIVE|||||||
33858171|NCT02960113|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33858172|NCT04609059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858173|NCT00657059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858174|NCT00926549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858175|NCT02108587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858176|NCT02861443|||||CROSS_SECTIONAL|||||||
34063702|NCT04365049|||COHORT||PROSPECTIVE|||||||
34063703|NCT03050047|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34063704|NCT02106143|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||RejuvenAir||||
34063705|NCT00869557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063706|NCT04471571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Selection bias: will be overcome by randomization and allocation concealment. Performance bias: will be overcome by standardized method of application by single operator.~Detection bias: will be overcome by blinding of the outcome assessor. Reporting bias: All the outcomes will be reported and published."|two-arm parallel group randomized controlled trial|t|t|f|t
34170347|NCT03743441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Two identical laser devices are used, where one is active and the other is sham. One laser device has a 3x60 mW output power and the other one has 0 mW output power (sham).~These are labelled with yellow or blue tape by a secretary who is otherwise not participating in the study.~Since the laser device has an invisible beam (904 nm wavelength) and is of such low power that heat is not detected, both the participant and the clinician will be blinded."||t|t|t|t
34170348|NCT00980187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170349|NCT03414775|RANDOMIZED|PARALLEL||OTHER||NONE||Critically-ill children who are medically stable and ready for enteral tube feeds will be randomized to receive either Pediasure or Nourish. Nutritional needs will be calculated per previously established standards at our institution and performed in conjunction with trained dieticians and nutritionists.||||
34170350|NCT06181526|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||In this study, a dose-escalation clinical trial is conducted to explore the maximum tolerated dose, and three dose groups are set: 0.5 μg/kg, 1 μg/kg, and 2 μg/kg, with 3 cases in the initial dose group and placebo group, and 6 cases in the follow-up dose group, with a total of 24 subjects.|t|f|t|f
33749201|NCT01578993|||COHORT||PROSPECTIVE|||||||
33749202|NCT03747926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749203|NCT05794269|||COHORT||PROSPECTIVE|||||||
33749204|NCT01260844|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33749205|NCT05751473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749206|NCT01733056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749207|NCT02234531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind randomized controlled trial (RCT)|f|f|f|t
33749208|NCT03637946|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, non-blinded, clinical trial 6 months in duration.||||
33749209|NCT01390467|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33858177|NCT04911816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858178|NCT02753140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858179|NCT00679588|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858180|NCT02145689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858181|NCT00261313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858182|NCT01638117|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33858183|NCT00597467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858184|NCT04351022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858185|NCT00246077|||||OTHER|||||||
33858186|NCT00532402|||COHORT||PROSPECTIVE|||||||
33858187|NCT01673568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33858188|NCT02714725|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33858189|NCT02803047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858190|NCT01538953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858191|NCT05964803|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858192|NCT04146415|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858193|NCT04231227|||OTHER||PROSPECTIVE|||||||
33858194|NCT01236248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858195|NCT04588623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33858196|NCT04694846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858197|NCT00701870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858198|NCT01549054|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858199|NCT04663100|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33858200|NCT01989767|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063707|NCT02503644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063708|NCT00636636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063709|NCT05234034|||COHORT||CROSS_SECTIONAL|||||||
34063710|NCT05681637|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Interventional prospective study||||
34063711|NCT00153010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063712|NCT06020209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063713|NCT01025375|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34063714|NCT05016297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063715|NCT03011541|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm- Arm 1. Comparator is natural history of the disease.||||
34063716|NCT04933032|||OTHER||PROSPECTIVE|||||||
34063717|NCT02839876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063718|NCT03453281|NA|SINGLE_GROUP||TREATMENT||NONE||Every subject was given the same treatment (intravitreal Aflibercept injection).||||
34063719|NCT06528171|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063720|NCT03362580|||COHORT||PROSPECTIVE|||||||
34063721|NCT03943927|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34063722|NCT00483704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858201|NCT02519309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. open label, non-randomized, before-and-after study of patients with type 2 diabetes who self-select the intervention (with education delivered via onsite group classes or web-based, self-selected by participant) or usual care~2. single arm, before-and-after study of patients with prediabetes who self-select to receive the intervention (no comparison group)"||||
33858202|NCT03355170|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33858203|NCT01645969|||COHORT||PROSPECTIVE|||||||
33858204|NCT02689596||||BASIC_SCIENCE||||||||
33858205|NCT02934022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858206|NCT05048537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858207|NCT02316366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858208|NCT02858869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858209|NCT04050137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858210|NCT02869776|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858211|NCT00485160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858212|NCT03909217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858213|NCT03635307|||CASE_ONLY||PROSPECTIVE|||||||
33858214|NCT05699226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This investigation will use allocation concealment and masking for subject assignment.|Randomized clinical trial with two arms: experimental (variable amplitude) and control (fixed amplitude). Participant and outcomes assessor will be masked to assignment.|t|f|f|t
33858215|NCT05422287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858216|NCT00171574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33858217|NCT04038853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858218|NCT02628301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33858219|NCT01376349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33858220|NCT05332379|||COHORT||PROSPECTIVE|||||||
33858221|NCT03998254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858222|NCT00371046|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063723|NCT00161694|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34063724|NCT00212316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063725|NCT01276119|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34063726|NCT02719834|||COHORT||PROSPECTIVE|||||||
34063727|NCT00675376|||COHORT||PROSPECTIVE|||||||
34063728|NCT00195494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858223|NCT00947713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858224|NCT00417534|||DEFINED_POPULATION||PROSPECTIVE|||||||
33858225|NCT00755651|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858226|NCT04068259|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33858227|NCT05561829|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33858228|NCT05016908|||COHORT||PROSPECTIVE|||||||
33858229|NCT02077595|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33858230|NCT05617911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858231|NCT04179331|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double blinded. Neither the investigators performing the experiments or the participants know the nature of the intervention on the two study days.|Acute physiological experiments conducted in healthy individuals in a University Hospital setting.|t|f|t|t
33858232|NCT00180362|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33893626|NCT00156663|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33893627|NCT02233842|||COHORT||CROSS_SECTIONAL|||||||
34063729|NCT01207115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063730|NCT01535586|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063731|NCT00098540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063732|NCT02440217|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063733|NCT04982978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be allocated to one of two experimental groups using a blocked randomization method; participants will be randomized within blocks such that an equal number are assigned to each treatment. Once participants are allocated to one block, each participant will then be assigned an ID number that will represent their block as well as their individual participant ID number (i.e., Participant '100-123' would be in the same group as participant '100-124'). At Day 7 (T1), participants in each group will be emailed their respective intervention video links. Participants will not be given any information regarding group allocation or additional intervention information until the Letter of Study End notification is sent out to private email accounts of participants.|Participants will be randomly divided into one of two blocks (A or B), each containing a maximum of 75 participants (PMT present intervention group or the control group). The PMT present group will include an 8-minute informational video that explains the current research and health risks associated with vaping, within the context of a threat appraisal focus (Perceived Vulnerability and Perceived Severity). The PMT absent group (control group) will feature an 8-minute nutrition and lifestyle information video as an attention control strategy in this study. During this video intervention, the general risks and benefits of nutrition and lifestyle choices will be presented.|t|f|f|f
34063734|NCT03174678|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator|Retrospective study|f|f|t|f
33959835|NCT03412994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858233|NCT04271007|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"To allow the study to be blinded, each participant will receive the product from the non-blind professional, delegated by the Principal Investigator, according to the allocation generated through the randomization list. Uncharacterized products will be dispensed with, making it impossible to identify them. The cream that each participant will receive will be non-transferable and confidential to the other research participants and to the employees of the research center, except for the non-blind professional; therefore, the research center should guide this conduct when dispensing.~The Sponsor will delegate a non-blind monitor other than the monitors responsible for the study's monitoring. The non-blind monitor will be responsible only for checking the randomization, accounting and adherence of the returned medication. This conference should be held in a room isolated from the other monitors in the study and other professionals in the research center."|"Participants will be randomized into two groups, as follows:~Group I: Use the drug Topison on one side of the upper limb and Mometasone Furoate 1mg /g Sanofi,Medley on the opposite side.~Group II: Use the drug Topison on one side of the upper limb and Mometasone Furoate 1mg / g Ache on the opposite side.~The side of the upper limb for the use of Topison or momofasone furoate Sanofi,Medley or Aché will be defined randomly."|t|f|t|f
33959836|NCT03155061|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959837|NCT02398500|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33959838|NCT00812227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858234|NCT01836653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858235|NCT02896179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858236|NCT04998734|||OTHER||PROSPECTIVE|||||||
33858237|NCT00182351|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858238|NCT02901366|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858239|NCT01382420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858240|NCT06206369|||COHORT||RETROSPECTIVE|||||||
33959839|NCT05775536|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33959840|NCT05407675|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33959841|NCT06068634|||CASE_ONLY||CROSS_SECTIONAL|||||||
33959842|NCT01093040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959843|NCT01068795|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959844|NCT06167135|||COHORT||CROSS_SECTIONAL|||||||
33959845|NCT05933499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Eligible participants will be randomized in a 2:2:1 ratio to one of the following 3 groups: (1) bimagrumab 30 mg/kg IV; (2) identical placebo IV infusions plus semaglutide 2.4mg SQ qweek; or (3) identical placebo IV infusions alone.||t|t|t|t
33959846|NCT05869019|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959847|NCT06696469|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33959848|NCT01925378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959849|NCT05756985|||CASE_ONLY||PROSPECTIVE|||||||
34063735|NCT05649917|||CASE_ONLY||PROSPECTIVE|||||||
33959850|NCT04639739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959851|NCT06702202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind||t|f|f|f
33959852|NCT06703866|||CASE_ONLY||PROSPECTIVE|||||||
33959853|NCT03869684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959854|NCT01141049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959855|NCT01379365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959856|NCT02305329|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959857|NCT00871104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959858|NCT03699319|NA|SINGLE_GROUP||TREATMENT||NONE||Single-armed study of patients with locally advanced pancreatic cancer, evaluating combination CPI-613 with modified FOLFIRINOX||||
33959859|NCT05268588|RANDOMIZED|PARALLEL||PREVENTION||NONE||The mHealth education and social support intervention includes tailored weekly educational content via interactive voice recognition and an android application, a phone-based provider-moderated group discussion, a provider-moderated group text chat, and referral to care as needed. Individuals are enrolled into groups of 20, have two intervention sessions prenatally and then have weekly meetings through six months postpartum for a total of 26 sessions. This model will be tested against the standard of care (3 postnatal visits in the first 7 days postpartum).||||
33959860|NCT05462756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063736|NCT00072059|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34063737|NCT02552498|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34063738|NCT00829088|NA|SINGLE_GROUP||||NONE||||||
34063739|NCT05865847|||COHORT||PROSPECTIVE|||||||
34063740|NCT01580345|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33959861|NCT03373045|||COHORT||PROSPECTIVE|||||||
34063741|NCT02068859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063742|NCT05659641|RANDOMIZED|PARALLEL||TREATMENT||NONE||Learning Curve+Parallel+Single Group||||
34063743|NCT02237560|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063744|NCT02847026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063745|NCT01011504|||CASE_ONLY||PROSPECTIVE|||||||
34063746|NCT02620085|||COHORT||PROSPECTIVE|||||||
34063747|NCT00769756|||FAMILY_BASED||PROSPECTIVE|||||||
34063748|NCT05940077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170351|NCT03527849|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The study will be structured as a parallel-group controlled trial. The Principal Investigator will assign participants into the three groups. This will allow for equalization of distribution of participants across the three groups. It will not be possible to blind the participants to which arm of the trial they are participating in, as the content or lack thereof of their activities will be obvious to them. For results analysis, collaborators at the UCD West Coast Metabolomics Center will be blinded to the treatment of the respective samples, thus eliminating potential bias during analysis.||f|f|f|t
34170352|NCT00672555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170353|NCT00562367|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170354|NCT00491465|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34063749|NCT00308750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063750|NCT00941824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063751|NCT00964015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063752|NCT01481272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170355|NCT02306746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170356|NCT01431612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34170357|NCT02718521|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34170358|NCT02271464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170359|NCT05261555|NA|SINGLE_GROUP||OTHER||NONE||||||
33858241|NCT04980885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858242|NCT04430465|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The intervention and data collection will be conducted unmasked. The data set will be masked before data analysis by staff not involved in the study.||f|f|f|t
33858243|NCT00985166|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858244|NCT02414581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858245|NCT01308957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858246|NCT03248674|||COHORT||PROSPECTIVE|||||||
33858247|NCT04054609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||FAZA PET/MRI scan pre and post standard of care endovascular treatment for critical limb ischemia patients||||
33858248|NCT02837835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858249|NCT03995901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858250|NCT05686382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858251|NCT02566265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33858252|NCT06412328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre-test - post-test, parallel, randomized controlled||||
33858253|NCT03457220|||OTHER||PROSPECTIVE|||||||
33858254|NCT04395118|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33858255|NCT01228708|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33858256|NCT02548260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858257|NCT00451100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858258|NCT06403189|NA|SINGLE_GROUP||OTHER||NONE||"* consultation with a neurologist~* Biologic samples (blood and lombar punction)~* MRI"||||
33858259|NCT01845220|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33858260|NCT02972463|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858261|NCT02443350|||COHORT||PROSPECTIVE|||||||
33959862|NCT03487614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We Are for Children, LLC (WAFC), is a collaboration of non-profit pediatric practices in West Michigan formed to help members respond to healthcare needs. Four primary care pediatric offices from WAFC were selected to participate in the current study based on site interest and capacity. Participating pediatric offices were then matched into pairs based on similarities in office size (i.e. physician FTEs and patient load) and patient demographics characteristics, after which one of each matched pair was assigned as a treatment or control site.||||
34170360|NCT03752138|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34170361|NCT01339689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170362|NCT05534074|||COHORT||OTHER|||||||
34170363|NCT04260685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|the outcome assessor the surgeon|"Group L (lidocaine group) (n=35): the Patient will receive IV bolus of 1.5mg/kg lidocaine 1% over ten minutes followed by continuous infusion of 1.5mg/kg/h and will be terminated 10 minutes before the end of surgery.~Group E(esmolol group) (n=35): the Patient will receive IV bolus of esmolol 0.5 mg/kg over ten minutes followed by continuous infusion of 100-300 ug/kg/min and will be terminated 10 minutes before the end of surgery."|f|t|f|t
34170364|NCT03539406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a phase I safety and feasibility study in a series of 12 patients who are suffering from recurrent ovarian, fallopian tube or primary peritoneal cancer. The first cohort of three patients will receive an intraperitoneal infusion of allogeneic UCB-NK cells generated ex vivo from CD34+ hematopoietic progenitor cells obtained from an allogeneic UCB unit without a preparative regimen. In the second group of three patients the same UCB-NK cell dosage will be given with a preparative regimen of four days non-myeloablative immunosuppressive conditioning regimen with cyclophosphamide and fludarabine (CyFlu). If no severe toxicity is seen in these 6 patients, an extension cohort of 6 patients will be included to answer the secondary objective.||||
34170365|NCT06410430|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170366|NCT02211794|||COHORT||PROSPECTIVE|||||||
34170367|NCT04265014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34170368|NCT04743830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170369|NCT05398367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind randomized controlled trial|Participants will be randomized into one of four treatment groups: Oat Mama Lactation Supplement (O), moringa supplement (M), shatavari supplement (S), or control (C).|t|t|t|f
34170370|NCT06012682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170371|NCT00938184|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33858262|NCT00329485|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33858263|NCT02272049|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858264|NCT05144009|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33858265|NCT03354806|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comparative, monocentric study including 2 parallel groups. Patient's allocation is based on recommended criteria for catheters for continuous peripheral nerve blocks uses such as anlagesic treatment (ropivacain) tolerance and acceptance or analgesic treatment refusal||||
33858266|NCT05335954|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient under anesthesia will not be aware of randomisation arm. the team collecting primary endpoint (hypotension under 55 mg during the 20 minutes after the start of anesthesia) will not be aware of patient assignation.||t|f|f|t
33858267|NCT06249568|||COHORT||CROSS_SECTIONAL|||||||
33858268|NCT00863109|||COHORT||PROSPECTIVE|||||||
33858269|NCT00572520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858270|NCT03975452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858271|NCT02345122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858272|NCT03406260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33893628|NCT02248779|||COHORT||CROSS_SECTIONAL|||||||
33893629|NCT02420886|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33893630|NCT01152853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959863|NCT05720793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959864|NCT03746080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959865|NCT06568926|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34170372|NCT04653116|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34170373|NCT01467141|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170374|NCT01945021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170375|NCT00628121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170376|NCT05020977|||COHORT||CROSS_SECTIONAL|||||||
34170377|NCT05990387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34170378|NCT02916966|||CASE_CONTROL||PROSPECTIVE|||||||
34170379|NCT00629863|RANDOMIZED|||DIAGNOSTIC||||||||
34170380|NCT03326596|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective Cohort||||
34170381|NCT02919644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170382|NCT00555412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170383|NCT05790889|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34170384|NCT06133335|NA|SINGLE_GROUP||OTHER||NONE||||||
34170385|NCT01480661|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34170386|NCT00959608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170387|NCT04277728|||COHORT||RETROSPECTIVE|||||||
34170388|NCT01590979|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34170389|NCT03091465|||COHORT||RETROSPECTIVE|||||||
34170390|NCT05106127|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34170391|NCT02520817|||CASE_ONLY||PROSPECTIVE|||||||
34170392|NCT04894721|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-Blind|Randomized controlled. Experimental and Control Group in relationship of 2:1|t|t|t|f
33858273|NCT03281837|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This is a single-blind study. There will be a blinded evaluator who will not be informed about the intervention (Hymovis + PEP or PEP alone) to which study subjects will be randomized|"This post-market, single blind, multicenter, randomized, controlled clinical study is designed to enroll a relatively young, active population of subjects with patellofemoral osteoarthritis (PFOA) and/or tibiofemoral osteoarthritis (TFOA), and to compare responses to treatment with HYMOVIS injections combined with a physical exercise program (PEP) to PEP alone. The study provides for subjects randomized to the PEP alone study group to cross over to HYMOVIS+PEP if improvement has not been achieved by the 3 month follow up visit.~Subjects will be recruited over a 18 month period. The duration of the trial per center will be approximately 27 months. This includes the enrollment period of 6 months, the follow-up period at 3 and 6 months and the additional follow-up period for patients who crossed-over; they will be followed for an additional 6 months following the initial 3month follow-up. The trial will end when the last subject makes the last visit."|f|f|t|t
34170393|NCT00702702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170394|NCT02732600|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170395|NCT04173806|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Participants will be randomly assigned to one of two groups|t|f|t|t
34170396|NCT02533414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170397|NCT01119053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170398|NCT00531284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170399|NCT01244685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170400|NCT04510714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170401|NCT04894032|||COHORT||PROSPECTIVE|||||||
34170402|NCT01160276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170403|NCT00923923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33858274|NCT04074785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858275|NCT06362213|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858276|NCT04159337|||COHORT||PROSPECTIVE|||||||
33893631|NCT04706572|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34170404|NCT05837338|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, 2-way crossover|t|f|t|f
34170405|NCT00881517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170406|NCT04610359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170407|NCT02316028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170408|NCT00113841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170409|NCT02542865|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170410|NCT02922530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170411|NCT06288555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34170412|NCT04843202|||COHORT||RETROSPECTIVE|||||||
34170413|NCT02693808|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170414|NCT04936607|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170415|NCT01815723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893632|NCT00590161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893633|NCT04030195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1: Participants with r/r CD20+ B-cell NHL or r/r CLL/SLL will be enrolled to 3 escalating dose groups and treated sequentially, with the possibility of a single de-escalation. Within each dose group, at least 3 and at most 6 study participants will be treated with a single dose of PBCAR20A using a standard 3 + 3 design. The starting dose of PBCAR20A will be 1 × 10\^6 chimeric antigen receptor (CAR) T cells/kg body weight. Subsequent dose groups will be treated with escalating doses to a maximum dose of 480 × 10\^6 CAR T cells (flat dose). In the absence of dose-limiting toxicities (DLTs) (as described in Section 3.8 of the protocol), the dose will be increased using a fixed-dose scheme.~Phase 2: Study PBCAR20A-01 did not proceed into Phase 2."||||
33893634|NCT06366373|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The interventional study model for this clinical trial is a quasi-randomized controlled trial design. The intervention is the exhibition, organized by Qixi Charity, will publicly display offline artworks reflecting the diverse dimensions of mental health and ill-health. In contrast, the control group in this study will receive either printed or online educational materials, serving as a more traditional educational intervention. The study will include a baseline survey before the interventions (T0), a follow-up survey in the first month after the interventions (T1), and a follow-up survey in the sixth month after the interventions (T2) in both the experimental group (those who attend the offline exhibition) and the control group (those who are unable to attend the exhibition but will be provided with printed/online education materials)."||||
33893635|NCT03038022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893636|NCT06041750|||COHORT||PROSPECTIVE|||||||
33959866|NCT04188405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959867|NCT04896918|||COHORT||RETROSPECTIVE|||||||
33959868|NCT00951717|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959869|NCT04245397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In this sequential model initially participant groups will enroll to receive SX-682 for six 28 day cycles in a dose escalation phase. A 3 + 3 participant design will be used to determine the safe dose. After 6 cycles at the specified dose of SX-682, SX-682 treatment can be continued. Once the safe dose level of SX-682 is determined, then participants will be enrolled at the this safe dose level of SX-682 in an expansion phase.||||
33959870|NCT01622816|||||PROSPECTIVE|||||||
33959871|NCT04709029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double (participant and outcome assessor)|Parallel assignment|t|f|f|t
33959872|NCT02356250|||CASE_ONLY||PROSPECTIVE|||||||
33959873|NCT00486577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33959874|NCT05848687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959875|NCT00391040|RANDOMIZED|FACTORIAL||ECT||NONE||||||
33893637|NCT02716376|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33893638|NCT04322708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893639|NCT02149992|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33893640|NCT02812004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893641|NCT04491279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to treatment allocation. They will evaluate participant's prior to neuropilates treatment commencing and after neuropilates 6 week treatment has been completed.|Pilot Randomised Controlled Trial|f|f|f|t
33893642|NCT04199923|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33893643|NCT02101008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893644|NCT06417515|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893645|NCT04122196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893646|NCT05324072|||COHORT||CROSS_SECTIONAL|||||||
33893647|NCT03947541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858277|NCT04452396|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Phase 1 - (diagnostic) The CGM device will be blinded to the patient and physician until investigations into hypoglycaemia are complete phase 2 - (treatment optimisation) The CGM device will be blinded to the patient and physician for the first 10 days of treatment, medication will be optimised and the patient will continue with CGM in an unblinded way for up to 20 further days to aid further treatment optimisation|"2 phases to study. Patients can enter at start of either phase and start phase 2 at the end of phase 1.~Phase 1 - CGM monitoring of people with suspected spontaneous/reactive hypoglycaemia phase 2 - CGM monitoring of patients with medically managed spontaneous/reactive hypoglycaemia"||||
33858278|NCT04476056|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Study||||
33858279|NCT00998426|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33858280|NCT00079742||||TREATMENT||||||||
33959876|NCT06453005|NA|SINGLE_GROUP||TREATMENT||NONE|"Participants are masked to treatment allocation, while care providers and investigators are not. Outcomes assessors remain masked to minimize bias. The biostatistician is blinded to treatment modality to avoid bias in data analysis, with data labeled as treatment modality 1 and treatment modality 2 in the Excel sheet."|Our study involves comparing two different dental treatment modalities (SMART Hall technique and standard SSC restoration) in a split-mouth design, where each participant serves as their control, the Single group model aligns with the structure of your study. This model indicates that all participants receive the intervention(s) being studied, which is consistent with our split-mouth study design.||||
33959877|NCT00572156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858281|NCT03977662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858282|NCT05768256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858283|NCT02019589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858284|NCT00273767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858285|NCT01529463|||COHORT||PROSPECTIVE|||||||
33858286|NCT04923854|||COHORT||PROSPECTIVE|||||||
33858287|NCT02624323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858288|NCT01415154|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858289|NCT00908232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858290|NCT00328900|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33858291|NCT06354686|NA|SINGLE_GROUP||OTHER||NONE||||||
33858292|NCT00975507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858293|NCT02528565|||COHORT||PROSPECTIVE|||||||
33858294|NCT03458286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analysis of data will be blinded and carried out by a statistician. Patient data will be coded and not identifiable directly. The key to the code book information will be secured separately from the dataset in an encrypted file, which will only be accessible by the researcher and the supervisors of the study. Therefore the each arm will be coded and none identifiable to the outcome assessor.|"Participants will be randomly allocated into an experimental arm and a control arm of the study. The experimental group will receive the adjunctive CUSECS treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.~The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment."|f|f|f|t
33858295|NCT05694520|RANDOMIZED|PARALLEL||TREATMENT||NONE||All subjects will be randomly assigned to intervention group (IG) or stand care control group (CG)), in an allocation ratio of (1:1) in blocks.||||
33858296|NCT03572322|||OTHER||OTHER|||||||
33858297|NCT00141323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858298|NCT04788498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858299|NCT02378831|||CASE_ONLY||PROSPECTIVE|||||||
33858300|NCT03343847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858301|NCT06221150|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33858302|NCT01862640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858303|NCT03736161|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized trial||||
33858304|NCT02441712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858305|NCT01906346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33858306|NCT02357381|||COHORT||PROSPECTIVE|||||||
33858307|NCT04484831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858308|NCT04465786|||CASE_CROSSOVER||PROSPECTIVE|||||||
33858309|NCT00107120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959878|NCT04946071|RANDOMIZED|CROSSOVER||OTHER||NONE||The study will employ a stepped-wedge, cluster randomized design involving crossover of clusters from the control to the intervention arm.||||
33959879|NCT05035407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063753|NCT06730282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this double-blind clinical trial, all participants, care providers, investigators, and outcomes assessors are masked to the group assignments. The study medications (Danggui Shaoyao San, Cuscuta Chinensis, combination therapy, and placebo) are prepared in identical medication containers with no distinguishable labeling. Randomization is conducted using a block randomization scheme, and the allocation sequence is securely managed by the study pharmacy. Neither the study team nor the participants have access to the randomization code until the trial concludes. This ensures unbiased treatment administration and assessment.|This study employs a randomized, double-blind, placebo-controlled, parallel assignment model. Participants are randomly allocated to one of four groups: Danggui Shaoyao San (DSS), Cuscuta Chinensis (Tu Si Zi), a combination of DSS and Tu Si Zi, or a placebo group. Each group receives its designated intervention throughout two consecutive menstrual cycles. The parallel design ensures that outcomes can be directly compared between groups without crossover, maintaining the integrity of the treatment effects. The double-blind approach minimizes bias by blinding both participants and investigators to group assignments.|t|t|t|t
34063754|NCT01018160|||CASE_ONLY||PROSPECTIVE|||||||
34063755|NCT02445859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34063756|NCT06112678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34063757|NCT03250585|||CASE_ONLY||PROSPECTIVE|||||||
34063758|NCT02237040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063759|NCT02331849|NA|SINGLE_GROUP||||NONE||||||
33858310|NCT00724295|||||PROSPECTIVE|||||||
33858311|NCT00394953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749210|NCT05812001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be kept unaware of the study's randomization into the designated groups, conducted by a research assistant who is not otherwise involved in the study and concealed in an opaque, sequentially numbered envelope. Therefore, participants will not know which group they are allocated to. In addition, the intervention groups (e-ACT or ACT) and the treatment-as-usual control group will receive equal amount of attention and time from the professional figure who administer the program. The researchers will also be blinded for the study since the participants' randomized assignment into the designated groups will be conducted by a research assistant who is not otherwise involved in the study. This project's data collection and analysis will also be conducted by that research assistant who is not otherwise involved in the study or data analysis and who is unaware of the study's hypotheses."|This randomized controlled trial (RCT) is multicentre, three-armed, parallel-group, double-blind RCT.|t|t|t|t
33749211|NCT05667246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33749212|NCT02716974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749213|NCT02385344|||OTHER||PROSPECTIVE|||||||
33749214|NCT05224570|||COHORT||RETROSPECTIVE|||||||
33749215|NCT06305351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33749216|NCT00987974|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749217|NCT04901858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749218|NCT02218567|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749219|NCT01856127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749220|NCT06448091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749221|NCT03386903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858312|NCT04173650|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a prospective, open label, randomized, multi-center study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks.||||
33858313|NCT00567216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33858314|NCT06528639|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33858315|NCT06051916|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Group A receives a strict voiding trial and group B receives a minimalistic voiding trial. In both groups the patient's catheter is removed at the operation room before returning to the gynecological ward.||||
33858316|NCT00658944|||||PROSPECTIVE|||||||
33858317|NCT05572268|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33858318|NCT05335720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749222|NCT05853848|RANDOMIZED|PARALLEL||SCREENING||NONE||Each intervention will be rolled out to only a subset of the total population each month, such that all patients will receive one of the interventions over the course of 7 months. Active arms will be compared contemporaneously against a passive control group consisting of active arm participants for whom the intervention has not yet begun, as well as a random subset of participants who are excluded before the future intervention begins.||||
33749223|NCT04541238|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749224|NCT05888597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Multi-center, randomized (ratio 1:1), double-blinded, placebo-controlled, crossover trial (RCT) design|t|t|f|f
33749225|NCT01740674|RANDOMIZED|PARALLEL||||NONE||||||
33749226|NCT04933747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749227|NCT04767386|||CASE_ONLY||CROSS_SECTIONAL|||||||
33749228|NCT02906150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749229|NCT04405596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749230|NCT01187758|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749231|NCT06580886|||COHORT||CROSS_SECTIONAL|||||||
33749232|NCT02376218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749233|NCT05211765|||CASE_ONLY||CROSS_SECTIONAL|||||||
33749234|NCT05634538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749235|NCT00702000|||CASE_ONLY||PROSPECTIVE|||||||
33749236|NCT05916768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749237|NCT02625103|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33749238|NCT01392560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749239|NCT03257826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749240|NCT06345027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749241|NCT02912403|||CASE_ONLY||PROSPECTIVE|||||||
33749242|NCT03756181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Pilot randomized controlled trial.|t|f|f|t
33749243|NCT06668896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749244|NCT04272268|||COHORT||PROSPECTIVE|||||||
33749245|NCT05027165|||COHORT||PROSPECTIVE|||||||
33749246|NCT03435874|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Double-blind.|A Phase Ib age de-escalation dose-escalation randomised, double-blind, controlled study of the safety and immunogenicity of heterologous prime-boost with the candidate malaria vaccines ChAd63 RH5 and MVA RH5|t|t|t|t
33858319|NCT01569165|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33858320|NCT04318951|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33858321|NCT04483076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858322|NCT01390181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858323|NCT01557283|||COHORT||PROSPECTIVE|||||||
33858324|NCT00091117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858325|NCT01121120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33858326|NCT04808622|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33858327|NCT00876694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858328|NCT04750174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A short practical training was performed before the study. The study was performed by a group of independent specialists blinded to treatment allocation.|Patients who met the study criteria were assigned to either the intervention group or the sham group after being questioned to provide their caregivers understanding of all study procedures and requirements for participation.|t|f|t|f
33858329|NCT04727879|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33858330|NCT06375889|||CASE_CONTROL||PROSPECTIVE|||||||
34063760|NCT02811575|||CASE_CONTROL||PROSPECTIVE|||||||
33749247|NCT05686057|||CASE_CONTROL||PROSPECTIVE|||||||
33749248|NCT05119920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858331|NCT00594126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858332|NCT03967639|||CASE_CONTROL||RETROSPECTIVE|||||||
33858333|NCT04744051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Upon receipt of the harvested tissue sample at the processing facility, eligible participants will be randomized in a one in four ratio to either the 50 million, 150 million or 300 million Adipose derives mesenchymal stem cell (ADMSC) dosage or Placebo.|The proposed study is a single-site, double-blinded, placebo-controlled study involving a single administration of either individual, autologous ATCell™ lines suspended in 5% dextrose lactated Ringer's solution or a vehicle (5% dextrose lactated Ringer's solution) not containing cells. Each ATCell™ cell line will be created from cells grown from the stromal vascular fraction (SVF) of a participant's own adipose tissue collected by liposuction, and each treated participant will only receive their own cells.|t|t|t|t
33858334|NCT04750096|||COHORT||PROSPECTIVE|||||||
33858335|NCT01833715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33858336|NCT00489892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33858337|NCT01104753|||||PROSPECTIVE|||||||
33858338|NCT03228381|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33858339|NCT04780308|||CASE_CONTROL||OTHER|||||||
33858340|NCT03311334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858341|NCT04972409|||OTHER||CROSS_SECTIONAL|||||||
33858342|NCT01482663|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858343|NCT05274984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, endoscopist, anesthetist, and data collection observers were all blinded to the group allocation.|Participants are randomly assigned to controll group or lidocaine group. Participants of control group are given placebo while participants of lidocaine group are given lidocaine.|t|t|f|t
33858344|NCT05185544|||COHORT||PROSPECTIVE|||||||
33858345|NCT06000020|||COHORT||RETROSPECTIVE|||||||
33858346|NCT04581096|||COHORT||PROSPECTIVE|||||||
33858347|NCT04841551|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, single arm open label treatment group||||
33858348|NCT00128076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858349|NCT05212454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858350|NCT04217122|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33858351|NCT01658098|||||PROSPECTIVE|||||||
33858352|NCT06119269|||COHORT||RETROSPECTIVE|||||||
33858353|NCT02895438|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33858354|NCT04101708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858355|NCT00521547|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33858356|NCT00606970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33858357|NCT00603200|||CASE_ONLY||PROSPECTIVE|||||||
33858358|NCT05172141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking participant and Investigator||t|f|t|f
33858359|NCT05898893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858360|NCT05601609|||COHORT||RETROSPECTIVE|||||||
33858361|NCT06317896|||COHORT||PROSPECTIVE|||||||
33858362|NCT01884753|||COHORT||PROSPECTIVE|||||||
33858363|NCT05495659|||COHORT||PROSPECTIVE|||||||
33858364|NCT02670941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858365|NCT00124852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858366|NCT04039256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858367|NCT02561533|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858368|NCT05631977|||COHORT||PROSPECTIVE|||||||
33858369|NCT04549337|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants are randomly allocated following successful completion of the baseline measurements. A researcher, that is not involved in testing or training procedures, generates a computer-generated block randomization schedule with balanced permutations. To ascertain allocation concealment, the block sizes will not be disclosed. The schedule is forwarded to a research assistant, who is not involved in any study procedures and stored on a password protected computer. Following the baseline measurements, the participants are given consecutive numbers. These are forwarded to the research assistant, who returns the corresponding allocation sequence to the study coordinator. The participants are blinded for treatment allocation until treatment assignment. However, following the initial two treatments blinding of the participants is no longer possible. All study personal involved with data collection will be blinded during baseline testing.|This study uses a randomized crossover trial testing the feasibility of 3 different training protocols.|t|f|f|t
33858370|NCT02749630|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33858371|NCT00001407||||TREATMENT||||||||
33858372|NCT06061016|||CASE_ONLY||CROSS_SECTIONAL|||||||
33858373|NCT00338364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858374|NCT00985322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858375|NCT04370457|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858376|NCT00803270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858377|NCT02913534|||CASE_ONLY||RETROSPECTIVE|||||||
33858378|NCT03200340|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Subjects and investigators will be blinded to treatment assignments|"2 stages: Stage 1 is a blinded parallel group safety study of 4 cohorts of 24 subjects randomized (1:1:1:1) to receive either EC-18 500 mg, 1000 mg, 2000 mg, or placebo.~Dosing will commence on the first day of radiation and continue until the last day of radiation. After of 4 weeks, an independent Data Safety Monitoring Board (DSMB) will evaluate safety endpoints in blinded fashion. DSMB assessment will be repeated after completion of dosing. Stage 2 of the study will evaluate both safety and efficacy.~Eighty (80) subjects will be randomized in a 1:1 scheme to receive placebo or EC-18 at the dose determined in Stage 1. The design of stage 2 is the same as stage 1."|t|f|t|f
33858379|NCT02672709|NA|SINGLE_GROUP||||NONE||||||
33858380|NCT04576741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063761|NCT02565706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34063762|NCT01612507|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34063763|NCT01273155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858381|NCT06452186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The PT, who evaluates the participants, is blinded for their previous training experience.|Two groups amputees go through the same training procedure with different prostheses. Their functionality will be compared before and the after the training.|f|f|f|t
33858382|NCT03480256||SEQUENTIAL||TREATMENT||NONE||||||
33858383|NCT02053987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858384|NCT03093350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858385|NCT00003941|RANDOMIZED|||TREATMENT||||||||
33858386|NCT00281333|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33858387|NCT02149082|||COHORT||PROSPECTIVE|||||||
33858388|NCT03739437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858389|NCT00329342|NON_RANDOMIZED|PARALLEL||||NONE||||||
33858390|NCT02022319|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858391|NCT00617188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858392|NCT02501174|||CASE_ONLY||OTHER|||||||
33858393|NCT05975385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will be under general anesthesia when treatment provided. They will not know whether or not they received acupuncture treatment. Postoperative assessors will not know which group the patient is in.|Randomized controlled trial. Group 1 - Acupuncture Group 2 - No acupuncture|t|f|f|t
33858394|NCT04557605|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The individual who will statistically analyze the data will be blinded to condition||f|f|f|t
33858395|NCT04962802|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33858396|NCT04047238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33858397|NCT01774110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858398|NCT01767207|||CASE_ONLY||PROSPECTIVE|||||||
33858399|NCT03776019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858400|NCT04473183|||COHORT||PROSPECTIVE|||||||
33858401|NCT05484245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858402|NCT00988195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858403|NCT05472948|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33858404|NCT06073626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Treating clinicians will be blind their patients group assignment. While participants cannot be blinded to group, they will be blinded to the study's specific hypotheses. Statisticians and outcome assessors will be blinded to allocation.|This study will employ a 2-arm parallel group randomized controlled trial to evaluate the efficacy of the relational agent/chatbot (RA) intervention compared to Enhanced Usual Care (EUC) among 428 Black cancer survivors. Randomization is at the patient level and will be balanced in a 1:1 ratio - with 214 participants randomized to each arm. Randomization will be in blocks and stratified by recruitment site (DC, NJ). The investigators also plan to enroll a total of 16 usability testing participants across all sites.|f|t|f|t
33858405|NCT01000636|NA|SINGLE_GROUP||OTHER||NONE||||||
33858406|NCT02723409|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858407|NCT03437174|||COHORT||CROSS_SECTIONAL|||||||
33959880|NCT06567964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomization and Blinding A computer-generated random number sequence was used for randomization. Allocation was concealed via sealed, opaque envelopes, which were opened just before the intervention. Both the patients and the outcome assessors were blinded to the group assignments. The anesthesiologist who administered the block was aware of the group allocation but did not participate in the postoperative assessments.|"Participants~Eligible participants were adults aged 18-70 years who were scheduled for elective lumbar spinal surgery with instrumentation. The inclusion criteria were as follows:~* Elective lumbar spine surgery involving instrumentation~* ASA physical status I-III~* Ability to provide informed consent~The exclusion criteria were as follows:~* Known allergies to local anesthetics~* Coagulopathy or anticoagulant therapy~* Infection at the injection site~* Preexisting neurological disorders affecting sensory perception~* Pregnancy~* Inability to understand the visual analog scale (VAS) for pain assessment The participants were randomly allocated into one of two groups: the ESPB group (Group E) or the WI group (Group W)."|t|f|f|t
33959881|NCT06541171|||COHORT||PROSPECTIVE|||||||
33959882|NCT06702852|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33959883|NCT00174486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33959884|NCT04192786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33959885|NCT00411762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959886|NCT06611475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33959887|NCT00921765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind (one making drug solutions) another administrating the drugs|Parallell Group design should be used when final dose had been found|t|t|t|t
33959888|NCT05892965|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33959889|NCT02233881|||COHORT||PROSPECTIVE|||||||
33959890|NCT01892605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959891|NCT04252326|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33959892|NCT06017011|||CASE_ONLY||PROSPECTIVE|||||||
33959893|NCT03894293|||COHORT||PROSPECTIVE|||||||
33959894|NCT04918810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959895|NCT01635686|RANDOMIZED|||||DOUBLE||||||
33959896|NCT06392321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33959897|NCT01059552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959898|NCT03906786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33959899|NCT06359418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959900|NCT02606370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858408|NCT05280587|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional pilot randomized controlled trial||||
33959901|NCT03555500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33959902|NCT05194280|||OTHER||RETROSPECTIVE|||||||
33959903|NCT06565819|||COHORT||PROSPECTIVE|||||||
33959904|NCT01988493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959905|NCT04900415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All study participants will receive baseline and follow up resting-state functional (rs-fMRI) brain scans during the study period. The radiologists assessing and analysing the rs-fMRI images will be blinded to the treatment regimens received by the study subjects.|"Patients with prolonged COVID-19-related olfactory dysfunction will be assigned to the intervention (group A or B) or control (group C) arms:~Intervention arm A. 14-day course of daily oral vitamin A 7500µg RAE (retinol activity equivalents) in combination with smell training three times per day for 4 weeks; or B. Smell training three times per day for 4 weeks alone; or~Control arm C. Observation"|f|f|t|t
33959906|NCT05880420|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33959907|NCT05377866|||OTHER||PROSPECTIVE|||||||
33959908|NCT00446771|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33959909|NCT00085826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063764|NCT03835065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34063765|NCT03994484|NA|SEQUENTIAL||TREATMENT||NONE||||||
34063766|NCT01069237|||||PROSPECTIVE|||||||
33749249|NCT01750138|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33749250|NCT01775904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33858409|NCT00823056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858410|NCT01387230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858411|NCT03333837|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All study assessments will be conducted by experienced staff certified annually on the proper conduct of study assessments and blinded to group assignment.|Randomized controlled trial. Investigators will use a 2x2 factorial design to test the separate and combined effects of social engagement and dance movement on QoL in 120 community-dwelling older adults adjudicated as having mild cognitive impairment (MCI) or early-stage dementia of the presumed AD or mixed AD/vascular type. Participants will be randomized to one of four 12-week interventions: 1) Dance Group 2) Non-group Dance, 3) Social Group, or 4) No Contact Control.|f|f|f|t
33858412|NCT05604833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Blinding Due to the characteristics of the study, blinding cannot be applied to the participants. In order to eliminate the bias, the data of the study will be collected and recorded by an impartial researcher (assistant researcher) who does not know the groups trained by the researcher. The statistics of the research will be carried out by an independent statistician who does not know the groups. In this way, the prevention of bias will be ensured.~The implementation phase of the research is indicated in Table 1 The Implementation Phases of the Research and the Consort diagram (Figure 1. Consort Scheme)."|A Randomized Controlled Study|f|f|t|t
33858413|NCT04855266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858414|NCT02864420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858415|NCT03189043|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33858416|NCT06172881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858417|NCT06027190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In patients with achalasia diagnosed by clinical symptoms, HREM and barium meal examination, functional connectivity analysis of DMV with three brain regions (precentral gyrus, postcentral gyrus and insula) was performed by scanning T1 structural magnetic resonance imaging, and brain regions with the strongest positive functional connectivity with DMV were selected as individualized rTMS targets by optical 3D navigation. All patients were randomly divided into four groups: sham-rTMS group, 5Hz-rTMS group, 10Hz-rTMS group, and 30Hz-rTMS group, and each group received acute and chronic stimulation, respectively.|t|f|f|f
33893648|NCT04554576|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective study with a secondary randomization to a remote, nonfrequent provider feedback sustainability intervention. All participants will receive the 6-week self-management intervention and do pre/post evaluations. After the 6-week intervention, half the group will be randomized to a every 6th week for 6 months healthcare provider phone/video visit session and half will be received to no treatment control for 6 months.||||
33893649|NCT04401059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893650|NCT01834495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893651|NCT01668277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33893652|NCT00246259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959910|NCT06479746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959911|NCT04389619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959912|NCT06703931|NA|SINGLE_GROUP||OTHER||NONE|Sponsor|Prospective, comparative, multi-centre interventional clinical investigation||||
33959913|NCT05953883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063767|NCT05390463|||COHORT||PROSPECTIVE|||||||
34063768|NCT05105399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063769|NCT04289090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only. Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.|Group A will begin anesthesia maintenance with sevoflurane-only, then will be switched after 30 minutes to anesthesia with propofol-only. Group B will begin anesthesia with propofol-only then will be switched to sevoflurane-only.|t|f|f|f
34063770|NCT04730115|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34063771|NCT04096898|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
34063772|NCT06365268|||COHORT||RETROSPECTIVE|||||||
34063773|NCT00465543|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34063774|NCT03402347|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Excess skin from corrective surgery will be evaluated ex vivo.||||
34063775|NCT00568334|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34063776|NCT05079321|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34063777|NCT05958108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Hybrid type 1 clinical trial, pragmatic, multicenter, open-label, with a 24-month follow-up. The primary healthcare centers will be randomly assigned to the intervention group (which will receive the SinergiAPS intervention - described below) and the control group (waitlist design: usual clinical practice during the 24-month follow-up, after which they will have access to the SinergiAPS intervention)|f|f|t|t
34063778|NCT06730451|||COHORT||PROSPECTIVE|||||||
34063779|NCT04663841|||CASE_ONLY||OTHER|||||||
34063780|NCT02195596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34063781|NCT02184910|||COHORT||PROSPECTIVE|||||||
34063782|NCT02572856|NA|SINGLE_GROUP||OTHER||NONE||||||
34063783|NCT06442202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063784|NCT00506207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063785|NCT00340106||||TREATMENT||||||||
34063786|NCT02335762|||COHORT||PROSPECTIVE|||||||
34063787|NCT06731569|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are randomly assigned to one of two groups, and each group receives a specific intervention:~Group A: Traditional rotary drill. Group B: AI drill.~Each group is treated independently, and the outcomes are compared at the end of the study."||||
33749251|NCT05238935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the primary investigator and the outcome assessor will assess all of the patients and will be blinded to the groups allocation.|Individuals who meet the inclusion criteria and had their guardian agreed to volunteer will be included in the study by signing the Informed Voluntary Consent Form and will be randomly allocated into either control group or treatment group. Patients in the control group will be given a home program by the orthopedic surgeon (common practice). Patients in the intervention (treatment) group will be treated with conventional physiotherapy 3 times a week for 6 weeks (4 times evaluation and 18 times treatment). all participants will be examined by the responsible examiner in physiotherapy clinic (blinded to the allocated group) at four main points: preoperative, postoperative (after the removal of spica cast), 3 weeks postoperative, 6 weeks postoperative.|f|f|t|t
33893653|NCT06060301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893654|NCT04957888|||COHORT||PROSPECTIVE|||||||
33893655|NCT04049279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893656|NCT03431038|||CASE_ONLY||PROSPECTIVE|||||||
34063788|NCT03092336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34063789|NCT02168452|||CASE_ONLY||PROSPECTIVE|||||||
33893657|NCT02580058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063790|NCT04415021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34063791|NCT02124070|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34063792|NCT01968902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063793|NCT04663347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063794|NCT05998317|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The pharmacists will prepare the study drug, either dexamethasone or saline in 10 mL similar syringes, according to the allocation. The syringe will be labeled with the patient's name and the allocation group, A or B. The study participants, caregivers, data collectors, and data analysts will all be blinded. The pharmacists will not participate in the study.|This is a randomized controlled trial superiority parallel trial. This is a pilot trial and the sample size will be updated after the pilot study completion and the approval of the local Institutional Review Board (IRB).|t|t|t|f
34063795|NCT00970424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063796|NCT02149095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063797|NCT02022475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063798|NCT02003456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063799|NCT05447910|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34063800|NCT04526574|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34063801|NCT02371668|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34063802|NCT03684421|||COHORT||PROSPECTIVE|||||||
34063803|NCT04935801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"* This trial is double-blinded (blinded to investigators and participants)~* Blinding will be maintained for the duration of the study~* All allocations will remain coded to all volunteers and investigators. An independent pharmacy team at CHUV will label the Vaccine and Comparator doses with coded participant numbers but will not have access to the identifier list linking the code to the participant identity. All Vaccine and Comparator doses will be prepared and labelled away form investigators and stored in identical conditions.~* The appearance of the comparators and doses will be identical. The solutions of both are indistinguishable within the dosage group and thus no shielding of the solution colour is needed."||t|t|t|t
34063804|NCT00248144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063805|NCT00106639|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063806|NCT04336852|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Three groups of subjects (young, older, cigarette smokers) complete the same intervention, in an independent-group design.||||
34063807|NCT06731400|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34063808|NCT01946698|||CASE_CONTROL||PROSPECTIVE|||||||
34063809|NCT03717168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063810|NCT06076889|||OTHER||PROSPECTIVE|||||||
34063811|NCT02286375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34063812|NCT06497556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063813|NCT00723463|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893658|NCT06012669|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33893659|NCT04701307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893660|NCT06657378|||COHORT||PROSPECTIVE|||||||
33893661|NCT03451448|||COHORT||PROSPECTIVE|||||||
33893662|NCT06657235|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33893663|NCT06221384|||COHORT||PROSPECTIVE|||||||
33893664|NCT05773456|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33893665|NCT01018407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959914|NCT06684405|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The subjects and their parents/guardians, the clinicians performing the examinations, the staff-members delivering the packages with solutions to the subjects, the trial investigators and the outcome assessors were blind to the allocation and group assignment. The solutions were distributed to the subjects in tubes pre-labelled with code numbers. The tubes had the same design independent of the solution with fluoride or placebo.~After the randomization, lists with code numbers were saved as sealed files in a safety-deposit box. The code was broken when the study was completed, and the assessment of the outcome measures were processed."|Two parallel arms; an intervention group receiving doses of fluoride in water to add to milk and a control group receiving water to add to milk|t|t|t|t
33959915|NCT06539988|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge cluster randomized controlled trial||||
33858418|NCT03706339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used.|patients were allocated to one of three groups after induction of general anesthesia and immediately prior to the operation and just before skin incision. they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min. Throughout the operation irrigation was done by 60 ml of (2g tranexamic acid (10 ml) diluted in 100 ml of sodium chloride 0.9%) or placebo ( 60 ml of sodium chloride 0.9%.).At the end of operation another dose of 60 ml of (1g tranexamic acid (10 ml) diluted in 50 ml of sodium chloride 0.9%) or placebo ( 60 ml of sodium chloride 0.9%.) was left intraabdominal|t|t|t|t
33959916|NCT02256319|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33959917|NCT05445830|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Upon collection, data will be pseudonymized (both group and intervention) to facilitate unbiased analysis.||t|f|t|f
33959918|NCT00731601|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33959919|NCT02703454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33959920|NCT02554344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959921|NCT01781689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34170416|NCT05118191|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Participants will undergo 4 weeks of baseline data collection followed by 4 weeks of data collection while utilizing an assigned sleep augmentation device each night during sleep. Augmentation devices will be assigned with respect to 1) eligibility of inclusion/exclusion criteria of each device and 2) interest in participating with the available devices based upon responses in the qualifying survey on sleep preferences. If participants indicated that they were willing to try both the OOLER \& the Embr Wave, \& were eligible to do so, they will be randomly assigned a device based upon current availability. Women who experience menstrual flow will be scheduled to ensure that flow occurs on weeks 4 \& 8 for consistency.~Participants will complete daily, weekly, \& monthly surveys, as well as weekly \& monthly cognitive assessments. Participants will also have their sleep monitored nightly via the OURA ring \& EEG headband. An additional exit survey will be completed at the end of week 8."||||
34170417|NCT02418871|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33749252|NCT04721054|RANDOMIZED|PARALLEL||OTHER||SINGLE||one group to be studied for effects of epidural anesthesia and other group for effects of general anesthesia|t|f|f|f
33858419|NCT03882905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858420|NCT05252052|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33858421|NCT06352047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Simple randomization method was used in the sample of the study. In previous studies, there were no published data on the effect of supine and prone positioning after extubation on the pulmonary functions of premature infants. Therefore, the sample size was calculated using the G-power 3.1.3 program according to the SpO2 level and standard deviation values of 4 infants who were mechanically ventilated in the neonatal intensive care unit. The study was conducted with a total of 42 premature babies, two groups of 21 premature babies, each of whom had the characteristics of the research groups. Premature infants were divided into two groups, the supine position and the prone group, by randomization using a computer-based random number generator (www.randomizer.org).|f|f|t|t
33858422|NCT04160338|||COHORT||PROSPECTIVE|||||||
33959922|NCT01973270|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33959923|NCT06640023|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE|The investigator is masked during data and safety monitoring only.|2x2||||
33959924|NCT01508325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959925|NCT05309031|NA|SINGLE_GROUP||TREATMENT||NONE||Single group repeated measures||||
33959926|NCT04772469|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study design is a cluster randomized controlled trial where the unit of randomization will be a clusters of men's close social network in study communities.||||
33959927|NCT04363931|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33959928|NCT02397174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959929|NCT04817683|||OTHER||CROSS_SECTIONAL|||||||
33959930|NCT03764592|||COHORT||PROSPECTIVE|||||||
33959931|NCT03199846|||COHORT||RETROSPECTIVE|||||||
34170418|NCT03439501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170419|NCT05239052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170420|NCT06251063|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170421|NCT03596905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170422|NCT02153632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749253|NCT03100617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749254|NCT03342638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749255|NCT00780208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749256|NCT04592068|||COHORT||PROSPECTIVE|||||||
33749257|NCT06669312|||COHORT||PROSPECTIVE|||||||
33749258|NCT02348073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749259|NCT00253591|RANDOMIZED|||TREATMENT||NONE||||||
33749260|NCT01581281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749261|NCT00249535|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749262|NCT02789280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858423|NCT02038439|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|t|f
33858424|NCT01890304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858425|NCT04752878|||OTHER||PROSPECTIVE|||||||
33858426|NCT05089357|||COHORT||PROSPECTIVE|||||||
33749263|NCT04371003|||CASE_CONTROL||PROSPECTIVE|||||||
33749264|NCT00687648|RANDOMIZED|||TREATMENT||NONE||||||
33858427|NCT05015946|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
33858428|NCT02769546|||COHORT||PROSPECTIVE|||||||
33858429|NCT00560053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858430|NCT01702597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858431|NCT03686280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858432|NCT04124081|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858433|NCT00656123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858434|NCT01868113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33858435|NCT00100854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858436|NCT04660630|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33858437|NCT02672215|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33959932|NCT00753909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959933|NCT05789511|||COHORT||PROSPECTIVE|||||||
33959934|NCT03576131|NA|SEQUENTIAL||TREATMENT||NONE||||||
33959935|NCT05697107|||OTHER||PROSPECTIVE|||||||
33959936|NCT01883518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959937|NCT01854515|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33959938|NCT02229487|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33959939|NCT04861831|RANDOMIZED|PARALLEL||PREVENTION||NONE||This delayed intervention trial begins as a parallel group design with the Delayed Intervention (Dl) group serving as a control arm comparison for the Immediate Intervention (II) group. There is no control intervention. The ll and the Dl groups will be assessed pre-intervention. After the 12-week intervention for the II group, resp. the waiting period for the DI group, the lI group will undergo their post-intervention assessment. At that time, the Dl group will undergo their 2nd pre-intervention assessment to document any change in baseline measures that may have occurred. No significant changes are expected, so that at the end of the trial, data from the ll and the Dl groups can be pooled to provide results on the overall changes in outcome measures for all participants post- versus pre-intervention. After the 2nd pre-intervention assessment, the Dl group will have their intervention, post-intervention assessment, follow-up period and final assessment, as with the II group.||||
33959940|NCT05366153|||COHORT||PROSPECTIVE|||||||
33959941|NCT01262404|||COHORT||CROSS_SECTIONAL|||||||
33959942|NCT00212810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33959943|NCT02574260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959944|NCT04179123|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Two phase feasibility trial:~Phase 1: 10 healthy subjects Phase 2: 10 patients already on PAP therapy"||||
33959945|NCT01734213|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33959946|NCT01805258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959947|NCT05270109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959948|NCT00022126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959949|NCT02343497|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33959950|NCT05357742|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33959951|NCT03797274|||COHORT||PROSPECTIVE|||||||
33959952|NCT06543186|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be assigned to one of the intervention groups based on designated locations within their schools: the main hall for the conventional oral health education group, classrooms for the WhatsApp group, and the computer lab for the Meta-OHE group. The interventions will be administered simultaneously to all groups by trained and calibrated researchers to minimize study contamination. This simultaneous approach ensures that each group receives the intervention under comparable conditions, thereby enhancing the reliability and validity of the study outcomes.||t|f|f|f
33959953|NCT02838329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33959954|NCT03541798|RANDOMIZED|PARALLEL||SCREENING||NONE||randomized controlled study||||
33959955|NCT04793165|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33959956|NCT02989610|||CASE_CROSSOVER||PROSPECTIVE|||||||
33959957|NCT01015456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959958|NCT03725722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959959|NCT05473247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959960|NCT06211803|||CASE_ONLY||CROSS_SECTIONAL|||||||
33959961|NCT06529276|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959962|NCT03954405|||COHORT||CROSS_SECTIONAL|||||||
33959963|NCT06536621|||OTHER||CROSS_SECTIONAL|||||||
33959964|NCT05265624|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be masked to their AMD risk until their disclosure. Outcomes assessor and investigator will be masked to treatment assignment until completion of study.||t|f|t|t
33959965|NCT06301737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33959966|NCT04161118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959967|NCT04095819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959968|NCT02792088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749265|NCT02388724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749266|NCT06335433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33749267|NCT03603665|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33858438|NCT03040622|||CASE_ONLY||PROSPECTIVE|||||||
33858439|NCT00205491|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33858440|NCT01118494|||CASE_ONLY||PROSPECTIVE|||||||
33858441|NCT05399121|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant will be randomized into one of two groups.||||
33858442|NCT05149430|||COHORT||PROSPECTIVE|||||||
33858443|NCT04853420|||CASE_ONLY||PROSPECTIVE|||||||
33959969|NCT03567200|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749268|NCT06579378|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|f|f|f|t
33749269|NCT00270218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33858444|NCT05964621|||COHORT||PROSPECTIVE|||||||
33858445|NCT05433350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858446|NCT01405937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959970|NCT03770832|||COHORT||PROSPECTIVE|||||||
33959971|NCT01715259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959972|NCT01992432|||COHORT||PROSPECTIVE|||||||
33959973|NCT05572424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33959974|NCT04201418|||COHORT||PROSPECTIVE|||||||
33959975|NCT04989231|||OTHER||PROSPECTIVE|||||||
33959976|NCT01184378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33959977|NCT04563416|||OTHER||OTHER|||||||
33959978|NCT04580173|||COHORT||PROSPECTIVE|||||||
33959979|NCT06701422|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33959980|NCT02125617|||COHORT||PROSPECTIVE|||||||
33959981|NCT02399059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33959982|NCT03795064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33959983|NCT04171089|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility and acceptability of the Child Safety Planning Intervention among children and their parents.||||
34063814|NCT04153968|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||The study is designed in two phases to allow the research team to firstly determine the absorption and bioconversion kinetics of pure βCX and provide external validation for single-sample prediction methods. The second phase aims to test the bioavailability of both pVACs in maize by comparing a high βCX:βC variety to a low βCX:βC variety in combination with external \[13C\]-labelled pVACs.||||
34063815|NCT04650126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063816|NCT00155857|||CASE_CONTROL||OTHER|||||||
34063817|NCT05383872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170423|NCT00239239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749270|NCT02611466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749271|NCT04385953|||COHORT||PROSPECTIVE|||||||
33749272|NCT02459873|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33749273|NCT06669936|||COHORT||RETROSPECTIVE|||||||
33959984|NCT01033201|||CASE_ONLY||PROSPECTIVE|||||||
33959985|NCT03345953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959986|NCT03015909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959987|NCT01855321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33959988|NCT00004009||||TREATMENT||||||||
33959989|NCT02413879|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33959990|NCT03914937|||COHORT||PROSPECTIVE|||||||
33959991|NCT04979078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33959992|NCT04814888|||COHORT||PROSPECTIVE|||||||
33959993|NCT05128331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33959994|NCT05598463|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33959995|NCT06567717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Statistician||t|t|t|t
33959996|NCT01984931|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33959997|NCT05381883|NA|SINGLE_GROUP||OTHER||NONE||||||
33959998|NCT06096259|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33959999|NCT03701490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960000|NCT05675930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|This is a phase 2, double-blind, randomized (1:1 ratio) study|t|t|f|f
33960001|NCT05875974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960002|NCT01018342|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33960003|NCT05796531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which group they are in but researchers will know.|Intervention and control arms|t|f|f|f
33960004|NCT05553600|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34063818|NCT02238756|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34170424|NCT05001334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170425|NCT02551835|||||PROSPECTIVE|||||||
34170426|NCT01860664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170427|NCT04657471|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentre prospective study||||
34170428|NCT00166218|||||PROSPECTIVE|||||||
33749274|NCT06014463|||OTHER||PROSPECTIVE|||||||
33749275|NCT05889143|||OTHER||PROSPECTIVE|||||||
33749276|NCT00639873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749277|NCT04182490|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Identical-appearing placebo capsules, pharmacy blind|Healthy adults are treated with LMN-101 or placebo followed by an oral challenge of campylobacter to measure protective efficacy against campylobacteriosis.|t|t|t|t
33749278|NCT01747772|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Biopsy specimens were assessed via Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) criteria by a pathologist who was blinded to the shear-wave elastography (SWE) values.||f|f|f|t
33749279|NCT04501861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749280|NCT06670339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33749281|NCT02119416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33749282|NCT03037710|||OTHER||PROSPECTIVE|||||||
33749283|NCT05148819|||OTHER||RETROSPECTIVE|||||||
33749284|NCT03244527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749285|NCT06042348|||COHORT||PROSPECTIVE|||||||
33749286|NCT00339924|||CASE_ONLY||CROSS_SECTIONAL|||||||
33960005|NCT06241794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960006|NCT05048602|||COHORT||RETROSPECTIVE|||||||
33960007|NCT06422156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960008|NCT02056431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33960009|NCT03210142|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33960010|NCT00854386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33960011|NCT04403386|||COHORT||PROSPECTIVE|||||||
33960012|NCT06453720|||COHORT||PROSPECTIVE|||||||
33960013|NCT04567160|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled parallel open label study||||
33960014|NCT04245930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960015|NCT02854722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960016|NCT02082431|||COHORT||PROSPECTIVE|||||||
33960017|NCT06543004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33960018|NCT04196582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|closed envelope.technique||t|f|f|f
33960019|NCT02006355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749287|NCT06090266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960020|NCT02069886|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960021|NCT04740801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960022|NCT00817778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960023|NCT04832178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749288|NCT06215274|||COHORT||PROSPECTIVE|||||||
33749289|NCT05337891|||CASE_CONTROL||PROSPECTIVE|||||||
33749290|NCT01300546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33749291|NCT05069350|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||double blinded randomized syudy|t|t|t|f
33749292|NCT06635369|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants are separated into four different groups. Young (25-44 years) with a healthy periodontium, young with periodontitis, old (≥65 years) with a healthy periodontium, and old with periodontitis||||
33749293|NCT04393441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749294|NCT06313333|||COHORT||PROSPECTIVE|||||||
33858447|NCT01789125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749295|NCT04139070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749296|NCT02088268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749297|NCT02423187|||COHORT||PROSPECTIVE|||||||
33858448|NCT01875172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749298|NCT02014714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749299|NCT06192485|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33858449|NCT03878498|||COHORT||OTHER|||||||
33858450|NCT04050462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858451|NCT01272947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858452|NCT00359190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858453|NCT00009620|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33858454|NCT03543696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858455|NCT01840605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858456|NCT00312533|||||PROSPECTIVE|||||||
33858457|NCT00696982|RANDOMIZED|CROSSOVER||||NONE||||||
34170429|NCT06528366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"The research includes the responsible researcher, assistant and collaborator. The Collaborating Researcher is responsible for applying the technique to the patient not knowing which stimulus will be true or sham. He must apply the research tools and fill out de forms. The Collaborating Researcher should alert the Main Researcher and Assistant Research if regards signs or symptoms in patient resulting adverse effects.~In this way, the patient and the Collaborating Researcher are blinding."|"Crossover Study Experimental Group Hospital phase (Group 1): Patients will receive 3mA current for 20 minutes with anodal stimulation through HD-tDCS (4x1) with 5 sessions on 5 consecutive days and before the surgical procedure.~Control Group (2) Sham: Patients receive the simulated HD-tDCS anodic current (4x1) with 3mA that accelerates for 30 seconds and decelerates for another 30 seconds, 5 sessions on 5 consecutive days and before the surgical procedure .~Washout period - surgery and recovery for discharge (on average 15 days). Experimental Group Outpatient phase (Group 1) - active for Chlorella pyrenoidosa - consume 10 tablets per day of Chlorella p for 30 days. (5g/day) and must return within 30 days for evaluation.~Control Group 2 - will not consumption of Chlorella pyrenoidosa and must return within 30 days for evaluation."|t|t|f|f
34170430|NCT05049590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170431|NCT04033562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170432|NCT05930119|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, 4-Period, Randomized 6-Sequence Study||||
34170433|NCT04220216|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33858458|NCT02993484|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33858459|NCT02088749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858460|NCT04448509|NA|SINGLE_GROUP||OTHER||NONE||||||
33858461|NCT01016964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858462|NCT06419751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33858463|NCT04459065|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single center, open-label, phase I/II image-guided surgery study to assess the image quality of IRDye800CW-nimotuzumab during surgery||||
33858464|NCT04025463|NA|SINGLE_GROUP||TREATMENT||NONE||Hybrid type II effectiveness/implementation study design||||
33858465|NCT02715531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858466|NCT04264078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858467|NCT06246708|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot RCT with an intervention group and a wait-list control group||||
33858468|NCT04071015|||CASE_ONLY||RETROSPECTIVE|||||||
34170434|NCT05794035|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After inclusion of patient aged ≥ 70 years with performance status OMS 0-3 who had completed surgery (R0) for SCC and BCC with at least one unfavorable prognostic factor, the patients will be randomized in 3 arms with stratification by center, time from surgery to wound healing and perineural invasion.~* Arm A: Surgery alone~* Arm B: Surgery + Moderate HF 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed.~* Arm C: Surgery + Extreme HF : 30Gy in 5 fractions of 6Gy, 1 fraction per week, over 5 weeks to the operative bed."||||
34170435|NCT00425035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170436|NCT00683878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170437|NCT00461006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170438|NCT05324111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170439|NCT06012123|||COHORT||PROSPECTIVE|||||||
34170440|NCT05354817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858469|NCT00421200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170441|NCT05400655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34170442|NCT04634084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170443|NCT02513563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170444|NCT01299844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170445|NCT03341416|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"After surgery patients will undergo a first washout period intended to allow their ataxia return to baseline (preoperative levels), thus avoiding post surgery effects bias.~Phase 1: Participants will be randomized to either ON or OFF stimulation. The assigned stimulation will be performed for one week.~Phase 2: Open label phase. All patients are in the ON stimulation condition and will be followed for 6 months.~Duration:~Phase 1 will last from one to 2 months and phase 2 will last six months."|t|t|f|t
34170446|NCT05529498|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 group pretest postest||||
34170447|NCT06239584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170448|NCT04228588|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IV, single-arm study Number of visits: 13 (W-4, W0, W4, W8, W12, W16, W20, W24, W28, W32, W36, W40, W44, W48) (W = week)||||
34170449|NCT03796507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170450|NCT03935126|||COHORT||PROSPECTIVE|||||||
34170451|NCT05651282|NA|SINGLE_GROUP||SCREENING||NONE||All eligible participants will move into the various steps of the trial.||||
34170452|NCT01307826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170453|NCT00839189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858470|NCT02251288|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33858471|NCT00029497|RANDOMIZED|||TREATMENT||||||||
33858472|NCT03622853|NA|SINGLE_GROUP||TREATMENT||NONE||To investigate the factors associated with improvement after intraarticular steroid injection for patients with Frozen shoulder||||
33858473|NCT06326853|||COHORT||OTHER|||||||
33858474|NCT01734408|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33858475|NCT04144634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858476|NCT04897672|||CASE_CONTROL||PROSPECTIVE|||||||
33858477|NCT00286078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858478|NCT04233593|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects will complete one 120-minute \[11C\]PBR28 PET scan before and one scan 3-hours after lipopolysaccharide (LPS; 1.0ng/kg; IV) administration. A subset of subjects will complete a follow-up \[11C\]PBR28 PET scan 24+ hours after LPS.||||
33858479|NCT01088256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858480|NCT02198430|||COHORT||PROSPECTIVE|||||||
33858481|NCT06428591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858482|NCT00137904|||CASE_CONTROL||OTHER|||||||
33858483|NCT01553097|||||PROSPECTIVE|||||||
34170454|NCT03426670|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization in a 1:1 ratio to either monthly HIVST with quarterly in-clinic testing (intervention) or quarterly in-clinic HIV testing (standard of care).||||
34170455|NCT04473209|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group1: diabetic patients with chronic periodontitis group2: non diabetic patients with chronic periodontitis|f|f|f|t
34170456|NCT03929185|||CASE_CONTROL||PROSPECTIVE|||||||
34170457|NCT03226717|||COHORT||PROSPECTIVE|||||||
34170458|NCT04051359|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial||||
34170459|NCT01122641|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34170460|NCT03831477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Evaluator blinded assessment of photographs|Prospective, single centre, evaluator-blind study|f|f|f|t
34170461|NCT00062712||||TREATMENT||||||||
34170462|NCT04260893|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will undergo three sessions of treatments with the Investigation devise||||
34170463|NCT02314962|||CASE_ONLY||PROSPECTIVE|||||||
34170464|NCT02314936|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34170465|NCT00152503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170466|NCT04338672|||COHORT||RETROSPECTIVE|||||||
34170467|NCT06316037|||COHORT||CROSS_SECTIONAL|||||||
34170468|NCT04279886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All included healthy volunteers received 6 three-dimensional scans, utilizing 3 different scanning systems (2 scans per system)||||
34170469|NCT02609308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Application of autologous platelet-rich plasma|Use of platelet rich plasma in patients with ankle sprain|f|f|t|t
33858484|NCT00118833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34170470|NCT00498940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170471|NCT04122365|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34170472|NCT05887869|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be clients at local WIC agency sites where either the telehealth solution is offered or where only usual care is available (control).||||
34170473|NCT04013607|NA|SINGLE_GROUP||OTHER||NONE||All subjects will consume a NDC bolus. When fermentation has started, isotopically 13C-labelled SCFAs will be delivered inside the intestine. Thereafter, production and inter-conversion of SCFAs and breakdown of fiber will be studied in luminal samples. Also blood samples will be taken to study integration of the 13C-label into various metabolic compounds.||||
34170474|NCT02364908|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34170475|NCT01147666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170476|NCT00101231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170477|NCT00883779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170478|NCT02003235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170479|NCT01100866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170480|NCT05861596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858485|NCT02039960|||CASE_ONLY||CROSS_SECTIONAL|||||||
33858486|NCT05094466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170481|NCT00000547|RANDOMIZED|||TREATMENT||DOUBLE||||||
34170482|NCT01674608|||COHORT||PROSPECTIVE|||||||
34170483|NCT04980534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170484|NCT02920892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"After screening assessments, participants who met entry criteria and agreed to participate entered a single-blind 4-month placebo lead-in during which study participants had therapy treatments as usual to control for the effects of the language intervention. The 4-month placebo lead-in allowed for placebo effects to stabilize.~At the end of the 4-month placebo lead-in, all participants will enter a double blind placebo controlled phase in which they will have a repeat battery of AFQ056 baseline assessments and will be randomized 1:1 to AFQ056 or placebo. Both treatment groups received an intensive language intervention for 6 months after 2 months of flexible dose titration to establish their maximum tolerated dose (MTD).~After 8 months of treatment in the placebo-controlled phase (including 6 months of language intervention), all participants had final assessments and entered the open label extension (OLE) of about 8 months."|The trial will use a double-blind placebo-controlled parallel-group flexible-dose forced titration design. 100 eligible subjects with Fragile X Syndrome age 32 months to 6 years will enter a 4-month single-blind placebo lead-in period, followed by an 8-month double-blind treatment period during which subjects will randomized 1:1 to AFQ056 or placebo and will receive 6 months of language intervention. Subjects will then be invited to participate in an open-label extension phase during which all participants will receive treatment with active drug and continue language intervention for up to 8 months.|t|f|t|f
34170485|NCT02313701|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33858487|NCT00337519|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858488|NCT05121363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858489|NCT00177983|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33858490|NCT03581201|||COHORT||PROSPECTIVE|||||||
33858491|NCT02208154|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study is a cluster-randomized multicenter study with crossover of interventions within study centers. The first study period is always the baseline period. After six months, the first intervention period (order is determined by randomization) is implemented, followed by the second and third intervention. The intervention periods are separated by a wash out period of one month.||||
33858492|NCT04508322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858493|NCT04721093|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Mild Cognitive Impairment||||
33960024|NCT04778176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960025|NCT04135456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960026|NCT01424085|||CASE_CONTROL||PROSPECTIVE|||||||
33960027|NCT06703970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of this study, blinding will not be possible for the treating surgeon and research staff. The participants will be blinded from the regimen that they receive, and both groups will have blood drawn and the injection will be covered in a manner to ensure participants cannot ascertain the treatment regimen.||t|f|f|f
33960028|NCT04711512|||CASE_ONLY||PROSPECTIVE|||||||
33960029|NCT05243966|||CASE_ONLY||PROSPECTIVE|||||||
33960030|NCT03309631|||COHORT||PROSPECTIVE|||||||
33960031|NCT06003673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960032|NCT02780999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170486|NCT00768417|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33960033|NCT01878500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960034|NCT02542722|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960035|NCT05875116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluators were blinded to the therapy group to which the patient belonged. The patient, family member or person in charge was instructed not to comment on their management or activities they carried out, only to carry out the activities indicated by the evaluator during the review.|Clinical Trial Randomized Single Blind|f|f|f|t
33960036|NCT05436184|||COHORT||PROSPECTIVE|||||||
33960037|NCT01453101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960038|NCT04824300|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33960039|NCT02321215|RANDOMIZED|PARALLEL||||NONE||||||
33960040|NCT05654103|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial where participants are assigned to receive a fistula created through surgery (open the skin) or endovascular surgery (through the skin). There is the option to not join the randomized portion and instead join a registry that will track the outcome of a participants fistula.||||
33960041|NCT00741117|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960042|NCT00895765|||CASE_ONLY||PROSPECTIVE|||||||
33960043|NCT05538286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960044|NCT05606913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960045|NCT02199665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960046|NCT00363220|||||RETROSPECTIVE|||||||
33960047|NCT05937750|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"This is a long-term follow-up trial following an open-label, non-randomized trial in highly sensitized adult kidney transplant patients with positive crossmatch (XM) against an available deceased donor.~The rational for the main trial, 20-HMedIdeS-19 (PAES), being non-randomized is that no other effective or approved desensitization protocol exists in deceased-donor kidney transplantation that would provide a suitable control. A non-comparative concurrent reference cohort from participating sites was included to address differences in-site practice and experience."||||
33960048|NCT06468280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960049|NCT06255574|||OTHER||CROSS_SECTIONAL|||||||
33960050|NCT06568029|||COHORT||RETROSPECTIVE|||||||
33960051|NCT05840601|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||In the lab, a functional test will be used to evaluate the feasibility of the device design as compared with a baseline condition. A subset of these subjects will test the investigational device at home for up to 2 weeks to provide feedback on the investigational device when used in everyday tasks.||||
33960052|NCT03659617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors collecting the data and conducting the appropriate statistical analyses for all outcomes in the study will be blinded.||f|f|f|t
34063819|NCT06731751|||COHORT||PROSPECTIVE|||||||
34063820|NCT03566056|||COHORT||OTHER|||||||
34170487|NCT03798717|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170488|NCT01186666|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34170489|NCT05559177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170490|NCT02784886|||COHORT||PROSPECTIVE|||||||
34170491|NCT02172430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170492|NCT03956186|||COHORT||PROSPECTIVE|||||||
33858494|NCT02376075|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33858495|NCT01037881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858496|NCT00769860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858497|NCT01384422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858498|NCT00005485|||COHORT||PROSPECTIVE|||||||
33858499|NCT02451241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34170493|NCT03186209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170494|NCT04871841|||CASE_ONLY||PROSPECTIVE|||||||
34170495|NCT04749134|||OTHER||OTHER|||||||
34170496|NCT03605667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170497|NCT04970277|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34170498|NCT06276322|RANDOMIZED|PARALLEL||OTHER||NONE||Low back pain group and healthy group||||
34170499|NCT06325059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients affected by nephropathy||||
34170500|NCT03780049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170501|NCT01581918|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34170502|NCT05525377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170503|NCT01984866|||CASE_ONLY||PROSPECTIVE|||||||
34170504|NCT03034486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170505|NCT04085419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858500|NCT03575767|||COHORT||PROSPECTIVE|||||||
33858501|NCT02742766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858502|NCT05708963|||COHORT||CROSS_SECTIONAL|||||||
33858503|NCT03891303|||COHORT||RETROSPECTIVE|||||||
33858504|NCT00528892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858505|NCT04854733|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858506|NCT06493591|||COHORT||PROSPECTIVE|||||||
33858507|NCT04945590|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33858508|NCT02342743|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33858509|NCT01412099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858510|NCT05519163|||COHORT||RETROSPECTIVE|||||||
33858511|NCT00295360|||DEFINED_POPULATION||OTHER|||||||
34170506|NCT05574478|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34170507|NCT05042674|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34063821|NCT04102683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34170508|NCT05383209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170509|NCT01062750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170510|NCT03921658|||COHORT||PROSPECTIVE|||||||
34170511|NCT00818610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170512|NCT00254319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170513|NCT02413307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170514|NCT01847352|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34170515|NCT06452537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170516|NCT01361971||PARALLEL||BASIC_SCIENCE||NONE||||||
34170517|NCT02538744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170518|NCT04192188|||COHORT||CROSS_SECTIONAL|||||||
34170519|NCT02119871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34170520|NCT02826746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170521|NCT04515004|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase IIa, single arm study using 2-3 weeks of oral LP treatment for stage I and II lung cancer patients before surgical resection of their tumors||||
34170522|NCT06244004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170523|NCT01548755|||CASE_ONLY||PROSPECTIVE|||||||
34170524|NCT03679975|NA|SINGLE_GROUP||OTHER||NONE||The original plan was to enroll 30 patients for a final sample size of 25 completed patients. With agreement from the FDA, the Sponsor decided to terminate the study after 9 completed patients, based on an interim analysis of the first 8 completed patients with no evidence of a harmful effect of one dose of 50 mg Riluzole Oral Film on swallowing function.||||
34170525|NCT02343042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170526|NCT04896996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||A randomized controlled cluster trial|f|t|t|t
34170527|NCT00960375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858512|NCT00655486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858513|NCT02787954|||COHORT||PROSPECTIVE|||||||
33858514|NCT02366377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858515|NCT04102306|||CASE_CONTROL||PROSPECTIVE|||||||
33858516|NCT02215460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858517|NCT03376607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858518|NCT04025723|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Young (18-30 y) and middle aged (35-50 y) men will perform 60 min of downhill running||||
33858519|NCT05610748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assignment of eligible patients to treatment will be recorded using sealed envelopes and will be disclosed to each clinical operator at the end of the screening appointment. The examiners will be kept blinded as to treatment allocation.|The study is designed as a single-blind, parallel-arm, randomized trial.|f|f|t|t
33858520|NCT00625950|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33858521|NCT03493711|||COHORT||PROSPECTIVE|||||||
33858522|NCT01295281|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33858523|NCT02404974|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33858524|NCT00009841||||TREATMENT||||||||
33858525|NCT04740008|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858526|NCT06078280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There is a study group that uses the device \& the data is monitored and sent to the physician. The second group is a control group that will not use the device and will continue with normal standard of care.|f|f|f|t
33858527|NCT01917019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858528|NCT03329443|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858529|NCT00669799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858530|NCT00621647|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33858531|NCT00984763|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858532|NCT00046085|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858533|NCT02699112|||COHORT||PROSPECTIVE|||||||
33858534|NCT05283304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the Data and Statistic Center (DSC) staff overseeing the random assignment schedule, a few Clinical Coordinating Center (CCC) staff, the central research pharmacy staff preparing the study medication and a single study staff role (Medical Personnel) to administer the injections are unblinded; all other study personnel and participants will remain blinded to treatment arm until the nationwide completion of the trial and the database is formally locked.||t|t|t|t
33858535|NCT03629587|||COHORT||PROSPECTIVE|||||||
33858536|NCT01071525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858537|NCT01303263|RANDOMIZED|||||||||||
33858538|NCT00124098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858539|NCT04189237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858540|NCT05620251|||COHORT||PROSPECTIVE|||||||
33858541|NCT00604864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858542|NCT01208688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858543|NCT01159379|NA|SINGLE_GROUP||||NONE||||||
33858544|NCT00279773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858545|NCT02148419|||CASE_CONTROL||PROSPECTIVE|||||||
33858546|NCT06383520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858547|NCT03774160|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two different districts are being used, one in which the intervention is implemented and the other is a no-intervention comparison site.||||
33858548|NCT04771611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858549|NCT03349892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170528|NCT04608981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In this proposed study, the participant, and the assessor will be blinded. The participants will be blinded to the study hypothesis as to which intervention is expected to be better.~The patients, who already do not know their treatment group, will assess the level of their post-endodontic pain.~* The laboratory technician at the microbiological department will not know the treatment group of the patients.~* The treatment groups will remain anonymous at the end of the study during assessment by the statistician."||t|t|t|t
34170529|NCT00799201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170530|NCT05958940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170531|NCT02398916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170532|NCT03222635|NA|SINGLE_GROUP||TREATMENT||NONE||"Upon achieving the designated sample size of 141 patients of the original PREFER-trial, the enrolment of further patients diagnosed with T1b N0M0 EAC and treated endoscopically will be continued as a registration cohort (no sample size) within the same study database.~The high-risk T1a group will also continue as a registration cohort, since there is no available data yet to calculate a reliable sample size with. The high-risk T1a patient group will be analysed separately from the T1b patient group."||||
34170533|NCT05846126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170534|NCT06079788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858550|NCT00452088|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858551|NCT06306885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33858552|NCT03532412|||COHORT||RETROSPECTIVE|||||||
33858553|NCT02975024|||COHORT||PROSPECTIVE|||||||
33858554|NCT02690558|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33858555|NCT02019888|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858556|NCT02530203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858557|NCT05166460|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE||1:1 randomization (Part B, 40 patients). This will be preceded with a single series of 5 consecutive patients (Part A).|t|t|f|f
33858558|NCT04940039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858559|NCT03741933|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be patients that have been screened within the Department of Dermatology at the GW MFA. Individuals meeting inclusion and exclusion criteria will be enrolled into the study. A total of 10 patients will be enrolled in the study and each patient will be given Apremilast 30 mg twice daily to be administered for a period of 6 months. Patients will present to clinic for clinical assessments, adverse event monitoring, laboratory testing, and/or photography at the following time periods of therapy: baseline and 2 weeks, 4 weeks, and every 4 weeks thereafter until completion of the 6 month treatment period. Additionally, all patients will be required to return for a 4-week follow up visit after completing the final dose of the study medication.||||
33858560|NCT05781776|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Two arms pretest-posttest design.|t|f|f|t
33858561|NCT01902056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858562|NCT01944735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858563|NCT06351306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858564|NCT01172405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858565|NCT05844787|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study.|t|t|f|f
33858566|NCT00524719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858567|NCT05135949|||COHORT||PROSPECTIVE|||||||
33858568|NCT06094270|||CASE_ONLY||PROSPECTIVE|||||||
33858569|NCT00991484|||FAMILY_BASED||PROSPECTIVE|||||||
33858570|NCT06433804|||COHORT||RETROSPECTIVE|||||||
33858571|NCT00797498|||COHORT||PROSPECTIVE|||||||
33858572|NCT04801186|||COHORT||RETROSPECTIVE|||||||
33858573|NCT04027322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858574|NCT00911079|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33858575|NCT04294732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Spinal anesthesia will be performed in all three groups. During procedure 8 ml saline with 8 ml bupivacaine will be apply to the first group and 8 ml bupivacaine and 16 ml of saline will be apply to the second group. Only spinal anesthesia will be given to the third group without peripheral nerve block. The patients participating in the study will not be informed about which group they belong to, the person who makes the block will not prepare the drug and the person who makes the block, the patient and the nurse will not know which concentration drug applied to which patient.|The study was designed to be prospective and randomized. Patients will be divided into 3 groups by simple randomization. The results of power analysis (G-power 3.1) revealed that a total of 60 patients were required to be included in the study. Because of that approximately 20 patients are planned for each group|t|t|t|t
33858576|NCT02222636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858577|NCT06048692|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33858578|NCT00398736|||CASE_ONLY||PROSPECTIVE|||||||
33858579|NCT05862896|||CASE_CONTROL||PROSPECTIVE|||||||
33858580|NCT02967354|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33858581|NCT03392025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858582|NCT01616433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858583|NCT00842881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858584|NCT01739153|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33858585|NCT03278951|RANDOMIZED|PARALLEL||OTHER||SINGLE|Following baseline visits, participants were randomized to a viideo conference (VC(, in person (IP) or control (CG) groups via the website https://www.randomlists.com/team-generator.|All participants were randomized in a balanced fashion and stratified by sex into either one of the two intervention groups (VC or in-person group) or a control group.|t|f|f|f
33858586|NCT01892137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170535|NCT04213547|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Aim 2 will be an interventional study design utilizing Fitbit to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration with text message feedback. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention.~A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging."||||
34170536|NCT05718973|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All study investigators and researchers involved in the data analyses will remain blinded to the trial arm allocation for the entire study duration. Unblinding will not be required.|This is a 4-armed, parallel, randomized controlled trial, conducted purely online|t|f|t|t
34170537|NCT06436235|||CASE_CONTROL||PROSPECTIVE|||||||
34170538|NCT05877066|||COHORT||OTHER|||||||
33858587|NCT03450720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858588|NCT03613753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858589|NCT02425709|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858590|NCT05337163|||COHORT||RETROSPECTIVE|||||||
33858591|NCT03652025|NA|SINGLE_GROUP||TREATMENT||NONE||premenopausal women with dull aching pain with ovarian point tenderness and post coital pain.||||
33858592|NCT05625594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858593|NCT01465204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858594|NCT03006354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858595|NCT06464003|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858596|NCT04107350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blinded randomized control trial Intervention by the physical therapist Evaluation by the physician|knee osteoarthritis status post total knee arthroplasty receive therapy on post-operation day 2 and post operation day 3 Study group: WBV+conventional physical therapy Control group: convention physical therapy|t|f|f|f
33858597|NCT04493190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858598|NCT01013766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858599|NCT05866887|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33858600|NCT02441166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858601|NCT04029935|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33858602|NCT05343026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33858603|NCT00037791|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33858604|NCT01088100|||CASE_CONTROL||RETROSPECTIVE|||||||
33858605|NCT01562509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33858606|NCT05859061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858607|NCT03630341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858608|NCT04302454|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, randomized study. A total of 280 patients will participate in this study, equally divided between both study groups||||
33858609|NCT01969591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33858610|NCT00538889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33858611|NCT01612741|||COHORT||PROSPECTIVE|||||||
33858612|NCT01354808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858613|NCT03279133|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label pilot, safety, feasibility study to treat candidates for HCT infected with hepatitis C prior to the transplantation to reduce the complications associated with hepatitis C in the post-transplant setting.||||
33858614|NCT00288353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858615|NCT04571866|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33858616|NCT03265041|||OTHER||RETROSPECTIVE|||||||
33858617|NCT03428737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858618|NCT01278251|||CASE_ONLY||RETROSPECTIVE|||||||
33858619|NCT00297570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858620|NCT05117723|||COHORT||OTHER|||||||
33858621|NCT00350805|||CASE_CONTROL||PROSPECTIVE|||||||
33858622|NCT04182503|||COHORT||PROSPECTIVE|||||||
33893666|NCT05066685|||COHORT||RETROSPECTIVE|||||||
33893667|NCT05839561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063822|NCT02507024|||OTHER||PROSPECTIVE|||||||
33960053|NCT00950001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960054|NCT03151226|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960055|NCT06440486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960056|NCT00822679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34063823|NCT06730373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960057|NCT06611033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34063824|NCT01764659|||CASE_ONLY||PROSPECTIVE|||||||
34063825|NCT06545630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063826|NCT02305446|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063827|NCT05133258|||COHORT||PROSPECTIVE|||||||
34063828|NCT04938713|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34063829|NCT00830518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063830|NCT05559528|||COHORT||PROSPECTIVE|||||||
34063831|NCT05270707|||CASE_ONLY||OTHER|||||||
34063832|NCT00553293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063833|NCT05616091|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Participants will not be informed about the intensities of the nociceptive stimuli administered during the experimental paradigm.|Each participant will participate in two identical experimental sessions. Sessions will be separated from each other by one month. During each session, participants will undergo an experimental paradigm of about 15 min duration. In this paradigm, 80 experimental painful stimuli of different intensities will be applied using a laser device (DEKA Stimul 1340, Calenzano, Italy). Participants will be asked to verbally rate the intensity of every stimulus on a scale ranging from 0 ('no pain') to 100 ('maximally tolerable pain'). At the same time, brain responses will be recorded by using electroencephalography (EEG). Autonomic responses will be operationalized by the recording of skin conductance responses (SCRs).|t|f|f|f
34063834|NCT05667207|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot study (feasibility)||||
34063835|NCT00444860|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34063836|NCT02423668|||COHORT||RETROSPECTIVE|||||||
34063837|NCT04135066|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33960058|NCT03546699|||COHORT||PROSPECTIVE|||||||
33960059|NCT04083066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063838|NCT05398705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants with a confirmed diagnosis of SARS-CoV-2 infection in alternate care site will be randomized (1:1:1) to receive low-dose cepharanthine, high-dose cepharanthine or placebo orally every 8 hours for 5 days.|t|t|t|t
34063839|NCT02773745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34063840|NCT05765448|RANDOMIZED|CROSSOVER||OTHER||NONE||Non-blinded, randomised crossover trial with each participant testing 5 different test ingredients on 5 separate study sessions on 5 days.||||
34063841|NCT02338466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063842|NCT05381922|||CASE_ONLY||CROSS_SECTIONAL|||||||
34063843|NCT02841956|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34063844|NCT00805519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34063845|NCT05335915|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded|All participants will complete all dose conditions (study arms) in a randomized order|t|t|f|f
34063846|NCT05389826|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot study involving cases and controls. Fifty outpatient patients with stage 4-5 CKD, including those on dialysis will be included. Twenty-five patients will be followed with the developed mobile web app, while another twenty-five patients will be treated according to the current clinical practice. Patients will be randomized blindly 1:1 to the study group or to the control group. The randomization technique consists of consecutively numbered sealed envelopes on which the signed group is written.||||
34063847|NCT02912455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063848|NCT00269477|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063849|NCT00390624|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34063850|NCT05083052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34063851|NCT05918861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the exception of the statistician to the DSMB and the DSMB all other individuals will remain blinded until the final analysis of the primary study parameter.|Placebo-controlled, randomized, double-blind, parallel group, multi-center|t|t|t|t
33749300|NCT04966468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The proposed investigation is a randomized, controlled, non-profit, single-center exploratory interventional study without drugs.||||
33749301|NCT02052505|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33749302|NCT01571505|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33749303|NCT06137261|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749304|NCT00657618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858623|NCT03299257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|donepezil and placebo will be dispensed to volunteers in similar pills and numbered boxes.|Randomized, parallel groups, 30-day trial|t|t|t|f
33858624|NCT04980937|||CASE_ONLY||RETROSPECTIVE|||||||
33858625|NCT02318992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858626|NCT02762812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858627|NCT01734174|||CASE_ONLY||PROSPECTIVE|||||||
33858628|NCT01487356|||||PROSPECTIVE|||||||
33858629|NCT00505869|||CASE_ONLY||PROSPECTIVE|||||||
33858630|NCT04851925|||COHORT||PROSPECTIVE|||||||
33858631|NCT02189356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858632|NCT01924351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858633|NCT01066468|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33858634|NCT05781217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858635|NCT00405470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960060|NCT06542731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960061|NCT04466956|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention 25 and control 25||||
33960062|NCT05776732|RANDOMIZED|PARALLEL||PREVENTION||NONE||3M CaviionTM||||
33960063|NCT01249690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063852|NCT03831269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34063853|NCT02004327|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34063854|NCT02394405|||COHORT||RETROSPECTIVE|||||||
34170539|NCT02527681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858636|NCT00852592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858637|NCT01367353||PARALLEL||BASIC_SCIENCE||NONE||||||
33858638|NCT01510522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858639|NCT02623374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858640|NCT00270465||||TREATMENT||||||||
33858641|NCT05412381|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"PRP is considered a biologic.~We designed a double-blinded randomized controlled clinical trial with two arms:~1. Control Arm (pre-op placebo injection, ACLR surgery + placebo injection)~2. Investigational Arm (pre-op PRP injection, ACLR surgery + PRP injection)."|t|t|f|f
33858642|NCT03520933|||OTHER||PROSPECTIVE|||||||
33858643|NCT01360060|||CASE_CONTROL||RETROSPECTIVE|||||||
33858644|NCT01339741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858645|NCT05877183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be performed by research investigators blinded to the treatment allocation. Participants and therapist are instructed not to tell the assessors which group they are from.|Randomized controlled trial.|f|f|f|t
33858646|NCT00308386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858647|NCT06251609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858648|NCT00822016|||||PROSPECTIVE|||||||
33858649|NCT04111042|||COHORT||PROSPECTIVE|||||||
33858650|NCT03149471|||COHORT||PROSPECTIVE|||||||
33960064|NCT03159611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960065|NCT04065386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960066|NCT04747678|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33960067|NCT02367807|||COHORT||PROSPECTIVE|||||||
33960068|NCT01728363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960069|NCT04078659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960070|NCT01450150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960071|NCT01111994|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33960072|NCT01519895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960073|NCT04641273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960074|NCT02645266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960075|NCT03534830|||COHORT||PROSPECTIVE|||||||
33960076|NCT03271541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960077|NCT00063700||||PREVENTION||||||||
33960078|NCT00530088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858651|NCT00615836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858652|NCT05149365|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, Multi-center, Open-label, Randomized, Controlled Clinical Trial||||
33858653|NCT04439721|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33858654|NCT05363696|||COHORT||PROSPECTIVE|||||||
33858655|NCT06071273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised controlled trial|t|t|f|t
33858656|NCT01480674|||COHORT||OTHER|||||||
33960079|NCT05779488|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind, matched-pair study design||t|f|t|f
33960080|NCT02591017|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33960081|NCT02378467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960082|NCT06412991|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Any patient admitted to the NorthEast Acute Care Surgery service on the Post Surgical Care 1 unit diagnosed with ileus, non-operative small bowel obstruction, or has had bowel surgery and with post operative small bowel obstruction and/or ileus.||||
33960083|NCT00788723|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960084|NCT06176989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858657|NCT02334033|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33858658|NCT03753633|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33858659|NCT02141984|||CASE_ONLY||PROSPECTIVE|||||||
33858660|NCT02032303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33858661|NCT04286490|NA|SINGLE_GROUP||OTHER||NONE||||||
33858662|NCT04065152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960085|NCT01831596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960086|NCT02806622|||COHORT||CROSS_SECTIONAL|||||||
33960087|NCT05435872|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960088|NCT05581199|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33960089|NCT01220128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960090|NCT04807634|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial (RCT).||||
33960091|NCT03911960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960092|NCT04215120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960093|NCT06648317|||CASE_ONLY||PROSPECTIVE|||||||
33960094|NCT00545441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960095|NCT00883740|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33960096|NCT05614479|NA|SINGLE_GROUP||OTHER||NONE||A quasi-experimental, longitudinal (pre-post, prospective and without a control group). This research is not a clinical trial, but a technology testing study at community level (community intervention). Therefore, the health and medical treatments provided to the person do not differ from those provided to the participants. Nevertheless, the participant is entitled to know of any unexpected discoveries or findings as part of research conducted in a study, just as if the individual were not participating in the study. The mixed-method approach will provide scientific evidence based on the effectiveness, and user experience of a self-managed mobile health application that recommends activities to promote healthy lifestyle habits.||||
33960097|NCT04662086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960098|NCT06385145|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33858663|NCT04935853|||COHORT||OTHER|||||||
33858664|NCT05073237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomized, double blind, placebo-controlled trial|In the current study, 40 women veterans with obesity, prediabetes and menopause who are experiencing bothersome menopause symptoms will be enrolled and randomized to receive either 16 weeks of CE/BZA or 16 weeks of placebo.|t|t|t|t
33858665|NCT03024853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170540|NCT05765682|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Subject, surgeon, and care team members will be blinded to the assigned randomization group. The anesthesiologist will not be blinded.||t|t|f|f
33858666|NCT01220232|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170541|NCT00973726|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33858667|NCT00733993|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33858668|NCT04731220|||CASE_CONTROL||PROSPECTIVE|||||||
34170542|NCT03303326|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170543|NCT04809831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a study in which patients are divided into two groups:~* Trial Group: professional dental hygiene at T0, T1 and T2 + Biorepair Peribioma Toothpaste and Mousse for domiciliary oral care twice a day until T2;~* Control Group: professional dental hygiene at T0, T1 and T2 + Curasept Toothpaste with chlorhexidine 0,2% twice a day until T2."|t|t|t|t
34170544|NCT05720650|||CASE_CONTROL||RETROSPECTIVE|||||||
34170545|NCT04406298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170546|NCT01386164|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34170547|NCT04138303|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34170548|NCT04499755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170549|NCT00000801||||TREATMENT||||||||
34170550|NCT00321789|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34170551|NCT00729534|||||PROSPECTIVE|||||||
33858669|NCT03029169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Provided by a dedicated study nurse||f|f|t|f
34170552|NCT02245477|||CASE_CONTROL||PROSPECTIVE|||||||
34170553|NCT05472935|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental with pre-test/post-test survey and measures.||||
33858670|NCT00577161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063855|NCT04344535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Staff in Transfusion Services (Blood Bank) at Stony Brook will be unblinded so they can collect, store, and dispense either convalescent plasma or standard plasma. They will affix an approved label with all required information, e.g. bar code, blood type, expiration date, and will indicate that the bag contains convalescent plasma/standard plasma.||t|t|t|t
34170554|NCT06086509|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blindness method was used to avoid bias in this study. The researcher, who evaluated the children's anxiety and fear levels during and after the tomography in order to prevent selection bias, did not know which group the children and their families were in.|They were divided into two groups: control group and experimental group.|t|t|t|t
34063856|NCT04536961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170555|NCT00517764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170556|NCT01838317|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170557|NCT05710055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34170558|NCT04420013|||CASE_CONTROL||PROSPECTIVE|||||||
34170559|NCT00354796|||COHORT||PROSPECTIVE|||||||
34170560|NCT00419393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170561|NCT01338441|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34170562|NCT05118646|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34170563|NCT01506271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170564|NCT02084485|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34170565|NCT00214045|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34170566|NCT04706949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170567|NCT03308344|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be assigned into three groups: (i) a mindfulness training with spouse trainers (MT-ST, n = 60) that will receive the training from peers who underwent an extensive training practicum; (ii) a mindfulness training with mindfulness expert trainer group (MT-ME, n = 30) that will receive the training from a mindfulness expert trainer; and (ii) a wait-list control group (WLC, n = 30) that will be tested before and after a no-training interval and may receive MT at a later time after their second testing if they are interested.||||
34170568|NCT03390465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170569|NCT00657046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858671|NCT03714204|RANDOMIZED|PARALLEL||PREVENTION||NONE|The names of individual participants|Randomized controlled trial||||
33858672|NCT01839500|||COHORT||PROSPECTIVE|||||||
33858673|NCT04856644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking will not be done|The intervention group: all patients recruited into the study will receive the 4-month regimen The comparator group: historical control in those who received the standard 6-month regimen||||
33858674|NCT01891721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858675|NCT04193488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to 30 patients with MTP block (Group MTP) and 30 patients with ESP block (Group ESP) and 30 patients with no block (Group K) in addition to patient-controlled analgesia (PCA).||||
33858676|NCT00510523|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33858677|NCT03919188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063857|NCT03769194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063858|NCT05464251|||CASE_CONTROL||PROSPECTIVE|||||||
34063859|NCT04557956|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I single-arm trial followed by randomized two-arm phase II trial with cross-over||||
34063860|NCT03433300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators who will conduct performance-based assessments will be blinded to the intervention.|Pilot randomized controlled trial|f|f|f|t
34063861|NCT03886714|||CASE_ONLY||PROSPECTIVE|||||||
34063862|NCT00261898||||TREATMENT||||||||
34063863|NCT05061485|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34170570|NCT03442816|NA|SINGLE_GROUP||OTHER||NONE||Subjects will undergo 1) an ophthalmic evaluation and 2) an evaluation with the device (camera)||||
34170571|NCT01869738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170572|NCT03025425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170573|NCT02507765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170574|NCT00610402|||CASE_ONLY||PROSPECTIVE|||||||
34170575|NCT04854343|||CASE_CONTROL||PROSPECTIVE|||||||
34170576|NCT02881788|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34170577|NCT01362413|||COHORT||PROSPECTIVE|||||||
34170578|NCT02190136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170579|NCT01152658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170580|NCT00963963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170581|NCT04061122|||CASE_CONTROL||PROSPECTIVE|||||||
34170582|NCT01292941|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34170583|NCT03820505|||COHORT||PROSPECTIVE|||||||
34170584|NCT00614575|||COHORT||PROSPECTIVE|||||||
34170585|NCT04847843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34170586|NCT02639494|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34170587|NCT06306833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170588|NCT04497649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170589|NCT04001712|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||randomized controlled phase 3 clinical trial|t|t|t|f
34170590|NCT00006275||||TREATMENT||||||||
34170591|NCT05754034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170592|NCT01081691|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34170593|NCT05087771|RANDOMIZED|PARALLEL||TREATMENT||NONE||one group randomized to oral naltrexone; one group randomized to injectable naltrexone||||
34170594|NCT04404426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Prospective, multicenter, placebo-controlled, randomized, double-blind, two-parallel study, specific enteral administration by citrulline in a subgroup of resuscitation patients admitted for ARDS secondary to COVID-19 pneumonia, at infectious risk nosocomial important because having biological stigmas of immunosuppression on admission and under invasive mechanical ventilation for a prolonged period.|t|t|t|f
34170595|NCT01066975|||CASE_ONLY||PROSPECTIVE|||||||
34170596|NCT00942903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170597|NCT01884077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170598|NCT00871767|RANDOMIZED|CROSSOVER||||NONE||||||
34170599|NCT06005935|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34170600|NCT04303455|||COHORT||PROSPECTIVE|||||||
34170601|NCT00648336|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34170602|NCT06274463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063864|NCT01971632|RANDOMIZED|PARALLEL||||DOUBLE||||||
34063865|NCT01688141|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063866|NCT02028169|||OTHER||PROSPECTIVE|||||||
34063867|NCT05687838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34170603|NCT04886323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34170604|NCT02040623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170605|NCT02368665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170606|NCT05143840|NA|SINGLE_GROUP||TREATMENT||NONE||Single group frontline asciminib||||
34170607|NCT05129748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||1:1 randomization between cisplatin alone, and cisplatin, sodium thiosulfate and mannitol.|f|f|f|t
34170608|NCT03936114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170609|NCT01295359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858678|NCT02041741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33858679|NCT05781919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063868|NCT04026711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masked study||t|f|t|f
34063869|NCT05739305|||CASE_ONLY||RETROSPECTIVE|||||||
34170610|NCT03309878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170611|NCT02319941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170612|NCT06298084|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34170613|NCT02203877|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170614|NCT00468299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170615|NCT04351217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two interventions, Music and Progressive Muscle Relaxation (PMR) were used. Music was Indian Classical Flute music, 23 minutes long. PMR was recorded for uniformity of delivery, and was 22 minutes in length.||||
34170616|NCT00333775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170617|NCT05425056|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34170618|NCT00763113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170619|NCT02530021|||CASE_ONLY||PROSPECTIVE|||||||
34170620|NCT04383509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Upon registration in the computer-based training, the computer will randomly allocate participants to either cognitive control training or placebo condition.|Participants will be assigned to either intervention or placebo.|t|f|f|t
34170621|NCT02608658|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170622|NCT04910295|||COHORT||PROSPECTIVE|||||||
34170623|NCT05574023|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a crossover, monocentric and randomized study with a post-market medical device.||||
34170624|NCT00786292||||TREATMENT||||||||
34170625|NCT00121017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858680|NCT04098354|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking|This study is designed as a pragmatic randomized controlled trial (RCT) of HBPT plus clinical case management compared to HBPT with usual care. Eligible patients will be randomized 1:1 to HBPT + BP case management versus HBPT + usual care. In the intervention arm, BP will be measured 4 times daily for 1 week, with medications titrated up or down by the study case manager until guideline targets (systolic BP \[SBP\]: \<130mmHg) are achieved. Once BP is controlled, (i.e., to guideline-concordant targets), this 1-week protocol will be repeated every 3 months for 1 year. Patients in the control arm will also follow the same BP measurement protocol, however, there will be no interactions with the case manager; they will share their BP readings with their primary care physicians or nurse practitioners at scheduled visits.||||
34170626|NCT04944459|NA|SINGLE_GROUP||OTHER||NONE||||||
33858681|NCT00134940|||COHORT|||||||||
33858682|NCT01072877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858683|NCT03302000|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Two kind of researchers will be part of the study: a) assessors, which are the researchers that will perform assessments and apply stimulation with the caregivers; b) ratters, which are the researchers that will rate the scales from videos. Assessors will not be blind to group allocation. Ratters will be masked to group allocation, since videos analyses will be performed using coded study allocation. The statistician will also be blind to group allocation.|2-arm, parallel-groups, pragmatic superiority randomised controlled trial. Allocation ratio will be 1:1|t|t|t|f
33858684|NCT05068518|||COHORT||PROSPECTIVE|||||||
33858685|NCT00003741||||TREATMENT||NONE||||||
33858686|NCT00198627|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858687|NCT03629951|||COHORT||PROSPECTIVE|||||||
33858688|NCT04051827|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33858689|NCT03598088|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33858690|NCT01034839|||COHORT||RETROSPECTIVE|||||||
33858691|NCT04254185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|This study is a double-blind, multicenter, phase 3, randomized controlled superiority trial examining the treatment effectiveness of in-situ decompression and subcutaneous anterior transposition for UNE.|t|f|t|f
33858692|NCT03700749|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Patients and outcome assessors will be blinded. The operating surgeon will not perform outcome assessment.|"FALCON 2x2 factorial trial with strata: (1) clean-contaminated and (2) contaminated/dirty. Eligible patients will be randomised at the level of the individual in a 1:1:1:1 ratio between:~A. 2% alcoholic chlorhexidine and non-coated suture B. 2% alcoholic chlorhexidine and triclosan-coated suture C. 10% aqueous povidone-iodine and non-coated suture D. 10% aqueous povidone-iodine and triclosan-coated suture"|t|f|f|t
33858693|NCT04740892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858694|NCT02025569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858695|NCT03125213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858696|NCT00465725|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33858697|NCT03773822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858698|NCT01762033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858699|NCT02090374|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33858700|NCT03130010|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33858701|NCT04495907|||COHORT||OTHER|||||||
33858702|NCT05908604|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized controlled clinical trial||||
33858703|NCT02354443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858704|NCT01786174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858705|NCT01185925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858706|NCT00407069|||CASE_CONTROL||PROSPECTIVE|||||||
33858707|NCT05643846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants are allocated randomly by means of computer generation sequencing. The allocation sequence with unique study number for each participant will be concealed in sequentially numbered, opaque, sealed, and stapled envelopes. This envelope will be opened by an anesthetist who was not involved in the study. This Anesthetist prepares the study medication as per the allocation and labels the syringe with the unique study number; this number will be used to identify the study medication and will be revealed only on completion of data collection at the end of the study. The investigators, participants and other healthcare providers who are involved in postoperative care, are blinded to the participant's group allocation.|It is a Prospective, Double-blinded, randomized and controlled clinical trial.|t|t|t|t
33858708|NCT02051270|||CASE_ONLY||CROSS_SECTIONAL|||||||
33858709|NCT02031289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170627|NCT00285909|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34170628|NCT03839368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Cards will have sequential numbers one number for each card then these cards will be placed within opaque sealed envelopes. Then these envelops will be placed in a container (box), each participant will grasp one envelope the day of procedure.|Randomized|t|f|f|f
34170629|NCT05608603|||COHORT||PROSPECTIVE|||||||
34170630|NCT01796925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170631|NCT01464086|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749305|NCT04232423|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A Double-Blind, Placebo-Controlled, Randomized Crossover Trial|t|t|t|t
33749306|NCT03030300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170632|NCT05478421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170633|NCT00488085|||DEFINED_POPULATION||OTHER|||||||
34170634|NCT01446627|||CASE_CONTROL||RETROSPECTIVE|||||||
34170635|NCT05326451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170636|NCT01803425|||COHORT||PROSPECTIVE|||||||
34170637|NCT01013129|||CASE_CONTROL||PROSPECTIVE|||||||
34170638|NCT01958996|NA|SINGLE_GROUP||TREATMENT||||||||
34170639|NCT03095079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170640|NCT02422498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170641|NCT03701139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170642|NCT00004925||||TREATMENT||||||||
34170643|NCT00713635|||COHORT||PROSPECTIVE|||||||
34170644|NCT01723423|||COHORT||PROSPECTIVE|||||||
34170645|NCT02472860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170646|NCT01026012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170647|NCT01859234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170648|NCT01507922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170649|NCT02854085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33858710|NCT04724226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170650|NCT01283555|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33858711|NCT03513874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858712|NCT06277102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858713|NCT04602377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858714|NCT03525990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33858715|NCT04209621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858716|NCT01539304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170651|NCT05563610|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34170652|NCT02251626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34170653|NCT02925897|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170654|NCT03308227|||COHORT||PROSPECTIVE|||||||
34170655|NCT00265564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34170656|NCT03211468|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34170657|NCT02118363|||CASE_CONTROL||PROSPECTIVE|||||||
34170658|NCT06237582|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170659|NCT01031719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170660|NCT06066216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170661|NCT05947188|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170662|NCT05252897|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised controlled 2 arm trial||||
33858717|NCT04386343|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and investigator are blinded to the treatment|Phase I: Three dose level - 50%, 100% and 167% of the expected dose level Phase II: Four dose level - 0% (Placebo), 50%, 100% and 167% of the expected dose level|t|f|t|f
34170663|NCT04133558|||COHORT||PROSPECTIVE|||||||
34170664|NCT05136508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170665|NCT01106599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170666|NCT04772703|||COHORT||PROSPECTIVE|||||||
34170667|NCT06301230|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170668|NCT05852834|||OTHER||CROSS_SECTIONAL|||||||
34170669|NCT04840446|||COHORT||PROSPECTIVE|||||||
34170670|NCT04643275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170671|NCT03502837|||OTHER||PROSPECTIVE|||||||
34170672|NCT01033240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170673|NCT02900794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170674|NCT02750189|||OTHER||RETROSPECTIVE|||||||
34170675|NCT06150521|||CASE_ONLY||RETROSPECTIVE|||||||
34170676|NCT01310465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170677|NCT00866177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170678|NCT03043534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34170679|NCT02936986|||COHORT||PROSPECTIVE|||||||
34170680|NCT04024917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170681|NCT05075330|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants assigned to intervention or control based on zip code of primary residence.|f|f|f|t
34170682|NCT03057496|NA|SINGLE_GROUP||OTHER||NONE|Although this is a single-arm study, participants will be masked in the sense that they will not know whether the device is operating in the active mode (intervention condition), when it gives warnings, or the silent mode (control condition), when it does not give warnings. The device will be programmed to generate a different randomized active/silent schedule for each subject. The investigator conducting the statistical analyses will also be masked as to whether the device was in the active or silent mode|The device will operate in two modes: active mode (intervention condition), when it gives warnings and, silent mode (control condition), when it does not give warnings. The device will be programmed to generate a different randomized active/silent schedule for each subject. Participants will not know whether it is in the active or silent mode.||||
34170683|NCT02267239|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34170684|NCT00325455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170685|NCT03284463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170686|NCT01547858|||OTHER||CROSS_SECTIONAL|||||||
34170687|NCT02942212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170688|NCT05256602|||COHORT||CROSS_SECTIONAL|||||||
34170689|NCT01131988|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170690|NCT01416818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170691|NCT03284177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170692|NCT03432507|||COHORT||CROSS_SECTIONAL|||||||
34170693|NCT00350025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170694|NCT03090477|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34170695|NCT05142748|||COHORT||RETROSPECTIVE|||||||
34170696|NCT06074848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170697|NCT04472663|||COHORT||OTHER|||||||
34170698|NCT04470518|RANDOMIZED|PARALLEL||OTHER||NONE|Owing to study procedures, children, their parents and physicians will not be masked to the practices' random allocation.|multicentre, cluster-randomized, parallel group pragmatic trial||||
34170699|NCT01616628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749307|NCT05317234|NA|SINGLE_GROUP||SCREENING||NONE||Patients between 2 and 17 years old, born from 34 weeks' gestation, with a diagnosis of cerebral palsy.||||
33858718|NCT01005225|||COHORT|||||||||
33858719|NCT00002151||||TREATMENT||DOUBLE||||||
33858720|NCT04682171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858721|NCT04803136|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858722|NCT01699789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33858723|NCT04071353|||COHORT||PROSPECTIVE|||||||
33858724|NCT00345930|||CASE_CONTROL||PROSPECTIVE|||||||
33858725|NCT01289171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858726|NCT01809184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858727|NCT04248270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858728|NCT00913120|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858729|NCT03920709|||CASE_CONTROL||PROSPECTIVE|||||||
33858730|NCT00225992|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33858731|NCT05946278|||COHORT||CROSS_SECTIONAL|||||||
33858732|NCT05427812|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a recommended phase 2 Dose (RP2D) is established in Phase 1, Phase 2 will be initiated for that indication. The Phase 2 design uses the Simon two-stage design with stopping rules for lack of activity, as well as stopping rules for toxicity. Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.||||
33858733|NCT01607801|||COHORT||RETROSPECTIVE|||||||
33858734|NCT04891328|||COHORT||PROSPECTIVE|||||||
33858735|NCT01315223|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858736|NCT04225702|||COHORT||PROSPECTIVE|||||||
33858737|NCT04658459|||COHORT||RETROSPECTIVE|||||||
33858738|NCT00910351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858739|NCT05292820|||COHORT||RETROSPECTIVE|||||||
33858740|NCT05286697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858741|NCT02389114|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33858742|NCT03141554|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||12 healthy volunteers will be randomized into 3 arms with 3 different treatment sequences with 4 healthy volunteers in each arm.|f|f|f|t
33858743|NCT02488889|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33858744|NCT00996112|||COHORT||PROSPECTIVE|||||||
33858745|NCT00367120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858746|NCT02725099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858747|NCT01631604||FACTORIAL||TREATMENT||||||||
33960099|NCT05472623|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study will enroll patients with newly diagnosed, biopsy-proven stage IB-IIIA NSCLC deemed surgically resectable and fit for surgery by a multidisciplinary thoracic oncology team. The study will accrue 42 patients to the following two arms sequentially:~* Arm A: oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery (21 patients)~* Arm B: oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240 mg every 2 weeks for 3 doses prior to surgery (21 patients)"||||
33960100|NCT06389968|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||sham-controlled|t|f|f|f
33960101|NCT01892020|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960102|NCT01304563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960103|NCT04179773|||CASE_CONTROL||PROSPECTIVE|||||||
33960104|NCT00149773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960105|NCT05277831|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33960106|NCT03669640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960107|NCT00835068|||COHORT||PROSPECTIVE|||||||
33960108|NCT03469440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960109|NCT04561934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The operator cannot be blinded because of the difference in operative and application procedures between control and intervention groups. The operator will blind until randomization into groups to avoid bias regarding the application of SDF to which tooth. However, the patients and assessors who carried out the radiographic assessment will be blinded of the treatment group. Finally, the treatment results will assess blindly by a statistician|eighty teeth are assigning into two equal groups of forty|t|f|f|t
33960110|NCT06270459|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a multi-site prospective clinical trial, with single-arm study design with independent assessment of outcome measures (i.e., robotic metrics, standardized outcomes, quality of life, subjective measures).||||
33960111|NCT06279676|||COHORT||PROSPECTIVE|||||||
33960112|NCT01399073|||COHORT||PROSPECTIVE|||||||
33960113|NCT06524401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960114|NCT03976349|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33960115|NCT06537258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960116|NCT02958774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960117|NCT04624750|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open-label, multi-centre, single arm, interventional, study to evaluate the safety, steady-state PK, and efficacy of mexiletine for the treatment of myotonia in paediatric population aged 6 to \< 18 years.~The study comprises a screening period of 30 days, a dose-titration period of 4 weeks, and a maintenance period of 4 weeks. After last visit, all patients will be offered follow-up in clinical study MEX-NM-303 (PIP Study 7)."||||
33960118|NCT00915473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170700|NCT04550858|||COHORT||PROSPECTIVE|||||||
34170701|NCT05896228|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33858748|NCT04328051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will not know the type of connection of his or her implant until the study has finished. Outcome Assessor will be blinded. In the radiographic evaluation the implant-abutment connection will be hidden to assess the marginal bone loss.|Active comparator: Ocean E.C.®, Avinent Implant System S.L., Santpedor, Spain. Active comparator: Ocean I.C.®, Avinent Implant System S.L., Santpedor, Spain. Active comparator: Ocean C.C.®, Avinent Implant System S.L., Santpedor, Spain.|t|f|f|t
33858749|NCT04359004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858750|NCT03310268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858751|NCT05141214|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858752|NCT05192538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858753|NCT05793177|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33858754|NCT00455273|||CASE_ONLY||PROSPECTIVE|||||||
33858755|NCT00936104|||COHORT||PROSPECTIVE|||||||
33858756|NCT05708326|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Participants will have previously completed the first arm (trial of the 16/8 intermittent fasting method), and are now invited to the second arm (the 5:2 Method), serving as their own control.|f|f|f|t
33858757|NCT00186771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858758|NCT04256330|||COHORT||PROSPECTIVE|||||||
33858759|NCT01500525|||CASE_CONTROL||PROSPECTIVE|||||||
33960119|NCT06471231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An expert nephrology consultant has been included among the investigators to assess the need for CRRT according to KDIGO criteria, and he will be blinded to the subject allocation. In addition, the physicians who will perform ultrasound evaluation will be blinded to the subject allocation, in order to reduce the potential bias of overestimating the efficacy of the study treatment.|"Patients will be divided and randomized in a 1:1 ratio through a computer-generated scheme, when the dose of norepinephrine administered is ≥ 0.25 mcg/kg/min, into the following groups:~* Group A: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.~* Group B (control): the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP."|f|f|t|f
33960120|NCT05818332|||COHORT||PROSPECTIVE|||||||
33960121|NCT05742061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960122|NCT01304875|||CASE_ONLY||CROSS_SECTIONAL|||||||
33960123|NCT02261974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960124|NCT03300830|||COHORT||PROSPECTIVE|||||||
34170702|NCT00434538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170703|NCT02864446|||COHORT||PROSPECTIVE|||||||
34170704|NCT03883256|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34170705|NCT04778735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170706|NCT03052101|||CASE_ONLY||CROSS_SECTIONAL|||||||
34170707|NCT05249023|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170708|NCT04189367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170709|NCT03153774|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|Open|||||
34170710|NCT05754294|||COHORT||RETROSPECTIVE|||||||
34170711|NCT03905096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170712|NCT03600272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One anesthetist who were not involved with clinical care or data collection performed the randomization procedure and the neuraxial block according to the group allocation. The other anesthetist blinds to the procedure preform the analgesia management after neuraxial block. This anesthetist and the obstetrician, the midwives, the patients , the outcomes collector and assessor are all blind to group allocation throughout.|Participants who request neuraxial labor analgesia are randomly assigned into two groups by a computer-generated random number table using Excel. One group received combined spinal-epidural analgesia during labor, the other group received epidural analgesia during labor.|t|t|t|t
34170713|NCT00976131|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34170714|NCT01161186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170715|NCT05480683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170716|NCT04014335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170717|NCT04467073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170718|NCT01277744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170719|NCT00297388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34170720|NCT00561652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170721|NCT01460966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749308|NCT01262651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749309|NCT01248338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858760|NCT04756960|NA|SINGLE_GROUP||OTHER||NONE||||||
33858761|NCT03054480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
33858762|NCT03602066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33858763|NCT02863887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33858764|NCT04561752|RANDOMIZED|CROSSOVER||OTHER||NONE||All participants will receive the same treatment but are randomized to one of two different treatment sequences in fed and fasted states.||||
33858765|NCT04624451|||CASE_CONTROL||PROSPECTIVE|||||||
33858766|NCT00253253|||||RETROSPECTIVE|||||||
33960125|NCT05657873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960126|NCT06540157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34063870|NCT05823467|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will randomize patients to three arms - patients will either be randomized to post operative antibiotic arm (1 week), post operative wound VAC arm (1 week), or no intervention.||||
34063871|NCT01839799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063872|NCT00181649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749310|NCT05166408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749311|NCT05972629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749312|NCT01348867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749313|NCT05652517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749314|NCT05777642|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34170722|NCT04068701|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization and double blind||t|f|f|f
34170723|NCT01021735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170724|NCT04176198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170725|NCT05260671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170726|NCT06235866|||CASE_ONLY||PROSPECTIVE|||||||
34170727|NCT04541407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase I, 3 + 3 dose escalation study of Temozolomide plus osimertinib, and temozolomide plus lorlatinib. The two drug combinations will each be examined separately in the 3 + 3 dose escalation schema to determine the MTD(Maximum tolerated dose) and RP2D(Recommended phase 2 dose).||||
34170728|NCT03588663|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|A blinded outcomes assessor will analyse all data. Participants will not be blinded from the study as they will know whether they are using the Bionic Leg in a given testing session or not.||f|f|f|t
34170729|NCT00049023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170730|NCT04905550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749315|NCT03138148|||COHORT||PROSPECTIVE|||||||
33749316|NCT04454866|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749317|NCT01859481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858767|NCT04950088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|participants didn't know if it was 'game day' or 'no game day' but were consented to fill out surveys regardless of the status of game day. Care providers provided games on game day or didn't provide games on 'no game day' but didn't have foreknowledge of which participants had consented to the study until they reached the peri-operative suite.|"Patients will be assigned into a Video Game group or a No Video Game group. All patients on any particular day will be assigned into the same group. This is done to prevent one patient from feeling disappointed after seeing another patient with a video game, and then learning they may not have one. Group assignment will alternate each day."|t|t|f|f
33858768|NCT01048567|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858769|NCT02679742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858770|NCT04100473|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, Open-Label, Cross-Over design||||
33858771|NCT03321487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960127|NCT05946382|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients are made aware of the study through information material at the primary care unit in the waiting room and on the therapists door. There they can notify the contact person about their interest. Letter with information about the study will be sent out to the interested patient. If the patient chooses to participate by answering positively on the information letter, they will be contacted by telephone by a psychologist at the respective primary care unit for the opportunity to ask questions and to book an appointment for a baseline measurement at the unit. After the baseline measurement the patient is randomly assigned to one of the treatment arms. Measurements with all self-assessment scales are carried out at week 0, at the end of treatment and 3 months after the end of treatment. The participants are then offered the opportunity for a follow-up 12 months after completion of treatment using the same scales as the 3-month follow-up.|"After assessment the participant receives either the RNT-ACT arm or the iCBT arm.~When the treatment is finished, the patient is called to an evaluation visit. If the person still needs care, we are faced with two choices. Either the patient is offered usual care and is thus removed from the three-month follow-up.Or it will wait for three-month follow up."||||
33960128|NCT05920707|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|t
33960129|NCT06462222|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33960130|NCT05307250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960131|NCT06567795|||COHORT||PROSPECTIVE|||||||
33960132|NCT06152341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960133|NCT04237779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063873|NCT02563691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063874|NCT03186989|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33749318|NCT06529107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749319|NCT00234065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749320|NCT02569580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749321|NCT06129773|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33749322|NCT05152433|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33749323|NCT04101643|NA|SEQUENTIAL||TREATMENT||NONE||||||
33858772|NCT05764109|||COHORT||PROSPECTIVE|||||||
33858773|NCT01793220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33858774|NCT03701113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A block randomised, controlled study among healthy, post-menopausal women with osteopenia receiving a milk-based protein supplement (MBPS) in the evening, or not (CONTROL), for a period of 24 weeks.||||
33858775|NCT04571281|||COHORT||PROSPECTIVE|||||||
33858776|NCT04687670|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33858777|NCT06026618|||COHORT||OTHER|||||||
33858778|NCT00231387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33858779|NCT01257789|||COHORT||PROSPECTIVE|||||||
33858780|NCT01019317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858781|NCT04629001|||COHORT||PROSPECTIVE|||||||
33858782|NCT00414128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858783|NCT04307082|NA|SINGLE_GROUP||OTHER||NONE||Open Label, single arm||||
33858784|NCT01366495|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33858785|NCT02532153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858786|NCT05913726|||COHORT||PROSPECTIVE|||||||
33858787|NCT02475174|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33858788|NCT03566810|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33858789|NCT03540953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858790|NCT05906823|||CASE_CONTROL||RETROSPECTIVE|||||||
33858791|NCT06227663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33858792|NCT00710996|||COHORT||CROSS_SECTIONAL|||||||
34170731|NCT06135961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Eligible women will be prospectively included in the cohort receiving conventional CTG monitoring. From the eligible women in the prospective cohort a random sample (90.9%) will be offered eCTG monitoring via a computer generated random collection. Participants will receive eCTG monitoring from the start of fetal monitoring during labour until 1.5 hour after delivery. A retrospective cohort of 2100 women who received conventional CTG monitoring between April 2019 and February 2023 will be added to the prospective cohort for statistical analysis.||||
34170732|NCT02690181|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170733|NCT05139043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858793|NCT01561222|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33858794|NCT02776345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858795|NCT03527914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858796|NCT03459014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33858797|NCT01496872|||COHORT||PROSPECTIVE|||||||
33858798|NCT01748487|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33960134|NCT04275232|NA|SINGLE_GROUP||TREATMENT||NONE||The patient will receive treatment with the interventional biologic product when she experiences recurrences of ligneous conjunctivitis||||
33960135|NCT00079963|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33960136|NCT06566508|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33960137|NCT05078398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960138|NCT06359756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960139|NCT04750928|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960140|NCT05474573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Tumor extent of resection will be assessed by radiologists blinded for the treatment arm||f|f|f|t
33960141|NCT05111626|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"This is a Phase 1b/3 study:~* Phase 1b (Part 1) is a single-arm open-label study, which will enroll about 20 participants~* Phase 3 (Part 2) is a randomized double-blind 2-arm study, which will enroll 508 participants"|t|f|t|f
33960142|NCT02808663|NA|SINGLE_GROUP||OTHER||NONE||||||
33960143|NCT06482437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960144|NCT01494649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960145|NCT05839028|||COHORT||PROSPECTIVE|||||||
33960146|NCT01771419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960147|NCT00002902||||TREATMENT||||||||
33960148|NCT02822807|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33960149|NCT00816517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960150|NCT01561586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960151|NCT04955873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960152|NCT02043093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960153|NCT00460252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960154|NCT03755245|NA|SINGLE_GROUP||OTHER||NONE||Whole-body distribution, plasma pharmacokinetics, radiation dosimetry, safety, tolerability and performance of \[68Ga\]Ga-DOTA-Siglec-9||||
33960155|NCT06566898|||CASE_CONTROL||OTHER|||||||
33960156|NCT00343642|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33960157|NCT06079853|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960158|NCT03233373|||OTHER||CROSS_SECTIONAL|||||||
33960159|NCT06541483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960160|NCT05357404|||OTHER||CROSS_SECTIONAL|||||||
33960161|NCT01749618|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960162|NCT03053193|||CASE_ONLY||PROSPECTIVE|||||||
33960163|NCT04701476|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label study in two indications. The mCRC cohort will be a randomized trial for TATE+Pembrolizumab versus standard 3rd line therapy for mCRC. The NSCLC cohort will be single-arm study.||||
33960164|NCT05222659|||COHORT||PROSPECTIVE|||||||
33960165|NCT02238886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170734|NCT02220257|||CASE_ONLY||PROSPECTIVE|||||||
34170735|NCT03590652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858799|NCT01176773|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33858800|NCT00059839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858801|NCT00069589|||CASE_CONTROL||PROSPECTIVE|||||||
33858802|NCT04992923|||COHORT||PROSPECTIVE|||||||
33858803|NCT01653184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858804|NCT01117857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858805|NCT04208009|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking exists due to the single-arm nature of this pilot trial.|Single group, open trial design with pre- and post-assessments.||||
33858806|NCT03890419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960166|NCT04569123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960167|NCT05683496|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-masked, placebo-controlled and open label|Up to 4 cohorts are planned, with each cohort receiving one of 5 different treatment doses|t|t|t|t
33749324|NCT03969719|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33749325|NCT05275894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960168|NCT00881452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960169|NCT01158976|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33960170|NCT01325701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960171|NCT02588742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33960172|NCT03413969|NA|SINGLE_GROUP||OTHER||NONE||||||
33960173|NCT01286207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960174|NCT05605184|||COHORT||PROSPECTIVE|||||||
33960175|NCT01818414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960176|NCT04389593|||CASE_ONLY||PROSPECTIVE|||||||
33960177|NCT06621251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960178|NCT05563584|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients randomized to Usual Care or Super Rehab plus Usual Care||||
33960179|NCT04583631|||CASE_CONTROL||PROSPECTIVE|||||||
33960180|NCT03456843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960181|NCT00752401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960182|NCT00535301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960183|NCT00874757|||COHORT||PROSPECTIVE|||||||
33960184|NCT06568133|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33960185|NCT01980082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960186|NCT02343822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960187|NCT05895214|||COHORT||PROSPECTIVE|||||||
33960188|NCT05451134|||CASE_CONTROL||RETROSPECTIVE|||||||
33960189|NCT04862052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960190|NCT02885974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960191|NCT04621097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group A : Pulsed electromagnetic field PLUS medications group B : Treadmill Training Plus Medications group C :medications only|t|f|f|f
33960192|NCT00646256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960193|NCT05764200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double-blinded||t|f|t|f
33960194|NCT05212272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960195|NCT05408728|||CASE_CONTROL||PROSPECTIVE|||||||
34170736|NCT04059510|||COHORT||PROSPECTIVE|||||||
34170737|NCT00786383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170738|NCT03554382|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization to study groups occurs after completion of informed consent, baseline assessments and questionnaires. Patients are randomly assigned in a 1:1 ratio to either the intervention group or the control group. The CONSORT-EHEALTH checklist will be followed.||||
34170739|NCT04179097|||CASE_ONLY||PROSPECTIVE|||||||
34170740|NCT02093884|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34170741|NCT03332459|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
34170742|NCT03912012|NA|SINGLE_GROUP||OTHER||NONE||||||
34170743|NCT01746368|RANDOMIZED|PARALLEL||||NONE||||||
34170744|NCT04802330|||CASE_ONLY||CROSS_SECTIONAL|||||||
34170745|NCT01029496|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34170746|NCT00936234|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34170747|NCT04608617|||CASE_CONTROL||RETROSPECTIVE|||||||
34170748|NCT02600481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170749|NCT04154436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and outcomes assessor will be masked in regards to which part of the face that the participant will receive water/sodium bicarbonate as neutralizing agent after chemical peeling|"Split Face~Left Side of the face will be given water / sodium bicarbonate as neutralizer~Right Side of the face will be given water/ sodium bicarbonate as neutralizer"|t|f|f|t
34170750|NCT05625321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170751|NCT02520726|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170752|NCT00530413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170753|NCT02166099|||CASE_ONLY||PROSPECTIVE|||||||
33960196|NCT00820183|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33960197|NCT05575128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study staff responsible for administering ratings and collecting outcomes throughout the study are blinded. The investigator(s) are also blinded. This blinding is kept throughout the study until data collection is complete. At the end of the follow-up, the study coordinator will complete a blinding question to try to guess the arm to which each participant was allocated.|Hybrid Type 1 effectiveness-implementation randomized controlled trial design|f|f|t|t
33960198|NCT05210998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960199|NCT04828629|||OTHER||PROSPECTIVE|||||||
33960200|NCT01222559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960201|NCT06672198|||CASE_ONLY||PROSPECTIVE|||||||
33960202|NCT02224300|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960203|NCT03909373|||COHORT||PROSPECTIVE|||||||
33960204|NCT03999229|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label phase I trial. Healthy young adult volunteers that would considered eligible by American Red Cross standards to donate blood will be screened by qualified practitioners for eligibility to participate in the above mentioned study. We anticipate an accrual number of 35, with subjects randomized to receive their blood (n=30) or saline (n=5) while breathing an SNO agent.||||
33960205|NCT06541730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960206|NCT03853213|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33960207|NCT00710060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33960208|NCT04118855|NA|SINGLE_GROUP||TREATMENT||NONE||Before surgery, patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.||||
33960209|NCT02177864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960210|NCT01281631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960211|NCT04348292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960212|NCT05780944|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|After each visit, three trained coders who are unaware of the experimental conditions and hypotheses of the study will score the videotaped records using an event recorder program (Observer XT, version 16; Noldus Information Technology, Heerlen, the Netherlands).||f|f|f|t
33960213|NCT05694156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960214|NCT02515461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960215|NCT06539039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||36 patients with generalized periodontitis, recruited from Ain-Shams University's outpatient clinic. Patients were divided into three groups: poorly controlled diabetes (HbA1c ≥ 7%), controlled diabetes (HbA1c \< 7%), and non-diabetic periodontitis. Full-mouth NSPT was performed, and clinical parameters (Plaque Index, Bleeding Index, Pocket Depth, Clinical Attachment Level) were assessed at baseline and eight weeks post-treatment. Venous blood samples were collected to measure TNF-α and IL-10 levels using ELISA kits.|f|f|f|t
33960216|NCT05980858|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33960217|NCT03141931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masked||t|f|t|f
33960218|NCT00774202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749326|NCT06635525|||COHORT||PROSPECTIVE|||||||
33749327|NCT06097312|||COHORT||PROSPECTIVE|||||||
33749328|NCT04682496|NA|SINGLE_GROUP||OTHER||NONE||||||
33960219|NCT03008252|||COHORT||PROSPECTIVE|||||||
33960220|NCT05614765|||CASE_ONLY||PROSPECTIVE|||||||
33960221|NCT01491282|||CASE_CONTROL||PROSPECTIVE|||||||
33960222|NCT01368757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960223|NCT04594200|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE||2x2 Pragmatic Factorial Randomized Control Trial|f|f|t|t
33960224|NCT05254093|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33960225|NCT03434808|NA|SINGLE_GROUP||OTHER||NONE||||||
33960226|NCT05673083|||COHORT||PROSPECTIVE|||||||
33960227|NCT03491228|||OTHER||PROSPECTIVE|||||||
33749329|NCT04656626|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"masking/ blindness was programmed in the system/website that was developed for this study; the participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment.~the system/ website For the sack of this study a new system was developed to be used for data collection. The system was designed as an electronic questioner with audio clips that is sent automatically to the participants' email and phones, where each participant receives their own special link.~the participants after responding to the pre intervention link will be automatically randomized by the system/website to intervention or control group.~the whole data collection and intervention process is automatic, virtual and blinded"||t|t|t|t
33749330|NCT02015676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749331|NCT05198960|RANDOMIZED|PARALLEL||PREVENTION||NONE||"AVAJAK is an academic multicenter phase 3 prospective, randomized, and open label trial.~\> Randomization of the patients: Patients corresponding to inclusion criteria will be randomized based on a 1:1 distribution.~* Experimental group (Patients allocated to receive low-dose DOAC, at the choice of the investigator)~  * Apixaban 2.5 mg BID or~ * Rivaroxaban 10 mg OD, at the choice of the investigator.~* Control group (Patients allocated to receive LDA)~  - Aspirin 100 mg OD Dispensation of treatments every 6 months for 24 months~* Stratification:~  * First stratification will be done by center~ * Second stratification will be done by pathology (PV/ET/ PreMF)~ * No stratification will be made based on DOAC drugs."||||
33749332|NCT01303900|||COHORT||PROSPECTIVE|||||||
33749333|NCT01354158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749334|NCT02539342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749335|NCT00092131|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33960228|NCT03690986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960229|NCT05920018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized after successful screening and inclusion. They will be randomized with a 1:1 ratio to receive either conjugated linoleic acid (CLA/Tonalin®) and probiotics (Vivomixx®) or the corresponding placebos as add-on therapy. Randomization will be stratified according to first-line therapy with Interferon-beta, Glatirameracetat / other glatirameroids, or Teriflunomid.|two-arm, randomized, double-blind, placebo-controlled, multicenter|t|t|t|t
33960230|NCT01770197|||CASE_CONTROL||PROSPECTIVE|||||||
33960231|NCT04648774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Nova Scotia Health (NSH) pharmacy will prepare either Ropivacaine 0.2% (2mg/ml) or normal saline in identical bags labelled as study drug such that the patient, clinical staff and the researchers are blinded to assigned group. The pharmacy will maintain the assignment list, only unmasking assignment in cases of suspected local anesthetic systemic toxicity (LAST) or allergic reactions."|A computer-generated random number will be assigned and tracked by the central pharmacy to randomize patients on a 1:1 basis to the Ropivacaine and placebo groups.|t|t|t|t
33858807|NCT03373487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Well-trained research assistants, who are conducting neuropsychological assessments, are blinded.||f|f|f|t
33858808|NCT02332109|||||PROSPECTIVE|||||||
33858809|NCT03292718|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open label, with intervention||||
34170754|NCT03531489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170755|NCT02006316|||CASE_ONLY||RETROSPECTIVE|||||||
33858810|NCT00001962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858811|NCT04700046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960232|NCT01307631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170756|NCT02568735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170757|NCT03885635|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hemiarch vs. extended arch repair in the setting of acute DeBakey type 1 aortic dissections||||
34170758|NCT05219357|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170759|NCT01140841|||COHORT||PROSPECTIVE|||||||
34170760|NCT05672329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34170761|NCT03900507|||COHORT||PROSPECTIVE|||||||
34170762|NCT04380506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170763|NCT00918385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170764|NCT02190071|||COHORT||PROSPECTIVE|||||||
34170765|NCT01476059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170766|NCT03189186|NA|SINGLE_GROUP||TREATMENT||NONE||This is a longitudinal single armed open-label trial for advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma.||||
34170767|NCT03243851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|Arm 1 : Low dose temozolomide+metformin Arm 2 : Low dose temozolomide+placebo|t|t|t|t
34170768|NCT03321357|||COHORT||PROSPECTIVE|||||||
34170769|NCT01343394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170770|NCT03274284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170771|NCT00447226|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34170772|NCT00195936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170773|NCT01479101|||CASE_ONLY||PROSPECTIVE|||||||
34170774|NCT01476423|||COHORT||PROSPECTIVE|||||||
34170775|NCT00702468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34170776|NCT03814707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|both the participants and the investigator can't be blinded only outcome assessor will be blinded .|"Parallel Assignment~* A randomized clinical trial.~* Parallel group study.~* A trial will be carried out in department of periodontology - Faculty of Oral and Dental medicine - Cairo University .~* Equal randomization : participants with equal probabilities for intervention.~* Positive controlled : Both groups receiving treatment."|f|f|f|t
34170777|NCT05075746|||CASE_ONLY||RETROSPECTIVE|||||||
34170778|NCT03622008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|double-blind study|"Subjects will receive one of the following IV treatments as a q8h infusion (90 min) regimen for 10 days:~* FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) (n=16)~* Placebo (n=4)"|t|t|t|t
34170779|NCT05366023|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34170780|NCT03422835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170781|NCT00204035|||COHORT||PROSPECTIVE|||||||
34170782|NCT05924061|||COHORT||PROSPECTIVE|||||||
34170783|NCT01342913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170784|NCT05903508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will get seperate treatment protocol and possible efforts will be put to mask the both groups about thier treatment|Its a randomized control trial,used to evaluate the comparative affect of functional task training versus functional therapy programsm on gross motor function, range of motion on, and balance in cerebral palsy children.Subject with hemiplagic Cerebral palsy (GMFCS level 1-11) meeting the predetermined inclusion and exclusion criteria will be divided into two groups using simple random sampling technique|t|f|f|f
34170785|NCT05607667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170786|NCT04042220|||COHORT||PROSPECTIVE|||||||
34170787|NCT06527014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170788|NCT02212808|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34170789|NCT06160232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Monocentric, randomized, double-blind, placebo-controlled, 1:1 parallel-group 7-month clinical trial comparing the effects of a high dose of psilocybin to those of a low dose of psilocybin (active placebo) provided within the context of a brief standardized psychotherapeutic intervention in 62 participants with severe alcohol use disorder.|t|t|t|t
34170790|NCT00797004|||COHORT||PROSPECTIVE|||||||
34170791|NCT03409614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1: Open label Part 2: Double blind||t|t|t|t
34170792|NCT03324776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170793|NCT03777943|||OTHER||PROSPECTIVE|||||||
34170794|NCT03177408|||CASE_CONTROL||PROSPECTIVE|||||||
34170795|NCT06162988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170796|NCT04607486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33960233|NCT05084209|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170797|NCT00061659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170798|NCT00689390|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170799|NCT04127721|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34170800|NCT02694744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858812|NCT06031896|||CASE_ONLY||RETROSPECTIVE|||||||
33858813|NCT01387919|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858814|NCT01681056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858815|NCT02042196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33858816|NCT04036032|||OTHER||PROSPECTIVE|||||||
33858817|NCT01179451|||COHORT||PROSPECTIVE|||||||
33858818|NCT00634010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858819|NCT03739931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858820|NCT02626754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858821|NCT02652650|NA|SINGLE_GROUP||||NONE||||||
34170801|NCT06091696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Concealed allocation will be performed by a researcher who will not be involved in the treatment of assessment. Permuted blocks will be used to ensure an equal 1:1 allocation ratio. Due to the nature of the study, the assessor and the data analyzer will be blindfolded (double-blinded)|a parallel model with 2 groups of study and control.|f|f|t|t
33858822|NCT04723186|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Sequential-Dose Escalation/De-escalation Trial||||
33858823|NCT04256434|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, sequential 2 cohort, intramuscular injection study in healthy volunteers.||||
34063875|NCT03032172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063876|NCT01294748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063877|NCT02778386|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34170802|NCT03925623|||OTHER||OTHER|||||||
34170803|NCT00455299|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34170804|NCT05901987|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749336|NCT00818857|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33749337|NCT04822220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a randomized controlled trial consisting of two groups: experimental and control.|t|f|f|f
33749338|NCT03369444|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749339|NCT02361320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749340|NCT03438123|NA|SINGLE_GROUP||OTHER||NONE||All subjects undergo baseline clinically referred routine nuclear scintigraphy imaging and sequential imaging on the CZT SPECT investigational device following a single dose of radiopharmaceutical. Some subjects will additionally undergo CT on the CZT SPECT-CT investigational device.||||
33749341|NCT00315250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749342|NCT05589051|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Tablets will be of similar appearance and provided in bottles labeled A and B|Subjects take randomly assigned condition for 4 weeks, then washout for 3 weeks before crossing over to other condition for 4 weeks.|t|f|t|f
33749343|NCT03816904|||COHORT||PROSPECTIVE|||||||
33749344|NCT06117449|||COHORT||PROSPECTIVE|||||||
33749345|NCT00901693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749346|NCT02202226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749347|NCT04798976|||COHORT||RETROSPECTIVE|||||||
33749348|NCT03008148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749349|NCT05529394|||COHORT||PROSPECTIVE|||||||
33749350|NCT04391023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749351|NCT00533377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749352|NCT02158676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749353|NCT04369092|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749354|NCT05137574|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33749355|NCT05061004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749356|NCT02243943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858824|NCT01938469|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33749357|NCT00736372|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749358|NCT06131866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A total of 8 groups, 4 intervention groups and 4 control groups|Randomised controlled trial consisting of a total of 8 groups, 4 experimental and 4 control|t|f|f|f
33858825|NCT05009745|RANDOMIZED|PARALLEL||OTHER||NONE|The participants, care providers, investigators and outcome assessors will not be masked.|Pilot phase of a prospective, allocation concealed two arm parallel RCT||||
33858826|NCT01728532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858827|NCT02652962|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33858828|NCT05247138|||OTHER||OTHER|||||||
34063878|NCT01618916|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34063879|NCT01944826|||COHORT||PROSPECTIVE|||||||
33858829|NCT02045966|NA|SINGLE_GROUP||||NONE||||||
33858830|NCT00728481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858831|NCT04186299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858832|NCT01135706|||COHORT||RETROSPECTIVE|||||||
33858833|NCT03635333|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33858834|NCT05988554|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33858835|NCT05300074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to group allocation.|Parallel Assignment|f|f|f|t
33858836|NCT01097239|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33858837|NCT02797353|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33893668|NCT03849729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded|Experimental, analytic, comparative, prospective, longitudinal and double-blinded study.|t|f|t|t
33893669|NCT05523180|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind|Randomization at 1:1 ratio for active or placebo|t|f|t|f
33893670|NCT00476138|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||||||
34063880|NCT01926197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063881|NCT03197740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063882|NCT02685072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34063883|NCT02957604|||COHORT||PROSPECTIVE|||||||
34063884|NCT04256213|NA|SINGLE_GROUP||OTHER||NONE||||||
34170805|NCT02462044|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|f|t
34170806|NCT05738135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170807|NCT05162521|||COHORT||PROSPECTIVE|||||||
34170808|NCT04555395|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34170809|NCT04634461|||COHORT||PROSPECTIVE|||||||
34170810|NCT03002961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170811|NCT03561675|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34170812|NCT00531765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170813|NCT05569434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858838|NCT04335240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A prospective randomized controlled trial will be conducted. Infants will be divided in two subgroups: an intervention group (that will undergo music therapy treatment) and a control group. To evaluate the effectiveness of the protocol, the effects of treatment in the short- and long-term period will be evaluated, with particular reference to the clinical course, the neuro-behavioral development of the premature baby and the relationship with his parents.|Prospective randomized controlled trial|t|t|t|f
33858839|NCT00701233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858840|NCT04571827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Before the treatment, it will be explained to the patient that the study seeks to observe if pain appears after the dry needling. During the explanation, the desired expectation will be introduced:~* Group with positive expectation: it is a very effective technique that achieves excellent results in the improvement of the cervical musculature~* Group with neutral expectations: It's a physical therapy technique used to treat neck pain and we're investigating its effects~* Group with negative expectation: this is a technique that will cause discomfort in the area of intervention of the cervical muscles after applying it .~Neither the subjects assigned to the groups nor the researchers who measured the variables knew which group they belonged to.~Patients will be randomly assigned through GraphPad Software's QuickCals application (La Joya, CA, USA) to one of the 3 study groups."|"Studio design:~A randomized, longitudinal, experimental, prospective, parallel and double-blind clinical trial will be carried out in which both the study subject and the researcher who made the measurements do not know which treatment group they belong to.~Participants The sample was composed of 42 healthy patients residing in the Community of Madrid, all of whom were personally recruited for the study. All of them will have 15 incisions with dry needles in the latent trigger point of the upper trapezium. All patients will read the information sheet that explains what the study will consist of, as well as the informed consent form, which they will voluntarily sign before the intervention.~Each group will be given a different sentence: one group will attempt to influence with a positive expectation, another with a neutral expectation, and yet another will attempt to influence with a negative expectation."|t|f|f|t
33858841|NCT02277405|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33858842|NCT05050253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858843|NCT03188354|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858844|NCT04777747|||COHORT||PROSPECTIVE|||||||
33858845|NCT03008447|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33858846|NCT00114192||||TREATMENT||NONE||||||
33858847|NCT04426448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized into two equal groups.|f|f|f|t
33858848|NCT02701738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858849|NCT02573454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858850|NCT01808729|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858851|NCT03837379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858852|NCT04354805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single centred, single-blinded randomised controlled trial. All subjects from a population of interest will be randomly assigned to one of two groups, one group who is exposed to the intervention or a second group who receive the routine care in the hospital.|t|f|f|f
33858853|NCT02804243|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858854|NCT01207661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893671|NCT01245244|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33960234|NCT06374121|RANDOMIZED|PARALLEL||TREATMENT||NONE||To compare the biochemical profiles of the perfusate obtained from 5 kidneys treated with perfusion and concomitant adsorption, with that of the perfusate obtained from 5 kidneys treated with perfusion without adsorption.||||
33960235|NCT05003895|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960236|NCT00396981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960237|NCT03674827|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960238|NCT02236390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960239|NCT00484588|||DEFINED_POPULATION||PROSPECTIVE|||||||
33960240|NCT06578559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960241|NCT03095963|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33960242|NCT03169660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960243|NCT03496935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960244|NCT03751319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33960245|NCT01535391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960246|NCT03884907|||COHORT||PROSPECTIVE|||||||
33960247|NCT04070599|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960248|NCT00057018|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33960249|NCT01385670|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960250|NCT03940027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The included patients were divided into two groups (stage III and stage IV) according to tumor staging, and the patients in the two groups were randomly divided into two groups for EUS-CPN treatment with ropivacaine + anhydrous alcohol regimen and bupivacaine + anhydrous alcohol regimen|t|f|f|f
33960251|NCT01545752|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33960252|NCT06542861|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33960253|NCT03496207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960254|NCT06164431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33960255|NCT05137301|||OTHER||PROSPECTIVE|||||||
33960256|NCT00320918|||COHORT||RETROSPECTIVE|||||||
33960257|NCT05515627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960258|NCT01506063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960259|NCT00766194|||COHORT||PROSPECTIVE|||||||
33960260|NCT04465916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind||t|t|t|f
33960261|NCT06138678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858855|NCT05259254|RANDOMIZED|PARALLEL||PREVENTION||NONE||Following the diagnosis of TB by physician, patients will be directed to take daily medication of antiTB drugs. Patients will be randomised to two different groups of intervention which are standard directly observed therapy (DOT) and mobile application DOT.||||
33858856|NCT04109196|NA|SINGLE_GROUP||TREATMENT||NONE||All participants who are eligible for this study will receive a 5 day PTSD treatment.||||
33858857|NCT00221195|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33858858|NCT03099200|||COHORT||CROSS_SECTIONAL|||||||
34170814|NCT05010811|||CASE_ONLY||RETROSPECTIVE|||||||
34170815|NCT05721495|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The study arm is masked until the oocyte recovery date, when we have to give a date in the control arm for the embryo transfer.|Randomized clinical trial with two parallel arms|t|t|t|t
34170816|NCT02866058|||COHORT||RETROSPECTIVE|||||||
34170817|NCT01308736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170818|NCT05342961|RANDOMIZED|PARALLEL||OTHER||NONE|During the study, it is difficult for researchers, operators and patients to blind the method due to objective reasons.|||||
34170819|NCT05405010|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34170820|NCT02680522|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34170821|NCT01402440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749359|NCT06385808|NA|SINGLE_GROUP||TREATMENT||NONE||The relapsed or refractory acute myeloid leukemia patients will pretreated with the MTBF regimen prior to salvageable allogeneic hematopoietic stem cells. The one-year recurrence-free survival after transplantation of these patients and the safty of the MTBF regimen will be studied.||||
33749360|NCT05122039|||COHORT||PROSPECTIVE|||||||
33858859|NCT00298909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858860|NCT05424913|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858861|NCT04326127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33858862|NCT00002997||||TREATMENT||||||||
33858863|NCT01208441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858864|NCT06186453|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33858865|NCT05548751|||CASE_ONLY||OTHER|||||||
33960262|NCT04707066|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Sequential, multiple assignment, randomized trials (SMART) design|f|f|f|t
33960263|NCT06514209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960264|NCT01106118|||COHORT||PROSPECTIVE|||||||
33960265|NCT03706274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960266|NCT02368769|||CASE_CONTROL||PROSPECTIVE|||||||
33960267|NCT03367273|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960268|NCT03567239|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants provide feedback of adaptive device they are provided. They, their caregiver, the investigator, and research staff are aware of all phases of the study.|Participants receive adaptive device and provide feedback.||||
33960269|NCT05810181|||COHORT||PROSPECTIVE|||||||
33960270|NCT04045600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960271|NCT00105352|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34170822|NCT04277949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170823|NCT02907034|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34170824|NCT03599206|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34170825|NCT00664547||PARALLEL||TREATMENT||||||||
34170826|NCT02987127|||CASE_ONLY||PROSPECTIVE|||||||
34170827|NCT03913858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34170828|NCT00317473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34170829|NCT05753410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170830|NCT03257761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170831|NCT05265975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170832|NCT05983419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170833|NCT01356160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170834|NCT02559011|||COHORT||PROSPECTIVE|||||||
34170835|NCT02629029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170836|NCT00871910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170837|NCT01478971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170838|NCT00855959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170839|NCT02867410|||||RETROSPECTIVE|||||||
34170840|NCT04349072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a parallel group treatment study with 2 treatment groups; subjects and investigators are blinded to treatment and dose for the first 16 weeks of treatment. Mavacamten dose is blinded throughout the study.|t|t|t|t
33960272|NCT01457729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960273|NCT00949572|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960274|NCT05031962|||CASE_ONLY||PROSPECTIVE|||||||
33960275|NCT01738009|NA|SINGLE_GROUP||OTHER||NONE||||||
33960276|NCT05643131|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|Prospective observational pre/post repeated-measures pilot intervention study||||
33960277|NCT06232369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960278|NCT03575611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960279|NCT05854173|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960280|NCT05037175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960281|NCT04208529|NA|SINGLE_GROUP||OTHER||NONE||Long Term Safety Follow-up||||
33960282|NCT06541821|||CASE_CONTROL||PROSPECTIVE|||||||
33960283|NCT06512389|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Within-subject randomized double-blind placebo controlled crossover trial|t|t|t|t
33960284|NCT05048745|||COHORT||PROSPECTIVE|||||||
33960285|NCT01339000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960286|NCT06472375|||OTHER||PROSPECTIVE|||||||
33960287|NCT03596879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960288|NCT06565806|||COHORT||PROSPECTIVE|||||||
33960289|NCT06340971|||COHORT||OTHER|||||||
33960290|NCT01836003|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960291|NCT02151162|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33960292|NCT05686317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33858866|NCT03057977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858867|NCT04291352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both taurine and placebo powder inside the capsules are a white crystalline, odorless powder. The powder is loaded into clear, vegetarian, odorless capsules. Placebo and Investigational Product capsules will be packaged in 500 cc HDPE bottles.|Prospective, double-blind, randomized control trial. Subjects are randomized to receive either taurine or placebo in addition to their standard chelation regimen for a 12 month period.|t|t|t|f
33858868|NCT05519397|||CASE_ONLY||PROSPECTIVE|||||||
33858869|NCT00217529||||TREATMENT||||||||
33960293|NCT00457418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960294|NCT06442930|||COHORT||PROSPECTIVE|||||||
33960295|NCT01396161|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33960296|NCT04152252|||COHORT||PROSPECTIVE|||||||
34063885|NCT06182384|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is a single-center, randomized, open-label, two-period, and two-sequence crossover design trial, consisting of two sequences (sequence A and sequence B) and two periods (first period and second period). Each sequence receives a same dose of SHR-1314 at every period.||||
34063886|NCT01761305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063887|NCT00421317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063888|NCT00669019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063889|NCT06730737|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Clinical Trial of Interactive Preventive Video Education||||
33749361|NCT05490615|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33749362|NCT06266338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858870|NCT02901041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858871|NCT02608281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858872|NCT05264428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33858873|NCT01110811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858874|NCT01298518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858875|NCT05798897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858876|NCT04487574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo.||t|f|t|f
33858877|NCT03823560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomised, double-blind, parallel groups, multicentric, placebo-controlled, prospective clinical study|t|t|t|t
33858878|NCT03295656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170841|NCT05243875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This is a two-arm study in which participants are randomized to an experimental (navigator) or comparison (education only) group.|t|f|f|f
34170842|NCT05208905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170843|NCT06090604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170844|NCT04458155|||COHORT||RETROSPECTIVE|||||||
34170845|NCT03315741|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 1, non-randomized, single arm, open label, single center clinical trial to determine the tolerability and safety of pirfenidone in patients with BOS associated with lung GVHD after hematopoietic cell transplant (HCT). Approximately 30 patients will be enrolled. All patients will follow the 'patient-centered' drug titration approach.||||
34170846|NCT00453154|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34170847|NCT00172146|||CASE_CONTROL||OTHER|||||||
34170848|NCT00624949|||COHORT||PROSPECTIVE|||||||
34170849|NCT03636074|||CASE_CONTROL||PROSPECTIVE|||||||
34170850|NCT00168441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34170851|NCT06368102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858879|NCT05928130|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33858880|NCT00010972|RANDOMIZED|||TREATMENT||||||||
33858881|NCT01306955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170852|NCT03812380|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|To provide adequate blinding, each medication sachet will be labelled with the study name, IRB number, principal investigator's name, expiration date and identification number of the study subject. Labels will be applied to the appropriate medication sachets once the subject has been randomized and assigned to a treatment group. Labelling of the sachets will be done by personnel who are not engaged in patient care.||t|t|t|t
33858882|NCT04725825|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33960297|NCT04178018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960298|NCT05383976|||COHORT||PROSPECTIVE|||||||
33960299|NCT01692639|||CASE_ONLY||PROSPECTIVE|||||||
34063890|NCT04849533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063891|NCT00659776|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063892|NCT04104594|NON_RANDOMIZED|PARALLEL||OTHER||NONE||control and patients||||
34170853|NCT02289664|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170854|NCT06527339|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two intervention groups will be generated for the study:~* One group will receive conventional dry needling treatment. The needle will be inserted into the myofascial trigger point (MTrP) using the quick in-and-out technique described by Hong (1994), with an approximate frequency of 1 insertion per second (1 Hz), without fully withdrawing the needle from the skin. This technique will be maintained for 30 seconds, aiming to produce a local twitch response. At the conclusion of the technique, firm compression with cotton will be applied to the treated area for three seconds.~* The other group will receive dry needling + vibration. In this case, no movements will be made with the needle after it is correctly inserted. Instead, vibratory stimulation will be applied to the needle for 10 minutes. Since this is a completely novel technique, the optimal application time is not yet established; however, 10 minutes is considered sufficient duration to observe an effect."||||
34170855|NCT04264858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170856|NCT02542657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960300|NCT01550042|||COHORT||PROSPECTIVE|||||||
33960301|NCT01976663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960302|NCT00392717|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33960303|NCT02494947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960304|NCT02525562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960305|NCT05536817|||COHORT||PROSPECTIVE|||||||
33960306|NCT02426827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960307|NCT05116631|||CASE_ONLY||PROSPECTIVE|||||||
33960308|NCT06063499|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960309|NCT04483427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960310|NCT05727592|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional study: parallel, single and non-blinded study.||||
33960311|NCT02741752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960312|NCT00887107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063893|NCT04482036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The principal investigator will be masked to arm allocation of participants. The outcomes assessor at time of 3 month and 6 month (final) assessment will also be masked to the allocation of participants.|The study design includes six 1-month periods. Those in the intervention group will be nested in a 2 x 6 cross-over design in which they will be randomly assigned to start with 1 of 2 schedules of Ecological Momentary Assessment (EMA) surveillance frequency (1) weekly or (2) monthly. The intervention participants will then cross-over at the end of each and every month to the other surveillance frequency condition, over a 6-month time horizon.|f|f|t|t
34170857|NCT05294926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||randomized double blinded clinical trial|t|t|f|t
34170858|NCT04319367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34170859|NCT05260047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170860|NCT06040411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician was blinded to analyze the data.|Prospective, parallel, randomized controlled clinical trial|f|f|f|t
34170861|NCT02892994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34170862|NCT01102335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170863|NCT05392608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170864|NCT06021314|||OTHER||PROSPECTIVE|||||||
34170865|NCT00546624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34170866|NCT02656277|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34170867|NCT02962258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34170868|NCT04077021|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34170869|NCT05851716|||OTHER||PROSPECTIVE|||||||
34170870|NCT03936998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a single-center, randomized, double-blind trial with four arms evaluating VE416 as pretreatment or concurrent treatment in comparison to low-dose peanut oral immunotherapy (PNOIT) alone.|t|t|t|t
34170871|NCT00908453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170872|NCT01636765|||CASE_ONLY||PROSPECTIVE|||||||
34170873|NCT03656003|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34170874|NCT00721006|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34170875|NCT04808817|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34170876|NCT04687306|||OTHER||OTHER|||||||
34170877|NCT01018030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170878|NCT00252421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170879|NCT05411718|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34170880|NCT06085534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170881|NCT02655185|||COHORT||RETROSPECTIVE|||||||
34170882|NCT03296514|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34170883|NCT02849379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749363|NCT00062127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749364|NCT06665763|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The study will be carried out as a single-blinded, randomized cross-over clinical investigational trial.|t|f|f|f
33749365|NCT01260220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749366|NCT06097468|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749367|NCT04010994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749368|NCT01692392|||COHORT||PROSPECTIVE|||||||
33749369|NCT00456638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33749370|NCT04018209|||COHORT||PROSPECTIVE|||||||
33749371|NCT05428735|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 Randomization between control and interventional group||||
33749372|NCT02978027|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33749373|NCT05615792|||COHORT||PROSPECTIVE|||||||
33749374|NCT06482281|||COHORT||RETROSPECTIVE|||||||
33749375|NCT04608370|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33749376|NCT05428566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33749377|NCT04003116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749378|NCT06145542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960313|NCT06539494|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2x 11 participants will be given the same intervention (omeprazol daily)||||
33960314|NCT00155259|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960315|NCT05931952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960316|NCT06617013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170884|NCT04227470|NA|SEQUENTIAL||TREATMENT||NONE||Dose exploration study. Two dose groups (340 mg and 680 mg) were planned, 6 subjects at most for 340 mg group and 6 to 12 subjects for 680mg group. Each subject will only participate in one dose group. Escalation to the next dose level decided by PIs and sponsor after evaluating safety data and PD data for lower dose group.||||
34170885|NCT01931540|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34170886|NCT05416138|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34170887|NCT04345341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170888|NCT04761263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||two different groups received different interventions at the same time|t|f|t|t
33749379|NCT03774628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749380|NCT01436058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858883|NCT04490733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33858884|NCT01163721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33858885|NCT03197363|||COHORT||PROSPECTIVE|||||||
33858886|NCT03130543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858887|NCT06138340|||COHORT||PROSPECTIVE|||||||
33858888|NCT02905760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858889|NCT01004380|NA|SINGLE_GROUP||||NONE||||||
33858890|NCT02580955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858891|NCT01603186|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960317|NCT02696525|||CASE_ONLY||PROSPECTIVE|||||||
33960318|NCT00005609||||TREATMENT||||||||
33960319|NCT04075045|RANDOMIZED|PARALLEL||PREVENTION||NONE||Approximately 500 participants will be randomized into four groups (n=125 per group). Some groups will receive the Wellth app providing reminders and regimen tracking, and some groups may have the opportunity to earn financial rewards for their adherence.||||
33960320|NCT02040207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960321|NCT06417203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|for patient - closed envelope system for Outcomes Assessor - will not participate perioperative period and will not know group of patients|"two gropus planned for study~1. group - Hyperbaric spinal anesthesia~2. group - Hypobaric spinal anesthesia"|t|f|f|t
33960322|NCT04212741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960323|NCT06351670|||CASE_ONLY||PROSPECTIVE|||||||
33749381|NCT05624658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients who did not reach the target LDL-C values 1 month after the development of ACS on the 2nd visit will be randomized into two groups of 60 patients each. Group 1 - taking PCSK9 inhibitors while taking Atorvastatin at a dose of 80 mg / day. Group 2 - receiving Ezetimibe at a dose of 10 mg in combination with Atorvastatin 80 mg / day. Also, on the 2nd visit, patients will undergo CCTA, an assessment of the CAVI index and a laboratory tests (blood count, lipid profile, ALAT, ASAT, Troponin I, Galectin -3, MMP -9, TIMP -1, high-sensitivity CRP, NGAL ). Every 3 months a visit is planned according to the schedule to monitor the effectiveness (blood count, ALAT, ASAT, lipid profile). Follow-up period will be 52 weeks, according to the schedule of visits. At the final visit, patients will undergo CCTA, assess the CAVI index and laboratory tests (blood count, lipid profile, Troponin I, Galectin-3, MMP-9, TIMP-1, high-sensitivity CRP, NGAL).|f|f|t|f
33749382|NCT00563108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33749383|NCT01452750|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749384|NCT04788758|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33749385|NCT05121753|||CASE_ONLY||OTHER|||||||
33749386|NCT00970034|||COHORT||PROSPECTIVE|||||||
33749387|NCT02265042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749388|NCT01457365|||COHORT||CROSS_SECTIONAL|||||||
33749389|NCT00937924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33960324|NCT01992068|||CASE_ONLY||PROSPECTIVE|||||||
33960325|NCT05284474|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34063894|NCT02174575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34063895|NCT01126008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063896|NCT05817500|||COHORT||PROSPECTIVE|||||||
33749390|NCT01435538|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34063897|NCT00677859|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34063898|NCT00372047|||||RETROSPECTIVE|||||||
34063899|NCT03965455|||COHORT||RETROSPECTIVE|||||||
33749391|NCT04067466|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33749392|NCT03297788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749393|NCT04897165|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749394|NCT05265468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33749395|NCT01745432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749396|NCT03695497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749397|NCT00057096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749398|NCT02409134|||COHORT||PROSPECTIVE|||||||
34063900|NCT02865200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34063901|NCT01879033|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749399|NCT05560672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749400|NCT02151279|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33749401|NCT03438162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749402|NCT01787617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33749403|NCT02323971|||CASE_ONLY||PROSPECTIVE|||||||
33749404|NCT04593446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749405|NCT02982252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749406|NCT03819491|RANDOMIZED|PARALLEL||OTHER||NONE||To evaluate the best dosage between 100 mg OD or 100 mg BID for COQUN ORAL FORMULATION in order to reach a level of plasma concentration which might assure its antioxidant effect if taken on a regular basis.||||
33858892|NCT00529022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858893|NCT05848505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858894|NCT01929980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858895|NCT01868139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858896|NCT01834196|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33858897|NCT06258330|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation||||
33858898|NCT01080287|||COHORT||PROSPECTIVE|||||||
33858899|NCT02775669|||COHORT||PROSPECTIVE|||||||
33893672|NCT03560362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893673|NCT04836286|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||ABAB design||||
33749407|NCT04059263|||COHORT||PROSPECTIVE|||||||
33749408|NCT00715546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749409|NCT04870216|||OTHER||CROSS_SECTIONAL|||||||
33749410|NCT05789043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749411|NCT03932448|||CASE_ONLY||PROSPECTIVE|||||||
33749412|NCT04817553|||COHORT||RETROSPECTIVE|||||||
33749413|NCT03581721|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749414|NCT03325712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33749415|NCT03812133|||COHORT||RETROSPECTIVE|||||||
33749416|NCT01650753|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33749417|NCT01233791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749418|NCT04838743|||COHORT||PROSPECTIVE|||||||
33749419|NCT05628324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2-arm randomized controlled trial|t|f|f|t
33749420|NCT03382496|||COHORT||PROSPECTIVE|||||||
33749421|NCT01453595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749422|NCT05309304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749423|NCT02269670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749424|NCT05252767|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33749425|NCT00928577|||COHORT||PROSPECTIVE|||||||
33749426|NCT01225718|||CASE_ONLY||RETROSPECTIVE|||||||
33749427|NCT01371851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749428|NCT06411457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749429|NCT02750111|||COHORT||PROSPECTIVE|||||||
33749430|NCT04325750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33858900|NCT05609409|NA|SINGLE_GROUP||TREATMENT||NONE||"Noncurrent Multiple Baseline Experimental Design where subjects will serve as their own control.~Participants will be randomized to different baseline durations."||||
33858901|NCT05882253|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Patients who have agreed to undergo an MRI and subsequent prostate needle biopsy will be approached to participate in the trial. The patient will undergo the prostate MRI as standard of care. The OnQ Prostate will be acquired at the same time as the standard of care MRI at no additional cost to the subject. The MRI images will be acquired using MRI equipment manufactured by 3 different companies, depending on which facility they have their imaging performed.||||
33858902|NCT01067157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858903|NCT01410136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858904|NCT03499197|||COHORT||PROSPECTIVE|||||||
33858905|NCT03113253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858906|NCT05938309|||COHORT||PROSPECTIVE|||||||
33858907|NCT06461403|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 randomization||||
33858908|NCT00915733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858909|NCT05428033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858910|NCT05861154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33858911|NCT00683566|NA|SINGLE_GROUP||||NONE||||||
33858912|NCT00031187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858913|NCT06475573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858914|NCT00984425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858915|NCT01175356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858916|NCT04656509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858917|NCT02546895|||COHORT||PROSPECTIVE|||||||
33858918|NCT01572870|||COHORT||PROSPECTIVE|||||||
33749431|NCT05836766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749432|NCT02568241|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749433|NCT05060328|||COHORT||PROSPECTIVE|||||||
33749434|NCT00796081|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749435|NCT05510843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33749436|NCT02049086|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33749437|NCT03204097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749438|NCT02263651|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33749439|NCT04320160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33749440|NCT05974696|||COHORT||PROSPECTIVE|||||||
33749441|NCT02245152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858919|NCT00298454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33858920|NCT04716530|||CASE_CONTROL||RETROSPECTIVE|||||||
33858921|NCT02949089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858922|NCT05708625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858923|NCT04452487|||CASE_CONTROL||PROSPECTIVE|||||||
33858924|NCT01859780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33858925|NCT03082131|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators will be blinded to the type of product (i.e. RS wheat or Regular Wheat) the subjects are consuming during each arm of the study.|Randomized, cross-over design consisting of two 1-week dietary intervention periods as well as a 2-week washout period in between|t|f|t|f
33858926|NCT01354171|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858927|NCT00863967|||COHORT||PROSPECTIVE|||||||
33858928|NCT04525482|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33858929|NCT01067326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749442|NCT05315193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749443|NCT01388816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749444|NCT00717990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749445|NCT05598190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749446|NCT00291785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749447|NCT05312138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749448|NCT04883632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be randomized to receive products from one of 2 productions sites. (C1 and HQ, respectively); as the products appear in an identical fashion only the batch numbers will allow identification of the production site; as the allocation of batch numbers to the respective site is not disclosed to the study site team, the entire team will be masked until break of blind|prospective, randomized, double-blind, parallel-group, multi-center study|t|f|t|t
33858930|NCT00979433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858931|NCT01013285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858932|NCT00243750|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33960326|NCT05730088|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The Effect of Post-Discharge Multiple Nursing Interventions on the Number of Hospital Admissions, Dyspnea Level, and Quality of Life in COPD Patients Receiving Home Oxygen Therapy: A Randomized Controlled Study|t|f|f|t
33858933|NCT02215538|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33858934|NCT02340091|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||split-face design study. Subjects were decided by randomization which side of the face would be injected with the test device. According to this randomization result, the other side would be determined to be injected with a comparator. It was determined just by one randomization.|t|f|f|t
33858935|NCT05083338|||COHORT||PROSPECTIVE|||||||
33858936|NCT00711529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960327|NCT03283007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858937|NCT05330338|NA|SINGLE_GROUP||OTHER||NONE||600 participants (150 single cases and 150 trio families)||||
33858938|NCT00664807|||CASE_CONTROL||PROSPECTIVE|||||||
33858939|NCT04359875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Cluster randomized trial with 2 subtrials : COVIQuest_CV and COVIQuest_MH.~COVIQuest_CV involves patients ≥ 70 years old suffering from chronic cardiovascular disease; and COVIQuest_MH involves patients suffering from a mental health disease.~As a note, both sub-trials are two-parallel group cluster randomized trials. Clusters will be defined as practices. Practices will be randomized into two groups A and B. For practices in group A: their CV patients constitute the experimental group for the COVIQuest_CV trial, their MH patients constitute the control group for the COVIQuest_MH trial. For practices in group B: their CV patients constitute the control group for the COVIQuest_CV trial, their MH patients constitute the experimental group for the COVIQuest_MH trial."||||
33858940|NCT02587429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33858941|NCT03105531|||COHORT||PROSPECTIVE|||||||
33858942|NCT05167123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the outcome assessor were blinded. The primary investigator blinding was impossible|Simple parallel randomization was performed by using computerized random numbers|t|f|f|t
33858943|NCT00733213|||CASE_ONLY||RETROSPECTIVE|||||||
33858944|NCT04003857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33858945|NCT05633732|||OTHER||PROSPECTIVE|||||||
33858946|NCT00198952|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33858947|NCT00292461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858948|NCT05057286|NA|SINGLE_GROUP||TREATMENT||NONE||Participants were recruited from patients who came for chief complaint of excess gingival display at the Dental Clinic of the Faculty of Odonto-stomatology, University of medicine and Pharmacy at Ho Chi Minh City. The study population included patients aged from eighteen years with an average length of excessive gingival display ≥ of 4 mm when maximum smiling (counted eight teeth, from the 14 to the 24 teeth) and the height of keratinized gingiva ≥ 3 mm.||||
33858949|NCT01813851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858950|NCT00827801|||CASE_ONLY||PROSPECTIVE|||||||
33858951|NCT01804725|||CASE_ONLY||CROSS_SECTIONAL|||||||
33858952|NCT01319214|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33858953|NCT01509131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858954|NCT05059834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858955|NCT00820027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858956|NCT00212628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33858957|NCT05373953|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858958|NCT02656160|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33858959|NCT06152861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858960|NCT02496910|RANDOMIZED|CROSSOVER||||NONE||||||
33858961|NCT02262923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858962|NCT04508634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||laparoscopic sleeve gastrectomy||||
33858963|NCT05900960|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33858964|NCT02496520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858965|NCT00225576|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33858966|NCT04805554|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33858967|NCT03313453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation of intervention arm and scoring of symptom and medication scire will be performed by a designated unblinded member of the study staff (i.e. a qualified person who is independent of the protocol-defined study assessments). Once prepared, active air-cleaner and mock device will be identical in appearance. The blinding of all those involved in the evaluation of the study treatment (e.g. physician/nurse as well as the subject) shall be maintained at all times.||t|t|t|t
33858968|NCT03035266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators recording thigh girth and isokinetic data will be blinded to group assignment.|This is a prospective, randomized control trial. After consenting, subjects will be randomized to one of two groups by using a computer generated random number.|f|f|t|t
33858969|NCT02441062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33858970|NCT05217563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel arm design|f|f|f|t
33960328|NCT03375996|||CASE_ONLY||PROSPECTIVE|||||||
33960329|NCT00168740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960330|NCT05188027|NA|SINGLE_GROUP||OTHER||NONE||||||
33858971|NCT01969318|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33858972|NCT04331353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33858973|NCT00516451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960331|NCT05479760|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960332|NCT00629629|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33960333|NCT02677402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960334|NCT03628001|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960335|NCT04506346|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33960336|NCT00296829|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33960337|NCT00254488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960338|NCT03001869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960339|NCT02238470|||COHORT||PROSPECTIVE|||||||
33749449|NCT03827954|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, open label, pilot clinical trial to examine feasibility and initial efficacy of the HeartMapp+CT (HeartMapp and computerized plasticity-based adaptive cognitive training).||||
34170889|NCT02804334|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749450|NCT01655030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749451|NCT05795582|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749452|NCT00827450|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34170890|NCT05539885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170891|NCT03224130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34170892|NCT00867581|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749453|NCT01027546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749454|NCT04013711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170893|NCT01575821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33749455|NCT05668728|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 GROUPS DİFFERENT TYPES OF DRY NEEDLİNG||||
34170894|NCT00057863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170895|NCT06411639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170896|NCT06343246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective Randomized Controlled Study|t|f|f|t
34170897|NCT01403623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170898|NCT00826644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749456|NCT00653640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749457|NCT02276846|||||PROSPECTIVE|||||||
33749458|NCT05292768|||COHORT||PROSPECTIVE|||||||
33749459|NCT04361929|||COHORT||PROSPECTIVE|||||||
34170899|NCT04777617|||COHORT||PROSPECTIVE|||||||
34170900|NCT00006269||||SUPPORTIVE_CARE||||||||
33749460|NCT00205569|||COHORT||PROSPECTIVE|||||||
33749461|NCT00512395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749462|NCT02552004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749463|NCT02676167|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33749464|NCT05314439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749465|NCT02866890|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34063902|NCT00222222|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749466|NCT03044301|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749467|NCT03910868|||CASE_ONLY||PROSPECTIVE|||||||
33749468|NCT01994174|||COHORT||PROSPECTIVE|||||||
33749469|NCT05978531|||CASE_ONLY||PROSPECTIVE|||||||
33749470|NCT05369975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open-label, non-randomised trial in highly sensitized adult kidney transplant patients with positive XM against an available deceased donor.~The rational for a non-randomised trial is that no other effective or approved desensitization protocol exists in deceased-donor kidney transplantation that would provide a suitable control.~A non-comparative concurrent reference cohort from participating sites will be included to address differences in-site practice and experience.~A non-comparative historical reference cohort from the CTS registry will be included to address the outcome in a less sensitized patient group."||||
33749471|NCT01786512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749472|NCT02732418|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749473|NCT00172978|||DEFINED_POPULATION||OTHER|||||||
33749474|NCT05160051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single application of 68Ga-68-FAPI-46 PET/CT imaging to detect tumour tissue in patients with newly diagnosed or recurrent cancer||||
33749475|NCT01662310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749476|NCT06309953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749477|NCT04210817|||CASE_ONLY||PROSPECTIVE|||||||
33749478|NCT01009268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749479|NCT00277667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34063903|NCT01766232|||||PROSPECTIVE|||||||
34063904|NCT04956627|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34063905|NCT01210144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170901|NCT04696081|||COHORT||PROSPECTIVE|||||||
34170902|NCT04831866|||OTHER||PROSPECTIVE|||||||
34170903|NCT02407223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170904|NCT01772446|RANDOMIZED|PARALLEL||||NONE||||||
34170905|NCT04566471|||COHORT||RETROSPECTIVE|||||||
34170906|NCT02414815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170907|NCT01562808|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34170908|NCT00323141|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170909|NCT01302483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34170910|NCT01590264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170911|NCT03762876|||COHORT||PROSPECTIVE|||||||
34170912|NCT01254253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170913|NCT01500772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170914|NCT00639197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34170915|NCT01532947|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34170916|NCT05512754|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization into two groups between Group A (No NSAIDs) or Group B (Ibuprofen 400 mg q 8 h for 10 days)||||
34170917|NCT04590014|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This trial is non-blinded by necessity, as there are distinct differences in size and appearance between the new and current HVNI device designs.|||||
34170918|NCT01112137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170919|NCT03761927|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34170920|NCT04589858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm parallel groups randomized clinical trial|t|f|f|t
34170921|NCT01404169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170922|NCT01895075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170923|NCT06050317|NA|SINGLE_GROUP||TREATMENT||NONE||Sintilimab Plus Chemotherapy and Radiotherapy||||
34170924|NCT01344265|||COHORT||PROSPECTIVE|||||||
34170925|NCT04301375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170926|NCT05007613|NA|SINGLE_GROUP||TREATMENT||NONE||cabozantinib and atezolizumab||||
34170927|NCT00522522|||||RETROSPECTIVE|||||||
34170928|NCT01512199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749480|NCT00737126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749481|NCT04528511|||COHORT||PROSPECTIVE|||||||
33749482|NCT00091312|RANDOMIZED|||TREATMENT||||||||
33749483|NCT01733004|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749484|NCT00441610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170929|NCT05164393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170930|NCT02259673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34170931|NCT02319200|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34170932|NCT01259817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170933|NCT00474955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170934|NCT02546232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170935|NCT00240058|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34170936|NCT03106571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170937|NCT04578275|||COHORT||PROSPECTIVE|||||||
34170938|NCT02413918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170939|NCT05274607|||COHORT||PROSPECTIVE|||||||
34170940|NCT06524102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Access to the data was restricted to the study investigators, health authorities and ISABIAL advisory bodies, when necessary, to check the study data and procedures, but always maintaining confidentiality.~The data collected for the study was identified by a code, so that no information that could identify the participants was included, and only the researchers were able to link the anonymized data to the clinical history."|"A total of 10 couples with no previous children in common, negative serology and normal karyotype were included. Females were aged less than 40 years and males less than 50 years at the time of treatment.~The semen sample of each couple was capacitated by density gradient centrifugation (DGC) and swim up, forming the control group. An aliquot was taken that was destined to pass through the annexin columns (MACS® ART, Miltenyl Biotic GmbH, Germany) constituting the study group. The oocytes obtained in each of the couples were pseudo-randomized and inseminated by ICSI with sperm from the study group and the control group. All couples benefited from the experimental treatment since they had the opportunity to inseminate their oocytes with sperm from both groups, thus excluding treatment bias or asymmetry."|t|t|f|t
34170941|NCT01848665|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34170942|NCT00981149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170943|NCT04072926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each of the two main groups are divided to two subgroups.|t|f|f|f
34170944|NCT03476200|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34170945|NCT03512834|NA|SINGLE_GROUP||TREATMENT||NONE||Paclitaxel + Avelumab||||
34170946|NCT05582486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170947|NCT02682953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170948|NCT00543257|||COHORT||CROSS_SECTIONAL|||||||
33749485|NCT04027556|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33749486|NCT03789266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|patient will not know which technique will be used for drain ablation||t|f|f|f
33749487|NCT05627180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The main researcher and PhD candidate will be blinded to the randomizing procedure. However, in this project, it is not feasible to blind the participants, HCPs or PhD candidate to the participants' group. The participants will be randomized right after the first assessment.|Randomized controlled trial|f|f|t|f
33749488|NCT05164744|||COHORT||PROSPECTIVE|||||||
33749489|NCT06418633|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a single-center, prospective, cross-sectional, proof-of-concept study,||||
33749490|NCT03071692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749491|NCT05808387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants in the control group will receive capsules identical to those in the intervention group, but with cornstarch.~The care provider and the participants do not have the information about which capsules the participant is taking, and do not have access to which groups the patients belong. Statistical analyses will be performed on a blinded database, i.e. without information of which groups the participants belong to.~Only the principal investigator of the study has this information."|Double blind randomized controlled trial, parallel and placebo-controlled.|t|t|f|f
33749492|NCT04303897|||CASE_ONLY||OTHER|||||||
33749493|NCT06427772|||COHORT||PROSPECTIVE|||||||
33858974|NCT02537626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858975|NCT04637477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170949|NCT05833958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170950|NCT01810484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34170951|NCT00627822|||||CROSS_SECTIONAL|||||||
34170952|NCT06136949|||COHORT||PROSPECTIVE|||||||
34170953|NCT04745364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This study uses a waitlist control design. The call for participants will be included in the Good Life Center newsletters sent the week of February 8th (if possible) and February 15th. Students will register by 11:59 pm on Friday, February 19th . If they are eligible, within the registration survey, participants will then progress to baseline assessments of stress, well-being, mindful awareness, cultural competence, and feelings of connectedness to the Yale community. Participants will be randomly assigned to either Session One or Session Two."||||
34170954|NCT06129526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33749494|NCT04788550|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1 The participants in group one will act as control group as they will be advised in using fluoridated toothpaste to brush twice daily during the follow up periods~Group 2 The participants in this group will received fluoride varnish (5% sodium fluoride) treatment~Group 3 The participants will be advised to use pea size CPP-ACP plus crème (900ppm fluoride)"||||
33749495|NCT03303157|||CASE_ONLY||PROSPECTIVE|||||||
33749496|NCT00074282|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749497|NCT06257069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749498|NCT02007291|||OTHER||PROSPECTIVE|||||||
33749499|NCT06535971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749500|NCT02284438|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33749501|NCT00594269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749502|NCT02580565|||CASE_CROSSOVER||PROSPECTIVE|||||||
33749503|NCT05736718|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cluster randomized design in which clinics will be randomized within healthcare systems||||
33749504|NCT01227889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33749505|NCT05197335|||COHORT||PROSPECTIVE|||||||
33749506|NCT01756092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749507|NCT01024569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33749508|NCT00568529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749509|NCT01603069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749510|NCT01694303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33749511|NCT04838899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749512|NCT01087008|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749513|NCT06265103|||COHORT||PROSPECTIVE|||||||
33749514|NCT05450848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Site investigators will load the digital photographs taken at each weekly assessment into each participant's MOSAIQ record. They will then send de-identified copies to the Central Trial Coordinator who will distribute them to the study investigators who will be performing the blinded assessment. Each weekly photograph will be independently assessed by two study investigators using the CTCAE 4.0 scale for radiation dermatitis (Appendix 1). The study investigators will complete the supplied photograph assessment form and return them to the Central Trial Coordinator.||f|f|f|t
33749515|NCT03594448|||CASE_ONLY||PROSPECTIVE|||||||
33749516|NCT00909012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33749517|NCT04450108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749518|NCT06427226|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749519|NCT04729257|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34063906|NCT04150068|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33749520|NCT05873114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33749521|NCT03843229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749522|NCT00046358||||TREATMENT||||||||
33749523|NCT02313428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063907|NCT05721300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063908|NCT01285492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063909|NCT04383340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All individual assessments were conducted by a clinical psychologist at the hospital who was blinded to the experimental condition of the participants.|Randomized controlled trial|f|f|f|t
34063910|NCT05639504|||COHORT||PROSPECTIVE|||||||
34063911|NCT03905538|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170955|NCT02476786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170956|NCT02266316|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34170957|NCT02571426|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33749524|NCT06669143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749525|NCT03050346|||OTHER||PROSPECTIVE|||||||
34063912|NCT04621643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded to their group allocation, but complete blinding is not possible as the participants may understand whether they have received the active or control condition.||t|t|f|t
34063913|NCT05822583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170958|NCT02753946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170959|NCT04914780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34170960|NCT06446921|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized placebo controlled double blind trial|t|t|t|t
34170961|NCT03920111|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749526|NCT04852354|||CASE_ONLY||PROSPECTIVE|||||||
33749527|NCT00491049|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33749528|NCT02351531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063914|NCT06184906|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data manager are blind to treatment|FP will be randomly assigned in a parallel 1:1 fashion to one of two intervention groups. A block randomization procedure will be considered for the allocation of FP to the intervention. To ensure unbiased allocation, this sequence will be concealed from investigators. Investigative sites will access the randomization information of enrolled participants through a dedicated online system via the RedCap interface10. In line with ethical considerations, enrolled participants and investigators will not be blinded to the study treatments, as the nature of the dietary intervention does not permit blinding. Therefore, unblinding will not be applicable in this trial. As part of the consent process, participants' permission will be sought to use their data even if they choose to withdraw from the trial. Additionally, participants will be asked for consent to share relevant data with researchers from participating universities or regulatory authorities, where relevant.|f|f|f|t
34063915|NCT00997217|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34063916|NCT00766844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063917|NCT06730412|||COHORT||PROSPECTIVE|||||||
34063918|NCT04610450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063919|NCT01980498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063920|NCT00535392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063921|NCT00201812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858976|NCT00026208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with tumors 5 to 10 cm were to be assigned to concurrent radiotherapy, and participants with tumors less than 5 cm were initially planned to not receive radiotherapy.||||
34063922|NCT02816541|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33749529|NCT06362681|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|using a block randomization technique in which a computer-generated sequence would be used to assign each participant to a particular group in the allocation ratio of 1:1.|The children will be randomly divided into the experiment groups: control (oral hygiene motivation only), fluoride varnish, clinpro white Varnish and pastes containing CPP-ACP and followed up for 24 months.|t|t|t|t
33858977|NCT04223830|NA|SINGLE_GROUP||OTHER||NONE||||||
33858978|NCT05336253|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Participants will be randomized on a 1:1 basis through survey software to the EVERYbody Project-Connect or the self-help workbook condition||||
33858979|NCT04033848|||COHORT||PROSPECTIVE|||||||
33858980|NCT02827253|||COHORT||PROSPECTIVE|||||||
33858981|NCT02207270|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized clinical trail||||
33858982|NCT04526197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants were randomized to 1 of 2 treatment sequences: A-B or B-A.||||
33858983|NCT06334302|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33858984|NCT00151736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858985|NCT06374355|||CASE_ONLY||RETROSPECTIVE|||||||
33858986|NCT05001854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33858987|NCT02007889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33858988|NCT02594826|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33858989|NCT02752646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858990|NCT00504010|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34063923|NCT01025648|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34063924|NCT01832909|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33749530|NCT05180760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749531|NCT01886924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749532|NCT01217710|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33749533|NCT00374322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749534|NCT05556525|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Raters will be blinded to patient history and cytologic/pathologic diagnosis.||f|f|f|t
33749535|NCT03459430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33749536|NCT02883114|RANDOMIZED|||BASIC_SCIENCE||NONE||||||
33749537|NCT02962908|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34063925|NCT00507832|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34063926|NCT00494221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063927|NCT03774316|||COHORT||PROSPECTIVE|||||||
34063928|NCT01366638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063929|NCT03595267|||OTHER||PROSPECTIVE|||||||
34063930|NCT05506514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34063931|NCT04627961|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients who consent to participate will receive oral TAS-102 for days 1-5 and 8-12 of a 28 day cycle.||||
34063932|NCT06112795|||CASE_ONLY||CROSS_SECTIONAL|||||||
34063933|NCT03246841|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063934|NCT00138502|||||PROSPECTIVE|||||||
34063935|NCT06671938|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Participants in each cohort will be randomly allocated in a 2:1 ratio to receive either exidavnemab or placebo.|The trial will evaluate 2 dose cohorts, dose 1 exidavnemab versus placebo (Cohort 1) and dose 2 exidavnemab versus placebo (Cohort 2)|t|t|t|t
34063936|NCT00006341|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063937|NCT00889187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170962|NCT04142034|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Each clinics will recruit up to 28 child/caregiver pairs.The site awardee investigators will be blinded. The site awardee investigator will also identify a back-up,research-trained blinded assessor from the awardee site. The blinded coordinator will not have access to clinic charts. The clinic coordinator will instruct participants not discuss the trial or previous weights/data collected. He or she, or the designated backup, will take the height and weight measurements at baseline and six months. In case the ISPCTN site-awardee coordinator is accidentally unblinded, the backup assessor will take over all assessments for that participant.~At each measurement time point, the blinded assessor will enter data into the electronic data capture system only for that time point-the system will blind them to data from any/all other data-collection time points. The blinded site coordinator will perform the 24-hour food recalls at recruitment and six months."|This feasibility trial is a multisite, RCT with two parts. In part 1, sites will be randomized into the order in which two recruitment methods, traditional or consecutive, are used to recruit study participants. In part 2, recruited participants will be randomized to receive a newsletter or newsletter plus the iAmHealthy behavioral intervention.|f|f|t|f
34170963|NCT00055302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170964|NCT06317558|||COHORT||RETROSPECTIVE|||||||
33858991|NCT05197751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33858992|NCT01026454|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33858993|NCT00441415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33858994|NCT03092895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33858995|NCT00944320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063938|NCT05461937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34063939|NCT02629432|||COHORT||PROSPECTIVE|||||||
34063940|NCT03061240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063941|NCT05014269|||CASE_ONLY||RETROSPECTIVE|||||||
34063942|NCT05717803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063943|NCT05999656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063944|NCT02253550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063945|NCT01054391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063946|NCT01287975|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34063947|NCT04633902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33858996|NCT05737186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33858997|NCT06503029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|To maintain anonymity, unique identification numbers will be generated for each patient, and the data obtained will be carefully coded. This will ensure that patient data is kept separate from other collected data and stored in a secure and protected location.||f|f|t|t
33858998|NCT03270566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33858999|NCT01353079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859000|NCT03279874|||CASE_ONLY||PROSPECTIVE|||||||
33859001|NCT05863520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be masked to condition and collect post- intervention data.|Up to 100 schools will be randomized to either Zones of Regulation or Facing Your Fears - School Based. Autistic students with anxiety within each school will be assigned to one of the programs.|f|f|f|t
33859002|NCT05239338|||COHORT||PROSPECTIVE|||||||
34063948|NCT04720950|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|True purpose of the study is blinded to participants.|Randomised crossover trial|t|f|f|f
34063949|NCT02862132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063950|NCT04902729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063951|NCT01040182|||CASE_CONTROL||RETROSPECTIVE|||||||
34063952|NCT01048086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063953|NCT03611582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170965|NCT04299165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170966|NCT03446872|||COHORT||PROSPECTIVE|||||||
34170967|NCT02670486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34170968|NCT00547274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34170969|NCT00379665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34170970|NCT06151548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|the Polish Youth Rowing Team|"All competitors will be randomly divided into two groups (double-blind):~A. supplemented (n = 15), who will receive three times a day one capsule of a supplement called THYROX (Atlantic krill oil).~B. control (n = 15) receiving placebo. The supplementation period will be six weeks."|t|t|t|f
33960340|NCT02908607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34170971|NCT04604535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170972|NCT04361734|||COHORT||CROSS_SECTIONAL|||||||
34170973|NCT05775068|||COHORT||RETROSPECTIVE|||||||
34170974|NCT04129593|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will undergo 1 of 2 conditions on Saturday and Sunday; Self awakening and natural waking, or snooze and natural waking.||||
34170975|NCT01731912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749538|NCT00522158|RANDOMIZED|PARALLEL||||NONE||||||
33749539|NCT06311708|||OTHER||OTHER|||||||
33749540|NCT00617760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749541|NCT05470868|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, controlled, non-comparative, single-center, open study.||||
33749542|NCT04183764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859003|NCT03902847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33859004|NCT06305000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859005|NCT00366704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34170976|NCT03255239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859006|NCT03959371|||COHORT||OTHER|||||||
33859007|NCT05882669|||COHORT||PROSPECTIVE|||||||
33859008|NCT02211352|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33859009|NCT05010187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859010|NCT03965325|||COHORT||OTHER|||||||
33859011|NCT04497909|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The three groups of participants are a pre-clerkship cohort consisting of first- and second-year medical students, a clerkship cohort consisting of third- and fourth-year medical students and the third cohort consisting of medical residents.||||
33859012|NCT04309864|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Initially, Veteran focus groups will inform researchers regarding needed device refinements; clinician focus groups will inform regarding app updates; then participants will trial the updated seating app for usability.||||
33859013|NCT04440410|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859014|NCT04001907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859015|NCT01686854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859016|NCT02203292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859017|NCT00435474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859018|NCT01308333|||COHORT||PROSPECTIVE|||||||
33859019|NCT05755074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170977|NCT00464698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170978|NCT02367508|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34170979|NCT04803877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170980|NCT02848469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170981|NCT05421741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170982|NCT00213512|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34170983|NCT04645368|||COHORT||PROSPECTIVE|||||||
34170984|NCT01233804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34170985|NCT04864756|NA|SINGLE_GROUP||OTHER||NONE|No masking applicable|Before and after comparison||||
34170986|NCT02097862|NA|SINGLE_GROUP||TREATMENT||||||||
34170987|NCT05650008|||COHORT||PROSPECTIVE|||||||
34170988|NCT01481922|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34170989|NCT05922579|||OTHER||PROSPECTIVE|||||||
33749543|NCT01777854|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749544|NCT02308384|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749545|NCT03877445|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
33859020|NCT04162223|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33859021|NCT04201756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960341|NCT00141479|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33960342|NCT00171756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33960343|NCT06569680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960344|NCT03036917|||COHORT||PROSPECTIVE|||||||
33960345|NCT04654286|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33960346|NCT00457587|||COHORT||PROSPECTIVE|||||||
33960347|NCT02670993|RANDOMIZED|PARALLEL||||NONE||||||
33960348|NCT00287235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960349|NCT06265584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960350|NCT02163694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960351|NCT05860608|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960352|NCT04142866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960353|NCT06459076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33960354|NCT05974865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960355|NCT04954209|||COHORT||PROSPECTIVE|||||||
33960356|NCT00209495|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33960357|NCT06372379|||COHORT||RETROSPECTIVE|||||||
33960358|NCT01227954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170990|NCT01342003|||COHORT||RETROSPECTIVE|||||||
34170991|NCT01941511||CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34170992|NCT00947375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34170993|NCT00509184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34170994|NCT00830999|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34170995|NCT06183346|||COHORT||PROSPECTIVE|||||||
34170996|NCT03174184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34170997|NCT05217277|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34170998|NCT03690817|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34170999|NCT02831621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34171000|NCT00467077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171001|NCT03070288|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171002|NCT04668469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization A Block randomization method was used to randomize the study participants into two groups that result in equal sample sizes. This method was used to ensure a balance in sample size across groups over time and keep the numbers of participants in each group similar at all times.|A multicenter randomized double blind controlled clinical trial (RCCT) study design was carried out on on 600 subjects; 400 patients and 200 health care and household contacts at Benha and Kafrelsheikh University Hospitals.|t|t|t|f
34171003|NCT05659108|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34171004|NCT01582061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171005|NCT00621374|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34171006|NCT02733263|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34171007|NCT02831764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171008|NCT06528197|||COHORT||OTHER|||||||
34171009|NCT05360927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171010|NCT02760940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171011|NCT02575534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171012|NCT00804726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171013|NCT05601804|||OTHER||CROSS_SECTIONAL|||||||
34171014|NCT05413746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171015|NCT04681235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960359|NCT04813861|||CASE_ONLY||RETROSPECTIVE|||||||
33960360|NCT04650516|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, comparative, open-label, controlled interventional pilot study||||
33960361|NCT05877235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants in the control group will receive capsules identical to those in the intervention group, but with cornstarch.~The care provider and the participants do not have the information about which capsules the participant is taking, and do not have access to which groups the patients belong. Statistical analyses will be performed on a blinded database, i.e. without information of which groups the participants belong to.~Only the principal investigator of the study has this information."|Double blind randomized controlled trial, parallel and placebo-controlled.|t|t|f|f
33960362|NCT00819273|||COHORT||RETROSPECTIVE|||||||
33960363|NCT06576089|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33960364|NCT05969782|||COHORT||PROSPECTIVE|||||||
33960365|NCT03159988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960366|NCT04440007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960367|NCT04903717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960368|NCT03904667|||COHORT||OTHER|||||||
33960369|NCT03343054|NA|SEQUENTIAL||TREATMENT||NONE||||||
33960370|NCT04457531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960371|NCT00061945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960372|NCT06045832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||At the beginning of the study, the demographic characteristics of the study participants were recorded in detail, including sex, age, history of smoking, alcohol consumption, presence of bad breath and GI symptoms. After that, a randomization list was generated using SPSS (version 25.0), and the included patients were randomized in a 1:1 ratio according to the randomization table to receive either MAXPOWER Biological Antibacterial Liquid gargle treatment (Gargle 3 times a day for 2 min each time for 7 days) or gargle with water (Gargle 3 times a day for 2 min each time for 7 days). Then, all patients were retested for oral H. pylori.|t|f|f|f
33960373|NCT01319305|||COHORT||PROSPECTIVE|||||||
33960374|NCT04653701|||CASE_ONLY||PROSPECTIVE|||||||
33960375|NCT01058876|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33960376|NCT06703463|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33960377|NCT01932801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking of the double-blind portion of the study was quadruple until after all data had been collected, when they were unblinded.||t|t|t|t
33960378|NCT00828516|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960379|NCT02773446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33960380|NCT02569164|||CASE_ONLY||PROSPECTIVE|||||||
33960381|NCT03757793|||COHORT||PROSPECTIVE|||||||
33960382|NCT06701760|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participant is not awake and is not told which arm they were randomized to Assessor is blinded to randomization allocation||t|f|f|t
33960383|NCT04557969|||COHORT||PROSPECTIVE|||||||
33960384|NCT03859570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Contracted biostatistician will be responsible for drug/placebo randomization. He will be able to conduct an early, interim data analysis following initial 30% enrollment, and will permit unblinding of subject data to the Data Safety Monitor (DSM) for reasons of safety assurance, as requested.||t|t|t|f
33960385|NCT01860690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960386|NCT02341209|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33960387|NCT01456494|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33960388|NCT04145349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960389|NCT04977687|||COHORT||RETROSPECTIVE|||||||
33960390|NCT02060240|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33960391|NCT05429931|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33960392|NCT01031342|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960393|NCT01803035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960394|NCT04876807|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960395|NCT00500695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960396|NCT05787860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open-Label|Open-Label Trial||||
33960397|NCT00571220|||CASE_CONTROL||PROSPECTIVE|||||||
33960398|NCT01771835|||COHORT||PROSPECTIVE|||||||
33960399|NCT02282826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960400|NCT05189145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960401|NCT05943873|||CASE_CONTROL||RETROSPECTIVE|||||||
33960402|NCT02996448|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960403|NCT02624817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960404|NCT04554927|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33960405|NCT00431236|RANDOMIZED|PARALLEL||PREVENTION||||||||
34171016|NCT04361435|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Patients will be randomized into one of the 2 arms (None-invasive oscillating device (NIOD) first or chest physiotherapy (CPT) first). Random allocation will be generated by an independent investigator in an equal number assigned to each intervention. Stratification will be applied for age (\>18 years or =\<18 years of age) and sites (CHUSJ and General Hospital).||||
33859022|NCT06494605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859023|NCT04696042|||COHORT||PROSPECTIVE|||||||
34171017|NCT04537975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859024|NCT05580419|NA|SINGLE_GROUP||OTHER||NONE||Single-blinded, stepped cluster design trial||||
33960406|NCT03875300|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Control Trial||||
33960407|NCT02015299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960408|NCT06348173|||COHORT||RETROSPECTIVE|||||||
33960409|NCT06263179|NA|SINGLE_GROUP||TREATMENT||NONE||Target Heartrate Aerobic Exercise||||
34171018|NCT00074165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171019|NCT00311766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171020|NCT05743660|||CASE_CONTROL||PROSPECTIVE|||||||
34171021|NCT02587221|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33749546|NCT03556462|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Stepped wedge cluster RCT Participating agencies (n=7) were randomly assigned to 'wedge 1' or 'wedge 2': Wedge 1 agencies will begin the intervention in Fall 2018 and Wedge 2 agencies will begin the intervention in Spring 2019.||||
33749547|NCT01404520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33749548|NCT05469373|||CASE_ONLY||PROSPECTIVE|||||||
33749549|NCT00704327|||CASE_ONLY||CROSS_SECTIONAL|||||||
33749550|NCT01166633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960410|NCT04310735|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33960411|NCT05065242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960412|NCT01979302|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33960413|NCT04164394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Allocation is 2:1 to probiotic and placebo arms|t|f|f|f
33960414|NCT03121989|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||"A total of 13 participants will be recruited for this study. Prior to the first study research MRI scan, 3 volunteer participants will be scanned with a known breast malignancy (Group 1). These participants will not have hyperpolarized 13C pyruvate administered. They will be scanned with a 13C phantom in order to test the functionality of the 13C coil.~Subsequently, up to 10 volunteer participants with breast cancer requiring NAC, between 18 and 80 years of age with pathology- and imaging-confirmed breast cancer requiring NAC will be studied (Group 2). Imaging confirmation involves highly suspicious masses on mammography and/or ultrasound. Pathology confirmation involves image-guided core biopsy of the suspicious mass."||||
33960415|NCT04908956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171022|NCT00000140|RANDOMIZED|||TREATMENT||||||||
34171023|NCT00348712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171024|NCT01258777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171025|NCT05717361|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171026|NCT06405360|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Investigators and outcomes assessors will be blinded to the intervention arm once the participant is enrolled.||f|f|t|t
33749551|NCT02244866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749552|NCT03813940|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749553|NCT05873855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and relationship partner will not know in advance which arm they are assigned and randomized to in the trial.|6-month pilot randomized controlled trial with delayed, no-attention control condition of 3 months.|t|f|f|f
33859025|NCT05280951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859026|NCT00662350|||CASE_ONLY||PROSPECTIVE|||||||
33859027|NCT03612284|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33859028|NCT06470594|||COHORT||PROSPECTIVE|||||||
33859029|NCT00069316|RANDOMIZED|||TREATMENT||DOUBLE||||||
33859030|NCT03735654|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859031|NCT02110147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859032|NCT01201343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859033|NCT02469896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749554|NCT01549613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171027|NCT05033197|NA|SINGLE_GROUP||TREATMENT||NONE||This study used 2 arms, quasi experimental study design with one intervention group and one control group. The intervention group included fourth-grade students of two fourth-grade classes taught by the physical education teacher who received the coordinated-bilateral ball skills (CBBS) intervention training at each of the five elementary schools. The control group included fourth-grade students of other two fourth-grade classes taught by the physical education teacher who did not receive the CBBS intervention training at each of the five elementary schools.||||
34171028|NCT00948064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171029|NCT02571114|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33749555|NCT05716698|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749556|NCT03838042|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I:~To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to adolescents 12-21 years with progressive, relapsed, refractory high-risk solid tumors and CNS tumors To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to children 6-11 years with progressive, relapsed, refractory high-risk solid tumors and CNS Tumors~Phase II:~To evaluate activity and safety of the combination treatment with nivolumab and entinostat in children and adolescents aged 2-21 years with refractory/relapsed/progressive high-risk solid tumors and CNS tumors with:~Group A: a high mutational load (\> 100 somatic SNVs/exome), Group C: Focal MYC(N) amplification or ATRT-MYC subgroup, Group E: high TILs or TLS positive (\> 600 cells/mm² or presence of TLS)."||||
33749557|NCT03966157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33749558|NCT01775228|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33749559|NCT04690855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749560|NCT04988854|RANDOMIZED|PARALLEL||OTHER||SINGLE||Children were randomly assigned to one of three conditions (positive, neutral or control)|t|f|f|f
33749561|NCT00415987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749562|NCT06635161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749563|NCT02205944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33749564|NCT04011553|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized||||
33749565|NCT03142048|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749566|NCT01546896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749567|NCT00581230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749568|NCT03146520|||CASE_CONTROL||OTHER|||||||
33749569|NCT03068338|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33749570|NCT04933955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749571|NCT06378450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33749572|NCT04027153|RANDOMIZED|PARALLEL||OTHER||NONE||one to one on an individual level||||
33749573|NCT03698851|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33960416|NCT04479488|||COHORT||PROSPECTIVE|||||||
33960417|NCT02682173|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960418|NCT00401700|||COHORT||PROSPECTIVE|||||||
33960419|NCT04359420|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A non-randomised fully counterbalanced study design will be used, to include equal numbers of participants from all sites who will be offered NHS-BSP and BC-Predict. Specifically, in the initial 8-month time period, women eligible for breast screening in three screening sites will be offered BC-Predict, whilst women in two screening sites are offered usual NHS-BSP. In the following 8-month time period the study sites switch to offer the other intervention (NHS-BSP rather than BC-Predict; and vice versa). This will allow estimates of effect to be obtained from both within-sample and between-sample analyses.||||
33960420|NCT05684497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960421|NCT05171920|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33960422|NCT05359380|||COHORT||PROSPECTIVE|||||||
33960423|NCT05567588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171030|NCT03249636|||COHORT||PROSPECTIVE|||||||
34171031|NCT00713609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171032|NCT03755206|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34171033|NCT05255146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Patients will be randomized to either study group before surgery without the patient's knowledge of which group they are in. The surgeons (care providers) will need to be aware of the intervention so that they can supply the cryoanalgesia or not peri-operatively. The investigator and data analyst will also be blind to the intervention type when collecting patient outcome information and doing statistical analysis. Randomization will be documented in secure password protected databases that only the surgeons will have access too, matching patient identifiers to intervention groups for reference for final data presentation.|This is a pilot, randomized, double-blinded, placebo-controlled trial evaluating the effect of intercostal cyroablation on the development of post-thoracotomy pain. With the use of computer-generated randomized blocks, patients will be assigned to either Cryoanalgesia or no-cryoanalgesia before undergoing surgery.|t|f|t|t
34171034|NCT03195881|||COHORT||PROSPECTIVE|||||||
33749574|NCT05838534|||COHORT||CROSS_SECTIONAL|||||||
33749575|NCT02967627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171035|NCT01650298|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34171036|NCT04999839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749576|NCT02552524|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33749577|NCT03215095|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study with the primary objective to assess the safety of administering the PD-L1 targeting agent durvalumab in combination with recombinant human thyroid stimulating hormone (rhTSH, Thyrogen) stimulated/prepared radioiodine (RAI; 131I) therapy in patients with RAI-avid (RAIA) recurrent and/or metastatic (R/M) thyroid cancer.||||
33749578|NCT01840267|||||PROSPECTIVE|||||||
33749579|NCT01968239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749580|NCT06669364|||COHORT||RETROSPECTIVE|||||||
33749581|NCT00864032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859034|NCT06264778|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm study that does not involve randomization or blinding, nor does it establish a parallel control group and uses external control.||||
33859035|NCT01141348|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33859036|NCT00514657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859037|NCT01888835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859038|NCT02248220|||COHORT||PROSPECTIVE|||||||
33859039|NCT00093171|NON_RANDOMIZED|||TREATMENT||NONE||||||
33859040|NCT00188422|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859041|NCT00321659|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33859042|NCT04845633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33859043|NCT04233736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33859044|NCT03678103|NA|SINGLE_GROUP||OTHER||NONE||||||
33960424|NCT03874585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33859045|NCT03756350|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded reviewer will evaluate the pre and post photos|||||
33859046|NCT03385070|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33960425|NCT02751255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171037|NCT00241228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960426|NCT05940870|||CASE_ONLY||PROSPECTIVE|||||||
33960427|NCT04317053|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34171038|NCT00866463|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34171039|NCT00399516|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171040|NCT03695224|||COHORT||PROSPECTIVE|||||||
34171041|NCT05412147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171042|NCT04618146|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171043|NCT03679039|||OTHER||PROSPECTIVE|||||||
34171044|NCT04401735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171045|NCT03655145|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective Phase III clinical trial comparing HLA 10/10 matched unrelated donor (standard arm) and haploidentical allogeneic hematopoietic stem cell transplantation (experimental arm) after myeloablative conditioning regimen||||
34171046|NCT01808196|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label study which means that all participants receive the study medicine||||
34171047|NCT02818309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171048|NCT03013868|||COHORT||PROSPECTIVE|||||||
33749582|NCT05061251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749583|NCT05382780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33749584|NCT04659980|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749585|NCT05164159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749586|NCT03281902|||CASE_ONLY||PROSPECTIVE|||||||
33749587|NCT03424824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749588|NCT01570101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749589|NCT06580626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749590|NCT06503211|NA|SINGLE_GROUP||TREATMENT||NONE||UTAA09 injection||||
33859047|NCT02716467|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33960428|NCT04270552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171049|NCT00656929|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33749591|NCT06497465|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1(n=50): DTG 50mg/3TC 300 mg FDC tablet (Dovato®) twice daily during TB therapy and for 2 weeks after, then Dolutegravir (DTG) 50mg / lamivudine (3TC) 300 mg fixed dose combination (FDC) tablet (Dovato®) once daily to week 52~Arm 2(n=50): DTG 50mg/300mg FDC tablet plus DTG 50mg at night during TB treatment and for 2 weeks after, then DTG 50 mg/ 3TC 300 mg FDC tablet (Dovato®) once daily to week 52~Arm 3(n=50): Local Standard of Care 3-drug ART (DTG 50mg + TDF/3TC) plus DTG 50 mg at night during TB treatment and for 2 weeks after, then Dolutegravir (DTG) 50 mg + Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC) FDC tablet once daily to week 52"||||
33749592|NCT01428765|||||CROSS_SECTIONAL|||||||
33749593|NCT02248870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749594|NCT03835533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749595|NCT01638910|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749596|NCT00327626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33749597|NCT05105295|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects aged ≥18 with infected with HIV who have completed the schedule of two doses for 3 months receive a third dose of inactivated COVID-19 vaccine.||||
33749598|NCT05711654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|None (Open Label)|Factorial Assignment|t|f|f|f
33749599|NCT01347333|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749600|NCT02813850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859048|NCT00464230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33859049|NCT02172339||PARALLEL||TREATMENT||NONE||||||
34171050|NCT04396366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859050|NCT03003559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859051|NCT03731832|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||All patients receive PId. Patients showing a biochemical relapse receive PICd afterwards, while patients showing a clinical relapse go off study.||||
34171051|NCT03081702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859052|NCT01602523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859053|NCT03799185|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33859054|NCT04719767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, surgeons and the ones who collect data will be masked.||t|t|f|t
33859055|NCT01477086|||COHORT||PROSPECTIVE|||||||
34171052|NCT02809157|||COHORT||PROSPECTIVE|||||||
34171053|NCT04907734|||OTHER||CROSS_SECTIONAL|||||||
34171054|NCT06217965|||COHORT||PROSPECTIVE|||||||
34171055|NCT06107777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171056|NCT03820765|||COHORT||PROSPECTIVE|||||||
34171057|NCT02355626|||COHORT||PROSPECTIVE|||||||
34171058|NCT01890343|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34171059|NCT03587376|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34171060|NCT00217958|RANDOMIZED|||TREATMENT||||||||
34171061|NCT02490683|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34171062|NCT01912066|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171063|NCT02517918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171064|NCT04789707|||CASE_CONTROL||PROSPECTIVE|||||||
34171065|NCT03678272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171066|NCT00299312|||COHORT||PROSPECTIVE|||||||
34171067|NCT05233865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34171068|NCT02468817|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34171069|NCT01590589|||COHORT||OTHER|||||||
34171070|NCT01045486|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34171071|NCT01045460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171072|NCT05093816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171073|NCT02160756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171074|NCT01469221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171075|NCT01417546|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34171076|NCT02542046|||OTHER||RETROSPECTIVE|||||||
34171077|NCT04875884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171078|NCT06316908|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Unilateral Approach Group: Patients in this group have received a unilateral percutaneous posterior approach for NCPB. The procedure was performed under fluoroscopic guidance.~Bilateral Approach Group: Patients in this group have undergone a bilateral percutaneous posterior approach for NCPB, following the same procedural guidance."||||
34171079|NCT04827108|||OTHER||CROSS_SECTIONAL|||||||
34171080|NCT01271777|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33960429|NCT06701604|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33960430|NCT05613920|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33960431|NCT01956123|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171081|NCT03755921|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The control group will receive speech therapy with weekly frequency, and the intervention group will participate in a brief and intensive therapy program that will take place during five days a week for three weeks, totaling fifteen sessions. The sessions will be of 40 minutes and, in both groups, the patients will receive care of individualized form, according to their needs|t|f|t|f
34171082|NCT00668148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859056|NCT00523042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859057|NCT03963752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859058|NCT01322984|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33859059|NCT03772353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859060|NCT00362453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859061|NCT05224336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and outcome assessor will not be made aware if participants are receiving psilocybin or placebo niacin.||t|f|t|t
33960432|NCT00301639|RANDOMIZED|CROSSOVER||||NONE||||||
33960433|NCT06619834|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33960434|NCT05226468|NA|SEQUENTIAL||TREATMENT||NONE||"3+3 design for dose escalation in Part 1 and Simon's optimal two stage design for dose expansion in Part 2.~NEI-01 as single agent in both Part 1 and Part 2."||||
33960435|NCT05728216|||OTHER||PROSPECTIVE|||||||
33960436|NCT06520995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960437|NCT05658107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960438|NCT01888978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171083|NCT03111875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"To maintain blinding, the anesthesia record will be sealed in an opaque envelope before patients leave the post-anesthesia care unit. The envelope will be marked Do not open until \[date 35 days after surgery\]. Some hospitals will have electronic records; in those cases, we will ask investigators evaluating postoperative outcomes not to access the anesthesia record."||f|f|f|t
34171084|NCT05606666|||OTHER||CROSS_SECTIONAL|||||||
34171085|NCT05234411|||OTHER||PROSPECTIVE|||||||
34171086|NCT01572181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171087|NCT05320081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171088|NCT03742765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171089|NCT06436794|||COHORT||PROSPECTIVE|||||||
34171090|NCT00073658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171091|NCT02432326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171092|NCT04371575|||COHORT||PROSPECTIVE|||||||
34171093|NCT02494193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171094|NCT06162585|||COHORT||PROSPECTIVE|||||||
34171095|NCT02987231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960439|NCT02515552|NA|SINGLE_GROUP||||NONE||||||
33960440|NCT06320093|NA|SINGLE_GROUP||OTHER||NONE||||||
33960441|NCT04064359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171096|NCT01791244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171097|NCT01067378|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34171098|NCT01071044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171099|NCT04096014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33859062|NCT05494060|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: Penpulimab + Anlotinib + XELOX； Active Comparator: XELOX||||
33859063|NCT03181451|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomized in a 1:1:1 ratio and stratified by co-variates for age and sex. This will ensure that a minimum of 25% of each gender and at least 3 children per age group are enrolled in each Ferric Maltol dose group.||||
33859064|NCT05127538|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33859065|NCT02591199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859066|NCT04766931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859067|NCT03457454|||CASE_ONLY||PROSPECTIVE|||||||
33859068|NCT05638893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859069|NCT05426759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859070|NCT02285426|||COHORT||PROSPECTIVE|||||||
33859071|NCT00778622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859072|NCT04445181|||COHORT||RETROSPECTIVE|||||||
33859073|NCT01001923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893674|NCT03482661|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33859074|NCT03308409|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who met the selection criteria were randomly assigned to one of three groups: weekly protocol, monthly protocol, or booster protocol, in a 1:1:1 ratio.||||
33960442|NCT05204940|||COHORT||PROSPECTIVE|||||||
33960443|NCT05478486|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|It is an open-label clinical trial with a single treatment arm.|At least 3 patients will be enrolled at only one dose level and dosed with one only dose of MSP008-22. Each dosed patient will be evaluated for 72.00 hours post-dose for primary and secondary endpoints (i) If there are no AE or abnormal laboratory results experienced by these three patients, the trial will move to the next dose level (next cohort of 3 different patients), (ii) If in a single Cohort, any one patient experiences any Dose Limiting Toxicity, additional 3 patients will be dosed at the same dose level, (iii) If in a single Cohort, more than 33% of the patients experience Dose Limiting Toxicity, the Cohort will be stopped, and further dose escalation will not happen in the study.||||
34171100|NCT05767008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171101|NCT03252548|||CASE_ONLY||PROSPECTIVE|||||||
34171102|NCT04441359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34171103|NCT02149381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171104|NCT00697502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171105|NCT02424773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859075|NCT00629655|||||CROSS_SECTIONAL|||||||
34171106|NCT05966649|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33859076|NCT05285488|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34171107|NCT00258141|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34171108|NCT00001572||||TREATMENT||||||||
34171109|NCT05534217|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants didn't know where they were grouped,and the experimenters did not know about the trial either.|Patients diagnosed with traumatic corneal epithelial abrasions are treated by complete debridement of the corneal epithelium|t|f|f|t
33859077|NCT01886820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859078|NCT00792805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859079|NCT04024774|||COHORT||PROSPECTIVE|||||||
33859080|NCT05961280|||COHORT||RETROSPECTIVE|||||||
33859081|NCT01918553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859082|NCT03658746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859083|NCT03707925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859084|NCT04622189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859085|NCT00519961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33859086|NCT05586607|||CASE_ONLY||RETROSPECTIVE|||||||
33859087|NCT01439919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960444|NCT06541106|||COHORT||PROSPECTIVE|||||||
33960445|NCT06104592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171110|NCT05994612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34171111|NCT05244616|||CASE_CROSSOVER||PROSPECTIVE|||||||
34171112|NCT03958383|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation design to determine maximum tolerated dose / maximum administered dose for each of 4 cohorts||||
34171113|NCT02773186|||||PROSPECTIVE|||||||
34171114|NCT04532307|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|single blind|2x2 factorial design|f|f|f|t
33859088|NCT03855553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859089|NCT01419041|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33859090|NCT00920920|||COHORT||PROSPECTIVE|||||||
33960446|NCT00639587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960447|NCT05835960|||COHORT||PROSPECTIVE|||||||
33960448|NCT02803190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34171115|NCT01991392|RANDOMIZED|PARALLEL||||NONE||||||
34171116|NCT01207700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171117|NCT03206216|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859091|NCT05703867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859092|NCT02787525|||CASE_CONTROL||RETROSPECTIVE|||||||
34171118|NCT03327909|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomized parallel group trial||||
34171119|NCT00634439|||COHORT||RETROSPECTIVE|||||||
33749601|NCT00969033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749602|NCT04534595|||CASE_ONLY||PROSPECTIVE|||||||
33749603|NCT04439422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749604|NCT03195257|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Randomized, double-blinded, cross-over study with 5 study days.||t|t|t|f
33749605|NCT00594854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171120|NCT04421079|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Participants and investigators will be masked to whether they are assigned to study supplement or placebo.|This is a single center, double-blind, placebo-controlled, randomized phase I trial. Each subject will be randomized to a daily low, medium or high dose of BDPP or placebo.|t|t|t|t
34171121|NCT00004838|RANDOMIZED|||TREATMENT||||||||
34171122|NCT04942587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171123|NCT02322281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171124|NCT00875186|||CASE_CONTROL||PROSPECTIVE|||||||
34171125|NCT02843724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171126|NCT06234033|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749606|NCT03902379|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33749607|NCT02170987|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33749608|NCT00463710|||||OTHER|||||||
34171127|NCT02773381|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34171128|NCT04562922|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33749609|NCT02703675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749610|NCT03735329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749611|NCT05630274|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33749612|NCT05124704|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Epidural puncture was performed by the fist anesthesiologist. First dosage and continuous infusion of ropivacaine was administered by the second anesthesiologist.|"60 adult gastric cancer patients between 18-75 years, ASA physical state I and II, undergoing open gastrectomy, were enrolled in this study.~Epidural puncture was performed in the left lateral position through the interspace between the eighth to ninth thoracic vertebra (T8-T9). Epidural catheter was inserted. In group TEA+GA, 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction, to obtain a bilateral segmentary sensory block to pinprick between T4 and T12 dermatomes. Continuous infusion of 4-6 ml 0.375% ropivacaine was applied using micro-infusion pump after induction. In group GA, same dose of normal saline was administered before induction and during surgery."|t|f|t|f
33749613|NCT04878094|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749614|NCT01008033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749615|NCT00003718||||TREATMENT||||||||
33859093|NCT03147079|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open intervention study with 2 control arms||||
33859094|NCT04734925|||COHORT||PROSPECTIVE|||||||
33859095|NCT01290601|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Only if Cohort 1 met specified endpoint criteria would Cohort 2 begin enrollment|t|t|t|t
33893675|NCT06196502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||There are three sections to it, and they will all be finished simultaneously. This is not a study of drugs or devices. The three arms of the study are the breastfeeding (standard care), kangaroo care, and gentle human touch groups.|t|f|t|t
34171129|NCT02805686|NA|SINGLE_GROUP||SCREENING||NONE||||||
34171130|NCT03651635|||COHORT||PROSPECTIVE|||||||
33893676|NCT04853940|||COHORT||PROSPECTIVE|||||||
34171131|NCT04974736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"After the intervention has been assigned at random to one practice in each of the six pairs, the intervention will be blinded at random with either the label A or the label B, and the other label will be assigned to the control practice. The statisticians will be blinded as to which of A and B is the intervention until the analyses are completed."|2-arm Randomized Control Trial with a stratified cluster randomization|f|f|f|t
34171132|NCT04527640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Masking is done for participants, care provider, and investigator. Masking is assigned by the pharmacy unit of Dr. Cipto Mangunkusumo Hospital.|This study is a double-blind, placebo-controlled, randomized clinical trial conducted on end-stage renal disease patients undergoing hemodialysis. Patients will be randomized into two arms: symbiotic and placebo. The study will take place in the hemodialysis unit of Dr. Cipto Mangunkusumo General Hospital in September 2020 to February 2021. A total of 60 participants will be recruited for the study (30 in each arm). Both investigators and patients will be blinded to the treatment, and blinding will be conducted by the pharmacy unit of Dr. Cipto Mangunkusumo General Hospital.|t|t|t|f
34171133|NCT03367767|||COHORT||PROSPECTIVE|||||||
34171134|NCT05876481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171135|NCT02536612|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171136|NCT03602677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171137|NCT02656017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171138|NCT03379454|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34171139|NCT04504422|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34171140|NCT01526447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171141|NCT05681650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171142|NCT04772872|||CASE_CONTROL||PROSPECTIVE|||||||
34171143|NCT06119126|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34171144|NCT05307497|||CASE_ONLY||CROSS_SECTIONAL|||||||
34171145|NCT04675970|||CASE_ONLY||PROSPECTIVE|||||||
34171146|NCT00430105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749616|NCT06670989|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749617|NCT05590819|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33749618|NCT03762473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749619|NCT06090045|||COHORT||PROSPECTIVE|||||||
33749620|NCT00050908|||||PROSPECTIVE|||||||
33749621|NCT04991168|||COHORT||PROSPECTIVE|||||||
33749622|NCT05163366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Rectal ketamine versus oral morphine in pain management in paediatric wound and burns|t|f|f|f
33749623|NCT01723111|||CASE_CONTROL||PROSPECTIVE|||||||
33749624|NCT00000831||||TREATMENT||||||||
34171147|NCT03342586|||COHORT||PROSPECTIVE|||||||
34171148|NCT00510835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171149|NCT00801736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171150|NCT05851118|||CASE_CONTROL||PROSPECTIVE|||||||
34171151|NCT03546985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749625|NCT03240848|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Slit-lamp photography and patient recruitment will be performed in each participating clinic by trained clinical staffs. The clinical staffs, investigators involved in data management and analysis, and experts providing the gold standard diagnosis by consensus in each clinic will be blinded to the group assignment. The study participants, the coordinator, senior consultants, and study personnel responsible for randomisation will not be masked.||f|f|t|t
33749626|NCT04339192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749627|NCT01474681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749628|NCT01283412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749629|NCT03479372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking will be maintained by using a coded drug supply.||t|t|t|t
33749630|NCT05305157|||CASE_ONLY||PROSPECTIVE|||||||
33749631|NCT05172765|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33893677|NCT05670977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33893678|NCT03612726|||COHORT||OTHER|||||||
33893679|NCT00768222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893680|NCT01549990|||COHORT||RETROSPECTIVE|||||||
33893681|NCT06170645|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33893682|NCT00811252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893683|NCT01122329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33893684|NCT00005104|RANDOMIZED|||TREATMENT||DOUBLE||||||
33893685|NCT05206643|||COHORT||PROSPECTIVE|||||||
33893686|NCT04351659|||COHORT||PROSPECTIVE|||||||
33893687|NCT06441630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893688|NCT02490852|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33893689|NCT05474092|||COHORT||PROSPECTIVE|||||||
33893690|NCT01440725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171152|NCT01428258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is a randomized, two-arm, crossover trial comparing the GMP diet and the AA diet in 30 subjects with PKU \> 12 years of age. Subjects were randomized to start with either the GMP diet or the AA diet which they followed for 3-wk at home, followed by a 3-wk washout period when they resumed their usual AA diet, and then 3-wk of either the GMP diet or the AA diet whichever they did not consume first. Each subject served as their own control; there was no control group. We studied medical foods - either AA or GMP medical foods which are not drugs. The FDA did not require that we have an IND.||||
33749632|NCT06470321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Intervention Model: Single Group Assignment This is a single-arm study where all participants will receive the same smoking cessation intervention after completing the initial assessments.||||
34171153|NCT03274323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171154|NCT04517461|||COHORT||PROSPECTIVE|||||||
34171155|NCT06303336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and outcome assessors will be kept blind about the intervention which the patients will be receiving||t|f|f|t
33749633|NCT00377234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33749634|NCT00882947|||COHORT||PROSPECTIVE|||||||
33749635|NCT01796574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749636|NCT00002933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171156|NCT03296917|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34171157|NCT03154866|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171158|NCT01139502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171159|NCT00192881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171160|NCT00788463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171161|NCT02578407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171162|NCT02972775|||COHORT||RETROSPECTIVE|||||||
34171163|NCT01848158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171164|NCT04814303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34171165|NCT04549285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749637|NCT02981550|||CASE_ONLY||PROSPECTIVE|||||||
33749638|NCT03839251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749639|NCT05316441|RANDOMIZED|PARALLEL||OTHER||SINGLE||The research was designed in an experimental model with an intervention-control group. The sample of the research; It consists of 60 students (30 controls, 30 experiments) with 80% power, 95% confidence interval and 0.05 margin of error.|t|f|f|f
33749640|NCT04982900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a double-blind trial, the investigator, care provider and patients are all blinded.|This study has two parallel arms, EGFR-TKI treatment arm and control arm (placebo) are included in this study.|t|t|t|t
33749641|NCT04259268|||CASE_ONLY||PROSPECTIVE|||||||
33749642|NCT02561858|NA|SINGLE_GROUP||OTHER||NONE||||||
33749643|NCT05208073|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749644|NCT02355808|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33749645|NCT03434951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749646|NCT01114568|RANDOMIZED|CROSSOVER||||NONE||||||
33749647|NCT04575896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749648|NCT01386528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749649|NCT00955084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749650|NCT06669520|||COHORT||PROSPECTIVE|||||||
33749651|NCT02047838|||CASE_CONTROL||RETROSPECTIVE|||||||
33840505|NCT05690997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To avoid bias in outcome assessment, evaluation of the primary and secondary outcome measures will be performed by a group who is independent from the clinical investigators and who will be blinded from all clinical, cognitive and radiological assessments.|"Intensive treatment group:~if the mean home SBP preceding clinic follow-up is \>130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.~Standard treatment group:~if the mean home SBP preceding clinic follow-up is \>140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified."|f|f|f|t
33893691|NCT01779609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34171166|NCT02264275|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34063954|NCT04655534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study was designed as a prospective and experimental study. Participants were randomly divided into two groups as the study group (IMW Group) and the control group (Standard IMT Group). The Standard IMT Group performed only inspiratory muscle training (IMT), while the IMW Group performed an inspiratory muscle warm-up (IMW) protocol for warming the inspiratory muscles before each IMT session. The IMT and IMW applied using a threshold pressure loading device.|t|f|f|t
34063955|NCT06397924|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||One group will be given the small chocolate patties containing the insect chitin for 30 days, and the other group will be given the patties containing the placebo. The study was double-blinded.|t|t|t|t
34063956|NCT06730269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063957|NCT04750200|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label randomized control trial||||
34063958|NCT06521112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||a randomized, controlled trial in pre-test post-test design||||
34063959|NCT04875689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063960|NCT01084213|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34063961|NCT04018807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063962|NCT04650334|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34063963|NCT00309790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34063964|NCT05926752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063965|NCT03660124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063966|NCT02279199|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34063967|NCT01804153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063968|NCT05849506|||COHORT||OTHER|||||||
34063969|NCT02164032|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34063970|NCT03854604|||OTHER||PROSPECTIVE|||||||
34063971|NCT00304941|||||PROSPECTIVE|||||||
34063972|NCT05762055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063973|NCT04621162|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34063974|NCT02209025|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34063975|NCT06730607|||CASE_CONTROL||RETROSPECTIVE|||||||
34063976|NCT00410670|||FAMILY_BASED||RETROSPECTIVE|||||||
34063977|NCT01001806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34063978|NCT05960032|NA|SINGLE_GROUP||OTHER||NONE||||||
34063979|NCT06283667|||COHORT||PROSPECTIVE|||||||
34063980|NCT06729905|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34063981|NCT04212143|||COHORT||PROSPECTIVE|||||||
34063982|NCT01804699|||FAMILY_BASED||PROSPECTIVE|||||||
34063983|NCT05551689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants are randomized by an independent assistant.|randomized clinical trial|f|t|f|t
34063984|NCT00008775|RANDOMIZED|||TREATMENT||NONE||||||
34063985|NCT01565798|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34063986|NCT00667797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34063987|NCT05575934|||COHORT||PROSPECTIVE|||||||
34063988|NCT02135705|||COHORT||PROSPECTIVE|||||||
34063989|NCT02101749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34063990|NCT01315795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063991|NCT01745107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34063992|NCT04170244|||COHORT||PROSPECTIVE|||||||
34171167|NCT00190437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171168|NCT06045130|||COHORT||PROSPECTIVE|||||||
33840506|NCT01384799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34063993|NCT06598189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34063994|NCT04064580|||COHORT||PROSPECTIVE|||||||
34063995|NCT04438954|||CASE_ONLY||PROSPECTIVE|||||||
34063996|NCT00004770||||TREATMENT||||||||
34171169|NCT00499486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171170|NCT04564664|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171171|NCT00332072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171172|NCT02804789|||COHORT||PROSPECTIVE|||||||
34171173|NCT01285141|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34063997|NCT01782560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34063998|NCT03877224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171174|NCT04467749|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171175|NCT01370980|||CASE_ONLY||PROSPECTIVE|||||||
34171176|NCT04190459|||COHORT||PROSPECTIVE|||||||
34171177|NCT03935958|RANDOMIZED|PARALLEL||OTHER||SINGLE|participants will not know if they are receiving curcumin or placebo|"20 participants in supplement (receiving curcumin) group 20 participants in control (receiving placebo) group~randomization 1:1"|t|f|f|f
33840507|NCT03328104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840508|NCT01682772|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34063999|NCT00232466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064000|NCT05490823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064001|NCT05062720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A total of 105 subjects will be randomized in 2:1 ratio into two cohorts that will receive a combination of LCT along with the systemic therapy or systemic therapy alone.||||
34064002|NCT01982552|||COHORT||PROSPECTIVE|||||||
34064003|NCT02689310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34064004|NCT01691703|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
34064005|NCT04294797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064006|NCT02095405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064007|NCT06065228|||COHORT||PROSPECTIVE|||||||
34064008|NCT00107354||||TREATMENT||NONE||||||
34064009|NCT06509789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064010|NCT00968097|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34064011|NCT02262416|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34064012|NCT06206122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34064013|NCT03466749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960449|NCT00665704|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960450|NCT05269316|NA|SEQUENTIAL||TREATMENT||NONE||||||
33749652|NCT05462665|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Intern nurses will be numbered from 1 to 75 and will be randomly divided into study and control groups from the random numbers table.~After the groups are determined by the randomization method, each intern nurse in the study and control groups will be interviewed face to face and their written informed consent will be obtained. Then, all nursing intern students participating in the research will be asked to fill in the IV tPA Treatment Knowledge Level Evaluation Form, Self-Efficacy Competence Scale. Intern nurses in both groups will be given 1-hour theoretical training on IV tPA treatment before, during and after the procedure. In addition, simulation-based training will be applied to the intern nurses in the study group regarding IV tPA treatment before, during and after the procedure."|"Intern nurses will be numbered from 1 to 75 and will be randomly divided into study and control groups from the random numbers table.~After the groups are determined by the randomization method, each intern nurse in the study and control groups will be interviewed face to face and their written informed consent will be obtained. Then, all nursing intern students participating in the research will be asked to fill in the IV tPA Treatment Knowledge Level Evaluation Form, Self-Efficacy Competence Scale. Intern nurses in both groups will be given 1-hour theoretical training on IV tPA treatment before, during and after the procedure. In addition, simulation-based training will be applied to the intern nurses in the study group regarding IV tPA treatment before, during and after the procedure."|t|f|f|f
33749653|NCT04622696|||OTHER||OTHER|||||||
34171178|NCT01620060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171179|NCT03263546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171180|NCT04449913|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34171181|NCT05698849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Double-blind, randomised, crossover design|t|f|t|f
33749654|NCT02073396|||CASE_CONTROL||PROSPECTIVE|||||||
33749655|NCT03028974|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33749656|NCT04227782|||OTHER||PROSPECTIVE|||||||
33749657|NCT02675361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749658|NCT01754662|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749659|NCT01428648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749660|NCT01691066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749661|NCT05842928|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|To avoid selection bias and Hawthorne bias, the collaborating units (GP practice and community pharmacy) in the intervention group are blinded to the target drugs (PSA-PIM) until the time of randomisation, and in the control group until the end of the study. The same applies to patient participants.||t|t|f|f
33749662|NCT00406835|||DEFINED_POPULATION||PROSPECTIVE|||||||
33749663|NCT00198562|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33749664|NCT04616768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33749665|NCT01898819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33749666|NCT04910893|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective interventional study with comparative matched septic shock cohort|t|f|f|t
33749667|NCT06213454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized, unblinded, single-center trial testing the hypothesis that surgeon-initiated wound infiltration with local anesthetic is non-inferior in providing postoperative pain control when compared with preoperative TAP analgesia.||||
33749668|NCT01401751|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33749669|NCT00829387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749670|NCT01737580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749671|NCT02283931|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33749672|NCT03130400|||CASE_CONTROL||RETROSPECTIVE|||||||
33749673|NCT02622854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749674|NCT04977882|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients were initially randomized for postoperative management into three arms to receive prolonged antibiotic prophylaxis (ABX group), abdominal drain placement (DRAIN group) or neither (NONE group) (I level randomization). The same patients were further randomized for surgical technique in two arms to receive RRC (RRC group) or standard hemicolectomy with D2 dissection (STANDARD group) (II level of randomization).||||
33749675|NCT05234827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749676|NCT06496945|||COHORT||PROSPECTIVE|||||||
33749677|NCT00636870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33749678|NCT01754467|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33749679|NCT00126438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749680|NCT02301143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749681|NCT04392544|||COHORT||PROSPECTIVE|||||||
33749682|NCT03834779|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749683|NCT02725632|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33749684|NCT02238262|||COHORT||PROSPECTIVE|||||||
33749685|NCT04544072|||COHORT||PROSPECTIVE|||||||
33749686|NCT03299608|||COHORT||PROSPECTIVE|||||||
33749687|NCT04832503|||CASE_ONLY||PROSPECTIVE|||||||
33749688|NCT03593655|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33749689|NCT03194802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749690|NCT01953081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840509|NCT03459872|||OTHER||PROSPECTIVE|||||||
33840510|NCT02594657|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33840511|NCT05821582|||COHORT||PROSPECTIVE|||||||
33960451|NCT05829473|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960452|NCT00334828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064014|NCT06535633|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34064015|NCT01990872|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34064016|NCT06731725|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical post-marketing quasi-experimental before-and-after trial, which includes 20 patients diagnosed with mild/moderate dry eye disease (defined by a score on the OSDI test ≥13 and ≤22) who attend the ophthalmology consultation at the outpatient building of the Araba University Hospital and meet the inclusion criteria with no exclusion criteria.||||
34064017|NCT01053130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960453|NCT04539158|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All patients will have 4 defibrillation pads placed: two pads placed in the right infraclavicular and left flank regions, plus two pads placed in the left infraclavicular and right flank regions. Patients will not be told which arm they are randomized to during the procedure.|"Patients will be randomly assigned in a 1:1 fashion to either single-DCCV or dual-DCCV treatment.~All patients will have 4 defibrillation pads placed: two pads placed in the right infraclavicular and left flank regions, plus two pads placed in the left infraclavicular and right flank regions.~Patients randomized to single-DCCV will receive a single 200J shock using the primary (or right anterior-left posterior) pair of pads. Patients assigned to dual-DCCV will receive two simultaneous 200J shocks (from both the primary and secondary set of defibrillator pads), totaling 400J delivered.~Patients in the single-DCCV group whose initial shock fails to restore normal sinus rhythm will be crossed over to the dual-DCCV group. Patients in the dual-DCCV group will receive up to three attempts at DCCV, as needed, at the discretion of the attending electrophysiologist."|t|f|f|f
33960454|NCT03620760|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients were randomly assigned in a 1:1 ratio to receive ticagrelor 90 mg twice daily plus aspirin 100mg once daily or ticagrelor 45 mg twice daily plus aspirin 100mg once daily.||||
33960455|NCT04341207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749691|NCT03521960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind placebo controlled study. Patients are randomized to receive either active buspirone or placebo, each of which is over-encapsulated to support blinding.|Patient completing a residential stay on the Pain Treatment Unit in which this study is being conducted will be enrolled and randomly assigned to receive either buspirone or placebo.|t|t|t|t
33749692|NCT06182995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Target sample size is 120 participants, randomized 1:1 to usual care or Anticipating Decline and Providing Therapy (ADAPT) arm.||||
33749693|NCT06670456|||COHORT||PROSPECTIVE|||||||
33749694|NCT02327026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749695|NCT04021953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749696|NCT06275204|||COHORT||PROSPECTIVE|||||||
33749697|NCT03031691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749698|NCT06241326|||OTHER||OTHER|||||||
33749699|NCT06367621|||OTHER||CROSS_SECTIONAL|||||||
33749700|NCT02420002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749701|NCT02313467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749702|NCT00083408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749703|NCT00716872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749704|NCT06371833|||COHORT||OTHER|||||||
33749705|NCT02470338|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33749706|NCT03667950|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749707|NCT01913067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749708|NCT00386880|||COHORT||PROSPECTIVE|||||||
33749709|NCT00754845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749710|NCT05218967|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749711|NCT04313881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749712|NCT00003334||||TREATMENT||||||||
33749713|NCT05483348|||COHORT||RETROSPECTIVE|||||||
33749714|NCT04266782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinician and outcome assessors at the beginning and after the training/no intervention will not have access to the assigned arm|"A group of Parkinson´s disease Patientserform physical acitivy training for three months followed by long-walking while a parallel group of PD patients will not be included in the training.~A group of age-matched controls will be included in the training protocol as well. matched with"|f|f|t|t
33749715|NCT01490996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749716|NCT00395902|||||RETROSPECTIVE|||||||
33749717|NCT03317600|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33749718|NCT03421054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749719|NCT04814329|||CASE_CONTROL||RETROSPECTIVE|||||||
33749720|NCT00440648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33749721|NCT01011829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749722|NCT03325517|||CASE_ONLY||PROSPECTIVE|||||||
33749723|NCT00811876|||COHORT||RETROSPECTIVE|||||||
33749724|NCT00344786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749725|NCT03119857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749726|NCT02420470|||COHORT||PROSPECTIVE|||||||
33749727|NCT00791765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749728|NCT00872352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749729|NCT05897437|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749730|NCT00907153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749731|NCT00417079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749732|NCT01016769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749733|NCT00517712|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749734|NCT02216058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749735|NCT04222348|RANDOMIZED|PARALLEL||TREATMENT||NONE||Inferiority, randomized, open, parallel arms, multicenter clinical trial||||
33749736|NCT03847324|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blind|Three armed, parallel groups, single blind, unicentric randomized controlled trial|f|f|f|t
33749737|NCT02098200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749738|NCT04377165|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33749739|NCT02297308|||CASE_ONLY||RETROSPECTIVE|||||||
33749740|NCT01433939|||COHORT||PROSPECTIVE|||||||
33749741|NCT03774186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Biostatistician is blinded to intervention assignment|Randomized clinical trial|f|f|f|t
33749742|NCT02478619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749743|NCT00003857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749744|NCT00942214|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749745|NCT02351453|||COHORT||PROSPECTIVE|||||||
33749746|NCT01493804|||||PROSPECTIVE|||||||
33749747|NCT05983822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749748|NCT02109367|||COHORT||PROSPECTIVE|||||||
33749749|NCT03543254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171182|NCT04076085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An employee outside the research team will feed data into the computer in separate datasheets so that the researchers can analyze data without having access to information about the allocation|Following randomization, subjects will be assigned either to receive Intervention OR CONTROL (Standard Care) throughout the entire study period (parallel design)|f|f|f|t
34171183|NCT04957446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator|This is a randomized, controlled, double-blind single-center study. Subjects will be randomized to either Group 1 (Sculptra Aesthetic) or Group 2 Placebo (Saline solution).|t|f|t|f
34171184|NCT03576508|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171185|NCT04032067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171186|NCT03401307|||COHORT||PROSPECTIVE|||||||
34171187|NCT03088891|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34171188|NCT01772966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960456|NCT06239467|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960457|NCT06540365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960458|NCT04529096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960459|NCT00004232||||SUPPORTIVE_CARE||||||||
33960460|NCT03733184|||COHORT||RETROSPECTIVE|||||||
33960461|NCT06360679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960462|NCT04373057|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomized, double blind study||t|t|t|t
33960463|NCT05719129|||COHORT||PROSPECTIVE|||||||
33960464|NCT04776291|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960465|NCT03772184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Using cervical inversion during cesarean section|t|t|t|t
34171189|NCT04896528|NA|SINGLE_GROUP||TREATMENT||NONE||Patients receiving combined targeted therapy (including but not limited to tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors) with immunotherapy (including but not limited to PD-1 inhibitors and/or PD-L1 inhibitors and/or CTLA-4 inhibitors); Patients experienced grade III or above thrombocytopenia (PC ≤50×109/L) at least once within 48 h of the screening period;||||
34171190|NCT04820595|||COHORT||PROSPECTIVE|||||||
34171191|NCT00056095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171192|NCT01865422|NA|SINGLE_GROUP||||NONE||||||
34171193|NCT03536013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Blind study|t|f|f|f
34171194|NCT05323136|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Sequence 1: planned to dose first 1 or 2 sentinels (1 or 2 moderate RI patients) before dosing remaining non-sentinel moderate RI patients. There will be 6 patients with moderate RI in Group 1: RF within 30-59 mL/min. Another group of 6 non-sentinel HVs (Group 2: normal RF, ≥ 90 mL/min) will be one-to-one matched to 6 patients of moderate RI by age, BMI, and gender and may be dosed in parallel to 6 moderate RI patients with same single dose of MT1002.~Sequence 2: same precaution in Sequence 1 will be used: use of staggered dosing schedule where 1 or 2 sentinel subjects (1 or 2 severe RI patients) will be dosed first before dosing remaining non-sentinel RI patients. There will be 6 patients with severe RI, Group 3: RF \< 30 mL/min. A group of up to 6 non-sentinel HVs (normal RF, ≥ 90 mL/min) will be one-to-one matched to 6 patients of severe RI by age, BMI, and gender and will be dosed with same single dose of MT1002."||||
34171195|NCT02325596|||CASE_CONTROL|||||||||
34171196|NCT02372643|NA|SINGLE_GROUP||OTHER||NONE||||||
34171197|NCT04281914|||CASE_ONLY||PROSPECTIVE|||||||
34171198|NCT02834481|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171199|NCT01723098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34171200|NCT01153386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171201|NCT00895635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171202|NCT04247386|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34171203|NCT06125366|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|The study is performed according to a single-blind design, i.e. the participant is blinded to the allocation of treatment.||t|f|f|f
34171204|NCT01213394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171205|NCT00734435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171206|NCT03784508|||COHORT||PROSPECTIVE|||||||
34171207|NCT03547778|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and the care providers (performing the procedure) will not know about the randomization. The research coordinator will perform the randomization and the medicine dispensed by the pharmacy. The study drug and placebo are similar looking, hence the participants and providers would not be able to identify them.|A Double Blind Randomized Controlled Trial|t|t|f|f
34171208|NCT02269124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960466|NCT03535506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960467|NCT05942131|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single blind randomized controlled trial|t|f|f|f
33960468|NCT03720522|||COHORT||PROSPECTIVE|||||||
33960469|NCT01875991|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960470|NCT00683904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171209|NCT01003158|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960471|NCT02549833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171210|NCT00111514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171211|NCT00291135|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171212|NCT04102397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients that fulfilled all the inclusion criteria and gave their informed consent to participate were assigned either to the control group or to the experimental group at random and with equal probability. The randomization sequence was generated with the program EPIDAT by a researcher who was not involved in the therapeutic treatment. It consisted of random permutation blocks, each with 4 to 6 elements of length to avoid imbalances in the groups in case of attrition. The sequence was concealed in sealed, serialized, opaque envelopes.|This is an analytical experimental study conducted as a randomized clinical trial with two parallel intervention levels: a control group and an experimental group. All patients diagnosed with IS by a rehabilitation specialist from the La Mancha Central Hospital were referred to the UFCO, where the study was duly explained to them. The final sample consisted of those patients who fulfilled the inclusion criteria and gave their informed consent in writing.|f|f|t|t
34171213|NCT02360566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171214|NCT04144153|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34171215|NCT05208502|||CASE_CONTROL||PROSPECTIVE|||||||
34171216|NCT00132392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171217|NCT03481894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171218|NCT03268772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960472|NCT04261322|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749750|NCT03157713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749751|NCT02071004|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749752|NCT04478968|||COHORT||CROSS_SECTIONAL|||||||
33749753|NCT03488901|||COHORT||RETROSPECTIVE|||||||
33960473|NCT03023007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960474|NCT06255730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960475|NCT00630448|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749754|NCT01733654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749755|NCT02834780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749756|NCT06406569|NA|SINGLE_GROUP||TREATMENT||NONE||"The study design is a pilot, clinical feasibility, assessor-blinded trial to evaluate the feasibility of Home RehabGym concept through deployment of three rehabilitation devices at patients' homes: MyoPanda, H-Man and ReHandyBot.~During the 6 weeks training at home phase, patients will be provided with two devices at any one time: with only the MyoPanda being used by the patient for 6 weeks. The H-Man and ReHandyBot will stay with the patient for 3 weeks (i.e. 21 days) each and then alternate."||||
33749757|NCT01210391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33749758|NCT06046274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749759|NCT02820623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33749760|NCT00837863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749761|NCT01667601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33960476|NCT04522310|||CASE_ONLY||PROSPECTIVE|||||||
33960477|NCT03759418|||CASE_ONLY||RETROSPECTIVE|||||||
33960478|NCT03872440|||COHORT||PROSPECTIVE|||||||
33960479|NCT02659826|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33960480|NCT06541834|||COHORT||PROSPECTIVE|||||||
33960481|NCT03027973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064018|NCT03953105|||OTHER||PROSPECTIVE|||||||
34064019|NCT03782805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the investigator nor the subjects were aware of the group allocation; the pharmacist (in charge of the placebo tablets as well as the packing and coding of the supplements) was the only person to know to which group each participant belonged.|In this randomized, controlled, double blind study, participants were randomized (using the simple randomization method) to receive either a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) or a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months|t|f|t|f
34064020|NCT03315611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The working hypothesis fo this study is, that local treatment with 'Eucerin AtopiControl Lotion' and 'Eucerin AtopiControl Gesichtscreme' compared to no treatment signifixantly reduces the increase of SCORAD that is elicited during challenge in an environmental challenge chamber (ECC) with grass pollen.|f|f|f|t
33749762|NCT00243204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33749763|NCT04459026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant won't know to what study group they are assigned and will be under general anaesthesia. The study medication will be prepared in the operating room right before use. This means that neither the anaesthesiologist nor the surgeon, performing the surgery, are blinded. The investigators filling in the questionnaires, the patients or the nurses of the recovery room will always be blinded to the study groups, as will the nurse contacting the patients for the follow up.|We will be using ropivacaine - naropin 7,5mg/ml, a local anaesthetic of the amide type. The administered dose of this local anaesthetic will be 3mg/kg for each patient. Depending on the study group the patient belongs to, this dose will be given in full by either local injection at the trocar entry points or by intraperitoneal injection or it will be divided between both injection sites|t|f|t|f
33749764|NCT02549898|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749765|NCT03777098|||CASE_ONLY||PROSPECTIVE|||||||
33859096|NCT06124053|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The allocation of participants to groups will be carried out through stratified sampling based on the Grade parameter of the GRBAS scoring. Accordingly, individuals conducting GRBAS scoring will listen to the recordings of participants in an anonymous manner.|Participants will be grouped based on the Grade scores on the GRBAS scale using a stratified sampling method.|f|f|f|t
33859097|NCT01231516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859098|NCT02818088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749766|NCT04146714|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants: Although they cannot be masked to the content of the intervention (questionnaire), they are only informed that the study is about health behaviours in general and not specifically about substance use. Thus, they are masked as to whether they are in the intervention or control group.||t|t|f|t
33749767|NCT06230848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749768|NCT02004782|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33749769|NCT00054353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749770|NCT05136820|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The Interventional cardiologist will be unblinded and the Heart failure cardiologist and participants will be blinded. There will also be an unblinded study coordinator and a blinded study coordinator.|Patients will be identified from the investigator's pool of heart failure patients who are symptomatic on stable guideline directed medical therapy. An electronic randomization scheme in the EDC system will be used to minimize risk of bias in the investigation|t|t|t|t
33859099|NCT00056862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859100|NCT02831205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859101|NCT00109499||||TREATMENT||NONE||||||
33859102|NCT01211197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171219|NCT04126694|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants will receive 12 sessions of in-person CBT delivered over 12 weeks. In weeks 1-2, participants will wear the CGM devices, but will not receive JITAIs and therapists will not have access to the clinician portal. During weeks 3-4, JITAIs will be turned on such that patients begin to receive push notifications based on CGM data and therapists will have access to the clinician portal. The A/B periods will be repeated (weeks 5-6 and 9-10, SenseSupport Off; weeks 7-8 and 11-12 SenseSupport On) to ensure that improvements in dietary restriction are due to SenseSupport and not simply to the effect of time in treatment. Similar to the approach used in prior studies, participants will be ran in small waves (n= 3-5 per wave). During each wave, feasibility, acceptability, and target engagement will be assessed, and if acceptable milestones have not been achieved, SenseSupport will be modified before beginning the next wave."||||
34171220|NCT04199507|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859103|NCT00979784|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33859104|NCT00328991|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33859105|NCT05424003|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859106|NCT02854293|||||PROSPECTIVE|||||||
33859107|NCT05267860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859108|NCT00975351|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33859109|NCT06279065|||CASE_CONTROL||PROSPECTIVE|||||||
33859110|NCT03457207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859111|NCT00887679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859112|NCT02756156|||CASE_ONLY||RETROSPECTIVE|||||||
33859113|NCT05000892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859114|NCT02379481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859115|NCT03266354|||CASE_ONLY||PROSPECTIVE|||||||
33859116|NCT01522157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859117|NCT02113241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859118|NCT00412971|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33859119|NCT05486546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859120|NCT02885090|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33859121|NCT03783546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859122|NCT02695641|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33859123|NCT03943862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064021|NCT04480333|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The dose escalation given to healthy volunteers across the following cohorts:~NA-831 cohorts:~0.1 mg/kg NA-831, number of subjects N=2 and 2 subjects on placebos 0.2 mg/kg NA-831, number of subjects N=4 and 2 subjects on placebos 0.5 mg/kg NA-831, number of subjects N=4 and 2 subjects on placebos~GS-5734 cohorts:~1. mg/kg GS-5734, number of subjects N=2 and 2 subjects on placebos~2. mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos~4 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos~NA-831 plus GS-5734 cohorts:~0.1 mg/kg NA-831 plus 1 mg/kg GS-5734, number of subjects N=2 and 2 subjects on placebos 0.2 mg/kg NA-831 plus 2 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos 0.5 mg/kg NA-831 plus 4 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos."|t|t|t|f
34064022|NCT03058523|||OTHER||OTHER|||||||
33859124|NCT02712229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33859125|NCT01436760|||CASE_ONLY||RETROSPECTIVE|||||||
33859126|NCT00482924|||COHORT||PROSPECTIVE|||||||
33859127|NCT02196714|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33859128|NCT00465244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859129|NCT01759212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859130|NCT05659277|||COHORT||CROSS_SECTIONAL|||||||
33859131|NCT03212430|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Pilot, Open label|t|t|f|f
33859132|NCT02422251|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33859133|NCT04498065|||COHORT||PROSPECTIVE|||||||
33859134|NCT01388790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859135|NCT05807607|NA|SEQUENTIAL||TREATMENT||NONE||||||
33859136|NCT01708213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859137|NCT04251663|||CASE_CONTROL||PROSPECTIVE|||||||
33859138|NCT02997371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859139|NCT03067012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859140|NCT04969887|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study, all patients receive the same treatment as per the protocol.|||||
33859141|NCT00775450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859142|NCT04658121|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33859143|NCT02886767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859144|NCT04326647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34171221|NCT01235091|RANDOMIZED|PARALLEL||PREVENTION||||||||
34171222|NCT01019187|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34171223|NCT00422851|||COHORT||CROSS_SECTIONAL|||||||
34171224|NCT05873049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171225|NCT01101399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171226|NCT03155165|||CASE_ONLY||CROSS_SECTIONAL|||||||
34171227|NCT03985241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171228|NCT01333748|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34171229|NCT00494403|||CASE_CONTROL||PROSPECTIVE|||||||
34171230|NCT02701517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171231|NCT05464901|||COHORT||RETROSPECTIVE|||||||
33960482|NCT04503031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859145|NCT04592861|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label randomized trial. Subjects will be randomized in a 2:1 ratio to receive carbon ion radiotherapy versus standard care for locally advanced pancreatic cancer.||||
34171232|NCT02955056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171233|NCT02424396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171234|NCT04579146|||CASE_ONLY||PROSPECTIVE|||||||
34171235|NCT05070936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171236|NCT05976555|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34171237|NCT05565365|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34171238|NCT05544526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171239|NCT01094795|||COHORT||PROSPECTIVE|||||||
34171240|NCT01777308|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171241|NCT04323696|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a single blinded randomisation whereby the patient is not aware on the staple-line suturing reinforcement used. Suturing reinforcement of the staple-line is our standard of care in all laparoscopic sleeve gastrectomy patients|All patients who underwent laparoscopic sleeve gastrectomy from March 2020 till February 2021 will be included|t|f|f|f
34171242|NCT01335776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171243|NCT04870658|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34171244|NCT04273607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171245|NCT06417840|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171246|NCT00232622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859146|NCT04723862|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Treatment allocation will be double-blinded. The blind will be broken in the event of any adverse effects that would also lead to study withdrawal. The blind for a given subject will be lifted after the subject completes the study and analysis is complete for that subject.|Randomized, placebo-controlled, crossover study|t|t|t|t
33859147|NCT05786443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33859148|NCT04579601|||COHORT||PROSPECTIVE|||||||
33859149|NCT04626895|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33859150|NCT05914246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960483|NCT04068155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960484|NCT05214599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960485|NCT05103488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960486|NCT02035683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960487|NCT05362409|NA|SEQUENTIAL||TREATMENT||NONE||Part A will include cohorts at escalating duration of sonication. Parts B and C will include the recommended duration as determined in Part A.||||
34171247|NCT04366414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind|parallel-group|f|f|f|t
34171248|NCT05868603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171249|NCT03901417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized split-face clinical trial|t|t|t|f
34171250|NCT03287401|||COHORT||PROSPECTIVE|||||||
34171251|NCT05948241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171252|NCT00663364|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171253|NCT03289793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33859151|NCT01791803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859152|NCT02284048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859153|NCT02263534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960488|NCT06016413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064023|NCT02408952|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34064024|NCT03107975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064025|NCT04683354|NA|SEQUENTIAL||TREATMENT||NONE||||||
34064026|NCT04112095|NA|SINGLE_GROUP||OTHER||NONE||"Drug: Norgestrel 0.075 mg tablets All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."||||
34064027|NCT01583205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171254|NCT02386046|||COHORT||PROSPECTIVE|||||||
34171255|NCT01456286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171256|NCT02389166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171257|NCT02699658|NA|SINGLE_GROUP||||NONE||||||
34171258|NCT03057093|||CASE_CONTROL||RETROSPECTIVE|||||||
34171259|NCT01418144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171260|NCT05668949|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171261|NCT01069484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34171262|NCT01702844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171263|NCT04735835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33859154|NCT03525899|||CASE_ONLY||RETROSPECTIVE|||||||
34171264|NCT05749146|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blind control|Subjects assigned to intervention or control arms in a 1:1 ratio|f|f|f|t
34171265|NCT04098822|||CASE_ONLY||PROSPECTIVE|||||||
33859155|NCT00207389|||COHORT||PROSPECTIVE|||||||
33859156|NCT02643836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171266|NCT05075408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. The randomization code will remain blinded to all participants, study sites personnel and Sponsor/CRO study team members until completion of the study and after the study database has been locked.||t|t|f|f
33859157|NCT00000712||PARALLEL||TREATMENT||||||||
34171267|NCT06266117|||OTHER||PROSPECTIVE|||||||
33859158|NCT02322138|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33859159|NCT01964807|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34171268|NCT00984984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171269|NCT03658421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34171270|NCT00743002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171271|NCT02446184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is an un-blinded, non-randomized, single arm Phase 1 study. Fetal intervention is usually offered to patients carrying fetuses with isolated LUTO that meet the inclusion criteria. Once the patient elected to have fetal intervention, fetal cystoscopy will be offered as an experimental procedure as an option to fetal vesico-amniotic shunting.||||
34171272|NCT01703078|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34171273|NCT03701776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will know that the participant has received balance or aerobic training, but will not be aware of which group the participant belonged.|Single blind randomized control trial|f|f|f|t
34171274|NCT02051764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749771|NCT02836808|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171275|NCT03760029|NA|SINGLE_GROUP||OTHER||NONE||||||
33859160|NCT03770559|RANDOMIZED|PARALLEL||TREATMENT||NONE||The development of study model was divided into 2 parrallel groups( Minimal Invasive RAMPS vs. Open RAMPS) based on the certain surgical procedure underwent||||
33859161|NCT04227548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171276|NCT06252181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171277|NCT04757506|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34171278|NCT04859322|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34171279|NCT00471653|||OTHER||PROSPECTIVE|||||||
34171280|NCT02913703|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33749772|NCT01205594|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33749773|NCT00115700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840512|NCT05646563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided evenly into two cohorts that will be evaluated in parallel. Both cohorts will evaluate NM8074 as a combination therapy with Soliris and Cohort 1 will also evaluate NM8074 as a monotherapy.||||
33840513|NCT03808818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33840514|NCT04395300|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33840515|NCT04822077|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II study||||
33840516|NCT06045715|||COHORT||RETROSPECTIVE|||||||
33840517|NCT05003024|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840518|NCT04761432|NA|SINGLE_GROUP||OTHER||NONE||||||
33840519|NCT01546870|||CASE_ONLY||PROSPECTIVE|||||||
33840520|NCT01409629|||COHORT||PROSPECTIVE|||||||
33840521|NCT03333213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840522|NCT03031496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33840523|NCT01886287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859162|NCT05155241|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33859163|NCT00226850|RANDOMIZED|PARALLEL||||NONE||||||
33859164|NCT02438319|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33859165|NCT00044915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859166|NCT03552822|||COHORT||PROSPECTIVE|||||||
33859167|NCT01137955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859168|NCT01689220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859169|NCT01568437|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33859170|NCT00090090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859171|NCT03491709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33859172|NCT03524300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859173|NCT02045407|||CASE_CONTROL||PROSPECTIVE|||||||
33859174|NCT05736991|||COHORT||PROSPECTIVE|||||||
33859175|NCT05624385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859176|NCT03600857|RANDOMIZED|PARALLEL||OTHER||NONE||Open label, multicentre, RCT||||
33859177|NCT03584113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859178|NCT02566161|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33859179|NCT02054325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859180|NCT00442299|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859181|NCT04021251|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33859182|NCT03933774|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859183|NCT02628756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859184|NCT00402038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171281|NCT01473771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171282|NCT02338726|||COHORT||PROSPECTIVE|||||||
34171283|NCT05494840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34171284|NCT00126035|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171285|NCT01410942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171286|NCT03340389|NA|SINGLE_GROUP||SCREENING||NONE||||||
34171287|NCT02559102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171288|NCT00292240|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34171289|NCT03431740|||OTHER||PROSPECTIVE|||||||
34171290|NCT05678179|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients seeking bariatric surgery will be randomized to a Telehealth Treatment Group or a Face-to-Face (F2F) treatment group.||||
34171291|NCT01673607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34171292|NCT06240637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171293|NCT06510933|NA|SINGLE_GROUP||TREATMENT||NONE|Double (Participant, Outcomes Assessor)|Longitudinal||||
34171294|NCT05364671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171295|NCT00751686|||COHORT||PROSPECTIVE|||||||
34171296|NCT03229122|||COHORT||CROSS_SECTIONAL|||||||
34171297|NCT05581602|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The first phase of this project is a bicentric cross-sectional study in 30 hemiparetic post-stroke subjects in chronic phase and 30 healthy subjects, age and gender matched.~The second phase is a 6-month longitudinal study, in a subgroup of 5 post-stroke subjects."||||
34171298|NCT01570413|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34171299|NCT06053853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171300|NCT00414635|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is designed to compare the control and the experimental arm groups for 24 weeks of treatment. After 24 weeks, subjects on the control arm then cross over to the experimental intervention.||||
34171301|NCT04834817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171302|NCT02344108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171303|NCT02211053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34171304|NCT00466232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171305|NCT04580355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171306|NCT04296656|RANDOMIZED|PARALLEL||OTHER||NONE||"Mothers in the intervention group were taught the infant calming intervention (the 5 S's). The mothers in both control and intervention groups received standard care and support provided by the midwives on the postpartum wards. Baseline data were collected before randomization in the hospital. Follow-up data were collected six to eight weeks postpartum at home.~The research groups were randomized in the following way: The mothers who were on one of the postpartum wards during the days when the intervention (5 S's) were taught, were randomly allocated to the group during the data collection period. The intervention was executed every second week, three days a week on Mondays, Wednesdays and Fridays. The intervention was executed until 120 mothers had participated in them. Control group mothers (n = 130) were recruited by in a similar fashion as the intervention group, but on alternate weeks."||||
34171307|NCT03623243|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single arm study||||
34171308|NCT01985295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171309|NCT02022137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34171310|NCT03494868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859185|NCT02460666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33859186|NCT03651986|||COHORT||PROSPECTIVE|||||||
33859187|NCT01589354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859188|NCT03761446|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33859189|NCT06270927|||COHORT||PROSPECTIVE|||||||
33859190|NCT04578912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859191|NCT03357952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859192|NCT00688012|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34171311|NCT05473988|||COHORT||RETROSPECTIVE|||||||
34171312|NCT01405768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34171313|NCT04299373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomly assigned to one of two routes of alcohol administration: (1) oral consumption, or (2) intravenous infusion.||||
34171314|NCT01311817|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34171315|NCT06182878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171316|NCT05555303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171317|NCT00204152|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33859193|NCT02039791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859194|NCT02347228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171318|NCT04480489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Prospective randomized controlled trial. Pre-clerkship (year 1 and 2) medical students from the University of Toronto Faculty of Medicine will be recruited to take part in the study. Participants will complete a baseline questionnaire collecting data quantifying key potentially confounding factors such as previous 360 videos, previous visits to Toronto Western Hospital, physical gait disability, and navigation experience.~A 2x2 study design will be used to implement counterbalancing as a way to control for two important sources of systematic variation in this type of study: practice and boredom effects"||||
33859195|NCT00003555||||SUPPORTIVE_CARE||||||||
33859196|NCT00963833|||COHORT||PROSPECTIVE|||||||
34171319|NCT02823769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171320|NCT00367328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171321|NCT03741088|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34171322|NCT04086017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial: intervention and usual care||||
34171323|NCT05736874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
34171324|NCT00754702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749774|NCT04637412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The study uses both a between- and within-subjects design.~Between-subjects design: Participants will be randomized to view restaurant menu items with a control label (QR code) or either one of two added sugars labels: an icon based label or the same icon plus text. (Within the icon condition, participants will be randomized to view 1 of 6 label icons. In the icon plus text condition, participants will be randomized to see 1 of 3 text options accompanying 1 of the 6 icons.~Within-subjects design:~To identify which label is perceived as most discouraging, participants will view the 3 labels one-by-one in random order, for a total of 3 conditions.~To identify which design variations in icon and text are perceived as most discouraging, participants will view 6 icon-only labels one-by-one in random order. Then participants will view each of the 3 text variations together with one of the icons one-by-one in random order."|f|f|t|f
33749775|NCT00944138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749776|NCT04298138|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Nine subjects will be assigned to the low dose group. Twenty-one days post inoculation, data will be reviewed for safety and if performance parameters are met. If safety profile is acceptable but performance parameters have not been met, dose escalation to the medium dose will proceed in nine additional subjects. Twenty-one days post middle dose inoculation, data will be reviewed as above and a determination will be made to proceed to the high dose.||||
33749777|NCT01383733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749778|NCT04075123|||COHORT||PROSPECTIVE|||||||
33749779|NCT03066336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749780|NCT05110092|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33749781|NCT01090453|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749782|NCT02199262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749783|NCT06670768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Consecutive patients with suspected coronary artery disease are enrolled. Patients are referred to dynamic and static MPI using 99mTc radionuclide imaged by SPECT, following coronary CTA examination.||||
33749784|NCT00126971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749785|NCT01440153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33749786|NCT03320070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749787|NCT02247427|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34171325|NCT02564666|RANDOMIZED|PARALLEL||||NONE||||||
34171326|NCT02620501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171327|NCT03431298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749788|NCT05080569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded superiority design|The LUMO study is a multicenter, randomized, placebo-controlled trial with cost-effectiveness analysis. Participating sites consist of academic and non-academic hospitals and fertility clinics. There are two treatment arms (MOH/IUI treatment with LPS vs MOH/IUI treatment with placebo) with a non-blinded superiority design. Participants are randomly distributed across both treatment arms for the entire study-period (six months, non-crossover).|t|t|t|t
33749789|NCT00881387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749790|NCT06167187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33749791|NCT05922358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859197|NCT06120348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859198|NCT06236698|||COHORT||RETROSPECTIVE|||||||
34171328|NCT02552966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171329|NCT01927497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171330|NCT01361022|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171331|NCT03449758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171332|NCT01762553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171333|NCT03091959|||OTHER||RETROSPECTIVE|||||||
34171334|NCT04834570|||COHORT||PROSPECTIVE|||||||
34171335|NCT02462694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171336|NCT04569877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171337|NCT03811340|||OTHER||CROSS_SECTIONAL|||||||
34171338|NCT01430871|||CASE_CONTROL||PROSPECTIVE|||||||
34171339|NCT02219646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34171340|NCT02767817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171341|NCT01445444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171342|NCT03776864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171343|NCT04839341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171344|NCT02193776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171345|NCT00617214|||CASE_ONLY||PROSPECTIVE|||||||
34171346|NCT03045367|||CASE_ONLY||PROSPECTIVE|||||||
34171347|NCT04601935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171348|NCT00768612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171349|NCT06380153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171350|NCT06416566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171351|NCT04040374|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34171352|NCT04355234|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"Prospective, multicenter, open study with inclusions of 2200 parturients. All parturients divided into 2 groups:~* 2200 patients whose SARS-Cov-2 status is unknown during pregnancy~* 300 patients who presented a SARS-CoV-2 infection confirmed by PCR during pregnancy whatever the term"||||
34171353|NCT01005251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171354|NCT01672385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34171355|NCT04939766|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal cohort study with a 6 months follow-up evaluation evaluating in type 1 diabetic patients under CSII the impact of closed loop use on quality of life and burden using different validated self questionnaires.||||
34171356|NCT02919774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171357|NCT01502748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171358|NCT04078802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171359|NCT06391554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171360|NCT01862146|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171361|NCT00666666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171362|NCT05919342|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"After agreeing to consent, patients will be randomised 1:1 to one of two arms; a Routine care arm in which patients will undergo routine care or a 2. Investigational arm - patients in this arm will have a blood sample performed for measurement of N-terminal prohormone of B-type natriuretic peptide (NT-proBNP). Patients with an elevated Roche NT-proBNP (≥125 pg/mL) will undergo a transthoracic echocardiogram, clinical examination for signs of HF, HF symptom assessment, an ECG). Patients will undergo echocardiography with a CE-marked, FDA-approved handheld point of care (POC) EchoNous echocardiogram device in all countries. The US2.ai algorithm (which is also CE-marked and FDA-approved) will generate an AI-automated echocardiogram report. In Scotland all patients will also undergo a conventional echocardiogram. Patients who are classified as having heart failure (HFrEF, HFmrEF and HFpEF) will be referred for appropriate follow up."||||
34171363|NCT04921943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171364|NCT03200444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34171365|NCT03691493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171366|NCT00228280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171367|NCT03816735|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open study||||
34171368|NCT01009060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171369|NCT05647681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients are randomly assigned to receive a topic analgesic Douloff or palcebo associated with an oral treatment Paracetamol or placebo"|multi-centre, randomized controlled trial|t|t|f|f
34171370|NCT02918617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171371|NCT02137863|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171372|NCT01229189|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34171373|NCT03324607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171374|NCT00329966|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34171375|NCT05221060|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34171376|NCT00497029|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34171377|NCT06062654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171378|NCT00000669||||TREATMENT||NONE||||||
34171379|NCT05350722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171380|NCT00911118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171381|NCT06081790|||COHORT||PROSPECTIVE|||||||
34171382|NCT03550118|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064028|NCT05818319|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"CF patients will perform a challenged urine bicarbonate test three times during this trial; 1) before, 2) during, and 3) after ETI therapy pause. Each test performance takes 90 min. and is accompanied by baseline blood sampling. First, a baseline urine sample is collected. Then the test person ingests 79 mg. NaHCO3/kg body weight dissolved in tap water (2,25 mL/kg body weight) together with the same amount of clean tap water. After 90 min. the test person delivers the second urine sample, and the test is completed. The test should preferably be performed between breakfast and lunch, at least one hour after intake of food. There should be at least three days between each test.~CF patients will be randomly allocated to an ETI treatment pause for either 12, 36, or 60 hours. Treatment will be resumed immediately after the pause is finished."||||
34064029|NCT00336388|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960489|NCT06701019|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in an online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option."||||
33960490|NCT04514809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician was also blinded for the data analysis purpose|Randomized Controlled Trial|f|f|f|t
34064030|NCT02325245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064031|NCT02090556|||COHORT||PROSPECTIVE|||||||
34064032|NCT04060199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064033|NCT04039321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33960491|NCT01838291|||COHORT||PROSPECTIVE|||||||
33960492|NCT00123305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960493|NCT02832739|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960494|NCT06338800|NA|SINGLE_GROUP||TREATMENT||NONE||During ongoing treatment for their anxiety disorder 30 children and adolescents (8-18 years) with an anxiety disorder will receive a session of exposure with VR. Before the session expectations of VR exposure will be assessed. Before and after the session willingness to participate in exposure in vivo will be measured. During the session anxiety, idiosyncratic expectations, and self-efficacy are measured. After the session, positive effects, experiences, and negative side effects will be asked for.||||
33960495|NCT06185556|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized clinical trial.||||
33960496|NCT06081283|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subjects will be enrolled irrespective of their electroencephalogram (EEG) results, whether positive(+) or negative(-) for epileptogenic activity. All enrolled subjects will undergo an initial resting-state functional MRI (rsfMRI). The results will categorize the patients based on the presence or absence of seizure networks (SzNET), resulting in 2 groups: SzNET+ and SzNET-. SzNET- participants will not undergo further interventions or tests, while SzNET+ subjects will be assigned to the intervention arm and will receive follow-up rsfMRI and EEG.~The study aims to fill 2 quotas in its intervention arm: Participants who are both SzNET+ and EEG+, and another for those SzNET+ but EEG-. Once either of these quotas is complete, the study will cease screening subjects with EEG results falling into that quota. The subjects discharged from hospital on antiseizure medications for medical reasons will be followed up at 3 months post-discharge to collect exploratory data"||||
33960497|NCT02296788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33960498|NCT00538707||PARALLEL||PREVENTION||NONE||||||
33960499|NCT05924568|NA|SINGLE_GROUP||TREATMENT||||||||
33960500|NCT01916759|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960501|NCT04108884|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|Patients and study team will remain blind to the assigned groups until the end of the trial. Only in case of a positive app finding, patients and site team will be unblinded for the remaining time of the trial.|"In this study, the effect of a smartphone application in detecting AF will be assessed in a double-blind randomised controlled trial. Patients will be randomized to an intervention arm (app group) and to a standard-of-care arm (control group). Both groups will have the app installed on their private smartphones and will be asked to perform a predefined measurement protocol. The only difference between the two groups will be, that patients in the app group will be informed by their local PI, if the recordings of the app indicate AF, whereas the patients in the usual care group will obtain the read out of the app at the end of the study (6 months after inclusion)."|t|t|t|f
33960502|NCT04916288|||COHORT||PROSPECTIVE|||||||
33960503|NCT06173986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960504|NCT05135143|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Double blind randomized|t|f|t|f
33960505|NCT05377359|NA|SINGLE_GROUP||TREATMENT||NONE||A single cohort of participants will receive and be assessed in all treatment/intervention conditions||||
33960506|NCT01266473|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960507|NCT05220046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are enrolled as patient/family dyad, with patient in intervention arm and family in observational arm||||
33960508|NCT04183218|||CASE_ONLY||PROSPECTIVE|||||||
33960509|NCT06147609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064034|NCT02974920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064035|NCT04328610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064036|NCT04790955|||CASE_ONLY||OTHER|||||||
34064037|NCT05180955|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be conducted as a, prospective, open label, non-inferiority, randomized controlled trial.||||
34171383|NCT04203511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171384|NCT05941416|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34171385|NCT02257398|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34171386|NCT03065816|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34171387|NCT02284204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34171388|NCT04087980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171389|NCT02559622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171390|NCT02648204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960510|NCT01637259|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33960511|NCT05288842|||CASE_CONTROL||PROSPECTIVE|||||||
33960512|NCT06317363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749792|NCT03734627|||CASE_CONTROL||PROSPECTIVE|||||||
33749793|NCT01747187|||COHORT||PROSPECTIVE|||||||
33749794|NCT01003899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749795|NCT01043770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33749796|NCT01997398|||CASE_ONLY||PROSPECTIVE|||||||
33749797|NCT02212704|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749798|NCT05247996|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is an open-label study. The participants and investigators are not blinded, but the outcomes assessor are blinded.||f|f|f|t
33749799|NCT04838262|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749800|NCT00001533||||TREATMENT||||||||
33749801|NCT01189916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749802|NCT02010840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33749803|NCT06722053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person administering the surveys will not know which group the participants are in, so blinding will be done.|There are two intervention groups and one control group.|f|f|f|t
33749804|NCT03953092|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double Blinded|Single Ascending Dose and Multiple Ascending Dose|t|t|t|f
33749805|NCT05962853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Application will be made by the researcher and the outcome will be assessements will be performed by a investigator who is blinded to group allocation|"Application of the experimental group: 2 hours after the surgery, TENS will be applied for 30 minutes and then TENS will be applied 3 times at 8 hour intervals. Postoperatively at the 2nd hour (just before TENS), at the 3rd hour (1 hour after the onset of TENS), at the 10th hour (just before the TENS), at the 11th hour (1 hour after the start of TENS), at the 18th hour ( Just before TENS) at the 19th Hour (1 hour after the start of TENS). In order to protect sleep integrity, TENS application hours will be arranged according to the patient.~Application of the control group: TENS will not be applied to this group"|t|f|f|t
33749806|NCT04666168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749807|NCT03229369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeons and participants of the study will not be blinded due to the intrinsic characteristics of the intervention trials, in which it is impossible to blind surgeons and avoid acknowledgement of the participants of which procedure they were assigned. However, outcome evaluation will be performed by an individual who will not have acknowledgement of which group the patient was allocated.||f|f|f|t
33749808|NCT04351867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749809|NCT02468427|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33749810|NCT00223860|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749811|NCT05185310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients will be blinded to strategy used|single blinded randomized trial comparing 3 ablation strategies|t|f|f|f
33859199|NCT04664010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blinding and blinding maintenance~(1)The biostatisticians and the personnel unrelated to the clinical trial complete the binding of the study drugs and emergency card preparation. The random coding table and corresponding parameters are recorded blindly. After drug designation, the personnel responsible for blinding of the study drugs will sign at the perforation of the blinding envelope.~A two-level blinding design will be adopted. The first-level code corresponds to intervention A or intervention B, and the second-level code presents the corresponding group. The envelope containing two-level blinding file will be preserved in Tianjin Angsai Cell Gene Engineering Co., Ltd., China until unblinding. The unblinding will not be performed during the study period."|participants are assigned to one of two or more groups in parallel for the duration of the study|t|f|f|f
34171391|NCT02436525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33749812|NCT01667432|||COHORT||PROSPECTIVE|||||||
33749813|NCT01852539|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33749814|NCT01990950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749815|NCT06635681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749816|NCT01834066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749817|NCT00209417|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33749818|NCT00794612|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33749819|NCT02372396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749820|NCT05283317|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749821|NCT06431282|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33749822|NCT05216094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859200|NCT00243360|RANDOMIZED|PARALLEL||ECT||NONE||||||
33859201|NCT04331054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859202|NCT02265263|||COHORT||PROSPECTIVE|||||||
33859203|NCT02674100|||COHORT||PROSPECTIVE|||||||
34171392|NCT02904798|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33859204|NCT06127056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960513|NCT06480565|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose Escalation Design||||
33960514|NCT05775146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960515|NCT01856686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33960516|NCT00485368|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34171393|NCT02715739|||COHORT||RETROSPECTIVE|||||||
34171394|NCT06373016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749823|NCT01229098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749824|NCT04876248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749825|NCT04551378|||COHORT||PROSPECTIVE|||||||
33749826|NCT03385122|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33749827|NCT01250977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double Blind|This is a double-blind, human laboratory study using a between-subject design between smokers who are randomized to either donepezil HCL (Aricept®) (n=15) or placebo (n=15) for 4 weeks. Treatment randomization will be done to match both groups for age and sex.|t|f|t|f
33749828|NCT03664687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749829|NCT01538550|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33749830|NCT04068753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749831|NCT01221987|||CASE_ONLY||CROSS_SECTIONAL|||||||
33749832|NCT04778033|||COHORT||PROSPECTIVE|||||||
33749833|NCT04793191|||COHORT||PROSPECTIVE|||||||
33749834|NCT05278169|||CASE_ONLY||PROSPECTIVE|||||||
33749835|NCT02114593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960517|NCT05104736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960518|NCT06113263|||COHORT||PROSPECTIVE|||||||
33960519|NCT05822024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33960520|NCT00965263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960521|NCT05115955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171395|NCT03660462|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34171396|NCT06072911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants will be randomized after the baseline assessment and will have the option to take part in an additional exercise intervention component.|Zelen design with randomization|t|f|f|t
34171397|NCT05802004|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The sleep techs who will score the sleep record and the fMRI personnel conducting the scanning sessions will also be masked.|This is a randomized, within-subjects, crossover design with two conditions: acoustic stimulation (STIM) and no acoustic stimulation (SHAM), followed by an at-home randomized, between-subjects design with two conditions: daily acoustic stimulation (STIM2) or no daily acoustic stimulation (SHAM2).|t|f|f|f
34171398|NCT04554420|NA|SINGLE_GROUP||PREVENTION||NONE||Participants (youth) will receive intervention (mental health curriculum) and a pre-intervention and post-intervention survey will be used to evaluate the intervention. Additionally, a set of focus groups will be conducted post-intervention to assess the feasibility, implementation process, and youth responsiveness. No control condition will be used for this pilot intervention.||||
34171399|NCT05489848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171400|NCT05897463|||CASE_CONTROL||RETROSPECTIVE|||||||
34171401|NCT04325802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34171402|NCT06088862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171403|NCT01367899|||COHORT||PROSPECTIVE|||||||
34171404|NCT01153165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171405|NCT04434079|||CASE_ONLY||PROSPECTIVE|||||||
33749836|NCT02570490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749837|NCT05556681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749838|NCT03624101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749839|NCT00423176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749840|NCT05022680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomize control trial||||
33749841|NCT05278455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749842|NCT05260801|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Investigators will examine a series of participants (N=36), each of whom will participate in a five-week experiment. Each participant will have a screening visit at their home. The study will be conducted over five successive one-week periods with two cohorts of participants experiencing the same series of lighting interventions. All data collection will be performed during the working days (Monday - Friday) when participants are exposed to the lighting in their home offices.|t|f|f|t
33749843|NCT01338363|||COHORT|||||||||
33749844|NCT03586102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Clinicians and technicians responsible for the assessment of infant body composition will be masked.||t|t|t|t
33749845|NCT01308918|||COHORT||PROSPECTIVE|||||||
33749846|NCT05150704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind randomized controlled trial|t|f|f|f
33749847|NCT03827187|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33749848|NCT01835886|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33749849|NCT06293157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749850|NCT02779153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749851|NCT04541134|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33749852|NCT03412669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33749853|NCT04380454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749854|NCT03543826|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749855|NCT03659838|||OTHER||CROSS_SECTIONAL|||||||
33749856|NCT04483050|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33749857|NCT00272857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749858|NCT01362738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749859|NCT05258162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749860|NCT05077579|||CASE_CONTROL||PROSPECTIVE|||||||
33749861|NCT01060293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749862|NCT05592119|||OTHER||PROSPECTIVE|||||||
33749863|NCT05131048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33749864|NCT04868266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749865|NCT03101735|||COHORT||PROSPECTIVE|||||||
33749866|NCT06548555|||COHORT||PROSPECTIVE|||||||
33749867|NCT05688995|||COHORT||CROSS_SECTIONAL|||||||
33749868|NCT04513990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749869|NCT06497400|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960522|NCT05674266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960523|NCT00486642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960524|NCT01581073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960525|NCT04605029|||COHORT||PROSPECTIVE|||||||
33859205|NCT00846456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859206|NCT02174796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859207|NCT00084266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859208|NCT03035786|||COHORT||PROSPECTIVE|||||||
33859209|NCT02235974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859210|NCT04242160|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants were randomized to the order of intervention. After completing the first RT technique assigned, participants complete the alternative RT technique||||
33859211|NCT01504750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859212|NCT01101477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33859213|NCT03672422|||COHORT||PROSPECTIVE|||||||
33859214|NCT03193788|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|||||
33859215|NCT05722054|||OTHER||PROSPECTIVE|||||||
33859216|NCT04747782|||COHORT||PROSPECTIVE|||||||
33859217|NCT03151317|||CASE_CONTROL||RETROSPECTIVE|||||||
33859218|NCT04143750|NA|SINGLE_GROUP||OTHER||NONE|unrandomization and open labeled study|single arm with single dose of 20mg vicagrel, containing about 120μCi \[14C\]Vicagrel||||
33859219|NCT01748357|||CASE_CONTROL||PROSPECTIVE|||||||
33859220|NCT00253877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171406|NCT01334060|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171407|NCT00001944||||TREATMENT||||||||
34171408|NCT03320668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blind analysis to prevent bias|Non-inferiority clinical trial, multicentric, simple blind|f|f|f|t
34171409|NCT05030025|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-dose, randomized, two-period, two-treatment, two-group, crossover study.||||
34171410|NCT00003343|RANDOMIZED|||TREATMENT||||||||
34171411|NCT03833323|||COHORT||PROSPECTIVE|||||||
34171412|NCT04050046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants are assigned to either receive real or sham tDCS without the option of crossover.|t|f|t|f
34171413|NCT05135871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171414|NCT03438617|NA|SINGLE_GROUP||TREATMENT||NONE||"Original Design: This study uses a stepped wedge design in three successive cohorts. Ten community health centers (CHC) will be randomized to one of three cohorts, 3 CHCs in the first cohort vs. 3 CHCs in the second cohort vs. 4 CHCs in the third cohort.~Actual Implementation: The Peer Leader program was designed as an implementation study to assess the feasibility, effectiveness and sustainability of integrating peer support with routine care in CHCs. 10 CHCs were selected in this community-based prospective cohort study according to their having in place the key organizational resources and willingness to collaborate. However, one CHC withdrew due to its administrator's judgement of insufficient staff resources for implementation, resulting in 9 CHCs. A planned, stepped wedge design to stagger introduction of the program over subsets of CHCs proved impractical within the realities of those sites. Finally, 9 CHCs participated in this study as one single interventional group."||||
34171415|NCT00790946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171416|NCT05763017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171417|NCT04445961|||CASE_ONLY||PROSPECTIVE|||||||
34171418|NCT03678207|||COHORT||PROSPECTIVE|||||||
34171419|NCT05919576|||COHORT||CROSS_SECTIONAL|||||||
34171420|NCT06349564|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749870|NCT02792075|||COHORT||PROSPECTIVE|||||||
33859221|NCT03693456|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33859222|NCT00599976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859223|NCT04631796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859224|NCT06526832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859225|NCT00872196|NA|SINGLE_GROUP||||NONE||||||
33859226|NCT00735735||PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33859227|NCT06321549|||CASE_CONTROL||RETROSPECTIVE|||||||
33859228|NCT00210301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33859229|NCT01975454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859230|NCT04134364|RANDOMIZED|PARALLEL||PREVENTION||NONE||open labeled, single-center randomized controlled trial||||
33859231|NCT04743479|||COHORT||PROSPECTIVE|||||||
33859232|NCT00846339|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893692|NCT05973409|RANDOMIZED|PARALLEL||OTHER||DOUBLE|At the fitting visit, only uncoated lenses will be used to determine the parameters of the lenses to be ordered. At both dispense visits, participants and investigators will be masked to the lens type dispensed. In order to achieve this, unmasked study personnel will determine the order of lens wear according to the randomization schedule and they will not share the lens labels or packs with the investigator. Instead, the lenses will be transferred to an unmarked case/container prior to being provided at the Dispense visit.||t|f|t|f
33960526|NCT05688670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960527|NCT05224206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be divided in two main parts. In Part I, we will use a randomized cross-over double-blinded design. The order of the iTBS conditions (active vs. sham) will be counterbalanced across participants. In part II, participants will receive a 6-week daily iTBS open-label treatment. Participants and research team members performing iTBS and analyses will be blind to the stimulation condition for Part I of the study. The order of the conditions will be determined by a separate research team member that will not be performing iTBS or analyses. Participants will be told that there is a sham condition, for Part I of the trial. The master randomization list was created by a scientist of the research centre that is not involved in the research project.||t|t|t|f
33960528|NCT06058507|||COHORT||RETROSPECTIVE|||||||
33960529|NCT06203288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960530|NCT00337129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960531|NCT01173588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960532|NCT00288119|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33960533|NCT06408428|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33960534|NCT06563973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960535|NCT02507258|||COHORT||PROSPECTIVE|||||||
33960536|NCT05503264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960537|NCT04426019|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960538|NCT03315715|||OTHER||PROSPECTIVE|||||||
33960539|NCT06285643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171421|NCT05683847|||COHORT||PROSPECTIVE|||||||
33859233|NCT04729764|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This trial uses a double-blind technique, that is, neither the investigator nor the subject knows what kind of drug they are taking. The sponsor or its designated unit shall provide the trial drug and placebo to ensure that the placebo's shape, color, smell, taste, and weight are consistent with the trial drug, and the drug randomization and supply management system (RTSM) is used for drug randomization|According to the initial dose and maximum dose interval, it is designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the initial dose group (20mg) has 8 subjects (including 2 placebo), and each of the others 10 subjects in the dose group (including 2 placebo), male and female.|t|f|t|t
33859234|NCT03812497|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"Intervention arm: every obese children will have individualized education program about diet control and exercise in usual life.~Control arm: normal weight children"||||
33960540|NCT01642693|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33960541|NCT03512067|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a device trial to examine the efficacy of the new mode of mechanical ventilation. It will be single-armed and open label.||||
33960542|NCT00896701|||CASE_ONLY||PROSPECTIVE|||||||
33960543|NCT05614466|NA|SINGLE_GROUP||OTHER||NONE||||||
34171422|NCT03424564|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34171423|NCT06081296|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Randomization by electronically generated list; Different examiners than operator; Bliding patient;|Randomized Clinical Trial|t|f|t|t
34171424|NCT05962866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|statistician||f|f|f|t
34171425|NCT00670215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34171426|NCT06579443|||COHORT||PROSPECTIVE|||||||
34171427|NCT00001959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171428|NCT05895474|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Randomization files will be provided by the sponsor and be blinded to the participants, care provider, and investigators|"Part One:~Each participant will receive 1 focused ultrasound stimulation conditions per visit for 4 visits~Part Two:~If called back, participant will receive 1 focused ultrasound stimulation conditions per visit for 4 visits"|t|t|t|f
34171429|NCT01772628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171430|NCT00806182|||CASE_CONTROL||OTHER|||||||
34171431|NCT03467321|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171432|NCT02890797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171433|NCT01476670|||COHORT||PROSPECTIVE|||||||
34171434|NCT05298488|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The participants will be allocated to either office from home for the first four weeks, followed by working at the office for four weeks, or vice versa.||||
34171435|NCT05957679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171436|NCT03552666|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized, examiner-blind, comparator-controlled crossover study|f|f|t|f
34171437|NCT03800056|||COHORT||PROSPECTIVE|||||||
34171438|NCT02974998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171439|NCT06525285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171440|NCT00646139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171441|NCT05219630|||COHORT||PROSPECTIVE|||||||
34171442|NCT03186612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments were conducted by masked evaluators. They were not related to the interventions.|It will be conducted a blinded randomized controlled trial (RCT). Non-probabilistic sampling of consecutive cases will be used.|f|f|f|t
34171443|NCT04233008|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34171444|NCT04472052|||COHORT||OTHER|||||||
34171445|NCT03515993|||COHORT||PROSPECTIVE|||||||
34171446|NCT05706922|||CASE_CONTROL||PROSPECTIVE|||||||
34171447|NCT03567772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171448|NCT00231777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34171449|NCT00799682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34171450|NCT02240485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171451|NCT00112736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171452|NCT00778934|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34171453|NCT03407898|||CASE_CROSSOVER||PROSPECTIVE|||||||
34171454|NCT00967564|||COHORT||PROSPECTIVE|||||||
34171455|NCT05091658|||COHORT||PROSPECTIVE|||||||
34171456|NCT02830737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171457|NCT02119585|||CASE_ONLY||PROSPECTIVE|||||||
34171458|NCT04262700|NA|SINGLE_GROUP||OTHER||NONE||||||
34171459|NCT03880539|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention group will consist of a single arm of patients treated with BEZLO + SOC oral VAN pulse/taper for multi-recurrent CDI, with a planned enrollment of 12 patients. To achieve the aim of the proposed study, we will compare the efficacy of BEZLO + SOC oral VAN pulse/taper to a historical cohort of patients treated with SOC oral VAN pulse/taper only. These patients will be matched 1:6 on criteria previously outlined in this proposal (BEZLO + SOC, n=12; SOC comparator, n=72; total number of patients in study, n=84).||||
34171460|NCT03957148|RANDOMIZED|PARALLEL||PREVENTION||NONE||The efficacy of the Information Motivation Behavior (IMB) behavior-change model articulated to child sugar sweetened beverage (SSB) consumption will be assessed using a randomized, pretest-posttest control group design involving approximately 400 primary caretakers of 3-5-year old children in 20 sites over a 3-year period. These sites will be randomly assigned to two experimental conditions: 10 sites will receive a 10-week SSB education intervention and 10 sites will be assigned to the control group and will receive 10 weeks of alternative nutrition education not related to SSB. Although the investigators expect the program to be widely implemented, the team will select 20 parents from each site to participate in the research study. Random assignment of sites to experimental conditions will be achieved using a random numbers table. Data collection for the two groups will be conducted at baseline (prior to education implementation) and at 1 week and 6 months post-intervention.||||
34171461|NCT00107692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171462|NCT02467179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171463|NCT02952365|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171464|NCT06064630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859235|NCT03834987|||COHORT||PROSPECTIVE|||||||
33960544|NCT00146133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34171465|NCT06421857|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34171466|NCT02495428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171467|NCT01157702|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171468|NCT04339257|||COHORT||PROSPECTIVE|||||||
34171469|NCT00242671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34171470|NCT03557970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171471|NCT00409071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859236|NCT00499356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33859237|NCT01506297|||COHORT||PROSPECTIVE|||||||
33859238|NCT00509587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859239|NCT01626703|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34171472|NCT06518356|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34171473|NCT02185911|||COHORT|||||||||
34171474|NCT04746508|||OTHER||RETROSPECTIVE|||||||
34171475|NCT01654848|||COHORT||PROSPECTIVE|||||||
34171476|NCT06117735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171477|NCT01962792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171478|NCT01363375|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171479|NCT00436150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33859240|NCT05608902|||OTHER||PROSPECTIVE|||||||
33859241|NCT05803590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of the operator and the patients will not be applicable due to the difference between the used mouthwashes. However, the statistician will be blinded.||f|f|f|t
33859242|NCT04720222|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33859243|NCT04599400|||OTHER||RETROSPECTIVE|||||||
33859244|NCT01028898|||CASE_CONTROL||PROSPECTIVE|||||||
33859245|NCT06087016|||CASE_CONTROL||PROSPECTIVE|||||||
33859246|NCT03699436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33859247|NCT05627713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33859248|NCT04576143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859249|NCT02823756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859250|NCT03722056|||CASE_ONLY||RETROSPECTIVE|||||||
33859251|NCT05821751|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859252|NCT04175002|||CASE_CONTROL||PROSPECTIVE|||||||
33859253|NCT02183532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171480|NCT02583061|||COHORT||PROSPECTIVE|||||||
34171481|NCT00167115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171482|NCT02660788|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34171483|NCT03609437|||CASE_CONTROL||PROSPECTIVE|||||||
34171484|NCT04862715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171485|NCT03969914|||COHORT||PROSPECTIVE|||||||
34171486|NCT03212326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171487|NCT04247347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34171488|NCT06211946|||COHORT||CROSS_SECTIONAL|||||||
34171489|NCT06077721|||OTHER||PROSPECTIVE|||||||
33859254|NCT02045654|||CASE_ONLY||RETROSPECTIVE|||||||
33859255|NCT00542594|||COHORT||PROSPECTIVE|||||||
33859256|NCT02211144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859257|NCT04510909|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33859258|NCT03877432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859259|NCT04417374|||COHORT||PROSPECTIVE|||||||
33859260|NCT00482196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859261|NCT02720614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859262|NCT02781272|||COHORT||PROSPECTIVE|||||||
33960545|NCT02163031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960546|NCT00791154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960547|NCT01441401|||CASE_ONLY||PROSPECTIVE|||||||
33960548|NCT06527846|||COHORT||PROSPECTIVE|||||||
34171490|NCT02893319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34171491|NCT05898906|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171492|NCT04532671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171493|NCT02761226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171494|NCT00188552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171495|NCT02348177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171496|NCT02476149|||COHORT||PROSPECTIVE|||||||
34171497|NCT01069432|||COHORT||PROSPECTIVE|||||||
34171498|NCT04743115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171499|NCT02743585|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34171500|NCT04540263|||CASE_ONLY||PROSPECTIVE|||||||
34171501|NCT02908022|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34171502|NCT01022021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171503|NCT04463472|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34171504|NCT01576341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171505|NCT00737113|NA|SINGLE_GROUP||||NONE||||||
34171506|NCT01210924|||COHORT||PROSPECTIVE|||||||
34171507|NCT03177863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171508|NCT05698641|||CASE_CONTROL||PROSPECTIVE|||||||
34171509|NCT06314386|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Crossover Cluster||||
34171510|NCT00711698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171511|NCT01528059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171512|NCT01722305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171513|NCT01198197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171514|NCT02785848|||COHORT||PROSPECTIVE|||||||
34171515|NCT00003605||||TREATMENT||||||||
34171516|NCT06279858|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is open label trial without masking, where each participant receives probiotic for 3 months (12 weeks). It will be single group assignment. In this approach, participants act as their own controls by measuring the microbiome and other parameters before and after taking the probiotics. This design was chosen because individual's microbiome is highly personalized. Even within a family, individuals can have distinct microbiomes. The unique composition of an individual's microbiome can have implications for the effectiveness of probiotics. Thus, changes in analyses and scores between baseline and 3-month study period will be assessed for everyone. Specifically, microbiome modifications that may be associated with changes in behavior and brain processing will be examined.||||
34171517|NCT03118310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171518|NCT05003375|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171519|NCT05671692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171520|NCT04789252|||COHORT||PROSPECTIVE|||||||
34171521|NCT00391885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171522|NCT04931264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171523|NCT02993614|||COHORT||PROSPECTIVE|||||||
34171524|NCT03517475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34171525|NCT06082934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171526|NCT06002412|||COHORT||PROSPECTIVE|||||||
34171527|NCT03598179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171528|NCT00271635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171529|NCT01182259|||CASE_CONTROL||PROSPECTIVE|||||||
34171530|NCT04669223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171531|NCT00675714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171532|NCT05255523|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171533|NCT01393834|RANDOMIZED|PARALLEL||||NONE||||||
34171534|NCT01519323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171535|NCT05077826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171536|NCT04051398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|. To minimize the impact of non-blinding investigators, will be designated a specific investigator who will be responsible for randomizing participants at the time of TENS application and performing the intervention do not allowing the investigators responsible for data collection know whether the patient will be BI or BC. After data collection, the same investigator will segregate the information from BC and BI keeping the subgroups identification in secret do not allowing the investigator who will perform the statistical analysis know what are the groups.|Randomized controlled trial|t|f|f|t
34171537|NCT02682381|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34171538|NCT05062122|||COHORT||OTHER|||||||
34171539|NCT05356208|||COHORT||RETROSPECTIVE|||||||
34171540|NCT02529540|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a randomized non-inferiority trial, and the margin of the non-inferiority is 20%.||||
34171541|NCT02855203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171542|NCT00002998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171543|NCT02153593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171544|NCT06524609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171545|NCT01814774|||COHORT||RETROSPECTIVE|||||||
34171546|NCT05255471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171547|NCT01619735|||COHORT||PROSPECTIVE|||||||
34171548|NCT03481478|||CASE_ONLY||PROSPECTIVE|||||||
33859263|NCT06038136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859264|NCT04908605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34171549|NCT03399058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960549|NCT06425146|NA|SINGLE_GROUP||PREVENTION||NONE||"A clinical-biological cohort of patients with epidermoid carcinomas of the oral cavity.~Blood sample and cytobrush sample at inclusion and before anti-cancer treatment."||||
33960550|NCT02041182|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33960551|NCT01396473|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33749871|NCT06187753|||CASE_CONTROL||PROSPECTIVE|||||||
33749872|NCT02866565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749873|NCT01726868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749874|NCT02324933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33749875|NCT05446987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749876|NCT03199625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749877|NCT06326515|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial design would be used in this study. It would be two arm study and there would be two groups an experimental and wait-list control group. Experimental group will receive intervention and another group would be placed in waitlist. In this research, parallel group design would be used. We will give treatment to all participants in a parallel way. Allocation ratio and framework would be equivalence i.e., treatment group and control group would be equal number of participants||||
33749878|NCT01641978|||||PROSPECTIVE|||||||
33749879|NCT05881616|||COHORT||CROSS_SECTIONAL|||||||
33749880|NCT02639130|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33749881|NCT05176808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants will receive the same outcome battery of assessments. The individual evaluating the child and all coders will be blind to condition.|Upon confirmation of eligibility and completion of the baseline assessments, participants will be randomly assigned to the TC or IPC study condition. Randomization will be done in randomly permuted groups of different sizes to reduce predictability of treatment assignment, with one half of the parent-child dyads in each block assigned to the IPC arm and one half assigned to the TC condition.|f|f|f|t
33749882|NCT03894865|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33749883|NCT00649194|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33749884|NCT01512862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749885|NCT05864690|||COHORT||PROSPECTIVE|||||||
33749886|NCT00006231||||TREATMENT||||||||
33749887|NCT06231173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33749888|NCT03872102|||COHORT||PROSPECTIVE|||||||
33749889|NCT01923155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33749890|NCT05188573|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33749891|NCT00664651|||CASE_CONTROL||RETROSPECTIVE|||||||
33749892|NCT06392776|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33749893|NCT06382350|||COHORT||PROSPECTIVE|||||||
33749894|NCT06580808|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in the Fontan group were randomized into the Fontan Training Group (FTG) and Fontan Control Group. The FTG performed inspiratory muscle training with the Power Breth device with an initial load of 40% of the maximum inspiratory pressure obtained by measuring the maximum inspiratory pressure by manovacuometry. The training lasted 2 months. The patient was asked to perform the training every day with 3 series of 20 breaths. The training was monitored in person and remotely by videoconference; the load was increased gradually when it was perceived that it was already easy or reported by the child.||||
33749895|NCT01200212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749896|NCT00517738|RANDOMIZED|PARALLEL||||NONE||||||
33749897|NCT05052801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749898|NCT00450762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749899|NCT02672631|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749900|NCT04650789|||COHORT||PROSPECTIVE|||||||
33749901|NCT04824404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749902|NCT06195917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960552|NCT02901509|||COHORT||PROSPECTIVE|||||||
33960553|NCT02465710|||CASE_ONLY||RETROSPECTIVE|||||||
33960554|NCT01154673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749903|NCT00674986|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960555|NCT02696018|||COHORT||PROSPECTIVE|||||||
33960556|NCT01502917|NA|SINGLE_GROUP||OTHER||NONE||||||
33960557|NCT00310700|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33960558|NCT01293318|||COHORT||PROSPECTIVE|||||||
33960559|NCT04929951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Micro Fragmented Adipose Tissue (MFAT) on Shoulder Osteoarthritis|t|f|f|t
33960560|NCT06521684|||CASE_ONLY||CROSS_SECTIONAL|||||||
33749904|NCT06496529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33749905|NCT03655353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigators will determine HER2 expression by ABY-PET without knowledge of the results from the biopsies (in Phase III part).|||||
33749906|NCT04897776|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||After controlling for implant effects and hippocampal stimulation, there will be a period of blinding for thalamic stimulation. Physician and patient will not know which seizures during this period receive stimulation or sham stimulation. The primary outcome measure will be comparing behavioral awareness scores during this period, sham stimulation compared to therapeutic stimulation.|t|f|t|f
33749907|NCT02748915|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33749908|NCT01045629|||COHORT||CROSS_SECTIONAL|||||||
33960561|NCT02218931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960562|NCT00116207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960563|NCT06445608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960564|NCT00293475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960565|NCT06538545|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960566|NCT05862116|||COHORT||PROSPECTIVE|||||||
33960567|NCT02231307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749909|NCT02576678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749910|NCT04786158|||COHORT||PROSPECTIVE|||||||
33749911|NCT04461977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Sham acupuncture|True acupuncture vs sham acupuncture|t|f|f|f
33749912|NCT02475096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749913|NCT03591068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749914|NCT01142206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749915|NCT04338100|||CASE_ONLY||PROSPECTIVE|||||||
33960568|NCT03663205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749916|NCT06011590|||COHORT||RETROSPECTIVE|||||||
33749917|NCT02001857|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33960569|NCT03447054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 (active, sham tDCS) x 2 (active, inactive response inhibition training) factorial design|t|t|f|t
33960570|NCT06537024|||COHORT||RETROSPECTIVE|||||||
33960571|NCT01578252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960572|NCT05117931|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, phase II study of Amivantamab.||||
33960573|NCT06004401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960574|NCT02282007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960575|NCT01816438|||COHORT||PROSPECTIVE|||||||
33960576|NCT04057573|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Participants will receive ruxolitinib cream or vehicle for 24 weeks, after which they will be offered the opportunity to continue in the treatment extension period. Participants initially randomized to vehicle will be crossed over to active drug, and participants treated with ruxolitinib cream will receive an additional 28 weeks of treatment with ruxolitinib cream.|t|f|t|t
33960577|NCT00003276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960578|NCT00684216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960579|NCT05764837|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33960580|NCT05974293|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This is a phase II, single-site, double-blind, randomized, placebo-controlled 2 by 2 crossover clinical trial designed to evaluate the efficacy of nabiximols compared to placebo for the treatment of NMOSD-related spasticity.|t|f|t|t
33960581|NCT01419873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960582|NCT03994419|||COHORT||PROSPECTIVE|||||||
33960583|NCT02554825|RANDOMIZED|PARALLEL||PREVENTION||||||||
33960584|NCT04871724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960585|NCT05112406|||COHORT||PROSPECTIVE|||||||
33960586|NCT04634526|||COHORT||PROSPECTIVE|||||||
33749918|NCT01640808|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33749919|NCT01987648|||COHORT||PROSPECTIVE|||||||
33749920|NCT02035280|||COHORT||PROSPECTIVE|||||||
33749921|NCT06669221|||COHORT||RETROSPECTIVE|||||||
33749922|NCT06211400|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33749923|NCT01929967|||COHORT||PROSPECTIVE|||||||
33960587|NCT03966196|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||half healthy subject, half COPD patients||||
33960588|NCT00265863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960589|NCT04221217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960590|NCT02742818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960591|NCT03870737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960592|NCT06542705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960593|NCT02866123|NA|SINGLE_GROUP||||NONE||||||
33960594|NCT05855525|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960595|NCT02256059|||COHORT||PROSPECTIVE|||||||
33960596|NCT01887860|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960597|NCT02367729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960598|NCT05926544|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Study staff who are rating fidelity will be blinded to whether the observation is from the standard implementation or virtual facilitation condition.|"The investigators will use an incomplete stepped wedge cluster randomized design, where units (pharmacies) begin in one condition (standard implementation approach) and crossover to the other condition (virtual facilitation)."|f|f|f|t
33960599|NCT03165331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960600|NCT02476500|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33960601|NCT06433986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960602|NCT00348218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960603|NCT03649256|||CASE_CONTROL||PROSPECTIVE|||||||
34171550|NCT06403007|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We will randomize clusters, our cluster units being schools that children attend. Cluster randomization is to one of two active teacher-delivered interventions: phonics plus morphology versus phonics plus morphology.|f|f|f|t
34171551|NCT04046328|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This study will be fully blinded, using the double dummy technique (combination of active ECC capsules and matching placebo in the low dose treatment arm).|Multiple-center, randomized, double-blind, double dummy, 2-period, 2-sequence cross-over design|t|t|t|t
33960604|NCT06583148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization will be supervised by the study statistician and data collection staff will be blind to group assignment.||f|f|f|t
33960605|NCT05981612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33749924|NCT00934466|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33749925|NCT03558048|||COHORT||PROSPECTIVE|||||||
33859265|NCT04858139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Numbered vials, prepared by hospital pharmacy||t|t|t|t
33859266|NCT00557583|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33859267|NCT05282615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859268|NCT06209671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859269|NCT05127369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33859270|NCT01933113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859271|NCT03178929|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859272|NCT04218955|||COHORT||CROSS_SECTIONAL|||||||
33859273|NCT04272970|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Each participant will receive at the time of recruitment a normalized code number that will remain confidential for the investigators, and which will hide his / her full identity|Within each family that will be studied for functional studies of platelets and MKs, subjects both harboring a variant gene / protein and presenting with CT will be compared to non CT family members with a normal gene / protein (control subjects) in parallel investigation ; when family control subject(s) will not be available, a subject external to the family with no evidence for CT will be recruited as a control subject|t|f|f|f
33859274|NCT04085627|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33859275|NCT03047759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33859276|NCT00419783|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33859277|NCT06430944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859278|NCT02553109|||COHORT||PROSPECTIVE|||||||
33859279|NCT00522912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859280|NCT00126022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859281|NCT00477854|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33859282|NCT05584228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859283|NCT04359251|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859284|NCT05214196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33859285|NCT05615532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Part A is Parallel design and Part B is a crossover design||||
33859286|NCT00647322|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33859287|NCT04620525|||OTHER||CROSS_SECTIONAL|||||||
33859288|NCT02950324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859289|NCT05031169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial with 1:1 ratio.||||
33859290|NCT03545009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33859291|NCT04973878|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patients undergoing same-day bidirectional endoscopy under deep sedation will be randomly assigned to either the colonoscopy-first group (colonoscopy followed by EGD, n = 272) or the EGD-first group (EGD followed by colonoscopy, n = 272).|t|f|f|f
33859292|NCT03142763|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33859293|NCT05601791|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research is designed as a randomized controlled trial, and will be conducted at the Clinic for Anesthesiology, Reanimatology and Intensive Medicine in the Department of Pain Management of the Osijek Clinical Hospital Center after obtaining the approval of the Ethics Committee. All patients will receive a written informed consent in which the procedure to be performed will be described, and the procedure will also be explained to them orally. After signing the informed consent, the patients will be divided into 2 groups using a random number generator, depending on whether there is discorradicular contact or not, and then according to the treatment method (ESI TF or PLDD). All subjects will be selected at the Institute for Pain Management of KBC Osijek.||||
33859294|NCT04635683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859295|NCT00662779|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33859296|NCT06330168|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|triple||t|f|t|t
33859297|NCT00331019|||COHORT||PROSPECTIVE|||||||
33859298|NCT03242551||SEQUENTIAL||TREATMENT||NONE||epirubicin, paclitaxol, cyclophosphamide, trastuzumab||||
33859299|NCT06073379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33859300|NCT04580797|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Part B is a sponsor open, double blind study where the investigator, medical monitor and the participants will be blinded.|"Part A is a partial cross over study with 4 periods; the first three periods are IR, MR1, MR2 in fasted condition and the fourth arm is either MR1 or MR2 in fed condition.~Part B is a multiple ascending dose study"|t|f|t|f
33859301|NCT03892993|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893693|NCT03810989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||the same groups of patients will be used for the experimental and control groups (self controlled study or time series study).||||
33893694|NCT02095561|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33893695|NCT03114033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A Randomised, Parallel Groups, Assessor Blinded, Clinical Trial|Parallel assignment|t|f|t|t
33960606|NCT05486663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The volunteer (newborn's mother or father) will not know which group she/he will be in before joining the study. After accepting to the participate in the study, the volunteer will be informed abouth which group her/his newborn will be in.|There will be two group. One is intervential group, other is control group|t|f|f|f
33893696|NCT03312218|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33893697|NCT03991247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893698|NCT00326261|||||PROSPECTIVE|||||||
33893699|NCT03212261|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893700|NCT02793284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171552|NCT06253988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Sixty-five patients having periodontitis stage III grade C molar-incisor pattern. Screening for A. actinomycetemcomians (A.a) and the JP2 genotype was done using conventional polymerase chain reaction (PCR). Patients positive for (A. a) were randomly divided into two groups. Group I: received conventional periodontal treatment combined with topically applied probiotic, while Group II: received conventional periodontal treatment only. Both groups were evaluated microbiologically and clinically.||||
34171553|NCT02473081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34171554|NCT00763412|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33749926|NCT05973071|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All data will be analyzed by a blind coding process, meaning that the researcher performing the analyses will be unaware of our research hypotheses. All date and timestamp information will also be removed to ensure that those analyzing the data cannot infer which patients were in the Tuune condition and which received a traditional patient appointment.|Participants will be block assigned to either the Tuune condition or the traditional contraceptive counseling condition.|f|f|f|t
33749927|NCT03173040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749928|NCT03905655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients are randomized 1:1:1:1 (12 subjects per group)|t|t|t|t
33749929|NCT03283904|NA|SINGLE_GROUP||PREVENTION||NONE||Control vs Intervention clusters of schools||||
33749930|NCT01724671|||CASE_CONTROL||RETROSPECTIVE|||||||
33749931|NCT04680455|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
33749932|NCT02968420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749933|NCT00891267|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33749934|NCT04217863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33749935|NCT02750254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749936|NCT04158531|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an early feasibility study in which the effect and safety of cortical network stimulation in patients with central lobe epilepsy is investigated.||||
33749937|NCT06082037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749938|NCT01037920|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33749939|NCT02211716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749940|NCT04160780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749941|NCT06354101|||COHORT||PROSPECTIVE|||||||
33749942|NCT05615298|||COHORT||RETROSPECTIVE|||||||
33749943|NCT05234684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749944|NCT00682734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749945|NCT02330042|||CASE_CONTROL||PROSPECTIVE|||||||
33749946|NCT01212770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749947|NCT04559789|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All study investigators that collect or analyze data are blinded to the group assignment for all participants.|Participants are randomly allocated to either the intervention or control group at the beginning of the study|f|f|t|t
33749948|NCT04745182|NA|SINGLE_GROUP||PREVENTION||NONE||All participants were in the same group and received the same intervention.||||
33749949|NCT04417023|||OTHER||OTHER|||||||
33749950|NCT04225338|||COHORT||RETROSPECTIVE|||||||
33749951|NCT01562574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749952|NCT05734560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749953|NCT02287935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749954|NCT03213535|||CASE_ONLY||PROSPECTIVE|||||||
33749955|NCT05576987|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33749956|NCT06302166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33749957|NCT00785369|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960607|NCT05070689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960608|NCT05110144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the initial 8- week period, this will be a double-blind study. Both subjects and all study personnel (except for the research pharmacist) will be blind to the treatment assignment. Unblinding for both subjects and study investigators will occur at the end of the 8-week blinded treatment period.~The subjects and all personnel involved with the conduct and the interpretation of the study, including the Investigators and other study personnel (except the research pharmacist) will be blinded to the treatment codes. Randomization data will be kept strictly confidential by the study statistician, and accessible only to authorized persons until the time of unblinding.~Only in the case of an emergency, when knowledge of the investigational product is essential for the welfare of a subject, the principal investigator may unblind a subject's treatment assignment during the 8-week blinded treatment period."|A total of 50 subjects who meet entry criteria will be randomly assigned in a 1: 1: 1: 1: 1 ratio to one of five treatment arms using stratified randomization in blocks of 10. Each arm will have two successive 4-week treatment periods (Blinded Period 1 \& 2). After this, patients will be unblinded and receive routine clinical care. Participation in the unblinded portion of the study is optional.|t|t|t|t
33749958|NCT05800132|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33749959|NCT02489500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749960|NCT05200195|||COHORT||RETROSPECTIVE|||||||
33749961|NCT00709969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749962|NCT00957866|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33749963|NCT00963365|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33749964|NCT03512327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749965|NCT00506064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33749966|NCT00778648|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33960609|NCT05140863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960610|NCT05632809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171555|NCT04578600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171556|NCT04935996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33749967|NCT03046459|NA|SINGLE_GROUP||OTHER||NONE||||||
33749968|NCT01253785|||||PROSPECTIVE|||||||
33859302|NCT06248931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either valproate or topiramate from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included topiramate, and Drug B included valproate. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will assess The number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.|f|f|t|t
34171557|NCT04801420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171558|NCT03617172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34171559|NCT01319981|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171560|NCT04921202|||COHORT||PROSPECTIVE|||||||
34171561|NCT06222632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171562|NCT05363553|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadrupole|Parallel assignment|t|t|t|t
34171563|NCT06185374|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34171564|NCT03913221|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The first cohort of 9 infants will receive a lower maintenance dose of caffeine. Following a safety review, an additional 9 infants will receive a higher maintenance dose.||||
34171565|NCT04686461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171566|NCT02560259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171567|NCT02836912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34171568|NCT00623272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171569|NCT00388349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171570|NCT02268890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171571|NCT00238576|||||CROSS_SECTIONAL|||||||
34171572|NCT05971316|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomiced Controlled Trial|t|f|f|f
34171573|NCT06305156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171574|NCT01412996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171575|NCT01083849|||COHORT||PROSPECTIVE|||||||
34171576|NCT02228707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171577|NCT03611023|||COHORT||PROSPECTIVE|||||||
34171578|NCT04400630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The person in charge of the assessments will not be involved in the treatment program and will be blinded to this process. Study evaluators will be blinded to the treatment branch|Longitudinal, interventional, randomized, controlled, simple-blind clinical trial|f|f|t|f
34171579|NCT04428398|||CASE_ONLY||PROSPECTIVE|||||||
34171580|NCT01535040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34171581|NCT01329315|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34171582|NCT03623113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171583|NCT00001499||||TREATMENT||||||||
34171584|NCT02855008|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171585|NCT05596955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171586|NCT01626326|||COHORT||PROSPECTIVE|||||||
34171587|NCT06196385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|post hoc test|t|f|f|t
34171588|NCT00724841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171589|NCT00451789|||DEFINED_POPULATION||PROSPECTIVE|||||||
34171590|NCT01110824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171591|NCT00889759|||COHORT||PROSPECTIVE|||||||
34171592|NCT05257278|||COHORT||PROSPECTIVE|||||||
34171593|NCT04386200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171594|NCT05746507|NA|SINGLE_GROUP||TREATMENT||NONE||Overnight infant respite care provided approximately 3 nights per week for 6 weeks (18 nights total) lasting eight hours per night. Overnight respite care will last for eight hours, with one hour reserved to provide teaching about infant-specific temperament and cues.||||
33749969|NCT00829257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33749970|NCT04440566|NA|SINGLE_GROUP||OTHER||NONE||||||
33749971|NCT03806153|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33749972|NCT04022668|||CASE_CONTROL||RETROSPECTIVE|||||||
33749973|NCT04151082|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33749974|NCT01343550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749975|NCT03465280|||COHORT||PROSPECTIVE|||||||
33749976|NCT04302727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators (excluding bio-statistician) will be masked to weight change and other major outcomes (will not have access to the data) until all data are collected. The bio-statistician will have access to study group assignment as liaison to the Data Safety Monitoring Committee|Study participants will be randomized to either the intervention group (Med-Diet Weight Loss Program) or an enhanced usual care control group (WW); both groups will participate in the respective programs for two years.|f|f|f|t
33749977|NCT06224452|||OTHER||RETROSPECTIVE|||||||
33749978|NCT01092273|||||PROSPECTIVE|||||||
33749979|NCT03095040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33749980|NCT00672074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749981|NCT05826392|NA|SINGLE_GROUP||TREATMENT||NONE|No blinding|Adolescents and young adults (AYA), ages 13-24 will receive a 30-minute, web-based single-session program about growth mindset.||||
33749982|NCT03725683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171595|NCT06425081|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|The study will double blinded|Double-blinded, randomized and placebo-controlled clinical trial|t|t|t|t
33749983|NCT05003531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33749984|NCT01917669|||COHORT||PROSPECTIVE|||||||
33749985|NCT02710799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33960611|NCT02795949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33749986|NCT01626248|||COHORT|||||||||
33749987|NCT06580028|||COHORT||PROSPECTIVE|||||||
33749988|NCT03966833|RANDOMIZED|PARALLEL||TREATMENT||NONE|Enumerators will be masked to the treatment assignment of the participants.|||||
33749989|NCT00379613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960612|NCT03220152|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33960613|NCT02067832|||CASE_CONTROL||PROSPECTIVE|||||||
33960614|NCT01333475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960615|NCT06426992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960616|NCT03120520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960617|NCT00922337|||CASE_ONLY||PROSPECTIVE|||||||
33960618|NCT03839784|||COHORT||PROSPECTIVE|||||||
33960619|NCT04696627|||CASE_CONTROL||RETROSPECTIVE|||||||
33960620|NCT00062452|||COHORT||PROSPECTIVE|||||||
34171596|NCT03238716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171597|NCT03396796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34171598|NCT06112665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|multicentre, randomized, double-blind, placebo-controlled study|This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least one NSAID, with objective signs of inflammation|t|t|t|t
34171599|NCT05036304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessor will be blinded.||f|f|t|t
34171600|NCT05450796|||COHORT||PROSPECTIVE|||||||
34171601|NCT05227456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171602|NCT05854108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34171603|NCT03541122|||OTHER||PROSPECTIVE|||||||
34171604|NCT03312049|||COHORT||PROSPECTIVE|||||||
34171605|NCT05884086|||COHORT||PROSPECTIVE|||||||
34171606|NCT05427981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33749990|NCT01653873|||COHORT||RETROSPECTIVE|||||||
33749991|NCT01353313|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33749992|NCT06089811|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators, and personnel involved in data analyses are blinded to the intervention. Unblinding occurs after all data has been collected AND analysed.|The present study is a parallel group randomized controlled trial (RCT) aiming to investigate whether two nutritional interventions (prebiotics and L-tryptophan) can improve intestinal barrier function, attenuate the stress response, affect cognitive processes, and prevent stress-induced hyperpermeability. Participants will perform 2 study visits of 3h each and with 28 days in between, in which participants will be subjected to the L-PAST. During the L-PAST, 3 cognitive tasks will be administered. Moreover, participants will be asked to take a basal intestinal permeability test at home 2 days before the test days.|t|f|t|t
33749993|NCT02044692|||COHORT||PROSPECTIVE|||||||
33749994|NCT06352957|||COHORT||PROSPECTIVE|||||||
33749995|NCT04813328|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33749996|NCT06530823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33749997|NCT05141669|||COHORT||RETROSPECTIVE|||||||
33749998|NCT04050189|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|double-blinded|2-arms randomized crossover pilot study|t|t|t|t
33960621|NCT06577090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960622|NCT06580353|||OTHER||CROSS_SECTIONAL|||||||
33960623|NCT01468168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171607|NCT03604952|||COHORT||PROSPECTIVE|||||||
34171608|NCT00287105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171609|NCT01671163|||CASE_ONLY||PROSPECTIVE|||||||
34171610|NCT00034307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33960624|NCT01998035|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960625|NCT06647420|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960626|NCT04200781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33960627|NCT06271837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is Open-Label Study.|||||
34171611|NCT05133024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Beetroot juice bottles are delivered at the central investigational site in labeled boxes indicating whether they are active or control juice. The bottles themselves are identical in appearance and only distinguishable by the manufacturer through the production code. Blinding of the juices is done by an independent party who is responsible for removing the labels, indicating whether the juices are active or nitrate-depleted juice, from the boxes, and assigning an intervention letter code to active or control beetroot juice as 'A' or 'B', without revealing which is which. Sets of 7 bottles, corresponding with the dosage regimen, from A or B according to the randomization list made by an independent statistician, are then labelled with an unique randomization letter code comprising of 2 randomly generated letters, followed by an underscore and a numerical index from 1 to 7 (e.g. AX_1,..., AX_7) to assure allocation concealment.|Multicentric double-blind randomized controlled prospective phase II study|t|t|t|t
34171612|NCT04268186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34171613|NCT02336282|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33859303|NCT02013505|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33859304|NCT02629289|RANDOMIZED|CROSSOVER||||NONE||||||
33859305|NCT04171622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859306|NCT04624373|||COHORT||PROSPECTIVE|||||||
33859307|NCT04727086|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||"This will be a within-subjects, counterbalanced, crossover trial with a washout period. Participants will receive either placebo or the interventional drug BP1.3656 during the initial 14-day phase of the study and receive the other intervention during the second 14-day phase of the study. The washout period will last a minimum of 14 days.~Participants will come in to the laboratory on two separate days near the end of each intervention phase to complete alcohol self-administration sessions."|t|t|t|t
33859308|NCT05564351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859309|NCT01561781|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34171614|NCT01077635|||COHORT||PROSPECTIVE|||||||
33859310|NCT04748796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859311|NCT05401526|||COHORT||PROSPECTIVE|||||||
33859312|NCT01504308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171615|NCT04500366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcome assessors, the study biostatistician, the investigative team, and the steering committee will be blinded to intervention assignments. Research assistants, study intervention personnel (pharmacist, instructors) and participants will not be blinded.|Participants will be randomized into two arms (35/arm based on sample size calculation) for 12-weeks of socialization only or multi-modal frailty rehabilitation. The socialization only arm will receive 1x/week phone calls from medical student volunteers. Multi-modal frailty rehabilitation will involve virtual care including 1x/week socialization, 2x/week exercise (small group physiotherapy live-streamed sessions), nutrition (virtual consult), and medication support (virtual pharmacist consult) all via a videoconferencing service.|f|f|t|t
33859313|NCT00231153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859314|NCT03844490|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859315|NCT05937633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Due to the nature of the study the subjects and investigator are not masked. However the outcome assessors are marked for analysis.|"This study uses a prospective, parallel group, randomized control group design to compare those received transformational leadership programme to standard educational booklet among charge nurses.~The samples will be divided into experimental and control group by randomly assigning the subjects to each group."|f|f|f|t
33859316|NCT05360498|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33859317|NCT02823808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859318|NCT05309434|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34171616|NCT00002328||||TREATMENT||||||||
33859319|NCT06211335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171617|NCT00003575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171618|NCT06162052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171619|NCT03161535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34171620|NCT03167892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|f|f|t|t
34171621|NCT04633668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Self-Monitoring of sleep|2 (group) X 3 (time)|t|f|f|f
34171622|NCT05771103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171623|NCT03068871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171624|NCT02203734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171625|NCT02237326|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34171626|NCT00537602|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34171627|NCT00189098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171628|NCT02934802|||COHORT||PROSPECTIVE|||||||
34171629|NCT00453713|||COHORT||PROSPECTIVE|||||||
34171630|NCT01743469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33749999|NCT04337814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Double blind placebo controlled randamized controlled trial|t|t|t|t
33750000|NCT06669468|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33750001|NCT00044317|||DEFINED_POPULATION||OTHER|||||||
33750002|NCT05690009|||COHORT||PROSPECTIVE|||||||
33750003|NCT01509729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750004|NCT03753438|||COHORT||PROSPECTIVE|||||||
33750005|NCT04364646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessments are made by a blinded investigator||f|f|f|t
33750006|NCT03036163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33750007|NCT04352179|NA|SINGLE_GROUP||OTHER||NONE||||||
33859320|NCT00564018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859321|NCT00759330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859322|NCT06005818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859323|NCT04973254|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Three-arm cohort study comparing adherence to HIV treatment of monthly injections delivered outside of standard clinical settings to treatment adherence in the HIV clinic setting and to HIV standard care delivered in the HIV clinic||||
33859324|NCT02463825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171631|NCT02038816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171632|NCT03810677|||CASE_ONLY||PROSPECTIVE|||||||
34171633|NCT03798106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859325|NCT05713279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33859326|NCT00823901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859327|NCT04065009|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Study drugs are blinded and administered perioperatively. Fully blinded for all (participants, assessors etc)|Randomised, double blind, prospective, multicenter|t|t|t|t
33859328|NCT01490645|||CASE_ONLY||PROSPECTIVE|||||||
33859329|NCT01530022|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33859330|NCT01464229|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33859331|NCT03425981|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859332|NCT04668586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is in narcosis when the designated treatment is decided by randomisation, and the treatment is about to start.|Arm 1: Holmium:YAG laser lithotripsy Arm 2: Thulium Fiber laser lithotripsy|t|f|f|f
33859333|NCT03010930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33859334|NCT02407366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960628|NCT06157502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960629|NCT05764434|||COHORT||PROSPECTIVE|||||||
33960630|NCT03986645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, exploratory, non-randomized, interventional study without control group.||||
33960631|NCT06435598|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an open-label two-arm randomized trial. Investigator will allocate half of the participants to the video-based health education and usual care, while the other half of the participants will receive usual care only. (Fig 1) Randomization: Block randomization will be done to allocate adults to intervention or usual care group.||||
33960632|NCT06025487|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective open-label phase II study comparing patients and healthy controls||||
33960633|NCT05452616|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, parallel, open-label, 1:1 individually randomized, non-inferiority trial||||
33960634|NCT01999322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960635|NCT03295968|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Water control and ibuprofen solution contained 0.8 g of Sucralose (Heartland Food Products Group, Amsterdam, HP, Netherlands) and 1.2 g of orange flavored Kool-Aid (Kraft Foods, Northfield, IL, United States) to mask the taste of the Motrin solution. To match sweetness and calorie content of the ibuprofen Motrin drink, the water control also contained 6 mL high fructose corn syrup (ACH Food Companies, Mississauga, ON, Canada).|Fifteen normal-weight boys (aged 13-18y) were randomly assigned in a crossover design to four sessions: 1) Water + Rest; 2) Rest + ibuprofen; 3) Water + high intensity exercise; 4) high intensity exercise + ibuprofen. High intensity exercise consisted of three 10min bouts of high intensity exercise at 75% VO2peak at 60-70RPM with 1:30min active rest interposed. IBU was given in a 300mg liquid solution. EI, visual analog scale ratings and plasma biomarkers of appetite, inflammation, stress and glucose control were measured.|t|f|f|f
33960636|NCT06703853|||COHORT||PROSPECTIVE|||||||
33960637|NCT01506570|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33960638|NCT01067989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960639|NCT03996980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960640|NCT06138756|||COHORT||PROSPECTIVE|||||||
33960641|NCT06551454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33960642|NCT05385796|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|To blind the participants, they will be told that both taping techniques have been used in the clinic and we want to investigate if they are effective and if one works better than the other.|This is a randomized, controlled, participant-blinded trial, with a 2-arm crossover design.|t|f|f|f
33960643|NCT05649852|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960644|NCT03928613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960645|NCT06289335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960646|NCT05019716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960647|NCT05147792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960648|NCT01791127|||CASE_ONLY||PROSPECTIVE|||||||
33960649|NCT01252446|||||RETROSPECTIVE|||||||
33960650|NCT03658356|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960651|NCT03490331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960652|NCT05517018|||CASE_CONTROL||PROSPECTIVE|||||||
33960653|NCT03801213|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960654|NCT04537936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960655|NCT00602979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960656|NCT00937053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960657|NCT00872365|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33960658|NCT04061057|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33960659|NCT00354731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960660|NCT06540326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859335|NCT06147635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859336|NCT01791257|||CASE_CONTROL||PROSPECTIVE|||||||
33859337|NCT02456662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859338|NCT02338349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859339|NCT01266135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859340|NCT05049486|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33859341|NCT06265766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham cTBS treatment is delivered with a sham TMS-coil.||t|t|f|t
33859342|NCT02231853|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33859343|NCT00867113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859344|NCT02039726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859345|NCT00954421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960661|NCT01779349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960662|NCT00701558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960663|NCT00195585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960664|NCT06217835|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33960665|NCT05426473|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171634|NCT06066177|||COHORT||PROSPECTIVE|||||||
34171635|NCT00251524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171636|NCT06381934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171637|NCT00358475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171638|NCT04641897|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33859346|NCT01968070|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33859347|NCT02366013|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33960666|NCT06542419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This will be a straight forward parallel intervention model. Even numbers of participants will be randomly assigned to the treatment or control arms. The treatment group will receive the brain cooling intervention during their visits, while the control group will not. All other environmental, timing, and testing measures will remain constant between the groups as indicated in the study description.||||
33960667|NCT05406622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960668|NCT00390949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960669|NCT05432245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960670|NCT02056574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960671|NCT06702332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In Part 1, Participants (n=8) will be randomized to receive either MSD-001 or placebo (6 active: 2 placebo) in each of 5 ascending dose levels (cohorts).~In Part 2, Participants (n=4) with a CYP2D6 poor metabolizing phenotype will all receive MSD-001 (4 active: 0 placebo) in each of 3 ascending dose levels (cohorts)."|t|t|t|t
33960672|NCT00435825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960673|NCT01832545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33960674|NCT05860712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960675|NCT06246513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960676|NCT02308865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171639|NCT00454714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171640|NCT02598401|||COHORT||PROSPECTIVE|||||||
34171641|NCT02111421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171642|NCT06513494|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Stepped-wedge, Cluster, and Randomized trial|f|f|f|t
34171643|NCT06582758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34171644|NCT05201144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug/placebo will be drawn up in amber syringes by investigational pharmacy to blind the bedside RN who will be administering the study drug. Only investigational pharmacy is unblinded.|randomized, double blinded, placebo controlled pilot trial|t|t|t|t
34171645|NCT00189540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171646|NCT04377763|||COHORT||RETROSPECTIVE|||||||
34171647|NCT00428766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171648|NCT03573414|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34171649|NCT05720286|||CASE_ONLY||PROSPECTIVE|||||||
34171650|NCT00500916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171651|NCT04038346|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled, non blinded||||
34171652|NCT03741153|||CASE_CONTROL||PROSPECTIVE|||||||
34171653|NCT06132269|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34171654|NCT03251118|||COHORT||OTHER|||||||
33859348|NCT02115425|||COHORT||RETROSPECTIVE|||||||
33859349|NCT04731766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33960677|NCT06396221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"1. Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7) as control group~2. Estetrol 15 mg/Drospirenone 3 mg (24/4) as intervention group"|f|f|t|f
33960678|NCT02388607|||OTHER||PROSPECTIVE|||||||
33960679|NCT05504369|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Participant and researchers where not aware of the magnetic tape versus placebo tape as the look and feel identical|Single group design with random allocation of intervention placebo versus treatment tape. Next day other intervention was used|t|f|t|f
33960680|NCT00190684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960681|NCT02534207|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960682|NCT00858039|||COHORT||PROSPECTIVE|||||||
33960683|NCT00430638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960684|NCT05629273|||COHORT||OTHER|||||||
33960685|NCT00478634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171655|NCT04083976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171656|NCT03741465|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|The ultrasonography was made by a consultant radiologist (M.D.) Although the consultant didn't know which position was for control and which was the one the study evaluates. Although investigators were trying to mask the outcomes assessor; the consultant saw the positions because there is no way to hide the sitting positions of the participants. So there is a paradox if the consultant is masked or not.|"Systematic randomization was made from 150 volunteers, and 50 participants were chosen.~All 50 participants were planned to sit on the stretcher in both of the two positioning techniques sequentially (one after another). The two positioning techniques are 1) sitting fetal position- the SFP ( a traditional position ) and 2) sitting fetal cross-legged- the ASP ( a new position, named as  Anatolian sitting position). The investigator was planned to record all of the participants' anatomical measurements in both of those positioning techniques evaluated via ultrasonography. After each position participants were planned to evaluate each positioning technique's comfort by 5-point numerical rating scale from minimum 1 meaning poor to maximum 5 meaning excellent."|f|f|f|t
34171657|NCT00003468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171658|NCT00032669||||TREATMENT||||||||
34171659|NCT06490809|NA|SINGLE_GROUP||SCREENING||NONE|An independent Researcher will perform a statistical analysis.|||||
34171660|NCT03493555|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171661|NCT01172106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34171662|NCT03416868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171663|NCT01718379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171664|NCT04744675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859350|NCT03298321|||COHORT||PROSPECTIVE|||||||
33859351|NCT00909454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33859352|NCT04195958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859353|NCT05482152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33859354|NCT03837314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859355|NCT05406804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33859356|NCT06027125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859357|NCT04876118|NA|SINGLE_GROUP||OTHER||NONE||||||
34171665|NCT04038502|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Unblinded, randomized (1:1) clinical study with study-drug treatment in metastatic castrate resistant prostate cancer in patients who have inactivation of the homologous DNA repair pathway, including BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L with cross-over to opposite study drug after progression or intolerance (whichever comes first).||||
33859358|NCT04478656|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinded vial|Participants will be assigned to sequential escalating dose level groups to receive vaccinations at 2.5 µg, 5 µg, or 10 µg or Placebo on Day 0 and 28 with follow-up for 12 months from initial administration of the investigational product.|t|f|t|f
33859359|NCT00650572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859360|NCT00893126|||CASE_CONTROL||PROSPECTIVE|||||||
33859361|NCT02684279|NA|SINGLE_GROUP||TREATMENT||NONE|open-label|||||
33859362|NCT05275712|||COHORT||CROSS_SECTIONAL|||||||
33859363|NCT00738309|||CASE_CONTROL||PROSPECTIVE|||||||
33859364|NCT03840226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The aim of the study is to test The impact of magnum versus placebo, on six-minute and clinical outcomes of patients with CHF (level 2-4).~The Primary endpoints are:~1. Improvement in Six-Minute walk test.~2. Improvement in clinical outcomes: death, CHF hospitalization, revascularization etc.~To test the hypothesis that the six-minute results between the two study groups are different, with significance level of 5% and power of at least 80%, we use the t-test. Based on Monica et al (2001), the mean six-minute results among these patients is 218 with SD=28. for an expected difference of at least 10 meter, we need a sample size of 125 patients in each group."|t|f|f|f
33859365|NCT05198687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859366|NCT00002646|RANDOMIZED|||TREATMENT||||||||
33859367|NCT02328287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859368|NCT06267573|||COHORT||PROSPECTIVE|||||||
33859369|NCT03425838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859370|NCT00389857|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859371|NCT05042037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, care provider, investigator and outcome assessor of the study is blinded about the allocation status of the participants (Double blinded)|Two-arm parallel assignment involves two groups of participants. One group receives probiotics , and the other group receives placebo.|t|t|t|t
33859372|NCT02302690|||COHORT||PROSPECTIVE|||||||
33859373|NCT00639561|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33859374|NCT03199937|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Assessor and observers will be blind to the treatment. Classroom observations will be conducted by partially blind classroom observers. Though the observer will not be told which schools are assigned to which treatment condition, we found that in our last trial occasionally an observer saw treatment materials that suggested which treatment the school had been assigned to. We will make every effort to minimize this, but it may occasionally happen. The pre-post direct child assessments will also be conducted by treatment-blind assessors, as much as possible."||f|f|f|t
33859375|NCT04615767|NA|SINGLE_GROUP||TREATMENT||NONE||Ten male volunteers are treated daily with 1 g D-chiro-inositol for 30 days (2 capsules containing 500 mg each, twice a day). The serum levels of the detected parameters at the end of treatment are compared to the values found in the volunteers at the baseline, used as controls. Parameters under analysis: Testosterone/Estradiol ratio, Testosterone, dehydroepiandrosterone, estradiol, estrone, glycemia and insulinemia with Homeostatic Model Assessment for Insulin Resistance (HOMA) index, follicle stimulating hormone, luteinizing hormone, D-chiro-inositol and myo-inositol.||||
33859376|NCT05146687|||COHORT||RETROSPECTIVE|||||||
33859377|NCT03002519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859378|NCT05651750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859379|NCT02076750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171666|NCT01755234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859380|NCT04427553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859381|NCT02709525|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33859382|NCT04032769|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33859383|NCT02023255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171667|NCT02994238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859384|NCT01372410|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33859385|NCT04220125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33859386|NCT03412370|||COHORT||PROSPECTIVE|||||||
33859387|NCT02877758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33859388|NCT02685670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859389|NCT00519155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893701|NCT06108661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a another person who will be unaware of the group the participant belong to.|This study is a randomized controlled trial which will consist of two groups. Once will receive conventional physical therapy and the second will receive conventional physical therapy and slump stretching. Both groups will be recruited concurrently.|f|f|f|t
33893702|NCT00004386||||TREATMENT||||||||
33893703|NCT04328480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Simple pragmatic randomized open controlled trial||||
34171668|NCT05729282|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Both investigators and participants will be blinded to the assigned treatment group. Routine unblinding will occur to investigators only after all of a participant's samples have been submitted for laboratory analysis. It should be noted that investigators may get a sense of group allocation based on changes in blood glucose. However, due to interindividual variability in extent of insulin resistance and body mass index, it will not be possible to assuredly decode the randomization prior to unblinding. The blinding of the study Principal Investigator (PI) will be repealed only in the case of early withdrawal and/or medical emergency (e.g., severe hyperglycemia), which in most cases will result in study termination anyway. Participants will be notified of their group assignment once all relevant data are collected and analyzed if opted in.||t|f|t|f
34171669|NCT00177788|||||RETROSPECTIVE|||||||
34171670|NCT00148902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750008|NCT04360148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33750009|NCT03240692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750010|NCT00517491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960686|NCT03411122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859390|NCT05447533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Functional capacity and Overall Quality of life will be performed on both groups by a trained blinded project assistant during planned visits to the patients. The project assistant will be blinded to randomization status in redcap database.|Parallel-group randomised clinical trial (RCT). The study compares two well-known organisations of care and does not involve experimental treatments or sampling of biological material outside of routine care. It is therefore classified as a quality improvement project by the Central Denmark Region Committees on Health Research Ethics (case number 1-10-72-1-21).|f|f|f|t
33859391|NCT04265924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859392|NCT05863312|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33859393|NCT00480246|NON_RANDOMIZED|PARALLEL||||NONE||||||
33859394|NCT03963687|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single Blind technique will be use, this means, research participants are not aware which educational intervention group they belong.|Randomized controlled trial, parallel design of two-group pretest and repeated posttest is proposed. At Period 1, research participants will be randomly assigned into two groups. Control Group (CG) will receive the the standard genomics education which is already available online. The Intervention Group (IG) will receive the Web-based Genomic Nursing Education which will be designed by the research team based on the results of Pre-test GNCI. After 12 weeks exposure to educational interventions, post-test 1 will be conducted, after 4 weeks post-test 2 will be done and then after 8 weeks post-test 3 will be done.|t|f|f|f
33859395|NCT06108804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded|A parallel study is a type of clinical study in which two or more groups of participants receive different interventions.|t|f|f|f
33859396|NCT04770311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859397|NCT00594529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171671|NCT03139760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33859398|NCT00633061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859399|NCT04673565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be a multi-center, prospective, randomized patient-blind controlled trial and employ a between-subject, pretest-posttest design.||t|f|f|f
33859400|NCT06471296|||COHORT||PROSPECTIVE|||||||
33859401|NCT05486117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859402|NCT00323297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859403|NCT00915304|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33859404|NCT04866654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859405|NCT04515069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization was done using a computer generated 2 column list by the aid of Random.org in a 1:1 ratio. Allocation concealment was achieved using numbered cards in opaque sealed envelopes. Aluminium foil was placed inside the envelope to render the envelope impermeable to intense light. These envelopes were placed in a box and each participant was allowed to grasp one envelop the day of operation. Allocation concealment was performed by an investigator with no clinical involvement in the trial. This study is a single blinded study as the assessor was blinded to the assigned study groups. Blinding of the participants was not applicable as one of the techniques required extra visits. Blinding of the operator was not applicable as one clinician performed the tooth preparation in both techniques.||f|f|f|t
33859406|NCT03193489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859407|NCT01300195|||COHORT||PROSPECTIVE|||||||
33859408|NCT06235931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859409|NCT02927418|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859410|NCT01601483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171672|NCT01863823|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34171673|NCT01452971|||CASE_ONLY||PROSPECTIVE|||||||
34171674|NCT01828177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171675|NCT05905094|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi-experimental study||||
34171676|NCT05866770|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34171677|NCT02174731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750011|NCT01464203|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34171678|NCT00097500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171679|NCT03095651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171680|NCT00287222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171681|NCT05767463|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34171682|NCT04362436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171683|NCT01476722|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34171684|NCT03920345|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, non-randomized, multi-center study, case series, clinical observation study of minimally invasive surgery for the treatment of SIJ arthropathy and chronic lower back pain (CLBP).||||
33750012|NCT05414682|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33859411|NCT02718807|||COHORT||PROSPECTIVE|||||||
33859412|NCT01416688|||OTHER||PROSPECTIVE|||||||
33859413|NCT05568602|||COHORT||RETROSPECTIVE|||||||
33859414|NCT00309556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859415|NCT01128894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859416|NCT00288509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859417|NCT01721005|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33859418|NCT02894112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171685|NCT03402542|||COHORT||RETROSPECTIVE|||||||
34171686|NCT02528084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171687|NCT02577172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171688|NCT00655265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171689|NCT04714606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171690|NCT01968486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171691|NCT05853016|||COHORT||PROSPECTIVE|||||||
34171692|NCT00149968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171693|NCT00467246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171694|NCT02308956|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34171695|NCT00701454|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34171696|NCT00529906|||FAMILY_BASED||OTHER|||||||
34171697|NCT01754103|NA|SINGLE_GROUP||||NONE||||||
34171698|NCT02976337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33859419|NCT01170546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859420|NCT00147823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859421|NCT06473376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients were randomly assigned to one of the following three groups: Group I (Control): patients treated by Hegab splint. Group II: patients treated by arthrocentesis with injection of HA/PRP mix plus Hegab splint. Group III: arthroscopy with injection of HA/PRP mix plus Hegab splint. The primary outcome variable was the change in pain using a visual analog scale, and improvement of maximum voluntary mouth opening. The secondary outcome variable was the change in joint sound. The third category of variables (age and sex) was evaluated in relation to the outcomes|t|f|f|t
33859422|NCT05227222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33859423|NCT03187977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study examiner (clinical research assistants or psychological examiners) will not know which group of participants is associated with each arm.|Participants will be randomized to either the intervention group to receive cognitive training or to the standard of care group who will not receive cognitive training.|f|f|f|t
33859424|NCT05873946|||COHORT||RETROSPECTIVE|||||||
33859425|NCT00410397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859426|NCT05221463|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859427|NCT06258915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859428|NCT00041067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859429|NCT03283280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will be blinded to the material type||f|f|f|t
33859430|NCT00301522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859431|NCT06224608|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859432|NCT06081452|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33859433|NCT04768387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859434|NCT00671554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859435|NCT05862571|||CASE_CONTROL||PROSPECTIVE|||||||
33859436|NCT03537287|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859437|NCT00286884|||CASE_CONTROL||OTHER|||||||
33859438|NCT02674594|||COHORT||RETROSPECTIVE|||||||
33859439|NCT01320267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859440|NCT02776449|||CASE_ONLY||PROSPECTIVE|||||||
33859441|NCT00124371|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859442|NCT04372758|||COHORT||RETROSPECTIVE|||||||
33859443|NCT06015451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treadmill test after completion of intervention is performed by an assessor that is blinded for group membership.||f|f|f|t
33859444|NCT04209699|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859445|NCT01080378|RANDOMIZED|PARALLEL||||NONE||||||
33859446|NCT02407184|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859447|NCT03249025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859448|NCT05251818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859449|NCT02309060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064038|NCT04788875|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded. (patients and research recruiter)|"2 Arms Arm1) Closure of laparotomy by small bites technique using PDS 2.0 Arm2) Closure of laparotomy by standardised large bites technique~This research will include all patients who will had laparotomy through a midline incision according to our inclusion criteria, they will be randomised using computer generated numbers by using (Random.org), to either closure by small bites technique using PDS 2.0 or standardised large bites technique."|t|f|f|t
34064039|NCT03567161|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064040|NCT03090633|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm clinical study. All participants will undergo laparotomy with exteriorization of the uterus followed by minimally-invasive, fetoscopic repair of the fetal spina bifida lesion.||||
34064041|NCT03007134|||COHORT||RETROSPECTIVE|||||||
34171699|NCT06276569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171700|NCT05372718|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|"At clinical centers, patients will be randomly distributed by the envelope method into two groups for assignation Fortelyzin® or surgical methods of treatment."||||
34171701|NCT04643808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Co-investigators analyzing diffusion MRI data were blinded to the timing of the MRI scans (pre- and post-treatment) and dose of taVNS.|The study investigators delivered taVNS once or twice a day during a bottle feed for 2 weeks. Stimulation was paired with nutritive sucking and swallowing, and was paused during rest or burping. If PO feeds had not progressed after 2 weeks of taVNS treatment, the parents and the clinical team made decisions about timing of G-tube placement. If substantial progress in po feeds was made during the treatment period, but the infant was not quite to full oral feeds, the clinical team and parents could elect to continue for 1-2 weeks.|f|f|f|t
33859450|NCT05711966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859451|NCT02138721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859452|NCT00725634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859453|NCT05232123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each participant will receive a different dose in consecutive weeks (one of which is a placebo), thus serving as their own control.|t|f|t|t
33859454|NCT05805098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859455|NCT00157183|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33859456|NCT04334434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33859457|NCT03196232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859458|NCT06512272|RANDOMIZED|PARALLEL||OTHER||NONE||"Randomisation on a ratio of 1:1~* A: allocated usual care~* B: allocated intervention group which include usual care plus video-recorded discharge"||||
33859459|NCT05829928|||CASE_ONLY||PROSPECTIVE|||||||
33859460|NCT02652143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859461|NCT03093779|||OTHER||CROSS_SECTIONAL|||||||
33960687|NCT03282617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be given CD137L-DC-EBV-VAX for about 5 - 7 times and be followed up until a maximum of 3 years from study entry.||||
33960688|NCT00812305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960689|NCT04991311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960690|NCT04739852|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||3 groups of different inclusion criteria (healthy, metabolic syndrome or rheumatoid arthritis) undergoing the same intervention||||
33960691|NCT00854607|||COHORT||PROSPECTIVE|||||||
33960692|NCT02582359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960693|NCT06044740|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33960694|NCT04437082|||COHORT||PROSPECTIVE|||||||
33960695|NCT06151158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33960696|NCT05652101|||COHORT||PROSPECTIVE|||||||
33960697|NCT05073302|NA|SINGLE_GROUP||TREATMENT||NONE||Test a new biomedical intervention in a small group of people for the first time to evaluate safety (e.g. to determine a safe dosage range and to identify side effects)||||
33859462|NCT00219713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33859463|NCT05650320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859464|NCT04183972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who have been scheduled to surgery will be recruited for collecting ultrasound images.||||
33859465|NCT02592512|||OTHER||PROSPECTIVE|||||||
33859466|NCT04868539|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The order in which subjects undergo the two sleep interventions will be randomized.|This study uses a within-subjects randomized crossover design to compare the effects of sleep restriction with and without ALAN on glucose metabolism. The order in which subjects undergo the two sleep interventions will be randomized.|t|f|f|f
33859467|NCT02827630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859468|NCT06277336|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33859469|NCT01486953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33859470|NCT03557723|||COHORT||PROSPECTIVE|||||||
33859471|NCT04258527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893704|NCT00000264||CROSSOVER||||DOUBLE|||t|t|f|f
33893705|NCT05283993|||COHORT||PROSPECTIVE|||||||
33893706|NCT03571464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All participants were requested to complete web-based assessment, with questionnaires relating to maladaptive beliefs, mood and OC symptoms at baseline (T1), 15 days following baseline (T2) and 30 days following baseline (T3). Participants in Immediate use GGRO group started using the app at baseline and continued using the app for 15 consecutive days. They were then requested to stop using the app until T3. Participants in the Delayed use GGRO group were requested to wait for 15 days and only then start using the app (cross-over) for 15 consecutive days.||||
33960698|NCT03760965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960699|NCT00540007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960700|NCT06569693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33960701|NCT00628745|||OTHER||PROSPECTIVE|||||||
33960702|NCT01179191|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960703|NCT06015217|NA|SINGLE_GROUP||TREATMENT||NONE||This study only has a single group, and all subjects receive the same treatment.||||
33960704|NCT04631185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960705|NCT05736952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960706|NCT04815356|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33960707|NCT04537130|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial will enroll 40 patients to be treated with either standard of care (control arm) or IN01 vaccine (experimental arm). Patients will be randomized in a 5:3 ratio to achieve 25 patients allocated in the experimental vs 15 patients in the control arm.||||
33960708|NCT05844644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960709|NCT04196270||SEQUENTIAL||DIAGNOSTIC||NONE|Double-blind|The biased coin up-and-down sequential design (BCD) should be considered for direct determination of higher quantiles (ED90 and ED95) which provide useful clinical knowledge. The BCD was developed in the field of pharmacology and toxicology and was formulated by Durham et al. in 1997. In the BCD, volume assignment is carried out in a sequential and interactive method, which avoids that patients are randomized to doses with toxicity risk and seeks to concentrate treatments around the suitable doses.||||
33960710|NCT04059276|||CASE_CONTROL||PROSPECTIVE|||||||
33960711|NCT06421623|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960712|NCT06141954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparison between effect of ultrasound and low level laser on sacroiliac joint pain in woman postpartum|t|f|f|f
33960713|NCT00425516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064042|NCT03464942|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with triple negative breast cancer will be randomised to receive either SABR 20Gy in one fraction or 24 Gy in 3 fractions , they will then go onto receive atezolizumab for up to 24 months||||
34064043|NCT01743534|||CASE_ONLY||PROSPECTIVE|||||||
33750013|NCT04763850|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study is set up as cross-sectional observation of gait under four conditions, which follows a randomized sequence in order to avoid carry over effects. Chronologically, the assessments will start with the tertiary observation, investigating agreements between declined/inclined ramp and treadmill walking. Thereafter, three out of four conditions (self-paced walking, self-paced walking with internal focus of attention, and self-paced walking with real-time feedback) are tested under block randomization of their six possible permutations . With three conditions (n=3), this represents the smallest number of permutations, equaling a Williams design, where each condition precedes each other condition equally often and each treatment occurs equally frequently at each position. The fourth corresponding condition (speed-matched walking) is exempted from the sequence randomization and always follows after self-paced walking with real-time feedback.||||
34064044|NCT02669914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064045|NCT03723421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As the study was a single-blind trial, the pain assessment was performed by another nurse, in the second minute after the injection, using the numerical pain rating scale, in order to provide neutrality. The nurse was informed by the researcher about the use of the scale.||f|f|f|t
34064046|NCT02798354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064047|NCT06355843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064048|NCT01589679|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064049|NCT01378832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064050|NCT00528632|||CASE_CONTROL||RETROSPECTIVE|||||||
34064051|NCT00601822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064052|NCT03982940|NA|SINGLE_GROUP||TREATMENT||NONE||Application of BeGraft Peripheral Plus (BGP+) Stent Graft System as bridging stent in Branched Endovascular Repair (BEVAR) for complex aortic aneurysms||||
34064053|NCT06730555|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33750014|NCT02959632|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750015|NCT04899518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750016|NCT06222450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750017|NCT05095753|||COHORT||CROSS_SECTIONAL|||||||
33750018|NCT01499329|||CASE_ONLY||PROSPECTIVE|||||||
33750019|NCT04669158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33750020|NCT06695546|||COHORT||PROSPECTIVE|||||||
33750021|NCT06470854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750022|NCT01554072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33750023|NCT02921815|||CASE_ONLY||PROSPECTIVE|||||||
33750024|NCT04783467|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33840524|NCT04148989|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE||"Patients presenting to the intervention emergency department after implementation of the care reorganization intervention - Code Sepsis protocol - will be compared to patients presenting prior to the intervention. Patients presenting to control emergency departments will receive usual care both before and after Code Sepsis implementation and are included in this study to control for changes in intervention-site outcomes over time unrelated to the tested intervention."|f|f|f|t
34064054|NCT04172857|||COHORT||RETROSPECTIVE|||||||
34064055|NCT04697212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064056|NCT00033306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064057|NCT05525780|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34064058|NCT06356818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||three groups with a conventional therapy control group.|t|f|t|f
34064059|NCT05580276|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064060|NCT02393326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064061|NCT05631782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34064062|NCT02424864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064063|NCT00053508|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064064|NCT01550107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34064065|NCT06371066|RANDOMIZED|PARALLEL||OTHER||SINGLE|it was an educational intervention. All participants were in the same class so we blinded only statisticians.|intervention, control|f|f|f|t
34064066|NCT04127175|||COHORT||PROSPECTIVE|||||||
34064067|NCT05622227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064068|NCT05786638|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sublingual versus subcutaneous allergen immunotherapy||||
34064069|NCT03286231|||COHORT||PROSPECTIVE|||||||
34064070|NCT02893423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750025|NCT03386968|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A Randomized Block Design will be utilized in order to attempt to match subjects according to functional level and diagnosis (cerebral palsy or acquired brain injury). Upon signing consent the subjects will be grouped based on their diagnosis. At that time gait speed for the 10 M Walk Test will be utilized to categorize all participants into a fast and slow group. (subjects performing the 10 M Walk Test at a speed less than .4 m/s will be placed in the slow group, and subjects testing at a speed greater than or equal to .4 m/s will be placed in the fast group After this determination is made, subjects will be randomized to control (usual care), and intervention one therapy session replaced with a session utilizing Active video games and the Rutger's V-step. A minimum of 2 subjects per grouping will be sought in order to analyze for differences."||||
33750026|NCT01093898|||FAMILY_BASED||PROSPECTIVE|||||||
33750027|NCT04180657|||CASE_CONTROL||PROSPECTIVE|||||||
33750028|NCT04292327|||OTHER||RETROSPECTIVE|||||||
33750029|NCT06304766|RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 80 patients will be randomized 1:1 between laparoscopic or open ablation after operability assesment.||||
33750030|NCT02293538|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33750031|NCT05268133|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33750032|NCT06496932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750033|NCT02139033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750034|NCT02701218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750035|NCT00361543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750036|NCT00978601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750037|NCT00960466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33750038|NCT00611013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750039|NCT02403726|||||RETROSPECTIVE|||||||
33750040|NCT03936855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750041|NCT06129747|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive once daily radiation for 15 fractions to 40.05 Gy total dose. Participants with high risk features (high grade disease, young age, close margins (\<2mm), triple negative subtype, HER2 positive tumors not receiving HER2 targeted systemic therapy) may receive a simultaneous boost to 48 Gy in 15 fractions.||||
33750042|NCT00564122|||CASE_CROSSOVER||PROSPECTIVE|||||||
33750043|NCT02724553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33750044|NCT03314415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Robotic-assisted weight loss||||
33750045|NCT05878197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750046|NCT00955357|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750047|NCT00941330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750048|NCT06304818|NA|SEQUENTIAL||TREATMENT||NONE||||||
33750049|NCT03524040|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750050|NCT04477642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750051|NCT03460977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750052|NCT04323813|||CASE_CONTROL||PROSPECTIVE|||||||
33750053|NCT05713617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will be independent from the intervention team and will not know the group condition of the participants|Phase I will be a single arm pre-post-test intervention study; Phase II will be a randomized controlled trial with a treatment and control arm.|f|f|f|t
33750054|NCT02158299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34064071|NCT03540992|||COHORT||PROSPECTIVE|||||||
34064072|NCT02147067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064073|NCT02585388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064074|NCT04866680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750055|NCT04126226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171702|NCT04097431|NA|SINGLE_GROUP||TREATMENT||NONE||"A consecutive controlled case series design will be used across the three proposed studies. In this design, all individuals who meet the inclusion criteria will experience the procedures described in that study.~Across studies, within-subject experimental designs with repeated measures will be used to examine the effects of the independent variables (environmental conditions) on the dependent variables (responding). Within-subject experimental designs are well suited for this type of research because the individual's SPB is used as his or her own control. Well-validated structural criteria will be employed (Hagopian et al., 1997; Roane et al., 2013) in these studies to determine when a series of conditions has a sufficient sample of behavior. The Study Team members have published numerous treatment evaluations employing this methodology (see Hagopian et al., 2011; Rooker et al., 2013)."||||
34171703|NCT05950282|||COHORT||CROSS_SECTIONAL|||||||
34171704|NCT02425345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34171705|NCT04381858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171706|NCT00367575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34171707|NCT05514600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171708|NCT01323023|||||PROSPECTIVE|||||||
34171709|NCT04131023|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171710|NCT06276062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171711|NCT05906030|||COHORT||PROSPECTIVE|||||||
34171712|NCT05532644|||CASE_CROSSOVER||PROSPECTIVE|||||||
34171713|NCT01007903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750056|NCT01538381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750057|NCT05744895|||CASE_CONTROL||PROSPECTIVE|||||||
33750058|NCT04625712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750059|NCT00818753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750060|NCT00605436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750061|NCT02085252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064075|NCT00561483|||COHORT||PROSPECTIVE|||||||
34064076|NCT05055856|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||academic, prospective study||||
34064077|NCT03146975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34064078|NCT01366300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34064079|NCT02919007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064080|NCT01337323|||COHORT||PROSPECTIVE|||||||
34064081|NCT02612688|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34064082|NCT01627782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171714|NCT04614727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34171715|NCT00269971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171716|NCT01560208|||CASE_ONLY||PROSPECTIVE|||||||
34171717|NCT04529733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171718|NCT03790566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34171719|NCT03040141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34171720|NCT00585481|||||PROSPECTIVE|||||||
33859472|NCT05532748|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The outcomes assessor of results will be masked, the data will be delivered encrypted with a code for the analysis of the measurement of each of the respiratory incentives.|The objective of this research is to compare the distribution of pulmonary ventilation using Electrical Impedance Tomography during the use of the Incentivo Modificado de Pachón and a commercial respiratory incentive, in healthy adults from the City of Cali (Colombia), for which A sample of 20 healthy subjects (10 men and 10 women) between 18 and 65 years of age will be used, who, after meeting the selection criteria, will undergo the first ventilation measurement using EIT with the incentive that has been randomly assigned to the participant, The second measurement will be carried out one week after the first measurement with the other incentive has been carried out, to complete the washout period, both measurements will be carried out by the principal investigator.|f|f|f|t
33960714|NCT05369299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking procedures are only applicable for the outcomes assessor. Due to the different colors of the compared implants, blinding procedures are not applicable for the investigator or the participants.|prospective controlled randomized trial|f|f|f|t
33960715|NCT06341192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Single-Bundle ACL + ALL Reconstruction Group:~* Patients in this group will undergo reconstruction of the anterior cruciate ligament (ACL) using a single-bundle graft technique.~* In addition, they will have the anterolateral ligament (ALL) reconstructed using a portion of the same graft material.~* For the ALL reconstruction, a commonly used technique is the Sonnery-Cottet ALL reconstruction using a split graft.~Double-Bundle ACL + ALL Reconstruction Group:~* Patients in this group will undergo anatomic double-bundle ACL reconstruction using two graft bundles to more anatomically replicate the native ACL's anteromedial and posterolateral bundles.~* Like the single-bundle group, they will also have supplemental ALL reconstruction performed using a portion of the graft material.~* The double-bundle ACL reconstruction aims to better restore the ACL's complex anatomic footprint and bundles' tension patterns."||||
33960716|NCT02857296|||||PROSPECTIVE|||||||
33960717|NCT01642927|||CASE_ONLY||CROSS_SECTIONAL|||||||
33960718|NCT06700590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the clinical interviews (CAPS-5, MINI-S, VLGT), the trained assessors will be blind to condition.|Randomized controlled trial|f|f|f|t
33960719|NCT05112679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960720|NCT04659837|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33960721|NCT03525327|||COHORT||RETROSPECTIVE|||||||
34064083|NCT04786665|RANDOMIZED|CROSSOVER||OTHER||NONE||Using a randomized crossover study design, the effects will be compared to the effects of 8 wk intake of a placebo drink-mix (with a 4 wk wash-out period between trials).||||
34064084|NCT00543998|||CASE_ONLY||PROSPECTIVE|||||||
34064085|NCT06548594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064086|NCT04400071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study personnel responsible for administering self report measures will be blinded to participant's study condition.||f|f|f|t
34064087|NCT00630201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064088|NCT06730035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064089|NCT04338191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171721|NCT04026321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171722|NCT00934453|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34171723|NCT00231426|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34171724|NCT00060645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171725|NCT02712346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34171726|NCT02747576|||CASE_CONTROL||PROSPECTIVE|||||||
34171727|NCT03382717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171728|NCT05683093|||COHORT||OTHER|||||||
34064090|NCT05462925|NA|SINGLE_GROUP||OTHER||NONE||This prognostic study examines how baseline measurements predict therapy response in a single group of participants.||||
34064091|NCT03193749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo||t|t|t|t
34064092|NCT00760812|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34064093|NCT00791830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064094|NCT00230919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064095|NCT01762449|||COHORT|||||||||
34064096|NCT03822494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064097|NCT04442438|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Longitudinal Stepped Wedge cluster randomized Trial with an open cohort||||
34171729|NCT00829738|||COHORT||PROSPECTIVE|||||||
34171730|NCT02587741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171731|NCT01474525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064098|NCT04548388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34064099|NCT06125340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants in all arms will receive 5 days of study medications.||t|t|t|t
34064100|NCT01669785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064101|NCT05844163|||COHORT||PROSPECTIVE|||||||
34064102|NCT06188104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171732|NCT05093439|||COHORT||RETROSPECTIVE|||||||
34171733|NCT00408122|||COHORT||PROSPECTIVE|||||||
34171734|NCT06199934|||COHORT||RETROSPECTIVE|||||||
34171735|NCT03305666|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority, randomized, clinical trial||||
34171736|NCT00659802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171737|NCT00328939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34171738|NCT02385929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34171739|NCT05604846|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized parallel-armed controlled trial (RCT) Registry based, double-blinded|t|t|t|f
34171740|NCT03870919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171741|NCT01913561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171742|NCT01975792|||COHORT||PROSPECTIVE|||||||
34171743|NCT06521710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171744|NCT05587816|NA|SINGLE_GROUP||OTHER||NONE||||||
34171745|NCT00866424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171746|NCT01285401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171747|NCT00989001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171748|NCT04924335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171749|NCT00997035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171750|NCT05503836|||COHORT||PROSPECTIVE|||||||
34171751|NCT04397510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171752|NCT01295385|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34171753|NCT03215238|||COHORT||PROSPECTIVE|||||||
34171754|NCT03142386|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34171755|NCT01766609|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34171756|NCT05868486|NA|SINGLE_GROUP||SCREENING||NONE||||||
34171757|NCT03961334|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinded endpoint assessment by independent CEC|||||
34171758|NCT05524467|||COHORT||CROSS_SECTIONAL|||||||
34171759|NCT05632523|||COHORT||PROSPECTIVE|||||||
34171760|NCT05529108|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34171761|NCT04146168|||CASE_ONLY||PROSPECTIVE|||||||
34171762|NCT02973100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171763|NCT00984477|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34064103|NCT00336323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064104|NCT01493700|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34171764|NCT03607214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34064105|NCT04030325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064106|NCT02525536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064107|NCT04847102|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34064108|NCT06020534|||COHORT||RETROSPECTIVE|||||||
34171765|NCT02282852|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34171766|NCT05842317|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171767|NCT02847962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171768|NCT06187896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34171769|NCT02517931|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34171770|NCT05409989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171771|NCT01488604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171772|NCT04439136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171773|NCT03667482|NA|SINGLE_GROUP||TREATMENT||NONE||A standard 3+3 design will be used to find the maximum tolerated dose (MTD) from 3 testing dose levels: 20, 40, and 60.||||
34171774|NCT01419769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171775|NCT03196908|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34171776|NCT00011596|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171777|NCT02463916|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171778|NCT01640002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171779|NCT06523985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34171780|NCT03217747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171781|NCT00208728|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171782|NCT01559636|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34171783|NCT00768989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171784|NCT01148550|||COHORT||PROSPECTIVE|||||||
34171785|NCT04472611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859473|NCT01881750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171786|NCT02218684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171787|NCT00430469|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171788|NCT00807118|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34171789|NCT01998230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171790|NCT05260268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a longitudinal intervention study utilizing diverse cohorts of liver transplant recipients. It is a 2-arm, patient-randomized controlled trial of de novo liver transplant recipients.||||
34171791|NCT02318160|||CASE_CONTROL||PROSPECTIVE|||||||
34171792|NCT05081908|NA|SINGLE_GROUP||OTHER||NONE||||||
34171793|NCT05894460|||COHORT||PROSPECTIVE|||||||
34171794|NCT03874468|||COHORT||CROSS_SECTIONAL|||||||
34171795|NCT04445935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study will be blinded to the above mentioned group. The PI is not involved in active treatment. Patients are sedated and ventilated when treatment starts and finally the outcome assessors will not be knowing the patients treatment.|This is a randomized controlled trial.|t|f|t|t
34171796|NCT00842569|||CASE_CONTROL|||||||||
34171797|NCT03191617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34171798|NCT04826172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171799|NCT02470221|||COHORT||PROSPECTIVE|||||||
34171800|NCT04978896|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33750062|NCT00005539|||COHORT||CROSS_SECTIONAL|||||||
33859474|NCT04642768|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33859475|NCT02909491|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859476|NCT04563000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33859477|NCT03507790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multi-center Phase 2, randomized, double-blind, placebo-controlled, parallel-group study.|t|t|t|t
33859478|NCT02998736|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33859479|NCT04717284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859480|NCT00328224|||CASE_CONTROL|||||||||
33859481|NCT05032079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859482|NCT01423253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859483|NCT02247908|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859484|NCT05171101|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Educational RCT||||
34064109|NCT00332631|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34064110|NCT03027323|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064111|NCT04492969|||COHORT||PROSPECTIVE|||||||
34064112|NCT03973697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label, comparative||||
34064113|NCT01920659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171801|NCT05085886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Treatment optimization assessor will be blinded to intervention vs. control start arm of the intervention.|2 arm design with provider being the unit of randomization and patients being nested within provider|f|f|f|t
34171802|NCT01387828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171803|NCT04480320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859485|NCT00435890|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33859486|NCT03346057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859487|NCT03865147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IIA, open, randomised, single and parallel group, therapy controlled single centre study||||
33859488|NCT02115451|||COHORT||PROSPECTIVE|||||||
33859489|NCT03471871|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33859490|NCT02606851|||CASE_ONLY||PROSPECTIVE|||||||
33859491|NCT02311946|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33859492|NCT04056936|||COHORT||PROSPECTIVE|||||||
33859493|NCT01890148|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33859494|NCT00056355||||TREATMENT||||||||
33859495|NCT00185250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960722|NCT05960708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Each IP will be labeled with a unique IP number, and the number will be associated with the randomized treatment group. Interactive Web Response System (IWRS) will be used to assign a randomization number and IP number.~As YH35324, placebo, and omalizumab differ in appearance, the assigned treatment group of subjects should be disclosed to study pharmacists and unblinded staff who prepare (taking an appropriate and correct amount (mL) of the IP based on the subject's body weight into a syringe), dispense, and administer the IPs, in order to maintain the blind. Therefore, the treatment group information of subjects will be checked through IWRS with limited access before administration of the IP, and only study pharmacists and unblinded staff are allowed to access the system.~The study pharmacists and unblinded staff should not disclose the assigned treatment group of enrolled subjects to the principal investigator or study staff."||t|t|t|t
33960723|NCT01314222|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33960724|NCT01935882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960725|NCT01529749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960726|NCT00116129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960727|NCT04534387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960728|NCT05410509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960729|NCT01359072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064114|NCT00638209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34064115|NCT04609709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064116|NCT03146728|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064117|NCT02454634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859496|NCT00693316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859497|NCT01744951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859498|NCT02129920|||COHORT||PROSPECTIVE|||||||
33859499|NCT00508248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859500|NCT03985085|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33859501|NCT04549025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859502|NCT00292799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859503|NCT04464265|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33859504|NCT02447757|||COHORT||RETROSPECTIVE|||||||
33859505|NCT05744271|NA|SINGLE_GROUP||TREATMENT||NONE|Performance on clinical measures will be evaluated by a physical therapist who is blind to the study purpose, design, and intervention.|A single-subject design will be used, allowing each participant to be his/her own control. Repeated assessments will be taken over three periods: a baseline (i.e. no intervention), intervention, and follow-up.||||
34064118|NCT06361615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although blinding is not possible for participants in exercise-intervention research, the outcome assessors and data analysts were masked to group assignments. The study was unblinded after the statistical analyses were completed.|Parallel Assignment|t|f|f|f
33750063|NCT02844946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33859506|NCT00221182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859507|NCT04758182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants were blinded; participants in experimental group were received HILT and sham ultrasound, while participants in control group were received ultrasound and sham HILT.~Outcome assessor was blinded to the treatment group"|Double blinded randomize control trial|t|f|f|t
33859508|NCT00969046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859509|NCT01507558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859510|NCT03545776|||OTHER||PROSPECTIVE|||||||
33859511|NCT02411578|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859512|NCT03715309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960730|NCT00303134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960731|NCT06539286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not know which laser will be used in the treatment group.||t|f|f|f
33960732|NCT05174078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A quasi-randomized control trial|f|f|f|t
33960733|NCT02488473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960734|NCT06613542|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064119|NCT04322786|||CASE_CONTROL||PROSPECTIVE|||||||
34064120|NCT01333956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064121|NCT05558800|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34064122|NCT05848323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750064|NCT01409538|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33750065|NCT03753061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750066|NCT04238806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The observers were blinded to the anesthetic protocol. Caregivers were not blinded, but they did not participate in data collection or data interpretation. Therefore, the study protocol is considered double-blinded, masked to observers.|In a prospective, randomized, double-blinded study, desflurane inhalational anesthesia was administered either continuously or intermittently (Group 1; n=60 versus Group 2; n=62).|t|t|f|f
33750067|NCT02535273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33750068|NCT03371420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750069|NCT06063135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33750070|NCT05238233|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33750071|NCT01798927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750072|NCT06605079|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Controlled, cluster-randomized, non-blinded, cross-over study in a stepped-wedge design.||||
33750073|NCT01608074|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33750074|NCT00624299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750075|NCT06496997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750076|NCT03112018|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750077|NCT05455099|||CASE_CONTROL||PROSPECTIVE|||||||
33750078|NCT03089918|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33750079|NCT02389972|||COHORT||PROSPECTIVE|||||||
33750080|NCT00988312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750081|NCT01763944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750082|NCT00230828|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750083|NCT06303739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study and limitations of study staffing, only those conducting assessments and ratings throughout the study will be masked to the treatments. All others, including participants, therapists, investigators, and study coordinator, will not be masked to the number of treatments a participant receives.|Participants are randomized into one of two groups and will receive either one single treatment of psilocybin-assisted therapy with follow-up therapy and assessments or two treatments spaced two weeks apart with follow-up therapy and assessments.|f|f|f|t
33750084|NCT00181948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750085|NCT04289818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750086|NCT01505296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750087|NCT06193252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Double-blind randomized controlled trial|t|f|t|f
33750088|NCT04154956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750089|NCT04344769|||CASE_CONTROL||PROSPECTIVE|||||||
33750090|NCT03902587|||COHORT||PROSPECTIVE|||||||
33750091|NCT01857531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750092|NCT02635880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750093|NCT05812157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All treatments will be numbered. The treatment number will be assigned according to the randomization list. All participants (patient/evaluator/etc.) will be blinded to the treatment administered. Only the hospital pharmacy will know the assigned treatment and will guarantee the blinding.|Multicenter, double-blind, prospective, randomized controlled study|t|t|t|t
33750094|NCT02916732|||COHORT||PROSPECTIVE|||||||
33750095|NCT02998281|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33750096|NCT06395662|||COHORT||PROSPECTIVE|||||||
33750097|NCT04989959|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750098|NCT00696254|||CASE_CONTROL||PROSPECTIVE|||||||
33750099|NCT06358573|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, open-label multicenter phase 2 clinical study to determine the clinical activity, safety and tolerability of INT230-6 in patients with early stage, operable TNBC who undergo neoadjuvant systemic treatment.||||
33750100|NCT03988868|||COHORT||PROSPECTIVE|||||||
33750101|NCT03310502|||OTHER||CROSS_SECTIONAL|||||||
33750102|NCT06541262|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750103|NCT00098969||||PREVENTION||NONE||||||
33750104|NCT05942001|NA|SINGLE_GROUP||TREATMENT||NONE||HRS-5041 single arm||||
33750105|NCT05596045|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33750106|NCT02363556|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33750107|NCT04240366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750108|NCT06351566|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33750109|NCT04339036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750110|NCT00889538|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33750111|NCT06062251|||OTHER||PROSPECTIVE|||||||
33750112|NCT04211038|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750113|NCT03756103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750114|NCT05077787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750115|NCT04699266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750116|NCT05717933|||CASE_ONLY||PROSPECTIVE|||||||
33750117|NCT03203369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750118|NCT03929029|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750119|NCT00867217|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33750120|NCT04989894|||COHORT||PROSPECTIVE|||||||
33750121|NCT06485817|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|Experimenters, care providers (nurses/physicians) and participants were blinded to both the stress induction condition and the drug in all sessions.|Cross-over 2\*2 design Drug (i.v. oxycodone/placebo) State induction (stress/control)|t|t|t|f
33750122|NCT03359265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750123|NCT01290432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750124|NCT03681626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859513|NCT05722132|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34064123|NCT03743402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessment will be conducted by Kaiser survey team which will be blind to treatment assignment.|Patients are individually randomized to pain self-management training for opioid taper or usual care. Those randomized to pain self-management training will be offered assistance with opioid taper during approximately the fourth session of pain self-management training.|f|f|f|t
34171804|NCT05244512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Tutors and researchers involved in the screening and baseline assessment will not be blind to the interventions provided during the trial. Participants, care providers and statistician will be kept blind to the study conditions.|A single-blind, individually randomised, two-arm parallel-group controlled feasibility trial design will be used.|t|t|f|f
33859514|NCT01608542|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33859515|NCT05439434|NA|SINGLE_GROUP||OTHER||NONE||||||
33859516|NCT06323122|||COHORT||RETROSPECTIVE|||||||
34171805|NCT06208657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750125|NCT00194558|RANDOMIZED|PARALLEL||||NONE||||||
33750126|NCT04243317|RANDOMIZED|PARALLEL||TREATMENT||NONE||Those with sleep impairment (sleep duration of ≤6.5hours per 24-hours; and/or poor sleep quality \[\<85% efficiency\]; and/or misaligned nocturnal sleep timing \[\>03:00 on weekdays\]) who are also obese (BMI ≥27.5 kg/m2) will be recruited and randomized to a 12-week weight loss intervention with/without sleep improvement. Volunteers will be followed for a further six months to assess multiple outcome measures.||||
33859517|NCT00483314|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859518|NCT02909270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33859519|NCT02952612|||CASE_ONLY||PROSPECTIVE|||||||
33859520|NCT04890678|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33859521|NCT02069210|||COHORT||PROSPECTIVE|||||||
33859522|NCT00416377||||TREATMENT||NONE||||||
33859523|NCT01538563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859524|NCT04683640|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33859525|NCT00551902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859526|NCT04261582|||CASE_CONTROL||PROSPECTIVE|||||||
33859527|NCT01486771|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33960735|NCT02252497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960736|NCT00438035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960737|NCT04476017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study had two parts: Part A and Part B with unique participants for each study part. Part B was started after Part A was completed.||||
34064124|NCT02086409|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34064125|NCT02456961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859528|NCT01178671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859529|NCT00499629|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33859530|NCT02745392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859531|NCT04757350|||CASE_ONLY||PROSPECTIVE|||||||
33859532|NCT01553474|||||PROSPECTIVE|||||||
33859533|NCT01198353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960738|NCT01288417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960739|NCT02404779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064126|NCT05825651|||COHORT||PROSPECTIVE|||||||
34064127|NCT00458575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064128|NCT04776278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064129|NCT03438058|||OTHER||RETROSPECTIVE|||||||
34064130|NCT02787213|||COHORT||PROSPECTIVE|||||||
34171806|NCT02068469|||COHORT||PROSPECTIVE|||||||
34171807|NCT04694222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical measurements were performed by a masked calibrated researcher to provide blindness|single-blind randomized controlled clinical study|f|f|f|t
34171808|NCT03600909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A three-arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and ATG||||
34171809|NCT06353997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171810|NCT06458946|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Tested fruit bites are masked. Confection control is hard to mask (open label).||t|t|t|t
34064131|NCT05429099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Both patient groups will receive the standard presurgical work-up including CT imaging, quality of life questionnaires, and a functional evaluation of bite force and jaw mobility.~Experimental arm - VSP: The trial research engineer (RE) will coordinate with the site surgeon (SS) to create and 3D-print surgical cutting guides for the mandible, for the fibula or scapula, and a 3D computed reconstruction. This reconstruction model will be used to pre-bend a titanium fixation plate. This plate and the surgical cutting guides will be sterilized prior to use. The SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide will be applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized using blood vessels in the neck.~Control arm - FHS: In FHS, the SS will proceed with surgery as per their routine practice."|t|f|f|t
34064132|NCT05698784|||CASE_ONLY||RETROSPECTIVE|||||||
33859534|NCT03602456|||COHORT||PROSPECTIVE|||||||
34064133|NCT06376305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171811|NCT05111860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859535|NCT01810237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34064134|NCT03220568|||COHORT||PROSPECTIVE|||||||
34064135|NCT04748952|||CASE_ONLY||PROSPECTIVE|||||||
34064136|NCT03414905|||COHORT||PROSPECTIVE|||||||
34064137|NCT05892549|||CASE_CONTROL||PROSPECTIVE|||||||
34064138|NCT04050527|||COHORT||PROSPECTIVE|||||||
34064139|NCT06438575|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064140|NCT02952872|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34064141|NCT06730932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171812|NCT00004652|RANDOMIZED|||TREATMENT||||||||
34171813|NCT04210648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171814|NCT04219774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prospective randomized open blinded end-point (PROBE) study|1:1 randomization, 1 non-randomized active comparator arm|f|f|f|t
34171815|NCT04849208|||OTHER||OTHER|||||||
34171816|NCT03922581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Staff members conducting the Clinician Administered PTSD Scale and the Mini-International Neuropsychiatric Interview will be blind to study arm assignment.|Participants will be randomized with block stratified randomization (in blocks of 20) to ensure variability in PTSD and MDD diagnosis in the two groups.|f|f|f|t
34171817|NCT00831961|||COHORT||PROSPECTIVE|||||||
34171818|NCT05946655|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective randomized open-label comparative parallel-group study||||
34171819|NCT02016781|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No parties are masked in this trial.|Two arms will enroll and have data collected on them simultaneously.||||
34171820|NCT03712943|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Regorafenib and Nivolumab||||
34171821|NCT04958824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33750127|NCT02278094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750128|NCT04649398|||COHORT||PROSPECTIVE|||||||
33750129|NCT00802074|RANDOMIZED|FACTORIAL||||NONE||||||
33750130|NCT01767740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750131|NCT04538729|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33750132|NCT06535048|||COHORT||RETROSPECTIVE|||||||
33750133|NCT06580691|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||both male and female patients with atrophic acne scars||||
34171822|NCT02937337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34171823|NCT00432484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171824|NCT03853330|RANDOMIZED|PARALLEL||OTHER||DOUBLE|prospective, double-blinded controlled trial; both the patient and data collector is unaware of the study nature||t|f|f|t
34171825|NCT05441826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171826|NCT04393675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171827|NCT01909895|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34171828|NCT00888693|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34171829|NCT06523296|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||MYASTHENIA, ALZHEIMER'S DISEASES, healthy control||||
34171830|NCT00010400|NON_RANDOMIZED|||TREATMENT||||||||
33750134|NCT01356875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750135|NCT02811861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750136|NCT06273423|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750137|NCT05170165|||COHORT||PROSPECTIVE|||||||
33859536|NCT06079489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859537|NCT01037907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859538|NCT06394440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859539|NCT02463188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859540|NCT05828043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859541|NCT00647673|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33859542|NCT00895674|||COHORT||PROSPECTIVE|||||||
33859543|NCT00429312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750138|NCT04079621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750139|NCT03112382|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33859544|NCT02537535|||OTHER||PROSPECTIVE|||||||
33859545|NCT00150969|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33859546|NCT01475578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859547|NCT01603537|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33859548|NCT00339170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960740|NCT05321121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Following informed consent patients will be randomized to either the intervention or control arm. Randomization and allocation concealment will be managed by a nominated independent individual(s) not involved in patient care or data extraction/analysis. The consenting physician will contact the randomization individual by phone. They will use a random number generator to assign group in a 1:1 ratio and then maintain a password protected randomization database that is only accessible to the principal investigator and randomization individual(s).~The intervention arm will receive an infusion of dexmedetomidine (precedex) at 0.4-0.6 mcg/kg/h (Based off ideal body weight). The control arm will receive an infusion of normal saline. Medication distribution and management will be handled by the Investigational Drug Service (IDS) at UCI medical center. A pharmacist who does not participate in the rest of the study will encode the study drug accordingly."|This is a prospective, randomized, double-blinded, placebo-controlled trial. Patients will be identified as they present to the trauma bay and meet eligibility criteria. Following informed consent patients will be randomized to either the intervention or control arm. Randomization and allocation concealment will be managed by a nominated independent individual(s) not involved in patient care or data extraction/analysis. The consenting physician will contact the randomization individual by phone. They will use a random number generator to assign group in a 1:1 ratio and then maintain a password protected randomization database that is only accessible to the principal investigator and randomization individual(s).|t|t|t|t
33960741|NCT00669136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960742|NCT01400373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960743|NCT02706041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960744|NCT02825472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960745|NCT02470442|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33960746|NCT01544816|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33960747|NCT02490527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960748|NCT04127682|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33960749|NCT00000318|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33960750|NCT01738490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960751|NCT04008082|||OTHER||PROSPECTIVE|||||||
33960752|NCT06309615|||CASE_CROSSOVER||PROSPECTIVE|||||||
33960753|NCT00381446|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33960754|NCT01550068|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34171831|NCT06082206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171832|NCT06150950|RANDOMIZED|PARALLEL||TREATMENT||NONE||At enrollment, participants will be randomized in a 1:1 ratio to cardiac rehabilitation or usual care using randomly permuted blocks of 2, 4, and 6. The randomization will be stratified by study site and time from Fontan palliation.||||
33960755|NCT01393626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34171833|NCT02021565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The objective outcomes assessor did not know whether the participants were in the intervention or control group.|This study was a wait list control design. Participating couples were either assigned to the intervention group and received the full CG ASSIST program (assessment, observation, recommendations, equipment, modifications, and training) or were assigned to the delayed intervention control group (assessment and observation only). Then, as the intervention group was evaluated, the delayed intervention control group received the full CG ASSIST program. Both groups received 3-month follow-up observations and assessments. Results are reported for Baseline to T1 Intervention and Control.|f|f|f|t
34171834|NCT05189743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34171835|NCT06413602|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||randomized, blinded, cross-over study|t|f|f|t
34064142|NCT05865158|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
34064143|NCT05672589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064144|NCT02373007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064145|NCT03946371|||COHORT||PROSPECTIVE|||||||
34171836|NCT06118385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The trial will be in 3 parts: Part A will investigate single ascending oral doses of BEN8744; Part B is a 2-way crossover assessment of the effect of food on the PK of BEN8744; and Part C will investigate multiple ascending oral doses of BEN8744|t|f|t|t
34171837|NCT05079165|||COHORT||RETROSPECTIVE|||||||
34171838|NCT04760756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171839|NCT04756765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171840|NCT05467592|||COHORT||PROSPECTIVE|||||||
33750140|NCT06115733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750141|NCT04897074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750142|NCT01456026|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33750143|NCT02057900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171841|NCT01755364|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34171842|NCT01994642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750144|NCT05063838|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients will remain blinded until the completion of data collection on post-operative day 30. Investigators assessing postoperative outcomes will remain blinded throughout study. Treating clinicians and study investigators will be unblinded to the pharmacogenomic results available for patients randomised to the active arm of the study group. Treating clinicians will remain blinded to the pharmacogenomic results available for patients randomised to the control arm of the study group, as this group will receive standard care that is provided at Peter MacCallum Cancer Centre.||t|f|f|t
33750145|NCT05695053|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|t|f|t
33750146|NCT05653466|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Research assistants responsible for coding data will be masked to treatment condition.||f|f|f|t
33750147|NCT05855980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750148|NCT05726929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33750149|NCT03640650|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33750150|NCT02115958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33750151|NCT05110885|||OTHER||CROSS_SECTIONAL|||||||
33750152|NCT03211000|||COHORT||CROSS_SECTIONAL|||||||
33750153|NCT03768167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171843|NCT00701285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171844|NCT05165160|NA|SINGLE_GROUP||OTHER||NONE||||||
33838280|NCT06066502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study team and leadership will be blinded to all analyses throughout the study. Unblinded statistician will perform analyses for the Data and Safety Monitoring Board (DSMB) and be sequestered from the remainder of the team.|"Participants will be randomized to the intervention arm or control arm.~Participants in the intervention group (precision ventilation), will have mechanical ventilation using settings directed by the amount of air pressure in the chest and lungs, using esophageal manometry. The treating clinical team is not masked to esophageal and transpulmonary pressure values and can view these data throughout the period of protocol-directed ventilation.~Participants in the control group (guided usual care), will have ventilator support (low tidal volume mechanical ventilation) managed by the clinical team per usual care. The treating clinical team is masked to esophageal and transpulmonary pressure values and cannot view or be informed of these data at any time during the period of protocol-directed ventilation. An esophageal catheter will be inserted strictly for monitoring of respiratory mechanics by study staff, but values will not be used to titrate the ventilator."|t|f|f|f
34171845|NCT03041688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171846|NCT03212898|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34171847|NCT00435916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171848|NCT00651924|NA|SINGLE_GROUP||||NONE||||||
34171849|NCT04274725|||OTHER||RETROSPECTIVE|||||||
34171850|NCT00748995|||COHORT||OTHER|||||||
34171851|NCT00534326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171852|NCT03128515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171853|NCT04426734|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Sustained Release Dexamethasone, 0.4 mg, intracanalicular insert~Thirty patients with anterior uveitis will be randomized to receive either:~Sustained Released 0.4 mg Dexamethasone intracanalicular insert in both upper and lower punctum.~OR~Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"||||
34171854|NCT03900494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34171855|NCT00297219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171856|NCT06435208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171857|NCT04346095|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization comparing standard procedure to experimental procedure||||
34171858|NCT00461617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171859|NCT03441438|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34171860|NCT00245323|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34171861|NCT04770532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171862|NCT00407771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171863|NCT05072418|||CASE_CONTROL||RETROSPECTIVE|||||||
34171864|NCT06302582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171865|NCT04604145|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34171866|NCT01936571|||COHORT||PROSPECTIVE|||||||
34171867|NCT02990026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171868|NCT04419831|||CASE_CONTROL||PROSPECTIVE|||||||
34171869|NCT02745171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171870|NCT00002403||||TREATMENT||NONE||||||
34171871|NCT02728115|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34171872|NCT01557153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171873|NCT06140602|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized, crossover, single-blinded study with one intervention (breakfast milkshake|t|f|f|f
34171874|NCT05724732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064146|NCT01900860|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34171875|NCT06203704|||COHORT||OTHER|||||||
34171876|NCT05388786|||COHORT||PROSPECTIVE|||||||
34171877|NCT05830708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization will be performed by the study statistician, who had no contact with the patients and not involve in the research project. The statistician is trained to randomize subjects who first enrol in the study into the three groups using computer system for randomization purpose. The allocation sequence will not be available to any member of the research team until databases had been completed and locked. Data collection will be performed by research assistants who were not involved in the study and do not know the objectives of the study. While data analysis will be carried out by the statisticians not involved in the study.|Three-armed, parallel-group, single-blind, multi-center randomized control trial|f|t|t|f
34171878|NCT05544864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171879|NCT05118971|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34171880|NCT00434408|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34171881|NCT05961267|||COHORT||PROSPECTIVE|||||||
34171882|NCT04970745|||COHORT||PROSPECTIVE|||||||
34171883|NCT01166139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750154|NCT05192525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The control group will be blinded to the allocation results and intervention. The experimental group will be informed the procedure of intervention. Before participants sign the consent form, the results of the group random assignments will be put in opaque envelopes handed out by a nurse, who will not be involved in the allocation and intervention, to participants during their pre-chemotherapy consultation. The data collectors will be blinded to the allocation results. The nurses and research assistants arranging the process of screening participants for eligibility will not be in charge of the group allocations and intervention. The nurses who will be responsible for the control group with routine care will not be involved in the intervention or the screening and group allocations.|"The study will be a double-blinded, randomized, controlled trial, including one intervention group (group A) and one control group (group B). The control group will be treated with routine care only. The intervention group participants will receive one core intervention mChemotherapy, one pre-chemotherapy consultation, and two scheduled visits. mChemotherapy is built on the official WeChat platform of the Ruijin Breast Health Centre and includes six components: (i) self-monitoring, (ii) alerts, (iii) reminder, (iv) consultation, (v) my prescription, (vi) knowledge base. The intervention group participants will take part in an mChemotherapy program for six weeks. The intervention nurses will deliver the intervention and contact patients through this platform."|t|f|f|t
33750155|NCT03506958|||COHORT||PROSPECTIVE|||||||
33750156|NCT04364958|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Assignment||||
33750157|NCT02871648|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33750158|NCT02395939|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750159|NCT06669689|||CASE_CONTROL||PROSPECTIVE|||||||
33750160|NCT04758312|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33750161|NCT06202066|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|All subjects will be unblinded to the research team at the time of the final analysis. In the presence of unexpected or severe adverse events, subjects may be unblinded to the Data Safety and Monitoring Committee upon request.|This is a two-part study. Part 1 is an open-label, single arm study. Part 2 is a blinded, randomized two-arm study. Part 2 will only proceed if part 1 is successful.|t|t|t|t
33750162|NCT06243146|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33750163|NCT05926401|||CASE_ONLY||OTHER|||||||
33750164|NCT04704375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171884|NCT02634463|NA|SINGLE_GROUP||OTHER||NONE||||||
34171885|NCT04300985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One professional of the team of providers will be responsible for conducting the electronic drawing on the website www.random.org, to distribute 90 numbers randomly into three groups. By following the results he or she will identify 90 opaque envelopes with numbers, and inside of each envelope will be a card with the name of corresponding group and the instructions about the corresponding intervention. This professional will not take part in any other part of the investigation. Every other professionals of the team and the patient will be blinded to group to which the patient belong. Each of the invited patient who accepts to participate and sign the consent form in the pre-anesthetic consultation, will receive the sequential envelope and be part of the corresponding group. At the arrival in the surgical center, one particular professional of the team will open the envelope and prepare the blinded solution, that will still be unclosed to any other people in the trial.|This is a prospective, controlled, blinded trial with random distribution.|t|t|t|t
33859549|NCT01742598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859550|NCT02827136|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859551|NCT00638612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171886|NCT05080517|||OTHER||PROSPECTIVE|||||||
34171887|NCT04037761|||COHORT||PROSPECTIVE|||||||
34171888|NCT01043107|||COHORT||RETROSPECTIVE|||||||
34171889|NCT05861076|RANDOMIZED|PARALLEL||OTHER||SINGLE|Baseline assessor will reveal the participants group, only after completing the baseline measurements. After provision of corresponding dosage (assignment), the group information will again be covered, per programming in the Excel file.||f|f|f|t
34171890|NCT03694561|||COHORT||PROSPECTIVE|||||||
34171891|NCT00089596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171892|NCT04948216|||OTHER||CROSS_SECTIONAL|||||||
34171893|NCT03844776|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||"* Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Amoxicillin 500 mg following the surgery for 5 days (control group)~* Treatment 2: 625 mg Co-Amoxiclav and 1g paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery but there is no additional course of antibiotic following the surgery.~* Treatment 3: 0.9% normal saline irrigation immediately after the surgery with course of antibiotic Co-Amoxiclav for five days postoperatively"|t|f|t|f
34171894|NCT01204099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171895|NCT05113563|||CASE_ONLY||PROSPECTIVE|||||||
34171896|NCT04992572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171897|NCT02466139|||COHORT||PROSPECTIVE|||||||
33859552|NCT00320021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859553|NCT04847960|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open label trial of BioGaia's Probiotic lozenges|intervention group||||
34150254|NCT06360614|RANDOMIZED|PARALLEL||SCREENING||SINGLE||"Before the application, data will be collected and recorded through a face-to-face interview (8-10 minutes) by a nurse who does not know which group the patients are in. Sleep times of patients will be measured with a smart bracelet. At this stage, the same procedure will be continued for the intervention and control groups.~Hand massage will be applied to the intervention group for 4 weeks, 2 days a week (Monday and Friday), 2 sessions each day. The control group will receive routine monitoring and nursing care for 4 weeks.~In the intervention and control groups, VAS-Pain, General Comfort Scale and Pittsburgh Sleep Quality were assessed by a face-to-face interview by a nurse who did not know which group the patients were in, on the 7th day (Monday), 14th day (Monday) and 28th day (Monday). Index measurement tools will be applied and patients' sleep times will be measured with a smart bracelet."|f|f|f|t
34171898|NCT04998071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859554|NCT04556643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859555|NCT01195142|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859556|NCT04750356|||COHORT||PROSPECTIVE|||||||
33859557|NCT05372822|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|During the 12 months following implantation of a spinal cord stimulation (SCS) system, the patients will undergo four three-month long periods with either burst SCS or no stimulation (sham) in a randomized order. All patients will undergo two periods of SCS and sham stimulation.||t|t|t|t
33859558|NCT02120716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33859559|NCT02858349|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Outcomes Assessor was blinded to study design, including when participant was in control phase versus intervention phase||f|f|f|t
33859560|NCT04297098|||CASE_CONTROL||PROSPECTIVE|||||||
33859561|NCT04923841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859562|NCT04242511|||CASE_CONTROL||PROSPECTIVE|||||||
33859563|NCT05351853|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859564|NCT01245075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33859565|NCT05123963|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two randomized groups in parallel (Exercise training in the morning versus exercise training in the evening). In each group, the protocol will be carried out as a within-subject in which each subject will serve as his/her own control (before/after acute or prolonged exercise).||||
33859566|NCT00956514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859567|NCT01648738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859568|NCT03236246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859569|NCT04112654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33859570|NCT05968287|||COHORT||PROSPECTIVE|||||||
33859571|NCT05311098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859572|NCT03099317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be randomized into sinew acupuncture group and sham acupuncture group in a 1:1 ratio.~Assessors will perform the assessment but not be involved in acupuncture treatment."|A randomized sham controlled, single blinded trial|t|f|f|t
33859573|NCT06026085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859574|NCT00544362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859575|NCT04709614|||CASE_ONLY||PROSPECTIVE|||||||
33859576|NCT04547049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859577|NCT00135759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859578|NCT01566656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859579|NCT00458809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859580|NCT02557321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859581|NCT01121679|||COHORT||PROSPECTIVE|||||||
33859582|NCT05419063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859583|NCT02847234|||COHORT||RETROSPECTIVE|||||||
33859584|NCT00287339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859585|NCT01369511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34171899|NCT06404099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|This platform protocol is designed to allocate participants into an intervention appendix based on their symptoms of sleep disturbance. Within the appendix, participants will be randomly assigned based on the appendix study design. Site investigators and personnel will be informed as to which study intervention appendix participants are assigned, but they will be blinded to whether participants are receiving the active study intervention or control, when possible. Similarly, participants will be blinded to active intervention or control, when possible. Randomization will be stratified by the study site; other stratification factors may be considered per appendix.|t|t|t|f
34171900|NCT00930696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171901|NCT03855696|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Sequential dose escalation model|t|f|t|f
34171902|NCT01784991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171903|NCT02676414|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171904|NCT06422377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171905|NCT02050113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171906|NCT01415882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171907|NCT05262114|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34171908|NCT01347502|||COHORT||PROSPECTIVE|||||||
34171909|NCT03029806|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Heathy volunteers||||
34171910|NCT06153134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171911|NCT01292135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171912|NCT00949182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171913|NCT02254811|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171914|NCT05599750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to intervention. Recurrence on imaging will be assessed by blinded assessors||t|f|f|t
34171915|NCT05477615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171916|NCT01759043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171917|NCT06329908|NA|SINGLE_GROUP||TREATMENT||NONE||single arm||||
34171918|NCT04283617|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34171919|NCT04936906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34171920|NCT06223711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838281|NCT00315471|||COHORT||PROSPECTIVE|||||||
33960756|NCT05288374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo pill provided by a hospital pharmacy will be administered orally on the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.|Celecoxib 100 mg orally on the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.|t|f|f|f
33960757|NCT03923309|||CASE_CONTROL||RETROSPECTIVE|||||||
33960758|NCT00831038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960759|NCT04308109|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized control trial||||
34171921|NCT03684863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960760|NCT01103401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960761|NCT00088712|||COHORT||CROSS_SECTIONAL|||||||
33960762|NCT05257954|||COHORT||PROSPECTIVE|||||||
33960763|NCT03473119|||CASE_CONTROL||PROSPECTIVE|||||||
34171922|NCT00197314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34171923|NCT03463421|||COHORT||OTHER|||||||
33838282|NCT01269151|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859586|NCT00277108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171924|NCT04853758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be carried out by the Heart Institute - School of Medicine of the University of São Paulo (InCor), using a RedCap platform, with blinded randomization being performed 1:1 for each arm of the study.|The ANSWER-HF will be a clinical, randomized, single-center, prospective, double-blind, controlled study. It will include 200 consecutive participants. This study will evaluate the benefit of sacubitril/valsartan compared with enalapril in patients with HF due to Chagas cardiomyopathy, with reduced ejection fraction(EF). Inclusion criteria are a positive serology for Chagas; age \> 18 years old; NYHA HF and functional class II, III or IV; LVEF \<40% at least in the last 3 months; patients using a beta-blocker with stable dose (1 month) and optimized; and using ACEI or ARB with a stable dose (1 month) and optimized. Exclusion criteria are participants who do not agree to participate in the study or do not want to receive sacubitril/ valsartan; with symptomatic hypotension; with SBP lower than 95 mmHg on randomization; with ClCr less than 30 mL/min; potassium \> 5.2 mmol/L; and with a history of angioedema or who experienced severe side effects with ACE inhibitors.|t|f|t|t
33859587|NCT00780754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859588|NCT00506233|||COHORT||PROSPECTIVE|||||||
33750165|NCT06670846|RANDOMIZED|PARALLEL||OTHER||NONE||Chidren were randomized into two groups to receive either intranasal midazolam at 0.3 mg/kg (group M) or distraction using a lollipop (group L) 15 minutes before entering the operating room||||
33859589|NCT00732628|||CASE_ONLY||PROSPECTIVE|||||||
33859590|NCT05716659|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859591|NCT04271787|||OTHER||CROSS_SECTIONAL|||||||
33859592|NCT04680494|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a within-subject study, all participants perform all conditions in cross-over randomized order.||||
33859593|NCT02655302|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960764|NCT03489031|||CASE_ONLY||CROSS_SECTIONAL|||||||
33960765|NCT01565122|||COHORT||PROSPECTIVE|||||||
33750166|NCT04474626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750167|NCT03620344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33750168|NCT05691868|||COHORT||OTHER|||||||
33750169|NCT04508894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750170|NCT02638038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|A randomized double blind parallel group study with 3mg, 1mg or placebo|t|t|t|t
33750171|NCT03991611|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||Stepped wedge cluster randomized trial|t|f|f|f
33750172|NCT05571631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750173|NCT04647851|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre- and post test design||||
33750174|NCT02854943|||COHORT||RETROSPECTIVE|||||||
33750175|NCT03477318|||OTHER||PROSPECTIVE|||||||
33960766|NCT00549120|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33960767|NCT03151967|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33960768|NCT01162135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171925|NCT03402737|NA|SEQUENTIAL||TREATMENT||NONE||"The range of dose-painting will be escalated in following levels:~* 2x 6-8Gy~* 3x 6-8Gy~The standard 3+3 design will be used for the this trial. To obtain more precise toxicity rate of the MTD we will double the number of patients at the first dose prescription that gives totally 6 patients. The 3 remaining dose levels will include 3 patients each. Thus, fifteen (6+3+3+3) patients will be included in this radiotherapy dose finding study investigating the MTD.~The number of patients will be doubled in case of 2 DLTs at the dose prescription I and 1 DLT at dose prescriptions II-IV with DLT in a maximum of 10 out of 30 patients.~* 3x 6-10Gy~* 3x 6-12Gy"||||
34171926|NCT00923520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171927|NCT03762408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded (blind third party evaluation) The physician performing the infiltration will be different and cannot be related to the investigator evaluating the results.||f|f|f|t
34171928|NCT03497065|||COHORT||CROSS_SECTIONAL|||||||
34171929|NCT06385769|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34171930|NCT04486534|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34171931|NCT00263094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34171932|NCT01923506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171933|NCT01434277|NON_RANDOMIZED|PARALLEL||||NONE||||||
34171934|NCT03293602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34171935|NCT05312944|||COHORT||RETROSPECTIVE|||||||
34171936|NCT06446401|||CASE_CONTROL||PROSPECTIVE|||||||
34171937|NCT06169202|||COHORT||RETROSPECTIVE|||||||
34171938|NCT03474614|RANDOMIZED|PARALLEL||OTHER||NONE||Two groups, intervention and control||||
34171939|NCT01273766|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171940|NCT00426166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171941|NCT02585401|||OTHER||CROSS_SECTIONAL|||||||
34171942|NCT05262075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171943|NCT06217042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171944|NCT03166917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34171945|NCT06457724|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34171946|NCT06257550|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors and data analysts will be masked to treatment allocation.||f|f|f|t
34171947|NCT02246725|||OTHER||PROSPECTIVE|||||||
34171948|NCT00211016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171949|NCT00380237|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34171950|NCT01739998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34171951|NCT00210574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171952|NCT00473434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171953|NCT03433937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34171954|NCT03950466|||COHORT||PROSPECTIVE|||||||
34171955|NCT03290846|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants receive drug and placebo infusion without knowing which day is which.|Single blinded randomised study, secretin infusion is given on one day, saline infusion on an other day.||||
34171956|NCT00594412|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750176|NCT05403801|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34171957|NCT03458338|||COHORT||CROSS_SECTIONAL|||||||
34171958|NCT03466385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171959|NCT02399215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171960|NCT02547181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171961|NCT03869658|||CASE_ONLY||PROSPECTIVE|||||||
34171962|NCT01879111|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
34171963|NCT04187898|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Considering two-phase study, where Expansion Phase followed Early Phase. The dosing within the Early Phase was in parallel assignment wherein participants were assigned to three arms in a 1:1:1 ratio. Patients completing Early Phase will enter the Expansion Phase to receive dosing in a single arm.||||
34171964|NCT03101280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171965|NCT01596803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34171966|NCT04854018|NA|SINGLE_GROUP||TREATMENT||NONE||open label, single centre, single arm, prospective feasibility study||||
34171967|NCT01182636|RANDOMIZED|PARALLEL||||DOUBLE||||||
34171968|NCT05095636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171969|NCT01762696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34171970|NCT03933969|||COHORT||PROSPECTIVE|||||||
34171971|NCT01383746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171972|NCT00262496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34171973|NCT02763059|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34171974|NCT04896086|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34171975|NCT02529917|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34171976|NCT04013308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34171977|NCT03913715|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34171978|NCT00207155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171979|NCT04113850|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|The study psychiatrist will be blind to MARS results at the time of the psychiatric interview that will confirm PTSD diagnosis and PTSD severity.|Single group, randomized (to sitting or standing postures)|f|f|t|f
34171980|NCT02455921|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34171981|NCT05625698|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a feasibility study||||
33960769|NCT05135286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960770|NCT05527834|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960771|NCT06298500|||COHORT||RETROSPECTIVE|||||||
34171982|NCT05847595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171983|NCT01766440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171984|NCT06219525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The two doses of zinc preparations were provided in identical bottles without indication of group identity or content by a neonatal registered pharmacist (assigned participants to interventions, only unblinded investigator) in the study center. A dedicated nurse (enrolled participants, obtained informed consent, monitored intervention, and recorded data), registered nurses and attending neonatologists (did routine neonatal care), statistician (generated the allocation sequence), and dedicated clinical psychologist were blinded the allocation groups.|The study design was approved by the ethics committee of our Center. Written informed consent was obtained from the parents of the infants enrolled in the study. Stratification was performed based on birthweight \[BW\] (401-999 or 1,000-1,499 or 1,500-1800 grams) and small for gestational age (yes or no). Participants were randomly allocated (1:1) to one of two treatments (higher or standard doses of zinc supplement). The allocation sequence was performed via computer generation, with permuted block and kept as consecutive numbers by statistician. Allocation concealment was ensured by using identical, opaque, and sealed envelopes.|t|t|f|t
34171985|NCT04420377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, parallel, randomized, placebo-controlled trial.|t|f|t|t
34171986|NCT02757989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171987|NCT04730440|||COHORT||PROSPECTIVE|||||||
34171988|NCT06159088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Two arms of participants will be assigned masked products (investigational formula and control formula) after randomization, while the participants of breastfeeding arm will not be assigned study products.||t|t|t|t
34171989|NCT01468558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34171990|NCT04725799|||COHORT||CROSS_SECTIONAL|||||||
34171991|NCT03572946|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34171992|NCT00382772|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34171993|NCT05857735|||COHORT||PROSPECTIVE|||||||
34171994|NCT05697627|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33960772|NCT03069131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960773|NCT05402865|||COHORT||RETROSPECTIVE|||||||
33960774|NCT03539848|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960775|NCT04265456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Up to 60 healthy male and female volunteers will be enrolled into one (1) of up to six (6) cohorts (n=10 per cohort).~Within each cohort, subjects will be randomized at a ratio of 4:1 to receive IP (1300 mg of IV APAP plus a cohort specific dose of IV PGB) or placebo (saline) (8 active:2 placebo)."||t|t|t|f
33750177|NCT02733900|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33750178|NCT03819153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33750179|NCT06029400|||COHORT||OTHER|||||||
33750180|NCT05568433|||CASE_ONLY||PROSPECTIVE|||||||
33750181|NCT06009081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotherapists who perform and evaluate the practice are different people.||f|f|t|f
33750182|NCT01339585|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33750183|NCT06241274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750184|NCT04192981|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, prospective trial||||
33750185|NCT02035800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750186|NCT06064227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33750187|NCT02527798|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33750188|NCT06665607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33750189|NCT06670157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750190|NCT05833750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants'personal information is hidden||t|f|f|f
33750191|NCT00905918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750192|NCT01140880|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750193|NCT06030674|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The exposure cannot be masked or blinded. Data analysts and chemists will be blinded.|This is an unblinded pilot study of an environmental exposure in one group.||||
33750194|NCT03851484|||COHORT||PROSPECTIVE|||||||
33750195|NCT02941302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750196|NCT03535935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment of primary outcomes is performed by an independent laboratory||f|f|f|t
33750197|NCT02414191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33750198|NCT06614504|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||2x2 factorial randomized controlled trial|t|f|t|t
33750199|NCT05314517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug will be provided in a blinded fashion and packaged and labeled to protect the blind.|A double-blinded, randomized, placebo-controlled, parallel group design has been selected for the study. All participants, regardless of treatment assignment in the Double-blind Treatment Period, may participate in the Open Label Extension period of the study.|t|t|t|t
33750200|NCT04334668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a double blind study. Subjects will be randomized to Sodium Chloride tablets and Placebos and picked up from pharmacy.|Heart Failure patients hospitalized for diuresis|t|t|f|f
33750201|NCT02311712|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33750202|NCT05625958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750203|NCT05422326|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Eligible subjects, who received 2 doses of aH5N1c in the parent study V89_18 are randomized in a 1:1 ratio to group 1 (two aH5N6c vaccinations, 3 weeks apart) or group 2 (aH5N6c vaccination and placebo, 3 weeks apart).~Eligible subjects, who received placebo in the parent study are allocated to group 3 (two aH5N6c vaccinations, 3 weeks apart)."|t|f|t|t
33750204|NCT00990990|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33750205|NCT04794803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750206|NCT02638948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750207|NCT06498661|NA|SINGLE_GROUP||PREVENTION||NONE|Samples will be shipped to BD-specified testing laboratories for blinded HPV testing as per BD-specified frequency and stability information.|||||
33750208|NCT02017340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34171995|NCT04976985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Interventional group: 70 patients with chronic migraine who consent to OMT will receive four standardized osteopathic manipulative treatments over the course of twelve weeks. MIDAS and HIT-6 Questionnaires will be obtained at time of consent prior to first treatment and again at the conclusion of treatment period of twelve weeks.~Control Group: 70 patients with the diagnosis of migraine headache will complete a MIDAS and HIT-6 questionnaire at week 0 and week 12 on standard of care for migraine treatment. A new prophylactic medication may be started at time of initial questionnaires and the patient can be on up to two prophylactic medications, with no changes during the 12 week period."||||
33750209|NCT05208138|NA|SINGLE_GROUP||OTHER||NONE||Prospective single arm, two-stage phase II study||||
33750210|NCT00001020||||PREVENTION||DOUBLE||||||
33750211|NCT04584060|||COHORT||PROSPECTIVE|||||||
33750212|NCT02039037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750213|NCT04006327|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750214|NCT06302751|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single-center, prospective, interventional case-series study with a historical cohort of comparison||||
33750215|NCT01921439|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33750216|NCT04597268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750217|NCT01009931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34171996|NCT01950858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34171997|NCT04834180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34171998|NCT02350517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750218|NCT01387880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750219|NCT01944904|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33750220|NCT03972514|||COHORT||PROSPECTIVE|||||||
33750221|NCT06630039|||OTHER||PROSPECTIVE|||||||
33750222|NCT04464928|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33750223|NCT02278328|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Each participant receives dose of drug or placebo. Both participant and investigator are masked to dose level/placebo. It is not open label.|All subjects receive placebo and two separate doses of STX209 (15mg, 30mg). The order of administration of these (at weekly intervals) is randomized into groups: (A) placebo, 15, 30 ; (B) 15, placebo, 30 and (C) 15, 30, placebo.||||
33750224|NCT04791449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Podiatrist and wound care technician will be blinded to an individual's participation and group assignment.|This study is based on a two-group repeated measures design.|f|t|f|f
33750225|NCT00222833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859594|NCT01141738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessors were blind to the group assignment of participants. The study group was not entered in the data entry program.|Consenting participants were assigned randomly, using a computer-generated assignment program, to either the Caregiver Problem-Solving Intervention (CPSI) or to a Wait-List control group.|f|f|f|t
34171999|NCT01393275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859595|NCT01744353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859596|NCT05689723|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33859597|NCT00364156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859598|NCT01910805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859599|NCT04556058|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33859600|NCT05795374|||COHORT||PROSPECTIVE|||||||
33859601|NCT01294683|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33859602|NCT00176345|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34172000|NCT06196541|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172001|NCT02361359|||COHORT||PROSPECTIVE|||||||
34172002|NCT02774460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34172003|NCT00976846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172004|NCT06394570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Safety lead-in which will assess safety of study therapy in a rule-based escalation approach, using the classic 3+3 design."||||
34172005|NCT06260540|||CASE_ONLY||CROSS_SECTIONAL|||||||
34172006|NCT01784224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172007|NCT00000376|RANDOMIZED|||TREATMENT||||||||
34172008|NCT01260493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172009|NCT00365014|||COHORT||CROSS_SECTIONAL|||||||
33750226|NCT00442143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172010|NCT03236896|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172011|NCT03332381|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34172012|NCT02848820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172013|NCT06553092|||COHORT||CROSS_SECTIONAL|||||||
34172014|NCT00726947|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172015|NCT02244541|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172016|NCT00952302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34172017|NCT02257593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33750227|NCT03630874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172018|NCT04177706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172019|NCT05997602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750228|NCT01802372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750229|NCT02810054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750230|NCT01661348|||CASE_CONTROL||PROSPECTIVE|||||||
33750231|NCT03210805|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750232|NCT03031938|NA|SINGLE_GROUP||OTHER||NONE||||||
33750233|NCT02506179|||COHORT||PROSPECTIVE|||||||
33750234|NCT02190331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33750235|NCT06225765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective case control study||||
33750236|NCT01891916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750237|NCT00675766|||CASE_CONTROL||PROSPECTIVE|||||||
34172020|NCT03582215|RANDOMIZED|PARALLEL||OTHER||NONE||Part 1 of the study has 4 parallel arms where 4 different sunscreen products will be studied. Part 2 of the study has 4 parallel arms where 4 sunscreen products (one from Part 1 and 3 new sunscreen products) will be studied.||||
34172021|NCT06211608|||COHORT||PROSPECTIVE|||||||
34172022|NCT00342446|||COHORT||PROSPECTIVE|||||||
34172023|NCT02096445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172024|NCT00115570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750238|NCT02349295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750239|NCT05642481|||CASE_ONLY||PROSPECTIVE|||||||
33750240|NCT03561090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750241|NCT02023970|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33750242|NCT01511848|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33750243|NCT00956865|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33750244|NCT01379066|||COHORT||PROSPECTIVE|||||||
33750245|NCT00036569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750246|NCT00221442|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33750247|NCT05449834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is not possible to blind the treating clinician to the randomised arm assignment|A prospective phase III, multi-centre, randomised, controlled, two arm parallel, open label trial evaluating the effect of FC compared to standard care (Cryo) in severely injured bleeding adult trauma patients with major haemorrhage and hypofibrinogenemia.|t|f|t|t
33750248|NCT01880723|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750249|NCT05962242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants on this study will undergo a reduced dose regimen starting with a boost to gross disease of 24 Gy, then 30-36 Gy to entire volume based on the plan for concurrent chemotherapy. Non-responders will receive a boost to the entire volume for an additional 10 Gy.||||
33750250|NCT04341116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750251|NCT01791218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750252|NCT03276351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded so that they do not know what type of implant construct they received. It will not be possible to blind the surgeon or the individual performing the RSA image processing.|Patients will be randomized to one of the two groups by block randomization using concealed envelopes, with the randomization and group assignment performed by a study coordinator at the time of surgery.|t|f|f|f
33750253|NCT05640349|||COHORT||RETROSPECTIVE|||||||
33750254|NCT00682487|||CASE_CONTROL||PROSPECTIVE|||||||
33750255|NCT01491854|NA|SINGLE_GROUP||OTHER||NONE||||||
33750256|NCT03288116|||CASE_CONTROL||PROSPECTIVE|||||||
33750257|NCT01414387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750258|NCT01734304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750259|NCT05748548|||COHORT||PROSPECTIVE|||||||
33750260|NCT04994457|||COHORT||PROSPECTIVE|||||||
33750261|NCT05054374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750262|NCT04885062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750263|NCT00014820|||CASE_CONTROL||RETROSPECTIVE|||||||
33750264|NCT01641250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750265|NCT06159634|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomized into one of two arms: Conventional ESD, or ESD with traction device||||
33750266|NCT02636634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750267|NCT05360992|||COHORT||PROSPECTIVE|||||||
33750268|NCT06670872|||COHORT||PROSPECTIVE|||||||
34172025|NCT02666781|||COHORT||PROSPECTIVE|||||||
34172026|NCT02646826|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750269|NCT05374980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750270|NCT00957476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33750271|NCT00961090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750272|NCT03466333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind randomised controlled trial (40 participants) Eligible women who decline to take art in the interventional arm, can consent to the observational arm of the study (up to 40 participants)|t|t|t|t
33750273|NCT02889991|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33750274|NCT01889953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750275|NCT04866173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33750276|NCT06423846|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants were randomized into two equal groups using a computer-generated list of random numbers sealed in an opaque envelope and were randomly allocated into two groups on a scale of 1:1.||||
33750277|NCT02083133|||COHORT||RETROSPECTIVE|||||||
33750278|NCT02492100|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750279|NCT00902304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750280|NCT01688700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750281|NCT06407388|||CASE_CONTROL||PROSPECTIVE|||||||
33750282|NCT00529399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33750283|NCT02025881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750284|NCT00951483|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750285|NCT05478655|||COHORT||OTHER|||||||
33750286|NCT06621602|||COHORT||PROSPECTIVE|||||||
33960776|NCT04675528|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a randomized, open-label, two-way crossover study consisting of two sequences (RT, TR) in patients with advanced solid tumor.||||
33960777|NCT02328404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960778|NCT05760482|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33960779|NCT01305135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960780|NCT03365973|||COHORT||PROSPECTIVE|||||||
33960781|NCT02406742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960782|NCT04511884|||COHORT||PROSPECTIVE|||||||
33960783|NCT05988593|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33960784|NCT03147521|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33960785|NCT03888092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960786|NCT03986918|||COHORT||PROSPECTIVE|||||||
33960787|NCT02147262|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960788|NCT03432026|||CASE_ONLY||PROSPECTIVE|||||||
33960789|NCT06232759|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with unresectable hepatocellular carcinoma were received transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab||||
33960790|NCT05380882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960791|NCT05513430|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172027|NCT04033796|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34172028|NCT00989911|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34172029|NCT05439122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172030|NCT05360069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960792|NCT00414986|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33960793|NCT00554177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960794|NCT01232114|||CASE_CONTROL||PROSPECTIVE|||||||
33960795|NCT05090085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In our clinical trial, double blinding will be performed, the participants and assessors will be blinded to the type of material used to reduce performance and ascertainment bias and also reduce biased estimates of treatment effects. The operator cannot be blinded in this trial because of the difference in the application procedures of each restorative material. Therefore, the operator (O.I.) will take care to treat the two allocation groups as equally as possible by standardizing the care of participants, frequency of follow-ups and management of complications.||t|f|f|t
33960796|NCT01233128|||COHORT||RETROSPECTIVE|||||||
33960797|NCT02428231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960798|NCT06406231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960799|NCT00057785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960800|NCT03654365|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
33960801|NCT01270607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960802|NCT02856763|||COHORT||PROSPECTIVE|||||||
33960803|NCT04931134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sham stimulation||t|t|t|t
33960804|NCT02543164|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33960805|NCT00705796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960806|NCT05073263|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33960807|NCT02729545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study was a randomized, drug-controlled, and parallel group trial|t|f|t|t
33960808|NCT00140101|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33750287|NCT01507168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750288|NCT01371331|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33960809|NCT02102022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172031|NCT02182622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172032|NCT05246046|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Bioanalytical laboratory will be blinded with regard to the sequence of the product administration|||||
34172033|NCT05314634|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomly assigned to three group, namely the concurrent exercise group (CE), the aerobic exercise group (AE), and the reading control group (RC). Participants in CE groups were asked to finish 5 min warm-up, 12 min aerobic exercise, 13 min resistance exercise, and 5 min cool down. Participants in the AE group were asked to finish 5 min warm-up, 25 min aerobic exercise, and 5 min cool down. Participants in RC group were required to finish 35 min reading. All groups took a 30 min cognitive test before and after the intervention. The blood lactate were collected before, 17 minutes after, and after the intervention.||||
34172034|NCT01387217|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34172035|NCT03877276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172036|NCT02723773|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34172037|NCT01718288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172038|NCT00642356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172039|NCT02249338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34172040|NCT02158169|||COHORT||PROSPECTIVE|||||||
34172041|NCT05193214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172042|NCT05535504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172043|NCT01274793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172044|NCT00127634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172045|NCT05892224|||CASE_CONTROL||PROSPECTIVE|||||||
33750289|NCT04534231|||CASE_ONLY||PROSPECTIVE|||||||
33750290|NCT03616548||SEQUENTIAL||DIAGNOSTIC||NONE||||||
33750291|NCT04100005|||CASE_ONLY||PROSPECTIVE|||||||
33750292|NCT00796770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172046|NCT00397501|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172047|NCT03649542|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pre/Post||||
34172048|NCT01826396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172049|NCT00472108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750293|NCT06619275|||COHORT||PROSPECTIVE|||||||
33750294|NCT04014608|||CASE_CONTROL||PROSPECTIVE|||||||
33750295|NCT04351256|RANDOMIZED|PARALLEL||TREATMENT||NONE||Durvalumab treatment and Thoracic Radiotherapy||||
33750296|NCT05935787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838283|NCT05175677|||COHORT||RETROSPECTIVE|||||||
34172050|NCT04388111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, provider, and laboratory technicians are blinded to the patient's study group. Only the research coordinator and necessary OR support staff are aware of the patient's study group.|Group 1: Receives an intraosseous injection of morphine (mixed with standard antibiotics) during their primary total knee replacement or Group 2: Serves as the control group and only receives an intraosseous injection of antibioitics during their total knee replacement.|t|t|t|f
34172051|NCT02854046|||CASE_CONTROL||RETROSPECTIVE|||||||
34172052|NCT04705688|||COHORT||PROSPECTIVE|||||||
34172053|NCT00505271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172054|NCT00956163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960810|NCT00791284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750297|NCT03950739|NA|SINGLE_GROUP||TREATMENT||NONE||Single-sequence in which subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT||||
33750298|NCT05022030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750299|NCT06430567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants between placebo and intervention group will be blinded||t|f|t|f
33750300|NCT06294184|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33750301|NCT01163097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750302|NCT01083251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750303|NCT04494516|||COHORT||PROSPECTIVE|||||||
33750304|NCT02648581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750305|NCT06246409|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33750306|NCT05163574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750307|NCT05959122|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33750308|NCT05511363|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33960811|NCT00279578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750309|NCT00411905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750310|NCT06455709|||COHORT||PROSPECTIVE|||||||
33750311|NCT01556373|||CASE_CONTROL||PROSPECTIVE|||||||
33750312|NCT03185533|||CASE_ONLY||PROSPECTIVE|||||||
33750313|NCT05953844|||COHORT||CROSS_SECTIONAL|||||||
33960812|NCT04536467|RANDOMIZED|PARALLEL||PREVENTION||NONE||Arm 1: Goserelin plus standard chemotherapy Arm 2 (control Arm): Standard chemotherapy||||
33750314|NCT01417026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750315|NCT05476146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750316|NCT00686166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750317|NCT05228600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960813|NCT06518720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960814|NCT03895307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960815|NCT05675072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859603|NCT03473704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions, while the control group (CG) will be evaluated in the same phases as the TG. For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed. There will be a follow-up at 3, 6 and 12 months.|f|t|f|f
33859604|NCT02685943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150255|NCT05583994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participants cannot be blinded to the intervention they are receiving. Outcome assessors and the main investigators are blinded to group allocation and will not have access to the intervention treatment lists. Only the statistician performing the randomization, the team member supporting the coordinator and the coordinator who is delivering the intervention are aware of group allocation.~However, previous experience has shown that participants may occasionally and inadvertently inform assessors of the treatment they are receiving. The research team aim to reduce this effect by explicit reminders to participants before assessment visits. The research team shall ask all assessors to record their estimate of which group they think the participant belongs, and their confidence in that prediction. This will enable to test whether inadvertent loss of blinding leads to bias, and to adjust for any bias detected."|Control and intervention groups (usual care vs new intervention)|f|f|t|t
34172055|NCT04595552|NA|SINGLE_GROUP||TREATMENT||NONE||interventional prospective study||||
34172056|NCT04703686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172057|NCT03042117|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172058|NCT02953522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34172059|NCT00599729|||COHORT||PROSPECTIVE|||||||
34172060|NCT03636659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172061|NCT01609348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859605|NCT00506545|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33859606|NCT00315939|RANDOMIZED|CROSSOVER||||NONE||||||
33859607|NCT00553956|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33859608|NCT05755490|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34172062|NCT04645147|NA|PARALLEL||OTHER||NONE||||||
34172063|NCT01611792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172064|NCT00339586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172065|NCT04077567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172066|NCT03371836|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive treatment and outcome is assessed; there is no control group.||||
34172067|NCT03800095|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
34172068|NCT04785495|||COHORT||PROSPECTIVE|||||||
34172069|NCT05618522|NA|SINGLE_GROUP||TREATMENT||NONE||prospective||||
34172070|NCT03122639|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Active drug and placebo will be made identical in appearance and given to participants in a blinded fashion.|Randomized double blind design|t|t|t|t
34172071|NCT02374840|||COHORT|||||||||
34172072|NCT01556399|||CASE_CONTROL||PROSPECTIVE|||||||
33960816|NCT05386238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33960817|NCT04501263|||OTHER||RETROSPECTIVE|||||||
33960818|NCT00765999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172073|NCT05966454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172074|NCT04004897|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34172075|NCT01009541|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34172076|NCT03901170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare with others who did not usage of letrozole||||
34172077|NCT01608711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172078|NCT01188772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172079|NCT00811161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172080|NCT04256694|||COHORT||PROSPECTIVE|||||||
34172081|NCT01044784|||COHORT||PROSPECTIVE|||||||
34172082|NCT04205006|||COHORT||PROSPECTIVE|||||||
34172083|NCT04068896|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33750318|NCT02111590|||COHORT||PROSPECTIVE|||||||
33750319|NCT03955601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750320|NCT03594669|NA|SINGLE_GROUP||PREVENTION||NONE|No masking will be used|This study will be conducted as pilot of a one-arm intervention using,1) pre- and post-participation measures of sensorimotor control and 2) injury incidence rate over the sports-season directly after completion of the intervention compared to injury incidence rate of a historical control (the 2017 soccer season at Mississippi College). Participants will include men and women athletes on soccer teams from one Division II institution.||||
33960819|NCT05315986|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|"Participant's and Investigators will be blinded to which participants are receiving the dietary saffron supplement and placebo. Random allocation will be conducted by an independent researcher.~Participants and investigators will not be blinded to which participants have been allocated ot the ESE intervention."|Forty-eight (i.e. n=12 per group; 4 groups) healthy older adults aged 55 and over with subjective sleep complaints will be recruited for this 4-week double blinded placebo controlled feasibility study. This project will adopt a 2 x 2 Factorial design.|t|f|t|f
33960820|NCT06462235|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Non-randomized, 2-part with four age cohorts in each part||||
33960821|NCT00300573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960822|NCT03150134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172084|NCT05306626|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomized controlled trial will include two arms. For the experimental arm, 70 participants will be enrolled in the BEAM group. Participants randomized to the BEAM intervention group will receive the app-based and group telehealth BEAM program. The other 70 participants will be randomized to the control group and will receive treatment as usual. Randomization will be stratified based on which telehealth group timeslots participants identify being available for during eligibility screening.||||
34172085|NCT04823988|||COHORT||CROSS_SECTIONAL|||||||
34172086|NCT06044025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34172087|NCT00359255|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34172088|NCT04446637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, single day, noninferiority study||||
34172089|NCT02250742|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172090|NCT04361071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172091|NCT00591006|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34172092|NCT00141453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172093|NCT00797381|||CASE_CONTROL||PROSPECTIVE|||||||
33859609|NCT02839954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859610|NCT05467774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859611|NCT00140231|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33859612|NCT03537950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators were blinded to the drug condition.|Repeated-measures cross-over study, where each subject received each of three pharmacological probes once (order of drug administration was pseudorandomised)|t|f|t|f
33859613|NCT02484339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859614|NCT04488497|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34172094|NCT03586297|||COHORT||PROSPECTIVE|||||||
33859615|NCT02564939|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859616|NCT02691260|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33859617|NCT04119973|||COHORT||PROSPECTIVE|||||||
33859618|NCT05814484|||COHORT||PROSPECTIVE|||||||
33859619|NCT03118349|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33859620|NCT03645057|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children (ages 2 to 15 years, inclusive) with ≤ moderate atopic dermatitis over a 12 week period of time.||||
33859621|NCT04251650|||OTHER||PROSPECTIVE|||||||
33859622|NCT03045042|||COHORT||PROSPECTIVE|||||||
33859623|NCT00813163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172095|NCT04496817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Double-blinded, randomized, placebo-controlled, parallel trial.|t|f|t|f
34172096|NCT01101217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859624|NCT05566925|||OTHER||RETROSPECTIVE|||||||
34172097|NCT05958446|||COHORT||PROSPECTIVE|||||||
33859625|NCT00373750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859626|NCT01033253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34172098|NCT03373578|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34172099|NCT03359629|||COHORT||PROSPECTIVE|||||||
34172100|NCT03064802|||OTHER||PROSPECTIVE|||||||
34172101|NCT03115359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although participants, therapists and outcome assessors cannot be blinded to the study intervention, investigators and analysts will be blinded to the group status until the first stages of analysis and reporting are completed.|Comparative effectiveness randomized controlled trial of two behavioral interventions|f|f|t|f
34172102|NCT02228941|||COHORT||PROSPECTIVE|||||||
34172103|NCT02832648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172104|NCT05379088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859627|NCT02678013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960823|NCT01888159|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960824|NCT00837031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960825|NCT05094986|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PC patients: Patients from the intervention PCCs received the IMA intervention but were not aware of the group they were assigned to.||t|f|f|f
33960826|NCT00111774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960827|NCT06037031|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960828|NCT06377969|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot prospective single arm interventional study||||
33960829|NCT02687763|NA|SINGLE_GROUP||OTHER||NONE||||||
33960830|NCT01445431|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33960831|NCT06125873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33960832|NCT04673266|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, open-label phase II study.||||
33960833|NCT00323635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960834|NCT00839007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960835|NCT05037552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960836|NCT02386722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34172105|NCT04148807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172106|NCT06376526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172107|NCT03354013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172108|NCT03908034|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Each participant will only receive the instruction pertaining to the arm to which he/she is assigned. The Research Assistant who conducts the study does not know about the hypothesis.|"The study has a 2 (presence of uncontrollable factor: yes vs. no) ✕ 2 (Anticipated regret induction: yes vs. no) between-subject design. Participants will be randomly assigned to one of the 4 between-subject conditions.~There is also a within-subject variable. Each subject will respond to 10 rounds of decision task with 5 different levels of overall disease risk reduction brought by the removal of X. The 5 levels of risk reduction are: (i) Removal of X reduces disease risk from 60% to 50% ; (ii) 60% to 40%; (iii) 60% to 30%; (iv) 60% to 20%; (v) 60% to 10%."|t|f|t|f
34172109|NCT03560882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859628|NCT04111432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859629|NCT01463384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859630|NCT01214538|||CASE_CONTROL||PROSPECTIVE|||||||
33960837|NCT02206724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960838|NCT00913016|||COHORT||PROSPECTIVE|||||||
33960839|NCT00566618|NA|SEQUENTIAL||TREATMENT||NONE||||||
33960840|NCT02483260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960841|NCT01222182|||CASE_CONTROL||RETROSPECTIVE|||||||
34172110|NCT04416763|||COHORT||PROSPECTIVE|||||||
34172111|NCT03397979|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|A single treating physician assessed outcomes and, along with those analyzing the data, was masked to group assignment. In other words, the care provider, investigator, and outcomes assessor were blinded to which bathing arm (twice daily or twice weekly) the study participants were in.|Randomized, Single-blinded, Prospective Crossover Controlled Trial|f|t|t|t
34172112|NCT02823509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859631|NCT04298723|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|CEC blinded DSMB blinded|multicenter, prospective, randomized, controlled, non-blinded clinical trial with a two-arm parallel group design|f|f|f|t
33859632|NCT02911246|||COHORT||PROSPECTIVE|||||||
33859633|NCT00730561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172113|NCT06420804|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site monadic study to evaluate the effect of a device on acne treatment.||||
34172114|NCT05248594|||COHORT||RETROSPECTIVE|||||||
34172115|NCT02122835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859634|NCT03099668|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Joint counts at 3 and 6 months will be done by a blinded investigator|1:1 parallel gruop allocation to multidisciplinary vs routine care|f|f|f|t
34172116|NCT02758210|NA|SINGLE_GROUP||OTHER||NONE||||||
34172117|NCT05633953|||OTHER||RETROSPECTIVE|||||||
34172118|NCT05471765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172119|NCT00132743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34172120|NCT04982562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172121|NCT05213832|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34172122|NCT00474123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172123|NCT02475590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172124|NCT04058444|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172125|NCT05219162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will be required to provide paired tissue and whole blood after disease progression following 1L Osimertinib. 200 tissue samples and 200 whole blood samples will be used to detect gene alteration by NGS, respectively. 200 tissue samples will be used to detect pathological transformation by IHC. Approximately 80-100 tissue samples will be used to test MET overexpression by MET IHC and MET amplification by FISH respectively. Approximately 80-100 whole blood samples will be used to test MET amplification by ddPCR.||||
34172126|NCT02359318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34172127|NCT01517750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172128|NCT04481412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34172129|NCT01793428|||CASE_ONLY||PROSPECTIVE|||||||
34172130|NCT00346216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172131|NCT04233801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172132|NCT04239001|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172133|NCT00948753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172134|NCT05383469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172135|NCT01381016|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172136|NCT06427213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172137|NCT03693703|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34172138|NCT02738801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172139|NCT05416333|RANDOMIZED|PARALLEL||TREATMENT||NONE||15 patients for the study will be randomized to one of two groups who consent to participate in a novel treatment with azelaic acid or the control (no additional treatment besides Subject's already prescribed drug)||||
34172140|NCT04350632|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172141|NCT04190602|||COHORT||OTHER|||||||
34172142|NCT02553304|||COHORT||PROSPECTIVE|||||||
34172143|NCT05195307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized study with an application and a control group.||||
34172144|NCT03314844|||COHORT||OTHER|||||||
34172145|NCT02010177|||COHORT||PROSPECTIVE|||||||
33750321|NCT02557152|||CASE_ONLY||OTHER|||||||
33750322|NCT05557045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750323|NCT03769142|||OTHER||PROSPECTIVE|||||||
34172146|NCT04739644|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study considers participants divided in two groups: the control group and the experimental group||||
34172147|NCT03164486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172148|NCT00723996|||||PROSPECTIVE|||||||
33750324|NCT02925455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750325|NCT05338333|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33750326|NCT01788748|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750327|NCT01952626|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33750328|NCT06063226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750329|NCT05019430|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33750330|NCT00615043|||CASE_ONLY||PROSPECTIVE|||||||
33859635|NCT05509933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859636|NCT06296745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172149|NCT00431990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172150|NCT03519074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172151|NCT00181896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172152|NCT06429150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172153|NCT02333461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172154|NCT00132574|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34172155|NCT00096902||||TREATMENT||||||||
34172156|NCT00146094||||BASIC_SCIENCE||||||||
34172157|NCT00837902|NA|SINGLE_GROUP||OTHER||NONE||||||
34172158|NCT05476445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and the assessor don't know the study group names.|"After the canal length was determined with the Apex locater, the canals were prepared using Ni-Ti endodontic rotary instrument files. Irrigation needles were kept 4-5 mm shorter than the working length, and irrigation of the channels was performed. A total of 5 ml of 1% NaOCl was washed for each canal, with 2 ml between each pecking movement of the files. The final washing of the channels was carried out using 5 ml of saline at room temperature.~After the last wash, in the cryotherapy group, unlike the first two groups, each canal was washed with 5 ml of 2°C cold physiological saline for 5 minutes. After the canals were dried with the help of a paper cone, the canals were filled by injecting iodoform and calcium hydroxide-containing canals. Then the restoration was completed with compomer. Following the restoration in the LLLT group, the diode laser was activated in biostimulation mode for a total of 1 minute, 30 seconds in the buccal and lingual/palatal regions at the root apex."|t|f|f|t
34172159|NCT05246917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised superiority study|f|f|f|t
34172160|NCT01155713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172161|NCT05958901|||COHORT||PROSPECTIVE|||||||
34172162|NCT03314493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172163|NCT05150769|||OTHER||CROSS_SECTIONAL|||||||
34172164|NCT05269914|NA|SEQUENTIAL||TREATMENT||NONE||Single infusion of autologous anti-CD19 car-t cells||||
34172165|NCT05355571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33750331|NCT06703060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750332|NCT01270126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960842|NCT02933827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960843|NCT05635773|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Assessors marking the recorded performances will be blinded as to which group the candidate had been allocated to in the first instance. The statistical analysis team will also be blinded to the allocation sequence.|Randomisation will be carried out using a randomization table made at www.randomizer.org to even/odd allocation numbers corresponding to 'Alexa first' vs 'No Alexa first' group with equal allocation between each arm. The randomisation sequence will be known only to the investigators issuing the initial grouping to the candidate, and allocations will be concealed from the video recording assessors and the statistical analysis team.|t|f|t|t
34172166|NCT03947619|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Blinding of the operator and patient is not possible given the nature of the treatment.|A prospective, multicenter, randomized, controlled open-label two-arm trial with an adaptive design|f|f|f|t
34172167|NCT02324946|||COHORT||PROSPECTIVE|||||||
34172168|NCT06353178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be notified of a waitlist assignment upon enrolling. Those on the waitlist will receive the intervention after 3 months.|Participants will be randomized to waitlist or intervention group. Those in intervention group will receive the peer program; those on the waitlist will receive it after being on the waitlist for 3 months.||||
34172169|NCT00333125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172170|NCT05899153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172171|NCT05035524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172172|NCT04743362|||COHORT||PROSPECTIVE|||||||
34172173|NCT04903210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study biostatistician will be blinded to group (NMN vs. controls)||f|f|f|t
34172174|NCT04309292|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34172175|NCT04835311|||COHORT||RETROSPECTIVE|||||||
34172176|NCT02337413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34172177|NCT02253914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34172178|NCT02666872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172179|NCT01526499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172180|NCT06345716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172181|NCT00884364|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34172182|NCT03111238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172183|NCT01245309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172184|NCT00382668|||COHORT||PROSPECTIVE|||||||
34172185|NCT00605852|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34172186|NCT03316092|||COHORT||RETROSPECTIVE|||||||
34172187|NCT01810770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172188|NCT05691595|||OTHER||CROSS_SECTIONAL|||||||
34172189|NCT03534609|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, open label||||
34172190|NCT06023394|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34172191|NCT02326285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172192|NCT03287791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172193|NCT04275323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172194|NCT01156662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172195|NCT02893917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172196|NCT05690984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172197|NCT05640323|||OTHER||PROSPECTIVE|||||||
34172198|NCT03974048|||COHORT||PROSPECTIVE|||||||
34172199|NCT05161897|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172200|NCT04069559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blindness was done for data collectors and statistician. There were two group as intervention group and control group|Intervention group and control group|f|f|f|t
34172201|NCT04423718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Up to Week 108: Participant and Investigator masked. Week 108 to Week 156: Participant and Investigator unmasked to treatment intervals.||t|t|t|t
34172202|NCT01648712|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34172203|NCT06446817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172204|NCT05765422|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172205|NCT01615250|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172206|NCT03253393|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Contralateral study|f|f|t|f
34172207|NCT05611671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172208|NCT06152302|NA|FACTORIAL||DIAGNOSTIC||NONE||"There is one arm in this study, without comparator group.~The comparison will be between data of movements in the outside water condition and data of inside water condition."||||
34172209|NCT04662567|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34172210|NCT01124110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172211|NCT01449162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172212|NCT02126722|||COHORT||PROSPECTIVE|||||||
34172213|NCT02326623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172214|NCT03488095|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34172215|NCT06408870|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-way crossover||||
34172216|NCT06398210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor|Single Blinded-Randomized Controlled Trial|f|f|f|t
34172217|NCT00445549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172218|NCT06068868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172219|NCT02560038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750333|NCT03896035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research staff conducting outcomes assessments will be blinded to whether the subject is in active or waitlist group|This pilot RCT will use a waitlist control|f|f|f|t
33750334|NCT00045110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750335|NCT00874861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750336|NCT04447326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750337|NCT04567472|NA|SINGLE_GROUP||OTHER||NONE||||||
33750338|NCT04461301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, parallel group, multi-centre, multidisciplinary, active controlled trial|f|f|f|t
33750339|NCT00496041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859637|NCT02326012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172220|NCT05440877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Individual randomization by serially numbered opaque sealed envelope (SNOSE) will be used to ensure the allocation sequence was concealed from both course teacher and participants before the group allocation. he participants will know the trial group and discussion group allocation by opening an envelop after they submit the consent form. All pre-post questionnaires are anonymous. All participants will be concealed of group allocation before consent, but they will not be blinded of the intervention. Two specialists in smoking cessation who will mark the group assignment will be blinded to group allocation of all participants.||f|f|t|t
33859638|NCT04156230|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Symptomatic subjects with a pretest score of deep vein thrombosis likely (Wells score ≥ 2) or a positive D-dimer test will receive \[18F\]GP1 PET/CT.||||
33859639|NCT01281007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859640|NCT00164125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859641|NCT02141789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859642|NCT03641105|||COHORT||PROSPECTIVE|||||||
33859643|NCT03494439|||OTHER||CROSS_SECTIONAL|||||||
33859644|NCT05753553|||COHORT||PROSPECTIVE|||||||
34172221|NCT05574296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized to usual care with or without treatment|f|f|f|t
34172222|NCT04049708|||COHORT||PROSPECTIVE|||||||
34172223|NCT04836468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172224|NCT03393585|||OTHER||PROSPECTIVE|||||||
34172225|NCT02558725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172226|NCT01849510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172227|NCT03313869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172228|NCT06061991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34172229|NCT05317286|||COHORT||PROSPECTIVE|||||||
34172230|NCT02782676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172231|NCT00058396||||TREATMENT||NONE||||||
34172232|NCT03482726|NA|SINGLE_GROUP||OTHER||NONE||||||
33750340|NCT00001587||||TREATMENT||||||||
33750341|NCT04653103|||COHORT||PROSPECTIVE|||||||
33750342|NCT05556928|||COHORT||PROSPECTIVE|||||||
33750343|NCT03330379|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750344|NCT04911868|||OTHER||RETROSPECTIVE|||||||
33750345|NCT02346383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33750346|NCT00541515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750347|NCT01445938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750348|NCT02597881|||COHORT||OTHER|||||||
33750349|NCT05187676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750350|NCT00160433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750351|NCT06500481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750352|NCT01850225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750353|NCT01152580|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33750354|NCT05619601|||COHORT||PROSPECTIVE|||||||
33750355|NCT05326464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750356|NCT00092534|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33750357|NCT02657980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750358|NCT06333925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All participants will engage in a behavioral training session (Cognitive Restructuring).~The study team member who will conduct the behavioral session will be kept blind to the type of neurostimulation the participant will receive. Participants will also be kept blinded to what neurostimulation they receive and their perception of what they received will be assessed at follow-up. The intervention provider will also be kept blind to the treatment condition to ensure non-biased administration of the intervention.~Participants will only be told about the type of neurostimulation at the end of the study to protect against different expectations"|In regards to the neurostimulation used in the study, there will be two conditions, receiving either active or sham neurostimulation. Both conditions will receive behavioral training in cognitive restructuring (CR; a type of emotion regulation skill). Randomization procedures will match participants on age, gender at birth, and misophonia impairment severity.|t|t|f|t
33750359|NCT01362140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33750360|NCT03195010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750361|NCT06298903|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator who will analyze the data will be blinded||f|f|t|f
33750362|NCT03088267|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|placebo-controlled|This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover study|t|f|t|f
33750363|NCT00608582|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33750364|NCT04789668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750365|NCT06724991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750366|NCT02776358|NON_RANDOMIZED|PARALLEL||||NONE||||||
33750367|NCT02154763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750368|NCT03266809|||COHORT||PROSPECTIVE|||||||
33750369|NCT05526105|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Patients will be assigned to be NPO after midnight (standard protocol) or feed up until call to OR then decompressed (liberal protocol).||||
33750370|NCT01959724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750371|NCT04340206|RANDOMIZED|PARALLEL||TREATMENT||NONE||Efficacy study||||
33750372|NCT03602131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750373|NCT05214872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33750374|NCT05696899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750375|NCT06176196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859645|NCT01776424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants who consented to COMPASS long-term open-label extension (LTOLE) part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part and no blinding procedures were applicable to the LTOLE part.||t|t|t|t
33859646|NCT05137860|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical Randomized Trial||||
33960844|NCT01336309|||||CROSS_SECTIONAL|||||||
33960845|NCT04767022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172233|NCT06408662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent evaluator (IE) will conduct study related assessments during the treatment and follow-up periods, and will be masked to treatment condition.|This project is a randomized controlled trial (RCT) that will compare the efficacy of a mindfulness-based intervention for tics (MBIT) to psychoeducation with relaxation and supportive therapy (PRST) in 150 adults with TS. The study interventions will be delivered in a group format and provided remotely using a secure telehealth services platform. The study assessments will be completed using a secure telehealth services platform and online electronic data capture systems. An independent evaluator (IE) masked to treatment condition will administer all assessments during the treatment and follow-up periods.|f|f|f|t
34172234|NCT02861612|||COHORT||PROSPECTIVE|||||||
34172235|NCT04066868|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33859647|NCT03539341|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This study will use a randomised controlled trial design to test the effects of the Parenting for Lifelong Health 2-9 Thailand programme in comparison to participants allocated to receiving care as usual in the control group (N = 120 parents and primary caregivers of children ages 2 to 9 years; 1:1 intervention to control group ratio).|f|f|t|t
33859648|NCT01187524|||||OTHER|||||||
33859649|NCT04029961|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859650|NCT00984035|||CASE_ONLY||PROSPECTIVE|||||||
33859651|NCT04011956|||COHORT||OTHER|||||||
33859652|NCT02598752|||COHORT||PROSPECTIVE|||||||
33859653|NCT00132613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859654|NCT00303641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33859655|NCT02593786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859656|NCT05997251|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859657|NCT00604279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859658|NCT01605695|||COHORT||PROSPECTIVE|||||||
33859659|NCT04867889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization into the study will be conducted by stratified block randomization. Randomization will be created via the RedCap system and a special assigned randomization personnel (the randomizer) not otherwise involved in the study. The randomizer has access to a set of patient identification codes to the Magpro X100 that determines if the patient will be given active or sham treatment. When a patient has been recruited to the study the rTMS operator will open next randomization envelope to achieve a patient code for the machine and will thereby be blinded to treatment allocation of the patient|"This is a four week parallel randomized controlled trial, with two arms; the first following a protocol for magnetic stimulation of the brain with intermittent theta-burst stimulation (iTBS), with one session daily for four weeks, and the other the same protocol with a sham coil (both treatment arms will have 20 sessions in total). Apart from assessment of mood symptoms, treatment effects is also assessed using structural and functional magnetic resonance imaging.~A random selection of the participating women will be invited to a sub-study and interviewed once during pregnancy as well as a second time 4-6 months postpartum. Questions will include inter alia their own description of being pregnant and depressed."|t|t|t|f
33859660|NCT04369989|||COHORT||OTHER|||||||
33859661|NCT04886453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859662|NCT05722704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859663|NCT01324323|NA|SINGLE_GROUP||OTHER||NONE||||||
33859664|NCT01289821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859665|NCT04337333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859666|NCT03351166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859667|NCT01416987|||COHORT||PROSPECTIVE|||||||
33859668|NCT02315027|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33859669|NCT01644344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33859670|NCT02491268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859671|NCT04771585|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||In part A of the study, aerosol emission of subjects will be characterized. From this population, the 10 highest-emitting subjects will enter part B of the study to investigate the effect of face masks on aerosol emission down to the submicron range.||||
33859672|NCT00118820|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33960846|NCT01284816||CROSSOVER||||NONE||||||
33960847|NCT01291069|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
10661547|NCT06566963|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33960848|NCT02754505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960849|NCT04155957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960850|NCT04144231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960851|NCT01700088|||CASE_ONLY||PROSPECTIVE|||||||
33960852|NCT01971229|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33960853|NCT03585868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960854|NCT03054935|||CASE_ONLY||CROSS_SECTIONAL|||||||
33960855|NCT05446480|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Own-control study - all participants perform each trial arm/intervention separated by a washout period. Order of trials is randomized for each participant.|t|f|t|f
33960856|NCT05163431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172236|NCT05797337|||OTHER||CROSS_SECTIONAL|||||||
34172237|NCT04333563|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
34172238|NCT01692184|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34172239|NCT01651481|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172240|NCT06340295|||COHORT||PROSPECTIVE|||||||
34172241|NCT02021201|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34172242|NCT02571023|||COHORT||PROSPECTIVE|||||||
34172243|NCT01706458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172244|NCT01512485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172245|NCT02660177|NA|SINGLE_GROUP||OTHER||NONE||||||
34172246|NCT06005415|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34172247|NCT01921205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859673|NCT05518864|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|double blinded by care provider (person giving the treatment) and the participant (blinded syringes en placebo product)|Study start as a normal double blinded RCT, but continues with an aggregated N-of-1 (multi-crossover) type trial|t|t|f|f
33859674|NCT04322942|||COHORT||CROSS_SECTIONAL|||||||
33859675|NCT02842892||||DIAGNOSTIC||||||||
33859676|NCT04702282|||COHORT||PROSPECTIVE|||||||
33960857|NCT04886869|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33960858|NCT02149862|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33960859|NCT01030250|||COHORT||PROSPECTIVE|||||||
34172248|NCT05356286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172249|NCT02857517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172250|NCT06438822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172251|NCT04836052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172252|NCT04558177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|sham procedure appears indistinguishable from intervention|double blind placebo controlled|t|t|f|f
34172253|NCT05694390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34172254|NCT04281407|NA|SINGLE_GROUP||OTHER||NONE||Single arm prospective study||||
34172255|NCT05011942|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||This is a randomized 1:1 treatment of placebo or standard of care irrigation and Irrisept solution.||||
34172256|NCT00674479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172257|NCT05901701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blocked randomization technique was used to divide the patients into two equal groups using sealed envelopes, the person who was in charge for randomization was blinded to the group allocation of the patients. The outcome assessor also didn't know the allocated groups, and the patients were instructed not to mention their groups to the assessors.|Group A: Patients received applications of low-level laser therapy. Group B: Patients received hard occlusal splints (Michigan splints).|f|f|f|t
34172258|NCT03469752|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized-controlled trial||||
34172259|NCT01691144|||CASE_ONLY||CROSS_SECTIONAL|||||||
34172260|NCT04169958|||COHORT||PROSPECTIVE|||||||
34172261|NCT01933581|||COHORT||PROSPECTIVE|||||||
33859677|NCT02393274|||COHORT||PROSPECTIVE|||||||
33859678|NCT01096342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859679|NCT02141074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859680|NCT04113668|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33859681|NCT02477579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859682|NCT02745262|||COHORT||RETROSPECTIVE|||||||
33859683|NCT05413174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Clinical Study Technician will then perform the 1:1 randomization. The randomization is automatically transmitted by email to the email of the radiology technician in charge of hypnosis.||f|f|f|t
33859684|NCT04544345|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33859685|NCT04269135|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859686|NCT00710827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859687|NCT04127422|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859688|NCT01491048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859689|NCT05266586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablet made to resemble active; placebo capsule made to resemble active|Placebo-controlled, double-blind, randomized|t|t|t|t
33859690|NCT04474223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859691|NCT06318767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859692|NCT02136420|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double masking applies to arms 9\&10. Other arms use participant masking only.|"The design includes three separate studies:~1. Arm 9\&10 follows a crossover design. These results were reported in Diaz-Artiles et al 2017.~2. Arms 1-4 are a separate study which follow a factorial design, with arm 2 serving as the placebo, arms 1 and 3 assessing the effects of two separate interventions and arm 4 assessing the effect of two combined interventions.~3. Arms 5-8 are a separate study which follow a factorial design, with arm 6 serving as the placebo, arms 5 and 7 assessing the effects of two separate interventions and arm 8 assessing the effect of two combined interventions."|t|f|t|f
33859693|NCT02804178|NA|SINGLE_GROUP||TREATMENT||NONE||Single treatment arm with up to 5 planned dosing periods with escalating doses. Subjects were dosed with each dose level for 2 weeks, followed by 2 weeks of matching placebo (subjects blinded).||||
33859694|NCT04896138|||OTHER||PROSPECTIVE|||||||
33859695|NCT01228955|||COHORT||PROSPECTIVE|||||||
33960860|NCT06442059|||CASE_ONLY||PROSPECTIVE|||||||
33960861|NCT00197509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33960862|NCT02736786|||COHORT||PROSPECTIVE|||||||
34172262|NCT02025894|||COHORT||PROSPECTIVE|||||||
34172263|NCT05425602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172264|NCT01145534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172265|NCT04590664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172266|NCT04002960|NA|SINGLE_GROUP||OTHER||NONE||||||
34172267|NCT04506840|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172268|NCT03447002|||CASE_CONTROL||PROSPECTIVE|||||||
34172269|NCT05549726|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants initially randomized to the Dynamic Choice Prevention delivery model will be given the option to use CAB-LA as part of the dynamic choice prevention delivery package. Participants initially randomized to standard of care will continue to receive standard of care.||||
34172270|NCT00574808|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33859696|NCT00327054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859697|NCT02608541|||COHORT||OTHER|||||||
33859698|NCT02448056|||CASE_ONLY||PROSPECTIVE|||||||
33960863|NCT00326300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859699|NCT00768391|NA|SINGLE_GROUP||||NONE||||||
33859700|NCT04008758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Randomized prospective trial~1. st group is sono group using lung ultrasound~2. nd group is control group"||||
33960864|NCT02706600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33859701|NCT00514761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960865|NCT06349434|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Randomized Clinical Trial|t|t|f|t
33960866|NCT01318200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960867|NCT06495125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960868|NCT04143997|||COHORT||RETROSPECTIVE|||||||
33960869|NCT04690322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy||||
33960870|NCT06521788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960871|NCT01364779|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172271|NCT00384345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33960872|NCT01372254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172272|NCT02763306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172273|NCT04254393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Study investigators and outcome assessors will be blind to the allocations status of participants. To ensure blinding, participants will be instructed to not disclose their allocation during assessment.~Fidelity of masking will be ensured by having assessors guess the allocation status of participants at the end of assessments."|Two arm, single blind, pilot cluster randomized controlled trial (cRCT)|f|f|t|t
34172274|NCT04647370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34172275|NCT06132451|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|In the first block, the treating physicians will not be informed about the study participation of their patient, in order to ensure that they will treat the patient according to what they perceive as the current usual practice. In the second block, the treating physicians will be informed about the study participation of their patients.|There will be block-wise randomization. During the first block, the study team will not interfere with the treating physician, in order to ensure that they will treat the patient according to what they perceive as the current usual practice. During the second block the patients receive no change of their original antihypertensive treatment.|f|t|f|f
34172276|NCT06144554|||COHORT||PROSPECTIVE|||||||
34172277|NCT03190837|||OTHER||PROSPECTIVE|||||||
34172278|NCT00308139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172279|NCT05490186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172280|NCT02570503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172281|NCT05356234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outside evaluators will remain blind to each condition throughout the study.|The Intervention group will start with assigning a Case Manager and conducting a series of workshops addressing responsible parenting and marriage and relationships as well as a complement of employment services and comprehensive case management.|f|f|f|t
34172282|NCT00772538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34172283|NCT00524485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172284|NCT03032562|||COHORT||PROSPECTIVE|||||||
34172285|NCT01320189|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34172286|NCT03834246|||COHORT||RETROSPECTIVE|||||||
34172287|NCT02433626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172288|NCT02482181|||CASE_ONLY||PROSPECTIVE|||||||
34172289|NCT00006016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859702|NCT00556153|||CASE_ONLY||PROSPECTIVE|||||||
33859703|NCT03252054|||COHORT||CROSS_SECTIONAL|||||||
33960873|NCT02476760|||COHORT||RETROSPECTIVE|||||||
33960874|NCT02433535|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33960875|NCT00881595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960876|NCT00549107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960877|NCT00388115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960878|NCT02100241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960879|NCT02106793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960880|NCT01256827|||COHORT||CROSS_SECTIONAL|||||||
33960881|NCT06240572|||COHORT||RETROSPECTIVE|||||||
33960882|NCT04523831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number|Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.|t|f|t|f
33960883|NCT04383080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33960884|NCT03786809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172290|NCT01439789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172291|NCT05994950|||OTHER||RETROSPECTIVE|||||||
33859704|NCT00690833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859705|NCT05387226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859706|NCT04003935|||COHORT||PROSPECTIVE|||||||
33893707|NCT03220412|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants did not know which condition they were in. Participants' parents were aware of the deception (hidden gun) and what condition their children were in (with or without guns). Research personnel knew conditions as well. Research assistants who transcribed recorded laboratory sessions did not know what condition they were coding (eg. what type of movie participants watched)|Participants are randomly assigned to watch a movie containing guns, or a movie not containing guns.|t|f|f|f
33859707|NCT04026139|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Design: Randomised controlled trial. Participants: Seventy patients diagnosed with T2DM together with knee OA. Intervention: Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week. The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.|t|f|f|f
34172292|NCT04384809|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-blinded, parallel randomized control trial||||
33859708|NCT00597077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172293|NCT00310765|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blinding was done to ensure minimum bias. Clinicians were not involved in the randomization process. Patients and clinicians were blinded to the identity of the drug as a look alike placebo was used. The randomization code was was maintained by the research assistant and kept in a locked file cabinet. Separated individuals generated the allocation sequence. The blind was maintained until all the decisions regarding data evaluability were made or in the event of a serious adverse event.|Patients were evaluated for the study and were entered into the study if they had documented abdominal adhesions and a daily pain score of 40 mm on a visual assessment scale and 4 on an eleven point Likert scale (0 none and 10 most pain). Patients were randomly assigned to active drug or look alike placebo for 7 weeks followed by an open label phase in which all patients received active drug pregabalin 300 mg daily for 4 weeks measuring pain and sleep scores during each phase of the study.|t|t|t|t
34172294|NCT05034913|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34172295|NCT03532542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859709|NCT01078207|||CASE_CONTROL||PROSPECTIVE|||||||
33859710|NCT00861263|NA|SINGLE_GROUP||||NONE||||||
33859711|NCT05418218|||COHORT||PROSPECTIVE|||||||
33859712|NCT01152762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859713|NCT06493812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33893708|NCT00005912||||TREATMENT||||||||
34172296|NCT01938079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172297|NCT02759757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172298|NCT03930836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172299|NCT03962465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an early-phase study evaluating the safety of inotuzumab ozogamicin administered in combination with a 3-drug and 4-drug re-induction regimen in participants with relapsed or refractory B-ALL. The trial is planned to first determine the maximum tolerated dose (MTD) of the 3-drug re-induction regimen in Part 1 and then to determine the MTD of the 4-drug re-induction regimen (including pegaspargase) in Part 2.||||
34172300|NCT05110638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172301|NCT03165617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Phase 3/4|t|t|t|t
34172302|NCT04471077|||COHORT||PROSPECTIVE|||||||
34172303|NCT01459302|||OTHER||PROSPECTIVE|||||||
34172304|NCT06196736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172305|NCT02099851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172306|NCT06092021|||OTHER||CROSS_SECTIONAL|||||||
34172307|NCT04823403|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1, Dose-Escalation (3+3 design), Open-label, single arm, single-center study, and expansion cohort. DLT will be captured within 1 month after HIA administration.~3 levels of dose of HIA ipilimumab will be tested. Starting by a dose 5 times lower than what is used for IV administration."||||
34172308|NCT04795778|||CASE_CONTROL||PROSPECTIVE|||||||
34172309|NCT00302809|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34172310|NCT00083889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172311|NCT03485755|||COHORT||PROSPECTIVE|||||||
34172312|NCT01413035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172313|NCT00740220|||COHORT||PROSPECTIVE|||||||
33960885|NCT00365469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33960886|NCT06169020|NA|SINGLE_GROUP||OTHER||NONE||||||
33960887|NCT00656019|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960888|NCT04227652|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was used in the study|The study subjects were enrolled in two parallel groups.||||
33960889|NCT05220865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, investigator evaluating treatment success at follow-up appointments and biostatistician will be blinded||t|f|t|t
33960890|NCT02305680|||COHORT||PROSPECTIVE|||||||
34172314|NCT05776017|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Vaccine recipients and their parent(s)/guardian(s) as well as all investigators and study personnel responsible for the vaccination, evaluation of safety and immunogenicity endpoints will all be unaware to the exact treatment given to the participant. Randomization will be programmed into the eCRF, as subjects are confirmed to be eligible for enrollment and to be vaccinated. A password protected electronic randomized vaccination allocation list will be sent to the designated vaccine pharmacist. The investigator will send a request for vaccination to the pharmacy using the subject randomization number (which will be the subject unique ID number) assigned by the eCRF. For each child, eligibility will have to be counter checked and signed by a second person before allocation of study ID number.||t|t|t|t
34172315|NCT04653480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172316|NCT01638455|NA|SINGLE_GROUP||OTHER||||||||
34172317|NCT05711576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes|At baseline, 1, 3, 6 months, full-mouth plaque score (FMPS), full-mouth bleeding score (FMBS), probing depth (PD), bleeding on probing (BOP), modified gingival index (mGI), and modified plaque index (mPlI) were assessed.|t|f|t|f
34172318|NCT04128137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172319|NCT06041568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859714|NCT04100850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Watsu, Aquatic Exercises, Control|f|f|t|t
33859715|NCT01051700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33859716|NCT04207866|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a prospective observational study with sequential enrolment of 40 cochlear implant recipients. The subjects will be continuously included in the study, and will be included in the teleconferencing or on-site groups based on willingness to travel and distance from the hospital. Individuals will first be assessed by an Audiologist to determine listening goals and provide structure for auditory training sessions in house. Follow-up sessions will involve TC or FTF sessions whereby the patient will work with a CDA on skills targeted to help the patient achieve listening goals. A review session may also occur with the Audiologist following several TC or FTF sessions to assess progress and reassess current goals.||||
33859717|NCT04417101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859718|NCT00460057|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33859719|NCT00651157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859720|NCT01849666|RANDOMIZED|PARALLEL||||NONE||||||
33859721|NCT02311257|||COHORT||CROSS_SECTIONAL|||||||
33859722|NCT04502134|||OTHER||CROSS_SECTIONAL|||||||
33859723|NCT00880035|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33859724|NCT02906839|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859725|NCT00904566|||COHORT||RETROSPECTIVE|||||||
33859726|NCT04270357|||OTHER||PROSPECTIVE|||||||
33859727|NCT03678987|||OTHER||PROSPECTIVE|||||||
33859728|NCT04687449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients with a diagnosis of COPD will be randomized to receive either a daily curcumin preparation or placebo for 90 days, in addition to the standard of care treatment.|t|f|t|f
33859729|NCT05649033|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859730|NCT01056133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859731|NCT05881057|||CASE_ONLY||PROSPECTIVE|||||||
33859732|NCT04496986|||COHORT||PROSPECTIVE|||||||
33859733|NCT01052688|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859734|NCT05591482|||COHORT||RETROSPECTIVE|||||||
33859735|NCT01679249|||CASE_ONLY||PROSPECTIVE|||||||
33859736|NCT02465463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859737|NCT02579174|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33859738|NCT01993446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859739|NCT02472080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859740|NCT03080688|||CASE_ONLY||PROSPECTIVE|||||||
33859741|NCT04637022|||CASE_CONTROL||PROSPECTIVE|||||||
33859742|NCT02005081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859743|NCT02069353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859744|NCT00897351|||OTHER||RETROSPECTIVE|||||||
33859745|NCT02336178||||TREATMENT||NONE||||||
33859746|NCT00280046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859747|NCT01098136|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33859748|NCT00760669|||COHORT||PROSPECTIVE|||||||
33859749|NCT04992962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859750|NCT04833322|NA|SINGLE_GROUP||TREATMENT||NONE||Before-and-after pilot clinical trial with a single group||||
33859751|NCT04214301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859752|NCT03744754|||COHORT||PROSPECTIVE|||||||
33859753|NCT02702973|||CASE_CROSSOVER|||||||||
33859754|NCT00496795|NA|SEQUENTIAL||TREATMENT||NONE||Sequential epirubicin and docetaxel||||
33859755|NCT02099903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859756|NCT00109720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893709|NCT05123157|||COHORT||RETROSPECTIVE|||||||
33960891|NCT00858234|NA|SEQUENTIAL||TREATMENT||NONE||||||
33960892|NCT01980316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960893|NCT04117217|||COHORT||PROSPECTIVE|||||||
34064147|NCT06346171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To ensure credible outcomes, robust blinding for participants, care providers, and outcome assessors is vital to minimize bias. Participants will be briefed generally about participating in VR distraction research, with no details on psychotherapy inclusion. Gastroenterologists and outcome assessors remain blinded to intervention types, using standard tools for unbiased outcome evaluation. The principal investigator, aware of the intervention nature, conducts psychotherapy sessions or engages in simple discussion for control arm VR exposure. Another gastroenterologist oversees randomization to maintain blinding. Standardized VR distractions and pre-programmed randomization ensure unbiased participant allocation, reinforcing study validity through meticulous concealment and blinding protocols.|The VRIPanx-COL study is an RCT investigating the efficacy of VR-facilitated integrative psychotherapy compared to VR distraction only and NSE-Col. Variance minimisation and propensity score matching are used to ensure that the groups are balanced and to supplement the internal validity of evaluating the efficacy of the intervention.|t|t|f|t
34064148|NCT03443258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients are assigned to either intervention or control group. The intervention group receives a nursing consultation using a need assessment and decision making tool. The control group receives usual care.||||
34064149|NCT01260961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064150|NCT02745327|||COHORT||PROSPECTIVE|||||||
34064151|NCT05426109|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both the investigators and participants are aware of the group assignment since the foods prepared and provided (peanut-containing or no peanut snacks) cannot be masked.|||||
34064152|NCT02768922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064153|NCT01335854|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34064154|NCT04436705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34064155|NCT02524808|||CASE_ONLY||PROSPECTIVE|||||||
34064156|NCT06158009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34064157|NCT04819412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33750376|NCT01557413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750377|NCT03671837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750378|NCT00251953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064158|NCT06597968|||COHORT||PROSPECTIVE|||||||
34064159|NCT06197308|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients with PSC||||
34064160|NCT03750409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34064161|NCT00814541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064162|NCT00300833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064163|NCT03017976|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34064164|NCT03797989|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34150256|NCT04468074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150257|NCT03598751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150258|NCT02193113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150259|NCT01944345|||CASE_ONLY||PROSPECTIVE|||||||
34150260|NCT02845076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150261|NCT03591172|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33750379|NCT01398800|||CASE_ONLY||RETROSPECTIVE|||||||
33750380|NCT03545854|RANDOMIZED|PARALLEL||TREATMENT||NONE||The cadavers will be randomized to receive the intervention (Erector Spinae Plane Block) on different levels (Vertebral level - T3, T12 and L4) and different volumes (10, 20 and 30ml)||||
33859757|NCT05179720|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Randomly assign patient groups according to the random number method.The biopsy sample inspector does not know the patient's biopsy method|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy.|f|f|f|t
33859758|NCT00439530|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33859759|NCT05898464|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859760|NCT02203123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150262|NCT05304312|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants that received the book (intervention) is followed up with different days and different hospitals with patients that were not receiving any book (control)|There are two groups in which one group will be given a Kegel Exercises guidebook and another group or control will not be given the book. Both groups were equally followed-up for 3 months and examined by UDI-6, IIQ-7, Perineometer, and 1-hour pad test.|t|f|f|f
34150263|NCT04394715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34150264|NCT02963701|RANDOMIZED|PARALLEL||TREATMENT||||||||
34150265|NCT01294163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150266|NCT03528005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150267|NCT02170909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859761|NCT04159350|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33960894|NCT01649245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859762|NCT05509985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859763|NCT00529724|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33859764|NCT05205057|||CASE_CONTROL||PROSPECTIVE|||||||
33859765|NCT05074849|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33960895|NCT02241200|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33960896|NCT06120452|NA|SINGLE_GROUP||OTHER||NONE||||||
33859766|NCT02974088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960897|NCT03679312|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized double-blind cross-over design|t|f|f|t
33960898|NCT04767217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172320|NCT01539759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172321|NCT00790803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172322|NCT05864729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172323|NCT04773951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172324|NCT00000266||||TREATMENT||||||||
34172325|NCT04956536|||CASE_ONLY||RETROSPECTIVE|||||||
34172326|NCT00719641|||OTHER||OTHER|||||||
34172327|NCT02321241|||COHORT||OTHER|||||||
34172328|NCT01935739|||CASE_CONTROL||PROSPECTIVE|||||||
33859767|NCT03015441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172329|NCT02361385|||OTHER||PROSPECTIVE|||||||
33859768|NCT02729623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859769|NCT04470609|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859770|NCT04907695|||COHORT||PROSPECTIVE|||||||
33859771|NCT01523639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859772|NCT05768061|||COHORT||RETROSPECTIVE|||||||
33859773|NCT06165939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859774|NCT05158556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859775|NCT01346488|||COHORT||PROSPECTIVE|||||||
33960899|NCT00995930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33960900|NCT04235764|||COHORT||PROSPECTIVE|||||||
33960901|NCT04281654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172330|NCT05566535|||COHORT||PROSPECTIVE|||||||
34172331|NCT03309020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960902|NCT04694339|||OTHER||PROSPECTIVE|||||||
33960903|NCT02253407|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34172332|NCT01095289|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750381|NCT03538015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blinded, randomized, placebo-controlled study in patients with Type 1 diabetes mellitus and hypoglycemia unawareness|t|f|t|f
33750382|NCT04461951|||COHORT||CROSS_SECTIONAL|||||||
33750383|NCT01818479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750384|NCT04662554|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
33750385|NCT03479320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750386|NCT00435604|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
33859776|NCT06420895|||COHORT||RETROSPECTIVE|||||||
33859777|NCT00670189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859778|NCT02569554||CROSSOVER||BASIC_SCIENCE||NONE||||||
33859779|NCT00579163|||CASE_ONLY||PROSPECTIVE|||||||
33859780|NCT05579158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859781|NCT03165539|||COHORT||PROSPECTIVE|||||||
33859782|NCT01936142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859783|NCT00594802|||||RETROSPECTIVE|||||||
33859784|NCT05277129|||COHORT||PROSPECTIVE|||||||
33859785|NCT02810899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859786|NCT02812901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960904|NCT03174925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Siemens Acuson S3000 ultrasound system||||
33960905|NCT04953208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960906|NCT06344988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150268|NCT02702687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150269|NCT00677755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150270|NCT02367404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150271|NCT02133807|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150272|NCT00438152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150273|NCT05161689|RANDOMIZED|PARALLEL||PREVENTION||NONE||The community-based, multilevel and theory-based intervention diffuses social support and empowers the YMSM community in order to establish social norms supportive of risk reduction and biannual HIV testing.||||
34150274|NCT01152177|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34150275|NCT03569839|||CASE_ONLY||PROSPECTIVE|||||||
34150276|NCT01179061|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34150277|NCT01422824|||COHORT||PROSPECTIVE|||||||
34150278|NCT03201159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a dose escalating Phase Ib study, in which up to 3 doses of VLX103 will be assessed for safety, pharmacodynamics and pharmacokinetics in separate patient cohorts receiving sequentially increasing doses of VLX103. A maximum of 18 well-defined moderate ASH patients will be enrolled and treated in the study, i.e. 6 per dosing cohort.||||
34150279|NCT00397007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34150280|NCT00681993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150281|NCT03483298|||COHORT||PROSPECTIVE|||||||
34150282|NCT03150732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Two groups|t|t|t|t
34150283|NCT02418104|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34150284|NCT01070108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150285|NCT03191370|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34150286|NCT01629472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150287|NCT05340166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34150288|NCT00002140||||TREATMENT||DOUBLE||||||
34150289|NCT01375465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150290|NCT01392287|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34150291|NCT04519060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33750387|NCT02497573|||COHORT||PROSPECTIVE|||||||
33750388|NCT05271864|||OTHER||CROSS_SECTIONAL|||||||
33750389|NCT02040116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172333|NCT05348902|||CASE_CONTROL||RETROSPECTIVE|||||||
34172334|NCT01679288|NA|SINGLE_GROUP||SCREENING||NONE||||||
34172335|NCT04041713|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This is an 18-week pilot, single site, randomized,double blind, placebo-controlled cross-over trial of Rett-T vs. placebo. Periods I and II of the randomized study are 8 weeks long with a 2 week washout period.|t|t|t|t
34172336|NCT05817903|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups (ARM A vs ARM B) in parallel for the duration of the study.||||
34172337|NCT06131632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172338|NCT00976807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172339|NCT00886002|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34172340|NCT01007786|||COHORT||PROSPECTIVE|||||||
34172341|NCT01486875|||COHORT||PROSPECTIVE|||||||
33750390|NCT06113250|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"60 male and female patients will participate in the study are divided into 3 groups (20 in each group). They will be randomly assigned to three equal groups: Group (A): twenty patients will receive shortwave diathermy and traditional physical therapy program (splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises).~Group (B): twenty patients will receive ultrasound waves and traditional physical therapy program (splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises).~Group (C): twenty patients will receive only traditional physical therapy program (splinting, stretching exercises, strengthening exercises and range of motion (ROM) exercises)"|t|f|f|f
33750391|NCT06258967|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33750392|NCT01595295|||OTHER||OTHER|||||||
33750393|NCT05245929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750394|NCT02126098|||COHORT||PROSPECTIVE|||||||
33750395|NCT02449200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750396|NCT00739349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750397|NCT05130151|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and providers are the parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.|Adolescents (N = 200) will be randomized into two arms - 100 into the adapted mobile phone-based intervention arm, and 100 into standard education provided in schools.|t|t|f|f
33750398|NCT01711203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750399|NCT04819269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750400|NCT03822533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Participants with suspected knee osteoarthritis are either randomised to a physiotherapist or a physician as primary assessor for assessment and treatment. After the first assessment that the patients are assigned to, the patients can choose to seek the other health care provider if they want to.~This study focuses on analysing cost efficiency of the health care processes for patients with suspected knee osteoarthritis in primary care."|f|f|f|t
33750401|NCT06173778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172342|NCT06334575|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34172343|NCT05045768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172344|NCT04050553|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34172345|NCT03053375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172346|NCT03372785|||COHORT||PROSPECTIVE|||||||
34172347|NCT02503592|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34172348|NCT02489435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172349|NCT02655029|||COHORT||PROSPECTIVE|||||||
34172350|NCT00409643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750402|NCT01567618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064165|NCT04931719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One of the investigator, blinded to the allocation groups, performed all the assessments. The patients were blinded, by preventing visual access to the injection field with a screen placed between them and their knee during the injection process. They were not informed of which HA they had received during the study period.|The purpose of this study was to compare the efficacy of a single Artz injection followed by PRP with a single HYAJOINT Plus injection followed by PRP in the management of knee OA.|t|f|f|t
33750403|NCT01114854|NA|SINGLE_GROUP||TREATMENT||NONE|It was a open-label study|||||
33750404|NCT00755482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750405|NCT02965950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172351|NCT06060236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33750406|NCT05956301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750407|NCT06236503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064166|NCT04420117|||COHORT||PROSPECTIVE|||||||
34064167|NCT00396916|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34064168|NCT02795936|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34064169|NCT01553994|||COHORT||RETROSPECTIVE|||||||
33750408|NCT00005076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750409|NCT05487664|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33750410|NCT02519010|RANDOMIZED|CROSSOVER||||NONE||||||
33750411|NCT00646477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33750412|NCT01308242|NA|SINGLE_GROUP||SCREENING||NONE||||||
33750413|NCT05377580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750414|NCT01835457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33750415|NCT05418036|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective study||||
33750416|NCT02414477|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750417|NCT02457039|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34064170|NCT00041041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064171|NCT04222842|NA|SEQUENTIAL||TREATMENT||NONE||||||
34172352|NCT03353675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172353|NCT05461859|||CASE_CONTROL||RETROSPECTIVE|||||||
34172354|NCT05039749|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750418|NCT03549910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750419|NCT02666547|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750420|NCT01295554|||CASE_ONLY||PROSPECTIVE|||||||
33750421|NCT06378554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750422|NCT05972096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial aims to test the efficacy of this expanded skills DBT-based intervention with self-compassion and contextual-based skills targeting long-lasting BPD compared with treatment as usual.|f|f|t|f
33750423|NCT02575885|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33750424|NCT05632146|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750425|NCT01708850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750426|NCT03816748|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750427|NCT00908479|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33750428|NCT06683742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750429|NCT01066221|||||PROSPECTIVE|||||||
33750430|NCT04219670|||COHORT||CROSS_SECTIONAL|||||||
33750431|NCT06315595|||COHORT||PROSPECTIVE|||||||
33750432|NCT00019916|RANDOMIZED|||TREATMENT||||||||
33859787|NCT04897451|||COHORT||PROSPECTIVE|||||||
33859788|NCT05281965|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33859789|NCT06017141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and statisticians are blinded to the type of anesthesia.||t|f|f|t
33859790|NCT04932538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33859791|NCT03484520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859792|NCT02025946|||COHORT||PROSPECTIVE|||||||
33859793|NCT00892372|||CASE_ONLY||RETROSPECTIVE|||||||
33859794|NCT05119426|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33859795|NCT01939054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859796|NCT00593801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172355|NCT04870762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172356|NCT05440097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859797|NCT00829582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859798|NCT00919555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859799|NCT03988322|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34172357|NCT05862753|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34172358|NCT02428166|||COHORT||RETROSPECTIVE|||||||
33859800|NCT05987722|RANDOMIZED|PARALLEL||TREATMENT||NONE|The experimental group and the control group were randomly assigned by lottery drawing.|Each patient underwent routine periodontal surgery procedures: (1) On the first day of surgery, the researchers confirmed the correctness of the patient's oral hygiene instructions before surgery; (2) All periodontal surgery was performed by the same dentist. After periodontal surgery was sutured, antibiotics (Amoxicillin 500 mg, every 8 h, for 7 days) and painkillers (Acetaminophen 250 mg, every 6 h as long as it is painful) were provided. The experimental group (N=15) returned home after the operation and used BGA toothpaste (Enoxolone) three times a day for oral cleaning for 12 weeks. The control group (N=12) used BGA-free toothpaste (Sensodyne) for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as those of the experimental group.||||
33859801|NCT03096366|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding is not possible given the nature of the intervention.|||||
33859802|NCT01057498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859803|NCT00521742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859804|NCT02789735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859805|NCT04005053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859806|NCT01695915|||CASE_CONTROL||PROSPECTIVE|||||||
33859807|NCT00555542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859808|NCT03519165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Flotrac System 4.0 Edwards Lifesciences, Irvine, CA, USA|t|f|f|t
33859809|NCT05023395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859810|NCT06473324|||COHORT||RETROSPECTIVE|||||||
33859811|NCT05516823|||CASE_CONTROL||RETROSPECTIVE|||||||
33859812|NCT02416856|||OTHER||PROSPECTIVE|||||||
33859813|NCT01030679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859814|NCT00935779|||CASE_CONTROL||PROSPECTIVE|||||||
33859815|NCT02579707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859816|NCT02881957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859817|NCT00983723|||COHORT||PROSPECTIVE|||||||
33859818|NCT01382264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859819|NCT01798277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859820|NCT03653533|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33859821|NCT02267356|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33859822|NCT04026204|||CASE_ONLY||PROSPECTIVE|||||||
33859823|NCT01885325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859824|NCT04234425|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33859825|NCT05364372|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33859826|NCT03528863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33859827|NCT01197833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33859828|NCT01505010|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group trial||||
33859829|NCT04384848|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33859830|NCT04888130|||COHORT||RETROSPECTIVE|||||||
33859831|NCT06236529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors were masked to treatment assignment||f|f|f|t
33859832|NCT03844542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859833|NCT00520104|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859834|NCT03838107|||CASE_CONTROL||PROSPECTIVE|||||||
33859835|NCT00559442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34064172|NCT03529344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064173|NCT03329105|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34150292|NCT03759470|||COHORT||PROSPECTIVE|||||||
33859836|NCT04773613|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33859837|NCT05997524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859838|NCT03168386|NA|SINGLE_GROUP||TREATMENT||NONE||Intenstive motor rehabilitation||||
33859839|NCT02711488|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859840|NCT02651077|||CASE_CONTROL||PROSPECTIVE|||||||
33859841|NCT00705835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859842|NCT00070863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859843|NCT00553579|||CASE_ONLY||PROSPECTIVE|||||||
33859844|NCT05022225|||COHORT||CROSS_SECTIONAL|||||||
33859845|NCT05429151|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33859846|NCT05411367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893710|NCT05464095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and study coordinators will be blinded to treatment arms|Randomized, single-blinded, parallel group, Phase II study of 100 subjects with PAH. Eligible subjects will be randomly assigned to receive the mHealth intervention or not for twenty-four weeks.|f|f|t|t
33893711|NCT03423355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Single center, prospective, randomized, double-blind, controlled, three-armed, parallel group, open-label reference group exploratory study|t|f|t|t
34150293|NCT02359773|||CASE_CONTROL||PROSPECTIVE|||||||
34150294|NCT01280097|||COHORT||PROSPECTIVE|||||||
34150295|NCT02780973|||COHORT||PROSPECTIVE|||||||
33893712|NCT00744289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33893713|NCT04990570|||CASE_CONTROL||PROSPECTIVE|||||||
33893714|NCT01729689|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893715|NCT02251743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893716|NCT06657417|RANDOMIZED|CROSSOVER||OTHER||NONE||The trial is a randomized 2x2 crossover design. Each procedure will be performed by the same participant in sequence with at least 3 days between the first and second round of procedures. The procedures will be performed in sequence to which the participants were randomized (TC: First Test and then Control or CT: First Control and then Test). A sequence of 6 intubations will be performed in each sitting (in order, 3 easy and 3 difficult).||||
33893717|NCT05261217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960907|NCT03980860|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||This is a case/control study comparing overweight/obese patients of three different groups (control, HIIT, LIT). The goal of a case/control is to show whether exposure to HIIT, two times a week for 6 weeks will decrease lean body mass versus control and LIT. If it turns out that lean body mass does decrease, then HIIT is not an effective exercise modality for overweight/obese patients, and in fact LIT or control may be a better option.|t|f|f|f
33960908|NCT02885259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960909|NCT03682627|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||single intuition, double blinded, randomized clinical trial.|t|f|t|t
33750433|NCT06161675|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The baseline, 2-, 4-, 8- and 12-week follow-ups will be administered telephonically by trained research assistants blinded to the participant's treatment.|Participants will be randomized via computerized block design after consenting to the study. Equal allocation across treatment combinations will be used and balance between treatment combinations will be maintained by use of randomly permutated blocks. The randomization is not blinded, the study team will know what conditions each subject is randomized to. The randomization schemes will be generated using the R statistical package and will be incorporated into the REDCap database prior to initiation of the study.|t|f|f|f
33750434|NCT04403698|RANDOMIZED|PARALLEL||PREVENTION||NONE||40 subjects randomized in 2 groups (n=20). 1 group will receive effervescent alendronate treatment for 24 weeks, the other group will receive the same treatment for 48 weeks.||||
33750435|NCT02560948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750436|NCT05349617|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants will be randomized in a 1:1 ratio to receive PXVX0317 or placebo within each age stratum. Participants will be stratified in two age subgroups (≥65 to \<75 and ≥75 years of age). This study will be conducted in the US, using up to 10 sites.|t|f|t|t
33750437|NCT01049126|||CASE_ONLY||RETROSPECTIVE|||||||
33750438|NCT04892355|RANDOMIZED|PARALLEL||TREATMENT||NONE||4-group clinical trial||||
33750439|NCT01654549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33750440|NCT04231812|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33750441|NCT06534632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33750442|NCT01993069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750443|NCT05175755|NA|SINGLE_GROUP||OTHER||NONE||||||
33750444|NCT05684328|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34150296|NCT00547950|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150297|NCT04734587|||CASE_CONTROL||PROSPECTIVE|||||||
34150298|NCT01498016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150299|NCT01761812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150300|NCT00483002|||CASE_ONLY||PROSPECTIVE|||||||
34150301|NCT03217799|||CASE_CONTROL||PROSPECTIVE|||||||
33893718|NCT03022461|||COHORT||PROSPECTIVE|||||||
33893719|NCT04708990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893720|NCT04681326|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33893721|NCT04912167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893722|NCT06018883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893723|NCT05172011|||OTHER||OTHER|||||||
33893724|NCT04854655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33893725|NCT04563364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33893726|NCT00839111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893727|NCT00150189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33893728|NCT01883570|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33893729|NCT06003959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893730|NCT05126108|||COHORT||PROSPECTIVE|||||||
33893731|NCT00284388|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150302|NCT05579769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150303|NCT05463991|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34150304|NCT01593891|||CASE_ONLY||RETROSPECTIVE|||||||
33893732|NCT06518629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150305|NCT04564872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150306|NCT03679351|||OTHER||CROSS_SECTIONAL|||||||
34150307|NCT02708420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150308|NCT06312241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150309|NCT05919485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The distribution of the sham or real stimulators will be based on the random allocation which makes it impossible to identify the sham or real stimulation for the participants and the test instructors. This double-blind masking procedure will be applied all throughout the study steps in line with the reference study. The randomization data will be confidential and will not be accessible except for the medical emergencies. After the above-mentioned blinding process has been ended, the participants will be managed as off-study.||t|t|t|f
34150310|NCT05629910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study is a pilot trial and designed as a order-randomized, cross-over trial. Infants will be randomised to treatment-order by block randomisation to ensure even distribution between the sequence of treatment. All infants will at study start receive nHFT via OptiFlow interface, and then be allocated to:~▪ Automated adjustment of FiO2 by O2Matic followed by manual FiO2 adjustment or ▪ Manual adjustment of FiO2 followed by Automated adjustment of FiO2 by O2Matic Each patient will serve as their own control, and each treatment-period will last 24 hours, and each patient will be exposed to 1 period of each treatment assignment."||||
34150311|NCT04969198|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34150312|NCT04671992|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34150313|NCT02461888|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150314|NCT05010447|NA|SINGLE_GROUP||OTHER||NONE||Micro-Randomized Trial||||
34172359|NCT04365972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172360|NCT05399069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893733|NCT05196893|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a two-level randomized intervention trial of students from 12 schools in three clusters.||||
33893734|NCT05200988|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label, phase 2 clinical trial||||
33893735|NCT00042809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893736|NCT03095937|||COHORT||PROSPECTIVE|||||||
33893737|NCT03622645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893738|NCT03313687|||COHORT||RETROSPECTIVE|||||||
34150315|NCT01536808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150316|NCT00933894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150317|NCT00548899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150318|NCT01124981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150319|NCT01085032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150320|NCT01139827|||COHORT||CROSS_SECTIONAL|||||||
34150321|NCT04218396|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34150322|NCT03079856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34150323|NCT03429257|||COHORT||PROSPECTIVE|||||||
34150324|NCT00306644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150325|NCT02473276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150326|NCT01101490|||CASE_CONTROL||PROSPECTIVE|||||||
34150327|NCT01260545|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150328|NCT00751855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150329|NCT02540291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150330|NCT00857519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150331|NCT01443832|||CASE_ONLY||RETROSPECTIVE|||||||
34150332|NCT02983994|||OTHER||PROSPECTIVE|||||||
34150333|NCT02483390|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150334|NCT01979939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150335|NCT01985360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150336|NCT06377891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34150337|NCT03219099|||OTHER||CROSS_SECTIONAL|||||||
34150338|NCT03987906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150339|NCT05006144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Random allocation of participants will be completed using a random number generator, with the allocation to either the control or selective dorsal rhizotomy group being concealed. The random numbers are generated by the principle physical therapists with every alternate number being marked either 1 or 2. However, the receptionist was blinded to the interventions assigned to group 1 (control group) and group 2 (SDR group). During allocation, every parent/legal guardian is asked to pick up one enclosed envelope from a box containing numbers from 1 to 30. Then, they are allocated to either group 1 or group 2 to minimize the risk of allocation bias."||t|t|f|t
34150340|NCT00156559|||||PROSPECTIVE|||||||
34150341|NCT00903331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150342|NCT02174744|||||CROSS_SECTIONAL|||||||
34150343|NCT02133313|||CASE_ONLY||PROSPECTIVE|||||||
34150344|NCT02022618|||COHORT||CROSS_SECTIONAL|||||||
34150345|NCT02745535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150346|NCT02982083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34150347|NCT04912752|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34150348|NCT03654001|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2-by-2 factorial design, open-label, multicenter, randomized, controlled trial, in patients with septic shock, as defined according to clinical criteria. Patients will be randomized in a 1:1:1:1 ratio to one of the 4 groups (Albumin + BAL, Albumin + NS, BAL, NS).||||
34150349|NCT06437067|||COHORT||PROSPECTIVE|||||||
34150350|NCT01399216|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34150351|NCT04001595|||COHORT||PROSPECTIVE|||||||
34150352|NCT01379300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150353|NCT01733433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150354|NCT05002387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150355|NCT04329117|||COHORT||PROSPECTIVE|||||||
34150356|NCT03615014|NA|SINGLE_GROUP||OTHER||NONE||||||
34150357|NCT06531031|||COHORT||CROSS_SECTIONAL|||||||
34150358|NCT02505568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859847|NCT06341153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"According to the a priori power analysis with a pairwise hypothesis, effect size of 0.409, significance level of 0.05 and power of 0.80; it was determined that the inclusion of a total of 72 newborns (Odor Stimulation: 24, Odor+taste stimulation: 24, Control: 24) in the study would provide sufficient sample size.~Inclusion Criteria; For the mother;~* Having a term and healthy baby,~* No communication and language problems,~* No maternal illness preventing breastfeeding (active chemotherapy, HIV positive, neurological or psychological problems, etc.),~* Willingness to breastfeed, For the baby;~* Not having a disease condition that prevents breastfeeding (cleft palate, cleft lip, galactotemia, choanal atresia, etc.),~* Being at normal birth weight (2500gr-4000gr),~* Apgar score of 7 and above."|The stratification and blocking method was used to assign the mothers who would participate in the study to the experimental and control groups, taking into account factors such as normal or cesarean delivery and breastfeeding experience. In order to ensure homogeneity in the groups, mothers were stratified as mode of delivery (Normal-Cesarean) and breastfeeding experience (Present-Non-existent). After the blocks were formed, the groups included in the study were randomly assigned to the strata with the letters A, B and C using the random numbers table obtained in the computer environment (www.random.org). Which letter would be in which group was determined by lot (A=Odor Stimulation, B=Odor+Taste Stimulation, C=Control Group).|f|f|t|f
33859848|NCT04846374|||COHORT||PROSPECTIVE|||||||
33859849|NCT03575143|||COHORT||CROSS_SECTIONAL|||||||
33859850|NCT05114915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859851|NCT02959450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859852|NCT00903955|||COHORT||CROSS_SECTIONAL|||||||
33859853|NCT00003108||||TREATMENT||||||||
33859854|NCT04727320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859855|NCT06502873|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective, monocentric, study aiming to recruit 2 types of patients (60 Crohn's disease (CD) suffering patients versus 60 control patients without IBD nor any other known intestinal pathology).||||
33859856|NCT01165645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859857|NCT04731077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859858|NCT03819010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Two arms of patients (according to Recurrence Score results), but both arms will be treated with the same treatment|This is an international, multicenter, open-label, non-comparative, Simon´s two-stage design, phase II clinical trial.||||
33859859|NCT03907410|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33859860|NCT04023721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859861|NCT04190420|||COHORT||PROSPECTIVE|||||||
33859862|NCT01907802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859863|NCT01601847|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859864|NCT00409253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859865|NCT05332184|||COHORT||PROSPECTIVE|||||||
33859866|NCT05329545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, randomized, placebo controlled (2:1 upifitamab rilsodotin: placebo). Parallel cohorts.|t|f|t|t
33859867|NCT02882932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859868|NCT05342220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859869|NCT04029350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859870|NCT05269836|||CASE_ONLY||OTHER|||||||
33859871|NCT00913354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859872|NCT04536753|||COHORT||RETROSPECTIVE|||||||
33859873|NCT00438347|||||PROSPECTIVE|||||||
33859874|NCT05295888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The following roles will be blinded: i) Investigators and care providers; ii) Enrolled participants; iii) Outcome assessors; iv) TI technician|This is a pilot, sham-controlled, quadruple-blind clinical trial to demonstrate feasibility, safety, tolerability, and preliminary therapeutic efficacy of TI stimulation in patients with MDD.|t|t|t|t
33859875|NCT05213754|||COHORT||PROSPECTIVE|||||||
33859876|NCT05607355|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859877|NCT04342832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicenter randomized clinical trial|f|f|f|t
33859878|NCT01062633|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33859879|NCT03979560|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33859880|NCT04592055|||CASE_ONLY||RETROSPECTIVE|||||||
33859881|NCT01060826|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859882|NCT04745767|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33859883|NCT05098613|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a prospective single-arm Phase 1/1b with four dose levels. Phase 1 will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design in CAR-naïve and CAR-treated patients. Phase 1b is an expansion phase designed to evaluate the preliminary efficacy of CD19x22 CAR T.||||
33859884|NCT02273726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859885|NCT02729103|||COHORT||RETROSPECTIVE|||||||
34172361|NCT03290040|||COHORT||PROSPECTIVE|||||||
34172362|NCT06348771|RANDOMIZED|CROSSOVER||PREVENTION||NONE|No masking but a note on the enrollment (n=18) is estimated, but if no dropouts, 16 will be enrolled as per the sample size calculation for this study.|Higher SFA meal vs higher MUFA (nut) meal in individuals with overweight and obese||||
34172363|NCT03563339|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172364|NCT03335384|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cross-sectional||||
34172365|NCT02160080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172366|NCT06070792|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomized controlled trial|t|t|t|t
34172367|NCT00184834|||DEFINED_POPULATION||PROSPECTIVE|||||||
34172368|NCT03337308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172369|NCT03597347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172370|NCT02945748|||CASE_CONTROL||PROSPECTIVE|||||||
34172371|NCT01943344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172372|NCT01011998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172373|NCT01205217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172374|NCT04479397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172375|NCT01384175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172376|NCT04477486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859886|NCT04058613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33859887|NCT00149422|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33859888|NCT06108180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859889|NCT00454532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859890|NCT06314282|||COHORT||PROSPECTIVE|||||||
33859891|NCT00752622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859892|NCT06414252|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33859893|NCT02523560|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33859894|NCT02279862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859895|NCT05956054|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33859896|NCT02929797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859897|NCT03502954|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33859898|NCT04327492|||COHORT||PROSPECTIVE|||||||
33859899|NCT04586517|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33859900|NCT02229045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859901|NCT01758263|||COHORT||RETROSPECTIVE|||||||
33859902|NCT01162213|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33859903|NCT01274013|||CASE_CONTROL||PROSPECTIVE|||||||
33859904|NCT01453777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33859905|NCT01660126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859906|NCT04461808|RANDOMIZED|PARALLEL||SCREENING||SINGLE|"It is not possible to mask the intervention for the patient, care provider, and investigator.~Only the assessment of one of the two co-primary outcomes, i.e. cumulative incidence of advanced breast cancer after the first round of screening, can be masked. This will be obtained through a blind review of an external panel of pathologists and radiologists reviewing cases retrieved by cancer registries."|Women 45-65 participating in the mammographic screening program will be randomized to one round of screening with tomosynthesis + synthetic 2D or with digital mammography. Then all women will be re-screened after 2 years (1 year for women 45-49) for at least one round with digital mammography.|f|f|f|t
33859907|NCT02513420|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33859908|NCT06441721|||CASE_CONTROL||PROSPECTIVE|||||||
33859909|NCT01603082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859910|NCT01862133|||COHORT||PROSPECTIVE|||||||
34064174|NCT04490018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study was performed in a partially observer-blind fashion:~In Groups 1 and 2~* Investigators and study staff who conducted the safety assessment, participants, parents/legally acceptable representatives, the Sponsor, and laboratory personnel performing the serology testing were kept blinded to the vaccine received.~* Only the study staff who prepared and administered the vaccine and were not involved with the safety evaluation know which vaccine was administered.~In Group 3~- Everyone involved in the study (i.e., Investigator, study staff, the Sponsor, participants, parents/legally acceptable representatives) know which vaccine was administered. This open-label design for Group 3 was due to the different vaccination schedule for this group than for Groups 1 and 2."|This was a parallel group prevention study with 2 groups that were observer blind (only the person administering the vaccine was unblinded), and 1 group that was open-label.|t|t|t|t
34064175|NCT01624402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064176|NCT02062775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064177|NCT04825496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064178|NCT02265757|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34064179|NCT06434363|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064180|NCT05844085|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|the test meals have similar appearance|Randomized, controlled, crossover trial|t|f|f|f
34064181|NCT00001341||||TREATMENT||||||||
34064182|NCT00381329|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34064183|NCT03712267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study participants will be randomized to either the intervention group or the control group through an online computer randomizing generator. This is not a blinded randomized control trial.||t|f|f|f
34064184|NCT01118572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064185|NCT02696434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064186|NCT06731556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective, randomized study|t|f|t|t
33859911|NCT00003251||||SUPPORTIVE_CARE||||||||
33859912|NCT06298812|NA|SINGLE_GROUP||TREATMENT||NONE||Patients treated with the REFLECT Scoliosis Correction System||||
33859913|NCT05188326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859914|NCT02862860|NON_RANDOMIZED|PARALLEL||||NONE||||||
33859915|NCT03142971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33859916|NCT00524212|||||PROSPECTIVE|||||||
33859917|NCT06076486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859918|NCT03217149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859919|NCT00568321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33859920|NCT02767375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172377|NCT04103216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a prospectively conducted randomized pilot study with 3 arms in children, where cryptosporidium infected children will receive Nitazoxanide treatment with or without the probiotic, Lactobacillus reuteriDSM 17938 and the third arm will receive the standard supportive care normally provided for Cryptosporidium infections.|t|t|f|f
33859921|NCT00548054|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33859922|NCT01674751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33859923|NCT00082303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859924|NCT03353558|||CASE_CONTROL||PROSPECTIVE|||||||
33859925|NCT02860663|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33859926|NCT00873353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859927|NCT03208322|||CASE_ONLY||PROSPECTIVE|||||||
33859928|NCT05016856|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Measures of adherence will be automatically collected and thus assessors will be blind to this outcome. Data will be coded and analyzed with arbitrary condition markers to mask condition during analysis. Participants will not be explicitly told which condition they are in, but will be aware of the reminder messages they are receiving, and thus are not truly blind.||f|f|t|t
33859929|NCT03404765|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|All personals involved the study (participants, community center supporting staff, investigators and outcome assessors) had not masked for treatment assignment.|"This interventional study involved two groups of participants, the experimental and usual-care control groups, with no randomization taking place. The participants were recruited from four community health centers and allocated to the experimental or control groups according to the centers to which they belonged.This arrangement avoided possible contamination of the experiment by diffusing the Tai Chi learning.~The intervention group received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long. The control group had no treatment regime and joined different recreational activity groups in the respective community centers as usual within the study period."||||
33859930|NCT06428136|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33859931|NCT06059781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33859932|NCT04633915|||COHORT||PROSPECTIVE|||||||
33859933|NCT02864381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859934|NCT06209346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33859935|NCT01026142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859936|NCT04178967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Randomized, double-blind, parallel group, placebo controlled|t|t|t|t
33859937|NCT00814112|||CASE_CONTROL||PROSPECTIVE|||||||
33859938|NCT04364334|||COHORT||PROSPECTIVE|||||||
33859939|NCT05217082|||COHORT||RETROSPECTIVE|||||||
33859940|NCT03717948|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Allocation concealment, assessor blinding||f|f|t|t
33859941|NCT00906360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859942|NCT03492788|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34064187|NCT06162377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859943|NCT03553654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33859944|NCT06178237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33859945|NCT03037164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859946|NCT03679806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33859947|NCT02926131|||CASE_ONLY||PROSPECTIVE|||||||
33859948|NCT00278460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859949|NCT02521467|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064188|NCT04174937|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34064189|NCT02203162|NA|SINGLE_GROUP||OTHER||NONE||||||
34064190|NCT04049006|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34064191|NCT03131934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064192|NCT04929860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064193|NCT02578563|||CASE_ONLY||PROSPECTIVE|||||||
34064194|NCT05621967|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial. Randomization for each subject occurs twice. First: One of two types of intervention. Second: Sequence for intervention and normal breathing sessions.||||
33859950|NCT06082089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859951|NCT00934141|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33859952|NCT04994327|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|Multicenter|t|f|t|f
33859953|NCT04632472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient blinded The echocardiographic analyses were done blinded to type of left ventricular lead.||t|f|f|f
33859954|NCT04744441|||COHORT||RETROSPECTIVE|||||||
33859955|NCT03744325|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients are randomized 2:1 to receive active HE OIT or continue on an elimination diet after which active HE OIT is started.||||
33960910|NCT03705403|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a multicentre, randomised controlled open-label phase II trial testing if the combination of (SAB)R and immunocytokine L19-IL2 improves the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC). The patients included in the trial will be stratified for the metastatic load (oligo; max 5 or diffuse; 6-10 metastases). After randomisation, patients will be assigned either to the experimental arm or the standard of care (SOC) arm. Depending on the metastatic load, patients with (max 5 metastases) will receive in the experimental arm SABR to all lesions followed by L19-IL2 followed by standard of care therapy. Patients with more extensive metastatic disease (6 to up to 10 metastasis) in the experimental arm will be included following first or second line treatment with a platinum doublet and receive radiotherapy (3x8 Gy) to at least one (symptomatic) lesion, followed by L19-IL2 followed by SOC.||||
33960911|NCT04831931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960912|NCT00963599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064195|NCT02485418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064196|NCT05835427|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Individuals with fibromyalgia and healthy individuals will be included in the study and the effectiveness of the treatment will be examined. Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.|f|f|t|f
34064197|NCT00426660|NON_RANDOMIZED|||TREATMENT||||||||
34064198|NCT01555918|RANDOMIZED|CROSSOVER||||NONE||||||
34064199|NCT01739764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064200|NCT04220099|||COHORT||PROSPECTIVE|||||||
33859956|NCT03224325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859957|NCT02643160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172378|NCT03784443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"To maintain double-masking, participants assigned to the control arm will receive sham implantation. This will be performed with an empty Luer Lock Syringe without a needle attached to it, that will not penetrate the eye nor deliver any drug.~The Iluvien and the sham injection should be performed by the unmasked investigator. The unmasked investigator should not be involved in any patient assessment in the study."|Double masking randomized control trial with 2 parallel treatment arms: intervention (Iluvien plus Ranibizumab) vs control (Sham plus Ranibizumab)|t|f|t|t
34172379|NCT01917617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172380|NCT04687475|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172381|NCT04135807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172382|NCT04325672|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172383|NCT06374368|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172384|NCT03168477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064201|NCT05307718|||CASE_CONTROL||PROSPECTIVE|||||||
34064202|NCT03818555|NA|SINGLE_GROUP||OTHER||NONE||||||
34172385|NCT04482140|||COHORT||PROSPECTIVE|||||||
34172386|NCT01043575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172387|NCT04796714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172388|NCT04261556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172389|NCT04689659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172390|NCT03350997|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172391|NCT05500287|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
34172392|NCT04294693|||COHORT||CROSS_SECTIONAL|||||||
33859958|NCT00186069|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33859959|NCT03496480|||COHORT||RETROSPECTIVE|||||||
33859960|NCT04051788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33859961|NCT04376853|||COHORT||PROSPECTIVE|||||||
33859962|NCT04286698|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33859963|NCT00002790||||SUPPORTIVE_CARE||||||||
33859964|NCT00470145|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33859965|NCT04237922|||COHORT||RETROSPECTIVE|||||||
33859966|NCT00106522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859967|NCT00697723|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33859968|NCT01774084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859969|NCT01366287|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33859970|NCT00622882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33960913|NCT00716586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960914|NCT05663216|||COHORT||PROSPECTIVE|||||||
33960915|NCT04859647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960916|NCT05799365|||COHORT||PROSPECTIVE|||||||
33960917|NCT00755937|||COHORT||PROSPECTIVE|||||||
33960918|NCT06129799|||CASE_CONTROL||PROSPECTIVE|||||||
33960919|NCT06190873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will not know which group they belong to.|There will be two groups, one is the control group and the other is the intervention group.|t|f|f|t
33960920|NCT01881217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064203|NCT04936113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064204|NCT00987597|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064205|NCT05432219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064206|NCT00049075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064207|NCT03157726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34064208|NCT01081405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064209|NCT05509010|||COHORT||OTHER|||||||
34064210|NCT04792372|NA|SINGLE_GROUP||SCREENING||NONE||Healing will be monitored of periodontitis patients who receive conventional initial treatment. The patients will be grouped according to their healing capacity at the end of the study.||||
34064211|NCT04172922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064212|NCT03856333|NA|SINGLE_GROUP||OTHER||NONE||||||
33859971|NCT02367365|||COHORT||PROSPECTIVE|||||||
33859972|NCT04201821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859973|NCT05843513|||OTHER||RETROSPECTIVE|||||||
33859974|NCT05743322|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33859975|NCT05197023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||SHR1819 injection dose-escalation in AD patients|t|t|t|f
33859976|NCT04646590|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33859977|NCT00866697|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34172393|NCT04084171|NA|SINGLE_GROUP||OTHER||NONE||||||
33859978|NCT05147883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33859979|NCT05313126|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A Cluster-Non Randomized Controlled Trial||||
33859980|NCT03408782|||COHORT||PROSPECTIVE|||||||
33859981|NCT05785702|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The trial is a single group pre-post test study at Haven of Hope Ming Tak Day Activity Centre. There will be a pre-test of 4-6 weeks and trial of 12 weeks. During pre-test, the alarm of the anti-wandering system will be muted, and the response time in spotting participants in selected unauthorized areas without system alarm can be recorded. During the trial period, the alarm will be turned on, so that care staff will be alerted when participants enter unauthorized area.||||
33859982|NCT00972777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859983|NCT00080496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859984|NCT00416169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33859985|NCT01475552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172394|NCT01847521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172395|NCT04552951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients receiving any form. of vitamin D excluded from the study. Randomized study (Initial serum calcidiol levels blinded )|t|f|f|t
34172396|NCT01917058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172397|NCT04785443|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Simple blind (only participant)|Monocentric, comparative, randomized, single-blind, controlled trial against the reference method|t|f|f|f
34172398|NCT04712188|||OTHER||PROSPECTIVE|||||||
34172399|NCT01868490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172400|NCT03977623|||OTHER||PROSPECTIVE|||||||
33859986|NCT05781633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33859987|NCT04631627|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33859988|NCT04283981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859989|NCT00999713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33859990|NCT02031939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859991|NCT06037369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned to two groups in parallel for the duration of the study||||
33859992|NCT03421431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33859993|NCT04014361|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33960921|NCT05241626|||CASE_CONTROL||PROSPECTIVE|||||||
34064213|NCT06442449|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial (RCT)||||
34064214|NCT06593652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data analysts will be masked to intervention condition.||f|f|f|t
34172401|NCT04567069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172402|NCT05748717|||OTHER||CROSS_SECTIONAL|||||||
34172403|NCT03120884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172404|NCT03205124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Three arm randomized controlled study|t|f|t|t
33859994|NCT03592290|||CASE_ONLY||CROSS_SECTIONAL|||||||
33859995|NCT01659372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33859996|NCT03255837|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be unaware of the order in which they receive the transcranial stimulation condition (anodal, cathodal, sham).|Each participant will receive the same 3 kinds of transcranial stimulation. However, the order in which they receive them will be randomly allocated.|t|f|f|f
33859997|NCT02796820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33859998|NCT06029725|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172405|NCT01472640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172406|NCT06320054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172407|NCT01198730|||COHORT||PROSPECTIVE|||||||
34172408|NCT02319330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33859999|NCT03516357|||CASE_ONLY||RETROSPECTIVE|||||||
33860000|NCT01983839|||CASE_ONLY||CROSS_SECTIONAL|||||||
33860001|NCT01904825|||COHORT||PROSPECTIVE|||||||
33860002|NCT02249767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860003|NCT00226187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860004|NCT03249714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860005|NCT06347653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860006|NCT06339619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860007|NCT02730988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33860008|NCT02715167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960922|NCT03224741|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|The subject receives the script and actions associated with the experimental condition she/he is assigned to according to the randomization. The subject receives a card consisting of three detachable parts. Each part includes a numerical ID that uniquely identifies each participant. The first part of the card will remain with the researchers. The second part of the card does to the medical personnel at the health facility if and when they go there to get tested. The third part of the card will remain with the participant. This procedure and the study ID will enable the research team to (a) associate participants to the treatment conditions and (b) determine the outcomes (whether they got tested or not, and what the results were), while preserving the anonymity of the participants.|Randomized Control Trial|t|f|f|f
33960923|NCT00768105|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33960924|NCT01327378|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33960925|NCT03601806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960926|NCT00892424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750445|NCT04408573|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||2 weeks of regular continuous high frequency (\>130Hz) stimulation, 2 weeks of cycling high frequency (\>130Hz) stimulation (40sec on, 2sec off), 2 weeks of low-frequency (80Hz) continuous stimulation and 2 weeks of cycling low frequency (80Hz) stimulation (40sec on, 2sec off)|t|t|f|t
34172409|NCT04735263|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective interventional trial for off label use of FDA approved drug||||
34172410|NCT05851209|||COHORT||PROSPECTIVE|||||||
34172411|NCT05222581|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prototype breast shield designs for the Freedom Double Electric Breast Pump with \<10 subjects per breast shield design||||
34172412|NCT02655328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960927|NCT01297569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960928|NCT01166997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172413|NCT03725670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172414|NCT04123886|NA|SEQUENTIAL||TREATMENT||NONE||||||
33960929|NCT03912350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960930|NCT03649906|NA|SINGLE_GROUP||TREATMENT||NONE||This study intends to use a single set of target values for non-randomized controlled trials, and enrolled 120 subjects who met the inclusion criteria. The small pulmonary nodules were located using an optimized pre-loaded microcoil puncture positioning method. Observe the clinical indicators such as pneumothorax incidence rate, positioning success rate, other complication rate, operation time, and number of operators, and evaluate the safety and effectiveness of the optimized CT-guided pulmonary nodule microcoil localization technique.||||
34172415|NCT02294383|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33960931|NCT02366039|||COHORT||PROSPECTIVE|||||||
34172416|NCT00308477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33960932|NCT06562296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960933|NCT01042002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750446|NCT00403832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750447|NCT04518878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960934|NCT02590978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960935|NCT00350194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33960936|NCT05225116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960937|NCT04089163||SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation design with expansion at recommended Phase 2 dose.||||
33960938|NCT01835808|||COHORT||PROSPECTIVE|||||||
33960939|NCT00850382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960940|NCT06078995|||COHORT||RETROSPECTIVE|||||||
33960941|NCT05510947|||COHORT||PROSPECTIVE|||||||
34172417|NCT03192176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172418|NCT03827343|||COHORT||RETROSPECTIVE|||||||
34172419|NCT04125563|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Capsules, taken orally, with standardised doses of Capsicum oleoresin corresponding to 0.4 mg pure capsaicin (from chili extract) in each capsule, will be compared to matched capsules with placebo, all capsules looking the same.|Randomised, crossover, double blind|f|f|f|t
34172420|NCT00963417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172421|NCT02931617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172422|NCT03301558|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Patients will be randomized in a 1:1 ratio to either receive low-dose (1500 mg/d) sodium bicarbonate followed by high-dose (3000mg/d) sodium bicarbonate (sequence A-B) or to receive high-dose sodium bicarbonate followed by low-dose sodium bicarbonate (sequence B-A) with washout-phases in between.||||
34172423|NCT05280717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172424|NCT00589225|||COHORT||RETROSPECTIVE|||||||
34172425|NCT03449511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34172426|NCT01628224|||COHORT||PROSPECTIVE|||||||
33750448|NCT02464189|||CASE_ONLY||PROSPECTIVE|||||||
33750449|NCT04707053|||CASE_ONLY||PROSPECTIVE|||||||
33750450|NCT05227742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled clinical trial.|t|t|t|t
33750451|NCT02962687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33750452|NCT02285946|||OTHER||PROSPECTIVE|||||||
33750453|NCT02380547|||COHORT||PROSPECTIVE|||||||
33750454|NCT03084055|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860009|NCT01765192|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33860010|NCT01071135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860011|NCT04583085|||OTHER||OTHER|||||||
33860012|NCT00247585|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33860013|NCT02437734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172427|NCT01150526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34172428|NCT04740983|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34172429|NCT03631602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172430|NCT05656339|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes Assessor will not know the randomization nor the phases of the study.|Male volunteers, aged between 18 and 27 years, healthy, with no report of acute illness during 3 months prior to the study will be included. Individuals with obesity (calculated body mass index above 30 kg/m2), those who reported consumption of alcoholic beverages or any nutritional supplement during the study period will be excluded. The 30 selected volunteers will be scheduled to came to the laboratory after an overnight fast of 12 hours. Participants in the fasting group will immediately collect blood samples. The CHO and the CHO+WP groups will drink 200 ml of the respective supplements described above. After an interval of three hours after ingestion of the supplement, blood samples will be collected again for biochemical assays.|f|f|f|t
34064215|NCT04373642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172431|NCT05627479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172432|NCT03247049|||CASE_ONLY||CROSS_SECTIONAL|||||||
34172433|NCT03910179|||COHORT||PROSPECTIVE|||||||
34172434|NCT00002022||||TREATMENT||||||||
34172435|NCT06164548|||OTHER||PROSPECTIVE|||||||
34172436|NCT00193336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172437|NCT04386369|||COHORT||RETROSPECTIVE|||||||
34172438|NCT00534365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172439|NCT02893566|NA|SINGLE_GROUP||PREVENTION||NONE||One group pretest-midtest-posttest design||||
34172440|NCT02216669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172441|NCT01392144|||COHORT||PROSPECTIVE|||||||
34172442|NCT00793988|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750455|NCT03609762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33750456|NCT01832116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860014|NCT04390750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||3 Groups - 2 Treatment Groups, 1 Control Group||||
33860015|NCT02964494|||OTHER||OTHER|||||||
33860016|NCT04569383|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860017|NCT03966261|||COHORT||PROSPECTIVE|||||||
33860018|NCT02949960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860019|NCT00372749|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33860020|NCT01666288|||CASE_ONLY||PROSPECTIVE|||||||
33960942|NCT00802776|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172443|NCT04915183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172444|NCT01798693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860021|NCT03786250|||COHORT||RETROSPECTIVE|||||||
33860022|NCT03392506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860023|NCT05073887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860024|NCT00457184|||DEFINED_POPULATION||OTHER|||||||
33860025|NCT03271346|||CASE_ONLY||PROSPECTIVE|||||||
33860026|NCT03085108|||COHORT||CROSS_SECTIONAL|||||||
33860027|NCT02016833|||CASE_ONLY||CROSS_SECTIONAL|||||||
33960943|NCT02732886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960944|NCT06552572|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with relapsed or refractory diffuse large B-cell lymphoma who respond to CD19 CAR T-cell therapy: Partial response at one or three months after CAR T-cell therapy||||
34172445|NCT01866540|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172446|NCT06098482|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172447|NCT01171859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860028|NCT00512304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860029|NCT01869257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860030|NCT02537938|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860031|NCT02821468|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33860032|NCT02103933|||CASE_ONLY||PROSPECTIVE|||||||
33860033|NCT05918939|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is an observer blind randomized controlled trial. There will be 2 groups in the trial. All subjects will have either CoronaVac or Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) vaccine as booster injection. There will be 350 subjects in the study.|There will be 2 groups in the study. First group will receive CoronaVac vaccine, manwhile the other group will receive Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) vaccine.|t|f|t|f
33960945|NCT00948181|||COHORT||PROSPECTIVE|||||||
33960946|NCT04196088|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Triple (Participant, Pathologist, Outcomes Assessor)||t|f|f|t
33960947|NCT00247130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33960948|NCT04501341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||5 subjects receive BM-MNC and 10 subjects receive UC-MSC||||
34172448|NCT05026528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator performing measurements and collecting data as well as the outcomes assessor will be blinded to group allocation.||f|f|t|t
34172449|NCT01811771|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172450|NCT03087396|||COHORT||OTHER|||||||
34172451|NCT01022736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172452|NCT03273426|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Comparison of pathological findings for residual tumor between minimally-invasive biopsy procedure and subsequent wide excision of the biopsied area||||
34172453|NCT04034368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172454|NCT04515875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Following consent, the project manager will arrange a time convenient for patient-caregiver dyads to separately complete the baseline (T1) measures by phone. A data collector, blinded to randomization status, will administer all measures at all time points via phone interviews in a quiet, private setting and be available for questions following data collection. Immediately following completion of the T1 measures; and enter patient scores on the PHQ-9 depression scale directly to the database. A web-based computer-generated stratified randomization scheme will be used to assign the patient-caregiver dyads to DEMA or the information support group in 1:1 ratio using a block-randomized approach stratified on a depression score PHQ-9 ≤ 4 vs. PHQ-9 ≥ 5 or higher will be used to determine the randomization scheme. The Project Manager will immediately schedule Session 1. Only the statistician, PI, project manager, and the intervener will know the patient-caregiver dyad's randomization status.|The study conceptual framework is based on: 1) pilot work, 2) the Canadian Model of Occupational Performance that describes how individuals are motivated, adjust to psychosocial context and cognitive decline, and choose to participate in essential and meaningful daily activities; 3) problem-solving therapy principles. These frameworks, commonly applied to health problems in older populations, provide a systematic structure to improve task initiation and completion in adults with depression or executive dysfunction.|t|t|f|t
33860034|NCT05350878|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel Cluster Randomized||||
33860035|NCT00276588||||TREATMENT||NONE||||||
33860036|NCT06513286|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33860037|NCT01087112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860038|NCT04047654|||COHORT||RETROSPECTIVE|||||||
33860039|NCT00215878|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34172455|NCT03151044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860040|NCT04239521|||COHORT||RETROSPECTIVE|||||||
34172456|NCT03630991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172457|NCT04325412|||COHORT||PROSPECTIVE|||||||
34172458|NCT05055843|NA|SINGLE_GROUP||SCREENING||NONE||||||
33860041|NCT01138007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860042|NCT04643509|||COHORT||PROSPECTIVE|||||||
34172459|NCT03491059|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172460|NCT01651728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172461|NCT05150028|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172462|NCT01319669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172463|NCT02607059|||CASE_ONLY||PROSPECTIVE|||||||
34172464|NCT00777712|||COHORT||PROSPECTIVE|||||||
34172465|NCT06048302|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a Phase 1, open-label, single-dose, parallel-group study to evaluate the plasma PK and safety of obicetrapib in participants with moderate hepatic impairment relative to participants with normal hepatic function. The purpose of the study is to investigate the effect of moderate hepatic impairment on obicetrapib PK and safety in otherwise healthy participants after a single oral 10 mg dose of obicetrapib.||||
34172466|NCT01068340|||COHORT||RETROSPECTIVE|||||||
34172467|NCT04468646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172468|NCT04755816|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34172469|NCT04658160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172470|NCT05357573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172471|NCT04283669|NA|SINGLE_GROUP||OTHER||NONE||Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles. Clinical response will be assessed by MRI (volumetrics, primary objective) and audiology at the end of every 3rd cycle. Subjects with volumetric tumor progression will be taken off protocol. Patients who complete 12 cycles of treatment without disease progression, but within the following 24 weeks show subsequent disease progression (defined as \>20% increase in target tumor volume compared to off-treatment volume), will be eligible for re-treatment on study for up to 48 additional weeks, provided they still meet study eligibility criteria.||||
33750457|NCT03502382|NA|SINGLE_GROUP||TREATMENT||NONE||Cases of osteoarthritis of the knee with varus deformity undergoing unilateral TKA.||||
33860043|NCT04154410|||COHORT||PROSPECTIVE|||||||
34172472|NCT06378775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172473|NCT00584948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172474|NCT06213818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172475|NCT05429216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172476|NCT02946437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172477|NCT03978130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|partial mask (outcomes assessor)||f|f|f|t
33860044|NCT02593591|||OTHER||PROSPECTIVE|||||||
33860045|NCT02536703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860046|NCT05147623|||COHORT||PROSPECTIVE|||||||
33860047|NCT04217590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860048|NCT03493841|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33860049|NCT01594866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960949|NCT00533585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172478|NCT04187118|||COHORT||PROSPECTIVE|||||||
34172479|NCT01796340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34172480|NCT02972931|||CASE_CONTROL||RETROSPECTIVE|||||||
34172481|NCT01893541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172482|NCT03909893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750458|NCT04491929|||CASE_ONLY||PROSPECTIVE|||||||
33960950|NCT02034227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960951|NCT02284152||CROSSOVER||BASIC_SCIENCE||NONE||||||
33960952|NCT05469503|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34172483|NCT04575506|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172484|NCT02970799|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34172485|NCT00449696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172486|NCT05783388|||COHORT||PROSPECTIVE|||||||
34172487|NCT00187616|||||PROSPECTIVE|||||||
33960953|NCT01188642|||CASE_ONLY||PROSPECTIVE|||||||
33960954|NCT02275182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960955|NCT01854801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172488|NCT01151488|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860050|NCT02231125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33860051|NCT04160169|||CASE_ONLY||CROSS_SECTIONAL|||||||
33860052|NCT02673151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172489|NCT02384551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172490|NCT04156061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172491|NCT03337230|NA|SINGLE_GROUP||PREVENTION||NONE||pre-post study design||||
34172492|NCT06094088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172493|NCT06308822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172494|NCT05271981|||COHORT||RETROSPECTIVE|||||||
34172495|NCT02616510|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172496|NCT04580238|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The proposed study will be a randomized, open-label, comparator controlled study investigating the safety and efficacy of Botox in Persistent Post Stroke (encompassing ischemic stroke, hemorrhagic stroke, CVST, Cervical Vessel Dissection and RCVS) headache patients relative to Placebo with or without concomitant standard pharmacologic and Non-pharmacologic treatments."||||
34172497|NCT05149404|||COHORT||RETROSPECTIVE|||||||
34172498|NCT04984031|||COHORT||PROSPECTIVE|||||||
34172499|NCT04416568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172500|NCT02113696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172501|NCT02745197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34172502|NCT00686101|||CASE_CONTROL||OTHER|||||||
34172503|NCT05312593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172504|NCT02500849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172505|NCT03380650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|only the doctor know the group the patient goes into||t|f|f|f
34172506|NCT05828862|NA|SINGLE_GROUP||PREVENTION||NONE||patients undergoing Hypotension Prediction Index||||
34172507|NCT06602518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172508|NCT05696483|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|matching placebo|Randomized, double-blind, four-part study of single ascending doses and multiple ascending doses in healthy adult participants, and as a single dose in healthy elderly participants. There is an option for an additional part to evaluate the effects of food.|t|t|t|t
34172509|NCT03882060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34172510|NCT00005766|RANDOMIZED|||TREATMENT||DOUBLE||||||
34172511|NCT05100342|||CASE_CONTROL||PROSPECTIVE|||||||
34172512|NCT03960541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double blinded, placebo controlled.|t|t|t|f
34172513|NCT05472038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Cohort 1 and Cohort 2 (18 years and older): Observer-blind Cohort 2 (12-17 years) and Cohort 3: Open-label Cohort 4: Observer-blind|Phase 1/2/3, randomized, active-controlled, parallel group study.|t|t|t|t
34172514|NCT01697202|||CASE_ONLY||PROSPECTIVE|||||||
34172515|NCT04970563|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34172516|NCT01736111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172517|NCT00900978|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34172518|NCT05696249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34172519|NCT00572377|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34172520|NCT04103879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172521|NCT05072639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172522|NCT04349891|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34172523|NCT05308875|NA|SEQUENTIAL||TREATMENT||NONE||0.5-2×10\^6/kgBW||||
34172524|NCT00431561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172525|NCT05051748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking was ensured as the baseline and follow-ups photographs were stored on a computer with a unique ID and the investigators were not disclosed about the participants' treatment protocol. Blinding of the participants was guaranteed as they didn't know each other, or the treatments received in other protocols|Fluorosed teeth|t|f|t|f
34172526|NCT05875532|||COHORT||RETROSPECTIVE|||||||
34172527|NCT05403996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot cluster randomized controlled trial|f|f|t|t
33750459|NCT03381495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750460|NCT01803893|||CASE_CONTROL||PROSPECTIVE|||||||
33860053|NCT01375361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860054|NCT00730834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860055|NCT01050348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860056|NCT06027723|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Vapes will be color coded and data recorded by color. Correspondence between color and condition will be unblinded at completion.|"The participant will be randomized to receive either the regular vape with nicotine or the placebo nicotine vape first and will complete a standardized vaping session with the assigned vape. Each participant will receive both vape conditions, one at each laboratory visit. Moreover, they will not know the order of administration.~After completing the vaping session, participants will be instructed on how to complete a version of the Go/No-Go task. They will see geometrical shapes on the screen, each of which will signal a particular trial type: go-win-win-reward, no-go-to-win-reward, go-to-avoid-losing, or no-go-to-avoid-losing. Participants will be explicitly instructed that the color of the cue edge will correspond to a specific trial: green will represent a win reward condition and red will represent an avoid losing condition."|t|f|t|f
33860057|NCT01244243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860058|NCT03140774|||COHORT||PROSPECTIVE|||||||
33860059|NCT01174238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860060|NCT03064386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33860061|NCT01832363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960956|NCT03033589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33960957|NCT04274088|||COHORT||PROSPECTIVE|||||||
33960958|NCT01610167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960959|NCT05947149|||COHORT||PROSPECTIVE|||||||
33960960|NCT04237259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33960961|NCT01725737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33960962|NCT00425282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33960963|NCT06116448|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The students who participated in the research were unaware of which group they were assigned to and attended the practices accordingly. During the clinical follow-up phase, a clinical breastfeeding nurse evaluated the practices using a checklist but did not know which group the students belonged to.|prospective, parallel, randomized, controlled quasi-experiment|t|f|f|f
33960964|NCT05049460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33960965|NCT00159081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960966|NCT05052827|RANDOMIZED|CROSSOVER||OTHER||SINGLE|As the study was a single-blind crossover design, the randomization of the protein type will be blinded to the participants only. The allocation concealment in relation to the liquid meal will be done by providing the same relative protein content (0.35 g/kg FFM) within the same volume of fluid, (8 ml/kg) to match the exercise-induced fluid loses, in opaque bottles. Additional carbohydrate (0.4g/kg) and artificial sweetener will be added to improve the organoleptic properties of the beverages.|Using a single-blind randomized counterbalanced crossover design, participants will complete three metabolic trials providing 0.35 g/kg FFM of either milk protein concentrate (MPC), rice protein isolate (RPI), or soy protein isolate (SPI) following a bout of variable intensity exercise.|t|f|f|f
33960967|NCT01832688|||COHORT||PROSPECTIVE|||||||
33960968|NCT01933412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960969|NCT00934778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33960970|NCT01563393|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33960971|NCT00309127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960972|NCT00976313|||COHORT||PROSPECTIVE|||||||
33960973|NCT02546037|||CASE_CROSSOVER||PROSPECTIVE|||||||
33960974|NCT00897429|||CASE_CONTROL||RETROSPECTIVE|||||||
33960975|NCT04390074|||CASE_CONTROL||OTHER|||||||
33960976|NCT06542796|RANDOMIZED|SINGLE_GROUP||SCREENING||TRIPLE|||t|t|f|t
33960977|NCT03864367|||COHORT||PROSPECTIVE|||||||
33960978|NCT00828581|NA|SINGLE_GROUP||OTHER||NONE||||||
33960979|NCT02231671|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33960980|NCT02015338|||COHORT||PROSPECTIVE|||||||
33960981|NCT05640375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33960982|NCT04215653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33960983|NCT00792675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960984|NCT04960774|||CASE_CONTROL||RETROSPECTIVE|||||||
34064216|NCT01183741|||||PROSPECTIVE|||||||
34064217|NCT03057964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860062|NCT03628365|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomisation controlled by the Hospital Pharmacy Intervention product masked by the Hospital Pharmacy|Randomised, double blind, controlled trial|t|t|t|t
33860063|NCT00330850|RANDOMIZED|||TREATMENT||DOUBLE||||||
33860064|NCT00047203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860065|NCT03258333|||COHORT||PROSPECTIVE|||||||
33860066|NCT03437018|||CASE_CROSSOVER||PROSPECTIVE|||||||
33860067|NCT05493839|||CASE_ONLY||RETROSPECTIVE|||||||
33860068|NCT03975023|||COHORT||CROSS_SECTIONAL|||||||
33860069|NCT00455325|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33860070|NCT03673865|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized clinical study with longitudinal follow-up||||
33860071|NCT03937726|RANDOMIZED|PARALLEL||TREATMENT||NONE|Primary outcome will be assessed by double-blind, placebo-controlled food challenge|||||
33860072|NCT04379050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33960985|NCT00607906|RANDOMIZED|PARALLEL||TREATMENT||||||||
33960986|NCT04698278|||COHORT||PROSPECTIVE|||||||
33960987|NCT01741428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33960988|NCT04863326|RANDOMIZED|PARALLEL||PREVENTION||NONE||The MPC curriculum aims to provide adolescents with the information and tools they need to reduce their risk of sexually transmitted diseases (STDs), HIV, and pregnancy. The curriculum emphasizes abstinence as the safest choice for avoiding pregnancy and STDs, but also encourages youth to use condoms and other methods of birth control if they do have sex. The curriculum includes video clips, student role-playing activities, and group discussions. It also involves skill-building activities for correct condom use, refusal techniques, and safer-sex negotiation, and opportunities for students to practice these skills.||||
33960989|NCT06476743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33960990|NCT02260752|||COHORT||PROSPECTIVE|||||||
33960991|NCT02985567|||COHORT||PROSPECTIVE|||||||
33960992|NCT02034994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33960993|NCT06301477|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The treating physician, study participants, and research coordinators and lab researchers will not have knowledge of the randomization codes and will be blinded as to study product allocation. Unblinding will occur only if necessary to ensure study participants safety. Only Dr. Mack (Co-PI) will request to break the blind for safety reasons. Once the blind is broken by Dr. Mack the patient will be discontinued from study product.|A single-center, randomized, placebo-controlled, double-blinded, pilot trial|t|t|t|t
33960994|NCT05959707|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33960995|NCT04252690|NA|SINGLE_GROUP||OTHER||NONE||non-randomized, open-labelled, monocentric study||||
33960996|NCT00999245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33960997|NCT06156579|NA|SINGLE_GROUP||TREATMENT||NONE||single center, one arm, open label clinical trial||||
33960998|NCT02524665|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33960999|NCT03620773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants in this study will receive the same intervention.||||
33961000|NCT04835415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant, outcomes assessor) Anesthetist not sharing in the study will assess patient.|Analgesia for postoperative pain after laparoscopic cholecystectomy by using ultrasound-guided retrolaminar block vs ultrasound-guided thoracic epidural analgesia.|t|f|f|t
33961001|NCT05298215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961002|NCT02797626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961003|NCT06198478|||COHORT||PROSPECTIVE|||||||
33961004|NCT05216328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961005|NCT02656615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064218|NCT00123461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064219|NCT02093403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064220|NCT01390571||||TREATMENT||NONE||||||
34064221|NCT05456633|||COHORT||OTHER|||||||
33860073|NCT04024748|||CASE_ONLY||CROSS_SECTIONAL|||||||
33860074|NCT06233721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Individuals who agreed to participate in the study were randomly assigned to intervention and control groups by using a randomizer (http://www.randomization.com). 150 individuals who were included in the study were randomly split into three groups by a person other than the researcher, and the three groups were given a code name. In order to generate random numbers for randomization (from 1 to 50), a software was used. Thus, determined numbers for each group were obtained. Both the participants and the researchers were blinded in group assignment.|Control group Intervention group 1 (face-to-face education group) Intervention group 2 (tele-education group)|t|f|t|f
33860075|NCT01058967|||CASE_ONLY||PROSPECTIVE|||||||
33961006|NCT01695837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961007|NCT02357173|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33961008|NCT03343145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064222|NCT02468713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34064223|NCT04283474|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34064224|NCT04081831|||COHORT||RETROSPECTIVE|||||||
34064225|NCT00203463|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34064226|NCT02735096|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064227|NCT04772521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34064228|NCT06084624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the allocation of the participants to the groups will be concealed . The bottles of both mouthwashes will be the same. The solution of both mouthwashes will be of the same colour, odor and consistency.|The study is a parallel 2 arm randomized controlled clinical trial where one group will be assigned to the rebamipide mouthwash, while the other group will be assigned to the betamethasone group randomly.|t|t|t|t
34064229|NCT02828137|||COHORT||RETROSPECTIVE|||||||
34064230|NCT00011206|||||RETROSPECTIVE|||||||
34064231|NCT01475032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172528|NCT06450912|||COHORT||RETROSPECTIVE|||||||
34172529|NCT00286858|||COHORT||PROSPECTIVE|||||||
33860076|NCT01394471|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33860077|NCT01585636|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33961009|NCT06539780|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline case series design: Patients wil be randomized to different lengths of baseline period and the effectiveness of the treatment is tested by comparing means and slopes of daily reported schema- or core beliefs, wellbeing and self esteem. Also psychotic and trauma symptoms will be measured.||||
33860078|NCT03638934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel Assignment||||
33961010|NCT01325896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961011|NCT00395330|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33961012|NCT04752085|||COHORT||PROSPECTIVE|||||||
33961013|NCT00103415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33961014|NCT05130086|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33961015|NCT01493063|||COHORT||PROSPECTIVE|||||||
33961016|NCT03564509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|FE 999302 and placebo were identical in appearance and the trial was considered double-blind as neither the subject nor the investigator knew whether the subject was receiving FE 999302 or placebo.||t|f|t|f
33961017|NCT01153022|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33961018|NCT00629668|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961019|NCT01817335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961020|NCT05106998|||CASE_CONTROL||RETROSPECTIVE|||||||
34172530|NCT04272918|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|For CSM, participants will not know their status (treatment vs control) and the existence of the other group. For PPE, there will be no masked information but exchange of information and cross discussion between two groups will be discouraged. For outcome assessment, a coordinator will be used and assessors will not know beforehand whether the case to assess is from treatment or control group.||t|f|f|t
34172531|NCT05620433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34172532|NCT04149912|||CASE_ONLY||CROSS_SECTIONAL|||||||
34172533|NCT06430697|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860079|NCT01215422|||CASE_CROSSOVER||PROSPECTIVE|||||||
33860080|NCT02209337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860081|NCT03926156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860082|NCT03359590|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a double-blind randomised trial. Except for the unblinded persons involved in the preparation of the IMP (these persons are not involved in any other trial activities), everyone involved in the trial will be blinded until completion of the trial and the final data review.|This is a postmarketing phase 2 trial. The trial is designed as single centre, randomised, double blind, two-way treatment, placebo controlled crossover trial in subjects with type 2 diabetes mellitus treated to fasting plasma glucose targets with insulin glargine and metformin.|t|f|t|t
33860083|NCT03240913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860084|NCT02832700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860085|NCT01089491|||CASE_ONLY||PROSPECTIVE|||||||
33860086|NCT03665896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860087|NCT01217268|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33860088|NCT02850211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860089|NCT05810272|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33860090|NCT04974515|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33860091|NCT01134016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860092|NCT00473421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961021|NCT04189068|||CASE_ONLY||RETROSPECTIVE|||||||
33961022|NCT04959279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2:1 randomization and also recruit a higher proportion of high-risk patients in each arm||||
33961023|NCT00916292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961024|NCT05503914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961025|NCT01052038|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33961026|NCT04815408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961027|NCT01257529|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33961028|NCT05059717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961029|NCT00875537|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33961030|NCT03901222|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|The device is preprogrammed by a third party non participating in any element in the study. They then chose (using opaque envelopes) the treatment code for each participant|Randomized, triple-blind, sham-controlled, crossover|t|f|t|t
34172534|NCT03044613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172535|NCT00388986|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172536|NCT06031519|||COHORT||RETROSPECTIVE|||||||
34172537|NCT05213975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34172538|NCT04789603|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|For randomization a computer software (www.random.org) will be used.||f|f|f|t
34172539|NCT01269593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860093|NCT00987688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860094|NCT00190827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860095|NCT02900469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860096|NCT00196872|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33860097|NCT04317560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961031|NCT02298595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961032|NCT06537206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Sequential Assignment|f|f|f|t
33961033|NCT00164086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961034|NCT06522607|||COHORT||PROSPECTIVE|||||||
33961035|NCT00306852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961036|NCT04192201|||COHORT||PROSPECTIVE|||||||
33961037|NCT01669278|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34172540|NCT05951400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172541|NCT05821699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172542|NCT01017484|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33860098|NCT03182166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860099|NCT03196986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860100|NCT00861835||||DIAGNOSTIC||||||||
33860101|NCT03243045|||CASE_ONLY||PROSPECTIVE|||||||
33860102|NCT00307528|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860103|NCT05222763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients participating in the study will know that they are in a randomized controlled study, but they will not know which group they are in until the study is completed.||t|f|f|t
34172543|NCT02356822|||COHORT||OTHER|||||||
34172544|NCT05009498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization at the level of the manufacturer, therefore all patients, investigators, care providers and outcomes assessors with be blinded throughout the duration of the investigation|randomized controlled trial|t|t|t|t
34172545|NCT02595983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860104|NCT03431181|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34172546|NCT01290458|NON_RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33860105|NCT01068353|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34172547|NCT04355754|NA|SINGLE_GROUP||OTHER||NONE||The flow divider is connected to the ventilator. Half of the fresh gas flows to the patient, hallf to the artificial lung ( 1:1 ratio). For adequate ventilation tidal volume set on the ventilator is then doubled. Chosen respiratory and circulatory parameters are beeing noted.||||
34172548|NCT00670553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860106|NCT00474669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860107|NCT05659355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860108|NCT00928746||||TREATMENT||||||||
34172549|NCT01406886|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34172550|NCT04111627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172551|NCT01147042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose frequency increased from once per week to three times per week, the recommended dose frequency.||||
33860109|NCT03370848|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34172552|NCT02994108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34172553|NCT05958615|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Waitlist Control Design||||
34172554|NCT04931069|NA|SINGLE_GROUP||OTHER||NONE||||||
34172555|NCT05971446|||CASE_CONTROL||PROSPECTIVE|||||||
34172556|NCT00798200|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34172557|NCT01777035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860110|NCT05223465|||OTHER||CROSS_SECTIONAL|||||||
33860111|NCT00036686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860112|NCT04184440|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The allocation of three groups is completed by the primary researcher,and unknown to participants and other reachers. It is the same in the size,color,shape and taste of capsules administrated by three groups.|Participants will be divided randomly into three groups，among which the intervention will start and end simultaneously.|t|f|f|t
33860113|NCT00281021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860114|NCT01380639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860115|NCT04575480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Randomized trial, conducted in Urology and Nephrology Centre in Mansoura, Egypt.~Including adults \>18 years with primary single renal stone amenable for SWL according to EUA guidelines (≤ 2 cm single calyceal renal stone in a normal functioning kidney) .~Exclusion criteria include contraindications to ESWL (uncontrolled Hypertension , coagulopathy etc), previous intervention for renal stones , congenital renal anomalies and solitary kidney.~Patients will be randomized to one of three groups (50 Patient in each): Group 1 will undergo SWL with 3 days between each session , Group 2 will undergo SWL with 7 days between each session and Group 3 will undergo SWL with 14 days between each session. pre-ESWL and post-ESWL values will be compared.Participants will be invited after signing an informed consent including the potential risks and benefits of each intervention in this clinical study."|t|f|f|f
33860116|NCT03623685|NA|SINGLE_GROUP||SCREENING||NONE||||||
33961038|NCT00944008|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34172558|NCT01591200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172559|NCT05781178|||COHORT||PROSPECTIVE|||||||
34172560|NCT01304264|||CASE_CROSSOVER||PROSPECTIVE|||||||
34172561|NCT03451812|||CASE_ONLY||PROSPECTIVE|||||||
34172562|NCT02840201|||COHORT||PROSPECTIVE|||||||
34172563|NCT02278406|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172564|NCT02356458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172565|NCT03121313|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with resected squamous cell carcinoma of oral cavity harboring extracapsular spreading of lymph node s/p adjuvant chemoradiotherapy||||
34172566|NCT03165487|||COHORT||PROSPECTIVE|||||||
34172567|NCT05397327|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized controlled trial|t|f|f|t
34172568|NCT06133244|||COHORT||OTHER|||||||
34172569|NCT04527952|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33750461|NCT03078270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750462|NCT06041035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750463|NCT03939052|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33860117|NCT04315987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized (1:1) to receive NestaCell (n=45) or Placebo (n=45).|t|t|t|t
33860118|NCT02301936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860119|NCT00725140|||COHORT||PROSPECTIVE|||||||
33860120|NCT05255081|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After completion of necessary operative procedures in the primary operation, barrier agent (AdSpray™or Placebo) will be sprayed to fully cover the organs under the laparotomy incision. At the second-look surgery, laparoscopic video recordings of the area under the laparotomy incision will be made in both groups. For the efficacy evaluation, based on the laparoscopic images of the abdominal cavity at the time of the second-look surgery, the presence, extent, and severity of adhesions will be assessed by the adhesion-assessment team which is independent of the study. The independent adhesion-assessment team will assess the extent and severity of adhesions under the laparotomy incision on a 4-grade scale.|Eligible subjects will be identified, and parents will be approached for patient recruitment. Once consent to participation is signed, the patients will be randomised into either treatment group (AdSpray™) or placebo-controlled group in 1:1 ratio using simple randomization. The adhesion-assessment team will be blinded to the group allocated. The spray will be prepared according to the group allocated by a dedicated scrub nurse. For treatment group, AdSpray™ will be instilled into the drug chamber; for placebo group, saline will be instilled instead.|t|f|f|t
33860121|NCT01266525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860122|NCT00587353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860123|NCT06512168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750464|NCT01284465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860124|NCT00498134|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33860125|NCT05890872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860126|NCT02783716|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860127|NCT00052754||||TREATMENT||NONE||||||
33860128|NCT03200964|||COHORT||PROSPECTIVE|||||||
33860129|NCT01884233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860130|NCT02024165|||CASE_ONLY||PROSPECTIVE|||||||
33961039|NCT05812924|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750465|NCT02522494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33750466|NCT05602714|||COHORT||OTHER|||||||
33750467|NCT02297581|||COHORT||PROSPECTIVE|||||||
33750468|NCT03577210|NA|SINGLE_GROUP||OTHER||NONE||||||
33860131|NCT03427333|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Intervention Model: Single Group Assignment||||
34064232|NCT06001541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|the PI will be blinded to randomization and outcomes.|The investigators propose a randomized clinical trial to evaluate the effectiveness of web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program. Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.|f|f|t|f
34064233|NCT03063099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064234|NCT01389258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860132|NCT03474471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860133|NCT02210377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860134|NCT00537368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860135|NCT00919087|||CASE_ONLY||PROSPECTIVE|||||||
33860136|NCT01549366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860137|NCT00646061|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33860138|NCT03500250|||COHORT||PROSPECTIVE|||||||
33860139|NCT03780426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860140|NCT04532853|||COHORT||RETROSPECTIVE|||||||
33860141|NCT05161832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The principal investigators will be blinded by anonymization of the subjects and will not be present during the ultrasound. Participants will be notified of their group allocation at the end of their experimental session (after the experiment).|Participants will attend two experimental sessions at the Research Center on Aging of the Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie, Sherbrooke. During the first one, the efficacy of their excitatory and inhibitory mechanisms will be assessed (thermode and cold water bath) and during the second one, their corticospinal excitability will be assessed by transcranial magnetic stimulation (before and during induced pain + placebo or nocebo echography of shoulder). Subjects will be randomized between 2 arms, nocebo (bad fake result) or placebo echography (good fake result). Participants will be allocated using minimization with 2 factors (age and sex). The two sessions will be separated by at least 48 hours.|t|f|t|f
33860142|NCT02897401|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860143|NCT00233805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860144|NCT05934851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After randomization, the surgical assignment will be revealed to the attending surgeon. Subjects will remain blinded until the six-month post-operative study visit.||t|f|f|f
33860145|NCT06286007|||COHORT||PROSPECTIVE|||||||
33860146|NCT00626964|||OTHER||PROSPECTIVE|||||||
33860147|NCT01261754|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33860148|NCT06472219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is double-blind study. While the study is in progress, access to tabular results of study outcomes by treatment allocation will not be available to the research team, Co-Investigators, trial statisticians, clinical teams, or members of the study coordinator (unless the Data Management Committee advises otherwise).~The Data Management Committee(DMC) and DMC statisticians will be unblinded to study allocation at predetermined times."||t|t|t|f
33860149|NCT03498846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860150|NCT01050205|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860151|NCT01249937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860152|NCT00082745|||CASE_CONTROL||PROSPECTIVE|||||||
33860153|NCT03511547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860154|NCT04213924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860155|NCT01012479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860156|NCT02057120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860157|NCT02335125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34064235|NCT02074800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064236|NCT04448639|||CASE_CONTROL||PROSPECTIVE|||||||
33860158|NCT05181865|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33860159|NCT04726462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860160|NCT02629471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860161|NCT04012437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A simple blind: The subjects do not know whether they are receiving an experimental treatment or a control treatment.|Randomized control trial|t|f|f|f
33860162|NCT04641780|||COHORT||PROSPECTIVE|||||||
34172570|NCT05495932|NA|SINGLE_GROUP||OTHER||NONE||"Case-control study including adult patients with severe asthma successfully treated with mepolizumab for at least 24 weeks, and then divided into two groups at inclusion : responders and non-responders according to the results of blood samples taken at inclusion, 1 month and 6 months during study follow-up~The clinical criteria used to define a complete response to mepolizumab are : Reduction of maintenance corticotherapy \> 50% reduction OR dose \>5mg/day; Reduction of exacerbation rate by \> 50%; ACQ-6 score \< 1.5 and no increase in score \> 0.5 since enrolment Patients lacking any one of the previous criteria are classified as non-responders.~Clinical response criteria are evaluated at each study visit, and the final classification at 6 months post-inclusion determines study groups to be matched and compared during statistical analyses"||||
34172571|NCT01453049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172572|NCT05397730|||CASE_CONTROL||PROSPECTIVE|||||||
34172573|NCT00330577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33860163|NCT05514821|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Supplements will be administered double blind (participant and researcher blind) in identical bottles. They will be identical in smell, taste, texture and colour.|Replicated cross-over trial|t|f|t|t
33860164|NCT06085651|||CASE_CONTROL||RETROSPECTIVE|||||||
33860165|NCT06486311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860166|NCT02349451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860167|NCT03605563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860168|NCT03617965|||COHORT||PROSPECTIVE|||||||
33860169|NCT00047320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860170|NCT04069351|NA|SINGLE_GROUP||OTHER||NONE||||||
33860171|NCT03024177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860172|NCT01128738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961040|NCT03454672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor shall be blinded to the type of intervention when assessing the outcome of the treatment.|The subjects will be randomly allocated to two equally sized groups, one shall be treated by the Tixel, and the other shall be treated by the laser comparator.|f|f|f|t
34172574|NCT06019624|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34172575|NCT05942365|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172576|NCT01690052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33860173|NCT05880017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective , randomized controlled, comparative study.|t|f|f|t
33893739|NCT03976089|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Families were randomly assigned to condition and either started new Recipe 4 Success home visits for 10 weeks or continued the standard Early Head Start home visits they had been receiving. Interviewers collecting all outcome data were blind to study condition.|2-arm randomized controlled trial comparing new home visit intervention delivered within Early Head Start to treatment as usual Early Head Start|f|f|f|t
33893740|NCT00263926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893741|NCT03162289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172577|NCT05930821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172578|NCT04989686|||OTHER||PROSPECTIVE|||||||
34172579|NCT01048008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172580|NCT01804478|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172581|NCT06423950|||CASE_ONLY||PROSPECTIVE|||||||
34172582|NCT00434226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172583|NCT05623332|||OTHER||PROSPECTIVE|||||||
34172584|NCT00102466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893742|NCT01870466|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33893743|NCT04808687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961041|NCT01586832|||COHORT||PROSPECTIVE|||||||
33961042|NCT00379925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33961043|NCT04745325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961044|NCT03726086|||COHORT||PROSPECTIVE|||||||
33961045|NCT04253756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961046|NCT05831267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961047|NCT06036537|||COHORT||PROSPECTIVE|||||||
34172585|NCT02588599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172586|NCT02249416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172587|NCT02343263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34172588|NCT00457717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34064237|NCT05155930|NA|SINGLE_GROUP||TREATMENT||NONE||The Internal Family Systems (IFS) model of psychotherapy is a trauma-informed promising practice that has shown promise for individuals who struggle with trauma related symptoms including PTSD, dissociation and depression, as well as disruptions in self-concept and self-regulation. IFS places a heavy emphasis on aiding individuals in building an internalized sense of self-efficacy and self-compassion that may then support the development of self-regulatory capacity and reductions in trauma-related symptoms.||||
34064238|NCT06338618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064239|NCT05464121|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be assessed for eligibility and if they meet the inclusion criteria they will be assigned to the single treatment group (single arm). All patients will receive the same blended intervention that combines the self-applied online TAO program with videoconferencing sessions with a therapist.||||
34064240|NCT01464853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064241|NCT03156569|||CASE_CONTROL||PROSPECTIVE|||||||
34064242|NCT02971800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064243|NCT05288933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
34064244|NCT04106271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34064245|NCT01469975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064246|NCT04456166|||COHORT||PROSPECTIVE|||||||
34064247|NCT03116009|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Two groups of obese pregnant women:~Group 1: They will be screened for diabetes mellitus before 20 weeks of gestation.~Group 2: They will be screened for diabetes mellitus at 24 - 28 weeks."||||
34064248|NCT00103298||||TREATMENT||NONE||||||
34064249|NCT03468452|||COHORT||RETROSPECTIVE|||||||
34064250|NCT02536781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064251|NCT06730984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064252|NCT05392088|||COHORT||OTHER|||||||
34064253|NCT02041052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064254|NCT00000290||CROSSOVER||TREATMENT||DOUBLE||||||
34064255|NCT00000923||||TREATMENT||||||||
34064256|NCT00645645|||COHORT||PROSPECTIVE|||||||
34064257|NCT00870610|||CASE_ONLY||PROSPECTIVE|||||||
34064258|NCT01903993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064259|NCT05859763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064260|NCT05892159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064261|NCT04715217|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34064262|NCT05376293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064263|NCT01025466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064264|NCT00094523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064265|NCT03278405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064266|NCT04165616|||COHORT||PROSPECTIVE|||||||
34064267|NCT06330220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064268|NCT00862459|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34064269|NCT00396383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172589|NCT03926286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172590|NCT05207293|||OTHER||OTHER|||||||
34172591|NCT02285855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172592|NCT02189525|||COHORT||PROSPECTIVE|||||||
34172593|NCT01303913|||COHORT||PROSPECTIVE|||||||
34172594|NCT06176261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172595|NCT04742101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172596|NCT03663829|||COHORT||RETROSPECTIVE|||||||
34172597|NCT02636699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172598|NCT04124939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172599|NCT06550375|||COHORT||OTHER|||||||
34172600|NCT01095549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172601|NCT02325934|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34172602|NCT02386020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172603|NCT04055064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172604|NCT06706479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The allocation of the participants will be sealed in an envelope, blinding the subjects and assessors, and a third person (intervention implementer) will perform the blinding.||t|f|f|t
34172605|NCT00974142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064270|NCT00577005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064271|NCT03472313|NA|SINGLE_GROUP||OTHER||NONE||||||
34064272|NCT00401401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064273|NCT01918072|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34064274|NCT02696928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064275|NCT06259786|||CASE_ONLY||CROSS_SECTIONAL|||||||
34064276|NCT02787083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064277|NCT04186949|||COHORT||PROSPECTIVE|||||||
34064278|NCT01375634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34064279|NCT00872183|||||PROSPECTIVE|||||||
34064280|NCT02273908|||OTHER||PROSPECTIVE|||||||
34064281|NCT02083653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064282|NCT06057181|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34064283|NCT03998137|||COHORT||PROSPECTIVE|||||||
34064284|NCT05513144|||COHORT||PROSPECTIVE|||||||
34064285|NCT06731231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172606|NCT03772899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172607|NCT03850353|||CASE_CONTROL||PROSPECTIVE|||||||
34172608|NCT03260881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double-blind, parallel group, placebo controlled study. The method of allocation generation will be a computerized random-number generator. The sequence will be generated by the process of restricted randomization. Computer-based randomization process will be managed by the UM Research pharmacy.|Double-blind, parallel group, placebo controlled study.|t|f|t|f
34172609|NCT02144181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172610|NCT04070781|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172611|NCT03383601|||COHORT||PROSPECTIVE|||||||
34172612|NCT01442246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172613|NCT00402857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172614|NCT05963334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective open-label non-randomized control study||||
33860174|NCT04785339|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"* Aim 1: Co-develop an acculturation stress intervention for adult Latinx immigrants to decrease stress, increase resilience, and prevent declines in mental and physical health.~* Aim 2: Examine the preliminary clinical impact, feasibility, and acceptability of a group acculturative stress in Latinx immigrants and collect information to inform subsequent implementation.~Aim 2a: Conduct pilot testing of the group intervention in Latinx immigrant participants (N=24-30) to evaluate its preliminary clinical impact from baseline to post-assessment on stress, resilience, and health outcomes (e.g., depression, anxiety, self-rated health).~o Aim 2b: Characterize the inner and outer context, facilitators, barriers, intent to adopt, and resources across the Duke University Health System through multiple stakeholder interviews with providers and administrators (n=8-10)."||||
33860175|NCT02344433|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33860176|NCT05146362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860177|NCT00559585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172615|NCT01404507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172616|NCT05824650|||OTHER||PROSPECTIVE|||||||
34172617|NCT01944137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172618|NCT06009562|||COHORT||PROSPECTIVE|||||||
34172619|NCT04741581|NA|SINGLE_GROUP||OTHER||NONE||prospective, open-label||||
34172620|NCT02017197|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34172621|NCT00303823|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34172622|NCT04083781|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised to concizumab prophylaxis (ppx) or no ppx or assigned into non-randomised treatment arms, based on their treatment regimen before entering the trial. Main part of trial is completed when participant has completed at least 24 weeks of participation in arm 1 or 32 weeks in arms 2, 3 and 4. After main part, all participants will be offered to continue in extension part and receive treatment until concizumab is commercially available in their countries or until 12 Nov 2025 for up to 241 weeks (arms 1-4) or up to 265 weeks (randomised to arm 1 before the pause). After extension part, participant will enter safety follow-up part on visit 26a, which defines end-of-treatment. Participant will receive last dose of trial drug at home on day prior to visit 26a. On visit 26a, participants will either start up commercially available concizumab or revert to previous ppx schedule or on-demand regimen. Follow-up part will start on visit 26a and lasts for 7 weeks.||||
34172623|NCT06214975|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34172624|NCT03586765|||CASE_CROSSOVER||PROSPECTIVE|||||||
34172625|NCT00005984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172626|NCT05843435|||COHORT||CROSS_SECTIONAL|||||||
34172627|NCT03803306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33893744|NCT01146925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172628|NCT04468061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172629|NCT03964350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34172630|NCT05086185|||OTHER||CROSS_SECTIONAL|||||||
33893745|NCT05531357|||COHORT||PROSPECTIVE|||||||
33893746|NCT05281523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double-blind study.|Participants will receive either depemokimab (GSK3511294) or placebo during the study.|t|t|t|f
33893747|NCT06559501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33893748|NCT04489238|||CASE_CONTROL||PROSPECTIVE|||||||
33893749|NCT01377493|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33893750|NCT05054192|||OTHER||PROSPECTIVE|||||||
34172631|NCT00001832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172632|NCT03217344|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized without restrictions||||
34172633|NCT05421949|||COHORT||PROSPECTIVE|||||||
34172634|NCT02647099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172635|NCT03992053|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34172636|NCT00186576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172637|NCT01064063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomised into two arms, one receiving the AGC CR cement knee system (control group), and the other receiving Vanguard CR cement knee system (trial group).|f|f|f|t
34172638|NCT04457206|||COHORT||OTHER|||||||
34172639|NCT06056310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172640|NCT04481243|NA|SINGLE_GROUP||PREVENTION||NONE||Will study immunological response to vaccination||||
34172641|NCT00991861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172642|NCT01161940|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172643|NCT02571712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172644|NCT02000895|||COHORT||CROSS_SECTIONAL|||||||
34172645|NCT05149235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33893751|NCT00427414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893752|NCT05746624|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33893753|NCT00312520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33860178|NCT03996499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."||||
33860179|NCT03402919|||COHORT||PROSPECTIVE|||||||
33860180|NCT05196581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860181|NCT03884998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860182|NCT05093725|||COHORT||PROSPECTIVE|||||||
33860183|NCT04918238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33893754|NCT06261788|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961048|NCT06039878|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961049|NCT04926740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, treating physicians, and outcome assessors will be blinded to assigned treatment. Our pharmacy will prepare an opaque covering over each fluid bag within study kits, which will not be removed during the infusion to maintain blinding. Each bag will be labelled with a kit number and scannable bar code to ensure the patient receives study fluid as ordered which will be entered on their Medication Administration Record.|This will be a single-centre, triple-blind pilot RCT evaluating the superiority of IV RL (intervention) compared to saline (comparator) in treating adult ED patients presenting with DKA over a one-year period.|t|t|f|t
33961050|NCT00002628||||TREATMENT||||||||
33961051|NCT03172104|||COHORT||PROSPECTIVE|||||||
33961052|NCT04264988|||COHORT||RETROSPECTIVE|||||||
33961053|NCT01479556|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33961054|NCT06114017|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Randomized experimental and control group||||
33961055|NCT00904189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961056|NCT02955394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961057|NCT06155825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961058|NCT03717974|RANDOMIZED|PARALLEL||OTHER||NONE||Monocentric, randomized controlled pilot study||||
33961059|NCT05886283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the investigator does not know the technique used to operate on the cataract during the follow-up|A randomized prospective, uncontrolled cohort study|f|f|t|f
33961060|NCT04219800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961061|NCT00530439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961062|NCT00869141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961063|NCT06111430|||COHORT||PROSPECTIVE|||||||
33961064|NCT06296459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A 2 arm study using two methods of imaging in a participant||||
33961065|NCT02681627|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33961066|NCT06200688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Experimental Group: Pregnant women who received the peanut ball application were provided with necessary information about the ball and how to use it through visual aids showing the positions provided by the midwife. A total of 5 positions were shown to the pregnant women. The peanut ball was used when the cervical dilation reached 6 cm. Pregnant women in active labor, the transition phase, and the second stage with the peanut ball were directed to change positions every 30-45 minutes. Emphasis was placed on selecting positions in which the pregnant women felt comfortable.~Control Group: No intervention was made other than routine practices within the clinic for pregnant women. It was observed that pregnant women generally spent the time before delivery lying down and connected to electronic fetal monitoring."|t|t|f|t
33961067|NCT05966259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intervention Group: intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health. The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.|t|f|f|f
33961068|NCT00893230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961069|NCT04819282|||OTHER||CROSS_SECTIONAL|||||||
33961070|NCT02977494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961071|NCT04048720|NA|SINGLE_GROUP||OTHER||NONE||||||
33961072|NCT02177773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961073|NCT05351073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961074|NCT00386100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961075|NCT05227807|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33961076|NCT02959554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961077|NCT06528067|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"Randomization in to one of two conditions:~1. Mindful Motivation Intervention~2. Active Control"|f|f|t|f
33961078|NCT05052320|||COHORT||PROSPECTIVE|||||||
33961079|NCT05155020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961080|NCT06401642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961081|NCT05785858|||COHORT||PROSPECTIVE|||||||
33961082|NCT04759716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33961083|NCT03349437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will receive two different interventions after exertion.||||
33961084|NCT03160365|NA|SINGLE_GROUP||OTHER||NONE||The patient will have some exams more than in the current way||||
33961085|NCT03203005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172646|NCT05633563|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34172647|NCT03253679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172648|NCT03460886|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33750469|NCT06644573|NA|SINGLE_GROUP||TREATMENT||NONE||"This clinical trial follows a Single Group Assignment model, where all enrolled participants receive the same intervention-PROSOMNIA Sleep Therapy (PSTx). The model is open-label, meaning both the participants and researchers are aware of the treatment being administered. There is no placebo or control group in this trial, as the focus is to directly evaluate the safety and efficacy of PSTx for chronic insomnia and related REM sleep disorders.~The intervention involves the use of monitored anesthesia care (MAC) to induce and regulate REM sleep, using Diprivan/Propofol under the supervision of an Anesthesiologist and a Certified Anesthetist. Continuous EEG monitoring ensures proper sleep architecture is achieved during the therapy session, and adjustments are made in real-time to optimize therapeutic outcomes."||||
33750470|NCT05396248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750471|NCT03755830|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750472|NCT05245344|||CASE_CONTROL||PROSPECTIVE|||||||
33750473|NCT00689546|||CASE_CONTROL||PROSPECTIVE|||||||
33750474|NCT06003803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33750475|NCT01352338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750476|NCT04756687|||CASE_ONLY||RETROSPECTIVE|||||||
33860184|NCT04646512|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Intervention with taurine and / or placebo supplementation and physical training|double blind trial|t|f|t|f
33860185|NCT04201132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860186|NCT02602054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860187|NCT04640389|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33860188|NCT00197808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860189|NCT04697121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860190|NCT05408104|||CASE_CONTROL||PROSPECTIVE|||||||
33860191|NCT02700204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860192|NCT04876534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The ophthalmologist assessing the ophthalmic changes is blinded to the patient's treatment|32 patients with active moderate-severe GO treated with i.v. tocilizumab; 32 patients with active moderate-severe GO treated with i.v. methylprednisolone.|f|t|f|f
33860193|NCT03963453|||COHORT||PROSPECTIVE|||||||
33860194|NCT01083628|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860195|NCT04151953|||COHORT||PROSPECTIVE|||||||
33860196|NCT00643669|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33860197|NCT01119001|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961086|NCT06449209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064286|NCT06601465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172649|NCT06415890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The information that the patients included in the research sample were assigned to groups A and B according to the randomization table will be kept by the consultant, the researcher will fill out the Informed Consent Form for all patients when he/she goes to the patient for the application, and then the consultant will share the information about which group the patient is in with the researcher. When the research is completed, the data will be transferred to the computer environment by a statistician who does not know the A and B groups and the data will be analyzed by a statistician independent of the research and the findings will be reported. Thus, the data analysis and statistics phase will be blinded to group assignment."|The study was planned as a prospective, two-arm randomized controlled clinical trial.|f|f|t|t
34172650|NCT04810325|||COHORT||CROSS_SECTIONAL|||||||
33860198|NCT02400034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860199|NCT05904054|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860200|NCT00849654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860201|NCT03875989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental, parallel-group randomised controlled trial (1:1), multicentric. The primary outcome and the secondary outcome 1 and 3 will be evaluated in double blind; only the secondary outcome 2 will not be evaluated in blind.|t|f|t|f
33860202|NCT02620267|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33961087|NCT01906034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961088|NCT01297634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33961089|NCT00246441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064287|NCT02398370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064288|NCT00546741|RANDOMIZED|CROSSOVER||||NONE||||||
34172651|NCT05318001|||OTHER||CROSS_SECTIONAL|||||||
34172652|NCT06568016|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34172653|NCT01172535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172654|NCT01723735|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172655|NCT03382613|||COHORT||PROSPECTIVE|||||||
33860203|NCT04625998|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860204|NCT04811638|||COHORT||PROSPECTIVE|||||||
33893755|NCT03609164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33961090|NCT02947425|||COHORT||PROSPECTIVE|||||||
33961091|NCT02818179|NA|SINGLE_GROUP||||NONE||||||
33961092|NCT00637052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34064289|NCT04484844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064290|NCT04081116|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Participant, care provider, investigator and outcomes assessor are blinded from the order of the settings tested. Only a technician change settings and know the order.|Three different settings are tested on the same patients but in randomized order.|t|t|t|t
34064291|NCT02102100|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Subjects in each of the 2 arms received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session. The randomized sequence of nicotine infusions was the same for each test session.|t|f|t|f
34064292|NCT02278692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064293|NCT04981600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172656|NCT03497663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Baseline Assessor|The families randomly assigned to the VIA Family Group will be offered regular contact with a case manager. A multidisciplinary team of specialists from adult mental health services/psychiatry , child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.|f|f|f|t
33860205|NCT05953779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants and any care provider and study personnel who interact with them will be blind to condition. The PI will utilize a randomization table to allocate participants to condition, and will inform the front-line study personnel and through them, the care provider, regarding which intervention to use without specifying whether it was personalized or randomly-chosen. The outcomes assessor will be blind even to the type of intervention utilized.|Randomized Control Trial with 2 conditions: Experimental condition (personalized-selected intervention) and control condition (randomly-selected or standard intervention focused on emotion-regulation).|t|t|f|t
33860206|NCT05640466|NA|SINGLE_GROUP||TREATMENT||NONE|Single intervention no masking|||||
33750477|NCT05283694|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33750478|NCT04299672|NA|SINGLE_GROUP||TREATMENT||NONE|Therapist and outcome assessors are independent|One group||||
33750479|NCT01053182|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750480|NCT02686268|||CASE_ONLY||PROSPECTIVE|||||||
33860207|NCT02036216|||CASE_ONLY||RETROSPECTIVE|||||||
33750481|NCT06189976|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750482|NCT06123286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750483|NCT00239174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860208|NCT02523053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860209|NCT06151145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860210|NCT05060289|||COHORT||PROSPECTIVE|||||||
33750484|NCT06410157|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33860211|NCT01473160|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34064294|NCT02527915|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860212|NCT05100485|||COHORT||RETROSPECTIVE|||||||
33860213|NCT02479334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33860214|NCT04600700|||CASE_CONTROL||PROSPECTIVE|||||||
33860215|NCT05532254|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, two-way crossover, open-label, laboratory blind, bioequivalence study||||
33860216|NCT03296891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893756|NCT03138564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Dialysis clinics are randomized to provide the intervention or usual care. Patients of those clinics will be given the opportunity to participate in the study and will receive the intervention or usual care based on which clinic they attend.||||
33893757|NCT02372617|||COHORT||PROSPECTIVE|||||||
33893758|NCT01708226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893759|NCT01725165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893760|NCT05170737|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33893761|NCT03139292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sequentially numbered, sealed, opaque envelopes: Participant and Outcome Assessor Blinded|Prospective randomized single blinded parallel group controlled study|t|f|f|t
33893762|NCT00319722|||CASE_CONTROL||PROSPECTIVE|||||||
33893763|NCT01670500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893764|NCT06656780|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064295|NCT03124355|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators will be blinded to the study drugs (placebo, galantamine, pyridostigmine). Participants will be blinded to the vagal stimulation (stimulation vs. sham).|Randomized, double-blind, crossover|t|f|t|f
34064296|NCT00076258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064297|NCT03035461|||COHORT||PROSPECTIVE|||||||
34064298|NCT03930784|||COHORT||PROSPECTIVE|||||||
34064299|NCT03213418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34064300|NCT02115061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064301|NCT04785560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064302|NCT02254057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064303|NCT02709681|||COHORT||RETROSPECTIVE|||||||
34064304|NCT05769920|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34064305|NCT02532452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172657|NCT01701206|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34172658|NCT03808090|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172659|NCT05656417|||COHORT||PROSPECTIVE|||||||
33893765|NCT06418542|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064306|NCT03648554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only centralized reading by the pathologist of the hepatic histology of the liver puncture biopsy (LPB) will be carried out in blinded procedure.|open, prospective, randomized, controlled study|f|f|f|t
34064307|NCT06404944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064308|NCT03271671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial comparing two modes of non invasive ventilation|f|f|t|t
34064309|NCT00422292|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34064310|NCT04812405|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34064311|NCT06655467|||COHORT||PROSPECTIVE|||||||
34064312|NCT03295175|||COHORT||PROSPECTIVE|||||||
34064313|NCT03307122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064314|NCT03669484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Simple blinding stipulates hiding the treatment group for a patient. In addition, the research team had a blinded anesthesiologist who did not know about a patient's therapy group throughout the trial. This anesthesiologist assessed a patient's condition by scales (modified Aldrete score, memory assessment, postoperative delirium diagnosis). Anesthesia depth assessment by bispectral index (BIS), administration and, if necessary, correction of the trial drug/reference drug dosage were carried out by another anesthesiologist.||t|f|f|f
34064315|NCT06233877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064316|NCT06731374|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34064317|NCT01242501|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||3 Group RCT|t|f|f|t
33893766|NCT04082247|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33893767|NCT00520598|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33893768|NCT05240144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893769|NCT01380899|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33893770|NCT06464211|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|no masking|The study was conducted using an experimental pre-test, post-test, follow-up randomized controlled group experimental research design||||
33893771|NCT00940706|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33893772|NCT05330039|||COHORT||PROSPECTIVE|||||||
33893773|NCT05173103|||CASE_ONLY||RETROSPECTIVE|||||||
33893774|NCT04345185|||COHORT||PROSPECTIVE|||||||
33893775|NCT06349551|||CASE_ONLY||PROSPECTIVE|||||||
33893776|NCT01553799|||COHORT||PROSPECTIVE|||||||
33893777|NCT02700529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893778|NCT04273724|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961093|NCT05517863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient didn't know the types of modes of laser applied even in the control group i used light not laser to equalize the blindness|group A received laser therapy in sequential mode, group B received laser therapy in separate mode and the control group C receive traditional wound care|t|f|f|t
33961094|NCT04526249|||CASE_ONLY||PROSPECTIVE|||||||
33961095|NCT06257186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A mixed-methods sequential explanatory design will be used. Phase one will be quasi-experimental study design, comparing women with FOC who received art therapy (experimental group) and women who received routine antenatal care (control group). A qualitative descriptive design will be used in phase two to explore the experiences of the participants who had art therapy for FOC.||||
33961096|NCT01831518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961097|NCT04604496|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33961098|NCT04210700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33961099|NCT06249269|||COHORT||PROSPECTIVE|||||||
33961100|NCT01370434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961101|NCT01206946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34172660|NCT04319952|||COHORT||PROSPECTIVE|||||||
34172661|NCT01323582|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34172662|NCT02905097|||COHORT||PROSPECTIVE|||||||
34172663|NCT03382132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172664|NCT00637689|||COHORT||PROSPECTIVE|||||||
34172665|NCT00334217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172666|NCT06297187|||COHORT||RETROSPECTIVE|||||||
34172667|NCT00924521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172668|NCT03715517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172669|NCT05952349|RANDOMIZED|PARALLEL||TREATMENT||NONE||cross-sectional study||||
34172670|NCT05288309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Children in the 5-12 age group||t|f|f|f
34172671|NCT05638932|||COHORT||RETROSPECTIVE|||||||
34172672|NCT03866746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172673|NCT01552070|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34172674|NCT03047941|||COHORT||PROSPECTIVE|||||||
34172675|NCT03052790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172676|NCT04869982|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study was conducted in an observer-blind manner. This means that during the course of the study, the vaccine(s) recipient and those responsible for the evaluation of any study endpoint were all unaware of which study intervention was administered. The laboratory in charge of the laboratory testing was blinded to the treatment, and codes were used to link the participant and study (without any link to the treatment attributed to the participant) to each sample.||t|t|t|t
34172677|NCT05236517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172678|NCT03795571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172679|NCT02799836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172680|NCT05025839|||CASE_CONTROL||PROSPECTIVE|||||||
34172681|NCT01857219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172682|NCT04991870|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34172683|NCT01393158|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||20mg cohort enrolled and completed before the 30mg cohort enrolled.||||
34172684|NCT03261336|NA|SINGLE_GROUP||TREATMENT||NONE||Calcitriol 10mcg QD X3, weekly + Ketoconazole 400mg po TID and Hydrocortisone 20mg AM, 10mg PM||||
34172685|NCT00315835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34172686|NCT05688059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172687|NCT05403606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172688|NCT03318549|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34172689|NCT01071681|||COHORT||PROSPECTIVE|||||||
34172690|NCT05295212|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172691|NCT05263739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34172692|NCT06593353|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The SAIA (an evidence-based implementation strategy) will be implemented monthly at clinics providing MOUD care. The investigators will apply SAIA at the clinics in Jail Health Services in King County, WA. Those patients who exit jail to the community on MOUD will be tracked to see if they link to any MOUD care services within 30 days. The primary outcome is linkage to MOUD care upon release at any MOUD provider in King County. The secondary outcome assesses whether the patient comes back after initially linking post jail release. SAIA will be implemented in 3 low barrier clinics and the rate of return (sustainment in care -- measured as second visit within 30 days of the first linkage visit will be compared between the three community based MOUD clinics implementing SAIA and all other community-based MOUD clinics.||||
34172693|NCT04213300|||COHORT||CROSS_SECTIONAL|||||||
34172694|NCT03293108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172695|NCT01095640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172696|NCT04860323|NA|SINGLE_GROUP||OTHER||NONE||||||
34172697|NCT03872375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All research assistants and senior staff involved in data collection and analysis will be blinded.|"Dietary Supplement: Meal-Replacement Therapy~To examine the effect of meal-replacement therapy on weight loss, behavior, and brain outcomes in overweight to obese aged adults with mild cognitive impairment."|f|f|f|t
33750485|NCT00243802|||CASE_CONTROL||PROSPECTIVE|||||||
33750486|NCT03343236|||COHORT||PROSPECTIVE|||||||
33750487|NCT05898867|||COHORT||CROSS_SECTIONAL|||||||
33750488|NCT05938647|||OTHER||RETROSPECTIVE|||||||
33750489|NCT02628210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750490|NCT01527929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961102|NCT05335473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961103|NCT04294641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750491|NCT05713240|||COHORT||PROSPECTIVE|||||||
33860217|NCT05428254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Individuals with non-specific CNP will be evaluated and referred by independent physicians from orthopedic department at Makkah hospitals. The first author will conduct the processes of participant enrollment and allocation. The allocation of patients is blinded to the assessor and to the therapist. By sealed envelopes, the allocation concealment is achieved. All participants will be eligible to participate after evaluation of independent physician. The physician conducts the processes of participant enrollment, and allocation. The same therapist will treat the patients and the study variables is measured by the same assessors. Randomization is performed using online GraphPad and creating a random number for each patient. Neither the assessor nor the CRRT applicant is oriented about the randomization process. The same therapist will treat the patients, and the study variables will be measured by the same assessor.|A total of 60 patients will participle in the study. They will be recruited from the hospital in Mecca, Saudi Arabia. They will be randomized into three groups. Group I will be treated with stretching exercises (EX) and manual therapy (Manual + EX group). Group II will be treated with CRRT plus EX without manual therapy (CRRT+ EX group). Group III will be treated by EX plus manual therapy applied during CRRT for groups (Manual + CRRT+ EX group). For group II and III, capacitive electrodes will be applied for five minutes. Then the resistive electrodes will be applied for 10 minutes and finally the capacitive will be applied again for another five minutes.|t|t|t|t
33860218|NCT00004239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860219|NCT00308269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860220|NCT00409097|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860221|NCT02196363|||COHORT||PROSPECTIVE|||||||
33860222|NCT02918604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860223|NCT02725957|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33893779|NCT00587223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961104|NCT06249217|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research design is a between-subjects experiment with pre- and post-intervention assessments. Random assignment to conditions will help to ensure that the intervention or waitlist control groups are equivalent prior to the intervention and that any subsequent changes are not due to initial group differences.||||
33961105|NCT06030479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961106|NCT04514146|||COHORT||PROSPECTIVE|||||||
33961107|NCT03564535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both patients and follow-up clinician will be blinded regarding the use of mesh fixation. The mesh fixation technique will only be entered in the master chart of the student but not in the Operation notes, in order to prevent accidental disclosure by a curious patient or follow up evaluator instead the phrase, TEP done by 11x15cm mesh will be written.'' For legal reasons details of the tack applicator device will be recorded on the nursing count sheet.) Follow-up will be performed by a different clinician to the operating surgeon. There would be no external clues such as differences in the location or size of skin incisions to indicate whether fixation had been performed or not."|Patients of uncomplicated inguinal hernia presenting to the outpatient department of AIIMS, Bhubaneswar will be recruited to the study. They would be put either in the conventional tacker group or self-fixating mesh group based on the sealed envelope which will be revealed once the patient is intubated. Random allocation done using random allocation software. Surgeries would be performed by single surgery team experienced in laparoscopic hernia repair.|t|f|f|t
33961108|NCT05235737|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33961109|NCT00118222|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961110|NCT00294632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961111|NCT02454322|||COHORT||PROSPECTIVE|||||||
33961112|NCT04493554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design|t|f|t|t
34172698|NCT05222958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34172699|NCT06525415|||COHORT||PROSPECTIVE|||||||
34172700|NCT00379847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172701|NCT00282763|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34172702|NCT03863886|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34172703|NCT03269526|NA|SINGLE_GROUP||TREATMENT||NONE||Standard of care chemotherapy followed by Anti-CD3 x anti-EGFR-Bispecific Antibody Armed Activated T-cells||||
34172704|NCT06223334|||CASE_ONLY||CROSS_SECTIONAL|||||||
34172705|NCT03595761|||COHORT||RETROSPECTIVE|||||||
34172706|NCT06706388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172707|NCT00828243|||CASE_CONTROL||PROSPECTIVE|||||||
34172708|NCT00004100|RANDOMIZED|||TREATMENT||||||||
33750492|NCT01921673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750493|NCT03364127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750494|NCT02739438|||COHORT||PROSPECTIVE|||||||
33750495|NCT03961568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860224|NCT04538612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|the investigators evaluate capillary refill time without knowing the status of vascular occlusion test.|||||
33860225|NCT01106027|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860226|NCT06261086|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33860227|NCT01280461|||COHORT|||||||||
33893780|NCT02948894|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33893781|NCT01520246|||CASE_ONLY||RETROSPECTIVE|||||||
33893782|NCT02364778|||COHORT||PROSPECTIVE|||||||
34064318|NCT04148859|NA|SINGLE_GROUP||TREATMENT||NONE||We will recruit 11 women who have to undergo amnioreduction due to TTTS. The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate. We will include cases of multiple pregnancies with TTTS who must undergo amnioreduction.||||
34064319|NCT03926468|||COHORT||PROSPECTIVE|||||||
34064320|NCT03588013|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Moderately or severely malnourished (weight for height Z score (WHZ) \< -2) children~2. Well-nourished (WHZ \> 0) children~3. Control group of children in the US with celiac disease~4. Control group of children in the US with Crohn's disease~5. Control group of healthy age-matched children in the US"||||
34172709|NCT04296760|||CASE_ONLY||PROSPECTIVE|||||||
34172710|NCT02923141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34172711|NCT03289208|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34172712|NCT03863184|NA|SINGLE_GROUP||TREATMENT||NONE||Study intervention begins with an induction phase consisting of 12 cycles of acalabrutinib, lenalidomide, and rituximab (ALR). Responding subjects will be eligible to enter a maintenance phase. Subjects will continue maintenance ALR until disease progression, development of unacceptable toxicity, or voluntary withdrawal. Subjects in CR wishing to attempt stem cell collection following at least 6 months of induction treatment can hold lenalidomide for up to 30 days, and restart following stem cell collection.||||
34172713|NCT04602403|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34172714|NCT04923477|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed research will be a prospective longitudinal cohort laboratory experimental design to examine mechanisms of a single bout and 2, 4, and 8 weeks of therapeutic exercise in participants with rotator cuff tendinopathy||||
34172715|NCT06579430|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"A multicenter study is being conducted using standardized ICG-NIRF imaging of the parathyroid glands following total thyroidectomy. Perfusion curves are generated and analyzed postoperatively, with flow parameters being linked to postoperative parathyroid function.~The study consists of two groups: the first group includes patients undergoing total thyroidectomy, where perfusion curves are compared between different patients. The second, smaller group is part of a root cause analysis, where the effects of injection speed and ICG concentration on the reproducibility of perfusion curves are evaluated by comparing curves within the same patient."||||
34172716|NCT00686777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172717|NCT04392323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Cohort||||
34172718|NCT01308541|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172719|NCT00739401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172720|NCT00983346|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172721|NCT01316523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172722|NCT05890248|||CASE_CONTROL||PROSPECTIVE|||||||
34172723|NCT05757141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172724|NCT04587518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172725|NCT03860792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcomes assessors are masked from participant group assignment.||f|f|f|t
34172726|NCT02272140|||COHORT||PROSPECTIVE|||||||
34172727|NCT03267368|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, intervention, outcome||||
33893783|NCT03406962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893784|NCT05069038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893785|NCT04354454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893786|NCT06656793|||COHORT||RETROSPECTIVE|||||||
33961113|NCT04084028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961114|NCT06260319|||CASE_ONLY||RETROSPECTIVE|||||||
33961115|NCT00779844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961116|NCT00003673||||TREATMENT||||||||
33961117|NCT05628766|||COHORT||PROSPECTIVE|||||||
33961118|NCT01915394|||COHORT||PROSPECTIVE|||||||
33961119|NCT00157729|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33961120|NCT02312531|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961121|NCT05072093|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33961122|NCT02517099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961123|NCT01087801|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33961124|NCT00666718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893787|NCT03206502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961125|NCT05199207|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34064321|NCT03666052|||CASE_ONLY||OTHER|||||||
34064322|NCT02084914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064323|NCT04565821|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33750496|NCT06151964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is single-blind with regard to treatment (AZD9550 or placebo). This means that the participant, investigator, Study Monitor, and the clinical unit staff will remain blinded during each part of the study and the randomisation code will only be available at each predefined decision point before the SRC meeting in order to review the data unblinded, if necessary. The sponsor will be unblinded throughout the study. AZD9550 and placebo will as far as possible be matched for formulation, appearance, and volume. Participants randomised to placebo will receive the same volume of injection (SC cohorts) as participants on active treatment.|"The study will randomise approximately 90 participants and will be conducted in 4 parts (A to D). Part D will be conducted exclusively in Japan. Part A: Approximately 45 participants will be screened to achieve 16 randomised to study intervention: Cohort 1 (n = 8) and Cohort 2 (n = 8). The study duration will be approximately 103 days.~Part B: Approximately 90 participants will be screened to achieve 30 randomised to study intervention. The study duration will be approximately 110 days. Part C: Approximately 90 participants will be screened to achieve 30 randomised to study intervention: Cohort 1 (n = 12) and Cohort 2 (n = 18). The study duration will be approximately 249 days.~Part D: Approximately 35 participants will be screened to achieve 12 randomised to study intervention. The study duration will be approximately 249 days."|t|t|t|f
33750497|NCT06455462|||COHORT||RETROSPECTIVE|||||||
33750498|NCT04321226|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective interventional case series||||
33750499|NCT01835626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750500|NCT02228265|||CASE_ONLY||PROSPECTIVE|||||||
33750501|NCT04999813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750502|NCT00651664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750503|NCT01597050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750504|NCT04594161|RANDOMIZED|PARALLEL||OTHER||NONE|No masking is possible because stent is visible to patient and physician|Randomised controlled trial||||
33750505|NCT01208454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750506|NCT05188001|||COHORT||RETROSPECTIVE|||||||
33750507|NCT01192438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172728|NCT05484804|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Arm 1 (Standard Care): NC Medicaid Care Management Arm 2 (Data Accountability and Transparency): NC Medicaid Care Management + Practice-level Data Accountability interventions Arm 3 (Community-Based Doula Support): NC Medicaid Care Management + CBD support intervention for high-risk women during pregnancy and postpartum Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): NC Medicaid Care Management + both Arm 2 and Arm 3 interventions||||
33750508|NCT05414591|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33750509|NCT05093036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will implement a multi-center, four-arm, non-inferiority randomised controlled trial to evaluate online PrEP care and/or a reduced schedule of monitoring visits against routine (face-to-face) PrEP care at the Centers of Sexual Health (CSH) of the Public Health Services (PHS) (standard-of-care). After eligibility screening and assessment, study participants are randomized (1:1:1:1) to the standard-of-care arm (i.e. location: CSH; 4 annual monitoring visits) or one of three interventions arms: arm 2 (location: CSH; 2 annual monitoring visit), arm 3 (location: online; 4 annual monitoring visits), arm 4 (location: online; 2 annual monitoring visits). In the randomization process, participants will be stratified based on PrEP experience (PrEP-naïve or experienced) and PHS catchment area (4 regions). In each arm, we aim to include at least 25% PrEP-naïve participants.||||
33750510|NCT04395105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750511|NCT04335682|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750512|NCT00473798|||OTHER||PROSPECTIVE|||||||
33750513|NCT06116903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860228|NCT03321734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All clinical team personnel and all research staff (except research pharmacist) will remain blinded to study group until study completion.|Randomized, placebo-controlled, double-blinded clinical trial A site-stratified randomly-permuted blocked randomization design will be used to ensure balance at each site. Randomization will also be stratified into 2 birth gestational age categories of \<28 wks and 28 wks + 0 days to 30 wks + 6 days gestation to ensure balance. The randomization scheme will be developed by the DCC using specialized software, and clinical sites will be provided appropriate enrollment logs and randomization procedures from the research pharmacy.|t|t|t|t
33860229|NCT04008355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860230|NCT06125249|||OTHER||PROSPECTIVE|||||||
33860231|NCT01717989|||COHORT||PROSPECTIVE|||||||
33860232|NCT02885805|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172729|NCT05201365|||CASE_CONTROL||PROSPECTIVE|||||||
34172730|NCT04907682|RANDOMIZED|PARALLEL||TREATMENT||NONE||Exploratory, prospective, controlled, multisite, open label, randomized clinical trial with two arms||||
34172731|NCT06381804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172732|NCT03852602|||COHORT||PROSPECTIVE|||||||
34172733|NCT03701958|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34172734|NCT03820609|NA|SINGLE_GROUP||PREVENTION||NONE|The outcome evaluation is a non-randomized open pilot trial. Therefore, all participants and project collaborators are aware that individuals enrolled in the study are asked to complete the prevention program.|A non-randomized open trial with a 1-month follow up will assess preliminary effects on attitudes and behaviors, and will establish procedures for assessing change in proximal (attitude) and distal (behavioral) outcomes in preparation for large-scale evaluation in a Phase 2 SBIR proposal.||||
34172735|NCT04776317|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172736|NCT02482376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961126|NCT06516393|RANDOMIZED|PARALLEL||TREATMENT||NONE||the patients were divided into subgroups by the sports physician according to age, height, body weight and body mass index. Patients with similar characteristics were randomized to one of two groups.||||
33961127|NCT06346600|||OTHER||PROSPECTIVE|||||||
33961128|NCT01051973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961129|NCT01856231|NA|SINGLE_GROUP||TREATMENT||NONE||Lifestyle physical activity self-efficacy||||
34172737|NCT04053335|||COHORT||OTHER|||||||
34172738|NCT03553901|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34172739|NCT01274026|||OTHER||PROSPECTIVE|||||||
33961130|NCT03405909|||COHORT||PROSPECTIVE|||||||
34064324|NCT03081091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants are blinded to the intervention. They will be provided with eye masks so that they cannot see which needles are used in their intervention. Moreover, the same type of equipment will be used with all the participants (although the guide tube to insert the needle is not necessary in true acupuncture).~Given the fact that the person who carries out the intervention is different than the one assessing its effects and the latter does not know which group the evaluated subjects belong to, as well as the fact that the person responsible for the statistics is a third person who ignores which of the two groups has received true acupuncture, this is a triple-blind study."||t|f|t|t
34172740|NCT05790551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172741|NCT03717688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The participants are on 4 study days with wash out period of minimum 2 weeks randomized to 4 intervention arms||||
34172742|NCT05794425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172743|NCT02140047|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34172744|NCT06532643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172745|NCT03806192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Site intermediary and referring MD||f|t|f|f
34172746|NCT00547508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33750514|NCT06217328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All subjects will be implanted with the device and randomized (2:1) to ON vs OFF. After the subjects complete the OFF period, their system will be activated and they will crossover to the ON group.||||
33961131|NCT06191185|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33961132|NCT02139085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961133|NCT02811211|||CASE_ONLY||CROSS_SECTIONAL|||||||
33961134|NCT05558852|NA|SINGLE_GROUP||TREATMENT||NONE|Only one attending surgeon will operate the all participants. The patients will be evaluated pre-operatively by the surgeon and postoperatively 6th months by a different physician ( who is practicing as a gynecologist in the same hospital).|Anticipated 25 patients will be evaluated and operated with meshless method.||||
33961135|NCT05672173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961136|NCT02360059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172747|NCT05001035|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Split mouth technique|t|f|t|t
34172748|NCT02134223|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34172749|NCT06253702|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE||double-blind placebo controlled design|t|f|t|f
34172750|NCT03820596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172751|NCT03608319|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3-Way Crossover Design||||
34172752|NCT01908426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172753|NCT00647517|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34172754|NCT04482517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172755|NCT05306964|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, two-center, unblinded, parallel-group, 2-arm, comparative effectiveness, stepped-wedge cluster-randomized trial.||||
34172756|NCT03667274|||COHORT||RETROSPECTIVE|||||||
34172757|NCT03867214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33961137|NCT05348707|||COHORT||RETROSPECTIVE|||||||
34172758|NCT06322849|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be aware that they will be assigned to an intervention designed to help them with depressive symptoms. Participants will be aware that there are other arms of the study to which other participants are randomized, but they will not be aware of what these other arms entail. Additionally, the measures will be self-administered, so there is no scope for evaluator bias.|Participants will be randomized to one of 8 different conditions (factorial trial), following the Multiphase optimization Strategy (MOST)|t|f|f|f
34172759|NCT01447654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860233|NCT02674191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860234|NCT04142450|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study. Blinding will only be employed for photograph review by an independent panel of physician reviewers with expertise in the areas of dermatology and/or plastic surgery.|||||
33860235|NCT04774991|RANDOMIZED|PARALLEL||TREATMENT||NONE|In the delivery trial, participants, implementers, and outcome assessors will not be actively masked from the delivery approach given the nature of the intervention.|The AVENIR delivery trial is a two-armed, cluster-randomized trial in the Dosso region in Niger. 80 Communities will be randomized in a 1:1 allocation to either door-to-door delivery or fixed-point delivery of azithromycin to children 1-59 months of age.||||
33860236|NCT02779725|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33860237|NCT01400789|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33961138|NCT00919802|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961139|NCT02689726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172760|NCT00774046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172761|NCT00003122||||TREATMENT||||||||
34172762|NCT05400317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860238|NCT05794750|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34172763|NCT00988832|||CASE_ONLY||RETROSPECTIVE|||||||
34172764|NCT00994552|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34172765|NCT04498221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34172766|NCT02641925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172767|NCT05732467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172768|NCT02356276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860239|NCT04567550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860240|NCT00328822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860241|NCT05192304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860242|NCT04141956|||CASE_CONTROL||PROSPECTIVE|||||||
33860243|NCT05515120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)|f|f|t|f
33860244|NCT01332565|NA|SINGLE_GROUP||||NONE||||||
33860245|NCT00779051|RANDOMIZED|CROSSOVER||||NONE||||||
33860246|NCT00403728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34172769|NCT06166056|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Part I: randomised, double-blind, placebo-controlled, single ascending dose, alternating cross-over design in HV and single dose in subjects with BE. Part II: randomised, double-blind, placebo-controlled, repeated-dose, 3-way cross-over design in subjects with BE.|t|t|t|t
34172770|NCT05920798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172771|NCT01909440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860247|NCT00628251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860248|NCT05745675|||CASE_ONLY||PROSPECTIVE|||||||
33860249|NCT01609751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961140|NCT06325176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961141|NCT02908698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33961142|NCT01280565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961143|NCT00379366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961144|NCT04565015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961145|NCT05219773|NA|SINGLE_GROUP||OTHER||NONE||||||
33961146|NCT02239601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961147|NCT02414074|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33961148|NCT01408056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961149|NCT01617720|||COHORT||PROSPECTIVE|||||||
33961150|NCT06072755|||COHORT||CROSS_SECTIONAL|||||||
34172772|NCT02423850|||COHORT||PROSPECTIVE|||||||
34172773|NCT04783350|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172774|NCT02066363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961151|NCT06365229|||COHORT||PROSPECTIVE|||||||
33961152|NCT06165510|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical study with 1:1 recruitment in each arm - Convergent AF Ablation with LARIAT procedure versus endocardial catheter ablation.||||
33961153|NCT04299737|||COHORT||PROSPECTIVE|||||||
33961154|NCT01005680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860250|NCT00874770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961155|NCT04938063|||OTHER||CROSS_SECTIONAL|||||||
33961156|NCT04924946|||COHORT||PROSPECTIVE|||||||
33961157|NCT06181448|||COHORT||PROSPECTIVE|||||||
33961158|NCT06566794|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33961159|NCT04638725|||COHORT||PROSPECTIVE|||||||
33961160|NCT06538753|||CASE_ONLY||CROSS_SECTIONAL|||||||
33961161|NCT04150588|||COHORT||PROSPECTIVE|||||||
33961162|NCT01289990|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961163|NCT05835999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This is a randomized, placebo-controlled, double-blind, 24-week clinical trial using everolimus in middle-aged to older adults. This study will follow a double-dummy design where participants will be randomized 1:1:1 in a double-blinded fashion to one of three groups: 1) everolimus once daily (0.5 mg/day) plus placebo once weekly, 2) placebo once daily plus everolimus once weekly (5mg/week) or 3) placebo once daily and placebo once weekly. The double dummy design preserves the double-blind for both placebo versus everolimus and for daily versus weekly dosing schedules. Everolimus and placebo will be over encapsulated to be indistinguishable from one another.~There will also be a group of young, healthy individuals who will complete baseline testing only and not the intervention. This group allows the determination if everolimus changes any molecular and physiological outcomes in older adults toward that of a young, healthy reference group."|t|f|t|t
33961164|NCT03668925|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33961165|NCT05232838|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33860251|NCT01207232|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33961166|NCT00471185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961167|NCT04991896|||COHORT||PROSPECTIVE|||||||
34064325|NCT04842799|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Participants are initially randomised 1:1 to receive genetic pre-test information either via the BRCA-DIRECT digital platform or a genetic counselling telephone appointment. Once the participants BRCA-gene test result becomes available, they are then randomised sequentially depending on the result of the genetic test. Participants with a negative (normal) result are randomised to receive this information either via the BRCA-DIRECT digital platform or a genetic counselling telephone appointment. Participants with a positive result will not be randomised and instead will always have a genetic counselling telephone appointment.||||
34172775|NCT06571305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860252|NCT04078165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172776|NCT03495661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective clinical randomised clinical trial|t|t|f|f
33860253|NCT02480790|||COHORT||PROSPECTIVE|||||||
34172777|NCT04417673|||COHORT||PROSPECTIVE|||||||
34172778|NCT04711655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172779|NCT00282035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860254|NCT00569816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961168|NCT01154400|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34172780|NCT01179724|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860255|NCT00194844|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33860256|NCT06295835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Capillary whole blood specimens will be tested in duplicate on the i-STAT 1 Analyzer with the CG8+ cartridge and a blood analyte testing comparator device.||||
33860257|NCT02718651|||COHORT||PROSPECTIVE|||||||
33860258|NCT00195858|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33860259|NCT04563585|||OTHER||CROSS_SECTIONAL|||||||
33860260|NCT06418438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860261|NCT00257686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860262|NCT06359951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860263|NCT02701088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860264|NCT00462189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860265|NCT02952001|||OTHER||PROSPECTIVE|||||||
33860266|NCT03496181|||COHORT||PROSPECTIVE|||||||
33860267|NCT00909792|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33860268|NCT00898443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33860269|NCT00150332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961169|NCT03409497|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34064326|NCT02791646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064327|NCT04799080|||COHORT||PROSPECTIVE|||||||
34064328|NCT01665677|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34064329|NCT04485494|||COHORT||PROSPECTIVE|||||||
34064330|NCT02095015|||OTHER||PROSPECTIVE|||||||
34064331|NCT01156051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064332|NCT02503371|||COHORT||PROSPECTIVE|||||||
34064333|NCT04587297|||COHORT||PROSPECTIVE|||||||
34172781|NCT04978350|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|No masking|This is single arm, interventional study of 15 patients diagnosed with Lynch Syndrome and 4 genetic counselors who are working with the 15 patients.||||
34172782|NCT03964103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, placebo-controlled, parallel-group|t|t|t|f
34172783|NCT02403557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172784|NCT06333106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172785|NCT05359172|||CASE_CONTROL||PROSPECTIVE|||||||
34172786|NCT03816033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiologist analysing the Holter results and/or loop recorders for recurrence of arrhythmia will not know the randomised treatment for the study participant.|This is a 1:1 randomised clinical controlled trial or a set of them, in our extensive program of research.|f|f|f|t
34172787|NCT05295017|||COHORT||PROSPECTIVE|||||||
33860270|NCT01055262|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33860271|NCT04488432|||COHORT||RETROSPECTIVE|||||||
33961170|NCT06536699|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of a shorter course of radiotherapy in 4 weeks with standard treatment of 6 weeks for head and neck cancers||||
33961171|NCT01035593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961172|NCT00203632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961173|NCT00529802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860272|NCT00826111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860273|NCT04958850|||OTHER||CROSS_SECTIONAL|||||||
33860274|NCT04940065|||COHORT||PROSPECTIVE|||||||
33860275|NCT01884649|||||CROSS_SECTIONAL|||||||
33860276|NCT03594851|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Administration of individualized advice to older people living at home complaining of sleep disorders||||
33860277|NCT01268722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860278|NCT06288321|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33860279|NCT00610597|||CASE_CONTROL||PROSPECTIVE|||||||
33860280|NCT01562171|RANDOMIZED|PARALLEL||||NONE||||||
33860281|NCT03510988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860282|NCT04312464|||CASE_CONTROL||RETROSPECTIVE|||||||
33860283|NCT00356460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860284|NCT05066698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled trial with Open-Label Extension|t|t|t|t
33860285|NCT00424866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961174|NCT01029080|||CASE_ONLY||PROSPECTIVE|||||||
33961175|NCT02375646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34172788|NCT04810650|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel randomized trials to assess effectiveness, fidelity and cost of prevention and treatment interventions.||||
34172789|NCT04818658|||COHORT||OTHER|||||||
34172790|NCT03351842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172791|NCT04642625|||OTHER||PROSPECTIVE|||||||
34172792|NCT05096624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34172793|NCT03991312|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172794|NCT03499717|||OTHER||RETROSPECTIVE|||||||
33860286|NCT01774851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860287|NCT01956500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860288|NCT01764113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961176|NCT03179956|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961177|NCT02674074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961178|NCT00034359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961179|NCT00891501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961180|NCT04074473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961181|NCT05273398|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||4 subject pilot study||||
33961182|NCT01839227|NA|SINGLE_GROUP||SCREENING||NONE||||||
33961183|NCT02146235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961184|NCT03067506|||COHORT||PROSPECTIVE|||||||
33961185|NCT01483612|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33961186|NCT04789811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomised controlled|f|f|f|t
34172795|NCT02969798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172796|NCT02592291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34172797|NCT04975841|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Six subjects will be randomized to Part 1 and start Part 2 once Part 1 is completed. Three subjects will be randomized directly to Part 2.||||
34172798|NCT03253796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"To evaluate the effect of treatment withdrawal compared to continued treatment with golimumab (either every month \[QM\] or every 2 months \[Q2M\]) on the incidence of a flare during up to 12 months in Period 2 (blinded therapy)."|t|f|t|f
34172799|NCT02883569|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34172800|NCT01673529|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34172801|NCT04451785|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172802|NCT02163902|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34172803|NCT04134416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is an open label except for the tCDS treatment which is double blind (AtDCS vs shamtDCS).||t|t|t|t
34172804|NCT00173472|||DEFINED_POPULATION||PROSPECTIVE|||||||
34172805|NCT02772601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860289|NCT03023228|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33860290|NCT03291704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860291|NCT01765179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860292|NCT05555511|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomized using computer generated random series into two groups according to the used drug into:~Group A: N-acetylcysteine group (23 Patients) Patients will receive N-acetylcysteine 600 mg intravenous(IV) every 12 hours 24 hours before surgery and will be continued for 48 hours after surgery.~Group B : Standard (control) group (23 Patients) Patients will not receive N-Acetylcysteine and will receive standard care according to our institutional protocol."||||
33860293|NCT00550368|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860294|NCT05689983|RANDOMIZED|PARALLEL||OTHER||NONE||Randomization will occur using a 1:1 ratio with random numbers generated using SAS 9.4||||
33860295|NCT03953703|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34172806|NCT00812994||||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34172807|NCT06079138|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||The participants will be divided into 2 groups. Intervention group will receive active tDCS with intensity 2 mA and control group will receive sham tDCS.|t|f|t|t
34172808|NCT05830058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172809|NCT02352480|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172810|NCT02438176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34172811|NCT01088789|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172812|NCT00453895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172813|NCT02847377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172814|NCT06439095|||CASE_CROSSOVER||PROSPECTIVE|||||||
34172815|NCT00002298||||TREATMENT||||||||
34172816|NCT06240052|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172817|NCT04291651|||OTHER||PROSPECTIVE|||||||
33860296|NCT04777253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||random selection to two groups (study group and control group)|t|f|t|t
33860297|NCT00118443|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172818|NCT03596034|NA|SINGLE_GROUP||OTHER||NONE||||||
34172819|NCT01832636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172820|NCT00773448|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34172821|NCT06204341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172822|NCT00380939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34172823|NCT01889667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172824|NCT03452540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172825|NCT03392103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172826|NCT03259230|||CASE_CONTROL||OTHER|||||||
34172827|NCT04453657|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34172828|NCT01288235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172829|NCT05112575|||COHORT||PROSPECTIVE|||||||
33860298|NCT05325697|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label feasibility study.||||
34172830|NCT02313766|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34172831|NCT02262585|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860299|NCT00533741|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33860300|NCT05442762|||OTHER||CROSS_SECTIONAL|||||||
33860301|NCT03114007|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33860302|NCT06048354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860303|NCT06435754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33860304|NCT00209456|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860305|NCT02549560|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33860306|NCT05467878|||CASE_CONTROL||RETROSPECTIVE|||||||
33860307|NCT03159923|||COHORT||PROSPECTIVE|||||||
33860308|NCT06348940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33860309|NCT00931554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860310|NCT02272855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860311|NCT03675672|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860312|NCT05502198|||COHORT||PROSPECTIVE|||||||
33893788|NCT01041092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893789|NCT05155098|||COHORT||PROSPECTIVE|||||||
33961187|NCT01826968|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33961188|NCT04508621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172832|NCT03728868|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34172833|NCT03446625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34172834|NCT06102096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172835|NCT06492005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172836|NCT05980806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172837|NCT02856412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172838|NCT05045885|||COHORT||OTHER|||||||
34172839|NCT00777140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172840|NCT06093906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind|Participants are randomized to receive PATH therapy or PMR.|f|f|f|t
34172841|NCT05963672|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34172842|NCT05192200|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible participants will have completed the treatment period of a qualifying Dermatomyositis parent study. All participants will receive active study drug.||||
34172843|NCT03446755|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||To evaluate the feasibility of a hearth shaped intrauterine balloon as antiadhesion method subsequent to a hysteroscopic adhesiolysis in terms of surgeon's and patient's experience.||||
34172844|NCT01716286|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34172845|NCT04149834|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Single blinded:~* Blinding of the participants is not applicable.~* Blinding of the operator is not applicable.~* Outcome assessor (primary and secondary outcomes) \& biostatistician will be blinded."|"• The patients will be randomly assigned into two groups: Group A (Test): Patients will receive Non-Incised Papilla Surgical Approach (NIPSA)~• Group B (Control): Patients will receive Modified Minimally Invasive Surgical technique (M-MIST)"||||
34172846|NCT04068402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking required|||||
34172847|NCT00261365|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34172848|NCT05872685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172849|NCT03663517|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33860313|NCT03898115|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will be multicenter, cluster randomized, step-wedged design. The unit of randomization will be the inpatient units admitted critically ill patients, with the initial intervention being carried out over 4 months. The study plans to enroll approximately 14 units at 2 sites. Four sequences will be enrolled into the intervention each month; each sequence will have 3-4 units||||
33860314|NCT00934804|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860315|NCT02904434|||COHORT||PROSPECTIVE|||||||
33860316|NCT05898386|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33860317|NCT04910646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33860318|NCT05227547|NA|SINGLE_GROUP||OTHER||NONE||||||
33860319|NCT06493604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860320|NCT05101616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860321|NCT01431534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860322|NCT04173546|||COHORT||PROSPECTIVE|||||||
33860323|NCT00863863|RANDOMIZED|CROSSOVER||||NONE||||||
33860324|NCT00719563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33860325|NCT00490009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860326|NCT02616523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860327|NCT02411682|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33860328|NCT02870413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860329|NCT00139087|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33860330|NCT00986440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860331|NCT00142051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860332|NCT06032936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860333|NCT05066009|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33860334|NCT01240083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961189|NCT05309707|||COHORT||PROSPECTIVE|||||||
33961190|NCT05971745|||OTHER||PROSPECTIVE|||||||
33961191|NCT02120859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961192|NCT05986214|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All patient participants will all be assigned to the VC-OPTIONS implementation strategy||||
33961193|NCT01926301|||CASE_CONTROL||PROSPECTIVE|||||||
33961194|NCT03833856|||CASE_ONLY||PROSPECTIVE|||||||
33961195|NCT03740178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961196|NCT04231994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961197|NCT02203188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961198|NCT06023303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects do not know which side of the face will be treated with either of the devices.|Subjects will be treated with the Potenza device on one side of the face and will receive treatment with Morpheus device on the other side of the face.|t|f|f|f
33961199|NCT00431574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961200|NCT03637920|||COHORT||PROSPECTIVE|||||||
33961201|NCT04596462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961202|NCT01866995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961203|NCT04870931|||COHORT||RETROSPECTIVE|||||||
33961204|NCT03598673|||OTHER||PROSPECTIVE|||||||
33961205|NCT00057252|||OTHER||OTHER|||||||
33961206|NCT03757741|||COHORT||PROSPECTIVE|||||||
33961207|NCT04663711|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33961208|NCT00974610|||OTHER||PROSPECTIVE|||||||
33961209|NCT02059031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961210|NCT01508572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961211|NCT03169699|||CASE_CONTROL||PROSPECTIVE|||||||
33961212|NCT04324307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961213|NCT00323271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961214|NCT03128073|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Intervention study, pilot/ feasibility for proof of concept of peritoneal ultrafiltration with the Carry Life system ultrafiltration (CLS UF)||||
33961215|NCT00244660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961216|NCT02026882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961217|NCT02065882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961218|NCT00282425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961219|NCT04033627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961220|NCT06202807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33961221|NCT06272812|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind||t|t|t|t
33961222|NCT02855788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961223|NCT00734617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34172850|NCT03866070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34172851|NCT01589796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172852|NCT00040586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172853|NCT02148926|||FAMILY_BASED||PROSPECTIVE|||||||
33961224|NCT02639195|||CASE_CONTROL||PROSPECTIVE|||||||
33961225|NCT05886673|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33961226|NCT04592198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961227|NCT03428009|||COHORT||PROSPECTIVE|||||||
33961228|NCT02493985|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33961229|NCT00975884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961230|NCT01196806|||CASE_ONLY||CROSS_SECTIONAL|||||||
33961231|NCT02604238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961232|NCT06537245|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34172854|NCT05557916|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised control trial||||
33961233|NCT04651218|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Masking true propose of study- assessing eating behaviors.|counter balanced crossover design, exercise group and control treatment.|t|f|f|f
33961234|NCT03625752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||single-center, double-blinded, placebo controlled, randomized study.|t|f|t|t
33961235|NCT05393882|||COHORT||CROSS_SECTIONAL|||||||
34172855|NCT00240123|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34172856|NCT02446977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172857|NCT03086096|||CASE_ONLY||PROSPECTIVE|||||||
33860335|NCT02300909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860336|NCT05755529|||COHORT||RETROSPECTIVE|||||||
33860337|NCT01922479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860338|NCT00499954|||DEFINED_POPULATION||OTHER|||||||
33860339|NCT00647751|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33961236|NCT01855100|||COHORT||PROSPECTIVE|||||||
33961237|NCT00102388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961238|NCT05932927|||CASE_CONTROL||PROSPECTIVE|||||||
33961239|NCT00393978|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34172858|NCT04937985|||OTHER||PROSPECTIVE|||||||
34172859|NCT03496259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, family and clinical care team (nurses, residents, physician assistants) will be blinded, as well as the research team collecting outcomes. The surgeons (including primary investigator) will not be blinded as will be placing the device.|Randomized, controlled study|t|t|f|t
34172860|NCT03593902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172861|NCT05581173|||COHORT||PROSPECTIVE|||||||
34172862|NCT05749341|||COHORT||RETROSPECTIVE|||||||
34172863|NCT03727815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34172864|NCT04006288|RANDOMIZED|PARALLEL||TREATMENT||NONE|laboratory personnel running pharmacodynamic testing will be blinded to treatment assignment.|Patients treated with either aspirin (81mg/qd) plus clopidogrel, aspirin (81mg/qd) plus ticagrelor (90mg/bid), or aspirin (81mg/qd) plus prasugrel (10mg/bid) will be identified. Each cohort will be randomized 1:1 to either maintain DAPT or to DPI. DPI consists in treatment with aspirin (81mg/qd) plus rivaroxaban (2.5mg/bid). Patients randomized to DAPT will continue their guideline recommended DAPT regimens.||||
34172865|NCT00002088||||TREATMENT||DOUBLE||||||
34172866|NCT01841281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34172867|NCT03650621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patients are preterm infants and therefore mask, health care providers will be masked as well as outcome assessors.|this is a 2-arm parallel design randomized controlled trial with 3 sites recruiting infants|t|t|f|t
34172868|NCT00149877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34172869|NCT03377582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34172870|NCT05933746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Condition assignment is done automatically, on-line, to two active experiences. Follow-up assessment is done automatically (on-line measure completion).||t|f|t|t
34172871|NCT04620785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172872|NCT04587947|NA|SINGLE_GROUP||TREATMENT||NONE||Heart rate variability measurement is carried out by means of a 12-channel ECG for 30 minutes in supine position followed by 10 minutes in standing position. All parameters, including blood values and echocardiographic parameters are assessed before beginning of sacubitril/ valsartan therapy and 3 months after starting treatment.||||
34172873|NCT06268314|||COHORT||PROSPECTIVE|||||||
33860340|NCT00707850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893790|NCT05418049|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Quadruple masking (participant, care provider, investigator and outcomes assessor)|This study was designed as a 4-intervention crossover, with all study participants receiving all possible interventions. These are placebo, baclofen, roflumilast, and memantine.||||
33893791|NCT05831085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961240|NCT00478673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961241|NCT00003119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961242|NCT01204073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961243|NCT05828745|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33961244|NCT00893867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860341|NCT03318939|NA|SINGLE_GROUP||TREATMENT||NONE||"Each treatment cycle is 28 calendar days in duration. There will be seven participant cohorts and eligible participants will be enrolled into each cohort in parallel based on EGFR or HER2 exon 20 mutation status and prior treatment status:~* Cohort 1: Previously treated participants with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)~* Cohort 2: Previously treated participants with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)~* Cohort 3: Treatment naïve participants with EGFR exon 20 insertion mutant positive NSCLC (fully enrolled)~* Cohort 4: Treatment naïve participants with HER2 exon 20 insertion mutant positive NSCLC~* Cohort 5: Participants who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed~* Cohort 6: Participants with acquired EGFR mutation who progressed while on treatment with first-line osimertinib~* Cohort 7: Participants with EGFR or HER2 activating mutations"||||
33860342|NCT02350179|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33860343|NCT04709822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860344|NCT02245126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860345|NCT04589182|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|During data collection, patients will be blinded to the condition. The leading experimenter will be unblind and have access to the keys that define whether the interventions, namely intervention 1 and intervention 2, are sham or verum. However, all experimenters will be blinded for analysis of outcome measures.|randomized, double-blind, sham-controlled cross-over trial|t|t|f|t
33860346|NCT04922060|||CASE_ONLY||PROSPECTIVE|||||||
33860347|NCT04946903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860348|NCT02297360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860349|NCT06146023|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded for participant groups and number of anastomosis during evaluation of scores.|Comparison of conventional manual microsurgery versus robot-assisted microsurgery|f|f|f|t
33860350|NCT03930368|NA|SINGLE_GROUP||TREATMENT||NONE||In vie of the fact that insulinoma is a rare disease and it will be difficult to enroll enough cases in this study, a prospective single-arm before-and-after study will be performed.||||
33860351|NCT04584203|||COHORT||PROSPECTIVE|||||||
33860352|NCT03570853|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860353|NCT00494858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860354|NCT01509326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860355|NCT05395104|NA|SEQUENTIAL||TREATMENT||NONE||||||
33860356|NCT00892177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860357|NCT00975715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860358|NCT01966393|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860359|NCT05933187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 4-period, 4-sequence crossover study. The 4 treatments are A- 30 milligrams (mg) emraclidine IR tablets (reference); B- 30 mg emraclidine IR test tablets 1; C- 30 mg emraclidine IR test tablets 2; D- 30 mg emraclidine IR test tablets 3. Participants will be randomized to 1 of 4 treatment sequences. Each participant will be administered each of the 4 treatments exactly once, i.e.,1 treatment per period and there will be a 7 day washout period between each treatment.||||
33860360|NCT01873495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860361|NCT00432887|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33860362|NCT02635022|||CASE_ONLY||PROSPECTIVE|||||||
33860363|NCT05398250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860364|NCT02678416|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33860365|NCT05893277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Medical care providers at the recruitment site will be blinded to intervention arm. The intervention and assessment study staff do not overlap and all reasonable care is taken to keep assessment staff blinded to intervention allocation for the whole duration of the study. Investigators know intervention arm on a need to know basis but do not have contact with participants directly.|Randomized controlled trial of 400 married couples, a priori randomized (1:1) to intervention or enhanced usual care. Intervention duration of 3 months, quarterly assessments over a 12 month follow-up period.|f|t|t|t
33860366|NCT05815290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860367|NCT01210079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860368|NCT05419843|NA|SINGLE_GROUP||OTHER||NONE||||||
33860369|NCT05386784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893792|NCT02363179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33893793|NCT01606462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33961245|NCT02440074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961246|NCT05138328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961247|NCT04106401|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||one group wintering at sea level and one group wintering at high altitude||||
33961248|NCT01746849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961249|NCT06542185|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel Assignment a clinical trial with experimental and control groups|t|f|f|f
33961250|NCT02860273|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961251|NCT03250507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, surgical team, nursing team, anesthesia team, and outcomes assessor will be blinded to the group assignment. The anesthetist performing the TAP block will not be blinded to the group assignment.|Patients will be randomized to one of three study groups.|t|t|t|t
33961252|NCT04093973|||CASE_CONTROL||PROSPECTIVE|||||||
33961253|NCT01547273|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33961254|NCT05020626|||COHORT||RETROSPECTIVE|||||||
33961255|NCT00393770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961256|NCT05841706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961257|NCT05409222|||CASE_CONTROL||PROSPECTIVE|||||||
33961258|NCT00720473|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33961259|NCT04822428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized, controlled, parallel study|f|f|f|t
33961260|NCT02139579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961261|NCT02173301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961262|NCT00758706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961263|NCT06418360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961264|NCT05723861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961265|NCT03284866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34172874|NCT05301985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The surgeons, anesthetists, and outcome assessors were masking to the treatment allocation.~A nurse from the Department of Surgery performed the allocation into groups. The night before the operation, the nurse managed the patients according to the assigned intervention, but was not included in the study protocol. The next morning, the surgeon and anesthetist performed open elective colon surgery under general anesthesia, but without knowledge of the type of intervention.~Independent outcomes assessors evaluated patients up to 30 days post-surgery and were also masked, without knowledge of the type intervention."|The patients with diagnosed colon cancer were hospitalized and prepared for elective, open colon surgery at the Department of Surgery. Before surgical procedure, the patients were undergoing to a preoperative anesthetic visit. During the visit, participants were assessed according to eligibility for enrollment in the study. The participants who have met the eligibility criteria have explained the nature of the study protocol. Those who agreed to participate in the study were randomized to one of two study groups for the duration of the study.|f|t|t|t
34172875|NCT02661321|||COHORT||PROSPECTIVE|||||||
34172876|NCT02151487|||OTHER||PROSPECTIVE|||||||
34172877|NCT04722900|||COHORT||PROSPECTIVE|||||||
34172878|NCT00525512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860370|NCT06026228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Masking will be carried out by the hospital pharmacy, which will dispense the appropriate batches to the team, following the randomisation list established by the Methodology and Data Management Centre.~The hospital pharmacy, will keep a batch matching table, which will be made available to the vigilance unit and the Methodology and Data Management Centre.~Masking will be maintained throughout the study."|"This is a study in two parallel groups of equal numbers: control group (placebo) and experimental group (probiotic).~The control group will receive daily a placebo capsule per os at mealtime (just before or after) for a period of 6 months.~The experimental group will receive daily per os one capsule of BioGaia® Gastrus probiotic , taken at mealtime (just before or after) for a period of 6 months."|t|f|t|t
34172879|NCT03082690|NA|SINGLE_GROUP||OTHER||NONE||||||
34172880|NCT02616991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172881|NCT02681809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34172882|NCT04404179|||CASE_ONLY||PROSPECTIVE|||||||
34172883|NCT02897921|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172884|NCT03577275|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34172885|NCT05594459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34172886|NCT03901495|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|"The first 50 eligible patients of the emergency outpatient unit in Geneva University Hospital are recruited into the control group (without access to Diaana). The next 50 eligible patients are recruited into the intervention group (with access to Diaana)."|||||
34172887|NCT01366768|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33860371|NCT03431857|||COHORT||OTHER|||||||
34172888|NCT01422096|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34172889|NCT05057065|||COHORT||RETROSPECTIVE|||||||
33860372|NCT02887807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860373|NCT00498251|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33860374|NCT05529823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Since there is no placebo group, masking only outcomes assessor.|While warm showers will be used during labor in the experimental group, routine midwifery care will be applied in the control group.|f|f|f|t
33860375|NCT01196533|NA|SINGLE_GROUP||SCREENING||NONE||||||
33860376|NCT05032768|||COHORT||PROSPECTIVE|||||||
33860377|NCT05198479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860378|NCT04209465|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33860379|NCT01344746|||CASE_CONTROL||PROSPECTIVE|||||||
33860380|NCT05099653|RANDOMIZED|PARALLEL||OTHER||NONE||"Comparisons of two parallel groups of patients. The constitution of the two groups will be done by randomisation.~* A group of 10 to 12 patients with physical activity (protocolised)~* A group of 10 to 12 patients without physical activity (protocolised)"||||
33860381|NCT04991922|||COHORT||PROSPECTIVE|||||||
33961266|NCT05751928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961267|NCT06134765|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33860382|NCT06170112|||CASE_ONLY||PROSPECTIVE|||||||
34172890|NCT06211439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Using a sham-controlled randomized double-blind design, 64 patients were randomly assigned to either a real or sham stimulation group. In the real stimulation group, stimulation of different frequencies (40Hz gamma, 4Hz theta) is applied to the left dorsolateral prefrontal cortex with a current intensity of 2mA for 20 minutes each day, continuously for 5 days. In the sham stimulation group, the tACS stimulation mode and frequency are the same as in the real stimulation group, but current is only applied during the first and last 30 seconds of the entire 20-minute stimulation period.|t|f|f|t
34172891|NCT03446235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172892|NCT00617786|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172893|NCT03819985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860383|NCT02920086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172894|NCT00400777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172895|NCT05968586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172896|NCT04251117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172897|NCT02113709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961268|NCT02179931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34172898|NCT00708292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961269|NCT01955031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172899|NCT05595837|||COHORT||CROSS_SECTIONAL|||||||
34172900|NCT00635414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961270|NCT04172779|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172901|NCT02490436|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34172902|NCT05273567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961271|NCT06112184|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A prospective, single-arm, feasibility study||||
33860384|NCT05848622|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33860385|NCT02505581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860386|NCT00443638|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33860387|NCT00651872|||COHORT||CROSS_SECTIONAL|||||||
33860388|NCT02101450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961272|NCT05117073|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33961273|NCT06567249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961274|NCT02106611|||COHORT||PROSPECTIVE|||||||
33961275|NCT04428060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961276|NCT06312501|||COHORT||RETROSPECTIVE|||||||
33961277|NCT04962711|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Outcomes assessor will receive study data based on pooled de identified dataset.|Randomization to CO-DMP or usual care|f|f|f|t
33961278|NCT04499430|||COHORT||PROSPECTIVE|||||||
34172903|NCT05419583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172904|NCT05219851|||COHORT||PROSPECTIVE|||||||
34172905|NCT02212639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172906|NCT03046186|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34172907|NCT00003229|RANDOMIZED|||TREATMENT||||||||
34172908|NCT04361708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172909|NCT05829070|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34172910|NCT06705244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172911|NCT03201068|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34172912|NCT00582361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172913|NCT04819126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961279|NCT06111560|||OTHER||RETROSPECTIVE|||||||
33961280|NCT02703974|RANDOMIZED|PARALLEL||||NONE||||||
33961281|NCT01788137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172914|NCT05887882|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34172915|NCT02490735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172916|NCT03804528|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34172917|NCT03753334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172918|NCT05482139|||COHORT||RETROSPECTIVE|||||||
34172919|NCT04218201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860389|NCT05860023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interventions and assessment will be performed by separate researchers.|"Control group will take routine gynecologic treatment. Aerobic exercise group will attend to aerobic exercise programme for seven days. Aerobic exercise will be given with an intensity of 65% to 75% of the maximum heart rate of the individuals monitored by pulse oximeter.Aerobic exercise will take 30 minutes consisting of 5 minutes warm up, 20 minutes jogging, and 5 minutes cool down.~Pelvic floor muscle strengthening group will be asked to perform six pelvic floor muscle strengthening exercise with moderate difficulty, recommended by the national association for incontinence for seven days. These exercises are straight leg raise, oblique reaches, partial curl up-obliques, pelvic tilt with crunch, quadruped hip extension, and bridge with adduction. Prior to discharge exercise sheet will be given to participants to do the exercises at home. Participants will be called daily to question their compliance to the exercise. Participants will be asked to keep exercise diary as well."|f|f|f|t
34172920|NCT05138302|||COHORT||PROSPECTIVE|||||||
33860390|NCT01317212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860391|NCT03150316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860392|NCT02907931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172921|NCT02005549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860393|NCT00174265|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860394|NCT05928091|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Centers will be randomized in two arms :~* control group : each center will manage hemorrhage of participation as they usually did~* interventional group : management of hemorrhage will be guided by the expert team"||||
34172922|NCT04771832|||CASE_CONTROL||PROSPECTIVE|||||||
34172923|NCT00579033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860395|NCT00993135|||COHORT||RETROSPECTIVE|||||||
34172924|NCT06235372|||OTHER||PROSPECTIVE|||||||
34172925|NCT00747903||||TREATMENT||NONE||||||
33860396|NCT02741583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860397|NCT03327116|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860398|NCT00470210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860399|NCT00204971|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33860400|NCT05629195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860401|NCT05426850|||OTHER||PROSPECTIVE|||||||
33961282|NCT03225066|NA|SINGLE_GROUP||TREATMENT||NONE|P.S. To assess the efficacy of Sculptra, via adapted Global Aesthetic Improvement Scale score determined by blind evaluator (Outcomes assessor ), in the treatment of skin flaccidity on the anteromedial region of arm and gluteal region, 4 months after initiating the treatment, based on the assessment of the corporal side randomized to be the first to receive treatment. I input as NO MASKING because appears ERROR when I included Outcomes assessor.|"The study sample will be stratified to include 50% of subjects, who will receive Sculptra treatment on the antero-medial side of the arms and approximately 50% of subjects, who will receive Sculptra treatment in the gluteal area, in order to exploratory analyzes by subgroup.~During the study, the subjects should come to the research site up to nine times: one for the screening/inclusion visit (SV), three treatment visits (TVs) for Side 1 (from 1 to 14 days after SV, and from 1 to 2 months after first session), three TVs for Side 2 (4, 5 and 6 months after the first S1 treatment session), one follow-up visit (FUV), 6 months after the first S2 treatment session) and a final visit (FV) (12 months after the first S1 session). After 4 months of the first treatment we will compare the results between the first treated side and non-treated side."||||
34172926|NCT04909736|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The investigators will use a sequential allocation approach where subsequent parameters of the study are adjusted based on the accrued data. Allocation methods will follow an up and down model, where patients musical exposure time will be determined based on the success or failure of the patient immediately preceding them.||||
34172927|NCT01267799|||OTHER||CROSS_SECTIONAL|||||||
34172928|NCT02163239|||||PROSPECTIVE|||||||
34172929|NCT04551989|||COHORT||PROSPECTIVE|||||||
34172930|NCT00485745|||||RETROSPECTIVE|||||||
34172931|NCT00490087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172932|NCT03080857|NA|SINGLE_GROUP||PREVENTION||NONE||Cohort study to assess a computer simulated electronic platform||||
33860402|NCT01679366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860403|NCT06225635|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860404|NCT04516668|||COHORT||RETROSPECTIVE|||||||
33860405|NCT02687425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172933|NCT01762410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172934|NCT00383552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860406|NCT02993653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860407|NCT06175546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860408|NCT01480284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172935|NCT05918640|NA|SINGLE_GROUP||TREATMENT||NONE||The first part of this study is a standard 3+3 design to test the safety, tolerability and pharmacokinetic profile of lurbinectedin administered on a day 1, 4 schedule in patients with FET-fusion tumors. The second part of this study is a single-stage phase 2 design and will accrue 17 patients in parallel to the exploratory cohort after the Recommended Phase 2 Dose (RP2D) is determined.||||
33860409|NCT00286351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860410|NCT03272568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||During interventional portion of the study, participants will be infused with either Eloctate (hemophilia A carriers) or Alprolix (hemophilia B carriers) to maintain FVIII or FIX \>48hours. Five out of the 16 enrolled patients will self-perform a hemoglobin check every other day using a novel device Anemocheck during 2 consecutive menstrual cycles.||||
33860411|NCT06227208|||COHORT||RETROSPECTIVE|||||||
33860412|NCT00187772|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860413|NCT06190795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to which group the research participants are in|Randomised Blinded Controlled Trial|f|f|f|t
33860414|NCT05373303|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, randomized, active drug-comparative, parallel-designed||||
33860415|NCT01409616|RANDOMIZED|CROSSOVER||||NONE||||||
33860416|NCT00888433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860417|NCT00210756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860418|NCT05754554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860419|NCT02173041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860420|NCT01800357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860421|NCT02624765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860422|NCT01256125|||CASE_CONTROL||RETROSPECTIVE|||||||
33860423|NCT06398860|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||The study uses a stepped wedge cluster-controlled design with open cohort, where workplace acts as a cluster.|f|f|f|t
33860424|NCT04112329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860425|NCT02887937|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33961283|NCT02421770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961284|NCT03503474|||CASE_CONTROL||OTHER|||||||
34172936|NCT04020029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34172937|NCT00379535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172938|NCT01241864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172939|NCT03995147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172940|NCT06271031|||OTHER||RETROSPECTIVE|||||||
34172941|NCT06009965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34172942|NCT01198886|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34172943|NCT04201431|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Group 2 is optional to be added only if fewer than 8 volunteers complete in Group 1.~Up to 6 volunteers from Group 1 will be invited to join Group 3."||||
34172944|NCT06312150|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34172945|NCT00175526|||CASE_ONLY||PROSPECTIVE|||||||
34172946|NCT03621813|NA|SEQUENTIAL||TREATMENT||SINGLE||Cancer survivors will be enrolled in a 6-week delayed entry control period followed by 6-week exercise rehabilitation program.|t|f|f|f
34172947|NCT00520962|||DEFINED_POPULATION||OTHER|||||||
33961285|NCT02672774|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34172948|NCT05541926|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped-wedge design||||
34172949|NCT03388034|||COHORT||PROSPECTIVE|||||||
34172950|NCT06267742|||COHORT||PROSPECTIVE|||||||
34172951|NCT06463093|||COHORT||RETROSPECTIVE|||||||
34172952|NCT00441623|||COHORT||PROSPECTIVE|||||||
34172953|NCT00382486|||||PROSPECTIVE|||||||
34172954|NCT05379179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blinding of the subjects is done by the investigators which is the block randomization; each block will alternate between each drug ketamine or fentanyl. Subject will not be told which pain medication they will receive.|Following enrollment, subject will be randomly assigned to receive either ketamine, or fentanyl. A randomization masterlist has been developed that will be used to assign drug. Subjects will be assigned in sequential order. Each block will alternate between each drug. Subjects will have 50/50 chance of being assigned to ketamine or fentanyl.|t|f|f|f
34172955|NCT03628092|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34172956|NCT04412759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172957|NCT00670579|||COHORT||PROSPECTIVE|||||||
34172958|NCT03904017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34172959|NCT02047812|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34172960|NCT04508946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172961|NCT02481154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961286|NCT05093192|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"A pilot, single-centre, Phase I trial containing 3 groups during different phases of CLL survivorship:~* Cohort 1 (Pre treatment) CLL patients with asymptomatic early-stage disease monitored without anti-CLL treatment.~* Cohort 2 (Treatment) Treatment eligible CLL patients receiving first-line anti-CLL treatment or patients receiving anti-CLL maintenance treatment.~* Cohort 3 (Post treatment) CLL patients in complete remission (CR), complete remission with incomplete marrow recovery (CRi) or partial remission (PR) for at least 6 months following the completion of anti-CLL treatment.~All participants will complete the study intervention."||||
33961287|NCT03196739|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34172962|NCT06088498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172963|NCT05685043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The performing interventional radiologist will be blinded for the result of the perfusion CT scan, except for the information where the occlusion of the major vessel is located.~The assessor of the mRS score at 90 days (primary outcome) will be blinded for the treatment allocation."||f|t|t|t
34172964|NCT01579903|RANDOMIZED|CROSSOVER||||NONE||||||
34172965|NCT05830500|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172966|NCT04507412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The present study will be double blinded: both participants and assessors will be blinded to the assigned treatment. Surgeons will be also blinded, only anaesthetists taking part to surgery will be aware of the group to which the patient was assigned but they will not take part to the follow-up visits.|This study is a 2-arm randomized controlled trial comparing i.v. dexamethasone supplementation (arm-A) and no steroid supplementation (arm-B) for total shoulder arthroplasty|t|f|f|t
34172967|NCT02511665|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33961288|NCT02428634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34172968|NCT00774761|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34172969|NCT05605678|||COHORT||PROSPECTIVE|||||||
34172970|NCT02819921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172971|NCT04921982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172972|NCT00582439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172973|NCT06551051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172974|NCT05408338|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34172975|NCT02962401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172976|NCT01922544|||CASE_CONTROL||RETROSPECTIVE|||||||
34172977|NCT03496493|||COHORT||PROSPECTIVE|||||||
34172978|NCT04463771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172979|NCT04673318|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33961289|NCT01093716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961290|NCT03577119|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||This study will employ a controlled, randomized, double-blinded crossover trial comparing two diets.|t|f|t|t
33961291|NCT01379079|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961292|NCT06537271|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33961293|NCT03944018|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33961294|NCT04266119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33961295|NCT05033028|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33961296|NCT00920400|||||PROSPECTIVE|||||||
34172980|NCT06237725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34172981|NCT01866332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34172982|NCT05493150|||COHORT||PROSPECTIVE|||||||
34172983|NCT00280917|NA|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34172984|NCT02070575|||COHORT||RETROSPECTIVE|||||||
34172985|NCT02962700|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34172986|NCT05605808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer randomization.|The model is composed of the aerobic and diet protocol group (Group A), the diet protocol group (Group B), and the aerobic training group (Group C).|f|f|f|t
34172987|NCT05298722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34172988|NCT03816696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34172989|NCT02590796|||OTHER||OTHER|||||||
34172990|NCT04522895|NA|SINGLE_GROUP||TREATMENT||NONE||single arm||||
34172991|NCT06432634|RANDOMIZED|PARALLEL||TREATMENT||NONE|The blinding of patients to their treatment group allocation is unattainable owing to the inherent nature of the exercise intervention.|||||
34172992|NCT00770653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34172993|NCT06155526|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34172994|NCT01998750|||COHORT||PROSPECTIVE|||||||
34172995|NCT00841841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34172996|NCT01260649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34172997|NCT05442840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The care provider (physician) will be aware the patient is participating in the study but will not be informed directly as to which arm they will be enrolled in, however if they review the electronic chart record they will be able to identify which arm|Participants will be randomly assigned to 1 of 2 arms, either control or pharmacist intervention|f|t|f|f
34172998|NCT02547311|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34172999|NCT05665036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173000|NCT04761601|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173001|NCT05400135|NA|SINGLE_GROUP||PREVENTION||NONE||The study utilizes a hybrid design with a two group community level four year interrupted time series design with an embedded five group community level dynamic wait-listed design. Youth participants (12-18 years) in each community are assigned to a single treatment group.||||
34173002|NCT03732339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173003|NCT02945579|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173004|NCT06262152|||COHORT||PROSPECTIVE|||||||
33750515|NCT04989790|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Stepped-wedge cluster Randomized Controlled Trial|f|f|f|t
33750516|NCT04635553|||COHORT||PROSPECTIVE|||||||
33961297|NCT02300818|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34173005|NCT00387881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173006|NCT06378021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173007|NCT02991183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34173008|NCT05526560|||CASE_ONLY||PROSPECTIVE|||||||
34173009|NCT00006088||||TREATMENT||||||||
34173010|NCT03058120|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34173011|NCT05302674|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173012|NCT01983475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34173013|NCT00079326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173014|NCT00555958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173015|NCT06676657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173016|NCT04237467|||COHORT||CROSS_SECTIONAL|||||||
34173017|NCT00298324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173018|NCT02534376|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34173019|NCT05672251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173020|NCT01298479|||OTHER||PROSPECTIVE|||||||
34173021|NCT04580017|||COHORT||PROSPECTIVE|||||||
34173022|NCT06482346|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34173023|NCT02544321|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34173024|NCT00474812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860426|NCT05620043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, single-center, comparative study|t|f|f|f
33860427|NCT06503094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860428|NCT02415465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860429|NCT04157140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173025|NCT01546103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860430|NCT03726762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173026|NCT02367573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173027|NCT01279434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173028|NCT02122016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860431|NCT05171439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173029|NCT00107653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860432|NCT02199808|||COHORT||CROSS_SECTIONAL|||||||
34173030|NCT05716477|||COHORT||PROSPECTIVE|||||||
34173031|NCT02070146|||COHORT||PROSPECTIVE|||||||
33860433|NCT03972007|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34173032|NCT05690451|||COHORT||PROSPECTIVE|||||||
34173033|NCT03630536|||OTHER||OTHER|||||||
34173034|NCT03724942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750517|NCT06564441|NA|SINGLE_GROUP||TREATMENT||NONE||The trial consists of two periods in a fixed sequence: period 1 (reference treatment) followed by period 2 (test treatment) within the BI 456906 titration scheme.||||
33860434|NCT00190632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860435|NCT03538379|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Individuals will complete the bleeding control basic (B-Con) course followed by evaluation of individuals ability to apply each of 5 different types of tourniquets. Each individual is evaluated for all 5 types of tourniquets. The order of testing for tourniquets for each individual is randomized.||||
33860436|NCT05202717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860437|NCT00509665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860438|NCT02797210|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33860439|NCT02884765|||CASE_ONLY||PROSPECTIVE|||||||
33860440|NCT01704833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860441|NCT03521414|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33860442|NCT00375219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860443|NCT06339255|||COHORT||PROSPECTIVE|||||||
33860444|NCT04903808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and outcome assessor will be blinded (double blind study )|It is a double-blinded randomised clinical trial with equal randomisation parallel design with allocation ratio 1:1|t|f|f|t
33860445|NCT01222637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173035|NCT03562195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind study. Subjects and investigator will be masked.|Eligible subjects will be randomized in 1:1 ratio to receive either mepolizumab or placebo along with existing standard of care therapy during the treatment period.|t|f|t|f
34173036|NCT06379789|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173037|NCT02787928|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34173038|NCT00442169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33750518|NCT02172755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750519|NCT02540018|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33750520|NCT03541070|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750521|NCT03492281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860446|NCT00874666|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33860447|NCT05111847|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||crossover in first part, parallel in second part||||
33860448|NCT03558256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860449|NCT06234254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860450|NCT01778660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860451|NCT00556920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860452|NCT01581541|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33860453|NCT02842840|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33860454|NCT04377828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860455|NCT03749603|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|no masking required. assessments are both done on same subjects.|Exploratory, interventional, one arm study||||
33860456|NCT00388154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860457|NCT00530296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33860458|NCT03142438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860459|NCT01688583|||COHORT||PROSPECTIVE|||||||
33860460|NCT06102577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The patient is randomized at the end of the treatment and the person in charge of collecting the data does not know which group each patient belongs to.||t|t|t|t
33860461|NCT06491407|||COHORT||CROSS_SECTIONAL|||||||
33860462|NCT01009203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860463|NCT05265910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-masked||t|f|t|f
33860464|NCT04260009|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33860465|NCT03299751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860466|NCT02798263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860467|NCT03445923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled trial|t|t|f|t
33860468|NCT01822977|NA|SINGLE_GROUP||||NONE||||||
33961298|NCT00004086||||TREATMENT||||||||
33961299|NCT06221683|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33961300|NCT02998515|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33961301|NCT00423488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961302|NCT05718882|NA|SINGLE_GROUP||TREATMENT||NONE||Bayesian Optimal Interval design||||
33961303|NCT02204774|||COHORT||PROSPECTIVE|||||||
34173039|NCT00691613|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34173040|NCT05915208|||COHORT||RETROSPECTIVE|||||||
34173041|NCT02928679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750522|NCT05197894|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||ESAS scores for 5 key symptoms (pain, shortness of breath, depression, anxiety, and well-being) and qualitative question(s) will be asked verbally by one of the investigators and recorded on an ipad directly into the Qualtrics form, before and after the VR session. Vital signs (blood pressure, heart rate, respiratory rate) will also be measured before and after the VR session. Participants will be given a list of VR applications to choose from. They will then be given instructions by a research assistant (approximately 10 minutes) on how to use the selected application using Oculus Quest 2 they have chosen, as well as time for any questions they may have before starting their VR experience. They will then have an approximately 30-minute session of that VR experience. They may or may not be accompanied by a family member or significant other and will also have a research assistant available to aid them in any difficulties experienced during the VR experience.||||
33860469|NCT05543655|NA|SINGLE_GROUP||OTHER||NONE||10 training courses including 4 nurses each are scheduled, i.e. 40 inclusions. The nurses will benefit from two half-days of simulation training three-months apart, dealing with the safety of medication administration. The training will include a high-fidelity scenario whose events will be adapted to medication administration in conventional care services.||||
33860470|NCT03159741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33860471|NCT04181944|NA|SINGLE_GROUP||OTHER||NONE||||||
33860472|NCT02080455|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33860473|NCT02883530|||COHORT||PROSPECTIVE|||||||
33860474|NCT05097716|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33860475|NCT00538304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860476|NCT01494454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860477|NCT02868177|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34173042|NCT06159621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned in an alternating fashion to Arm A (PD1 - LVGN 3616) or Arm B (PD1 LVGN 3616)+CD40 (LVGN 7409)). At a separate infusion visit after enrollment, patients in arm A or arm B will receive a single administration of LVGN3616 (300 mg.) or LVGN3616 (300 mg.) and LVGN7409 (1mg/kg), respectively. In case of patient drop-out after screening/consent and before drug administration, that slot will be assigned to the next available patient||||
34173043|NCT02882958|||COHORT||PROSPECTIVE|||||||
34173044|NCT00823862|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34173045|NCT05183061|||CASE_CONTROL||RETROSPECTIVE|||||||
34173046|NCT05093855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173047|NCT04202848|||COHORT||PROSPECTIVE|||||||
34173048|NCT00758771|||CASE_CONTROL||PROSPECTIVE|||||||
34173049|NCT06173336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173050|NCT04024150|||CASE_CONTROL||PROSPECTIVE|||||||
34173051|NCT04891614|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, open-label study||||
33750523|NCT05074628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750524|NCT03299010|||COHORT||RETROSPECTIVE|||||||
33750525|NCT03328754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was done with Simple Randomisation method to ensure 1:1 allocation ratio and allocation concealment was achieved with similar looking sealed opaque envelopes. The name of the groups 'Forsus' and 'PowerScope' were written on 13 pieces of paper resulting in total 26 pieces of paper which were folded and shuffled in a box, then taken out and without opening put in 26 opaque envelopes which were then sealed and kept again in the box. The envelopes were shuffled inside the box each time the patient was asked to pick one envelope from the box .The patient was assigned to the group mentioned in the envelope which was opened by the primary investigator who was not involved in data analysis..|Comparative evaluation of treatment effects of PowerScope and Forsus|t|f|f|t
33860478|NCT01685736|||CASE_ONLY||PROSPECTIVE|||||||
33860479|NCT04190433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33860480|NCT02009891|||OTHER||PROSPECTIVE|||||||
33860481|NCT00954174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860482|NCT04286568|NA|SINGLE_GROUP||PREVENTION||NONE||quasi-experimental non-randomized||||
33860483|NCT02711618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860484|NCT00564304|||CASE_ONLY||PROSPECTIVE|||||||
33860485|NCT00471796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860486|NCT05659433|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33860487|NCT02292368|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33860488|NCT01031264|||COHORT||PROSPECTIVE|||||||
33860489|NCT01209312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860490|NCT00982007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860491|NCT06287723|||COHORT||PROSPECTIVE|||||||
33860492|NCT01881581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860493|NCT03035903|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173052|NCT04662385|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|third professional person give the one of opaque coded toothpaste to the participant|twenty-four adult patients with generalized gingivitis participated in the double blinded randomized controlled crossover study divided into two groups, aloe vera and colgate toothpaste used during seven days , one group received aloe vera toothpaste twice times daily and the second group received colgate toothpaste twice dialy .|t|f|t|f
34173053|NCT05241262|NA|SINGLE_GROUP||TREATMENT||NONE||18 Carrier relatives will participate in a dose finding study of NAC.||||
33860494|NCT05211739|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34173054|NCT03475667|||COHORT||CROSS_SECTIONAL|||||||
34173055|NCT00231816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33860495|NCT02755623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173056|NCT05134688|||COHORT||PROSPECTIVE|||||||
34173057|NCT01064440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173058|NCT06117930|||COHORT||PROSPECTIVE|||||||
33860496|NCT04817891|NA|SINGLE_GROUP||TREATMENT||NONE|Investigator, Outcomes Assessor, and Participant/Care Provider will all know the participant is receiving intervention/stimulation. There is no placebo condition.|Eligible participants receive individualized intervention/stimulation based on their fMRI and PET imaging.||||
33750526|NCT01108848|||COHORT||PROSPECTIVE|||||||
33750527|NCT01460940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750528|NCT00974324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750529|NCT02157805|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33750530|NCT04656834|||COHORT||PROSPECTIVE|||||||
33750531|NCT03214562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750532|NCT01774149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750533|NCT05662033|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"The study consists of 4 parts:~Part 1 (SAD): In this part, healthy participants will be randomised in 5 cohorts (may add up to 3 additional cohorts) to receive AZD6793 with 8 evaluable participants in each cohort.~Part 2 (MAD): In this part, healthy participants will be randomised in 3 cohorts (may add up to 3 additional cohorts) to receive AZD6793 with 8 evaluable participants in each cohort.~Part 3 (Bioavailability and Food Effect Cohort): In this cohort, 15 healthy participants will be randomised to receive AZD6793 with 12 evaluable participants.~Part 4 (COPD Cohort): 15 COPD participants will be randomised in the ratio 2:1 to receive AZD6793 or placebo."|t|f|f|f
33750534|NCT04934865|NA|SINGLE_GROUP||OTHER||NONE||||||
33750535|NCT05931692|||OTHER||CROSS_SECTIONAL|||||||
33750536|NCT04389099|||CASE_CONTROL||PROSPECTIVE|||||||
33750537|NCT00002574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750538|NCT05729763|||COHORT||PROSPECTIVE|||||||
33860497|NCT05051137|||COHORT||OTHER|||||||
33860498|NCT03876990|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Randomized assignation. Half of the patients will be diagnosed by the rapid test in addition to current diagnosis strategy and the other half by current diagnosis strategy alone.|t|f|f|f
33860499|NCT03127150|||COHORT||PROSPECTIVE|||||||
33860500|NCT01419353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860501|NCT04256603|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860502|NCT06072560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860503|NCT00064389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173059|NCT04291846|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34173060|NCT02457390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173061|NCT02845323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173062|NCT05409209|||COHORT||PROSPECTIVE|||||||
34173063|NCT04094597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Follow up of the patients with CRP and different cultures.|placebo group 100 patient will receive 2 ml saline for one month in comparison with oral lactoferrin for the same period to another 100 patient|f|f|t|f
34173064|NCT00951353|||COHORT||PROSPECTIVE|||||||
34173065|NCT03744910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173066|NCT03253302|||CASE_ONLY||PROSPECTIVE|||||||
34173067|NCT05535894|||COHORT||PROSPECTIVE|||||||
34173068|NCT00003714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173069|NCT03921749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||group A : focused shock wave, group B: focused shock wave|t|f|t|t
34173070|NCT05097820|||COHORT||PROSPECTIVE|||||||
34173071|NCT01884051|||COHORT||PROSPECTIVE|||||||
34173072|NCT03309969|||COHORT||PROSPECTIVE|||||||
33750539|NCT02280044|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860504|NCT04695496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860505|NCT04260802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860506|NCT00340210|||COHORT||PROSPECTIVE|||||||
33860507|NCT00820937|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33860508|NCT04560569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860509|NCT05536609|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randmoised controlled study||||
33860510|NCT03587857|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33860511|NCT05683249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Placebo-controlled, parallel-arm design.|t|t|t|t
33860512|NCT05559021|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized clinical trial will be conducted between October 2022 and December 2023 in 52 female patients impacted by Fibromyalgia who will undergo a myofascial treatment approach or mobilization treatment approach , with 3 months of follow-up post-treatment.||||
33750540|NCT02650869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860513|NCT05715853|||COHORT||PROSPECTIVE|||||||
33860514|NCT04401969|||CASE_ONLY||CROSS_SECTIONAL|||||||
33860515|NCT01351623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860516|NCT04087954|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33860517|NCT02870569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860518|NCT06072287|||COHORT||PROSPECTIVE|||||||
34173073|NCT05230940|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Only the study nurse is unblinded.|Multi-Centered, Randomized, National, Observer-blinded, Active-controlled, Phase IIB|t|t|t|t
34173074|NCT02916186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173075|NCT06123377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173076|NCT05836441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173077|NCT04579991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Pharmacist will provide the same color and texture of product and identical package for both active emulgel and emulgel only products. She is the only person who knows the code of product and prepare the product in the opaque envelop for all participants.~The statistician will generate the code of product to all participants with block-of-four randomization method.~The nurse will distribute and help the participants fill all questionnaires."||t|t|t|t
33860519|NCT00782288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34173078|NCT04090918|||CASE_CONTROL||PROSPECTIVE|||||||
33860520|NCT05427721|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Capsules with the same characteristics (smell, color, taste). Random assignment.|Clinical trial|t|f|t|f
33860521|NCT02778256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860522|NCT03990857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34173079|NCT05718947|||COHORT||PROSPECTIVE|||||||
34173080|NCT04427527|RANDOMIZED|FACTORIAL||SCREENING||TRIPLE|Primary care clinics randomized to usual care do not receive intervention materials or attention|Primary care clinics randomized to intervention or usual care|t|t|f|t
33860523|NCT00001023|RANDOMIZED|||TREATMENT||||||||
33860524|NCT05541211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients and independent investigators collecting outcome data will be blinded.|The randomization sequence will be generated by Microsoft Excel software. Blocked randomization will be done with an allocation ratio of 1:1. This will be prepared by a statistician unaware of the nature of the clinical study. The sequence will be concealed in opaque envelopes and opened by an investigator just before the procedure. The patients and independent investigators collecting outcome data will be blinded|t|f|t|t
33860525|NCT03672877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physical therapy assessors will be blinded to the child's group assignment.|Participants will be randomly assigned to receive 3 months of intervention immediately (Immediate Group) or to be observed for 6 months (Delay Group). Participants in the Delay Group will be offered the intervention once the observation period is complete.|f|f|f|t
33860526|NCT04292002|NA|SINGLE_GROUP||PREVENTION||NONE|Not relevant|The investigators are looking at uptake and reach of general health checks offered to up to 650 employees in the construction industry.||||
33860527|NCT00324129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860528|NCT04740528|||CASE_ONLY||CROSS_SECTIONAL|||||||
33860529|NCT00493545|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33860530|NCT01842685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173081|NCT04640441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Participants who were screened as failure to sit-to-stand after discharged from medication ICU 48 hours were enrolled in the study. In the assignment procedure, participants were stratified by able to remain sitting upright without falling or unable to remain sitting upright and then 1:1 randomly assigned to the intervention or usual care groups. Participants in intervention group received both usual care and an STS care once daily for two weeks or discharged within two weeks or death. In contrast, control group will accept regular care. Participants were followed for one year after ICU discharge at 5 point:48 hours, 14day, 1, 3, and 12 months. A comprehensive functional evaluation (success rate of sit-to-stand, scores of FSS-ICU, scores of MRC scale, muscle strength at knee extensors, scores of barthel index for ADL, scores of IADL, walking distance by 6-minute walk test, numbers of sit-to-stand repetitions in 30 seconds) and rates of bed-bound status and mortality were performed."|f|f|f|t
33860531|NCT00293722|||COHORT||PROSPECTIVE|||||||
34173082|NCT03177902|||COHORT||PROSPECTIVE|||||||
33860532|NCT04580862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33860533|NCT05615324|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The research assistants and ph.d.-students in charge of the assessment are blinded in regards to which treatment the families have received. All outcome scores are set in consensus with the other outcome assessors. In case of unblinding, it is the team setting the score, not the assessor.|SAFIR Family Talk is i randomized controlled trial carried out in the capital region of Denmark. The trial examines the Family Talk intervention, developed by William Beardslee, as opposed to service as usual (SAU) in out patient clinics in the public health sector in the capital region of denmark. All participating families will be assessed at baseline, 4 months follow-up and 12 months follow-up.|f|f|t|t
33860534|NCT04630756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173083|NCT05511181|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173084|NCT03001557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173085|NCT05645718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860535|NCT03167957|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34173086|NCT05931081|||CASE_ONLY||PROSPECTIVE|||||||
33860536|NCT03782142|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750541|NCT04681339|||COHORT||PROSPECTIVE|||||||
34173087|NCT06151522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34173088|NCT06138899|RANDOMIZED|PARALLEL||OTHER||NONE||Hybrid Type I implementation-science cluster-randomized clinical trial||||
34173089|NCT00910104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173090|NCT04647539|||COHORT||RETROSPECTIVE|||||||
33750542|NCT04618185|||COHORT||PROSPECTIVE|||||||
33750543|NCT05735067|||COHORT||CROSS_SECTIONAL|||||||
33750544|NCT02100176|||COHORT||PROSPECTIVE|||||||
33750545|NCT03025906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750546|NCT06236022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750547|NCT02394782|||COHORT||PROSPECTIVE|||||||
33961304|NCT01846052|||COHORT||PROSPECTIVE|||||||
34173091|NCT06453538|||CASE_CONTROL||PROSPECTIVE|||||||
34173092|NCT00493493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173093|NCT01725906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961305|NCT06236152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single blind study protocol was followed.|Patients were randomly assigned to two groups, A and B using lottery method. Group A is receiving the standard of care treatment for tuberculosis plus steroids in a low dose (10 mg per day) whereas Group B is receiving the standard of care plus a placebo|t|f|f|f
34173094|NCT03664297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173095|NCT05198817|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-2002 injection monotherapy and in combination with other anti-cancer therapy||||
34173096|NCT03820544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961306|NCT04713228|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34173097|NCT04532268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173098|NCT03363737|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34173099|NCT00210535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173100|NCT05620667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173101|NCT03482622|||OTHER||RETROSPECTIVE|||||||
34173102|NCT05220722|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1b: Escalating doses of SD-101 will be administered alone (Cohort A), together with pembrolizumab (Cohort B), or together with combined ipilimumab and nivolumab. Three weekly doses of SD-101 are delivered over two cycles via HAI using the Pressure Enabled Drug Delivery (PEDD) method of administration.~Phase 2: Three weekly infusions of SD-101 will be delivered via PEDD/HAI over two cycles at the dose selected from Phase 1b in combination with systemic single- or dual-agent checkpoint blockade."||||
34173103|NCT04635449|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm, parallel-group, single centre, randomised controlled trial||||
34173104|NCT01998256|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34173105|NCT00832663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34173106|NCT03392935|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome assessors are masked and will not know which photos are pre-treatment or follow-up visit 1, however, they do know that all subjects received treatment at some point. They will rate the dermatofibromas to determine efficacy. However, there is only one arm of this study. All patients are receiving the same treatment. Outcomes assessors are the only masked roles.|All subjects will have their dermatofibromas treated with the laser at week 0, and week 4. Blinded outcome assessors will rate photos (pre-treatment and follow-up visit 1) to determine efficacy.||||
34173107|NCT05485740|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group which received the selected exercise program and the study group received the same exercise training program in addition to cognitive multisensory rehabilitation program||||
34173108|NCT00625131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173109|NCT04828421|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34173110|NCT00938158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173111|NCT01048879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173112|NCT04890652|NA|SINGLE_GROUP||PREVENTION||NONE||"All participants received a 4-week digital intervention, Emotion regulation via Breathing for Alcohol reduction (EBA), which combines alcohol intervention with stress reduction techniques based on self-regulated breathing exercises. The preliminary efficacy of this digital intervention was evaluated through assessments conducted before and immediately after the intervention, as well as during a follow-up assessment 30 days later."||||
33961307|NCT04101084|NA|SINGLE_GROUP||TREATMENT||NONE||to evaluate the effect of the rocking chair therapy in agitation for home care residents with dementia.||||
33961308|NCT04598685|||COHORT||CROSS_SECTIONAL|||||||
33961309|NCT04030884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Participants were blinded regarding which gastrointestinal complication was going to be evaluated after the surgery. Participants were informed that the intervention was for postoperative gastrointestinal comfort, without nausea and vomiting being mentioned in order to avoid psychological leading to PONV.~The nurses who collected the data were blinded for the group information (intervention or control) though they were informed the days of participant allocation (each morning they were informed that the current operating list included participants) for the proper use of the data collection forms."|Randomized controlled trial with two types of surgery compared, each consisting intervention and control groups.|t|t|f|t
34064334|NCT06516874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After randomization, the research assistance in charge of the end-of-treatment and follow-up measurements, as well as the person performing the preliminary effectiveness analyses, will be blinded. Patients and therapists are not blinded, they are aware of the intervention received and implemented.|This study is a superiority pilot/feasibility study. Participants will be randomized to intervention or control group|f|f|f|t
34173113|NCT00297544|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
34173114|NCT01898455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173115|NCT04321018|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Crossover Assignment|t|t|t|t
34173116|NCT01698489|||OTHER||CROSS_SECTIONAL|||||||
34173117|NCT06179108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Patients will be randomized 3:3:3:1 to receive with placebo (n \~ 105), 50 mg LB-102 QD (n \~ 105), 75 mg LB-102 QD (n \~ 105), 100 mg LB-102 QD (n \~ 35) orally.|t|t|t|t
34173118|NCT02927301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173119|NCT04839510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173120|NCT02515747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173121|NCT03983733|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860537|NCT01903018||PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173122|NCT00291616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173123|NCT04368026|||OTHER||CROSS_SECTIONAL|||||||
34173124|NCT05711810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The crossover model intervenes on the precarditis and myocarditis happenings on the patient, and evaluates the cause of the symptoms. Basic medicines are tested against the pathogens with the immune responses of the patient.||||
34173125|NCT02149914|NA|SINGLE_GROUP||SCREENING||NONE||||||
33860538|NCT04169386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34173126|NCT04392739|NA|SINGLE_GROUP||OTHER||NONE||||||
34173127|NCT03327493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Refractory cardiogenic shock patients under ECLS. Assessment at ECLS start, day 3 and Day ECLS weaning for various biological variables"||||
34173128|NCT05332600|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34173129|NCT00908986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173130|NCT00783523|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34173131|NCT01590784|||||CROSS_SECTIONAL|||||||
34173132|NCT03763032|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Because this is a pilot study, all participants will be receiving the same intervention and no blinding will take place.|All patients will be assigned a patient navigator, who will provide a psychosocial assessment and palliative counselling||||
34173133|NCT06316830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173134|NCT04762511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173135|NCT03392064|NA|SEQUENTIAL||TREATMENT||NONE||||||
34173136|NCT03939000|||CASE_ONLY||RETROSPECTIVE|||||||
34173137|NCT01075243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173138|NCT02022059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173139|NCT05597202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173140|NCT04722614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Computer generated randomization (www.randomizer.org) will be used to randomly assign patients to groups. Information of allocation was available to the principal researcher only. Patients will be assigned in sequential numbers that will be placed in an opaque, sealed envelope by the researcher. After patients enrollment, the envelope will be opened. The nurses could not be blinded to the allocation because of the nature of the intervention. However, the outcome assessment of the patients was blinded.|Three-group pre-test and repeated post-test study|f|t|f|f
34173141|NCT00675181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34173142|NCT04044690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173143|NCT03858101|||OTHER||CROSS_SECTIONAL|||||||
34173144|NCT00761475|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33860539|NCT02547233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860540|NCT02801903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860541|NCT05817760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860542|NCT04757532|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Single-center, non-randomized, unblinded, uncontrolled clinical trial in healthy male volunteers, at a single dose of the five study drugs (bupropion, anastrozole, testosterone cyclopentylpropionate, danazol and chlorthalidone).||||
33860543|NCT04815954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomisation will be supervised centrally by the leader center. Generated numbers will be closed in non-transparent envelopes numbered sequentially and shipped to each participating center. A center is supposed to use the envelopes for group assignment consecutively with increasing numbers.||f|t|t|f
33860544|NCT01143103|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860545|NCT02882919|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33860546|NCT04322422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33860547|NCT01788267|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33860548|NCT02563093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961310|NCT05301452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not know whether they belong to the placebo group, or the active photobiomodulation group, seeing as the laser application will be simulated.||t|f|f|f
33961311|NCT04388527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064335|NCT04241393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173145|NCT03255408|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173146|NCT06343831|NA|SINGLE_GROUP||OTHER||NONE||Patients planning to undergo autologous fat transfer for breast or chest wall reconstruction will be enrolled prospectively. Participants will undergo standard photographs (2-D imaging) of their chest wall and torso, including the breasts, and complete a validated questionnaire (BREAST-QTM) to evaluate patient satisfaction, and quality of life, all standard of care. The 3D photographs, MRI, and US are routinely used in practice but will be performed for research purposes in this study.||||
34173147|NCT04413071|||COHORT||CROSS_SECTIONAL|||||||
34173148|NCT01537666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173149|NCT03655132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in Phase 3 will be randomly assigned to either a wait-list control condition, or to receive the intervention of VACT-CP, including the 8 online-module based weekly sessions of treatment.||||
34173150|NCT03813355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34173151|NCT05746611|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34173152|NCT04196686|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173153|NCT01358877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173154|NCT03159416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-Label|||||
34173155|NCT03757546|||COHORT||PROSPECTIVE|||||||
34173156|NCT00232765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173157|NCT05541458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173158|NCT02493439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173159|NCT04648280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173160|NCT06177977|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34173161|NCT05188586|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34173162|NCT01288573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860549|NCT01009034|||COHORT||PROSPECTIVE|||||||
33860550|NCT02460497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860551|NCT05687643|||CASE_CONTROL||PROSPECTIVE|||||||
33860552|NCT02626325|||||RETROSPECTIVE|||||||
33860553|NCT00315003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173163|NCT05280340|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation||||
33860554|NCT00472329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860555|NCT03272542|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, placebo-controlled pilot trial with a parallel-arm design|t|t|t|t
33860556|NCT04620811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173164|NCT00774371|RANDOMIZED|PARALLEL||PREVENTION||NONE||Weight list control group was the comparison to the immediate treatment group.||||
34173165|NCT05763810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860557|NCT05665088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blinded|Randomized|f|f|t|t
33860558|NCT03798223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatment protocol is masked for the patient and for the nurses conducting measures of intraocular pressure during follow-up.||t|f|f|t
33860559|NCT05138523|||OTHER||PROSPECTIVE|||||||
33860560|NCT01103635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860561|NCT03539783|||CASE_CONTROL||PROSPECTIVE|||||||
33860562|NCT06046755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Postmenopausal women (n=130) diagnosed with primary, histologically confirmed, incident postmenopausal breast cancer and with 50-70 years at diagnosis will be recruited. A group of 60 breast cancer patients with obesity (BMI≥30) will be invited to follow a weight loss treatment based on a 4 months-energy restriction-ketogenic intervention arm or a behavioural group intervention. Those groups will be compared with a non-intervention control arm of with 30 breast cancer with obesity and 30 normal weight women.~On the other hand, a group of 90 tumor-free postmenopausal women (50-17 years) will be recruited in the Endocrinology and Nutrition Service of reference hospitals where 30 women will have a normal weight and the other 60 will be women with obesity. These last women will be subjected to a 4 months-energy restriction-ketogenic intervention arm or a behavioural group intervention and compared with a group of tumor-free normal weight subjects."|t|t|t|f
33860563|NCT06101953|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33860564|NCT00528866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860565|NCT05091723|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860566|NCT01605253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860567|NCT01478360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860568|NCT01572701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860569|NCT00168480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961312|NCT05365347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The psychometrist assessing participant outcomes will not be aware of the participants allocation.|24 participants who will be randomized to either treatment as usual in an Early Intervention for Psychosis Service (EIS) with 1 hour of psychoeducation or EIS plus cognitive enhancement therapy for alcohol misuse.|f|f|f|t
33961313|NCT01304017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173166|NCT01380353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173167|NCT04516746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind: two or more parties are unaware of the intervention assignment.|Participants are assigned to one of two or more groups in parallel for the duration of the study.|t|t|t|t
34173168|NCT03252769|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173169|NCT00517296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeon did not have access to EUS data for the control group prior to exam under anesthesia (EUA) and surgical intervention.||f|t|f|f
34173170|NCT04002817|||CASE_ONLY||RETROSPECTIVE|||||||
34173171|NCT05736666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173172|NCT05094622|NA|SINGLE_GROUP||TREATMENT||NONE||single subject design||||
34173173|NCT00837382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173174|NCT02714400|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34173175|NCT03114319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173176|NCT01045967|RANDOMIZED|CROSSOVER||||NONE||||||
34173177|NCT04730908|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|the products are coded with different color in the label.|Crossover study testing 4 dental gel for brushing teeth. the brushing period of use :7 days, 3 times daily with wahs-out periods of one week.|t|t|t|f
34173178|NCT02914158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860570|NCT05165147|||OTHER||RETROSPECTIVE|||||||
33860571|NCT03933397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33860572|NCT02690805|||CASE_ONLY||PROSPECTIVE|||||||
33860573|NCT02315677|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33860574|NCT06243471|||CASE_CONTROL||PROSPECTIVE|||||||
33860575|NCT04062253|||COHORT||OTHER|||||||
33860576|NCT05777096|||COHORT||CROSS_SECTIONAL|||||||
33860577|NCT01335919|||COHORT||PROSPECTIVE|||||||
33860578|NCT04760886|||COHORT||RETROSPECTIVE|||||||
33860579|NCT04968197|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33860580|NCT00126633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860581|NCT00122928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860582|NCT04293289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860583|NCT02710773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33860584|NCT02064855|||COHORT||PROSPECTIVE|||||||
33860585|NCT01698983|||COHORT||PROSPECTIVE|||||||
33860586|NCT04193267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860587|NCT05737966|||OTHER||PROSPECTIVE|||||||
33860588|NCT04338555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33860589|NCT01108250|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33860590|NCT03358511|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860591|NCT00350662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860592|NCT05107050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This protocol is double-blinded. Subjects will be randomized 1:1 to have their wound cleansed with either NSS-HG and AMC-AMG. Unblinded staff will prepare the solutions for the two arms the morning of the day of enrollment. NSS-HG and AMC-AMG will be placed in labeled containers consistent with the randomization scheme. Finally, the unblinded research staff will provide the subject with their 4-week supply of NSS-HG and AMC-AMG to take home. The unblinded staff will not assess the study ulcer.|Randomized double-blind controlled clinical trial comparing a synergistic antimicrobial cleanser and gel to normal saline comparing to an amorphous gel in reducing bioburden and promoting healing in chronic lower extremity ulcers|t|f|t|f
33860593|NCT06486350|||COHORT||PROSPECTIVE|||||||
33860594|NCT05483205|||CASE_ONLY||PROSPECTIVE|||||||
33860595|NCT04916041|||COHORT||PROSPECTIVE|||||||
33860596|NCT02717754|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33860597|NCT00198549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860598|NCT06041386|NA|SINGLE_GROUP||OTHER||NONE|There will be no masking in this study.|||||
33860599|NCT03226405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860600|NCT06143085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860601|NCT01397864|||COHORT||PROSPECTIVE|||||||
33860602|NCT04657419|||COHORT||PROSPECTIVE|||||||
33860603|NCT02204566|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33860604|NCT01691391|||COHORT||PROSPECTIVE|||||||
33860605|NCT05370066|NA|SINGLE_GROUP||OTHER||NONE|open label study|Data collection for algorithm development CS6BP data will be collected in parallel with commercially available blood pressure monitor measurement.||||
33860606|NCT03483558|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33860607|NCT00162032|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860608|NCT02800226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860609|NCT02701426|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33860610|NCT01213589|||COHORT||PROSPECTIVE|||||||
33860611|NCT00576836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860612|NCT04498455|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized placebo-controlled trial of a fiber supplement \[Prebiotin\] compared to placebo \[maltodextrin\]|t|f|f|f
33860613|NCT03725163|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized using block randomization to be assigned to a waitlist control condition or the treatment condition. Participants assigned to the waitlist control will have a 12-week waiting period prior to starting treatment. Those assigned to the treatment condition will begin therapy immediately.||||
33860614|NCT02838485|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860615|NCT06153771|||COHORT||PROSPECTIVE|||||||
33860616|NCT02187809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860617|NCT04079166|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, uncontrolled study.||||
33860618|NCT06502899|||COHORT||RETROSPECTIVE|||||||
33860619|NCT05355233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860620|NCT02642510|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33860621|NCT00305175|||COHORT||PROSPECTIVE|||||||
33860622|NCT04950725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33860623|NCT01353456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860624|NCT04864509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded||t|t|t|t
33860625|NCT01106404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860626|NCT03874325|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173179|NCT03429335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized individually in permuted blocks with randomly varying sizes of 2 and 4, and allocation ratio 1:1 for intervention and control groups.||||
34173180|NCT01404819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34173181|NCT02456012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860627|NCT01544023|||COHORT||RETROSPECTIVE|||||||
33860628|NCT00355979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860629|NCT01975428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860630|NCT04034550|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33860631|NCT01568645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860632|NCT05317754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33860633|NCT06335992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860634|NCT02153372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860635|NCT00279630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860636|NCT02853721|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860637|NCT04930224|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33860638|NCT00881218|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33860639|NCT05671913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860640|NCT04011254|||COHORT||PROSPECTIVE|||||||
33860641|NCT02736136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860642|NCT01669304|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33860643|NCT03643120|NA|SINGLE_GROUP||OTHER||NONE||Qualitative interviews, 15 - 20 participants.||||
33860644|NCT01615380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860645|NCT01243541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860646|NCT02645513|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33860647|NCT04009850|RANDOMIZED|PARALLEL||OTHER||NONE||Within-subject design comparing smoking behavior when using menthol vs. non-menthol cigarettes with either menthol or tobacco flavored e-cigarettes||||
33860648|NCT06064656|||COHORT||RETROSPECTIVE|||||||
33860649|NCT01940354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860650|NCT00897416|||||PROSPECTIVE|||||||
33961314|NCT05921331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33961315|NCT01308658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961316|NCT02103634|||CASE_ONLY||PROSPECTIVE|||||||
33961317|NCT03529318|||CASE_ONLY||PROSPECTIVE|||||||
33750548|NCT05861934|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33750549|NCT04546581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860651|NCT03794908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The outcome assessors and participants were blinded to condition. The PI and lab manager remained unblinded, and performed the fidelity and side-effects assessments. Participants were asked and reminded throughout the study to only speak about their light treatment with either the PI or lab manager.||t|f|f|t
33860652|NCT02538003|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860653|NCT06044844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860654|NCT00982215|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34173182|NCT05057091|RANDOMIZED|PARALLEL||TREATMENT||NONE|A power analysis was conducted to determine the number of cases to be included in the study. In order for the study to be performed at 80% strength and with a 5% margin of error, at least 23 people from each group should be included in the study to find a difference of 30 N/m after application, in the case where the lumbal extensor November hardness is 320 N/m and the standard deviation is 74 N/m|This research is planned as a double blind randomized controlled trials||||
34173183|NCT05000294|NA|SEQUENTIAL||TREATMENT||NONE||||||
34173184|NCT02868112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173185|NCT01994252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173186|NCT05517135|||COHORT||PROSPECTIVE|||||||
34173187|NCT05454735|||COHORT||PROSPECTIVE|||||||
34173188|NCT00860002|||CASE_CONTROL||PROSPECTIVE|||||||
34173189|NCT06275451|||OTHER||CROSS_SECTIONAL|||||||
34173190|NCT00788216|||||PROSPECTIVE|||||||
34173191|NCT01089504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173192|NCT06294795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173193|NCT01925560|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34173194|NCT00656357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34173195|NCT06065488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|t|f
34173196|NCT00979901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173197|NCT02074826|||COHORT||PROSPECTIVE|||||||
34173198|NCT03566602|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173199|NCT03596216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34173200|NCT05110872|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The study design included automated randomization of the conditions per person at the time of completion, via Qualtrics Software.|Participants will complete different purchasing scenarios in the Experimental Tobacco Marketplace in which different cigarette and e-cigarette flavors are available. In all scenarios, a range of other tobacco products will also be available.|f|f|t|f
34173201|NCT00670423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173202|NCT04559568|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173203|NCT01007201|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173204|NCT02437916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173205|NCT04889417|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Treatment assignment will be known only by the research coordinators, therapists, and research staff overseeing the administration of the program or active control. The remaining research staff, neuropsychology professionals performing the assessments, and clinicians will be blinded. Participants will be blinded to their group assignment.||t|t|f|t
34173206|NCT05132153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173207|NCT00703456|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34173208|NCT02602366|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173209|NCT00322777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173210|NCT03585660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173211|NCT06034808|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173212|NCT05622630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173213|NCT06212804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 1, randomized, placebo-controlled, double-blind, single ascending dose study|t|t|t|t
34173214|NCT00121563||||TREATMENT||||||||
34173215|NCT04055220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173216|NCT04975906|||COHORT||RETROSPECTIVE|||||||
34173217|NCT05095961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinicians grading blood loss and surgical field disability on the recorded video footage will be blinded to patient identity and group status. Data analysis will be done by a blinded assessor.|Patient's will be randomized to one of two groups: pre-operative oral steroids or no control|f|f|f|t
34173218|NCT03647930|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized trial||||
33860655|NCT03456531|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized clinically controlled study .||||
33860656|NCT05975957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, multicenter randomized, double-blind, placebo-controlled clinical trial.|t|t|t|f
33860657|NCT01361295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860658|NCT02536573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860659|NCT01810692|||||CROSS_SECTIONAL|||||||
33860660|NCT05148611|||COHORT||PROSPECTIVE|||||||
33860661|NCT05182996|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860662|NCT01158651|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860663|NCT01728220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860664|NCT04165928|||OTHER||RETROSPECTIVE|||||||
33860665|NCT03304353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860666|NCT00120640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961318|NCT05526274|||COHORT||CROSS_SECTIONAL|||||||
33961319|NCT06004076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Release of upper track of deep front fascial line and supervised corrective exercises|t|f|f|t
34173219|NCT02474446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173220|NCT04637386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34173221|NCT02211560|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34173222|NCT03864835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173223|NCT00360230|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34173224|NCT02700308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173225|NCT05769296|||CASE_ONLY||PROSPECTIVE|||||||
34173226|NCT05444556|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34173227|NCT06406712|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34173228|NCT02669810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173229|NCT01999478|||COHORT||PROSPECTIVE|||||||
34173230|NCT05478408|||COHORT||CROSS_SECTIONAL|||||||
34173231|NCT04125095|||COHORT||PROSPECTIVE|||||||
34173232|NCT02997215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173233|NCT04637568|||CASE_CONTROL||RETROSPECTIVE|||||||
34173234|NCT04865159|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Tipifarnib will be administered with a meal at a starting single dose of 900 mg, orally, once on Day 1, Cycle 1 followed by 600 mg, orally bid on Cycle 1 Days 2-7 and Days 15-21 for a 28-day treatment cycle.||||
34173235|NCT01544296|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34173236|NCT00299767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173237|NCT00894803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34173238|NCT03533673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173239|NCT04477265|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 210 women with overactive bladder will be recruited and randomized to 3 arms: drug only, exercise only and combination arm.||||
34173240|NCT06360458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173241|NCT03224208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173242|NCT00758732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173243|NCT05498649|||COHORT||PROSPECTIVE|||||||
34173244|NCT05195164|||COHORT||PROSPECTIVE|||||||
34173245|NCT02171221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173246|NCT02421172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173247|NCT01673308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173248|NCT00637611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173249|NCT04842747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be a randomized, double-blind, placebo-controlled study. Randomization will be stratified by baseline WHO Ordinal Scale score of 4,5 and 6 such that subjects with a WHO Ordinal Scale of 4, 5 and 6 at screening are approximately equally distributed between the treatment groups. An emergency code break will be available to the investigator / pharmacist / investigational drug storage manager. This code break option in IWRS may only be disclosed in emergency situations when the identity of the trial drug must be known to the investigator in order to provide appropriate medical treatment or if required to assure safety of trial participants. If the code break for a patient is opened, the sponsor and CRO will be informed immediately via IWRS notification. The reason for the IWRS unblinding of the subject must be documented on the appropriate eCRF page along with the date and the initials of the person who broke the code.|Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital. Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.|t|t|t|f
34173250|NCT03893071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750550|NCT06665308|||COHORT||CROSS_SECTIONAL|||||||
33750551|NCT00109616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33860667|NCT02467348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860668|NCT01287065|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33860669|NCT00078754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860670|NCT01524341|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860671|NCT02241239|||COHORT||PROSPECTIVE|||||||
33860672|NCT02676661|||COHORT||PROSPECTIVE|||||||
33860673|NCT04746625|||COHORT||OTHER|||||||
33860674|NCT01301651|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33860675|NCT03047551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860676|NCT02047643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"randomized crossover design. Subjects with type 1 diabetes participated in a structured soccer session on two separate dates at least one week apart. During one session a subject's basal insulin rate was continued (off-algorithm), while during the other session the algorithm (see algorithm monitoring below) was in effect (on-algorithm); the order of on- versus off-algorithm was chosen at random. The rate of hypoglycemia during exercise were compared between each group.~Hypoglycemia was defined as (1) any meter blood glu~cose (BG) reading of =60 mg/dl, (2) two consecutive meter~BG readings =70 mg/dl done within one hour, or (3) any instance in which carbohydrates were given at a subject's request for symptoms of hypoglycemia (regardless of corre sponding meter BG reading)."||||
33961320|NCT00871065|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173251|NCT03728907|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Outcomes assessors and participants will not be aware of which hearing setting (audiologist adjusted vs. self-adjusted) they are wearing|Repeated-measures crossover design|t|f|f|t
34173252|NCT00623948|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34173253|NCT03441477|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173254|NCT00937352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173255|NCT02454790|||COHORT||PROSPECTIVE|||||||
34173256|NCT00436332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173257|NCT06366737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173258|NCT00242268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173259|NCT06208553|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Patient and clinician outcome measures are self-reported and therefore not blinded to study phase. Chart auditors will not be blinded to study phase.|Single phase (step) of larger stepped-wedge cluster randomized trial design in which 3-month baseline period serves as pre-test after which implementation intervention is introduced (intervention phase) and then post-test data collected (similar to time series design).||||
34173260|NCT03777358|||COHORT||PROSPECTIVE|||||||
34173261|NCT03223402|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study, one arm. We do not evaluate a specific drug. It is an Evaluation of a combination with just two instead of three drugs for the Treatment of HIV||||
34173262|NCT04978883|||CASE_CONTROL||RETROSPECTIVE|||||||
34173263|NCT05329246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173264|NCT01349959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173265|NCT04306471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study subjects will be randomized, to receive either evolocumab or placebo. Each participant will have equal chance of receiving evolocumab or placebo. The study participant, the care provider and the investigator will not know to which study arm the participant was assigned.|This is a double-blinded, prospective, randomized, pilot, study|t|t|t|f
34173266|NCT04236427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34173267|NCT06269224|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173268|NCT04715620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173269|NCT01391364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173270|NCT01861808|NA|SINGLE_GROUP||OTHER||NONE||||||
34173271|NCT04199221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173272|NCT02332538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173273|NCT02123303|||COHORT||RETROSPECTIVE|||||||
34173274|NCT00259545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173275|NCT01187017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173276|NCT04087018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173277|NCT04889846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind randomised controlled trial|f|f|f|t
34173278|NCT03297957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173279|NCT00935181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173280|NCT01952132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173281|NCT02777021|||COHORT||PROSPECTIVE|||||||
34173282|NCT01628146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173283|NCT03740048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961321|NCT05676879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34173284|NCT02695095|||COHORT||RETROSPECTIVE|||||||
33961322|NCT03791918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173285|NCT02234843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173286|NCT02719808|||COHORT||PROSPECTIVE|||||||
34173287|NCT01131975|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173288|NCT05595707|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34173289|NCT01218334|||CASE_ONLY||PROSPECTIVE|||||||
34173290|NCT06240234|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34173291|NCT05732298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173292|NCT00949468|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173293|NCT04731636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173294|NCT00286728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173295|NCT01349608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173296|NCT02125396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173297|NCT02426580|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34173298|NCT01873937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173299|NCT06460545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173300|NCT01943643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961323|NCT01284725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173301|NCT03507257|||COHORT||PROSPECTIVE|||||||
34173302|NCT04855916|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will complete 10 gait training sessions during a 5-week period with one of the two devices (ABLE Exoskeleton or KAFO orthoses) followed by a post-training assessment. After the training program with the first device, participants will have 2 weeks resting time, after which they will repeat the process with the other device. The initial device assignment (ABLE Exoskeleton or KAFO) is performed randomly.||||
34173303|NCT03828032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173304|NCT04938908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34173305|NCT03659266|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173306|NCT02306330|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34173307|NCT05933135|||COHORT||RETROSPECTIVE|||||||
34173308|NCT02649413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173309|NCT02404961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173310|NCT01025908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173311|NCT03341299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173312|NCT05285774|||OTHER||PROSPECTIVE|||||||
34173313|NCT04108364|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||two arm, randomized, waitlist-controlled, crossover group design|f|f|f|t
34173314|NCT04401371|||OTHER||OTHER|||||||
34173315|NCT01821079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34173316|NCT00104585|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34173317|NCT04906928|||COHORT||PROSPECTIVE|||||||
34173318|NCT06473727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups|t|f|f|f
34173319|NCT04663607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173320|NCT00192933|||DEFINED_POPULATION||OTHER|||||||
34173321|NCT05953181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173322|NCT03972059|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 12-week training program will be divided into 3 phases (4 weeks each phase). Completion of each phase means that the subjects have increased their physical fitness and will get to the next phase where the intensity of exercise will increase in order to gain more physical fitness benefits (e.g. increased caloric expenditure). There will be a control group as well, where participants will not participate in any intervention.||||
34173323|NCT03874546|NA|SINGLE_GROUP||OTHER||NONE||||||
34173324|NCT04006041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173325|NCT06705751|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"The prospective part involves the enrollment of patients with AAOCA at the San Donato Polyclinic in order to validate the entire system developed in the retrospective part and to assess the role of autonomic response in individuals with AAOCA. A total of 38 subjects with AAOCA will be recruited and will undergo an active standing test. For this prospective sample, demographic, clinical data, and DICOM files from diagnostic CT angiographies for AAOCA (previously performed for medical reasons) will also be collected to be used as a validation set for the created tool. The patients in this cohort will undergo an active standing test to evoke an autonomic response. During this examination, the following data will be collected: continuous ECG, non-invasive blood pressure (BP), and respiration in both supine and prone positions.~The retrospective part includes four main tasks: development of U-NET and AI, FEA simulation, risk prediction model, and creation of the online platform."||||
34173326|NCT00928486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173327|NCT06705556|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|The study was single, and assessor blinded. Participants were masked about other groups, but they were knowing what treatment they were receiving. Principal investigator was also not masked or blinded because investigator was applying the techniques on participants of both groups. So participant and principal investigator cannot be blinded. Only assessor was blind and was taken outcome measures without knowing the problem and treatment techniques.||f|f|f|t
34173328|NCT02065830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173329|NCT05539027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34173330|NCT00556569|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34173331|NCT06393296|||COHORT||CROSS_SECTIONAL|||||||
34173332|NCT00576355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173333|NCT01319708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173334|NCT02685319|NA|SINGLE_GROUP||OTHER||NONE||||||
34173335|NCT01497041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961324|NCT03964090|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173336|NCT01626014|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34173337|NCT02174965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173338|NCT05017415|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Children will be randomised in two groups, with evaluation with a standard toilet seat or a toilet seat with decreased hip angle.|t|f|f|t
34173339|NCT02015273|||COHORT||OTHER|||||||
33961325|NCT02773888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961326|NCT04495192|||COHORT||PROSPECTIVE|||||||
34173340|NCT01446159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173341|NCT06279741|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Phase 1 is an open-label, dose-escalation and single-arm study. In phase 2, Investigators will remain blinded to each subject's assigned treatment throughout the study. The Sponsor will put in place procedures to maintain this blind. Indeed, to ensure the blinding of the groups, the preparation and administration of the test product will be organized by different teams. In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded study treatment records at the site(s) to verify that randomisation/dispensing has been done accurately. Blinding will be broken by the Investigator for emergency purposes only, where knowledge of the blinded treatment could influence further subject care. In addition, subjects will be unblinded for safety reports, as per regulatory requirements. Study blind will be broken after the database lock.|Phase 1 is an open-labelled, dose-escalated, and single-arm of EXOB-001. Phase 2 is a randomised, double-blind, placebo-controlled, and dose-finding of EXOB-001.|t|f|t|f
34173342|NCT06533475|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173343|NCT00981656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173344|NCT05829772|||OTHER||PROSPECTIVE|||||||
34173345|NCT00699036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173346|NCT00927108|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Cell culture||||
34173347|NCT02064673|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34173348|NCT05068908|||COHORT||CROSS_SECTIONAL|||||||
34173349|NCT06172452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to either the intervention condition or the supportive therapy control.|t|f|f|f
34173350|NCT04011540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173351|NCT01573039|||COHORT||PROSPECTIVE|||||||
34173352|NCT00001986||||TREATMENT||||||||
34173353|NCT02923973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173354|NCT02339922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173355|NCT01419002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173356|NCT01176201|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173357|NCT00727467|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961327|NCT02198755|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33961328|NCT05021588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33961329|NCT02719782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961330|NCT04141137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173358|NCT03768414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173359|NCT02979977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173360|NCT05699187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173361|NCT04504500|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||The trial herein discussed is a stepped-wedge cluster randomized trial involving random and sequential crossover of maternity units (clusters) from observation (routine practice, control) to intervention (educational, behavioral and organizational interventions), until all maternity units (clusters) have been exposed. The primary and secondary outcomes of the two phases (observation and intervention) are compared.|f|f|f|t
34173362|NCT04601818|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34173363|NCT05580523|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|PI, participating research doctors, pharmacists at the local clinical trial pharmacy, project managers and others involved in the trial are all blinded to the investigational medicinal product (IMP). The tablets and capsules will be identical, so it will not be possible to distinguish between the different IMPs.||t|t|t|t
34173364|NCT02025686|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34173365|NCT06247995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173366|NCT00617734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173367|NCT06581705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961331|NCT00616707|||OTHER||CROSS_SECTIONAL|||||||
33961332|NCT01123980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961333|NCT01551394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961334|NCT03998215|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33961335|NCT02095626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961336|NCT03090919|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to recieve either a platelet transfusion or a saline transfusion.||||
33961337|NCT01833221|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961338|NCT04427514|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33961339|NCT00876811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961340|NCT01258881|||CASE_ONLY||RETROSPECTIVE|||||||
33961341|NCT01098383|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33961342|NCT03932435|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||single-dose, 2-sequence||||
33961343|NCT01340703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961344|NCT04567719|||CASE_ONLY||PROSPECTIVE|||||||
33961345|NCT02345863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961346|NCT04313686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961347|NCT03663959|||COHORT||RETROSPECTIVE|||||||
33961348|NCT01874730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961349|NCT05282823|||COHORT||PROSPECTIVE|||||||
33961350|NCT03963700|||CASE_CONTROL||RETROSPECTIVE|||||||
33750552|NCT05103020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750553|NCT01489033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961351|NCT00005588|RANDOMIZED|||TREATMENT||||||||
33961352|NCT03205007|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-Post changes in dietary behavior||||
33961353|NCT04499690|||COHORT||PROSPECTIVE|||||||
33961354|NCT02148731|||COHORT||PROSPECTIVE|||||||
33961355|NCT00089310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961356|NCT02572973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961357|NCT05521087|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33961358|NCT03121469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961359|NCT00996632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961360|NCT05983029|||CASE_CROSSOVER||PROSPECTIVE|||||||
33961361|NCT00272818|||CASE_ONLY||PROSPECTIVE|||||||
33961362|NCT02582801|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33961363|NCT03945760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961364|NCT03333382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961365|NCT01900392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34064336|NCT06605118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study medication will be prepared by the center research pharmacies from a list provided by the independent data coordinating center, with the active and placebo medication having identical appearance. No other individuals, including the participant or any other clinical or research staff will be informed of the study assignment.|Participants will be randomized shortly before delivery to receive either azithromycin administered intravenously or a placebo control of normal saline administered intravenously|t|t|t|t
34064337|NCT01726621|NA|SINGLE_GROUP||||NONE||||||
33860677|NCT05995639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and outcomes assessors will be blinded to the procedures.|In this prospective randomized study to be conducted in Üsküdar state hospital, patients diagnosed with myofascial pain syndrome in the upper part of the trapezius muscle will be divided into 3 equal groups.|f|f|t|t
33860678|NCT04423354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860679|NCT05938244|||CASE_CONTROL||PROSPECTIVE|||||||
33860680|NCT03935503|||CASE_CROSSOVER||PROSPECTIVE|||||||
33860681|NCT00916630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860682|NCT06051578|||COHORT||PROSPECTIVE|||||||
33961366|NCT03816956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961367|NCT04320992|||COHORT||PROSPECTIVE|||||||
33961368|NCT02937662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961369|NCT03775382|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33961370|NCT02711579|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33961371|NCT02641171|||COHORT||CROSS_SECTIONAL|||||||
33961372|NCT01398982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961373|NCT03467828|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33961374|NCT01458132|||COHORT||PROSPECTIVE|||||||
33961375|NCT01652573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961376|NCT04769908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961377|NCT04509752|||COHORT||PROSPECTIVE|||||||
33961378|NCT00592709|||OTHER||RETROSPECTIVE|||||||
33961379|NCT04333199|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants (i.e., patients) will not be informed specifically of their assignment to different arms throughout the study.|Every day within the designated study period, an email will be sent to patients who 1) fulfill inclusion criteria, 2) have been randomized to one of the email conditions (rather than the control group), and 3) have not already been randomized to a study condition on a previous day (i.e. no patient will be emailed for this study twice).|t|f|f|f
33961380|NCT00006225|RANDOMIZED|||TREATMENT||||||||
33961381|NCT00437437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961382|NCT06266507|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33961383|NCT00943384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961384|NCT03593772|RANDOMIZED|SINGLE_GROUP||OTHER||NONE|There are no masked roles|This research study will evaluate a CIH intervention to manage pain and PTSD related outcomes within a bio-psychosocial framework. The proposed intervention, Mission Reconnect (MR), a user-driven, dyadic, self-care management program delivered online and by mobile app that has previously shown to be effective in a non-clinically defined community-based Veteran/military population.||||
33961385|NCT01238731|||COHORT||CROSS_SECTIONAL|||||||
33961386|NCT04278365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961387|NCT03849170|RANDOMIZED|PARALLEL||PREVENTION||NONE||Independent, randomized groups, longitudinal study||||
33961388|NCT03843268|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Trained professionals, not directly involved in the research treatment and blind to patients group allocation, will perform clinical assessments. All subjects will undergo inpatient rehabilitation consisting of a treatment cycles using the Gondola device, once effective (AMPS treatment) and once placebo (Sham treatment).|Subjects will be randomized in 2 groups, one starting with AMPS treatment, the other with placebo treatment. At the end of the first cycle of 6 stimulations over a 3 weeks' time (AMPS or Sham), all subject will undergo a washout period of minimum 6 weeks, then will undergo another equivalent treatment cycle (Sham or AMPS)|t|f|t|f
33961389|NCT04238780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064338|NCT04477876|||COHORT||PROSPECTIVE|||||||
34064339|NCT05422768|||COHORT||RETROSPECTIVE|||||||
34064340|NCT01135875|||CASE_CONTROL||PROSPECTIVE|||||||
34064341|NCT03904368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064342|NCT01030471|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34064343|NCT03001479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34064344|NCT00000997||||TREATMENT||NONE||||||
34064345|NCT05083806|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064346|NCT04296851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind randomized||t|t|t|t
34064347|NCT01239082|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064348|NCT01353573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064349|NCT01375582|NA|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34064350|NCT02702141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064351|NCT04825886|||COHORT||PROSPECTIVE|||||||
34064352|NCT05095311|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33961390|NCT04977635|||COHORT||PROSPECTIVE|||||||
33961391|NCT03528837|||CASE_ONLY||PROSPECTIVE|||||||
33961392|NCT02134769|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33961393|NCT01255579|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961394|NCT02702271|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A total of 400 main cohort subjects and 58 roll-in subjects were enrolled at 29 investigational centers in the United States.||||
33961395|NCT05165017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Placebo Controlled Double Blinded|t|t|t|t
33961396|NCT04106856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064353|NCT01108692|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34064354|NCT05838911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34064355|NCT03900221|||COHORT||PROSPECTIVE|||||||
34064356|NCT01160094|||COHORT||PROSPECTIVE|||||||
34064357|NCT05677815|||COHORT||PROSPECTIVE|||||||
33860683|NCT05700201|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study involves examining the effects of a 12-session healthy lifestyle program (focused on physical activity, nutrition, sleep, and stress management) administered in an individual format as an adjunct to usual care psychotherapy, compared with a usual care psychotherapy-only control condition. The control group will only attend the outcome assessments and usual care psychotherapy sessions. Therefore, the design relies on a between-groups comparison of the two conditions.||||
33860684|NCT01264367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860685|NCT01285466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173368|NCT02903914|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33860686|NCT03205215|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173369|NCT06116149|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the cluster design and intervention program, the study participants, health coaches, DPP Coordinators, WIC clinic staff, and research staff who collect clinical outcome data will not be blinded.|Cluster-randomization of 36 Women, Infants, and Children (WIC) clinics||||
33860687|NCT05467254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860688|NCT01446016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860689|NCT02499081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860690|NCT04398641|||COHORT||PROSPECTIVE|||||||
33860691|NCT04247009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All data will be given a new code Before statistical analysis to mask treatment (study meal or Control) to the outcome assessor||f|f|f|t
33860692|NCT01377077|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33860693|NCT00567268|||CASE_ONLY||PROSPECTIVE|||||||
33860694|NCT03450798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860695|NCT02506478|||||CROSS_SECTIONAL|||||||
33860696|NCT01322048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860697|NCT03330457|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|t|t|f
33860698|NCT05918172|||CASE_CONTROL||PROSPECTIVE|||||||
33860699|NCT05211154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860700|NCT02944994|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33860701|NCT00000913||||TREATMENT||||||||
33860702|NCT06393790|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33860703|NCT00172107|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34173370|NCT05019690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173371|NCT05071209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173372|NCT04663321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|t|f
34173373|NCT04031599|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173374|NCT03205800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a split-mouth design|f|f|f|t
34173375|NCT06100562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173376|NCT05818488|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173377|NCT05789745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Doses prepared by unblinded pharmacist. Placebo and Drug are undistinguishable in syringe for administration.||t|t|t|t
34173378|NCT06321328|||CASE_ONLY||PROSPECTIVE|||||||
33750554|NCT04760418|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-Concurrent Multiple Baseline Design||||
33750555|NCT04087538|||COHORT||PROSPECTIVE|||||||
33750556|NCT02372201|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750557|NCT01625897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750558|NCT02901457|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33860704|NCT02977208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860705|NCT06470802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33860706|NCT02183285|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33860707|NCT01980654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860708|NCT03679156|||OTHER||RETROSPECTIVE|||||||
33860709|NCT05315596|||COHORT||PROSPECTIVE|||||||
33961397|NCT02567266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33961398|NCT00145652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961399|NCT02190383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961400|NCT02396069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961401|NCT01819701|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33961402|NCT04779411|||OTHER||PROSPECTIVE|||||||
33961403|NCT00002126||||TREATMENT||||||||
33961404|NCT06319521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961405|NCT01837485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961406|NCT02470078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961407|NCT01880541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961408|NCT03865992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33961409|NCT04217031|||CASE_ONLY||RETROSPECTIVE|||||||
34064358|NCT00911586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064359|NCT00520767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064360|NCT01245153|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173379|NCT06445543|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the intervention, blinding of participants or MFeast staff is not possible, but data collectors will be blinded to arm.|The study design is a two parallel-arm pilot randomized controlled trial. The investigators will be applying the principles of a hybrid type 1 implementation-effectiveness randomized controlled trial.|f|f|f|t
34173380|NCT04830137|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173381|NCT00335699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173382|NCT06704828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173383|NCT02348476|||COHORT||RETROSPECTIVE|||||||
34173384|NCT05011981|||COHORT||PROSPECTIVE|||||||
34173385|NCT04281290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173386|NCT06536023|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|f|t|f
34173387|NCT00002649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173388|NCT03188016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are effectively masked since their parents/carers giving consent on their behalf will be masked regarding which arm their children are assigned to. (Participants themselves lack intellectual capacity to understand or consent to study participation)|Homogenous group randomly split into experimental and control groups to receive same number and duration of treatments|t|f|f|t
34173389|NCT01199354|NA|SINGLE_GROUP||||NONE||||||
34173390|NCT06467981|||OTHER||RETROSPECTIVE|||||||
34173391|NCT05009875|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34173392|NCT04986163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The results of the pain monitors are masked for the investigator||f|f|t|f
34173393|NCT02873871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173394|NCT05284773|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking of participants and intervention administrators will not be possible due to the nature of the intervention. Primary outcome assessors will be masked to allocation.|One group will be randomized to intervention + standard of care; one group will be randomized to standard of care only|f|f|f|t
34173395|NCT04763980|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860710|NCT03397849|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients that are randomized to usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.~Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)."||||
33860711|NCT05777473|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Three-arm cluster randomized controlled trial (cRCT)||||
33860712|NCT00561496|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860713|NCT06421896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33860714|NCT00901030|||COHORT||PROSPECTIVE|||||||
34173396|NCT04819945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860715|NCT01215175|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33860716|NCT03985345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860717|NCT02939872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860718|NCT02482766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860719|NCT02748837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860720|NCT01002456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860721|NCT04836663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860722|NCT00248027|||DEFINED_POPULATION||PROSPECTIVE|||||||
33860723|NCT02020863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860724|NCT03082703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33860725|NCT01178333|||CASE_ONLY||RETROSPECTIVE|||||||
33860726|NCT00764751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33860727|NCT04294069|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33860728|NCT03231943|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study with subjects and the site-staff blinded and sponsor unblinded.|This is a dose-escalation study and dose will be escalated based on the safety data of the initial dose.|t|f|t|f
33860729|NCT04158596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860730|NCT04506307|NA|SINGLE_GROUP||OTHER||NONE||||||
33860731|NCT02467218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860732|NCT05880277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Team physician will exam images but will be blinded from participant. Will only see participant number.|female collegiate jumping athletes||||
33860733|NCT03475017|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33860734|NCT00154336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860735|NCT04206592|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34173397|NCT05034367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173398|NCT04351542|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Ayurveda care provide was blinded||f|t|f|f
33750559|NCT06361147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Interventional groups and Control groups|t|f|f|f
33750560|NCT04644250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750561|NCT04806880|||COHORT||PROSPECTIVE|||||||
33750562|NCT03694639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750563|NCT02477696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750564|NCT06657326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patient will be randomized to one of the treatment arms to receive either the BioFreedom™ Ultra DCS or BioFreedom™ DCS|t|f|f|f
33750565|NCT02808364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750566|NCT05596370|||COHORT||PROSPECTIVE|||||||
33750567|NCT06723574|||OTHER||OTHER|||||||
33750568|NCT06672991|||COHORT||RETROSPECTIVE|||||||
33860736|NCT01023854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33860737|NCT04010513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860738|NCT05794646|NA|SINGLE_GROUP||TREATMENT||NONE||This type 2 hybrid 'effectiveness-implementation' study makes it possible to simultaneously evaluate the efficiency of the model on clinical criteria of HCV cure, and its feasibility by measuring the potential obstacles and the relevance of its implementation.||||
33860739|NCT04580589|||CASE_CONTROL||RETROSPECTIVE|||||||
33860740|NCT00414895|||COHORT||PROSPECTIVE|||||||
33860741|NCT02891551|||COHORT||PROSPECTIVE|||||||
33860742|NCT06494917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860743|NCT01649570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860744|NCT05140733|||COHORT||PROSPECTIVE|||||||
33750569|NCT02450318|NA|SINGLE_GROUP||OTHER||NONE||||||
33750570|NCT00858065|RANDOMIZED|PARALLEL||PREVENTION||NONE|Families were assigned either to a group with no choice or with choice but were aware that they would be randomly assigned but knew which option they received.|||||
33860745|NCT06434389|||OTHER||PROSPECTIVE|||||||
33860746|NCT00506428|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34173399|NCT06251167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be aware that there will be different types of insole interventions for this study, but will not be aware of the exact details of the insoles.~Given that biomechanical assessment will be conducted in the intervention insole, it is not possible to mask the outcome assessor to intervention arm for participants. Instead, an investigator not involved in data collection will process all biomechanical data without knowledge of the intervention for a given participant."|We will conduct a two-arm, parallel group, multi-centre randomized controlled pilot study to assess the feasibility of our unique clinical biomechanics study, as well as the preliminary efficacy of the interventions on clinical and biomechanical outcomes at the feet and knees.|t|f|t|f
34173400|NCT04337580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750571|NCT04916535|NA|SINGLE_GROUP||OTHER||NONE||Observational cohort prospective multicenter study on patients with MAD||||
33750572|NCT05598216|||COHORT||RETROSPECTIVE|||||||
33750573|NCT05050136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860747|NCT04898413|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750574|NCT03044379|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33750575|NCT06035029|||CASE_CONTROL||PROSPECTIVE|||||||
33750576|NCT01188434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750577|NCT00279227|||DEFINED_POPULATION||OTHER|||||||
33750578|NCT05282238|||COHORT||PROSPECTIVE|||||||
33750579|NCT01640522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only person evaluating outcomes|Intervention versus standard of care|f|f|f|t
33750580|NCT00884585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750581|NCT04524468|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33750582|NCT00000154|RANDOMIZED|||TREATMENT||||||||
33750583|NCT00913484|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33750584|NCT05812651|NA|SINGLE_GROUP||OTHER||NONE||||||
33750585|NCT01801020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750586|NCT06367803|||COHORT||RETROSPECTIVE|||||||
33750587|NCT03668080|||OTHER||OTHER|||||||
33750588|NCT00070902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750589|NCT01107184|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33750590|NCT04110613|RANDOMIZED|PARALLEL||PREVENTION||NONE||Once scheduled for the bedside PEG procedure, patients will be randomized to either the experimental NoFAST group or the control FAST group.||||
33750591|NCT04230499|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients will receive one of three doses in a dose-escalating fashion. Cohort 1 will receive 0.5mg every other day, Cohort 2 will receive 0.5mg daily with 7 days on therapy followed by 7 days off therapy, and Cohort 3 will receive 0.5 mg daily. Patients will serve as their own control; no placebo will be given.~Additionally, a subset of participants will be included in a randomized, balanced, single-schedule, two-treatment period (fed versus fasted) crossover study.~Participants will receive eRapa under fed or fasted conditions in the first period, and then crossover to the other treatment (fed to fasted and vice versa) following a 2 week washout. Under this design, participants serve as their own control and will allow the assessment of the effect of food on the anticipated R2PD of eRapa"||||
33750592|NCT06194227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750593|NCT03528018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750594|NCT05687474|||COHORT||PROSPECTIVE|||||||
33750595|NCT01016210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750596|NCT06496048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750597|NCT04118530|||COHORT||PROSPECTIVE|||||||
33750598|NCT01669629|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33750599|NCT05704075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750600|NCT06534398|||COHORT||RETROSPECTIVE|||||||
33750601|NCT03562936|||COHORT||PROSPECTIVE|||||||
33860748|NCT04026841|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm||||
33860749|NCT03732508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860750|NCT04572022|RANDOMIZED|PARALLEL||OTHER||NONE||Participants are assigned to one of two groups (intervention and control) in parallel for the duration of the study.||||
33860751|NCT05261971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860752|NCT01862302|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860753|NCT04549519|||OTHER||CROSS_SECTIONAL|||||||
33860754|NCT00635726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860755|NCT05241509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961410|NCT03962660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"HaRTS-TRENDS, in which participants will attend 4, 30-minute sessions with research staff. They will discuss participants' current smoking and their goals around reducing smoking-related harm and improving their health-related quality of life. Participants will also engage in discussions about the safety profiles of different nicotine products. One group of these products, e-cigarettes, is 95% safer than smoking and will be made available to participants to help them achieve their harm-reduction goals. They will receive instructions and demonstrations for its safe and proper use.~-OR-~Standard care, in which will attend 4, 30-minute sessions of brief advice to quit."|t|f|f|f
33750602|NCT01995461|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750603|NCT03302338|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33750604|NCT03588026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961411|NCT03384420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961412|NCT04352036|||COHORT||PROSPECTIVE|||||||
33961413|NCT02185235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961414|NCT03743675|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33961415|NCT02426125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961416|NCT05699577|||CASE_ONLY||CROSS_SECTIONAL|||||||
33961417|NCT04339361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961418|NCT05406596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961419|NCT04618315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principle investigators and the audiologists conducting the outcome measures will be blinded to group assignment.|Three arm blinded randomized control trial.|f|f|t|t
33961420|NCT06060639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961421|NCT05598645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961422|NCT02606682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961423|NCT03676673|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33961424|NCT06053437|||COHORT||RETROSPECTIVE|||||||
33961425|NCT02149199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961426|NCT05576285|||COHORT||PROSPECTIVE|||||||
33961427|NCT01946087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33961428|NCT04876859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961429|NCT02946619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33961430|NCT03593239|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33961431|NCT00047554|||COHORT||PROSPECTIVE|||||||
33961432|NCT00005893||||TREATMENT||||||||
33961433|NCT02858076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750605|NCT00169169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750606|NCT05895266|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33961434|NCT01787188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961435|NCT03812601|||COHORT||PROSPECTIVE|||||||
33961436|NCT06191380|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants will be blinded to the hypothesized effect of each exercise condition.|||||
33961437|NCT05273606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961438|NCT04239638|||COHORT||RETROSPECTIVE|||||||
33961439|NCT00207974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961440|NCT06556745|||COHORT||PROSPECTIVE|||||||
33961441|NCT03804931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750607|NCT05155865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750608|NCT01683864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750609|NCT00707031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750610|NCT02863926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Autologous bone marrow derived mesenchymal stromal cells will be delivered intramuscularly in the lower extremity of participants undergoing lower extremity major amputation to assess incidence of wound healing and infection prevention.||||
33750611|NCT05986175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750612|NCT01604538|||COHORT||PROSPECTIVE|||||||
33750613|NCT02446158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750614|NCT05770999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33750615|NCT00537966|||COHORT||PROSPECTIVE|||||||
33750616|NCT03511755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750617|NCT02683096|||OTHER||PROSPECTIVE|||||||
33750618|NCT02405221|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750619|NCT01525732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750620|NCT01791933|||COHORT||PROSPECTIVE|||||||
33750621|NCT04037501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33750622|NCT00226239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750623|NCT06700915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750624|NCT06580834|||OTHER||PROSPECTIVE|||||||
33750625|NCT00285142|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33750626|NCT01455610|||CASE_ONLY||PROSPECTIVE|||||||
33750627|NCT03610126|||COHORT||PROSPECTIVE|||||||
33750628|NCT04597853|||COHORT||PROSPECTIVE|||||||
33750629|NCT01632774|||CASE_ONLY||RETROSPECTIVE|||||||
33750630|NCT03625570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750631|NCT02234869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750632|NCT05420155|||CASE_ONLY||RETROSPECTIVE|||||||
33750633|NCT00287599|||CASE_ONLY||PROSPECTIVE|||||||
33750634|NCT02242474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750635|NCT02724631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750636|NCT05200871|||COHORT||CROSS_SECTIONAL|||||||
33750637|NCT01467180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750638|NCT06613217|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750639|NCT04253743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750640|NCT04546308|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33961442|NCT00960310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961443|NCT03060148|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Medtronic neurostimulation|f|f|f|t
33961444|NCT06536725|||COHORT||PROSPECTIVE|||||||
33961445|NCT06462209|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33961446|NCT03001518|||COHORT||PROSPECTIVE|||||||
33961447|NCT05187663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double (Participant, Investigator, Sub-investigator) Single Blind|Parallel Assignment|t|f|t|t
33961448|NCT01364259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961449|NCT05117866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961450|NCT01909817|||COHORT||RETROSPECTIVE|||||||
33961451|NCT05672160|||COHORT||RETROSPECTIVE|||||||
33961452|NCT05437510|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1 in-person randomization visit, with monthly safety and efficacy follow-up conducted through electronic contact through the first 6 months post-dosing/randomization.~The study will also include a 12-month (D366) follow-up telephone call. The D366 follow-up telephone call will be the final follow-up telephone call for France, Germany and UK non-reconsented participants. The study will include an 18-month (D546) and a 24-month (D731, final telephone call) follow-up telephone call for UK reconsented participants."||||
33961453|NCT02049554|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33961454|NCT05361811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961455|NCT02756078|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33750641|NCT06164717|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33961456|NCT05319977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961457|NCT03422081|||COHORT||PROSPECTIVE|||||||
33961458|NCT03806478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple Blind|Exploratory Phase 2 Trial|t|t|f|t
33961459|NCT03857139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961460|NCT03102788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The research assistant who will examine the participants at baseline and follow-ups and the statistician who perform the main effect analysis will be blinded for group allocation.|In this randomized controlled trial, participants will be allocated to receive their first consultation in specialist health care by either an occupational therapy specialist or a rheumatologist. The occupational therapist may thereafter refer the patient to a consultation with a rheumatologist if necessary, and vice versa.|f|f|t|t
33961461|NCT00116376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961462|NCT05630001|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan||||
33961463|NCT03538522|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33961464|NCT04717232|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33961465|NCT06460246|NA|SINGLE_GROUP||OTHER||NONE||||||
33961466|NCT01027026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33961467|NCT00542958||SEQUENTIAL||TREATMENT||NONE||||||
33961468|NCT00417859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961469|NCT01294605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33961470|NCT04800367|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|12 months of romosozumab followed by 12 months of denosumab||||
33961471|NCT06102967|||CASE_CONTROL||RETROSPECTIVE|||||||
33961472|NCT06122571|NA|SINGLE_GROUP||OTHER||NONE||||||
33961473|NCT01566474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33961474|NCT00468312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961475|NCT00129532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33961476|NCT06382220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961477|NCT02941822|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33961478|NCT00677586|RANDOMIZED|PARALLEL||TREATMENT||NONE||Rectal cancer patients with synchronous resectable liver metastasis were randomized to simultaneous resection of primary and metastatic lesions or staged resection||||
33961479|NCT00208000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961480|NCT00877214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750642|NCT01542918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750643|NCT06337175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consisted of two distinct groups. The first group comprised 464 patients who did not experience hemorrhagic infarction, while the second group comprised 152 patients who experienced hemorrhagic infarction.||||
33750644|NCT04938245|||COHORT||PROSPECTIVE|||||||
33750645|NCT01261611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750646|NCT05737875|||COHORT||RETROSPECTIVE|||||||
33750647|NCT04116437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750648|NCT02546661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750649|NCT00362518|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33750650|NCT02439710|||OTHER||PROSPECTIVE|||||||
33750651|NCT01751438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750652|NCT05572138|||COHORT||PROSPECTIVE|||||||
33750653|NCT05378633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750654|NCT06632301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750655|NCT00504270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750656|NCT03254082|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33750657|NCT02860143|||CASE_ONLY||PROSPECTIVE|||||||
33750658|NCT04568434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750659|NCT00962728|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33750660|NCT06520111|||COHORT||PROSPECTIVE|||||||
33750661|NCT05686070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750662|NCT03169387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33961481|NCT06542783|||COHORT||PROSPECTIVE|||||||
33961482|NCT06107959|||COHORT||PROSPECTIVE|||||||
33961483|NCT06051734|||CASE_CROSSOVER||PROSPECTIVE|||||||
33961484|NCT03414307|NA|SINGLE_GROUP||OTHER||NONE||Subject enrolled serve as their own control to evaluate the effect of ROSA robotic-assisted intracerebral catheter placement.||||
33750663|NCT02216175|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33750664|NCT00864903|||CASE_ONLY||PROSPECTIVE|||||||
33750665|NCT06085248|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Subjects will complete a 6MWT without RAS and then complete a 6MWT with RAS||||
33750666|NCT04913753|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750667|NCT05339529|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33750668|NCT00450411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750669|NCT05371496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750670|NCT02508948|||COHORT||PROSPECTIVE|||||||
33750671|NCT06462989|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750672|NCT01782066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750673|NCT05319067|||CASE_CONTROL||PROSPECTIVE|||||||
33750674|NCT04642508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750675|NCT05646186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blinded randomized controlled study. The participants will be blinded to the dietary interventions and the care providers will apply the diets that were allocated to them without knowing which diet they are applying. The investigators will not be able to obtain data until the data collection is finished.||t|t|t|f
33961485|NCT03560674|||OTHER||CROSS_SECTIONAL|||||||
33961486|NCT02781688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961487|NCT06148337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The clinical investigator, sub-investigators, study personnel (including outcomes assessor), and study participants will be blinded to treatment until completion of the study. Only the clinical supply coordinator will be aware of treatment assignment.|single-center, randomized, double-blind, placebo-controlled trial design|t|t|t|t
33961488|NCT00675701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961489|NCT03943121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34064361|NCT01638403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173401|NCT06617312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||We will randomize 64 non-treatment seeking adults who smoke cigarettes (N=32 cytisinicline, N=32 placebo; 50% females) in a double-blind, placebo-controlled laboratory study testing the effects of cytisinicline on the neural substrates of cigarette cue reactivity. All participants will be daily combustible cigarette smokers. Interested individuals will call the lab and complete a telephone screening interview. Individuals who are deemed eligible will receive a full explanation of study procedures and provide written, informed consent. Participants will then complete a behavioral screen and physical exam. Eligible participants will then be randomized to a medication, cytisinicline (3 mg, 3 times daily) or placebo (0mg, 3 times daily). Participants will complete brief daily diary self-reports of cigarette use and craving during the outpatient medication period. Following 2- to 3-weeks of cytisinicline, or placebo, treatment participants will complete a cigarette cue-exposure fMRI task.|t|t|t|f
34173402|NCT03299959|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-Label, adaptive design with interim analyses|Open-label Randomized Controlled Trial||||
34173403|NCT02721940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750676|NCT06061510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study was a randomised, double-blind trial, and neither the subjects nor the research workers knew the exact subgroups or the progress of the treatment|The study was a randomised, double-blind trial.|t|f|t|f
33750677|NCT04769427|NA|SINGLE_GROUP||OTHER||NONE||||||
33750678|NCT00712023|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750679|NCT03919383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750680|NCT06670664|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750681|NCT02024906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750682|NCT00862134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750683|NCT04180618|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750684|NCT05656950|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750685|NCT04117035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||single-blinded randomised control pilot study|t|f|f|t
33750686|NCT02573974|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33750687|NCT05346289|||COHORT||RETROSPECTIVE|||||||
33750688|NCT06501781|RANDOMIZED|PARALLEL||OTHER||NONE||A pilot study to evaluate the feasibility and effectiveness of a peer-delivered intervention for LAI-PrEP/ART adherence among predominately Black substance-using populations.||||
33750689|NCT04550312|||OTHER||RETROSPECTIVE|||||||
33750690|NCT02212028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750691|NCT00003298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750692|NCT06732908|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33750693|NCT05231798|NA|SINGLE_GROUP||OTHER||NONE||||||
33750694|NCT00145093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750695|NCT05885672|||COHORT||PROSPECTIVE|||||||
33750696|NCT06426550|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Randomization will be carried out by a blind clinician for the initial assessment of participants, using a computer program (Spyder 5.5.4), in which each patient will be randomly selected to define the site to receive one of the treatments. Next, gels will be encoded in a syringe and applied by a researcher blind to the sites and reagents, each of the 4 sites will receive one of the following treatments: 1 - photosensitization with 0.005% AM gel (Fórmula e Ação Farmácia, São Paulo, SP, Brazil) for 5 minutes, and apply photodynamic therapy with a red laser; 2 - photobiomodulation with red laser; 3 - photobiomodulation with infrared laser; and 4 - control, application of saline gel and, after 5 minutes, simulate the application of the laser, with the device in inactive mode, in order to maintain blinding of the patients (control). In groups 2 and 3, as no gel will be applied, the application of the gel with an empty syringe will be simulated, to keep patients blind|Clinical, laboratory, longitudinal split-mouth study carried out in humans.|t|f|t|t
33961490|NCT00287352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961491|NCT00419900|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE||||||
34064362|NCT06731179|||COHORT||RETROSPECTIVE|||||||
34064363|NCT06730711|||COHORT||RETROSPECTIVE|||||||
34064364|NCT05032729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34064365|NCT04851418|||COHORT||PROSPECTIVE|||||||
34064366|NCT05184660|||OTHER||PROSPECTIVE|||||||
33750697|NCT01577979|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33750698|NCT05903651|||OTHER||CROSS_SECTIONAL|||||||
33750699|NCT01903473|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"DTI arm~* 10 patients will be included in the DTI (Treg) + IL-2 arm.~* Treg infusion + rapa+ IL-2 will be considered safe if no patients die because of Treg infusion, less than 4 patients die of nonrelapse causes the first 90 days after inclusion in the study, and less than 4 patients experience chronic GVHD progression within the first 90 days after inclusion.~* The study will be closed at any time a fourth patient experience nonrelapse mortality within 90 days of inclusion or experience GVHD progression within 90 days of inclusion.~Control arm~* Up to 25 patients will be included in the control arm.~* Rapa administration will be considered safe if less than 4/10, 8/20 or 10/25 patients die of nonrelapse causes the first 90 days after inclusion in the study and less than 4/10, 8/20 or 10/25 patients experienced chronic GVHD progression within the first 90 days after inclusion.~* This arm of the study will be closed at any time the above criteria can no longer be met."||||
33750700|NCT03883633|||CASE_ONLY||PROSPECTIVE|||||||
33750701|NCT04847869|NA|SINGLE_GROUP||TREATMENT||NONE||7 eyes with branch retinal vein occlusion, 7 with central retinal vein occlusion||||
33750702|NCT05545553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33750703|NCT01318226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750704|NCT00605280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961492|NCT06541912|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33961493|NCT03716999|||OTHER||OTHER|||||||
33961494|NCT00764816|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34064367|NCT00676416|||CASE_CONTROL||PROSPECTIVE|||||||
33961495|NCT00451594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961496|NCT04801030|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33961497|NCT02556931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961498|NCT05481554|||COHORT||PROSPECTIVE|||||||
33961499|NCT05785416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|outcome assessor-blinded pre-test post-test randomized controlled trial|30 males aged 55-75 years were randomly assigned into 3 arms - PNF group (n=10), Static Stretch group (n=10) and Control group (n=10)|f|f|f|t
33961500|NCT01397656|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33961501|NCT02170142|||COHORT||PROSPECTIVE|||||||
33961502|NCT05785221|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33961503|NCT00203931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961504|NCT05904145|||COHORT||PROSPECTIVE|||||||
34064368|NCT00028522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064369|NCT05219097|||COHORT||PROSPECTIVE|||||||
34173404|NCT04773392|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized, prospective clinical trial. Patients will be screened prior to surgery and randomized 1:1 to each arm.||||
34173405|NCT03080155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173406|NCT06304103|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173407|NCT06552286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Coordinator who is assessing goals of participants is masked from knowing which group each participant was randomized to.|Randomized Clinical Trial - A study in which the participants are divided by chance into separate groups that compare different treatments or other interventions.|f|f|f|t
34173408|NCT01657864|||||CROSS_SECTIONAL|||||||
34173409|NCT03562273|||COHORT||PROSPECTIVE|||||||
34173410|NCT06105060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|This study will be randomized controlled, parallel and prospective 6-months duration study. Accepted patients will be randomized into 4 groups. The size of the sample is calculated using open EPI software (www.openepi.com) and according to NASH prevalence in Egypt.|t|f|t|f
34173411|NCT05254678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Independent assessors will be used for collection of objective outcomes. The independent assessors will be blinded to group allocation.|Randomized controlled feasibility trial|f|f|f|t
34173412|NCT06632639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173413|NCT04685798|NA|SINGLE_GROUP||OTHER||NONE|All anonymized MRI studies will be blindly evaluated by at least two experienced neuroradiologists|||||
34173414|NCT04706208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34064370|NCT00371709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173415|NCT06362746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither patient nor investigator knows treatment assignment. All eligible patients will be randomized in two equal groups for administration of non-immunogenic recombinant staphylokinase or placebo.|"At clinical sites patients will be equally randomized into two groups to receive non-immunogenic recombinant staphylokinase or placebo.~Non-immunogenic recombinant staphylokinase or placebo will be administered intravenously at a dose of 15 mg as a single bolus for 10-15 seconds. All patients will be examined for 30 days."|t|f|t|f
34173416|NCT03344757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34173417|NCT05371613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173418|NCT04056416|NA|SINGLE_GROUP||OTHER||NONE||||||
34173419|NCT05663710|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173420|NCT06706492|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173421|NCT05620420|||OTHER||CROSS_SECTIONAL|||||||
34173422|NCT05553509|||COHORT||PROSPECTIVE|||||||
34173423|NCT03751241|NA|SINGLE_GROUP||SCREENING||NONE||||||
34173424|NCT01374334|||OTHER||CROSS_SECTIONAL|||||||
34173425|NCT01623102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173426|NCT03352635|||COHORT||CROSS_SECTIONAL|||||||
34173427|NCT02083471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750705|NCT05712590|||COHORT||CROSS_SECTIONAL|||||||
33750706|NCT00546585|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33750707|NCT02829853|||COHORT||PROSPECTIVE|||||||
33750708|NCT03283774|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33750709|NCT04591522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750710|NCT00959933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33750711|NCT03986112|||CASE_ONLY||PROSPECTIVE|||||||
33750712|NCT04091074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961505|NCT03989037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multi-center, randomized, single-blind, positive drug parallel controlled equivalence clinical trial.|t|f|f|t
33961506|NCT06309121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double-blind placebo-controlled study with a treatment group and an active control parallel group.|t|t|t|t
33750713|NCT02019160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750714|NCT05920629|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33750715|NCT04368429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33750716|NCT05028218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750717|NCT04184791|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33750718|NCT00001768||||TREATMENT||||||||
33750719|NCT00455065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750720|NCT05653999|||COHORT||PROSPECTIVE|||||||
33750721|NCT04427202|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33750722|NCT05614349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750723|NCT01744522|||COHORT||PROSPECTIVE|||||||
33750724|NCT06265597|RANDOMIZED|PARALLEL||TREATMENT||NONE||There is a control and intervention group.||||
33750725|NCT01792063|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33750726|NCT03662204|||COHORT||CROSS_SECTIONAL|||||||
33750727|NCT05071157|||CASE_CONTROL||PROSPECTIVE|||||||
33961507|NCT01578343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961508|NCT02632227|||COHORT||PROSPECTIVE|||||||
33961509|NCT01692431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33961510|NCT01374906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961511|NCT02997969|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34173428|NCT06305286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173429|NCT04917146|||OTHER||CROSS_SECTIONAL|||||||
34173430|NCT01810341|||COHORT||PROSPECTIVE|||||||
34173431|NCT04749940|NA|SINGLE_GROUP||TREATMENT||NONE|"Each patient will be dressed with both Aquacel® and PRF dressing. Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.~3 days after surgery the patients will be asked to complete a VAS questionnaire. A week and 2 weeks after surgery, patients will have their dressing changed as in the first treatment, and will answer VAS(9) and bluebelle(10) questionnaires. The wound will be photographed again for follow-up. Three weeks, 6 weeks and 3 months after surgery the scar in the donor area will be evaluated. The photographs will be shown to the blinded evaluator, to evaluate wound healing by epithelialization estimation."|A prospective single-blind study, where the evaluator is blinded to the treatment. Each patient will be dressed with both Aquacel® and PRF dressing. Half of the donor site area will be dressed with PRF dressing, and half with Aquacel®.||||
34173432|NCT04544813|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34173433|NCT02341560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961512|NCT00589693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961513|NCT04872127|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33961514|NCT03690726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Placebo Controlled Clinical Intervention Study|t|t|f|t
33961515|NCT01817569|||COHORT||PROSPECTIVE|||||||
33961516|NCT06542497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-masked, placebo-controlled|Parallel assignment|t|f|t|t
33961517|NCT02706522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34173434|NCT06151418|||COHORT||RETROSPECTIVE|||||||
34173435|NCT00771914|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33750728|NCT02369094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750729|NCT03683485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750730|NCT05865106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750731|NCT00114868|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33750732|NCT02944136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33750733|NCT01603264|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34173436|NCT01032616|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33750734|NCT06359938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750735|NCT04463836|||COHORT||PROSPECTIVE|||||||
33750736|NCT05441072|||OTHER||PROSPECTIVE|||||||
33750737|NCT01016938|||OTHER||PROSPECTIVE|||||||
33750738|NCT00863174|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33750739|NCT00369330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750740|NCT04414267|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Patients vaccinated with placebo or BCG|t|t|t|t
33750741|NCT04150679|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||group I, retrospective group , data retrieved from medical records, cases treated with hepaticojejunostomy without access group II prospective group cases treated with hepaticojejunostomy with access||||
34173437|NCT02929953|||COHORT||CROSS_SECTIONAL|||||||
34173438|NCT05267080|||COHORT||PROSPECTIVE|||||||
34173439|NCT04230187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173440|NCT06706375|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34173441|NCT02099240|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173442|NCT04861129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinding of participants and outcome assessor will be adopted. Independent assessors who conduct outcome measures are blinded to the group assignments, so allocation concealment and masking can be preserved throughout the study.||t|f|f|t
34173443|NCT06304961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173444|NCT05410522|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173445|NCT01346358|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173446|NCT06033547|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173447|NCT02492035|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34173448|NCT05831033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173449|NCT04085575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007 (Microsoft Corporation, Seattle, Washington, USA).|They were assigned in two groups: The G1 group received 1 g of intra-articular tranexamic acid (TXA) and the G2 group received 2 g of intra-articular tranexamic acid. Both groups received 15 mg / kg IV at 20 min at induction and then 10 mg / kg in oral administration 6 and 12 hours after induction dose IV of tranexamic acid.|t|t|f|f
34173450|NCT05306925|NON_RANDOMIZED|PARALLEL||OTHER||NONE|This is not blinded or randomized.|There will be parallel assignment of supplemented parenteral nutrition (PN) and standard parenteral nutrition dependent upon stock availability of intervention PN.||||
34173451|NCT05795166|||COHORT||CROSS_SECTIONAL|||||||
34173452|NCT02570984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34173453|NCT02169518|||CASE_ONLY||OTHER|||||||
34173454|NCT06301958|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34173455|NCT06705309|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33750742|NCT05154682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750743|NCT05787639|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II clinical trial for AJCC (American Joint Committee on Cancer) VIII Stage I T1-2N1M0 HPVOPC, including patients amenable to surgical resection, excluding patients with solitary lymph nodes less than 3 cm who are amenable to surgical therapy alone. Stereotactic radiation therapy (SBRT (8GyX3)) will be delivered to gross tumor volume (GTV) +3mm, followed by Pembrolizumab 200 mg IV and Evorpacept 45 mg/kg IV every three weeks x 2 cycles followed by surgical resection of primary tumor and neck dissection. The primary endpoint is pathologic response compared to historical standard of care rates of locoregional control, and secondary endpoints are clinical response, survival, and safety and toxicity.||||
33750744|NCT02947126|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33750745|NCT03221387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750746|NCT02375620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750747|NCT03880305|||OTHER||CROSS_SECTIONAL|||||||
33750748|NCT02293044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750749|NCT00617344|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33750750|NCT02339831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750751|NCT03096405|||COHORT||RETROSPECTIVE|||||||
33750752|NCT00278668|||||PROSPECTIVE|||||||
33750753|NCT02046330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750754|NCT01954979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750755|NCT01072461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750756|NCT02901015|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750757|NCT05356858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750758|NCT05607095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750759|NCT03612791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750760|NCT05355974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750761|NCT05101239|||COHORT||OTHER|||||||
33750762|NCT03516448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33750763|NCT02938351|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patient and caregiver will receive an IPAD with Vidyo software to complete the treatment sessions||||
33750764|NCT04298593|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective registry||||
33750765|NCT02696655|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750766|NCT04294966|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33750767|NCT02852551|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33750768|NCT02063126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33750769|NCT01830127|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750770|NCT00003954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750771|NCT00598429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750772|NCT06091865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750773|NCT05774366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750774|NCT01735773|||COHORT||CROSS_SECTIONAL|||||||
33961518|NCT00434148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961519|NCT00817258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961520|NCT00800722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961521|NCT04432818|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961522|NCT03076528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34173456|NCT06366607|||OTHER||CROSS_SECTIONAL|||||||
34173457|NCT03996070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173458|NCT05043363|||COHORT||PROSPECTIVE|||||||
34173459|NCT00784563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860756|NCT05628116|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Blinding was carried out by using placebo equivalent to XC243 tablets without active pharmaceutical ingredients (API) and the corresponding labeling of the ID.|The dose cohorts will be included into the study subsequently based on preliminary safety results evaluation performed by the DSMC. 2 doses of XC243/placebo (50 mg, 100 mg) were used in the single-dose ascending study. 1 dose of XC243/placebo (200 mg) were used in the single-dose food effect study. 1 dose of XC243/placebo (200 mg) were used in the repeated dose study.The duration of exposure to the ID is planned 1 day in single dosing cohorts and 14 days in multiple dosing cohort.|t|f|t|f
34173460|NCT05000021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34173461|NCT03210948|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33860757|NCT01210989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860758|NCT02754713|||COHORT||PROSPECTIVE|||||||
33860759|NCT03066752|||CASE_CONTROL||PROSPECTIVE|||||||
33860760|NCT00875095|||CASE_ONLY||CROSS_SECTIONAL|||||||
33860761|NCT04936841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860762|NCT01721603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173462|NCT05791253|||COHORT||RETROSPECTIVE|||||||
33860763|NCT02729389|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33860764|NCT00165633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860765|NCT01248702|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34173463|NCT05109364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173464|NCT01242423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173465|NCT03043313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173466|NCT06202365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173467|NCT00168844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173468|NCT01447381|||COHORT||PROSPECTIVE|||||||
34173469|NCT02306720|||CASE_CONTROL||PROSPECTIVE|||||||
34173470|NCT03023449|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34173471|NCT01848015|||||PROSPECTIVE|||||||
34173472|NCT02722564|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||||||
34173473|NCT03027310|||CASE_CONTROL||PROSPECTIVE|||||||
34173474|NCT05858086|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34173475|NCT05842031|||COHORT||PROSPECTIVE|||||||
34173476|NCT03304678|NA|SINGLE_GROUP||OTHER||NONE||||||
34173477|NCT05108246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173478|NCT02035761|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173479|NCT05020028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173480|NCT00007202||||TREATMENT||||||||
34173481|NCT05757505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173482|NCT04207034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (investigator and outcome Assessor)|"The study was performed according to split- mouth design, and all teeth in the mouth were treated randomly using either the left or the right side of the maxilla and mandible for control , and the opposite side for the therapy. Each patient was entered into a clinical protocol consisting of two different treatment modalities.~Group I (n=10) - Test group ( diode laser + flap surgery) Group II (n=10) - control group (flap surgery)"|f|f|t|t
34173483|NCT04526106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1 (multiple ascending doses):~• Unresectable or metastatic CCA or other unresectable or metastatic solid tumor~Part 2 (RP2D determined in Part 1):~* Group 1: CCA patients w/ an FGFR2 fusion previously treated w/ an FGFRi treatment~* Group 2: CCA patients w/ an FGFR2 fusion w/ prior chemotherapy but no prior FGFRi treatment~* Group 3: Non-CCA patients w/ an FGFR2 fusion and no prior FGFRi~* Group 4: Non-CCA patients w/ an FGFR2 amplification and no prior FGFRi treatment~* Group 5: Non-CCA patients w/ an FGFR2 mutation and no prior FGFRi treatment~* Group 6: CCA patients w/ an FGFR2 fusion with no prior chemotherapy and no prior FGFRi treatment~* Group 7: CCA patients w/ an FGFR2 mutation or amplification and no prior FGFRi treatment~Part 3 (Extension of Part 2, Group 2):~• CCA patients w/ an FGFR2 fusion with prior chemotherapy but no prior FGFRi treatment~Part 4 (Rollover):~• Ongoing Parts 1, 2, and 3 patients enrolled on study and receiving RLY-4008"||||
34173484|NCT06103396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173485|NCT02371044|||COHORT||PROSPECTIVE|||||||
34173486|NCT04478201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34173487|NCT05642351|||CASE_ONLY||PROSPECTIVE|||||||
34173488|NCT03017963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173489|NCT06049641|||COHORT||CROSS_SECTIONAL|||||||
34173490|NCT06243198|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173491|NCT00786669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173492|NCT01457651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173493|NCT05559450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173494|NCT02675946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrollment to Single Agent Dose Expansion, Roll-over Cohort, Phase 1b CGX1321-101 in combination with pembrolizumab dose expansion and Phase 1b CGX1321 in combination with encorafenib + cetuximab dose escalation and dose expansion||||
34173495|NCT06704555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173496|NCT02014324|||COHORT||PROSPECTIVE|||||||
34173497|NCT05714267|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34173498|NCT05805631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173499|NCT01231984|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34173500|NCT06538584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized model with 2 arms/interventions consisting of caffeine v. saline placebo|t|f|t|f
33860766|NCT06494254|||COHORT||PROSPECTIVE|||||||
33860767|NCT00928564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33860768|NCT04586998|NA|SINGLE_GROUP||OTHER||NONE||||||
34173501|NCT01140308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34173502|NCT00531531|||COHORT||CROSS_SECTIONAL|||||||
33860769|NCT00153361|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33860770|NCT03270332|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33860771|NCT02535663|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33860772|NCT03706950|||CASE_CONTROL||PROSPECTIVE|||||||
33961523|NCT01291667|||||PROSPECTIVE|||||||
33961524|NCT00148473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173503|NCT00771394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173504|NCT03851445|NA|SEQUENTIAL||SCREENING||NONE||The Lung-MAP study is an umbrella protocol which contains a screening component and a clinical trial component. Patients are allowed to participate in the screening component either at progression on prior therapy or to be pre-screened while receiving therapy for stage IV or recurrent NSCLC. The clinical trial component consists of biomarker-driven studies evaluating drug-biomarker combination for patients determined to have a matching biomarker and non-match studies evaluating therapies in patients without any of the study biomarkers.||||
34173505|NCT04765371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173506|NCT05935553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173507|NCT04811703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173508|NCT04997317|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a, two-step, cross-over, open-label phase 0 study comparing the therapeutic index of 177Lu-DOTA-JR11 and 177Lu-DOTATOC followed by a single-arm open-label Phase I/II study.||||
34173509|NCT06472661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173510|NCT06585878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173511|NCT02028806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750775|NCT04223518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Once the consent is signed, each participant will be assigned a unique study number, which will replace any identifiable data for the remainder of the study. The code key will be stored in a divisional research University of Texas, Houston-secure website. The participants will then be randomized to receive either SBI or placebo (in form of hydrolyzed collagen) to be taken once daily for a total of 60 days. The medical products will be supplied to the participants in a blinded manner by the principal investigator and study co-ordinator.|Single-center, randomized control double blinded prospective clinical trial|t|t|t|f
33750776|NCT06058650|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33750777|NCT06088264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173512|NCT04960527|RANDOMIZED|CROSSOVER||PREVENTION||NONE||2-way crossover, randomised controlled trial. Participants will be allocated to consume tart cherry juice or a neutral water control on separate occasions. The order of this allocation will be randomised.||||
33860773|NCT05490979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants only receive information about the condition they have been assigned to and are not explicitly informed about the other conditions or the overall purpose of the study. All participants will be debriefed when the study has ended.||t|f|f|f
33860774|NCT00827762|||CASE_ONLY||PROSPECTIVE|||||||
34173513|NCT05382494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The saline is the same colour and consistency to the active drug (intranasal steroid) and will have the same sensation when sprayed into the nostril. Randomisation will be stratified by site, Royal Children's Hospital (RCH) and Monash Health (MH), with permuted random block randomisation. An independent statistician in the Clinical Epidemiology and Biostatistics Unit (CEBU) at Murdoch Children's Research Institute (MCRI) will arrange the randomisation schedules, which will be given to the Clinical Trials Pharmacy at RCH and MH. This schedule will remain blinded to all other study staff.|Multicentre, double-blind, randomised control trial|t|t|t|t
34173514|NCT00689039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173515|NCT01667900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173516|NCT01360697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173517|NCT03201796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The present study will be performed in double blind condition. Consequently, during the study, neither the Investigator nor the patient will be aware of the treatment assigned.|Double-blind, levofloxacin controlled, multicentre, international, prospective study.|t|f|t|f
34173518|NCT05644834|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34173519|NCT01773681|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173520|NCT03917849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173521|NCT03469947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective observational cohort administered TXA prehospital and a retrospective cohort for matched controls.||||
34173522|NCT06705049|||COHORT||OTHER|||||||
34173523|NCT02363335|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173524|NCT04003285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized, double-blind, placebo-controlled trial. All roles will be masked with the exception of the research pharmacist|Participants will be randomized to receive 0 nM ALLO (placebo), 50 nM ALLO (lower dose ALLO) or 150 nM ALLO (higher dose ALLO).|t|t|t|t
34173525|NCT01893463|||||PROSPECTIVE|||||||
34173526|NCT01344941|||CASE_ONLY||PROSPECTIVE|||||||
34173527|NCT01598766|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173528|NCT00703014|||OTHER||PROSPECTIVE|||||||
34173529|NCT02474797|NA|SINGLE_GROUP||SCREENING||NONE||||||
34173530|NCT03107481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173531|NCT00987376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173532|NCT05449821|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173533|NCT05835505|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blinded study.|This a crossover study in which everyone will have a period of time on the active medication and a period of time on the placebo.|t|t|t|t
34173534|NCT05236270|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Investigators who are providing the intervention and conducting analysis will be masked to study assignment|Interventions will address three primary areas to improve vaccination uptake: (1) process (text messages); (2) teachable moment messaging (motivational interviewing); and (3) barrier elicitation and reduction (electronic survey with tailored questions/prompts). In a factorial research design, two or more independent variables are concurrently examined within the same trial. The three factors are crossed with one another to create a total of eight experimental conditions. An equal number of sites are randomly assigned to each condition, using a random number generator.||||
34173535|NCT01303341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173536|NCT04545749|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33750778|NCT06624137|||OTHER||PROSPECTIVE|||||||
33750779|NCT03784339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860775|NCT00565942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860776|NCT00752531|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33860777|NCT00160355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860778|NCT02896504|||COHORT||PROSPECTIVE|||||||
33750780|NCT06235736|||OTHER||PROSPECTIVE|||||||
33860779|NCT03116854|||COHORT||PROSPECTIVE|||||||
33860780|NCT01034293|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33750781|NCT01737372|||COHORT||CROSS_SECTIONAL|||||||
33860781|NCT02306382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860782|NCT00601250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860783|NCT00882453|||COHORT||PROSPECTIVE|||||||
33860784|NCT04013516|RANDOMIZED|PARALLEL||OTHER||NONE||Participants randomly assigned to different incentive amounts (treatment arms), a pure control arm, and a placebo arm which consisted of a phone call without an additional incentive.||||
33860785|NCT01979835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860786|NCT04110119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860787|NCT00004639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860788|NCT02422485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860789|NCT01131403|||CASE_CONTROL||PROSPECTIVE|||||||
33860790|NCT01859286|||COHORT||PROSPECTIVE|||||||
33860791|NCT01337804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860792|NCT01684904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860793|NCT00833911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860794|NCT06012968|||COHORT||PROSPECTIVE|||||||
33860795|NCT00233844|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33860796|NCT04869280|||COHORT||PROSPECTIVE|||||||
33860797|NCT01238289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860798|NCT02838147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860799|NCT01704820|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33860800|NCT03270904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860801|NCT04005651|RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 150 subjects will be implanted bilaterally with 50 subjects implanted with the POD L GF lenses, 50 subjects implanted with the Symfony® intraocular lenses, and 50 subjects implanted with the AcrySof® monofocal lenses. The objective is to complete approximately 141 subjects through 12 month post-operative follow-up (\~47 subjects in each cohort).||||
33860802|NCT06068660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33860803|NCT02494466|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33860804|NCT05781568|||CASE_CONTROL||OTHER|||||||
33860805|NCT05245409|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860806|NCT01306890|||COHORT||PROSPECTIVE|||||||
33860807|NCT05145062|||COHORT||PROSPECTIVE|||||||
33860808|NCT04691999|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33860809|NCT05968183|||COHORT||PROSPECTIVE|||||||
33860810|NCT01549782|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33860811|NCT02120625|||COHORT||PROSPECTIVE|||||||
33961525|NCT06199973|RANDOMIZED|PARALLEL||TREATMENT||NONE||SHR-A1811 for Injection with TAS-102||||
33961526|NCT05786521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33961527|NCT04184479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860812|NCT01009554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33961528|NCT03820999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study, due to the intervention (lectures) and the criteria for receiving the intervention (Lyme neuroborreliosis incidens \> 4.6/100.000), the study cannot be blinded.|Open label interventional study where primary Health care Physicians in areas on Funen Island, Denmark, are included if they have their practice in an area with Lyme Neuroborreliosis incidens \> 4.6/100.000||||
33961529|NCT02043561|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33961530|NCT01211496|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33961531|NCT01350531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961532|NCT04542330|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to treatment. The physicians administering the BCG vaccine or placebo will not be blinded.|Placebo-controlled randomized trial.|t|f|f|t
33961533|NCT00666731|||OTHER||PROSPECTIVE|||||||
33961534|NCT01489696|RANDOMIZED|CROSSOVER||||NONE||||||
33961535|NCT06537908|||COHORT||PROSPECTIVE|||||||
33860813|NCT03154762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Similar equipment will be used, the programming of the positive pressure device will be performed by an external person and a cover will be placed on the screen.|Experimental, prospective, longitudinal, comparative, parallel group study|t|f|t|f
33860814|NCT01677351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860815|NCT00786396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860816|NCT00809081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860817|NCT01398293|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33860818|NCT04005417|||OTHER||RETROSPECTIVE|||||||
33860819|NCT03241212|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33860820|NCT06093750|||COHORT||PROSPECTIVE|||||||
33860821|NCT06396793|||COHORT||PROSPECTIVE|||||||
33860822|NCT05142020|||CASE_CONTROL||PROSPECTIVE|||||||
33860823|NCT02274636|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33860824|NCT01835197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34064371|NCT03782532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064372|NCT03763058|NA|SINGLE_GROUP||TREATMENT||NONE||A monocentric prospective before-after study on patients carried out in chronic pain department of the CHU Sud Reunion. Patients will be evaluated for inclusion in the study, and will complete the 3-month music intervention. Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month. Before starting the musicotherapy program, retrospective data will be collected on the month prior regarding migraine attacks (frequency, severity, duration, treatment intake).||||
34064373|NCT01014481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064374|NCT01997970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064375|NCT02464865|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34064376|NCT00320151|||OTHER||OTHER|||||||
34064377|NCT01052623|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064378|NCT05080361|||COHORT||CROSS_SECTIONAL|||||||
34064379|NCT04544163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064380|NCT04441749|||COHORT||PROSPECTIVE|||||||
33860825|NCT00462865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860826|NCT00821431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860827|NCT05409833|||OTHER||CROSS_SECTIONAL|||||||
33860828|NCT02685553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860829|NCT02608879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860830|NCT01836042|||COHORT||RETROSPECTIVE|||||||
33860831|NCT05886582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860832|NCT06072443|||COHORT||PROSPECTIVE|||||||
33860833|NCT04184960|||CASE_CONTROL||PROSPECTIVE|||||||
33860834|NCT00208897|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33860835|NCT03820375|||COHORT||PROSPECTIVE|||||||
33860836|NCT02686424|||COHORT||RETROSPECTIVE|||||||
33860837|NCT01596907|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33860838|NCT01877863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860839|NCT02129153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants in the study do not know if they are in the intervention group.||t|f|f|f
33860840|NCT04561804|||CASE_ONLY||PROSPECTIVE|||||||
33860841|NCT00593749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860842|NCT05001282|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Dose Escalation Dose Expansion, Simon's 2-stage||||
33860843|NCT03485781|||CASE_ONLY||PROSPECTIVE|||||||
33860844|NCT00723879|||COHORT||PROSPECTIVE|||||||
33860845|NCT01578967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860846|NCT05980910|||COHORT||PROSPECTIVE|||||||
33860847|NCT02898311|NA|SINGLE_GROUP||TREATMENT||||||||
33860848|NCT00269165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860849|NCT02014155|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33860850|NCT01868451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860851|NCT04370977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860852|NCT04367532|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants will be allocated to intervention (foam rolling, tissue flossing) or control group (without any intervention) using a randomized list of allocated numbers generated by a computer program. Investigator and Outcomes Assessor will be blinded to the allocation process.|Randomized controlled trial|f|f|t|t
33860853|NCT00331812|||||PROSPECTIVE|||||||
33860854|NCT05437198|||CASE_CONTROL||PROSPECTIVE|||||||
33860855|NCT01794585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860856|NCT04388540|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33860857|NCT03236051|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, parallel, controlled, open study.||||
33860858|NCT03595592|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel randomization to the study arms||||
33860859|NCT03641053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know which intervention substance they have been assigned to|A three-arm parallel assignment where one group receives honey, the second group receives povidone-iodine, and the third group receives paraffin gauze as wound dressing.|t|f|f|f
33860860|NCT00399451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860861|NCT02378454|||COHORT||CROSS_SECTIONAL|||||||
33860862|NCT03952806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Subject||t|t|t|f
33860863|NCT02442713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860864|NCT04566627|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Evaluators were blinded to the intervention condition of the schools.|Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33860865|NCT00769613||||SUPPORTIVE_CARE||NONE||||||
33860866|NCT05134090|||CASE_CONTROL||RETROSPECTIVE|||||||
33860867|NCT05196672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33860868|NCT02926469|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860869|NCT00312325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860870|NCT00399230|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33860871|NCT05511896|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860872|NCT01522482|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33860873|NCT02833480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860874|NCT03872453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Subject||t|t|t|f
34173537|NCT05723653|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of nGage, it is not possible to blind participants, interventionists, and investigators. However, we take the following steps to minimize bias, assess contamination, and enhance rigor: (1) collecting baseline data prior to randomization; (2) Treatment as Usual (TAU) providers are blinded to allocation; and (3) assessing contamination at follow-up surveys by identifying overlap between the networks of those in the nGage and TAU groups.|"Following study registration (at which a unique Study Identification (ID) will be assigned), Index participants will be randomized to either the nGage intervention group (n=300) or Treatment as Usual (TAU, n=300). Intervention arm Indexes will identify a Support Confidant (SC) (creating Index-SC dyads). Study staff will discuss pros and cons of TAU (equipoise induction) to balance the desirability of the two intervention conditions.~After the 12-month follow-up survey, we will re-randomize the 300 Index-SC dyads in the nGage condition with equal probability to continue receiving standard nGage mini-boosters \[referred to as Sustained nGage (n=150 Index-SC dyads)\] or a return to TAU (n=150 Index-SC dyads). Blocked randomization determined by recruitment site will be used to ensure balance across study arms. The randomization schedule will be prepared in advance, and treatment assignment will be obtained using the randomization module in REDCap."||||
33860875|NCT00238667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750782|NCT04575636|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33750783|NCT05964140|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Non-inferiority RCT||||
33750784|NCT04857268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750785|NCT03875027|||CASE_ONLY||RETROSPECTIVE|||||||
33750786|NCT04166409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750787|NCT06732765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Study will be single blind, assessor will be kept blind because patients and clinicians were difficult to mask due to well distinguished treatment protocol.||t|f|t|f
34173538|NCT03674528|||COHORT||PROSPECTIVE|||||||
34173539|NCT06459479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34173540|NCT02056743|RANDOMIZED|PARALLEL||||NONE||||||
34173541|NCT04803383|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34173542|NCT06459375|RANDOMIZED|PARALLEL||TREATMENT||NONE||after randomization patients will be divided into two groups through computer generated number programme. Patients in group A will receive modified Otago exercises with conventional treatment. Patients in group B will receive Action Observation Training with conventional treatment||||
34173543|NCT00657319|||COHORT||RETROSPECTIVE|||||||
34173544|NCT05948267|RANDOMIZED|PARALLEL||OTHER||SINGLE||The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.|t|f|f|f
34173545|NCT02623946|||COHORT||PROSPECTIVE|||||||
34173546|NCT06579755|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Cohort 1 is randomized and double-blinded. Cohort 2 is non-randomized and open label.||t|f|t|t
34173547|NCT03919396|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34173548|NCT05359458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33750788|NCT03717961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|this study is double blind masking: Both participants and investigators are unaware of the intervention assignment, others including statistician|Multicenter, double-blind, randomized, placebo-controlled, parallel groups, phase III|t|t|t|t
33750789|NCT04163705|||COHORT||PROSPECTIVE|||||||
33750790|NCT02223923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750791|NCT00859391|||COHORT||PROSPECTIVE|||||||
33750792|NCT02085408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750793|NCT04066348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750794|NCT02189551|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33860876|NCT04548414|||COHORT||PROSPECTIVE|||||||
33860877|NCT05741346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860878|NCT04460677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860879|NCT05118555|||COHORT||PROSPECTIVE|||||||
33860880|NCT04119960|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33860881|NCT01068925|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33860882|NCT01535014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860883|NCT02178553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860884|NCT00973154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860885|NCT00770237||CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33860886|NCT03040310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860887|NCT03057171|||CASE_ONLY||PROSPECTIVE|||||||
33860888|NCT01422850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860889|NCT06459323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33860890|NCT02795416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860891|NCT01746680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860892|NCT06528652|||COHORT||PROSPECTIVE|||||||
33860893|NCT04174547|||COHORT||OTHER|||||||
33860894|NCT01251120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860895|NCT03362879|||COHORT||CROSS_SECTIONAL|||||||
33860896|NCT04010773|||OTHER||PROSPECTIVE|||||||
33860897|NCT00704002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860898|NCT00922103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961536|NCT01825616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33860899|NCT01153802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860900|NCT04288895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860901|NCT06200298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33860902|NCT06348368|||CASE_CONTROL||RETROSPECTIVE|||||||
33860903|NCT01768650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33860904|NCT05425706|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33860905|NCT03459144|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34173549|NCT04391374|||COHORT||PROSPECTIVE|||||||
33860906|NCT05802758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064381|NCT03518411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173550|NCT00668421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173551|NCT03963765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Transepidermic Application of Metilaminolevulinate in Daylight Photodynamic Therapy in the Treatment of Photodamaged Skin||||
34173552|NCT04228471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||f|f|t|t
34173553|NCT05621330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34173554|NCT05433246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173555|NCT01904188|||COHORT||RETROSPECTIVE|||||||
34173556|NCT05911542|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173557|NCT06549478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173558|NCT02506894|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34173559|NCT02395458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173560|NCT05083416|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173561|NCT06706531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial|t|f|f|f
34173562|NCT01274949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173563|NCT03213340|RANDOMIZED|CROSSOVER||OTHER||SINGLE||3 cohorts, crossover within cohort|t|f|f|f
34173564|NCT03101969|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34173565|NCT03270943|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of the interventions tested in this study does not allow for masking of subjects, instructors, or other personnel involved in program delivery. To preserve unbiased outcome assessments, study personnel involved in clinical assessments or data analysis will be masked with respect to group assignment. To minimize differences in subject expectancy, the programs will be described to participants as two programs, both of which have been previously found to be beneficial to teens.|After the first two intervention-refinement groups, participants will be randomized to one of two groups: a mindful self-compassion program or an active attention control program. Randomization will be stratified by gender. As soon as 20 eligible adolescents qualify for enrollment, they will be allocated to either the MFY or healthy lifestyle groups, using a specially-designed computer program which utilizes a random number generator with a permuted block design to ensure that the number of subjects allocated to the two arms over time are equal and to conceal the allocation. This will continue through 3 additional cohorts of adolescents for a total sample size of 80 (including test groups). Randomization is designed to assess feasibility of the randomization plan, in addition to general feasibility issues of the delivery of the educational programs.|f|f|f|t
34173566|NCT02632799|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33860907|NCT06064513|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34173567|NCT04923867|||CASE_ONLY||RETROSPECTIVE|||||||
34173568|NCT06599736|NA|SINGLE_GROUP||TREATMENT||NONE||Active treatment for all subject enrolling prospectively.||||
34173569|NCT03431532|||COHORT||OTHER|||||||
34173570|NCT05641545|NA|SINGLE_GROUP||OTHER||NONE||||||
34173571|NCT05119777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173572|NCT06487260|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173573|NCT00865345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173574|NCT03291067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33860908|NCT01296035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860909|NCT06104202|||COHORT||OTHER|||||||
33860910|NCT02600455|||COHORT||PROSPECTIVE|||||||
33860911|NCT02636153|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33860912|NCT06280326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental trial|t|f|f|f
33860913|NCT02884726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860914|NCT01364363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860915|NCT06466863|||COHORT||PROSPECTIVE|||||||
33860916|NCT03136419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860917|NCT04543604|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860918|NCT05506501|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860919|NCT00640016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961537|NCT05384327|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33961538|NCT02034500|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33961539|NCT00471588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961540|NCT00441207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961541|NCT03478345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961542|NCT03446716|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to the ADHD or Typically Developing group based on diagnosis history. Each then completes the intervention (EXTENSION) either preceded or followed by a week of baseline sleep (CONTROL). The order is pseudo-randomized.||||
33961543|NCT00467038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961544|NCT00660608|||CASE_CONTROL||PROSPECTIVE|||||||
33961545|NCT06562530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial (RCT). True experimental research design study|t|f|f|f
33961546|NCT01682512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961547|NCT06032819|||CASE_CONTROL||RETROSPECTIVE|||||||
33961548|NCT03354923|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34064382|NCT06509919|||COHORT||PROSPECTIVE|||||||
34064383|NCT01134861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064384|NCT03488069|||OTHER||PROSPECTIVE|||||||
34173575|NCT01605006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173576|NCT02250222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173577|NCT06577259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33750795|NCT05579418|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is an investigator-initiated, prospective, randomized, open-label study. All patients presenting with STEMI will be screened for the trial, those patients with LDL-C levels higher than guideline-recommended targets despite prior high-intensity statin therapy, or when the LDL-C not projected to decrease below the recommended targets if they are newly initiated on high intensity statin therapy, will be considered for the study.~Participants will be randomly assigned using permuted block design with a computer random number generator, the block size is fixed (8 per block) with random allocation within the block to either the control group or the interventional group (4 for each group, patient allocation within the block is randomly assigned). Once the patient has given consent to be included in the trial, he/she is then irreversibly randomized by opening the next sealed envelope, within the current block, containing his/her assignment."||||
33750796|NCT01214772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33750797|NCT01254058|||CASE_CONTROL||PROSPECTIVE|||||||
33750798|NCT00636610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750799|NCT04678492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750800|NCT00439868|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||||||||
33750801|NCT02711774|||CASE_CROSSOVER||PROSPECTIVE|||||||
33750802|NCT03461003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750803|NCT01835951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33750804|NCT03977038|||CASE_CONTROL||PROSPECTIVE|||||||
33750805|NCT05265611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33750806|NCT03528538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and the participants remained blind until after the total completion of the experiment.|Subjects will complete 3 assessments during the study at Day 0, Week 4, and Week 8. At each assessment, they complete the following: self-report inventories (e.g., Aging Male Symptoms Questionnaire, Trait Anxiety Inventory, Health-related Quality of Life), body composition via BOD POD, heart rate, blood pressure, and blood draws. The subjects will be randomized to one of the following three conditions: (1) AlphaFenTM fenugreek (400 mg/d), (2) AlphaFenTM fenugreek (500 mg/d), or (2) placebo control. The subjects will be asked to take one capsule of the fenugreek supplement or placebo daily for eight weeks.|t|f|t|f
33750807|NCT03919422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750808|NCT06443775|||COHORT||PROSPECTIVE|||||||
33750809|NCT05181163|||OTHER||CROSS_SECTIONAL|||||||
33750810|NCT00689767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750811|NCT00908154|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33750812|NCT05261633|||COHORT||PROSPECTIVE|||||||
33750813|NCT05476328|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33750814|NCT06670625|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33750815|NCT02291887|||COHORT||RETROSPECTIVE|||||||
33750816|NCT02045238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750817|NCT05616988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173578|NCT05948735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assessor will be blinded to the allocation of participants to groups and will not be involved in the intervention process.||f|f|t|t
34173579|NCT03285724|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34173580|NCT06375200|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750818|NCT03204279|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33750819|NCT02739581|RANDOMIZED|PARALLEL||TREATMENT||||||||
33750820|NCT01495429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750821|NCT03553810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750822|NCT01914094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750823|NCT05156918|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750824|NCT02726451|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34173581|NCT01447589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173582|NCT00176696|||COHORT||PROSPECTIVE|||||||
34173583|NCT04988295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173584|NCT04166812|||COHORT||PROSPECTIVE|||||||
34173585|NCT00781768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173586|NCT05981196|||COHORT||PROSPECTIVE|||||||
34173587|NCT06334393|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34173588|NCT03987360|||COHORT||PROSPECTIVE|||||||
34173589|NCT06112171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173590|NCT05125835|||COHORT||RETROSPECTIVE|||||||
34173591|NCT03938311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre-admission trial assistants and medical staff aware of group allocation will not have contact with the patients. At each study site, a group of physiotherapists will be responsible for the interventions for all three study groups. Multi-disciplinary physicians, assessors, data analysts, and statisticians will be blinded to the group allocation.|Patients with acute ischemic stroke fulfilling the inclusion and exclusion criteria will be randomly allocated to either either (1) the very early mobilization group in whichmobilization is initiated within 24 hours from stroke onset, (2) the early mobilization group in which mobilization begins between 24 and 72 hours poststroke, or (3) the late mobilization group in which mobilization is started after 72 hours poststroke.|f|f|f|t
34173592|NCT05968820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173593|NCT04874714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.~The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.~So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance."|Prospective, randomized, placebo-controlled, multi-center trial|t|f|t|t
34173594|NCT00265694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173595|NCT03631485|||OTHER||CROSS_SECTIONAL|||||||
34173596|NCT05249140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173597|NCT05986916|||COHORT||PROSPECTIVE|||||||
34173598|NCT04604600|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173599|NCT04410497|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomised trial were children, after Guardians written consent,are randomized to one of two dressings.||||
34173600|NCT02948855|||CASE_ONLY||PROSPECTIVE|||||||
34173601|NCT03010696|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173602|NCT03842696|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173603|NCT03298360|||OTHER||OTHER|||||||
34173604|NCT03290443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173605|NCT03272750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173606|NCT00481832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173607|NCT02043756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173608|NCT01820299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173609|NCT01322100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173610|NCT03220971|||COHORT||RETROSPECTIVE|||||||
34173611|NCT04818268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34173612|NCT02948608|||COHORT||PROSPECTIVE|||||||
34173613|NCT00002814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173614|NCT01394055|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34173615|NCT01961505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173616|NCT06349798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, investigator and outcome assessor will be blind., A nurse anesthetist who will not be involved in the follow up of the patient will receive the kit and prepare the syringes.|Multicenter, double-blind, randomized controlled trial in 3 parallel groups (placebo group, nefopam bolus group and nefopam Continuous Intra-Venous Infusion CIVI group).|t|f|t|t
34173617|NCT01856608|||||PROSPECTIVE|||||||
34173618|NCT05814185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34173619|NCT05564104|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961549|NCT00150475|RANDOMIZED|CROSSOVER||ECT||SINGLE||||||
33961550|NCT04058600|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking.|Single center prospective randomized two arms study||||
33961551|NCT01593709|||OTHER||PROSPECTIVE|||||||
33961552|NCT00243282|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961553|NCT02913261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961554|NCT05309174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961555|NCT06183866|||CASE_CONTROL||RETROSPECTIVE|||||||
33961556|NCT02791711|NA|SINGLE_GROUP||OTHER||NONE||||||
33961557|NCT06541899|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33961558|NCT05842694|||OTHER||RETROSPECTIVE|||||||
33961559|NCT02460133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961560|NCT05318807|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility pilot study||||
33961561|NCT02615197|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961562|NCT01883531|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33961563|NCT00074386|||COHORT||PROSPECTIVE|||||||
33961564|NCT06539637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961565|NCT06030271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961566|NCT01866137|||CASE_ONLY||PROSPECTIVE|||||||
33961567|NCT05706454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, Investigator and Outcome Assessor Blinded Method of concealment: Pharmacy-controlled Randomization|Randomized, Parallel Group, Placebo Controlled Trial|t|t|t|t
33961568|NCT01139892|||CASE_ONLY||PROSPECTIVE|||||||
33961569|NCT01376180|||||PROSPECTIVE|||||||
33961570|NCT04430101|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be blinded for the result of the stress fluoroscopy.|"Participants are evaluated by weightbearing radiographs. Patients with no signs of dislocation on the weightbearing radiographs will undergo stress fluoroscopy. Patients with negative stress fluoroscopy are allocated to Cohort 1, patients with positive stress fluoroscopy are allocated to Cohort 2.~The study design is a non-inferiority study, proving to show that the outcomes of Cohort 2 are non-inferior compared to Cohort 1.~Patients with positive weightbearing radiographs (interval between medial cuneiform and base of second metatarsal increased by \> 2 mm compared to the contralateral side) will be operated with minimally invasive stabilization (eg. isolated homerun screw) and followed up prospectively as a single cohort (Cohort 3)."|t|f|f|f
33961571|NCT05496101|NA|SINGLE_GROUP||TREATMENT||NONE||Intraoperative CLI + FAR LightPath imaging with comparator-Standard-of-care histopathology (gold standard)||||
33961572|NCT03643406|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33961573|NCT00788684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961574|NCT02365818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961575|NCT03851731|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34173620|NCT00301808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173621|NCT05475249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is designed as double blind, as patient and the clinical examiner (LS) will not have information at any time of which type of abutment is placing, this would be possible due to the identical aspect of both type of abutments. The randomization will be done by the other examiner (AC), that will inform the laboratory.||t|f|f|t
34173622|NCT05411562|||COHORT||PROSPECTIVE|||||||
34173623|NCT00006319|||COHORT||PROSPECTIVE|||||||
34173624|NCT06098469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750825|NCT01854099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173625|NCT05937841|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34173626|NCT05757713|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized, open-label, multi-center study||||
34173627|NCT05473026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The principal investigator will inform participants of their group assignment and provide intervention details. The research assistant and biostatistician will be blind to group allocation.|Two-group parallel random-assignment experimental design.|f|f|f|t
34173628|NCT02251262|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34173629|NCT04308421|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34173630|NCT05245435|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173631|NCT04892641|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34173632|NCT04675593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173633|NCT00659412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34173634|NCT05705947|||CASE_ONLY||PROSPECTIVE|||||||
34173635|NCT06035562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173636|NCT03863795|||COHORT||PROSPECTIVE|||||||
34173637|NCT04829734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (active PBMT-sMF or placebo PBMT-sMF) and will be instructed not to inform the patients or other researchers as to the type of treatment (active PBMT-sMF or placebo PBMT-sMF). Therefore, the researcher responsible for the treatment, the investigator and the outcome assessor will be blinded to the type of the treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active PBMT-sMF or placebo PBMT-sMF).||t|t|t|t
33750826|NCT05652062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750827|NCT06634368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a single-blind, parallel group, randomized pilot trial of a 3-month caregiver support intervention for caregivers of hospitalized Veterans with dementia compared to health education. Participants will be assigned at random to the intervention (Hospital GamePlan4Care) or health education control. Assessment of the primary and secondary outcomes will occur pre-intervention at baseline and post-intervention at 1 and 3 months.|f|f|f|t
33750828|NCT06669169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173638|NCT03316196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two arm randomized controlled trial|t|f|t|t
34173639|NCT04131413|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three dose level cohort study||||
34173640|NCT02195765|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33750829|NCT04780334|||CASE_CONTROL||PROSPECTIVE|||||||
33750830|NCT02833168|||CASE_CONTROL||PROSPECTIVE|||||||
33750831|NCT06701994|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33750832|NCT00274638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750833|NCT05956119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750834|NCT04801004|||COHORT||PROSPECTIVE|||||||
33750835|NCT01401439|||COHORT||PROSPECTIVE|||||||
34173641|NCT06044675|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173642|NCT03919773|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double-blind|double-blind randomized controlled crossover pilot study|t|t|t|t
34173643|NCT03151629|||COHORT||PROSPECTIVE|||||||
33750836|NCT02660827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750837|NCT00260468|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33750838|NCT04432597|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750839|NCT06302101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961576|NCT01241266|||CASE_ONLY||PROSPECTIVE|||||||
33961577|NCT04619069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961578|NCT00377715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961579|NCT06390423|||COHORT||PROSPECTIVE|||||||
33961580|NCT01254994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961581|NCT03526185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 separate cohorts are included in the study design. These groups will not be directly compared.||||
33961582|NCT02827422|||COHORT||PROSPECTIVE|||||||
33961583|NCT03023098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961584|NCT04871997|||OTHER||PROSPECTIVE|||||||
33961585|NCT03180346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33961586|NCT00898131|||COHORT||PROSPECTIVE|||||||
34173644|NCT05935761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded study, all are blinded except for the research pharmacist who creates the randomization schedule.|Randomized, double-blind, placebo controlled trial.|t|t|t|t
34173645|NCT02371057|||CASE_CONTROL||PROSPECTIVE|||||||
34173646|NCT05977413|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34173647|NCT04541589|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This will be a double-blind treatment until the final database lock of Core study (NCT03905525).~Participants, Investigator, site staff, and persons performing the assessments will remain blinded to the identity of the treatment until the final database lock of Core study (NCT03905525)"|"Upon completion of the core study (NCT03905525), Investigators will use their clinical judgment including responder definitions to decide if it is beneficial for participants to continue with the Extension study based upon response to therapy at the end of the treatment period of the core study.~Participants will be re-assigned to one of the following two treatment arms:~* Arm 1 - Iscalimab Dose 1 s.c. Q2W~* Arm 2 - Iscalimab Dose 2 s.c. Q2W and Placebo~At Week 60 of the TWINSS core study (NCT03905525), all eligible participants from the core study can opt to be enrolled in the extension study"|t|t|t|f
34173648|NCT04458636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173649|NCT01844765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173650|NCT00468169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961587|NCT06537856|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the study, participant blinding was performed by ensuring that the participants did not know which group they were in|In the study, there are two parallel groups as control and intervention groups|t|f|f|f
34173651|NCT05583773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34173652|NCT01874197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173653|NCT05295485|||OTHER||CROSS_SECTIONAL|||||||
34173654|NCT03922100|NA|SEQUENTIAL||TREATMENT||NONE||"This is an open-label Phase I/II, first-in-human (FIH), non-randomized, multi-center study conducted in two parts: a Phase I including patients with AML and CMML and a Phase II exploratory study comprising two parallel cohorts of AML FLT3 mutated patients.~The Phase II portion of the study is currently being conducted in EU only."||||
34173655|NCT04421053|||COHORT||PROSPECTIVE|||||||
34173656|NCT05158270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Computer-generated randomization numbers will be used to randomly assign patients into 3 groups using sealed opaque envelopes that will be randomly selected by each patient and contained a group number in which the patient was enrolled. Once enrolled in the study, patients will be randomly assigned into 3 groups;~Group I (ESP Group): will receive US-guided ESPB. Group II (AQL Group): will receive US-guided AQLB. Group III (Control Group): will receive IV multimodal analgesia only.~Both patients and data collector responsible for assessing outcomes will be blinded to group assignment (double-blinded clinical trial)."||t|f|f|t
34173657|NCT02570178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34173658|NCT05178173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor)|Randomized, placebo-controlled, double-blind prospective trial to test the efficacy and acceptability of 5 therapeutic, antiseptic mouth rinses to inactivate SARS-CoV-2 virus in saliva of COVID-19 positive patients.|t|t|f|t
34173659|NCT00173407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173660|NCT05603793|||COHORT||PROSPECTIVE|||||||
34173661|NCT05724277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two different interventions (mindfulness meditation and virtual reality) will be applied to two different experimental groups before surgery. The control group has no intervention.|t|f|f|t
34173662|NCT05034146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Experimental: 68Ga-FAPI PET/CT Investigators select subjects from patients who have underwent whole-body 18F-FDG PET/CT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET/CT scan with time interval of one to four week.||||
34173663|NCT03113851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173664|NCT05708911|NA|SINGLE_GROUP||TREATMENT||NONE||Study of healthy subjects||||
34173665|NCT02996344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34173666|NCT04688450|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No masking|This is a single arm feasibility study||||
34173667|NCT04056819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173668|NCT05428332|RANDOMIZED|PARALLEL||TREATMENT||NONE|No one will be masked/blinded in this study.|Two groups. One brace (intervention) group and one no brace (control) group.||||
34173669|NCT04617782|RANDOMIZED|CROSSOVER||OTHER||NONE|open label|Phase 1, open-label, randomized, 3-period, 3-treatment, crossover PK study to evaluate the steady-state pharmacokinetics||||
34173670|NCT03524846|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a prospective randomized, single-blind, placebo-controlled study||||
34173671|NCT06544174|||COHORT||PROSPECTIVE|||||||
34173672|NCT04889872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173673|NCT00114569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961588|NCT00188279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961589|NCT02905318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961590|NCT05805956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961591|NCT02320838|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33893794|NCT06145750|RANDOMIZED|PARALLEL||SCREENING||NONE||Physician practices (the study participants) will be randomized 1:1:2 to Arm A1 (control), Arm A2 (Control) or Arm B (intervention). Arm A practices will be further randomized 1:1 into two groups (A1:A2) to observe lung cancer screening standard of care. Practices in A1 will be observed; practices in A2 will receive standard education on lung cancer screening for Continuing Medical Education (CME) credit. Randomizing within Arm A aims to delineate the impact standard lung cancer screening education may have on utilization. Arm B (intervention) practices will receive education on FirstLook™ and have access to order FirstLook™ at the providers' discretion. A limited data set (LDS) will be extracted from the primary care practice EMRs for the study analysis. The study will be conducted under a waiver of consent as it is embedded into standard care, and the risk to patients is considered minimal.||||
34064385|NCT03541707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients will be allocated, based on chance, to receive active therapy or a as if stimulation, with no knowledge of patient or therapist who receives the active therapy"|Fifty-two adolescent patients suffering from major depression that are still severely ill after at least one psychological treatment and at least 2 adequate treatments knowledge of patient or doctor who receives the active therapy. Patients will be evaluated for efficacy, side effects, and cognitive performance. Brain waves (using EEG) will be monitored to see if they can predict who will respond to deep TMS.with medications, will be recruited. After the informed consent of guardians and patients, a systematic clinical evaluation with the aid of appropriate questionnaires will be performed. Patients will be allocated in a randomized double blind placebo controlled manner to dTMS or Sham treatments for about half an hour per day over 20 consecutive working days.|t|t|t|t
34064386|NCT02787057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064387|NCT05983510|||COHORT||RETROSPECTIVE|||||||
34064388|NCT00313287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064389|NCT06058611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The professionals responsible for the assessments will be blinded and will be different from the professionals carrying out the intervention. Both will be trained.|Parallel allocation Two intervention group (GI1 and GI2) and a control group (CG) with the same characteristics are included|f|f|f|t
34064390|NCT01835028|||COHORT||PROSPECTIVE|||||||
34064391|NCT02661061|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Masking took place by sealed envelope random allocation and double blinding of participants and raters was assessed throughout. The anaesthesiologist administering infusions was aware of the allocation.|A randomised, double-blind, placebo-controlled study designed to assess feasibility of recruitment, randomisation and retention.|t|t|t|t
34064392|NCT05887024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The selected patients will be allocated by computerized block randomization.|"A. Control group (Group A) thirty patients will receive conventional physical therapy program (TENS, electric heating packs, and McKenzie back exercises).~B. Study group (Group B) thirty patients will receive radial extracorporeal shock wave therapy and conventional physical therapy program (TENS, electric heating packs, and McKenzie back exercises)."|t|f|f|f
34064393|NCT03331731|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label, phase II, international, multicentre study||||
34064394|NCT01724684|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064395|NCT06319560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064396|NCT01643278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064397|NCT06252467|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||"Crossover Assignment~Crossover, randomized, double-blind trial (blinding of the cyclists and the researcher responsible for evaluations)"|t|t|t|t
34064398|NCT06400004|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34064399|NCT03394625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064400|NCT06046209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34064401|NCT04373564|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34064402|NCT06176469|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34064403|NCT01417858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34064404|NCT02942043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064405|NCT05981014|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I: Single-arm, dose-escalation and dose-expansion study Phase II: Two-arm parallel assignment||||
34064406|NCT00397592|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34064407|NCT01065909|||COHORT||PROSPECTIVE|||||||
34064408|NCT02045732|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34064409|NCT06209281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064410|NCT01714856|RANDOMIZED|CROSSOVER||||NONE||||||
34064411|NCT01420042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173674|NCT03182374|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blind study where subjects and evaluators are blinded to treatment up to 12-months. During the long-term follow-up phase (12 - 48 months), only subjects will be blinded to the study treatment resulting in single-blind design following 12-month follow-up time point.|During the long-term follow-up phase (12 - 48 months), subjects may also elect to cross over to the other treatment arm and receive additional injections of the other treatment as frequently as needed, provided they did not experience any significant clinical concerns after previous treatment administrations and are benefiting from it, as determined by the investigator. Subjects may only cross over from their originally assigned treatment group to the other treatment group one time during the study.|t|t|t|t
34173675|NCT01492933|||COHORT||CROSS_SECTIONAL|||||||
33893795|NCT01925703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893796|NCT05056831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893797|NCT02602509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893798|NCT06657508|||COHORT||PROSPECTIVE|||||||
33893799|NCT03754933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173676|NCT06114121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173677|NCT05595655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893800|NCT03285815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173678|NCT05574322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The RCT is divided into 3 distinct periods (see study diagram in Appendix 1): a 4-week control period, an 8-week intervention period and a 4-week follow-up period. This 3-period experimental design was designed to was designed to reduce various methodological biases|This is a single-center randomized controlled trial (RCT) in 2 parallel groups of athletic participants (18-40 years) in good general health: one receiving an 8-week muscle strengthening program (PRP group), the other not (control group) strengthening program (PRP group), the other not (control group).|t|f|f|f
34173679|NCT00334880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173680|NCT00476125|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34173681|NCT06705504|||COHORT||RETROSPECTIVE|||||||
34173682|NCT01572207|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173683|NCT00099801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173684|NCT06197321|||CASE_CROSSOVER||PROSPECTIVE|||||||
34173685|NCT06362850|RANDOMIZED|PARALLEL||OTHER||NONE||In a manikin-based simulation study, the participants will be randomized to either performing the scenario with tele-support or without tele-support (80 participants 40 groups, 20 groups with tele-support, 20 groups without tele-support).||||
34173686|NCT05983458|NA|SEQUENTIAL||TREATMENT||NONE||||||
34173687|NCT06486103|NA|SINGLE_GROUP||TREATMENT||NONE||An Open-Label, Single-Arm, Prospective Interventional Proof-of-Science Study.||||
34173688|NCT00028067||||TREATMENT||||||||
34173689|NCT02249364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173690|NCT06475664|NA|SINGLE_GROUP||OTHER||NONE||This is a single center single-arm, pilot study||||
34173691|NCT00272363|||FAMILY_BASED||PROSPECTIVE|||||||
34173692|NCT04045535|RANDOMIZED|PARALLEL||TREATMENT||NONE|Intervention can't be masked. Statistician conducting the analysis will not know to which study arm a given patient has been assigned.|||||
33893801|NCT02318004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893802|NCT04727515|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33893803|NCT00393562|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893804|NCT05219812|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33893805|NCT02249715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893806|NCT04281797|||COHORT||PROSPECTIVE|||||||
33893807|NCT04775823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893808|NCT04437264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care team and study staff in the ICU will be aware of arm assignment. Study staff abstracting outcome data will be blinded to arm assignement.||f|f|f|t
33893809|NCT00863616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961592|NCT03510013|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive sevoflurane 8% with O2:N2O or O2:air 1:1 L/min under controlled ventilation. Time to achieve alveolar concentration of sevoflurane of 1%, 1.5%, 2%, 2.5%, 3% and 3.5% will be recorded.||||
33961593|NCT06365931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961594|NCT05762120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064412|NCT03236116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34064413|NCT03497572|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173693|NCT02219464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893810|NCT06468371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893811|NCT03002506|NA|SINGLE_GROUP||OTHER||NONE||||||
33893812|NCT05241652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33893813|NCT06158139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893814|NCT00561353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893815|NCT01011257|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173694|NCT04156022|||CASE_ONLY||OTHER|||||||
33893816|NCT01856673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33893817|NCT01938183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860920|NCT05203523|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The group assignment is known only by the study coordinator and the PI. Group assignment will be randomized into either Group 1 or Group 2 using PROC PLAN procedure of SAS randomization. The group assignment of a participant could potentially be unblinded on compassionate ground (e.g., if a participant comes from a different city for the duration of the study) or request of the participant or any emergency situation (although very rare). In that case the participant's data may be excluded from the analysis totally or depending on when this unblinding occur, half of the data might be usable for analysis (if unblinding occur during the waiting period before crossing over). The unblinding decision will be made by the PI.|"This human research study is a crossover, placebo controlled and double-blind study. It will have two groups of subjects matched in age, and sex and cognitive level (measured by Montreal Cognitive Assessment: MoCA).~Group 1 (G1) participants will receive active tACS simultaneously with cognitive exercises.~Group 2 (G2) participants will receive sham tACS simultaneously with cognitive exercises.~The volunteers who cannot tolerate application of tACS and focus on the cognitive exercises at the same time, will be enrolled in a third group (G3); they will receive only cognitive exercises with the same protocol as in G1 and G2.~We will use only two periods design (one time crossing over)."|t|t|f|t
33860921|NCT06249503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860922|NCT04540848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860923|NCT03513172|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||f|t|t|t
33860924|NCT00300781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860925|NCT03840850|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33860926|NCT03786939|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860927|NCT02640820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860928|NCT00051480||||TREATMENT||||||||
33860929|NCT00408603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860930|NCT03576703|RANDOMIZED|CROSSOVER||PREVENTION||NONE||randomized crossover||||
33860931|NCT01256658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860932|NCT03712189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33860933|NCT02300051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860934|NCT03411954|||COHORT||PROSPECTIVE|||||||
33860935|NCT00577850|RANDOMIZED|PARALLEL||||NONE||||||
33860936|NCT02171650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860937|NCT00125879|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33860938|NCT05635916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization scheme will be developed using NQuery Software (Statistical Solutions, Boston, MA). The analyst will provide the research coordinator with randomization assignments in sequentially-numbered opaque envelopes. As the study is unblinded, both patients and providers will be aware of the randomization assignment. To help mitigate bias, the team members collecting and entering data will be masked regarding the patient's assignment. The REDCap database has the randomization assignments in an instrument separate from the study data collection instruments, allowing for data entry without seeing which group the subject is in.||f|f|f|t
33860939|NCT03486288|||CASE_CONTROL||PROSPECTIVE|||||||
34064414|NCT00571025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064415|NCT01657656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064416|NCT02005900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064417|NCT04150705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064418|NCT00006378||||TREATMENT||||||||
34064419|NCT00586898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064420|NCT04184635|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter, prospective, randomized, comparative open trial will be conducted on two parallel groups of patients with AMI complicated by cardiogenic shock.||||
34064421|NCT00004901||||TREATMENT||||||||
34064422|NCT01709773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064423|NCT03850223|||CASE_ONLY||PROSPECTIVE|||||||
34064424|NCT06730399|||OTHER||PROSPECTIVE|||||||
34064425|NCT04902079|||OTHER||PROSPECTIVE|||||||
34064426|NCT05914389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064427|NCT04960397|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, site investigators, and study personnel performing any study-related assessments following study product administration are blinded to product received. Laboratory personnel performing immunological assays will receive serum blinded to participant ID number, specimen visit number, and allocation group.||t|f|t|t
34064428|NCT04168840|||OTHER||PROSPECTIVE|||||||
34064429|NCT04344574|||CASE_CONTROL||RETROSPECTIVE|||||||
34064430|NCT05111509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064431|NCT02290145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064432|NCT00002575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064433|NCT03555942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Overall, 44 oocyte donors women will be asked to participate in a trial in which they will undergo 2 consecutive ovarian stimulation protocols within a period of 6 months with 150μg corifollitropin alfa followed by 200 IU rFSH in a fixed GnRH antagonist protocol starting in the early follicular, and luteal menstrual cycle phase||||
33860940|NCT05987566|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33860941|NCT02291302|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33860942|NCT00001333||||TREATMENT||||||||
33860943|NCT02855671|||COHORT||PROSPECTIVE|||||||
33860944|NCT04712825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860945|NCT02924298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860946|NCT06075238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860947|NCT06323200|||CASE_CONTROL||OTHER|||||||
33860948|NCT05193266|||COHORT||PROSPECTIVE|||||||
34064434|NCT03129295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34064435|NCT06217744|RANDOMIZED|PARALLEL||OTHER||NONE||cluster RCT, with students nested into classrooms (level of randomization)||||
34064436|NCT01587417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064437|NCT01708720|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34064438|NCT04478500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064439|NCT05057117|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-center, prospective, randomized, intra-individual, clinical trial comparing longterm efficacy of two treatments for axillary hyperhidrosis||||
33860949|NCT03533621|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double-blind, placebo-control trial. Investigators, subjects, and assessors were unaware of which group they were randomized to. Subjects received pills in a paper bad that looked identical to each other.|Subjects were randomized to probiotic or placebo group, and remained in that group for the 12 week study period.|t|f|t|t
33860950|NCT02927587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860951|NCT02880553|||OTHER||CROSS_SECTIONAL|||||||
33860952|NCT05779592|||COHORT||OTHER|||||||
33860953|NCT01369901|RANDOMIZED|PARALLEL||TREATMENT||||||||
33860954|NCT00681954|||COHORT||PROSPECTIVE|||||||
33860955|NCT03354442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A person who is not related to the research will paste a piece of paper over the Patient's name and the date of the photo then will give each x-ray a code and blind these codes on the researcher during the assessing process.||f|f|f|t
33860956|NCT01708239|||COHORT||PROSPECTIVE|||||||
33860957|NCT04536454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860958|NCT05827211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33860959|NCT04792658|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33860960|NCT04645771|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 50 patients with varicose veins of lower extremities treated with microwave ablation catheter were selected to observe their venous closure rate and postoperative adverse reactions.||||
33860961|NCT04213014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|After baseline data collection, adolescents and parents at each school will be told whether they will receive the GOAL intervention or not. We see no way to blind participants as to which group they are in. Adolescents, parents, principals, school staff, interventionists, and process evaluators will not be told about study aims and hypotheses. Process evaluators (trained by Co-I Pfeiffer) will be independent and not involved in other study areas. Data collectors and biostatistician will not be aware of any adolescent's or parent's (the dyad's) randomization status. Data collectors and interventionists are in separate teams and have separate training and meetings.|"The 16-wk intervention has 3 components.~1. After-School GOAL Club for moderate-to-vigorous physical activity (MVPA) and healthy eating/cooking skill-building (13 weeks; 120 min/event \[N=26\]; 2 days/week; not offered for 3 weeks of holiday, winter, spring school breaks).~2. Three Parent Meetings to empower participants regarding physical activity (PA) and healthy eating and cooking (90 min/meeting \[N=3\]; Weeks 1, 6, \& 11).~3. GOAL Social Networking Website for Parents to help their adolescents with MVPA and healthy eating and cooking (parents will complete weekly healthy habit-forming tasks; Weeks 1-16). The website will offer information, encouragement, and behavioral strategies to help parents increase their adolescents' PA and healthy eating."|f|f|f|t
33860962|NCT02982187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961595|NCT06114810|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This is an open-label, controlled, inequality, 4 arm randomized clinical trial assessing immunogenicity of several poliovirus vaccines and doses||||
34064440|NCT00851864|NA|SINGLE_GROUP||||NONE||||||
34064441|NCT01074151|||OTHER||PROSPECTIVE|||||||
34064442|NCT02900261|||OTHER||CROSS_SECTIONAL|||||||
34064443|NCT04937907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961596|NCT00319020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961597|NCT03800186|||CASE_CONTROL||RETROSPECTIVE|||||||
33961598|NCT04986566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34064444|NCT05971472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (participant)||t|f|f|f
34064445|NCT02810171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34064446|NCT04239443|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients fulfilling Eligibility Criteria will be included in our study. NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d).~Treatments will be administrated until disease progression, death, or unacceptable toxicity."||||
34064447|NCT03477643|||CASE_ONLY||RETROSPECTIVE|||||||
34064448|NCT05013281|||CASE_ONLY||RETROSPECTIVE|||||||
34173695|NCT06404112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|This platform protocol is designed to allocate participants into an intervention appendix based on their symptoms of sleep disturbance. Within the appendix, participants will be randomly assigned based on the appendix study design. Site investigators and personnel will be informed as to which study intervention appendix participants are assigned, but they will be blinded to whether participants are receiving the active study intervention or control, when possible. Similarly, participants will be blinded to active intervention or control, when possible. Randomization will be stratified by the study site; other stratification factors may be considered per appendix.|t|t|t|f
34173696|NCT05179252|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33860963|NCT03054207|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33860964|NCT03654313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860965|NCT03644251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961599|NCT03791515|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"100 patients with PPTH and 100 healthy controls will undergo a deep phenotyping of clinical characteristics and associated comorbidities. This is followed by a single MRI-session for all subjects.~Lastly, the 30 patients with PPTH will participate in a randomized, double-blind, placebo-controlled, 2-way crossover study. These patients will be allocated to receive intravenous infusion of CGRP or placebo (isotonic saline) over 20 minutes on 2 study days."||||
33860966|NCT03198598|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33860967|NCT05461482|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33860968|NCT00563667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961600|NCT04112615|||CASE_CONTROL||PROSPECTIVE|||||||
33961601|NCT04103411|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33961602|NCT04977817|||COHORT||OTHER|||||||
33961603|NCT02821117|NA|SINGLE_GROUP||OTHER||NONE||||||
33961604|NCT00927979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064449|NCT05948332|||COHORT||CROSS_SECTIONAL|||||||
34173697|NCT01950416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173698|NCT01274858|||COHORT||RETROSPECTIVE|||||||
34173699|NCT04001244|||COHORT||CROSS_SECTIONAL|||||||
34173700|NCT04487041|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34173701|NCT05411211|||COHORT||PROSPECTIVE|||||||
33750840|NCT06672471|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study uses a triple blinded trial design to reduce bias, ensuring that neither the primary clinical teams, the patients, nor the post-operative assessors know the assigned treatment groups. The surgical and anesthetic teams performing the operation are blinded to group allocation, following standard care protocols without knowing if a patient receives postoperative antibiotics. Similarly, assessors who evaluate patients for surgical site infections (SSIs) during follow-up are blinded, preventing any influence on SSI assessment from knowledge of the patient's treatment group.|"To determine whether postoperative antibiotic prophylaxis is necessary in patients undergoing Clean-contaminated head and neck surgery, or if a single perioperative antibiotic dose suffices.~Primary Outcome Measure:~Incidence of Surgical Site infection (SSI) This will be assessed on Post Operative Physical Clinic visits and will be recorded by an assessor who will be blind to whether the patient received Post Operative antibiotic or not.~Secondary Outcome Measure:~Post-Operative Complications The Secondary outcome measure, post-operative complications will be recorded as per the Clavien Dindo Classification (CDC)"|t|f|t|t
33750841|NCT01018394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750842|NCT02301312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750843|NCT01825538|||COHORT||RETROSPECTIVE|||||||
33750844|NCT04996758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750845|NCT05920551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33750846|NCT06369389|||COHORT||CROSS_SECTIONAL|||||||
33750847|NCT01952327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860969|NCT05686187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33860970|NCT01584154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860971|NCT02089841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33860972|NCT03157141|||COHORT||PROSPECTIVE|||||||
33860973|NCT04283266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33860974|NCT00376454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33860975|NCT03282487|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33860976|NCT01898689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only individual aware of the treatment group assignments is the investigational pharmacist who has no interaction with the study subjects. Treatment group assignments were released by the investigational pharmacy only after completion of data collection.|This is a split-body study in which each study subject receives both treatments: one on each side of the body. Which treatment is applied to which side of the body is randomized (and masked).|t|t|t|t
33860977|NCT02598557|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33860978|NCT01969825|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33860979|NCT05748353|||CASE_CONTROL||RETROSPECTIVE|||||||
33860980|NCT04423861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to receive either nitazoxanide 600 mg BID or Placebo (1:1)|t|t|t|t
33961605|NCT05467865|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961606|NCT04753918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173702|NCT01740830|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34173703|NCT05482308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34173704|NCT03709680|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1 portion: The palbociclib plus irinotecan and temozolomide combination part of the study will comprise of a dose escalation cohort (following a rolling 6 design), a dose expansion cohort.~The palbociclib plus topotecan and cyclophosphamide will comprise of a dose determination cohort(following a modified rolling 6 design), a dose expansion cohort, and Neuroblastoma tumor -specific cohort.~Phase 2 open-label, randomized portion of the study will randomize patients in a 2:1 ratio to receive either palbociclib in combination with irinotecan and temozolomide (Arm A) or irinotecan and temozolomide chemotherapy alone (Arm B). Randomization will be stratified using block randomization by type and time of current disease recurrence (primary refractory or 1st recurrence \< 2 years versus 1st recurrence ≥ 2 years or 2nd or greater recurrence)."||||
34173705|NCT05288816|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34173706|NCT00005906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173707|NCT00683436|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34173708|NCT02950350|||CASE_CONTROL||PROSPECTIVE|||||||
34173709|NCT06125522|NA|SEQUENTIAL||TREATMENT||NONE||"Phase 1b will use an escalation/de-escalation approach to determine the RP2D of ARV-471 when administered in combination with samuraciclib. The decision to escalate the starting dose level of ARV-471 will be using mTPI-2 decision criteria based on the number of DLT-evaluable participants and the number of DLTs in those participants during the DLT observation period (Cycle 1).~Phase 2 will further evaluate the preliminary antitumor activity and safety of the combination RP2D.~In addition, the potential drug-drug interaction (DDI) between ARV-471 and samuraciclib will be evaluated, at the doses selected as recommended dose for expansion (RDE(s)), in a DDI Assessment Cohort(s)"||||
34173710|NCT03945383|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled subjects will be treated with the investigational device||||
34173711|NCT04738786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective multicenter randomized non-inferiority clinical trial, comparing two groups; 1.5 cm surgical safety margin versus 1.0 cm surgical safety margin in curative resection for cT1-2N0 oral tongue cancer|t|f|f|t
34173712|NCT05490017|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34173713|NCT04935957|NA|SINGLE_GROUP||OTHER||NONE||||||
34173714|NCT00178477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173715|NCT02217163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173716|NCT04935385|||COHORT||PROSPECTIVE|||||||
34173717|NCT03726489|RANDOMIZED|PARALLEL||OTHER||NONE||Pragmatic, randomized, active comparator effectiveness study||||
34173718|NCT03896139|||COHORT||CROSS_SECTIONAL|||||||
33750848|NCT05725317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33860981|NCT05232253|NA|SINGLE_GROUP||OTHER||NONE||||||
33860982|NCT06296134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860983|NCT05452590|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33860984|NCT02953366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33860985|NCT04820777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33860986|NCT03597412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860987|NCT04431050|||COHORT||CROSS_SECTIONAL|||||||
33860988|NCT01008696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860989|NCT05356468|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34173719|NCT03413007|||COHORT||PROSPECTIVE|||||||
34173720|NCT04885569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173721|NCT01607502|||COHORT||PROSPECTIVE|||||||
34173722|NCT04027855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33860990|NCT04914143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173723|NCT05732116|||COHORT||PROSPECTIVE|||||||
34173724|NCT05371769|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|It was explained to all students that training was given over the website https://www.agriegitimi.net and the starting time of the training was announced on the website. Students were told that they were be able to attend training and testing at the relevant time according to notifications. Students were not know that they were in the experimental or control group. In this way, students were blinded. Only the software specialist could know the students in the intervention and control groups. The data could sent to the statistician by the software specialist as group A and B data. This way the statistician could be blind. The researcher could not present at any stage of data collection. After the statistical analysis was done and the research report was written, the coding of the experimental and control groups were explained to the researcher by the software specialist.|"Randomization: After applying the exclusion criteria to a total of 94 students, the students who accepted to participate in the study was randomly selected into two groups (A and B) of 35 students by simple random sampling by creating a computer-assisted simple random numbers table (www.randomizer.org). Selected students was randomly assigned so that the general academic achievement grades of both groups were homogeneous. The groups was randomly assigned to the intervention or control group by the code A and B by the software specialist."|t|f|t|t
33860991|NCT00319332|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173725|NCT00671658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173726|NCT02407808|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34173727|NCT02343835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34173728|NCT04079439|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two-armed randomised controlled study|t|f|f|f
34173729|NCT01028989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173730|NCT02780401|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33860992|NCT04281589|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Double|sequential|t|f|t|t
33860993|NCT01272154|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33860994|NCT04144751|||COHORT||PROSPECTIVE|||||||
34173731|NCT03432325|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33860995|NCT03595605|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34173732|NCT05384249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173733|NCT00370058|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33860996|NCT01891435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173734|NCT05397717|||COHORT||PROSPECTIVE|||||||
34173735|NCT00933699|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34173736|NCT01622439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173737|NCT00837252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173738|NCT05763563|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34173739|NCT03572920|||CASE_ONLY||PROSPECTIVE|||||||
33750849|NCT06059495|NA|SINGLE_GROUP||TREATMENT||NONE||"After inclusion all patients will receive dostarlimab at 500 mg q3w (± 2-3 days) for 4 cycles (C1-C4).~An adaptive treatment strategy will be determined based on clinical assessment of the patient at weeks 12 (±1 week) and week 24 (±1 week)."||||
33750850|NCT03547089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750851|NCT05536700|||CASE_ONLY||RETROSPECTIVE|||||||
33860997|NCT05409040|||OTHER||CROSS_SECTIONAL|||||||
33860998|NCT01998126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173740|NCT02136979|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34173741|NCT03688269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||allocation to one of the 2 arm after randomization|t|t|t|t
34173742|NCT00002754||||TREATMENT||||||||
34173743|NCT06092762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173744|NCT04951115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173745|NCT05829551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173746|NCT03246971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173747|NCT06347731|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, open-label, non-randomized, single-arm objective performance criteria||||
34173748|NCT03000244|||COHORT||PROSPECTIVE|||||||
33750852|NCT04437654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750853|NCT06213532|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The first cohort of participants will be enrolled on the Beta Arm or intervention development. Once developed, new participants will be randomized into Groups 1 and Groups 2.||||
33750854|NCT03595644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33860999|NCT03991091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861000|NCT00264225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173749|NCT03897426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34173750|NCT02574403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173751|NCT05620108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173752|NCT06359652|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34173753|NCT06186323|||COHORT||CROSS_SECTIONAL|||||||
33861001|NCT00705432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173754|NCT06491693|||COHORT||PROSPECTIVE|||||||
33861002|NCT05169125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173755|NCT02023424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173756|NCT06045988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173757|NCT01924845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173758|NCT05528705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173759|NCT05493709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173760|NCT01364896|||COHORT||PROSPECTIVE|||||||
34173761|NCT06566118|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|During the application to the group that would receive sham auricular vagus nerve stimulation, the device was shown to the participants while it was being operated, but no current was given to the participants because headphones without conductive properties were used.|Uncontrolled study with the same sample in two groups|t|f|f|f
33861003|NCT02429297|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34173762|NCT00161200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34173763|NCT04416204|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|A total of 34 subjects participated.|||||
34173764|NCT01702974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173765|NCT06479343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173766|NCT00681382|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173767|NCT00347789|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34173768|NCT05226507|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A dose escalation followed by Part B, expansion in ovarian cancers.||||
34173769|NCT05589389|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Subjects will be assigned to one or 24 possible treatment sequences.|f|f|t|t
34173770|NCT04864522|NA|SINGLE_GROUP||TREATMENT||NONE||SLAMF7 FPBMC||||
33750855|NCT06143826|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The research is a pre-test, post-test, cross-sectional, descriptive research.||||
33861004|NCT04392453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173771|NCT05685329|||CASE_CROSSOVER||PROSPECTIVE|||||||
33861005|NCT00148954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861006|NCT03807674|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861007|NCT05559593|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33861008|NCT03037619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173772|NCT03402217|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173773|NCT05460754|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double (Participant, Investigator) Organic grass-fed and conventional-fed steak meals were designed to be comparable in size, taste and appearance. The steaks are cut, measured in terms of size and appearance and coded prior to receipt by the research team. Randomization is for order of coded steaks.|The design is 2 x 2 crossover design, where the healthy adults will be randomized into Organic grass-fed and conventional-fed conditions for the first round of data collection and then crossover to the other condition for the second round of data collection.|t|f|t|f
34173774|NCT04627818|||COHORT||PROSPECTIVE|||||||
34173775|NCT04426929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173776|NCT01052155|||||RETROSPECTIVE|||||||
33861009|NCT01126151|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33861010|NCT06153238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861011|NCT03552796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750856|NCT06047626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750857|NCT03180060|||OTHER||OTHER|||||||
33750858|NCT03166761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861012|NCT04678323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study|This study will randomize participants in a 1:1 manner to receive phentermine plus lifestyle therapy or placebo plus lifestyle therapy.|t|t|t|t
33750859|NCT02187991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750860|NCT02161133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33750861|NCT06128109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects and Evaluating Investigator will be blinded to study device assignment. The subject will be blind-folded during treatment. The Evaluating Investigator is unaware of the device assignment and has no access to study data that could potentially contain unblinding information|Split-Face Design with random assignment of test device and comparator device to be injected either into right or into left Mid Face Area|t|f|f|t
33750862|NCT06269770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750863|NCT03711773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750864|NCT05669339|NA|SEQUENTIAL||TREATMENT||NONE||||||
33750865|NCT01443481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750866|NCT00720889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33750867|NCT06473896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will not be exposed to the treatment arm they will receive|"The patients will be classified into 2 groups:~The Ketalar group - who will receive, in addition to the general anesthesia, a bolus of Ketalar during induction and during the operation, continuous ketamine.~The Dexmedetomidine group - in addition to the general anesthesia, they will also receive a Dexmedetomidine bolus in the induction and during the operation continuous Dexmedetomidine"|t|f|f|f
33750868|NCT03717896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861013|NCT03532646|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients who underwent RYGB and MGB/OAGB readmitted for complications in our centre of excellence are getting observed||||
33861014|NCT01230853|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33861015|NCT03868969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861016|NCT05373524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The efficacy will be assessed by a vascular surgeon blinded to the study group during consultation|Rheopheresis procedure/Shamapheresis procedure|f|f|t|f
33861017|NCT05109676|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33861018|NCT06196983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861019|NCT02955576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861020|NCT02018757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750869|NCT04528836|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750870|NCT00435773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33750871|NCT01983748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750872|NCT03923348|NA|SINGLE_GROUP||TREATMENT||NONE||Non-blinded non-comparative pilot trial in which subjects with pure urge urinary incontinence (UUI) or urge-predominant mixed urinary incontinence (U-MUI) who are candidates for pelvic floor physical therapy or other first line treatments for UUI/U-MUI use the leva® system twice-daily at home in addition to behavioral therapies for 8 weeks.||||
33750873|NCT04877522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750874|NCT06171191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomised controlled trial. Prétest, posttest, follow-up test design. Intervention group receives intervention in between prétest en posttest. Control group receives intervention after follow-up|t|f|f|f
33750875|NCT05707533|||COHORT||RETROSPECTIVE|||||||
33750876|NCT06095726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33750877|NCT06733584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861021|NCT01550913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33861022|NCT03503513|NA|SINGLE_GROUP||PREVENTION||NONE||For each participant, six month pre-treatment data is compared to data collected during treatment (count of UTIs) and immediately after treatment (self-reported measures).||||
33861023|NCT00456768|||COHORT|||||||||
33861024|NCT05019157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||supervised, randomised controlled trial|f|f|t|f
33750878|NCT05888636|||COHORT||PROSPECTIVE|||||||
33861025|NCT02150525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33861026|NCT06065501|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33750879|NCT01339754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750880|NCT04617639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective randomized controlled trial with blinded endpoint evaluation|f|f|f|t
33750881|NCT05817695|||CASE_ONLY||PROSPECTIVE|||||||
33961607|NCT04160676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All data will be collected by intensivists who will be blinded about the study groups.|Parallel assignment Prospective study|t|f|t|t
33961608|NCT04147052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961609|NCT04957914|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34173777|NCT05998369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173778|NCT02498925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34173779|NCT06464458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pharmacokinetics results of patients in Arm A||t|f|f|f
34173780|NCT01885429|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34173781|NCT06261034|||COHORT||CROSS_SECTIONAL|||||||
34173782|NCT05224271|||COHORT||PROSPECTIVE|||||||
34173783|NCT05441384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173784|NCT00521950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34173785|NCT06015945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173786|NCT01105819|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173787|NCT01710345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173788|NCT04543396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Investigator will be blinded to subject intervention group assignments.|Four study groups will be assessed in parallel. Subjects will encompass patients who have sought physical therapy or chiropractic care for nonspecific lower back pain. Clinical care selection will be made by subject and clinical care team prior to study enrollment and will be made in the best interest of the subject. Intervention groups will consist of standard of care and an 8-week physical training supplement performed that will consist of concentric and eccentric resistance exercises as well as dynamic warm-up and cool-down periods. These interventions will be performed in addition to the standard regimen of clinical care.|f|f|t|f
34173789|NCT06032065|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|For the beetroot juice vs. placebo comparison, this will be a double blinded study where both the participant and the people collecting data will be blinded. For the supervised exercise vs. home-based exercise comparison, the participant and investigator will not be blinded, but the outcomes assessor will be blinded.|The investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. In this 2 x 2 factorial design, participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.|t|t|t|t
34173790|NCT03388632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173791|NCT05027594|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Dose escalation part followed by a Dose Expansion part.||||
34173792|NCT06098300|||OTHER||PROSPECTIVE|||||||
34173793|NCT06334822|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Only outcomes assessors will be blinded.|"This 6-month study involves up to 210 patients using the Heartfelt device at home. It is a crossover trial with a 21-day break between two 69-day periods to prevent overlap effects. Patients will either receive standard care or standard care plus Heartfelt alerts. The Heartfelt group is further divided into three 23-day sub-studies to test different alert systems.~Another 60 patients will have monthly measurements taken at the pharmacy without being part of the main randomisation."|f|f|f|t
34173794|NCT00802581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173795|NCT04935346|||OTHER||CROSS_SECTIONAL|||||||
34173796|NCT02452307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173797|NCT03573882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173798|NCT01246674|||COHORT||PROSPECTIVE|||||||
34173799|NCT06091475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173800|NCT04800965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34173801|NCT04128865|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173802|NCT00259909|||COHORT||PROSPECTIVE|||||||
34173803|NCT00176384|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34173804|NCT00702481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173805|NCT01237756|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
34173806|NCT05668234|||CASE_ONLY||RETROSPECTIVE|||||||
34173807|NCT03033277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173808|NCT02638116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750882|NCT03948568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750883|NCT04301778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750884|NCT01284608|||COHORT||PROSPECTIVE|||||||
33750885|NCT00146575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750886|NCT04442074|||COHORT||RETROSPECTIVE|||||||
33750887|NCT00558428||PARALLEL||TREATMENT||||||||
33750888|NCT03681158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750889|NCT02196649|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750890|NCT05427461|NA|SINGLE_GROUP||OTHER||NONE||||||
33750891|NCT03249519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750892|NCT06025565|||COHORT||CROSS_SECTIONAL|||||||
33750893|NCT02541708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750894|NCT02858895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750895|NCT03712891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33961610|NCT06381375|||COHORT||PROSPECTIVE|||||||
33961611|NCT04766593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33961612|NCT04390035|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given that the intervention involves a device that will be physically applied to the participant's post-operative leg, masking is not feasible for this study.|Participants will be randomized into either a control group or the test group at time of enrollment at a 1:1 ratio. Participants will undergo standard post-surgery rehabilitation (control group) or standard post-surgery rehabilitation with supplemental blood flow restriction (test group).||||
33961613|NCT02966574|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961614|NCT01959230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173809|NCT00206635|||COHORT||CROSS_SECTIONAL|||||||
34173810|NCT06199635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173811|NCT01649895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173812|NCT01733420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34173813|NCT05408377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Considering the particularity of acupuncture manipulation, acupuncturists in this trial cannot be blinded. The patients, evaluators, and statistical analysts will be blinded to the group allocation. The manipulation of needles will be similar in both groups. Unblinding will only be performed in cases of an emergency event.|This study is a 2-arm randomized controlled trial. According to the ratio of 1：1 and block randomization, a total of 108 eligible CM patients will be randomly allocated to either MA(n=54) or SA(n=54).|t|f|t|t
34173814|NCT02760459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173815|NCT01874236|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34173816|NCT05316948|||COHORT||PROSPECTIVE|||||||
33750896|NCT03584451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750897|NCT01900938|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33750898|NCT01190592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750899|NCT05065866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750900|NCT03818672|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, repeat-dose, parallel-design study in 12 subjects with severe hepatic impairment and 6 healthy subjects with normal hepatic function.||||
33750901|NCT03152630|||CASE_ONLY||PROSPECTIVE|||||||
34173817|NCT06030596|||COHORT||PROSPECTIVE|||||||
34173818|NCT01766050|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34173819|NCT02249806|||COHORT||PROSPECTIVE|||||||
34173820|NCT06066034|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33750902|NCT04110769|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33750903|NCT02210364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750904|NCT00574587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861027|NCT02401412|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33861028|NCT02772523|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34173821|NCT03118414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173822|NCT04356222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173823|NCT02654782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34173824|NCT02969122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173825|NCT04414241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173826|NCT06706362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither participants, providers, investigators or outcome assessors will know to which of these groups participants are assigned. In case of an emergency, however, the study doctor can get this information.|a double-blinded randomized controlled trial|t|t|t|t
33861029|NCT00839943|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33861030|NCT00407589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173827|NCT01280006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34173828|NCT02381561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861031|NCT00583570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861032|NCT00065325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861033|NCT03277326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33861034|NCT03537599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861035|NCT02686021|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33861036|NCT02622880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861037|NCT00601991||||TREATMENT||NONE||||||
33861038|NCT05989191|||OTHER||PROSPECTIVE|||||||
33861039|NCT00410293|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33861040|NCT03689647|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33861041|NCT01504256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861042|NCT00143481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861043|NCT03461874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861044|NCT02017041|||COHORT||PROSPECTIVE|||||||
33861045|NCT03859713|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Participants and clinicians cannot be blind to treatment received. The investigators will remain blind to group assignment and follow-up assessments will be conducted by assessors who are blind to treatment group.|Our design is a sequential multiple randomization (SMART) study design with 2 treatment phases with a possibility of 2 randomizations per participant.|f|f|t|t
33861046|NCT04492345|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861047|NCT00747630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961615|NCT03506425|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961616|NCT00315328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961617|NCT00035399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750905|NCT03232970|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Control Trial||||
33750906|NCT05622669|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33961618|NCT06640244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Statistician||t|t|t|t
33961619|NCT03336489|||CASE_ONLY||PROSPECTIVE|||||||
33961620|NCT00450177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961621|NCT05442359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33961622|NCT02770053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961623|NCT02192541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173829|NCT05705024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Thirty eight (38) patients will be recruited in this randomized clinical trial study with a 2:1 allocation for randomization. Twenty-five (25) patients will be recruited for the MSC treatment and thirteen (13) patients will be assigned to the control group. At any stage, if the results of MSC group were significantly better than the control group, using the control group would be stopped. This process will be supervised by Charlotte Joselin who is the person in charge for blinding and for the formulation and distribution of the proper study drug for injection.||t|t|f|f
34173830|NCT02228681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173831|NCT01003301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34173832|NCT06492330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173833|NCT04842903|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|t|f
34173834|NCT00111046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34173835|NCT01983202|||COHORT||PROSPECTIVE|||||||
34173836|NCT06251557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173837|NCT05119036|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33750907|NCT02756767|||OTHER||PROSPECTIVE|||||||
33750908|NCT00754026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750909|NCT01431625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33750910|NCT03282318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750911|NCT04075500|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patient will be randomized to either receive 24-h Holter Monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). Patient will either undergo 28-day ECG recording using a commercially available Holter Recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).|f|f|f|t
33750912|NCT04016090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33750913|NCT02043496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33750914|NCT02268201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750915|NCT00535730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33750916|NCT03911791|||OTHER||CROSS_SECTIONAL|||||||
33750917|NCT03120962|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33750918|NCT01843426|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750919|NCT03876080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750920|NCT03254680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750921|NCT06724757|||CASE_ONLY||CROSS_SECTIONAL|||||||
33750922|NCT02423512|||COHORT||PROSPECTIVE|||||||
33750923|NCT01099904|NON_RANDOMIZED|PARALLEL||||NONE||||||
33750924|NCT04729322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750925|NCT00999375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750926|NCT02002481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750927|NCT03788837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750928|NCT04984148|||COHORT||PROSPECTIVE|||||||
33750929|NCT06489743|RANDOMIZED|CROSSOVER||OTHER||NONE||Each highlander with HAPH will perform a 6 MWT with and without SOT according to a cross-over design.||||
33750930|NCT01049048|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33750931|NCT00454051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750932|NCT03519854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961624|NCT01950338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33961625|NCT01094509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33961626|NCT01095029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33961627|NCT00979238|NA|SINGLE_GROUP||OTHER||NONE||||||
34173838|NCT05282550|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study drug will be compounded by the Investigational Drug Service (IDS) at Johns Hopkins Bayview Medical Center. The IDS will prepare blind medication using opaque capsules and randomly assign eligible participants to treatment order (ie, starting with trazodone vs. placebo treatment).|We will administer trazodone and placebo for 4 weeks each with a 4-week washout.|t|t|t|t
34173839|NCT02253225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173840|NCT05752760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34173841|NCT04007666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173842|NCT00301899||||TREATMENT||NONE||||||
34173843|NCT03624634|||COHORT||PROSPECTIVE|||||||
34173844|NCT05644119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Split-mouth Design|f|f|f|t
34173845|NCT01099696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861048|NCT03478150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"the examiner who will carry the microbiological analysis of dentin samples will be blinded to the type of agent applied during treatment. Finally, the treatment results will be assessed blindly by a statistician.~Blinding:~Blinding of the operator is not possible, because the natures of both interventions are obviously different. The operator is blinded until randomization into groups, to avoid biases with regard to the application of antibacterial agent. Also, the examiner who will carry the microbiological analysis of dentin samples will be blinded to the type of agent applied during treatment. Finally, the treatment results will be assessed blindly by a statistician also to avoid the risk of bias of results in favor of one intervention over the other."||f|f|f|t
33861049|NCT00651001|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33861050|NCT04193878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861051|NCT06357351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861052|NCT02580396|NA|SINGLE_GROUP||OTHER||NONE||||||
33861053|NCT01309230|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized 2 (Group A (Vigil)):1 (Group B (Standard of Care)). Randomization was only applicable to participants enrolled prior to approval of Protocol Amendment 8, dated June 19, 2014. All participants enrolled after approval of Protocol Amendment 8 were assigned to Group A (Vigil).||||
33861054|NCT05434962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861055|NCT01458704|||CASE_ONLY||PROSPECTIVE|||||||
33961628|NCT05538169|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective case series of patients who have received radiotherapy for SCC of the head and neck||||
33961629|NCT02322242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961630|NCT01189071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961631|NCT05430568|||COHORT||PROSPECTIVE|||||||
33961632|NCT03229239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961633|NCT00782275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173846|NCT03253692|||CASE_ONLY||CROSS_SECTIONAL|||||||
33961634|NCT00149552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750933|NCT00862160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961635|NCT05375682|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33961636|NCT04593680|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|"An open-label, randomized, two-arm prospective PK study of HIV-negative TGM taking MHT and daily PrEP:~Arm 1: Twenty HIV-negative TGM will take daily TDF/FTC-based PrEP~Arm 2: Twenty HIV-negative TGM will take daily F/TAF-based PrEP"|||||
33961637|NCT00161330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961638|NCT02802137|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33961639|NCT04179474|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33961640|NCT01674959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961641|NCT03256708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Double-blind parallel placebo-controlled randomized study|t|f|t|f
33961642|NCT01586117|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33961643|NCT02421107|NA|SINGLE_GROUP||||||||||
33961644|NCT01040676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173847|NCT03272802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173848|NCT03978936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized, parallel, superiority trial with two intervention groups|f|f|t|t
34173849|NCT04375384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173850|NCT06547437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded study|"Intervention Group: Combined use of papaverine (80 mg intravenous mg in 100 mL saline once concurrent with the start of oxytocin) and oxytocin.~Control Group: Oxytocin plus 100 mL saline."|t|t|t|t
34173851|NCT00758017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173852|NCT02755428|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
33961645|NCT05949931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961646|NCT01375036|||||PROSPECTIVE|||||||
33961647|NCT00230620|||FAMILY_BASED||OTHER|||||||
33961648|NCT05445037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The selected patients will be divided into two groups: group 1 general anesthesia + interscalene brachial plexus block and group 2 sedation + interscalene brachial plexus block. Each group will be divided into two groups, one with hemodynamic continuous monitoring and one with standard hemodynamic monitoring, totaling 4 groups in total in the study. Group 1A general anesthesia + interscalene brachial plexus block with continuous monitoring; group 1B general anesthesia + interscalene brachial plexus block with standard monitoring; group 2A sedation + interscalene brachial plexus block with continuous monitoring; group 2B sedation + interscalene brachial plexus block with standard monitoring.|t|f|f|t
33961649|NCT06084273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961650|NCT03942952|||COHORT||PROSPECTIVE|||||||
33961651|NCT03175445|||OTHER||RETROSPECTIVE|||||||
33961652|NCT05968755|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33961653|NCT03667170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961654|NCT03445247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150359|NCT03441503|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study is a rapid cycle randomized control trial. Participating units will alternate between the intervention arm (day of discharge survey via inpatient television) and control arm (post-discharge mailed survey). Patients will be assigned to the intervention or control arm depending on the status of their discharging unit. Units will alternate arms throughout the study period.||||
34150360|NCT01533922|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34150361|NCT03258060|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150362|NCT00584207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150363|NCT02058394|||COHORT||PROSPECTIVE|||||||
34150364|NCT01455194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150365|NCT06292676|||COHORT||PROSPECTIVE|||||||
34150366|NCT02440126|||COHORT||OTHER|||||||
34150367|NCT01431885|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34150368|NCT02846012|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34150369|NCT02631265|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34150370|NCT00785174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150371|NCT03150784|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Measures taken at Baseline (0 weeks), Post Intervention (6-7 weeks), and follow up (12 weeks)||||
33961655|NCT03499249|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a Phase 2 clinical trial using the two-stage minimax design described by Simon (Simon, 1989). As a Phase 2 trial, the trial's objective is to determine whether NAC has sufficient biological activity as adjunctive therapy for BA to warrant further study. By choosing the two-stage minimax design, we gain two advantages: (i) early termination if the drug is not efficacious, and (ii) using historical controls and therefore an overall smaller sample size to test the hypothesis, i.e., no randomization or control arm. This study design only identifies large effects (response \>20%). For BA this is appropriate, because the field is in need of a robust therapy that can substantially limit liver damage and delay/prevent need for liver transplantation."||||
33961656|NCT05212831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961657|NCT02513173|||CASE_CONTROL||PROSPECTIVE|||||||
34173853|NCT03737123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173854|NCT05400291|||OTHER||PROSPECTIVE|||||||
34173855|NCT06464497|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34173856|NCT04261439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173857|NCT04895254|||COHORT||PROSPECTIVE|||||||
34173858|NCT06615076|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34173859|NCT05533671|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a prospective randomized controlled trial investigating outcomes (recurrent dislocation rates and participant reported outcomes) in two groups of participants following a primary patella dislocation. Half of the participants will be randomized to operative intervention with a standard medial patellofemoral ligament (MPFL) reconstruction and the other half will be randomized to conservative management with a standardized rehabilitation protocol (non-operative group).||||
34173860|NCT06384079|||COHORT||PROSPECTIVE|||||||
34173861|NCT05549895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173862|NCT06595888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173863|NCT01572597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173864|NCT04332822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173865|NCT06561919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173866|NCT05054075|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173867|NCT05607407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173868|NCT05427344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34173869|NCT04443244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173870|NCT05405920|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the cluster design and intervention program, the study participants, primary care physicians, nurses, community health workers, and research staff who collected clinical outcome data will not be blinded. The outcome adjudication committee members, however, will be blinded to randomization assignment for adverse event evaluation.|cluster-randomization of 40 primary care clinics||||
34173871|NCT05608434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173872|NCT03797651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173873|NCT01500590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173874|NCT05132010|||OTHER||CROSS_SECTIONAL|||||||
34173875|NCT06478667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34173876|NCT06466577|NA|SINGLE_GROUP||OTHER||NONE||||||
34173877|NCT04467736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will be randomly allocated to the 'test group (Hyaluronic acid)' or the 'control group (No hyaluronic acid). An equal number of sealed envelopes will be prepared internally labelled as 'test group' or 'control group'. Just after alveolar ridge preservation, a sealed envelope will be randomly selected and opened to reveal further treatment.~The measuring investigator will not be involved in the treatment of any of the patients and will be blinded to allow unbiased registrations."|Randomized clinical trial|f|t|f|t
34173878|NCT05616104|||COHORT||PROSPECTIVE|||||||
34173879|NCT06705361|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173880|NCT06034210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34173881|NCT06175767|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
34173882|NCT04366349|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|This is a double blind study and participants and investigator will be masked.|This is a single arm study.|t|f|t|f
33750934|NCT00229333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750935|NCT01082536|||COHORT||PROSPECTIVE|||||||
33750936|NCT04149405|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33750937|NCT03651089|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||This study is set up as 3 sequential parallel studies, each testing a different drug dosage against placebo. In each dosing cohort, three patients (2 active and 1 placebo) will be randomized to receive a single study drug infusion on separate days, at least 24 hours apart. The remaining subjects in each dosing cohort (1 placebo and 4 active) will receive study drug after at least 24 hours from the 3rd subject.|t|t|t|f
33750938|NCT05794542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750939|NCT04178733|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33750940|NCT02693743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33750941|NCT04958018|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, parallel groups||||
33750942|NCT01164358|||COHORT||PROSPECTIVE|||||||
33750943|NCT06379594|||COHORT||PROSPECTIVE|||||||
33750944|NCT03707977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173883|NCT03918850|RANDOMIZED|PARALLEL||TREATMENT||NONE|The primary outcome is assessed in a masked fashion by a central laboratory, but there is no masking for other outcomes.|This is an intent-to-treat, two-arm, open-label, pragmatic randomized controlled trial.||||
34173884|NCT00971659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173885|NCT06102954|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34173886|NCT05225311|||COHORT||PROSPECTIVE|||||||
34173887|NCT03629964|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34173888|NCT04993859|||COHORT||PROSPECTIVE|||||||
34173889|NCT06352723|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study||||
33961658|NCT02344459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173890|NCT03245203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||70 patients with rectal adenocarcinoma clinical staging in Stage II or Stage III were included for neoadjuvant therapy followed by TME, of which 35 underwent neoadjuvant radiotherapy, and other 35 underwent neoadjuvant chemotherapy+beacizumab.|t|f|f|f
34173891|NCT00062439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173892|NCT04808115|NA|SEQUENTIAL||TREATMENT||NONE||||||
34173893|NCT02236286|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34173894|NCT03028311|NA|SINGLE_GROUP||TREATMENT||||||||
34173895|NCT05589103|||CASE_ONLY||RETROSPECTIVE|||||||
34173896|NCT03900832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects will be aware if they are being heated or not, but data analysis process is blinded.|The investigators will examine (using a prospective observational design) if heating will affect walking ability, blood pressure and heart rate responses in PAD patients. Each subject will serve as their own control. Additionally, we will compare these responses between PAD patients and healthy controls subjects.|f|f|f|t
34173897|NCT05830864|||COHORT||PROSPECTIVE|||||||
33961659|NCT04006691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961660|NCT02067585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173898|NCT05230134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173899|NCT05493202|||COHORT||PROSPECTIVE|||||||
34173900|NCT06593171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34173901|NCT05955911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173902|NCT04289181|RANDOMIZED|PARALLEL||OTHER||NONE|It is not feasible to blind participants and clinic staff to assignment post enrollment.|Enrolled patients will be randomized to 1 of 2 arms: 1) MTM; or 2) usual care in a 1:1 ratio. A computer-generated list of random numbers will be prepared in advance by the study biostatistician and loaded into a REDCap randomization tool to ensure the research staff are blinded to assignment pre-randomization.||||
34173903|NCT06005051|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will consume the meals using the cgm and fitbit devices and log their meal intake.||||
34173904|NCT04877626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173905|NCT05808686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173906|NCT06539884|||COHORT||PROSPECTIVE|||||||
34173907|NCT01349426|RANDOMIZED|PARALLEL||||NONE||||||
34173908|NCT04785222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The outside of the envelope is an individual code (e.g., IC2, CY1). Inside an envelope is a group (DB, BP, or NS). A nurse will prepare local anesthetics in a two 3-ml syringe and put them in the envelope according to the allocation order. The syringe will be containing the same volume of clear drugs which are unable to be distinguished between groups.|"Intervention and group assignment: The subjects will be randomized into three groups, as following.~Group DB: Bilateral infraorbital nerve block with dexmedetomidine 5 mcg mixed with 0.5% plain bupivacaine, in total volume of 2 ml per side Group BP: Bilateral infraorbital nerve block with 0.5% plain bupivacaine, a volume of 2 ml per side Group NS (control): Bilateral infraorbital nerve block with normal saline 2 ml per side"|t|t|t|t
33750945|NCT02541552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750946|NCT05505656|||COHORT||PROSPECTIVE|||||||
33961661|NCT01921036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33961662|NCT00995488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961663|NCT00200590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961664|NCT06540612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33861056|NCT04687761|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1: Study treatment will start at level 1 and therapeutic level will be escalated or descalated depending on the apparition of DLT. DLT will be monitored during cycle 1 and it is defined as any grade 3-4 related extrahematological toxicity or grade 4 neutropenia not recovered on day 56 since C1D1 not attributable to persistent leukemia.~Phase I will consist of two parallel dose escalation cohorts, with consecutive assignment to each group (first patient will be assigned to AZA-based schedule, second to LDAC-based, third to AZA-based, etc).~Phase II includes two treatment arm groups (AZA-based RP2D vs. LDAC-based RP2D). Patients will be enrolled at diagnosis, within a maximum 28 days screening period, will be assessed for eligibility and therefore randomized to follow the assigned treatment arm (open label design). All screening activities will be performed after patient's informed consent form is signed. Patients will start the assigned regimen 48h maximum after randomization."||||
33861057|NCT00201838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861058|NCT05632107|||COHORT||PROSPECTIVE|||||||
33861059|NCT01171352|||CASE_ONLY||PROSPECTIVE|||||||
34173909|NCT04554784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. Investigator will be blinded and responsible for obtaining informed consent.~2. Outcome Assessor who will be responsible to perform the Endurance Strength Test (EST) and assist patients in completing questionnaires, will be blinded to measure the EST during the study period."|Patients will be randomly allocated to receive either conventional treatment or Bowen Therapy, following the computer-generated sequence (1= Control, 2= Bowen Therapy). The randomization sequence will be prepared by a research assistant, who will not take part in the study. The randomization sequence will be placed in a brown, and sealed envelopes: Group 1 (n= 40): Control (conventional treatment); and Group 2 (n= 40): Bowen Therapy.|f|f|t|t
34173910|NCT00982293|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34173911|NCT03486821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861060|NCT00187395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861061|NCT00794443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750947|NCT03036358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33861062|NCT04308824|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33861063|NCT05839756|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The preoperative aerosolized drug will be applied by an anesthetist who is not involved in further patient care|Patients will be randomly allocated into two equal groups via opaque coded envelopes|t|f|t|f
33861064|NCT00195923|||DEFINED_POPULATION||OTHER|||||||
33861065|NCT00803829|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33861066|NCT02067182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861067|NCT00816309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861068|NCT01990534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861069|NCT04586504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Sequential selection procedure|t|t|t|t
33861070|NCT01526551|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861071|NCT01810016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861072|NCT03877250|||COHORT||PROSPECTIVE|||||||
33961665|NCT03537222|||OTHER||CROSS_SECTIONAL|||||||
33961666|NCT02595541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33961667|NCT06125964|NON_RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|The majority of study staff will be blinded to participant assignment for most of the study period. Data will be analyzed blind to allocation, and participants will be blind to their allocation.|Treatment components targeting intensity-based goals and affect-based goals will be tested separately in four groups of n=9 participants: (1) intensity-based goal setting alone; (2) affect-based goals + TYPE/CONTEXT; (3) affect-based goals + SAVOR; and (4) affect-based goals + TYPE/CONTEXT + SAVOR.|t|f|t|t
33750948|NCT04949373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33750949|NCT02275676|||COHORT||PROSPECTIVE|||||||
33750950|NCT06450132|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants and the examining investigator will not be masked to intervention. All measurements are objective in nature and not subject to examiner bias. All data images acquired will be coded to obscure participant ID by a study team member masked to intervention. This coding will allow for the examining investigator to complete image processing while masked to randomization assignment, thereby minimizing the chance of bias.||f|f|f|t
33750951|NCT05703568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each participant will be requested to draw either number one, number two or number three from a box. Number one will be allocated to group 1, number two will be allocated o group 2 and number two will be allocated o group 3. The group 1 consists of 14 elderly participants who received intervention protocol of group- based virtual reality training program in which total 16-sessions were given for twice a week for eight weeks for 45-minutes. The group 2 consists of 14 elderly participants who received intervention protocol of individual virtual reality training in which total 16-sessions were given for twice a week for eight weeks for 45-minutes. The group 3 consists of 14 elderly participants will continue their routine daily activities.|f|f|f|t
33750952|NCT01592318|RANDOMIZED|CROSSOVER||||NONE||||||
33961668|NCT04972760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961669|NCT02528318|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173912|NCT03994874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded independent review committee, comprised of experienced cardiologist and nephrologists, who are non-participating investigators in this study, will be appointed to confirm the primary end-point.|Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving no PUF therapy.|f|f|f|t
34173913|NCT06572865|||CASE_ONLY||CROSS_SECTIONAL|||||||
34173914|NCT05034497|NA|SEQUENTIAL||TREATMENT||NONE||||||
34173915|NCT03323892|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||a prospective sibling oocyte study: both study arms will be applied to the oocytes of 1 patient||||
34173916|NCT01463969|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34173917|NCT06289751|NA|SINGLE_GROUP||TREATMENT||NONE||a multicentre, single-arm, phase 2 trial||||
34173918|NCT00171379|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34173919|NCT00182130|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34173920|NCT04949191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173921|NCT00837434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34173922|NCT04917172|||COHORT||PROSPECTIVE|||||||
34173923|NCT02958995|||COHORT||PROSPECTIVE|||||||
34173924|NCT02082496|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34173925|NCT04871906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34173926|NCT04212416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173927|NCT06043024|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34173928|NCT06296849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34173929|NCT05758116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173930|NCT01368588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173931|NCT05480995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173932|NCT06095986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Parallel group analysis|t|t|t|t
34173933|NCT05484102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Enrolled children will be randomly assigned, with the use of a computer-generated randomization list to receive milk fermented with Lactobacillus paracasei CBA L74 or placebo|double blind randomized placebo controlled clinical trial|t|t|t|t
34173934|NCT02854072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173935|NCT05524493|||COHORT||PROSPECTIVE|||||||
34173936|NCT04285112|||COHORT||PROSPECTIVE|||||||
34173937|NCT02107417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34173938|NCT03969485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173939|NCT05672654|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34173940|NCT02008396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34173941|NCT02720393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34173942|NCT05301959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double-blind, blinded, evaluator-blinded, controlled clinical trial will be conducted in parallel groups (experimental treatment vs. sham treatment), with a follow-up at 26 and 52 weeks after the first intervention. Non-probability and intentional sampling will be performed.|t|t|t|f
34173943|NCT02058043|||OTHER||PROSPECTIVE|||||||
34173944|NCT01575444|||COHORT||PROSPECTIVE|||||||
34173945|NCT05202808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be randomized 2:1 to undergo experimental or control treatment.|f|f|f|t
34173946|NCT04564417|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34173947|NCT04235140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173948|NCT04938960|||COHORT||PROSPECTIVE|||||||
34173949|NCT02787564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173950|NCT05777408|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive conventional physical therapy along with Natural apophyseal glides and the second will receive Natural Apophyseal Glides in addition to cranial base release with conventional physical therapy. Both groups will be recruited concurrently.||||
34173951|NCT05361395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750953|NCT06579222|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33750954|NCT01045746|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33750955|NCT06448754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750956|NCT06303050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961670|NCT03515837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961671|NCT00488839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34173952|NCT03962062|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Prospective, age-stratified, adaptive, open-label, single-dose study with 3, age-defined cohorts. Cohort 1 (12 to 17 years, n = 9) and Cohort 2 (8 to 11 years, n = 9) will receive moxidectin 8 mg. Cohort 3 (4 to 7 years, n = 9) will receive moxidectin at a dose to be determined from safety and pharmacokinetic data analyses of Cohorts 1 and 2.~If the starting dose for Cohorts 2 and 3 results in at least 3 subjects with moxidectin exposures above the target range, a revised dose will be determined in decrements of 2 mg and the Cohort(s) will be repeated with at least 9 new subjects. For Cohort 3, if the starting dose results in at least 3 subjects with moxidectin exposures below the target range, a revised dose will be determined in increments of 2 mg to a maximum dose of 8 mg.Therefore, it is expected that the study will enroll 27 subjects. However, if additional cohorts are required to meet pharmacokinetic outcomes, up to a maximum of 63 subjects may be enrolled."||||
33750957|NCT03691467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|by addition of placebo gel in the control group|randomized clinical trial|t|f|t|f
33750958|NCT01461876|||CASE_CONTROL||RETROSPECTIVE|||||||
33750959|NCT06249932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33750960|NCT06150547|||COHORT||PROSPECTIVE|||||||
33750961|NCT04292626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961672|NCT03319693|||COHORT||RETROSPECTIVE|||||||
33961673|NCT03858660|||COHORT||CROSS_SECTIONAL|||||||
33961674|NCT06309472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Mirtazapine and placebo manufactured to appear identical through over-encapsulation||t|t|t|t
33961675|NCT00158795|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961676|NCT03558789|||CASE_CONTROL||PROSPECTIVE|||||||
33961677|NCT02588352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33750962|NCT01936584|||COHORT||PROSPECTIVE|||||||
33750963|NCT02806375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961678|NCT01488071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961679|NCT00550420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750964|NCT01296451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750965|NCT01764737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750966|NCT00000779|RANDOMIZED|||PREVENTION||||||||
33750967|NCT04822038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The MD who processed the data and molecular proceedings unknown the intervention in each individual.|Open clinical trial|f|f|t|f
33750968|NCT03626597|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel, non-blinded, patient preference model.||||
33750969|NCT03436394|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33750970|NCT00930293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861073|NCT04176965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In order to minimize bias, site personnel performing postoperative study assessments of visual performance will be masked to subject treatment assignment until after the final database lock (masked assessors)."|Approximately 501 subjects will be screened across up to 24 study sites to complete 300 subjects implanted bilaterally with the FINEVISION HP and 150 subjects implanted bilaterally with the control monofocal Alcon AcrySof SN60AT.|t|f|f|t
33861074|NCT03455192|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||double-blind randomized placebo-controlled clinical trial|t|f|t|f
33861075|NCT04398511|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients were treated with identical lozenges containing probiotic or placebo. The treatments were revealed only after statistical analysis.|randomized, double-blind, placebo-controlled, clinical trial|t|t|f|t
33861076|NCT05532436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33861077|NCT05508750|RANDOMIZED|PARALLEL||OTHER||TRIPLE||A decentralized, randomized, controlled trial of healthy term breastfed and formula-fed infants for 16 weeks|f|t|t|t
33861078|NCT00002951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861079|NCT00907257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33861080|NCT02708017|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33861081|NCT02206165|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33861082|NCT01050686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861083|NCT00536809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861084|NCT05929560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Paired design Same patients receive conventional impression and digital"||||
33861085|NCT02715661|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861086|NCT02805049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861087|NCT03457883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33861088|NCT03042078|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861089|NCT02352766|||CASE_ONLY||CROSS_SECTIONAL|||||||
33861090|NCT01957605|||||CROSS_SECTIONAL|||||||
33861091|NCT04092972|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33861092|NCT00261846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750971|NCT02597400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750972|NCT06402734|||OTHER||CROSS_SECTIONAL|||||||
33861093|NCT01032382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861094|NCT03030235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861095|NCT04646070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861096|NCT02340728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961680|NCT01447316|||CASE_ONLY||PROSPECTIVE|||||||
33961681|NCT03711942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961682|NCT05412069|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961683|NCT01755780|||CASE_CONTROL||PROSPECTIVE|||||||
33961684|NCT01000142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961685|NCT03312725|||CASE_ONLY||PROSPECTIVE|||||||
34173953|NCT06549998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34173954|NCT06475352|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173955|NCT00918281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173956|NCT02488577|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34173957|NCT05016479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|With regard to the treatment, to ensure that both participants and investigators are blind to the condition (active or sham), the selection of the operation mode (15 Hz, sham) will be pre-programmed by member of the that will not be involved in data collection and analysis. Study personnel will not know which mode is being activated. Sham stimulation will use the same coil placement as that used for active stimulation. Outcomes Assessors will not be present during the rTMS sessions.|double blind, randomized, sham-controlled with a 1:1 allocation into 2 parallel arms|t|f|t|t
34173958|NCT05858541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators, and research staff involved in data collection and analysis will be masked to the assignment of participants||f|f|t|t
34173959|NCT00407121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750973|NCT05775614|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"2 arms with randomization 1:1~1. Uro-Tainer® Polihexanide two weekly rinses compared to two weekly rinses with saline for 6 months.~2. Uro-Tainer® with citric acid: Two weekly rinses compared to two weekly rinses with saline for 6 months."|f|f|t|t
33750974|NCT03757000|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation||||
33750975|NCT02895087|||COHORT||PROSPECTIVE|||||||
33750976|NCT04026776|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33750977|NCT06530862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly divided into 2 groups and will be treated with ESWT or Dry needling|t|f|f|t
33750978|NCT02808481|||COHORT||RETROSPECTIVE|||||||
33750979|NCT03009045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750980|NCT03655769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33750981|NCT00760929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173960|NCT03521349|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33750982|NCT04758637|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33750983|NCT01544322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750984|NCT01147224|||COHORT||PROSPECTIVE|||||||
33750985|NCT03453268|RANDOMIZED|PARALLEL||OTHER||NONE||Therapeutic strategies: reduction of the antihypertensive treatment (intervention arm) vs. usual treatment (control arm)||||
33750986|NCT01509898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33750987|NCT05071118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33750988|NCT00796380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33750989|NCT02077257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33750990|NCT01773070|NA|SINGLE_GROUP||OTHER||NONE||||||
33750991|NCT03905889|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a single-arm, non-randomized prospective phase Ib study with expansion. The goal is to determine the maximal tolerated dose by assessing dose limiting toxicities. A classic 3+3 design is used. There are a total of 3 dose levels (level -1, 1, and 2) with dose level 1 as the starting dose. Once the maximum tolerated dose is established, a cohort of an additional 10 subjects will be enrolled at the established dose."||||
33961686|NCT02952794|||COHORT||PROSPECTIVE|||||||
33961687|NCT00657917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173961|NCT04985929|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double-blind, placebo-controlled|Randomized, double-blind, placebo-controlled cross-over design|t|t|t|f
33961688|NCT06315608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961689|NCT05154994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961690|NCT00484120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33750992|NCT01201590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33750993|NCT02742948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33750994|NCT05597969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33750995|NCT00127101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33750996|NCT00408473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33750997|NCT05278910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33750998|NCT04118153|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33750999|NCT05856448|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33751000|NCT05564234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838284|NCT03917745|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is part of a large longitudinal cohort study among pregnant women. The study targets a specific subgroup of pregnant women with symptoms of psychological distress (depression and anxiety). Women who score above cut off on the Edinburgh Depression Scale (EDS) and Tilburg Pregnancy Distress Scale (TPDS) at 12 weeks of gestation, will be randomly allocated to the intervention or control group. Women in the intervention group will be contacted and invited to participate in the mindfulness-based intervention, which consists of 8 weeks of internet mindfulness training. The control group will receive care as usual.||||
33838285|NCT06546943|||CASE_ONLY||PROSPECTIVE|||||||
33961691|NCT04382690|||COHORT||CROSS_SECTIONAL|||||||
34173962|NCT03466658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34173963|NCT03228446|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34173964|NCT05219825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173965|NCT02262936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173966|NCT04397835|||COHORT||PROSPECTIVE|||||||
34173967|NCT02251015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173968|NCT03866122|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One or more neonatal temperature monitors will be applied to the same infant; results between the monitors will be compared.||||
34173969|NCT02568969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173970|NCT00693407|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34173971|NCT04932395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173972|NCT06126614|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34173973|NCT06165809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173974|NCT06582212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34173975|NCT00317551|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34173976|NCT02735863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34173977|NCT02529852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173978|NCT04961710|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34173979|NCT03021057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173980|NCT06390397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34173981|NCT05945784|||CASE_ONLY||PROSPECTIVE|||||||
34173982|NCT05305443|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||SMART Design||||
34173983|NCT03290937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34173984|NCT06704568|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||1st group N=30 control group, 2nd group N=30 core exercise group, 3rd group N=30 breathing exercises group will be randomly divided into 3 groups.||||
34173985|NCT04850105|||COHORT||PROSPECTIVE|||||||
34173986|NCT04857255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34173987|NCT02849808|||COHORT||PROSPECTIVE|||||||
34173988|NCT03346434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|"Part A: Open Label;~Part B: Masked, Randomized"|"Part A: Single-ascending-dose cohorts staggered by age;~Part B: Parallel Group"||||
34173989|NCT03567564|||COHORT||PROSPECTIVE|||||||
34173990|NCT03826706|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34173991|NCT00005567||||ECT||||||||
34173992|NCT01893996|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34173993|NCT06205992|||COHORT||PROSPECTIVE|||||||
34173994|NCT04459143|||COHORT||PROSPECTIVE|||||||
34173995|NCT03489863|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized||||
34173996|NCT00676858|||COHORT||PROSPECTIVE|||||||
34173997|NCT05766683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be randomized using computer generated randomization list provided by PHS to either receive onabotulinumtoxinA neurotoxin injections in the glabellar complex at depth of 2mm or at depth of 4mm (or above periosteum if depth of 4mm cannot be reached)|t|t|t|f
34173998|NCT05062174|||CASE_CROSSOVER||PROSPECTIVE|||||||
34173999|NCT06508411|||COHORT||CROSS_SECTIONAL|||||||
34174000|NCT06541938|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||We have 2 groups (IBD patients \& healthy controls) so 30 per group||||
34174001|NCT00187291|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174002|NCT03784872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174003|NCT06026046|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174004|NCT00636090|||COHORT||PROSPECTIVE|||||||
34174005|NCT00261690|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174006|NCT05196828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174007|NCT05680714|||OTHER||PROSPECTIVE|||||||
34174008|NCT00939549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174009|NCT03604367|||OTHER||OTHER|||||||
34174010|NCT02197312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174011|NCT00280982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174012|NCT05206747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be informed that the investigators are studying the effects of two different types of light filters without more detail so they will not know which is the experimental vs. control condition. With possible un-blinding from other sources of information and lens color, the investigators will assess the integrity of the blind by asking participants whether they thought they received the experimental or the control glasses at the end of the study. Participates will also be encouraged not to share details of their glasses assignment with other participants and physicians to avoid unblinding.|The investigators plan to conduct an up to two-week single-blind, randomized controlled trial of blue-blocking glasses added to treatment as usual for mania. Participants will be randomized 1:1 to wearing blue blocking glasses or lightly-tinted glasses. To ensure temporal and geographic balance, randomization will be stratified by the three sites in blocks of four.|t|t|f|t
34174013|NCT01991808|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174014|NCT05766397|NA|SEQUENTIAL||OTHER||NONE||This is a phase other study. This is a phase other, Health Canada regulated, non-clinical occupational exposure laboratory study, where 30 healthy human participants will inhale methoxyflurane following a protocol and during which occupational exposure of methoxyflurane will be measured via strategically positioned samplers (active and passive) according to a pre-set protocol, including single and multiple consecutive events.||||
34174015|NCT05323695|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34174016|NCT05992675|||COHORT||RETROSPECTIVE|||||||
34174017|NCT04362839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174018|NCT05930938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants who meet the study criteria will be randomly assigned in a 1:1 ratio using minimization to Arm A or arm B|t|t|t|f
34174019|NCT00246519|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174020|NCT03386981|||OTHER||PROSPECTIVE|||||||
34174021|NCT04013386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34174022|NCT04364477|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34174023|NCT05830552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||In the intervention group, the researcher provided feedback on the participants' exercise amount through telephone contact every two weeks during the 12-week study period. It includes recommendations for continuing exercise therapy based on the recommendations for physical activity. Through phone consultations, they answered questions about exercise or discussed problems, were encouraged to continue exercising, answered questions or discussed problems related to wearable devices and apps, and encouraged for continuous data transmission.|t|f|t|f
34174024|NCT05301660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174025|NCT03392896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|SAD period in HV is single-blind (unblinded clinical site staff member who is not a member of study team administers dose). SAD period in Group B (PH1 and PH2 patients) is open-label.|Two-arm (active and placebo), single-blind, SAD period (Group A, HVs) followed by open-label, SAD period (Group B, PH1 and PH2 patients).|t|f|t|f
33838286|NCT03193983|RANDOMIZED|PARALLEL||TREATMENT||NONE||"two groups Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.~Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks."||||
33861097|NCT06465888|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Brand name of eggs on cartons will be covered so participants will not know which eggs they were eating.|This is a 30-day study. Serum analysis and diagnostic testing will be conducted at baseline. Participants will be randomly assigned to a no-egg control or one of the following dietary treatment groups: 4 large egg whites daily; 2 large whole eggs daily; 2 large whole omega-3 fortified eggs daily; or 4 large egg yolks daily. Participants will be asked to follow their routine food and beverage intake other than the assigned dietary treatment guidelines. Fifteen food logs will be completed. The last two weeks will include 15 Neurotracker 3-D cognitive training sessions over 10 days with diagnostic measures, physical activity, and sleep patterns recorded. Serum blood draw at day 30.|t|f|f|f
33961692|NCT06537284|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Investigators plan to use the double-blind procedure, as neither therapists will be informed about the arm (arms will be coded in the scripts), nor participants will be informed about conditions in the study, the research hypotheses will be masked.||t|t|f|f
33961693|NCT04742816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||iohexol||||
33961694|NCT00355680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961695|NCT04622618|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Drug formulation will be done by one of the researchers making the dosage of the three groups the same in number and shape of the capsules and then given to a junior anesthetist who is neither involved nor interested in any way in the sample to be administered to the patients surveyed. Blind grouping will be kept to all including the patients themselves, until the completion of the study. Data collection will be done by another anesthesiologist who is blinded to the given medication during the study and not included in the research team.|A total of (150) adult patients who will undergo elective abdominal laparoscopic surgery will be included in the study. Written informed consent will be obtained from all patients before randomization. Patients will be divided randomly and equally into three groups (50 patients each(.|t|t|f|t
33961696|NCT01315301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961697|NCT03654092|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174026|NCT06479590|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174027|NCT01184586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33838287|NCT03214770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be a single-blinded study so that the participant will be blinded, the researcher and the data analysis will be unblinded.||t|f|f|f
33961698|NCT01841398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961699|NCT02022410|||COHORT||PROSPECTIVE|||||||
33838288|NCT05733182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized clinical trial|t|f|t|f
33838289|NCT05994638|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961700|NCT01380860|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33961701|NCT06567470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961702|NCT00118573|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33961703|NCT06567158|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study will be preceded by a screening period to check which participants are eligible for the study and a two-week run-in period during which, participants will be asked to document their eating patterns for one week in a digital food diary to base the moderate carbohydrate diet on.~Participants will be randomized into two groups (1:1). One group will start at baseline with the traditional diet and after four weeks they will cross-over to the moderate carbohydrate diet for four weeks. The second group will start at baseline with the moderate carbohydrate diet and after four weeks they will crossover to the traditional diet for four weeks. Between the two diet periods there will be a wash-out period of six weeks."||||
33961704|NCT00002774|RANDOMIZED|PARALLEL||TREATMENT||||||||
33961705|NCT01844869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961706|NCT03222895|||COHORT||PROSPECTIVE|||||||
33961707|NCT00436397||||TREATMENT||||||||
33961708|NCT04295044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064450|NCT03341117|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|"A randomized double blind, placebo controlled clinical trial was carried out in 21 drug naïve adults,regimen was prescribed to the subjects.~The allocation was 1:1 concealed and done by simple randomization using a table of random numbers. After randomization, 11 patients received of ASA 300 mg once daily and 10 patients received placebo (calcined magnesia) in the same pharmacological presentation for 90 days, the dose was based in the non-affectation of renal uric acid resorption."|A randomized double blind, placebo controlled clinical trial was carried out in 21 drug naïve adults (35-50 year of age) with DM2 with \<5 years since diagnosis. They were overweight or obese (BMI 25.0 - 35.0 kg/m2), had glycosylated hemoglobin A1C (HbA1c) level between 6.5 - 9%. This protocol study was reviewed and approved by the hospital based ethics committee, and written informed consent was obtained from all volunteers. Subject was selected from the same residential area and socioeconomic status. No participants were excessively sedentary or participated in heavy physical activity. All individuals were nonsmokers. Their body weight was stable for al last 3 months before the study.|t|f|t|f
34064451|NCT05167916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064452|NCT05360914|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174028|NCT01962935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34174029|NCT03549923|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34174030|NCT03577795|||COHORT||PROSPECTIVE|||||||
33838290|NCT04962997|||COHORT||CROSS_SECTIONAL|||||||
33838291|NCT03735472|||COHORT||PROSPECTIVE|||||||
33838292|NCT03907267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838293|NCT04966026|||COHORT||PROSPECTIVE|||||||
34174031|NCT05588336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34174032|NCT03980886|||COHORT||PROSPECTIVE|||||||
34174033|NCT06173830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174034|NCT02946086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174035|NCT02944409|||COHORT||PROSPECTIVE|||||||
34174036|NCT04180930|||OTHER||PROSPECTIVE|||||||
34174037|NCT05979493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34174038|NCT05292794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174039|NCT05134935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174040|NCT06596174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174041|NCT00451360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33751001|NCT05537220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||438 participants will be enrolled and randomized at approximately 30 clinical sites in the Americas and Europe. Patients will be eligible if both eyes have an RP phenotype consisting of severe loss of rod function (night blindness) followed by progressive constriction of visual fields with best-corrected visual acuity (BCVA) of 20/60 or better. Gradable ellipsoid zone (EZ) width on the horizontal fovea spectral domain-optical coherence tomography (SD-OCT) scan must be \< 8000 µm and ≥ 1500 µm. Eligible patients will be randomized 2:1 to NAC 1800 mg bid versus placebo. The primary efficacy objective is to determine if the progressive loss in EZ width measured as the cumulative loss of EZ (calculated as the area above the curve) between baseline and month (M) 45 is significantly less in eyes of participants taking NAC 1800 mg bid compared with that in eyes of participants taking placebo. The safety objective is to evaluate the long-term safety and tolerability of oral NAC for 45 months.|t|t|t|t
33751002|NCT03273634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Similarly looking tablets and placebo with care providers not knowing which is which. Packets are marked heads and tails for randomization"||t|t|f|f
33751003|NCT06237205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174042|NCT04913272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|"This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter clinical trial to evaluate the safety and efficacy of KT-301 (formerly US-APR2020) in patients with CKD Stage IV.~Following Screening and Enrollment, patients will be Randomized to either Group KT-301 or Placebo. In Group KT-301, the drug KT-301 will be administered orally at 2 capsules per day (one capsule in the morning and one capsule in the evening, after meals, for a total daily dose of 90 Billion CFUs) for six months. Subjects will be followed for 6 months. Patients in Placebo Group will be administered Placebo tablets in similar routine."|t|t|t|t
33751004|NCT03422250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33751005|NCT06497166|||OTHER||OTHER|||||||
33751006|NCT00990691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751007|NCT05195645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064453|NCT01250171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064454|NCT04111861|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064455|NCT02024737|||CASE_ONLY||PROSPECTIVE|||||||
34174043|NCT06335641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174044|NCT02593916|||COHORT||PROSPECTIVE|||||||
34174045|NCT06272799|||COHORT||CROSS_SECTIONAL|||||||
34174046|NCT05401162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174047|NCT00352508|RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
34174048|NCT06693570|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter Prospective Randomized Comparative Effectiveness Clinical Trial||||
34174049|NCT01788852|||COHORT||PROSPECTIVE|||||||
34174050|NCT04710901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174051|NCT05976360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174052|NCT01593839|||CASE_ONLY||CROSS_SECTIONAL|||||||
34174053|NCT00353730|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174054|NCT04444817|||COHORT||PROSPECTIVE|||||||
34174055|NCT00308802|||CASE_ONLY||PROSPECTIVE|||||||
34064456|NCT01608516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064457|NCT05278494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064458|NCT05691166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174056|NCT04297865|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34174057|NCT06219629|||COHORT||PROSPECTIVE|||||||
34064459|NCT03261440|||OTHER||PROSPECTIVE|||||||
34064460|NCT00628927|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064461|NCT03252197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded to study arm, Outcome assessor measured outcome variables based on recorded images.||f|f|f|t
33751008|NCT06205602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33751009|NCT05876546|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||Induction period (3 weeks): the experimental and control product will be applied through a patch test on the participants' back for 3 consecutive weeks, with 3 weekly applications, with the first week being the primary irritation phase and the two consecutive weeks being the irritation phase. accumulated irritation. Rest period (10 to 15 days): corresponds to the rest period, when participants will remain without any contact test applied to their back, which will follow the induction period, where there will be no application of the experimental and control product. Challenge period (3 days): the experimental and control product will be applied to the participants' back, in a naïve area. Products will be removed after 48 hours, with readings taking place after removal and approximately 24 hours after removal. This period corresponds to the sensitization phase.|f|f|f|t
33751010|NCT02464449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33751011|NCT02625896|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33751012|NCT04166994|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Control Trial||||
33861098|NCT05885880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861099|NCT02700243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174058|NCT06211920|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Due to the nature of the intervention, the clinicians performing the intervention cannot be blinded. This is also the case for patients along with any legally designated representatives at the scene. As it is common to note the prehospital treatment in the patient's medical records clinicians at the ED and/or ICU will not necessarily be blinded either. For the same reason, investigators involved in data entry will also not be blinded meaning that outcomes such as change in arterial pH are entered without blinding. However, there is little - if any - subjectivity in evaluating these outcomes and blinding is therefore likely of minor importance.~A patient - or alternatively the consenting legally designated representatives - will not be informed of the allocation until the end of follow-up and only per request on the consent form."|Investigator-initiated, randomized 1:1, clinical trial||||
34174059|NCT04215224|||COHORT||OTHER|||||||
33861100|NCT00936845|||COHORT||RETROSPECTIVE|||||||
34174060|NCT04915846|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The study is a placebo-controlled double-blinded design. A select few (pharmacist and study staff in charge of pharmacokinetics) and Data Safety Monitoring Board (DSMB) are unblinded.|Double-blinded, placebo-controlled, single cross-over study with washout period before cross-over|t|t|t|t
33861101|NCT01130974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174061|NCT06215508|||COHORT||PROSPECTIVE|||||||
34174062|NCT04823585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861102|NCT01974596|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34174063|NCT04162249|||COHORT||PROSPECTIVE|||||||
34174064|NCT03985930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174065|NCT04156841|||COHORT||RETROSPECTIVE|||||||
34174066|NCT02397798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34174067|NCT04099563|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single-arm, single- and multiple-dose study||||
34174068|NCT02374697|||CASE_CONTROL||PROSPECTIVE|||||||
34174069|NCT00656903|||||PROSPECTIVE|||||||
34174070|NCT04715113|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33861103|NCT02221986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861104|NCT01947452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861105|NCT02670681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861106|NCT05176184|||COHORT||PROSPECTIVE|||||||
33861107|NCT04540133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861108|NCT02466438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861109|NCT06071403|||COHORT||PROSPECTIVE|||||||
33861110|NCT04900922|||OTHER||CROSS_SECTIONAL|||||||
33861111|NCT04575103|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861112|NCT02590263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861113|NCT02581293|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33861114|NCT03075423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861115|NCT04092062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Assessors will not be exposed to the type of brush the subject is using or to the group they are assigned to (treatment or control).|Double arm, single blind prospective study|f|f|f|t
33861116|NCT00805662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861117|NCT03607123|||CASE_CROSSOVER||PROSPECTIVE|||||||
33861118|NCT03970551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be 6 stands that will involve standing from a sitting position and performing physical counter-maneuvers or a stress test either prior to or following the stand. The order of the interventions will be randomized. Both healthy participants and IOH patients will perform all stands.||||
33861119|NCT00235326|||COHORT||PROSPECTIVE|||||||
33861120|NCT05538273|||COHORT||RETROSPECTIVE|||||||
33861121|NCT03919981|||COHORT||PROSPECTIVE|||||||
33861122|NCT01187069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33861123|NCT02326714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174071|NCT03164668|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34174072|NCT02335619|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174073|NCT02997631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174074|NCT00315926|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861124|NCT01449318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33861125|NCT00966823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861126|NCT05079412|||COHORT||PROSPECTIVE|||||||
33861127|NCT04641507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861128|NCT05335148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Perform a phase I study for evaluating the safety of oral colchicine in preventing and treating radiation-induced dermatitis among head and neck cancer patients.||||
33861129|NCT02329665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861130|NCT05626049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients, clinicians delivering care, LBP schedulers and site research coordinators will not be blinded to clinic intervention assignment in this pragmatic clinical trial. There will be both blinded and unblinded analysis teams.|Primary care clinics across three academic HCS will be allocated 1:1 to each arm (PSP model versus usual care) of the study. Clinics randomized to provide the PSP model will provide patient information regarding the ACP guideline for LBP and an LBP scheduling assistant will help patients make an appointment with either a DC or PT at the initial point of contact.|f|f|f|t
33861131|NCT06245811|||CASE_CONTROL||RETROSPECTIVE|||||||
33861132|NCT03606837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861133|NCT05066269|||COHORT||PROSPECTIVE|||||||
33861134|NCT03146468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861135|NCT04864483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross over design||||
33861136|NCT00297557|||DEFINED_POPULATION||OTHER|||||||
34064462|NCT03597139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a Phase 2, multi-center, Investigator-masked, randomized, parallel-group study to evaluate the tolerability, efficacy and safety of VOS versus Restasis® over a 28-day treatment period in subjects with mild to moderate DED. Approximately 90 subjects will be randomized to either VOS or Restasis® at approximately 7 centers located in the US.|f|f|t|f
33861137|NCT04140383|||CASE_CONTROL||RETROSPECTIVE|||||||
33861138|NCT00887250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861139|NCT06474104|||COHORT||PROSPECTIVE|||||||
33861140|NCT04100395|||CASE_CONTROL||RETROSPECTIVE|||||||
33861141|NCT01631695|||COHORT||CROSS_SECTIONAL|||||||
33861142|NCT03873493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861143|NCT03258125|||CASE_CONTROL||RETROSPECTIVE|||||||
33861144|NCT01513525|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064463|NCT06731842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064464|NCT01446250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174075|NCT00068068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174076|NCT03002441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174077|NCT05121766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Everybody but the pharmacy team dispensing the drug will be masked.||t|t|t|t
34174078|NCT06199570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open Trial phase: Unblinded, single-site, single-arm open trial (n=10). Pilot RCT phase: Unblinded, single-site, feasibility pilot randomized controlled trial (n=50; adapted stress management program vs. enhanced usual care).||||
34174079|NCT05128669|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arms, randomized assignment to intervention group (CPIP + ECS) or control group (ECS only), single masked (outcomes assessor), multi-centre trial||||
33861145|NCT04157504|NA|SINGLE_GROUP||SCREENING||NONE||||||
33861146|NCT05549778|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be on abiraterone/prednisone plus polaprezinc, or with other treatments according to patients'wishes in consultation with physicians.|f|f|t|t
34174080|NCT00074711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174081|NCT04357743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174082|NCT06236906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861147|NCT03698890|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174083|NCT06272994|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be performed as a single center, pragmatic, randomized clinical trial.||||
33861148|NCT00229554|||||RETROSPECTIVE|||||||
34174084|NCT02425410|||CASE_ONLY||RETROSPECTIVE|||||||
34174085|NCT05362487|||COHORT||PROSPECTIVE|||||||
34174086|NCT01872793|||COHORT||PROSPECTIVE|||||||
34174087|NCT05587270|||COHORT||PROSPECTIVE|||||||
34174088|NCT02845297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861149|NCT05827250|||COHORT||PROSPECTIVE|||||||
34174089|NCT01352117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861150|NCT01317225|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33861151|NCT06414915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861152|NCT06267157|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33861153|NCT04118296|NA|SINGLE_GROUP||TREATMENT||NONE||This research is a clinical trial research with an experimental research design. Epidemiological association analysis is obtained by calculating Relative Risk (RR) because the research use experimental design and the nature of the two variables studied is categorical.||||
33861154|NCT04042558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multicentre, non-randomized two parallel cohorts phase II study||||
33861155|NCT01039025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961709|NCT05622552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The random numbers generated by the computer software and corresponding to the serial number were assigned to the DLPFC 2mA once/day group and the sham stimulation once/day group, and the random number sequence was recorded. Patients eligible for inclusion were randomly assigned to different treatment groups in a 1:1 ratio. Those who determine the random number grouping shall not participate in the inclusion of subjects.~The implementation of randomization and the verification and storage of grouping information were operated by specialists. Study operators, clinical evaluators, and patients were not aware of their intervention grouping. In case of urgent adverse events, blinding should be undone, and the relationship between adverse events and treatment should be studied and reported to the ethics committee."|"tDCS stimulation, which was performed once a day sessions of active or sham anodal tDCS to the right dorsolateral prefrontal cortex and cathode to the left OFC (2 mA, 20 minutes, 10 sessions).~In the active group, current stimulations were gradually ramped up to 2 mA (in 30 seconds) intensity for 20 minutes, once a day, for 10 days. For sham stimulation, the procedure was identical, except that the current was gradually ramped up to 2mA and rapidly down to zero (in 30 seconds), thus leading to the same initial sensations of tDCS."|t|f|t|t
33961710|NCT04700735|||COHORT||PROSPECTIVE|||||||
33961711|NCT03779113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064465|NCT05471336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064466|NCT03970200|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label, comparative||||
34064467|NCT03906851|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064468|NCT01282333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174090|NCT00965601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33861156|NCT01277770|||COHORT||RETROSPECTIVE|||||||
33861157|NCT03478163|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label, randomized controlled trial||||
33861158|NCT01615653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861159|NCT04830956|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33861160|NCT05356117|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33861161|NCT05989607|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized, counter-balanced, cross-over design||||
33861162|NCT02407522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861163|NCT06140212|||OTHER||CROSS_SECTIONAL|||||||
33861164|NCT04793269|||COHORT||RETROSPECTIVE|||||||
33861165|NCT00781820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861166|NCT01910233|||COHORT||PROSPECTIVE|||||||
33861167|NCT05055414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064469|NCT00198432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064470|NCT04499105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064471|NCT04422314|||COHORT||PROSPECTIVE|||||||
34174091|NCT05594550|||COHORT||RETROSPECTIVE|||||||
34174092|NCT06630598|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomly assigned to a training group or a wait-list control group.||||
34174093|NCT04175249|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174094|NCT00805350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174095|NCT06527898|NA|SINGLE_GROUP||TREATMENT||NONE||Hypofractionated radiotherapy combined with immunotherapy||||
34174096|NCT06435936|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34174097|NCT05183178|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stepped wedge cluster randomized evaluation in the SWEDEHEART-registry||||
34174098|NCT04310540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174099|NCT01275352|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33961712|NCT01624155|NA|SINGLE_GROUP||PREVENTION||NONE||"The patient is contacted by a specialist in the CTIS Pregnancy Health Information in the Department of Pediatrics at UCSD, and a brief patient interview is conducted with a risk assessment and counseling regarding her medication and the potential effects if she were to become pregnant. The patient is also given information about contraceptive methods, efficacy rates, and the safety of each method based on the USMEC guidance for the patient's medical condition.~After the counseling is completed, the patient is asked if she is interested in participating in the research study. If the patient consents to participation, she is contacted one week, one month, and three months after the initial telephone interaction and asked several questions regarding her current contraceptive utilization and any changes from the time of the last interview. Upon completion of the three-month follow-up, participants are asked to complete a satisfaction survey."||||
33961713|NCT01431235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961714|NCT03399435|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Sponsor, personnel of the central research pharmacy at the site, the pharmacy CRA and the bioanalytical lab are not blinded.|"Part A: 8 cohorts (equivalent to 40 subjects) are planned to be treated with ascending doses of neosaxitoxin combined with fixed doses of bupivacaine and epinephrine.~Part B: Part B will start at the earliest after 4 cohorts of Part A have been treated. Ascending doses of neosaxitoxin combined with fixed doses of bupivacaine.~Part C: Part C will comprise 4 treatment groups in which all participants will receive the same neosaxitoxin dose alone, or neosaxitoxin combined with epinephrine, or neosaxitoxin combined with bupivacaine with or without epinephrine."|t|f|t|t
33961715|NCT03951181|NA|SINGLE_GROUP||OTHER||NONE||||||
33961716|NCT04816500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961717|NCT06260384|||COHORT||PROSPECTIVE|||||||
34064472|NCT02411318|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961718|NCT04254731|NA|SINGLE_GROUP||TREATMENT||NONE||Patients included were stabilized on per os methadone maintenance treatment and had automatically ECG recorded QTc interval greater or equal to 450 ms. The patients were switched to pure R-methadone per os (half dose of the racemic methadone used). Doses, serum drug concentrations, QTc-time were recorded before and after drug switch. Serum-electrolytes (Mg, K, Ca) and opioid withdrawal symptom scale (OWS) were also measured and scored before and after drug switch.||||
34064473|NCT01935128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064474|NCT00005896||||TREATMENT||||||||
33961719|NCT03789058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The treatment regimens were masked for both participants and care provider (Clinical investigator)|Parallel Assignment a single-center double-blind randomized controlled trial|t|t|f|f
33961720|NCT04456985|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064475|NCT01511003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961721|NCT00338494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064476|NCT00133653|||DEFINED_POPULATION||PROSPECTIVE|||||||
33961722|NCT04114409|||CASE_CONTROL||PROSPECTIVE|||||||
34064477|NCT05636358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although the children and GP's cannot be blinded to the allocation, researchers performing the analyses will be blinded for allocation.|This study is a pragmatic randomised controlled trial (RCT) with a total follow-up of 12 months executed in primary care in the Netherlands. Participating children will be randomised 1:1 on the patient level to either the intervention or the care as usual group. The intervention group will receive 3 months home-based hypnotherapy by self-exercises in addition to care as usual by their GPs according to the Dutch Society of GPs' (NHG) guideline. The control group will receive usual care (UC) by their GPs alone according to the Dutch Society of GPs' (NHG) guideline.|f|f|f|t
34064478|NCT02867202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064479|NCT00819572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064480|NCT06195475|||COHORT||OTHER|||||||
34064481|NCT01216046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064482|NCT05339412|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomized to one of two conditions: (1) technology based training tool only; or (2) technology based training tool plus live supervision.||||
33961723|NCT05748522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064483|NCT05836675|NA|SINGLE_GROUP||TREATMENT||NONE|Since it is an exercise intervention, the participants cannot be masked. When the analysis and interpretation of the data is preformed, the investigator will not know the participants identification data.|There will be one single group that will act as their own control throughout the intervention||||
34064484|NCT03710369|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34064485|NCT00033878||||TREATMENT||||||||
34064486|NCT05917808|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, non-randomized, open, pre-post design||||
34064487|NCT04375501|||COHORT||PROSPECTIVE|||||||
34064488|NCT05917067|||OTHER||PROSPECTIVE|||||||
34064489|NCT03905356|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064490|NCT05807438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician and the physiotherapist who performed the tests were blinded to the study, and the participants were also blinded to the study.||t|f|t|f
34064491|NCT06351852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064492|NCT00715845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064493|NCT04728555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Non-blinded|A non-blinded randomized waiting list control study||||
34064494|NCT05011097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174100|NCT01109264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174101|NCT00236223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174102|NCT06241742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174103|NCT01402089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861168|NCT04433351|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Two types of rehabilitation will be compared, a simple rehabilitation (S, based on conventional speech therapy) and an enriched rehabilitation (E, based on the use of sensory-motor integration in addition to conventional speech therapy). The investigators will constitute two cohorts of patients (N=18 per cohort): a cohort SE which will carry out first the simple rehabilitation protocol followed by enriched rehabilitation, and a cohort ES which will carry out first the enriched rehabilitation protocol followed by simple rehabilitation. The protocol starts at T0 (inclusion according to defined criteria) and after a first evaluation (T1), patients will then perform the first part of the rehabilitation protocol during 4 weeks. After these 4 weeks, a second evaluation will be performed (T2). Then, the second part of the rehabilitation protocol will be carried out during 4 weeks. At the end, the T3 evaluation will be performed.||||
33961724|NCT05365022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961725|NCT05645055|||COHORT||PROSPECTIVE|||||||
34174104|NCT03803293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The Mayo Clinic Biobank is an institutional resource comprised of adult community volunteers who donated biological specimens, provided risk factor data, access to EHR data, and consented to participate in additional studies. Subjects in the Mayo Clinic Biobank are the cohort that was recruited to participate in the RIGHT study.||||
34174105|NCT01359488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174106|NCT05123872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174107|NCT04040764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The following people will be blinded as to which arm of the study the patient is allocated to:~* The patient~* The statistician who performs the analysis of the results~* The radiographer reporting upon the DXA scan results"|An internal pilot study comparing 2 different types of knee prosthesis; uncemented vs cemented total knee replacement|t|f|f|t
34174108|NCT03741010|||COHORT||PROSPECTIVE|||||||
34174109|NCT04324034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174110|NCT04605601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174111|NCT06525428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174112|NCT01493323|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174113|NCT03817164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174114|NCT02412306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961726|NCT04930198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174115|NCT05697770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"An unblinded research coordinator, pharmacist or nurse not involved in data collection or bedside care will prepare the drug.~The bedside nurse who administers the drug, other care providers, all investigators and outcome assessors will be blinded."|Patients will be randomly allocated in a 1:1 ratio to receive either an infusion of D5W + sodium bicarbonate, or D5W alone.|t|t|t|t
34174116|NCT03045744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174117|NCT03501589|||CASE_ONLY||PROSPECTIVE|||||||
34174118|NCT03064529|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174119|NCT04906499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961727|NCT01461369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961728|NCT03894917|||COHORT||PROSPECTIVE|||||||
33961729|NCT02505165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961730|NCT02264301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174120|NCT06039839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174121|NCT00272493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961731|NCT06108674|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34174122|NCT03703700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174123|NCT04068025|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174124|NCT06403787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind clinical trial with random allocation into three groups, all undergoing aerobic training. One group will receive ginkgo biloba extract, another will be administered atorvastatin, and a third will receive a placebo of calcined magnesia|t|f|t|f
34174125|NCT05120713|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174126|NCT00209911|||NATURAL_HISTORY||PROSPECTIVE|||||||
34174127|NCT00217984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174128|NCT02366494|||OTHER||PROSPECTIVE|||||||
34174129|NCT04072783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with craniosynostosis only||||
34174130|NCT03449017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||2 session x 2 condition within participant||||
34174131|NCT03839940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33861169|NCT01685190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861170|NCT05231486|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||The study design is similar to a matched case-control study using Single Case Experimental Design (SCED) methodology with a multiple baseline design across subjects.|f|f|f|t
33861171|NCT04574479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Two group simple-blinded RCT: placebo vs fascia iliaca group. Surgeon and patient are blinded of the patient's group. Investigator and loco-regional technique provider know the patient's group.||t|f|t|f
33861172|NCT01617850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33861173|NCT02249754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861174|NCT00760396|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33861175|NCT03785678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861176|NCT00786123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861177|NCT02973425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961732|NCT05043727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||each participant will be requested to draw either number one or two from box. Group number one will receive exer gaming treatment plan Each Patient received twenty four sessions. Each treatment session will of 50 minutes with two minutes rest between each exercise. Group two will receive conventional treatment plan which will include balance training, gait training, stretching and strengthening exercises.Treatment session will be of 50 minutes with 2 minutes rest period between each exercise.|f|f|f|t
33961733|NCT04793932|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2 by 2||||
33961734|NCT03863652|||COHORT||PROSPECTIVE|||||||
33961735|NCT01238211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961736|NCT00078312|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961737|NCT06418880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064495|NCT05584800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34064496|NCT06240988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment.|It will be Randomized Controlled Trial in which non probability convenient sampling technique will be used. two groups of 6 to 14 years of age will be formed in which participants will be randomly divided. Group A will be given Modified CIMT and the other group B will receive motor imagery technique on upper limb in hemiparetic CP.|t|f|f|f
34064497|NCT02656563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064498|NCT06730152|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34174132|NCT04571749|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34174133|NCT04517123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174134|NCT06528288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be masked to the treatment arm. The research team (outcomes assessors) involved in evaluation of subjects will be blinded to the treatment arm.||t|f|f|t
34174135|NCT06704789|||CASE_CROSSOVER||PROSPECTIVE|||||||
34174136|NCT02779439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174137|NCT03120052|||COHORT||PROSPECTIVE|||||||
33861178|NCT03496324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861179|NCT00531882|RANDOMIZED|PARALLEL||OTHER||NONE|No person associated with the study was masked|||||
34064499|NCT02295787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064500|NCT00636961|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34064501|NCT01666210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064502|NCT05869877|RANDOMIZED|FACTORIAL||OTHER||NONE||Randomized controlled trial evaluating a peripheral intravenous catheter (PIVC) inserting using a bundled approach. Will evaluate the for extended dwell time and less complications compared to a PIVC using a non-bundled approach||||
34150372|NCT03404622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Randomization will be based on the sequence generation created by computer and randomization tablets. Consenting patients fulfilling inclusion criteria will be randomizes into one of the following 2 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. the envelopes will contain a card on with the designated study group will be written. after enrollment of the patients in the study , the envelopes marked with study number will be unsealed and the patients allocated to either groups|200 pregnant women will be included in this study, will be divided into two groups Group 1 IUCD will be inserted immediate post-placental removal and include 100 pregnant women Group2 IUCD will be inserted 6 weeks postpartum and include 100 pregnant women.|t|t|f|f
34150373|NCT01380704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174138|NCT03260946|||COHORT||PROSPECTIVE|||||||
34174139|NCT03772249|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This is a double-blind study in which the study site team, the Sponsor, and the participants will be blinded to treatment assignment. The unblinded pharmacist will cover each syringe, prior to transport to the bedside, to ensure blinding. The drug will be injected by an unblinded nurse or physician who is not part of the study team. Participants will be centrally assigned to randomized study intervention using an Interactive Voice/Web Response System (IVRS/IWRS). Cohorts 4c and 5c will be open label.|Progression from the SAD phase to the first cohort in the MAD phase is contingent upon the Safety Review Committee (SRC) review of a minimum of 14 days post-dose safety and tolerability data from all NHV in at least the first 2 SAD cohorts. The SRC will select one (or more) well-tolerated dose(s) from the SAD phase for administration in the SD and MAD phases. Group B at 3 mg/kg will start in parallel with Group C at the 3 mg/kg dose level. In all study phases, dosing will be staggered with the use of sentinel participants to allow time for the assessment of safety before additional subjects are exposed to study drug. The fixed dosing regimen for Cohorts 4c and 5c was determined following SRC review and assessment of all data up to Cohort 3c. No sentinel dosing will occur in Cohorts 4c and 5c.|t|t|t|f
34174140|NCT04224129|||COHORT||PROSPECTIVE|||||||
34174141|NCT06523335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174142|NCT05626738|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multi Centre, Post Market, Single Arm, Open-Label, Interventional Study||||
34174143|NCT05840198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174144|NCT05023733|||COHORT||PROSPECTIVE|||||||
34174145|NCT02231112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174146|NCT06313892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research project collaborator who is not informed about grouping of participants will obtain outcome measurements of the functional test. Outcome adjudicators, and data analysts will be kept blinded to the allocation. Moreover, all investigators, staff, and participants will be kept masked to outcome measurements and trial results.|Participants will be randomly allocate to intervention group or control group and will be examined in the same way.|f|f|f|t
34174147|NCT06514157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174148|NCT06706674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174149|NCT04780867|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"For aim 1, an observational design will be used to examine the influence of psychosocial and lifestyle factors at the start of basic Army training on immune health (e.g. respiratory infection and antibody response to influenza vaccination) and injury during training.~For aim 2, the recruited cohort will be divided into two groups: (i) Routine vaccination group: to receive first hepatitis B vaccination at initial medical assessment upon entry to basic training and second hepatitis B vaccination 1 month later; (ii) Delayed vaccination group: to receive first hepatitis B vaccination during week 5 of training and second hepatitis B vaccination 1 month later."||||
34174150|NCT04723511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The enrolled participants will be masked (single blind study) and randomly assigned into two groups without being informed whether they are in the control or the study(experimental) group.||t|f|f|f
34174151|NCT05286554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174152|NCT03808116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174153|NCT04205240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174154|NCT03145090|||COHORT||RETROSPECTIVE|||||||
34174155|NCT01941485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174156|NCT02670317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174157|NCT05231226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174158|NCT00704210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34174159|NCT00762359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174160|NCT02164253|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174161|NCT05955612|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Procalcitonin measurements.|||||
34174162|NCT05251714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion for monotherapy and combination arms with fulvestrant||||
34174163|NCT04588246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34174164|NCT04714840|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34174165|NCT00778154|||COHORT||PROSPECTIVE|||||||
34174166|NCT02049775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174167|NCT05560425|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||parallel assignment randomized controlled trial feasibility study|t|f|t|f
34174168|NCT02654886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861180|NCT05169216|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861181|NCT01749540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861182|NCT00818181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861183|NCT03393715|RANDOMIZED|CROSSOVER||TREATMENT||NONE||open label randomised controlled trial with crossover of perindopril administered in the morning versus evening on blood pressure control||||
33861184|NCT05227157|||COHORT||PROSPECTIVE|||||||
33861185|NCT02218190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861186|NCT00617604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861187|NCT01168739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33861188|NCT05089409|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33861189|NCT04448756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861190|NCT01798992|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33861191|NCT04444622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861192|NCT05576922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel-arm|f|f|f|t
34174169|NCT06705686|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174170|NCT05406674|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients in Arm A are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cispaltin-based HIPEC with a dosage of 100 mg/m2.~Patients in Arm B are treated with interval cytoreductive surgery (with no more than 1 cm residual disease) and cisplatin- based HIPEC with a dosage of 40 mg/L perfusate."||||
34174171|NCT04051996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174172|NCT00537134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174173|NCT04612335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174174|NCT01466608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174175|NCT01691534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861193|NCT00355056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861194|NCT03938038|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Randomization will not occur at the individual patient level. Instead, assessment techniques (US-guided versus usual care) will be randomly assigned to care team clusters. Because teams change each month, the assignment will be to US-guided care during the first half or the second half of the month.||||
33861195|NCT01028456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174176|NCT06230575|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33861196|NCT04663750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Experimental arm: pars plana vitrectomy, sub retinal injection of recombinant tissue plasminogen activator (TPA), intravitreal sulfahexafluoride (SF6) gas tamponade and intravitreal aflibercept.~Active comparator arm: intravitreal aflibercept."|f|f|f|t
33861197|NCT03971656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861198|NCT05713773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||single-dose, randomized, open label, five-treatment, five-period, five-sequence crossover, at one study site||||
33861199|NCT01622179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961738|NCT01777607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961739|NCT03749525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961740|NCT03672396|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single-arm study with \~30 men being recruited and 20-25 who complete all aspects of the study.||||
33961741|NCT01083758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961742|NCT06539325|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33961743|NCT03648398|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174177|NCT06547554|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized, Double-Blind, Controlled, Crossover, ascending single dose design|t|t|t|f
33961744|NCT02363101|||||CROSS_SECTIONAL|||||||
34174178|NCT04079361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174179|NCT02192658|||||CROSS_SECTIONAL|||||||
34174180|NCT06583941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961745|NCT06168331|||COHORT||CROSS_SECTIONAL|||||||
34174181|NCT04614311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual who evaluates joints clinically will be blinded to study information.|Parallel intervention were participants are assigned to either the control group or intervention group.|f|f|f|t
34174182|NCT03799146|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with two groups: intervention group and waiting-list control group||||
33861200|NCT02301650|||CASE_CONTROL||PROSPECTIVE|||||||
33861201|NCT00501527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861202|NCT00701207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861203|NCT01209845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861204|NCT02885298|||COHORT||PROSPECTIVE|||||||
33861205|NCT00146679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33961746|NCT05062031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961747|NCT01075373|||CASE_ONLY||PROSPECTIVE|||||||
33961748|NCT03596060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33961749|NCT01462552|||COHORT||RETROSPECTIVE|||||||
34174183|NCT03104881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174184|NCT04896866|RANDOMIZED|PARALLEL||OTHER||NONE||Hospital beds are randomized prior to enrolment to intervention versus observation. Intervention consists of antimicrobial stewardship prospective audit and feedback.||||
34174185|NCT04860830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174186|NCT06705478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861206|NCT02627755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861207|NCT04894162|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Research questionnaire for all patients sequentially admitted to a specialist palliative care inpatient unit - 2 NHS inpatient units and 1 independent hospice.~This is not part of standard care and data does not contribute to usual care. As such this is 'interventional' research."||||
33861208|NCT01372553|||CASE_CROSSOVER||PROSPECTIVE|||||||
33861209|NCT05653323|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33961750|NCT04961073|||COHORT||CROSS_SECTIONAL|||||||
33961751|NCT00351078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961752|NCT02881970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961753|NCT01577966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961754|NCT00388674|||COHORT||PROSPECTIVE|||||||
33961755|NCT00275236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961756|NCT04922788|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33961757|NCT00810615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961758|NCT05495360|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961759|NCT01063439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961760|NCT02149537|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Adult patients to start to receive fixed low dose hydroxyurea (10 mg/kg) per day for six months and then crossover to no hydroxyurea treatment for six months, or start with no hydroxyurea treatment for six months and then crossover to receive fixed low dose hydroxyurea (10 mg/kg) per day for six months.||||
34174187|NCT05343754|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Patients are aware of another treatment possibility (hyperbaric Oxygen therapy) which will be investigated.|The study design is a pragmatic prospective cohort study: a group of patients with therapy refractory pyoderma gangrenosum despite standard wound care and anti-inflammatory treatment for at least 6 weeks will be treated with hyperbaric oxygen therapy.||||
34174188|NCT06582433|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33861210|NCT05212896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861211|NCT00463268|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861212|NCT05226754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||After enrolment, patients will be randomized (n=20 per group) 1:1 to receive either diacerein 50 mg or placebo treatment every 12 hours for 10 days. The research electronic data capture (REDCap) platform will be used as a randomization system. Patients, investigators and other support staff will be blinded to the experimental therapy. The study drug, diacerein (Artrodar®-capsules 50mg) and placebo capsules (lactose and magnesium stearate), will be similar in size and appearance to maintain blinding. All laboratory analyses will be performed blinded to the treatment. Identification of the study drug will only occur after locking the dataset.|t|t|t|t
33861213|NCT04225468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33861214|NCT05887817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Assignment|t|t|t|t
33861215|NCT00682565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861216|NCT04339114|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33861217|NCT04334733|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This randomized controlled experimental study was carried out with 164 children in the 5-12 age group in the pediatric echocardiography unit of a Training and Research Hospital between February 2019 and November 2018. In the study, nonpharmacological methods were applied to the children in the experimental groups (Cartoon Group (n=41), Kaleidoscope Group (n=41), Cartoon+Kaleidoscope Group (n=41), Control group (Routine echocardiography) (41) . The data were collected using the Introductory Information Form, Children's Fear and Anxiety Scale (CFAS)."||||
33861218|NCT02673203|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33861219|NCT00066742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861220|NCT01119326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861221|NCT03882710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861222|NCT05511623|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized (1:1) to Arm A or Arm B.||||
33861223|NCT02072434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861224|NCT02959567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861225|NCT05128721|RANDOMIZED|PARALLEL||PREVENTION||NONE||A Randomized, Open-label, Phase 1 Clinical trial.||||
33861226|NCT01603732|||COHORT||PROSPECTIVE|||||||
33861227|NCT04888520|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All participants will receive the intervention (application of elastic bandage) and will be blind to which of the two groups belongs. All interventions will be carried out in a private room, one participant at a time. The evaluators (initial and final) and the researcher responsible for analyzing the results will also be blind to the conditions of the groups analyzed. However, the professional who applies the intervention will have knowledge of which group each participant belongs to based on the process of randomizing the participants into two groups. Randomization will be performed by a collaborator not involved in the research.|The muscle strength of the right knee flexors and extensors will be verified using the isokinetic dynamometer and the muscular activation of the right knee extensors (rectus femoris muscle) will be assessed using surface electromyography. The elastic bandage will be applied over the muscular belly of the right rectus femoris muscle. Initially, all participants will be evaluated without tape, immediately receiving it without tension and, after 20 minutes of rest, they will be reassessed. All will be randomized into two groups and both will receive adhesive tape with or without tension in the application. In the eighth and last week, before the last application of the tape, everyone will be reevaluated without the tape. Then, the last application of the adhesive tape will be carried out with or without tension (according to their respective groups) and after 20 minutes of rest, everyone will be evaluated again with the last application of the tape.|t|f|t|t
33861228|NCT04393051|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II randomized clinical trial to evaluate the efficacy and safety of baricitinib in patients with SARS-CoV2 pneumonia||||
33861229|NCT05871866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861230|NCT04376970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The allocation sequence of the treatment was generated by chance and concealed until all the study was over and all outcomes were assessed. Consecutive patients with subepithelial infiltrates were randomly allocated to one of the two groups by a parallel assignment (1:1).||t|t|t|t
33861231|NCT05679284|||CASE_CONTROL||PROSPECTIVE|||||||
33861232|NCT02234323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861233|NCT02544217|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33861234|NCT03065023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study was to be conducted in 2 groups:~* Group A: participants with transdermally/transmucosally injectable tumors, and~* Group B: participants with injectable liver tumors or liver metastases. However, Group B was not started."||||
33861235|NCT04140279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All participants will receive both the investigational and placebo treatments, with 1 eye receiving LBN 0.024% and the contralateral eye receiving placebo.|f|f|t|f
33861236|NCT03551964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861237|NCT04703478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33861238|NCT04628299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861239|NCT00702845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861240|NCT02936934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861241|NCT00551109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861242|NCT01353625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861243|NCT04908176|NA|SINGLE_GROUP||OTHER||NONE||||||
33861244|NCT01967303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33861245|NCT01821378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174189|NCT04748861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A pragmatic, randomized controlled trial with blinded clinical and imaging outcomes|f|t|t|t
34174190|NCT00095693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174191|NCT06424366|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention (ballet classes) and that caregivers will be completing all questionnaires, masking is not possible.|The study will use a waitlist control design. The first arm will be the experimental arm and will immediately begin the intervention post recruitment. The second arm will be the waitlist control arm and will begin the intervention after the first arm's completion.||||
33861246|NCT03267953|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33861247|NCT01479829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861248|NCT00584168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861249|NCT05175651|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861250|NCT04872881|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups: ETT Group and LMA Group||||
33861251|NCT00145925|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33861252|NCT05374304|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomized controlled trial (CRT)||||
33861253|NCT02121496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33861254|NCT00024414||||TREATMENT||||||||
33861255|NCT04680403|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861256|NCT04147325|||COHORT||PROSPECTIVE|||||||
33861257|NCT01786239|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33861258|NCT05318222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174192|NCT00688896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861259|NCT00528567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861260|NCT04660071|||COHORT||PROSPECTIVE|||||||
33861261|NCT01956656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861262|NCT00931333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961761|NCT03922815|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Neither participant nor colonoscopic procedure provider are aware of the type of monitoring utilised during procedure.||t|t|f|f
33961762|NCT06516302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961763|NCT03745573|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the behavioural nature of the intervention, it is not possible to mask allocation to participants. Outcome assessors will not be told of allocation, but due to the nature of the intervention they should be assumed to be unmasked. The statistician performing the main trial analyses related to primary and secondary outcomes will be masked to allocation, but other investigators will not.|Schools will be randomised to receive the intervention or a wait-list control condition. Assignment will be parallel.||||
34174193|NCT01088568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174194|NCT03665636|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an interventional, open-label, feasibility pilot project to study the safety, efficacy, and tolerability of triheptanoin in patients with GSD I.||||
34174195|NCT06179407|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34174196|NCT05945420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174197|NCT03478540|||COHORT||PROSPECTIVE|||||||
34174198|NCT05891600|||COHORT||OTHER|||||||
34174199|NCT03935984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174200|NCT06615206|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multiple doses of a single intracerebroventricular injection of HG204||||
34174201|NCT02226367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174202|NCT00641771|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33861263|NCT04873414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174203|NCT05826912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174204|NCT06399406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174205|NCT01052792|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174206|NCT00323323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174207|NCT05098028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174208|NCT05539066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861264|NCT03250832|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33861265|NCT04035850|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open label study||||
33861266|NCT02914691|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33861267|NCT00959972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861268|NCT02673619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861269|NCT00352885|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33861270|NCT00434551|||COHORT||PROSPECTIVE|||||||
33861271|NCT04706754|||OTHER||OTHER|||||||
33861272|NCT04657757|NA|SINGLE_GROUP||PREVENTION||NONE|The test persons are numbered so that the laboratory technician who performs the analysis of the platelets cannot be assigned a name. Blinding with regard to the materials is not possible, as the color differences of the alloys allow for a classification.|||||
33861273|NCT00525889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861274|NCT03655379|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861275|NCT06449950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor -performing the final examination- carried out the final OHI-S index scoring blindly without knowing which Oral Hygiene Instruction group (verbal and video-based) the participants were in.|For each age group (6-9 and 10-12) participants were randomly assigned to verbal and video-based oral hygiene instruction groups.|f|f|f|t
33861276|NCT06290063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861277|NCT06314204|||OTHER||PROSPECTIVE|||||||
33861278|NCT05208801|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33861279|NCT02847351|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33861280|NCT01875822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861281|NCT03667144|||COHORT||CROSS_SECTIONAL|||||||
33861282|NCT01381354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174209|NCT05512403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients presenting with brain lesions that lack contrast enhancement on MRI, that are suspected to be LGGs and that are referred for biopsy or surgery within the following 6 months will be eligible for the study.||||
34174210|NCT05057611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174211|NCT03441165|||COHORT||PROSPECTIVE|||||||
34174212|NCT02411630|||CASE_ONLY||RETROSPECTIVE|||||||
34174213|NCT01897025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174214|NCT06357481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eighty patients who needed endodontic retreatment were assingned to 2 groups according to symptomatic or asymptomatic teeth and 4 subgroups with rotary and resiprocal files.|t|f|f|f
34174215|NCT02191462|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34174216|NCT01259063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861283|NCT01869075|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33861284|NCT02877927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861285|NCT05116046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861286|NCT02435589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33861287|NCT00795951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861288|NCT02884427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33861289|NCT02847741|NA|SINGLE_GROUP||||NONE||||||
33861290|NCT06257992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861291|NCT01554488|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861292|NCT01875536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861293|NCT01442116|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33861294|NCT00010062||||TREATMENT||||||||
33861295|NCT01678209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861296|NCT00154076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861297|NCT04608669|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33861298|NCT03248934|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861299|NCT03228758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will not be made aware of the orientation approach to the endoscopic myotomy.|Subjects will be randomized to either the anterior or posterior orientation approach to the endoscopic myotomy.|t|f|f|f
33861300|NCT03027557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861301|NCT00596934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861302|NCT06141044|RANDOMIZED|PARALLEL||OTHER||NONE||National, randomised, prospective, non-inferiority, multicentre clinical trial.To comparatively evaluate the rate of postoperative pancreatic fistula in patients undergoing distal pancreatectomy in one group with and one group without surgical drainage.||||
33861303|NCT02929745|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33861304|NCT03343951|||COHORT||CROSS_SECTIONAL|||||||
33861305|NCT06093789|||COHORT||PROSPECTIVE|||||||
33861306|NCT01856166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33861307|NCT00301223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861308|NCT00786825|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33861309|NCT01920594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861310|NCT06188169|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Patients will be randomly allocated by a computer-generated list into one of the study groups. The randomization sequence will be concealed in sealed envelopes and will be opened by an independent nurse.~Patients and data collectors will be blind to group assignments."|This is a comparative prospective randomized controlled study.|t|t|t|f
33861311|NCT00695617|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861312|NCT06119009|||COHORT||RETROSPECTIVE|||||||
33861313|NCT02450396|||COHORT||PROSPECTIVE|||||||
33861314|NCT04624490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861315|NCT02357823|||CASE_ONLY||PROSPECTIVE|||||||
33861316|NCT02160704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861317|NCT02157350|NA|SINGLE_GROUP||TREATMENT||NONE||Panretinal photocoagulation||||
33861318|NCT02849301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861319|NCT06094426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861320|NCT05294354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel Assignment||||
33861321|NCT03889431|RANDOMIZED|PARALLEL||TREATMENT||NONE||The mother-child dyads were randomly assigned either to receive iodine capsule (n = 53) or iodized salt (n = 53). The iodine capsule group received 225 µg of iodine daily as potassium iodide for 6 months.The iodized salt group was provided with iodized salt (30 to 40 mg iodine/kg as KIO3). One packet of salt (450 g) per household was provided starting within one week of delivery for 6 months.||||
33861322|NCT00296179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861323|NCT00372021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33861324|NCT01241552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861325|NCT06397807|||COHORT||PROSPECTIVE|||||||
33961764|NCT01954082|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34174217|NCT04982731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174218|NCT05101590|NA|SINGLE_GROUP||PREVENTION||NONE||Monitored with HDA||||
34174219|NCT05616286|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174220|NCT00672698|||CASE_ONLY||RETROSPECTIVE|||||||
34174221|NCT04530123|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34174222|NCT06266481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174223|NCT03758781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751013|NCT06385457|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The participants are partly masked. The control group will be masked; however, the intervention group will not be masked.~There is no care provider nor outcome assessor as all measures are self-reported and collected through online questionnaires.~Analyses of data and interpretation of results will be done masked."|"Participants will be recruited via social media, and randomly allocated to an intervention group (receiving information about Mindhelper.dk) or a control group (no information about Mindhelper.dk). Outcomes, will be measured at 2-, 6-, and 12-weeks post-randomization and analysed using the intention-to-treat approach.~According to the investigators' power calculation, at least 3,142 participants (1,571 in each group) are required at follow-up 2 weeks after the randomization (primary endpoint). In the test phase, the investigators retrieved a response proportion of 64% for this follow-up survey. Assuming a similar retention proportion the investigators aim to include 4910 participants at baseline. The proportion of participants responding to the follow-up surveys will be regularly reviewed to evaluate if the assumption on retention is correct or if the number of participants included should be increased or decreased."|f|f|t|f
33751014|NCT06103851|||CASE_ONLY||PROSPECTIVE|||||||
33751015|NCT02102087|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33751016|NCT02160587|NA|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33751017|NCT03993769|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33751018|NCT01384994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751019|NCT03568864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33751020|NCT04954118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel Assignment|f|t|f|f
33751021|NCT01692782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961765|NCT01242332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961766|NCT06537635|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961767|NCT04442178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unblinded Pharmacist will prepare blinded syringes of colorless drug or placeb|randomized controlled of treatment vs placebo|t|t|t|t
33961768|NCT03248778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators will assess feasibility and acceptability and get a broad sense of the initial efficacy of the intervention with a two-arm RCT implemented with 10 HIV+ mothers: 5 will be randomly assigned to the disclosure-support counseling intervention and 5 to a treatment-as-usual (TAU) condition.||||
33961769|NCT01227096|||CASE_CONTROL||RETROSPECTIVE|||||||
33961770|NCT04307225|||COHORT||PROSPECTIVE|||||||
34174224|NCT06151405|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will not be made aware of the diet allocation. However, due inherent differences in macronutrient content of the diets, participants may perceive differences in the quantity of various food groups or in the taste, texture or smell of foods present in the diet. To address this, diets will be designed to minimize noticeable differences for the participant. The investigator and outcomes assessor will remain fully masked to diet provision.||t|t|t|t
33751022|NCT03686852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751023|NCT06530940|||CASE_CONTROL||PROSPECTIVE|||||||
33751024|NCT06540066|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751025|NCT00002538||||TREATMENT||||||||
33751026|NCT04681612|||COHORT||PROSPECTIVE|||||||
33751027|NCT03798938|||COHORT||CROSS_SECTIONAL|||||||
34174225|NCT05133297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174226|NCT04908423|NA|SINGLE_GROUP||TREATMENT||NONE|To assess if Xeomin® injection into the hemiparetic arm is associated with changes in hemiparetic elbow range of motion, a blinded investigator will visually observe the position of the injected arm during their 10-meter walk test, using video tape sequences of the pre- and post-test gait analysis sessions.|A one-group pretest-post-test experimental design will be used. Participants will be tested on the primary and secondary outcome measures before upper extremity injection with Xeomin® and 4 to 6 weeks thereafter.||||
34174227|NCT05671107|||COHORT||PROSPECTIVE|||||||
34174228|NCT04479878|||OTHER||PROSPECTIVE|||||||
34174229|NCT00377520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174230|NCT02254603|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33751028|NCT02261493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751029|NCT03432975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||20 patients (=40 half-mouth); 20 half-mouth per group|t|f|f|f
33751030|NCT00508066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751031|NCT04899830|NA|SINGLE_GROUP||OTHER||NONE||||||
33751032|NCT01247142|||||PROSPECTIVE|||||||
33961771|NCT01496079|||COHORT||PROSPECTIVE|||||||
33961772|NCT06290258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961773|NCT02235337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174231|NCT02620839|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34150374|NCT04280874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|two dinoprostone agents are randomly applied and compared - one in patient's cervix and the other in vagina without the patient knowing which agent is applied|212 pregnant women are randomly assigned into 2 groups for application of one of two dinoprostone agents used for labor induction (intravaginal or intracervical dinoprostone)|t|f|f|f
34150375|NCT06259682|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled pilot study using mixed methods investigation.||||
34174232|NCT06195709|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized, multicentric, open-label, phase III trial conducted in patients with ER+ HER2- metastatic breast cancer progressing on first line treatment with CDK4/6 inhibitor and aromatase inhibitor, and which aims at evaluating the combined value of 18F-FES PET/CT and circulating biomarkers to guide second line treatment decision between investigator's choice second line endocrine therapy (with or without targeted therapy) and chemotherapy.||||
34174233|NCT04960046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized, triple-blind controlled study (participant, surgeon and evaluator).|Single-center, prospective, randomized controlled, triple blind|t|t|f|t
34174234|NCT03028766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174235|NCT00474422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174236|NCT05724940|||CASE_ONLY||CROSS_SECTIONAL|||||||
34174237|NCT05686239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174238|NCT03868215|||CASE_ONLY||PROSPECTIVE|||||||
34174239|NCT04435925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The opioid selection disguised to the patient. Eligible subjects will be randomized so that each research subject has the same opportunity to be included in both groups.|This is a single-blind, randomized control trial. It provides a controlled treatment of general anesthesia with an opioid regimen between remifentanil and fentanyl.|t|f|f|f
34174240|NCT02161770|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174241|NCT05322707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34174242|NCT00966836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174243|NCT01707342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174244|NCT04654923|||CASE_ONLY||RETROSPECTIVE|||||||
34174245|NCT04307797|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Imaging analysis performed by Antaros Medical (blinded to infusion)|Single-centre, single-blinded, physiological pilot study|t|f|f|f
34174246|NCT06604169|||COHORT||PROSPECTIVE|||||||
34174247|NCT02848131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174248|NCT04623346|||COHORT||RETROSPECTIVE|||||||
34174249|NCT06456567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174250|NCT04888624|RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy subjects drawn from the general population. will undergo a 1.5cm incision on the volar forearm of each arm. The incision will be closed with streriostrips. The subject's incisions will then be randomized to receive either a Tegaderm® + Pad transparent film dressing or DrySee® dressing with moisture detection. The incisions will be photographed three times per week. Data on dressing wear time, integrity and adverse events will be collected every two days in the clinic.||||
34174251|NCT05574686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No Masking|Using the telemonitoring kit of iPad to access daily health sessions and remote blood pressure cuff to monitor blood pressure measurements. Patients will then obtain a BP measurement using the appropriate technique described above. Patients are asked to obtain two consecutive BP measurements during each session and register at least 6 sessions per week. Every 2 weeks, BP measurements will be assessed.||||
34174252|NCT05037240|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34174253|NCT02602769|||CASE_CONTROL||PROSPECTIVE|||||||
34174254|NCT06445348|||COHORT||PROSPECTIVE|||||||
34150376|NCT02706665|||COHORT||PROSPECTIVE|||||||
34150377|NCT02406729|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34150378|NCT05322330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150379|NCT02395341|||COHORT||PROSPECTIVE|||||||
34174255|NCT04819464|RANDOMIZED|SEQUENTIAL||OTHER||NONE||The 3 groups will be sequentially studied. Dosing will start in the participants with mild hepatic impairment.||||
34174256|NCT02031575|RANDOMIZED|PARALLEL||||NONE||||||
34174257|NCT00647764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174258|NCT00566436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174259|NCT01126749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174260|NCT01914003|||CASE_CONTROL||PROSPECTIVE|||||||
34174261|NCT03092583|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34174262|NCT02989493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861326|NCT04699734|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33861327|NCT00652392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961774|NCT05719844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961775|NCT00064935|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE||||||
33961776|NCT04236635|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33961777|NCT05498831|||COHORT||PROSPECTIVE|||||||
33961778|NCT03056001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174263|NCT00000794||PARALLEL||TREATMENT||||||||
34174264|NCT04564846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Care Provider, and Investigator will be masked to the intervention (ORMD-0801 or placebo)|The subject will receive either placebo or ORMD-0801|t|t|t|f
34174265|NCT03744312|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174266|NCT03010917|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33961779|NCT02806635|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33961780|NCT00995540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961781|NCT06329076|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Randomized placebo-controlled double-blind between-subject design||t|f|t|f
33961782|NCT02513693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34174267|NCT06346626|||OTHER||PROSPECTIVE|||||||
34174268|NCT02870738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174269|NCT03040999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174270|NCT04964635|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174271|NCT03610256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174272|NCT02973386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174273|NCT05789524|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174274|NCT04424537|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33861328|NCT05564871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861329|NCT02746666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33861330|NCT06062225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861331|NCT01386658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861332|NCT01270087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861333|NCT02119325|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33861334|NCT05257408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861335|NCT04410250|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"Blindness The interventions will always be made by the same researcher and will not participate in the evaluations.~Examiner 1 will be blinded to the group in which the examined children were allocated. Mothers will be advised not to disclose the group in which they were allocated during the evaluations."|"Sample Size in Brazil: 102~Groups into which survey participants will be divided at this center:~Group 1: 51 (Newborns whose parents will receive oral hygiene guidelines prior to tooth eruption) Group 2: 51 ( Newborns whose parents will be advised not to perform oral hygiene prior to tooth eruption.)"|f|f|t|t
33861336|NCT02512198|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861337|NCT02493894|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33961783|NCT01169844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961784|NCT01680289|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33961785|NCT04475068|||COHORT||PROSPECTIVE|||||||
33861338|NCT02047825|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33861339|NCT01318720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861340|NCT01047696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33861341|NCT00016263|RANDOMIZED|||TREATMENT||NONE||||||
33861342|NCT01116141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861343|NCT04586595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Researchers responsible for analysis of error rate and rate of suboptimal prescribing will not know which arm the results have come from|Parallel two-arm randomised pilot study|f|f|f|t
33861344|NCT04406311|||COHORT||PROSPECTIVE|||||||
33861345|NCT06010069|||COHORT||PROSPECTIVE|||||||
33861346|NCT05033808|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Study medication is provided in colored infusion bags with additional covers|Sequential dose escalation with three dosing groups and placebo.|t|t|t|t
34174275|NCT05773846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Before the start of the study, a computer-generated randomization schedule will be prepared for each site. The randomization codes will be stored in a secured area. Uniquely numbered study medication kits will be assigned to subjects according to the randomization codes.~Randomization will take place on the day of surgery (Day 1) after performance of baseline assessments. Subjects who continue to meet eligibility criteria will be randomized in a 2:2:1 ratio to 1 of the 3 treatment groups:"|The study is a randomized, double-blind, placebo and active-controlled study.|t|t|t|t
33861347|NCT06118125|||COHORT||RETROSPECTIVE|||||||
33861348|NCT06379308|||COHORT||PROSPECTIVE|||||||
33861349|NCT05061563|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33861350|NCT05817175|||COHORT||PROSPECTIVE|||||||
33861351|NCT05229926|||CASE_ONLY||PROSPECTIVE|||||||
33861352|NCT00711256|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33861353|NCT04273698|NA|SINGLE_GROUP||TREATMENT||NONE||Five families were each offered five parent-child psychotherapy sessions, based on the Tavistock Under-Fives model, and data was gathered and analysed from both the clinical intervention and from interviews and standardised outcome measures.||||
33861354|NCT01121978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861355|NCT06191471|||CASE_ONLY||RETROSPECTIVE|||||||
33861356|NCT03956368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible subjects will be randomised upon admission to receive atorvastin 20mg nocte or placebo for 8 weeks.|t|t|t|t
33861357|NCT03598322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33861358|NCT03619538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861359|NCT02921269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861360|NCT05783102|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861361|NCT01480453|||COHORT||PROSPECTIVE|||||||
33861362|NCT04638582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861363|NCT00947778|RANDOMIZED|PARALLEL||||NONE||||||
33861364|NCT01635465|||CASE_CONTROL||PROSPECTIVE|||||||
33861365|NCT05193240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861366|NCT03106181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861367|NCT04095078|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled, multicenter trial||||
33861368|NCT04436237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861369|NCT04028908|||COHORT||PROSPECTIVE|||||||
33861370|NCT03656978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33861371|NCT05528250|||COHORT||PROSPECTIVE|||||||
33861372|NCT01297413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861373|NCT01556035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861374|NCT03516851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861375|NCT03434353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861376|NCT03259594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to two groups.One group participants are with endophytic simple renal cysts, and the other are with exophytic simple renal cysts.||||
33861377|NCT01118325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861378|NCT00253487||||TREATMENT||||||||
33861379|NCT00523718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861380|NCT02087748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861381|NCT04097522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A number of the studies include double-blind neurofeedback, where half of the participants receive sham neurofeedback, and half receive actual neurofeedback from a region thought to increase pain resilience. The experimenter, participant, and care provider will all be blinded as to which condition the participant is in until the participant leaves the study.|Half of the participants that take part in the neurofeedback procedures will receive sham neurofeedback, whilst the other half will receive neurofeedback from an area the investigators believe to be associated with increasing pain resilience. Participants may or may not receive sham neurofeedback, and will be made aware of this fact.|t|t|t|f
33861382|NCT01521819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861383|NCT05678322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861384|NCT01770912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861385|NCT03174990|||COHORT||PROSPECTIVE|||||||
33861386|NCT01019291|RANDOMIZED|||||DOUBLE|||t|f|t|f
33961786|NCT04189406|||COHORT||PROSPECTIVE|||||||
33961787|NCT02533505|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961788|NCT04153097|||COHORT||PROSPECTIVE|||||||
34174276|NCT04206540|NA|SINGLE_GROUP||OTHER||NONE||||||
34174277|NCT01590030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174278|NCT05767515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Treatment of PCOS with Myo/D-chiro Inositol and comparison with metformin|t|f|t|f
34150380|NCT00745797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150381|NCT06086587|||CASE_ONLY||PROSPECTIVE|||||||
33961789|NCT03991065|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Of the patients included in the cohort, some will be eligible to perform the endoscopy added for research||||
33961790|NCT04462133|RANDOMIZED|PARALLEL||TREATMENT||NONE||Empirical treatment versus tailored therapy||||
34150382|NCT03048760|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33961791|NCT01066273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150383|NCT02014584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150384|NCT04033094|||COHORT||RETROSPECTIVE|||||||
34150385|NCT05637892|||COHORT||PROSPECTIVE|||||||
34174279|NCT04045860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind randomization of patients and investigator outcome assessor. Patients that agree to participate will be randomized into a CDT treatment arm or a control arm that does not receive CDT. One speech pathologist on the study team will perform the CDT and will only be aware of the participant's cohort arm at the time of random assignment. The second speech pathologist will be blinded to the cohort arm and will be responsible for taking the cranio facial measurements for all participants to minimize investigator bias.|Randomized Control|t|f|f|t
34174280|NCT01305720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174281|NCT04581278|||COHORT||PROSPECTIVE|||||||
34174282|NCT03403803|||CASE_CONTROL||PROSPECTIVE|||||||
34174283|NCT06313255|||CASE_ONLY||RETROSPECTIVE|||||||
34174284|NCT05083273|||COHORT||PROSPECTIVE|||||||
34174285|NCT03439280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174286|NCT02217839|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34174287|NCT00966186|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34174288|NCT03459287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel group|t|t|t|t
34174289|NCT04565067|||COHORT||PROSPECTIVE|||||||
34174290|NCT05020821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174291|NCT06048133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174292|NCT06105502|||COHORT||PROSPECTIVE|||||||
34174293|NCT01434017|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34174294|NCT06651749|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34174295|NCT02752022|||COHORT||PROSPECTIVE|||||||
33961792|NCT00101894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961793|NCT05754437|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961794|NCT00006044||||TREATMENT||||||||
33961795|NCT06500052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961796|NCT05139901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind randomised|t|t|f|t
33961797|NCT05709626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961798|NCT00104117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150386|NCT04049929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150387|NCT03239938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The trial will randomize 120 patients with chronic WAD, aged between 18 and 65 years, to the experimental (modern neuroscience approach including 3 sessions of therapeutic pain neuroscience education followed by 15 sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques (n = 60)) or the control treatment (usual care physiotherapy: 3 sessions of neck school followed by 15 sessions of exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles (n= 60)).|t|f|t|t
34150388|NCT00114088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34150389|NCT06288971|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150390|NCT02230813|||COHORT||PROSPECTIVE|||||||
34150391|NCT03713541|||COHORT||CROSS_SECTIONAL|||||||
34150392|NCT03765827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient and the epidemiology nurse will not know the treatgment assigned.||t|f|f|t
34150393|NCT00724529|||COHORT||PROSPECTIVE|||||||
34150394|NCT03500588|||CASE_CONTROL||PROSPECTIVE|||||||
34150395|NCT05334277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150396|NCT02004977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150397|NCT02378207|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150398|NCT05549154|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34150399|NCT06347250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150400|NCT03670784|||COHORT||RETROSPECTIVE|||||||
34150401|NCT06464419|||CASE_CONTROL||PROSPECTIVE|||||||
34150402|NCT02312778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150403|NCT03556020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150404|NCT02391493|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33861387|NCT04379648|NA|SINGLE_GROUP||OTHER||NONE||All patients with a diagnosis of Post Traumatic Stress Disorder will be seen by a physician psychiatrist or psychologist who will introduce them to the study. They will be given an information letter and a consent form. If patients agree to participate in the study, and after signing the consent form, they will be included and will complete the assessment scales.||||
33861388|NCT03872232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861389|NCT02870699|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33861390|NCT03073226|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33861391|NCT02577952|||COHORT||CROSS_SECTIONAL|||||||
33861392|NCT01099020|||CASE_ONLY||PROSPECTIVE|||||||
33861393|NCT05932004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not informed about the intervention|prospective randomized controlled study|t|f|f|f
33861394|NCT01630434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861395|NCT02281279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861396|NCT03370471|RANDOMIZED|CROSSOVER||OTHER||NONE||2x2 crossover design comparing two learning paradigms (Study Only vs. Retrieval Practice) and two training conditions (Moderate Intensity Exercise vs. Gentle Stretching)||||
33861397|NCT01409863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861398|NCT01708122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33861399|NCT04710888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33861400|NCT00676598|||COHORT||RETROSPECTIVE|||||||
33861401|NCT02936063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861402|NCT00260117|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861403|NCT01794364||CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33861404|NCT04897269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients who have progesterone levels below 10 ng/mL on the day of embryo transfer will be randomized into 2 groups:~1. Those who will be supplemented with intramuscular progesterone 50mg per day till day of beta-hcg testing~2. Those who will continue their regular medications"|f|f|f|t
33861405|NCT01233453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861406|NCT01349335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861407|NCT04721821|||COHORT||RETROSPECTIVE|||||||
33961799|NCT00323687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961800|NCT00415311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961801|NCT03709407|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961802|NCT03137758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33961803|NCT03455647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961804|NCT05539599|||COHORT||PROSPECTIVE|||||||
33961805|NCT04808765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961806|NCT01177319|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33961807|NCT00843063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150405|NCT05375864|NA|SINGLE_GROUP||SCREENING||NONE|"1. Laboratory staff assessing the paracetamol assay will be blinded to the results of the plasma oseltamivir assay and vice versa.~2. The investigators will be blinded to the assays."|||||
34150406|NCT01469403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34150407|NCT01994993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150408|NCT05023278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150409|NCT00031460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150410|NCT00290667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751033|NCT03047200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751034|NCT04468438|||COHORT||PROSPECTIVE|||||||
33861408|NCT00433342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861409|NCT03691090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861410|NCT02420132|||CASE_CONTROL||PROSPECTIVE|||||||
33861411|NCT06087679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are randomized 1/1: active/control, and a person, who has no direct contact to the participants, performs the randomization. The study is open to the participating participants and the instructors of the active group. The study is blinded to all others, including the statisticians who make the main analyses.|Single-center parallel placebo-controlled randomized trial|f|t|f|f
33861412|NCT00042406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861413|NCT05832008|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||At the start of the trial, clinicians who do not opt-out will be randomized to the intervention (clinician nudge) or control arm (no clinician nudge). Eligible patients will be randomized, stratified by clinician, to either the intervention (patient nudge) or control group (no patient nudge).|f|f|f|t
33861414|NCT01681810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861415|NCT02570893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861416|NCT00672061|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33861417|NCT00186862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961808|NCT05409807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961809|NCT03576469|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group||||
33861418|NCT02614534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861419|NCT00445068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861420|NCT05298982|||COHORT||PROSPECTIVE|||||||
33861421|NCT05627206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33861422|NCT02366728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751035|NCT04943198|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751036|NCT03491761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751037|NCT01855776|RANDOMIZED|FACTORIAL||||NONE||||||
33861423|NCT02939755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33861424|NCT05088902|||COHORT||PROSPECTIVE|||||||
34064503|NCT04023305|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is an open label trial because the patients are included from a group depending to the morphotype of ARDS. However, all subsequent evaluations will be conducted by clinical research staff according to the attributed group|"Inhaled sedation with sevoflurane, will be vaporized via the miniaturized Anesthesia Conserving Device (AnaConDa-S®, Sedana Medical, Uppsala, Sweden).~Sevoflurane infusion rate will be adapted from manufacturer's instructions in order to reach a target of expired sevoflurane fraction (FEsevo) of 0.8-1.1.~Mechanical ventilation will be protocolized in both arms, based on recent results of a RCT from our group, in which 90-day survival was improved in patients with nonfocal ARDS when an individualized ventilation strategy was applied, compared to the ARDSNet strategy (PEEP set according to FiO2). We will recommend sites wait at least 12 hours before proning, as in the PROSEVA study.~In both groups, patients will receive cisatracurium besylate for neuromuscular blockade, and deep sedation will be protocolized to Richmond Agitation-Sedation Scale (RASS) of -4 to -5 (Ramsay of 5-6, or Riker of 1-2) before starting, and during, the cisatracurium besylate infusion."|f|f|f|t
33861425|NCT05729568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064504|NCT03760458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064505|NCT02742714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861426|NCT04066803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861427|NCT00858520|||CASE_CONTROL||PROSPECTIVE|||||||
33861428|NCT01410578|||CASE_CONTROL||PROSPECTIVE|||||||
33861429|NCT05945966|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients will be allocated to intervention groups by randomization Patients in group A will be given MRP and PNF techniques to involve side Patients In group B will be given exercises same as above but on unaffected side.The strengthening exercises also given to this group||||
33861430|NCT06211465|||COHORT||PROSPECTIVE|||||||
33861431|NCT03305068|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33861432|NCT03805009|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All the clinical assessments are routinely administered by both participating centers, and the outcome assessors are blinded to the study protocols.|Single blinded, non randomized, pilot study|f|f|f|t
33861433|NCT01857778|||CASE_CROSSOVER||PROSPECTIVE|||||||
33861434|NCT02576236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861435|NCT03732079|||COHORT||PROSPECTIVE|||||||
34064506|NCT01417585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34064507|NCT02156973|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34064508|NCT03967210|||COHORT||RETROSPECTIVE|||||||
34064509|NCT01451164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064510|NCT06510920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34064511|NCT03580499|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064512|NCT02801526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064513|NCT05099172|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34064514|NCT03339336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064515|NCT02398513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064516|NCT05571423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The dental providers and study subjects will be blinded to the intervention: medical or routine play|Prospective, randomized clinical controlled trial|t|t|f|f
34064517|NCT02890849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064518|NCT01053338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064519|NCT04739332|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT||||
34064520|NCT04647994|||COHORT||PROSPECTIVE|||||||
34064521|NCT00935064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064522|NCT01725360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064523|NCT00089635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064524|NCT03139864|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking is used. All involved know the identity of the intervention assignment|||||
34174296|NCT05666323|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This study will use a Sequential Multiple Assignment Randomized Trial (SMART) Design, which will allow investigators to address questions like those of traditional factorial design and assess dynamic treatment regimens to inform the development of adaptive interventions. An adaptive intervention contains a sequence of individually tailored decision rules that specify the intensity or type of intervention at critical points in the delivery of care. Modifying intensity or type of intervention over time can improve outcomes if an individual is not responding, or may reduce costs and patient burden if more resource intensive treatment is not necessary. As such, the proposed SMART design informs the development of adaptive and stepped care interventions, and the reduction in patient burden is particularly important to ensure that the interventions are as patient centered as possible.||||
34174297|NCT06704425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174298|NCT03405883|||COHORT||PROSPECTIVE|||||||
34174299|NCT00712751|||COHORT||PROSPECTIVE|||||||
34174300|NCT05624580|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34174301|NCT05878210|||COHORT||PROSPECTIVE|||||||
34174302|NCT04734639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861436|NCT03839407|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33861437|NCT06350851|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33861438|NCT02927743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861439|NCT02461030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861440|NCT01839253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33861441|NCT02992483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861442|NCT03659279|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post intervention study||||
33861443|NCT00256880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861444|NCT04603586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861445|NCT00527254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33861446|NCT04396314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher will be blinded to group of participant|randomized controlled clinical trial|f|f|f|t
33861447|NCT05573321|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
33861448|NCT02271074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33861449|NCT02545322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861450|NCT02797067|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33861451|NCT02003014|||COHORT||PROSPECTIVE|||||||
33961810|NCT05055778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961811|NCT05596552|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33961812|NCT04015479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|PI and Co-Is will be blind to participant randomization. One study staff member will be responsible for administering the supplements to participants per randomization|Intervention group will receive the supplement during the study period and the wait-listed control group will receive the supplement after the study period. Both groups will participate in resistance training during the 10 week period|f|f|t|t
33961813|NCT03540407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A double blind||t|f|t|f
33961814|NCT04949984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961815|NCT01079078|RANDOMIZED|CROSSOVER||||NONE||||||
33961816|NCT04167280|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34064525|NCT05888181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34064526|NCT01699308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174303|NCT03580512|||COHORT||PROSPECTIVE|||||||
34174304|NCT00005780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174305|NCT06579014|||OTHER||CROSS_SECTIONAL|||||||
34174306|NCT04180397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174307|NCT04327206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The control group will receive a placebo of 0.9% sodium chloride (NaCl). Members of the research team doing the follow-up of participants and analysis will be blinded to the group allocation (by the removal of this variable and all other variables related to BCG from the dataset) until the formal detailed statistical analysis plan is confirmed and signed by all investigators and all data cleaning/preparation is complete.|Phase III, two group, multicentre, randomised controlled trial|t|f|f|t
34174308|NCT00253812|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
34174309|NCT05414526|NA|SINGLE_GROUP||OTHER||NONE||"InterCARE is the name of the package of implementation strategies proposed by the investigators that are intended to integrate cardiovascular care services into existing HIV care systems in Botswana.~The InterCARE package includes 3 main interventions:~1. a tailored inter-professional training curriculum on management of CVD risk and HIV~2. adaptation of the existing electronic health records (PIMS)~3. adoption of a treatment partner support system."||||
34174310|NCT03853473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are randomized by the study statistician to receive either the intervention (remote ischemic conditioning) or standard of care. Participants cannot be blinded using this model.|Prospective, Randomized, Blinded, Controlled Trial|f|t|t|t
34174311|NCT03676842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174312|NCT02719535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174313|NCT03173885|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT (randomized controlled trial)||||
34174314|NCT03581942|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, phase Ib/II trial of the pan-Phosphoinositide 3-kinase (PI3K) inhibitor Copanlisib in combination with the Bruton Tyrosine Kinase (BTK) inhibitor Ibrutinib in patients with recurrent or refractory primary central nervous lymphoma (PCNSL and frail/elderly newly diagnosed PCNSL patients, not eligible to receive standard first-line chemotherapy).||||
34174315|NCT05497180|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174316|NCT02324881|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34174317|NCT05088564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174318|NCT05803356|||OTHER||PROSPECTIVE|||||||
34174319|NCT05623124|||COHORT||PROSPECTIVE|||||||
34174320|NCT06077656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Multicenter, randomized, active-controlled, observer-blind study to evaluate safety, tolerability, and immunogenicity of three formulations of IVT PCV-25 in which healthy adult participants will be randomized in a 4:3:2:2 ratio to receive 1 of 3 formulations or control.|t|t|t|t
34174321|NCT01616966|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34174322|NCT02592031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174323|NCT06526494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861452|NCT03702803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both treatments have an identical appearance and are packed in hard gelatin capsules, which are packed in individual aluminum and PVC blisters with 10 doses each. Three blisters with ten doses are introduced in cardboard boxes and identified through a folio number.|Participants will be randomly assigned to one of the two groups: the experimental group receiving a phytopharmaceutical elaborated with the standardized extract from G. glauca, and a control group receiving an identical formulation containing Alprazolam|t|t|t|t
33861453|NCT05097014|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33861454|NCT00557388|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33861455|NCT02790957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33861456|NCT02339987|||CASE_ONLY||PROSPECTIVE|||||||
33861457|NCT02887690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064527|NCT06295497|NA|SINGLE_GROUP||SCREENING||NONE||||||
34064528|NCT06239571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064529|NCT01669200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861458|NCT04369222|||COHORT||PROSPECTIVE|||||||
33861459|NCT00201435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861460|NCT04071795|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arm cluster randomized study design||||
33861461|NCT02233283|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861462|NCT01681134|RANDOMIZED|CROSSOVER||||NONE||||||
33861463|NCT00974090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861464|NCT06242054|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064530|NCT05920668|||COHORT||PROSPECTIVE|||||||
34064531|NCT04424771|||COHORT||PROSPECTIVE|||||||
34064532|NCT02254122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861465|NCT06059651|||COHORT||PROSPECTIVE|||||||
33861466|NCT05583799|||OTHER||PROSPECTIVE|||||||
33861467|NCT03435003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34064533|NCT04257253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064534|NCT00969514|||CASE_ONLY||RETROSPECTIVE|||||||
33861468|NCT06177249|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|double blind|Lyophilized rabies vaccine for human use (Vero cell) and control vaccine|t|t|t|t
33861469|NCT05496751|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized trial||||
34064535|NCT04108663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33861470|NCT03015792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861471|NCT06168136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33861472|NCT03600623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to one of two treatment arms: Arm 1 is Folfirinox (5FU/Leucovorin/Irinotecan/Oxaliplatin) and Arm 2 is Gemcitabine-nab-Paclitaxel (Abraxane). Either arm will be followed with SBRT for eligible patients.||||
33861473|NCT04214314|||CASE_CONTROL||PROSPECTIVE|||||||
33861474|NCT06495450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861475|NCT01437696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33861476|NCT02852902|||COHORT||RETROSPECTIVE|||||||
33861477|NCT02392221|||COHORT||RETROSPECTIVE|||||||
33861478|NCT03948360|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||The study model is sequential. Arm I will consist of the first 3 participants, with each participant receiving LIMB phototherapy over standard of care (SOC). The subsequent participants will comprise Arm II, with each participant to receive only LIMB phototherapy without standard of care. Dose modifications of the phototherapy can be made in Arm II, and will be determined based on any treatment-related adverse events observed in Arm I. Up to 12 participants in total will be enrolled.||||
33861479|NCT01399190|||COHORT||PROSPECTIVE|||||||
33861480|NCT03787225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|Participants will be randomised to 1 of 6 treatment arms, in 3 receiving active NNC0174-0833 and 3 receiving placebo. For statistical analysis and reporting of results, data from the 3 placebo arms will be pooled.|t|t|t|t
33861481|NCT00261911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064536|NCT03482570|||COHORT||PROSPECTIVE|||||||
34174324|NCT04912583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, principal investigator, outcome assessors, and statistician will be blinded to tidal volume assignment.||t|f|t|t
33861482|NCT01736085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861483|NCT04553068|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33861484|NCT00889226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861485|NCT04772950|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33861486|NCT05742503|||COHORT||PROSPECTIVE|||||||
34174325|NCT02988297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174326|NCT02182895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174327|NCT06560203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174328|NCT05795179|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34174329|NCT05953545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174330|NCT01258543|||CASE_ONLY||CROSS_SECTIONAL|||||||
34174331|NCT03732573|RANDOMIZED|PARALLEL||OTHER||SINGLE||"After completing an online questionnaire, participants will be randomized to intervention or control condition. Participants in the intervention condition will receive text messages designed to promote goal setting in the first week, text messages designed to promote goal operating in the second week, and message designed to promote self-monitoring messages in the third week. All text messages will seek to encourage usage of shared bike schemes (e.g. How many times can you use a shared bike scheme over the next week? Set yourself a goal and challenge yourself!). Control group participants will receive no messages during the course of the study."|t|f|f|f
34174332|NCT04827368|||CASE_CONTROL||PROSPECTIVE|||||||
34174333|NCT02060721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174334|NCT01097668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174335|NCT05443191|||COHORT||PROSPECTIVE|||||||
34174336|NCT01809938|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34174337|NCT06114238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174338|NCT06706557|||COHORT||PROSPECTIVE|||||||
34174339|NCT00287898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174340|NCT00654667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174341|NCT05334732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174342|NCT05036252|||COHORT||PROSPECTIVE|||||||
34174343|NCT06244433|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34174344|NCT03662867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174345|NCT06510374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174346|NCT05200143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751038|NCT06487455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751039|NCT06664918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751040|NCT05214755|||CASE_ONLY||CROSS_SECTIONAL|||||||
33751041|NCT02031887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34174347|NCT05509595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174348|NCT03859024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174349|NCT05412901|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33861487|NCT00427232|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33861488|NCT01685424|||COHORT||RETROSPECTIVE|||||||
33861489|NCT06099210|||COHORT||PROSPECTIVE|||||||
33861490|NCT00893282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33861491|NCT05044026|||COHORT||PROSPECTIVE|||||||
33861492|NCT00475618|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33861493|NCT05591820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors who will code the records of mealtime routines made by parents will be unaware of in which arm parents in the study are participating. The audio records will therefore be a masked measure.|To examine the research objectives, a randomized controlled trial with two arms is used. Referred children and their parents will be randomly assigned (equal randomization) to (a) brief parent training, with optional booster sessions up to one year after the training, or (b) care as usual (CAU), as regularly provided by the mental health centers involved. Children in the brief parent training group will not receive CAU until the first posttreatment assessment (T1). After that, CAU is allowed and parents can make use of booster sessions (maximum once every four weeks) with the therapist who provided the training.|f|f|f|t
33861494|NCT03061461|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"A medical assistant in the Wound Care Unit, Dept on Internal Medicine, Kuala Lumpur Hospital (Kuala Lumpur, Malaysia) will allocate interventions by means of opaque sealed envelopes that will be marked according to the allocation schedule. The medical assistant will be unaware of the size of the blocks.~The randomized intervention assignment as outlined above will be concealed from both patients and health care staff until recruitment will be complete and irrevocable.~Therapists applying the treatments will not be blinded.~All assessments before the first treatment (baseline) and during the follow-up period (either three months after start of the treatments or until complete epithelialization, respectively) will be performed by assessors blind to the intervention."|"Randomized controlled trial (RCT), no blinding of therapists applying the treatments, blinding of patients, blinding of evaluators.~Partial cross-over design: patients in the control group will be offered to be treated with rESWT starting three months after the last sham treatment. This will guarantee that every patient will receive a real rESWT treatment independent of blind allocation to one of the treatment groups."|t|f|t|t
33861495|NCT02166866|||COHORT||PROSPECTIVE|||||||
33861496|NCT04733781|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Participants, Care Providers, Investigator and Outcome Assessors will not know the concentration of epinephrine, either 1mg/L or 2mg/L, in the tumescent solution of lidocaine (1gm/L) to be injected subcutaneous in a participant.|double-blind, non-inferiority, randomized clinical trial|t|t|t|t
33861497|NCT01896752|||COHORT||PROSPECTIVE|||||||
33861498|NCT04617756|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients with an estimated glomerular filtration rate equal to or over 60 ml/min./1.73² (cohort 1) will receive treatment combining Durvalumab and gemcitabine with Cisplatin.~Patients with an estimated glomerular filtration rate of under 60 ml/min./1.73² and over 40 ml/min./1.73² (cohort 2) will receive treatment combining Durvalumab and gemcitabine with Carboplatin."||||
33861499|NCT03575286|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33861500|NCT02637115|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Subjects and physicians were both blinded to the treatment allocation.||t|t|f|f
33861501|NCT01102803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861502|NCT01695577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861503|NCT03342248|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861504|NCT00181987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861505|NCT01865565|||CASE_ONLY||PROSPECTIVE|||||||
33861506|NCT05045326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33861507|NCT05184686|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861508|NCT06005389|||CASE_CONTROL||PROSPECTIVE|||||||
33861509|NCT04880447|||CASE_ONLY||PROSPECTIVE|||||||
33861510|NCT04116424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33861511|NCT00584883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861512|NCT00583024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861513|NCT03019471|||COHORT||PROSPECTIVE|||||||
33861514|NCT03367715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861515|NCT03910712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861516|NCT03436706|||COHORT||PROSPECTIVE|||||||
33861517|NCT00770835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861518|NCT01326195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174350|NCT05968274|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34174351|NCT00972413|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174352|NCT05584059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174353|NCT06406764|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34174354|NCT04924062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174355|NCT02246530|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34174356|NCT03796273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174357|NCT06430853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174358|NCT01782898|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34174359|NCT03173924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174360|NCT02898818|||COHORT||OTHER|||||||
34174361|NCT05883969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174362|NCT03452969|||CASE_ONLY||PROSPECTIVE|||||||
34174363|NCT06437301|RANDOMIZED|CROSSOVER||OTHER||NONE||This study is a prospective, controlled study involving healthy adult volunteers all of whom are resident and faculty physicians, or other medical staff. There will be no financial compensation.||||
34174364|NCT05811442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174365|NCT05989009|||COHORT||PROSPECTIVE|||||||
34174366|NCT03472625|||COHORT||PROSPECTIVE|||||||
34174367|NCT03519269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861519|NCT06331780|NA|SINGLE_GROUP||SCREENING||NONE||||||
33861520|NCT04304781|NA|SINGLE_GROUP||SCREENING||NONE||||||
34064537|NCT03438188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"Smoking participants will be studding under both smoking as usual and abstinent conditions (crossover) and non-smokers only under abstinence."|This is a within-subject cross-over neuroimaging investigation of 3 potential neural mechanisms of increased caloric intake during initial smoking cessation. Eighty smokers will be scanned on 2 occasions: (1) after 4 days of monitored abstinence (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced). In addition, 30 healthy non-smokers (matched for sex, age, and education) will complete one period of the study to serve as a baseline comparison group.||||
34064538|NCT01790516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861521|NCT04141254|RANDOMIZED|PARALLEL||OTHER||SINGLE||It is a multicenter, randomized trial with blind evaluation, parrallel arm, and using a Zelen randomization process|f|f|f|t
33861522|NCT04758299|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Participants will be randomized to receive either information from the FDA authorized home test kit for what actions to take for a negative or positive COVID-19 test (usual care) or a decision science-based design of similar length (intervention).~There are 4 groups (clinical scenarios) within each randomized arm (the scenarios are patient with no symptoms and no exposure; no symptoms and exposure; symptoms and no exposure; symptoms and exposure."|f|f|t|f
33861523|NCT05683587|NA|SINGLE_GROUP||OTHER||NONE||||||
33861524|NCT02228187|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33861525|NCT01748409|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33861526|NCT05334537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33861527|NCT01135680|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33861528|NCT06227884|||OTHER||RETROSPECTIVE|||||||
33861529|NCT06008886|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33861530|NCT03460379|||CASE_ONLY||PROSPECTIVE|||||||
33861531|NCT01217151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861532|NCT01306422|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33861533|NCT01771068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961817|NCT04356092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|2D-perfusion imaging and analysis of the DICOM files was performed after revascularization, by an investigator blinded to the name of the patient or the result of the angioplasty procedure. The participant was also blinded to the results of the perfusion outcomes during follow up.|In total, 7 consecutive patients were included in the study. The 2D-perfusion imaging and analysis of the DICOM files were performed after revascularization.||||
33961818|NCT03336645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961819|NCT04261517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961820|NCT04193033|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|Because this is a stepped wedge design QI clinical trial, masking is not feasible.|Randomization will be at the site level. All 9 sites will receive the intervention, using a stepped wedge design. Sites will be randomly allocated to one of three cohorts, and all sites within a cohort will receive the intervention at the same time. Cohort start dates will be offset by three months to allow examination of time effects.||||
33961821|NCT02688101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961822|NCT04477317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961823|NCT03087773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064539|NCT00495859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34064540|NCT01065363|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064541|NCT03807401|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34064542|NCT05731336|||COHORT||PROSPECTIVE|||||||
34174368|NCT04101630|||CASE_ONLY||PROSPECTIVE|||||||
34174369|NCT05413590|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174370|NCT06702319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174371|NCT02973971|||COHORT||PROSPECTIVE|||||||
34174372|NCT04875325|RANDOMIZED|PARALLEL||OTHER||NONE||Trials within Cohorts (TwiCs)||||
33861534|NCT06450756|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Only the study participants were masked.||t|f|f|f
33861535|NCT03820089|||COHORT||PROSPECTIVE|||||||
33861536|NCT06258343|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33861537|NCT02323633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961824|NCT01393548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961825|NCT06099041|NA|SINGLE_GROUP||OTHER||NONE||||||
33961826|NCT05371418|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961827|NCT03154931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961828|NCT02350322|RANDOMIZED|PARALLEL||||NONE||||||
33961829|NCT02380066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064543|NCT01004718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064544|NCT01593254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064545|NCT05843240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064546|NCT00221039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174373|NCT01533792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174374|NCT00525720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174375|NCT02873858|NON_RANDOMIZED|PARALLEL||||NONE||||||
34174376|NCT02299596|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34174377|NCT06522906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34174378|NCT04357717|||COHORT||PROSPECTIVE|||||||
34174379|NCT05425784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subjects will be randomized to the study group and the control group by using a sealed envelope system.|90 participants are randomized into two arms: the Lumoral-treatment arm and Control arm.|t|t|t|f
34174380|NCT06526260|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174381|NCT06303960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174382|NCT01293903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861538|NCT00615238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861539|NCT00849719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33861540|NCT02257216|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33861541|NCT05459285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861542|NCT04058379|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861543|NCT00603655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33861544|NCT00000820||PARALLEL||TREATMENT||||||||
33861545|NCT06360809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861546|NCT03836807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The double-blinding is provided by Placebo that is identical to OKITASK® 40 mg granules.~The drug will be packaged and labeled in a manner that will exclude unblinding. IWRS will assign the study drug kit number that should be administrated by the subject."||t|f|t|f
33861547|NCT02018367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861548|NCT03575390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33861549|NCT02960373|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33861550|NCT01612143|RANDOMIZED|CROSSOVER||||NONE||||||
33961830|NCT03448601|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomized in equal proportions either to receive 1) a standard, non-tailored educational brochure on Alzheimer's Disease (AD), the value of precision medicine (PM), and the importance of research (control); OR 2) to receive a culturally tailored brochure with graphics and identical information; OR 3) to view a digital story featuring personal narratives of AI/ANs (intervention).||||
33861551|NCT03050151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961831|NCT04754919|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Next 50 eligible young people entering transition||||
33961832|NCT02561000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33961833|NCT06170840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33961834|NCT00949052|||OTHER||OTHER|||||||
33961835|NCT00727896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961836|NCT00654446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174383|NCT06589531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174384|NCT02921035|||COHORT||PROSPECTIVE|||||||
34174385|NCT00764699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861552|NCT05807880|NA|SINGLE_GROUP||TREATMENT||NONE||The combination of anlotinib, penpulimab and capecitabine.||||
33861553|NCT04636866|||CASE_ONLY||RETROSPECTIVE|||||||
33861554|NCT01372670|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33861555|NCT00472940|||OTHER||CROSS_SECTIONAL|||||||
33861556|NCT04985890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861557|NCT06024681|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Human participants with NAFLD and fibrosis||||
33861558|NCT00716053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861559|NCT00256425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861560|NCT05974592|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33861561|NCT04356248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33861562|NCT00105950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861563|NCT03355313|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Nutritional status of 50 children will be measured according the World Health Organization. The volume of saliva will be measured and, also, the salivary flow rate(mL/min) and buffering capacity will be determined. Concentrations of salivary IgA in all samples will be measured using a ELISA kit. Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands. Three sessions of laser therapy will occur (after the collection of saliva, 7 and 14 days after the first session, respectively). The final saliva collection will be performed after the third laser session. The laser will be adjusted according to the following parameters: 808nm, 4 J, Continuous and contact mode,100mW, Irradiation at target (mW/cm2)=2500,Irradiated area (cm2)=0.40.|t|t|t|t
33861564|NCT01349023|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33861565|NCT01351012|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33861566|NCT06412484|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33861567|NCT03180749|||COHORT||RETROSPECTIVE|||||||
33861568|NCT03388255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861569|NCT03354741|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33861570|NCT05069896|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33861571|NCT00620568|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33861572|NCT03986866|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33861573|NCT00895336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861574|NCT03049735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861575|NCT02809573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961837|NCT04902261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961838|NCT04498299|||COHORT||PROSPECTIVE|||||||
33961839|NCT05766761|RANDOMIZED|PARALLEL||PREVENTION||NONE||Eligible women are randomized to either (1) the intervention condition, the usual prenatal plus the alcohol intervention, or (2) the comparison condition, usual prenatal care only.||||
33961840|NCT06138431|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel groups, each of 10 parents of children with food allergies, receiving either virtual CBT group therapy or wait-listed to be in a future CBT group. This will be repeated 3 times, for a total of 60 participants.||||
34174386|NCT05647135|||COHORT||PROSPECTIVE|||||||
34174387|NCT04723992|||OTHER||RETROSPECTIVE|||||||
34174388|NCT05816252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174389|NCT05064735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174390|NCT04727970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174391|NCT04079296|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174392|NCT04053036|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34174393|NCT02553213|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34174394|NCT06029426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor will also be blinded||t|t|t|t
34174395|NCT03807986|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34174396|NCT03973229|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Randomization will be double blind, with the key held by the study coordinator in a locked file. The study coordinator will do checks of appropriate enrollment to groups after each 20 participants, but no blind will be broken to individuals analyzing study data. Grady pharmacy services will also hold the randomization schedule, as they will dispense the appropriate patch at the appropriate time point.|Women will participate in one cycle with the estrogen patch and one cycle with the placebo patch. Each cohort will include 40 participants in each of the three study arms for a total of 240 participants.|t|f|t|f
34174397|NCT05675059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174398|NCT06591949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174399|NCT01286675|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174400|NCT05730725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174401|NCT06601608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174402|NCT05941546|||CASE_ONLY||RETROSPECTIVE|||||||
34174403|NCT06600867|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Descriptive interventional clinical study||||
33751042|NCT05799755|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Subjects, investigators, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial will remain blinded with regard to the randomized treatment assignments until after the database lock.|Randomization will be 1:1 for nintedanib: placebo and stratified by underlying immunosuppressive therapy (mycophenolate vs. others). All patients must be on the standard of care (SOC) immunosuppression (IS) at screening as per the protocol and should remain on stable doses throughout the trial. After 12 weeks both arms will receive an additional 12 weeks of nintedanib (150 mg twice a day, maximum dose of 300 mg a day) through week 24 (final study visit).|t|t|t|t
33751043|NCT05836493|||COHORT||CROSS_SECTIONAL|||||||
33751044|NCT06071962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751045|NCT05671848|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-center, open-label, prospective cohort pilot study.||||
33751046|NCT04850846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751047|NCT02519348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751048|NCT03536806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|t|f|f
33751049|NCT03750552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel assignment|t|t|t|t
33751050|NCT01037348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751051|NCT03934398|||COHORT||CROSS_SECTIONAL|||||||
33751052|NCT03877094|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|This study has no masking|||||
33751053|NCT03385928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a prospective phase II randomised, double-blind, placebo-controlled, investigator-driven trial in acute intracerebral haemorrhage patients. The study has 2 arms with 1:1 randomisation to either intravenous tranexamic acid or placebo.|t|t|t|t
33751054|NCT01440491|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751055|NCT01387139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33751056|NCT01187251|||COHORT||PROSPECTIVE|||||||
33751057|NCT05777226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751058|NCT05118685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized clinical trial that will be performed in a Fayoum university hospital. It includes 100 pt. complaining of atrophic vaginitis it will be divided into two groups, each group will contain 50 pt|t|f|t|f
33751059|NCT05929950|||CASE_CONTROL||PROSPECTIVE|||||||
33751060|NCT00605293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751061|NCT05890599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751062|NCT03217110|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33751063|NCT00490893|RANDOMIZED|CROSSOVER||||SINGLE||||||
33751064|NCT05190991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751065|NCT03195933|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33751066|NCT04099108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33751067|NCT01483924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751068|NCT05865431|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751069|NCT00103246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751070|NCT04216316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751071|NCT04572048|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33751072|NCT01628029|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33751073|NCT01508039|NA|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33751074|NCT01516047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751075|NCT05261399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33861576|NCT04556136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A computer-generated block design was created by an onsite biostatistician and used by the research pharmacist to randomize subjects. Once a subject met the inclusion criteria, the pharmacist was notified and she relayed the group assignment to the Project Coordinator. The study team had no knowledge of the group assignment in advance.|For volunteers assigned to the phototherapy kiosk, a measured dose of UVB was administered under conditions of full body exposure of 0.6 minimal erythemal dose (MED) every other week for 10 weeks. The stimulation of cutaneous vitamin D and subsequent 25(OH)D production from phototherapy was compared to the effect of a Recommended Daily Allowance (RDA) based dose of 600 IU vitamin D3 supplement daily for 10 weeks.|t|f|t|t
33861577|NCT01540383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861578|NCT03249077|||COHORT||PROSPECTIVE|||||||
33861579|NCT05009186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We measured PSA value during and after Covid-19 infection||||
34064547|NCT03583905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064548|NCT06365450|NA|SINGLE_GROUP||OTHER||NONE||Each participant is required to attend (in person or virtually via Zoom) two educational sessions one on breast cancer and the other on cervical cancer.||||
34064549|NCT06182618|||OTHER||RETROSPECTIVE|||||||
34064550|NCT02769936|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34064551|NCT01621971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064552|NCT04736641|||OTHER||PROSPECTIVE|||||||
34064553|NCT01912352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33861580|NCT00529451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861581|NCT00253188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861582|NCT01638091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861583|NCT05784987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861584|NCT01605981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861585|NCT00708175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861586|NCT04058951|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861587|NCT02307864|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33861588|NCT05374720|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861589|NCT06312748|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|A block randomization method will be used to randomize participants into equal groups and will be handled by investigational pharmacist.||t|t|t|f
33861590|NCT06509178|RANDOMIZED|PARALLEL||OTHER||NONE||Two randomized control group. One applied Halsted , other applied Peyton 4-step model on nursing students.||||
33861591|NCT00366483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861592|NCT01955122|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33861593|NCT00619905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861594|NCT03920813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861595|NCT00930514||PARALLEL||TREATMENT||NONE||||||
33861596|NCT01571765|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861597|NCT00002016||||TREATMENT||||||||
33861598|NCT02600962|||COHORT||PROSPECTIVE|||||||
33861599|NCT00294385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861600|NCT06277908|||COHORT||PROSPECTIVE|||||||
33861601|NCT03142308|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33861602|NCT01170039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861603|NCT06214871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861604|NCT03653221|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|investigator, outcome assessors will be blinded for group allocation.|"1. standardized patients with VRNET~2. standardized patients"|f|f|t|t
33861605|NCT04141267|||COHORT||RETROSPECTIVE|||||||
33861606|NCT05867953|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective, multi-center, single-arm, interventional study||||
33861607|NCT01183026|||COHORT||PROSPECTIVE|||||||
33861608|NCT03299634|||OTHER||CROSS_SECTIONAL|||||||
33861609|NCT01106820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861610|NCT01481389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861611|NCT00860821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33861612|NCT03445988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861613|NCT06510647|||CASE_CONTROL||PROSPECTIVE|||||||
33861614|NCT02323763|||CASE_ONLY||CROSS_SECTIONAL|||||||
33861615|NCT00958620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861616|NCT04629716|||CASE_CONTROL||PROSPECTIVE|||||||
33861617|NCT03759977|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||pre- posttest with control group||||
34064554|NCT05691959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each formulation is masked by the pharmacy department.|Randomized Placebo Controlled Double Blind Study|t|t|t|t
34064555|NCT03303391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064556|NCT03770351|||COHORT||PROSPECTIVE|||||||
34064557|NCT01910220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34064558|NCT04991038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064559|NCT03008772|||COHORT||OTHER|||||||
34064560|NCT04792307|RANDOMIZED|PARALLEL||OTHER||NONE||will randomly allocate participants offering half of them additional protein supplementation over and above their ordinary diet||||
34064561|NCT06533267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064562|NCT00006220|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
34064563|NCT01803776|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A single-centre controlled trial in which the participants are allocated to a combined physical activity and dietary intervention group and a control group||||
34064564|NCT05386732|||COHORT||PROSPECTIVE|||||||
34064565|NCT00928655|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33961841|NCT01372527|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33961842|NCT06183645|||CASE_ONLY||PROSPECTIVE|||||||
34174404|NCT04675567|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The Safety-Net Model consists of the delivery of intensively integrated clinical care within pediatrics, combined with community-based parent support from family support specialists. Innovations include child mental health specialists joining the pediatrics team for huddles, psychiatry notes shared with pediatricians via the Electronic Medical Records and active inclusion of pediatricians in pre-evaluation discussions with the Safety-Net Team and post-evaluation recommendations for the families. In addition, the Safety-Net model includes active communication with school personnel, child welfare, and community-based resources, when needed."||||
34174405|NCT06100900|NA|SEQUENTIAL||TREATMENT||NONE||Multiple dose levels of BCX10013 are planned for escalation.||||
34174406|NCT06068933|RANDOMIZED|PARALLEL||OTHER||NONE||Participants in Phase 2-A MCI Focused Trial will be randomized into a two arms: immediate intervention and delayed intervention. Participants in Phase 2-B KA Older Adult Focused Trial will not be randomized.||||
34174407|NCT06296290|||COHORT||PROSPECTIVE|||||||
33751076|NCT04315077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-Blind, Parallel, Randomized, Placebo-Controlled Trial|t|f|t|t
33751077|NCT00834769|||COHORT||RETROSPECTIVE|||||||
33751078|NCT04193800|||OTHER||RETROSPECTIVE|||||||
33751079|NCT04866212|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751080|NCT02247609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751081|NCT03280758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not know the intervention of each subjects||f|f|f|t
33751082|NCT05011851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751083|NCT03278418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751084|NCT03015402|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33751085|NCT04750746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751086|NCT01624038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751087|NCT04948099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33751088|NCT00262821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751089|NCT01625221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751090|NCT04696666|NA|SINGLE_GROUP||TREATMENT||NONE||It is a multicenter single-arm clinical study aimed at assessing the efficacy and tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) provided in routine clinical practice in patients presenting with symptoms of moderate to severe hemorrhagic cystitis.||||
33751091|NCT06276868|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm clinical study||||
33751092|NCT04648150|RANDOMIZED|PARALLEL||OTHER||TRIPLE|ratio 1 :1 in each centre on an online randomization module|"Experimental arm (VERUM): delivery of an active medical device for a period of 2 months. Then delivery of a second active medical device for a period of 4 months.~Control arm (SHAM): delivery of an inactive medical device for a period of 2 months of use then delivery of an active medical device from M2 to M6 after inclusion."|t|t|t|f
33751093|NCT01039701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751094|NCT02332590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||During the OLE period of this study, all participants received sarilumab 200 mg or 150 mg q2w via prefilled syringe.|t|t|t|t
33751095|NCT01618162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751096|NCT03322969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751097|NCT03907124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study raters will be kept blinded to the two arms of the study to avoid assessment bias.|This is a randomized prospective cohort study which will compare the utility of an interpretive report based on pharmacogenomic testing between study subjects receiving psychotropic medication with guidance from an interpretive report (i.e., Genetically-Guided Group) and those receiving psychotropic medications without the implementation of the interpretive report (Genetically-Unguided Group).|f|f|f|t
33751098|NCT01575366|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33751099|NCT06533228|||COHORT||PROSPECTIVE|||||||
33751100|NCT03265600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms, intervention and low-dose comparator, which are randomly assigned at the same time and are implemented in parallel.||||
33751101|NCT04823884|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|after completion of data collection personal data is anonymized. Outcomes assessor adds up the scores without knowing the type of surgery. The principal investigator as well as the statistical investigator do receive the completed anonymized excel file for doing the statistical analysis||f|f|t|t
33751102|NCT00381940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751103|NCT03059550|||OTHER||PROSPECTIVE|||||||
33961843|NCT05397288|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33961844|NCT06566911|||COHORT||PROSPECTIVE|||||||
34064566|NCT03545646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174408|NCT02329444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174409|NCT06285435|||CASE_CONTROL||PROSPECTIVE|||||||
34174410|NCT03802578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174411|NCT06378944|||COHORT||PROSPECTIVE|||||||
34174412|NCT02893293|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34174413|NCT06573996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This study employs a split-mouth, parallel design, where each participant serves as their own control. The active treatment (TENS device) is applied to one side of the mouth, while a placebo (non-functioning device) is applied to the other side, both during the same session. The allocation of sides (left or right) for the active treatment versus placebo is randomized. This design allows for direct intra-subject comparison of pain levels between the treated and untreated sides, minimizing variability in pain perception and enhancing the reliability of the study outcomes.~Each arm represents one of the four possible treatment locations where either the TENS device or the placebo will be applied: upper right, upper left, lower right, and lower left."|t|t|t|t
34174414|NCT02358473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174415|NCT04252547|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34174416|NCT06521086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174417|NCT02869711|||||PROSPECTIVE|||||||
34174418|NCT05022550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174419|NCT00262860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174420|NCT06704958|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Iterative intervention Development||||
34174421|NCT05135702|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34174422|NCT00269178|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174423|NCT05011188|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174424|NCT04464863|||CASE_CONTROL||PROSPECTIVE|||||||
34174425|NCT04024865|||COHORT||RETROSPECTIVE|||||||
34174426|NCT05389293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174427|NCT06444516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174428|NCT05104853|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33751104|NCT01168284|RANDOMIZED|SINGLE_GROUP||OTHER||||||||
33861618|NCT00222404|||COHORT||PROSPECTIVE|||||||
34064567|NCT06460610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064568|NCT04236336|||COHORT||PROSPECTIVE|||||||
34064569|NCT00422422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064570|NCT00348426|||DEFINED_POPULATION||PROSPECTIVE|||||||
34174429|NCT01026844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174430|NCT04418791|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Skin severity will be assessed by blinded physician for quantification of Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA)||f|f|f|t
33861619|NCT04129918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study was conducted on 126 patients with 56 subjects in experimental group and 56 in control group in the MICU. Effect of ear plugs \& eye mask on sleep among ICU patients: a randomized control trial The participants were randomly divided into two groups: with ear plugs and eye mask (experimental group) for 3 successive nights and without ear plugs and eye mask (control group). participants were provided a Sequentially numbered opaque sealed envelopes.|This is a single-center, prospective, randomized control trial in the medical intensive care unit of the Shin Kong Wu Ho-Su Memorial Hospital.|f|f|f|t
33861620|NCT01643954|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33861621|NCT03318809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient, investigator, investigative staff, medical monitor and care provider will not be masked for the study.|This is a multisite (approximately 3 sites), open-label, non-randomized, single-dose study in participants with severely impaired kidney function and healthy participants. About 12 participants will be assigned to two groups: Group 1: 6 with severely impaired kidney function , and Group 2: 6 with normal kidney function.||||
33861622|NCT02429622|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861623|NCT04911088|||COHORT||PROSPECTIVE|||||||
33861624|NCT06038825|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33861625|NCT00006159||||TREATMENT||||||||
33861626|NCT05406388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two model for this study. The first group is erector spinae plane block group. The second one is control group.|t|f|f|t
33861627|NCT02593669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861628|NCT02762825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861629|NCT05226026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861630|NCT01303965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861631|NCT02091895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861632|NCT03231696|||COHORT||RETROSPECTIVE|||||||
33861633|NCT00771004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861634|NCT03133806|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a multicenter, prospective, single arm design.||||
33861635|NCT04978142|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33861636|NCT01448213|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33861637|NCT06502249|||CASE_CONTROL||RETROSPECTIVE|||||||
33861638|NCT02805725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861639|NCT00076362|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33861640|NCT04195581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will use each lens and solution combination for a month in random sequence for a total of six months.||||
33861641|NCT02970734|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33861642|NCT00691886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33861643|NCT00800423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861644|NCT02183922|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33861645|NCT06470412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33861646|NCT02536755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861647|NCT00002313||||TREATMENT||||||||
33861648|NCT03985956|||CASE_ONLY||CROSS_SECTIONAL|||||||
33861649|NCT02962544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861650|NCT02354313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861651|NCT04956042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33861652|NCT00170612|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861653|NCT04604678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861654|NCT02220309|||COHORT||PROSPECTIVE|||||||
34064571|NCT01326507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064572|NCT02565199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064573|NCT00722163|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
34064574|NCT06505928|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a three-arm, parallel-group, randomized, open-label, delayed-controlled phase IIb clinical trial.||||
33861655|NCT04273256|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon consent, recruited women will be randomly allocated into either one of the study groups using a simple randomization method by computer-generated random numbers||||
33861656|NCT01245634|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33861657|NCT01176968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861658|NCT00438321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861659|NCT03909204|NA|SINGLE_GROUP||TREATMENT||NONE|Supportive Care|||||
33861660|NCT04746378|||COHORT||PROSPECTIVE|||||||
33861661|NCT06425276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861662|NCT04825769|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33861663|NCT04603664|||CASE_ONLY||PROSPECTIVE|||||||
33861664|NCT00459966|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34064575|NCT02362152|||COHORT||PROSPECTIVE|||||||
34064576|NCT05935423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064577|NCT01239901|||CASE_ONLY||CROSS_SECTIONAL|||||||
34064578|NCT06084247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064579|NCT03203174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subject's received treatment to one palm and the other palm was used as a control.|t|f|t|t
34064580|NCT02907775|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34064581|NCT05118048|||COHORT||PROSPECTIVE|||||||
34064582|NCT03623295|||COHORT||OTHER|||||||
33861665|NCT03982342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Enrolled participants will be randomly assigned to one of two PDA treatment approaches, both receiving treatment at the same time.|f|f|f|t
33861666|NCT00565383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861667|NCT04923048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861668|NCT06219070|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Their information may need to be kept confidential||t|f|f|t
33861669|NCT00665743|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861670|NCT05757115|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Parents with children with special needs who want to participate in the study will be determined. The assessments will be applied to parents before and after play training. These trainings aim to develop the skills of playing games with their children.||||
33861671|NCT00274404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861672|NCT03696615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861673|NCT04469166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded study|Randomized controlled trial|t|f|t|t
33861674|NCT01557348|||COHORT||PROSPECTIVE|||||||
33861675|NCT04637698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861676|NCT05638750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861677|NCT05619978|||COHORT||RETROSPECTIVE|||||||
33861678|NCT05761223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study will be conducted in 4 parts: Phase I dose-escalation and dose-expansion parts with FB849 monotherapy and Phase II dose-escalation and dose-expansion parts of FB849 in combination with pembrolizumab.||||
33861679|NCT02336763|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861680|NCT05867459|||COHORT||PROSPECTIVE|||||||
33861681|NCT03937284|||CASE_ONLY||CROSS_SECTIONAL|||||||
33861682|NCT04437160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861683|NCT05282277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel group, randomized placebo-controlled study|t|f|f|t
33861684|NCT00696930||||TREATMENT||||||||
33861685|NCT05421962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861686|NCT04706351|||OTHER||RETROSPECTIVE|||||||
33861687|NCT05474586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sequentially numbered, sealed, opaque envelopes|Randomized, Parallel Group, Placebo Controlled Trial|t|t|t|f
33861688|NCT01460186||||OTHER||||||||
33861689|NCT05039398|RANDOMIZED|PARALLEL||PREVENTION||NONE|None (Open Label) During inspection by the WEA the intervention status is masked for both the inspector and the assessed workplace. After the inspection is complete and all violation notices are sent to the company, the intervention group additionally receives invitation to a dialogue and guidance meeting. From this point the intervention is not masked.|"Parallel Assignment Each workplace assigned for inspection by the WEA is randomized to either of two intervention groups (physical meeting dialogue and guidance, telephone meeting dialogue and guidance) or a control group. If the workplace receives a WEA notice of material violations of work environment regulations, the workplace receives an offer for dialogue and guidance if they are in one of the two intervention groups. The comparison group receives treatment as usual.~Randomization as follows:~1/3 are randomized to treatment-as-usual comparison status 1/3 are randomized to receive dialogue and guidance over telephone 1/3 are randomized to receive dialogue and guidance at a physical meeting"||||
33861690|NCT04669977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33861691|NCT00690625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861692|NCT00006036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861693|NCT04118517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The model is based on the concept that if amino acids in protein become labelled with an isotopic tracer within the food matrix, their appearance in the blood gives a measure of their bioavailability following digestion and absorption of the protein; which is independent of other proteins in the food and independent of endogenous body proteins and gut bacterial proteins. Amino acids in the common bean were labelled with deuterium, by adding a bolus dose of deuterium oxide (2H2O) to the irrigation water. Then a dual tracer technique is used to measure the bioavailability of amino acids in the bean. After consuming a diet prepared with the mature bean, comparative tracer appearance in blood of the deuterium labelled amino acids from the bean and amino acids derived from a reference protein labelled within another tracer (U-13C- spirulina) gives a direct measure of bioavailability of the bean amino acids.||||
33861694|NCT04568551|||COHORT||PROSPECTIVE|||||||
33861695|NCT00398970|RANDOMIZED|PARALLEL||||NONE||||||
33861696|NCT03082950|||COHORT||CROSS_SECTIONAL|||||||
33861697|NCT05295316|||CASE_CONTROL||RETROSPECTIVE|||||||
33861698|NCT00510250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861699|NCT02213432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861700|NCT02342756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861701|NCT02290522|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751105|NCT04319510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigator who will perform the group assignment will have no contact to the study participants. The outcome assessors will be blinded to group allocation. The statistician who will perform the analyses will kept blind to the group intervention by renaming groups with numbers.||f|f|t|t
33751106|NCT00214357|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751107|NCT00162370|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751108|NCT02190539|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064583|NCT06228508|||COHORT||PROSPECTIVE|||||||
34064584|NCT05229952|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33751109|NCT04654780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants were masked to the nature of the price sets to which they were assigned (although they were obviously exposed to the prices in the virtual supermarket). They were informed in the informed consent that the study was to evaluate fiscal policies.|"Experimental design that simulates real purchase scenarios to evaluate the effects of a fiscal policy on purchase intention. Participants will be randomly assigned to the different intervention and control groups. Each participant must make a purchase in the virtual supermarket.~The study groups used in this research :~1. First intervention group (IG1), a High in food tax will be applied to study the changes in the purchasing and consumption behavior of the participants in this group. The tax will correspond to a 20% increase over the market price, that is, a tax that reaches the levels recommended by the WHO.~2. second intervention group (IG2), a subsidy will be applied to fruits and vegetables that means a reduction of 20% in their price, to study the changes in the purchasing and consumption behavior of the participants of said group.~3. control group (CG) the market or current prices of High in foods and subsidies of fruits and vegetables will be applied."|t|f|f|f
33751110|NCT05698810|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||volunteers||||
34064585|NCT03462992|||COHORT||PROSPECTIVE|||||||
34064586|NCT01397240|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34064587|NCT03338244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064588|NCT00099632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751111|NCT00380848|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34064589|NCT04760223|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized controlled trial|t|f|f|f
34064590|NCT01488396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064591|NCT03478189|||COHORT||PROSPECTIVE|||||||
34064592|NCT03385616|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Treatment with Gala Airway Treatment System||||
34064593|NCT04255966|||COHORT||PROSPECTIVE|||||||
34064594|NCT00753753|||COHORT||PROSPECTIVE|||||||
34064595|NCT06396013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064596|NCT05501067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064597|NCT05266924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor including the investigator, outcoume assessor (sonography, embyrologist) shall be blinded.|This is a Randomized, Parallel-group, Multi-Center, Assessor-blind Phase 3 Study.|f|f|t|t
34064598|NCT06192498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34064599|NCT04521114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064600|NCT03174691|NA|SINGLE_GROUP||TREATMENT||NONE||IVF patients triggered with hCG||||
34064601|NCT01260584|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34064602|NCT05577234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064603|NCT04504149|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD, hereafter PRIMED, is a primary care-based shared decision making (SDM) intervention that the investigators will develop using UCD methods for VA Primary Care-Mental Health Integration (PC-MHI) clinics to engage Veterans in first-line treatments for PTSD.||||
34064604|NCT05646966|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33751112|NCT05917795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751113|NCT02621931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751114|NCT00037401|||||RETROSPECTIVE|||||||
33751115|NCT03150472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Only the graft performing sub-investigator and the study coordinator will be un-blinded to the patient allocation. All efforts and measures would be taken by the study team to keep the patient and blinded assessors blinded of allocation (allocation of each extracted site) - semi double blinded study.~Shipment tubes for biopsy (primary endpoint) are labelled with the appropriate blinded coded specimens."|The Ivory Dentin Graft study is a prospective, randomized, semi double blinded with blinded assessments study comparing patients grafted with Ivory Dentin Graft (study arm) and patients grafted with OsteoBiol Gen Os (control arm) for alveolar ridge preservation following tooth extraction.|t|f|f|t
34064605|NCT00540488|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34064606|NCT00047229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064607|NCT01790152|||CASE_ONLY||PROSPECTIVE|||||||
34064608|NCT06105541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Participants will be randomized to one of two paralell groups:~Group 1: Double-blind phase Active, Open-label phase Active Group 2: Double-blind phase Sham, Open-label phase Active"|t|t|t|t
34064609|NCT04291365|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064610|NCT02623608|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34064611|NCT01425606|||COHORT||PROSPECTIVE|||||||
34064612|NCT05967923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group (a) Group (b) Group (c)||||
34064613|NCT02800941|||COHORT||PROSPECTIVE|||||||
34064614|NCT00827658|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34064615|NCT01981148|||COHORT||PROSPECTIVE|||||||
34064616|NCT05805605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064617|NCT04426669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34064618|NCT00461110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064619|NCT06164236|||CASE_ONLY||RETROSPECTIVE|||||||
34064620|NCT05827406|||OTHER||CROSS_SECTIONAL|||||||
34064621|NCT00354042|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33751116|NCT03399695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751117|NCT00478348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751118|NCT05488392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751119|NCT05803226|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Slow Art Plus programme will involve a full 90-minute engagement, one that is built upon the existing Slow Art programme with added layers of mindfulness and self-compassion practices, as well as a response art activity that fosters symbolic dialogue and an emotional aesthetic experience between participants and the selected art piece.||||
33751120|NCT02234674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751121|NCT02089880|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33751122|NCT03326375|RANDOMIZED|PARALLEL||TREATMENT||NONE|open labled|||||
33751123|NCT01508468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751124|NCT04552964|NA|SINGLE_GROUP||OTHER||NONE||This will be a single centre, single-arm, prospective pilot study.||||
33751125|NCT02828722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751126|NCT03468010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751127|NCT04986176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, superiority, interventional, placebo-controlled, double-blinded, randomized, parallel-assignment study|t|t|t|f
33751128|NCT01967732|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33751129|NCT05366777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The nurse who is not involved in this study knows the allocated group and sends the bottle of the drug which looks the same in both groups, to the operation room and ward.~The care provider, investigator, patients, and outcomes assessor will be not informed of the infusion of the drug by not attaching an identifiable label so that it cannot be distinguished from normal saline."|A prospective randomized double-blinded study|t|t|t|t
33751130|NCT06200766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751131|NCT02137161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751132|NCT01655589|||CASE_ONLY||RETROSPECTIVE|||||||
33751133|NCT01435083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751134|NCT03832595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes are ascertained by data programmers who are blinded to study arm assignment|Cluster randomized controlled trial with randomization occurring at the Primary Care Physician practice level|f|f|f|t
33751135|NCT01089426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751136|NCT06540339|||COHORT||PROSPECTIVE|||||||
33751137|NCT03932604|RANDOMIZED|PARALLEL||SCREENING||NONE||Patients are randomly assigned as atrial sensing ON or Off mode||||
33751138|NCT00636649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064622|NCT05086666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064623|NCT00607542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751139|NCT04656535|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Masking will only occur in the surgical cohort B (4 arms) during the first cycle prior to surgery. The masking will be removed after surgery and all patients will receive open label treatment with both zimberelimab and domvanalimab.|After the initial safety cohort confirms the safety of the dosing schedule an expansion surgical cohort will be enrolled and this cohort will be randomized to one of four treatment arms for the first cycle prior to surgery,|t|t|t|f
33751140|NCT02605486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751141|NCT01611701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751142|NCT01163370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751143|NCT00330083|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33751144|NCT06683508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861702|NCT06132854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants cannot be blinded due to the nature of the study. The radiologists, anesthesiology team, MRI staff and the second research assistant administering post-procedure questionnaires and coding anesthesiology data intended to be blinded, however, children may disclose their group by talking about their experience.||f|t|t|t
33751145|NCT03792126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861703|NCT01306188|||COHORT||PROSPECTIVE|||||||
33861704|NCT00973596|||COHORT||PROSPECTIVE|||||||
33751146|NCT02930733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751147|NCT06649292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751148|NCT03816774|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33751149|NCT02045485|||CASE_CONTROL||PROSPECTIVE|||||||
33751150|NCT06398327|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33751151|NCT00599612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751152|NCT02246127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751153|NCT05245669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Arm 1: ENZ215 Arm 2 : EU Sourced Prolia Arm 3: US Sourced Prolia|t|f|t|f
33751154|NCT01022762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751155|NCT06393348|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33861705|NCT03042780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861706|NCT05400642|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33861707|NCT05915897|||OTHER||PROSPECTIVE|||||||
33861708|NCT02055521|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961845|NCT04064333|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study will use an exploratory, cross sectional study design for the pre-post analysis of voluntary cough, measured through spirometry, laryngeal penetration/aspiration during swallow with thin liquids, measured under videofluoroscopy, and dysphagia-related quality of life, measured via questionnaire and diet texture modification scale. There is no control group; all participants will receive the same slow-stream expiratory muscle strength training protocol.||||
33961846|NCT05417126|NA|SINGLE_GROUP||TREATMENT||NONE||6 subjects will be enrolled for vMCO-010 treatment||||
33961847|NCT05353426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||A prospective, double-blinded, randomized clinical trial involving patients undergoing laparoscopic sleeve gastrectomy.|t|f|t|f
33961848|NCT02585973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064624|NCT04050579|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33751156|NCT01839110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751157|NCT03430674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751158|NCT04218461|||OTHER||PROSPECTIVE|||||||
33751159|NCT01280279|||COHORT||PROSPECTIVE|||||||
33751160|NCT01085851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751161|NCT06372769|||COHORT||CROSS_SECTIONAL|||||||
33751162|NCT06668376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Randomized Prospective Study|t|f|t|f
33751163|NCT05822115|NA|SINGLE_GROUP||OTHER||NONE||||||
33751164|NCT01581827|||COHORT||PROSPECTIVE|||||||
33751165|NCT06270966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|f|t
33751166|NCT03583216|||CASE_CONTROL||PROSPECTIVE|||||||
33751167|NCT05446168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751168|NCT00313404|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33751169|NCT04435665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174431|NCT06207786|RANDOMIZED|PARALLEL||PREVENTION||NONE||This randomized, open-label, single site clinical trial will be comprised of 2 comparison groups. Treatment arm 1 will be patients undergoing MMS for malignant cutaneous neoplasms receiving nasal povidone-iodine swabs prior to skin reconstruction. Treatment arm 2 will be patients undergoing MMS for malignant cutaneous neoplasms randomized to receive standard of care.||||
34174432|NCT05314868|||OTHER||RETROSPECTIVE|||||||
34174433|NCT03473678|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33861709|NCT03831425|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The Sick Kids research pharmacist will be responsible for dispensing the CoQ10 capsules which will be of highest grade, purity and safety from Webber Natural Pharmaceuticals Limited. A placebo will be prepared by the Sick Kids research pharmacy and will consist of lactose-filled capsules. The CoQ10 and placebo capsules will not be identical in colour, shape or taste. However, as stated above, researchers, participants and families will be blinded to the treatment phase. They will know they are receiving one capsule for one part of the study and another capsule for the next part. No one (except the pharmacist and an unblinded study team member, who will only distribute and collect the medication given to the family (will not conduct any testing)) will know which capsule contains CoQ10 and which contains the placebo|prospective, randomized, double-blind, controlled, cross-over study with CoQ10 and placebo arms|t|t|t|t
33861710|NCT04850157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861711|NCT01544699|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|no change|no change|t|t|t|t
33861712|NCT00325039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861713|NCT03156127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861714|NCT03954574|||COHORT||PROSPECTIVE|||||||
33861715|NCT02525861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861716|NCT02216487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861717|NCT02761746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861718|NCT05136365|NA|SINGLE_GROUP||TREATMENT||NONE||Xiongdan Wan is used in patients diagnosed with Major Depressive Disorder.||||
33861719|NCT01782079|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174434|NCT04752618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors and preventive case planners are blind to treatment arm.|P-STAIR vs Supportive Counseling|f|f|f|t
34174435|NCT00148395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174436|NCT02659163|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33861720|NCT02030405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861721|NCT00937833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34174437|NCT01169103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174438|NCT00257413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34174439|NCT01615146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174440|NCT04931940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751170|NCT04789538|||CASE_ONLY||OTHER|||||||
33751171|NCT06723951|||CASE_CONTROL||PROSPECTIVE|||||||
33751172|NCT00006123||||TREATMENT||||||||
33751173|NCT01915615|||CASE_ONLY||PROSPECTIVE|||||||
33861722|NCT00219050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861723|NCT03326895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861724|NCT01212250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33861725|NCT00056511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861726|NCT04849182|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33861727|NCT04633707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174441|NCT04854135|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174442|NCT00791349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34174443|NCT04065139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174444|NCT06046040|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer (mCRPC). Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design||||
34174445|NCT05127044|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174446|NCT06706258|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34174447|NCT03277989|||OTHER||PROSPECTIVE|||||||
34174448|NCT05361551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751174|NCT06442150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the unique nature of the intervention, it is not feasible to mask the participants and investigators in the treatment allocation. However, the outcomes assessor will be blinded to minimize potential bias in data analysis.|Parallel Assignment|f|f|f|t
33751175|NCT03529474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33751176|NCT03345238|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Randomized controlled trial with double-blind|t|f|f|t
33751177|NCT01895972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861728|NCT03152279|||CASE_CONTROL||PROSPECTIVE|||||||
33861729|NCT01283698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33861730|NCT02092350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861731|NCT01647750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064625|NCT02311270|||COHORT||CROSS_SECTIONAL|||||||
34064626|NCT03218228|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064627|NCT00395642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861732|NCT05522816|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Randomization and masking will be conducted in stage 1 and stage 2. Eight patients are randomized to received KX01 or placebo control in a ratio of 3:1 (KX01 versus placebo) in these 2 stages. Double blind are applied to the assignment of KX01 and placebo.|The study will be sequentially performed in four stages, including stage 1 to stage 4. If no major safety concern was identified in the previous stage, as well as an unanimous consent by the sponsor and the principle investigator(s), the study will proceed to the next stage.|t|t|t|t
33861733|NCT04228809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|sham||t|t|f|t
33861734|NCT04381455|||COHORT||PROSPECTIVE|||||||
33861735|NCT04978311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861736|NCT01184053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961849|NCT06538454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Exercise training studies cannot blind therapists or participants to the intervention or exercise administred. Our study will blind the statistical analysis because we will code the data to avoid knowledge about the intervention performed and who was the participants.|The study will be conducted in two stages: one acute and one chronic. In the acute stage, with a crossover design, the subjects will be perform in a random order two resistance training sessions with different intensity. Following this stage, the subjects will be randomized in one of two groups of intensity in a randomized clinical trial design with 10 week of intervention (resistance training).|f|f|t|f
33961850|NCT04149769|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Poorly-ambulatory subjects previously enrolled in Studies 1 and/or 2, and as such will have prior experience walking in the exoskeleton.||||
33961851|NCT06224478|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33961852|NCT04767542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33961853|NCT05980351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961854|NCT03936777|NA|SINGLE_GROUP||TREATMENT||NONE|None (open label)|Single Group Assisgnment||||
33961855|NCT04525859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Subjects will receive poly-ICLC once within the pleural mesothelioma. Up to twenty one days later he/she will undergo surgery per the standard of care by the thoracic surgeon. The type of surgery will be decided upon by the treating thoracic surgeon. Follows up visits are scheduled every three months for the first year and then every 6 months thereafter. CT scans or surveillance scans to look for recurrences will be ordered by the treating surgeon and/or medical oncologist per the standard of care. If there is a need for adjuvant (after surgery) therapy, such as chemotherapy or radiation, this will be discussed with the study subject per the standard of care by the surgeon and/or a medical oncologist or radiation oncologist.||||
33961856|NCT00386854|RANDOMIZED|CROSSOVER||ECT||NONE||||||
33961857|NCT06135519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A with MSCs Group B with Fat||||
33961858|NCT05955235|||CASE_ONLY||PROSPECTIVE|||||||
33961859|NCT03983746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064628|NCT00347321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064629|NCT03621891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33961860|NCT01175161|RANDOMIZED|PARALLEL||||NONE||||||
33961861|NCT05691699|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33961862|NCT02964884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064630|NCT06294444|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will get separate treatment protocol and possible efforts will be put to mask the both groups about their treatment|Randomized Control Trial|t|f|f|f
34064631|NCT04318132|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064632|NCT04693156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064633|NCT02001272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064634|NCT00473824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064635|NCT02972333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064636|NCT03761823|||COHORT||PROSPECTIVE|||||||
34064637|NCT03402230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064638|NCT05303233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064639|NCT02590757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064640|NCT02498509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064641|NCT05863793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174449|NCT06120712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174450|NCT06500390|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174451|NCT03672331|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174452|NCT05263934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study.|Participants will receive either depemokimab plus placebo matching mepolizumab or mepolizumab plus placebo matching depemokimab|t|t|t|t
33861737|NCT03947125|||CASE_CONTROL||RETROSPECTIVE|||||||
33861738|NCT05285709|||COHORT||PROSPECTIVE|||||||
33861739|NCT02750098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861740|NCT02706301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861741|NCT00300287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33861742|NCT02679950|||CASE_ONLY||PROSPECTIVE|||||||
33861743|NCT06176170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861744|NCT05003713|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33861745|NCT04356781|||COHORT||OTHER|||||||
33861746|NCT00005074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861747|NCT05036616|||CASE_CONTROL||PROSPECTIVE|||||||
33861748|NCT05922176|||CASE_CONTROL||PROSPECTIVE|||||||
33861749|NCT03220087|||CASE_CONTROL||RETROSPECTIVE|||||||
33861750|NCT04286425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861751|NCT02900534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861752|NCT05788822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861753|NCT04628884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861754|NCT02624466|||COHORT||PROSPECTIVE|||||||
33861755|NCT02257957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064642|NCT06263517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomization list will be performed with Proc Plan procedure by SAS ® Software (release 9.4 or later) software using the block randomization method with block size of 4.~Subjects eligible at Baseline will be randomly allocated to receive 2, 5, 10 /2ml or placebo according to the balanced randomization list."|Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled|t|t|t|t
34064643|NCT02440854|||OTHER||PROSPECTIVE|||||||
34064644|NCT05445700|NON_RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Groups will be determined according to frailty status.|t|t|t|f
34064645|NCT04854083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064646|NCT06266520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064647|NCT06249321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861756|NCT00820976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861757|NCT02696772|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861758|NCT02693613|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861759|NCT02987179|||COHORT||PROSPECTIVE|||||||
34064648|NCT00700154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861760|NCT04845360|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We performed non--invasive recording of the radial arterial pulses for 36 pregnant women, and then compared the harmonics of the radial arterial pulse after Fourier transformation with those of 50 healthy nonpregnant women (controls).||||
33861761|NCT05805566|||COHORT||OTHER|||||||
33861762|NCT05166135|||COHORT||RETROSPECTIVE|||||||
33861763|NCT02169817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861764|NCT00151554|RANDOMIZED|PARALLEL||||NONE||||||
33861765|NCT06270433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861766|NCT02997488|||CASE_CONTROL||PROSPECTIVE|||||||
33861767|NCT01641211|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861768|NCT02849340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861769|NCT05717426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861770|NCT06361784|||COHORT||PROSPECTIVE|||||||
33861771|NCT05319028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861772|NCT02945150|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861773|NCT01975818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961863|NCT01329705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961864|NCT05100849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961865|NCT04403191|||COHORT||PROSPECTIVE|||||||
33961866|NCT04738188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961867|NCT03923400|||CASE_CONTROL||RETROSPECTIVE|||||||
33961868|NCT02583607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961869|NCT01938521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33961870|NCT02498119|||||PROSPECTIVE|||||||
33961871|NCT02999919|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33961872|NCT04064437|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064649|NCT05817214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064650|NCT02301039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064651|NCT00366652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064652|NCT02420678|||COHORT||PROSPECTIVE|||||||
34064653|NCT05571215|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study - intervention group only||||
34064654|NCT05074342|||COHORT||PROSPECTIVE|||||||
33861774|NCT04696991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants didn't know which group they were allocated. The participants will be blind when they take postpartum discharge training with PechaKucha method from investigators.|"The research is a single-blind randomized controlled experimental study. In view of the two groups called E and C, the total number of blocks was calculated as 20 blocks and the number of the participant mothers per block was calculated as 12 mothers, namely, 6 mothers for group E and 6 mothers for group C. Through MS Office Excel 2013, 13 numbers were randomly selected from among numbers from 1 to 20 (9, 17, 19, 4, 14, 3, 14, 1, 20, 16, 12, 8, 20, 2, and 5). By ensuring that each group has 78 mothers, a total of 156 mothers were assigned to experimental and control groups in equal numbers and homogeneously.~In this context, the research was completed with the participation of 140 mothers, namely, 70 mothers in the experimental group and 70 mothers in the control group."|t|f|f|f
33861775|NCT04725383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All individuals involved in the study will be blinded as to drug or placebo condition, except for one psychiatry co-investigator who will remain unblinded and check that amitriptyline levels are not above the maximum for the laboratory therapeutic range.|Randomized double-blind placebo-controlled clinical trial.|t|t|t|t
33861776|NCT00592761|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861777|NCT01685710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861778|NCT04052568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861779|NCT01674335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861780|NCT06046911|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||In this experiment, the experimental group will practice Yang Style Tai Chi.The control group will be the daily activity group, maintaining daily activities such as walking. There are males and females in each parallel group.|t|f|f|t
33861781|NCT02802930|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33861782|NCT02423018|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33861783|NCT02169180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861784|NCT00992511|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33861785|NCT01672788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861786|NCT01418820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861787|NCT04980950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33861788|NCT04111965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Masking will be done through the primary and secondary packaging.~They will be identified by means of identical tags. Which, in compliance with current and applicable regulations, must contain at least:~* Name, address and telephone number of the sponsor.~* Pharmaceutical form and route of administration.~* Lot Number.~* Legend Exclusively for clinical studies~* Date of Expiry."|Phase I-II clinical trial, comparative, non-inferiority with active control, double blind with randomisation. Safety analysis when completing the visits of the first 12 subjects|t|f|t|f
33861789|NCT01790126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861790|NCT01822522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In this study, cabozantinib doses were escalated within 3 strata defined by the participant's antiretroviral regimen||||
33861791|NCT04803799|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33861792|NCT06494527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861793|NCT00906919|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861794|NCT01693081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064655|NCT03111615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Aromatase inibitor therapy to start immediately after biopsy results are available Letrozole 2.5mg or Anastrazol 1 mg|t|t|f|t
33861795|NCT02488187|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33861796|NCT06402981|||CASE_CONTROL||RETROSPECTIVE|||||||
33861797|NCT04366921|||COHORT||PROSPECTIVE|||||||
33861798|NCT04921007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861799|NCT05364268|||CASE_ONLY||PROSPECTIVE|||||||
33861800|NCT04403750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861801|NCT06226831|||CASE_CONTROL||RETROSPECTIVE|||||||
33861802|NCT00809211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861803|NCT06046625|||COHORT||PROSPECTIVE|||||||
33861804|NCT05385133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861805|NCT01195545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861806|NCT02646748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861807|NCT03088722|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33861808|NCT02665065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861809|NCT04408261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861810|NCT03366493|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33861811|NCT02431650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861812|NCT03879850|||COHORT||PROSPECTIVE|||||||
33861813|NCT01729156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33861814|NCT04063254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861815|NCT05092633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33861816|NCT00400309|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33861817|NCT00072332||||TREATMENT||NONE||||||
33861818|NCT01420809|||OTHER||PROSPECTIVE|||||||
33861819|NCT03559920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861820|NCT05912387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33861821|NCT02390817|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33861822|NCT01854645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861823|NCT01772004|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33861824|NCT04722926|||COHORT||RETROSPECTIVE|||||||
33861825|NCT03519958|||COHORT||PROSPECTIVE|||||||
33861826|NCT05020288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861827|NCT04622033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861828|NCT00388622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861829|NCT04350216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861830|NCT02405923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861831|NCT00960960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861832|NCT04081454|||FAMILY_BASED||PROSPECTIVE|||||||
33861833|NCT00179725|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34064656|NCT01575041|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34064657|NCT01785758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064658|NCT05223088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861834|NCT03730974|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study has a randomized 2-sequence, 2-period, 2-treatment crossover design.||||
33861835|NCT05558176|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The packaging of the trial drugs will be carried out under sterile hygienic condition in the hospital pharmacy department by two of the hospital pharmacists who will be dedicated to the study, they will prepare sequentially ordered packs labelled with individual study identification numbers containing identical tablets of sildenafil citrate or placebo, they will be the only one who know which number is assigned to sildenafil citrate or placebo.~Women, clinicians, and principal investigator will be unaware of allocation. Clinical staff managing the labour will be blinded to the ultrasound results and retained responsibility for all decisions regarding intrapartum care. At LTH Ogbomoso, all decisions for caesarean delivery are made by the obstetrics team under the supervision of consultant Obstetrician."|"Selection of patients into each arm of the study will be through a computer generated sequence in a 1:1 ratio to receive either sildenafil citrate or placebo in variable blocks of up to six (Stata Statistical Software, Release 14; College Station, TX; StataCorp LP. StataCorp 2013) in a sealed opaque envelope. Each participant's study identification number will be recorded in the clinical notes.~The packaging of the trial drugs will be carried out under sterile hygienic condition in the hospital pharmacy department by two of the hospital pharmacists who will be dedicated to the study, they will prepare sequentially ordered packs labelled with individual study identification numbers containing identical tablets of sildenafil citrate or placebo, they will be the only one who know which number is assigned to sildenafil citrate or placebo. The same brand of sildenafil citrate"|t|t|t|t
33861836|NCT01581944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33861837|NCT05539859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861838|NCT02298296|||COHORT||PROSPECTIVE|||||||
33861839|NCT05737290|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33861840|NCT01118689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861841|NCT01054651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861842|NCT04027231|||CASE_ONLY||CROSS_SECTIONAL|||||||
33861843|NCT00654342|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33861844|NCT05104008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861845|NCT03620019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861846|NCT05699135|||CASE_ONLY||RETROSPECTIVE|||||||
33861847|NCT04441112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861848|NCT01723813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861849|NCT01831830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861850|NCT00034450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33861851|NCT01499953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861852|NCT01641809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861853|NCT04399122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomization was accomplished by the pharmacy and the medication bottles were not labeled.|Patients will be randomized to Group 1 or Group 2|t|f|t|f
33861854|NCT03552861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861855|NCT00028821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861856|NCT05047783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
33861857|NCT06274671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33861858|NCT04769453|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33861859|NCT00737919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861860|NCT02838069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861861|NCT06148857|||COHORT||RETROSPECTIVE|||||||
33861862|NCT05276557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861863|NCT03580772|||COHORT||CROSS_SECTIONAL|||||||
33861864|NCT02540538|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861865|NCT03985215|||COHORT||CROSS_SECTIONAL|||||||
33861866|NCT01331265|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33861867|NCT05432128|||COHORT||PROSPECTIVE|||||||
33861868|NCT03334409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861869|NCT00859950|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33861870|NCT01557023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33861871|NCT02941926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861872|NCT06059066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861873|NCT03049787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861874|NCT02141542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861875|NCT04877717|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-A1904 monotherapy||||
33861876|NCT03227055|||COHORT||PROSPECTIVE|||||||
34064659|NCT01438931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064660|NCT04632056|||COHORT||PROSPECTIVE|||||||
34064661|NCT03919344|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34064662|NCT02977728|||CASE_CONTROL||PROSPECTIVE|||||||
34064663|NCT00567697|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34064664|NCT03986229|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||15 patients exposed to the AB sequence and 15 patients exposed to the BA sequence||||
33861877|NCT04581967|||COHORT||PROSPECTIVE|||||||
33861878|NCT01109173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34064665|NCT00978393|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33861879|NCT04987892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861880|NCT00120406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861881|NCT00134316|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861882|NCT03504514|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||monocentric, open, randomized, crossover study||||
33861883|NCT05336656|||OTHER||RETROSPECTIVE|||||||
33861884|NCT04943003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All examiners will be blinded to the type of treatment the patient received (active stimulation or sham) and other assessments. Thus, all guidelines established by CONSORT 2010 (Consolidated Standards of Reporting Trials) will be complied with, as pointed out by Moher et al. (2010), with variable control following systematized and countersigned procedures: random sequence generation, allocation concealment, blinding of participants and professionals, blinding of outcome evaluators and attrition bias (loss analysis using the last observation carried forward method) (Higgins \& Green, 2011).|Participants will be divided into 02 groups, each with 25 patients, totaling 50 volunteers: Active - participants who will receive real current; Sham - participants who will receive simulated stimulation. Participants entered into the study through the eligibility criteria will be randomly allocated in a simple way, at a rate of 1:1.|t|t|f|t
33861885|NCT05713188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861886|NCT02540863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861887|NCT00021450|RANDOMIZED|||TREATMENT||||||||
34064666|NCT04371211|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Study||||
34064667|NCT04993599|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064668|NCT04652986|||OTHER||PROSPECTIVE|||||||
34064669|NCT04046926|||COHORT||PROSPECTIVE|||||||
34064670|NCT01955109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064671|NCT06413823|||COHORT||PROSPECTIVE|||||||
34064672|NCT03377413|||CASE_ONLY||CROSS_SECTIONAL|||||||
34064673|NCT04451252|||OTHER||PROSPECTIVE|||||||
34064674|NCT00003215|RANDOMIZED|||TREATMENT||||||||
34064675|NCT05811078|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Adolescents who met the inclusion criteria of the study were listed and their names were written to someone who was not involved in the study. The adolescents included in the list formed by this person who was excluded from the study were randomly assigned to the experimental and control groups according to the block randomization method in order to eliminate the selection bias and to ensure the balance in the number of individuals between the groups. From here, all possible possibilities were created and the blocks were arranged so that there were 4 individuals (2 experiments, 2 controls) in each block. Each block was given a number and the assignment was made using the https://www.randomizer.org/ address.|randomized controlling trail|t|f|f|f
34064676|NCT00179894|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34064677|NCT02006056|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064678|NCT05941442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064679|NCT02250950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34064680|NCT02245919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064681|NCT01454414|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34064682|NCT00550264|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34064683|NCT03292471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be assigned to receive 10 sessions of inhibitory rTMS to right hemisphere pars triangularis (RH PTr), either preceded by a 6 Hz priming rTMS stimulation sequence or not.|f|f|f|t
34064684|NCT00111202|||||OTHER|||||||
34064685|NCT02433899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34064686|NCT04451668|NA|SINGLE_GROUP||TREATMENT||NONE||Open label treatment with FT218 (once nightly sodium oxybate extended release)||||
34064687|NCT02711943|||COHORT||PROSPECTIVE|||||||
34064688|NCT03252366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064689|NCT01899105|RANDOMIZED|CROSSOVER||||NONE||||||
34064690|NCT05869656|RANDOMIZED|PARALLEL||OTHER||NONE||Feasibility RCT with an alert intervention that is clinician facing||||
34064691|NCT01399489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064692|NCT01055080|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861888|NCT01326728|||CASE_CONTROL||PROSPECTIVE|||||||
33861889|NCT00422526|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33861890|NCT03786978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcomes assessor made a blind evaluation from the study outcomes.|Randomized clinical trial study|f|f|f|t
33861891|NCT03878004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a double-blind, randomized (in 3:1 ratio -vaccine : placebo) study|t|f|t|f
33861892|NCT06493877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861893|NCT02859961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064693|NCT01296594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064694|NCT05166850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34064695|NCT00069563|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34064696|NCT03602794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomised Controlled|t|f|f|t
34064697|NCT06011512|||COHORT||PROSPECTIVE|||||||
34064698|NCT03071510|||COHORT||CROSS_SECTIONAL|||||||
34064699|NCT01256970|||COHORT||PROSPECTIVE|||||||
34064700|NCT05908500|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The statistical analysis will be masked as to which intervention subjects received, with a simple A and B designation for the 2 arms."|The study will be a prospective, cluster-randomized controlled trial with 2 arms: control (standard instructor-led CPR training), and gamified experience. The intervention and cluster randomization will occur at the classroom level and outcomes reported at the individual level. We assume negligible intra-class correlation because classes will be randomized in an alternating fashion to eliminate time-of-day differences. For example, 1st period is randomized to control, 2nd period to game.|f|f|f|t
34064701|NCT00509353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861894|NCT04866888|NA|SINGLE_GROUP||TREATMENT||NONE||Uterus will be incised 5mm above the placenta bulge. Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally. After 3 months ultrasound and out-patient hysteroscopy will be done to check for any uterine abnormalities||||
33861895|NCT04834687|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33861896|NCT04047693|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single institution, Open-label, Phase 2||||
33861897|NCT01609465|||COHORT||PROSPECTIVE|||||||
33861898|NCT00438503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861899|NCT00953719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861900|NCT03067155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861901|NCT02809742|||COHORT||PROSPECTIVE|||||||
33861902|NCT02610153|||COHORT||PROSPECTIVE|||||||
33861903|NCT04288830|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861904|NCT01580280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861905|NCT04820374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33861906|NCT04194281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861907|NCT02915471|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33861908|NCT05522049|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled trial|t|f|f|f
33861909|NCT04311567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors of lung evaluation with HRCT and joint evaluation with joint counts (number of tender and swollen joints)|"A study in two parts:~1. Screening with HRCT. Patients will be stratified based on the the findings to: cohort A, with pulmonary abnormalities; and cohort B, with normal findings (who will end further participation in the main trial).~2. Randomization of cohort A to 48 weeks of active treatment. Parallel group design from baseline to week 24."|f|f|f|t
33861910|NCT05881889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861911|NCT04626817|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33861912|NCT02785497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961873|NCT01488799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961874|NCT01518621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961875|NCT04345887|||COHORT||PROSPECTIVE|||||||
33961876|NCT03944707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961877|NCT05202600|||COHORT||RETROSPECTIVE|||||||
33961878|NCT05161559|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34174453|NCT06308952|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The subject numbers and corresponding medication numbers are permanently identified and unique for each successfully randomized patient. If any patients who have been successfully randomized do not receive the trial medication or cannot be reassigned to others, their medication and medication numbers will be invalidated by the medication administrator. To ensure blinding during the trial execution, unblinded personnel responsible for administering and configuring the trial drug must sign a confidentiality agreement.|The subject numbers and corresponding medication numbers are permanently identified and unique for each successfully randomized patient. If any patients who have been successfully randomized do not receive the trial medication or cannot be reassigned to others, their medication and medication numbers will be invalidated by the medication administrator. To ensure blinding during the trial execution, unblinded personnel responsible for administering and configuring the trial drug must sign a confidentiality agreement. Investigators, other blinded investigators, subjects, and sponsors will not have access to any information regarding group assignment or related documents pertaining to the trial drug.|t|t|t|t
34174454|NCT03535922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174455|NCT05252546|NA|SINGLE_GROUP||TREATMENT||NONE||Pyrotinib alone and then combined with Montmorillonite Power or Loperamide||||
34174456|NCT03314103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34174457|NCT06329440|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
34174458|NCT04739982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174459|NCT02307890|||COHORT||PROSPECTIVE|||||||
34174460|NCT04057859|||CASE_ONLY||PROSPECTIVE|||||||
34174461|NCT04790188|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34174462|NCT06299683|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study assessors will be blinded to the study primary outcome but will be aware of study treatment conditions.|The study involves a two group parallel design, with one group receiving individual psychosocial intervention online and another pelvic floor physical therapy.||||
33861913|NCT05570474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study products (protein or placebo drinks) are provided to study participants. Study product is marked by a unique batch number, corresponding to protein or placebo in the ingredients list.|Participants are randomly allocated to either protein group or placebo group.|t|t|t|f
33861914|NCT00120913|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33861915|NCT06159192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A group of 80 patients (male and female) diagnosed as type 2 diabetes mellitus, will be included in the study. Their age will be ranged from 40-60 years. Their weight ranged from 80 - 100 k.g. and their height ranged from 160 - 180 cm. Patients will divide into two groups: Study groups (A) 40 patients type 2 diabetes mellitus with clinically proved peripheral neuropathy. And control group (B) 40 patients with asymptomatic type 2 diabetes mellitus. They will be selected from South valley university hospitals. Group A will receive low intensity extracorporeal shock wave therapy for two per week for four weeks. Group B will receive shame low intensity extracorporeal shock wave therapy.|Monitor the effect of low intensity extracorporeal shock wave therapy on impaired nitric oxide synthase and microcirculation changes in type 2 diabetes mellitus with peripheral neuropathy|t|f|f|f
33961879|NCT01629134|||COHORT||PROSPECTIVE|||||||
33961880|NCT04040907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study|t|t|t|t
33961881|NCT05940519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not informed about the intervention|prospective randomized controlled study|t|f|f|f
33961882|NCT02046369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961883|NCT05243654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To maintain blinding to treatment allocation, all subjects will receive treatment with identical tablets and the same number of tablets (two tablets once daily).|Multi-center, randomized double-blind, controlled phase 2 proof-of-concept trial. Subjects will be randomised 1:1 ratio to receive metformin 1000 mg XR tablets OD or matching placebo for 24 weeks. Randomization will be stratified by BI (BI ≥ or \< 4) and participating study site.|t|t|t|t
34174463|NCT05782868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34174464|NCT04696484|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34174465|NCT05602493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blinded Study|"Prospective Randomized Clinical Trial Phase (IIIa), Unicentric, Placebo Controlled, Double-Blinded Study"|t|f|t|f
34174466|NCT04066062|||COHORT||OTHER|||||||
34174467|NCT06593431|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174468|NCT03770234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each participant will apply Transtec 35 µg/hour transdermal patch, once for 96 hours (Treatment A) and once for 72 hours (Treatment B) in randomized order. Between removal of the first patch and application of the second patch, there will be a washout period of at least 10 days.||||
34174469|NCT02718079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961884|NCT00997672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961885|NCT05564273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once enrolled, participants are randomized into one of the three arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.|Randomized, blinded, cohort study divided into three arms: 1) control group (placebo), 2) condition-based supplement, 3) precision-supplement|t|f|f|f
33961886|NCT06241651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961887|NCT05449158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961888|NCT00197470|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961889|NCT00397072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961890|NCT03638752|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The endoscopist and endoscopy nurse will not know to which treatment arm the patient belongs as only the research assistant will has taken down this information. This information does not travel with the patient to the endoscopy room. The patient is also instructed to not reveal to the endoscopist or endoscopy nurse if he or she has taken or not taken the comprehensive education.||f|t|t|f
33961891|NCT01251692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961892|NCT05815186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961893|NCT00862888|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961894|NCT05000918|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33961895|NCT00504842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33961896|NCT00350337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33961897|NCT00362427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961898|NCT06566495|||OTHER||CROSS_SECTIONAL|||||||
33961899|NCT00861731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961900|NCT01106352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961901|NCT05658289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be unaware of the procedure they were randomized to until the 1-year time point.|Patients that have consented to the study have a 50% chance of being randomized to 1 of 2 surgical procedures.|t|f|f|f
33961902|NCT02962869|NA|SINGLE_GROUP||OTHER||SINGLE||||||
33961903|NCT01003782|||COHORT||PROSPECTIVE|||||||
33961904|NCT00647426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961905|NCT04976088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
33961906|NCT03923114|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33961907|NCT01712152|||COHORT||PROSPECTIVE|||||||
33961908|NCT01459679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861916|NCT03096925|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be consecutively included and randomized to two groups, intervention group or control group. We will use a web-based randomisation procedure, conducted at a place remote from where the study takes place.||||
33961909|NCT01977859|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33961910|NCT00359840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33961911|NCT05605457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961912|NCT04599673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33861917|NCT00866749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961913|NCT04931758|||CASE_CONTROL||PROSPECTIVE|||||||
33961914|NCT02540473|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33961915|NCT02970175|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33961916|NCT05349188|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are blinded to the intervention.|The study utilizes a multiple crossover design to conduct N-of-1 trials in individuals.|t|f|f|f
33961917|NCT00709735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961918|NCT04246840|||CASE_CONTROL||PROSPECTIVE|||||||
34174470|NCT04756310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34174471|NCT03316781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174472|NCT02640274|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174473|NCT05503030|||COHORT||PROSPECTIVE|||||||
34174474|NCT04922086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751178|NCT03131557|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Phonak Audéo B and a line extension of the Phonak Audéo B hearing aid product family will be fitted to the participants individual hearing loss.|t|f|f|f
33861918|NCT03365050|||COHORT||RETROSPECTIVE|||||||
33861919|NCT05881980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861920|NCT05187156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861921|NCT03940547|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33861922|NCT05987397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861923|NCT01219647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861924|NCT05296525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861925|NCT01423812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861926|NCT05933486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961919|NCT05812222|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention group and control group, randomized controlled, experimental study.||||
33961920|NCT00814619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961921|NCT01745419|||CASE_CONTROL||RETROSPECTIVE|||||||
33961922|NCT01957020|||CASE_ONLY||RETROSPECTIVE|||||||
33961923|NCT01387360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961924|NCT01188070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33961925|NCT00140322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33961926|NCT04811911|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34064702|NCT04554342|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||doppel- blind testing of 5 different variations of a candy in each participant by (unstimulated and stimulated) salivary flow rate; each participant is testing each variation of candy once in a randomized order at 5 consecutive days|t|f|t|t
34064703|NCT02733575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064704|NCT03439462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064705|NCT03471234|||COHORT||PROSPECTIVE|||||||
34064706|NCT00926640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064707|NCT05958069|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;||||
34064708|NCT05768009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064709|NCT00467402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34064710|NCT01491269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064711|NCT05593237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed of their assigned stimulation frequency. Analysis of outcomes will be conducted by an investigator blinded to the treatment that participants received.|Blinded, randomized pilot TMS treatment trial|t|f|f|f
34064712|NCT01272375|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34064713|NCT02357615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064714|NCT03737266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064715|NCT03346304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064716|NCT00743678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064717|NCT00001237||||TREATMENT||||||||
34064718|NCT04131491|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064719|NCT02287259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064720|NCT04177888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||experimental group received who received hot pack, which was a single-use pack filled with magnesium sulfate and water, squeezed between the hands to activate the warming effect, applied to the lower back area. The control group received routine care including Entonox.||||
34064721|NCT01524068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064722|NCT00360802|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34064723|NCT00758108|||||OTHER|||||||
34064724|NCT05328284|||COHORT||PROSPECTIVE|||||||
34064725|NCT05618184|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34064726|NCT05680376|||CASE_CONTROL||RETROSPECTIVE|||||||
34064727|NCT03845101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064728|NCT01586871|||CASE_CONTROL||RETROSPECTIVE|||||||
34174475|NCT06209658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||A total of 70 people, 35 in the experimental group and 35 in the control group, will be included in the study.|t|t|t|t
34174476|NCT03193840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174477|NCT04268459|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial||||
34174478|NCT06150612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861927|NCT05216900|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be conducted as a prospective multicenter single arm interventional pilot study. The primary endpoint is post-surgical complications at three months after the latest patient has received the final reconstructive surgery.||||
33861928|NCT00588510|||COHORT||PROSPECTIVE|||||||
33861929|NCT01464125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861930|NCT04806698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861931|NCT04202952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861932|NCT04254744|||COHORT||PROSPECTIVE|||||||
33961927|NCT00958685|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33961928|NCT00142844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961929|NCT03957317|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled study comparing effects of wearing eye masks and ear plugs for sensory deprivation against the standard-of-care (no treatment). Primary outcome is measuring difference between RCSQ scores (sleep quality survey).||||
33961930|NCT04791865|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33961931|NCT06177509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, controlled, single-blind parallel group design.|f|f|f|t
34064729|NCT05547776|NA|SINGLE_GROUP||OTHER||NONE||This is a feasibility trial with a single group of 30 participants who are using an app and providing feedback on the app.||||
34064730|NCT06294873|||COHORT||PROSPECTIVE|||||||
34064731|NCT02240303|||||PROSPECTIVE|||||||
34064732|NCT03014622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861933|NCT00049556||||TREATMENT||||||||
33861934|NCT03738969|||COHORT||RETROSPECTIVE|||||||
33861935|NCT01499472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33861936|NCT02082236|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33861937|NCT04997928|||CASE_CONTROL||PROSPECTIVE|||||||
33861938|NCT00597753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064733|NCT04799106|||COHORT||PROSPECTIVE|||||||
34064734|NCT05427747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33861939|NCT05545033|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single centre, single-arm pilot study||||
33861940|NCT01431326|||COHORT||PROSPECTIVE|||||||
33861941|NCT03661164|||COHORT||RETROSPECTIVE|||||||
33861942|NCT01033617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Stem cell or placebo|t|t|t|t
33961932|NCT00732342|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33961933|NCT06093594|||CASE_CROSSOVER||PROSPECTIVE|||||||
33961934|NCT02858518|||COHORT||PROSPECTIVE|||||||
33961935|NCT05207579|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33961936|NCT02995265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33961937|NCT01651494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961938|NCT05180630|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33961939|NCT00864409|RANDOMIZED|||TREATMENT||TRIPLE|||t|f|t|t
33961940|NCT02717936|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064735|NCT03709121|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34064736|NCT03442699|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive up to 10 daily sessions of CBT (depending on length of stay), for about an hour each day. During this time the therapist will work with participants to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.||||
34064737|NCT00019422||||TREATMENT||||||||
34064738|NCT00323700|||COHORT||PROSPECTIVE|||||||
34064739|NCT06285136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064740|NCT03737630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064741|NCT01092637|||COHORT||CROSS_SECTIONAL|||||||
34064742|NCT05956522|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064743|NCT00204477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Research pharmacist dispensed blinded assigned sachets according to a pre-generated randomization list. Pharmacists were blinded to all other aspects of the research protocols.~Subjects, investigators, research staff, and statisticians were all blinded to treatment assignment."|Randomized, double-blind, placebo controlled, 2 parallel groups|t|t|t|t
34064744|NCT01553435|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34064745|NCT00030680||||TREATMENT||||||||
34064746|NCT00795769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064747|NCT05804461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064748|NCT00803309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064749|NCT03229967|||COHORT||PROSPECTIVE|||||||
34064750|NCT01245816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064751|NCT05847296|||COHORT||PROSPECTIVE|||||||
34064752|NCT05172791|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34064753|NCT05649943|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized||||
34064754|NCT00463840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064755|NCT02926417|||COHORT||PROSPECTIVE|||||||
34064756|NCT02804867|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064757|NCT01715142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064758|NCT00438256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861943|NCT04160143|NA|SINGLE_GROUP||TREATMENT||NONE||This innovative study is an open-label unblinded single-arm prospective trial evaluating induction SBRT followed by pulmonary metastasectomy. As a Phase 2 trial, the primary purpose is to assess the efficacy of SBRT on metastatic tumor viability and the safety of SBRT as induction treatment prior to surgery||||
33861944|NCT04537273|||COHORT||RETROSPECTIVE|||||||
33861945|NCT03948217|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patients are unaware of the type of Circadian lighting regimen that is provided|Single blind, cross-over, controlled|t|t|f|f
33861946|NCT05542485|||OTHER||PROSPECTIVE|||||||
33861947|NCT05117697|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Parallel Assignment~A comparative,randomized, prospective, single-center clinical study. Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy."||||
33861948|NCT02734823|||CASE_ONLY||PROSPECTIVE|||||||
33861949|NCT04370288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861950|NCT06286228|||COHORT||PROSPECTIVE|||||||
33861951|NCT03175965|||COHORT||PROSPECTIVE|||||||
33861952|NCT00555555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861953|NCT00315081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33861954|NCT06466811|||COHORT||PROSPECTIVE|||||||
33861955|NCT01717963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861956|NCT02722174|||COHORT||PROSPECTIVE|||||||
33961941|NCT04976387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers will not be blinded during the process of recruitment of patients due to necessity of prescribing specific medications. Researchers will be blinded during outcome assessment and data analysis.|Patients will be randomized to one of three groups prior to surgery. Patients will be prescribed Hydrocodone/acetaminophen, Ibuprofen, and/or Acetaminophen. Patients assigned to treatment Group 1 will take the opioid medication for initial pain control followed by Ibuprofen if pain is not adequately controlled. Group 2 patients will take Ibuprofen for initial pain control followed by the opioid medication if pain is not adequately controlled. Group 3 patients will take Ibuprofen for initial pain control followed by Acetaminophen if pain is not adequately controlled.|f|f|t|t
33961942|NCT01839565|||CASE_ONLY||PROSPECTIVE|||||||
33961943|NCT00187057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961944|NCT02754180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961945|NCT05371483|||CASE_CROSSOVER||PROSPECTIVE|||||||
33961946|NCT02962739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33961947|NCT01629693|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33961948|NCT02540720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33961949|NCT05459168|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study consists of multiple phases/aims, but within each phase/aim (excluding Aim 2 as this is just app development), there is a single group assignment. The intervention model layout described herein was the most appropriate method to describe each of the involved phases and steps.||||
33961950|NCT06520241|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961951|NCT01416298|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961952|NCT04572399|NA|SINGLE_GROUP||TREATMENT||NONE||Intubated patients with confirmed SARS-CoV-2 will receive UV light treatment to potentially reduce bacterial and viral burden.||||
33961953|NCT05958459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33961954|NCT05563025|||COHORT||RETROSPECTIVE|||||||
33961955|NCT03368547|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33961956|NCT00938418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064759|NCT02009371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064760|NCT05022628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751179|NCT05618795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751180|NCT03235167|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33751181|NCT05582720|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34064761|NCT04660773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064762|NCT01262248|||COHORT||PROSPECTIVE|||||||
33751182|NCT05403866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751183|NCT01252173|||||PROSPECTIVE|||||||
33861957|NCT02486809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861958|NCT01436071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961957|NCT02083588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961958|NCT01333631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33961959|NCT04316949|||COHORT||RETROSPECTIVE|||||||
33961960|NCT03091400|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33961961|NCT05048771|||CASE_ONLY||PROSPECTIVE|||||||
33961962|NCT00929864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33961963|NCT01099280|RANDOMIZED|PARALLEL||||NONE||||||
33961964|NCT05554874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Real or sham pulsed electromagnetic fields|f|f|f|t
33961965|NCT06280027|||COHORT||CROSS_SECTIONAL|||||||
33961966|NCT00634192||CROSSOVER||TREATMENT||NONE||||||
33961967|NCT04742725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961968|NCT05724316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One arm will receive vitamin D supplements, the other arm will not receive supplements.||||
34064763|NCT00426972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064764|NCT03756818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150411|NCT05071430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An unblinded pharmacist will be utilized to assign bottles to each patient using an IVRS central randomization system. Study treatment or placebo will be dispensed to patients in blinded bottles.|A sample size of 80 patients is planned for the study to be randomized in a 1:1 ratio of active to control.|t|t|t|f
34150412|NCT04969536|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind|60 minutes of moderate (65% of VO2max) endurance exercise with either a branched chain amino acid supplement or a placebo consumed immediately prior to and 30 minutes into the exercise bout.|t|f|t|f
34150413|NCT03972410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150414|NCT01113346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150415|NCT00439881|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150416|NCT05885737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174479|NCT03796728|NA|SINGLE_GROUP||OTHER||NONE||All participants will sign an informed consent form, and begin at the Screening Visit. Filler treatment (Juvéderm® VOLIFT™ with Lidocaine) will be performed at (Initial Treatment visit) and data will be collected at this visit for all relevant parameters as per the Schedule of Study Procedures, Treatments and Assessments. Fourteen days after the initial treatment, participants will return to the clinic and the Investigator will assess whether a Touch-up treatment is to be performed at this visit. Follow up visits will occur at Day 30 and 3, 6, and 12 months after the last treatment.||||
34174480|NCT05381948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174481|NCT05101317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174482|NCT02438163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34174483|NCT02731638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34174484|NCT05657223|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33861959|NCT05592067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcomes Assessor are blind.|"Patients will be randomly divided into 3 groups.Group A (kinesio taping with I tape technique + exercise to tendon and median nerve slipping), Group B (kinesio taping with button hole technique + exercise to tendon and median nerve slipping) and They will be divided into Group C (tendon and median nerve gliding exercise).~In the first group, kinesio taping with the I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.~In the second group, kinesio taping with the Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.~In the third group, exercises will be taught to the patient and a total of 21 sessions will be applied once a day."|f|f|t|t
34174485|NCT05142787|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174486|NCT05317104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All outcomes and measurements are done by a blinded assessor.|30 esports players aged 18-25, playing in the university esports team, will be included in the study.|t|f|t|t
34174487|NCT06670001|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34174488|NCT00980954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174489|NCT02365155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34174490|NCT05924022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Only the HBOT personnel will be aware of the treatment assignments; the rest of the research team and participants will be blinded to condition.|Participants will be randomized into 1 of 2 trial arms that will receive: 1) a 2-day medically-supervised full-dose HBOT treatment, or 2) a 2-day sub-therapeutic dose HBOT condition as a placebo control. Both groups will be receiving standard of care for addiction withdrawal symptoms, as managed and provided by their clinic physician and neither the full or sub-therapeutic HBOT dose are expected to affect their ongoing treatment. Updated to 3 arms 11/23/24: Participants will be randomized into one of three trial arms: (active arm of n = 12 in HBOT 100% oxygen and 2.0 ATA, active arm of n = 12 in HBOT 100% oxygen and 1.3 ATA, and sham arm of n = 12 in HBOT 21% oxygen and 1.3 ATA). All groups will be receiving standard of care for addiction withdrawal symptoms, as managed and provided by their clinic physician and neither the full or sub-therapeutic HBOT dose are expected to affect their ongoing treatment.|t|f|t|t
34174491|NCT04097678|RANDOMIZED|PARALLEL||OTHER||DOUBLE|This is a semi-blinded trial. Investigators performing the surgery will know whether or not a sponge is present but the investigators reviewing the images will not. Subjects will not be told which study group they are in.|This is a prospective, randomized study with two cohorts: one experimental and one control.|t|f|f|t
34174492|NCT04592874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861960|NCT05908955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861961|NCT00227188|||||PROSPECTIVE|||||||
33861962|NCT05535634|||CASE_ONLY||PROSPECTIVE|||||||
33861963|NCT05103696|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33861964|NCT01753154|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33861965|NCT03383549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33861966|NCT05279209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33861967|NCT02261038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064765|NCT05583045|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The masking is from the responsibility of the tea supplier which was asked to send the tea/placebo codified and only reveal the codification after the end of the trial.|"Participants will be divided into two groups (A or B):~A: Olive leaf tea + Lifestyle behavior change program B: Placebo tea + Lifestyle behavior change program"|t|t|t|t
34064766|NCT06289530|||COHORT||PROSPECTIVE|||||||
34174493|NCT06705517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessors, including the study neurologist and researchers analyzing biological samples, will be blinded to the allocation of the patients. Patients will be instructed to keep this information confidential during their neurological evaluations. Before data analysis, the dataset will be anonymized a second time to perform a blind data analysis, so also investigators will be partially blinded.|This is an interventional, non-pharmacological, superiority, randomized, controlled, single-center, masked study with two parallel groups.|f|f|f|t
34174494|NCT06538896|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention||||
34174495|NCT06603038|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34174496|NCT02014688|||COHORT||PROSPECTIVE|||||||
34174497|NCT02327546|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34174498|NCT02546167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174499|NCT03037996|||COHORT||PROSPECTIVE|||||||
34174500|NCT01034826|||CASE_ONLY||PROSPECTIVE|||||||
34174501|NCT05951114|||COHORT||PROSPECTIVE|||||||
34174502|NCT04133883|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34174503|NCT06601257|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174504|NCT03261648|||OTHER||PROSPECTIVE|||||||
33861968|NCT01920386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861969|NCT01866397|NA|SINGLE_GROUP||||NONE||||||
33861970|NCT03849443|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33861971|NCT02367326|||COHORT||PROSPECTIVE|||||||
33861972|NCT06054412|NA|SINGLE_GROUP||OTHER||NONE||||||
33961969|NCT05588375|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All participants received cases in independent clinics, and patients, attending physicians and nursing staff did not know the group assignment|This study used a quasi-experimental, two-group repeated measurement design, purposive sampling. The experimental group received the Home-based exercise with telemonitoring and control group according to regular nursing care.Both the experimental group and the control group were patients included in the case management of heart failure in the hospital. The experimental group received 59 cases who participated in remote home sports, and the control group received 59 cases who received routine care for heart failure case management. Data were collected at baseline (T0), post-tests will be conducted right after the intervention period (T1). Additionally, detraining effects will be measured 12 weeks after program cessation (T2).|t|f|f|f
33961970|NCT01716507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33861973|NCT00291174|||COHORT||PROSPECTIVE|||||||
33961971|NCT04296799|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34174505|NCT04523688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174506|NCT04690829|||OTHER||RETROSPECTIVE|||||||
34174507|NCT04175223|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174508|NCT06705803|||COHORT||PROSPECTIVE|||||||
33861974|NCT02478723|||CASE_ONLY||PROSPECTIVE|||||||
33861975|NCT01109836|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33861976|NCT00046397||||TREATMENT||||||||
33861977|NCT01193881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861978|NCT04852263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33861979|NCT04817384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861980|NCT05158933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174509|NCT06255275|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174510|NCT04565158|||CASE_CONTROL||PROSPECTIVE|||||||
34174511|NCT04517513|||COHORT||OTHER|||||||
34174512|NCT00435409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174513|NCT05988645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment Traditional safety and performance study, following a single-center prospective and noncomparative.||||
34174514|NCT06697717|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34174515|NCT05531786|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174516|NCT02769923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174517|NCT04844814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861981|NCT02676856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861982|NCT05571046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33861983|NCT03187171|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized comparative outcomes study, in which all subjects who fit the inclusion and exclusion criteria and who agreed to be part of the study will be randomized to either Allograft or Cohere PEEK fusion group and will be followed for approximately 12 months following surgery according to the standard-of-care.||||
33861984|NCT02653300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33861985|NCT01775839|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33861986|NCT02030756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33861987|NCT06085911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial (RCT) comparing two intervention groups|f|f|f|t
33861988|NCT02746341|||COHORT||PROSPECTIVE|||||||
34174518|NCT04721860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Stratified Randomization|f|f|f|t
34174519|NCT05334368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double-blind study with respect to allocation of depemokimab or placebo to participants. All site staff, participants, and investigator will be blinded.|This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study.|t|t|t|t
34174520|NCT01723241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33861989|NCT06456450|||COHORT||PROSPECTIVE|||||||
34174521|NCT05959044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174522|NCT03977792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174523|NCT04392960|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33861990|NCT00931944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174524|NCT06282432|||CASE_ONLY||PROSPECTIVE|||||||
33861991|NCT02445196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174525|NCT06164951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174526|NCT06389396|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34174527|NCT06021483|||COHORT||PROSPECTIVE|||||||
34174528|NCT03827434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174529|NCT02624115|||COHORT||PROSPECTIVE|||||||
33861992|NCT04970043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174530|NCT06455228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33861993|NCT01569360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33861994|NCT00993915|||CASE_ONLY||PROSPECTIVE|||||||
33861995|NCT00324701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961972|NCT05827965|NA|SINGLE_GROUP||PREVENTION||NONE||before and after education and drug adjustement||||
33961973|NCT06566066|||CASE_ONLY||OTHER|||||||
33961974|NCT06568653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961975|NCT00002973||||TREATMENT||||||||
33961976|NCT05166473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|it was calculated that 80% power could be achieved in the 95% confidence December when at least 42 people (at least 21 people for each group) were taken into the study. In all tests, the statistical significance level was taken as p\<0.05.|Randomized controlled study|t|f|f|f
33961977|NCT03153631|||OTHER||PROSPECTIVE|||||||
33961978|NCT01906580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961979|NCT04291911|||COHORT||RETROSPECTIVE|||||||
33751184|NCT03239119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33861996|NCT00270478||||TREATMENT||||||||
33861997|NCT06052150|||COHORT||PROSPECTIVE|||||||
33861998|NCT00000138|RANDOMIZED|||TREATMENT||||||||
33861999|NCT05745454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961980|NCT01592227|RANDOMIZED|CROSSOVER||||NONE||||||
34174531|NCT04733768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174532|NCT06577896|||COHORT||PROSPECTIVE|||||||
34174533|NCT06525298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174534|NCT03207126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Women offered and received ultrasound guided biopsy||||
34174535|NCT00241384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174536|NCT03939546|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This is a single-center, open-label, prospective, cohort study. A prospective control cohort of 15 infants will initially be enrolled. Fifteen (15) infants will then be enrolled into the B. infantis cohort.||||
34174537|NCT03363373|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive cycles of GM-CSF and Naxitamab every 4 weeks up to a total of 101 weeks. Safety and efficacy will be investigated with short-term follow-up at minimum 4 weeks after last treatment and with long-term follow-up for up to 3 years after end of treatment visit.||||
34174538|NCT03633396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34174539|NCT01378364|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34174540|NCT00976274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174541|NCT06700733|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||All selected patients will receive maxillary complete dentures and mandibular screw-retained prosthesis either from PEEK or Titanium framework in a crossover design.|t|f|f|t
33862000|NCT00980681|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862001|NCT00667355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862002|NCT05780411|||COHORT||CROSS_SECTIONAL|||||||
33862003|NCT06171412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862004|NCT04679779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Control grouprecivedvDesigned occupational therapy programe including Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.~• study group will recieve Wii virtual reality games~1. Bowling~2. Frisbee~3. Basketball~4. Boxing"|t|t|t|t
33862005|NCT02347475|||COHORT||PROSPECTIVE|||||||
33961981|NCT06190899|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC. The study is comprised of two phases:~* Phase 1 Dose Finding (2 Parts)~  o Part 1: DLT evaluation and determination of tolerated doses~* Part 2: Determination of RP2D~* Phase 2 Dose Expansion"||||
33961982|NCT01702766||PARALLEL||PREVENTION||||||||
33961983|NCT01383954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961984|NCT05654857|||CASE_ONLY||CROSS_SECTIONAL|||||||
33961985|NCT02845102|NA|SINGLE_GROUP||OTHER||NONE||||||
33961986|NCT05863182|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster rct - will randomly assign 1/5 schools to serve as intervention school and 1/5 schools to serve as control school.||||
34064767|NCT02343380|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33751185|NCT01999049|||CASE_ONLY||PROSPECTIVE|||||||
33862006|NCT03247036|||COHORT||CROSS_SECTIONAL|||||||
33862007|NCT02410941|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174542|NCT00716677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174543|NCT06546163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34174544|NCT01612338|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33751186|NCT02371954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751187|NCT00377949|||CASE_ONLY||PROSPECTIVE|||||||
33862008|NCT05955404|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.||||
34174545|NCT04609098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blind randomised controlled trial. The treating physician and staff involved with assessing all laboratory outcomes of the study are blinded, but no placebo will be used. The study pharmacist will be unblinded and responsible for randomisation and treatment administration.||f|f|f|t
34174546|NCT03590444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174547|NCT01026545|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34174548|NCT05602298|||COHORT||PROSPECTIVE|||||||
34174549|NCT05975723|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (outcomes assessor)||f|f|f|t
34174550|NCT05899257|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-group pre-post design with a one-month follow-up||||
34174551|NCT04179552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174552|NCT06690658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174553|NCT01853020|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33751188|NCT04973865|||OTHER||PROSPECTIVE|||||||
33751189|NCT05066724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862009|NCT05149703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33862010|NCT05662410|NA|SINGLE_GROUP||TREATMENT||NONE||Three monthly injections of intravitreal aflibercept during the first 3 months.||||
33862011|NCT00878852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174554|NCT01395797|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862012|NCT05053477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862013|NCT04537169|||CASE_ONLY||PROSPECTIVE|||||||
33862014|NCT02075411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862015|NCT04536584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862016|NCT01407172|||COHORT||CROSS_SECTIONAL|||||||
33862017|NCT04640844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34064768|NCT05821465|||COHORT||PROSPECTIVE|||||||
34174555|NCT05690841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174556|NCT00079469|RANDOMIZED|||PREVENTION||||||||
34174557|NCT03188094|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34174558|NCT04114006|||COHORT||PROSPECTIVE|||||||
33862018|NCT02367235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862019|NCT01859078|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174559|NCT05062655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174560|NCT03985761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174561|NCT01489540|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174562|NCT05716958|||COHORT||RETROSPECTIVE|||||||
34174563|NCT06594393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intra-subject control|t|t|t|t
34174564|NCT02135861|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174565|NCT00157885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174566|NCT02686372|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34174567|NCT06487572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862020|NCT06138964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862021|NCT05806125|||COHORT||RETROSPECTIVE|||||||
33862022|NCT04828694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862023|NCT02383589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862024|NCT00301158||||PREVENTION||||||||
33862025|NCT05453019|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862026|NCT04249414|||COHORT||PROSPECTIVE|||||||
33862027|NCT04009317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862028|NCT00908063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862029|NCT05042518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33862030|NCT04257565|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled clinical trial||||
33862031|NCT03998293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862032|NCT01725048|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862033|NCT00611195|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34064769|NCT01022216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064770|NCT02703818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064771|NCT03851978|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34064772|NCT01158014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064773|NCT02578940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||PET Imaging study||||
34064774|NCT06511115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34174568|NCT02647125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862034|NCT02217189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862035|NCT03165318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862036|NCT06012383|||CASE_ONLY||PROSPECTIVE|||||||
33862037|NCT06445309|||OTHER||CROSS_SECTIONAL|||||||
33862038|NCT02427152|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174569|NCT05555290|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The study will enroll 17 participants in Part 1 and 88 participants in Part 2|t|t|t|t
34174570|NCT01650506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174571|NCT06309940|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34174572|NCT05286814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174573|NCT05331339|||COHORT||RETROSPECTIVE|||||||
34174574|NCT06156020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174575|NCT05950464|NA|SEQUENTIAL||TREATMENT||NONE||||||
34174576|NCT04377100|||COHORT||CROSS_SECTIONAL|||||||
34174577|NCT00500617|||OTHER||PROSPECTIVE|||||||
34174578|NCT02803788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174579|NCT00627393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174580|NCT06485635|||COHORT||RETROSPECTIVE|||||||
34174581|NCT04719390|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Microrandomized trial||||
34174582|NCT06705595|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Statisticians:~The statisticians analyzing the data will remain blinded to the group assignments during the initial stages of analysis to avoid any bias in the interpretation of the results. Unblinding will occur only after the data is fully collected and the analysis plan is in place.~Data Collection Staff:~The staff collecting data in the operating room, recovery room, and patient wards (e.g., monitoring vital signs and postoperative complications) will be blinded to the specific treatment group of the patient. This minimizes any potential bias during the collection of clinical data."||t|f|f|t
34174583|NCT01874639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174584|NCT06598969|NA|SINGLE_GROUP||OTHER||NONE||To evaluate the antileukemic activity and safety/tolerability of the TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia||||
34174585|NCT05081882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34174586|NCT04333914|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* COHORT 1 : Patients with mild symptoms or asymptomatic~* COHORT 2 : Patients with moderate/severe symptoms"||||
34174587|NCT03858049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064775|NCT03944993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is designed as a double-blinded, randomised, controlled pilot study. As a pilot study, 33 healthy adults will be enrolled and randomised into the intervention or sham arm at 2:1 ratio. Within the intervention arm, 50% of the participants will receive PEMFs in the non-dominant leg and the remaining 50% will receive intervention in the dominant leg (n = 11, 11). There are no restrictions based on race or gender.|t|t|t|f
34174588|NCT06491030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174589|NCT01102686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174590|NCT04684719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174591|NCT06655220|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Two-way crossover trial||||
34174592|NCT05014776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174593|NCT03467958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174594|NCT03157830|||COHORT||PROSPECTIVE|||||||
34174595|NCT05979064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174596|NCT06706024|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a quasi-experimental study with a single group pretest-posttest design.||||
34174597|NCT02558894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174598|NCT04855552|NA|SINGLE_GROUP||TREATMENT||NONE|12 patients (and possibly up to 20) (2 telehealth groups with at least 6 participants; 1 group leader per group)|Single-arm longitudinal group to examine patient-reported outcomes, body mass, and mammographic density changes pre-and post-intervention.||||
34174599|NCT05250505|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34174600|NCT00882440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174601|NCT04698343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174602|NCT06190093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174603|NCT05317403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174604|NCT05615818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174605|NCT04974671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751190|NCT05521516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigational Drug Service will create the randomization tables and provide the investigators with the appropriate device (active or sham), leaving all participants, investigators, and the statistician masked to treatment group assignment.|Parallel Assignment: Randomized, Triple-Masked, Placebo-Controlled, Parallel-Arm Human Subjects Clinical Trial|t|t|t|t
33751191|NCT02738866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751192|NCT05646667|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33751193|NCT06166927|||COHORT||PROSPECTIVE|||||||
33751194|NCT05842408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751195|NCT05844813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a prospective non-randomized controlled study. After meeting the inclusion and exclusion criteria, patients will be allocated either into the Surgery-only Group or the Neoadjuvant therapy group. Patients in the surgery-only group will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy, while in the neoadjuvant therapy group, patients will receive neoadjuvant chemotherapy combined with target treatment for three circles followed by the sarcoma resectional surgeries.||||
33751196|NCT00771810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33751197|NCT03732183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33751198|NCT02212756|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33751199|NCT04068337|||COHORT||RETROSPECTIVE|||||||
33751200|NCT06034587|||COHORT||PROSPECTIVE|||||||
33751201|NCT04777500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33751202|NCT00840853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751203|NCT03127865|||COHORT||PROSPECTIVE|||||||
33751204|NCT05099042|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33751205|NCT01211925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751206|NCT02942472|||CASE_ONLY||PROSPECTIVE|||||||
33751207|NCT00233077|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33751208|NCT06733038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751209|NCT06128668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33751210|NCT01785966|RANDOMIZED|PARALLEL||||NONE||||||
33751211|NCT05601102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicentre Randomized (1:1), waitlist Controlled, parallel-group Trial (RCT).|t|f|f|f
33751212|NCT04310995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751213|NCT00322348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751214|NCT01261338|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33862039|NCT02202551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862040|NCT06090526|||CASE_CONTROL||PROSPECTIVE|||||||
33862041|NCT05236933|||COHORT||PROSPECTIVE|||||||
33862042|NCT04638517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862043|NCT06371287|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34174606|NCT01598935|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34174607|NCT03924622|RANDOMIZED|PARALLEL||OTHER||NONE||Stratified randomized control trial with subjects assigned to either the simulated aeromedical evacuation (standard mattress or vacuum spine board) or Prolonged Field Care arms with or without the intervention. Stratification will be based on body fat percentage. Study does not involve FDA-regulated drug.||||
34174608|NCT06580496|NA|SINGLE_GROUP||TREATMENT||NONE||As a single arm study all participants will receive a game-based biofeedback intervention with offline CBT-based materials. They are encouraged to engage with the intervention in an entirely self-directed manner. Study analyses will seek to understand the impact of differential engagement with the intervention (offscreen materials + biofeedback vs. biofeedback alone) in a post-hoc manner.||||
34174609|NCT05292326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862044|NCT03716050|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33862045|NCT02743416|||COHORT||PROSPECTIVE|||||||
33862046|NCT06260189|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862047|NCT05128825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862048|NCT00288977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862049|NCT02052063|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862050|NCT04910503|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34064776|NCT01187264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064777|NCT03646487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862051|NCT05761730|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants will be allocated to two groups randomly the aim of this randomized clinical study is to assess the effect of dexamethasone on the reduction of pain in mandibular molars with irreversible pulpitis, without performing conventional pulpotomy ( intervention group ) in comparison to pain following pulpotomy ( control group )||||
33862052|NCT04553510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862053|NCT04907110|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and Investigator will be blinded for the study material (i.e. NR or placebo).|The present study is a randomized, double-blinded, placebo-controlled double arm longitudinal intervention study in a pre and post design.|t|f|t|f
33862054|NCT05218681|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33862055|NCT05606887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Given the nature of the intervention (i.e., participants in the intervention arm receiving a wearable device and investigators and analysts reviewing biometric data for this group), the study will not be masked.|Participants will be assigned to the intervention arm (with wearable devices or EMAs) or control (survey-only) in parallel and will remain in their assigned arm throughout their participation in the survey.||||
33862056|NCT01840891|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33862057|NCT06246617|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot||||
33862058|NCT03051581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862059|NCT03697434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33961987|NCT06265961|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"Mixed methods research is defined as a research approach used in the field of health, social and behavioral sciences in which the researcher collects both quantitative and qualitative data to understand the research problems, integrates two data sets, and then draws conclusions using the advantages of integrating these two data sets. The study will be carried out in an embedded intervention research model using a combination design (Quantitative + Qualitative) in the intervention design, which is one of the advanced mixed methods designs. In the embedded mixed research model where the quantitative approach is dominant, randomized controlled research and qualitative research will be conducted simultaneously."||||
33961988|NCT04000373|NA|SINGLE_GROUP||TREATMENT||NONE||uncontrolled pre-post intervention study of the use of the Ekso GT™exoskeleton in gait training in the MS population||||
33961989|NCT00763269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33961990|NCT01274273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33961991|NCT01374880|||COHORT||PROSPECTIVE|||||||
33961992|NCT05084807|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Study Type: descriptive cross-sectional study, prospective. Estimated enrollment: 20 individuals. Estimated duration of the project: 12 months.||||
33961993|NCT00866528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33961994|NCT02034617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33961995|NCT02255734|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33961996|NCT06500039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The research was planned as a randomized controlled prospective study. It will be carried out in two groups.|t|f|t|f
33961997|NCT01128153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33961998|NCT03213080|||COHORT||PROSPECTIVE|||||||
33961999|NCT06301256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962000|NCT01467869|||CASE_CONTROL||PROSPECTIVE|||||||
33962001|NCT06416761|||OTHER||OTHER|||||||
33962002|NCT00740480|||CASE_ONLY||PROSPECTIVE|||||||
33962003|NCT00074009||||TREATMENT||NONE||||||
33962004|NCT02634567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962005|NCT05305378|||COHORT||PROSPECTIVE|||||||
33962006|NCT03975088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064778|NCT05606770|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34064779|NCT05929248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064780|NCT05772507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064781|NCT03715387|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|Patients will receive a container for each cheek where the contents will be randomized between the study ointment and the control ointment. Only one investigator will have knowledge of the contents. The care providor, patient, and assessor will all be blinded.|Patients will serve as their own self matched controls with one study cheek and one control cheek.|t|t|f|t
34064782|NCT00047788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064783|NCT03721211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064784|NCT02334098|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|all participants and research assistants are blind to condition for the two fruit juice groups|3 parallel groups: (1) omega-3 + fruit juice (2) fruit juice only (3) controls (no drink).|t|t|t|t
34064785|NCT05197205|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34064786|NCT00004982|RANDOMIZED|||TREATMENT||NONE||||||
34064787|NCT04538287|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34064788|NCT01140828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174610|NCT05272683|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174611|NCT06005688|NA|SEQUENTIAL||OTHER||NONE||||||
34174612|NCT06220032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174613|NCT04390880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174614|NCT05493891|||COHORT||RETROSPECTIVE|||||||
34174615|NCT05457790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174616|NCT04986007|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized parallel clinical trial of digital cognitive behavioral therapy for insomnia versus waitlist control with subsequent crossover to digital cognitive behavioral therapy for insomnia.||||
34174617|NCT04866810|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33751215|NCT05717868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751216|NCT04320927|||OTHER||RETROSPECTIVE|||||||
33751217|NCT05091710|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174618|NCT04058938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study participants were not informed of randomization, and providers involved in patient care, consent, and postoperative questionnaire administration were blinded.|All study participants received a study folder with information about the study and consent; the instrument was included in this folder for the intervention group. The control group received standard of care, including standard patient counseling from the surgical teams. In conjunction with oncologic psychology and plastic surgery, an instrument was developed to be provided as a single-paged paper handout to the intervention group. The instrument included information about expectations for pain control, information about the pain scale, and examples of opioid and adjunct medications which may be used as part of a multi-modal approach to pain control during the perioperative period.|t|t|t|f
34174619|NCT06092749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33751218|NCT01639885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751219|NCT04203693|||CASE_ONLY||PROSPECTIVE|||||||
33751220|NCT06733064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33962007|NCT05761015|NA|SINGLE_GROUP||TREATMENT||NONE||cohort||||
33962008|NCT05912179|||COHORT||PROSPECTIVE|||||||
34174620|NCT06594757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34174621|NCT03111303|||COHORT||RETROSPECTIVE|||||||
34174622|NCT03310138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962009|NCT03405701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174623|NCT01704027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174624|NCT04657679|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34174625|NCT05845385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174626|NCT04467983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174627|NCT04861597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174628|NCT06338774|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Six week parallel group intervention, followed by a 12 week exercise program.|t|f|f|t
34174629|NCT06560385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Attending physicians, investigators performing assessments in clinic visits and study participants will be blinded to the group allocation until study completion.|All subjects will be randomized into two group to take BLHK03 or active placebo (Vitamin B7) daily from the start of the chemotherapy cycle to 2 months after the final dose of chemotherapy.|t|f|t|f
34174630|NCT04251130|||COHORT||PROSPECTIVE|||||||
34174631|NCT04921436|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the first patient gets into the group of preventive therapy, the next one does not get into the group, and so on (1:1)|In group I, antibiotics-inhibitors of microbial metabolism are used in the perioperative period and the next 2 postoperative days The second group uses standard antibiotic prophylaxis|t|f|f|f
34174632|NCT05687058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-center, non-randomized, two-arm intervention study||||
34174633|NCT06285591|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34174634|NCT02739230||PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34174635|NCT06026592|||COHORT||PROSPECTIVE|||||||
34174636|NCT05978622|||COHORT||PROSPECTIVE|||||||
34174637|NCT05332288|||CASE_ONLY||PROSPECTIVE|||||||
34174638|NCT03770260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174639|NCT06555068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174640|NCT03655340|||COHORT||PROSPECTIVE|||||||
34174641|NCT06520787|||COHORT||PROSPECTIVE|||||||
34174642|NCT04737512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174643|NCT00006359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174644|NCT01033981|||COHORT||PROSPECTIVE|||||||
34174645|NCT04648033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Time-to-Event Continual Reassessment Method to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC||||
34174646|NCT03611738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174647|NCT05961553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34174648|NCT06453148|||COHORT||PROSPECTIVE|||||||
34174649|NCT04242355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174650|NCT05762679|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33751221|NCT06462508|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751222|NCT05261152|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33751223|NCT02405520|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33751224|NCT03724643|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Prospective randomized controlled trial|t|t|t|t
33751225|NCT05736848|||OTHER||RETROSPECTIVE|||||||
33751226|NCT00990834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751227|NCT06268574|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33751228|NCT05311657|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33962010|NCT05190640|NA|SINGLE_GROUP||OTHER||NONE||||||
33962011|NCT04309955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962012|NCT06232707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962013|NCT02738489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962014|NCT00842894|||COHORT||PROSPECTIVE|||||||
33962015|NCT00913861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962016|NCT00646178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962017|NCT01272739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962018|NCT00096200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962019|NCT03799094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962020|NCT00741520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33962021|NCT04098159|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962022|NCT02200614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862060|NCT03750383|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||2-Part Single Group study||||
33862061|NCT00752687|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33862062|NCT01233869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862063|NCT03548987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33862064|NCT01338129|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33862065|NCT05355025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomisation system will generate an email containing details of arm allocation which will be sent to the trial manager. The rest of the research team who will be blind to randomisation will only receive an email stating that a participant has been randomised. The treatment to which a participant is assigned will be determined by a computer generated pseudo-random code using random permuted blocks of varying size, created by the web developers and held on a secure server. Participants will be allocated with equal probability to each treatment arm and stratified by site (GP practice). Only the trial coordinator, or their nominee, will have password access to the randomisation data. Participants will not be blind to treatment group.~Arm allocation will remain concealed to the research team until recruitment and follow up are complete. The trial coordinator will not be blind to allocation."|Single blind, parallel-arm, randomised controlled trial|f|f|t|t
33962023|NCT03526796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962024|NCT04682561|NA|SINGLE_GROUP||TREATMENT||NONE||3 month, within-subjects longitudinal study, with each participant receiving 8 weekly sessions of the STEP psychotherapy intervention designed to help mitigate the effects of stress and trauma on their ability to provide patient care.||||
34174651|NCT04728958|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will only be aware of the arm they are allocated to and not the other arms available. They will also be unaware as to whether this is a treatment arm or the comparator control|"T-tests compare the mean differences between groups split across the two IVs (intervention \& time), due to the between factors and within factors levels of the two IVs.~Descriptive Statistics \& t-tests will be used to compare and assess cumulative gratitude week-by-week"|t|f|f|f
33962025|NCT00826722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962026|NCT02747251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962027|NCT04580524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962028|NCT02016755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962029|NCT06564649|||COHORT||PROSPECTIVE|||||||
33962030|NCT02108366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962031|NCT05003167|NA|SINGLE_GROUP||TREATMENT||NONE||All participants enrolled will receive the intervention.||||
33962032|NCT00898742|||CASE_ONLY||RETROSPECTIVE|||||||
33962033|NCT02639507|||CASE_ONLY||PROSPECTIVE|||||||
33962034|NCT04794400|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33962035|NCT05478603|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33962036|NCT03607656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962037|NCT02593084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33962038|NCT05110430|||COHORT||RETROSPECTIVE|||||||
34174652|NCT02647281|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33962039|NCT06310473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962040|NCT04330482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A full-scale randomized, controlled trial: 20 participants will be randomized to receive a tablet pre-loaded with a list of internet links relevant to dementia caregiving and 20 participants will be randomized to receive a tablet pre-loaded with the CARE-Well App. Both groups will be instructed to use their tablets at least 4 times per week for 3 months.|f|f|f|t
33962041|NCT00332345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34174653|NCT04489316|NON_RANDOMIZED|PARALLEL||OTHER||NONE||There will be an intervention group that receives 3 sessions in narrative medicine, and a control group that will receive the standard curriculum||||
33962042|NCT00085722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962043|NCT00984828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962044|NCT04256057||SEQUENTIAL||DIAGNOSTIC||NONE||||||
34174654|NCT03158844|||COHORT||PROSPECTIVE|||||||
34174655|NCT06703307|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174656|NCT06704841|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174657|NCT05216016|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33862066|NCT00564005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862067|NCT00279110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962045|NCT01385501|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33962046|NCT01573494|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962047|NCT02963909|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33962048|NCT01117714|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34064789|NCT03372642|||COHORT||CROSS_SECTIONAL|||||||
34064790|NCT01652625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064791|NCT01631838|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34064792|NCT03985189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174658|NCT02588690|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34174659|NCT06706180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know that there are two motivational conditions. All outcomes are self-reported.||t|f|f|f
34174660|NCT05992883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After enrollment and completion of the initial clinical evaluation, patients will undergo the injection procedure while blinded to the medication they receive. The injecting physician will also be blinded to the medication being administered.|This trial will be a single center, comparative, randomized (1:1 ratio), prospective, double-blind trial with two groups evaluated concurrently. One group will be given triamcinolone injections while the second, experimental group will receive ketorolac injections.|t|t|f|f
34174661|NCT05325125|||COHORT||PROSPECTIVE|||||||
34174662|NCT03858985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The study staff and principle investigator will be blinded to treatment and therefore this study is considered randomized and double blinded.|A sham and active non-invasive vagus nerve stimulator (nVNS) will be used. Both sham and active produce reliable sensation on subject skin over the cervical neck area. The sham device is identical in appearance to the nVNS device. Both devices carry out stimulation for the exact same time period, approximately 2 minutes. Subjects are assigned to sham and nVNS device therapy given once daily for 1 week.|t|t|t|t
34174663|NCT05684536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862068|NCT03661125|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34174664|NCT02019966|||COHORT||PROSPECTIVE|||||||
34174665|NCT04902053|||COHORT||PROSPECTIVE|||||||
34174666|NCT04335656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Double-blind, placebo-controlled, 2:1 randomly assigned|t|t|t|t
34174667|NCT06704438|||CASE_CONTROL||PROSPECTIVE|||||||
34174668|NCT04448964|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34174669|NCT03027427|||CASE_ONLY||PROSPECTIVE|||||||
34174670|NCT03965130|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will participate in two studies: one without and one with a 3 hour infusion of glucagon during the PINTA study||||
34174671|NCT02188264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174672|NCT06159361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174673|NCT00038753||||DIAGNOSTIC||||||||
34174674|NCT06705972|||CASE_ONLY||PROSPECTIVE|||||||
34174675|NCT04482179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The individual administering TMS will keep the master file of subject assignments, but all other individuals in contact with the subject or their data will be unaware of group assignment. Participants will not be informed of their assignment to active or sham status.|Participants will be randomized to either TMS or sham TMS in a 2:1 allocation ratio.|t|t|t|t
34174676|NCT01612351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174677|NCT05614492|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel: Participants will be assigned to one of three groups in parallel for the duration of the study.||||
34174678|NCT04677647|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174679|NCT04494256|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34064793|NCT00727987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174680|NCT06009653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34174681|NCT02317328|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174682|NCT06699979|||COHORT||PROSPECTIVE|||||||
33751229|NCT01229761|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33751230|NCT06731959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751231|NCT00436657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751232|NCT05095818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33862069|NCT03513510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174683|NCT03685760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and outcomes assessor are masked as well as all investigators except one co-investigator.|Three Group Randomized Controlled Trial|t|f|f|t
34174684|NCT05506540|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34174685|NCT06097221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751233|NCT01992003|||COHORT||PROSPECTIVE|||||||
33751234|NCT06579716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862070|NCT04226833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862071|NCT03475810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862072|NCT00234494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751235|NCT01311960|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33893818|NCT06205030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Anti-diabetic herbal and placebo syrups with the same color, shape, and box but different codes in two groups A and B are employed. After enrollment, each patient is allocated a code. Patients, researchers, and physicians who collect information in this study, assess outcomes, and analyze data for the study are blinded to the assigned treatment (anti-diabetic herbal or placebo) so that all patients are evaluated using their specific assigned code and treatment groups A or B.|All the volunteers who meet the entry criteria were directed to the laboratory so that biochemical tests can be performed on them before taking the drug. Volunteers are asked to take the received medicine three times a day after food. they will be divided into two groups by a person outside the research team, one group will drink herbal syrup and the other group will receive a placebo. A placebo with the same appearance as herbal syrup will drink nectar. On a weekly basis, the researcher will make phone calls with the applicants and, while reminding and recording the amount of herbal syrup consumed by drinking nectar, will also ask about the possible side effects of consuming herbal syrup drinking nectar. Then, at the end of the six week, the patient was asked to visit the clinic for a final evaluation.|t|t|t|f
33962049|NCT05027373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174686|NCT06586593|||CASE_ONLY||RETROSPECTIVE|||||||
33862073|NCT03234062|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|Participant dietary arm assignment is randomized by a randomization plan created by the study coordinator at www.randomization.com. Each of the 3 hormonal related demographic groups (male, premenopausal females, and postmenopausal females) will have a list of the same order of diets created by the randomizer. Each participant will be assigned upon entry into the study into the next open diet for their group as ordered by the randomizer. No one collecting or processing data will be informed of the choline levels the participant is experiencing in their dietary arms at any given time to attempt to eliminate bias and ensure appropriate data collection. All staff who interact with participants or who are handling samples/data, will not be informed of the code linking dietary choline levels to diet order.|Healthy volunteers (n=20), will consume meals, provided by the investigator, in two week intervals with 3 different levels of choline (Cho). Participants will receive 100% of the recommended daily intake (RDI) of Cho (550 mg Cho/day); 50% of the RDI of Cho (275mg/day); and 25% of the RDI of Cho (137.5 mg/day). The meal order will be randomly assigned and all participants will receive all diets at some point in the study. There will be a minimum of a two week washout between diet intervals where participants return to their regular diets. Both participants and researchers will be blinded to the diet order.|t|f|t|t
33862074|NCT00720655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862075|NCT04267718|RANDOMIZED|PARALLEL||PREVENTION||NONE||The experimental group includes a number of centres that will be randomized to systematically evaluate all eligible patients with the Padua and IMPROVE Bleeding scores within 48 h after hospitalization. The control group includes A number of centres will be randomized to the Control arm of the study, in which patients will be evaluated for their thrombotic and hemorrhagic risk according to clinical judgment only.||||
33862076|NCT01348386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862077|NCT04332601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33862078|NCT01284062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862079|NCT00418951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862080|NCT05292014|||COHORT||PROSPECTIVE|||||||
33862081|NCT02724124|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34174687|NCT04943744|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This STRING companion study will examine markers of esophageal inflammation during the COMBINE study using a minimally-invasive testing device, the esophageal string test (EST). If participants of COMBINE consent to this companion study, they will undergo an esophageal string test at the following time points in COMBINE:~* During screening, prior to week 0, which will be baseline for the STRING esophageal test~* Week 8, After the 8 weeks of treatment with omalizumab/placebo~* If dose-related gastrointestinal (GI) side effects occur during the week 10-32 treatment period (OIT and dupilumab/placebo)~* At Week 32, after 24 weeks of treatment with OIT and dupilumab or placebo"||||
33862082|NCT02819622|||CASE_CONTROL||PROSPECTIVE|||||||
33862083|NCT04295096|NA|SINGLE_GROUP||OTHER||NONE||||||
33862084|NCT04032730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862085|NCT05175612|||COHORT||PROSPECTIVE|||||||
33862086|NCT00041951|||CASE_CONTROL||PROSPECTIVE|||||||
33862087|NCT01432834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862088|NCT06475391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862089|NCT01978353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862090|NCT00350922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862091|NCT02274168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862092|NCT02155036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862093|NCT01762670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862094|NCT01452854|||COHORT||PROSPECTIVE|||||||
33862095|NCT05887453|||COHORT||PROSPECTIVE|||||||
33862096|NCT05398068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862097|NCT06006338|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33862098|NCT01978795|RANDOMIZED|PARALLEL||||NONE||||||
33862099|NCT00528255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862100|NCT03707509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862101|NCT01088191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862102|NCT04439071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862103|NCT02106754|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33862104|NCT05642182|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label||||
33862105|NCT03359213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862106|NCT03623581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862107|NCT00393328|RANDOMIZED|CROSSOVER||||NONE||||||
33862108|NCT03938077|NA|SINGLE_GROUP||PREVENTION||NONE||To examine the preliminary efficacy of the S4E intervention in improving the uptake of HIV self-testing immediately post-intervention and the feasibility(e.g., enrollment rates, eligibility) and acceptability (e.g., satisfaction) of S4E .||||
33862109|NCT06207357|||COHORT||RETROSPECTIVE|||||||
33962050|NCT04222556|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33962051|NCT03078530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962052|NCT00552617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962053|NCT05593783|||COHORT||PROSPECTIVE|||||||
34174688|NCT06220721|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
34174689|NCT06706037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study participants were made to exercise for 6 weeks, but they were not informed about the purpose of the study and evaluation.|prospective cross-sectional randomized controlled study|t|f|f|f
33962054|NCT00429091|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33962055|NCT01864525|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33862110|NCT00913250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33893819|NCT01320228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33962056|NCT03563235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962057|NCT00934622|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962058|NCT01456871|||COHORT||CROSS_SECTIONAL|||||||
33962059|NCT00000754||||TREATMENT||||||||
33962060|NCT01812291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751236|NCT05918068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33751237|NCT00206791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064794|NCT02634983|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34064795|NCT02962206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064796|NCT02771925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34064797|NCT03718195|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34064798|NCT00957905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751238|NCT05940532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751239|NCT00002411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751240|NCT06288906|||COHORT||OTHER|||||||
33751241|NCT03475550|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33751242|NCT01928719|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33751243|NCT05086133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants will be randomized into experimental group or sham group by a predetermined randomization table. The participants, care provider, investigators and outcomes assessor will be blind to the grouping. The physician who perform the TMS intervention is not blind to the grouping.|1 group for intervention and 1 group for sham stimulation|t|t|t|t
33751244|NCT00728390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751245|NCT06657937|||CASE_ONLY||PROSPECTIVE|||||||
33751246|NCT06139887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be blinded to treatment allocation and will remind the participant at each contact to not disclose their treatment status.|Participants are assigned to one of two groups in parallel: BESST plus standard care vs. standard care alone.|f|f|f|t
33751247|NCT03392714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751248|NCT05357612|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751249|NCT05858996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751250|NCT04884438|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064799|NCT02444039|||COHORT||PROSPECTIVE|||||||
34064800|NCT02425202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064801|NCT01621828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34064802|NCT03409120|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|"This study will run in conjunction with Biomarkers to Guide Directional DBS for Parkinson's Disease (ClinicalTrials.gov Identifier: NCT03353688). It is a double blinded study investigating the effectiveness of directional DBS leads in which participants and some investigators will have no knowledge of the DBS settings participants experience."|To measure the effects of directional DBS on dystonia, we will measure the change in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery versus preoperative baseline||||
34064803|NCT02914431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064804|NCT06730828|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Subjects undergoing cardiac surgery via complete median sternotomy|t|t|f|f
34064805|NCT03705845|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34174690|NCT06706713|NA|SINGLE_GROUP||TREATMENT||NONE||This study is designed with two cohorts, each comprising approximately 100 subjects. Subjects receive BEBT-109 capsules treatment with a dosage of 120mg bid (twice a day), and each 28-day period constitutes a cycle. In case of intolerance during the treatment, dose adjustments can be made according to the adjustment plan.||||
34174691|NCT01711554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174692|NCT03679247|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Groups of patients sharing the same PCP will be randomized. The groups will be stratified based on two factors (size of group and mean SBP). Within these strata, groups will be randomized to intervention and control arms in a 1:1 ratio. The intervention will be in place for 12 months and data collection will continue for an additional 6 months.||||
34174693|NCT05876689|||COHORT||PROSPECTIVE|||||||
34174694|NCT05499832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34174695|NCT06704308|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751251|NCT00211679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33751252|NCT00091481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34064806|NCT03887117|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34064807|NCT00871364|RANDOMIZED|CROSSOVER||||NONE||||||
34064808|NCT04029064|||COHORT||RETROSPECTIVE|||||||
34064809|NCT02097459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064810|NCT02249013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064811|NCT02477709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064812|NCT00220233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174696|NCT04652973|||OTHER||RETROSPECTIVE|||||||
34174697|NCT04838171|||CASE_ONLY||PROSPECTIVE|||||||
34174698|NCT05816395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174699|NCT03078114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34174700|NCT05656859|||CASE_ONLY||CROSS_SECTIONAL|||||||
34174701|NCT05083351|NA|SINGLE_GROUP||OTHER||NONE||||||
34174702|NCT06705725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174703|NCT04813588|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33751253|NCT01680848|||COHORT||CROSS_SECTIONAL|||||||
33751254|NCT03958370|||COHORT||PROSPECTIVE|||||||
33751255|NCT06073821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862111|NCT03575455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized block design using age and sex to randomize into 3 injured groups (40%, 60%, CON) and matching for 3 healthy groups (40%, 60%, CON)|f|f|f|t
34064813|NCT03379129|||COHORT||PROSPECTIVE|||||||
34064814|NCT02238938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064815|NCT02940873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150417|NCT03769311|NA|SINGLE_GROUP||TREATMENT||NONE||Single site, open label, window of opportunity study||||
34150418|NCT05549375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150419|NCT00865839|RANDOMIZED|CROSSOVER||||NONE||||||
34150420|NCT00076232|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34150421|NCT04429399|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34150422|NCT06194500|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34150423|NCT04378296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34150424|NCT02412059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33962061|NCT01954784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064816|NCT03057067|NA|SINGLE_GROUP||TREATMENT||NONE||All female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital are eligible for initial assessment||||
34064817|NCT00870506|RANDOMIZED|PARALLEL||||NONE||||||
34174704|NCT03661723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174705|NCT03096834|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34174706|NCT04151940|NA|SINGLE_GROUP||OTHER||NONE||||||
34174707|NCT04002141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34174708|NCT05821985|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34174709|NCT06705114|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34174710|NCT03184064|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Incomplete block cross-over design. Each participant receives placebo plus 3 out of 4 active treatments.|t|f|t|f
34174711|NCT00139152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174712|NCT03525444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174713|NCT05027321|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34174714|NCT05346120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind for subject and investigator. Only unblinded is the Cellular Therapy Core which manufactures, randomizes and dispenses MSCs|Single site, double blind, placebo-controlled, longitudinal study with a 1:1 ratio randomization|t|t|t|t
34174715|NCT06584188|NA|SEQUENTIAL||TREATMENT||NONE||||||
34174716|NCT04875286|||COHORT||CROSS_SECTIONAL|||||||
34174717|NCT02640586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174718|NCT02340026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174719|NCT01680341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174720|NCT03589859|||COHORT||CROSS_SECTIONAL|||||||
34174721|NCT01149993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174722|NCT03497936|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants randomly assigned to one of two arms (intervention, no intervention). Intervention participants receive Women's Stories. No intervention participants receive treatment as usual. All participants are administered a pretest and two post tests, and clinical records are examined for vaccination outcomes.||||
34174723|NCT03267277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174724|NCT00271674|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34174725|NCT02535312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174726|NCT03694158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, placebo controlled.|This is a genotype stratified, double-blind, randomized, placebo-controlled, parallel-group, phase IV clinical trial|t|t|t|t
34174727|NCT01935934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174728|NCT04803318|NA|SINGLE_GROUP||TREATMENT||NONE||To treat recurrent or refractory advanced solid tumors with multiple targeting drugs that inhibit several critical signaling pathways in cancer cells.||||
34174729|NCT06173687|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174730|NCT05147220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to maintain blinding, a double-dummy design will be used|Eligible participants will be randomized in a 1:1 ratio|t|f|t|f
34174731|NCT05137041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174732|NCT05622734|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174733|NCT05543603|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The hospital staff consecutively assigned each participant a code following the order from a previously randomly generated table.~The code were unknown to the personnel who processed the samples and to those that analyzed the data.~Participants were blinded by using identical tubes with the same volume for both mouthwashes and placebo."|A multicentre, randomized, blind, four-parallel-group, placebo-controlled trial|t|f|t|t
34174734|NCT02370329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174735|NCT03918304|||CASE_ONLY||PROSPECTIVE|||||||
34174736|NCT01052493|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This was a double-blind study|There were three dosing periods. Each subject (n=12) was randomised to receive up to two doses of placebo and/or up to three ascending doses of PP 1420 dosed as s.c. injection. During each dosing period eight subjects received active drug and four received placebo. Subjects could also be randomised to receive one further dose of PP 1420 or placebo, if needed, to explore an intermediate dose based upon a review of safety, tolerability, and PK data from the previous cohorts.|t|f|t|f
34174737|NCT05470504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174738|NCT00179621|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34174739|NCT05222984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174740|NCT02138617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174741|NCT06706401|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This trial is a 2\*2 factorial design, multicentric, randomised, Phase III study||||
34174742|NCT05914766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to either the intervention or enhanced usual care. Randomization will be stratified by treatment sequence (e.g., chemotherapy first vs. concurrent chemoradiation first).||||
34064818|NCT04183465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The members of the Clinical Event Committee will be blinded to randomization arm during all phases of the adjudications of the adverse events||f|f|f|t
34064819|NCT03173365|NA|SINGLE_GROUP||TREATMENT||NONE||The respective palm to be treated will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.||||
34064820|NCT00758134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064821|NCT00592592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064822|NCT03412006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064823|NCT00479297|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34064824|NCT01063231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064825|NCT04277767|||CASE_CONTROL||PROSPECTIVE|||||||
34064826|NCT04214405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174743|NCT06327100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174744|NCT04398771|||OTHER||PROSPECTIVE|||||||
34174745|NCT06706089|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34174746|NCT05607446|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34174747|NCT01414634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174748|NCT06602986|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34174749|NCT04257721|||COHORT||PROSPECTIVE|||||||
34174750|NCT02774759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174751|NCT01779830|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34174752|NCT04965142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Lung and liver transplant recipients will be randomized to home exercise group versus usual care group.||||
34174753|NCT02360579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174754|NCT06706232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174755|NCT06397781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174756|NCT05126563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Amber bags will be used to 'blind' the participant and investigator to which group the subject belongs in.|Randomized Double-Blind|t|t|t|f
34174757|NCT02726503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174758|NCT06374550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174759|NCT00667628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174760|NCT05907759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174761|NCT05741424|||OTHER||PROSPECTIVE|||||||
34174762|NCT00060528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174763|NCT04387448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multiple-ascending, placebo-controlled|t|f|t|f
34174764|NCT06602934|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34174765|NCT05214534|||COHORT||RETROSPECTIVE|||||||
34174766|NCT01568177|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174767|NCT01942928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34174768|NCT00119847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174769|NCT06600477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174770|NCT01654354|||CASE_CONTROL||PROSPECTIVE|||||||
34174771|NCT05208476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174772|NCT06071845|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Prospective multi-center case control study||||
34174773|NCT01881191|||CASE_CONTROL||PROSPECTIVE|||||||
34174774|NCT04290130|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34174775|NCT05544240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174776|NCT04586374|||CASE_CONTROL||PROSPECTIVE|||||||
34174777|NCT00644423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174778|NCT01305954|||CASE_ONLY||PROSPECTIVE|||||||
34174779|NCT05939414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174780|NCT01383928|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174781|NCT06593132|||COHORT||PROSPECTIVE|||||||
34174782|NCT05356702|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34174783|NCT05940402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174784|NCT05895786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sponsor, participants, site personnel, including the investigator with be masked to study treatment and will not know whether active study medication or placebo is being administered to participants.|"Randomized, double-blind, placebo-controlled, parallel-group study to assess whether the study medicine will work to lessen muscle weakness and skin symptoms in adults with active polymyositis (PM) or dermatomyositis (DM). Eligible participants are required to have active disease at the time of enrollment and are required to enter the study on protocol-permitted standard of care (SOC) background medication.~The study will be conducted in 2 parallel cohorts: Cohort 1 (DM) and Cohort 2 (PM)."|t|t|t|t
34174785|NCT05390073|||CASE_ONLY||CROSS_SECTIONAL|||||||
34174786|NCT05632640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174787|NCT05552027|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomly assigned to the intervention group or control group upon arrival at the study visit. Assignment status will not be concealed from the research assistants enrolling the participant, the participants themselves, or the rest of the study team.|This study is a randomized control trial with 2 arms (intervention and control). The intervention group will participate in a series of three safety seat misuse scenarios with the CCS system enabled, and participants in the control group will participate in the same series of three safety seat misuse scenarios without the CCS system. Misuse scenarios include insecure attachment of the seat to the vehicle, incorrect harness straps, and improper orientation of the safety seat. In each scenario, participants will be asked to identify and correct each error. Each participant will be randomly assigned to either the control or intervention group. Each participant will receive the same scenarios in the same order.|t|f|f|f
34174788|NCT03696160|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174789|NCT06705985|NA|SINGLE_GROUP||OTHER||NONE||"The objective of the clinical investigation is to evaluate the safety and performance of the LMP system and to demonstrate that the system is able to replace the function of the natural meniscus to provide pain relief in the lateral compartment of the meniscus-deficient knee. No formal hypothesis testing will be conducted, given the feasibility design of this clinical investigation.~Evaluation of safety of the LMP system will occur throughout the investigation with the reporting of the nature and frequency of all adverse events observed during the clinical investigation and their timing, severity and relatedness to the investigational device or procedure. In addition, the incidence and nature of secondary surgical intervention will be assessed."||||
34174790|NCT04952779|||COHORT||PROSPECTIVE|||||||
34174791|NCT05889156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174792|NCT05993689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174793|NCT03237624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34174794|NCT05695950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174795|NCT06005194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34174796|NCT06474286|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, pilot study, interventional study||||
34174797|NCT06410248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174798|NCT01394601|||COHORT||RETROSPECTIVE|||||||
34174799|NCT05625737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174800|NCT00706368|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751256|NCT03152526|NA|SINGLE_GROUP||TREATMENT||NONE||"In summary, the study will take place in two parts:~Stage 1: Enroll 24 patients with 1:1 randomization for NK cell processing (CD3-/CD19- versus CD3-/CD56+) Stage 2: Enroll an additional 17 patients using the optimal NK cell product identified during stage 1.~If neither product achieves success at the end of stage 1, the study will stop and the platform redesigned"||||
33751257|NCT03876405|NA|SINGLE_GROUP||OTHER||NONE||||||
33751258|NCT04137042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||comparison between two intraoperative iv. fluids|t|f|t|t
33751259|NCT05349344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751260|NCT06603220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751261|NCT03285139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064827|NCT05524038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be done by random sequence number generated by the computer kept in sealed envelopes. Those envelopes will be opened on the day of surgery when the patient is in the operating room and participant will receive either (QLB) or (ESPB) as per the envelope.|"1. (QL) QLB group~2. (ESB) group"|t|t|f|f
33751262|NCT02119507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064828|NCT04687566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064829|NCT01290198|RANDOMIZED|PARALLEL||||NONE||||||
33751263|NCT05757219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751264|NCT00498719|||CASE_ONLY||PROSPECTIVE|||||||
33751265|NCT02859792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751266|NCT03971682|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751267|NCT03932851|||COHORT||RETROSPECTIVE|||||||
33751268|NCT00057668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751269|NCT05298735|||CASE_CONTROL||PROSPECTIVE|||||||
33751270|NCT00265889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751271|NCT01990027|||COHORT||PROSPECTIVE|||||||
34064830|NCT04716504|||COHORT||PROSPECTIVE|||||||
33751272|NCT06511141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751273|NCT06731933|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751274|NCT01877538|||||CROSS_SECTIONAL|||||||
33751275|NCT02738268|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33751276|NCT00430768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751277|NCT05903417|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751278|NCT03078348|RANDOMIZED|PARALLEL||SCREENING||NONE||"In this modified block random assignment, all individuals recruited from the same geographic unit will receive the intervention assigned to that area in order to reduce intervention contamination. Individuals will not be made aware of their randomization (intervention) condition until after baseline assessment. The research assistants will also be assigned at random to work with one geographic area (i.e., one intervention condition) in order to reduce risk of intervention contamination by study staff."||||
33751279|NCT06580262|||COHORT||PROSPECTIVE|||||||
33751280|NCT03902704|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"part 1 its single group of participants(50 patients without difficult airways predictors). this group receives direct laringoscopy with common laryngoscope (L) during the initial phase of the trial, followed by videolaryngoscope (VL) Cleverscope (used for intubation) during a later phase.~part 2 of the study its two-by-two cross-over assignment involves two groups of participants(84 patients with difficult airways predictors). One group receives VL with C-MAC during the initial phase of the trial, followed by Cleverscope for intubation during a later phase. The other group receives VL with Cleverscope during the initial phase, followed by C-MAC VL used for intubation. So during the part 2 trial, participants cross over to the other videolaringoscopy."||||
33751281|NCT04204629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174801|NCT04805502|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|those performing measurements on participants will be blinded to group allocation.|PRegnant women will be randomized to one of four groups: aerobic exercise, resistance exercise, combination (aerobic + resistance), or control (no exercise). All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, rating of perceived exertion (RPE), 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.|f|t|t|t
34174802|NCT06297837|||OTHER||RETROSPECTIVE|||||||
34174803|NCT06299098|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34174804|NCT04146181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174805|NCT03968679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174806|NCT06383858|||COHORT||PROSPECTIVE|||||||
34174807|NCT05601219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized dose escalation followed by dose expansion.||||
34174808|NCT04484961|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized to either receive standard physical therapy or standard physical therapy with blood flow restriction therapy.||||
34174809|NCT05930678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Morbidly obese patients (BMI greater than or equal to 35).||||
34174810|NCT06633562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All research staff will be blinded to treatment given.|Randomized, Double-blind, Placebo-controlled, Single Site, Single Ascending Dose Study|t|t|t|t
34174811|NCT05806645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|This is a waiver of consent trial, participants will be randomized to an enhanced discharge care pathway vs usual care in the electronic health record.||f|f|t|t
34174812|NCT01000090|||COHORT||RETROSPECTIVE|||||||
34174813|NCT05000398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174814|NCT05387083|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34174815|NCT05498883|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34174816|NCT06404814|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174817|NCT05099770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174818|NCT05551299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174819|NCT06368050|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34174820|NCT05615376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174821|NCT02210572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174822|NCT05003401|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be provided with the Keen2 wrist-worn device to determine whether this device increases awareness of automatic hair pulling behaviors over a period of 4 weeks.||||
34174823|NCT04505059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174824|NCT05943964|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33862112|NCT02749448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862113|NCT01474863|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34174825|NCT00704015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862114|NCT01444651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174826|NCT05640830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174827|NCT06639594|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174828|NCT02300207|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862115|NCT01916863|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33862116|NCT05292950|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33862117|NCT06440057|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33962062|NCT01424618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962063|NCT04254263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962064|NCT04300907|NA|SINGLE_GROUP||TREATMENT||NONE||open-label||||
33962065|NCT04474288|||CASE_CONTROL||OTHER|||||||
33962066|NCT04647279|||OTHER||PROSPECTIVE|||||||
33751282|NCT06598306|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33751283|NCT00695669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962067|NCT04175678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174829|NCT04880980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to group one or two.|Randomized controlled trial|t|f|f|f
33862118|NCT06368427|||OTHER||OTHER|||||||
33862119|NCT01750541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862120|NCT05477381|||COHORT||PROSPECTIVE|||||||
33862121|NCT06437964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862122|NCT06736002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||RCT study with Mega-Vitamin D compare placebo Experimental group: Mega-Vitamin D 100.8 million IU for three months Control group: placebo for three months|t|t|t|t
33962068|NCT00712491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962069|NCT02700074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862123|NCT00347672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862124|NCT04112446|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862125|NCT00036894||||TREATMENT||||||||
33862126|NCT06452004|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||In Uganda, India and Bangladesh eligible women in geographic areas are invited to perform self-test for hrHPV. hrHPV-positive women are invited for further examination of the cervix using VIA. In all VIAs pictures are taken with the device and the AI decision support system is activated. Health workers will give an independent VIA assessment before the AI assessment can be accessed. An expert panel gives an independent assessment without knowing the health worker or AI assessment.||||
33862127|NCT03376477|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will continue on a standard dose of lenalidomide. Patients on the myeloma vaccine arm will receive injections in addition to lenalidomide unless otherwise clinically indicated, or until progression. Patients on myeloma plus Prevnar vaccine arm will receive injections of both allogenic myeloma vaccine and Prevnar vaccine in addition to lenalidomide unless otherwise clinically indicated, or until progression. Patients on the myeloma vaccine placebo arm will receive myeloma vaccine placebo on the same schedule as allogeneic myeloma vaccine. If assigned to either of the two arms that do not include Prevnar, then patients will receive placebo in lieu of Prevnar on the same schedule. The placebo will be saline. All patients will be followed for a minimum of 3 years.||||
33862128|NCT05651932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862129|NCT01491217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862130|NCT02115399|||COHORT||PROSPECTIVE|||||||
33862131|NCT01320787|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862132|NCT04127825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862133|NCT05330403|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33862134|NCT02041754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862135|NCT03942406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862136|NCT03511404||SEQUENTIAL||DIAGNOSTIC||NONE||A correlation study between clinical examination by Numeric Pain Rating Scale (NPRS) and electrophysiology assessment by surface EMG will be conducted at enrollment and 6 weeks physiotherapy.||||
33862137|NCT06717230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The child participants and the legal guardian of each participating child and the statistician were blinded.||t|t|f|t
33862138|NCT02952391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862139|NCT04780490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33862140|NCT00002326||||TREATMENT||||||||
34064831|NCT04268628|||OTHER||RETROSPECTIVE|||||||
34064832|NCT03739580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174830|NCT03987035|NA|SINGLE_GROUP||TREATMENT||NONE||Application of BeGraft Peripheral Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms||||
34174831|NCT03646604|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174832|NCT06595602|||COHORT||PROSPECTIVE|||||||
34174833|NCT06178419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34174834|NCT04962776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34174835|NCT06169540|||COHORT||RETROSPECTIVE|||||||
34174836|NCT06704412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Ankle application in floss band group and sham group|t|f|t|f
34174837|NCT03379818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to one of two possible groups. In both groups, they will receive an intervention, however participants and their parents will not know which one. At the end of the study, participants and their parents will be informed about which group they were in and a document containing a detailed description of each intervention will be provided to them.|Over a series of 9 weekly sessions, children diagnosed as Late Talkers will be assessed in different tasks that can be divided into 5 phases: Vocabulary and developmental assessments, initial cognitive assessments, training sessions, word learning test 1, and word learning test 2. Each group (shape training group and specific word training group) will receive a different training programme, however the other assessments will be identical across the groups. In the shape training group, participants will be taught to attend to shape when learning and extending novel labels. In the specific word training group, participants will be taught specific words that they do not know. Before and after the intervention, participants vocabulary will be assessed to compare which intervention enhances word learning. One year later, all participants will be assessed with a language test and a cognitive test. The same assessments will be used in both groups.|t|f|f|f
33862141|NCT04847531|||COHORT||RETROSPECTIVE|||||||
33862142|NCT04289740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862143|NCT04081584|||CASE_ONLY||PROSPECTIVE|||||||
34064833|NCT05310526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Cluster-Randomized Trial|f|f|t|t
34064834|NCT02550704|NA|SINGLE_GROUP||SCREENING||NONE||||||
34064835|NCT00815425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174838|NCT05292586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174839|NCT05089019|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34174840|NCT05259566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34174841|NCT02842203|||CASE_ONLY||PROSPECTIVE|||||||
34174842|NCT03633370|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||A Stepped Wedge Cluster Randomized Controlled Trial|f|f|f|t
33751284|NCT05847426|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"The intervention (provision of additional fNIRS information) will be applied to audiologists in a cross-over design, wherein each audiologist will receive the anonymized current audiological information about a particular infant twice: once with, and once without the additional fNIRS information. Each time, the audiologist will answer questions about key management decisions via a questionnaire and rate their confidence in their decision using a sliding scale. The change in confidence (difference between the two sliding scale answers for the audiologist) when having access to additional fNIRS information will be the raw data analysed.~To test the main hypothesis (that including fNIRS information increases confidence in making management decisions) separately for different hearing loss category groups and different points in the care pathway, 232 infants will be recruited to undergo fNIRS testing, divided into subgroups each with target numbers based on power calculation."||||
33862144|NCT01717768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751285|NCT00726726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751286|NCT03606330|||COHORT||PROSPECTIVE|||||||
33751287|NCT05029765|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"50 men and women with mild cognitive impairment and more than 60 years will follow three dietary intervention periods of 24 weeks each, with a randomized crossover design. Dietary periods will be: 1.- Healthy diet (WHO recommendations) + placebo; 2.- Mediterranean diet + placebo and ; 3.- Mediterranean diet plus (Mediterranean diet + Biopolis-MIX42 (a capsule containing 10\^9 colony forming units of Lactobacillus rhamnosus and Bifidobacterium longum))."|t|t|t|f
33751288|NCT02156583|||COHORT||PROSPECTIVE|||||||
33751289|NCT03873948|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33751290|NCT06141811|||CASE_CONTROL||PROSPECTIVE|||||||
33862145|NCT04806139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The intervention will be offered to two groups (goal sample size of 15 participants in each group, with additional recruiting to account for attrition). The second Remote Enhance Fitness group will begin following the completion of the first group.|t|f|f|f
33862146|NCT04125667|||OTHER||OTHER|||||||
33862147|NCT01179672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862148|NCT00822354|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862149|NCT02586220|||COHORT||PROSPECTIVE|||||||
33862150|NCT06725121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862151|NCT00164827|||DEFINED_POPULATION||PROSPECTIVE|||||||
33862152|NCT00049452|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33862153|NCT05419375|NA|SINGLE_GROUP||OTHER||NONE||||||
33862154|NCT01548924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862155|NCT03671746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant medical team will be blinded to the treatment or placebo intervention|Compare the effectiveness of a NSAID to placebo in acute trauma setting.|t|t|t|f
33862156|NCT00801996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862157|NCT01881503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862158|NCT02639468|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064836|NCT04225494|||COHORT||PROSPECTIVE|||||||
34064837|NCT03960424|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Mixed Methods Design, incorporating adaptations before RCT trial commencement.||||
34064838|NCT00771979|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34064839|NCT02236078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064840|NCT00951106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064841|NCT05619770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064842|NCT05277272|||COHORT||PROSPECTIVE|||||||
34064843|NCT02348554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34064844|NCT02895139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064845|NCT04930653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064846|NCT05369494|NA|SINGLE_GROUP||OTHER||NONE||||||
34064847|NCT06088368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064848|NCT01892878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064849|NCT03216655|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34064850|NCT06118450|||COHORT||PROSPECTIVE|||||||
34064851|NCT05640388|||OTHER||OTHER|||||||
34064852|NCT05982808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||with/without novel CLIF correction|t|t|t|t
34064853|NCT00003037||||TREATMENT||||||||
34064854|NCT00821015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064855|NCT01028495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064856|NCT05162755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064857|NCT00856843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064858|NCT05816759|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064859|NCT02325921|||COHORT||PROSPECTIVE|||||||
34064860|NCT04965636|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study|This is a single arm study||||
34064861|NCT02342977|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34064862|NCT00610233|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34064863|NCT05805007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174843|NCT05366335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174844|NCT05020951|||OTHER||RETROSPECTIVE|||||||
34174845|NCT05489965|||OTHER||OTHER|||||||
34174846|NCT04694534|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|This is a blinded study for neuropsychological assessment.|"1 Control group~1 Experimental group"|f|f|f|t
34174847|NCT06365879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174848|NCT00868634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174849|NCT02642601|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174850|NCT04757766|||OTHER||OTHER|||||||
34174851|NCT01751061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174852|NCT06609174|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34174853|NCT01917500|||COHORT|||||||||
34174854|NCT03379675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34174855|NCT05131594|||COHORT||PROSPECTIVE|||||||
34174856|NCT04531410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The supplement only differ by colour on capsulae, no labelling|Parallel, double blind, randomized|t|t|t|t
34174857|NCT06204679|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34174858|NCT06247917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174859|NCT05380973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751291|NCT02274714|||CASE_CONTROL||PROSPECTIVE|||||||
33751292|NCT05101980|||OTHER||PROSPECTIVE|||||||
33751293|NCT05614102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751294|NCT05567900|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34174860|NCT05177510|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double parallel group randomised control trial|Double-blinded parallel group randomised control trial. Intervention arm Mifepristone plus standard care, comparator arm placebo plus standard of care .|t|t|t|t
33751295|NCT05881759|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751296|NCT04575051|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|The data collectors will be masked to which phase the facility is in.|Open cohort stepped-wedge cluster randomized design with a phased, randomized roll out|f|f|f|t
33751297|NCT02019368|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33751298|NCT06279325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34174861|NCT02105896|||||PROSPECTIVE|||||||
34174862|NCT02331056|||CASE_CONTROL||PROSPECTIVE|||||||
34174863|NCT06512064|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174864|NCT06704880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751299|NCT01064232|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751300|NCT00673972||PARALLEL||DIAGNOSTIC||NONE||||||
33751301|NCT06433908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||4-way crossover study.||||
33751302|NCT00338065|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33751303|NCT05945433|||OTHER||PROSPECTIVE|||||||
33862159|NCT01329016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862160|NCT05699018|NA|SINGLE_GROUP||SCREENING||NONE||"The SOPRANO study is a multicenter prospective comparative diagnostic study . Evaluation of a simple blood test (e-LIFT) for the diagnosis of advanced liver fibrosis.~Reference for advanced liver diagnosis : composite criteria :~* Elastometry between 8 kPa and 14.9 kPa and histologic evaluation of fibrosis ≥ F3 (NASH CRN ) OR~* Elastometry ≥ 15 kPa"||||
33862161|NCT04987658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862162|NCT04752475|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Consenting women will be assigned to Lasix (furosemide) or placebo in a 1:1 ratio according to a randomization scheme achieved using a computer generated algorithm. Neither the participant nor the clinical care team will be aware of the allocation arm.|The study is a randomized controlled clinical trial of 82 women with one or more high-risk factors for de novo postpartum hypertension, randomized to one of two arms: 20 mg PO Lasix (furosemide) daily for 5 days or identical-appearing daily placebo for 5 days.|t|t|t|f
33862163|NCT06018272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862164|NCT03509896|||COHORT||RETROSPECTIVE|||||||
33862165|NCT00382603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33862166|NCT05492188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862167|NCT05679466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33862168|NCT05046574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862169|NCT06638671|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind|Randomized, double-blind, placebo-controlled crossover design|t|f|t|f
33862170|NCT02852161|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33862171|NCT05737134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33862172|NCT00530868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862173|NCT04166383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862174|NCT00648089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893820|NCT02636309|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893821|NCT06427447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893822|NCT06487377|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation||||
33862175|NCT03794921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study staff communicating randomization assignments to subjects will be different from study staff conducting follow-up outcome assessments.|As the primary aim, the investigators propose a RCT to study the efficacy of a web-based, pedometer-mediated physical activity intervention to increase physical activity in persons with COPD who would benefit from but cannot access conventional pulmonary rehabilitation, compared to usual care. The investigators anticipate that 120 subjects will be randomized 1:1 to either the intervention or usual care.|f|f|f|t
33862176|NCT06032338|RANDOMIZED|PARALLEL||SCREENING||NONE||"The number of study arms will differ according to age-group:~* In 50 or 51 yrs age-group, individuals (n=5760 ) will be randomised in 3 groups: C, B1 and B2 (allocation ratio 2:1:1)~* In the age-group older than 51 yrs, individuals (n=58240) will be randomised in 2 groups: C, and B1 (allocation 1:1) In the main analysis including both age-groups, B1 and B2 arms would be pooled."||||
33862177|NCT00611962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862178|NCT04011228|||COHORT||PROSPECTIVE|||||||
33862179|NCT04471948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862180|NCT03531281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862181|NCT00698464|NA|SINGLE_GROUP||OTHER||NONE||||||
33862182|NCT05317988|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33862183|NCT05343897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862184|NCT03613662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862185|NCT05821530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862186|NCT03916289|||COHORT||PROSPECTIVE|||||||
33862187|NCT00288795|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862188|NCT02592018|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862189|NCT03558022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33862190|NCT03296462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and research assistant are blind to next allocation. Outcome assessors (physiotherapist and exercise physiologist) and one investigator are blinded to group of allocation. Statistician will be masked to group of allocation.||f|f|t|t
33862191|NCT00395551|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33862192|NCT04382196|||COHORT||PROSPECTIVE|||||||
33862193|NCT03778814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862194|NCT02827240|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33862195|NCT05488236|||COHORT||PROSPECTIVE|||||||
33862196|NCT00378833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862197|NCT02243098|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33862198|NCT05491915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862199|NCT01542268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862200|NCT04226807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33862201|NCT00038584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33862202|NCT06050954|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862203|NCT05718570|||CASE_ONLY||PROSPECTIVE|||||||
33862204|NCT00146328|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862205|NCT06260202|||COHORT||RETROSPECTIVE|||||||
33862206|NCT06273605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862207|NCT04802564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862208|NCT06418854|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862209|NCT04793620|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Sequential-group dose-escalation study.|t|f|t|f
33862210|NCT06396650|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862211|NCT03382652|||COHORT||PROSPECTIVE|||||||
33862212|NCT00907049|||||PROSPECTIVE|||||||
33862213|NCT02818920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862214|NCT04307277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862215|NCT05503563|||COHORT||PROSPECTIVE|||||||
33862216|NCT05302934|||COHORT||PROSPECTIVE|||||||
33862217|NCT05070039|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||formalin fixed and paraffin embedded blocks of urinary bladder malignant neoplasms will be obtained and sectioned. from each block, one tissue section will be stained by H\&E, other section will be stained immunohistochemically by anti Cortactin antibodies.||||
33862218|NCT04521699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862219|NCT01585220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33862220|NCT06415838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862221|NCT05773950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized placebo-controlled trial|t|t|t|t
33862222|NCT05532449|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33862223|NCT05579990|NA|SINGLE_GROUP||OTHER||NONE|All participants enrolled in the study will receive the meal delivery intervention, so blinding is not possible.|||||
33862224|NCT06735885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862225|NCT05033652|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Cluster step wedge||||
33862226|NCT01159912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862227|NCT01768988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962070|NCT01119352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33962071|NCT04369079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"A total of 61 patients who underwent total mastectomy for breast cancer with axillar lymph dissection and adjuvant radiotherapy were enrolled in this trial.~The patients were randomized by toss of a coin to the treatment (n=30) or control (n=26) groups; of these, 48 met all study protocol requirements, including the final assessment. Inclusion criteria were: presence of functional difficulties in the shoulder area and/or upper torso on the surgical side, and 2) eligibility for physiotherapy (determined by the treating physician). Patients with recurrent disease and/or inflammatory or acute ailments were excluded. All patients gave their informed consent to participate in the study.~The treatment group received myofascial treatment while patients in the control group received conventional therapy consisting of exercise and massage."||||
33962072|NCT03904043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962073|NCT01146431|||CASE_CONTROL||PROSPECTIVE|||||||
33962074|NCT01010321|||CASE_ONLY||PROSPECTIVE|||||||
33751304|NCT05257096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The EEG reading will be blinded to the intervention arm|"The children will be divided to either group randomly according to the day of the test.~1. 50 Children performing the EEG at the days that the medical clown is available will be included in the study group.~2. 50 Children performing the EEG at the days that the medical clown is unavailable will be included in the control group."|f|f|t|f
33751305|NCT06626282|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751306|NCT03900468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751307|NCT01270347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862228|NCT03374085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862229|NCT02964858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862230|NCT00004912||||SUPPORTIVE_CARE||||||||
33862231|NCT06140472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862232|NCT05520645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33862233|NCT03591783|||COHORT||PROSPECTIVE|||||||
33862234|NCT04903106|||COHORT||PROSPECTIVE|||||||
33862235|NCT02515578|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33862236|NCT01690897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862237|NCT06734884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862238|NCT02642484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862239|NCT04510688|||CASE_ONLY||OTHER|||||||
33862240|NCT05629650|NA|SINGLE_GROUP||PREVENTION||NONE||two intervention groups (1) those with MCI (2) those with dementia||||
33862241|NCT02455934|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33862242|NCT05452096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"After the intake visit with the occupational health physician (OHP) of the relevant service region, all data of the drivers that have agreed to participate and have given their informed consent will be coded, and therefore encrypted data will be sent to the PI for further evaluation.~The stratified randomization will be done by Qminim a web-based randomization system which uses minimization to ensure a similar distribution of the stratifying factors between the study conditions."|SHIFTPLAN is a randomized controlled interventional trial. It can be situated in occupational health and field research. The drivers will be 1:1 randomized to either the intervention or the control group according to a parallel group design.|f|f|t|t
33862243|NCT03920150|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient will be recruited by their general practitioner. Patients will be randomly assigned to be supplemented with monthly solution (control group), monthly capsules (IMP group) or weekly capsules after calculation of a individual loading dose (IMP + loading dose group).||||
33751308|NCT04728321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751309|NCT01693757|||CASE_CONTROL||PROSPECTIVE|||||||
33751310|NCT01952535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962075|NCT06461676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962076|NCT05785026|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33962077|NCT01552629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962078|NCT01050673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962079|NCT02777931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962080|NCT00047294||||TREATMENT||NONE||||||
33962081|NCT00189267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962082|NCT03022188|||COHORT||PROSPECTIVE|||||||
33962083|NCT01608776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962084|NCT06066866|||COHORT||PROSPECTIVE|||||||
33962085|NCT00420888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962086|NCT04654156|||CASE_CONTROL||RETROSPECTIVE|||||||
33962087|NCT02407756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962088|NCT00707122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962089|NCT04816162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blinded(participants and outcome assessors)|"A computer-generated table will be used to divide patients equally into three study groups~* In group C (control group):21 ml of normal saline 0.9% will be I.V infused at a rate of 0.3-0.4 mg/kg/h to the patient.~* In group K: ketofol (a mixture of ketamine and propofol will be prepared in a ratio of (1:4) respectively), will be I.V infused at a rate of 0.3-0.4 mg/kg/h to the patient.~* In group D: adding dexmedetomidine 2 ml (200 µg) to 19 ml of 0.9% normal saline to start I.V infusion to the patient"|t|f|f|t
33962090|NCT02076230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962091|NCT04075188|NA|SINGLE_GROUP||TREATMENT||NONE||Selected patients with both diagnosis of polypoidal choroidal vasculoparthy and pachychoroid will be treated with combined therapy consisting in photodynamic therapy and 3 intravitreal therapy of Aflibercept monthly||||
33962092|NCT05105360|RANDOMIZED|PARALLEL||PREVENTION||NONE||non-inferior study, multicenter, prospective, randomized controlled study||||
33962093|NCT05924451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinician performs the treatment of implant placement and prosthesis and the investigator analyzes the hard and soft tissue changes recorded over time.|Patients will be randomly assigned into two main groups according to the time of implant loading, in group A, an early loading will be applied with a PMMA and in group B, an immediate functional loading protocol will be applied with the zirconia prosthesis over the implants.|f|f|t|f
33962094|NCT02000310|||COHORT||PROSPECTIVE|||||||
33962095|NCT02609178|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33962096|NCT02503566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962097|NCT06232538|||COHORT||PROSPECTIVE|||||||
33962098|NCT03239795|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were identified by a number|Registry based cluster randomized trial. The population was the patients aged over 16 of 75 FPs, with an indication for seasonal influenza immunization (pregnancy, long lasting disease, age over 65). The main outcome is the proportion of vaccinated patients, based on the number of vaccination units dispensed in community pharmacies. This number is retrieved from the SIAM-ERASME claim database of the Lille-Douai Health Insurance Fund.|t|f|f|f
33962099|NCT02709122|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33962100|NCT03512626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Consecutive patients with bilateral cataract were included after meeting all the inclusion and none of exclusion criteria and when written informed consent was obtained from all patients.~Patients were randomly assigned to have bilateral implantation with either a monofocal IOL (AR40e, AMO-Abbot 30 Laboratories Inc. Abbot Park, Illinois, USA) or multifocal IOL (OptiVis™, Aaren Scientific, Inc, Ontario, CA, USA)."|t|f|t|f
33962101|NCT00769158|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33962102|NCT03665480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962103|NCT03801759|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||"Each arm has fixed sequence design.~1. Arm 1 (n = 20): Digoxin 0.5 mg alone, vadadustat 600 mg alone and digoxin + vadadustat~2. Arm 2 (n = 16): adefovir 10mg alone, vadadustat 600 mg QD alone and adefovir + vadadustat~3. Arm 3 (n=22) : furosemide 40mg alone, vadadustat 600 mg QD alone, and furosemide + vadadustat"||||
33962104|NCT01672307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962105|NCT00203957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962106|NCT00053027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962107|NCT05066607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862244|NCT06707636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862245|NCT06735287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||this study is a prospective, single-center, historical control trial, with a planned enrollment of 30 participants.||||
34174865|NCT03932903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"This study involve a 28-day micro-randomized pilot trial (i.e., a sequential factorial design) of a just-in-time adaptive intervention called ADAPTS ADAPTS is an app that will deliver contextually-tailored mobile messages (adapted to current states, such as mood, pain, and location) designed to promote oral chemotherapy adherence. Each AYA in the study (planned n=30) will be micro-randomized (with a 60% probability) to receive a contextually-tailored message each day that supports abilities to self-manage and maintain adherence, delivered prior to their scheduled dose, over a 28-day period (i.e., the period between follow-up appointments). The remaining 40% of days, participants will be assigned to receive no messages (i.e., no intervention).~We will also request, but not require, that a caregiver enrolls in the study and pilots the caregiver version of the app (planned n=30 caregivers). The caregiver app does not include any micro-randomization."|t|f|t|f
34174866|NCT03924661|||COHORT||CROSS_SECTIONAL|||||||
33862246|NCT02628314|||COHORT||PROSPECTIVE|||||||
34174867|NCT06474195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized controlled study. The participants will be randomly assigned to treatment as usual arm or intervention arm. The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The participant will also be asked a task of daily routine during the same time of medication. The Treatment as Usual (TAU) Arm will not get any reminders but the baseline assessment will be similar to the intervention arm. There will be 2 follow-ups, 1st follow-up will be 30 days after the baseline assessment and the second will be 90 days after the baseline assessment. repeated during both follow-up visits. TAU will also be followed up at 30 days and 90 days after baseline assessment.||||
33862247|NCT04626583|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A longitudinal assessment using a classic dose-escalation study design to assess the safety of locally delivered allogenic mesenchymal stromal cells for promoting corneal repair.||||
33862248|NCT02950402|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33862249|NCT04341896|||COHORT||RETROSPECTIVE|||||||
34174868|NCT00825292|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174869|NCT02825498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174870|NCT03485924|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33862250|NCT02500381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 is double-blind and randomized; Part 2 is open-label.||t|t|t|t
33962108|NCT05347082|NA|SINGLE_GROUP||TREATMENT||NONE||47 participants who met the inclusion criteria were included and all received 8000 IU of vitamin D orally for four weeks.||||
33962109|NCT01693731|||||CROSS_SECTIONAL|||||||
33862251|NCT04244487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33862252|NCT06735989|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Blinding will be maintained for allocation concealment, which will be carried out through closed and opaque mails by a blind operator. Subjects will be labelled with a numerical code to ensure anonymisation. Subjects, teachers, evaluators and statisticians will be blind to allocation. Specifically, teachers of both groups will be not informed about the aim of the study. They will be provided with specular material for the seminar (same structure and number of slides). They will be only informed to not answer to specific questions about dilemmas. Subjects of a group will be informed that the other group is attending a seminar on reasoning. They will be separated until the end of the post-test phase."|Intervention study, monocentric, randomized, double-blind, and multiparametric.|t|f|f|t
33862253|NCT04628468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862254|NCT01958190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862255|NCT05320250|||CASE_CONTROL||PROSPECTIVE|||||||
33862256|NCT01829425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33862257|NCT05553704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33862258|NCT05555251|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a Phase 1/2a, FIH, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab.~The study will consist of 2 Phases:~* Phase 1, the dose-escalation part of the study, the aim of which is to assess safety and tolerability and to determine the RP2D of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors.~* Phase 2a, comprising of 2 separate expansion cohorts treated at the RP2D of BI-1607 in combination with trastuzumab in subjects with locally advanced or metastatic HER2+ breast cancer and subjects with HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma. The aim of Phase 2a is to collect additional safety data to further support RP2D, and to detect early signs of clinical activity."||||
33862259|NCT01852604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862260|NCT06179251|||CASE_CONTROL||RETROSPECTIVE|||||||
33862261|NCT03356171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33862262|NCT02705209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862263|NCT03417518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862264|NCT05204017|||CASE_CONTROL||PROSPECTIVE|||||||
33862265|NCT06736145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862266|NCT05604131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862267|NCT05555667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893823|NCT05177796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893824|NCT02652000|||||RETROSPECTIVE|||||||
33893825|NCT02528344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893826|NCT05049785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862268|NCT04243603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, a blinding of participants and therapists (intervention providers) is not possible. Blinded outcome assessment and data management will be performed. Statistical analyses will be performed by two blinded statisticians presenting independent reports. Based on the two blinded conclusions, two abstracts will be written and published (on a website).|Single-center, feasibility trial including a randomization procedure in a parallel group design with blinded outcome assessment.|f|f|f|t
33862269|NCT02079012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862270|NCT05467683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862271|NCT02030951|||COHORT||PROSPECTIVE|||||||
33862272|NCT02774551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862273|NCT03079232|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||One group of patients One group of non skin cancer patients||||
33862274|NCT02215837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862275|NCT00800943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862276|NCT05813717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862277|NCT00420602|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862278|NCT05630144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862279|NCT00365898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33862280|NCT02612025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862281|NCT04622683|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862282|NCT06516952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862283|NCT01426516|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33862284|NCT01920945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862285|NCT01949155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33862286|NCT02780674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862287|NCT03025399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862288|NCT05207670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862289|NCT00437671|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33862290|NCT00137124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862291|NCT04376060|NA|SINGLE_GROUP||TREATMENT||NONE||Fourteen patients (1 male, 13 females) aged between 27 and 64 years old were selected from the Department of Periodontology of the Faculty of Dentistry, Saint Joseph University Beirut.||||
33862292|NCT02556866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862293|NCT02225717|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33862294|NCT00828633|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34174871|NCT05351749|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33862295|NCT00419718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862296|NCT01367964|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862297|NCT05071495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862298|NCT01241305|||COHORT||PROSPECTIVE|||||||
34174872|NCT04575194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862299|NCT04231136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862300|NCT02279823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862301|NCT00001163|||FAMILY_BASED||OTHER|||||||
33962110|NCT02475967|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33962111|NCT00819858|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862302|NCT02315599|||COHORT||PROSPECTIVE|||||||
33862303|NCT05103943|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862304|NCT03910426|||COHORT||PROSPECTIVE|||||||
33862305|NCT04384913|||CASE_CONTROL||PROSPECTIVE|||||||
33862306|NCT04863664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862307|NCT00007813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862308|NCT05794113|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33862309|NCT01288872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862310|NCT02558192|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33862311|NCT00762749|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862312|NCT06735495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862313|NCT05290051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Gold standard analyses run as usual with results issued to patients Evaluated analyses run and analyzed blind to care provider and investigator Comparison of results between gold standard and tested analyses at the end of the study|Comparison of new diagnostic procedures with gold standard used in clinical setting||||
33862314|NCT06378411|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33862315|NCT05013853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33862316|NCT04592913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-blind, Placebo-controlled study|t|t|t|t
34174873|NCT00003994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174874|NCT05748873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2). In Cohorts 5 and 6 of Step 2, subjects and the designated study personnel will be masked to subject's dose assignment. Cohort 4 (untreated group) will be unmasked.|Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2)|t|t|t|t
34174875|NCT04373902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174876|NCT02943174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174877|NCT00548665|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33862317|NCT04426604|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The assessors will not be blind about the type of intervention/control assessment methods. However it will not be allowed amongst the examiners to exchange any information throughout the entire study period||f|f|f|t
33862318|NCT03589690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study will be conducted as a parallel randomized double-blind clinical trial. patient will randomly be divided into two groups, each will receive supplement or placebo for 12 weeks .Before the study, containers will be coded as A and B by a person other than the study researchers according the concealment rules .|In this study, samples will be randomly divided into two groups receiving the supplement or placebo.|t|t|t|f
33862319|NCT00144612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862320|NCT05581979|||COHORT||PROSPECTIVE|||||||
33862321|NCT01777087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862322|NCT00005002||||TREATMENT||DOUBLE||||||
33862323|NCT01793168|||CASE_ONLY||PROSPECTIVE|||||||
33862324|NCT05958368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigators and outcome assessors will be blinded to study treatment.|This study utilizes a randomized crossover design with each period/treatment being approximately 5 weeks. Participants will be randomized to either Hass Avocado or other fruit(s) consumption groups. The treatments will be isocaloric as will the Hass Avocado vs. the other fruit(s). All subjects will consume a diet provided by the metabolic research kitchen. The diet will be matched on energy (kcal).|f|f|t|t
33862325|NCT04203862|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33862326|NCT00486876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862327|NCT06102603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The clinical trial was approved by the research ethics review committee of the author's hospital (Number XXX) and informed consent was obtained from the legal guardian of each patient. Between Feb 2022 and Nov 2022, all children (age range, 4-15 years) with radiography-diagnosed stable upper limb fractures (including radius, ulna, and distal humerus fractures such as Garland type I9 supracondylar fractures of the humerus) diagnosed at the orthopedic outpatient clinic or emergency room of a tertiary trauma center hospital were eligible for recruitment.|t|t|t|t
33862328|NCT06604442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Positron Emission Tomography (PET) Imaging study||||
33862329|NCT06650995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator (PI) will not receive information on group allocation. Group allocation and data will be saved in a password-secured database, which will not be accessible to the PI.|1:1 randomization will be done into interventional and control groups with the aid of sealed envelopes|f|f|t|f
33862330|NCT01123954|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33862331|NCT04822168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862332|NCT01970488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862333|NCT01255852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33862334|NCT02150330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862335|NCT04212988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||single blind|t|f|f|f
33862336|NCT05010954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862337|NCT03818087|||COHORT||PROSPECTIVE|||||||
33862338|NCT05452850|||COHORT||PROSPECTIVE|||||||
33962112|NCT02307188|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962113|NCT04404816|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33962114|NCT06541860|||COHORT||OTHER|||||||
33962115|NCT02828228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962116|NCT00116259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34174878|NCT02236208|||COHORT||PROSPECTIVE|||||||
33962117|NCT02080065|||COHORT||RETROSPECTIVE|||||||
33962118|NCT05743686|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33751311|NCT04708444|||COHORT||PROSPECTIVE|||||||
33962119|NCT05415826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33962120|NCT05078801|||COHORT||RETROSPECTIVE|||||||
33962121|NCT04833452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962122|NCT00937599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862339|NCT04094896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174879|NCT05915806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The prior systematic review included a meta-analysis of aggregated data of trials that examined the effects of an enteral supplementation with high-dose DHA during the neonatal period on the risk for BPD (any definition), death, BPD severity (any definition) and a combined outcome of BPD or death in preterm infants born less than 29 weeks of gestation. Information on data sources (searched up to August 1st, 2022), search strategy, selection process, data extraction and risk of bias assessment were detailed in the prior protocol and publication. All four trials included in the prior systematic review will be considered for inclusion in this IPD meta-analysis.~Upon the early period of selecting studies for the prior systematic review, the principal investigator (IM) has contacted the primary author of trials for potential agreement to share de-identified IPD for the purpose of this participant-level meta-analysis. All IPD datasets will be harmonised and combined into one large dataset."||t|t|t|t
34174880|NCT00396123|||CASE_ONLY||PROSPECTIVE|||||||
34174881|NCT04026113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174882|NCT06705790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174883|NCT06705322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174884|NCT01660971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174885|NCT03071120|NA|SINGLE_GROUP||TREATMENT||NONE||One group, pre, post-test||||
34174886|NCT04104282|||COHORT||PROSPECTIVE|||||||
34174887|NCT03892200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174888|NCT05523765|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34174889|NCT06253351|||COHORT||RETROSPECTIVE|||||||
34174890|NCT06131255|||CASE_ONLY||PROSPECTIVE|||||||
34174891|NCT05182086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174892|NCT06704373|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into intervention (manipulation group) and control group.||||
34174893|NCT01283958|||CASE_ONLY||RETROSPECTIVE|||||||
33751312|NCT04588350|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study in cardiac surgery||||
33751313|NCT06496633|||CASE_ONLY||RETROSPECTIVE|||||||
33751314|NCT03599648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751315|NCT04221997|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double Blind|During the acute treatment phase, 90 patients will be randomized to sertraline and 30 patients will be randomized to placebo (3:1).|t|f|t|f
33862340|NCT05183048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862341|NCT03463733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862342|NCT01479933|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33862343|NCT02690779|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33862344|NCT04406623|NA|SEQUENTIAL||TREATMENT||NONE||||||
33862345|NCT06375434|||COHORT||PROSPECTIVE|||||||
33862346|NCT05845216|RANDOMIZED|CROSSOVER||OTHER||SINGLE||The Primary Purpose of this clinical trial is to test a prototype device for feasibility and not health outcomes. This study is conducted to confirm the design and operating specifications of a device before beginning a full clinical trial.|t|f|f|f
33862347|NCT02066051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862348|NCT04357145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174894|NCT06706154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34174895|NCT00698854|||COHORT||PROSPECTIVE|||||||
34174896|NCT04165070|RANDOMIZED|PARALLEL||TREATMENT||NONE||Only participants in Part A will be randomized.||||
34174897|NCT06245941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174898|NCT04387344|||CASE_ONLY||RETROSPECTIVE|||||||
33862349|NCT05432869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862350|NCT04871165|||COHORT||PROSPECTIVE|||||||
33751316|NCT02570126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33751317|NCT00925613|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33751318|NCT01798329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751319|NCT06733363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Data Collector will be masked to treatment assignment||f|f|f|t
33751320|NCT02303184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33751321|NCT00501176|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751322|NCT02192502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33751323|NCT06185764|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33751324|NCT01302847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064864|NCT00890240|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862351|NCT00772213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174899|NCT05206734|||COHORT||RETROSPECTIVE|||||||
34174900|NCT03735303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34174901|NCT05351944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control clinical trial|t|f|f|f
34174902|NCT05892432|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Participants will be blind to medication assignment, as will all care providers and investigators.|Double-blind placebo controlled clinical trial.|t|t|t|t
34174903|NCT05363267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174904|NCT06579768|||COHORT||PROSPECTIVE|||||||
34174905|NCT06272240|||CASE_ONLY||PROSPECTIVE|||||||
34174906|NCT05829694|||CASE_CONTROL||RETROSPECTIVE|||||||
34174907|NCT05558696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174908|NCT05672784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34174909|NCT04448002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Block randomization will ensure a 1:1 ratio|f|f|t|t
34174910|NCT06231381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174911|NCT05609565|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34174912|NCT06663670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated.||f|f|f|t
34174913|NCT06551272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174914|NCT04232319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174915|NCT04474470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751325|NCT02543034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33751326|NCT03484975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751327|NCT04089033|||COHORT||PROSPECTIVE|||||||
33751328|NCT05467891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751329|NCT00223834|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33751330|NCT03886532|||COHORT||PROSPECTIVE|||||||
33751331|NCT02133534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751332|NCT02738567|||COHORT||PROSPECTIVE|||||||
33751333|NCT06732310|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||"In pregnancy: Women who receive the PMEP complete a structured set of sessions delivered over the course of 5 weeks, each session lasts 2 hours in duration: (1) becoming a group \& safety planning, (2) identifying and understanding sources of stress, (3) strategies to build resilience and resolve conflict, (4) perinatal health and infant care, and (5) positive parenting. Women who are not randomized to PMEP participate in a contact-equivalent, non-directive social support group.~In early childhood: Each of the 5 RET sessions are 1 hour in duration. The program is manualized and each session includes teaching/review of skills, instructions/activity with rationale, reminiscing practice, and immediate video feedback by a family coach. Families who are not randomized to the RET condition will be mailed a kit containing 5 packets to be opened weekly. Each packet includes a family activity and a newsletter with parenting materials."|t|f|f|t
33751334|NCT03540914|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33751335|NCT00686881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751336|NCT01752673|RANDOMIZED|PARALLEL||||NONE||||||
33862352|NCT00595023|||CASE_ONLY||PROSPECTIVE|||||||
33862353|NCT05287412|||COHORT||PROSPECTIVE|||||||
33862354|NCT04165590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862355|NCT02606461|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862356|NCT00249353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33862357|NCT04687150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|e|Randomized placebo-controlled pilot study. Accrued participants were randomized 1:1 using a computer generated randomization algorithm (www.random.org).|t|t|t|f
34174916|NCT01950897|||OTHER||PROSPECTIVE|||||||
34174917|NCT06706206|||OTHER||CROSS_SECTIONAL|||||||
34174918|NCT05871541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded study||t|t|t|t
34174919|NCT05154773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel randomized controlled trial|f|t|f|t
33862358|NCT05398510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||SHR-2010 injection compared with placebo|t|f|t|f
33862359|NCT01494350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862360|NCT06026683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is blinded for the patient and for the echocardiographers.|Patients will be randomized into 2 groups according to pacing site: CSP vs RVAP.|t|f|f|t
34174920|NCT01451606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study drug allocation was determined by University pharmacy, using a random allocation algorithm unknown by researchers or patients.|One group receiving active drug treatment and second group receiving an indistinguishable placebo pill.|t|f|t|f
34174921|NCT05849155|||COHORT||PROSPECTIVE|||||||
34174922|NCT05025787|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Blinding of the randomization assignment from trial subjects, staff from the Clinical Sites, CCC, and DCC will be ensured through the use of the IXRS.|The study will employ a randomized, allocation-concealed, multicenter, placebo-controlled, multi-period crossover design.|t|t|t|t
34174923|NCT02373709|||CASE_CONTROL||RETROSPECTIVE|||||||
34174924|NCT05961839|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174925|NCT00780195|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
34174926|NCT05682625|||CASE_ONLY||PROSPECTIVE|||||||
34174927|NCT00322855|||COHORT||RETROSPECTIVE|||||||
34174928|NCT02489058|||COHORT||OTHER|||||||
34174929|NCT02944110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33751337|NCT02053818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751338|NCT05758844|||CASE_ONLY||PROSPECTIVE|||||||
33962123|NCT01403428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962124|NCT01517568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962125|NCT00289731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962126|NCT05303480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an observational and interventional study in 20 Mycosis Fungoides patients and 10 healthy volunteers (observational only).||||
33962127|NCT04307030|||COHORT||CROSS_SECTIONAL|||||||
33962128|NCT05241899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962129|NCT05405530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962130|NCT06515093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962131|NCT02026102|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962132|NCT04127435|||COHORT||PROSPECTIVE|||||||
33962133|NCT02377284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962134|NCT06336226|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34150425|NCT01038713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150426|NCT04159584|NA|SINGLE_GROUP||TREATMENT||NONE||This is an uncontrolled, interventional pilot study to determine feasibility||||
34150427|NCT03755661|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor is not provided with randomization information for the subjects|Participants are randomly assigned to one of two groups|f|f|f|t
34150428|NCT03408210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150429|NCT00162266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150430|NCT03631277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150431|NCT02126007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150432|NCT01357759|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34150433|NCT03826823|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150434|NCT01420419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150435|NCT00788359|||CASE_ONLY||PROSPECTIVE|||||||
34150436|NCT06373887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Single-blinded|To compare the weight-loss efficacy of different carbohydrate degradation status under two different diet arm (low carbohydrate or low fat diet) to evaluate the benefits of initial gut microbiota profiling in precision weight loss dietary interventions.||||
34150437|NCT06508034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150438|NCT01569230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862361|NCT01764048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862362|NCT03553095|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862363|NCT05538598|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Repeated measures design with pre-post measures||||
33962135|NCT04416295|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33962136|NCT04406883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This event was a double-blind study (neither the patients nor the clinicians were aware of the rinsing solution used). Consequently, all periods of treatment, clinical parameters were recorded by an examiner who was blinded to the kind of medication received by the subjects while another clinician gave treatment.|This study is a Double-blind, Randomized, Parallel-group, split-mouth.|t|f|f|f
33962137|NCT02913469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962138|NCT01653223|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33962139|NCT05137418|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962140|NCT00842088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962141|NCT01198301|||COHORT||PROSPECTIVE|||||||
33962142|NCT04007588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962143|NCT02208388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962144|NCT02026037|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962145|NCT05436301|||COHORT||PROSPECTIVE|||||||
34174930|NCT03190928|||COHORT||PROSPECTIVE|||||||
34174931|NCT06311864|||COHORT||PROSPECTIVE|||||||
34174932|NCT05466422|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34174933|NCT06591169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962146|NCT05983731|||OTHER||PROSPECTIVE|||||||
34174934|NCT02145143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174935|NCT04930445|||OTHER||PROSPECTIVE|||||||
33862364|NCT03352011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862365|NCT05493761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Multicenter, non-randomized, non-blinded, parallel group, one-year clinical trial||||
33862366|NCT02072928|||COHORT||OTHER|||||||
33862367|NCT04594785|||COHORT||RETROSPECTIVE|||||||
33862368|NCT06044337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962147|NCT04252040|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label extension exploratory study. All eligible subjects will receive active tDCS with guided imagery.||||
33962148|NCT06539091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962149|NCT06540599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962150|NCT00584896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962151|NCT00255476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962152|NCT00921804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962153|NCT03079674|||COHORT||PROSPECTIVE|||||||
33962154|NCT01598415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962155|NCT06358807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962156|NCT04992481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients have been randomly divided (using number random generator) into five groups (n=30), including four study groups (I, II, III, IV) and one control group (K).|To participate in the study 167 healthy adults (16-50 years) who began orthodontic treatment with fixed appliances bonded to both dental arches were eligible and consecutively invited. Informed consent was obtained from 150 patients (111 women and 39 men). The patients have been randomly divided (using number random generator) into five groups (n=30), including four study groups (I, II, III, IV) and one control group (K).|f|f|t|f
33962157|NCT05151796|||COHORT||RETROSPECTIVE|||||||
33962158|NCT05384197|RANDOMIZED|PARALLEL||PREVENTION||NONE||In the available literature, we lack the risk categorization of infectious complications after RIRS with subsequent recommendation as regard to AP in different risk patients. Therefore we are planning to investigate the optimal protocol for AP prior to RIRS in high-risk population through comparing the enhanced regimen (2days) vs. the extended regimen (7 days) in a randomized controlled trial (RCT).||||
33962159|NCT01041937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34174936|NCT06296953|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34174937|NCT04737616|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174938|NCT03041038|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34174939|NCT04231773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34174940|NCT05323253|NA|SINGLE_GROUP||TREATMENT||NONE||This is an International Multicenter, Pivotal, Single Arm, Open Label pivotal trial with DaRT for the treatment of Recurrent Cutaneous Squamous Cell Carcinoma||||
34174941|NCT04529083|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study to evaluate feasibility||||
34174942|NCT05428501|||COHORT||CROSS_SECTIONAL|||||||
34174943|NCT00054886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174944|NCT03559114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34174945|NCT06074835|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34174946|NCT03840317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862369|NCT03355391|||COHORT||PROSPECTIVE|||||||
33862370|NCT04162925|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Cancer screening utilization rates and cancer screening perspective of hospitalized women on internal medicine service||||
34174947|NCT04887558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862371|NCT03447951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174948|NCT06550934|||COHORT||PROSPECTIVE|||||||
34174949|NCT06554574|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34174950|NCT04569006|||CASE_ONLY||CROSS_SECTIONAL|||||||
34174951|NCT03497676|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174952|NCT03960827|RANDOMIZED|PARALLEL||OTHER||NONE||The randomized trial is conducted in accordance with an intent-to-treat (ITT) design.||||
34174953|NCT06705387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174954|NCT03825120|||COHORT||PROSPECTIVE|||||||
34174955|NCT04965623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174956|NCT05616624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174957|NCT03291535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174958|NCT06586073|||OTHER||OTHER|||||||
34174959|NCT04672239|RANDOMIZED|PARALLEL||OTHER||NONE||3-group proof-of-concept RCT||||
34174960|NCT04265963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174961|NCT06652243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174962|NCT02010892|||COHORT||PROSPECTIVE|||||||
34174963|NCT05739981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174964|NCT04405791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical psychologists who participate in diagnosis and symptom evaluation and subjects conduct double-blindness that make it impossible to know which group they are assigned to, and only the PI and treatment implementer can know the allocation group.||t|f|f|t
34174965|NCT02333435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174966|NCT05156593|||COHORT||PROSPECTIVE|||||||
34174967|NCT04721223|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174968|NCT06705166|||CASE_CONTROL||PROSPECTIVE|||||||
34174969|NCT06456320|||COHORT||OTHER|||||||
34174970|NCT06453044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862372|NCT00799279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34174971|NCT04014829|||COHORT||PROSPECTIVE|||||||
34174972|NCT01351909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174973|NCT03020667|||COHORT||PROSPECTIVE|||||||
34174974|NCT01212055|||CASE_CONTROL||PROSPECTIVE|||||||
34174975|NCT06392165|NA|SINGLE_GROUP||OTHER||NONE|all participants will receive the same up to 12 test samples, which are randomized intra-individual.|intra-individual test with up 12 test samples per study run; this treatment is announced here as single group study.||||
34174976|NCT05863052|||CASE_CONTROL||RETROSPECTIVE|||||||
34174977|NCT05595148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862373|NCT04694872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174978|NCT06337461|||COHORT||OTHER|||||||
33862374|NCT05809128|||COHORT||PROSPECTIVE|||||||
33862375|NCT03681886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862376|NCT05788978|||OTHER||PROSPECTIVE|||||||
33862377|NCT01031160|||COHORT||OTHER|||||||
33862378|NCT05179369|RANDOMIZED|PARALLEL||PREVENTION||NONE||Hybrid Type 1 randomized effectiveness-implementation trial||||
33862379|NCT02627352|NA|SINGLE_GROUP||TREATMENT||NONE||Diode Laser Cyclophotocoagulation||||
33862380|NCT06689449|||OTHER||PROSPECTIVE|||||||
33862381|NCT02259998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862382|NCT04258371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study|Patients will be randomized to 10mg PO dapagliflozin daily or matching placebo.|t|t|t|t
33862383|NCT01923116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862384|NCT06717867|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33862385|NCT02400450|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33862386|NCT06505603|||COHORT||PROSPECTIVE|||||||
34174979|NCT04114123|||COHORT||OTHER|||||||
34174980|NCT01715181|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34174981|NCT04371432|||CASE_CONTROL||PROSPECTIVE|||||||
34174982|NCT05696236|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participants and families, the food allergy nurse administering the oral food challenge (OFC), and the allergist physician assessing and treating the patient will be blinded to the study arm status.||t|t|f|f
34174983|NCT06517082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The stepped wedge design involves staggered implementation of an intervention across different providers over multiple time periods, allowing all providers to eventually receive the intervention.||||
34174984|NCT02538510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174985|NCT06706076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34174986|NCT03011008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174987|NCT05157386|||COHORT||RETROSPECTIVE|||||||
34174988|NCT00379015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34174989|NCT06518954|||CASE_CONTROL||RETROSPECTIVE|||||||
33862387|NCT06493981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862388|NCT06570044|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34174990|NCT06506253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Of necessity, the coordinator, subjects, and therapists will know their randomized group assignment. Other study staff interacting with participants, including the investigator completing adverse event assessments, will be masked to the treatment assignment. Participants randomized to a treatment arm will be asked not to disclose their assigned treatment to those staff members. The study coordinator and therapists performing the SMT and LT interventions will not discuss subjects' treatment assignment with other staff at any time during the study. The study statistician will perform and report the primary and secondary outcome analyses using masked treatment codes. The non-masked coordinator will have access to the study randomization schedule and may unmask subjects only in the case of emergency, or if necessary, to establish proper follow-up treatment for a condition that arises during the course of the study.|This is a two-arm, randomized, single masked study investigating the effects of Swedish massage therapy (SMT) vs. a light touch (LT) control on brain activity, clinical response, and autonomic function in subjects with GAD.|f|f|t|t
34174991|NCT00771758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34174992|NCT05163041|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34174993|NCT02859922|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34174994|NCT00383786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34174995|NCT02375854|||COHORT||PROSPECTIVE|||||||
34174996|NCT02910817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34174997|NCT05862766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34174998|NCT03317860|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants will receive both conditions (active and sham transcranial direct current stimulation paired with arm rehabilitation training \[repetitive task-specific practice\]) in this cross-over design study. Individuals will be randomized to determine which condition they receive first and the participant and treatment therapist and assessor will be blinded to the order that the interventions are delivered. The PI will oversee randomization so that each patient is randomized and assigned a unique five digit code. When this code is entered on the tDCS device, the device will automatically assign the patient to receive either real or sham stimulation. Because the sham stimulation provides a ramp up/ramp down stimulation for 15 seconds at the start and end of the session the participant may perceive the sham stimulation as active stimulation.||t|f|t|t
34174999|NCT06706635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175000|NCT03084211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34175001|NCT05461430|||COHORT||PROSPECTIVE|||||||
34175002|NCT06256185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862389|NCT00167050|||DEFINED_POPULATION||OTHER|||||||
34175003|NCT06706648|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175004|NCT05531656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175005|NCT05600543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175006|NCT06031727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862390|NCT06512337|||COHORT||PROSPECTIVE|||||||
34175007|NCT03433651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized using a random number generator to receive either creatine monohydrate or a placebo for 90 days. Both subjects and investigators will be blinded to the study group assignments||t|f|t|f
34175008|NCT05414500|NA|SEQUENTIAL||TREATMENT||NONE||3+3 dose de-escalation design. Mogamulizumab at 1mg/kg and Brentuximab Vedotin at 3 different doses||||
34175009|NCT06124807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175010|NCT05198869|NA|SINGLE_GROUP||OTHER||NONE||||||
34175011|NCT01277016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862391|NCT02613351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175012|NCT04798183|||CASE_CONTROL||PROSPECTIVE|||||||
33862392|NCT00285077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862393|NCT04977310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175013|NCT03550027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862394|NCT06581263|||CASE_CROSSOVER||OTHER|||||||
33862395|NCT04170712|||COHORT||PROSPECTIVE|||||||
33862396|NCT00800787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862397|NCT04280965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862398|NCT02841228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862399|NCT02679339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862400|NCT03701763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862401|NCT03571763|||COHORT||PROSPECTIVE|||||||
33862402|NCT00364871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33862403|NCT04924504|||CASE_CONTROL||PROSPECTIVE|||||||
33862404|NCT04304651|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33862405|NCT03758521|||COHORT||PROSPECTIVE|||||||
33862406|NCT06736262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962160|NCT01898858|||CASE_ONLY||PROSPECTIVE|||||||
34175014|NCT06537817|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34175015|NCT01436149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962161|NCT05349032|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34175016|NCT01634477|||COHORT||PROSPECTIVE|||||||
34175017|NCT04829292|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34175018|NCT01024517|RANDOMIZED|CROSSOVER||||NONE||||||
34175019|NCT02365649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175020|NCT05099302|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34175021|NCT06705205|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34175022|NCT06705582|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34175023|NCT02190526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175024|NCT05972278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|This is a phase 1, single-site, double-blind, randomized, placebo-controlled, 2 period, fixed-sequence, pharmacodynamic study in healthy participants meeting the eligibility requirements. Participants will be randomized in a 1:1 ratio to either obicetrapib or matching placebo, and evenly distributed between treatment groups based on their Screening Lp(a) values; ≥ 30 mg/dL vs \< 30 mg/dL. LDL-C levels ≥ 100 mg/dL and ≤ 190 mg/dL have been selected for this study as the target population as this is the population of patients targeted for treatment with obicetrapib as an adjunct to statin therapy.|t|t|t|t
34175025|NCT06705127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175026|NCT05823116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175027|NCT06204965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Women with Polycystic Ovary Syndrome (n=52), aged 18-40.|f|f|f|t
34175028|NCT03710187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175029|NCT02991469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175030|NCT05975827|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34175031|NCT06108232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175032|NCT02064803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175033|NCT04223115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175034|NCT00279318|||COHORT||PROSPECTIVE|||||||
34175035|NCT05906953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175036|NCT05681546|||OTHER||PROSPECTIVE|||||||
34175037|NCT05894369|||COHORT||PROSPECTIVE|||||||
34175038|NCT04590274|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34175039|NCT04419025|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are assigned to one of two groups in parallel for the duration of the study.~One arm is the intervention arm - those receiving N-acetylcysteine (NAC). One arm is the control group - those not receiving N-acetylcysteine (NAC)."||||
34175040|NCT05542069|||OTHER||CROSS_SECTIONAL|||||||
34175041|NCT03305614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175042|NCT06413576|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34175043|NCT00317980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34175044|NCT06256458|||CASE_ONLY||PROSPECTIVE|||||||
34175045|NCT05673928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175046|NCT06399900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double blinded study where both the participant and the people collecting data will be blinded.|Thirty-two participants with PAD will be randomized to either 660 nm light + home-based exercise or sham light + home-based exercise for four months. Both groups will receive the same home-based high intensity walking exercise intervention.|t|t|f|t
34175047|NCT04337177|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two different dose levels of VAL-413 (Orotecan®) will be studied in combination with fixed-dose temozolomide using a standard 3 + 3 phase I design. The first three patients will receive temozolomide in combination with Orotecan® at 90 mg/m2/day, which is the standard dose of irinotecan. If no dose-limiting toxicity (DLT) occurs during Cycle 1 in these patients, then subsequent patients will start Cycle 1 using a Orotecan® dose of 110 mg/m2/day. In the event the starting dose of 90 mg/m2/day is not tolerable due to toxicity, a lower starting dose of 75 mg/m2/day may be implemented.||||
33962162|NCT00695981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962163|NCT00837577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962164|NCT02516878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962165|NCT04149054|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962166|NCT01725841|||||RETROSPECTIVE|||||||
33862407|NCT00227487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862408|NCT05191069|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862409|NCT04260451|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33862410|NCT04337346|||CASE_CONTROL||PROSPECTIVE|||||||
33862411|NCT02838862|||||RETROSPECTIVE|||||||
33862412|NCT03733067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962167|NCT05069428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blinded, placebo controlled|t|t|t|t
33962168|NCT05037942|RANDOMIZED|PARALLEL||OTHER||SINGLE|Given the perceptual response that occurs under different occlusion pressures, it is difficult to mask the participant to the experimental conditions. Efforts will be made to minimise detection bias by blinding the outcome assessor to the study conditions and the timepoints from which the data has been collected.|The study uses a within-between, unilateral design, in which participants will be randomly allocated into one of two experimental groups using a stratified random allocation technique. Each group will perform blood flow-restricted exercise with one leg and the same exercise protocol without BFR with the contralateral leg. Experimental groups will be differentiated by the tourniquet pressure used during the BFR condition: i) tourniquet pressure set to 40% of limb occlusion pressure or ii) tourniquet pressure set to 80% of limb occlusion pressure. Legs will be counterbalanced such that the BFR and control conditions in each study group contain an equal number of dominant and non-dominant legs. This study design allows comparison between the two experimental conditions (i.e., 40% vs. 80% limb occlusion pressure), while allowing participants to serve as their own control condition.|f|f|f|t
34064865|NCT06444711|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An endpoint adjudication committee, blinded to allocation, will review observations, laboratory measures and GP medical records data for the participant to establish adherence of care to guidelines.|Multicentre pragmatic prospective randomised open-label blinded-endpoint strategy trial (PROBE).|f|f|f|t
34064866|NCT04151966|||COHORT||PROSPECTIVE|||||||
34064867|NCT00699712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175048|NCT06699927|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A randomized crossover trial will be conducted and participants will be randomly assigned to 1 of 2 conditions: Condition 1 consists of training type 1 followed by training type 2, whereas Condition 2 consists of training type 2 followed by training type 1. They will be assigned to Non-Gamified Span training and Gamified Span training.|t|f|f|t
34175049|NCT00754663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175050|NCT06705660|RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistician blinding method will be applied to perform statistical analyses objectively. In this way, the statistician will not know which participant belongs to which group, thereby increasing the objectivity and reliability of the analysis results|Within the scope of the study, women with Premenstrual Syndrome (PMS) will be divided into three groups. The first group will receive web-based lifestyle interventions, while the second group will be given web-based progressive relaxation training. The third group will serve as the control group and will not receive any training. Assessments will be planned at two stages: before the intervention (baseline assessments) and after the intervention (8 weeks later). The web-based lifestyle interventions and progressive relaxation training will be provided by monitoring the participants' menstrual cycles, ensuring that the training is administered over two menstrual cycles. Evaluations will be conducted both before and after the training periods, and an additional follow-up assessment will be performed one month (4 weeks later-the next cycle) after the completion of the training, to monitor the effects. This approach aims to observe the long-term outcomes of the training.|f|f|f|t
34175051|NCT06704802|||CASE_CONTROL||PROSPECTIVE|||||||
33862413|NCT01291199|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33862414|NCT06736470|||CASE_CONTROL||PROSPECTIVE|||||||
33862415|NCT02414724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862416|NCT03470675|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33862417|NCT00152698|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862418|NCT05082116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064868|NCT01349127|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34064869|NCT00082459|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064870|NCT00579891|||CASE_ONLY||PROSPECTIVE|||||||
34064871|NCT01196936|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34064872|NCT00237276|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34064873|NCT06731257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34064874|NCT05131932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064875|NCT02666638|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064876|NCT05698537|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064877|NCT05433272|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34064878|NCT04617964|||COHORT||PROSPECTIVE|||||||
34064879|NCT01815775|NA|SINGLE_GROUP||||NONE||||||
34064880|NCT04685928|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial, 1:1 allocation||||
34175052|NCT01968447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34175053|NCT06018350|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34064881|NCT01239524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34064882|NCT05628857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064883|NCT06504524|||COHORT||RETROSPECTIVE|||||||
34064884|NCT00516802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175054|NCT02101775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862419|NCT04694898|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study is part of the evaluation of the Government project SURE. SURE intervention districts were pre-selected in four regions out of the nine regions in Ethiopia. The regions were selected because they are agrarian and have high food insecurity and stunting prevalence (Oromia, Amhara, SNNPR and Tigray). A total of 36 districts were selected and assigned to the SURE intervention.~Comparison control districts were selected in equal number in the same four agrarian regional strata. Districts were roughly matched based on stunting prevalence tertiles (low, medium or high) and food insecurity scores. Eligible households are households with at least one child under the age of 2 years. The intervention started in 2016 and included 4299 households, 2146 of which were included in the intervention group and 2153 in the control group. After baseline data collection, all households in the intervention group received counselling at household and community levels."||||
33862420|NCT01543386|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862421|NCT00141804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862422|NCT00818389|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33862423|NCT03253939|||CASE_CONTROL||RETROSPECTIVE|||||||
33962169|NCT03971669|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Volunteers who choose to take part in this study will receive the licensed FDA-approved Oral Typhoid Vaccine (Vivotif).||||
33962170|NCT01891786|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962171|NCT00368914||||TREATMENT||||||||
33962172|NCT03202186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind, placebo controlled|Placebo controlled parallel arm study for 12 weeks|t|t|t|f
33962173|NCT05440084|||COHORT||PROSPECTIVE|||||||
33962174|NCT01739088|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33962175|NCT03395509|||COHORT||PROSPECTIVE|||||||
33962176|NCT05292430|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962177|NCT00297206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962178|NCT03994679|||COHORT||RETROSPECTIVE|||||||
33962179|NCT00123058|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33962180|NCT05355987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962181|NCT05264766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962182|NCT05098626|||COHORT||CROSS_SECTIONAL|||||||
33962183|NCT02623309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962184|NCT04734431|||COHORT||RETROSPECTIVE|||||||
33962185|NCT00743119|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Placebo-controlled, double-blind||t|f|t|f
33962186|NCT01743768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962187|NCT00276965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962188|NCT02336698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962189|NCT00291330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962190|NCT01200316|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33962191|NCT01078324|||COHORT||PROSPECTIVE|||||||
34175055|NCT00684866|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34175056|NCT05856422|NA|SINGLE_GROUP||OTHER||NONE||||||
34175057|NCT04462640|||COHORT||PROSPECTIVE|||||||
34175058|NCT05676203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175059|NCT06435663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175060|NCT04963166|||COHORT||PROSPECTIVE|||||||
34175061|NCT04291547|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34175062|NCT05537883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to type of Transversus Abdominis Plane (TAP) block used.|This study is a 2-arm parallel single blinded randomized equivalency, single-center, clinical trial.|t|f|f|f
34175063|NCT05635344|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33862424|NCT03540472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862425|NCT04919252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862426|NCT02195258|||CASE_ONLY||PROSPECTIVE|||||||
33862427|NCT01096888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33862428|NCT00685685|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33862429|NCT00307125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862430|NCT06734234|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||This is sequential double-blind study|t|t|t|f
33862431|NCT01323621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862432|NCT05572684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862433|NCT03445260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862434|NCT06569186|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention and Control groups||||
33862435|NCT06115967|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33862436|NCT06735443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862437|NCT03817710|||CASE_ONLY||RETROSPECTIVE|||||||
33862438|NCT06734117|||COHORT||PROSPECTIVE|||||||
33862439|NCT05638087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962192|NCT00172094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962193|NCT01594580|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33962194|NCT04144387|NA|SINGLE_GROUP||SCREENING||NONE||||||
33962195|NCT03185299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33962196|NCT01382901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962197|NCT01339884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962198|NCT02632383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962199|NCT04872868|||COHORT||PROSPECTIVE|||||||
33962200|NCT04620863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Transcranial direct current stimulation (t-DCS) was delivered by an expert technician (V.G.) that was not otherwise involved in the management of the patients. The managing physician as well as the physiotherapist were instead blind to the type of stimulation.|The study was a randomized, double-blind, controlled trial|t|f|t|f
33862440|NCT02830997|||COHORT||PROSPECTIVE|||||||
34175064|NCT06601413|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
34175065|NCT01901445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175066|NCT06555406|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes will be assessed by interviewers. Where possible, interviewers will be unaware of the treatment condition (interviewers will evaluate symptoms for more than one study, allowing us to keep them unaware of treatment condition).|All participants will be assigned to time-restricted eating. Adherence levels are expected to predict change in outcomes and proposed mechanisms. Key hypothesized mechanisms include salivary dim-light melatonin onset and buccal swab assessment of circadian clock genes to assess the amplitude of clock gene expression.||||
34175067|NCT06706700|||COHORT||PROSPECTIVE|||||||
34175068|NCT00915954|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33862441|NCT04435379|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The reconstitution of trial intervention will be done by unblinded site personnel who will not be involved in the collection or evaluation of outcome data. Administration of the trial intervention will be done by blinded site personnel.|Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or Placebo.|t|f|t|t
33862442|NCT02743819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862443|NCT01400581|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862444|NCT02231788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862445|NCT00152139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862446|NCT06735716|||COHORT||PROSPECTIVE|||||||
33862447|NCT05541029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study team members responsible for collecting data pre-post session will be masked to the condition received and condition order.|Participants will receive 3 conditions in a random order, via within-subject block randomization, each day for 3 consecutive days.|f|f|f|t
33862448|NCT03606980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862449|NCT01650285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862450|NCT00160381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33862451|NCT06735456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Since the application will be performed by the researcher, patients will be blinded in this study. The statistician will be blinded in the evaluation of the data.|Two groups with a mandala group and control group|t|f|f|t
33862452|NCT01260727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33862453|NCT05905510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962201|NCT03896919|||CASE_CONTROL||PROSPECTIVE|||||||
34064885|NCT05960149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064886|NCT06281158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064887|NCT00442481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064888|NCT02772809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064889|NCT01618461|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34064890|NCT04990271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150439|NCT01975610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150440|NCT01762995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150441|NCT02343705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150442|NCT03442582|||COHORT||PROSPECTIVE|||||||
34150443|NCT06231433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150444|NCT03433105|||COHORT||PROSPECTIVE|||||||
34150445|NCT03984656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150446|NCT04122170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150447|NCT01606033|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150448|NCT01836393|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34175069|NCT00352768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175070|NCT02918370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175071|NCT05764525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175072|NCT00010816|RANDOMIZED|||TREATMENT||DOUBLE||||||
34175073|NCT02539823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34175074|NCT04078841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175075|NCT02202122|||COHORT||PROSPECTIVE|||||||
34175076|NCT02133495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175077|NCT02673372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175078|NCT05876078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175079|NCT00002682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175080|NCT06147843|NA|SINGLE_GROUP||OTHER||NONE||||||
34175081|NCT04841447|||COHORT||PROSPECTIVE|||||||
34175082|NCT04197934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175083|NCT03210558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The testosterone cream and the placebo cream will be of identical appearance and will have the same texture to maintain double blind treatment.|A double-blind, randomized, placebo-controlled, phase II trial of in total 50 women randomized to two parallel groups (1:1): Group A treated with transdermal testosterone or Group B treated with placebo for ten weeks.|t|t|t|t
34175084|NCT06499844|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will complete one laboratory visit to assess endothelial function in the cutaneous microvasculature.||||
34175085|NCT01149850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175086|NCT00034567|||DEFINED_POPULATION||PROSPECTIVE|||||||
34175087|NCT04696757|NA|SINGLE_GROUP||TREATMENT||NONE||Aim: 1) to analyze the treatment results after receiving capecitabine adjuvant chemotherapy for 4 months after non-surgical treatment in patients who had completed and could have clinical complete remission with capecitabine preoperative chemoradiotherapy with capecitabine for mid-to-lower rectal cancer 2) to investigate the feasibility of non-surgical treatment.||||
34175088|NCT06396039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862454|NCT03157232|NA|SINGLE_GROUP||OTHER||NONE||||||
33862455|NCT05940610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175089|NCT05176899|||COHORT||PROSPECTIVE|||||||
34175090|NCT06470308|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175091|NCT04768504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175092|NCT03534804|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, non-randomized phase 2 study||||
34175093|NCT02196896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175094|NCT02913339|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34175095|NCT01095185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175096|NCT01740167|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33862456|NCT01521897|||CASE_ONLY||PROSPECTIVE|||||||
33862457|NCT02017379|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33862458|NCT02728882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175097|NCT01964651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175098|NCT05924984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||During CT scan, the patient lay in a supine position on the examination bed, with the patient's toes facing up and fixed with an ankle fixator, the perforator was placed on the outside of the patient's thigh, the base was extended or shortened according to the length of the patient's thigh, and the iliac patella positioning rod was slipped so that the iliac crest positioning rod was located on the anterior superior spine of the patient's iliac and the patella positioning rod was located on the lateral margin of the patient's patella. And mark the anchor point on the skin with a pen, and mark the skin with a pen. After CT examination, the computer carried out three-dimensional reconstruction of blood vessels, and moved the perforating branch locator rod according to the calculated scale to make it correspond to the scale, and marked the corresponding skin position according to the perforating branch locator rod.||||
34175099|NCT00642200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175100|NCT02443467|||COHORT||PROSPECTIVE|||||||
34175101|NCT01611714|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34175102|NCT06114615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175103|NCT05005260|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|||||
34175104|NCT06538480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175105|NCT04426422|NA|SINGLE_GROUP||TREATMENT||NONE||newly diagnosed type 2 diabetes was treated with metfomin for 3 months.||||
34175106|NCT00836368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175107|NCT06356922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175108|NCT04904692|||COHORT||PROSPECTIVE|||||||
34175109|NCT05941793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175110|NCT04372017|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34175111|NCT03183453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175112|NCT04441307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be asked to participate in a parenting program but will not be informed about which arm of the study they have been assigned. To avoid bias in the evaluation of the interventions, outcome assessors will not be informed about which arm of the study participants have been assigned.|In both arms, couples will experience a parenting program for expecting first time parents. In one arm, parents will receive an adapted Family Foundations program. In the other arm, parents will receive an empirically supported community parenting program.|t|f|f|t
34175113|NCT02018562|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unable to mask because patients and care providers were able to visualize the type of tracheostomy tub that was used.|||||
34175114|NCT03074409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34175115|NCT05955898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175116|NCT05198921|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomized crossover double-blind trial. It is a pre-post study with follow-up at 1 month|t|t|t|t
34175117|NCT04583280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175118|NCT06705088|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34175119|NCT06002620|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Stratified by sex, randomization was done by a team not participating in the study implementation and the randomization scheme sent directly to the assigned distribution staff The products under investigation are packed in similar containers differentiated by a code number only known to the distribution staff who is equally blinded of the products contents.|"The study has four arms namely: Control arm (CA), Enriched nutrition arm (ENA), Nutrition education arm (NEdA) and a Combined Nutrition Education and enriched nutrition (CEdNA).~Cricket Enriched flour(CEF) - with cricket, maize, millet, mineral and vitamin premix Corn-Soy Blend plus(CSB+) - with mineral and vitamin premix Nutrition Education- with video, face to face session and SMS reminder"|t|t|t|t
34175120|NCT02044354|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175121|NCT05975671|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Multicenter, mixed methods, implementation science study with a quasi-experimental design.||||
34175122|NCT04244448|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34175123|NCT04160182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175124|NCT03181022|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34175125|NCT06600555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175126|NCT02706652|||COHORT||PROSPECTIVE|||||||
34175127|NCT06705075|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175128|NCT03572504|||COHORT||PROSPECTIVE|||||||
34175129|NCT00754962|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34175130|NCT00436449|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34175131|NCT01860339|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34175132|NCT04844827|||CASE_ONLY||PROSPECTIVE|||||||
33862459|NCT05734183|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862460|NCT00067951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862461|NCT06462521|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862462|NCT00982969|||CASE_ONLY||PROSPECTIVE|||||||
33862463|NCT01012154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862464|NCT02090153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862465|NCT05172167|||COHORT||PROSPECTIVE|||||||
33862466|NCT01839721|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33862467|NCT04385888|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34064891|NCT03193034|NA|SINGLE_GROUP||TREATMENT||NONE|An independent radiographic reviewer will be assessing all radiographs from the study.|||||
33862468|NCT05772468|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Randomization will not be blinded since both the provider and patient know if the patient will be wearing the VR system during wound care or not wearing the VR system.|||||
33862469|NCT03482843|||COHORT||PROSPECTIVE|||||||
33862470|NCT04287842|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862471|NCT02956512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175133|NCT06159335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862472|NCT06441526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome is fistula closure based on MRI (completely fibrotic fistula tract). A radiologist blinded to treatment allocation will score fibrosis and inflammation of the tract based on MRI.|This is an international, multicentre, prospective, comprehensive cohort design trial to identify the most optimal treatment of Crohn's high perianal fistulas. In a comprehensive cohort design patients with a preference will be treated accordingly, whereas only those indifferent to treatment will be randomised in the usual way (combined randomised and preference cohort).|f|f|f|t
33862473|NCT05241782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862474|NCT06460285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be unaware of what group they are in.|Due to the objectives and nature of the study, the identity of test and control treatments will be known to investigators and research staff. Participants will, however, be blind to their conditional assignment. The active control condition was carefully selected to ensure that participants would be unaware if they were in the experimental or control condition, similar to using a taste-matching agent in a drug trial|t|f|f|f
33862475|NCT05542511|||COHORT||PROSPECTIVE|||||||
33862476|NCT01647529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862477|NCT04363073|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33862478|NCT01423877|||CASE_ONLY||PROSPECTIVE|||||||
33862479|NCT06330883|||CASE_CONTROL||PROSPECTIVE|||||||
33862480|NCT01479114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862481|NCT01667107|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862482|NCT02827357|||COHORT||RETROSPECTIVE|||||||
33862483|NCT06735027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two study arms, with each arm receiving one of two interventions: corticosteroid shoulder injection or suprascapular nerve block|f|f|t|t
33862484|NCT06343012|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|A quasi-experimental study design utilized two groups, study and control groups.|A quasi-experimental study design utilized two groups, study and control groups|t|f|f|f
33862485|NCT06057545|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multi-center, prospective, interventional, open-label, randomized, two-phase, two-sequence, single dose, crossover, phase III b||||
33862486|NCT04960423|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33962202|NCT03412461|RANDOMIZED|PARALLEL||OTHER||DOUBLE|To maintain partial blindness, researchers administering surveys will not be aware of the group allocation of participants. A researcher who will not be in contact with participants will conduct the randomization. Recruitment materials do not include any reference to the intervention (Thought Spot) and therefore, mitigates any potential demand characteristics among participants|Students will be recruited and randomized to the intervention arm or the control arm. The intervention group participants will have access to the Thought Spot platform. The control group participants will receive a pamphlet that outlines mental health services and wellness services across the GTA. Both groups will also have access to usual care.|t|f|t|f
33962203|NCT01890694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962204|NCT02284373|RANDOMIZED|PARALLEL||TREATMENT||NONE||This investigation is a randomized clinical trial of a prospective cohort of subjects with venous ulcers, with an observational cohort of 50 subjects with lymphedema. Venous ulcer subjects will be randomized into two arms||||
33962205|NCT02379676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175134|NCT03742076|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34175135|NCT05041413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175136|NCT06705257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm. All the recruited preterm infants will undergo increasing and decreasing levels of PEEP and the effect of EIT with various PEEP levels will be studied.||||
33862487|NCT00087750|RANDOMIZED|||TREATMENT||DOUBLE||||||
34175137|NCT06334432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175138|NCT02730858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175139|NCT03954639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|t|f|f
34175140|NCT04829136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175141|NCT04388592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research team will randomize consented patients who meet inclusion criteria on a 1:1 ratio on a centralized secure website. Block randomization (using variable block sizes) will be used to ensure there are equal participants in the intervention and control arms and to further conceal allocation. Participants will be randomized to either the intervention group of NP-led care or the control group of standard care provided by community neurologist and registered nurse. Due to the nature of the intervention, blinding of the providers or patients will not be possible. However, the statistician will be blinded as to which group represents the intervention and control. All participants will be given appointment with the NP, either within 4 to 6 weeks if randomized to the intervention arm, or at 6 months after study conclusion if in usual care arm.|A parallel prospective randomized controlled trial with two equal groups, testing for superiority, with the patient as the unit of randomization.|f|f|f|t
33962206|NCT00572247|RANDOMIZED|PARALLEL||||NONE||||||
33962207|NCT06390358|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33962208|NCT03386669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175142|NCT04525755|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized in a 2:1:1 ratio to receive a 4-week sample of varenicline, NRT, or not, with outcomes assessed through 12 weeks of follow-up. Participants in the varenicline sampling group will be given standard instructions on titration but ultimately will decide on their own as to if and how it is used. Dosing is lower than most industry trials of varenicline (1mg BID) but consistent with two trials of lower dosing that showed efficacy and with fewer side effects. Varenicline participants can choose to titrate 2mg if they wish, with shorter duration of sampling experience. Participants in NRT group will receive 28 day supply of nicotine patch (1patch x 28 days @ 14mg) and lozenge (14 per day x 28 days @4mg) with instructions to use based on number of cigarettes smoked per day. Like varenicline participants, smokers in NRT group can use as much or as little of the NRT as they wish.||||
34175143|NCT06228625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant|Randomize Controlled Double Blind Study|t|f|f|t
34175144|NCT05194124|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34175145|NCT00755664|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34175146|NCT04523194|||CASE_ONLY||RETROSPECTIVE|||||||
34175147|NCT04736888|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175148|NCT01584869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175149|NCT00739921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175150|NCT03028233|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175151|NCT06705881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175152|NCT03366545|||OTHER||PROSPECTIVE|||||||
33862488|NCT05930782|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Part 1: PQP tablet / dispersible granule administered in fasting condition of at least 10 hours.~* Group 1: PQP hard tablet, 320 mg (N=12)~* Group 2: PQP dispersible granule, 320 mg (N=12)~Transition to Part 2:~To minimize the risk to healthy participants, a decision on transitioning from Part 1 to Part 2, will be taken by the Safety Review Committee (SRC), based on the safety and preliminary PK interim report of the granule formulation, compared to the PQP hard tablet, with safety data obtained up to Day 15 and PK data obtained up to Day 8. If necessary, doses may be readjusted for the Part 2 to assess the food effect.~Part 2: PQP dispersible granule administered in fed conditions (planned as 320 mg)~* Group 3: High-fat meal (N=12)~* Group 4: Low-fat meal representative of African diet (N=12)~* Group 5: Whole milk 250 ml (N=12)"||||
34175153|NCT03773978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962209|NCT01399424|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33962210|NCT06538233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962211|NCT01212601|||COHORT|||||||||
34175154|NCT02470897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175155|NCT03542487|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Primary care practices will be assigned to a provider-side treatment (physician orientation) or to control. Within treatment assigned practices, individual patients will be assigned to one of four reminder messaging groups (one of which is no messaging).||||
34175156|NCT02670447|||CASE_ONLY||PROSPECTIVE|||||||
34175157|NCT06378541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34175158|NCT03576885|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Masked randomized controlled trial|t|t|t|t
34175159|NCT06704698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34175160|NCT04845152|||OTHER||RETROSPECTIVE|||||||
34175161|NCT02157818|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34175162|NCT01278043|||CASE_ONLY||PROSPECTIVE|||||||
34175163|NCT06705673|||COHORT||CROSS_SECTIONAL|||||||
34175164|NCT05816811|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group pilot trial aimed at examining the feasibility of a 10-week power-focused resistance training intervention for people with stroke||||
34175165|NCT04649541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862489|NCT03442790|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The participants will not have any knowledge of the intervention and the investigator who is doing the ultrasound confirmation will not have access to the results of the chest x-ray confirmation until the end of the study period when all the data is analyzed.||t|t|f|f
34175166|NCT05635786|||COHORT||RETROSPECTIVE|||||||
34175167|NCT04039087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The participants, care provider, investigator and those assessing the outcomes will be blinded to treatment designation.|Subjects will be randomized 1:1 to the sildenafil or placebo groups|t|t|t|t
33838294|NCT05860829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A pre-test will be conducted to explore the level of knowledge of the caregivers regarding oral hygiene and nutrition literacy of children with ASD. In-depth interviews will be conducted in order to identify the problems faced by caretakers till the saturation is reached. A semi-structured interview guide and caregiver education program will be developed related to dietary intake and oral hygiene of the child with autism for the caregivers. A dentist will provide education on oral hygiene and a registered dietician on nutrition literacy and diet diversity via telehealth. A post-test will be conducted after completion of all the sessions to assess the impact of the intervention.||||
33838295|NCT02423889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838296|NCT02530710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862490|NCT00950430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862491|NCT04644380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862492|NCT01711151|||CASE_CONTROL||PROSPECTIVE|||||||
33862493|NCT05211310|||OTHER||PROSPECTIVE|||||||
33962212|NCT05268965|||CASE_CONTROL||PROSPECTIVE|||||||
33962213|NCT00660049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962214|NCT02329496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962215|NCT05763277|||COHORT||PROSPECTIVE|||||||
33962216|NCT02735226|||COHORT||PROSPECTIVE|||||||
33962217|NCT05951231|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Single center, prospective, open, observational study||||
33962218|NCT00789568|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33962219|NCT03840642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962220|NCT03560115|||OTHER||PROSPECTIVE|||||||
33962221|NCT05902637|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962222|NCT01124526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962223|NCT02236364|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962224|NCT06564610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33962225|NCT02923115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962226|NCT05058703|||OTHER||PROSPECTIVE|||||||
33962227|NCT02637609|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962228|NCT06303882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962229|NCT04591600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962230|NCT02394431|||COHORT||PROSPECTIVE|||||||
33962231|NCT00179374|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33962232|NCT02953132|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33962233|NCT00552227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962234|NCT00291512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962235|NCT04349826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34175168|NCT05294588|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and laboratory and clinical staff conducting Ng challenge and assessment of infection and immune responses will be blinded to study arm assignment. Randomization group assignments will be maintained throughout the study.|The study intervention is vaccination with two doses of BEXSERO™and with two commercially available FDA-approved vaccines that do not have relevance to Neisseria gonorrhoeae: quadrivalent influenza (FLULAVAL™) and tetanus/diphtheria (TDVAX™). At enrollment, participants are randomized in a 1:1 ratio to the control vaccine arm or the experimental vaccine arm. Participants assigned to the control arm of the study receive immunization with control vaccinations prior to Neisseria gonorrhoeae challenge and with BEXSERO™after Neisseria gonorrhoeae challenge. Participants assigned to the experimental arm of the study receive immunization with BEXSERO™ prior to Neisseria gonorrhoeae challenge and with after control vaccinations Neisseria gonorrhoeae challenge.|t|t|t|f
34175169|NCT06420960|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175170|NCT05267262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862494|NCT03886792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind to treatment group|Feasibility Randomized Controlled Trial with one experimental and one control group|f|f|f|t
33962236|NCT03967106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Participants will be randomly allocated to either the treatment or sham condition.|t|t|f|t
33962237|NCT04529499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a prospective, interventional, multi-centre, phase III, randomized, double blind, placebo-controlled, parallel design trial to evaluate the efficacy, safety and tolerability of favipiravir as adjunct ('add on') to supportive care, in comparison to placebo with supportive care, in the acute treatment of patients who have tested positive for SARS-CoV-2 and presenting with moderate to severe COVID-19.|780 patients are randomized into two treatment groups at a 1:1 ratio, so as to have approximately 390 patients in favipiravir + supportive care group and 390 patients in placebo + supportive care group.|t|t|t|t
34175171|NCT05963880|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34175172|NCT03322956|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||One way, mixed, Randomized Controlled Trial(RCT), intention to threat design, level 2b.|t|f|f|f
34175173|NCT05390372|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33838297|NCT00945672|RANDOMIZED|||TREATMENT||TRIPLE|||t|t|t|f
33838298|NCT04792476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33862495|NCT03288870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862496|NCT01938807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862497|NCT06048315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862498|NCT03171727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962238|NCT00221572|||OTHER||PROSPECTIVE|||||||
33862499|NCT06101823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo controlled|t|t|t|t
33862500|NCT04706611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862501|NCT02311998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962239|NCT02374931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962240|NCT01459354|||CASE_CONTROL||PROSPECTIVE|||||||
33962241|NCT01225237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962242|NCT04981405|||CASE_CONTROL||RETROSPECTIVE|||||||
33962243|NCT03355807|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|A Patient, investigator and anesthesiologist who was blinded to the assignment of the patients recorded levels of sedation, pain, cumulative morphine consumption, and hemodynamic variables|The patients undergoing sleeve gastrectomy.|t|t|t|t
33962244|NCT00712660|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962245|NCT06016101|||OTHER||OTHER|||||||
33962246|NCT04385264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962247|NCT05627349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33962248|NCT06521281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962249|NCT04807231|||CASE_ONLY||PROSPECTIVE|||||||
34064892|NCT01230216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838299|NCT05120037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33838300|NCT01008553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838301|NCT05795803|||OTHER||CROSS_SECTIONAL|||||||
33838302|NCT01048697|NA|SINGLE_GROUP||||NONE||||||
33838303|NCT02780518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838304|NCT06179745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants in both groups (BCI, Sham) are fitted with the exact same equipment (EEG cap, FES device, assistive hand orthosis). In the BCI group, FES stimulation and orthosis triggering are only initiated when the BCI infers on line the presence of adequate SMRs or ERD/ERS within the epoch. That is, there is precise contingency between the efferent motor command and the afferent feedback induced by BCI-driven actuators (the patient feels he/she can move his upper limb when he wants to do it). Conversely, in the sham group, the any EEG signals of motor intention will be ignored and FES/orthosis triggering is decided at random. Each closed-loop BCI sub-movement epoch operates with a timeout of 2 seconds. In case the BCI detects no adequate SMR EEG correlates within this interval, the auditory cue commands an additional movement attempt and the epoch will be repeated as many times as needed."|Allocation to the two experimental groups (BCI and Sham) will be taking place at the University of Essex, so as to ensure therapists in the recruitment center remain blind to this information. A toolbox implementing Frane's minimization algorithm (Frane 1998), built by the University of Essex partners will be employed. Use of a covariate adaptive randomization algorithm is dictated by several reasons. First, patients will be recruited on the fly and the studied sample will not be known at trial onset, so that an adaptive allocation method is needed and stratified randomization methods are excluded. The identified possible confounding factors that will be balanced are: Group (BCI vs Sham), Age (in years), Gender, Time since CVA (in months), Primary outcome at pre-intervention screening time point, Lesion type (haemorrhagic vs ischemic), Lesion location (cortical vs subcortical), Lesion side (left vs right), Pre-treatment of spasticity (yes or no).|t|t|f|t
33862502|NCT04132960|NA|SINGLE_GROUP||TREATMENT||NONE||"The main objective is to evaluate the anti-tumor activity of DS-8201a in three cohorts of advanced breast cancer patients:~* Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)~* Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)~* Cohort 3: HER2 non-expressing (IHC0+)"||||
33862503|NCT02068365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862504|NCT00248690|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33862505|NCT02618824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175174|NCT06257303|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants will be blinded to the purpose of the study. In this way, it is planned to prevent them from making corrections in their alignment or posture.~The evaluator will also be blind to the groups. After the frontal plane projection angle measurement, it will be determined which group the participant will be in. Still, this information will not be shared with the evaluator who makes other evaluations."|Participants will be divided into two groups according to the presence of frontal plane projection angle and their demographic characteristics will be compared.|t|f|f|t
34175175|NCT02707627|||COHORT||PROSPECTIVE|||||||
34175176|NCT06706115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled design|t|f|f|t
34175177|NCT05856500|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862506|NCT06734793|||COHORT||CROSS_SECTIONAL|||||||
34175178|NCT04732520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175179|NCT06704529|||COHORT||CROSS_SECTIONAL|||||||
34175180|NCT00756106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175181|NCT06127784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A prospective, randomized controlled trial at a single centre with 2 groups of 90 adults. The intervention group will receive a one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients delivered within a motivational interviewing counselling session with a clinical nurse specialist. The standard care group will receive standard of care treatment.||||
34175182|NCT01225874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862507|NCT00841893|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34175183|NCT06399666|||COHORT||PROSPECTIVE|||||||
34175184|NCT06219889|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34175185|NCT05831228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34175186|NCT04576507|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study comprises a 16-day inpatient stay. On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.||||
34175187|NCT00537394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175188|NCT03856060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34175189|NCT05890833|||COHORT||PROSPECTIVE|||||||
34175190|NCT03409796|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33862508|NCT00588536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175191|NCT06703164|||COHORT||PROSPECTIVE|||||||
34175192|NCT06334003|||COHORT||PROSPECTIVE|||||||
34175193|NCT00374140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175194|NCT06229626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175195|NCT05160337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175196|NCT03156101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175197|NCT04475081|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomized by study nurse|MMR vaccine vs placebo|t|f|f|f
34175198|NCT04841122|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34175199|NCT01702207|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34175200|NCT00335491|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34175201|NCT04745559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175202|NCT05897541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175203|NCT03264586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34175204|NCT04682197|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This will be a single site, open label, randomized, waitlist controlled pilot clinical trial, enrolling healthcare workers aged 18 or older, who have self-reported symptoms of stress or anxiety, and meet a threshold score on self-reported inventories. Up to 166 participants will be enrolled in order to have at least 138 to complete the study. Participants will be randomly assigned to either an Early Intervention (EI) group which will receive 4 CR sessions of audible tones echoing current brainwave activity, following enrollment, or a Delayed Intervention (DI) group which will continue current care only, and will serve as a control group. Participants in both groups will continue their other current care throughout the study.||||
34175205|NCT05699642|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33862509|NCT03350776|||OTHER||CROSS_SECTIONAL|||||||
33862510|NCT03517384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862511|NCT04256486|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33862512|NCT03374098|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33862513|NCT00764933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862514|NCT06428825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838305|NCT01027130|||CASE_CONTROL||PROSPECTIVE|||||||
34175206|NCT06473233|||COHORT||OTHER|||||||
34175207|NCT06230900|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33838306|NCT04843267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838307|NCT00264303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33838308|NCT02878603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838309|NCT02600312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33838310|NCT01528319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838311|NCT02579395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838312|NCT06517238|||COHORT||RETROSPECTIVE|||||||
33838313|NCT04341129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862515|NCT06736054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862516|NCT04570111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862517|NCT06735105|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33862518|NCT01704963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862519|NCT06115408|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study will be conducted on 40 women; they will be subdivided into 2equal groups .each group receive different intervention|f|t|f|f
33862520|NCT01473316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862521|NCT01132066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862522|NCT06712550|||CASE_CONTROL||PROSPECTIVE|||||||
33862523|NCT01301820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862524|NCT01651013|||COHORT||PROSPECTIVE|||||||
33862525|NCT04828083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33962250|NCT03953911|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants at the Schools, providers of the mobile clinic and the outcomes assessor will be masked from the allocation of participants to the arms to ensure reduction in bias.|In this parallel study, three middle schools located in Los Angeles County will be assigned to 2 intervention arms: control (mobile clinic-only every 6-months); intervention (mobile clinic every 6-months or every month PLUS weekly educational sessions for parents).|t|t|f|t
33962251|NCT04207554|||CASE_ONLY||PROSPECTIVE|||||||
33962252|NCT01885507|||CASE_CONTROL||PROSPECTIVE|||||||
33962253|NCT00902252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962254|NCT03276962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962255|NCT05114018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, placebo-controlled, parallel group, multi-center trial|t|t|t|t
33962256|NCT02225028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962257|NCT03828201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962258|NCT01891188|||COHORT||PROSPECTIVE|||||||
34175208|NCT05927818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No party in our clinical trial are prevented from having knowledge of the interventions assigned to individual participants.|A single arm interventional study aiming at the detection of the effectiveness of sentinel lymph node biopsy compared to systemic lymphadenectomy in participants who has high suspicion of an adnexal mass for early ovarian cancer clinically before operation in a single center. Clinical exam, radiological evaluation and tumor markers are primary determinants in using an adnexal mass to be assigned as 'highly suspicious'. The interventional and control arms are the same participant (each participant becomes its own control since the sentinel node biopsy- interventional arm - results are to be compared to systematic lymphadenectomy -control arm- results). Intervention is injection of 2-4 mL sterile charcoal to the infundibulopelvic ligament or mesovarium of the suspicious adnexal mass followed by collection of stained sentinel lymph nodes and lymph nodes by systematic lymphadenectomy.||||
34175209|NCT04120285|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Participant recruiters will be blinded to the participant's intended treatment arm.~Survey data collectors will be blinded to each participant's treatment arm."|There are three treatment arms: 1) treatment as usual 2) treatment as usual with unguided eCBT and 3) treatment as usual with guided eCBT||||
34175210|NCT06595173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175211|NCT04279496|||CASE_ONLY||OTHER|||||||
34175212|NCT06011759|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A multi-faceted implementation intervention including qualitative interviews and feedback and optional delivery of Academic Detailing and/or LEAP.||||
34175213|NCT06026384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33838314|NCT01745575|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33838315|NCT02657499|||CASE_CONTROL||PROSPECTIVE|||||||
33838316|NCT01682265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838317|NCT00046969|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33838318|NCT02847039|||OTHER||PROSPECTIVE|||||||
33862526|NCT02209155|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962259|NCT05352256|||COHORT||PROSPECTIVE|||||||
33962260|NCT02984215|||||RETROSPECTIVE|||||||
33962261|NCT06120179|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, multi-center study. The Bashir™ Endovascular Catheter (BEC||||
33962262|NCT02151396|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33962263|NCT01462474|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962264|NCT03716258|||COHORT||PROSPECTIVE|||||||
33962265|NCT05418257|||COHORT||PROSPECTIVE|||||||
33962266|NCT02484235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33962267|NCT04924114|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33962268|NCT06008639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The subjects will be randomly assigned to the treatment group or the control group for 30 minutes/day (5-6 days a week) for 4 months while the treatment group is active settings and the control group is sham settings.|t|t|f|t
33962269|NCT02740673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962270|NCT00068445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33962271|NCT01681979|||COHORT||RETROSPECTIVE|||||||
33962272|NCT01257828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962273|NCT00918697|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962274|NCT04737811|||COHORT||PROSPECTIVE|||||||
34064893|NCT02152124|||CASE_CONTROL||PROSPECTIVE|||||||
34175214|NCT06344208|||COHORT||PROSPECTIVE|||||||
34175215|NCT06057753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175216|NCT03378869|||CASE_ONLY||RETROSPECTIVE|||||||
34175217|NCT06552273|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms are compared, an experimental group to which bias correction training will be applied and a control group, to which a non-specific mindfulness intervention will be used. Subjects will be randomly assigned to one group or the other.||||
33862527|NCT06736418|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation and Dose Expansion||||
33862528|NCT00935545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862529|NCT06725719|||COHORT||PROSPECTIVE|||||||
33862530|NCT02223403|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34175218|NCT04634097|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Control group : Standard follow-up patient related to pain. Specific to each center : with or without existing local ETP program (standard care).~Experimental group : Clusters will be proposed LE DECLIC EPRI intervention, which is a complex intervention, associating 3 components,:~A. DECLIC program set up in the centers, open to concerned patients.~B. 3 training sessions :~* one public of primary care physicians in order to give them the opportunity to be involved in the medical care in charge of the patient suffering from cancer pain.~* one public of cancer physicians, leaders of opinions in each cancer centers participating to the study and one public of health professionals in order to train them to be educators (team building).~* for healthcare professionals in order to train them as educators in this program.~C. The collaboration of one primary care network, specialized in pain management, in order to reinforce the patient care pathway."||||
33962275|NCT02929537|||OTHER||PROSPECTIVE|||||||
33862531|NCT00292656|NON_RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
33862532|NCT01383161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33862533|NCT04582981|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is an open-label, randomized, controlled, multi-centered phase II clinical trial||||
33862534|NCT05798078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are blind as to whether they have been allocated to the active training condition or sham training condition.||t|f|f|f
33862535|NCT04662151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Phase 1b portion is a randomized, dual-armed, dose escalation study to establish the safest \& most tolerated AT-100 dose tested as compared to air-sham alone.|t|f|f|f
33862536|NCT01313403|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33862537|NCT01186939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862538|NCT00564785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33962276|NCT02941380|||COHORT||PROSPECTIVE|||||||
33962277|NCT06073184|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, open label, multicentre, phase II, non-comparative study to determine the efficacy and safety of a GLP-1R/GIPR coagonist in combination with standard pIUD in patients with EC/AH who wish to preserve their fertility.||||
33962278|NCT04182984|||COHORT||PROSPECTIVE|||||||
33962279|NCT03422796|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33962280|NCT00470119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33962281|NCT05884138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962282|NCT02237118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962283|NCT00140738|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33962284|NCT04626765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962285|NCT03047473|NA|SINGLE_GROUP||TREATMENT||NONE||single center, add on, open label, single dose, single arm||||
33962286|NCT04441801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor, who took the measurements for both the intervention and control groups, was blinded to the subject's group, while the treating therapist was not blinded to the treatment intervention.|A prospective, parallel-group, randomized clinical trial participants will be randomly assigned to the control group or one of the 3 intervention groups .The three experimental groups was stretched for 15, 30, and 60 seconds, respectively the control group did not stretch|f|f|f|t
33962287|NCT04391400|||CASE_ONLY||PROSPECTIVE|||||||
33962288|NCT03434626|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessor conducting interviews does not have information on group assignment||f|f|f|t
33962289|NCT04033900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962290|NCT04701658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962291|NCT00196573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962292|NCT00858559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962293|NCT00990093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962294|NCT05301101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962295|NCT04071275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962296|NCT00200473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962297|NCT02726672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962298|NCT00694031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962299|NCT02353299|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33962300|NCT03711669|||COHORT||PROSPECTIVE|||||||
33962301|NCT01185730|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962302|NCT06265285|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962303|NCT00420355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962304|NCT01560182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962305|NCT04573361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Care was provided by chiropractors,|Three arms depending on the access to chiropractic care (no access, one visit or more than one) during the 14-days period of the trial. Measures were taken at the beginning and at the end of the 14-day period.||||
33962306|NCT04040959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962307|NCT04326569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962308|NCT01130701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962309|NCT02691312|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962310|NCT05620459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962311|NCT02558660|NA|SINGLE_GROUP||||NONE||||||
33962312|NCT01241812|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33962313|NCT05294770|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be randomized in a 1:1 ratio|||||
33962314|NCT00106379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962315|NCT00406107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751339|NCT04510805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"All patients who are screened for enrolment will be allocated an enrolment number. The recruiting clinician will record into a logbook the details of all patients screened for enrolment, including the reason for exclusion from trial entry.~A randomization sequence using block randomization with random block sizes of 4, 6 and 8 (to maintain equal sample size in each arm) will be created by researchers using PASS. Assignments will be enclosed in sequentially numbered, opaque, sealed envelopes.~Participants who provide written informed consent and are enrolled will be allocated to study arm by the study pharmacists. The pharmacist will be responsible for opening envelopes sequentially, writing the participant enrollment number on the envelope prior to opening, and recording the envelope number and study arm allocation in the CRF. On conclusion of the data collection phase, the (actual) study allocation status of the participants will be compared to the randomization sequence."|"Current warfarin dose individualization methods tend to be empirical, rather than based upon pharmacological and statistical principles. A theory-based model of warfarin pharmacokinetics and pharmacodynamics (PKPD) has been developed for dose individualization when used in conjunction with a Bayesian forecasting tool (NextDose).~This study compares standard of care clinician judgement for warfarin management with the use of a web-based dosing tool (NextDose). Computer-assisted anticoagulant dosing has been shown to be helpful using empirical models. This study will evaluate a theory-based model which has shown superior performance over empirical models in predicting clinical doses of warfarin. The study is also guided by quality and service improvement principles."|t|f|f|f
33751340|NCT00275197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33751341|NCT06682299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label patient preference trial||||
33751342|NCT06733662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33751343|NCT02200718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751344|NCT03141320|||COHORT||RETROSPECTIVE|||||||
33751345|NCT00447057|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751346|NCT04247672|||COHORT||PROSPECTIVE|||||||
33862539|NCT04423913|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a purely descriptive, non randomized, non controlled, prospective sequential-type pilot study on the first use in the indication for prostatic arterial embolization using beads loaded with doxorubicin in increasing doses: 0 mg, 2.5mg, 5 mg and 10 mg. It is a study with escalating doses of doxorubicin : 3 patients with non-loaded beads, 3 patients with beads loaded at 2.5 mg (1/20 of the dose administered for liver tumors), 3 patients with beads loaded at 5mg and 3 patients with beads loaded at 10mg.||||
33862540|NCT05803616|||COHORT||PROSPECTIVE|||||||
33862541|NCT01330914|||COHORT||PROSPECTIVE|||||||
33862542|NCT03218462|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33862543|NCT00348062|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33862544|NCT00486798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862545|NCT02876835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175219|NCT04144569|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34175220|NCT06581835|||COHORT||PROSPECTIVE|||||||
34175221|NCT00579774|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34175222|NCT02050438|||CASE_ONLY||PROSPECTIVE|||||||
34175223|NCT02814916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175224|NCT06704763|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175225|NCT06706414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175226|NCT06702631|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175227|NCT03745534|||OTHER||PROSPECTIVE|||||||
34175228|NCT05375669|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be screened as part of the clinical routine and will be included if they satisfy the eligibility criteria and sign the informed consent. All the study subjects who are included are patients who undergo surgery||||
34175229|NCT04272294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175230|NCT03626727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175231|NCT02168868|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862546|NCT06211673|||CASE_ONLY||PROSPECTIVE|||||||
34175232|NCT03934112|||COHORT||RETROSPECTIVE|||||||
34175233|NCT06705738|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"This study will be single-blinded for the neuropsychological assessment evaluators regarding the dietary intervention and double-blinded for the participants and the neuropsychological assessment evaluators regarding the SUPOL intervention to minimise selection bias.~The PI and the SUPOL supplier will be blinded to SUPOL administration for the proper conduct of this clinical study. If the PI deems medically necessary to reveal the participant's SUPOL or placebo allocation by breaking the blind, every possible effort must be made to keep participants and evaluators blinded until the end of intervention period."|The overall design of the study will be a randomized 4-arm parallel controlled clinical trial, single-blinded for the dietary intervention (MeDi and Western diet) and double-blinded for the intervention (SUPOL and placebo).|t|f|t|t
34175234|NCT06651593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175235|NCT06360302|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross-sectional comparative study with repeated measures||||
34175236|NCT03117751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only certain outcome measures as indicated will be blinded to the outcomes assessor.||f|f|f|t
34175237|NCT05192889|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All eligible patients receive a common first block of therapy and therapy in the 2nd block being determined by CD19 expression on leukemic blasts.||||
34175238|NCT04146376|||COHORT||PROSPECTIVE|||||||
34175239|NCT05131308|||COHORT||RETROSPECTIVE|||||||
34175240|NCT05090696|||CASE_ONLY||PROSPECTIVE|||||||
33862547|NCT01127945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175241|NCT03998410|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE||Recording Doppler US signals over the right wall chest|t|t|t|t
34175242|NCT06582225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study personnel who can be blind to study aims/hypotheses and group allocation, will be blind. Assessors conducting post-treatment and follow-up assessments will be external to the research team and blind to study aims/hypotheses and treatment allocation for the full duration of the trial (up to the 6-month follow-up). The assessors will not receive any information about the study design, objectives or treatment conditions in order to maximise the blinding integrity. At each follow-up assessment, participants will be reminded by their assessor to not reveal details about their treatment.|Multisite parallel-group randomised controlled superiority trial.|f|f|f|t
34175243|NCT06018441|||COHORT||PROSPECTIVE|||||||
34175244|NCT04105036|||COHORT||CROSS_SECTIONAL|||||||
33862548|NCT02511678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175245|NCT05604040|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34175246|NCT06705699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|data analyst||t|f|f|f
34175247|NCT06702644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175248|NCT03479814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862549|NCT00309868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862550|NCT00152555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064894|NCT01827709|NA|SINGLE_GROUP||OTHER||NONE||||||
33751347|NCT04609033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751348|NCT04329039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized on a 1:1 ratio to either somatostatin analogues with perioperative antibiotics vs. placebo with perioperative antibiotics|Randomized control trial comparing somatostatin analogues with perioperative antibiotics versus prolonged antibiotics|t|f|f|f
33862551|NCT01310803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862552|NCT05938855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862553|NCT02082041|||CASE_ONLY||CROSS_SECTIONAL|||||||
33862554|NCT00088907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862555|NCT04259294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862556|NCT06104644|||COHORT||PROSPECTIVE|||||||
33862557|NCT05750797|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862558|NCT06734663|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33862559|NCT00490880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862560|NCT05344768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group assignments will seal in sequentially numbered opaque envelopes by a investigator who will not involved in data collection. Investigators who will make evaluations and outcome measurements will not know the distribution of the groups throughout the study and will be blind.|The patients included in the study will be divided into six groups; the control group (20 adolescents), the moderate continuous aerobic exercise training group (20 adolescents), the high-intensity interval training group (20 adolescents), the resistance exercise training group (20 adolescents), combination of moderate continuous aerobic exercise training with resistance exercise training group (20) and combination of high-intensity interval training with resistance exercise training (20 adolescents).|f|f|t|f
33862561|NCT06249945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862562|NCT06342284|||OTHER||PROSPECTIVE|||||||
33962316|NCT05933226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33962317|NCT00068406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962318|NCT03954964|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962319|NCT02962531|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33962320|NCT00736931|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33962321|NCT02762968|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33962322|NCT03013517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962323|NCT02258607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962324|NCT01863095|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962325|NCT04291534|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34175249|NCT06150040|NA|SINGLE_GROUP||TREATMENT||NONE||"The therapeutic combinations NP137 + \[AZACITIDINE+VENETOCLAX\] will be administered on the first 6 patients enrolled in the study at Dose Level (14 mg/kg). According to safety rules based on the dose limiting toxicities occurence, a dose reduction of NP137 at Dose Level -1 (9 mg/kg) will be assessed in 6 additional patients.~After the safety run in part, study will be opened with 35 patients (including patients from the safety run in) at DL or DL-1."||||
34175250|NCT04455906|||COHORT||PROSPECTIVE|||||||
34175251|NCT02236026|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34175252|NCT03244878|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to either the wait-list controlled group or intervention group. Intervention period is 8 weeks. Data collection occurs at baseline, 4 weeks, and 8 weeks, with longer-term follow-up assessments.||||
33751349|NCT01795833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751350|NCT04196179|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33751351|NCT05885022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862563|NCT01438021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862564|NCT01019980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962326|NCT01514409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962327|NCT02951884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study uses a single blind masking scheme|Participants will be randomized to receive aspiration of the joint alone, receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine, or receive no injection or aspiration therapy|t|f|f|f
33962328|NCT00919048|||COHORT||RETROSPECTIVE|||||||
33962329|NCT03694093|||CASE_ONLY||PROSPECTIVE|||||||
33962330|NCT03183973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962331|NCT02111382|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34175253|NCT05913882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175254|NCT04965987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175255|NCT04435704|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Oxytocin will be administered by intravenous infusion at increasing and decreasing rates||||
33862565|NCT03214133|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"Alkalized (0.01 mg epicatechin/g) ) and non alkalized cocoa (4.1 mg epicatechin/g) will be mixed in various ratios to achieve the desired 0, 1, 2, 3 mg/ kg body mass but maintaining equally weighed dose of cocoa for each intervention.~For Arm 2, the same quantity of either alkalized or non alkalized cocoa will be given to achieve the optimized dosed of epicatechin."|Arm 1 of the project will employ a randomized single-blinded crossover design with subjects completing all 4 of the epicatechin-rich chocolate trials (0, 1, 2 and 3 mg.kg-1). Arm 2 will use a randomized parallel double-blind design with neither the subjects nor the investigators knowing who is on which treatment (optimized epicatechin-rich chocolate dose or Dutch processed/epicatechin depleted placebo.|t|f|t|f
33962332|NCT01979588|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962333|NCT00303433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33962334|NCT05965622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part of the research team that will collect and analyse the data are blinded.|A randomized, controlled, pragmatic, multicentre, trial in the Netherlands and Belgium with 13 participating sites.|f|f|t|t
33962335|NCT00767884|||OTHER||OTHER|||||||
34175256|NCT04927546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||RA patients will be divided into 2 groups, according to the pharmacological treatment (tocilizumab or anti-TNF). A third group will be composed by healthy controls. The acute responses of insulin sensitivity after an acute session of exercise will be assessed by the hyperinsulinemic euglycemic clamp, and the molecular pathways will be assessed by muscle biopsy and gene and protein expression analysis. Positron emission tomography-magnetic resonance imaging (PET/MRI) will be performed to quantify skeletal muscle glucose uptake.||||
34175257|NCT06706323|||COHORT||PROSPECTIVE|||||||
34175258|NCT05370495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Double-masked, parallel, randomized|t|t|t|t
34175259|NCT03497637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175260|NCT05985954|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175261|NCT05291520|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20||||
34175262|NCT05725395|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34175263|NCT06029296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34175264|NCT05216250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34175265|NCT05021354|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34175266|NCT06416306|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Outcomes will be determined from phonetic transcription of participants' speech during assessment sessions. All transcriptions will be completed by research assistants unaware of the condition (simple or complex treatment target), arm of the study (English or Spanish language of intervention) or phase of the intervention study (Pre, Post, or Follow-up).~The participant will be unaware of the relative complexity of their treatment target (i.e., condition: simple or complex)."|Two prospective treatment studies that share an identical study design, differing only in the language of treatment (Spanish or English). Both studies will employ a within- and across-subjects, single-subject experimental design (SSED) with multiple staggered baselines across two conditions (singleton consonant target vs. consonant cluster target).|t|f|f|t
34175267|NCT06211114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175268|NCT06572631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175269|NCT03631043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175270|NCT05499910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175271|NCT06345066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34175272|NCT06374992|||OTHER||CROSS_SECTIONAL|||||||
34175273|NCT06592417|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential Assignment||||
34175274|NCT05007405|||COHORT||RETROSPECTIVE|||||||
34175275|NCT01827137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175276|NCT04525586|||COHORT||PROSPECTIVE|||||||
34175277|NCT00558584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175278|NCT06706427|NA|SEQUENTIAL||TREATMENT||NONE||||||
34175279|NCT06601244|||OTHER||PROSPECTIVE|||||||
34175280|NCT06245889|NA|SEQUENTIAL||TREATMENT||NONE||Eligible patients with stage 2 and 3 TNBC (ER\<10% eligible) will be treated with 4 cycles of paclitaxel/carboplatin/pembrolizumab prior to surgery. A PET scan will be performed at baseline and after 1 cycle of therapy. A breast MRI will be performed after treatment completion. Patients with complete clinical response will proceed to surgery. Patients with RD will complete neoadjuvant rescue with 4 cycles of doxorubicin/cyclophosphamide prior to surgery. If residual disease identified after surgery, adjuvant therapy to be determined by the treating oncologist (may include doxorubicin/cyclophosphamide/pembrolizumab, capecitabine etc).||||
34175281|NCT01950624|||COHORT||CROSS_SECTIONAL|||||||
33751352|NCT06083207|NA|SEQUENTIAL||TREATMENT||NONE||||||
33962336|NCT05762263|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33962337|NCT00003692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175282|NCT06706609|||COHORT||CROSS_SECTIONAL|||||||
34175283|NCT05876754|NA|SINGLE_GROUP||TREATMENT||NONE|All patients, care providers, investigators, and outcomes assessors will know that each patient is taking the active study drug, ivosidenib.|||||
33862566|NCT04298463|||COHORT||RETROSPECTIVE|||||||
33862567|NCT06651632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862568|NCT05390359|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The order of the interventions will be randomized by a third person not involved in the treatment, assessment or statistical analysis. Once the care provider has inserted the needle in each subject, the investigator that apply the treatment will choose the treatment protocol assigned on the stimulator, previously programmed and codified. Thus, nobody (participant, care provider, investigator and the outcome assessor) will know what intervention is applied.|Randomized intervention of repeated measures, quadruple-blinded|t|t|t|t
33862569|NCT06315842|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||The participating physicians will be grouped into 4 clusters (5 physicians each). Each cluster will progressively (every 3 months) incorporate the use of a level of diagnostic and therapeutic intensity tool into their usual clinical practice.|f|f|f|t
33862570|NCT00222053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064895|NCT00596999|||CASE_ONLY||PROSPECTIVE|||||||
34064896|NCT02303834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175284|NCT03284710|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34175285|NCT04706364|||COHORT||CROSS_SECTIONAL|||||||
34175286|NCT04066439|||OTHER||RETROSPECTIVE|||||||
34175287|NCT06704542|||CASE_CONTROL||RETROSPECTIVE|||||||
34175288|NCT04675931|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Although the study is open label however in order to minimize the potential impact of treatment knowledge, treatment allocation, dose information, PK/AAG assessment schedule and concentration data, as well as other data that may result in systematic unblinding will not be available to the Clinical Trial Team (CTT) (particularly clinicians, trial statisticians, trial programmers) until the database is locked after IA of Cohorts 1-2. After interim database lock, the CTT would be unblinded with the results, however, the blinding will then be continued for Cohorts 3-5 until the final database is locked.|This will be an adaptive, multicenter, randomized, open label, sequential cohort study in participants aged ≥ 12 years old in Cohorts 1-2 and \< 12 years old to ≥ 6 months in Cohorts 3-5 with a diagnosis of moderately severe and severe P. falciparum malaria. In Cohorts 1-2, participants will get randomized to one of the three treatment arms (2 dose of intravenous cipargamin or intravenous artesunate - comparator ). After Cohort 2, interim analysis will be performed to take one best dose of intravenous cipargamin forward for Cohorts 3-5. Participants in Cohorts 3-5 with be randomized to one of two treatments arms ( intravenous cipargamin or intravenous artesunate - comparator).|f|f|f|t
34175289|NCT06531395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175290|NCT05989230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175291|NCT05986240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175292|NCT06216925|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175293|NCT04822675|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized trial||||
34175294|NCT04638088|||COHORT||PROSPECTIVE|||||||
34175295|NCT05148286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175296|NCT05823948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175297|NCT03366610|||COHORT||PROSPECTIVE|||||||
34175298|NCT01824238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175299|NCT04195646|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34175300|NCT06596083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and investigators are blinded from the experimental condition (KE or CON). Supplements are provided in non transparent tubes and the control supplement is identical in taste and viscosity to the ketone supplement.|Participants will go through the entire 5 week training camp and 1 week follow up while taking either ketone ester supplements (KE) or an isocaloric placebo (CON).|t|f|t|f
34175301|NCT03986970|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-label, randomised controlled trial (RCT)||||
34175302|NCT04968990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175303|NCT05537753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175304|NCT04607668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blinded Trial||t|f|t|f
33862571|NCT01636414|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862572|NCT03476330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862573|NCT04989699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||3:1|t|t|t|f
33862574|NCT02024451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862575|NCT03020238|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33862576|NCT04420650|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33862577|NCT05302583|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33862578|NCT02599454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862579|NCT00609843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862580|NCT04450654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blinded, placebo-controlled phase 2 trial.|t|t|t|t
33962338|NCT00646087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962339|NCT05836922|||COHORT||PROSPECTIVE|||||||
33962340|NCT03628222|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962341|NCT03584204|||COHORT||RETROSPECTIVE|||||||
33962342|NCT03485131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Raters were blind as was PI.|Two group randomized, parallel design|t|f|t|t
33962343|NCT00665509|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33962344|NCT01759225|||CASE_ONLY||RETROSPECTIVE|||||||
33962345|NCT02018042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962346|NCT05582200|||OTHER||OTHER|||||||
33962347|NCT03232554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||One third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Ferrous Sulfate，and the another third will receive Buxue Yimu Pills and Ferrous Sulfate in combination.|t|f|t|f
33962348|NCT01393717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962349|NCT06036901|||COHORT||PROSPECTIVE|||||||
33962350|NCT06134973|||COHORT||PROSPECTIVE|||||||
33962351|NCT01246986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962352|NCT03908502|||COHORT||PROSPECTIVE|||||||
33962353|NCT02028156|NA|SINGLE_GROUP||||NONE||||||
33962354|NCT01664000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962355|NCT03893305|||OTHER||OTHER|||||||
33962356|NCT05280873|RANDOMIZED|PARALLEL||TREATMENT||NONE||We randomly divided the patients into two groups and received pirfenidone combined with methylprednisolone or methylprednisolone.||||
33962357|NCT00985049|||COHORT||PROSPECTIVE|||||||
33962358|NCT03577652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962359|NCT05744531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The volunteer and the researcher (caregiver) before agreeing to participate in the study will not know which group they will be in. After accepting the research, the participant and the researcher will know who will be in which group.|There will be two group. One is interventional group; other is control group.|t|t|t|f
33962360|NCT04209829|||COHORT||PROSPECTIVE|||||||
33962361|NCT02065973|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33962362|NCT06454903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study investigators will not inform outcome assessors during Stage 3 (Phase 1b clinical trial) of participant condition assignments.|Stages 1 of this project will focus on developing content for a smartphone intervention (ACT to RECOVER) with input from stakeholders; Stage 2 will conduct iterative usability assessment of a beta version of ACT to RECOVER to via iterative small waves of field-testing to assess content acceptability and system usability; Stage 3 will conduct a Phase 1b randomized clinical trial, examining the acceptability and feasibility of comparing ACT to RECOVER to a smartphone-based symptom monitoring control group. Outcomes within Stage 3 will include treatment acceptability, procedural feasibility, and assessment of changes in psychosocial functioning and symptoms of opioid use disorder.|f|f|f|t
33962363|NCT04514328|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33962364|NCT05797857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962365|NCT02029313|RANDOMIZED|CROSSOVER||||NONE||||||
33962366|NCT06348004|||COHORT||RETROSPECTIVE|||||||
33862581|NCT01188473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862582|NCT01557179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862583|NCT04780932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862584|NCT02650414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862585|NCT00313040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33862586|NCT05999396|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multicenter, dose escalation and dose expansion part, Phase I clinical trial, designed to gain evidence of maximally tolerated and recommended phase-II dose of CC-3 in adult patients with CRC.||||
33862587|NCT02877836|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33862588|NCT00614107|||COHORT||PROSPECTIVE|||||||
33862589|NCT01177722|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862590|NCT05189769|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Design. This project will include a 5-year randomized control trial with four conditions: (a) PBIS and CP (serving as control), (b) SWPBIS+ and CP, (c) SWPBIS and CP+, and (d) SWPBIS+ and CP+.|2X2 randomized control trial across 2 districts|t|f|f|f
33962367|NCT06456398|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33962368|NCT03304990|||COHORT||PROSPECTIVE|||||||
33962369|NCT00000282||||TREATMENT||||||||
34064897|NCT01326000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862591|NCT04123990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862592|NCT05915988|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33862593|NCT00636688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862594|NCT03856658|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study without blinding||||
33862595|NCT03382184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, dual-arm study involving the Fraxel DUAL or Halo laser for the regrowth of hair after alopecia.||||
33862596|NCT03331653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind, masking the patient and the outcomes assesor. A simple randomization will be performed with Epidat software.|Randomized Clinical Trial (RCT) with two groups.|t|f|f|t
33862597|NCT04536610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33862598|NCT00902954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862599|NCT01910116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862600|NCT00669487|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33862601|NCT01856465|||COHORT||PROSPECTIVE|||||||
34175305|NCT02953652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175306|NCT01327625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150449|NCT00538993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34150450|NCT04343118|||COHORT||PROSPECTIVE|||||||
34150451|NCT02667756|||COHORT||PROSPECTIVE|||||||
34150452|NCT04437992|||OTHER||PROSPECTIVE|||||||
34175307|NCT04495218|||CASE_ONLY||PROSPECTIVE|||||||
34175308|NCT05985161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150453|NCT00618878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150454|NCT03639142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150455|NCT01364740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175309|NCT04864210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150456|NCT02032654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150457|NCT05006508|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants get access to the tool or get assigned to a control group without access.||||
34150458|NCT02605317|||CASE_ONLY||RETROSPECTIVE|||||||
33751353|NCT03598413|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Single blind trial, analysis of all samples blinded to investigation team.|Prospective Randomised controlled trial|f|f|t|f
33751354|NCT00520078|||||OTHER|||||||
33751355|NCT00067015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150459|NCT02772770|||COHORT||PROSPECTIVE|||||||
33751356|NCT03213158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751357|NCT03677713|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single center, non-blinded, randomized controlled trial (RCT) will be conducted as a pilot study.||||
33751358|NCT05143827|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33751359|NCT05871138|||COHORT||PROSPECTIVE|||||||
34150460|NCT01019837|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751360|NCT03731468|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33751361|NCT05045625|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33751362|NCT00030719|RANDOMIZED|||TREATMENT||||||||
33751363|NCT05151302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150461|NCT04397458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175310|NCT02543684|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34175311|NCT04647227|NA|SINGLE_GROUP||TREATMENT||NONE||ATHN 16 is a phase IV multi-center, US-centric, open-label, safety study||||
34175312|NCT03547518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant blinded to interventional or sham treatment|Randomized, single blind parallel assignment|t|f|f|f
34175313|NCT04141748|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Prospective, multi-center, assessor-blinded, cross-over study|f|t|f|t
34175314|NCT04204447|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175315|NCT01810471|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34175316|NCT06704893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175317|NCT05324293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751364|NCT03178266|||CASE_CONTROL||PROSPECTIVE|||||||
33751365|NCT03141359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751366|NCT04085328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751367|NCT05870748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751368|NCT04197843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751369|NCT00726206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751370|NCT06498765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|t|f|f|f
33751371|NCT00950469|||COHORT||PROSPECTIVE|||||||
33751372|NCT01992380|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33751373|NCT05549973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751374|NCT00000502||CROSSOVER||TREATMENT||||||||
33751375|NCT01420055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838319|NCT00680992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838320|NCT01701102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838321|NCT04684433|||COHORT||RETROSPECTIVE|||||||
33838322|NCT05508815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838323|NCT04329572|NA|SINGLE_GROUP||TREATMENT||NONE||All patients included in the study will receive hydroxychloroquine (HCQ) 400 mg (BID/ 7 days) and azithromycin (AZT) (500 mg/ 5 days) on top of standard care. Patients that do not consent to participate or that do not fulfill eligibility criteria will be invited to participate as control group and will receive standard care only.||||
33838324|NCT04743531|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838325|NCT01200290|NA|SINGLE_GROUP||OTHER||NONE||||||
33838326|NCT03296800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838327|NCT06089005|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|pre post test single group intervention study design||||
33838328|NCT01998789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838329|NCT00000490|RANDOMIZED|||PREVENTION||||||||
33838330|NCT01686737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838331|NCT05441462|||OTHER||RETROSPECTIVE|||||||
33838332|NCT01225380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838333|NCT05449405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multi-center, Phase 2/3 Study to evaluate the efficacy and safety of nasally administered CPM in subjects with symptomatic COVID-19 with a positive PCR test.|t|f|t|f
33838334|NCT05543239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"An independent physiotherapist performs vagus nerve stimulation or sham stimulation according to the group envelope; Investigators (physicians) are only responsible for administering medications other than vagus nerve stimulation;Before treatment, all subjects were told that the intensity of this treatment method may not be felt; The therapeutic device is placed in an opaque airtight pouch that is invisible to both the clinician and the patient during use. The control strategy used transient sham stimulation, which allows for subjects blinding while delivering a true placebo treatment. Data analysts will be blinded to the allocated treatment group."||t|t|t|t
33838335|NCT03402074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175318|NCT06329830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175319|NCT03019406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175320|NCT03355976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175321|NCT01384981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175322|NCT05544162|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175323|NCT01925885|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34175324|NCT03851458|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34175325|NCT06384066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175326|NCT06704581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175327|NCT04806386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175328|NCT03189368|||CASE_CROSSOVER||PROSPECTIVE|||||||
34175329|NCT04985604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175330|NCT05488678|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study will enroll approximately 32 participants assigned to groups based on renal function.||||
34175331|NCT00629980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175332|NCT05293769|||CASE_CONTROL||PROSPECTIVE|||||||
34175333|NCT04107948|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175334|NCT03035032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862602|NCT06007742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862603|NCT06227403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors will be masked to study condition.|Randomized Control Trial|f|f|f|t
33862604|NCT01559194|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33862605|NCT00626210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862606|NCT04279847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||monotherapy and ruxoltinib combination||||
33862607|NCT00147290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862608|NCT04309279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The randomization will be performed by an independent assessor using a computer-generated list of numbers. A 2-hour online Zentangle class will be delivered to the Zentangle group by a certified Zentangle teacher via online webinar. The Zentangle group will complete a short qualitative questionnaire and participate in a 15-minute brief discussion right after the Zentangle class. They will also be encouraged to practice Zentangle daily for two weeks. Both Zentangle group and waitlist control group will complete a set of online questionnaires before the intervention commences, immediately after the intervention and 2 weeks after the intervention. An online Zentangle class will be provided to the waitlist control group after the post-intervention data of the Zentangle group has been collected.|f|f|f|t
33862609|NCT03508167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862610|NCT06493682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862611|NCT00774865|||COHORT||PROSPECTIVE|||||||
33862612|NCT00819260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862613|NCT05208164|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Group A will be assigned as the intervention group and Group B will be assigned as the usual care group. During the pilot RCT, Group A will run in parallel with Group B.||||
33862614|NCT06735508|NA|SEQUENTIAL||TREATMENT||NONE||||||
33862615|NCT00619190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862616|NCT02513186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862617|NCT02869555|||COHORT||PROSPECTIVE|||||||
33862618|NCT05608577|||COHORT||OTHER|||||||
33862619|NCT00824824|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33862620|NCT04110964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862621|NCT01493258|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33862622|NCT01878643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862623|NCT06736015|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group will receive myo-inositol and selenium and one group will not be treated||||
33862624|NCT02190669|||COHORT||PROSPECTIVE|||||||
33862625|NCT04582890|||COHORT||PROSPECTIVE|||||||
33838336|NCT00566189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838337|NCT00953615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838338|NCT04311918|||CASE_ONLY||PROSPECTIVE|||||||
33838339|NCT00346905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838340|NCT05442684|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|observer-blind clinical trial|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O, Ad5-nCoV/O-IH or mRNA-based COVID-19 vaccine in a ratio of 2:2:1.|f|f|t|f
33838341|NCT01931111|||OTHER||CROSS_SECTIONAL|||||||
33838342|NCT00003704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838343|NCT05127759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838344|NCT01252355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838345|NCT03670004|||COHORT||PROSPECTIVE|||||||
33838346|NCT05759962|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33838347|NCT04843397|||OTHER||PROSPECTIVE|||||||
33838348|NCT02798497|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838349|NCT04149938|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33838350|NCT05389553|||COHORT||PROSPECTIVE|||||||
33838351|NCT04532567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33838352|NCT05917353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33838353|NCT02713477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838354|NCT05355857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Healthy volunteers||||
33838355|NCT05372042|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Participants will receive text messages 3 days a week for a 4 week period. To keep text messages within the length of standard SMS limits (160 characters), each day's message will be sent in the form of two brief texts (each will be 160 characters or less). The content of the text messages will vary as a function of condition. Participants will be assigned to CBT text messages plus one of six combinations of framing (3: loss vs. gain vs. no framing) and mindsets (2: growth vs reminder) texts. The combination that consists of no framing and simple reminder is an active comparator as it is the version of CBT text messages closest to what has been tested previously.||||
33838356|NCT00136643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33838357|NCT00689182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838358|NCT02737826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838359|NCT05969301|||COHORT||PROSPECTIVE|||||||
33838360|NCT03197753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor|Parallel|f|f|f|t
33838361|NCT02525692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175335|NCT06586684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175336|NCT06473246|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, Double-Blind and Placebo controlled|t|t|t|f
34175337|NCT06700668|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175338|NCT05904158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled design||||
34175339|NCT06317181|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Data is collected in a defined group of patients (all patients listed for elastography or for ultrasonic investigation due to a focal lesion in participating departments). Afterwards performances of algorithms are compared based on this group.||||
34175340|NCT06250699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175341|NCT06175338|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34175342|NCT06501001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175343|NCT02400216|||CASE_ONLY||CROSS_SECTIONAL|||||||
33862626|NCT03312088|||COHORT||PROSPECTIVE|||||||
33862627|NCT06693310|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33862628|NCT02037646|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33862629|NCT03675776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862630|NCT01636791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862631|NCT06441890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862632|NCT00613054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862633|NCT00146757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862634|NCT00979251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862635|NCT02294123|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33862636|NCT04689997|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participating teens and parents will not know that their primary care provider has extra tools for their health supervision visit devoted to substance use prevention, reduction, or care. Statisticians will be blind to assignment.|We will employ a cluster randomized two-group pretest-posttest design, clustered at the provider level.|t|f|f|t
33862637|NCT04583891|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Sequential, Multiple Assignment, Randomized Trial (SMART)|t|f|f|f
33962370|NCT05151172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||ESCAPE-MeVO is a multicenter, prospective, randomized, open- label study with blinded endpoint evaluation (PROBE design). Subjects will be allocated (1:1) to best guideline-based best medical care plus endovascular therapy (EVT) vs. best guideline- based best medical care alone.|f|f|f|t
33962371|NCT06416007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962372|NCT01953627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962373|NCT03903952|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34064898|NCT03171740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will not know which group they will be allocated. The anesthesia care provider will not know which premedication the patient received because another professional, who is not from the research team, will provide it to the child. The investigator and outcome assessor will only know the allocated group latter by a code which will be revealed after the end of the analysis.|All participants will receive an intranasal and an oral drug. One group will receive oral midazolam and intranasal saline, the other will receive oral saline and intranasal dexmededomedine.|t|t|t|t
34064899|NCT06730724|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064900|NCT02094950|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
34064901|NCT04634032|||CASE_CONTROL||PROSPECTIVE|||||||
34064902|NCT03726736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064903|NCT04481165|||COHORT||PROSPECTIVE|||||||
34064904|NCT04283526|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064905|NCT01601002|NA|SINGLE_GROUP||||NONE||||||
34150462|NCT02920723|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150463|NCT02138357|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34175344|NCT04772170|||COHORT||PROSPECTIVE|||||||
34175345|NCT03617562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175346|NCT06333184|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33862638|NCT06552299|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33862639|NCT01674712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862640|NCT01762176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862641|NCT01793363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862642|NCT01230554|NA|SINGLE_GROUP||OTHER||NONE||||||
33862643|NCT04858906|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33862644|NCT06495385|||COHORT||PROSPECTIVE|||||||
34150464|NCT03770104|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Clinicians and neonatal nurses will not masked to group assignment. However, Neonatal Intensive Care Unit nurses who take care of the patient will be mask, as well as both pediatric radiologist who will determine the main outcome of the study.||t|f|f|t
34150465|NCT06312033|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Neither participant or investigator knew the timepoint of drug or placebo administration. Pills were prepared by independent members of the university hospital.|The intervention assessed the effect of estradiol administration on stress reactivity using a double blind randomized within -between placebo-controled design with repeated measures.|t|f|t|t
34150466|NCT02063763|||CASE_ONLY||RETROSPECTIVE|||||||
34150467|NCT04548362|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE|It is not possible to mask foods and for the explorative analysis of results, masking is not required.|Subjects were randomised to four meals with meats and starchy foods in such a way that all volunteers had each meat and each starchy food once and so that all combinations of meats and starchy foods were equally common. Each volunteer was also randomised to the sequence of the meals.||||
34150468|NCT03141541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The invistigator performing the data analysis is unaware of group allocation. Due to the study design (pain management intervention versus usual care) it is not possible to blind patients and care providers.~Furthermore, as outcomes are selfreported, masking of assessors is not possible, as the patients are the assessors."|Parallel group randomised controlled trial|f|f|t|f
34150469|NCT00434798|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862645|NCT06719544|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33862646|NCT04942028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862647|NCT00642551|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33862648|NCT05922020|NON_RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|"1. Study participants will not be aware of the inspired O2 concentration in their breathing gas mixture. All participants will be breathing through a non-rebreather mask, which will be connected via a Y -piece to both the O2 and air wall outlets.~2. The investigator who will regulating the O2 inspired concentration-related intervention, will be blinded to the continuous TcPCO2 measurement. In addition, the sleep medicine specialist who will assess the breathing pattern offline and score the number and nature of apnea/hypopnea episodes, will also be blinded to the treatment arm."|With the patients' admission to the post-anesthesia care unit and after a 20-minute-long stabilization period, two 40-minute-long treatment sessions will be applied to the study patients. In the first 6 patients Conservative O2 treatment will be applied first, whereas in the rest (patients 7-10) the order of the interventions will be reversed. The order of the interventions will not be revealed to the participants before completing the study. In the Conservative O2 treatment session, O2 supplementation will be titrated to an SpO2 between 90% and 94%, while in the Liberal O2, O2 administration will be titrated to an SpO2 \> 96%.|t|f|f|t
33862649|NCT06634680|||COHORT||PROSPECTIVE|||||||
33862650|NCT06629506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862651|NCT06717399|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental, one-group pretest-posttest, quantitative design||||
33862652|NCT03427125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862653|NCT06198842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862654|NCT06589258|NA|SINGLE_GROUP||PREVENTION||NONE||"One group of sixty breastfeeding mothers with CBD's consumption~Two subgroups: thirty subjects by group:~* only CBD intake~* CBD and others psychoactive substances"||||
33862655|NCT01983397|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33862656|NCT00129623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862657|NCT04442360|||OTHER||PROSPECTIVE|||||||
33862658|NCT03875287|NA|SEQUENTIAL||OTHER||NONE||||||
33862659|NCT02616666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862660|NCT05207735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862661|NCT01765868|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862662|NCT02185209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862663|NCT02330510|||COHORT||PROSPECTIVE|||||||
33862664|NCT00517777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862665|NCT03786159|||COHORT||PROSPECTIVE|||||||
33862666|NCT01292798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862667|NCT01428661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862668|NCT04895072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862669|NCT02212873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862670|NCT03423823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862671|NCT01410435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862672|NCT06735313|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33862673|NCT00425880|||COHORT||PROSPECTIVE|||||||
33862674|NCT03838354|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862675|NCT01791023|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862676|NCT06431009|||COHORT||PROSPECTIVE|||||||
33862677|NCT06166979|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Both participants and investigator are blinded.|This is a randomized double-blind baseline controlled pilot study with no crossover.|f|f|t|f
33862678|NCT05682079|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33862679|NCT05026710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862680|NCT03462472|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33862681|NCT05497648|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862682|NCT00526981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862683|NCT01515293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862684|NCT00984490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150470|NCT06219421|||COHORT||RETROSPECTIVE|||||||
34150471|NCT03782922|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34150472|NCT03025178|NA|SINGLE_GROUP||OTHER||NONE||||||
33862685|NCT04562194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862686|NCT02796001|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Volunteers who were infected with RV16 by experimental challenge were eligible for participation by re-challenge with either RV16 or RV39 to assess the host response to homologous or heterologous rechallenge.|t|f|f|f
33862687|NCT01387048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33862688|NCT06735651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862689|NCT00680563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862690|NCT03533595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34150473|NCT00628147|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33862691|NCT02221232|RANDOMIZED|PARALLEL||||NONE||||||
33862692|NCT01817855|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33862693|NCT05593874|||COHORT||PROSPECTIVE|||||||
33862694|NCT04031586|||COHORT||PROSPECTIVE|||||||
33862695|NCT03201913|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, accelerated dose escalation study.||||
33862696|NCT05737043|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||DOUBLE|||f|t|t|f
33862697|NCT02941133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33862698|NCT03570333|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862699|NCT02849158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862700|NCT02653287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862701|NCT06683560|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33962374|NCT06541613|RANDOMIZED|PARALLEL||OTHER||TRIPLE|the investigator responsible for block administration will not be aware of the content of the medications prepared whether they are the local anesthetics or normal saline. also the patients will not be aware of the group assignment.|38 patients will be enrolled in the study and divided into two groups either (EOIPB group (E) or Control group (C). Randomization will be done by allocation 1:1 of scheduled cases per day.|t|t|t|f
33862702|NCT01050907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962375|NCT06537037|||COHORT||PROSPECTIVE|||||||
33962376|NCT01094873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962377|NCT03417531|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||2x2 factorial design|t|f|t|t
33962378|NCT03582501|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33962379|NCT04209244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962380|NCT06073717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Regarding the control of experimental bias, simple blinding will be used. Thus, participants will be blinded to the research problem. They will be informed that three interventions will be applied (without comment on specific details of each one) randomly allocated, to compare the impact on cognitive functions, circulating levels of certain biomarkers, and different symptoms associated with breast cancer. Therefore, study participants will not be able to know to which experimental or control group they belong.|This study has been designed as a randomised, controlled, longitudinal (20 weeks), three-arm, parallel study with a follow-up phase (12 weeks).|t|f|f|f
33962381|NCT00422773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150474|NCT05141955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34150475|NCT05614648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|Clonidine Micropellet vs Sham-Control|t|f|t|t
34150476|NCT01930513|||COHORT||PROSPECTIVE|||||||
34150477|NCT00358839|NON_RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34150478|NCT03358940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Will be included in the student a patient who is maximum 24 weeks pregnant with miscarriage complications or not, or threatened miscarriage, or voluntary termination of pregnancy using misoprostol.||||
34150479|NCT02747017|||COHORT||PROSPECTIVE|||||||
34150480|NCT05097352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150481|NCT05506839|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34150482|NCT06546072|||COHORT||RETROSPECTIVE|||||||
34150483|NCT00174070|||DEFINED_POPULATION||OTHER|||||||
34150484|NCT05362474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150485|NCT02758301|||COHORT||PROSPECTIVE|||||||
34150486|NCT06271330|||COHORT||RETROSPECTIVE|||||||
34150487|NCT01031862|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34150488|NCT01566487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150489|NCT01992562|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34150490|NCT02115360|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34150491|NCT02950844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150492|NCT05104541|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Study||||
34150493|NCT01170078|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34150494|NCT06423560|||CASE_CONTROL||RETROSPECTIVE|||||||
34150495|NCT01132586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150496|NCT00249613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150497|NCT00494910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150498|NCT04057885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150499|NCT06065436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150500|NCT02995499|||OTHER||PROSPECTIVE|||||||
34150501|NCT03802903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150502|NCT01597024|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34150503|NCT02179814|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34150504|NCT05548062|||COHORT||PROSPECTIVE|||||||
34150505|NCT04190797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150506|NCT05710419|||COHORT||PROSPECTIVE|||||||
34150507|NCT06064123|||COHORT||PROSPECTIVE|||||||
34150508|NCT03716661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150509|NCT00453973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150510|NCT05848765|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34150511|NCT02168985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150512|NCT00002961|RANDOMIZED|||TREATMENT||||||||
34150513|NCT05776628|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34150514|NCT00778895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150515|NCT01874938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150516|NCT01723540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150517|NCT05852821|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150518|NCT02648217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175347|NCT05993806|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862703|NCT01727583|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862704|NCT06655610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862705|NCT05493852|||OTHER||OTHER|||||||
33862706|NCT03902561|||COHORT||CROSS_SECTIONAL|||||||
34175348|NCT06527794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34175349|NCT00609102|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34175350|NCT04990024|RANDOMIZED|PARALLEL||TREATMENT||NONE|The design is open label as it is impossible to blind the participants and the research team for the study intervention. Each of the dietary interventions will be delivered in the format of intensive individual sessions about the diet, food selection and food recipes. Outcome assessors will be blind to the intervention|"A computer-generated allocation sequence will be used, with a permuted block randomization (1:1). The biostatistician (MB) will generate the randomization sequence and will share it with a trial coordinator (MR) who is independent of the study team. Upon the recruitment of every participant, the study RA will contact the independent trial coordinator to receive the randomization code, in an opaque and sealed envelope.~Randomization will take place at 1-30 days after starting Semaglutide. Treatment allocation will be in batches at the end of each month."||||
33862707|NCT03430219|||CASE_ONLY||PROSPECTIVE|||||||
33862708|NCT04778969|||COHORT||RETROSPECTIVE|||||||
33862709|NCT03089554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862710|NCT02627222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862711|NCT06735118|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
33862712|NCT05990218|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The patients were masked from being randomized to operator and endoscopic method|Patients randomized to 4 arms: control with experienced operator, control with beginner operator, AI with experienced operator, AI with beginner operator|t|f|f|f
33862713|NCT04338152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"FFT-CHR assists families with (1) recognizing the youth's psychosis risk symptoms and warning signs of escalating risk, (2) understanding vulnerability to psychosis and interventions, and (3) operating effectively as a unit. The manual includes session instructions and handouts.~The Enhanced care (EC) condition has also been manualized and tested as a family educational treatment in CHR and bipolar youth. The 3 weekly sessions involve an abridged form of FFT-CHR psychoeducation. Then the youth has monthly individual sessions focused on applying the prevention plan and nondirective problem-solving of conflicts. The clinician serves as case manager.~See further description below."|f|f|f|t
33862714|NCT03765775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862715|NCT03265535|||OTHER||PROSPECTIVE|||||||
33862716|NCT03854396|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33862717|NCT01484392|||COHORT||PROSPECTIVE|||||||
33862718|NCT06704620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862719|NCT01012843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33862720|NCT05802992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862721|NCT02676388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862722|NCT04292028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862723|NCT02322229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862724|NCT04997187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150519|NCT02904655|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150520|NCT02672592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175351|NCT05302089|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will not know the direction of our hypothesis. A blinded statistician will perform the primary analysis.|||||
34175352|NCT02356263|||||CROSS_SECTIONAL|||||||
34175353|NCT05345444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175354|NCT06699160|||COHORT||OTHER|||||||
34175355|NCT04607005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The site staff and central study team will be blinded to each participant's eosinophil count (including white blood count differential) and to central overread nasal polyps scores following randomization.|Participants will be randomized in a ratio of 1:1 to receive a single SC dose of 100 mg mepolizumab or placebo every 4 weeks during 52-week treatment period.|t|t|t|f
34175356|NCT06173947|||COHORT||PROSPECTIVE|||||||
34175357|NCT01415271|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34175358|NCT06584903|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34175359|NCT02595125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175360|NCT01794429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175361|NCT06481683|||CASE_CONTROL||PROSPECTIVE|||||||
33862725|NCT00256334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150521|NCT05167903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150522|NCT03046524|||COHORT||RETROSPECTIVE|||||||
34150523|NCT04054999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open-Label, pilot study to describe the efficacy of hydroxocobalamin vs methylene blue||||
34150524|NCT02625870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150525|NCT02335060|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34150526|NCT02310997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150527|NCT04886700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150528|NCT03764930|||CASE_ONLY||RETROSPECTIVE|||||||
34150529|NCT05946512|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34150530|NCT03594214|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150531|NCT02074072|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34150532|NCT03108508|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34150533|NCT05505604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized to receive either a PENG or FICB. Baseline characteristics will be collected and NRS pain scores collected preblock and at specified time points post block.||||
34150534|NCT02270255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34150535|NCT05577637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150536|NCT04058548|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34150537|NCT04654260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Primary outcomes will be assessed by an independent evaluator who will be blinded to subject's treatment assignment"|This is randomized controlled trial of behavior therapy for irritability versus a supportive therapy control condition|f|f|f|t
33862726|NCT06426043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862727|NCT01161901|||||CROSS_SECTIONAL|||||||
33862728|NCT01883986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862729|NCT00523120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33862730|NCT00163423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33862731|NCT04411927|||COHORT||CROSS_SECTIONAL|||||||
33962382|NCT03406039|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm RCT will be conducted to evaluate the proposed online intervention. Eligible participants will be randomized to either the online integrated treatment condition, or the psycho-educaton (i.e., control) condition.||||
33962383|NCT01697449|||COHORT||PROSPECTIVE|||||||
33962384|NCT03016104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962385|NCT04009057|||COHORT||PROSPECTIVE|||||||
34175362|NCT04839705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175363|NCT05940103|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33862732|NCT04962789|||COHORT||PROSPECTIVE|||||||
34175364|NCT06596369|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175365|NCT05851651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34175366|NCT06434272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175367|NCT06277739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175368|NCT04007692|||COHORT||PROSPECTIVE|||||||
34175369|NCT04997486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175370|NCT03085004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175371|NCT01511406|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34175372|NCT03474588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175373|NCT05472090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175374|NCT03982355|||OTHER||RETROSPECTIVE|||||||
34175375|NCT01082770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175376|NCT06483230|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175377|NCT02296164|||COHORT||PROSPECTIVE|||||||
34175378|NCT05926817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175379|NCT04846829|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
34175380|NCT03796559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175381|NCT05502939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Participants will not be masked to the intervention group assignment but will be blinded to the outcome measures.~One research coordinator, fluent in English and in Spanish, will be unblinded to the participants' designated intervention. This individual will be responsible for all necessary follow up communications with the participants and their families.~One graduate student research assistant will be unblinded to participant's designated intervention. They will be responsible for completing all fidelity and attendance measures. They will be in direct contact with program staff of the music and the afterschool enrichment program.~Dr. Mack as the primary trial statistician and oversight on data analysis will be blinded to intervention assignments. All research staff involved in data analysis will be blinded to the intervention group assignment and all outcome measures."||f|f|t|t
34175382|NCT04101955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175383|NCT06170385|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi-experimental single group before and after study||||
34175384|NCT06702722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2-arm individually randomized controlled trial|f|f|t|t
34175385|NCT06585241|NA|SINGLE_GROUP||PREVENTION||NONE||This is a Phase 3b/4 open-label study.||||
34175386|NCT06612320|||COHORT||PROSPECTIVE|||||||
34175387|NCT03239626|NA|SINGLE_GROUP||TREATMENT||NONE||One group for hypofractionaed IMRT for adjvuant cervical cancer patients||||
34175388|NCT06587776|||COHORT||PROSPECTIVE|||||||
34175389|NCT04361396|NA|SINGLE_GROUP||OTHER||NONE||||||
34175390|NCT03544957|||COHORT||PROSPECTIVE|||||||
34175391|NCT04277975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175392|NCT05526716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34175393|NCT06706349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34175394|NCT05604534|||CASE_ONLY||OTHER|||||||
34175395|NCT04516447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862733|NCT03203551|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33862734|NCT01215500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862735|NCT02183636|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962386|NCT04295109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33962387|NCT03850561|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Parallel Assignment||||
34175396|NCT06374836|||COHORT||PROSPECTIVE|||||||
34175397|NCT05375539|NA|SEQUENTIAL||TREATMENT||NONE||After the first subject is enrolled, a 14-day waiting period must occur between each subject before the next subject can be enrolled and dosed. If one subject develops a DLT at any dose level, that subject will cease treatment but will continue safety assessments follow-ups. If a second subject develops a DLT at the same dose level, the trial will be stopped and the dose level below will be the MTD. Any subjects who are at higher dose level at the time of 2nd DLT occurrence, will also stop with no further escalation. All subjects will start at the 800 mg dose (visit 2). Each subject will continue to the next week's dose until a DLT has been reached. However, if 2 DLTs occur at the starting 800 mg dose level, trial will be suspended.||||
34175398|NCT06534372|||COHORT||PROSPECTIVE|||||||
34175399|NCT06062420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175400|NCT05391503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175401|NCT02379429|||CASE_CONTROL||PROSPECTIVE|||||||
34175402|NCT02884869|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34175403|NCT06163963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"A single arm interventional study aiming at the comparison of the effectiveness of detection for sentinel lymph node biopsy using double tracer compared to classic single tracer in early stage endometrial cancer. So, we aimed to investigate whether the sentinel lymph node detection rates may be improved with double tracer injected at two different sites (charcoal carbon black dye injected in subserosa and ICG injected into cervix) compared to standard single tracer injected in early-stage endometrial cancer, especially the para-aortic sentinel lymph nodes. Sterile charcoal carbon black dye is an agent previously used for sentinel lymph node detection in various cancers such as breast cancer.~Sentinel lymph node detection rates of each region (pelvic, obturator, inframesenteric para-aortic, supra-mesenteric - infrarenal para-aortic), bilaterality/ unilaterality and staining with single or double tracer will be discussed compared to literature data."||||
34175404|NCT05407441|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175405|NCT06533969|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175406|NCT04977375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175407|NCT06394024|||COHORT||CROSS_SECTIONAL|||||||
34175408|NCT01894139|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34175409|NCT04258566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175410|NCT04104243|RANDOMIZED|PARALLEL||PREVENTION||NONE||There will be 6 intervention cycles. Approximately 50 men will be randomized 1:1 to each study arm. There will be 4 control cycles for every intervention workshop. Therefore we will have 6 intervention workshops and 24 control workshops. The participants will be randomized to either undergo Power-Up or standard Diabetes Prevention Program sessions.||||
34175411|NCT04166006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175412|NCT06705712|RANDOMIZED|PARALLEL||PREVENTION||NONE||SnartForældre/Activity is designed as a two-armed randomized controlled trial, including 530 women, who are trying to conceive. Included participants will be randomized in a 1:1 ratio to an intervention group or a control group. The participates are followed during preconception for up to a year or until they conceive. The participants who conceive during the study period are followed during their first trimester of the pregnancy or until they experience a pregnancy loss. Collection of data for assessment of the outcomes was through bimonthly follow-up questionnaires linked with registry data. Time frames and methods for assessment of outcomes are specified elsewhere.||||
34175413|NCT04867616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Upon completion of the 80-week Double-blind Treatment Period, study participants will be eligible to enter a 48-week Open-label Extension Period with planned treatments of bepranemab for 44 weeks, followed by a Safety Follow-up Visit 20 weeks after the last infusion of investigational medicinal product.|t|t|t|t
34175414|NCT06369909|||COHORT||PROSPECTIVE|||||||
34175415|NCT05370651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sham Emsella treatment will provide sensation without active HIFEM technology. The sham treatment amplitude setting will be limited to below the therapeutic level.|We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue enrolling participants on to phase 2, which is a sham controlled, randomized blinded study. Patients who meet all eligibility criteria will be randomized (1:1) to receive Emsella chair or sham treatments. In phase 2, the subject and biostatistician will be blinded to the group allocation throughout the study. The initial analysis of data, performed by the biostatistician will not include group assignment.|t|f|f|t
34175416|NCT04281485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be quadruple blind.|Parallel up to the measurement of the primary outcome at Week 52. At the beginning of study Year 2 participants who were originally assigned to placebo will have the opportunity to receive PF-06939926. All participants will be followed for 5 years following treatment with PF-06939926.|t|t|t|t
34175417|NCT03740022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34175418|NCT04942717|||COHORT||PROSPECTIVE|||||||
34175419|NCT04683627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175420|NCT04863170|||OTHER||PROSPECTIVE|||||||
34175421|NCT05497830|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893827|NCT04791943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The surgeon and the patient will be masked, the research coordinator will not be masked.|Patients will receive either melatonin or a placebo for three nights prior to surgery and the investigator will measure pre-operative anxiety, preoperative sleep quality, post op pain medication consumption, post op pain scores, and blood values. The investigators would like to determine if melatonin can prevent preoperative anxiety, improve preoperative sleep, prevent excess narcotic consumption, and decrease post operative inflammation.|t|t|f|f
33893828|NCT04390685|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893829|NCT04214080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33893830|NCT03386708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893831|NCT05420766|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175422|NCT06587685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175423|NCT04218968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175424|NCT04239898|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34175425|NCT06547619|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34175426|NCT00726921|||OTHER||PROSPECTIVE|||||||
34175427|NCT06699823|||COHORT||PROSPECTIVE|||||||
34175428|NCT04752215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893832|NCT06341231|||COHORT||PROSPECTIVE|||||||
34175429|NCT05296226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175430|NCT06552871|NA|SINGLE_GROUP||OTHER||NONE||Initial pre-post pilot test||||
34175431|NCT06647394|||COHORT||PROSPECTIVE|||||||
34175432|NCT04479358|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two sub-studies in parallel, each of three arms (maximum).||||
34175433|NCT01364051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175434|NCT05201547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175435|NCT05572359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"During the baseline visit the preoperative questionnaires will be obtained from the patient and the physical examination tests will be performed. Only after this is finished, at the end of this visit, the randomisation will be performed by opening a sealed envelope.~All patients will be invited for a study control visit after 6 weeks. During the appointment a blinded assessor (not one of the researchers involved in the baseline measurements) will first perform the physical examination tests, after which a check of the completeness of the questionnaires will be done. Finally, the log will be checked. Patients are instructed not to talk about the intervention they received until the log was checked. In this way the preceding measurements can be performed blinded."|Patients will be randomly allocated to receive either cryo- and compression therapy during the first six weeks after surgery or standard care.|f|f|f|t
34175436|NCT05139992|||COHORT||PROSPECTIVE|||||||
34175437|NCT03602612|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175438|NCT00005800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175439|NCT06706297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This research was planned as a prospective, randomized controlled, experimental type study with pretest-posttest measurements to determine the effect of breathing exercise on dyspnea, respiratory function and quality of life in patients with COPD.|t|f|f|f
34175440|NCT06024941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175441|NCT04838782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175442|NCT06704243|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34175443|NCT06139328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor team is also masked||t|t|t|f
34175444|NCT04221945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34175445|NCT03777306|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Multi-modality didactic education program implemented in parallel to standard cancer treatment to improve QoL for patients with MM||||
34175446|NCT03513770|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|These two trials (A and B) will be performed in random order and in a doubleblind fashion for subjects and the data analyzing team. The medical staff who prepare and administrate the drugs and monitor the subject's safety, will not be blinded.|The investigators will examine (using a prospective observational design) if a COX blockade will inhibit the Muscle Sympathetic Nerve Activity response to venous distension, and if a COX blockade will alter vein sizes during venous distension using MRI. Each subject will serve as their own control.|t|f|t|t
34175447|NCT06457373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||20 sockets will be grafted with Demineralized Dentin Allograft (DDA) and 20 sockets will be grafted with Demineralized Dentin Autograft (Auto-DD)|t|f|f|t
34175448|NCT00601224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175449|NCT05217615|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|RAs collecting baseline data are blind to the participant initial randomization condition until all surveys are completed. Once the parent participant has been randomized to their initial condition (e.g., ezParent, ezParent+coach, control, control+coach), they will be provided specific instructions based on their condition.|2x2 Factorial Design|f|f|f|t
34175450|NCT00878501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175451|NCT01351103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175452|NCT05577754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175453|NCT06586125|||CASE_ONLY||PROSPECTIVE|||||||
34175454|NCT05380466|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel group, randomized controlled study||||
34175455|NCT02218372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34175456|NCT00984256|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34175457|NCT03670823|||CASE_CONTROL||PROSPECTIVE|||||||
34175458|NCT05655598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175459|NCT06587113|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Basic Experimental Studies Involving Humans (BESH)||||
34175460|NCT05719311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175461|NCT06595043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175462|NCT06320457|NA|SINGLE_GROUP||OTHER||NONE||||||
34175463|NCT02004236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893833|NCT00004980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33893834|NCT00345891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893835|NCT00300027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893836|NCT06623981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962388|NCT00390169|RANDOMIZED|PARALLEL||||NONE||||||
34175464|NCT05899634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175465|NCT01239199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175466|NCT02610296|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34175467|NCT01003808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175468|NCT06314711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175469|NCT06590636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34175470|NCT03330925|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34175471|NCT06600451|||OTHER||RETROSPECTIVE|||||||
34175472|NCT01365923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34175473|NCT04765722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be assigned to one of the two possible treatment arms generated by a computer-generated randomization schedule prepared by McMaster University, with a ratio of 1:1, mepolizumab or placebo. As there is a known imbalance in the prevalence and cough rates, the study will include sex as a randomization factor. This will mitigate the possibility of the intervention being confounded by sex differences in the 2 arms of the study. Blinded study drug supplies will be provided in sequentially numbered identical syringes in accordance with the randomization schedule and dispensed by a pharmacist who shall not be delegated any other role in the study. Subjects, investigators, research staff (with the exception of the pharmacist) and the sponsor will be masked to the treatment sequence assignment. A sealed code-break envelope for each subject containing details of the treatment allocated will be kept in a locked safe at the study site.|Single-centre, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate the effectiveness of 4 doses of mepolizumab for the treatment of refractory chronic cough in patients with asthma and non-asthmatic eosinophilic bronchitis. The study will have 2 arms, each with 15 participants, and a total of 9 visits per subject. Subjects will be screened and within 2 weeks randomized to the intervention (mepolizumab) or placebo arm. Subjects will receive the intervention over a 12 week period at visits 3, 4, 5, and 7. The primary outcome will be measured at visit 14 which will occur 2 weeks after the final intervention dose.|t|t|t|t
34175474|NCT05831774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded study|2 groups - one control, one treatment|t|f|t|f
34175475|NCT05031819|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Step wedge design. One group with a cross over.||||
34175476|NCT01432899|||CASE_CONTROL||PROSPECTIVE|||||||
33862736|NCT04767737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Since this study was a double-blind randomized controlled study, no information about the drug (topical lavender oil, topical water) was given to the nurse (researcher) who gave insulin injection, and the patient to reduce bias. The drug to be used was applied in spray bottles without any labels.|The sample was determined as 159 (53 for each group) patients for three groups (lavender oil group, placebo group, control group) by using the power analysis method (G\*Power 3.1.9.6 program), with the margin of error α=0.05, 0.25 medium effect size, and 0.80 (80%) target strength of the test. However, 7 patients who met the study inclusion criteria were added to each group (60 in the lavender oil group, 60 in the placebo group, 60 in the control group) in case some of the participants quit the study for any reason (Figure 1). While the patients were randomized, different application groups (topical lavender oil, placebo, control group) were determined by lot in different months (May, June, and July) to minimize the possibility of being affected by each other.|t|t|f|f
33862737|NCT04321980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33862738|NCT02693769|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34064906|NCT04118556|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized (1:1) phase II open label study of DSC compared to Investigator choice Best Available Therapy (BAT) in allogeneic hematopoietic stem cell transplant recipients with Grades II-IV steroid refractory acute graft vs. host disease. Patients will receive 2 doses of DSC. Additional doses (up to 4 doses) may be given depending on response.~No cross-over are planned in the second stage of the study."||||
33862739|NCT00726934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33862740|NCT00850850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33862741|NCT03211247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064907|NCT05116943|||CASE_CONTROL||PROSPECTIVE|||||||
34064908|NCT03333408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34064909|NCT03752060|RANDOMIZED|PARALLEL||TREATMENT||NONE||Following enrollment, participants will complete familiarization and be randomly assigned to an aerobic training (AT; n = 20), a resistance training (RT; n = 20), or a control (CON; n = 20) group.||||
34064910|NCT04483284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862742|NCT04980508|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Corpus cavernosum electromyography, penile color Doppler ultrasonography and hormonal examinations were compared between the groups of patients with erectile dysfunction who did not have COVID-19, who were diagnosed with COVID-19 and were treated as outpatients or inpatients.||||
33862743|NCT01180920|||CASE_CONTROL||PROSPECTIVE|||||||
34064911|NCT06143787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|randomized, double-blind, multi-center, placebo-controlled, parallel-group|t|t|t|t
34064912|NCT03623659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34064913|NCT00554541|||COHORT||PROSPECTIVE|||||||
34064914|NCT06449508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064915|NCT03370237|||CASE_ONLY||CROSS_SECTIONAL|||||||
34064916|NCT00315042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064917|NCT04148898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|Crossover Assignment|f|f|f|t
34064918|NCT02180607|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064919|NCT02647489|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34064920|NCT03885999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064921|NCT02998359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34064922|NCT06230952|||OTHER||CROSS_SECTIONAL|||||||
34064923|NCT02860390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34064924|NCT05507502|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.||||
34064925|NCT02941354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064926|NCT05528432|||COHORT||PROSPECTIVE|||||||
34064927|NCT04093557|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||All patients will be assessed for the most appropriate bowel preparation prior to colonoscopy (standard vs. extended) based on a novel scoring tool that accounts for various clinical conditions.||||
34064928|NCT02481115|||COHORT||PROSPECTIVE|||||||
34064929|NCT02802644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064930|NCT05297500|||CASE_ONLY||PROSPECTIVE|||||||
34064931|NCT00466206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064932|NCT04255407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064933|NCT00858468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34064934|NCT03366961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064935|NCT00526552|||CASE_ONLY||PROSPECTIVE|||||||
34064936|NCT02414802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862744|NCT01629784|NA|SINGLE_GROUP||||NONE||||||
33862745|NCT00495404|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
33862746|NCT06734702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862747|NCT03374995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862748|NCT05117255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not know which study group participants have been assigned to.||f|f|f|t
33862749|NCT01209871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862750|NCT06352411|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862751|NCT00954863|||CASE_ONLY||PROSPECTIVE|||||||
33862752|NCT02577601|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33862753|NCT06111482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be treated with an intended pulsed light device. Subjects may also receive split treatments where one side of the face and/or body will be treated with the study device, and the contralateral side will be treated with a similar IPL device or a similar microneedling device. Randomization will not be used as the group the subject will be assigned to will be determined based on dermatologic condition the subject presents with and this will be determined by the Investigator.||||
33862754|NCT03951779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064937|NCT03889938|||CASE_CONTROL||RETROSPECTIVE|||||||
34064938|NCT01196663|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064939|NCT01589809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064940|NCT01072981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064941|NCT01399476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064942|NCT01620333|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34064943|NCT01626404|||COHORT||PROSPECTIVE|||||||
34064944|NCT04275102|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34064945|NCT03129113|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2 by 2 factorial randomisation to one of the 4 arms.|f|f|f|t
34064946|NCT02716506|||COHORT||PROSPECTIVE|||||||
34064947|NCT05565352|||COHORT||PROSPECTIVE|||||||
34064948|NCT02179476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064949|NCT05988333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34064950|NCT04339309|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33862755|NCT05011682|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are their own controls. All participants will follow their usual diet in the first 2 weeks, and then during the next 2 weeks the 10-point nutrition plan according to Joslin Diabetes Center.||||
33862756|NCT04393025|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two armed medical study||||
33862757|NCT04390048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33862758|NCT06735417|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862759|NCT02177890|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33862760|NCT01846325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862761|NCT01449877|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33862762|NCT00638560|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862763|NCT04264429|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33862764|NCT03085758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double Blind, Placebo-Controlled, Randomized, Multicenter Proof of Concept and Dose-Finding Phase II Clinical Trial|t|f|t|f
33862765|NCT05111041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862766|NCT02196623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862767|NCT03690141|NA|SINGLE_GROUP||TREATMENT||NONE||tomivosertib (eFT508) will be supplied as 100-mg capsules by the Sponsor. Capsules are packaged in 200-cc high-density polyethylene wide-mouth, round, white bottles, at either 100 or 150 units per bottle, induction sealed and capped with a 38-mm child-resistant closure.||||
33962389|NCT04034199|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective open-label controlled trial. All patients will continue calcium (1000mg daily) and vitamin D supplementation (at least 800 international unit daily). Patients with osteopenia or osteoporosis in a baseline DEXA scan will be randomized by computer-generated blocks in 1:1 ratio into receiving denosumab (treatment group) or zoledronic acid (controlled group). Denosumab is given at 60mg subcutaneously every 6 months, following the FDA approved dosage. Zoledronic acid is administered intravenously at 5mg yearly. DEXA scan will be repeated after 12 months of treatment.||||
33962390|NCT02104401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862768|NCT04227951|RANDOMIZED|PARALLEL||TREATMENT||NONE|The leading surgeon and the patient will be blinded to the arm assigned until the end of the operation. No blinding is provided for the patient, care providers, or coordinating researcher after the operation. After the operation we thought that was unreliable to go ahead with participants blindness considering that one arm has an evident drain and the other arm has no drain. Considering that clinicians will need to check drain quality and remove the tube in treatment group we considered not possible to mask the care providers or investigators on this practice.|||||
33962391|NCT05854277|NA|SINGLE_GROUP||SCREENING||NONE||||||
33862769|NCT04426955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962392|NCT05245617|||COHORT||OTHER|||||||
33862770|NCT05981911|||COHORT||PROSPECTIVE|||||||
33862771|NCT04994379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomly allocated to one of the three groups of active 1 mA, active 1.5 mA, or the sham group.|t|f|t|f
33862772|NCT01782118|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33962393|NCT05467449|||COHORT||PROSPECTIVE|||||||
33962394|NCT03753373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962395|NCT02094430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962396|NCT02917356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962397|NCT04078087|||CASE_CONTROL||PROSPECTIVE|||||||
33962398|NCT05005676|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34064951|NCT03402672|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34064952|NCT00085098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962399|NCT00205465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962400|NCT01816126|||CASE_CONTROL||PROSPECTIVE|||||||
33962401|NCT03550794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization list will be prepared by an independent statistician using 1:1 randomization in blocks of two and four. This list will be provided to the research pharmacy, and the research pharmacy will be the only unblinded people involved with the study, and will have no patient contact or role in the analysis or other aspects of the study. Thiamine is colorless and odorless, and the 200mg dose is mixed in 5mL of normal saline. Placebo will be 50mL of normal saline and is indistinguishable in appearance from thiamine. Study team, clinical team and patient and family will all be blind to the allocation.||t|t|t|t
33962402|NCT03545529|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962403|NCT03874533|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962404|NCT06538636|RANDOMIZED|FACTORIAL||SCREENING||NONE||We will use a factorial stepped wedge design (SWD) over 15 calendar quarters, with 14 sequence arms and 2 trial sites randomized per sequence to support estimation of separate and combined effects for two intervention types (1-PCP-facing tools and 2-LCS team population management tools). Each half of the arms will sequentially implement one of the interventions, followed by implementation of the second intervention||||
33962405|NCT03745027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962406|NCT05155072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962407|NCT01741909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962408|NCT03149965|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective cohort study||||
34064953|NCT01142765|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175477|NCT06705868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175478|NCT04471909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175479|NCT05975476|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34175480|NCT05532566|NA|SINGLE_GROUP||OTHER||NONE||Phase II, open-label, non-randomized trial, with no control group of subjects.||||
34175481|NCT02659930|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175482|NCT00456053|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34175483|NCT06512727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34175484|NCT05138653|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34175485|NCT05491590|||COHORT||PROSPECTIVE|||||||
34175486|NCT03564600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862773|NCT06735339|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge randomised design including 6 hospital clusters of general practitioners in the Central Denmark Region.||||
33862774|NCT06504342|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The time-restricted eating intervention will be single-blind, only the investigators/outcomes assessors will be blinded. The tinted glasses intervention will be double-blind.|2 by 2 factorial design. Only 3 of the 4 arms will be implemented, with the double control arm not implemented in the pilot.|t|f|t|t
33862775|NCT06253221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862776|NCT06735664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862777|NCT00674193|||COHORT||PROSPECTIVE|||||||
33862778|NCT06333288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||PRO-APPLE Study is a 2-arm pilot Randomized Control Trial (RCT).|f|f|f|t
33862779|NCT03945006|||CASE_CONTROL||PROSPECTIVE|||||||
33862780|NCT01357577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962409|NCT04635904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor that assess mental imagery content (see secondary outcomes) are blind to the condition.||f|f|f|t
33962410|NCT04089137|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will receive an online intervention targeting alcohol misuse and sexual assault among college students. This will include a personalized normative feedback approach. In the first part of the study, there will be an open pilot (1 arm) and in the second part of the study there will be a control condition (2 arms - intervention + control)||||
33962411|NCT03871569|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962412|NCT06528327|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Split Mouth Design||||
33962413|NCT00769431|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962414|NCT03876873|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The surgeon, anesthesiologist, operating room staff, and participants will not know the group assignment at the time of subject recruitment. No blinding will occur during the clinical portion of the study or during data analysis.|Participants will be assigned into one of two groups (per a randomization schedule) for face mask ventilation. The sequence of face mask ventilation head positions will be determined by group assignment. Each position will be performed for one minute. Group A: (1) neutral position, (2) head rotation, (3) neutral position. Group B: (1) head rotation, (2) neutral position, (3) head rotation.|t|t|t|f
33962415|NCT06428526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33962416|NCT05784727|NA|SINGLE_GROUP||OTHER||NONE||The main research question about the robustness of the Earswitch will be calculated based on the whole participant pool. There is no evidence to suggest that the tensor tympani contraction will physically differ between participants with or without assistive technology needs, and therefore the data is equally valid in determining whether the algorithms accurately detect the tensor tympani contraction.||||
33962417|NCT05200507|||COHORT||PROSPECTIVE|||||||
33962418|NCT00640614|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962419|NCT05100394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessor was unaware of allocation into experimental or control groups.|Two-arm parallel-groups|t|f|f|t
34064954|NCT04904783|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||To explore the role of low dose pulmonary radiotherapy (LDRT) in moderate disease category of COVID-19 patients with pneumonitis in terms of the following primary and secondary objectives. The outcome of LDRT in a pilot group of 10 patients (Study group) would be compared with another 10 patients (Control group) who have not given consent for LDRT and/or would not able to be able to lie down still for the entire treatment duration in the radiotherapy unit. This is not a randomized but a case-control study.||||
33862781|NCT03703245|||OTHER||RETROSPECTIVE|||||||
34064955|NCT04554758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative double arm study||||
34175487|NCT05310279|NA|SINGLE_GROUP||OTHER||NONE||||||
34175488|NCT06144957|||CASE_ONLY||PROSPECTIVE|||||||
34175489|NCT02521285|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34175490|NCT00988494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175491|NCT04364386|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34175492|NCT06204068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175493|NCT04983251|||CASE_ONLY||PROSPECTIVE|||||||
33962420|NCT01835470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962421|NCT04307537|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Within patient comparison||||
33962422|NCT02317094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962423|NCT01412710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962424|NCT02215239|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962425|NCT01558869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962426|NCT06568965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind|Randomized, Double blind, Parallel Group, Placebo Controlled Trial|t|f|t|f
33962427|NCT04959006|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Nutritional supplements will be provided in a randomised, double-blinded manner. Both the participants and research testers will be masked from knowing the specifics of the supplement intervention.|Participants randomly assigned to either placebo or antioxidant-rich olive extract in a parallel, double blind manner|t|f|t|f
33962428|NCT05257174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962429|NCT01638754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962430|NCT00983879|||CASE_ONLY||PROSPECTIVE|||||||
34064956|NCT03943823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064957|NCT03920423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34064958|NCT02911259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34064959|NCT00002525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064960|NCT03489902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175494|NCT06104228|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175495|NCT04767659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175496|NCT04819217|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175497|NCT02167490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175498|NCT04166643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862782|NCT02774902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862783|NCT04093427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862784|NCT00650065|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33862785|NCT03739762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomized into one of two cohorts/arms: one called i-STAND with coaching sessions focused directly on sitting less and standing more; the other called Healthy Living with coaching sessions focused on various topics related to a healthy lifestyle, but without a focus on standing more. Those randomized to the i-STAND intervention will also be re-randomized half-way through the study, with half of that cohort moving on to phase 2, which involves booster sessions on sitting less and standing more. All participants regardless of cohort will be mailed a blood pressure monitor and a scale to keep. UPDATE: As of March 31, 2022, beginning in our final year (year 5) of the study, participants randomized to the i-STAND intervention will no longer be re-randomized at 6 months. We will no longer follow participants to the 12-month timepoint and will end all activities after the 6-month timepoint."||||
33862786|NCT02073734|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33862787|NCT06134206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||1 Group of 20 patients who all underwent the same examination||||
33862788|NCT00216203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862789|NCT04631926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962431|NCT04580472|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Participants will not be told if they are receiving the antibiotic or placebo. Dermatologic surgeons who are performing the surgery and assessing for surgical site infections will be blinded to which arm of the study the patient is randomized. In order to accomplish this, study nurses will be responsible for randomizing each participant and will administer the antibiotic or placebo to each participant after each patient has consented and after the dermatologic surgeon has placed the order for cephalexin/placebo or clindamycin/placebo (based on patient's allergies) in the electronic medical record."|Patients meeting inclusion criteria will be assigned to one of three participant categories: 1) patients undergoing repair with skin flap or graft on the nose, 2) patients undergoing repair with skin graft, flap, or wedge resection on the ear, or 3) patients undergoing Mohs surgery with closure or partial closure or surgical excision on the lower extremity below the knee. Within each category, participants will be randomized into one of two groups: group one will receive a preoperative placebo pill and group two will receive preoperative antibiotic prophylaxis (either a single dose of Cephalexin 2g PO or single dose of Clindamycin hydrochloride 600 mg PO if allergy to penicillin or cephalosporin). These doses for cephalexin and clindamycin hydrochloride are standard doses for adults. The administration time of the oral antibiotics (as well for placebo group) will be 5-15 minutes prior to surgery in the nose and ear group and 30 minutes prior incision in the leg group.|t|t|t|t
33962432|NCT00127569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962433|NCT02603159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962434|NCT05398731|||CASE_CONTROL||RETROSPECTIVE|||||||
33962435|NCT02881463|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962436|NCT03775304|||CASE_ONLY||RETROSPECTIVE|||||||
33962437|NCT01538589|||COHORT||PROSPECTIVE|||||||
33962438|NCT06566105|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962439|NCT03821831|||COHORT||PROSPECTIVE|||||||
33962440|NCT02693652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962441|NCT00437710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962442|NCT06254521|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients with locally advanced rectal cancer who met the inclusion criteria received two or four cycles of Tislelizumab combined Capecitabine and Oxaliplatin regimen chemotherapy and were evaluated by enhanced CT and MRI\\TRUS. Then, these patients will receive curative surgery for rectal cancer.~Interventions:~Drug: Oxaliplatin Drug: Capecitabine Drug: Tislelizumab Procedure: curative surgery for rectal cancer"||||
33962443|NCT02268019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962444|NCT04744077|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33962445|NCT00566631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962446|NCT00517257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962447|NCT01770678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962448|NCT01284569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962449|NCT01048268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33962450|NCT00546832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962451|NCT05341115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962452|NCT01445873|||COHORT||RETROSPECTIVE|||||||
33962453|NCT00802269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962454|NCT02441179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962455|NCT01925742|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33962456|NCT04363294|NA|SINGLE_GROUP||SCREENING||NONE||Participants undergoing TAVR for symptomatic severe aortic stenosis, with pre-TAVR echocardiography and post-implantation invasive hemodynamic assessment are eligible for study participation. The AVi will be recorded from post-implantation invasive hemodynamic assessment. Participants will undergo bone scintigraphy (99mTc-pyrophosphate Planar/SPECT imaging) within 28 days after TAVR. Participants with abnormal bone scintigraphy require evaluation for a monoclonal protein with blood/urine laboratory testing, and possible tissue biopsy/Hematology consultation to exclude light-chain amyloidosis. Participants who are ATTR positive will receive comprehensive heart failure management and possible genetic testing to evaluate for mutated ATTR.||||
33962457|NCT04559217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective pilot study||||
33962458|NCT02306434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962459|NCT05050357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33962460|NCT03940586|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962461|NCT04304846|||CASE_ONLY||PROSPECTIVE|||||||
33962462|NCT03719261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded The patient is also outcome assessor will be blinded as well as data analyst person.||t|f|f|t
33962463|NCT00731510|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
34064961|NCT00513266||||TREATMENT||NONE||||||
34064962|NCT01225289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064963|NCT05743998|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34064964|NCT00001756|||CASE_CONTROL||PROSPECTIVE|||||||
34175499|NCT06028919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded to which trial arm they have been assigned.|patient-blinded, prospective, multi centre, two-arm, randomised controlled trial|t|f|f|f
34175500|NCT03004872|||COHORT||PROSPECTIVE|||||||
34175501|NCT03154346|||COHORT||PROSPECTIVE|||||||
34175502|NCT04968288|||COHORT||PROSPECTIVE|||||||
33862790|NCT05823701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862791|NCT05027763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33862792|NCT04254588|||COHORT||PROSPECTIVE|||||||
33862793|NCT06467487|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33862794|NCT04919525|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33862795|NCT02403622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862796|NCT04460014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33962464|NCT05764902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessors who analyze the data will be blinded to the allocation of patients to the intervention or control group.|This randomized controlled trial will evaluate the impact of tailored interventions on loneliness levels of patients admitted to the Cardiac ICU (CICU) at the Baruch Padeh Poriya Medical Center. A questionnaire using a 12-point Likert scale, adapted from the University of California Los Angeles (UCLA) and De Jong Gierveld Loneliness Scales, will be used to assess loneliness levels at CICU admission and discharge. Patients will be randomized into the intervention or control group. The intervention group will receive an additional questionnaire to assess their individual needs and preferences. CICU staff will provide individualized interventions to address the expressed needs and preferences of the intervention group, while the control group will receive standard care. Changes in loneliness levels during CICU hospitalization will be compared between the groups.|f|f|f|t
33962465|NCT02585531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175503|NCT05161377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175504|NCT05640271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study statistician will generate randomizations using the method of permuted block randomization. The pharmacy will access the prepared randomization list via REDCap (a module separate from the clinical REDCap database) to guide tocilizumab versus placebo administration at the time of placing an inpatient order. Prior to randomization, the SpO2 to FiO2 ratio will be determined over an 8-hour period to serve as a baseline measure. Thus, randomization will be done at the time of placing the initial order for inpatient tocilizumab versus placebo, not at the time of enrollment. Patients, study investigators, and inpatient clinicians will all be blinded to the patient's randomized group assignment. Only the investigational pharmacy will be aware of the randomization arm.|All participants will receive tocilizumab 80 mg on one day and placebo (normal saline 50 mL) on another day, separated by 48 hours, and the order of these two doses will be randomized. Half the patients will receive tocilizumab at the time of acute chest syndrome diagnosis and subsequent randomization, and then that half will receive placebo two days later. The other half will receive placebo first and then tocilizumab two days later.|t|t|t|t
33962466|NCT03341715|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34175505|NCT04918420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962467|NCT06515171|||COHORT||PROSPECTIVE|||||||
33962468|NCT04242368|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33962469|NCT04276285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33962470|NCT04325061|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, controlled, open-label trial involving mechanically ventilated adult patients with ARDS caused by confirmed COVID-19 infection||||
33962471|NCT00732394|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33962472|NCT02460315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962473|NCT03964220|||COHORT||RETROSPECTIVE|||||||
33962474|NCT03604601|||CASE_ONLY||RETROSPECTIVE|||||||
33962475|NCT04442373|||COHORT||PROSPECTIVE|||||||
33962476|NCT04055571|||COHORT||RETROSPECTIVE|||||||
34175506|NCT04729907|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962477|NCT01020773|RANDOMIZED|PARALLEL||TREATMENT||||||||
33962478|NCT02129530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33962479|NCT02295280|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175507|NCT06300580|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175508|NCT06672406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The preterm infant subjects and their parents were blinded to whether they received the probiotic intervention or were in the control group.|This randomized controlled trial aims to assess the effect of probiotic Lactobacillus reuteri on serum bilirubin levels in preterm infants. The study will be conducted at NICUs in Makassar, Indonesia, enrolling infants born at 32 to \<37 weeks gestation with birth weights of 1000-2499 grams. Forty infants will be randomized to receive either L. reuteri probiotic (5 drops daily for 7 days) or no probiotic. The primary outcome is serum bilirubin levels measured at baseline and after 7 days. Secondary outcomes include incidence of hyperbilirubinemia requiring phototherapy and changes in bilirubin levels in those receiving phototherapy. Blood samples will be collected to measure total and direct bilirubin. This trial will provide evidence on whether L. reuteri supplementation can reduce hyperbilirubinemia severity in preterm infants, potentially informing clinical practice regarding probiotic use as an adjunctive therapy for neonatal jaundice in this vulnerable population.|t|f|f|f
34175509|NCT03766789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34175510|NCT03054519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175511|NCT03754725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175512|NCT06390722|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34175513|NCT06673017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a multi-center, non-randomized, single-arm, open-label, phase Ib dose escalation/dose expansion study of PTM-101 in subjects with pancreatic ductal adenocarcinoma (PDAC).||||
34175514|NCT02455791|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175515|NCT06368700|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33862797|NCT04775251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862798|NCT01536236|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862799|NCT05261438|||COHORT||RETROSPECTIVE|||||||
33862800|NCT06736301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862801|NCT06065748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862802|NCT06734572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862803|NCT01430351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862804|NCT05181722|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The patient navigator and statistician will be unblinded to the patient groups.|Study participants will be randomly assigned to either the usual care group or the intervention group.|f|t|t|f
33862805|NCT05746481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862806|NCT06318455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33862807|NCT03457350|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34064965|NCT06025994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators in charge of follow-up visits and questionnaire collections will be different from investigators in charge of recruitment, baseline questionnaires collection and randomization procedure. The investigators in charge of follow-up procedures will be completely blinded to the randomization, as well as patient identifying information. Regarding clinical outcomes, an independent Clinical Event Committee (CEC) will adjudicate all endpoints. The CEC members and the CEC management team will be completely blinded to the randomization, as well as patient identifying information. Other measures to avoid or minimize bias introduced by the open-label design will include intent-to-treat principles of analysis and use of objective measures for endpoint classification.|"The  Standardizing the Management of patients with Coronary Microvascular Dysfunction (SAMCRO)  trial is an all comers, prospective, randomized, multicenter, open-label study with blinded adjudicated evaluation of endpoints (PROBE)."|f|f|f|t
34064966|NCT02717442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34064967|NCT01308632|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34064968|NCT05241275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34064969|NCT03208608|||COHORT||CROSS_SECTIONAL|||||||
34064970|NCT04555499|||CASE_ONLY||PROSPECTIVE|||||||
34064971|NCT01868165|||COHORT||PROSPECTIVE|||||||
34064972|NCT01403259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064973|NCT02094248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064974|NCT01683877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34064975|NCT01117415|||CASE_ONLY||PROSPECTIVE|||||||
34064976|NCT06215794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34064977|NCT04966078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064978|NCT04886362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34064979|NCT04631107|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34064980|NCT04562220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064981|NCT04565483|NA|SINGLE_GROUP||OTHER||NONE||||||
34064982|NCT05765825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064983|NCT01259674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34064984|NCT01532206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064985|NCT03503734|||COHORT||PROSPECTIVE|||||||
34064986|NCT02006550|||COHORT||PROSPECTIVE|||||||
34064987|NCT01065714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34064988|NCT00513890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34064989|NCT02715310|||CASE_ONLY||RETROSPECTIVE|||||||
34064990|NCT01010009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34064991|NCT05170334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064992|NCT05145608|RANDOMIZED|CROSSOVER||OTHER||NONE||Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design||||
34064993|NCT02474355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064994|NCT06730594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment A randomized, double-blind, two-arm, placebo-controlled clinical study|t|t|t|t
34064995|NCT05458440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34064996|NCT05067894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Observer blind: Investigational Product and Active Comparator are masking. Lot number is masking||t|f|t|f
34064997|NCT01022164|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34064998|NCT01342406|||OTHER||PROSPECTIVE|||||||
34064999|NCT05636982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34065000|NCT05345756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065001|NCT01301885|||CASE_CONTROL||PROSPECTIVE|||||||
34065002|NCT00369161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175516|NCT06511973|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The treatments (IPs and control) will not be blinded to investigative personnel involved in the preparation/application and removal of treatments. However, the Investigator and trained evaluator involved in the evaluation of responses, will remain blinded during the course of the study until Database Lock and finalization of the Statistical Analysis Plan.||t|f|t|t
34175517|NCT04432935|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be carried out by Data management unit and all investigators /dispensers and participants will be masked to the randomization.|"Group 1:~Bovine lactoferrin (bLF) will be administered (300mg) from day 0 of birth to 6 weeks of life with a single daily dose mixed with milk (preferentially breast milk otherwise premature formula milk).~Group 2:~Placebo will be administered from day 0 of birth to 6 weeks of life. (Placebo will be physically identical to the bLF mixed with breast milk or premature formula milk)."|t|t|t|t
34175518|NCT06369870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither the participant, anesthesiologist, study nurse, surgeon, nor the doctors and nurses in the Intensive Care Unit will know the participant's group assignment.|The trial is designed as a single-center, prospective, double-blind, randomized controlled superiority trial. Patients will be randomly assigned to either the IPP-PSP block group or the sham block group (placebo).|t|t|t|t
34065003|NCT06355856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065004|NCT02626650|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34065005|NCT05470855|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175519|NCT06503432|||COHORT||PROSPECTIVE|||||||
34175520|NCT04717427|||CASE_ONLY||OTHER|||||||
33862808|NCT03292861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33862809|NCT04117009|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Baseline echocardiographic examination will be performed to evaluate the systolic and diastolic function of the left ventricle in the spontaneously breathing subjects right before anesthesia and study drug infusion begins. Then the same participants will be given remifentanil (ultiva at a concentration of 20 micg/ml) at a rate to reach a target plasma level of 2 ng/mL by means of a target controlled Infusion pump. Once the target drug concentration is reached (which is expected to take around 10-15 minutes), the final echocardiographic examination will be performed to assess systolic and diastolic function again.||||
34175521|NCT03557749|||COHORT||PROSPECTIVE|||||||
34175522|NCT01468285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175523|NCT03507842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175524|NCT06501534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175525|NCT04934748|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34175526|NCT06194825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatment assignment of the 24-week double-blind treatment phase will be kept blinded to sponsor until the end of double-blind treatment phase and kept blinded to participants and investigators until the end of study.|Eligible participants will be randomized in a 3:1 ratio to either eplontersen or placebo in the double-blind treatment phase, followed by the open label treatment phase (participants initially assigned to placebo will switch to eplontersen treatment from Week 24), to evaluate long term safety and tolerability of eplontersen treatment.|t|f|t|f
34175527|NCT03524612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175528|NCT06079008|||COHORT||RETROSPECTIVE|||||||
34175529|NCT00995761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175530|NCT05331638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862810|NCT00139646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33862811|NCT04783922|||COHORT||PROSPECTIVE|||||||
33862812|NCT03269643|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||The RHEA device and Patient Monitor are used to monitor the heart rate (HR) and respiratory rate (RR) of participants at the same time in Test 1. The reference device and patient monitor are used to monitor the hear rate and respiratory rate of the same participant at the same time at Test 2. The two tests results will be compared and evaluated the accuracy of the two devices. And the RHEA device is used alone to evaluate the accuracy of motion and no motion.||||
33862813|NCT01809535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862814|NCT01794533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34175531|NCT06377176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A quasi-experimental design was utilized in this investigation; it comprised a pre-test and a post-test administered to two distinct groups. The intervention group was subjected to pre-testing before receiving the intervention, and after the intervention, mother and infant massage treatment was delivered to the intervention group. Post-testing was performed on both groups, with the control group receiving mother and infant massage.||||
34175532|NCT06006208|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The patients will be randomly assigned to 2 arms above and the patients are not informed about which arm they are assigned.|"After IRB approval and obtaining a written informed consent, patients will be randomly assigned to the one of the following 2 arms. However, AMBU bag arm patients may be switched to Hamilton C1 at an anesthesia provider's discretion based on post cardiopulmonary bypass right ventricular function, PaO2/FiO2, and PaCO2. These patients will be excluded from the AMBU bag arm.~Arm 1: AMBU bag manual ventilation during transport to the ICU Arm 2: Hamilton C1 ventilator during transport to the ICU"|t|f|f|f
34175533|NCT04909710|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The investigators will use parallel assignment to compare the device feasibility across children with autism and neurotypical children, who will serve as controls.||||
34175534|NCT06569238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants will be randomized 1:1 to the control and intervention arms using block randomization. Only tissue review will be randomized.|f|f|f|t
34175535|NCT04065048|RANDOMIZED|PARALLEL||OTHER||NONE||This is an open label single center study to compare the effect of a soy-based diet or an identical diet without soy on the composition and metabolite production of gut bacteria in Crohn's disease (CD) patients in remission or active disease, and in healthy controls. Crohn's subjects will be pre-screened by the treating gastroenterologist for eligibility criteria during their normally scheduled appointment. The treating gastroenterologist will ask suitable patients whether they are interested in participating in the described dietary intervention study during the patient appointment. Initial verbal consent will be obtained by the treating gastroenterologist. Healthy controls will be recruited in the same manner, as well as via a hospital flyer advertisement. Subjects will then be contacted by the study investigator to schedule a screening visit (visit 1) and if study eligibility is confirmed, and informed consent provided, enrolled into the study.||||
34175536|NCT05687604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized control trial with 2 parallel intervention arms. One arm will be the active treatment group, and the other an enhanced usual-care control group. Assessors will be blinded to study condition, and intervention will be behavioral.|f|f|f|t
34175537|NCT06296147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175538|NCT05318131|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34175539|NCT06600230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Before - after trial|t|f|f|f
34175540|NCT06239272|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34175541|NCT04934800|||COHORT||PROSPECTIVE|||||||
34175542|NCT06593704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175543|NCT00596921|||CASE_ONLY||CROSS_SECTIONAL|||||||
34175544|NCT02955589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175545|NCT02455245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175546|NCT02890329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862815|NCT02198092|||CASE_CONTROL||PROSPECTIVE|||||||
33862816|NCT00194766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862817|NCT02287311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862818|NCT03588299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862819|NCT04084964|NA|SINGLE_GROUP||TREATMENT||NONE||The NWE-Chance feasibility study is an international, multicenter, single-arm prospective and interventional study.||||
33862820|NCT04337255|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single ( Outcomes assessor)|MIND diet intervention|f|f|f|t
33862821|NCT01729858|||COHORT||PROSPECTIVE|||||||
33862822|NCT02693782|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33862823|NCT00518388|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33862824|NCT01866865|||||RETROSPECTIVE|||||||
33862825|NCT01205997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862826|NCT06428500|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33862827|NCT06735599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862828|NCT06734650|||COHORT||PROSPECTIVE|||||||
33862829|NCT03149614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33862830|NCT05388851|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34175547|NCT03380728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175548|NCT06705933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175549|NCT06037421|||COHORT||PROSPECTIVE|||||||
34175550|NCT06136169|NA|SINGLE_GROUP||OTHER||NONE||||||
34175551|NCT05253209|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization via an IWRS. Study drug or placebo will be prepared and labeled with the appropriate subject identifiers only; no information that would reveal the contents of the dose to be administered (active versus placebo) will be included on the label. Study drug (citrulline or placebo) will be provided in either identical syringes or bags and mask labeled. The bags will be the same size, shape, and fluid clarity, and hence masked to both investigators and staff administering the drug. Only the pharmacist and the unblinded monitor responsible for performing drug accountability (a different monitor than the person performing routine data monitoring) will be aware of the treatment assignment.||t|t|t|t
34175552|NCT06592404|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This is a multiple baseline single case (MBSC) study, involving individuals receiving long-term disability care and experiencing difficulties in daily structure and planning. Each participant serves as its own control and receives the person-oriented intervention involving a social robot. Participants are randomly assigned to one of four clusters. This randomization determines the duration of three phases during the 13-week study period:~* Control period (care as usual): 2, 3, 4 or 5 weeks, depending on cluster.~* Intervention period (start using the robot): 6 weeks.~* Effect measurement period: 5, 4, 3 or 2 weeks, depending on cluster.~The study period lasts 13 weeks, with a 2-week follow-up measurement scheduled 6 months after the intervention period. The goal is to integrate the social robot into the participants' care plan, with the intention that they continue using the social robot after the study."||||
33862831|NCT05706012|||COHORT||PROSPECTIVE|||||||
33862832|NCT06549101|||CASE_ONLY||RETROSPECTIVE|||||||
33862833|NCT05322850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862834|NCT00628303|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33862835|NCT06735222|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Acute, randomized, cross-over, controlled study.|t|f|t|f
33862836|NCT02978079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862837|NCT03944135|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This is a quasi-experimental design with non-equivalent groups (pretest-posttest) carried out in a more realistic setting, where the dependent variables of interest were manipulated by the researcher under controlled conditions.|f|f|t|f
33862838|NCT02877472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862839|NCT00025454||||TREATMENT||||||||
33862840|NCT01770613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862841|NCT04575025|||COHORT||PROSPECTIVE|||||||
33862842|NCT00244127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862843|NCT02682472|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33862844|NCT00387764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862845|NCT00404456|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33862846|NCT06630286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862847|NCT04191187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862848|NCT03298672|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33862849|NCT04061551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"The comprehensive intervention will be implemented at all participating sites, although specific components of the intervention will be tailored to the needs of each site. The model consists of five stages:~1. Baseline site assessment~2. Co-design intervention to streamline HCV clinical pathways~3. Implementation~4. Six-monthly review~5. End line review"||||
33862850|NCT02088814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862851|NCT06093815|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Injections will be in redundant abdominal tissue scheduled to be removed at end of study||||
33862852|NCT00516620|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33862853|NCT06105788|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a pilot randomized cross-over study. Once enrolled, all participants will undergo 3 laboratory visits, each separated at least by a week as a wash-out period: day 1, baseline assessment; day 2, randomized to either arm exercise (AE) or leg exercise (LE) ; and day 3, AE or LE alternative to the exercise on day 2.||||
33862854|NCT04351763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical events will be validated blindly by an independent clinical event committee (CEC) unaware of the treatment allocation.|parallel group, randomized trial|f|f|f|t
33862855|NCT06248502|||CASE_ONLY||PROSPECTIVE|||||||
33862856|NCT05483309|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33862857|NCT03483467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862858|NCT05945927|||COHORT||PROSPECTIVE|||||||
33862859|NCT02764450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33862860|NCT02031783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33862861|NCT00775736|||COHORT||PROSPECTIVE|||||||
33893837|NCT05520879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention study products will be packaged in sachets that cannot be differentiated between the two.|Sharnali-1 and Sharnali-2 would be provided among 450 severely acute malnourished children divided into two groups to assess the proportion of children graduating from SAM to non-acute malnutrition status (MUAC ≥ 125 mm or WLZ/WHZ ≥ -2 for two consecutive weeks) by 90 days of intervention.|t|t|t|t
33893838|NCT06203431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893839|NCT02261441|||COHORT||PROSPECTIVE|||||||
33893840|NCT04442607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an investigator-initiated non-randomized prospective interventional trial to validate the performance of a novel state-of-the-art computer-aided detection (CADe) tool for colorectal polyp detection implemented as second observer during routine diagnostic colonoscopy and to evaluate its feasibility in daily endoscopy.||||
33893841|NCT01044355|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33893842|NCT02400125|||COHORT||PROSPECTIVE|||||||
33893843|NCT03417765|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||QUADRUPLE|Double-blind|Placebo-control, ascending dose|t|t|t|t
33893844|NCT06185920|||COHORT||CROSS_SECTIONAL|||||||
33893845|NCT06217991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962480|NCT01456000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962481|NCT00959387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175553|NCT01721135|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34175554|NCT06543953|NA|SINGLE_GROUP||OTHER||NONE||||||
34175555|NCT03991780|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Single centre, not randomised, open label||||
34175556|NCT01281618|||CASE_ONLY||PROSPECTIVE|||||||
34175557|NCT05239143|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label, 3 + 3 design of dose-escalating cohorts with open label, dose expansion at recommended phase 2 dose (RP2D)||||
34175558|NCT06428110|||COHORT||PROSPECTIVE|||||||
34175559|NCT06705179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175560|NCT01760057|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34175561|NCT03406884|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first 10 participants will be enrolled in Group A to assess safety and feasibility. An additional 22 participants will be enrolled in Group B and will be randomized to either the Treatment or Control Group.||||
34175562|NCT02906514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175563|NCT00182026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175564|NCT06389526|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175565|NCT02079896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175566|NCT06064929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175567|NCT01584232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175568|NCT01064388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175569|NCT04892498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175570|NCT06706544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* the oncologists/hematologists who treat and follow the patient regularly,~* researchers who carry out biochemical determinations or functional tests,~* the staff who obtain the economic data,~* statisticians"|Randomized, triple-blind clinical trial|t|t|f|t
34175571|NCT04742634|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175572|NCT06597526|||OTHER||PROSPECTIVE|||||||
34175573|NCT06564389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175574|NCT03767933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Research staff, emergency department staff, and participants will be masked with respect to the allocated treatment. The data analyst will also be masked using codes that will not identify treatment groups until analysis is complete.|This study will be comprised of two Phase 2, six-centre, randomized, double blind, placebo-controlled trials that will be run simultaneously. The investigators expect that the number of participants recruited and the time to completion of both trials will be more efficient as recruitment for both will occur simultaneously. They propose to conduct this study with a novel preference-informed complementary trial design, in which they will conduct two simultaneous 'sister' trials. Caregiver/child pairs presenting to the ED with acute MSK limb injury will decide in which trial they wish to participate: the Opioid trial or the Non-Opioid trial. The design of each trial will be informed by its sister, or complementary, trial. Once the caregiver/child pair has chosen their preferred trial, conduct within each trial will follow traditional randomized, double-blind placebo-controlled superiority trial methodology. Study endpoints will be identical for both trials within this study.|t|t|t|t
34175575|NCT04610346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to one of two study arms, immediate or delayed treatment.|f|f|f|t
34175576|NCT05845827|||COHORT||PROSPECTIVE|||||||
34175577|NCT05954130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant|experimental and control|t|f|f|f
34175578|NCT05539625|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34175579|NCT04318977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled trial with two active and one placebo arm|t|f|t|f
34175580|NCT03466918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175581|NCT03212911|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|Open-label, randomized controlled trial (RCT) with 1:1 allocation in parallel arms||||
34175582|NCT03793049|||CASE_CONTROL||PROSPECTIVE|||||||
34175583|NCT05398757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34175584|NCT06462339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups as exercise group and control group|t|f|t|f
34175585|NCT06700135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175586|NCT06071377|||COHORT||PROSPECTIVE|||||||
34175587|NCT06469294|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|the material that will be deposited, in this case, gels for the control and placebo groups will be masked by aluminum foil for research. Gels will be encoded in a syringe and applied by researcher blind to the sites and reagents, each 4 sites will receive one og the following treatments: 1 -photodynamic therapy with red laser and photosesitization with 0,005% AM gel + 2% chlorhexidine (Fórmula e Ação Farmácia, São Paulo, SP, Brazil), 2: gel saline + lasertherapy.|Clinical, laboratory, longitudinal split-mouth study carried out in humans.|t|f|t|f
34175588|NCT05160480|||OTHER||PROSPECTIVE|||||||
34175589|NCT06047834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893846|NCT03395678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893847|NCT06411821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter phase 2 trial evaluating the efficacy and safety of monotherapy ulixertinib, an oral selective extracellular signalregulated kinase (ERK) inhibitor, for patients with histiocytic neoplasms:||||
33893848|NCT03027167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893849|NCT01496664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893850|NCT02983084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33893851|NCT05229965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"study medications consists of a randomly sequence generated numbers.~patients and the research associate who collected the outcome data are blinded from the study group"||t|f|f|f
33893852|NCT01241786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893853|NCT03751384|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|pseudo-anonymized|Allocation, not randomized|f|f|f|t
33862862|NCT04669288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Equal allocation randomization tables will be provided by the Data Coordinating Center (DCC) to the central research pharmacy. The central research pharmacy will prepare consecutively numbered study kits according to the randomization schedule. Study kits will be sent to the clinical sites.~Study products will be labeled with numerical codes that will maintain allocation concealment. Blinding/labeling of study medication bottles will be completed at the site pharmacy prior to dispensing to the patient.~Randomization tables will be created at the Data Coordinating Center using permuted-block randomization stratified by clinical site and baseline severity of symptoms. Permuted blocks of random lengths 2, 4, and 6 will be used. The randomization number will be recorded in the database."|This Phase III trial is designed as a parallel group, placebo-controlled, double-blind, randomized, multi-center evaluation of AZ for the treatment of acute wheezing episodes. This short-term study has three planned visits. All enrolled patients will participate on the Day 0 visit for screening, the informed consent process, enrollment, randomization and dispensing. A sub-group of 370 randomly selected patients will participate in two follow-up visits on Day 5 - 8 and Day 14 - 21 where they will be tested for antibiotic resistance.|t|t|t|f
33862863|NCT05920356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862864|NCT02441673|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33862865|NCT04004429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicenter, two-part, randomized, double-blind, placebo-controlled 4-week study with repeated doses of AP1189|t|f|t|t
33862866|NCT06724016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862867|NCT04219696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be obtained by a research assistant who will be blinded to group allocation.||f|f|f|t
33862868|NCT05717478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective and superiority therapeutic study with participants randomly distributed in two arms of equal size, one arm to receive Experimental treatment and the other Control treatment and blinded to participants and outcomes assessors.|t|f|f|t
33862869|NCT00616434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33862870|NCT02616445|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33862871|NCT04530461|||COHORT||PROSPECTIVE|||||||
33862872|NCT01535183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862873|NCT02597803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175590|NCT05358366|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 arms, intervention and wait-listed control group. Participants in the intervention group will receive the 4 episodes of the Love infection intervention (one episode weekly) after the baseline assessment. Participants in the wait-listed control group will receive the intervention after completing the 3-month assessment.||||
34175591|NCT06586996|||COHORT||CROSS_SECTIONAL|||||||
34175592|NCT00729144|||COHORT||PROSPECTIVE|||||||
34175593|NCT06517160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Doctors at health clinics were not aware of the subjects in the control group.|||||
34175594|NCT05788510|||COHORT||RETROSPECTIVE|||||||
33862874|NCT04654585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33862875|NCT04808986|NA|SINGLE_GROUP||OTHER||NONE||This is a monocentric cross-sectional epidemiological study, with descriptive and analytical aims, carried out in metropolitan France. This study is qualified as research involving the human person of category 2 (RIPH2) as defined in the 2nd of article L. 1121-1 of the public health code, i.e. interventional research that involves only minimal risks and constraints, the list of which is set by order of 12 April 2018 of the minister in charge of health, after the opinion of the director general of the National Agency for the Safety of Medicines and Health Products (ANSM).||||
33862876|NCT00235820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862877|NCT02885948|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33862878|NCT03099239|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33893854|NCT01816087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893855|NCT04057170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893856|NCT05098483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962482|NCT04857684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962483|NCT05614999|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33962484|NCT02362594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962485|NCT01234428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962486|NCT00665626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175595|NCT06441643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175596|NCT05791981|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34175597|NCT06340581|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34175598|NCT06700824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175599|NCT04527796|||OTHER||RETROSPECTIVE|||||||
34175600|NCT05980260|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"A two-period cluster crossover design will be used in this study. Study sites will be randomized in a 1:1 allocation ratio to one of two sequences:~1. A three-week run-in period followed by a scheduled opioid taper approach for five months followed by a three-week washout period followed by a symptom-based dosing approach for five months.~2. A three-week run-in period followed by a symptom-based dosing approach for five months followed by a three-week washout period followed by a scheduled opioid taper approach for five months."||||
34175601|NCT06569212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175602|NCT04539496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175603|NCT06705101|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34175604|NCT05880199|||COHORT||PROSPECTIVE|||||||
34175605|NCT02931188|||COHORT||CROSS_SECTIONAL|||||||
34175606|NCT05153746|RANDOMIZED|PARALLEL||SCREENING||SINGLE||"3D-colonoscopy vs. conventional 2D-colonoscopy Setting: Multi-centers~Eligibility:~Age 40 or above Indication for colonoscopy, including screening, surveillance, symptomatic, etc~Exclusion:~Poor and inadequate bowel preparation Incomplete study because of obstructive lesion, including cancer, stenosis, etc.~Failure of cecal intubation, difficult insertion Inflammatory bowel disease Hereditary polyposis, (FAP, Lynch syndrome, hyperplastic polyposis, etc.)"|t|f|f|f
33862879|NCT05712057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants will engage in a behavioral training session (either cognitive restructuring or emotional awareness training). The clinician who will conduct this behavioral session will be kept blind to thetype of neurostimulation the participant will receive. The neurostimulation technician will be kept blind to the behavioral training that the participant receives. Participants will only be told about the specific type of neurostimulation they receive at the end of the study to protect against different expectations.|Group 1 (G1) and 2 (G2) participants will receive training in cognitive restructuring, while Group 3 (G3) participants will receive training in emotional awareness. All participants will undergo negative emotion induction using autobiographical stressors. Depending on group participants could receive one of two types of neurostimulation . Randomization procedures will match subjects on: 1) severity of emotional dysregulation (high/very high), 2) sex at birth, and 3) treatment status (psychotropics/no psychotropics).|t|f|f|t
33862880|NCT02031484|||CASE_ONLY||PROSPECTIVE|||||||
33862881|NCT02187614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862882|NCT05315453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862883|NCT03298568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862884|NCT02231021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862885|NCT02704338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862886|NCT01050413|||COHORT||PROSPECTIVE|||||||
33862887|NCT02017639|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33862888|NCT01699854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33862889|NCT03932825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862890|NCT00119041|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962487|NCT05178043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962488|NCT06538168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and/or assessors are unaware of who receives the intervention (treatment) or control. This reduces bias by ensuring that knowledge of the treatment does not influence outcomes assessment, thus enhancing the reliability of study results.|In an interventional parallel study design, participants are assigned to either an intervention group and a control group. The intervention group receives the treatment or intervention being tested, while the control group does not receive the intervention and serves as a comparison. This allows researchers to assess the effectiveness of the intervention by comparing outcomes between the two groups under controlled conditions.|t|f|f|t
34065006|NCT00895570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862891|NCT01883479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862892|NCT05634252|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33862893|NCT04881461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862894|NCT06734403|||COHORT||RETROSPECTIVE|||||||
33862895|NCT03788395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862896|NCT06735209|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Clinic Study Staff (except for Pharmaceutical Operations), Study Statistician and Lab staff will be unaware of the treatment group assignment. Products for administration will be indistinguishable to the participants, the persons administering vaccine, and persons conducting laboratory assays, and this blinding will be maintained by study staff for clinical evaluations thereafter until after the CHMI phase is completed.||t|t|t|t
33862897|NCT06286254|||CASE_CONTROL||PROSPECTIVE|||||||
33862898|NCT06451887|||CASE_CONTROL||PROSPECTIVE|||||||
33862899|NCT01133379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33862900|NCT02289352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862901|NCT05870254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33862902|NCT05476926|||COHORT||PROSPECTIVE|||||||
33862903|NCT00269568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962489|NCT02875067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962490|NCT00530452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962491|NCT02453100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962492|NCT00410215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33962493|NCT05652816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962494|NCT03087929|||CASE_ONLY||PROSPECTIVE|||||||
33962495|NCT05303831|||COHORT||PROSPECTIVE|||||||
33962496|NCT01311856|||COHORT||PROSPECTIVE|||||||
33962497|NCT06212232|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33962498|NCT02023320|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33962499|NCT01474954|||COHORT||PROSPECTIVE|||||||
33962500|NCT02194231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962501|NCT04395131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962502|NCT04492007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33962503|NCT02243059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962504|NCT05715788|||COHORT||PROSPECTIVE|||||||
33962505|NCT03554642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Sequential randomization into one of two groups within first week after admission.|f|f|f|t
33962506|NCT06279936|||COHORT||PROSPECTIVE|||||||
33962507|NCT05147285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962508|NCT03673475|||OTHER||PROSPECTIVE|||||||
33962509|NCT04069104|||OTHER||CROSS_SECTIONAL|||||||
33962510|NCT04368182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962511|NCT01783899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962512|NCT02693847|||COHORT||PROSPECTIVE|||||||
33962513|NCT05602935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962514|NCT00776269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962515|NCT00324090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33962516|NCT00047437|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962517|NCT02135094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751376|NCT03386279|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"PF-04965842 and placebo oral tablets will be prepared in the CRU by 2 operators, 1 of whom is an unblinded pharmacist. PF-04965842 and placebo will be administered in blinded fashion to the subject.~Moxifloxacin 400 mg tablets will be packaged in an open-label manner at the CRU in the individual dosing containers by 2 operators, 1 of whom is an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician's assistant, practitioner, or pharmacist)."||t|t|t|t
33751377|NCT00853814|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33751378|NCT02877043|||COHORT||RETROSPECTIVE|||||||
33751379|NCT06486467|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
33751380|NCT05845138|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-A1811 combined with capecitabine||||
33751381|NCT01846182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Three arms comparing placebo to duloxetine and pregabalin|t|t|t|t
33751382|NCT06133400|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751383|NCT03118583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33751384|NCT05574569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751385|NCT03722186|NA|SEQUENTIAL||TREATMENT||NONE||||||
33751386|NCT05646875|NON_RANDOMIZED|PARALLEL||OTHER||NONE||3 groups: 1) post-ROSC patients 2) cardiac arrest survivors already discharged 3) healthy volunteers||||
33751387|NCT03333850|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||There will be sequential inclusion to each cohort. Each sequence includes 18 patients (corresponding to the number of beds at the department). Thus the patients hospitalised during the first period will receive feedback (exposed cohort). In the second period the patients will not receive feedback (non-exposed cohort), and so forth. A total of 108 patients will be included resulting in 6 periods of 18 patients each.||||
33862904|NCT01217216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33862905|NCT00378235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862906|NCT04088383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862907|NCT06632444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862908|NCT03312699|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33862909|NCT04898049|||COHORT||PROSPECTIVE|||||||
33862910|NCT04194853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be two treatment groups of participants, Experimental group will receive Isometric exercises with EMGBF( Electromyographic Biofeedback ) and control group receive exercises without EMGBF.|There will be two treatment groups of participants, Experimental group will receive Isometric exercises with EMGBF( Electromyographic Biofeedback ) and control group receive exercises without EMGBF.|t|f|f|f
33862911|NCT05895604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175607|NCT04983017|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||Participants will receive a formulation of dietary supplements based on the iAge test. Different formulations contain different combinations of dietary supplements.|t|f|t|f
33862912|NCT05326113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862913|NCT04838769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862914|NCT01483833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862915|NCT03144804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862916|NCT06423612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized hybrid type 1 effectiveness trial|f|f|t|t
34175608|NCT03316924|||CASE_ONLY||CROSS_SECTIONAL|||||||
34175609|NCT06321510|||COHORT||RETROSPECTIVE|||||||
34175610|NCT05890664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A randomization list will be provided by the Clinical Trial Unit Basel to an unblinded person at the sponsor's site. The unblinded person will allocate the randomization numbers. Patients and research staff involved in patient recruitment, data management, outcome adjudication and data analyses will fully be blinded|Prospective, randomized, double-blind, placebo-controlled trial.|t|f|t|t
34175611|NCT03359538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|treatment double blinded to patients and physicians||t|f|t|f
34175612|NCT05820412|||COHORT||PROSPECTIVE|||||||
34175613|NCT06444568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175614|NCT05797246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34175615|NCT04882488|||COHORT||PROSPECTIVE|||||||
34175616|NCT02250846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175617|NCT01402752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175618|NCT03737695|||OTHER||PROSPECTIVE|||||||
34175619|NCT01004952|||COHORT||PROSPECTIVE|||||||
34175620|NCT05278962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175621|NCT05506683|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34175622|NCT05655351|NA|SINGLE_GROUP||PREVENTION||NONE||"This is a pilot observational, single-center study with prospective longitudinal follow-up.~Type of study: Non-Health Product. Category according to the Jarde law : Interventional research involving human subjects with minimal risks and constraints, Category 2."||||
34175623|NCT04049032|||COHORT||PROSPECTIVE|||||||
34175624|NCT06223867|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome evaluators will be blinded to study condition. It is not possible to blind participants, the research staff enrolling the participant, or the treating clinicians.||f|f|f|t
33751388|NCT03201939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled RCT|Double-blind, placebo-controlled RCT|t|t|t|t
33751389|NCT05214833|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||"Two arms will be investigated. The first one will receive real neurofeedback. The second one will receive sham neurofeedback (comparator).~During sham neurofeedback, a signal which resembles the participant's brain activity is used instead of the actual brain activity."|t|f|t|f
33751390|NCT06579118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistics expert||f|f|f|t
33862917|NCT00179166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862918|NCT02407470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862919|NCT03913481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33862920|NCT05802394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862921|NCT02764164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962518|NCT04368663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962519|NCT04741139|NA|SINGLE_GROUP||TREATMENT||NONE||"Single hospital system, single-arm year-long pilot to evaluate the feasibility of enrolling children with ITP who are receiving IVIG for treatment of disease to a scheduled post-infusion medication for 72 hours following IVIG infusion.~This year-long feasibility pilot will test the (1) feasibility of enrollment and the willingness of families to participate in a scheduled medication regimen and (2) adherence of patients and families to the scheduled medication regimen. Clinical outcomes, as defined by rates of headache or nausea/vomiting or other adverse event following IVIG, return to medical care, and need for further laboratory or imaging studies, will be collected. These rates will be compared to retrospective, historical data from Texas Children's Hematology Center from 2010 to 2019. However, due to the rate at which these events occur following IVIG, this feasibility pilot is not fully powered to detect differences in clinical outcomes."||||
33962520|NCT06338189|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862922|NCT01807923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862923|NCT00497601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862924|NCT00819286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant blinded to treatment assignment until completion of study.||t|f|f|f
33862925|NCT05192798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862926|NCT06734897|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized study with a start group A and a delayed group B. Group A will begin six months of music therapy immediately after cochlear implantation, group B six months later. Another group consists of persons who do not receive any music therapy, will form the control group. The speech intelligibility values resulting from the OLSA sentence test are compared between the three groups after six and twelve months."||||
33862927|NCT00325962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33862928|NCT00846885|RANDOMIZED|CROSSOVER||||NONE||||||
33862929|NCT06049082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862930|NCT02947477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862931|NCT00000604|RANDOMIZED|||TREATMENT||||||||
33862932|NCT01177384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33862933|NCT03612011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Cosmetic product Onco-Repair and placebo will be filled in the tubes with same appearance and smell. The tubes will be marked anonymusioly"|"Phase III multicenter, double blind, superiority, prospective, randomised controlled study Subjects will be randomized to receive either cosmetic product Onco-Repair or placebo in a 1:1 ratio"|t|f|t|f
33862934|NCT02258503|||||CROSS_SECTIONAL|||||||
33962521|NCT04229277|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33962522|NCT06540755|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33962523|NCT02306473|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33962524|NCT00803673|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33962525|NCT05458622|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients with stable or quiescent SLE will be included and followed-up in routine clinical care until a flare or until the 2 years end-of-study (EOS) visit.||||
33962526|NCT06515717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33962527|NCT01416207|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33962528|NCT00886782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962529|NCT05433688|||CASE_CONTROL||PROSPECTIVE|||||||
34065007|NCT01085084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065008|NCT04224220|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065009|NCT06169956|||COHORT||PROSPECTIVE|||||||
34065010|NCT01689233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065011|NCT02859688|||FAMILY_BASED||PROSPECTIVE|||||||
34175625|NCT06529536|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This is a quasi-experimental trial, with a single-arm prospective intervention and retrospective comparator. Forty-five SOT recipients will be recruited from The Royal Children's Hospital Melbourne (with 45 retrospective controls taken from the immediately prior 3-5 years).~For all eligible SOT patients, a pre-emptive CYP3A5 genotype will be combined with a population PK model to predict optimal initial tacrolimus dose. In addition, genotype-informed Bayesian revised dosing will be applied to all transplant recipients over the subsequent 12-weeks post-transplant.~The prospective arm will be compared with a retrospective arm (using standard mg/kg dosing plus therapeutic drug monitoring) with primary outcome based on proportion in therapeutic range immediately post-transplant (day 4 and day 10). Finally, time within therapeutic range over the first 12-weeks post-transplant will be tested using mixed effects logistic regression."||||
34175626|NCT03629886|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175627|NCT03648905|||COHORT||PROSPECTIVE|||||||
34175628|NCT05516537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175629|NCT03523819|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Randomized for Part 3 of the study|||||
34175630|NCT04514185|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized counterbalanced cross-over design||||
33962530|NCT03990246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33962531|NCT00387868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862935|NCT03099005|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Participants will receive vaporized cannabis using Volcano vaporizers (Storz and Bickel) with either 3.74% THC + 0.49% CBD, 3.49% THC + 4.17% CBD, or 3.11% THC + 15.76% CBD at each of three visits. Allocation assignment of visits will be assigned using a Web-based random number- generating program, Research Randomizer (http:// www.randomizer.org/). The allocation schedule will be kept in the pharmacy and concealed from other study personnel."|Acutely administered CBD/THC will reduce HIV-neuropathic pain in a stair-step manner; the highest CBD dose will provide the greatest pain reduction (high CBD \> medium CBD \> low CBD).|t|t|t|t
33862936|NCT01554735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862937|NCT02019420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862938|NCT06012929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862939|NCT06734585|||COHORT||RETROSPECTIVE|||||||
33862940|NCT03538353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862941|NCT06734221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862942|NCT05287672|||COHORT||RETROSPECTIVE|||||||
33862943|NCT04585646|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33862944|NCT03412279|||COHORT||CROSS_SECTIONAL|||||||
33862945|NCT03274609|||COHORT||PROSPECTIVE|||||||
33862946|NCT06388681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33862947|NCT00517751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862948|NCT05017220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33862949|NCT03687814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33862950|NCT01125943|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33862951|NCT06734624|||COHORT||PROSPECTIVE|||||||
33862952|NCT01081457|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33862953|NCT00199433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33862954|NCT01116518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862955|NCT05231629|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Eligible patients are enrolled in arm M for induction therapy, corresponding to 6 cycles of Dara-VRd.~Upon completion of induction, patients undergo MRD assessment by next-generation sequencing utilizing ClonoSEQ® (MRD1) and undergo mobilization and collection of autologous hematopoietic progenitor cells for future AHCT.~Upon confirmation of adequate hematopoietic cell collection (≥2 x 10\^6 CD34+ cells/kg) and result of MRD1 patients will undergo randomization according to the MRD-assigned cohort~* MRD negative cohort - Patients will be randomized between arm A and arm B for intensification and maintenance.~* MRD positive cohort - Patients will be randomized between arm C and arm D for intensification, consolidation and maintenance."||||
33862956|NCT03846739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33862957|NCT05474066|||COHORT||PROSPECTIVE|||||||
33862958|NCT05794763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor at the 3-month follow-up is blind to participant randomization.||f|f|f|t
33862959|NCT01388296|||CASE_ONLY||PROSPECTIVE|||||||
33862960|NCT03217188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase II study evaluating proton reirradiation for patients who have a recurrent or a second primary head and neck cancer.||||
34065012|NCT00201617|||CASE_CONTROL||PROSPECTIVE|||||||
34065013|NCT06405659|||CASE_ONLY||RETROSPECTIVE|||||||
34065014|NCT00596726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065015|NCT04395313|||COHORT||RETROSPECTIVE|||||||
34065016|NCT05726422|||COHORT||CROSS_SECTIONAL|||||||
34175631|NCT06069128|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|This is a single-center, open label clinical study. Up to 11 subjects will be enrolled to use the Neuro-trigger device for blinking stimulation for a duration of 14 days.||||
34175632|NCT05280496|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34175633|NCT03567733|||CASE_ONLY||PROSPECTIVE|||||||
34175634|NCT00412139|||CASE_CROSSOVER||PROSPECTIVE|||||||
34175635|NCT06597851|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, experimental, single-arm, explorative study. The study aims to perform a functional study of the coronary microcirculation with pressure guides, in patients with angina and non obstructive coronary artery disease. Also a tranthoracic echocardiography will be performed. Following this, the patient will undergo hyperinsulinemic-euglycemic clamp test to evaluate insulin resistance and the metabolic risk. The primary endpoint is to assess the correlation between the index of microcirculatory resistance and the M-value evaluated with clamp test as a measure of insulin resistance. Follow up will continue up to 1 year from enrollment through telephone contacts, outpatient visits and review of clinical data.||||
34175636|NCT03757091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175637|NCT02749396|||COHORT||RETROSPECTIVE|||||||
34175638|NCT00610870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175639|NCT01339832|||COHORT||RETROSPECTIVE|||||||
34175640|NCT05164120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomizations, assigned 1:1||t|t|t|t
34175641|NCT06362421|||COHORT||PROSPECTIVE|||||||
34175642|NCT06348927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175643|NCT04430920|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34175644|NCT03638453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175645|NCT04519008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34175646|NCT04106297|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Part 1 and 1bis (SAD), Part 2 (MAD) and Part 4 (psoriasis subjects) are randomized, double-blind, placebo-controlled; Part 3 (FE-rBA) and Part 3bis (FE) are randomized, open-label.|t|t|t|t
34175647|NCT06340685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175648|NCT04733638|||CASE_CONTROL||RETROSPECTIVE|||||||
34175649|NCT04195945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175650|NCT06596785|||OTHER||PROSPECTIVE|||||||
34175651|NCT03075787|||COHORT||RETROSPECTIVE|||||||
34175652|NCT03546023|||COHORT||PROSPECTIVE|||||||
34175653|NCT05650710|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All patients who meet eligibility will undergo uni- or bilateral neck dissection and other indicated procedures for management of head and neck cancer and will have measurements and photos/videos of the common trunks taken. An electrode will be placed on one or both common trunks to stimulate infrahyoid muscles.||||
34175654|NCT05992935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34175655|NCT05219500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065017|NCT02513602|||CASE_CONTROL||PROSPECTIVE|||||||
34065018|NCT05000853|||COHORT||PROSPECTIVE|||||||
33862961|NCT05891353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862962|NCT03651583|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33862963|NCT05429983|||COHORT||PROSPECTIVE|||||||
33862964|NCT04279262|||COHORT||RETROSPECTIVE|||||||
33962532|NCT05743478|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This community-partnered cluster-randomized study will examine the effectiveness of a racial, gender, and economic justice focused youth violence prevention program called Forging Hopeful Futures among youth ages 13-19.The study will be located in 16 neighborhoods with concentrated disadvantage ('clusters') across Pittsburgh, Pennsylvania and urban Washington D.C. and Maryland metro areas randomized either to receive the Forging Hopeful Futures program (i.e., intervention neighborhood, n=8) or wellness check-ins (i.e. control neighborhood, n=8)."||||
33962533|NCT01890109|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34065019|NCT03901508|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The device is preprogrammed by a third party non participating in any element in the study. They then chose (using opaque envelopes) the treatment code for each participant|Randomized, triple-blind, sham-controlled, crossover|t|f|t|t
34065020|NCT01977716|||COHORT||PROSPECTIVE|||||||
34065021|NCT05837793|||COHORT||RETROSPECTIVE|||||||
33862965|NCT06559163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065022|NCT04221022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065023|NCT00448812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065024|NCT03216603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065025|NCT06146699|||CASE_ONLY||CROSS_SECTIONAL|||||||
33862966|NCT06734143|||OTHER||CROSS_SECTIONAL|||||||
34065026|NCT06137209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A Staff member will be assigned to distribute blinded samples. The investigator will not be aware of the dose groups.|"Participants will be randomly assigned to one of two groups applying serum containing Micrococcus luteus Q24 at a low or higher dose of probiotic.~Group A: Probiotic Micrococcus luteus Q24 serum (dose:1e7 colony forming units per application of serum).~Group B: Probiotic Micrococcus luteus Q24 serum (dose:1e6 colony forming units per application of serum)"|t|f|t|f
34065027|NCT05213026|||CASE_CONTROL||RETROSPECTIVE|||||||
34065028|NCT04441385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065029|NCT04080089|||CASE_CONTROL||RETROSPECTIVE|||||||
34065030|NCT00956605|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34065031|NCT02922075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065032|NCT04699825|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||enrollment of infants born from preeclampsia mother and control from infants born from normal pregnancies||||
34065033|NCT06516185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is designed following CONSORT guidelines as a randomized equivalence clinical trial, controlled, with two parallel arms, and single-blind.|t|f|f|f
34065034|NCT02724410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33862967|NCT02082587|||COHORT||PROSPECTIVE|||||||
34065035|NCT05420493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175656|NCT03422913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both patients and surgeons are blinded, and anesthesiologist opened the envelope during the operation||t|f|t|f
34175657|NCT06288581|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33862968|NCT00738413|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33862969|NCT04755205|||COHORT||PROSPECTIVE|||||||
33962534|NCT03478774|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Patients will be blinded as they receive general anesthesia. Care providers cannot be blinded, due to obvious differences in set-up of the different interventions.|single centre, prospective, randomized-controlled trial|t|f|f|f
33862970|NCT05360082|||CASE_CONTROL||PROSPECTIVE|||||||
33862971|NCT00512330|||||PROSPECTIVE|||||||
33862972|NCT06692153|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial (RCT)||||
33893857|NCT03511339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962535|NCT03163069|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||factorial assignment|t|f|t|f
33962536|NCT03677635|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33962537|NCT05107154|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33962538|NCT00857493|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33962539|NCT06569108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065036|NCT02525302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065037|NCT02441751|||COHORT||PROSPECTIVE|||||||
34065038|NCT00997022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065039|NCT02079298|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065040|NCT01856504|||COHORT||PROSPECTIVE|||||||
34065041|NCT02185807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065042|NCT03706001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065043|NCT03474094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065044|NCT06365593|||COHORT||RETROSPECTIVE|||||||
34065045|NCT05020366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants collecting outcome measures will be blinded to study assignment.|Pilot RCT will follow a 2:1 randomization scheme with 2 participant families (parent + child) assigned to intervention (Pro-PEAR) for every 1 assigned to control (enhanced usual care) for a total of 24 participant families.|f|f|f|t
33862973|NCT04554238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Regarding masking, it is impossible for the treating occupational therapist to be unaware of the treatment to be carried out by the treated patient, just as it is impossible for the patient not to identify the treatment to which they access, therefore, this study is single-blind, considering only who performs the evaluations of the study will not know which group corresponds to the evaluated patient.|The type of study to be developed corresponds to a parallel group randomized clinical trial (RCT) with a superiority study framework, as it seeks to compare the effectiveness of Armeo spring robotic therapy versus conventional occupational therapy in terms of the functionality of the upper limb of children with hemiparesis infiltrated simultaneously with BTA. The trial phase corresponds to phase III.|f|f|f|t
34175658|NCT06591390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive loading doses of cilostazol and aspirin or ticagrelor and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 900 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included cilostazol. Both groups received an open-label loading dose of 300 mg of aspirin and continued on aspirin 75 mg daily.|The investigators will conduct our single-blinded randomized controlled trial, which will contain two arms; the cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day). The ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd to the 90th day). Both groups received an open-label loading dose of 300 mg aspirin and continued on open-label aspirin 75 mg daily.|f|f|t|t
33862974|NCT05726045|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34175659|NCT03957551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175660|NCT05682170|NA|SEQUENTIAL||TREATMENT||NONE||||||
33862975|NCT06493331|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|participants do not know which group they are in||t|f|f|f
33862976|NCT01686360|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33962540|NCT02523729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962541|NCT05296369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175661|NCT06180135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Therre Groups. Group were comprised of control group, fennel tea drink group, turkısh coffee drink group.|t|t|t|t
34175662|NCT05984121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly divided into 3 groups. (They will be selected by simple random sampling using the closed envelope method). They will be divided into Group 1 (local ozon injections and exercise) and group 2 (local dextroz prolotherapy and exercise) and group 3 (exercise) Outcome evalutions in the stduy will be carried out by a researcher who is blind to group allocation|Three groups with a conventional therapy control group|f|f|f|t
34175663|NCT05983965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175664|NCT00558142|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34175665|NCT02197884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175666|NCT03600233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175667|NCT06541028|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175668|NCT01614249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34175669|NCT03125928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175670|NCT02633059|NA|SEQUENTIAL||TREATMENT||NONE||||||
34175671|NCT02192515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175672|NCT02620774|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175673|NCT04975698|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34175674|NCT04182516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Dose escalation part followed by a Dose Expansion part.||||
34175675|NCT05324358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175676|NCT04937036|||COHORT||PROSPECTIVE|||||||
33862977|NCT00460174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862978|NCT04418544|||COHORT||CROSS_SECTIONAL|||||||
33862979|NCT03584971|||OTHER||PROSPECTIVE|||||||
33862980|NCT04328779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33862981|NCT00095355||||TREATMENT||||||||
33962542|NCT00577954|||COHORT||PROSPECTIVE|||||||
33962543|NCT05813665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962544|NCT01542684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962545|NCT02085005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962546|NCT00448630|||COHORT||PROSPECTIVE|||||||
33962547|NCT06562712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175677|NCT06268236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33862982|NCT06734598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33962548|NCT06361316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175678|NCT06600932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175679|NCT06704321|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, double-blinded, parallel, placebo-controlled study.|t|t|t|t
34175680|NCT06705647|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34175681|NCT01672645|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34175682|NCT02592265|||CASE_ONLY||PROSPECTIVE|||||||
34175683|NCT05861466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34175684|NCT04348240|||COHORT||PROSPECTIVE|||||||
34175685|NCT03378557|||CASE_ONLY||PROSPECTIVE|||||||
34175686|NCT02183675|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34175687|NCT02891174|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34175688|NCT01539824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175689|NCT05462145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175690|NCT05625360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33962549|NCT03028558|||CASE_CONTROL||PROSPECTIVE|||||||
33962550|NCT02432456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962551|NCT06536686|||COHORT||PROSPECTIVE|||||||
33962552|NCT03823339|||COHORT||PROSPECTIVE|||||||
33862983|NCT01882218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33862984|NCT02131909|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33862985|NCT06654024|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33862986|NCT06735846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33862987|NCT05274802|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33962553|NCT03347227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded|Prospective, parallel arm randomized clinical trial|t|f|f|f
34175691|NCT06078241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34175692|NCT00001483||||TREATMENT||||||||
34175693|NCT06599489|RANDOMIZED|PARALLEL||TREATMENT||NONE||operation surgical intervention||||
33862988|NCT00730431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962554|NCT03547531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner was blind to the allocation of the group|the data were gathered from two groups of participants (control and intervention groups)|f|f|f|t
33962555|NCT06082531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962556|NCT06290427|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33962557|NCT02190344|NA|SINGLE_GROUP||OTHER||NONE||||||
33962558|NCT03406832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33962559|NCT02733458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962560|NCT01838525|||CASE_CONTROL||PROSPECTIVE|||||||
33962561|NCT04520282|||COHORT||PROSPECTIVE|||||||
33962562|NCT01444274|||CASE_CONTROL||PROSPECTIVE|||||||
33962563|NCT06127004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised Controlled Trial|t|f|f|t
34175694|NCT04894591|||OTHER||PROSPECTIVE|||||||
34175695|NCT06216613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of our intervention precludes blinding of the interventionists and participants; however, investigators not involved in the intervention, data analysts and research assistants will be blinded to condition.|Randomized controlled trial with 50 participants who will be randomized 1:1 to either the Sensory Enhanced Aquatics intervention or control condition with standard swim lessons.|f|f|f|t
34175696|NCT02163538|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34175697|NCT06342934|||COHORT||PROSPECTIVE|||||||
34175698|NCT05443308|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33962564|NCT05531838|NA|SEQUENTIAL||PREVENTION||NONE||||||
33962565|NCT00438932|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33962566|NCT03118765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962567|NCT05324709|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33962568|NCT01046721|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33962569|NCT05049304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33962570|NCT06087302|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|there would be two groups intervention group and a control group.|Child-Parent Relationship Therapy (CPRT) is a play-established therapy process for young children, aged between 3-10, who have attachment issues, and behavioral, social, or emotional issues. It is based on ten weekly, two-hour group sessions for a group of 5-8 members in the group. Learning skills, receiving feedback on skill practice, and connecting with other parents for support are all critical components of the CPRT program. Parents learn skills and prepare for future play sessions with their children during sessions 1-3. Parents practice their new skills with their children in weeks 4-10, while the therapist provides feedback in a small group setting.|t|f|t|f
34065046|NCT00224406|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All personnel involved and patients participating in the study were to remain blinded to the patient randomization codes with the exception of those involved in packaging and labelling the study medication. After the database lock of data recorded in the main part of the study, corresponding to the Month 1 follow-up visit of the last patient in, the blind code was broken and the study continued in an open fashion.||t|f|t|f
34065047|NCT03367897|||CASE_CONTROL||PROSPECTIVE|||||||
34175699|NCT05764564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34175700|NCT04758572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175701|NCT04595071|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Voice-Activated Prosthesis Interface||||
34175702|NCT03479723|||CASE_ONLY||OTHER|||||||
34175703|NCT05738174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34175704|NCT06539598|NA|SINGLE_GROUP||OTHER||NONE||||||
34175705|NCT03473756|NA|SINGLE_GROUP||TREATMENT||NONE|Part A is open-label.|||||
34175706|NCT04882735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175707|NCT06592092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175708|NCT06234059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175709|NCT03338777|NA|SINGLE_GROUP||TREATMENT||NONE||Suicide plus immunogene therapy||||
34175710|NCT03516123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175711|NCT06705283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34175712|NCT01781936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175713|NCT06705231|||COHORT||RETROSPECTIVE|||||||
33862989|NCT04353453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862990|NCT05943535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33862991|NCT05905393|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33862992|NCT04978181|||CASE_ONLY||RETROSPECTIVE|||||||
33862993|NCT04301362|||COHORT||PROSPECTIVE|||||||
33862994|NCT00785824|||COHORT||PROSPECTIVE|||||||
33862995|NCT03057314|NA|SINGLE_GROUP||TREATMENT||NONE||OPEN LABEL SINGLE ARM STUDY||||
33862996|NCT01864772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33862997|NCT02880826|||CASE_ONLY||PROSPECTIVE|||||||
33962571|NCT01838278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175714|NCT00000336||||TREATMENT||DOUBLE||||||
34175715|NCT05460104|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175716|NCT04028713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized non-inferiority study|f|f|f|t
33862998|NCT01430806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33862999|NCT05440643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 and 2 is open label. Part 3 is blinded.|Part 1 and 2 is sequential Part 3 is parallel|t|t|t|t
34175717|NCT04096430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained assessors, blinded to group allocation, will complete the measures with families. Family members will be blinded to all initial responses on the measures.|We will use a pragmatic, cluster randomized controlled trial (RCT) design with therapists randomized to one of two groups; the ENGAGE intervention group or the usual care control group.|f|f|f|t
33863000|NCT06690138|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33863001|NCT00823303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175718|NCT05108870|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863002|NCT04136184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863003|NCT06734416|||CASE_CONTROL||PROSPECTIVE|||||||
34175719|NCT03678064|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33863004|NCT05767866|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863005|NCT02341703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863006|NCT01104142|||COHORT||PROSPECTIVE|||||||
33863007|NCT04452903|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The participant (patients of the physiotherapists) are unaware of the intervention.~The outcome assessor will not know who was in the intervention group and who was in the control"|A randomized controlled trial|t|f|f|t
33863008|NCT00912652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863009|NCT06390319|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863010|NCT05251623|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863011|NCT04728126|||COHORT||PROSPECTIVE|||||||
33863012|NCT01252810|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34175720|NCT06586736|||COHORT||PROSPECTIVE|||||||
34175721|NCT05668351|NA|SINGLE_GROUP||TREATMENT||NONE||Stereotactic Ablative Body Radiotherapy||||
34175722|NCT06466746|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34175723|NCT06704451|||COHORT||PROSPECTIVE|||||||
34175724|NCT05856877|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34175725|NCT05891431|NA|SINGLE_GROUP||TREATMENT||NONE||A within groups study design||||
33863013|NCT06282276|||COHORT||CROSS_SECTIONAL|||||||
33863014|NCT04048980|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863015|NCT01068392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863016|NCT06725147|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863017|NCT01448122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863018|NCT05227872|||OTHER||CROSS_SECTIONAL|||||||
33863019|NCT06637501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863020|NCT01726452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863021|NCT01223950|||CASE_CONTROL||PROSPECTIVE|||||||
33863022|NCT06585267|||OTHER||PROSPECTIVE|||||||
33863023|NCT02033603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863024|NCT06495333|||OTHER||CROSS_SECTIONAL|||||||
33863025|NCT06335524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33863026|NCT03692572|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Only research nurse will have an access to the randomization sheet.|2 groups of women (early and normal menopause transition) will be enrolled to crossover design study in a fashion of randomized and double-blinded.|t|f|t|t
33863027|NCT05671653|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The overall design is randomized, open-label, fixed-sequence. Cohort 1 will consist of 9 periods while Cohort 2 will consist of 4 periods.||||
33863028|NCT06320405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863029|NCT03422289|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All the patients were given orally Inofolic® (Lo.Li. Pharma, Rome, Italy), containing 2 g myo-inositol and 0.2 mg folic acid twice a day for three months, in order to induce ovulation. Then, non-responder partecipants were administered orally with 2 g myo-inositol plus 50 mg α-lactalbumin, twice a day for three months||||
33863030|NCT04471454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33863031|NCT01604603|||COHORT||RETROSPECTIVE|||||||
33863032|NCT03166163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This was a double -blind study as the investigator was unaware about the sampling of the groups and study subjects were unaware about the mouthwash they were using||t|f|t|f
33863033|NCT05059236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863034|NCT05931003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751391|NCT05517317|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous BMMC infusion||||
33863035|NCT04866368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33863036|NCT00108992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33863037|NCT06322056|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33863038|NCT03876171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We will test the CIFFTA model against the Standard of Care currently being offered by the Miami-Dade's Juvenile Service Department (JSD) to Haitian adolescents in their diversionary program.|This study will develop and implement a culturally specific, family-based individual, drug use, sexual risk and delinquency risk reduction program for Haitian adolescents aged 13-17 in Miami-Dade County. The goal of the pilot study is to obtain preliminary data on CIFFTA's feasibility, cultural acceptability and efficacy.|t|f|f|f
33863039|NCT06735235|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33863040|NCT00633711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863041|NCT04555837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863042|NCT01572922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863043|NCT02717663|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33863044|NCT03829709|NA|SINGLE_GROUP||TREATMENT||NONE||Rehabilitation||||
33863045|NCT06506266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33863046|NCT06735690|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863047|NCT00729781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863048|NCT03139825|NA|SINGLE_GROUP||OTHER||NONE||||||
33863049|NCT05179642|||OTHER||PROSPECTIVE|||||||
33863050|NCT06100718|||COHORT||PROSPECTIVE|||||||
33863051|NCT02991105|||COHORT||RETROSPECTIVE|||||||
34065048|NCT01929954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863052|NCT03504007|||COHORT||PROSPECTIVE|||||||
33962572|NCT06070493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The control group received a classical physiotherapy program including transcutaneous electrical nerve stimulation, hot pack and exercise, while the treatment group received the same classic physiotherapy program along with the myofascial release technique. All treatments were planned for 4 weeks and a total of 10 sessions.|f|f|f|t
33863053|NCT04693260|NA|SINGLE_GROUP||SCREENING||NONE||||||
33863054|NCT06726928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863055|NCT05560581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|double-blind||t|t|t|t
33962573|NCT05251922|||COHORT||PROSPECTIVE|||||||
33751392|NCT03597568|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Subjects will be randomized to either receive the following intervention: placebo or resveratrol for six weeks and then after a two week washout will be assigned the alternate study drug.|t|t|t|t
34065049|NCT03027076|||COHORT||PROSPECTIVE|||||||
33962574|NCT01392170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962575|NCT03959137|||COHORT||PROSPECTIVE|||||||
33751393|NCT00204048|||COHORT||CROSS_SECTIONAL|||||||
34065050|NCT00973895|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33962576|NCT05967494|||CASE_CROSSOVER||PROSPECTIVE|||||||
33962577|NCT00735033||||TREATMENT||||||||
33962578|NCT05597163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962579|NCT03246334|||COHORT||PROSPECTIVE|||||||
33962580|NCT05354427|||OTHER||RETROSPECTIVE|||||||
33962581|NCT03424694|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Radiation: HDR brachytherapy monotherapy (1 vs 2 fractions on single implant)~Brachytherapy in this study consists of treatment with a single interstitial HDR brachytherapy procedures with temporary interstitial catheters. The number of temporary interstitial catheters will be based on the size and shape of the prostate (at least 16 catheters will be implanted).~In one arm patient will received a single fraction of 19.5 Gray (Gy), in the other arm patient will received 29 Gy/ 2 fractions of 14.5 Gy separated by 6 hours on a single implant.~Implant will be done with transperineal insertion of interstitial catheters under sterile conditions guided by transrectal ultrasounds.~Optimization of treatment plan will be done with Oncentra (Elekta) based on MRI imaging done post-implant."||||
33962582|NCT04581031|NA|SINGLE_GROUP||OTHER||NONE|The treating team on the ward will be blinded to the observations recorded by the wearable vital signs sensors|||||
34065051|NCT01995864|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34065052|NCT05867693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065053|NCT00576004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065054|NCT01361867|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34175726|NCT03743272|||COHORT||CROSS_SECTIONAL|||||||
34175727|NCT00492817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175728|NCT06031623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175729|NCT03730909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34175730|NCT03901274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175731|NCT05622864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175732|NCT02340793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175733|NCT06070766|||COHORT||CROSS_SECTIONAL|||||||
34175734|NCT06571253|RANDOMIZED|PARALLEL||SCREENING||NONE||This clinical trial employed a randomized controlled design to investigate the effects of a corrective exercise program delivered via the Fiziu Digital Physiotherapy Platform compared to a paper-based exercise program on forward head posture (FHP) in a cohort of adult volunteers.||||
33863056|NCT03235440|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863057|NCT02514733|||COHORT||RETROSPECTIVE|||||||
33863058|NCT00403754|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33863059|NCT06120166|NA|SEQUENTIAL||TREATMENT||NONE||||||
33863060|NCT02659579|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33863061|NCT05216757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962583|NCT01412073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33962584|NCT04228289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized in a 1:1 manner to one of two drug conditions|t|t|t|t
33962585|NCT05467709|NA|SINGLE_GROUP||OTHER||NONE||||||
33962586|NCT00452998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962587|NCT00154830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962588|NCT03635619|||CASE_CONTROL||PROSPECTIVE|||||||
34065055|NCT01487213|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065056|NCT02289105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34065057|NCT03257969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863062|NCT02792179|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863063|NCT00807963|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33863064|NCT05397496|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863065|NCT00549627|RANDOMIZED|PARALLEL||||NONE||||||
34065058|NCT02552888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065059|NCT05462275|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This study don't require any types of masking.|Interventional observational study. The investigators conduct this study to analyze the impact of patient position on the success in placing triple-cuffed double lumen endotracheal tube.||||
34065060|NCT03994406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|3-digit randomized number assignment with matching by age within 10 years, and within 5 years of lens wear. Study drug:placebo, 1:1.|1:1, study drug:placebo; block design.|t|t|t|t
34065061|NCT00211627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065062|NCT01777737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065063|NCT05658952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Independent Clinical Event Committee will perform the blinded adjudication of the events. The Independent Angiography and Physiology Core-lab will perform the primary endpoint analysis|two nested, randomized, multicenter, open-label trials|f|f|f|t
34065064|NCT02927002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34065065|NCT02194764|NA|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34065066|NCT02515084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863066|NCT00932685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33863067|NCT02907710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863068|NCT01981239|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33863069|NCT03953508|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33863070|NCT01843868|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863071|NCT01764126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863072|NCT05037526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863073|NCT03878446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863074|NCT03793426|||COHORT||PROSPECTIVE|||||||
33863075|NCT01508546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863076|NCT06736444|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863077|NCT03152357|||COHORT||RETROSPECTIVE|||||||
33863078|NCT06735638|NA|SINGLE_GROUP||OTHER||NONE||||||
33863079|NCT03644654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863080|NCT06070194|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33863081|NCT03876314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The outcomes assessor will be masked to intervention assignment and APOE4 carrier status. The interventionist will be masked to APOE4 carrier status.||f|t|f|t
33863082|NCT03587688|||COHORT||OTHER|||||||
33863083|NCT03999658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863084|NCT04971785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863085|NCT04642599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Evaluation of bimanual motor skill learning||||
33962589|NCT02399488|||CASE_ONLY||PROSPECTIVE|||||||
33962590|NCT06018246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962591|NCT02899442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962592|NCT03849079|NA|SINGLE_GROUP||OTHER||NONE||||||
33962593|NCT03077594|||CASE_ONLY||PROSPECTIVE|||||||
33962594|NCT00189696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33751394|NCT03882333|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomised controlled study in patients with chronic pain and healthy controls||||
33962595|NCT02686710|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962596|NCT04568642|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33962597|NCT00888030|||COHORT||PROSPECTIVE|||||||
33962598|NCT02898064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962599|NCT02476851|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33962600|NCT04234373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962601|NCT02234258|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33962602|NCT03224117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962603|NCT04974645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962604|NCT02670512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33962605|NCT04824144|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a multi-site, open-label, single-arm phase 1/2 proof-of-concept, dose-finding, feasibility, and preliminary efficacy clinical trial.||||
33962606|NCT04552080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962607|NCT05021328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962608|NCT05285917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962609|NCT01101581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962610|NCT05854316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962611|NCT02287506|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962612|NCT02044965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962613|NCT00829439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962614|NCT02862535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962615|NCT03791619|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33962616|NCT05506163|||COHORT||RETROSPECTIVE|||||||
33962617|NCT05388630|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33751395|NCT00126412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751396|NCT01632748|NON_RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33751397|NCT00408213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751398|NCT05386888|NA|SINGLE_GROUP||TREATMENT||NONE||Primary Purpose: ORR||||
33751399|NCT01894295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33751400|NCT01911403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863086|NCT06736431|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33863087|NCT01481623|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863088|NCT05120856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, and outcomes assessors will be unaware (blinded) of the condition to which participants have been randomly allocated.|A double-blind, randomised, parallel-group controlled superiority trial with alcohol treatment outpatients will be conducted. Participants will be randomised to one of 2 groups with a 1:1 allocation ratio.|t|f|t|t
33863089|NCT05131581|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33863090|NCT04235023|NON_RANDOMIZED|PARALLEL||OTHER||NONE||patients with OSA 'apnea hypopnea index ≥ 15 per hour) as compared to controls (an apnea hypopnea index \< 15 per hour)||||
33863091|NCT06579092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863092|NCT06558227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962618|NCT01148680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962619|NCT02011516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962620|NCT01188005|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33863093|NCT05236114|||COHORT||PROSPECTIVE|||||||
33863094|NCT05905575|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This two-arm randomized controlled trial (RCT) will test the feasibility, acceptability and efficacy of a family-dyad-focused intervention. A convenience sample will be recruited at clinics/pharmacy at Central Ohio. We will enroll a total of 208 participants in the study with104 African-Americans with T2D and one family member of each patient (104 patient-family member dyads). Patients with T2D will be randomized 1:1 to the intervention or control arm (n=52/arm). The family member of each patient will receive the same treatment as that assigned to the patient.||||
33863095|NCT05883540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33863096|NCT05879913|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863097|NCT06735248|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33863098|NCT06736275|NA|SEQUENTIAL||TREATMENT||NONE||"Accelerated titration and 3+3 dose escalation: This study plans to start dose escalating from 2 mg, followed by 4 mg, and 10 mg as tentatively designated escalating dose groups. An accelerated titration strategy will be implemented in the early dose escalation phase (2 mg dose group) in this study, with only 1 subject enrolled."||||
33863099|NCT06549530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863100|NCT05760846|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Not aware being of the different versions of the tasks||t|f|f|f
33863101|NCT04713423|||CASE_ONLY||OTHER|||||||
33863102|NCT04666571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962621|NCT01872858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175735|NCT06047093|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Five groups according to HBsAg quantification (3 distinct groups with or without nucleoside analogues), HDV co-infection and HBsAg loss.||||
34175736|NCT03888612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175737|NCT05247372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175738|NCT04519164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|study medications will be blinded to the participant, investigator, outcomes assessors, and the care providers of the participants. Only the research pharmacists who prepare the study medications will be aware.|Participants will be randomized to receive either eplerenone or chlorthalidone with potassium chloride|t|t|t|t
34175739|NCT06465524|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental design of a double-blind, non-controlled clinical trial||||
34175740|NCT06584539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175741|NCT03808974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34175742|NCT06100588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Particpants will be randomly assigned to either of the following groups:~* Treatment with manual therapy;~* Treatment with manual therapy in combination with dry needling."|f|f|t|t
34175743|NCT06490900|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34175744|NCT06595472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The treatment and control cooking oil were indistinguishable in appearance and taste. The investigators and participants remained blinded to individual subject assignment throughout the study.|The study was designed as a double-blinded randomized controlled trial, with 8 week intervention period, and conducted in Bogor district, West Java, Indonesia. The study subjects were volunteers residing in Bogor city and Bogor district, with known mild-moderate hypercholesterolemia. Subjects were supplied with either control or treatment cooking oil bottle every week, to be consumed as substitution of usually used cooking oil.|t|f|t|f
34175745|NCT04017221|||COHORT||RETROSPECTIVE|||||||
34175746|NCT03404817|RANDOMIZED|CROSSOVER||OTHER||NONE||"3-period, 3-sequence crossover evaluating 3 treatments~* Treatment-1: new formulation under fed conditions~* Treatment-2: new formulation under fasted conditions~* Treatment-3: original formulation under fed conditions"||||
34175747|NCT05881018|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34175748|NCT06547827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34175749|NCT05058976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34175750|NCT00633477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175751|NCT00434746|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34175752|NCT05902169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175753|NCT04720183|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34175754|NCT02878499|NA|SINGLE_GROUP||OTHER||NONE||||||
34175755|NCT06601036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175756|NCT04197700|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Pragmatic, prospective, single-center, unit-based cluster crossover, open-label registry||||
34175757|NCT04521790|||CASE_CONTROL||OTHER|||||||
34175758|NCT03630289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175759|NCT03940963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175760|NCT06077968|||CASE_CONTROL||RETROSPECTIVE|||||||
34175761|NCT05414461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175762|NCT01186263|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34175763|NCT04193046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175764|NCT06128382|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Dose escalation|t|f|t|f
34175765|NCT05874674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34175766|NCT06585566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175767|NCT02405689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34175768|NCT05917899|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34175769|NCT05691270|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All adolescents who engage with the IN-Control program will be asked if they would like to formally enroll as a study participant after interaction with the navigator; however, enrollment is not required to utilize the services of the navigator,||||
34175770|NCT06175676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175771|NCT03369691|||COHORT||CROSS_SECTIONAL|||||||
33962622|NCT02613416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962623|NCT05091879|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33863103|NCT06249386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to treatment condition. The participant, study therapist, and PI (providing clinical consultation and evaluating therapist fidelity to treatment protocol) will not be blinded to participants' assigned treatment condition.|Participants will be block randomized to either Behavioral Activation treatment (n=23) or Relapse Prevention treatment (n=23).|f|f|f|t
33863104|NCT06607172|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a randomized, controlled, examiner blind, parallel-group clinical trial|f|f|t|t
33863105|NCT06274723|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33863106|NCT04567667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863107|NCT04888884|||COHORT||PROSPECTIVE|||||||
33863108|NCT05805709|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants and the clinical care teams (nurse navigator, pharmacist, and study physician) will not be masked due to unblinded nature of the intervention. Research coordinators who carry out screening, enrollment, and study visits at baseline, 3, 6 and 12 months will be masked from participant group assignment. Similarly, study visits performed by research coordinator at baseline (enrollment), 3 months and 12 months will be masked. Similarly, assessment of study endpoints will be blinded to group assignment.|"This is a randomized, pragmatic, parallel-arm kidney trial conducted to find out if an enhanced care team approach can improve a patient's outcomes after hospitalization with acute kidney injury (AKI). Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site."|f|f|f|t
33863109|NCT06562985|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33962624|NCT05899478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962625|NCT05626231|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The single-arm intervention will test an online, asynchronous gender-affirming training intervention.||||
33962626|NCT03840135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962627|NCT05677984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962628|NCT01696227|||||PROSPECTIVE|||||||
33962629|NCT00180752|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34175772|NCT03405220|RANDOMIZED|FACTORIAL||PREVENTION||NONE||"Study 1 will use a 2 (self-affirmation: self-affirmation, control) X 3 (Mode of example: none, write, imagine) experimental design. In the self-affirmation condition, participants will complete the self-affirmation kindness quiz (10 questions) and in the control condition they will complete a personal opinion survey (10 questions). Depending on the mode of example condition, participants will not be asked to provide examples, asked to write examples for each of the 10 questions, or asked to imagine examples for each of the 10 questions.~Based on examination of data from Study 1 (i.e., which items receive more yes responses and for which items examples are provided), in Study 2 we will test whether using fewer self-affirmation items influences dependent variables. Study 2 will use a 3 (Number of questions: 10, 5, 3) X 3 (Mode of example: none, write, imagine) experimental design."||||
34175773|NCT04205227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||3+3 Dose Escalation and Open Label Expansion||||
34175774|NCT05386043|||COHORT||PROSPECTIVE|||||||
34175775|NCT05354661|||CASE_CONTROL||RETROSPECTIVE|||||||
34175776|NCT05254626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175777|NCT05590481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175778|NCT05025059|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34175779|NCT04251052|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a non-randomized prospective trial to determine if bilateral salpingectomy (BLS) is non-inferior to bilateral salpingo-oophorectomy (BSO) in terms ovarian, primary peritoneal, and fallopian tube cancer risk among gBRCA1m carriers between 35 and 50 years old. Individuals choose the treatment they want to receive in collaboration with their physician(s).||||
34175780|NCT03915717|||COHORT||PROSPECTIVE|||||||
34175781|NCT04848675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|f|f|t|t
34175782|NCT00823511|||COHORT||PROSPECTIVE|||||||
34175783|NCT05654246|||OTHER||OTHER|||||||
34175784|NCT03524430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is a diagnostic study. The RDI operator that assesses patient response to therapy using the RDA test is blinded to patient outcome. The clinicians and patients will not receive the RDI score in order to not act on the RDA test result (because this is an investigational study).|||||
34175785|NCT02985827|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34175786|NCT06136871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcomes assessors will be blinded to participant study group assignment.|After baseline assessment, subjects will be randomized to one of two groups: (1) a 10-session Cognitive Orientation to daily Occupational Performance (CO-OP) intervention; or (2) a 10-session inactive control group.|f|f|f|t
34175787|NCT00273221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175788|NCT05298579|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The assessors will be blind to the group allocation. The investigators will be blind to the outcomes.||f|f|t|t
33962630|NCT04775368|NA|SINGLE_GROUP||SCREENING||NONE||||||
33962631|NCT00004288||||TREATMENT||||||||
33962632|NCT05610982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751401|NCT05530213|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Data analysis will be carried out by investigators who are blind to the location of where the data was collected.|A single group of participants will be tested in 3 locations. Their results across the three locations will be compared|f|f|f|t
33863110|NCT06064851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking; open label|Participants with VWD and HMB will be enrolled in the study over the course of two consecutive menstrual cycles. First Menstruation will be baseline. Second Menstruation participants will self-administer 2, 1-hour sessions of active tAN daily beginning Day 1 of second menstruation through the final day of second menstruation.||||
33863111|NCT06735755|NA|SEQUENTIAL||TREATMENT||NONE||up to 4 planned, single-ascending-dose, dose-exploration cohorts||||
33863112|NCT04897009|||CASE_ONLY||PROSPECTIVE|||||||
33863113|NCT03811639|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of changes in autonomic heart regulation caused by radio-frequency ablation and cryoballoon ablation||||
33863114|NCT06447818|||COHORT||PROSPECTIVE|||||||
33863115|NCT05440266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Only the study team will know which stimulation will be applied on which intervention. The participant won't be informed about the applied stimulation type.|randomized, crossover, single-blinded experimental proof of concept investigation in healthy volunteers|t|f|f|f
33751402|NCT06006546|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863116|NCT01889056|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33863117|NCT00003181||||TREATMENT||||||||
33863118|NCT05686590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863119|NCT03848988|||OTHER||PROSPECTIVE|||||||
33863120|NCT00621894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863121|NCT06086886|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33863122|NCT05578495|NA|SINGLE_GROUP||OTHER||NONE||||||
33863123|NCT02112435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863124|NCT05328583|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This is a randomized, double-blinded, placebo-controlled study|t|t|t|f
33863125|NCT01710592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863126|NCT06044922|||COHORT||PROSPECTIVE|||||||
33863127|NCT06611111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants who meet inclusion/exclusion criteria will be randomized 1:1 into receiving ceftriaxone or placebo. At day 181, the study will be unblinded and participants in the placebo group will be invited to receive ceftriaxone on the same schedule.|t|t|t|t
33863128|NCT06065735|NA|SINGLE_GROUP||OTHER||NONE||||||
33863129|NCT04066049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Standardized and observational measures will be conducted by independent observers and assessors (master's level bilingual speech-language pathologists) who are blind to the experimental conditions.|Participants in the Treatment group will receive a hybrid therapist-implemented and caregiver-implemented intervention and be compared to a BAU control group. Caregivers and children will be assessed at baseline, after the intervention, 6 months after intervention, and 12 months after intervention.|f|f|f|t
33751403|NCT01461668|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863130|NCT06735794|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This clinical trial is a single-blinded study. Participants will be blinded to the iTBS condition they are receiving in Visits 1-4. The individual administering iTBS (i.e., the interventionist) will not be blinded to the iTBS condition being administered. To maintain participant blinding, each of the three iTBS interventions (iTBS-c, iTBS-s, and iTBS-sh) were designed to be similar in length and structure.|This study will employ a randomized, single-blind cross-over design with three experimental iTBS conditions (iTBS-c, iTBS-s, and iTBS-sh).|t|f|f|f
33863131|NCT06386640|||COHORT||PROSPECTIVE|||||||
33863132|NCT00020501|RANDOMIZED|||TREATMENT||||||||
33863133|NCT06408649|||COHORT||OTHER|||||||
33863134|NCT04458272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863135|NCT04274283|||COHORT||PROSPECTIVE|||||||
33863136|NCT06735092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants in the study are blind to the group distribution and do not know the reason for their assignment to specific groups.|This study involves three groups with exercise therapy: one with exercise only, one with exercise in addition to an elbow orthosis, and one with exercise in addition to a wrist orthosis.|t|f|f|f
33962633|NCT01692418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962634|NCT04379973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962635|NCT02176642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962636|NCT01327209|||CASE_ONLY||PROSPECTIVE|||||||
33962637|NCT02949778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962638|NCT06218888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962639|NCT01174368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962640|NCT02917928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962641|NCT02955810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962642|NCT04088734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962643|NCT02440100|RANDOMIZED|||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33962644|NCT01678924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962645|NCT04449588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863137|NCT06735404|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33863138|NCT02612740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863139|NCT03858452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863140|NCT04296097|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Crossover study conducted in double blind design :~* one month Deep Brain Stimulation (DBS) ON, 15 days wash out stimulation OFF, and one month Deep Brain Stimulation (DBS) OFF or~* one month Deep Brain Stimulation (DBS) OFF, 15 days wash out stimulation OFF, and one month Deep Brain Stimulation (DBS) ON"|Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)|t|f|t|f
33863141|NCT06735469|||OTHER||CROSS_SECTIONAL|||||||
33863142|NCT06736184|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33863143|NCT05419401|NA|SEQUENTIAL||TREATMENT||NONE||||||
33863144|NCT06734182|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking|single group assignment||||
33863145|NCT01889238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863146|NCT05909059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863147|NCT06734936|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33863148|NCT06578117|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863149|NCT06155604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863150|NCT05471908|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Owing to the nature of the comparators, blinding of participants and their medical providers is not possible. However, outcomes that require adjudication will be adjudicated by persons blinded to the subject's randomized group. Outcomes requiring adjudication in FAAN-C are the safety outcomes (hospital readmissions related to the index infection and medical errors). Specifically, a clinician will determine if the readmission was related to the index infection and a separate clinician will score parent-reported medical errors in terms of severity (as described in the Safety Reporting section of the protocol). The clinicians performing adjudication of these outcomes will be blinded to the subject's randomized group.||f|f|f|t
33863151|NCT06735001|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||prospective multicentric study||||
34175789|NCT06602076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding participants will not be possible because participants will be able to tell if they are in the treatment group versus control group due to the volunteer activities in the treatment group and absence of such activities in the control group. Investigators will remain blinded to the group assignments. Randomization will use a centralized and automated system to ensure allocation concealment from outcomes analysts. If manual allocation is required, sequentially numbered, opaque, sealed envelopes will be utilized to maintain allocation concealment and managed internally at OU. Additionally, the following blinded outcome assessment procedures are planned: Outcome assessors will be a separate and unique team from those managing allocation and tracking of participants during the research activities; Participants will be assigned unique codes that do not reveal their identity and group to the outcome assessors.|In a 2-arm, 12-week pilot randomized controlled trial (RCT) with Week 24 follow up, N=50 SGM adults willing to quit smoking from Oklahoma (OK) and the San Joaquin Valley (SJV) in California will be randomized to receive either the NCI's QuitGuide smoking cessation smartphone app and free nicotine replacement therapy (NRT; control, n=25), or QuitGuide and NRT plus ECHO, which includes online SGM-serving volunteer activities (≥4 sessions) and a digital hub (Facebook) to foster social support across sites.|f|f|t|t
33962646|NCT02624349|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962647|NCT06515366|||COHORT||PROSPECTIVE|||||||
33962648|NCT01818037|||CASE_ONLY||PROSPECTIVE|||||||
33962649|NCT01547637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962650|NCT03801018|||OTHER||OTHER|||||||
33962651|NCT03430089|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase I-like, open-label, descriptive, monocenter study, which includes 5 groups of participants of varying ages and doses||||
34175790|NCT04742556|NA|SEQUENTIAL||TREATMENT||NONE||||||
34175791|NCT03463057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175792|NCT01647789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175793|NCT05712460|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34175794|NCT04043910|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175795|NCT06121102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175796|NCT05661149|||COHORT||RETROSPECTIVE|||||||
34175797|NCT00003127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175798|NCT00489996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175799|NCT06088888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175800|NCT05167851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175801|NCT01814111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175802|NCT06154291|NA|SINGLE_GROUP||TREATMENT||NONE||"The Part I component is a multicenter, open-label, multiple-dose, dose escalation, first-in-human study. Six dose levels are planned: 1.5; 3; 6; 12; 16 and 20mg/kg, Q2W (once every two weeks). Up to 45 participants with relapsed or refractory, advanced or metastatic solid tumors will be included.~The Part II component is a multi-center, open-label, non-randomized, multi-cohorts, expansion trial with adaptive design.~The selected cohorts of the study will investigate RP2D to determine the anti-tumors efficacy, safety, and tolerability of XON7 in participants with relapsed or refractory, advanced or metastatic solid tumors after failure to standard of care treatments.~Up to 7 cohorts could be investigated. A maximum of 30 participants will be enrolled in each cohort."||||
33863152|NCT01994239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863153|NCT03057002|||CASE_CONTROL||PROSPECTIVE|||||||
33863154|NCT06259396|RANDOMIZED|PARALLEL||TREATMENT||NONE||feasibility randomised controlled trial||||
33863155|NCT06734910|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Randomization of two study sites in three steps:~Step 1: Both study sites acting as control. Step 2: One study site acting as control, 1 study site acting as intervention. Step 3: Both study sites acting as intervention."||||
33863156|NCT04663308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863157|NCT04557085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863158|NCT03386513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863159|NCT06548750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not know which participant received which intervention.|There will be an equal number of participants in the two groups randomized by the computer|f|f|t|f
33863160|NCT02227225|||COHORT||PROSPECTIVE|||||||
33863161|NCT05538897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863162|NCT00005689|||||RETROSPECTIVE|||||||
33863163|NCT04911270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The intervention group includes pediatric patients that will be started on intravenous (IV) vancomycin. Once consent is obtained, their age, weight, length, sex, serum creatinine will be entered into Lyv which will generate a dose for the patient. Levels will be drawn intermittently and dosage will be adjusted accordingly. This interventional group will be compared to matched historical controls who were treated with IV vancomycin with dosage adjustments based on trough levels.||||
33863164|NCT05967351|NA|SINGLE_GROUP||OTHER||NONE||||||
33863165|NCT03039023|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863166|NCT01350830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751404|NCT06477575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751405|NCT01881126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33751406|NCT01380340|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863167|NCT02243865|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A placebo module, with one input and 6 outputs, was added to the Chordate S200 system. Some outputs delivered active treatment and others placebo. The operator received a coded envelope and according to that, either active treatment or placebo was selected. The operator did not know which outputs delivered treatment and which did not.||t|f|t|f
33863168|NCT06278207|||COHORT||RETROSPECTIVE|||||||
33863169|NCT06734169|||COHORT||CROSS_SECTIONAL|||||||
33863170|NCT06735352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33863171|NCT02656420|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33863172|NCT04261569|RANDOMIZED|PARALLEL||TREATMENT||NONE||One control arm : patients without any medical device One illuminated arm : patients with intraventricular near-infrared light illumination||||
33863173|NCT00354081|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33863174|NCT06735807|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175803|NCT06587009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175804|NCT04776395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175805|NCT04696120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175806|NCT04309734|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Part A is randomized, double-blind. Part B is open label.||t|t|t|f
34175807|NCT05130788|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175808|NCT02086175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175809|NCT06222866|||COHORT||PROSPECTIVE|||||||
33863175|NCT06402838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863176|NCT01324206|||CASE_ONLY||PROSPECTIVE|||||||
33863177|NCT01034540|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33863178|NCT00067457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34175810|NCT05404139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175811|NCT05516992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, placebo-controlled study.||t|t|t|f
34175812|NCT06704204|||OTHER||PROSPECTIVE|||||||
34175813|NCT02649166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175814|NCT04640025|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Individual patients will continue to be treated with itacitinib in accordance with the parent study under which they were enrolled.||||
33863179|NCT03050996|||CASE_ONLY||PROSPECTIVE|||||||
33863180|NCT06736392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A calculated minimum sample of 60 patients candidate for hip replacement surgeries (will have spinal anesthesia with hyperbaric bupivacaine 0.5%) will be randomly assigned into one of two equal groups (1:1 design) (Group-C (control) (n=30); will have PENG block using 20ml of isobaric bupivacaine 0.25% and Group-D (n=30); will have PENG block with 1.5μg/kg dexmedetomidine as an adjuvant to 20ml of isobaric bupivacaine 0.25%, to have 80% power to detect an absolute difference of 0.1 in the mean of the postoperative analgesic consumption in nine repeated measures(at 0,2,4,6,8,10,12,16,24 hours postoperatively), at significance level of 0.05.||||
34175815|NCT05361941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863181|NCT06204224|||CASE_ONLY||CROSS_SECTIONAL|||||||
33863182|NCT06506565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All team members and patients are blinded to study treatment, except pharmacy staff.|Patients will be randomly enrolled by blocks according to age, burn size, and opioid use history. Study treatment will occur for up to 7 days. Assignment will be to placebo or ketamine and all participants and staff will be blinded, except pharmacy. Each patient will receive standard of care fentanyl and midazolam during wound care regardless of study assignment.|t|t|t|t
33863183|NCT04711798|||COHORT||PROSPECTIVE|||||||
33863184|NCT02275585|||COHORT||PROSPECTIVE|||||||
33863185|NCT04139265|||OTHER||PROSPECTIVE|||||||
34175816|NCT03542812|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Single dose pharmacokinetic studies using population PKs Steady-state pharmacokinetic studies using population PKs||||
34175817|NCT05141019|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34175818|NCT05027230|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175819|NCT02814396|||CASE_ONLY||PROSPECTIVE|||||||
34175820|NCT06706583|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomized clinical trial||||
34175821|NCT06513858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175822|NCT01343953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175823|NCT04970134|||OTHER||RETROSPECTIVE|||||||
34175824|NCT01838395|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study (Part 1) will include escalating dose groups and be considered the 'escalation phase'. Five potential dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 and evaluated for dose escalation.~Dose escalation will be permitted until the Maximum Tolerated Dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 5 (1.5 mg/kg)."||||
34175825|NCT06705816|||COHORT||PROSPECTIVE|||||||
34175826|NCT00782535|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34175827|NCT01869608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175828|NCT05750251|||OTHER||PROSPECTIVE|||||||
34175829|NCT05734768|||CASE_CONTROL||PROSPECTIVE|||||||
34175830|NCT05476289|||COHORT||CROSS_SECTIONAL|||||||
34175831|NCT04268641|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34175832|NCT04377035|||COHORT||PROSPECTIVE|||||||
34175833|NCT03824223|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants randomised to uniform balanced crossover (new/old or old/new hypoxic challenge test components).||||
34175834|NCT06444308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cluster randomized, controlled, non-inferiority trial, each of 15 clusters of geographically grouped communities in the San Lucas Toliman municipality of Guatemala will be randomized to either CHW or physician care||||
34175835|NCT01690143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175836|NCT04308148|||COHORT||PROSPECTIVE|||||||
34175837|NCT03907852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175838|NCT06701864|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Randomised to either palpation or ultrasonography~The participants are thus randomised to use either palpation or to use ultrasonography to DIAGNOSE the position of the cricothyroid membrane"||||
34175839|NCT05355701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175840|NCT03511807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175841|NCT05491616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175842|NCT04750824|||COHORT||RETROSPECTIVE|||||||
34175843|NCT06589284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients were randomized to line securement with either silk 0-0 suture or 2-octyl cyanoacrylate and, then, covered by chlorhexidine gluconate dressing.||||
34175844|NCT06581016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority, quality assurance study comparing a period where single-use gastroscopes are used with a period where reusable gastroscopes are used.||||
34175845|NCT06568159|||CASE_CONTROL||PROSPECTIVE|||||||
33863186|NCT05609279|||COHORT||PROSPECTIVE|||||||
33863187|NCT06710067|||COHORT||PROSPECTIVE|||||||
33863188|NCT06549556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863189|NCT04311008|||OTHER||CROSS_SECTIONAL|||||||
33962652|NCT06375954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962653|NCT03457337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962654|NCT04334330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962655|NCT02559531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175846|NCT06008860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This is a double-blind clinical trial. Randomization schedules will be generated and stratified by age (18-30, 31--40, 41-50, and ≥50 years) and sex, using computer-generated random numbers and alternating block sizes. Only the study statistician will have access to the randomization lists. The assigned treatment for each study subject will be obtained via REDCap. The Investigational Drug Service (IDS) pharmacy will be used to distribute the drug or placebo as provided by Bayer. The pharmacy will also help to coordinate and track randomization.|All subjects will be sent an instructional video and be given written instructions which will educate them on how to use the drug or placebo nasal spray. Patients will follow the dosing instructions for Astepro® 0.15% nasal spray.|t|t|t|t
34175847|NCT00892905|||||PROSPECTIVE|||||||
34175848|NCT00848809|||CASE_ONLY||PROSPECTIVE|||||||
34175849|NCT05188222|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Packets of the study drug will be prepared by Enhanced Medical Nutrition and look identical. The placebo has been formulated to taste the same as Maltodextrin as well|Patients will be assigned to the intervention or control group based on a computer-generated 1:1 stratified block randomization by procedure type in blocks of 4, stratified by sex.|t|t|t|t
34175850|NCT05256901|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34175851|NCT01334021|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33863190|NCT05851274|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the experimental group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm; In the control group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.||||
33863191|NCT04813926|||COHORT||PROSPECTIVE|||||||
33863192|NCT02064634|||COHORT||PROSPECTIVE|||||||
34175852|NCT05804747|||COHORT||PROSPECTIVE|||||||
34175853|NCT01314196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33863193|NCT05341648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863194|NCT01666184|||CASE_ONLY||PROSPECTIVE|||||||
33863195|NCT06174987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863196|NCT03579082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863197|NCT04979052|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label adaptive randomized interventional study||||
33863198|NCT04692454|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863199|NCT03628937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863200|NCT05296798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962656|NCT01030276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962657|NCT05413902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34175854|NCT06599190|RANDOMIZED|PARALLEL||TREATMENT||NONE|none(open RCT)|"They will be randomly distributed into 2 groups equal in numbers:~Group (A) (Control group) consists of 25 female athletes. They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.~Group (B) (Study group) consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months."||||
34175855|NCT04697667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
34175856|NCT05872737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A multi-centre, two-arm randomised controlled trial (RCT) with a repeated-measures parallel-group design|f|t|t|t
34175857|NCT03288675|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34175858|NCT06704659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175859|NCT03851835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863201|NCT03255057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the interventional device and treatment, the study participants, care providers, and investigators will not be masked. However, an independent Clinical Endpoint Committee will be masked for adjudication of the primary endpoint and serious adverse events. An independent Data and Safety Monitoring Board will make study continuation recommendations based on the statistical analysis plan and the overall safety and efficacy endpoints without masking.|Prospective, multi-center, randomized, controlled, two-arm, open-label, adaptive, two-strata, pivotal trial|f|f|f|t
33863202|NCT01286454|RANDOMIZED|CROSSOVER||||NONE||||||
33863203|NCT04304820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863204|NCT05323084|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Liquid that looks and tastes the same, but only one has the three food components. The order in which the subjects get the 3-component supplement and the placebo is randomly assigned and balanced.|1 week of treatment with a three component supplement or a placebo in people with insomina on two occasions separated by a 2-week washout|t|t|t|f
33863205|NCT05146284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863206|NCT05591274|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patients will be randomized into one of three groups (interactive virtual reality, static virtual reality, and no virtual reality). Randomization sequence will be generated using a validated random number generator, and allocation concealment will be achieved via opaque envelope. Treatment (vasectomy with interactive VR, vasectomy with static VR, or vasectomy with no VR) will be known to patient and care provider only once the vasectomy procedure begins.|Patients will be randomized into one of three groups (interactive virtual reality, static virtual reality, and no virtual reality).||||
33863207|NCT06135727|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863208|NCT06070649|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33863209|NCT02754882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863210|NCT06548828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study staff will be instructed to assign allocated numbers to participants in sequential order as they are enrolled. Once the assignment (1, 2 or 3) is revealed to the study team, study information per that assignment will be explained to the participant. It is essential for the research team to know the allocation in order to provide the correct intervention materials and relevant counseling. Thus, the design is open-label, with only outcome assessors blinded.||f|f|f|t
33863211|NCT06089239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33863212|NCT06679803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863213|NCT02076217|||COHORT||PROSPECTIVE|||||||
33863214|NCT06116136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863215|NCT06723418|||CASE_ONLY||CROSS_SECTIONAL|||||||
33863216|NCT03654014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Honest broker will determine and record PEMF+ and PEMF- treated patients keeping investigator team blinded as to treatment until data analysis has been completed.|Double blinded treatment with PEMF+ and PEMF- groups with CSF and serum biomarkers compared to values from patients with normal pressure hydrocephalus.|t|t|t|t
33863217|NCT05614661|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|-it's impossible to mask whether receiving the therapy treatment|This is a 2-group (Mom Power (MP) vs. control), pre-post RCT of mothers with OUD to test the effect of MP on drug craving, mood and electrophysiological responses to own infant faces (MP n=40; control n= 10)||||
33863218|NCT06692972|||CASE_ONLY||RETROSPECTIVE|||||||
34175860|NCT04032028|||COHORT||PROSPECTIVE|||||||
34175861|NCT05036096|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"Two groups of patients:~Screening: patients who are scheduled for annual breast cancer screening. Diagnostic: patients who have an abnormality detected by Breast Self Exam, or Clinical Breast Exam (CBE), or have an abnormality detected by an imaging modality."||||
33863219|NCT06528964|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33863220|NCT05630768|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863221|NCT06581861|||COHORT||PROSPECTIVE|||||||
33863222|NCT06179160|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863223|NCT02136745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863224|NCT05118724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863225|NCT05112926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863226|NCT06736288|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33863227|NCT05696626|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label, randomized, parallel-group, multicenter study||||
34175862|NCT02558959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175863|NCT03839524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175864|NCT02198014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175865|NCT05130008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor team will be blinded to the intervention assignments of participants. Due to the nature of the intervention, the participants, the investigator, and the care providers are unable to be blinded to the participant assignments.|Randomized Controlled Trial|f|f|f|t
34175866|NCT06706193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||After obtaining informed consent, the participants were randomized to a surgical intervention with the use of 60 sealed envelopes which were opened by the surgeon in theatre just before surgery.|t|f|f|f
34175867|NCT06382168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175868|NCT02437045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175869|NCT00717574|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34175870|NCT06597929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175871|NCT03556228|NA|SEQUENTIAL||TREATMENT||NONE||"* Dose Escalation: Tablet formulation (ongoing); Capsule formulation (complete)~* Cohort Expansion with RP2D;"||||
33863228|NCT06579989|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863229|NCT02761486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33863230|NCT06734715|||FAMILY_BASED||PROSPECTIVE|||||||
33863231|NCT01668719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175872|NCT04750317|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175873|NCT06602154|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863232|NCT04457466|||COHORT||PROSPECTIVE|||||||
33863233|NCT02575040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863234|NCT01927185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863235|NCT00757003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962658|NCT06568250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962659|NCT02528422|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33962660|NCT02036827|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962661|NCT01382134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962662|NCT05457660|||OTHER||PROSPECTIVE|||||||
33962663|NCT06057909|||COHORT||PROSPECTIVE|||||||
33962664|NCT01966341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175874|NCT05973942|NA|SEQUENTIAL||PREVENTION||NONE||Stepped Wedge. The US Air Force is implementing Wingman-Connect (Wyman et al, 2020) in collaboration with University of Rochester researchers in the context of First Term Airmen Classes (FTAC) across 8 operational bases. The AF has agreed to stagger implementation based on randomization informed by a stepped-wedge design. Wingman-Connect training will be rolled out at 8 USAF bases in pairs at 3 month intervals and will continue for a total of 51 months.||||
34175875|NCT05524025|||CASE_CONTROL||PROSPECTIVE|||||||
34175876|NCT04913610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175877|NCT05595486|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research team abstracting the data and performing the analyses will be masked to the randomization arm.|Families will be randomized into either the control or intervention group.|f|f|f|t
33863236|NCT04824781|||OTHER||RETROSPECTIVE|||||||
33863237|NCT05758714|||COHORT||CROSS_SECTIONAL|||||||
33863238|NCT06120283|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863239|NCT06538038|||COHORT||PROSPECTIVE|||||||
33863240|NCT06368167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863241|NCT05716087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962665|NCT03633019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863242|NCT05864001|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Upon their consent to participate in the study, baseline measurement will be conducted for each participant before their random allocation to different treatment arms. The research group will be blinded to the treatment assignment. The treatment assignment key will be revealed only after the intervention has been concluded and the analysis has been conducted|One-sided crossover|f|f|t|f
33962666|NCT03460119|||COHORT||RETROSPECTIVE|||||||
33863243|NCT02296450|||CASE_ONLY||PROSPECTIVE|||||||
33863244|NCT03518554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863245|NCT06272435|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Treatments will be labeled A-D. Subjects will be provided prepared beverages prepared in cup.|Semi-blinded, placebo controlled, crossover design|t|f|f|f
33863246|NCT04175639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863247|NCT06088199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863248|NCT04661501|RANDOMIZED|PARALLEL||OTHER||SINGLE|Treatment information will be non-blinded to the surgical staff who will then proceed to order the appropriate ADM product to be available at the time of the study participants scheduled breast reconstruction. Additionally, randomization will occur independently for each surgeon prevent bias from arising as a result of the surgeon performing the reconstruction.||t|f|f|f
33863249|NCT00162890|||CASE_CONTROL||PROSPECTIVE|||||||
33962667|NCT02364219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962668|NCT06150131|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33962669|NCT01315054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962670|NCT01963221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962671|NCT01732198|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962672|NCT02532140|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33962673|NCT05678218|||COHORT||PROSPECTIVE|||||||
33863250|NCT02296151|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33962674|NCT04156763|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962675|NCT02313519|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33962676|NCT05595174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962677|NCT02337426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962678|NCT06251323|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34065067|NCT06408597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34175878|NCT02669953|||COHORT||PROSPECTIVE|||||||
34175879|NCT06207188|||COHORT||PROSPECTIVE|||||||
34175880|NCT06270147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34175881|NCT05237960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33863251|NCT06716333|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863252|NCT03801902|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863253|NCT01839162|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863254|NCT06734832|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863255|NCT01224704|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33863256|NCT05359991|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863257|NCT05739942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962679|NCT00053599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962680|NCT02221583|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33962681|NCT02268188|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33962682|NCT04641754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962683|NCT01096407|||COHORT||PROSPECTIVE|||||||
33962684|NCT03996382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863258|NCT06191484|NA|SINGLE_GROUP||OTHER||NONE||||||
33962685|NCT03360188|||COHORT||RETROSPECTIVE|||||||
34175882|NCT04771494|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33962686|NCT03001856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962687|NCT03608696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962688|NCT03918395|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33962689|NCT06520878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962690|NCT02106117|||COHORT||PROSPECTIVE|||||||
33962691|NCT04288115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34175883|NCT06027580|||COHORT||PROSPECTIVE|||||||
34175884|NCT05096195|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34175885|NCT05006352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175886|NCT04325789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blinded study. The patient will be blinded to the treatment group.|"Use of the nanofiber scaffold during the rotator cuff repair is the intervention in this study. Study participants will be randomized into either treatment or control group. The control group will undergo routine rotator cuff repair without the scaffold to determine if improved healing is demonstrated with the graft.~Group 1 (control) Group 2 (nanofiber scaffold)"|t|f|f|f
34175887|NCT04523714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary and secondary outcome assessors will be masked to treatment assignment. It is not feasible for participants to be masked to treatment arm assignment due to the type of intervention. The PI and select Co-Investigators and study staff who are involved in the oversight and delivery of the interventions will also be aware of treatment assignment.|The study uses a 3-arm, parallel intervention design; both intervention arms will be compared to usual care services.|f|f|f|t
33751407|NCT06542874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33863259|NCT04640961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863260|NCT06734559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||two groups with control|t|t|t|t
33863261|NCT04134559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863262|NCT03272763|NA|SINGLE_GROUP||TREATMENT||NONE||After a period of baseline, all enrolled participants will be put on the same trial mask.||||
33863263|NCT02877212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863264|NCT05843123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a single center, open labelled, randomized controlled trial with one to one allocation to two invasive mechanical ventilation modes used in clinical care as intervention arms||||
33863265|NCT04534933|RANDOMIZED|PARALLEL||TREATMENT||NONE||controlled, prospective||||
33863266|NCT05342181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863267|NCT02251925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863268|NCT01365585|||COHORT||RETROSPECTIVE|||||||
33863269|NCT03225131|||COHORT||PROSPECTIVE|||||||
33863270|NCT06003192|NA|SINGLE_GROUP||SCREENING||NONE||Interrupted Times Series Model||||
33863271|NCT04174755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863272|NCT01965639|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863273|NCT04975256|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863274|NCT05697731|||COHORT||PROSPECTIVE|||||||
33863275|NCT04307381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863276|NCT05675579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863277|NCT04752293|||COHORT||PROSPECTIVE|||||||
33863278|NCT05186025|||COHORT||PROSPECTIVE|||||||
33863279|NCT06260956|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Due to the nature of the intervention, the subjects must know which arm they are assigned to, however, biostatistician and investigators will be blinded to study assignment.|National, parallel, two arm (one-to-one allocation), single blinded, randomized controlled trial.|f|t|t|t
33863280|NCT02721823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962692|NCT00479401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962693|NCT06541236|NA|SINGLE_GROUP||TREATMENT||NONE||. The study included 80 patients in need of extraction of tooth and further dental im-plantation following proposed inclusion criteria. After selection, complex oral rehabil-itation was carried out to restore chewing function. All patients (n=80) were divided into 4 equal groups depending on the used preservative material.||||
33962694|NCT04114526|NA|SINGLE_GROUP||OTHER||NONE||||||
33962695|NCT04473729|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The model is ABA design, that is participants get an initial, pre-treatment noise assessment, then get individualized training, then get a post-noise assessment. This is designed to look for change from baseline after training.||||
33863281|NCT03718663|||COHORT||PROSPECTIVE|||||||
33863282|NCT04000035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||two groups: intervention and control||||
33962696|NCT04722081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962697|NCT06541418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental and control groups were masked in the study.|randomized controlled trial|t|f|f|f
33863283|NCT04795843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863284|NCT01828853|||CASE_CONTROL||PROSPECTIVE|||||||
33863285|NCT06179511|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34175888|NCT05236556|RANDOMIZED|PARALLEL||TREATMENT||NONE||After removing providers who opted out, the investigators will randomize the remaining providers to either intervention or control in a 1:1 ratio, using randomly permuted blocks; randomization will be stratified jointly by provider type (cardiologist/primary care provider) and study site (University of Massachusetts/University of Florida). The allocation of the provider conducting the first visit for a patient will dictate the allocation for the patient.||||
33863286|NCT00733694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175889|NCT02615600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175890|NCT06702410|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This study use a stepped wedge design. Participants in the same kindergarten are defined as a cluster. The study includes four sequence, each sequence includes five clusters. Each Sequeces will transform into mhGAP-IG intervention as predominated order. Thus the study includes 20 clusters totally.||||
33962698|NCT02815930|||COHORT||RETROSPECTIVE|||||||
33863287|NCT05014295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863288|NCT06734520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863289|NCT04412538|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863290|NCT04164199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863291|NCT02193360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863292|NCT02249624|||CASE_ONLY||PROSPECTIVE|||||||
33863293|NCT04663737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962699|NCT05652894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962700|NCT06262633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962701|NCT00571597|||CASE_ONLY||PROSPECTIVE|||||||
33962702|NCT04656574|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants didn't know which group they were allocated. The participants will be blind when they receive simulation based training from researcher.|The study was conducted as a single blind, prospective, and simple randomized controlled trial. A power calculation was performed and with a standard deviation of 0.25 and statistical significance of 0.05, the number of students needed to total participate was determined to be 116, 58 per group. Out of 79 students, 60 were randomly assigned to the experimental group receiving education using simulation-based training and out of 90 students, 60 were randomly assigned to the control group that received the course explaining vaginal delivery for the first time.|t|f|f|f
33962703|NCT03339531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962704|NCT04690387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962705|NCT05473858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33962706|NCT02953262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants were not explicitly told which group they were randomized to||t|f|f|f
33962707|NCT01601171|||CASE_CONTROL||OTHER|||||||
33962708|NCT04585906|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigators will use a randomized control design.||||
33863294|NCT06678945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863295|NCT06540547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863296|NCT05976581|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study involves a randomized trial embedded within a quasi-experiment. During the 1-year study period, we anticipate that 1,500 patients will be exposed to the electronic health record modification performed as part of the quasi-experiment. Regarding the randomized trial, if 100 patients are enrolled during the 1-year study period, including 50 in intervention patients and 50 controls, we anticipate that we will have sufficient precision to estimate the difference in binary outcomes (e.g., antibiotic discontinuation within 5 days) between the two groups with a margin of error of approximately 15% based on a 95% confidence interval.||||
33863297|NCT06360406|||CASE_ONLY||OTHER|||||||
33863298|NCT05583201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863299|NCT00518414|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33863300|NCT04065776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863301|NCT00954291|||CASE_ONLY|||||||||
33863302|NCT05044819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863303|NCT06735326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962709|NCT05739227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962710|NCT00725725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962711|NCT02523274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962712|NCT04656171|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33962713|NCT05191407|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33962714|NCT02491307|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962715|NCT03046147|||CASE_ONLY||PROSPECTIVE|||||||
33962716|NCT04959565|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"One group will receive video lectures + individual consultations, while the other intervention group will receive video lectures only.~A control group was planned for Spring 2020 but do to the COVID-19 pandemic the investigators had to cancel the reqruitment of the control group.~Now the investigators plan a new recruitment of a control group for Authum 2021."||||
33962717|NCT01987258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962718|NCT01426321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962719|NCT05380622|||COHORT||PROSPECTIVE|||||||
33962720|NCT02321774|||||PROSPECTIVE|||||||
33962721|NCT00709020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863304|NCT03482778|||COHORT||RETROSPECTIVE|||||||
34175891|NCT03949569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants will be unaware of which study arm they are assigned. Individuals performing the interventions will be blind to study condition. The investigator will be blind to study condition until data analysis. Video data will be coded by observers blind to the study condition. The primary outcomes assessor is not blind to study condition.|The investigators will use a randomized crossover design. All children will receive two interventions during a single study visit. Children will be assigned to one of three research design arms using a stratified random sampling approach with child sex balanced across arm (N=110 in each group). All children will participate in the same tasks, in the same order. The only difference between research design arms is the timing of the interventions. In one arm the child will interact with the therapy dog prior to the psychosocial stress test and will interact with the stuffed toy dog prior to the behavioral tasks; the reverse is true for children in the second arm. In the third arm, the child will watch a 5 minute puppy video prior to the psychosocial stress test and will interact with the stuffed toy dog prior to the behavioral tasks|t|t|t|f
33863305|NCT05122897|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Double-blinded with the patient not knowing which material is placed, and the investigator and laboratory technicians have no information about the ring material.|All patients enrolled in the current investigation will wear both the test and control ring material for a within-subject comparison. Ideally, biofilm sampling can be performed in a split mouth design (randomly allocated materials within subjects) with one patient having two implants for placing the test and the control material at the same time. In addition, patients providing one implant, will receive test and control push-on rings in a randomly assigned order, so that both materials are assessed in a consecutive manner.|t|f|t|f
33863306|NCT06731777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863307|NCT06678438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the intervention, it is unfeasible to blind the patients, the doctor who performs the brachial plexus nerve block and the doctor who performs the standard care and the closed reduction. As a result, data on patient evaluated outcomes, i.e. maximum pain score during closed reduction; maximum pain within the first 24 hours after closed reduction; pain at rest; discomfort related to the anaesthetic procedure; overall satisfaction with the treatment; PRWE; DASH; EQ-5D-5L; and data on the closed reduction, i.e. number of attempts used for closed reduction and difficulty of closed reduction of the fracture, will be reported unblinded. Importantly, other caregivers and all outcome assessors are blinded, including the doctor who evaluate the radiographic results and assess the need for surgery, as well as all personnel involved in the subsequent outcome evaluations.||f|f|t|t
33962722|NCT00109629||||TREATMENT||||||||
33962723|NCT05224518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33962724|NCT02030834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962725|NCT00883142|||COHORT||PROSPECTIVE|||||||
34175892|NCT06387264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175893|NCT05131165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and outcomes assessor will be blinded to treatment assignment of study participants.|A pilot randomized controlled trial with two intervention arms and a control group, that will receive intervention for three months with follow-on assessment for six months after the intervention period ends.|f|f|t|t
34175894|NCT05107336|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study center staff including the Investigator have to remain blinded during the clinical conduct of a given cohort with regard to study intervention (AZD2693 or placebo). The study will be blinded for all study personnel including the Investigator during the clinical conduct of the study and the Sponsor will remain blinded up to the unblinded safety review committee review of the data from the study||t|t|t|f
34175895|NCT01692561|||CASE_CONTROL||PROSPECTIVE|||||||
34175896|NCT06203054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175897|NCT05684055|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Randomization for the two TwiCs will be done at cluster level, meaning that all people with aHT in one village will be offered the same care package from their local CC-VHW.~ComBaCaL aHT TwiC 1 and aHT TwiC 2 are two cluster-randomized controlled trials that are identical in intervention, design and endpoints. They only differ in the trial population and trial hypothesis. TwiC 1 enrols individuals with uncomplicated aHT with baseline BP values above treatment targets. TwiC 2 enrols individuals with uncomplicated pharmacologically controlled aHT. In the intervention clusters community-based treatment is offered. In the control clusters participants are referred to the facility for further care after diagnosis."||||
34175898|NCT04672642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34175899|NCT06330623|||COHORT||PROSPECTIVE|||||||
33962726|NCT05085249|||COHORT||PROSPECTIVE|||||||
33962727|NCT03178422|RANDOMIZED|PARALLEL||TREATMENT||NONE||combination product||||
33962728|NCT05221879|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962729|NCT06282666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will not be aware of the type of continuous blockade. Care providers, including doctors and nurses, will not be aware of patient allocation.~Physiotherapists assessing outcomes will not be aware of patient allocation."|Two groups will be randomly allocated to Epidural and ESPB (1:1)|t|t|f|t
33962730|NCT02063386|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33962731|NCT00994721|||CASE_CONTROL||PROSPECTIVE|||||||
33962732|NCT06413589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962733|NCT00781131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962734|NCT04398888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962735|NCT01116765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863308|NCT06538311|NA|SINGLE_GROUP||OTHER||NONE|Through use of SHAM rTMS stimulation|Within-subject crossover design||||
33863309|NCT01109329|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863310|NCT04600479|NA|SINGLE_GROUP||OTHER||NONE||||||
33863311|NCT04290299|||COHORT||PROSPECTIVE|||||||
33863312|NCT06671730|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||We will investigate the acceptability and feasibility of a novel 8-week occupational therapy (OT) program among 38 rural and urban breast cancer (BC) survivors that features: 1) 8 weekly telehealth OT sessions, and 2) self-regulatory strategies known to support aerobic physical activity (PA) and muscle strengthening exercise (MSE) adoption and maintenance, emphasizing components of the Self-Determination Theory (SDT), and the provision of a wearable device (e.g., a fitness tracker) programmed to supplement individually tailored goals.||||
33863313|NCT03228667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863314|NCT04104321|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||In the Open Label part of the study, there will be a single group of 150 subjects (expected) all receiving Aramchol 300mg BID.|t|t|t|t
33863315|NCT05443594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863316|NCT01207596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962736|NCT04626882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962737|NCT02294552|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962738|NCT02843347|||COHORT||PROSPECTIVE|||||||
33962739|NCT05817084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962740|NCT04297553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962741|NCT02394353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962742|NCT00305071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33962743|NCT00091507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962744|NCT05001373|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33962745|NCT06038266|||COHORT||PROSPECTIVE|||||||
33962746|NCT05182983|||COHORT||PROSPECTIVE|||||||
33962747|NCT00103259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962748|NCT00929786|||CASE_CONTROL||PROSPECTIVE|||||||
33962749|NCT04098068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962750|NCT03948737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double masking. No any information about treatment or placebo in participant, investigator, care provider and outcome assessor|Beta thalassemia major children|t|t|t|t
33962751|NCT04337515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962752|NCT03651895|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33962753|NCT05802979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962754|NCT01904552|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962755|NCT03305783|||CASE_CONTROL||PROSPECTIVE|||||||
33962756|NCT06520267|||CASE_ONLY||PROSPECTIVE|||||||
33962757|NCT04098471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33962758|NCT06540313|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33962759|NCT01261416|||COHORT||PROSPECTIVE|||||||
33962760|NCT04075383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers involved in the assessment of all outcomes will be not aware of the randomisation|randomised controlled parallel clinical trial|f|f|f|t
33962761|NCT01136005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962762|NCT06528990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962763|NCT03078192|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|The outcomes assessor, the radiologist who is reading the imaging will be blinded to treatment.|This will be a single blinded open label study enrolling volunteers and patients with pure PAH (10 subjects), pure left heart disease (10 subjects) and pure lung disease (10 subjects), 5 CTEPH in Aim 1; followed by a larger cohort of 92 subjects with PAH or other cardiac or pulmonary disease for MRI scans|f|f|f|t
33962764|NCT02623426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962765|NCT00000160|RANDOMIZED|||TREATMENT||||||||
34175900|NCT04641442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subject, investigator, and sponsor blinding via manual randomization during Period 2, Randomized Withdrawal Period|"This study includes:~* Screening~* Period 1: Open-Label Treatment Period to identify responders to MAS825~* Period 2: Randomized Withdrawal Period consists of a randomized treatment withdrawal period to primarily assess the efficacy of MAS825 compared to placebo.~* Period 3: Open-Label, Long-Term Safety follow-up~* End of Study~Patients will participate in all 3 periods of the study if they have never been treated with MAS825 before.~Patients who are enrolled from the Managed Access program will participate in Period 3 only after completing screening and baseline assessments."|t|t|t|f
34175901|NCT01489475|||CASE_ONLY||PROSPECTIVE|||||||
34175902|NCT04008940|||CASE_ONLY||RETROSPECTIVE|||||||
34175903|NCT04540185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel assignment|t|t|t|t
34175904|NCT04785300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175905|NCT05393791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group and experimental group||||
34175906|NCT06704399|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two groups included experimental and control group, pre-test, post-test and follow-up test.||||
34175907|NCT05131204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175908|NCT00178295|||COHORT||PROSPECTIVE|||||||
34175909|NCT05889728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Female patients aged 18 or above with ER/PR+ HER2 - metastatic breast cancer presenting for standard of care staging/restaging prior to treatment of metastatic disease.||||
34175910|NCT02938130|||CASE_ONLY||PROSPECTIVE|||||||
34175911|NCT01593826|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34175912|NCT06425380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175913|NCT04575155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34175914|NCT00116103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34175915|NCT05182372|RANDOMIZED|PARALLEL||OTHER||SINGLE|The principle investigator will be blind to the group assignment|Random assignment into experimental and control conditions at a 1:1 ratio|f|f|t|f
34175916|NCT04982250|RANDOMIZED|PARALLEL||PREVENTION||NONE||The pilot study will be a single group model (anticipated N=104), and the RCT will be a parallel model (anticipated N=400).||||
34175917|NCT04364867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175918|NCT06589492|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34175919|NCT06022861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863317|NCT00504153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863318|NCT02719431|NA|SINGLE_GROUP||||NONE||||||
33863319|NCT01025492|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863320|NCT02374398|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33863321|NCT00668031|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33863322|NCT04187105|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment to Arm 1||||
33863323|NCT05939440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessors who conduct surveys are blind to study assignment|Randomized controlled prospective trial|f|f|f|t
33863324|NCT06162494|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863325|NCT02651051|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33863326|NCT06704594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863327|NCT01423383|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33863328|NCT02473042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33863329|NCT04379336|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blinded|Efficacy will be determined based on documented SARS-CoV-2 infection and incidence of hospitalization. The analysis will be an intention-to-treat analysis with estimation of hazard ratio between the two arms using a Cox proportional hazard model. Adverse events will be summarized using descriptive statistics per study arm. The analysis will be a model-based analysis of cumulative data on general health status as a function of risk factors, treatment arm and time.|t|t|t|t
33863330|NCT06734208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863331|NCT06655493|||COHORT||CROSS_SECTIONAL|||||||
33863332|NCT00179504|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33863333|NCT02449213|||COHORT||PROSPECTIVE|||||||
33893858|NCT03655028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both investigator and outcome assessor will be blinded to patient allocation|Randomized controlled trial in which COPD patients in the intervention group and COVID19 patient in the intervention group will undergo a home-based, exercise program augmented with RAS-enhanced music while COPD patients in the control group and COVID19 patients in the control group will undergo a home-based, exercise program without music. Outcomes of the home-based exercise program with music will be comparecd to the outcomes of home-based exercise alone. Outcomes are listed below.|f|f|t|t
33893859|NCT05819892|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893860|NCT03989830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751408|NCT02210117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751409|NCT06140524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751410|NCT06733480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751411|NCT03129828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751412|NCT04105231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751413|NCT00797654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893861|NCT04007276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Each patient will be randomized to receive the study medication in one eye and placebo in the other eye.|t|t|t|t
33962766|NCT06112405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34175920|NCT03624881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175921|NCT01937286|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34175922|NCT05531643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and all study staff involved in participant evaluations will be blinded to treatment allocation. Each device will have the stimulation program pre-set according to the randomization assignment and be numbered. The randomization assignment will be held by the study statistician to match the device number to the intervention assignment. Devices will be distributed in numeric order according to the participant's chronologic order of enrollment.||t|f|t|t
34175923|NCT06586697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175924|NCT06547684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175925|NCT04017052|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34175926|NCT04240210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175927|NCT06458855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863334|NCT04109950|NA|SINGLE_GROUP||TREATMENT||NONE|open - label|"This is a 52-week, outpatient, multicenter, flexible-dose, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 (25 to 100 mg/day) for treatment of participants with schizophrenia who have completed Treatment Period of one of two following double-blind studies: Study SEP361-301 (NCT04072354) or Study SEP361-302 (NCT04092686).~The study will consist of two periods: An Open-Label Extension (OLE) Treatment Period (up to 52 weeks); and a Follow-up visit at 7±2 days after last study drug dose for participants who complete the Treatment Period \& those who prematurely discontinue from study.~The adolescent cohort includes participants who were 13 to 17 years of age, at time of consent in the SEP361-301 study. For adolescent participants, a reliable informant (e.g., parent, legal guardian, or caregiver) of participant should accompany participant at each visit and support and monitor the participants compliance with taking study medication."||||
33863335|NCT02042430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863336|NCT06734845|||COHORT||PROSPECTIVE|||||||
33863337|NCT00324051|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863338|NCT04375228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned either rituximab or tocilizumab based on clinical rationale and consensus recommendation by investigators.||||
33863339|NCT06736106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863340|NCT06506461|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with severe sickle cell disease (SCD)||||
33863341|NCT06734013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863342|NCT06283719|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863343|NCT04784767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863344|NCT05255120|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863345|NCT05275881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is an exploratory interventional, comparative, single-center, randomized research into 2 parallel groups. The study will compare the use of virtual reality versus usual practices for two iterative and painful acts: lumbar puncture and connection to an implantable chamber.||||
33863346|NCT00960908|||CASE_CONTROL||PROSPECTIVE|||||||
33863347|NCT05240183|||COHORT||PROSPECTIVE|||||||
33863348|NCT06653426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962767|NCT01585831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962768|NCT02276911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962769|NCT03435822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962770|NCT04060472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962771|NCT02840214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962772|NCT03304210|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33962773|NCT01117090|||COHORT||PROSPECTIVE|||||||
33962774|NCT00730470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962775|NCT06567236|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34175928|NCT00013572||||PREVENTION||||||||
34175929|NCT03600324|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||A prospective, single-blind, four-group multi-center randomized controlled trial|t|t|f|f
34175930|NCT05228574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a single-centre, randomized, double-blinded, and placebo-controlled clinical trial with a secondary open-label part.|t|t|t|f
33863349|NCT05204329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A longitudinal assessment using a classic dose-escalation study design to evaluate the safety and maximal tolerated dose of topical MSC Secretome eye drops||||
33863350|NCT04910568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863351|NCT06063317|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962776|NCT06373419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962777|NCT02878967|||OTHER||PROSPECTIVE|||||||
33962778|NCT06282068|||CASE_ONLY||PROSPECTIVE|||||||
33962779|NCT06070168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33962780|NCT00302939|||COHORT||PROSPECTIVE|||||||
33962781|NCT02228031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33962782|NCT01436669|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34065068|NCT04294251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175931|NCT06025916|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34175932|NCT06109467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175933|NCT00174577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34175934|NCT03573648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175935|NCT06204042|||COHORT||CROSS_SECTIONAL|||||||
34175936|NCT06425861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175937|NCT06557616|||CASE_ONLY||PROSPECTIVE|||||||
34175938|NCT06433791|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation||||
34175939|NCT04701008|||COHORT||PROSPECTIVE|||||||
33863352|NCT03599895|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863353|NCT06397716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863354|NCT06096610|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863355|NCT06718452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple-blinded|Longitudinal study|t|t|t|t
34175940|NCT05495815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863356|NCT06500676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863357|NCT04416061|||COHORT||RETROSPECTIVE|||||||
33863358|NCT05577078|||COHORT||PROSPECTIVE|||||||
33863359|NCT01748942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33863360|NCT05838196|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863361|NCT06735820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863362|NCT05500001|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A longitudinal pre-post study design will be used. A non-equivalent comparison group will be available for some measures.||||
33863363|NCT04559828|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33863364|NCT02824731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863365|NCT04981821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175941|NCT05413291|||OTHER||PROSPECTIVE|||||||
33863366|NCT02094833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175942|NCT06706466|||COHORT||RETROSPECTIVE|||||||
34175943|NCT06270784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175944|NCT04555486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are randomly assigned to one of two interventions: the study drug DCR-PHXC (also known as nedosiran) or the placebo comparator Sterile Normal Saline. For every 2 participants that receive DCR-PHXC, 1 participant will receive placebo. Thus, 4 participants are expected to receive DCR-PHXC, and 2 participants are expected to receive placebo.|t|t|t|t
34175945|NCT03748823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175946|NCT06647238|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Control group will not directly interact with investigators. Will perform retrospective chart review only.||||
34175947|NCT04631042|||COHORT||PROSPECTIVE|||||||
33863367|NCT05614973|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Enrolled patients will be randomly allocated to either the conventional group or coaxial/plugging group for percutaneous liver biopsy. After the procedure, the rates of biopsy-related complications as well as diagnostic yield will be compared.||||
33863368|NCT06314776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175948|NCT05797233|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863369|NCT03203421|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34175949|NCT06705608|||COHORT||RETROSPECTIVE|||||||
33863370|NCT06736223|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863371|NCT00165256|NA|SINGLE_GROUP||OTHER||NONE||||||
33863372|NCT06077812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33863373|NCT04454437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175950|NCT03443141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34175951|NCT03651700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The individual administering TMS will keep the master file of subject assignments, but all other individuals in contact with the subject or their data will be unaware of group assignment. Participants will not be informed of their assignment to active or sham status.|Participants will be randomized to either TMS or sham TMS in a 2:1 allocation ratio.|t|t|t|t
34175952|NCT05282095|||COHORT||PROSPECTIVE|||||||
33863374|NCT06480513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863375|NCT06726174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175953|NCT04421677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175954|NCT06491186|||CASE_ONLY||PROSPECTIVE|||||||
34175955|NCT04188743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"150 participants will be randomly allocated to an intervention group (100p) and a no intervention group (50p). Participants in the intervention group will be randomised (double blind) to either fecal microbiota transfer with donor stool (allogenic FMT) or fecal microbiota transfer with own stool (autologous FMT). Participants in the no intervention group will be monitored without receiving a fecal microbiota transfer."|t|t|t|t
34175956|NCT02961413|||COHORT||PROSPECTIVE|||||||
33863376|NCT06736210|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33863377|NCT05548452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863378|NCT06014242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863379|NCT00800241|||||RETROSPECTIVE|||||||
33863380|NCT02495350|||OTHER||PROSPECTIVE|||||||
33863381|NCT06660264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33863382|NCT06593249|||COHORT||RETROSPECTIVE|||||||
33893862|NCT02322762|||COHORT||PROSPECTIVE|||||||
33893863|NCT04969913|||COHORT||PROSPECTIVE|||||||
34175957|NCT06705335|||COHORT||PROSPECTIVE|||||||
33962783|NCT03092089|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical study is a prospective single-center, single-arm investigation of sonothrombolysis in adult patients presenting with high-risk STEMI within 6 hrs of the onset of clinical symptoms and receiving reperfusion therapy with PCI. All patients will receive standard therapy. Patients will immediately receive an iv infusion of commercially available ultrasound contrast agent (Definity) and myocardial contrast echocardiography will be performed to document the size of the perfusion defect. Loops of 15 cardiac cycles will be recorded using low mechanical index (MI) ultrasound. These recordings will also be used to assess regional wall motion as well as LV volumes and ejection fraction. Immediately after the diagnostic ultrasound, the therapeutic ultrasound will start using the same transducer by applying multiple high MI ultrasound impulses. These pulses will be applied to the apical windows that contained the risk area. The intervals between HMI impulses will vary from 5 to 15 s.||||
33962784|NCT03746886|||CASE_ONLY||OTHER|||||||
33962785|NCT03961945|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962786|NCT00184210|||COHORT||CROSS_SECTIONAL|||||||
33962787|NCT01156831|||COHORT||PROSPECTIVE|||||||
33962788|NCT02764073|||COHORT||PROSPECTIVE|||||||
33962789|NCT06537804|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34175958|NCT03302325|||CASE_ONLY||PROSPECTIVE|||||||
33962790|NCT04170049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962791|NCT00004861|RANDOMIZED|||TREATMENT||||||||
33962792|NCT00004161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33962793|NCT02232269|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962794|NCT03448809|RANDOMIZED|PARALLEL||TREATMENT||NONE||No sample size calculation was performed for this parallel, two-arm feasibility RCT. Because the study population was heterogeneous and included children with a broad spectrum of emotional and behavioral mental health problems, 100-120 children were needed in the new experimental MMM arm to answer the research questions related to implementation and acceptability of the MMM manual. Therefore the goal was to include 150 children to be randomly allocated (3:1) to MMM versus TAU. The central, computerized randomization was performed by DEFACTUM using concealed computer-generated allocation sequences with variable block size, and stratification by region (Zealand or Central Denmark), and by age (6-10 years or 11-16 years).||||
33962795|NCT01083901|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33962796|NCT02354352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962797|NCT00612794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962798|NCT02726373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962799|NCT02535247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks. Copanlisib is given intravenously at RP2D determined from Phase I study 18 in cohort 1 (pembrolizumab alone; completed); 27 in Cohort 2; 4-12 in cohort 2a (phase I); 18 in cohort 2b (phase II). Total up to 48||||
33962800|NCT05700110|||COHORT||RETROSPECTIVE|||||||
33962801|NCT06536816|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized Clinical Trial|t|f|f|f
33962802|NCT06542471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962803|NCT01758315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33962804|NCT02602080|||COHORT||PROSPECTIVE|||||||
33962805|NCT04184154|||OTHER||CROSS_SECTIONAL|||||||
33962806|NCT03216954|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33962807|NCT04628221|NA|SINGLE_GROUP||OTHER||NONE||||||
33962808|NCT00233350|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962809|NCT01825915|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33962810|NCT00583245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962811|NCT01277406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962812|NCT04783844|||COHORT||PROSPECTIVE|||||||
33962813|NCT04664283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962814|NCT01128010|||CASE_CONTROL||PROSPECTIVE|||||||
33962815|NCT03137485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065069|NCT05087121|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-group design in which eligible participants are randomized via permuted block, with a block size of seven, to either the intervention (CBT-I-F) condition or a no intervention control condition. Unequal allocation to groups based on 60:40 split, intervention:control. Randomization stratified according to gender identity.||||
34175959|NCT05048979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrollment in a 12-week, 3 day a week, aerobic training program in a self-selected location. The exercise training will be via telehealth. Arm 1 will receive aforementioned intervention. Arm 2 will received no intervention.||||
34175960|NCT06518824|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34175961|NCT06705634|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-Test Post-Test Design||||
34175962|NCT06704282|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either the experimental group, receiving mindfulness-based VR observational meditation, or the control group, undergoing standard relaxation techniques.||||
34175963|NCT06093282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors and the Investigators are blinded to individual participants' treatment assignment.|Two-arm, parallel group design|f|f|t|t
34175964|NCT06600620|||COHORT||PROSPECTIVE|||||||
34175965|NCT03692208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175966|NCT06442475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175967|NCT05200208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175968|NCT02402816|RANDOMIZED|PARALLEL||||NONE||||||
34175969|NCT05203614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34175970|NCT06254638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34175971|NCT05575830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175972|NCT04530981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175973|NCT02753270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175974|NCT06705270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34175975|NCT03800381|||COHORT||PROSPECTIVE|||||||
33863383|NCT06735677|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Data collection forms were administered to 100 pregnant women who attended the pregnancy school of a city hospital in a province of Türkiye and agreed to participate in the study. The participants were then randomly assigned by lot into intervention (n=50) and control (n=50) groups. Pregnant women in the intervention group received four training sessions over one month. These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy. Following the completion of the training sessions, the Sexual Quality of Life-Female (SQOL-F) questionnaire and the Female Sexual Function Index (FSFI) were re-administered to all participants for final evaluation. Written informed consent was obtained from all participants before the study commenced. The study was completed with 90 participants (45 in the intervention group and 45 in the control group).||||
34175976|NCT06503510|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will be treated with Lebrikizumab and will receive 3 pruritogens: Histamine, cowhage and BAM8-22.||||
34175977|NCT06548126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study Staff members involved with contacting families for scheduling purposes, administering the Family Interaction Tasks and administering Target Child surveys are prevented from having knowledge of individual participants' randomization assignment. The principle investigator and outcome assessor are also masked and prevented from having knowledge of individual participants' randomization assignment.|Families will be recruited using stratified random sampling within the four PIM language groups; 180 families will be recruited from each (English, Spanish, French, Arabic), from which 90 families will be assigned to the intervention. This study will randomly select intervention and control families as they enter the study following a 1:1 randomization scheme.|f|t|t|t
34175978|NCT04386993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175979|NCT02173769|||COHORT||PROSPECTIVE|||||||
34175980|NCT06629168|||CASE_ONLY||OTHER|||||||
34175981|NCT04198870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34175982|NCT03980509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175983|NCT04290949|||OTHER||PROSPECTIVE|||||||
34175984|NCT06336239|||OTHER||CROSS_SECTIONAL|||||||
34175985|NCT03632239|||COHORT||OTHER|||||||
33863384|NCT05096351|||COHORT||PROSPECTIVE|||||||
33863385|NCT04836936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The only person unblinded to treatment allocation will be the Principal investigator or individual who will perform the auriculotherapy treatment.|A Randomized, Double-Blind, Placebo-Controlled trial involving patients undergoing partial or total nephrectomy.|t|t|f|t
33863386|NCT05615844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34175986|NCT06593158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The primary outcomes: The Gross Motor Function Measure (GMFM-66), Melbourne Assessment 2 will be videotaped, and the scoring will be done by blind trained examinors.~In secondary outcomes: ACTIVLIM-CP-WA, PEDI, COPM, WHOQOL-Bref will be answered by the caregivers."|The trial will be a single-blind, randomized controlled trial. Participants will be randomly assigned to one of two groups: HABIT-ILE Camp with Caregivers or HABIT-ILE at Home with Caregivers. Both groups will have longitudinal assessments two weeks before baseline, at baseline, at the end of the two-weeks intervention, and 3 months after baseline.|f|f|f|t
33863387|NCT01294150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863388|NCT06700356|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863389|NCT05309668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175987|NCT03396809|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Investigators will be performing a case crossover study. First patients who consent will be asked to complete an Ocular Surface Disease Index (OSDI). Those whose score indicates a diagnosis of dry eye will eligible for the study. Three to five days after their intravitreal injection, patients will be contacted over the telephone and asked to complete the OSDI. At their next visit, one month later, a punctal plug will be inserted before their second injection. Three to five days after their second injection, they will be asked to complete the OSDI over the telephone. At their third visit they will receive an intravitreal injection and three to five days after they will be asked to complete a final OSDI. If patients are receiving bilateral intravitreal injections, and the OSDI survey indicates dry eyes bilaterally, then only one of the eyes will be randomly chosen for plug insertion. The other eye will then be used as a control.||||
34175988|NCT02081924|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant won't know whether they are receiving placebo or which dose of kisspeptin|This is a prospective, single-blinded placebo-controlled study. Women will receive an 8-h SC infusion of kisspeptin-54 0·1, 0·3 or 1·0 nmol/kg/h or saline in the early follicular phase of 4 separate menstrual cycles. Luteinising Hormone (LH), Follicle stimulating hormone (FSH) and oestradiol will be measured every 10 min during the infusions.|t|f|f|f
34175989|NCT06599346|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in this study will be randomly assigned to one of two groups in parallel. The control group will receive standard care for mucosal injuries (such as oral rinses and supportive care), while the intervention group will receive MSC supernatant treatment in addition to standard care. The treatments will be administered concurrently, and both groups will be monitored for the duration of the study to assess the effectiveness and safety of MSC supernatant in healing mucosal injuries caused by HSCT, chemotherapy, and radiotherapy.||||
34175990|NCT04410991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34175991|NCT04506853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34175992|NCT06100887|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33863390|NCT05317247|||COHORT||CROSS_SECTIONAL|||||||
33863391|NCT05829707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|On the one-year control examination, the investigator was blinded on the type of postoperative analgesia||f|f|t|t
34175993|NCT06560489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34175994|NCT04191538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized by an objective third party, who will provide electrical stimulation at the appropriate time given randomized cohort. Patients, surgeon, and investigator will be unaware of arm of study.|Randomized control trial|t|t|t|t
34175995|NCT03901755|||COHORT||PROSPECTIVE|||||||
34175996|NCT06198933|||CASE_ONLY||PROSPECTIVE|||||||
34175997|NCT06705855|||COHORT||PROSPECTIVE|||||||
33751414|NCT06282809|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective multi-center, single-arm, feasibility trial.||||
34175998|NCT02515916|||COHORT||PROSPECTIVE|||||||
34175999|NCT04471714|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and researchers will be blinded. The research technician will be not be blinded|This is a double blinded, cross-over, retrospective cohort design where the size of the H-reflex and motor unit firing rates will be examined before and after oral intake of baclofen or placebo.|t|f|t|f
34176000|NCT04917107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Delayed design|f|f|f|t
34176001|NCT06123325|||COHORT||PROSPECTIVE|||||||
34176002|NCT05659030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34176003|NCT03270436|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparison of two diabetes prevention program curricula in the Marshallese population.||||
34176004|NCT00948246|||CASE_ONLY||PROSPECTIVE|||||||
33751415|NCT00421551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751416|NCT06733909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863392|NCT06736119|NA|SINGLE_GROUP||TREATMENT||NONE|No one will be masked.|it will be qusai experimental study in which non-probability convenient sampling technique will be used. Interventional group of 4 to 12 age will be pormed in which participants will recieve task oriented interventions.||||
33863393|NCT02868970|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33863394|NCT05552326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863395|NCT02885194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863396|NCT02823626|||CASE_ONLY||PROSPECTIVE|||||||
33863397|NCT01633866|||OTHER||PROSPECTIVE|||||||
33863398|NCT05472961|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Manipulation is within-participant. Participants view multiple visual search arrays in an experimental session. They will be masked with regards to the difficulty and timing manipulations until they experience them on a trial.|Participants are asked to view an array of objects on a computer screen equipped with a noninvasive eye tracker. They are asked to search for a target object among one or more distractor objects and may be asked to respond to a feature of the target object with a key press that was selected via a gaze shift.||||
33863399|NCT02294435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863400|NCT06734949|||COHORT||PROSPECTIVE|||||||
34176005|NCT05430854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863401|NCT05724121|||CASE_CONTROL||PROSPECTIVE|||||||
33863402|NCT05024630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We used participant single blindness. To ensure single blindness, femoral artery puncture and renal arteriography were performed in the control group after cryoablation.|Hypertensive patients with symptomatic paroxysmal atrial fibrillation who are to be treated by cryoablation with substandard blood pressure (SBP ≥ 150 mmHg or DBP ≥ 90 mmHg in the clinic with at least one antihypertensive drug)|t|f|f|f
33893864|NCT03642184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893865|NCT01974323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893866|NCT00446030|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893867|NCT06357221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893868|NCT01994343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893869|NCT02451956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893870|NCT06362785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33893871|NCT03893292|||COHORT||PROSPECTIVE|||||||
33893872|NCT04888611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893873|NCT02286401|||COHORT||PROSPECTIVE|||||||
33893874|NCT05983393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33893875|NCT04228419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893876|NCT06007612|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||2 groups enrolled in a one-time behavioral paradigm||||
33893877|NCT00921869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176006|NCT05330481|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176007|NCT05491265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||- To study the vital sign ,oxygen arterial saturation of preterm babies provided skin to skin contact versus conventional care from birth to discharge||||
34176008|NCT04076696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176009|NCT03538197|NA|SINGLE_GROUP||PREVENTION||NONE||Cohort study||||
34176010|NCT06589466|||OTHER||OTHER|||||||
34176011|NCT06705920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176012|NCT06504628|||COHORT||CROSS_SECTIONAL|||||||
34176013|NCT04571944|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34176014|NCT06704854|||CASE_CONTROL||PROSPECTIVE|||||||
34176015|NCT00005942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176016|NCT05065060|||COHORT||OTHER|||||||
34176017|NCT03350529|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"This study is an early phase 1 non-randomized prospective single-institutional and four arm study to determine the applicability, feasibility and safety of MRI guided transurethral HIFU ablation of prostate separately in each pre-specified group/arm (10 patients per group).~Due to the encouraging feasibility and safety results, an amendment was made to the original study protocol to increase the amount of salvage group patients and BPH group patients. With the approval of the ethics committee, the sample size of the salvage group and BPH group was increased to a total of 40 patients and 30 patients, respectively."||||
34176018|NCT04504253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, double-blind, placebo-controlled. Block randomization protocol.||t|t|t|t
34176019|NCT04490174|||COHORT||PROSPECTIVE|||||||
33751417|NCT06733753|||COHORT||PROSPECTIVE|||||||
33751418|NCT04887454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751419|NCT02110641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751420|NCT05835297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33751421|NCT04101305|||COHORT||PROSPECTIVE|||||||
34176020|NCT06051305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176021|NCT05552664|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Randomization will be concealed from study participants; enrolled patients and relatives will not be aware that their family has been randomized into one of four trial arms and provided a different intervention experience than the other study participants. Concealment is necessary for this study so that the trial can observe differences across the trial arms without a) negatively impacting study enrollment and biasing the study, and b) causing unnecessary negative emotional reactions in study participants.|The trial is a 2x2 factorial prospective RCT|t|f|f|f
34176022|NCT04211961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176023|NCT06705036|||COHORT||CROSS_SECTIONAL|||||||
34176024|NCT06052475|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33863403|NCT04694508|RANDOMIZED|PARALLEL||PREVENTION||NONE|Music therapy was administered before initiating anesthetic induction with the patient lying flat on the surgical table. A pair of non-reusable headphones (Disok, Alicante, Spain) were used in both groups which were connected to a tablet Fire 7 (Amazon, Seattle, WA, US) that was used as a music player device connected to Spotify. Two music lists were downloaded and reproduced without the need of access to WIFI to ensure good reproducibility. Group A was played a list consisting of rhythmic tones of 60-80bpm, music from the Seatwork 60bpm playlist with a duration of 11h and 5 minutes. Group B was played an empty playlist. Volume was set at a standard of 68dB. The surgical supervisor was responsible for opening the opaque envelope for each patient and to play the list according to the allocated group. Only the surgical supervisor knew the allocation for each patient, the rest of the surgical team were blinded to the allocation result.|Patients were randomly assigned to either receiving intraoperative music therapy (Group A) or undergoing standard management without music therapy (Group B). Randomization was performed by a nurse specialist blinded to the study using anonymized, opaque envelopes provided by the Vall d'Hebron Research Institute. Participants were then randomized (i.e. given an envelope) to either Group A or Group B during the preoperative visit. The randomization allocation was performed using the ralloc function in STATA which randomly assigned participants in either of the two study groups in blocks of 2, 4, 6, until the total number of patients was achieved (n = 80).||||
33863404|NCT06237218|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind randomised controlled trial|t|t|t|t
33863405|NCT04722341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33863406|NCT04091386|||COHORT||PROSPECTIVE|||||||
33863407|NCT06736080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863408|NCT01096212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863409|NCT01141088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863410|NCT06734130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863411|NCT05992623|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomized to a Zoll or Lifepak defibrillator to perform the DCCV. All shocks will be full output (200J for Zoll shocks and 360J for Lifepak shocks). Follow up will be assessment and documentation of rhythm 1 minute after the last shock is delivered. Participants who do not have first shock success will have a second full output shock ≥1 minute after the first shock. Participants who do not have success after a second full output shock will be crossed over to the other defibrillator waveform and receive up to 2 full output shocks with a minimum of 1 minute between each shock to ascertain the outcome of the immediately prior shock.||||
33863412|NCT00016380|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33863413|NCT04277637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863414|NCT05085665|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863415|NCT03760341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34150538|NCT03481621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants will get real treatments, the first group patients will get acupuncture treatments focus on the points within pudendal nerve distribution area; the second group patients will get acupuncture treatments focus on the points from traditional meridian theory. And the third group will get the standard care (no acupuncture). Participants and outcomes assessor will be blinded for the study aims.|Acupuncture 1: focus on the points within pudendal nerve distribution arae; Acupuncture 2: focus on the points from traditional meridian theory; Standard care: no acupuncture, but use physical therapy, pain medications, nerve blocking, etc.|t|f|f|t
34150539|NCT05921279|||COHORT||PROSPECTIVE|||||||
34150540|NCT03911024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150541|NCT03113604|||COHORT||RETROSPECTIVE|||||||
34176025|NCT05974241|NA|SEQUENTIAL||TREATMENT||NONE||A three-step, open-label, 10 week pilot study||||
34176026|NCT05690139|||OTHER||PROSPECTIVE|||||||
34176027|NCT01456637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176028|NCT03796650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An open-label, partly assessor blinded trial.|Randomized clinical trial with two parallel treatment arms with a 1:1 allocation.|f|f|f|t
34176029|NCT06581471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176030|NCT02595892|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34176031|NCT06692673|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34176032|NCT02702492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176033|NCT04603846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176034|NCT02290392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176035|NCT05593380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176036|NCT05800210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176037|NCT05552846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176038|NCT05997225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176039|NCT05702463|RANDOMIZED|CROSSOVER||PREVENTION||NONE|laboratory personnel doing the platelet function assay will be blinded to minimize potential assessment bias.|triple crossover||||
34176040|NCT05896163|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label/randomized||||
34176041|NCT03925454|||COHORT||PROSPECTIVE|||||||
33863416|NCT00450216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863417|NCT04579744|||CASE_ONLY||RETROSPECTIVE|||||||
33863418|NCT05546554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34176042|NCT04418024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176043|NCT06702072|||COHORT||PROSPECTIVE|||||||
34176044|NCT02061787|||COHORT||PROSPECTIVE|||||||
34176045|NCT04440033|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Case-control||||
34176046|NCT06178796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176047|NCT03916133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176048|NCT03889184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized study||||
33863419|NCT05211401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863420|NCT03471936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863421|NCT06689618|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled participants will undergo pre-test assessments within 2-4 days before and after the intervention period. The pre-test assessment visit will be scheduled for 3.5 hours, and the post-test assessment visit for 2.5 hours, reflecting that the pre-test visit will incorporate consenting and screening procedures. The intervention will consist of 2 visits per week for 4 weeks; each intervention visit will be scheduled for 1.5 hours.||||
33863422|NCT01938131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33863423|NCT06210009|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34150542|NCT02495454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150543|NCT02643589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176049|NCT03084146|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863424|NCT05791383|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33863425|NCT05683171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863426|NCT06518681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863427|NCT06138639|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751422|NCT04749030|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The study is a 8-week, randomised, double-blinded, placebo-controlled pilot trial of oral FMT versus placebo in patients with DM1 and severe GI neuropathy. The intervention period consists of a first 4 weeks where patients receive either FMT or placebo and a second 4 weeks where all patients receive FMT. The patients will undergo the investigations before and after each 4-week period.|t|t|t|t
33751423|NCT05909332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863428|NCT06095505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863429|NCT04521361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893878|NCT04925570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893879|NCT05163665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150544|NCT04496453|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150545|NCT00127309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150546|NCT03996317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150547|NCT00654459|||CASE_CONTROL||PROSPECTIVE|||||||
34150548|NCT05728073|||CASE_CONTROL||RETROSPECTIVE|||||||
34150549|NCT02030990|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34150550|NCT00911573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150551|NCT00845065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150552|NCT01283542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150553|NCT04029818|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150554|NCT03135210|RANDOMIZED|PARALLEL||TREATMENT||NONE||24 total subjects will be recruited; 12 per group. Approximately 3-5 patients are admitted to UMMC each month who are undergoing ECMO and could be considered for study inclusion.||||
34150555|NCT04816604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150556|NCT02297555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150557|NCT02652468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150558|NCT02843139|||COHORT||CROSS_SECTIONAL|||||||
34150559|NCT03024866|||COHORT||PROSPECTIVE|||||||
34150560|NCT01932255|||CASE_CONTROL||RETROSPECTIVE|||||||
34150561|NCT02995798|||CASE_CONTROL||RETROSPECTIVE|||||||
34150562|NCT03303612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150563|NCT02048371|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34150564|NCT00994994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34150565|NCT06089902|||CASE_ONLY||PROSPECTIVE|||||||
34150566|NCT01524081|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34150567|NCT03774342|||COHORT||PROSPECTIVE|||||||
34150568|NCT00544284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150569|NCT04320108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150570|NCT06507800|||COHORT||RETROSPECTIVE|||||||
34150571|NCT05648682|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34150572|NCT00315809|||CASE_ONLY||PROSPECTIVE|||||||
34150573|NCT05986617|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
34150574|NCT02503514|||COHORT||PROSPECTIVE|||||||
34150575|NCT02153814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863430|NCT05410353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The randomized portion of this protocol will employ a blinding design so that the CHAMPS study personnel and investigators who are collecting and assessing outcome data (i.e., weight) will not know a participant's group assignment status (blinded to assignment). Neither the participants, nor the study staff who provide the intervention, will be blinded to assignment. All participants will be asked not to reveal their CHAMPS study group assignment to blinded clinic personnel. All intervention-related information will be kept separately from outcome data and will not be accessible to blinded staff.|This is a 2-arm, parallel, randomized, controlled clinical trial. Eligible participants will be randomly assigned in a 1:1 ratio to either a behavioral weight loss intervention group delivered via Health IT with telephonic support (Active Intervention Group) or the Comparison Group. Because intervention delivery does not depend on clinic site, the study team has opted for a more powerful individual randomization over cluster randomization (but the team will potentially include clinic site as a grouping effect in the analysis).|f|f|t|t
33863431|NCT06631430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33863432|NCT06681922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962816|NCT04911660|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Empagliflozin and placebo will be provided in identically looking bottles. Besides the consecutive number, packs and pack content will look identical. Therefore, all trial personnel that is involved in recruitment and care of patients, trial assessment, monitoring and analyses will be blinded to the assigned trial arm.|Eligible individuals will be randomized in equal proportions to 25 mg empagliflozin or placebo, taken once daily per os in the morning. Placebo will be administered to individuals randomized to that treatment in a form identical to empagliflozin. Patients will remain on the assigned IMP for 14 days. The following 14 days (days 15 - 28) will be a wash out period without IMP intake; this wash out time can be extended to up to 6 weeks if necessary. On day 29 of the study (or later according to the length of the wash out phase), a second 14 days period with IMP intake starts (empagliflozin or placebo, whichever was not received initially).|t|t|t|t
33962817|NCT01956539|||COHORT||PROSPECTIVE|||||||
33962818|NCT02851953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962819|NCT04629131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962820|NCT05675384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33962821|NCT01777802|||COHORT||PROSPECTIVE|||||||
33962822|NCT05786781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962823|NCT00412438|||CASE_CONTROL||OTHER|||||||
33962824|NCT00601276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962825|NCT02319954|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33962826|NCT01896700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962827|NCT02715466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863433|NCT02509897|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33863434|NCT05462795|||CASE_ONLY||PROSPECTIVE|||||||
33863435|NCT06149156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893880|NCT01961427|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33893881|NCT00435552|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33893882|NCT00659295|||COHORT||PROSPECTIVE|||||||
33962828|NCT04471558|||CASE_CONTROL||PROSPECTIVE|||||||
33962829|NCT04727619|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Analyses will be done by blinded assessor.||f|f|f|t
34065070|NCT05203198|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|"Subjects will know the condition to which they are randomized when opening their CATCH-IT login, as the number of components will be apparent on the sidebar of the webpage.~All clinical evaluators conducting the MINI Kid and other psychological assessments will work out of the Boston Call Center and they will be the only staff blinded to group assignment."|The Multiphase Optimization Strategy (MOST) will be utilized to optimize a primary care, technology-based intervention (CATCH-IT) for the prevention of depression in at-risk adolescents to optimize efficacy, tolerability and scalability for implementation studies and eventual dissemination. This MOST process includes: (1) theoretical organization of components, target behaviors and links to preventive outcomes (vulnerability and protective factors, likelihood of developing depressive episode), (2) selection of components for factorial design, (3) optimization criteria and (4) factorial design (randomization, intervention delivery, assessments, analysis and optimization). The theoretically grounded components selected are: (1) behavioral activation modules; (2) cognitive-behavioral therapy modules; (3) interpersonal psychotherapy modules; and (4) parent program modules.|f|f|f|t
34150576|NCT03464916|NA|SEQUENTIAL||TREATMENT||NONE||To determine DLT and MTD, the design uses a 3+3 rule-based design. Dose escalation is permitted between successive cohorts based upon a specified algorithm, using discrete dosage steps.||||
34150577|NCT00208520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150578|NCT00580463|||CASE_ONLY||PROSPECTIVE|||||||
33962830|NCT00921219|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34150579|NCT02090361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962831|NCT03232905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962832|NCT03091283|||COHORT||PROSPECTIVE|||||||
34150580|NCT00290498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150581|NCT00084656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150582|NCT03395002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150583|NCT02801890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150584|NCT03898076|||COHORT||RETROSPECTIVE|||||||
34150585|NCT05835583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34150586|NCT00819494||PARALLEL||DIAGNOSTIC||NONE||||||
34150587|NCT00716742|||COHORT||PROSPECTIVE|||||||
34150588|NCT00206934|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
34150589|NCT01009177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150590|NCT01364909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150591|NCT06269237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150592|NCT03869476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150593|NCT01694979|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150594|NCT04628065|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150595|NCT00638976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34150596|NCT01264770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150597|NCT02671565|||COHORT||RETROSPECTIVE|||||||
33863436|NCT05228730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and those evaluating reactogenicity will be blinded to the vaccine allocation for the first 28 days following vaccination. After that, both clinical investigators and participants will be aware of their investigational product allocation. Laboratory staff will remain blinded to the investigational product allocation during the immunology testing.|Study participants who have received two doses of either Pfizer or Astrazena vaccine as their primary vaccine will be randomised into one of four groups. The four groups consists of a standard or fractional dose of either Pfizer or Moderna vaccine.|t|f|f|t
34176050|NCT06277687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||After performing CTA examination, input the CTA data into Cinematic Anatomy reconstruction software to analyze blood vessels, muscles and other tissues are reconstructed in three dimensions. Before the operation, the Finder is used to restore the position of the thigh during CTA examination. The Hololens is used to match the reconstructed three-dimensional image with the Finder and the thigh. Before the operation, the pedicles of the descending branches of the lateral arteries and the perforating vessels are marked on the skin of the thigh to achieve the positioning and marking of the perforating branches.||||
34176051|NCT06220214|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176052|NCT04188912|||COHORT||PROSPECTIVE|||||||
34176053|NCT04172584|||OTHER||CROSS_SECTIONAL|||||||
34176054|NCT04595773|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34176055|NCT05010707|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants who agreed to be in the study will undergo block randomization into three groups:~1. daily sublingual 17 beta estradiol~2. twice daily sublingual 17 beta estradiol~3. transdermal 17 beta estradiol~All patients will also receive spironolactone as antiandrogen."||||
34176056|NCT04496960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863437|NCT04616248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863438|NCT06506604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blind to the variables of change.|Multiple Baseline Single Case Design|t|f|f|f
33863439|NCT04154332|||COHORT||PROSPECTIVE|||||||
33863440|NCT06420661|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled trial||||
34150598|NCT03238924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150599|NCT05073198|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34150600|NCT06094400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150601|NCT03718858|RANDOMIZED|PARALLEL||OTHER||TRIPLE|On the day of surgery, patients will be randomly assigned (1:1) to one of two groups according to a computer-generated list. The patients, the clinical care team (anesthesiologist providing intraoperative care, nurses, and surgeons), data collectors, outcome adjudicators, and the study statisticians will all remain blinded to randomization and group allocation. The anesthesiologist who will perform the intervention will be aware of group allocation, but the anesthesiologist providing intraoperative care will remain blinded. Situations such as patient refusal at any time of the study, any adverse event or complication necessitating withholding the intervention would result in voluntary un-blinding of study investigators.|This is two-arm, prospective, parallel, double blind, multi center, randomized controlled trial|t|t|t|f
33863441|NCT05103228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863442|NCT02905422|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33863443|NCT01917487|||||PROSPECTIVE|||||||
33863444|NCT00328744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863445|NCT06613100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863446|NCT04605445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33863447|NCT05715723|||CASE_CONTROL||PROSPECTIVE|||||||
33863448|NCT05323591|||COHORT||PROSPECTIVE|||||||
34150602|NCT02178267|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150603|NCT01370759|NA|SINGLE_GROUP||SCREENING||NONE||||||
34150604|NCT05601661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150605|NCT03369613|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34150606|NCT00491881|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150607|NCT01553812|||||CROSS_SECTIONAL|||||||
34150608|NCT01872013|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34150609|NCT01281228|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34150610|NCT01363934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150611|NCT00069355||||TREATMENT||||||||
34150612|NCT02116998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150613|NCT01856621|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34150614|NCT00288314|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34150615|NCT02694952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150616|NCT04608734|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34150617|NCT06071481|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm-1: Standard treatment, Arm-2: Standard treatment and 2,00,000 IU Vitamin D oral solution, Arm 3: Standard treatment and 4,00,000 IU Vitamin D oral solution||||
34150618|NCT04931589|||CASE_ONLY||RETROSPECTIVE|||||||
34150619|NCT00885300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34150620|NCT03469024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34150621|NCT03389737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34150622|NCT02970526|||OTHER||CROSS_SECTIONAL|||||||
34150623|NCT06341010|||CASE_ONLY||PROSPECTIVE|||||||
34176057|NCT05652010|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33863449|NCT05551767|NA|SINGLE_GROUP||TREATMENT||NONE||3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg) followed by (chemo)radiation.||||
33863450|NCT06263023|||COHORT||PROSPECTIVE|||||||
33863451|NCT06734871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176058|NCT05757843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863452|NCT05874713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Eligible subjects are randomized in a 2:1:1 ratio to Treatment Arm A, B, or C, respectively, and will receive two priming doses of the allocated aH5N8c/aH5N6c vaccine 3 weeks apart, ie, at Day 1 and Day 22, and a booster dose of aH5N8c vaccine at Day 202.|t|f|t|t
34176059|NCT01787500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176060|NCT03928132|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Health professionals will self-select their attendance at one or other of the interventions (control or experimental CPD activity) without knowing that they are different (one including sex and gender considerations, the other excluding them).|A non-randomized controlled trial|t|f|f|f
33863453|NCT06137833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33863454|NCT05580744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863455|NCT06734481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962833|NCT06271135|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863456|NCT06358326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study; the patients will not be informed about their groups (training group or the control group) and they will be evaluated and trained at different places and times.|Parallel Assignment|t|f|t|t
34150624|NCT04067778|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34150625|NCT02868658|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150626|NCT01987583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150627|NCT00109577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150628|NCT00034736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150629|NCT02445573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150630|NCT05403229|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study.|Participants are assigned to one of two groups in parallel for the duration of the study.||||
34150631|NCT05023148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors and laboratory analyst do not know which group that participants was assigned in|There are two groups of intervention. The first group is getting electroacupuncture treatment and the second group is getting thread embedded acupuncture treatment.|f|f|f|t
34150632|NCT06448494|||COHORT||OTHER|||||||
34150633|NCT00450554|||||PROSPECTIVE|||||||
34150634|NCT05320159|||COHORT||RETROSPECTIVE|||||||
34150635|NCT02905006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150636|NCT02388542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150637|NCT02705274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150638|NCT05727423|||COHORT||PROSPECTIVE|||||||
34150639|NCT03107988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150640|NCT05821725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34150641|NCT05109260|||OTHER||PROSPECTIVE|||||||
34150642|NCT06025812|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150643|NCT01826435|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33863457|NCT06616272|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33863458|NCT06575738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863459|NCT06735976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863460|NCT04121403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two independent blinded radiologists assess the primary endpoint, New or enlarging T2 lesions. The blinding is asserted by transfer of deidentified MRIs to a Research server, from where the assessment is performed, so that the radiologists know only the ID, not the treatment allocation of the patients from whom the assess MRIs.|A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study, designed to establish non-inferiority of the test treatment rituximab compared with the comparator oral cladribine for consecutively included patients with active RMS. Randomization rituximab:cladribine is 1:1.|f|f|f|t
33863461|NCT06534437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065071|NCT04733222|RANDOMIZED|PARALLEL||PREVENTION||NONE||"After the pre-training tests, participants will be randomly allocated to either the perturation or control group. To produce groups of similar size a permuted block randomization will be used. Allocation concealment will be maintained using random block sizes (4, 6, or 8) and by the randomization code only being available for non-blinded research staff.~The perturbation group will undergo three initial training sessions on two days within a week, and a booster-session after six months. The active control group will perform treadmill walking at a preferred speed to match the training dose of the perturbations group."||||
34065072|NCT03066037|||COHORT||RETROSPECTIVE|||||||
34065073|NCT00002379||||TREATMENT||||||||
34065074|NCT01819844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065075|NCT05487053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065076|NCT05604872|||COHORT||RETROSPECTIVE|||||||
34065077|NCT03899207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomize control trail|t|f|f|f
34065078|NCT01002560|||CASE_CONTROL||RETROSPECTIVE|||||||
34065079|NCT01243294|RANDOMIZED|CROSSOVER||||NONE||||||
34176061|NCT05264779|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The assessors of the primary outcome will be blinded to the participant's treatment group. The investigators will utilize a two-research assistant (RA) recruitment approach, wherein one RA collects the T0/T1 information and randomizes the patient to a study arm; and a second RA collects the T2-T4 data, remaining a blinded assessor of the primary outcomes of interest. Further, all other research personnel, including the data manager, statistician, and study investigators will be blinded to the participant's treatment group to minimize the potential for bias in the analysis.|Randomization tables will be generated with SAS v9.4 and will be stratified by recruitment site. The randomization tables will be uploaded into REDCap's randomization module by the data manager. RAs will not be allowed access to these randomization tables to ensure that the data collection remains unbiased.|f|f|t|t
34176062|NCT05296473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176063|NCT04377971|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34176064|NCT00581438|||CASE_ONLY||RETROSPECTIVE|||||||
34176065|NCT06477055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176066|NCT06122688|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||In each county, 10 sites will participate (10 high schools in Los Angeles and 10 Primary Care Clinics in Riverside), with sites randomized to cross over from control to intervention status in a step wedged design each Fall following the beginning of the school year. Three months is allowed for training and setup at each site prior to intervention delivery.||||
34176067|NCT04909307|||COHORT||PROSPECTIVE|||||||
34176068|NCT06091241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The principal investigator will be unblinded. The study coordinator will be blinded, unable to access procedure notes and randomization assignment||t|f|f|t
34176069|NCT06589921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34176070|NCT05795049|||CASE_CONTROL||PROSPECTIVE|||||||
34176071|NCT01903356|||OTHER||PROSPECTIVE|||||||
34176072|NCT04090203|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective open label phase I||||
34176073|NCT06472284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176074|NCT04907058|NA|SEQUENTIAL||TREATMENT||NONE||||||
34176075|NCT04533919|||CASE_ONLY||CROSS_SECTIONAL|||||||
34176076|NCT05872308|||COHORT||PROSPECTIVE|||||||
34176077|NCT03526133|||COHORT||PROSPECTIVE|||||||
34176078|NCT06147986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176079|NCT04504734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo controlled||t|t|t|t
34176080|NCT04584424|||COHORT||PROSPECTIVE|||||||
34176081|NCT06569368|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176082|NCT06601283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176083|NCT06596863|||CASE_CONTROL||RETROSPECTIVE|||||||
34176084|NCT03381690|||CASE_CONTROL||RETROSPECTIVE|||||||
34176085|NCT05547347|||COHORT||PROSPECTIVE|||||||
34176086|NCT04534075|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Capsules that look alike, with dietary fiber or placebo.|Random allocation of patients and blinding of researchers, patients, healthcare professionals and outcome assessors.|t|t|t|t
34176087|NCT05635461|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34176088|NCT06520501|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176089|NCT04337372|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176090|NCT06005467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176091|NCT06600854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176092|NCT03893396|||COHORT||CROSS_SECTIONAL|||||||
34176093|NCT06176118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176094|NCT04991402|||COHORT||PROSPECTIVE|||||||
34176095|NCT03541850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065080|NCT01466517|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34176096|NCT06206447|||COHORT||PROSPECTIVE|||||||
33863462|NCT05837182|||CASE_ONLY||PROSPECTIVE|||||||
33962834|NCT04348344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962835|NCT00504127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962836|NCT01132001|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065081|NCT04505618|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34065082|NCT05846113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065083|NCT03000530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962837|NCT05322421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study is designed as a parallel randomized control clinical trial|t|f|f|f
33962838|NCT00400426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962839|NCT04419077|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|"44 patients for the cohort  chemotherapy  and 22 patients for the cohort  invasive act ."|||||
33962840|NCT01003548|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33962841|NCT04877561|||COHORT||PROSPECTIVE|||||||
33962842|NCT00689208|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33962843|NCT03065452|||COHORT||PROSPECTIVE|||||||
33962844|NCT03679845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962845|NCT03907475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962846|NCT01677169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962847|NCT04839315|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962848|NCT04973839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962849|NCT03402165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962850|NCT04948385|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962851|NCT02996617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962852|NCT03361917|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33962853|NCT06506097|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled (pre-post) clinical trial||||
33962854|NCT01185639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962855|NCT03516838|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|During treatment, the type of filling material was concealed from the patient, and the patient had no information which material was used in each side of the mouth. The type of material was not mentioned in the patient's file. Instead, it was replaced by a combination which the outcomes assessors were not familiar with. The operator was also blinded for the type of restoration during tooth preparation and was informed only at the time of restoration placement. The purpose of this discretion was to ensure double blinding both at the patient, as well as the outcomes assessor level.|"Experimental prospective double blinded split-mouth randomized controlled trial .~Each patient receive both types of treatment in the oral cavity, one type of the treatment on each side.~The patients act as their control"|t|f|f|t
33962856|NCT04243499|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to a dose level of ICT01 at the time of their enrollment||||
33962857|NCT04662684|RANDOMIZED|PARALLEL||PREVENTION||NONE|open-label|This study aims to evaluate the safety and efficacy of rivaroxaban 10 mg OD for 35+/-4 days versus no intervention after hospital discharge in COVID-19 patients who were at increased risk for VTE and have received standard parenteral VTE prophylaxis during hospitalization, with a composite efficacy endpoint of symptomatic VTE, VTE-related death, and/or VTE detected by mandatory bilateral lower limbs venous duplex scan and computed tomography pulmonary angiogram on day 35+/-4 post-hospital discharge.||||
33962858|NCT04860726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962859|NCT02055183|||CASE_ONLY||PROSPECTIVE|||||||
33962860|NCT06529458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065084|NCT00938587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065085|NCT03482895|||COHORT||CROSS_SECTIONAL|||||||
34065086|NCT05612464|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065087|NCT06534827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065088|NCT03241433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863463|NCT05017753|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is a pragmatic controlled, randomized, multicenter open label trial with including patients admitted with pleural effusion related to systolic heart failure. Patients will be randomized 1:1 to standard-of-care medical treatment only or standard-of-care medical treatment and referral to thoracentesis. Randomization will be stratified according to whether patients are treated with oral anticoagulation.||||
33863464|NCT03769766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||placebo/active Curcumin|t|f|t|f
33863465|NCT06735170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two armed study with each arm receiving one of two interventions: biologic tuberoplasty procedure or subacromial balloon spacer|f|f|f|t
33863466|NCT06476314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel assignment experimental model using randomized pretest and posttest with control group||||
33863467|NCT06736561|||COHORT||OTHER|||||||
33863468|NCT05424757|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33863469|NCT04486157|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33863470|NCT05121662|||CASE_ONLY||PROSPECTIVE|||||||
33863471|NCT04961996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863472|NCT06735053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863473|NCT06548360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33863474|NCT04047797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863475|NCT04192435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matched TxA and placebo vials|double-blind, placebo-controlled, randomised trial of TxA versus placebo|t|t|t|t
33863476|NCT03715088|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863477|NCT06736132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised controlled trial|t|t|f|f
33863478|NCT05314764|NA|SINGLE_GROUP||OTHER||NONE||Open-label, descriptive, pharmacokinetic study||||
33863479|NCT06679413|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||In this single arm study the participants will receive a single dose of the cocktail of probe drugs at the first pre-specified timepoint followed by a washout and repeated oral doses of ZX008 and a single dose of the cocktail of probe drugs at the second pre-specified time point.||||
33863480|NCT05393713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863481|NCT06046586|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34176097|NCT03864783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The supplier of Meriva® and placebo capsules (Indena® Aps, Milan, Italy) sends the tablets to the research department. After packaging of tablets in bags with tablets for 42 days (+7 extra tablets) and labelling of bags with a bag number, a person not otherwise involved in the study will generate a list with a randomization number and a bag number using a random list generator. When an investigator enrols a participant in the study, the participant is assigned with a randomization number (in consecutive order), and the corresponding bag number will be handed to the participant. An emergency code will be kept at Gentofte Hospital. If a subject develops adverse events (AEs) that demand knowledge of the content of the intervention, the code may be broken."|At the end of the randomization visit, the patients will randomly be assigned to one of two interventions: 6 weeks of Meriva® (two capsules of 500 mg (corresponding to 200 mg curcumin) twice daily) or identically looking placebo (two capsules twice daily). There will be a stratification with respect to HbA1c, ensuring that if we include people with HbA1c ≥ 48 mmol/mol, they will be equally distributed in the two treatment arms.|t|t|t|t
34176098|NCT05165667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176099|NCT05099809|||COHORT||PROSPECTIVE|||||||
34176100|NCT00759590|||COHORT||PROSPECTIVE|||||||
34176101|NCT04175613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176102|NCT03306914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34176103|NCT01540279|||COHORT||PROSPECTIVE|||||||
34176104|NCT01262417|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176105|NCT04207996|||CASE_ONLY||PROSPECTIVE|||||||
34176106|NCT06650514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176107|NCT06612944|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34176108|NCT03659188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176109|NCT03626454|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"An anesthesia resident who will not be involved with the conduct of the study will prepare and label the drug in the syringes according to the randomization codes.~An investigator who will not be involved in subsequent patient care or assessment will open the topmost of 300 opaque sequentially numbered envelopes. One 50 ml and one 10 ml will be labeled as study drug and the 50 ml syringe will be connected to a syringe infusion pump. These two study drug syringes will be a part of double dummy technique to facilitate blindness. In group B, 50 ml syringe will contain saline, and 10 ml syringe will contain norepinephrine (.6 µg/ml). In group I, 50 ml syringe will contain norepinephrine (6 µg/ml) with, and 10 ml syringe will contain saline. Participant in both groups will receive bolus from 10 ml syringe over 30 seconds and infusion dose of 1 ml/kg/h simultaneously to expedite blinding."||t|t|t|f
34176110|NCT04267120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176111|NCT04386317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176112|NCT02432443|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176113|NCT05172128|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176114|NCT06318741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176115|NCT05052268|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176116|NCT06511791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|t|f|f
34176117|NCT05295849|NA|SINGLE_GROUP||OTHER||NONE||single-arm usability pilot||||
33863482|NCT06735066|||COHORT||PROSPECTIVE|||||||
33863483|NCT06226285|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863484|NCT00450658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863485|NCT05285683|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33863486|NCT05794906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863487|NCT06375733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863488|NCT03914742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase 1: BGB-290 in combination with TMZ in patients w/ IDH1/2-mutant WHO grade II-IV recurrent glioma: Phase 2: Grade II-III patients in will be stratified into 2 arms based on the timing of prior alkylator chemotherapy exposure; a third arm will include the subset of glioblastoma (grade IV) patients||||
33863489|NCT00298168|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33863490|NCT06736249|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863491|NCT03704350|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863492|NCT04408014|||OTHER||CROSS_SECTIONAL|||||||
33863493|NCT05315947|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33863494|NCT06734260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863495|NCT06686394|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33962861|NCT04200339|||COHORT||CROSS_SECTIONAL|||||||
33962862|NCT00614458|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33962863|NCT01472315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962864|NCT03958071|||COHORT||RETROSPECTIVE|||||||
33863496|NCT05908344|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|"This study is a double-blind trial, in which bedside controllers for Sleep Pad systems are coded and either activated or deactivated (sham/control) by the manufacturer prior to receipt for use in the research. A deactivated Sleep Pad bedside controller retains all functionality (and evidence of functionality) of an activated bedside controller Sleep Pad, excepting the stimulation. The blind is maintained by a designated study team member who will have access to the list linking device code IDs to their relative active/sham group, and who does not have interaction with study participants. This blind will be lifted if relevant for safety reasons in cases of serious adverse event on a participant case-by-case basis, and on the whole for other researchers after completion of the entire trial for interpretation of analyses."|All participants in this study will experience all study conditions (i.e. a sham (Control) and an active (Intervention) Sleep Pad bedside controller device) in a randomized crossover design.|t|f|t|t
33863497|NCT06138782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863498|NCT06736158|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863499|NCT03691935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863500|NCT04640298|NA|SINGLE_GROUP||TREATMENT||NONE||CINGAL||||
33863501|NCT00041054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863502|NCT05873569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863503|NCT02338011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863504|NCT06145724|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33863505|NCT05553366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863506|NCT02113852|||OTHER||OTHER|||||||
33863507|NCT05728502|||COHORT||OTHER|||||||
33863508|NCT06718907|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863509|NCT06675565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863510|NCT06735261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, single-center, randomized, open-label study,|f|f|f|t
33863511|NCT06734741|||COHORT||PROSPECTIVE|||||||
33863512|NCT05001880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863513|NCT01924221|||COHORT||PROSPECTIVE|||||||
33863514|NCT06578156|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863515|NCT05621616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863516|NCT06487858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863517|NCT03399409|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33863518|NCT05702021|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes will be exported from electronic medical records. Data analysts will not know who was receiving the intervention at what time point.|Stepped-wedge trial|f|f|f|t
33863519|NCT06465030|||COHORT||RETROSPECTIVE|||||||
33863520|NCT05267587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863521|NCT05563948|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33863522|NCT06360796|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863523|NCT02887729|||COHORT||PROSPECTIVE|||||||
33863524|NCT05756153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863525|NCT05495971|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will serve as their own control using objective baseline data.||||
33863526|NCT05152927|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only participants will be masked to the intervention||t|f|f|f
33863527|NCT03001128|||COHORT||PROSPECTIVE|||||||
33863528|NCT04274764|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned at a 1:1 ratio to the study intervention.||||
33863529|NCT04109365|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33863530|NCT05753345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863531|NCT05540574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33863532|NCT05978284|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863533|NCT00233363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33863534|NCT05090995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible subjects will be randomized into either the Assessment or Feedback group. Subjects in the assessment group will not receive personalized health feedback or advice on their health behaviors. They will wear a consumer- level PPG device daily and complete electronic diaries about bedtime behavior and sleep from the previous night for six weeks. Subjects in the feedback group will also wear a consumer-level PPG device and complete diaries each morning for six weeks. Subjects in this group will monitor their health behaviors and receive personalized feedback and advice. Subjects will also be able to receive daily information regarding their health behaviors from the PPG device application. At weeks two, four, and six subjects will will receive written reports that summarize their alcohol usage and the links made between their drinking and health outcomes from the PPG application results. Subjects will also receive advice on how to improve health behaviors.|t|f|f|f
33863535|NCT06734780|||COHORT||RETROSPECTIVE|||||||
33863536|NCT02909985|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33863537|NCT06735560|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863538|NCT04711668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33863539|NCT00659893|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34065089|NCT05404633|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065090|NCT05321472|||OTHER||RETROSPECTIVE|||||||
34065091|NCT00300443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065092|NCT01603394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065093|NCT05514743|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34176118|NCT05141383|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"3 cohorts of 118 patients in the aim to have 90 evaluable participants will be included in the study:~* 40 patients with prostate cancer, or~* 40 patients with suspected cancer without confirmation on biopsy, or with hyperplasia of the prostate and~* 38 healthy donors."||||
34176119|NCT04642027|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|2 randomised arms||||
34176120|NCT04908579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34176121|NCT03959423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176122|NCT06410027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176123|NCT04784325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176124|NCT05642728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34176125|NCT04648462|||COHORT||PROSPECTIVE|||||||
34176126|NCT06271408|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34176127|NCT04887116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176128|NCT03662776|||CASE_CROSSOVER||PROSPECTIVE|||||||
33863540|NCT06734494|||COHORT||RETROSPECTIVE|||||||
33863541|NCT05933863|||CASE_CONTROL||RETROSPECTIVE|||||||
33863542|NCT03652259|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863543|NCT03226704|||COHORT||PROSPECTIVE|||||||
33863544|NCT05978180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|"Prospective, multicenter, controlled, single blind, randomized in parallel groups Clinical Investigation.~Subjects will receive one of three viscosupplementations depending on the randomization.~The study includes two periods :~* The first period (26 weeks) : prospective, multicenter, randomized in three parallel groups study, comparing the two forms of Pandora gel (HO-1 and HS-3) to SINOVIAL® ONE. The comparison between HO-1 and SINOVIAL® ONE is realized in single blind and the comparison between HS-3 and SINOVIAL® ONE is realized without masking.~* The second period (26 weeks) is an exploratory, prospective, multicenter phase comparing these same devices without masking."|t|f|f|f
33863545|NCT04202250|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized to the catheter tip configuration as CEMP (closed-ended multiport catheter) group and OESP (open-ended single port catheter) group||||
33863546|NCT03878472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863547|NCT00096057||||TREATMENT||NONE||||||
33863548|NCT05046171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863549|NCT05406752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863550|NCT05431361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized 2:1 (intervention:control)||||
33863551|NCT04447768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863552|NCT01182766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863553|NCT04650724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863554|NCT05076175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863555|NCT06222697|||COHORT||PROSPECTIVE|||||||
33863556|NCT06734676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33863557|NCT04624880|||COHORT||RETROSPECTIVE|||||||
33863558|NCT06519773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Twenty surgical sites will be divided into two groups; each of which has ten surgical sites. Grouping will be done randomly sequentially numbered, opaque, sealed envelopes (SNOSE)||t|f|f|t
33863559|NCT05078619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863560|NCT03412045|NA|SINGLE_GROUP||TREATMENT||NONE||a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be the intervention and used as a treatment drug.||||
33863561|NCT02612051|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34176129|NCT03243695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|due to the nature of the study only the participant could be blinded||t|f|f|f
33863562|NCT05794412|||CASE_ONLY||PROSPECTIVE|||||||
33863563|NCT05200104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962865|NCT06346054|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants with gastro-esophageal cancer, participants with Barrett's esophagus and Healthy controls will be monitored in parallel to identify oncometabolic biomarkers related to cancer||||
33962866|NCT02284295|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33962867|NCT00878137|||CASE_CONTROL||PROSPECTIVE|||||||
33962868|NCT02494310|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962869|NCT01351727|||CASE_ONLY||PROSPECTIVE|||||||
34176130|NCT06323291|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176131|NCT02657096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34176132|NCT05174247|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34176133|NCT05501236|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All patients who meet eligibility will undergo the screening sleep study, muscle stimulation during operative DISE procedure, and muscle stimulation during second sleep study.||||
34176134|NCT00783159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176135|NCT05945121|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176136|NCT05747443|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176137|NCT01414868|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176138|NCT03450161|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|Only an otherwise uninvolved anesthesiologist will know dosing schemes.|randomized, double-blinded, three arm study|t|t|t|t
34176139|NCT05880979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be told in the consent form that they may receive information about dating violence during their well-visit or they may not. They will not be specifically told if their provider is the intervention provider or control provider.|Randomization will occur at the provider-level|t|f|f|f
34176140|NCT05064150|||COHORT||PROSPECTIVE|||||||
34176141|NCT05804188|||COHORT||PROSPECTIVE|||||||
33962870|NCT05160727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863564|NCT06736197|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The study was performed in 200 patients planned for general anaesthesia for elective surgery, aged 18-65 years, ASA 1-2 physical status, without premedication and ETO2 \<90% at the end of the 3rd minute with spontaneous TVB of 100% oxygen. The patients were randomly assigned to one of two groups (Group TVB and Group PSV) according to a computer-generated randomisation table. In the patients included in Group TVB, the tidal volume breathing was maintained for a further two minutes. Group PSV received inspiratory pressure support of 6 cm H2O for +1 min. At the end of four minutes, patients whose ETO₂ value had not reached a minimum of 90% were randomly divided once more into two groups. One group continued with PSV, while the other was administered 4 cm H₂O PEEP in addition to PSV (Group PSV+PEEP).||||
33863565|NCT06618859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863566|NCT06736509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863567|NCT06318897|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863568|NCT02954939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863569|NCT03531788|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to trial a dynamic arm support (Armon Ayura (Kinova) or JAECO WREX)||||
33863570|NCT06735482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor is blinded for the assessed children's allocation in groups. in both preprogram and postprogram assessments.|Quasi experimental|f|f|f|t
33863571|NCT01134835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863572|NCT03666000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863573|NCT04849741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065094|NCT01134289|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34065095|NCT01713894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176142|NCT03297047|RANDOMIZED|PARALLEL||TREATMENT||NONE||one Group with upper arm cast one Group with forearm cast||||
34176143|NCT06690359|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176144|NCT00300417||||TREATMENT||||||||
34176145|NCT06038409|||COHORT||CROSS_SECTIONAL|||||||
34176146|NCT00611936|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34176147|NCT01768715|||CASE_CONTROL||PROSPECTIVE|||||||
34176148|NCT04413500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176149|NCT03164616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176150|NCT04993885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176151|NCT02187848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176152|NCT06459817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176153|NCT03484130|||COHORT||PROSPECTIVE|||||||
34176154|NCT05501873|||COHORT||PROSPECTIVE|||||||
34176155|NCT05468814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study, in which both the patient and the evaluating staff are unaware of the surgical technique used (both surgeons will perform both techniques). A traumatologist will analyze (before and after surgery) the clinic, strength and satisfaction of the patients.|Patients will be randomly assigned to one of two treatment groups in a 1:1 ratio, using a computer-generated random assignment list|t|t|f|f
34176156|NCT05504070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176157|NCT06306599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||20 participants scan five patients over the course of fours hour and collect their diagnostics analyses on paper forms.||||
34176158|NCT05650606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176159|NCT03630354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34176160|NCT05124925|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open label study (with no control arm) with a 5 weeks screening period, a 6-month treatment period and a follow up period of up to 2 years after the last dose The study consists of a first Run-in Phase that includes Screening and Baseline period of 35 days. After signing the Informed Consent, participants will be assessed as per inclusion/exclusion criteria. All study participants who successfully pass the screening will be considered eligible for the treatment period.~All eligible participants will enter the 6 months treatment period and will have the two other biopsies taken at the end of treatment (6 months after the screening) and end of the study (EOS) after blood B cell recovery (from 5 months up to 2 years after the last dose)."||||
34176161|NCT00392327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176162|NCT02403505|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Open Label|"* Single Usage~* Single Dosage"||||
34176163|NCT05605574|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176164|NCT06477211|||COHORT||RETROSPECTIVE|||||||
34176165|NCT03596502|||COHORT||RETROSPECTIVE|||||||
34176166|NCT06548230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176167|NCT06541990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176168|NCT03397966|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The participant and study investigators will be blinded as to which infusion the participant is receiving at which visit. Also, the individuals analyzing the energy expenditure and fat gene expression will be blinded.|In this cross-over study, each subject will receive BNP infusion at one visit and placebo (control) at the other visit, in random order. The sequence of the treatments will be randomized. There will be a washout period (at least 14 days) between visits.|t|f|t|t
34176169|NCT03016156|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34176170|NCT05720182|NA|SINGLE_GROUP||OTHER||NONE|No true masking possible, as the study only uses healthy participants and all participants will get measurements to both legs.|A performance validation pilot of the CPMX1 device in healthy volunteers. There will only be one study arm, no comparator, and no randomization.||||
34176171|NCT06134180|NA|SINGLE_GROUP||OTHER||NONE||||||
34176172|NCT04170153|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-Label||||
34176173|NCT06704230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176174|NCT03697304|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176175|NCT04390529|||COHORT||PROSPECTIVE|||||||
34176176|NCT04609956|RANDOMIZED|PARALLEL||OTHER||NONE||This study is a monocentric interventional prospective comparative randomized study||||
34176177|NCT06704711|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||double-blind, randomized, placebo-controlled crossover trial design|t|f|f|f
34176178|NCT00492999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065096|NCT01540084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176179|NCT06704178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The study is double-blind; participants, care providers, investigators, and outcomes assessors are all masked to the allocation of intervention or placebo.|A randomized, double-blind, placebo-controlled, two-arm trial.|t|t|t|t
33863574|NCT05770375|NA|SINGLE_GROUP||TREATMENT||NONE||Ascending-dose tolerability study||||
33863575|NCT03446391|||CASE_CONTROL||OTHER|||||||
33863576|NCT05661578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863577|NCT02321826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863578|NCT03909815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863579|NCT02595931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863580|NCT04509960|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33863581|NCT01563185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863582|NCT02826447|||COHORT||PROSPECTIVE|||||||
33863583|NCT05828082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962871|NCT01395693|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33962872|NCT03969784|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962873|NCT00003290|RANDOMIZED|||TREATMENT||||||||
33962874|NCT02551302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962875|NCT02038959|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33962876|NCT04234152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The primary outcome is the concentration of peroxides in the urine. The urine samples will not indicate the arm of the study.||f|f|f|t
33962877|NCT04064528|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Young (21-30 years old) and older (60-75 years) adults will each receive an oral bolus of 10 g of essential amino acids.||||
34176180|NCT01969344|||COHORT||PROSPECTIVE|||||||
33962878|NCT01409018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962879|NCT01077531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962880|NCT03174509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The pre and post extubation parameters are recorded by an outcome assessor who do not know the assigned extubation method.~The assigned extubation method is coded to minimize potential bias during data analysis."|Non-inferiority trial|f|f|t|t
33962881|NCT00063596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34176181|NCT06704984|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intervention Group: Intervention based on the IMB model through WeChat official account~Control Group: No intervention, maintaining normal life and study status"||||
34176182|NCT00497614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176183|NCT04678895|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Investigational Pharmacy will perform the randomization process and remain unblinded throughout the study.|Randomized, double-blind, placebo-controlled, crossover trial.|t|f|t|f
34176184|NCT03821896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An external party (Women and Children's Health Research Institute, University of Alberta) will run data analysis for the study.||f|f|f|t
34176185|NCT06513910|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will be screened, consented, and enrolled in dyads.||||
34176186|NCT04408313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863584|NCT04269005|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Hospital employees who will assign patients to the wards and clusters are blinded to randomization. Blinding of staff involved in the recruitment process is limited as phase 1 and phase 2 will consist of different study information and consent sheets. Trained staff will perform the follow-up assessment, and we intend to blind them regarding study phase allocation of the patients (if procedural aspects allow it).||f|f|f|t
33863585|NCT02649153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863586|NCT03387475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863587|NCT06734637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962882|NCT02464085|||COHORT||PROSPECTIVE|||||||
33962883|NCT01523769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962884|NCT05402319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There will be 150 patients involve in the study. The investigators have prepared 150 paper balls with numbers for the lottery. If the patient meets the inclusion criteria, the patient will be allowed to read the written instructions for invitation to participate in the study. The doctors and nurses will answer questions from patients. A signature is required if the patient agrees to participate in the study. The patient will then be allowed to draw a ball of paper, and the nurse or doctor will register the corresponding number in the computer. Patients 1-50 will be the first group, 51-100 the second group, and 101-150 the third group.|The patients will be divided randomly into 3 individual groups: (1) systemic antibiotic monotherapy; (2) systemic antibiotic combination therapy; and (3) bladder antibiotic lavage (topical therapy).|f|t|t|t
33962885|NCT02006407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962886|NCT03989180|||COHORT||PROSPECTIVE|||||||
34065097|NCT01476306|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065098|NCT05206786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065099|NCT01860118|||COHORT||PROSPECTIVE|||||||
34065100|NCT05194852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participants and outcome assessor didn't know the group classification||t|f|f|t
34065101|NCT01170819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065102|NCT06066255|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34065103|NCT00239499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34176187|NCT02743208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176188|NCT03670680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176189|NCT05678608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176190|NCT05656534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34176191|NCT02537977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863588|NCT05393401|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"The Primary Purpose of this clinical trial is to test a prototype device for feasibility and not health outcomes. This study is conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. Primary Purpose is therefore Device Feasibility"||||
33863589|NCT02632760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863590|NCT05539833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863591|NCT05964998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants randomized to either active tDCS stimulation or sham.|t|t|t|t
33863592|NCT02146560|||COHORT||PROSPECTIVE|||||||
33962887|NCT05721716|RANDOMIZED|PARALLEL||TREATMENT||NONE|Assessment of outcome will be by self-report measures administered by an online survey. Therefore, assessment of outcome will be masked from the researchers, but not the participants themselves.|||||
34176192|NCT06542029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a parallel-arm non-randomized controlled clinical trial. The participants are assigned to the different intervention arms based on their preference (the students can sign up for an intervention of their choosing).||||
34176193|NCT03388346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176194|NCT02432703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176195|NCT01112826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176196|NCT05614531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176197|NCT05442749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176198|NCT05471076|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Whether a participant receives a bolus dose or fractionated dose will be known, but randomization will occur within a given arm and both participants and clinicians will be blinded within a given arm.||t|f|t|f
34176199|NCT01243164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34176200|NCT04916990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176201|NCT05844501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176202|NCT05661682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34176203|NCT05774353|NA|SINGLE_GROUP||OTHER||NONE||||||
34176204|NCT00907595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176205|NCT05720897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176206|NCT01769742|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176207|NCT06206317|||CASE_CONTROL||PROSPECTIVE|||||||
34176208|NCT00785759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176209|NCT06599996|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34176210|NCT00057200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176211|NCT06409169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176212|NCT06433999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176213|NCT02516696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176214|NCT01151917|||CASE_ONLY||PROSPECTIVE|||||||
34176215|NCT01808755|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34176216|NCT03021200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176217|NCT06593535|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Ten young healthy physically active male college students. Participants were crossed over for AST or placebo supplements, which was completed in four days. Between the crossover trials, participants had a one-week washout period to nullify the effects of the supplement|t|t|t|t
34176218|NCT06602336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176219|NCT05571137|||COHORT||RETROSPECTIVE|||||||
34176220|NCT06705010|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE||"2H-MRSI and 1H-MRSI pulse sequences will be developed and protocols optimized in vitro.~Suitable MR-protocols will be further optimized in vivo.~These DMI-MRSI protocols will be applied after 1H/2H-glucose supplementation:~1. in a group of 20 healthy persons younger that 40 years old after deuterated glucose intake~2. in a group of 20 healthy person elder 40 years old after deuterated glucose intake~3. in a group of 10 young healthy persons to measure task based functional 2H-MRSI response.~4. in a group of 10 Alzheimer's disease patients after deuterated glucose intake~5. in a group of 10 mild cognitive impairment patients after deuterated glucose intake~6. in a group of 10 diabetes mellitus patients after deuterated glucose intake~7. in a group of 10 high grade carotid stenosis patients after alpha-D-glucose intake"|f|f|f|t
34176221|NCT06041737|||COHORT||RETROSPECTIVE|||||||
34176222|NCT05532150|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either the physical therapy (conservative) group or the operative (surgery) group if they agree to participate in the study.||||
34176223|NCT06446882|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176224|NCT04644224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176225|NCT05264857|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34176226|NCT03009058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176227|NCT06465589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators will not know which specific condition the participants were in for the initial analysis. The blind will be broken for the investigators after first interpretation of the results.|The study is a single-center partially randomized patient preference trial with four conditions (program version: standard vs. anonymous and allocation: randomized vs. preferred)|f|f|t|f
34176228|NCT05308537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176229|NCT05575453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176230|NCT05900986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176231|NCT00521079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176232|NCT06108414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176233|NCT06271512|||COHORT||PROSPECTIVE|||||||
34176234|NCT05387278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176235|NCT06018337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176236|NCT06577363|||COHORT||PROSPECTIVE|||||||
33863593|NCT06601842|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863594|NCT06181461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863595|NCT06069206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will be performed as a pragmatic, randomized controlled clinical trial with parallel group assignment.||||
33863596|NCT01287364|RANDOMIZED|CROSSOVER||||NONE||||||
33863597|NCT06294769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33962888|NCT05013255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176237|NCT05545930|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Subjects will be blinded to the order of intervention.||t|f|f|f
33863598|NCT04858854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a multicentre randomized double-blinded controlled trial lasting 20 weeks with two study periods. The first 12 weeks will constitute a treatment period with BSE (BSE group) or placebo (Control group) depending on the randomization of the group allocation. After that, patients from both groups will be followed for another eigth weeks, called post-study observational period.|t|t|t|f
34065104|NCT06465069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863599|NCT04160052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863600|NCT05339087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled trial|t|f|t|f
33863601|NCT02199600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863602|NCT06734546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33863603|NCT06735430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863604|NCT05264974|NA|SEQUENTIAL||TREATMENT||NONE||||||
33863605|NCT05484882|||COHORT||PROSPECTIVE|||||||
33863606|NCT03235622|||COHORT||RETROSPECTIVE|||||||
34065105|NCT01922154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065106|NCT03539185|RANDOMIZED|PARALLEL||OTHER||NONE||Non-inferiority trial. Alpha risk de 2,5%, Power 90 %||||
34065107|NCT02687295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34065108|NCT03882957|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||This is a within-subject design where each participant is randomly assigned to all three arms.|t|f|f|f
34065109|NCT01966302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150644|NCT03820960|||CASE_CONTROL||RETROSPECTIVE|||||||
34150645|NCT03094390|||COHORT||PROSPECTIVE|||||||
33863607|NCT06704932|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a Sponsor unblinded study. For dose escalation decisions, the Sponsor study team (except blinded Clinical Research Associate who is in close contact with the site) will have access to unblinded data. However, when interacting with the site staff (including during dose escalation meetings), all data will be presented in a blinded manner in order to protect the blind towards the Investigator.||t|f|t|f
34150646|NCT02532985|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34150647|NCT00506168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150648|NCT05674110|NA|SINGLE_GROUP||OTHER||NONE||||||
34150649|NCT01610986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34150650|NCT00498121|||||PROSPECTIVE|||||||
34150651|NCT00521222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150652|NCT00383396|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34150653|NCT03882645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of dietary intervention, it is impractical to blind the cook, dietitian and the study staff who are responsible for preparing the foods and taking all measurements of the diets. However, staffs conducting the outcome assessments will be blinded to the allocation of intervention assignments. In addition, every effort is made to blind the study participants to their intervention assignment. First, they will not be told of their group assignment. Second, the two groups will consume their meals in separate rooms. Third, the same dishes using similar food materials will be used for both groups at the same meal.|Multi-center, randomized, single-blind, parallel controlled intervention is proposed in this study. 360 subjects are anticipated to be enrolled from each research centers (Qingdao and Beijing, Shanghai, Guangzhou, Chengdu). After the one-week run-in period baseline information of eligible participants will be collected. Then the subjects will be allocated to intervention group or control group through central randomization. Subjects in intervention group will be given free CHH-Diet for four weeks, while the subjects in the control group will be given free usual diet conforming to local characteristics for four week.|t|f|f|t
34150654|NCT02208349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150655|NCT03726931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In this multicenter observational study with invasive measurements, patients with clinically ER+/HER2- LABC and LRR breast cancer will be included. All patients will undergo the current 'standard' diagnostic procedures including a histological biopsy of the primary tumor, cytology of axillary lymph nodes and imaging procedures with mammography, ultrasound of breast and axilla, magnetic resonance imaging (MRI) breast and whole body \[18F\]FDG PET combined with diagnostic chest/abdominal CT. In addition, all patients will undergo the 'experimental' imaging procedure with \[18F\]FES PET/CT. After evaluation of the obtained scans (independently for both scans), an 'experimental histological biopsy' of a lymph node metastasis will be obtained and clinically relevant \[18F\]FDG+ and/or \[18F\]FES+ lesions and/or suspicious lesions on CT will be biopsied according to standard clinical practice for pathological analyses.||||
34150656|NCT02390180|||||CROSS_SECTIONAL|||||||
34150657|NCT02726945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150658|NCT05257707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150659|NCT05614921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150660|NCT01266317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150661|NCT03346967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||30 patients with sexual hormone deficiency will be injected AD-MSCs||||
34150662|NCT04478578|||CASE_ONLY||PROSPECTIVE|||||||
34150663|NCT04496024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150664|NCT05203159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34150665|NCT04294446|||COHORT||PROSPECTIVE|||||||
34150666|NCT01581619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150667|NCT04907045|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized parallel groups pilot study to evaluate intervention delivery, data collection, and analysis procedures. Two primary care clinics will implement the reSET and reSET-O digital therapeutics for substance use disorders. There will be one clinic per arm in this pilot study. Implementation strategies will be varied across arms.||||
34150668|NCT05423392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients were randomly and equally assigned to treatment groups. The study was planned as a double-blind. Thus, neither the patients nor the researchers knew which anesthetic will be applied. Only practioner, who will injected anesthetic will know what tipe of anesthetic is it - 4% articain or 2% lidocain chlorid. Number of participials is 60, divided into two equal groups.|A RANDOMIZED DOUBLE BLIND|t|t|t|t
34150669|NCT03693911|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking was carried out|Comparison between AcceptME and waitlist control group||||
33863608|NCT04115826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator interpreting final stone clearance pancreatograms will be blinded to the intervention received.||f|f|f|t
33863609|NCT03633708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863610|NCT01974388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863611|NCT04130503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized to usual care or PAP- acute and subacute patients will receive different PAP treatments (non-randomized).|f|f|t|t
33863612|NCT05754073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All subjects and all study staff except the pharmacist will be blinded to treatment assignment.||t|f|t|f
33863613|NCT03769064|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind, randomized|The study will consist of a 2-period crossover Qualification Phase (Part 1) to ensure subject eligibility for the treatment phase of the study, and a 4-period crossover Treatment Phase (Part 2) to determine the effect of concomitant administration of MPH and NTX on subjective pharmacodynamic (PD) measures of abuse, relative to MPH and placebo.|t|t|t|f
33863614|NCT04782388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33863615|NCT05100706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized to one of the two groups using a computer-generated random numbers table. The randomization will be done before the beginning of the study and will define which study number is going to be managed as interventional group (continuous adductor canal block - CACB) or control group (sham continuous adductor canal block - ShACB). Each patient will receive a study number following the order of their entrance on the study. The elastomeric pumps to be used connected to the catheter will be previously prepared by hospital pharmacy, accordingly to the randomization made and the subject study number, with no identification of the content (NaCl 0.9% or Ropivacaine 0.2%). Hospital pharmacy will not be blinded for which study number and elastomeric pump will be linked to the study group. Research coordinator, professional who performs the adductor canal catheter insertion and researcher who collects the data will be blinded to which group each patient was randomized.|Randomized controlled prospective trial, blinded for patient and evaluator, in patients undergoing outpatient primary TKA at Sinai Health.|t|t|t|t
33863616|NCT05622812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Investigator blinding will be accomplished by having a Treating Investigator administer the treatments and having a Blinded Evaluator, to whom randomization and treatment are concealed, conduct blinded assessments.~Investigator blinding will be accomplished by having a Treating Investigator administer the treatments and having a Blinded Evaluator, to whom randomization and treatment are concealed, conduct blinded assessments. Safety assessments will be performed by non-blinded personnel."|"A prospective, randomized, evaluator-blinded, no treatment controlled, parallel group, multicenter phase IV study to evaluate effectiveness and safety of Restylane Lyft Lidocaine for jawline definition.~A parallel study: two or more groups of participants receive different interventions. Trial participants are assigned to one of the treatment arms at the beginning of the trial and remain in that trial arm throughout the length of the trial. A randomized group is usually assigned."|f|f|f|t
33863617|NCT06725225|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A symptom cluster care intervention plan is being developed, and a research team is formed. Based on relevant literature and qualitative interviews, and guided by symptom management theory and the Knowledge-Attitude-Practice (KAP) behavior model, an initial draft of the care intervention plan is created and refined through expert consultation to finalize the plan.||||
33863618|NCT06735144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863619|NCT05927922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The study will be a double-blinded randomized controlled trial where the patient \& operator will not be aware of the intervention used.~-the treatment groups will be anonymous to the assessing statistician at the end of the trial."||t|t|f|t
33863620|NCT05777720|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33863621|NCT00376181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150670|NCT03329261|RANDOMIZED|PARALLEL||TREATMENT||NONE||A comparative, interventional, multicenter, randomized, prospective, two-arm study with monotherapy in two different doses||||
34150671|NCT03001778|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150672|NCT01274910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150673|NCT03874390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150674|NCT00668538|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34150675|NCT05200689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150676|NCT04619355|||COHORT||PROSPECTIVE|||||||
34150677|NCT00037154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150678|NCT02974894|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150679|NCT00880646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34150680|NCT02648672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150681|NCT01665534|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34150682|NCT06287307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34150683|NCT02047097|||COHORT||PROSPECTIVE|||||||
34150684|NCT02206880|||OTHER||PROSPECTIVE|||||||
34150685|NCT05319119|||OTHER||RETROSPECTIVE|||||||
34150686|NCT03327064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150687|NCT00348647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34150688|NCT03582696|NA|SINGLE_GROUP||PREVENTION||NONE||The participants who are engaged with CHWs will be assessed in terms of weight and blood pressure compared to pre-intervention levels and will also complete pre and post dietary and physical activity questionnaires.||||
34150689|NCT02345096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34150690|NCT04229355|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded about patients' allocation.||f|f|f|t
34150691|NCT01329913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150692|NCT05583032|||COHORT||PROSPECTIVE|||||||
34150693|NCT02552160|||CASE_CONTROL||OTHER|||||||
34150694|NCT04350307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization was done separately for each provider based on a computer generated algorithm. Patients were blinded to the gauge of the needle used for the procedure.|This was a prospective single blind randomized clinical trial.|t|f|f|f
34150695|NCT04382872|||COHORT||PROSPECTIVE|||||||
34150696|NCT00001978|||COHORT||PROSPECTIVE|||||||
33863622|NCT05012982|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33863623|NCT05477953|||COHORT||PROSPECTIVE|||||||
33863624|NCT00314678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863625|NCT03745924|||COHORT||PROSPECTIVE|||||||
33863626|NCT03148678|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||A combination of sequential (mindfulness vs. mind wandering intervention) and parallel design (contingent vs. non-contingent RT-fMRI-NF)|t|f|f|t
33863627|NCT03695315|||CASE_ONLY||PROSPECTIVE|||||||
33863628|NCT02803853|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33863629|NCT00331123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863630|NCT01701674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863631|NCT04565041|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863632|NCT06736457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863633|NCT06291285|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33863634|NCT05758545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Permuted block randomization will be applied to generate randomization codes using a mix of blocks of size 2 and 4. Randomization will be stratified by site and age (\<65 years, ≥65 years). Both the COMS One device and the Sham device will be prepared to appear to be identical to the subject to achieve the double-blind purposes and each device will be given a unique serial identifier.~To avoid assessment bias, each site will have an Inter-observer (blinded assessor) who will be blinded to treatment and perform and document all assessments of the target DFU evolution. Following target DFU assessment, the treatment will be performed by another assigned clinician, who will not have any involvement with the Inter-observer. Furthermore, both parties will be instructed not to discuss target DFU evolution or treatment with each other. This will provide an adequate level of masking to ensure that the trial is double-blinded."|"The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device through 24 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.~Following randomization, subjects will be assigned treatment with either COMS One device or the Sham device in conjunction with SOC. At least 50% of subjects are required to be 65 years or older at randomization.~Prospective, randomized, double-blinded, placebo-controlled trials provide the most objective methods for analyzing the outcomes of multiple treatment groups. The blinded use of a sham device allows for a true comparison of COMS One treatment in conjunction with SOC to SOC alone."|t|f|t|f
33863635|NCT06730438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind Sham-Controlled Study|t|t|t|t
33863636|NCT06691165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863637|NCT05476068|||OTHER||OTHER|||||||
33863638|NCT06734767|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Course participants are offered to enroll anonymously in this survey study and are unaware of the who the study results reviewers will be.|Medical practitioners who choose to register for a free mindfulness course are evaluated for improvements in their ability to manage stress and mitigate burnout.|t|f|t|t
33863639|NCT06734065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863640|NCT02673606|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double blind placebo control study||t|f|t|f
33863641|NCT06664879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863642|NCT04539366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863643|NCT04144907|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863644|NCT06735183|||OTHER||PROSPECTIVE|||||||
33863645|NCT06072482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863646|NCT04662619|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33863647|NCT05533775|NA|PARALLEL||TREATMENT||NONE||||||
33863648|NCT04354090|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33863649|NCT05433168|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Monocentric randomized controlled cross-over trial with allocation of patients according to a ratio (1:1)|t|f|t|f
33863650|NCT01360879|||||PROSPECTIVE|||||||
33863651|NCT01842386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863652|NCT05932342|NA|SINGLE_GROUP||OTHER||NONE||The intervention will be provided over 3 iterative group of 6 participants each||||
33863653|NCT05479890|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863654|NCT06002750|||OTHER||PROSPECTIVE|||||||
33863655|NCT05215132|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||If a research MRI is combined with a clinically ordered MRI, the research scan will add about 15 minutes to the clinical MRI procedure. If a research MRI is conducted during a separate visit, it is expected that the research-only MRI visit will last about 1-2 hours. An individual may voluntarily participate in the study on multiple occasions.||||
33863656|NCT06467617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863657|NCT04142177|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This is a single-blinded study. The participants, Local Site Investigators (LSIs) and Site Coordinators will have the information on participant treatment assignment. Centralized Outcome Assessors (COAs) who collect primary and secondary outcome measures over the phone will be blinded to treatment assignment. The study team who manage the day-to-day study operations (including Study Chairs, National Study Coordinator, and study team members at Cooperative Studies Program Coordinating Centers \[CSPCC\] and Clinical Research Pharmacy Coordinating Centers \[CRPCC\] may have information on specific individual participant treatment assignment only when the information is needed to perform their work.|sequential randomized, pragmatic, 2-step comparative effectiveness study design|f|f|f|t
33863658|NCT06588504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863659|NCT06735391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Phase 3, randomized, positive-controlled. To evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with previously untreated, locally advanced, or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.|t|f|f|f
33863660|NCT01187849|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33863661|NCT04523350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863662|NCT04179370|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33863663|NCT06734078|||COHORT||RETROSPECTIVE|||||||
33863664|NCT03608267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863665|NCT05993559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863666|NCT05965440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863667|NCT01580033|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33863668|NCT06305780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|In each Appendix trial, each participant will be assigned with equal probability to one of the factorial combinations based on two factors: (1) a study intervention/control and (2) non-pharmacologic intervention/control if the participant is eligible for the study intervention.|t|t|t|f
33863669|NCT00019084||||TREATMENT||||||||
33863670|NCT06074198|NA|SINGLE_GROUP||TREATMENT||NONE|One physical therapist will perform the pre- and post-test assessment measures and another pediatric physical therapist will perform the intervention sessions.|feasibility study||||
33863671|NCT01205438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863672|NCT00000268|NA|SINGLE_GROUP||TREATMENT||||||||
34176238|NCT06590519|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (Participants)|Randomized Controlled Trial (RCT)|t|f|f|f
34176239|NCT03501082|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Crossover design for dietary intervention (non-industrialized-type diet compared to participants' usual diet); parallel design for L. reuteri probiotic (L. reuteri PB-W1, L. reuteri DSM-20016T, and placebo).|t|f|t|f
34176240|NCT04500158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34176241|NCT06264973|||COHORT||PROSPECTIVE|||||||
34176242|NCT06172959|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33863673|NCT03078595|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33863674|NCT02049034|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Placebo to IMP (lixisenatide) or IMP (lixisenatide) to placebo|t|t|t|t
33751424|NCT03215797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751425|NCT02498483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33863675|NCT04323839|||COHORT||PROSPECTIVE|||||||
33863676|NCT06734312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863677|NCT06564844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label, sponsor-blinded|Participants will be randomised in a 2:1:2 ratio to one of the following groups: Arm 1 - Dato-DXd in combination with rilvegostomig, Arm 2 - rilvegostomig monotherapy or Arm 3 - SoC (either observation only or investigator's choice of chemotherapy (ICC)).|f|f|f|t
34176243|NCT06589219|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The majority of this study will be conducted double-blind; treatment assignment will not be known to the subjects, the Sponsor (with exception of an unblinded bioanalytical specialist who will review PK and PD and blind data for presentation to blinded team) and staff involved in the clinical evaluation of the subjects and the analysis of data. The randomization schedule and disclosure envelopes will be generated by an unblinded statistical team. The unblinded statistical team will not be involved in decisions relating to populations for analysis prior to unblinding. Prior to database lock and unblinding, all original randomization materials will be held by the unblinded statistical team. There may be instances where interim data has the potential to reveal treatment. In these cases, every effort will be made by the unblinded bioanalytical specialist to maintain blinding by appropriate presentation of data to the study team.|"Part 1 Cohorts 1-4: double-blind, assess single ascending doses (SAD) of nebulized CMR316. Cohort 5: open label, single dose (at a dose previously determined to be safe) \& incl. lung sample collection via bronchoscopy for PK \& PD.~Part 2: double blind, assess multiple ascending dose (MAD) cohorts of CMR316 administered once weekly for 4 weeks. If further PK/PD data from lung samples is required to determine appropriate RP2D then a sub-group of open-label participants who will undergo bronchoscopies may be enrolled to any or all MAD cohorts.~Parts 1 \&2 are not required to be conducted entirely sequentially if justified by PK \& safety obtained. The first MAD cohort will not start until data are available from SAD Cohort 3 \& dosing for each MAD cohort will not exceed a dose level previously deemed safe in a SAD cohort. Part 3: IPF patients, will not start until data are available and reviewed from Parts 1 \& 2 and will not exceed a dose level previously deemed safe in a SAD/MAD cohort."|t|t|t|t
34176244|NCT03684616|||COHORT||RETROSPECTIVE|||||||
34176245|NCT02227914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176246|NCT03964727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176247|NCT04586478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176248|NCT02177695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176249|NCT05864274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176250|NCT05669716|||CASE_CONTROL||RETROSPECTIVE|||||||
34176251|NCT05341817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment doctor during the Day 21-28 follow-up visit will be blinded to the treatment allocation of the study participant.||f|t|f|f
34176252|NCT05763043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176253|NCT04790474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176254|NCT06595095|||COHORT||CROSS_SECTIONAL|||||||
34176255|NCT03957954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176256|NCT01746836|NA|SINGLE_GROUP||TREATMENT||||||||
34176257|NCT04945746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176258|NCT06218277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective in one group of patients||||
34176259|NCT05687851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176260|NCT06580392|||OTHER||PROSPECTIVE|||||||
34176261|NCT06119282|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The research will be conducted as a randomized controlled intervention study to evaluate and compare the effects of massage and inhaler aromatherapy on acute pain, comfort level and anxiety in primiparous cesarean section women.||||
34176262|NCT04435288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled trial|"The SPARTACUS clinical trial consists of 2 phases (duration phase A is up to 60 weeks, phase B up to 3 years).~SPARTACUS Phase A: Remission-Induction Phase: (Baseline to (maximum) week 60) All patients (n=112) will be randomized (1:1) to either immediately receiving TNFi (golimumab) monotherapy (TNFi Induction-group) (n=56), or to the step-up regimen with csDMARDs (csDMARD Step-up-group) (n=56).~SPARTACUS Phase B: Drug-Free Remission Phase: cessation of therapy and exploration of drug-free remission in patients that achieve sustained clinical remission while on therapy in phase A (Duration: max. 3 years)."|t|t|t|t
34176263|NCT06604260|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176264|NCT06462625|||COHORT||OTHER|||||||
34176265|NCT03537963|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||After the first part of the study (Qualitative Interviews), the hematopoietic cell transplant (HCT) survivors will be randomized to 3 different study arms for the intervention portion of the study.||||
34176266|NCT06601673|RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective, randomized-controlled trial||||
34176267|NCT06529380|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34176268|NCT01648465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176269|NCT04127604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176270|NCT06577181|||COHORT||RETROSPECTIVE|||||||
34176271|NCT05231954|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||This is a pragmatic cluster randomized control trial with randomizing clinic and with wavier of consent for human subjects. The data collection is from the EHR. There is no research data collection outside the EHR.|f|f|t|t
34176272|NCT06598995|||COHORT||RETROSPECTIVE|||||||
34176273|NCT04218240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Penn Investigational Drug Service (IDS) will prepare blinded pregabalin capsules by over encapsulation of the drug into capsules shells matching the placebo capsules. Blinded pregabalin capsules will be packaged into blister packs along with lofexidine tablets, in separate compartments that are labeled for dosing times on days 1-7 and ship them to the research sites.|for the primary comparison of longitudinal subjective withdrawal measures, comparing the groups on rate of decrease across detox days, using a linear group by time effect for the mixed effects models described above. We have one primary outcome, so use an alpha level of 0.05, and we use two-sided tests. 90 subjects, 30 from each of three sites, who will be randomized into two groups, with 30 assigned to Lofexidine plus Placebo, and 60 to Lofexidine plus a starting daily dose of 400 mg of pregabalin and increasing to 600mg Pregabalin on day 2.|t|t|t|f
34176274|NCT06195748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34176275|NCT06595264|||COHORT||RETROSPECTIVE|||||||
34176276|NCT03745508|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind||t|f|f|t
34176277|NCT03286036|||COHORT||PROSPECTIVE|||||||
33863678|NCT00164619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962889|NCT04716673|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Study helpers|The investigators aim to evaluate the effect of closed-loop auditory stimulation during sleep in healthy children, adolescents and adults, as well children, adolescents and adults with epilepsy. During closed-loop auditory stimulation, a brief, quiet, non-arousing auditory stimuli, e.g. brief bursts of pink noise (50ms), are presented at specific moments during sleep (STIM condition). This procedure allows to noninvasively interact with endogenous brain activity and to influence sleep-dependent neuroplasticity. During one experimental night, closed-loop auditory stimulation will be applied (STIM night). In the SHAM night, the experimental set-up is the same as in the experimental night, but no sounds will be presented.|t|t|t|f
33962890|NCT00569335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176278|NCT03572517|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||"Patients will be allocated sequentially in 2 groups. Sequential allocation will be used in order to control age as a possible confounding factor for the outcome of interest. The randomization will be performed through free software R version 3.4.~1. Balanced general anesthesia.~2. Balanced general anesthesia associated with subarachnoid block with 0.5% heavy bupivacaine (3ml).~All patients will receive morphine 50 mcg via the spinal route."|t|f|f|f
33962891|NCT06536933|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962892|NCT02311543|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33962893|NCT00176501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962894|NCT03467971|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33962895|NCT05291156|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized (2:1) as follow:~* Cetuximab + avelumab~* Cetuximab only"||||
33962896|NCT00153868|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962897|NCT04123483|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study of EnBrace HR in a single group of women who experience PMS with prominent mood symptoms or a menstrual related mood disorder (MRMD). All women will be experiencing clinically significant menstrual related mood symptoms at the time of enrollment. In this study, EnBrace HR is studied for acute treatment PMS with prominent mood symptoms and MRMD.||||
33962898|NCT04144725|||COHORT||PROSPECTIVE|||||||
33962899|NCT03665974|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33962900|NCT00827073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33962901|NCT05673369|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962902|NCT03251209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962903|NCT05567601|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962904|NCT04943055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962905|NCT06568861|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is non-randomized, open-label, parallel group study. Cohort 1 will enroll moderately hepatically impaired subjects and Cohort 2 will enroll subjects without hepatic impairment.||||
33962906|NCT01752322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962907|NCT05341076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962908|NCT00299273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962909|NCT02046499|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33962910|NCT01733186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176279|NCT05643495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176280|NCT06584552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176281|NCT00860873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176282|NCT06305650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double（Participant,Investigator）||t|f|f|f
34176283|NCT03779256|||COHORT||PROSPECTIVE|||||||
34176284|NCT06587711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34176285|NCT05655741|||COHORT||PROSPECTIVE|||||||
34176286|NCT05156281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to maintain blinding, a double-dummy design will be used|Eligible participants will be randomized in a 1:1 ratio|t|f|t|f
34176287|NCT05014256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34176288|NCT06510660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176289|NCT02439723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176290|NCT05226442|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization ratio of 1:1 for anticoagulation with Argatroban or Unfractionated Heparin||||
34176291|NCT06704607|||COHORT||PROSPECTIVE|||||||
34176292|NCT03454763|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparative||||
34176293|NCT06649045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863679|NCT01910909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863680|NCT04671667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863681|NCT01608867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863682|NCT06726616|||COHORT||PROSPECTIVE|||||||
33863683|NCT03118037|||COHORT||PROSPECTIVE|||||||
33863684|NCT03519867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863685|NCT00177138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863686|NCT00955851|||COHORT||PROSPECTIVE|||||||
33863687|NCT00694850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863688|NCT04697810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo capsules are identical in appearance to namodenoson capsules.|Subjects will be randomly assigned in a 2:1 ratio of namodenoson 25 mg or matching placebo, according to a computer-generated randomization schedule. Blocked randomization will be programmed using a pre-specified block size. Double-blinding will be maintained throughout the trial.|t|t|t|t
33863689|NCT01028222|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33863690|NCT03167203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863691|NCT06736067|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863692|NCT05975801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863693|NCT06729918|RANDOMIZED|PARALLEL||OTHER||SINGLE|Data will be entered into the study by someone other than the researchers. Statistical analysis will be performed by someone other than the researchers. Due to the nature of the study, participants will know which group they are in. Therefore, blinding of participants will not be possible. The implementation of the study and collection of data will be performed by the researchers. Therefore, the researchers were not blinded to the study.|A randomized controlled trial|f|f|f|t
33863694|NCT06540768|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center unblinded randomized controlled trial||||
33863695|NCT00257829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863696|NCT05309551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33863697|NCT06736483|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33863698|NCT05855941|||CASE_ONLY||PROSPECTIVE|||||||
33863699|NCT03549000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176294|NCT01235897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863700|NCT00361491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863701|NCT06626425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized active-controlled wait-list trial|f|f|t|t
33863702|NCT03903874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|assessment staff will be blind to condition||f|f|f|t
33863703|NCT05917041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863704|NCT06607263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this clinical trial, masking involves several key roles to ensure unbiased results. The Participant, Care Provider, Investigator, and Outcomes Assessor are all masked in this double-blind study. This means that the participants do not know which group they have been assigned to, the care providers administering the treatments are unaware of the specific products being used by each participant, the investigators conducting the study do not know the group assignments, and the outcomes assessors evaluating the results are blind to the treatment allocations. This comprehensive masking approach is designed to minimize any potential biases and maintain the integrity of the study results.|This is a Phase III, randomized, controlled, double-blind, parallel-group clinical trial|t|t|t|t
34176295|NCT06093100|||COHORT||CROSS_SECTIONAL|||||||
34176296|NCT02700607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176297|NCT04999462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34176298|NCT05672381|||COHORT||PROSPECTIVE|||||||
34176299|NCT01146769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176300|NCT05134038|||COHORT||PROSPECTIVE|||||||
34176301|NCT05017363|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34176302|NCT04621981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176303|NCT02038517|||COHORT||PROSPECTIVE|||||||
34176304|NCT00636025|||CASE_ONLY||PROSPECTIVE|||||||
34176305|NCT05619575|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34176306|NCT02192580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34176307|NCT01992796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34176308|NCT06253832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||comparer le traitement conservateur chirurgical à l'hystérectomie dans le traitement du placenta accreta||||
34176309|NCT02315586|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176310|NCT05054309|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33863705|NCT05254496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will be blinded to participant group.||f|f|f|t
33863706|NCT05100862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863707|NCT06734507|||COHORT||RETROSPECTIVE|||||||
33863708|NCT03546335|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The first 2 patients will receive 1 mCi of 89Zr-DFO-CZP. Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.||||
33863709|NCT06244641|NA|SINGLE_GROUP||OTHER||NONE||||||
33863710|NCT06735300|||OTHER||PROSPECTIVE|||||||
33863711|NCT05977946|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomized into two 30-minute stimulation sessions. One session will be active and the other sham. Participants are blinded to treatment group as well as the stimulation session.|t|f|t|f
33863712|NCT06279871|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962911|NCT00177099|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33962912|NCT03547596|||COHORT||PROSPECTIVE|||||||
34176311|NCT02028858|||CASE_ONLY||PROSPECTIVE|||||||
34176312|NCT00169182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176313|NCT05624606|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a parallel-group prevention study with up to 6 arms that will be blinded to participants, investigators / sub-investigators, outcomes assessors, and laboratory personnel (with the exception of the sentinel safety portion of the study, which will be open-label). The Sponsor study staff will be unblinded (except laboratory testing personnel).|"Sentinel Cohort: Open label~Main Cohort:~* Open label (Sponsor, except laboratory testing personnel)~* Blinded (Sites, except for those preparing/administering study intervention)"|t|f|t|t
34176314|NCT03008291|||COHORT||PROSPECTIVE|||||||
34176315|NCT04747041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176316|NCT05728463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176317|NCT06509659|||CASE_ONLY||PROSPECTIVE|||||||
34176318|NCT06588556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All outcomes are self-reported by participants directly via the intervention apps and so not seen by the study team. The site PIs are blinded to study group.||f|f|t|t
34176319|NCT02928068|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176320|NCT06548776|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962913|NCT01225315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962914|NCT01718301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962915|NCT04027816|||COHORT||PROSPECTIVE|||||||
33962916|NCT02488707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33962917|NCT02602561|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34176321|NCT06602557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176322|NCT00467688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34176323|NCT02476617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176324|NCT02318732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176325|NCT03774654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176326|NCT06246292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176327|NCT06590623|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176328|NCT04445753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34176329|NCT03415321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||A randomized controlled trial with a two-group pre-test and post-test design.|f|f|t|t
34176330|NCT04834102|||OTHER||RETROSPECTIVE|||||||
34176331|NCT05015426|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176332|NCT04448886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176333|NCT06604221|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863713|NCT03877107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluation of urinary symptoms before and after depletive lumbar puncture and after shunt surgery||||
33863714|NCT05043090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863715|NCT04680351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863716|NCT02954094|||COHORT||PROSPECTIVE|||||||
33863717|NCT06292650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33863718|NCT00786812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863719|NCT06735586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measuements were performed by blind assessor|By randomly dividing the individuals investigators included in our study into two groups, investigators applied only the hip and quadriceps strengthening program to one group and the additional Mulligan rigid taping technique to the hip and quadriceps strengthening exercises in the other group, and examined the first and post-test measurements investigators will make before and after each group separately, at the same time. İnvestigators are planning to evaluate the results investigators have obtained by making comparisons between groups in both groups. Dilber Coşkunsu, who is a blind evaluator, will make the evaluations. The person making the evaluation will make an evaluation without knowing which treatment the patient is receiving.|f|f|f|t
33863720|NCT00076557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863721|NCT00607880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33863722|NCT05054257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863723|NCT05590689|NA|SEQUENTIAL||TREATMENT||NONE||A modified 3+3 design is used. The maximum tolerated dose of repeated RDT (consisting of 5-ALA dosing an radiotherapy) and safety will be determined in 9 cohorts.||||
33863724|NCT05304065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is not possible to mask intervention condition from participants. Care providers in the ED will be masked to randomized condition. Outcomes assessors will be masked to randomized condition.||f|t|f|t
33863725|NCT04582370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863726|NCT06734754|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|single||t|f|f|f
33863727|NCT03692897|||COHORT||OTHER|||||||
33863728|NCT03410017|||CASE_ONLY||PROSPECTIVE|||||||
33863729|NCT06313073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863730|NCT06062264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Pragmatic comparative effectiveness trial with a standard-of-care control group|t|f|f|f
33863731|NCT05736159|||COHORT||PROSPECTIVE|||||||
33863732|NCT06164301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be assigned into either; A)Elemental Amino group ; post-operative within the first 3 hours the patient will receive 250 ml of elemental protein( 250 ml Peptamen = 6 scoops (55g) + 210ml water ) repeated at ( 6, 8 , 10 , 12 hours postoperative ) , Second day ordinary food will be supplemented by half the dose of the first day from elemental protein (250 ml / 6 hours ) or to the dose to achieve the daily protein adequacy 1.3 mg/kg/day. B) The standard group will be NPO till the return of bowel functions.|f|f|f|t
33863733|NCT06585488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863734|NCT06147076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statisticians will be blinded to group assignment when assessing outcomes.|Control group versus interventional group. Questionnaire completed by interventional group and their social support networks pre and post.|f|f|f|t
33863735|NCT03132532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863736|NCT05011058|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm study utilizing a basket trial design.||||
33863737|NCT03222531|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863738|NCT01879787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863739|NCT03444727|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either pre-treatment with ice inside a sterile glove or with room-temperature water inside an exam glove.||||
33863740|NCT05589064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863741|NCT03410836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The drug administered intraoperatively (intravenous lidocaine or intravenous placebo) will be blinded to patient, anesthesiologist, research nurse for the entire duration of the study.|Two groups of patients. Randomization into the treatment group or placebo group according to a randomization list for a total number of patients of 60.|t|t|t|t
33863742|NCT00239226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33863743|NCT05966662|NA|SINGLE_GROUP||TREATMENT||NONE||Shockwave C2+ 2Hz Coronary IVL Catheter with Shockwave Intravascular Lithotripsy (IVL) System||||
33962918|NCT00004375||||TREATMENT||||||||
33962919|NCT01210742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962920|NCT00387231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176334|NCT05578846|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34176335|NCT05786625|||COHORT||PROSPECTIVE|||||||
34176336|NCT03512821|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34176337|NCT03909152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-randomized, open, multicenter phase 2 study.||||
33751426|NCT04794361|||CASE_ONLY||RETROSPECTIVE|||||||
33751427|NCT06331884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751428|NCT04837066|||COHORT||PROSPECTIVE|||||||
33751429|NCT04936152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751430|NCT01570829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751431|NCT06732583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33751432|NCT04726020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two comparison groups: an intervention group (intensive phone monitoring of adverse event reactions) compared with a placebo group (standard monitoring)||||
33863744|NCT02887027|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863745|NCT06734273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863746|NCT06044493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863747|NCT02817230|||CASE_CONTROL||PROSPECTIVE|||||||
33863748|NCT03346941|||COHORT||PROSPECTIVE|||||||
33863749|NCT04987489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33863750|NCT06561386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863751|NCT02550522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863752|NCT05458024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This will be a blinded study. Investigators, participants, and coordinators will be blinded to the treatment assignment. Active and placebo treatments will be indistinguishable.|A randomized clinical trial enrolling motor vehicle collision survivors within 24 hours after injury (n=90, 45 non-Hispanic Black, and 45 non-Hispanic White) will be randomized in 1:1 allocation of a one-time dose of either Vitamin D or placebo|t|t|t|t
33863753|NCT06053749|||COHORT||OTHER|||||||
33863754|NCT01984944|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863755|NCT06708520|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Phase 1, single dose, open-label, parallel group||||
34176338|NCT06311838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to intervention condition.|Using a dismantling, randomized controlled design, researchers will examine the singular and combined impact of Motivational Interviewing/Community Reinforcement Approach (MI/CRA) and Strengths-Based Outreach and Advocacy (SBOA) on substance use, mental health and other outcomes (e.g., housing stability, education, employment) with Youth Experiencing Homelessness (YEH) recruited from a local drop-in center.|f|f|f|t
34176339|NCT02157532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176340|NCT02029677|||COHORT||PROSPECTIVE|||||||
34176341|NCT00020800||||TREATMENT||||||||
34176342|NCT06513845|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176343|NCT04588545|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176344|NCT00202280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176345|NCT05139472|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label trial||||
34176346|NCT04093297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34176347|NCT04609943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176348|NCT06597045|||COHORT||PROSPECTIVE|||||||
34176349|NCT03926208|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group will be randomized to receive a betadine soak and scrub (in addition to the standard of care) prior to surgery. The control group will receive the standard of care.||||
34176350|NCT06408558|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study is a randomised crossover study at two different ambient pressures one at normal ambient pressure (760 mmHg) and the other at 560 mmHg mimicking the repressurised cabin environment at 8000 feet.||||
34176351|NCT05878418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which group to belong to.|Parallel Assignment randomised controlled trial|t|f|f|f
34176352|NCT04163562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176353|NCT05846789|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are stratified by either Black or non-Black (race-based cohort) and are then randomized 1:1 to either the monotherapy or combination arm. This requires 42 patients (21 per treatment arm) in stage I for each race-based cohort. If the no. of response in experimental - no. of response in control is no greater than -1, the trial is early stopped at stage I for futility. Otherwise, additional 42 patients for each race-based cohort will be enrolled and randomized to the study in stage II for a total of 168 subjects across all 4 arms.||||
34176354|NCT06583135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only participant masking was performed|This study is a parallel group randomized controlled study|t|f|f|f
34176355|NCT04788888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176356|NCT06594887|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176357|NCT06297395|||CASE_ONLY||OTHER|||||||
34176358|NCT02718898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176359|NCT06540053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176360|NCT02706756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751433|NCT01657058|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33751434|NCT02102867|||OTHER||OTHER|||||||
33751435|NCT04940429|||COHORT||PROSPECTIVE|||||||
33751436|NCT05874063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33751437|NCT03901326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751438|NCT04497168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34176361|NCT06700473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After being randomized as experimental and control groups, primiparous pregnant women will be prevented from interacting with each other in order not to be affected by the interventions.|Single-Blind Randomized Controlled Trial|t|f|f|f
34176362|NCT06599229|||COHORT||PROSPECTIVE|||||||
34176363|NCT04231669|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34176364|NCT04139733|||COHORT||PROSPECTIVE|||||||
34176365|NCT04412863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176366|NCT05415761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized to one of the 3 study arms, using a 1:1:1 allocation scheme||t|t|t|f
34176367|NCT01345240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176368|NCT05724134|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will be blinded to study group assignment.|All participants will undergo (i.e., cross over between) both pancreatic clamp protocols (MH, RE) separated by 2-8 weeks. The order of the clamp protocols (i.e., MH \> RE, RE \> MH) will be randomized.|t|f|f|f
34176369|NCT06459674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All members of the research staff (i.e., those collecting data during experimental visits) will be blinded to the treatment group. The PI, who will not be part of data collection, will not be blinded.||t|f|t|f
34176370|NCT06706128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34176371|NCT05958082|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34176372|NCT05189275|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Study participants will be randomly assigned to 1 of 4 groups and followed throughout the 8 week intervention period.|t|t|t|f
34176373|NCT03598036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176374|NCT05789537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863756|NCT06735157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to their intervention group.|Participants will be split into two groups, one that will receive real rTMS and one that will receive sham rTMS.|t|f|f|f
33863757|NCT04653740|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33863758|NCT01107340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176375|NCT04935606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||3-arm single blind RCT that compares: QUIT-Mobile, QUIT, and Usual Care, to assess the effectiveness among these interventions in reducing highest scoring risky drug use across time (at 3, 6 and 12 months follow-up).|t|f|f|f
33863759|NCT04936243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176376|NCT06196008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176377|NCT06406855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176378|NCT02025543|||COHORT||PROSPECTIVE|||||||
34176379|NCT06285396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176380|NCT05592665|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34176381|NCT06592677|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Investigator: senior statistician will be blinded for condition. Junior statistician will not, due to practical barriers (double role as the study coordinator). The person responsible for randomization will be blinded for the outcome of the screening (T0) and baseline (T1) assessments.~Outcome assessors: graduate psychology students who will perform the clinical interviews will be blinded for condition."|Parallel two-armed multicenter add on randomized controlled trial.|f|f|t|t
34176382|NCT00829426|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34176383|NCT03016728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176384|NCT04073966|||OTHER||PROSPECTIVE|||||||
34176385|NCT04732845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176386|NCT04628039|||COHORT||PROSPECTIVE|||||||
34176387|NCT05627830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176388|NCT06706011|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863760|NCT05790850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863761|NCT05900050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863762|NCT04090853|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assessed patient feedback regarding satisfaction post treatment||||
33863763|NCT06616298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33863764|NCT02253368|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33863765|NCT06007898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863766|NCT03435016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176389|NCT06472141|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was planned as a randomized controlled trial. The individuals included in the study will be divided into 2 groups as Stabilization and Control group by block randomization method.||||
34176390|NCT06536413|NA|SEQUENTIAL||TREATMENT||NONE||||||
34176391|NCT04224870|||COHORT||PROSPECTIVE|||||||
34176392|NCT02339974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863767|NCT03525535|||COHORT||PROSPECTIVE|||||||
34176393|NCT03583099|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Practitioners at sites randomized to the COPD education only intervention will be blinded to CAPTURE scores.~Practitioners in both intervention arms will be blinded to research spirometry results.~Participants will be blinded to spirometry results."|"Participating primary practices will be randomized to one of 2 arms.~* Arm 1: Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education (CAPTURE+ COPD education).~* Arm 2: Practice clinicians will receive basic COPD education only (COPD education)."|t|t|f|f
34176394|NCT06705777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176395|NCT06578364|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34176396|NCT06384495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34176397|NCT06473389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and care provider, the physician performing the assessment and the physiotherapist treating the patient will be blind to what procedure is being performed.|This study was designed as a prospective, triple-blind, randomised controlled study. Patients hospitalised in the stroke clinic of our hospital and diagnosed with haemorrhagic or ischaemic stroke will be included in our study.Patients will be randomised into three groups of 28 patients as the first group RF Group (RFG), the second group Suprascapular Nerve Blockade Group (SSBG) and the third group Intraarticular Steroid Group (SG) with the 'Research Randomizer' computer program. The treatments of the patients will be organised as a total of 20 sessions for 4 weeks, 5 days a week, first TENS and hotpack, then exercise. 15 minutes of hotpack, 15 minutes of TENS will be applied, followed by 30 minutes of upper extremity exercises.The degree of maximum passive ROM measurements of the shoulder, the degree of passive ROM, Visual Analogue Scale (VAS), Shoulder Pain and Disability Index score (SPADI), Goal Attainment Scale (GAS), Modified Barthel Index at baseline, 1st, 4th, 12th weeks.|t|t|f|t
34176398|NCT05177393|||COHORT||PROSPECTIVE|||||||
34176399|NCT02038166|||COHORT||PROSPECTIVE|||||||
34176400|NCT05710718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||1:1 Crossover||||
33751439|NCT02002169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751440|NCT06258590|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33751441|NCT02917707|||CASE_CONTROL||RETROSPECTIVE|||||||
33863768|NCT05667285|||CASE_ONLY||OTHER|||||||
33863769|NCT06444217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863770|NCT05928286|||CASE_CONTROL||PROSPECTIVE|||||||
33863771|NCT03220477|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, multi-center, therapeutic study. All patients will be assigned to receive all three study therapies. The phase 1 portion of the study will proceed as a 3+3 dose-escalation with escalating doses of guadecitabine and mocetinostat, along with fixed dose of pembrolizumab.||||
33962921|NCT02759627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962922|NCT03433326|||CASE_ONLY||PROSPECTIVE|||||||
33962923|NCT02172183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33962924|NCT01564173|||CASE_ONLY||CROSS_SECTIONAL|||||||
33751442|NCT01978613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962925|NCT04405674|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962926|NCT02865473|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33962927|NCT02952937|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33962928|NCT05152407|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34176401|NCT06572683|NA|SINGLE_GROUP||TREATMENT||NONE||"The investigators will identify the participant's individual resonant frequencies (RF) by a series of pulse trains between 5-18 Hz at 0.5 Hz intervals, at a total of 27 unique frequencies, delivered in a random order. The total procedure takes 35 minutes. The investigators will conduct this procedure 3 times over the course of 3 days, 1 procedure per day. The investigators will then determine the optimal resonant frequency by ranking all interrogated frequencies based on their degree of elicited connectivity changes within the defined target circuit. The optimal RF (RFMAX) will be the stimulation frequency that ranks highest with regard to connectivity increase (RFMAX). RFMIN is the lowest ranked frequency. Participants will then undergo six rTMS treatment sessions: two at RFMAX, two at RFMIN, two at 10 Hz in random order. The two sessions at the same frequency will be administered on the same day, separated by 1 hour."||||
33962929|NCT00000891||||TREATMENT||NONE||||||
34176402|NCT00496522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176403|NCT04843566|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Radiologists assessing MRI results are blinded to treatment assignment. Pathologists assessing biopsy results are blinded to treatment assignment.|Men enrolled in this prospective, randomized trial will be randomized in a 1:1 ratio to receive either transperineal MRI-targeted or transrectal MRI-targeted prostate biopsy.|f|f|f|t
34176404|NCT06595225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were assigned randomly into either the control or intervention group based on 4 aspects which were: gender, 0 co-morbidities, 1 co-morbidity, 2 or more co-morbidities, whereas the interventional group received nutrition education sessions of various topics related to general nutrition knowledge, with more focus on nutrition related to patients living with HIV (PLHIV) for a 6 months period, were there was one encounter per month and follow up was weekly over a social media platform (Whatsapp)||||
34176405|NCT06301490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176406|NCT05371886|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The main objective is to estimate a dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling.||||
34176407|NCT05077124|||COHORT||OTHER|||||||
34176408|NCT05567458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176409|NCT01419236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176410|NCT04290598|||CASE_ONLY||PROSPECTIVE|||||||
34176411|NCT01544205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176412|NCT02452736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176413|NCT05453526|||COHORT||RETROSPECTIVE|||||||
34176414|NCT05291260|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not possible for surgical intervention vs cast immobilization|||||
34176415|NCT06614881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176416|NCT06264843|||COHORT||PROSPECTIVE|||||||
34176417|NCT05891704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176418|NCT01864018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176419|NCT04038359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176420|NCT06510153|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176421|NCT05278260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34176422|NCT02250326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176423|NCT06706050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176424|NCT05236816|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34176425|NCT06388226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176426|NCT06016387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176427|NCT01657383|||COHORT||PROSPECTIVE|||||||
34176428|NCT06033222|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Prospective randomized, placebo-control study of effect of castor oil on intestinal and colonic permeability|t|f|t|f
34176429|NCT04863729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176430|NCT03891706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176431|NCT06219694|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants were randomized by computer software (Excel 2016 for Windows) and the randomization process was overseen by the Institutional Review Board at Taichung Veterans General Hospital. All the participants and our collaborative case-manager were blinded to treatment types.|The patients was divided to sham group or laser acupuncture group. After 1 months treatment, and followed up for 6 months., the sham group received complementary laser acupuncture for 1 months and followed up for another 3 months.|t|t|f|t
34176432|NCT02546609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176433|NCT06068309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176434|NCT04638907|||CASE_ONLY||PROSPECTIVE|||||||
34176435|NCT03789825|||OTHER||PROSPECTIVE|||||||
34176436|NCT04718415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176437|NCT05642676|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176438|NCT06458283|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176439|NCT01264341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176440|NCT06704750|||COHORT||PROSPECTIVE|||||||
34176441|NCT00079417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176442|NCT05507723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized clinical trial||||
33751443|NCT05703854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962930|NCT05876208|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
34176443|NCT05650749|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176444|NCT04181359|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34176445|NCT05478265|||COHORT||PROSPECTIVE|||||||
34176446|NCT01561014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176447|NCT06705543|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176448|NCT05568225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176449|NCT05735327|||COHORT||PROSPECTIVE|||||||
34176450|NCT06705621|||OTHER||PROSPECTIVE|||||||
33962931|NCT03039205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176451|NCT05388877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962932|NCT03797222|NA|SINGLE_GROUP||OTHER||NONE||This open-label tolerability and feasibility pilot clinical study will use a before-and-after design, with blood tests and fasting oral protein tolerance test performed prior to and after 2 weeks of daily oral Vitamin E supplementation in individuals with HI/HA syndrome.||||
33962933|NCT06117982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962934|NCT04506125|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot, multicentre, randomized, controlled, single-blind, pilot study comparing two strategies for transfusion of red blood cell concentrates||||
33962935|NCT00677677|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33962936|NCT04283838|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34176452|NCT02648308|||CASE_ONLY||PROSPECTIVE|||||||
34176453|NCT03612817|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Only the dosing coordinator is aware of the treatment used.|Patients first undergo a baseline, habitual 24-hour pressure assessment with branded, or generic latanoprost. Suitably qualified open-angle glaucoma patients (latanoprost-treated, mean 24-hour pressure greater than 20 mm Hg) are randomized for Period 1 to receive either tafluprost/timolol fixed combination drops once in the evening (20:00) and placebo drops in the morning (08:00), or tafluporst/timolol drops once in the morning (08:00) and placebo in the evening (20:00). After 3 months of chronic therapy (± 2 weeks) study patients undergo a treated, habitual 24-hour pressure assessment. Study subjects are then switched to the opposite treatment regimen for Period 2 (tafluprost/timolol in the evening instead of morning etc) and after another 3 months they undergo the third and final evaluation of their 24-hour pressure.|f|f|t|f
34176454|NCT05579678|||COHORT||PROSPECTIVE|||||||
34176455|NCT06706687|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176456|NCT05139680|||COHORT||RETROSPECTIVE|||||||
34176457|NCT06589544|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34176458|NCT06016517|||OTHER||PROSPECTIVE|||||||
34176459|NCT05368038|||COHORT||PROSPECTIVE|||||||
34176460|NCT05268809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||We will randomize 70 overweight/obese SZ and BD participants to receive either a ketogenic or Diet as Usual.||||
34176461|NCT04963920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176462|NCT06235515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176463|NCT04582903|||COHORT||PROSPECTIVE|||||||
34176464|NCT03101917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients who meet eligibility requirements and choose to participate will undergo the image guided surgical cochlear implantation procedure as described in the protocol.||||
34176465|NCT06493760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176466|NCT04873037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sham Emsella treatment will provide sensation without active HIFEM technology. The sham treatment amplitude setting will be limited to below the therapeutic level.|Patients who meet all eligibility criteria will be enrolled in the study and randomized (1:1) to receive Emsella chair or sham treatments. The subject and biostatistician will be blinded to the group allocation throughout the study. The initial analysis of data, performed by the biostatistician will not include group assignment.|t|f|f|t
34176467|NCT06341166|||COHORT||OTHER|||||||
34176468|NCT06594731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176469|NCT04477759|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study will use a time-to-event continual reassessment method (TITE-CRM) for assigning subjects to the radiation therapy dosages.||||
34176470|NCT00298012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34176471|NCT05075265|||COHORT||PROSPECTIVE|||||||
34176472|NCT05380427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176473|NCT04636814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176474|NCT06527066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind (researcher and statistician), it was not possible to blind the participants, since the geranium EO (Pelargonium graveolens) has a characteristic aroma. The researcher/investigator is also the one who will provide care and evaluate the results.|G1 will be composed of those whose intervention will only be with the carrier base, the All.me Beauty® Gel Sérum Biocompatível, which serves as a way of diluting the EO and does not interfere with its action and therapeutic process, acting as a placebo. In G2 there will be participants who will receive intervention with geranium EO (Pelargonium graveolens), diluted in All.me Beauty® Gel Sérum Biocompatível, respecting a concentration of 1%, determined based on the work of Sabzghabaee et al. (2011), where tolerability was shown in the application of this 1% EO, on oral mucosa, for the treatment of denture stomatitis; For the present study, the sensitivities of the facial skin and smell were taken into account. The intervention with geranium EO (Pelargonium graveolens) will be made available to G1 after the end of the study protocol, in consideration of the ethical precepts of research involving human beings, according to Resolution nº 466/2012.|f|t|t|t
34176475|NCT04077801|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176476|NCT00001069|||NATURAL_HISTORY|||||||||
34176477|NCT03735875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176478|NCT05241873|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The primary objectives of this study are in Phase 1 to identify the MTD and/or RP2D of BLU-451, and in Phase 2, to evaluate the anti-tumor activity of BLU-451.||||
34176479|NCT06599333|||CASE_ONLY||CROSS_SECTIONAL|||||||
34176480|NCT06050265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176481|NCT05665738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176482|NCT04125836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176483|NCT06258369|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Patients with coxarthrosis (any stage) without surgery~Patients with coxarthrosis (any stage) with THP (Total Hip replacement)~Patients with coxarthrosis (any stage) with RHT (Hip resurfacing)"||||
34176484|NCT06704490|||CASE_ONLY||PROSPECTIVE|||||||
33751444|NCT06105632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962937|NCT06136494|RANDOMIZED|CROSSOVER||TREATMENT||NONE||iCBT versus attention control||||
33962938|NCT02619734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962939|NCT02643394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962940|NCT05292469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized Trial||||
33751445|NCT04677972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751446|NCT02690064|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34176485|NCT05849454|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176486|NCT06366217|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176487|NCT00562224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176488|NCT06596551|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post single arm study design will measure psychosocial health outcomes before and again after the intervention is implemented. This study design is adopted for the purposes of a pilot investigation to observe if the ARCH intervention can have temporary effects or no effects on psychosocial health outcomes.||||
34176489|NCT04564898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176490|NCT01514799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomisation in the OR, (closed envelopes, blocks of six) no further info to ward or follow-up unit. No specific info as to randomisation outcome given to patients, all patients follow same protocol.~Code number in operative charts."|Randomised study between long and standard biliopancreatic limb in gstric bypass surgery|f|f|t|t
34176491|NCT06589388|||COHORT||PROSPECTIVE|||||||
34176492|NCT06590922|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176493|NCT06587152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176494|NCT06592547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176495|NCT04232566|||COHORT||PROSPECTIVE|||||||
34176496|NCT06292169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Electronic random number generator Single-blinded (concealed to the study participant only, Investigator blinded not feasible)||t|f|f|f
34176497|NCT06487988|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34176498|NCT04993651|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176499|NCT06333314|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, multicenter, comparative phase II trial||||
34176500|NCT06593483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176501|NCT03879512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176502|NCT06587438|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176503|NCT05520203|||COHORT||PROSPECTIVE|||||||
34176504|NCT06594718|||COHORT||PROSPECTIVE|||||||
34176505|NCT04008368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863772|NCT05206695|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants, care providers, and investigators cannot be masked due to the nature of the intervention. However, outcomes assessors will be masked.|Participating hospitals will be randomized into either an intervention group (will test simultaneous implementation of 3 clinical pathways) or control (will continue to provide standard care)|f|f|f|t
33863773|NCT04723147|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33863774|NCT05751434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863775|NCT05901246|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33863776|NCT05440409|||COHORT||RETROSPECTIVE|||||||
33863777|NCT06734429|||COHORT||RETROSPECTIVE|||||||
33863778|NCT04977869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863779|NCT06736171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863780|NCT04408820|||COHORT||PROSPECTIVE|||||||
33863781|NCT06601660|RANDOMIZED|PARALLEL||TREATMENT||NONE||Using the randomization function of Microsoft Excel software, participants (n = 60) will be allocated into 3 experimental groups.||||
33863782|NCT06735612|||CASE_CONTROL||PROSPECTIVE|||||||
33863783|NCT02978534|||COHORT||PROSPECTIVE|||||||
33863784|NCT05129241|||COHORT||PROSPECTIVE|||||||
34176506|NCT05518500|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176507|NCT03955198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863785|NCT04276922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863786|NCT02791113|||CASE_ONLY||PROSPECTIVE|||||||
33863787|NCT06736340|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is an open-label, non-randomized, parallel group study comparing the PK after administration of a single 10 mg dose of rupatadine to participants with hepatic impairment with matched control participants with normal hepatic function (matched in terms of age, gender, and body weight).||||
33863788|NCT06086301|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33863789|NCT00187213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33863790|NCT04786951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863791|NCT03566433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863792|NCT05987449|NA|SEQUENTIAL||TREATMENT||NONE||||||
33863793|NCT04649268|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a pilot study and 24 participants will be randomised into one of two rehabilitation groups incorporating OKS treatment with Optokinetic DVD (Group A) or VR headset (e.g. Oculus Quest headset) (Group B).||||
34176508|NCT00688116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176509|NCT04494841|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Consecutive low back pain patients were offered to try a new device and give feedback on a prototype. Once the feedback was obtained, the changes were incorporated into a production-ready model and re-evaluated.||||
33751447|NCT04712942|RANDOMIZED|PARALLEL||TREATMENT||NONE||With Cross-Over option||||
33751448|NCT02868359|||COHORT||PROSPECTIVE|||||||
33863794|NCT03579849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863795|NCT06456658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33863796|NCT05484050|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863797|NCT06734091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Donors tissue will be send to Pathological Anatomy to perform intraoperative examination according to standard of care procedures and to perform intraoperative examination according to experimental methods (with possible immunohistochemistry).||||
33863798|NCT00132496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863799|NCT06735742|||COHORT||PROSPECTIVE|||||||
33863800|NCT06245356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962941|NCT03455335|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Advanced Therapeutic Medicinal Product ( ATMP) Bone Marrow Derived Mesenchymal Stem Cells||||
33962942|NCT01092390|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33962943|NCT02813707|||CASE_CONTROL||RETROSPECTIVE|||||||
33962944|NCT02010970|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33962945|NCT04099082|||CASE_CONTROL||PROSPECTIVE|||||||
33962946|NCT00567346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962947|NCT04215107|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34176510|NCT06590753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176511|NCT05146388|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single (Outcomes Assessor) Two raters will independently assess dosing errors. Raters will be kept blinded to each other's estimated dose volumes and dosing error assessment in order to minimize bias.||f|f|f|t
34176512|NCT06247813|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176513|NCT05976087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751449|NCT06481709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"In each period, subjects will receive one of the following treatments, according to the randomization scheme:~Treatment A: 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fasting conditions.~Treatment B: 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered without water under fed conditions.~Treatment C: 1 x 10 mg/kg dose\* of sapropterin dihydrochloride oral suspension 100 mg/mL administered with water under fed conditions.~Treatment D: 1 x 10 mg/kg dose\* of Kuvan (sapropterin dihydrochloride) 100 mg powder for oral solution dissolved in water and administered under fed conditions"||||
33751450|NCT04783155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a double-blinded, randomized study||t|f|t|f
33840585|NCT05942820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized in a 3:1 ratio of BWC0977 and Placebo. The following controls will be employed to maintain the double-blind status of the study Infusion solution containing active drug and placebo will be indistinguishable in appearance Randomization list will be provided to the study center pharmacist for dispensing purposes and kept in the pharmacy, accessible to the pharmacist and authorized personnel only PK results for the interim analyses between cohorts will be presented in a blinded fashion.|Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose (SAD and MAD) trial|t|f|t|f
33840586|NCT00978367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840587|NCT00003397||||TREATMENT||||||||
33840588|NCT04896242|||COHORT||PROSPECTIVE|||||||
33863801|NCT05776225|||COHORT||PROSPECTIVE|||||||
33962948|NCT00906685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962949|NCT05774210|||COHORT||PROSPECTIVE|||||||
33962950|NCT04220034|||COHORT||PROSPECTIVE|||||||
34176514|NCT04340895|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176515|NCT04659044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176516|NCT02444338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"PROBE~* outcome assessment: blinded~* patient \& investigator: open"||f|f|f|t
34176517|NCT06586892|||COHORT||PROSPECTIVE|||||||
34176518|NCT05865990|NA|SINGLE_GROUP||TREATMENT||NONE||An international, multicenter, single-arm, three-cohort, two-stage optimal Simon's design, phase II clinical trial.||||
33840589|NCT03832842|||COHORT||PROSPECTIVE|||||||
33840590|NCT01541384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33840591|NCT02328118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840592|NCT04753086|||COHORT||PROSPECTIVE|||||||
33840593|NCT03931746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will not have knowledge of or access to the intervention that was performed and represents a provider not involved in the surgical care of the patient.|To compare wound healing and scar quality following the placement of a porcine xenograft compared to second intention healing of leg wounds following Mohs or excisional surgery.|f|f|f|t
33840594|NCT04547647|||CASE_ONLY||CROSS_SECTIONAL|||||||
33840595|NCT06158932|NA|SINGLE_GROUP||OTHER||NONE||||||
33840596|NCT01721928|||CASE_CONTROL||PROSPECTIVE|||||||
33840597|NCT04990362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840598|NCT01734239|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33840599|NCT05025670|||CASE_ONLY||PROSPECTIVE|||||||
33840600|NCT02199223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840601|NCT02710175|||CASE_CONTROL||PROSPECTIVE|||||||
33840602|NCT04052815|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33840603|NCT04439045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The clinical trial is designed as a double-blind (observer blind) study. Observer-blind means that during the course of trial, the companions/parents/guardians of the subjects and the study personnel responsible for the evaluation of any study endpoint will be unaware which vaccine was administered.||t|t|f|f
33840604|NCT00749957|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840605|NCT02512731|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33840606|NCT04617249|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||anesthesia with median route versus paramedian route|t|t|t|t
33840607|NCT02888652|||OTHER||PROSPECTIVE|||||||
33840608|NCT04551677|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840609|NCT04267965|||COHORT||PROSPECTIVE|||||||
33840610|NCT04606498|||COHORT||OTHER|||||||
34176519|NCT06222099|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"Participants cannot be effectively blinded as they receive feedback from the device or RPMC in specific arms, and false alerts could alter the control arm's dynamics. The RPMC cannot be effectively blinded to study arms due to access to additional patient data.~The focus of blinding is the Clinical Events Committee (CEC), which adjudicates outcomes from EHR/claims data.~The CEC is blinded to patient interactions and Heartfelt device data, with Heartfelt data removed from EHR before CEC review. This ensures unbiased outcome assessment, with the CEC not accessing device alert data."|"This trial is a crossover randomized study with four arms:~1. Standard Care: Home-installed device capturing data without alerts or transmission to RPMC;~2. Standard Care + Heartfelt: Device provides alerts to patients/family but doesn't transmit data to RPMC;~3. RPMC Care Only: Data sent to RPMC without patient alerts;~4. RPMC + Direct-to-Patient Alerts: Data and alerts sent to both RPMC and patients/family.~Post-randomization, patients may opt for long-term follow-up, alternating between the RPMC + Direct-to-Patient Alerts mode and Standard Care."|f|f|f|t
34176520|NCT06409806|NA|SINGLE_GROUP||OTHER||NONE||||||
34176521|NCT05255679|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Person performing electrophysiology assessments will not know group assignment|Non-randomized control group design|f|f|f|t
34176522|NCT06573723|||COHORT||OTHER|||||||
34176523|NCT05188443|||COHORT||RETROSPECTIVE|||||||
34176524|NCT05590377|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176525|NCT05100121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176526|NCT05621070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33962951|NCT05269056|||COHORT||PROSPECTIVE|||||||
34176527|NCT03300128|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomized 1:1 into a treatment group (IY-ASD parent training program) or comparison group (Circle of Parents parent support program). The 14-week parent groups will be offered twice per year. Once participants are enrolled in the study, they will complete a set of baseline measures (described in Section 5). The study coordinator will provide Dr. Dababnah a complete list of participants (unique identifiers only which do not contain identifiable information). Dr. Dababnah will randomize participants using a computer-generated randomization plan into either IY-ASD or Circle of Parents support group. While participants and the research team will not be blinded to group assignment, only the PI and her Research Assistant(s) at UMB will have access to the randomization plan. Dr. Dababnah and her team will review baseline measures for each period after individuals have been randomized."||||
34176528|NCT04327700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176529|NCT00242931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176530|NCT05238675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176531|NCT04676529|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176532|NCT06594315|||COHORT||PROSPECTIVE|||||||
34176533|NCT01855529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176534|NCT06654011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176535|NCT00541372|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34176536|NCT05057637|||COHORT||PROSPECTIVE|||||||
34176537|NCT05520034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized control trial (RCT) study||||
34176538|NCT06086795|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34176539|NCT04534244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176540|NCT03373240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either a (1) cognitive remediation program (training tasks) specifically designed to address cognitive-affective dysregulation or (2) control tasks (verbal fluency tasks).||||
34176541|NCT02085460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176542|NCT05776940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176543|NCT02420717|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176544|NCT04351711|||CASE_CONTROL||PROSPECTIVE|||||||
34176545|NCT05410743|RANDOMIZED|PARALLEL||TREATMENT||NONE||phase 1 To evaluate response to the different groups with doses of 2.22 GBq(60 mCi) and 3.33GBq (90 mCi) and 4.99 GBq (135mCi) of 177Lu-LNC1010 in patients with advanced or metastatic SSTR2-positive tumors;Phase 2 will reassess treatment efficacy and safety using a fixed dose identified in Phase 1.||||
34176546|NCT03457493|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840611|NCT05119062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33840612|NCT05380206|||CASE_ONLY||RETROSPECTIVE|||||||
33962952|NCT00563524|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33962953|NCT01120522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962954|NCT03137095|||CASE_CONTROL||PROSPECTIVE|||||||
33962955|NCT05627388|NA|SINGLE_GROUP||OTHER||NONE||||||
33962956|NCT01966237|||CASE_CONTROL||PROSPECTIVE|||||||
34176547|NCT02346123|||||CROSS_SECTIONAL|||||||
34176548|NCT02661139|||COHORT||PROSPECTIVE|||||||
34176549|NCT03555422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind placebo controlled study||t|t|t|t
34176550|NCT06590805|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two Parallel Groups for Comparison.||||
34176551|NCT00129402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176552|NCT00196547|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34176553|NCT04156373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33962957|NCT01055574|||COHORT||PROSPECTIVE|||||||
33962958|NCT04624841|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|The patient is blinded to the intervention S/he receives. The surgeon, investigator, and outcomes assessor are masked but not strictly blinded up to the point when the near-infrared camera is switched on|Prospective randomized controlled trial|t|t|t|t
33962959|NCT00627458|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33962960|NCT05640583|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Study Arm = 10 patients diagnosed with colonic IBD (5 diagnosed with Ulcerative Colitis and 5 diagnosed with Crohn's Disease) scheduled for a surveillance colonoscopy~Control Arm = 10 patients scheduled for a routine screening colonoscopy who do not have a history of IBD symptoms or IBD diagnosis"||||
33962961|NCT03880929|||CASE_ONLY||RETROSPECTIVE|||||||
33962962|NCT02876705|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962963|NCT04162730|||CASE_ONLY||PROSPECTIVE|||||||
33962964|NCT01766310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751451|NCT06620042|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective open-label observational study of patients with treatment resistant bipolar depression referred for intravenous ketamine, with an interventional component of fMRI. All participants will receive an acute series of ketamine consisting of twice weekly infusions over three weeks. Non-responders will have their End of Study visits within 5 days of the last ketamine infusion. Responders (participants who achieve a ≥ 50% decrease on their QIDS-SR-16 score from Baseline) will return for three weeks of continuation treatment (weekly ketamine) and then have their End of Study visit within 5 days of the last continuation treatment. All participants will undergo fMRI prior to their first ketamine infusion and after completion of their acute series.||||
33751452|NCT06205420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751453|NCT05821309|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Only objective data in the form of fecal microbiome diversity will be obtained via 16s rRNA sequencing. Neither the participant nor the investigators will be blinded.|||||
33751454|NCT04821778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751455|NCT02998073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751456|NCT05823259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751457|NCT01687023|||COHORT||CROSS_SECTIONAL|||||||
33751458|NCT00688818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751459|NCT03923933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838582|NCT04996433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of interventions, blinding of patients/therapists concerning the treatment program is impossible, but all assessments as well as data analysis will be blinded to treatment allocation. Notably, patients are blinded to the study hypothesis by the Informed Consent process, as patients are told in the patient information and educational discussions about the study that they will in any case receive one of two different scientifically based psychotherapy programs, although it is unclear which of the two programs is more effective. Similarly, the members of the treatment teams of each study ward are not informed about the study hypothesis; however, they are informed that it has not yet been scientifically clarified which therapy is more effective.|Prospective, multicenter, evaluator-blinded, parallel-group, randomized controlled intervention trial with an active control condition|f|f|f|t
33838583|NCT02744248|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33962965|NCT00176852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962966|NCT02023788|||CASE_ONLY||PROSPECTIVE|||||||
33962967|NCT01002131|||CASE_ONLY||CROSS_SECTIONAL|||||||
33962968|NCT00656396|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33962969|NCT01485705|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33962970|NCT06102837|||OTHER||OTHER|||||||
33962971|NCT03250013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33962972|NCT01353105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150697|NCT06047496|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel study design of TRE vs SE on the outcomes listed. 80 participants will be recruited (40 per group) with an interim analysis performed after 34 participants are recruited (17 per group).||||
34150698|NCT03951090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is an un-blinded, 2-arm randomized control trial of a brief, user friendly GA report in real time which summarizes GA-identified deficits and includes recommendations for evidence informed multidisciplinary interventions to address these deficits.||||
34150699|NCT04506203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Lung Collapse will be diagnosed by a blind researcher that does not know the air test results|||||
34176554|NCT03456128|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|1: 1. The outcome assessor will be unaware of which groups the older adults are assigned to.|The study is a single-masked, two-group, randomized trial to test the effectiveness of CAPABLE in reducing ADL difficulties compared to those randomized to usual care.|f|f|f|t
34176555|NCT06704256|||CASE_ONLY||PROSPECTIVE|||||||
34176556|NCT01149096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176557|NCT06567145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176558|NCT06039579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176559|NCT02173080|||COHORT||CROSS_SECTIONAL|||||||
34176560|NCT05031520|||COHORT||PROSPECTIVE|||||||
34176561|NCT06336005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34176562|NCT06654492|||CASE_ONLY||RETROSPECTIVE|||||||
34176563|NCT05502562|||COHORT||PROSPECTIVE|||||||
34176564|NCT02300792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150700|NCT02456857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838584|NCT01370655|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33838585|NCT05614622|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33838586|NCT03965442|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34150701|NCT02557984|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34150702|NCT04928729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150703|NCT05011721|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150704|NCT00370513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150705|NCT05323097|||COHORT||RETROSPECTIVE|||||||
34150706|NCT00410306|||COHORT||PROSPECTIVE|||||||
34150707|NCT01071824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150708|NCT00005056||||TREATMENT||||||||
34150709|NCT05224037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150710|NCT00129961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150711|NCT02968147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150712|NCT03878303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150713|NCT03680872|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-cohort early feasibility trial to determine whether an investigational device called the Bidirectional Neural Bypass System can lead to the restoration of movement and sensation in the hand and wrist of up to three individuals with tetraplegia.||||
34150714|NCT02663141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150715|NCT05831254|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34150716|NCT00428844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150717|NCT03377192|||CASE_ONLY||PROSPECTIVE|||||||
34150718|NCT00734721|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||f|t|t|t
34150719|NCT00002506||||TREATMENT||||||||
34176565|NCT06704165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34176566|NCT05813574|||COHORT||OTHER|||||||
34150720|NCT06055660|||CASE_ONLY||RETROSPECTIVE|||||||
34176567|NCT00810823|||COHORT||PROSPECTIVE|||||||
34176568|NCT06594380|RANDOMIZED|PARALLEL||TREATMENT||NONE||Using a new oropharyngeal airway set||||
33751460|NCT06719505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The sample randomization will be conducted secretly by a professional who is unaware of the study and the volunteers. This professional will perform the randomization using random numbers to assign the study sample into two groups: the Multicomponent Group (EM) (n=50) and the Pilates Group (EP) (n=50). The same professional will then place the assignments in opaque envelopes, which will be sealed and contain the group allocation inside. Participants will be informed that they may be allocated to either group during the recruitment and selection process. Moreover, both the participants and the researchers will only know which group each individual is assigned to at the moment of envelope delivery.~Assessments will be conducted before the intervention, during the treatment (3 months), and after its completion (6 months) by the same professional, who will be blinded to the identities of the volunteers."|The interventions will last for six months, three times per week, for one hour, on non-consecutive days. The interventions for the Multicomponent group will consist of exercises for aerobic training, strengthening, resistance, balance, and flexibility, with one protocol for the first 3 months and a second protocol for months 4-6. The number of repetitions for each exercise will range from 3 sets of 8 to 10 repetitions, totaling 18 exercises. The Pilates exercise group will perform stretching and strengthening exercises targeting the main muscle groups, with one protocol for the first 3 months and a second protocol for months 4-6. Each protocol will consist of 17 exercises, with 3 sets of 8 to 10 repetitions.|f|f|t|t
34176569|NCT04964362|||COHORT||PROSPECTIVE|||||||
34176570|NCT06595381|||COHORT||PROSPECTIVE|||||||
34176571|NCT02832258|||CASE_ONLY||PROSPECTIVE|||||||
34176572|NCT06424236|NA|SINGLE_GROUP||TREATMENT||NONE|Arm is Open-label as noted in the arm description|||||
34176573|NCT06099184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
33751461|NCT03532295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751462|NCT02257099|||CASE_ONLY||OTHER|||||||
33751463|NCT01717118|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33751464|NCT06732115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|statistician||t|f|f|t
33751465|NCT02207816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751466|NCT05668117|||COHORT||RETROSPECTIVE|||||||
33751467|NCT05289362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751468|NCT04530292|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33751469|NCT06200181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33751470|NCT05225246|||COHORT||RETROSPECTIVE|||||||
33751471|NCT04109703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded with a control condition using a low level heating (37 degree C) device. The active experimental device used heast that intermittently pulsed to 45 degrees C.|Double blinded, randomized, active placebo controlled trial|t|t|t|t
33751472|NCT04534374|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33751473|NCT00817362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751474|NCT06561529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751475|NCT06732817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751476|NCT05109299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150721|NCT04726059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to either an ABT+TSCS or ABT+SHAM arm. Participants who are assigned to ABT+SHAM will have the opportunity to complete an ABT+TSCS open-label follow-up.|t|f|f|f
34150722|NCT04030247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176574|NCT04335253|NA|SEQUENTIAL||TREATMENT||NONE||||||
34150723|NCT05378074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34150724|NCT02645617|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150725|NCT03825237|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34150726|NCT01642758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150727|NCT02265796|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34150728|NCT04670783|||CASE_ONLY||PROSPECTIVE|||||||
34176575|NCT06280924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|An independent assessor will conduct the post-intervention assessment. The independent assessor will be blinded to group assignment.|Randomized controlled trial|f|f|f|t
34176576|NCT06184529|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34176577|NCT05068752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176578|NCT00965354|||COHORT||PROSPECTIVE|||||||
34150729|NCT04021823|||COHORT||PROSPECTIVE|||||||
34150730|NCT02162966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150731|NCT00820872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150732|NCT02139904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150733|NCT02037490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176579|NCT03204188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176580|NCT06357247|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34176581|NCT06345313|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34176582|NCT00619034|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34176583|NCT03868423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176584|NCT05088876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176585|NCT06521749|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|the investigator responsible for data collection and the patients participating in the study will not be aware of the group assignment.|"Patients will be allocated, according to the study group into:~1. Bougie Group: (Group A) Endotracheal intubation will be attempted using the video laryngoscope and the USB device will be used as a bougie.~2. Stylet Group: ( Group B) Endotracheal intubation will be attempted using the video laryngoscope and using the USB device as a stylet.~3. Control Group: (Group C) Intubation of the trachea with an endotracheal tube will be attempted by using only the video laryngoscopy."|t|f|f|t
34176586|NCT02968134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176587|NCT06594965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176588|NCT01282034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176589|NCT03587506|||COHORT||PROSPECTIVE|||||||
34176590|NCT06600022|NA|SEQUENTIAL||TREATMENT||NONE||||||
33863802|NCT04886154|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner.|"* The Phase I safety lead-in will follow a staggered enrolment~* Phase II will start only after a positive outcome from the internal Safety Review Committee (iSRC) review of the safety data from participants receiving vaccination in Phase I of the study."|t|t|t|t
34176591|NCT03541083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863803|NCT05009160|||COHORT||PROSPECTIVE|||||||
34176592|NCT03729453|||COHORT||PROSPECTIVE|||||||
34176593|NCT06596213|||COHORT||RETROSPECTIVE|||||||
34176594|NCT04084158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176595|NCT04408989|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34176596|NCT03178214|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751477|NCT04495179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751478|NCT01374542|||COHORT||PROSPECTIVE|||||||
33751479|NCT05612490|||CASE_ONLY||PROSPECTIVE|||||||
33751480|NCT01041638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751481|NCT02374905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33751482|NCT00088231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751483|NCT02656433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33751484|NCT02862457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751485|NCT04687891|||CASE_ONLY||CROSS_SECTIONAL|||||||
33751486|NCT04941599|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Subjects will be randomized to treatment with either 2-Hydroxybenzylamine (2-HOBA) , a naturally occuring dicarbonyl scavenger, or placebo for 6 weeks.|t|t|t|t
33751487|NCT02654626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751488|NCT02724943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751489|NCT06221566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant|Parallel Assignment|t|f|f|f
33751490|NCT03181100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751491|NCT04082546|||COHORT||CROSS_SECTIONAL|||||||
33751492|NCT01175603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751493|NCT03209804|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Traditional therapy group：traditional management of AVMs, such as unsimultaneous endovascular interventional embolisation, radiotherapy followed by microsurgical resection, will be conducted to patients involved in this group.~Hybrid operation group: A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously to patients in this group."|f|f|f|t
33751494|NCT03725917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All assessments will be made by an experienced Podiatrist, who will not have other functions in the study|Randomized Controlled Trial|f|f|f|t
33751495|NCT03704766|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|For patients with inflamed joints, the medical team will be blind to the results of the alpha-defensin assay and other experimental tests for a period of 2 weeks, after which results may be divulged to the clinical team at their request. As such, the results will not influence the physician/surgeons' decision for acute treatment of the patient, as the decision to treat suspected septic arthritis is typically made within 24 hours, and the final diagnosis is made within 2 weeks (pending culture results). As the testing of the leukocyte esterase strips will occur in the operating room, the surgeon will not be blinded to these results. A blinded team member will read the pictures of all of the leukocyte test strip results at once, after they have all been collected. The patient will be made aware of results at the physician/surgeon's discretion. For normative controls, the results of experimental testing will not be divulged to the clinical team or to the patient.|Participants are assigned as either cases of infection/inflammation, or normative controls, and receive the same diagnostic testing for the duration of the study.|t|t|f|f
33751496|NCT03213223|||COHORT||PROSPECTIVE|||||||
33751497|NCT06732544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863804|NCT06299436|||COHORT||PROSPECTIVE|||||||
33863805|NCT05775562|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863806|NCT05789797|||CASE_CONTROL||PROSPECTIVE|||||||
33863807|NCT06584071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150734|NCT04571996|NA|SINGLE_GROUP||OTHER||NONE||||||
34150735|NCT00626405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150736|NCT03743064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This was a double-blind study. The blinding of the study drugs was guaranteed by the use of anamorelin HCl film-coated tablets and matching placebo tablets. Patients were randomized using the Interactive Web Response System (IWRS). Any unblinding of the study treatment was performed using the IWRS.|Randomized, Double-Blind, Placebo-Controlled, Multicenter Study|t|t|t|t
34150737|NCT05772910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial|f|f|f|t
34150738|NCT03848949|RANDOMIZED|PARALLEL||PREVENTION||NONE|Both patients and surgeons are aware whether they are being assigned to the control group or the experimental group|"Subjects are randomly assigned to two groups using a blocked randomization schedule.~Subjects assigned to the control group receive the standard treatment for their condition, which must be at least 2 weeks of weight bearing as tolerated in a controlled ankle movement boot in order for them to meet inclusion criteria.~Subjects assigned to the experimental group receive the orthotic for use on the contralateral limb, which is the only alteration to their treatment of at least 2 weeks of weight bearing as tolerated in a controlled ankle movement boot (required to meet inclusion criteria)."||||
34176597|NCT06593990|||CASE_ONLY||CROSS_SECTIONAL|||||||
34176598|NCT05177965|||COHORT||PROSPECTIVE|||||||
34176599|NCT05856812|||OTHER||PROSPECTIVE|||||||
34176600|NCT02784080|||COHORT||PROSPECTIVE|||||||
34176601|NCT05699408|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial||||
34176602|NCT06592469|||COHORT||PROSPECTIVE|||||||
34176603|NCT05975255|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Sequential allocation to drug dosage according to result of previous participant||||
34176604|NCT06601530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34176605|NCT04717635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176606|NCT03715556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176607|NCT06177483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Open label - all are aware of intervention assignment|Randomized, Parallel group absorption study||||
34176608|NCT01066013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176609|NCT06467825|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34176610|NCT05077215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176611|NCT06476132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176612|NCT06704737|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176613|NCT05996575|||COHORT||CROSS_SECTIONAL|||||||
34176614|NCT03293615|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176615|NCT03361137|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176616|NCT03389477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176617|NCT03268317|||COHORT||PROSPECTIVE|||||||
34176618|NCT01901159|RANDOMIZED|CROSSOVER||||NONE||||||
34176619|NCT04292275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176620|NCT04887441|||CASE_ONLY||PROSPECTIVE|||||||
34176621|NCT02429323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33863808|NCT04091022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This trial will be double-blinded. The clinical team and patient will remain blinded to the randomization.~All study drug will be blinded except to the pharmacists. Records will be kept to document receipt, distribution and disposition of the drugs. Unblinding will only be done at the end of the study or as medically indicated with consent of the study PI and the biostatistician, after consulting the NIH Project Officer."|randomized, placebo-controlled, double-blind|t|t|t|t
34176622|NCT04487366|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34176623|NCT06212947|||COHORT||PROSPECTIVE|||||||
34176624|NCT04944277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176625|NCT06432153|||COHORT||PROSPECTIVE|||||||
34176626|NCT06179303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176627|NCT05313984|||COHORT||PROSPECTIVE|||||||
34176628|NCT05579782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only participants will be masked to the intervention.|"NIRAF detection technology is used as an adjunctive tool for intraoperative parathyroid identification in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND) in the interventional group.~Generic Name of Device: Parathyroid Autofluorescence Detection Device (NIRAF detection technology).~The Parathyroid Autofluorescence Detection Device consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nanometer (nm) laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 Milliwatts (mW). The device has an FDA clearance for clinical use in general surgeries and dermatological use (Class 2 device)."|t|f|f|f
34176629|NCT05865028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176630|NCT05119647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176631|NCT06356337|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34176632|NCT05514977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34176633|NCT02741128|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33863809|NCT01789099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863810|NCT03732651|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Each patient served as his own control.|f|f|f|t
33863811|NCT02911090|||COHORT||PROSPECTIVE|||||||
33863812|NCT04692818|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33863813|NCT04246086|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33863814|NCT04280276|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33863815|NCT06252519|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Each treatment was assigned a letter and provided to subjects in a paper cup.|Randomized cross-over single-blinded study|t|f|f|f
33962973|NCT06332365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomization: The enrolled subjects were randomly assigned to one of two treatment protocols using a computer-generated table. This method ensures impartial allocation and avoids biases in treatment selection for each patient.~Masking: Medications were prepared and packaged in identical, sealed, and numbered envelopes by the hospital pharmacy and a clinician not involved in the subsequent phases of the study. Each sealed envelope contained the protocol assignment for individual patients and written instructions for the application of the medications. Moreover, clinicians involved in treatment evaluation at each follow-up session were blinded to the treatment assigned to each patient."||t|f|t|f
33962974|NCT00127192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33962975|NCT03242993|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single arm study. No placebo or other comparator will be used. \[18F\]-AzaFol is used as a PET tracer, all patients successfully enrolled will be assigned to the treatment group.||||
33962976|NCT02248285|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33962977|NCT04985942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962978|NCT02846467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33962979|NCT01447979|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33962980|NCT04312399|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||10 study groups: 9 groups who start with hormonal treatment and 1 control group who doesn't start with hormonal treatment||||
33962981|NCT02156466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33962982|NCT04724928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962983|NCT05285631|||COHORT||PROSPECTIVE|||||||
33962984|NCT04071392|||COHORT||PROSPECTIVE|||||||
33962985|NCT04394910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33962986|NCT06515444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962987|NCT06365151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962988|NCT04643054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33962989|NCT02410031|||OTHER||OTHER|||||||
33962990|NCT00226902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33962991|NCT02789124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33962992|NCT01032330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33962993|NCT00479765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176634|NCT06067516|||COHORT||PROSPECTIVE|||||||
34176635|NCT01506596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176636|NCT06599216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176637|NCT05221931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical outcome assessment will be performed under blinded assessment about the allocated treatment group.|Prospective, multi-center, open-label, randomized controlled, noninferiority trial|f|f|f|t
34176638|NCT04126161|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34176639|NCT04339764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176640|NCT02278510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176641|NCT06211179|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150739|NCT05833178|||COHORT||PROSPECTIVE|||||||
34150740|NCT00303511|||COHORT||RETROSPECTIVE|||||||
34150741|NCT03465787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176642|NCT03939143|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34150742|NCT05962359|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176643|NCT02908061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176644|NCT05942586|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||This trial will be conducted as a single-blinded, 2 × 2 factorial design intervention study to systematically compare the effects of the probiotic (L. reuteri PB-W1™), the prebiotic blend (comprising 50 % raffinose and 50 % xylooligosaccharide), the synbiotic (a combination of the probiotic and the prebiotic blend) and relevant placebo controls (maltodextrin in place of the prebiotic blend and placebo capsules in place of the probiotic)|t|f|t|t
34150743|NCT00444067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962994|NCT02221622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150744|NCT04702113|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|This is an open label study.|"There will be two study arms:~1. Conventional therapy (controls)-treatment with clopidogrel and no pre-emptive genotyping~2. Genotype-guided therapy (experimental)"||||
34150745|NCT01864421|||CASE_CONTROL||PROSPECTIVE|||||||
34150746|NCT04195386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Compare the survival of restorations performed with chemically activated composite resin alkasite and resin- modified glass ionomer cement.|t|f|f|f
34150747|NCT00462748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150748|NCT03046225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838587|NCT06460324|||COHORT||RETROSPECTIVE|||||||
33838588|NCT04080037|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study will enroll practicing PCPs in the US. All eligible and consented participants will complete a multiple-choice pre-assessment, the complete 6 weekly patient simulations with feedback and peer benchmarking, then complete a multiple-choice post-assessment.||||
33838589|NCT02871505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33962995|NCT01917188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33962996|NCT04765189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33962997|NCT05224479|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Radiologists will be blinded when using machine learning and random triage methods.|Radiologists will triage chest radiographs using traditional, machine learning, and random methods.|t|f|f|f
33962998|NCT04667026|||COHORT||RETROSPECTIVE|||||||
33962999|NCT04675073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150749|NCT02619643|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||t|f|t|f
33963000|NCT01437137|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34150750|NCT02078388|||CASE_ONLY||PROSPECTIVE|||||||
34150751|NCT01313962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150752|NCT06026956|||OTHER||PROSPECTIVE|||||||
34150753|NCT04133194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150754|NCT06030284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33838590|NCT06336187|||COHORT||PROSPECTIVE|||||||
33838591|NCT05057338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor is masked for group allocation|RCT with two arms: intervention group and control group.|f|f|f|t
33838592|NCT00214747|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33963001|NCT01122043|||COHORT||PROSPECTIVE|||||||
33963002|NCT05537142|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963003|NCT00295620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963004|NCT00972153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33963005|NCT04318535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The whole study will be divided into three treatment periods. For each treatment period, eligible participants will be randomized to either T1T2R, T2RT1 or RT1T2 treatment sequence according to 1:1:1 ratio||||
33963006|NCT01900379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963007|NCT06061718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963008|NCT04347031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963009|NCT05357209|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study is divided into two arms. Arm A will contain subjects with diagnosed AF, and arm B will contain all other subjects. This is a prospective, parallel-cohort, non-randomized study using an enriched population.||||
34150755|NCT04397328|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150756|NCT03825159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150757|NCT00756951|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34150758|NCT00945230|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34150759|NCT03153488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150760|NCT05670509|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two major groups were included (home and ER group) and each were subdivided into 3 groups according to route of administration (nasal, buccal and IM)||||
34150761|NCT02505360|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150762|NCT05349383|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150763|NCT02254395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150764|NCT02654665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150765|NCT00459472|NA|SINGLE_GROUP||||NONE||||||
33963010|NCT04556838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked|Double-masked parallel|t|t|t|t
33963011|NCT04818151|||COHORT||RETROSPECTIVE|||||||
34065110|NCT05535400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants could not be blinded due to the nature of the intervention. Patients will be reminded to keep the intervention content confidential and not discuss this with participants in the control group to avoid contamination. Also, the research assistant (RA1) who responsible for assessing all the outcomes will be blinded to the group allocation.|We aim to have two study group, including the eight-week Physical-Psychological Integrative online intervention group and the brief online didactic education control group.|f|t|f|t
34065111|NCT04497974|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomised controlled intervention study|t|f|t|f
34065112|NCT00307853|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34065113|NCT01233752|||COHORT||PROSPECTIVE|||||||
34065114|NCT01603407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065115|NCT05230745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065116|NCT01080170|||COHORT||PROSPECTIVE|||||||
34065117|NCT01031017|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34065118|NCT02867891|||COHORT||PROSPECTIVE|||||||
34176645|NCT06420882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176646|NCT01251965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase I is a standard 3+3 design and will be used to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and no formal evaluation of efficacy (response rate will be implemented. Patients in Phase I part who were treated at the MTD will be included toward patients assessed for response in the phase II stage.||||
34176647|NCT00148278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963012|NCT06565728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963013|NCT03084978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065119|NCT02949141|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065120|NCT05947435|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomisation was designed as 3 (n= 25) named Groups A, B, and Group C in a 1:1:1 ratio with a computer-based algorithm and sealed in opaque envelopes by the surgeon assigned to the study. The investigative anesthesiologist selected an envelope in the order of numbers on it, and Group A continued with an IV infusion of 10 mg/kg tranexamic acid for 20 minutes just before the surgical incision. In Group B, 10 mg/kg tranexamic acid was placed in the first irrigation solution, and in Group C, no drug was given in either way. The urologist was blind to the study groups and was the evaluator of an intraoperative visual score. Postoperative Hb and Hct values and complications were followed by the surgeons who were also blinded to the groups, and the decision of blood replacement was made according to the Hct values according to our standard protocol of the urology department.||t|f|f|t
34065121|NCT05724199|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34065122|NCT00893139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065123|NCT02309190|||COHORT||PROSPECTIVE|||||||
34065124|NCT06306768|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34065125|NCT05979974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065126|NCT06131216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065127|NCT02905643|||COHORT||PROSPECTIVE|||||||
34065128|NCT05498064|||CASE_ONLY||PROSPECTIVE|||||||
34065129|NCT00335010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34065130|NCT01350375|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34065131|NCT01862666|||COHORT||PROSPECTIVE|||||||
34065132|NCT05697302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34065133|NCT04582565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34176648|NCT06345079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176649|NCT06101212|||CASE_ONLY||PROSPECTIVE|||||||
34176650|NCT06222853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176651|NCT03299556|||COHORT||PROSPECTIVE|||||||
34176652|NCT00575185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176653|NCT00683527|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176654|NCT01440959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065134|NCT04015778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065135|NCT00492232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065136|NCT01303133|||COHORT||CROSS_SECTIONAL|||||||
34065137|NCT01255384|||CASE_CONTROL||PROSPECTIVE|||||||
34065138|NCT02897167|||CASE_CONTROL||RETROSPECTIVE|||||||
34065139|NCT04883684|NA|SINGLE_GROUP||OTHER||NONE||||||
34065140|NCT01251497||PARALLEL||SUPPORTIVE_CARE||||||||
34065141|NCT06668103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065142|NCT03073356|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized dobbel-blinded crossover|t|f|t|t
34065143|NCT03383094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065144|NCT01438385|||OTHER||PROSPECTIVE|||||||
34065145|NCT03304275|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065146|NCT01260272|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065147|NCT00579332|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34065148|NCT02215109|||CASE_ONLY||PROSPECTIVE|||||||
34065149|NCT06071572|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065150|NCT02632084|||CASE_ONLY||PROSPECTIVE|||||||
34065151|NCT05233579|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34065152|NCT00214214|RANDOMIZED|PARALLEL||||NONE||||||
33863816|NCT03875209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants in SC dosing Arm 4 Groups J and K will be blinded as will providers and members of the study site team. Study pharmacists will not be blinded. Safety monitoring committee will not be blinded. All participants treated IV and participants treated 1 mg/kg SC will not be masked (open-label).|Dose escalation, open-label (IV or SC administration), placebo-controlled (SC administration)|t|t|t|f
33863817|NCT04038840|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863818|NCT06352827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will be enrolled in the observational intervention group first.||||
33863819|NCT06225986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33863820|NCT05512247|NA|SINGLE_GROUP||PREVENTION||NONE|All participants enrolled in the study will receive the meal delivery intervention, so blinding is not possible.|All participants will receive the meal delivery intervention to examine feasibility metrics (e.g., recruitment, attrition, adherence, safety) and pre-post intervention changes. A quasi-experimental design utilizing a comparison group derived from de-identified hospital records will be used for exploratory analyses of intervention impact on gestational weight gain and blood pressure compared to standard care.||||
33863821|NCT04179448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065153|NCT03181243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Because the length of sperm retrieval procedure is significantly different between groups, we use matched pairs based on the length of procedure as the matching variable for the primary outcome (pain relief) by specify two in one block. We create a block 2 to assign sample numbers equally to each group (MadaJet or needle injection) and assign equitably the block to each procedure (TESE or PESA). Therefore, patients will be randomized, using a computer-generated randomization list in a 1:1 ratio and block 2, to either the MadaJet group or to needle injection group after the assessment of eligibility and signing informed consents. Allocation of patients will be done by a third-party via telephone according to the specified list. The patients don't know which anaesthesia technique will be performed.|t|f|f|f
34176655|NCT06706284|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the treatment assignment. The study team will be unblinded. The investigators will deliver the treatment assignments to the hospital pharmacist as they occur.|Controlled 2 arm assignment study. The investigators will stochastically match the patient characteristics between the two arms using for a 2:1 design in terms of level of gender (male, female), level of injury (tetraplegia, paraplegia), dichotomized baseline HbA1c (above or below 7.5%), dichotomized age (above or below a median age for this population) and dichotomized BMI (above or below a median BMI for this population)|t|f|f|f
34176656|NCT05375461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176657|NCT06494020|NA|SINGLE_GROUP||OTHER||NONE||||||
33863822|NCT05619744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176658|NCT06512584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176659|NCT04381832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176660|NCT05794321|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomly assigned to treatment arms. One treatment arm will include the use of IV TXA, the other treatment arm will receive the standard of care for treatment. Patients then remain in that same treatment arm throughout the course of the study||||
34176661|NCT05321134|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, prospective, open-label, investigator initiated, non-randomized, interventional case-control study||||
33863823|NCT00458341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863824|NCT06734195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863825|NCT04155268|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33863826|NCT04683731|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Provider-participants will know that their enrolled patient-participant is participating in the study but will not know what arm they were assigned.|2x2, randomized, controlled trial|t|f|f|f
33863827|NCT06289673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863828|NCT03715023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863829|NCT06735365|||COHORT||RETROSPECTIVE|||||||
33863830|NCT05505045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcomes assessors will be blinded to participant study group assignment.|After baseline assessment, subjects will be randomized to one of two groups: (1) a 10-session Cognitive Orientation to daily Occupational Performance (CO-OP) intervention; or (2) a 10-session attention control group.|f|f|f|t
33863831|NCT03898492|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||One intervention group and one control group||||
33863832|NCT06212999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Cohort C is open-label.||t|t|t|t
33863833|NCT05666518|||COHORT||PROSPECTIVE|||||||
34065154|NCT00462176|||COHORT||RETROSPECTIVE|||||||
34065155|NCT03299725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065156|NCT02012959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065157|NCT02968680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065158|NCT01846468|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34176662|NCT06592365|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34065159|NCT05636072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Waitlist control group Randomized Control Design|t|f|f|f
34065160|NCT02854605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863834|NCT04972929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The chiropractic clinician will not be blinded in order to deliver the assigned treatment (spinal manipulation or Sham spinal manipulation) but all other assessors and study personnel will be blinded to the group assignment.|e plan to conduct a randomized pilot parallel-group randomized controlled trial (RCT) with appropriate SM and Sham SM treatment groups.|t|f|f|t
34065161|NCT05097599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065162|NCT03104452|||COHORT||PROSPECTIVE|||||||
33863835|NCT05593055|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants are randomized to chlorthalidone or eplerenone.|t|t|t|t
33863836|NCT05862818|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33863837|NCT00501826|NA|SINGLE_GROUP||TREATMENT||||||||
33863838|NCT06735781|||COHORT||RETROSPECTIVE|||||||
33963014|NCT03986164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participating individuals will be allocated within each group through a computer-generated list, stored in a brown opaque envelope, under the care of an individual (TCB) other than the examiner. Only the professional responsible for the treatments will have access to the codes and both the patients and the examiners will be blind to the group to which each patient belongs, making possible the characterization of the study as double-blind.|This is a longitudinal parallel randomized clinical trial, in Piracicaba Dental School, State University of Campinas (FOP-UNICAMP), periodic follow-ups will be performed for one year after the installation of implants in the anterior maxilla, by means of computer-assisted dental implant surgery or conventional surgery. The study will be conducted according to the Helsinki Declaration (2008), following the protocol for randomized clinical trials (Consort) (Schulz et al., 2010). The implant placement evaluations; radiographic and clinical evaluations of peri-implant tissues; as well as the success of the implants and the rehabilitation will be carried out immediately, 6 and 12 months after the implant installation.|f|f|t|t
33963015|NCT00649155|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33963016|NCT03744065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963017|NCT06309290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065163|NCT04107701|||OTHER||OTHER|||||||
34065164|NCT04845945|||COHORT||PROSPECTIVE|||||||
34065165|NCT01040715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065166|NCT00750256|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34065167|NCT03581617|||COHORT||PROSPECTIVE|||||||
34065168|NCT03853876|||COHORT||PROSPECTIVE|||||||
34065169|NCT06497504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double-blind study.||t|t|t|t
34065170|NCT02109406|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34065171|NCT05175521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34065172|NCT03919591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subject will receive one titre of the Challenge Virus intranasally.||||
34065173|NCT03951545|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34065174|NCT03502694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065175|NCT02690597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34065176|NCT00675870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065177|NCT06730659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065178|NCT02570750|||OTHER||PROSPECTIVE|||||||
34065179|NCT02278965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065180|NCT04361214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065181|NCT05690763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065182|NCT06424509|||CASE_CONTROL||OTHER|||||||
34065183|NCT00839787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065184|NCT04909372|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065185|NCT03528564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065186|NCT02364154|||CASE_CONTROL||PROSPECTIVE|||||||
34065187|NCT05412966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065188|NCT02281240|||||PROSPECTIVE|||||||
34065189|NCT05587413|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34176663|NCT05743868|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed.~Randomized crossover within group design."||||
34176664|NCT03905707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176665|NCT04005378|RANDOMIZED|PARALLEL||OTHER||NONE||Assigned to either treatment as usual or to the disengagement treatment||||
34176666|NCT02352025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176667|NCT02524327|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34176668|NCT05990296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a cluster randomized (at clinician level) design in terms of assignment to no-intervention control, multiprong CDS with GDMT order set, and multiprong CDS with referral to pharmacist co-management, and non-randomized (at clinic level) in terms of assignment to education versus delayed education arms.||||
33863839|NCT03226418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963018|NCT02711189|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33963019|NCT03117777|||COHORT||PROSPECTIVE|||||||
33963020|NCT02212561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065190|NCT00581425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065191|NCT01547052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065192|NCT02190409|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34065193|NCT02379507|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34065194|NCT05132790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065195|NCT03954717|||CASE_CONTROL||PROSPECTIVE|||||||
34065196|NCT05792605|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065197|NCT01516645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065198|NCT03693001|NA|SINGLE_GROUP||SCREENING||NONE||||||
34065199|NCT05255237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065200|NCT05998460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176669|NCT03192267|||COHORT||PROSPECTIVE|||||||
34176670|NCT04244253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176671|NCT03904394|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33863840|NCT06735729|||COHORT||CROSS_SECTIONAL|||||||
34176672|NCT06567028|||OTHER||CROSS_SECTIONAL|||||||
34176673|NCT06491446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind masking||t|f|t|f
33863841|NCT03382145|||COHORT||RETROSPECTIVE|||||||
33863842|NCT01553877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33863843|NCT00002860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863844|NCT03508258|||COHORT||RETROSPECTIVE|||||||
33863845|NCT01357421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963021|NCT05587101|||CASE_ONLY||PROSPECTIVE|||||||
33963022|NCT01570218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33863846|NCT04744571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863847|NCT05185986|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The principal investigator was blinded to participant allocation, and the analyses were performed blinded to the group. Participants' individual identification numbers assigned at baseline were used during the course of the trial. Identifying information were removed, such that no participant could be identified in the working dataset through one, or a combination of different variables.|Randomized Control Trial|f|f|t|t
33863848|NCT06418204|||COHORT||PROSPECTIVE|||||||
33963023|NCT01638637|||COHORT||CROSS_SECTIONAL|||||||
33863849|NCT06709196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863850|NCT06252233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963024|NCT05833373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All participants are randomized 1:1 to either the verum- or the sham-group. Both device look similar and are used in the same way so the participants are blinded. This is achieved with a conducting and a non-conducting ear electrode.~The care provider and the investigator is blinded as well. The researcher who randomises the patient is strictly separated from the investigator who is responsible for the follow-up. Only after the patient completed the last follow-up the outcome assessor will match the patient data with the affiliation to either the sham- or the verum-group."||t|t|t|f
33963025|NCT03740685|||COHORT||CROSS_SECTIONAL|||||||
33963026|NCT02007187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963027|NCT03970382|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963028|NCT01895088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963029|NCT06419673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963030|NCT05211752|||COHORT||CROSS_SECTIONAL|||||||
33963031|NCT03428048|||COHORT||PROSPECTIVE|||||||
33963032|NCT03613077|||CASE_ONLY||PROSPECTIVE|||||||
33963033|NCT05355831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Intervention pilot- and feasibility trial|t|t|t|t
34176674|NCT05567198|||COHORT||RETROSPECTIVE|||||||
34176675|NCT01480154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176676|NCT04942574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a monocentric exploratory study.||||
34176677|NCT00599872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176678|NCT04514887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the anesthetist administering the anesthesia and mechanical ventilation is Awarem of the arm.||t|f|t|t
34176679|NCT06565429|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34176680|NCT04872413|NA|SINGLE_GROUP||SCREENING||NONE||||||
34176681|NCT03128866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176682|NCT06271291|||COHORT||PROSPECTIVE|||||||
33863851|NCT05900388|||COHORT||RETROSPECTIVE|||||||
33863852|NCT05856123|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863853|NCT06734988|||COHORT||PROSPECTIVE|||||||
33863854|NCT04433806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963034|NCT03820778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963035|NCT02328001|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|t|f|f
33963036|NCT05190900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963037|NCT01440023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33963038|NCT00297492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963039|NCT02458898|RANDOMIZED|PARALLEL||||NONE||||||
33963040|NCT03362242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963041|NCT03134417|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33963042|NCT05535595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963043|NCT04031066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized using IRT system|double-blind, randomized 2:1 to either velmanase alfa:placebo|t|t|t|t
34065201|NCT04460131|||COHORT||PROSPECTIVE|||||||
34065202|NCT02958332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176683|NCT06363461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176684|NCT00375999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176685|NCT04456023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176686|NCT03043014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . We assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.|f|f|t|f
33863855|NCT06496295|||COHORT||PROSPECTIVE|||||||
33863856|NCT00570817|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33863857|NCT03952338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators will be blinded to group allocation if participants elect to complete data collection by telephone. Participants cannot be blinded to group assignment but will be blinded to the study objectives.||t|f|t|f
33863858|NCT01930149|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33863859|NCT02061605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863860|NCT03763240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Each participant receives the kit that corresponds to his/her study ID. The randomization is blind to both participants and the Investigator during the study.~The randomization list is kept with the local pharmacy during the entire study. Sealed envelopes with randomization information for each participant are send to investigator and may be opened in case of emergency."|Parallel arm study with placebo and intervention substance|t|t|t|t
34176687|NCT04239911|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data analyst will be blinded to study arm.|104 home health aides will be recruited from VNS Health and randomized to either enhanced usual care arm (heart failure training course; n = 52) or the intervention (heart failure training course plus mHealth app; n =52). Four nurses will also be recruited to the study. The total duration of each home health aides' involvement will be 90 days.|f|f|f|t
34176688|NCT06066788|NA|SINGLE_GROUP||OTHER||NONE||Social Sciences Wait-list control feasibility study||||
33751498|NCT03602118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All efforts will be made to blind the investigator and other key personnel of which dosage the participant was randomized to. Study drug will be dispensed by the pharmacy via a syringe to the investigator or their designee. The study medication label should only contain the protocol number, subject number and any other pertinent information. If after 1 hour following the completion of the study drug infusion, the seizure is not controlled with the initial loading dose, the patient will be considered a treatment failure in the primary efficacy analysis of this protocol/study. At this point, the blinding for the treating provider/investigator will be lifted.|This is a 1:1 randomized, double-blind, parallel-group, Phase 3 study.|f|t|t|f
34176689|NCT06587529|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176690|NCT06268808|NA|SINGLE_GROUP||OTHER||NONE||||||
34176691|NCT03975010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34176692|NCT04771156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176693|NCT05315102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Research|t|f|t|t
34176694|NCT05156047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, randomized withdrawal|t|f|t|t
34176695|NCT03088696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The care provider get's an envelope from the study nurse when going to the patient in the operating room. Only the study nurse knows if an acupuncture needle is in the envelope.|randomized comparative double blind prospective study|t|f|f|t
34176696|NCT06587802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176697|NCT02288286|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33751499|NCT04088409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751500|NCT02612948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751501|NCT06670261|||CASE_CONTROL||RETROSPECTIVE|||||||
33751502|NCT01912612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Trial was initially a randomized cross-over design. Soon after study initiation the trial design was amended because of poor accrual, and instead was a single arm open label trial in which all patients with pain were treated with study drug. Since so few patients had been enrolled at the time of study redesign, the only data analyzed were from the single treatment arm portion of the trial, and the non-intervention (baseline only) comparator.||||
33751503|NCT05363566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751504|NCT00725673|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751505|NCT04321538|||CASE_ONLY||PROSPECTIVE|||||||
33751506|NCT05318794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751507|NCT03863340||SEQUENTIAL||PREVENTION||NONE|Participants were informed that the study investigates neuro-motor mechanisms but not about the more specific research questions.|Randomized controlled laboratory experiment. 30 subjects are randomly assigned to two full day experiments either starting with the conditions including additional short interventions or without them.||||
33751508|NCT06516289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751509|NCT01088932|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33751510|NCT00657345|||CASE_ONLY||PROSPECTIVE|||||||
33751511|NCT04906395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176698|NCT05793333|||COHORT||PROSPECTIVE|||||||
33838593|NCT01441635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838594|NCT02944162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838595|NCT06274398|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind|Randomized, Placebo-controlled, Double-blind|t|t|t|t
33838596|NCT03805776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838597|NCT02475512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838598|NCT05387967|NA|SINGLE_GROUP||TREATMENT||NONE||Open label non-randomized clinical trial||||
33838599|NCT02634086|||COHORT||RETROSPECTIVE|||||||
33838600|NCT00013585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33838601|NCT03872245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963044|NCT06146686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The blinding of the operator is not possible due to the nature of the technique used. Trial participants, outcome assessors and statistician will be blinded||t|f|f|t
33963045|NCT00570726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176699|NCT02453737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176700|NCT03641417|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double blind, placebo-controlled, within-subject, crossover mechanistic study|t|f|t|f
34176701|NCT06191458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176702|NCT00829569|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34176703|NCT06598046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176704|NCT04956120|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34176705|NCT02516280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840613|NCT00790205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176706|NCT05357625|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34176707|NCT00746681|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33963046|NCT03352219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963047|NCT00717873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176708|NCT06579300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33751512|NCT05648110|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|For the Sentinel Safety Cohort and Main Cohort, neither the participant nor any of the Investigators or Sponsor staff who are involved in the treatment or clinical evaluation and monitoring of the participants will be aware of the study intervention received. Since AZD5156, AZD3152, and placebo are visually distinct prior to dose preparation (due to differences in vial volumes and container closure), study intervention will be handled by an unblinded pharmacist and administered by an unblinded administrator (or designee, in accordance with local and institutional regulations) at the study site who will be independent of safety evaluations and other trial evaluations. Personnel preparing and administering study intervention may be the same individual. Syringe masking will be required in order to maintain the blind.|"D7000C00001 is a Phase I/III study (Parent study) being conducted in conjunction with a Phase II sub study that will be conducted in approximately 3706 participants (approximately 3256 in the Parent study and 450 in the sub study) to evaluate the safety, efficacy, PK, and neutralizing activity of AZD3152 compared with comparator for pre exposure prophylaxis of COVID-19, and separately evaluate the safety and PK of AZD5156, a combination of AZD3152 and AZD1061.~The Parent study will consist of 2 cohorts: a Sentinel Safety Cohort and a Main Cohort. The Sentinel Safety Cohort will compare AZD5156 with placebo, while the Main Cohort will compare AZD3152 with placebo.~The sub-study will have an initial Sentinel Safety Cohort that will include 12 healthy volunteers; all other participants in the study will be either immunocompromised or immunocompetent with all degrees of SARS-CoV-2 infection risk. Participants will be randomized 2:1 to receive AZD3152 or AZD7442 (EVUSHELD)."|t|t|t|t
33751513|NCT03845153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind perspective study|40 post-menopausal women with a bone fracture divided into two groups each of 20, randomly assigned to administration with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily or with placebo.|t|f|f|t
33751514|NCT03088826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751515|NCT03678753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751516|NCT05895461|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first 3 cohorts of this study were a single group pre-post design. Based on findings from those, the fourth cohort was changed to include a control group (arm 2). A control group was not originally planned until the next phase of the study; however, it was included at this stage in order to put achievement of weight benchmarks into context and inform potential progression decision-making.||||
33751517|NCT00002803||||TREATMENT||||||||
33751518|NCT03817424|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33963048|NCT00001144||||TREATMENT||||||||
33963049|NCT05807347|NA|SINGLE_GROUP||TREATMENT||NONE|Open lable|||||
33963050|NCT05590325|NA|SINGLE_GROUP||PREVENTION||NONE||Phase I/II, open-label, single arm, two-stage pharmacokinetic and safety study||||
33963051|NCT04472065|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Randomization will be performed by the unblinded study pharmacist. All study staff will be blinded to treatment assignment. The infant will be assigned to the same group as their mother.|Expectant mothers who meet eligibility criteria will be randomized 1:1, stratified by C-section or vaginal delivery, to either the probiotic dietary supplement group or the placebo group and will be blinded to treatment assignment.|t|t|t|t
33963052|NCT06045429|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the nature of the intervention nurses can't be blinded to allocation (the mouthwash type - nature of the fluid, its odour etc.), but are strongly inculcated not to disclose the allocation status of the participant at the follow up assessments. As the ICU is paperless and fully computerised, the data in the computer can be acquired and analysed by the researchers without having access to information about the allocation.|Eligible patients will be recruited in medical-surgical ICU at Kralovske Vinohrady University Hospital (FNKV), managed under an intensivist-led closed ICU, with a 1:1 nurse-to-patient ratio and randomised in equal proportions between 3% hydrogen peroxide arm and 0,2% chlorhexidine digluconate arm.|f|f|t|t
34065203|NCT01678599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065204|NCT01897571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065205|NCT05981404|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||Experimental trial beta-glucan or experimental trial control (placebo)|t|t|t|t
34065206|NCT01429974|||CASE_ONLY||PROSPECTIVE|||||||
34065207|NCT04491526|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34065208|NCT00714584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065209|NCT03071679|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
34176709|NCT00259597|||COHORT||PROSPECTIVE|||||||
34176710|NCT05271578|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Blinding to nicotine and placebo containing standardized electronic research cigarettes and standardized tobacco research cigarettes.|"The study will be conducted in a three-period crossover design and will involve active e-cig (electronic cigarette) and tobacco cigarette users undergoing three different interventions (blinded to the investigators).~The three periods will consist of (1) electronic cigarette vaping without nicotine, (2) electronic cigarette vaping with nicotine, (3) tobacco cigarette smoking. Sequence order will be established by means of a computer-generated randomization scheme."|t|f|t|f
34176711|NCT02179697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176712|NCT06419270|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176713|NCT05163158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176714|NCT05810740|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34176715|NCT06423885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176716|NCT03850379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176717|NCT04338321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176718|NCT05953389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176719|NCT02262806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176720|NCT05289310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176721|NCT02152891|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863861|NCT06402357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176722|NCT05215431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176723|NCT04436991|||COHORT||PROSPECTIVE|||||||
34176724|NCT05005182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176725|NCT02732275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863862|NCT02521584|||COHORT||RETROSPECTIVE|||||||
33863863|NCT05047263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863864|NCT06735196|NA|SINGLE_GROUP||OTHER||NONE||||||
33863865|NCT04622046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863866|NCT03519464|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863867|NCT03631745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The National Alliance on Mental Illness (NAMI) of California has developed Mental Health 101, a suite of contact-based education programs tailored for culturally diverse populations including Latino populations. Another NAMI program, FaithNet, provides resources and training on how churches can shape norms and overcome shame and stigma related to mental illness and treatment. NAMI FaithNet also assists with facilitating linkages to mental health services from providing referrals to partner mental health agencies to forming multi-sector collaboratives of social service organizations, clergy, and mental health providers to create a more holistic, coordinated system of care. The multi-component, church-based, intervention will build on NAMI's existing resources, with tailoring for Latino church-based settings.||||
33863868|NCT05681572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Physicians, the nurse responsible for administration, the staff following the patient and the patient will be blinded to randomisation.~Only the nurse involved in the preparation of experimental treatments is not blinded. She will not be involved in the follow-up of the study."|"Patients are randomized to 2 groups to received pharmacologic premedication or placebo.~For the premedication group, children are randomly allocated to be premedicated with either with the midazolam or dexmedetomidine (2 sup-groups)."|t|f|t|f
33863869|NCT06525675|||COHORT||RETROSPECTIVE|||||||
33863870|NCT00408330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863871|NCT02811549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863872|NCT06143839|||COHORT||PROSPECTIVE|||||||
33863873|NCT06734806|||CASE_CONTROL||RETROSPECTIVE|||||||
33863874|NCT01558583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176726|NCT05454033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863875|NCT06179498|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176727|NCT01708408|||OTHER||PROSPECTIVE|||||||
34176728|NCT01452906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34176729|NCT04930367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A cluster-randomized trial to compare the effectiveness of the CombinADO strategy versus optimized standard of care (SOC) on viral suppression, ART adherence and retention in HIV care among AYAHIV ages 10-24yrs attending participating health facilities. Clinics are the units of intervention allocation and randomization. The control condition will be implemented at all facilities (n=12) participating in the trial. The enhanced intervention condition will be superadded to this at a randomly selected half (n=6) of facilities.||||
34176730|NCT01375140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176731|NCT02574624|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34176732|NCT04415944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176733|NCT04776083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176734|NCT06537726|||CASE_CONTROL||PROSPECTIVE|||||||
34176735|NCT05487612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients undergoing elective or urgent coronary artery bypass grafting, aortic valve replacement or both procedures CABG+AVR using extracorporeal circulation without circulatory arrest will be randomised (1:1 ratio) to having surgery using Minimal Invasive Extracorporeal Circulation (MiECC) or conventional cardiopulmonary bypass (cCPB).|f|f|f|t
34176736|NCT05621057|||CASE_ONLY||CROSS_SECTIONAL|||||||
34176737|NCT04515771|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The study consisted of two groups, an active treatment group and a waitlist control group. Participants randomized to the active treatment group received the peer-administered intervention program for 6 months and then were followed for 3 months after completion of the program. The waitlist control group received the peer-administered intervention program for 6 months following a 6-month waiting period.||||
34176738|NCT05748275|||CASE_CROSSOVER||PROSPECTIVE|||||||
34176739|NCT04092504|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Elderly trauma patients|Implementation research with control group|t|f|f|f
34176740|NCT02916212|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34176741|NCT06592482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176742|NCT05266222|||COHORT||PROSPECTIVE|||||||
34176743|NCT05924633|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blinded parallel study|Parallel randomised control trail|t|f|t|f
34176744|NCT05176314|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34176745|NCT04421950|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinded randomized control||t|t|t|f
34176746|NCT06096519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34176747|NCT03025971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863876|NCT05861739|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33863877|NCT05168124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963053|NCT02107963|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963054|NCT00179153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963055|NCT06500299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176748|NCT06002919|RANDOMIZED|PARALLEL||OTHER||NONE||This is a a two-arm parallel assignment that involves two groups of participants. One group receives the MindWalk intervention, and the other group is the control group.||||
34176749|NCT04851691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33863878|NCT06130501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Research Coordinator, Project Manager, and Site PI will be unblinded so that the participant receives the appropriate device for their assigned treatment condition, they are able to provide technical support, and give the participant feedback on their dose compliance throughout the study. The participant, all outcomes assessors, and the participant's buprenorphine care provider will be blind to condition.|1:1 randomization|t|t|f|t
33863879|NCT04995419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863880|NCT05444335|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863881|NCT01297764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176750|NCT05960097|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is an observer-blind study.||t|f|t|t
33863882|NCT06736314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863883|NCT06518603|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Masking will be maintained throughout the study and only the study pharmacists will be aware of the treatment group. The study pharmacist will prepare the 28-day supply of either caffeine citrate or placebo in indistinguishable clear solutions and same vials of equivalent volumes for the infant to continue at home. All other study staff, facility staff, follow-up staff, and family members will be masked to the treatment allocation. Identical vials will be prepared for the placebo arm with only a specific code written on the vials differentiating it from caffeine citrate. This code will be known only to the study pharmacist. Caffeine levels will not be checked routinely and checking levels will be discouraged to optimize masking.|Double blind, placebo-controlled, 1:1 parallel allocation|t|t|t|t
33863884|NCT03798678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863885|NCT04782011|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Being a feasibility study that will use patient records, no blinding will be done.|The number of health facilities will be split evenly between the intervention and non intervention arms. These will be randomly selected in the districts of Mbarara, Bushenyi and Kasese.||||
33863886|NCT06460233|||COHORT||PROSPECTIVE|||||||
34065210|NCT01137461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065211|NCT05258799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065212|NCT05775926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single||t|f|f|f
34065213|NCT02699476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34176751|NCT03525379|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||DOUBLE|The randomization codes will be maintained in REDCap. The principal investigator will have authority to unblind patients if safety concerns arise.|"After providing written informed consent, patients who qualify will be randomized via the web-based system coordinated by Research Electronic Data Capture (REDCap) at the University of Alberta. A patient's eligibility will be confirmed and a unique identifier will be assigned.~Blinding of the patients and study personnel is preserved by using matching placebo capsules. Clinical outcomes will be adjudicated by a Clinical Events Committee, and core laboratories will assess the CMR measures and biomarkers independently and blinded to treatment assignment."|t|t|f|f
34176752|NCT01527149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176753|NCT06601452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"(i) Types of trial design: Multicentre, prospective, cross-sectional study; multicentre, prospective, double-blind, randomised controlled trial.~(II) Principles of trial design~1. Number of cases: A total of 650 cases were included in the study, including 300 healthy women of reproductive age (divided into three groups according to age: 21-27 years old, 28-34 years old, 35-41 years old, 100 cases in each group), 150 cases of women with normal ovarian function who underwent in vitro fertilization-embryo transplantation (IVF-ET) due to male factor (divided into three groups according to age: 21-27 years old, 28-34 years old, 35-41 years old, 100 cases in each group). 34 years old, 35-41 years old, 50 cases in each group), 100 cases of PCOS infertility, 100 cases of DOR infertility.~2. Random control: According to the accepted principles of validity, safety and comparability, SPSS 27 statistical software, define the random seed number '20240001', according to 1:1 to generate the random se"|t|f|f|f
34176754|NCT04825574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176755|NCT03632135|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Study investigators will be kept blind to the schedule. All participants will be screened by the ChemoID drug response assay; however, the treating physician will receive the ChemoID results only for those participants who are randomized to ChemoID-guided treatment arm.|parallel group randomized controlled clinical trial|t|t|t|t
34176756|NCT05907174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study uses a parallel design. Two existing teams of healthcare workers will be randomized 1:1 at the team level to either have a PRC integrated onto their team or to continue their patient care as usual.||||
34176757|NCT05025020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176758|NCT06551610|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Step-Wedged Cluster Randomized||||
34176759|NCT05507541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176760|NCT05335330|||OTHER||CROSS_SECTIONAL|||||||
34176761|NCT04613362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The participant will be randomized by mode of delivery to the telehealth or TAU treatment stratified by site (VA Medical Center). Upon completion of the baseline evaluation, the project coordinator will assign random assignment. The research assistants will be masked to random assignment.|This is a randomized, controlled feasibility pilot with a single intervention arm, and a usual care control arm. The intervention arm includes participation in the TENACITY telehealth cognitive behavioral therapy CBT program for headache plus education. The usual care arm includes behavioral treatment as usual which may include outpatient clinic-based health psychology in the VA or in the community, or mindfulness sessions by LCSW.|t|f|f|t
34176762|NCT05492708|||COHORT||PROSPECTIVE|||||||
34176763|NCT05990179|NA|SINGLE_GROUP||SCREENING||NONE||||||
34176764|NCT04747964|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176765|NCT06599112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* Participants and investigator couldn't be blinded.~* Outcome assessor and biostatistician will be blinded."|Three groups. Control Group Intervention group (A) Intervention group (B)|f|f|f|t
34176766|NCT06335849|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33751519|NCT06053476|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33751520|NCT01587508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33963056|NCT02872337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176767|NCT01849263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176768|NCT05781542|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33751521|NCT02515760|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751522|NCT06722222|||OTHER||CROSS_SECTIONAL|||||||
33751523|NCT01687816|||||PROSPECTIVE|||||||
33751524|NCT00259051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33863887|NCT02908425|NA|SINGLE_GROUP||OTHER||NONE||||||
33963057|NCT05786053|RANDOMIZED|PARALLEL||TREATMENT||NONE||Forty patients from 3 to 18 years old with V pattern strabismus and primary IOOA were evaluated by prism cover test to assess the grade of IOOA and amplitude of V-pattern. Graded recession of IO muscle depends on the amplitude of the V-pattern and degree of IOOA. Eight mm recession for amplitude 7.5to 10 degree and mild IOOA (10 degree or +1) ,10 mm recession for amplitude 11- 15 degree and moderate IOOA (11 -15 degree or +2) and maximum recession for amplitude more than 15 degree and marked IOOA (15 or +3). Simultaneous correction of the horizontal deviation was performed at the same sitting. Follow up after one week,1 month ,3 month and 6-month.||||
33863888|NCT06734286|RANDOMIZED|PARALLEL||OTHER||SINGLE||In this study, participant randomization into intervention and control groups will be performed using computer-generated random numbers. The goal is to successfully recruit 10 MCI patients (5 in the intervention group and 5 in the control group) who are willing to undergo blood draws for p-Tau 217 level determination. For ethical reason, at the end of trial at 3 months, the control group will also be offered the CogMed intervention.|f|f|t|f
33863889|NCT06734442|||COHORT||RETROSPECTIVE|||||||
33863890|NCT05890222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863891|NCT06145516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33863892|NCT06494241|||CASE_ONLY||PROSPECTIVE|||||||
33863893|NCT05778578|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33863894|NCT06736093|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33863895|NCT06593769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Participants who meet the eligibility criteria will be randomized in 1:1 allocation ratio to one of the sequences (i.e., randomization groups):~* sequence 1 = whey-protein microgel (WPM) in Day 2-Day 5 (period 1) and placebo in Day 9-Day 12 (period 2)~* sequence 2 = placebo in period 1 and WPM in period 2. Randomization will be carried out using Medidata Rave RTSM."||||
33863896|NCT04618133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863897|NCT04568759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863898|NCT05151848|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, multicenter,randomized trial||||
33863899|NCT06557148|||COHORT||PROSPECTIVE|||||||
33963058|NCT00000737||||TREATMENT||NONE||||||
33963059|NCT03910582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963060|NCT01259700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963061|NCT01143272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34176769|NCT06060899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176770|NCT04991649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors and researchers (and health care staff of the study hospital) are blind to the group assignment and intervention undertaken and concealed to the participant list.|Parallel Assignment; repeated-measures 2-arm randomized controlled trial|f|f|t|t
34176771|NCT04907370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176772|NCT04935658|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants receive an intervention throughout the protocol||||
34176773|NCT02135250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34176774|NCT06703320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176775|NCT06367764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176776|NCT06412159|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34176777|NCT01742143|||COHORT||PROSPECTIVE|||||||
34176778|NCT04458051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176779|NCT02020265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34176780|NCT05404828|||COHORT||CROSS_SECTIONAL|||||||
34176781|NCT01782027|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176782|NCT02893397|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33751525|NCT01568333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751526|NCT04445441|||COHORT||PROSPECTIVE|||||||
34176783|NCT05728411|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34176784|NCT06597175|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Device: ORIGO||||
34176785|NCT02711891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176786|NCT06366711|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||15 participants split in to three arms. The sample size has been determined as a pragmatic sample taking into consideration the needs of the feasibility study to meet the stated objectives as well as being achievable within the time and cost constraints of the study. 15 participants will ensure a thorough assessment of the stated objectives.||||
34176787|NCT05690308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed if they are allocated to the experimental intervention or the control 'sham' intervention.|Randomized Controlled Trial|t|f|f|f
34176788|NCT06194448|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive open-label osimertinib induction treatment for 8 weeks (± 1 week window to account for patient variability and CRT scheduling), followed by CRT treatment for 6 weeks (± 1 week) and then osimertinib maintenance treatment until RECIST 1.1-defined radiological progression by investigator unless there is evidence of unacceptable toxicity or if the patient requests to stop the study treatment.||||
33863900|NCT05029414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"A treatment-blinded person will assess the primary outcome dependency and disability in everyday life (measured with the modified Rankin Scale (mRS)) at 90 days. All interviewers will be certified for the conductance of mRS.~interviews."|Pragmatic, parallel group, randomized, open label, superiority trial with blinded endpoint assessment|f|f|f|t
33863901|NCT06540391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963062|NCT04280094|||OTHER||PROSPECTIVE|||||||
33963063|NCT06225778|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding|Randomized Controlled Trial|t|t|f|f
33963064|NCT02455583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963065|NCT01692080|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33963066|NCT02076932|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33963067|NCT00552526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963068|NCT02968641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176789|NCT06486519|||COHORT||PROSPECTIVE|||||||
34176790|NCT01730599|||COHORT|||||||||
34176791|NCT04733326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants didn't know to which group they are allocated and the outcome assessor received the data in an excel sheet|Participants presenting with symptomatic irreversible pulpits and apical periodontitis in their mandibular molars|t|f|f|t
34176792|NCT06508333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963069|NCT00021229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963070|NCT05294614|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"The present work should be considered as a closed cohort study, since the same participants will be evaluated over time through a series of time points defined a priori and the inclusion of new participants will not be allowed once the trial has started. The design used for this study is composed by 3 sequences (3 different starts of the treatment phase). The assignment of each of the 6 participating centers (2 per each autonomous community) to one of the 3 sequences will be randomly performed. The established sequences look like:~A B B B B B B B B C C C C C C A A B B B B B B B B C C C C C A A A B B B B B B B B B C C C C In these sequences A represent the control phase, B the treatment phase and the C the maintenance phase.~Participants will be masked to the information related to the sequences that they will follow. The masking will be established according to the randomization applied to each center."|The general framework determined for the study design is that indicated by Hermes. A hybrid type II design, where effectiveness and implementation will be evaluated is selected. Regarding the specific design of the empirical study, a stepped wedge (SW) design will be used, which represent a variation of the clinical trials randomized by clusters. All groups receive the treatment but its initiation is done in a randomized order and the treatment is introduced to different groups in a staggered and sequential way. The duration of each phase (e.g. control and treatment), it is determined randomly for each group. The study should be considered a closed cohort, since the same participants will be evaluated over time through a series of time points defined a priori and the inclusion of new participants will not be allowed once the trial has started. sequences will be randomly assigned.|t|f|f|f
33963071|NCT00773552|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33963072|NCT02937038|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33963073|NCT03008031|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34176793|NCT04192565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176794|NCT03401801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176795|NCT03771716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Neither the investigator, nor outcomes assessors will know participants' group assignments. Participants will be instructed to refrain from speaking about their group's activities when visiting the lab for follow-up assessment. In addition, special care was taken to ensure that non-blinded laboratory staff (e.g., staff member notifying participants of their group assignments, staff monitoring the intervention classes) are not located in the same proximity in the laboratory, further preventing accidental unblinding.|180 African American older adults between the ages of 60-80 will be randomly assigned to one of two groups: African Dance or Africana Culture. Both groups will meet 3 times per week for 1 hour over a period of 6-months. Cognitive and brain metrics will be assessed at baseline and following the completion of the intervention.|f|f|t|t
33863902|NCT06654947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863903|NCT04352296|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33863904|NCT06734299|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863905|NCT06107933|||COHORT||CROSS_SECTIONAL|||||||
33863906|NCT02901925|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|open label|Pilot feasibility study||||
33863907|NCT03509636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863908|NCT06387394|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33863909|NCT05937347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33863910|NCT02634203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863911|NCT05714956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863912|NCT06736574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863913|NCT04679753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Brainsway Deep TMS with intermittent Theta Burst Stimulation (iTBS)||||
33863914|NCT06113471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176796|NCT04940299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176797|NCT00802386|||COHORT||PROSPECTIVE|||||||
34176798|NCT05287113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized to 1 of 3 treatment groups.|t|t|t|f
34176799|NCT02205736|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34176800|NCT04709068|||COHORT||PROSPECTIVE|||||||
34176801|NCT06705400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34176802|NCT05908591|||COHORT||PROSPECTIVE|||||||
34176803|NCT02898181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176804|NCT04414111|||COHORT||PROSPECTIVE|||||||
34176805|NCT06226649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34176806|NCT04071990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||After randomization the patient an family member will be allocated to one of the two groups: (a) CBGT with involvement of family (intervention) or (b) CBGT without involvement of family (control), both groups will exist of 12 sessions|f|t|f|t
34176807|NCT04558060|RANDOMIZED|PARALLEL||OTHER||SINGLE|Motivational interviewing skill is coded by assessors blind to training condition and assessment time point.||f|f|f|t
34176808|NCT01441999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33863915|NCT04275297|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study involves a two group parallel design, with one group receiving individual psychosocial intervention online/in person and another individual symptom monitoring and discussion via telephone.||||
34176809|NCT04984616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176810|NCT06583668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34176811|NCT00648102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176812|NCT04205448|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT||||
34176813|NCT03333343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176814|NCT00879736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34176815|NCT06602895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||pretest-posttest gender-based parallel group comparative design|f|f|t|t
34176816|NCT03818854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||For this Phase 2b trial, after informed consent is given, an assignment will be made by computer-generated randomization to administer either hMSCs therapy or placebo with a 1:1 allocation to the hMSCs:placebo arms.|t|t|t|f
34176817|NCT00002327||||TREATMENT||||||||
33863916|NCT05655091|RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no blinding in this study. The antibiotic concentrations in the control group will be measured but not communicated to the study team or the treating physician.|Single-centre, randomised, controlled, interventional pilot trial||||
33863917|NCT06734611|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863918|NCT05084833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863919|NCT06094504|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Data analyst will be blinded as to lighting condition exposure of subject (spectral lighting period vs control lighting period) when analyzed samples were collected.|N-of-1 study design in which each subject will serve as their own control.||||
33863920|NCT01005745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863921|NCT06408389|||COHORT||RETROSPECTIVE|||||||
33863922|NCT03219320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Treatment arms, dose levels, and randomization algorithm are masked.|Subjects will be randomized to receive placebo or NYX-2925.|t|t|t|f
33863923|NCT05944016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded study using capsules.|Experimental intervention: Dapagliflozin (standard dose 10 mg p.o. once daily). Control intervention: Placebo therapy.|t|f|t|f
33863924|NCT00004022||||TREATMENT||||||||
33863925|NCT03617003|NA|SINGLE_GROUP||TREATMENT||NONE||This a prospective, single institution, non-randomized open label phase 1 study.||||
33863926|NCT03781323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863927|NCT00813319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863928|NCT05817942|||COHORT||PROSPECTIVE|||||||
33863929|NCT05159154|||COHORT||PROSPECTIVE|||||||
33863930|NCT05847010|||COHORT||PROSPECTIVE|||||||
33863931|NCT06178341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Investigator, the subjects and the data analyst will not be blinded. The persons evaluating the recordings of inhalation maneuvers will be blinded to study intervention.|Multicenter study in up to 15 study sites in Germany that follows a randomized, controlled, parallel-group, adaptive two-stage design.|f|f|f|t
33863932|NCT04560660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators will use a sequentially numbered, opaque, sealed envelopes, pharmacy-controlled allocations, and coded identical containers for adequate concealment allocation. Administration of study drugs and infusion monitoring will be conducted by research nurse keeping blinding from investigators and independent outcome assessors.|Subjects will be randomly assigned to one of two parallel treatment conditions: 1) adjunctive ketamine infusions to prolonged exposure therapy or 2) adjunctive midazolam (active placebo) infusions to prolonged exposure therapy.|t|t|t|t
33863933|NCT05050942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863934|NCT02834416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"An a priori decision was made to not include additional covariates in the ANCOVA model due to a smaller than anticipated sample size. Only trial centre, length of ADT, and baseline 6MWT will be included in the model.~In addition, we have modified the wear time criteria for accelerometry from 600 minutes of wear time to 500 minutes of wear time. This allows for the inclusion of more participant data and more accurately reflects the clinical nature of this population.~Amendment date: 17-Sep-20"|f|f|f|t
33863935|NCT00108069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176818|NCT05884554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863936|NCT05119621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blinded|Parallel Assignment|t|f|f|f
34176819|NCT06706570|||COHORT||PROSPECTIVE|||||||
34176820|NCT06026033|||COHORT||PROSPECTIVE|||||||
34176821|NCT06610682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176822|NCT05914623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176823|NCT00534612|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34176824|NCT06378229|NA|SINGLE_GROUP||TREATMENT||NONE||Open label feasibility study||||
34176825|NCT05522660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176826|NCT01174901|||COHORT||PROSPECTIVE|||||||
34176827|NCT03536572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33863937|NCT02979925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33863938|NCT04938830|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33863939|NCT06735378|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Open label, randomized, controlled, crossover trial with 2 conditions and 4 dialysis sessions.||||
33863940|NCT06107972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863941|NCT02819076|||COHORT||PROSPECTIVE|||||||
33863942|NCT05008926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863943|NCT06508541|||COHORT||RETROSPECTIVE|||||||
33863944|NCT06735547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33863945|NCT04784715|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This study is open-label with respect to the control arm. Pertuzumab/placebo in the experimental arms will be blinded to the investigator and patients.~The study will be Sponsor-blind. To maintain the integrity of the study, Sponsor personnel directly involved in study conduct will not undertake or have access to efficacy data aggregated by treatment group prior to final data readout for the primary endpoint."|"Study will consist of three arms:~Arm A - trastuzumab deruxtecan with pertuzumab-matching placebo Arm B - trastuzumab deruxtecan with pertuzumab Arm C - standard of care (taxane \[docetaxel or paclitaxel\], trastuzumab and pertuzumab)"||||
33863946|NCT05836051|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33863947|NCT01640210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863948|NCT06442800|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33863949|NCT06734247|||COHORT||PROSPECTIVE|||||||
33963074|NCT00127257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33963075|NCT06003491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963076|NCT03937973|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Participants will be blind to condition until the debriefing, which occurs the morning following the social-rejection task.|All participants will complete two nights in the sleep laboratory. One night will be a non-rejection control night. The other night will be a rejection task night. In this regard, African American and Caucasian American participants will be randomized to one of two conditions. All participants will be exposed to social rejection prior to bedtime; however, they will either be rejected by a person of their own race (in-group member) or a different race (out-group member)|t|f|f|t
33963077|NCT01862120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176828|NCT06602323|NA|SEQUENTIAL||TREATMENT||NONE||"A 3+3 de-escalation design comprising a patient safety-lead phase will be applied in successive patient cohorts:~Initially, 3 patients will be treated at the starting TMLI dose (Dose Level 1, 1200 cGy). If 0 or 1 dose-limiting toxicity is observed among the first 6 patients at Dose Level 1, then 28 additional patients will be treated at this dose level (allowing for the evaluation of 34 patients treated at the target dose level). If ≥2/6 patients experience a dose-limiting toxicity at Dose Level 1, then the maximum tolerated dose has been exceeded and the next lower TMLI dose (Dose Level -1, 1100 cGy) will be expanded to up to 6 patients. If 0 or 1 patient out of 6 experiences a dose-limiting toxicity, this dose level will be further evaluated (n=28 additional patients). If ≥2/6 patients experience a dose-limiting toxicity, the next lower dose (Dose Level -2, 1000 cGy) level will be expanded applying the same criteria."||||
34176829|NCT05703945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"A centralized randomization will be performed at the 3rd visit so that participants do not know which group they will be assigned to during the control period.~Participants do not know which group they will be assigned to during the control period."|This is a randomized controlled trial with repeated measures, monocentric, in 2 parallel groups of elderly subjects (60-85 years) in good general health: one receiving an 8-week muscle strengthening program (PRP group), the other not (control group).|t|f|f|f
34176830|NCT06472518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176831|NCT00687596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176832|NCT05943639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Foreign students in the experimental and control groups will be masked.|The study was planned as a prospective, two-armed (1:1), randomized controlled experimental study. This randomized controlled trial will be reported according to the CONSORT guidelines.|t|f|f|f
34176833|NCT04725773|||COHORT||CROSS_SECTIONAL|||||||
34176834|NCT03400735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863950|NCT04045951|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessors involved in data management and analysis will be blinded to the group assignment. The study participants, the investigators responsible for randomization will not be masked.||f|f|f|t
34176835|NCT06351124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Eligible consenting patients will be randomized to either standard of care therapy (control) vs standard of care therapy plus BHB supplementation (intervention). BHB will be supplemented as a capsule taken orally three times daily for four weeks for those randomized to the intervention arm.|This will be a prospective, open-label, randomized, two-arm pilot trial of adults||||
34176836|NCT04315948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* the treatment arm SOC + hydroxychloroquine has been ceased since May 24, 2020;~* the treatment arm SOC + lopinavir / Ritonavir and lopinavir / ritonavir + interferon ß-1a has been ceased since June 29, 2020~* the treatment arm SOC + remdesivir has been ceased since January 19, 2021~* the treatment arm SOC + AZD7442"|"From March 22, 2020 to May 24, 2020, the study randomized participants 1:1:1:1:1 to standard of care alone (control) or with investigational product added.~From May 24, 2020 to June 29, 2020, the study randomized participants 1:1:1:1 to standard of care alone (control) or with investigational product added.~From June 29, 2020 to January 19,2021, the study randomized participants 1:1 to standard of care alone (control) or with investigational product added.~Since April, 2021, the study will randomize participants 1:1 to standard of care with placebo (control) or standard of care with investigational product added."|t|f|t|t
34176837|NCT05877521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863951|NCT04564976|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863952|NCT00378768||||TREATMENT||NONE||||||
33863953|NCT06181201|||OTHER||PROSPECTIVE|||||||
33863954|NCT02708095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863955|NCT06565442|||COHORT||PROSPECTIVE|||||||
33863956|NCT04475666|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33863957|NCT00935272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863958|NCT06528691|NA|SINGLE_GROUP||TREATMENT||NONE||Pediatric patients \<3 years of age, with NTRK1/2/3 or ROS1-fused high-grade gliomas and other CNS tumors will be treated with frontline single-agent entrectinib.||||
33863959|NCT06735274|||COHORT||PROSPECTIVE|||||||
33963078|NCT05012085|||OTHER||RETROSPECTIVE|||||||
33963079|NCT00738920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963080|NCT01345890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33963081|NCT01908998|NA|SINGLE_GROUP||SCREENING||NONE||||||
34176838|NCT06579261|NA|SINGLE_GROUP||OTHER||NONE||||||
34176839|NCT02242773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176840|NCT04606134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176841|NCT03505762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176842|NCT04985617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The intervention and measurements were carried out by the first researcher, and the patients discovered their own groups when the postoperative warming intervention was applied to them. Because of the nature of the intervention, blinding could not be performed|This was a prospective, randomized controlled experimental study.||||
34176843|NCT05866952|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176844|NCT01231906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176845|NCT04088890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176846|NCT06595277|||COHORT||PROSPECTIVE|||||||
34176847|NCT05235009|||CASE_CONTROL||RETROSPECTIVE|||||||
34176848|NCT06705829|||CASE_ONLY||CROSS_SECTIONAL|||||||
34176849|NCT06112093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be blind and randomly assigned to either the Active rTMS or the Sham rTMS group.|The Active rTMS group will receive 12 sessions (3 sessions/week) of rTMS and the Sham rTMS group will receive rTMS from a sham coil at the same location and duration as the Active rTMS group.|t|f|f|t
34176850|NCT06335329|RANDOMIZED|PARALLEL||OTHER||SINGLE|All participants will be randomized on a 1:1 ratio to be able to see and discuss their ultrasound results, or remain blinded to them.||t|f|f|f
34176851|NCT03279081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176852|NCT05183828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176853|NCT03590028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176854|NCT06071234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176855|NCT06070454|NA|SINGLE_GROUP||SCREENING||NONE||||||
34176856|NCT00576706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34176857|NCT04588922|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open Label, Multi-center||||
34176858|NCT05920590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked assessor will conduct the measurements|In this study, 90 patients with knee osteoarthritis scheduled for unilateral total knee arthroplasty will participate. Each will follow a 4-week physiotherapy program immediately after surgery, according to the latest guidelines. The program will start on the second postoperative day in the hospital and continue with home visits after discharge. After the initial 4-week period, participants will be randomly assigned to one of three groups. The first group will follow a six-week PNF exercise protocol (PNF group). The second group will follow the same PNF regimen with added targeted vibration therapy on the tendon of the vastus medialis and rectus femoris (PNF + Tendon Vibration group). The third group (control group) will receive instructions and an exercise leaflet for home practice without additional treatment. The intervention will last six weeks, starting four weeks post-surgery, with measurements at baseline, at the 6th week, and at six months post-intervention.|f|f|f|t
34176859|NCT06103591|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34176860|NCT06545929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34176861|NCT05106959|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal single group pilot study.||||
34176862|NCT03117010|||COHORT||PROSPECTIVE|||||||
34176863|NCT06180343|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomize controlled trial|t|f|f|t
33863960|NCT05139849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176864|NCT05957835|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The lead researcher, data collectors, and participants were blinded to the conditions. The distribution of supplements for each condition was performed by a researcher that was not formally involved in data collection processes, thereby limiting the potential of bias.|In a double-blind, randomised, crossover design, participants were assigned to four experimental trials to consume a total of 4 beetroot juice shots during each condition: (a) 4 x 70 ml of nitrate-depleted beetroot juice for placebo (PL), (b) 1 x 70 ml of nitrate-rich beetroot juice 3 x 70 ml nitrate-depleted beetroot juice for a low dose of nitrate-rich beetroot juice (BR-LOW; \~6.5 mmol of nitrate total), (c) 2 x 70 of nitrate-rich beetroot juice and 2 x 70ml of nitrate depleted beetroot juice for a moderate dose of nitrate-rich beetroot juice (BR-MOD; \~13 mmol of nitrate total), and (d) 4 x 70 ml of nitrate-rich beetroot juice for an elevated dose of nitrate-rich beetroot juice (BR-HIGH; \~26 mmol of nitrate total).|t|f|f|t
34176865|NCT06058533|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176866|NCT06269120|||COHORT||PROSPECTIVE|||||||
34176867|NCT04906668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176868|NCT05734027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34176869|NCT06705452|NA|SINGLE_GROUP||OTHER||NONE||||||
34176870|NCT02506543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34176871|NCT06444659|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34176872|NCT00886379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34176873|NCT06542302|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176874|NCT06066697|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The statistician conducting analyses will be blinded to randomized arm.||f|f|f|t
34176875|NCT05753046|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients will be sedated for the procedure and unaware of when the TAP block is administered.|Patients who meet all eligibility criteria will be enrolled in the study and randomized (1:1) to receive either early or late TAP block. The subject and biostatistician will be blinded to the group allocation throughout the study. Research staff responsible for obtaining consent. To maintain the blind, initial analysis of the data performed by the biostatistician will not include group assignment.|t|f|f|t
34176876|NCT05464667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751527|NCT05824026|NA|SINGLE_GROUP||TREATMENT||NONE||non-comparative, one-armed, open-labelled, multi-centre study.||||
33751528|NCT00149513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751529|NCT00898885|||COHORT||PROSPECTIVE|||||||
33751530|NCT05036044|||COHORT||RETROSPECTIVE|||||||
33751531|NCT02264028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751532|NCT03252392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751533|NCT01464541|NA|SINGLE_GROUP||||NONE||||||
33751534|NCT05989178|||COHORT||PROSPECTIVE|||||||
33751535|NCT05198830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751536|NCT06005233|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, intraindividual-controlled, multicenter clinical study.||||
33751537|NCT06732752|||COHORT||PROSPECTIVE|||||||
33751538|NCT02630628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863961|NCT05691504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33863962|NCT02884154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863963|NCT06678373|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33863964|NCT02675023|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863965|NCT02874365|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33863966|NCT03116412|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963082|NCT00669838|||CASE_CONTROL||PROSPECTIVE|||||||
34176877|NCT04948645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176878|NCT01283841|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34176879|NCT03261271|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34176880|NCT01630148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33751539|NCT06118411|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33751540|NCT03731273||CROSSOVER||PREVENTION||NONE||||||
33963083|NCT00727298|||COHORT||PROSPECTIVE|||||||
33863967|NCT04985305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The GPs are blinded to their allocation prior to recruiting patients. Due to the nature of the intervention, it will not be possible to blind the participants, providers of care or other members of the research team after the allocation. The primary outcome is blinded to the research team when analyzed.|This trial is designed as a cluster randomized, non-blinded parallel group superiority trial with 1:1 allocation ratio. Enhanced care-as-usual will be used as a comparator.|f|f|f|t
34176881|NCT04031105|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be told which arm they belong to|Randomized, single blind, parallel group experiment|t|f|f|f
33863968|NCT04333745|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33863969|NCT04762888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176882|NCT04434482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176883|NCT00904943|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34176884|NCT04208919|NA|SINGLE_GROUP||OTHER||NONE||||||
34176885|NCT03216772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176886|NCT04714892|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176887|NCT06599463|||COHORT||RETROSPECTIVE|||||||
34176888|NCT04500912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will be blinded for the stent that is used||t|f|f|f
34176889|NCT05111210|||CASE_CONTROL||PROSPECTIVE|||||||
34176890|NCT05791643|NA|SINGLE_GROUP||TREATMENT||NONE||"During the four weeks after hospital discharge, each time a participant reports elevated (\&gt; 0 but \&lt; 8 out of 10) levels of suicidal intent or high (\&gt;= 8 out of 10) suicidal urge on a momentary smartphone survey, they will be randomized to either receive a real-time intervention or no real-time intervention promoting safety plan or coping strategy use. If randomized to receive a real-time intervention, the intervention type will also be randomized to consist of either recommended coping strategies from their personalized safety plan or general coping strategies for suicidal thoughts.~During the post-discharge phase, participants will have 24/7 access to their full safety plan within the study app. At reported high (\&gt;= 8 out of 10) levels of suicidal intent, no micro-randomization will occur, and a longstanding risk management protocol that includes direct, phone-based outreach to participants for further risk assessment and intervention will be used."||||
34176891|NCT01578447|RANDOMIZED|CROSSOVER||||NONE||||||
34176892|NCT06543745|NA|SINGLE_GROUP||OTHER||NONE||||||
34176893|NCT03745495|||COHORT||PROSPECTIVE|||||||
34176894|NCT01372709|||COHORT||PROSPECTIVE|||||||
34176895|NCT06308718|||OTHER||PROSPECTIVE|||||||
34176896|NCT06603415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176897|NCT06046924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176898|NCT06704685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The subjects will be randomly assigned in a 1:1 ratio to two groups: a butylphthalide group and a placebo group.The Butylphthalide group received 100ml of butylphthalide injection twice a day for 7±2 days, followed by butylphthalide soft capsules (2 capsules, three times a day) from the day of discharge to day 30±2. The placebo group received the same dosage of butylphthalide injection and soft capsules placebo.|t|t|t|f
33751541|NCT06733285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33751542|NCT01106105|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33751543|NCT06240442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33751544|NCT06701539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33751545|NCT01887938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751546|NCT05338970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751547|NCT05388370|||COHORT||PROSPECTIVE|||||||
33751548|NCT05289726|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33751549|NCT02362529|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33751550|NCT04416269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751551|NCT00734110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751552|NCT02444390|NA|SINGLE_GROUP||SCREENING||NONE||||||
33751553|NCT06231862|||COHORT||PROSPECTIVE|||||||
33751554|NCT06021301|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series||||
33751555|NCT04373239|||COHORT||OTHER|||||||
33751556|NCT06454747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized 3-arm tranche of main cohorts|t|f|t|t
33751557|NCT03031652|||CASE_ONLY||RETROSPECTIVE|||||||
33751558|NCT04431596|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants receive three cooling treatments on separate study visits: 1) passive cooling 2) mist-fan cooling and 3) forearm immersion cooling||||
33751559|NCT04486391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751560|NCT00663572|||||PROSPECTIVE|||||||
33751561|NCT04988451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Single Case Design - interrupted time series. Participants will receive intervention in 6-week on/off blocks. Measurements are taken in both on and off weeks.~The Bayesian procedure developed by Swaminathan et al. (2014) involves fitting piece-wise linear or curvilinear trends across the phases, modeling dependencies in the observations with a suitably chosen autoregressive error scheme, and using the Markov Chain Monte Carlo (MCMC) method to obtain the posterior distributions of the model parameters and effect size measures"||||
33751562|NCT05801081|||OTHER||PROSPECTIVE|||||||
33751563|NCT05690386|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open label, parallel group with subjects randomized into 1 of 4 treatment groups (1:1:1:1)||||
33751564|NCT06733337|||COHORT||PROSPECTIVE|||||||
33751565|NCT02707835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751566|NCT06733922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a Phase IV, interventional, multi-center, single-arm, open-label, exploratory, descriptive study conducted across geographical regions of Canada to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS initiating ofatumumab.||||
33751567|NCT05971719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751568|NCT05599828|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751569|NCT06733623|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751570|NCT04064034|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33751571|NCT02566954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863970|NCT05017142|||COHORT||OTHER|||||||
33863971|NCT05932017|||COHORT||PROSPECTIVE|||||||
33863972|NCT03203499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33863973|NCT06374914|||CASE_CONTROL||RETROSPECTIVE|||||||
34176899|NCT04936945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34176900|NCT05975840|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study will be observer blind.||t|t|t|t
34176901|NCT06597825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176902|NCT02677493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751572|NCT05418699|||COHORT||RETROSPECTIVE|||||||
33751573|NCT03637205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838602|NCT04165044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinician who performed the measurements as well as the statistic were blind|Randomized controlled clinical trial of parallel group (1:1)|f|f|t|t
33863974|NCT06617793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176903|NCT05464680|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176904|NCT05740137|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A quasi randomized controlled multicenter study||||
34176905|NCT05243823|||COHORT||RETROSPECTIVE|||||||
34176906|NCT03297450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||aphasia therapy (45 minutes) in combination with (sham or real) tDCS (20 minutes)|t|f|t|t
34176907|NCT05853497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34176908|NCT03486912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176909|NCT04174417|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The investigators diveded the patients to two groups. Patients were divided into two groups with a lottery. Surgeons did not know which hypotensive anesthesia technique were used. And surgeons evaluated surgical satisfaction and bleeding scores|A total of 60 ASA 1-2 patients aged between 18-75 who underwent elective rhinoplasty and orthognathic surgery were included the study.The patients were divided into two groups. One group received hypotensive anesthesia according to MBP an done group received SBP. Continuous regional cerebral oxygen saturation was monitored by NIRS in both groups. Blood samples were taken from all patients before anesthesia induction and at the and of the operation and stored for TAS, TOS, HIF 1a. At the and of the operation patients were fallowed in the post anesthesia care unit for 30 minutes and pain and nause vomiting scores were evaluated. İn addition, surgical satisfaction and bleeding scores and anesthetic consumption of both groups were recorded|t|f|f|f
34176910|NCT06221995|||COHORT||PROSPECTIVE|||||||
34176911|NCT05908487|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34176912|NCT03231891|||COHORT||PROSPECTIVE|||||||
34176913|NCT04324827|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|There was a blind assessor (Physical Therapist) and completed the Optojump testing. Participants are also blinded.||t|f|f|t
34176914|NCT06706245|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34176915|NCT06595160|||CASE_ONLY||PROSPECTIVE|||||||
34176916|NCT01364636|||COHORT||PROSPECTIVE|||||||
34176917|NCT04935034|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|single-blinded crossover study|The is a 4 arm single-blinded crossover study|t|f|f|f
34176918|NCT06051201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176919|NCT06603506|||COHORT||PROSPECTIVE|||||||
34176920|NCT06179199|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"* Active tDCS stimulation ;~* Placebo tDCS stimulation."|t|t|t|t
34176921|NCT06599749|||COHORT||PROSPECTIVE|||||||
34176922|NCT02601612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33838603|NCT02935803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838604|NCT02694445|||CASE_ONLY||CROSS_SECTIONAL|||||||
33838605|NCT02938676|||||PROSPECTIVE|||||||
33838606|NCT06199895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838607|NCT04456075|||COHORT||PROSPECTIVE|||||||
33838608|NCT03863015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomized in a 1:1 fashion to receive IL-6RA or placebo. Patients being allocated to IL-6RA will receive a one-hour infusion of 8 mg tocilizumab per kg body weight (maximum dose 800 mg, 40 mL), equivalent to 0.4 mL per kg bodyweight (study drug concentration 20 mg/mL). Patients being allocated to placebo will receive a one-hour infusion of 0.4 mL /kg body weight of normal saline (maximum dose 40 mL)|t|t|t|t
33838609|NCT06477861|||COHORT||PROSPECTIVE|||||||
33838610|NCT02510833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838611|NCT00269906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33863975|NCT01264653|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33863976|NCT05958017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863977|NCT00995007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863978|NCT03836755|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33863979|NCT03747978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blind head to head trial|t|t|t|t
33863980|NCT06217094|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33838612|NCT03735043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838613|NCT00733395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33838614|NCT05822492|||COHORT||PROSPECTIVE|||||||
33963084|NCT03673839|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33963085|NCT06106737|||COHORT||PROSPECTIVE|||||||
33963086|NCT02096029|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33963087|NCT03358342|||COHORT||PROSPECTIVE|||||||
33963088|NCT01461148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963089|NCT00653887|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33963090|NCT05969028|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||We propose a factorial-design, cluster randomized controlled trial. In brief, this means that two interventions (the type of rescue breathing treatment and chest compression rate) will be studied in the same patient; and that randomizing patients to these treatments will switch over various time periods between groups of fire departments in King County. That is, some fire departments will be performing BVM with a compression rate of 100 compressions per minute over a specified time period, and will thereafter switch to the i-gel and a different chest compression rate for a specified time period.|f|f|t|t
33963091|NCT04622488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34176923|NCT05983211|NA|SINGLE_GROUP||TREATMENT||NONE||"Stage 1 \[Enrolment closed\]:~A prospective, single-arm, open-label pilot trial evaluating the safety, feasibility and changes in neuronal excitability biomarkers of accelerated rTMS using cTBS inhibitory paradigms over M1 in patients with ALS~Stage 2 \[CURRENTLY ENROLING\]:~A prospective, single-arm, open-label pilot trial evaluating the safety, target engagement via biomarkers, and dose discovery of multi-targeted, accelerated continuous theta burst stimulation (cTBS) regimen of repetitive transcranial magnetic stimulation (rTMS) over multiple primary motor cortex (M1) regions bilaterally with repeated maintenance cTBS sessions for 24 weeks in patients with ALS."||||
34176924|NCT04781478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients are divided in two groups. Both groups are treated with non-surgical periodontal therapy (baseline and 1, 3, 6 months after the first professional oral hygiene). Patients in the first group receive Biorepair gel in quadrants Q1 and Q4 and chlorhexidine 1% gel in quadrants Q2 and Q3; for patients in the second group the situation is inverted. In this way, it is possible to compare the general periodontal condition and the quadrants treated with the two different gels.|t|t|t|t
34176925|NCT04797611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176926|NCT06182137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176927|NCT05032040|NA|SEQUENTIAL||TREATMENT||NONE||||||
34176928|NCT02753283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34176929|NCT02616640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176930|NCT06211088|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34176931|NCT03095495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34176932|NCT06290115|||OTHER||CROSS_SECTIONAL|||||||
33863981|NCT05161572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863982|NCT06735014|||COHORT||CROSS_SECTIONAL|||||||
33863983|NCT06735937|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33863984|NCT05827653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Study is double-blind. Only personnel involved in randomization and creating reports to facilitate safe dose escalation, are planned to be unblinded during study.|"A double-blind, randomized, placebo-controlled, multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic effects of multiple intravenous infusions of NX210c. Two doses will be investigated.~Subjects will participate for approx. 124 days; up to 84 days for screening, 26 days of treatment and 14 days Follow-up. As part of the screening process subjects will undergo MRI and Mini-Mental State Examination to establish normal cognitive capacity and exclude any major neurological condition. Blood for PK will be drawn as well as for biomarkers testing. A CNS battery of pharmacodynamic measures including EEG and MRI will be performed, as well as Lumbar punctures for cerebrospinal fluid drug concentration determination and biomarker testing.~The study will be overseen by a safety review committee, sentinel dosing will be applied for each cohort. The rest of the cohort will be dosed if administration of NX210c is safe and well tolerated."|t|f|t|f
33863985|NCT06593093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863986|NCT06715540|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Stage 1: 3+3 design (dose escalation). Stage 2: parallel arms (dose expansion)"||||
33863987|NCT06735131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863988|NCT05501678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33863989|NCT02779738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33863990|NCT05398783|||CASE_CONTROL||PROSPECTIVE|||||||
33863991|NCT04016896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33863992|NCT04505865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33863993|NCT06210854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33863994|NCT05133245|||CASE_ONLY||PROSPECTIVE|||||||
33863995|NCT05257941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863996|NCT05987852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||5-day intervention period; 12 months observational period through standard of care visits and follow-up|t|f|t|t
33863997|NCT04450511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34065214|NCT00627809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34176933|NCT05550779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants do not know which condition they are in, nor that there is another condition. They only know what mental exercise they will do in their assigned condition.|Participants are randomly assigned to one of two mental exercises before performing a proper name production task and completing other measures.|t|f|f|f
34065215|NCT00871013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065216|NCT03341494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176934|NCT00368888|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176935|NCT06604676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176936|NCT02177123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176937|NCT05131945|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34176938|NCT02046967|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34176939|NCT06582446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176940|NCT06623240|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This clinical trial is a double-blinded study, meaning that the subjects and the researchers both do not know the group assignments. Research staff and subjects may be unblinded once all study data has been collected, all study-related procedures and follow-ups are completed, and all monitoring has been completed. (The first 6 patients (Cohort 1) will only receive active treatment; therefore, blinding is not applicable).|This study is a randomized, double-blind, Phase 2, efficacy and safety cross-over study of allogeneic HB-adMSCs vs placebo for the treatment of oligoarticular and polyarticular juvenile idiopathic arthritis. Cohort 1 (first 6 patients) will undergo a screening period (up to 35 days) and an 8-week active treatment period, followed by a 64-week follow-up. Cohort 2 (remaining 60 patients) will undergo a screening period (up to 35 days), an 8-week active treatment period and an 8-week inactive treatment period (placebo) with a washout period of 12 weeks between the treatment periods. Subjects assigned to Cohort 2 - Group AB will receive allogeneic HB-adMSCs before the washout period, while subjects assigned to Cohort 2 - Group BA will receive allogeneic HB-adMSCs after the washout period. Group AB will undergo a safety follow-up of 64 weeks after their last infusion of HB-adMSCs, while Group BA will undergo a safety follow-up of 44 weeks after their last infusion of HB-adMSCs.|t|t|t|t
34176941|NCT05120830|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Phase 1 is an open label non-randomized study Phase 2 is a randomized, double-blind, placebo-controlled study||t|f|t|f
34176942|NCT06596902|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This study will test the efficacy and sustainability of an extended, 12-month AFL Program, plus a 12-month active sustainability phase through a two-group parallel arm, cluster randomized controlled trial (RCT) utilizing a Hybrid Type 1 design while also gathering critical information about the implementation process. Participants will be 290 dyads consisting of one parent/caregiver (18 years or older) and one child (6-11 years) from the same household concurrently attending intervention sessions. The child will be the unit of analysis. In each region, 2 of the 4 community centers will be randomized to one of two conditions: 1) a 12-month AFL program or 2) a control group where participants will have access to all recreation center programs available, with exception of the AFL program.|t|f|t|t
34176943|NCT06521476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo pill matched to look like active drug.|Participants will be randomized in 1:1 fashion to one of two parallel arms (active drug versus placebo).|t|t|t|t
34176944|NCT05636748|||COHORT||PROSPECTIVE|||||||
34176945|NCT06592729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental and control groups will be determined using https://www.randomizer.org|This research will be conducted as an experimental study with pretest- posttest randomised control group design|t|f|f|f
34176946|NCT00375908|||CASE_CONTROL||PROSPECTIVE|||||||
34176947|NCT05670093|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional prospective study. Each participant is ventilated both on PS and NPS at 3 different support levels.||||
34176948|NCT04227899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176949|NCT03980769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176950|NCT06297083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, outcome assessors, other research staff, treating clinicians, investigators and trial statistician will be blinded to treatment allocation.|This is a three-arm, multi-center, head-to-head randomized study|t|t|t|f
34176951|NCT04595656|||CASE_ONLY||RETROSPECTIVE|||||||
34176952|NCT05722873|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled study||||
34176953|NCT04049604|||COHORT||PROSPECTIVE|||||||
34176954|NCT01761916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34176955|NCT02363920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176956|NCT05735743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34176957|NCT05684835|||COHORT||RETROSPECTIVE|||||||
33863998|NCT03369223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33863999|NCT01855698|||CASE_ONLY||PROSPECTIVE|||||||
33864000|NCT06643312|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will include 50 participants, 20 with SCI who are able to stand independently for short periods of time (\<1 hour) (Groups 1 \& 3), 20 participants with SCI who are unable to stand independently (Groups 2 \& 4), and 10 non-disabled individuals (Group 5). Group 1 (n=10) will be evaluated before and after receiving stand training with the TPAD. Group 2 (n=10) will be evaluated before and after receiving stand training with the TPAD. Group 3 (n=10) will be evaluated without receiving any intervention. Group 4 (n=10) will be evaluated without receiving any intervention. Groups 3 and 4, who will not receive any intervention, will undergo the Stable Standing Assessment and the Postural Perturbation Assessment only. Group 5 (n=10) will undergo assessments only. Each individual will serve as their own control, reducing the variability among individuals. Motor patterns recorded from the SCI participants will be also compared to those collected from non-disabled individuals.||||
34065217|NCT06403618|||CASE_ONLY||PROSPECTIVE|||||||
34065218|NCT01551706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34065219|NCT03699813|||CASE_CONTROL||RETROSPECTIVE|||||||
34176958|NCT04243564|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Investigators hypothesize PLMA and I-gel are both effective as temporary ventilatory device in morbidly obese patients.|t|f|f|t
33963092|NCT00343122|||DEFINED_POPULATION||PROSPECTIVE|||||||
34176959|NCT06706102|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176960|NCT06598813|||COHORT||PROSPECTIVE|||||||
34176961|NCT04699864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34176962|NCT02374450|||COHORT||PROSPECTIVE|||||||
34176963|NCT06376253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176964|NCT06706453|||COHORT||PROSPECTIVE|||||||
34176965|NCT02554292|||COHORT||PROSPECTIVE|||||||
34176966|NCT05444465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176967|NCT06303869|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, non-randomized, open-label, descriptive, experimental.||||
34176968|NCT05731583|||COHORT||PROSPECTIVE|||||||
34176969|NCT05708703|||COHORT||PROSPECTIVE|||||||
34176970|NCT04425967|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomization between the standard arm A of 50 Gy in 5 weeks or arm B with hypofractination of 14x3Gy||||
34176971|NCT06592651|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176972|NCT03361800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34176973|NCT02689440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864001|NCT00075088|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34176974|NCT06600880|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34176975|NCT05397145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group.|There are two models for this study. Iliopsoas plane block (IPB) group, and PENG block group.|t|f|f|t
34176976|NCT01703910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176977|NCT06594211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34176978|NCT06502483|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176979|NCT04137952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34176980|NCT05495789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34176981|NCT05538325|||COHORT||RETROSPECTIVE|||||||
34176982|NCT02852655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176983|NCT01325077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34176984|NCT04126798|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34176985|NCT06704360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34176986|NCT06593626|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-center, multi-dose, open-dosing study||||
34176987|NCT06177132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants cannot be blinded to their assigned groups, as they will be aware of the protocol received at any given time. The assessment of primary and secondary outcome measures will be conducted by a separate outcome assessor who will be blinded to patient allocation. Data analysis procedures will not involve blinding since they will be performed by the same individual responsible for conducting the rehabilitation sessions.|Two-parallel group, superiority, randomised controlled crossover trial with 1:1 allocation ratio|f|f|f|t
34176988|NCT05883501|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34176989|NCT03818256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
34176990|NCT06513871|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34176991|NCT06586749|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34176992|NCT05317728|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34176993|NCT03247647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34176994|NCT06270888|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34176995|NCT06281587|||COHORT||RETROSPECTIVE|||||||
34176996|NCT06093477|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33864002|NCT06605807|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33864003|NCT05179863|||COHORT||PROSPECTIVE|||||||
33864004|NCT05539365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864005|NCT05335018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864006|NCT05839041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 2 - Double Masked, Randomized, Multi-Center|Part 1 - Open Label, Multi-Center, Dose Escalation|t|t|t|t
33864007|NCT02149212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864008|NCT05984277|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33864009|NCT04032691|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864010|NCT06167317|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33864011|NCT05443230|||CASE_CONTROL||PROSPECTIVE|||||||
33864012|NCT02060383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864013|NCT06734468|NA|SINGLE_GROUP||PREVENTION||NONE||A pre-post design will be used, with all participants receiving the intervention.||||
33864014|NCT06735521|||COHORT||PROSPECTIVE|||||||
33864015|NCT06246656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864016|NCT06556147|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Stage 1 is a sequential assignment followed by Stage 2 parallel assignment.|t|f|f|t
33864017|NCT02743884|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Cross-over.||||
33963093|NCT05005650|||COHORT||RETROSPECTIVE|||||||
33963094|NCT04895319|||COHORT||RETROSPECTIVE|||||||
33963095|NCT04793438|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33963096|NCT01418352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34176997|NCT05196269|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective randomized open trial with parallel groups||||
34176998|NCT05136976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization will be performed by the pharmacy. The treatment group will not be mentioned to the clinicians.|The THERAMAG study is a French academic multicentre, randomized, double-blind trial sponsored by the University Hospital of Saint-Etienne, comparing rituximab infusion to placebo infusion in anti-MAG patients presumed as good clinical responders.|t|f|t|f
34176999|NCT03609645|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|An unblinded study personnel not directly involved in patient care will prepare all study drugs. The anesthesiologist, patient, surgeon and the investigator collecting outcome data will be unaware of study group allocation.|This is a double-blinded randomized prospective study involving patients with hip fracture who are undergoing surgical fixation.|t|t|t|t
34177000|NCT00581308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177001|NCT04629508|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177002|NCT04819451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||rospective, interventional, double-blind, completely randomized, stratified controlled clinical trial|t|t|t|t
33864018|NCT04500041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study outcome is determined from serial radiographs. Radiographic readers will be blinded to the treatment assigned or received.|Treatment (casting or bracing) via randomized assignment OR based on family preference|f|f|f|t
34177003|NCT05330897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751574|NCT06627296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding was done by ensuring that the participant did not know which group the subject was they were in. Also, the other researcher assessing the measurements did not know which treatment the patients received.|Two groups with a intervention group including Nmes and exercise therapy and a control group including exercise therapy|f|f|f|t
33751575|NCT03583554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The research pharmacist compiles and has unique access to the randomization key|placebo-controlled, randomized, double-blind, cross-over|t|f|t|t
33751576|NCT06517043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)||t|f|t|t
33751577|NCT05920369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|a well-experienced outcome assessor and participants are blind to the assignment of groups.|controlled, double-blinded, randomized clinical trial, three arms|t|f|f|t
33751578|NCT00626431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864019|NCT06736548|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33864020|NCT04870359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864021|NCT05727384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34177004|NCT05018624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177005|NCT06062433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177006|NCT02426398|||CASE_CONTROL||PROSPECTIVE|||||||
33864022|NCT01955447|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33864023|NCT00044551|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864024|NCT03292289|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33864025|NCT05384379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864026|NCT04689724|||COHORT||RETROSPECTIVE|||||||
33864027|NCT05173142|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751579|NCT04632875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33751580|NCT00269490|||||PROSPECTIVE|||||||
33864028|NCT03443505|||COHORT||PROSPECTIVE|||||||
33864029|NCT05874323|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33864030|NCT00025441||||TREATMENT||||||||
33864031|NCT00103428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864032|NCT00765986|||COHORT||PROSPECTIVE|||||||
33864033|NCT04853355|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, pilot study||||
33864034|NCT03920722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864035|NCT02428010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864036|NCT05661227|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33864037|NCT06211192|||COHORT||RETROSPECTIVE|||||||
33864038|NCT04282122|||OTHER||PROSPECTIVE|||||||
33864039|NCT02303704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864040|NCT00037869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864041|NCT00626756|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864042|NCT01438151|NA|SINGLE_GROUP||||NONE||||||
34177007|NCT02362815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34177008|NCT05417438|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177009|NCT03582475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177010|NCT04431479|||COHORT||PROSPECTIVE|||||||
34177011|NCT05653492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177012|NCT06590571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Simple randomization was performed at the end of each coronary angiography procedure using a randomization table provided by the website (http://stattrek.com/Tables/Random.aspx). Investigators were able to identify the assignment only after the coronary angiography procedure and before the removal of the sheath catheter.||||
34177013|NCT04451525|||COHORT||PROSPECTIVE|||||||
34177014|NCT00979940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177015|NCT05556473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864043|NCT05653440|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Research assistants responsible for coding data will be masked to treatment condition.||f|f|f|t
34177016|NCT05070923|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33751581|NCT05809752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751582|NCT05531773|||COHORT||OTHER|||||||
33751583|NCT01751828|NA|SINGLE_GROUP||||NONE||||||
33751584|NCT03921515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751585|NCT06419322|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive the optimized rehabilitation program (intervention). An external control group will be used to determine the potential efficacy.||||
33751586|NCT02069444|||CASE_CONTROL||PROSPECTIVE|||||||
33864044|NCT03044886|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33864045|NCT05094336|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33864046|NCT05949151|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the investigator didn't know which patients belonged to which group|two group Group I: received a complete removable mandibular implant supported overdenture. While Group II: received implant supported fixed bridge.|f|f|f|t
33864047|NCT04779190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33864048|NCT05693168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864049|NCT00895141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34177017|NCT06584695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34177018|NCT04250857|||COHORT||PROSPECTIVE|||||||
34177019|NCT04216524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751587|NCT06732232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751588|NCT06542198|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The study is conducted in two parts. Part 1: Double-blind Part 2: Open-label|The study is conducted in two parts. Part 1: Cross-over proof-of-concept study Part 2: Single arm case-control pilot study||||
33751589|NCT00072267||||TREATMENT||NONE||||||
33751590|NCT03341793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751591|NCT05500469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751592|NCT05127174|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751593|NCT04360733|||OTHER||PROSPECTIVE|||||||
33751594|NCT02427126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963097|NCT05826769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|According to national regulations, distribution of infant formula inside the hospital without a proper label is not allowed; therefore, subjects can not be blinded in this study.|"* Patients are randomized before surgery in blocks of 2 using a computer-generated randomization list into intervention and control groups~* This will be An open, 2-arm,randomized controlled trial"||||
33751595|NCT01402453|RANDOMIZED|PARALLEL||||NONE||||||
33751596|NCT05243758|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||60 patients aged between 18-65 years, who were operated in the operating room of our hospital, with an EGRI score of \>4 and an ASA (American Society of Anesthesiologists) score of \<4 were included.|t|f|f|f
33751597|NCT06052696|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33751598|NCT06311695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751599|NCT04274907|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751600|NCT00038051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751601|NCT00916682|||CASE_CONTROL||PROSPECTIVE|||||||
33751602|NCT00071617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751603|NCT05202301|||COHORT||RETROSPECTIVE|||||||
33751604|NCT06661733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751605|NCT03937154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study will consist of a screening period of up to 4 weeks, a treatment period long enough to allow for assessment of 3 planned cycles of chemotherapy, a follow-up visit, and LTFU. Given that subjects are required to have 3 remaining planned cycles of chemotherapy, the chemotherapy cycles may be 3 or 4 weeks in duration, and the investigational product dose adjustment guidelines allow for up to 12 weeks of dosing before a subject is declared a non-responder, the majority of study subjects will receive investigational product for a range of 10-24 weeks.|t|t|t|t
33751606|NCT03912558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751607|NCT04453631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751608|NCT05198466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Devices may be active or sham.|"Participants will be randomized to intervention (IG) or control group (CG) with ratio of 1:1. The entire cohort will receive daily electrical stimulation (EE) in lower extremity (e.g. Gastrocnemius muscle) for up to 1 hour. The EE device will be functional for IG and non-functional for CG.~Phase II will include previously hospitalized patients (n=20) who had recover from severe COVID-19 infection, but present persistent neuromuscular sequelae. This will be performed in an outpatient clinic. The time frame will be 4 weeks."|t|t|f|f
33751609|NCT01684748|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33751610|NCT05916326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33751611|NCT05156190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|t|f|t
33751612|NCT06112756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751613|NCT06519968|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33751614|NCT02471196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751615|NCT06662227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751616|NCT03969862|||CASE_CONTROL||PROSPECTIVE|||||||
33751617|NCT01016665|RANDOMIZED|||BASIC_SCIENCE||DOUBLE||||||
33751618|NCT06685861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751619|NCT04998357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751620|NCT04576091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751621|NCT06095570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|People who were unaware of the experiment helped to randomize the groups and inject the test drug according to the groups, and the patients who participated in the experiment as well as the doctors were unaware of the groups.|Group C: Ciprofol + sufentanil + rocuronium bromide Group R: Remimazolam+ sufentanil + rocuronium bromide|t|f|t|t
33751622|NCT04781374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751623|NCT05410938|||CASE_CONTROL||RETROSPECTIVE|||||||
33751624|NCT05113628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751625|NCT05644977|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33751626|NCT00783926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33751627|NCT06443463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864050|NCT01009827|||COHORT||CROSS_SECTIONAL|||||||
34177020|NCT04440475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patient and the person performing the analysis will be masked|"The investigators will perform a pilot randomized control trial, where one group will be receiving TAP blocks whereas the other group will be receiving regular postoperative pain medications (acetaminophen, ibuprofen, tramadol orally upon discharge). Randomization will be completed using a computer-generated randomization sequence using 1:1 ratio with blocking in groups of 4. The randomization sequence will kept in our research office and investigators enrolling subjects will not have access. Sequentially numbered sealed opaque envelopes will be prepared following the randomization sequence, randomized participants will receive an envelope in sequential order.~The patient and the person performing the statistical analyses will be blinded."|t|f|f|t
34177021|NCT00003989||||TREATMENT||||||||
34177022|NCT05632653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177023|NCT04952922|||COHORT||PROSPECTIVE|||||||
34177024|NCT06603116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34177025|NCT02226393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177026|NCT06596850|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33864051|NCT03659851|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34177027|NCT06595316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants recruited will be cancer patients who attend to the Queen's Centre for Oncology and Haematology at Castle Hill Hospital, whose confirmed diagnosis is ER+ HER2- breast cancer, and whose chemotherapy regimen is 3 cycles of epirubicin and cyclophosphamide (EC) followed by 3 cycles docetaxel over a period of 18 weeks. They will be identified, screened and selected according to the study's inclusion and exclusion criteria, and then approached by their Consultant Clinical Oncologist in charge and/or the researcher. Patients will be offered the opportunity to be part of the study. Individuals will only participate if they have provided informed consent.~Participants will be randomly allocated in a 1:1 ratio, either to intervention group, or the control group (usual care) by an unrestricted simple random sampling technique, until the maximum number of participants has been reached, which is a total of 15 individuals per group over a period of maximum 15 months."||||
33864052|NCT05329896|||COHORT||RETROSPECTIVE|||||||
33864053|NCT06725017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, placebo-controlled|t|t|t|t
33864054|NCT03447366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864055|NCT05880940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864056|NCT02718599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864057|NCT00115791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864058|NCT02791022|||CASE_ONLY||PROSPECTIVE|||||||
33864059|NCT01892306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864060|NCT01313715|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33864061|NCT00217191|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33864062|NCT03173066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||single-arm, open label||||
33864063|NCT02462928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864064|NCT03647553|||COHORT||CROSS_SECTIONAL|||||||
33864065|NCT02163083|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864066|NCT02740296|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34177028|NCT05537909|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All patients and their controls will have a sample of urine, stool, saliva and blood taken during a follow-up visit. Patients will not be specifically asked to take these samples, they will be taken during a follow-up visit, during which these samples are usually already taken.||||
33864067|NCT05520541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|Two groups as clinical group and home group|t|f|f|t
33864068|NCT02959749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864069|NCT03869281|||CASE_CONTROL||RETROSPECTIVE|||||||
33864070|NCT04621734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864071|NCT03724734|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patients will not be told which form of stimulation is being applied and the main measures used to evaluate the outcome of the study will be video-taped performance on a number of motor tasks and the video-taping of mobility during arousals and awakenings from sleep.|Patients will be randomised as to whether they receive conventional DBS or adaptive DBS first. Thereafter they will cross-over to the second type of stimulation.|t|f|f|t
33864072|NCT01162239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864073|NCT01211535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33864074|NCT02595021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864075|NCT00096668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864076|NCT04332250|||COHORT||RETROSPECTIVE|||||||
33864077|NCT02564107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864078|NCT05033665|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864079|NCT05835089|||CASE_CONTROL||PROSPECTIVE|||||||
33864080|NCT06734156|||COHORT||PROSPECTIVE|||||||
33864081|NCT00051285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864082|NCT04749342|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The purpose of this report is to compare short-term outcomes of complete decongestive therapy and compression bandaging on patients with advanced secondary upper and lower extremity lymphedema.||||
33864083|NCT02699957|||COHORT||PROSPECTIVE|||||||
34177029|NCT01450020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864084|NCT05810831|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864085|NCT04925986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963098|NCT06568185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The participants then will be randomized to either intervention or control group. The intervention group will receive a fixed dose combination of alpha lipoic acid and vitamin B preparations, and the control group will receive a placebo (look-alike substance that contains no drug).|t|f|t|f
33963099|NCT00136734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177030|NCT01063049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34177031|NCT03160638|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized pilot study||||
34177032|NCT05773937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177033|NCT02449122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864086|NCT00908583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864087|NCT05326425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864088|NCT06230653|||OTHER||PROSPECTIVE|||||||
34177034|NCT04854174|NA|SINGLE_GROUP||OTHER||NONE||||||
33864089|NCT04885036|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Clinical Trial comparing Emotion-focused skills training (EFST) up against treatment as usual in an outpatient specialist mental health clinics family team.||||
33864090|NCT00648804|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33864091|NCT04475900|||CASE_CONTROL||PROSPECTIVE|||||||
33864092|NCT04199234|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33864093|NCT06495242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"the participants are blinded to the type of treatment provided, the care provider is masked only during the early stages of teh procedure but subsequently masking is not possible due to different treatment protocols.~Block randomization. and sealed envelop technique are used. Principal investigator and evaluator are blinded to the type of treatment provided"|Parallel randomized clinical trial including 2 treatment groups with 1;1 allocation ration|t|f|t|t
33864094|NCT04268043|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33864095|NCT00024401||||TREATMENT||||||||
33864096|NCT01870557|||COHORT||CROSS_SECTIONAL|||||||
33864097|NCT03670706|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33864098|NCT05206591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864099|NCT06723756|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33864100|NCT02681250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864101|NCT04411953|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34177035|NCT00960622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177036|NCT04506437|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a dynamic wait-listed design in which the investigators will test a theory-driven family-based navigator treatment engagement intervention (FCFN) while also collecting data on the FCFN model's potential implementation and adoption within child welfare and behavioral health settings.||||
34177037|NCT06584006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177038|NCT06582524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177039|NCT04526613|||COHORT||PROSPECTIVE|||||||
34177040|NCT04569240|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177041|NCT05525416|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Due to the study design, masking is not possible. The time points and dosages of the study drug will be known to the participant.|Participants will partake in both arms of the study, which include: 1) low altitude and 2) high altitude assessments.||||
34177042|NCT03675126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177043|NCT06586905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177044|NCT04817670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177045|NCT06586060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34177046|NCT06360380|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||A prospective, multicenter, single-arm, within-patient-controlled, pivotal trial, enrolling patients with decompensated heart failure and/or CKD stage 2-3 inadequately responding to current medical treatment, indicated by persistent or worsening congestion despite a daily dose of ≥40 mg furosemide or equivalent.||||
34177047|NCT06439017|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34177048|NCT06053697|||COHORT||PROSPECTIVE|||||||
34177049|NCT06601881|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double||t|f|f|t
34177050|NCT06561295|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177051|NCT03199976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177052|NCT06420947|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34177053|NCT04664517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicenter, randomized superiority trial. Parallell patient choice arm.|f|f|t|t
34177054|NCT04665401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177055|NCT06603142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177056|NCT05418179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Study participants and researchers were masked over consumption and distribution of supplementation, respectively.~Laboratory technicians who performed the blood collection were also masked as to the distribution of supplementation.~Supplements and placebo were pre-packaged by the supplier in opaque and closed sachets with randomization codes, being identical in physical appearance, taste and color. Supplement identification codes were only disclosed by the supplier after statistical analysis of study data."||t|t|t|t
33864102|NCT01610687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864103|NCT02432313|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864104|NCT00287274|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864105|NCT03005951|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33864106|NCT03153709|||COHORT||PROSPECTIVE|||||||
33864107|NCT05957354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864108|NCT06363669|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33864109|NCT00230438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963100|NCT05244174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|One of the collaborator of the study will define which treatment group is assigned each patient (Group A and Group B). Only that investigator and the person who perform the ERCP (care provider) will know to which group is assigned the patient. Patients, investigators and outcome assessor are blinded.|Patients with pancreatic head adenocarcinoma will be randomized to biliary stent placement versus bilio-pancreatic stent placement using the computer-generated total randomization method. The randomization process will be carried out by one of the collaborating researchers who will not participate in the follow-up of patients|t|f|t|t
33963101|NCT05645224|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Researcher conducting the post-procedural survey is blinded to the group assignment|Participants will be randomly assigned to either the intervention group (VR-PAT) or the control group (same VR google without game) at the first laser procedure and will then cross-over to the alternative group for the second laser procedure.|f|f|t|f
33963102|NCT01857674|||||PROSPECTIVE|||||||
33963103|NCT02488902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963104|NCT04264663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|f|f|t|t
33963105|NCT04671160|||COHORT||PROSPECTIVE|||||||
33963106|NCT02245360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177057|NCT06109142|||COHORT||PROSPECTIVE|||||||
34177058|NCT04214535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, single arm clinical study to evaluate fusion status and patient reported outcomes utilizing the Stryker Tritanium® C Anterior Cervical interbody device||||
34177059|NCT03282656|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-randomized, single center, pilot and feasibility, single arm cohort study||||
34177060|NCT06602115|||COHORT||RETROSPECTIVE|||||||
34177061|NCT06446453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177062|NCT01412697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177063|NCT06599476|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177064|NCT06507943|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177065|NCT06594328|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34177066|NCT01508689|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34177067|NCT03439306|||CASE_ONLY||PROSPECTIVE|||||||
34177068|NCT05869708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34177069|NCT06604728|||COHORT||OTHER|||||||
33864110|NCT02663284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864111|NCT04197726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Double-blind randomised crossover study|t|f|t|t
33864112|NCT00024167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864113|NCT05466812|NA|SINGLE_GROUP||TREATMENT||NONE||Sr-89 treatment||||
33864114|NCT01561495||SEQUENTIAL||TREATMENT||NONE||||||
33864115|NCT01888926|||||PROSPECTIVE|||||||
33864116|NCT03878173|||COHORT||PROSPECTIVE|||||||
33864117|NCT05244707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33864118|NCT02901873|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864119|NCT02677376|||CASE_ONLY||PROSPECTIVE|||||||
33864120|NCT01475604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864121|NCT02794454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864122|NCT01636479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864123|NCT03178968|RANDOMIZED|PARALLEL||OTHER||SINGLE|single-blind, randomised intervention study (blinded for the surface roughness measurements, step height measurements and microhardness testing)||f|f|f|t
33864124|NCT01289795|||COHORT||PROSPECTIVE|||||||
33864125|NCT01816412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864126|NCT05881967|||CASE_CONTROL||RETROSPECTIVE|||||||
33864127|NCT05690945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864128|NCT01919320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33963107|NCT04315818|||CASE_CONTROL||OTHER|||||||
34177070|NCT05222529|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants, investigator staff, persons performing the assessments, data analysts and the Sponsor Clinical Trial Team (CTT) will remain blind to the identity of the treatment from the time of randomization until database lock.||t|t|t|t
34177071|NCT06603909|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864129|NCT05279703|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33864130|NCT03599557|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will use a cluster RCT study design to test the impact of the communication intervention to reduce missed opportunities (MOs) and raise HPV vaccine rates||||
33864131|NCT00526396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864132|NCT06494865|||CASE_ONLY||CROSS_SECTIONAL|||||||
33864133|NCT02119754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864134|NCT01595113|||COHORT||RETROSPECTIVE|||||||
34177072|NCT06588127|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Select two communities of comparable size and level, with one community recruiting participants as a control group and the other community recruiting participants as an intervention group.||||
34177073|NCT03628768|||COHORT||CROSS_SECTIONAL|||||||
34177074|NCT05206708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|117 dyads will be enrolled||t|f|f|f
34177075|NCT05160181|||COHORT||RETROSPECTIVE|||||||
34177076|NCT03044509|||COHORT||PROSPECTIVE|||||||
34177077|NCT05632159|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||Evaluating the effect of intraoperative administration of Magnesium sulphate on the occurrence of post-operative delirium and insomnia in those patients.|t|f|t|t
34177078|NCT06598982|||OTHER||CROSS_SECTIONAL|||||||
34177079|NCT04073875|||COHORT||PROSPECTIVE|||||||
34177080|NCT02674035|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34177081|NCT04370301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177082|NCT06318468|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34177083|NCT04310462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34177084|NCT05175547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible patients will be randomized 1:1 to a systolic blood pressure goal after successful MT (mTICI 2c or greater) of either: 90-120 or 90-160mmHg.|f|f|f|t
34177085|NCT04760613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial will employ a double-blind pharmacologic intervention methodology where the investigational drug (CBD) and matched placebo oral pills will be masked in identically appearing capsules provided by the drug sponsor.||t|f|t|f
34177086|NCT06600217|||COHORT||PROSPECTIVE|||||||
34177087|NCT05830812|||COHORT||RETROSPECTIVE|||||||
34177088|NCT05542420|||COHORT||RETROSPECTIVE|||||||
34177089|NCT05292664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177090|NCT05642741|||CASE_ONLY||PROSPECTIVE|||||||
34177091|NCT04927442|||COHORT||PROSPECTIVE|||||||
34177092|NCT03571438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177093|NCT06494267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34177094|NCT05730023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34177095|NCT06122831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177096|NCT04753190|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34177097|NCT05204719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864135|NCT04236648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864136|NCT01198093|||COHORT||PROSPECTIVE|||||||
33864137|NCT06197334|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963108|NCT02995694|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33963109|NCT06352398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963110|NCT01858129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963111|NCT02983227||PARALLEL||TREATMENT||NONE||||||
33963112|NCT00757276|||COHORT||PROSPECTIVE|||||||
33963113|NCT00488046|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33963114|NCT04658446|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|The assessor shall not know which group is which in the accuracy outcome.|8 Patients with Split-mouth trial design. Full permanent dentition. In need of Orthodontic treatment with fixed appliance therapy.|f|f|f|t
34177098|NCT02649582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177099|NCT03160261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-group, open-label||||
34177100|NCT03008278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177101|NCT02257138|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177102|NCT06601582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864138|NCT00594321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864139|NCT02603471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864140|NCT04573751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864141|NCT03222739|NA|SINGLE_GROUP||OTHER||NONE||A single-arm unblinded group of patients will receive ultrasound imaging of spine.||||
33864142|NCT02091583|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33864143|NCT02815917|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33864144|NCT02426528|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33864145|NCT00891319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864146|NCT05804279|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065220|NCT06182436|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Every patient (98) will be their own control (98+98=196). Allocation to either intervention or control will be randomized at first then switched at the crossover period.||||
34177103|NCT06565962|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The research will be conducted in a randomised controlled experimental design. The participants randomly assigned to the groups will first be administered data collection forms as a pre-test. Then, the experimental group will be made to watch the training videos prepared by AFAD on disaster preparedness, disaster moment and post-disaster by using virtual reality goggles. Then, data collection for the post-test will be carried out from both groups. After a 3-month follow-up period, follow-up test questionnaires will be collected from both groups. No intervention will be made to the control group. Personal information form, disaster literacy scale, disaster preparedness scale and disaster resistance scale will be used to collect the research data.|parallel group 1:1 single blind randomised controlled experimental study|t|f|t|f
34177104|NCT06212856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34177105|NCT05620628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177106|NCT06210646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, a specially trained and qualified nurse randomly assigned participants to receive either citicoline or a placebo. We prepared Sequentially numbered opaque sealed envelopes and 800 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 800. Envelopes were attached to the patient\&amp;#39;s files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included citicoline 2000 mg, and Drug B included a citicoline 1000mg. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will conduct our randomized controlled trial, which will contain 2 arms: the citicoline arm, which consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and the placebo arm, consisting of 400 patients who received 1000 mg citicoline once daily for 12 months; both groups will receive open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.|f|f|t|t
34177107|NCT05085353|||CASE_ONLY||PROSPECTIVE|||||||
34177108|NCT06591429|||COHORT||OTHER|||||||
34177109|NCT04631510|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33864147|NCT00137163|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864148|NCT03399097|||OTHER||OTHER|||||||
33864149|NCT00684229|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33864150|NCT01475682|||COHORT||PROSPECTIVE|||||||
33864151|NCT00943020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33864152|NCT00000125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864153|NCT02811055|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33864154|NCT04578886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864155|NCT04515472|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||MTF and FTM non-diabetic transsexuals will be compared to healthy female and male subjects respectively.||||
33864156|NCT01714778|||COHORT||PROSPECTIVE|||||||
33864157|NCT00153647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864158|NCT04841512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Unblinded pharmacy, blinded clinical staff for administration and assessments||t|f|t|f
33864159|NCT04147026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will not know if his bDMARD treatment was prescribed with or without the help of SinnoTest® software|"The study is a prospective, phase III, controlled, multicenter, and randomized in 2 parallel groups, single-blind (patient) with binded outcome assessment clinical trial.~* Intervention arm: Prescription of biotherapy (rituximab, adalimumab, abatacept) using SinnoTest® software~* Control arm: Prescription of biotherapy without the SinnoTest® software which corresponds to current practice (all biotherapies)."|t|f|f|t
33864160|NCT00846651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864161|NCT00437385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864162|NCT04441034|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm parallel randomized clinical trial||||
33864163|NCT06473974|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Open-label, Safety and Efficacy||||
33864164|NCT01591317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864165|NCT05903872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The sample of the study included a total of 36 postpartum mothers with preterm newborns in 2 groups~18 mothers in aromatherapy massage group 18 mothers in back massage group"||||
33864166|NCT04655469|||COHORT||RETROSPECTIVE|||||||
33864167|NCT04465097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864168|NCT05940922|||CASE_ONLY||RETROSPECTIVE|||||||
33864169|NCT06407791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864170|NCT06730321|||COHORT||PROSPECTIVE|||||||
33864171|NCT00334126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33963115|NCT06128031|||CASE_CONTROL||RETROSPECTIVE|||||||
33963116|NCT00831922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963117|NCT04898400|NA|SINGLE_GROUP||OTHER||NONE||||||
33963118|NCT02073305|||COHORT||PROSPECTIVE|||||||
33963119|NCT00646100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963120|NCT06143319|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33963121|NCT01989195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065221|NCT04939454|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an observational, etiological, cross-sectional case-control type, monocentric, multi-departmental study.||||
34065222|NCT00034918|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34065223|NCT05649813|||COHORT||PROSPECTIVE|||||||
34065224|NCT02657070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065225|NCT05881122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065226|NCT02394015|||OTHER||RETROSPECTIVE|||||||
34065227|NCT06249828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065228|NCT01516294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963122|NCT04185701|NA|SEQUENTIAL||DIAGNOSTIC||NONE||"* Eye examination by an expert including optimal correction in distance and near vision~* Eye examination by a technician with the SiVIEW system~* Analysis of the SiVIEW report by the expert who conducted the second review"||||
33751628|NCT06732505|NA|SEQUENTIAL||TREATMENT||NONE||||||
33751629|NCT03332368|||COHORT||PROSPECTIVE|||||||
33751630|NCT05875181|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33751631|NCT06124209|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized controlled trial|t|t|f|t
33751632|NCT05138419|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized control pilot study using non-nephrology clinicians to educate patients at high risk for CKD how to protect the kidneys and be ready for RRT if needed utilizing nephrology developed educational tools. Pharmacists screen subjects in the MTM program or with the same medical conditions, enroll them in familial or peer clusters of 1 or more subjects and randomized into 1 of the 3 study arms using a site specific randomization schedule. In clusters of more than 1 subject, the group chooses a leader who receives the assigned intervention and shares it other cluster members. All subjects will receive pre and post testing, health literacy evaluation and completes a program evaluation. The 3 arms include 2 education arms and a control arm with various levels of intervention. The two education arms use the CKD: What You Need to Know Workbook including the CKD AP as self-study tools. The control arm receives the CKD AP and a list of CKD Web-based Resources.||||
33751633|NCT05926180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751634|NCT05979441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751635|NCT04475757|||COHORT||PROSPECTIVE|||||||
33751636|NCT03292250|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"During or after palliative 1st line platinum based chemotherapy, we will perform prescreening NGS based molecular characterization.~Molecular tumor board to determine characterization will be held for every patients. Once each patients have relevant genetic pathway, the patients will be allocated each treatment arm.If the patients have no relevant genetic alteration, such a patients will allocated to durvalumab+/- tremelimumab arm regardeless of PD-L1 positivity. If the patients who allocated to BYL719(Arm1),poziotinib(Arm2), nintedanib(Arm3), and abemaciclib(Arm4) experience disease progression but still meet the inclusion/ exclusion criteria for durvalumab+/- tremelimumab arm((Arm5) the cross over to durvalumab+/- tremelimumab arm will be permitted. Vice versa (cross over from durvalumab+/- tremelimumab arm to another arms) is not permitted."||||
33751637|NCT03175133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751638|NCT03715933|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751639|NCT00737165|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751640|NCT04840589|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751641|NCT01320046|||CASE_CONTROL||PROSPECTIVE|||||||
33751642|NCT04347551|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is an observational within-subjects design that involves a pre/post cervical spine manipulation intervention on participants (n=20) with chronic neck pain and asymptomatic controls (n=20). All participants will complete an eye movement and head movement Fitts' task before and after cervical spine manipulation to identify any changes in eye and head movement time, eye and head peak velocity, and time to peak eye and head velocity.||||
33751643|NCT06670235|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751644|NCT01627327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751645|NCT03146624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33751646|NCT02525874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751647|NCT04930068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|closed enveloped|Group (A) consisted of 25 females who treated by ultrasonic cavitation, group (B) consisted of 25 females who performed aerobic exercise.|f|f|f|t
33751648|NCT05476939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751649|NCT04461002|||CASE_ONLY||RETROSPECTIVE|||||||
33751650|NCT04719780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be a randomized controlled trial (RCT) carried out across three study sites (Ottawa, Denver, Victoria). We will have two study groups, treatment (n=44) and wait-list control (n=44). The wait-list control will be given an online transdiagnostic cognitive-behavioural treatment for depression and anxiety that has been empirically validated. The treatment condition group will be provided 12-15 sessions of Emotionally Focused Therapy for Individuals. Approximately 22 experienced EFT therapists will be given training in EFIT and will provide treatment to 2-3 clients each. Therapy will be carried out in person and/or online.|f|f|f|t
33751651|NCT05805592|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a parallel group randomized controlled study.||||
33751652|NCT00951275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751653|NCT03835455|||OTHER||PROSPECTIVE|||||||
33751654|NCT00802854|||CASE_ONLY||OTHER|||||||
33751655|NCT06421012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33751656|NCT00712361|NA|SINGLE_GROUP||SCREENING||NONE||||||
33864172|NCT06228651|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The protocol for tourniquet application during TKA began with encasing the patient's thigh in a stockinette sleeve, followed by the fitting of the tourniquet cuff which was connected to the Zimmer A.T.S 3000 tourniquet system. To ascertain the individualized optimal pressure, a pulse oximeter was momentarily placed on the patient's limb before the cuff was inflated. The tourniquet was used from the start of the incision and was released just prior to closure of the joint capsule to ensure optimal hemostasis during the final stages of the procedure.|We conducted a prospective, randomized, double -blinded trial including patients with simultaneously performed bilateral TKA in a fast-track setup at Lillebaelt Hospital - Vejle, Denmark. After randomization, tourniquet was inflated to only one knee facilitating direct comparison with patients acting as their own controls. Postoperative evaluations were performed at predetermined intervals. Patient reported outcomes were measured for the following year postoperative|t|f|t|f
33864173|NCT05912803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864174|NCT05439668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963123|NCT02561013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963124|NCT06542757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963125|NCT05027009|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33963126|NCT06520228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33963127|NCT01089985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963128|NCT03497988|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33963129|NCT04748809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33963130|NCT01825876|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963131|NCT02846740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963132|NCT06528860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study will utilize a Central Randomization System (CRS) for the random grouping and glasses allocation of study subjects during the clinical trial. Investigators and participants will be blinded to the intervention received until unblinding.|"Intervention Group: Daily disposable bifocal soft corneal contact lenses: MiSight® 1 day soft contact lens (CooperVision, material: omafilcon A, water content: 60%).~Control Group: Daily disposable single-focus soft corneal contact lenses: Proclear® 1 day soft contact lens (CooperVision, material: omafilcon A, water content: 60%)"|t|t|t|f
33963133|NCT01963676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177110|NCT05060211|||COHORT||CROSS_SECTIONAL|||||||
34177111|NCT05809908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177112|NCT06274060|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This fractional factorial design includes four strategies resulting in 16 trial arms/conditions. The design compares results in arms with and without each of the strategies, but is not fully powered to test every combination of strategies.Thus, each strategy will be received by half of the participants, though the combinations of strategies will vary.||||
34177113|NCT06704815|||CASE_CONTROL||PROSPECTIVE|||||||
34177114|NCT03814811|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34177115|NCT01607957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751657|NCT03043508|||COHORT||OTHER|||||||
33751658|NCT03418766|||COHORT||PROSPECTIVE|||||||
33751659|NCT03162224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751660|NCT03119467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751661|NCT03200262|||OTHER||OTHER|||||||
33751662|NCT00527566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177116|NCT01212835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177117|NCT06453746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33864175|NCT05682924|||COHORT||PROSPECTIVE|||||||
33864176|NCT01990092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34177118|NCT05784844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, single center trial||||
34177119|NCT00941746|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34177120|NCT02099864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177121|NCT04199351|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34177122|NCT06041763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177123|NCT03985839|||OTHER||PROSPECTIVE|||||||
34177124|NCT03496844|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34177125|NCT00445081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177126|NCT01856270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177127|NCT04771455|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34177128|NCT01500733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177129|NCT05974722|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be blinded to the intervention. Additionally, there will be blinded outcome assessors/study team including 3 surgeons reviewing recurrence imaging|Patients will be randomized to receive mesh or pledgeted suture reinforcement of the crural repair|t|t|f|f
34177130|NCT05884307|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177131|NCT05313295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34177132|NCT06218316|RANDOMIZED|PARALLEL||TREATMENT||NONE||one-way analysis of variance (ANOVA)||||
34177133|NCT06591507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177134|NCT05719103|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34177135|NCT06586567|||OTHER||PROSPECTIVE|||||||
34177136|NCT03995368|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will have the same tasks delivered in the same manner.||||
34177137|NCT04879030|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was an open-label, randomized study using two types of treatments. Participants were divided into two groups using a randomization procedure. Within 24 hours of admission, patients were assigned randomly to two groups, one to receive a course of single-antibiotic therapy with only beta-lactam antibiotics and the other to get concomitant antibiotic treatment, defined as the use of two antibiotics, including one beta-lactam antibiotic and one fluoroquinolone. When antibiotic therapy failed, the attending physician had the right to reevaluate the clinical status and to replace the antibiotic therapy in the study with a more appropriate treatment. Patient data is stored in electronic medical records.||||
34177138|NCT05682508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant: Patients in the control group||t|f|f|f
34177139|NCT06450067|||COHORT||PROSPECTIVE|||||||
34177140|NCT05202119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and investigators are unaware of what stimulation (active or sham) the device delivers.||t|t|t|f
33864177|NCT02365753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864178|NCT04640974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864179|NCT02761551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33864180|NCT04939519|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients will not know if they are in the TM or TM+PN intervention arm.|Patient-level, two-arm randomized design for the Population Health Management interventions, TM or TM+PN.|t|f|f|f
33864181|NCT04236895|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The trial will be a randomized, double-blind, multicenter, single-dose, 3-way crossover, 3-treatment, euglycemic glucose clamp trial in male subjects with type 1 diabetes mellitus|t|f|t|f
33864182|NCT04616196|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1: Dose escalation cohorts will be sequential Phase 2: Cohorts A and B will be in parallel||||
33864183|NCT02770443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864184|NCT02193542|||COHORT||PROSPECTIVE|||||||
33864185|NCT02172287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864186|NCT01905124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864187|NCT04699175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HR021618 compared with placebo|t|t|t|t
33864188|NCT01456689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864189|NCT01167751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864190|NCT03426826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864191|NCT05894265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864192|NCT00838214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864193|NCT00857532|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33864194|NCT00190710|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864195|NCT04357704|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33864196|NCT00335894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33864197|NCT02488499|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864198|NCT02342366|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33963134|NCT00624975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963135|NCT06527573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33963136|NCT06209424|RANDOMIZED|CROSSOVER||OTHER||NONE|"Participants will be randomized to either begin their participation with the at-home or in-person phase of the study. There is no need to conceal the randomization as this study is not blinded - this does not affect our outcome as we are looking at physiological changes with feeding."|"Randomized Counter-Balanced Crossover Design~Following familiarization, participants will be split into an in-person phase, consisting of a habitual rest and subsequent whole-body resistance exercise metabolic trials, and an at-home phase, which includes a habitual rest followed by a step-reduction metabolic trial. Participants will be randomized through a counterbalanced approach to either start with the in-person or at-home phases of our study as outlined below. Participants will be grouped by sex to ensure the same number of individuals from both males and females will undergo the in-person or at-home phases first"||||
33963137|NCT02239692|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33963138|NCT02277639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.||||
33963139|NCT06540508|||COHORT||PROSPECTIVE|||||||
33963140|NCT06540274|||COHORT||PROSPECTIVE|||||||
34177141|NCT05358236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|No intervention will be made by the responsible researcher. Thus, she will be blinded to the experimental and control groups. The training intervention and data collection process will be carried out by the co-researcher. It will also enter the data into the SPSS program as A and B groups. The analysis will be carried out by the researcher blinded to the groups. After the reporting process is completed, it will be announced to which groups A and B groups belong. Participants will also be blind to each other.|The research is an experimental study with parallel groups including randomized controlled, experimental, and control with educational intervention|f|f|t|t
33864199|NCT01122576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864200|NCT01526044|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864201|NCT02992886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864202|NCT03289910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864203|NCT00163462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864204|NCT04344691|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33864205|NCT00627029|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864206|NCT05125068|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33864207|NCT03763669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo administered|Patients will be randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) alone, or (n. 40) diet, folic acid (400 mcg per day) and myoinositol (2 g. twice a day + 50 mg alfa-lactalbumin) supplementation. The insulin sensitivity index (HOMA-IR) and fetal sonographic profile will be monitor for each patient at GDM diagnosis and after 4 and 8 weeks of treatment.|t|t|f|f
33864208|NCT00452049|||COHORT||PROSPECTIVE|||||||
33864209|NCT02877862|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864210|NCT05334004|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||modified 3+3 design with increasing concentrations of study drug and thorough assessment of potential toxicities.||||
33864211|NCT04120610|||COHORT||PROSPECTIVE|||||||
33864212|NCT05116150|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34177142|NCT06511258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patient-reported outcome assessors will be blinded and abstractors collecting routine data are unaware of allocation.~To support blinding, improve enrollment and reflect usual care, widely available physical activity (World Health Organization Recommendations for Physical Activity for ages 18-64 and \>65) and healthy eating recommendations (Canada's Food Guide Snapshot) documents will be provided to control participants (without active or online support)."||t|f|f|t
33864213|NCT03917485|||COHORT||PROSPECTIVE|||||||
33864214|NCT05217303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864215|NCT06267287|||COHORT||RETROSPECTIVE|||||||
33864216|NCT00302510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963141|NCT03186963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963142|NCT06567041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33963143|NCT03601468|||OTHER||CROSS_SECTIONAL|||||||
33963144|NCT05396443|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33963145|NCT01467570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963146|NCT03208283|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34177143|NCT06599203|||COHORT||PROSPECTIVE|||||||
33963147|NCT01846832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864217|NCT02180620|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33864218|NCT00576433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864219|NCT01954186|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33864220|NCT06200649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will not be clearly stated to the independent statistician which group the intervention and control group participants are in, the groups will be identified with letters as A-B and sent to the statistician for data analysis. The statistical analysis phase of the study will be blinded.||f|f|f|t
33963148|NCT01576627|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33963149|NCT04150926|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Products are visibly differing from each other.|Meal studies in randomised order|t|f|f|f
33963150|NCT01247974|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33963151|NCT05099783|||COHORT||RETROSPECTIVE|||||||
33963152|NCT05803538|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33963153|NCT03715673|||CASE_CONTROL||PROSPECTIVE|||||||
33963154|NCT04280393|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33963155|NCT06155669|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963156|NCT06334250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864221|NCT05001451|NA|SEQUENTIAL||TREATMENT||NONE||||||
33864222|NCT03289949|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33864223|NCT01549626|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33963157|NCT06476873|NA|SINGLE_GROUP||OTHER||NONE||cohort||||
33963158|NCT03138239|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963159|NCT00899288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963160|NCT02956005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963161|NCT04622865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963162|NCT00670267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963163|NCT02446665|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963164|NCT01398137|||COHORT||PROSPECTIVE|||||||
33963165|NCT05492019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigators will not know which arm patients have been assigned to or if they receive doxycycline or placebo.|The patients will be randomly allocated into two arms: control and intervention. Patients in intervention arm consisted of 30 patients who will receive levodopa plus doxycycline orally for 8 weeks. On the other hand, control arm consisted of 30 patients who will receive levodopa plus placebo for 8 weeks.|t|f|t|f
33963166|NCT05265169|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label multicenter trial||||
33963167|NCT01399125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963168|NCT02331069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963169|NCT02056405|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33963170|NCT06539806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963171|NCT06371261|||COHORT||PROSPECTIVE|||||||
33963172|NCT05801640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single (participant and outcomes assessor)|Parallel Assignment After explaining the study to eligible and accepting parents, informed consent signatures will be obtained. Randomization will be done after obtaining informed consent from the parent. Random assignment will be made to one control group or one intervention group (faciliated tucking position:1, reiki: 1) with sequentially numbered, sealed, opaque envelopes containing randomly generated numbers in randomization. These envelopes are for a person not involved in any other trial procedure. Will be made by Randomization will be performed using the random numbers table.|t|f|f|t
33963173|NCT02349009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963174|NCT00971685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963175|NCT05697146|||COHORT||PROSPECTIVE|||||||
33963176|NCT00109135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963177|NCT02947659|||COHORT||PROSPECTIVE|||||||
33963178|NCT03171610|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963179|NCT01425931|||COHORT||PROSPECTIVE|||||||
33963180|NCT03888716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751663|NCT05139108|||COHORT||PROSPECTIVE|||||||
33963181|NCT02580201|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33963182|NCT00922090|||CASE_ONLY||PROSPECTIVE|||||||
33963183|NCT00981864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963184|NCT03001011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963185|NCT01556854|||||PROSPECTIVE|||||||
34177144|NCT05638256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177145|NCT01752426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177146|NCT06496620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751664|NCT02495272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33751665|NCT05402280|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33751666|NCT05152680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751667|NCT05566041|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"In this study, patients will be randomized to 1 of 2 groups or arms. Patients in Arm 1 will receive the study drug, RRx-001, once a week for 3 weeks followed by up to 4 cycles of platinum doublet (platinum plus etoposide) chemotherapy. Patients with stable disease or better will go on to the Platinum Stacking Phase and will receive RRx-001 once a week for 2 weeks followed by 2 cycles of single agent platinum chemotherapy in a repeating pattern until such time as their cancer gets worse.. Patients in Arm 2 will receive the standard of care platinum doublet (platinum plus etoposide) chemotherapy for up to 4 cycles. . Patients in arm 2 whose cancer gets worse (as determined by imaging scans), may cross-over to the Platinum Stacking Phase of Arm 1 (see study schema below)."||||
33751668|NCT04606355|||CASE_ONLY||CROSS_SECTIONAL|||||||
33751669|NCT06440915|NA|SEQUENTIAL||TREATMENT||NONE||||||
33751670|NCT01920451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864224|NCT02633410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864225|NCT03100201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients will be recruited in three different clinics in Germany and randomised into an intervention and a control group. All patients will receive conventional occupational- and physiotherapy. The intervention group will receive an additive robotic-assisted training using the Armeo®Spring robot for three weeks.|f|f|f|t
33864226|NCT06692322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864227|NCT01764971|||CASE_ONLY||PROSPECTIVE|||||||
33864228|NCT01688180|||CASE_CONTROL||PROSPECTIVE|||||||
33864229|NCT05023863|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A prospective, randomized, controlled, single blinded study|t|t|f|t
33864230|NCT03719638|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33864231|NCT06074991|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33864232|NCT05715528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, personnel directly involved in the conduct of study, and sponsor will not know the treatment participants received.||t|f|t|f
33864233|NCT03208751|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm intervention with exercise training as secondary prevention strategy||||
33864234|NCT00188591|||COHORT||CROSS_SECTIONAL|||||||
33963186|NCT04821570|||CASE_ONLY||PROSPECTIVE|||||||
33963187|NCT02861352|NA|SINGLE_GROUP||OTHER||NONE||||||
33864235|NCT05506826|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants will be divided in two groups. Patients in group A will receive conventional therapy for four weeks sixty minutes per day, five days per week. In Group B patients will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy||||
33864236|NCT04069754|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive the intervention. There are no other groups.||||
33864237|NCT02905253|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33864238|NCT03585985|||CASE_CONTROL||PROSPECTIVE|||||||
33864239|NCT04100629|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|participants' unique numeric identifiers will be separated into two groups by the random generator with the exception of male participants. To enhance similarity among the control and experimental groups, male participants will be evenly distributed between groups (every other male, in sequential order of data collection, will be placed into each group) and not randomized (Polit \& Beck, 2017).|A prospective, RCT design with an experimental and control group is proposed for this study to determine if a digital support intervention impacts Newly Licensed Nurses' stress, resiliency, perceived sense of support, and Intention To Leave their current jobs.|t|f|f|f
33864240|NCT00294489|||DEFINED_POPULATION||PROSPECTIVE|||||||
33864241|NCT00659529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864242|NCT02004951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864243|NCT02558478|||FAMILY_BASED|||||||||
33864244|NCT00404066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864245|NCT06715917|||COHORT||PROSPECTIVE|||||||
33864246|NCT02888314|||COHORT||RETROSPECTIVE|||||||
33864247|NCT06735833|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a prospective, multi-center, feasibility study in which up to 50 subjects will be consented to achieve a total of 30 subjects treated with TRUFILL n-BCA bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine in up to 5 US centers.||||
33864248|NCT03560947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864249|NCT05729295|||COHORT||OTHER|||||||
33963188|NCT05011019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963189|NCT00631800|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33963190|NCT05555186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963191|NCT04408300|NA|SINGLE_GROUP||OTHER||NONE||||||
33963192|NCT02600273|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33963193|NCT06418087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963194|NCT01000857|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33963195|NCT03031405|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33963196|NCT05885529|||COHORT||PROSPECTIVE|||||||
33963197|NCT04970264|||CASE_ONLY||PROSPECTIVE|||||||
34065229|NCT01211132|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33751671|NCT05946811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065230|NCT01273662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065231|NCT01722032|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34065232|NCT05279118|RANDOMIZED|PARALLEL||TREATMENT||NONE||pilot randomized RCT||||
34065233|NCT06264037|||COHORT||PROSPECTIVE|||||||
34065234|NCT05891106|||COHORT||RETROSPECTIVE|||||||
33751672|NCT01187693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33751673|NCT02065336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177147|NCT05611151|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel trial design||||
34177148|NCT05917626|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"* Clinicians referring participants will be unaware of the study phase~* Outcomes will be assessed with an online survey"|This study will employ a stepped wedge cluster randomized design in which hospitals are randomized sequentially to initiate the intervention. Prior to initiating patient recruitment, each of the 6 hospitals will be randomized to one of two waves in the stepped wedge design. During the non-exposure periods, patients will receive usual care from the hospital.|f|t|t|t
33751674|NCT06332885|||OTHER||PROSPECTIVE|||||||
33751675|NCT05575076|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label extension||||
34177149|NCT06079697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177150|NCT02864394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177151|NCT03799107|||COHORT||OTHER|||||||
34177152|NCT01280903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177153|NCT05164289|||COHORT||PROSPECTIVE|||||||
34177154|NCT04503070|||CASE_ONLY||PROSPECTIVE|||||||
34177155|NCT06297525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be assigned to a dose level of STP938 (Phase 1a) or an expansion cohort (Phase 1b) at the time of their enrollment.||||
34177156|NCT05649969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177157|NCT04774289|||COHORT||RETROSPECTIVE|||||||
34177158|NCT02946580|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34177159|NCT00005975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34177160|NCT04746391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34177161|NCT06499363|||COHORT||OTHER|||||||
34177162|NCT03723655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Site, Care Provider and Patients are blinded to study dose. Sponsor is now unblinded to study dose.||t|t|t|f
34177163|NCT06588140|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33751676|NCT03821168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751677|NCT05964660|||CASE_ONLY||PROSPECTIVE|||||||
33864250|NCT05710926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An experienced first clinician will make the initial assessment without knowing the assignment to the two groups. Similarly, a second expert clinician will evaluate the participants at the end of th.e intervention without knowing the assignment to the two groups. The data will then be anonymized and a statistician will analyze them without knowing which group corresponds to which treatment|Participants are randomly assignedon a 1:1 ratio to one of two groups in parallel for the duration of the study. Each participant will access a talk therapy lasting 6 months (24 weekly sessions).|f|f|t|t
33864251|NCT06013657|||COHORT||OTHER|||||||
34177164|NCT02977663|NA|SINGLE_GROUP||OTHER||NONE||||||
34177165|NCT06599450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177166|NCT04227808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751678|NCT05452057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized (1:1)||||
33751679|NCT05483504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751680|NCT05027139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||single-arm, open-label, multi-cohort, multi-center study||||
33864252|NCT06736535|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33864253|NCT02682225|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33864254|NCT04323826|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33864255|NCT01621997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864256|NCT03516890|||COHORT||RETROSPECTIVE|||||||
33864257|NCT02287376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864258|NCT05221801|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The measurement would be done in 4 seat inclination angles (5, 15, 30, 45) and for 3 different food types for each subject.||||
33864259|NCT05227053|||COHORT||PROSPECTIVE|||||||
33864260|NCT01009723|||CASE_CONTROL||PROSPECTIVE|||||||
33751681|NCT00000179|RANDOMIZED|||TREATMENT||DOUBLE||||||
33751682|NCT00698646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751683|NCT00810264|||COHORT||PROSPECTIVE|||||||
33751684|NCT03306212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33751685|NCT02341430|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33751686|NCT06335888|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Cross-over, randomized, open label, single-centre||||
33864261|NCT02509104|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34177167|NCT04304768|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177168|NCT00072462|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34177169|NCT06423326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177170|NCT03804840|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34177171|NCT01803009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751687|NCT02645734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751688|NCT03387553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The trial will consist of two phases. The first lead in phase will enroll 12 participants evenly divided into two arms (alternating enrollment) with different initial priming vaccination schedules.~Following accrual of this initial group of 12 patients, HER2 ELISPOT post vaccination responses will be assessed to determine which of the two sequences provides the greater increase in anti HER2 response at week 4 over baseline. This will determine which sequence will be used in the second expansion phase of accrual. If both arms are determined equal then Arm A will be selected as the default sequence."||||
33751689|NCT03733262|||COHORT||PROSPECTIVE|||||||
33751690|NCT06200558|||OTHER||RETROSPECTIVE|||||||
34177172|NCT05713630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Research Assistant Research Coordinator|Vanguard trial|t|t|t|f
34177173|NCT04905134|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33751691|NCT00344461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177174|NCT06596928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177175|NCT04441905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177176|NCT05745909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177177|NCT06593145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177178|NCT03558711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||intravenous \[18F\]-PSMA-11||||
34177179|NCT05777187|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177180|NCT06330805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177181|NCT06234228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177182|NCT06401486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34177183|NCT03910634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177184|NCT04125589|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34177185|NCT04685863|||COHORT||PROSPECTIVE|||||||
34177186|NCT04895644|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Control Trial||||
34177187|NCT04895033|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study uses a within-subjects design with all participants completing the no-responsibility and responsibility conditions.||||
34177188|NCT04782713|NA|SINGLE_GROUP||SCREENING||NONE||This is a single-arm intervention with historical control trial where the direct recipients of the intervention are PCPs. There are three components to the project with corresponding data collection activities - I) PCP Evaluation of the Smart PSA Screening Guidelines||||
34177189|NCT04308122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177190|NCT03774732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177191|NCT03882021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects enrolled will undergo the same mapping and ablation protocol.||||
33751692|NCT06109987|||CASE_CONTROL||PROSPECTIVE|||||||
33751693|NCT00538135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751694|NCT04062266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751695|NCT03577366|||OTHER||RETROSPECTIVE|||||||
33751696|NCT05502432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751697|NCT03054792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751698|NCT01692340|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33751699|NCT03692533|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2 groups : Group A include cases and Group B includes controls||||
34065235|NCT03859180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assistant performing data checks will mask the random assignments; written on index cards and sealed in security envelope. Opened following informed consent signature obtained and time one outcome measures completed.|Mixed methods, 6 week randomized clinical trial. Using a block size of 4, a computer generated randomization schedule will be generated for an intervention arm and a waitlist arm.|f|f|f|t
34177192|NCT02423213|||OTHER||PROSPECTIVE|||||||
34177193|NCT06603701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177194|NCT05758168|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Two blinded observers will record their scores independently using the POSAS instrument.||f|f|f|t
34177195|NCT06435351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177196|NCT06587321|||OTHER||PROSPECTIVE|||||||
34177197|NCT02137746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177198|NCT04156087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177199|NCT00641433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177200|NCT05537103|||OTHER||CROSS_SECTIONAL|||||||
34177201|NCT06591533|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177202|NCT04036682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177203|NCT03755934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|f|t|t
33751700|NCT03532074|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|OPEN|||||
34177204|NCT05226624|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"This is a Stepped Wedge-Cluster Randomized Controlled Trial (SW-cRCT) of 8 hospitals with NICUs and post-partum/pediatric units. The SW-cRCT is ideally suited to interventions that require implementation by multiple team members in which there is an impact on workflow and the structure of care delivery. There is sequential roll-out of the intervention to all hospitals over time. Baseline or historical data acts as the pre-intervention comparison or control.~Hospitals will implement the intervention following a computer-generated stratified random allocation sequence created by the independent study statistician."||||
34177205|NCT06588192|||COHORT||RETROSPECTIVE|||||||
34177206|NCT05799287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177207|NCT01652235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177208|NCT04699591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177209|NCT06008730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177210|NCT06054126|||COHORT||RETROSPECTIVE|||||||
34177211|NCT06602440|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34177212|NCT06586424|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065236|NCT00253370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177213|NCT00563056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177214|NCT02484391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177215|NCT00823316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177216|NCT06587737|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind|Double-blind, randomized, placebo-controlled, phase III study|t|t|t|t
34177217|NCT05062785|NA|SEQUENTIAL||TREATMENT||NONE||For every 6 participants, iterations of a Bayesian model will be performed to associate the administered dose with the frequency of dose-limiting hypoglycemia or other adverse events. The model will adaptively reallocate the dose increments for the next 6 participants. To provide more precise and reproducible estimates of dose-limiting toxicity, the trial will modify the size of dose increments based on the developing model to allocate more administrations to areas of the model with greatest uncertainty, or to higher doses in the absence of dose-limiting hypoglycemia.||||
34177218|NCT05916183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177219|NCT06587581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34177220|NCT00817297|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subject was blinded to device identity||t|f|f|f
34177221|NCT05552287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177222|NCT06269133|||COHORT||OTHER|||||||
34177223|NCT04328714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study uses a rolling 6 dose escalation design with two independently accruing expansion cohorts: adults and pediatrics. Accrual in the pediatric tier will commence after the maximum dose tolerated has been determined in adults.||||
34177224|NCT05804591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177225|NCT06587698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177226|NCT03939624|||COHORT||RETROSPECTIVE|||||||
34177227|NCT05498610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177228|NCT06604273|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Half of the study participants will undergo PET CT imaging. Therefore, the interventional study model only applies to half of the study partcipants.||||
34177229|NCT02439853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177230|NCT05458908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Blinded assessment of outcome events through an independent Core-Lab|Cross-sectional non-inferiority investigation with prospective open label data collection and blinded endpoint assessment||||
34177231|NCT05195398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized to 15- 30 minute sessions of A-tDCS + CCT versus sham-intervention + CCT over a 5 week period|t|t|f|t
34177232|NCT06585046|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34177233|NCT06588010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34177234|NCT06587048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177235|NCT05118022|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34177236|NCT01404741|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34177237|NCT06603441|||COHORT||PROSPECTIVE|||||||
34177238|NCT00530478|RANDOMIZED|PARALLEL||||NONE||||||
34177239|NCT05225038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177240|NCT06281730|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177241|NCT06480747|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34177242|NCT05048459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study design is a 1:1 randomized clinical trial.||||
34177243|NCT04097470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751701|NCT06732739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065237|NCT00524706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065238|NCT05262166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34177244|NCT06599177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants will complete a questionnaire for this study and subsequently will get interviewed. Then, half of them will be randomly assigned to intervention group and control group, the intervention group participants will receive an informational leaflet that will provide information regarding psychosocial support. After, six (6) months all participants will be contacted by the P.I. to re-complete each questionnaire and repeat the interview.|t|f|f|f
34177245|NCT01870206|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34177246|NCT02800668|||CASE_ONLY||RETROSPECTIVE|||||||
34177247|NCT04252911|||COHORT||PROSPECTIVE|||||||
34177248|NCT06590935|||COHORT||PROSPECTIVE|||||||
34177249|NCT00412984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34177250|NCT06313736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be aware that they will be assigned to an intervention designed to help them with depressive symptoms. They will know that the study compares multiple interventions but will not know to which arm they have been assigned. Additionally, the measures will be self-administered, so there is no scope for evaluator bias. There will be no interaction between participants and investigators.|Participants will be assigned to one of four different conditions.|t|f|t|f
34177251|NCT05856734|||COHORT||OTHER|||||||
34177252|NCT06405932|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34065239|NCT03126253|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34177253|NCT01861314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177254|NCT05170126|||COHORT||PROSPECTIVE|||||||
34177255|NCT06184061|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34177256|NCT06593964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177257|NCT03223766|||COHORT||PROSPECTIVE|||||||
34177258|NCT01460212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177259|NCT02486718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177260|NCT03844347|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177261|NCT05760365|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34177262|NCT04853186|||OTHER||PROSPECTIVE|||||||
34177263|NCT00580619|NON_RANDOMIZED|PARALLEL||||NONE||||||
34065240|NCT03184129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177264|NCT05449418|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34177265|NCT03842358|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34177266|NCT04019379|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34177267|NCT06600061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34177268|NCT06056596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177269|NCT05889104|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34177270|NCT02275702|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34177271|NCT03365414|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Phase I (albumin or normal saline): 4 weeks -\> washout/crossover: 4 weeks -\>Phase II(albumin or normal saline, whichever wasn't administered in phase I): 4 weeks|t|f|f|f
34177272|NCT06070779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||randomised controlled trial|t|t|t|t
34177273|NCT05857995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The principal investigators and outcomes assessors will be masked to the random assignment of participants.|Two-group randomized clinical trial|f|f|t|t
34177274|NCT06600958|||COHORT||RETROSPECTIVE|||||||
34177275|NCT00370734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177276|NCT04557410|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177277|NCT00000211||||TREATMENT||||||||
34177278|NCT03548532|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Based on the randomisation list, patients fulfilling the inclusion criteria will be assigned to one of each arm. A total of 119 patients are needed in every arm in this superiority trial.||||
34177279|NCT01968746|||COHORT||PROSPECTIVE|||||||
34177280|NCT05535257|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177281|NCT06599528|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34177282|NCT06564181|||OTHER||CROSS_SECTIONAL|||||||
34177283|NCT06247124|NA|SINGLE_GROUP||PREVENTION||NONE||high school students are enrolled as research participants to develop a multi-channel campaign to promote HPV vaccination||||
34177284|NCT04246788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177285|NCT03809728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177286|NCT01210313|||CASE_ONLY||PROSPECTIVE|||||||
34177287|NCT01729780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34177288|NCT03735537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Images of incident fractures and vertebral fractures will be assessed by an independent clinical adjudicator blinded to treatment allocation.|Multicentre, parallel arm, open-label, phase IV randomised controlled trial|f|f|f|t
34177289|NCT06508385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
34177290|NCT06250205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, multiple-dose, fixed sequence, drug-drug interaction study.||||
34177291|NCT04759274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177292|NCT04921241|||COHORT||CROSS_SECTIONAL|||||||
34177293|NCT06485479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177294|NCT06527560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, care providers and investigators will not be aware of the treatment arm. Statistical analysis will be performed using pre-established criteria to access coded treatment|Randomized, parallel, non-inferiority trial|t|t|t|f
34177295|NCT00270985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177296|NCT00001711|||OTHER||PROSPECTIVE|||||||
33751702|NCT02744534|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34177297|NCT03020303|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34177298|NCT05407389|NA|SINGLE_GROUP||TREATMENT||NONE||This is an extension open-label multicenter study to evaluate the long-term safety and efficacy of KT-301 (formerly US-APR2020) in patients with CKD Stage IV. KT-301 will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).||||
33840614|NCT06479369|RANDOMIZED|PARALLEL||OTHER||NONE||The motivational process of teachers influences the way they teach PE lessons, which in turn will influence the motivational process of students.||||
33840615|NCT00000877||PARALLEL||TREATMENT||||||||
33840616|NCT02348944|||COHORT|||||||||
33840617|NCT05045274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33840618|NCT06265714|||COHORT||PROSPECTIVE|||||||
33840619|NCT03771794|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Active Comparator: ReguRate RR2 active. Device: ReguRate neurostimulation system~Sham Comparator: ReguRate RR2 placebo. Device: Sham ReguRate electrical stimulation - mock sham stimulation mode"|t|f|t|f
33840620|NCT05719753|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840621|NCT01448577|||COHORT|||||||||
33840622|NCT02090010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33840623|NCT05624151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840624|NCT01221636|RANDOMIZED|PARALLEL||||NONE||||||
33840625|NCT01735903|||COHORT||PROSPECTIVE|||||||
33840626|NCT02712268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840627|NCT00874731|NA|SINGLE_GROUP||TREATMENT||SINGLE|Participants will be blinded to treatment during Part 1 only.||t|f|f|f
33840628|NCT01876277|||COHORT||CROSS_SECTIONAL|||||||
33840629|NCT02881372|NA|SINGLE_GROUP||OTHER||NONE||||||
33840630|NCT02056353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840631|NCT02280876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840632|NCT01580540|||CASE_CONTROL|||||||||
33840633|NCT01357122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840634|NCT00472784|||COHORT||PROSPECTIVE|||||||
33864262|NCT05411549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data is de-identified upon collection, Lab teams will not be aware of arm allocation, nor will the participants be aware of the opposite group of which they are enrolled. However, due to the nature of this study, masking of the clinical team and participant is not feasible in order for diet changes to occur safely.|2 Arm Interventional Diet Modification Study Arm 1: Mediterranean Diet Counselling (Intervention) Arm 2: Continue Normal Diet (Control)|t|f|f|t
33864263|NCT03930147|RANDOMIZED|CROSSOVER||OTHER||NONE||"Two different phases of ventilation (passive versus active) will be monitored in each patient.~In each phase, two different modes of ventilation will be performed in a randomized order and will be monitored (Pressure-Control Ventilation and ASV during the passive ventilation phase, Pressure-Support Ventilation and ASV during the active ventilation phase). Washout periods will be performed between the different modes of ventilation."||||
33963198|NCT03845322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blinded, randomized placebo-controlled pilot study. The patients, neurosurgeons, nurses and clinical coordinators will be blinded except for the research pharmacists who will keep a key linking a code # on a bottle handed to the clinical coordinator and the patient's medical record number (MRN #). The pill bottles handed to the clinical coordinator will be identical for placebo and CC.|This is an experimental study, each consented subject will be instructed that he/she will be randomized to either the placebo group or the curcumin group.|t|t|t|t
33963199|NCT00201734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963200|NCT00509340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963201|NCT05517954|||COHORT||RETROSPECTIVE|||||||
33963202|NCT04385082|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.|t|f|t|f
33963203|NCT01298154|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34177299|NCT02338674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177300|NCT05720143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding Participant and Statistician||t|f|f|f
34177301|NCT03173560|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study was initially double-blind.|||||
34177302|NCT04615949|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind|Double-blind, placebo-controlled, parallel study, randomization 1:1|t|t|t|t
34177303|NCT00543036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177304|NCT06474676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177305|NCT03593525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177306|NCT06159790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177307|NCT06118866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177308|NCT02548546|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34177309|NCT06590844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177310|NCT05338528|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A quasi-experimental unblinded interrupted time-series (ITS) design in three phases: pre-intervention; during intervention; post-intervention. A before-and-after analysis methodology for complications, functional performance, and patient satisfaction.||||
34177311|NCT01700413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177312|NCT04576156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177313|NCT06592235|||CASE_ONLY||CROSS_SECTIONAL|||||||
34177314|NCT03076697|||COHORT||PROSPECTIVE|||||||
34177315|NCT03016533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177316|NCT06601556|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34177317|NCT06562205|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||his is an open label, prospective, randomized cross over (or single arm) study designed to support the development of new accessories for PAP devices.|t|f|f|f
34177318|NCT01417533|||COHORT||PROSPECTIVE|||||||
34177319|NCT05512897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The block will be preformed under anesthesia. The patients will not know what intervention group they are allocated|Patients will be randomized to 2 groups - standard care vs standard care+ESP block|t|f|f|f
34177320|NCT05514548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177321|NCT00459459|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34177322|NCT05379803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177323|NCT05543265|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34177324|NCT04515615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177325|NCT05079334|NA|SINGLE_GROUP||SCREENING||NONE||Participants with MeTree recommendations and clinic visits with Genetic Counselors are compared to visits without MeTree recommendations to determine if MeTree improves quality and time of visit.||||
34177326|NCT05322343|||COHORT||PROSPECTIVE|||||||
34177327|NCT05882591|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34177328|NCT03768128|||OTHER||PROSPECTIVE|||||||
34177329|NCT04786743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will be blinded to the randomization allocation and will not participate in the practical treatment and intervention; in particular, two scientific researchers specializing in gastroenterology with more than three years of clinical rotation experience will serve as the outcome assessors. Professional academic statisticians blinded to the group allocation will conduct all the analyses. However, the endoscopists will not participate in the outcome assessment. Furthermore, they will not need to disclose details of their interventional procedures to the outcome assessors.|"Eligible patients are randomly assigned in a 1:1 ratio to receive endoscopic intervention either within 6h or 6-24h. Randomization is conducted by permuted block randomization stratified by age, systolic blood pressure (SBP), and pulse rate. The block size is pre-specified, but physicians and investigators are not notified of this during the study. Allocation concealment is implemented by the mobile client randomization tool Randomization Allocation Tool (RAT)."|f|f|f|t
34177330|NCT04074044|NA|SINGLE_GROUP||PREVENTION||NONE||Single group, open label evaluation||||
34177331|NCT05058365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34177332|NCT04640545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864264|NCT04611438|NA|SINGLE_GROUP||TREATMENT||NONE||Patients would be from 2 to 18 years old diagnosed with Dravet syndrome or Lennox-Gastaut syndrome, who are intractable to more than 2 antiepileptic medications. Caregivers would purchase cannabidiol and give it to the patient according to titration schedule. Patients would go through laboratory, neuropsychologic, and electroencephalographic tests before, during and after the intervention.||||
33864265|NCT02806154|||COHORT||PROSPECTIVE|||||||
33864266|NCT04276766|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33864267|NCT04173715|||OTHER||CROSS_SECTIONAL|||||||
33864268|NCT04319302|||COHORT||RETROSPECTIVE|||||||
33864269|NCT02846636|||CASE_ONLY||PROSPECTIVE|||||||
33864270|NCT02241291|||OTHER||PROSPECTIVE|||||||
33963204|NCT01528631|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33963205|NCT01858558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963206|NCT02670200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33963207|NCT06154915|||COHORT||PROSPECTIVE|||||||
34177333|NCT06594484|||COHORT||RETROSPECTIVE|||||||
34177334|NCT05759728|NA|SEQUENTIAL||TREATMENT||NONE||||||
33963208|NCT05862519|NA|SINGLE_GROUP||OTHER||NONE||||||
34177335|NCT06508580|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Micro-randomized 2x2x2x2 factorial model; participants randomized to receive or not receive one of 4 feedback conditions each week for 16 weeks|f|f|f|t
33864271|NCT06027567|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled clinical treatment trial Patients are randomly assigned 1:1 to standard-of-care or intervention||||
33963209|NCT04834999|||COHORT||PROSPECTIVE|||||||
33963210|NCT01339858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963211|NCT01178112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963212|NCT06538103|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34177336|NCT05519241|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I, single-group, dose-escalation trial||||
34177337|NCT06588335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177338|NCT01519908|||CASE_ONLY||PROSPECTIVE|||||||
34177339|NCT05300503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned in a 1:1 fashion to either the control group or intervention group.||||
34177340|NCT03043794|NA|SINGLE_GROUP||TREATMENT||NONE||SBRT to the breast follow by standard of care surgery||||
34177341|NCT05194969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Following the surgical procedure, the principal investigator (PI) will exit the exam room. The PI will not be present for bandaging administration and training and thus be blinded to the wound dressing technique. The patient will not be blinded as bandaging will be administered at home.|This study will be a randomized, blinded trial of two postoperative bandaging techniques: wet-to-dry dressings vs. petrolatum with non-stick bandaging.|f|t|t|t
34177342|NCT03891134|NA|SINGLE_GROUP||TREATMENT||NONE||quasi-experimental design||||
34177343|NCT04150614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized 1:1 to either Arm 1 transdermal granisetron OR Arm 2 intravenous ondansetron||||
34177344|NCT06088823|||COHORT||RETROSPECTIVE|||||||
34177345|NCT06598358|||OTHER||OTHER|||||||
34177346|NCT06339099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinding. Parents were also blinded.|Children were randomly assigned into two equal groups.|t|f|f|t
34177347|NCT04673643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Transcutaneous Auricular Vagus Nerve Stimulation|t|t|f|t
34177348|NCT03494660|||COHORT||OTHER|||||||
34177349|NCT05922137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34177350|NCT04522765|||COHORT||PROSPECTIVE|||||||
34177351|NCT06595979|||COHORT||PROSPECTIVE|||||||
34177352|NCT06600438|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34177353|NCT03848325|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Technicians processing biospecimens will be blinded to whether samples were collected on Day 1 or Day 2. Similarly, the assessor of brachial artery reactivity measurements will be blinded to whether ultrasound images were collected on Day 1 or Day 2.|All participants will undergo one night of normal sleep (Night 1) followed by a subsequent night (Night 2) of sleep deprivation. Outcomes will be assessed the morning (Day 1 and Day 2) after each condition.||||
34177354|NCT05750264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177355|NCT06599866|||CASE_ONLY||PROSPECTIVE|||||||
34177356|NCT00734149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177357|NCT04179175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients considered HiSCR responders will be randomized 2:1 to continue their current regimen or undergo withdrawal to placebo. HiScr non-responders will enter open label therapy with Secukinumab if desired|Multicenter, double-blind, randomized withdrawal extension, parallel group study followed by an open-label, active-treatment period with two Secukinumab dose regimens in approximately 856 patients with moderate to severe hidradenitis suppurativa (HS)|t|t|t|f
33963213|NCT02119182|||COHORT||PROSPECTIVE|||||||
33963214|NCT05012735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963215|NCT04829279|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34065241|NCT00692497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34177358|NCT06007872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864272|NCT03915808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a parallel randomized, double-blinded, placebo-controlled trial. Sixty-six overweight or obese men and women aged from 18 to 50 years with elevated body fat percentage, who also meet our inclusion and exclusion criteria, will be randomly assigned to: the treatment group, daily supplementation of 3.2 g CLA (Cis-9, trans-11 isomers and trans-10, cis-12 isomers) plus lifestyle counselling weight loss program; or the control group, daily supplementation of sunflower oil. The intervention will include a 3-day run-in phase and 12-week interventional phase. At baseline and the end of the intervention, physical examination including questionnaires, anthropometric measurement, body composition by Dual Energy X-ray Absorptiometry (DXA), biological sample collection will be undertaken. During the invention, regular lifestyle counselling sessions will be delivered, and detailed record will be tracked for all participants to monitor and improve the adherence and safety.|t|f|t|f
33864273|NCT06736496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177359|NCT04742491|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Intermediate Intervention Arm vs Deferred Intervention Arm||||
33864274|NCT02198612|NA|SINGLE_GROUP||||NONE||||||
33864275|NCT06235840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A pretest-posttest study design with one experimental group and two control (passive and active control) groups was applied.||||
33864276|NCT04608513|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Single-center, double-blind, randomized, placebo-controlled, single- and multiple-ascending dose|t|t|t|t
33864277|NCT06162000|RANDOMIZED|PARALLEL||OTHER||SINGLE|During the statistical analysis phase, codes as a and b will be given to the control and intervention groups and thus statistical bias will be controlled.|Posttest with control group|f|f|f|t
33864278|NCT04356911|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33864279|NCT03348865|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33963216|NCT01252836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963217|NCT02615873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963218|NCT06428006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963219|NCT01335399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963220|NCT01213719|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34177360|NCT06598579|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because a cluster-randomization design is being used, with random assignment at the pagoda-level to avoid cross-group contamination, masking is not possible.|||||
34177361|NCT05919875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177362|NCT06598163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34177363|NCT02194387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177364|NCT06600464|||OTHER||CROSS_SECTIONAL|||||||
34177365|NCT04094285|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34177366|NCT06279351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177367|NCT06698653|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Group 1 (phase A = experimental (7 days), then phase B= control (7 days)) Group 2 (phase B = control (7 days), then phase A = experimental (7 days))||||
34177368|NCT06477536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177369|NCT05583552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177370|NCT03270982|||COHORT||OTHER|||||||
34177371|NCT00355108|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34177372|NCT02388308|||COHORT||PROSPECTIVE|||||||
34177373|NCT02798666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177374|NCT01263769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177375|NCT06463795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177376|NCT05120245|||COHORT||RETROSPECTIVE|||||||
34177377|NCT06403514|NA|SINGLE_GROUP||OTHER||NONE||The design is a single-case approach with the application of range-bound changing criterion design.||||
34177378|NCT06261021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single-blinded. Only the efficacy assessor will be blinded in this study (for subjects with randomized areas). The assessor will only assess efficacy and will not have any other interactions with the subject.|Intra-individual|f|f|f|t
34177379|NCT06593340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177380|NCT06592716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177381|NCT04196777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The behavioral intervention will be delivered at 3 intervention hospitals.||||
34177382|NCT00034177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177383|NCT05225090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177384|NCT05743400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177385|NCT06586879|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34177386|NCT04375150|||CASE_CONTROL||RETROSPECTIVE|||||||
34177387|NCT00671294|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34177388|NCT06478550|||COHORT||PROSPECTIVE|||||||
34177389|NCT04513951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177390|NCT01504815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177391|NCT05628363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963221|NCT00524394|||COHORT||PROSPECTIVE|||||||
33963222|NCT06568198|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33963223|NCT01602198|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33963224|NCT01784419|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
33963225|NCT01463566|||CASE_ONLY||PROSPECTIVE|||||||
34177392|NCT04837443|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34177393|NCT06006299|NA|SINGLE_GROUP||TREATMENT||NONE||All of the participants who are eligible will be in the taVNS group.||||
34177394|NCT02678182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177395|NCT03793244|||CASE_ONLY||PROSPECTIVE|||||||
34177396|NCT03153592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients will not know the arm of assignment. Care providers and investigators will know the arm, making the masking not possible.||t|f|f|f
33751703|NCT02446405|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stratification factors:~1. High volume disease (yes versus no), characterised as:~   * 4 or more bone metastases, one of which is outside the vertebral column and pelvis AND/OR~  * Visceral metastases (e.g. lung, pleura, liver, adrenal and others) Lymph node involvement or bladder invasion do NOT qualify as visceral disease.~2. Study site~3. Concomitant anti-resorptive therapy to delay skeletal related events when commencing ADT~4. Co-morbidities according to the Adult Co-morbidity Evaluation (ACE-27: 0-1 vs 2-3)~5. Early use of docetaxel defined as use of docetaxel in conjunction with initiation of ADT."||||
33751704|NCT00554970|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34177397|NCT04979546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The participants will know if they have been randomized to the intensive arm or the control arm, by whether they are completing PROMs every 6 months versus 1 year. The treating neurologists will know which arm their patients are enrolled into by whether they receive all PROM measurements every 6 months on their patients versus solely a text response of the top 3 things their patient would like their neurologist to know at that time.~Data analysis will be anonymized and aggregated for the research team in analysis."|"Intervention group: All participants randomized to the intervention group will be asked to complete PROM questionnaires at baseline, 6 months and 12 months (12 month study duration). Their treating neurologist will view the participant scores in addition to the text response to the 3-item prompt.~Control group: those in the control group will complete the same questionnaires at baseline and at 12 months. Additionally, the treating neurologist will only be prompted to view the text response to the 3-item prompt, and will not be able to access the PROM questionnaire scores for participants in the control group."|f|f|f|t
33751705|NCT04720079|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177398|NCT06586008|||CASE_ONLY||CROSS_SECTIONAL|||||||
34177399|NCT05662462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment of the primary outcome of glycemic control (Hemoglobin A1c \<6.5%) will assessed blinded to study arm.||f|f|f|t
34177400|NCT06594120|||CASE_ONLY||PROSPECTIVE|||||||
34177401|NCT04151212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177402|NCT05901298|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Simple random sample selection will be made using the 'www.randomizer.org' program, and the pregnant women who accepted to participate in the study will be divided into intervention and control groups. To ensure randomization; Age, education level and number of births will be matched. The research will be designed in two groups as the mobile nursing practice group (intervention) and standard care group (control). In the study The sample size was calculated at the 95% confidence level by using the G. Power-3.1.9.2 program. As a result of the analysis, with considering the data loss, 10 people will be added to the groups and 44 people will be reached for the intervention group and 44 for the control group."|The research will be designed in two groups as the mobile nursing practice group (intervention) developed based on Dennis's Breastfeeding Self-Efficacy Theory and Pender's Health Promotion Model and standard care group (control).|f|f|f|t
34177403|NCT06603467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177404|NCT06585800|||COHORT||OTHER|||||||
34177405|NCT03733626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the randomization group and which bone graft is used during surgery|Subjects will be randomized to either: 1) treatment arm where the investigator will use an FDA approved/cleared DePuy Synthes spinal pedicle screw system with ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft or the 2) control arm where the investigator use the same DePuy Synthes spinal pedicle screw system with local autologous bone graft mixed with cortical/cancellous allograft. Randomization is 1:1|t|f|f|f
34177406|NCT06036745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177407|NCT06512129|||COHORT||PROSPECTIVE|||||||
33751706|NCT01567384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751707|NCT04797754|||COHORT||PROSPECTIVE|||||||
33751708|NCT04324944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant who completes the assessments will be blind to condition, and will not attend any clinical team meetings or otherwise participate in any non-study related PRRC activities to maintain blindness. No study participants will be blinded. No other staff will be blinded.|The experimental design for this study is a 2-group randomized effectiveness trial, with assessments at baseline (month 0), post-intervention (month 2), and 3-month post-intervention follow-up (month 5). Veterans will be randomly assigned to either the CDST condition or to AC after completing baseline assessments. To maximize power for between-group comparisons, randomization will be 1:1 resulting in 36 participants per group. Participants will be randomly assigned by cohort, so that for each cohort, there are 12 participants each in CDST and AC. Stratification may be introduced if necessary due to uneven or statistically different groups in key demographic domains (e.g., age, gender). Quantitative analyses will compare improvements in primary, secondary, and exploratory outcomes between the two groups, as described elsewhere. There are also qualitative outcomes associated with this study.|f|f|f|t
33864280|NCT01889303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177408|NCT01999608|||||PROSPECTIVE|||||||
34177409|NCT05734391|||COHORT||PROSPECTIVE|||||||
34177410|NCT04526730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177411|NCT06590012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A randomized, double-blinded, placebo-controlled trial|A randomized controlled trial with two parallel groups of participants|t|t|t|f
34177412|NCT03649880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177413|NCT06343571|||COHORT||RETROSPECTIVE|||||||
34177414|NCT05468099|NA|SINGLE_GROUP||PREVENTION||NONE|Each participant and operator know the model which was assigned to them. The research assistant conducting the analysis is not able to identify the samples until analysis time.|||||
34177415|NCT04251715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864281|NCT00351416|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This is a physiologic study designed to investigate the relative roles of estradiol and inhibin A or inhibin B in the control of FSH secretion during normal menstrual cycles using an aromatase inhibitor. Subjects serve as their own control with no intervention in cycle 1 and letrozole administration in cycle 2. Subjects are studied in the early follicular phase or the late follicular phase.||||
33864282|NCT03984903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864283|NCT05643612|||OTHER||RETROSPECTIVE|||||||
33864284|NCT02566577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33864285|NCT01871636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33864286|NCT02778347|||CASE_ONLY||PROSPECTIVE|||||||
33864287|NCT01235793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864288|NCT06154655|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessment will be carried at four months post baseline by 2 outcome assessors blind to study arm.|A pilot trial will be conducted with 60 perinatal adolescents (30 in the E-zineMH arm and 30 in the control arm). Participants will be assigned to each arms at the beginning of the trial and continue in that arm throughout the trial. Two clinics, with wide geographic seperation will be used in the study. One of the clinics will serve as the intervention clinic and the other will serve as control.|f|f|f|t
33864289|NCT02378220|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33864290|NCT00226265|||CASE_ONLY||PROSPECTIVE|||||||
33864291|NCT05639413|NA|SINGLE_GROUP||PREVENTION||NONE||"The COBRAF study was designed as a prospective, multicenter, study. The study is without a therapeutic intervention and is of minimal risk and constraints (category 2 according to the Loi Jardé). The study will be conducted in patients with mCRC harboring a BRAFV600E mutation."||||
33864292|NCT05431101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864293|NCT00388505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864294|NCT02605681|||COHORT||PROSPECTIVE|||||||
33864295|NCT06387849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864296|NCT05245019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Males \& Females Patients ≥ 18 years Individuals not undergoing topical fluoride therapy, other chemotherapeutic procedures, antibiotics, and drugs having an effect upon the salivary function or salivary pH Individuals not suffering from any systemic diseases/ taking any medication that affects salivary secretion|f|f|t|f
33963226|NCT03012620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963227|NCT00039507||||TREATMENT||||||||
33963228|NCT03886428|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34177416|NCT04057144|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a three group randomized controlled trial with 162 patient in each group, six different measurement points, of which pre-treatment and 52 weeks after start of the treatment are the crucial points.||||
34177417|NCT04434768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177418|NCT04910048|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the interventions, masking or blinded participation is not possible.|Two group randomized control trial comparing the intervention (POPOP) and standard of care (SOC).||||
34177419|NCT06498583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177420|NCT06602700|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34177421|NCT03679923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||treatment versus placebo|t|t|t|t
34177422|NCT04892823|||COHORT||PROSPECTIVE|||||||
34177423|NCT00520949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177424|NCT06598345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34177425|NCT06598098|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Pregnant women will be randomized to one of four groups: aerobic exercise, resistance exercise, combination (aerobic + resistance), or control (no exercise). All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, rating of perceived exertion (RPE), 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.|f|t|t|t
34177426|NCT06594302|||COHORT||PROSPECTIVE|||||||
34177427|NCT06598956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177428|NCT00626106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864297|NCT03512691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study is a randomized parallel experiment with two treatment groups and one control group. Randomized assignment of treatment will be done at the level of the barangay, which is the smallest administrative unit in the Philippines roughly equivalent to an electoral ward. The 847 barangays in the Nueva Ecija province will be stratified by urban/rural classification.|t|f|f|f
33864298|NCT03025763|||OTHER||OTHER|||||||
33864299|NCT02823249|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33864300|NCT02354781|NA|SINGLE_GROUP||OTHER||NONE||||||
33864301|NCT05075395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864302|NCT04042740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864303|NCT02237404|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33864304|NCT01708291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33864305|NCT00448435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864306|NCT01817283|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34177429|NCT04586530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177430|NCT06527469|||COHORT||PROSPECTIVE|||||||
34177431|NCT04029233|||COHORT||PROSPECTIVE|||||||
34177432|NCT06091163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177433|NCT03792633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177434|NCT04347798|||CASE_CONTROL||PROSPECTIVE|||||||
34177435|NCT03025282|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34177436|NCT06594549|||COHORT||PROSPECTIVE|||||||
34177437|NCT02325102|||COHORT||CROSS_SECTIONAL|||||||
34177438|NCT03657628|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177439|NCT02740946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177440|NCT04243525|||OTHER||OTHER|||||||
34177441|NCT03502928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177442|NCT06220643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34177443|NCT04758351|||CASE_ONLY||PROSPECTIVE|||||||
34177444|NCT06503263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864307|NCT03661944|||COHORT||PROSPECTIVE|||||||
33864308|NCT01717287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963229|NCT01337609|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33963230|NCT04250519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963231|NCT04282044|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963232|NCT05096026|RANDOMIZED|PARALLEL||PREVENTION||NONE|Telephone interviewers were blind to study group assignment.|||||
33963233|NCT01831531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963234|NCT02345317|||COHORT||PROSPECTIVE|||||||
33864309|NCT04634396|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single arm proof of concept study||||
33864310|NCT05104021|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864311|NCT00478101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864312|NCT04633174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864313|NCT00251381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864314|NCT01951781|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33864315|NCT02500667|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864316|NCT03305939|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864317|NCT01292447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33864318|NCT01052896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864319|NCT05934162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded assessors are used Participants know that are given a CBT treatment for PTSD|Randomized controlled trial|t|f|f|t
33864320|NCT00356616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864321|NCT04119141|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33864322|NCT03794583|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is not blinded. All participants will begin titration of study drug once all entry criteria have been met.||||
33864323|NCT01528813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864324|NCT06734052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864325|NCT06292000|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33963235|NCT03528798|||COHORT||RETROSPECTIVE|||||||
33963236|NCT00467337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34177445|NCT06595576|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||The study will be a within-subjects, double-blind, placebo-controlled, randomized and counterbalanced human laboratory experiment assessing the effects of a range of doses of cannabis edibles on driving simulator performance. These 4 drug exposure conditions are: placebo, low dose (2 + 2% mg THC), medium dose (10 + 2% mg THC), and high dose (20 + 2% mg THC).|t|f|t|t
34177446|NCT04139330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177447|NCT05998018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177448|NCT05562791|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, single-arm pilot study of 68Gallium PSMA-PET/CT imaging in patients with metastatic urothelial carcinoma or Melanoma.||||
34177449|NCT06474767|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177450|NCT05123001|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177451|NCT02764385|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34177452|NCT03736863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177453|NCT06596941|||COHORT||RETROSPECTIVE|||||||
33864326|NCT05368961|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not a blinded study|Group 1: usual care Group 2: distraction||||
33864327|NCT02194036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864328|NCT02630446|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33864329|NCT06734364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864330|NCT00233688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963237|NCT01180842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963238|NCT02523079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963239|NCT03355222|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Chickens are how we intervene and this is not possible to blind'. Two villages will be far apart. We will not disclose nature of intervention to examiners."|Subjects to be drawn from two simlar villages: one is intervention village and other is control village.||||
33963240|NCT05948436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963241|NCT02162511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963242|NCT03849794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the outcome assessors ( Physiotherapists), and data analysts will remain blinded to group allocation throughout the study period.||t|f|f|t
33963243|NCT00276731|RANDOMIZED|||TREATMENT||||||||
34065242|NCT01403506|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751709|NCT04956302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751710|NCT05390840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Part 1 - Open Label (24 Participants); Part 2 - Single-Blind to Participant (12 Participants)||t|f|f|f
33751711|NCT01273454|||CASE_ONLY||PROSPECTIVE|||||||
33751712|NCT00430794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33751713|NCT04474236|||COHORT||PROSPECTIVE|||||||
33864331|NCT02555969|||OTHER||PROSPECTIVE|||||||
33864332|NCT04706650|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864333|NCT02656498|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864334|NCT02917668|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33864335|NCT02366975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864336|NCT05511090|||COHORT||PROSPECTIVE|||||||
33864337|NCT00763971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864338|NCT04070755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864339|NCT06735703|||COHORT||PROSPECTIVE|||||||
33963244|NCT02014649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963245|NCT00623909|NA|SINGLE_GROUP||TREATMENT||NONE|Not applicable, study terminated prior to enrollment and closed.|||||
33963246|NCT01804530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963247|NCT02509520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065243|NCT04280614|||COHORT||CROSS_SECTIONAL|||||||
34177454|NCT06262412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study personnel who can be blind to study aims/hypotheses and group allocation, will be blind. Assessors conducting post-treatment and follow-up assessments will be external to the research team and blind to study aims/hypotheses and treatment allocation for the full duration of the trial (up to the 6-month follow-up). The assessors will not receive any information about the study design, objectives or treatment conditions in order to maximise the blinding integrity. At each follow-up assessment, participants will be reminded by their assessor to not reveal details about their treatment.|Multisite parallel-group randomised controlled superiority trial.|f|f|f|t
34177455|NCT05737069|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33864340|NCT06379048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864341|NCT03979222|||COHORT||PROSPECTIVE|||||||
33864342|NCT00000420|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33864343|NCT03602274|||COHORT||PROSPECTIVE|||||||
33864344|NCT02459769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33963248|NCT05700929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study is a hybrid type 1 effectiveness-implementation trial, conducted as a two-armed randomized controlled trial including a comprehensive process evaluation for future implementation. After baseline assessment, participants will be randomized to the intervention group or the waitlist-control group. Randomization will be performed using stratified permuted block randomization. The waitlist-control group are offered to participate in the communication skills training after data collection has been finished.||||
33963249|NCT00267007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963250|NCT00407043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33963251|NCT04175652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single|Parallel Assignment Randomization; participants were divided into two groups by using simple random numbers table, and then the first group which was drawn by lot method was named as the experimental group.|f|f|t|f
33963252|NCT01498900|||COHORT||PROSPECTIVE|||||||
34065244|NCT04829630|NA|SINGLE_GROUP||OTHER||NONE||"* 90 subjects in Cambodia or Madagascar who received ID PEP by 3 sessions/1 week at least two (30 subjects), five (30 subjects) or 10 years earlier (30 subjects),~* 90 subjects in Cambodia or Madagascar who received ID PEP by 4 sessions/1 month at least two (30 subjects), five (30 subjects) or 10 years earlier (30 subjects),"||||
34065245|NCT05720117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065246|NCT06476431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065247|NCT02026804|||COHORT||PROSPECTIVE|||||||
34065248|NCT02290379|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34177456|NCT05941702|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series||||
34177457|NCT03594513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34177458|NCT06016803|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177459|NCT04369729|||CASE_CONTROL||PROSPECTIVE|||||||
34177460|NCT02254863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177461|NCT05632042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177462|NCT06224205|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||This is a pragmatic cluster randomized control trial with randomizing clinic and with wavier of consent for human subjects. The data collection is from the EHR. There is no research data collection outside the EHR.|f|f|t|t
34177463|NCT05035537|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The patients (individual participants) are prevented from having knowledge of the interventions assigned|All patients who met eligibility criteria were randomised, using a computer generated randomization list, to either Group 1 (PGDT, intervention group) where minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide a goal directed fluid administration protocol, and Group 2 (control) managed according to local and international best practice guidelines using standard hemodynamic monitoring.|t|f|f|f
34177464|NCT03112681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
34177465|NCT05038475|||COHORT||PROSPECTIVE|||||||
34177466|NCT00834977|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34177467|NCT00400179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177468|NCT05700669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation followed by dose expansion||||
33864345|NCT00324753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33864346|NCT05371509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864347|NCT02903069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864348|NCT05762523|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is an open-label, controlled, parallel-group clinical trial.||||
33864349|NCT01891097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864350|NCT02555696|||COHORT||CROSS_SECTIONAL|||||||
33864351|NCT01777412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864352|NCT06296589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864353|NCT04752020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065249|NCT02820181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065250|NCT01734590|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34177469|NCT04576988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study participants, care providers. Investigators and outcomes assessor will be masked to the study intervention until the final participant completes the 24-week efficacy assessment.|Participants will be randomized to one of two treatment arms to receive either sotatercept (0.7 mg/kg) by subcutaneous administration once every 3 weeks, or placebo. All participants will be on concurrent, stable background PAH therapy. Randomization will be stratified by baseline WHO Functional Class (Class II or III) and by background PAH therapy (mono/double or triple therapy)|t|t|t|t
34177470|NCT05841186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177471|NCT05612854|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled, open-label, parallel-assignment, prospective study||||
34177472|NCT04590885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177473|NCT03614182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177474|NCT05569759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177475|NCT06570577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized using REDCap software. If the participant is randomized to the ISP Block group, it will be completed after the participant has been administered General Anesthesia and prior to surgery start.|This is a randomized, blinded, 2-arm study of 60 participants. Two groups of 30 patients will be randomized to either 1) Routine pain management or 2) Inter-semispinalis Plane (ISP) Block plus Routine Pain Management.|t|f|f|f
34177476|NCT04297904|||OTHER||CROSS_SECTIONAL|||||||
34177477|NCT04323956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177478|NCT03448926|||COHORT||PROSPECTIVE|||||||
34177479|NCT03387670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177480|NCT06596967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34177481|NCT05221918|||CASE_ONLY||PROSPECTIVE|||||||
34177482|NCT06589362|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||a single-blind sham-controlled randomized crossover pilot study|t|f|f|f
34177483|NCT06437769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34177484|NCT05374785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In all treatment arms the investigated product/ placebo is to be administered orally in a blinded fashion. In order to maintain the blind and minimize bias, all subjects will receive the same number and types of tablets each day of treatment (4 tablets BID)||t|f|t|f
34177485|NCT03012399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177486|NCT05443295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An external physiotherapist will be used to supervise the intervention carried out, so that the evaluator does not know at any time which group each subject belongs|A single-blind randomized controlled trial.|f|f|t|f
34177487|NCT05018000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34177488|NCT06601374|||COHORT||PROSPECTIVE|||||||
34177489|NCT06602661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177490|NCT06369142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study participant as well as the follow-up physicians and site personal are blinded.||t|f|f|t
34177491|NCT00742612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177492|NCT06590662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177493|NCT04052334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177494|NCT02380573|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34177495|NCT02800538|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34177496|NCT06595082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177497|NCT06166654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will employ a triple-blind design (Participants and relatives, investigators and clinicians, and data analysts and outcome adjudicators)|3-arm parallel group RCT|t|t|t|t
34177498|NCT06593821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177499|NCT03096808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177500|NCT06052761|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34177501|NCT06590207|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The study will be conducted in a double-blind manner - the preparation/placebo will be provided by the pharmacy in a sealed bag.|double-blind randomized controlled study.|t|t|t|f
34177502|NCT04966013|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Volunteers meeting all inclusion criteria and none of the exclusion criteria will be randomized to the RD-X19 treatment arm or the sham treatment arm within each cohort in a 2:1 ratio according to a fixed schedule via a permuted block design.|t|t|t|t
33864354|NCT03426423|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"According to the article 18 of the LRH, participants will not be given the full information regarding the main purpose of the study (assess the efficacy of a smoking cessation trial) in order not to influence participants regarding the intervention and also to decrease selection bias (only smokers motivated to quit would take part and thus induce a selection bias). Methodologically, such a blinding to procedure would allow a better assessment of its efficacy. Furthermore, risks associated to the intervention are considered as very low. Participants will be informed a posteriori once they have completed the study or before in case they remove their consent or quit the study.~The outcome assessor will be a research collaborator independent of the study nurse who performed the intervention and blinded to the intervention."||t|f|f|t
33864355|NCT05803434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065251|NCT02447575|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34065252|NCT00815334||PARALLEL||TREATMENT||NONE||||||
34065253|NCT03012295|||COHORT||PROSPECTIVE|||||||
33963253|NCT04843800|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Ultrasound data analysis will be blinded.|"The patients will be randomized in three groups (allocation 1:1). Group 1 will receive a standardized acupuncture treatment and Group 2 will receive a standardized chiropractic treatment. Both groups will receive one treatment session per week for 3 consecutive weeks. Following the third treatment, at week 4, the US exam will be repeated and the questionnaires will be administered again.~Group 3 will be placed on a waiting list for 3 weeks and will be reexamined by US and respond to the questionnaires at week 4. Then the group 3 patients will undergo a standardized therapeutic massage treatment consisting of one treatment session per week for 3 consecutive weeks. Following the third treatment, at week 7, the US exam will be repeated and the questionnaires will be administered again."|f|f|f|t
33963254|NCT02511119|||COHORT||PROSPECTIVE|||||||
33963255|NCT05957692|||CASE_ONLY||RETROSPECTIVE|||||||
33963256|NCT00947609|||COHORT||PROSPECTIVE|||||||
34177503|NCT05159830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"CLEAVER LEAVES - ECOMEDICS SAS produce Oral oil of Cannabidiol and Placebo of similar galenic form. They will be responsible for the pharmaceutical analyses of the product.~Eurofins-LC2 will import the oral oil after authorization from the ANSM, and will relabeled individual vials for each participant, and regular dispatching into the hospital pharmacy.~Local hospital pharmacies will be in charge to deliver treatment individual vials to the investigators for dispensing."|CARAMEL is a phase-2, national, multi-site, interventional (category 1), double-blind, randomized, placebo-controlled trial, conducted in 76 subjects.|t|t|t|t
34177504|NCT06589622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177505|NCT04017546|NA|SINGLE_GROUP||TREATMENT||NONE||One to 6 patients will be entered at a given CYC065 dose level. Dose escalation will be 33% after at least one patient has completed the first treatment cycle without ≥ grade 2 toxicity considered by the investigator to be related to CYC065. Upon the first occurrence of grade 2 toxicity related to CYC065, at least 3 patients will be entered at each dose level. If no DLT is observed in any patients, dose escalation will continue to be 33%. If one of 3 patients experienced a DLT at a given dose level, dose escalation will continue at 25% until MTD is reached. If 2 or more patients experienced a DLT at a given dose level, dose escalation will be stopped. At least 6 patients will be treated at MTD.||||
34177506|NCT01658371|||||CROSS_SECTIONAL|||||||
34177507|NCT04500587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177508|NCT06600386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177509|NCT01048918|||COHORT||PROSPECTIVE|||||||
34177510|NCT03376880|||COHORT||PROSPECTIVE|||||||
34177511|NCT06594809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A triple-blinded randomized controlled trial will be conducted, ensuring that patients, the research assistant (who serves as the examiner for all patients), and the statistician are blinded to the treatment group.||t|f|f|t
34177512|NCT03056794|||COHORT||OTHER|||||||
34177513|NCT05924243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177514|NCT01876836|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34177515|NCT00434317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177516|NCT06594172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177517|NCT05446649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|dry needling and instrumented assisted soft tissue mobilization|t|f|f|t
34177518|NCT05636917|||COHORT||CROSS_SECTIONAL|||||||
34177519|NCT04086927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177520|NCT06589739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177521|NCT02052778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177522|NCT06029322|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|It concerns a surgical intervention. Hence, the treating surgeon and patient cannot be masked. The investigators and outcome assessors are masked.|Split-mouth design, intra-subject RCT Patients receive both treatments: collagen matrix and collagen membranes|f|f|t|t
34177523|NCT02575586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34177524|NCT04245111|||COHORT||PROSPECTIVE|||||||
34177525|NCT04488666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177526|NCT03264404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177527|NCT01502293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177528|NCT03991221|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34177529|NCT06052319|||COHORT||PROSPECTIVE|||||||
34177530|NCT06600035|||CASE_CONTROL||OTHER|||||||
34177531|NCT06593613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177532|NCT05911984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177533|NCT05101902|||COHORT||PROSPECTIVE|||||||
34177534|NCT05696054|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751714|NCT06732999|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Participants will be assigned to three groups with varying intervals between the pre-assessment and the start of treatment, following a multiple-baseline design (Group A - 1 week; Group B - 2 weeks; Group C - 3 weeks). All participants will receive the same treatment (GC-MRT).||||
33751715|NCT06495853|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33840635|NCT01158079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840636|NCT04558398|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Due to the nature of the exercise interventions, there will be no masking|"Participants will all receive baseline assessments of their mitochondrial function, muscle mass and functional assessments.~Participants with both cancer types (Prostate and colorectal) will be randomly allocated to either Resistance based or high-intensity interval training based home exercises for 4 weeks prior to their planned surgical date.~Participants will then all be re-assessed on the day of their planned surgical procedure."||||
33840637|NCT04523753|||CASE_ONLY||RETROSPECTIVE|||||||
33840638|NCT03929874|||CASE_ONLY||PROSPECTIVE|||||||
33840639|NCT02138786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840640|NCT04745975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840641|NCT00162916|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33840642|NCT04531904|||CASE_ONLY||PROSPECTIVE|||||||
33840643|NCT04446754|||COHORT||CROSS_SECTIONAL|||||||
33840644|NCT03728270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840645|NCT04064996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33864356|NCT05351047|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This study is single-blind (in which the study center staff remain blinded during the clinical conduct of a given cohort) with regard to treatment (AZD2373 or placebo) at each dose level. Study participants will be blinded to treatment allocation throughout the study.||t|f|t|f
33864357|NCT04692038|||CASE_ONLY||OTHER|||||||
33864358|NCT04613856|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized, counterbalanced, crossover study||||
33963257|NCT03701620|||COHORT||PROSPECTIVE|||||||
34177535|NCT03389828|||OTHER||CROSS_SECTIONAL|||||||
34177536|NCT06587867|NA|SINGLE_GROUP||TREATMENT||NONE||open label administration of efgartigimod||||
34177537|NCT05344950|||COHORT||PROSPECTIVE|||||||
34177538|NCT03940352|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177539|NCT06599827|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive CapeOx chemotherapy, anti-PD-1 mAb immunotherapy, and moderately hypofractionated radiotherapy.||||
34177540|NCT06062563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177541|NCT06225128|||COHORT||PROSPECTIVE|||||||
34177542|NCT06599008|||COHORT||OTHER|||||||
34177543|NCT03269422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177544|NCT05820581|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177545|NCT03733717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177546|NCT05325736|||COHORT||PROSPECTIVE|||||||
34177547|NCT06485843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177548|NCT06000540|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177549|NCT01666249|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177550|NCT04102423|||COHORT||PROSPECTIVE|||||||
34177551|NCT03792659|||OTHER||OTHER|||||||
34177552|NCT06587984|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Patients (recipients of text message reminders) will not know which group they are in.||t|f|f|f
34177553|NCT06535880|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34177554|NCT00294450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177555|NCT05494788|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34177556|NCT03353688|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a triple blind study. Participants, raters, and investigator are masked to the assignment of directional versus omnidirectional unilateral subthalamic deep brain stimulation guided by behavioral programming for Parkinson's disease with motor fluctuations. For the nested exploratory arm evaluating directional DBS guided by electrophysiology biomarkers, the study is double-blind (investigator is not blinded).|This is a triple blind, randomized crossover study of directional versus omnidirectional unilateral subthalamic deep brain stimulation for Parkinson's disease with motor fluctuations.|t|f|t|t
34177557|NCT05096403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177558|NCT05420935|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34177559|NCT05635656|NA|SINGLE_GROUP||OTHER||NONE||||||
34177560|NCT02435212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177561|NCT06371768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34177562|NCT06384222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177563|NCT06595784|||COHORT||PROSPECTIVE|||||||
33864359|NCT00686270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864360|NCT04910477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33864361|NCT02200835|||COHORT||RETROSPECTIVE|||||||
33864362|NCT01375335|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34177564|NCT06655376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864363|NCT01434251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864364|NCT01921855|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33864365|NCT04652713|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Single-blind randomized crossover trail with three intervention meals.|t|f|f|f
33864366|NCT06268951|||COHORT||PROSPECTIVE|||||||
33864367|NCT00303420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864368|NCT03746951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33864369|NCT02304848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963258|NCT01878682|||COHORT||PROSPECTIVE|||||||
33963259|NCT06497361|NA|SEQUENTIAL||TREATMENT||NONE||||||
34177565|NCT06595992|||COHORT||PROSPECTIVE|||||||
34177566|NCT05943834|||COHORT||PROSPECTIVE|||||||
34177567|NCT01373021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33963260|NCT03241407|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This investigation was designed as double-blind, randomized, crossover study|t|f|t|t
34177568|NCT02209714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34177569|NCT04683042|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a pragmatic clinical trial in outpatient PT practices utilizing cluster randomization by facility and facility size. Sites will be randomized to enroll all eligible and consented participants with FM to TENS with PT, or PT only (no TENS). We have identified 25-35 clinics across 6 healthcare systems in both rural and urban settings.||||
34177570|NCT04957485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind randomized||t|f|t|f
33864370|NCT05218590|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33864371|NCT06727240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864372|NCT03706404|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864373|NCT00347165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864374|NCT03916887|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post intervention||||
33864375|NCT04726007|||COHORT||OTHER|||||||
33864376|NCT02288520|||COHORT||PROSPECTIVE|||||||
33864377|NCT01851356|||||PROSPECTIVE|||||||
33864378|NCT04345081|||COHORT||PROSPECTIVE|||||||
33864379|NCT01795300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864380|NCT03626584|||COHORT||PROSPECTIVE|||||||
33864381|NCT02086851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963261|NCT01676311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963262|NCT05636774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Note: We involve blinded and unblinded study investigators.||t|t|t|t
33864382|NCT04877795|||COHORT||PROSPECTIVE|||||||
33864383|NCT05248451|||COHORT||RETROSPECTIVE|||||||
33864384|NCT06083831|||CASE_CONTROL||PROSPECTIVE|||||||
33864385|NCT06142760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963263|NCT06087185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a Randomized Clinical Trial (RCT) comparing the effectiveness of the adapted Mindful Eating protocol to the control with exposure to videos promoting quality of life in adults with anxiety and obesity.|f|f|f|t
33963264|NCT00612079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33963265|NCT03438331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963266|NCT01618773|||COHORT||PROSPECTIVE|||||||
33864386|NCT02393677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33864387|NCT02187679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864388|NCT04621396|||COHORT||PROSPECTIVE|||||||
33864389|NCT02903082|||CASE_CONTROL||PROSPECTIVE|||||||
33864390|NCT06007638|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33864391|NCT02966223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864392|NCT03967782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864393|NCT06131333|||COHORT||RETROSPECTIVE|||||||
33864394|NCT05232006|NA|SINGLE_GROUP||TREATMENT||NONE||Two-stage optimal Simon design||||
33864395|NCT06288945|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864396|NCT02073071|||COHORT||PROSPECTIVE|||||||
33864397|NCT00467389|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33864398|NCT02098720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864399|NCT02247765|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864400|NCT00796848|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963267|NCT06420401|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963268|NCT04545658|||COHORT||RETROSPECTIVE|||||||
33963269|NCT03082820|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33963270|NCT05925569|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33963271|NCT05603728|||COHORT||OTHER|||||||
33864401|NCT05716009|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Tagraxofusp-erzs dose escalation study combined with a fixed dose of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7.~Dose level 1, cycle 1 of tagraxofusp-erzs will be 7mcg/kg/day on days 10, 11 and 12.~Subsequent cycles at dose level 1 will consist of gemtuzumab ozogamicin 3mg/m2/day on day 1 and tagraxofusp-erzs 7mcg/kg/day on days 4, 5, and 6.~For dose levels 2 through 4, gemtuzumab will continue to be administered at a fixed dose of 3mg/m2/day on days 1, 4, and 7 while tagraxofusp-erzs will be administered at escalating doses of 9mcg/kg/day then 12mcg/kg/day on days 5, 6, and 7 of cycle 1 and days 1, 2, and 3 of subsequent cycles."||||
33864402|NCT01756469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33864403|NCT06241209|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864404|NCT04830150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study was a prospective, pre-and post-test randomised controlled trial.|t|f|f|f
33864405|NCT04788576|||COHORT||PROSPECTIVE|||||||
33864406|NCT06735963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864407|NCT04257383|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Our study works with Laterite to oversee data collection in the field. Laterite enumerators are blind to study condition and therefore do not know which study arm participants have been clustered and randomized into.|The proposed study design consists of a two-arm cluster randomized control trial (CRT), which will span approximately 36 cells in 3 districts of Rwanda to compare outcomes among VUP eligible households with at least one child birth-36 months old in the following study arms: treatment and waitlist control. For the embedded quasi experimental study, we aim to enroll 540 households. These households will be assessed at baseline (pre-intervention), midline (post-intervention) and endline (12-months follow-up).|f|f|f|t
33864408|NCT01843972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33864409|NCT06494709|NA|SINGLE_GROUP||OTHER||NONE||||||
33864410|NCT06249724|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33864411|NCT01130051|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34177571|NCT04969939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|"Part 1: is a 16-week study were one group of participants will receive two doses of NNC0165-1875 a week, in combination with one injection dose of semaglutide a week. The other group will receive a placebo.~Part 2: is a 40-week study were one group of participants will receive one dose of NNC0165 a week, in combination with one injection dose of semaglutide a week. The other group will receive a placebo."|t|t|t|t
33864412|NCT03536390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Double-blind, placebo-controlled, parallel group study.|t|t|t|t
33864413|NCT03707132|||CASE_CONTROL||PROSPECTIVE|||||||
33963272|NCT03606239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963273|NCT03014531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963274|NCT01155284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963275|NCT03031431|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963276|NCT02736526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177572|NCT03240601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33963277|NCT01672814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963278|NCT03115060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33963279|NCT02438865|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33963280|NCT03661294|NA|SINGLE_GROUP||OTHER||NONE||||||
33963281|NCT01655433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963282|NCT00975273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963283|NCT04120714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963284|NCT04664569|||COHORT||PROSPECTIVE|||||||
33963285|NCT06545448|||COHORT||RETROSPECTIVE|||||||
33963286|NCT01176474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963287|NCT03881579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes will be assessed by blinded research associates|"patients will be randomized to one of two groups:~1. (usual care) or (2). enhanced usual care i.e. usual care plus supportive care provided by a trained and supervised nurse"|f|f|f|t
33963288|NCT06394921|||COHORT||CROSS_SECTIONAL|||||||
33963289|NCT01286688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963290|NCT05181761|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963291|NCT02038101|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33963292|NCT02830490|||COHORT||PROSPECTIVE|||||||
33963293|NCT04171986|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33963294|NCT05525299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33963295|NCT05787210|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33963296|NCT06567938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963297|NCT03656809|||CASE_CONTROL||PROSPECTIVE|||||||
33963298|NCT02757131|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963299|NCT04816422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963300|NCT06246526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963301|NCT03586037|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963302|NCT01745484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963303|NCT02369627|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33963304|NCT04078945|||COHORT||PROSPECTIVE|||||||
33963305|NCT05250947|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot safety study.||||
33963306|NCT01202994|NA|SINGLE_GROUP||SCREENING||NONE||||||
33963307|NCT00002084||||TREATMENT||||||||
33963308|NCT04061889|||COHORT||RETROSPECTIVE|||||||
34177573|NCT02582528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177574|NCT05418816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864414|NCT00470236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864415|NCT03176563|||COHORT||PROSPECTIVE|||||||
33864416|NCT06706310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864417|NCT02370680|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864418|NCT04961853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864419|NCT00749879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33864420|NCT01614821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864421|NCT04906616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Couples will be randomized 1:1 to intervention or control arm||||
33864422|NCT02742467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33864423|NCT03859726|||COHORT||PROSPECTIVE|||||||
33864424|NCT06735898|||CASE_CONTROL||PROSPECTIVE|||||||
33864425|NCT05731570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177575|NCT05586581|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In this study, people living with treated suppressed HIV infection (PLWH) and matched HIV-negative controls will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two SV2A PET scans (baseline and 2 years). A subset of PLWH participants will be asked to complete a TSPO PET scan on the same day as the baseline SV2A PET scan. Participants will undergo phlebotomy and medical/mental health and substance use histories for eligibility, and may also complete an ECG, blood tests, an optional lumbar puncture, neurocognitive testing \& behavioral/mood questionnaires.||||
33864426|NCT05184998|||OTHER||RETROSPECTIVE|||||||
33864427|NCT00727649|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33864428|NCT06091761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be unaware of their random allocation into either the intervention or placebo group. Sham Thread embedding acupuncture (Sham-TEA) will be administered in a manner similar to TEA, but without the insertion of threads, ensuring that no threads are left at the acupoints after the procedure.~The physician responsible for administering the treatments will be aware of the group assignments but remain uninvolved in the evaluation of outcomes and subsequent data analysis. Those responsible for outcome assessment and data analysis will be kept blinded to the treatment assignments."||t|f|t|t
33864429|NCT00390611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864430|NCT02992314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33864431|NCT01606020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33864432|NCT05997381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864433|NCT00955487|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33864434|NCT01558427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864435|NCT06272292|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"3 study groups, based on clinical examination and medical imaging:~* symptomatic CAM-FAI patients~* asymptomatic CAM controls~* healthy controls"|Cross-sectional, case-control prospective clinical study|t|f|f|f
33963309|NCT00411801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33963310|NCT05400200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963311|NCT02850445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963312|NCT05033379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864436|NCT01880021|||CASE_ONLY||PROSPECTIVE|||||||
33864437|NCT06177028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Beside the clinical pharmacologist and biostatistician, all parties involved in the present study will be blinded until all data are collected, including medical staff, patients and his/her car giver, imaging staff, and scientists collecting data from biosamples. The blinding will be lifted only after all data are acquired, and before statistical analysis|"This study will take place at a single site. We will enroll 45 male and female participants, 50-90 years of age, in general good health, with mild cognitive impairment due to AD. The trial will last up to 30 weeks in duration. Lenalidomide 10 mg/day vs. placebo taken daily orally (ratio 2:1).~Participants completing the study will be involved for up to 45 weeks in duration, from screening to end of the study."|t|t|t|t
33864438|NCT06202404|||COHORT||PROSPECTIVE|||||||
33864439|NCT04970550|||COHORT||RETROSPECTIVE|||||||
33864440|NCT02827669|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864441|NCT01660451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864442|NCT03829241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Subject||t|t|t|f
33963313|NCT04769128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963314|NCT00730288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963315|NCT01856374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963316|NCT02798783|||CASE_ONLY||PROSPECTIVE|||||||
33963317|NCT02228746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963318|NCT00297986|||COHORT||PROSPECTIVE|||||||
33963319|NCT03963856|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963320|NCT02844179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963321|NCT01437345|||COHORT||CROSS_SECTIONAL|||||||
33963322|NCT03862937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963323|NCT01746563|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33963324|NCT05661656|NA|SINGLE_GROUP||TREATMENT||NONE||Adult female had stage III,IV breast cancer with no prior chemotherapy, radiotherapy, or definitive surgical therapy for breast cancer.||||
34065254|NCT00575510|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33963325|NCT04693182|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All statistical analyses will be done by a researcher who is masked to group allocation.|A parallel-group cluster RCT in a target sample of more than 4000 healthcare workers at Haukeland University Hospital in Norway will be conducted. More than 70 hospital units will be assessed for eligibility and randomized to a work schedule without quick returns for six months or continue with a schedule that maintains quick returns|f|f|f|t
33963326|NCT01514656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864443|NCT04295616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33864444|NCT03836820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864445|NCT05196425|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33864446|NCT00631189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963327|NCT03208257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963328|NCT02299674|||CASE_CONTROL||PROSPECTIVE|||||||
33963329|NCT05602233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapist who made the evaluations will be blind to the groups. He will not know which treatment method will be applied to the participants.|Participants between the ages of 18-25, diagnosed with chronic ankle sprain who met the inclusion criteria will be included in the study. Sample size of the study is calculated as 21. All evaluations of the participants, including postural control, weight bearing dorsiflexion angle measurement, function and kinesiophobia will be made by the same physiotherapist. The physiotherapist who made the evaluations will not know which treatment method will be applied to the participants.|f|f|f|t
33963330|NCT05205668|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34177576|NCT04040569|NA|SINGLE_GROUP||TREATMENT||NONE||All patients in each dose cohort will be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 30 Gy. Subsequent cohorts of patients will receive an additional 4 Gy per treatment. If significant toxicity is encountered at the starting dose, a de-escalation will occur (step -1) to 26.5 Gy. As we are currently concluding an adjuvant single fraction phase I protocol (ClinicalTrials.gov Identifier: NCT02685332) to 30 Gy in a single fraction for early stage breast cancer, if we meet our endpoints of this study, we will start our dose escalation at 34Gy instead of the 30 Gy, as safety of the 30 Gy arm will have already been established.||||
33963331|NCT04221984|||COHORT||PROSPECTIVE|||||||
33963332|NCT00333073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963333|NCT00627627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963334|NCT01834690|||COHORT|||||||||
33963335|NCT00991042|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177577|NCT04570371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a stepped wedge cluster randomized pragmatic clinical trial.||||
34177578|NCT04104256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34177579|NCT06589752|||COHORT||RETROSPECTIVE|||||||
33864447|NCT04528862|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33864448|NCT04300582|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of the fast pharmaco-invasive strategy with the standard pharmaco-invasive strategy in patients with ST-elevation myocardial infarction stratified by the forearm approach||||
33864449|NCT00890929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864450|NCT03976791|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33963336|NCT03506854|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963337|NCT00003061||||TREATMENT||||||||
34177580|NCT04856358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Part 1 Single Ascending Dose (SAD) and Part 2 Multiple Ascending Dose (MAD) are randomized, double-blind, placebo-controlled; Part 3 Food-effect (FE) is randomized, open-label, crossover|t|t|t|t
34177581|NCT06588114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177582|NCT06354647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34177583|NCT06603649|||CASE_ONLY||RETROSPECTIVE|||||||
34177584|NCT05270057|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1a will involve a standard 3+3 dose escalation design to find the maximal tolerated dose (MTD) and/or recommended dose for expansion.||||
33864451|NCT00717054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864452|NCT04733339|||COHORT||PROSPECTIVE|||||||
33864453|NCT00158873|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864454|NCT01355146|||COHORT||PROSPECTIVE|||||||
33864455|NCT05599789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864456|NCT01755845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864457|NCT00905684|||COHORT||PROSPECTIVE|||||||
33864458|NCT03864445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864459|NCT00244972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864460|NCT06508112|||CASE_CONTROL||PROSPECTIVE|||||||
33864461|NCT05327556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study kits in either arm will be identical, and only the research pharmacy and the study statisticians will have access to the populated Master Randomization List.||t|t|t|f
34065255|NCT04402359|||COHORT||PROSPECTIVE|||||||
34177585|NCT06498349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Better personalized therapy adaptation and care for patients with behavioral disorders is possible. This is often currently not possible in routine clinical practice. The scale for primary outcome used as the main target has been tested for use and is suitable for the study purpose of monitoring ICD. We now want to examine what patients with ICD benefit most from.||||
34177586|NCT06590324|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Study||||
34177587|NCT01076478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177588|NCT01705119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177589|NCT04897711|RANDOMIZED|PARALLEL||TREATMENT||NONE||300 listeners will be recruited and enrolled. Each participant will be randomly assigned to receive perceptual training with one of 5 speakers with dysarthria, such that 30-50 listeners will be assigned to each speaker with dysarthria. All listener participants will receive the perceptual training intervention.||||
34177590|NCT04865627|||COHORT||CROSS_SECTIONAL|||||||
34177591|NCT03896438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177592|NCT04638231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|We will use block randomization with a series of computer-generated random numbers to ensure balance (1:1) between the two treatment groups. The randomisation codes will be transmitted by an independent statistician via text message directly to the blinded researcher's password-protected phone line with a secure online backup|This is a two-arm randomized non-inferiority pilot trial in which patients with MDD receiving usual care are randomized to receive either daily supportive email messaging or daily supportive text messaging of the same content.|f|f|t|f
34177593|NCT06276309|||COHORT||RETROSPECTIVE|||||||
34177594|NCT05322954|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177595|NCT01893307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177596|NCT06299475|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||A cluster randomized crossover trial||||
34177597|NCT06294626|||CASE_ONLY||RETROSPECTIVE|||||||
34177598|NCT05178810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177599|NCT05336864|||COHORT||PROSPECTIVE|||||||
33864462|NCT05126901|RANDOMIZED|PARALLEL||TREATMENT||NONE|12 weeks open label treatment|The study will include 98 subjects in the 2 - 17 years age group, randomised 1:1 between ferric maltol and ferrous sulfate: 49 in each treatment group. The study will also include up to 12 subjects in the 1 month to less than 2 years age group.||||
34177600|NCT03453164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177601|NCT06588569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177602|NCT06032871|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|The group will be coded and masked to the investigator and the outcome accessor.|||||
34177603|NCT06588088|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Nutritional study with a single-arm cross-over design||||
34177604|NCT02939807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177605|NCT05932862|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177606|NCT01775501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177607|NCT02689427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177608|NCT05615922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864463|NCT01584076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864464|NCT05351151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864465|NCT03398525|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomization with 1:1 allocation ratio||||
33864466|NCT00184080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864467|NCT05487339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864468|NCT00628173||PARALLEL||TREATMENT||SINGLE||||||
33864469|NCT00016029||||DIAGNOSTIC||||||||
33864470|NCT04964570|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized Controled Trial|t|f|f|f
33864471|NCT05273957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33864472|NCT00631501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864473|NCT01506960|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864474|NCT06734390|||COHORT||RETROSPECTIVE|||||||
33864475|NCT00894686|NON_RANDOMIZED|||PREVENTION||NONE||||||
33864476|NCT02888665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864477|NCT00473577|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864478|NCT03882242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33864479|NCT04900558|||COHORT||OTHER|||||||
33864480|NCT05798234|||COHORT||RETROSPECTIVE|||||||
33963338|NCT05741983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to the surgical procedure (with or without membrane). The outcome assessor who will complete the AOFAS and TAS will not be the physician who performed the surgery, the examiner is blinded to the treatment group to which the patient was allocated.|Double blind RCT (Randomized Controlled Trial)|t|f|f|t
33963339|NCT04048174|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
33963340|NCT01808014|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33963341|NCT01485224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963342|NCT04252508|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963343|NCT04113538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177609|NCT06139276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study plans to collect 120 individuals diagnosed with frozen shoulder by both Western and Traditional Chinese medicine practitioners, randomized in a 1:1 ratio to receive either standard treatment or a combination of small needle-knife therapy and standard treatment.|f|f|f|t
34177610|NCT05014971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||tele-neurohub model of care||||
33864481|NCT00247936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864482|NCT02032602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963344|NCT01392586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963345|NCT03887819|||COHORT||PROSPECTIVE|||||||
33963346|NCT01293409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065256|NCT01037036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065257|NCT04519762|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34065258|NCT04358315|||COHORT||PROSPECTIVE|||||||
34177611|NCT05071287|RANDOMIZED|PARALLEL||OTHER||NONE||"Randomized controlled trial with 2 arms. Randomization will be done in clusters:~1. overweight/obese adults with type 2 diabetes (T2D) but no chronic kidney disease (CKD)~2. overweight/obese with T2D without CKD~3. overweight/obese with early stage CKD"||||
33864483|NCT06710613|||COHORT||RETROSPECTIVE|||||||
33864484|NCT02946593|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864485|NCT00232583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864486|NCT05743504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864487|NCT05613166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864488|NCT00419120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864489|NCT05087160|||OTHER||CROSS_SECTIONAL|||||||
33864490|NCT02308007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33864491|NCT05638022|||COHORT||PROSPECTIVE|||||||
33963347|NCT06389565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33963348|NCT01600014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963349|NCT04373161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177612|NCT03668873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177613|NCT02265458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34177614|NCT06586268|||COHORT||PROSPECTIVE|||||||
34177615|NCT04060303|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||A stepped-wedge, cluster-randomized study design will be used in which the participating sites will be randomly assigned to one of three clusters with each cluster, in turn, being randomly assigned to an intervention start period.||||
34177616|NCT05613569|||CASE_ONLY||PROSPECTIVE|||||||
34177617|NCT06604338|||CASE_CONTROL||RETROSPECTIVE|||||||
34177618|NCT04768738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||46 healthy young individuals aged 19.2±1.5 years participated in the study. The participants were randomly divided into 3 groups as Above Threshold Group (n:15; 10 females, 5 males), Under Threshold Group (n:15; 10 females, 5 males) and Control Group (no stimulation) (n:16; 11 females, 5 males) according to the sensation of electrical current on ears. The participants were evaluated 3 times; before the application, after the first and second bicycle exercises. Numerical pain scale (NPS), pulse rate, blood pressure, respiratory rate, and distance travelled during exercise for sportive performance were recorded in kilometers as the evaluation method. The stimulation was done during the first bicycle exercise with 5 minutes of duration. The Kruskal-wallis, mann-whitney u test were used for the quantitative independent data obtained. In the analysis of qualitative independent data, chi-squared test was used.|t|f|f|t
34177619|NCT01082861|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177620|NCT06585657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177621|NCT05101096|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177622|NCT05762757|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177623|NCT04896060|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34177624|NCT06414798|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34177625|NCT05315414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177626|NCT06601426|NA|SINGLE_GROUP||OTHER||NONE||||||
34177627|NCT06151288|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34177628|NCT03403608|||COHORT||PROSPECTIVE|||||||
33864492|NCT05661058|||COHORT||PROSPECTIVE|||||||
33864493|NCT00369785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33864494|NCT05455710|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||In order to verify the effectiveness of the mobile application for post-discharge surveillance the developed infection of the surgical site, a randomized clinical trial of superiority will be carried out.||||
34177629|NCT02006472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177630|NCT00628368|NON_RANDOMIZED|||DIAGNOSTIC||||||||
34177631|NCT06555120|NA|SINGLE_GROUP||OTHER||NONE||||||
34177632|NCT06291441|||OTHER||PROSPECTIVE|||||||
34177633|NCT06589375|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study involves multiple groups of participants who will undergo EEG analysis during olfactory stimulation to assess brain wave responses. The groups include normosmics, hyposmics, tinnitus patients with hyposmia, and tinnitus patients without hyposmia. The study aims to differentiate between these groups and investigate the relationship between olfactory disorders and also highlight the olfactory features of patients with tinnitus. Each group will receive the same olfactory tests and EEG recordings, but they will be compared against each other to understand the different responses and interactions.||||
34177634|NCT02818907|NA|SINGLE_GROUP||OTHER||NONE||||||
34177635|NCT04346745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled trial||||
34177636|NCT06273774|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34177637|NCT02586181|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34177638|NCT00498875|||CASE_ONLY||PROSPECTIVE|||||||
34177639|NCT05708755|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177640|NCT05467007|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||1 to 1 RCT||||
34177641|NCT04777851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177642|NCT04584255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864495|NCT00249210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864496|NCT05214170|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective, non-randomized, single-arm trial||||
33864497|NCT06495502|||OTHER||RETROSPECTIVE|||||||
33864498|NCT00839709|||CASE_CONTROL||PROSPECTIVE|||||||
33864499|NCT03763851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864500|NCT02695849|||COHORT||CROSS_SECTIONAL|||||||
33864501|NCT05370612|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Participant will know what arm they are randomized to, participants and physicians in Arm 2 will be blinded to CGM data collected for 10 days at 2 timepoints.|pilot, prospective, randomized trial||||
33963350|NCT01626131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963351|NCT00593931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963352|NCT00884663|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33963353|NCT00642031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963354|NCT02197221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065259|NCT00182533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065260|NCT04707365|NA|SINGLE_GROUP||PREVENTION||NONE||Retrospective and prospective monocentric cohort study||||
33864502|NCT03684642|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study was open-label for the tested versus comparator drug and double blind for the doses.|||||
33864503|NCT05531487|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33963355|NCT03797365|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is a controlled randomized single blind multicentric study on a sample of 40 women stress or mixed urinary incontinent. Participants will be randomized in two groups with a 1/1 ratio with data processing software at the first visit at the therapist practicing the perineal rehabilitation. The first group will receive Classical perineal rehabilitation for duration of height weeks. The second group will receive perineal rehabilitation associated to a double task cognitive therapy for duration of height weeks. Participants will be evaluated during the consultation."||||
33963356|NCT00908531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963357|NCT03061773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963358|NCT04463745|||COHORT||PROSPECTIVE|||||||
33963359|NCT04685941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963360|NCT02149069|||||PROSPECTIVE|||||||
33963361|NCT02761265|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34177643|NCT05632081|||COHORT||PROSPECTIVE|||||||
34177644|NCT03932344|||CASE_ONLY||RETROSPECTIVE|||||||
34177645|NCT05535387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177646|NCT06591858|||OTHER||CROSS_SECTIONAL|||||||
34177647|NCT05109325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34177648|NCT05150327|||CASE_ONLY||RETROSPECTIVE|||||||
34177649|NCT06431048|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The two groups per arm in this study are:~1. Nutrition will be stopped when the patient is called to the OR for scheduled procedure.~2. Nutrition will be stopped 2 hours before the scheduled procedure."||||
34177650|NCT02947685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177651|NCT02325622|||COHORT||PROSPECTIVE|||||||
34177652|NCT04452721|||COHORT||OTHER|||||||
34177653|NCT03221556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34177654|NCT06061094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177655|NCT06590779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator blinded, randomised study|Arm 1: Finasteride 1mg Arm 2: Finasteride 1mg + Aminexil® active+ lotion|f|f|t|f
34177656|NCT03026062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177657|NCT06419465|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177658|NCT02656381|||COHORT||PROSPECTIVE|||||||
34177659|NCT05220618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a pilot study with a mixed between-subject design (experimental condition that will receive the training, and control condition that will only receive the assessment) and within-subject (pre/post-training assessment and 2-week follow-up). Continuous assessments will also be used to longitudinally evaluate participants during the 14 days of training and the 14 days of follow-up.|t|f|f|f
34177660|NCT04887909|||OTHER||RETROSPECTIVE|||||||
33864504|NCT00936403|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864505|NCT06734377|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant receives all three types of stimulations (delta, theta, arrhythmic) in both brain regions, with the order of stimulation randomized for each session. Across the 12 task blocks in each session with the stimulation, the type of stimulation is interleaved, ensuring that all conditions are represented in a balanced manner. The number of trials for each stimulation condition is counterbalanced within and across blocks to provide equal exposure to each type.||||
33864506|NCT02613689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963362|NCT04979065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Independent party masked the intervention and control product||t|t|t|t
33963363|NCT04543305|NA|SEQUENTIAL||TREATMENT||NONE||||||
33963364|NCT04754321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963365|NCT02387307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065261|NCT04949763|||COHORT||PROSPECTIVE|||||||
34065262|NCT04271540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065263|NCT03888183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177661|NCT06600737|||COHORT||PROSPECTIVE|||||||
34177662|NCT05311306|||COHORT||PROSPECTIVE|||||||
34177663|NCT03975491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34177664|NCT04663763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177665|NCT04836429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177666|NCT04142203|||COHORT||PROSPECTIVE|||||||
34177667|NCT00248625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177668|NCT05171816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177669|NCT06576505|||COHORT||PROSPECTIVE|||||||
34177670|NCT04042441|||COHORT||PROSPECTIVE|||||||
34177671|NCT06540742|||COHORT||RETROSPECTIVE|||||||
34177672|NCT04091620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177673|NCT04329247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34177674|NCT06600997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177675|NCT00896402|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34177676|NCT02582021|||COHORT||PROSPECTIVE|||||||
34177677|NCT06588712|||COHORT||CROSS_SECTIONAL|||||||
34177678|NCT04154072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177679|NCT04833361|||FAMILY_BASED||OTHER|||||||
34177680|NCT05442554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177681|NCT04081493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864507|NCT06227273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator is blinded to computer-generated condition assignment.|Two different 16-week dosing schedules will be compared: A standard dose of hydrogen water as compared to a standard dose followed by an increased dose of hydrogen water.|f|f|t|f
33864508|NCT01383096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864509|NCT04495010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864510|NCT00612261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864511|NCT06723457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864512|NCT04695392|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre-post study||||
33864513|NCT01223521|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33864514|NCT01910350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33864515|NCT05521035|||COHORT||RETROSPECTIVE|||||||
33864516|NCT04059016|||OTHER||OTHER|||||||
33864517|NCT00892619|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33864518|NCT00774813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864519|NCT03308942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study.|Participants will receive niraparib either as monotherapy or in combination with pembrolizumab during Stage 1 of the study. Participants will receive niraparib in combination with TSR-042 (dostarlimab) during Stage 2 of the study.||||
33864520|NCT03262792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo controlled, parallel groups study.|t|f|t|t
33864521|NCT00184236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864522|NCT04092517|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33864523|NCT03178708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||the role of preoperative administration of Amantadine Sulphate on the duration of wake up test and postoperative opiod consumption in patients undergoing major spine deformities corrective surgeries.|t|t|f|f
33864524|NCT00399386|||COHORT||PROSPECTIVE|||||||
33864525|NCT00640055|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|t|f|f
33864526|NCT05235399|||COHORT||PROSPECTIVE|||||||
33864527|NCT02737540|||CASE_CONTROL||PROSPECTIVE|||||||
33864528|NCT06262854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Granules of calcium sulphate with and without antibiotics are identical and undistinguishable.||t|t|t|t
33864529|NCT02183155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864530|NCT03627767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864531|NCT04513262|||COHORT||RETROSPECTIVE|||||||
33864532|NCT04158921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864533|NCT01475929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33864534|NCT01713751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864535|NCT00909350|||CASE_ONLY||PROSPECTIVE|||||||
33864536|NCT01472380|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864537|NCT05698823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All clinical assessments at baseline and at 6 months shall be performed by one calibrated examiner who is blinded for the subjects' allocation to the study and control groups.||f|f|f|t
33864538|NCT02598609|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33864539|NCT04162496|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33864540|NCT00872664|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33864541|NCT05817253|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants have been randomly divided into three groups which received the intervention at different times. Pooled data on the primary outcome (first-line prescribing for uncomplicated UTI) of those who received the intervention (mailed copy of personalized Portrait) early will be compared to that of those who received the delayed intervention.|t|f|f|f
33864542|NCT00614705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864543|NCT02529267|||COHORT||PROSPECTIVE|||||||
33864544|NCT04998487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33864545|NCT00446238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864546|NCT01754857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864547|NCT00311701|||||RETROSPECTIVE|||||||
33864548|NCT06716671|||COHORT||PROSPECTIVE|||||||
33864549|NCT04651010|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34065264|NCT06729944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The patients' biological sample will be analysed by NGS and the results obtained will be compared with the morphological data||||
34065265|NCT03004547|||COHORT||PROSPECTIVE|||||||
33751716|NCT04808401|RANDOMIZED|PARALLEL||OTHER||SINGLE|TEE images will be coded and analysed in batches at a later date by a blinded reader|Patients start with a crossover design undergoing both TEE images at normoxia and hyperoxia in random order and then are randomized a second time to receive either normoxia or hyperoxia for the remaining procedure in a parallel design.|f|f|f|t
33751717|NCT04769037|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33864550|NCT00473551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864551|NCT01161290|RANDOMIZED|||TREATMENT||||||||
33864552|NCT02827305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864553|NCT05263063|||CASE_ONLY||PROSPECTIVE|||||||
33864554|NCT05948475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864555|NCT00904696|||CASE_ONLY||PROSPECTIVE|||||||
33864556|NCT03570372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177682|NCT06147037|NA|SEQUENTIAL||TREATMENT||NONE||||||
34177683|NCT06313112|||COHORT||RETROSPECTIVE|||||||
34177684|NCT00297310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177685|NCT06467929|||CASE_ONLY||PROSPECTIVE|||||||
33864557|NCT04801134|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||50 families will be followed over 6 months, providing nutrition education and support with community resources to mitigate the families food insecurity.||||
33864558|NCT04997460|||COHORT||PROSPECTIVE|||||||
33864559|NCT05440838|||COHORT||PROSPECTIVE|||||||
33864560|NCT00238628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864561|NCT06178965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864562|NCT05029466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177686|NCT05684419|||COHORT||RETROSPECTIVE|||||||
34177687|NCT03690193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177688|NCT02503436|||COHORT||PROSPECTIVE|||||||
33864563|NCT00447486|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33864564|NCT02427880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864565|NCT05197413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864566|NCT04564144|NA|SEQUENTIAL||PREVENTION||NONE||||||
33864567|NCT02507622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864568|NCT01320982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864569|NCT03574441|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients were randomized using a random number table to be allocated to one of three groups with sealed envelopes, based on the type of dressing to be used to secure the epidural catheter after its insertion:~1. TegadermTM plus catheter support pad.~2. Dressing with TegadermTM plus Steri-StripTM bands~3. Dressing with TegadermTM only"||||
33864570|NCT06416735|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study is a non-pharmacological interventional, single-center, national, non-randomised, comparative and open label.||||
33864571|NCT01600976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864572|NCT03564743|||COHORT||PROSPECTIVE|||||||
33864573|NCT04846582|||CASE_ONLY||OTHER|||||||
33864574|NCT05221723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864575|NCT05691517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864576|NCT05327621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864577|NCT01226823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864578|NCT02755168|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33864579|NCT02679599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864580|NCT03904745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864581|NCT04401748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864582|NCT03528278|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34177689|NCT02535481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177690|NCT05928936|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34177691|NCT05355532|||CASE_CONTROL||PROSPECTIVE|||||||
34177692|NCT01953640|||COHORT||PROSPECTIVE|||||||
34177693|NCT06589557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177694|NCT06190158|||COHORT||PROSPECTIVE|||||||
33864583|NCT00551551|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33864584|NCT03769909|||COHORT||PROSPECTIVE|||||||
33864585|NCT05146804|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33864586|NCT05339321|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33864587|NCT06006325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33864588|NCT01418651|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864589|NCT01112176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864590|NCT05301673|||COHORT||PROSPECTIVE|||||||
33864591|NCT00800683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864592|NCT00521053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864593|NCT05444751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864594|NCT06073236|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Parents of preschoolers in the intervention region are aware that they are taking part in a health promoting intervention|Cluster randomized controlled trial (preschools are unit of randomization) with an intervention and a control including a pretest (T0), a posttest (T1) and a follow-up (T2)||||
33864595|NCT00420017|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864596|NCT02471950|||COHORT||PROSPECTIVE|||||||
33864597|NCT00285129|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864598|NCT00916149|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963366|NCT05940688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Study is a pilot randomized trial (n=40) randomizing eligible participants to usual care (n=10), or usual care plus a digital health intervention (n=10), or usual care plus a community health worker intervention (n=10), or usual care plus both a digital health intervention and a community health worker intervention.|f|t|f|f
33963367|NCT02622503|||CASE_ONLY||RETROSPECTIVE|||||||
34177695|NCT04696692|NA|SINGLE_GROUP||OTHER||NONE||||||
33864599|NCT06494007|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Each participant was assigned an identification number indicating their treatment group. An emergency nurse prepared the treatment solutions just before administration based on the assigned identification number and stored them in labeled containers with no indication of their content. A clinician with eight years of experience, who was blinded to the study's null hypothesis and did not participate in the evaluation of results, administered the treatments and recorded patient data onto a pre-prepared case data form. Another physician, who was not present during the treatment, assessed the findings post-treatment.|Single center|t|f|t|t
33864600|NCT06442865|||COHORT||PROSPECTIVE|||||||
34177696|NCT05804838|NA|SINGLE_GROUP||TREATMENT||NONE|Since the study is a doctoral thesis, blinding cannot be done due to its nature.|Randomized controlled treatments will be carried out in a design. These randomized controlled restrictions should be followed by the Consolidated Standards of Reporting Trials (CONSORT) 2010 guideline controls. The study will consist of an Intervention and a control group.||||
33864601|NCT06494787|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2 study to determine the efficacy and safety of the Aliya PEF System combined with pembrolizumab in treating patients with advanced soft tissue sarcoma.||||
33864602|NCT02414568|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33864603|NCT05877222|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33864604|NCT06326892|||COHORT||RETROSPECTIVE|||||||
33963368|NCT04783792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"A randomized double-blind clinical intervention with two parallel groups lasting 3 months is proposed to elucidate the beneficial effect of a novel food supplement on OA.~Participants will undergo clinical and biochemical testing and will provide a complete medical history and history of the disease. Demographics, smoking, alcohol consumption, eating habits and physical activity, pain, and functional inability to enroll in the study will also be recorded."|t|t|t|t
33963369|NCT00045604||||TREATMENT||||||||
33963370|NCT03822936|NA|SINGLE_GROUP||TREATMENT||NONE||The trial enrolls subjects that will receive in order: chemotherapy, carbon ion therapy, followed by surgical resection after 4/6 weeks then adjuvant chemotherapy.||||
33963371|NCT05294198|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33963372|NCT00303381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864605|NCT01909427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33963373|NCT00667719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963374|NCT03503227|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34177697|NCT06595693|||COHORT||PROSPECTIVE|||||||
34177698|NCT01285557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177699|NCT03294707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized with an overall ratio of 3:1 to AG10: placebo within each cohort||t|t|t|t
34177700|NCT06590077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||A double-blind, randomised controlled experiential pilot study with a test and a control product both of which contain essential oil fragrances.|t|t|t|f
34177701|NCT05425979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, the anesthesiologist performing the block and assessing the block efficacy over time will all be masked as to which local anesthetic is being used||t|t|f|t
34177702|NCT04044950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177703|NCT01874002|||COHORT||PROSPECTIVE|||||||
34177704|NCT06601491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34177705|NCT05569161|||CASE_ONLY||PROSPECTIVE|||||||
34177706|NCT05701423|||COHORT||PROSPECTIVE|||||||
34177707|NCT03532451|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort 1: Nivolumab alone (Completed November 20, 2019). In the absence of the occurrence of high rate of treatment related adverse events, the study will proceed with enrollment into Cohort 2: Nivolumab/Lirilumab.||||
34177708|NCT04247139|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Both types of kefir will be flavoured the same, and visually look the same.||t|f|f|f
34177709|NCT06595654|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177710|NCT06586619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34177711|NCT02663492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751718|NCT04392765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751719|NCT05090579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33864606|NCT03624205|||CASE_ONLY||PROSPECTIVE|||||||
33864607|NCT01098812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864608|NCT02604225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864609|NCT04165993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864610|NCT03931967|||COHORT||PROSPECTIVE|||||||
33864611|NCT05125289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864612|NCT03914391|||COHORT||PROSPECTIVE|||||||
33864613|NCT01103245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963375|NCT05350098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963376|NCT00952185|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963377|NCT02583178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177712|NCT05618613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864614|NCT03432351|||COHORT||PROSPECTIVE|||||||
33864615|NCT02191020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864616|NCT01210690|||COHORT||PROSPECTIVE|||||||
33864617|NCT01017588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33864618|NCT05556278|||CASE_ONLY||CROSS_SECTIONAL|||||||
33864619|NCT05378854|NA|SINGLE_GROUP||OTHER||NONE||Single Group: Clinical trials with a single arm A prospective, time-series design will be employed, whereby the LifeChamps platform will be deployed for a total of 3 months.||||
33963378|NCT00316576|||||PROSPECTIVE|||||||
33963379|NCT03782584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963380|NCT01178580|||COHORT||PROSPECTIVE|||||||
33963381|NCT01316588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33963382|NCT01070277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963383|NCT00116285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33963384|NCT02118207|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33963385|NCT03666546|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33963386|NCT03860519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864620|NCT03967379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177713|NCT05363020|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34177714|NCT06599931|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants are blinded from the type of intervention (sham, 50 Htz or 70 Htz)|"Three sessions active tACS 20 minutes, 50Htz active tACS 20 minutes, 70 Htz sham~Order will be randomized"|t|f|f|t
34177715|NCT05708196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177716|NCT06305364|NA|SINGLE_GROUP||SCREENING||NONE|Gastroenterologist performing standard of care colonoscopy post Gixam test will be blinded to the Gixam prediction score.|||||
34177717|NCT02012439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177718|NCT02541097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177719|NCT04531176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177720|NCT05362656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional, prospective, non-randomized, non-controlled, single-center clinical investigation as part of the premarket clinical evaluation of VX1+ (medical device).||||
33864621|NCT01368809|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34177721|NCT06596590|NA|SINGLE_GROUP||TREATMENT||NONE||Modified Water Vapor Thermal Therapy (REZUM) in Management of Patients With Large-volume Benign Prostatic Hyperplasia. The modified methods mainly include ablation optimization and combined imaging techniques.||||
34177722|NCT03747549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34177723|NCT06595017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864622|NCT00022048||||TREATMENT||||||||
33864623|NCT03971994|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33963387|NCT00913471|||COHORT||PROSPECTIVE|||||||
33963388|NCT03338088|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33963389|NCT04446819|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963390|NCT05448768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.||||
33963391|NCT00918229|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177724|NCT06604000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177725|NCT06285825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177726|NCT03392480|||CASE_CONTROL||PROSPECTIVE|||||||
34177727|NCT03459079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind, placebo-controlled trial.|A two arm randomized (1:1), double-blind, placebo-controlled, trial.|t|t|t|t
34177728|NCT05902117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864624|NCT06734533|||OTHER||RETROSPECTIVE|||||||
33864625|NCT05366920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
33864626|NCT01288222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864627|NCT01067755|||CASE_ONLY||PROSPECTIVE|||||||
33864628|NCT05672472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963392|NCT02673853|||CASE_ONLY||PROSPECTIVE|||||||
33963393|NCT03838588|||COHORT||PROSPECTIVE|||||||
33963394|NCT05115331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33963395|NCT04901871|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
33963396|NCT04496882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963397|NCT01834573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963398|NCT06567093|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33963399|NCT00973037|||CASE_ONLY||PROSPECTIVE|||||||
34177729|NCT06292286|NA|SINGLE_GROUP||TREATMENT||NONE||Neoadjuvant carboplatin and paclitaxel followed by cytoreductive surgery||||
34177730|NCT06406751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177731|NCT02039115|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34177732|NCT06604247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177733|NCT01962350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177734|NCT06222554|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34177735|NCT04939610|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177736|NCT03635892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single institution open-label phase II trial of cabozantinib and nivolumab in patients with advanced or metastatic non-clear cell Renal Cell Carcinoma (nccRCC), who have not received prior PD-1/PD-L1 directed therapy. This study is designed as separate cohorts defined by histology across three cohorts.||||
33864629|NCT02798822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864630|NCT02619968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864631|NCT04569409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34177737|NCT04389775|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"One of up to six (6) sequential cohorts (Cohorts A1 to A6). Participants in each cohort will be randomised to receive a single subcutaneous (SC) dose of either XW003 or matching placebo on Day 1 following an overnight fast. Two sentinel participants will receive a single SC dose of XW003 initially. If dosing of these sentinel participants proceeds without clinically significant safety signals in the first 48 hours post-dose, the remaining participants will receive a single dose of XW003 or placebo according to the randomisation schedule.~Participants in Cohorts B1 to B3 (n=10 per cohort) will be randomized to receive a single SC dose of either XW003 (n=8) or matching placebo (n=2) once weekly for 6 weeks. Doses will be administered following an overnight fast of at least 10 hours."|t|f|t|f
33864632|NCT04697043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Centralized randomization will take place immediately after the diagnosis of primary distant metastatic breast cancer, using computer-generated randomization. dominant location of distant metastases (bone, soft tissue (lymph nodes and subcutaneous metastases) and visceral metastases), hormonal receptor status (ER and/ or PR positive or both negative) and HER2Neu status (overexpression yes or no) will be recorded.||t|f|t|f
33864633|NCT00002920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864634|NCT03948633|RANDOMIZED|PARALLEL||OTHER||SINGLE|Students will not be aware of whether they are in the intervention or control group. Care providers who are trained in the intervention are aware of the group allocation. They will not communicate with care providers not trained in the intervention. Care providers that are trained in the intervention will not deliver care to participants in the control group and care providers that are not trained in the intervention will not deliver care to participants in the intervention group.|This is a feasibility study including 2 community health centres that have been randomly selected to either the multi-faceted knowledge translation intervention (CARD) or control (standard care) out of 8 community health centres anticipated to participate in a future cluster trial. Within each community health centre, 5 individual schools will be randomly selected to participate.|t|f|f|f
34177738|NCT06598644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177739|NCT06604494|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34177740|NCT05772390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177741|NCT05506384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34177742|NCT03160118|NA|SINGLE_GROUP||OTHER||NONE||||||
34177743|NCT05536336|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34177744|NCT04162288|RANDOMIZED|PARALLEL||OTHER||TRIPLE|When a participant is randomised to the trial, the private firm will assign a trial group following a pre-selected list of randomisation (given by the private firm). The employee of the private firm will be the one non-blinded in our study, by giving participant access to one of the formation. The ''Care Provider'' is not present in this study; in fact, all interactions are via the private firm and is directed towards an online-intervention. A randomisation list will be kept by the private firm and send to the research team after the data analysis. The Investigator are blinded also by the randomisation process. There is no officially Outcomes Assessor, because the outcomes of interest are self-reported (intention of using a DA) or pre-measured (for example; with the knowledge test, rightful answer are already known).|This is a multi-center, two-arm, controlled trial (RCT). Thirty-six participants will be randomly allocated to either 1) an experimental group that is exposed to our complete 3 hours online training program intervention (n = 18) or 2) a control group that is exposed to an intervention which will be a 3 hours online training program focused on prenatal screening.|t|t|t|f
34177745|NCT06088992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177746|NCT06000228|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177747|NCT03074136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|f|t|t
34177748|NCT05713656|||COHORT||PROSPECTIVE|||||||
34177749|NCT00791635|||COHORT||PROSPECTIVE|||||||
34177750|NCT03897777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34177751|NCT04305834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177752|NCT01203800|||||RETROSPECTIVE|||||||
34177753|NCT04570930|RANDOMIZED|PARALLEL||TREATMENT||NONE||This behavioral trial will use a 2-arm randomized controlled design.||||
34177754|NCT06597643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|statistician will be blind to the details of allocation and intervention in each group||t|f|f|t
34177755|NCT04266067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34177756|NCT06604377|||OTHER||RETROSPECTIVE|||||||
34177757|NCT06600841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864635|NCT02946632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864636|NCT06499025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864637|NCT06302647|||OTHER||PROSPECTIVE|||||||
33864638|NCT02367066|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33864639|NCT02887872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864640|NCT05933161|||COHORT||PROSPECTIVE|||||||
33864641|NCT00002355||||TREATMENT||||||||
33864642|NCT00137813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864643|NCT05558306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864644|NCT02208297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864645|NCT02434445|||COHORT||PROSPECTIVE|||||||
33864646|NCT01560923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864647|NCT01290705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864648|NCT01573078|||OTHER||CROSS_SECTIONAL|||||||
33864649|NCT04775225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|f|t|f
34177758|NCT05354596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Radiation: SBRT of central located and ultra-centrally located tumors in the lung. Primary lung tumors and lung metastasis from solid tumors.||||
34177759|NCT01522222|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34177760|NCT06597604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34177761|NCT02941263|||COHORT||PROSPECTIVE|||||||
34177762|NCT06601127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177763|NCT05617755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177764|NCT01292486|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177765|NCT06470971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177766|NCT02367898|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34177767|NCT06035068|||COHORT||PROSPECTIVE|||||||
34177768|NCT05854966|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II, Simon's two-stage study evaluating the feasibility and effectiveness of combination CPI-613 and metformin in relapsed or refractory acute myeloid leukemia. The first stage will consist of 9 evaluable patients. If the study continues to stage 2, a total of 17 evaluable patients will be enrolled.||||
34177769|NCT01375829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177770|NCT05884645|||COHORT||PROSPECTIVE|||||||
34177771|NCT00900653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177772|NCT06600828|||COHORT||RETROSPECTIVE|||||||
34177773|NCT06067802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177774|NCT06599814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34177775|NCT00632229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177776|NCT05777486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34177777|NCT06589193|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||4-day plaque regrowth study model|t|t|t|t
34177778|NCT06585098|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study was planned with two groups (control, intervention). In order to prevent information sharing between groups, at the beginning of the research, the students involved in the study were asked to keep the information and documents given to them confidential. In addition, in order to prevent influence and information exchange, the control group was first invited to the application, then the game was sent to the intervention group and they were allowed to play the game for a week, and then the intervention group was put into the application.|The intervention is a study with an experimental model with a control group.|t|f|f|f
34177779|NCT06588816|||OTHER||CROSS_SECTIONAL|||||||
34177780|NCT06279000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, anaesthesia providers and all other health care workers involved in the treatment and the study personal will be blinded to the group allocation by provision of equal looking study drugs (verum and placebo), which are repacked for blinding.|randomized, double-blinded, placebo-controlled, multicenter|t|t|t|t
33864650|NCT06494930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33864651|NCT05334017|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33864652|NCT00493220|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33864653|NCT03268733|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open trial||||
33864654|NCT00076492|RANDOMIZED|||TREATMENT||DOUBLE||||||
33864655|NCT00343876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864656|NCT05555355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center study||||
33864657|NCT05223751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864658|NCT03239483|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33864659|NCT00640484|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33864660|NCT06167603|||COHORT||PROSPECTIVE|||||||
33864661|NCT03184324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864662|NCT00271778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33963400|NCT03527537|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a randomized, controlled trial of 284 women with a diagnosis of GDM. Women will be consented and randomized at the time of their diagnosis. All women with GDM will receive counseling regarding diet and exercise and instructions on self-monitoring blood glucose values. The investigators will apply cutoffs of 95 mg/dL for fasting and 120 mg/dL for 2-hour post-prandial levels. Once randomized, the first treatment arm will be assigned to a limit of 20% abnormal values before we start treatment and to titrate up dosages as needed, while using the 20% threshold of abnormal CBG values at each subsequent review of glucose log. To specify, if more than 20% of values for the week are elevated, treatment would be initiated. Once treatment is initiated, the dosage of medication will be adjusted with cutoff of 20% of abnormal values per week. The second treatment arm will utilize the same protocol, however, the limit to start medications or adjust dosages will be 40% abnormal values.||||
33963401|NCT04810507|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Multi-center, Active controlled, Randomized, Double-blinded, Parallel Study||||
33963402|NCT03168269|||COHORT||PROSPECTIVE|||||||
33963403|NCT05799859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963404|NCT01918982|||COHORT||PROSPECTIVE|||||||
33963405|NCT01589029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963406|NCT00618631|RANDOMIZED|PARALLEL||SCREENING||||||||
33963407|NCT04603079|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A total of 200 nurses will be sampled. A 100 nurses each will be randomly assigned to the control and experiment group each.||||
34177781|NCT03038061|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group assignment. Approx. 20 patients during laparoscopic surgery with capnoperitoneum.||||
34177782|NCT05962541|RANDOMIZED|PARALLEL||TREATMENT||NONE||Italian, single-center, phase IV, open-label, randomized controlled trial, with patients randomized in a 1:1 ratio to one of two arms||||
34177783|NCT06030648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177784|NCT05826314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study includes a quasi-experimental design (non-randomized controlled trial), with repeated measures.||||
34177785|NCT06592105|||COHORT||RETROSPECTIVE|||||||
34177786|NCT06599970|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33864663|NCT05829590|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33864664|NCT01159613|||||PROSPECTIVE|||||||
33864665|NCT04409275|||CASE_ONLY||PROSPECTIVE|||||||
33864666|NCT00252304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963408|NCT06007573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33963409|NCT04951973|||COHORT||PROSPECTIVE|||||||
34177787|NCT05733832|RANDOMIZED|CROSSOVER||TREATMENT||NONE|No masking; all sites will start out as control groups and all will eventually cross over to the TLC model. All sites will know into which group their and all other sites are enrolling.|This study is a stepped-wedge randomized trial of 1,000 patients with advanced liver disease at four high-volume centers over 45 months (250 participants/site; \<6 participants/site/month) to evaluate the efficacy of the Transitional Liver Clinic (TLC) compared to control. In the stepped-wedge design, all sites provide usual care (control) during the initial 9-month enrollment interval. At each subsequent 9-month interval, one site is randomized via a computer-generated randomization scheme to crossover to implement the TLC, which will continue through the final interval where all sites will have implemented the TLC. All sites enroll for the entire 45 months and thus contribute patients to both the control and TLC groups.||||
34177788|NCT06603662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, single-blinded controlled trial|t|t|f|t
34177789|NCT01485029|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34177790|NCT00441909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34177791|NCT05223920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177792|NCT01394016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864667|NCT03512639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The medications were packed in bottles, each containing 5 grams of the preparation, and consecutively numbered. The prefix 'A' indicated Arnica montana, and 'B' Bellis perennis .~Participants were randomly allocated into groups given either homeopathic medication (Arnica montana C30 and Bellis perennis C30) or placebo (alcohol 40% and alcohol 40%) in a 1:1 ratio. . The randomization code was held in confidence and the code was not broken until the data analysis. The same randomization list was used to blind the Arnica montana and the Bellis perennis, creating similar pairs. The placebos and the active medication were indistinguishable in appearance, taste and smell."|RCT|t|t|t|f
33864668|NCT06493487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33864669|NCT05985642|||COHORT||PROSPECTIVE|||||||
33864670|NCT01073241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864671|NCT00417040|NA|SINGLE_GROUP||OTHER||NONE||||||
34177793|NCT05306899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34177794|NCT06588803|||OTHER||OTHER|||||||
34177795|NCT06591377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive loading doses of cilostazol and aspirin or ticagrelor and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 900 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included cilostazol. Both groups received an open-label loading dose of 300 mg of aspirin and continued on aspirin 75 mg daily.|The investigators will conduct our single-blinded randomized controlled trial, which will contain two arms; the cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day). The ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd to the 90th day). Both groups received an open-label loading dose of 300 mg aspirin and continued on open-label aspirin 75 mg daily.|f|f|t|t
34177796|NCT00269061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34177797|NCT05823363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|f|t
34177798|NCT06587607|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single non-randomized group will be used to gather evaluation data on needed modifications to enhance program fit to the SCI population needs to develop a tailored curriculum for SCI. Outcomes will involve pre-post evaluation of measures to determine if there are any direct or indirect impacts of the mindfulness program as a preliminary feasibility study.||||
34177799|NCT05294978|||CASE_CONTROL||RETROSPECTIVE|||||||
34177800|NCT02867436|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177801|NCT06103500|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Statistical analyst will be blind to treatment allocation.|Cluster Randomized Cross-Over Trial||||
34177802|NCT01869907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177803|NCT02480972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177804|NCT06171009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177805|NCT06590909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177806|NCT06600165|||COHORT||CROSS_SECTIONAL|||||||
33864672|NCT06544694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864673|NCT02376608|RANDOMIZED|CROSSOVER||||NONE||||||
33864674|NCT01514136|NA|SINGLE_GROUP||||NONE||||||
33864675|NCT05484570|||COHORT||PROSPECTIVE|||||||
33864676|NCT01054950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33864677|NCT04959955|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864678|NCT04389190|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a single center non blinded quasi experimental design. Data will be collected prospectively.||||
33864679|NCT02376556|||CASE_CONTROL||PROSPECTIVE|||||||
33864680|NCT02462213|||OTHER||PROSPECTIVE|||||||
33864681|NCT00655447|||COHORT||PROSPECTIVE|||||||
33864682|NCT00334945|||COHORT||PROSPECTIVE|||||||
33864683|NCT03247426|||COHORT||PROSPECTIVE|||||||
33864684|NCT01237340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864685|NCT02142907|||CASE_CONTROL||PROSPECTIVE|||||||
33864686|NCT03491839|||CASE_ONLY||RETROSPECTIVE|||||||
33864687|NCT00956267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864688|NCT00524849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864689|NCT06727110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33864690|NCT06724978|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33864691|NCT01767051|||CASE_CONTROL||PROSPECTIVE|||||||
33864692|NCT05312489|||COHORT||OTHER|||||||
33864693|NCT00407654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864694|NCT04987567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Double blind study|Is not a drug, is a food supplement.|t|t|t|f
33864695|NCT06502106|NA|SINGLE_GROUP||TREATMENT||NONE||Prolonged exposure will be offered in a brief digital format with therapist support for three weeks. Treatment comprises of psychoeducation, rationales, in vivo exposure, imaginal exposure and relapse prevention.||||
33864696|NCT00127868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864697|NCT01491295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864698|NCT03715153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||6-month, randomized, double-blind, placebo-controlled, parallel groups followed by an open label active 6-month treatment period with bumetanide.|t|t|t|t
33864699|NCT05362383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864700|NCT04338828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864701|NCT00909181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864702|NCT05737706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33864703|NCT03533413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864704|NCT05425069|||CASE_CROSSOVER||PROSPECTIVE|||||||
33864705|NCT00932425|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864706|NCT06322225|||CASE_CONTROL||PROSPECTIVE|||||||
33864707|NCT03632109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864708|NCT01412554|||COHORT||OTHER|||||||
33864709|NCT02125305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864710|NCT02994420|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864711|NCT01956825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864712|NCT00832117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864713|NCT04910113|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864714|NCT01873716|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864715|NCT06035991|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864716|NCT05611788|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants are pseudo-randomly assigned (matched for age, sex, intelligence and flexibility) to one of the following intervention groups: (1) Structure Learning and (2) No training (Passive Control)|t|f|f|f
33963410|NCT02915588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963411|NCT04175873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients will be listening to music with MP3 headphones for 1 hour preoperatively and throughout the operation.|The patients will be listening to music with MP3 headphones for 1 hour preoperatively and throughout the operation.|f|t|f|f
33963412|NCT05970809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly allocated at a 1:1 ratio to receive treatment with Device type A or B.||t|f|t|f
33963413|NCT05154188|||COHORT||PROSPECTIVE|||||||
33963414|NCT02253654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963415|NCT04765852|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34177807|NCT04340505|||COHORT||PROSPECTIVE|||||||
34177808|NCT05433662|||COHORT||PROSPECTIVE|||||||
34177809|NCT04124848|||COHORT||PROSPECTIVE|||||||
34177810|NCT05148156|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm study, involving one time administration of Urolift in outpatient setting prior to stereotactic body radiation therapy||||
34177811|NCT06559267|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|(participants will be masked during randomization process, after randomization they will be informed which condition they receive. Outcomes assessors will be masked to randomization and randomization outcome to the best of our ability)|All schools that participate in the study will receive Remaking Recess. Additionally, half of the schools will be randomized to receive TEAM, an additional implementation support intervention.|t|f|f|t
34177812|NCT06587126|||COHORT||PROSPECTIVE|||||||
34177813|NCT06056297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177814|NCT01650532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34177815|NCT06382727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||CONTINUE is a multi-centre, open-label, prospective parallel, pilot randomised controlled trial being conducted in Australia.||||
34177816|NCT04370691|||COHORT||PROSPECTIVE|||||||
34177817|NCT02731469|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177818|NCT04476862|||COHORT||PROSPECTIVE|||||||
34177819|NCT04521413|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion for monotherapy and combination arms with pembrolizumab||||
33864717|NCT04874181|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Arm study||||
33864718|NCT05778188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded study team members (eg, Investigators and study staff) and participants' parent(s)/legal guardian(s) will be blinded to treatment group assignments throughout the study.|Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study|t|t|t|t
33864719|NCT00809523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864720|NCT02684513|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33864721|NCT05370716|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (open label)|"* Group A: Pregabalin + Polmacoxib~* Group B: Polmacoxib~* Group C: Pregabalin"||||
33864722|NCT00050765|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33864723|NCT06404268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial with the study group and control group|f|f|f|t
33864724|NCT00978835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864725|NCT03686956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963416|NCT02595528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963417|NCT05663931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963418|NCT03933839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963419|NCT01268319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963420|NCT02522754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33963421|NCT05177237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177820|NCT04236817|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label randomized controlled trial. The patient population included 114 patients, followed by primary care physicians at the Cleveland Clinic Stephanie Tubbs Jones Health Center, taking four or more medication doses daily. They were randomized either to the intervention group or the control group. Patients in the intervention group received prescriptions pre-packaged in individual packets that were delivered by the pharmacy. Patients in the control group continued to receive medications from pharmacies as they did prior to enrollment. The primary outcome was the percentage of missed pills in the intervention group versus the control group after four months of enrollment. The secondary outcome was the number of daily doses missed. The number and percentages of missed pills for each subject was calculated and summarized by group. The primary analysis compared the mean percentage of missed pills between the two groups using t-test analysis.||||
34177821|NCT06602999|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177822|NCT05922878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177823|NCT06526676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177824|NCT06603753|||COHORT||PROSPECTIVE|||||||
34177825|NCT01474317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864726|NCT05575154|||COHORT||CROSS_SECTIONAL|||||||
33864727|NCT00120263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864728|NCT03653104|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|This is a safety and feasibility pilot with a single intervention arm, an education control arm, a usual care control arm, and an interview only arm. The intervention arm includes participation in the melodica training program and education about pulmonary health. The education control arm includes pulmonary health education only. The interview only arm includes participation in a semi-structured interview about facilitators and barriers to participation.||||
33864729|NCT02615704|||OTHER||OTHER|||||||
33864730|NCT00427089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864731|NCT02232620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065266|NCT06079632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In the first experiment, multiple baseline design will be used to examine the feasibility of the interventions. Each participant will first receive parent-child interaction strategy coaching every week via Telehealth, followed by sensory processing strategy coaching (C1) provided every week via Telehealth. In the second experiment, RCT design will be applied to explore the efficacy of the interventions. Participants will be randomly allocated to the treatment group or the control group. The intervention group will receive weekly, one-on-one parent-child interaction and sensory processing strategy coaching via Telehealth for 12 weeks. The control group will be provided with weekly self-learning materials and group discussion session for 12 weeks. Measures will be taken at pre-test, post-test, and 3-month follow-up.|f|f|t|t
34065267|NCT04793373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065268|NCT02453256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065269|NCT04769739|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34065270|NCT05731752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065271|NCT03602625|||CASE_CONTROL||PROSPECTIVE|||||||
34065272|NCT00256620|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34065273|NCT01814215|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34065274|NCT00211315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065275|NCT04265300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34177826|NCT01831024|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34177827|NCT01910285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864732|NCT05919290|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33864733|NCT00457873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893883|NCT04714372|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is performed in two stages, with Stage 1 having two potential steps. A minimum of 28 days separates each patient cohort. Stage 1 step 1 uses a fast-track design (1 patient per cohort) starting at Dose Level 1. The study moves to Stage 1 Step 2 when a pre-defined adverse event occurs during fast-track enrollment, specifically, any Grade 3 non-hematologic event within 72 hours after an FT538 infusion. The cohort size increases from 1 to 3 patients with 2 additional patients added to the current cohort if the event being a Dose Limiting Toxicity (DLT) event. No intra-cohort staggering is required. Escalation in Step 2 continues until the 1st DLT event at which point Stage 2 (CRM) is activated. Stage 2 follows Continual Reassessment Method (CRM) and is initiated at the 1st DLT||||
34065276|NCT06141421|||COHORT||CROSS_SECTIONAL|||||||
34065277|NCT05387694|NA|SINGLE_GROUP||OTHER||NONE||||||
33864734|NCT05949996|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This study will use a stepped wedge cluster randomized controlled trial design in which the intervention is introduced stepwise across study units. All study units will be asked to sign a consent form for study participation and will start with the 4-month control situation (i.e. No nurse-led symptom distress screening program at the beginning of the study). Then, the study units are randomized to one of the three roll-out schedules with a 4-month duration each. At each time point, a new group of 2 or 3 study units will cross over from the control condition to the implementation condition. For each eligible patient who is approached and being screened for symptom distress, the HA nursing staff will explain the objective of the symptom distress screening and obtain written consent for agreeing to participate in the screening program.||||
34177828|NCT03197298|||COHORT||PROSPECTIVE|||||||
33864735|NCT02137122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963422|NCT04895228|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be a prospective, single-center, randomized, blind clinical trial. It will be performed on patients following in the rheumatology and rehabilitation department in Sohag University Hospitals, Faculty of Medicine:~N=60 fulfilling ASAS 2010 criteria for axial SpA, will be divided randomly into 2 groups. Group 1 the active group will receive triamcinilone 40 mg injection (Kenacort) + 4 ml of .5 % lidocaine hydrochloride (Xylocaine) under ultrasound guidance. Group 2 will receive similar amount of saline injecteed subcutaneously. Only the patient will be blinded. Particpants will be initially studied with no certain condition for medications wich will be kept unchanged during the study. MRI will be done at base line and BME will be considered as an entry criteria. SPArcc score will be berfoemed at baseline and in the follow-up at 24 weeks post-injection."||||
34177829|NCT00549146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33963423|NCT00000773||||PREVENTION||NONE||||||
33963424|NCT06307327|||COHORT||PROSPECTIVE|||||||
33963425|NCT02123069|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33963426|NCT00783562|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34177830|NCT05446129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963427|NCT00089115|RANDOMIZED|||TREATMENT||DOUBLE||||||
33963428|NCT06284707|NON_RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The care provider will be responsible for administering the training program. Two different people will develop swimming training and rhythmic gymnastics training. Each participant will be assigned a code. The researcher will process the data with the code of each participant.||t|t|t|f
33963429|NCT02434575|||CASE_CONTROL||PROSPECTIVE|||||||
33963430|NCT02897453|||COHORT||PROSPECTIVE|||||||
33963431|NCT05165433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963432|NCT04445129|||COHORT||PROSPECTIVE|||||||
33963433|NCT00787670|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33963434|NCT05001399|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot and Feasibility Study||||
33963435|NCT02688309|||COHORT||PROSPECTIVE|||||||
33963436|NCT00844727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34177831|NCT06596252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177832|NCT06582160|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individuals are assigned to one of three conditions upon enrollment: 1) Long form screening; 2) Short form screening; 3) control||||
34177833|NCT06593470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177834|NCT06597552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician was blind.||f|f|f|t
34177835|NCT05097079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|A Phase 3, multicenter, randomized, double-blind, placebo-controlled, single treatment study designed to assess the efficacy, safety, and tolerability of 2 dose levels of MYOBLOC compared to placebo for the treatment of chronic sialorrhea in pediatric subjects ages 3 to \< 17 years.|t|t|t|t
34177836|NCT02231086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864736|NCT00680823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864737|NCT06117371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase Ⅰa:~Six dose levels are carried out, and the initial dose of BEBT-607 tablets is set as 100mg/ day. The climbing study is carried out by accelerated titration method combined with 3+3 mode.~Phase Ⅰb:~According to the pharmacokinetics, safety, and preliminary efficacy results of phase Ⅰa , one to three cohorts with target dose or tumor species are selected for dose extension trial, in which participants receive continuous administration of the experimental drug BEBT-607 tablets until disease progression or toxicity became intolerable or patients stopped or died."||||
33864738|NCT01852682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864739|NCT04643314|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the nature of the intervention, the participants (resident trainees) cannot be blinded, however the assessors (attending surgeons) who will rate performance will be unaware of group allocation. Any inadvertent unblinding will be reported.|The study will be a parallel, two-groups, assessor-blind, single-center, pilot randomized controlled trial.|f|f|f|t
33864740|NCT00121693|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33963437|NCT05532046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963438|NCT01631370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963439|NCT04493385|||COHORT||RETROSPECTIVE|||||||
33963440|NCT00508235|||CASE_ONLY||PROSPECTIVE|||||||
33963441|NCT03362528|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963442|NCT05269017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blinded to the patient's group||f|f|f|t
33963443|NCT04667273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The sample of the study will consist of patients with subacromial impingement syndrome (SIS) who were referred to Istanbul University Cerrahpaşa Physical Therapy and Rehabilitation Department by an orthopedist. Forty eight SIS patients will be included in the study. Patients who meet the inclusion criteria will be divided into two groups.~Group 1: Exercise Training+ Neuromuscular Electrical Stimulation Group 2: Exercise Training"|t|f|f|f
33963444|NCT06439264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963445|NCT02072174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963446|NCT01355523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963447|NCT06481423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963448|NCT00831467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963449|NCT04093167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963450|NCT05976217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963451|NCT05474937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective randomized clinical trial||||
33963452|NCT03324022|||CASE_CONTROL||PROSPECTIVE|||||||
34065278|NCT04510389|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will receive indistinguishable sachets containing 30g of maltodextrin (placebo) or 30g whey protein. The sachets codification and patient allocation will be prepared by an individual without any contact with patients or the team which will follow patients|randomized|t|f|t|f
34177837|NCT05847517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both metoprolol and saline are supplied in 5 ml ampoules of the same shape, structure and colour|"Randomization (1:1) will be stratified according to the severity of ARDS and by participating centre:~* Moderate (PaO2/FiO2 of 100-200 mmHg).~* Severe (PaO2/FiO2 ≤100 mmHg)."|t|t|t|t
34177838|NCT03002870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177839|NCT06426342|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34177840|NCT05207774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34177841|NCT04583618|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34177842|NCT04272242|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177843|NCT05273645|||OTHER||RETROSPECTIVE|||||||
34177844|NCT06603194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34177845|NCT03811821|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants who do not demonstrate at least a 75% reduction in FI following a 4-week trial of EMM will be randomized to one of two treatments (INJ or BIO) and assessed after three months. All participants who experience a 75% decrease in FI after three months of treatment, compared to baseline, will then be followed-up for two years. To assess the long-term response to treatment, those who demonstrate an improvement of less than 75% in FI episodes will be offered an additional treatment with either the treatment to which they were not initially randomized or SNS.~An anticipated 285 participants will be enrolled in the EMM to ensure a sample size of 97 in each of the two treatments arms."||||
34177846|NCT06599034|||COHORT||PROSPECTIVE|||||||
34177847|NCT06493864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864741|NCT01062945|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33864742|NCT02320955|||CASE_ONLY||PROSPECTIVE|||||||
33864743|NCT03209934|||COHORT||RETROSPECTIVE|||||||
33864744|NCT05812040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864745|NCT06736028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864746|NCT01566682|||CASE_ONLY||PROSPECTIVE|||||||
33864747|NCT02843685|||||RETROSPECTIVE|||||||
33864748|NCT05137496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864749|NCT00313222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864750|NCT01903291|||COHORT||PROSPECTIVE|||||||
33864751|NCT01672034|||CASE_ONLY||PROSPECTIVE|||||||
33864752|NCT04597814|||COHORT||RETROSPECTIVE|||||||
33864753|NCT03384914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864754|NCT02872077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33864755|NCT03565276|NA|SINGLE_GROUP||PREVENTION||NONE||As part of the dose-escalation design, the investigators will start with 5mg/kg, half the smallest described dose, on a sample of up to 5 women. They will continue to administer TxA doses in increments of 5mg/kg to each successive batch of 5 women. If the number of treatment successes cannot statistically rule out a value \< 75% (\< 4 of 5 women are successes due to values in the low range), the dose will be increased by 5mg/kg for the next set of 5 women, and so on, until a maximum dose of 30mg/kg is reached, a dose deemed safe based on earlier studies in different populations. Once treatment success is determined at a certain dose, i.e. 4/5 women have levels in the therapeutic range), a total of 20 women will be administered that dose to ensure that 75% i.e. 18/20 women are successes at that dose.||||
33864756|NCT00578786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177848|NCT06589700|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864757|NCT01655927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34177849|NCT05782283|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33864758|NCT02236884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864759|NCT06006663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864760|NCT04272541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33864761|NCT01129726|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33864762|NCT05656625|||OTHER||RETROSPECTIVE|||||||
33864763|NCT02900183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864764|NCT03517189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864765|NCT01290055|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33864766|NCT05135026|RANDOMIZED|PARALLEL||TREATMENT||NONE|One research staff, who will not be involved any of the research activity of this trial, will do this randomization.|From the urban area \[Dhaka Medical College \& Hospital (DMCH) and Sir Salimullah Medical College \& Hospital (SSMCH)\], we will randomly select one hospital for intervention group and another hospital for the control group and from the rural area (Munsigonj General Hospital and Savar Upazila Health Complex), one hospital will be randomly selected as intervention site and other hospital will be selected as comparison site.||||
33864767|NCT05097729|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||All participants will receive all the 3 modalities of stimulation in a randomized order. Each round is composed by 5 daily sessions of stimulation. Participants will have a second MRI only after Modality one (hippocampal).|t|t|f|t
33864768|NCT06387121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864769|NCT01131949|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864770|NCT03015519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864771|NCT00182182|RANDOMIZED|PARALLEL||ECT||NONE||||||
33864772|NCT06022783|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The data analysed by a independent researcher from the data collection and coding procedures.|crossover designed randomized controlled study|f|f|f|t
33864773|NCT00644553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33864774|NCT03482687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864775|NCT02977754|||COHORT||PROSPECTIVE|||||||
33864776|NCT06147570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864777|NCT01530412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34177850|NCT00566774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33864778|NCT00587392|||COHORT||PROSPECTIVE|||||||
33864779|NCT06179329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864780|NCT04662398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Case control|t|t|f|t
33864781|NCT01766726|||COHORT||PROSPECTIVE|||||||
33864782|NCT06428981|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33864783|NCT00581685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177851|NCT06384469|||COHORT||PROSPECTIVE|||||||
34177852|NCT06450418|||COHORT||PROSPECTIVE|||||||
34177853|NCT05665634|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-subject design. Each participant will undergo the same TMS/EEG procedures twice with one week in between sessions.||||
33864784|NCT02952040|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33864785|NCT04559204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33864786|NCT04414371|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized waitlist control cross over||||
33864787|NCT02938481|||COHORT||PROSPECTIVE|||||||
33864788|NCT02416752|||CASE_CONTROL||PROSPECTIVE|||||||
33864789|NCT04263012|||COHORT||PROSPECTIVE|||||||
33864790|NCT04062773|RANDOMIZED|PARALLEL||TREATMENT||NONE||12 week parallel trial.||||
33864791|NCT00058695|||CASE_CONTROL||PROSPECTIVE|||||||
33864792|NCT03583450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864793|NCT05336916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864794|NCT04052529|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33864795|NCT02920424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864796|NCT03827772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177854|NCT06462937|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The randomization is performed by a study personnel not involved in data collection. Patients are asked not to inform their care-giver or the physiotherapist who perform the study tests which group the patient is allocated to.|"Baseline: randomization to intervention (Exercise) or control (Usual care) 1:1.~3 months: randomization to intervention (Exercise remotely delivered plan with personalised weekly follow-up) or control (Exercise remotely delivered plan without weekly follow-up)"|f|t|f|t
34177855|NCT02862678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177856|NCT05387122|||CASE_ONLY||PROSPECTIVE|||||||
34177857|NCT04715191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177858|NCT06548152|||COHORT||RETROSPECTIVE|||||||
33864797|NCT04952740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864798|NCT02560116|||COHORT||PROSPECTIVE|||||||
33864799|NCT00409929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864800|NCT02912416|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33864801|NCT04229511|||COHORT||PROSPECTIVE|||||||
33864802|NCT03477513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864803|NCT03505385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33864804|NCT03841695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33864805|NCT05354076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864806|NCT03965078|||COHORT||PROSPECTIVE|||||||
33864807|NCT00914992|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33864808|NCT03339869|NA|SINGLE_GROUP||OTHER||NONE||patient hospitalized in intensive care unit||||
33864809|NCT02501382|||COHORT||PROSPECTIVE|||||||
33864810|NCT04085796|||OTHER||CROSS_SECTIONAL|||||||
33864811|NCT00514774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864812|NCT00617136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864813|NCT04611620|||CASE_ONLY||CROSS_SECTIONAL|||||||
33864814|NCT03870516|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with rheumatic severe mitral regurgitation||||
33864815|NCT01561625|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33864816|NCT06346184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33864817|NCT01369823|||CASE_ONLY||PROSPECTIVE|||||||
33864818|NCT05687903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33864819|NCT01388231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864820|NCT00323908|||COHORT||PROSPECTIVE|||||||
33864821|NCT03610399|RANDOMIZED|PARALLEL||TREATMENT||NONE||We plan to compare 3 different regimens of primaquine for P. vivax treatment.||||
33864822|NCT04055181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33864823|NCT01236664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864824|NCT03779919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33963453|NCT04403373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded from the group allocation and the participants are instructed not to reveal what kind of intervention he/she received.||f|f|f|t
33963454|NCT01067859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963455|NCT00084617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963456|NCT05200806|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Cohort Study, without randomization, and evaluation of a single intervention.||||
33963457|NCT05761132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963458|NCT05660473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864825|NCT00264524|NON_RANDOMIZED|||DIAGNOSTIC||NONE||||||
33864826|NCT03000088|||CASE_CONTROL||PROSPECTIVE|||||||
33864827|NCT01681628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864828|NCT04327830|||CASE_ONLY||RETROSPECTIVE|||||||
33864829|NCT03351881|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33864830|NCT00659399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864831|NCT01536457|||||RETROSPECTIVE|||||||
33864832|NCT05491252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data Collectors / Outcome Assessors will be blinded of which treatment group subject is assigned to.|In parallel arm design, subjects are randomized to one or more study arms and each study arm will be allocated a different intervention. After randomization each subject stays in their assigned treatment arm for the duration of the study. Subjects receive the same treatment throughout the trial. The results are then compared.|f|f|f|t
33963459|NCT04778007|||CASE_CONTROL||PROSPECTIVE|||||||
33963460|NCT00525564|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33963461|NCT03634488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation was concealed from all other study personnel, except statisticians.|A 12-week, open label, randomized controlled feasibility trial in children with sickle cell anemia between 5 and 12 years of age to treat uncomplicated severe malnutrition.|f|f|t|f
34177859|NCT06204705|||CASE_ONLY||PROSPECTIVE|||||||
34177860|NCT04446416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177861|NCT06593184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial, double blinded (therapist/avaluator, patient) Initial avaluation, followed by 10 days of treatment, followed by a revaluation immedeatly after and follow-up 30 days after finishing.|t|t|t|f
34177862|NCT06592170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177863|NCT03136887|||COHORT||PROSPECTIVE|||||||
34177864|NCT05842889|||COHORT||PROSPECTIVE|||||||
34177865|NCT01048593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33864833|NCT05558826|||COHORT||PROSPECTIVE|||||||
33864834|NCT01029977|||CASE_ONLY||CROSS_SECTIONAL|||||||
33864835|NCT00496236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864836|NCT01829360|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Research assistants that collect and score the pre/post outcomes are blind to arm assignment.||f|f|f|t
33864837|NCT00143065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864838|NCT01603329|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34177866|NCT03063528|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177867|NCT06347705|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177868|NCT06498206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751720|NCT05886270|NA|SINGLE_GROUP||PREVENTION||NONE||A total of 300 homes in Baltimore City and Baltimore County will be studied, which will be referred from two of GHHI's currently active programs, DSS Foster Care Homes Program (FCHP, n=200 homes) and Amerigroup Maryland Asthma Program (AMAP, n=100 homes), which are Medicaid eligible children referred from Amerigroup-Maryland into GHHI's asthma home-visiting program. The investigators selected families in FCHP and AMAP because they are a representative and generalizable population of low-income children known to have a greater risk of home injuries.||||
33751721|NCT04326543|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751722|NCT01527734|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33963462|NCT04434638|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Every other patient admitted to the stroke service (i.e. those enrolled first, third, fifth, seventh, etc.) will be allocated to receive the intervention whereas patients falling between those admissions will be allocated to the control group.|"Participants in this study will be derived from the pool of patients admitted for ischemic stroke to Georgetown University Medical Center. Patients admitted for a primary diagnosis of ischemic stroke with discharge plan for acute rehab or home will be included in this study.~Upon admission, patients will be randomized to receive the standard diagnostic studies and treatment for ischemic stroke under the care of either a transitions of care coordinatory (TOCC group) or the standard evidenced-based protocol of transitioning from acute care hospital to acute rehab setting (Control group). Due to the prospective nature of the study protocol, randomization will be performed based on the order in which the patients are enrolled in the trial."|t|f|f|f
33963463|NCT00002227||||TREATMENT||||||||
33963464|NCT04831801|||COHORT||PROSPECTIVE|||||||
33963465|NCT04521439|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963466|NCT00367679|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177869|NCT06072794|NA|SINGLE_GROUP||TREATMENT||NONE||This is a dose escalation study. The study participants are organized in groups of 3 where each participant will receive one study treatment.||||
34177870|NCT06522256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Transversal, non-comparative, multicenter study.||||
34177871|NCT02905461|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34177872|NCT02208310|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34177873|NCT06601985|||COHORT||PROSPECTIVE|||||||
34177874|NCT05416203|NA|SINGLE_GROUP||TREATMENT||NONE|No masking will occur as this is a one-arm trial.|Participants will all be enrolled to receive the active intervention, Brief Enhanced Anxiety Sensitivity Treatment.||||
34177875|NCT04146597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177876|NCT06598735|NA|SINGLE_GROUP||TREATMENT||NONE||monotherapy||||
34177877|NCT02678949|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34177878|NCT06478277|||COHORT||PROSPECTIVE|||||||
34177879|NCT06595186|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34177880|NCT06305182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-controlled, double-blind, randomized trial. The efficacy of Metreleptin in Anorexia Nervosa patients will be tested against an inactive Placebo.|t|t|t|t
33751723|NCT03074630|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open Label|||||
33751724|NCT05958121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751725|NCT04609891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864839|NCT02939989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864840|NCT03934255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Constant routine protocol in Blacks with dipping and non-dipping blood pressure||||
33864841|NCT00643526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864842|NCT06086093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33864843|NCT02645929|||COHORT||PROSPECTIVE|||||||
33864844|NCT03407404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Drugs will be premixed and coded for ketamine-midazolam or morphine-midazolam. The colorless drug mixture shall be provided to the attending physician to start the infusion at 2ml/hour and to be titrated to the desired level of sedation.~The investigator and participant will be unaware of which group a certain patient is under."|Patients will be randomized to either receive ketamine-midazolam or morphine-midazolam for continous sedation at enrollment, then followed up for outcomes.|t|f|t|f
33864845|NCT00847184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864846|NCT02123316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864847|NCT00691990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864848|NCT00146081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864849|NCT03892512|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33864850|NCT02611661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864851|NCT02975492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864852|NCT01049243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864853|NCT05065931|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33864854|NCT04603365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864855|NCT06494384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33864856|NCT02022085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864857|NCT00034190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864858|NCT05989802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864859|NCT03575078|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 Dose Escalation||||
33864860|NCT02786134|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The CIRT-CFR study is a sub-study based off the main CIRT trial.|t|f|t|f
33864861|NCT01444014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864862|NCT02316184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33864863|NCT05440396|||COHORT||PROSPECTIVE|||||||
33864864|NCT06087887|||OTHER||RETROSPECTIVE|||||||
33864865|NCT05259579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864866|NCT04549727|||CASE_CONTROL||PROSPECTIVE|||||||
33864867|NCT05041023|||COHORT||PROSPECTIVE|||||||
33893884|NCT03419793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177881|NCT03913936|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864868|NCT04546568|RANDOMIZED|CROSSOVER||TREATMENT||NONE|"This study is randomised but not blinded. Infants will be randomised to commence on either automated (servo) control using either Leoni plus CLAC or IntellO2, Vapotherm. SpO2 (range 90-95%) will be continuously monitored as per normal standard of care.~To remove selection bias the 20 infants will be randomised using sealed, windowless, envelopes. Half will instruct to commence on automated (servo) control using Leoni plus CLAC (Leoni plus, Löwenstein Medical, Germany) to target SpO2 to 90-95%, and half will have instructions to commence on automated (servo) control using IntellO2 Precision Flow (IntellO2, Vapotherm, USA)."|This is a randomised cross-over study of servo-controlled oxygen targeting in premature infants, with infants acting as their own controls||||
33864869|NCT02468596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864870|NCT04450563|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33864871|NCT01776736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864872|NCT00283036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864873|NCT03286049|||OTHER||PROSPECTIVE|||||||
33864874|NCT00741325|||||PROSPECTIVE|||||||
33864875|NCT02572791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177882|NCT05587764|||CASE_ONLY||OTHER|||||||
34177883|NCT06399952|||COHORT||PROSPECTIVE|||||||
34177884|NCT04163341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963467|NCT04874220|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34177885|NCT06452784|||COHORT||PROSPECTIVE|||||||
34177886|NCT05589662|||CASE_CONTROL||PROSPECTIVE|||||||
33963468|NCT03325452|NA|SINGLE_GROUP||OTHER||NONE||The hypothesis of our study is that the evaluation of the initial lactate in the early cardiopulmonary resuscitation could be a prognostic factor of RACS||||
33963469|NCT00850005|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33963470|NCT01711671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963471|NCT03763617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A d-ptfe membrane is placed between the buccal bone and periosteum of an extraction socket to prevent the precursors of the bone resorbing cells (osteoclasts) from adhering to the bone surface.|t|f|t|f
33963472|NCT03612401|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, pilot study comparing baseline measurement anticholinergic agent vs. study intervention mirabegron (MYRBETRIC ®) to evaluate cognitive impact and efficacy (SCIMYR)||||
34177887|NCT06603974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177888|NCT04011176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177889|NCT06122194|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|4 period 4 sequence crossover design||||
34177890|NCT06595368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33864876|NCT03987724|NA|SINGLE_GROUP||OTHER||NONE||Each subject will serve as their own control (tumor blood flow at rest vs. blood flow during exercise).||||
33864877|NCT00703053|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33864878|NCT03086265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33893885|NCT02038322|NA|SINGLE_GROUP||||NONE||||||
33893886|NCT01849133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893887|NCT06387615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33893888|NCT00577187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963473|NCT01155635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963474|NCT06291259|||COHORT||PROSPECTIVE|||||||
33963475|NCT04413669|NA|SINGLE_GROUP||SCREENING||NONE||||||
33963476|NCT00348569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963477|NCT04895631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963478|NCT01058044|NA|SINGLE_GROUP||||NONE||||||
34177891|NCT06210711|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be allocated 1:1 into the Brief PE intervention or treatment as usual control group.||||
34177892|NCT01729741|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177893|NCT05954468|||COHORT||RETROSPECTIVE|||||||
34177894|NCT03646877|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34177895|NCT05583422|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177896|NCT06537700|||COHORT||PROSPECTIVE|||||||
34177897|NCT05191095|||CASE_ONLY||PROSPECTIVE|||||||
34177898|NCT01056822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177899|NCT03783143|||COHORT||PROSPECTIVE|||||||
34177900|NCT05591092|||CASE_ONLY||PROSPECTIVE|||||||
34177901|NCT03354949|||COHORT||PROSPECTIVE|||||||
34177902|NCT04261244|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, multicenter||||
34177903|NCT05935735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177904|NCT01312857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177905|NCT05082857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"The study team will employ a blind randomized design to assign individuals to either the traditional Parents as Teachers (PAT) or the hybrid PAT model."|t|f|t|f
34177906|NCT03613532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177907|NCT03874338|||OTHER||PROSPECTIVE|||||||
33864879|NCT04914325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1. Recording the sulcus depth and gingival condition prior to preparation. 2. Conservative tooth preparation will be prepared after local anesthesia has been given as required. 3. Full coverage preparation will be carried out . 3. After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction.|t|f|t|t
33864880|NCT04343248|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33864881|NCT04462341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33864882|NCT02882490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864883|NCT05163470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The population of the study will be divided randomized in two groups, each of the group it will follow a different functional on field rehabilitation framework in low limb musculoskeletal injuries after sustain an acute injury.The two groups will be divided in subgroups,each of group with the same division ,based on the nature of musculoskeletal injury.A physician,will evaluate the players on initial time of the acute injury and after the compliancy of the rehabilitation.Each of the functional on field rehabilitation framework will be applied from one physiotherapist.All the subject will receive the same physiotherapy treatment ,i.e. manual therapy and specific therapeutic exercise protocol depending of the nature of the injury.After return to sports all the participants will be follow the same prevention program depending of the nature of the injury for two months.|t|f|f|f
33864884|NCT05443893|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864885|NCT02765620|||CASE_ONLY||PROSPECTIVE|||||||
33864886|NCT00148265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33864887|NCT03359525|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33864888|NCT02445755|||COHORT||PROSPECTIVE|||||||
33864889|NCT04609332|||COHORT||PROSPECTIVE|||||||
33864890|NCT02015325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177908|NCT03716180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177909|NCT06150638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34177910|NCT04825678|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34177911|NCT06592690|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, cross-over, double-blind, multicenter study|t|f|f|t
34177912|NCT04909450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177913|NCT05455021|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is a prospective, nonrandomized, multicenter, open-label feasibility study of the VRS for the treatment of atherosclerotic de novo or restenotic lesions in the SFA and/or PA after sub-optimal PTA or atherectomy angiographic outcomes.||||
34177914|NCT04914364|||COHORT||PROSPECTIVE|||||||
34177915|NCT06220435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177916|NCT06603285|||COHORT||PROSPECTIVE|||||||
34177917|NCT05358665|||COHORT||CROSS_SECTIONAL|||||||
34177918|NCT05520255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Two-centre prospective cohort phase III study||||
34177919|NCT03911505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177920|NCT05630924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34177921|NCT00399308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177922|NCT01043068|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177923|NCT03123692|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A randomised, two arm, double-blind, placebo-controlled, cross-over, once daily for 14 days and 28 days follow up|t|f|f|f
34177924|NCT03059849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963479|NCT03569020|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Investigators will not know which assignment the participants were given. The laboratory measuring uric acid will not know which intervention the participants were assigned.|Half of participants will be randomly assigned 1 of 2 potential sequences. All participants will ultimately participate in each study period, but the order will be randomly assigned 1:1.|f|f|t|t
33963480|NCT01431378|||CASE_CROSSOVER||PROSPECTIVE|||||||
33963481|NCT02556099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963482|NCT05066100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963483|NCT03952663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded ,participant and outcomes assessor|"* Randomized clinical trial.~* double blinded, with 1:1 allocation ratio, parallel design."|t|f|f|t
34177925|NCT01074970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963484|NCT01946971|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34177926|NCT05684237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177927|NCT05817890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177928|NCT04986865|NA|SEQUENTIAL||TREATMENT||NONE||||||
34177929|NCT04161859|||COHORT||RETROSPECTIVE|||||||
34177930|NCT04186429|||COHORT||PROSPECTIVE|||||||
34177931|NCT03241732|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|This is an Open Label study.|"There were two intervention arms of the study and a control group. Enrollment for these groups was 120 subjects. One arm focused on adjusting dietary practices to eat foods that have a lower amount of inflammatory molecules that might help reduce overall inflammation in the brain and body. The second arm was the N-acetyl cysteine group to provide patients with a natural supplement that support antioxidants in the body. The third arm of the study is a waitlist control group.~The fourth arm is a substudy that may re-enroll and re-consent 30 subjects from the original 3 groups, and will recruit additional subjects as needed, who continue to have distress associated with TBI. Subjects will receive sessions with the Neuro Emotive Technique. Participants enrolled in the 4th NET group will be counted in the cohort of 30 for the NET substudy."||||
34177932|NCT06059482|||OTHER||CROSS_SECTIONAL|||||||
34177933|NCT01852877|||COHORT||PROSPECTIVE|||||||
34177934|NCT06603363|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34177935|NCT03458676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34177936|NCT03079921|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|"Conditions of testing for Group 1 (intra-hepatic islet recipients) will remain double-blind for each subject until their completion of all testing visits, unless for safety concerns, either the PI or Medical Monitor request an unblinding. Groups 2 and 3 will have no masking."|"This study is a within subject and across group mechanistic design.~Islet cell hormonal responses to a hyperinsulinemic euglycemic-hypoglycemic clamp will be assessed in Group 1 on three occasions with randomized, double-blind administration of the α-adrenergic blocker phentolamine, the β-adrenergic blocker propranolol, or placebo.~Responses in Group 1 under the placebo condition will be used for comparison to those obtained from hyperinsulinemic euglycemic-hypoglycemic clamp testing on one occasion in subjects in each of Group 2 and Group 3."|t|t|t|t
34177937|NCT00080158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34177938|NCT06589817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177939|NCT01727284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963485|NCT05331846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33963486|NCT02453867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751726|NCT06733090|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The study will be conducted in two stages. In the first stage; Nurse Information Form and Ventilator Associated Pneumonia Knowledge pretest will be applied to nurses who accept to participate in the study before the training. A 2-week training program will be applied to nurses by the researcher. In the second stage of the study, the forms in the second stage will be applied to patients who meet the criteria for inclusion in the study and the process will be followed in the same way in two separate groups. According to the research sample calculation, it is planned to include at least 25 patients in the experimental group and 25 patients in the control group.||||
33751727|NCT03229954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751728|NCT01039051|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751729|NCT00000727||PARALLEL||TREATMENT||||||||
33751730|NCT01845675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751731|NCT01579591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751732|NCT04879901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751733|NCT05185531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751734|NCT01257906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751735|NCT06096064|||OTHER||RETROSPECTIVE|||||||
33751736|NCT06733571|||COHORT||PROSPECTIVE|||||||
33751737|NCT06733051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751738|NCT06376084|||CASE_ONLY||PROSPECTIVE|||||||
33751739|NCT03340519|||CASE_CONTROL||PROSPECTIVE|||||||
34177940|NCT04956796|||CASE_CROSSOVER||PROSPECTIVE|||||||
34177941|NCT06543940|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34177942|NCT02027155|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33963487|NCT06542770|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized prospective parallel study||||
33963488|NCT05101356|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963489|NCT01893151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963490|NCT05223439|||COHORT||PROSPECTIVE|||||||
33963491|NCT01533584|||CASE_ONLY||CROSS_SECTIONAL|||||||
33963492|NCT01749033|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33963493|NCT02269007|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33963494|NCT04632628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963495|NCT00736060|||||RETROSPECTIVE|||||||
33963496|NCT02884011|||COHORT||RETROSPECTIVE|||||||
33963497|NCT01124682||||TREATMENT||NONE||||||
33963498|NCT00000478|RANDOMIZED|||TREATMENT||||||||
33963499|NCT04998773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963500|NCT04247594|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963501|NCT04399720|||COHORT||PROSPECTIVE|||||||
33963502|NCT05567094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The patients, surgeons, anesthetists, data collectors, and outcome assessors are all blinded. Only the data manager and the specific study coordinator are unblinded to the group allocation.|Patients will be randomized to receive 0.2 mg/kg dexamethasone or saline placebo, administered as an intravenous bolus within 5 minutes after induction of anesthesia.|t|t|t|t
33963503|NCT03485508|||COHORT||RETROSPECTIVE|||||||
33963504|NCT02820935|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963505|NCT04518319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963506|NCT02611245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963507|NCT03218631|NA|SINGLE_GROUP||TREATMENT||NONE||"1. Male~2. Age 18 to 35 years (inclusive) at the time of screening~3. Body mass index \[BMI, body weight (kg)/height (m)2\] below 30 kg/m2~4. Medically healthy"||||
33963508|NCT05233371|||COHORT||PROSPECTIVE|||||||
33963509|NCT00481962|||COHORT||PROSPECTIVE|||||||
33963510|NCT06539065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963511|NCT03783845|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33963512|NCT06542744|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963513|NCT05141279|||COHORT||PROSPECTIVE|||||||
33963514|NCT04726514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963515|NCT01997099|||CASE_ONLY||PROSPECTIVE|||||||
33963516|NCT00840541|||COHORT||RETROSPECTIVE|||||||
33963517|NCT00955760||||||NONE||||||
33963518|NCT02421809|||CASE_CONTROL||PROSPECTIVE|||||||
33963519|NCT04181216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963520|NCT04058431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963521|NCT01782950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963522|NCT05244382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963523|NCT02542228|||COHORT||PROSPECTIVE|||||||
33751740|NCT02429882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751741|NCT06109870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751742|NCT04876729|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33751743|NCT05972551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840646|NCT05715177|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Pretest post-test control group design will be used to investigate the effect of kinesio-taping on electrical activity and peak torque of the quadriceps femoris muscle during concentric and eccentric contraction after arthroscopic partial meniscectomy (APM) surgery||||
33963524|NCT03329586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963525|NCT02918825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963526|NCT02073188|RANDOMIZED|PARALLEL||||NONE||||||
33963527|NCT05182931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with BRAF V600E mutant thyroid cancer will receive Dabrafenib + Trametinib; Participants with RAS mutant thyroid cancer will receive Trametinib alone.||||
33963528|NCT02059369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963529|NCT06538363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded to their group|Control and Intervention group|t|f|f|f
33963530|NCT04676919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sham||t|f|f|f
33963531|NCT01697397|||COHORT||PROSPECTIVE|||||||
33963532|NCT00890227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963533|NCT02873468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963534|NCT02079922|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33963535|NCT04901130|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33963536|NCT02872155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963537|NCT04553692|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Phase 1a is non-randomized; Ph1b is randomized|||||
33963538|NCT04911673|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The name of students were listed in alphabetical order. The researchers gave each students a number. Then, the odd numbers were determined as the experimental and the even numbers as the control group with the lottery method. Using the table of random numbers, the intervention groups were divided into intervention group 1 (music therapy) and intervention group 2 (chocolate group).||t|f|t|f
33963539|NCT00405210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963540|NCT00569231|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33963541|NCT01230437|||||PROSPECTIVE|||||||
34065279|NCT03374657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|"This is a partially masked study. The patients will not be masked. The treating physicians and personnel at the surgical location (surgeons, anesthesiologist, operating room personnel and others) will not be masked.~At the clinical sites, there will be an unmasked ophthalmologist. The remaining assessors at the clinical sites (ophthalmologist, study nurse, ophthalmic technician, etc) doing the ophthalmic examinations should be masked to the study (treated) eye.~The following unmasked sponsor roles are required for this study:~Sponsor clinical staff required to assist in the management and re-supply of investigational drug product.~The independent committee assessing unmasked interim results and the independent analysis team.~All other sponsor staff will stay masked to treatment assignments"|This is a non-confirmatory, open-label single ascending dose gene replacement-therapy study to assess safety, tolerability and efficacy of CPK850 in patients with RLBP1 retinitis pigmentosa due to biallelic mutations in the RLBP1 gene. The trial design uses a staggered patient enrollment.|f|f|f|t
34065280|NCT06393010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065281|NCT00183833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065282|NCT00014885|||||RETROSPECTIVE|||||||
34065283|NCT00184093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177943|NCT04033926|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34177944|NCT01796145|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177945|NCT02802306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177946|NCT03063892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177947|NCT04794855|||COHORT||PROSPECTIVE|||||||
34177948|NCT05879185|NA|SINGLE_GROUP||TREATMENT||NONE||This phase II, open-label, single-center study.||||
34177949|NCT04080635|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open label, non-randomized study||||
34177950|NCT02658526|||COHORT||PROSPECTIVE|||||||
34177951|NCT06478420|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34177952|NCT03152760|||CASE_CONTROL||PROSPECTIVE|||||||
34177953|NCT00780546|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34177954|NCT03198650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177955|NCT05546827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177956|NCT04421820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized - Arm VII only||||
34177957|NCT00904969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177958|NCT01649349|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34177959|NCT05819463|||COHORT||PROSPECTIVE|||||||
34177960|NCT05935670|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||The investigators will enroll and complete visits for 30 individuals within the study including individuals post-stroke (n = 10), their age- and sex-matched controls (CON, n = 10), and young healthy controls (CONyoung, n = 10). This study includes 2 visits to the Athletic and Human Performance Research Center (AHPRC) at Marquette University. The investigators will measure femoral blood flow to passive limb movement and active contractions pre-/post- ischemic conditioning high (225 mmHg) and ischemic conditioning low (25 mmHg).|t|f|t|t
34177961|NCT05991414|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants in Control Group will be offered opportunity to crossover to the Intervention Protocol after their initial 6-month study period.|f|f|t|t
34177962|NCT00685230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177963|NCT05077163|||CASE_ONLY||RETROSPECTIVE|||||||
34177964|NCT04006405|||COHORT||PROSPECTIVE|||||||
34177965|NCT03913455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177966|NCT05525897|RANDOMIZED|PARALLEL||OTHER||NONE||"The investigators will use a pre-post design with a multi-case study approach to evaluate the feasibility and implementation of the psycho-educational intervention in four university settings.~In specific, three universities (CY, GR, SP) will run a single-arm study, while the fourth university (NL) will run an RCT pilot study (see RCT pilot study methods for details).~A mixed-methods design will be used to determine the feasibility and acceptability of a novel soft-skills psychoeducational course."||||
34177967|NCT06371612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The children and their parents will be blinded to the groups. The principal researchers (R1, R2) will be blinded to the research hypotheses. The opaque envelopes are stored in a locked cabinet by the researcher who performed the randomization. Data entries will be performed using the codes A, B and C. Codes will be shared with the researchers after statistical analyses are conducted and the research report is written.||t|f|f|t
34177968|NCT06602648|||COHORT||RETROSPECTIVE|||||||
34177969|NCT06020014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177970|NCT05561920|||COHORT||PROSPECTIVE|||||||
34177971|NCT05611931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind placebo-controlled study||t|f|t|f
34177972|NCT05995210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||prospective randomized controlled single-blind|t|f|f|f
34177973|NCT02657798|||OTHER||CROSS_SECTIONAL|||||||
34177974|NCT05549960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177975|NCT05475015|||COHORT||PROSPECTIVE|||||||
34177976|NCT06327945|NA|SINGLE_GROUP||OTHER||NONE||||||
34177977|NCT03558659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34177978|NCT04984551|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840647|NCT06246487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177979|NCT05363527|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Blinded infusion|Endotoxin vs. Placebo|t|t|t|t
34177980|NCT03659396|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177981|NCT06010654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34177982|NCT03134196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177983|NCT00896857|||COHORT||PROSPECTIVE|||||||
34177984|NCT00801957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34177985|NCT02681523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840648|NCT05260879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34177986|NCT04230304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177987|NCT02422745|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34177988|NCT03108807|||COHORT||PROSPECTIVE|||||||
33840649|NCT03189277|||OTHER||CROSS_SECTIONAL|||||||
33840650|NCT06147349|||COHORT||PROSPECTIVE|||||||
33840651|NCT01791504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840652|NCT05337475|||CASE_ONLY||CROSS_SECTIONAL|||||||
33840653|NCT06126458|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34177989|NCT03589716|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34177990|NCT03118869|||CASE_ONLY||PROSPECTIVE|||||||
34177991|NCT06586866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34177992|NCT00907426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34177993|NCT06601088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34177994|NCT02129543|||COHORT||PROSPECTIVE|||||||
34177995|NCT06591013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864891|NCT06155838|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33864892|NCT04764851|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33864893|NCT04668651|||COHORT||PROSPECTIVE|||||||
33864894|NCT04031820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864895|NCT02492477|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33864896|NCT00376584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33864897|NCT03912181|||COHORT||RETROSPECTIVE|||||||
33864898|NCT02442726|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34177996|NCT06243458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34177997|NCT06310187|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Williams Design for Cross over-trials with a 6-period 6-treatment cross-over design in 36 healthy daily cigarette smokers.||||
34177998|NCT04437628|||COHORT||PROSPECTIVE|||||||
34177999|NCT06589895|||COHORT||RETROSPECTIVE|||||||
34178000|NCT05377996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864899|NCT02709590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33864900|NCT01701999|NA|SINGLE_GROUP||OTHER||NONE||||||
33864901|NCT04261504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33864902|NCT04048395|||COHORT||RETROSPECTIVE|||||||
33864903|NCT00125762|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator unaware of biopsy results|||||
33864904|NCT00911625|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible participants are randomized to one of the two dosing groups using a 1:1 allocation||||
33864905|NCT02290860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178001|NCT06434116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178002|NCT03560037|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Participants will be enrolled to receive either conventional colonoscopy or colonoscopy with addition of Endocuff Vision device.|t|f|f|f
34178003|NCT06328686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178004|NCT06183762|||COHORT||PROSPECTIVE|||||||
34178005|NCT02717234|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34178006|NCT06597682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178007|NCT05228470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178008|NCT05304039|||COHORT||PROSPECTIVE|||||||
34178009|NCT05197426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178010|NCT04731701|||COHORT||CROSS_SECTIONAL|||||||
34178011|NCT04922944|||COHORT||PROSPECTIVE|||||||
34065284|NCT04165096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178012|NCT06008951|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Due to the nature of the study and the music intervention, it is not possible to blind participants and investigators. However, participants will not be informed of the study arm to which they are randomized in advance.|This randomized controlled trial will have a Latin-square design and investigates the effect of self-chosen music and researcher-chosen music. Each participant will receive the same three interventions (self-chosen music, researcher-chosen music and control) in a randomized order. Listening to an informative podcast will serve as a control condition. During each intervention subjects will receive electric stimuli (experimental phase). The highest electric stimuli to tolerate (pain tolerance) will be detected. Each experimental phase will last 20 minutes and in between a wash-out period of 20 minutes will be completed.||||
34178013|NCT01195766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065285|NCT03530319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178014|NCT05003505|||COHORT||PROSPECTIVE|||||||
34065286|NCT05482906|||OTHER||PROSPECTIVE|||||||
34178015|NCT04080661|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open label, non-randomized study||||
34178016|NCT01967849|||COHORT||PROSPECTIVE|||||||
34178017|NCT06593743|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34178018|NCT06331559|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178019|NCT05261646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178020|NCT05546879|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentric prospective single arm phase 1b trial||||
34178021|NCT04774393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178022|NCT06594601|||COHORT||PROSPECTIVE|||||||
34178023|NCT06281756|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Both prescribing physicians and participants will be blind to phenotype and treatment groups.|A 4-site (Hershey, Pennsylvania; Pittsburgh, Pennsylvania; Denver, Colorado; and Quebec, Canada) cohort study will examine the effect of CBT-I as a recommended first-line treatment for insomnia. This will be followed by a placebo-controlled randomized controlled trial (RCT) in those who do not remit in the Cohort Study. The subsequent RCT will compare the efficacy of trazodone vs. placebo among CBT-I non-remitters.|t|t|t|f
34178024|NCT00270881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178025|NCT05929274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Using a sham-controlled randomized double-blind design, 10 patients were randomly assigned to group A or B.|t|f|f|t
34178026|NCT06229444|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants will be blinded to their study participation status, participants will not be asked to take any action to enroll in the study.||t|f|f|f
34178027|NCT02814006|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34178028|NCT06593379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and outcomes assessors will be blinded to the participant condition.|50 Veterans with suicidal ideation will be randomized to either MIST plus Treatment as Usual and Safety Planning versus Treatment as Usual and Safety Planning|f|f|t|t
34178029|NCT06588920|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178030|NCT03558737|RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants will be stratified by GA (24 0/7 to 25 6/7, 26 0/7 to 28 6/7) and randomized to either nHFJV or NIPPV||||
34065287|NCT04516863|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34065288|NCT00076869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065289|NCT00041210|RANDOMIZED|||TREATMENT||||||||
34065290|NCT00662428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065291|NCT02864316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065292|NCT00000356||||TREATMENT||||||||
34065293|NCT00072488||||DIAGNOSTIC||NONE||||||
34065294|NCT02410213|NA|SEQUENTIAL||TREATMENT||NONE||Eligible subjects were enrolled sequentially in Cohort 1 (FCM at 7.5 mg/kg with a maximum single dose of 750 mg) and Cohort 2 (FCM at 15 mg/kg with a maximum single dose of 750 mg). Enrollment in Cohort 2 was initiated only after all subjects in Cohort 1 completed 4 weeks of therapy and a Data and Safety Monitoring Board (DSMB) approved continuation.||||
34065295|NCT03526055|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34065296|NCT00980655|NON_RANDOMIZED|||PREVENTION||NONE||||||
33864906|NCT04915651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864907|NCT05859750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864908|NCT01827579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864909|NCT00727233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864910|NCT01979224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33864911|NCT03038750|||COHORT||CROSS_SECTIONAL|||||||
33864912|NCT04587011|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33864913|NCT06343428|||COHORT||PROSPECTIVE|||||||
33864914|NCT00918047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864915|NCT02091661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864916|NCT03730441|||OTHER||RETROSPECTIVE|||||||
33864917|NCT02863627|NA|SINGLE_GROUP||OTHER||NONE||||||
33864918|NCT02111460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864919|NCT06013592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|single-blinded, randomized order|within participant|t|f|f|f
33864920|NCT04260412|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, interventional, two parallel arm study.||||
33864921|NCT01546974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864922|NCT00503243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864923|NCT03248830|||COHORT||PROSPECTIVE|||||||
33864924|NCT05603884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864925|NCT05300321|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33864926|NCT05889455|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33864927|NCT05546294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864928|NCT01731535|||||RETROSPECTIVE|||||||
33864929|NCT06212635|||COHORT||PROSPECTIVE|||||||
33864930|NCT03343392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This was a triple-mask study, in which the patient, operator and evaluator were blinded to the group assignment.|This was a randomized, parallel, placebo-controlled, triple-mask clinical trial, in which the patient, operator and evaluator were masked to the group assignment. A third researcher, not involved in the evaluation process, was responsible for the randomization process, and delivery and guidance on the administration of the drugs. This study was performed from 01/2016 to 12/2017 in the city of Cascavel (Paraná, Brazil). All bleaching procedures were carried out within the Clinics of the Dental School of the State University of Oeste do Paraná (Cascavel, Paraná, Brazil).|t|f|t|t
33864931|NCT00057356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864932|NCT00598260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33864933|NCT00277251|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33864934|NCT03248583|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33864935|NCT01516658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864936|NCT06157957|NA|SINGLE_GROUP||SCREENING||NONE||||||
33864937|NCT01969097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065297|NCT04938414|||COHORT||PROSPECTIVE|||||||
34065298|NCT03922841|||COHORT||PROSPECTIVE|||||||
34065299|NCT05569993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded clinical trial Masking for patient,their relatives and outcome assessor|2 groups will recieve glutamine ,the other will be placcebo group|t|t|f|t
33963542|NCT03494205|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized parallel design||||
33963543|NCT02487173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178031|NCT05297409|||COHORT||PROSPECTIVE|||||||
33864938|NCT00635856|NA|SINGLE_GROUP||||NONE||||||
34178032|NCT05685914|||COHORT||PROSPECTIVE|||||||
33864939|NCT02615470|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33864940|NCT00172653|||||PROSPECTIVE|||||||
34178033|NCT06135805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178034|NCT06601829|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34178035|NCT02783690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178036|NCT03105713|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|"All participants are masked for the study outcomes. In intervention arm, the participants are not masked for the checklist intervention.~Care Providers are masked for patients receiving the intervention and for outcomes.~Outcome assessors are masked for patients receiving the intervention. Investigators are partially masked for the outcomes across clusters in the intervention phase"|Stepped Wedge Cluster RCT is considered to align a cross-over design.|t|t|f|t
34178037|NCT06397456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The care provider will not be involved in the enrollment or assessment process. The outcomes assessor will analyze the outcomes without knowledge of allocation.||f|t|f|t
34178038|NCT03280719|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33840654|NCT06222827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||First period: two groups of patients who receive either satralizumab, or placebo. Second period: all patients receive satralizumab|t|f|t|f
33840655|NCT00929942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840656|NCT02158923|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33864941|NCT03787524|||CASE_CONTROL||PROSPECTIVE|||||||
33864942|NCT00345189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864943|NCT02944253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864944|NCT05834686|||COHORT||PROSPECTIVE|||||||
33864945|NCT04687813|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
33864946|NCT06267989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33864947|NCT02878551|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33864948|NCT03708172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Open Label for rTMS, Double-Blinded for Cognitive Training||t|t|t|t
33864949|NCT01326078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33840657|NCT02759653|||COHORT||PROSPECTIVE|||||||
33840658|NCT02964533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840659|NCT06415526|||CASE_ONLY||RETROSPECTIVE|||||||
33840660|NCT04117295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840661|NCT03598153|||COHORT||PROSPECTIVE|||||||
33840662|NCT01735227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33840663|NCT01627951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33840664|NCT03455270|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840665|NCT03290053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840666|NCT03985696|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33840667|NCT00756041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840668|NCT01209377|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33840669|NCT03313492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840670|NCT00434265|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840671|NCT01185275|||COHORT||PROSPECTIVE|||||||
33840672|NCT06191224|||COHORT||PROSPECTIVE|||||||
33840673|NCT00636805|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33864950|NCT06656364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864951|NCT00010920|RANDOMIZED|||PREVENTION||DOUBLE||||||
33864952|NCT02347488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864953|NCT00217243|||COHORT||PROSPECTIVE|||||||
33864954|NCT02102334|||COHORT||PROSPECTIVE|||||||
33864955|NCT02843763|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33864956|NCT00860951|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33864957|NCT00005920||PARALLEL||TREATMENT||||||||
33864958|NCT04873050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864959|NCT00580710|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864960|NCT05065749|||CASE_ONLY||PROSPECTIVE|||||||
33864961|NCT02877940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864962|NCT01212978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33864963|NCT06178250|NA|SINGLE_GROUP||OTHER||NONE||46 pregnant women diagnosed with gestational diabetes mellitus, 93 pregnant women with normal glycemic index||||
33864964|NCT02649049|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33864965|NCT00000551|RANDOMIZED|||PREVENTION||||||||
33864966|NCT00335465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33864967|NCT00005007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864968|NCT01157520|||CASE_ONLY||PROSPECTIVE|||||||
33864969|NCT05401864|||OTHER||CROSS_SECTIONAL|||||||
33864970|NCT00430482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864971|NCT05290688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||20 untreated RRMS patients divided into 2 groups: 10 RRMS in relapsing phase 10 RRMS in relapse.||||
33864972|NCT05144568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled experimental study|t|f|f|f
33864973|NCT05644457|||COHORT||PROSPECTIVE|||||||
34178039|NCT04876521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The proposed study will be rater-blinded. The ratings would be done by a psychiatrist who would be blinded to the nature of the intervention provided|Randomized, parallel-group, rater-blinded, clinical trial.|f|f|f|t
33864974|NCT03764150|||COHORT||PROSPECTIVE|||||||
33864975|NCT00351442|||CASE_CONTROL||PROSPECTIVE|||||||
33864976|NCT00626249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178040|NCT00181168|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34178041|NCT05165134|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pretest and posttest Control group randomized control trial|f|f|f|t
33864977|NCT00961753|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34178042|NCT03988400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomly assigned to either an Experimental (n=22) or Control (n=22) group. These groups will differ only in terms of how vibration is delivered to the hip musculature during training sessions. In the Experimental group, vibration magnitude will be controlled by the real-time mechanical state of the user's body. In the Control group, vibration magnitude will be randomly varied.|t|t|f|t
34178043|NCT00880516|||CASE_CONTROL||PROSPECTIVE|||||||
33963544|NCT06039098|||COHORT||PROSPECTIVE|||||||
33963545|NCT02577900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963546|NCT02522949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963547|NCT00349882|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33963548|NCT01208168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963549|NCT04133090|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split-mouth study||||
33963550|NCT04785833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963551|NCT01330862|||COHORT||PROSPECTIVE|||||||
33963552|NCT04316299|||CASE_CONTROL||RETROSPECTIVE|||||||
33963553|NCT01317420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963554|NCT05474560|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 90 subjects are enrolled in this study. After the initial screening, the subjects were randomly divided into the control group and the drug treatment group. The control group was given lifestyle intervention for 24 weeks, and the experimental group was given febuxostat oral therapy or allopurinol oral therapy on the basis of lifestyle intervention.||||
33963555|NCT00970931|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963556|NCT01973842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178044|NCT06289101|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 groups will be enrolled and randomized to receipt or not receipt of the intervention.||||
34178045|NCT01144793|||COHORT||PROSPECTIVE|||||||
34178046|NCT01535339|||COHORT||PROSPECTIVE|||||||
34178047|NCT06584630|||COHORT||PROSPECTIVE|||||||
34178048|NCT02151864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178049|NCT05406232|||COHORT||PROSPECTIVE|||||||
34178050|NCT06524297|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34178051|NCT02043457|||COHORT||PROSPECTIVE|||||||
34178052|NCT01617824|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34178053|NCT06184633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178054|NCT03982121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label, dose-escalation combination phase 1 study||||
34178055|NCT06398652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34178056|NCT06226129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864978|NCT00633165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864979|NCT04711148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33864980|NCT02530372|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33864981|NCT05018767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33864982|NCT05315362|RANDOMIZED|PARALLEL||PREVENTION||NONE|only laboratory personnel is masked. Because of the different administration routes it is not possible to mask the participants or investigators|open-label, randomised-controlled, proof-of-concept vaccine study||||
33864983|NCT01431274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33864984|NCT03602404|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33864985|NCT03186118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are assessed during the parent study for total CD 19 load in bone marrow. Participants meeting eligibility criteria are transitioned into one of 3 arms in PLAT-03.||||
34178057|NCT04809987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178058|NCT04777799|NA|SINGLE_GROUP||OTHER||NONE||Interventional, prospective, open-labelled, multicenter, French study||||
34178059|NCT05186233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178060|NCT02273934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178061|NCT06350643|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178062|NCT04965025|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants cannot be blinded because of the nature of the surgery. Treating surgeon cannot be blinded. Blinding of outcome assessors, data analysts and authors of the manuscript was considered, but lifted due to practical considerations.|RCT with two arms.||||
34178063|NCT03200249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178064|NCT06586762|||CASE_CONTROL||PROSPECTIVE|||||||
33864986|NCT05490173|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants (ELBW infants GA 25/0-27/6 week) are randomized to one of two groups in parallel for the duration of the study. The first group (exosome treatment group) will receive intranasal administration of exosomes and the second (control group) will not receive exosomes. Patients in both groups will receive standard basic therapy|t|f|f|f
33864987|NCT03919929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864988|NCT01157013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33864989|NCT04219813|NA|SINGLE_GROUP||OTHER||NONE||"The researchers will evaluate the urine samples of patients affected with NCGS/NCWS, diagnosed by double-blind placebo-controlled wheat challenge, on GFD. The patients will be recruited among those diagnosed in two centers: Ambulatorio di Celiachia ed Intolleranze Alimentari (Prof. Pasquale Mansueto) of the Geriatric Division (Director Prof. Mario Barbagallo) of the Azienda Ospedaliera-Universitaria Paolo Giaccone', and the Internal Medicine Unit (Director Prof. Antonio Carroccio) of the Cervello-Villa Sofia Hospital, both in Palermo, Italy. The researchers will deliver to each patient 10 kits for the analysis of the GIP and we will ask them to use them two times per week, for 5 weeks. Furthermore, the patients will test urine GIP in the event of symptoms/signs that they attribute to the accidental intake of gluten, within the same 5 weeks."||||
33864990|NCT00261014|||||PROSPECTIVE|||||||
33864991|NCT01147198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33864992|NCT03210103|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 Arm study randomized in a 1:1 ratio||||
33864993|NCT03817866|||COHORT||PROSPECTIVE|||||||
33864994|NCT04384393|NA|SEQUENTIAL||TREATMENT||NONE||||||
33864995|NCT03163979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963557|NCT04608578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33963558|NCT01852773|||COHORT||PROSPECTIVE|||||||
33963559|NCT05177705|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33963560|NCT00931385|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34178065|NCT03288532|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-Arm Multi-Stage Design||||
34178066|NCT06595758|||COHORT||OTHER|||||||
34178067|NCT03913533|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|the outcome assessed will be masked to group allocation||f|f|f|t
34178068|NCT06591364|||COHORT||CROSS_SECTIONAL|||||||
34178069|NCT04179500|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 2 single arm multi-center, open-label clinical trial in DR-TB participants. Participants will receive bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks together with pretomanid 200 mg~+ moxifloxacin 400 mg + pyrazinamide 1500 mg once daily (BPaMZ) for 26 weeks.~Participants will be followed for 52 weeks after end of treatment"||||
34178070|NCT04403204|||COHORT||PROSPECTIVE|||||||
34178071|NCT06578468|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Stepped-wedge randomised control trial||||
34178072|NCT06517446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864996|NCT02921568|NA|SINGLE_GROUP||OTHER||NONE||||||
33963561|NCT03124173|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34065300|NCT00783328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065301|NCT02560857|||COHORT||PROSPECTIVE|||||||
34065302|NCT04043208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33864997|NCT06234150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33864998|NCT02113579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33864999|NCT00962390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963562|NCT01644409|||COHORT||PROSPECTIVE|||||||
33963563|NCT00644098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963564|NCT04794452|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33963565|NCT02579369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963566|NCT01086735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963567|NCT06304545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963568|NCT06129565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963569|NCT06330077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065303|NCT05186259|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34065304|NCT04604964|||COHORT||RETROSPECTIVE|||||||
34065305|NCT05469022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065306|NCT04528329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065307|NCT05535322|||COHORT||RETROSPECTIVE|||||||
34065308|NCT05919524|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34065309|NCT06220487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065310|NCT01658397|NA|SINGLE_GROUP||OTHER||NONE||||||
34065311|NCT04379765|||COHORT||PROSPECTIVE|||||||
34065312|NCT02650700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065313|NCT05850104|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065314|NCT00236899|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34065315|NCT00224237|||COHORT||PROSPECTIVE|||||||
34065316|NCT01492101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065317|NCT06239805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065318|NCT01590849|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34065319|NCT04766099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065320|NCT00729040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065321|NCT02658708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065322|NCT05799404|||CASE_CONTROL||RETROSPECTIVE|||||||
34065323|NCT00359294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065324|NCT05031377|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34065325|NCT05626218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34065326|NCT00464555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065327|NCT05070143|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065328|NCT05584085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor who is responsible for collecting outcome data and data entry has no idea about the group allocation or participants.|Participants will be randomly allocated (1:1 ratio) to either the intervention group that receive 1 6-week ACT-DE programme, while participants in the control group receive one session of diabetes education.|f|f|f|t
34065329|NCT00956488|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751744|NCT03722134|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Our study aim was to assess the applicability and safety of MOCA in short term as well as occlusion rate and disease specific quality of life one year after the procedure, and compare it with currently used thermal ablation methods of laser ablation (EVLA) and radiofrequency ablation (RFA) in a randomized controlled trial.~Randomization took place by a study nurse after the appointment, using block randomization with sealed envelopes into EVLA, RFA, or MOCA in ratio 1:1:2."||||
34178073|NCT05467527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The randomisation procedure will be carried by a clerical staff who has no involvements in this project. For parents, all participants will use the same mobile app tentatively branded as Calm Parents but receive different assigned contents of the app."|Parallel Assignment; repeated-measures 2-arm randomized controlled trial|t|f|t|t
34178074|NCT04650815|||COHORT||PROSPECTIVE|||||||
34178075|NCT03729115|NA|SINGLE_GROUP||SCREENING||NONE||||||
33865000|NCT01541579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865001|NCT01326208|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33865002|NCT05745051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865003|NCT04014036|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|While subjects receive Sham therapy, the machine turning on but the energy is zero.|We prospectively assessed the clinical outcome of LI-ESWT for the treatment of CPPS. This study was approved by the institutional review board at National Taiwan University Hospital (NTUH, No. T-NTUH-57401).|t|f|f|f
33865004|NCT05831553|||CASE_ONLY||OTHER|||||||
33865005|NCT04121611|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865006|NCT04180150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865007|NCT03858790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865008|NCT01050504|||CASE_CONTROL||PROSPECTIVE|||||||
33865009|NCT05378646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178076|NCT04649229|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33865010|NCT00617539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865011|NCT00789750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865012|NCT05749536|||COHORT||OTHER|||||||
33865013|NCT02838082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865014|NCT04262635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865015|NCT01512563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33963570|NCT04056299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|2:1 randomization|t|t|t|f
33963571|NCT03751527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963572|NCT04385199|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33963573|NCT04896723|||CASE_CONTROL||PROSPECTIVE|||||||
33963574|NCT06008977|RANDOMIZED|PARALLEL||OTHER||NONE||We will use stratified block randomization to assure non-biased assignment to the exercise intervention arm. Within each treatment setting, adjuvant and neoadjuvant, 10 patients will be randomized to the exercise intervention arm and 10 to the standard treatment arm. Within the neoadjuvant setting, randomization also will be blocked within disease type.||||
33963575|NCT05930509|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will receive the same treatment|Open clinical trial||||
34178077|NCT04334824|||COHORT||RETROSPECTIVE|||||||
34178078|NCT03933007|NA|SINGLE_GROUP||TREATMENT||NONE|all participants will perform the pharmacokinetic study and take colchicine 1 mg + 0.5 mg 1 hour later, midazolam 1 mg and fexofenadine 120 mg.|"all participants will perform the pharmacokinetic study and take colchicine 1 mg + 0.5 mg 1 hour later, midazolam 1 mg and fexofenadine 120 mg.~A pharmacokinetic study is an interventional study with only one arm."||||
34178079|NCT04109547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34178080|NCT06596746|||COHORT||PROSPECTIVE|||||||
34178081|NCT06588699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial is a double-blind placebo controlled trial to assess the effect of digoxin oral, versus placebo, on histologic improvement of NASH. Study team members will be blinded except for the unblinded pharmacist and the individual monitoring digoxin level.|A centrally administered randomization strategy will be used to randomize patients.|t|t|t|t
34178082|NCT06581211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178083|NCT04335669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178084|NCT05083923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178085|NCT05533385|NA|SINGLE_GROUP||OTHER||NONE||Phase II, open-label, non-randomized trial, with no control group of subjects.||||
34178086|NCT05823571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178087|NCT05272007|||COHORT||PROSPECTIVE|||||||
34178088|NCT02825693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178089|NCT04142606|||COHORT||PROSPECTIVE|||||||
34178090|NCT04818671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178091|NCT02415608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178092|NCT04561206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178093|NCT00417326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178094|NCT04538859|||COHORT||PROSPECTIVE|||||||
34178095|NCT06592846|||COHORT||RETROSPECTIVE|||||||
33865016|NCT03767036|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, randomized, crossover design with three treatment periods and six sequences (A3-A1-A2, A1-A2-A3, A2-A3-A1, A3-A2-A1, A1-A3-A2, A2-A1-A3) with single administration of tramadol (A1), ketorolac (A2) or tramadol and ketorolac (A3). Treatment periods were separated by a washout period of at least 4 days.||||
33865017|NCT00005081||||TREATMENT||||||||
33751745|NCT06133387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751746|NCT01154920|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751747|NCT06666491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751748|NCT06010082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33751749|NCT01923259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751750|NCT06636877|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751751|NCT00002564|RANDOMIZED|||TREATMENT||||||||
34178096|NCT03104868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|We will blind: 1) research interviewers involved with outcomes assessment, 2) personnel involved in statistical analyses (Dr. Kwasny, Ms. Patel), 3) principal investigators (Wolf, Ladner). Site project managers will have access to study arm assignments to initiate TAKE IT components to those randomized to receive them.|Participants will be randomized to one of two arms: TAKE IT strategy or usual care.|t|f|t|f
33865018|NCT04255147|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865019|NCT01221727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865020|NCT00041080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865021|NCT01069250|||CASE_ONLY||PROSPECTIVE|||||||
33865022|NCT03407651|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178097|NCT05523089|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34178098|NCT03587844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. If neither dose is found promising, cohort 2 will not start.||||
34178099|NCT04524637|||CASE_ONLY||PROSPECTIVE|||||||
34178100|NCT02230410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178101|NCT05923125|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34178102|NCT04762290|RANDOMIZED|PARALLEL||OTHER||SINGLE|Certain direct outcome measure assessors will be masked|The study model is a waitlist control. There is an active group and a waitlist control group.|f|f|f|t
34178103|NCT01174615|||OTHER||PROSPECTIVE|||||||
34178104|NCT02514135|||COHORT||PROSPECTIVE|||||||
34178105|NCT06569901|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"After recruitment of 25 participants, they will be randomized into five clusters. One cluster at a time, will cross over to the intervention group. This recruitment period will be repeated three times to include a total of 75 participants. Prior the intervention, participants will receive care as usual and serve as controls."||||
34178106|NCT05522153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|patients are blinded as to their randomization group|randomized controlled study|t|f|f|f
34178107|NCT06358612|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
34178108|NCT01641094|||COHORT||PROSPECTIVE|||||||
34178109|NCT00262340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34178110|NCT06306105|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34178111|NCT05919420|||COHORT||PROSPECTIVE|||||||
34178112|NCT06586476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34178113|NCT05562466|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Patients, investigator staff, persons performing the assessments, data analysts and the Sponsor Clinical Trial Team (CTT) will remain blind to the identity of the treatment from the time of randomization until database lock.||t|t|t|t
34178114|NCT04430452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178115|NCT05052125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178116|NCT03090360|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34178117|NCT06602375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be a pragmatic, parallel randomized controlled trial. Participants will be randomly assigned to either the experimental (standard care plus physical therapy) or control (standard care) group.|f|f|f|t
34178118|NCT06600503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34178119|NCT06559696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178120|NCT06601790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34178121|NCT01772472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178122|NCT04897997|||CASE_CONTROL||PROSPECTIVE|||||||
34178123|NCT05773664|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865023|NCT00281372|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33865024|NCT05398887|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33865025|NCT05782322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865026|NCT04754633|||CASE_CONTROL||RETROSPECTIVE|||||||
33865027|NCT03764163|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865028|NCT04454697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventiongroup: Personalized GWR Controlgroupt: standardized radiation protection tooth splints||||
33865029|NCT01174511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33865030|NCT00094796||||TREATMENT||||||||
33865031|NCT00684450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865032|NCT02066623|||CASE_ONLY||PROSPECTIVE|||||||
33865033|NCT04088825|||COHORT||PROSPECTIVE|||||||
33865034|NCT03155373|||COHORT||PROSPECTIVE|||||||
33865035|NCT05921396|NA|SINGLE_GROUP||TREATMENT||NONE||The study subjects will be enrolled into one study group.||||
33865036|NCT00900523|||CASE_ONLY||PROSPECTIVE|||||||
33865037|NCT01710683|||COHORT||RETROSPECTIVE|||||||
33865038|NCT00528983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865039|NCT03684590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865040|NCT04465448|||CASE_CONTROL||PROSPECTIVE|||||||
33865041|NCT02180971|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34178124|NCT04786119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178125|NCT06587477|||CASE_CONTROL||PROSPECTIVE|||||||
34178126|NCT03255603|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34178127|NCT05307575|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178128|NCT06593717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178129|NCT02698215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178130|NCT03548285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865042|NCT00929656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865043|NCT06159023|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33865044|NCT06033157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33865045|NCT05662696|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33865046|NCT00713817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33865047|NCT05967117|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33865048|NCT06232928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865049|NCT04480060|||COHORT||RETROSPECTIVE|||||||
33865050|NCT00512746|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33865051|NCT01379573|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34178131|NCT06698289|||COHORT||PROSPECTIVE|||||||
33751752|NCT01557231|||COHORT||PROSPECTIVE|||||||
33751753|NCT03045666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33751754|NCT00097058|||COHORT||PROSPECTIVE|||||||
33751755|NCT03321331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessments regarding body weight and waist circumference will be conducted by nurses at the University Health Services clinics, who are blind to treatment allocation. The assessor will go through an assessment training program and will be informed about the study, but not about the allocation or treatments. Due to the nature of the intervention neither participants nor staff can be blinded to allocation, but are strongly inculcated not to disclose the allocation status of the participant at the follow up assessments.||f|f|f|t
33865052|NCT03762720|NA|SINGLE_GROUP||TREATMENT||NONE|Blind researcher|RANDOMIZED CLINICAL TRIAL WITH BLIND EVALUATION BY THIRD PARTIES, LONGITUDINAL AND PROSPECTIVE.||||
33865053|NCT00469001|||COHORT||PROSPECTIVE|||||||
33865054|NCT01791647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865055|NCT03640468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178132|NCT06597357|||COHORT||CROSS_SECTIONAL|||||||
33751756|NCT00818116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751757|NCT06490562|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865056|NCT01923350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33751758|NCT01704170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751759|NCT06445491|RANDOMIZED|CROSSOVER||OTHER||NONE||All participants will receive all 6 iterations of testing order, but the order of test sequences will be randomized.||||
33865057|NCT05915520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865058|NCT03373981|NA|SINGLE_GROUP||TREATMENT||NONE||open label single arm||||
33865059|NCT04329481|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|"Mycodigest supplementation and placebo will be manufactured by 'Mycolivia Medicinal Mushrooms' LTD, to be identical in size, shape and color."|"The crossover study design is suitable for the aims of this study given that Crhon disease (CD) and ulcerative colitis (UC) patients are both chronic conditions. The treatment investigated is hypothesized to effect patient's symptoms and consequent quality of life.~Patients will be screened and randomly allocated to be treated with 'Mycodigest' supplementation or placebo for 8 weeks.~Between the two interventional periods, all participants will undergo a wash-out period of 2 weeks in order to address the potential carryover effect of the first period. As the microbiome is known change rapidly, we assume that this time period will be suitable for minimizing the potential carryover effect of the first period intervention"|t|t|t|f
33865060|NCT05671783|||COHORT||PROSPECTIVE|||||||
33865061|NCT05145335|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33865062|NCT04612452|||COHORT||PROSPECTIVE|||||||
33865063|NCT01507467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751760|NCT06488859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751761|NCT00528775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865064|NCT02361944|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33865065|NCT03641495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865066|NCT01831921|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33865067|NCT01968850|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865068|NCT00792454|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751762|NCT01410773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865069|NCT00385203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865070|NCT05290922|||COHORT||CROSS_SECTIONAL|||||||
33865071|NCT04453436|||CASE_CONTROL||PROSPECTIVE|||||||
33865072|NCT00482443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33865073|NCT01965977|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865074|NCT02844621|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751763|NCT05300425|||COHORT||PROSPECTIVE|||||||
33865075|NCT05197036|||COHORT||PROSPECTIVE|||||||
33865076|NCT00702325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751764|NCT05703100|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No Masking is possible since participants and investigators know which type of test (control, hyperthermia and glycogen depletion) is being performed.|||||
33751765|NCT02308748|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33865077|NCT06159855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33865078|NCT03591354|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled trial of 3 months at home closed loop system vs. predictive-low glucose suspend.||||
34178133|NCT06192654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178134|NCT04780061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178135|NCT06705296|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"The study will consist of four (4) phases 1) Open label phase (from surgery until postoperative week 24); 2) Double-blinded on/off phase (from postoperative week 25 to 33); 3) Prolonged exposure therapy (from postoperative week 34to 44); 4) Closed-loop DBS (from postoperative week 45 to60)."|t|f|t|f
34178136|NCT04058717|RANDOMIZED|PARALLEL||OTHER||DOUBLE||2 X 2 factorial design|t|f|t|f
34178137|NCT03317405|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33865079|NCT04076254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865080|NCT02722876|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34178138|NCT01473134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178139|NCT04291781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178140|NCT04442022|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Phase 2 Portion of the Study: open label; Phase 3 Portion of the Study: double blinded||t|f|t|f
34178141|NCT04644952|||CASE_ONLY||RETROSPECTIVE|||||||
34178142|NCT06206031|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"This small-n pilot study in physiology aims to validate the concept and serve a basis for in-depth studies on space physiology. Two clinical centers will be involved, each providing measurements in its area of expertise, and two sub-protocols with complementary objectives will be implemented:~* Sub-protocol 1 (16 males of 20-40 yrs with usable data): Study of cortical bone vascular reactivity and its reproducibility at medial tibia (Angers University Hospital);~* Sub-protocol 2 (16 males of 20-70 yrs with usable data): Study of bone perfusion at distal and ultradistal tibia, and comparison of bone measurements by ultrasound to those by peripheral quantitative computed tomography (Saint-Etienne University Hospital).~Bone ultrasonography will be performed for both sub-protocols."||||
34178143|NCT06591494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178144|NCT06580704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178145|NCT05136586|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Performance is evaluated by assessors who are blind to the intervention|4 parallels groups|f|f|t|t
34178146|NCT06145737|NA|SINGLE_GROUP||OTHER||NONE||||||
34178147|NCT04921670|||COHORT||PROSPECTIVE|||||||
34178148|NCT05794620|||COHORT||PROSPECTIVE|||||||
33865081|NCT00472173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865082|NCT06100653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865083|NCT00334386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865084|NCT02744300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33865085|NCT04297501|||COHORT||PROSPECTIVE|||||||
33865086|NCT02276664|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33865087|NCT03307434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963576|NCT00654888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963577|NCT06385665|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33963578|NCT01358708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963579|NCT00822263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963580|NCT02549274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963581|NCT02331030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34178149|NCT03119259|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34178150|NCT06591702|||COHORT||PROSPECTIVE|||||||
34178151|NCT05130580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33865088|NCT05093322|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study will be conducted in 2 parts:~Part 1 - evaluation of tolerability and safety of surufatinib administered in combination with gemcitabine, and confirmation of the recommended clinical dose of surufatinib in pediatric patients with recurrent or refractory solid tumors or lymphoma. Part 2 - evaluation of anti-tumor activity and confirmation of tolerability of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory osteosarcoma, Ewing sarcoma, RMS, and NRSTS."||||
33865089|NCT05355779|||OTHER||OTHER|||||||
33865090|NCT04374643|||COHORT||PROSPECTIVE|||||||
33865091|NCT05971862|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865092|NCT03526354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865093|NCT00411281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865094|NCT02101515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865095|NCT05665491|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33865096|NCT02162368|||CASE_CONTROL||RETROSPECTIVE|||||||
33865097|NCT03800290|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blinded, placebo-controlled, cross-over, single-center study|t|f|t|f
33865098|NCT03862365|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865099|NCT05986513|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The MRI analysis methods are quantitative and unbiased by convention. Furthermore, they will require the researcher to input the age and sex of the participant and indicate if the participant was a healthy control or experimental to allow for group comparisons, but that will not influence the analyses or outcomes.|Adults who have been clinically diagnosed with knee osteoarthritis (pain free, localized knee pain, or knee and widespread pain) will all receive the same intervention and study protocol.|f|f|f|t
33865100|NCT06085027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865101|NCT00041275|RANDOMIZED|||TREATMENT||DOUBLE||||||
33865102|NCT05000541|||COHORT||PROSPECTIVE|||||||
33865103|NCT00814567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865104|NCT05426642|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34178152|NCT03175679|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Four planned loading dose of iNKT cells for 10 patients.||||
34178153|NCT06599957|||COHORT||PROSPECTIVE|||||||
34178154|NCT06585826|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34178155|NCT00174408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178156|NCT06407921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant's will get separate treatment protocols and possible efforts will be put to msk the both group about the treatment.|It will be randomized control trial in which non probability convenient sampling will be used. Two groups of 6-12 age will be formed in which participants will be randomly divided. group A will only receive Whole Body Vibration therapy and group B will only receive BOSU ball.|t|f|f|f
34178157|NCT04066283|||COHORT||CROSS_SECTIONAL|||||||
34178158|NCT06594055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178159|NCT06590974|||COHORT||PROSPECTIVE|||||||
34178160|NCT06113068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178161|NCT00033332|RANDOMIZED|||TREATMENT||||||||
34178162|NCT05904704|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178163|NCT02129036|||CASE_ONLY||RETROSPECTIVE|||||||
34178164|NCT06595849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178165|NCT02121223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865105|NCT05871255|||COHORT||PROSPECTIVE|||||||
33865106|NCT02771314|NA|SINGLE_GROUP||OTHER||NONE||||||
33865107|NCT02988687|||COHORT||PROSPECTIVE|||||||
33865108|NCT02410655|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963582|NCT02366065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963583|NCT02112422|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33963584|NCT00755508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963585|NCT03519022|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34178166|NCT06554873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178167|NCT05849142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178168|NCT04599244|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34178169|NCT06599359|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34178170|NCT06510439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and research assistant completing baseline, mid-point and end-point interview are blind to treatment allocation. Data analyst will be blind to participant condition.||f|f|t|t
34178171|NCT05367778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178172|NCT02212015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178173|NCT05224973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178174|NCT02314468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178175|NCT06598839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178176|NCT01703195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178177|NCT03732417|||OTHER||PROSPECTIVE|||||||
34178178|NCT06307340|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The data analyst is blinded to participant arm.||f|f|f|t
33865109|NCT03635814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects who finally meet inclusion/exclusion criteria will be randomized into lower dose group (YD312 Tablet 50 mg), middle dose group (YD312 Tablet 150 mg), higher dose group (YD312 Tablet 350 mg), and placebo group as a ratio of 1:1:1:1 and the relevant investigational product will be administered for 12 weeks.|t|t|t|f
33865110|NCT04039854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865111|NCT04992325|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865112|NCT00067392|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33865113|NCT03452514|||COHORT||PROSPECTIVE|||||||
34178179|NCT05722535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
34178180|NCT06599762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled pilot trial|t|t|t|t
34178181|NCT05002127|RANDOMIZED|PARALLEL||TREATMENT||NONE|Phase 2 is Open Label; Phase 3 is blinded|||||
34178182|NCT04950127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigator will be blinded to the study treatment.|Participants will be randomized to receive linerixibat and/or placebo during the study.|t|f|t|f
34178183|NCT02484248|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34178184|NCT06166732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178185|NCT06134518|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Intervention group control group||||
34178186|NCT06603545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34178187|NCT03269578|||COHORT||RETROSPECTIVE|||||||
34178188|NCT05432856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865114|NCT00383357|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33865115|NCT02914054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865116|NCT02910765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34178189|NCT05279196|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Comparative study of two groups of subjects formed a posteriori from a cohort follow-up||||
34178190|NCT00107198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178191|NCT06213571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34178192|NCT03536104|||CASE_CONTROL||PROSPECTIVE|||||||
34178193|NCT06588023|||COHORT||PROSPECTIVE|||||||
34178194|NCT04282486|||COHORT||CROSS_SECTIONAL|||||||
34178195|NCT06322199|||CASE_ONLY||PROSPECTIVE|||||||
34178196|NCT01967238|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178197|NCT05229887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178198|NCT04466943|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Only the attending anesthesiologist and anesthesia assistant are going to be aware of the allocation in order to administer the required level of NMB||t|t|t|t
34178199|NCT06598826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865117|NCT04084106|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized clinical trail||||
33865118|NCT00150293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865119|NCT03053258|||CASE_ONLY||PROSPECTIVE|||||||
33865120|NCT06470009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The active Study Intervention device will deliver high-pulse stimulation and the sham Study Intervention device will deliver no-pulse stimulation although participants will be instructed to not assume being assigned an active or sham device based on whether they can feel the stimulation in the tongue or not.|Randomized controlled trial.|t|t|t|t
34178200|NCT06591065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178201|NCT06406595|||COHORT||CROSS_SECTIONAL|||||||
34178202|NCT03970746|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178203|NCT05682430|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental groups conduct the speed-based HIIT with mechanical work. In contrast, the control group take heart rate based HIIT.|t|f|t|t
34178204|NCT05328609|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34178205|NCT04265144|NA|SINGLE_GROUP||OTHER||NONE||||||
34178206|NCT05894109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Repeated Measures ANOVA (Continuous Data) McNemar Test (Categorical Data)|t|t|t|t
34178207|NCT00809185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178208|NCT06117306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Access to the randomization code will be strictly controlled and only available to the un-blinded VA San Diego Research Pharmacist.|Eligible participants will be randomized in a stratified 1:1 manner to the standard dose MDMA or low dose MDMA condition.|t|t|t|t
34178209|NCT06281132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751766|NCT03860168|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study will be conducted using a pragmatic stepped-wedge cluster randomized trial (RCT) design, with each PICU acting as one cluster. In a traditional stepped-wedge (TSW) design, all clusters begin in the control group and then transition to the intervention group at sequential and randomly assigned periods, facilitating the delivery of a desired intervention to all clusters, in this case, all participating PICUs.||||
33751767|NCT04429516|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33751768|NCT00542802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751769|NCT06578962|||COHORT||PROSPECTIVE|||||||
33751770|NCT06625775|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1a: sequential/parallel, Phase 1b: parallel||||
33751771|NCT03062969|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33865121|NCT04200495|||COHORT||PROSPECTIVE|||||||
33865122|NCT01039753|||COHORT||PROSPECTIVE|||||||
33865123|NCT05087420|||COHORT||CROSS_SECTIONAL|||||||
33865124|NCT03580239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865125|NCT02896829|||OTHER||PROSPECTIVE|||||||
33865126|NCT04236063|||OTHER||CROSS_SECTIONAL|||||||
33865127|NCT00199602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865128|NCT04637672|||COHORT||PROSPECTIVE|||||||
33865129|NCT05486026|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided into two groups, first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals.||||
33865130|NCT03862157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865131|NCT01810835|||COHORT||RETROSPECTIVE|||||||
33865132|NCT03463798|||COHORT||PROSPECTIVE|||||||
33865133|NCT01824680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865134|NCT01855451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865135|NCT02649296|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33865136|NCT01886313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865137|NCT05593666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865138|NCT00533026|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865139|NCT00221650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865140|NCT06310954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178210|NCT06588179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178211|NCT02900729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178212|NCT00200486|||COHORT||PROSPECTIVE|||||||
34178213|NCT04877613|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The is a Phase I dose finding study to determine the safety of CART-GFRa4 cells. Dose escalation and determination of maximum tolerated dose (MTD) will be based on the standard 3+3 design to explore 3 possible dose levels.||||
33751772|NCT01725828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33865141|NCT05623397|||COHORT||PROSPECTIVE|||||||
33865142|NCT00314249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865143|NCT01033656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865144|NCT02334787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865145|NCT03210272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865146|NCT03899363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865147|NCT05755945|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865148|NCT00197405|||CASE_CONTROL||RETROSPECTIVE|||||||
33865149|NCT06335108|||COHORT||PROSPECTIVE|||||||
33865150|NCT03618186|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33865151|NCT01503710|||COHORT||CROSS_SECTIONAL|||||||
33865152|NCT06418217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865153|NCT02157753|||COHORT||PROSPECTIVE|||||||
33865154|NCT00886704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865155|NCT01156233|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865156|NCT04680442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865157|NCT02478970|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33865158|NCT00565591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34178214|NCT06585111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The participants were divided into two groups: intervention and control groups. Interventions and follow-ups were carried out in six determined time periods.||||
34178215|NCT04299464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751773|NCT06724510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34178216|NCT04488679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33751774|NCT06285877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Control Group (CG), which received their usual sessions of conventional therapy sessions, and an Experimental Group (EG), which received therapy with Nintendo Switch plus their conventional therapy sessions.||||
33751775|NCT06102057|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental Arm (FDG-PET-based small volume accelerated radiotherapy with concurrent standard of care chemotherapy) Conventional Arm (standard FDG-PET-based radiotherapy with concurrent standard of care chemotherapy)||||
33751776|NCT06654089|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34178217|NCT06329817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34178218|NCT06342037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178219|NCT06090422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33751777|NCT02821767|||COHORT||CROSS_SECTIONAL|||||||
33751778|NCT01886898|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34178220|NCT04686474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751779|NCT03158883|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups (n=13) of non-responders and progressors will go through the same treatment regime.||||
33751780|NCT02353650|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33751781|NCT03199222|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33751782|NCT01397838|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751783|NCT02695082|||COHORT||RETROSPECTIVE|||||||
34178221|NCT06604663|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will evaluate the intervention using a stepped-wedge design whereby clinics are assigned the intervention in sequential order, and in batches. Specifically, the investigators will implement the decision support tool at 5 or 6 clinics per month over a period of 6 months. By the end of 6 months, all clinics will be receiving the decision support tool.~There may be some variation in the allocation, owing to readiness of individual clinics to begin using the decision support tools. To ensure balance in allocation, randomization will be stratified by geographic location, clinic size and pre-intervention appointment default rate."||||
34178222|NCT00453206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178223|NCT01915784|RANDOMIZED|CROSSOVER||||NONE||||||
34178224|NCT03702127|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participant will receive active and sham stimulation at varying points during the study.|||||
33751784|NCT00299650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178225|NCT03773640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study group I (20 patients) and control group II (20 patients) consisted of patients, aged 19 to 45 years, of both sexes, who reported to the Consulting Room of Temporomandibular Joint Dysfunction at The Institute of Dentistry in Krakow to undertake prosthetic treatment of pain form of temporomandibular disorders, with the dominant muscle component.||||
34178226|NCT02443688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178227|NCT05686603|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This prospective, randomized, split-face, controlled trial. Enrolled participant was randomized to receive split-face treatment with fractional 1064-nm Nd:YAG picosecond lasers (PicocareTM, Wontech, Korea) on one side and ablative fractional 2940-nm Er:YAG laser (Dermablate MCL31, Asclepion Laser Technologies, Germany) on the other side. The block randomization was used to assign the treatment modality.|t|f|t|f
34178228|NCT06597812|||OTHER||PROSPECTIVE|||||||
34178229|NCT01885299|||COHORT||OTHER|||||||
34178230|NCT01863784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178231|NCT03177317|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34178232|NCT04542837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178233|NCT04927429|||COHORT||PROSPECTIVE|||||||
34178234|NCT03727217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178235|NCT04282187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178236|NCT05914090|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34178237|NCT02167971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178238|NCT02715609|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178239|NCT06586294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1b/II, open-label, 2-part, multicenter, non-randomized, multiple-dose study||||
34178240|NCT06596655|NA|SINGLE_GROUP||OTHER||NONE||||||
34178241|NCT04268979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178242|NCT05199337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178243|NCT01223534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178244|NCT00541658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178245|NCT06407414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178246|NCT05962528|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34178247|NCT05908461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34178248|NCT00603317|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34178249|NCT03664531|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The statistician will also be masked from the treatments.|Participants will be required to be on a gluten-free diet for a period of 3 weeks before starting the study. Participants will then be randomized to take muesli bars containing either purified gluten, non-purified gluten with amylase trypsin inhibitors, or nocebo for 1 week followed by 2 weeks of washout, and then repeated for the two remaining dietary challenges so that at the end all participants have been on all dietary challenges. At the beginning and end of each challenge period, participants will visit the clinic to be evaluated for changes in IBS symptoms.|t|t|t|t
34178250|NCT04690686|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|Open-label, phase 2a pilot study of Immunicom's LW-02 column-combined with low-dose chemotherapy or immunotherapy.||||
34178251|NCT01527370|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34178252|NCT03131024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33751785|NCT04514341|||COHORT||PROSPECTIVE|||||||
33751786|NCT00003532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751787|NCT06219746|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33751788|NCT02975973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178253|NCT06601309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This parallel assignment interventional study evaluates the efficacy and safety of biomarker-based neoadjuvant treatments in resectable locally advanced esophageal squamous cell carcinoma (ESCC). Patients are stratified by PD-L1 expression (CPS) into three groups:~1. High PD-L1 Expression (CPS ≥ 20) Neoadjuvant immunotherapy alone.~2. Moderate PD-L1 Expression (CPS 10-20): Neoadjuvant chemotherapy combined with immunotherapy.~3. Low PD-L1 Expression (CPS \< 10): Standard neoadjuvant chemoradiotherapy.~All treatments are followed by surgical resection. The primary endpoint is the pathological complete response (pCR) rate post-surgery. Secondary endpoints include treatment-related toxicity, R0 resection rate, and 3-year disease-free survival (DFS). Exploratory endpoints include identifying molecular biomarkers linked to treatment efficacy."||||
34178254|NCT03072407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||placebo-control , parallel|t|f|f|f
34178255|NCT05518812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178256|NCT04230759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178257|NCT03481088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178258|NCT06147817|||COHORT||RETROSPECTIVE|||||||
34178259|NCT02453620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178260|NCT05943691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178261|NCT04895891|NA|SINGLE_GROUP||OTHER||NONE||||||
34178262|NCT05933941|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33751789|NCT01088139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33751790|NCT01814592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33751791|NCT01395381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178263|NCT06592560|||COHORT||PROSPECTIVE|||||||
34178264|NCT04416217|||COHORT||PROSPECTIVE|||||||
34178265|NCT03562364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178266|NCT06234189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178267|NCT06650709|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label study.||||
34178268|NCT05558332|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will recieve the adapted YST treatment (YST-CHR) and the other group will receive treatment as usual. Participants receiving the existing treatment will be offered YST-CHR after the study is over if appropriate||||
34178269|NCT01269203|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34178270|NCT04665453|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34178271|NCT06603051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178272|NCT06123338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178273|NCT06588777|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34178274|NCT04820075|NA|SINGLE_GROUP||PREVENTION||NONE||stepped wedged randomization||||
34178275|NCT05120180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178276|NCT01314183|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34178277|NCT06592612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178278|NCT06092723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178279|NCT01183689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34178280|NCT03894124|NA|SINGLE_GROUP||OTHER||NONE||Single cohort pharmacokinetic (PK) study||||
34178281|NCT01553656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178282|NCT02581085|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33865159|NCT04634981|||CASE_ONLY||PROSPECTIVE|||||||
33865160|NCT02747953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865161|NCT04812067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865162|NCT01519934|||COHORT||RETROSPECTIVE|||||||
33865163|NCT02435342|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33865164|NCT03311321|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865165|NCT03156751|||CASE_ONLY||PROSPECTIVE|||||||
33865166|NCT04993833|||OTHER||PROSPECTIVE|||||||
33865167|NCT04354298|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33865168|NCT04216186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865169|NCT00836251|||COHORT||PROSPECTIVE|||||||
33865170|NCT00656773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865171|NCT00097942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865172|NCT04434196|NA|SEQUENTIAL||TREATMENT||NONE||||||
33865173|NCT00105404||||TREATMENT||||||||
33865174|NCT00228085|||DEFINED_POPULATION||OTHER|||||||
33865175|NCT02489136|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|f|t
33865176|NCT01062048|||CASE_ONLY||PROSPECTIVE|||||||
33865177|NCT03985475|||COHORT||PROSPECTIVE|||||||
33865178|NCT02714257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865179|NCT00882310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865180|NCT03197857|RANDOMIZED|CROSSOVER||PREVENTION||NONE|open|||||
33865181|NCT01092975|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865182|NCT01759004|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865183|NCT04175665|||COHORT||RETROSPECTIVE|||||||
33865184|NCT05110339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessor did not know the allocation of the participants. The patient is not informed of the medication used in the erector spinae block.|A prospective randomized double-blinded study|t|f|f|t
33865185|NCT03300167|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33865186|NCT00606450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865187|NCT03139708|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The PI measuring pupil size will not know the subject assignment.||f|f|f|t
33865188|NCT01017068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865189|NCT01826851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865190|NCT04415658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865191|NCT02761824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865192|NCT05119218|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33865193|NCT03819062|NA|SINGLE_GROUP||TREATMENT||NONE||proof of concept||||
33865194|NCT04156503|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33865195|NCT04468620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865196|NCT03173079|||COHORT||PROSPECTIVE|||||||
33865197|NCT03615235|||COHORT||PROSPECTIVE|||||||
33865198|NCT05151471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865199|NCT02449681|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single arm two-stage, phase-2 study||||
33865200|NCT06041620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865201|NCT03743883|||COHORT||RETROSPECTIVE|||||||
33865202|NCT02955420|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33865203|NCT04667910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865204|NCT00201968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865205|NCT01282281|||CASE_CONTROL||PROSPECTIVE|||||||
33865206|NCT01599910|||COHORT||PROSPECTIVE|||||||
33865207|NCT05067426|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned in either one of 2 intervention groups or a control group (ratio 1:1:1).||||
33865208|NCT01580150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33865209|NCT02129205||||TREATMENT||NONE||||||
33865210|NCT01191541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865211|NCT04939662|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional Arm||||
33865212|NCT02873650|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||open-label, parallel group||||
33865213|NCT05488210|||OTHER||PROSPECTIVE|||||||
33865214|NCT01115530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865215|NCT05138666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865216|NCT03319407|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865217|NCT00868426|RANDOMIZED|CROSSOVER||||NONE||||||
33865218|NCT04505904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
33865219|NCT05563922|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients will receive neoadjuvant chemoradiotherapy ( CapOx + radiotherapy) for 2 cycles, one week after chemoradiotherapy, the first evaluation including MRI, colonoscopy, digital rectal examination and serum CEA will be conducted. Patients without tumor progression will continue 4 cycles of chemotherapy （CapOx） until next imaging and serum assessment. After the second assessment, for patients with tumor regression and suitable for TEM will receive local resection otherwise TME. Following treatment strategy will be made base on the final pathology evaluation after surgery, patients with good pathological response (ypT 0-1 without neural vascular invasion) will enter into the follow-up period, otherwise TME will be operated.||||
33865220|NCT04160351|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open label, cross-over group, single-centre randomised controlled trial comparing MCO Dialyser with High Flux Dialyser in patients with end-stage renal disease on chronic haemodialysis.||||
33751792|NCT02224768|||COHORT||CROSS_SECTIONAL|||||||
33751793|NCT03419481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751794|NCT04084314|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33751795|NCT00335322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751796|NCT06373432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33751797|NCT05256589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The purpose of this study is to validate the performance of the Sona Saliva C-19 rapid Self-Test for detection of SARS_CoV_2 infection when using saliva specimens. A prospective study to evaluate a rapid point of care antigen test for the detection of viral proteins and compared against an approved RT-PCR test.~Saliva samples will be collected along with the current standard of care collection."||||
33751798|NCT03580733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751799|NCT06580678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33751800|NCT01659931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751801|NCT01285583|NA|SINGLE_GROUP||||NONE||||||
33751802|NCT05554952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33751803|NCT01656551|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33751804|NCT04732455|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33751805|NCT01972958|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33751806|NCT06645327|||OTHER||PROSPECTIVE|||||||
33751807|NCT00879138|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33751808|NCT03577717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751809|NCT02477111|||COHORT||PROSPECTIVE|||||||
33751810|NCT01258608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751811|NCT04273451|||OTHER||PROSPECTIVE|||||||
33751812|NCT06305338|||COHORT||PROSPECTIVE|||||||
33751813|NCT02535910|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33751814|NCT06733311|||COHORT||PROSPECTIVE|||||||
33751815|NCT00965432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751816|NCT05275192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178283|NCT05249556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator and research staff will be aware of the ascending dose design of the clinical investigation; however, the investigator, the research staff, and the participants will be blinded with respect to who is receiving active drug versus PBO.|This is a global, double-blind, randomized, PBO-controlled trial of adjunctive GNX treatment in participants 6 months to less than 2 years of age with genetically confirmed CDD|t|t|t|f
34178284|NCT02575963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178285|NCT06592209|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Three-arm trial wherein participants self-selected a movement break dose to follow (5 min movement breaks every 30, 60, or 120 min)||||
34178286|NCT06246539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178287|NCT06590506|||COHORT||PROSPECTIVE|||||||
34178288|NCT06600659|||COHORT||PROSPECTIVE|||||||
34178289|NCT05903794|NA|SEQUENTIAL||TREATMENT||NONE||Dose-escalation Study with four cohorts of three participants in each.||||
34178290|NCT03641755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178291|NCT01128374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751817|NCT02067260||PARALLEL||TREATMENT||||||||
33751818|NCT00175604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751819|NCT03355326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33865221|NCT02543827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34178292|NCT04077073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178293|NCT06511037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751820|NCT01271322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751821|NCT05887011|||COHORT||PROSPECTIVE|||||||
33751822|NCT06576726|||CASE_CONTROL||PROSPECTIVE|||||||
33751823|NCT04398277|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|Participants are randomized to dose condition without their knowledge for the first 7 days. The primary investigator is blinded to conditions.|All participants receive the intervention. There is a brief randomized manipulation for dosage in the first 7 days only then all participants receive the higher dose.|t|f|t|f
33751824|NCT02250612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751825|NCT05560854|NA|SINGLE_GROUP||TREATMENT||NONE||Prolonged exposure will be offered in a digital format with therapist support for ten weeks. Treatment comprises of psychoeducation, rationales, in vivo exposure, imaginal exposure, problems that can arise during exposure, hot spots and relapse prevention.||||
33751826|NCT01838798|||COHORT||PROSPECTIVE|||||||
33751827|NCT04432987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751828|NCT03105310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751829|NCT01650766|||CASE_ONLY||PROSPECTIVE|||||||
33751830|NCT02650648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751831|NCT06527638|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33751832|NCT06733142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-Blinded||t|f|f|f
33751833|NCT03752684|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Evaluate urinary oxalate excretion before and after colonization with the oxalate degrading bacterium Oxalobacter formigenes||||
33751834|NCT05480475|NA|SEQUENTIAL||OTHER||NONE||Three-period, fixed-sequence design||||
33751835|NCT04585932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865222|NCT01803477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33865223|NCT02807051|NA|SINGLE_GROUP||OTHER||NONE||||||
33865224|NCT01412749|||CASE_ONLY||PROSPECTIVE|||||||
33865225|NCT01892514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865226|NCT03765242|||COHORT||RETROSPECTIVE|||||||
34178294|NCT04474080|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The following trial uses a nested stepped-wedge randomized controlled trial design. Specialty residency programs will be the unit of randomization, with each program being randomized to receive the virtual peer support intervention across varying time-points. An in-depth evaluation of the interventions acceptability will be completed using a nested qualitative study design, wherein a subgroup of participants (preferably across residency programs) will be invited to participate in a brief 10-minute interview to explore their experiences with the intervention.||||
33865227|NCT04784897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865228|NCT02537548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178295|NCT00593346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865229|NCT04066660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33865230|NCT04555161|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, non-randomized early feasibility study to evaluate the safety and feasibility of the Aria CV PH System in patients with pulmonary hypertension and right heart dysfunction.||||
34178296|NCT06589609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865231|NCT03838198|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This Sequential, Multiple Assignment, Randomized Trial (SMART) pilot of a Motivational Interview (MI)-enhanced safety planning intervention is designed to inform the development of a technology-augmented adaptive intervention for youth at risk for suicide. The MI-SafeCope intervention includes three components: (1) MI-enhanced safety plan delivered during hospitalization (encompassing individual and family meetings); (2) post-discharge booster call; and (3) post-discharge daily text message boosters. In this SMART pilot, adolescents will be randomized to either MI-enhanced safety plan alone or in combination with text boosters for two weeks after discharge (Phase 1 intervention). At the end of week 2, adolescents will be re-randomized to two additional weeks of either: continuation of Phase 1 intervention or continuation of Phase 1 intervention with the addition of post-discharge booster call. Thus, participants will receive one of four treatment sequences (Groups A-D).||||
33865232|NCT01343589|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33865233|NCT04688723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865234|NCT02542384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865235|NCT03419338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865236|NCT00956657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
33865237|NCT02422407|||COHORT||PROSPECTIVE|||||||
33865238|NCT00621231||PARALLEL||BASIC_SCIENCE||||||||
33865239|NCT01849497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865240|NCT00932984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865241|NCT02292966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865242|NCT04490395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865243|NCT01641237|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33963586|NCT06468735|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963587|NCT04438629|||COHORT||PROSPECTIVE|||||||
33963588|NCT05041244|RANDOMIZED|PARALLEL||TREATMENT||NONE||Superiority, multi-centre randomised parallel groups||||
34178297|NCT06588439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178298|NCT05372757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178299|NCT06513026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178300|NCT06595589|||OTHER||CROSS_SECTIONAL|||||||
34178301|NCT02963246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178302|NCT05750823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178303|NCT03768492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178304|NCT02704455|||COHORT||PROSPECTIVE|||||||
34178305|NCT05005429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178306|NCT06590701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751836|NCT06551974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751837|NCT05381974|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33751838|NCT00931372|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33751839|NCT03818412|NA|SINGLE_GROUP||OTHER||NONE||||||
33865244|NCT00454285|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33865245|NCT00576017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865246|NCT00736034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865247|NCT04251754|||COHORT||OTHER|||||||
33865248|NCT04615104|||COHORT||PROSPECTIVE|||||||
33865249|NCT05804760|||COHORT||PROSPECTIVE|||||||
33963589|NCT00266552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33963590|NCT05819931|NA|SEQUENTIAL||TREATMENT||NONE||before-after comparison of the treatment||||
33963591|NCT05816044|||CASE_CONTROL||RETROSPECTIVE|||||||
33963592|NCT05336682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963593|NCT01987024|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963594|NCT04649801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963595|NCT02445989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963596|NCT01958593|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34178307|NCT06587880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||"The study coordinator will carry out the randomization as mentioned to have a list for the order in which interventions will be given, the same coordinator will prepare opaque bags, then they will move mouthwashes into new opaque bottles and put them in the bags at the same order in the randomization list, instructions sheets will be provided also for the specific mouthwash in the bag.~The research assistant will have the bags without knowing what is inside them, they will give them to the surgeon after finishing the extraction procedure according to the assigned numbers of the patients which is determined according to the order of visits, the research assistant will leave the surgery room then the surgeon will open the bag to see the instructions to deliver them verbally to the patient and make sure they understand them fully then putting them back in the bag and giving it to the participant."|t|t|t|t
34178308|NCT02662673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865250|NCT01335009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865251|NCT01318954|||COHORT||PROSPECTIVE|||||||
33865252|NCT01255969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865253|NCT00697450|||COHORT||PROSPECTIVE|||||||
33865254|NCT00174590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865255|NCT02379767|||CASE_CONTROL||PROSPECTIVE|||||||
33865256|NCT03415126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865257|NCT04304976|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33865258|NCT02933736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865259|NCT05902377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865260|NCT00455013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865261|NCT04620850|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33865262|NCT01859468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865263|NCT02276287|||COHORT||CROSS_SECTIONAL|||||||
33865264|NCT00108186|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865265|NCT00590044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865266|NCT02715713|||CASE_CONTROL||PROSPECTIVE|||||||
33865267|NCT05031988|||OTHER||PROSPECTIVE|||||||
33963597|NCT05171699|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34065330|NCT01797094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065331|NCT00000841||||TREATMENT||||||||
34178309|NCT04467437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34178310|NCT01682239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34178311|NCT03041740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865268|NCT06239298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865269|NCT01467453|||CASE_ONLY||PROSPECTIVE|||||||
33865270|NCT06075160|||COHORT||PROSPECTIVE|||||||
33865271|NCT05030454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065332|NCT01111422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178312|NCT06359158|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33865272|NCT05503862|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized to one of two arms: standard of care office-based pathway or the at home semen testing pathway utilizing the FDA, commercially approved YoSperm® device.||||
33865273|NCT04869254|||COHORT||RETROSPECTIVE|||||||
33865274|NCT04044183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865275|NCT02830763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865276|NCT01980420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865277|NCT01453673|||||RETROSPECTIVE|||||||
33865278|NCT01318252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865279|NCT04411628|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33865280|NCT04353466|NA|SINGLE_GROUP||TREATMENT||NONE||The objective of this study is to assess Elelyso treatment on bone disease in Gaucher patients currently treated with other enzyme replacement therapy||||
33865281|NCT05837351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751840|NCT02127424|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34178313|NCT04375891|RANDOMIZED|PARALLEL||OTHER||NONE||A study design of 2:1 randomization scheme (RT plus PVA/RFA:RT), the study will be adequately powered with 52 patients (35 in the RT plus PVA/RFA arm and 17 in the RT arm). Assuming a 5% ineligibility rate, a death rate of 15%, and a patient non-compliance rate of 15%, the total sample size required would be 80 patients.||||
34178314|NCT02954536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178315|NCT02610855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178316|NCT06493552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178317|NCT05846243|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind Study|This was a clinical study of VAC∆6 vaccine designed to induce specific immunity to human-pathogenic orthopoxviruses (VARV, MPXV, CPXV, VACV)|t|f|t|f
34178318|NCT04172181|||COHORT||PROSPECTIVE|||||||
34178319|NCT00456846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178320|NCT06591676|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This will be a randomized controlled trial to evaluate the feasibility and acceptability of delivering a new intervention. Participants who meet the inclusion criteria will be randomly allocated to intervention or control groups in a 1:1 ratio||||
34178321|NCT04160117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178322|NCT06305702|||CASE_ONLY||RETROSPECTIVE|||||||
34178323|NCT00522093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178324|NCT06379659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this study, a double-blind methodology will be employed to minimize bias. Patients will be administered medication without knowing the study group and placebo or treatment intervention. To ensure uniformity between growth hormone and placebo, which has a similar appearance to the placebo, will be prepared by an individual informed of the enrolled patients in the study and will be provided to the administering physician. The evaluator assessing outcomes such as clinical pregnancy rate and endometrial thickness will not know which treatment each patient received. Laboratory staff will also be unaware of the treatment groups.|This study was designed as a randomized controlled exploratory clinical trial, controlled with a parallel placebo group and random allocation using an online based system.|t|t|f|t
34178325|NCT04005846|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Double-blind randomized sham controlled crossover|t|t|t|t
34178326|NCT00278343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178327|NCT06593847|NA|SINGLE_GROUP||TREATMENT||NONE|Participants are blind to the study hypothesis and outcomes are assessed by participant self-report.|Single session VR-based exposure therapy||||
34178328|NCT04625946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178329|NCT06653933|||COHORT||PROSPECTIVE|||||||
34178330|NCT06595550|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34178331|NCT01684917|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34178332|NCT04115761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178333|NCT03756519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The patient will be partially blinded by our not providing full details on the two interventions being studied. Participants will be instructed that, Participants in this study will be randomized (chosen as by a coin flip) to receive one of two different types of advice and instruction on maintaining mobility and performing exercise."|t|f|f|f
34178334|NCT05809934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study|t|t|t|t
34178335|NCT06061809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751841|NCT04653766|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33751842|NCT02654808|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33751843|NCT00205283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751844|NCT02677116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751845|NCT02821273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33751846|NCT04326270|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751847|NCT01259037|||CASE_ONLY||PROSPECTIVE|||||||
33751848|NCT06653855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The physical therapist providing the standard physical therapy treatment and the outcomes assessment will be masked to group allocation. However, the therapist administering the cupping and placebo cupping treatments will not be masked to group allocation.||t|t|f|t
33865282|NCT03506737|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33865283|NCT05648058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865284|NCT05470946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865285|NCT06274008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33865286|NCT02790125|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33865287|NCT02614391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178336|NCT05665231|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The envelopes were prepared prior to the start of the clinical study, mixed and stored. before each surgery, an envelope was randomly taken for the preparation of the surgery|The sample consists of 20 clinical cases of unitary tooth loss in the region of the incisors, canines, and maxillary premolars of patients from the clinic of the Faculty of Dental Medicine of the University of Porto. Clinical cases were randomly grouped into 2 implant groups (triangular shape - implant V3 form Mis® and cylindrical shape - implant C1 from Mis®) by a closed envelope allocation (triangular shape implant: 10 clinical cases; cylindrical shape: 10 clinical cases). Three consecutive measurements were performed for each parameter, using their average for statistical analysis. The envelopes were prepared prior to the start of the clinical study, mixed and stored. before each surgery, an envelope was randomly taken for the preparation of the surgery.|t|t|t|t
34178337|NCT04245150|||COHORT||PROSPECTIVE|||||||
34178338|NCT00830752|||CASE_ONLY||PROSPECTIVE|||||||
34178339|NCT03603782|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34178340|NCT02877108|||COHORT||PROSPECTIVE|||||||
33865288|NCT02450604|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865289|NCT05132270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865290|NCT00630461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865291|NCT03202784|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Three way crossover to evaluate two formulations of BCX7353 and to determine if there is a food effect||||
33865292|NCT04424173|||COHORT||PROSPECTIVE|||||||
33865293|NCT01219049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865294|NCT03312348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865295|NCT02654366|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33865296|NCT03234166|||COHORT||RETROSPECTIVE|||||||
33865297|NCT04607928|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|doble blinded, IVRSystem|2:1 (treatment:placebo)|t|t|t|f
34178341|NCT05577247|||CASE_CONTROL||PROSPECTIVE|||||||
34178342|NCT02190253|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178343|NCT05795452|||COHORT||PROSPECTIVE|||||||
34178344|NCT03777982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178345|NCT04324151|||COHORT||RETROSPECTIVE|||||||
34178346|NCT06037161|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34178347|NCT02470286|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34178348|NCT02612272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34178349|NCT04126135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34178350|NCT06590220|||COHORT||PROSPECTIVE|||||||
34178351|NCT06212024|||COHORT||PROSPECTIVE|||||||
34178352|NCT06592950|||COHORT||PROSPECTIVE|||||||
34178353|NCT04142931|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178354|NCT05432648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178355|NCT04353141|||COHORT||PROSPECTIVE|||||||
34178356|NCT03962491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178357|NCT06597149|NA|SINGLE_GROUP||OTHER||NONE|Individuals will be either assigned to either the Active or the Sham groupings. The active group will receive a mild stimulation from the TaVNS device and the sham group will receive no stimulation but will believe that they are receiving a stimulus.|Healthy adults will receive mild transcutaneous stimulation of the auricular branch of the vagal nerve in order to determine if the stimulation affects plasma insulin levels.||||
34178358|NCT06585839|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178359|NCT03969004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178360|NCT02078206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178361|NCT06594640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178362|NCT04879589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178363|NCT00761423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178364|NCT06655636|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34178365|NCT06592196|||OTHER||RETROSPECTIVE|||||||
34178366|NCT03730649|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178367|NCT06599437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178368|NCT05819658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178369|NCT06540521|||CASE_ONLY||PROSPECTIVE|||||||
34178370|NCT06588062|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34178371|NCT05257356|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are not fully instructed about the purpose before and during the test but will be debriefed after testing.|"Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."|t|f|f|f
34178372|NCT06570447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178373|NCT04354129|||COHORT||PROSPECTIVE|||||||
34178374|NCT05222451|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|Participants will not be made aware of the diet allocation. However, due inherent differences in macronutrient content of the diets, participants may perceive differences in the quantity of various food groups or in the taste, texture or smell of foods present in the diet. To address this, diets will be designed to minimize noticeable differences for the participant. The investigator and outcomes assessor will remain fully masked to diet provision.||t|f|t|t
34178375|NCT04841863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178376|NCT04088877|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Independent assessors will assess outcomes|||||
33865298|NCT06113484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865299|NCT05394220|||CASE_CONTROL||PROSPECTIVE|||||||
33865300|NCT00180154|||COHORT||PROSPECTIVE|||||||
33865301|NCT01753583|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865302|NCT01448239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178377|NCT01400308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178378|NCT05422443|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178379|NCT04689139|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178380|NCT06295185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178381|NCT06589167|||OTHER||CROSS_SECTIONAL|||||||
33865303|NCT03459118|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||This is an intervention study testing Function Focused Care. The supplement, however, addresses a subsample of the population with dementia and explore the impact of pain on function and behavior and explores if this is a differential impact of the intervention between those with and without dementia. It is a descriptive study.|f|f|f|t
34178382|NCT04424095|||COHORT||PROSPECTIVE|||||||
34178383|NCT06345274|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34178384|NCT03774446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178385|NCT04335721|RANDOMIZED|PARALLEL||TREATMENT||NONE||6 participants will take voxelotor 1500mg once a day 6 participants will be observed while receiving standard of care (SOC)||||
34178386|NCT02700321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865304|NCT05834309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34178387|NCT05144373|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"We will recruit 45 infants with DS from the greater Atlanta area and beyond. There will be three groups: (a) gross motor (GM) group (n=15), entering the study at about 10 months of age; (b) gross motor plus fine motor (GM+FM) group (n=15), entering the study at about 10 months; and (c) control group (n=15), entering the study at about 20 months. The GM group will receive a home-based, parent-guided practice of treadmill stepping from 10 months of age until walking onset. The GM+FM group will receive both treadmill intervention from 10 months of age until walking onset as well as fine motor experience in practice of grasping using sticky mittens from 10 months of age for about five months. The control group will not receive an intervention."|f|f|f|t
34178388|NCT02021877|||COHORT||PROSPECTIVE|||||||
34178389|NCT06591052|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34178390|NCT03467750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The PACU nurses will be blinded to ketorolac administration, but will be informed of all other medications given. The PACU nurses will evaluate the patients using FLACC scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. Morphine will be administered to obtain a FLACC score of less than 3.||f|t|f|f
33865305|NCT03410199|||CASE_CONTROL||PROSPECTIVE|||||||
33865306|NCT03858036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178391|NCT03712813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized in a 1:1 ratio to LIV or the standard of care. The total patient enrollment will be 72 patients with 36 patients in each arm. Upon registration, subjects will be randomized and given an automated sequence number.||||
34178392|NCT04069689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178393|NCT01870349|||COHORT||CROSS_SECTIONAL|||||||
34178394|NCT04853173|NA|SINGLE_GROUP||OTHER||NONE||Assess pain management modalities in adult outpatient tonsillectomy surgery||||
34178395|NCT01190397|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34178396|NCT00020488||||TREATMENT||||||||
34178397|NCT05052996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178398|NCT05920759|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34178399|NCT04717037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178400|NCT06588959|||OTHER||CROSS_SECTIONAL|||||||
34178401|NCT06601920|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34178402|NCT05058339|||CASE_ONLY||CROSS_SECTIONAL|||||||
34178403|NCT01394237|||CASE_ONLY||PROSPECTIVE|||||||
34178404|NCT03030586|||COHORT||PROSPECTIVE|||||||
34178405|NCT06603948|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34178406|NCT06131801|||OTHER||PROSPECTIVE|||||||
34178407|NCT05322798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178408|NCT06594224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178409|NCT01710982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865307|NCT03887845|||CASE_CONTROL||PROSPECTIVE|||||||
33865308|NCT01802489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865309|NCT03778853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865310|NCT06476236|NA|SINGLE_GROUP||OTHER||NONE||Open label single arm intervention pilot||||
33865311|NCT05377190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33865312|NCT03768505|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with Zandelisib (ME-401) (60 mg) given orally once a day on an intermittent schedule||||
33865313|NCT05744336|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled observational trial||||
33865314|NCT05594316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865315|NCT05315323|||COHORT||PROSPECTIVE|||||||
33865316|NCT00361426|||CASE_CONTROL||PROSPECTIVE|||||||
33865317|NCT01115842|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865318|NCT06224309|||COHORT||PROSPECTIVE|||||||
33865319|NCT03327441|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34178410|NCT04669886|||CASE_ONLY||PROSPECTIVE|||||||
33865320|NCT03480412|||COHORT||PROSPECTIVE|||||||
33865321|NCT04812496|||COHORT||RETROSPECTIVE|||||||
33865322|NCT05144074|||COHORT||PROSPECTIVE|||||||
33865323|NCT02053909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865324|NCT03792386|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865325|NCT03519685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33865326|NCT04665336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|t|f|f|f
33865327|NCT02678143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865328|NCT00918853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865329|NCT02607449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865330|NCT01150825|||CASE_CONTROL||PROSPECTIVE|||||||
33865331|NCT02082899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865332|NCT00515957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865333|NCT00210184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865334|NCT02807649|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33865335|NCT00591825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865336|NCT00255762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963598|NCT04535271|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.||||
33963599|NCT01637675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963600|NCT05589428|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33963601|NCT03471182|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178411|NCT06378047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178412|NCT06069193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were not aware which experimental condition they were allocated to.|participants are assigned to one of two experimental groups in parallel for the duration of the study|t|f|f|f
34178413|NCT06059664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||150 kidney transplant recipients will be randomized in a 2:1 ratio to finerenone versus placebo, with an embedded biopsy substudy in 50 participants (25 finerenone/25 placebo) who undergo a research kidney biopsy prior to randomization and at the end of active treatment.|t|t|t|t
34178414|NCT04385277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178415|NCT04634422|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, parallel-grouped, stratified, centrally randomised controlled trial.||||
34178416|NCT05964842|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Due to the nature of the intervention, participants will not be blinded to the study arm though data analysis will be blindly conducted.|This will be an individual randomized controlled trial with five arms. The study arms will include; i) Standard of care (SOC - control group) ii) SMS only iii) phone call only iv) SMS and mobile money incentive v) Phone call and mobile money incentive|f|t|f|t
34178417|NCT01945008|||COHORT||PROSPECTIVE|||||||
34178418|NCT04847817|||CASE_CONTROL||PROSPECTIVE|||||||
34178419|NCT01135277|||COHORT||PROSPECTIVE|||||||
34178420|NCT01592734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34178421|NCT06603324|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO||||
34178422|NCT06586086|||COHORT||CROSS_SECTIONAL|||||||
34178423|NCT06592053|||COHORT||PROSPECTIVE|||||||
34178424|NCT06592352|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, open-label design to evaluate the effect of modafinil on cognitive deficits in adult patients with multiple sclerosis and identify predictors of response using functional Magnetic Resonance Imaging (fMRI).||||
34178425|NCT06378008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34178426|NCT06365697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178427|NCT03475004|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178428|NCT06536101|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||A first in human, randomized, double-blind, placebo-controlled, dose escalation study of single and multiple oral doses of GIM-407 in healthy adult participants. The study will include 2 parts, a single ascending dose (SAD) part (Part 1) and a multiple ascending dose (MAD) part (Part 2), which will proceed in a staggered manner with a partial overlap|t|f|t|f
34178429|NCT03579251|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||1) Semi-structured, qualitative interviews; 2) protocol development; 3) single-arm pilot study||||
34178430|NCT04531085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Non-inferiority RCT 1:1 ratio|f|f|t|t
34178431|NCT03884829|NA|SINGLE_GROUP||TREATMENT||NONE||One to three patients will be entered at a given dose level of CYC140. During the first cycle, all patients will be evaluated for DLTs. If DLT occurs, additional patients (up to 3) will be dosed at that dose. If no additional DLTs observed, dose escalation will continue per protocol. If a DLT does occur, dose escalation will be stopped. At least 6 patients will be treated at the RD to confirm its tolerability.||||
33865337|NCT06036251|||COHORT||PROSPECTIVE|||||||
34178432|NCT06592885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178433|NCT02473848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178434|NCT05954858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178435|NCT00272584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34178436|NCT02130817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178437|NCT03631940|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Cluster Randomized Crossover||||
33865338|NCT05452811|||COHORT||RETROSPECTIVE|||||||
33865339|NCT00105144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865340|NCT01615926|||COHORT||PROSPECTIVE|||||||
33865341|NCT03255850|||COHORT||CROSS_SECTIONAL|||||||
33865342|NCT05327374|||CASE_ONLY||PROSPECTIVE|||||||
33865343|NCT05597865|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33865344|NCT02493504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865345|NCT04457076|NA|SINGLE_GROUP||TREATMENT||NONE||LevoCept Intrauterine Device (IUD)||||
33865346|NCT01200238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The original dose (Cohort A) was amended based on phase 1 data for safety. Therefore there are 2 separate arms reported.||||
33865347|NCT05881174|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a 3 arm non-randomized, crossover-design clinical investigation using rescue acupuncture for the treatment of PTSD symptoms. Each patient receiving rescue acupuncture for PTSD will be their own control."||||
33865348|NCT04429854|RANDOMIZED|PARALLEL||TREATMENT||NONE||483 patients with 2:1 randomization. 320 patients receiving Convalescent Plasma - 163 patients receiving Standard of Care||||
33865349|NCT02848950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963602|NCT00802529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963603|NCT03860571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Blinded:~The people receiving the treatment/s The people administering the treatment/s The people assessing the outcomes"|Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)|t|f|t|t
33963604|NCT06237699|||COHORT||PROSPECTIVE|||||||
33963605|NCT05792865|||COHORT||OTHER|||||||
33963606|NCT00750009|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33963607|NCT02910453|||CASE_CONTROL||PROSPECTIVE|||||||
33963608|NCT01884116|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33963609|NCT06522334|||COHORT||OTHER|||||||
33865350|NCT02177721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865351|NCT02437617|||COHORT||PROSPECTIVE|||||||
33865352|NCT02567539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865353|NCT02041208|||CASE_ONLY||RETROSPECTIVE|||||||
34178438|NCT04294134|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||We will use a quasi-experimental trial design with historical controls as well as qualitative interviews to assess effectiveness and efficiency of MIO-CPP when paired with CRS, on parent and child outcomes including therapy engagement, parent/caregiver well-being, child well-being, and family well-being. The study will take place over two phases. Eligible caregivers in Phase 1 will receive MIO-CPP (control), while participants enrolled in Phase 2 will receive a MIO-CPP while also being paired with a CRS.||||
34178439|NCT02900118|||COHORT||PROSPECTIVE|||||||
34178440|NCT00311675|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34178441|NCT06053268|NA|SINGLE_GROUP||OTHER||NONE||||||
34178442|NCT04634071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a parallel design. However, it is part of a broader sequential cohort design to compare the effects of preference driven tobacco treatment upon cessation versus effects of a previous cohort from a separate randomized controlled trial.||||
34178443|NCT01349946|||CASE_CONTROL||PROSPECTIVE|||||||
34178444|NCT06142786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, their parents/guardians, the neurofeedback/sham feedback trainer, the investigator, and outcome assessors will be blinded to the allocation of conditions. An independent senior research assistant from our team, who is not involved in the mentioned roles, will execute the random allocation algorithm and set the neurofeedback training protocol (either verum or sham) before each visit|Once eligible participants are enrolled in this study, they will be randomly allocated either to the neurofeedback intervention group or the sham feedback group. Participants in both groups will receive treatment/sham treatment at the same period.|t|t|t|t
34178445|NCT06502860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them. The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects.|Randomized Controlled Experimental Design|t|f|f|f
34178446|NCT06603727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking will affect participants and study personnel, with exception to the personnel supervising the training programs.||t|f|t|t
34178447|NCT06588452|||COHORT||PROSPECTIVE|||||||
34178448|NCT06276556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178449|NCT04300192|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178450|NCT06599086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician performing the evaluation will be blind to which procedure is performed.|Our study was designed as a prospective, single-blind randomized controlled study.Patients who applied to our hospital's PMR outpatient clinic and with|f|f|f|t
34178451|NCT06602284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865354|NCT03368950|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Wait list or Intervention Arms||||
33865355|NCT01296984|||CASE_CONTROL||RETROSPECTIVE|||||||
34178452|NCT04945681|NA|SINGLE_GROUP||PREVENTION||NONE||Before vs. after quasi-experimental study. Entire study population is offered the intervention.||||
34178453|NCT04797585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178454|NCT02121158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178455|NCT06597188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178456|NCT05773755|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|N/A. This is open label study.|All participants will be implanted with the study device and receive open label, active DBS stimulation||||
33865356|NCT06427291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865357|NCT02713035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865358|NCT00608296|||COHORT||PROSPECTIVE|||||||
33865359|NCT01768897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865360|NCT02294682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865361|NCT00962156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865362|NCT04332224|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated measures design||||
33865363|NCT00993954|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865364|NCT02941653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865365|NCT00571233|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178457|NCT06604741|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865366|NCT05696275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33865367|NCT02975193|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34178458|NCT04559815|||COHORT||PROSPECTIVE|||||||
34178459|NCT04981925|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178460|NCT06596512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34178461|NCT04791579|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Placebo|Patients will be randomized at a 1:1 allocation ratio to two parallel treatment arms - intervention versus placebo|t|t|t|t
34178462|NCT06038864|||COHORT||PROSPECTIVE|||||||
34178463|NCT03435211|NA|SINGLE_GROUP||OTHER||NONE||||||
34178464|NCT04555551|NA|SINGLE_GROUP||TREATMENT||NONE||This phase I trial will follow a standard 3-by-3 dose escalation design.||||
34178465|NCT05679388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178466|NCT04359810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 219 eligible subjects will be randomized in a 2:1 ratio to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or non-convalescent fresh frozen plasma (control plasma).|t|f|f|t
34178467|NCT04638543|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34178468|NCT05306873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178469|NCT01564160|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
34178470|NCT06590090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178471|NCT05527015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be masked to their treatment group, given that their spectacles either will or will not have a visible flat-top bifocal. The investigator treating each participant also will not be masked to treatment group. Therefore, an examiner masked to treatment group will measure eye alignment and stereoacuity at all follow-up visits and conduct the binocular function testing at the required follow-up visits.|"Random assignment (1:1) to:~* Single vision spectacles (SVLs)~* Bifocal spectacles (BFLs): +3.00 D flat-top 35"|f|f|f|t
34178472|NCT06590142|||CASE_CONTROL||PROSPECTIVE|||||||
34178473|NCT06007534|NA|SINGLE_GROUP||OTHER||NONE||||||
34178474|NCT02464696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178475|NCT06313515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, single-blind, sham-controlled trial with two arms (tSCS paired with arm-crank exercise compared to sham stimulation with exercise). Participants will be randomized into either the intervention or sham stimulation arm. Those in the sham arm only will initially receive sham stimulation, but then cross over to receive the active treatment arm, such that by the end all participants will have been exposed to the tSCS. tSCS participants will not receive sham stimulation.|t|f|f|t
34178476|NCT05554133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178477|NCT04711746|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34178478|NCT04298697|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34178479|NCT03793946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of care providers and investigators is not feasible. Outcome assessors and data analysts will be blinded to the study arm allocation.|International, multicenter stepped-wedge cluster randomized trial|f|f|f|t
34178480|NCT01692600|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178481|NCT02965911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178482|NCT06596200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178483|NCT06157515|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||This is a prospective crossover interventional study comparing two vibrating mesh nebulizer modalities - continuous versus breath-actuated - for delivering a bronchodilator, tested in healthy adult volunteers. Participants will receive an approved therapeutic dosage (2.5 mg salbutamol) via both devices in an alternating sequence. Outcome measurements focus on pharmacokinetic results, specifically urinary drug recovery.||||
34178484|NCT06024408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178485|NCT06600113|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34178486|NCT05538741|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33865368|NCT03404089|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865369|NCT06308432|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33865370|NCT05543278|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865371|NCT03244748|||COHORT||PROSPECTIVE|||||||
33865372|NCT04597957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33865373|NCT02556125|||CASE_ONLY||PROSPECTIVE|||||||
33865374|NCT01789762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865375|NCT00732251|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865376|NCT00657436|||COHORT||PROSPECTIVE|||||||
33865377|NCT04340336|||COHORT||RETROSPECTIVE|||||||
33865378|NCT00247741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865379|NCT06325618|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865380|NCT02408107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065333|NCT04679948|NA|SINGLE_GROUP||TREATMENT||NONE||Two Periods (Period 1 and Period 2) for each participant.||||
34065334|NCT01507532|NA|SINGLE_GROUP||OTHER||NONE||||||
34178487|NCT06322160|||COHORT||PROSPECTIVE|||||||
34178488|NCT03396341|||COHORT||PROSPECTIVE|||||||
34178489|NCT05227417|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The recruiter will be masked to the group assignment. Participants will be randomized after signing the consent form. Because of the nature of the study, healthcare providers and participants will not be masked to group assignment during the delivery of the intervention.|Randomized controlled trial with 2 parallel arms: intervention and control.|f|t|f|f
34178490|NCT01054014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178491|NCT03171402|||OTHER||CROSS_SECTIONAL|||||||
34178492|NCT04054557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178493|NCT06139510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This study does not involve drug or biologic products. Masking is non-applicable.|||||
34178494|NCT04444076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865381|NCT01946451|||CASE_CONTROL||RETROSPECTIVE|||||||
33865382|NCT04769050|||COHORT||PROSPECTIVE|||||||
33865383|NCT05196217|||FAMILY_BASED||PROSPECTIVE|||||||
34178495|NCT06591689|||OTHER||RETROSPECTIVE|||||||
33865384|NCT03706495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants involved in the study and the physiotherapist doing the assessment do not know which exercise group they will be involved in.|Randomized double-blind|t|f|t|f
33865385|NCT00261612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865386|NCT00267709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865387|NCT06165822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865388|NCT00122811|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34178496|NCT03234699|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33865389|NCT06033885|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865390|NCT05757336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865391|NCT05716750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865392|NCT01387165|||OTHER||CROSS_SECTIONAL|||||||
33963610|NCT06330428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The experimental group will receive sexuality-based family planning education via podcast and outcome assessment will be performed by an investigator who was blinded to group assignment.|One control group, one experimental group|t|f|f|t
34065335|NCT00264030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34065336|NCT02739451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065337|NCT06133478|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34178497|NCT06174246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Outcome assessment is masked as all outcomes are derived from self-administered questionnaires that will be filled online without the presence of any member of the research team.~Data analysis will be masked (intervention groups will be coded)."|Self-management program, with or without support from a physiotherapist.|f|f|f|t
34178498|NCT05722860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open label|Open label single arm study||||
34178499|NCT04200534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178500|NCT06589882|||COHORT||PROSPECTIVE|||||||
33865393|NCT00710736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865394|NCT01009892|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33865395|NCT02104154|||COHORT||PROSPECTIVE|||||||
33865396|NCT01025024|||CASE_CONTROL||PROSPECTIVE|||||||
33865397|NCT04087278|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind placebo randomized controlled trial|t|t|t|t
33865398|NCT00298467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751849|NCT05699733|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||the recruited sample will be subjected to 3 treatment conditions according to the traction force used. pre-post comparisons and between conditions comparisons will be conducted|t|f|f|t
33865399|NCT05275426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065338|NCT00753844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065339|NCT00063297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065340|NCT03056365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065341|NCT02412254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065342|NCT02622087|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178501|NCT03744793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178502|NCT03317158|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open-Label|||||
33865400|NCT01105091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865401|NCT02022345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865402|NCT01480921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865403|NCT02648516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865404|NCT05646212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized trial||||
33865405|NCT05053516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33865406|NCT04722770|||COHORT||PROSPECTIVE|||||||
33865407|NCT03752008|RANDOMIZED|PARALLEL||OTHER||NONE||10 childcare centers were cluster-randomized to receive either a physical activity or outdoor free play curriculum.||||
34178503|NCT04639336|||COHORT||PROSPECTIVE|||||||
34178504|NCT01841099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065343|NCT00513357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178505|NCT03645122|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Transcranial magnetic stimulation targeting the region of the brain responsible for voluntary movement control and electrical stimulation to a peripheral nerve innervating hand muscles will be triggered at an interval that elicits action potentials arriving in a set sequence and predetermined delay in the spinal cord.||||
34178506|NCT03537989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34178507|NCT04287218|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Survey: The study is population based and cross sectional. Participants will be invited to complete an electronic questionnaire to screen for fear of cancer recurrence and other psychological factors.~RCT: This part of the study is a population based, randomized, controlled clinical superiority trial. Participants are randomized to internet-based, therapist guided iConquerFear or augmented treatment as usual (1:1).~If the planned number of participants (estimated by power calculation) has not been enrolled through the scheduled screening process, colorectal cancer survivors diagnosed during 2019 will be invited to the screening, and if needed, also colorectal cancer survivors diagnosed in 2020.~The additional screening invitations will be sent out immediately after the last round of screening, i.e. before any follow-up data have been obtained. Hence, the statistical analyses will not be affected in any way."||||
34178508|NCT04998331|||COHORT||RETROSPECTIVE|||||||
34178509|NCT06562790|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34178510|NCT04929249|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, two-arm, parallel-group, open-label, multicenter clinical trial||||
34178511|NCT04353349|||CASE_CONTROL||PROSPECTIVE|||||||
34178512|NCT06556121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, anesthesiologist in the operating room|Randomized, parallel-group, double-blind|t|t|t|f
34178513|NCT01805011|||COHORT||RETROSPECTIVE|||||||
34178514|NCT00437112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34178515|NCT04443803|||CASE_ONLY||PROSPECTIVE|||||||
34178516|NCT05907785|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"An educational intervention to improve physical activity and promote healthy dietary habits will be carried out in two groups of children/adolescents: (1) a prepubertal group and (2) a postpubertal group. Within each group, there will be volunteers with normal weight (NW), overweight (OW), and obesity (OB).~A total of 180 volunteers will be assessed for eligibility (90 for each group), and 60 of them (30 for each group) will be allocated to study (intervention study)."||||
34178517|NCT00004217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178518|NCT06593028|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34178519|NCT06601972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178520|NCT03779009|NA|SINGLE_GROUP||OTHER||NONE||||||
34178521|NCT06600919|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two parallel arms (intervention group receiving passive music therapy and control group not receiving it)||||
34178522|NCT02759614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178523|NCT06594536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo|Parallel Assignment|t|t|t|t
34178524|NCT06275685|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178525|NCT03373123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865408|NCT03597971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind, randomized, placebo-controlled, dose-escalating, single dose study in healthy volunteers followed by a double blind, randomized, placebo-controlled, dose-escalating, multiple dose study in healthy volunteers.|t|t|t|f
33865409|NCT04394481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865410|NCT00771641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865411|NCT04741386|||COHORT||PROSPECTIVE|||||||
33865412|NCT04830592|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865413|NCT02010606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178526|NCT06388512|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33751850|NCT02428114|||COHORT||OTHER|||||||
33865414|NCT02069925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865415|NCT01493557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865416|NCT00550654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865417|NCT02465385|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33865418|NCT01669967|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33865419|NCT05446428|||COHORT||PROSPECTIVE|||||||
33865420|NCT02345304|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33865421|NCT01961661|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33865422|NCT05573659|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865423|NCT01937572|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178527|NCT06598683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178528|NCT02439697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178529|NCT03815929|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subject be placed into three different study arms. Subjects undergoing surgery will be randomized to receive either standard hormone therapy or individualized hormone therapy. These arms will be compared against each other as well as a third arm of healthy timed-control subjects||||
34178530|NCT06210724|||COHORT||PROSPECTIVE|||||||
34178531|NCT06603233|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||TRIPLE||Using the prior knowledge (α = 0.05, β = 0.2) and an effect size of 0.61, the actual power of the comparison between the AI model and dentists on 34 test images is at least 80%, which is deemed sufficient. Therefore, randomly selected 35 images on the test dataset were labeled by three dentists without seeing the ground truth and were predicted by the AI model. Then, the intersection over union (IoU) score of these labeled and predicted images were calculated. The IoU score, which computes the ratio between the intersection and the union of two sets, is commonly used to evaluate the accuracy of prediction on semantic segmentation. AI model's dental plaque predictions compared with predictions from three dentists.|f|t|t|t
34178532|NCT04238910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178533|NCT06599307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34178534|NCT05737485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178535|NCT01141751|||COHORT||PROSPECTIVE|||||||
34178536|NCT02849418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178537|NCT03521570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178538|NCT00966654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178539|NCT05118945|||COHORT||PROSPECTIVE|||||||
34178540|NCT02366286|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34178541|NCT04890860|NA|SINGLE_GROUP||OTHER||NONE||||||
34178542|NCT05958251|||COHORT||PROSPECTIVE|||||||
34178543|NCT01694953|||COHORT||PROSPECTIVE|||||||
34178544|NCT06255249|||COHORT||RETROSPECTIVE|||||||
34178545|NCT02759419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178546|NCT05203302|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34178547|NCT06300697|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34178548|NCT05116384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34178549|NCT06266429|||COHORT||PROSPECTIVE|||||||
34178550|NCT06381765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178551|NCT04810091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178552|NCT03938233|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster randomised control trial|f|f|f|t
34178553|NCT06592820|||OTHER||PROSPECTIVE|||||||
34178554|NCT01043302|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178555|NCT01829620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178556|NCT06590688|||COHORT||PROSPECTIVE|||||||
34178557|NCT06554795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178558|NCT06186050|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34178559|NCT01239953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178560|NCT02234882|NA|SINGLE_GROUP||OTHER||NONE||||||
34178561|NCT05094206|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178562|NCT06013735|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34178563|NCT02991768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178564|NCT06595251|||COHORT||PROSPECTIVE|||||||
34178565|NCT06591546|NA|SINGLE_GROUP||TREATMENT||NONE||Growing child (3-12 ys) Bony deformities with other symptoms and signs of OI||||
34178566|NCT04438486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178567|NCT00170586|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34178568|NCT05762302|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|applicable only for control arm||f|t|f|f
34178569|NCT02967991|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34178570|NCT02569385|||CASE_ONLY||PROSPECTIVE|||||||
34178571|NCT02504593|NA|SINGLE_GROUP||||||||||
34178572|NCT05387564|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34178573|NCT02514083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178574|NCT06591091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The design of this pilot study is a randomized double-blind. Only the study Pharmacist will be unblinded to the placebo-controlled design.|The design of this pilot study is a randomized double-blind, placebo-controlled design with one arm standard antidepressant treatment plus placebo (n=20) and one arm standard antidepressant treatment plus clemastine (5.36 mg PO daily; n=60) for 12 weeks with primary outcomes related to improvement in the level of depression and white matter integrity.|t|t|t|t
33865424|NCT00892320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33865425|NCT00851682|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33865426|NCT02336841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865427|NCT06465693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||will compare CGM plus nutrition therapy to nutrition therapy only in participants with type 2 diabetes|t|f|f|f
33865428|NCT02427230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33865429|NCT02654249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865430|NCT05024305|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865431|NCT04466644|||OTHER||PROSPECTIVE|||||||
33865432|NCT03352700|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33865433|NCT00000626||||TREATMENT||||||||
34178575|NCT05249582|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178576|NCT05902988|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178577|NCT06012916|||CASE_ONLY||PROSPECTIVE|||||||
34178578|NCT01581801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865434|NCT00068588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178579|NCT06514326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178580|NCT06594510|||OTHER||PROSPECTIVE|||||||
34178581|NCT06303115|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178582|NCT03527420|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178583|NCT04443413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Panel-assessed cosmetic outcome||f|f|f|t
34178584|NCT06597838|||OTHER||RETROSPECTIVE|||||||
34178585|NCT06596720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||For cognitive assessments of the individuals, the Standardized Mini-Mental State Examination, Stroop Test, T-BAG form, Wechsler Digit Span subtest, and Letter Cancellation Test were used. The individuals with stroke in the study group underwent 30 minutes of moderate-intensity cycling on a cycle ergometer. The individuals with stroke in the control group were left in a quiet room for 30 minutes. After this period, both groups had their pulse, saturation, and blood pressure measured again, and the Stroop Test T-BAG Form, Wechsler Digit Span Tests, and Letter Cancellation Tests were repeated.|t|f|f|f
34178586|NCT03669536|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34178587|NCT06088069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178588|NCT06058299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|TBAJ-876 and the first 8 weeks of bedaquiline will be blinded. Participants randomized to TBAJ-876 or bedaquiline arms will received active TBAJ-876 (and placebo TBAJ876 to blind the dose) and placebo bedaquiline or placebo TBAJ-876 and active bedaquiline|Participants who meet all of the inclusion criteria and none of the exclusion criteria will be randomised in a 1:1:1:1:1 ratio using an interactive response technology that stratifies based on country and severity of disease (AFB 3+ and/or bilateral cavitation) to 1 of the 5 treatment arms:|t|t|t|t
33865435|NCT00992979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963611|NCT05741775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single blinding method will be used. The participant will not know whether he or she belongs to experimental group. Only the primary researcher performing the study will know if the participants are into aerobic training, biofeedback training or control group. Single blinding will be used in this study because the results produced are less likely to be biased.|"Three groups will be present. One group receives aerobic training, second group receives biofeedback training and the last group receives patient education. So during the trial, participants in one group receive aerobic intervention in parallel to participants in the other group, who receive biofeedback training and patient education."|t|f|f|f
33963612|NCT00849524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963613|NCT05447429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Forty patients had divided into two groups; TAP block group (TAP-B) and placebo (P) group. Every group contained 20 patients and randomization was performed by sealed envelope method. Patient and the data collector resident didn't know the which procedure was done thus single-blinded randomization were provided.|t|f|f|t
34178589|NCT04331587|||CASE_ONLY||PROSPECTIVE|||||||
34178590|NCT06587646|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients randomised to either standard care or a virtual EUA (3D reconstruction imaging) via a computerised randomisation software.||||
34178591|NCT05246592|||COHORT||PROSPECTIVE|||||||
33865436|NCT04216251|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865437|NCT00627302|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33865438|NCT04440189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865439|NCT05039255|||COHORT||PROSPECTIVE|||||||
33963614|NCT06352931|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33963615|NCT03109860|||COHORT||PROSPECTIVE|||||||
34178592|NCT06047210|||CASE_CONTROL||OTHER|||||||
34178593|NCT03875378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled|t|t|t|t
34178594|NCT06143566|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants will be randomized in 1:1 fashion.||||
34178595|NCT03996824|||OTHER||PROSPECTIVE|||||||
34178596|NCT06593041|||COHORT||PROSPECTIVE|||||||
34178597|NCT06596486|||CASE_ONLY||PROSPECTIVE|||||||
34178598|NCT03587961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178599|NCT04730258|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion for monotherapy and combination arms with azacitidine||||
33963616|NCT05257863|||COHORT||RETROSPECTIVE|||||||
33963617|NCT00561405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751851|NCT02141126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Feasibility study Randomised and controlled|f|f|f|t
33751852|NCT04070924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751853|NCT00591890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751854|NCT02434692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865440|NCT00074854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865441|NCT05709236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865442|NCT04164576|||COHORT||PROSPECTIVE|||||||
33865443|NCT00726622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865444|NCT04311554|||CASE_ONLY||PROSPECTIVE|||||||
33963618|NCT00165711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963619|NCT02746029|||COHORT||PROSPECTIVE|||||||
33963620|NCT06134739|||CASE_ONLY||RETROSPECTIVE|||||||
33963621|NCT00867126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963622|NCT04072744|||COHORT||RETROSPECTIVE|||||||
34065344|NCT02308371|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963623|NCT05277922|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Subjects will receive increasing doses of C21||||
34178600|NCT06602869|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178601|NCT06654622|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178602|NCT06604611|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly 1:1 allocate into either a colchicine-treated group or a blank control group, and patients included in different centers will be uniformly randomized by the main centre.||||
34178603|NCT05888883|||CASE_CONTROL||PROSPECTIVE|||||||
34178604|NCT05642039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178605|NCT05775367|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study group will receive a cochlear implant under the age of three and be tested at the age of five. Two control groups, both five years old, will be tested as well. The control groups will consist of children with typical hearing in both ears and children with single-sided deafness who have not received a cochlear implant.||||
34178606|NCT06628284|||CASE_ONLY||PROSPECTIVE|||||||
34178607|NCT06596057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178608|NCT00006394|RANDOMIZED|||TREATMENT||DOUBLE||||||
34178609|NCT06589479|||OTHER||CROSS_SECTIONAL|||||||
34178610|NCT06595407|||CASE_CONTROL||PROSPECTIVE|||||||
34178611|NCT00281463|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178612|NCT05093270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34178613|NCT06591988|||COHORT||CROSS_SECTIONAL|||||||
34178614|NCT06194864|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34178615|NCT05378165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|While participants and researchers were not blinded to group allocation, the biostatistician remained blinded.|Single centre, open-label, randomized, parallel-group trial|f|f|f|t
34178616|NCT03667378|||CASE_CONTROL||PROSPECTIVE|||||||
34178617|NCT06588374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||hemorrhoidectomy alone versus hemorrhoidectomy with lateral internal sphincterotomy||||
34178618|NCT06585995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34178619|NCT03409016|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178620|NCT06593873|RANDOMIZED|PARALLEL||OTHER||NONE||This study included 60 fourth-year undergraduate students from Faculty of Dentistry, randomly divided into two groups. Both groups received one hour of theoretical periodontal training: the first, lasting 30 minutes, covered detailed instruction on comprehensive periodontal examination and supragingival instrumentation process through a multimedia presentation, and the second, also 30 minutes, demonstrated practical aspects (working area, support techniques, and positioning) on a patient. Group 1 received theoretical training, while Group 2 had the theoretical plus 60 minutes of preclinical practical training using a typodont-phantom head with artificial calculus. Immediately before performing supragingival instrumentation on their first patients, students completed a state anxiety test. After the procedures, participants completed VAS to rate training satisfaction. The student\&amp;#39;s clinical performance was evaluated using the scaling operation score sheet.||||
34178621|NCT05783622|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178622|NCT01821690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178623|NCT05683028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Upon registration in the computer-based training, the computer will randomly allocate participants to either cognitive control training or placebo condition.|Participants will be assigned to either intervention or placebo.|t|f|f|t
34178624|NCT05813106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||2 groups One group will receive IV dexmedetomidine Other control group receive normal saline|t|t|t|t
34178625|NCT01516905|||COHORT||PROSPECTIVE|||||||
34178626|NCT04700098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to group assignment.|Individuals will be assigned to either an internet-based behavioral treatment for insomnia or online insomnia patient education.|f|f|f|t
34178627|NCT04249999|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Physical activity intervention. Assignment to intervention or control group cannot be blinded.~Follow-up assessments will be conducted by blinded assessors.~UPADTE JUNE 2021: As noted in update above, all participants will perform procedures themselves within their own homes (i.e. physical activity, lung function, questionnaires). Therefore, use of blinded assessors is no longer applicable."|||||
34178628|NCT02298894|||CASE_ONLY||PROSPECTIVE|||||||
34178629|NCT06592300|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33751855|NCT01945606|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33751856|NCT03190473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751857|NCT04171466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33751858|NCT03404505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751859|NCT04656054|||COHORT||PROSPECTIVE|||||||
33963624|NCT00709475|||COHORT||PROSPECTIVE|||||||
33963625|NCT06540300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study used a randomized, double-blind study method that controlled true and false stimuli. Except for the study leader, neither the actual operators nor the patients themselves knew whether they were receiving real or fake stimuli.~A two factor mixed trial design was adopted, with a detection time of 2 (pre stimulus vs post stimulus) x 2 (stimulus type: right IPL vs pseudo stimulus). The stimulus type was an inter subject factor, and the detection time was an intra subject factor.~The enrolled NSSI patients were randomly divided into a study group (right IPL group) and a control group (pseudo stimulus group) using a random number table method. Collect general demographic scales, symptom scales, and magnetic resonance imaging data before treatment, and conduct symptom scale retesting and magnetic resonance imaging data collection 2 weeks after treatment."|t|t|f|f
34178630|NCT01243190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178631|NCT03670940|||COHORT||RETROSPECTIVE|||||||
34178632|NCT03094416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178633|NCT03557294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178634|NCT03133221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178635|NCT04989751|||COHORT||PROSPECTIVE|||||||
34178636|NCT06392841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178637|NCT02474316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751860|NCT06732193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751861|NCT05911204|||COHORT||PROSPECTIVE|||||||
33751862|NCT05245071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751863|NCT06480773|||COHORT||PROSPECTIVE|||||||
33751864|NCT04866017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751865|NCT06732947|||CASE_ONLY||RETROSPECTIVE|||||||
33751866|NCT02275104|||COHORT||RETROSPECTIVE|||||||
33751867|NCT03188848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865445|NCT04047160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865446|NCT01098981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178638|NCT02903771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178639|NCT06603272|||COHORT||RETROSPECTIVE|||||||
34178640|NCT04865276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178641|NCT06596837|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The investigators employed a repeated-measures crossover design. Participants were divided into Experimental: respondents exposed to highly immersive virtual reality (Cold River) or Other: respondents exposed to low-immersive virtual reality (static images) groups based on the sequence of their informed consents: even-numbered participants were assigned to the Other group, and odd-numbered participants to the Experimental group. Each participant attended two consecutive wound care sessions, which consisted of dressing removal, wound cleaning, and the application of new dressings. The investigators incorporated virtual reality (VR) into one segment of each session: either during the initial phase (dressing removal) or the concluding phase (wound cleaning and new dressing application). In their subsequent sessions, participants experienced VR during the segment opposite to their initial session.||||
34178642|NCT02432378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178643|NCT04907799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34178644|NCT02875496|||COHORT||PROSPECTIVE|||||||
34178645|NCT06588361|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||It is a randomized controlled experimental study||||
34178646|NCT05168839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34178647|NCT04263623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178648|NCT06593925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178649|NCT03990961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178650|NCT01349543|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178651|NCT01623570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178652|NCT05446272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trial PIs are unaware of treatment allocation for individual subjects||f|f|t|f
34178653|NCT05138757|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34178654|NCT02811068|||COHORT||OTHER|||||||
33751868|NCT04804553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The participants will be randomized to receive apremilast or placebo in the double-blind 16 week treatment phase. Then, the participants will all receive apremilast for a further 36 weeks in the active treatment phase. The participants not continuing to receive apremilast through the Post-Trial Access Program or Open-label Extension study will then complete the 30 days safety follow-up period after the last dose of apremilast in the active treatment phase.|t|t|t|t
33751869|NCT00572741|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33751870|NCT04699279|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33751871|NCT05293080|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33751872|NCT05108792|||COHORT||RETROSPECTIVE|||||||
33751873|NCT00000648||PARALLEL||TREATMENT||||||||
33751874|NCT01930110|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751875|NCT03481049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865447|NCT01852240|||COHORT||CROSS_SECTIONAL|||||||
33865448|NCT02626468|||COHORT||PROSPECTIVE|||||||
33865449|NCT02698748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33865450|NCT05830578|||COHORT||PROSPECTIVE|||||||
33865451|NCT01887639|||COHORT||PROSPECTIVE|||||||
33865452|NCT05823545|||COHORT||RETROSPECTIVE|||||||
33865453|NCT02923089|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33865454|NCT04872452|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865455|NCT03808688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865456|NCT03663881|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm, Phase 1 study. 24 participants are anticipated, assuming that 6 participants are recruited in each of the levels of dose titration based on the 3 +3 design.||||
33865457|NCT05929703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Stepped-wedge, cluster randomized|f|f|t|t
33865458|NCT02690220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865459|NCT04757441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865460|NCT04745013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34178655|NCT06593509|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|Parallel Assignment||||
34178656|NCT05525104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and parents will be blinded to the treatment. The outcome assessor will be blinded as well.|Randomised controlled trial|t|f|f|t
34178657|NCT03770546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865461|NCT02906345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865462|NCT03156348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||parallels groups: control arm will receive usual care, intervention arm will receive a Clinical Pharmacist Care|f|f|f|t
34178658|NCT06599775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178659|NCT05929963|||COHORT||RETROSPECTIVE|||||||
34178660|NCT06410274|||COHORT||PROSPECTIVE|||||||
34178661|NCT04532528|||COHORT||PROSPECTIVE|||||||
34178662|NCT06603168|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot study design is a pretest-posttest cohort study.||||
34178663|NCT06590545|NA|SEQUENTIAL||TREATMENT||NONE||this is a two-stage interventional, prospective, open-label study. This study has one treatment arm (open-label KYV101), but sequential treatment (two groups). Second group of participants are assigned to receive interventions based on the achievement of the previous milestone (28 days after treatment of the third patient of group 1). A data safety monitoring board (DSMB) will decide whether to proceed to phase II ≥ 28 days after treatment of the third subject.||||
34178664|NCT04599010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data analyzer will be masked to the allocation|The sample size for this pilot study will be 40 with 20 infants randomized into each arm.|f|f|f|t
34178665|NCT06596421|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34178666|NCT01414803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178667|NCT03162146|||COHORT||RETROSPECTIVE|||||||
34178668|NCT06603428|NA|SEQUENTIAL||TREATMENT||NONE||||||
34178669|NCT06593197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178670|NCT02231515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178671|NCT04318678|NA|SINGLE_GROUP||TREATMENT||NONE||Due to review of dose limiting toxicity.||||
34178672|NCT04611386|||CASE_CONTROL||PROSPECTIVE|||||||
34178673|NCT03889223|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|The ultrasonography was made by a consultant radiologist (M.D.) The consultant didn't know which position was for control and which was the one the study evaluates. Although investigators were trying to mask the outcomes assessor; the consultant saw the positions because there is no way to hide the sitting positions of the participants.|"Systematic randomization was made from 150 volunteers, and 50 participants were chosen. All 50 participants were planned to sit on the stretcher in both of the two positioning techniques sequentially (one after another). The two positioning techniques are SCF and LDF. The investigator was planned to record all of the participants' anatomical measurements in both of those positioning techniques evaluated via ultrasonography. After each position participants were planned to evaluate each positioning technique's comfort by 7-point numerical rating scale from minimum~1 meaning very bad to maximum 7 meaning excellent."|f|f|f|t
34178674|NCT06194188|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178675|NCT00998686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178676|NCT05220436|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
34178677|NCT04838405|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34178678|NCT01969136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178679|NCT05805176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178680|NCT06601725|||CASE_ONLY||PROSPECTIVE|||||||
34178681|NCT02081677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178682|NCT06587555|||OTHER||CROSS_SECTIONAL|||||||
34178683|NCT06587061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178684|NCT04639245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178685|NCT00705055|||COHORT||PROSPECTIVE|||||||
34178686|NCT03798951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33751876|NCT00498030|||COHORT||PROSPECTIVE|||||||
33751877|NCT01588184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All participants were assigned the same treatment. The Number of Arms represent the reporting groups of all subjects according to disease.||||
33751878|NCT06211205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865463|NCT02247154||||TREATMENT||||||||
33751879|NCT04592770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33751880|NCT06015204|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33751881|NCT04763902|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33751882|NCT04439526|||COHORT||PROSPECTIVE|||||||
33751883|NCT03632382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective||||
33751884|NCT05856162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33751885|NCT06246396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751886|NCT06491147|||COHORT||PROSPECTIVE|||||||
33751887|NCT02794285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751888|NCT03686046|||OTHER||PROSPECTIVE|||||||
34178687|NCT06591481|||CASE_CONTROL||RETROSPECTIVE|||||||
33865464|NCT00791336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865465|NCT02827123|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865466|NCT05406154|||COHORT||PROSPECTIVE|||||||
33865467|NCT02607553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865468|NCT05238129|||COHORT||PROSPECTIVE|||||||
34178688|NCT01254136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178689|NCT04023669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178690|NCT04701814|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients were divided randomly in two equal groups (A and B): Group A (controlled group):~They were received traditional physical therapy program including: passive range of motion (PROM)/ active assisted range of motion (AAROM)/ active range of motion (AROM), strengthen of rotator cuff, biceps, shoulder and scapular muscles, ultrasound (5 min. - 1.5 W/c.m2 - 1 MHZ), electrical stimulation ( interferential bipolar technique for 20 min. on shoulder joint). Group B (study group): they have received the same physical therapy program as in group A, in addition to Biomechanical scapular mobilization with movement and motor learning."||||
34178691|NCT06595433|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Weightlifters were randomly divided into three groups (A, B, C) of four people. Throughout the study, all groups practiced each warm-up protocol sequentially on different days.|The study was designed according to a randomized crossover experimental design. All study sessions were conducted in the fitness center in the weightlifting hall.|t|f|f|f
34178692|NCT05162781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Tester will be blinded to group assignment of participants.|"Half of the participants will receive CICT, which consists of SOPT, IADL training in the lab, and a Transfer Package targeting IADL performance outside it. The other half will receive BF-HELP, which consists of SOPT, in-lab training on relaxation, nutrition, and sleep hygiene, and a Transfer Package targeting implementation of these lifestyle changes outside it. Half of the CICT group will receive 15 follow-up phone calls over the course of one year. The other CICT participants will receive none. The same will apply to the BF-HELP group. The phone calls will support integration of the behavioral changes targeted during treatment to everyday life afterwards.~For all participants, outcome testing will take place one month before treatment (Baseline 1), one day before treatment (Baseline 2 aka Pre-treatment), one day afterwards (Post-treatment), 6-months afterwards (6-month Follow-up), and 12-months afterwards (12-month follow-up). Randomization will take place after Baseline 2."|f|f|f|t
34178693|NCT03994081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Using sham stimulation.||t|t|t|t
34178694|NCT04470154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a multicenter study, which is divided into two stages. The first stage is a dose escalation, randomized, double-blind, placebo-controlled study of multiple intravenous administration within one week in hemodialysis subjects. The second stage is a randomized, double-blind, placebo-controlled study of Administration for 12 weeks in hemodialysis subjects with moderate or severe pruritus.|t|f|t|f
34178695|NCT02635373|||||PROSPECTIVE|||||||
34178696|NCT00189722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34178697|NCT00169416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178698|NCT04769479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178699|NCT04004234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178700|NCT05412082|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178701|NCT04144686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This RCT has a single mask (assessor blinded). The blinded outcome assessors will collect all the outcome measure data at baseline (week 0) and follow-up (week 6 and 12). The outcome assessor will be asked to record any incidences of unblinding and how this occurred. Blinded outcome assessors will all be trained by Dr Marousa Pavlou or Ms Viktoria Azoidou on how to complete all assessments for parity. During the course of the study, blinded assessors will be MSc students who will work on the project as part of their MSc thesis or other PhD students in the department.|Single Blinded Randomised Controlled Trial|f|f|f|t
34178702|NCT04971746|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34178703|NCT04211753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34178704|NCT06158399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178705|NCT06590883|||COHORT||PROSPECTIVE|||||||
33865469|NCT00220558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865470|NCT05838404|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865471|NCT03978221|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33865472|NCT02525393|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33865473|NCT02973087|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33963626|NCT04507789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963627|NCT01854073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33963628|NCT05136456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963629|NCT04768023|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34178706|NCT06588517|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34178707|NCT06591130|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33865474|NCT03371758|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865475|NCT00904293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33865476|NCT01910051|||CASE_CONTROL||PROSPECTIVE|||||||
33865477|NCT01785667|||COHORT||PROSPECTIVE|||||||
33865478|NCT00789867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865479|NCT04787094|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33865480|NCT04029116|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Open label (acute phase treatment) followed by Randomized, Double Blinded phase|t|f|t|t
33865481|NCT06394596|||COHORT||RETROSPECTIVE|||||||
33865482|NCT00724919|||COHORT||PROSPECTIVE|||||||
33865483|NCT01099163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33865484|NCT06439173|||COHORT||PROSPECTIVE|||||||
33865485|NCT00357214|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33865486|NCT05547282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865487|NCT00862303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865488|NCT06154551|||OTHER||RETROSPECTIVE|||||||
33865489|NCT03245567|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, open-label study||||
33865490|NCT01557933|||CASE_ONLY||PROSPECTIVE|||||||
33865491|NCT05171946|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33865492|NCT05048693|||CASE_ONLY||PROSPECTIVE|||||||
34178708|NCT00970047|||CASE_ONLY||PROSPECTIVE|||||||
34178709|NCT06091111|NA|SINGLE_GROUP||OTHER||NONE|As the study device is obviously different to the currently used device, and all subjects will use the same treatment.|Single group cross over. Study subjects are randomized to sequence of device use. To either start with reference of study device.||||
34178710|NCT02650960|||COHORT||PROSPECTIVE|||||||
34178711|NCT01521117|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34178712|NCT05083741|||COHORT||PROSPECTIVE|||||||
34178713|NCT06585215|||OTHER||CROSS_SECTIONAL|||||||
34178714|NCT05485896|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34178715|NCT00579215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178716|NCT05798494|RANDOMIZED|PARALLEL||PREVENTION||NONE||140 couples will be recruited and randomized to either intervention og control. Participants includes the mother, father and 1st and 2nd child, therefore the total number of participants will be 560.||||
34178717|NCT01379898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178718|NCT06581328|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178719|NCT04986072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178720|NCT01747447|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Double Blind||t|f|t|t
34178721|NCT05557110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178722|NCT06589063|||COHORT||PROSPECTIVE|||||||
34178723|NCT01646580|NA|SINGLE_GROUP||||NONE||||||
34178724|NCT02971748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178725|NCT04985279|RANDOMIZED|CROSSOVER||TREATMENT||NONE|No masking involved.|"The ultrasound operators will be randomised to perform either~1. Skin marking after lumbar ultrasonography using marker pens (standard practice)~2. Skin marking after lumbar ultrasonography using PAMS~After completion of the first procedure, the ultrasound operators will then crossover and perform the other procedure."||||
33751889|NCT06265428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963630|NCT04189289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomised controlled|t|f|f|f
33963631|NCT02390466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963632|NCT05355337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized placebo-controlled with two arms plus one arm of healthy controls with no intervention|t|f|t|f
33963633|NCT06005337|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be randomly assigned to Group A or Group B in this study.~Group A will receive three of six blogshots over a 4-week period (a different blogshot will be sent by email to them each week for three weeks, then in the final week they will receive the same three blogshots in one summary email to review). Group B will receive the other three of six blogshots, following the same email sequence and timing. The reason for assigning them into a group is to help us evenly share the blogshots between all participants. Each group will act as their own control.~All participants from both groups will be asked to complete one baseline questionnaire at the start of the study and a follow-up questionnaire at week 5, month 3 and month 6 about different common acute childhood conditions, the blogshots and their content.~All participants can also participate in an optional semi-structured interview to give their thoughts on the blogshots and their experience in the study."||||
33963634|NCT05201820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963635|NCT00515385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963636|NCT05958810|||COHORT||PROSPECTIVE|||||||
33963637|NCT00206219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963638|NCT02669628|||COHORT||PROSPECTIVE|||||||
33963639|NCT05036239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants perform one bout of eccentric exercise with one arm, while the contralateral arm serves as control. Which arm who receives eccentric exercise is randomized between dominant/non-dominant arm.|f|f|f|t
33963640|NCT01665573|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34065345|NCT05743062|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34065346|NCT01465256|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34065347|NCT00723697|||COHORT||PROSPECTIVE|||||||
34065348|NCT01048905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065349|NCT00085813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065350|NCT05127655|||OTHER||OTHER|||||||
34178726|NCT05172024|||OTHER||OTHER|||||||
34178727|NCT06604130|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34178728|NCT06233240|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34178729|NCT05167409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178730|NCT04595968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178731|NCT06592274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178732|NCT06595615|||COHORT||PROSPECTIVE|||||||
34178733|NCT06598267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178734|NCT02608190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178735|NCT06242132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of clopidogrel or cilostazol by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 870 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 870. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included clopidogrel, and Drug B included cilostazol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|The investigators will conduct our single-blinded randomized controlled trial, which will contain 2 arms; the clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day). The cilostazol arm will receive (a 200mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day).|f|f|t|t
34178736|NCT03828825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178737|NCT06588829|||COHORT||CROSS_SECTIONAL|||||||
34178738|NCT00022191|RANDOMIZED|||TREATMENT||NONE||||||
33865493|NCT00619528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865494|NCT00408395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34178739|NCT06493578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, double-blind, vehicle-controlled||t|t|t|t
34178740|NCT06654518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178741|NCT03691376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178742|NCT02042417|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865495|NCT05545605|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Statistical researchers from the partner Shanghai Green Valley Pharmaceutical Co., LTD., used statistical software packages to generate two sets of 58 random drug numbers, which were determined in the form of files after the codes were formed.Masking the participant and investigator.||t|t|t|t
33865496|NCT02785679|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865497|NCT04830033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking of participants not possible due to the nature of the intervention.||f|f|t|t
33865498|NCT00798135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751890|NCT03520322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33865499|NCT03138811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865500|NCT03998176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178743|NCT05452486|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This study is a repeated measures experimental design in which participants will complete auditory processing tests in both English (L2) and Spanish (L1). The presentation of Spanish and English test materials will be counterbalanced across participants to minimize fatigue and practice effects.||||
34178744|NCT06374238|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-arm, phase III randomized controlled effectiveness trial. Participants will be randomized 3:3:2 into (1) CBT + peer, (2) self-guided CBT, or (3) UC, stratified by site||||
34178745|NCT06604507|||COHORT||PROSPECTIVE|||||||
34178746|NCT06462794|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178747|NCT05764265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178748|NCT06595498|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34178749|NCT06604702|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm prospective interventional trial where all participants undergo submucosal fat injections for the treatment of rectocele.||||
33865501|NCT04891341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178750|NCT03464734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178751|NCT05403385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple masking : The dose-finding part (Part 1) of this study is open-label whereas the randomized part (Part 2) is double-blinded. Therefore, for Part 2, the subject, the Investigator and Sponsor personnel or delegate(s) who are involved in the treatment administration or clinical evaluation of the subjects will be unaware of the group assignments. The chemotherapy agents administered during Part 2 will be open label.|Single Group Assignment Part 1 sequential dose escalation. Part 2 randomized double-blind.|t|t|t|t
34178752|NCT06591637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34178753|NCT03837041|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34178754|NCT04169035|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178755|NCT04367727|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34178756|NCT03448406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178757|NCT02568267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178758|NCT06594341|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A total of 39 health areas including 39 health centers and 52 secondary sites will be be randomised into : 1) providing simplified treatment as per on-going routine protocol, 2) providing simplified treatment with a reduced visit frequency for children in the moderate phase, 3) providing simplified treatment without a transition period for children admitted with severe malnutrition when they progress to moderate phase and 4) providing simplified treatment with a reduced visit frequency for children in the moderate phase and without a transition phase for children admitted with severe malnutrition when they porgress to modera phase.||||
34178759|NCT06212362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducting 12 weeks-assessments will be blind to treatment allocation. The outcome measure (PARS) is identical for both groups, ensuring that the assessors remain blind. At the 12 week-assessment, participants will be reminded to not reveal their arm allocation. To measure blinding integrity, all assessors will record whether the participating families inadvertently reveal their group allocation, and subsequently guess each participant's treatment allocation.|Multi-site randomised non-inferiority trial. Half of the participants will be randomised to receive Step-by-step, and half of participants will be randomised to receive Cool Kids.|f|f|f|t
33865502|NCT00533468|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33751891|NCT03885531|||CASE_ONLY||RETROSPECTIVE|||||||
33751892|NCT04092374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751893|NCT03178149|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865503|NCT03422172|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open-label study; hence, there will be no masking.|Eligible subjects will receive oral doses of CAB for 4 weeks followed by IM dosing with CAB LA at Week 5, Week 9, Week 17, Week 25 and Week 33.||||
33751894|NCT06106711|||COHORT||PROSPECTIVE|||||||
33751895|NCT06536127|NA|SINGLE_GROUP||OTHER||NONE||||||
33751896|NCT06140199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessor is blinded.|Multicentre, single-blinded, randomised, controlled, superiority trial. It|f|f|f|t
33751897|NCT06733649|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Perinatal women and the woman's community support will receive one treatment education session.||||
33751898|NCT06734039|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded to each of the frequency settings they are utilizing.||t|f|f|f
33751899|NCT06733181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865504|NCT02626286|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865505|NCT05683535|||CASE_ONLY||PROSPECTIVE|||||||
33865506|NCT02041260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865507|NCT00074581|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33865508|NCT01927328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865509|NCT00000353||||TREATMENT||||||||
33865510|NCT04409899|||COHORT||PROSPECTIVE|||||||
34178760|NCT05408429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study is partially masked. Participants randomized to receive 2 doses of 20vPnC will not have treatment masking. Participants randomized to receive 1 dose of 20vPnC or 13vPnC will have treatment masking.||t|t|t|t
34178761|NCT06595485|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|we will collected outcomes via online application||f|t|f|t
34178762|NCT02925286|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178763|NCT05179785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34178764|NCT00144807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178765|NCT06601738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178766|NCT00213044|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34178767|NCT06140589|||COHORT||RETROSPECTIVE|||||||
34178768|NCT06604585|RANDOMIZED|PARALLEL||PREVENTION||NONE||The pilot study will be conducted as a randomized clinical trial. We will use a two-group design where half of the participants are randomized to the intervention group with access to the digital parent support program and half to the control group with conventional parental support without access to the digital parental support program, 1. Conventional parental support and digital parent support program. (n=15). 2. Conventional parental support (n=15).||||
34178769|NCT06221280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178770|NCT06591351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive loading doses of clopidogrel and aspirin or cilostazol and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 870 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 870. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included clopidogrel, and Drug B included cilostazol. Both groups received an open-label loading dose of 300 mg of aspirin and continued on aspirin 75 mg daily|The investigators will conduct our single-blinded randomized controlled trial, which will contain two arms; the clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day). The cilostazol arm will receive (a 200mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day). Both groups received an open-label loading dose of 300 mg aspirin and continued on open-label aspirin 75 mg daily|f|f|t|t
34178771|NCT06522620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178772|NCT01221896|||COHORT||PROSPECTIVE|||||||
34178773|NCT05760898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178774|NCT04060498|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34178775|NCT04386304|NA|SEQUENTIAL||TREATMENT||NONE||||||
34178776|NCT06597383|||CASE_CONTROL||RETROSPECTIVE|||||||
34178777|NCT05887375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
11470391|NCT06438341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178778|NCT06602505|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The person assessing the pain scores and the other observation parameters in the postoperative period was blinded to the group to which the patient was assigned.||f|f|f|t
34178779|NCT03531151|||COHORT||PROSPECTIVE|||||||
34178780|NCT05403437|||OTHER||CROSS_SECTIONAL|||||||
34178781|NCT00593216|||CASE_CONTROL||RETROSPECTIVE|||||||
34178782|NCT05817058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178783|NCT03278457|||COHORT||OTHER|||||||
34178784|NCT03215056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178785|NCT00821795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178786|NCT04282161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865511|NCT02389647|||COHORT||PROSPECTIVE|||||||
33865512|NCT00981513|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865513|NCT06104982|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigators included thirty-four participants with thoracic complete SCI in this randomized controlled and prospective study. Investigators divided the participants into two equal groups, where one group received the biofeedback triggered superimposed functional electrical stimulation (SiFES) applied to the abdominal muscles, and the control group received transcutaneous electrical stimulation (TE) only, applied three times a week for four weeks.||||
33865514|NCT00445523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865515|NCT04440787|||COHORT||PROSPECTIVE|||||||
33865516|NCT05910307|||OTHER||OTHER|||||||
33865517|NCT01516151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865518|NCT01865396|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33865519|NCT03229408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34178787|NCT02796170|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33865520|NCT03097952|||COHORT||PROSPECTIVE|||||||
33865521|NCT03881228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33865522|NCT06461182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865523|NCT00246597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865524|NCT02602626|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33865525|NCT05823025|||COHORT||PROSPECTIVE|||||||
33865526|NCT04562987|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33865527|NCT05712135|||OTHER||PROSPECTIVE|||||||
33865528|NCT04347850|||COHORT||PROSPECTIVE|||||||
33865529|NCT04026061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33865530|NCT01613495|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33963641|NCT04591769|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient will be intubated by an anesthesiologist who is aware of the grouping. After tracheal intubation is finished, the cuff is connected to the pressure monitor system and another blinded assessor will adjust and record the minimal volume that is required for sealing the tracheal tube-ventilator. The cuff pressure will be monitored and recorded all throughout the surgical period. A blinded assessor will follow up the patient after the surgery and do the voice analysis. Patients are unaware of the type of tracheal tube they used and will score subjectively for the sore throat and postoperative dysphonia.||t|f|f|t
33963642|NCT05614388|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The participants include health care workers, non-medical hospital staff and medical students at ZMC; and faculty, students and supporting staff at the Pacchunga University College. All these groups will be participating in the study simultaneously. The study results will be compared for all these 6 groups.||||
33963643|NCT01219088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963644|NCT04909125|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Patients will be randomised to one of the arms and will be notified for the randomization results. Randomisation ratio 2:1 (hypofractionation : standard)|||||
33963645|NCT02768220|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963646|NCT01799213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33963647|NCT01675869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33963648|NCT05422235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physiotherapist who evaluated the individuals participating in the study and the physiotherapist who took the treatment will not be the same. in addition, an independent statistician will do the analysis.|Parallel Assignment|f|f|t|t
33963649|NCT00481871|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865531|NCT00003370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963650|NCT03941223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963651|NCT01964898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963652|NCT00003981||||TREATMENT||||||||
33963653|NCT01897558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963654|NCT05695079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be informed of the study interventions before providing informed consent but will be masked to the order of the arms until exposure (i.e., participants will not know the fan conditions). Data will be blinded prior to analysis.|Each participant will complete 3 simulated heat wave exposures in random order: i) no electric fan (control); ii) electric fan generating air flow of 2 m/s at the front of the body; and iii) electric fan generating air flow of 4 m/s at the front of the body.|t|f|f|t
33865532|NCT03530917|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34178788|NCT00915746|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34178789|NCT06604637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178790|NCT00563875|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178791|NCT01843829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178792|NCT04837716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178793|NCT02002598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178794|NCT06599905|NON_RANDOMIZED|PARALLEL||OTHER||NONE||To evaluate differences in the response to offset analgesia (OA) paradigm between episodic and chronic migraine patients and controls||||
34178795|NCT06047561|||COHORT||PROSPECTIVE|||||||
34178796|NCT03128294|||CASE_ONLY||RETROSPECTIVE|||||||
34178797|NCT05773729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178798|NCT06599411|||COHORT||PROSPECTIVE|||||||
34178799|NCT06596044|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will be blinded to treatment allocation and will remind the participant at each contact to not disclose their treatment status.|Participants are assigned to one of two groups in parallel: VA BIC plus standard care vs. standard care alone|f|f|f|t
34178800|NCT06591104|||OTHER||CROSS_SECTIONAL|||||||
33865533|NCT02351479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865534|NCT01148706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178801|NCT04558125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178802|NCT06019754|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization assignments will be kept in sealed envelopes until all preprocedural measurements will be completed|Using a point puncture approach instead of two punctures to perform lumbosacral plexuses block in the interventional group.|f|t|f|t
34178803|NCT05820932|||COHORT||PROSPECTIVE|||||||
34178804|NCT04593784|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Anticoagulant drugs will be administered in an open-label manner. Ciraparantag or placebo (PBO) will be administered in a double-blind manner. Subjects and all study site personnel except the study pharmacist will be blinded to individual subject treatment assignment (ciraparantag or PBO). The Sponsor will be unblinded to individual treatment assignments.|The study will be conducted in separate cohorts; each cohort will evaluate the reversal of a different anticoagulant drug. Within each cohort, an initial group of subjects (Group 1) will be enrolled for evaluation of a target dose of ciraparantag. Depending on the efficacy and safety results from Group 1, a second group (Group 2) may be enrolled to evaluate a different dose of ciraparantag for that cohort.|t|t|t|f
33865535|NCT01135862|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178805|NCT06292260|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178806|NCT03945240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178807|NCT06497543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178808|NCT05674656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178809|NCT03873883|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178810|NCT03635281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178811|NCT01933737|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34178812|NCT00125255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178813|NCT06586671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34178814|NCT06599164|||COHORT||PROSPECTIVE|||||||
34178815|NCT06227481|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective controlled trial that will be conducted at Dermatology, venereology, and andrology Department, Al-Azhar university hospital, Assiut, in the period from December 2023 to December 2025, to assess the efficacy of combination of scar subcision with platelet rich plasma, polydioxanone mono threads or fractional carbon dioxide laserin the treatment of severe atrophic acne scars with 1:1:1 ratios and to compare between these modalities regarding safety and efficacy.||||
34178816|NCT01779765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34178817|NCT04234113|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178818|NCT06597253|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865536|NCT05261035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33865537|NCT03341741|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, open label clinical study||||
33865538|NCT05361109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865539|NCT04739267|||COHORT||PROSPECTIVE|||||||
33865540|NCT01145495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865541|NCT04215666|||CASE_ONLY||OTHER|||||||
33865542|NCT02483624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865543|NCT01668407|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865544|NCT00478933|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|patients and investigators were blinded to the genetic markers during the study. Therefore, no arm is specified as this is not applicable.||t|t|t|f
33865545|NCT04682704|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33865546|NCT02176187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34178819|NCT04065269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multiple two-stage parallel cohorts||||
34178820|NCT02638220|||COHORT||PROSPECTIVE|||||||
34178821|NCT06224413|||COHORT||PROSPECTIVE|||||||
34178822|NCT04410978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178823|NCT06311487|NA|SINGLE_GROUP||OTHER||NONE||||||
34178824|NCT05727306|||COHORT||RETROSPECTIVE|||||||
34178825|NCT06481163|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
34178826|NCT01058980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178827|NCT02405741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178828|NCT06591923|||OTHER||RETROSPECTIVE|||||||
34178829|NCT03081117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double-blind placebo-controlled clinical trial|t|t|t|t
34178830|NCT06596993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178831|NCT04730609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178832|NCT03706417|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178833|NCT06586944|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||After the research groups were formed, a six-session interview program was created for the participants included in the experimental group. During these sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping, cognitive restructuring) based on RAM were conducted to address the negative situations caused by anxiety and anxiety experienced by individuals.|f|f|t|f
34178834|NCT03651349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178835|NCT00611104|||CASE_CONTROL||PROSPECTIVE|||||||
34178836|NCT05083234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assigment,||||
34178837|NCT03363841|NA|SINGLE_GROUP||TREATMENT||NONE||non comparator, single arm||||
34178838|NCT04370210|||COHORT||PROSPECTIVE|||||||
33865547|NCT01611753|RANDOMIZED|PARALLEL||||NONE||||||
34178839|NCT03502005|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective 48 week single cohort study to evaluate the efficacy and safety of switching from ATRIPLA to BIKTARVY® in HIV-1 infected adult subjects who are virologically suppressed (HIV-1 RNA \< 50 copies/mL).||||
34178840|NCT05893186|NA|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34178841|NCT05893485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33865548|NCT00514163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178842|NCT06602570|||COHORT||PROSPECTIVE|||||||
34178843|NCT06586437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Cerebral Palsy participants will undergo baseline sham or stim intervention/brain imaging/clinical assessments, and then repeat with opposite intervention.~Non-Cerebral Palsy controls will undergo the same baseline testing once as a reference group to determine a normative state of neuromodulation."|t|f|f|t
34178844|NCT06592781|||OTHER||CROSS_SECTIONAL|||||||
34178845|NCT04981223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178846|NCT06559826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178847|NCT04977453|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178848|NCT04119739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34178849|NCT05602454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178850|NCT04328792|||COHORT||OTHER|||||||
34178851|NCT05587777|||CASE_CONTROL||PROSPECTIVE|||||||
34178852|NCT03793751|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This will be a prospective, randomized, placebo-controlled, double-blind clinical trial. The patients will be recruited according to the inclusion criteria and will be distributed to one of the groups according to computer-generated random assignment. The personnel involved in the study, including statisticians, investigators, anaesthetists, surgeons and the patients will be blinded to the specific experimental scheme implementation Patients will be randomized into one of the two groups using a computer based random number generator. https://www.randomizer.org. All recordings would be performed by an anaesthesiologist blinded to the group allocation.||t|t|t|t
34178853|NCT05867407|RANDOMIZED|PARALLEL||SCREENING||NONE||Clinicians in primary care practice groups will be consented for enrollment into the study. Practice groups that decide to participate in the study will be randomized to have the software available or to provide care as usual without the software.||||
34178854|NCT04562389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase 1, open-label, selinexor dose escalation and expansion part (enrollment completed). Phase 3, randomized, double-blind, placebo-controlled part.|t|f|t|f
34178855|NCT03271086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34178856|NCT04971642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751900|NCT06298916|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Part 1: Metastatic Sarcoma Part 2: Non-metastatic sarcoma or gastrointestinal tract (GIT) cancer (esophageal, gastric, pancreatic, colorectal cancer)||||
33751901|NCT02696148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865549|NCT02615821|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33865550|NCT02933632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751902|NCT02265562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33865551|NCT03720899|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants will be randomized to one of two interventions||||
33865552|NCT03298425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865553|NCT05744570|||COHORT||PROSPECTIVE|||||||
33865554|NCT03476564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Computer generated random number table will be used for randomization. Group assignments will be placed in sealed opaque sequentially numbered envelopes|Endometrial thickness will be measured on the day of the HCG prescription in both groups by one of the two attending physicians. Chemical pregnancy will be detected by serum beta-hCG analysis 14 days after embryo transfer and transvaginal ultrasound scan will be scheduled 2 weeks later to confirm the diagnosis of clinical pregnancy. The intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.|t|f|f|f
33865555|NCT02925572|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33865556|NCT00097487|||||PROSPECTIVE|||||||
33865557|NCT05511493|RANDOMIZED|PARALLEL||TREATMENT||NONE||"(Group A): Subjected to fractional erbium: yttrium-aluminum-garnet (Er: YAG) laser (FotonaXs Dynamis, Slovenia) with the energy of 1400 mJ in short pulse mode (SP) with spot size of 7 mm diameter, frequency of 3 Hz, and pixel 1. PRP is applied over the treated areas.~(Group B): Subjected to microneedling using electronic dermapen device (Dr Pen Derma Pen Ultima A6®) which has a disposable head that personalized for each patient . The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern from the perilesional areas toward the depigmented center until pinpoint bleeding appears then the PRP is applied over the treated areas.~* This procedure will be repeated every two weeks for six months."||||
33865558|NCT02261779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865559|NCT02334124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865560|NCT05723354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865561|NCT00186264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865562|NCT06491082|||COHORT||PROSPECTIVE|||||||
33865563|NCT02080247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178857|NCT06602713|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||one group of volunteers, one group of patients||||
34178858|NCT01423500|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178859|NCT04448392|NA|SINGLE_GROUP||OTHER||NONE||||||
34178860|NCT04827069|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm 1:10 mg Arm 2:20 mg Arm 3:40 mg Arm 4:55 mg Arm 5:70 mg Arm 6: 100 mg||||
34178861|NCT06597461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were not informed which group they were in.|Two groups with a control group|t|f|f|f
34178862|NCT06597474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Two-group cluster RCT|t|f|t|t
34178863|NCT02694185|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34178864|NCT03351764|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34178865|NCT05002868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178866|NCT06599372|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178867|NCT06601855|||COHORT||RETROSPECTIVE|||||||
34178868|NCT04008745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator (allocation, statistics, data processing) and assessor will be blid to the subjects allocation. To evaluate whether or not there was a failure in blinding of the outcome assessor, investigators and other assessors, they will be asked to guess which group the patients belonged to at the end of 8-weeks of treatment. Then the assessors will classify the certainty of their opinions according to a scale (1 = not sure, 5 = completely sure). To ensure that the assessor is not induced to correctly guess the participants' allocation, the patient will be instructed to not disclose any behavior details during the previous 8-weeks.|Assignment|f|f|t|t
33865564|NCT05691049|NA|SINGLE_GROUP||TREATMENT||NONE||30 subjects undergoing HCC_45 treatment of acne scars of the face by using a subcision + injection technique, the Needle (25 Gauge) or Cannula (25 Gauge) (wider areas are treated with Cannula) is inserted into the skin and made to move with a back-and-forth motion in order to detach scar collagen bundles. Then HCC_45 is injected. 3 visits: Day 0 (treatment) Day 30 (1 month after Day 0 treatment) Day 120 (4 months after Day 0 - follow-up).||||
33865565|NCT01106495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865566|NCT03122275|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33865567|NCT06417463|||COHORT||PROSPECTIVE|||||||
33865568|NCT01782365|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33865569|NCT01942148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865570|NCT04077450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only participants will be blinded as to which study arm he or she was assigned.|Randomized controlled trial in which participants will be randomized into (a) the modified waitlist-control arm or (b) the intervention arm.|t|f|f|f
33865571|NCT00343616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865572|NCT04392245|||OTHER||PROSPECTIVE|||||||
33865573|NCT01968395|NA|SINGLE_GROUP||OTHER||NONE||||||
33865574|NCT00916539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865575|NCT04056065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751903|NCT01329367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178869|NCT05654259|||COHORT||PROSPECTIVE|||||||
34178870|NCT01929421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178871|NCT04834661|||COHORT||RETROSPECTIVE|||||||
34178872|NCT06586814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178873|NCT03902431|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A stratified clustered randomized stepped wedge design.||||
34178874|NCT06597162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34178875|NCT06598917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178876|NCT06596343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178877|NCT06604650|||COHORT||PROSPECTIVE|||||||
34178878|NCT00360841|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34178879|NCT05205031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178880|NCT06603610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistician||f|f|f|t
34178881|NCT00791934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178882|NCT02357654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865576|NCT03332914|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover||||
33865577|NCT05662475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Sixty-six patients were randomly divided into six equal groups; group 1: systemically and periodontally healthy individuals, group 2: systemically healthy individuals with periodontitis, group 3: controlled type 2 diabetes and periodontally healthy individuals, group 4: controlled type 2 diabetes and periodontitis, group 5: uncontrolled type 2 diabetes and periodontally healthy individuals, group 6: uncontrolled type 2 diabetes and periodontitis. The study was planned as a randomized, single-blind, parallel design. Periodontal indexes were recorded clinically and the concentrations of visfatin, fetuin-A and sirtuin 1 in gingival crevicular fluid were assessed biochemically. After baseline examinations \[Silness-Löe plaque index (PI), Löe-Silness gingival index (GI), probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP)\], initial periodontal treatment was completed using a full-mouth treatment protocol. Data were collected at baseline and at 3 months.|t|f|t|t
33865578|NCT00843648|||COHORT||PROSPECTIVE|||||||
33865579|NCT05638815|||COHORT||PROSPECTIVE|||||||
33865580|NCT05141162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33865581|NCT03123250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865582|NCT05112627|||COHORT||CROSS_SECTIONAL|||||||
33865583|NCT02671045|||COHORT||PROSPECTIVE|||||||
33865584|NCT02079090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865585|NCT03171766|||COHORT||PROSPECTIVE|||||||
33865586|NCT03759483|||OTHER||OTHER|||||||
33963655|NCT06293573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be assigned randomly into three groups of equal number (study group A, study group B, and group C) the randomization will be performed by computerized randomization. Assessors will be blinded to the groups of the subjects.||t|f|f|t
33963656|NCT04965402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963657|NCT01682278|||COHORT||PROSPECTIVE|||||||
33963658|NCT00005578|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33963659|NCT05882968|||COHORT||PROSPECTIVE|||||||
33963660|NCT02257827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963661|NCT05517967|||COHORT||PROSPECTIVE|||||||
33963662|NCT00795782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33963663|NCT00237328|||COHORT||PROSPECTIVE|||||||
33963664|NCT04157361|||COHORT||PROSPECTIVE|||||||
33963665|NCT01755611|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33963666|NCT00268151|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963667|NCT01188161|||COHORT||RETROSPECTIVE|||||||
33963668|NCT00256100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065351|NCT05472818|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In this study, patients with cannabis use disorder (CUD) and matched healthy controls will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart. CUD participants will be asked to abstain from cannabis for the 4 week period. A small subset of CUD participants will be asked to continue abstaining for an additional approx. 4 weeks to complete one additional scan. Participants may also complete a neurocognitive battery, various psychiatric evaluations, a physical examination, an ECG, blood tests, and questionnaires. CUD participants will complete bi-weekly study visits to confirm abstinence.||||
33963669|NCT02533323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065352|NCT04928469|||COHORT||RETROSPECTIVE|||||||
34065353|NCT02773277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065354|NCT02299505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963670|NCT03779685|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33963671|NCT00085852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963672|NCT03611751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065355|NCT04842643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065356|NCT03886389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment||||
34065357|NCT03017521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065358|NCT03863691|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|randomized, double blind, placebo controlled, between subjects design||t|f|t|f
34065359|NCT00098202|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34065360|NCT00047736|RANDOMIZED|||TREATMENT||DOUBLE||||||
34065361|NCT01611428|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34065362|NCT01836185|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34065363|NCT01904747||CROSSOVER||BASIC_SCIENCE||NONE||||||
34065364|NCT06210386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover randomized trial||||
34065365|NCT05476666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065366|NCT05380986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963673|NCT05991570|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||cohort study|t|f|f|f
33963674|NCT03334526|NA|SINGLE_GROUP||OTHER||NONE||this study is interventional because of it acts on the physical and respiratory capacities of patients||||
33963675|NCT01431417|||COHORT||PROSPECTIVE|||||||
33963676|NCT01000545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963677|NCT05088824|||OTHER||PROSPECTIVE|||||||
33963678|NCT06539273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963679|NCT02020655|||||PROSPECTIVE|||||||
33963680|NCT04268784|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34065367|NCT06536322|RANDOMIZED|PARALLEL||OTHER||SINGLE|Care providers and participants in the intervention group know they are testing a new tool. Care providers and participants in the control group continue care as usual and do not know about the new tool.|cluster randomized controlled trial|f|f|f|t
34065368|NCT01980745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065369|NCT01232374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065370|NCT01030354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065371|NCT03544125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178883|NCT02603146|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34178884|NCT01194830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34178885|NCT06587893|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34178886|NCT03144427|||COHORT||PROSPECTIVE|||||||
34178887|NCT00087152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178888|NCT05822804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963681|NCT06485492|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single-group, target-controlled clinical study||||
33963682|NCT02105831|||CASE_ONLY||PROSPECTIVE|||||||
33963683|NCT04437537|||CASE_ONLY||PROSPECTIVE|||||||
33865587|NCT05018260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|particiapants, investigators and outcome assessors are blind to allocation||t|f|t|t
33963684|NCT02665611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065372|NCT04374292|RANDOMIZED|PARALLEL||TREATMENT||NONE|After providing written consent, 177 children with obesity (BMI ≥ 95 pc) of age 5-11 years and their mothers were randomly assigned to participate in the intervention group (IG) or the control group (CG).|After providing written consent, 177 children with obesity (BMI ≥ 95 pc) of age 5-11 years and their mothers were randomly assigned to participate in the intervention group (IG) or the control group (CG). None of the participating children were receiving pharmacological treatment for obesity, were morbidly obese or were associated with a genetic syndrome. Intervention group mothers (n = 90) attended six weekly group sessions, which were led by nutritionists and lasted 90 minutes.||||
34065373|NCT03306979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178889|NCT05799820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865588|NCT02232126|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33865589|NCT03182985|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34178890|NCT06263010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865590|NCT03207113|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865591|NCT00228566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178891|NCT00412334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178892|NCT06586047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34178893|NCT04953104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178894|NCT06599515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|daVinci Xi (Intuitive Surgical) robotic system|HugoTM Ras (Medtronic) robotic system||||
34178895|NCT03954366|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178896|NCT06587620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34178897|NCT05983757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One investigator or designee will remain blinded at each site to perform primary outcome assessment at Day 30 and Day 90.|The randomization employs a 1:1 ratio of endovascular thrombectomy (EVT) with the use of Trevo NXT ProVue Retrievers, AXS Vecta 46 Intermediate Catheter and AXS Catalyst 5 Distal Access Catheter, versus standard medical management (SMM) in patients who suffer a distal medium vessel occlusion (DMVO) stroke within 12 hours from time last seen well (TLSW) and have evidence of salvageable brain tissue on perfusion imaging. Randomization will be done under a minimization process using age (≤67 vs. \>67 years), baseline NIHSS (≤12 vs. \>12), use of IV thrombolysis (none vs. within 120 minutes from randomization vs. \> 120 minutes from randomization), site of occlusion (M2 vs. M3 vs. ACA vs. PCA), baseline infarct volume (≤15mL vs. \>15-30mL vs. \>30-50mL), perfusion mismatch volume (≤15mL vs. \>15-30mL vs. \>30-50mL), therapeutic window (0-4.5 vs. 4.5-8 or \>9-12 hours after TLKW), and participating site.|f|f|f|t
33963685|NCT01715415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963686|NCT02911779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963687|NCT03969667|||OTHER||CROSS_SECTIONAL|||||||
33963688|NCT00566215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963689|NCT04244994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparison of self-taken penile meatal swabs (intervention) versus first-catch urine (control) for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium in all participants||||
33963690|NCT05647200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind, masked to observer|"In two consecutive randomized controlled trials, we study the effect of prime fluid strategies on perfused vessel density (part I) and the effect of additional albumin during cardiopulmonary bypass compared with ringers on perfused vessel density (part II).~In this study part (II), the effect of additional albumin during cardiopulmonary bypass compared with ringers on perfused vessel density."|t|f|t|f
33963691|NCT05777070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are masked to group assignments, investigators are masked to assessments, and outcomes assessors are masked to intervention groups|Triple blinded, randomized controlled trial|t|f|t|t
33963692|NCT01543607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963693|NCT04127968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963694|NCT03853356|||CASE_ONLY||PROSPECTIVE|||||||
33963695|NCT04717999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065374|NCT00824434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065375|NCT03595865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065376|NCT03024827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065377|NCT02463006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065378|NCT03322436|||COHORT||PROSPECTIVE|||||||
33865592|NCT00647153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865593|NCT04858984|NA|SINGLE_GROUP||OTHER||NONE||Qualitative research||||
33865594|NCT00910195|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33865595|NCT03600597|||COHORT||PROSPECTIVE|||||||
33865596|NCT03805750|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33865597|NCT01823731|||CASE_ONLY||PROSPECTIVE|||||||
33865598|NCT03436381|||COHORT||PROSPECTIVE|||||||
33865599|NCT05085951|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33865600|NCT00618436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865601|NCT00356889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865602|NCT03426787|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||pre-post within subjects design||||
33865603|NCT05008536|NA|SINGLE_GROUP||TREATMENT||NONE||Anti-BCMA CAR-NK Cells||||
33963696|NCT05756868|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34178898|NCT03242915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178899|NCT03537755|||CASE_ONLY||CROSS_SECTIONAL|||||||
34178900|NCT05826743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178901|NCT00901836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178902|NCT06598475|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a stepwise cluster randomized control design study. There will be 3 clusters (FQHC's) having 3 practices each||||
34178903|NCT06591845|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Partially Double-Blind|This clinical study will last for a total of 59 days, including a 26-day screening period, admission day (Day -2) preceding the first treatment period, 4 treatment periods with 8 days washout in-between and a safety follow-up period (7 ± 1 days after the last dose).|t|f|f|f
34178904|NCT00212108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178905|NCT05852119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178906|NCT05546853|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentric prospective single arm phase 1b trial.||||
34178907|NCT01423175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178908|NCT06599801|||COHORT||RETROSPECTIVE|||||||
34178909|NCT04756427|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cohort after intervention.||||
34178910|NCT01899521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34178911|NCT06234761|||COHORT||PROSPECTIVE|||||||
34178912|NCT05279651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34178913|NCT01648751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34178914|NCT06582901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One clinical rater will be unaware of the treatment condition|This is a randomized controlled trial (RCT) study that is comparing two interventions: one is experimental and involves computer-based cognitive training using HappyNeuron and the Neuropsychological Educational Approach to Cognitive Remediation (CT-NEAR) model vs Enhanced Treatment as Usual (E-TAU).|f|f|f|t
34178915|NCT04088149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178916|NCT06141226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178917|NCT06008314|NA|SEQUENTIAL||TREATMENT||NONE||||||
34178918|NCT05862220|||CASE_CONTROL||RETROSPECTIVE|||||||
34178919|NCT06191796|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34178920|NCT06596330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34178921|NCT05569044|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34178922|NCT06588387|||COHORT||RETROSPECTIVE|||||||
34178923|NCT00573222|||||PROSPECTIVE|||||||
34178924|NCT06592963|||CASE_ONLY||CROSS_SECTIONAL|||||||
34178925|NCT05494190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178926|NCT06594822|RANDOMIZED|PARALLEL||TREATMENT||NONE||Simple random selection of patients. Assigned to 2 groups by computer generated method. Group A received standard treatment of analgesics, glucocorticoids and methotrexate and or sulfasalazine. Group B was the interventional group that received probiotics in addition to standard treatment.||||
34178927|NCT01219114|||||PROSPECTIVE|||||||
34178928|NCT04971954|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Nicotine (6 mg) will be administered in the form of polacrilex gum that is available as an over-the-counter medication. The placebo will also be a commercially available gum that resembles the nicotine gum in flavor, size, shape, color, and texture.|The nicotine and placebo gums will be administered in randomized, double-blind, counterbalanced fashion.|t|f|t|f
34178929|NCT06367933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178930|NCT06284005|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34178931|NCT06599918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The trial will be double-blind. The delivery of the investigational product will not contain information about the assigned treatment arm or the administered dose. Both interventions will have the same presentation format and identical visual characteristics. Therefore, both the patient and the Endocrinology specialist facilitating the intervention will be unaware of the assigned treatment arm.~All personnel from the sponsor and investigator's center involved in the study will undergo masking concerning the assigned treatment, with the following exceptions:~The pharmacy staff at the center involved in the preparation. The Pharmacy Service at Sant Pau Hospital will mask the study medication, labeling it with consecutive code numbers following the randomization table.~The sponsor's pharmacovigilance personnel reporting adverse events to health authorities."|A controlled, randomized, double-blind, and multicenter clinical trial has been designed to explore the proof-of-concept regarding the effects of nicotinamide (NAM) administration on hepatic inflammation and fibrosis in individuals with obesity and type 2 diabetes (DM2). The trial adopts a parallel design, incorporating a placebo control group.|t|t|t|t
34178932|NCT05328102|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Part 1 Single Arm Multiple Dose Followed by Part 2 Randomized||||
34178933|NCT05756179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840674|NCT06036849|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcomes assessor will be blinded to treatment allocation. It will not be possible to blind participants with respect to treatment allocation. However, participants will be blinded to the study hypothesis.|Randomized, mechanistic, cross-over clinical trial.|f|f|f|t
33840675|NCT02224404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865604|NCT00126074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33963697|NCT00667498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865605|NCT01995578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865606|NCT00525044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865607|NCT00064519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865608|NCT02693522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865609|NCT06378671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a prospective, single-center, double-blind ,randomized controlled clinical trial|t|f|t|f
33865610|NCT04422990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865611|NCT02293447|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33963698|NCT05417490|||COHORT||PROSPECTIVE|||||||
33963699|NCT04372888|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|participants are blinded to arm and decision frame|Randomization to 1 of 6 decision frames for two disease testing scenarios (arms)|t|f|f|f
33963700|NCT00118196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178934|NCT06497842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data and statistical analysis will be performed by a researcher blinded to groups and participants' identities.|Participants will undergo anthropometrics, familiarization, and strength test, and will be randomized to a high-effort, or a low-effort resistance training protocol, that will be carried out 2 days/week, for 16 weeks, and will be composed of 7 exercises (hex bar squat, seated chest press, leg press, lat pulldown, leg extension, shoulder press, leg curl, always in this order). Load will be set at 10-RM load (75% 1-RM). Participants will be instructed to perform the concentric (lifting) phase of the repetition as fast as they can (\~0.5 seconds), and to perform the eccentric phase in 2 seconds. Psychological responses (perceived exertion, enjoyment, feeling scale, discomfort, and self-efficacy) will be assessed. Anthropometrics will be repeated after training, and before and after the training period, glycemic control will be assessed via a continuous glucose monitoring device. The main outcomes will be compared between training interventions, pre-training data will used as comparator.|f|f|f|t
34178935|NCT06208514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178936|NCT05698485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865612|NCT04558463|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be divided into two groups: favipiravir and oseltamivir as adjuvant therapy in addition to standard therapy||||
33865613|NCT00286481|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33865614|NCT01555151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865615|NCT01378104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865616|NCT04818424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomly assigned to either intervention of (1) REAL, or (2) Control.|f|f|f|t
33865617|NCT05269342|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865618|NCT05189613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865619|NCT05016206|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This was a double-dummy, placebo- and positive-controlled study.|t|f|t|f
33865620|NCT05972382|||OTHER||CROSS_SECTIONAL|||||||
34178937|NCT00687193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178938|NCT02459106|||CASE_CONTROL||PROSPECTIVE|||||||
34178939|NCT02030808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34178940|NCT05888038|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865621|NCT00278850|||CASE_CONTROL||PROSPECTIVE|||||||
33865622|NCT02783131|RANDOMIZED|PARALLEL||||NONE||||||
33865623|NCT02483377|||CASE_ONLY||PROSPECTIVE|||||||
33865624|NCT00268307|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33865625|NCT00199914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The treatment group received short-wave diathermy (SWD) plus exercise whereas the control group received exercise alone.|t|t|t|t
33865626|NCT02777229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865627|NCT05151120|||OTHER||PROSPECTIVE|||||||
33865628|NCT00865904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865629|NCT01908972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865630|NCT00421473|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865631|NCT05806775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865632|NCT04608760|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33865633|NCT00480688|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865634|NCT03842163|||CASE_ONLY||CROSS_SECTIONAL|||||||
33865635|NCT04159766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865636|NCT05844371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865637|NCT01582542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865638|NCT02695433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33865639|NCT01526096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865640|NCT03420079|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In the dose escalation cohort of FCN-411, the dose will be escalated from 4 mg, 8 mg, 16 mg, 24 mg to 32 mg. The MTD will be expanded to ascertain the RP2D.||||
33865641|NCT04575142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865642|NCT01033435|||CASE_CONTROL||PROSPECTIVE|||||||
33865643|NCT00566917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865644|NCT00773136|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33865645|NCT04341168|||COHORT||PROSPECTIVE|||||||
33865646|NCT02752750|||COHORT||PROSPECTIVE|||||||
33865647|NCT02094963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865648|NCT00947362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865649|NCT00686296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865650|NCT04535180|||CASE_ONLY||PROSPECTIVE|||||||
33865651|NCT04966793|||COHORT||PROSPECTIVE|||||||
33865652|NCT02991508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865653|NCT03920202|||COHORT||PROSPECTIVE|||||||
34178941|NCT06473064|NA|SINGLE_GROUP||TREATMENT||NONE||"* The Nipple areola complex (NAC )margins on both sides are marked as circular.~  * Around the initial circle, a second circle (external) was drawn 1 cm broader than the boundary.~ * The skin was resected, with deepithelialization between the two circles.~ * A transdermal incision was made through the border of the external circle.~* The breast tissue around the pedicle was lifted over the pectoral fascia and excised by preserving the NAC and the underlying breast pedicle~  -The base of the mammary pedicle under the NAC was infixed at the farthest end of the mastectomy area by using 3/0 absorbable multifilament suture material~* Hence, the space formed after mastectomy was filled with a breast pedicle located posterior to the NAC.~* The closure of the circular deepithelialized area around the NAC with a diameter of 1 cm accomplished by using 4/0 absorbable monofilament suture material and the surgery was completed"||||
34178942|NCT06587958|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A three-way randomized controlled crossover study will investigate the effects of fermented plant-based foods, non-fermented plant-based foods and the habitual diet on cardiometabolic risk factors. Each intervention will be ongoing for six weeks with six weeks washout in-between. During the fermented/non-fermented plant-based foods intervention, participants will add several corresponding food products to their habitual diet. The study has been dimensioned based on the estimated effect on hsCRP.||||
34178943|NCT03341377|||COHORT||PROSPECTIVE|||||||
34178944|NCT02928887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34178945|NCT02199002|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178946|NCT05715931|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT) Drug: Trastuzumab Drug: Toripalimab||||
34178947|NCT05978193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178948|NCT02524925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34178949|NCT05473364|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Escalating dose finding trial.||||
34178950|NCT06284265|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34178951|NCT05387239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178952|NCT06596915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865654|NCT04221854|RANDOMIZED|PARALLEL||SCREENING||NONE||Subjects will received either Stool-based SDC2 DNA Methylation Test or Fecal Immunochemical Test.||||
33865655|NCT00611338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Study investigators were blind to the condition of study participants until all intervention sessions and assessments were completed. The data were coded to mask the intervention conditions for all data analyses.||f|f|t|t
33865656|NCT02193048|||CASE_ONLY||PROSPECTIVE|||||||
33865657|NCT02510781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865658|NCT00392353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865659|NCT04374838|||COHORT||CROSS_SECTIONAL|||||||
33865660|NCT05726539|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865661|NCT06318351|||COHORT||PROSPECTIVE|||||||
33865662|NCT04358510|||COHORT||RETROSPECTIVE|||||||
33865663|NCT02514408|||CASE_ONLY||PROSPECTIVE|||||||
33865664|NCT04677699|||COHORT||PROSPECTIVE|||||||
33865665|NCT00181584|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33865666|NCT01509079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33865667|NCT05597709|||COHORT||PROSPECTIVE|||||||
33865668|NCT05054595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865669|NCT02560064|||COHORT||PROSPECTIVE|||||||
33865670|NCT01345396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865671|NCT00072358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865672|NCT04635566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865673|NCT01621048|||OTHER||PROSPECTIVE|||||||
33865674|NCT04156217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865675|NCT05990751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865676|NCT01519076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865677|NCT01726244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865678|NCT02763228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33865679|NCT03718065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865680|NCT00930722|||CASE_ONLY||PROSPECTIVE|||||||
34178953|NCT06601361|||CASE_ONLY||CROSS_SECTIONAL|||||||
34178954|NCT03904849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178955|NCT04137068|NA|SINGLE_GROUP||OTHER||NONE||||||
33865681|NCT01525251|||||PROSPECTIVE|||||||
33865682|NCT05518903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865683|NCT02360930|||COHORT||PROSPECTIVE|||||||
33865684|NCT01243229|||OTHER||OTHER|||||||
33865685|NCT05909930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865686|NCT01956734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178956|NCT03205423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will be randomized to receive one of two treatment conditions: gabapentin 0 mg or gabapentin 1800 mg/day first. Participants crossover to the 2nd gabapentin condition following a washout period.|t|f|f|t
34178957|NCT06603350|||COHORT||PROSPECTIVE|||||||
34178958|NCT06001047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34178959|NCT06592807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The researchers who collected data and analyzed the study results were different.||f|f|t|t
33865687|NCT01028950|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33865688|NCT04593667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||60 patients, randomized into one of three arms||||
34178960|NCT06595901|||COHORT||PROSPECTIVE|||||||
33865689|NCT03665467|||COHORT||PROSPECTIVE|||||||
33865690|NCT02112136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865691|NCT02114775|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33865692|NCT02472379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33865693|NCT01063829|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865694|NCT02049268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33865695|NCT04229953|||COHORT||PROSPECTIVE|||||||
33865696|NCT01846624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865697|NCT04230707|||CASE_ONLY||PROSPECTIVE|||||||
33865698|NCT03492554|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865699|NCT02632565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865700|NCT00445705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865701|NCT04199962|||COHORT||PROSPECTIVE|||||||
33865702|NCT04860986|||COHORT||PROSPECTIVE|||||||
33865703|NCT04338373|NA|SINGLE_GROUP||TREATMENT||NONE||Open prospective clinical trial with historical control||||
33865704|NCT00888381|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865705|NCT00990054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865706|NCT02982239|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865707|NCT06321926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcomes will be selected via lime survey. Allocation to the groups will be concealed.|Participants are assigned to the intervention group or the waitlist control group. The intervention group uses the ActiveWaiting App for a week, the waitlist control group starts with a control period (one week), before using the App for a week.|f|t|f|t
33865708|NCT00303979|||COHORT||PROSPECTIVE|||||||
33963701|NCT01731574|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33963702|NCT02020785|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33963703|NCT02222285|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34178961|NCT00100971||||TREATMENT||||||||
34178962|NCT06541574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Doctor Administring the medication are not masked and are not involved with primary follow up of the patients|"1:1:1:1 randomization strategy into four groups:~1. Control group - receiving no methotrexate~2. Injection group - receiving standard surgery without intraoperative methotrexate followed by postoperative 400µg intravitreal methotrexate injections 1, 3, 6, and 10 weeks after surgery.~3. Infusion group - receiving surgery with intraoperative intraocular methotrexate infusion as described above and postoperative sham injections.~4. Combined Infusion/Injection group - receiving both intraoperative intraocular methotrexate infusion and postoperative 400µg intravitreal methotrexate injections 1, 3, 6, and 10 weeks after surgery."|t|f|t|f
33963704|NCT04972071|NA|SINGLE_GROUP||OTHER||NONE||A Stepped Wedge-Controlled Randomized Trial||||
34178963|NCT03760718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178964|NCT02102646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178965|NCT03696836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178966|NCT05030272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178967|NCT04225195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178968|NCT04735471|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose Escalation Design||||
34178969|NCT05540132|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Within subject, randomized cross-over study|t|t|t|f
34178970|NCT05106647|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865709|NCT03472924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865710|NCT02433171|||COHORT||PROSPECTIVE|||||||
34178971|NCT06599723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34178972|NCT06191341|||COHORT||RETROSPECTIVE|||||||
34178973|NCT06591520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34178974|NCT01195701|||CASE_CONTROL||PROSPECTIVE|||||||
34178975|NCT02623972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178976|NCT06597409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33865711|NCT05735808|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865712|NCT01169220|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33865713|NCT05632978|||COHORT||PROSPECTIVE|||||||
33963705|NCT05475678|RANDOMIZED|PARALLEL||TREATMENT||NONE||The enrolled patients were randomly assigned to the experimental group and the control group in a ratio of 2:1.||||
33963706|NCT04921150|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33963707|NCT01246973|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33865714|NCT00444392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865715|NCT00646594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865716|NCT00005666||||TREATMENT||NONE||||||
33865717|NCT05785572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind trial|randomized clinical trial with two groups of study|t|t|f|t
33865718|NCT02281929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865719|NCT01576172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865720|NCT01434550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963708|NCT03263871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33963709|NCT05189483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963710|NCT02009982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963711|NCT00067288|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33963712|NCT04726761|||OTHER||PROSPECTIVE|||||||
33963713|NCT03358732|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized into 2 groups 1. study group had endometrial navigation using IUI catheterone day before embryo transfer control group no intervention||||
33963714|NCT03765944|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33963715|NCT00751998|||CASE_ONLY||PROSPECTIVE|||||||
33963716|NCT00003682|RANDOMIZED|||TREATMENT||||||||
34065379|NCT04889352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomization will be performed after the endoscopy physician consent and enrolment into the study. A computer generated randomization sequence will used in blocks of eight. Stratification for surgical and gastroenterology endoscopy physician will be performed as there might be differential adherence to recommendations by specialty of training.Randomization will be performed and the application distributed by study personnel different than those involved in data extraction from medical records so that the person extracting the data remains blinded to the randomized group assignment. Patients of participating physicians will not require blinding as they will not be approached by the study investigators and will get routine care decided by their physicians.|This will be a cluster randomized controlled trial in which individual endoscopy physicians (gastroenterologists and surgeons) will be randomized (stratified by physician specialty) to one of two groups: A) provided access to the application (intervention group) or B) not provided access to the application (control group). The clusters of patients will be defined by the endoscopy physician providing the colonoscopy.|f|f|t|f
34065380|NCT02046278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065381|NCT06010524|||COHORT||RETROSPECTIVE|||||||
34065382|NCT00614757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065383|NCT01080859|||CASE_CONTROL||PROSPECTIVE|||||||
34065384|NCT03647072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065385|NCT02121236|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065386|NCT00913224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065387|NCT05613075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065388|NCT01530724|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||f|t|t|t
34065389|NCT05763056|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Single (Participant)|Parallel Assignment Prospective Randomized, Placebo-Controlled Clinical Trial|t|t|t|t
34065390|NCT06153732|||COHORT||PROSPECTIVE|||||||
34065391|NCT04719429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34065392|NCT04579614|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Providers do not know that that multiple arms of performance feedback designs exist for this study.|Providers are randomized to receive one of three designs of performance feedback, related to their rate of successful flu vaccinations among total flu opportunities|t|f|f|f
34065393|NCT00337779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065394|NCT01826045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065395|NCT06460337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single-blinded study, where the researcher who will assess outcomes, will be masked to group allocation.|It will be a randomized clinical trial. Through the computerized table generator method of randomization, the selected individuals will be evenly divided into two groups, one undergoing Frenkel's exercises and the other modified Otago exercises.|f|f|f|t
34065396|NCT00286065|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34065397|NCT02929615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065398|NCT01029613|||COHORT||PROSPECTIVE|||||||
34065399|NCT03350204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Testing both meniscus patients and uninjured individuals for comparison|t|f|f|f
34065400|NCT01485302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065401|NCT01147003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065402|NCT03453996|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34065403|NCT04610502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065404|NCT05475457|||COHORT||PROSPECTIVE|||||||
34065405|NCT04525131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065406|NCT04769154|||COHORT||PROSPECTIVE|||||||
34065407|NCT05993091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study participants and outcome assessors will be blind to group allocation (i.e., experimental, comparative, or control group) of the participants.||t|f|f|t
34178977|NCT05233189|RANDOMIZED|PARALLEL||OTHER||NONE||"Cohort multiple randomised controlled trial design. Patients randomized no MOOC group will not be aware of the MOOC. Patients randomized group with MOOC will be composed of all former patients who will be offered the MOOC, whether they accept it or not"||||
33865721|NCT03130179|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33865722|NCT03100669|||COHORT||PROSPECTIVE|||||||
33865723|NCT02080351|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865724|NCT02527525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865725|NCT06476041|||OTHER||PROSPECTIVE|||||||
33865726|NCT01682122|||COHORT||PROSPECTIVE|||||||
33865727|NCT04967781|||CASE_CONTROL||RETROSPECTIVE|||||||
33963717|NCT03539731|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33963718|NCT02612415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963719|NCT02039817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963720|NCT01654471|||CASE_ONLY||PROSPECTIVE|||||||
34178978|NCT06596122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only the neurologist conducting the Modified Total Neuropathy Score (mTNS) assessment will be blinded.||f|f|f|t
33865728|NCT04886310|||COHORT||PROSPECTIVE|||||||
33751904|NCT04322682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This will be a randomized, double-blind, placebo-controlled, multi-center study. Following signature of the informed consent form, approximately 6000 subjects meeting all inclusion and no exclusion criteria will be randomized to receive either colchicine or placebo (1:1 allocation ratio) for 30 days. Follow-up phone or video assessments will occur at 15 and 30 days following randomization for evaluation of the occurrence of any trial endpoints or other adverse events.|t|t|t|f
33751905|NCT06018480|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33751906|NCT03335462|NA|SINGLE_GROUP||OTHER||NONE||||||
33751907|NCT00827918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33751908|NCT00006155||||TREATMENT||||||||
33751909|NCT06426537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The subjects of this study are patients with ST-Elevation Myocardial Infarction (STEMI) who have undergone Percutaneous Coronary Intervention (PCI) and those without reperfusion. Subject selection was conducted using purposive sampling. Patients who received early PCI without reperfusion were divided into four groups: 1). Early PCI with Colchicine, 2). Early PCI with placebo, 3). STEMI without reperfusion with Colchicine and STEMI without reperfusion with placebo. This approach aims to rigorously evaluate the effects of Colchicine in managing inflammation and cardiac remodeling in STEMI patients, comparing its efficacy against standard placebo treatment.|This study investigates the impact of Colchicine on patients with ST-Elevation Myocardial Infarction (STEMI) undergoing different treatment strategies, including percutaneous coronary intervention (PCI) and no revascularization.|t|f|f|f
33751910|NCT02634411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751911|NCT05706506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751912|NCT01913418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751913|NCT01925508|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751914|NCT06423703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751915|NCT00324870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751916|NCT06386588|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33751917|NCT05761860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a within-participant study so that each participant receives all conditions.|t|f|f|t
33751918|NCT05637840|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33751919|NCT03565887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751920|NCT03526822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33751921|NCT00499031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751922|NCT05646706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751923|NCT02118220|NA|SINGLE_GROUP||SCREENING||NONE||||||
33751924|NCT04195308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751925|NCT06233279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751926|NCT05832138|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33751927|NCT01970982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33751928|NCT01299168|||COHORT||PROSPECTIVE|||||||
33751929|NCT01928368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33751930|NCT05121519|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33751931|NCT02429765|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33751932|NCT06732557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751933|NCT02099474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865729|NCT00445484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865730|NCT03891290|||COHORT||PROSPECTIVE|||||||
33865731|NCT00730964|NA|SINGLE_GROUP||||NONE||||||
33865732|NCT01919554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865733|NCT02710136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751934|NCT05615415|||COHORT||CROSS_SECTIONAL|||||||
33751935|NCT05395091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751936|NCT06111612|||COHORT||PROSPECTIVE|||||||
33751937|NCT03339674|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751938|NCT05758337|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The second is a group of subjects whose rehabilitation was carried out by the well-known classical method|The first group is a group of subjects on whom, after implantation, a new technique was applied, including the effect of vibropneumostimulation on the pereimplant tissues|t|f|f|f
33751939|NCT02018393|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33751940|NCT04098133|||COHORT||OTHER|||||||
33751941|NCT05196464|RANDOMIZED|PARALLEL||TREATMENT||NONE||two intervention randomized clinical trial||||
33751942|NCT05331170|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865734|NCT03518138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865735|NCT06417918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33865736|NCT05109286|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865737|NCT02237781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865738|NCT02087072|||COHORT||PROSPECTIVE|||||||
33865739|NCT06047847|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||An ex vivo clinical approach.||||
33865740|NCT02825004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865741|NCT05031754|||COHORT||PROSPECTIVE|||||||
33865742|NCT04179747|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33751943|NCT05227001|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33751944|NCT00142441|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33751945|NCT01398150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33751946|NCT02145546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751947|NCT05358821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751948|NCT04262518|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33751949|NCT03494387|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33751950|NCT04817449|||CASE_ONLY||PROSPECTIVE|||||||
33751951|NCT06614127|||CASE_ONLY||PROSPECTIVE|||||||
33751952|NCT06388694|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33751953|NCT01584622|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33751954|NCT05814913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers doing outcome assessment will be blind to treatment allocation||f|f|f|t
33751955|NCT00083018||||DIAGNOSTIC||||||||
33751956|NCT03474341|||COHORT||PROSPECTIVE|||||||
34178979|NCT04827407|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre randomised clinical trial evaluating the efficacy and safety of the Efferon LPS device in extracorporeal hemoperfusion in patients with abdominal sepsis complicated with septic shock.||||
33751957|NCT02554968|||OTHER||CROSS_SECTIONAL|||||||
33751958|NCT02614716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33751959|NCT04867369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33751960|NCT03321916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751961|NCT06411067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Medication is drawn in unlabeled syringes by nurse. Investigators and outcomes assessors are blinded to treatment arm.|Prospective, randomized, double blinded, placebo controlled study.|t|f|t|t
33751962|NCT03915782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33751963|NCT04801550|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"This is an exploratory and prospective study. Each volunteer will undergo two MEG examinations (4h-long each) without knowing the millimeter wave emitter status. Each volunteer acts as their own control. The status of exposure to millimeter waves is randomized.~The study is cross-over and double-blinded."|t|f|t|f
33751964|NCT00066248|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33751965|NCT04522076|||COHORT||PROSPECTIVE|||||||
33751966|NCT06178991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but all other study personnel, including the principal investigator, and the participant, will be blinded.||t|f|t|f
33751967|NCT06582745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178980|NCT04959435|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34178981|NCT05277766|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I study with dose escalation according to two-stage time-to-event continual reassessment method (TITE-CRM): 3x30 - 3x45 - 4x60 - 4x 75 - 16x90 mg/m2 (number of patients x assigned dose). Dose escalation is continued until dose-limiting toxicity (DLT) is observed. Only DLTs that take place within 14 weeks of the start of the treatment are considered.~From that moment, TITE-CRM updates an initial prior estimate of the probabilities of DLT based on all available information, including patients with incomplete follow-up. Newly accrued patients are assigned the dose whose estimated probability of DLT at that time is closest to target probability. This method allows for continuous, staggered accrual of patients. The target-probability of DLT is 30%. The estimated MTD will be the dose whose estimated posterior probability of DLT is closest to that targeted probability."||||
34178982|NCT03446794|||CASE_ONLY||OTHER|||||||
33751968|NCT06307587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751969|NCT01605513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751970|NCT06732622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33751971|NCT03889743|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||In Sweden and Finland children who are rhinovirus negative but otherwise fulfill the inclusion criteria, will be included for comparison. They will not be randomized and participate in the intervention but receive follow-up as rhinovirus positive participants.|t|f|t|t
33751972|NCT01171248|||COHORT||CROSS_SECTIONAL|||||||
33751973|NCT06315556|||COHORT||CROSS_SECTIONAL|||||||
33751974|NCT03943030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized clinical trial, performed with two groups: intervention and controls (usual care).|f|f|t|t
33751975|NCT00353717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33751976|NCT05268679|||COHORT||OTHER|||||||
33751977|NCT02666950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33751978|NCT02846974|||OTHER||PROSPECTIVE|||||||
33751979|NCT06732180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751980|NCT06733519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751981|NCT02970500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33751982|NCT04729114|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751983|NCT05981768|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33751984|NCT00398008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33751985|NCT03734731|NA|SINGLE_GROUP||TREATMENT||NONE||Individual physician patient studies with all products and services being used on FDA label. Study process being referred to in NCD 310.1 as Clinical Trial Policy (CTP), will be approved by the Principal Investigator||||
33751986|NCT06124040|||CASE_CONTROL||PROSPECTIVE|||||||
33751987|NCT06539429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751988|NCT01198080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33751989|NCT04166357|||CASE_ONLY||RETROSPECTIVE|||||||
33751990|NCT05973110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the nature of the clinical trial, the study staff members delivering the intervention are unable to remain blind and are the only individuals who will be aware of the study arm assignment. Assessment staff members, investigators, and participants will be blinded to study arm assignment and will never be involved in the randomization.|Participants will be randomized to either 12 sessions over 6 weeks of a cognitive remediation intervention or 12 sessions over 6 weeks of an active control intervention. Both conditions will involve activities in virtual reality.|t|f|t|t
33751991|NCT02897713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751992|NCT03085485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|The design is a pilot, randomized (3:1, active:placebo), double-blind, placebo-controlled study|t|f|t|t
33751993|NCT03579498|||COHORT||PROSPECTIVE|||||||
33751994|NCT04669171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33751995|NCT06158698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-parallel groups randomized, single-blinded, multi-center phase III-controlled trial|t|f|f|f
33751996|NCT01311544|||CASE_ONLY||PROSPECTIVE|||||||
33751997|NCT03712644|RANDOMIZED|PARALLEL||TREATMENT||NONE||non-blinded, open-label, prospective 1:1 randomized controlled multicentric trial.||||
33751998|NCT01494831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33751999|NCT01834131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752000|NCT06145763|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Random assignments will be concealed from participants and research staff throughout the trial.||t|t|t|t
33752001|NCT04731779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each participant will receive a different dose in consecutive weeks (4 doses total, one of which is a placebo), thus serving as their own control.|t|f|t|t
33752002|NCT06179524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752003|NCT04421781|||COHORT||RETROSPECTIVE|||||||
33752004|NCT06386315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752005|NCT01986465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752006|NCT01429532|||CASE_CONTROL||PROSPECTIVE|||||||
33752007|NCT05574660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33752008|NCT06732271|||OTHER||RETROSPECTIVE|||||||
33865743|NCT06301672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33865744|NCT00298025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865745|NCT00401739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865746|NCT00481897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865747|NCT05120635|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33865748|NCT03019250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865749|NCT01845454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865750|NCT00979706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865751|NCT01334476|||OTHER||OTHER|||||||
33865752|NCT01552655|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33963721|NCT04366778|||COHORT||PROSPECTIVE|||||||
33963722|NCT00639665|||COHORT||PROSPECTIVE|||||||
33963723|NCT01186952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963724|NCT03836365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963725|NCT02586545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963726|NCT01038882|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33963727|NCT03458026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963728|NCT01477957|||CASE_CONTROL||PROSPECTIVE|||||||
33963729|NCT05529628|||COHORT||PROSPECTIVE|||||||
33963730|NCT02855632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34065408|NCT02008006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178983|NCT06588348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34178984|NCT00568295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178985|NCT04515251|||OTHER||PROSPECTIVE|||||||
34178986|NCT03141021|||COHORT||OTHER|||||||
34178987|NCT06046118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178988|NCT04967391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be masked to the randomization group. Investigators that will be reviewing the graft images will also be masked to the randomization group.|saline vs saline with epinephrine|t|f|t|f
34178989|NCT04799964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178990|NCT05877924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178991|NCT06146907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the assessor will be blind to the allocation of participants in the two groups. the participants will not be aware of the presence of other treatment groups.||t|f|f|t
33865753|NCT06027736|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33865754|NCT03840694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Participants will abstain from smoking for 24 hours before one MRI scan and continue smoking as usual before the other.|t|f|t|t
33865755|NCT03392792|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33865756|NCT01638078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865757|NCT01731314|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33865758|NCT03016390|||CASE_CROSSOVER||PROSPECTIVE|||||||
33865759|NCT03428074|||CASE_CONTROL||RETROSPECTIVE|||||||
33865760|NCT04948242|||COHORT||PROSPECTIVE|||||||
33865761|NCT01733342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865762|NCT06495528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33865763|NCT04559945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865764|NCT00067860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865765|NCT02897232|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33865766|NCT02464228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865767|NCT04474457|||COHORT||PROSPECTIVE|||||||
33963731|NCT04529161|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||Patients will follow a 6-months period of FMD followed by a 6-months of routinary eating habits (Group A) or viceversa (Group B)|t|t|t|t
33865768|NCT03599037|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865769|NCT05636189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33865770|NCT04561596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865771|NCT03027375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865772|NCT05340725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent investigator not involved in the study will open the envelopes 1 h before induction of anesthesia and will prepare the study drug solutions in identical syringes and formulations with matching random codes.|This study will investigate the population pharmacokinetics and pharmacodynamics of rectal dexmedetomidine Niosomes for Postoperative Analgesia in Pediatric Cancer Patients undergoing bone marrow biopsy and aspiration in comparison with the intravenous and rectal plain formulation.|t|t|t|t
33865773|NCT04085341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label study design|Parallel-arm design||||
33865774|NCT00418665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33865775|NCT02012296|RANDOMIZED|PARALLEL||TREATMENT||NONE||We report here the phase 2 results||||
33865776|NCT03801954|||COHORT||PROSPECTIVE|||||||
33865777|NCT01893229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34178992|NCT06244628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178993|NCT05511415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34178994|NCT05271669|||COHORT||PROSPECTIVE|||||||
34178995|NCT06118021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34178996|NCT04398433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34178997|NCT06589232|||COHORT||RETROSPECTIVE|||||||
34178998|NCT05979883|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34178999|NCT05766800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179000|NCT06589856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized single-blinded, placebo-controlled crossover study.|t|f|t|t
34179001|NCT05572255|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-dose, 6-sequence, 3-period, 3-treatment crossover study||||
34179002|NCT04050358|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34179003|NCT05227196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179004|NCT03844750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179005|NCT06598527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179006|NCT05814666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179007|NCT06409533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This trial implemented a double-masking protocol involving both the patients (participants) and the outcome assessors. Patients (participants) were unaware of their group assignment and the specific heart rate targets set for them. While the treating physicians (care providers) were informed about the heart rate control targets for their respective patients, the outcome assessors remained blinded to the participants' group allocations.||t|f|f|t
34179008|NCT05569408|||COHORT||RETROSPECTIVE|||||||
34179009|NCT06117605|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|Care providers will be unblinded in that nurses and clinicians will be aware if they receive an alert for the patient.|"If a patient is randomized to a group without an alert, the alert will instead be a hidden silent alert that does not display. However, a timestamp of when the alert was triggered is still recorded even though the alert did not display. This timestamp is used for the primary and secondary outcomes."|t|f|t|t
34179010|NCT04097938|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34179011|NCT02854345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179012|NCT05360004|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open-labelled, controlled trial||||
34179013|NCT04089748|||CASE_CONTROL||PROSPECTIVE|||||||
34179014|NCT04907357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a double-blind, sham-controlled study.|t|f|t|f
34179015|NCT00495196|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34179016|NCT05994482|||COHORT||RETROSPECTIVE|||||||
34179017|NCT06600594|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34179018|NCT05356897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179019|NCT06587243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179020|NCT04824339|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963732|NCT00520494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963733|NCT03156582|||COHORT||RETROSPECTIVE|||||||
34179021|NCT06288997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179022|NCT05954676|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179023|NCT00976183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179024|NCT04994067|||COHORT||PROSPECTIVE|||||||
34179025|NCT06397079|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34179026|NCT04536909|||COHORT||PROSPECTIVE|||||||
34179027|NCT05890729|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34179028|NCT04544917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179029|NCT06592599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179030|NCT05860413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34179031|NCT06596824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179032|NCT03916770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blind to treatment|Whole Body Vibration (WBV) will be applied to Poststroke Hemiplegia. The patients are divided in two groups; WBV group and shame WBV group.|t|f|f|f
34179033|NCT04907396|||COHORT||OTHER|||||||
34179034|NCT00274586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34179035|NCT03789669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179036|NCT06589869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179037|NCT00414830|||||PROSPECTIVE|||||||
34179038|NCT02780648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179039|NCT03041519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179040|NCT03886285|||OTHER||PROSPECTIVE|||||||
34179041|NCT01664975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179042|NCT06442943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34179043|NCT06591273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963734|NCT02869295|NA|SEQUENTIAL||TREATMENT||NONE||||||
33963735|NCT01470586|RANDOMIZED|FACTORIAL||||TRIPLE|||t|t|t|f
34179044|NCT06057766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179045|NCT05949736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179046|NCT06589843|||CASE_ONLY||PROSPECTIVE|||||||
34179047|NCT01849146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179048|NCT03515486|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34179049|NCT06587724|||COHORT||PROSPECTIVE|||||||
34179050|NCT03052829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179051|NCT06597721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179052|NCT06600347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179053|NCT06602804|NA|SINGLE_GROUP||OTHER||NONE||||||
34179054|NCT06599268|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34179055|NCT04880278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34179056|NCT00003149|RANDOMIZED|||TREATMENT||||||||
34179057|NCT06588998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34179058|NCT01278225|||COHORT||PROSPECTIVE|||||||
34179059|NCT04868786|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34179060|NCT04526340|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34179061|NCT03708731|||COHORT||PROSPECTIVE|||||||
34179062|NCT05661643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179063|NCT02559453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34179064|NCT06106360|||COHORT||PROSPECTIVE|||||||
33865778|NCT00558155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065409|NCT06096298|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The study is double-masked - neither the researchers or the participants know which bread they are eating.||t|f|t|f
34065410|NCT01455285||||TREATMENT||||||||
34065411|NCT00935454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065412|NCT05773625|NA|SINGLE_GROUP||OTHER||NONE||||||
34065413|NCT02069093|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34065414|NCT05899647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065415|NCT04659902|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participant will not be told which drink they will ingest until the end of the study.~Individuals not collaborating on the study will randomise the drink order and make up the drinks so the investigator is blinded to which drink the participant will ingest."|There are 4 conditions where participants will ingest different forms of protein in the presence or absence of calcium.|t|f|t|f
34065416|NCT02620358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065417|NCT01892904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065418|NCT03201393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065419|NCT05144048|RANDOMIZED|PARALLEL||TREATMENT||NONE|The women will be randomized using a secure survey tool to an inpatient or outpatient setting.|All eligible women will be recruited form a midwife and/or doctor. After the inclusion the women will be randomized to either inpatient or outpatient setting.||||
34065420|NCT04423575|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065421|NCT01828216|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34065422|NCT01448863|||CASE_CONTROL||PROSPECTIVE|||||||
34065423|NCT03084315|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All participants are blinded to intervention group|Blocked randomization, block size unknown to staff or investigators|t|f|f|f
34065424|NCT01122017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065425|NCT02105649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065426|NCT05410704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865779|NCT00018850|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33865780|NCT00161486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865781|NCT05135221|||OTHER||OTHER|||||||
33865782|NCT04907747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865783|NCT00851123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865784|NCT06373471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865785|NCT00509067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865786|NCT00915772|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33865787|NCT00189189|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33865788|NCT05823298|||CASE_ONLY||CROSS_SECTIONAL|||||||
33865789|NCT01095367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865790|NCT00222573|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33865791|NCT06461767|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||the patient will divide into 4 groups first group will receive stimulation over the left motor cortex second group will receive stimulation over left dorsolateral prefrontal cortex third group will receive stimulation over both left motor cortex and left dorsolateral prefrontal cortex fourth group will receive sham stimulation|t|f|f|f
33865792|NCT02790255|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33865793|NCT02485457|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33865794|NCT02163460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865795|NCT00870766|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33865796|NCT00733304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865797|NCT06425484|RANDOMIZED|PARALLEL||OTHER||SINGLE|APS team will be assessing participants pain score in the ward and documented the data.|Total sample size of 46 subjects, divided into 2 groups epidural alone (Group E) and epidural with bilateral US TAP block (Group T)|f|f|f|t
33865798|NCT01301456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865799|NCT00585429|||COHORT||PROSPECTIVE|||||||
33865800|NCT01486641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865801|NCT04611854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each client will select either self-guided or guided option.||||
33865802|NCT02871973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33865803|NCT05148182|||COHORT||PROSPECTIVE|||||||
33865804|NCT00709111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865805|NCT06383156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865806|NCT02700568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865807|NCT03957395|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33865808|NCT00062517|||COHORT||PROSPECTIVE|||||||
33865809|NCT00003653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865810|NCT00108914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33865811|NCT01549483|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865812|NCT00880555|||||PROSPECTIVE|||||||
33963736|NCT00495638|||||OTHER|||||||
33963737|NCT00744601|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33963738|NCT01179139|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33963739|NCT01498107|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
33963740|NCT05437484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33963741|NCT02751073|||COHORT||PROSPECTIVE|||||||
33963742|NCT03252574|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33963743|NCT02143089|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33963744|NCT04637685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome assessors will be masked to treatment group allocation. The surgeon will not be masked.||f|f|f|t
33963745|NCT05827783|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was a randomized controlled experimental study.|f|f|t|f
33963746|NCT04395885|||OTHER||CROSS_SECTIONAL|||||||
33963747|NCT03966573|NA|SINGLE_GROUP||SCREENING||NONE||||||
33963748|NCT04497090|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33963749|NCT02080533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963750|NCT06522230|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34065427|NCT05509686|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34065428|NCT00600392|||COHORT||PROSPECTIVE|||||||
34065429|NCT01813734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065430|NCT04026334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065431|NCT04167683|||COHORT||PROSPECTIVE|||||||
34179065|NCT04270266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179066|NCT06597630|||COHORT||PROSPECTIVE|||||||
34179067|NCT04324125|||COHORT||RETROSPECTIVE|||||||
34179068|NCT06588790|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A three-arm household-randomized controlled implementation trial to assess two community-based intervention strategies for rapid diagnostic screening/testing, as compared to passive standard-of-care clinic-based screening/testing. Enrolled households will be randomized 1:1:1 to either one of two intervention arms, or the standard-of-care arm.||||
34179069|NCT06589947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179070|NCT06590870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179071|NCT05978167|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34179072|NCT06589427|||COHORT||RETROSPECTIVE|||||||
34179073|NCT06604182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179074|NCT06595446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179075|NCT06035159|NA|SINGLE_GROUP||OTHER||NONE||||||
34179076|NCT01719198|||COHORT||PROSPECTIVE|||||||
34179077|NCT04443712|||COHORT||CROSS_SECTIONAL|||||||
34179078|NCT05981235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179079|NCT02364700|NA|SINGLE_GROUP||OTHER||NONE||||||
34179080|NCT03454568|||COHORT||PROSPECTIVE|||||||
34179081|NCT00000827||||TREATMENT||||||||
34179082|NCT00811590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179083|NCT00844701|||CASE_CONTROL||PROSPECTIVE|||||||
34179084|NCT02952508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179085|NCT03955146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179086|NCT06448559|||OTHER||PROSPECTIVE|||||||
34179087|NCT06594666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179088|NCT03861897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179089|NCT03598842|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34179090|NCT06104462|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179091|NCT04272086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only people who will be unblinded are the members of the block team, who are not members of the care team nor the study team. They will open the envelopes, draw up the medications and cover the syringes with opaque paper such that no one can tell the contents.|Double blind randomized control trial with intervention arm as liposomal bupivacaine tap and intervention as standard bupivacaine tap|t|t|t|t
34179092|NCT05155280|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Pathophysiological comparative study||||
34179093|NCT05742542|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The order of training protocols was randomized and the training programs had a washout period of at least one month.|t|f|f|f
34179094|NCT05766592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be immediately assigned to either condition.||t|f|f|f
34179095|NCT02451722|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34179096|NCT05173194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluators of outcomes will be masked as for the study group of each participant.||f|f|f|t
34179097|NCT05398172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179098|NCT03418389|||COHORT||OTHER|||||||
34179099|NCT03481400|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind study.|Placebo-controlled, crossover design.|t|f|t|f
34179100|NCT00007254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34179101|NCT06206564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, placebo-controlled|Double blind, placebo-controlled randomized trial|t|t|t|f
34179102|NCT03003026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34179103|NCT03432676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179104|NCT03819192|||CASE_CONTROL||PROSPECTIVE|||||||
34179105|NCT04218526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179106|NCT06429917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179107|NCT03724136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to one of 3 arms with monitoring and retesting at 1,3,6 and 12 months following treatment.||||
34179108|NCT00055393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179109|NCT05635019|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34179110|NCT04410900|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179111|NCT06591234|||COHORT||CROSS_SECTIONAL|||||||
34179112|NCT03005444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179113|NCT04489173|NA|SINGLE_GROUP||TREATMENT||NONE||"Multicenter, single arm, phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.~Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days."||||
34179114|NCT06600984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179115|NCT02456415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179116|NCT05074056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Prospective Randomized Study|t|t|t|t
34179117|NCT03312231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34179118|NCT05516446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, single-center, randomized and controlled trial|f|f|f|t
34179119|NCT06431594|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34179120|NCT01735422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179121|NCT04436354|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34065432|NCT06350786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065433|NCT06097273|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865813|NCT04652154|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are invited to either intervention or treatment as usual||||
33865814|NCT03075969|||CASE_ONLY||PROSPECTIVE|||||||
33865815|NCT04521036|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a randomized comparative trial. Patients will be randomized between the infusion of 500mL of Convalescent Plasma versus the standard of care||||
33865816|NCT00209365|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33865817|NCT01992133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33865818|NCT00564824|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33865819|NCT04720404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes on psychiatric interview will be assessed by independent research assistants blind to condition. Participants will be instructed to avoid unblinding as much as possible.|Randomized, controlled clinical trial of interactive MBSR program added to support as usual (MBSR + SAU) versus support as usual with daily self-help mindfulness exercises via a YouTube-channel (SAU + DMYT)|f|f|f|t
33865820|NCT00487396|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34065434|NCT01048970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34065435|NCT01529411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065436|NCT04062071|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34065437|NCT04549623|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34065438|NCT04685278|||COHORT||PROSPECTIVE|||||||
34065439|NCT01652066|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34065440|NCT04209439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34065441|NCT05725876|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||15 naive patients before treatment and 10 control patients during treatment in both diseases. So 2 arms in each disease.||||
34065442|NCT02253732|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34065443|NCT02671656|||OTHER||PROSPECTIVE|||||||
34065444|NCT01994902|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34065445|NCT05977465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065446|NCT02215785|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34065447|NCT00037037|RANDOMIZED|||TREATMENT||NONE||||||
34065448|NCT04328415|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065449|NCT01968512|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34065450|NCT02488590|||COHORT||PROSPECTIVE|||||||
34065451|NCT02999061|||OTHER||CROSS_SECTIONAL|||||||
34065452|NCT02928146|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34065453|NCT03900156|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34065454|NCT03853902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not be told which is the treatment group|Participants will be randomized into a mindfulness course online or a mindfulness course in-person|t|f|f|f
34179122|NCT06596434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects in both aims will be assigned to Group A or Group B using a randomization scheme. Each study participant for each aim is randomly assigned to either treatment or placebo using permuted block randomization.|This is a double-blind, randomized, placebo-controlled trial design.|t|t|t|f
34179123|NCT06654687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34179124|NCT06587906|||COHORT||PROSPECTIVE|||||||
34179125|NCT03850899|||COHORT||PROSPECTIVE|||||||
34179126|NCT05655299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will employ a double-blind design. Subjects, Investigators, study center staff, persons performing the assessments, and the Sponsor are to remain blinded to the identity of the study treatment from the time of randomization until the database lock for the study.||t|t|t|t
34179127|NCT06058910|||OTHER||PROSPECTIVE|||||||
34179128|NCT04327154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179129|NCT01761877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865821|NCT04701385|||COHORT||PROSPECTIVE|||||||
33865822|NCT00788762|||COHORT||PROSPECTIVE|||||||
33865823|NCT00127920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865824|NCT04686578|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865825|NCT01364623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865826|NCT05425914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865827|NCT05058287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865828|NCT02530983|||CASE_ONLY||PROSPECTIVE|||||||
34065455|NCT00630591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065456|NCT02061644|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34065457|NCT03476655|||COHORT||RETROSPECTIVE|||||||
34065458|NCT00427999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065459|NCT03466879|||CASE_CONTROL||PROSPECTIVE|||||||
34065460|NCT02753296|||COHORT||PROSPECTIVE|||||||
34065461|NCT02562092|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34065462|NCT01794832|||CASE_ONLY||PROSPECTIVE|||||||
34065463|NCT00182000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065464|NCT01711619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065465|NCT05986864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065466|NCT03951753|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34065467|NCT00467558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065468|NCT02193711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065469|NCT02206737||CROSSOVER||BASIC_SCIENCE||NONE||||||
34065470|NCT06524895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participants will be blinded to intervention assignment so in every other aspect aside from the energy healing, Sham practitioners should resemble the Reiki healers, and will be stratified by surgery type. Clinical staff who take objective recovery metrics will be blinded to the intervention and control arm status."|Consented participants will be allocated in a 1:1 ratio between the Reiki and the Sham Reiki arms. Participants will be assigned to the intervention arms using a permuted block randomized design. Blocks of two (75%) and four (25%) will be used to randomize patients.|t|f|f|t
34065471|NCT05559372|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34065472|NCT02282163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065473|NCT00588939|||COHORT||PROSPECTIVE|||||||
34065474|NCT04986943|||CASE_ONLY||PROSPECTIVE|||||||
34065475|NCT02669667|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34065476|NCT00970515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179130|NCT06586801|||COHORT||PROSPECTIVE|||||||
34179131|NCT00926237|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34179132|NCT04379414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34179133|NCT06592534|||OTHER||PROSPECTIVE|||||||
34179134|NCT02839096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Clinical Research Unit provides randomization order to the Investigational Pharmacy, which provides treatment or placebo tablets sets to the care provider.||t|t|t|t
34179135|NCT02941081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179136|NCT06602765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A single-blind trial will be conducted where the outcome assessor/statistician will be blind to the intervention received by the participants in different groups.|Control, Interventional group 1, Interventional group 2|f|f|f|t
34179137|NCT05146882|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179138|NCT05232682|NA|SINGLE_GROUP||OTHER||NONE||Single group, open label trial||||
34179139|NCT02637245|||COHORT||PROSPECTIVE|||||||
34179140|NCT06592872|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention will consist of a suite of serious (educational) videogames and interactive teacher-led classroom sessions. The intervention is designed to address the urgent need for an effective primary prevention approach to the problem of bullying and cyberbullying among elementary school students. The intervention enhances personal self-management skills, social skills, refusal skills, and other life skills needed to successfully navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.||||
34179141|NCT06602687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179142|NCT00631514|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34179143|NCT05873751|||COHORT||RETROSPECTIVE|||||||
34179144|NCT06407726|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized through lottery method and allocated into two groups. Group A (n=22) participants will receive Virtual Reality intervention with conventional treatment, while Group B (n=22) will receive Vestibular Exercises with conventional treatment.||||
34179145|NCT06604572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34179146|NCT06654804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179147|NCT05701748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179148|NCT05076006|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Only designated pharmacist will have knowledge of treatment assignment||t|t|t|t
34179149|NCT05462951|||COHORT||PROSPECTIVE|||||||
34179150|NCT06292351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179151|NCT01977547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179152|NCT01033019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179153|NCT03003325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179154|NCT05856721|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34179155|NCT06326411|NA|SEQUENTIAL||TREATMENT||NONE||||||
33865829|NCT03980834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179156|NCT00736541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34179157|NCT04701827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179158|NCT05908916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179159|NCT05601232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752009|NCT02610348|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752010|NCT00796302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752011|NCT01335204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752012|NCT03728829|||COHORT||PROSPECTIVE|||||||
33752013|NCT01988779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865830|NCT03465631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865831|NCT01671423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33865832|NCT00171444|RANDOMIZED|PARALLEL||||NONE||||||
33865833|NCT05944042|||COHORT||OTHER|||||||
33865834|NCT01447368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cinacalcet medical treatment versus total parathyroidectomy with forearm autografting surgical treatment|f|f|f|t
33865835|NCT03627897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The children will randomly assigned into two study groups by a computer-generated random number list. The children in group B will be administered bilateral ESPB with 0.25% bupivacaine by non-blinded researcher to the study groups), while the children in group C will be not administered any intervention.||t|t|f|t
33865836|NCT03517787|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33865837|NCT00440076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865838|NCT03753009|||COHORT||RETROSPECTIVE|||||||
33865839|NCT01495858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33865840|NCT03100799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm, exploratory non-drug, interventional biomarker study in patients with active osteoarthritis to investigate the degree of senescence-associated disease||||
33865841|NCT01537536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865842|NCT05094739|||OTHER||CROSS_SECTIONAL|||||||
33865843|NCT01141400|||COHORT||RETROSPECTIVE|||||||
33865844|NCT00192738|||DEFINED_POPULATION||PROSPECTIVE|||||||
33865845|NCT02838095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865846|NCT03621527|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865847|NCT03380351|||CASE_ONLY||PROSPECTIVE|||||||
33865848|NCT02014740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865849|NCT05766709|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33865850|NCT03306355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893889|NCT05641649|RANDOMIZED|CROSSOVER||OTHER||NONE||"On the first study day, volunteers will be grouped into two. One group will be given test formulation and other will be given innovator formulation. Simple randomization technique will be used for this. Predose blood sample will be collected 15 minutes before drug administration. Later 3 ml blood sample will be collected at 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 hours after drug administration.~After giving a washout period of 7 days, group of volunteers who have received test formulation on first study day will be given innovator and those who received innovator on the first study day will be given test formulation on the second study day."||||
33865851|NCT05291442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"To integrate Family System Care and Theme Care Action Module to improve resilience, family function, self-efficacy, and quality of life for stroke patients and their caregivers.~First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."|f|f|t|f
33865852|NCT04901481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Research staff will not provide any details that would cause participants to become unblinded to the treatment groups.|At enrollment, participants will be randomized (1:1) to receive either the active or sham treatment for the duration of the 6-week study.|t|f|t|t
33865853|NCT00393796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865854|NCT02281357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179160|NCT06290336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor blinded to group allocation|Multi-center randomized controlled trial|f|f|f|t
33752014|NCT06723912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33865855|NCT05923021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The project adopts a central random system for random grouping and obtains a random number. The random number does not reflect grouping information, so blind method can be implemented for subjects and evaluators. However, due to the setting of sham cheek acupuncture in the project grouping, blind method can't be implemented for researchers.|The specific method is to randomly assign 126 patients with moderate depressive disorder to cheek acupuncture group, sham cheek acupuncture group and drug group, evaluate the treatment effect with HAMD-17, PSQI and HAMA, observe the improvement of cheek acupuncture on depression, anxiety and sleep of patients with moderate depressive disorder, and observe the changes of functional links in various brain regions of patients in each group before and after treatment through resting state functional magnetic resonance imaging technology.|t|t|f|t
33865856|NCT00283348|||COHORT||PROSPECTIVE|||||||
34065477|NCT02982148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065478|NCT02676635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065479|NCT02943785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065480|NCT06212713|||OTHER||CROSS_SECTIONAL|||||||
34065481|NCT05347745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065482|NCT00542100|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34065483|NCT03159845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Case-control study, open, without placebo||||
34065484|NCT00005821||||TREATMENT||||||||
34151272|NCT04424693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Each study site will designate an injection nurse who will be responsible for preparing both placebo and Tdap administration and will be the only one knowing when a patient gets either Tdap injection at week 28 or placebo injection at week 28, or gets Tdap injection at week 36 or placebo injection at week 36. This person will be the only one at each site who will know the randomization of each subject and is the only one who will administer the injection. Every subject will receive Tdap either at week 28 or week 36 and receive placebo injection on the other injection time."|Pregnant women enlisted in the double blinded study will be randomized to receive Tdap vaccination either at week 28 or week 36 and observed and treated with standard of care.|t|t|t|t
34151273|NCT03999086|||CASE_CONTROL||PROSPECTIVE|||||||
34179161|NCT02876510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179162|NCT06592326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179163|NCT03589846|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All patients who meet eligiblity will undergo muscle stimulation at the same time as the operative DISE procedure.||||
34179164|NCT02345447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34179165|NCT06236802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179166|NCT04732312|||COHORT||PROSPECTIVE|||||||
34179167|NCT02891447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179168|NCT06218056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179169|NCT03036098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151274|NCT03901404|||COHORT||PROSPECTIVE|||||||
34151275|NCT02319135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179170|NCT02388269|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34179171|NCT04383600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179172|NCT04692064|||FAMILY_BASED||PROSPECTIVE|||||||
34179173|NCT06591156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34179174|NCT06600698|NA|SEQUENTIAL||TREATMENT||NONE||"This is a one-arm, sequential Phase I/II study to evaluate INM176. Phase I uses a 3+3 dose escalation design to find the recommended Phase 2 dose (RP2D) based on dose-limiting toxicities. Phase II includes two stages: Stage 1 involves 13 subjects to test early efficacy; if ≥1 responds (PSA decline/stabilization), the study moves to Stage 2. Stage 2 enrolls 14 more subjects (total 27) to assess efficacy. A PSA response rate \>5% is declared if ≥4 subjects show response. Safety and efficacy will be evaluated with descriptive statistics, linear mixed-effects models, and regression analyses for PK and biomarkers.~Intervention Type: Drug"||||
34179175|NCT02723708|NA|SINGLE_GROUP||OTHER||NONE||||||
34179176|NCT02105740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179177|NCT03365102|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Neither participant or outcome aware of condition|anodal tDCS over the rIFG, anodal tDCS over the lOFC, sham stimulation condition|t|f|f|t
34179178|NCT06584968|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34179179|NCT05271643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179180|NCT02258737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179181|NCT06016114|||COHORT||PROSPECTIVE|||||||
33752015|NCT05092191|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33752016|NCT02061202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752017|NCT05750953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomization will be blinded for the researchers performing the data analysis.|A randomized controlled trial with intervention and control group|f|f|t|f
33752018|NCT06647836|||COHORT||OTHER|||||||
34151276|NCT03002272|||CASE_CONTROL||OTHER|||||||
34151277|NCT04797962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179182|NCT06472427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Both participants and investigators actively parttaking in the study are blinded.~Participants are misinformed that all sessions will be hypoxic, in order to prevent identification of normoxic vs hypoxic conditions. Therefore, participants are also misinformed about the supplements, where they think they will receive 4 different compositions of ketones."|"1 session with normoxic post-exercise recovery, supplemented with placebo (NPL)~1 session with normoxic post-exercise recovery, supplemented with ketones (NKE)~1 session with hypoxic post-exercise recovery, supplemented with placebo (HPL)~1 session with hypoxic post-exercise recovery, supplemented with ketones (HKE)"|t|f|t|f
34179183|NCT00751296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179184|NCT06591260|||CASE_CONTROL||OTHER|||||||
34179185|NCT04008472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865857|NCT04095780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752019|NCT04321239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752020|NCT00006136||||TREATMENT||||||||
33752021|NCT00740948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752022|NCT00177554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752023|NCT03001284|||COHORT||PROSPECTIVE|||||||
33752024|NCT01727739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752025|NCT03352791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33752026|NCT05016505|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||"The proposed design will be a borough-stratified, four-arm, factorial-design, cluster RCT that will target 64 randomly selected buildings (16 buildings per arm) in separate New York City Housing Authority (NYCHA) developments.~The investigators will recruit and follow 8 randomly selected residents stratified by smoking status- 4 smokers and 4 non-smokers- per building (n=512 residents) into four arms: (1) reduction (relocation and reduction in personal smoking)/cessation, (2) resident endorsement, (3) reduction (relocation and reduction in personal smoking)/cessation plus resident endorsement and (4) the standard approach (128 participants per arm)."|t|f|f|t
33752027|NCT01550458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752028|NCT05653219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752029|NCT04975516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865858|NCT04516707|||OTHER||RETROSPECTIVE|||||||
33865859|NCT01931748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865860|NCT02890758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865861|NCT01108965|||COHORT||CROSS_SECTIONAL|||||||
33752030|NCT06733779|||CASE_ONLY||CROSS_SECTIONAL|||||||
33752031|NCT04004611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752032|NCT06099626|||COHORT||CROSS_SECTIONAL|||||||
33752033|NCT05156658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752034|NCT06008717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|motor scores will be blindly rated by an independent movement disorders neurologist who will be unaware of treatment assignment, ON vs OFF treatment status, or visit sequence||f|f|f|t
33752035|NCT06733740|||COHORT||PROSPECTIVE|||||||
33752036|NCT00977353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752037|NCT02660632|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33752038|NCT00403416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752039|NCT01421563|RANDOMIZED|CROSSOVER||||NONE||||||
33752040|NCT06722248|RANDOMIZED|PARALLEL||OTHER||SINGLE|The allocation of students into the block lists (intervention or control group) on the computer will be kept confidential and sealed in envelopes.|Block randomization with random block size 4, 6 will be used to allocate participants into intervention or control group using a online block randomization list generator|t|f|f|f
33752041|NCT02242864|||COHORT||PROSPECTIVE|||||||
33752042|NCT05536362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||preserving hemodynamic stability, dropping post-operative pain, and dipping morphine intake|t|f|f|f
33752043|NCT02460718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752044|NCT00195910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33752045|NCT03552874|||COHORT||PROSPECTIVE|||||||
33752046|NCT03871595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752047|NCT03896646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752048|NCT00256581|||CASE_CONTROL||PROSPECTIVE|||||||
33752049|NCT02952352|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752050|NCT01659190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151278|NCT02265315|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
34151279|NCT00849862|RANDOMIZED|CROSSOVER||||NONE||||||
34151280|NCT03834220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151281|NCT02894450|||COHORT||PROSPECTIVE|||||||
34151282|NCT03460912|||COHORT||PROSPECTIVE|||||||
34151283|NCT03572790|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants will be randomly allocated to one of two groups (prucalopride or placebo). Participants in the prucalopride group will receive 1mg once daily for seven days. Participants in the placebo group will receive a lactose placebo once daily for seven days. Note that the study is not assessing the safety or efficacy of prucalopride, rather it is using prucalopride to assess the behavioural and neural effects of 5-HT4 partial agonists.|t|f|t|t
34151284|NCT04080856|||COHORT||PROSPECTIVE|||||||
34151285|NCT01252524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151286|NCT05269030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blinded to the patient's group||f|f|f|t
34151287|NCT00678548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151288|NCT01257035|||CASE_ONLY||PROSPECTIVE|||||||
34151289|NCT02437084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151290|NCT02910102|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34151291|NCT04374058|||CASE_CONTROL||PROSPECTIVE|||||||
33865862|NCT04778345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865863|NCT03961971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865864|NCT00518427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865865|NCT03228069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The volunteers who participated in the previous clinical trials were invited to join this study. Of which, there were 2 groups, one received a single visit 4-site intradermal rabies booster vaccination. The another received a conventional intramuscular rabies booster vaccination on day 0 and 3.||||
34179186|NCT04253691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179187|NCT04003701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34179188|NCT05978271|||CASE_CROSSOVER||PROSPECTIVE|||||||
34179189|NCT05910073|||COHORT||RETROSPECTIVE|||||||
34179190|NCT06597669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179191|NCT05472779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179192|NCT04379700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179193|NCT04021719|||OTHER||OTHER|||||||
34179194|NCT02241824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179195|NCT00509977|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34179196|NCT06116045|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34179197|NCT06599645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34179198|NCT04298047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The design is a unicentre (Jewish General Hospital; Montreal, Quebec, Canada), clinical, randomized, controlled, single blinded (i.e.; investigators), superiority trial, with two parallel arms (Intervention and Control groups), comparative (comparison between Intervention and Control groups) and analyzed with the intention-to-treat.|f|f|t|f
34179199|NCT06258200|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study will have two arms, an intervention and comparison arm, and participants will be grouped into arms based on their community of residence. Participants in the intervention arm will receive behavioral interventions, including household visits, participation in couple discussion groups, and messaging from community leaders.||||
34179200|NCT06284382|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||This is a prospective, single-center, double-blind, parallel-group controlled trial with two arms.|t|t|t|f
34179201|NCT01801592|||COHORT||OTHER|||||||
34179202|NCT03271762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179203|NCT05491811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179204|NCT01651026|||COHORT||PROSPECTIVE|||||||
33752051|NCT03505112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, single-center, double-blind, parallel-group, randomized, controlled trial|t|t|t|t
33752052|NCT04820855|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33752053|NCT06454552|||COHORT||PROSPECTIVE|||||||
33752054|NCT05214274|||OTHER||OTHER|||||||
33752055|NCT01012830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752056|NCT06732596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to one of two groups: 75 will receive the ECA intervention in addition to usual care, while 25 will receive only usual care. The ECA group will be further divided into three subgroups based on different engagement strategies.||||
33752057|NCT02526732|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752058|NCT06308510|||COHORT||PROSPECTIVE|||||||
33752059|NCT04735549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The treatment method cannot be hidden from the participants and the researcher because of the very different method of treatment: laser treatment and the use of local hormones on their own. However, the specialists involved in the study (cytologist and ultrasound specialist) will not know which group the participant belongs to. The researcher will refer participants (or their materials) to these specialists, indicating their name and visit number. The Researcher will keep a document matching the participant's name and number.~The conversation will be held with participants. A participant must not disclose his group when visiting an ultrasound specialist."||f|f|f|t
33752060|NCT00694603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752061|NCT04983316|||COHORT||PROSPECTIVE|||||||
33752062|NCT01475968|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33752063|NCT05618574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After a participant agrees to consent, their group placement is randomly determined using high quality pseudo-random deviate generator in SAS. Participants in both groups will receive either 140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK) for 14 days versus a 210 ml of nitrate depleted placebo depending on their group placement.|In a randomized controlled, blinded design, participants will receive 140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK) for 14 days versus a 210 ml of nitrate-depleted placebo. All participants are encouraged to undergo physical therapy 2-3 times per week based on tolerance for activity and recovery needed after each session. Physical therapy will be offered on site or at home (or a hybrid combination).|t|f|t|f
33838615|NCT05005377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who analyzed the data was blinded from the procedure ( The participants were assigned to A and B groups and it was not clear for the investigator which data belonged to which procedure).|48 patients were randomly divided into two groups for anterior ridge preservation with PRF and FDBA. At 12 months after implant placement and prosthetic delivery, bone loss was evaluated radiographically while soft tissue changes were evaluated by measuring gingival recession, papilla index, and bleeding on probing (BOP).|f|f|t|f
33838616|NCT02679326|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Double blinded RCT|t|f|f|t
33838617|NCT04281251|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm case series||||
33865866|NCT05223114|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33865867|NCT03734549|||COHORT||PROSPECTIVE|||||||
33865868|NCT06256809|||CASE_ONLY||PROSPECTIVE|||||||
34065485|NCT04191122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized to receive COPES plus TAU or TAU via a random sequence generation computer algorithm within STATA to generate (stratified) randomised (block) allocations. Randomisation will be carried out by the study statistician using an independent computerised randomisation system with a randomly sized block design with block sizes of 2, 4 and 6. The study population will be stratified for those receiving TAU and those receiving COPES plus TAU. Researchers completing study assessments will be masked to treatment allocation, facilitated by briefing members of the research team and participants on the need to avoid disclosure of treatment details. The trial will follow an Intent-To-Treat (ITT) protocol. Attrition and reasons for drop-out will be recorded where possible. Guidance will be sought from the patient advisory group on how to manage and minimise attrition over the study period.|"COPES is a brief (4 + 1 sessions, 50 minutes) psychotherapy based on psychodynamic and cognitive analytic principles that was developed to help those struggling with SH and depression. COPES is designed to be brief and accessible and involves working collaboratively with a client to try and identify patterns or conflicts in emotional experiences and interpersonal relationships, linked to depressed mood and acts of SH. The therapist works with the client to build a shared map or understanding of these experiences. A goal of therapy is to work towards a small number of specific exits, representing helpful steps the client might make to improve their difficulties. Therapy would take place either in the participant's home or in a community setting (e.g. health centre or clinic) depending on preference.~Safety for the therapist and/or mobility for the patient will be reviewed throughout the recruitment period. Participants in the COPES arm of the trial will also receive TAU."|t|t|f|f
34179205|NCT06585956|||OTHER||CROSS_SECTIONAL|||||||
34065486|NCT03828682|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective cohort of de novo kidney transplant recipients will be assigned to treatment group and compared to historical controls||||
34065487|NCT03353948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179206|NCT06588049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065488|NCT00817505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179207|NCT00253149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34179208|NCT04106557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant/Care Giver and Investigator/Outcomes Assessor)||t|f|t|f
34179209|NCT06597786|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, open-label, phase 1b dose-expansion trial of neoadjuvant (preoperative) exercise therapy in patients with prespecified solid tumors.||||
33865869|NCT06079944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865870|NCT04796922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded||t|f|t|t
33865871|NCT02906787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865872|NCT03340649|||CASE_ONLY||PROSPECTIVE|||||||
34065489|NCT02157597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065490|NCT06286020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065491|NCT04102384|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not know which group (smart phone or embedded link) is the intervention vs. control group.|Intervention- one group will use a smartphone application to fill out surveys while the other group fills out surveys via an emailed embedded link.|t|f|f|f
34065492|NCT00285376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065493|NCT03525756|||COHORT||PROSPECTIVE|||||||
34065494|NCT04414189|||CASE_ONLY||PROSPECTIVE|||||||
34065495|NCT05056571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34065496|NCT02901301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065497|NCT06274151|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34065498|NCT03079076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065499|NCT04833400|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34065500|NCT03955900|||COHORT||PROSPECTIVE|||||||
34065501|NCT04707560|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34065502|NCT03013985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065503|NCT04697654|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34065504|NCT00507988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065505|NCT00886925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065506|NCT05553535|||CASE_CONTROL||RETROSPECTIVE|||||||
34065507|NCT05492422|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34179210|NCT04971161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, placebo-controlled, double-blind, dose-ranging, interventional, multicenter, phase IIb clinical trial|t|f|t|f
33865873|NCT05444842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|insulin iontophoresis and topical insulin|t|f|f|t
33865874|NCT05510765|NA|SINGLE_GROUP||OTHER||NONE||Prospective||||
33865875|NCT00890253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865876|NCT02901496|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33893890|NCT04925115|RANDOMIZED|PARALLEL||OTHER||SINGLE|According to study|Two groups with randomization, Assignment: Brisk walking|t|f|f|f
33893891|NCT02626377|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065508|NCT01275963|||CASE_CONTROL||PROSPECTIVE|||||||
34065509|NCT05589402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065510|NCT05837546|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Due to the nature of the conditions, the experimenters and the participants cannot be blinded as it is obvious if the animal is present or not. Nevertheless, participants will not be informed of the order of the conditions before the beginning of the measurement and to minimize bias they will not be informed about our hypotheses and that we are interested in the effects of the presence of a dog.|within-subject randomized controlled trial with repeated measurement||||
33963751|NCT03372083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963752|NCT01039584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963753|NCT00611741|NA|SINGLE_GROUP||||NONE||||||
33963754|NCT02458365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963755|NCT05678699|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Evaluation of policy interventions at the state level comparing within state and across states over time.||||
33963756|NCT01656967|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33963757|NCT01453374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963758|NCT01185483|||CASE_ONLY||PROSPECTIVE|||||||
33963759|NCT01384864|NA|SINGLE_GROUP||SCREENING||NONE||||||
33963760|NCT01250626|||CASE_ONLY||PROSPECTIVE|||||||
33865877|NCT04876755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"For the dose comparison phase, five entry dosing regimens will be explored and represented by Cohort 1 through Cohort 5.~The first 3 patients (Cohort 1) will begin with a total daily dose (TDD) of 600 mg of MBM-02.~The study will employ a 3+3 design with Cohort 5 dose at 1600 mg/day.~Cohort 6 will enroll up to 40 patients at 1600 mg/day of MBM02."||||
33963761|NCT04564040|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065511|NCT03768921|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The research design is a longitudinal, quantitative and analytical clinical trial.|||||
34065512|NCT03230136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065513|NCT00768339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065514|NCT03647423|RANDOMIZED|PARALLEL||TREATMENT||NONE||Chordoma Vaccine: A randomized phase 1b/2 trial of the NANT chordoma vaccine vs. radiation in subjects with unresectable chordoma.||||
34065515|NCT02401061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065516|NCT00404924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065517|NCT03757403|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||phase 2a randomized double-blinded placebo-controlled cross-over|t|t|t|f
34065518|NCT05563935|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865878|NCT03846349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865879|NCT02637479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865880|NCT00941668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865881|NCT05378841|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33865882|NCT02677948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865883|NCT00003111||||TREATMENT||||||||
33865884|NCT06490302|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33893892|NCT06447012|||COHORT||PROSPECTIVE|||||||
33963762|NCT02889731|||||PROSPECTIVE|||||||
33963763|NCT06541210|||COHORT||PROSPECTIVE|||||||
33963764|NCT05829382|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|A randomized, double-blind, placebo controlled, cross-over trial to investigate the effect of the Investigational Product (DailyColors™) on age-related pathways in adults. Participants will receive DailyColors™ or placebo for a week, then one week wash-out, and then placebo/Dailycolors™ for a week, in random order. In addition, participants will be asked for consent to be contacted for participation in an open-label extension study for 3 months at a later date.|A randomized, double-blind, placebo controlled, cross-over clinical trial.|t|t|t|t
33963765|NCT00574379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963766|NCT02633761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963767|NCT00001574|||COHORT||PROSPECTIVE|||||||
33963768|NCT02121405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963769|NCT04892342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
33963770|NCT05870826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963771|NCT06403566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33963772|NCT00344526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963773|NCT00913588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963774|NCT06354465|||COHORT||CROSS_SECTIONAL|||||||
33963775|NCT03007537|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33963776|NCT04626557|||CASE_CONTROL||PROSPECTIVE|||||||
33963777|NCT03676894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, 3-arm parallel pilot study|t|f|f|f
33963778|NCT06469476|||OTHER||RETROSPECTIVE|||||||
33963779|NCT02491619|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963780|NCT04024085|||COHORT||PROSPECTIVE|||||||
33963781|NCT03491319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|First anaesthesiologist performed the spinal anaesthesia, gave table tilt using clinometer according to group allocation and assessed spinal blockade till 10 min after intrathecal injection. Thereafter it was done by the second anaesthesiologist who was blinded to the patient grouping|Patients were randomly allocated to one of the 3 groups by closed envelope method|f|t|t|t
33963782|NCT00415142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963783|NCT05258435|||CASE_ONLY||PROSPECTIVE|||||||
33963784|NCT04538768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065519|NCT04712513|||CASE_ONLY||PROSPECTIVE|||||||
34065520|NCT06305260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065521|NCT03865394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065522|NCT02205697|NA|SINGLE_GROUP||||NONE||||||
34065523|NCT03020394|||COHORT||PROSPECTIVE|||||||
34065524|NCT02055274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065525|NCT03124537|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants are aware of the nature of the App features they are given. They are not aware of whether they are in an experimental or control condition.|Both conditions will receive the App for use on an iphone. The control group will just have the accelerometer program to set step goals and to count steps. The experimental condition will have the accelerometer to set goals and count steps in addition to the schedule, map and social components.|t|f|f|f
34065526|NCT01991899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34065527|NCT00428922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963785|NCT05402631|||COHORT||PROSPECTIVE|||||||
34065528|NCT00444496|||||RETROSPECTIVE|||||||
34065529|NCT02227719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065530|NCT04843358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34065531|NCT01555710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065532|NCT06171594|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33865885|NCT04860375|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective, open label, cohort study using design of intervention and registries data. Eligible patients for intervention group will be recruited consecutively from patients referred to the COPD-Center at the Sahlgrenska University Hospital, after a hospital admission because of acute or progressive worsening dyspnea. The control group will be recruited from the Swedish Airway Register and selection will be based on propensity score matching. A total of 110 patients will be included in the intervention group and 220 in the control group.||||
33865886|NCT01298583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865887|NCT02810847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865888|NCT04431336|||COHORT||PROSPECTIVE|||||||
33865889|NCT05837520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865890|NCT04060563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865891|NCT02078635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33865892|NCT02417155|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865893|NCT02088788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865894|NCT02150499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865895|NCT05039333|||CASE_ONLY||PROSPECTIVE|||||||
33865896|NCT04860037|||COHORT||RETROSPECTIVE|||||||
33865897|NCT03329196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865898|NCT04020939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865899|NCT01248286|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865900|NCT02265861|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33865901|NCT02556996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865902|NCT05973097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865903|NCT05942430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865904|NCT02678338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963786|NCT00267020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963787|NCT02093065|||COHORT||PROSPECTIVE|||||||
33963788|NCT02067988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963789|NCT03016845|||CASE_ONLY||PROSPECTIVE|||||||
33865905|NCT01958723|||COHORT||PROSPECTIVE|||||||
33963790|NCT01704235|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33963791|NCT01925807|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34179211|NCT04946851|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34179212|NCT04973449|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind: two or more parties are unaware of the intervention assignment.|"Previously vaccinated individuals will receive 1 dose of~AZD1222 or AZD2816 on Day 1. Previously unvaccinated participants will receive one of the following 2-dose vaccinations:~* 1 dose of AZD2816 on Day 1 and on Day 29~* 1 dose of AZD1222 on Day1 and on Day 29~* 1 dose of AZD1222 on Day 1 and 1 dose of AZD2816 on Day 29~* 1 dose of AZD2816 on Day 1 and on Day 85. Participants will be followed up for safety for 180 days after last study vaccine administration."|t|t|t|t
34179213|NCT06604364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179214|NCT03130738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, investigators, and study staff will not be masked as to the treatment duration assigned to each subject (7 versus 14 days). For subjects receiving the 14-day treatment with study drug, the contents of the study drug (active versus placebo) will be masked to the subject, investigator, and study staff.||t|t|t|t
34179215|NCT06655753|||OTHER||OTHER|||||||
34179216|NCT06203327|||COHORT||PROSPECTIVE|||||||
34179217|NCT06591936|||COHORT||RETROSPECTIVE|||||||
34179218|NCT06540261|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179219|NCT03712696|NA|SINGLE_GROUP||OTHER||NONE||Open Label||||
33865906|NCT06035796|||COHORT||PROSPECTIVE|||||||
33865907|NCT02765087|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33865908|NCT00698204|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33865909|NCT06328998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33865910|NCT00001181||||TREATMENT||||||||
33865911|NCT03085979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865912|NCT05614687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865913|NCT00338663|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33865914|NCT02438891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865915|NCT06271642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33865916|NCT02389751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865917|NCT00375557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865918|NCT00236925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33865919|NCT04458103|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865920|NCT03128476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865921|NCT01820936|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33865922|NCT02051920|||||PROSPECTIVE|||||||
33865923|NCT03966781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865924|NCT00294242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33865925|NCT02274181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963792|NCT03235765|||COHORT||PROSPECTIVE|||||||
34065533|NCT00005796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065534|NCT00696228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34065535|NCT02372435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065536|NCT01658904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065537|NCT01911780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065538|NCT06031675|||COHORT||PROSPECTIVE|||||||
34065539|NCT05175950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34065540|NCT00573586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179220|NCT06553703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the study, it is not possible to blind the researcher implementing the intervention and the participants. To prevent bias in the study, the pretest will be applied before randomization. It is planned to blind the statistical and report writing process in the study. The assignment of students to the intervention and control groups will be made by a statistician independent of the study. The researcher and students will not know which group they are in until the application begins. After applying the follow-up tests, the researcher will code the data as A and B groups and transfer it to SPSS. With this method, it is planned that the statistician will do the analysis and reporting without knowing which group is the intervention and which group is the control group. It is planned to explain the codes of the groups after the analysis and reporting of the data. In this way, detection bias, statistical bias, and reporting bias will be prevented.|In the study, 54 students were taken as sampling, 27 of which were experimental and 27 were control.|f|f|f|t
34179221|NCT05584514|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking -- participants are presented various stimuli in different experimental conditions.|"This basic science experiment meets the NIH criteria of a BESH (Basic Experimental Study with Humans) Trial. All participants are exposed to all experimental conditions (i.e., interventions) in a complete factorial 2 x 3 within-subjects experimental design. Interventions involve presenting various speech stimuli to participants."||||
33865926|NCT02650336|||CASE_CONTROL||PROSPECTIVE|||||||
33865927|NCT05495139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865928|NCT00273936|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33865929|NCT03189862|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33865930|NCT04249323|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33865931|NCT05107804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865932|NCT05365555|||COHORT||PROSPECTIVE|||||||
33865933|NCT01924013|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33865934|NCT06316245|||COHORT||PROSPECTIVE|||||||
33865935|NCT04749966|||OTHER||CROSS_SECTIONAL|||||||
33865936|NCT03623451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865937|NCT04184492|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This study was blinded for Sponsor, investigators and analytical laboratory|two-way crossover|f|f|f|t
33865938|NCT05740033|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will become aware of what arm they were randomly assigned to: those in the STSG arm will be to see their additional thigh scar; those in the local flap arm will lack this scar. As such, participants will only be blinded prior to their treatment. The surgeons may not be blinded as they will be performing the procedure on the participants and following up with them as per standard of care post-operatively.|The study will have two arms: one with participants receiving a split-thickness skin graft from the thigh to close the radial forearm donor site, and the other using a local (hatchet) flap to close this site. These two arms will be populated randomly and in parallel.||||
33865939|NCT03694613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Clinical team (care provider) will be blinded to the Placental/Umbilical Cord Blood sepsis evaluation results|||||
33865940|NCT05458050|NA|SINGLE_GROUP||PREVENTION||NONE|The medical device will give an ID number but the results from the measurement will be masked until data base is locked (DBL). The data from the measurement will be available after DBL|Double blind||||
34179222|NCT05271604|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179223|NCT03011918|||CASE_ONLY||RETROSPECTIVE|||||||
34179224|NCT03924050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179225|NCT04562870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179226|NCT05781906|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34179227|NCT01315925|||COHORT||PROSPECTIVE|||||||
33865941|NCT03452293|||COHORT||PROSPECTIVE|||||||
33865942|NCT01398865|||CASE_ONLY||PROSPECTIVE|||||||
33865943|NCT05867082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865944|NCT00625352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865945|NCT01851278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33865946|NCT00119145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865947|NCT04693754|||CASE_ONLY||RETROSPECTIVE|||||||
33865948|NCT03742635|NA|SINGLE_GROUP||SCREENING||NONE||"Conduct General Movements Assessments (GMA) both in-person/via telemedicine (real-time) and through recordings (standard of care)."||||
33865949|NCT01165372|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33865950|NCT03564951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865951|NCT03540082|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33865952|NCT04429906|||OTHER||CROSS_SECTIONAL|||||||
33865953|NCT01347775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865954|NCT06247852|||COHORT||PROSPECTIVE|||||||
33865955|NCT00902187|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33865956|NCT04374409|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33865957|NCT06241807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179228|NCT04501042|||CASE_CONTROL||PROSPECTIVE|||||||
34179229|NCT02064946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34179230|NCT06467370|||OTHER||PROSPECTIVE|||||||
34179231|NCT01391962|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179232|NCT03115866|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||2 interventions evaluated against the other and a control.||||
33865958|NCT01627002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179233|NCT05035862|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179234|NCT00312156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179235|NCT02689635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179236|NCT01710501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865959|NCT02525250|NA|SINGLE_GROUP||||NONE||||||
34179237|NCT06326060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34179238|NCT01979068|||CASE_CONTROL||PROSPECTIVE|||||||
34179239|NCT05636228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865960|NCT00099996||||TREATMENT||||||||
34179240|NCT01029275|RANDOMIZED|PARALLEL||||NONE||||||
33865961|NCT00789880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179241|NCT04665141|||COHORT||OTHER|||||||
34179242|NCT05559710|||COHORT||PROSPECTIVE|||||||
34179243|NCT05260736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double-Blind, Prospective, Interventional|t|t|f|t
34179244|NCT05373537|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot Randomized control trial Comparing a home-based vs a web-based approach to CBT-Insomnia||||
33865962|NCT02048618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865963|NCT01274936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865964|NCT00188565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33865965|NCT05793138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34179245|NCT06470555|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomised into one of three strategies for haemostasis (with a final allocation ratio of 1:1:1):~* Conventional arm: Manual compression with 4-hours of bed rest;~* Intervention arm 1: A figure-of-eight suture secured with a three-way tap (Fo8s-3wt) with 4-hours of bed rest;~* Intervention arm 2: A Fo8s-3wt with 2-hours of bed rest."||||
33963793|NCT05734170|RANDOMIZED|PARALLEL||PREVENTION||NONE||This pilot study was a small, randomized controlled trial at an academic primary care center. Each patient provided voluntary written consent prior to participating in the project. At the beginning of the study, each participant was randomly assigned to the red, white or blue group. They were then assigned a number within that group. The red group was instructed to consume one serving of Cheerios according to package instructions each morning for 30 days, the white group one packet of instant oatmeal, and the blue group one packet of instant oatmeal with two tablespoons of chia seeds. Subjects will be questioned to ensure to contraindications to participation. All other dietary or exercise habits will be maintained to reduce risk of confounding variables.Cholesterol profiles and weight will be measured at the beginning and end of the study.||||
33963794|NCT01244607|RANDOMIZED|||||||||||
34179246|NCT06602778|NA|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34179247|NCT05911724|||CASE_CONTROL||PROSPECTIVE|||||||
34179248|NCT06594900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34179249|NCT06181240|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, single-arm, multicenter, interventional study in adults (≥18 years of age) with de novo, calcified, stenotic coronary artery lesions.||||
34179250|NCT04701762|RANDOMIZED|CROSSOVER||OTHER||NONE||Cluster randomized multiple crossover design||||
34179251|NCT04029883|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34179252|NCT06583876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179253|NCT06586502|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34179254|NCT04345796|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"To study efficacy of carvedilol, participants will be assigned to a carvedilol or to placebo and the identity of the treatment will be concealed by the use of study drugs that are identical in packaging, labeling, appearance and odor. Participants allocated to the SGLT2 inhibitor arm will receive empagliflozin 10mg.~All imaging studies will be analyzed by core laboratory investigators who will be blinded to treatment assignment from the time of randomization until database lock."|2 x 2 factorial|f|f|f|t
34179255|NCT06600373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179256|NCT05349214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators, investigator staff, persons performing the assessments and Novartis Clinical Trial Team will remain blinded to the identity of the treatment from the time of randomization until the final database lock||t|t|t|t
34179257|NCT05561478|||CASE_CONTROL||PROSPECTIVE|||||||
34179258|NCT02956395|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34179259|NCT06598865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179260|NCT05967585|NA|SINGLE_GROUP||OTHER||NONE||||||
34179261|NCT01708200|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33865966|NCT02231463|||CASE_ONLY||PROSPECTIVE|||||||
33865967|NCT00061165|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33865968|NCT00963248|||COHORT||PROSPECTIVE|||||||
33865969|NCT01191372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865970|NCT00791258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865971|NCT02762279|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33865972|NCT04924712|||COHORT||PROSPECTIVE|||||||
33865973|NCT03911973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865974|NCT01212653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33865975|NCT03932734|||CASE_ONLY||RETROSPECTIVE|||||||
33865976|NCT00252135|||COHORT||PROSPECTIVE|||||||
33865977|NCT03601936|NA|SINGLE_GROUP||SCREENING||NONE||||||
33865978|NCT00245544|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33865979|NCT05525728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||a group of patient suffering from vestibular pathology will be investigated regardless the etiology of the vertigo or dizziness||||
33865980|NCT06424951|NA|SINGLE_GROUP||OTHER||NONE||||||
33865981|NCT01805960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865982|NCT00380770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865983|NCT01648894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33865984|NCT02638350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33865985|NCT02742753|||OTHER||RETROSPECTIVE|||||||
33865986|NCT00348920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865987|NCT03497806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33865988|NCT00300768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33865989|NCT01773642|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33865990|NCT04215614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33865991|NCT03217942|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Double blind||t|f|t|f
33865992|NCT05989698|NA|SINGLE_GROUP||OTHER||NONE||||||
33865993|NCT05178550|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33865994|NCT04654481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistician and data analysts will be blinded to treatment cohort.||f|f|f|t
33865995|NCT06363279|NA|SINGLE_GROUP||OTHER||NONE||||||
33865996|NCT06252259|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33865997|NCT02822950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179262|NCT01854411|||COHORT||PROSPECTIVE|||||||
34179263|NCT04771806|||COHORT||PROSPECTIVE|||||||
34179264|NCT06603311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||After discontinuation of the standard treatment of patients with compensated liver disease and chronic hepatitis delta in subjects who received BLV for at least 48 weeks at the discretion of their treating physicians and have reached HDV RNA below 100 IU/ml for at least 24 weeks patients will followed-up for 48 weeks to identify the diagnostic value of biomarkers associated with HDV RNA relapse after stopping BLV and to evaluate the concept of finite BLV treatment.||||
34179265|NCT06595836|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Each product will be labeled with a randomly generated code|This study is a masked (investigators, research staff), two-way crossover, randomized to sequence of use study designed to evaluate the acceptability and functional performance (breakage, slippage) of a silicone lubricated polyisoprene condom and a silicone lubricated natural rubber latex condom|f|f|t|t
34179266|NCT06591026|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33865998|NCT01657097|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33865999|NCT02491567|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866000|NCT03752775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The device assisted treatment will be administrated to patients with subacute stroke and chronic stroke. The subacute stroke group will be compared in parallel with a control group receive the conventional physical and occupational therapies.|f|f|f|t
33866001|NCT04221698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33866002|NCT06428487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866003|NCT03391206|||COHORT||PROSPECTIVE|||||||
33866004|NCT06417112|||CASE_CONTROL||PROSPECTIVE|||||||
33866005|NCT00757536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866006|NCT05913310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866007|NCT01132612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866008|NCT02801955|||COHORT||PROSPECTIVE|||||||
33866009|NCT01091584|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866010|NCT05149027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866011|NCT03873766|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either IPFT or surgery for treatment of their complex pleural space infection||||
33866012|NCT05010850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866013|NCT01473342|NA|SINGLE_GROUP||||NONE||||||
33866014|NCT00411125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33866015|NCT04224844|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34179267|NCT04158362|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to standard combination of endocrine therapy with abemaciclib as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, high burden disease.~Duration of one cycle of either treatment : 3 weeks"||||
34179268|NCT06583980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It is not possible to blind the intervention to the participants and the healthcare professionals in this trial. To ensure blinding in the analyses, all patient participants will be given a number for reference and the person performing the statistical analyses will be blinded to allocation group. A research nurse will inform the participants about group allocation.|Experimental group and control group (usual care)|f|f|t|f
34179269|NCT04793360|||COHORT||PROSPECTIVE|||||||
34179270|NCT03069937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866016|NCT05805943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866017|NCT02934997|||COHORT||PROSPECTIVE|||||||
33866018|NCT04636424|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33866019|NCT01188720|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33866020|NCT05571748|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33866021|NCT05619302|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866022|NCT02663050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866023|NCT01145716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866024|NCT00437502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179271|NCT06589336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179272|NCT05886621|RANDOMIZED|PARALLEL||OTHER||NONE||2-group pilot randomized controlled trial||||
34179273|NCT06588933|||COHORT||PROSPECTIVE|||||||
34179274|NCT01285323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179275|NCT06065449|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179276|NCT04750915|||COHORT||RETROSPECTIVE|||||||
34179277|NCT05913232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179278|NCT05316597|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants and research staff conducting the intervention will be masked to the exposure|Participants are assigned to both arms in random order|t|f|t|f
34179279|NCT04475458|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34179280|NCT00385216|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34179281|NCT05255900|||COHORT||PROSPECTIVE|||||||
34179282|NCT06586229|||OTHER||CROSS_SECTIONAL|||||||
34179283|NCT06235775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179284|NCT04286984|||COHORT||PROSPECTIVE|||||||
34179285|NCT02479399|||CASE_CONTROL||PROSPECTIVE|||||||
34179286|NCT04295148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179287|NCT06589206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179288|NCT06592898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838661|NCT05600140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"For the first phase of the study, we aim to include 48 children aged 5-12 years for each group (i.e. normal Vision, ocular visual impairment, cerebral visual impairment). For the second phase of the study 60 children with visual impairment aged 5-9 years will be included (ocular impairment: n=30, cerebral visual impairment: n=30).~In the second phase of the project, children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol based. A textbook is used to describe the reactions of the children during training."||||
33866025|NCT00909233|||COHORT||PROSPECTIVE|||||||
33866026|NCT02361827|||COHORT||PROSPECTIVE|||||||
33866027|NCT01377064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866028|NCT06393582|NA|SINGLE_GROUP||TREATMENT||NONE||One group of patients will receive both conventional and digital impressions||||
33866029|NCT04299191|NA|SEQUENTIAL||TREATMENT||NONE||"An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors.~The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard 3+3 design to establish dose-limiting toxicity (DLT) and a safe dose of LAM561 followed by an expanded safety cohort of up to 10 patients treated at the Maximum Tolerated Dose (MTD). If the MTD is well tolerated in the expanded safety cohort, that dose becomes the Recommended Phase 2 Dose (RP2D).~Glioma patients and other solid tumor patients (including non-glial brain tumors) will be treated as a single cohort. Patients with either tumor type will be allowed to enroll on the study as positions are made available. No tumor type will be given priority over another and there is no minimum number of glioma patients or solid tumor patients that must be enrolled on the trial."||||
33866030|NCT00393952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866031|NCT02308631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866032|NCT06392295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866033|NCT06018818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866034|NCT06116227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34179289|NCT03845205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research Coordinator is blinded to treatment assignment|Integrated AUD treatment (IAT) v Treatment as usual (TAU)|f|f|f|t
34179290|NCT06602973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34179291|NCT01381939|||COHORT||RETROSPECTIVE|||||||
34179292|NCT06593262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179293|NCT03995134|||COHORT||PROSPECTIVE|||||||
34179294|NCT05736380|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Over the course of two visits to the laboratory, each participant will be randomised to either real or sham cerebellar rTMS. Each participant will undergo both procedures.|Over the course of two visits to the laboratory, each participant will undergo either real or sham cerebellar rTMS. Afterwards they will have functional magnetic resonance imaging of their brains.|t|f|f|f
34179295|NCT06590727|||COHORT||PROSPECTIVE|||||||
34179296|NCT03902418|||COHORT||PROSPECTIVE|||||||
34179297|NCT05400967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179298|NCT06593301|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34179299|NCT02170376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179300|NCT05726305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Living donor versus deceased donor||||
34179301|NCT04716764|||COHORT||PROSPECTIVE|||||||
34179302|NCT01767090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179303|NCT06596109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179304|NCT01915810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179305|NCT04232358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
34179306|NCT04386291|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to one of three treatment arms: Anxiety Reduction Training (A.R.T.), ART with Kundalini Yoga, ART with Meditation||||
34179307|NCT04792645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179308|NCT05501041|||COHORT||PROSPECTIVE|||||||
34179309|NCT06597500|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Click here to enter text.|||||
34179310|NCT01951443|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34179311|NCT06600724|RANDOMIZED|PARALLEL||TREATMENT||NONE||CAMPAIGN uses a Prospective Modified Platform Multicenter Randomized Controlled Clinical Trial design.||||
34179312|NCT06596733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179313|NCT02181777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179314|NCT06594939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179315|NCT06326450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179316|NCT06563700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179317|NCT03103542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179318|NCT01490151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963795|NCT03296774|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33963796|NCT04527003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind of study team (PI, Sub-I's and all research staff) and subjects. Randomization will be completed by Investigational Pharmacy and will keep the blind.||t|f|t|f
34179319|NCT05885438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179320|NCT04522388|NA|SINGLE_GROUP||TREATMENT||NONE||Ensure Enlive, Nutritional shake, twice a day||||
34179321|NCT06591663|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34179322|NCT06362824|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34179323|NCT06590831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179324|NCT06603740|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34179325|NCT06597422|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34179326|NCT06591715|||COHORT||PROSPECTIVE|||||||
34179327|NCT06490289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179328|NCT06601777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34179329|NCT03560297|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34179330|NCT06597864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179331|NCT06588764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179332|NCT04852224|||COHORT||PROSPECTIVE|||||||
33866035|NCT03385720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866036|NCT03056560|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179333|NCT03175367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179334|NCT06202521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179335|NCT05153694|||COHORT||PROSPECTIVE|||||||
34179336|NCT05532189|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to the ACL reconstruction without internal bracing group (control) or to the ACL reconstruction with internal bracing (experimental).||||
34179337|NCT06604039|||COHORT||PROSPECTIVE|||||||
34179338|NCT06169839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34179339|NCT06036225|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Focus groups, experience based co-design and a feasibility study||||
34179340|NCT01350947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179341|NCT06590714|RANDOMIZED|PARALLEL||TREATMENT||NONE||Rotator cuff tear patients||||
34179342|NCT00603408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179343|NCT06600516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pilot randomized clinical trial with 4 treatment groups: stimulus control, sleep restriction, sleep compression, waitlist control|t|f|f|f
34179344|NCT05939206|||COHORT||PROSPECTIVE|||||||
34179345|NCT06240260|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179346|NCT06585397|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34179347|NCT06100809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179348|NCT05458128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179349|NCT02780843|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34179350|NCT05972317|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34179351|NCT06603935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study utilizes a parallel assignment model. Participants are randomized into two groups: one group receives standard care (STC) for allergic rhinitis, and the other group receives both standard care and the use of the digital medicine tools, Allergy Management Evaluation (AME) and Allergic Rhinitis Intervention Steps (ARIS), provided through the QHSLab platform. The intervention group will receive continuous digital monitoring, personalized feedback, and treatment adjustments based on patient-reported outcomes. Both groups will be followed for 12 months with assessments at baseline, 3, 6, and 12 months to evaluate symptom severity, adherence, and healthcare utilization.||||
34179352|NCT06246084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179353|NCT06593015|||COHORT||RETROSPECTIVE|||||||
34179354|NCT05030155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179355|NCT04326972|||CASE_ONLY||PROSPECTIVE|||||||
34179356|NCT02938299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866037|NCT01145014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866038|NCT03812484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866039|NCT01321359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866040|NCT06190236|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two arms, one a control and the other arm utilizing a stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder. This study will utilize a 3:1 randomization favoring intervention.||||
34179357|NCT00103584|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34179358|NCT06491238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179359|NCT06594952|||COHORT||PROSPECTIVE|||||||
34179360|NCT06166992|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179361|NCT00289653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179362|NCT00570115|||COHORT||PROSPECTIVE|||||||
34179363|NCT04919109|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34179364|NCT06345690|||CASE_ONLY||PROSPECTIVE|||||||
34179365|NCT04662021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179366|NCT06598501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179367|NCT02792686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179368|NCT00546806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33866041|NCT03970850|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866042|NCT03819036|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignment||||
33866043|NCT00844207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33866044|NCT05747508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866045|NCT04373681|||OTHER||PROSPECTIVE|||||||
33866046|NCT03373682|||COHORT||PROSPECTIVE|||||||
33866047|NCT00763230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065541|NCT03891823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Randomized study of MitraClip vs. medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."|t|t|t|t
34065542|NCT01180049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065543|NCT04439058|RANDOMIZED|PARALLEL||OTHER||DOUBLE||US machine Mindray M5 (Shenzhen Mindray Bio-Medical Electronics Co., LTD. Shenzhen, China.) with a linear 38-mm high frequency 10-12 MHz transducer), with an imaging depth of 4 cm. A 50-mm short bevel 22-gauge insulated stimulating needle (PAJUNK® GmbH Medizin technologie, Deutschland) was used|t|f|t|f
34065544|NCT01162720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34065545|NCT00718068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065546|NCT03453112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065547|NCT02455024|||OTHER||PROSPECTIVE|||||||
34065548|NCT03855085|||CASE_ONLY||PROSPECTIVE|||||||
34065549|NCT04570163|||COHORT||PROSPECTIVE|||||||
34065550|NCT04246502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065551|NCT02769039|||COHORT||PROSPECTIVE|||||||
34065552|NCT01559688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065553|NCT06336122|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065554|NCT02269254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065555|NCT05415241|NA|SEQUENTIAL||PREVENTION||NONE||||||
34065556|NCT03864666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065557|NCT06509490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065558|NCT04953286|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065559|NCT05517733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065560|NCT05107206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a prospective, multinational, randomized (adaptive), parallel group controlled, blinded, non-inferiority study.|f|f|f|t
34065561|NCT01844973|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34065562|NCT03309514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065563|NCT00405782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065564|NCT02232555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065565|NCT00536315|||COHORT||PROSPECTIVE|||||||
34065566|NCT00349635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065567|NCT03887429|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34065568|NCT01827878|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065569|NCT05907252|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34065570|NCT01812850|||COHORT||PROSPECTIVE|||||||
34065571|NCT05330585|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34065572|NCT02546076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065573|NCT02107950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065574|NCT04030936|||OTHER||CROSS_SECTIONAL|||||||
34065575|NCT02272153|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34065576|NCT00524680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065577|NCT03519113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866048|NCT03341572|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866049|NCT04114188|NA|SINGLE_GROUP||TREATMENT||NONE||This is a confidence-interval-estimation based early phase design, aiming to estimate a plausible range of the population treatment effect which is not bound to a formal hypothesis.||||
33866050|NCT00910572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866051|NCT02256605|||COHORT||PROSPECTIVE|||||||
33866052|NCT01760928|||COHORT||RETROSPECTIVE|||||||
33866053|NCT00775723|||COHORT||PROSPECTIVE|||||||
33866054|NCT00020618||||SUPPORTIVE_CARE||||||||
34065578|NCT04573166|NA|SINGLE_GROUP||TREATMENT||NONE||After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the levels of AOP and MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 12 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.||||
34065579|NCT03717415|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34065580|NCT01964716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065581|NCT02089087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065582|NCT06261541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065583|NCT02451397|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34179369|NCT05521607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179370|NCT06494358|||COHORT||PROSPECTIVE|||||||
33866055|NCT06272786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessor will be different persons.|Randomised controlled|f|f|t|t
33866056|NCT01085552|NON_RANDOMIZED|PARALLEL||||NONE||||||
34065584|NCT01653327|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34065585|NCT02018978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065586|NCT01080391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065587|NCT02945111|RANDOMIZED|PARALLEL||||NONE||||||
34065588|NCT06446284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34065589|NCT02181218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065590|NCT00178269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065591|NCT02781376|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34179371|NCT06592859|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34179372|NCT06084611|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34179373|NCT02698696|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34179374|NCT06588478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179375|NCT06599125|||COHORT||PROSPECTIVE|||||||
34179376|NCT06590857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179377|NCT04494672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179378|NCT01766934|||COHORT||PROSPECTIVE|||||||
34179379|NCT06009939|||COHORT||PROSPECTIVE|||||||
34179380|NCT01600326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179381|NCT01341834|NA|SINGLE_GROUP||OTHER||NONE||||||
34179382|NCT04976231|||COHORT||PROSPECTIVE|||||||
34179383|NCT06252038|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34179384|NCT04091555|NA|SINGLE_GROUP||OTHER||NONE||||||
33963797|NCT04023318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963798|NCT05186350|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|t|f|f
33963799|NCT04416672|||OTHER||PROSPECTIVE|||||||
33963800|NCT00183469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963801|NCT02475980|||COHORT||PROSPECTIVE|||||||
33963802|NCT04399850|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33963803|NCT03096717|||COHORT||PROSPECTIVE|||||||
33963804|NCT04466696|||COHORT||PROSPECTIVE|||||||
33963805|NCT06149195|||CASE_CONTROL||PROSPECTIVE|||||||
33963806|NCT00115258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963807|NCT02169531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179385|NCT06597240|||COHORT||PROSPECTIVE|||||||
34179386|NCT04945733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179387|NCT00497094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34179388|NCT01786005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179389|NCT03493997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179390|NCT03205709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963808|NCT02690584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963809|NCT06312774|||COHORT||PROSPECTIVE|||||||
33963810|NCT03732729|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963811|NCT04209218|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|For dexamethasone administration, all participants, care providers, investigators, and outcomes assessors are masked. For blood pressure management, participants and outcome assessors are masked.|A 2 × 2 factorial randomized controlled trial|t|f|f|t
34179391|NCT02472821|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179392|NCT00027534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179393|NCT06596070|||CASE_CONTROL||PROSPECTIVE|||||||
34179394|NCT06592027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The aim of our study is to assess and compare the efficacy of two different doses of dexmedetomidine (0.5 μg/kg and 1.0 μg/ kg) to find out its optimal dose in attenuation of hemodynamic pressor response to laryngoscopy and intubation with the use of Cardiometry for continuous CO monitoring beat by beat.|t|t|t|t
34179395|NCT04775381|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34179396|NCT04009408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed until the end of study whether they received active intervention or sham intervention|Parallel group, double blind, sham controlled study|t|f|f|t
34179397|NCT05135000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838662|NCT03143738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants not aware of the type of continuous blockade.|Two groups of patients randomly allocated: adductor canal group or femoral nerve group|t|f|f|f
33838663|NCT06508866|||COHORT||PROSPECTIVE|||||||
33838664|NCT04481685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33838665|NCT03755011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33838666|NCT06231810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33838667|NCT02450812|||COHORT||PROSPECTIVE|||||||
33838668|NCT04243512|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838669|NCT06105853|NA|SINGLE_GROUP||TREATMENT||NONE||"* longitudinal~* multimodal~* interventional"||||
33838670|NCT00542204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33838671|NCT02202785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838672|NCT01885689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838673|NCT06457243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838674|NCT05602753|||COHORT||PROSPECTIVE|||||||
33838675|NCT06249997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838676|NCT00527787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838677|NCT03363139|||COHORT||PROSPECTIVE|||||||
33838678|NCT04445298|||COHORT||PROSPECTIVE|||||||
33838679|NCT01395004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179398|NCT04524949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179399|NCT05891379|||COHORT||PROSPECTIVE|||||||
34179400|NCT04552301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research coordinators (RCs) are blinded to study randomization and treatment arm for each participant.|Data from the observational component of the study will be used to identify WTC workers with asthma and PTSD for the pilot. Eligibility will be determined based on Asthma Control Questionnaire (ACQ) score \>1.5, indicating uncontrolled asthma and results of the Structured Clinical Interview for DSM-5 Disorders (SCID) and/or PCL-5 showing evidence of PTSD. Participants will be consented by trained research staff and randomized 1:1 (stratified by level of asthma control) into an intervention (combined asthma self-management and cognitive processing therapy for PTSD) or an active attention control arm (supportive psychotherapy plus asthma education) after completing their 12-month visit.|f|f|f|t
34179401|NCT06603389|||OTHER||CROSS_SECTIONAL|||||||
34179402|NCT06596395|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Triple-blind, cross-over, randomized controlled-trial|t|f|t|t
34179403|NCT02828826|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179404|NCT00497458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963812|NCT01532011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179405|NCT02933008|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34179406|NCT06586385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"The simple random sampling method will be used among the women who took the handicraft technology course at Erzincan Public Education Center, which constitutes the sample of the research. According to the sample pool formed by the women included in the research, the participants will be assigned to 2 groups as experimental and control with the Research Randomizer program (https://www.randomizer.org/). Each group will consist of at least 60 people."|t|f|t|f
34179407|NCT05179135|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179408|NCT05902416|||COHORT||PROSPECTIVE|||||||
34179409|NCT06592976|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179410|NCT05876442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34179411|NCT05298514|||OTHER||OTHER|||||||
34179412|NCT06473181|NA|SEQUENTIAL||TREATMENT||NONE||||||
34179413|NCT04602663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963813|NCT04657237|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33963814|NCT04084054|||COHORT||PROSPECTIVE|||||||
33963815|NCT06519734|||CASE_ONLY||PROSPECTIVE|||||||
33963816|NCT01520766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963817|NCT06006351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Exercise therapy and Applying a Hypervolt massager|f|f|f|t
33963818|NCT04528277|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963819|NCT00108758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963820|NCT06160479|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33963821|NCT02845635|||CASE_CONTROL||PROSPECTIVE|||||||
33963822|NCT04011839|||COHORT||PROSPECTIVE|||||||
33963823|NCT02162901|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33963824|NCT00533884|||COHORT||PROSPECTIVE|||||||
34065592|NCT00791492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065593|NCT05091619|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34179414|NCT06166147|||CASE_CONTROL||PROSPECTIVE|||||||
34179415|NCT06197997|RANDOMIZED|PARALLEL||PREVENTION||NONE||The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence.||||
34179416|NCT05431933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179417|NCT05965258|||COHORT||PROSPECTIVE|||||||
34179418|NCT01542047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179419|NCT05411016|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Outcomes Assessor: pharmacokinetic person, pharmacodynamic analysis person and investigational drug administration person are unblinded.||t|t|t|t
34179420|NCT02866786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179421|NCT00870740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179422|NCT06482944|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study arms are, BY DESIGN, not able to be totally blinded. Investigators/data collection staff are blinded as to arm of an individual participant (collection staff will be blinded to the extent possible). Main outcome assessors are blinded as to the intervention the individual participant is receiving to the extent possible.||f|f|t|t
34179423|NCT01556022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179424|NCT00385671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179425|NCT06603714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each participant will complete two visits. During one visit the treatment will be performed at short, whilst during the other at long muscle lengths.||||
34179426|NCT03651752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838680|NCT04944667|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33963825|NCT02253758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963826|NCT04790409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065594|NCT00561691|||CASE_ONLY||PROSPECTIVE|||||||
34065595|NCT06245798|||COHORT||RETROSPECTIVE|||||||
33838681|NCT04689464|||CASE_ONLY||CROSS_SECTIONAL|||||||
33838682|NCT00887770|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33838683|NCT04977791|||CASE_ONLY||PROSPECTIVE|||||||
33838684|NCT02274155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838685|NCT01338753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838686|NCT00439192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33838687|NCT02754362|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838688|NCT02175953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838689|NCT00003877|RANDOMIZED|||TREATMENT||||||||
33838690|NCT00360295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838691|NCT01133080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838692|NCT03916796|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838693|NCT05615584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838694|NCT00951470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838695|NCT00863512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963827|NCT04084912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33963828|NCT05286099|||COHORT||PROSPECTIVE|||||||
33963829|NCT01875133|RANDOMIZED|CROSSOVER||||NONE||||||
33963830|NCT01253889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963831|NCT05883020|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33963832|NCT00133094|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963833|NCT05351281|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Sites will crossover from control to the intervention group in a random order. During the study all parties have knowledge of the interventions assigned to individual participants|A stepped-wedge cluster randomized study. The stepped-wedge design involves random and sequential crossover of 7 clusters (=7 different study sites) from the control to the intervention group, until all clusters are exposed. All clusters will start as control sites, where care is provided as usual. Every twelve weeks, one site will crossover from control to intervention group||||
33963834|NCT03307707|||COHORT||PROSPECTIVE|||||||
33963835|NCT03045029|||COHORT||PROSPECTIVE|||||||
33963836|NCT02638961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963837|NCT03181178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blind cluster randomized trial - all participants in a community received the same treatment.|The study has three intervention arms and one cross sectional growth monitoring follow up group.|t|f|f|f
33963838|NCT02832882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963839|NCT05161663|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|No mask|"This peer-driven intervention (PDI), modified based on respondent-driven sampling (RDS) or snowball sampling, is a chain referral approach. Index peers will be purposefully selected to reflect the diversity of African American (AA) and Hispanic/Latino (H/L) men who have sex with men (MSM) and are required to take a formal training about pre-exposure prophylaxis (PrEP) and HIV. These index peers will educate members of their social networks and encourage them to initiate PrEP. Those referred peers will schedule an appointment to complete a short survey and will be referred to our PrEP clinic if they are interested in PrEP uptake. The referred peers will serve as index peers for the following wave of recruitment. It is expected to achieve a robust sample of AA and H/L within six waves of recruitment. This PDI approach is potential to engage AA and H/L who are most at risk of HIV acquisition in PrEP uptake and could contribute to reducing the concentrated HIV epidemic."||||
33963840|NCT06526767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963841|NCT05891873|||COHORT||PROSPECTIVE|||||||
33963842|NCT04135573|||CASE_CONTROL||PROSPECTIVE|||||||
34065596|NCT05921422|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065597|NCT03030274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065598|NCT04475718|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Interviews were conducted with 24 pregnant and postpartum women. From this research and other activities, the investigators built a prototype program. Once the prototype was completed, the investigators conducted a clinical trial with 87 participants. The pre-test captured key outcome measures (resilience, stress, anxiety, depression, fear, knowledge, and variables related to COVID-19) and other descriptive variables. All participants who completed the pre-test were given access to the prototype mobile postpartum tool. Participants were asked to actively engage with the tool for 4 weeks, during which time they provided real-time user experience feedback. At the end of the 4-week period, the investigators conducted a post-test to measure change in outcomes.||||
34065599|NCT01194050|||COHORT||PROSPECTIVE|||||||
34065600|NCT01538394|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
34065601|NCT02972450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065602|NCT02489474|||COHORT||PROSPECTIVE|||||||
34065603|NCT02455713|||CASE_CROSSOVER||PROSPECTIVE|||||||
33963843|NCT00818831|NA|SINGLE_GROUP||||NONE||||||
33963844|NCT03750825|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963845|NCT04765254|||CASE_CONTROL||PROSPECTIVE|||||||
33963846|NCT05880628|||COHORT||RETROSPECTIVE|||||||
33963847|NCT04829409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33963848|NCT00439751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963849|NCT01949207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963850|NCT06469138|NA|SINGLE_GROUP||TREATMENT||NONE|N/A - study is open label|All participants will be assigned to active treatment and will be dosed within a single cohort of up to 8 participants (with 6 required to complete).||||
33963851|NCT06537167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"At the time of enrollment, each participant will be assigned a unique identification number (e.g., 001). The coded information will be stored in a secure database accessible only to designated members of the research team. A random number table will be generated using SPSS software, and participants will be allocated to either the stimulation experimental group or the sham stimulation control group according to the generated random numbers. Randomization information will be strictly confidential, ensuring that participants, outcome assessors, and statistical analysts are all blinded to the group assignments."||t|f|f|t
33963852|NCT00033631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963853|NCT06204276|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33963854|NCT01929369|||CASE_CONTROL||PROSPECTIVE|||||||
33963855|NCT02059187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065604|NCT03351153|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34065605|NCT01672294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34065606|NCT05025683|||COHORT||RETROSPECTIVE|||||||
34065607|NCT00682994|NA|SINGLE_GROUP||||NONE||||||
34065608|NCT03798392|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34065609|NCT02249689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065610|NCT03718169|||CASE_ONLY||PROSPECTIVE|||||||
34065611|NCT03126955|||COHORT||PROSPECTIVE|||||||
34065612|NCT00960167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179427|NCT05048134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||HRS2300 monotherapy or combined with SHR-1316, SHR-1701, trametinib, and Almonertinib||||
34179428|NCT03563014|||COHORT||RETROSPECTIVE|||||||
34179429|NCT01668784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179430|NCT06603090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34179431|NCT00910650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179432|NCT06590272|||COHORT||RETROSPECTIVE|||||||
34179433|NCT01495949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866057|NCT00521924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866058|NCT00522054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866059|NCT05037864|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866060|NCT06348550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866061|NCT03045783|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33963856|NCT00534209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33963857|NCT00760188|||COHORT||PROSPECTIVE|||||||
33963858|NCT03151785|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963859|NCT02625207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963860|NCT04476316|||COHORT||CROSS_SECTIONAL|||||||
33963861|NCT01887379|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963862|NCT05978999|||OTHER||PROSPECTIVE|||||||
33963863|NCT06064409|||COHORT||PROSPECTIVE|||||||
33963864|NCT01583803|||COHORT||PROSPECTIVE|||||||
33963865|NCT04421066|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33963866|NCT02270905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963867|NCT04259801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|Part 1: Single ascending dose Part 2: Multiple ascending dose|t|t|t|t
33963868|NCT04768764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There are two groups: the first group is adductor block and the second group is femoral block.|t|t|f|f
33963869|NCT05571657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33963870|NCT05003128|NA|SINGLE_GROUP||OTHER||NONE||||||
33963871|NCT03883971|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||3D ultrasound only or 3D ultrasound and printed model of fetal face||||
34065613|NCT02074332|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34065614|NCT05337384|||COHORT||PROSPECTIVE|||||||
34065615|NCT02588664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34065616|NCT05994300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065617|NCT02263612|||COHORT||RETROSPECTIVE|||||||
34065618|NCT05423366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065619|NCT00691561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065620|NCT05268016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065621|NCT02622490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34065622|NCT04494594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomisation occurs when a quick response (QR) code is generated and a unique proxy identifier and participant gender is assigned. At this point, participants are automatically randomised to receive the control or intervention arm and are blinded. Block randomisation, of size 2, will be used to ensure equal gender distribution across both conditions. The randomisation procedure is done automatically by the Drinks:Ration platform with no human involvement except to provide a proxy identifier and gender.|This is a two-arm participant blinded (single-blinded) RCT, comparing a smartphone app (control arm) which includes feedback on baseline self-reported alcohol consumption, with a smartphone app (intervention arm) that includes individualised normative feedback, plus features designed to enhance participant motivation, app interactive feedback and self-efficacy in modifying their alcohol consumption. In this study, both the control and intervention arms will be delivered via one smartphone app known as Drinks:Ration. Participants in the control arm are given access only to alcohol consumption feedback based on publicly available health guidance and reminder messaging to consult the feedback. Those in the intervention arm are given full access to the app which includes all theoretically driven components and messaging (discussed further in Intervention section). Both arms will be asked to use the app for 28-days.|t|t|f|f
34065623|NCT02265939|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34065624|NCT00110799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065625|NCT00865579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065626|NCT01289574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065627|NCT03009253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065628|NCT03749109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065629|NCT02450422|||COHORT||PROSPECTIVE|||||||
34065630|NCT00525876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065631|NCT02651649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065632|NCT00453830|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34065633|NCT05540730|||CASE_CONTROL||PROSPECTIVE|||||||
34179434|NCT05657340|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866062|NCT01440868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866063|NCT04234165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866064|NCT01905163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065634|NCT02638376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065635|NCT02578849|||COHORT||CROSS_SECTIONAL|||||||
33866065|NCT04311216|||COHORT||CROSS_SECTIONAL|||||||
33866066|NCT04601623|||COHORT||PROSPECTIVE|||||||
33866067|NCT06359366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|when the participants are enrolled in this study, they will be allocated to groups randomly by an independent researcher and sign the consent form. The care providers will not know the outcomes of this study, they just provide treatment for pregnant women; therefore, the care providers could be masked. an independent investigator will send a questionnaire to the participant, and the investigator does not know the intervention participants received; thus they could be masked.||f|t|f|t
33866068|NCT00544648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866069|NCT06267170|||OTHER||PROSPECTIVE|||||||
33866070|NCT05728515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866071|NCT00964145|||||CROSS_SECTIONAL|||||||
33866072|NCT04553848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866073|NCT05788003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866074|NCT06062745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866075|NCT00515736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33866076|NCT01007032||SEQUENTIAL||TREATMENT||NONE||||||
33866077|NCT05554796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065636|NCT03298308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065637|NCT01870297|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34065638|NCT06532058|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||a single-arm, open, multicenter Phase IIa study with dose escalation and dose extension||||
34179435|NCT05043454|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34179436|NCT06283355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179437|NCT04401813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179438|NCT00344201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179439|NCT01426100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179440|NCT06448117|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Subjects in the intervention group participate in a 6-month nutrition counseling program, including two individual and three group-based sessions. The content of the sessions is described in the Arms and Interventions section. The behavioral intervention utilizes theoretical frameworks of goal attainment, psychoeducation, peer support, motivational interviewing, mindfulness, and flexible eating restraint."||||
34179441|NCT06324162|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179442|NCT02419495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179443|NCT04447807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients eligible for this study will be randomized into two groups: Metacognitive Training Intervention (9 weeks) or Treatment as Usual (9 weeks).|f|f|t|f
34179444|NCT00794716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179445|NCT06604208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179446|NCT06591143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179447|NCT05056415|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34179448|NCT01459211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179449|NCT06284343|||COHORT||PROSPECTIVE|||||||
34179450|NCT06590194|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34179451|NCT06601348|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34179452|NCT06417216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects perform study tasks under head-active conditions, and then are crossed over to the head-cancelled condition.||||
34179453|NCT05754645|||COHORT||PROSPECTIVE|||||||
34179454|NCT06474455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179455|NCT04074720|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179456|NCT03849586|||COHORT||PROSPECTIVE|||||||
34179457|NCT06070506|||OTHER||RETROSPECTIVE|||||||
34179458|NCT05450679|||COHORT||PROSPECTIVE|||||||
34179459|NCT05714410|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33866078|NCT02705521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866079|NCT03244410|||OTHER||OTHER|||||||
33866080|NCT01031550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866081|NCT05175313|||CASE_CONTROL||PROSPECTIVE|||||||
33866082|NCT03138187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and physical trainer blinding will not be feasible due to the characteristics of prescribed exercise sessions. However, the evaluators will be blinded to the following endpoints: weight, body composition, appetite, energy intake and laboratorial biomarkers.||f|f|f|t
33866083|NCT03856307|||CASE_CONTROL||PROSPECTIVE|||||||
33866084|NCT05467215|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The participants with SCI will be masked. The experimenter collecting the sensory data and the experimenter analyzing the reflex data will be masked to the oxygen/air exposure, to avoid bias. The participant and the experimenter will be unmasked once all data collection has been completed for the participant.|Prospective, double-blind, randomized crossover design|t|f|f|t
33866085|NCT05035576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866086|NCT02748330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866087|NCT05023564|||COHORT||PROSPECTIVE|||||||
33866088|NCT03713749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866089|NCT05589779|||OTHER||CROSS_SECTIONAL|||||||
33866090|NCT02906592|||CASE_CONTROL||OTHER|||||||
33866091|NCT00000387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866092|NCT02380950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33866093|NCT06474910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866094|NCT01704040|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33866095|NCT02163187|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33866096|NCT01540825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866097|NCT04475640|NA|SINGLE_GROUP||SCREENING||NONE||||||
33866098|NCT03089242|||COHORT||PROSPECTIVE|||||||
33866099|NCT04754282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866100|NCT03254654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866101|NCT00580255|||COHORT||PROSPECTIVE|||||||
33866102|NCT05782270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866103|NCT01166503|||CASE_CONTROL||PROSPECTIVE|||||||
33866104|NCT06257771|||CASE_CONTROL||PROSPECTIVE|||||||
33866105|NCT03764371|||COHORT||PROSPECTIVE|||||||
33866106|NCT04532736|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized, Controlled, Triple Armed, Parallel, Open-label Phase 2 Clinical Trial||||
33866107|NCT04728022|NA|SINGLE_GROUP||OTHER||NONE||All students in the study will be in the same group, as it is a pre-post measurement based on a summer mentored high school program. Findings will be supplemented with focus groups and interviews.||||
33866108|NCT02170779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866109|NCT00972426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866110|NCT04823611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A: Single blind Part B: Double blind Part C: Single blind|Parallel Assignment|t|t|t|f
33866111|NCT04993794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866112|NCT01138267|||COHORT||RETROSPECTIVE|||||||
33866113|NCT00017121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866114|NCT04280445|NA|SINGLE_GROUP||TREATMENT||NONE||The study will employ an adjudicated Hermeneutic Single Case Efficacy Design (HSCED) series with three participants. Following Elliott's (2002; Elliott et al., 2009) approach, a crucial aspect of HSCED research is the formation of rich case records. Developed for each client, these consist of data from various time points in the study, and include demographic, quantitative (outcome measures, treatment fidelity measures etc.) and qualitative sources (Change Interview, therapy feedback, therapy process notes and recordings). The rich case records are then cross-referenced and synthesised into an affirmative and sceptic brief. These briefs are then presented to an expert panel to be adjudicated on the process of change. The resulting decisions will then allow for a between-participant analysis of what components contributed towards change and why.||||
34179460|NCT02747355|||OTHER||RETROSPECTIVE|||||||
34179461|NCT06595641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blinded randomized controlled trial|t|f|f|t
34179462|NCT06597123|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Primary care provider (PCP) participants will be randomly assigned to intervention (IG) or control (CG) groups, with the Basic IG receiving two ReadMI (Real-time Evaluation of Dialogue in Motivational Interviewing)-supported motivational interviewing (MI) trainings and the Plus IG receiving four MI trainings. Plus will receive two MI trainings at the same time as Basic and will receive two additional MI trainings one year later.||||
34179463|NCT00770263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179464|NCT02023086|||CASE_CONTROL||PROSPECTIVE|||||||
34179465|NCT05523453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179466|NCT00418678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179467|NCT06650527|RANDOMIZED|CROSSOVER||OTHER||NONE||Using a crossover design, caregivers will be randomized to either cognitive empathy training (n=59) or a control condition (n=59). Neuroimaging, questionnaire, and biomarker data will be collected before the 10-day training, immediately after the training, and six months after. At the 6 month visit, participants will cross over to the other treatment||||
34179468|NCT05818085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179469|NCT04351334|||CASE_ONLY||RETROSPECTIVE|||||||
34179470|NCT05444855|NA|SINGLE_GROUP||OTHER||NONE||Participants will enroll as a Peer Leader (THO+) or they can enroll as part of a Friend Network. Teens who enroll as a Peer Leader will attend a training session in-person or online with our study team to learn about sexual and mental health information and how to share information with their friends (like text or social media). Teens who enroll as a Friend Network will receive the shared information from the Peer Leader who invited them to be a part of the study.||||
34179471|NCT00634023|||||CROSS_SECTIONAL|||||||
34179472|NCT00259662|RANDOMIZED|PARALLEL||||DOUBLE||||||
34179473|NCT01411345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179474|NCT06478186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, assessors and biostatistician are blinded to the treatment allocation through use of physical blinds to the intervention being administered and coded participant ID's.|Blinded, Randomized Controlled Trial of 2 interventions|t|f|t|t
34179475|NCT06604455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179476|NCT05349591|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179477|NCT06589349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The sample size of the study was calculated using the G power program. In the power analysis performed with the t test, one-way hypothesis, 0.80 effect size, 90% power, 0.05 significance level, assignment rate: 1, it was determined that a total of 56 preterm babies (Experiment: 28, Control: 28) would provide sufficient sample size.|In the study, randomization will be done by stratifying according to type of nutrition (breast milk-formula milk) and week of gestation (28-31+6 32-37), as it may affect sleep. After the blocks are created, the groups included in the study will be randomly assigned to the layers with the letters A and B, using the random numbers table obtained in the computer environment (www.random.org). Which group the children included in the study will be included in will be determined by an independent statistician and will be given to the researcher in a sealed envelope|f|f|t|f
34179478|NCT06105177|||COHORT||PROSPECTIVE|||||||
34179479|NCT06555107|NA|SINGLE_GROUP||OTHER||NONE||||||
34179480|NCT06590948|||CASE_CONTROL||PROSPECTIVE|||||||
34179481|NCT05939453|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34179482|NCT06598748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers who evaluated the participants were not informed of how the participants were grouped. Participants were informed that they would receive one of two different interventions without indicating which group should undergo mechanical interface mobilization technique or exercise therapy program.|Participants were randomly assigned to the experimental group or control group. Participants were not notified which group was assigned to|t|f|f|t
34179483|NCT06653907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866115|NCT05148039|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Tertiary clinic versus a selective community cohort||||
33866116|NCT04048590|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33866117|NCT03617250|||CASE_CONTROL||PROSPECTIVE|||||||
33866118|NCT02412020|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33866119|NCT01043679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866120|NCT04340557|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized into one of two groups: Standard of Care or Standard of Care plus an ARB.||||
33866121|NCT04710953|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study Design: Randomised control trial Settings: Posts more than 8000 feet (2400m) where Medical officer is available Study Duration: 01 year after the study is approved Sampling Technique: Non probability consecutive sampling Distribution of patients in to two groups (Gp A and Gp B) by consecutive sampling Group A will be given CPAP in addition to standard of care and Group B will be offered Gamow bag in addition to standard of care"||||
34065639|NCT04309903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065640|NCT00004896||||TREATMENT||NONE||||||
34179484|NCT06476106|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34179485|NCT06473857|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179486|NCT05600634|||OTHER||PROSPECTIVE|||||||
34179487|NCT03052270|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization between two arms: short cervix with vaginal progesterone and Arabin pessary (study group) versus short cervix with vaginal progesterone alone (control group)||||
34179488|NCT04328805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34179489|NCT06588036|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34179490|NCT06598020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179491|NCT06413355|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179492|NCT05444348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179493|NCT05920889|RANDOMIZED|PARALLEL||TREATMENT||NONE||"140 patients will be randomized to treatment arm with semaglutide and standard medical therapy, and control arm with standard medical therapy alone in a 1:1 ratio."||||
34179494|NCT05996016|||COHORT||PROSPECTIVE|||||||
34179495|NCT04589741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179496|NCT06331299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179497|NCT02992288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840676|NCT06022341|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Patients will be recruited in the French biobank of MPN (BCB INCa FIMBANK) and the FILO's national biobank of acute leukemias (FILOthèque). All clinical and biological data are anonymized.|||||
33840677|NCT05150743|||COHORT||PROSPECTIVE|||||||
33840678|NCT05348941|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840679|NCT00350038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840680|NCT03952078|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840681|NCT04374539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter open label randomized controlled clinical trial||||
33840682|NCT01609062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840683|NCT03738475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double-blind placebo-controlled|t|t|t|t
33840684|NCT04768855|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33840685|NCT05796362|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, balanced, single dose, three-treatment, three-period, crossover bioavailability study of azithromycin oleogel in healthy, adult, human subjects under fasting condition.||||
33840686|NCT00087776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840687|NCT03427151|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33840688|NCT01934348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179498|NCT06591442|||COHORT||PROSPECTIVE|||||||
34179499|NCT00364637|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34179500|NCT06609460|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34179501|NCT06594081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34179502|NCT06425458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179503|NCT01477918|||CASE_ONLY||CROSS_SECTIONAL|||||||
34179504|NCT03077971|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179505|NCT06539832|||CASE_CONTROL||RETROSPECTIVE|||||||
34179506|NCT05562999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34179507|NCT05484635|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34179508|NCT06590584|||OTHER||CROSS_SECTIONAL|||||||
34179509|NCT00006020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866122|NCT00695851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866123|NCT01293968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33866124|NCT04525339|||COHORT||RETROSPECTIVE|||||||
33866125|NCT03274050|||CASE_CONTROL||OTHER|||||||
33866126|NCT03443128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866127|NCT00284206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866128|NCT04384406|||COHORT||RETROSPECTIVE|||||||
34179510|NCT06235190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomized in a 2:1 ratio to Felix and Sham and be followed for 90 days. After the 90-day follow-up, all subjects will be encouraged to participate in the continued access phase, where subjects randomized to the Sham arm will cross over to Felix and all subjects will be followed up to 1 year (from randomization).|t|f|f|t
33866129|NCT01131416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866130|NCT05524922|||COHORT||PROSPECTIVE|||||||
33866131|NCT03934606|||COHORT||PROSPECTIVE|||||||
33866132|NCT01091597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179511|NCT03085862|||OTHER||PROSPECTIVE|||||||
33963872|NCT05423301|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will be a single-center open-label comparative randomized clinical study, in two parallel arms, at the Bordeaux University Hospital. Patients extubated during working hours on Mondays to Friday in the presence of the physiotherapy team will be included in the study and randomized with a 1: 1 ratio between the experimental arm and the control arm. In both groups, patients are routinely alternated between high-flow oxygenation and NIV, adjusted to patient-specific goals, as recommended for these patients.||||
33963873|NCT01909388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963874|NCT04067024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33963875|NCT02833558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963876|NCT01780688|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33963877|NCT01586624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33963878|NCT02232139|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963879|NCT03774173|RANDOMIZED|CROSSOVER||OTHER||NONE||"Subjects will receive oral doses of aramchol at 300 mg twice daily (every 12 h) for 9 days in one period, with a single dose in the morning of Day 10, and 600 mg once daily (every 24 h) for 10 days in the other period.~Enrolment of 16 subjects is planned with each subject taking part in the 2 study periods. The subjects will be randomised 1:1 so that 8 subjects receive each regimen in the first period and the alternate regimen in the second period."||||
33963880|NCT04478370|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study is a human challenge model with five arms corresponding to controlled exposure to bites of uninfected laboratory-adapted colonies of Anopheles minimus, An. maculatus, An. dirus, Aedes. aegypti or Ae. albopictus.||||
33963881|NCT01984229|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963882|NCT06339008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963883|NCT03987022|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34179512|NCT06594978|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34179513|NCT06119048|NA|SINGLE_GROUP||OTHER||NONE||||||
34179514|NCT01950182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179515|NCT06504992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a randomized controlled trial blinded to participants and end-point assessors. Participants will be randomized to either receiving the treatment, intra-operative intrawound topical vancomycin powder on open fractures in addition to intravenous antibiotics with irrigation and debridement, or the control, intravenous antibiotics with irrigation and debridement alone.|t|f|f|t
34179516|NCT06177080|NA|SINGLE_GROUP||SCREENING||NONE||30 nulliparous and 70 multiparous total 100 singleton pregnant women measured descent angle and head symphysis distances by transperineal ultrasound in the active phase of labor.||||
34179517|NCT03413891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179518|NCT04089787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179519|NCT06589141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34179520|NCT05074979|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34179521|NCT03712358|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34179522|NCT04475978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34179523|NCT03098875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34179524|NCT06317051|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34179525|NCT03193255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179526|NCT06599151|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All enrolled subjects (Pain Patients and Healthy Volunteers) will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.||||
34179527|NCT01742026|||CASE_ONLY||PROSPECTIVE|||||||
34179528|NCT06017518|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34179529|NCT06271993|NA|SINGLE_GROUP||OTHER||NONE||This will be a single center, with no randomization or blinding, study design in 20 healthy adult subjects, age 18-70 years. Based on prior experience approximately 30 subjects will be enrolled to ensure 20 subjects complete the study.||||
34179530|NCT02003924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179531|NCT04815876|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Radiologists assessing MRI results are blinded to treatment assignment. Pathologists assessing biopsy results are blinded to treatment assignment.|Men enrolled in this prospective, randomized trial will be randomized in a 1:1 ratio to receive either transperineal MRI-targeted or transrectal MRI-targeted prostate biopsy.|f|f|f|t
34179532|NCT05452863|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label study||||
33866133|NCT01553175|||CASE_ONLY||RETROSPECTIVE|||||||
33866134|NCT04139044|RANDOMIZED|PARALLEL||TREATMENT||NONE||The sample of the study consists of athletes with a history of CAI who registered as a team player at Yeditepe University Culture and Sports Directorate between February 2019 and June 2019.||||
33866135|NCT04107883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866136|NCT01131026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866137|NCT04280536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel cohorts of patients will be enrolled : Cohort A : patients with prior exposure to fluoropyrimidines Cohort B : patients without prior exposure to fluoropyrimidines||||
33866138|NCT01899625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866139|NCT02636933|||CASE_CONTROL||PROSPECTIVE|||||||
33752064|NCT03801785|RANDOMIZED|PARALLEL||OTHER||NONE||The RCT includes two parallel arms. In the intervention arm, children will suck a pacifier of identical shape and type. In the control arm, children will be induced by the DDSs to stop sucking. Children's parents will be also advised by an ad hoc information sheet how to stop their children's NNS habit. Children in both arms will undergo computerized postural balancing and gait control measures every 6 months up to 36 months by video-recordings done at home or at the OBG site in Palidoro (Rome). Children in the two arms will also undergo an EEG while sucking, at enrolment and when follow-up ends. Parents will report in a diary time spent by their children on pacifier or finger-thumb sucking, crying time, afternoon and night-time sleep induction, awakenings, and day-sleep hours. Every 6 months, parents will bring the children and the diaries to the hospital. DDSs will visit the child, record oral examinations, and also report findings from parents' diaries in electronic and paper CRF.||||
33752065|NCT01702727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752066|NCT06304831|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This study consists of a randomized controlled experiment involving 660 mothers with children less than 2 years old. Participants will be randomly assigned to one of two groups: 1) a control group that will not receive any information about providers and 2) an intervention group that will receive biweekly updates about quality ratings based on reviews collected from mothers of young children in the study areas. The unit of randomization will be the individual participant. A simple random number draw generated by the ODK package installed on the tablets will be used to assign participants to treatment and control with equal probability.||||
33752067|NCT06727513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752068|NCT04435366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant, Evaluating Investigator, Reading Center Personnel, and Sponsor Personnel are masked"||t|f|f|t
34179533|NCT06595927|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33752069|NCT06241248|||COHORT||PROSPECTIVE|||||||
34179534|NCT06318143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179535|NCT06587542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients having anogenital warts will be divided into 2 groups, i.e. HIV and non-HIV groups. Both groups will receive a single injection of tuberculin PPD.||||
34179536|NCT06518239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will be monitored by the standard of care anesthesia machines intraoperatively. An EIT belt will be attached to the patient intraoperatively, and data from the belt will be compared to the anesthesia machines.||||
34179537|NCT06590649|NA|SINGLE_GROUP||OTHER||NONE||||||
34179538|NCT00688987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34179539|NCT04047602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179540|NCT02249663|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34179541|NCT06594991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be enrolled in parallel across two independent cohorts, each with a nonrandomized two stage trial design. Cohort A (46 patients) will include patients whose melanoma progressed on prior anti-PD-1 monotherapy, and Cohort B (42 patients) will include patients whose melanoma has progressed on prior PD-1 and LAG-3 blockade.||||
34179542|NCT05438849|||COHORT||PROSPECTIVE|||||||
34179543|NCT00762164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179544|NCT01533207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179545|NCT01391416|||CASE_ONLY||CROSS_SECTIONAL|||||||
33752070|NCT03756428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752071|NCT05203926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752072|NCT04050683|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All patients undergoing TIPS will have the following hemodynamic measurements obtained: systolic, diastolic and mean RAP; systolic, diastolic and mean right ventricular pressure (RSV). Peak systolic right ventricular (PSRV) pressure will serve as surrogate for pulmonary artery pressure (PAP). There are 2 groups in this project. Subjects will be enrolled in 1 of the 2 groups based on their heart pressure measurements (high or normal). If a subject does not meet criteria for 1 of the 2 groups, they will not be in the study.||||
34179546|NCT05135533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179547|NCT06593795|||COHORT||PROSPECTIVE|||||||
33752073|NCT06733506|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||All participants received a brief safer-injection training (Intervention A), which consisted of a one-to-one private discussion with a healthcare provider lasting \~5-10 minutes to encourage skin swabbing prior to drug injection. In addition, participants randomized to a Chlorhexidine swab group received a 2-week supply of chlorhexidine swabs which they were instructed to use for 2 weeks, while those randomized to a usual care condition were supplied with a 2-week supply of standard care isopropyl alcohol swabs.|f|f|f|t
33752074|NCT06291428|||COHORT||PROSPECTIVE|||||||
33866140|NCT05303870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866141|NCT02611804|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33866142|NCT03388918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33866143|NCT01280448|||CASE_CONTROL||PROSPECTIVE|||||||
33866144|NCT05891184|||CASE_CONTROL||PROSPECTIVE|||||||
34179548|NCT03841461|||OTHER||CROSS_SECTIONAL|||||||
34065641|NCT02679885|||COHORT||CROSS_SECTIONAL|||||||
34065642|NCT02380859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179549|NCT01980017|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179550|NCT05536635|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34179551|NCT03566290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179552|NCT00771277|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34179553|NCT06545188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study 1) Urologists: RCT; two arms - Intervention group \& control group Study 2) Patients with urological cancer: RCT; two arms - Intervention group \& control group|f|f|t|f
34179554|NCT06597708|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34179555|NCT00894816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34179556|NCT06602882|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Blinding of the study participants will not be possible. However, as the questionnaires will be completed via an online platform instead of instant messaging app (i.e. WhatsApp), the outcome assessor will be blinded during data collection.||f|f|f|t
34179557|NCT00162487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179558|NCT06596980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179559|NCT03234595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179560|NCT05424081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participant outcomes will be assessed by an outside company with no knowledge of randomization status.||f|f|f|t
34179561|NCT06603129|||CASE_CROSSOVER||PROSPECTIVE|||||||
34179562|NCT01838694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179563|NCT05168202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179564|NCT04464317|||COHORT||RETROSPECTIVE|||||||
34179565|NCT06654479|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34179566|NCT04626388|||COHORT||RETROSPECTIVE|||||||
33866145|NCT01186900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33866146|NCT02618005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33866147|NCT00195312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866148|NCT04538872|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33866149|NCT06472583|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33866150|NCT03662139|||CASE_CONTROL||PROSPECTIVE|||||||
33866151|NCT01283230|||COHORT||PROSPECTIVE|||||||
33866152|NCT03978351|||CASE_CONTROL||RETROSPECTIVE|||||||
33866153|NCT04263350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33866154|NCT00579683|||CASE_ONLY||PROSPECTIVE|||||||
33866155|NCT00805025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866156|NCT02790138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866157|NCT00779792|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33866158|NCT01956149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866159|NCT01406288|||COHORT||PROSPECTIVE|||||||
33866160|NCT05869292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only investigators who will assess outcome including radiographic assessment, clinical outcomes and patients clinicians' satisfaction will be blinded all time. These investigators would not be familiar with group allocation.|The study is design as a prospective, randomised, controlled clinical trial. Depending on number of extracted teeth patients will be randomly allocated into Test group in which immediate loading following surgical procedure will be conducted Control group in which early loading (six weeks postoperatively) will be performed.|f|f|f|t
33866161|NCT03553914|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866162|NCT05968599|||COHORT||RETROSPECTIVE|||||||
33866163|NCT00718549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866164|NCT06182150|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33866165|NCT02785965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866166|NCT05529056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866167|NCT02248259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866168|NCT01195753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866169|NCT04653168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33866170|NCT03595319|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Participant will not know allocation (sevoflurane concentration) and will be under general anesthesia|"Adaptive up and down methodology. Anesthesia will be induced using etomidate, rocuronium and remifentanil. After intubation and mechanical ventilation, a high fresh gas flow and variable vaporizer target concentration will be used to stabilize the patient's target end tidal sevoflurane in less than two minutes.~Each patient's target end tidal sevoflurane is determined by the concentration used in the previous patient of the same group and by the incidence of hypotension. If the previous patient suffered hypotension, next patient's target concentration will drop. If there was no hypotension, next patient's target concentration will rise. The first patient on each group will be 2%. Target end tidal will vary 0.4% until the first crossover, then drop to 0.2% until the second crossover and will vary 0.1% thereafter."|t|f|f|f
33866171|NCT04401163|||COHORT||PROSPECTIVE|||||||
33866172|NCT00687440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866173|NCT05661513|||CASE_ONLY||RETROSPECTIVE|||||||
33866174|NCT00745693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33866175|NCT00832520|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33866176|NCT04110548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33866177|NCT06270342|||CASE_CONTROL||OTHER|||||||
34179567|NCT06586242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34179568|NCT06472362|||COHORT||RETROSPECTIVE|||||||
34179569|NCT06586034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179570|NCT06600542|||COHORT||PROSPECTIVE|||||||
34179571|NCT03858179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A researcher will program the device (placebo or PMBT) and will be instructed not to inform the volunteers or other researchers as to the type of treatment (PMBT or placebo). Therefore, the researcher responsible for the treatment will be blinded to the type of treatment being administered to the volunteers. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or PBMT).||t|t|t|t
34179572|NCT03951103|||COHORT||OTHER|||||||
34179573|NCT06599294|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179574|NCT06586840|||COHORT||PROSPECTIVE|||||||
34179575|NCT05497947|||COHORT||PROSPECTIVE|||||||
33752075|NCT06583031|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Modified double-blinded for the sentinel and main cohorts.~* Blinding for vaccine group assignment: participants, outcome assessors, Investigators, laboratory personnel (for both sentinel and main cohort); Sponsor study staff (except biostatistician) and Sponsor SMT (Safety Management Team) for main cohort~* No blinding for vaccine group assignment: those preparing and administering the study interventions; Sponsor study staff and Sponsor SMT for sentinel cohorts"||t|t|t|f
33752076|NCT00485290|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33866178|NCT05658016|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study will be partially blinded. The patient and investigator as well as site personnel will be blinded as to whether TK-90 or TK-90 placebo is administered. The CRO, sponsor, and site pharmacist will know whether the patient was administered active drug or TK-90 placebo.|A total of 24 patients will be enrolled into one of 2 different: TK112690 treated or placebo treated.|t|t|t|f
33866179|NCT04485273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866180|NCT01951079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866181|NCT00528736|||DEFINED_POPULATION||PROSPECTIVE|||||||
33866182|NCT06235450|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label, Prospective, Therapeutic Intervention||||
33866183|NCT04248309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866184|NCT06374472|||COHORT||RETROSPECTIVE|||||||
33866185|NCT04645043|NA|SINGLE_GROUP||OTHER||NONE||||||
33866186|NCT00006090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065643|NCT03227107|||COHORT||PROSPECTIVE|||||||
34065644|NCT02910934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34151292|NCT00389350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151293|NCT03898128|||COHORT||RETROSPECTIVE|||||||
34151294|NCT04761848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151295|NCT06431230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151296|NCT03517462|NA|SINGLE_GROUP||OTHER||NONE||Participants are all given a standard treatment (ivermectin) for onchocerciasis.||||
34151297|NCT00000932|||COHORT||PROSPECTIVE|||||||
34151298|NCT02628548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34151299|NCT01774188|||CASE_CONTROL||PROSPECTIVE|||||||
34151300|NCT00881504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151301|NCT00242307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151302|NCT04851756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151303|NCT01893736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151304|NCT01895309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151305|NCT01508260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151306|NCT02869698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151307|NCT03959917|||COHORT||PROSPECTIVE|||||||
34151308|NCT01833000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151309|NCT04896372|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34151310|NCT04943120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1:1|t|f|f|t
34151311|NCT04354272|||COHORT||PROSPECTIVE|||||||
34151312|NCT00605891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151313|NCT02502981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151314|NCT01997190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151315|NCT06542991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151316|NCT02460341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34151317|NCT06212830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34151318|NCT02139670|||COHORT||PROSPECTIVE|||||||
34151319|NCT03652519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34151320|NCT04088526|NA|SINGLE_GROUP||SCREENING||NONE||||||
34151321|NCT04193774|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The nurse application the drops receives a closed envelope wherein the information about which eye receives what type of drop is included. The executor is blinded.|When the patient is under general anesthesia for another reason, he or she receives a drop of artificial tears in one eye and a drop of anesthetic in the other eye in a randomized way.|f|t|t|f
34151322|NCT03688243|||COHORT||PROSPECTIVE|||||||
34151323|NCT00843154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151324|NCT00221494|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34151325|NCT06026501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151326|NCT01441466|||COHORT||PROSPECTIVE|||||||
34151327|NCT01501994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151328|NCT03242798|||COHORT||PROSPECTIVE|||||||
34151329|NCT04054804|||COHORT||PROSPECTIVE|||||||
34151330|NCT02133976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151331|NCT04487457|||COHORT||PROSPECTIVE|||||||
34151332|NCT00490776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151333|NCT03327168|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each subject participates in PET/CT scans in room temperature conditions, during cold exposure and during i.v. infusion of adenosine.||||
34151334|NCT02513316|||COHORT||PROSPECTIVE|||||||
34151335|NCT01976143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151336|NCT02693379|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151337|NCT05477914|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866187|NCT03031379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33866188|NCT00502489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866189|NCT02371122|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33866190|NCT04928690|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866191|NCT06033781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33963884|NCT04537585|RANDOMIZED|PARALLEL||PREVENTION||NONE|The fact that you can't really study anything unless there's funding for it because the insurance companies and the hospitals are not going to pay for things on a trial unless there is funding. Then you add to that there is no funding for food as medicine, and things as herbs like Vernonia amygdalina that improve the quality of life in COVID-19 patients and they are not pharmaceutical. Those are sort of the real-world complaints, investigators would say, on the front lines to follow participants in parallel group i.e. compare the ones who take herbs as medicine for their survival and other who use others means to fight COVID-19 symptoms.|Investigators couldn't agree more to wait without to know how to treat their patients better and want to learn about therapeutic nutrition approach called TOMEKA versus prophylaxis dosing of antioxidant as Vernonia amygdalina as a study. Investigators are learning about that here in September, why wasn't that done in April? Investigators would submit to follow a parallel group, just speaking as researchers about randomisation, one of the reasons difficult to reach that elaborate study design is sometimes bureaucracy is just daunting.||||
33963885|NCT04749810|||OTHER||PROSPECTIVE|||||||
33963886|NCT02543736|NA|SINGLE_GROUP||SCREENING||NONE||||||
33963887|NCT03241966|||CASE_ONLY||CROSS_SECTIONAL|||||||
33963888|NCT02116413|||COHORT||PROSPECTIVE|||||||
33963889|NCT01364298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963890|NCT04440098|||CASE_ONLY||CROSS_SECTIONAL|||||||
33963891|NCT00112515||||SUPPORTIVE_CARE||||||||
34179576|NCT04456504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33963892|NCT03301428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179577|NCT01751698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179578|NCT06597903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179579|NCT06598618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179580|NCT01003977|||COHORT||RETROSPECTIVE|||||||
33866192|NCT06470399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33866193|NCT01131351|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866194|NCT03779971|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Treatments will be color coded, and samples will be labeled only by subject number and date. Investigators and outcomes assessors will not know the treatments nor the color code until after the data analyses are complete.||f|f|t|t
33866195|NCT01958788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866196|NCT02000427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866197|NCT05924737|NA|SINGLE_GROUP||SCREENING||NONE||Sleep deprivation followed by a short and a long recovery nigjht||||
34179581|NCT01361230|RANDOMIZED|PARALLEL||||NONE||||||
34179582|NCT03307109|||COHORT||PROSPECTIVE|||||||
34179583|NCT06597032|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34179584|NCT01932593|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Double Blind|autologous bone marrow cells|t|t|t|f
34179585|NCT04162418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179586|NCT06599242|RANDOMIZED|PARALLEL||PREVENTION||NONE||Athletes who play American football at Yeditepe University American Football Team Club and volunteered to participate in the study||||
34179587|NCT06184516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179588|NCT02505607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179589|NCT05881304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179590|NCT03020251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179591|NCT06010160|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessment interviewer will be blinded to study arm allocation of the participants at baseline only|Individual randomization to one of two parallel groups, the intervention or usual care (no intervention) control group|f|f|f|t
34179592|NCT03162926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179593|NCT01140529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179594|NCT06588972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752077|NCT02415101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752078|NCT05008146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Cocaine Use disorder and Healthy control groups will receive same interventions||||
33752079|NCT03144713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752080|NCT03657277|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33866198|NCT00464347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33866199|NCT01069172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866200|NCT00797290|||COHORT||PROSPECTIVE|||||||
33866201|NCT01794520|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866202|NCT03137186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866203|NCT05584254|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||3 study products (2 different forms of yeast-beta glucan and a placebo) taken in a cross-over design.|t|f|t|t
33866204|NCT01713270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866205|NCT02383290|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33866206|NCT04517734|||COHORT||PROSPECTIVE|||||||
33866207|NCT01485263|||CASE_ONLY||PROSPECTIVE|||||||
33866208|NCT00744133|RANDOMIZED|PARALLEL||||NONE||||||
33866209|NCT02463721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866210|NCT05617183|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33866211|NCT02529007|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33866212|NCT05538520|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized and controlled clinical trial|f|f|f|t
33866213|NCT04509141|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|the patient did not know that there were two groups divided in each participants, and the doctor who measures the outcome also did not know which person belongs to which group|A randomized controlled trial with control was conducted on 34 subjects with migraine who were randomly allocated into the manual group of acupuncture (n = 17), as well as the medicine group (n = 17). The assessment of frequency, duration and intensity of migraine attacks assessed at the time before treatment, at the fourth and eight week from baseline|t|t|f|t
33866214|NCT04278300|||CASE_CONTROL||PROSPECTIVE|||||||
33866215|NCT03325478|||OTHER||PROSPECTIVE|||||||
33866216|NCT00495820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866217|NCT00471900|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33866218|NCT00000808||||TREATMENT||||||||
33866219|NCT00695695|||||PROSPECTIVE|||||||
33866220|NCT03126526|RANDOMIZED|PARALLEL||TREATMENT||NONE||The model includes two interventions (i.e. inhibitory control training and implementation intentions) that aim to target cognitive processes that have been reported to play a role in the onset and maintenance of eating disorders. Moreover, three arms exist, one for healthy controls including only one EEG assessment, and two interventional arms for participants with eating disorders. Participants in one interventional arm will receive food-specific inhibitory control training, while participants in the other interventional arm will receive general inhibitory control training. These are delivered through a website task (go/no-go training),||||
33866221|NCT02053324|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation design||||
33866222|NCT02859376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866223|NCT04175106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33866224|NCT02753660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866225|NCT04377711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33866226|NCT05774145|||CASE_CONTROL||RETROSPECTIVE|||||||
33866227|NCT00601705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866228|NCT00861913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866229|NCT04946396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized into two groups of 35 patients each: 1) patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h) (DEX group) or 2) control group, patients who will receive continuous infusion of 0.9% saline solution (CONT group).|t|t|t|t
33866230|NCT01458366|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866231|NCT04098042|||COHORT||RETROSPECTIVE|||||||
33866232|NCT02675816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866233|NCT00706550|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33866234|NCT01715753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33963893|NCT03050528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The academic Statistician (Dr Ricardo Segurado) and the Senior Researcher (Maire-Brid Casey) will be blind to group allocation. Dr Segurado will be responsible for data analysis. Máire-Bríd Casey will be responsible for data entry and will assist with data analysis.||f|f|t|f
33963894|NCT04394052|||COHORT||PROSPECTIVE|||||||
33963895|NCT02733601|||COHORT||PROSPECTIVE|||||||
33963896|NCT05710315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179595|NCT04206124|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be recruited based on sex, age, and medical history including BMI (lean, \<25, or obese, \>30), medication list, and health status. Included patients indicated for thyroidectomy, parathyroidectomy, or cervical spine injury surgery, who are able to consent, will have a soybean-sized amount of brown fat removed from the neck during surgery. These tissue samples will be further analyzed using biochemical tools after being de-identified from patient records.||||
34179596|NCT05330559|||OTHER||PROSPECTIVE|||||||
34179597|NCT06586970|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|f|t
34179598|NCT05349487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34179599|NCT04167657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179600|NCT06595056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34179601|NCT05927935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking is single-blinded to the outcome assessor, whom is unaware of the participant's treatment group. The outcome assessor is blinded to the allocation of the participant´s and participant's are asked not to disclose their allocation during test.||f|f|f|t
34179602|NCT02675465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179603|NCT05732311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179604|NCT06145321|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|We aimed to enroll 40 hospitalized patients in this phase 4 clinical trial. Patients with an ANC lower than 500 cells/mm3 will be randomly categorized into experimental and controlled arms. The experimental arm was designed to receive G-CSF intravenous infusion for 5 hours at a dose of 5 mcg/kg. The controlled arm was designed to receive a G-CSF bolus injection within one minute at a dose of 5 mcg/kg. Three days after treatment initiation, serum white blood cell and differential counts will be followed daily to determine the timing of steady neutrophil recovery. In the following time of another neutropenia event, the experimental arm would cross-switch to the controlled arm and receive corresponding G-CSF according to the study design.|Investigational product(s)：G-CSF (filgrastim) Route of administration: intravenous infusion (with a 5 hours infusion period) or intravenous bolus (with an infusion period of less than one minute)|t|f|f|f
34179605|NCT04421898|||CASE_CONTROL||RETROSPECTIVE|||||||
34179606|NCT03496311|||CASE_CONTROL||PROSPECTIVE|||||||
34179607|NCT04645355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single center, open-label study. Twenty-five subjects are planned (15 with new-onset guttate psoriasis and 10 with chronic plaque psoriasis). Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44.||||
34179608|NCT06586931|||COHORT||PROSPECTIVE|||||||
34179609|NCT06596265|||COHORT||PROSPECTIVE|||||||
34179610|NCT05169541|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34179611|NCT04474834|||COHORT||PROSPECTIVE|||||||
33866235|NCT03526887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups depending on when the progression disease is diagnosed but the treatment after progression will be the same: Pembrolizumab||||
33963897|NCT03086083|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"All participants was invited to one session of brief Psychotherapy with a new model.~To the outcome assessor was said to study if was significant difference between those data from two groups α e β."|A randomized, parallel, before-after, blind study was performed. Thirty nine subjects were randomly distributed to two groups: one session of EMDR psychotherapy standard and other with EMDR standard protocol without its typical brain bilateral stimulation. The results of the Beck scales for anxiety, depression and hopelessness and the impact of events test were compared between groups.|t|f|f|t
33963898|NCT04694131|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963899|NCT02454309|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33963900|NCT04023747|||COHORT||PROSPECTIVE|||||||
33963901|NCT05980988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double（Participant, Investigator)||t|f|f|f
33866236|NCT03520478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866237|NCT03712436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|blinded|A randomized controlled trial of standard oncologic care versus standard oncologic care plus palliative care in a newly diagnosed oncology population.|t|t|f|f
33963902|NCT04660409|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33963903|NCT03695406|NA|SINGLE_GROUP||OTHER||NONE||||||
33963904|NCT05807048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963905|NCT06540573|||CASE_CONTROL||PROSPECTIVE|||||||
33963906|NCT01382927|||CASE_CONTROL||PROSPECTIVE|||||||
33963907|NCT01210885|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33963908|NCT02514031|NA|SINGLE_GROUP||OTHER||NONE||||||
33963909|NCT04887974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963910|NCT04444752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963911|NCT03917563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963912|NCT00785278|||CASE_CONTROL||PROSPECTIVE|||||||
33963913|NCT01945554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963914|NCT00665171|||FAMILY_BASED||PROSPECTIVE|||||||
33963915|NCT04675307|||COHORT||PROSPECTIVE|||||||
33963916|NCT00575328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All subjects, investigators, and clinical assessors were blinded to the intervention.|Maca root will be compared against inactive placebo as a treatment for sexual dysfunction induced by psychotropic drugs.|t|f|t|t
33963917|NCT04322227|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33963918|NCT03179501|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double-blind|Single-site, randomized, double-blind, placebo-controlled|t|t|t|t
33963919|NCT05918575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963920|NCT05282355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were blinded to either the supplement or placebo. The capsules were identical in appearance and size. Blinding was accomplished via an investigator not directly involved with data collection.||t|f|t|f
33963921|NCT00887666|||COHORT||PROSPECTIVE|||||||
33866238|NCT04820283|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled non-inferiority trial with two arms. A non-inferiority margin of Cohen's d 0.3 on the primary outcome Perceived Stress Scale at post-treatment (change from baseline to 12 weeks) will be used. For test of non-inferiority on the primary outcome, a one-sided 95% confidence interval (CI) will be used. If the two-sided 95% CI (exploratory analyses) does not include 0 this will be interpreted as indicating superiority of the corresponding treatment.||||
33866239|NCT05590936|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33866240|NCT00395889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065645|NCT03152487|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will randomized to either a group that receives Celiac Plexus Neurolysis or Radiofrequency Ablation.||||
34065646|NCT06145529|RANDOMIZED|FACTORIAL||OTHER||NONE||This randomized controlled trial (RCT) investigates the impact of resistance training (RT) with and without gamification on 300 children aged 10-12. Conducted in Valencia, Spain, six schools are randomly selected and assigned to three groups: EG1 (RT program), EG2 (RT with gamification), and CG (control). Participants are from grades 5 and 6, selected based on specific criteria. Interventions replace 15 minutes of PE in intervention schools. Sample size, determined for muscular fitness outcome, is ≃300 to account for potential dropout. Data analysis involves ANCOVA and multi-factor ANOVA, controlling for confounders. The study has received ethics approval.||||
34065647|NCT02013102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065648|NCT03561545|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34065649|NCT06272695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752081|NCT03176836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752082|NCT05321498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"* (2:1) XPro1595 (1mg/kg), placebo~* Weekly subcutaneous injections"|t|t|t|t
33752083|NCT01499004|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33752084|NCT04197713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752085|NCT06580639|||COHORT||PROSPECTIVE|||||||
33752086|NCT00231634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33752087|NCT05830162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752088|NCT03781752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study team is performing a pharmacokinetic (PK) study using a single dose of methylphenidate (MPH) for children with ADHD diagnoses.||||
33752089|NCT06732297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33752090|NCT01515410|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752091|NCT04348305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752092|NCT02934490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752093|NCT05663424|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33752094|NCT02990533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752095|NCT06354634|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will receive both interventions.||||
33752096|NCT00798720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752097|NCT05215587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data are collected and stored using the Research Electronic Data Capture (REDCap) software. Overall access is granted only to the Data and Safety Monitoring Committee and the Trial Steering Committee.|The trial is a randomized, open label, clinical trial with parallel assignment of patients in multiple centres in Denmark, Sweden, Norway, Finland, Iceland, New Zealand, and the Netherlands. Recruited subjects will undergo stratified randomization based on the centre to either a control or intervention arm.|f|f|f|t
33752098|NCT03609112|||COHORT||PROSPECTIVE|||||||
33752099|NCT06733246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752100|NCT04064489|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
33752101|NCT00951041|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33752102|NCT01001052|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33752103|NCT04080804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stage II-IVa locally advanced (LA) resectable HNSCC; stratified by HPV, LAG-3 and PD-L1 status||||
33752104|NCT04762368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and the researcher will be blind to which group any given participant is assigned to.|Group A: 6 training sessions with active brain stimulation and perceptual training Group B: 6 training sessions with sham brain stimulation and perceptual training|t|f|t|f
33752105|NCT04098094|||COHORT||PROSPECTIVE|||||||
33752106|NCT03141060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752107|NCT03902054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33752108|NCT01087892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33752109|NCT05808101|||COHORT||CROSS_SECTIONAL|||||||
33752110|NCT01506193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752111|NCT05800535|||COHORT||RETROSPECTIVE|||||||
33752112|NCT00400335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752113|NCT02823951|||COHORT||RETROSPECTIVE|||||||
33752114|NCT06732609|||COHORT||CROSS_SECTIONAL|||||||
33866241|NCT01028326|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34065650|NCT06034678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065651|NCT03233789|||OTHER||CROSS_SECTIONAL|||||||
34065652|NCT01665482|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33866242|NCT01251263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866243|NCT05552625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double Blind||t|t|t|t
33866244|NCT02224599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866245|NCT06235814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866246|NCT01721057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33963922|NCT03276533|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34179612|NCT05804136|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigator-initiated, academic, prospective, randomized-controlled, interventional, monocenter study||||
34179613|NCT01694940|||COHORT||PROSPECTIVE|||||||
34179614|NCT03435250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179615|NCT06601543|||OTHER||PROSPECTIVE|||||||
34179616|NCT05424406|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||Two-step mechanistic randomized controlled trial design stratified by high and low sleep reactivity. Step 1: active versus control light therapy; Step 2: Cognitive Behavioral Therapy (CBT) versus sleep education control.|t|f|t|f
34179617|NCT06588881|NA|SEQUENTIAL||OTHER||NONE||Single center, prospective, medical device usability and feasibility study.||||
34179618|NCT00023959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179619|NCT03167749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34179620|NCT01060332|||COHORT||CROSS_SECTIONAL|||||||
34179621|NCT05902260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179622|NCT04365725|||COHORT||RETROSPECTIVE|||||||
34179623|NCT02953002|||COHORT||PROSPECTIVE|||||||
34179624|NCT06589011|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||pressure support versus spontaneous assisted ventilation during extubation from bariatric surgeries.|t|t|t|f
34179625|NCT01156428|||CASE_CONTROL||PROSPECTIVE|||||||
34179626|NCT02626312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179627|NCT04883281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179628|NCT06268704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179629|NCT06595745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179630|NCT05708053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179631|NCT02063724|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34179632|NCT06060925|||CASE_CONTROL||PROSPECTIVE|||||||
34179633|NCT06596408|NA|SINGLE_GROUP||OTHER||NONE||||||
34179634|NCT05430178|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross-sectional design in which all participants receive all interventions in the form of short-term observations following oral consumption of test materials.||||
33963923|NCT06122272|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179635|NCT05834634|||COHORT||PROSPECTIVE|||||||
34179636|NCT05510583|||COHORT||RETROSPECTIVE|||||||
34179637|NCT01484119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179638|NCT06331013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866247|NCT05995015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866248|NCT06400342|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects deemed eligible for both redo-TAVR and TAVR-explant by the Heart Team for the treatment of failed THV will be randomized on a 1:1 basis to either redo-TAVR or TAVR-explant.||||
33866249|NCT00786565|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33963924|NCT05491278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179639|NCT06085664|NA|SEQUENTIAL||TREATMENT||NONE||||||
34179640|NCT05641337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179641|NCT02080806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179642|NCT02156843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179643|NCT03868995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179644|NCT06604468|||COHORT||PROSPECTIVE|||||||
34179645|NCT02183662|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34179646|NCT03772886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179647|NCT05783141|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33963925|NCT00612482|NON_RANDOMIZED|PARALLEL||||NONE||||||
33963926|NCT00449930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963927|NCT04628143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179648|NCT06262815|||CASE_CONTROL||PROSPECTIVE|||||||
34179649|NCT06589401|NA|SEQUENTIAL||TREATMENT||NONE||||||
34179650|NCT04215731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179651|NCT05405062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179652|NCT06654882|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34179653|NCT02011906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179654|NCT04322890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179655|NCT03324100|||COHORT||PROSPECTIVE|||||||
34179656|NCT01481844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179657|NCT06586554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179658|NCT03206814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Centralized reading of ECG, echocardiography and ABPM, blinded for treatment group assignment||f|f|f|t
34179659|NCT00190918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179660|NCT04574271|RANDOMIZED|PARALLEL||PREVENTION||NONE||"* Intervention Group: Intensitve nutritional advice and exercise prescription adapted to physical performance.~* Control Group: Usual nutritional advice and exercise prescription."||||
34179661|NCT01484704|||CASE_CONTROL||PROSPECTIVE|||||||
34179662|NCT02214797|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34179663|NCT00904982|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34179664|NCT00665652|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34179665|NCT06273800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||collection of serum sample blood at first day of neo adjuvant treatment||||
34179666|NCT04340752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866250|NCT04656639|||COHORT||PROSPECTIVE|||||||
33866251|NCT05868551|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866252|NCT06343935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866253|NCT03366675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963928|NCT01581762|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33963929|NCT01804192|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33963930|NCT02406703|||CASE_CONTROL||PROSPECTIVE|||||||
33963931|NCT00002269||||TREATMENT||DOUBLE||||||
33752115|NCT06733467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will typically be unaware of the conditions presented, though because these involve manipulations of stimuli or task demands, they may be aware of the manipulation. This is not expected to impact the primary outcome measures (e.g., BOLD signal activation patterns).|This is a basic science study in which all participants will participate in all task conditions within each experiment (repeated-measures design).||||
33963932|NCT00280774|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33752116|NCT02703922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752117|NCT05308329|||COHORT||PROSPECTIVE|||||||
33752118|NCT02306070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963933|NCT00213031|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33963934|NCT00141531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963935|NCT02956824|NA|SINGLE_GROUP||OTHER||NONE||||||
33963936|NCT04297488|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963937|NCT04283487|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomised, double-blind, placebo-controlled, crossover|t|f|t|f
33963938|NCT00245427|NON_RANDOMIZED|PARALLEL||||NONE||||||
33963939|NCT00987194|||||PROSPECTIVE|||||||
33963940|NCT02272881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963941|NCT04972006|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|This study uses a multiple baseline design in which participants are assigned to either a one-week, two-week, or three-week baseline period before beginning the study treatment. Participants in all three baseline groups receive the same treatment, both in dose and form.||||
34065653|NCT03385551|||COHORT||PROSPECTIVE|||||||
34065654|NCT04274309|||COHORT||PROSPECTIVE|||||||
34179667|NCT04311099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179668|NCT06586372|||CASE_ONLY||CROSS_SECTIONAL|||||||
34179669|NCT04445285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179670|NCT05179928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34179671|NCT04543708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179672|NCT06586723|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|PBIS coaches will be masked to HELM randomization|All schools that participate in the study will receive PBIS. Additionally, half of the schools will be randomized to receive HELM, an additional implementation support intervention.|f|f|f|t
34179673|NCT05208060|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization will be done in a 1:1 ratio in blocks of 6, through a random list. It will be impossible for investigators to know to which group a subject will be assigned before being included in the study.||t|f|t|f
34179674|NCT03651310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179675|NCT06596161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179676|NCT05703607|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|SSA: Observer-blinded, Sponsor Open label SSB: Observer-blinded||t|t|t|t
34179677|NCT01744262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34179678|NCT04422184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752119|NCT04096300|||CASE_ONLY||RETROSPECTIVE|||||||
33752120|NCT00006257||||TREATMENT||||||||
33752121|NCT00006213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752122|NCT05061238|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752123|NCT04492254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, multicentre, multi-national, randomized controlled trial.||||
33752124|NCT00440531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33752125|NCT00514735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752126|NCT05356260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pragmatic non-inferiority randomized controlled trial|f|f|f|t
33752127|NCT03644186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752128|NCT06283472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups.||t|f|f|f
33752129|NCT04886024|||CASE_CONTROL||PROSPECTIVE|||||||
33752130|NCT02243605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752131|NCT01140217|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752132|NCT06296550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752133|NCT06734000|||COHORT||PROSPECTIVE|||||||
33752134|NCT04504487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33752135|NCT02598492|||COHORT||PROSPECTIVE|||||||
33752136|NCT06113848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752137|NCT06367166|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Patients with varicose veins will be assigned to different treatments to assess the venous wall remodeling parameters throughout treatment||||
33866254|NCT00591214|NA|SINGLE_GROUP||||NONE||||||
33866255|NCT02128451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33963942|NCT03707522|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33963943|NCT02576054|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34179679|NCT00796939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179680|NCT05500794|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179681|NCT04800276|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel arms||||
34179682|NCT02993107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179683|NCT05835284|||COHORT||PROSPECTIVE|||||||
34179684|NCT03564808|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi experimental||||
33866256|NCT00719550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866257|NCT05830799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open label, one group||||
34065655|NCT05235971|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34179685|NCT02372604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179686|NCT01902576|||COHORT||PROSPECTIVE|||||||
34179687|NCT06599060|||COHORT||OTHER|||||||
34179688|NCT05383937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179689|NCT01586546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179690|NCT06253442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179691|NCT04377126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the research team collecting data and study participants will be blinded to group assignment (i.e. double blinded status).|Participants will be randomized to subcutaneously administered unacylated ghrelin or placebo.|t|f|f|t
34179692|NCT03459755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179693|NCT02603887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179694|NCT05625126|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline case series||||
34179695|NCT01488890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179696|NCT04457739|||COHORT||PROSPECTIVE|||||||
34179697|NCT03880097|||COHORT||PROSPECTIVE|||||||
33866258|NCT03294525|||COHORT||PROSPECTIVE|||||||
33866259|NCT01419782|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33866260|NCT06466785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33866261|NCT01294488|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33866262|NCT01238445|||CASE_ONLY||PROSPECTIVE|||||||
33866263|NCT03825055|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866264|NCT04302584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33866265|NCT00619255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866266|NCT01531322|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33866267|NCT05295004|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomize à Arm 1 (No Treatment), Arm 2 (Mindfulness Video @ Pre-Op), Arm 3 (Mindfulness Video @ Pre-Op, 1 Day Prior to surgery, 3 day's Post OP, 2 Weeks Post OP)||||
33866268|NCT01763151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866269|NCT02098642|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866270|NCT03135171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866271|NCT01118416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866272|NCT00143091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866273|NCT00290186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866274|NCT01490853|||CASE_ONLY||RETROSPECTIVE|||||||
33866275|NCT02294084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866276|NCT03652246|||COHORT||OTHER|||||||
33866277|NCT04822610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|open|Study group - Study group- Control group|f|f|f|t
33866278|NCT02761395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866279|NCT02257996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866280|NCT00701090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866281|NCT01372722|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33866282|NCT01022502|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33866283|NCT02575404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866284|NCT04809311|||COHORT||PROSPECTIVE|||||||
33866285|NCT03881384|||COHORT||PROSPECTIVE|||||||
33866286|NCT03614312|||COHORT||PROSPECTIVE|||||||
33866287|NCT00052039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866288|NCT06489756|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Each highlander with HAPH will perform a echocardiography with and without SOT according to a cross-over design||||
33866289|NCT06320288|||CASE_CONTROL||PROSPECTIVE|||||||
33866290|NCT04100967|||COHORT||PROSPECTIVE|||||||
34179698|NCT01010880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866291|NCT00236860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866292|NCT02716675|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866293|NCT05483036|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866294|NCT04375787|RANDOMIZED|PARALLEL||PREVENTION||NONE||200 diabetic patients with indication for coronary intervention participated in the study. 100 patients were randomly assigned to receive atorvastatin (80 mg) just before coronary intervention (statin group) and 100 patients received placebo (control group).||||
33866295|NCT02901574|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33866296|NCT00813332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866297|NCT03700151|NA|SINGLE_GROUP||TREATMENT||NONE||A group of 20 participants with severe speech sound disorders will receive the proposed intervention. Pre- and post-test data will be collected to study the treatment efficacy||||
33866298|NCT00237848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866299|NCT06232512|NA|SINGLE_GROUP||OTHER||NONE||||||
33866300|NCT02912299|||CASE_CONTROL||PROSPECTIVE|||||||
33866301|NCT05406843|||OTHER||RETROSPECTIVE|||||||
33866302|NCT03274583|||CASE_CONTROL||PROSPECTIVE|||||||
33866303|NCT01931787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866304|NCT04712396|NA|SINGLE_GROUP||OTHER||NONE||||||
33866305|NCT00510991|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866306|NCT00259779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866307|NCT02029820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866308|NCT01358760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866309|NCT00594516|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33866310|NCT01524133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866311|NCT04167748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation information will be handled by researcher coordinators only.|Prospective randomized clinical trial|t|f|t|t
33866312|NCT02194062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179699|NCT01001026|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179700|NCT03380312|||COHORT||PROSPECTIVE|||||||
34179701|NCT05343182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179702|NCT05125341|||OTHER||OTHER|||||||
34179703|NCT06595914|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Because the intervention disseminates clinical implementation strategies to clinicians, clinicians will not be masked. Patient participants will be masked to whether their outcomes are being collected pre- versus post-clinician intervention. Patient participants will not be masked with regard to having received the mHealth tool for post-discharge education.|The study will enroll and follow emergency department clinicians and their patients. Clinicians will be the focus of the intervention.|t|f|f|f
34179704|NCT00135031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179705|NCT06591624|||COHORT||RETROSPECTIVE|||||||
33752138|NCT06205342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|This is a pilot, randomized, double-blind, placebo-controlled, stratified randomization study to determine the efficacy of a single intravenous infusion of allogeneic bone marrow-derived mesenchymal stromal cells in subjects with painful chronic pancreatitis (CP).|t|t|f|t
33752139|NCT02444065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752140|NCT01991626|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33752141|NCT05684796|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be 1:1 to either anticoagulation alone (AC Group) or anticoagulation plus mechanical aspiration thrombectomy with the Indigo Aspiration System (Indigo Group).||||
33752142|NCT04737460|NA|SINGLE_GROUP||TREATMENT||NONE||An initial low dose cohort followed by a subsequent a high dose cohort||||
33752143|NCT03089684|||OTHER||OTHER|||||||
33752144|NCT06732895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752145|NCT02373800|||COHORT||PROSPECTIVE|||||||
33752146|NCT04710810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752147|NCT00952367|||||PROSPECTIVE|||||||
34179706|NCT01774721|RANDOMIZED|||TREATMENT||NONE||||||
34179707|NCT06592638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179708|NCT06590155|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34179709|NCT02491684|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34179710|NCT05731986|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|During the two testing days, participants will be blinded to the order of the stimulation. One testing day will include an orthostatic sit-up test with optimal stimulation (for a blood pressure response), while the other will include a sit-up test with sham stimulation|Twelve individuals admitted to inpatient rehabilitation after sustaining a spinal cord injury will be enrolled. They will complete baseline assessments including an orthostatic sit-up test and neurophysiological mapping. Subsequently, the intervention will consist of two days of stimulation mapping to locate the optimal spinal segment for a blood pressure response. Participants will then be randomly assigned to two groups that would determine the order of the two testing days (optimal/sham), where stimulation is applied during an orthostatic test.|t|f|f|f
34179711|NCT05128916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of interventions (oral versus intralesional), both patient and treating investigator will not be blinded, but the assessment of outcome will be carried out by two dermatologists who will be blinded to the treatment type.|Patients will be randomly assigned to 3 groups. In PRP group, patients with onychomycosis will receive intralesional injections of PRP (study group 1). In PRP + terbinafine group, patients with onychomycosis will receive intralesional PRP in addition to oral terbinafine 250 mg daily (study group 2). In terbinafine group, patients with onychomycosis will receive oral terbinafine 250 mg daily (study group 3) (control group)|f|f|f|t
34179712|NCT03592186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179713|NCT02541175|||CASE_ONLY||CROSS_SECTIONAL|||||||
34179714|NCT01071304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179715|NCT06595355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179716|NCT01298089|||COHORT||RETROSPECTIVE|||||||
33752148|NCT03983512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752149|NCT02319811|||CASE_ONLY||PROSPECTIVE|||||||
33752150|NCT02496624|NA|SINGLE_GROUP||OTHER||NONE||||||
33752151|NCT03230708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752152|NCT04828954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Occupational therapy (blinded to length of immobilization)||f|t|f|f
33752153|NCT06062680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752154|NCT01353352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752155|NCT06732024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33752156|NCT05620875|||CASE_ONLY||PROSPECTIVE|||||||
33752157|NCT03206203|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752158|NCT05195931|||COHORT||PROSPECTIVE|||||||
33752159|NCT06733974|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752160|NCT02270333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33752161|NCT04518787|||COHORT||PROSPECTIVE|||||||
34179717|NCT06588270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding of allocation will be maintained for the research workers until all outcome measures for all participants have been collected. Blindness will be maintained using a range of measures (e.g. separate offices for therapist and researchers, protocols for answering phones and emails and security for electronic randomization information). The trial statistician will be also blind to the randomization outcome.|The study will be a double-blind, randomized controlled trial (RCT). Patients will be divided into two groups. The intervention group will receive a VR experience with a treatment software, while the control group will receive a VR experience without the software. All patients will continue on their current medications|f|t|t|t
34179718|NCT06591117|NA|SINGLE_GROUP||TREATMENT||NONE||Vizio Aqueous Microshunt (VAM) - an implantable device intended to reduce intraocular pressure (IOP) by shunting aqueous humor from the anterior chamber to the surface of the eye.||||
34179719|NCT00256594|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34179720|NCT06322186|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only the statistician will remain blinded during the final analysis.|"Eligible patients will be randomized 1:1 to receive either the experimental or control arm.~Experimental arm: 2 Ready-Heat 4-panel blankets Control arm: standard of care (use of warmed blankets and forced air warmed blanket \[FAWB\])"|f|f|f|t
34179721|NCT01152255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179722|NCT02167698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179723|NCT00140452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179724|NCT02855125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179725|NCT04097639|||COHORT||PROSPECTIVE|||||||
34179726|NCT02920632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179727|NCT06594653|||OTHER||RETROSPECTIVE|||||||
34179728|NCT05526885|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||In this study a paired screen-positive design is used to directly compare two screening/triage approaches in the same individual based on a paired analysis: CAD4TB screening only (approach 1) versus CAD4TB screening with POC-CRP triage algorithm (approach 2).||||
34179729|NCT03406377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179730|NCT00144547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179731|NCT04080648|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open label, non-randomized study||||
34179732|NCT00726063|RANDOMIZED|PARALLEL||TREATMENT||NONE||implant types were randomized- 2 different surface treatments||||
34179733|NCT01253746|||FAMILY_BASED||PROSPECTIVE|||||||
34179734|NCT04909996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179735|NCT04546711|||COHORT||PROSPECTIVE|||||||
34179736|NCT05518097|||COHORT||PROSPECTIVE|||||||
34179737|NCT06600529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* Estimated Enrollment: 100 Patients~* Allocation: Randomized~* Intervention Model: Parallel Assignment~* Masking: Single (Participant)~* Primary Purpose: Treatment"|t|f|f|f
34179738|NCT05387200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179739|NCT03868514|||COHORT||PROSPECTIVE|||||||
34179740|NCT06594185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179741|NCT00651742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179742|NCT05766813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179743|NCT06600191|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34179744|NCT06600204|||OTHER||RETROSPECTIVE|||||||
34179745|NCT04908631|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34179746|NCT01010828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179747|NCT04115306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752162|NCT03154216|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33752163|NCT02961465|||COHORT||PROSPECTIVE|||||||
33752164|NCT05251051|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed by blinded neuromotor examiners.|Infants will be assigned to an intervention or control group based on the city of residence at discharge (Chicago or not-Chicago)|f|f|f|t
33752165|NCT06372470|||COHORT||PROSPECTIVE|||||||
33752166|NCT00772226|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33752167|NCT03974620|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33752168|NCT03671005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded psychiatrist who works independently of the (co-) therapist conducts the rater-questionnaires. Due to the psychotherapeutic nature of the study, information about the treatment allocation has to be shared with the co-therapist and the participants. Randomization is conducted by the Random Group Generator (pubmed, 2018).|A single-centered randomized controlled trial with a parallel-groups design is utilized, comprising of mindfulness-based group therapy (MBGT) in addition to treatment as usual (TAU) in the experimental condition, and TAU in the control condition|f|f|f|t
33752169|NCT04739605|||COHORT||PROSPECTIVE|||||||
33752170|NCT01724138|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752171|NCT00070473||||TREATMENT||||||||
33752172|NCT06211569|||CASE_ONLY||PROSPECTIVE|||||||
33752173|NCT03073148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||2/3 of patients will be assigned to the Tangible Boost treatment arm of the study, and 1/3 of patients will be assigned to the placebo control arm.|t|t|f|f
33752174|NCT02381886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752175|NCT06584136|||COHORT||PROSPECTIVE|||||||
33752176|NCT01851148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752177|NCT04602728|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Youth and parent/caregiver dyads will participate in the same intervention.||||
33752178|NCT04240262|||COHORT||PROSPECTIVE|||||||
33752179|NCT05465161|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33752180|NCT04354467|||COHORT||PROSPECTIVE|||||||
33752181|NCT03018405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The maximum number of patients to be enrolled is 146:~* 36 in the dose escalation segment (cohorts 1-6, 18 per arm),~* 24 in the additional cohorts 8-11 (12 per arm),~* 86 patients in the Phase I expansion segment (note that the analysis of this segment will also include a maximum of 12 additional patients from the dose escalation segment)."||||
33752182|NCT04929769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752183|NCT04364373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752184|NCT02680873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179748|NCT05919186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The data registry utilized internal and external measures to ensure accuracy. SOPs were developed for registry operations and data analysis. Data were recorded in clinical records and clinic-specific databases. Regular backups and monthly audits were conducted to safeguard data and verify accuracy. External audits occurred every 6 months. Access controls protected privacy. Appropriate statistical techniques and sample size assessment were used for data analysis. A study on embryo development analyzed 3603 zygotes, assessing blastocyst outcomes and detailing procedures for ovarian stimulation, retrieval, sperm preparation, and assisted reproduction techniques. These measures ensured accurate and reliable results.|t|f|f|f
34179749|NCT02587637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179750|NCT06448676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Trial participants, data collectors, the statistician, and outcome assessors were blinded to the study-group assignments. Blinded syringes are labeled a sticker containing no information other than the allocated study number. After reconstitution, syringes were stored under hygienic non-sterile conditions between 39-46F in medical refrigerators. The safety related to this sterile transfer is substantiated by several studies.|This study is a triple-blind, multi-center, parallel-group randomized controlled trial designed to compare the efficacy and safety of onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, prabotulinumtoxinA, and daxibotulinumtoxinA, for the treatment of glabellar rhytides.|t|t|f|t
34179751|NCT06597110|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study involved sixty participants, divided evenly into four groups: three intervention groups (A, B, C) and one control group. For five consecutive days, the intervention groups engaged in pre-sleep ASMR listening sessions lasting 10, 20, and 30 minutes, respectively. Sleep quality was evaluated using mobile application tools and the subjective Sleep Quality Scale.||||
34179752|NCT06492733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179753|NCT00635206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179754|NCT06602531|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind||t|t|t|t
34179755|NCT04298320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179756|NCT04003467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179757|NCT06598904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34179758|NCT05527977|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigators have two research assistants who will perform retrospective chart review. The participants will not be informed of the incentive used (i.e., participants will now know whether the investigators have control/experimental group nor pre/post design)|"To answer the research question, the investigators will extract data at the visit-level and perform the analysis at the physician-level. The investigators will perform descriptive statistics of physician and patient characteristics. Depending on the distribution of the data, the primary analysis will be paired t-test or Wilcoxon signed rank test comparing 6 weeks of baseline data for each physician to 12 weeks of data with compensation incentives. Performance by each physician during the baseline and incentivized periods will be assessed as a proportion at the visit level. The investigators will perform a multivariate interrupted time series as a sensitivity analysis. Patient and physician variables will be used as covariates in the multivariate analysis.~The intevestigators will compare baseline documentation (Arm #1) with incentivized documentation (Arm #2)"|f|f|f|t
34179759|NCT05986955|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33752185|NCT05474274|||COHORT||PROSPECTIVE|||||||
34179760|NCT00730717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179761|NCT05854368|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients with gastric lesion (including preneoplasia or cancer) and Healthy Volunteers (control)||||
34179762|NCT01624350|||||PROSPECTIVE|||||||
34179763|NCT04225585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study staff conducting assessments will be blind to group assignment. To maintain blinding, we will use the following approaches: 1) all study staff will be trained on the importance of blinding and study procedures to maintain blinding; 2) participants will be provided with the rationale and instructions not to disclose their group assignment; 3) the study staff who conduct post-intervention assessments will not be given information about group assignment prior to the assessment; and 4) if a breach occurs, it will be documented and the participant will complete their assessment with a new assessor.||f|f|f|t
34179764|NCT06591221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179765|NCT06589635|NA|SEQUENTIAL||TREATMENT||NONE||||||
34179766|NCT04164875|||COHORT||PROSPECTIVE|||||||
34179767|NCT01748747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752186|NCT05937724|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33752187|NCT04049175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Placebo controlled|t|t|t|t
33752188|NCT06733857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33752189|NCT06720259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33752190|NCT03583255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33752191|NCT02069782|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33752192|NCT05392062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752193|NCT01175850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752194|NCT06732648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179768|NCT05079659|||OTHER||CROSS_SECTIONAL|||||||
34179769|NCT06592625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179770|NCT02203396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179771|NCT06604052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179772|NCT06503614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179773|NCT00919217|||OTHER||PROSPECTIVE|||||||
33752195|NCT05394246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752196|NCT02669784|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752197|NCT03533712|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The intervention study is a randomized controlled 2x2 factorial efficacy trial. At study inclusion, eligible pregnant women will be randomly assigned to the prenatal intervention or control group, and randomly assigned to a postnatal intervention or control group. The intervention group will receive daily a fortified BEP supplement to be consumed under supervision for the duration of pregnancy/lactation. Both control and intervention group will receive the standard iron and folic acid tablet through the regular ante natal care program.||||
33752198|NCT04088552|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752199|NCT05095610|||COHORT||CROSS_SECTIONAL|||||||
34179774|NCT03146585|||COHORT||PROSPECTIVE|||||||
34179775|NCT06053307|NA|SINGLE_GROUP||OTHER||NONE||||||
34179776|NCT05348538|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34179777|NCT05187689|RANDOMIZED|PARALLEL||TREATMENT||NONE||The two intervention arms will be compared to the control arm of the study using a pre- and post-intervention survey. There will also be a follow-up survey 8 weeks after the study is complete.||||
34179778|NCT06211361|NA|SINGLE_GROUP||TREATMENT||NONE||Our project is a quantitative study||||
33752200|NCT05722002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both study staff performing outcome assessment and data analysis will be masked to treatment assignment.|Randomization of patients will be stratified by site, sex, age (greater or equal to 65 years old), and type of surgery, via permuted block randomization with a variable block size.|f|f|f|t
33752201|NCT06431503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179779|NCT01887327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34179780|NCT06593444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179781|NCT01751529|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179782|NCT06589037|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Forty-eight subjects who meet the inclusion criteria will be recruited and randomly assigned to each intervention group. The control group will receive local shock wave therapy, while the experimental group will receive shock wave therapy along the course of the sciatic nerve.||||
34179783|NCT06058923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled double-blind parallel-design clinical trial with a longitudinal duration of 12 months per participant, involving surgical therapeutic intervention.||||
34179784|NCT06655675|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34179785|NCT06596876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752202|NCT04711889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752203|NCT06733818|||OTHER||CROSS_SECTIONAL|||||||
33752204|NCT06722183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752205|NCT06441968|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33752206|NCT04702568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752207|NCT01320007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752208|NCT06733805|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||"The investigators randomized actively practicing family physicians and nurse practitioners into two groups, n = 3,407 in each group. They then looked at who was registered for Portrait Online at the time of generating the early portrait data, and there were n=259 in Group 1, and n=256 in Group 2 for a total of 515 individuals.~Group 1 received the intervention materials on January 15, 2024, while Group 2 received nothing (thus serving as the control group). Group 2 received the intervention materials nine months later, on October 15, 2024."|t|f|f|f
34179786|NCT06598215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34179787|NCT00523510|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34179788|NCT02589938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34179789|NCT06597214|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single group assignment compared to a historical control||||
34179790|NCT03011320|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34179791|NCT00000385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179792|NCT06413992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179793|NCT05530252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients did not know their group or the drugs they were given||t|f|f|f
34179794|NCT02457962|||OTHER||PROSPECTIVE|||||||
34179795|NCT00536744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179796|NCT01364935|||COHORT||PROSPECTIVE|||||||
34179797|NCT04909047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34179798|NCT01651156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179799|NCT01062932|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34179800|NCT05733546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179801|NCT05383196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179802|NCT03956849|||OTHER||PROSPECTIVE|||||||
34179803|NCT03992560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34179804|NCT05910684|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will enroll primary care physicians practicing in the US from a population of participants who completed phase 1 of the study. All participants will keep their arm assignments from the phase 1 study. All eligible and consented participants will complete a round of three patient simulations.~The intervention arm will have access to the Aegis test and will be asked to use this test on patients who meet the eligibility criteria."||||
33752209|NCT00773968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752210|NCT04212091|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33752211|NCT05884346|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752212|NCT01112579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752213|NCT06722976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33752214|NCT06253494|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866313|NCT01761045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33866314|NCT02170675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866315|NCT02745366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866316|NCT01817751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866317|NCT04360499|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be aware of the type of exercise intervention. Assessors will be blind for the group allocation of the participants|Participants will be randomly allocated in two groups: the LLHR group and the Pilates group. Both exercise programs will be performed in groups lasting for three months and performed 3 times per week.|t|f|f|t
33866318|NCT04678596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866319|NCT03076931|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866320|NCT01687010|||||PROSPECTIVE|||||||
33866321|NCT01279850|||CASE_ONLY||PROSPECTIVE|||||||
33866322|NCT03725514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed Opaque Envelopes||t|f|t|f
33963944|NCT01532037|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33963945|NCT06292806|||COHORT||PROSPECTIVE|||||||
33963946|NCT06089850|NA|SINGLE_GROUP||OTHER||NONE||||||
33963947|NCT04618952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Group A and group B|block|t|t|t|t
33963948|NCT04992338|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33963949|NCT04726839|||COHORT||PROSPECTIVE|||||||
33963950|NCT05949216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963951|NCT00243815|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33963952|NCT02482571|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963953|NCT05279326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33963954|NCT00411294|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33963955|NCT01721967|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963956|NCT02357407|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33963957|NCT00747422|NA|SINGLE_GROUP||OTHER||NONE||||||
33963958|NCT02493088|||CASE_ONLY||PROSPECTIVE|||||||
33963959|NCT01797952|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866323|NCT03890991|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33866324|NCT06007365|||COHORT||OTHER|||||||
33866325|NCT00447512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33866326|NCT00381563|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33866327|NCT03452644|||OTHER||RETROSPECTIVE|||||||
33866328|NCT05861687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866329|NCT06465719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly assigned to treatment or conservative group, so masking is only for outcome assessors||f|f|f|t
33866330|NCT02495220|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866331|NCT04030039|||COHORT||PROSPECTIVE|||||||
33866332|NCT06134050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants blinded. Care provider/surgeon not possible to mask. Investigator masked. Outcome assessor masked/blinded data set.|Randomized controlled trial|t|f|t|t
33866333|NCT04029181|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866334|NCT00201669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866335|NCT01164566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866336|NCT01454245|RANDOMIZED|CROSSOVER||||NONE||||||
33866337|NCT03923751|||COHORT||RETROSPECTIVE|||||||
33866338|NCT00068744|RANDOMIZED|||TREATMENT||||||||
33866339|NCT02674698|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33866340|NCT04731038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866341|NCT02568475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866342|NCT02109562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866343|NCT06401564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866344|NCT01460095|NA|SINGLE_GROUP||||NONE||||||
33866345|NCT02024568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866346|NCT06345521|||COHORT||PROSPECTIVE|||||||
33866347|NCT06059924|||COHORT||RETROSPECTIVE|||||||
33866348|NCT06335810|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33866349|NCT02661698|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33866350|NCT05482074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866351|NCT00589407|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866352|NCT05563675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators will be blinded for the treatment allocation, but the trial participants will not be blinded. However, since all endpoints are assessed using prespecified registry-based definitions, bias should be negligible.|Patients will be randomized 1:1 to one of two treatment strategies by computer-generated allocation, to either LAMA administration in the morning or evening. Randomization groups will be allocated according to a computer-generated randomization. Data will be entered by participants directly into REDCap questionnaires. Consent and randomization will take place on day 0. The result of the randomization will be shown directly to the participant on their screen and sent to the participant's official electronic mailbox.|f|f|t|t
33866353|NCT01363388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866354|NCT01053442|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33866355|NCT00003042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866356|NCT03353974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866357|NCT02830672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33866358|NCT02895503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866359|NCT00545402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866360|NCT01848886|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33866361|NCT00580372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866362|NCT01580865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866363|NCT01482585|||CASE_CONTROL||PROSPECTIVE|||||||
33866364|NCT02046096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866365|NCT02248948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866366|NCT05147467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866367|NCT04766476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866368|NCT04513886|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned to one of two groups in parallel for the duration of the study: This study was a non-masked, randomized, controlled clinical trial, with a parallel design, comparing early healing of palatal wounds after harvesting subepithelial connective tissue graft using the single incision technique, with and without palatal sutures.||||
33866369|NCT04795726|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33866370|NCT04262050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866371|NCT05013645|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33866372|NCT02726971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33866373|NCT00660270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866374|NCT04142528|||CASE_ONLY||PROSPECTIVE|||||||
33866375|NCT02368067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866376|NCT03494751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866377|NCT01656421|||COHORT||PROSPECTIVE|||||||
33866378|NCT05893602|||COHORT||PROSPECTIVE|||||||
33866379|NCT04312373|||OTHER||PROSPECTIVE|||||||
33866380|NCT01875302|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866381|NCT00020579||||TREATMENT||NONE||||||
33866382|NCT01622751|||CASE_CONTROL||PROSPECTIVE|||||||
33866383|NCT04442191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient's nurse will be instructed to place the blood product in a paper bag so the label on the product is not visible to the study physicians or to the patient.||t|f|t|t
33866384|NCT04171518|||COHORT||PROSPECTIVE|||||||
33866385|NCT00896779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866386|NCT03702751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866387|NCT05436769|RANDOMIZED|CROSSOVER||OTHER||NONE||A single center, open Label, Randomized, Two Way Cross over, Two Period, Two Treatment, two Sequence Bioequivalence Study||||
33866388|NCT03093753|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33866389|NCT01500850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866390|NCT03710486|||COHORT||RETROSPECTIVE|||||||
33866391|NCT03974334|NA|SINGLE_GROUP||TREATMENT||NONE||There are 2 cohorts taking part in the same intervention at 2 separate times.||||
33866392|NCT04349878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33866393|NCT00302562|||NATURAL_HISTORY||OTHER|||||||
33866394|NCT01587378|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866395|NCT04927689|||COHORT||PROSPECTIVE|||||||
33866396|NCT00053703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866397|NCT01903070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866398|NCT04713202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33866399|NCT05740020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866400|NCT00077051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963960|NCT04567173|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase 3, randomized, non-placebo controlled, open-label, non-blinded, single-center clinical trial which will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma given from the 3rd to 14th day of illness after the onset of symptoms in preventing ICU admission among COVID-19 patients compared to standard of care. Consequently enrolled patients will be randomized using the REDCap randomization module||||
33963961|NCT05672134|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||crossover multi-centre, double-blind, randomized control trial.|t|t|t|t
33963962|NCT03492580|||COHORT||RETROSPECTIVE|||||||
33963963|NCT02824991|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33963964|NCT06311539|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The evaluator who will perform isokinetic assessments and vertical jump measurements will be blinded to the participants' chronotype.|Randomized Controlled Study|f|f|f|t
33963965|NCT05818163|||COHORT||PROSPECTIVE|||||||
33963966|NCT06542211|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33963967|NCT00309413|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33963968|NCT05174728|||COHORT||PROSPECTIVE|||||||
33963969|NCT03548324|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms multicenter randomized controlled trial designed according to the intention-to-treat model. The assignement to one of the two arms (NCPAP or HHHFNC) is by block randomization. The randomization program is designed to obtain, in each research unit, a balance between the two arms according to gestation age (GA \<28 weeks and GA ≥ 28 weeks).||||
33963970|NCT00770354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963971|NCT01072916|||CASE_CONTROL||PROSPECTIVE|||||||
33963972|NCT00724074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963973|NCT05723341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RANDOMISED SINGLE BLINDED INTERVENTIONAL|f|f|f|t
33963974|NCT00163436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963975|NCT03448952|||COHORT||CROSS_SECTIONAL|||||||
33963976|NCT04975282|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33963977|NCT00568152|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33963978|NCT06256731|||COHORT||PROSPECTIVE|||||||
33963979|NCT04416828|||COHORT||PROSPECTIVE|||||||
33963980|NCT05385471|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33963981|NCT05124431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963982|NCT03162354|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The study statistician will remain blinded to PICU site group membership (control vs. intervention sites).|The stratified cluster randomized trial design will facilitate direct comparison of child abuse evaluations at four, randomly selected, control sites to four matched intervention sites, where investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application.|f|f|f|t
33963983|NCT02127229|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|t|f|f
33866401|NCT01643525|||CASE_CONTROL||PROSPECTIVE|||||||
33866402|NCT00623974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866403|NCT05831826|||COHORT||PROSPECTIVE|||||||
33866404|NCT00515255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866405|NCT05697263|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The testleader will be blinded to which group the subject belongs to.||f|f|f|t
33866406|NCT05668039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Masking of participants - the sham procedure includes the same location of pneumatic blood-pressure cuffs used for the intervention; and will be perfoemd in the same frequency and duration as the intervention. Participants will be invited for the procedures at separate times to avoid connection between them.~Masking of investigator and outcome assessor - unblinded nurses and one unblinded physician will be responsible for performing the procedures (either intervention or sham), without involving other team members (other investigators or outcome assessors), who would remain blinded to the treatment arm."|Double blind, outcome assossor blind, randomized controlled trial|t|f|t|t
33866407|NCT02409290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866408|NCT05953558|||COHORT||OTHER|||||||
33866409|NCT03109548|||COHORT||PROSPECTIVE|||||||
33866410|NCT06070844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||randomised controlled trial|t|t|t|t
33866411|NCT01020591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866412|NCT00074022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866413|NCT06155747|||OTHER||RETROSPECTIVE|||||||
33866414|NCT04879641|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The study is a single-center, factorial trial with four experimental factors (treatment components, i.e., psychoeducation, cognitive restructuring, attention training, and exposure) each evaluated at two levels (presence vs. absence) resulting in 16 treatment conditions.|t|f|f|f
33866415|NCT03120806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866416|NCT00341744|||CASE_ONLY||PROSPECTIVE|||||||
33866417|NCT03933384|RANDOMIZED|PARALLEL||TREATMENT||NONE||The eligible chronic hepatitis B patients are randomly assigned (1:1) to receive once-daily oral doses of tenofovir alafenamide 25 mg or entecavir 0.5mg.||||
33866418|NCT02486848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866419|NCT02202291|NA|SINGLE_GROUP||OTHER||NONE||||||
33866420|NCT02204384|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33866421|NCT01552720|||CASE_ONLY||RETROSPECTIVE|||||||
33866422|NCT05449197|||OTHER||CROSS_SECTIONAL|||||||
33866423|NCT01704287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866424|NCT04157816|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|In this trial, the Outcome Assessors administering study assessments at baseline and at endpoint will be masked to the intervention arm that participants are allocated to receive. The Study Investigators will also be masked to the intervention arm that participants are allocated to receive. Masking Outcome Assessors and Study Investigators will minimize potential bias due to knowledge of which arm the participant is allocated to, and can ensure unbiased ascertainment of study outcomes is possible. For allocation concealment, the intervention allocation for each participant will not be revealed to the participant until they have been enrolled into the trial, to avoid selection bias.|This study employs a 3-arm parallel randomized controlled trial design. Participants are randomly allocated to one of three training interventions: 1) low-intensity digital training (DGT); 2) high-intensity digital training with additional coaching support (DGT+); and 3) traditional face-to-face training (F2F).|f|f|t|t
33866425|NCT05485584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33866426|NCT04672265|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"The screening invitees randomized to the control group are not informed about this study. They receive care as usual, the screening invitation letter in Norwegian language."|Participants are randomized to receive the invitation in the major official native language in the country the participant is born and Norwegian, or in Norwegian only, consecutively when it is their turn to be invited to screening.|t|f|f|f
33866427|NCT04533087|||COHORT||PROSPECTIVE|||||||
33866428|NCT02954146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866429|NCT00804570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866430|NCT04253535|||CASE_ONLY||RETROSPECTIVE|||||||
33866431|NCT01117454|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33866432|NCT00492323|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33963984|NCT04185831|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Combined umbrella and basket trial. Treatment selection based on mutation status.||||
33963985|NCT01296152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963986|NCT06368661|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33963987|NCT02199834|NON_RANDOMIZED|PARALLEL||||NONE||||||
33963988|NCT05928273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963989|NCT05053919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33963990|NCT04367922|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33963991|NCT06044259|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial of two groups||||
33963992|NCT03423589|NA|SINGLE_GROUP||OTHER||NONE||||||
33963993|NCT05016765|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive MNS at 12 Hz, pulse width 200µs. After initial threshold determination and training on device usage, individual participants will choose duration and intensity of treatment depending on their momentary symptom severity and history of response to treatment.||||
33963994|NCT03229382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33963995|NCT02464527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33963996|NCT05954338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33963997|NCT02805582|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34179805|NCT04046367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A person external to the monitoring and evaluation of the patients will generate a random sequence (by computer), to assign the participants to their corresponding treatment group. The intervention sequence will be transcribed to cards that will be introduced in an envelope each. The envelopes will be opaque, sealed and numbered consecutively. Each time a patient agrees to participate in the trial, he/she signs the informed consent and we verify that he/she meets the inclusion criteria, but not the exclusion criteria, the corresponding envelope will be opened in correlative order.~Patients will be assigned to one of two group interventions, unaware of the components in each group. The assessment of most of the outcomes will be blinded, too."|"Randomized, controlled clinical trial, which will compare two group interventions in patients on the waiting list for bariatric surgery.~Duration: 4-month intervention, with biweekly 2-hour group sessions c / un, followed by a monthly reinforcement session of 1h until surgical intervention.~Intervention A: Educational program and cognitive-behavioral intervention (group control) Intervention B: Educational program and cognitive-behavioral intervention, with specific training aimed at increasing physical activity, capacity functional and conditioning of the respiratory musculature (group of intervention)."|t|f|f|t
34065656|NCT00279604|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179806|NCT00394017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34179807|NCT02718404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179808|NCT06597136|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|In the 1st group, only conventional treatment will be applied, in the 2nd group, diaphragmatic kinesiology taping will be applied in addition to conventional treatment, in the 3rd group, kinesiological taping will be applied to the auxiliary respiratory muscles in addition to conventional treatment, and in the 4th group, sham taping will be applied.||t|f|f|t
34179809|NCT02642822|||COHORT||PROSPECTIVE|||||||
34179810|NCT05961722|||OTHER||PROSPECTIVE|||||||
34179811|NCT06598280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179812|NCT06464601|||COHORT||RETROSPECTIVE|||||||
34179813|NCT04502030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34179814|NCT04465344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752215|NCT03064568|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|Randomization to treatment arm done by 3rd party. Randomization will be performed by a third party so that neither the surgeon nor patient will know which intervention was performed, and interventions will be placed in sealed, sequentially numbered, opaque envelopes. The code will only be broken at time of data analysis once all patients have been enrolled.|Prospective double-blinded study completed at a tertiary care center|t|t|t|f
33752216|NCT01832948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752217|NCT06202287|||CASE_ONLY||CROSS_SECTIONAL|||||||
33752218|NCT04957537|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Interventional, monocentric, prospective, randomised, controlled research. Single Case Experimental Design type study in multiple baselines with 2 successive phases (A-B design) for each patient. For each subject, phase A constitutes the baseline (6 to 8 weeks), phase B is characterised by semantic rehabilitation (5 weeks). The beginning of the intervention will be sequential and the duration of the baseline will be randomised for each patient."||||
33752219|NCT06470165|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752220|NCT06732791|||COHORT||PROSPECTIVE|||||||
33752221|NCT06064396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding,refers to a practice where study participants are prevented from knowing certain information that may somehow influence them-thereby tainting the results.|Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial.|f|f|f|t
33752222|NCT05845320|||OTHER||CROSS_SECTIONAL|||||||
33752223|NCT03925077|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcome assessor will be blinded to participants' group assignments throughout the study.||f|f|f|t
33752224|NCT05229068|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752225|NCT02633826|||COHORT||PROSPECTIVE|||||||
33752226|NCT06720662|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33752227|NCT06221189|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33752228|NCT06723301|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33752229|NCT01696201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33752230|NCT06443268|||COHORT||PROSPECTIVE|||||||
33752231|NCT05661734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752232|NCT04981678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752233|NCT04733040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752234|NCT01413568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752235|NCT04376138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752236|NCT04728529|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Outcome of mortality rate, macrocirculation hemodynamic parameter, and microcirculation laboratory parameter are objective measurement (does not influenced by assessors's subjectiveness).~However, the assessor of liver enlargement and lung US score will not be masked."|Each eligible patient will be randomized into 2 groups of treatment, the USSM protocol or the ACCM protocol. All of subjects in each group will receive emergency management: oxygen support, vascular access, and fluid resuscitation. In intervention group, each step of fluid and vasoactive management will be guided by clinical sign and Doppler ultrasonography, whereas in control group only guided by the clinical sign.||||
33752237|NCT01361503|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752238|NCT04269499|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, interventional, feasibility||||
33752239|NCT05680272|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|In the first stage of the research, it is planned to take a sample of at least 5-10 times the number of items of the scale planned to be developed. The sample size should be at least 200 to reveal the psychometric structure of the scale adequately, 300 and ideally over 500 to reveal the factor structure. In the second phase, it is aimed to reach at least 72 people, 36 in the intervention group and 36 in the control group.|education-centered randomized controlled experimental study||||
33752240|NCT05318287|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752241|NCT00291967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752242|NCT03136445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33752243|NCT04556578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752244|NCT04491448|||COHORT||CROSS_SECTIONAL|||||||
34179815|NCT01917760|||||PROSPECTIVE|||||||
34179816|NCT01955135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33963998|NCT06558201|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will have completed the 12-week randomized controlled trial (NCT06221852), and will follow the ketogenic diet in this open label extension.||||
33963999|NCT02523807|||OTHER||PROSPECTIVE|||||||
33866433|NCT03216811|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects that meet the inclusion/exclusion criteria and have provided informed consent will undergo a 4-week period of lifestyle advice and changes. If, after the 4 weeks, LDL values are confirmed above the established cutoffs, the subjects receive CARDIOVIS COLESTEROLO 3 mg for 8 weeks. After the 8-week treatment period, all biological paprameters will be reassessed. Finally, a last blood samples to assess a potential rebound effect after nutraceutical suspension is collected 4 weeks after the treatment stop.||||
33866434|NCT00350168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866435|NCT04198454|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Sequential, multiple assignment, randomized trials (SMARTs)|f|f|f|t
33964000|NCT05430282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator responsible for clinical assessment will be blinded to subject's intervention group||f|f|t|t
33964001|NCT01866982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33964002|NCT03940937|||COHORT||CROSS_SECTIONAL|||||||
33964003|NCT06181682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33964004|NCT06543160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33866436|NCT01992120|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33964005|NCT03530722|||CASE_ONLY||PROSPECTIVE|||||||
33964006|NCT03262545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964007|NCT02527616|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34179817|NCT03674411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179818|NCT06590363|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34179819|NCT06069843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179820|NCT00906204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179821|NCT04484077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179822|NCT02015260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179823|NCT04323124|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34179824|NCT06587828|||CASE_ONLY||PROSPECTIVE|||||||
33866437|NCT03837704|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33866438|NCT05902078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866439|NCT01843582|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866440|NCT05106504|||CASE_ONLY||PROSPECTIVE|||||||
33866441|NCT04054089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866442|NCT04062526|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33866443|NCT03003481|||CASE_ONLY||PROSPECTIVE|||||||
33866444|NCT06098898|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33866445|NCT05956145|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind|Prospective, randomized, double-blind, placebo-controlled study.|t|f|t|f
33866446|NCT03100071|||COHORT||PROSPECTIVE|||||||
33866447|NCT02576444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866448|NCT02357134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33866449|NCT05137249|||CASE_CONTROL||PROSPECTIVE|||||||
33866450|NCT03392272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician will randomly assign the patient into the tisseel group or the sutures group|A prospective randomized study|f|t|f|f
33964008|NCT00181116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964009|NCT00681824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964010|NCT00823459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964011|NCT03875560|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33964012|NCT00681577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964013|NCT00442715|||||OTHER|||||||
34179825|NCT03435796|NA|SINGLE_GROUP||OTHER||NONE||||||
34179826|NCT03606369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179827|NCT06601153|||COHORT||OTHER|||||||
34179828|NCT06595732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34179829|NCT06592430|||COHORT||PROSPECTIVE|||||||
34179830|NCT04202601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866451|NCT00951301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866452|NCT03882203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866453|NCT04795856|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The healthy group will establish a baseline for the moderate- severe mitral valve regurgitation (PMR) group.||||
33866454|NCT00058552||||TREATMENT||NONE||||||
33866455|NCT00490633|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33866456|NCT01553188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964014|NCT04828902|||COHORT||PROSPECTIVE|||||||
33964015|NCT02419469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964016|NCT03627182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964017|NCT01472809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964018|NCT00064779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964019|NCT06276894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964020|NCT00934037|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33964021|NCT04926688|||CASE_ONLY||RETROSPECTIVE|||||||
33964022|NCT02536131|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964023|NCT01367821|||COHORT||PROSPECTIVE|||||||
33964024|NCT03147001|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Masking was done by providing similar tasting drinks at both trails. One was placebo, one was protein a drink||t|f|f|f
33964025|NCT05202522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33964026|NCT06208852|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||The sub-study will involve a rigorous mixed-methods design. The qualitative phase of the sub-study will consist of semi-structured interviews. During the semi-structured interviews, 10 eligible women will be recruited to identify barriers and facilitators to accessing virtual mental health services. This information will be used to adapt an evidence-based patient navigation intervention for virtual use and an engagement measure. For the intervention phase of the sub-study, 30 women with persistent postpartum depression (PPD) symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period.||||
33964027|NCT04522011|||CASE_CONTROL||PROSPECTIVE|||||||
33964028|NCT00904501|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179831|NCT06593002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The universe of the study consisted of hospitalized children aged 3-6, their primary caregivers, and 3rd year nursing students taking the Pediatric Nursing course.~Children and Parents: G\*Power 3.1.9.6. program was used to calculate the sample size of the study. According to the a priori power analysis of the study with one-way hypothesis, 0.634 effect size, 0.05 significance level, and 0.80 power; it was determined that including a total of 64 (Experiment: 32 children + parents, Control: 32 children + parents) children in the study would provide a sufficient sample size.~Nursing students: No sample calculation method was used, and all students who wanted to make therapeutic toys and play games with their patients were included in the study. 141 students who wanted to participate in the study out of a total of 178 students taking the course were included in the study."|t|f|f|f
33866457|NCT06161662|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Four or six patients were defined as a block group and the results were sealed in envelopes using computer-generated block randomisation by a researcher not involved in clinical anesthesia. After the patients were enrolled, the study nurse opened the envelope according to the corresponding enrollment number and obtained the group results.||t|f|t|f
34179832|NCT03173248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179833|NCT04760808|||CASE_CONTROL||PROSPECTIVE|||||||
34179834|NCT03249207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179835|NCT05206565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34179836|NCT02529072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752245|NCT01358695|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33752246|NCT04907708|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752247|NCT02815891|||COHORT||OTHER|||||||
33752248|NCT04891419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752249|NCT01937052|||COHORT||PROSPECTIVE|||||||
33866458|NCT03589495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33866459|NCT03165435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065657|NCT04626700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179837|NCT02345135|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179838|NCT00811122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179839|NCT02488915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179840|NCT06586463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinding|kinetic control training|t|f|f|t
34179841|NCT02708836|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34179842|NCT06596603|||COHORT||RETROSPECTIVE|||||||
34179843|NCT06500338|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34179844|NCT06486025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179845|NCT04959994|||COHORT||PROSPECTIVE|||||||
34179846|NCT05121064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data manager overseeing data collection and the biostatistician analyzing study outcomes will not be aware of participant study arm until the data are locked for analysis of the primary outcome.|People meeting criteria will be assigned at random to one of 3 study arms.|f|f|t|f
33752250|NCT06722170|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33752251|NCT06597487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752252|NCT06542536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33752253|NCT00695643|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33752254|NCT02855931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752255|NCT01689064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752256|NCT04715568|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All investigators, research staff, and subjects, with the exception of the San Francisco Veteran's Administration (VA) Medical Center Research Pharmacist, will be blinded to the treatment.|Double-blind randomized placebo-controlled crossover clinical trial|t|t|t|t
33752257|NCT04861987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752258|NCT05506787|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33752259|NCT05082038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752260|NCT02626780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752261|NCT06733948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients are randomly assigned in a 1:1 ratio to Arm 1 and Arm 2. A web-based number generator will be used to generate random allocation lists using block sizes n =4 each. The treatment assignation is not masked. Subjects in the intervention group will receive the addition of dental stent to their radical concurrent chemoradiation, while those in the control group will receive radical concurrent chemoradiation with no dental stent. The process is not blinded to patient and investigators.||||
33752262|NCT01394965|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33752263|NCT05682053|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752264|NCT05645328|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33752265|NCT00211705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752266|NCT04235036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752267|NCT06401356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752268|NCT05420103|||COHORT||RETROSPECTIVE|||||||
33752269|NCT03621605|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Investigator and subject are blinded, sponsor and site pharmacist are unblinded.|A minimum of 56 subjects will be enrolled in 7 planned SAD cohorts (8 subjects per cohort). Subjects enrolled in SAD cohorts will be admitted to a Phase 1 unit and randomized to receive a single dose of VIB9600 or placebo administered by slow IV infusion or SC injection. A minimum of 16 subjects will be enrolled in 2 planned MAD cohorts (8 subjects per cohort). Subjects enrolled in the MAD cohorts will receive VIB9600 or placebo Q2W for 4 weeks (3 doses in total: one each on Days 1, 15 and 29).|t|t|t|f
33752270|NCT06733545|||COHORT||PROSPECTIVE|||||||
33752271|NCT03331198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1: subjects will be assigned to receive JCAR017, or JCAR017 + ibrutinib, or JCAR017 + venetoclax Phase 2: subjects will be assigned to receive JCAR017 at the recommended dose||||
33752272|NCT05828979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752273|NCT05304169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752274|NCT05277571|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33752275|NCT01622595|||CASE_ONLY||RETROSPECTIVE|||||||
33752276|NCT06733415|||COHORT||PROSPECTIVE|||||||
34179847|NCT02530515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179848|NCT03645824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866460|NCT01262937|||CASE_ONLY||PROSPECTIVE|||||||
33866461|NCT03483909|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|participants, outcome assessors and raters are blinded. rTMS application is performed by an unblinded investigator|randomized, double-blind, cross-over trial of 3 rTMS protocols|t|t|f|t
33866462|NCT00156351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964029|NCT05134259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964030|NCT06377865|||COHORT||CROSS_SECTIONAL|||||||
33964031|NCT06140615|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964032|NCT01212731|||COHORT||PROSPECTIVE|||||||
33964033|NCT01542736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964034|NCT03533920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065658|NCT04723407|||COHORT||RETROSPECTIVE|||||||
33964035|NCT00039416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179849|NCT03365271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866463|NCT01091688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866464|NCT03561792|RANDOMIZED|PARALLEL||OTHER||SINGLE|The ICU team on charge takes the decision to continue spontaneous breathing trial (SBT) according to the local practice protocols which depends on the traditional RSBI (RSBI \< 105 predicts successful weaning). The ICU team will not be allowed to know the results of diaphragmatic ultrasound.||f|t|f|f
33964036|NCT02729493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964037|NCT01027884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964038|NCT05775263|||COHORT||PROSPECTIVE|||||||
33964039|NCT03483844|||OTHER||PROSPECTIVE|||||||
33964040|NCT01995006|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33964041|NCT06055062|||COHORT||PROSPECTIVE|||||||
33964042|NCT02643966|NA|SINGLE_GROUP||SCREENING||NONE||||||
33964043|NCT05851482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective descriptive study||||
33964044|NCT02898766|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33964045|NCT06412068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964046|NCT00273247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964047|NCT05762510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964048|NCT03177642|||COHORT||PROSPECTIVE|||||||
33964049|NCT02913508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964050|NCT02007746|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33964051|NCT05727280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the randomization process, those who meet the criteria for inclusion in the sample and accept to participate in the study do not know that they will be included in the intervention group or the control group, so it will be single-blind.|The research is a randomized controlled single-blind quasi-experimental research design.|t|f|f|f
33964052|NCT00156286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964053|NCT03398460|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33964054|NCT04202354|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33964055|NCT01154127|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33964056|NCT01256346|||CASE_ONLY||PROSPECTIVE|||||||
33964057|NCT02878811|||COHORT||PROSPECTIVE|||||||
33964058|NCT04934891|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33964059|NCT00251771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964060|NCT00501696|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33964061|NCT00383019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065659|NCT01489059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065660|NCT03983785|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33866465|NCT02818166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33866466|NCT06227364|||COHORT||OTHER|||||||
33866467|NCT00391664|||||PROSPECTIVE|||||||
33866468|NCT06426485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866469|NCT03611621|||COHORT||PROSPECTIVE|||||||
33866470|NCT02448225|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964062|NCT04121299|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33964063|NCT05143086|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||A randomized, triple-blind crossover clinical trial study was performed to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of mouthwash with experimental fluoride for one week, with wash-out periods between them|t|t|t|f
33964064|NCT00438958|RANDOMIZED|||TREATMENT||||||||
33964065|NCT02156518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33964066|NCT03365219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964067|NCT03880331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded investigator will assess photographs of completely healed wounds|Randomized controlled trial|f|f|f|t
33964068|NCT06267677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964069|NCT03470909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964070|NCT04923269|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33964071|NCT05540977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964072|NCT01406275|||OTHER||PROSPECTIVE|||||||
33964073|NCT00047242||||TREATMENT||||||||
33964074|NCT00211666|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964075|NCT03576430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||RCT, 1:1 inclusion active:control|t|f|t|t
33964076|NCT01977352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33964077|NCT05103397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964078|NCT05861440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964079|NCT02648399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33964080|NCT03303300|||COHORT||PROSPECTIVE|||||||
33964081|NCT06539455|||CASE_CONTROL||RETROSPECTIVE|||||||
33964082|NCT01972542|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34065661|NCT05271123|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065662|NCT06455696|||COHORT||PROSPECTIVE|||||||
34065663|NCT04558489|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will use an open trial design, where all participants will receive the Growth Mindset Intervention.||||
34179850|NCT06655168|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179851|NCT06585813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34179852|NCT06586359|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866471|NCT03901573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065664|NCT02613611|||CASE_ONLY||PROSPECTIVE|||||||
34065665|NCT01064635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065666|NCT02994641|||COHORT||PROSPECTIVE|||||||
34065667|NCT05538923|||CASE_CONTROL||PROSPECTIVE|||||||
34065668|NCT00120341|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34065669|NCT05857332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065670|NCT01490307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179853|NCT06587594|NA|SINGLE_GROUP||TREATMENT||NONE||One group pre and post-test design||||
34179854|NCT03379181|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34179855|NCT03931941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179856|NCT00517387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34179857|NCT04968002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179858|NCT06588465|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34179859|NCT06559683|||COHORT||PROSPECTIVE|||||||
34179860|NCT03040492|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34179861|NCT00344409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34179862|NCT01099267|||OTHER||RETROSPECTIVE|||||||
34179863|NCT01456884|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34179864|NCT05163080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|This is a prospective, randomized, placebo-controlled, multi-center study of patients with newly diagnosed Glioblastoma (nGBM)to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide given together with locally administered sargramostim plus adjuvant oral temozolomide (Arm A) versus saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide (Arm B)|t|t|t|f
34179865|NCT04633265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179866|NCT05534165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical placebo|Randomized 1:1|t|t|t|t
33866472|NCT01086410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866473|NCT03914404|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33866474|NCT01585948|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866475|NCT06170905|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Each participant will undergo two oral glucose tolerance tests (i) one with whey protein pre-load and (ii) one without, in a randomized order.|f|f|f|t
33866476|NCT05198336|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866477|NCT03311451|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with previously untreated (by means of ablation therapy) flat type Barrett's Esophagus (BE) (extent BE ≤C3 and ≥M1) with Low-Grade Dysplasia (LGD) or High-Grade Dysplasia (HGD), or residual BE after endoscopic resection of dysplasia or early adenocarcinoma.||||
33866478|NCT02756351|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33866479|NCT04727203|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There are 6 groups in this intervention||||
33866480|NCT06061679|NA|SINGLE_GROUP||OTHER||NONE||Open, single-arm, real-life, prospective study||||
33866481|NCT05876091|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34179867|NCT06601205|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The drugs and placebo were purchased through the Galliera Hospital Pharmacy, encapsulated to preserve blinding, then packaged and labelled for the study under GMP.|The study was a prospective, randomized, phase IIB, placebo controlled, double-blind, pre-surgical trial of Finasteride 5 mg day versus Flutamide 250 mg day versus placebo in men with PCa. Patients with a biopsy proven, clinically intracapsular prostate cancer who were candidate to radical retropubic prostatectomy were enrolled in four different institutions in Northern Italy. Different biopsy criteria according to each contributing centre were acceptable provided that a minimum of 8 cores were evaluable. Patients were randomized to receive either flutamide, 250 mg/day orally, or finasteride, 5 mg/day orally, or oral placebo in a double-blind manner beginning 4 to 6 weeks before surgery.|t|t|t|t
34179868|NCT06590766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179869|NCT04486768|||FAMILY_BASED||PROSPECTIVE|||||||
34179870|NCT03682419|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||A performance evaluation study.||||
34179871|NCT00150085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179872|NCT05447052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179873|NCT03814603|||COHORT||PROSPECTIVE|||||||
34179874|NCT05893888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1/2, Open-Label, Single-Arm||||
34179875|NCT05154786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179876|NCT03198715|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34179877|NCT06188637|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 2-center prospective open-label study with an 11 week follow-up period and extra disease activity check at week 26.||||
34179878|NCT03264326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant blinded to group assignment, assessor blinded to group assignment, investigator blinded to analysis.||t|f|f|t
34179879|NCT06340802|NA|SINGLE_GROUP||OTHER||NONE||||||
34179880|NCT03255122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators masked to each participating family's treatment condition will perform all structured diagnostic interviews and generate responder status data|Families are randomly designed to receive either immediate treatment (I-CALM) or waitlist and then I-CALM|f|f|f|t
34179881|NCT02835378|||COHORT||PROSPECTIVE|||||||
34179882|NCT05803252|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded|Assigned by the investigator but not randomized|f|f|f|t
34179883|NCT05156567|||COHORT||PROSPECTIVE|||||||
34179884|NCT03460795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179885|NCT06597305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179886|NCT06590129|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, longitudinal, randomized clinical study, including 50 patients diagnosed with CTS. Two groups were compared: one received physical therapy and the other received median nerve ultrasound guided hydrodissection plus physiotherapy evaluated initially, 4 and 12 weeks with the Boston questionnaire and the Visual Analogue Scale (VAS).||||
34179887|NCT05964218|NA|SINGLE_GROUP||OTHER||NONE||One-group pilot study with baseline assessment (T1) only.||||
34179888|NCT05388110|||COHORT||PROSPECTIVE|||||||
34179889|NCT05740254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34179890|NCT06589180|||COHORT||RETROSPECTIVE|||||||
34179891|NCT04335006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179892|NCT06591247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179893|NCT00393159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179894|NCT04901793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A non-blinded computer-randomized prospective trial with two parallel study groups.||||
34179895|NCT04865770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34179896|NCT02940795|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34179897|NCT06600048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179898|NCT06600178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Double Blind, Randomized, single site|t|t|t|t
34179899|NCT03882294|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, care provider, and investigators will be blinded for the treatment assignment. A controller will be recruited to determine the two groups into probiotic and placebo groups.|Randomized , double-blind, placebo-controlled, parallel trial|t|t|t|f
34179900|NCT03476486|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind masking (assessor)|controlled interventional clinical trial|f|f|f|t
34179901|NCT06594276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179902|NCT06598111|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34179903|NCT01084655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179904|NCT02808221|||COHORT||RETROSPECTIVE|||||||
34179905|NCT06281925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179906|NCT06445530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the intervention, blinding of participants or MFeast staff is not possible, but data collectors will be blinded to arm.|The study design is a two parallel-arm pilot randomized controlled trial. The investigators will be applying the principles of a hybrid type 1 implementation-effectiveness randomized controlled trial.|f|f|f|t
34179907|NCT01724346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|||||
34179908|NCT03216525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind design.|This is a prospective, randomized, single-center double blind trial of Alvimopan versus placebo for improving patient outcomes and cost during radical cystectomy and urinary diversion.|t|f|t|f
34179909|NCT06402656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179910|NCT01615484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179911|NCT05512884|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34179912|NCT04779268|||COHORT||PROSPECTIVE|||||||
34179913|NCT05671146|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|knee osteoarthritis||t|f|f|f
34179914|NCT05525325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34179915|NCT03361761|||CASE_ONLY||PROSPECTIVE|||||||
34179916|NCT06594835|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179917|NCT04338594|||COHORT||CROSS_SECTIONAL|||||||
34179918|NCT04733469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34179919|NCT06590103|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179920|NCT06150391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Ophthalmologists at the Pediatric Ophthalmologic Unit (Care Provider and Outcomes Assessor) will decide if volunteers meet inclusion criteria. They will assign the patient to GA or GB. They will be responsible for final and after treatment visual evaluations.~The Quality Service of the Merida Hospital (Investigator) will randomize GA and GB volunteers into treatment or control subgroups. This service will be responsible for the custody of documentation and the statistical final analysis.~Visionary team (Investigator) will communicate the patient about the treatment (occlusion or Visionary software, or both).~Optometrists at the Pediatric Ophthalmologic Unit (Outcomes Assessor) will oversee BCVA and stereoacuity measurements during treatment."|"Participants will be divided in two groups: GA, 60 participants without previous occlusion treatment; GB, 60 participants with previous occlusion or penalization.~In GA, participants will be assigned to an Experimental subgroup (GA-E) or to a Control subgroup (GA-C). GA-E volunteers will be prescribed computer-based exercises (Visionary). GA-C patients will be prescribed occlusion.~In GB, all participants will receive occlusion. There will be two subgroups, Experimental (GB-E) and Control (GB-C), and both will be prescribed exercises using Visionary. In GB-E the computer will adjust Gabor patches frequency to visual acuity, as normal; but in GB-C Gabor frequencies will always be low.~Importantly, those patients with deviations (10 to 25 prismatic diopters) will be assigned to experimental or treatment subgroups following an independent randomization."|t|t|f|t
33866482|NCT01925898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179921|NCT01981408|NA|SINGLE_GROUP||||NONE||||||
34179922|NCT06593223|||CASE_CONTROL||PROSPECTIVE|||||||
33866483|NCT02290626|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33866484|NCT05622825|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients must receive 2 DC/AT hepatic artery infusion and be treated with cryoablation technique.~Phase Ⅰ The first 3 subjects were enrolled by Sequential enrollment. The next subject can be enrolled only after the first subject has completed the return transfusion and the safety assessment (V7). After the sixth subject completes the safety assessment (V7), the next nine subjects can be enrolled in phase IIA of the trial to evaluate the efficacy of the trial. If less than two of the first six subjects have a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 level 3 or higher adverse event related to the test drug Phase Ⅱ Phase IIA to evaluate the efficacy and implementation. However, if two of the first six subjects have a Grade 3 or higher trial drug-related adverse event or one or more deaths, the trial will be terminated immediately and all cell product process-related factors in this trial will be fully investigated."||||
33866485|NCT06494215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|None (Open Label)|All the participants shall be exposed to the same situations (variation of pressure support and inspiratory/expiratory pauses)||||
33866486|NCT02774616|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33866487|NCT00731055|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34179923|NCT03546309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33866488|NCT05320562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179924|NCT04730804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34179925|NCT06375161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179926|NCT04983680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179927|NCT06199843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179928|NCT06084026|||CASE_CONTROL||PROSPECTIVE|||||||
34179929|NCT01131507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179930|NCT02947321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179931|NCT04278599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179932|NCT00500123|||COHORT||PROSPECTIVE|||||||
33866489|NCT04444960|||CASE_ONLY||PROSPECTIVE|||||||
33964083|NCT04680299|||COHORT||PROSPECTIVE|||||||
33964084|NCT04517981|||COHORT||PROSPECTIVE|||||||
33964085|NCT05632003|||COHORT||PROSPECTIVE|||||||
33964086|NCT00193570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964087|NCT04630366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964088|NCT00127348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964089|NCT05741268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33964090|NCT00819026|||||CROSS_SECTIONAL|||||||
33866490|NCT05199675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Using a hybrid type III trial with a cluster randomized design, a total of 100 Singaporean students from 4 classes in a high school will be randomly allocated to the intervention or wait-list control arm. The intervention arm will undergo bite size modules on the four active ingredients of youth mental well-being-specifically, Mattering, selfhood, compassion and mindfulness, which will be delivered through training workshops, simulation activities, and homework assignments. Students in the wait-list control arm will receive the the training program after the conclusion of the trial with the intervention arm. The pre-post with control evaluation design will be utilized to evaluate program outcomes.||||
33866491|NCT04983368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study treatment is blinded for participants, investigators.|Volunteer subjects will be randomly assigned to 1 of 3 treatment groups to receive either 5 mg Xanamem®, 10 mg Xanamem® or placebo in the ratio of 1:1:1 with approximately 35 subjects in each treatment group. This sample size has been selected to allow for approximately 30 subjects per treatment group to complete the study.|t|f|t|t
33866492|NCT02937025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866493|NCT03975270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866494|NCT02749032|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33866495|NCT03342313|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Randomized cross-over design||||
33866496|NCT02739620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33866497|NCT01727765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866498|NCT04869163|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33866499|NCT04673591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo-controlled|t|f|t|f
33866500|NCT03122496|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study evaluating durvalumab (MEDI4736) and tremelimumab in combination with standard-of-care stereotactic body radiotherapy (SBRT) in patients with metastatic anaplastic thyroid cancer.||||
33866501|NCT02879604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866502|NCT01821833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33866503|NCT04495855|||COHORT||PROSPECTIVE|||||||
33866504|NCT03685864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33866505|NCT01440842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866506|NCT03109158|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
33866507|NCT05803304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33964091|NCT00051636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964092|NCT05576909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964093|NCT02266966|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33964094|NCT02983526||PARALLEL||TREATMENT||NONE||||||
33964095|NCT01334736|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33964096|NCT03182686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964097|NCT04499235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964098|NCT05966636|NA|SINGLE_GROUP||TREATMENT||NONE|Study statistician will be masked|The investigators will perform pre and post assessment of laser treatment techniques to improve scar mobility and skin health in a pilot sample of individuals with lower extremity limb loss who use artificial limbs for mobility.||||
33964099|NCT06118671|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33752277|NCT06731881|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomised, interventional proof of concept pilot trial in which patients undergoing nasal surgery will be selected for either photodisinfection therapy with the Steriwave™ ND System, or control with nares swabbed with 'photosensitizer formulation' (0.01% methylene blue with 0.25% chlorhexidine solution) prior to surgery||||
33866508|NCT06127927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866509|NCT00715195|RANDOMIZED|PARALLEL||||NONE||||||
33866510|NCT02018406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866511|NCT01974089|||COHORT||PROSPECTIVE|||||||
33866512|NCT01518283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866513|NCT06490393|||CASE_CROSSOVER||PROSPECTIVE|||||||
33866514|NCT02218242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866515|NCT04353596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|unmasked|open-label, randomized design|f|f|f|t
33866516|NCT02523118|||CASE_ONLY||OTHER|||||||
33964100|NCT02260141|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study using ribose for alzheimers||||
33964101|NCT00833547|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33964102|NCT01168700|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33964103|NCT04947020|||COHORT||RETROSPECTIVE|||||||
33964104|NCT05259228|||OTHER||PROSPECTIVE|||||||
33964105|NCT02067715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33964106|NCT05465707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179933|NCT06065670|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"This is a 6-month randomized double-blinded, placebo-controlled, delayed treatment study examining clemastine fumarate as a remyelinating agent in participants with multiple sclerosis. This trial will include n = 44 patients with a confirmed diagnosis of acute demyelinating lesions.~Patients who fulfill the enrollment criteria will be randomly assigned (1:1) via block randomization using a random number generator to receive either clemastine for 90 days followed by placebo for 90 days (Clemastine 12 mg for 14 days, clemastine 8 mg for 76 days, then Placebo) or placebo for 90 days followed by clemastine for 90 days (Placebo, then Clemastine 12 mg for 14 days, the clemastine 8 mg for 76 days).~If they are on one, patients will be permitted to remain on their standard disease-modifying treatment during the course of the study. These therapies have no identified effect on remyelination."|t|t|t|t
34179934|NCT02242604|||CASE_ONLY||PROSPECTIVE|||||||
34179935|NCT05544019|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34179936|NCT03549936|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Infants who develop NAS will continue to receive blinded formula as part of non-pharmacological treatment and will also receive pharmacological treatment (morphine/methadone) as per hospital guidelines directed by their medical care providers. Pharmacological treatment will be optimized and weaned as per standard hospital guidelines. Use of blinded formula A or B will be continued until 2 weeks of age at which point its use as study intervention will be completed. After this point, parents/home care providers and medical care providers may use formula of their preference. However we will offer them a choice of continuing the blinded formula until the infant is discharged at which point standard formula will have to be initiated. General clinical data will be collected at discharge including length of stay and weight.|Randomized Double Blind Clinical trial on Role of Low Lactose Formula In the Management of Neonatal Abstinence Syndrome|t|t|t|t
34179937|NCT05759026|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34179938|NCT00003475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179939|NCT01630369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752278|NCT04594031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752279|NCT01177904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752280|NCT06722846|||COHORT||PROSPECTIVE|||||||
33866517|NCT02217436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866518|NCT03008954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866519|NCT01191866|||COHORT||PROSPECTIVE|||||||
33866520|NCT00670501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866521|NCT00636467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866522|NCT00833144|||CASE_CONTROL||PROSPECTIVE|||||||
33866523|NCT01865526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866524|NCT04680728|||COHORT||PROSPECTIVE|||||||
33893893|NCT06273163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Complete masking is not feasible given the nature of the interventions - the program coordinator and participants will know if the participant receives home delivered medically tailored meals, a smart device application subscription, or usual care. The care provider will not be told the participants group assignment, but the participant may reveal it themselves in discussions with the provider.|Randomized repeated measures between-subjects design|f|t|t|t
33964107|NCT00344305|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964108|NCT00827359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964109|NCT01779908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33964110|NCT00238056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964111|NCT05320614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33964112|NCT03061279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964113|NCT00690768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964114|NCT00240305|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33964115|NCT01159119|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33964116|NCT02766088|NA|SINGLE_GROUP||OTHER||NONE||||||
33964117|NCT01548183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33964118|NCT00701519|||CASE_ONLY||RETROSPECTIVE|||||||
33964119|NCT00095095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33964120|NCT00935896|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33964121|NCT01952639|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964122|NCT02214498|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33964123|NCT01105260|||COHORT||PROSPECTIVE|||||||
33964124|NCT05508074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study double-blind.|Patients will be randomised in a 2:1 allocation ratio to receive either IFB-088 + riluzole 100 mg or placebo + riluzole 100 mg.|t|f|t|f
33964125|NCT03250065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964126|NCT01120600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964127|NCT04681222|||CASE_CONTROL||RETROSPECTIVE|||||||
33964128|NCT02495870|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33964129|NCT05698420|||COHORT||PROSPECTIVE|||||||
33964130|NCT05416359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964131|NCT05040815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964132|NCT05186922|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33964133|NCT02341963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964134|NCT03568526|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33964135|NCT00553748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964136|NCT02919982|||COHORT||PROSPECTIVE|||||||
33964137|NCT04073693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964138|NCT03523013|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33964139|NCT05906498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964140|NCT06543212|||COHORT||PROSPECTIVE|||||||
33964141|NCT01147016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964142|NCT01824108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964143|NCT01845701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33964144|NCT05799378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964145|NCT03744988|||COHORT||PROSPECTIVE|||||||
33964146|NCT02780921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964147|NCT06545526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752281|NCT05110742|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866525|NCT04714736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Patients will be then randomized into 2 groups: 1) DyeVert group, and 2) Control group.~DyeVert group: injection will be handled by the DyeVert system. Control group: injection will be carried out by manual injection syringe. Patients don't know the arm in which they are assigned."|Patients included into the study will be treated according to the following strategy. Patients will receive intravenous 0.9% sodium chloride as soon as in the catheterization laboratory. The hydration regimen will be defined according to the hemodynamic conditions, as defined below. The patients will be then randomized into two groups: 1) DyeVert group, and 2) Control group.|t|f|f|f
33866526|NCT00048620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866527|NCT01486797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866528|NCT01338623|RANDOMIZED|CROSSOVER||||NONE||||||
34179940|NCT05879354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group will apply the Active Cycle of Breathing Techniques with video twice a day for 28 days and the control group will not.||||
33866529|NCT04248582|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33866530|NCT04977102|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33866531|NCT03332329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866532|NCT06401122|||COHORT||CROSS_SECTIONAL|||||||
33866533|NCT01881893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866534|NCT01034592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866535|NCT00006345||||SUPPORTIVE_CARE||||||||
33866536|NCT02423304|||COHORT||CROSS_SECTIONAL|||||||
33866537|NCT03042182|NA|SINGLE_GROUP||TREATMENT||NONE||one arm open label study to last 2 months||||
33866538|NCT05183113|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33866539|NCT00605592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866540|NCT01739569|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33866541|NCT01519765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866542|NCT01085786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964148|NCT00640822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33964149|NCT05407337|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34179941|NCT05823480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179942|NCT06604013|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34179943|NCT04764799|||COHORT||PROSPECTIVE|||||||
34179944|NCT00015210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179945|NCT05075980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179946|NCT00136396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179947|NCT04712682|||CASE_ONLY||CROSS_SECTIONAL|||||||
34179948|NCT03745014|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34179949|NCT06603870|NA|SINGLE_GROUP||TREATMENT||NONE||Apixaban 2.5 mg twice daily||||
34179950|NCT03536156|||OTHER||PROSPECTIVE|||||||
34179951|NCT05023551|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a Phase 1 dose-escalation study with a Part 2 expansion to evaluate the safety, PK, PD, and preliminary antitumor activity of orally administered DSP 0390 in patients with recurrent high-grade glioma. Patients in this study will receive DSP-0390 orally once daily. The study will be divided into 28-day cycles for safety and response assessments. Patients will continue treatment until progression of disease, unacceptable toxicity, withdrawal of consent, loss to follow-up, or discontinuation of the patient by the investigator.~Dose-escalation will evaluate increasing dose levels of DSP-0390 to determine the MTD and/or a suitable lower dose for expansion (the RDE) in patients with recurrent WHO Grade III or IV malignant glioma. Once the MTD and/or RDE has been established, the dose escalation (Part 2) will evaluate preliminary clinical activity and the safety and tolerability of DSP-0390 in patients with recurrent WHO Grade 4 glioblastoma multiforme (GBM)."||||
34179952|NCT00359645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34179953|NCT06577610|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34179954|NCT04965818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179955|NCT05697328|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind placebo control|prospective randomized double-blind placebo control study design (enrollment ratio 1:1)|t|t|t|t
34179956|NCT01412502|||COHORT||PROSPECTIVE|||||||
34179957|NCT00992108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34179958|NCT05024539|||COHORT||RETROSPECTIVE|||||||
34179959|NCT06474026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866543|NCT00432536|||COHORT||PROSPECTIVE|||||||
33893894|NCT05829057|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arms and Interventions： Experimental: Arm of P-IL-2 Based on platelet count： Cohort 1：8×10\^9 PLT； Cohort 2：2.5×10\^10 PLT； Cohort 3：8×10\^10 PLT； Cohort 4：2.5×10\^11 PLT/kg BW； Experimental: P-IL-2 plus Anti-PD-1 Monoclonal Antibody||||
33964150|NCT02033577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34179960|NCT05479877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34179961|NCT06585917|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study uses a Parallel Assignment model, where participants are randomly assigned to one of two groups: the 7F sheath intervention group or the 6F sheath control group. Each group will receive a different size sheath for coronary intervention via distal radial artery access. The study is designed to compare the outcomes between these two groups, with no crossover between groups during the trial. This model allows for a direct comparison of the efficacy and safety between the two sheath sizes under similar clinical conditions.||||
34179962|NCT00471939|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34179963|NCT06503874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"First, participants will complete the pre-treatment assessment. Participants then will be randomized to either immediate APT-3 group, delayed APT or Music activity group.~The interventions (APT-3 or Music activity) will last 4 weeks. At the end of the intervention participants will undergo another assessment battery, and once again at 1-month post intervention follow-up.~Following the maintenance assessment, participants from the Music activity group will have the option to receive the APT-3 intervention. If they accept, they will undergo another assessment battery at the end of the 4-week intervention.~Participants from the delayed APT-3 group will undergo the week 5 assessment and will then be offered to enroll in the APT-3 training. If they accept, they will undergo another assessment battery at the end of the 4-week intervention."|f|f|f|t
34179964|NCT01773044|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34179965|NCT05371626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179966|NCT03850756|||CASE_CONTROL||PROSPECTIVE|||||||
33893895|NCT04982133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33893896|NCT04549987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention was randomly allocated to either the right or left side using the permuted random block size of 2 with 1:1 allocation ratio. The random sequences for each intervention to either right or left sides was concealed in opaque envelopes and shuffled before the intervention to increase the unpredictability of the random allocation sequence. Each patient was asked to pick a sealed envelope to assign the intervention to either the right or left side. Allocation concealment was aimed to prevent selection bias and to protect the assignment sequence until allocation.|Working archwire status|t|f|f|t
33893897|NCT03451929|||COHORT||PROSPECTIVE|||||||
33964151|NCT05350982|||COHORT||PROSPECTIVE|||||||
34179967|NCT05743491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065671|NCT00533559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34065672|NCT04467710|||CASE_CONTROL||RETROSPECTIVE|||||||
34065673|NCT02452554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179968|NCT03521128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179969|NCT02403128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179970|NCT06603454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179971|NCT01995708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179972|NCT03010449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34179973|NCT06590597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179974|NCT04407754|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34179975|NCT01185236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179976|NCT05933317|||COHORT||PROSPECTIVE|||||||
34179977|NCT05170919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179978|NCT01891253|||COHORT||PROSPECTIVE|||||||
34179979|NCT00460876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065674|NCT03274362|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is a prospective, randomized, non-blinded comparative group clinical trial.|The study will use a parallel study model that consists of a treatment arm (ie. Headspace mindfulness app group) and a control arm (ie. standard care where patients receive a list of resources on mindfulness and health).||||
34065675|NCT04810559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Subject enrollment is by unblinded staff and testing is by blinded healthcare providers|Cross-sectional, prospective, field trial (near patient study)||||
34065676|NCT04103515|||COHORT||RETROSPECTIVE|||||||
34179980|NCT00283296|NA|SINGLE_GROUP||||NONE||||||
34179981|NCT04217525|||COHORT||PROSPECTIVE|||||||
34179982|NCT00551642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34179983|NCT06586177|||COHORT||PROSPECTIVE|||||||
34179984|NCT00524511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179985|NCT05130528|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34179986|NCT02998463|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065677|NCT04176081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065678|NCT04186897|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34065679|NCT00624039|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34065680|NCT03593187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065681|NCT03948763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065682|NCT05090306|||COHORT||PROSPECTIVE|||||||
34065683|NCT05588999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179987|NCT01318577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34179988|NCT05127954|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34179989|NCT05329948|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34179990|NCT05342155|||CASE_CONTROL||PROSPECTIVE|||||||
34179991|NCT05689372|||COHORT||PROSPECTIVE|||||||
34179992|NCT04951921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34179993|NCT00433173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34179994|NCT06591585|||COHORT||RETROSPECTIVE|||||||
34179995|NCT00131222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34179996|NCT06591000|||CASE_CONTROL||RETROSPECTIVE|||||||
34179997|NCT05030337|RANDOMIZED|PARALLEL||OTHER||NONE||Participating infants will be randomised either to manual oxygen control or closed-loop automated oxygen control, adjusted by clinical staff as necessary.||||
34179998|NCT04567628|||COHORT||RETROSPECTIVE|||||||
33893898|NCT05204563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893899|NCT02568436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893900|NCT05679882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34179999|NCT05845060|||OTHER||PROSPECTIVE|||||||
34180000|NCT05666739|||OTHER||OTHER|||||||
33866544|NCT04582942|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The allocation assignment of patients was performed by a designated technician at each center based on a computer-generated random sequence. The designated technician was not involved in the colonoscopy procedure.|Patients scheduled for colonoscopy were stratified into low- and high-risk patients based on the inclusion criteria. Low- and high-risk patients were randomized to the PEG alone or lactulose combined with PEG group respectively.|f|f|t|f
33866545|NCT01936909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866546|NCT00572962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866547|NCT03773198|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964152|NCT01731860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964153|NCT02766400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964154|NCT01001715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964155|NCT03429374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients are randomly allocated to group 1 or group 2:~* Group 1: Mesh fixation with tacks.~* Group 2: Mesh fixation with glue."|t|f|f|f
33964156|NCT03799874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study drug will be blinded to the study staff using identical tanks containing either CO or placebo air. The administering respiratory therapist (RT) and a physician study staff member will be unblinded to the treatment assignments.||t|t|f|f
33964157|NCT06160882|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"The primary endpoint will be to evaluate the functional, biomechanical, metabolic outcomes, and user satisfaction while using a powered prosthesis suspended by an OI interface compared to their prescribed traditional socket~The secondary endpoint will be to determine changes in EMG signal quality and neural information resulting from OI and TMR as compared to an instrumented socket for control of a powered leg prosthesis."||||
33964158|NCT05680311|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33964159|NCT03552679|||CASE_ONLY||PROSPECTIVE|||||||
33964160|NCT02280356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964161|NCT05725564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34180001|NCT03043872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180002|NCT03059134|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|"The study population consisted of male and female outpatients meeting the legal minimum age requirement of the region with symptoms of OAB for more than 3 months. Patient demographics data will be recorded as detailed as possible, including previous urodynamic study results. The study consisted of four arms:~1. Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks~2. Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks~3. Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks~4. Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,"||||
34180003|NCT02516137|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180004|NCT00101179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180005|NCT01550003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180006|NCT00210496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34180007|NCT05585905|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866548|NCT00283049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866549|NCT01329887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866550|NCT00698451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866551|NCT00698997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964162|NCT04904601|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Both the participant and investigator are blinded. Randomization and blinding will be done by a third party.|"Kale (blanched freeze-dried Kale) group 1 (N=50 adult obese Saudi women)~Placebo (Blanched Freeze-dried Peas) group 2 (N=50 adult obese Saudi women)"|t|f|t|f
33964163|NCT06119074|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964164|NCT00990028|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33964165|NCT03724968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964166|NCT01162018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964167|NCT00366678|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964168|NCT03687437|||CASE_ONLY||PROSPECTIVE|||||||
33964169|NCT02071758|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180008|NCT04267354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180009|NCT06597318|||COHORT||PROSPECTIVE|||||||
34180010|NCT02092610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180011|NCT06586853|||COHORT||PROSPECTIVE|||||||
34180012|NCT04953858|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Potential recruiters will be approached in routine adolescent HIV treatment and services and those enrolled will approach peers to become network members who then come in for HIV testing||||
34180013|NCT03377608|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180014|NCT05222334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866552|NCT03662217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866553|NCT01032096|||COHORT||PROSPECTIVE|||||||
33866554|NCT01439217|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180015|NCT03708900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180016|NCT06594003|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34180017|NCT03013998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866555|NCT00441181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866556|NCT02232282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866557|NCT01087957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866558|NCT02443649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866559|NCT01903642|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33866560|NCT04170790||SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Eighteen healthy volunteers will be recruited in Sequential, single center study to determine pharmacokinetic parameters of Saxagliptin, and sildenafil,(AUC0→∞), (AUC0→t); Cmax; tmax; t½, k; ka) will be measured using validated LC-MS/MS method. Therapeutic doses will be given to volunteers as follows: Sildenafil 50 mg single dose on day 1, then washout period from day 2 till day 8. Saxagliptin 5 mg once/day will be given from day 9 till day 12, then on day 13 the two drugs will be co-administered. Blood samples (5ml) for pharmacokinetic analysis will be collected on days 1 and 13 for Sildenafil as well as on days 12 and 13 for Saxagliptin||||
33866561|NCT02855398|||OTHER||CROSS_SECTIONAL|||||||
33866562|NCT02910960|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33866563|NCT02126033||PARALLEL||BASIC_SCIENCE||||||||
33866564|NCT01507779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866565|NCT03143010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33964170|NCT01931137|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964171|NCT05357781|||COHORT||PROSPECTIVE|||||||
33964172|NCT04974359|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33964173|NCT01140620|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33964174|NCT06567587|||OTHER||RETROSPECTIVE|||||||
33964175|NCT02830230|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33964176|NCT02594345|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964177|NCT00524576|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33964178|NCT03764553|RANDOMIZED|PARALLEL||TREATMENT||NONE||phase 2 study||||
33964179|NCT01938885|||CASE_ONLY||RETROSPECTIVE|||||||
33964180|NCT05180344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964181|NCT02424656|||CASE_CONTROL||PROSPECTIVE|||||||
34065684|NCT02516956|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34065685|NCT02327013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065686|NCT05290428|||COHORT||OTHER|||||||
34065687|NCT01865877|||COHORT||PROSPECTIVE|||||||
34180018|NCT06593678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Outcomes Assessor)|Prospective, sigle-blind randomized clinical trial with two parallel interventions|f|f|f|t
34180019|NCT02601846|||COHORT||PROSPECTIVE|||||||
34180020|NCT05324566|||COHORT||PROSPECTIVE|||||||
34180021|NCT03011099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180022|NCT04900324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180023|NCT05050331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180024|NCT05327296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180025|NCT05498571|||COHORT||RETROSPECTIVE|||||||
34180026|NCT06595420|||COHORT||PROSPECTIVE|||||||
34180027|NCT05664737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180028|NCT03518853|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I/II study of radiotherapy fractionation||||
34180029|NCT04495023|||CASE_CONTROL||RETROSPECTIVE|||||||
34180030|NCT03574233|||COHORT||RETROSPECTIVE|||||||
34180031|NCT01825460|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34180032|NCT06597227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180033|NCT06242574|||COHORT||PROSPECTIVE|||||||
33866566|NCT00744211|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33866567|NCT01587339|||||RETROSPECTIVE|||||||
33866568|NCT01069120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866569|NCT05843682|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33866570|NCT03771586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33866571|NCT06490432|||CASE_ONLY||CROSS_SECTIONAL|||||||
33893901|NCT03939208|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants include students, parents, and clinicians. Students and parents are prevented from having knowledge of the interventions assigned. Clinicians are aware of their intervention assignment.||t|f|f|f
33893902|NCT02363829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893903|NCT02844361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065688|NCT00004358||||TREATMENT||||||||
34065689|NCT02188524|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34065690|NCT05290077|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34065691|NCT00642070|||CASE_ONLY||PROSPECTIVE|||||||
34065692|NCT05368922|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|A multi-center randomized controlled trial will be implemented across three different locations. Twenty-two children will be randomly divided into an experimental group that will follow a virtual reality rehabilitation protocol with a pre-test and two post tests and with three weekly sessions for four weeks, and a control group which will only carry out the pre and posttests.||||
34180034|NCT02195518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180035|NCT04911140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Pre and post treatment assessments will be made by three examiners (three plastic surgeons) who will not be aware of the group in which each patient will be allocated. Participants will not be aware of whether or not they have received the application of the FBM, as they will be using ocular sales. The person responsible for the application will position the equipment in the irradiation locations in all participants and will only activate the light when provided for in the specific experimental group. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM.||t|f|f|t
34180036|NCT06593392|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm phase IIb clinical trial||||
33964182|NCT04931147|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Part A \& Part B of the study will assume a double blind design whereby both study participants and investigators will be blinded to active IMP versus placebo assignment. Within each cohort, 4 participants will be randomised to active versus 2 placebo participants.~Part C of the study will assume an open-label design whereby all participants will receive active RXC007.~A designated individual will generate the randomisation code under the guidance of a statistician. All other site and Sponsor personnel involved in the study will be blinded with regards to the IMP being administered. The Pharmacist (or designee) responsible for the preparation of participant doses and emergency code break envelopes will not be blinded."|"This study is a first-in-human, single ascending (SAD) and multiple ascending dose (MAD) study, including the evaluation of drug-drug interactions. Each cohort will adopt a dose leader design with 2 participants being dosed on the first dosing day of each cohort. Of these 2, 1 will be on active drug and 1 on placebo. The remainder of the cohort will be dosed at least 24 h later pending an acceptable safety profile in the dose-leader group and will contain at least 1 additional placebo participant.~In both Part A (SAD) and Part B (MAD), sequential cohorts will be exposed to increasing doses of RXC007. Prior to dose escalation between cohorts, safety and PK data from the previous cohort will be reviewed by the Dose Escalation Review Committee (DERC) to determine whether it is appropriate to proceed to the next cohort/dose level."|t|t|t|t
33964183|NCT03125629|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All participants receive both scans.||||
33964184|NCT04397250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964185|NCT04821492|||COHORT||CROSS_SECTIONAL|||||||
33964186|NCT00120068||||PREVENTION||NONE||||||
33964187|NCT02068404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065693|NCT00926536|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34180037|NCT06269432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34180038|NCT00159393|||COHORT||PROSPECTIVE|||||||
34180039|NCT06589102|||COHORT||RETROSPECTIVE|||||||
34180040|NCT06133179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Proof of concept, exploratory, single group, non-comparative, uncontrolled study||||
34180041|NCT04812210|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180042|NCT03864107|||OTHER||CROSS_SECTIONAL|||||||
34180043|NCT00685412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180044|NCT04672863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180045|NCT01452438|||COHORT||PROSPECTIVE|||||||
34180046|NCT06356454|||COHORT||PROSPECTIVE|||||||
34180047|NCT05427422|||COHORT||PROSPECTIVE|||||||
34180048|NCT03391362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180049|NCT06025032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180050|NCT05826639|||CASE_CONTROL||PROSPECTIVE|||||||
34180051|NCT01490463|||COHORT||PROSPECTIVE|||||||
34180052|NCT06593561|||OTHER||PROSPECTIVE|||||||
34180053|NCT06654167|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34180054|NCT04262388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180055|NCT02574117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964188|NCT06272370|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||patient randomized trial of three different drug combinations||||
33964189|NCT02107937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180056|NCT05975203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention blinding of participant and care provider is not possible. The investigators are part of the care providing team.||f|f|f|t
33866572|NCT06374875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients and investigators will not be blinded to treatment assignment. The treatment assignment will remain unknown until the patient is randomized after meeting all eligibility requirements.~Pathologists who report the liver biopsies (to assess the primary end point of study) are blinded to treatment assignment"|Patients will be randomized in a 1:1 ratio into 1 of the 2 arms using a computer-generated randomization plan, stratified to ensure that there are equal number of patients with/without T2DM and with/without F4 (cirrhosis) according to the baseline liver biopsy in each treatment group (surgical group vs non-surgical group). The participant sites are regrouped into three geographic regions. All patients in each region will be randomized separately to have equal number of patients with/without T2DM and with/without F4 in each treatment group in each region.|f|f|f|t
33866573|NCT00827684||||TREATMENT||||||||
33866574|NCT05030103|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Open, propensity score method||||
33964190|NCT03393169|||COHORT||PROSPECTIVE|||||||
33964191|NCT01255696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964192|NCT02280642|||||PROSPECTIVE|||||||
33964193|NCT00393835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964194|NCT04267016|||COHORT||PROSPECTIVE|||||||
33964195|NCT03522090|||COHORT||RETROSPECTIVE|||||||
33964196|NCT00769782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964197|NCT00646152|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33964198|NCT00878449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964199|NCT00197184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964200|NCT01183845|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964201|NCT00765466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964202|NCT00879424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964203|NCT00191620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964204|NCT02914496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180057|NCT06594874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180058|NCT01682434|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34180059|NCT03481777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant. Outcome assessor.|Prospective, randomized, patient-assessor blinded, sham-controlled trial|t|f|f|t
34180060|NCT06598488|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34180061|NCT01955252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180062|NCT06185816|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34180063|NCT00728689|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34180064|NCT00743834|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34180065|NCT03278275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180066|NCT04643210|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a combination of a qualitative and a quantitative, interventional (quasi experimental) design. A focus group and content analysis will be implemented for the qualitative assessment of the educational needs of adults with a bipolar disorder. The educational intervention (MoB EI) will be developed according to the qualitative data on patients' educational needs and relevant literature, aiming to include combination of face to face (F2F) and technology-based interventions via design of a Digital platform. The effectiveness of the MoB EI regarding the acquired self-management skill will be assessed via structured instruments in the quantitative part of the study using descriptive and inferential statistics (SPSS version 24.0).||||
34180067|NCT05932238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180068|NCT03457896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180069|NCT05309070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind randomized controlled trial|t|t|t|t
34180070|NCT06375551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180071|NCT03820843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind: only the art therapist knows the randomization arm. The investigators involved in the outcomes assessement, will remain blinded with regard to the randomized treatment assignments|The investigators will evaluate the reorganization of functional and structural brain connectivity maps before and after rehabilitation of aphasia with art therapy and standard orthophonic rehabilitation versus a control group that received only standard orthophonic rehabilitation.|f|f|t|t
34180072|NCT05771987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180073|NCT00807508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34180074|NCT00915252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180075|NCT04951947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180076|NCT01783613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180077|NCT06601062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180078|NCT01186289|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34180079|NCT05207488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study is a double-blind, placebo-controlled study.|The study is a randomized, controlled trial with a 6-week intervention period with two groups: 1) Exercise + Prebiotic and 2) Exercise + Placebo.|t|f|t|t
34180080|NCT00967746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34180081|NCT00852683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866575|NCT00024050||||TREATMENT||||||||
33866576|NCT06143150|||COHORT||PROSPECTIVE|||||||
33866577|NCT02941887|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866578|NCT06034535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866579|NCT04596982|||CASE_ONLY||PROSPECTIVE|||||||
33866580|NCT00117507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866581|NCT02934308|NA|SINGLE_GROUP||OTHER||NONE||||||
34180082|NCT06592183|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Due to the interactive nature of rehabilitation, masking the intervention to patients and research investigators is impossible. Therefore, separate outcome assessors will be blinded, who will not be involved in the treatment procedures, to minimize bias.|This is a single-center, investigator-blinded, randomized, crossover effectiveness study. After recruitment, the participants will be randomly assigned to one of two groups: Group 1 will first receive smartphone-based speech therapy and then usual care as a control, whereas Group 2 will be on waitlist control first and then receive speech therapy. In this study, both the objective and subjective measurements will be performed three times: at baseline, post-phase 1 study (week 4), and post-phase 2 study (week 8). The study includes three intervention cycles, and for each research cycle, 12 subjects will be recruited to participate (6 per each group × 3 cycles).|f|f|f|t
33866582|NCT03800888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized using the 1:1:1 allocation ratio to the following arms: 1) Fixed and linked SMS reminders, 2) SMS notifications to social supporters, and 3) no SMS (control). All participants will have adherence monitored in real-time for 6 months.||||
34180083|NCT03085095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180084|NCT06602843|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34180085|NCT01968200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180086|NCT05813236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients and the observers (assessors) will be blinded to the applied suture material.~Patients will not be informed which suture material will be applied. The observers (assessors) who will perform the assessment of the wounds will also be unaware of the applied suture type."|"Patients undergoing resective periodontal surgery will randomly (1:1) receive Novosyn Quick (control group) or Monosyn Quick (treatment group).~Randomization will take place intraoperatively through dynamic allocation with minimisation algorithm to a suture group. Randomization will be stratified by study site."|t|f|f|t
34180087|NCT06592287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180088|NCT05322655|||COHORT||PROSPECTIVE|||||||
34180089|NCT06595537|||CASE_ONLY||PROSPECTIVE|||||||
34180090|NCT02266368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34180091|NCT06442046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180092|NCT05323227|||COHORT||RETROSPECTIVE|||||||
33866583|NCT01473563|NA|SINGLE_GROUP||||NONE||||||
33866584|NCT04747093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866585|NCT05606250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Control group: The subjects will receive physiotherapy treatment and the experimental group will receive combined treatment of physiotherapy and ultrasound-guided percutaneous neuromodulation.|t|f|t|f
33866586|NCT00393809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866587|NCT01401842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33866588|NCT03772470|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized to one of four airtime incentive amounts: 1) no incentive; 2) 1X incentive; 3) 2X incentive or 4) a lottery incentive, in which one out of every 20 participants will receive the incentive. Airtime incentives were sent if participants completed the noncommunicable disease risk factor survey.|f|f|f|t
33866589|NCT03059927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866590|NCT05688462|||COHORT||PROSPECTIVE|||||||
33866591|NCT02794467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866592|NCT00227565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866593|NCT02454335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866594|NCT01101438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866595|NCT02596243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866596|NCT02478905|||COHORT||PROSPECTIVE|||||||
33866597|NCT01422356|||COHORT||PROSPECTIVE|||||||
33866598|NCT01444768|||COHORT||PROSPECTIVE|||||||
33866599|NCT05014334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866600|NCT02320136|||CASE_CONTROL||PROSPECTIVE|||||||
33866601|NCT01848353|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33866602|NCT05322928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866603|NCT02448693|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33866604|NCT04919291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866605|NCT01841190|||COHORT||PROSPECTIVE|||||||
33866606|NCT04062019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866607|NCT02558387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866608|NCT01655329|||CASE_CONTROL||PROSPECTIVE|||||||
34180093|NCT06436131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It was a double-blind study in which neither the participants nor the assessor and the trainer knew who's been assigned to either group.|Subjects were randomized in two groups. Experimental group received an exercise program based on in-phase bilateral exercises, whereas the active control group receives conservative exercises. The duration of the study was 12 consecutive weeks for both groups.|t|t|f|t
33866609|NCT03708120|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There is no blinding employed since the outcome measures are based on tick behaviour.|This is a single group trial with the participants acting as their own controls, one arm will be treated with insect repellent, and the other left untreated.||||
33866610|NCT02700152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866611|NCT01701076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893904|NCT02704962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893905|NCT00942162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893906|NCT05842798|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
33964205|NCT06242873|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34180094|NCT02220920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33964206|NCT05852587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964207|NCT04737915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible participants were randomly assigned to one of three conditions: a) single session virtual reality exposure; b) single session in vivo exposure; c) waitlist control||||
33964208|NCT02686489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180095|NCT05957380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180096|NCT02151058|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34180097|NCT06279234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34180098|NCT03085043|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34180099|NCT06536673|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A retrospective control group with patients starting DP before January 2020 will be included and compared with an intervention group that will systematically include all patients starting DP since the start of the study.||||
34180100|NCT06604351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180101|NCT01085227|||FAMILY_BASED||PROSPECTIVE|||||||
34180102|NCT05609487|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study is structured in three phases: 1) translation and adaptation of the safety plan into French; 2) effectiveness study; and 3) evaluation of the implementation of the safety plan in practice||||
34180103|NCT05162976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180104|NCT05324462|||COHORT||RETROSPECTIVE|||||||
34180105|NCT04223479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180106|NCT05274997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180107|NCT04230629|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination.|t|f|t|f
34180108|NCT00828594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893907|NCT06489288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33893908|NCT01901224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893909|NCT03091023|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33893910|NCT03335501|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33893911|NCT00013052|RANDOMIZED|FACTORIAL||||NONE||||||
33964209|NCT00822861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964210|NCT00561184|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33964211|NCT05496595|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33964212|NCT01283711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964213|NCT05805774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964214|NCT02972970|NA|SINGLE_GROUP||OTHER||NONE||||||
33964215|NCT01533051|||COHORT||PROSPECTIVE|||||||
33964216|NCT00012194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964217|NCT03124797|NA|SINGLE_GROUP||OTHER||NONE||||||
33964218|NCT03264066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964219|NCT03956511|||COHORT||PROSPECTIVE|||||||
33964220|NCT01074307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964221|NCT05525637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964222|NCT04156867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964223|NCT01794156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180109|NCT04862585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180110|NCT06603779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|f|t
34180111|NCT06591962|||COHORT||PROSPECTIVE|||||||
34180112|NCT03842527|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
34180113|NCT00570986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180114|NCT05657002|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|"Participant will be blinded, they do not know in what group they belong (thus which record they receive with the accurate or inaccurate problem list) and the participants are not informed that impact of problem list accuracy is investigated.~An independent researcher produced a randomization schema where per block of 10 participants a balanced random order of patient A with accurate problem list + patient B with inaccurate problem list or patient A with inaccurate problem list + patient B with accurate problem list is produced. The investigator (ESK) follows this list for the consecutive participants and gives access to the appropriate patient records as defined by the randomisation schema. The independent researcher checks afterwards whether the right order is followed based on time stamps and randomisation schema.~We performed a power analysis before conducting any experiment, which resulted in a required number of 157 participants."|Participants will be presented with 2 patient records in EPIC, one with an accurate problem list and the other that conveys the complete information in the patient record (in free text notes) but with an inaccurate problem list with missing diagnoses and duplicates. Each participant answers a total of 4 questions for 2 separate patient cases (2 questions per case), one of those cases having the inaccurate and the other having the accurate problem list. Using 2 separate patient cases rather than one was decided to prevent a memory effect, i.e., participants would have had time to understand the patient's conditions described in the record which could impact the time required to answer questions in round 2. Additionally, the order in which patients cases are provided is not randomized, since in practice it also happens that a new patient is followed up by another new patient which requires professionals to systematically go through two separate records with little time in between.|t|f|f|f
34180115|NCT05839964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180116|NCT03149562|||COHORT||PROSPECTIVE|||||||
34180117|NCT06210568|||CASE_CONTROL||PROSPECTIVE|||||||
34180118|NCT02946723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180119|NCT05742685|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34180120|NCT00914849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180121|NCT04222309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866612|NCT06493539|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intervention~Following amputation, at POD 1, CiNPWT will be applied in an envelope-like fashion, incorporating the incison line as well as \~10 cm of intact proximal residual limb tissue. The underlying skin will be protected with a contact layer and the negative pressure foam is applied for maximal surface area coverage. Negative pressure parameters are set to dynamic pressure control therapy (DPC) from -25 mmHg to -125 mmHg with a 2 minute on/2 minute off cycle and the dressing is left in place for three to five days.~A patient may always be removed from treatment intervention whenever they wish.~Control~Following amputation, at POD 1, application of standard care (short stretch compression bandages and standard post-operative wound care) daily."||||
33866613|NCT06150573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866614|NCT06474975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866615|NCT00761852|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33866616|NCT01812889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866617|NCT01591967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866618|NCT01017367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964224|NCT00493181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964225|NCT05103085|||OTHER||CROSS_SECTIONAL|||||||
33964226|NCT00907465|||COHORT||PROSPECTIVE|||||||
33964227|NCT02917837|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33964228|NCT02932384|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964229|NCT01422720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964230|NCT00123331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964231|NCT06542094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964232|NCT00148928|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33964233|NCT00503932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964234|NCT05262933|||CASE_CONTROL||PROSPECTIVE|||||||
33964235|NCT04739956|||COHORT||PROSPECTIVE|||||||
33866619|NCT01295476|||COHORT||PROSPECTIVE|||||||
33866620|NCT01864187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866621|NCT03654976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Parallel-group|t|t|t|t
33866622|NCT00295633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866623|NCT03809455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"A phase II, prospective, multicentre, single-blinded, randomised study (when fentanyl citrate is used outside of its marketing authorisation) Patients will be enrolled in an observational cohort when the fentanyl citrate is used according to its marketing authorisation.~The study will randomise patients (2:1; FAR Arm: Placebo Arm)~Stratified by:~* Centre~* Type of examination: diagnostic (PET-CT scan or SPECT-CT scan) versus therapeutic (radiotherapy, tomotherapy, or dosimetric scanner)"|t|t|t|f
33866624|NCT04275141|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Case control study||||
33964236|NCT00457665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866625|NCT00075595||||TREATMENT||NONE||||||
33964237|NCT04147611|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964238|NCT03179371|||OTHER||PROSPECTIVE|||||||
33964239|NCT00123487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964240|NCT01132235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964241|NCT02543086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752282|NCT04499092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Caregivers of participants are blinded to treatment allocation.|"The study will have the following steps:~* Adaptation/preliminary validation of the CRS-R for the Italian context (typically developing children, healthy volunteers) (N=64)~* Preliminary validation of the CRS-R in a sample of Italian patients with disorder of consciousness (N=80)~* Evaluation and comparison of the efficacy of two multidomain neuropsychological treatments (CORE-ABI vs SET-ABI) in children emerged from a disorder of consciousness (N=40; sample size determined through power-analysis)"|t|f|f|t
33866626|NCT00563628|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866627|NCT05169684|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33964242|NCT01386619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964243|NCT02869828|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33964244|NCT05506475|||COHORT||PROSPECTIVE|||||||
33964245|NCT03174041|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33964246|NCT02120482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964247|NCT02097368|||OTHER||PROSPECTIVE|||||||
33964248|NCT01770782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964249|NCT02007369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964250|NCT03726437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were told that study was to determine efficacy of a web-based health promotion program for female freshmen.||t|f|f|t
33964251|NCT01800669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34180122|NCT05801120|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34180123|NCT01635166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180124|NCT04856046|||COHORT||PROSPECTIVE|||||||
34180125|NCT04895839|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34180126|NCT05440942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation/de-escalation and dose expansion design.||||
33752283|NCT06665386|||COHORT||RETROSPECTIVE|||||||
33964252|NCT03449615|||CASE_ONLY||PROSPECTIVE|||||||
33964253|NCT02902666|RANDOMIZED|CROSSOVER||||NONE||||||
33964254|NCT00881049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964255|NCT00351728|||COHORT||PROSPECTIVE|||||||
33964256|NCT00196443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33964257|NCT05617573|||COHORT||PROSPECTIVE|||||||
33964258|NCT05474261|||CASE_CONTROL||RETROSPECTIVE|||||||
33964259|NCT03648086|RANDOMIZED|PARALLEL||TREATMENT||NONE||an open label, parallel study||||
34180127|NCT05778604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At all follow-up outcome points, the accessor will be blind to the study arm each participant was randomized to.|We will employ an intention-to-treat, single- blinded, parallel, two-arm clustered randomized controlled trial (RCT).|f|f|f|t
34180128|NCT03136744|NA|SINGLE_GROUP||OTHER||NONE||||||
34180129|NCT06588231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180130|NCT05515965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding was ensured by patients and rheumatologist were unaware the type of physiotherapy treatment application||t|f|f|t
34180131|NCT00723736|||COHORT||PROSPECTIVE|||||||
34180132|NCT02234167|NA|||PREVENTION||||||||
33752284|NCT06733077|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study (before and after)||||
33752285|NCT06733428|||COHORT||PROSPECTIVE|||||||
33866628|NCT02146599|||CASE_ONLY||PROSPECTIVE|||||||
33866629|NCT01010633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866630|NCT00141895|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866631|NCT04422548|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33866632|NCT02794077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866633|NCT02091154|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
33866634|NCT00578136|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33866635|NCT03808389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||40 patients with Parkinson's disease (Hoehn \& Yahr score 2-3) will be randomly allocated (20 vs. 20) to either fecal microbiota transplantation with donor stool or autologous fecal microbiota transplantation (= own stool).|t|t|t|t
33866636|NCT04967222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866637|NCT00714467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866638|NCT00234507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866639|NCT05546450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866640|NCT05075837|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, open-label, single-arm, non-randomized study, monocentric.||||
33866641|NCT00036439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866642|NCT00938717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866643|NCT05188820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Study Design: Triple-blinded randomized controlled trial Patient Sample: Fifty participants with radiological signs of osteoarthritis and Z-Joint LBP confirmed by dual intra-articular local anesthetic injections will be recruited and randomized in two groups: CS and LP-PRP injection groups.|t|t|t|t
33866644|NCT02596620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33866645|NCT02463071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866646|NCT06388304|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33866647|NCT00332839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866648|NCT02980120|||CASE_CONTROL||PROSPECTIVE|||||||
33866649|NCT04042870|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre / Post Single Control||||
33866650|NCT02626481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866651|NCT02851420|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866652|NCT05982899|||COHORT||PROSPECTIVE|||||||
33964260|NCT03912688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Interventions were performed by a designated investigator who was not involved in the anaesthesia or the follow-up. The stimulator was placed in an opaque box to blind the surgical team and the anesthesiologists to the group allocation.||f|t|t|t
33964261|NCT01774695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964262|NCT02184507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33964263|NCT06514924|||COHORT||CROSS_SECTIONAL|||||||
33964264|NCT01521767|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34065694|NCT03419130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065695|NCT03213925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065696|NCT06445582|||COHORT||PROSPECTIVE|||||||
34065697|NCT01472978|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34065698|NCT02585687|NA|SINGLE_GROUP||SCREENING||NONE||||||
34065699|NCT04509817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be masked.||f|f|f|t
34180133|NCT00217399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180134|NCT06207461|||COHORT||PROSPECTIVE|||||||
34180135|NCT03404193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180136|NCT01089101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752286|NCT06506435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866653|NCT04354220|||COHORT||PROSPECTIVE|||||||
33866654|NCT00237822|RANDOMIZED|PARALLEL||OTHER||SINGLE||||||
33866655|NCT05080699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065700|NCT05777564|NA|SINGLE_GROUP||TREATMENT||NONE||prospective study design||||
34065701|NCT01303614|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180137|NCT06601049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180138|NCT03840018|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34180139|NCT04842175|||OTHER||PROSPECTIVE|||||||
34180140|NCT06287294|||COHORT||PROSPECTIVE|||||||
34180141|NCT02454088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180142|NCT02786017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180143|NCT00630838|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180144|NCT00389610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065702|NCT04126317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-masked: The patients, visual acuity examiners, imaging technicians and reading center will be masked to treatment assignment.||t|f|f|f
34065703|NCT02971618|||CASE_CONTROL||RETROSPECTIVE|||||||
34180145|NCT05931419|||COHORT||PROSPECTIVE|||||||
34180146|NCT02376998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180147|NCT04165577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Arms denoted as open-label do not include masking||t|f|f|f
34180148|NCT03831152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752287|NCT06621238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33752288|NCT00449176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866656|NCT05197517|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A Randomized, Single-Dose, Two-Way Crossover, Open-Label, Bioequivalence Study||||
33866657|NCT02795533|||COHORT||RETROSPECTIVE|||||||
33866658|NCT00001990||||TREATMENT||NONE||||||
33866659|NCT04540770|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33866660|NCT04353479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866661|NCT03001960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964265|NCT06254391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"After collecting basic clinical information about the patients, patients undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome (within 24-48 hours after the procedure) will be randomized in a 1:1 scheme using the mobile application Randomizer for Clinical Trial (Medsharing, France) to one of the two arms of the study receiving ticagrelor at a maintenance dose of 90 mg twice daily, in which the following treatment sequence will be used (open-label crossover design):~1. Aspirin (ASA) 30 mg once daily (morning) for 14 days followed by ASA 75 mg once daily (morning) for 14 days or~2. ASA 75 mg once daily (morning) for 14 days, then ASA 30 mg once daily (morning) for 14 days.~All patients will receive a loading dose of aspirin 300 mg before PCI"||||
33964266|NCT05766215|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33964267|NCT03843255|||CASE_ONLY||OTHER|||||||
33964268|NCT04288011|||COHORT||PROSPECTIVE|||||||
33964269|NCT03285334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* The patients will drag an envelope and will not know to which group they will be assigned.~* The patients who already do not know their treatment group will assess the level of their post-operative pain and will record the number of analgesic tablets used.~* The laboratory technician at the microbiological department will not know the treatment group of the patients."||t|f|f|t
34065704|NCT03682029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization performed by the independent provider of study medication (Glostrup Pharmacy).|Prospective, randomized, placebo-controlled trial.|t|t|t|t
34065705|NCT03173261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065706|NCT06257160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180149|NCT02984813|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180150|NCT05458713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34180151|NCT02273479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34180152|NCT00222612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180153|NCT00265603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180154|NCT03480581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180155|NCT05867368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned based on which camp is being offered that summer. The investigators enroll on a first-come, first serve basis, until the camp is full.||||
34180156|NCT06593548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180157|NCT03184688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180158|NCT04693767|||COHORT||PROSPECTIVE|||||||
34180159|NCT03599674|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34180160|NCT06603584|||CASE_ONLY||RETROSPECTIVE|||||||
34180161|NCT06592391|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180162|NCT03561220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180163|NCT06592573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180164|NCT00690508|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34180165|NCT06598085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180166|NCT01466712|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33752289|NCT02352038|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33752290|NCT06663722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752291|NCT06731946|||CASE_ONLY||RETROSPECTIVE|||||||
33752292|NCT02612311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752293|NCT05911503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752294|NCT04369560|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic Test - Magnetic Resonance Imaging||||
33752295|NCT06333587|||CASE_ONLY||PROSPECTIVE|||||||
33866662|NCT05916105|||OTHER||RETROSPECTIVE|||||||
33866663|NCT06037603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Non-blinded randomized trial with a wait-list control design|Non-blinded randomized trial with a wait-list control design||||
33866664|NCT05922657|||COHORT||PROSPECTIVE|||||||
33866665|NCT00449670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866666|NCT02309333|||COHORT||PROSPECTIVE|||||||
33866667|NCT02803528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065707|NCT01133288|NA|SINGLE_GROUP||||NONE||||||
34065708|NCT02850549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065709|NCT02005627|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34065710|NCT05643326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065711|NCT05542394|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34065712|NCT01758159|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34065713|NCT05519072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065714|NCT00519792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065715|NCT00360009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065716|NCT05286164|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with bone marrow aplasia for more than 3 weeks after CART administration will receive eltrombopag treatment at a dose of 150 mg for 8 weeks.||||
34065717|NCT00594386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065718|NCT04334889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065719|NCT04401280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180167|NCT00561925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34180168|NCT05098834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866668|NCT00382018|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866669|NCT01114282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866670|NCT00450242|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33866671|NCT06025669|NA|SINGLE_GROUP||OTHER||NONE||||||
34180169|NCT05397925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Eligible participants will be recruited by the nurses of each institution. A baseline assessment will be carried out and the instruments will be applied after informed consent by participants. Participants will be randomly allocated to ADSProgram (experimental group). The control group will receive the treatment as usual (TAU). In both groups will be maintained the TAU. All participants will be re-assessed at the end of the program by assistant researchers. Principal Investigator will receive documental anonymized data.|"ADSProgram - Program for self-management of Substance Dependence. It is a program based on a holistic view of the person and the ability to help people to reach their full potential based on their personal resources. It is also based on the need to focus interventions on the assessment and monitoring of substance addiction consequences. Is a harm reduction paradigm program to support self-management of this chronic condition. Aim: Training for self-management of substance addiction consequences; Promote adherence to the therapeutic project; Promote positive mental health. Therapeutic strategies - The principles of motivational interviewing, brief interventions with cognitive behavioral orientation and based on the assumptions of helping relationship to support the process of change."|f|f|t|t
34180170|NCT06653075|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180171|NCT06652893|||COHORT||PROSPECTIVE|||||||
34180172|NCT02512822|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34180173|NCT01051895|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34180174|NCT06601816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The three methods used to lift the sinuses were randomized: piezosurgery using a surgical guide, a drill specifically made for lateral sinus lift, and traditional drills.|f|f|f|t
34180175|NCT05270759|||COHORT||PROSPECTIVE|||||||
34180176|NCT01811992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180177|NCT06600607|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34180178|NCT00678782|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34180179|NCT00830882|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34180180|NCT00578539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866672|NCT00610545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866673|NCT00780013|RANDOMIZED|CROSSOVER||||NONE||||||
33866674|NCT03459599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866675|NCT02310776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866676|NCT04841824|||OTHER||PROSPECTIVE|||||||
33866677|NCT06231576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866678|NCT06372951|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866679|NCT02667873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866680|NCT03843281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866681|NCT01504165|NON_RANDOMIZED|PARALLEL||||NONE||||||
33866682|NCT01555047|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33752296|NCT03204253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752297|NCT03155997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752298|NCT04270292|||OTHER||CROSS_SECTIONAL|||||||
33752299|NCT03581981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will not be aware of patient condition and patients will be instructed and reminded not to disclose information that may lead to unblinding||f|f|f|t
33752300|NCT02285439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752301|NCT06682234|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752302|NCT06508281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Students who agreed to participate in the study were divided into experimental and control groups using the randomization method.~It consisted of 148 students studying in the first grade. There were students who did not meet the study criteria and did not take the pre-tests and post-tests. As a result, 95 participants were included in the study, 46 in the experimental group and 49 in the control group."|it was planned to conduct a randomized controlled trial on the effect of model video activity in anatomy education on the anatomy education of medical faculty students in a pretest-posttest order.|t|f|f|f
33752303|NCT04205838|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752304|NCT02351804|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33752305|NCT06733402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866683|NCT00003172||||TREATMENT||||||||
33866684|NCT05410613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866685|NCT00768326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866686|NCT06464757|||CASE_CONTROL||PROSPECTIVE|||||||
33866687|NCT05845658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866688|NCT00347126|||CASE_ONLY||PROSPECTIVE|||||||
33866689|NCT06429267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized to one of two groups which will determine the type of screw (stainless steel or bioabsorbable) in their surgery.|t|t|f|f
34180181|NCT04501523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180182|NCT05370196|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Each product will be labeled with a randomly generated code.||t|f|t|t
34180183|NCT04362241|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective study will use a fellow-eye design for 30 participants, summing to 60 eyes total. All eyes will receive cataract surgery. Per participant, one eye will be randomized to receive DEXTENZA® insertion at the end of the surgery, while the other eye will be assigned to a standard of care prednisolone acetate 1% eye drop regimen.||||
34180184|NCT02317900|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866690|NCT02042651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866691|NCT02284620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866692|NCT00478465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866693|NCT01806857|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33866694|NCT01488279|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Drugs were dispensed by the pharmacy with both the patient and investigator blinded|Double blind, placebo controlled crossover study|t|f|t|f
33866695|NCT03811457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866696|NCT00161876|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33866697|NCT00502346|RANDOMIZED|PARALLEL||||DOUBLE||||||
34065720|NCT00208234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065721|NCT02577627|||COHORT||RETROSPECTIVE|||||||
34065722|NCT05457114|||COHORT||RETROSPECTIVE|||||||
34065723|NCT05448092|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180185|NCT01176682|||COHORT||PROSPECTIVE|||||||
34180186|NCT00499070|||COHORT||PROSPECTIVE|||||||
34180187|NCT06347380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180188|NCT06590896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180189|NCT05433181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180190|NCT02473536|NA|SINGLE_GROUP||TREATMENT||NONE||6 for Lead-in phase; 23 for phase II||||
33866698|NCT02767323|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33866699|NCT00978549|RANDOMIZED|||TREATMENT||NONE||||||
33866700|NCT00962442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866701|NCT05659589|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33866702|NCT02602912|NA|SINGLE_GROUP||OTHER||NONE||||||
33866703|NCT05024799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866704|NCT02675842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866705|NCT03600064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866706|NCT00000180|RANDOMIZED|||TREATMENT||DOUBLE||||||
33866707|NCT03926754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866708|NCT06209008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866709|NCT02421068|||COHORT||PROSPECTIVE|||||||
34065724|NCT04782414|||COHORT||PROSPECTIVE|||||||
33752306|NCT06229860|||CASE_ONLY||PROSPECTIVE|||||||
33752307|NCT00313820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752308|NCT02807558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752309|NCT04359472|NA|SINGLE_GROUP||OTHER||NONE||||||
33752310|NCT06482359|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33752311|NCT06717295|||OTHER||PROSPECTIVE|||||||
33752312|NCT01130948|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33752313|NCT01750073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752314|NCT00743366|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33752315|NCT02503748|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33752316|NCT06733883|NA|SINGLE_GROUP||TREATMENT||NONE||Music therapy||||
33752317|NCT05830955|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Participants will be in three groups according to the interventions. The preterm newborns who are going to listen a live lullaby from their mothers' voice will be the first group (Lullaby group). The preterms in the second group (Breast milk group) are going to smell their mothers' breast milk. The preterms in the third group (Control group) are going to recieve rutin nursing care interventions.||||
33752318|NCT06359665|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind Randomized Controlled Trial|The study design will be a double-blind, randomized controlled trial with crossover.|t|t|t|t
33752319|NCT03101748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752320|NCT02767258|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33752321|NCT05620823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized 1:1:1 to Povorcitinib Dose A, Povorcitinib Dose B, or placebo once a day (QD); participants who complete the placebo controlled (PC) 12-week period may continue to a 42-week extension(EXT) period with Povorcitinib (Dose A or Dose B) QD.|t|t|t|t
33752322|NCT06733324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752323|NCT00765674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752324|NCT04593433|NA|SINGLE_GROUP||OTHER||NONE||||||
33752325|NCT05708612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752326|NCT06733766|||COHORT||PROSPECTIVE|||||||
33752327|NCT04473885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752328|NCT06397768|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* Blinding for vaccine group assignment: participants, parents or legally acceptable representatives (LAR) and laboratory personnel at the Sponsor~* No blinding for study staff who prepare and administer the study interventions, investigators or Sponsor study staff"||t|t|f|t
33752329|NCT00225654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33752330|NCT00233922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752331|NCT02385305|NA|SINGLE_GROUP||||NONE||||||
33752332|NCT01982357|||CASE_ONLY||CROSS_SECTIONAL|||||||
33964270|NCT03151993|RANDOMIZED|PARALLEL||TREATMENT||NONE|"All eligible patients will be randomized in two equal groups for administration recombinant nonimmunogenic staphylokinase (Fortelyzin) or alteplase (Actilyse) by using envelope method of randomization."|"All eligible patients will be randomized in two equal groups for administration recombinant nonimmunogenic staphylokinase (Fortelyzin) or alteplase (Actilyse) by using envelope method of randomization. It is an open-lable study. Each of agents will be administered no longer then 4,5 hours from symptoms onset. Comparative agent will be administered as prescribed in its instructions. All patients will be examination for 90 days"||||
33964271|NCT05472857|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and Bayesian optimal interval design (BION) dose escalation design||||
33964272|NCT00429468|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33964273|NCT02684669|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33964274|NCT05620238|||OTHER||PROSPECTIVE|||||||
33964275|NCT00148694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964276|NCT02614885|||COHORT||PROSPECTIVE|||||||
33964277|NCT01373476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964278|NCT01371890|||CASE_CROSSOVER||PROSPECTIVE|||||||
33964279|NCT04890704|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|stratified randomization and allocate concealment|prospective, double-blinded, randomized placebo-controlled study|f|f|t|f
33964280|NCT02378090|||CASE_ONLY||PROSPECTIVE|||||||
33964281|NCT00701935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065725|NCT04562857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34065726|NCT04629872|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065727|NCT02537652|||COHORT||CROSS_SECTIONAL|||||||
34065728|NCT03358680|||COHORT||PROSPECTIVE|||||||
34065729|NCT01904630|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34065730|NCT01246778|||CASE_ONLY|||||||||
34065731|NCT01230099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34180191|NCT06038643|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Intergenerational Social Motivation Behavioral Intervention using a Technology-based Platform~Our research will test an innovative, technology-based, and readily scalable cross-generational social behavior intervention to enhance physical activity in at-risk older adults through a randomized controlled trial."|t|f|f|f
34180192|NCT06654817|||COHORT||PROSPECTIVE|||||||
34180193|NCT02671708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180194|NCT01167075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180195|NCT05106426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34180196|NCT00284947|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33964282|NCT03333460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|With regard to the treatment, to ensure that both participants and investigators are blind to the condition (active or sham), the selection of the operation mode (15 Hz, sham) will be pre-programmed by member of the that will not be involved in data collection and analysis. Study personnel will not know which mode is being activated. Sham stimulation will use the same coil placement as that used for active stimulation. Outcomes Assessors will not be present during the rTMS sessions.|double blind, randomized, sham-controlled with a 1:1 allocation into 2 parallel arms|t|f|t|t
34180197|NCT04596267|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This study is double-blind. Medications are over-encapsulated.|This is a double-blind, randomized, placebo-controlled, crossover design trial that will test the effect of pitolisant on alcohol self-administration and craving following a priming dose of alcohol.|t|t|t|t
34180198|NCT01207414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964283|NCT01004900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180199|NCT06588985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants do not know which group they are assigned to.|Participants will be randomly assigned to either the treatment group or waitlist control group.|t|f|f|f
34180200|NCT03138369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Parallel Assignment in 1:1 active to control allocation|t|t|t|t
34180201|NCT01796808|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180202|NCT04670302|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34180203|NCT03662178|||COHORT||OTHER|||||||
34180204|NCT05383118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Efforts will be made to blind participants to their allocation group (intervention or control). To do this, we will ensure that promotional advertisements do not contain logos or direct website links. The informed consent form will not contain the exact outcome measures or the title of the intervention. To the best of our abilities, allocation concealment will be aided by referring to the intervention as 'e-learning about cognitive impairment and dementia prevention', without biasing participants to study hypotheses or study design.||t|f|f|f
34180205|NCT00437944|||DEFINED_POPULATION||OTHER|||||||
34180206|NCT04662489|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control and treatment arms. Control group refers to pulmonary vein isolation ablation. Treatment group refers to pulmonary vein isolation plus radial ablation of rotational activity sites.||||
34180207|NCT04506229|||CASE_ONLY||PROSPECTIVE|||||||
34180208|NCT02561884|RANDOMIZED|CROSSOVER||||NONE||||||
34180209|NCT02364375|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34180210|NCT02576483|||COHORT||PROSPECTIVE|||||||
34180211|NCT04911296|NA|SINGLE_GROUP||OTHER||NONE||||||
33964284|NCT01387308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33964285|NCT05199831|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33964286|NCT01528566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964287|NCT06438237|||COHORT||PROSPECTIVE|||||||
33964288|NCT04515511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964289|NCT04711278|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964290|NCT01168882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964291|NCT05676138|||COHORT||PROSPECTIVE|||||||
33964292|NCT01168128|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33964293|NCT05529719|NA|SINGLE_GROUP||TREATMENT||NONE|Due to the nature of the intervention, it was impossible to blind the participants and the researcher; however, we provided blinding during data collection.|This is a randomized controlled trial. Participants were randomly assigned to the intervention group and control group.||||
33964294|NCT05233774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study consists of 4 study arms of 12 patients each.|t|t|t|t
33964295|NCT05139173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Device: Smart Physiotherapy Activity Recognition System (SPARS)||||
33964296|NCT04397354|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized||||
33964297|NCT02038400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964298|NCT03479242|||COHORT||PROSPECTIVE|||||||
33964299|NCT02887482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964300|NCT02744625|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33964301|NCT03823677|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|volunteers|15 different Groups are analysed: control Group, 5000ft Group, 8000 ft Group, 10000ft Group and 15000ft Group - all for 15, 30, and 60 minutes.|t|f|f|f
33964302|NCT00807625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964303|NCT02402933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964304|NCT04211272|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33964305|NCT02268331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964306|NCT00729365|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964307|NCT01456585|NA|SINGLE_GROUP||TREATMENT||||||||
33964308|NCT01860768|||COHORT||PROSPECTIVE|||||||
33964309|NCT05626010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180212|NCT04939714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180213|NCT06587815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180214|NCT01046396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34180215|NCT06586775|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and the outcome assessor will be blinded with the participants preoperative characteristics and allocation group.||f|f|t|t
34180216|NCT05036863|||COHORT||PROSPECTIVE|||||||
34180217|NCT04836650|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34180218|NCT05036018|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Blinding of cardiologists, anesthesiologists and patients is not possible due to the type of interventions.|Patients will be randomized to one of four treatment groups in a 1:1:1:1 ratio||||
33866710|NCT02419326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866711|NCT06475313|||CASE_ONLY||CROSS_SECTIONAL|||||||
34180219|NCT00648063|RANDOMIZED|CROSSOVER||||NONE||||||
33866712|NCT04541290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180220|NCT03276338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34180221|NCT06604312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Forty volunteers participated in the study and these participants were divided into sacroiliac joint manipulation group (n=20) and control group (n=20). The sacroiliac joint manipulation was performed in the lateral decubitus position and the control group did not underwent any manipulation. Assessment methods were performed immediately after the manipulation. The frequency and percentage values for categorical variables and the mean, standard deviation, and median values for numerical data were displayed, respectively. Since there were less than thirty data points in each group, nonparametric tests were used to examine the data. The Mann-Whitney U test was used to compare the data between the two groups, and the Wilcoxon sign test was utilized to examine the difference between the two measures for each group. Measurement time differences were recorded, and the Mann-Whitney Test was used to compare the groups.|t|f|f|t
34180222|NCT03711968|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
34180223|NCT01524575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180224|NCT00003403||||TREATMENT||||||||
34180225|NCT04238923|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33866713|NCT01671813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180226|NCT00207077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866714|NCT01740960|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33866715|NCT00142350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866716|NCT00156234|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33866717|NCT00029913|||COHORT||PROSPECTIVE|||||||
33964310|NCT04744064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33964311|NCT04494282|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Random control trial|t|f|f|f
33964312|NCT06320899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964313|NCT02415868|||COHORT||PROSPECTIVE|||||||
33964314|NCT05450042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964315|NCT05114265|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33964316|NCT04358731|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964317|NCT06383208|||COHORT||PROSPECTIVE|||||||
33964318|NCT01508351|||CASE_ONLY||PROSPECTIVE|||||||
33964319|NCT01016496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33964320|NCT04952441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized into either the intervention group or the wait-list control group||||
33964321|NCT03605771|||COHORT||PROSPECTIVE|||||||
33964322|NCT03364985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964323|NCT03882216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964324|NCT00139490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964325|NCT03252132|RANDOMIZED|PARALLEL||OTHER||DOUBLE||International, randomized controlled training trial|f|f|t|t
34180227|NCT06651450|||OTHER||PROSPECTIVE|||||||
34180228|NCT06414590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180229|NCT06600568|||OTHER||OTHER|||||||
33964326|NCT00973856|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964327|NCT00092651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964328|NCT00786266|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33964329|NCT05097378|RANDOMIZED|PARALLEL||TREATMENT||NONE||Neoadjuvant and adjuvant administration schedule||||
34180230|NCT05558527|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34180231|NCT02594124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"During the blinded loading period, the following participants will be masked:~* Key site personnel (Investigator, Study Coordinator, and Outcomes Assessors)~* Participant~* The sponsor~After the loading period has been completed, subsequent doses will be unblinded."|||||
34180232|NCT04395976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180233|NCT01988155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180234|NCT03056222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180235|NCT02596867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180236|NCT03877510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180237|NCT00411684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180238|NCT00566670|||COHORT||PROSPECTIVE|||||||
34180239|NCT00928408|||OTHER||PROSPECTIVE|||||||
34180240|NCT05997290|NA|SINGLE_GROUP||PREVENTION||NONE|Open-label|Phase 2/3, controlled study||||
34180241|NCT06594419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180242|NCT01948206|||COHORT||PROSPECTIVE|||||||
34180243|NCT01972217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180244|NCT05134584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and investigators were not masked to group assignment. An independent statistician was masked for the data analysis.||f|f|f|t
34180245|NCT06595511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964330|NCT02713243|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33964331|NCT00765323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964332|NCT00283686|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34180246|NCT01245530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866718|NCT00267033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866719|NCT05260905|||OTHER||PROSPECTIVE|||||||
33866720|NCT02000596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866721|NCT00152282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893912|NCT04710108|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel randomized controlled trial||||
33893913|NCT01412437|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893914|NCT04937270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33893915|NCT00040157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964333|NCT02476734|||OTHER||PROSPECTIVE|||||||
33964334|NCT01389206|||CASE_ONLY||PROSPECTIVE|||||||
33964335|NCT02015468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964336|NCT00608556|||||PROSPECTIVE|||||||
34180247|NCT02302599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators and participants were masked to treatment allocation. The independent data monitoring committee and the statisticians supporting the committee's activities were the only people with access to unblinded data.|UC-MSCs (1.5×106/kg) or the same volume of placebo (suspension liquid without UC-MSCs)|t|t|t|t
33752333|NCT05352802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752334|NCT06005766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There are three groups in the study. One is the intervention group (n=20-25), one consists of patient controls (n=30), and the last one consists of non-patient controls (n=30).||||
33752335|NCT04790240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be randomly divided into two groups by computer. The conventional practitioners who prescribe medications for the participants will not know who will go to the treatment group. Participants will know which group they are in.|The participants are randomly divided into two groups: the treatment group and the control group. Both groups receive the same medications, but the treatment group also receives medical herbs to compare both groups' differences on their symptoms and blood data, virus marks.|t|t|f|f
33752336|NCT00765388|RANDOMIZED|CROSSOVER||||NONE||||||
33752337|NCT02380092|||COHORT||PROSPECTIVE|||||||
33752338|NCT05925127|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33752339|NCT06132880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752340|NCT04406493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"COVID 19 patients are admitted to Infectious Diseases Unit, will undergo examination using lung impedance device. The first value that has been measured will be set as BASAL.~During the hospitalization each patient will undergo this examination twice a day until discharged.~Changes in impedance values during admission will be evaluated as POSITIVE AND NEGATIVE PREDICTIVE values for clinical deterioration and improvement of COVID 19 patients and as a factor which predicts mechanical ventilation The time between lung impedance started to decrease (expression of the lung fluids accumulation) and the need in mechanical ventilation will be measured."||||
33752341|NCT06582706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The size and shape of the placebo pill will be chosen to most closely match the other treatment tablets. The drugs will be placed into identical bottles and will be labeled with a unique identifier and stored in a locked, temperature monitored room. Randomization instructions from RedCap will designate a participant and their assigned uniquely identified bottle which will be given to them at randomization with instructions. At the 30-day visit a pill count will be undertaken to reinforce compliance. The bottle and any remaining pills will be collected at the end of the study and compliance will be assessed. All pill counts and pill instructions will be given by a separate study coordinator (due to inability to have a perfectly matching placebo) so that primary study coordinator and principal investigator remain blinded throughout the study.|This study is a randomized, placebo controlled, blinded trial that includes a single intervention arm. The intervention is extended release niacin 500mg. The control/placebo group will use microcrystalline cellulose tablets.|t|f|t|t
33752342|NCT03728673|NA|SINGLE_GROUP||TREATMENT||NONE||grade IV glioma patients treated with SSRIs during a 17 week study period||||
33752343|NCT06710834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752344|NCT03746366|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||\[C-11\]PiB||||
33752345|NCT06733688|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33752346|NCT04728438|||CASE_CROSSOVER||PROSPECTIVE|||||||
33752347|NCT06479070|NA|SINGLE_GROUP||OTHER||NONE||Cohorte, prospective and multicenter study.||||
33893916|NCT03456115|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will be unaware of which nasal dilator they are trialing.|All participants will undergo the same intervention, which is a trial of various internal nasal dilators.||||
33964337|NCT00990119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180248|NCT03625349|||OTHER||PROSPECTIVE|||||||
34180249|NCT04788316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34180250|NCT00857012|||CASE_ONLY||PROSPECTIVE|||||||
34180251|NCT06462846|||CASE_ONLY||RETROSPECTIVE|||||||
34180252|NCT02633163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180253|NCT06382597|||OTHER||OTHER|||||||
34180254|NCT06600789|NA|SEQUENTIAL||TREATMENT||NONE||||||
34180255|NCT01713816|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180256|NCT06601400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964338|NCT00964223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180257|NCT05733286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Dosing labels will be attached to each study drug dose and include pre-printed fields with~* Protocol number~* Personal ID number~* Participant initials~* Date~* Time"||t|t|t|f
34180258|NCT06592118|||COHORT||RETROSPECTIVE|||||||
34180259|NCT04592939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180260|NCT04411641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180261|NCT00667199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180262|NCT06595069|||COHORT||RETROSPECTIVE|||||||
34180263|NCT05313971|NON_RANDOMIZED|PARALLEL||OTHER||NONE||After the recruitment period, of the 27 initially enrolled, 24 attended more than 70% of a 28-hour online course, forming the intervention group. The control group was recruited in order to match the age, gender, academic year and teaching faculty variables with the intervention group and people with these characteristics were invited to participate.||||
34180264|NCT06655103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34180265|NCT05074992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893917|NCT05059132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pilot, parallel randomized study of an exercise + behavioral support intervention to reduce dyspnea and improve walking behavior among lung cancer survivors following curative intent therapy. Forty participants will be randomized 1:1 to the intervention or control arm, with assessments of feasibility, acceptability, safety, and patient-centered outcomes. The intervention period is 12 weeks.||||
33893918|NCT03723447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893919|NCT02039557|||COHORT||RETROSPECTIVE|||||||
33893920|NCT02493179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34180266|NCT06591312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive loading doses of clopidogrel and aspirin or ticagrelor and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 900 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included clopidogrel. Both groups received an open-label loading dose of 300 mg of aspirin and continued on aspirin 75 mg daily.|The investigators will conduct our single-blinded randomized controlled trial, which will contain two arms; the clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day). The ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd to the 90th day). Both groups received an open-label loading dose of 300 mg aspirin and continued on open-label aspirin 75 mg daily|f|f|t|t
34180267|NCT02536976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180268|NCT03818646|||COHORT||PROSPECTIVE|||||||
34180269|NCT00077246||||TREATMENT||NONE||||||
34180270|NCT02859220|RANDOMIZED|PARALLEL||||NONE||||||
34180271|NCT06474338|||CASE_ONLY||RETROSPECTIVE|||||||
34180272|NCT04214821|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The qualified patients will be randomized on a 1:1 ratio into each treatment arm. Qualified eyes were further randomized into one of four subgroups, which specified the time between the last drop of study medication and the time of aqueous and vitreous humor sample collection (i.e., 1-, 2-, 4-, and 6-hour subgroups- about 32 patients per subgroup. Within each subgroups, there will be 16 of Levofloxacin group and 16 of Moxifloxacin group.|t|t|t|t
34180273|NCT00732056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180274|NCT06600295|||COHORT||PROSPECTIVE|||||||
34180275|NCT03998306|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34180276|NCT04587336|||CASE_ONLY||PROSPECTIVE|||||||
34180277|NCT01503203|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34180278|NCT06646614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The statistician analyzing the data will be masked from the experimental treatment and the control. The principal investigator overseeing the trial will have access to the data but will not know which specific arm (treatment or control) each participant belongs to.|explain random and two groups|f|f|t|t
34180279|NCT06144619|||COHORT||PROSPECTIVE|||||||
34180280|NCT05179226|NA|SINGLE_GROUP||TREATMENT||NONE||The study includes a PK-part. 24 subjects will be part of a PK assessment and have total- iron PK-parameters measured 7 or 8 times between baseline visit and week 1.||||
34180281|NCT01113255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180282|NCT03480048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180283|NCT04734691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180284|NCT00646165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180285|NCT03493464|NA|SEQUENTIAL||DIAGNOSTIC||NONE||A total of sixty (60) subjects will be evaluated in the study. The first 10 subjects enrolled in the study will receive BR55 at a dose of 0.03 mL/kg. Assuming these first 10 subjects will show technically adequate images, subsequent subjects enrolled in the study will continue to receive 0.03 mL/kg dose of BR55; otherwise, subjects will be switched to a 0.05 mL/kg dose of BR55.||||
34180286|NCT02289586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180287|NCT04451044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180288|NCT04885907|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant and vaccinator will be blinded to vaccine vs placebo|Randomised, placebo-controlled trial|t|t|f|f
34180289|NCT06595524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|collecting all outcomes at baseline and post-intervention by using online web-based method|Phase I: one group pre-posttest Phase II: randomized control trial|f|f|f|t
34180290|NCT06118138|||COHORT||PROSPECTIVE|||||||
34180291|NCT01999881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180292|NCT06604390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Objective:~This clinical trial aims to investigate the effects of gambir catechin supplementation on cognitive function, and plasma levels of APP, MAPT, BDNF, IL-10, TGF-beta, and MDA in the elderly.~Research Design: A randomized controlled trial (RCT) design will be used. Population and Sample:The target population for this study is the elderly aged 60 years and above with mild cognitive impairment (MoCA-INA score of 20-25) residing in Padang City, West Sumatra, Indonesia.~Intervention~1. Participants will be randomly assigned to either the intervention or control group.~2. The intervention group will receive gambier catechin supplementation (Uncaria gambir Roxb) at a daily dose of \[224 mg\] for 12 weeks.~3. The control group will receive a placebo."|t|f|t|f
34180293|NCT04267380|||COHORT||RETROSPECTIVE|||||||
34180294|NCT05153967|||COHORT||OTHER|||||||
34180295|NCT06052579|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This one-year prospective controlled study compared two approaches (Wiltse TLIF vs P-TLIF) for hand-held retractors-assisted TLIF was approved by the Institutional Review Board (IRB) of our hospital. Written informed consent was obtained from all study participants. 60 eligible patients were included in this study and were divided into two groups.30patientswere included in the study group and underwent Wiltse TLIF, and 30 were included in the control group and underwent P-TLIF.|f|f|f|t
33893921|NCT00432198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893922|NCT05090241|||COHORT||PROSPECTIVE|||||||
33893923|NCT05723146|NA|SINGLE_GROUP||SCREENING||NONE||60 patients with right stroke will be included in this study: a group of 30 patients with USN will be compared to a group of 30 patients without USN.||||
34180296|NCT05516381|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|Study and research staff will be blinded to randomization and the cohort allocation until after consenting and eligibility is determined. Subjects will be blinded to the randomization (MA TKA or restricted iKA TKA) until the completion of the study.|Randomization list (block randomized, computer generated, two equal-size groups) will be created within the EDC system|t|t|t|f
34180297|NCT03783572|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups, one with 40 stroke patients and the control group with 40 healthy subjects prospective, longitudinal, without blinding, multicenter.||||
34180298|NCT05320445|RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistician analyzing the data will be blinded to group allocation||f|f|f|t
34180299|NCT02427308|||CASE_ONLY||PROSPECTIVE|||||||
34180300|NCT04828681|||COHORT||PROSPECTIVE|||||||
34180301|NCT00602602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180302|NCT01241721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180303|NCT04372381|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Prospective randomized||||
34180304|NCT01569191|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34180305|NCT04861103|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34180306|NCT04228523|RANDOMIZED|PARALLEL||OTHER||NONE||therapeutic education or speaking group||||
33752348|NCT01417572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752349|NCT03783182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Administrator gives the study number and check the randomization list and thereafter gives the drug/placebo to a Health care personnel, who does not know if it is placebo or drug.|Double-blinded, placebo controlled and randomized study|t|t|t|f
33752350|NCT00575575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752351|NCT04224077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752352|NCT05038267|||COHORT||PROSPECTIVE|||||||
33752353|NCT05258110|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752354|NCT03163758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752355|NCT06300229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893924|NCT00047411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893925|NCT00934609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893926|NCT04290182|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I/IIa open, single-arm clinical study evaluating the safety and tolerability as well as the influence on VF function, of local injection of the autologous MSC product KI-MSC-PL-204, in patients suffering from chronic VF dysfunction.||||
33893927|NCT04317807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33893928|NCT06657677|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33893929|NCT03979729|||COHORT||OTHER|||||||
33893930|NCT01597869|||CASE_ONLY||PROSPECTIVE|||||||
33893931|NCT00275080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893932|NCT02135536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893933|NCT06059885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752356|NCT03154008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752357|NCT06088290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752358|NCT05530174|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Blinding will not be applicable, because it is considered infeasible to expose participants and clinical personnel to this in either of the groups since any specific clinic will follow their allocated specific (single- or multiple-dose) routine during an entire 1-year period and their routine treatment of any complication (before switching).|The Pro-Hip-Quality Trial is a Cluster Randomized Trial with an embedded Cross-Over Design where each clinical center (C: 1, 2, 3, ...., 36 individual sites) will be running a specific intervention (i.e. single- or multiple-dose antibiotics) throughout 12 months, and the subsequent year the clinical department will automatically switch to the opposite intervention (i.e. multiple- or single-dose antibiotics).||||
33752359|NCT01873924|||COHORT||PROSPECTIVE|||||||
33752360|NCT02530489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752361|NCT06571266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33752362|NCT05592275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752363|NCT05351801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo-controlled, parallel group Phase II study with randomization to one of the four treatment arms: 1) 10 mg mg THC , 2) 800 mg CBD , 3) 10.8 mg THC + 10 mg CBD , and 4) placebo. The 8-week treatment phase comprises a 2-week up-titration, 4 weeks maintenance on the target dose followed by 2 weeks down-titration, to minimize cannabis withdrawal syndrome. The two-weeks up titration phase is to minimize side effects and improve tolerability. Efficacy will be assessed by responses during the 4-week target dose phase.|t|t|t|t
33752364|NCT05670899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752365|NCT06723717|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33752366|NCT06732804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752367|NCT05756387|||COHORT||PROSPECTIVE|||||||
33752368|NCT05275257|RANDOMIZED|PARALLEL||TREATMENT||NONE||The uridome is changed daily in the intervention group, while the control group will continue to receive the usual incontinence treatment.||||
33752369|NCT05514353|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33752370|NCT06205667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752371|NCT00148967|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33752372|NCT05011760|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group, correlational analyses||||
33866722|NCT03090087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"The project will be conducted as an open controlled interventional study performed on two days separated by at least one day.~The test persons will be randomly allocated to two groups, one group in which protocol 1 is followed by protocol 2, and the other group with the two protocols performed in the reverse order.~Protocol 1: A) Using a Dynamic Vessel Analyzer, the diameter of a larger retinal vascular arcade arteriole will be recorded for 90 seconds at baseline followed by a similar recording during stimulation with flickering light and a recording during rest, altogether lasting 4.5 minutes. B) Intravenous injection of 0,4 mg regadenoson and repetition of the procedures in step A.~Protocol 2: The procedures are similar to those of protocol 1 but are performed during breathing of a hypoxic gas mixture."||||
33866723|NCT00118391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866724|NCT03366051|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Non-Inferiority Trial||||
33866725|NCT02019823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866726|NCT04543058|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33866727|NCT02866799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33866728|NCT04373954|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants were randomly assigned to two treatments (Forgiveness Therapy and Carey Guides), without being informed about which type of treatment they received.|It is a cross-over design. For the first period of treatment, after the pretest, the experimental group received 6-month Forgiveness Therapy and the control group received 6-month alternative treatment-Carey Guides. The Carey Guides is a primary educational program deliberately picked by the Department of Corrections in Wisconsin. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. For the second period of treatment, after the post-test, the control group turned to the second experimental group and received 6-month Forgiveness Therapy, while the first experimental group had a rest for 6-month and then they finished the follow-up test or second post-test. For both experimental group and control group, they met once per week, one hour in a group setting. The remaining participants will be remeasured 12 months after the second period of treatment for one-year follow-up test.|t|f|f|f
33866729|NCT04323085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180307|NCT03264677|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Since this will be a blind study, the product randomization codes will be generated by study team member different from Study Manager, Study Director, Principle Investigator and any data producers or influencer. The product randomization codes and the corresponding product information (i.e. product name, formula number, batch number, manufacturing/expiry date, etc.) will be sealed in an envelope and before study filed work complete kept by PI until there is a unblinding needs due to medical emergency or report drafting.~In this study, in total 4 IPs include 3 facial creams and 1 facial cleanser will be evaluated. Subjects will be assigned to 3 groups randomly and evenly with different facial product regimens (one cleanser + one cream). The product regimens will be applied on the whole face for on-site study and the 8-week HUT. For each subject, left or right cheek area will be randomly chosen as experimental area for evaluation and middle upper chest will be the untreated control area"|"Subjects will be randomly and evenly divided into 3 groups (approx. 40 subjects per group) with different facial care regimens during the 8-week home use study.~Group 1: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel Group 2: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel Group 3: NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion"|t|f|t|t
34180308|NCT02761330|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34180309|NCT06413121|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866730|NCT01937598|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33866731|NCT00502073|RANDOMIZED|PARALLEL||||DOUBLE||||||
33866732|NCT01095406|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866733|NCT04233164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34180310|NCT05371717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180311|NCT01036646|||COHORT||PROSPECTIVE|||||||
34180312|NCT00265993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866734|NCT00848133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866735|NCT01421927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180313|NCT04412512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||study the effect of a treatment and evaluate outcome postoperative|f|f|t|f
34180314|NCT06603337|||OTHER||OTHER|||||||
34180315|NCT06189521|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|"1. Participant : patients with lateral epicondylitis~2. Care provider: physiotherapist who applied the treatment (ESWT,US,iontophoresis)~3. Investigator: examine the patients and evaluates the results of the study"|This single-blind prospective randomized study. Patients were randomized into three groups by a physiotherapist with sealed envelopes. The researchers were blinded to the patient's groups.|t|t|t|f
34180316|NCT01074502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180317|NCT05580653|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Statisticians, Laboratory personnel|Randomized cross-over|f|f|t|t
34180318|NCT02629718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180319|NCT00832702|||OTHER||PROSPECTIVE|||||||
34180320|NCT05318313|||COHORT||PROSPECTIVE|||||||
34180321|NCT06051890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180322|NCT05815147|NA|SINGLE_GROUP||OTHER||NONE||||||
34180323|NCT04006587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34180324|NCT02418169|||CASE_ONLY||PROSPECTIVE|||||||
34180325|NCT05897658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180326|NCT00842114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180327|NCT05459363|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34180328|NCT05321901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180329|NCT03871777|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34180330|NCT03398317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180331|NCT03292926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34180332|NCT03817216|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180333|NCT01723982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180334|NCT05650736|NA|SINGLE_GROUP||TREATMENT||NONE||moderate to severe GA affecting at least 5% body surface area||||
34180335|NCT01871012|||COHORT||PROSPECTIVE|||||||
34180336|NCT04404413|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34180337|NCT03836313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34180338|NCT06655454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Three types of additional treatment after standard nonsurgical endodontic procedures may be given. These include an additional injection of bupivacaine, an additional mock or placebo injection, and no additional injection.|t|f|f|f
34180339|NCT04144608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180340|NCT02132962|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34180341|NCT02264730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180342|NCT05082610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180343|NCT00161759|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180344|NCT01317472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180345|NCT00904449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180346|NCT04762095|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Postmenopausal Women|Research is quasi-experimental|t|f|f|f
34180347|NCT02552043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180348|NCT02871986|||COHORT||PROSPECTIVE|||||||
33866736|NCT05438589|||OTHER||PROSPECTIVE|||||||
33866737|NCT03734250|||CASE_CONTROL||PROSPECTIVE|||||||
33866738|NCT01971983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866739|NCT05796726|||COHORT||RETROSPECTIVE|||||||
33866740|NCT04695067|||COHORT||CROSS_SECTIONAL|||||||
34180349|NCT02318316|||CASE_ONLY||PROSPECTIVE|||||||
33866741|NCT00445874|RANDOMIZED|PARALLEL||||DOUBLE||||||
33866742|NCT03088475|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33866743|NCT05824286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866744|NCT02584322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180350|NCT00367822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34180351|NCT04148625|||CASE_ONLY||PROSPECTIVE|||||||
34180352|NCT06322966|NA|SINGLE_GROUP||OTHER||NONE||||||
33866745|NCT03476941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Written consent will be obtained from all participants. Then, each participant will be randomized into two arms. Nurse will administer the drain flush either with normal saline or antibiotic irrigation.|There will be two group, study and control group. In control group, patient will receive standard intra-abdominal drain care with daily flushing of the drain with normal saline. In study group, patient will receive daily flush with antibiotic for 7 days.|t|f|f|f
34180353|NCT05715099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34180354|NCT00485979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180355|NCT00222300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34180356|NCT03593369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180357|NCT06593080|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Stepped Wedge Design||||
34180358|NCT03115710|||COHORT||PROSPECTIVE|||||||
34180359|NCT06591208|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180360|NCT03043417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180361|NCT00430014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180362|NCT02365025|NON_RANDOMIZED|PARALLEL||||NONE||||||
34180363|NCT01128933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866746|NCT05529459|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33866747|NCT01092143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866748|NCT03554551|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866749|NCT03517891|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|We will use a random allocation process for each clinic with the exception of the 2 satellite clinics which will be randomly assigned separately to ensure assignment of 1 satellite clinic per treatment arm. Additional attention to the distribution of the satellite clinics is deemed necessary as the flow of participants at these sites differs from other clinics due to extended working hours and location of facilities (shopping malls). Randomization will take into account the number of pregnant participants per clinic as well as breastfeeding statistics as an important determinant of future infant obesity. Changes in clinic location and service hours have been documented during the course of the study to account for operational changes implemented by our community partner in response to extraordinary events.|Cluster-randomized controlled trial in 16 WIC clinics. We will randomly assign 8 clinics to the intervention arm and 8 to control (usual care) arm. The intervention will combine key messages and activities designed to promote sound parenting skills that support and sustain healthy lifestyles beginning at birth until the infant is 12 months of age. Participants will be recruited at the WIC clinics during in the last trimester of pregnancy. The primary, intention-to-treat, analysis will evaluate the effect of the intervention on excessive weight gain and rate of weight gain from birth until 12 months. The intention-to-treat approach will allow us to evaluate the expected effect of adding the proposed intervention to the current WIC curriculum. Secondary analyses will include effects of the intervention on objective measures of infant activation, sedentary behaviors and sleep, diet quality, and feeding practices.|f|t|t|t
33866750|NCT00971763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180364|NCT04794777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180365|NCT05164003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180366|NCT01152268|||CASE_ONLY||PROSPECTIVE|||||||
34180367|NCT04847804|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180368|NCT05683457|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34180369|NCT06651541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180370|NCT04984746|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study were designed by two cohorts The control group and the interventional group. The intervention lasted for 10 days and 100gr of lettuce per day was consumed.||||
34180371|NCT01553084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180372|NCT05122975|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|S48168 and exact matching placebo||t|t|t|t
34180373|NCT03895203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180374|NCT00037843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180375|NCT04992312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34180376|NCT05310955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180377|NCT01948596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180378|NCT03520998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180379|NCT04450238|||COHORT||PROSPECTIVE|||||||
34180380|NCT02389296|||COHORT||PROSPECTIVE|||||||
34180381|NCT04699617|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|single-blind (blind rater for primary and secondary outcomes)|A two-arm, randomized, single-blind (blind rater for primary and secondary outcomes), delayed-start feasibility and efficacy trial.|f|f|f|t
34180382|NCT04103138|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The subject and the outcome assessor analysing the EEG subsequently will be blinded to group allocation.|Randomised Controlled Trial|t|f|f|t
34180383|NCT05406817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180384|NCT05122806|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34180385|NCT00061438|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34180386|NCT00325897|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180387|NCT00655902|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180388|NCT03432598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180389|NCT05951933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34180390|NCT02660749|||CASE_CONTROL||PROSPECTIVE|||||||
34180391|NCT05240820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34180392|NCT04046497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180393|NCT02495506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180394|NCT01586364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180395|NCT04894968|||COHORT||PROSPECTIVE|||||||
34180396|NCT06396884|||COHORT||OTHER|||||||
34180397|NCT02077010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180398|NCT03673800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180399|NCT04314284|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180400|NCT02744053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180401|NCT02496286|NA|SINGLE_GROUP||TREATMENT||||||||
34180402|NCT02783534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180403|NCT02211846|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34180404|NCT05535946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All eligible subjects will be randomized to either the double blind, placebo-controlled Part #1 (ABX464 50mg or 25mg or placebo) or randomized to double-blind Part #2 (ABX464 50mg or 25mg) depending on their clinical response at the end of induction.|"Among both induction studies, subjects assessed as responders will be randomized as follows into Part 1 of the maintenance study according to their induction treatment:~* ABX464 Dose 50 mg QD~* ABX464 Dose 25 mg QD~* Placebo. All subjects with clinical response who were dosed with placebo in the induction studies will be randomized into the placebo group.~Among both induction studies, subjects assessed as non-responders will be randomized as follows into Part 2 of the maintenance study according to their induction treatment:~* ABX464 Dose 50 mg QD (all subjects who received 50 mg in induction)~* ABX464 Dose 25 mg QD (all subjects who received 25 mg in induction)~* Subjects who were allocated to placebo in the induction study will be randomized to obefazimod 50 mg or 25 mg in a blinded manner."|t|t|t|f
34180405|NCT02170623|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180406|NCT00150436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180407|NCT05733351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180408|NCT05056935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180409|NCT05721456|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180410|NCT02143804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752373|NCT06733272|||OTHER||CROSS_SECTIONAL|||||||
33752374|NCT05534009|||COHORT||OTHER|||||||
33752375|NCT03859635|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients are randomized into one of three groups:~1. Ultrasound guided LB Erector Spinae Plane Block with 20ml of Exparel and 10ml 0.25% bupivacaine~2. Ultrasound guided SB Erector Spinae Plane Block with 30ml 0.5% bupivacaine~3. Surgeon Infiltration under video guidance with 20ml of Exparel and 10ml of 0.25% bupivacaine"||||
33752376|NCT04446858|||COHORT||PROSPECTIVE|||||||
33752377|NCT06647550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752378|NCT02170740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752379|NCT06733558|||COHORT||PROSPECTIVE|||||||
33752380|NCT04450264|NA|SINGLE_GROUP||SCREENING||NONE||This trial will have a single arm design. All participants will receive the same intervention as the purpose of the current study is to assess feasibility and acceptability of the intervention. The intervention will however, be delivered in English or French (according to language preference of the participant).||||
33752381|NCT03372200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752382|NCT03464968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065732|NCT02700880|||COHORT||PROSPECTIVE|||||||
34180411|NCT05614817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180412|NCT00133484|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34180413|NCT03911167|||CASE_CONTROL||RETROSPECTIVE|||||||
34180414|NCT03586661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180415|NCT00279175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180416|NCT01713920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180417|NCT05902910|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Assessors will not know what phase the patient is in at the time of assessment or what experimental design the patient was randomized to.|The multiple-baseline SCED design is a prospective design that allows the intensive study of a few individuals to measure their baseline and condition related to a therapeutic intervention. Each subject is his own control with repeated measurements of the primary endpoint. Randomization in the MBD formats of SCED studies relates to the duration of the phases. The experimental plan includes 3 rehabilitation phases: A (Baseline), B (1.5hours a day 5/7 of conventional rehabilitation and 30mn of training with the Luna robot 5/7) and C (2 hours a day 5/7 of conventional rehabilitation). The duration of phase A is fixed (2 weeks). As the effect of the treatment on the upper limb is unknown in its latency, the duration of the second phase of the study will be randomized (2 to 3.5 weeks). Finally, the duration of the third phase is fixed (2 weeks)|f|f|f|t
33752383|NCT01310387|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752384|NCT04098939|||COHORT||PROSPECTIVE|||||||
33752385|NCT06046235|||OTHER||PROSPECTIVE|||||||
33752386|NCT02425839|NA|SINGLE_GROUP||||NONE||||||
33752387|NCT06626412|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752388|NCT00328510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752389|NCT06429254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33752390|NCT00778765|RANDOMIZED|CROSSOVER||||NONE||||||
33752391|NCT04603352|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective, exploratory research study will employ a randomized controlled trial research design. The independent variables will be two conditions: usual care with the addition of a Hip Helpers® orthotic garment home program and usual care with no addition to the home program. The dependent variable will be an assessment of gross motor function over time as measured by the GMFM-88. Participants will be tested on the GMFM-88 each month, regardless of group.||||
33752392|NCT03747341|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants will be blinded to treatment with buprenorphine or placebo during Periods 1 and 2 in Part A only.|"Part A is a 3 period study in approximately 18 healthy subjects. Subjects will be randomized in a 1:1 ratio to 2 treatment sequences determined by the order in which they receive buprenorphine or placebo (periods 1 and 2). An optional open-label Period 3 may be conducted in which subjects will receive buprenorphine only.~Part B is an open label study of approximately 8 opioid tolerant patients. All will undergo a washout of their own opioids which will be replaced with oral oxycodone and continue at stable doses from at least 48 hours prior to Period 1 to the end of Period 2. All will receive placebo plus fentanyl during Period 1 and buprenorphine plus fentanyl during Period 2."|t|f|f|f
33752393|NCT03930342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Women will be randomized 1:1 to the intervention or usual care conditions.|t|f|f|f
33752394|NCT06716034|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33752395|NCT02721082|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752396|NCT01695564|||CASE_CONTROL||RETROSPECTIVE|||||||
33752397|NCT04214704|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752398|NCT06579807|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33893934|NCT03295305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065733|NCT03632538|||CASE_ONLY||PROSPECTIVE|||||||
34065734|NCT03510078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065735|NCT01082796|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34065736|NCT05383833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065737|NCT00546494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065738|NCT01738256|RANDOMIZED|PARALLEL||||NONE||||||
34065739|NCT04878302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators assessing outcomes are kept unaware of the specific treatment condition and pre-treatment assessment scores.|Eligible families will be randomly assigned to an immediate treatment group or a 1-month waitlist.|f|f|f|t
34065740|NCT05212779|||COHORT||PROSPECTIVE|||||||
34180418|NCT01067053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180419|NCT03846492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Individuals with AD + agitation will receive a 2 week course of active/sham cathodal tDCS to frontal brain region in a double blind 1:1 randomized control design.|t|t|t|t
34180420|NCT00048425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34180421|NCT00931619|||||PROSPECTIVE|||||||
34180422|NCT03541551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible patient after screening will be assigned consecutive randomization numbers in ascending order upon enrollment. The patient will be randomized in 1:1ratio to one of two study groups, namely combined trabeculotomy with trabeculectomy with ologen® Collagen Matrix as adjunctive wound modulator(Group A) or combined trabeculotomy with trabeculectomy alone without any adjunctive (Group B). The assigned randomization number will be recorded in each subject's DCF. The randomization scheme will be generated using random function in excel before patient enrollment in order to avoid investigator's patient selection bias.|Product:ologen® Collagen Matrix, Model: 830601, Shape:Round cylindrical, Size:6mm (diameter) x 2mm (thickness, Manufacturer: Aeon Astron Europe B. V.|t|f|t|f
34180423|NCT01670084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180424|NCT05078047|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized 1:1 into two arms:~• Experimental arm: Reduced dose intensity of IO~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision.~• Control arm: Standard IO~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice.~Random allocation will be stratified by tumour type, by response status (partial response versus complete response) evaluated 6 months after the initiation of standard IO, by treatment line (first line vs others), and by type of IO"||||
34180425|NCT00746382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180426|NCT04311021|||OTHER||PROSPECTIVE|||||||
34180427|NCT04760782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Primary outcome will be measured from CT by a radiologist blinded to whether the patient was part of the control or treatment group.||f|f|f|t
34180428|NCT01347112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180429|NCT06586580|||CASE_ONLY||RETROSPECTIVE|||||||
34180430|NCT05728437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180431|NCT03908801|RANDOMIZED|CROSSOVER||OTHER||NONE||The participants are first randomized to the intervention or control group and when the intervention for the first group is completed, the intervention is given to the second group (former control group). Since the prevalence of profound intellectual and multiple disabilities is low, the project is carried out as a multicenter study.||||
34180432|NCT06587932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180433|NCT06164106|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180434|NCT06654908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180435|NCT04969926|||COHORT||PROSPECTIVE|||||||
34180436|NCT04400877|||COHORT||RETROSPECTIVE|||||||
34180437|NCT06594029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data analyst, research assistant conducting research interviews at baseline and post-treatment will be blind to participant allocation||t|f|f|t
34180438|NCT00126243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180439|NCT01167777|||COHORT||PROSPECTIVE|||||||
34180440|NCT01106612|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34180441|NCT04083612|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open label, non-randomized study||||
34180442|NCT02929394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180443|NCT02497534|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180444|NCT06651853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180445|NCT06602609|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-centre, prospective, randomised controlled, parallel-group study with open-label randomisation concealment. A total of 216 patients will have a random assignment 1:1 into the active arm (remote monitoring) or control group (standard of care), employing computer-generated randomisation via a minimisation design based on sex and age (75 years ± 8 years).||||
34180446|NCT04970485|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individual randomized control trial||||
34180447|NCT06326814|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34180448|NCT02965391|||CASE_ONLY||PROSPECTIVE|||||||
34180449|NCT02874521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34180450|NCT06286202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Upon randomization, the co-investigators will indicate the allocated group in a separate spreadsheet from the outcome measurements. The co-investigator who is collecting baseline, post-intervention and 8-week outcome measurements will be blinded to the treatment allocation of each participant.|The intervention study model is a parallel randomized controlled trial. There will be two arms. The experimental arm is 'cognitive remediation' and the control arm is 'standard psychiatric rehabilitation'. Participants will be assigned to one of the treatment arms at the beginning of the trial and will continue in that arm throughout the length of the trial. Assignment to the group is done using a computer randomization generator. All eligible participants will be randomly assigned to one of the treatment arms (experimental or control arm) based on a 1:1 treatment allocation. Hence, those who are randomly allocated to the experimental arm will receive cognitive remediation throughout the trial, while those randomly allocated to the control arm will receive standard psychiatric rehabilitation throughout the trial. Both treatment arms will run in parallel.|f|f|f|t
34180451|NCT01032538|||COHORT||PROSPECTIVE|||||||
33964339|NCT03523507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964340|NCT00673322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964341|NCT03313479|||COHORT||PROSPECTIVE|||||||
33964342|NCT04672057|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964343|NCT05578222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964344|NCT00002594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964345|NCT06541717|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33964346|NCT02052037|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33964347|NCT02758587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964348|NCT00923728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964349|NCT05818631|||OTHER||PROSPECTIVE|||||||
33964350|NCT05122962|||COHORT||PROSPECTIVE|||||||
33964351|NCT05564702|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Only care provider Dr. Patel will know the identity of each patient.|This will be randomized study of patients undergoing IVF treatment. The treatment given to one arm will be based on Opt-IVF decision support tool and standard doctor specified treatment with other arm.|t|f|t|t
34065741|NCT04638803|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||In the first arm a fixed order crossover of a PRX-P4-003 followed by administration of the (-)-FCF after a washout period. In the second arm a separate cohort will be administered PRX-P4-003 under fed conditions.||||
33866751|NCT03926845|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||This is a randomized, vehicle controlled, double-blind study and is performed at the Institute of Dermatology. Subjects are randomized into 2 groups by a computer prior to the start of the study - group 1 receives Isobutylamido-thiazolyl-resorcinol 0.2% cream and group 2 receives vehicle cream for 12 weeks. Both Study products have to be applied twice daily.Total of 4 clinical sessions are carried out in order to evaluate Isobutylamido-thiazolyl-resorcinol 0.2% efficacy and tolerability at week 4, 8 and 12. Subjects and investigators are blinded about allocation. The appearance of the vehicle formulation was similar to the verum formulation and could not be distinguished neither by patients nor by the investigator.|t|t|t|t
33866752|NCT01855763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866753|NCT02772640|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964352|NCT02293642|||COHORT||PROSPECTIVE|||||||
33964353|NCT06345742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33964354|NCT01850303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964355|NCT01819584|||COHORT||PROSPECTIVE|||||||
34065742|NCT02204358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065743|NCT01874418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065744|NCT05508945|NA|SINGLE_GROUP||OTHER||NONE|Participants are not informed which dressing is Dermabond Prineo and which is SERI scaffold with dermaFLEX adhesive. Participants are informed they will be receiving both interventions|subjects receive 50% surgical incision coverage with experimental silk/adhesive prototype and 50% surgical incision coverage with FDA approved Dermabond Prineo OR FDA approved Steri-Strip.||||
34065745|NCT03163459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34065746|NCT01655134|NA|SINGLE_GROUP||||NONE||||||
34065747|NCT00001037||||PREVENTION||||||||
34065748|NCT03358381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065749|NCT04052360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065750|NCT01917604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065751|NCT02070978|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065752|NCT05409508|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065753|NCT04553003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180452|NCT03761992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the patient nor the investigator will know which treatment that the patient is receiving.|Gingko baloba extract (GBE) versus placebo|t|f|t|f
34180453|NCT02012140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180454|NCT06590740|NA|SINGLE_GROUP||OTHER||NONE||||||
34180455|NCT02586298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34180456|NCT06452563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34180457|NCT04293575|||COHORT||PROSPECTIVE|||||||
34180458|NCT06597201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866754|NCT02145533|||COHORT||PROSPECTIVE|||||||
33866755|NCT00189072|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33866756|NCT02931942|||COHORT||PROSPECTIVE|||||||
33866757|NCT06281067|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866758|NCT05966610|||COHORT||PROSPECTIVE|||||||
33866759|NCT02553122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866760|NCT00078325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964356|NCT02958748|||COHORT||PROSPECTIVE|||||||
33964357|NCT03191019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible participants will be randomized to the intervention group or control group using a computerized and automated process. An email will be automatically sent to the participants with the link to download the corresponding version of the mobile-phone app (intervention app or control app). Researchers who will gather data and those who will measure carbon monoxide in exhaled air will be masked to treatment allocation.|Two-arm, randomized clinical trial of a smoking cessation intervention based on a mobile-phone app. Participants will be randomly assigned to the intervention group or control group, in parallel for the duration of the study (6 months follow-up).|f|f|t|t
33964358|NCT00615628|||FAMILY_BASED||PROSPECTIVE|||||||
34180459|NCT06588244|||COHORT||PROSPECTIVE|||||||
34180460|NCT05906719|||COHORT||CROSS_SECTIONAL|||||||
34180461|NCT02404935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180462|NCT00460161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180463|NCT01135173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866761|NCT02289651|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866762|NCT03989076|||CASE_CROSSOVER||PROSPECTIVE|||||||
33866763|NCT04274777|||COHORT||PROSPECTIVE|||||||
33866764|NCT03738878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33866765|NCT05998083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In addition to the individual training program they received from the special training center, the experimental group was given goal-oriented balance and coordination exercises for 40 minutes, 2 days a week.|f|f|f|t
33866766|NCT02179879|||COHORT||PROSPECTIVE|||||||
33866767|NCT01033526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866768|NCT02423044|||CASE_CONTROL||PROSPECTIVE|||||||
33866769|NCT05829642|||CASE_CONTROL||PROSPECTIVE|||||||
33866770|NCT03889665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866771|NCT04494230|||CASE_CONTROL||PROSPECTIVE|||||||
33866772|NCT04616391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The trial is a two-centers, randomized controlled, parallel group study. Patients will be followed up during approximatively 3 months.||||
33866773|NCT02116257|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33866774|NCT03988231|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomized, double blind, placebo controlled trial||t|t|t|f
33866775|NCT04828187|||COHORT||PROSPECTIVE|||||||
33866776|NCT06306079|NA|SINGLE_GROUP||OTHER||NONE||"A gait modification (Lateral wedge insole) program will be conducted over 4 to 6 weeks in the physiotherapy gym or adjusted treadmill and outside the clinic during the day (at least 8 hours per day).~* During the session, the researcher will observe participants inside the clinic and ensure that the modified gait application is applied, and outside the clinic will be followed by telephone.~* Participants will walk on the gym floor or an adjusted treadmill for at least 15 to 20 minutes during each session. Participants will be instructed to use the mirror for feedback and achieve the target modified gait procedure. However, it will be emphasised gait modification procedures exhibited at baseline pain and function, and then at the end of the trial, it will focus on subjects' acceptability."||||
33866777|NCT01788657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866778|NCT02732041|||COHORT||PROSPECTIVE|||||||
33866779|NCT02964299|||CASE_CONTROL||PROSPECTIVE|||||||
33866780|NCT01898936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33866781|NCT00711425|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866782|NCT03329222|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind|Randomized, two arms|t|t|t|t
33866783|NCT03521830|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients from Arm A can crossover to Arm B or Arm C||||
33866784|NCT06432088|NA|SINGLE_GROUP||OTHER||NONE||||||
33866785|NCT05512793|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Patients who fulfill criteria will be randomly allocated to perform the first withdrawal with the standard technique versus PolyDeep assisted colonoscopy. All colorectal detected polyps will be resected. After a second cecal intubation, second withdrawal will be performed with the opposite technique||||
33866786|NCT03021395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866787|NCT02575248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866788|NCT02689284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866789|NCT05794165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double-blind study.|Multi-center, placebo-controlled, randomized, double-blind study|t|t|t|t
33866790|NCT04942652|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866791|NCT03275181|||CASE_CONTROL||PROSPECTIVE|||||||
33866792|NCT03051282|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33866793|NCT02985099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866794|NCT02339064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866795|NCT04196803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33866796|NCT05515861|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065754|NCT03077386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The investigators will test the effectiveness of the ENCOMPASS program using a parallel, two-arm, pragmatic, wait-list control, cluster-randomized trial. Half the clinics will be randomized to receive the intervention immediately, serving as the intervention group, while the other half will receive the intervention after a 6 month waiting period, acting as control sites during their first 6 months. Once implemented, the ENCOMPASS program will remain available to clinics until the end of the funding period. Control patients will continue to receive usual care until their clinic becomes eligible for the program.|f|f|f|t
33866797|NCT01120548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866798|NCT05214417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34180464|NCT02337777|||COHORT||RETROSPECTIVE|||||||
34180465|NCT06079112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180466|NCT06590168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180467|NCT04100083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180468|NCT03736590|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Pediatricians and outcomes assessors will not be aware of study arm.|Randomized controlled trial||||
34180469|NCT02072668|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34180470|NCT03027609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180471|NCT03692598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180472|NCT05356377|||COHORT||CROSS_SECTIONAL|||||||
34180473|NCT06434519|RANDOMIZED|PARALLEL||TREATMENT||NONE||5 patients will enrolled in 4 study arms. Each study arm will represent a different combination of moisturizer applied to the face, followed by metronidazole cream. No moisturizer will be applied to the left side of each patient's face, permitting for each patient to represent their own negative (no metronidzole cream applied) and positive control (metronidazole cream + no moisturizer). Metronidazole penetrance in the stratum corneum will be assess with tape strips and LC-MS||||
34180474|NCT01283139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180475|NCT00628420|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34180476|NCT00231738|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180477|NCT00001188||||TREATMENT||||||||
34180478|NCT06599385|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective non-inferiority open-label randomised trial with two comparative groups||||
34180479|NCT06491459|||COHORT||RETROSPECTIVE|||||||
34180480|NCT01484587|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34180481|NCT01416220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180482|NCT04796155|||COHORT||PROSPECTIVE|||||||
33866799|NCT01512602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33866800|NCT03146767|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33866801|NCT06287814|||COHORT||PROSPECTIVE|||||||
33866802|NCT03011697|||COHORT||PROSPECTIVE|||||||
33866803|NCT01678482|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33866804|NCT05513625|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Sequence for all subjects:~Treatment 1: single dose of 100 mg PTV followed by Wash out period (4weeks) followed by Treatment 2: single dose of 100 mg PTV Day 1 and 40 mg/day ESO from Day -3 to Day 1"||||
33866805|NCT00943527|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866806|NCT03126396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866807|NCT02644850|||CASE_ONLY||PROSPECTIVE|||||||
33866808|NCT06471426|NA|SINGLE_GROUP||TREATMENT||NONE||This study will utilize a pretest-posttest design which will measure changes in the following in response to a 4-week OMT intervention.||||
33866809|NCT02413450|||FAMILY_BASED||PROSPECTIVE|||||||
33866810|NCT06115941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180483|NCT03666754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The randomised clinical trial with participants randomised1:1 to either:~'Standard' therapy consisting of multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed) Early endovenous glue embolization of superficial venous reflux(within 2 weeks) in addition to standard therapy"|f|f|f|t
33866811|NCT01909648|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866812|NCT02460705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866813|NCT05793294|||COHORT||PROSPECTIVE|||||||
33866814|NCT03429439|RANDOMIZED|PARALLEL||TREATMENT||NONE||an open label, parallel study||||
33866815|NCT04347070|||COHORT||RETROSPECTIVE|||||||
33866816|NCT06071767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866817|NCT01765842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866818|NCT02871804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866819|NCT00745199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866820|NCT01045798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866821|NCT02126449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866822|NCT01817907|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34180484|NCT00307801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180485|NCT01457508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180486|NCT04382950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180487|NCT06598657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180488|NCT04591483|||COHORT||PROSPECTIVE|||||||
34180489|NCT00821548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180490|NCT05628064|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross-over controlled trial||||
34180491|NCT06654063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180492|NCT03278249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180493|NCT00888173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180494|NCT02546518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180495|NCT03484754|RANDOMIZED|PARALLEL||TREATMENT||NONE|blinding impossible|"The main pitfall of these studies is indeed the difficulty in ensuring a double-blind when the TB is injected into the corrugator and the procerus with placebo as physiological saline, since the patient as the examiner can guess which product was administered.~The main objective of our study is therefore to evaluate the efficacy of OnaA injections in the glabellar zone , using lateral muscle injection orbicularis oculi (involved in crow's feet wrinkles) as another injection zone in comparison."||||
34180496|NCT05323812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180497|NCT06588543|||COHORT||OTHER|||||||
34180498|NCT05936580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866823|NCT04719494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180499|NCT01178047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866824|NCT02140333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866825|NCT03660709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33866826|NCT03039166|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866827|NCT04169022|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33866828|NCT04416347|||COHORT||RETROSPECTIVE|||||||
33866829|NCT00128284|||CASE_CONTROL||PROSPECTIVE|||||||
33866830|NCT00941161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33866831|NCT02465983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866832|NCT02263521|||COHORT||CROSS_SECTIONAL|||||||
33866833|NCT03645265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single case experimental design||||
33866834|NCT02739750|||COHORT||PROSPECTIVE|||||||
33866835|NCT03535714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866836|NCT02616744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866837|NCT00001096||||PREVENTION||DOUBLE||||||
33964359|NCT01135108|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33964360|NCT04590898|||COHORT||RETROSPECTIVE|||||||
34065755|NCT06038006|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|During this study, results of the radar-based Sleep Respiratory Monitoring System are not known by the investigator and outcomes assessor, including the personnel who scores PSG.|||||
34065756|NCT01528137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065757|NCT03208413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065758|NCT04296669|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Controlled trial (2 intervention groups)||||
34065759|NCT03191123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33866838|NCT01202279|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180500|NCT06317961|||COHORT||PROSPECTIVE|||||||
33866839|NCT05349526|||COHORT||RETROSPECTIVE|||||||
33752399|NCT03346226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the intervention is happend in the operation，the outcome assessment is going after the operation|Dexmedetomidine group：dexmedetomidine is given to patients under spinal anesthesia until the end of surgery propofol group:Propofol is given to patients uunder spinal anesthesia until the end of surgery|f|f|f|t
33752400|NCT04496180|RANDOMIZED|PARALLEL||PREVENTION||NONE||"* Study Type: Interventional (Clinical Trial)~* Estimated Enrollment: 334~* Allocation: Randomized control trial~* Intervention Model: Parallel Assignment~* Intervention Model Description: 2 separate treatment arms~* Primary Purpose: Prevention~* Official Title: Standard wound dressing versus prophylactic negative-pressure wound therapy after emergency laparotomy~* Estimated Study Start Date: 09.2020~* Estimated Primary Completion Date:09.2021~* Estimated Study Completion Date: 09.2025"||||
33752401|NCT00668122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752402|NCT05154279|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752403|NCT04967768|||OTHER||CROSS_SECTIONAL|||||||
33866840|NCT01555723|||COHORT||PROSPECTIVE|||||||
33752404|NCT02070055|||CASE_ONLY||CROSS_SECTIONAL|||||||
33866841|NCT01835925|||CASE_CONTROL||PROSPECTIVE|||||||
34180501|NCT06586203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"A) A pragmatic trial designed to evaluate the effectiveness of GENOCORDIA PRS testing in real-life routine practice conditions.~B) Randomization of participants into informed and uninformed populations of the Polygenic risk score test result.~C) Adaptive trial for the treatment of subjects initially uninformed of their PRS test result after 12 months if positive results."|t|t|f|f
33752405|NCT05962788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752406|NCT05624125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866842|NCT00617487|||COHORT||PROSPECTIVE|||||||
33866843|NCT02293850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866844|NCT03129451|||CASE_ONLY||PROSPECTIVE|||||||
33866845|NCT04022187|||OTHER||PROSPECTIVE|||||||
33866846|NCT04843215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180502|NCT04675125|||COHORT||PROSPECTIVE|||||||
33866847|NCT03511534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants will choose to enter the psychotherapy or pharmacotherapy arm.||||
34180503|NCT06587295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34180504|NCT01188343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180505|NCT06596278|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Stage 1||||
34180506|NCT06586333|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study Design and Participants The study is a prospectively designed, nonrandomized controlled study. It was conducted for six months at the EICU and GICU of a training and research hospital between 1 Jun 2023 and 1 December 2023.~The study involved GICU patients as the standard care services observation group (OG). The use of SUP in the GICU was only monitored and noted. In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines \[1\]. The study duration was six months concurrently in the EICU and the GICU. Before inclusion, written informed consent was obtained from each patient or their parent(s)/legal guardian(s). Subjects with incomplete data were excluded. The inclusion criteria were patients aged ≥18 years and hospitalized for ≥24 hours in the EICU/GICU. Patients with a history of stomach cancer, admission to the ICU because of GI bleeding, subtotal/tot"||||
34180507|NCT06035016|||COHORT||PROSPECTIVE|||||||
34180508|NCT03384615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Block randomization in REDcap (copyright by Vanderbuilt University, USA) conducted by external biostatistician|f|f|f|t
34180509|NCT06161246|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive comfort intervention on one side of face, and will not receive comfort intervention on the other side of face.||||
34180510|NCT02863692|||OTHER||PROSPECTIVE|||||||
34180511|NCT00817843|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34180512|NCT05068297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180513|NCT06101784|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind|Double-Blind, Placebo-Controlled, Randomized, Adaptive, First-in-Human Study, Single and Multiple Ascending Oral Doses|t|t|t|t
34180514|NCT04909463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34180515|NCT06597981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180516|NCT05696288|RANDOMIZED|PARALLEL||PREVENTION||NONE||To compare the incidence of oxygen desaturation in patients ventilated with the Optiflow™ system to that of patients treated according to the standard technique.||||
34180517|NCT02470364|||COHORT||PROSPECTIVE|||||||
34180518|NCT02320084|||COHORT||OTHER|||||||
34180519|NCT00441077|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180520|NCT06520033|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180521|NCT06173323|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Statistician is masked||f|f|t|t
34180522|NCT00092417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180523|NCT00247663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180524|NCT00700479|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34180525|NCT02599571|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33866848|NCT04427683|RANDOMIZED|PARALLEL||TREATMENT||NONE||Recruited and eligible participants will be randomised into an intervention group and a wait-list control group.||||
33866849|NCT01148849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866850|NCT02748850|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33866851|NCT05049980|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752407|NCT04958109|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33866852|NCT00314509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866853|NCT01536951|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33866854|NCT02630732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33866855|NCT02608060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866856|NCT01504490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866857|NCT03195751|||COHORT||PROSPECTIVE|||||||
33866858|NCT00136409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866859|NCT05718479|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention consists of four weekly individual sessions. In Step One, participants identify ways of coping with stress and create a behavior change plan with measurable goals. An initial 1-hour semi-structured interview provides an opportunity to self-assess motivation to change a health behavior. Step Two facilitates a behavior plan assisting participants to identify a measurable goal, barriers to achieving their goal, strategies to mitigate triggers, social supports, and progress rewards. Sessions 2-4 include a 10-minute check-in to assess the status of targeted behaviors, troubleshoot potential barriers, modify the plan, and reinforce progress followed up with 20-minutes of practicing mindfulness. In Step Three, participants will learn and practice mental wellness skills (e.g., tracking, resourcing, grounding, gesturing), which can be applied to changing a behavior.||||
33866860|NCT06473883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33866861|NCT03433495|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A neuropsychologist blinded to the patients' clinical characteristics and the group to whom the patient was allocated evaluated outcome variables.||f|f|f|t
33752408|NCT02194270|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752409|NCT03806270|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752410|NCT05137132|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized controlled, double-blinded, placebo-controlled|t|t|t|f
33752411|NCT03327987|||CASE_ONLY||PROSPECTIVE|||||||
33752412|NCT02800850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33752413|NCT00549588|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33752414|NCT02045394|||COHORT||PROSPECTIVE|||||||
33752415|NCT06732661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752416|NCT05335317|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The treatment method cannot be hidden from the participants and the researcher because of the very different method of treatment: laser treatment and the use of local hormones on their own. However, the specialists involved in the study (cytologist and ultrasound specialist) will not know which group the participant belongs to. The researcher will refer participants (or their materials) to these specialists, indicating their name and visit number. The Researcher will keep a document matching the participant's name and number.~The conversation will be held with participants. The participant must not disclose his group when visiting an ultrasound specialist."||f|f|f|t
33752417|NCT06343610|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33752418|NCT02392013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752419|NCT01911039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752420|NCT00425048|||||PROSPECTIVE|||||||
33752421|NCT01184287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752422|NCT04859504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33752423|NCT06430983|||COHORT||PROSPECTIVE|||||||
33752424|NCT03058588|||FAMILY_BASED||PROSPECTIVE|||||||
33752425|NCT06580964|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded||f|f|f|t
33752426|NCT03833999|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind|double-blind, two-period, two-treatment crossover trial|t|f|t|f
33752427|NCT05280301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866862|NCT00943709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866863|NCT03573609|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33866864|NCT01772901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866865|NCT02809014|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|masking by color and QR code|The intervention was based on the use of dentifrices: experimental dentifrices: placebo (without F and without tara gum), 100-TGF (NaF associated with tara gum, 1100 mg/L F), 50-TGF (50% NaF associated with tara gum + 50% free NaF, 1100 mg/L F), positive control (PC) (free NaF, 1100 mg/L F), and TG (with tara gum and without F) (Savoy SA, São Paulo, Brazil).|t|t|t|f
33866866|NCT04615468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866867|NCT00246909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866868|NCT06034171|RANDOMIZED|PARALLEL||TREATMENT||NONE||two arms, split-mouth, randomized||||
33866869|NCT00873366|||CASE_ONLY||PROSPECTIVE|||||||
33866870|NCT04596020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will not be aware of group allocation.||f|f|f|t
34180526|NCT06591806|||COHORT||PROSPECTIVE|||||||
34180527|NCT02700061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34180528|NCT06193096|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, prospective, double-blind, placebo-controlled|t|f|t|t
34180529|NCT02968758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180530|NCT02084992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180531|NCT00595088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180532|NCT06591299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive loading doses of clopidogrel and aspirin or cilostazol and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 870 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 870. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included clopidogrel, and Drug B included cilostazol. Both groups received an open-label loading dose of 300 mg of aspirin and continued on aspirin 75 mg daily.|The investigators will conduct our single-blinded randomized controlled trial, which will contain two arms; the clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day). The cilostazol arm will receive (a 200mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day). both groups received open-labelloading dose 300 mg aspirin and continued on open-label aspirin 75 mg daily|f|f|t|t
34180533|NCT00004688||||TREATMENT||||||||
34180534|NCT04734028|||CASE_CONTROL||PROSPECTIVE|||||||
34180535|NCT04906811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180536|NCT03331315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180537|NCT05902364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180538|NCT05844579|||COHORT||PROSPECTIVE|||||||
34180539|NCT06346717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34180540|NCT06389422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180541|NCT06262321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180542|NCT05833763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180543|NCT00853307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180544|NCT04021654|||COHORT||PROSPECTIVE|||||||
34180545|NCT06450899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study will be a placebo-controlled, double blinded trial. Intervention and placebo are non-identical though very similar in appearance and will be stored in opaque vials. A non-blinded study team member will be solely in charge of dispensing medications.|Prospective double-blind, placebo controlled randomized controlled trial|t|t|t|t
34180546|NCT05129345|||OTHER||CROSS_SECTIONAL|||||||
34180547|NCT06473740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180548|NCT01547923|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180549|NCT06601439|||COHORT||CROSS_SECTIONAL|||||||
33752428|NCT05385120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Randomised Pilot study||||
33752429|NCT06635486|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive the intervention (n = 60) or wait list control (n = 30).||||
33752430|NCT03680755|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the obvious differences between those who will receive the Internet-based dental anxiety and those who will not (i.e., those who are assigned to the control condition), we will not be able to blind patients to this aspect of randomization. Patients will not be informed about the professional affiliation of therapy aides, who will dress similarly (e.g., professional dress and a lab coat) and who will be instructed not to respond to questions related to this topic.|This will be a single-center parallel groups study with randomization to one of three arms: (1) a treatment condition (Tr1) in which the dental anxiety intervention is administered by CBT personnel (n=150), (2) a treatment condition in which the dental anxiety intervention is administered by dental staff (Tr2) (n=150), or (3) an active control (AC) group (notification of the dental providers of the patient's score on a dental anxiety scale before their dental treatment appointment). In addition, control participants will be asked to view a video of nature scenes for a period of time equivalent to the dental anxiety intervention.||||
33752431|NCT06669624|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||RCT with a waitlist control group|f|t|t|t
33752432|NCT06700343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33866871|NCT01747967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866872|NCT04533282|||COHORT||PROSPECTIVE|||||||
33866873|NCT01891708|||CASE_ONLY||PROSPECTIVE|||||||
33866874|NCT03453073|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33866875|NCT00307333|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866876|NCT00454857|||COHORT|||||||||
33866877|NCT03364361|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33866878|NCT00224094|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866879|NCT03306082|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Cohort study||||
33866880|NCT00346554|||COHORT||PROSPECTIVE|||||||
33866881|NCT04195048|||CASE_CONTROL||RETROSPECTIVE|||||||
33866882|NCT03821818|||CASE_CONTROL||PROSPECTIVE|||||||
33866883|NCT04494139|RANDOMIZED|PARALLEL||PREVENTION||NONE||Arm 1: Canteen only intervention Arm 2: Canteen and behavioral intervention||||
33866884|NCT04714528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866885|NCT00750971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866886|NCT03496012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866887|NCT05707832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866888|NCT05638451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866889|NCT03677050|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|colonoscopist accessing BBPS scores will be blinded; investigator will also assess BBPS scores (not blinded)|Randomized clinical trial|f|f|f|t
33866890|NCT04162184|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33866891|NCT03086057|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In Stage 1, individuals will be randomized (1:1) to receive the experimental PrEP navigation or standard of care. Among those who uptake PrEP in Stage 1, we will randomize those participants in Stage 2 (1:1) to receive the experimental adherence counseling or standard of care.|f|f|f|t
33866892|NCT02033954|||CASE_ONLY||PROSPECTIVE|||||||
33866893|NCT04973020|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study is a single-center, open, single-dose, self-controlled clinical trial.||||
33866894|NCT03084406|RANDOMIZED|PARALLEL||OTHER||NONE||The pilot test will employ a Hybrid Type II study design to simultaneously test the clinical evidence-based program as well as the implementation strategy.||||
33866895|NCT00004152||||DIAGNOSTIC||||||||
33866896|NCT05048953|||CASE_CONTROL||PROSPECTIVE|||||||
33866897|NCT00570973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866898|NCT06466538|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34180550|NCT03823521|NA|SINGLE_GROUP||OTHER||NONE||||||
34180551|NCT06394050|||COHORT||RETROSPECTIVE|||||||
34180552|NCT04030143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180553|NCT04069234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180554|NCT02949336|||CASE_CONTROL||PROSPECTIVE|||||||
34180555|NCT05469386|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34180556|NCT01801163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180557|NCT00664443|||COHORT||PROSPECTIVE|||||||
34180558|NCT02124369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180559|NCT01843621|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34180560|NCT05413759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180561|NCT01001221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180562|NCT05710224|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34180563|NCT03056092|NA|SINGLE_GROUP||TREATMENT||NONE||This study will include patients with 3 different diseases who will receive the same treatment (ranibizumab injections) but that will be independently analyzed. One population will be composed of patients with neovascular age related macular degeneration, the other of diabetic macular edema and the third of patients with macular edema secondary to retinal vein occlusion.||||
34180564|NCT03479255|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective clinical trial that will randomize patients in 1:1 ratio to smartphone-enabled structured exercise therapy (SE-SET) vs. standard exercise therapy (usual care)||||
34180565|NCT02991222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180566|NCT00620451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|randomized, parallel- group, double-blind, multicenter|t|f|t|f
34180567|NCT03706755|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180568|NCT04475367|RANDOMIZED|PARALLEL||SCREENING||SINGLE|blind research assistant|The participants will be randomized into 2 intervention groups|f|f|f|t
34180569|NCT01451112|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34180570|NCT06577155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180571|NCT03299166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180572|NCT06602245|||COHORT||PROSPECTIVE|||||||
34180573|NCT02835248|||COHORT||PROSPECTIVE|||||||
34180574|NCT03629977|||COHORT||PROSPECTIVE|||||||
34180575|NCT00999947|||COHORT||PROSPECTIVE|||||||
34180576|NCT00696072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180577|NCT02017405|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34180578|NCT05855798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180579|NCT00004563|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180580|NCT03960749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants are not informed about the allocated needle. The follow-up telephone calls (outcome assessment) are made by an assistant nurse who is unaware of randomization allocation.|Randomized, parallel group. Randomization between three different lumbar puncture needles and between stylet reinsertion of not before needle withdrawal.|t|f|f|t
34180581|NCT06603025|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|The statistician will not know which group the intervention is for. Data entry will be made as A and B.|prospective randomized controlled trial with experimental and control groups|f|f|f|t
34180582|NCT03551236|||COHORT||PROSPECTIVE|||||||
34180583|NCT02799446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180584|NCT04123470|NA|SEQUENTIAL||TREATMENT||NONE||Participants treated with LOAd703 at two dose levels (1x10e11 VP and 5x10e11VP) and fixed dose of atezolizumab||||
34180585|NCT04207814|NA|SINGLE_GROUP||OTHER||NONE||Case couples||||
34180586|NCT05843097|||COHORT||PROSPECTIVE|||||||
34180587|NCT03745612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180588|NCT06593782|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180589|NCT06597084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180590|NCT04423666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were randomly assigned through a toss of a coin to either the intervention or control|Convenience sample, randomized, intervention, pre-post design|t|f|f|f
34180591|NCT00736021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180592|NCT06602310|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33866899|NCT01408433|RANDOMIZED|PARALLEL||||NONE||||||
33866900|NCT00589498|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33866901|NCT04962217|||OTHER||OTHER|||||||
33866902|NCT03413852|||COHORT||PROSPECTIVE|||||||
34065760|NCT02652598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065761|NCT02907619|NA|||TREATMENT||NONE||||||
34065762|NCT01329666|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34180593|NCT05132556|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The experimenter will be blinded to what condition the participant is in, and all data analysis will be conducted blinded to the condition as well.|The intervention is to provide participants with either nitrate-rich (\~12.8 mmol nitrate; 140 mL) beetroot juice or an indistinguishable equal volume placebo with nitrate removed, the order of which will be randomized.|f|f|t|f
34180594|NCT03852056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All clinical product will be in a plain white toothpaste tube or over wrapped with white laminate material to conceal any product identity. All study treatments will have a clinical label attached that contains study information and a unique product code.|Tooth brushing study. Subjects brush their whole mouth 2x/day for 1 minute each time. The study duration is 6 months|t|f|t|t
34180595|NCT06599788|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34180596|NCT02807402|||COHORT||PROSPECTIVE|||||||
34180597|NCT02085967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964361|NCT04062461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Experimental group:~-Self-care promotion using a multifaceted strategy based on the use of a tele-monitoring device, based on short message system (SMS) messages and self-care teaching tools.~Patients will receive daily messages to optimize self-care in heart failure with the following functions:~* customized reminders about medication schedules~* weight and symptoms of decompensation monitoring assessing a decision tree with diuretics adjustment if needed and alerts that define the need to contact a health professional for early intervention before deterioration of the clinical state, identifying situations that require clinical intervention.~* educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)~* diary for registration of visits to health services and clinical setting.~Control group:~-Usual outpatient care"|A randomized, multicenter, national, phase II clinical trial aimed at evaluating the effectiveness of self-care promotion using a multifaceted strategy based on sending text messages SMS to patients with heart failure.|f|f|f|t
33964362|NCT02760784|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065763|NCT00846690|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34065764|NCT01478607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065765|NCT02668159|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34065766|NCT00414193|||OTHER||RETROSPECTIVE|||||||
34065767|NCT03541434|||COHORT||PROSPECTIVE|||||||
34065768|NCT04794114|NA|SEQUENTIAL||TREATMENT||NONE||||||
34065769|NCT05436678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065770|NCT01330056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065771|NCT06229613|||CASE_ONLY||PROSPECTIVE|||||||
34065772|NCT04065581|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34065773|NCT00408187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065774|NCT01824121|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34065775|NCT02860871|||COHORT||PROSPECTIVE|||||||
34180598|NCT03013231|||COHORT||PROSPECTIVE|||||||
34180599|NCT06595966|||COHORT||PROSPECTIVE|||||||
34180600|NCT01342861|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180601|NCT06429280|||COHORT||RETROSPECTIVE|||||||
34180602|NCT05625113|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One arm with participants who are not blinded. All participants benefit from the intervention (neuroprosthesis). Some outcomes (functional unimanual and bimanual task, ARAT) are blinded regarding whether or not the neuroprosthesis is activated (assessment from videos).||||
34180603|NCT03544749|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized controlled trial|t|f|f|t
34180604|NCT00896077|RANDOMIZED|CROSSOVER||||NONE||||||
34180605|NCT02086578|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180606|NCT00464633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180607|NCT04777331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180608|NCT06587945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multi-centre participant- and assessor-masked placebo-controlled randomised superiority trial with two parallel groups.|t|t|t|t
34180609|NCT05122338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34065776|NCT00392496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065777|NCT02634905|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34180610|NCT06591832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
34180611|NCT06519942|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34180612|NCT03865979|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180613|NCT00307710|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34180614|NCT06594861|||CASE_CONTROL||PROSPECTIVE|||||||
34180615|NCT06204757|||COHORT||PROSPECTIVE|||||||
34180616|NCT06585852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866903|NCT00102960|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study had two parts: Part A where children were enrolled with CD4% ≥ 25% and Part B where children were enrolled with CD4% \< 25%. Part A had three arms: ART-Deferred, ART-40W and ART-96W where ART-40W and ART-96W were the early therapy arms for 40 and 96 weeks respectively. Part B were enrolled into two Arms: ART-40W and ART-96W. The primary efficacy analysis for CHER was based on 377 children that were enrolled in Part A in the first phase of the study. The NIH African data safety and monitoring board recommended that primary analysis be focussed on 377 children enrolled in the first phase of Part A. Additionally, all the key manuscripts have been analysed using this group. Hence all the results presented in clinicaltrials.gov will be specific to this group with three arms.||||
33866904|NCT06456528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866905|NCT00854698|NON_RANDOMIZED|PARALLEL||||NONE||||||
33866906|NCT01699542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866907|NCT04045704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866908|NCT05627544|||OTHER||RETROSPECTIVE|||||||
33866909|NCT03078712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866910|NCT03161288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866911|NCT02841202|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33964363|NCT06098222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33964364|NCT03474289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964365|NCT01669668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866912|NCT02386527|||COHORT||PROSPECTIVE|||||||
33964366|NCT03291678|RANDOMIZED|PARALLEL||TREATMENT||NONE||one group which is control group will not subjected to internal ring ligation and another group will subjected to closure of the internal ring||||
33964367|NCT05079152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Serum testing technicians were masked.||f|f|f|t
34180617|NCT03546686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180618|NCT01374438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964368|NCT04507529|NA|SINGLE_GROUP||OTHER||NONE||||||
34180619|NCT03583892|||CASE_CONTROL||PROSPECTIVE|||||||
34180620|NCT02431637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180621|NCT03051178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180622|NCT06125041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180623|NCT06587022|||COHORT||OTHER|||||||
34180624|NCT01114243|||CASE_ONLY||PROSPECTIVE|||||||
34180625|NCT04125927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180626|NCT04084236|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34180627|NCT01941810|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34180628|NCT02749422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34180629|NCT04900116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33752433|NCT04763200|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized, parallel-controlled, open-label two-arm trial with an adaptive design.||||
33752434|NCT06162767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866913|NCT04434950|NA|SINGLE_GROUP||SCREENING||NONE||||||
33866914|NCT06214247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866915|NCT01809132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866916|NCT04354909|||COHORT||PROSPECTIVE|||||||
33866917|NCT03101774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866918|NCT01161043|NA|SINGLE_GROUP||OTHER||NONE||||||
33752435|NCT04490486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752436|NCT06575439|||COHORT||OTHER|||||||
33752437|NCT02568930|||OTHER||PROSPECTIVE|||||||
33964369|NCT01523522|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33964370|NCT02720224|NA|SINGLE_GROUP||OTHER||NONE||||||
33964371|NCT02412956|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964372|NCT05956171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-arm study with one hydrodilatation group compared with the standart treatment group(cortisteroid injection)|f|f|f|t
33964373|NCT05573373|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752438|NCT04250129|||CASE_CONTROL||PROSPECTIVE|||||||
33964374|NCT00897273|||COHORT||PROSPECTIVE|||||||
33752439|NCT06350032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752440|NCT03575325|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single arm, single center, phase 2 pilot study of Vyxeos induction \& consolidation in relapsed and refractory ALL.||||
33752441|NCT06720948|||COHORT||OTHER|||||||
34180630|NCT05574387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|t|f|f
34180631|NCT05788770|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, multinational, randomized controlled, open-label, trial||||
34180632|NCT03530215|||CASE_ONLY||CROSS_SECTIONAL|||||||
34180633|NCT06422819|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The participants won't be informed of the condition to which they belong. A debriefing will be done at the end of the last intervention (V3) for each participant.|This study consists of 5 visits (V1, V2, V3, V4, V5). At V1, participants will be randomized into two groups: HRV-BFB (experimental group) or Pseudo HRV-BFB (control group). Participants will remain single-blinded after randomization. Depending on the assigned group, participants will practice one specific intervention during the first 30-day period (V1-V2). At V2, participants will switch to the other arm and practice the second intervention during the second 30-day period (V2-V3). At V3, both interventions will end, and participants will be unblinded and encouraged to continue HRV-BFB at home. Clinical evaluation will be repeated 5 times at day 1 (V1), days 30 +/- 10 (V2), days 60 +/- 10 (V2), 6 months (V4) and 1 year (V5). The research team will exercise extreme caution to ensure consistent instructions and feedback, minimizing biases associated with lack of double-blinding.|t|f|f|f
34180634|NCT04276896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752442|NCT04659655|NA|SINGLE_GROUP||OTHER||NONE||||||
33752443|NCT04994834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964375|NCT04844307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964376|NCT03597399|||COHORT||OTHER|||||||
33964377|NCT01524588|||COHORT||PROSPECTIVE|||||||
33964378|NCT05103514|||COHORT||PROSPECTIVE|||||||
33964379|NCT03005379|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180635|NCT01712035|||CASE_CONTROL||PROSPECTIVE|||||||
34180636|NCT03100149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180637|NCT03067077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180638|NCT06603480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180639|NCT06599593|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180640|NCT05800080|RANDOMIZED|PARALLEL||TREATMENT||NONE||"one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy Penpulimab (single immunity, fixed dose 200mg) orCadonilimab (double immunity, fixed dose 500mg), which will be administered on the first day of each cycle and repeated every three weeks; Anlotinib Hydrochloride Capsules: 12mg, administered on the 1-14th day of each cycle~Other Names:~Teggio Oxaliplatin"||||
34180641|NCT01052727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180642|NCT05899426|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups will receive different exercise program for 12 weeks.||||
34180643|NCT01456039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180644|NCT02087280|||COHORT||PROSPECTIVE|||||||
34180645|NCT05809557|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Providers, who were selected based on having at least 20 new patients with metastatic solid tumors in a 6-month period in 2021, will be randomized in a 1:1 ratio, stratified by quartiles of patient volume.|t|f|f|f
34180646|NCT03806361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will not know which treatment they will receive, outcome assessors will also be blinded.|Randomized, controlled, clinical trial with 2 parallel comparison groups|t|f|f|t
34180647|NCT01217229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752444|NCT05402657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors completing assessments of mood (primary outcome) will be blinded to the participant's treatment allocation until the database is locked and the primary analysis completed. Hospital ward personnel, if not involved in the delivery of ECT, will also be blinded.||t|f|f|t
33752445|NCT02624362|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33964380|NCT04971915|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34180648|NCT06507111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34180649|NCT02961894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180650|NCT03217604|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34180651|NCT06655051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180652|NCT04530617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The masking of the protocol will be maintained throughout the duration of the study. This will be done with the use of a matched placebo and a non-continuous coding (tablets in the case of camostat and tea bags/coffer for Artemisia) that has the same description and dose as the interventions so that both, the investigators and the patient does not know the treatment assignment.|A randomized, placebo-controlled, parallel, multicenter, multi-arm, phase II trial of novel agents for treatment of high-risk COVID-19 positive outpatients. Subjects who meet the inclusion/exclusion criteria and have properly signed the informed consent will be randomized to the test group or placebo group in the ratio of 1:1:1:1.|t|t|t|f
34180653|NCT05423210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180654|NCT04558619|NA|SINGLE_GROUP||OTHER||NONE||||||
34180655|NCT01748292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180656|NCT01632696|NA|SINGLE_GROUP||OTHER||NONE||||||
34180657|NCT06654128|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||comparison of 2 groups of patients undergoing tandem colonoscopy||||
34180658|NCT03609073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180659|NCT04502095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964381|NCT05699811|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33752446|NCT06636981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752447|NCT06731998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752448|NCT02122133|||CASE_CONTROL||PROSPECTIVE|||||||
33752449|NCT02635269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33752450|NCT05668962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964382|NCT00451269|||CASE_CONTROL||PROSPECTIVE|||||||
33964383|NCT04407468|||COHORT||RETROSPECTIVE|||||||
33964384|NCT01398774|||COHORT||CROSS_SECTIONAL|||||||
33964385|NCT04664829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964386|NCT02966522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964387|NCT02124746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964388|NCT00124475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964389|NCT02751242|||COHORT||PROSPECTIVE|||||||
33964390|NCT01160198|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33964391|NCT04429373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation sequence will be masked from participant, outcome assessor and statistician|We will conduct a split-mouth design randomized clinical trial|t|f|t|t
33964392|NCT06517732|||CASE_ONLY||PROSPECTIVE|||||||
33964393|NCT03811249|NA|SINGLE_GROUP||TREATMENT||NONE||A non-randomized single group design. All subjects who were implanted with the VisAbility™ Micro Insert (360 subjects) will be invited to participate. Actual sample size will be determined at the completion of enrollment.||||
33964394|NCT05795517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964395|NCT01829295|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33964396|NCT01278199|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964397|NCT00046384||||TREATMENT||||||||
33964398|NCT00142454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964399|NCT01869712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964400|NCT03556917|RANDOMIZED|FACTORIAL||TREATMENT||NONE||It is a longitudinal and randomized||||
33964401|NCT06257576|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964402|NCT00971399|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33964403|NCT05229315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866919|NCT05563519|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||Fifty patients were included for the randomized, prospective, split mouth and single-blind study. Two groups were formed in the study. The lower right and lower left wisdom teeth of the patients with extraction indication for lower impacted wisdom teeth were included in separate groups. In the first group (on one side of the same patients), leukocyte platelet-rich fibrin (L-PRF, 2700rpm,12 min) was obtained after lower impacted wisdom tooth surgery, applied into the socket and sutured. The other tooth of the patient was operated 5 weeks after the operation of the region included in the first group. In the second group (to the other side of the same patient), injectable platelet-rich fibrin (I-PRF, 700rpm, 3min) was obtained and 1\*2 cm type 1 collagen plug (ACE RCP, Resorbable Collagen Plug, Collagen Matrix, Inc. Oakland, New Jersey) USA)) was impregnated and applied into the socket as such. It was followed for 4 weeks.|t|t|t|t
33866920|NCT02002351|||COHORT||PROSPECTIVE|||||||
33866921|NCT02154542|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33866922|NCT02616757|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33866923|NCT05827055|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double blinded||t|t|t|f
33866924|NCT05166915|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Randomized, Sham Control|Subjects will be randomized 1:1 to receive treatment with the functional UVA light catheter or the sham control device.|t|t|f|f
33866925|NCT03618784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33866926|NCT00453648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866927|NCT00193089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964404|NCT01901146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964405|NCT00568776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964406|NCT03826771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964407|NCT05266976|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Design with 2 study arms: endurance exercise and resistance exercise||||
33964408|NCT04313023|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964409|NCT03755700|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33964410|NCT00418080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33964411|NCT00079144||||TREATMENT||NONE||||||
33964412|NCT01142466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866928|NCT03868852||SEQUENTIAL||TREATMENT||NONE||Simons two-stage design method requires the enrollment of 13 patients in the first stage. If more than 7 patients fail to reach the expected end point, the first stage fails and the patients do not need to enter the second stage. A total of 48 patients were enrolled. If more than 30 patients did not reach the expected end point, the overall trial failed.||||
33866929|NCT04666350|||OTHER||PROSPECTIVE|||||||
33866930|NCT01732796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866931|NCT04243850|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with either preserved or impaired renal function with or without type 2 diabetes|t|t|t|t
33866932|NCT02958007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866933|NCT02560363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34180660|NCT04013997|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Prospective subjects were recruited following admission to the SCI inpatient unit at Mount Sinai Hospital. Attending physicians and rehabilitation clinicians identified patients admitted to the unit who may be eligible for the study. Consent forms were given to prospected participants. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation. The study team monitored participants for adverse events (safety), tracked the amount of walking provided during the inpatient stay (feasibility), and explored the improvement of activities of daily living compared to matched control group who didn't have Ekso training chosen from retrospective chart review.||||
34180661|NCT06601595|||COHORT||PROSPECTIVE|||||||
33866934|NCT06493344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866935|NCT00963755|||COHORT||PROSPECTIVE|||||||
33964413|NCT05674071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964414|NCT00581386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964415|NCT01625286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180662|NCT03800992|||COHORT||PROSPECTIVE|||||||
34180663|NCT05855707|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34180664|NCT04080505|RANDOMIZED|PARALLEL||OTHER||NONE||"All participants complete a baseline neck ultrasound no less than 7 days prior to surgery, to obtain vascular flow imaging. Participants are then randomized to receive 7 days of pre-operative SSKI or not receive any drug. In the practice at Columbia, all patients with Graves' disease receive SSKI preoperatively, though this is not standard practice across the country, thus the 'no drug' group is experimental for research.~All participants complete a second ultrasound on the operating table before surgery, to assess for change in vascularity (experimental, as not all patients receive intra-operative ultrasounds before surgery). Both ultrasounds are performed by the surgeon."||||
34180665|NCT02360254|||COHORT||PROSPECTIVE|||||||
34180666|NCT04475146|||OTHER||PROSPECTIVE|||||||
34180667|NCT06586645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34180668|NCT06603766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180669|NCT03730753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180670|NCT02515370|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180671|NCT01473888|NA|SINGLE_GROUP||||NONE||||||
34180672|NCT06414369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180673|NCT06595797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180674|NCT04611646|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be conducted as a five-week intervention. In the heat-suit arm, participants will conduct a 50-minute low-intensity cycling session with heat suit five time a week. In the none-heat-suit arm, participants will conduct similar amounts of low-intensity cycling without heat suit. These training sessions will complement the habitual training of the participants. Participants will be allocated into the two arms in a planned randomized manner. In short, participants will be stratified based on baseline performance levels (VO2max), whereby they will be allocated into the two intervention arms in a manner that ensures similar average performance levels between the two arms.||||
34180675|NCT06587841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinded, sham-controlled clinical trial|"* Intervention Phase 1 (stimulation sessions) - 8 weeks: Participants will be randomized into one of two groups and be blinded to treatment assignment: Group 1 (treatment condition) will receive TSCS for 1 hour, 3 times/week; Group 2 (sham condition) will receive sham stimulation for 1 hour, 3 times/week.~* Intervention Phase 2 (stimulation sessions) -8 weeks: Group 1 will continue to receive TSCS for 1 hour, 3 times/week, and Group 2 will switch from sham stimulation to TSCS for 1 hour, 3 times/week."|t|f|f|f
34180676|NCT04857476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180677|NCT02883712|||COHORT||PROSPECTIVE|||||||
34180678|NCT04029636|||COHORT||CROSS_SECTIONAL|||||||
34180679|NCT03889808|||OTHER||CROSS_SECTIONAL|||||||
34180680|NCT00524836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34180681|NCT05005234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180682|NCT05196152|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are assigned to either: 1) MomMoodBooster or 2) MomMoodBooster + phone coaching.||||
34180683|NCT02476877|||COHORT||PROSPECTIVE|||||||
34180684|NCT06011850|||COHORT||CROSS_SECTIONAL|||||||
34180685|NCT04257357|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Due to the intervention (exercise versus usual care) patients and trainers cannot be masked. Outcome assessors will be masked, as it will be different persons performing the 8-week follow-up, who have no knowledge of the group allocation. Furthermore, nurses and doctors providing usual care for the patients at the cardiologic departments are masked for group allocation.|Randomized clinical pilot trial with 8 weeks of follow-up|f|t|f|t
34180686|NCT06594198|NA|SINGLE_GROUP||OTHER||NONE||Single-centre, prospective, interventional clinical study||||
34180687|NCT06590259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180688|NCT01670344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180689|NCT03371667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180690|NCT00406250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180691|NCT06591559|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34180692|NCT05283031|||COHORT||PROSPECTIVE|||||||
34180693|NCT06428968|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33866936|NCT00929604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33866937|NCT05761054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866938|NCT04352192|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33866939|NCT02986581|||COHORT||PROSPECTIVE|||||||
33866940|NCT01721876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866941|NCT04180748|||OTHER||PROSPECTIVE|||||||
33866942|NCT04543799|||COHORT||PROSPECTIVE|||||||
33964416|NCT00096486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964417|NCT02050607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964418|NCT00676611|||CASE_ONLY||RETROSPECTIVE|||||||
33964419|NCT05585268|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This quality improvement, parallel group, superiority trial will use two different dialysis sites of the McGill University Health Centre. One unit will act as a control unit. The other will act as an intervention unit. Participants are automatically enrolled in the study and assigned to the intervention when the MedSafer reports are handed to the clinical team at the time of performing a medication reconciliation.||||
33964420|NCT04912635|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33964421|NCT01653470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964422|NCT00331773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964423|NCT03841565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180694|NCT05408741|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34180695|NCT03928184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180696|NCT05419895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180697|NCT06477120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||1:1 allocation ratio. Randomization will be stratified by participant age (18-30 and 31-44 years old) and preconception body mass index (BMI) 40-44.99 - 45-50.0 kg/m2.|f|f|f|t
34180698|NCT06587451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180699|NCT02731586|NA|SINGLE_GROUP||OTHER||NONE||||||
34180700|NCT03296605|||CASE_CONTROL||PROSPECTIVE|||||||
34180701|NCT03104127|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34180702|NCT00084071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33866943|NCT04246801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||At least 210 participants will be randomized in a 2:1 randomization ratio (140 to clobetasol arm, 70 to placebo arm) in order to have 202 evaluable participants (4% lost to follow-up rate expected)|t|f|t|f
33866944|NCT04468789|||COHORT||PROSPECTIVE|||||||
33964424|NCT02164539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964425|NCT03536468|||COHORT||PROSPECTIVE|||||||
33964426|NCT02252484|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964427|NCT05644938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are only blinded to the allocation.|A prospective, randomized, controlled, single blind when patients are only blinded to the allocation, our clinical trial was conducted comparing One-stop (OS) management with our standard workflow (SW) in treatment of acute ischemic stroke from 12/2022 - 11/2023 at Can Tho SIS General Hospital. Patients were enrolled according to 1:1 enroll ratio (OS: SW). The OS group transferred directly to biplane flat panel detector computed tomography perfusion (FD-CTP) to consider recanalization by either intervention or recombinant Tissue Plasminogen Activator (rTPA) in the angiosuite, whereas the SW group was either transferred to angiosuite or received rTPA, if indicated, after the results of Magnetic resonance imaging (MRI) and Magnetic resonance angiography (MRA) at admission|t|f|f|f
34180703|NCT05955716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34180704|NCT02851277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180705|NCT05189717|NA|SINGLE_GROUP||TREATMENT||NONE||HRS-8080 tablets monotherapy and combined with other anti-cancer therapy||||
34180706|NCT06603896|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34180707|NCT05087706|||COHORT||PROSPECTIVE|||||||
33866945|NCT01056172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866946|NCT00429351|||CASE_CROSSOVER||PROSPECTIVE|||||||
33866947|NCT02479945|NA|SINGLE_GROUP||OTHER||NONE||||||
33866948|NCT04726384|||COHORT||PROSPECTIVE|||||||
33866949|NCT03372850|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33866950|NCT05031845|||COHORT||PROSPECTIVE|||||||
33866951|NCT01466530|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33866952|NCT01811784|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33866953|NCT02629796|||CASE_CONTROL||PROSPECTIVE|||||||
33866954|NCT03502239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866955|NCT01500122|NA|SINGLE_GROUP||||NONE||||||
33866956|NCT00544050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33866957|NCT01971502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33866958|NCT04700384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will not know the purpose of trial|Randomized Controlled Trial|t|f|f|t
33866959|NCT01172197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866960|NCT02887014|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33866961|NCT04115579|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33866962|NCT06417320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33866963|NCT05570591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33866964|NCT01728415|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33866965|NCT04146779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33866966|NCT03482557|NA|SINGLE_GROUP||SCREENING||NONE||||||
33866967|NCT05508009|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study has two cohorts (Cohort 1b which will be safety lead-in with 4 patients, and then cohort 2a of 8 patients). The data generated will be compared with historical data available on outcomes of KT performed as SoC in this patient population.||||
33866968|NCT03537859|RANDOMIZED|CROSSOVER||OTHER||NONE||After enrollment, patients will be allocated in either the AR group or the NoAR group. The order of the intervention will be randomly selected before recruitment. A 48 hour wash-out will take place before the second intervention.||||
33866969|NCT06144775|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33866970|NCT04722120|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants, investigators, and outcome assessors were all masked to the allocation||f|t|f|f
33866971|NCT03302104|||OTHER||CROSS_SECTIONAL|||||||
33866972|NCT01735279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33866973|NCT00959998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33866974|NCT00243698|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33866975|NCT00021151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866976|NCT04821713|||COHORT||CROSS_SECTIONAL|||||||
33866977|NCT01689675|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33866978|NCT05586048|||COHORT||PROSPECTIVE|||||||
33866979|NCT01961206|||COHORT||PROSPECTIVE|||||||
33866980|NCT05439161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33866981|NCT05045898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33866982|NCT04960020|||COHORT||RETROSPECTIVE|||||||
33866983|NCT05204823|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33866984|NCT01070121|||COHORT||PROSPECTIVE|||||||
33866985|NCT02116504|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33866986|NCT04213027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33866987|NCT01582295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866988|NCT03712748|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.||||
33866989|NCT01194583|||COHORT||PROSPECTIVE|||||||
33866990|NCT06405711|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180708|NCT02269969|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33866991|NCT00504907|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33866992|NCT06216184|||COHORT||PROSPECTIVE|||||||
33866993|NCT03083847|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964428|NCT06521606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964429|NCT00044005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964430|NCT00843804|||COHORT||PROSPECTIVE|||||||
33964431|NCT06402045|||OTHER||CROSS_SECTIONAL|||||||
33964432|NCT03817632|||COHORT||PROSPECTIVE|||||||
33964433|NCT00907855|||COHORT||PROSPECTIVE|||||||
33964434|NCT03296553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964435|NCT01358019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33866994|NCT04182633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, double-blind, placebo-controlled study.|This is a randomized, double-blind, placebo-controlled study.|t|t|t|t
33964436|NCT04399902|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33964437|NCT00447707|RANDOMIZED|PARALLEL||||SINGLE||||||
34180709|NCT01479296|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180710|NCT03422900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|cover label|Comparison of two formulas of enteral nutrition (diabetes-specific enteral formula (lower glycemic index and presence of soluble and insoluble fiber) compared to an standard formula (isocaloric and isonitrogenated formula without fiber)) in patients without diabetes mellitus admitted due to stroke and with indication of nutritional support by nasogastric tube|t|t|f|f
33866995|NCT05304650|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Open Label Study||||
33866996|NCT01999374|||OTHER||PROSPECTIVE|||||||
33866997|NCT04838665|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33866998|NCT04807855|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33866999|NCT03611868|NA|SEQUENTIAL||TREATMENT||NONE||||||
33867000|NCT02485990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867001|NCT00117546|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33867002|NCT03109379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33867003|NCT03086395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867004|NCT01309139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867005|NCT04824638|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants of group 1 will receive two administrations of BNT162b2 at Day1 and Day29 then at Month8 Participants of group 2 will receive one administration of BNT162b2 at Day1, then at Month8||||
33964438|NCT02624921|||CASE_CROSSOVER||PROSPECTIVE|||||||
33964439|NCT00698425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964440|NCT00926653|||COHORT||PROSPECTIVE|||||||
33964441|NCT01332513|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180711|NCT05784480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180712|NCT05705934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180713|NCT06594237|||COHORT||PROSPECTIVE|||||||
34180714|NCT00673101|||COHORT||PROSPECTIVE|||||||
34180715|NCT04403334|RANDOMIZED|PARALLEL||OTHER||TRIPLE|unlabelled syringe containing interventional drug||t|f|t|t
33964442|NCT02529085|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964443|NCT03140085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33964444|NCT04133545|||COHORT||PROSPECTIVE|||||||
33964445|NCT03927781|NA|SINGLE_GROUP||TREATMENT||NONE|There will be no blinding for this pilot|All participants will receive 300mg PO pregabalin one hour before procedure start||||
33964446|NCT04583904|||COHORT||PROSPECTIVE|||||||
34065778|NCT03576352|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Anesthesiologist, pediatric intensivists, surgeons, and emergency physicians who are most likely to need to perform FONA in small children, shall learn to perform RST emergent pediatric tracheotomy in less than 60 seconds. The investigators seek to measure and study their learning curves for establishing an artificial airway using the RST.~Single-center interventional trial. The only inclusion criterion is informed consent. A high quality instructional video demonstrating the RST on a rabbit cadaver will teach the participants. Performance time will be defined (from touching the skin until ventilation of the trachea with a standard self-inflating bag connected to the tube)."||||
34065779|NCT04759456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065780|NCT01832818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065781|NCT01438814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065782|NCT00396877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065783|NCT04025515|||COHORT||PROSPECTIVE|||||||
34065784|NCT00312104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065785|NCT02510703|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34065786|NCT04628078|||COHORT||PROSPECTIVE|||||||
34065787|NCT00840736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180716|NCT06654154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Each patient is his own witness to express the variation in the serum level of vitamin B12: this way we overcome individual variability.|"Determination of serum level of vitamin B12 and data collection in a patient:~* At study inclusion~* If an infection or a AI/ID relapse is suspected~* At remission in case if inclusion during AI/ID relapse~* At tocilizumab initiation if happening along with inclusion~* At Day 3 (+/-1) if an infection or AI/ID relapse is suspected and if the patient is hospitalized and if a blood test is realised"||||
34180717|NCT05135767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180718|NCT02032459|||COHORT||PROSPECTIVE|||||||
34180719|NCT06654349|||COHORT||PROSPECTIVE|||||||
34065788|NCT03321409|||OTHER||PROSPECTIVE|||||||
34065789|NCT03927326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Unblinded randomized trial|f|f|f|t
34065790|NCT04166292|NA|SINGLE_GROUP||TREATMENT||NONE|"The facial volume loss will be retrospectively assessed by a blinded independent evaluator using the Facial Volume Loss Scale (FLVS) on 3D photographs from V1 (D0 before) and at the following visits: V2 (D30 before), V3 (D90), V4 (D180), V5 (D360) and V6 (D540). The evaluator is blinded to treatment and visit number.~The overall improvement level will be retrospectively assessed by a blinded independent evaluator using the GAIS on 3D photographs at the following visits (in comparison with 3D photographs before injection): V2 (D30 before), V3 (D90), V4 (D180), V5 (D360) and V6 (D540). The evaluator is blinded to treatment and visit number."|||||
34180720|NCT03715114|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34180721|NCT06654934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180722|NCT03697148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180723|NCT02631408|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34180724|NCT04317287|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34180725|NCT04119115|||CASE_CONTROL||PROSPECTIVE|||||||
34180726|NCT04944992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180727|NCT01706133|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34180728|NCT01883258|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34180729|NCT00502476|||DEFINED_POPULATION||PROSPECTIVE|||||||
34180730|NCT06604156|||OTHER||PROSPECTIVE|||||||
34180731|NCT06600360|||OTHER||CROSS_SECTIONAL|||||||
34180732|NCT02309346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180733|NCT06313307|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34180734|NCT02850653|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34180735|NCT06595329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly divided into two groups in a 1:1 ratio. Randomization will be performed using a computer program. A research coordinator will be designated to distribute and preserve randomization results. A person designated for data analysis will be blinded for intervention performed in each group.|"Prospective, single-center, randomized controlled trial. The study will take place in the University Hospital of Split, Departments of Anesthesiology, Reanimatology and Intensive Care Medicine, and the Department of Urology.~Patients undergoing open radical or partial nephrectomy for renal cancer will be randomized to one of the two groups: Epidural analgesia (Control) or intrathecal opioid (Intervention) group. Physiologic functions (blood pressure, heart rate, peripheral oxygen saturation) will be monitored during and after the surgery. Postoperatively, pain scores at rest as well as during movement will be recorded. A total dose of intraoperative opioids, time to first rescue analgesic, and total dose of rescue analgesics as well as adverse effects during the first 72 hours postoperatively will be recorded. These parameters will be compared between the two groups."|f|f|f|t
34180736|NCT05121272|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34180737|NCT06104826|||OTHER||PROSPECTIVE|||||||
34180738|NCT05972655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180739|NCT06078501|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34180740|NCT04739761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180741|NCT00000996||PARALLEL||TREATMENT||||||||
34180742|NCT05866458|||COHORT||PROSPECTIVE|||||||
33867006|NCT03194178|||CASE_ONLY||PROSPECTIVE|||||||
33867007|NCT00492830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867008|NCT03241199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964447|NCT06110221|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33964448|NCT01197456|||COHORT||PROSPECTIVE|||||||
33964449|NCT05221385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964450|NCT04495465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups: experimental group and placebo group, receiving the intervention at the same time|t|f|f|t
33964451|NCT00619619|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33867009|NCT02269787|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33867010|NCT00041301|||CASE_ONLY||PROSPECTIVE|||||||
33867011|NCT02179671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867012|NCT04635410|||COHORT||PROSPECTIVE|||||||
34180743|NCT00361296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180744|NCT00117351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867013|NCT00791674|||COHORT||PROSPECTIVE|||||||
33867014|NCT00897806|||CASE_ONLY||PROSPECTIVE|||||||
33867015|NCT00112931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180745|NCT01184092|RANDOMIZED|CROSSOVER||||NONE||||||
34180746|NCT05271240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180747|NCT03902444|||COHORT||PROSPECTIVE|||||||
34180748|NCT04719078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, single-centre, non-randomised, non-blinded trial with MR-Imaging of patients. All of the patients undergo MR-Imaging as well as the two standard diagnostic procedures: CT and lung function tests.||||
34180749|NCT04174469|||CASE_ONLY||RETROSPECTIVE|||||||
34180750|NCT01393821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180751|NCT06601023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867016|NCT02321930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867017|NCT01653964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34180752|NCT04011046|||OTHER||PROSPECTIVE|||||||
34180753|NCT05049252|||COHORT||RETROSPECTIVE|||||||
34180754|NCT02736253|||COHORT||PROSPECTIVE|||||||
34180755|NCT03708432|||COHORT||RETROSPECTIVE|||||||
34180756|NCT03574584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|"Three (3) cohorts are planned. In each cohort subjects will be assigned to trial product. Subjects will be randomised in a 3:1 manner within cohorts to receive either:~1. Semaglutide and NNC0165-1562 once weekly (9 subjects per cohort)~2. Semaglutide and placebo once weekly (3 subjects per cohort)"|t|t|t|t
34180757|NCT06603922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessment should be provided blind to patients' allocation (MCT vs. P-MCT). Researchers should pay attention that assessors do not learn the conditions allocation. Assessors should not discuss the content of the MCT/P-MCT sessions. At the same time, assessors should not discuss patient allocation with clinical staff. Assessors should be experienced in clinical interviews with patients suffering from psychosis.|The sample will be randomized into P-MCT or classical MCT in a RCT where the user's participants (patients diagnosed with non-affective psychoses) and evaluators will be blind to the treatment condition.|t|f|f|t
34180758|NCT06587503|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34180759|NCT02113982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180760|NCT04051424|RANDOMIZED|CROSSOVER||OTHER||NONE||Design: The proposed experiment is a randomized clinical crossover (repeated measures) trial of three oral bite-block devices with device order randomized and blinded prior to recruitment.||||
34180761|NCT01069003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34180762|NCT05417815|||CASE_ONLY||RETROSPECTIVE|||||||
34180763|NCT06245954|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867018|NCT00350584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867019|NCT02238951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33867020|NCT03276377|||CASE_CONTROL||RETROSPECTIVE|||||||
33867021|NCT00284323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867022|NCT00291798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867023|NCT02849197|||COHORT||RETROSPECTIVE|||||||
33867024|NCT02780050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867025|NCT05038917|||COHORT||PROSPECTIVE|||||||
33893935|NCT05383820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Blinded, the orthodontist performing the clinical intervention and the investigator|"A double-blind clinical trial will be carried out with a placebo control group and random drug allocation. Patients who begin orthodontic treatment in the Orthodontic Specialty of the Comprehensive Dental Clinics of the University Center for Health Sciences and who decide to participate in the study with the signing of informed consent will be included. Three groups will be formed with 8 patients in each one.~The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS)."|t|t|t|f
33893936|NCT00093236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964452|NCT04167488|NA|SINGLE_GROUP||OTHER||NONE||||||
33964453|NCT01014026|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33964454|NCT01354639|||CASE_ONLY||PROSPECTIVE|||||||
33964455|NCT04001205|||CASE_CONTROL||RETROSPECTIVE|||||||
33964456|NCT03056352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964457|NCT01315366|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964458|NCT05982574|||CASE_CONTROL||RETROSPECTIVE|||||||
33964459|NCT03446079|NA|SINGLE_GROUP||PREVENTION||NONE|Investigators and participants will be blinded to the results genetic testing results during the trial duration. Only participants will be blinded to the identity of the study product.|Cross sectional will utilize gene-specific candidate and genome wide association analysis to identify SNP's that may be associated with response to a topical product.||||
33964460|NCT04800900|NA|SINGLE_GROUP||OTHER||NONE||||||
33964461|NCT05951517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867026|NCT03929081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assessors will be blinded for treatment allocation. Partcipants and clinicians will be requested not to reveal information about treatment allocation to the assessors.|This is a multicenter, randomized controlled non-inferiority trial. 203 OCD patients will be recruited. During intake for treatment, patients willing to participate, will be invited for a baseline visit, after the Informed Consent process (IC). Then the patient will be randomized to 20 sessions IBA or 20 sessions CBT. Randomization ratio is 1:1, stratified by site. OCD symptom severity will be assessed by a blind assessor at baseline, after 20 sessions, and 6 and 12 months after posttest. Further, OCD symptom severity and insight in OCD symptoms will be assessed (self-report) weekly. To explore working mechanisms, 43 patients of each treatment arm will receive pre- and posttreatment brain imaging and neuropsychological assessment. After randomization, patients are screened for MRI eligibility, until the sufficient amount of participants is reached. A complementary IC will be signed. 43 healthy controls will receive a single brain imaging and neuropsychological testing session.|f|f|t|f
33867027|NCT06041399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33867028|NCT03588988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180764|NCT01452698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180765|NCT06109896|||COHORT||PROSPECTIVE|||||||
34180766|NCT02326155|||COHORT||PROSPECTIVE|||||||
34180767|NCT04533503|||CASE_ONLY||PROSPECTIVE|||||||
34180768|NCT06542835|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34180769|NCT06586346|||COHORT||PROSPECTIVE|||||||
34180770|NCT02083900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34180771|NCT06214689|||COHORT||OTHER|||||||
34180772|NCT05174416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180773|NCT06604559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180774|NCT06597071|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180775|NCT06594471|||COHORT||PROSPECTIVE|||||||
34180776|NCT02584686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180777|NCT04263285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180778|NCT05045586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180779|NCT03742557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|A double-blind randomized clinical trial (initially) will be performed, followed by an open-label trial.|t|t|t|t
34180780|NCT05104112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To ensure blinding, the primary endpoint, assessed on video, will be measured at the end of the study by a blinded investigator from the randomization group and from a different center than the inclusion center.|A pragmatic, multicenter, randomized, delayed-onset, stepped-wedge cluster study.|f|f|f|t
34180781|NCT06604403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180782|NCT03545555|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34180783|NCT06592989|||OTHER||PROSPECTIVE|||||||
34180784|NCT06603259|||COHORT||OTHER|||||||
34180785|NCT04537624|||COHORT||PROSPECTIVE|||||||
34180786|NCT05613140|||COHORT||RETROSPECTIVE|||||||
34180787|NCT06592131|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"This is a first-in-human, single center, randomized, double-blinded, single and multiple ascending doses (SAD and MAD) and food effect Phase I study in healthy adult volunteers (HV).~The SAD cohorts will consist of five cohorts of eight participants (6 randomized to treatment + 2 randomized to placebo) in each cohort (Total 40 HV). Additional cohorts may be added.~The food effect (FE) cohort will consist of 12 participants who receive a single dose of BF844 in a cross-over manner. Each participants will receive the same single dose of BF844 under two separate conditions: one after an overnight fast, and the second following a high-fat breakfast 30 minutes prior to dosing.~The MAD cohorts will consist of 3 cohorts of eight participants (6 randomized to treatment + 2 randomized to placebo) in each cohort (Total 24 HV). The subjects in MAD cohorts will be dosed once daily for 7 consecutive days. Additional cohorts may be added."|t|f|t|t
33867029|NCT06455592|RANDOMIZED|CROSSOVER||PREVENTION||NONE||experimental, randomized, cross-over, single-center therapeutic trial, controlled||||
33867030|NCT01743924|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33867031|NCT01861028|||COHORT||PROSPECTIVE|||||||
33867032|NCT02508051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867033|NCT05091749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867034|NCT01660321|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33867035|NCT05983549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant will be blinded in knowing the arm, outcome assessors will be not involved in the study||t|f|f|t
33867036|NCT02401321|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34180788|NCT06521398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867037|NCT03520959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867038|NCT02846350|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33867039|NCT00297635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867040|NCT05560282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867041|NCT01996813|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33867042|NCT05222971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867043|NCT01637909|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867044|NCT01766271|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867045|NCT02713165|NA|SINGLE_GROUP||OTHER||NONE||||||
33867046|NCT04924569|||COHORT||PROSPECTIVE|||||||
33867047|NCT01473979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867048|NCT01408784|||CASE_ONLY||CROSS_SECTIONAL|||||||
34180789|NCT04874025|||COHORT||RETROSPECTIVE|||||||
34180790|NCT01222689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180791|NCT04269668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34180792|NCT05701189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180793|NCT02889952|||||CROSS_SECTIONAL|||||||
34180794|NCT01256788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The two treatment groups were:~1. Received saline injection~2. Received viscosupplementation injection"|t|f|f|f
34180795|NCT02757235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180796|NCT01806441|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34180797|NCT03729739|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Randomized clinical non-inferiority trial|f|f|f|t
33867049|NCT01619111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867050|NCT06209554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33867051|NCT02061566|||COHORT||PROSPECTIVE|||||||
33867052|NCT02604953|||COHORT||PROSPECTIVE|||||||
33867053|NCT04930809|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33867054|NCT00784290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867055|NCT04241289|||COHORT||PROSPECTIVE|||||||
33867056|NCT04503304|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups; hip abductors strengthening (HAS) group a will receive hip abductors strengthening exercises, and knee extensors strengthening (KES) group will receive quadriceps strengthening exercise.||||
33893937|NCT00291629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752451|NCT06135337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects and Evaluating Investigator will be blinded to study device assignment. The subject will be blind-folded during treatment. The Evaluating Investigator is unaware of the device assignment and has no access to study data that could potentially contain unblinding information|Parallel-Group Design with random assignment to test device or comparator device in a 2:1 ratio|t|f|f|t
33752452|NCT06723808|||OTHER||CROSS_SECTIONAL|||||||
33752453|NCT01375348|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33752454|NCT04802538|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Early feasibility device study||||
33752455|NCT06323928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33752456|NCT06732778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled Trial|t|t|f|f
33752457|NCT05949723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752458|NCT04603534|NA|SINGLE_GROUP||OTHER||NONE||||||
33752459|NCT06135103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752460|NCT05183971|||CASE_CONTROL||PROSPECTIVE|||||||
33752461|NCT04407390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double-blind case-control trial|t|t|t|t
33752462|NCT06580665|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33867057|NCT04122404|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Open label multi-center stepped wedge cluster-randomized controlled implementation trial of the use of urine-based LF-LAM in addition to routine sputum-based TB diagnostic tests to guide initiation of TB treatment among adult hospitalized patients with advanced HIV. The design offers a randomised method of evaluation of the intervention at cluster level. Applying the stepped wedge design ensures that all participating HIV/ART clinic attached wards will have received the intervention at the end of the study period, and provides the basis for the LF-LAM test to become an integrated part of TB health care services also after the project finishes. Clinic staff will be trained on how to use and interpret the LF-LAM test and in TB diagnostic guidelines as outlined by WHO. An Audit and feedback study will identify leaky steps in the TB diagnostic pathway and further strengthen the implementation and possible impact of the LF-LAM test.||||
33867058|NCT05057260|||COHORT||PROSPECTIVE|||||||
33867059|NCT05831748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867060|NCT05926388|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33867061|NCT06429384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In a double-blind design, the researchers, the researchers involved in the trial effect evaluation, the data managers, the statistical analysts, and the subjects and their relatives or guardians were blind to the treatment groups.|Y-3 low dose group (20 mg/ time, qd), medium dose group (40 mg/ time qd), high dose group (60mg/ time, qd) and placebo control group.|t|t|t|t
33867062|NCT00572026|RANDOMIZED|CROSSOVER||||NONE||||||
33867063|NCT03571529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867064|NCT06372938|||CASE_CONTROL||RETROSPECTIVE|||||||
33867065|NCT01184742|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867066|NCT01444482|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33867067|NCT03054922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867068|NCT00006392|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33867069|NCT00449384|||DEFINED_POPULATION||OTHER|||||||
33867070|NCT00000536|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33867071|NCT04669340|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking not possible due to mode of intervention.|||||
33867072|NCT01621542|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33867073|NCT06023316|NA|SINGLE_GROUP||OTHER||NONE||||||
33867074|NCT04048265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867075|NCT04533490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867076|NCT01950247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867077|NCT00853749|NON_RANDOMIZED|||OTHER||NONE||||||
34180798|NCT06598566|||CASE_ONLY||PROSPECTIVE|||||||
34180799|NCT06586307|||COHORT||RETROSPECTIVE|||||||
34180800|NCT03227913|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180801|NCT05894330|||COHORT||CROSS_SECTIONAL|||||||
34180802|NCT03656159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180803|NCT01263080|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34180804|NCT02201953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180805|NCT04369404|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||A usual care arm was recruited first, then the intervention arm was recruited.||||
34180806|NCT03659045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180807|NCT00854750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180808|NCT04234477|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180809|NCT01245556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180810|NCT00375063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180811|NCT04804241|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This is a double-blind study. All subjects and staff will be blinded to treatment allocation. Investigational drug pharmacy will maintain unblinded randomization information.|Subjects will be randomized 3 to 1 to receive active study medication versus placebo.|t|t|t|t
34180812|NCT00423579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180813|NCT06599892|||OTHER||PROSPECTIVE|||||||
34180814|NCT00154999|||NATURAL_HISTORY||PROSPECTIVE|||||||
34180815|NCT01781546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180816|NCT06588621|||COHORT||PROSPECTIVE|||||||
34180817|NCT00656448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34180818|NCT01128634|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180819|NCT02474693|||||CROSS_SECTIONAL|||||||
34180820|NCT04565132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180821|NCT06603792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The project will investigate two randomized groups: a 'true' EEG-NF-group and 'sham' EEG-NF-group.|t|f|f|t
34180822|NCT06587672|||OTHER||PROSPECTIVE|||||||
34180823|NCT02202421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180824|NCT05994196|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180825|NCT03604783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180826|NCT03521284|||OTHER||PROSPECTIVE|||||||
34180827|NCT06594692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752463|NCT04062357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomized evenly categorized into two treatment groups. Patient's distribution in the two groups was according to randomized encoded ballots, and they were unobservant of the type of the topical medications used.|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system). Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks (One to two applications (1-2 ml) of alcohol 70% sprays).|f|f|t|f
33752464|NCT06438588|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838696|NCT04697953|NA|SINGLE_GROUP||TREATMENT||NONE||"Study design~This study is a 104-week, single arm, open label, Ph IIIb multicenter study in Canadian nAMD patients.~Neovascular AMD patients will be switched from aflibercept Q6-12W to brolucizumab at the same dosing interval at baseline. At the second visit the treating physician will conduct a disease activity assessment. If patient is stable, treatment will be extended by up to two (2) weeks using a Treat and Extend regimen interval. If the patient remains stable, the extension will also occur at next visits until maximum of Q20 Weeks."||||
34180828|NCT02703597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know if they are receiving the intervention to be tested or the comparative intervention.||t|f|f|f
33838697|NCT05099900|||OTHER||CROSS_SECTIONAL|||||||
33838698|NCT00340808|||CASE_ONLY||PROSPECTIVE|||||||
33867078|NCT01146704|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867079|NCT03522051|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with symptomatic deep caries in a permanent molar tooth will receive pulpotomy treatment and placement of a calcium silicate based material (Neo MTA plus) over the pulp and followed by restoration.||||
33867080|NCT05699265|||CASE_ONLY||PROSPECTIVE|||||||
33867081|NCT01810653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867082|NCT05573776|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867083|NCT00227292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867084|NCT05082376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867085|NCT00946504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867086|NCT00278759|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867087|NCT03480568|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, nonrandomized study||||
34065791|NCT03313011|||COHORT||PROSPECTIVE|||||||
34065792|NCT03245190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065793|NCT01226680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180829|NCT00594490|||OTHER||PROSPECTIVE|||||||
34180830|NCT01314586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180831|NCT01553890|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34180832|NCT06435000|||COHORT||PROSPECTIVE|||||||
34180833|NCT00860860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180834|NCT06319690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial (RCT)|f|f|f|t
34180835|NCT04420234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180836|NCT06474832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838699|NCT06091059|||COHORT||PROSPECTIVE|||||||
33838700|NCT02474043|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33838701|NCT02188680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838702|NCT03254043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33838703|NCT05567107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838704|NCT02610075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838705|NCT00611975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34180837|NCT05333263|NA|SINGLE_GROUP||OTHER||NONE||||||
34180838|NCT00573508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180839|NCT05695521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded, Placebo Control|This is a randomized two-arm, multi-center phase Ib trial of CK0803 (cryopreserved, allogeneic, cord blood derived T regulatory cells that express neurotropic homing markers) versus placebo for treatment of adults with amyotrophic lateral sclerosis (ALS) having onset within 5 years of trial entry. This trial will consist of a 6-patient safety run-in followed by a randomized comparative trial with up to two stages (stages 1 and 2), each stage of size 30 patients, with a safety rule applied after stage 1 that may terminate the trial early, for a maximum total sample size of 6+30+30 = 66 patients.|t|t|t|t
34180840|NCT06331819|||COHORT||PROSPECTIVE|||||||
34180841|NCT01907854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180842|NCT00783783|||COHORT||PROSPECTIVE|||||||
33838706|NCT03922789|||COHORT||PROSPECTIVE|||||||
33838707|NCT04723290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838708|NCT06022549|||CASE_ONLY||CROSS_SECTIONAL|||||||
33838709|NCT05884489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33838710|NCT02053610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838711|NCT02432664|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33838712|NCT00101946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33838713|NCT04047277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Blinded randomization into 2 groups: Treatment \& Waitlist Control. Treatment group receives treatment right away. Waitlist group receives treatment after 6 week wait.|f|f|f|t
33838714|NCT05685225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Full-Factorial|t|t|t|t
33867088|NCT03410459|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34180843|NCT01151189|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33867089|NCT06030336|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment to the intervention or control group in blocks of four households, to maintain balance in the intervention and control groups over the course of study enrollment.||||
34180844|NCT06591910|||COHORT||PROSPECTIVE|||||||
34180845|NCT02878031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180846|NCT00180648|||CASE_CONTROL||PROSPECTIVE|||||||
34180847|NCT02386813|||COHORT||RETROSPECTIVE|||||||
34180848|NCT01961037|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34180849|NCT05963711|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||In those with BV-associated penile microbiome, a decolonization attempt will be conducted, (daily wash for 5 days with chlorhexidine gluconate 4%). if decolonization fails, an antibiotic cream will be used to eradicate BV associated bacteria.||||
34180850|NCT05895188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|There are two groups in the study and the informed consent texts of these groups are different. In this way, the participants will not know which group they belong to. The randomization table of the study was made by an independent researcher, so the researcher would not know which patient was in which group. At the end of the research, data analysis will be done by an independent statistician, and the statistician will not know which patient's data belongs to which group.|In the study, there are two groups, the virtual reality group in which virtual reality glasses were applied and the control group, which did not apply any intervention.|t|f|t|t
34180851|NCT04415372|||CASE_CONTROL||PROSPECTIVE|||||||
34180852|NCT01895413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180853|NCT06591416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1|f|f|f|t
34180854|NCT06117618|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|Care providers will be unblinded in that nurses and clinicians will be aware if they receive an alert for the patient.|"If a patient is randomized to a group without an alert, the alert will instead be a hidden silent alert that does not display. However, a timestamp of when the alert was triggered is still recorded even though the alert did not display. This timestamp is used for the primary and secondary outcomes."|t|f|t|t
34180855|NCT00331201|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34180856|NCT06589570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180857|NCT00974792||||TREATMENT||NONE||||||
34180858|NCT00237302|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34180859|NCT06001918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For this trial, neither the patient nor investigator will be blinded to the study group assignment. However, members of the Sponsor, the CT core laboratory and the various committees reviewing subject data, such as the Clinical Events Committee (CEC), will be blinded to the randomization and assignment arm for an individual subject under review.|Prospective, randomized, controlled trial comparing the efficacy of the treatment arm to the control arm.|f|f|f|t
34180860|NCT02815384|||COHORT||PROSPECTIVE|||||||
34180861|NCT06184022|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34180862|NCT06287580|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34180863|NCT00648440|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34180864|NCT05038098|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34180865|NCT05258721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180866|NCT06600399|||COHORT||PROSPECTIVE|||||||
34180867|NCT06377540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180868|NCT06589765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||HRS-7535 tablet compared with dapagliflozin tablet|t|f|t|f
33838715|NCT02269423|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33838716|NCT05383144|||COHORT||PROSPECTIVE|||||||
33838717|NCT04653233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is designed in a randomized controlled experimental type.||||
33838718|NCT01616862|||COHORT||PROSPECTIVE|||||||
33838719|NCT02712489|||||PROSPECTIVE|||||||
33838720|NCT05634148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33838721|NCT01799980|||COHORT||PROSPECTIVE|||||||
33838722|NCT00823953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838723|NCT01465763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838724|NCT00631553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838725|NCT04520568|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33867090|NCT05071365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867091|NCT00864890|RANDOMIZED|CROSSOVER||||NONE||||||
33867092|NCT02375542|||COHORT||PROSPECTIVE|||||||
33867093|NCT00073528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867094|NCT06243731|||COHORT||RETROSPECTIVE|||||||
33964462|NCT04553484|||COHORT||PROSPECTIVE|||||||
33964463|NCT02801851|NA|SINGLE_GROUP||SCREENING||NONE||||||
33964464|NCT06253754|||CASE_CONTROL||PROSPECTIVE|||||||
33964465|NCT06424678|||COHORT||PROSPECTIVE|||||||
33964466|NCT01789008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33964467|NCT01493531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964468|NCT02173626|NA|SINGLE_GROUP||||NONE||||||
33964469|NCT06552377|||OTHER||CROSS_SECTIONAL|||||||
33964470|NCT03402620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964471|NCT03865524|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Multicenter, prospective trial with a CE-marked medical device||||
33964472|NCT06537895|||COHORT||PROSPECTIVE|||||||
33964473|NCT06295575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964474|NCT01957631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964475|NCT03719729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964476|NCT04493060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964477|NCT03680482|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|the participant has no knowledge of the intervention assignment|The experimental design was developed 3 times. Each intervention was performed separately for a minimum period of 7 days out and a maximum of 14 days, depending on the availability of the experimental subjects. Cross treatment design (crossover) each subject serves as its own control The first intervention corresponded to the control group, in order to maintain the ignorance of the type of sweetener they were receiving, between day 7 or maximum 14 days post-intervention the order of the test of the ENN was reversed. Therefore, during the second or third intervention they were given to drink water with sucralose or stevia respectively|t|f|f|f
33964478|NCT01327638|||COHORT||RETROSPECTIVE|||||||
33964479|NCT02017535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33964480|NCT04322968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All study personnel, including rater, patients, and data analysts, were blinded to randomization order. Only the anesthesiologist performing the infusion was not blinded in order to prepare for possible side effects of each medication.|Patient with and without PTSD were randomized to receive either ketamine or ketorolac. Single IV infusion of ketamine hydrochloride (0.5 mg/kg) was administered over 40 minutes. Ketorolac 15 mg was reconstituted in 500 cc of normal saline administered over 40 minutes.|t|f|f|t
34180869|NCT05944302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|In the study, block randomization will be done to eliminate selection bias and to provide balance in the number of individuals between groups. In this method, the number of groups and probabilities must be equal in each block. If we evaluate a study in which 2 different treatment methods (A and B) will be applied and the evaluations are equally probable; A total of 4 individuals are assigned to each block, with 2 subjects assigned to each treatment group. Thus, at the end of each quadruple assignment, the number of subjects in the 2 treatment groups is equalized.|This study is two-stage. In the first stage, a randomized controlled trial type will be used to compare the effect of EMDR on pain in patients in the intervention and control groups, and in the second stage, a qualitative (qualitative) descriptive research type will be used to evaluate the experiences of the patients in the intervention group with the EMDR program.||||
34180870|NCT04718077|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34180871|NCT05286749|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will be informed of random assignment into two groups. Participants will not be aware of which group they belong to. Participants in the control group are initially only provided educational materials about the standard of care for cervical cancer screening and offered clinician-collection for screening as the recommended method. Whereas the intervention group is provided additional materials about self-collection in the core educational material and is offered the Evalyn Device for self-collection as a screening option immediately at the end of the workshop. All participants will be made aware during a debrief session at the end of the study about what information could not be given at the time of consenting, and why they could not be told at that time.|Workshops are randomized to either a control or intervention group|t|f|f|f
34180872|NCT06604065|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34180873|NCT03111823|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33964481|NCT03580759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34180874|NCT04345120|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34180875|NCT03164265|NA|SINGLE_GROUP||OTHER||NONE||||||
34180876|NCT02994121|||COHORT||PROSPECTIVE|||||||
33964482|NCT05578885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180877|NCT06351228|||COHORT||RETROSPECTIVE|||||||
34180878|NCT06553937|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34180879|NCT06655519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180880|NCT05847192|||COHORT||PROSPECTIVE|||||||
34180881|NCT01105481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34180882|NCT04560400|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34180883|NCT05954637|||COHORT||CROSS_SECTIONAL|||||||
34180884|NCT02190695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180885|NCT03591406|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, parallel design, randomised controlled multi-centre trial in Chinese subjects||||
34180886|NCT05270434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180887|NCT01817153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180888|NCT00089297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964483|NCT02077959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964484|NCT02757300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964485|NCT04695639|||OTHER||PROSPECTIVE|||||||
33964486|NCT02323139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964487|NCT05199311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964488|NCT05234242|||CASE_CONTROL||PROSPECTIVE|||||||
33964489|NCT04636398|NA|SINGLE_GROUP||PREVENTION||NONE||Non-randomized quasi-experimental exploratory study. All small groups will receive the same intervention which is exposure to a variety of intervention modalities (3 main modalities: information delivery, facilitation strategy, text management).||||
33964490|NCT04715386|||COHORT||PROSPECTIVE|||||||
34180889|NCT01980563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180890|NCT03846336|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34180891|NCT01409707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867095|NCT01079273|NA|SINGLE_GROUP||||NONE||||||
33867096|NCT04133454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867097|NCT00681174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33867098|NCT06410690|||COHORT||OTHER|||||||
33867099|NCT03426293|||COHORT||PROSPECTIVE|||||||
33867100|NCT03777150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group I: admitted into the ICU for postoperative care Group II: admitted into a standard ward for postoperative care||||
33867101|NCT03707613|NA|SINGLE_GROUP||OTHER||NONE||||||
34180892|NCT05752617|||COHORT||PROSPECTIVE|||||||
34180893|NCT00535496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180894|NCT06384196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The main study of this project proposal is a multi-center, single-blind, parallel-group randomized clinical trial (RCT) conducted in Catalonia (Spain).|f|f|t|f
34180895|NCT04032301|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Experimental versus Placebo|t|f|t|f
33867102|NCT03502291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Physical blind folds worn by participant. Unblinded research nurses to deliver the vaccines|DBRCT performed as two studies over two flu seasons. 2 arms to each study.|t|f|t|f
33867103|NCT02902081|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33867104|NCT05962047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcome assessor)||f|f|f|t
33867105|NCT01383980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects are randomized to remain NPO at midnight prior to surgery or to continue to receive tube feeding up until surgery time.||||
33867106|NCT01322503|NON_RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33867107|NCT05234554|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33964491|NCT00764049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180896|NCT04306276|||CASE_CONTROL||RETROSPECTIVE|||||||
34180897|NCT04271878|NA|SINGLE_GROUP||OTHER||NONE|All participants will be fitted with a face mask connected to a tube supplied with gas from the RespirAct™ system. The participants will not be informed about the concentration of gases during the tilt tests. After the study completion they will be informed about the order of interventions.|"All participants must have been diagnosed with POTS, they will all complete up to 6 head-up tilt tests (HUTTs) on a single day. They will all receive the following interventions:~1. Normal not coached breathing and room air~2. Normal not coached breathing with ETCO2 clamped at baseline levels - The baseline CO2 levels will be defined from the mean end-tidal CO2 (ETCO2) measured through the mask over the last 5 min of the first baseline phase (ETCO2 normal values range between 35mmHg and 45mmHg).~3. Normal not coached breathing with mild ETCO2 levels (45mmHg)~4. Normal not coached breathing with high ETCO2 levels (55mmHg)~5. Fast breathing and resultant low ETCO2 levels (target ETCO2 19-24mmHg);~6. Fast breathing and ETCO2 clamped at baseline levels"||||
34180898|NCT00168584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867108|NCT00360906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867109|NCT05979376|||CASE_CONTROL||PROSPECTIVE|||||||
33867110|NCT06478355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867111|NCT01102348|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Before and after||||
33867112|NCT04124484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867113|NCT04143360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867114|NCT02036411|||CASE_ONLY||PROSPECTIVE|||||||
33867115|NCT04853836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investor will assign patients to one of the groups before Sniff test evaluation at T0|Single-blinded randomized clinical trial|f|f|t|t
33867116|NCT03874663|||COHORT||PROSPECTIVE|||||||
33867117|NCT01750372|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867118|NCT02064920|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34065794|NCT05855408|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065795|NCT02826252|||CASE_CROSSOVER||OTHER|||||||
34180899|NCT04073173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and data analyst will be masked.||t|f|f|t
33867119|NCT06201247|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 Phase I||||
33867120|NCT01230281|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33867121|NCT01657474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867122|NCT05050708|||COHORT||PROSPECTIVE|||||||
33867123|NCT03470038|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33867124|NCT06414928|||COHORT||PROSPECTIVE|||||||
33867125|NCT05164055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867126|NCT02207998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867127|NCT03188562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867128|NCT02674542|||COHORT||PROSPECTIVE|||||||
33867129|NCT06438848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Controlled parallel groups|t|t|f|f
34180900|NCT02582775|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180901|NCT06654466|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34180902|NCT00129246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180903|NCT06472609|NA|SEQUENTIAL||PREVENTION||NONE||Diabetic patients have had poor blood glucose control in the past year, and have a record of glycated hemoglobin (HbA1C%) greater than 9%.||||
34180904|NCT00303069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34180905|NCT03212274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180906|NCT05724329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180907|NCT06596239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180908|NCT04459884|||COHORT||PROSPECTIVE|||||||
34180909|NCT04246684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|multicentre, open-labeled, Phase III study|Investigator-driven|f|f|t|f
34180910|NCT01796184|||||CROSS_SECTIONAL|||||||
34180911|NCT05382845|NA|SINGLE_GROUP||SCREENING||NONE||Prediction modelling, where risk factors such as earlier trauma to the pelvis, earlier low back pain, earlier pregnancy related pelvic girdle pain, physically demanding job, contraception and the outcomes of the pain provocation tests will predict to what degree a woman is at risk of developing symptoms.||||
34180912|NCT03026595|||OTHER||CROSS_SECTIONAL|||||||
34180913|NCT03304626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||20 subjects will receive open label Budesonide along with standard immune suppression and their outcomes will be compared to 20 matched controls receiving standard of care treatment including prednisone plus standard immune suppression||||
34180914|NCT00810563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34180915|NCT03208829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The random allocation step will be conducted through Randomizers - www.random.org by a research assistant. The assistant responsible for randomization will not be involved in any other phase of the study and the secrecy of the allocation will be maintained through opaque envelopes. A second independent assistant will administer the agenda and all communication between the participants and the researchers involved|Patients with total hip arthroplasty, will be assigned to two different treatment groups.|t|f|f|t
34180916|NCT01816737|||CASE_CONTROL||PROSPECTIVE|||||||
34180917|NCT06596707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180918|NCT02158546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180919|NCT03469557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180920|NCT03891407|RANDOMIZED|PARALLEL||PREVENTION||NONE|Peer-led recruitment strategy.|Participants who agree to self-test will receive pretest counseling and a 10 minute demonstration, including a video in addition to verbal instructions, of how to use an oral self-test kit from a trained HIV counselor. After counseling, participants will receive 2 oral fluid self-test kits to conduct the self-test at home or in a private location during the next 3 months, a phone number to call in case they need assistance when performing the self-test at home, and a location where to return the used self-test kits and collect more test kits throughout the study period. Upon returning the used self-test kits after every 3 months, participants will be able to share their self-test result with the counselor. Participants will also be asked at each pick-up time to demonstrate they can use the kit to ensure participants continue to receive correct self-test results throughout the study period.||||
33838726|NCT03678090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|t|f|f
33838727|NCT00538772|||OTHER||PROSPECTIVE|||||||
33838728|NCT04727177|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33838729|NCT04922177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838730|NCT05680753|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Due to the nature of the intervention, blinding of participating physiotherapists is not possible. However, neither physiotherapists nor patients in the usual physiotherapy care arm will be informed about the Stratified Blended Approach arm.~During the analyses, the researchers will be blinded to group allocation until the entire analysis will be completed."|A multicenter, pragmatic, two-arm, parallel-group, cluster randomized controlled trial (cRCT) will be conducted.||||
33838731|NCT00701324|RANDOMIZED|||TREATMENT||NONE||||||
33838732|NCT03714659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838733|NCT03546153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838734|NCT01821768|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838735|NCT02149238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33838736|NCT03414021|||COHORT||PROSPECTIVE|||||||
33838737|NCT03412851|||COHORT||PROSPECTIVE|||||||
33838738|NCT03993210|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838739|NCT01879449|||COHORT||CROSS_SECTIONAL|||||||
33838740|NCT03317821|||COHORT||PROSPECTIVE|||||||
33838741|NCT03377686|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33838742|NCT01396772|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838743|NCT00329212|||DEFINED_POPULATION||OTHER|||||||
33838744|NCT02429453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838745|NCT04292340|||CASE_ONLY||PROSPECTIVE|||||||
34180921|NCT00373854|||CASE_CONTROL||PROSPECTIVE|||||||
34180922|NCT03923166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180923|NCT04271852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180924|NCT06380621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180925|NCT05127733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180926|NCT00999102|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34180927|NCT03193957|NA|SINGLE_GROUP||OTHER||NONE||||||
34180928|NCT06070883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180929|NCT06331936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|At the recruitment phase, the participants and the social workers who lead the intervention will not know which arm the participants will be assigned. A cluster of approximately 10 participants formed a group based on their attendance date in the intervention program. This group will be randomly assigned to one of the two intervention arms through pre-prepared randomization list calculated by random allocation software.|Children will be randomly assigned to two groups: intervention and waitlist control groups. Children in the waitlist control group will receive experimental intervention after treatment for the experimental group finishes.|t|f|f|f
34180930|NCT06003972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180931|NCT04624126|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34180932|NCT04400643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180933|NCT06592157|||COHORT||PROSPECTIVE|||||||
34180934|NCT03907904|||OTHER||PROSPECTIVE|||||||
34180935|NCT00907335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34180936|NCT04789070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180937|NCT06514950|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is a small (N = 20) prospective cohort with a single unblinded intervention of Ujjayi resistance breathing at Spaulding Hospital Cambridge. Participants will have two lab visits: a baseline assessment and a post-intervention assessment six weeks later, each lasting about 4 hours. Cardiovascular and respiratory variables will be recorded during controlled and uncontrolled breathing. Coaching sessions in weeks 1 and 4 and virtual sessions via Zoom will train participants in the intervention, focusing on resistance breathing techniques. Participants will practice these techniques twice daily at home (\~20 min/day) over six weeks, totaling \~10 hours of in-person lab time.||||
34180938|NCT05311709|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, multinational phase II trial||||
34180939|NCT06016309|||COHORT||PROSPECTIVE|||||||
34180940|NCT04764071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, the Data Collector, and the statistician were blinded to the arms of the study.|To compare the difference between the two procedures regarding stone-free rates, operative time, hospital stay, procedures cost, and operative complications including blood loss, the need for blood transfusion, and extravasation or urine leakage|t|f|t|t
34180941|NCT06544824|||OTHER||RETROSPECTIVE|||||||
34180942|NCT04902976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34180943|NCT03137381|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33752465|NCT05884840|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will be conducted as a clustered randomized pragmatic clinical trial (CRT) in primary care practice. During the period of two years (2023-2025), randomization of the eight Health Regions (274 primary care centres) in Catalonia will take place. The current strategy, in Catalonia, for cardiovascular risk screening is based on risk assessment using Framingham-REGICOR risk function. In the intervention group, a screening program with ABI will be added to all 50-74-year-old individuals with Framingham-REGICOR risk ≥7% and high probability of having ABI≤0.9. The probability of having ABI≤0.9 will be estimated using the REASON function and will be defined as a probability ≥7%. People that are classified as ABI≤0.9 high-risk, will undergo a PAD screening program using ABI test. If the result of the ABI is equal and lower than 0.9, indications of the Health Catalan Institute's CV and lipid guidelines will be recommended by physicians to the patients.||||
33752466|NCT05054608|||CASE_CONTROL||RETROSPECTIVE|||||||
33867130|NCT05223660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Part 1 of the study is open-label. Part 2 of the study is double-blinded||t|f|t|f
33867131|NCT03877978|||COHORT||PROSPECTIVE|||||||
34180944|NCT06654986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Thirty-six healthy, well-trained men and women will be randomized into three distinct groups, each receiving one of the following interventions: 1) salmeterol with amino acid availability, 2) salmeterol, or 3) a placebo, administered twice daily over a 6-week intervention period. This design aims to elucidate the impact of amino acid availability on the muscle anabolic response to beta2-adrenergic stimulation.|t|t|t|t
34180945|NCT06596096|||OTHER||PROSPECTIVE|||||||
34180946|NCT02677441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180947|NCT06489951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34180948|NCT01708356|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34180949|NCT04806685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34180950|NCT06182254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33867132|NCT00317720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867133|NCT02562079|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867134|NCT02375724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867135|NCT04625842|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Focus group interview study||||
33867136|NCT03921320|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to be submitted to sequential bilateral sympathectomy or unilateral sympathectomy on the dominant side. After 4 to 6 months participants of the unilateral group can make the contralateral sympathectomy||||
33867137|NCT01037491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867138|NCT04498169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867139|NCT00002117||||TREATMENT||||||||
33867140|NCT00759733|||CASE_CONTROL||PROSPECTIVE|||||||
33867141|NCT05570942|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The patient were given bottle of placebo with same appearance of bottle of probiotics.|Arm 1: probiotics group; arm 2: control group (no probiotics; placebo)|t|f|t|f
33867142|NCT06210750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867143|NCT03057613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867144|NCT02098265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867145|NCT02524548|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867146|NCT05097144|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34065796|NCT02904694|||CASE_ONLY||PROSPECTIVE|||||||
34065797|NCT05239117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, open-label, non-randomized clinical investigation||||
34065798|NCT03573401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867147|NCT04301232|||COHORT||PROSPECTIVE|||||||
34065799|NCT03904316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867148|NCT01485341|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33867149|NCT05526742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867150|NCT00874445|||COHORT||PROSPECTIVE|||||||
33867151|NCT03406143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33867152|NCT02452905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867153|NCT05149183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|this trial has two groups, one experimental and one control|t|f|f|t
34180951|NCT04854187|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Prospective, randomized cross over study|t|f|f|t
34180952|NCT04003246|NA|SINGLE_GROUP||TREATMENT||NONE||Patient registration Stage III non-small cell lung cancer Zubrod 0 or 1||||
33867154|NCT01244295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34180953|NCT05673967|||COHORT||RETROSPECTIVE|||||||
34180954|NCT05640193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180955|NCT00656513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One arm Phase II followed by a two-arm Phase III||||
34180956|NCT06306807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867155|NCT03457545|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Testing a home-based intervention to treat frailty in adult lung transplant candidates using a mobile health technology||||
33893938|NCT01476930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893939|NCT02790489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893940|NCT01014715|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34180957|NCT01795677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180958|NCT00488371|||||PROSPECTIVE|||||||
34180959|NCT00952510|||COHORT||PROSPECTIVE|||||||
34180960|NCT02856568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180961|NCT03878563|||CASE_CONTROL||PROSPECTIVE|||||||
34180962|NCT02638194|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34180963|NCT03513159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The patients data will be anonymized and entered into an electronic Case Report form. The Outcomes Assessor will only see the anonymized data.|The Intervention Group will be supported by the activities of the pathfinder, the Control Group will not. Both Groups will be tested for functional and nutritional Status and for Quality of life and stress scores.||||
34180964|NCT03350594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752467|NCT06732570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pretest posttest randomized controlled trail.|f|f|f|t
33752468|NCT03785561|||COHORT||PROSPECTIVE|||||||
33752469|NCT04332042|NA|SINGLE_GROUP||TREATMENT||NONE||prospective cohort study||||
33752470|NCT02942108|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33752471|NCT05129319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065800|NCT03850405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065801|NCT05639686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The operating surgeon will be blinded to the type of anesthesia used by applying a surgical drape between surgeon and patient and anesthesia team. The patient will also not know which anesthesia arm they will be placed in as the randomization will occur prior to surgery and will only be known to the anesthesia team and other study team members who are not operating on the patient.|Double Blind, Randomized Cohort|t|t|f|f
34180965|NCT01816217|NA|SINGLE_GROUP||||NONE||||||
34180966|NCT06332599|||OTHER||RETROSPECTIVE|||||||
34180967|NCT05396547|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm interventional study||||
33752472|NCT00528138|||COHORT||PROSPECTIVE|||||||
33752473|NCT01292928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752474|NCT03576157|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33752475|NCT06107426|||COHORT||PROSPECTIVE|||||||
33752476|NCT04768400|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752477|NCT04987879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752478|NCT06522152|||COHORT||PROSPECTIVE|||||||
33752479|NCT03404570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study drug will be provided as oral tablets with active and placebo indistinguishable in product and packing characteristics.|Subjects will be randomized (1:1:1) to one of three Treatment Arms|t|t|t|t
33752480|NCT03424005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752481|NCT06120907|||COHORT||PROSPECTIVE|||||||
33752482|NCT05600920|NA|SEQUENTIAL||TREATMENT||NONE||||||
34180968|NCT02116036|NA|SINGLE_GROUP||OTHER||NONE||||||
34180969|NCT01202786|||CASE_CONTROL||PROSPECTIVE|||||||
34180970|NCT05984017|||COHORT||PROSPECTIVE|||||||
33893941|NCT04084392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Programmatic evaluation - eligible participants will be individually randomized to either direct referral to a long-term outpatient addiction provider or referral to the Bridge Clinic while long-term outpatient addiction provider is located/identified.|f|f|f|t
34180971|NCT01253837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34180972|NCT03000608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34180973|NCT03933202|||COHORT||PROSPECTIVE|||||||
34180974|NCT02254070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752483|NCT00419263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752484|NCT02068807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33752485|NCT05571280|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33752486|NCT06533943|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752487|NCT06592664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752488|NCT05447117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752489|NCT04908735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752490|NCT05190146|||COHORT||PROSPECTIVE|||||||
33752491|NCT06216054|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34180975|NCT00586378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34180976|NCT02631239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180977|NCT04885998|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34180978|NCT03873116|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34180979|NCT02166346|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34180980|NCT04730102|||COHORT||CROSS_SECTIONAL|||||||
34180981|NCT02798627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34180982|NCT01148368|NON_RANDOMIZED|PARALLEL||||NONE||||||
33752492|NCT06733935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752493|NCT05908786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752494|NCT03091374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752495|NCT03298009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Placebo-controlled, double-blind, randomized crossover 2-week intervention study.|t|f|f|t
33752496|NCT00965224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752497|NCT00226330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33752498|NCT05242991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will not know the laser protocol of each patient.|Patients will be randomized to one of two groups for the duration of the study.|f|f|f|t
33752499|NCT01219348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752500|NCT04250454|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752501|NCT06471530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33752502|NCT05356910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33752503|NCT05965687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752504|NCT02675387|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33752505|NCT04980118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752506|NCT06023329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33752507|NCT06732141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752508|NCT06724965|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752509|NCT06733103|NA|SINGLE_GROUP||OTHER||NONE||||||
33752510|NCT06626490|||COHORT||RETROSPECTIVE|||||||
33867156|NCT06025890|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Collect blood samples from 600 cases of language disorder and 800 cases of ADHD, and complete an fNIRS task test from 800 ADHD patients. Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training, and/or mindfulness training, aerobic exercise, and other intervention forms can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area."||||
33867157|NCT01877915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867158|NCT03486886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065802|NCT05528484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065803|NCT04416646|||COHORT||PROSPECTIVE|||||||
33752511|NCT05400330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752512|NCT00382057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33752513|NCT06681909|||COHORT||PROSPECTIVE|||||||
33752514|NCT01901068|||COHORT||PROSPECTIVE|||||||
33752515|NCT06722482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded in regards to group allocation.|single center, pilot, randomized, clinical trial|f|f|f|t
33752516|NCT06564974|||COHORT||PROSPECTIVE|||||||
33752517|NCT01716429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752518|NCT06526299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964492|NCT06248034|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|To reduce bias, the research assistant collecting assessment data will be blinded to treatment allocation. Participants will also be instructed not to reveal details about their group assignment to the outcome assessor to maintain blinding.|The investigators will perform stratified randomization by surgeons, are evenly distributed between the 2 treatment arms. Arm 1: Smartphone Home-based Rehabilitation Program (N=15); Arm 2: Hospital-based rehabilitation program (N=15).|f|f|f|t
33964493|NCT01318785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964494|NCT02145572|||OTHER||CROSS_SECTIONAL|||||||
33964495|NCT03844568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964496|NCT01981629|||CASE_ONLY||PROSPECTIVE|||||||
33964497|NCT02766231|||COHORT||PROSPECTIVE|||||||
34180983|NCT05706298|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
34180984|NCT01222052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34180985|NCT04230889|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34180986|NCT04231578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participating couples are either non-randomized in early phases of project or randomized to either immediately receive the Internet-delivered Couple HOPES intervention or to a delayed intervention group, where they receive access to Couple HOPES 8 weeks later.|f|f|f|t
34180987|NCT06474247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34180988|NCT05285371|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study participants will be randomized into one of two groups - Continuous (CONT) or Bolus (BOL).~CONT group will receive traditional continuous D50.45% NaCl + 20 mEq/L KCl solution at 2/3 maintenance rate.~BOL group will receive intravenous boluses of Lactated Ringer\&#39;s at 2/3-maintenance rate."||||
34180989|NCT05159440|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34180990|NCT02680249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34180991|NCT03642587|||COHORT||PROSPECTIVE|||||||
34180992|NCT06586099|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, open label, single arm clinical study||||
34180993|NCT02987426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Mindfulness Intervention|f|f|f|t
34180994|NCT05794958|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34180995|NCT06594458|NA|SINGLE_GROUP||OTHER||NONE||||||
34180996|NCT06202482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34180997|NCT04829201|||CASE_ONLY||PROSPECTIVE|||||||
34180998|NCT02435953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34180999|NCT03977961|||COHORT||PROSPECTIVE|||||||
34181000|NCT04268004|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants, the interventionist, and research staff will not be blinded.|Families will be randomly assigned to receive standard care or to receive standard care plus the investigator's study intervention. All families will then be followed for a year to assess outcomes.|f|f|t|t
34065804|NCT05876559|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The investigators plan to conduct a 3-month, parallel-group, randomized controlled trial (RCT) to evaluate the effectiveness on improving maternal functioning.||||
34181001|NCT01310777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181002|NCT05557084|||COHORT||PROSPECTIVE|||||||
34181003|NCT05030129|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a single-blind study, meaning the participant and his family/caregivers will not know what drug or combination the participant is receiving during each time period. The investigator and study coordinator will know what drug the participant is taking. The remainder of the study team performing assessments such as the Vineland, eye tracking, ERP, Toolbox, and the KiTAP will not know the type of treatment the patient is on when testing is done.|"This study will use a single-blind, 4-period sequential design. Fifteen participants with Fragile X Syndrome ages 18-45 years will enter a Screening period of up to 28 days followed by four 4 week single-blind treatment periods (summarized below).~* Period 1: Ergoloid mesylates 1 mg and matching placebo for 5-Hydroxytryptophan 100 mg, taken three times per day~* Period 2: Ergoloid mesylates 1 mg and 5-Hydroxytryptophan 100 mg, taken three times per day~* Period 3: 5-Hydroxytryptophan 100 mg and matching placebo for Ergoloid mesylates 1mg, taken three times per day~* Period 4: Matching placebo for Ergoloid mesylates 1mg and matching placebo for 5- Hydroxytryptophan 100mg, taken three times per day"|t|f|f|t
34181004|NCT05649215|||CASE_ONLY||PROSPECTIVE|||||||
34181005|NCT06603805|||COHORT||RETROSPECTIVE|||||||
34181006|NCT06397170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided into Group A (N=19) will receive Graded repetitive arm supplementary program and Patients in Group B (N=19)will receive Task based training.||||
34181007|NCT06590285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to standard of care monitoring or an educational intervention aimed at improving sleep and activity management during the transplantation process.||||
34181008|NCT06599853|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The research was planned as a randomized controlled study with experimental and control groups.||||
34181009|NCT04467593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34181010|NCT00897832|||CASE_ONLY||PROSPECTIVE|||||||
34181011|NCT03010215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181012|NCT06591611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181013|NCT06472440|||OTHER||RETROSPECTIVE|||||||
34181014|NCT03524508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181015|NCT01709721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181016|NCT06473753|||CASE_CONTROL||PROSPECTIVE|||||||
34181017|NCT04384484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065805|NCT05544903|||COHORT||PROSPECTIVE|||||||
33838746|NCT03899831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be administered by a blinded independent evaluator.|Participants will be randomly assigned to FBET or PEP in a 1:1 ratio using random permuted blocks of size 2 and 4. After Wk 16, participants in the PEP group will be offered the FBET.|f|f|f|t
34065806|NCT02175342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065807|NCT02256306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838747|NCT03743779|||OTHER||RETROSPECTIVE|||||||
33838748|NCT00667394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838749|NCT03336554|||COHORT||PROSPECTIVE|||||||
33838750|NCT03348410|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065808|NCT01107873|||||PROSPECTIVE|||||||
34065809|NCT01636947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065810|NCT05603156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065811|NCT01985958|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34065812|NCT05296200|||CASE_CONTROL||PROSPECTIVE|||||||
34065813|NCT00957424|NA|SINGLE_GROUP||||NONE||||||
34065814|NCT01781052|||COHORT||PROSPECTIVE|||||||
34065815|NCT03011411|||||RETROSPECTIVE|||||||
33867159|NCT05140122|||COHORT||PROSPECTIVE|||||||
34065816|NCT04719130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Another researcher collaborator (blinded) will be carried out the outcomes investigated.|This is a randomized parallel study (two arms) with blinded outcome assessments.|f|f|f|t
33867160|NCT00872976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867161|NCT03447938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867162|NCT00245310|||COHORT||PROSPECTIVE|||||||
33867163|NCT00505596|RANDOMIZED|PARALLEL||||NONE||||||
33867164|NCT04825171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867165|NCT01667536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867166|NCT06469099|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||active soldiers will perform baseline examinations for the musculoskeletal system. following, an exercise intervention program will be conducted with follow-up examination at the termination of program.|t|f|f|t
33867167|NCT05242042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel|t|t|t|t
33867168|NCT06065176|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will elect whether they are in the vaccinated group or decline to be in the vaccinated group. So, all participants will be aware of their group assignment. However, those participants in the vaccinated group as well as study investigators will be blinded to study arm assignments within the vaccinated group. A limited number of study staff handling and administering the vaccines will be aware of vaccine assignment and will be trained not to divulge vaccine assignment information to the investigator and study team. Study staff administering vaccine will not be involved with study surveillance to avoid involvement with measurement of study outcomes. The study will provide electronic documentation confirming that participants received one of the study vaccines (without indicating which vaccine) with date of vaccine administration. The electronic documentation of vaccine administration will be password protected to maintain blinding.|This randomized, three arm, active comparator trial will compare the clinical efficacy of a single dose of the Novavax 2023-2024 updated COVID-19 vaccine (Arm 1) with a single dose of the Pfizer mRNA 2023-2024 updated COVID-19 vaccine (Arm 2) as well as non-vaccinated comparison group (Arm 3). The participants who elect to receive a 2023-2024 updated COVID-19 vaccine are randomized into the Novavax (Arm 1) or Pfizer mRNA (Arm 2) vaccine groups. The non-vaccinated comparison group is nonrandomized.|t|f|t|t
33867169|NCT01177436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065817|NCT02577926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065818|NCT05072587|RANDOMIZED|PARALLEL||PREVENTION||NONE||This pilot study is a longitudinal prospective randomized clinical trial with two parallel arms. Participants in both arms of the study will receive prepared meals based on ADA dietary guidelines for 12 weeks. One group will be given a plant-based ADA diet that contains no oxysterols (PB-ADAØ). The other group will be given the Standard ADA diet (SADA). The dietary 7-KC content of both diets will be estimated from oxysterol food composition databases. Sample meals from both groups will be analyzed to determine the 7-KC food content and the accuracy of the estimates.||||
34065819|NCT03035916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34065820|NCT04286334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Surgeon is masked until the envelope opening at the end of the surgery, just before surgery.||t|t|t|t
34065821|NCT06304402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065822|NCT04950517|||COHORT||CROSS_SECTIONAL|||||||
34065823|NCT05475626|||OTHER||PROSPECTIVE|||||||
34065824|NCT05277064|||CASE_ONLY||PROSPECTIVE|||||||
34065825|NCT02811653|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34065826|NCT03129789||SEQUENTIAL||OTHER||SINGLE|participants perform ultrasound and the principle investigator is unaware of the identity of the participant||t|f|f|f
34181018|NCT06603376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181019|NCT06595771|||CASE_CONTROL||PROSPECTIVE|||||||
34181020|NCT06543199|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181021|NCT02425293|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181022|NCT02345070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181023|NCT04953494|||CASE_ONLY||PROSPECTIVE|||||||
34181024|NCT04102098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181025|NCT03439228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181026|NCT04018755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181027|NCT04882202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181028|NCT02506088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34181029|NCT06592066|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34181030|NCT02080715|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34181031|NCT04020809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181032|NCT01011894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065827|NCT04315844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065828|NCT00575263|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065829|NCT02053259|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34181033|NCT05016531|NA|SINGLE_GROUP||OTHER||NONE||||||
34065830|NCT04092088|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|neither the participant nor the investigator and outcomes assessor will be aware whether active tDCS/TENS will be applied to a particular case.|randomized, triple-blind, multi-center, factorial clinical trial|t|f|t|t
34065831|NCT05022420|||OTHER||PROSPECTIVE|||||||
34065832|NCT04093492|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065833|NCT01290497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065834|NCT00553358|RANDOMIZED|||TREATMENT||NONE||||||
34065835|NCT00570180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065836|NCT00741585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065837|NCT01456364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065838|NCT00385294|||COHORT||PROSPECTIVE|||||||
34065839|NCT02300142|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34065840|NCT00409032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065841|NCT02510300|||COHORT||PROSPECTIVE|||||||
34065842|NCT02540967|||OTHER||PROSPECTIVE|||||||
34181034|NCT02294708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065843|NCT03601741|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34065844|NCT02178527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34065845|NCT05559944|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34181035|NCT01164514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34181036|NCT06441201|||COHORT||PROSPECTIVE|||||||
34181037|NCT01236209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181038|NCT05838846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34181039|NCT06595667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor received the anesthetic record form by unknown of the patient and group allocation.|Two study groups are parallel according to the block of four randomization.|t|f|f|t
34065846|NCT02407587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181040|NCT05180227|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The last two (or three) visits, the participants will be blinded to the order of completing an orthostatic tilt with and without stimulation.|All participants will complete transcutaneous stimulation mapping sessions to determine the optimal parameters to increase and maintain systolic blood pressure between 110-120 mmHg for males and 100-120 mmHg for females. The last two (or three) visits, the participants will be blinded to the order of completing an orthostatic tilt with and without stimulation. The third visit might be needed if the amplitude of the intensity that was found to be optimal in the seated position needs to be increased during a tilt to increase systolic blood pressure.|t|f|f|f
34181041|NCT06451406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181042|NCT05559749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The randomization table will be prepared by the study statistician, uploaded by the developer, and concealed from the PI and coordinators in the REDCap data management system until after consent, enrollment and baseline data collection is complete, to minimize bias - once participants are randomized it is just outcome assessor who is truly blinded|This is a randomized, single-blind hybrid effectiveness-implementation study of a neurology clinic-based 24-week collaborative care intervention versus usual neurology care among a total of 60 adults having epilepsy with anxiety and/or depression symptoms, during 6 months follow-up. Participants will be randomized in a 1:1 ratio to collaborative care intervention versus usual neurology care.|f|f|f|t
34181043|NCT02323789|NA|SINGLE_GROUP||OTHER||NONE||||||
34181044|NCT01031212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181045|NCT00346580|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34181046|NCT05984576|||OTHER||PROSPECTIVE|||||||
34065847|NCT04757324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34065848|NCT04419766|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective experimental Before-After-Control-Intervention test will be carried out with two groups: a) Intervention (community of Tambai): with indoors and outdoors spraying with IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) and b) Control (community of Micheu 1): without spraying.||||
34065849|NCT06229977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065850|NCT00939406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065851|NCT02649426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181047|NCT05755412|||COHORT||PROSPECTIVE|||||||
34181048|NCT04351581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181049|NCT05880134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181050|NCT00508794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065852|NCT05040919|||COHORT||RETROSPECTIVE|||||||
34065853|NCT04205487|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Sequential Multiple Assignment Randomized Trial (SMART)||||
34065854|NCT02857413|||COHORT||PROSPECTIVE|||||||
34065855|NCT01849718|||CASE_CONTROL||OTHER|||||||
33867170|NCT02729740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867171|NCT06114277|||CASE_ONLY||PROSPECTIVE|||||||
33867172|NCT02873936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867173|NCT04195035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867174|NCT06280222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867175|NCT02484326|||COHORT||PROSPECTIVE|||||||
33867176|NCT06001996|||COHORT||PROSPECTIVE|||||||
33867177|NCT03104075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized assignment to group will be in a 1:1 ratio utilizing block randomization in blocks of 10 to receive Prevnar-13 or Pneumovax 23. Following randomized assignment of vaccine, the study will be open-label.||||
33867178|NCT00955812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867179|NCT01062139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867180|NCT02219321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867181|NCT00537498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867182|NCT04012879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065856|NCT04956341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||At Visit 10 (final visit), those in the non-acupuncture group still experiencing symptoms will be offered the opportunity to be rolled into the acupuncture treatment arm of the study as outlined above. This will not be part of the analysis. If a patient in the acupuncture group is still having symptoms they will be referred back to their primary care manager for further evaluation at the conclusion of the study.||||
33867183|NCT00657865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33867184|NCT04819256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867185|NCT02876120|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33867186|NCT05799599|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|In addition, we will have a blind coder who will code child-peer communication as an outcome measure.|Children with ASD and peer partners will be randomized to a first stage Stay-Play-Talk (SPT) Basic speech generating device (SGD) intervention with spoken peer input only (i.e., peers taught to model language) or SPT Plus intervention with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons). Each child's response to treatment after 5 weeks will determine that child's next phase in the SMART design. Children showing a positive response will continue in their originally assigned group. Children who are slow responders after 5 weeks, will be randomly assigned to receive added treatment components, either SPT Plus or SPT Advanced. SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts) to increase peer-directed communication.|t|f|f|t
33867187|NCT04557319|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Sequential dose-increase cohorts in healthy volunteers||||
33867188|NCT01467349|||CASE_CONTROL||RETROSPECTIVE|||||||
33867189|NCT01433757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867190|NCT00378469|RANDOMIZED|CROSSOVER||||NONE||||||
33867191|NCT01881945|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33867192|NCT05400681|||COHORT||PROSPECTIVE|||||||
33867193|NCT01111942|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893942|NCT02863848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893943|NCT05526534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065857|NCT01702922|||CASE_ONLY||CROSS_SECTIONAL|||||||
34065858|NCT01906281|||COHORT||PROSPECTIVE|||||||
34065859|NCT03129711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065860|NCT00430456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065861|NCT01250353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065862|NCT05761704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065863|NCT02133833|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34065864|NCT03848624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065865|NCT00506714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752519|NCT06356220|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Study Design: Prospective randomized controlled trial.~2. Study population: Children (N=120) with newly diagnosed CeD~3. Intervention: Gluten-Free Food Guide, a nutritional education program focused on minimizing ultra-processed foods in gluten-free die(GFFG), OR a conventional GFD nutritional education class. The nutrition educational program will be based on validated GFD education program. The investigators will use a randomized control trial to assess improvement of overall diet quality, changes in body composition, and minimize toxic and nutrient metal exposures associated with processed gluten-free foods."||||
33752520|NCT06722261|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33752521|NCT02618967|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33752522|NCT00536133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33752523|NCT06580223|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752524|NCT03805724|||CASE_CONTROL||OTHER|||||||
33752525|NCT06336330|||COHORT||PROSPECTIVE|||||||
33752526|NCT06502366|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind|This is a Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of BDA MDI HFO Compared with BDA MDI HFA in Participants with Asthma.|t|t|t|t
33752527|NCT06504615|||COHORT||PROSPECTIVE|||||||
33752528|NCT05000957|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment method cannot be hidden from the participants and the researcher because of the very different method of treatment: laser treatment followed by colporrhaphy and colporrhaphy only. However, the histologists involved in the study will not know which group the participant belongs to. The researcher will refer participants (or their materials) to these specialists, indicating their name. The Researcher will keep a document matching the participant's name and identification number.||f|f|f|t
33752529|NCT05230173|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33893944|NCT02631304|||COHORT||PROSPECTIVE|||||||
33893945|NCT05305716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893946|NCT01769521|NA|SINGLE_GROUP||||NONE||||||
33893947|NCT05200039|||COHORT||CROSS_SECTIONAL|||||||
33893948|NCT06042140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893949|NCT00601978|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893950|NCT00187083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181051|NCT03501498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomised cross-over study. Volunteers will be assessed at baseline, then after either taking loperamide or senna at the maximally tolerated dose for 2 days prior to the 'assessment period' then during the assessment period (5-7 days). After a washout period of at least 21 days, volunteers will then repeat the same assessments but cross over to take the second drug either loperamide or senna.||||
34181052|NCT05647408|RANDOMIZED|CROSSOVER||OTHER||NONE||2 PERIODS, 2 TREATMENTS, 2 SEQUENCES, CROSSOVER 2X2.||||
34181053|NCT05411029|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34181054|NCT06470711|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181055|NCT01499836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181056|NCT04383210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181057|NCT05409625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181058|NCT02528994|RANDOMIZED|PARALLEL||||NONE||||||
34181059|NCT02351817|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34181060|NCT03964831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752530|NCT06429176|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33752531|NCT04286139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33752532|NCT06634030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752533|NCT06442956|RANDOMIZED|CROSSOVER||PREVENTION||NONE||randomized crossover||||
33752534|NCT01521676|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33752535|NCT03458572|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33893951|NCT05075642|||CASE_ONLY||PROSPECTIVE|||||||
33893952|NCT01656642|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33893953|NCT00538681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893954|NCT04990076|||CASE_CONTROL||PROSPECTIVE|||||||
33893955|NCT00676507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893956|NCT04516304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893957|NCT06656988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893958|NCT05462093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893959|NCT04622852|||CASE_CONTROL||PROSPECTIVE|||||||
33867194|NCT03947450|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|"In whole stump injection subjects: Subjects will be blinded to which injections they will receive. At the end of the study, subjects who received vehicle injections will be notified and offered whole stump volar fibroblast injections. Blinding will occur for outcomes assessor during measurements of epidermal thickness/area.~In localized injection subjects: Sites were labeled as A and B, and mask for outcome assessors and subjects. All these are in the same subject."|"Single arm crossover, subjects will be randomized 1:1 into whole stump injections of volar fibroblasts and vehicle injections respectively. Subjects will be blinded to which injections they will receive. At the end of the study, subjects who received vehicle injections will be notified and offered whole stump volar fibroblast injections. Blinding will occur for research staff both during measurements of epidermal thickness/area.~If the PI or subject determines that they do not qualify for whole stump injection, do not desire whole stump injection, or are already enrolled as localized stump injections- the study will continue as a parallel interventional study model in which 2 locations are selected for fibroblast and vehicle injections on the same subject. Subjects who receive localized injections will be offered whole stump fibroblast injection at the end of the study."|t|f|f|t
33867195|NCT05738811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867196|NCT04786457|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33867197|NCT01628107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867198|NCT02741804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33867199|NCT00058474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867200|NCT04654520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867201|NCT04296279|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867202|NCT06188819|||COHORT||RETROSPECTIVE|||||||
33867203|NCT01375257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867204|NCT04888299|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867205|NCT06028087|||CASE_ONLY||PROSPECTIVE|||||||
33867206|NCT01025596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867207|NCT05510921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867208|NCT05629429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867209|NCT05479279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867210|NCT00517322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867211|NCT02903251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867212|NCT03662672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33867213|NCT01918423|||COHORT||PROSPECTIVE|||||||
33867214|NCT03846999|||COHORT||RETROSPECTIVE|||||||
33867215|NCT01514097|||CASE_ONLY||PROSPECTIVE|||||||
33867216|NCT01887951|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33867217|NCT02960178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867218|NCT00797836|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867219|NCT01471314|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867220|NCT00431756|||COHORT||PROSPECTIVE|||||||
33867221|NCT01358890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867222|NCT06465251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867223|NCT04612036|||COHORT||RETROSPECTIVE|||||||
33867224|NCT02114268|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33867225|NCT00488111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867226|NCT05147064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867227|NCT01873417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867228|NCT00904631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867229|NCT00344565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867230|NCT01038804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867231|NCT05800340|NA|SINGLE_GROUP||TREATMENT||NONE||3 cycles of neoadjuvant Toripalimab (240mg every 3 weeks) with nab-paclitaxel + carboplatin, or pemetrexed + carboplatin (decided by investigators; nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every 3 weeks; pemetrexed, 500mg/m2 d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including chemotherapy for 3-4 cycles or rare mutations-TKIs for up to 2 year or till disease progression or unacceptable toxicity.||||
33867232|NCT02221349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867233|NCT04158544|||COHORT||PROSPECTIVE|||||||
33867234|NCT03378323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867235|NCT04128345|||CASE_ONLY||PROSPECTIVE|||||||
33867236|NCT04349163|||COHORT||PROSPECTIVE|||||||
34065866|NCT02376140|||COHORT||CROSS_SECTIONAL|||||||
34065867|NCT03301831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2-arm RCT with participants randomized to either the intervention or attention control group.||||
34065868|NCT01836913|||COHORT||PROSPECTIVE|||||||
34065869|NCT01309984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065870|NCT05254470|||COHORT||RETROSPECTIVE|||||||
34065871|NCT03267602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867237|NCT03092206|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: F/TAF ; oral; Dose: 25/200 mg; Frequency: QD Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD||||
33867238|NCT05221905|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a double-blind study, where neither the investigators nor the subjects will know whether the participants are receiving the active supplement or placebo supplement until study conclusion.|Subject are stratified randomized to consume either beetroot juice with, or without, inorganic nitrate and will consume this same supplement throughout all testing|t|f|t|f
34181061|NCT03375788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo controlled phase for first 12 months, followed by open-label phase for 6 months during which all participants receive active medication (tesamorelin)|t|t|t|t
34181062|NCT04220307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181063|NCT05967507|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34181064|NCT06597877|||OTHER||PROSPECTIVE|||||||
34181065|NCT06597799|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Sequential Ascending Doses, Multiple Ascending Doses|t|t|t|t
34181066|NCT02931877|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181067|NCT00228267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34181068|NCT02948933|||COHORT||PROSPECTIVE|||||||
34181069|NCT00169286|RANDOMIZED|FACTORIAL||OTHER||SINGLE||||||
34181070|NCT02787902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181071|NCT06587178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181072|NCT04692259|NA|SINGLE_GROUP||PREVENTION||NONE||Retrospective analysis of correlation between MRI dynamics and the risk of postoperative liver failure after liver resection.||||
34181073|NCT03942796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181074|NCT03104907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181075|NCT01629264|||COHORT||PROSPECTIVE|||||||
33867239|NCT01178320|||COHORT||PROSPECTIVE|||||||
33867240|NCT00182832|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33867241|NCT01457391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867242|NCT04960540|||CASE_ONLY||PROSPECTIVE|||||||
33867243|NCT02715336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867244|NCT02874560|||COHORT||PROSPECTIVE|||||||
33867245|NCT05221047|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33867246|NCT01925352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867247|NCT00897143|||||RETROSPECTIVE|||||||
33867248|NCT00729378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33867249|NCT01033552|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867250|NCT00263029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867251|NCT00585611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867252|NCT02650999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867253|NCT01688284|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33867254|NCT02546765|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33867255|NCT03950349|||COHORT||PROSPECTIVE|||||||
33867256|NCT03612362|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized control trial||||
33867257|NCT04795297|||COHORT||RETROSPECTIVE|||||||
33867258|NCT03175354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867259|NCT05102578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33867260|NCT04667000|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||parallel group randomized controlled study|f|f|t|t
34181076|NCT01808586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181077|NCT06064279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181078|NCT04106492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 dose escalation part of the study was done sequentially. The Phase 2 part of the study will be done in parallel between the four groups.||||
34181079|NCT00702221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752536|NCT06732011|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752537|NCT04086628|||CASE_CONTROL||PROSPECTIVE|||||||
33752538|NCT06048822|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867261|NCT04785170|NA|SINGLE_GROUP||TREATMENT||NONE||safety and efficacy of amino acid in single arm group of Healthy Individuals.||||
33867262|NCT01984164|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33867263|NCT03202823|||CASE_CONTROL||PROSPECTIVE|||||||
33867264|NCT02372565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867265|NCT02794142|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33867266|NCT00305968|RANDOMIZED|PARALLEL||||NONE||||||
33867267|NCT01368536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181080|NCT05380180|RANDOMIZED|PARALLEL||OTHER||SINGLE|All primary and secondary outcome assessments completed at Week 4 and Week 8 are blinded. Participants are told ahead of time to not share their group information with the blinded assessor during administration of measures. Supplementary outcome measures require the assessor to know the group assignment, as these measures pertain to their current experience in the intervention. Thus, all supplementary outcome measures are administered at a separate time by an unblinded assessor|Participants will be screened and assigned to either intervention group or wait-listed group.|f|f|t|f
34181081|NCT02144610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867268|NCT01129050|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33867269|NCT06357507|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867270|NCT06476522|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention Group and Control Group||||
33867271|NCT00501514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867272|NCT06441045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867273|NCT05708950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181082|NCT04228211|||COHORT||PROSPECTIVE|||||||
34181083|NCT00298402|||CASE_CONTROL||PROSPECTIVE|||||||
34181084|NCT06655831|||OTHER||CROSS_SECTIONAL|||||||
33867274|NCT06396585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867275|NCT03747042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867276|NCT04838223|||OTHER||PROSPECTIVE|||||||
33867277|NCT04248387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867278|NCT00376337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867279|NCT00794495|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33867280|NCT04646681|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867281|NCT02887235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867282|NCT02386748|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33867283|NCT01088464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867284|NCT05392504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867285|NCT04643080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867286|NCT01505270|||CASE_ONLY||RETROSPECTIVE|||||||
33867287|NCT02020057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867288|NCT01876251||||TREATMENT||NONE||||||
33867289|NCT01998620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867290|NCT04032704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893960|NCT02762058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33893961|NCT06380244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|t|f
34181085|NCT06396273|||CASE_CONTROL||PROSPECTIVE|||||||
34181086|NCT02819011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181087|NCT01213888|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|t|f|f
34181088|NCT05903898|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181089|NCT02741739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33752539|NCT00679471|||COHORT||PROSPECTIVE|||||||
33752540|NCT05750290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838751|NCT02902770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838752|NCT03624153|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33838753|NCT05022862|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838754|NCT02354651|||COHORT||PROSPECTIVE|||||||
33838755|NCT05444270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838756|NCT00930345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838757|NCT04420247|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two arms - Intervention and Control Intervention received unblinded treatment with Chloroquine or Hyroxycloroquine for 5 days, as well as standard treatment available and recomended by the Brazilian Guidelines for COVID-19.~Control group received just the standard treatment available and recomended by the Brazilian Guidelines for COVID-19."||||
33838758|NCT01443403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838759|NCT01485497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838760|NCT02859740|||COHORT||PROSPECTIVE|||||||
33838761|NCT01167452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838762|NCT03660735|||OTHER||PROSPECTIVE|||||||
33838763|NCT02708381|||CASE_ONLY||PROSPECTIVE|||||||
33838764|NCT02693015|||COHORT||PROSPECTIVE|||||||
33838765|NCT00532207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838766|NCT04204382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838767|NCT02858570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33838768|NCT02100358|||COHORT||PROSPECTIVE|||||||
33838769|NCT05492851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33838770|NCT04874753|||CASE_ONLY||RETROSPECTIVE|||||||
33838771|NCT03468478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181090|NCT02059278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181091|NCT03149679|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, open labeled, phase 2 clinical trial, where patients are selected for treatment based on upfront TP53 mutation status; i.e. only patients with TP53 mutated tumors may be included in the single treatment arm. The informed consent, however needs to be signed prior to a biopsy for TP53 mutation analyses; thus, all patients are formally enrolled in the study prior to tissue collection, and the full population tested will be accounted for despite the fact that only patients with TP53 mutated tumors may enter the single treatment arm.||||
34181092|NCT02642185|||COHORT||PROSPECTIVE|||||||
34181093|NCT04094558|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181094|NCT00183755|||COHORT||PROSPECTIVE|||||||
34181095|NCT03135327|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181096|NCT00780312|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34181097|NCT02944149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181098|NCT06061796|NA|SINGLE_GROUP||TREATMENT||NONE||"patient in pp (maximum 48h) until the following criteria are reached for 4 consecutive hours:~* P/F ratio \> 150 mm Hg~* FiO2 \< 60%~* Positive End-Exhalation Pressure (PEEP)"||||
34181099|NCT02191111|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181100|NCT02055885|||COHORT||RETROSPECTIVE|||||||
34181101|NCT06600256|||COHORT||PROSPECTIVE|||||||
34181102|NCT00363259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181103|NCT00005966|RANDOMIZED|||TREATMENT||||||||
34181104|NCT05338684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients diagnosed with pulsatile tinnitus clinically||||
34181105|NCT04636125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181106|NCT06588075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181107|NCT03324269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All patients wear NOL monitoring and are aware of it. Anesthesiologist can read NOL values.|Patients undergoing non-cardiac and cardiac surgery have NOL monitoring||||
33867291|NCT05435170|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open-label study|Participants will be randomized to one of the 2 sequences. In sequence AB, participants will receive linerixibat under fed state (Treatment A) in Period 1, then linerixibat under fasted state (Treatment B) in Period 2. In Sequence BA, the 2 treatments will be reversed. The washout period will be of at least 7 days.||||
33867292|NCT04450667|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33867293|NCT04649957|||COHORT||PROSPECTIVE|||||||
33867294|NCT06174051|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will have an open label, since the care provider (the psychologist) needs to know which procedure to follow and the participants will understand in which group they are once the therapy start.|In this study, three groups are compared in a parallel setting. One group will receive EMDR following the flashforward procedure, one group will receive EMDR following the flashback procedure, and the last group will be on a wait list and fill out the questionnaires without receiving EMDR treatment.||||
33867295|NCT06273384|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867296|NCT02006823|||COHORT||PROSPECTIVE|||||||
33867297|NCT04173884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33867298|NCT00741572|||CASE_ONLY||PROSPECTIVE|||||||
33867299|NCT02813278|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867300|NCT04607148|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be masked until database lock of the parent study (NCT03972709/GR40973). After the masked period, the study will follow an open-label design. The Outcome Assessor is masked for BCVA assessments.||t|f|f|t
33867301|NCT00841204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33867302|NCT03032406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867303|NCT04143399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867304|NCT01882842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867305|NCT02774395|||OTHER||PROSPECTIVE|||||||
33867306|NCT00077532|RANDOMIZED|||TREATMENT||||||||
33867307|NCT00454038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867308|NCT00277420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867309|NCT00958945|||||RETROSPECTIVE|||||||
33867310|NCT03035695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867311|NCT03163784|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33867312|NCT01535495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867313|NCT04989426|||COHORT||PROSPECTIVE|||||||
33867314|NCT02860195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867315|NCT00290290|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33867316|NCT05518227|||COHORT||PROSPECTIVE|||||||
33867317|NCT00189618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181108|NCT01615939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181109|NCT04514861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-arm, non-randomized, effectiveness and performance study with confirmatory device in subjects with PAD||||
34181110|NCT05493917|||COHORT||PROSPECTIVE|||||||
34181111|NCT02396576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181112|NCT03497624|||OTHER||PROSPECTIVE|||||||
34181113|NCT04043299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Similar gas tanks will be used for both the intervention and control group|The intervention group will receive 100% medical oxygen while the control group will receive medical air|t|t|t|t
34181114|NCT05277415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, parallellel intervention study|t|t|t|t
34181115|NCT01910298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867318|NCT01978535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867319|NCT01411020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867320|NCT01378260|||COHORT||PROSPECTIVE|||||||
33867321|NCT06419192|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867322|NCT05490836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867323|NCT03770091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893962|NCT00375245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181116|NCT04790617|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The ENCOMPASS study will evaluate the effectiveness of a community health navigator program using a two-armed, pragmatic, randomized controlled trial. The intervention arm will receive the CHN program for six months. The control arm will receive their usual health care. This study will employ patient-level block randomization stratified by study site. Research staff will be blinded to block size. In the case where participants live together in the same residence, they will be randomly assigned to the same study arm.||||
33867324|NCT03569046|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The same surgeons performed all the operations to ensure consistency in the estimation of the surgical field. To eliminate the observer bias, the observing anesthetist did not attend the induction of block. Also, the operating surgeon was blinded to the pharmacological treatments, anesthesia and performance of the used techniques.||t|t|t|t
33867325|NCT01200004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867326|NCT01961375|||COHORT||PROSPECTIVE|||||||
33867327|NCT01698866|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33867328|NCT03043521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867329|NCT00467779|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867330|NCT01611064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867331|NCT04643756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181117|NCT02383576|||COHORT||RETROSPECTIVE|||||||
33867332|NCT05126186|NA|SINGLE_GROUP||OTHER||NONE||||||
33867333|NCT02959528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867334|NCT00112775||||TREATMENT||NONE||||||
33867335|NCT01353508|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33867336|NCT03755570|||COHORT||PROSPECTIVE|||||||
33964498|NCT03536247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the study will be blinded to treatment arm. Care providers and Investigators will be unblinded to treated arm.|Patients will be randomized using a pre-generated randomization schedule with concealed allocation in a 1:1 assignment to initial cholangioscopy guided lithotrispy or papillary dilation. Randomization will be blocked in groups of 12.|t|f|f|f
33964499|NCT03793595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964500|NCT00789828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964501|NCT05717088|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The random numbers will be placed in sequentially numbered, sealed, opaque envelopes and will be opened after obtaining informed consent and just before the procedure by one of the study investigators to ensure allocation concealment.||t|t|t|t
33964502|NCT01051999|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964503|NCT05440994|||COHORT||RETROSPECTIVE|||||||
34181118|NCT04647188|||COHORT||PROSPECTIVE|||||||
34181119|NCT05716802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181120|NCT06338098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181121|NCT02887677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181122|NCT02283853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181123|NCT06507774|||COHORT||RETROSPECTIVE|||||||
34181124|NCT02111668|||CASE_ONLY||OTHER|||||||
34181125|NCT05943600|||COHORT||CROSS_SECTIONAL|||||||
34181126|NCT06587971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181127|NCT03525236|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181128|NCT01235312|||COHORT||PROSPECTIVE|||||||
34181129|NCT03405246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34181130|NCT04135274|||CASE_ONLY||PROSPECTIVE|||||||
33752541|NCT06170541|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||blinded, prospective single-center study.|f|f|f|t
33867337|NCT04416399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, open label parallel group controlled clinical trial||||
33893963|NCT02220387|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33893964|NCT04320095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964504|NCT02100852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964505|NCT03728699|||COHORT||PROSPECTIVE|||||||
33964506|NCT00141596|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964507|NCT04676516|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II, randomized, open label, multi-center, parallel design, window of opportunity trial||||
33964508|NCT02755233|||CASE_ONLY||PROSPECTIVE|||||||
33964509|NCT01098734|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33964510|NCT03373409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3-way single dose crossover||||
33752542|NCT06475612|||CASE_CONTROL||RETROSPECTIVE|||||||
33752543|NCT06545097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893965|NCT04062955|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33964511|NCT06398145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964512|NCT02580318|NA|SINGLE_GROUP||OTHER||NONE||||||
33893966|NCT06198920|||COHORT||PROSPECTIVE|||||||
33893967|NCT00013806||||TREATMENT||||||||
33964513|NCT01559818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964514|NCT01282827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964515|NCT06274125|||CASE_CONTROL||PROSPECTIVE|||||||
34181131|NCT05625308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||40 HPV-positive women displaying chronic cervicitis, mild dysplasia or moderate dysplasia.||||
33964516|NCT01336608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964517|NCT01999790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181132|NCT00812708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181133|NCT00338845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181134|NCT05007054|||COHORT||RETROSPECTIVE|||||||
34181135|NCT01826019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181136|NCT01184157|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34181137|NCT01782378|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The participant and the person administering treatments wore goggles (LS-DIO, Phillips Safety Products, Inc.) that blocked 600-900nm wavelengths including red 633 nm wavelength, emitted from the red Intranasal diode. All participants were randomly assigned by computer to Group 1 (Sham First) or Group 2 (Real First) in blocks of 10.|This was a blinded, randomized, sham-controlled partial crossover study, with 2 Groups. Group 1: Sham LED Series First followed by optional Real LED Series Second. Group 2: One Real LED Series, only. Neuropsychological (NP) tests were completed at Entry (T1), within 1 week post- (T2) and at 1 month post- the 15th treatment (T3) (First series). NP testing was administered after the optional Second Real Series within 1 week post- (T4) and at 1 month post- the 15th treatment (T5). Primary Outcome Measures included NP tests in 3 domains: 1) Attention/Executive Function; 2) Learning and Memory; 3) Psychomotor/Visual Spatial. The Secondary Outcome Measures included sleep, pain, fatigue, and mood.|t|t|t|t
34181138|NCT04323969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181139|NCT04682366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867338|NCT03611283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study and placebo products had an identical appearance and were packaged identically. The sacs were numbered consecutively from 1 to 28. The company prepared and numbered the bag and all the participants were blinded to the treatment. Blinding was revealed after all participants finished the trial and all the data were collected.|Randomized double-blind placebo controlled study|t|t|f|f
34181140|NCT00121498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34181141|NCT02023463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181142|NCT06582927|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34181143|NCT05511233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34181144|NCT05806580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181145|NCT00199381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181146|NCT00231569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181147|NCT02008799|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34181148|NCT05270720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181149|NCT02491632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181150|NCT03536208|NA|SINGLE_GROUP||TREATMENT||NONE||patients will be assigned to warfarin by mouth daily on an outpatient basis. The first 5 patients enrolled will be assigned to the 1 mg QD dose level, the next 5 patients enrolled will be assigned to the 2 mg QD dose level, and so forth until all dose levels enrolled 5 patients.||||
34181151|NCT06430970|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181152|NCT06600009|||COHORT||RETROSPECTIVE|||||||
34181153|NCT04849247|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a first-in-human 3 + 3 study design to identify dose limiting toxicity and recommended phase 2 dose Masking: None (Open Label)||||
33867339|NCT02616614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867340|NCT01538628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964518|NCT03880864|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33964519|NCT00171119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964520|NCT02793999|||COHORT||PROSPECTIVE|||||||
33964521|NCT02293811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964522|NCT00885807|||CASE_ONLY||CROSS_SECTIONAL|||||||
34181154|NCT01141517|||CASE_CONTROL||PROSPECTIVE|||||||
34181155|NCT05707728|||CASE_ONLY||PROSPECTIVE|||||||
34181156|NCT04964180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181157|NCT01323114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181158|NCT06593730|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34181159|NCT02241616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181160|NCT02172274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181161|NCT05900596|||COHORT||CROSS_SECTIONAL|||||||
34181162|NCT01780974|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33867341|NCT02591381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867342|NCT04506814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867343|NCT04862533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|t|t|f
33867344|NCT04532216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964523|NCT02011802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964524|NCT03631459|||COHORT||PROSPECTIVE|||||||
34181163|NCT00512889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181164|NCT06271577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181165|NCT06146920|NA|SINGLE_GROUP||OTHER||NONE||All consented participants with evidence of disease control / response after at least 1 year of immune checkpoint inhibition (monotherapy or in combination) with negative ctDNA will be invited to stop systemic therapy and continue with active surveillance.||||
33867345|NCT01687179||SEQUENTIAL||TREATMENT||NONE||||||
33867346|NCT00372242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867347|NCT01837069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867348|NCT02867124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867349|NCT06537739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomly assigned to groups. One of the researchers will then give the person a verbal message (dependent on the study group). The physiotherapist performing the joint manipulation will not know which study group a given patient belongs to. The researcher collecting results and performing statistical analysis will also be blinded.|It will be a prospective follow-up study, with a type of message used as a differentiating variable (positive - placebo, negative - nocebo, neutral).|t|t|f|t
33867350|NCT03128970|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The gynecologist performing the embryo transfer as well as the patients undergoing frozen embryo transfer will be blinded to group allocation||t|t|f|f
33867351|NCT04346498|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Mothers were masked only for the presence or absence of a sequence in the trial. Hospital staffs, students, and investigators of the study were all blinded to allocation of the intervention. Until the study was finalized, access to the database was restricted to the data manager only||t|f|t|f
33867352|NCT06386965|||CASE_CONTROL||PROSPECTIVE|||||||
33867353|NCT02834169|||COHORT||OTHER|||||||
33867354|NCT04630587|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Restorations are rated independently by blinded dentists who are not involved with the insertion of the indirect and the direct restorations and are unaware of the group status of the fillings.|Each patient requires pairwise number of restorations. The randomizations are performed by each tooth to be restored by direct technique vs. indirect technique utilizing 3D printing.|f|f|f|t
33867355|NCT00630851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867356|NCT06258889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867357|NCT05232851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathologist will be blinded to study treatment arm.||f|f|f|t
33867358|NCT03017638|||CASE_CONTROL||PROSPECTIVE|||||||
34065872|NCT05730348|||CASE_ONLY||PROSPECTIVE|||||||
34065873|NCT00004197||||TREATMENT||||||||
34065874|NCT03316066|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34065875|NCT06234527|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065876|NCT00901082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33752544|NCT05501054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867359|NCT02730052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867360|NCT04941547|||CASE_CONTROL||RETROSPECTIVE|||||||
34065877|NCT01486186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065878|NCT03871829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065879|NCT02743065|||COHORT||PROSPECTIVE|||||||
34065880|NCT01717391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065881|NCT04787861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34065882|NCT05243667|||CASE_ONLY||PROSPECTIVE|||||||
34065883|NCT01132300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181166|NCT01770418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181167|NCT06654778|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"The patients will be assigned into three equal groups of 20 patients each:~1. Group I: PEEP of 8 cm H2O and fluid management: 500 ml + 4 mL/kg/hour Ringer's lactate~2. Group II: PEEP/RM group, addition of RM (30 cm H2O for 30 s)~3. Group III: PEEP/RM group and restricted fluid management 3 mL/kg/hour Ringer's lactate~A total sample size of 60 patients will be involved."|t|t|f|f
34181168|NCT06651944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181169|NCT00122083|RANDOMIZED|PARALLEL||ECT||NONE||||||
34181170|NCT06072053|||COHORT||PROSPECTIVE|||||||
34181171|NCT02307825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867361|NCT00316251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867362|NCT02252536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867363|NCT00136526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867364|NCT04344301|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients will be randomly allocated to AUDIO or UC alone using a block-randomization technique with the clinician acting as the blocking variable; this strategy will ensure an equal number of patients per clinician will be randomly assigned to each study arm.||||
33867365|NCT00404820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867366|NCT00806676|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33867367|NCT00497783|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867368|NCT03947983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be randomized into two arms of intervention group or control group. The control group will receive only the weight monitoring and physical activity sensors while the intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors|t|f|f|t
33867369|NCT01109342|||CASE_CONTROL||PROSPECTIVE|||||||
33867370|NCT00842231|||COHORT||PROSPECTIVE|||||||
33867371|NCT00646906|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33867372|NCT03244514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33867373|NCT02194530|||CASE_CONTROL||PROSPECTIVE|||||||
33867374|NCT02692664|||OTHER||PROSPECTIVE|||||||
33867375|NCT00436618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867376|NCT01639768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867377|NCT02247960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893968|NCT01346800|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33893969|NCT04619576|||COHORT||CROSS_SECTIONAL|||||||
33964525|NCT00175383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964526|NCT04711863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964527|NCT05975463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964528|NCT06538129|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split-mouth||||
33964529|NCT00420160|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964530|NCT02465580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964531|NCT05613335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181172|NCT02739906|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33964532|NCT02803645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181173|NCT06513091|||OTHER||OTHER|||||||
34181174|NCT02512705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181175|NCT01655459|||COHORT||CROSS_SECTIONAL|||||||
34181176|NCT00305513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34181177|NCT02446964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181178|NCT04730700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181179|NCT01605708|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34181180|NCT00403377|RANDOMIZED|PARALLEL||||NONE||||||
34181181|NCT05303012|||COHORT||PROSPECTIVE|||||||
34181182|NCT02187419|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34181183|NCT04538521|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181184|NCT06259916|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34181185|NCT00181272|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34181186|NCT04054986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181187|NCT04670588|||COHORT||PROSPECTIVE|||||||
34181188|NCT05796583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Investigational Drug Service will create the randomization tables and provide the investigators with the appropriate device (active or sham), leaving all participants, investigators, and the statistician masked to treatment group assignment with the exception of the study coordinator who receives the study device from the Investigational Drug Service.|Parallel Assignment: Randomized, Triple-Masked, Placebo-Controlled, Parallel-Arm Human Subjects Clinical Trial|t|f|t|t
34181189|NCT06654245|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33964533|NCT04811222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Ga-DOTATATE PETMRI scan||||
33893970|NCT05294900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867378|NCT05948007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All participants will receive any medical care they would normally receive, including post-surgery exercise program. Those randomized to the usual care group are free to seek whatever treatment, if any, they would like to take.|t|f|f|f
33867379|NCT00502814|||CASE_ONLY||PROSPECTIVE|||||||
34181190|NCT06467227|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective longitudinal, self-controlled, single-case repeated measures, randomized and counterbalanced cross-over experimental trial design, comparing cardiopulmonary response and endurance with different modes of exercise||||
33867380|NCT03056950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867381|NCT03130062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The collaborators who carried out these evaluations were unaware of the allocation of volunteers.|The division of the groups was obtained through randomization through a computer program. An opaque envelope containing the group allocation was given to the volunteer by the blind evaluator. After randomization, the sequential numbers were kept in opaque and closed envelopes and, as patients passed the initial evaluations, were allocated to one of the groups.|f|f|f|t
33867382|NCT00615472|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34181191|NCT04814277|||COHORT||PROSPECTIVE|||||||
33867383|NCT06490705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study design uses cluster randomization to assign subjects to three groups different exercise groups. This study employs a single-blind design to minimize bias, where the participants are blinded to the group allocations.|"This is a longitudinal research design using cluster randomization. Participants were randomly divided into three groups by computer, 30 people per group:~Group 1 received tongue resistance exercises. Group 2 received both tongue strengthening exercises and tongue resistance exercises.~Group 3: control group received oral and cheek bulging exercises. The exercise intervention is divided into two stages. After completing the pre-test (T1), the first stage of 12 weeks of exercise begins, with evaluations conducted at the 4th week (T2), 8th week (T3), and 12th week (T4). After a 12-week rest period (T5), the second phase of Boosters exercise is conducted for another 12 weeks, followed by an immediate post-test (T6) and a final evaluation after another 12 weeks of rest (T7). Participants received exercise 6 days a week, 3 times a day (before meals), with each session lasting 30 minutes."|t|f|f|f
33867384|NCT05125094|||COHORT||PROSPECTIVE|||||||
33867385|NCT00958984|||COHORT||PROSPECTIVE|||||||
33867386|NCT00621751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867387|NCT02809131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867388|NCT00528164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867389|NCT01793805|||COHORT||PROSPECTIVE|||||||
33867390|NCT01210170|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34181192|NCT06601803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181193|NCT03713736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867391|NCT01089998|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867392|NCT03951051|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department.||f|f|f|t
33867393|NCT01236105|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34065884|NCT02544958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065885|NCT04774276|||COHORT||OTHER|||||||
33867394|NCT00486772|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
33867395|NCT00151983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065886|NCT02000882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065887|NCT06404905|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34065888|NCT03810235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-center, single blind, randomized controlled trial|t|f|f|f
34065889|NCT00394316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065890|NCT06201208|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This study is a non-randomized experimental study with pre-test, post-test, follow-up and control groups.|f|f|f|t
34065891|NCT01723020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065892|NCT01892800|||COHORT||PROSPECTIVE|||||||
34065893|NCT04865991|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34065894|NCT02579317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34065895|NCT00819949|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34065896|NCT00349999|||COHORT||PROSPECTIVE|||||||
34181194|NCT06184217|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181195|NCT01912833|||COHORT||PROSPECTIVE|||||||
34181196|NCT02614001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34181197|NCT00802308|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34181198|NCT04461275|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is an investigator-initiated, single-center prospective feasibility study. This feasibility study will compare 30 consecutive patients following the ERAS 2.0 program to 30 patients of a retrospective cohort who followed the current standard ERAS 1.0 protocol.||||
34181199|NCT06565949|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||The research will be conducted as a randomised experimental study with pretest-posttest control group.|t|f|f|f
33867396|NCT03877562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33867397|NCT01624259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867398|NCT02047539|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33964534|NCT01407679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964535|NCT03767673|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Control group: Age and sex matched healthy volunteers.|||||
33964536|NCT03371238|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33964537|NCT00078819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181200|NCT00023660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181201|NCT03568214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34181202|NCT03802006|||COHORT||PROSPECTIVE|||||||
34181203|NCT05826938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867399|NCT01395251|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34181204|NCT02784756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181205|NCT04645758|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|M.M.K outcome blind assessor|Participants will be assigned to two groups in parallel for the duration of the study.|f|f|f|t
34181206|NCT00707083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181207|NCT03925012|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34181208|NCT01499940|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181209|NCT06370806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181210|NCT01352715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181211|NCT06591039|||COHORT||PROSPECTIVE|||||||
34181212|NCT05074290|NA|SEQUENTIAL||TREATMENT||NONE||||||
34181213|NCT06592378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181214|NCT04869826|||CASE_ONLY||PROSPECTIVE|||||||
34181215|NCT05996237|||COHORT||PROSPECTIVE|||||||
34181216|NCT03431259|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867400|NCT03347981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867401|NCT00433680|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33867402|NCT01723215|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33867403|NCT05281796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867404|NCT05060705|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking, open label|"Participants are assigned to the one of two parallel groups: 1) treated with study drug Efesovir; 2) treated with referent drug Remdesivir."||||
33867405|NCT04903925|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33867406|NCT03171844|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867407|NCT05345535|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two randomized controlled group||||
33867408|NCT00049803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867409|NCT04863079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867410|NCT01700270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867411|NCT00002296||||TREATMENT||DOUBLE||||||
33867412|NCT04973579|||COHORT||PROSPECTIVE|||||||
34065897|NCT02721017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065898|NCT04909814|||COHORT||PROSPECTIVE|||||||
34065899|NCT04402450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||prospective randomized comparison between two analgesic techniques|t|t|f|t
34065900|NCT06147752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065901|NCT04012424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34065902|NCT00853879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181217|NCT03915795|||COHORT||PROSPECTIVE|||||||
34181218|NCT05637710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Participants who meet all eligibility criteria will be randomized to one of the following treatment groups:~Investigational group: FDC levocetirizine 5mg / pseudoephedrine 240mg from Eurofarma Laboratórios S.A. (investigational drug) Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.~Comparator group: Levocetirizine 5mg (Zina® - comparator drug) Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina® 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days."|t|t|t|f
34181219|NCT04464486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181220|NCT05361668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181221|NCT06592339|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181222|NCT06588595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laboratory personnel processing blood samples will be blinded to the allocation of the participants.||f|f|f|t
33964538|NCT01164397|||CASE_ONLY||RETROSPECTIVE|||||||
33964539|NCT03020836|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34181223|NCT02667119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181224|NCT02895165|||COHORT||PROSPECTIVE|||||||
34181225|NCT02252666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181226|NCT01750151|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33964540|NCT03156270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964541|NCT01698762|||CASE_CONTROL||PROSPECTIVE|||||||
33964542|NCT02464059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34065903|NCT00003394||||TREATMENT||||||||
34065904|NCT03704012|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The control group included all preterm infants from months 1-6 and 19-24 of the study. The intervention group included all the premature newborns from the 7-18 months of the study.|f|f|t|f
34065905|NCT02479464|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34065906|NCT05699876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34065907|NCT00493987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065908|NCT05077319|||COHORT||RETROSPECTIVE|||||||
34065909|NCT06232395|||COHORT||PROSPECTIVE|||||||
34065910|NCT06406374|||COHORT||PROSPECTIVE|||||||
34065911|NCT02868398|||CASE_CONTROL||PROSPECTIVE|||||||
34065912|NCT02030496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752545|NCT04859608|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized (2:1) controlled study, open-label, with Markov modeling.||||
33752546|NCT06720051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867413|NCT00493090|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33867414|NCT05328726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Enrollment of up to 56 subjects in up to 7 cohorts may occur. Randomization is 3:1 (active drug:placebo) across all cohorts. Within each cohort, 6 subjects will be randomized to receive GZR18, and 2 subjects will be randomized to receive placebo.|This is a double-blinded, randomized, placebo-controlled, sequential, dose-escalating, single-dose study.|t|f|t|f
33867415|NCT02019225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867416|NCT06194513|RANDOMIZED|PARALLEL||TREATMENT||NONE||The infants included in the study will be divided to 3 groups and will be treated at the same time as a control group and 2 treatment groups.||||
33867417|NCT01231256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867418|NCT01460953|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33867419|NCT01256151|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33867420|NCT02081404|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33867421|NCT04203745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867422|NCT01316185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867423|NCT00041925|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33867424|NCT04049955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867425|NCT02882542|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34181227|NCT06200662|RANDOMIZED|CROSSOVER||OTHER||NONE||"This is a single-centre crossover study which plans t o include up to 48 newborns (objective: 40 analysable subjects, visit S and visit M carried out) for whom two different analgesic strategies will be applied, each at one of the two time points of the crossover:~* a control treatment, referred to here as treatment S: standard and recommended non- pharmacological analgesic strategies carried out by the carer alone~* an experimental treatment, referred to here as treatment M: overall non-pharmacological analgesic strategies carried out by the mother The groups are therefore the order S then M group and the order M then S group.~The order of visits was determined randomly (prior randomisation) for each mother-child dyad."||||
33867426|NCT05059158|||COHORT||PROSPECTIVE|||||||
33867427|NCT04609813|||OTHER||CROSS_SECTIONAL|||||||
33867428|NCT04588194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867429|NCT04472143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867430|NCT01715220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181228|NCT02904681|||COHORT||RETROSPECTIVE|||||||
34181229|NCT01298674|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34181230|NCT02450370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181231|NCT05459181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181232|NCT05156385|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34181233|NCT06597890|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||3x sequential 3-group randomised controlled trials (RCTs), embedded within the 6-month digital cohort study.|t|f|f|t
34181234|NCT04614363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|To minimize bias, all PET/CT images will be interpreted by a board certified radiologist. They will be blinded to the final outcome, such as histopathology of any biopsies and the outcome of subsequent imaging.|All subjects will receive the Investigational Product.||||
34181235|NCT02943434|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34181236|NCT06604091|||COHORT||PROSPECTIVE|||||||
34181237|NCT02435186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181238|NCT06073938|||COHORT||PROSPECTIVE|||||||
33867431|NCT01484899|||CASE_CONTROL||PROSPECTIVE|||||||
33867432|NCT03961217|||CASE_ONLY||PROSPECTIVE|||||||
33867433|NCT01752660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33867434|NCT01386918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867435|NCT02607592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867436|NCT05997433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33867437|NCT01878526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867438|NCT03059095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867439|NCT05731258|||COHORT||RETROSPECTIVE|||||||
33867440|NCT04637893|||COHORT||RETROSPECTIVE|||||||
33867441|NCT04206995|||CASE_CONTROL||PROSPECTIVE|||||||
33867442|NCT00943579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181239|NCT05375032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181240|NCT03888443|||CASE_CONTROL||PROSPECTIVE|||||||
34181241|NCT06597097|||OTHER||PROSPECTIVE|||||||
33867443|NCT01410682|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33867444|NCT00331448|||DEFINED_POPULATION||OTHER|||||||
33867445|NCT02600104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867446|NCT03372928|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, cross-over controlled trial|t|f|t|f
33867447|NCT02722382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33867448|NCT06321289|NA|SEQUENTIAL||TREATMENT||NONE||||||
33867449|NCT05692856|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34181242|NCT04862468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181243|NCT01995838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181244|NCT06600139|NA|SINGLE_GROUP||SCREENING||NONE||||||
34065913|NCT04918407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181245|NCT03519035|||OTHER||PROSPECTIVE|||||||
34065914|NCT04466605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065915|NCT06396143|||COHORT||PROSPECTIVE|||||||
34181246|NCT06595628|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study follows a parallel assignment model. Patients are randomly assigned to one of two groups: the Lichtenstein mesh-based repair group (L group) or the combined modified Guarnieri-Desarda tissue-based repair group (C group). The interventions are performed independently in each group, with outcomes compared between the two. There is no blinding in this study, and both the participants and the surgeons know which procedure is being performed (open-label study). The primary focus is on comparing the effectiveness and safety of the two surgical techniques.||||
34181247|NCT00000982||||TREATMENT||||||||
34181248|NCT06446661|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34181249|NCT05007769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181250|NCT02922244|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34181251|NCT00569400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181252|NCT04631419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind|The 14 patients maxillary and mandibular arches will be allocated into a split-mouth design, so the sample will be set up each patient to act as his/her own control|f|f|f|t
33867450|NCT04202523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867451|NCT06508918|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867452|NCT04271085|||COHORT||PROSPECTIVE|||||||
33867453|NCT00006254||||TREATMENT||||||||
33867454|NCT03337542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867455|NCT06191432|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|"Patients will be assigned by a computerized algorithm to start the challenge with the sachets containing triticum monococcum or triticum aestivum. At the end of the first challenge and after an adequate wash-out period, the patients will undergo crossover with the other type of wheat sachets.~The sachets, called A or B, will be completely indistinguishable from each other both in terms of their organoleptic characteristics and the quantity of content (80g of flour) and in terms of their packaging. The company that will supply the flours will be the custodian of the randomization code, and the key will be provided to the experimenters only at the end of all the challenges."|Prospective, randomized, double-blind, cross-over, single center clinical trials.|t|t|t|t
33867456|NCT01508195|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867457|NCT04964713|||CASE_CONTROL||PROSPECTIVE|||||||
33867458|NCT03827382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867459|NCT03514030|||OTHER||RETROSPECTIVE|||||||
33867460|NCT05732662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867461|NCT00329667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34065916|NCT00469495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065917|NCT03373461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065918|NCT00282152|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34065919|NCT04148235|||CASE_ONLY||PROSPECTIVE|||||||
34181253|NCT06142058|||OTHER||PROSPECTIVE|||||||
34181254|NCT05626621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Arm 1 is not blinded because this is the spray group. Arm 2 and 3 are blinded because these are both irrigation groups-either just mometasone or mometasone combined with azelastine||t|f|f|f
34181255|NCT04716231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181256|NCT02328924|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181257|NCT04369573|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open|Multicentre Prospective Controlled Randomized Trial in patients with ADHF complicated by CS. Patients will be randomized 1:1 to early IABP versus standard of care. Early IABP will be defined as IABP implantation for CS patients within 6 hours since CS symptoms onset.||||
34181258|NCT04041635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181259|NCT00935584|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34181260|NCT01296880|||CASE_CONTROL||PROSPECTIVE|||||||
34181261|NCT05024968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181262|NCT03133793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181263|NCT05610345|RANDOMIZED|PARALLEL||TREATMENT||NONE||Placenta Blood Drained Placenta Blood Not Drained||||
34181264|NCT01850667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181265|NCT05533606|||OTHER||RETROSPECTIVE|||||||
34181266|NCT00960999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181267|NCT06155292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parallel randomized trial at the physician level.|t|f|f|f
34181268|NCT02809235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867462|NCT02706704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867463|NCT05769023|NA|SINGLE_GROUP||PREVENTION||NONE||pilot of an intervention||||
33867464|NCT04762641|NA|SEQUENTIAL||TREATMENT||NONE||||||
33867465|NCT02575053|||COHORT||PROSPECTIVE|||||||
33867466|NCT03891342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33867467|NCT00489814|||COHORT||PROSPECTIVE|||||||
33867468|NCT04297813|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with advanced therapy medicinal product||||
33867469|NCT06048107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867470|NCT03021148|||COHORT||PROSPECTIVE|||||||
33867471|NCT05351983|NA|SINGLE_GROUP||OTHER||NONE||||||
33867472|NCT03649282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34181269|NCT02654444|||COHORT||RETROSPECTIVE|||||||
33867473|NCT00627783|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867474|NCT06010498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33867475|NCT05973552|||COHORT||PROSPECTIVE|||||||
33867476|NCT05040724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized into one of two groups in a 1: 1 ratio The randomization will be centralized and carried out electronically by IWRS.|Prospective, multicenter, double-blind, randomized trial in two parallel groups|t|f|t|t
34181270|NCT03672578|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34181271|NCT05672758|||COHORT||PROSPECTIVE|||||||
34181272|NCT01396304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181273|NCT06599398|||COHORT||PROSPECTIVE|||||||
33867477|NCT06423482|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867478|NCT01978834|||COHORT||CROSS_SECTIONAL|||||||
33867479|NCT05022394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867480|NCT00346099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867481|NCT04759261|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Differantiation of tumor tissues than normal tissues in same patients.||||
33964543|NCT02759211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964544|NCT03302299|NA|SINGLE_GROUP||OTHER||NONE||||||
33964545|NCT02060552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964546|NCT00869089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964547|NCT05778708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Except for the primary research assistant who will inform the patients of their group allocation, all researchers on the team will be blinded to patients' group assignment.||f|f|t|t
33964548|NCT03207360|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33964549|NCT04703530|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research was a randomized controlled trial. Participants were randomly allocated to the experimental group and the control group. The experimental group was given a hot footbath with a temperature of 41℃±1℃ for 20 minutes at about 1-2 hours before sleep, and this was repeated five times a week for four weeks; the control group was given routine care for four weeks. The CPSQI was used to collect the pre- and post-test data. Through this method, we explored whether the trial could effectively improve patients' sleep quality.||||
33964550|NCT00891878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964551|NCT00272961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065920|NCT03326752|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|N/A - There is no masking in this study.|"* In the Dose Escalation phase of the study, 5 DV281 dose cohorts will be evaluated in combination with an approved anti-PD-1 Inhibitor.~* The Dose Expansion phase of the study will establish the Recommended Phase 2 Dose of DV281 in combination with an approved anti-PD-1 inhibitor."||||
34181274|NCT05197972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Control group : classic management of the preoperative period Experimental group: classic management of the preoperative period with a cardiac coherence program coupled with hypnosis||||
34181275|NCT03077334|||COHORT||PROSPECTIVE|||||||
34181276|NCT06388993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181277|NCT05176288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181278|NCT03416985|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34181279|NCT04859907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34181280|NCT05419050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181281|NCT05465317|||COHORT||RETROSPECTIVE|||||||
34181282|NCT06594432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181283|NCT06654921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867482|NCT04163900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Imaging scans will be assessed by blinded independent review according to RECIST v1.1|1:1 randomization model to either Arm A or Arm B|f|f|f|t
33867483|NCT03410186|||CASE_CONTROL||PROSPECTIVE|||||||
33867484|NCT03723317|||COHORT||RETROSPECTIVE|||||||
33867485|NCT04227886|||COHORT||PROSPECTIVE|||||||
33867486|NCT05635968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blinded (subject)||t|t|f|f
33867487|NCT02777697|||OTHER||PROSPECTIVE|||||||
33867488|NCT03926715|||OTHER||PROSPECTIVE|||||||
33867489|NCT01011439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867490|NCT01112020|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33867491|NCT03250936|||COHORT||PROSPECTIVE|||||||
33867492|NCT01833962|||COHORT||RETROSPECTIVE|||||||
33867493|NCT00272883|||CASE_ONLY||OTHER|||||||
33867494|NCT02580942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964552|NCT05347030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964553|NCT02883387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181284|NCT06602401|||COHORT||PROSPECTIVE|||||||
34181285|NCT01798043|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181286|NCT01720108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181287|NCT06600646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181288|NCT05985499|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181289|NCT04683484|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34181290|NCT05376150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181291|NCT04197245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181292|NCT05992922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181293|NCT04032964|NA|SEQUENTIAL||TREATMENT||NONE||Open-label, phase 1 dose confirmation study in patients with advanced, unresectable and/or metastatic soft tissue sarcoma||||
34181294|NCT03675347|||CASE_ONLY||RETROSPECTIVE|||||||
34181295|NCT03322696|||CASE_ONLY||PROSPECTIVE|||||||
34181296|NCT01183806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181297|NCT06601114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181298|NCT04062630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181299|NCT06591325|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34181300|NCT05659953|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34181301|NCT04799834|||COHORT||OTHER|||||||
34181302|NCT04181333|||CASE_ONLY||PROSPECTIVE|||||||
34181303|NCT00686413|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867495|NCT01050452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181304|NCT03782246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181305|NCT06243536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181306|NCT06601231|||COHORT||PROSPECTIVE|||||||
34181307|NCT01966016|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181308|NCT01669837|||COHORT||PROSPECTIVE|||||||
34181309|NCT00237406|||COHORT||PROSPECTIVE|||||||
34181310|NCT00751582|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34181311|NCT03576586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34181312|NCT05353270|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181313|NCT02995746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181314|NCT02558088|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181315|NCT02886819|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181316|NCT04529902|||COHORT||RETROSPECTIVE|||||||
34181317|NCT06038110|||COHORT||RETROSPECTIVE|||||||
34181318|NCT00905164|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33867496|NCT00162760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867497|NCT06021899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964554|NCT01612702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181319|NCT06300463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181320|NCT06654973|NA|SINGLE_GROUP||OTHER||NONE||||||
34181321|NCT06596798|||OTHER||RETROSPECTIVE|||||||
34181322|NCT02546388|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181323|NCT06446089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181324|NCT04608552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34181325|NCT06593899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181326|NCT06471972|||COHORT||PROSPECTIVE|||||||
34181327|NCT06588309|||OTHER||PROSPECTIVE|||||||
34181328|NCT02244892|||CASE_ONLY||CROSS_SECTIONAL|||||||
34181329|NCT03776968|NA|SEQUENTIAL||TREATMENT||NONE||||||
33752547|NCT06733714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A random 5 digits password will be given to the care provider. This password will make the stimulation device enter SHAM mode or true stimulation mode, without the care provider or the patient knowing which mode it will be in.~The SHAM mode has the Ramp up and Ramp down periods, so the participant allocated in the control-SHAM group will feel the effects of the eletric current on the scalp for some seconds in the begining and end of each session.~Outcome assessors will also not be informed which group the participant is allocated."||t|t|f|t
33752548|NCT06720545|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33752549|NCT06733454|||OTHER||CROSS_SECTIONAL|||||||
33752550|NCT04251819|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of three interventions.||||
33752551|NCT06639061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752552|NCT06265350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752553|NCT02808624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752554|NCT06479161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This will be a double blinded study, with both patient and surgeon blinded to study group.~Collaboration with Saint Francis' pharmacy team will be performed to ensure appropriate blinded administering of the oral TXA and placebo medication."||t|t|t|f
33752555|NCT00032695|RANDOMIZED|||TREATMENT||DOUBLE||||||
33752556|NCT02635854|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33867498|NCT05296642|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33867499|NCT02486653|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893971|NCT03903471|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181330|NCT04765683|||CASE_ONLY||PROSPECTIVE|||||||
34181331|NCT04179136|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double blinded randomized control trial|t|t|t|t
34181332|NCT05092100|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181333|NCT00124943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181334|NCT03953352|NA|SINGLE_GROUP||OTHER||NONE||||||
34181335|NCT04994509|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34181336|NCT02636595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181337|NCT01722617|RANDOMIZED|PARALLEL||||NONE||||||
34181338|NCT01748734|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181339|NCT01695226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34181340|NCT05148468|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Patients and examiners will be blinded to stimulation status|Double blinded randomized placebo controlled cross over study|t|t|t|t
34181341|NCT02123901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752557|NCT03849274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All subjects will be asked to removed all the treatment materials before they entered the assessment rooms to ensure the blinding of the assessor. The ultrasound data will be processed and analysed by blinded analysts.||f|f|f|t
34065921|NCT01473706|||||PROSPECTIVE|||||||
33752558|NCT06229145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752559|NCT02807896|||COHORT||RETROSPECTIVE|||||||
33752560|NCT01191164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752561|NCT05652270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752562|NCT06724900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752563|NCT05051761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752564|NCT06495294|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre, pragmatic, randomized controlled, open-label, parallel group two arm trial.||||
33752565|NCT06376097|||OTHER||PROSPECTIVE|||||||
33752566|NCT01292239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752567|NCT00361374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752568|NCT02846623|NA|PARALLEL||TREATMENT||NONE||||||
33752569|NCT04508699|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Some participants and care providers might not be aware of their child's language impairment|Compare behavioral and EEG outcomes of semantic learning in children with and without developmental language disorder|t|t|f|f
33752570|NCT04666610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752571|NCT01106833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752572|NCT06643117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752573|NCT01394393|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33867500|NCT05916781|RANDOMIZED|PARALLEL||TREATMENT||NONE||First, participants are randomly assigned into 2 groups: steroid tapering group and steroid maintenance group. In steroid tapering group, participants without flare will be assigned into 2 groups: mycophenolate mofetil group and tacrolimus group. In steroid maintenance group, participants without flare will stop the use of steroid for 6 months. Participants without lupus flare after the stop of steroid will be assigned into 2 groups: mycophenolate mofetil group and tacrolimus group.||||
33867501|NCT04434599|RANDOMIZED|PARALLEL||TREATMENT||NONE||114 patients randomised 1:1:1 to either fluoroscopically guided OR contact force guided OR local impedance guided radiofrequency catheter ablation of typical atrial flutter||||
33867502|NCT06090851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181342|NCT04177823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study has 3+3 dose escalation design.||||
34181343|NCT03922386|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Post market, multicenter, international, prospective, open label, two arms and longitudinal non comparative non randomized study.||||
34181344|NCT04133818|||COHORT||RETROSPECTIVE|||||||
34181345|NCT01809600|||CASE_ONLY||RETROSPECTIVE|||||||
33867503|NCT05872490|||COHORT||PROSPECTIVE|||||||
34181346|NCT00836693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964555|NCT05297071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181347|NCT01763697|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34181348|NCT05386420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181349|NCT06655389|||OTHER||CROSS_SECTIONAL|||||||
33752574|NCT06732700|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental Group: Group A INIT+ Posture Corrective Exercises Control Group: Group B Posture corrective exercise||||
33752575|NCT04598698|||COHORT||PROSPECTIVE|||||||
33752576|NCT06089577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752577|NCT00944502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34065922|NCT06443606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181350|NCT01873872|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181351|NCT06208969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181352|NCT03405792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181353|NCT00698763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181354|NCT00782990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181355|NCT06216717|||COHORT||RETROSPECTIVE|||||||
33867504|NCT03726606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the examiner will be blinded to the arms.|Participants will be randomly allocated to one of two arms: Trifocal or extended depth of focus intraocular lenses.|t|f|f|t
34181356|NCT06169969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|post hoc test|t|f|f|t
33867505|NCT02508142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964556|NCT00032656|||NATURAL_HISTORY||OTHER|||||||
33964557|NCT01032759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964558|NCT04773171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964559|NCT05634018|||COHORT||PROSPECTIVE|||||||
33964560|NCT05028751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33964561|NCT05783609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964562|NCT03292133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964563|NCT01801085|||COHORT||PROSPECTIVE|||||||
33964564|NCT05726773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33964565|NCT00503854|||COHORT||PROSPECTIVE|||||||
33867506|NCT05544188|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33867507|NCT00174005|||DEFINED_POPULATION||OTHER|||||||
33867508|NCT06467162|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867509|NCT03229421|||CASE_ONLY||PROSPECTIVE|||||||
34065923|NCT01313351|||COHORT||PROSPECTIVE|||||||
34065924|NCT00288808|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065925|NCT04085159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065926|NCT00750919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181357|NCT05467059|||CASE_ONLY||PROSPECTIVE|||||||
34181358|NCT00330434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181359|NCT06600945|||OTHER||PROSPECTIVE|||||||
34181360|NCT03146923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As with most education based interventions compared to routine care it is difficult to reliably mask either the subjects or the investigators to the proposed intervention. We will attempt to blind patients referring only to the diets as diet A and diet B and avoiding the use of terminology such as old and new. We will reprint the dietary information for both arms so they do not resemble current illustrated formats.|Multicentre Parallel Arm Randomised Controlled Trial|t|f|f|f
34181361|NCT04322526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded|This is a pharmaco-fMRI study of one single dose of naltrexone or placebo followed by an fMRI session in a crossover design.|t|f|t|f
34181362|NCT02821234|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181363|NCT04356898|||COHORT||PROSPECTIVE|||||||
34181364|NCT06595810|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34181365|NCT04020549|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34181366|NCT03414502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181367|NCT06029946|||COHORT||PROSPECTIVE|||||||
34181368|NCT05907863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181369|NCT06494449|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34181370|NCT00394095|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34181371|NCT06655259|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label, prospective Phase II clinical trial. The model focuses on evaluating the combination of TURP (Transurethral Resection of the Prostate) and standard systemic therapy in patients newly diagnosed with metastatic prostate cancer (mPCa). All participants will receive TURP followed by androgen deprivation therapy (ADT), and second-generation anti-androgens such as abiraterone or enzalutamide. The study aims to assess both the efficacy and safety of this combined approach, with radiographic progression-free survival (rPFS) as the primary outcome, and secondary outcomes including overall survival (OS), biochemical progression-free survival (bPFS), and PSA response. The trial is conducted at a single center with a targeted enrollment of 200 patients.||||
34181372|NCT06080334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34181373|NCT03410277|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181374|NCT02398890|||COHORT||PROSPECTIVE|||||||
34181375|NCT06597773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Given the nature of the intervention, the study will be open and participants will know which group they were randomized to. However, the study will be blinded to the statistician in order to reduce the risk of introducing bias when interpreting the data.||f|f|f|t
34181376|NCT02342808|RANDOMIZED|PARALLEL||TREATMENT||||||||
34181377|NCT06263582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181378|NCT00985764|||CASE_ONLY||PROSPECTIVE|||||||
34181379|NCT03401346|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181380|NCT01954498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181381|NCT01328886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181382|NCT00832299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181383|NCT02894346|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867510|NCT03590015|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33867511|NCT05608382|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33867512|NCT03259750|||CASE_CROSSOVER||PROSPECTIVE|||||||
33867513|NCT01329250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867514|NCT02703415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33867515|NCT04666467|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm registry||||
34065927|NCT02738229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181384|NCT06586632|RANDOMIZED|PARALLEL||TREATMENT||NONE||An exploratory, randomized, controlled, open-label, parallel design will be used to investigate 60 adult individuals with newly diagnosed type 1 diabetes. Randomization will occur in a 1:1 ratio to either the AID group (intervention group) or the CGM group (control group) using a digital randomization program.||||
34181385|NCT06651684|RANDOMIZED|PARALLEL||OTHER||SINGLE||Pragmatic, single-blind|f|f|t|f
33867516|NCT01611948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867517|NCT04006496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867518|NCT03052504|||CASE_CONTROL||PROSPECTIVE|||||||
34065928|NCT04746365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Unlabelled tablets were prepared for each patient in a special envelope in a time-based manner in the central pharmacy|Randomized, double-blinded, controlled clinical trial|t|t|f|f
34065929|NCT01026337|||COHORT||PROSPECTIVE|||||||
34065930|NCT01044758|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34065931|NCT05128149|||COHORT||CROSS_SECTIONAL|||||||
34065932|NCT02152098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838772|NCT04492059|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to the blood flow restriction augmented physical therapy group following surgery or will undergo the usual physical therapy. Various measurements will be taken at follow up appointments as well as patient reported outcomes and compared between the two groups.||||
33838773|NCT02373579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838774|NCT05173389|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective Paralel Group Comparison Study|t|f|f|f
33838775|NCT01888874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838776|NCT02817906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867519|NCT03462420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867520|NCT05212506|||COHORT||PROSPECTIVE|||||||
33867521|NCT03920553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33867522|NCT01688128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867523|NCT01810133|||COHORT||RETROSPECTIVE|||||||
33867524|NCT04446962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867525|NCT05489692|||COHORT||RETROSPECTIVE|||||||
33867526|NCT05058417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838777|NCT06519084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838778|NCT01303250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181386|NCT04976621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care providers at the medical center will not have knowledge of the intervention or control condition assigned to individual participants. The research interviewer at the follow-up interview (the outcome assessor) also has no knowledge of the intervention or control condition assigned to individual participants.|"At the baseline interview, the interviewer will review the study, answer questions, obtain Informed Consent, conduct screening for eligibility, and conduct the baseline interview. The interview will be conducted in the rehabilitation clinic office or home. Veterans who do not wish to continue with the study after the baseline interview will not be randomized.~Within 48 hours of the baseline interview, eligible veterans will be randomized using the method of random permuted blocks and concealed allocation. Those randomized to BA will be contacted within 5 days by the interventionist and scheduled for the first session. They will receive the 6-session BA intervention (as well as treatment as usual \[TAU\]). Control participants will receive TAU only (which may include current medical and mental health treatments.) Three months after Baseline, a blinded interviewer will conduct the follow-up interview in person or on the phone with all veterans."|f|t|f|t
34181387|NCT06594250|||COHORT||PROSPECTIVE|||||||
33867527|NCT03588455|||COHORT||RETROSPECTIVE|||||||
33867528|NCT03007979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867529|NCT02025842|||COHORT|||||||||
33867530|NCT02277977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867531|NCT00809419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867532|NCT02730273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867533|NCT00288990|||CASE_CONTROL||PROSPECTIVE|||||||
33867534|NCT01687140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867535|NCT02422342|||COHORT||PROSPECTIVE|||||||
33867536|NCT03805997|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867537|NCT03686098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867538|NCT02124395|||COHORT||PROSPECTIVE|||||||
33867539|NCT02171273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33838779|NCT02377167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838780|NCT03908567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|For intranasal subjects, allocation is blinded. The oral arm is an open-label arm.||t|t|t|t
33838781|NCT02511262|||COHORT||PROSPECTIVE|||||||
33838782|NCT05762562|||OTHER||OTHER|||||||
33838783|NCT00402805|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33838784|NCT01680575|||COHORT||PROSPECTIVE|||||||
33838785|NCT01674023|||CASE_CONTROL||PROSPECTIVE|||||||
33838786|NCT01115179|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33838787|NCT02700659|||COHORT||PROSPECTIVE|||||||
33838788|NCT01853267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33838789|NCT03236623|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a study with an experimental research design, such as a randomizedclinical trial, parallel, prospective and monocentric.||||
33838790|NCT04884919|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each of the participants is treated with 2 different treatments on different areas of the same wound at the same time.|t|f|f|f
33838791|NCT03924700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838792|NCT01378806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838793|NCT04600388|||OTHER||RETROSPECTIVE|||||||
33838794|NCT06519864|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||A cross-sectional design|t|f|f|f
33838795|NCT01169376|||CASE_ONLY||RETROSPECTIVE|||||||
33838796|NCT02834338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838797|NCT00445835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838798|NCT03274453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33838799|NCT04392492|||COHORT||PROSPECTIVE|||||||
33838800|NCT00430833|RANDOMIZED|PARALLEL||||DOUBLE||||||
33838801|NCT01590706|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867540|NCT00534820|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33867541|NCT00517153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867542|NCT04457180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867543|NCT05932836|||COHORT||PROSPECTIVE|||||||
33867544|NCT01444742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867545|NCT03382015|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33867546|NCT05553483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867547|NCT02669966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867548|NCT02432222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867549|NCT01671020|RANDOMIZED|CROSSOVER||||NONE||||||
33867550|NCT00664495|RANDOMIZED|PARALLEL||TREATMENT||||||||
34181388|NCT00425269|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181389|NCT02067078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181390|NCT05666869|||COHORT||PROSPECTIVE|||||||
34181391|NCT06368635|||COHORT||PROSPECTIVE|||||||
34181392|NCT00093041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181393|NCT01611844|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
34181394|NCT01657006|||COHORT||PROSPECTIVE|||||||
34181395|NCT05437939|||COHORT||PROSPECTIVE|||||||
34181396|NCT00807911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181397|NCT01875809|||CASE_CONTROL||PROSPECTIVE|||||||
34181398|NCT05686902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34181399|NCT06654414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181400|NCT00957567|||CASE_CONTROL||RETROSPECTIVE|||||||
34181401|NCT00921375|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34181402|NCT06653959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181403|NCT00349518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181404|NCT06163443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34181405|NCT06653972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181406|NCT04632680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181407|NCT04402086|||OTHER||PROSPECTIVE|||||||
34181408|NCT04614649|||COHORT||PROSPECTIVE|||||||
34181409|NCT05228587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181410|NCT06521125|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34181411|NCT06655246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181412|NCT03542877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181413|NCT00625170|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33867551|NCT03279185|||COHORT||PROSPECTIVE|||||||
33867552|NCT04375579|||COHORT||PROSPECTIVE|||||||
33867553|NCT03227471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867554|NCT05133401|||COHORT||PROSPECTIVE|||||||
33867555|NCT05937308|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective, Multicenter, Single-arm, Post-market Interventional Registry. Collect real-world evidence.||||
33867556|NCT01040065|||CASE_CONTROL||PROSPECTIVE|||||||
33867557|NCT04103489|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an open label, phase 1 clinical trial. The investigators will investigate if eculizumab halts or prevents worsening or HELLP syndrome in women at 23-28 weeks gestation.||||
33867558|NCT03151642|||COHORT||PROSPECTIVE|||||||
33867559|NCT00282178|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33867560|NCT03042104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867561|NCT05895162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867562|NCT01825642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867563|NCT04326699|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33867564|NCT03525106|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867565|NCT02632396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867566|NCT05454436|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two group :~Group A: The treatment will be in a single visit Group B:The treatment will be in Multi visit"||||
33867567|NCT06026748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181414|NCT06070064|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|"Participants will complete two additional randomised, counterbalanced visits, each with a different condition: (a) Music (b) Non-Music.~To ensure participants are blinded, they will be given detailed instructions on the Study Information Sheet, indicating that they will come to the laboratory to perform the assessment tests in different environmental conditions that will not impact on their health status.~which will not affect their health status. Experimental measurements will be taken in the morning, at the same time of day (±0.5 h) for each individual, to standardise the influence of circadian rhythm, at a temperature of 23°C (±1°C)."|"The investigators intend to conduct an experimental trial with a randomised crossover design in 12 participants physically active young women adults with strength training experience aged 18-30 years.~The study will be conducted in the laboratory of Physical Activity and Sport Sciences of the University School of Osuna.~In this way, at the end of the study will have contrasted scientific information on the effects of music on the following variables of speed of execution in the back squat exercise."|t|f|t|t
34181415|NCT01287962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181416|NCT05310019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181417|NCT01122238|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34181418|NCT04774094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181419|NCT05279755|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34181420|NCT00264186|RANDOMIZED|PARALLEL||||DOUBLE||||||
34181421|NCT02088008|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181422|NCT06055140|||COHORT||CROSS_SECTIONAL|||||||
34181423|NCT06651606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181424|NCT03925090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181425|NCT06319014|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Pregnant women will be randomized to one of four groups: aerobic exercise, resistance exercise, combination (aerobic + resistance), or control (no exercise). All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, rating of perceived exertion (RPE), 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data.|f|t|t|t
34181426|NCT03760094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181427|NCT05798767|||COHORT||PROSPECTIVE|||||||
34181428|NCT00424684|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181429|NCT04927195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181430|NCT02458313|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34181431|NCT06436092|||COHORT||PROSPECTIVE|||||||
34181432|NCT06492902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181433|NCT03159429|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given that the experimental and comparator interventions concern behaviour and exercises, it is not possible to blind participants.|The included population will be randomized into two parallel groups. One group will be assigned the experimental intervention. The other group will be assigned standard care. Outcomes will be compared between the two randomized groups.||||
34181434|NCT04232722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181435|NCT02480387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181436|NCT03910244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181437|NCT03722238|NA|PARALLEL||OTHER||NONE||The Actual Use Trial (AUT) design utilizes a real world setting to assess the ability of consumers to use an investigational product that will be marketed in an over-the-counter setting according to the proposed product labelling. The primary objective of this AUT is to evaluate compliance with the labeled dosing directions for Advil 12 Hour and to understand why misuse occurred and if it was a conscious decision by the subject. A secondary objective is to evaluate the safety of Advil 12 Hour in unsupervised actual use and how it relates to misuse.||||
34181438|NCT06655441|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||randomized contralateral eye-controlled trial|t|f|t|f
34065933|NCT02830932|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33867568|NCT05768581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34181439|NCT00474487|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33867569|NCT06057584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33867570|NCT05080972|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867571|NCT00966420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867572|NCT05102084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867573|NCT01265615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867574|NCT01187550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867575|NCT03636620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||TACE vs.TACE+RFA|f|f|f|t
33867576|NCT01499784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867577|NCT00932360|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33867578|NCT04000789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study examining DM patient with NPDR or PDR complication with decrease corneal sensitivity. Patient with decreased corneal sensitivity were grouped between NPDR and PDR. NPDR group divided into treatment group (combination of sodium hyaluronate, vitamin A and Vitamin E eye drops given 6 times/day) and control group (Sodium Hyaluronate eye drops only given 6 times/day). Likewise, PDR group divided into treatment group (combination of sodium hyaluronate, vitamin A and Vitamin E eye drops given 6 times/day) and control group (Sodium Hyaluronate eye drops only given 6 times/day).|t|f|t|f
33867579|NCT02685579|||COHORT||PROSPECTIVE|||||||
33867580|NCT02782936|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33867581|NCT02008279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867582|NCT04946279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867583|NCT01089920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33867584|NCT01462136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867585|NCT05803408|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33867586|NCT00780819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867587|NCT02101021|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867588|NCT05287971|||COHORT||PROSPECTIVE|||||||
33867589|NCT03838055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
33867590|NCT04290520|||COHORT||RETROSPECTIVE|||||||
33867591|NCT01516840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867592|NCT05615051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
33964566|NCT05666674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|The trial will be composed of two arms: an experimental group with VR with activated Tremor Stabilization Algorithms (TSA-ON). And an active comparator group that is exposed to VR without Tremor Stabilization Algorithms (TSA-OFF control). In both arms, study subjects will be immersed in a stock VR testing environment and will perform a tremor eliciting PTT test.|t|f|t|t
33964567|NCT02039583|||ECOLOGIC_OR_COMMUNITY|||||||||
33964568|NCT00397839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964569|NCT03722537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964570|NCT05731388|||OTHER||PROSPECTIVE|||||||
33964571|NCT00821457|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34181440|NCT03228550|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Participants blinded to dietary intervention, but not exercise. Outcomes assessor blinded to both intervention and exercise group.|There are two interventions, a multi-nutrient dietary supplement and exercise. The study will have four groups; 1. multi-nutrient supplement and exercise, 2. multi-nutrient non-exercise, 3. placebo supplement and exercise and 4. placebo supplement non-exercise.|t|f|t|t
34181441|NCT04788329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181442|NCT03276507|||CASE_ONLY||PROSPECTIVE|||||||
34181443|NCT02706977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181444|NCT01697670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181445|NCT02743052|||COHORT||PROSPECTIVE|||||||
34181446|NCT05767749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|0.5mL of local anesthetic will be injected into the skin of each participant by the one dermatologic surgeon (PI of the study, Dr. Kira Minkis, KM). Dr. Minkis will be unblinded to the laterality of the anesthetics and will not be involved in further assessments.||t|f|t|t
34181447|NCT04524780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 60 patients with atrial fibrillation were scheduled to receive left atrial appendage occlusion, which were divided into two groups. The operation was performed under the guidance of intracardiac echocardiography and left atrial appendage radiography, respectively (allocation ratio 1:1).|t|f|f|t
34181448|NCT03109496|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181449|NCT05916235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181450|NCT06458088|||COHORT||PROSPECTIVE|||||||
34181451|NCT01152957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|single blinded|||||
34181452|NCT02948127|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181453|NCT02781714|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34181454|NCT05535725|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"the randomization sequence was created using Stata 9.0 ware statistical software and was stratified by center with a 1:1 allocation using random block sizes of 2, 4 and 6. Participants were randomly assigned following simple randomization procedures to 1 of 2 treatment groups"|t|f|t|t
34181455|NCT03790202|||COHORT||PROSPECTIVE|||||||
34181456|NCT00944853|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181457|NCT06599424|||COHORT||PROSPECTIVE|||||||
34181458|NCT01761968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181459|NCT06590311|||CASE_CONTROL||PROSPECTIVE|||||||
34181460|NCT01135550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34181461|NCT00347022|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34181462|NCT03248908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, the performer of the pupillary reflex measurement, and the postoperative health care provider are masked for the study arms.|Double blinded randomized controlled trial|t|t|f|t
34181463|NCT05248815|||COHORT||PROSPECTIVE|||||||
34181464|NCT05900167|||OTHER||PROSPECTIVE|||||||
34181465|NCT03207971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181466|NCT05479695|RANDOMIZED|FACTORIAL||OTHER||SINGLE|54 pre-filled sealed envelopes were prepared for the randomization process of the participants who met the inclusion and exclusion criteria determined in the study. 27 envelope series consists of 1 number and 27 envelope series consists of 2 number. The control group (KG) using Chêneau type spinal orthosis was given number 1, and the group using Chêneau type spinal orthosis and insoles (TG) was given number 2. Each of the participants chose one of the sealed envelopes in turn. Participants included in the study were randomly assigned to the KG group or the TG group according to the number on the selected envelope.|The first group uses spinal orthoses. The second group uses spinal orthosis and insoles.|t|f|f|f
34181467|NCT02939287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181468|NCT01815918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181469|NCT04402138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964572|NCT04087785|||OTHER||RETROSPECTIVE|||||||
33964573|NCT05584774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964574|NCT04500691|||COHORT||RETROSPECTIVE|||||||
33964575|NCT02908828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964576|NCT05086120|NA|SINGLE_GROUP||TREATMENT||NONE||Adolescents (age 13-18) with major depressive disorder.||||
33964577|NCT00196222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964578|NCT04317963|||CASE_CONTROL||RETROSPECTIVE|||||||
33964579|NCT05449327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33964580|NCT01241162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964581|NCT03911089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964582|NCT04610073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33867593|NCT02801136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065934|NCT01402505|||COHORT||PROSPECTIVE|||||||
33867594|NCT03429881|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33867595|NCT00005036|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33867596|NCT02862405|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867597|NCT04638959|||CASE_CONTROL||OTHER|||||||
34065935|NCT00369148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867598|NCT01758458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181470|NCT02786849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867599|NCT01409213|||COHORT||PROSPECTIVE|||||||
33867600|NCT04196738|RANDOMIZED|CROSSOVER||OTHER||NONE||patients exposed to 3 ventilatory mode in 2 different possible orders||||
33867601|NCT00215124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34181471|NCT01187602|||CASE_CONTROL||PROSPECTIVE|||||||
34181472|NCT06296069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181473|NCT06034769|||CASE_ONLY||CROSS_SECTIONAL|||||||
34181474|NCT04469907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181475|NCT01951963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181476|NCT00828776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867602|NCT00613444|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34181477|NCT05202886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Liver from deceased donors||||
34181478|NCT03785015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181479|NCT02436772|||OTHER||PROSPECTIVE|||||||
34181480|NCT02288741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181481|NCT04852172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind placebo controlled (Part 2)|Open-label Dose-Finding Study with Subsequent Double-blind, Placebo-controlled, Randomized Study of L-citrulline in Sickle Cell Disease Presenting to Emergency Department (ED) in Vaso Occlusive Crisis (VOC) in Children, Adolescents and Young Adults (6 to 21 years).|t|t|t|t
34181482|NCT01065727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34181483|NCT00941213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181484|NCT01187355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181485|NCT05270395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181486|NCT03129620|||CASE_ONLY||PROSPECTIVE|||||||
34181487|NCT04506411|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181488|NCT06653998|||COHORT||PROSPECTIVE|||||||
33867603|NCT01128361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181489|NCT05417620|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181490|NCT02110069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867604|NCT03762356|||OTHER||OTHER|||||||
33867605|NCT06292572|||COHORT||RETROSPECTIVE|||||||
33867606|NCT01805596|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33867607|NCT00699803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33867608|NCT04969445|||COHORT||PROSPECTIVE|||||||
33867609|NCT00943891|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34065936|NCT01840800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065937|NCT04674735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065938|NCT04665518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomised controlled trial|t|f|f|t
34065939|NCT00413309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181491|NCT05947357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Patients as part of a nutrition assistance program will randomly receive food vouchers for $40.00 each month for use in the produce section of local grocery stores for 6 months.|f|t|t|t
34181492|NCT01764217|||COHORT||PROSPECTIVE|||||||
33867610|NCT05501145|||COHORT||RETROSPECTIVE|||||||
34065940|NCT02026869|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33867611|NCT02941874|||COHORT||PROSPECTIVE|||||||
33867612|NCT01490684|||COHORT||PROSPECTIVE|||||||
33867613|NCT05380258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867614|NCT01181076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867615|NCT06072989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867616|NCT03253757|||OTHER||PROSPECTIVE|||||||
33867617|NCT03745833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867618|NCT04042168|NA|SINGLE_GROUP||TREATMENT||NONE||UAB Pulmonary Clinic Patients with history of COPD||||
33867619|NCT00445653|||CASE_CONTROL||PROSPECTIVE|||||||
34181493|NCT00017212||||TREATMENT||||||||
34181494|NCT06082362|||CASE_CONTROL||PROSPECTIVE|||||||
34181495|NCT05483777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||It is planned to include 7 patients for the experimental group and 7 patients for the control group (14 patients in total) in this research.||||
34181496|NCT02923726|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34181497|NCT04568616|NA|SINGLE_GROUP||TREATMENT||NONE||Patients receive letrozole orally (PO) once daily (QD) for 4-16 weeks up to the day of surgery in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery. After surgery, a subset of patients start a hormone therapy (letrozole, anastrozole, or tamoxifen) and remain in the study for up to 3.5 years.||||
34181498|NCT02870595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181499|NCT03131323|||CASE_ONLY||CROSS_SECTIONAL|||||||
34181500|NCT03157817|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181501|NCT00631072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181502|NCT06595199|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33867620|NCT05464706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double blind: supplement therapy versus placebo||t|t|t|t
33867621|NCT00955279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181503|NCT04145661|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be aware of the type of hearing aid setting they are experiencing. All participants will experience both .|Participants will be split into two groups depending on whether or not they have 'cochlear dead regions'. All participants will experience both conventional processing and frequency compression for six weeks. The order of which will be randomised and counterbalanced between groups.|t|f|f|f
34181504|NCT04790916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181505|NCT01940952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181506|NCT04381364|RANDOMIZED|PARALLEL||TREATMENT||NONE||This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm||||
34181507|NCT06508190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The authors of this clinical trial and patients do not provide the study outcome examiners with information regarding device therapy or free walking exercise.|Forty patients suffering from obstructive sleep apnea are divided into two groups: one for CPAP and the other for CPAP and free walking program.|f|f|f|t
34181508|NCT03755713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181509|NCT04117555|||CASE_CONTROL||PROSPECTIVE|||||||
34181510|NCT06116838|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||The purpose of these visits is to determine the optimal waveform and stimulation location. In order to make this determination, we will first determine what stimulation waveform allows us to reach Resting Motor Threshold (RMT) with the lowest intensity but it is the most comfortable when walking at higher intensities. We will use a test-retest design comparing neurophysiologic measures while participants receive various combinations of stimulation waveforms, modulation frequencies, and stimulation locations.|t|f|f|f
34181511|NCT04409925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181512|NCT01434615|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181513|NCT06655779|||CASE_CONTROL||PROSPECTIVE|||||||
34181514|NCT05684822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will not know that they are recieving acupuncture or sham acupuncture|This study is designed according to the Impaired Sleep Model, and is a single-blind randomized clinical trial.|t|f|f|f
34181515|NCT00574197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181516|NCT00434291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34181517|NCT02578069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181518|NCT06541548|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181519|NCT03938259|||COHORT||PROSPECTIVE|||||||
33964583|NCT02005146|||COHORT||RETROSPECTIVE|||||||
34181520|NCT03898544|||CASE_CONTROL||PROSPECTIVE|||||||
34181521|NCT01716377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34181522|NCT02706106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181523|NCT03207295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867622|NCT05197348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Control Trial, efficacy Study|t|f|t|f
33867623|NCT00098150|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33867624|NCT02823795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867625|NCT00998049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867626|NCT05273879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181524|NCT06591793|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34181525|NCT04139798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181526|NCT05335707|||OTHER||PROSPECTIVE|||||||
33867627|NCT02319668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34181527|NCT03088449|||COHORT||PROSPECTIVE|||||||
34181528|NCT03626103|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33964584|NCT02718976|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33964585|NCT03335943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964586|NCT05103267|||CASE_ONLY||PROSPECTIVE|||||||
33964587|NCT03312582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964588|NCT02197169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964589|NCT00335790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964590|NCT04091685|||COHORT||CROSS_SECTIONAL|||||||
33964591|NCT05957107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964592|NCT06130709|||COHORT||RETROSPECTIVE|||||||
33964593|NCT01822015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964594|NCT00965913|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33964595|NCT03187080|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participants will be blinded as to which treatment arm within their group that they are allocated. The surgery team including the surgeon (PI) and resident will be blinded as well. Anesthesiologists will not be blinded.|There are four serial aims of this study. The overarching goal is to prospectively assess the use of PVB as an adjunct for postoperative pain control both alone and in the setting of related ERABS strategies in elective breast surgery (both breast reduction and breast augmentation, two of the most common non-oncologic breast operations performed in an ambulatory setting). The methodologies used to assess postoperative pain, the set of collective ERABS strategies, the potential risks and benefits of study participation, and the inclusion/exclusion criteria will be the same in the groups studying breast reduction and those studying breast augmentation.|t|t|t|f
33964596|NCT06174519|||CASE_CONTROL||RETROSPECTIVE|||||||
33964597|NCT03213054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964598|NCT03044431|||COHORT||PROSPECTIVE|||||||
34181529|NCT05650697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Doctors assessing pictures of the forehead scars will blinded as to which ointment was placed on the top half and which ointment was placed on the bottom half.|Adult participants will consent to treat their forehead wound scar with silicone oil on half of the scar and CBD oil + silicone on the other half. Participants will be randomized as to which ointment they will place on the top half and the other ointment on the bottom half.|f|f|f|t
34181530|NCT02741063|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34181531|NCT03430297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181532|NCT04201262|NA|SINGLE_GROUP||TREATMENT||NONE||External Placebo-Controlled, Open-Label Design||||
34181533|NCT04027517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181534|NCT00911170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181535|NCT00648609|||COHORT||PROSPECTIVE|||||||
34181536|NCT02770014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181537|NCT01023763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181538|NCT04049786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181539|NCT00006396||||PREVENTION||DOUBLE||||||
33752578|NCT03390439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Clinical evaluators will evaluate the photos after the treatments blindly for which type of treatment applied.~Evaluators of skin biopsies will be blinded to what type of treatment is applied and for pre-treatment and post-treatment."|Each patient will have the abdomen divided equally. Each segment of the abdomen will be randomized using the Excel 2013 program to receive laser or microneedle treatment.|f|f|t|t
33752579|NCT02360436|||CASE_ONLY||PROSPECTIVE|||||||
33838802|NCT05447234|NA|SINGLE_GROUP||TREATMENT||NONE||"① 1x10\^7/m2~* 3x10\^7/m2；~  * 1x10\^8/m2；~    * 3x10\^8/m2；~      * 1x10\^9/m2。"||||
33838803|NCT00657462|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838804|NCT04510181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838805|NCT02988323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838806|NCT04419922|||COHORT||PROSPECTIVE|||||||
33838807|NCT02283476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838808|NCT03142269|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33964599|NCT03841721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964600|NCT02490566|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33964601|NCT01457768|||COHORT||PROSPECTIVE|||||||
33964602|NCT03039582|||CASE_ONLY||PROSPECTIVE|||||||
33964603|NCT00496106|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33964604|NCT03966469|||COHORT||PROSPECTIVE|||||||
33964605|NCT04347161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, participants and their care providers (including investigators) will not be blinded. The primary analyst and outcomes assessor will be blinded. Blinding may be broken in an emergency.|Patients with lung cancer receiving oral targeted therapies at recruitment sites will be randomized (1:1 stratified by drug class and prescription status) to receive intervention or usual care.|f|f|f|t
34181540|NCT00227240|||COHORT||PROSPECTIVE|||||||
34181541|NCT06079814|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34181542|NCT01367106|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181543|NCT00332150|||COHORT||PROSPECTIVE|||||||
34181544|NCT02976038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181545|NCT03788512|||COHORT||PROSPECTIVE|||||||
34181546|NCT03753802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization will be performed by the study website and will be only known by the physiotherapist. The parents are not allowed to be in the room of physiotherapy during the physiotherapy session. They don't know which treatment is allocated to their child. The evaluator physician doesn't know which treatment is allocated to the child. The biostatistician doesn't know which treatment is allocated to which group during the analyses.|The treated group will receive respiratory physiotherapy treatment using slow extended and passive expiratory maneuvers. The control group will not receive physiotherapy treatment.|t|t|t|t
34181547|NCT01355952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181548|NCT05695378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181549|NCT01094236|RANDOMIZED|PARALLEL||||NONE||||||
34181550|NCT00061087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181551|NCT04031313|||COHORT||PROSPECTIVE|||||||
34181552|NCT04764708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial with Repeated Measures|t|t|f|t
34181553|NCT03614650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181554|NCT02553226|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181555|NCT00710411|||CASE_CONTROL||PROSPECTIVE|||||||
34181556|NCT06054490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the first session, the operator explained to the study subjects the alternatives, benefits and possible complications of the treatments, it was also indicated that at the time of treatment administration they would not be explained to which group they were assigned to protect the blinding of the treatments. The study of the information was carried out with the necessary precautions to allow masking and blinding of the results obtained, achieving an objective analysis of the results by the outcomes assessor|The patients were contacted by telephone the day before each session appointment to avoid dropouts and to remember to keep an exercise record if applicable. The treatment of the subjects consisted of 5 sessions. (S1) evaluation and diagnosis of recruited subjects; (S2) three days after S1, SM instruction and explanations of the follow-up sessions were given to all subjects, in addition home exercises were instructed and explained to the SM+EX group; (S3) first control and reinforcement of SM (or SM and exercises) at 2 weeks; (S4) second control and reinforcement of SM (or SM and exercises) at 6 weeks; (S5) third control and is encouraged to continue with SM. Referral to a specialist is made if initial symptom remission has not been achieved.|t|f|f|t
34181557|NCT03882606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181558|NCT01930968|||COHORT||PROSPECTIVE|||||||
34181559|NCT00733018|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34181560|NCT03230461|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Participants and researchers are blinded to the actual depth achieved during each CPR run.|Prospective, randomised.|t|f|t|f
34181561|NCT00610896|||COHORT||PROSPECTIVE|||||||
33752580|NCT04766684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"On the day of or after the final casting visit, the participant will be randomized in equal proportion (1:1) to either the control group (receive L.M.X.4 cream with J-Tip saline injection) or the intervention group (placebo cream with J-Tip with 0.25mL of 1% Xylocaine MPF). Researchers, physicians, nurses, CCLS, caregivers, and patients will be blinded to which group the patient is assigned to. The only person who will remain unblinded is the research coordinator.~An outside pharmacy, the Health \& Wellness Compounding Pharmacy, will provide and blind the L.M.X.4 and placebo creams. The Vanderbilt Investigational Drug Service will provide the blinded J-Tip 1% Xylocaine MPF and saline vials. The Investigational Drug Service will store the creams provided by the outside pharmacy and the J-Tip vials. They will assist in dispensing the creams/vials to the outpatient clinic."||t|t|t|t
33752581|NCT02411565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752582|NCT06487195|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Outcome assessors, researchers and clinical staff are blind to the group and intervention assignment; they are also concealed to the participant lists.|Parallel assignment; repeated-measures, multi-centre 3-arm RCT|f|t|t|t
33752583|NCT00538551|||COHORT||PROSPECTIVE|||||||
33752584|NCT04960111|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752585|NCT05773573|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752586|NCT03972111|||COHORT||PROSPECTIVE|||||||
33752587|NCT03728972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752588|NCT02920827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34181562|NCT01529970|||||CROSS_SECTIONAL|||||||
33752589|NCT06732323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752590|NCT01749982|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33752591|NCT02679261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752592|NCT04404712|NA|SINGLE_GROUP||OTHER||NONE||||||
33752593|NCT00515502|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33752594|NCT05223985|||OTHER||CROSS_SECTIONAL|||||||
33752595|NCT05717634|||COHORT||PROSPECTIVE|||||||
33752596|NCT02869087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752597|NCT03647306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964606|NCT04549909|||COHORT||RETROSPECTIVE|||||||
33964607|NCT01189578|||CASE_ONLY||CROSS_SECTIONAL|||||||
33964608|NCT01615302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964609|NCT01998516|||OTHER||CROSS_SECTIONAL|||||||
33964610|NCT03148288|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33964611|NCT01027637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964612|NCT02290028|NA|SINGLE_GROUP||OTHER||NONE||||||
33964613|NCT00762983|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33964614|NCT02170428|||COHORT||PROSPECTIVE|||||||
33964615|NCT00056459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964616|NCT02477007|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33964617|NCT02602964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34181563|NCT03889496|NA|SINGLE_GROUP||OTHER||NONE||||||
34181564|NCT04197596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181565|NCT06599944|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34065941|NCT03246802|NA|SINGLE_GROUP||TREATMENT||NONE||High Dose Rate brachytherapy||||
34065942|NCT03985488|||CASE_ONLY||PROSPECTIVE|||||||
34065943|NCT00858078|||FAMILY_BASED||OTHER|||||||
34065944|NCT03552042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34065945|NCT04958291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065946|NCT01935713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34181566|NCT03643848|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind (participant, outcome assessor) for Aim 3 (sham versus target sounds)|"Per NIMH policy at the time of funding, the current trial is considered a clinical trial due to prospective, randomized assignment to an intervention to observe effects on behavioral or health related outcomes. The intervention for Aim 3 (n=60) includes randomized assignment to sham sounds (sounds unrelated to the memory task) or target sounds (sounds that were played during the time of the memory task) that are played during sleep to cue memory processing."|t|f|f|t
34181567|NCT00000306|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33752598|NCT01814969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181568|NCT01003717|||COHORT||RETROSPECTIVE|||||||
33752599|NCT01746693|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33752600|NCT05763628|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33752601|NCT03512652|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One randomly selected knee is treated by the intervention device Patello||||
33752602|NCT04524871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752603|NCT05809596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752604|NCT01492075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065947|NCT04212832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34065948|NCT05775861|RANDOMIZED|PARALLEL||TREATMENT||NONE|"The patient, the anesthesiologist that will perform the block and the operating room staff cannot be blinded for treatment group allocation since the material differs in the 2 groups. We did not want to remain blind at all costs by installing catheters in all participants, with a continuous infusion of saline for the dexmedetomidine group, since the insertion of a catheter is not without risk for the patient and the initial bolus would have been diluted.~The nurse staff, anesthesiologists and the research staff evaluating the patient by phone on postoperative days 1,2 and 3 will not be blinded to the patients' study care group allocation because they will also be looking for minor complications that involve the catheter or the infusion pump."|"All patients will be first met either at our preoperative investigation clinic or by phone in the days leading to surgery to present the project and obtain consent. Consent will be dynamic and participants will have the possibility to withdraw from the study at all times.~A web-based inclusion and randomization form will be provided to the investigators. Randomization will be done in a 1:1 ratio. Envelopes will be made, one for each patient, and will contain the randomization information and in which group they are in: D in the single shot dexmedetomidine added to ropivacaine or R for the continuous interscalene brachial plexus block with ropivacaine."||||
34065949|NCT01840137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065950|NCT06194266|||CASE_ONLY||PROSPECTIVE|||||||
34065951|NCT04959214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181569|NCT03780244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181570|NCT05482971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181571|NCT02142699|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34181572|NCT04670731|||COHORT||CROSS_SECTIONAL|||||||
34181573|NCT03857854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181574|NCT03301311|RANDOMIZED|CROSSOVER||TREATMENT||NONE||We are using a series of N-of-1 trials where patients alternate (cross) between the two study interventions at set intervals. N-of-1 trial results will be examined at the individual and population level (through meta-analysis of individual N-of-1 trials)||||
34181575|NCT03772392|||COHORT||PROSPECTIVE|||||||
34181576|NCT01745939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34181577|NCT04772001|NA|SINGLE_GROUP||TREATMENT||NONE|No mask.|All participants will be included in one arm and receive chemoradiotherapy and anlotinib according to the protocol||||
34181578|NCT06169371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181579|NCT01517399||SEQUENTIAL||OTHER||NONE||||||
34181580|NCT01016249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181581|NCT05304754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181582|NCT02756286|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181583|NCT06069752|||COHORT||PROSPECTIVE|||||||
34181584|NCT01752335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181585|NCT06591650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181586|NCT03431207|||CASE_CONTROL||PROSPECTIVE|||||||
34181587|NCT02612779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181588|NCT05902689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the investigator knew about the grouping, and the subjects did not know whether they were an experimental or control group or blank group.|The control group underwent natural healing, and the experimental group underwent alveolar ridge preservation using Bio-Oss Collagen and Sticky Bone, respectively.|t|f|f|f
34181589|NCT02651207|||OTHER||PROSPECTIVE|||||||
34181590|NCT05777499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Researchers and care providers measuring Barthel and NWPDS primary outcome measures, and all secondary outcomes post-10 weeks intervention will be blinded to group allocation. The only outcome measures to be obtained by individuals who are not blinded to intervention group will be (i) post-intervention FIM+FAM, which will be carried out by a clinical therapist providing regular clinical input to the participant, and (ii) weekly pain and mood visual analogue scores, which will be carried out by the individual providing the intervention. All analyses will be carried out by individuals blinded to the experimental conditions.|Parallel-armed randomised controlled trial|f|t|t|t
34181591|NCT02420821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867628|NCT04502004|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"To assess differences between groups, use the student t-test or the Mann-Whitney U-test for quantitative variables; and the chi-square test or Fisher's exact test for qualitative variables.~Correlations are examined by the Spearman or Pearson rank correlation. Paired or related sample tests will be used to assess intra-group differences. A value of p \<0.05 will be considered an indicator of a significant difference."||||
33867629|NCT00797875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867630|NCT02957591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181592|NCT05771363|||CASE_ONLY||CROSS_SECTIONAL|||||||
34181593|NCT03913520|NA|SINGLE_GROUP||OTHER||NONE||||||
34181594|NCT00515372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181595|NCT06293599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|scapular stabilization and virtual reality exercise|f|f|t|t
34181596|NCT02194660|||CASE_ONLY||PROSPECTIVE|||||||
34181597|NCT00887809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181598|NCT05397951|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34181599|NCT00538902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181600|NCT05069948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181601|NCT03649646|||CASE_ONLY||PROSPECTIVE|||||||
34181602|NCT06600308|NA|SINGLE_GROUP||OTHER||NONE||||||
34181603|NCT04495244|||COHORT||PROSPECTIVE|||||||
34181604|NCT04862546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181605|NCT06554184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181606|NCT02614300|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34181607|NCT00053651|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181608|NCT04294043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181609|NCT00520182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34181610|NCT02704325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a dose escalation trial that will begin with the minimal efficacious dose as determined by preclinical studies and approved by the FDA. During the course of the trial, if safety is shown the dose will be escalated according to the clinical protocol.||||
33752605|NCT06353321|||CASE_ONLY||PROSPECTIVE|||||||
33752606|NCT06733896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752607|NCT01245712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752608|NCT06126783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867631|NCT01368042|||||PROSPECTIVE|||||||
33867632|NCT05575037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867633|NCT01039077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752609|NCT06732531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752610|NCT03457753|NA|SINGLE_GROUP||OTHER||NONE||This is a multi-center, open label safety and tolerability trial. Approximately twenty-five (25) individuals with amyotrophic lateral sclerosis (ALS) will be enrolled.||||
33752611|NCT02251990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752612|NCT02792166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752613|NCT03441451|||OTHER||PROSPECTIVE|||||||
33867634|NCT06289322|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility study||||
33867635|NCT00122681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33867636|NCT00110292|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33867637|NCT04551222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a three-site, double-blinded, randomized, placebo controlled, parallel design, trial in a 1:1 fashion of 1 gr. orally of probenecid twice daily or identical placebo for 180 days. The investigators propose to recruit 120 subjects (power analysis below) with HFrEF (LVEF 40%), NYHA II-III on guideline directed medical therapy.|t|t|t|t
33867638|NCT06460675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867639|NCT00956774|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33867640|NCT02967705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181611|NCT06594562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The quality of the teleultrasound images will be assessed by a radiologist who did not participate in the telementoring session, to minimize novelty bias. Additionally, the radiologist conducting the direct examinations will be distinct from the remote expert who provided telementoring, ensuring that they do not rely on prior knowledge from the remote sessions. While no formal masking will be implemented, these measures are taken to reduce potential bias in the assessment process.|||||
34181612|NCT04663204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181613|NCT03529695|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel Assignment Randomization occurs at the level of home visitors who deliver the home visitation program curriculum. Home visitors will be randomized to deliver the home visitation program curriculum with (Experimental comparator) or without (Active Comparator) the obesity prevention enhancement module. Mother-child dyads enrolled in home visitation programs, and who agree to participate in the study, will receive the intervention arm delivered by their home visitor.|f|f|f|t
34181614|NCT06654219|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34181615|NCT04139057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181616|NCT03819439|||COHORT||PROSPECTIVE|||||||
34181617|NCT05674786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181618|NCT03239392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181619|NCT03725397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|randomized double blinded|two cohort double blinded clinical trial|t|f|f|f
34181620|NCT03484208|||COHORT||PROSPECTIVE|||||||
34181621|NCT05455879|||COHORT||RETROSPECTIVE|||||||
34181622|NCT03733015|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34181623|NCT00011687|||||OTHER|||||||
34181624|NCT04499326|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181625|NCT06357689|||CASE_CONTROL||RETROSPECTIVE|||||||
34181626|NCT01959503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181627|NCT05417646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34181628|NCT06351878|||CASE_ONLY||PROSPECTIVE|||||||
34181629|NCT03554525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181630|NCT02368587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181631|NCT01264796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181632|NCT04798196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34181633|NCT05908825|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33838809|NCT04263987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838810|NCT00912392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838811|NCT00609856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838812|NCT01825798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867641|NCT02932995|||COHORT||PROSPECTIVE|||||||
33964618|NCT03360656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964619|NCT06542276|NA|SINGLE_GROUP||TREATMENT||NONE||This study, known as the REDUCE study, was a prospective, non-randomized, single-site, non- comparative study that evaluated the efficacy of a single vectored thermal pulsation (VTP) treatment in patients who were currently being treated with topical immunomodulator agents. This study was conducted in compliance with the Declaration of Helsinski and was reviewed and approved by the WCG institutional review board (IRB). The study is registered in clinictrials.gov. All participants provided written informed consent.||||
33964620|NCT00704717|||CASE_ONLY||PROSPECTIVE|||||||
33964621|NCT06247293|||COHORT||RETROSPECTIVE|||||||
33964622|NCT01754090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34065952|NCT01069770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181634|NCT05791708|||OTHER||PROSPECTIVE|||||||
34181635|NCT04756856|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181636|NCT04280250|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34181637|NCT05924217|||COHORT||PROSPECTIVE|||||||
34181638|NCT06653985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181639|NCT03220035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181640|NCT02633150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181641|NCT02267551|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||||||||
34181642|NCT04680468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181643|NCT05572073|||CASE_ONLY||OTHER|||||||
34181644|NCT06515197|RANDOMIZED|PARALLEL||OTHER||NONE|No masking is used in this study as participants and investigators are aware of the group assignments.|This study follows a parallel assignment model with three arms: motivational music, self-selected music, and no music control.||||
34181645|NCT04636684|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34181646|NCT05577299|||OTHER||RETROSPECTIVE|||||||
34181647|NCT02714816|||COHORT||PROSPECTIVE|||||||
34181648|NCT00804076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181649|NCT05864859|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34181650|NCT06651619|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33752614|NCT04072159|RANDOMIZED|PARALLEL||PREVENTION||NONE||This pilot intervention is a randomized controlled trial that uses a pre-test/post-test design. Caregivers of HPV vaccine age-eligible minors who are patients of a federally qualified health center, Adelante Healthcare Mesa, will be randomized to Intervention Group (pharmacy), or Control Group (usual care).||||
33752615|NCT03428867|||COHORT||PROSPECTIVE|||||||
33752616|NCT06698887|||COHORT||PROSPECTIVE|||||||
33752617|NCT05356806|||COHORT||PROSPECTIVE|||||||
33752618|NCT05494853|||CASE_CONTROL||PROSPECTIVE|||||||
33752619|NCT04754607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867642|NCT02043548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867643|NCT01059227|||CASE_CROSSOVER||PROSPECTIVE|||||||
33867644|NCT02161575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867645|NCT00878111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867646|NCT03824470|||OTHER||PROSPECTIVE|||||||
33867647|NCT03270072|||COHORT||PROSPECTIVE|||||||
33867648|NCT06452966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||a non-randomized real world data||||
33867649|NCT00856960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33867650|NCT01848184|||COHORT||PROSPECTIVE|||||||
33867651|NCT04651543|||CASE_CONTROL||PROSPECTIVE|||||||
34181651|NCT03469453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181652|NCT06300112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized-controlled trial with pretest-posttest control group||||
34181653|NCT06598150|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181654|NCT05177016|||COHORT||RETROSPECTIVE|||||||
34181655|NCT04312178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181656|NCT05987930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181657|NCT06596681|NA|SINGLE_GROUP||TREATMENT||NONE||A group of patients with refractory neuropathic pain||||
34181658|NCT05514886|||CASE_ONLY||CROSS_SECTIONAL|||||||
34181659|NCT01622166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181660|NCT01138449|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34181661|NCT05991635|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34181662|NCT01580163|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181663|NCT05809375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be performed by an investigator who was blinded to group allocation. Coping Skills Training was given to the control group participants, if they wanted to, after the final evaluation.|This study was designed as an assessor-blind, randomized controlled, and parallel-group study.|f|f|f|t
34181664|NCT03545958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Research Coordinator will manage recruitment and enrolment of study participants, and will not be involved in either measurement or the intervention. Research personnel performing the outcome assessments and data analysis will be blinded to group allocation but it is not possible to blind participants and personnel delivering the interventions.||f|f|t|t
34181665|NCT02746653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181666|NCT02952820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752620|NCT05072873|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|a double-blind randomized controlled study|a double-blind randomized controlled study|t|t|t|t
33752621|NCT06733220|||COHORT||PROSPECTIVE|||||||
33752622|NCT01953848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33752623|NCT01059565|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33752624|NCT05081713|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||two separate longitudinal observational studies with interventions at different phases (duration) of recovery post-stroke||||
33752625|NCT04155866|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752626|NCT00476372|||COHORT||CROSS_SECTIONAL|||||||
33752627|NCT01744652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752628|NCT05773768|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752629|NCT06553976|||COHORT||PROSPECTIVE|||||||
33752630|NCT06733207|||COHORT||PROSPECTIVE|||||||
33752631|NCT00934284|||OTHER||PROSPECTIVE|||||||
33752632|NCT05320731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the anesthesiologist performing the fibroscopy and the data collector will be blind to group assignment.||f|t|f|t
33752633|NCT03853109|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33838813|NCT00713505|RANDOMIZED|||||||||||
33838814|NCT06164535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|all patient information will be anonymized giving only corresponding numbers, which will be revealed by the PI after assessment.||f|f|f|t
33838815|NCT06297434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838816|NCT05833646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Self-controlled, quasi-experimental||||
33838817|NCT02070770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838818|NCT02806362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838819|NCT01691950|||COHORT||OTHER|||||||
33838820|NCT01850589|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33838821|NCT04977115|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33838822|NCT04358718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33838823|NCT01810523|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33838824|NCT03176147|||COHORT||PROSPECTIVE|||||||
33838825|NCT03325790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|DOUBLE-BLIND|RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED|t|t|t|t
33838826|NCT05197920|||COHORT||PROSPECTIVE|||||||
33838827|NCT03965715|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33838828|NCT05250219|||COHORT||RETROSPECTIVE|||||||
33838829|NCT05385380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"A total of 727 pregnant women were recruited and followed up to six months after delivery in this quasi-experimental, two-arm, controlled study. In the intervention group, eligible pregnant women received training to promote safe motherhood, supported by the story Why Did Mr. X Die, Retold? and a booklet on working with individuals, families and communities to promote maternal and neonatal health. Pregnant women received counselling (12 sessions/4 sessions per cluster) and biweekly check-ins were performed by community health workers. Pregnant women are encouraged to stay in maternity waiting homes, which have been upgraded to accommodate pregnant women while they wait for their baby to arrive. The control group received standard maternal health information and services as part of the standard health care system."||||
33752634|NCT06711510|NA|SINGLE_GROUP||OTHER||NONE||"Nine evaluations (every 3 months) over a 2-year follow-up, with the same standardized protocol for all participants, including:~* At the inclusion visit (M0), after 12 months (M12) and after 24 months (M24):~  * clinical (neurological) evaluation~ * behavioral examination~ * cognitive testing~ * blood sampling (determination of carrier / non-carrier status by means of GRN testing will be done at M0 visit; results will remain strictly confidential and not disclosed to study participants and investigators)~ * brain MRI~ * olfactory swab sampling with nasal brush~ * skin punch biopsy (optional)~ * lumbar puncture for CSF sampling (optional)~* For the remaining visits (M3, M6, M9, M15, M18, M21):~  * clinical evaluation~ * blood sampling"||||
34065953|NCT00784056|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752635|NCT06340620|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|f|t
33752636|NCT06732427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using a computer-generated randomized number table, the patients were divided into two groups: group L (fospropofol disodium group) and group B (propofol group). After determining the group of enrolled patients, the drug was administered by two fixed anesthesiologists. The study drug is prepared by someone who do not participate in the study.||t|f|t|f
33752637|NCT04378348|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752638|NCT05460325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752639|NCT04632927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752640|NCT02739282|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752641|NCT04731688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessments will be conducted by staff members who are masked to the participant's intervention group assignment.|Two site randomized controlled trial|f|f|f|t
33752642|NCT06418373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33752643|NCT06568237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752644|NCT05630547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded treatment (Part A) and open-label long-term extension period (Part B)||t|t|t|t
33752645|NCT05031013|||COHORT||PROSPECTIVE|||||||
33752646|NCT04945317|RANDOMIZED|PARALLEL||OTHER||NONE|blinding not possible given nature of intervention|Multi-center non-blinded randomized controlled trial (presence or absence of trained cytotechnologist providing on-site cytopathology feedback to bronchoscopist).||||
34181667|NCT05992831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each participant will be randomized to one of six possible dose-steps for the duration of the 6 treatment days (of their choosing) within a span of 2 weeks.|Each participant will be randomized to one of six possible dose-steps for the duration of the 6 treatment days (of their choosing) within a span of 2 weeks. We will use the FDA-approved MagVenture MagPro TMS System. Total treatment time will be controlled; all participants will perceive receiving treatment for 10 3-min stimulation sessions with 10-15 min inter-session intervals, resulting in a 2-3 hour treatment day. In addition to block randomization to dose step (which determines how many total active sessions they receive), the order of daily active and/or sham sessions will also be randomized. For example, if a participant is assigned to receive 4 active sessions in a day, 6 sham sessions will be given at random. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.|t|f|t|f
34181668|NCT06142682|NA|SINGLE_GROUP||TREATMENT||NONE||The Cochlear Implant (CI) Mi1250 +FLEX28 DEX (CIDEXEL) is the Investigational Medical Device (IMD) under investigation. MED-EL CI systems consist of an implantable part (i.e. CIDEXEL), external components (i.e. technically compatible audio/speech processor and its accessories) and software that controls and powers the implant. The IMD CIDEXEL will be the implantable part of this new MED-EL CI System and shall only be used together with technically compatible MED-EL external components.||||
34181669|NCT00002534||||TREATMENT||||||||
34181670|NCT03441321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181671|NCT01884467|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33752647|NCT06721000|||CASE_CONTROL||PROSPECTIVE|||||||
33752648|NCT06733792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752649|NCT05222282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752650|NCT06383585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752651|NCT04106726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752652|NCT03094260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752653|NCT00360438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752654|NCT06453265|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Assessment of the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users|t|t|t|t
33752655|NCT04866550|||COHORT||PROSPECTIVE|||||||
33752656|NCT04401514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752657|NCT06733636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752658|NCT04674124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752659|NCT04875481|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752660|NCT06017024|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33752661|NCT04412044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752662|NCT06579599|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33752663|NCT05952180|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Monocentric cross-over trial comparing the combination of cycloergometer and virtual reality to standard cycloergometer, in ICU, over the actively covered distance in kilometers.||||
33752664|NCT04776980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752665|NCT06192823|||COHORT||PROSPECTIVE|||||||
33752666|NCT03178617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752667|NCT04871789|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752668|NCT02883738|NA|SINGLE_GROUP||||NONE||||||
33752669|NCT00701038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752670|NCT05193591|||CASE_ONLY||PROSPECTIVE|||||||
33752671|NCT05323318|||COHORT||PROSPECTIVE|||||||
33752672|NCT06732401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752673|NCT01918995|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33752674|NCT03083899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33752675|NCT03258580|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34065954|NCT04267588|||COHORT||PROSPECTIVE|||||||
34065955|NCT01402986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34065956|NCT01027897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181672|NCT00800670|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33752676|NCT05731128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893972|NCT06108284|RANDOMIZED|PARALLEL||TREATMENT||NONE|can't be done as the two devices are completely different.|eligible patients will be randomized to either the conventional arm (non invasive positive pressure ventilation) vs the intervention arm using the Biphasic Cuirass Ventilation.||||
33893973|NCT00904124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33893974|NCT05207267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181673|NCT04379856|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34181674|NCT05593367|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181675|NCT06387693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181676|NCT05251558|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
34181677|NCT02964689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181678|NCT01703143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181679|NCT03854175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181680|NCT00765206|RANDOMIZED|CROSSOVER||||NONE||||||
34181681|NCT00371150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181682|NCT06591754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181683|NCT01553968|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181684|NCT04353648|||COHORT||PROSPECTIVE|||||||
34181685|NCT06595680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each patient will sequentially receive during two 4 hours hemodialysis session separated by one week a perfusion of Medialipide and a perfusion of NaCl 0,9%. The order of intervention will be determined by randomization.||||
34181686|NCT04257110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181687|NCT02705742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181688|NCT04424134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181689|NCT06652932|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34181690|NCT03747562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Both patient groups will receive gabapentin or a matching placebo additional to the standard analgesic therapy, and will be asked to consume the content following the predefined directions provided to them. Both the investigators and the patients will be blinded for the IMP, since gabapentin and the matching placebo will appear identical.~The clinical pharmacist responsible for clinical trials as well as Bimetra clinics will receive a sealed envelope from the statistician with the information necessary for decoding."|Randomised-controlled trial where patients are randomised to either the experimental group (E) receiving gabapentin or the control group (C) receiving a matching placebo, both in addition to standard analgesic therapy (WHO ladder steps 2 and 3).|t|t|t|f
34181691|NCT05670301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Pseudonymisation of samples and clinical data for the investigator|||||
34181692|NCT00514839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181693|NCT06587074|||COHORT||PROSPECTIVE|||||||
34181694|NCT03399019|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This study compares to the same intervention (monitor BIS scores and OAA/S scores timely) between all of three sedative drugs.|t|t|t|f
34181695|NCT02300961|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181696|NCT06604117|||COHORT||PROSPECTIVE|||||||
34181697|NCT05162963|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34181698|NCT05692375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The investigators developed an experimental approach, where we ensured randomization in sample identification and where a control group was present, favoring a strongest level of contribution to the evidence. This is a cross-sectional study with quantitative data collection following a Randomized Controlled Trial (RCT) design.|t|f|f|f
34181699|NCT04592302|||CASE_CROSSOVER||PROSPECTIVE|||||||
34181700|NCT06521320|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All patients were given a speaking valve combined with airway pressure measurement and bronchoscopy.||||
33752677|NCT04538742|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will consist of 2 phases: a dose escalation phase (Part 1) and a dose expansion phase (Part 2). Part 1 of each module will enroll patients with locally assessed HER2-positive advanced/MBC in second-line or later.Part 2 of each module will enroll patients with locally assessed HER2-positive breast cancer who have not received prior treatment for advanced/metastatic disease.||||
33752678|NCT00907829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33752679|NCT00713648|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33752680|NCT06523673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752681|NCT06096493|||COHORT||RETROSPECTIVE|||||||
33752682|NCT06615921|||COHORT||RETROSPECTIVE|||||||
33752683|NCT00970138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752684|NCT06723262|NA|SINGLE_GROUP||OTHER||NONE||||||
33752685|NCT01761097|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33752686|NCT04598724|||COHORT||PROSPECTIVE|||||||
33752687|NCT06075108|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33752688|NCT05885724|||COHORT||PROSPECTIVE|||||||
33752689|NCT00002153||||TREATMENT||||||||
33752690|NCT02816151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752691|NCT06121063|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, label, multi-center, randomized study||||
33752692|NCT05279170|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752693|NCT01328080|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33752694|NCT06596642|||COHORT||OTHER|||||||
33752695|NCT00775710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752696|NCT04973605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752697|NCT04889430|NA|SINGLE_GROUP||TREATMENT||NONE|Open label single arm study|||||
33893975|NCT02814773|||COHORT||PROSPECTIVE|||||||
33893976|NCT06545604|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893977|NCT06655922|||COHORT||PROSPECTIVE|||||||
33893978|NCT05006053|||OTHER||CROSS_SECTIONAL|||||||
33893979|NCT01960010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893980|NCT01151072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893981|NCT00584662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893982|NCT02262637|||COHORT||PROSPECTIVE|||||||
33867652|NCT01932242|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Study drug will be prepared by an unblinded pharmacist not involved with the conduct of the study. The pharmacist will assign the correct study drug (16 mg/kg ETI-204 or placebo) to each subject according to the randomization scheme.|"Seventy subjects will be randomized in a 1:1 ratio to one of the following two treatment sequences:~* Sequence A: ETI-204 on Days 1 and 14 and placebo on Day 120~* Sequence B: ETI-204 on Days 1 and 120 and placebo on Day 14"|t|t|t|f
33867653|NCT00498160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867654|NCT02841098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867655|NCT01415011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867656|NCT06091085|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|4-week open-label acetazolamide extension and optional||t|t|t|t
33867657|NCT00518999|||DEFINED_POPULATION||OTHER|||||||
33867658|NCT05520437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33867659|NCT02589496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867660|NCT00314626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867661|NCT04564963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre, pragmatic, open label, two-arm parallel-group Vanguard feasibility randomized controlled trial||||
33867662|NCT02036632|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867663|NCT03150862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|||||
33867664|NCT04662944|||COHORT||OTHER|||||||
33964623|NCT06543017|NA|SINGLE_GROUP||PREVENTION||NONE||The participates of the study were 16 male freestyle wrestlers from Sichuan Province, China, preparing for the 2024 Chinese Wrestling Championships (4th to 12th May 2024). Based on their competition categories, they were to participate in five weight classes (57, 61, 65, 70, and 74 kg), with a total of 16 individuals (four in the 70 kg class, and three per other class). The study period was 38 days prior to the competition. Based on the training schedule and weight reduction characteristics, it was divided into a slow weight reduction phase (where athletes reduced weight slowly by adjusting their dietary structure and increasing the volume of aerobic exercise) and a rapid weight reduction phase (where athletes achieved rapid weight loss by further restricting water intake and adjusting their diet).||||
33964624|NCT04727346|||OTHER||PROSPECTIVE|||||||
33964625|NCT00420849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964626|NCT02688816|||COHORT||CROSS_SECTIONAL|||||||
33964627|NCT06496906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964628|NCT04934111|NA|SINGLE_GROUP||PREVENTION||NONE||This phase I clinical study builds on clinical experience using the LNP nCoV saRNA vaccine currently under evaluation in COVAC1 (Being conducted in the UK). The trial will be conducted in 18-45 year olds in a single centre supervised by the Chief Investigator, by allocating the 42 participants into two groups, based on seroconversion status. These will include 21 SARS-CoV-2 seronegative and 21 SARs-CoV-2 seropositive individuals. Participants in each group will be given a dose of 5.0ug at 0 weeks and 4 weeks.||||
33964629|NCT01433198|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964630|NCT06527001|||COHORT||RETROSPECTIVE|||||||
33964631|NCT03113825|NA|SINGLE_GROUP||TREATMENT||NONE||Period 1 will enroll approximately 35 patients to evaluate conditions to achieve maximal differences in fluorescent signals between malignant and nonmalignant tissue. Period 2 will enroll approximately 120 patients to test dosing and imaging conditions determined in Period 1 and accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.||||
33964632|NCT05824156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964633|NCT02971345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964634|NCT06161740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964635|NCT01096706|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33752698|NCT03979573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective' Single-Arm, Phase-II Study||||
33752699|NCT05109091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867665|NCT06043856|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867666|NCT02056054|||COHORT||PROSPECTIVE|||||||
33867667|NCT00575536|||CASE_ONLY||RETROSPECTIVE|||||||
33867668|NCT04029220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Staff supporting on-line data collection will not be aware of arm participation|The study will employ a randomized trial to provide a preliminary test of the impact of Parent Peer Navigation (PPN) on key caregiver and child outcomes. We will recruit children and families through schools and through those families contacting Family Run Organizations directly in Pennsylvania and Wyoming, who will then be referred randomly to either a (1) Family Support Organization or Service (FSO) that provides only information and referrals by staff who are not family members with lived experience or (2) one of the FROs (Allegheny Family Network in Pennsylvania or UPLIFT in Wyoming) that provides PPN by family members with lived experience..|f|f|f|t
34065957|NCT04146623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34181701|NCT06590792|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Echocardiographer and biochemistry expert will be blind to participants type (sedentary or football player)|Two groups including 20 participants in each of them will be involved the study. One group will consist of adolescent football players, while the other group will consist of non-athlete healthy participants|f|f|t|t
34181702|NCT00758667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181703|NCT03501849|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34181704|NCT04912258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34181705|NCT03122509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a Simon two-stage design, phase II study. It will be conducted to determine the efficacy and safety of (1) durvalumab and tremelimumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy; and, (2) durvalumab and tremelimumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy.||||
34181706|NCT04784247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot study evaluating the efficacy of lenvatinib plus pembrolizumab in the treatment of select metastatic and/or unresectable soft tissue sarcomas. Patients will be enrolled in one of five cohorts.||||
33867669|NCT00001764||||TREATMENT||||||||
33867670|NCT02742597|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867671|NCT03568045|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||a pilot randomized control trial of 3 cohort groups.|f|f|f|t
33867672|NCT06141850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181707|NCT06590246|NA|SEQUENTIAL||TREATMENT||NONE||||||
34181708|NCT02263599|||COHORT||PROSPECTIVE|||||||
33867673|NCT05104645|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34181709|NCT01857492|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33867674|NCT02728661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867675|NCT02510092|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33867676|NCT03045445|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33867677|NCT05520346|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867678|NCT01854320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181710|NCT06590818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867679|NCT05452330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867680|NCT03633526||SEQUENTIAL||TREATMENT||NONE||||||
33867681|NCT00187096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867682|NCT05765266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study where subjects and evaluators are blinded to treatment.||t|f|f|t
33867683|NCT02000076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34181711|NCT00744497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181712|NCT04886635|||COHORT||PROSPECTIVE|||||||
34181713|NCT00948376|||COHORT||PROSPECTIVE|||||||
34181714|NCT02065037|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34181715|NCT06599281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181716|NCT03216512|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participant won't know whether they are receiving the noise cancelling headphones or the sham control.|Proof-of-concept, randomized, within-subject cross-over design.|t|f|f|f
34181717|NCT05602246|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34181718|NCT04593862|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants and investigators will not be blinded to group assignment given the nature of the intervention. Outcome assessors will be blinded to group assignment for the clinical outcomes of tumour recurrence and progression.||f|f|f|t
34181719|NCT04467905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181720|NCT01560663|||CASE_CONTROL||PROSPECTIVE|||||||
34181721|NCT04965701|||COHORT||PROSPECTIVE|||||||
34181722|NCT03829228|NA|SINGLE_GROUP||TREATMENT||NONE|"Given the small sample size in this pilot study and the potential drop-out rate, we did not include a placebo group to control for the placebo effect. Nonetheless, we implemented a deceptive double-blinding design, i.e., all on-site care-providers and investigators and all participants were told that this study was placebo controlled, and that each participant had a 50/50 chance of receiving treatment or placebo. This masking helps decreasing the expectation bias from the participants that confound the study result."|Subjects with Protective Qi Insufficiency||||
34181723|NCT03072797|||COHORT||PROSPECTIVE|||||||
34181724|NCT02386397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181725|NCT03580811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two groups of 15 patients . One with soft tissue grafting and implant placement and other with soft and hard tissue grafting with implant placement.|f|f|f|t
34181726|NCT06587763|||COHORT||PROSPECTIVE|||||||
34181727|NCT06654869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34181728|NCT02775786|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867684|NCT06228287|||COHORT||RETROSPECTIVE|||||||
33867685|NCT04650282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867686|NCT03778567||SEQUENTIAL||TREATMENT||NONE||||||
33867687|NCT04540549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867688|NCT04677673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867689|NCT05168748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181729|NCT06257433|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181730|NCT05842616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181731|NCT03171363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181732|NCT02392637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181733|NCT03129568|NA|SINGLE_GROUP||TREATMENT||NONE||Transcoronary infusion||||
34181734|NCT00091949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181735|NCT01437657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181736|NCT00412009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181737|NCT05482997|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|single-blinded (subject only)||t|f|f|f
34181738|NCT04493008|NA|SINGLE_GROUP||OTHER||NONE||Single group will be assessed before and after an educational session||||
34181739|NCT01502826|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181740|NCT01820338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181741|NCT03632850|||COHORT||CROSS_SECTIONAL|||||||
34181742|NCT06600334|||OTHER||CROSS_SECTIONAL|||||||
33867690|NCT03389295|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: TPF regimen comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) Radiotherapy：Reduced Target Delineation||||
33867691|NCT05520151|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Multicentric, prospective non-randomized clinical study comparing the group of patients who received a 7-days course of ORAL IMAPCT to a retrospective cohort of patients operated between 2016 and 2019: cystectomy and nephrectomy by laparotomy.||||
33867692|NCT02495844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867693|NCT05203874|||COHORT||RETROSPECTIVE|||||||
33867694|NCT02491957|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867695|NCT03579420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867696|NCT03429023|||COHORT||PROSPECTIVE|||||||
34181743|NCT03525678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181744|NCT01224145|NA|SINGLE_GROUP||TREATMENT||NONE||laparoscope for bupivacaine sponge (200 mg bupivacaine hydrochloride) placement in laparoscopic hernia repair.||||
34181745|NCT05519982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181746|NCT06591195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking for allocation. After allocation, there is no possibility for blinding the intervention.|Paediatric patients between the age of 5-12 years with minor and superficial partial thickness burn injuries who require dressing changes in the outpatient clinic, without sedation, will be randomized into two groups: the control group will receive standard practice of care which concerns a dressing change without any distraction methods, and the intervention group will receive distraction by use of a kaleidoscope as additional method for potential pain alleviation. Patients in both groups will receive paracetamol or non-steroidal anti-inflammatory drugs when required according to hospital protocol.|t|t|t|t
33867697|NCT00036751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867698|NCT04311736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33867699|NCT03422679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867700|NCT00352287|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33867701|NCT01168973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867702|NCT03281967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867703|NCT02067195|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33867704|NCT00812799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33867705|NCT03713034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33867706|NCT02067442|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33867707|NCT02656459|||COHORT||PROSPECTIVE|||||||
33867708|NCT06365866|NA|SINGLE_GROUP||TREATMENT||NONE||Add-on treatment to standard treatment (fixed doses allowing dose reduction or dose delay according to the tolerability of individual patients); No control group.||||
33867709|NCT05577286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867710|NCT00356083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867711|NCT01640912|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33867712|NCT04886648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Video footage in the study was made by three experts. Experts blindly evaluated the groups to which the videos they evaluated belonged to.|The study will be conducted in a randomized controlled manner.|t|f|f|t
33867713|NCT03528759|||OTHER||CROSS_SECTIONAL|||||||
33867714|NCT00003765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867715|NCT00321750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867716|NCT03831061|RANDOMIZED|PARALLEL||TREATMENT||NONE||An intervention group and a control group with the same characteristics are included.||||
33867717|NCT00217048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867718|NCT03559036|||CASE_CONTROL||PROSPECTIVE|||||||
33867719|NCT06476574|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33867720|NCT02237963|||COHORT||PROSPECTIVE|||||||
33867721|NCT04647877|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34151402|NCT03765203|RANDOMIZED|PARALLEL||OTHER||NONE||The study is a pre-post, two round controlled trial of care practices in a nationally representative sample of practicing nephrologists randomly assigned to a control or an intervention arm. All providers will be asked to propose care for a total of 6 CPV simulated patients who are adults aged 30-75; three or more months post-transplant; and presenting with signs, symptoms and laboratory findings suggestive of allograft rejection. Each assessment round will consist of 3 simulated patients. In between assessment rounds, physicians randomized into the intervention arm will receive educational materials on the new allograft rejection test.||||
34181747|NCT00535639|RANDOMIZED|PARALLEL||||DOUBLE||||||
34181748|NCT03208946|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181749|NCT01727219|||COHORT||CROSS_SECTIONAL|||||||
33867722|NCT04885868|||COHORT||PROSPECTIVE|||||||
33867723|NCT03016936|||COHORT||PROSPECTIVE|||||||
33867724|NCT00516048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867725|NCT00134264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33867726|NCT03422419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867727|NCT04651621|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Identical sham coil, masked by an independent person.|First phase is a cross-over with two randomized blinded sessions with either verum cTBS or sham with wash-out, for each participant, and a second open feasibility treatment phase with 5 sessions/day over four days for participants with distressing auditory verbal hallucinations|t|t|t|t
33964636|NCT05759169|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking done|This study was done in a randomized controlled experimental research pattern to determine the effect of the foot bath applied in the last 30 minutes of dialysis treatment on comfort, fatigue and dialysis symptoms for hemodialysis patients.||||
33964637|NCT05990647|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Cohort study|f|f|t|f
33964638|NCT00986154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964639|NCT02980562|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33964640|NCT05974345|||OTHER||OTHER|||||||
33964641|NCT00029328|NON_RANDOMIZED|||TREATMENT||NONE||||||
33964642|NCT04362345|||CASE_ONLY||OTHER|||||||
33964643|NCT01248611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181750|NCT04833582|NA|SEQUENTIAL||TREATMENT||NONE||||||
34181751|NCT03980080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Part 1 (SAD) primary objective : safety and tolerability profile of single ascending IV (Cohort A) and SC (Cohort B) doses given to healthy subjects, compared to placebo.~Part 2 (MAD) primary objective : safety and tolerability profile of two IV doses given on two separate occasions to healthy subjects, compared to placebo."|t|f|t|f
34181752|NCT03737929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181753|NCT00174187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181754|NCT00860093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181755|NCT03833505|||OTHER||CROSS_SECTIONAL|||||||
34181756|NCT05247671|||COHORT||PROSPECTIVE|||||||
34181757|NCT06654609|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181758|NCT00671736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181759|NCT05910996|||COHORT||RETROSPECTIVE|||||||
34181760|NCT05410210|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participants and assessors evaluating MDS-UPDRS were blinded in this study||t|f|f|f
34181761|NCT01625299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34181762|NCT06417424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Participants, investigators and outcomes Assessor don't know receiverd which intervention, only care Providers know it.|1. Received both gastrointestinal external stimulation and transcutaneouselectrical acupoint stimulation; 2. Received gastrointestinal external stimulation singly; 3. Received transcutaneouselectrical acupoint stimulation singly; 4. No stimulation was given. All groups received oral administration of polyethylene glycol for intestinal cleansing.|t|f|t|t
34181763|NCT02875353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34181764|NCT00507780|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34181765|NCT02604394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181766|NCT06587165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181767|NCT03841396|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|This was a double blind study and it was conducted under double blind conditions. The study medications, as well as the placebo, were contained in pre-packaged syringes which are different in physical appearance. Therefore to ensure double blinding conditions, the study medications (Fraxiparine, Clexane and Placebo) were packaged in an identical boxes and labelled identically (apart from the treatment number). To further ensure that the participants remained blinded during the study, a blindfold was put over the eyes of each participant at each visit that required IP administration.|This study was planned to be a replicated 3x3 Latin square design (5 replicates), each enrolled and randomised participant should have received a single sequence of subcutaneous injections of Placebo, Fraxiparine and Clexane, in randomised order, on three separate occasions.|t|f|t|f
34181768|NCT00459251|||DEFINED_POPULATION||OTHER|||||||
34181769|NCT05535296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34181770|NCT02550639|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34181771|NCT04281862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181772|NCT05481151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181773|NCT00773006|||COHORT||PROSPECTIVE|||||||
34181774|NCT06175806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181775|NCT06188910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181776|NCT06655571|RANDOMIZED|PARALLEL||OTHER||NONE||caudal block based on anatomical landmarks (group C) or ultrasound-guided (group E)||||
34181777|NCT02415322|||COHORT||PROSPECTIVE|||||||
34181778|NCT04404491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181779|NCT04971434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181780|NCT00598338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181781|NCT06524843|||COHORT||RETROSPECTIVE|||||||
34181782|NCT06655012|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34181783|NCT00571493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181784|NCT00854958|||COHORT|||||||||
34181785|NCT04769934|||CASE_ONLY||PROSPECTIVE|||||||
34181786|NCT05784038|||COHORT||PROSPECTIVE|||||||
34181787|NCT00106704|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34181788|NCT01942694|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34181789|NCT05274815|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34181790|NCT01463501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752700|NCT03509116|||OTHER||OTHER|||||||
33752701|NCT05968651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752702|NCT01027936|||CASE_CONTROL||PROSPECTIVE|||||||
33964644|NCT01339078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964645|NCT03798522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"* erector spinae plane block group (ESPB)~* general anesthesia group (GA)"|t|f|f|f
33964646|NCT01796041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964647|NCT00659581|||CASE_ONLY||PROSPECTIVE|||||||
33964648|NCT05025982|||COHORT||RETROSPECTIVE|||||||
33964649|NCT01611168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964650|NCT00918632|RANDOMIZED|CROSSOVER||||NONE||||||
33964651|NCT05491213|RANDOMIZED|PARALLEL||SCREENING||NONE||Quantitative measures of the PRISM constructs will be collected via internet surveys from the patient and nurse navigators, clinic directors, and clinicians (n = 130 surveys), and through medical record review. Participants followed at the TELESCOPE arm sites will also complete a measure of intervention acceptability at the one week survey for Aim 2. Semi-structured interviews will be conducted for Aim 2 with a mix of 20 clinical, nursing, and administrative directors at the participating sites. All 10 study navigators, and 20 clinicians from the TELESCOPE arm sites will also be interviewed.||||
34065958|NCT03061799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The product manufactured as clinical food and placebo are identical in shape, color and weight. In addition, clinical trial food should be labeled by affixing the same label with placebo so that it remains blind to both subjects and the investigator. Lot number of the label, includes reference number of the test food and reference number of the placebo together.~Dispensing of food and placebo for clinical trials is handled by the management pharmacist.~Clinical tester supplies clinical trial food corresponding the random assignment code assigned to subjects. Except inevitable cases such as occurrence of adverse events resulted by clinical food, the code will not be released until the end of the clinical trial. In case of deficiency or breakage of food for clinical trial, extra clinical food with unique code will provided to subjects, therefore maintain blinding."|This clinical trial will be conducted in parallel with the test group or the control group randomly assigned.|t|t|t|f
34065959|NCT02574416|||CASE_ONLY||OTHER|||||||
34181791|NCT03957928|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34181792|NCT02606643|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34181793|NCT05599893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treating therapists could not be blinded due to practical feasibility. Assessing therapists measured the outcomes of each participant at each interval without knowing the group allocation. Participants were also blinded by requesting them not to disclose their allocation to the assessing therapists and co-participants at any time during the study.|The participants were randomized into either of these two groups in 1:1 ratio through two block (block size 12-15) simple random sampling method. Tele - physical therapy group (TPG; n = 68) and a control intervention group (CIG; n = 68). To ensure allocation concealment, an independent therapist randomly picked up an envelope that contained patient information, in a blinded fashion and segregated the patient into either of these two groups.|t|f|f|t
34181794|NCT04321057|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867728|NCT06231420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181795|NCT06655818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867729|NCT03677596|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will be conducted in 2 phases: a run in phase and a randomized phase.~Run in phase: a total of up to 22 patients will be enrolled to receive the starting dose of 1.2 mg/m2/cycle (dose level 2). A Simon Two Stage optimal design will be used. If acceptable efficacy (CR/CRi and MRD negativity) is observed in the run in phase, the study will enter the randomized phase.~Randomized phase: if acceptable efficacy is observed in the run in phase, the study will enter the randomized phase. A total of approximately 80 patients will be randomized (1:1) to 1 of 2 dose levels of inotuzumab ozogamicin (40 patients per dose level)."||||
33867730|NCT01292382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867731|NCT06171620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the visual presence of the VR, masking is not feasible.|Two group design, Standard of care (control) vs Standard of care + VR intervention (Intervention group)||||
33867732|NCT00761787|||COHORT||PROSPECTIVE|||||||
33867733|NCT00121836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867734|NCT03193762|||CASE_ONLY||PROSPECTIVE|||||||
33964652|NCT02165566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181796|NCT06506812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181797|NCT05913765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, single-blind, placebo-controlled case-control design|t|f|f|f
34181798|NCT00587522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867735|NCT04683978|||COHORT||PROSPECTIVE|||||||
33867736|NCT05865444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation will be concealed to the participants and teachers. Assessment will be done online through self-reports.|A randomized controlled trial with two groups will be used. Randomization will be done by clusters, using the classroom as the unit. First, the schools will be selected according to their characteristics. Then, for each school and grade, half of the classrooms will be randomly assigned to the experimental condition (values alignment condition) and the other half to the active control condition (traditional educational intervention) in parallel for the duration of the study.|t|f|f|t
34181799|NCT03012503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181800|NCT06591871|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi-experimental research design was used for this study.||||
34181801|NCT04959877|||OTHER||PROSPECTIVE|||||||
33964653|NCT05842811|||COHORT||OTHER|||||||
33964654|NCT04501549|||CASE_CONTROL||PROSPECTIVE|||||||
33964655|NCT04916886|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33964656|NCT02677675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33964657|NCT00388570|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33964658|NCT05839860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33964659|NCT02130895|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33964660|NCT02486471|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34181802|NCT03631251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964661|NCT02524496|||COHORT||PROSPECTIVE|||||||
33964662|NCT00454311|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33964663|NCT02122471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964664|NCT01890330|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33964665|NCT06542627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964666|NCT04089280|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Quadruple|prospective, single center , interventional|t|t|t|t
33964667|NCT05130866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking applies to Cohort B only.|A Two-staged, Phase 2/3, Randomized, Multicenter Efficacy and Safety Study.|t|f|t|f
33964668|NCT02584205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964669|NCT00149669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181803|NCT06655025|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34181804|NCT03102437|NA|SINGLE_GROUP||TREATMENT||NONE||Continued Access||||
34181805|NCT06522646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34181806|NCT06341257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181807|NCT04496713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181808|NCT04930471|||COHORT||PROSPECTIVE|||||||
34181809|NCT04163016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181810|NCT04457882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181811|NCT00495313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34181812|NCT03171649|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34181813|NCT02611297|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181814|NCT04103619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181815|NCT06492239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181816|NCT03171961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181817|NCT01780506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181818|NCT05369741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181819|NCT06103435|||COHORT||RETROSPECTIVE|||||||
34181820|NCT04249245|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34181821|NCT04053660|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181822|NCT02691507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964670|NCT01289938|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964671|NCT02965469|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34181823|NCT02000206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181824|NCT03371498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181825|NCT01815346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181826|NCT02833233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181827|NCT04402034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181828|NCT00002894|RANDOMIZED|||TREATMENT||||||||
33964672|NCT00665717|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34065960|NCT03142373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34065961|NCT01004458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065962|NCT05879224|NA|SINGLE_GROUP||OTHER||NONE||Combination Product: Revised case management package||||
34065963|NCT02427802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181829|NCT02769117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181830|NCT03110523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181831|NCT05747235|||COHORT||PROSPECTIVE|||||||
34181832|NCT00674817|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34181833|NCT01512927|||COHORT||PROSPECTIVE|||||||
34181834|NCT04254003|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
34181835|NCT04417517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181836|NCT01481753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181837|NCT06655272|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34181838|NCT02201394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181839|NCT02115048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181840|NCT04617678|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Non-randomized prospective two-arm clinical trial||||
34181841|NCT04155762|NA|SINGLE_GROUP||OTHER||NONE||||||
34181842|NCT06314802|||CASE_CONTROL||RETROSPECTIVE|||||||
34181843|NCT02037971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34181844|NCT03865901|||COHORT||PROSPECTIVE|||||||
34181845|NCT04986904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181846|NCT06390436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The primary endpoint will be assessed by blinding the allocated treatment group to investigator.~Thus, ophthalmological response will be assessed in a standardised manner by an ophthalmologist, blinded to the treatment strategy. The occurrence of infections will also be assessed in a manner blinded to the by an independent adjudication committee."|SMOOTH is a multicenter, randomized, controlled, parallel-group, blinded end-point trial (Prospective Randomised Open, Blinded End-point, PROBE) designed to demonstrate the superiority of a TDM-based strategy of therapeutic de-escalation via the spacing of ADA administrations versus a conventional ADA-based therapeutic strategy.|f|f|t|f
34181847|NCT01804400|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33752703|NCT05615649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181848|NCT06403397|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The population of the study consists of all nurses working in the intensive care units of Prof. Dr. Cemil Taşcıoğlu City Hospital. There are a total of 142 nurses working in the adult intensive care units of the hospital.|This study is a cross-controlled experimental research conducted to determine the effect of using the CEASE care package on patient monitor alarms and nurse alarm fatigue in adult intensive care units|f|t|f|f
33752704|NCT06340906|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-arm, prospective pilot/feasibility study.||||
33867737|NCT00516542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181849|NCT04513223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181850|NCT04907136|RANDOMIZED|CROSSOVER||PREVENTION||NONE||During this research project, HWLs will be tested on the ENDS device in a clinical lab cross-over study, where each subject uses ENDS in 2 sessions; 1) their preferred product without HWL (control), and 2) their preferred product with pictorial HWL on the ENDS device. This design will test the main study hypothesis: compared to control, using ENDS with the HWLs is associated with decreased satisfaction, dependence suppression, and puffing behavior, but increased knowledge about harm and intention to quit.||||
34181851|NCT00566319|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34181852|NCT00949702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181853|NCT04978168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"A Type 1 hybrid implementation-effectiveness study conducted in two phases. The first recruits as staff/leaders from probation agencies and community treatment agencies. The second phase (which starts after the implementation in the first period is completed) recruits adults on probation and staff of probation agencies. The Core Implementation study (first phase) involves a pre-post design. The effectiveness study (second phase) uses randomized parallel assignment with two arms.~The initial Core Implementation study involved four phases: Exploration (baseline), Preparation, Implementation, Sustainability (6- and 12-month follow-ups). The subsequent Effectiveness study starts after the Implementation phase is completed, with its own baseline data and follow-ups up to 6 months."||||
34181854|NCT01958164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181855|NCT02120898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181856|NCT04633278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181857|NCT05830396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181858|NCT05589857|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34181859|NCT03530982|NA|SINGLE_GROUP||TREATMENT||NONE|The assessor will not know the aims and content of the intervention procedures.|Individualized intensive training of functional priorities presented by adolescents with CP. The intervention will happen during 2 weeks, 5 days/week, during 3 hours in a local rehabilitation center. Trained occupational and physical therapists will conduct the intervention procedures||||
34181860|NCT06589908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181861|NCT04500899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181862|NCT05828147|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, all patients will receive anti-CD20 antibodies.||||
34181863|NCT05786651|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive each level of visual information (target or distractor)||||
34181864|NCT03619668|||COHORT||PROSPECTIVE|||||||
33867738|NCT02436564|||CASE_ONLY||PROSPECTIVE|||||||
33867739|NCT04868721|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867740|NCT00005950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867741|NCT00005641||||TREATMENT||||||||
33867742|NCT02536768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867743|NCT00069732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867744|NCT06186713|||COHORT||RETROSPECTIVE|||||||
33867745|NCT03492528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867746|NCT00492427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867747|NCT00574145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867748|NCT01184222|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33867749|NCT02131675|||COHORT||CROSS_SECTIONAL|||||||
33867750|NCT01538290|||COHORT||CROSS_SECTIONAL|||||||
33867751|NCT05500820|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33893983|NCT02395835|||COHORT||PROSPECTIVE|||||||
33893984|NCT05057351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single center, randomized, double-blind, placebo-controlled, parallel group study, carried on 2 groups of 22 subjects.|t|f|t|f
34181865|NCT03039218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Study subjects will be randomized in a 2:1 ratio to either active treatment or the control. The investigator and his staff do not know which applicator is the sham/placebo control and which are the active applicators. For the active treatment, a regular EMSE shockwave applicator will be used. The treatment group is further split into two equal groups, with both groups receiving the identical active treatment. In order to preserve the blinding of the investigator, the treatment devices are provided with two applicators (one for each of the active treatment groups), which while identical in function, differ slightly in appearance.~For the sham treatment, a placebo applicator, including an absorber without emitting shockwaves, will be used. However, all three applicators (two to use with the active device and one with the sham) are going to produce exactly the typical shock wave sound with equivalent noise to reduce or eliminate bias from the investigator"|A total of 100 subjects will be randomized to either the Active or Sham/Placebo group. Following completion of the 3 month follow-up visit, subjects will be unblinded. Subjects who received the Placebo/Sham treatment will be offered treatment using the Active device applicator.|t|f|t|f
34181866|NCT06231589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181867|NCT05311488|||CASE_CONTROL||PROSPECTIVE|||||||
34181868|NCT05758194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181869|NCT06603857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The blinded investigator will perform assessments at all study visits.|Prospective, placebo-controlled, double-blinded, randomized study|f|f|f|t
34181870|NCT01213316|||COHORT||PROSPECTIVE|||||||
34181871|NCT02135796|||COHORT||PROSPECTIVE|||||||
34181872|NCT03876223|||COHORT||PROSPECTIVE|||||||
34181873|NCT02897323|||COHORT||PROSPECTIVE|||||||
34181874|NCT06650579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All principal investigators and co-investigators will be blinded to randomization block. All cardiac computed tomography images will be analyzed by a blinded level 3 boarded cardiac imaging expert.||f|f|t|t
34181875|NCT03622489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181876|NCT01584375|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34181877|NCT06053671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181878|NCT03902977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon who operates the patient will neither perform the follow up visits nor contact other investigators. A blinded investigator will see the patient at the following visits after surgery: week 1, week 4 and week 12. In case the patient develops a seroma which needs aspiration, aspiration will be performed by the blinded investigator.|All patients have undergone surgery for treatment of breast cancer. During surgery they are assigned to one of two groups (randomization 1:1): quilting or conventional suture.|t|t|f|f
34181879|NCT05056233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34181880|NCT05999357|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label, 2-cohort phase II study. Cohort A: asymptomatic, untreated BM, Cohort B: asymptomatic, treated BM.||||
34181881|NCT01812863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181882|NCT06653413|||COHORT||PROSPECTIVE|||||||
34181883|NCT01310452|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181884|NCT04728633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181885|NCT06474715|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The FT4W program is founded on social cognitive theory, which posits that human behavior is the product of the dynamic interplay of personal, behavioral, and environmental influences. Social cognitive theory emphasizes reciprocal determinism in interactions between people and their environments. The majority of physical activity interventions use social cognitive theory as indicated by the theory and technique tool developed by the Human Behavior Change Project. The study team also used the theory and technique tool to align the FT4W program components and mediating pathways with behavior change techniques and mechanisms of action substantiated in behavior change literature and expert consensus. For our study, the study team will measure social influence via social cohesion.|t|f|t|f
34181886|NCT03150953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181887|NCT00295555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752705|NCT06326905|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessment collector will be blinded as to whether a participant is in the intervention or waitlist group|Waitlist Control Trial|f|f|f|t
34181888|NCT01469169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181889|NCT02246790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181890|NCT06593756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752706|NCT01417299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964673|NCT02195960|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients, doctors, RT technicians, investigators and statisticians who participated or evaluated the study outcomes were blinded to the nature of the supplements. Anthocyanin and placebo stick packs and soluble granulated products were identical for organoleptic properties and coded as A and B by the producer. Only after completion of statistical analyses of trial results, blind codes were opened by the provider.|Corn cobs-derived extracts of soluble anthocyanins given to breast cancer patients undergoing radiotherapy, to test prevention of skin toxicity.|t|t|t|t
33964674|NCT01531868|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33964675|NCT03210441|||COHORT||PROSPECTIVE|||||||
33964676|NCT02572479|||CASE_ONLY||PROSPECTIVE|||||||
34065964|NCT00004036||||SUPPORTIVE_CARE||||||||
34065965|NCT01368887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34065966|NCT01998464|||CASE_CONTROL||PROSPECTIVE|||||||
34065967|NCT03604575|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|This study was blinded for Sponsor, investigators and analytical laboratory|two-way crossover|t|t|t|t
34065968|NCT05052697|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|SSA: observer-blinded, sponsor unblind SSB: single-blind, sponsor unblind||t|t|t|t
34065969|NCT03459859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose escalation, traditional 3:3 design||||
33752707|NCT04610671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752708|NCT06491511|||COHORT||PROSPECTIVE|||||||
33752709|NCT02101229|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33752710|NCT00745745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752711|NCT01092338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752712|NCT04063189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065970|NCT01634451|RANDOMIZED|PARALLEL||||NONE||||||
34065971|NCT03300713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752713|NCT06733233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects who are eligible for the study and have signed informed consent will receive T-DXd in combination with an immune checkpoint inhibitor. The specific dosing regimen is as follows: T-DXd (5.4 mg/kg i.v. q3w) every 3 weeks for a total of 8 courses. Teraplizumab (240 mg/kg i.v. q3w), 1 course every 3 weeks for a total of 8 courses. Upon discontinuation of the study, subjects will receive post-neoadjuvant therapy according to local clinical criteria.||||
34065972|NCT05672043|||COHORT||PROSPECTIVE|||||||
34065973|NCT05933564|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34181891|NCT03987269|RANDOMIZED|PARALLEL||OTHER||NONE||One intervention group and one control group||||
34181892|NCT01529892|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34181893|NCT06086717|RANDOMIZED|PARALLEL||TREATMENT||NONE||Concurrent Parallel Randomized Clinical Trial||||
34181894|NCT03516188|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Asymptomatic obese patients will be randomised into either groups according to alginate antacid group \[Gaviscon Advance (GA), Reckitt Benckiser, UK\] and non antacid alginate group \[simple antacid\]. Both groups will be studied for 48 hours using the ambulatory wireless capsule and pH impedance. Participants according to their group will take either alginate antcid \[Gaviscon Advance (GA), Reckitt Benckiser, UK\] or non alginate antacid \[simple antacid\] which has equivalent strength of antacid after taking late night standardised meals.||||
34181895|NCT06593860|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Due to the interactive nature of rehabilitation, masking the intervention to patients and research investigators is impossible. Therefore, we will blind the separate outcome assessors, who will not be involved in the treatment procedures to minimize bias.|A total of 32 dyads of PD participants will be recruited (4 groups of 8 participants in each). The PD participants must be monolingual speakers of Korean living in the United States. Using the waitlist randomized controlled trial (RCT) design, three wait control groups (Groups 2, 3, 4) will serve as untreated comparison groups first, but will serve as intervention groups in the following cycle. The proposed study is divided into two kinds of outcome measures, primary (speech function of PD patients) and secondary (communication participation and well-being of PD patients and their families). Each set of outcome measures will address one of the Specific Aims.|f|f|f|t
34181896|NCT02580539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181897|NCT01850121|||CASE_ONLY||PROSPECTIVE|||||||
34181898|NCT04363008|||COHORT||PROSPECTIVE|||||||
34181899|NCT01477398|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34181900|NCT04530214|||COHORT||PROSPECTIVE|||||||
33752714|NCT04310592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental: Minimal Residual Disease (MRD) positive AML patients; Cyclophosphamide + Fludarabine + CYNK-001. On Days 0, 7, and 14, (and 21 in certain arms) CYNK-001 at 3 varying dose levels.~Experimental: Relapsed/Refractory AML patients; Cyclophosphamide + Fludarabine + CYNK-001. On Days 0, 7, and 14, (and 21 at certain dose levels) CYNK-001 at 3 varying dose levels."||||
33752715|NCT05979909|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752716|NCT05536349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752717|NCT03543930|||CASE_CROSSOVER||PROSPECTIVE|||||||
33752718|NCT06723678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33752719|NCT03663231|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33752720|NCT06031272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752721|NCT00614666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752722|NCT05105594|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33752723|NCT00785655|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
33752724|NCT03452007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752725|NCT03213652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752726|NCT06732921|NA|SINGLE_GROUP||OTHER||NONE||||||
33752727|NCT06724601|||COHORT||PROSPECTIVE|||||||
34065974|NCT03626324|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34065975|NCT02260349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34065976|NCT00607659|||CASE_CONTROL||PROSPECTIVE|||||||
34065977|NCT04976530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867752|NCT06354582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parturients are randomly assigned to either vitamin C(1,2,3) or control. The vitamin C group received 1 g, 2g, and 3g of vitamin C intravenously respectively and the control group received normal saline, administered after the induction of epidural labor anesthesia. There will be 100 cases in each group. The infusion speed will be set at 5ml/min.|t|f|t|f
33867753|NCT05726851|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33867754|NCT03851003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Women will not know which arm they were allocated to|Uterine incision repair will include or exclude suturing of the endometrium|t|f|f|f
34181901|NCT03071588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups of patients, each group received the investigated intervention at baseline and being followed up in parallel for one year.|t|f|f|t
34181902|NCT04931563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind||t|t|t|t
34181903|NCT01598532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181904|NCT03448796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical assessors are blinded when applicable.|Prospective randomized controlled trial.|f|f|f|t
34181905|NCT05488665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181906|NCT03384134|RANDOMIZED|PARALLEL||OTHER||NONE||Following informed consent, participants will be randomized to the intervention or control group using a blocked randomization scheme with block size equal to 4 and stratified by age group, gender and diagnosis. An online program to will be used to derive an assignment. Patients will be randomized at a 1:1 ratio with equal numbers randomized to the intervention and control groups.||||
33867755|NCT02613845|||COHORT||RETROSPECTIVE|||||||
33867756|NCT02224313|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34065978|NCT03609957|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34065979|NCT02803359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34181907|NCT06389955|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34181908|NCT02969746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181909|NCT04536558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34181910|NCT06038539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
34181911|NCT00599014|||COHORT||PROSPECTIVE|||||||
33867757|NCT03672370|||COHORT||PROSPECTIVE|||||||
33867758|NCT00123071|||COHORT||PROSPECTIVE|||||||
33867759|NCT00403676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867760|NCT03975920|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this RCT, it is not feasible to blind patients, surgeons, or dental assistants to treatment after the intervention assignments have occurred, so they will not be blinded. It is, however, feasible to mask the sequence of treatment assignments until the moment each assignment is made, and this will be done, as described in Section 5.4.1, above.|In this two-arm parallel randomized clinical trial (RCT) design, 294 patients undergoing 3rd molar extractions with moderate/deep sedation or general anesthesia will be randomly allocated to Usual Care (UC) or Experimental Care (EC). The study intervention for EC is use of the Restful Jaw version 2 (RJ2) device, which supports the jaw during the extractions, with concurrent use of a bite block. The study control is UC, which involves the dental assistant supporting the jaw during the extractions with concurrent use of a bite block.|f|f|t|f
33867761|NCT02663271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867762|NCT01910376|||CASE_CONTROL||PROSPECTIVE|||||||
33867763|NCT03687645|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33867764|NCT01087099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867765|NCT02198339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964677|NCT05771116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent observer who will be blind to the group assignment checked the intraoperative and postoperative data also patient will be be blinded also||t|f|t|f
33964678|NCT02219295|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33964679|NCT00868582|||OTHER||PROSPECTIVE|||||||
33964680|NCT01862718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964681|NCT03985033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Split-mouth design allowing to assess two types of treatment in the same patient.|f|t|f|t
34181912|NCT00653510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34181913|NCT03962036|||COHORT||PROSPECTIVE|||||||
34181914|NCT03886896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34181915|NCT03075072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181916|NCT04618536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181917|NCT06566989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181918|NCT00759213|||COHORT||PROSPECTIVE|||||||
34181919|NCT02749838|||CASE_ONLY||PROSPECTIVE|||||||
34181920|NCT01318915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181921|NCT03429699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181922|NCT06025773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964682|NCT03403920|||CASE_ONLY||PROSPECTIVE|||||||
33964683|NCT03513978|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33964684|NCT05860790|||COHORT||PROSPECTIVE|||||||
33964685|NCT01757236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964686|NCT00379184|||COHORT||CROSS_SECTIONAL|||||||
34065980|NCT00435188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867766|NCT02522676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867767|NCT00940381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867768|NCT04993534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964687|NCT01674179|||CASE_CONTROL||RETROSPECTIVE|||||||
34065981|NCT03590990|||COHORT||CROSS_SECTIONAL|||||||
33964688|NCT04858074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Data recorded by computer application remotely. Investigator will not be aware of patient group; the active and placebo medications are alike|Double-blind, placebo-controlled cross-over study|t|f|t|f
33964689|NCT04953481|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33964690|NCT01249391|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964691|NCT06381505|||COHORT||PROSPECTIVE|||||||
33964692|NCT00739687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181923|NCT04618302|||COHORT||PROSPECTIVE|||||||
34181924|NCT06653361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181925|NCT03939689|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study population includes patients with PSMA-avid mCRPC whose disease has progressed despite abiraterone therapy, and are planned for treatment with enzalutamide.||||
34181926|NCT06327269|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34181927|NCT03762057|||COHORT||PROSPECTIVE|||||||
34181928|NCT05848557|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34181929|NCT06023238|||CASE_ONLY||PROSPECTIVE|||||||
34181930|NCT01213563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34181931|NCT03887923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867769|NCT01068197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867770|NCT03366090|||CASE_CONTROL||PROSPECTIVE|||||||
33867771|NCT00571844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181932|NCT00320450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34181933|NCT01694914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34181934|NCT03303963|||COHORT||PROSPECTIVE|||||||
34181935|NCT00368407|||||PROSPECTIVE|||||||
34181936|NCT01040910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34181937|NCT06094478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study is a multicenter, prospective cluster-randomized, controlled study designed to establish the effectiveness of a multi-component DIDO intervention, the HI-SPEED Protocol, to reduce the median DIDO time for acute ischemic stroke (primary outcome) and for hemorrhagic stroke (secondary outcome) and increase the proportion of acute ischemic stroke patients with good functional outcomes after endovascular therapy (secondary outcome), defined as a 3-month modified Rankin Score of 0-2.||||
34181938|NCT02667795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34181939|NCT04646473|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34181940|NCT03140241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34181941|NCT02628288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181942|NCT03510650|||COHORT||PROSPECTIVE|||||||
34181943|NCT01294553|||OTHER||PROSPECTIVE|||||||
34181944|NCT01457703|NON_RANDOMIZED|PARALLEL||||NONE||||||
34181945|NCT00577889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181946|NCT02323217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34181947|NCT02963506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867772|NCT05298189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34065982|NCT01156883|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34181948|NCT00945958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181949|NCT02386475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34181950|NCT00963859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181951|NCT04817163|NA|SEQUENTIAL||TREATMENT||NONE||The stepped care CBT-I (active intervention) is being implemented sequentially in the four participating hospitals over a number of equally spaced time periods of 4 months (wedges), for a total of 5 time points, over a period of 20 months.||||
34181952|NCT04684888|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34181953|NCT02665390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181954|NCT00342810|||COHORT||RETROSPECTIVE|||||||
34181955|NCT05370638|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34181956|NCT00301314|||||RETROSPECTIVE|||||||
34181957|NCT06655506|||COHORT||PROSPECTIVE|||||||
33867773|NCT04126083|NA|SINGLE_GROUP||TREATMENT||NONE|Open label design|Open label design||||
33867774|NCT04559191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867775|NCT01583933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867776|NCT05514704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867777|NCT03469583|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33867778|NCT04537546|NA|SINGLE_GROUP||PREVENTION||NONE||Feasibility study, single arm, interventional and prospective.||||
33867779|NCT04754750|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Total of 72 participants, including 41 men and 31 female, were received the PP1M three months. The stable participants were shifted to PP3M for one year.||||
33867780|NCT05289050|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33867781|NCT00396994|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33867782|NCT03972579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867783|NCT01937936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867784|NCT03275571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893985|NCT01589731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33893986|NCT03586362|||COHORT||PROSPECTIVE|||||||
33893987|NCT02213718|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33752728|NCT06733493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participating Healthcare-professionals can not be fully masked, since they are aware of the new team member in form of a ward psychologist (intervention) or aware that a ward psychologist was employed in another ward (control). Yet they are not aware about key efficacy components of the intervention (as the team integration, mere presence, ...)|"Multi-center study on 3 sites and 8 ICU wards, with cluster-randomization of intervention (n=4) and control wards (n=4).~Data-collection in a mixed design:~* Between-subject factor: Affiliation to intervention or control ICU ward~* Between-subject factor: Affiliation to the group of healthcare professionals, relatives or patients~* Within-subject factor: Time of data collection (baseline or follow-up)~* Healthcare professionals: baseline (first 6 weeks of treatment) and follow-up (last 6 weeks of treatment)~* Relatives: baseline (during treatment of their patient in the ICU and up to 4 weeks after), follow-up (4 months after completing baseline)~* Patients: No baseline data-collection since this would produce a biased sample (only mildly impaired ICU patients), follow-up (4 months after ICU stay)"|t|f|f|f
33752729|NCT01563536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752730|NCT06399614|||COHORT||RETROSPECTIVE|||||||
33752731|NCT05047120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752732|NCT02176551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752733|NCT06579703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator, subject, bedside nurse and provider assessing at the bedside will be blinded. There will be an unblinded personnel for dose preparation.|Randomized to 1 of 2 arms, parallel dosing|t|t|t|t
33752734|NCT06481592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752735|NCT05807074|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752736|NCT06723834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|(Secondary outcome) PTSD Severity and symptoms via blinded clinician rating, employing the Clinician-Administered PTSD Assessment for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM-V (CAPS-5-R, Range 0-80, Lower scores indicate a better outcome)||f|f|f|t
33752737|NCT06313424|||CASE_CONTROL||RETROSPECTIVE|||||||
33752738|NCT00329069|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33752739|NCT03319940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient, investigator, investigative staff, medical monitor and care provider will not be masked for the study.|This is an open-label, ascending, multiple doses, phase 1 study evaluating tarlatamab monotherapy, in combination with anti-PD1 therapy and with additional CRS mitigation strategies in participants with SCLC. The dose exploration phases of the study will estimate the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of tarlatamab either as monotherapy or in combination with pembrolizumab. This will be followed by dose expansion phase to confirm RP2D and to obtain further safety and efficacy data.||||
33752740|NCT05746845|||COHORT||RETROSPECTIVE|||||||
33752741|NCT06191627|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study is a two-armed randomized trial. Patients will be recruited from the cohort already undergoing patch testing at our clinic. Enrolled and consented patients will be randomized in a 1:1 ratio to the legs or back study arm via a predetermined randomization order. Patches will be placed as indicated per each patient case, either on the thighs or back. At the 48-hr time point, patches will be removed. Study coordinators will grade success of testing by noting total patches applied and counting patches with a complete circular indentation, partial indentation, or absent indentation from the Finn chambers. Patients will then complete a survey prior to interpretation of their testing by the physician. The predetermined randomization order and survey data will be stored in the secure PN server.||||
33752742|NCT04050865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867785|NCT04623372|RANDOMIZED|PARALLEL||OTHER||SINGLE|One month after the inclusion a photograph of the scar will be taken. This picture will be evaluated by a blind independent investigator without the presence of the patient.|two parallel groups, in a non-inferiority setting, without any pairing or stratification|f|f|f|t
33867786|NCT02057796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867787|NCT06170320|||OTHER||CROSS_SECTIONAL|||||||
33867788|NCT04420611|||OTHER||PROSPECTIVE|||||||
33867789|NCT02522507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867790|NCT05850754|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Study participants will be randomly assigned to 1 of 2 groups and followed throughout a 4 week intervention period.|t|t|t|f
33867791|NCT02398448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867792|NCT00698932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867793|NCT04603105|||COHORT||PROSPECTIVE|||||||
33867794|NCT05950295|||CASE_ONLY||PROSPECTIVE|||||||
33867795|NCT00884325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867796|NCT05966467|||COHORT||PROSPECTIVE|||||||
33867797|NCT03974399|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33867798|NCT05926154|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33867799|NCT03228355|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33867800|NCT02065167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867801|NCT06303284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867802|NCT00592033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867803|NCT01414699|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33867804|NCT02452281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867805|NCT01247987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867806|NCT02800408|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33867807|NCT06401720|||CASE_CONTROL||PROSPECTIVE|||||||
33867808|NCT00064220||||TREATMENT||NONE||||||
33867809|NCT01468220|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33867810|NCT04791995|||COHORT||PROSPECTIVE|||||||
33867811|NCT05383404|||COHORT||PROSPECTIVE|||||||
34065983|NCT02617134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065984|NCT05110989|||COHORT||OTHER|||||||
33867812|NCT04016831|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||an implementation intervention to explore and address agency preparation needs in order to promote implementation success||||
33893988|NCT01403077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893989|NCT04074486|||COHORT||PROSPECTIVE|||||||
33893990|NCT02792257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752743|NCT06043739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33752744|NCT06732882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752745|NCT01753687|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33752746|NCT06733961|||CASE_CONTROL||PROSPECTIVE|||||||
33752747|NCT02472964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752748|NCT06078904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752749|NCT03814733|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33752750|NCT06732726|||COHORT||PROSPECTIVE|||||||
33752751|NCT06476197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752752|NCT06721026|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Cross-sectional, non-therapeutic, intervention study||||
33752753|NCT06297486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned into one of three cohorts, each receiving the same study treatment.||||
33752754|NCT06723327|||COHORT||PROSPECTIVE|||||||
33752755|NCT06723873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752756|NCT05770479|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessors will be blind to treatment group assignment.|Two group randomized controlled trial|f|f|f|t
33752757|NCT01580072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752758|NCT05509296|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, multicenter, randomized control,non-inferiority clinical study||||
33752759|NCT06085430|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33752760|NCT04739813|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33752761|NCT02948569|NA|SINGLE_GROUP||TREATMENT||NONE|There is only one treatment arm in this study and the subjects are all aware that they are on active treatment. The outcomes assessor will be masked as to which data are from the baseline visit and which are from the follow-up visit. In other words, data will be analyzed in the lab in a blinded fashion as to whether the samples are from before or after treatment.|||||
33752762|NCT01446081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752763|NCT05694741|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Sponsor-open|Placebo-control|f|t|t|f
34181958|NCT03723642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"After obtaining written informed consent from patients/legal guardians the patients will be randomized 1:1 to one of the two surgical techniques. Randomization is carried out using the web-based Randomizer for Clinical Trials program at the Institute of Medical Informatics, Statistics and Documentation at the Medical University of Graz (www.randomizer.at)."|40 patients aged 6-18 years suffering from acute appendicitis are to be included. These are divided into 2 groups. Group 1 (n = 20) with laparoscopic and group 2 (n = 20) with open appendectomy.|t|f|f|f
34181959|NCT02279914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34181960|NCT06586450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181961|NCT05259189|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34181962|NCT00313014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34181963|NCT02567669|||COHORT||PROSPECTIVE|||||||
34181964|NCT05942196|||COHORT||PROSPECTIVE|||||||
34181965|NCT01765283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752764|NCT05566600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752765|NCT01045473|||||PROSPECTIVE|||||||
33752766|NCT04620278|||FAMILY_BASED||PROSPECTIVE|||||||
33752767|NCT06695195|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-Blind Randomized Controlled Trial|The study design will be a double-blind, randomized controlled trial with crossover.|t|t|t|t
33752768|NCT06618547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752769|NCT05974449|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33752770|NCT06348199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752771|NCT06467331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33752772|NCT01889433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752773|NCT06658431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752774|NCT06731985|||COHORT||PROSPECTIVE|||||||
33752775|NCT02506842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752776|NCT05286827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752777|NCT06416800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752778|NCT00100685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752779|NCT04380402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752780|NCT06607302|||COHORT||PROSPECTIVE|||||||
33964693|NCT00752154|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33964694|NCT01017458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964695|NCT03687021|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33964696|NCT01340274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964697|NCT03829033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181966|NCT03271658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The doctor will not be told which intervention was used with the patient. The patient/family are told that they will have one of two ways to see the information about life support, but are blind to which is classified as the study intervention and standard care.|This study includes 1) a randomized controlled trial and 2) an embedded observational qualitative study. The randomized control trial will compare a convenience cohort of participants who receive usual care (approximately n=60 patients or patient/surrogate pairs) to a cohort of participants who receive the intervention (approximately n=60 patients or patient/surrogate pairs).|t|t|f|f
33964698|NCT00956683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964699|NCT00031837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964700|NCT01591031|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33964701|NCT03802188|||COHORT||RETROSPECTIVE|||||||
34181967|NCT01658033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964702|NCT06386471|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Appearance, flavor, and texture of whole grain vs refined bread could not be masked|Randomized, controlled, crossover||||
33964703|NCT01873079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964704|NCT03459833|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Patients with premature ejaculation according to the definition of Fourth International Consultation on Sexual Medicine 2015|t|f|f|f
34181968|NCT04170608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181969|NCT04994288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This includes a 24-week double-blind treatment period, followed by a 28-week open-label treatment period.|"This clinical trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase III ).~Subjects were randomly assigned to once-weekly subcutaneously injected Supaglutide 1mg, 2mg, 3mg and placebo according to a 2:2:2:1 ratio. During the IIb period, after Interim analysis and IDMC confirmed the RP3D high and low doses, subjects were randomly assigned to Supaglutide RP3D high dose, RP3D low dose and placebo group according to a 2:2:1 ratio."|t|f|t|f
34181970|NCT02644655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181971|NCT00183040|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34181972|NCT02261935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34181973|NCT01002339|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34181974|NCT05759702|||COHORT||CROSS_SECTIONAL|||||||
34181975|NCT02621450|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34181976|NCT02633124|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34181977|NCT06326320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181978|NCT02379728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34181979|NCT01679314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181980|NCT02659696|||COHORT||PROSPECTIVE|||||||
34181981|NCT05250284|||COHORT||PROSPECTIVE|||||||
34181982|NCT06276829|||COHORT||CROSS_SECTIONAL|||||||
34181983|NCT04184700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34181984|NCT00071890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181985|NCT06215170|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34181986|NCT03938090|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Single-center, prospective, two-arm, randomized 1:1, crossover study|t|f|t|f
34181987|NCT06205277|||COHORT||RETROSPECTIVE|||||||
33964705|NCT00811265|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964706|NCT00185328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964707|NCT00871728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964708|NCT00357474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964709|NCT00798785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181988|NCT00305188|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34181989|NCT06593808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34181990|NCT04062539|||CASE_CONTROL||PROSPECTIVE|||||||
34181991|NCT03762811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34181992|NCT06655350|||COHORT||RETROSPECTIVE|||||||
33964710|NCT02197754||PARALLEL||PREVENTION||NONE||||||
33964711|NCT01667965|||CASE_ONLY||PROSPECTIVE|||||||
33964712|NCT06394778|||CASE_CONTROL||PROSPECTIVE|||||||
33964713|NCT00597207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964714|NCT01879982|||COHORT||PROSPECTIVE|||||||
34181993|NCT04819607|||COHORT||PROSPECTIVE|||||||
33752781|NCT01791725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752782|NCT06698250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752783|NCT03663868|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752784|NCT04041362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752785|NCT06733376|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33752786|NCT05480150|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752787|NCT06247319|||COHORT||PROSPECTIVE|||||||
33964715|NCT05329090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This trial will be comparative, randomized, double-blind and double-dummy in order to limit performance and evaluation bias.~Neither patients, nor physicians will know the treatments allocated to their patients.~Investigators will be in blind of the leukocyte formula during all study period, from day 1.~Neither patients, nor physicians will know the treatments allocated to their patients.~Investigators will be in blind of the CD19+ count during all study period, from day 15."|"Design of trial :~* Controlled (the comparator is a Placebo)~* Randomised~* Double blind~* Parallel groupe~* With a double layering"|t|f|t|f
34181994|NCT02946658|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34181995|NCT06440434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Randomly allocated to order of night shifts (midnight-4am vs.4am-8am)|A 2 (midnight-4am vs.4am-8am) within factor x 2 (below vs. above median on morningness) between factor experimental design||||
34181996|NCT01123798|||COHORT||PROSPECTIVE|||||||
34181997|NCT04575389|||CASE_CONTROL||RETROSPECTIVE|||||||
34181998|NCT03755310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34181999|NCT06359730|||COHORT||RETROSPECTIVE|||||||
33867813|NCT03700580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The intervention encompassed a topical application on the ulcer bed of the active fraction 0.1% P1G10 dispersed in hydrosoluble vehicle. The control group received hydrogel with the same frequency adopted for P1G10 (Three times per week during 16 weeks). Regardless the intervention prior to each application the ulcer bed was cleaned with 0.9% physiological serum without antiseptic.|t|t|t|t
33867814|NCT01083524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867815|NCT03621865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This pharmacokinectic study is designed as a monocentric, randomized, cross-over, pilot and open clinical trial||||
33867816|NCT00000787||||TREATMENT||||||||
33867817|NCT00173745|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33867818|NCT03975101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators screen patients with similar knee condition to ensure a small difference, and they randomized different numbers of VSELs to the patients.|Three experimental groups were injected with different doses of VSEL, and the control group was injected with platelet-containing serum that dissolved VSEL.|f|f|t|f
33867819|NCT05273476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867820|NCT01898897|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867821|NCT02418780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33867822|NCT00382239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867823|NCT00807326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182000|NCT00815659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182001|NCT06655805|||COHORT||PROSPECTIVE|||||||
34182002|NCT00469599|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182003|NCT06362044|||COHORT||PROSPECTIVE|||||||
34182004|NCT06305728|||COHORT||PROSPECTIVE|||||||
34182005|NCT04949490|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34182006|NCT01101867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182007|NCT05751187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182008|NCT04030507|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34182009|NCT06218797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34182010|NCT01253278|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34182011|NCT05743335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded study|2 age groups will be enrolled in parallel for Phase 1 (18-64 age group and 65+ age group).|t|t|t|t
34182012|NCT01704716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182013|NCT03397069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182014|NCT05438862|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization between early surgical and conventional watchful waiting strategy.||||
34182015|NCT03523988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The medications were prepared by the Kelley-Ross Compounding Group (Seattle, WA) and were identical in appearance. The bottles were labeled as A, B, or C and the identity of the medications were not revealed until after the data analysis was completed."|Patients of the University of Washington Graduate Orthodontics Clinic|t|t|t|f
34182016|NCT02271269|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182017|NCT04617626|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34182018|NCT00231010|||FAMILY_BASED||OTHER|||||||
34182019|NCT03234322|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A pragmatic blinded parallel group superiority cluster randomized controlled trial. Clusters are PCPs (general practitioners, medical practitioners and internists working as general practitioners).|t|f|f|t
34182020|NCT04004741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182021|NCT00848601|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34182022|NCT01008020|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182023|NCT05678881|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182024|NCT05607381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182025|NCT01650909|||||PROSPECTIVE|||||||
34182026|NCT06228170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34182027|NCT00993577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182028|NCT01486407|||CASE_CONTROL||PROSPECTIVE|||||||
34182029|NCT04148300|||OTHER||CROSS_SECTIONAL|||||||
34182030|NCT02046577|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182031|NCT06595134|||COHORT||PROSPECTIVE|||||||
34182032|NCT02946138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182033|NCT04252144|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||Dietary assessment with the use of computer-based food frequency questionnaire will be performed to patients with established diagnosis of gastroesophageal reflux disease in comparison to the representatives of a control group (without the disease).||||
34182034|NCT03310788|||COHORT||PROSPECTIVE|||||||
34182035|NCT00389259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182036|NCT01352793|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182037|NCT04894266|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, exploratory clinical study to assess the patient safety and effect of oral apabetalone for up to 4 weeks in hospitalized subjects with Covid-19 infection. Subjects at each center will be randomized into 2 cohorts to receive SOC plus apabetalone or SOC alone.||||
34182038|NCT03223896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A: max 8 mg/per day naloxone nasal spray~Group B: max 16 mg/per day naloxone nasal spray"||||
33867824|NCT04357873|NA|SINGLE_GROUP||TREATMENT||NONE||6 independent cohorts (head and neck, cervix, lung, anus, vulva, and penis) evaluating the association of pembrolizumab and vorinostat||||
34182039|NCT06655090|||COHORT||PROSPECTIVE|||||||
34182040|NCT01345617|||CASE_CONTROL||PROSPECTIVE|||||||
34182041|NCT01440894|||COHORT||RETROSPECTIVE|||||||
34182042|NCT02826070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182043|NCT06303388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182044|NCT00424710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182045|NCT02293694|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182046|NCT05510388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34182047|NCT05972980|||COHORT||PROSPECTIVE|||||||
34182048|NCT01540552|||CASE_ONLY||RETROSPECTIVE|||||||
34182049|NCT02135432|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34182050|NCT00001614||||TREATMENT||||||||
34182051|NCT05254535|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized trial with a stepped-wedge initiation of the intervention at each site||||
34182052|NCT00783068|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182053|NCT04944797|||COHORT||PROSPECTIVE|||||||
34182054|NCT06653114|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34182055|NCT04906564|||COHORT||PROSPECTIVE|||||||
34182056|NCT06566456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34182057|NCT01213680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182058|NCT05760040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182059|NCT01049022|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34182060|NCT04438265|||COHORT||PROSPECTIVE|||||||
34182061|NCT00614302|||COHORT||PROSPECTIVE|||||||
34182062|NCT02772458|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182063|NCT03161704|||CASE_CONTROL||PROSPECTIVE|||||||
34182064|NCT03763084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182065|NCT00646048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182066|NCT03470610|||COHORT||PROSPECTIVE|||||||
34182067|NCT02578147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182068|NCT02987712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182069|NCT05836506|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182070|NCT00986765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182071|NCT01094119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34182072|NCT02177032|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182073|NCT04199806|NA|SINGLE_GROUP||OTHER||NONE||||||
34182074|NCT05100550|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group is assigned for health education intervention and zinc supplementation, and the comparison group receives only standard antenatal care.||||
34182075|NCT03469037|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34182076|NCT06589076|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182077|NCT04552652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182078|NCT04111380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182079|NCT06029348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study is designed to measure cardiovascular responses to brief (\~4 minute) mental arithmetic task (a psychological challenge) under laboratory conditions. Cardiovascular activity will be measured during (1) a resting period prior to the task (\~5min), then (2) during the task(\~4 min), and then (3) after the task is complete (\~10min) for all study volunteers. Cardiovascular responses will be examine in relation to other study outcome measures.||||
34182080|NCT02353208|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34182081|NCT02466893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182082|NCT02559284|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182083|NCT03525795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182084|NCT01582477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752788|NCT01458197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752789|NCT03328299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752790|NCT02698124|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33752791|NCT03318523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752792|NCT03321396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752793|NCT05496374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752794|NCT00501254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33752795|NCT06141148|||OTHER||CROSS_SECTIONAL|||||||
33752796|NCT03345498|||CASE_ONLY||PROSPECTIVE|||||||
33752797|NCT05945875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752798|NCT06435286|NA|SINGLE_GROUP||SCREENING||NONE||Participants will be enrolled based on criteria for surveillance or screening for esophageal squamous cell carcinoma. They will receive standard-of-care endoscopy and the artificial intelligence mobile high-resolution microendoscopy procedures.||||
33752799|NCT00999258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867825|NCT02991742|||COHORT||PROSPECTIVE|||||||
33867826|NCT02241382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867827|NCT04211636|||COHORT||PROSPECTIVE|||||||
33867828|NCT02267603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867829|NCT01366261|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33867830|NCT04572880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752800|NCT04113122|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||"A study will be performed consisting of two cohorts. Cross-sectional study Testicular cancer survivors treated between 2000 and 2005 or between 2006 and 2012 with cisplatin-combination chemotherapy and were extensively phenotypically mapped within two longitudinal trials will be invited to participate in a single cross-sectional follow-up study visit 5-20 years after chemotherapy.~Longitudinal study~Patients with metastasized testicular cancer who are about to start with cisplatin-combination chemotherapy will be invited. Study participation involves four study visits:~Visit 1: before start of chemotherapy Visit 2: before third cycle of chemotherapy Visit 3: one month after completion of chemotherapy Visit 4: one year after start of chemotherapy~Patients with stage I testicular cancer will serve as control group with three study visits:~Visit 1: at time of orchidectomy Visit 2: one month after orchidectomy Visit 3: one year after orchidectomy"||||
34182085|NCT03740451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be divided randomly into 3 groups, using the website www.random.org.|A randomized clinical trial will be conducted where patients will be divided randomly, through the website www.random.org, in three groups: 2 of them will be the experimental group and the other one will be the control group.|f|f|f|t
33752801|NCT01994954|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33752802|NCT06560931|||OTHER||OTHER|||||||
33752803|NCT03646799|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752804|NCT06723587|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33752805|NCT05978921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The persons in charge of the evaluation of the participants will be unaware of the assignment of the participants.||f|f|f|t
34182086|NCT03817359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||84 patients scheduled for breast cancer surgery were randomly allocated to receive TIVA with propofol and remifentanil separately by two TCI pump (Separate group) or with remifentanil-propofol mixture by single TCI pump (Mix group), all TCI concentration adjustments during operation were based on BIS and ANI monitor.|t|f|f|f
33752806|NCT06724068|||COHORT||RETROSPECTIVE|||||||
33752807|NCT06379919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Microbiology lab assessing cultures are blinded to the assigned irrigation treatment arm throughout the length of the study.|Participants are assigned at the beginning of the study to treatment arm involving 1 of 2 types of irrigation treatment for their surgery. They continue in that arm through the length of the study and complete the same study procedures, as well as same standard of care.|t|f|f|t
33752808|NCT05847933|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33752809|NCT04278287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182087|NCT04349267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182088|NCT02930863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33752810|NCT03042065|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33752811|NCT02071173|NA|SINGLE_GROUP||TREATMENT||NONE||Every subject had access to two study devices and were followed as a single group.||||
33752812|NCT03854071|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients will be selected in each group by the clinical specialist/research team as per the published guidelines and local protocols - Group 1, Group 2, Group 3, Group 4 and Group 5.||||
33752813|NCT04881201|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752814|NCT02301702|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33752815|NCT04538326|NA|SINGLE_GROUP||OTHER||NONE|Participants were told that the purpose of the study was to learn more about what type of exercise they liked. There was no indication that intensity was an outcome measure.|Repeated measures, counter-balanced||||
33752816|NCT06351358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752817|NCT06637371|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33752818|NCT03954782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752819|NCT03227354|||COHORT||PROSPECTIVE|||||||
33752820|NCT05215340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752821|NCT05891002|||CASE_ONLY||PROSPECTIVE|||||||
33867831|NCT03437564|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33867832|NCT03584828|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893991|NCT03716726|RANDOMIZED|PARALLEL||SCREENING||NONE||Pragmatic pilot cluster RCT to examine the implementation of WE CARE as standard of care in two of the four outpatient pediatric hematology clinics.||||
33893992|NCT06656598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893993|NCT00650923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893994|NCT05036278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964716|NCT05839093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33964717|NCT01325129|||COHORT||RETROSPECTIVE|||||||
33964718|NCT00467623|||||PROSPECTIVE|||||||
34182089|NCT02930512|||OTHER||CROSS_SECTIONAL|||||||
34182090|NCT06558643|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Appearance matching of the placebo is not possible; therefore, non-blinded dosing teams will be used to preserve the study blind. IMP labels will state MMV371 or placebo and use a common expiry date. IMP accountability logs will be maintained by unblinding the randomisation schedule and disclosure envelopes will be generated by an unblinded statistician. The unblinded statistician will not be involved in any decisions relating to populations for analysis or study decisions prior to unblinding. Documentation and unblinded files will be stored in a secure location and shared with unblinded staff only using sealed envelopes. Interim PK parameter estimations will be performed using bioanalytical data applied with participant aliases. There may be instances where interim PK data have the potential to be treatment revealing. Every effort will be made by the pharmacokineticist to maintain the study blind by appropriate presentation of data to the study team.|Three cohort, single ascending dose, randomised, double-blinded, placebo-controlled study|t|f|t|f
34182091|NCT02724891|||CASE_CROSSOVER||PROSPECTIVE|||||||
34182092|NCT04077099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182093|NCT04071717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182094|NCT06007950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34182095|NCT06474611|RANDOMIZED|PARALLEL||OTHER||NONE|No masking involved. This is a quality improvement project where patients who have an upcoming Primary Care visit receive an electronic or paper letter notification that they qualify for lung cancer screening and that they should talk to their dr at the upcoming visit.|||||
33893995|NCT00861900|||COHORT||PROSPECTIVE|||||||
33893996|NCT01401569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964719|NCT00812435|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964720|NCT01495169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964721|NCT05742399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|parallel assignment|t|f|t|f
33964722|NCT01255722|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33752822|NCT05594979|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752823|NCT03322605|||CASE_CONTROL||PROSPECTIVE|||||||
33752824|NCT00318357|||COHORT||PROSPECTIVE|||||||
33752825|NCT01297959|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33752826|NCT02200731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33752827|NCT06732375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33752828|NCT02968784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752829|NCT05415813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752830|NCT00319540|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752831|NCT01055821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752832|NCT04914611|||COHORT||PROSPECTIVE|||||||
33752833|NCT05901545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752834|NCT00912548|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33752835|NCT05292625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752836|NCT04526366|||COHORT||OTHER|||||||
33752837|NCT06733389|||COHORT||PROSPECTIVE|||||||
33752838|NCT02899780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752839|NCT02934620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752840|NCT03721939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752841|NCT06579326|||CASE_CONTROL||PROSPECTIVE|||||||
33752842|NCT02763800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752843|NCT06701435|||OTHER||CROSS_SECTIONAL|||||||
33752844|NCT06731907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a multi site, rolling-arm study.|f|f|f|t
33752845|NCT06733831|||OTHER||CROSS_SECTIONAL|||||||
33752846|NCT04331704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752847|NCT04039399|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study PI will be blinded to the intervention until after all plasma samples have been analyzed.||f|f|t|t
33752848|NCT02593994|||COHORT||PROSPECTIVE|||||||
33752849|NCT04884334|||COHORT||PROSPECTIVE|||||||
33752850|NCT04914286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752851|NCT06177158|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|lab technician and statistician will be masked||f|f|f|t
33752852|NCT06550986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752853|NCT04766944|||COHORT||PROSPECTIVE|||||||
33752854|NCT02515279|||COHORT||PROSPECTIVE|||||||
33752855|NCT00609427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33752856|NCT04439292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752857|NCT04217681|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each patients will have a medical consultation and will have to fill-in questionnaires (T0). After, patients will have to participate in a 5-session psycho-education programme. After, the care staff will have a multidisciplinary discussion and will randomize the participants to different treatment groups : self-hypnosis/self-care and music/self-care. Another group will be included but will not be randomized because it includes patients who demand to learn self-hypnosis/self-care (non-malignant and malignant pain). After, participants will receive a 7 months (2 hours session a month) learning program of self-hypnosis/self-care animated by a therapist specialized in hypnosis or music/self-care (identical procedure but the hypnosis is replaced by music) at the end if which they will complete the same questionnaire (T2). A follow-up at 6 (T3) and 12 (T4) months will also be conducted to account for any long term effect.||||
33752858|NCT05584410|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33752859|NCT04672941|||COHORT||PROSPECTIVE|||||||
33752860|NCT03683069|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The screened, eligible hypertensives will enter a two-week single blind placebo washout phase.|Parallel Design|t|f|t|t
33752861|NCT06733987|||COHORT||PROSPECTIVE|||||||
33752862|NCT05982457|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33752863|NCT04573933|||COHORT||RETROSPECTIVE|||||||
33752864|NCT06117280|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33752865|NCT03334292|||COHORT||PROSPECTIVE|||||||
33752866|NCT05112965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752867|NCT05934370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752868|NCT01460550|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33752869|NCT06732973|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33752870|NCT03927950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752871|NCT06682520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization to one of two study arms: Postpartum Standard of Care (Control arm). Postpartum NEST-Rural Program Service model (Experimental arm).||||
33752872|NCT03673306|||COHORT||RETROSPECTIVE|||||||
33752873|NCT02769286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752874|NCT06732466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this clinical trial, masking involves several key roles to ensure unbiased results. The participant and the investigator are masked in this double-blind study. This means that the participants do not know which group they have been assigned to and the investigators conducting the study do not know the group assignments. This comprehensive masking approach is designed to minimize any potential biases and maintain the integrity of the study results.|Phase III, one-center, parallel group, double blind and randomized trial|t|f|t|f
33752875|NCT00024479|||COHORT||PROSPECTIVE|||||||
33752876|NCT01292954|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33752877|NCT02878473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752878|NCT05376891|||OTHER||PROSPECTIVE|||||||
34182096|NCT05163522|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind (sponsor unblinded) study.||t|f|t|f
34182097|NCT00000197||||TREATMENT||||||||
34182098|NCT01108185|||||PROSPECTIVE|||||||
34182099|NCT06430034|||CASE_ONLY||PROSPECTIVE|||||||
34182100|NCT06037902|NA|SINGLE_GROUP||TREATMENT||NONE||all patients undergo two simulations.||||
34182101|NCT04642092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and therapists will know if they are from the control or the experimental group. This study will be blinded only for the evaluators (the ones who will apply the psychological tests). Psychologists with the the role of evaluators will not give any therapy to the participants, and will not know from which group the patients are, neither who gave them the treatment.||t|t|f|f
34182102|NCT06185725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|he patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Modified Perichondral Approach Thoracoabdominal Nerve block (M-TAPA block) group, and Transversus Abdominal Plane Block (TAP block) group|t|f|f|t
34182103|NCT04123197|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34182104|NCT03774576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182105|NCT04143035|||CASE_ONLY||PROSPECTIVE|||||||
34182106|NCT01114698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182107|NCT06323434|||COHORT||PROSPECTIVE|||||||
34182108|NCT05939882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34182109|NCT02080598|RANDOMIZED|CROSSOVER||||||||||
34182110|NCT06325813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34182111|NCT02540629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182112|NCT01149291|||CASE_ONLY||PROSPECTIVE|||||||
34182113|NCT06160843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182114|NCT00622050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182115|NCT02660151|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182116|NCT05132907|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34182117|NCT02817646|||CASE_ONLY||RETROSPECTIVE|||||||
34182118|NCT03607890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182119|NCT00312429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182120|NCT03543644|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34182121|NCT03544684|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34182122|NCT04960202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants with a confirmed diagnosis of SARS-CoV-2 infection will be randomized (1:1) to receive PF-07321332/ritonavir or placebo orally every 12 hours for 5 days (10 doses total).|t|t|t|t
34182123|NCT00133783|||DEFINED_POPULATION||OTHER|||||||
34182124|NCT01334177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182125|NCT01619280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182126|NCT05324267|||CASE_ONLY||CROSS_SECTIONAL|||||||
34182127|NCT00414596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182128|NCT03561480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182129|NCT03054246|NA|SINGLE_GROUP||OTHER||NONE||Healthy volunteers||||
34182130|NCT05125354|||CASE_ONLY||RETROSPECTIVE|||||||
34182131|NCT05258344|||OTHER||PROSPECTIVE|||||||
34182132|NCT00904605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182133|NCT03645720|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33752879|NCT00587327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752880|NCT06706960|||CASE_ONLY||CROSS_SECTIONAL|||||||
33752881|NCT04293146|RANDOMIZED|PARALLEL||OTHER||SINGLE|blinded outcome assessment for aesthetic results|The study will objectively assess the results and complication of two surgical techniques and thus provide evidence to assess whether there are differences between these techniques.|f|f|f|t
33893997|NCT04278131|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33893998|NCT02757495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33893999|NCT05124275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894000|NCT02188095|||COHORT||PROSPECTIVE|||||||
33894001|NCT06169215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894002|NCT03468608|||OTHER||PROSPECTIVE|||||||
33894003|NCT02665689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Observer-masking (assessment of BCVA, macular thickness, capillary drop-out) is done to guard against detection bias.||f|f|f|t
33964723|NCT00013182|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33964724|NCT04449640|||COHORT||RETROSPECTIVE|||||||
33964725|NCT00323388|||OTHER||OTHER|||||||
33964726|NCT05443217|||COHORT||PROSPECTIVE|||||||
33964727|NCT02131337|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33964728|NCT03153059|||CASE_CONTROL||PROSPECTIVE|||||||
33964729|NCT00481273|||COHORT||PROSPECTIVE|||||||
33964730|NCT03708861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964731|NCT05233800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33964732|NCT03787173|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33964733|NCT00659854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182134|NCT02902458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182135|NCT00006445|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182136|NCT02277938|||CASE_ONLY||RETROSPECTIVE|||||||
34182137|NCT04291469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182138|NCT04313244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182139|NCT04190641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A non-randomized confirmatory study||||
33964734|NCT04128696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind study.|This will be a randomized, parallel group treatment study with eligible participants receiving GSK3359609 plus pembrolizumab or placebo plus pembrolizumab.|t|f|t|f
34182140|NCT03772158|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Blinding of the test and reference products to study subjects is not feasible, because the products are different dosage forms (chewable tablets and IR tablets) and administered in different ways (with or without water and fasted or fed). Personnel conducting the bioanalyses of samples will not know the treatment sequence. The randomization code will not be available to them until the analytical tables have been finalized and audited by the Algorithme Pharma (An Altasciences Company) Quality Assurance (QA) department.|"This is a randomized, single-dose, four-treatment crossover bioequivalence and food effect study of Cetirizine Chewable Tablets versus ZYRTEC® Immediate Release (IR) Tablets (US reference) and REACTINE® IR Tablets (EU and Australian marketed reference product).~The study will be conducted in two parts. Part 1 of the study will have a randomized, four way crossover study design in which 40 healthy subjects, ages 18 to 55 years, will be randomized to four sequences of Treatments A, B, D and E over consecutive periods. No less than approximately 40% of either gender will be represented in the study population. Part 2 of the study will assess a potential food effect in which all subjects will be administered Treatment C in the fifth period."|f|f|f|t
34182141|NCT06592586|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182142|NCT05310240|||COHORT||CROSS_SECTIONAL|||||||
34182143|NCT02251314|||OTHER||PROSPECTIVE|||||||
34182144|NCT05855811|RANDOMIZED|PARALLEL||PREVENTION||NONE||Analysis will be performed according the ITT principe and will include all randomized patients. Incidence of events by arm will be compared assuming a Poisson distribution. Cumulative incidence curves against time will we compared between treatment arms. Follow-up of each patient will be calculated from randomisation to death or last follow-up for alive patients.||||
34182145|NCT04935710|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34182146|NCT02937116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182147|NCT05132023|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34182148|NCT02734875|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34182149|NCT03829540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182150|NCT01062958|||CASE_CONTROL||RETROSPECTIVE|||||||
34182151|NCT05266989|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34182152|NCT03613441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182153|NCT03915197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|no masking|||||
34182154|NCT00000817|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34182155|NCT00069472|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34182156|NCT06655857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182157|NCT03585881|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34182158|NCT01417806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182159|NCT02200302|||COHORT||PROSPECTIVE|||||||
34182160|NCT06651905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964735|NCT01799642|||CASE_CONTROL|||||||||
33964736|NCT03614871|||COHORT||RETROSPECTIVE|||||||
33964737|NCT00280501|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33964738|NCT06229522|||COHORT||PROSPECTIVE|||||||
33964739|NCT01019005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33964740|NCT04004273|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomised control trial. Participants are randomised to an exercise group (treatment) or a control group (usual care/no treatment) for 6 weeks. Assessments occur at baseline and after 6 weeks||||
33867833|NCT04063241|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||"Parents:~Phase A (Pre-implementation): Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized). Phase A was completed as an observational study.~Phase B (Implementation): Provider training (see below) Phase C (Post-implementation): Doctors and nurses will customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions.~Providers:~Pediatric residents knowledge, attitudes, and practices will be assessed at baseline. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. Assessments will be performed for those who use the health literacy-informed tool at least once during the study period."|f|f|f|t
34182161|NCT02464540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182162|NCT06602622|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomized, clinical trial. Individuals who meet the inclusion criteria will be randomized to maintain their integrase inhibitor regimen (BIC/TAF/FTC, DTG/ABC/3TC or DTG+TDF/FTC) or to DOR/TDF/3TC.||||
34182163|NCT02322632|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182164|NCT05094362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182165|NCT02426021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182166|NCT06519604|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This study was open for subjects, sponsor and investigators except for analytical laboratory.|two-way crossover||||
34182167|NCT02481674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182168|NCT01487798|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182169|NCT03898739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients with cervical radiculopathy, caused by cervical paramedian disc protrusion at C5-C6 or C6-C7 levels will participate in the study. They will be assigned randomly into three equal groups; A, B and C.|One independent variable with many levels.|t|f|f|t
34182170|NCT04042064|||COHORT||PROSPECTIVE|||||||
34182171|NCT00260871|||CASE_CONTROL||PROSPECTIVE|||||||
34182172|NCT04013009|||OTHER||OTHER|||||||
34182173|NCT06590415|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182174|NCT03063177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants won't know the SMT dosage they are assigned to.||t|f|f|f
34182175|NCT02972437|||COHORT||PROSPECTIVE|||||||
34182176|NCT01723878|||COHORT||PROSPECTIVE|||||||
34182177|NCT00966134|||COHORT||PROSPECTIVE|||||||
34182178|NCT03269825|||COHORT||RETROSPECTIVE|||||||
34182179|NCT03123731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182180|NCT02888600|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34182181|NCT01546610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182182|NCT02906748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34182183|NCT00458263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867834|NCT03558165|||COHORT||PROSPECTIVE|||||||
34182184|NCT01407432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182185|NCT02842619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182186|NCT01698333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182187|NCT01107054|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182188|NCT05039086|||COHORT||RETROSPECTIVE|||||||
34182189|NCT02581813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182190|NCT00034502||||TREATMENT||||||||
34182191|NCT03135600|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34182192|NCT04668456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"75 Patients were assigned into three equal groups, all patients received 2.5 ml of local anesthetic mixture through subtenon block and IV infusion of drugs as follows: Group C (control group): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.~Group SD ( subtenon dexmedetomidine): received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ 0.5 μg/kg dexmedetomidine (0.5 ml) and IV infusion of saline 0.9% over 10 min. before subtenon block.~Group ID (iv dexmedetomidine): received received subtenon LA mixture of bupivacaine 0.5% (1 ml) + lidocaine 2% (1 ml)+ saline 0.9% (0.5 ml) and IV infusion of 0.5 μg/kg dexmedetomidine over 10 min. before subtenon block."|t|t|f|f
34182193|NCT03096288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled||t|t|t|t
34182194|NCT02087761|||CASE_ONLY||PROSPECTIVE|||||||
34182195|NCT06491277|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964741|NCT06171217|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The original cohort will continue treatment per planned protocol schedule of evaluations, and a new cohort will join with consent, a 3-month screening period, and treatment per planned protocol schedule of evaluations.||||
34182196|NCT02435992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182197|NCT06654427|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The OBTIC toolkit will be used in an obstetrics clinic for a 9 month period. Baseline will be evaluated 3 months pre-implementation trial and follow-up will be measured 3 months post-implementation trial.||||
34182198|NCT02324101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182199|NCT00628667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34182200|NCT04557891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182201|NCT00961285|||||PROSPECTIVE|||||||
33867835|NCT04204863|||COHORT||RETROSPECTIVE|||||||
33867836|NCT00774280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867837|NCT00533143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33867838|NCT01163812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065985|NCT04701489|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||The participants will be randomized to two groups: ultrasound group and control group. All participants will still receive standard clinical care. The ultrasound group will receive daily ultrasound application to the spleen for up to 7 days, in addition to the standard clinical care. The control group will receive standard clinical care without ultrasound stimulation.||||
34065986|NCT02385110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182202|NCT03044106|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Subjects and assessors were blinded to treatment allocation. The subject was face down, eyes closed, and wearing protective eyewear that blocks the specific wavelength of the laser light during the intervention.~After each treatment session, the participants completed a de-blinding questionnaire administrated by the assessor providing a dichotomous 'yes' or 'no' answer as to whether active treatment was received. This response was followed by a second question regarding how certain they were that active treatment was received on a 0-10 numeric rating scale (NRS), where 0 represents absolutely uncertain and 10 represents absolutely certain."|Subjects who meet the inclusion criteria and give consent were randomized to one of the following for the first treatment period: 1) active CLRT; or 2) sham laser. At the first intervention visit, the research assistant entered the subject's assigned identification into an online computer program (selected by study biostatistician) to determine assignment to one of the two periods. The study biostatistician used computer-generated random numbers to generate the allocation sequence using random blocks of random sizes. A one-week washout period minimized carryover effects.|t|f|f|t
33752882|NCT06733844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752883|NCT06258109|||CASE_CONTROL||RETROSPECTIVE|||||||
33840689|NCT05259423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be aware of their group assignment as all families will receive education about nine play activities. Sealed envelopes created prior to enrollment will conceal assignments (i.e., appropriate educational materials) and the next envelope for the correct block \[Block 1: typical development (TD), low SES; Block 2: TD, mid-high SES; Block 3 developmental delay (DD), low SES; Block 4: DD, mid-high SES\] will be handed to families by the blind assessor at in-person visits or emailed to virtual participants by a team member not engaged in the blind assessments.|Participants will be assigned to receive the Enriched Education Program (EEP) or the Typical Education Program (TEP).|f|f|t|t
33867839|NCT03228472|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will undergo a cerebral pacing program listed below and differentiated according to the type of symptom presented. All conventional therapies taken by patients will be recorded by the operators. Patients will be divided into Stimulation and Sham (control) groups and will be evaluated at zero time before starting treatment (T-0W) after 6 weeks to evaluate the effects at the end of treatment (T-6W) and at 12 weeks (T-12W) to evaluate the maintenance of long-term effects. Randomization will be balanced in accordance with age, sex and schooling.||||
33867840|NCT04013789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33867841|NCT00814671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182203|NCT02194335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34065987|NCT00602446|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34065988|NCT02159885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065989|NCT04262960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34182204|NCT04337645|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Two treatment modalities will be applied. Test group will be treated bu resective approach combined with implantoplastry, whilst control group will be treated by resective approach alone. Randomization will be performed by means of randomisation envelopes.||||
34182205|NCT00912808|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34182206|NCT00017576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182207|NCT03848728|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized trial||||
34182208|NCT05200403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182209|NCT01532596|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34182210|NCT03428984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182211|NCT00859196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34182212|NCT03346538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182213|NCT04962763|||CASE_CONTROL||OTHER|||||||
34182214|NCT06375967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182215|NCT06654635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182216|NCT05990010|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182217|NCT03788213|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, controlled, open-label, two arm, multicenter, randomized controlled trial with two parallel groups||||
34182218|NCT03406312|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182219|NCT02161016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182220|NCT02733016|||COHORT||PROSPECTIVE|||||||
34182221|NCT04244292|NA|SINGLE_GROUP||OTHER||NONE||||||
34182222|NCT05023642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers who will perform both pre and post-test evaluations, as well as data analysis, will be blinded regarding randomization. Blinding will be ensured by asking investigators at the end of the trial if investigators knew the arm to which each subject will be allocated prior to opening the envelope.||f|f|t|t
34182223|NCT04428853|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34182224|NCT05609292|||CASE_CROSSOVER||PROSPECTIVE|||||||
34182225|NCT02303496|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34182226|NCT06533787|||COHORT||PROSPECTIVE|||||||
34182227|NCT03298334|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34182228|NCT05557188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34182229|NCT01028820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182230|NCT04013477|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182231|NCT04181658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182232|NCT06139120|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182233|NCT04050735|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34182234|NCT06239675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34182235|NCT05562895|||CASE_ONLY||PROSPECTIVE|||||||
34182236|NCT00568022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182237|NCT01341353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182238|NCT00000393|NON_RANDOMIZED|||TREATMENT||NONE||||||
34182239|NCT03469414|||CASE_ONLY||CROSS_SECTIONAL|||||||
34182240|NCT03860649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind (Investigator, Outcomes Assessor)||f|f|t|t
34182241|NCT06310031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182242|NCT06592937|||COHORT||RETROSPECTIVE|||||||
34182243|NCT04870047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182244|NCT03773224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182245|NCT03839160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182246|NCT02405078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182247|NCT06042205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182248|NCT03697252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182249|NCT00799786|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34182250|NCT06587997|||OTHER||PROSPECTIVE|||||||
34182251|NCT01696110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182252|NCT05442853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182253|NCT00224575|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182254|NCT05494385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182255|NCT06071078|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|The evaluation will be carried out centrally for all the subjects included, 90 days after the announcement to the emergency room, by a psychologist, trained in the data collection interview, on the telephone, without the knowledge of the group (training provided or not to caregivers).|Stepped-wedge trial|f|f|f|t
34182256|NCT06274645|||COHORT||PROSPECTIVE|||||||
34182257|NCT03208010|RANDOMIZED|PARALLEL||PREVENTION||NONE|Given the nature of behavioral programs, we are not able to mask participant involvement. Some primary care providers may not know the details of their patients' participation in the study.|"The study involves an examination of the effectiveness of a culturally-tailored diabetes prevention intervention using a randomized, repeated measures, pretest/post-test control group design. Groups are randomly assigned to: 1) the diabetes prevention intervention; or 2) an enhanced usual care control group. Outcome measurements are made at 3, 6, 12, 24, and 36 months post entry into the study to examine changes over time in key diabetes and health indicators."||||
34182258|NCT02768857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182259|NCT00267059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182260|NCT03586492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182261|NCT05050318|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182262|NCT05133388|||CASE_CONTROL||RETROSPECTIVE|||||||
34182263|NCT06651840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182264|NCT04318353|||COHORT||PROSPECTIVE|||||||
34182265|NCT06033326|||COHORT||PROSPECTIVE|||||||
34182266|NCT03415685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned to one of two treatments group depending on the dermatologic condition to be treated.||||
33964742|NCT02505711|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34182267|NCT05099952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182268|NCT02643914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182269|NCT01703234|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34182270|NCT02864784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182271|NCT03505502|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients were randomized to three groups, each compromised of thirty-five patients according to a three-blocked randomization list which was coded (1 or 2 or 3) at 1:1:1 ratio. The three parallel groups were prepared using a Computer-generated randomization system. The allocated groups will be concealed in serially numbered sealed opaque envelopes that will only be opened after recruitment. The patient allocation will be performed prior to the induction of anesthesia by an independent person, who will not otherwise be involved in this study. The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used.|a double-blinded randomized placebo-controlled trial|t|t|t|t
34182272|NCT02876432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34182273|NCT02033395|||COHORT||PROSPECTIVE|||||||
34182274|NCT01392339|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34182275|NCT03371069|||COHORT||RETROSPECTIVE|||||||
33964743|NCT00059514|||OTHER||CROSS_SECTIONAL|||||||
33964744|NCT00344630|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33964745|NCT00190554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964746|NCT05793788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel-arm randomized control trial|t|t|f|f
33964747|NCT03390634|||COHORT||RETROSPECTIVE|||||||
33964748|NCT04804982|||COHORT||PROSPECTIVE|||||||
33964749|NCT00579254|||COHORT||PROSPECTIVE|||||||
34182276|NCT01281514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182277|NCT04467203|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182278|NCT06586710|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33867842|NCT01274663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33867843|NCT03034031|||COHORT||PROSPECTIVE|||||||
34065990|NCT05699785|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33867844|NCT03521050|||COHORT||OTHER|||||||
33964750|NCT04718857|||OTHER||PROSPECTIVE|||||||
33964751|NCT05052515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964752|NCT00003054||||TREATMENT||||||||
33964753|NCT02409537|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33867845|NCT00655954|||OTHER||PROSPECTIVE|||||||
33964754|NCT05674994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34065991|NCT03813641|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34065992|NCT03500926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|implant|randomized 1/1 comparison|t|f|f|f
34065993|NCT02323737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34065994|NCT01851980|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34065995|NCT05788107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34065996|NCT04008485|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34065997|NCT00538954|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34065998|NCT04933617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34065999|NCT06386900|||COHORT||PROSPECTIVE|||||||
34066000|NCT01080274|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066001|NCT02748733|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34066002|NCT03972020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34066003|NCT01733823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066004|NCT05173285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34066005|NCT05262790|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066006|NCT04575584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066007|NCT03681041|||COHORT||PROSPECTIVE|||||||
34066008|NCT01325571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066009|NCT03433859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066010|NCT03429283|||OTHER||RETROSPECTIVE|||||||
33867846|NCT05242757|NA|SINGLE_GROUP||OTHER||NONE||||||
33867847|NCT02717884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867848|NCT04497116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation, expansion and phase 2||||
33867849|NCT06397755|||COHORT||OTHER|||||||
33867850|NCT02996188|||COHORT||PROSPECTIVE|||||||
33867851|NCT04296877|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, non-comparative study.||||
33867852|NCT00890149|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33867853|NCT02768233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33867854|NCT00573209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867855|NCT03959124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867856|NCT06273007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867857|NCT04922463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867858|NCT00602095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867859|NCT01617590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867860|NCT00319280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867861|NCT03337360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicentre, randomised double blind placebo controlled clinical trial/superiority study.|t|t|t|f
33867862|NCT03193645|||COHORT||PROSPECTIVE|||||||
33867863|NCT00121784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964755|NCT02964897|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33964756|NCT01340365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33964757|NCT00685022|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33964758|NCT02270931|||COHORT||PROSPECTIVE|||||||
33867864|NCT04223843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867865|NCT04047550|||OTHER||PROSPECTIVE|||||||
33867866|NCT03965936|RANDOMIZED|PARALLEL||TREATMENT||NONE||split face||||
33867867|NCT05092919|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33867868|NCT00474708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867869|NCT00309465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964759|NCT02100527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964760|NCT01890785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33964761|NCT03373266|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34066011|NCT00824707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066012|NCT06432946|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will undergo two interventions consecutively, with the order of evaluation randomized.||||
34066013|NCT01262924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34066014|NCT00282386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34066015|NCT01202552|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34066016|NCT00618124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066017|NCT05391945|||COHORT||PROSPECTIVE|||||||
34066018|NCT01353612|||OTHER||PROSPECTIVE|||||||
34066019|NCT03787199|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"Feasibility study, including a comparison between Andago and treadmill walking conditions (as we include a heterogeneous group of participants concerning age (children/adolescents), diagnosis, walking ability, etc., we include in this feasibility study 20 participants - rather than the usual 10).~Patients participate in 3 appointments (planned within 10 days):~Appointment 1 (60 min): patient characteristics, clinical tests (Selective Control Assessment of the Lower Extremity / Manual Muscle Testing / 10 meter walk test or 10MWT); practising on treadmill and in Andago; questions to participants~Appointment 2 (45 min): determine accuracy of the unloading system; practicing on treadmill and in Andago; questions to participant~Appointment 3 (60-90 min): 10MWT at onset and end; measurement of stride length, leg muscle EMG and joint kinematics during walking on treadmill with bodyweight unloading and walking overground with Andago with 3 levels of bodyweight unloading"||||
34066020|NCT06307509|||CASE_ONLY||PROSPECTIVE|||||||
33867870|NCT03629236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840690|NCT00872755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33840691|NCT06068751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840692|NCT06161207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840693|NCT04883359|||OTHER||CROSS_SECTIONAL|||||||
33840694|NCT00970762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867871|NCT00468520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867872|NCT03592966|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, cross-over, double-blind, placebo-controlled study.|t|f|t|f
33867873|NCT01841463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867874|NCT05672511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33867875|NCT05260853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867876|NCT02607683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840695|NCT03599687|||CASE_CROSSOVER||PROSPECTIVE|||||||
33840696|NCT03901001|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized trial into either oseltamivir and adjunctive sirolimus or oseltamivir alone||||
33840697|NCT03097731|||CASE_CROSSOVER||PROSPECTIVE|||||||
33867877|NCT02596802|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33867878|NCT04415957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization sequence was computer-generated and implemented by an investigator not involved in recruitment, assessment, or treatment. Concealment allocation was assured by placing the randomization in opaque envelopes sequentially numbered. An envelope for every participant was opened in sequential order after baseline assessments. The participants and physical therapists who performed the intervention could not be blinded due to the nature of the intervention. However, all the outcomes and statistical assessors were blinded to group allocation and previous test results.||f|f|t|t
33867879|NCT03969849|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33867880|NCT00446524|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867881|NCT05534906|||COHORT||CROSS_SECTIONAL|||||||
33867882|NCT06457295|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867883|NCT04355741|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867884|NCT03221738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867885|NCT04668053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752884|NCT06002165|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study design for the clinical trial component of the ACHIEVE initiative is a hybrid type III, multiple baseline design. Study team members will recruit and collect data from up to 20 outpatient clinics that serve pregnant patients. The clinic staff and providers will receive the intervention (a set of tailored implementation strategies) to increase their capacity to deliver timely care to patients with severe hypertension. The participating clinics will receive the intervention in three consecutive and overlapping cohorts. The first cohort, outpatient prenatal care clinics in Orange and Alamance Counties, will receive the intervention in Months 7-18 of the study. The second cohort, clinics in Durham County, will receive the intervention in Months 13-24, six months after Cohort 1 begins. The third cohort, clinics in Durham and Wake Counties, will receive the intervention in Months 19-30, twelve months after Cohort 1 begins.||||
33964762|NCT00056082|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33964763|NCT03744806|||CASE_CONTROL||RETROSPECTIVE|||||||
34182279|NCT05698550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182280|NCT03843814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182281|NCT06064721|RANDOMIZED|PARALLEL||PREVENTION||NONE||Buerger-Allen exercise and Routine care||||
33752885|NCT04330638|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33752886|NCT06574009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Data analyst will be masked.|||||
33752887|NCT01536132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752888|NCT01643590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752889|NCT04436068|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752890|NCT03716908|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752891|NCT05169515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752892|NCT03535337|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Multiple Assignment Randomized Trial||||
33752893|NCT06579742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33752894|NCT06721091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33752895|NCT05755308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752896|NCT01860703|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33752897|NCT01432548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840698|NCT02774811|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840699|NCT00773331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964764|NCT04799470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964765|NCT05798871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964766|NCT00003299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964767|NCT00924183|||CASE_ONLY||PROSPECTIVE|||||||
33964768|NCT05580549|||COHORT||CROSS_SECTIONAL|||||||
33964769|NCT02498899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33964770|NCT00296452|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33964771|NCT04068571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33964772|NCT03779100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066021|NCT00520754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182282|NCT03113461|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||CPAP intervention|f|f|f|t
34182283|NCT04443361|||OTHER||PROSPECTIVE|||||||
34182284|NCT02372188|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182285|NCT01334450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34182286|NCT05681182|NA|SINGLE_GROUP||PREVENTION||NONE||Patients undergoing isolated cardiac arterial bypass surgery or isolated valve surgery, via complete median sternotomy||||
34182287|NCT04762602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33964773|NCT03412019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"There will be two arms of this randomized controlled trial as follows:~* Control group: baseline hemodynamics and anxiety screen; no music~* Intervention group - Mozart: A study investigator will turn on a playlist of pre-selected Mozart music."||||
33964774|NCT00786019|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34066022|NCT02897180|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066023|NCT06360770|||COHORT||PROSPECTIVE|||||||
34182288|NCT05993858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182289|NCT06587087|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34182290|NCT02170571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182291|NCT05690802|NA|SINGLE_GROUP||TREATMENT||NONE||Palonosetron hydrochloride capsules||||
34182292|NCT05147363|||CASE_ONLY||PROSPECTIVE|||||||
34182293|NCT04684836|||COHORT||RETROSPECTIVE|||||||
34182294|NCT05663606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective, randomized, controlled study||||
34182295|NCT04363970|||OTHER||PROSPECTIVE|||||||
34182296|NCT01373840|||CASE_CONTROL||PROSPECTIVE|||||||
34182297|NCT06593119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||60 patients total (30 in the TM-HTN intervention group, 30 in the control group).||||
34182298|NCT04664686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182299|NCT00003469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182300|NCT01831388|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34182301|NCT00941096|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34182302|NCT04488614|||CASE_ONLY||PROSPECTIVE|||||||
34182303|NCT04893369|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participating patients will be blinded to their therapist's allocation. Outcomes assessor will be blinded to the participants' allocation since data will be coded.|Two-arm nonrandomized pragmatic cluster clinical trial|t|f|f|t
34182304|NCT02536053|||COHORT||PROSPECTIVE|||||||
33964775|NCT00802633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964776|NCT06515340|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33964777|NCT03503019|||COHORT||PROSPECTIVE|||||||
33964778|NCT02359734|||||PROSPECTIVE|||||||
33964779|NCT03608410|RANDOMIZED|PARALLEL||OTHER||NONE||"The randomization will be done by the AmbuFlex-system (a generic on-line system for self-recorded patient reported outcomes) as a part of the inclusion process.~A text message reminder is sent weekly for patients in the intervention group by the system.~Quality of Life questionnaires will automatically be sent via a safe internet connection to participants in both groups every 2 months."||||
33964780|NCT05459051|||COHORT||PROSPECTIVE|||||||
33964781|NCT02521831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964782|NCT00192088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964783|NCT02586688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964784|NCT06432205|||CASE_CONTROL||PROSPECTIVE|||||||
33964785|NCT00736099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964786|NCT01788059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066024|NCT03131700|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34066025|NCT03229317|||COHORT||PROSPECTIVE|||||||
34066026|NCT00511485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752898|NCT06087341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm A: systemic transduced donor-derived NKG2D-CAR memory T cells infusion. Arm B: dual treatment, with both systemic and locally transduced donor-derived NKG2D-CAR memory T cells infusion.||||
33752899|NCT05227261|||COHORT||PROSPECTIVE|||||||
33752900|NCT02567084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752901|NCT04733287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects assigned to the heat therapy and the sham heat therapy will not know if they are truly receiving the heat therapy or not. The muscle heater (shortwave diathermy) will be placed on the muscle during each visit, but, unbeknownst to the heat and sham group, will not be turned on for the sham group.|"Young (18-35 years) and Older (60+ years) will be randomly assigned to one of 3 different conditions (High Intensity Exercise Training of the Knee Extensors, Heat therapy of the Knee Extensors or Sham Heat therapy of the Knee Extensors). Muscle function will be measured before and after 6 weeks of the randomized treatment.~A separate set of 40 young adults (18-35 years) will undergo 2 weeks of leg immobilization. Half of the subjects will receive daily heat therapy, while the other half will receive a sham heat therapy treatment. Muscle function and critical power will be measured before and after immobilization for both groups"|t|f|f|f
33752902|NCT02478411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752903|NCT06732128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752904|NCT05737082|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33752905|NCT00626028|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33752906|NCT06648915|||COHORT||PROSPECTIVE|||||||
33752907|NCT03598270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Atezolizumab and placebo treatment will be double blinded, unknown to both the subject and the study staff, including the treating physician. In order to maintain the blind, atezolizumab and placebo will be identical in appearance and packaging.~The study medication will be labeled using a unique kit id number, which is linked to the randomization scheme. The active and placebo kits will be presented in the same packaging to ensure blinding of the study medication Individual treatment codes, indicating the treatment randomization for each randomized patient, will be available to the investigator(s) or pharmacists from the IVRS/IWRS. Routines for this will be described in the Interactive Voice Response System/Interactive Web Response System (IVRS/IWRS) user manual that will be provided to each centre."|Randomized, double-blinded, multi-center study|t|t|t|f
33752908|NCT01938612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752909|NCT05047250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752910|NCT05188469|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752911|NCT00254202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752912|NCT02184793|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33752913|NCT00713440|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33752914|NCT05438927|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066027|NCT06511271|RANDOMIZED|PARALLEL||OTHER||SINGLE||Patients in the study group underwent progressive relaxation exercises at the 2nd, 6th, 12th and 24th hours after surgery|f|f|f|t
34066028|NCT04886245|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34066029|NCT06403904|||CASE_CONTROL||RETROSPECTIVE|||||||
34066030|NCT04375098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066031|NCT01200277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182305|NCT04225897|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"This is a multicentre, 3-part study to evaluate safety, tolerability, PK, PD, and antiviral effect of single and multiple dosing of RV521 in infants hospitalised due to RSV LRTI. Due to the adaptive study design, the number of enrolled subjects may vary depending on the obtained PK and safety profiles.~The clinical study consists of 3 parts:~* Part A is an open-label, multicentre, single dose study in infants hospitalised with RSV LRTI (Cohorts 1 \& 2)~* Part B is a randomised, double-blind, placebo-controlled, multicentre multiple dose study in infants hospitalised with RSV LRTI (Cohorts 3, 4 \& 5)~* Part C is a randomised 1:1, double-blind, placebo-controlled, multicentre, multiple-dose study in infants hospitalised with RSV LRTI"|t|t|t|f
34182306|NCT05922917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182307|NCT01047358|||CASE_ONLY||PROSPECTIVE|||||||
34182308|NCT03430284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182309|NCT03651479|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
34182310|NCT02153086|||COHORT||PROSPECTIVE|||||||
34182311|NCT02678026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182312|NCT06112808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182313|NCT00400465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34182314|NCT03787511|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182315|NCT01353898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182316|NCT02007096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34182317|NCT04985123|||COHORT||PROSPECTIVE|||||||
34182318|NCT03390946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182319|NCT06530446|||OTHER||CROSS_SECTIONAL|||||||
34182320|NCT02490098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182321|NCT05964582|||OTHER||PROSPECTIVE|||||||
34182322|NCT06026917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182323|NCT03711513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182324|NCT00321620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34182325|NCT01857817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182326|NCT02726568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182327|NCT00066157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182328|NCT01615120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182329|NCT04442295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182330|NCT04434937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182331|NCT01300754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182332|NCT01697917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182333|NCT01967940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part 1 Sentinel Cohort: Open-label, non-randomized Part 1 Randomized Cohort: Double-blind, randomized Part 2: Open-label, non-randomized|Part 1 (Sentinel Cohort followed by a Randomized Cohort), 14-day washout period, then Part 2|t|f|t|f
34182334|NCT06527950|||COHORT||CROSS_SECTIONAL|||||||
34182335|NCT06499064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182336|NCT03021785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066032|NCT04229199|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|data collectors were unaware of participants groups.|randomized controlled trial|f|f|f|t
34066033|NCT01296737|||CASE_ONLY||PROSPECTIVE|||||||
34182337|NCT00518778|||COHORT||RETROSPECTIVE|||||||
34182338|NCT00436696|||CASE_ONLY||CROSS_SECTIONAL|||||||
33752915|NCT06723275|||COHORT||PROSPECTIVE|||||||
34066034|NCT04837105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre-test and post-test evaluation are made by one physiotherapist ignoring the patient's arm.|randomized control trial - 2 groups|f|f|f|t
34066035|NCT05329727|||COHORT||RETROSPECTIVE|||||||
34066036|NCT00006110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066037|NCT06333782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Participants would be randomized on two groups: Genefill Contour or comparator (Desirial Plus) at a ratio 1:1|t|f|f|f
34066038|NCT01210352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066039|NCT00590538|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34066040|NCT00944307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34066041|NCT02824588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066042|NCT06135116|||COHORT||CROSS_SECTIONAL|||||||
34066043|NCT04988113|||OTHER||RETROSPECTIVE|||||||
34066044|NCT00401427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182339|NCT02633514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182340|NCT06595563|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33752916|NCT06733298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752917|NCT03640208|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33752918|NCT06577714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the data manager and biostatistician will retain the master list that identifies the randomization allocation and be unblinded. The Data Safety and Monitoring Board and all those who contact patients, the steering PIs, and advisory committee will be blinded.||t|t|t|t
33752919|NCT06695897|||COHORT||PROSPECTIVE|||||||
33752920|NCT04919213|||CASE_ONLY||CROSS_SECTIONAL|||||||
33752921|NCT00095225||||TREATMENT||||||||
33752922|NCT04185805|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33752923|NCT06280196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double-blind, randomized|t|t|t|f
33752924|NCT03752216|NA|SINGLE_GROUP||TREATMENT||NONE|Open|||||
33752925|NCT06729021|||COHORT||PROSPECTIVE|||||||
34066045|NCT01340443|||COHORT||PROSPECTIVE|||||||
34066046|NCT00940641|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34066047|NCT00882128|||COHORT||CROSS_SECTIONAL|||||||
34066048|NCT01082393|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34182341|NCT05236582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182342|NCT01389596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182343|NCT00043862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182344|NCT04587284|||COHORT||RETROSPECTIVE|||||||
34182345|NCT04081103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182346|NCT05313555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182347|NCT03656289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34182348|NCT00959855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182349|NCT01872416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182350|NCT02933749|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34182351|NCT06654544|||OTHER||CROSS_SECTIONAL|||||||
34182352|NCT06590233|||CASE_CONTROL||RETROSPECTIVE|||||||
34182353|NCT00196482|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34182354|NCT02547818|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34182355|NCT01962506|||COHORT||PROSPECTIVE|||||||
34182356|NCT01476111|||COHORT||PROSPECTIVE|||||||
34182357|NCT05793853|||COHORT||PROSPECTIVE|||||||
34182358|NCT02354898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182359|NCT03784586|||CASE_CONTROL||PROSPECTIVE|||||||
34182360|NCT03410706|||COHORT||PROSPECTIVE|||||||
34182361|NCT06233136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||t|f|f|f
34182362|NCT02233777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182363|NCT00565188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182364|NCT03483857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two arm study assessing to determine feasibility and acceptability of a pilot PN intervention among 100 HIV-positive MSM. We will explore associations between PN participation and continuum of care outcomes in a cohort of 55 HIV-positive MSM receiving PN, as compared to a cohort of 48 HIV-positive MSM receiving standard-of-care clinical referral, in preparation for a full-scale multi-site behavioral efficacy trial.||||
34182365|NCT06184776|||OTHER||CROSS_SECTIONAL|||||||
34182366|NCT05182593|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The randomization was done by employees of the hospital that were otherwise not involved in the study by drawing concealed envelops. The interventions were meal boxes which looked similar.|Randomized, Double-blind, Cross-over Trial|t|f|t|f
34182367|NCT05761782|||OTHER||OTHER|||||||
34182368|NCT02066181|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182369|NCT05577507|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A total of 80 patients will be recruited and divided into 2 groups: -~Group 1: (cholestyramine 12 gram), 40 patients will take a dose of cholestyramine 4-gram sachet three times daily with standard therapy(Calcimate).~Group 2: Control group, 40 patients will take only the standard therapy (Calcimate).~Time of the trial will be two months (8 weeks trial period)"||||
34182370|NCT03969212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182371|NCT02729532|||COHORT||PROSPECTIVE|||||||
34182372|NCT02826317|||COHORT||PROSPECTIVE|||||||
34182373|NCT03184168|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open-label, radiolabeled, single-dose study of an oral solution of \[14C\]lorlatinib (100 mg/100 µCi) in 6 healthy male volunteers. Confinement from Day -1 through Day 14 (or until 1 of 2 early release criteria is met). No returns; one follow-up phone call (at 28 to 35 days post dose).||||
34182374|NCT04330118|||CASE_CONTROL||PROSPECTIVE|||||||
34182375|NCT00023777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182376|NCT00459316|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182377|NCT06609577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182378|NCT02891499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34182379|NCT00710697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182380|NCT05442957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34182381|NCT01458392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182382|NCT01526863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182383|NCT06597578|||COHORT||PROSPECTIVE|||||||
34182384|NCT06049849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All products are individual coded. All other visible characters are identical.|This study is a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. All patients with chronic stroke will participate in the live-in observational study by sleeping on Tesla MedBed in a special hotel.|t|t|t|t
34182385|NCT01113086|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34182386|NCT06011187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded and a data monitoring willbe done on data|Stepped wedge cluster randomized controlled trial|f|f|f|t
34182387|NCT06201026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182388|NCT01928212|||CASE_CONTROL||RETROSPECTIVE|||||||
34182389|NCT03141827|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182390|NCT00791505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182391|NCT03621475|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34182392|NCT00224640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182393|NCT03516630|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Subjects and the investigator administering the study products and collecting the data are blinded with respect to Trazodone and placebo treatments, and open with respect to moxifloxacin treatment. Trazodone and placebo final solutions for administration is prepared by an independent Pharmacist under open conditions.||t|f|t|f
34182394|NCT01639378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752926|NCT05985538|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752927|NCT03691116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752928|NCT05750459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867886|NCT04006340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867887|NCT03560999|||COHORT||PROSPECTIVE|||||||
34182395|NCT05795036|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will be randomly assigned to either the intervention group or the control group|||||
34182396|NCT05183360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182397|NCT05917197|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34182398|NCT05670886|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182399|NCT05373459|||COHORT||RETROSPECTIVE|||||||
34182400|NCT02835287|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182401|NCT00269217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182402|NCT06498076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A total of 126 parturienst are randomly divided into two equal groups by an investigator not directly linked to the study.~Groupe N : patients will received norepinephrine boluses (8 µg) ; prophylactic bolus immediately after spinal anesthesia induction and therapeutic boluses when systolic blood pressure falls to ≤ 20% of baseline. Groupe E : parturients will received ephedrine boluses (6 mg) ; systematic bolus after the induction of spinal anesthesia and therapeutic boluses if hypotention.~The syringes will be labeled as syringe A and syringe B and the anesthesiologist who will give the bolus cannot know if it is ephedrine or norepinephrine."|"Groupe N : parturients will received norepinephrine boluses (8 µg) ; prophylactic bolus immediately after spinal anesthesia induction and therapeutic boluses when systolic blood pressure falls to ≤ 20% of baseline.~Groupe E : parturients will received ephedrine boluses (6 mg) ; systematic bolus after the induction of spinal anesthesia and therapeutic boluses if hypotention."|t|t|f|t
34182403|NCT03963817|||CASE_ONLY||CROSS_SECTIONAL|||||||
34182404|NCT00445042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182405|NCT05318586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182406|NCT03238378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182407|NCT00669734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182408|NCT06061926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized double-blind|Double-blind, controlled clinical trial|t|f|t|f
34182409|NCT01184963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182410|NCT05969496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182411|NCT03959514|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34182412|NCT04907409|||COHORT||PROSPECTIVE|||||||
34182413|NCT05367466|||COHORT||RETROSPECTIVE|||||||
34182414|NCT05893784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34182415|NCT02939911|||COHORT||PROSPECTIVE|||||||
34182416|NCT06071247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182417|NCT05940220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34182418|NCT03213691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182419|NCT05717153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The patient, principal investigator, and all members of the research team involved in sample collection will be blinded to each patient's assignment until after the catheter has been placed.||t|t|t|f
34182420|NCT03182049|||COHORT||PROSPECTIVE|||||||
34182421|NCT00863278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182422|NCT03594630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182423|NCT01198795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182424|NCT04002232|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The placebo and the CPP-ACP-NaF varnishes will be supplied by the manufacturer labeled as either A or B. The blinding code is provided in a sealed envelop should there be a need to unblind the experiments.|Split mouth|t|t|t|t
34182425|NCT01446055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182426|NCT01322945|||COHORT||PROSPECTIVE|||||||
34182427|NCT05299307|||CASE_CONTROL||PROSPECTIVE|||||||
34182428|NCT02900378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182429|NCT03251495|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34182430|NCT06654453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182431|NCT05596032|||COHORT||PROSPECTIVE|||||||
34182432|NCT03694353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182433|NCT04551547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34182434|NCT06053502|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33752929|NCT04867837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded||t|f|t|f
33752930|NCT06684496|||COHORT||PROSPECTIVE|||||||
33752931|NCT05274074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752932|NCT03624465|NA|SINGLE_GROUP||OTHER||NONE||||||
33752933|NCT04526795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752934|NCT06575140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33752935|NCT03248102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33752936|NCT03048851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33752937|NCT06496490|NA|PARALLEL||TREATMENT||NONE||||||
33867888|NCT03111485|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33867889|NCT05187052|||OTHER||PROSPECTIVE|||||||
33867890|NCT00578110|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867891|NCT05988268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The control group will receive a routine warm-up protocol. Outcome measurement will be performed by an investigator who was blinded to group allocation|Three groups as follows: Vibration Foam Rolling Group, Non-Vibration Foam Rolling Group, and Control Group|t|f|f|t
33867892|NCT02931136|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33867893|NCT04952103|||COHORT||PROSPECTIVE|||||||
33867894|NCT04660526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33867895|NCT00867633|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867896|NCT01547585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33867897|NCT04169087|||COHORT||PROSPECTIVE|||||||
33867898|NCT01550861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867899|NCT05206409|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867900|NCT04410588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34182435|NCT03779295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The investigators will not remind the participant or other investigators which side of the face received laser therapy, however the investigators cannot completely blind either the participant or other investigators as they will be awake or performing the therapy, respectively."|This will be a split face prospective trial. The face will be treated in halves. The halves will be randomized to receive topical clindamycin or PDL therapy and clindamycin. Both halves of the face will be treated with topical clindamycin. Per randomization, half of the face will be treated with pulse dye laser therapy at 595 nm, using 6.5 J/cm2, 10 mm spot size and a 6 millisecond pulse width.|t|f|f|f
34182436|NCT05816889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867901|NCT04883320|||OTHER||PROSPECTIVE|||||||
33964787|NCT03803085|RANDOMIZED|PARALLEL||PREVENTION||NONE||A total of 60 adults were recruited and randomly assigned to either the control condition (n=30) or the treatment condition (n=30). The 60 participants completed the study in one of three subgroups, with 20 participants randomly assigned to two groups (10 in the treatment group and 10 in the control group). Both conditions will use the WeChat App for use on a smartphone. The control group used the WeRun program to count their own steps. The treatment condition used the WeRun to engage in social contact and compare their steps with others in the group.||||
33964788|NCT00263796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964789|NCT05772234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33964790|NCT01660490|||CASE_ONLY||RETROSPECTIVE|||||||
33964791|NCT00895583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964792|NCT03319303|||COHORT||PROSPECTIVE|||||||
33964793|NCT06530043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182437|NCT01419964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182438|NCT05935124|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||randomized crossover study|t|f|f|f
34182439|NCT04226599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182440|NCT05471323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182441|NCT01970293|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34182442|NCT06245343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.|Parallel Assignment|t|f|t|t
34182443|NCT02485873|||COHORT||RETROSPECTIVE|||||||
34182444|NCT06598709|||COHORT||PROSPECTIVE|||||||
34182445|NCT06595862|NA|SINGLE_GROUP||OTHER||NONE||This is a single group open pilot trial, in order to test the usability of the EA-Avatar digital intervention and feasibility of the research protocols of the EA-Avatar intervention.||||
34182446|NCT03351725|||COHORT||PROSPECTIVE|||||||
34182447|NCT03354195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"During surgery, the ACL will be inspected, manually stressed and probed following standard techniques to assess its structure and function.(20, 21) The state of the ACL will be recorded and classified into one of four categories per these intra-operative examinations (22) and available pre-operative MRI data:~Group 1 - intact ACL ligament~Group 2 - intact but fibrillated (frayed) ligament)~Group 3 - nearly completely torn ligament (\>50% and disrupted)~Assessment will be performed by the PI. Knees with ACLs classified as Group 1 and Group 2 will be accepted as functionally intact. Those classified as Group 3 will be deemed as having functionally absent ACLs"||||
34182448|NCT06594679|NA|SINGLE_GROUP||OTHER||NONE||||||
34182449|NCT03473054|||CASE_ONLY||PROSPECTIVE|||||||
34182450|NCT00551408|||CASE_CONTROL||PROSPECTIVE|||||||
34182451|NCT02336152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182452|NCT04744246|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34182453|NCT01203202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182454|NCT00949169|||CASE_ONLY||CROSS_SECTIONAL|||||||
33867902|NCT02047136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33867903|NCT04981314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatments \& placebos are coded. The code will not be revealed to investigators until the end of the study.|Double blind, placebo controlled, randomised.|t|t|t|f
33867904|NCT02132884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867905|NCT04825795|||COHORT||RETROSPECTIVE|||||||
33867906|NCT04570501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867907|NCT06343506|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867908|NCT03420794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964794|NCT06536920|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33964795|NCT01258816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964796|NCT01460121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964797|NCT01453920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964798|NCT02496221|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33867909|NCT04613154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Closed envelope randomisation.||t|t|t|t
33867910|NCT01247415|||CASE_CONTROL||RETROSPECTIVE|||||||
33867911|NCT06070077|||CASE_CROSSOVER||OTHER|||||||
33867912|NCT00280306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867913|NCT04765475|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The Research Program Assistants (responsible for collecting assessments) will be blinded to participant status as they will be functioning as independent evaluators.|Study investigators will employ a 2x2 factorial design to evaluate the relative merits of a brief culturally-tailored motivational interviewing (MI) intervention and an m-health intervention (COVID-19 daily symptom text messaging system-CS) among two high-risk and inter-related age groups-young adults and elders-on preventive behaviors, promoting rapid COVID-19 testing after symptom onset, and isolation and appropriate care-seeking among those who test positive.|f|f|t|f
33867914|NCT05105555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867915|NCT03819881|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind|"Patients will be randomized into two arms in three sequential age-descending cohorts:~Part 1: 18-40 years of age Part 2: 12-17 years of age Part 3: 2-11 years of age"|t|t|t|t
33867916|NCT03289936|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33867917|NCT02844920|||COHORT||PROSPECTIVE|||||||
33867918|NCT01377025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33867919|NCT04541979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867920|NCT00713479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33867921|NCT06051032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients diagnosed with arteriovenous fistula (AVF) thrombosis and eligible for endovascular treatment, based on predefined inclusion and exclusion criteria, will be enrolled in this study. They will be randomly assigned to receive either balloon thrombectomy or thromboaspiration systems.|t|t|f|f
33867922|NCT04455061|||CASE_CONTROL||PROSPECTIVE|||||||
33867923|NCT05781230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were block-randomized based on intensity of exercises. The randomization sequence was produced by an external investigator using a computer-generated randomization sequence (Microsoft Excel, Microsoft, Redmond, WA, USA) to generate either a 0 or 1, corresponding with high intensity exercises or low intensity exercises, respectively||t|f|f|f
33867924|NCT00003936||||TREATMENT||||||||
33867925|NCT02933099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182455|NCT00103896|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34182456|NCT01607710|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182457|NCT06346418|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34182458|NCT04318873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182459|NCT06497270|NA|SINGLE_GROUP||PREVENTION||NONE||PILOT study||||
34182460|NCT06164184|||CASE_ONLY||RETROSPECTIVE|||||||
34182461|NCT05414409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The investigators will examine the differences in the gut microbiome between lean and obese youth with type 1 diabetes and then enroll the obese youth with type 1 diabetes into the clinical trial to receive metformin as an intervention.||||
34182462|NCT05621434|NA|SINGLE_GROUP||TREATMENT||NONE||single arm study||||
34182463|NCT06599541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182464|NCT01851642|||CASE_CONTROL||PROSPECTIVE|||||||
34182465|NCT02713893|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34182466|NCT00192985|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34182467|NCT01599637|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34182468|NCT02936596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182469|NCT04672668|||CASE_CONTROL||PROSPECTIVE|||||||
33752938|NCT06308380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752939|NCT04611503|NA|SEQUENTIAL||TREATMENT||NONE||||||
33867926|NCT00528515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33894004|NCT05425771|NA|SEQUENTIAL||TREATMENT||NONE||Pilot study of mucosal ablation for therapy refractory reflux disease||||
33894005|NCT00783627|||CASE_CONTROL||PROSPECTIVE|||||||
33752940|NCT06732869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894006|NCT04636918|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894007|NCT03214835|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33894008|NCT02495779|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894009|NCT05811312|||COHORT||OTHER|||||||
33894010|NCT02993237|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33894011|NCT04641286|||COHORT||PROSPECTIVE|||||||
34066049|NCT01330199|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182470|NCT01271946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182471|NCT05893745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182472|NCT04119414|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34182473|NCT06294106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|eTMS coil will have an 'active' and 'sham' side and the application will look identical to the participant. The technician will not know which side of the coil is which and will additionally be blinded.|10 participants will receive eTMS treatment 10 participants will receive sham eTMS treatment|t|f|t|f
34182474|NCT05116852|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182475|NCT01403532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182476|NCT05902247|NA|SINGLE_GROUP||TREATMENT||NONE||A clinical prospective, single-center, single-arm, phase I dose escalation therapy study.||||
34182477|NCT01312532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182478|NCT05740072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33867927|NCT04961268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To blind the experiment, each of the 50 patients in each group was randomly allocated a code consists of 2 letters and one number. Only the random numbers identified the medications; thus, the patient and doctor were uninformed of which medication was given to them.|The study included five study groups, each consists of 50 patients who exhibited symptomatic irreversible pulpitis of a mandibular first or second molar. The patients received identically appearing capsules containing either tramadol 50 mg, tramadol 100 mg, ibuprofen 600 mg, ibuprofen 600 mg/acetaminophen 1000 mg or placebo by mouth 60 min before the administration of an IANB. Endodontic access was begun 15 min after completion of the IANB, and all patients used for data analysis had profound lip numbness. The IANB success was defined as no or mild pain (visual analog scale recordings) on pulpal access or instrumentation.|t|f|t|f
33867928|NCT00924105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867929|NCT04641299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867930|NCT01003210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33964799|NCT01946282|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33964800|NCT02856815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182479|NCT04336774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182480|NCT00025688|RANDOMIZED|||TREATMENT||||||||
34182481|NCT03256461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This trial is a prospective, multicenter, single-blind, parallel-group, central-randomized, controlled trial|t|f|f|t
34182482|NCT04498832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Modified double-blind: the participant and the Investigator remain unaware of the treatment assignments throughout the study. An unblinded qualified trial staff member will administer the appropriate vaccine but will not be involved in the immunogenicity and safety evaluations.|Participants randomized in each group were stratified by site and age (60 to 64, 65 to 74, and 75 years of age and older).|t|t|t|t
34182483|NCT04934540|||COHORT||PROSPECTIVE|||||||
34182484|NCT04301960|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Study||||
34182485|NCT03606902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|• double blinded randomized controlled study.|double blinded randomized controlled study|t|t|t|t
34182486|NCT05506124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182487|NCT02628912|||COHORT||PROSPECTIVE|||||||
34182488|NCT01302652|||CASE_CONTROL||PROSPECTIVE|||||||
34182489|NCT01134185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182490|NCT02158442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182491|NCT04883008|||COHORT||PROSPECTIVE|||||||
34182492|NCT03352102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182493|NCT06589973|||COHORT||OTHER|||||||
34182494|NCT03329157|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group design.||||
34182495|NCT03834545|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34182496|NCT06310876|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34182497|NCT01081652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182498|NCT04178668|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182499|NCT04336553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182500|NCT03747861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182501|NCT06654583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182502|NCT00888134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182503|NCT04824924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182504|NCT01314313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182505|NCT02667093|||CASE_CONTROL||PROSPECTIVE|||||||
34182506|NCT01712477|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182507|NCT04169217|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34182508|NCT02310698|||COHORT||PROSPECTIVE|||||||
34182509|NCT01723384|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182510|NCT00873483|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34182511|NCT05739721|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34182512|NCT05405803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182513|NCT02032732|||COHORT||PROSPECTIVE|||||||
34182514|NCT04689607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182515|NCT02004093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182516|NCT03315663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open Label|This Pivotal Study will be a multicenter, parallel group, open-label randomized controlled trial with a planned period of 12-month follow-up with the primary effectiveness endpoint assessed at 6 months to compare Sweetch's mHealth Personalized Intervention Program (PIP) to usual care for adults with prediabetes. We intend to enroll 155 subjects in each arm, for a total of 310 subjects in this Study. Subjects will attend a total of 3 visits during the study period with point-of-care measurement of A1C at each study visit (0, 6, and 12 months). A difference in change in A1c of 0.1 between the intervention and control arms and in favor of the intervention arm will be considered clinically meaningful.||||
34182517|NCT03771924|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182518|NCT03524976|||COHORT||PROSPECTIVE|||||||
34182519|NCT03968393|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, randomized, open-label clinical trial with blinded outcome assessment|f|f|f|t
33752941|NCT00114010|RANDOMIZED|||TREATMENT||SINGLE||||||
33752942|NCT00336674|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33752943|NCT00717860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33752944|NCT05491148|||CASE_CONTROL||PROSPECTIVE|||||||
33752945|NCT01568671|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33752946|NCT03605095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33752947|NCT01505023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33752948|NCT02578238|||CASE_ONLY||PROSPECTIVE|||||||
34182520|NCT01815970|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34182521|NCT02858622|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182522|NCT06173102|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||randomization sequence will be created using Microsoft Excel 2022 with a 1:1 allocation using random block sizes of 2 and|f|f|f|t
33752949|NCT03260166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752950|NCT05008666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752951|NCT01869010|||CASE_CONTROL||PROSPECTIVE|||||||
33752952|NCT02524392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33752953|NCT03115983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, prospective, concurrently controlled, non-blinded study. Balance between groups will be achieved through sub classification using propensity scores. Prospective patient sample supplemented with retrospective and/or historical control subjects.||||
33752954|NCT06732388|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participants as well as the study team will be blinded to the study drug assignment. The study endoscopist will be blinded to the treatment group to avoid bias. Will ensure that the laboratory personnel running the assays are blinded to the allocation.||t|f|t|t
33752955|NCT05747196|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"The study protocol indicates that subjects signing consent will be enrolled; however, the number of subjects treated with the investigational device will be less due to screening for inclusion / exclusion criteria."||||
33752956|NCT04014920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33752957|NCT06226246|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752958|NCT01421576|RANDOMIZED|CROSSOVER||||NONE||||||
33752959|NCT00142493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182523|NCT00785785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182524|NCT05962060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182525|NCT01099722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182526|NCT06463808|||COHORT||PROSPECTIVE|||||||
34182527|NCT02545088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182528|NCT03217071|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182529|NCT05077202|||COHORT||PROSPECTIVE|||||||
34182530|NCT02643212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182531|NCT05765916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This study is a two-armed RCT with a 1:1 allocation ratio: (1) an online mindfulness and acceptance therapy-based intervention; and (2) treat as usual.|t|f|f|t
34182532|NCT03013270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182533|NCT02147639|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34182534|NCT01510483|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34182535|NCT04616456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182536|NCT00602017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182537|NCT01986426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182538|NCT01777386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182539|NCT01808456|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34182540|NCT00637975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182541|NCT01578486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182542|NCT04871126|||COHORT||RETROSPECTIVE|||||||
34182543|NCT03281798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182544|NCT04950647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182545|NCT06516380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182546|NCT04166422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34182547|NCT00188344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182548|NCT01100619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182549|NCT04698369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not know the vibration intensity they receive. The care provider will be blinded on the vibration intensity as well. The outcome assessor will be blinded on which group the participants are.|"Subjects will be randomized using a computer-generated random table in four blocks of four (four different vibration intensities) to equalize the group numbers across the study period.~The four vibration intensities are: 60 Hz 0.2 mm, 60 Hz 2 mm, 120 Hz 0.2 mm, and 120 Hz 2mm."|t|t|f|t
34182550|NCT05026593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182551|NCT03719079|||COHORT||PROSPECTIVE|||||||
34182552|NCT06392477|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182553|NCT03824249|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34182554|NCT00155636|||DEFINED_POPULATION||OTHER|||||||
34182555|NCT02057250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182556|NCT02700906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182557|NCT05647317|NA|SINGLE_GROUP||OTHER||NONE||Single arm study||||
34182558|NCT02815501|||COHORT||PROSPECTIVE|||||||
34182559|NCT03413488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182560|NCT01595542|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182561|NCT02904278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182562|NCT00855881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182563|NCT03397810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182564|NCT01349244|||CASE_ONLY||PROSPECTIVE|||||||
34182565|NCT01574469|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34182566|NCT04889638|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-post study design||||
34182567|NCT00437229|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182568|NCT03340675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each individual bottle is labelled with a unique numeric code that identifies the contents to the unblinded sponsor representative.|Randomized, placebo-controlled, double-blind, dose-ranging|t|t|t|t
34182569|NCT01434212|||COHORT||PROSPECTIVE|||||||
34182570|NCT04235608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"At each participating center, patients will be followed up for primary and secondary endpoints by members of the research staff who will be unaware of the trial group allocation. Information on whether the primary and secondary outcomes occur will be collected and entered into the electronic web-based case report form (eCRF) by trial or clinical trained personal (clinical research associate), blinded to the allocation group, under the supervision of the local principal investigator (PI) or designee who will also be unaware of the trial group allocation.~Finally, the independent trial statistician and the members of the data monitoring and safety committee (DMSC) will also remain blinded for the allocation during analysis. However, the observation of differences in serious adverse events between the two groups will allow, for safety reasons may the DMSC deem necessary, to unblind allocation groups."|Investigator-initiated, multicenter, prospective, randomized, stratified, parallel-group clinical trial with blinded outcome assessment and concealed allocation of patients with moderate-to-severe ARDS to a strategy of inhaled sedation with sevoflurane or to a strategy of current intravenous sedation practice using propofol.|f|f|f|t
34182571|NCT02106598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182572|NCT05114954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182573|NCT03755778|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||3-Part Single Group study||||
34182574|NCT00897494|||CASE_ONLY||PROSPECTIVE|||||||
34182575|NCT02061488|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34182576|NCT06044779|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33752960|NCT01311674|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33752961|NCT05003349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33752962|NCT02125201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33840700|NCT02113683|||CASE_ONLY||PROSPECTIVE|||||||
33840701|NCT00387426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840702|NCT00143104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840703|NCT00478751|||COHORT||PROSPECTIVE|||||||
33840704|NCT03026959|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33840705|NCT05025592|||COHORT||PROSPECTIVE|||||||
33840706|NCT03312413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840707|NCT02217215|||COHORT||RETROSPECTIVE|||||||
33840708|NCT04862442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The assessors will be blind to the group allocation. The investigators will be blind to the outcomes.|"A total of 30 volunteer research subjects will be selected in an age range of 18 to 65, who categorized as inactive (\<600 metabolic equivalent-min/hf) with respect to International Activity Readiness Survey. Groups will be randomized as Group A (n=15) and Group B (n=15)."|f|f|t|t
33840709|NCT06178263|||OTHER||PROSPECTIVE|||||||
33840710|NCT02049645|||COHORT||PROSPECTIVE|||||||
33840711|NCT06462664|||CASE_ONLY||PROSPECTIVE|||||||
33840712|NCT03856983|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840713|NCT03156192|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
33840714|NCT01869504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840715|NCT03137043|||CASE_CONTROL||PROSPECTIVE|||||||
33840716|NCT05952726|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Crossover randomisation of different levels of expiratory cycling during randomised levels of pressure support ventilation in critically ill patients undergoing assisted mechanical ventilation.||||
33752963|NCT06732934|RANDOMIZED|PARALLEL||OTHER||SINGLE||"In this study, a parallel group design is used, where participants are randomly assigned to one of three independent groups:~Basic Body Awareness Therapy Group Aerobic Exercise Group Control Group Each group receives a different intervention (body awareness therapy, aerobic exercise, or no intervention for the control group) and is observed over the study period. The study aims to compare the effects of body awareness therapy and aerobic exercise on telomere length in young individuals. The control group serves to assess the natural variation in telomere length without any intervention. This design allows for a clear comparison of the outcomes between the different groups, ensuring that any observed effects can be attributed to the specific intervention each group received.~In summary, each group follows its own intervention pathway independently, and the results from each group are analyzed to understand the impact on telomere length."|f|f|f|t
33752964|NCT03826160|||COHORT||PROSPECTIVE|||||||
33752965|NCT00850473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867931|NCT04857996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be double masked, so patients and Investigators are masked to the treatment assigned, while certain roles at the site and at the Sponsor are unmasked. Sites will have a qualified injector who is unmasked to perform the study treatment injection or sham procedure, as well as certain post-injection assessments on Day 1 only.||t|f|t|f
34182577|NCT04613648|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867932|NCT04787445|||COHORT||PROSPECTIVE|||||||
33867933|NCT02372916|||CASE_CONTROL||PROSPECTIVE|||||||
33867934|NCT03685383|RANDOMIZED|PARALLEL||TREATMENT||NONE||two-groups (treatment vs. control), pseudo-randomized, monocentric, nonblinded||||
33867935|NCT02443896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867936|NCT06238674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182578|NCT00131079|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34182579|NCT04046913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182580|NCT04240535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182581|NCT02620202|||COHORT||CROSS_SECTIONAL|||||||
34182582|NCT00842335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182583|NCT04114760|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34182584|NCT06409546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes||t|f|t|f
34182585|NCT02686749|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study randomizes subjects to already FDA approved treatment modalities. Approved anti-arrhythmic medications or AF ablation. There are no investigational drug or devices used.||||
34182586|NCT01238068|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182587|NCT04254458|||CASE_CONTROL||PROSPECTIVE|||||||
33867937|NCT00470054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182588|NCT00761995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182589|NCT04757168|NA|SINGLE_GROUP||OTHER||NONE||||||
34182590|NCT05468996|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34182591|NCT03160443|NA|SINGLE_GROUP||OTHER||NONE||||||
34182592|NCT04942821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182593|NCT03693924|||COHORT||RETROSPECTIVE|||||||
34182594|NCT00491634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182595|NCT02936804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182596|NCT01614886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182597|NCT01435382|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34182598|NCT00879502|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182599|NCT06655129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182600|NCT01660048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182601|NCT03426891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182602|NCT05784493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34182603|NCT04393454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182604|NCT01181063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182605|NCT06526039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182606|NCT00914316|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34182607|NCT00057720|RANDOMIZED|||TREATMENT||NONE||||||
33867938|NCT02895620|NA|SINGLE_GROUP||||NONE||||||
33867939|NCT05515705|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182608|NCT03678493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182609|NCT04418648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867940|NCT01945502|||CASE_CONTROL||PROSPECTIVE|||||||
33867941|NCT04315194|||CASE_CONTROL||PROSPECTIVE|||||||
33867942|NCT04263064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor and patient blinded to the medications in the block that the patient receives.|Prospective, randomized, observer blinded study will attempt to determine if there is any benefit to the addition of clonidine to a HVLC caudal block, both in duration of analgesia and occurrence of emergence agitation.|t|f|f|t
33867943|NCT05046847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867944|NCT02198443|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33867945|NCT01194713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33867946|NCT03208764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867947|NCT00311376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867948|NCT03428022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867949|NCT01555567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867950|NCT01058070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867951|NCT01021787|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34182610|NCT01063751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182611|NCT05338346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182612|NCT05379374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Anaesthetic technician will prepare the study drug~* Anaesthesiologist who is blind to the study drug will perform UG TAP block and collect data intra and post-operatively.~* Patient will also be blind about the drug administered."|"After obtaining written informed consent from a total of 40 patients fulfilling inclusion criteria will be enrolled. A 40 envelopes with number indicating the sequence of the patient on the outside and the allocated group and study drug inside will be made by an anaesthesiologist. An anaesthetic technician will prepare the study drug. The participants, clinicians and the investigator who is involved in patient assessment and collecting data postoperatively will be blinded.~The study groups received the following study medication Group B - 0.25% bupivacaine 20 ml in TAP block Group BM - 0.25% bupivacaine 20 ml with 3 mg morphine in TAP block"|t|t|t|t
34182613|NCT01025726|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34182614|NCT01082016|NA|SINGLE_GROUP||||NONE||||||
34182615|NCT03549182|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34182616|NCT00335088|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34182617|NCT01929317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182618|NCT00003449||||TREATMENT||||||||
34182619|NCT00752778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182620|NCT06530147|||COHORT||PROSPECTIVE|||||||
34182621|NCT04681443|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182622|NCT06232304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be masked to who received TEACH and who did not.|Randomization occurs at the site level. Participants enrolled will either receive TEACH, a coping skills program, or medical treatment as usual.|f|f|f|t
34182623|NCT05373407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182624|NCT02928042|||COHORT||PROSPECTIVE|||||||
34182625|NCT06379204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182626|NCT06127030|RANDOMIZED|PARALLEL||TREATMENT||NONE|N/A The investigator will not perform any outcome assessments.|To examine the research objectives, a randomized controlled trial with two arms will be used. Teachers will be randomly assigned (equal randomization) to (a) brief teacher training with practice as usual (PAU) or (b) PAU only||||
34182627|NCT02952404|||COHORT||RETROSPECTIVE|||||||
34182628|NCT01812252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752966|NCT05441163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"expermiental arm : supervised 8-week combined APA and nutrition individualized program~control arm : standard of care specific to each site"||||
33752967|NCT05691478|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single-arm Feasibility Phase study followed by a randomized, parallel 4-arm Efficacy Phase study||||
33752968|NCT06235801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752969|NCT06310291|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The Single Ascending Dose part of the trial contains a placebo controlled randomized 4+2 design, where four participants will receive active IMP and two placebo. The Multiple Ascending Dose is a standard sequential design|t|t|t|t
33752970|NCT06346899|||COHORT||RETROSPECTIVE|||||||
33752971|NCT03901235|NA|SINGLE_GROUP||TREATMENT||NONE||Non-controlled, non-randomized, open label study||||
33752972|NCT04879550|||COHORT||PROSPECTIVE|||||||
33752973|NCT06050850|||FAMILY_BASED||PROSPECTIVE|||||||
33752974|NCT03278262|||COHORT||RETROSPECTIVE|||||||
33752975|NCT05864781|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33752976|NCT06733012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752977|NCT03687749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33752978|NCT06459297|||COHORT||PROSPECTIVE|||||||
33752979|NCT03740282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752980|NCT05938270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomised, phase 1 multicentre study||||
33752981|NCT06676319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752982|NCT02982005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33752983|NCT03998787|||CASE_ONLY||OTHER|||||||
33752984|NCT03407599|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33752985|NCT06732492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33752986|NCT01029054|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33752987|NCT06431802|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33752988|NCT04943874|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33752989|NCT03362333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33752990|NCT04341701|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||diagnostic imaging pilot study, exploratory, prospective, multi-center||||
33752991|NCT05953337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33752992|NCT06513351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Single Center Pragmatic Randomized Controlled Clinical Trial||||
33752993|NCT06144840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33752994|NCT06732206|RANDOMIZED|PARALLEL||PREVENTION||NONE|It will be reported that the reasons for being included in the group are taken by a random method.|pretest - posttest experimental study with control group||||
33752995|NCT05807451|||CASE_CONTROL||PROSPECTIVE|||||||
33752996|NCT01487811|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34066050|NCT05715424|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33752997|NCT04856722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33752998|NCT06678178|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to view a fast-food menu with one of five labeling schemes applied: (1) a QR code on all items (control); (2) a high climate impact warning label on high impact items; (3) traffic light labeling on all items by level of impact; (4) climate grade labels on all items by level of impact; and (5) numeric labels on all items. All fast-food menus will include main items, sides, desserts, and drinks. Labels will only appear alongside main menu items and will be assigned using thresholds for greenhouse gas emissions set a priori in kilograms of CO2 equivalent per kilogram of food. Participants will be instructed to select a hypothetical lunch meal order. The investigators will record participant meal selections and, using publicly available nutritional information for each item selected, calculate a score of overall meal healthfulness.||||
33752999|NCT02732938||||TREATMENT||NONE||||||
33753000|NCT00454948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33753001|NCT05930340|||COHORT||RETROSPECTIVE|||||||
33753002|NCT02434380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753003|NCT06714955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753004|NCT06717685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Modified Valsalva with adenosine will be administered on Monday and Tuesday Conventional Valsalva with adenosine will be administered on Wednesday and Thursday Modified Valsalva with verapamil will be administered on Friday and Saturday|Standard Valsalva maneuver or modified Valsalva maneuver will be attempted on patients according to their allocation of groups. After Three attempts with 5 minutes interval between each attempt if normal sinus rhythm was not achieved. IV pharmacological intervention will made. it includes Injection verapamil 5 mg or adenosine. Each patient will be kept under observation for one hour after normalization of sinus rhythm.|t|f|f|f
33753005|NCT03931148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Analyses of functional imaging results (MRI and/or EEG) will be carried out blindly from the results of the geriatric assessment of decision-making ability. The results between the geriatrician's assessment of decision-making ability and the results of functional imaging tests will then be compared.|||||
33753006|NCT03360942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066051|NCT05908747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066052|NCT06073756|||COHORT||CROSS_SECTIONAL|||||||
34066053|NCT00196430|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34066054|NCT02673242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066055|NCT02483572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066056|NCT06061250|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Two separate groups of patients will undergo same anesthetic procedure, except for chewing a gum for 2 minutes or swallowing saliva twice 10 minutes before the induction of anesthesia.|f|f|f|t
34066057|NCT02152215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182629|NCT01246596|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182630|NCT05304195|||CASE_CONTROL||PROSPECTIVE|||||||
34182631|NCT00169897|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34182632|NCT02252003|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34182633|NCT03837223|||COHORT||RETROSPECTIVE|||||||
34182634|NCT00180778|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182635|NCT03343912|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single centre, open-label, randomized (assignment to treatment group), parallel-group, three-arm single-dose clinical trial with application performed over 1 treatment cycle of 21 days.||||
34182636|NCT00658385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182637|NCT05956015|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34182638|NCT02751723|||OTHER||PROSPECTIVE|||||||
34182639|NCT00334048|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182640|NCT05201313|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label: due to the different methods of administration, the blindness of the obstetrician-gynecological team cannot be guaranteed.|"Randomized controlled trial (RCT) of superiority, with two parallel treatment arms.~Phase 3 study. Randomized controlled single-center perspective study."||||
34182641|NCT03826303|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182642|NCT04146948|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182643|NCT04690764|||OTHER||PROSPECTIVE|||||||
34182644|NCT05505955|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Single-dose and multi-dose, dose escalation, placebo-controlled study|t|t|t|t
34182645|NCT03461835|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34182646|NCT00135824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34182647|NCT02348749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR or PET/CT scanner||||
34182648|NCT02352896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182649|NCT05813600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182650|NCT00684021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182651|NCT02785549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182652|NCT00225316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182653|NCT02070536|||COHORT||PROSPECTIVE|||||||
34182654|NCT03975985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182655|NCT01656408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182656|NCT03119987|||COHORT||RETROSPECTIVE|||||||
34182657|NCT04495595|||COHORT||CROSS_SECTIONAL|||||||
34182658|NCT02282618|||COHORT||PROSPECTIVE|||||||
34182659|NCT00784914|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753007|NCT02264678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753008|NCT04830475|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Retrospective Analysis||||
33753009|NCT00365443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33840717|NCT06334705|NA|SINGLE_GROUP||OTHER||NONE||||||
33840718|NCT05639608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33840719|NCT01585155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840720|NCT04274491|||COHORT||PROSPECTIVE|||||||
33840721|NCT00055588||||TREATMENT||||||||
33840722|NCT03170687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840723|NCT05495321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840724|NCT00239408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840725|NCT04087811|||OTHER||PROSPECTIVE|||||||
33840726|NCT01817322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840727|NCT02936843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840728|NCT00008476||||TREATMENT||||||||
33840729|NCT00941070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840730|NCT05650762|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33840731|NCT03447301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840732|NCT00304304|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33840733|NCT06159179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Hospitalized adults age 18 - 75 years old; Willing to be involved in the research; Undiagnosed transudative and exudative pleural effusion post-thoracentesis twice on right and left lung; Patients can undergo medical thoracoscopy under local anesthesia, based on ATS and BTS guideline.||||
33840734|NCT00132275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840735|NCT00730873||||TREATMENT||||||||
33840736|NCT01845506|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33840737|NCT00601263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840738|NCT01546077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840739|NCT04985578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The assessor will not know if patients have received the dry needling technique or not.~Participants in the sham group will told they will receive a normal dry needling protocol"|A randomized controlled trial|f|f|f|t
33840740|NCT04383470|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33840741|NCT01681277|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33840742|NCT05922982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840743|NCT06114303|||CASE_CONTROL||PROSPECTIVE|||||||
33840744|NCT03349151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective randomised||||
33753010|NCT04452149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Study site personnel and subjects will remain blinded to the subject's randomization assignment until the 13-month timepoint at which point the subjects will be in the intervention arm for the remainder of their participation regardless of original allocation, or until the time of investigator and/or subject contact in relation to a high risk status in an intervention arm subject."|Following Reveal LINQ™ device insertion, subjects will be randomly allocated in a blinded fashion in a 1:1 ratio to either the observation arm or the intervention arm. Subjects in the observation arm will start with an observational period of 13 months and then transition to the intervention arm for the remainder of their participation in the study.|t|t|t|t
33753011|NCT06732154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753012|NCT05400434|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial was originally designed as a parallel randomized trial. Due to the coronavirus pandemic, the study has been amended to a non-randomized trial.||||
33753013|NCT06122077|||COHORT||PROSPECTIVE|||||||
33753014|NCT01263808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753015|NCT06533449|RANDOMIZED|PARALLEL||OTHER||NONE||The study will enroll 250 mother-infant pairs at the research location (total n=500, 250 mothers and the infants (250). Half of the pairs (n=250; 125 mothers, 125 infants) will be allocated the Couplet Care Bassinet from enrollment on the postnatal unit through discharge. The other half (n=250; 125 mothers, 125 infants) will be enrolled and assessed as controls with the standard bassinet used at the research site||||
33753016|NCT03607929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The methodology for carrying out the clinical trial followed the directives proposed in the CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials (Schulz et al. 2010).~Randomization and masking Women who fulfill the inclusion criteria will assigned in a masked manner into one of two groups according to a randomization list generated in the hospital's Care Research Unit using Epidat software version 3.1. Allocations will be disclosed through opaque, sealed, consecutively numbered envelopes at the moment the woman is recruited into the study . Given the difficulty of masking allocations from the persons carrying out the intervention and collecting the information, in addition to using objective variable measurement systems, collaborators will be blinded to the results during their analysis."|"INTERVENTION GROUP  OPTIMAL HYDRATION LABOR: they will be initiated the administration of crystalloid solutions in continuous perfusion at a rate of 200ml/h, until delivery, alternating each of them: (1)Physiological Serum (2)Physiological Serum (3)Ringer Lactate. The oral intake of mineral water will be promoted, at a rate of 100ml/h. To avoid bias, the mineral water will be administered by the research team.~IMMEDIATE PUERPERIUM: Women who have had a low-risk delivery will drink mineral water at a rate of 100ml / h during the two hours of the immediate puerperium. Suspending Hydration i.v.~CONTROL GROUP  VARIABILITY IN HYDRATION The women will be hydrated in accordance with the midwives' experience, training and clinical criteria, either independently or jointly with the attending clinicians (obstetricians, gynecologists and anesthetists)."|t|f|f|t
33753017|NCT05712356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753018|NCT04881006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753019|NCT04937153|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The starting dose is 15 mg administered as a flat dose. Dose escalation steps are based on safety data.||||
33753020|NCT04536272|RANDOMIZED|PARALLEL||OTHER||NONE||Randomization between anticoagulation targets during ECLS of: 1). 2-2.5 times baseline aPTT (usual care, about 60-75 sec.), 2). 1.5-2.0 times baseline aPTT (45-60 sec.) or 3). LMWH guided by weight and renal function.||||
33753021|NCT06732167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753022|NCT06388499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867952|NCT05355272|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm futility trial.||||
33867953|NCT00238173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867954|NCT00907751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867955|NCT02822885|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867956|NCT02282566|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33867957|NCT01761825|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33867958|NCT02798679|||COHORT||PROSPECTIVE|||||||
33867959|NCT00745407||CROSSOVER||TREATMENT||||||||
33867960|NCT03018587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867961|NCT04018794|NA|SINGLE_GROUP||TREATMENT||NONE||One group with behavioral/organizational skills intervention augmented with digital health application||||
33867962|NCT02791282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33867963|NCT02483559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33753023|NCT05667051|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753024|NCT06325969|||CASE_CONTROL||PROSPECTIVE|||||||
33867964|NCT02975427|||COHORT||PROSPECTIVE|||||||
33867965|NCT00310804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33867966|NCT02036944|||COHORT|||||||||
33867967|NCT00693914|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33867968|NCT00865683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867969|NCT00192387|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34182660|NCT03915275|||COHORT||RETROSPECTIVE|||||||
34182661|NCT01266629|||CASE_ONLY||PROSPECTIVE|||||||
34182662|NCT02267837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182663|NCT04855851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182664|NCT05153616|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182665|NCT06337123|||COHORT||OTHER|||||||
33867970|NCT00163267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182666|NCT06373965|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182667|NCT05755516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182668|NCT02762916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182669|NCT00163176|||COHORT||PROSPECTIVE|||||||
34182670|NCT04771117|||COHORT||CROSS_SECTIONAL|||||||
34182671|NCT02556177|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182672|NCT02704364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182673|NCT06016504|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33753025|NCT06616831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753026|NCT03079154|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33753027|NCT04150003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753028|NCT00610116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753029|NCT05205330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, open label, non-randomized, single-arm (non-controlled), multiple ascending dose (dose escalation) in MSS mCRC patients, followed by a fixed-dose (at RDE) Study Extension in other metastatic GI cancers||||
33840745|NCT00000300|RANDOMIZED|||TREATMENT||||||||
33840746|NCT05591053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Target enrollment for the assessment of esophageal anastomoses is a total of 70 patients powered to detect \~ 2-3 cm discordance between ICG and LSCI lines of demarcation between well vascularized and less vascularized site in the gastric conduit. Since ActivSight™ can detect the difference of \> 2 cm between perfused versus less perfused in comparison to ICG with 80 % confidence at p\<0.05 in a sample size of n = 21, the investigators estimate that the study will require an accrual of 63 patients. With potential unforeseen dropout and mortality, the investigators recruit a total of 70 patients for the proposed study.||||
33867971|NCT05711264|||COHORT||CROSS_SECTIONAL|||||||
33840747|NCT05799105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Endoscopists diagnosing and surveying healing of marginal ulcers will be blinded to the subject's treatment arm. A single, unmasked provider will be responsible for randomizing and prescribing either open- or intact-capsule PPI after subjects are enrolled in the study. This unmasked provider will not take part in diagnosis, monitoring or assessment of ulcer healing, or in data analysis.|prospective single-blinded randomized control trial|f|t|t|f
33840748|NCT02551653|NA|SINGLE_GROUP||OTHER||NONE||||||
33840749|NCT00234702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840750|NCT02499523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964801|NCT00000512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182674|NCT05647798|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182675|NCT06164002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34182676|NCT02917096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182677|NCT00416910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182678|NCT06298799|NA|SINGLE_GROUP||OTHER||NONE|no masking|"The study population consists of two cohorts:~A. Type 2 Diabetic participants cohort B. Healthy participants cohort"||||
34182679|NCT06047015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a pilot study examining 6 patients treated with IRE and checkpoint inhibitor (first 6, non-randomized) and 6 patients treated with IRE and checkpoint inhibitor and CpG||||
34182680|NCT02874040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182681|NCT03856788|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Group allocation and instructions on preparing the injectate solution for the subcostal TAP block will be included in a sealed envelope. On the day of the surgery, the group allocation will be revealed to an anesthesiologist not involved with the research study. The anesthesiologist not involved in the study or the care of the patient will prepare the solution to be used for the subcostal TAP block.|The study consists of two study arms. Patients will be getting a subcostal transversus abdominis plane block with either bupivacaine or saline.|t|t|t|f
34182682|NCT04815941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182683|NCT01112917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34182684|NCT02868593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182685|NCT04324437|NA|SINGLE_GROUP||OTHER||NONE||Consecutive recruitment based on patient choice into two cohorts: access to internet at home or not||||
34182686|NCT00494676|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34182687|NCT06654284|||COHORT||PROSPECTIVE|||||||
34182688|NCT01520506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182689|NCT00005804||||TREATMENT||||||||
34182690|NCT05876182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the randomization phase, subjects and all personnel directly involved in the conduct of the study will be blinded to the treatment assignment.|Group A: vancomycin 750 mg daily Group B: vancomycin1500mg daily Group C: placebo|t|f|t|f
34182691|NCT06284889|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled multi-center trial||||
34182692|NCT02141295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182693|NCT05689476|NA|SINGLE_GROUP||TREATMENT||NONE|none (open label)|||||
34182694|NCT05234307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182695|NCT00912535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182696|NCT02987686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182697|NCT02585856|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182698|NCT06110026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182699|NCT01626469|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34182700|NCT01840241|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34182701|NCT05318417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182702|NCT06055946|||COHORT||PROSPECTIVE|||||||
34182703|NCT04004988|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34182704|NCT00419406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182705|NCT06654362|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34182706|NCT03909789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double Blind Placebo Controlled|t|t|t|t
34182707|NCT00872820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182708|NCT06600893|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participant is placed behind a screen wearing headphones so they cannot see if the noise of shocking is coming from the shockwave device or from the recording playing on a bluetooth speaker as applicator is placed on the various locations for treatment with energy or simulated sham treatment without energy. Outcomes are assessed without identification of whether the assessment is after active or sham treatment.|Sham group crosses over to active treatment while active group does a second follow up assessment without additional treatment intervention|t|f|f|t
34182709|NCT06514625|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34182710|NCT04785313|||COHORT||RETROSPECTIVE|||||||
34182711|NCT00668278|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34182712|NCT04268667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182713|NCT02732574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34182714|NCT01874899|||CASE_CROSSOVER||PROSPECTIVE|||||||
34182715|NCT02237417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182716|NCT04139018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867972|NCT03442036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomized using a computer-generated list and opaque, sealed envelopes to one of two treatment groups (blocks of 4, no stratification): perineural catheter insert using (1) through-the-needle technique or (2) suture technique.|t|f|f|t
33867973|NCT02050503|||COHORT||PROSPECTIVE|||||||
34182717|NCT02951377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182718|NCT03672708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182719|NCT03863080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded|Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension|t|t|t|t
34182720|NCT01050296|||COHORT||PROSPECTIVE|||||||
34182721|NCT02940834|||CASE_CONTROL||PROSPECTIVE|||||||
33867974|NCT01456650|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33867975|NCT00068575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867976|NCT00299052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867977|NCT05932875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867978|NCT01977820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33867979|NCT01534013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33867980|NCT03226314|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33867981|NCT02773030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867982|NCT03837782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomized to be distributed to any group.|multicenter, randomized trial|t|f|f|t
33867983|NCT03410849|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33867984|NCT05195944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33867985|NCT04582149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33867986|NCT05717842|||COHORT||PROSPECTIVE|||||||
33867987|NCT02247245|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182722|NCT00961077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182723|NCT02628990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182724|NCT06297369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182725|NCT04497259|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182726|NCT00905944|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34182727|NCT06615349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||prospective, randomized, controlled|f|f|f|t
34182728|NCT06486194|RANDOMIZED|PARALLEL||OTHER||NONE||"Phase 1: Validation of the Preemie sensor, encompassing 2 different analytical studies for assessing the accuracy (1) and the precision/reproducibility (2) of the system~Phase 2: Open label randomised controlled trial to test use of Preemie ecosystem in clinical practice for the delivery of targeted individualised breast milk fortification"||||
34182729|NCT05642403|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34182730|NCT02531802|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182731|NCT06267755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|extracorporeal shockwave and traditional therapy|f|f|t|t
34182732|NCT05760339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182733|NCT00936286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182734|NCT01074814|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34182735|NCT06371092|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, triple-blind clinical trial|t|f|t|t
34182736|NCT00289042|RANDOMIZED|||TREATMENT||NONE||||||
34182737|NCT04336917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective study|t|f|f|t
34182738|NCT04461717|||COHORT||PROSPECTIVE|||||||
34182739|NCT01491607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182740|NCT01682889|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34182741|NCT00701350|||CASE_ONLY||PROSPECTIVE|||||||
33867988|NCT05765006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867989|NCT02018198|||CASE_ONLY||PROSPECTIVE|||||||
33867990|NCT02707380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33867991|NCT05915637|||COHORT||RETROSPECTIVE|||||||
33753030|NCT06732245|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|"With regards to NA-931 and placebo-NA-931, the participants, Investigator and Sponsor will be blinded.~Due to Tirzepatide being pre-filled, packaged and labeled by manufacturer, it is not possible to blind Tirzepatide"|The study is designed to have three periods. The 48-week core treatment period has 9 treatment arms, with combinations of 3 Tirzepatide doses (none, 2.5 mg and 5 mg and 10 mg injectable) and 3 NA-931 doses (0, 60 mg and 150 mg oral). The core treatment period is then followed by an open-label 12-week treatment extension period during which participants originally assigned to either placebo or NA-931 60 mg will switch to NA-931 150 mg. All other treatment assignments will remain the same. The extension period is then followed by a 12-week post-treatment period, during which all study treatments will be withdrawn from all arms.|t|f|t|f
33753031|NCT06732089|||CASE_ONLY||RETROSPECTIVE|||||||
33753032|NCT04554914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840751|NCT00306813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840752|NCT05519566|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33840753|NCT01509547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840754|NCT04185129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840755|NCT01828762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840756|NCT04210921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840757|NCT06314100|||COHORT||CROSS_SECTIONAL|||||||
33840758|NCT02408991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867992|NCT03924336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the type of intervention only the outcome assessor and the statistician will be blinded.||f|f|f|t
33867993|NCT02078570|||CASE_ONLY||PROSPECTIVE|||||||
33867994|NCT02153554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33867995|NCT02538016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867996|NCT03409848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33867997|NCT01484977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33867998|NCT05251740|NA|SINGLE_GROUP||TREATMENT||NONE||Single participant case study||||
33867999|NCT05427136|||COHORT||PROSPECTIVE|||||||
33868000|NCT00931242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868001|NCT03687073|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33868002|NCT03679611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study investigators, research coordinator, patients, surgeons, anesthesiologists, health care personnel will be blinded to the treatment arm allocation in the study.|This study is a prospective, double-blinded randomized controlled superiority trial with two parallel groups. Randomization will be performed with a 1:1 allocation into reversal of NMBD with sugammadex or neostigmine.|t|t|t|t
33964802|NCT02581761|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33964803|NCT01614925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753033|NCT06097728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open-label study for the personnel at study sites; the specific treatment to be taken by a participant will be assigned using an Interactive Response Technology/Randomization and Trial Supply Management. To maintain the integrity of the study, AstraZeneca personnel directly involved in the study conduct will not undertake or have access to efficacy data aggregated by treatment arm prior to final data readout for the primary endpoint.|This is a randomized, open-label, Phase III trial in participants with untreated unresectable pleural mesothelioma. Approximately 600 participants across histology subtypes will be randomized in a 1:1 ratio to receive volrustomig in combination with carboplatin plus pemetrexed or the investigator's choice of nivolumab plus ipilimumab or platinum plus pemetrexed chemotherapy for participants with epithelioid histology, and nivolumab plus ipilumab for participants with non-epithelioid histology.|f|f|f|t
33964804|NCT00491673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964805|NCT06201910|||COHORT||RETROSPECTIVE|||||||
33964806|NCT06521671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34182742|NCT05251480|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking cannot be accomplished as one intervention will require application of an advanced wound care product (DermGEN™) and the other arm (control) will not receive the intervention. This will be quite obvious to all.|An interventional, two-arm, randomized, prospective study of (1) standard of care (control) vs. (2) DermGEN™ - a decellularized dermal matrix (treatment) will be used in the treatment and management of DFU. Patients will be randomized to each arm (n=60 per arm) based on power calculations using data from our Pilot study.||||
34066058|NCT02932813|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182743|NCT03503032|||COHORT||PROSPECTIVE|||||||
34182744|NCT05327348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182745|NCT03959891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182746|NCT05101122|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182747|NCT03472885|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Four groups will be studied and enrolled sequentially.||||
34182748|NCT03056196|||COHORT||PROSPECTIVE|||||||
33753034|NCT02676375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753035|NCT04219540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753036|NCT01428076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753037|NCT02036489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753038|NCT06191198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||NIH Stage 2 behavioral clinical trial|t|t|t|f
33964807|NCT03909568|NA|SINGLE_GROUP||TREATMENT||NONE|Patients will be initially masked to which treatment is performed on each side, but will be notified at the follow-up appointment. In addition, the outcomes assessor carrying out the periodontal measurements (clinical attachment level and probing depths), will be unaware which treatment will be performed. The same surgical flap designs will be used for the treatment of both the right and left third molars, regardless of whether a coronectomy or extraction is carried out, and therefore the patient and clinician should be unable to differentiate between the procedures performed. Intervention will only be revealed to care provider once surgical flaps have been raised.|Split-mouth||||
33964808|NCT00683332|||CASE_ONLY||PROSPECTIVE|||||||
33964809|NCT00505505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34182749|NCT06086769|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182750|NCT01735006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182751|NCT06573879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The study participants will be divided into two different groups - a control group and an exercise group.~Control Group: 15 Exercise Group: 15 Exercise Program: A strength training program will be provided to the exercise group, carried out 3 days a week with 3 sets of 10 repetitions each day.~Total Duration: 8 Weeks (approximately 2 months)"|f|f|t|f
33868003|NCT06472154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This study intervened in music-based intervention for 86 older adults with depression and anxiety, and divided the 86 subjects into an experimental group (with Chinese five elements music based on midnight-noon ebb-flow theory) and a control group (with Chinese five elements music).|t|f|t|t
33868004|NCT01775332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34182752|NCT02808598|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34182753|NCT01109472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34182754|NCT03713658|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182755|NCT04806464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182756|NCT04845282|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be aware of their intervention, but the primary investigator and research staff performing assessments will not be masked.|Participants will be randomized into one of two groups. The first group will consume a set schedule of additional dietary protein, while the second group will consume a diet with the recommended dietary allowance of protein.|f|f|t|f
33868005|NCT02650115|||COHORT||PROSPECTIVE|||||||
34182757|NCT00003553|NA|SINGLE_GROUP||TREATMENT||NONE||patients with progressive metastatic renal cell carcinoma.||||
34182758|NCT01703767|||CASE_CONTROL||RETROSPECTIVE|||||||
33868006|NCT04442971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182759|NCT05246306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182760|NCT04293406|||COHORT||PROSPECTIVE|||||||
34182761|NCT04659876|||COHORT||RETROSPECTIVE|||||||
34182762|NCT06315712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182763|NCT02372955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182764|NCT00013533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182765|NCT00220896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33868007|NCT01863875|||COHORT||PROSPECTIVE|||||||
34182766|NCT01046487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182767|NCT02911844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182768|NCT00232661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182769|NCT05663814|||COHORT||PROSPECTIVE|||||||
34182770|NCT00491452|||CASE_CONTROL||RETROSPECTIVE|||||||
34182771|NCT06586983|||COHORT||PROSPECTIVE|||||||
34182772|NCT03052075|||COHORT||RETROSPECTIVE|||||||
34182773|NCT06655597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182774|NCT01590719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34182775|NCT03912194|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34182776|NCT00260975|||COHORT||PROSPECTIVE|||||||
34182777|NCT03631992|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants and outcome assessors will be blind to hypotheses and group assignment. Investigators will be blind to the group assignment during statistical analyses.|The intervention group will receive snacks lower in added sugar and sweetness (children) and educational lessons on dental care, food labels, added sugar, and portion size (mothers) whereas the control group will receive typical snacks (children) and educational lessons on portion size, sleep, screen time, and physical activity (mothers). Control group will receive the educational lessons of the intervention group at the end of the trial.|t|f|t|t
34182778|NCT03859934|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized, placebo controlled, double blinded crossover study|t|t|t|f
34182779|NCT01087463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182780|NCT04949997|||CASE_CONTROL||PROSPECTIVE|||||||
34182781|NCT06655116|||CASE_CONTROL||PROSPECTIVE|||||||
34182782|NCT04804384|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34182783|NCT02266511|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182784|NCT00494728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182785|NCT05689996|NA|SINGLE_GROUP||TREATMENT||NONE||"Preparation of nanostructure lipid carriers (NLCs):~The emulsification-solvent evaporation technique was used to prepare the NLCs. The method was followed by ultrasonication as reported \[1\]. In brief, the lipid phase was composed of stearic acid (solid lipid, 300 mg and oleic acid (liquid lipid, 300 mg) dissolved in ethanol (2 mL, 1:1, v/v) at 70oC. In total, 20 mL of the distilled water containing 2% of the Tween® 80 were heated at 70 oC to prepare the aqueous phase. Then, both phases, aqueous and lipid phases, were mixed at the same temperature using 2000 rpm stirring for 15 min. The resulting pre-emulsion obtained from the mixture of the aqueous and lipid phases was sonicated by a probe-type sonicator (Cole-Parmer, Vernon Hills, IL, USA) for 10 min at pulse-ON for 3 s and pulse-OFF for 5 s (40 W). The obtained dispersion was allowed to cool to RT under continuous stirring for 60 min at 1000 rpm for 1 h to obtain the NLCs dispersions."||||
33868008|NCT00184626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868009|NCT00243386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868010|NCT00771823|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33868011|NCT05161533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868012|NCT01177683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868013|NCT00123695|||COHORT||PROSPECTIVE|||||||
34182786|NCT05371652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182787|NCT02040324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182788|NCT02132026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182789|NCT00119184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182790|NCT05590923|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Subjects will be randomly assigned to either the DEX group to receive dexamethasone or to the OLA group to receive olanzapine for the first cycle of chemotherapy.~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (days 2-3 after MEC).~OLA group: olanzapine (Zyprexa)10 mg oral each night on days 1-4 after HEC (days 2-3 after MEC).~For the second cycle of chemotherapy, the subject will switch to the other group.~Groups:~OLA then DEX; DEX then OLA"||||
34182791|NCT00389038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182792|NCT03529032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182793|NCT01839955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182794|NCT05365425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182795|NCT01099176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33868014|NCT01483716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868015|NCT00888420|||CASE_ONLY||PROSPECTIVE|||||||
33868016|NCT00626704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868017|NCT00922480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868018|NCT03040791|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II, two-stage, multi-center, single-arm, and open-label trial of Nivolumab (BMS-936558) in patients with mCRPC who have progressed to a taxane-based chemotherapy regimen previously.||||
33868019|NCT04354545|||COHORT||PROSPECTIVE|||||||
33868020|NCT00282295|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33868021|NCT02964026|||COHORT||RETROSPECTIVE|||||||
33868022|NCT05981170|||COHORT||PROSPECTIVE|||||||
33868023|NCT05106673|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There is no masking.|The study will include two groups: one intervention group (IG) and one control group (TAU). The intervention group includes three different interventions.||||
33868024|NCT06417359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868025|NCT02319291|||COHORT||OTHER|||||||
34182796|NCT05929300|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"The study design entails randomizing \~34 Veterans who are undergoing radical prostatectomy (RP) for prostate cancer (PCa) to either usual care or a twice-weekly hybrid (in-person and virtual) yoga program that includes up to 4 weeks of pre-habilitation yoga and 8 weeks of post-RP yoga. Participants will provide data at three time points: baseline/pre-yoga (T1), completion of\~ 4 weeks of pre-RP yoga (T2), and completion of 8 weeks of post-RP yoga (T3). Veterans randomized to the intervention will be asked to routinely practice yoga (at least 15 min/day). The control group will consist of usual care patients. It is current practice for all patients to: 1) receive a handout that covers Kegel exercises; and, 2) instruction from a nurse who teaches the patient how to perform the exercises. There is no referral to a physical therapist unless progression indicates a need for it"||||
33964810|NCT03338270|||CASE_CONTROL||PROSPECTIVE|||||||
33753039|NCT02559336|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33753040|NCT02753790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840759|NCT04197362|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The subjects will be fitted in random order of a pair of ASICS Women's Gel-Venture 6 Running-Shoe, Nike Air Max 270, La Vida+ athletic shoes. Subjects will be pre-assigned randomly to start and continue with specific shoe groups, ultimately exhausting all options.||||
34182797|NCT05333198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182798|NCT05654974|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34182799|NCT01444612|||COHORT||RETROSPECTIVE|||||||
34182800|NCT00519753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182801|NCT01281982|||||PROSPECTIVE|||||||
34182802|NCT00740038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182803|NCT03715348|RANDOMIZED|PARALLEL||OTHER||NONE||Pragmatic pilot, open label, phase II randomised controlled trial||||
33840760|NCT05476315|||COHORT||RETROSPECTIVE|||||||
33840761|NCT04333446|||COHORT||RETROSPECTIVE|||||||
33840762|NCT03969368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840763|NCT00003094||||PREVENTION||||||||
33840764|NCT06180785|||CASE_ONLY||RETROSPECTIVE|||||||
33868026|NCT03846570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868027|NCT00415506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868028|NCT03505047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868029|NCT02428712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868030|NCT04776473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868031|NCT05863975|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33868032|NCT05311670|||COHORT||PROSPECTIVE|||||||
33868033|NCT03223870|||OTHER||PROSPECTIVE|||||||
34182804|NCT06590298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be blinded.|Two-arm randomized control trial|t|f|f|t
33868034|NCT04275505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"the participants did not know if they were in tratment group or control group. both of the group participants were asked to put their elbow into the shortwave diathermy device and they did not know if the device was turned on or off.~the investigator (Naciye Bilgin Badur) did not know the participants group while performing physical examination before and after intervention in control visits.~investigator and outcome assessor are the same person who is Naciye Blgin Badur"|this study has 2 groups of participants. treatment group and control group. It is designed as randomized controlled double blind clinical trial.|t|f|t|t
33868035|NCT03593850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computer block randomization was used to generate allocation sequence of codes. Allocation was done on the same day of the intervention, patients were given opaque envelope according to the randomization codes. The envelop contained instructions to access the allocated intervention. After baseline data collection patients entered the intervention room and opened the envelop inside while investigator waited outside. Both patients had headphones on and used the same device to access the intervention assuring blinding of the investigator. After the intervention ended, patient closed the intervention file and account to the intervention. All patients were instructed to nor reveal or comment anything about the intervention at any time after the intervention was completed.|Single blinded, two parallel group, randomized clinical trial. The experimental group received listen to a son composed exclusively for this trial while control group rested for the same amount of time in silence.|f|t|t|t
33868036|NCT01063387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868037|NCT00047671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868038|NCT05316532|||COHORT||PROSPECTIVE|||||||
33868039|NCT06537648|NA|SINGLE_GROUP||OTHER||NONE||||||
33868040|NCT03848754|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33868041|NCT03260634|||OTHER||OTHER|||||||
33964811|NCT05110950|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Both the pathologist and the patient are not aware of the type of adopted aspiration technique||t|f|f|t
33964812|NCT02460965|||||CROSS_SECTIONAL|||||||
33964813|NCT04609865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964814|NCT02059577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066059|NCT06377332|||COHORT||CROSS_SECTIONAL|||||||
34066060|NCT02475759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34066061|NCT00379171|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34182805|NCT01115413|||COHORT||RETROSPECTIVE|||||||
34182806|NCT02317471|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182807|NCT06602947|||COHORT||PROSPECTIVE|||||||
34182808|NCT02651675|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation||||
34182809|NCT05257850|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182810|NCT02271204|||COHORT||PROSPECTIVE|||||||
34182811|NCT05322681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182812|NCT00260533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182813|NCT03510546|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182814|NCT01161277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182815|NCT04277897|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34182816|NCT06655766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182817|NCT03758053|||CASE_CONTROL||PROSPECTIVE|||||||
34182818|NCT06520917|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Patients that were included in the study underwent temporomandibular joint arthroscopy using the Locator-Positioner Device, as opposed to the usual/classic procedure of temporomandibular joint arthroscopy without the aid of the Locator-Positioner Device||||
34182819|NCT00002476||||TREATMENT||||||||
34182820|NCT04074889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised, double-blind, placebo-controlled trial|t|t|t|t
34182821|NCT04718155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34182822|NCT05703711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182823|NCT01735162|||COHORT||PROSPECTIVE|||||||
34182824|NCT05846984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, participants, intervention facilitators, and the PI will be unblinded. Individuals collecting follow up surveys will be blinded to treatment condition, as will the study's statistician and data manager.||f|f|f|t
34182825|NCT04455347|||COHORT||PROSPECTIVE|||||||
34182826|NCT00257244|||COHORT||PROSPECTIVE|||||||
34182827|NCT01131832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34182828|NCT00999804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182829|NCT00722072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182830|NCT02048670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182831|NCT03612934|||COHORT||PROSPECTIVE|||||||
34182832|NCT02563652|||COHORT||PROSPECTIVE|||||||
34182833|NCT03367793|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182834|NCT02129699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182835|NCT02557139|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34182836|NCT01054989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34182837|NCT05931302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182838|NCT06654661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182839|NCT00607204|||COHORT||PROSPECTIVE|||||||
34182840|NCT06596811|||OTHER||RETROSPECTIVE|||||||
34182841|NCT02510521|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182842|NCT05860946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34182843|NCT00492258|RANDOMIZED|||TREATMENT||NONE||||||
34182844|NCT00391586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182845|NCT05072600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182846|NCT01547611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182847|NCT02915822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182848|NCT03219723|||COHORT||PROSPECTIVE|||||||
34182849|NCT05623878|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182850|NCT05567783|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34182851|NCT00871975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182852|NCT06129708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182853|NCT02864290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182854|NCT04491318|||COHORT||PROSPECTIVE|||||||
34182855|NCT04668755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* Sixty patients with Charcot neuroarthropathic foot ulcer (Chronic stage) recruited in the study.~* Patients divided in to two equal groups in number:~  * Group A (Study group):~This group compose of 30 patients whom they received the same standard medical treatment as group B in addition fitting with Charcot Restraint Orthotic Walker 3d printed sole for 12 weeks.~- Group B (Control group): This group compose of 30 patients whom they received the standard medical treatment in addition fitting with Generic Charcot Restraint Orthotic Walker for 12 weeks."|f|f|t|f
34182856|NCT03854266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182857|NCT02243995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182858|NCT00551317|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34182859|NCT06598176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182860|NCT03109964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182861|NCT02917122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868042|NCT06110260|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33868043|NCT05006157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868044|NCT04290338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||RCT characterized by the comparison between two groups (treated / untreated)|t|f|f|f
33868045|NCT01761279|||COHORT||PROSPECTIVE|||||||
33868046|NCT02551614|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33868047|NCT03262987|||COHORT||PROSPECTIVE|||||||
34182862|NCT06380491|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with a non-dipper pattern in blood pressure will randomly enter one of two options: 1) usual medical treatment; 2) treatment with melatonin plus usual care.||||
34182863|NCT05722392|||COHORT||PROSPECTIVE|||||||
34182864|NCT05682716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182865|NCT06249802|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Patient recruitment into study will be continuous during first three years of project duration. Two arms will be created - receiving nebivolol or placebo. Dosage of nebivolol will be determined based on blood pressure and heart rate. The investigators aim to enroll a total of 100 patients - 50 for β-blocker treatment arm and 50 for placebo arm. At baseline, included patients will undergo detailed clinical examination, MRI to assess aneurysm morphology and wall, as well as vascular Doppler ultrasound to provide boundary condition for computer modelling. During first 6 months of trial, monthly control visits for each patient will be established, during which they will undergo physical examination. After 6 and 12 months all examinations will be repeated. Further follow-up will then be adopted.|t|t|t|t
34182866|NCT01004068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182867|NCT01203969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182868|NCT03378986|||COHORT||PROSPECTIVE|||||||
34182869|NCT04603599|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182870|NCT05183035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182871|NCT06587373|||CASE_CONTROL||PROSPECTIVE|||||||
33868048|NCT05360173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||These two groups will be given true acupressure and sham acupressure twice daily. The participant will be observation the postoperative pain and postoperative recovery.|t|f|f|f
33868049|NCT03991000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868050|NCT04814810|||COHORT||PROSPECTIVE|||||||
33868051|NCT02146742|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33868052|NCT05009927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868053|NCT02942719|||COHORT||PROSPECTIVE|||||||
33868054|NCT00228397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33868055|NCT02435108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868056|NCT03089775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868057|NCT03269370|RANDOMIZED|PARALLEL||PREVENTION||NONE|There is no masking in this study.|"RCT with 4 arms, one being a waitlist arm that allows for re-randomization into one of the 3 active study arms."||||
33964815|NCT06306794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||In the calculation of the sample size, the power level is 80% and the significance level is 5%. It was determined by the statistical expert that the number of babies that should be included for each group is 26 and the total number of babies required for the whole study is 52 when the effect size is determined as 0.8 for the investigation of the difference between the experimental and control groups in terms of the premature infant pain profile (PIPP) variable. Based on aforementioned information, the study sample was determined as 80 preterm infants in which 40 for experimental groups and 40 for control groups. Block randomization method will be applied for the randomization of the groups.|t|f|t|t
33964816|NCT00532454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964817|NCT04146454|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Potential participants diagnosed with Parkinson's disease will be randomly assigned to either of two groups (intervention group and control group).|Study participants will be assigned to either of two groups (intervention group and control group)|f|f|t|f
33964818|NCT01691599|||CASE_ONLY||PROSPECTIVE|||||||
33964819|NCT02857374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964820|NCT01011907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33964821|NCT02543268|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33964822|NCT01619085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964823|NCT02903316|||CASE_ONLY||PROSPECTIVE|||||||
33964824|NCT02343562|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Probiotic Sachets|Probiotic Sachets|t|t|f|t
33964825|NCT02153931|||COHORT||PROSPECTIVE|||||||
33964826|NCT02197182|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964827|NCT06339021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964828|NCT00119132|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33964829|NCT02420899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33964830|NCT01436019|||COHORT||PROSPECTIVE|||||||
33964831|NCT05302284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964832|NCT05138393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964833|NCT05105711|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33964834|NCT01838161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33964835|NCT04981626|||COHORT||PROSPECTIVE|||||||
33964836|NCT00475111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964837|NCT02528630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964838|NCT03906149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33964839|NCT02834065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964840|NCT04049890|||CASE_ONLY||CROSS_SECTIONAL|||||||
33868058|NCT00555477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868059|NCT02254577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868060|NCT03848689|||OTHER||PROSPECTIVE|||||||
33964841|NCT01201356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964842|NCT06430099|||CASE_ONLY||CROSS_SECTIONAL|||||||
34066062|NCT05033483|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Supplements were packaged by LifeCare Compounding Pharmacy and labelled by staff not involved in the trial, with 2 colours per treatment group.~The randomisation schedule was prepared by an independent statistician. The schedule allocates women to one of the four colours in the ratio 1:1:1:1 using randomly permuted blocks."|A randomized, controlled, researcher and participant blinded trial with two parallel groups|t|f|t|t
34066063|NCT03843645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator completing the questionnaires will not be aware of patient group assignment||f|f|f|t
34066064|NCT04908475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066065|NCT05394454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
34066066|NCT00590642|||CASE_ONLY||PROSPECTIVE|||||||
34066067|NCT05192395|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066068|NCT03632577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066069|NCT04640038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868061|NCT01347424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868062|NCT04968041|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34066070|NCT02020070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066071|NCT04858360|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34066072|NCT03103217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066073|NCT00427219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066074|NCT06426277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066075|NCT00916071|||CASE_ONLY||CROSS_SECTIONAL|||||||
34066076|NCT04342013|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, non-blinded, parallel-arm clinical trial to assess the incidence of medication errors and adverse medication events with and without the use of an electronic clinical decision support application.||||
34066077|NCT02792335|||COHORT||RETROSPECTIVE|||||||
34066078|NCT00983138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066079|NCT02981732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066080|NCT04886388|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Randomized, Controlled||||
34066081|NCT03310892|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34066082|NCT01072578|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34066083|NCT01636089|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34066084|NCT03439410|||COHORT||PROSPECTIVE|||||||
34066085|NCT06040216|||CASE_CONTROL||RETROSPECTIVE|||||||
34066086|NCT03132974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066087|NCT01556932|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34066088|NCT01776177|||COHORT||RETROSPECTIVE|||||||
34066089|NCT06367777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33868063|NCT04153773|||CASE_CONTROL||RETROSPECTIVE|||||||
33868064|NCT02963038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868065|NCT00916279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868066|NCT04844684|||COHORT||PROSPECTIVE|||||||
33868067|NCT00000475|RANDOMIZED|||PREVENTION||||||||
33868068|NCT04239105|||COHORT||PROSPECTIVE|||||||
34066090|NCT05275634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|This trial has four groups; three experimental and one group control.|t|f|f|t
34066091|NCT06001853|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a double-blind study. Patients and providers will be blinded. After 6 months, patients randomized to Arm B: DMSO will be unblinded and crossed over to Arm A: treatment then be followed for 12 months.The statistician will generate the randomization list. Research personnel involved in patient recruitment and other activities will have no access to the randomization list.|After confirming eligibility, patients will be randomized to Arm A: Treatment or Arm B: DMSO. After 6 months, patients randomized to Arm B: DMSO will be unblinded and cross-over to Arm A: treatment then be followed for 12 months.|t|t|t|f
34066092|NCT04432454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066093|NCT05128045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066094|NCT02268682|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34066095|NCT03907670|||OTHER||CROSS_SECTIONAL|||||||
34066096|NCT02380963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066097|NCT02764203|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34066098|NCT01162122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066099|NCT00442819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066100|NCT00135590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066101|NCT03067259|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34066102|NCT06337747|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A prospective, randomized-controlled trial||||
34066103|NCT02548884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066104|NCT06311526|||COHORT||PROSPECTIVE|||||||
34066105|NCT04468815|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066106|NCT04544553|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34066107|NCT05562141|||CASE_CONTROL||PROSPECTIVE|||||||
33868069|NCT00613353|||CASE_ONLY||PROSPECTIVE|||||||
33868070|NCT00220168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868071|NCT03420014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868072|NCT00199446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868073|NCT04291248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868074|NCT02336789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868075|NCT02026921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066108|NCT03192410|||COHORT||PROSPECTIVE|||||||
34066109|NCT04891627|||CASE_CONTROL||PROSPECTIVE|||||||
34066110|NCT05232799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33868076|NCT05896449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868077|NCT02894710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868078|NCT05503784|NA|SINGLE_GROUP||OTHER||NONE||Open label||||
33868079|NCT01013181|||COHORT||RETROSPECTIVE|||||||
33868080|NCT03001973|||COHORT||PROSPECTIVE|||||||
33868081|NCT06395233|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomly allocated to their group and will not be aware of the incentives received by the other groups. Randomisation will be done by team setting up the study in the BetterPoints system and the principle investigator will only receive anonymised data and be blind to who has been allocated to each group.|Three group randomised trial with no control|t|f|t|f
34182872|NCT05471466|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Neither the participants nor the outcomes assessor were aware of which side of the incision was made using the scalpel or the electrosurgical unit device.|Randomized controlled double-blinded|t|f|f|t
34182873|NCT05929482|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 arms, intervention and wait-listed control group. Participants in the intervention group will receive the 4 episodes of the Love infection intervention (one episode weekly) after the baseline assessment. Participants in the wait-listed control group will receive the intervention after completing the 6-month assessment.||||
34182874|NCT03212742|NA|SEQUENTIAL||TREATMENT||NONE||||||
34182875|NCT05344313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||interventional cohort study||||
34182876|NCT06312852|||CASE_CONTROL||PROSPECTIVE|||||||
34182877|NCT01427764|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34182878|NCT04652752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182879|NCT03944577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868082|NCT03439436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Bottles kept in neutral outer boxes. Staff performing assessments kept unaware of treatment.||t|f|t|t
33868083|NCT06238609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Devices may be active or sham.|"Participants will be randomized to intervention (IG) or control group (CG) with ratio of 1:1. The entire cohort will receive daily neuromodulation in lower extremity (e.g. Gastronemius muscle) for up to 1 hour. The neuromodulation device will be functional for IG and non-functional for CG.~Phase I will include patients admitted to the Intensive care Unit. The study duration will be 4 weeks or until hospital discharge, whichever comes first."|t|t|f|f
33868084|NCT02504359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868085|NCT03527082|||OTHER||PROSPECTIVE|||||||
33868086|NCT00653042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33868087|NCT03511053|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant receives a saline lavage followed by the lumbar epidural steroid injection||||
33868088|NCT05353699|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33868089|NCT05069506|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single (Investigator)|Other: Glucose as reference food Other: goat milk yogurt as test food Other: goat milk yogurt with currants as test food Other: currants as test food Other: sultanina raisins as test food Other: goat milk preload Other: milk with lactic acid preload|f|f|t|f
33868090|NCT04118270|NA|SINGLE_GROUP||SCREENING||NONE||||||
33964843|NCT03433118|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial (RCT) comparing standard care against standard care with additional acupuncture||||
33964844|NCT06446947|||CASE_CONTROL||PROSPECTIVE|||||||
34182880|NCT02784548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182881|NCT06163690|||COHORT||PROSPECTIVE|||||||
34182882|NCT02338596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182883|NCT00026260||||TREATMENT||||||||
34182884|NCT04958473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182885|NCT05874635|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single-arm study||||
34182886|NCT06655064|||COHORT||PROSPECTIVE|||||||
34182887|NCT04588064|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants with lung adenocarcinoma undergo contemporaneous 68Ga-FAPI and 18F-FDG PET/CT for tumor staging before treatment.||||
34182888|NCT01454102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868091|NCT01120392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868092|NCT05407597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and investigators will be blinded to treatment allocation. An unblinded research nurse will administer the study medication.|Patients will be randomly allocated to receive either Icatibant (30mg) or 0.9% Sodium Chloride (3mls)|t|t|t|f
33868093|NCT00298129|||NATURAL_HISTORY||PROSPECTIVE|||||||
33964845|NCT06541535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964846|NCT05394558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964847|NCT04861090|||COHORT||RETROSPECTIVE|||||||
33964848|NCT03076671|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a stepped-wedge design, meaning that during the first year all patients enrolled will continue to receive usual care provided by their neurologist, who is also enrolled in the study. During years 2 and 3, every 6 months, 4-5 neurologists will receive training in supportive and palliative care. The timing of the training will be randomly assigned. Once their neurologist has received training, all of their enrolled patients will be switched to the intervention arm, and be eligible for additional care via telemedicine with the university supportive and palliative care team. During the final year of the study, all the neurologists will have received care, and all of their patients will be in the intervention arm.~On a separate level, we will be evaluating the effects of training on the enrolled neurologists through assessments of palliative skills, knowledge, and attitudes before and after the training, as well as through qualitative interviews."||||
33964849|NCT05014347|||COHORT||PROSPECTIVE|||||||
33868094|NCT04058925|||CASE_ONLY||PROSPECTIVE|||||||
33868095|NCT03945591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868096|NCT02113943||CROSSOVER||||TRIPLE|||t|t|t|f
33868097|NCT06004648|||OTHER||PROSPECTIVE|||||||
33868098|NCT05704686|||COHORT||RETROSPECTIVE|||||||
34182889|NCT04663009|||COHORT||RETROSPECTIVE|||||||
34182890|NCT04195763|||COHORT||PROSPECTIVE|||||||
34182891|NCT01287702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182892|NCT01523366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182893|NCT00525161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182894|NCT03367988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single Blinded: Study participants will not know what form of anesthesia they are being given.|Randomized Controlled Trial|t|f|f|f
34182895|NCT05494515|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"participants in the routine care group would still receive the swallowing education.~Care providior and investigator did not know what groups do the patients belongs to."|two groups, the early swallowing rehabilitation program, or the routine care group|t|t|t|f
34182896|NCT06130488|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Quasi experimental study model with pre and post intervention evaluation,||||
34182897|NCT00567814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182898|NCT03126591|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182899|NCT04396756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182900|NCT06116669|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34182901|NCT05642364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will both receive virtual reality exposure, specifically the treatment condition will receive a 5-week VR-based positive psychological intervention and the control arm will be exposed to 2-dimensional wildlife footage and nature-based settings with inert music. The outcome assessor will not be aware of trial arm assignment and will not have interaction with patient enrollees in any other capacity of the trial.|2-arm randomized controlled trial, inclusive of treatment group and attention-control condition|t|f|f|t
34182902|NCT05019144|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34182903|NCT04978675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34182904|NCT01096875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182905|NCT00551811|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34182906|NCT00560989|||CASE_CONTROL||RETROSPECTIVE|||||||
34182907|NCT03583814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The overall study utilizes a stepped wedge trial design with cluster randomization at the community level. All communities will have a baseline control period, active trial phase, and post-active trial phase follow-up period. During the active trial phase of this project, the strategy used to assign interventions to participants follows a Parallel Assignment study intervention model. During the active trial phase, individuals within that community will be assigned to an asthma intervention (1. CASE or 2. CASE and HARP) based on the child's level of asthma control. The SWT also allows us to compare community-level outcomes for participants who are not in the Active Trial (Intervention) period at that time and who are receiving standard care."||||
34182908|NCT02633904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34182909|NCT05595213|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34182910|NCT03203096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182911|NCT04961775|||OTHER||PROSPECTIVE|||||||
34182912|NCT02156076|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34182913|NCT00826202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182914|NCT02735811|||COHORT||RETROSPECTIVE|||||||
34182915|NCT05967975|||COHORT||PROSPECTIVE|||||||
34182916|NCT06655311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868099|NCT04516317|||COHORT||RETROSPECTIVE|||||||
33868100|NCT05175573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33868101|NCT04977765|||COHORT||PROSPECTIVE|||||||
33868102|NCT06387173|||COHORT||PROSPECTIVE|||||||
33868103|NCT01550120|||CASE_CROSSOVER||PROSPECTIVE|||||||
33868104|NCT00353834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868105|NCT05259813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868106|NCT04307160|||COHORT||PROSPECTIVE|||||||
33868107|NCT01406236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964850|NCT00002338||||TREATMENT||||||||
33868108|NCT04862624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33868109|NCT05317884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and providers will not know that email reminders were randomized. Participants who received an email (and their providers if they shared this email) will know that they have received an email, but it is not likely that they will know that other participants did not receive an email (and vice-versa).|No reminder group vs. reminder group|t|t|f|f
33868110|NCT00652730|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33868111|NCT03276312|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
33964851|NCT01060631|||CASE_CONTROL||PROSPECTIVE|||||||
33964852|NCT06286410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"During Phase 2 of the study:~The participants found to have residual amblyopia following standard care treatment (completed treatment but still have unequal vision) and asymmetrical accommodation (following their PR3 measurements and data interpretation), will be offered an intervention dependent upon their type of asymmetrical accommodation. There will not be any cross over in the treatment arms, and no randomisation during this pilot study, as the interventions differ and are bespoke to each patient.~Asymmetrical accommodation can be one of two things: Aniso-A and Anti-A."||||
33964853|NCT02832076|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964854|NCT01375010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964855|NCT01656954|||||PROSPECTIVE|||||||
33964856|NCT01920074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066111|NCT00123656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066112|NCT01244217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066113|NCT05063526|||COHORT||PROSPECTIVE|||||||
34066114|NCT06428994|||COHORT||RETROSPECTIVE|||||||
34066115|NCT00407407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066116|NCT04012307|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department. Study participants will be aware they will receive different formulations of the same drug, without being informed which product (Test or Reference) is being administered.||f|f|f|t
34066117|NCT04620694|||COHORT||PROSPECTIVE|||||||
33868112|NCT04603131|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Chikungunya vaccine is an inactivated virus vaccine. There will be three study arms and subjects will be vaccinated in a dose escalation manner.In each arm, vaccine will be administered on day1, day29, day57. Vaccine will be administered through intramuscular route.||||
33868113|NCT00173316|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33868114|NCT02413840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868115|NCT06449924|||COHORT||PROSPECTIVE|||||||
34182917|NCT06655688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental: Intervention group ''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group Intervention: Behavioral: Acceptance and Commitment Therapy No Intervention: Control group Only data collection was carried out. No attempt was made by the researcher during the study.|Intervention and control group|t|f|f|f
34182918|NCT04479995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34182919|NCT06016049|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34182920|NCT06654115|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34182921|NCT01152424|||CASE_CONTROL||PROSPECTIVE|||||||
34182922|NCT04941209|||CASE_CONTROL||PROSPECTIVE|||||||
34182923|NCT02015637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868116|NCT04979689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182924|NCT06074341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33868117|NCT00798057|||COHORT||PROSPECTIVE|||||||
33868118|NCT03339388|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33868119|NCT03302975|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33868120|NCT04069195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blinded, randomized, placebo controlled|Double Blinded, Randomized, Placebo controlled|t|t|t|t
33868121|NCT01847430|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33868122|NCT03419039|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34182925|NCT04845568|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking. Outcomes will be assessed via surveys.|Participants are randomized to control or intervention. The control condition is watching a video and playing a brief computer game, while the intervention condition consists of the virtual reality experience. Each provides child-friendly nutrition education as well as education on consideration of future consequences.||||
33868123|NCT00520455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868124|NCT01214863|||CASE_ONLY||PROSPECTIVE|||||||
33868125|NCT01766960|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34182926|NCT03879772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182927|NCT04053777|||COHORT||PROSPECTIVE|||||||
34182928|NCT02593006|||COHORT||PROSPECTIVE|||||||
33868126|NCT05005455|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34182929|NCT03674853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182930|NCT00157131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182931|NCT03693092|||CASE_ONLY||PROSPECTIVE|||||||
34182932|NCT02633098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182933|NCT06411262|||COHORT||CROSS_SECTIONAL|||||||
34182934|NCT04705831|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34182935|NCT00768014|||CASE_CONTROL||PROSPECTIVE|||||||
34182936|NCT00763035|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33868127|NCT00993265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964857|NCT04514770|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A: Early amniotomy was performed for the participant of the first group at 3 cm cervical dilatation with Kocher's forceps provided the head is well fitted to the cervix. Group B: late amniotomy was performed for the participant of the second group at 7 cm cervical dilatation.||||
33964858|NCT03271463|||COHORT||PROSPECTIVE|||||||
34066118|NCT04823806|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind study (participants nor experimenters know who receives placebo or spermidine supplementation)|2 groups of different inclusion criteria (healthy or depressive disorder) each group undergoing one out of two conditions (spermidine vs. placebo Supplementation) (randomized)|t|f|t|f
34066119|NCT03527862|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33868128|NCT01025960|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868129|NCT04741555|||COHORT||RETROSPECTIVE|||||||
33868130|NCT01867372|||||OTHER|||||||
33868131|NCT03069885|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will not be blinded, since the PrevenaTM-device makes a sound, when generating negative pressure, and the dressing looks a lot different compared to the conventional post-operative dressing.|The project is conducted as a randomized controlled trial. Patients included in the study will be randomized to either conventional post-operative dressing or PrevenaTM iNPWT treatment. Patients are allocated in a 1:1 ratio, with 30 patients treated with PrevenaTM and 30 patients treated with conventional post-operative dressing.||||
33868132|NCT01348932|||CASE_CONTROL||RETROSPECTIVE|||||||
33868133|NCT01907542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868134|NCT03632590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33868135|NCT01371136|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33868136|NCT02923661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868137|NCT00596661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868138|NCT00688155|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Data collection related to study outcomes was performed by staff who were masked to intervention assignment.|Participants were randomly assigned, with equal probability to one of four conditions: an educational control condition, moderate-intensity physical activity training, repetition lag cognitive training, or both physical activity and repetitive lag training.|f|f|f|t
33868139|NCT01963429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868140|NCT02476825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33868141|NCT00685880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33868142|NCT02632721|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I Dose Escalation: Open-label, single-arm, dose escalation~- To determine the maximum tolerated dose (MTD) and the recommended dose for Phase I Extension (RExP1D)~Phase I Extension: Open-label, two consecutive groups (cohort A and B) - To collect additional data on safety, pharmacokinetics and efficacy and to decide if the RExP1D will become the Recommended Phase II Dose (RP2D)~Phase II: Open-label, two-arm randomized~- To investigate efficacy, safety and pharmacokinetics of BI 836858 in combination with decitabine compared to decitabine monotherapy"||||
33868143|NCT05494021|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33868144|NCT02580851|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868145|NCT00253643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33868146|NCT03269851|||CASE_ONLY||CROSS_SECTIONAL|||||||
33868147|NCT03755791|RANDOMIZED|PARALLEL||TREATMENT||NONE||At least 740 eligible subjects with advanced HCC will be randomized in a 2:1:1 ratio. Experimental arm (at least 370 subjects) will receive cabozantinib plus atezolizumab. Control arm (at least 185 subjects) will receive sorafenib. Single-agent cabozantinib arm (at least185 subjects) will receive single-agent cabozantinib||||
33868148|NCT02520895|||COHORT||PROSPECTIVE|||||||
33868149|NCT03956316|||COHORT||RETROSPECTIVE|||||||
33868150|NCT01195090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868151|NCT00175214|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33868152|NCT00813644|||COHORT||PROSPECTIVE|||||||
33964859|NCT01585311|||COHORT||RETROSPECTIVE|||||||
33964860|NCT04852692|||COHORT||PROSPECTIVE|||||||
33964861|NCT04276168|||COHORT||PROSPECTIVE|||||||
33964862|NCT02387788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964863|NCT02850705|||COHORT||PROSPECTIVE|||||||
33964864|NCT02236754|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33964865|NCT01343628|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33964866|NCT00678379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964867|NCT06496113|||COHORT||RETROSPECTIVE|||||||
33964868|NCT05260983|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33964869|NCT01493726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964870|NCT02542150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33964871|NCT04989621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964872|NCT00018746|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33964873|NCT03319901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964874|NCT03046537|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||ovulatory women will be compared to women who do not ovulate regularly (PCOS)||||
33964875|NCT01947387|||||RETROSPECTIVE|||||||
33964876|NCT00189345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964877|NCT05068206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964878|NCT05616611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33964879|NCT00054015||||TREATMENT||NONE||||||
34066120|NCT05073861|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be allocated with IDs so that individuals can not be identified.|Classes will be randomly distributed to an experimental or control group. The experimental group will go through a 12-lesson program online and conduct related science experiments with the experimental kits they receive. The control group will receive an e-book for 3 topics (completed in 12 sessions). They will receive arts and craft kits upon completion. All students will receive and complete free assessments before and after the program. The program lasts for 2-3 months.|t|f|f|f
34066121|NCT05368909|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34066122|NCT01063894|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34182937|NCT00994513|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33868153|NCT05014360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868154|NCT00487136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868155|NCT01724333|||COHORT||CROSS_SECTIONAL|||||||
33868156|NCT01683214|||CASE_CONTROL||PROSPECTIVE|||||||
33868157|NCT00018551|RANDOMIZED|||PREVENTION||DOUBLE||||||
33868158|NCT01799187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868159|NCT03427567|||COHORT||RETROSPECTIVE|||||||
33868160|NCT05275348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182938|NCT00539591|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182939|NCT06518096|||COHORT||RETROSPECTIVE|||||||
34182940|NCT05003843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182941|NCT04280510|||COHORT||PROSPECTIVE|||||||
34182942|NCT02545985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182943|NCT01185210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182944|NCT02121535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33868161|NCT05119608|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study of a psycho-therapeutic intervention vs treatment as usual, therefore no masking of the treatment given.|1:1 randomized controlled trial||||
33868162|NCT02529982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868163|NCT02150148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33868164|NCT00037011||||TREATMENT||||||||
33868165|NCT03882138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868166|NCT05165355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868167|NCT03995732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Since the appearance of PC-SOD preparations cannot be identical to that of placebo, and treatment groups have different administration doses, the study will be conducted in a single-blind manner, where only subjects (and families) are blinded and do not know whether they are treated by PC-SOD or placebo before unblinding.~Interpretation of cardiac MRI and ECG will also be conducted in a blinding manner. Images of all subjects will be evaluated blindly by researchers not directly involved in the study."||t|f|f|f
33868168|NCT02583880|||||RETROSPECTIVE|||||||
33868169|NCT02114411|||COHORT||PROSPECTIVE|||||||
33868170|NCT00175955|RANDOMIZED|PARALLEL||||DOUBLE||||||
33964880|NCT05149287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One group will receive an intravenous dose of ceftriaxone and the other will receive an intravenous dose of lidocaine in saline. The syringes will be blinded to ensure that both the investigator administering the injection and the patient will be blinded to the group assignment.|After providing informed consent, patients undergoing arthroscopy of the knee for meniscal or cartilage injuries will be randomized into one of two groups. At the time of surgery, while the patient is under anesthesia, one group will receive a single intravenous dose of 1 gram of ceftriaxone and the other will receive a single intravenous dose of 1% lidocaine in saline.|t|t|t|t
33964881|NCT02593890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33964882|NCT06536842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964883|NCT04582409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964884|NCT06206109|||CASE_ONLY||CROSS_SECTIONAL|||||||
33964885|NCT04198350|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a phase II prospective, interventional, open-labeled, proof-of-concept study.~2 years per participant, 2 years 6 months in total Total n=6"||||
33964886|NCT05183100|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33964887|NCT00389649|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33964888|NCT06066307|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Research staff involved in the smell tests and questionnaires administration will not be aware of the subjects allocation (whether OT or control)|Randomized controlled trial|f|f|f|t
33964889|NCT05436496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964890|NCT04071626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind study|Parallel assignment, active controlled, single center experimental design.|t|t|f|f
33964891|NCT00567528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964892|NCT04741685|||COHORT||CROSS_SECTIONAL|||||||
33964893|NCT02717286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964894|NCT02135367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964895|NCT03786874|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Case group:~Healthcare teams benefiting first the implementation of the coaching model other (centered round the following steps: identify, understand and act) : just after the first measure~Control group:~Healthcare teams benefiting first the implementation of the coaching model (centered round the following steps: identify, understand and act) : after the second measure (impact of the device on case group)."||||
33964896|NCT01677442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964897|NCT02115737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964898|NCT03775148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964899|NCT03706560|||COHORT||PROSPECTIVE|||||||
33964900|NCT02980328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964901|NCT03812679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964902|NCT01375569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964903|NCT03855124|||OTHER||CROSS_SECTIONAL|||||||
33964904|NCT01273922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964905|NCT01496690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964906|NCT02629237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182945|NCT00668213|||CASE_ONLY||PROSPECTIVE|||||||
34182946|NCT05327907|||COHORT||OTHER|||||||
34182947|NCT02027051|||CASE_ONLY||CROSS_SECTIONAL|||||||
34182948|NCT05294549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182949|NCT01662765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34182950|NCT00503763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182951|NCT02433418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182952|NCT05609552|||OTHER||PROSPECTIVE|||||||
34182953|NCT06066320|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be unaware of the true nature of experimental trials until a final debrief scheduled after acute stress exposure.|Between subjects design to compare psychobiological responses in participants randomised to either the MMST or the TSST. Stratified block randomisation will be used to evenly distribute participants to the MMS or the TSST based upon sex (male or female) and trait anxiety (low STAI-T score \<40 or high STAI-T score ≥40).|t|f|f|f
34182954|NCT06404450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34182955|NCT02622126|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34182956|NCT02254135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34182957|NCT06587425|NA|SINGLE_GROUP||TREATMENT||NONE||The study is divided into a safety lead-in phase and an expansion phase. The safety lead-in phase will evaluate the dose-limiting toxicity (DLT) of the LM-302 combined with cadonilimab and capecitabine regimen in patients with unresectable, recurrent, or metastatic CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. Based on the safety data obtained from the lead-in phase, the expansion phase will determine the drug dosage and assess the efficacy and safety of the LM-302 combined with cadonilimab and capecitabine regimen in the same patient population.||||
34182958|NCT04316845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient undergoes both 18F-fluorocholine PET/CT and sestamibi scan||||
34182959|NCT06594614|||COHORT||RETROSPECTIVE|||||||
34182960|NCT06004739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182961|NCT06516900|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34182962|NCT00632814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182963|NCT05603702|NA|SINGLE_GROUP||TREATMENT||NONE||"1. Patients in the first cohort are treated at dose level 1.~2. Once a cohort of three patients has been recruited at a given dose level, recruitment will temporarily be held until all three patients have been evaluated for delayed adverse events, at 21 ±3 days following completion of drug therapy.~3. To assign a dose to the next cohort of patients, conduct dose escalation/de-escalation according to BOIN design rules.~4. Repeat step 2 until the maximum sample size of 24 is reached or stop the trial if the number of patients treated at the current dose reaches 15."||||
34182964|NCT03210194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34182965|NCT05679752|RANDOMIZED|PARALLEL||OTHER||SINGLE|single blind RCT in which just participants do not know in which group they are being treated|Randomized control trail|t|f|f|f
34182966|NCT06210997|||COHORT||CROSS_SECTIONAL|||||||
34182967|NCT02368834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34182968|NCT00495352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34182969|NCT01868997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34182970|NCT05355246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34182971|NCT02570607|||OTHER||PROSPECTIVE|||||||
34182972|NCT03481595|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34182973|NCT04748198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182974|NCT06614790|||OTHER||RETROSPECTIVE|||||||
34182975|NCT06418802|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34182976|NCT02981446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34182977|NCT00149266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182978|NCT05357651|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182979|NCT01108016|RANDOMIZED|CROSSOVER||||NONE||||||
34182980|NCT04436757|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized, single-centre, comparative, interventional study, treated in open parallel groups, measuring the impact of professional body image intervention on improving body self-esteem in patients with severe mental health problems."||||
34182981|NCT00224822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34182982|NCT03107871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo and active drug will be dispensed in identical amber bottles with identical labeling.||t|t|t|t
34182983|NCT06318949|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective multicentre study of biomarker validation||||
34182984|NCT01269021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182985|NCT03902353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868171|NCT03372109|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33868172|NCT01489202|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33868173|NCT03022331|||COHORT||PROSPECTIVE|||||||
33964907|NCT03468374|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33964908|NCT01964105|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33964909|NCT05991245|||COHORT||RETROSPECTIVE|||||||
34182986|NCT03497195|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34182987|NCT03420599|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34182988|NCT06109571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge, one-way crossover, cluster randomized trial||||
34182989|NCT05417516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants will be made unaware of treatment allocation to prevent any potential bias in their assessment of cosmesis.||t|f|f|f
33868174|NCT03034460|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33868175|NCT05680571|||CASE_CONTROL||PROSPECTIVE|||||||
33964910|NCT02380378|||OTHER||PROSPECTIVE|||||||
33964911|NCT00087399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33964912|NCT02837367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33964913|NCT02579785|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33868176|NCT04402970|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Nebulized dornase alfa will be administered through the ventilator circuit at a dose of 2.5 mg, 12 hours apart, for 3 consecutive days. Patients will also receive lung protective ventilation (VC 6-8 ml/kg predicted body weight), plateau pressure \< 30 centimeters of water pressure (cmH2O), targeted driving pressure \< 15, neuromuscular blockade if indicated, and prone positioning based upon arterial blood content to fraction of inspired oxygen ratio (PaO2/FiO2) \< 150 or upon treating physician decision; along with all other ICU care based upon best practice standards and evidence based medicine.|t|f|f|f
33868177|NCT05284279|||OTHER||CROSS_SECTIONAL|||||||
33868178|NCT04777435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868179|NCT04801875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study was based on pre-test and post-test methods. Musicians who met inclusion criterion were assigned to violin and ney groups according to performing musical instrument.|f|f|f|t
33868180|NCT03992664|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33868181|NCT05353049|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33868182|NCT03055754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868183|NCT03066908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868184|NCT05505136|||CASE_ONLY||RETROSPECTIVE|||||||
33868185|NCT03451084|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34066123|NCT06413745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066124|NCT04184778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34066125|NCT01865604|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34066126|NCT00280813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34182990|NCT02626871|||COHORT||RETROSPECTIVE|||||||
34182991|NCT03569735|||COHORT||PROSPECTIVE|||||||
34182992|NCT04434443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor not aware of group assignment||f|f|f|t
34182993|NCT00597220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34182994|NCT05464342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Parameters such as questionnaires' scores, polysomnography outcomes, indices of health, gut microbiome, miRNA and other data will be masked and coded for blind analysis by the main investigator.|This is a randomized controlled trial. The study is composed of three groups, differentiating on evening carbohydrate quantity and quality (glycaemic index) intake. The trial period will last for 1 month for all groups. Intervention includes lifestyle changes, targeting exercise, and diet. The design is parallel.|f|f|f|t
34182995|NCT03989258|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34182996|NCT01930006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34182997|NCT04257448|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34182998|NCT05505084|||CASE_CONTROL||PROSPECTIVE|||||||
34182999|NCT05433207|||CASE_ONLY||PROSPECTIVE|||||||
34183000|NCT06213857|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized parallel study that will be conducted on 44 adult patients with newly diagnosed Ulcerative Colitis. Patients will be enrolled after obtaining an informed consent from them or their guardians.~Patients will be recruited from Rajhy Hospital Outpatient Clinics and Health Insurance Outpatient Clinics at Mabarra Hospital in Assiut, Egypt. The patients will be randomized based on hospital admission days into two groups:~* Group Ⅰ (control group): 22 patients will receive mesalamine (4g\\day induction \& 2g\\day maintenance) only for 6 months.~* Group Ⅱ (silymarin group): 22 patients will receive mesalamine (4g\\day induction \& 2g\\day maintenance) and silymarin (140 mg\\day) for 6 months.~The primary outcome will be clinical improvement defined as a 2 point or more decrease in the Mayo score from baseline. The secondary outcomes will be the change in the level of fecal calprotectin, superoxide dismutase and TNF-α."||||
34183001|NCT05856617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Did not tell them about assigned group till all the measurement ends.||t|f|f|f
34183002|NCT03095859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind study. Treating medical team and therapist delivering standard care will remain blinded to participant allocation. Participants and therapist delivering intensive intervention will be unable to be blinded as they will be receiving / providing intervention. Outcome assessors will be blinded to group allocation.|"Randomized, parallel feasibility trial.~Stratification as per:~\<55 years of age~≥ 55 years"|f|t|f|t
34183003|NCT06404385|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE|single-blind|A prospective, controlled, examiner- and statistician-blinded, parallel-arm quasi-experimental study|t|f|t|t
33868186|NCT01093625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33868187|NCT01993212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868188|NCT00003757||||TREATMENT||NONE||||||
33868189|NCT02090413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868190|NCT02445625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868191|NCT00777777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868192|NCT00347334|||||PROSPECTIVE|||||||
33868193|NCT00173147|||||RETROSPECTIVE|||||||
33868194|NCT04824820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868195|NCT04475575|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868196|NCT06470789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868197|NCT03180164|NA|SINGLE_GROUP||SCREENING||NONE||||||
33868198|NCT05126472|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a phase I, open-label study to assess safety and tolerability of a local delivery (intravesically or intratumorally) of an anti-CD40 agonist antibody (2141-V11) for the treatment of subjects with BCG-unresponsive NMIBC who are considered ineligible for or have elected not to undergo radical cystectomy.||||
33868199|NCT02147366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34066127|NCT00445744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066128|NCT02346994|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34066129|NCT05707949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868200|NCT01649973|||CASE_CROSSOVER||PROSPECTIVE|||||||
33868201|NCT01073267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868202|NCT05144113|||COHORT||CROSS_SECTIONAL|||||||
33868203|NCT04595253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33868204|NCT02526797|||CASE_ONLY||RETROSPECTIVE|||||||
33868205|NCT02295345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868206|NCT02511457|||CASE_ONLY||PROSPECTIVE|||||||
33868207|NCT00224614|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868208|NCT05728931|||OTHER||RETROSPECTIVE|||||||
33868209|NCT02361450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868210|NCT04675749|||COHORT||PROSPECTIVE|||||||
33868211|NCT05104333|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Serum testing technicians will be masked.||f|f|f|t
33868212|NCT01415128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868213|NCT00577928|||CASE_CONTROL||RETROSPECTIVE|||||||
33868214|NCT06489639|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
33868215|NCT05146245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868216|NCT02127671|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33868217|NCT05529849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868218|NCT06268171|||COHORT||PROSPECTIVE|||||||
33868219|NCT03349099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Videos will be analyzed by blinded urologists who will rate the extent of ureteral damage on a standardized scale of 0 to 4 according to the study published by Traxer et al. 2013. After the study, subjects will not be contacted.||f|t|f|f
33868220|NCT05410444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33868221|NCT05069064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868222|NCT04824963|||COHORT||RETROSPECTIVE|||||||
33868223|NCT03404284|||OTHER||OTHER|||||||
33868224|NCT04345770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868225|NCT01878942|NA|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33868226|NCT00930839|||COHORT||PROSPECTIVE|||||||
33964914|NCT03970668|||COHORT||RETROSPECTIVE|||||||
33964915|NCT02462382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33964916|NCT02971332|||CASE_ONLY||PROSPECTIVE|||||||
33964917|NCT04575974|||COHORT||PROSPECTIVE|||||||
33964918|NCT06538272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964919|NCT05087199|||CASE_ONLY||CROSS_SECTIONAL|||||||
33964920|NCT06265688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183004|NCT02955667|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34183005|NCT00893438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183006|NCT03812731|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The attending anaesthesiologist will not be blinded to the technique utilised to administer GA. An independent assessor blinded to the technique of GA will follow up the patients to determine the incidence of uretherocutaneous fistula|"30 male patients aged 1-8 years, ASA physical status I/II, and undergoing distal hypospadias repair will be randomly allocated to one of the following two groups:~GROUP I- (Caudal group, n= 15) Children will receive general anesthesia (GA) and analgesia will be maintained with caudal epidural block (CEB) with 0.2% ropivacaine:1 ml/kg.~GROUP II- (Non-caudal group, n= 15) Children will receive general anaesthesia (GA) and analgesia will be maintained with intravenous fentanyl citrate 1mcg/kg/hr.~roup-1 \[CLADS Group, n=60\]: Anaesthesia will be induced and maintained with propofol administered using the BIS feedback-based automated CLADS. Group-2 \[Desflurane Group, n=60\]: Anaesthesia will be induced with propofol CLADS and will be maintained intraoperatively by Desflurane titrated to BIS monitoring."|t|f|f|t
34183007|NCT02286349|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34183008|NCT04307329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Two cohorts; high TILs (≥ 5%) and low (\< 5%) TILs|Simon's two-stage minimax design||||
34183009|NCT04730453|||CASE_ONLY||PROSPECTIVE|||||||
34183010|NCT00251732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183011|NCT05609591|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34183012|NCT05061511|||OTHER||CROSS_SECTIONAL|||||||
34183013|NCT00566761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183014|NCT00135551|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183015|NCT06514066|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34183016|NCT03058146|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial with ongoing enrollment into each arm (individual intervention)||||
34183017|NCT04429711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind randomized|t|t|t|t
34183018|NCT04820569|||COHORT||OTHER|||||||
34183019|NCT04476797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Phase 2 is a randomized, placebo-controlled study|After the open label Phase 1 portion, subjects in the Phase2 portion will be randomized in a 1:1 ratio to receive GC4711 or placebo before each fraction of SBRT|t|t|t|f
34183020|NCT06095063|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183021|NCT05434286|||COHORT||PROSPECTIVE|||||||
34183022|NCT05826028|||COHORT||RETROSPECTIVE|||||||
34183023|NCT01675752|||COHORT||CROSS_SECTIONAL|||||||
34183024|NCT05019326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183025|NCT00460616|||CASE_CONTROL||PROSPECTIVE|||||||
34183026|NCT02191735|||COHORT||RETROSPECTIVE|||||||
33964921|NCT00982774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183027|NCT05605002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183028|NCT01143376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183029|NCT05867238|||OTHER||PROSPECTIVE|||||||
34183030|NCT01890460|||CASE_ONLY||PROSPECTIVE|||||||
34183031|NCT01286480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183032|NCT03228225|NA|SINGLE_GROUP||TREATMENT||NONE||single arm non-blinded remote monitored multidisciplinary secondary prevention intervention||||
34183033|NCT01371396|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33868227|NCT00510081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868228|NCT02390479|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33868229|NCT02840110|||CASE_ONLY||PROSPECTIVE|||||||
33868230|NCT02228720|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Propel Nova Sinus Implant||||
33964922|NCT02192216|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33868231|NCT00500630|NON_RANDOMIZED|PARALLEL||||NONE||||||
33868232|NCT01889082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868233|NCT03405805|||COHORT||PROSPECTIVE|||||||
33868234|NCT04532385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An external pharmacy laboratory encapsulated the GTE and placebo, blinded and coded the study treatments.|patients were randomly assigned to receive green tea extract (sunphenon 90D, TAIYO international, Minneapolis, US) at a 400 mg/12 hrs dose or calcined magnesia (400 mg/12 hrs).|t|f|t|f
33868235|NCT04425603|||COHORT||PROSPECTIVE|||||||
33868236|NCT04336670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33964923|NCT02400073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964924|NCT04562298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066130|NCT04616846|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||Retrospective and prospective (ambispective), multicentric study to evaluate the occurrence of venous thromboembolism during COVID-19 infection.||||
34183034|NCT00306501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183035|NCT00684931|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183036|NCT05447780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868237|NCT01310790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183037|NCT03687060|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Stepped-wedge cluster randomized trial||||
34066131|NCT01304303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868238|NCT04387955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Cohort||||
33964925|NCT02692352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066132|NCT00262002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183038|NCT06361069|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study was conducted using the pre-post test unpaired group model, one of the quasi-experimental methods."||||
34183039|NCT03527108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183040|NCT03394820|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The patient will be randomized prior to surgery. The pre-randomized envelope will be given to the anesthesia assistant by the blinded research associate. The anesthesia assistant will then prepare the four mini-bags labelled with the time each bag should be hung.The four bags will include 1 active drug and 3 placebo, to administer to the patient. The clinical fellow who will be administering the four doses will be blinded, as well as the research associate.|the patients will be randomized into four differently times groups. The patients will receive dexamethasone either 1 hour before the block, during the block, 1 hour after the block or 2 hours after the block|f|t|t|f
34183041|NCT04046809|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183042|NCT06177496|||COHORT||RETROSPECTIVE|||||||
34183043|NCT02157025|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183044|NCT03675997|||COHORT||PROSPECTIVE|||||||
34183045|NCT04684277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183046|NCT06019702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183047|NCT04690023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Non-inferiority controlled RCT with two groups simple-blinded|Non-inferiority randomized controlled clinical trial|t|f|f|t
34183048|NCT00549835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34183049|NCT05661617|||COHORT||PROSPECTIVE|||||||
33868239|NCT06313450|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33868240|NCT03135275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868241|NCT03484286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Cardiovascular events will be adjudicated as heart failure related or not.~Data analysis will be performed by staff blinded to the patients IDs."|Parallell randomized clinical trial with continuous sampling and a 1:1 randomization.|f|f|f|t
33868242|NCT00513110|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33868243|NCT04530903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868244|NCT05407909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868245|NCT04534491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964926|NCT03235531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964927|NCT03996707|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will be assessing the difference in two groups; immediate protected weight-bearing in a CAM walking boot vs. strict non-weight-bearing for 6 weeks following foot and ankle surgery.||||
33964928|NCT05938335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964929|NCT03443219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|opening a sealed envelope, provided by an independent physician blinded to patient's allocation In addition, outcome assessor were blinded||t|t|f|t
33964930|NCT00368238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33964931|NCT04987671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964932|NCT00279799|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066133|NCT06224036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066134|NCT03089801|||COHORT||OTHER|||||||
34066135|NCT05689008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066136|NCT05995951|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34183050|NCT06341478|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Post-hoc biomarker analyses of ongoing phase 2 studies||||
33753041|NCT06732479|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were systematically selected using a stratified random sampling approach. The schools were first categorised into three strata based on the number of enrolled children: those with more than 100 children, those between 25 and 100 children, and those with fewer than 25 children. Schools were randomly chosen from each stratum. Two schools with more than 100 children were randomly selected, one designated as the experimental group and the other as the control group. Six schools in the 25 to 100 children were randomly chosen and equally divided into experimental and control groups. Similarly, in the stratum of schools with less than 25 children, four schools were randomly selected and equally split into experimental and control groups. It is important to note that all participants who met the predetermined selection criteria within each selected school for specific purposes were invited to participate in the study, ensuring a comprehensive and representative sample.||||
34183051|NCT03801408|||OTHER||OTHER|||||||
33753042|NCT05297812|||COHORT||PROSPECTIVE|||||||
33753043|NCT05776173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753044|NCT05130970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753045|NCT04496219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868246|NCT06098625|RANDOMIZED|PARALLEL||TREATMENT||NONE||This EmLina Renal trial is an investigator initiated, single-center, prospective, open-label, randomized clinical study to examine the safety and effect of empagliflozin 25 mg once a day vs. linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus||||
33868247|NCT05804643|||COHORT||CROSS_SECTIONAL|||||||
34183052|NCT02397577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183053|NCT00240513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34183054|NCT02659254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868248|NCT03351790|||COHORT||PROSPECTIVE|||||||
33868249|NCT04012034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868250|NCT01541020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34183055|NCT01919502|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34183056|NCT02057185|||COHORT||CROSS_SECTIONAL|||||||
34183057|NCT05024019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183058|NCT00613873|||COHORT||PROSPECTIVE|||||||
34183059|NCT02098785|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183060|NCT00000715||PARALLEL||TREATMENT||||||||
34183061|NCT00643747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183062|NCT03848026|||CASE_ONLY||PROSPECTIVE|||||||
34183063|NCT03022552|||COHORT||PROSPECTIVE|||||||
33753046|NCT06724276|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be a randomized controlled trial, adhering to the CONSORT checklist. Randomization will be conducted using the RandStuff online random number generator, where the number on the stationary card will correspond to the patient's number.~The study will include 116 participants with long-term non-healing wounds from chronic obliterating disease of the lower extremities across three cities in Kazakhstan.~Groups:~* Main: 58~* Control: 58~* Total: 116~* Main Group: Combined treatment (balloon angioplasty or stenting + fibroblast transplantation).~* Control Group: Endovascular interventions + traditional debridement. Procedures will include balloon angioplasty or stenting, followed by fibroblast transplantation."||||
34183064|NCT03957577|||COHORT||PROSPECTIVE|||||||
33753047|NCT06644287|||OTHER||PROSPECTIVE|||||||
34183065|NCT00533455|RANDOMIZED|PARALLEL||||DOUBLE||||||
34183066|NCT02507232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183067|NCT00918255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753048|NCT06733610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753049|NCT06229002|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants and experimenters (including α-tACS operator) will not be informed about the nature (active or placebo) of the stimulation they will receive|Double-blind, placebo-controlled, randomized parallel arms study including 40 healthy participants who will receive active and placebo α-tACS|t|f|t|t
34183068|NCT00716417|NON_RANDOMIZED|||TREATMENT||NONE||||||
33753050|NCT06368765|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33753051|NCT06568562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753052|NCT05905926|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Open label study||||
33753053|NCT04253522|RANDOMIZED|PARALLEL||OTHER||NONE||N of 1 Trials with multiple Baseline with 3 phases||||
33753054|NCT03842995|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33753055|NCT05140928|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants are randomly assigned to two groups; the intervention group that received dadiah pudding and the control group that received pudding without dadiah in parallel for the duration of the study.|t|t|t|t
33753056|NCT06732336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||89Zr-trastuzumab PET imaging of HER2-low breast cancer patients||||
33753057|NCT05612880|||CASE_ONLY||PROSPECTIVE|||||||
33753058|NCT06025474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183069|NCT01507259|||CASE_CROSSOVER||PROSPECTIVE|||||||
34183070|NCT06400199|||COHORT||PROSPECTIVE|||||||
34183071|NCT00384670|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34183072|NCT02873416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183073|NCT04465708|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34183074|NCT01303016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753059|NCT06406309|NA|SINGLE_GROUP||TREATMENT||NONE||Micro-longitudinal (3 weeks total, daily measurement) observational baseline (1 week) and 2 week intervention study trialing a bedtime manipulation intervention.||||
33753060|NCT01176162|||CASE_ONLY||PROSPECTIVE|||||||
33868251|NCT03179891|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This was a multicenter, open-label study comprised of 2 treatment periods with a minimum 14 days washout between the 2 treatment periods.||||
33753061|NCT02159742|||COHORT||PROSPECTIVE|||||||
33753062|NCT04859764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unmarked sleeves will be used. Half will be Reparel sleeves, and half will be placebo. Participants and sleeve numbers will be randomized via REDCap.||t|t|t|t
33753063|NCT06684119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753064|NCT05451251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753065|NCT06395272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The design is a prospective longitudinal randomised controlled trial|t|f|f|t
33753066|NCT05240716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753067|NCT03952858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants in the two groups will be asked not to inform the test investigator to which intervention they have been allocated. Baseline test will be performed before randomization in the hospital ward or in the participants home. Before re-test the participants in the intervention groups will ensure that the computer used for exercise is not visible in the room where the re-test is done.||f|f|f|t
33753068|NCT03548740|||CASE_CONTROL||PROSPECTIVE|||||||
33868252|NCT01888120|||CASE_ONLY||PROSPECTIVE|||||||
33868253|NCT02642770|||COHORT||PROSPECTIVE|||||||
33868254|NCT03363750|NA|SINGLE_GROUP||OTHER||NONE||||||
33868255|NCT04157920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients undergoing TAVR for severe aortic stenosis with two different transcatheter devices. One arm received Medtronic Evolut R/Pro. The other is receiving Boston Scientific ACURATE NEO/TF||||
33868256|NCT05798130|||COHORT||PROSPECTIVE|||||||
33868257|NCT06306287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and the assessors will not have access to the conditions to which participants are assigned until all data are collected.|Youth (n=120) will be randomly assigned to one of three conditions (40 youths per condition): ePACE, eFACE, or waitlist comparison (WC) condition.|f|f|t|t
34066137|NCT00163033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066138|NCT04780243|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
34183075|NCT00335036|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
34183076|NCT04979312|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||f|t|t|t
34183077|NCT05540938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183078|NCT00286247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183079|NCT00599846|||CASE_ONLY||PROSPECTIVE|||||||
34183080|NCT02695108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183081|NCT04579107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The added Contrast Enhanced Mammography will be evaluated by a radiologist blinded from the radiologists evaluating the standard of care examinations.|||||
34183082|NCT03252379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will be randomized into three groups according to the surgical procedure performed as follows:~* Group A: Patients undergoing modified hepaticojejunostomy with gastric access loop~* Group B: Patients undergoing modified hepaticojejunostomy with subcutaneous access loop~* Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop"|t|f|f|f
34183083|NCT01601236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The 32U group was discontinued after 2 patients met pre-specified criteria related to tolerability and patients assigned to the 32U were re-assigned to the 16U group.|t|f|t|f
34183084|NCT06266247|NA|SINGLE_GROUP||SCREENING||NONE||||||
33868258|NCT04201990|NA|SINGLE_GROUP||TREATMENT||NONE||About two to three weeks after cryoablation, Eligible patients sign informed consent and then begin treating with Camrelizumab and Apatinib.||||
34183085|NCT05085938|||COHORT||RETROSPECTIVE|||||||
34183086|NCT00212641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183087|NCT03520829|||OTHER||PROSPECTIVE|||||||
34183088|NCT03038100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183089|NCT02441543|||COHORT||PROSPECTIVE|||||||
34183090|NCT06649578|||COHORT||RETROSPECTIVE|||||||
34183091|NCT02951000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183092|NCT05403346|||OTHER||PROSPECTIVE|||||||
34183093|NCT04248426|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34183094|NCT02144896|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34183095|NCT01853670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183096|NCT02032017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183097|NCT04154904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183098|NCT02501291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183099|NCT03197896|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34183100|NCT03739268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34183101|NCT01798771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183102|NCT04077216|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Crossover trial|t|f|f|f
34183103|NCT03253952|||COHORT||PROSPECTIVE|||||||
34183104|NCT03056872|||COHORT||PROSPECTIVE|||||||
34183105|NCT02512783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183106|NCT06655662|NA|SINGLE_GROUP||TREATMENT||NONE||This phase 1 study employs a single-group, open-label design to evaluate the safety and preliminary efficacy of a gene therapy product. It is anticipated that 8 participants will be enrolled to receive a single administration of the investigational gene therapy. The primary focus will be on monitoring participants for adverse events and assessing the product's safety profile and potential therapeutic benefits.||||
34183107|NCT04509726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183108|NCT06459206|||CASE_ONLY||PROSPECTIVE|||||||
33753069|NCT05111561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868259|NCT05339581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868260|NCT02705807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868261|NCT04737408|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label design|Patients are randomized 1:1 to two different lipid lowering medical treatment strategies||||
33868262|NCT04656314|||COHORT||PROSPECTIVE|||||||
33868263|NCT01865630|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33868264|NCT02445118|||COHORT||PROSPECTIVE|||||||
34183109|NCT02817048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183110|NCT06440616|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34183111|NCT03429114|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34183112|NCT03337477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183113|NCT02609919|||COHORT||PROSPECTIVE|||||||
34183114|NCT00107341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183115|NCT02699749|NA|SINGLE_GROUP||OTHER||NONE||||||
34183116|NCT01655485|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34183117|NCT02202200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183118|NCT03131570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||To compare the secukinumab-receiving mild psoriasis subjects (Group 1) and the placebo-receiving mild psoriasis subjects (Group 2).|t|t|t|t
34183119|NCT03114683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183120|NCT04448535|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183121|NCT06277427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183122|NCT02211807|||COHORT||RETROSPECTIVE|||||||
34183123|NCT02364570|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34183124|NCT02119377|||CASE_ONLY||CROSS_SECTIONAL|||||||
34183125|NCT04382040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Patients will be randomized in a manner of 2:1 for study drug (ArteminC) and Standard of Care to Placebo and Standard of Care.~Patient study period will last 2 weeks. During this time, patients will be monitored for adverse events.~There will be a follow up period (until hospital discharge) in order to check side effects and study drug efficacy"|t|t|t|t
33868265|NCT02097524|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33868266|NCT06215521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a partially double-blind study (for LOXO-305 only, not moxifloxacin).||t|f|t|f
33868267|NCT05896514|||OTHER||PROSPECTIVE|||||||
33868268|NCT05690282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183126|NCT03763838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Participants in the standard of care arm will not be blinded; however, the two self-acupressure arms will be blinded as to which acupressure treatment they have been randomized. All study staff and researchers will remain blinded until after the completion of data analyses."||t|t|t|t
34183127|NCT01549899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183128|NCT02794909|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183129|NCT03024476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183130|NCT02083354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183131|NCT00106483|||COHORT||RETROSPECTIVE|||||||
34183132|NCT04954105|||COHORT||CROSS_SECTIONAL|||||||
34183133|NCT03408392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183134|NCT05233306|||CASE_CONTROL||PROSPECTIVE|||||||
34183135|NCT02346058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183136|NCT02524782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183137|NCT03499483|NA|SINGLE_GROUP||PREVENTION||NONE||Open Label single arm study||||
34183138|NCT00767364|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753070|NCT06171542|NA|SINGLE_GROUP||TREATMENT||NONE||All glenohumeral joint injections will be performed by a physician under the guidance of either ultrasound or fluoroscopy to ensure and document intra-articular needle placement. 2cc of CTM Flow will be injected. The glenohumeral joint will be injected with the medication under the discretion of the treating surgeon.||||
34183139|NCT01702311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183140|NCT06166615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183141|NCT05393440|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34183142|NCT01686919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753071|NCT04073238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753072|NCT05714514|||COHORT||PROSPECTIVE|||||||
33753073|NCT04665635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753074|NCT06723366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753075|NCT03965897|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a double-blind study. Participants and outcome assessors are blinded to treatment. Allocation to intervention group remains concealed until the beginning of the workshop when all invited participants have arrived. Those in attendance will receive the assigned intervention.|This study uses a cluster randomization approach where the unit of randomization is the workshops. Randomization occurs at the start of each workshop so that all participants attending that workshop are randomized to that intervention (i.e. ACT vs. AC). Statistician Dr. Zimmerman generates the randomization sequence using PLAN procedure (SAS v9.2). Randomization of workshops occurs in permuted blocks of 2 and 4 and are stratified by site (i.e. Iowa City versus Houston).|t|f|f|t
33753076|NCT05368779|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33753077|NCT05807139|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33753078|NCT03795298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753079|NCT04447170|||CASE_CONTROL||OTHER|||||||
33753080|NCT00109291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753081|NCT06723015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753082|NCT06732063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753083|NCT01105611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753084|NCT06733194|||COHORT||RETROSPECTIVE|||||||
33753085|NCT02644187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753086|NCT00493922|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868269|NCT05610904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33753087|NCT01106768|||COHORT||PROSPECTIVE|||||||
33753088|NCT00059358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964933|NCT05889026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33964934|NCT03124056|||COHORT||PROSPECTIVE|||||||
33964935|NCT02684383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33964936|NCT06157333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964937|NCT03757052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33964938|NCT03531515|||COHORT||PROSPECTIVE|||||||
33964939|NCT03038282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants, Investigator||f|f|f|t
33964940|NCT01671735|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964941|NCT04230954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964942|NCT04264559|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33964943|NCT04259879|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study was an Interventional study. There were three evaluations: the basal one was an initial evaluation after overnight fasting, the second evaluation 24 hours later (36 hours fasting) and the third one 24 hours post-refeeding.||||
33964944|NCT03095482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, treatment administrators, and outcome assessors will be blind to tDCS condition.|Participants will be randomly assigned to receive either (a) excitatory tDCS of the medial prefrontal cortex and inhibitory tDCS of right dorsolateral prefrontal cortex, or (b) sham tDCS|t|t|t|t
34183143|NCT02131259|||COHORT||PROSPECTIVE|||||||
33753089|NCT04244032|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868270|NCT00241995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33868271|NCT02741869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868272|NCT04144270|||COHORT||PROSPECTIVE|||||||
33868273|NCT00021320||||TREATMENT||||||||
33868274|NCT05472766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868275|NCT03922542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868276|NCT02720770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868277|NCT03461172|||COHORT||RETROSPECTIVE|||||||
33868278|NCT00766090|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33868279|NCT03623594|NA|SINGLE_GROUP||TREATMENT||NONE||Repair of the abdominal rectus diastasis with a double row plication using absorbable Quill||||
33868280|NCT01350921||CROSSOVER||BASIC_SCIENCE||NONE||||||
33868281|NCT02721030|||COHORT||PROSPECTIVE|||||||
33868282|NCT04807699|||COHORT||PROSPECTIVE|||||||
33868283|NCT03960073|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33868284|NCT02806089|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33868285|NCT03453658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be a different examiner who will be unaware of the allocated group.|Randomized, single-blind, controlled clinical trial with two parallel arms.|f|f|f|t
33868286|NCT04841980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33964945|NCT05547100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964946|NCT03060031|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33964947|NCT01414361|||CASE_ONLY||RETROSPECTIVE|||||||
33964948|NCT00405483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33964949|NCT00885131|||||PROSPECTIVE|||||||
33964950|NCT00202657|||CASE_CONTROL||PROSPECTIVE|||||||
33964951|NCT00690924|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33964952|NCT01241565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964953|NCT01341522|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33964954|NCT00830388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066139|NCT06303414|||COHORT||PROSPECTIVE|||||||
34066140|NCT04748848|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34066141|NCT04146844|||COHORT||CROSS_SECTIONAL|||||||
33964955|NCT04554407|NA|SINGLE_GROUP||PREVENTION||NONE||All participants receive the SOMAVAC® 100.||||
34183144|NCT03873142|NA|SINGLE_GROUP||TREATMENT||NONE|No party will be masked in this study. There is only one arm and participants will act as their own controls.|A single-group case-series design will be adopted, whereby one group of participants will complete daily and weekly measures over the course of 1) a 2-week baseline period; 2) an 8-week intervention period; 3) an 8-week follow up period. Variables collected during the intervention and follow-up period will be compared with those from the baseline period.||||
34183145|NCT00382707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183146|NCT01387477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183147|NCT00732030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183148|NCT00670254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868287|NCT03200054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33868288|NCT05353400|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868289|NCT05744622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964956|NCT05035485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33964957|NCT01677403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964958|NCT01457131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066142|NCT04686812|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183149|NCT02878343|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34183150|NCT00402948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183151|NCT04144790|||CASE_ONLY||PROSPECTIVE|||||||
34183152|NCT00739869|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33868290|NCT05054647|||COHORT||PROSPECTIVE|||||||
33868291|NCT04288063|||COHORT||PROSPECTIVE|||||||
33868292|NCT03154814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Retrospective cohort study||||
33868293|NCT01906775|||CASE_ONLY||PROSPECTIVE|||||||
33868294|NCT03013673|||COHORT||PROSPECTIVE|||||||
33868295|NCT01582087|||COHORT||RETROSPECTIVE|||||||
33868296|NCT03912311|||CASE_ONLY||PROSPECTIVE|||||||
33964959|NCT05974020|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964960|NCT00947245|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33964961|NCT03820973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964962|NCT01950806|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33964963|NCT00524875|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33964964|NCT05913388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964965|NCT04953585|||COHORT||RETROSPECTIVE|||||||
33964966|NCT01866488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964967|NCT04371419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33964968|NCT04632693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33964969|NCT02631044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964970|NCT01645228|||CASE_CONTROL||PROSPECTIVE|||||||
34066143|NCT01422707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183153|NCT05114421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183154|NCT01475760|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34183155|NCT00910416|||COHORT||PROSPECTIVE|||||||
34183156|NCT03125395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183157|NCT05395975|||COHORT||PROSPECTIVE|||||||
34183158|NCT00497081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964971|NCT00811070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33964972|NCT06412237|NA|SINGLE_GROUP||TREATMENT||NONE||Single site, pilot, feasibility study that focuses on the transition of technology use from the clinic to home environment.||||
33964973|NCT04627870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753090|NCT02381041|||COHORT||PROSPECTIVE|||||||
33753091|NCT01239030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33964974|NCT02832791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33964975|NCT04428502|||COHORT||RETROSPECTIVE|||||||
33964976|NCT06543316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, two-arm, crossover clinical study||||
33964977|NCT02642107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964978|NCT04729218|||OTHER||PROSPECTIVE|||||||
34066144|NCT01056913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066145|NCT06333483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183159|NCT05482126|||CASE_CONTROL||PROSPECTIVE|||||||
33753092|NCT05732909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Two-day cross-over design.|t|f|t|f
33753093|NCT05936567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183160|NCT02555267|||COHORT||PROSPECTIVE|||||||
34183161|NCT06025214|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
34183162|NCT04171843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In Phase I, 3 escalating dose groups will be enrolled and treated sequentially, with the possibility of a single de-escalation. Within each dose group, at least 3 and at most 6 study participants will be treated with a single dose of PBCAR269A using a standard 3 + 3 design. The starting dose of PBCAR269A will be 6 x 105 CAR T cells/kg body weight. Subsequent dose groups will be treated with escalating doses to a maximum dose of 6 x 106 CAR T cells/kg. In the absence of DLTs, the dose will be increased using a fixed-dose scheme.||||
34183163|NCT02869152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183164|NCT04367974|||CASE_CONTROL||PROSPECTIVE|||||||
34183165|NCT00299299|||||PROSPECTIVE|||||||
34183166|NCT00408317|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33868297|NCT05473377|||COHORT||CROSS_SECTIONAL|||||||
33868298|NCT02900079|||COHORT||PROSPECTIVE|||||||
34151403|NCT04506333|NON_RANDOMIZED|CROSSOVER||OTHER||NONE|Investigators and assessors will need to know which device is associated with each measurement to perform analysis as specified in ISO/ESH/AAMI standards, but observers taking manual reference blood pressure measurements will be blinded as to each other's measurements.|The ISO/ESH/AAMI standards for validating blood pressure measurement devices will be used. In this model, participants' blood pressures are taken alternating between the test device and a reference device.||||
34183167|NCT00130572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151404|NCT05184933|NA|SINGLE_GROUP||OTHER||NONE||All participants will complete all parts of the study. The order of completion of the second experiment (Overnight Sleep and Rested Wakefulness trials) will be randomized.||||
34151405|NCT02478255|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151406|NCT03332160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183168|NCT02295904|||COHORT||PROSPECTIVE|||||||
34183169|NCT04677088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183170|NCT03500718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868299|NCT06099899|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33868300|NCT01396226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34151407|NCT00536952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34151408|NCT03744520|NA|SINGLE_GROUP||SCREENING||NONE||||||
34151409|NCT02686502|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868301|NCT01595984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868302|NCT01442194|||COHORT||PROSPECTIVE|||||||
33868303|NCT03524885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868304|NCT04200235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Dexmedetomidine hydrochloride nasal spray compared with placebo|t|t|t|t
33868305|NCT03314077|||COHORT||OTHER|||||||
33868306|NCT01733966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868307|NCT02665299|||COHORT||PROSPECTIVE|||||||
33868308|NCT02470026|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34151410|NCT02606357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151411|NCT02561559|||COHORT||PROSPECTIVE|||||||
34151412|NCT00006094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151413|NCT05819619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151414|NCT05521438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
34151415|NCT02641717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151416|NCT04237246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151417|NCT05976009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151418|NCT04863690|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34151419|NCT06191575|||COHORT||PROSPECTIVE|||||||
34151420|NCT05701566|NON_RANDOMIZED|PARALLEL||OTHER||NONE||pilot randomized controled study||||
34151421|NCT00189904|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151422|NCT00004874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151423|NCT00313859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151424|NCT00083928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151425|NCT03300778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34151426|NCT00110461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151427|NCT01436266|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151428|NCT00709410|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151429|NCT04124003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151430|NCT02407782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151431|NCT00747409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151432|NCT01657708|RANDOMIZED|CROSSOVER||||DOUBLE|||t|t|f|f
34151433|NCT02182271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151434|NCT04477031|||OTHER||PROSPECTIVE|||||||
34151435|NCT00337792|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34151436|NCT01705912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151437|NCT03583736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151438|NCT00436592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151439|NCT06444126|||COHORT||PROSPECTIVE|||||||
34151440|NCT02582047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151441|NCT05760534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151442|NCT01286103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151443|NCT02626390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151444|NCT05329207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was in the design type with pretest-posttest control group, repeated measures in randomized groups.||||
34151445|NCT05026853|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There will be two arms (1: 1 randomization) of the trial to assess PRO integration into care||||
34151446|NCT04413760|||COHORT||CROSS_SECTIONAL|||||||
34151447|NCT00694304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151448|NCT01067365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151449|NCT03890367|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind: the participant (or legally acceptable representative), and the Investigator remained unaware of the treatment assignments throughout the study. An unblinded vaccine administrator administered the appropriate vaccine but was not involved in safety data collection.||t|t|t|t
34151450|NCT01171209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151451|NCT05840588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151452|NCT06303895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151453|NCT02092766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151454|NCT00772681|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151455|NCT03380052|||CASE_CONTROL||PROSPECTIVE|||||||
34151456|NCT00169221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151457|NCT05031078|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151458|NCT03918707|||COHORT||PROSPECTIVE|||||||
33868309|NCT02023242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868310|NCT01299376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868311|NCT00161460|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868312|NCT02169050|||CASE_ONLY||CROSS_SECTIONAL|||||||
33964979|NCT04945161|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Study design:~1. □Control: ■placebo~   * active (please specify name and dosage)~  * other~  * Uncontrolled~2. Blinding: □open-label □evaluator blind □single blind ■double blind~   □double dummy □other~3. Randomized: ■yes □no~4. ■Parallel □Cross-over □Other~5. Duration of treatment: Six (6) weeks~6. Titration: □forced □optional ■none~7. □Multi-national ■Multi-center(Taiwan): 2 sites □Single center"|A randomized, double-blind, placebo-controlled clinical study to explore the mechanism of action (MOA) of ON101 cream in patients with diabetic foot ulcers (DFUs).The primary objective is to explore the mechanistic role of ON101 cream in healing diabetic foot ulcers by determining the molecular targets of ON101 cream.|t|f|t|f
33964980|NCT04448691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective study with serial CCTA||||
34183171|NCT04124809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|only the investigator knew the procedure provided for each case|patients with sibling blastocysts divided into 2 groups: Study group (artificially laser-collapsed blastocysts; n=71) \& control group (blastocysts were vitrified without laser collapse; n=66) then reexpansion speed and survival rate was assessed immediately \& at 140 min after thawing and compared between two groups.|t|t|f|t
34183172|NCT05173558|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34183173|NCT03743168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183174|NCT02851615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183175|NCT02476253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183176|NCT03857867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183177|NCT02756559|||CASE_CONTROL||PROSPECTIVE|||||||
34183178|NCT04881994|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183179|NCT06431152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183180|NCT01322620|||COHORT||CROSS_SECTIONAL|||||||
34183181|NCT00078585|RANDOMIZED|||TREATMENT||DOUBLE||||||
34183182|NCT04725578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183183|NCT01021020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34183184|NCT02487615|||COHORT||CROSS_SECTIONAL|||||||
34183185|NCT00940771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183186|NCT02796599|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183187|NCT02919995|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34183188|NCT01254617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183189|NCT02919839|||CASE_ONLY||PROSPECTIVE|||||||
34183190|NCT06431997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183191|NCT06588946|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind masking|placebo-controlled parallel-arm model|t|f|t|f
34183192|NCT01383356|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34183193|NCT05588921|||COHORT||RETROSPECTIVE|||||||
33753094|NCT05530551|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Blinding will not be applicable, because it is considered infeasible to expose participants and clinical personnel to this in either of the groups since any specific clinic will follow their allocated specific (single- or multiple-dose) routine during an entire 1-year period and their routine treatment of any complication (before switching).|The Pro-Hip-Quality Trial is a Cluster Randomized Trial with an embedded Cross-Over Design where each clinical center (C: 1, 2, 3, ...., 36 individual sites) will be running a specific intervention (i.e. single- or multiple-dose antibiotics) throughout 12 months, and the subsequent year the clinical department will automatically switch to the opposite intervention (i.e. multiple- or single-dose antibiotics).||||
33753095|NCT02048332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753096|NCT03464812|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33868313|NCT03210350|||CASE_ONLY||PROSPECTIVE|||||||
33868314|NCT03305289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33868315|NCT06388850|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A stepped wedge cluster randomized clinical trial design will be used to assess the efficacy of two linked curricula of the Healthy Relationships Project (HRP): Care for Kids (Pre-K through 2nd Grade) and We Care Elementary (3rd through 5th Grade). The HRP includes a 1.5 hour training for school staff prior to implementation, six 30-minute classroom lessons delivered to students once per week for 6 weeks, and 3 caregiver workshops.||||
34183194|NCT04793217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34183195|NCT01875653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183196|NCT01532986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34183197|NCT00004854||||DIAGNOSTIC||||||||
34183198|NCT05606445|||COHORT||CROSS_SECTIONAL|||||||
34183199|NCT01711840|||COHORT||PROSPECTIVE|||||||
34183200|NCT02202759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183201|NCT02755246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868316|NCT03832803|RANDOMIZED|PARALLEL||OTHER||NONE|Investigator masking for randomisation purposes only. Masking not possible for intervention whilst on treatment.|50 patients receiving radical radiotherapy to the prostate were randomised using 1:1 into 2 groups. Group A followed the conventional drinking protocol at our centre (200ml prior to treatment) and group B were treated with an empty bladder. Baseline, end of treatment and 6 week follow up scores were prospectively collected for IPSS, LENT SOMA bowel toxicity and quality of life questionnaires.||||
33868317|NCT04611971|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753097|NCT04895722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868318|NCT05275075|||COHORT||CROSS_SECTIONAL|||||||
33868319|NCT01764542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33868320|NCT06037642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183202|NCT01834989|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34183203|NCT00425802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183204|NCT05072236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33753098|NCT04401267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation of the MRIs defining the primary endpoint will be performed by a blinded radiologist.||f|f|f|t
33753099|NCT03939377|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33868321|NCT00482703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868322|NCT05038254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33868323|NCT06432829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are informed of the assigned intervention condition before the start of the intervention|Participants will be recruited through the Psychological Care Unit (UNAP) of the University of Cordoba (Spain). The UNAP will refer to the research team those persons whose reason for consultation refers to an emotional problem (anxious and/or depressive symptomatology). Potential participants will be contacted by the research team via email and will be sent an information sheet about the study and informed consent, which they will be able to read and sign online through a Google Forms link.|t|f|f|f
33964981|NCT06527391|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Manufacturer of choline and placebo tablets will randomize the regimens and hold the randomization key|Randomized, double-blinded, placebo-controlled trial of 9 months of daily choline supplementation of 300 6-month-old Ugandan infants with iron deficiency anemia|t|t|t|t
33964982|NCT00529568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964983|NCT06516497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33964984|NCT06348654|||CASE_ONLY||RETROSPECTIVE|||||||
33964985|NCT06536790|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|Randomized clinical trial|f|f|f|t
33964986|NCT01303874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183205|NCT03408093|||COHORT||CROSS_SECTIONAL|||||||
34183206|NCT04819542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183207|NCT04646421|||CASE_CONTROL||OTHER|||||||
34183208|NCT01497496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183209|NCT04436952|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Group 1 - 20 patients undergoing DTMS treatment using the H7 coil~2. Group 2 - 20 patients undergoing rTMS treatment using the cool D-B80 coil~3. Group 3 - 20 patients undergoing DTMS treatment using the H7 coil + ERP~4. Group 4 - 20 patients undergoing rTMS treatment using the cool D-B80 coil + ERP~5. Group 5 - 20 patients undergoing ERP only"||||
34183210|NCT02762396|||CASE_ONLY||PROSPECTIVE|||||||
34183211|NCT02655120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183212|NCT06469034|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34183213|NCT06256406|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study adopts a comprehensive approach to explore the effects of three interventions on the well-being and development of newborns in the Neonatal Intensive Care Unit (NICU). The interventions include optimizing the NICU environment for comfort, implementing kangaroo care for parent-infant bonding, and integrating music therapy. The research focuses on two distinct groups within the NICU: premature infants and those undergoing surgical procedures. By examining these interventions across these groups, the study aims to provide nuanced insights into enhancing the holistic care of newborns in critical care settings, tailoring approaches to the unique needs of each population.||||
34183214|NCT03426748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183215|NCT05669274|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||New World milk containing both a1 and a2 beta-casein vs. Old World milk containing only a2 beta-casein|t|f|t|t
34183216|NCT00497484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183217|NCT00381901|RANDOMIZED|||TREATMENT||||||||
33868324|NCT00795249|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33964987|NCT04636801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33964988|NCT03805178|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183218|NCT06654596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753100|NCT04130516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753101|NCT02063828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34183219|NCT03581279|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|All patients are assigned a unique study ID number to de-identify them.||t|f|t|t
33868325|NCT05445284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data analysts|"Active arm: Participants randomized to the active arm will be asked to attend ≥ 3 group education sessions for parents of adolescents with T1D, in addition to their usual diabetes clinic visits every 3 months, over the 12-month intervention period. Group education sessions will coincide with regularly scheduled clinic visits.~Control arm: Participants randomized to usual care will attend their usual 3-month interval diabetes clinic visits, over the 12-month intervention period, which consists of visits with their diabetes care physician."|f|f|f|t
34183220|NCT05738486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase 3b|t|f|t|f
34183221|NCT01075529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183222|NCT02239419|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34183223|NCT04276467|||CASE_ONLY||PROSPECTIVE|||||||
34183224|NCT04466319|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled experimental study in patients with open gastrointestinal tract surgery to evaluate the effect of rocking chair movement to be given in addition to standard care at the start of postoperative bowel functions (post-operative first gas, initial defecation||||
33868326|NCT00312221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868327|NCT03715842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868328|NCT03555513|||COHORT||CROSS_SECTIONAL|||||||
33868329|NCT00908024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868330|NCT01672567|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33868331|NCT06409039|||COHORT||OTHER|||||||
33868332|NCT04993235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33868333|NCT00659620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868334|NCT02289170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33868335|NCT01129921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34183225|NCT04402372|||COHORT||PROSPECTIVE|||||||
34183226|NCT02481219|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183227|NCT06603519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183228|NCT01295814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183229|NCT05265429|||COHORT||OTHER|||||||
34183230|NCT00422682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183231|NCT00025181||||TREATMENT||||||||
34183232|NCT06002880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183233|NCT00643864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183234|NCT02982746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183235|NCT06316102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183236|NCT04087109|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|The investigator will receive anonymous data and when performing the analysis will not know if the participant received the intervention or not. The same is true for the outcome assessor (blinded to study intervention). All patient and time identifiers stripped from the outcome adjudication.|Stepped wedge randomized control trial|f|f|t|t
34183237|NCT04004364|||OTHER||PROSPECTIVE|||||||
34183238|NCT02118584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183239|NCT00912197|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34183240|NCT04255238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753102|NCT05596448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753103|NCT05554354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753104|NCT01421433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753105|NCT04466748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868336|NCT03071614|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
33868337|NCT03072784|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33964989|NCT04618679|||CASE_ONLY||CROSS_SECTIONAL|||||||
33964990|NCT03956667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"Participants will be recruited to the experimental (Live Music) arm on days that the musicians are working in the Emergency Department.~Participants will be recruited to the control (Non Music) arm on days that there are no musicians present in the Emergency Department."|||||
33964991|NCT01081483|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33964992|NCT01113294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183241|NCT02844569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183242|NCT00661050|||COHORT||PROSPECTIVE|||||||
34183243|NCT04693819|||COHORT||CROSS_SECTIONAL|||||||
33964993|NCT01452113|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33964994|NCT03548207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33964995|NCT01001871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33964996|NCT00218621|||COHORT||PROSPECTIVE|||||||
33964997|NCT04946422|||OTHER||RETROSPECTIVE|||||||
33964998|NCT00845754|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33964999|NCT04504929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33965000|NCT00966082|RANDOMIZED|PARALLEL||PREVENTION||NONE||Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol||||
33965001|NCT00861055|||COHORT||PROSPECTIVE|||||||
33965002|NCT04137991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965003|NCT05148130|||CASE_CONTROL||PROSPECTIVE|||||||
33965004|NCT00508638|||COHORT||PROSPECTIVE|||||||
33965005|NCT05927805|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33965006|NCT00213213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965007|NCT00328042|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34066146|NCT04337476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After acquiring informed consent, participants will be randomized randomly through computerized, block randomization by intervention group or group of control, which will assign a specific group to the newborns (mom voice, dad voice, music therapist voice or no voice). The clinical team and parents will be blind to the study group and will not know when the recordings will be reproduced. The administration of the PAL and the reproduction of the relative voices will be performed by the music therapist.|Prospective randomized controlled trial, divided into four parallel groups of preterm infants|f|t|t|f
34183244|NCT05087004|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participating Planned Parenthood affiliates recruited teens to their Teen Council program each study year during the spring and summer months. Interested teens completed an application and, if after review they were deemed by the program to be good candidates, they were interviewed. Active consent was obtained from the parents or guardians of all eligible youth and teen assent was also collected. Twice as many qualified applicants as spots on each Teen Council were accepted and their names were submitted to Philliber for random assignment to the program or survey-only groups.||||
34183245|NCT00400166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183246|NCT01590355|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183247|NCT00153244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183248|NCT01498068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183249|NCT00638677|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34183250|NCT01544257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183251|NCT01765933|NA|SINGLE_GROUP||||NONE||||||
34183252|NCT02839200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183253|NCT01213472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183254|NCT01238926|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34183255|NCT02875236|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34183256|NCT00756899|||CASE_CONTROL||PROSPECTIVE|||||||
34183257|NCT01658436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183258|NCT05021406|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183259|NCT05849493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183260|NCT01881828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183261|NCT04866784|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The experimenter and subject will be blinded to the treatment conditions. A second experimenter will administer the Active or Placebo TENS, or the Control to ensure appropriate blinding (to ensure no bias from knowing which TENS condition is given at each visit).|The study is a prospective, randomized, double-blinded and placebo-controlled crossover design (all participants complete each of the 3 conditions) with randomization to: 1) Active TENS; 2) Placebo TENS; or 3) No Treatment Control. Each subject will receive the 3 TENS treatments in randomized order (one visit per week in three separate weeks). The visits do not have to take place in three consecutive weeks (will depend on participant scheduling preferences), but all three visits must take place within one year|t|f|f|t
34183262|NCT05287906|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34183263|NCT04135417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183264|NCT01017302|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183265|NCT02892344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183266|NCT02074501|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34183267|NCT01745458|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33965008|NCT04188496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965009|NCT02657356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965010|NCT03178019|||OTHER||CROSS_SECTIONAL|||||||
33965011|NCT03570580|||COHORT||PROSPECTIVE|||||||
33965012|NCT01807962|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33965013|NCT00002747|RANDOMIZED|||TREATMENT||||||||
34066147|NCT01941537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066148|NCT04257630|||COHORT||PROSPECTIVE|||||||
34066149|NCT02838472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066150|NCT01381380|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066151|NCT00649246|||COHORT||PROSPECTIVE|||||||
34183268|NCT04284228|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"There are two parts to this study. The initial Safety Evaluation Phase will determine the safety and tolerability of a single dose of NEXI-001 T cells.~The second part of the study, the Dose Expansion Phase, to further define the safety and evaluate the initial efficacy of the NEXI-001 T cells at the dose established from the Safety Evaluation Phase."||||
34183269|NCT01829958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868338|NCT03360097|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will be randomized by an intention to treat approach. Randomization at the blastocyst stage is chosen to avoid cycle cancellation if randomized earlier. All components of the IVF/ICSI cycle including stimulation medications, monitoring protocols, etc. will be at the discretion of the participant's primary physician; while this information will be documented it will not constitute criteria for enrolment. The group allocation will take place the day of the embryo transfer. The clinician will randomize all included patients into one of the two study groups using an open computer-generated list. An interim analysis is planned and sample size will be plan accordingly, under the Pocok method, including 2 stages, with p-value as boundary scale, calculated to have 80% power to detect a 20% difference with a reference proportion of 25% clinical pregnancy rate and a one-sided (upper) alpha of 0.025||||
33868339|NCT05066321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868340|NCT05388552|||CASE_ONLY||PROSPECTIVE|||||||
33868341|NCT04057534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868342|NCT00003865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868343|NCT02098512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868344|NCT02327052|||OTHER||CROSS_SECTIONAL|||||||
33868345|NCT04586400|||COHORT||PROSPECTIVE|||||||
33868346|NCT04021199|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868347|NCT00593944|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868348|NCT03540225|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||2 x 2 factorial designed trial with two factors of 200mg vs. 400mg vaginal progesterone daily from 11-14 weeks' gestation vs. 20-24 weeks'|t|t|t|f
33868349|NCT01084915|||CASE_ONLY||RETROSPECTIVE|||||||
33868350|NCT03543111|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34183270|NCT00926770|||CASE_CONTROL||PROSPECTIVE|||||||
34066152|NCT03486964|||COHORT||RETROSPECTIVE|||||||
34183271|NCT00002337||||TREATMENT||NONE||||||
34183272|NCT02233517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183273|NCT05306535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34183274|NCT01894893|||COHORT||PROSPECTIVE|||||||
34183275|NCT01523912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183276|NCT03366896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066153|NCT01587625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183277|NCT06373367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34183278|NCT00462995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183279|NCT01249261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183280|NCT00013221|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33868351|NCT00314353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868352|NCT01665547|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33868353|NCT04350255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868354|NCT05811715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33868355|NCT01249820|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34066154|NCT00808470|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066155|NCT03300180|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34066156|NCT04333225|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066157|NCT04624542|||OTHER||CROSS_SECTIONAL|||||||
34183281|NCT06306716|||CASE_ONLY||PROSPECTIVE|||||||
34183282|NCT00095888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183283|NCT00612144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183284|NCT01202968|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34183285|NCT01197118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183286|NCT01487343|||COHORT||PROSPECTIVE|||||||
34183287|NCT04899596|||CASE_ONLY||RETROSPECTIVE|||||||
34183288|NCT04570007|||COHORT||PROSPECTIVE|||||||
34183289|NCT02351622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183290|NCT01356576|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34183291|NCT03834181|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34183292|NCT05827172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183293|NCT00036985|RANDOMIZED|||TREATMENT||NONE||||||
34183294|NCT04279717|||COHORT||CROSS_SECTIONAL|||||||
34183295|NCT04321213|||CASE_ONLY||CROSS_SECTIONAL|||||||
34183296|NCT00533208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868356|NCT01213875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868357|NCT04285242|||COHORT||PROSPECTIVE|||||||
33868358|NCT02539420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868359|NCT03441334|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183297|NCT00076635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183298|NCT03136510|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||"60 patients with two subgroups~* 30 patients with new diagnosis of atrial fibrillation (vitamin K antagonist treatment shorter than 1 week) : initiated with Apixaban 5 mg~* 30 patients previously chronically treated by VKA for more than 3 months and switched to Apixaban 5 mg"|f|f|f|t
34183299|NCT04220463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Patient randomization will be done online.~SETTING UP AND MAINTAINING THE INSU People having knowledge of the randomization group~* Doctor in charge of the patient~* Doctor/IDE dedicated to hypnosis (present throughout the procedure, regardless of the randomization group)~* Patient People not having knowledge of the randomization group~* assessor = other IDE or doctor not directly taking care of the patient assessor present at 4 times: inclusion, H0, H2 and H24 but absent during the procedure 1 single assessor for the 4 times of the same patient"|Prospective monocentric, controlled, randomized, superiority, open study with a blind assessor, on two parallel groups.|f|f|f|t
33868360|NCT05968898|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183300|NCT01198496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183301|NCT02148874|||CASE_CONTROL||PROSPECTIVE|||||||
34183302|NCT00472576|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34183303|NCT04073108|||CASE_ONLY||PROSPECTIVE|||||||
34183304|NCT01317602|||CASE_ONLY||PROSPECTIVE|||||||
34183305|NCT00986648|||COHORT||PROSPECTIVE|||||||
34066158|NCT04368832|||OTHER||PROSPECTIVE|||||||
34066159|NCT01421992|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34183306|NCT03086811|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Mealtime interactions by videotaped home setting feeding were evaluated using the Chatoor feeding scale by blinded to group viewers.|Intervention group got 4 sequential weekly training meetings, in small workshop groups setting, by a highly experience pediatric dietitian and social worker. The program covered nutritional aspects, as well as feeding and parenting topics. Training took place when infants were 4-6 months old. Thereafter, internet-based support continued until infants reached 12 months. The control group received customary support via municipal mother-child health clinics. Mealtime interactions by videotaped home setting feeding were documented at 12-13 months.|f|f|f|t
34183307|NCT01356628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183308|NCT05943002|||COHORT||PROSPECTIVE|||||||
34183309|NCT02902289|RANDOMIZED|CROSSOVER||||NONE||||||
34183310|NCT06654336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183311|NCT01470521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183312|NCT03768934|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized to one of four airtime amounts: 1) no incentive; 2) 1X incentive; 3) 2X incentive or 4) a lottery incentive, in which one out of every 20 participants will receive the incentive.|f|f|f|t
34183313|NCT05330286|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183314|NCT05799885|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33868361|NCT01800448|||COHORT||PROSPECTIVE|||||||
34066160|NCT00574691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066161|NCT06142734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183315|NCT03925285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients are administered with bevacizumab-800CW. 2-4 days later, fluorescence imaging will be performed peroperatively||||
34183316|NCT04591613|NA|SINGLE_GROUP||OTHER||NONE||||||
34183317|NCT00587314|||COHORT||PROSPECTIVE|||||||
34183318|NCT03388710|||COHORT||PROSPECTIVE|||||||
34183319|NCT00131768|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183320|NCT05073874|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183321|NCT01642576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183322|NCT01486719|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34183323|NCT06242652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183324|NCT00577304|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34183325|NCT01162096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183326|NCT05847946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Core stability and pelvic floor exercises will be compared with kinesiotape application.|f|f|f|t
34183327|NCT02922322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34183328|NCT05048277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183329|NCT04876820|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34183330|NCT04341246|||CASE_CONTROL||PROSPECTIVE|||||||
33868362|NCT00063570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183331|NCT02910479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183332|NCT03824769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183333|NCT04412551|||COHORT||PROSPECTIVE|||||||
34183334|NCT04591808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183335|NCT03638193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183336|NCT00942604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183337|NCT05216549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183338|NCT04374669|||COHORT||PROSPECTIVE|||||||
34183339|NCT03414983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183340|NCT01849991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183341|NCT00610298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183342|NCT05104138|||COHORT||RETROSPECTIVE|||||||
34183343|NCT01371357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183344|NCT06654193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This multicenter, prospective, randomized, double-blind, placebo controlled pragmatic Phase 1/Phase 2a clinical study will enroll severely injured trauma or burn patients who have developed Stage 2 AKI. Eligible patients will be randomized to receive Hope Biosciences (HB)-adMSCs or placebo administered within 24 hours of consent and in 3 doses, each 24 hours apart.~The investigators will enroll 10 patients in Cohort 1, the Phase 1 safety substudy. All patients in Cohort 1 will receive active investigational product (IP).~The investigators will enroll 60 patients in Cohort 2, the Phase 2a substudy; 30 patients will receive active IP, and 30 will receive placebo via randomization.~The study population is trauma and burn patients admitted to participating hospitals who meet the inclusion and exclusion criteria. The study population will be reflective of the general trauma population at the participating sites."|t|t|t|f
34183345|NCT05490225|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pivotal, interventional, prospective, single arm, open-label study.||||
34183346|NCT02559141|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183347|NCT06589323|||COHORT||PROSPECTIVE|||||||
34183348|NCT05432440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessors for collecting outcome data at 1 and 2 months will be masked to group allocation. They will also be prohibited to contact patients directly.|After informed consent provision and baseline assessment, participants will be allocated into two groups, including the intervention group (IG) and the control group (CG). The intervention will be a computer-based asthma self-management education entitled Module of Inhaler and Asthma Triggers for Children (MIRACLE) and usual care. It will consist of interactive narratives and a serious game, an asthma action plan, and a video of the inhaler technique. The control group will receive a paper-based asthma education (booklet) and usual care. The study duration will be set for 2 months by applying those media for 7 days at home and the minimum required time for using the MIRACLE program will be 15 minutes per day. Two groups will be equipped with a peak flow meter and an asthma action plan, and they will be encouraged to write their daily symptoms and activities in a diary.|f|f|f|t
34183349|NCT05462522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868363|NCT01683279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868364|NCT02806128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868365|NCT00194181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868366|NCT00136422|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868367|NCT04366050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868368|NCT01342484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868369|NCT02363348|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33868370|NCT04935398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Simple blind||f|f|t|f
33868371|NCT05913154|||COHORT||CROSS_SECTIONAL|||||||
33868372|NCT04622332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded||t|t|t|t
33868373|NCT00609193|||COHORT||PROSPECTIVE|||||||
33868374|NCT02430350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868375|NCT00649259|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33868376|NCT04288986|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study will use a pretest-posttest quasi experimental design. Participants will complete a serious of questionnaires prior to participating in an 8 week activity programme and again after completing the programme.||||
33868377|NCT04950179|||CASE_ONLY||RETROSPECTIVE|||||||
33868378|NCT04027699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868379|NCT01022996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868380|NCT04024644|||OTHER||OTHER|||||||
34066162|NCT06311409|||COHORT||PROSPECTIVE|||||||
34066163|NCT01858259|||COHORT||PROSPECTIVE|||||||
34066164|NCT06347393|NA|SINGLE_GROUP||SCREENING||NONE||||||
34183350|NCT00432172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183351|NCT03771664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183352|NCT01080079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183353|NCT00686712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183354|NCT01219881|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34183355|NCT05110924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The patient will go through the stratification and randomization process and will be randomly allocated to either the treatment or the non-treatment arm of the study.~The treatment (i.e. surgery, topical treatment or CO2-laser) will be performed by an independent dermatologist of the investigator's department who is blinded and is not aware of the patient's participation in this study."||f|t|f|f
34183356|NCT00518102|||COHORT||RETROSPECTIVE|||||||
34183357|NCT01482208|||CASE_ONLY||PROSPECTIVE|||||||
34183358|NCT04634253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183359|NCT01780740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33753106|NCT02668081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753107|NCT05390970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33753108|NCT06733116|||COHORT||PROSPECTIVE|||||||
33753109|NCT05060016|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33868381|NCT00002128||||TREATMENT||||||||
33868382|NCT00823849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868383|NCT06450249|||COHORT||RETROSPECTIVE|||||||
33868384|NCT02301663|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868385|NCT00121108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868386|NCT03953430|||COHORT||RETROSPECTIVE|||||||
33868387|NCT01520233|||COHORT||RETROSPECTIVE|||||||
33868388|NCT05065372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868389|NCT03574753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868390|NCT05328479|||COHORT||RETROSPECTIVE|||||||
33868391|NCT04194788|||COHORT||PROSPECTIVE|||||||
33868392|NCT06350838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868393|NCT05903248|||OTHER||OTHER|||||||
33868394|NCT02349594|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33868395|NCT01929239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868396|NCT02131441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868397|NCT03029741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868398|NCT03341975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33868399|NCT05476042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33868400|NCT03926689|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868401|NCT00998270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868402|NCT03073668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868403|NCT02831192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868404|NCT01194453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868405|NCT04941066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants are randomly assigned to a cognitive process-based real-time fMRI neurofeedback (CNF) or a sham condition.|t|t|t|t
33868406|NCT03786562|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868407|NCT01400035|||CASE_CONTROL||PROSPECTIVE|||||||
33868408|NCT01210092|||||PROSPECTIVE|||||||
33868409|NCT01898871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868410|NCT01421940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33868411|NCT02630342|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868412|NCT05315050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868413|NCT04165226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868414|NCT01154244|||||PROSPECTIVE|||||||
33868415|NCT06010771|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33868416|NCT01634035|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33868417|NCT03423420|||COHORT||RETROSPECTIVE|||||||
33868418|NCT03086499|||CASE_ONLY||RETROSPECTIVE|||||||
33868419|NCT04026347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject and assessor blinded to randomization result||t|f|f|t
34066165|NCT05680142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the block, another anesthetist who did not know which group the patient belonged to was included in the study blindly. The patients were taken to the recovery unit in the postoperative period, and their analgesic needs, frequency of nausea and vomiting, VAS scores and additional problems were followed up by the nurse who was blindly included in the study.|In the preoperative period, the participant groups will be divided into two separate groups, Group cESP and Group sCPB, according to the type of block applied.|f|t|f|t
34066166|NCT05975918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066167|NCT02637388|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34183360|NCT00242502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183361|NCT01621269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183362|NCT04541472|||COHORT||CROSS_SECTIONAL|||||||
34183363|NCT04247685|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The investigators will aim to recruit 2-3 patients per month, with a total of 40 patients over two years. These 40 patients will be assigned into two MRI groups -12-lead ECG gating system as the study group and 3-lead ECG gating system as the control group. The study group patients will have MRI with 12-lead ECG monitoring device produced by a Massachusetts-based medical device company MiRTLE Medical, while the control group will have MRI with 3-lead ECG gating which is standard of care. Diagnostic image quality and severity of artifact will be evaluated to compare these two groups.||||
34183364|NCT04588038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183365|NCT06025864|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter Randomized Clinical Trial||||
34183366|NCT02096302|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34183367|NCT05511584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183368|NCT01394796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183369|NCT01192191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183370|NCT02260687|||COHORT||PROSPECTIVE|||||||
34183371|NCT00042822||||TREATMENT||||||||
34183372|NCT02071394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183373|NCT03891381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be under anesthesia and unaware of type of monitoring used in the operating room|Patients will be randomized to a qualitative (peripheral nerve stimulator) or quantitative (Tetragraph) monitor|t|f|f|f
34183374|NCT00545636|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|t|f|f
34183375|NCT00760032|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34183376|NCT04299607|||COHORT||PROSPECTIVE|||||||
34183377|NCT01307696|||COHORT||RETROSPECTIVE|||||||
34183378|NCT01958372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183379|NCT02132988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753110|NCT05471960|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Outcome assessor will be blind to the group status during data processing and analyses|Prospective (assessments at baseline and 24 months) cross sectional design. Two groups (iRBD, controls)||||
33753111|NCT05934513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753112|NCT05697848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868420|NCT03664154|NA|SINGLE_GROUP||PREVENTION||NONE||A one-group longitudinal repeated measures design. Data will be collected at baseline, 8-weeks, 12-weeks, and 16-weeks||||
33868421|NCT01839396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33965014|NCT00950599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965015|NCT05485688|||CASE_CONTROL||PROSPECTIVE|||||||
34183380|NCT00068692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183381|NCT05656144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183382|NCT02195102|||COHORT|||||||||
34183383|NCT02343640|||COHORT||PROSPECTIVE|||||||
33868422|NCT04568278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Statistician who will analyze the results of the study will be blinded|Randomized Controlled Trial, Single center, Open label||||
33868423|NCT06208384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965016|NCT05934552|||COHORT||PROSPECTIVE|||||||
33965017|NCT01448265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868424|NCT00773721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868425|NCT01776762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33868426|NCT03000179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868427|NCT02794818|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33868428|NCT05453032|NA|SINGLE_GROUP||TREATMENT||NONE||we recruited 10 patients who attended a 10-session of tDCS stimulation. Each session lasted for 20 minutes in a 2-week.||||
33868429|NCT04169490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blinded study, which means that neither the evaluating physician nor the subject will know which treatment is administered. A separate study staff member will administer the treatment, as well as answer questions and discuss any problems prior to starting, and for the duration of, the study.|"The study consists of five Treatments across two study Arms of which include a placebo, a 510(k) market-approved Active comparator with and without FS2, and two cosmetic, moisturizer formulation variants that have not demonstrated therapeutic efficacy, but are hypothesized to improve the appearance of scar-prone wounds once healed. The Placebo moisturizer serves as the negative control, whereas the silicone gel serves both purposes as a negative control for the FS2 incorporated silicone gel and active comparator for both FS2 silicone gel and the moisturizing products."|t|f|t|f
33965018|NCT05424107|NA|SINGLE_GROUP||PREVENTION||NONE||This is a study with pre-and post-intervention evaluation, randomized intervention in parallel groups EG and CG, in schoolchildren with analytical data of pre-diabetes. The study design was divided into two phases. In each phase, a follow-up was carried out with five visits, from the initial visit (v0) to the final visit (v4).||||
33965019|NCT00137358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965020|NCT00945152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965021|NCT04596930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965022|NCT05103059|||COHORT||PROSPECTIVE|||||||
34066168|NCT01857102|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34066169|NCT01074255|||CASE_ONLY||PROSPECTIVE|||||||
34066170|NCT01873157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066171|NCT01197014|RANDOMIZED|CROSSOVER||||NONE||||||
34066172|NCT00816322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066173|NCT06434688|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066174|NCT05366296|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34066175|NCT03027245|||COHORT||PROSPECTIVE|||||||
34066176|NCT01189708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066177|NCT04789057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066178|NCT05484596|||COHORT||PROSPECTIVE|||||||
33753113|NCT04967417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Non-squamous cell carcinoma:~4 cycles of pemetrexed 500mg/m2 + carboplatin AUC 5.0 + pembrolizumab 200mg every 3 weeks Followed by pemetrexed 500mg/m2 + pembrolizumab 200mg every 3 weeks up to 35 cycles~Squamous cell carcinoma:~4 cycles of paclitaxel 200mg/m2 + carboplatin AUC 6.0 + pembrolizumab 200mg every 3 weeks Followed by pembrolizumab 200mg every 3 weeks up to 35 cycles"||||
33753114|NCT03351972|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33753115|NCT00201084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753116|NCT03528070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066179|NCT04103034|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34066180|NCT00111306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066181|NCT05054686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|Prospective Parallel Group Comparison Study|t|f|t|f
34066182|NCT01807728|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34066183|NCT03409939|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34066184|NCT00255320|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34066185|NCT04912414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066186|NCT04102488|RANDOMIZED|PARALLEL||SCREENING||NONE||two different hand hygiene techniques (six steps and three steps) and two different application times for hand rub (30 seconds and 15 seconds)||||
34066187|NCT04764383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||double-blind randomized cross-over|t|f|t|f
34066188|NCT04792047|||COHORT||PROSPECTIVE|||||||
34066189|NCT03491397|NA|SINGLE_GROUP||TREATMENT||NONE||The stratification will not be randomized, but each category will be limited to 20 patients.||||
34066190|NCT01994473|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34151459|NCT03335254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants receive identical dosing for Period 1 and Period 2. Beginning with Period 3 subjects are assigned to one of several doses based on dose adjustments. Period 3 dosing groups are run in parallel for the duration of the study.||||
34151460|NCT03339973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, placebo-controlled, double-blind, interventional, multicenter, phase I/IIa clinical trial|t|f|t|f
34151461|NCT00665769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151462|NCT04329494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151463|NCT00001909||||TREATMENT||||||||
34151464|NCT04617015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Children with asthma and depression versus children with asthma without depression are compared for presence of allergies, airway inflammation, and response to bronchodilation with ipratropium.||||
34151465|NCT01601210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151466|NCT06213181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To assign participants to the control and intervention groups, random sampling will be carried out using sealed and completely opaque envelopes. It will be carried out by a researcher who will not intervene in the different phases of the intervention: neither in the initial phase nor in the subsequent evaluation phase. Therefore, the rest of the researchers will not know to which group each participant who has been included in the study has been assigned.The assignment will be communicated using sealed and totally opaque envelopes. The analysis of the results will be carried out by a researcher unrelated to the group assignment and the intervention.||f|t|f|t
34151467|NCT04070495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183384|NCT06591338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive loading doses of clopidogrel and aspirin or ticagrelor and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 900 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included clopidogrel. Both groups received an open-label loading dose of 300 mg of aspirin and continued on aspirin 75 mg daily.|The investigators will conduct our single-blinded randomized controlled trial, which will contain two arms; the clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day). The ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd to the 90th day). Both groups received an open-label loading dose of 300 mg aspirin and continued on open-label aspirin 75 mg daily.|f|f|t|t
34183385|NCT02220543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183386|NCT01704599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753117|NCT04283448|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will utilize a parallel intervention of meals with 0.66 cups of lentils each day versus macronutrient-matched (not including fiber) meals with 0 cups of lentils each day for 12 weeks in OW/OB adults with demonstrated risk for T2D and CVD.||||
33753118|NCT00643916|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753119|NCT06733532|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|treatments labeled A-C. Subjects will be provided the beverage in plastic cups without product labels|semi-blinded|t|f|f|f
33868430|NCT04192851|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm trial of 12 patients with mandibular large vertical defects treated using synthetic bone graft around titanium screws to tent out the soft tissue matrix.||||
33868431|NCT03487809|||COHORT||PROSPECTIVE|||||||
33868432|NCT00073151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868433|NCT04778020|||COHORT||PROSPECTIVE|||||||
33868434|NCT00535314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868435|NCT01751399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868436|NCT03837626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868437|NCT03906383|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33868438|NCT03275220|||COHORT||CROSS_SECTIONAL|||||||
33868439|NCT02034630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183387|NCT02863419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183388|NCT04892381|||CASE_CONTROL||PROSPECTIVE|||||||
34183389|NCT00489619|||||PROSPECTIVE|||||||
34183390|NCT03053817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183391|NCT03303976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34183392|NCT00923793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183393|NCT03623165|||CASE_ONLY||PROSPECTIVE|||||||
34183394|NCT03835195|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34183395|NCT04690049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|f|f|t|t
34183396|NCT05205122|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34183397|NCT02994446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183398|NCT00960882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868440|NCT04095728|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34183399|NCT02647619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868441|NCT01054144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868442|NCT00037570|RANDOMIZED|||PREVENTION||||||||
33868443|NCT04925167|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34183400|NCT05987553|||COHORT||PROSPECTIVE|||||||
34183401|NCT02242526|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34183402|NCT01512615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||RCT|f|f|f|t
34183403|NCT00755053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33868444|NCT02330822|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33868445|NCT02968069|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183404|NCT06200610|||CASE_CONTROL||RETROSPECTIVE|||||||
33868446|NCT03648775|||COHORT||PROSPECTIVE|||||||
33753120|NCT02395042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753121|NCT04428879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753122|NCT04528069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753123|NCT03034642|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study will analyze both healthy subjects (never-smokers and current- or ex-smokers) in one arm, and also subjects with COPD (current- or ex-smokers).||||
33753124|NCT00293683|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33753125|NCT02799966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868447|NCT00253396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868448|NCT00183768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868449|NCT05239611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183405|NCT02446522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183406|NCT06595212|||COHORT||PROSPECTIVE|||||||
34183407|NCT01281124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753126|NCT01025440|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33753127|NCT00160680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753128|NCT04701684|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753129|NCT00480103|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33753130|NCT03280121|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, investigator initiated, multicenter, non-randomized single arm, open label.||||
33753131|NCT02780531|||FAMILY_BASED||PROSPECTIVE|||||||
33753132|NCT00526643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753133|NCT04009369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753134|NCT01958632|||CASE_CONTROL||PROSPECTIVE|||||||
33868450|NCT00250653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868451|NCT03947840|||COHORT||PROSPECTIVE|||||||
33868452|NCT00947700|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33868453|NCT02342496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868454|NCT03897907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This research study is a double-blinded randomized controlled trial. The participants will not be made aware which education video they watch is the control and which is the intervention. The study staff will be blinded to group allocation until after measurements are completed.||t|f|t|t
33868455|NCT05052073|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33868456|NCT03246139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868457|NCT00362414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868458|NCT00829049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33868459|NCT01422148|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33868460|NCT01550250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33868461|NCT06304077|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, multi-arm (4-arm), open-label pilot controlled trial with an allocation ratio of 1:1:1:1 (per intervention group (urban, rural, forest) : control). The study setup is multicentric (Geriatrische Klinik St. Gallen, Spitäler Schaffhausen, Spital Zollikerberg).||||
33868462|NCT04661722|||COHORT||PROSPECTIVE|||||||
33965023|NCT02301780|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151468|NCT06115356|||COHORT||CROSS_SECTIONAL|||||||
34151469|NCT05635474|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34151470|NCT03392012|||CASE_ONLY||OTHER|||||||
34151471|NCT01522261|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
34151472|NCT05412628|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34151473|NCT06186115|||COHORT||PROSPECTIVE|||||||
34151474|NCT03821194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||chronic knee joint pain patients||||
34151475|NCT05518708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151476|NCT03824093|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Practices will be randomly assigned to the AFIX only or AFIX+ communication training study arms. Both groups will receive identical AFIX consultations, but only practices assigned to the AFIX+ communication training arm will receive brief, provider communication training and commitment poster displays. Once practices have been randomized, parents of adolescent patients will be exposed to one of the interventions based on their practice location. Participants will not be informed of their practice's study arm.||t|f|f|f
34151477|NCT03416075|||COHORT||RETROSPECTIVE|||||||
34151478|NCT02974569|||CASE_ONLY||PROSPECTIVE|||||||
34151479|NCT00687102|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34151480|NCT05658380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151481|NCT06544759|||OTHER||CROSS_SECTIONAL|||||||
34151482|NCT03305393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183408|NCT03760042|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Crisaborole 2% ointment and matching crisaborole vehicle will be supplied by Pfizer to the CRU as packaged 60 gram tubes and labeled according to local regulatory requirements in an unblinded fashion.~Crisaborole and vehicle ointment doses for the 14 pre-specified application sites bilaterally will be prepared by the unblinded PCRU pharmacist and provided to the blinded investigational site staff in individual dose containers. Subjects will be blinded to side of body treated with crisaborole and side of body treated with vehicle."|Using surrogate markers of skin sensitivity (current perception threshold and lactic acid stinging test responses) to stratify risk for developing application site treatment emergent adverse events (AS-TEAEs), within-subject comparisons will quantify AS-TEAE frequency and severity in healthy participants following double-blind applications of crisaborole ointment and vehicle ointment at 7 sensitive skin anatomic locations.|t|t|t|f
34183409|NCT05536401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151483|NCT05481047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183410|NCT05950815|NA|SEQUENTIAL||TREATMENT||NONE||||||
34151484|NCT01705834|||CASE_ONLY||PROSPECTIVE|||||||
34151485|NCT00671437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151486|NCT02231385|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151487|NCT00141115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151488|NCT06547515|||COHORT||PROSPECTIVE|||||||
34151489|NCT02831322|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34066191|NCT06482619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher who did not have any contact with the participants and the physiotherapist who performed the physical rehabilitation intervention and the assessments randomly divided the participants to the creatine or placebo groups in a computerized random list with a 1:1 allocation using the software Research Randomizer (www.randomizer.org).||t|t|t|t
33868463|NCT03862144|NA|SINGLE_GROUP||PREVENTION||NONE||Phase II study, one stage Fleming design, open-label, multicenter, not comparative||||
34066192|NCT02085070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066193|NCT03620383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34066194|NCT02476864|RANDOMIZED|CROSSOVER||||NONE||||||
34066195|NCT05804253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized clinical trial.|t|f|f|f
34066196|NCT01537991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066197|NCT02261831|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183411|NCT02079246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183412|NCT04033497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183413|NCT02664935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183414|NCT01337960|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34183415|NCT05618977|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34183416|NCT05604170|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label, single arm study with no blinding as all participants will receive adjunctive GNX|||||
34183417|NCT00898781|||COHORT||PROSPECTIVE|||||||
33868464|NCT01131520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868465|NCT06247631|||COHORT||PROSPECTIVE|||||||
33868466|NCT03184077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868467|NCT05701098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868468|NCT03708549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868469|NCT02937194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066198|NCT03324074|||COHORT||CROSS_SECTIONAL|||||||
34183418|NCT06203743|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study randomization will be done in sealed envelopes using computer-generated randomization codes by a doctor who will not participate in patient follow-up. For the quality and standardization of the block with bupivacain, the caudal and ilioinguinal-iliohypogastric block will be performed by an anesthetist experienced in regional anesthesia. Postoperative Flacc pain scale, type and amount of additional analgesic will be recorded by a doctor blinded to the groups.|The research is a prospective controlled, randomized, double-blind study|t|t|t|t
34183419|NCT02930824|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34183420|NCT06237985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients who will be treated and the assessor who will perform the analysis in lab will be blinded regarding which file is used for each patient.|Patients will be divided into 3 different file system randomly in order to measure the inflammatory mediators and postoperative pain.|t|f|f|t
34183421|NCT02015910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183422|NCT02199184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183423|NCT03475147|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34183424|NCT06516679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Low risk group : KMT2A wild type \& minimal residual disease(MRD) (-) after consolidation 1~* Intermediate risk group : Intermediate risk (If one of the two cases below applies)~  * KMT2A: MLL mutation (+) \& minimal residual disease (MRD) (-) after consolidation 1~    * KMT2A: wild type \& minimal residual disease (MRD) (+) after consolidation 1~* High risk group : Somatic KMT2A mutation (+) \& minimal residual disease (MRD) (+) after consolidation 1"||||
33868470|NCT02911506|||CASE_CONTROL||PROSPECTIVE|||||||
33868471|NCT00237575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183425|NCT01499355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183426|NCT05006638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183427|NCT04180761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868472|NCT05337787|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Students were divided into intervention and control groups by simple randomization method.||t|f|f|f
33868473|NCT03268928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066199|NCT02087137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868474|NCT03429842|||COHORT||PROSPECTIVE|||||||
33868475|NCT05051150|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868476|NCT04760951|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|2 blinded arms (Active and Placebo)||t|t|t|t
33868477|NCT01892592|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868478|NCT06210477|||COHORT||RETROSPECTIVE|||||||
33868479|NCT04190979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868480|NCT02941705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868481|NCT05149664|NA|SINGLE_GROUP||TREATMENT||NONE|N/R|Prospective, single arm, open-label design of the VibratoSleeve TUS device.||||
33868482|NCT00474110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868483|NCT01294904|||CASE_CONTROL||PROSPECTIVE|||||||
34066200|NCT04838431|||COHORT||PROSPECTIVE|||||||
34066201|NCT05480553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066202|NCT01256385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066203|NCT00153816|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34066204|NCT06523998|||OTHER||RETROSPECTIVE|||||||
34066205|NCT04735159|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34066206|NCT02838589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066207|NCT00543920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066208|NCT01864252|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34066209|NCT04159324|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||For a 12-months period patients undergoing aftercare treatment as usual are enrolled as an active control group. Subsequently, the intervention is implemented (StroCare treatment) and enrolment of the intervention group takes place for another 12 months. Patients in both groups are assessed after the index ischemic event and 12 months thereafter. Further sources of information are the medical record, the electronic portal (only intervention group), routine data provided by the collaborating BARMER health insurance agency (for the intervention and control group and additionally for a historic control).||||
34183428|NCT03632889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183429|NCT00393731|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34183430|NCT06654180|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34183431|NCT05670067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor will not know the grouping of the study he will only know that immediate implant was placed in both groups|two group in which the same procedure is done ( immediate implant placement) using different bone grafts|f|f|f|t
34183432|NCT04687982|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34183433|NCT04005131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant does not know the allocation.||t|f|f|f
34183434|NCT00370968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183435|NCT03420118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183436|NCT02757209|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34183437|NCT06655584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single-center, randomized, controlled, open-label interventional study on two parallel groups||||
34183438|NCT01957007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183439|NCT04594980|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183440|NCT00570830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183441|NCT05623046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183442|NCT00255489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183443|NCT04388969|||COHORT||RETROSPECTIVE|||||||
34183444|NCT02630615|||CASE_ONLY||PROSPECTIVE|||||||
34183445|NCT03703284|||CASE_CONTROL||PROSPECTIVE|||||||
34183446|NCT00506363|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34183447|NCT00928239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183448|NCT05448196|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Patients who consent to participation will complete an 11-item screener (the COST22; see Primary Outcome and Screener). Participants who are not at risk of financial toxicity (COST score ≥26) will be followed longitudinally (i.e., they will be given baseline and 4-month follow up assessments). Patients who score \<26 will be identified as being at risk of financial hardship and will be eligible for randomization to a coordinated financial navigation program or usual care."||||
34183449|NCT00533117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183450|NCT02928614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066210|NCT05951920|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34066211|NCT04239196|RANDOMIZED|PARALLEL||TREATMENT||NONE||optimal Simon two-stage design||||
34066212|NCT02614404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066213|NCT05574907|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066214|NCT04631237|||COHORT||PROSPECTIVE|||||||
34066215|NCT02760121|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34066216|NCT02066077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066217|NCT00777192|||COHORT||PROSPECTIVE|||||||
34066218|NCT02749799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066219|NCT05619380|RANDOMIZED|PARALLEL||OTHER||SINGLE|Double (Participant,Investigator)||f|f|t|f
34066220|NCT03294200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066221|NCT02635009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34066222|NCT03287648|||COHORT||CROSS_SECTIONAL|||||||
34066223|NCT01130324|||COHORT||PROSPECTIVE|||||||
34066224|NCT00482599|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066225|NCT02249507|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34066226|NCT03421275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066227|NCT04649034|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066228|NCT00615147|||COHORT||PROSPECTIVE|||||||
34066229|NCT02146820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34066230|NCT04946526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Supplements (broccoli seed extract, BSE, and vitamin C (VC) with or without mustard seed powder, MSP) will be in identical capsules, with the double blind code held by the sponsor until after the study is over.|Randomized crossover with a 7 day washout period between trials.|t|f|t|f
34066231|NCT05904132|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34066232|NCT01179646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183451|NCT03918837|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The masking model will use the same rTMS coil as the active group, bit with a 180° rotation, making the magnetic field face the opposite direction, and thus not being able to produce Neuromodulation on the patient. The stimulation intensity will be decreased at 30% of the motor threshold, to keep the characteristic sound of active rTMS. The patient will not know their group; neither will the investigator nor the rater. Only the rTMS performing technician will know the randomization group to be able to choose the right setting.|The investigators will randomize participants between two parallel groups using a randomization list. One group will undergo active rTMS while the second one will undergo sham rTMS. The second group will have the possibility of performing an active rTMS treatment at the end of each patient's participation. All subjects will undergo a MRI with anatomical and ASL sequences one week before treatment and four weeks after treatment.|t|f|t|t
34183452|NCT04399655|||COHORT||OTHER|||||||
34183453|NCT05142813|||COHORT||PROSPECTIVE|||||||
34183454|NCT04605172|||CASE_CONTROL||RETROSPECTIVE|||||||
34183455|NCT05461209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183456|NCT02416336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183457|NCT05955248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The blinding of exercise is not possible therefore participants will be aware if they are in the MM group. However, research personnel performing outcome assessments will be blinded to group allocation. Groups CTRL and NUT will be double-blinded. Supplements will be packaged by the supplier in coded-labeled sachets (for powder) and bottles (for oil). The supplier will disclose the code to a research person not associated with the trial. Research staff will prepare boxes of supplements (or placebo) according to coded group allocation. All participants will be instructed to not self-supplement with commercially available products, to minimize the risk of group contamination. All data and biological samples will be coded such that participant's identification will not be disclosed to research personnel conducting analyses.|Randomized controlled trial, 3 parallel arms (multimodal intervention, MM; nutritional supplement, NUT; control, CTRL), double-blind and placebo-controlled for supplement, single centre.|t|t|t|t
34183458|NCT06097494|||COHORT||RETROSPECTIVE|||||||
34183459|NCT00519441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183460|NCT00112996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34183461|NCT00936767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183462|NCT01365884|||COHORT||PROSPECTIVE|||||||
34183463|NCT01432041||||PREVENTION||||||||
34183464|NCT03218046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183465|NCT03905018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind clinical trial with randomization and control group|A double-blind clinical trial with randomization and control group will be carried out. Male patients aged 25-60 years, BMI ≥30, without comorbidities will be included.|t|f|t|f
34183466|NCT00059462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183467|NCT06414629|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study Birthing Centers were categorized into Intervention Birthing Center and Control Birthing Center||||
34183468|NCT05752162|||COHORT||PROSPECTIVE|||||||
34183469|NCT06655649|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with a history of moderate-severe sleep apnea, who are using CPAP, will be included. KETO-SLEEP 1 (n=20) will examine the pharmacokinetics, GI tolerability, and sleep impacts of ingesting open-label Ketone-IQ (1,3-butanediol) before sleep at 2 doses (20 or 40 g). All sleep studies are performed at home while using CPAP. at home. Some nights will involve ingesting Ketone-IQ before bedtime and wearing a sleep monitoring device (Sleep Profiler). Other nights involve waking up to check capillary ketone levels. Questionnaires will be given to ask about sleep quality and GI tolerability.||||
34066233|NCT00904917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066234|NCT02376205|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34066235|NCT03585946|||COHORT||PROSPECTIVE|||||||
34066236|NCT04723836|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066237|NCT04925778|||OTHER||PROSPECTIVE|||||||
34066238|NCT05572892|||COHORT||PROSPECTIVE|||||||
34066239|NCT04122625|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34066240|NCT04401202|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, controlled clinical study||||
34066241|NCT01529294|NON_RANDOMIZED|PARALLEL||||NONE||||||
34066242|NCT01118988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066243|NCT04171141|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34066244|NCT00825981|||COHORT||PROSPECTIVE|||||||
34066245|NCT02375828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066246|NCT04577222|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34066247|NCT05560009|||CASE_ONLY||PROSPECTIVE|||||||
34066248|NCT00088816||||TREATMENT||NONE||||||
34066249|NCT03834714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34066250|NCT01584505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183470|NCT02511548|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34183471|NCT04444726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183472|NCT01910363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183473|NCT06268275|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||RCT|t|t|f|t
34183474|NCT05862077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34183475|NCT05064215|||COHORT||RETROSPECTIVE|||||||
34183476|NCT00988806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183477|NCT04874246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183478|NCT02290769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183479|NCT03338192|||CASE_CONTROL||PROSPECTIVE|||||||
34183480|NCT06207591|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34183481|NCT03862326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The Investigator and outcome assessor did not know what treatment the indivdual women got.|3 arms, one with group exercises, one with individual exercises and one with ), Individual exercises guided by ultrasonography imaging|f|f|t|t
34183482|NCT00120302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183483|NCT00608374|RANDOMIZED|||TREATMENT||NONE||||||
34183484|NCT03079622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183485|NCT03112603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183486|NCT03524729|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|No masking|"The osteoarthritis participants will wear the control shoe, rocker bottom shoe, and AFO for multiple weeks each. The order of the treatments (control shoe, rocker bottom shoe, and AFO) will be randomize.~The control group will only wear the control shoe."||||
34183487|NCT01118182|||COHORT||CROSS_SECTIONAL|||||||
33965024|NCT03473470|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34183488|NCT02233686|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34183489|NCT06365424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183490|NCT05592106|||OTHER||RETROSPECTIVE|||||||
34183491|NCT04798573|||COHORT||PROSPECTIVE|||||||
34183492|NCT02516241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183493|NCT06655402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34183494|NCT00167843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34183495|NCT03633032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Bone anatomy will be compared between different imaging modalities||||
33965025|NCT04097119|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33965026|NCT02001870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965027|NCT00606801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066251|NCT05047484|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34066252|NCT01544764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34066253|NCT03346863|||COHORT||PROSPECTIVE|||||||
34183496|NCT02134158|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34183497|NCT05784896|||OTHER||PROSPECTIVE|||||||
34183498|NCT00740649|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34183499|NCT05839301|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34183500|NCT04713241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183501|NCT05064436|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34183502|NCT03650231|||CASE_ONLY||RETROSPECTIVE|||||||
34183503|NCT03290885|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33965028|NCT01037101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965029|NCT03598452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965030|NCT02593734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33965031|NCT06327477|NA|SEQUENTIAL||TREATMENT||NONE||||||
33965032|NCT03089099|||OTHER||PROSPECTIVE|||||||
33965033|NCT04682431|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A: Dose escalation of PY159 alone and in combination with pembrolizumab in a standard 3+3 design; Part B: Dose expansion of one or more dose levels of PY159 administered alone and in combination with pembrolizumab for predefined tumor histology||||
33965034|NCT00595387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965035|NCT04725565|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33965036|NCT00046371||||TREATMENT||||||||
33965037|NCT03521544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965038|NCT00783978|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33965039|NCT05865665|||COHORT||PROSPECTIVE|||||||
33965040|NCT02701816|||CASE_ONLY||PROSPECTIVE|||||||
34066254|NCT05697861|||CASE_ONLY||PROSPECTIVE|||||||
34066255|NCT04424615|||COHORT||PROSPECTIVE|||||||
34066256|NCT01421394|||CASE_ONLY||PROSPECTIVE|||||||
34066257|NCT05461365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066258|NCT01047124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753135|NCT06481865|||COHORT||OTHER|||||||
33753136|NCT05636527|||COHORT||OTHER|||||||
34183504|NCT04731818|NA|SINGLE_GROUP||PREVENTION||NONE||This is a Phase 1a, single center, open-label, crossover, mechanism of action and proof of concept study.||||
34183505|NCT05973032|||CASE_ONLY||RETROSPECTIVE|||||||
34183506|NCT06654843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The FT4W program is founded on social cognitive theory, which posits that human behavior is the product of the dynamic interplay of personal, behavioral, and environmental influences. Social cognitive theory emphasizes reciprocal determinism in interactions between people and their environments. The majority of physical activity interventions use social cognitive theory as indicated by the theory and technique tool developed by the Human Behavior Change Project. The study team also used the theory and technique tool to align the FT4W program components and mediating pathways with behavior change techniques and mechanisms of action substantiated in behavior change literature and expert consensus. For our study, the study team will measure social influence via social cohesion.|t|f|t|f
34183507|NCT03319147|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34183508|NCT06064214|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled study||||
34183509|NCT02134496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183510|NCT00852449|RANDOMIZED|||||TRIPLE|||t|f|t|t
34183511|NCT00740246|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34183512|NCT04921644|||COHORT||PROSPECTIVE|||||||
34183513|NCT01698840|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34183514|NCT03265314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Person-level random control trial. Participants randomly assigned to intervention (LeadHer) OR control (Sassy Science). Unit of analysis is individual (not groups/clusters). Baseline data collection is before randomization, in enrollment sessions, to prevent differential attrition post-randomization. Randomization via database developed for project. Evaluation Strategies (AFG's independent partner) developed an automated randomization method via random number generator. All randomized participants are tracked for study duration. In database, the button disappears once randomization occurs. The button is not active until consent/assent and all baseline measures are input to database. This randomization will occur after enrollment session, once enough participants for a cohort are enrolled. This helps prevent post-random sample loss. Randomization is electronic, via database, before first session. Once randomization occurs, AFG contacts enrolled girls about which their assigned program.|t|t|f|f
34183515|NCT01772316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183516|NCT06104800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person who will perform the biochemical determinations and the statistical analysis will be blinded from the intervention group by assigning each patient.|The groups will receive the treatment simultaneously.|f|f|f|t
34183517|NCT06091488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753137|NCT05591027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Drug product and placebo will be prepared at Oregon's Wild Harvest using a formula that matches taste, smell, and appearance. The Research Pharmacy at Oregon Health and Science University will maintain information on product allocation (drug or placebo) to individual participants.|48 participants will be randomized to receive either Centella asiatica water extract product (CAP) or placebo treatment. Participants will be stratified by sex so that CAP and placebo arms have equal numbers of each sex.|t|t|t|t
33753138|NCT04393974|||CASE_ONLY||RETROSPECTIVE|||||||
33753139|NCT06144866|||COHORT||PROSPECTIVE|||||||
33753140|NCT04208841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753141|NCT05253248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open-label micronutrient supplementation trial in healthy adult volunteers. We are planning to supplement healthy adult volunteers, once a day, with a standard over-the-counter multivitamin supplement for a period of 30 consecutive days.||||
33753142|NCT03765866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753143|NCT04199949|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33753144|NCT02355002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965041|NCT04336488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participant, investigator as well as outcome assessor are blinded|double equal arms|t|f|t|t
33753145|NCT03602170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753146|NCT01543061|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33965042|NCT01861119|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33965043|NCT01411670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965044|NCT05785078|||COHORT||PROSPECTIVE|||||||
33965045|NCT01559870|||CASE_ONLY||PROSPECTIVE|||||||
33965046|NCT00390988|||||PROSPECTIVE|||||||
33965047|NCT01311310|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33965048|NCT03110393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965049|NCT06204432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, care providers, investigators, and outcome assessors will all be blinded to which study arm a participant is in. Only the compounding pharmacy will have access to the non-blinded group assignments, and they oversee the randomization.|Participants will be randomized to one of two intervention groups. One will use sodium citrate nasal spray and olfactory training twice a day for 12 weeks. The other will use normal saline nasal spray and olfactory training twice a day for 12 weeks.|t|t|t|t
33965050|NCT04817098|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33965051|NCT04242381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants were assessed by the same clinician (F.B) at the baseline and at the two week after completing the interventions by visual analog scale (VAS), range of motion (ROM) and Disabilities of the Arm, Shoulder and Hand Questionnaire (Q-DASH). KT and sham-KT applications were made by same clinician (N.M). For ultrasnogohraphic (US) measurements, the participants were sent to a clinician (D.G.K) who was blinded to the group allocation.|A Randomized Sham-Controlled Study|f|f|t|f
33965052|NCT00543439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965053|NCT03984383|||OTHER||PROSPECTIVE|||||||
33965054|NCT02868905|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183518|NCT05408078|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Study participants and care providers cannot be blinded because they will notice whether they receive / deliver an actual treatment or a monitoring control. Due to the crossover cluster design (randomization of wards to either TAU plus sleep monitoring or TAU plus SLEEPexpert), patients who are on the same ward at the same time will not get in contact with patients who are in the other arm. Thus, contamination due to exchange between patients will be reduced as far as possible.~Outcome assessors (interviewers) and data analysts will be blinded. In the respective documents and database entries, patients will be identified with a code. The key for assigning the codes to patients will not be known to the interviewers and data analysts."|This project is a prospective randomized controlled clinical pilot trial with a cluster-crossover design involving two groups: An interventional group (TAU, plus SLEEPexpert) and a control group (TAU plus sleep monitoring).|f|f|f|t
33965055|NCT01593150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965056|NCT06250400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965057|NCT01169987|||COHORT||PROSPECTIVE|||||||
33965058|NCT01071109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183519|NCT00787644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183520|NCT03405194|RANDOMIZED|PARALLEL||TREATMENT||NONE||Same-Day ART with Genvoya vs. EFV/TDF/3TC||||
34183521|NCT00027235|||DEFINED_POPULATION||OTHER|||||||
34183522|NCT05060367|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34183523|NCT03863106|||COHORT||RETROSPECTIVE|||||||
34183524|NCT01238367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183525|NCT05973617|||COHORT||PROSPECTIVE|||||||
34183526|NCT05991271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183527|NCT05581342|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The OCT assessor was blinded to the histopathological examination of the independent dermatopathologist, whereas the dermatopathologist was blinded to the OCT assessment.|Patients who were non-invasively treated for superficial basal cell carcinoma within five years post-treatment could be included. If CDE or OCT rose suspicion for recurrence a biopsy was obtained. When no suspicion for recurrence was raised; patients were asked to voluntarily undergo a control biopsy to verify absence of recurrence.|f|f|f|t
34183528|NCT06143332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183529|NCT01440777|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34183530|NCT03604302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183531|NCT02809482|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34183532|NCT01068847|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34183533|NCT06374563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753147|NCT06089356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753148|NCT01214876|||COHORT||PROSPECTIVE|||||||
33965059|NCT04389047|||CASE_CONTROL||PROSPECTIVE|||||||
33965060|NCT01701778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33965061|NCT04863833|||CASE_ONLY||PROSPECTIVE|||||||
33965062|NCT04249752|||COHORT||CROSS_SECTIONAL|||||||
33965063|NCT04782219|||COHORT||PROSPECTIVE|||||||
33965064|NCT01726478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965065|NCT03780569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965066|NCT06394531|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Crossover Assignment|t|f|t|f
33965067|NCT03508362|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965068|NCT04386668|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33965069|NCT00355160|||COHORT||PROSPECTIVE|||||||
33965070|NCT04608084|NA|SINGLE_GROUP||TREATMENT||NONE||prospective||||
33965071|NCT04032275|||COHORT||RETROSPECTIVE|||||||
33965072|NCT05747833|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33965073|NCT06147700|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33965074|NCT03398928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066259|NCT03571022|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34066260|NCT05964439|NA|SINGLE_GROUP||OTHER||NONE||||||
34066261|NCT01247506|||CASE_CONTROL||RETROSPECTIVE|||||||
34066262|NCT03494244|||COHORT||PROSPECTIVE|||||||
34066263|NCT03510221|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A group of hypertensive patients and a group of normotensive individuals|t|f|f|f
33753149|NCT02825082|||COHORT||OTHER|||||||
33965075|NCT02079428|||COHORT||PROSPECTIVE|||||||
33965076|NCT02499185|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965077|NCT04965649|||COHORT||RETROSPECTIVE|||||||
33965078|NCT00346372|||COHORT||PROSPECTIVE|||||||
33965079|NCT06495749|||COHORT||PROSPECTIVE|||||||
33965080|NCT00903591|||CASE_CONTROL||PROSPECTIVE|||||||
33965081|NCT02751632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965082|NCT02440932|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33965083|NCT01476345|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33965084|NCT01872468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965085|NCT05872074|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33965086|NCT05706428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965087|NCT02841605|NON_RANDOMIZED|PARALLEL||||NONE||||||
33965088|NCT04643782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will use ANNE Sleep system during one night of polysomnography recording in sleep lab.||||
33965089|NCT03667625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34066264|NCT00914082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34066265|NCT06115200|||COHORT||CROSS_SECTIONAL|||||||
33965090|NCT03242382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183534|NCT03585764|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34183535|NCT02194543|||CASE_CONTROL||PROSPECTIVE|||||||
34183536|NCT02648919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183537|NCT01795053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34183538|NCT02846025|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34183539|NCT01875094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34183540|NCT03997188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||note Study Phase\* A medical device is a substance; whose purpose is comparable to the drug ( therapy, prevention, diagnosis, restoration of functions), but it is different from the drug because the drug acts with pharmacological, metabolic and immunological means, while the medical device acts through a mechanical action. Hepilor is a medical device in the form of a syrup with specific properties to protect and repair the gastro-intestinal mucosa. The functional substances of the medical device (Zinc-L-Carnosine and Sodium Alginate) thanks to their mucoadhesive properties act as a physical barrier protecting the damaged areas. In consideration of this we have designed a randomized phase III to to determine whether ZLC prevented or delayed esophagitis in breast cancer patients undergoing HeT to SC/IC lymph nodes and residual breast or chest wall.|t|f|f|f
34183541|NCT06137937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The sample in this study was determined randomly using a computer; subjects in the treatment group underwent routine hemodialysis by committing to an intradialysis aerobic exercise program|Thirty-four participants receiving hemodialysis were randomized to the intervention and control groups.||||
34183542|NCT05199103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066266|NCT00285792|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34183543|NCT03013803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183544|NCT02902237|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, mono-center, open-label phase I trial with intraindividual dose escalation||||
34183545|NCT03347721|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34183546|NCT04746677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183547|NCT03743181|||COHORT||PROSPECTIVE|||||||
34183548|NCT00897234|||COHORT||PROSPECTIVE|||||||
34183549|NCT02417766|||FAMILY_BASED||PROSPECTIVE|||||||
34183550|NCT05871216|||CASE_ONLY||OTHER|||||||
34183551|NCT01662102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183552|NCT00489658|NA|SINGLE_GROUP||||NONE||||||
34183553|NCT06333912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183554|NCT00100269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183555|NCT00438009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183556|NCT04575948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Masking of all caregivers, examiners (I) and (II), as well as patients are planned. No one other than HSE at the NRC will know which mouthwash is in each bottle. HSE will not be involved in patient recruitment, follow-up or assessment||t|t|f|f
34183557|NCT05976412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183558|NCT02341677|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183559|NCT06286345|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled cohort study||||
34183560|NCT03262480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The management will be carried out by a member of research team only aware of allocation group. The attending anesthesiologist, surgeons and nursing staff will be totally blind of randomization schedule or the hydration regimen used. All postoperative clinical staff handling patient care will be also unaware of the aim of the work.|"Two groups:~* Stroke volume optimization group (SVO group).~* Central venous pressure dynamic group(CVPdyngroup)."|t|t|f|t
34183561|NCT02556385|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34183562|NCT02454517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183563|NCT01177371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183564|NCT02865447|||COHORT||PROSPECTIVE|||||||
34183565|NCT00361348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183566|NCT01721044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753150|NCT03871179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants, care providers, and diagnostic clinicians are blinded to the diagnostic output of the ASD diagnostic device|||||
33753151|NCT05633875|||OTHER||OTHER|||||||
33753152|NCT01847703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753153|NCT02002026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753154|NCT00917579|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33753155|NCT02215122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753156|NCT04909242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753157|NCT03575273|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The investigators will recruit thirty individuals meeting criteria for opioid dependence of which 15 will be receiving MMT (O+MMT) and 15 will be on no opioid agonist therapy (O-MMT). The investigators will attempt to match the O-MMT group to the O+MMT group for clinical characteristics and smoking burden. Fifteen obese/overweight adults without history of opioid/substance use will be matched to the patient groups for age, gender, education, smoking and BMI.||||
33753158|NCT05125770|||CASE_CONTROL||PROSPECTIVE|||||||
33753159|NCT02696421|||CASE_ONLY||PROSPECTIVE|||||||
33753160|NCT01519531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753161|NCT04133155|||COHORT||RETROSPECTIVE|||||||
33753162|NCT05977231|||COHORT||RETROSPECTIVE|||||||
33753163|NCT00290641||||TREATMENT||NONE||||||
33753164|NCT01790269|||CASE_ONLY||PROSPECTIVE|||||||
33753165|NCT05616962|NA|SINGLE_GROUP||TREATMENT||NONE||three (3) month open-label case study||||
33753166|NCT06576362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective diagnostic study vs. reference technique||||
33753167|NCT06733727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753168|NCT00483184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965091|NCT01433133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183567|NCT06210217|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"There are five groups (Participant, surgeon, anesthesiologist, data collector, outcome evaluator).~Participants, surgeons, and outcome evaluators will be unaware of the grouping. Blinding will be maintained until data analysis is completed."|In the dobutamine group, TEE will guide fluid rehydration to ensure preload, and dobutamine will be injected intravenously. In the control group, fluid will be limited by the principle of LCVP and the same amount of normal saline will be injected intravenously.|t|f|f|t
33868484|NCT05712148|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34183568|NCT05894915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183569|NCT03694886|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be made aware if they have or have not received caffeine to not bias results.|"Participants will be randomly assigned to one of four groups:~1) 90 mg caffeine with a 1 mm diameter sucrose pillule; 2) no caffeine with the small sucrose pillule; 3) 90 mg caffeine with a 5 mm sucrose pillule; 4) no caffeine with the large sucrose pillule."|t|f|f|f
34183570|NCT03553355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183571|NCT03327662|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with CTC count \>5 CTC/7.5 mL at screening will be randomised 1:1 to either the control group (standard of care) or intervention group (CTC guided treatment). All patients will commence first line chemotherapy with docetaxel 75mg/m2 three-weekly and will receive a minimum of 3 cycles of treatment before any recommendation to discontinue first-line docetaxel.||||
34183572|NCT05960071|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blinded study where participants were not aware to the study design.|60 adult obese patients (18-65 years), with American Society of Anaesthesiologists physical Status classification 1-2, enrolled in 2 groups; Group S: received protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery. Group D: received protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.|t|f|f|f
34183573|NCT02692521|||CASE_ONLY||PROSPECTIVE|||||||
33753169|NCT01532128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753170|NCT02801994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868485|NCT05954923|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||randomized, double-blinded, single-arm study. Participants act as their own controls.||||
33965092|NCT04597554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33753171|NCT02305927|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868486|NCT05985148|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I clinical trial investigating the use of frameless single-fraction stereotactic radiosurgery (SRS) to treat chronic unilateral thoracoabdominal wall pain limited in distribution to three or fewer spinal levels from T3-T11 through ablation of the dorsal spinal nerve root.||||
33868487|NCT01953575|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868488|NCT04568395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|single (outcomes assessor) code|Crossover with 1 week washout||||
33868489|NCT04067479|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33868490|NCT00754351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868491|NCT02205411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868492|NCT05040893|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label pilot study investigating the feasibility of the POETIC intervention. POETIC will test a patient-oriented, outpatient physiotherapy intervention tailored to each patient based on their symptoms, functional limitations, and goals.||||
33868493|NCT03013283|||COHORT||PROSPECTIVE|||||||
33868494|NCT05080049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868495|NCT00130702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868496|NCT04906356|||COHORT||PROSPECTIVE|||||||
33868497|NCT05060120|||CASE_CONTROL||PROSPECTIVE|||||||
33868498|NCT03877536|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, open-label study||||
33868499|NCT04755348|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33868500|NCT05492734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868501|NCT00590330|||FAMILY_BASED||PROSPECTIVE|||||||
33868502|NCT03087188|||CASE_ONLY||PROSPECTIVE|||||||
33868503|NCT02246582|RANDOMIZED|PARALLEL||||NONE||||||
33868504|NCT05740085|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33868505|NCT05510154|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, randomized clinical trial of e-cigarette training and training dose among smokers with COPD. Smokers with COPD (n=45) stratified by e-cigarette use history (naïve vs. current use) will be randomized (1:1:1) to receive 1) brief advice to switch to e-cigarettes, 2) single session e-cigarette training, or 3) enhanced e-cigarette training||||
33868506|NCT01667081|||COHORT||PROSPECTIVE|||||||
33868507|NCT03364582|||COHORT||PROSPECTIVE|||||||
33868508|NCT03199664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183574|NCT06313671|||COHORT||PROSPECTIVE|||||||
33868509|NCT01829971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868510|NCT05111665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868511|NCT00618410|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33868512|NCT02313298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868513|NCT03157505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868514|NCT00164047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33868515|NCT03493087|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33868516|NCT00445224|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33868517|NCT05150600|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33868518|NCT02774447|||CASE_ONLY||PROSPECTIVE|||||||
34066267|NCT04496973|||COHORT||PROSPECTIVE|||||||
34066268|NCT04045990|NA|CROSSOVER||TREATMENT||SINGLE|All participants will undergo SHAM stimulation as a control condition. They will be blinded as to whether they are receiving active or SHAM stimulation.|Patients with each condition will each undergo, in a crossover, within-subject design, two clocks of rTMS: active and SHAM.The order of active and SHAM blocks will be counterbalanced across subjects.|t|f|f|f
34183575|NCT00705016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868519|NCT03772782|||OTHER||OTHER|||||||
34183576|NCT03290066|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each woman will be assigned to a sequence of treatments, including two treatments (kinesiotape and usual dysmenorrhea treatment). The sample will be randomized in two different sequences of treatments (kinesiotape/usual treatment or usual treatment/kinesiotape)|f|f|f|t
33868520|NCT05608005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Modified double-blind:~* Investigators and study staff who conduct the safety assessment, laboratory personnel who analyze the blood samples, Sponsor's personnel and study Team members, and the participant will not know which study dose is administered~* Only the study staff who prepare and administer the study intervention and are not involved with the safety evaluation will know which study dose is administered"|Eligible participants (18-64 years of age and ≥65 years of age) will be randomized in a 3:3:1 ratio to receive 2 doses, 21 days apart, by intramuscular (IM) route of either Panblok H7+MF59 (dose 1), Panblok H7+MF59 (dose 2), or unadjuvanted Panblok H7 (dose 3) at D01.|t|t|t|t
33868521|NCT00004172||||TREATMENT||||||||
34066269|NCT01807468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066270|NCT04104997|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34066271|NCT00087464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066272|NCT01742416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183577|NCT06299059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183578|NCT05484752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34183579|NCT02341183|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34183580|NCT00638014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34183581|NCT02353975|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183582|NCT01495403|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33868522|NCT00110981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868523|NCT01686009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868524|NCT06273670|||OTHER||CROSS_SECTIONAL|||||||
33868525|NCT04353284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868526|NCT04994197|||COHORT||PROSPECTIVE|||||||
33868527|NCT03857204|NA|SINGLE_GROUP||OTHER||NONE||||||
33868528|NCT05082584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868529|NCT02518451|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33868530|NCT01492764|||CASE_CONTROL||OTHER|||||||
33868531|NCT03228303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183583|NCT00169065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183584|NCT04636268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183585|NCT04641182|||COHORT||PROSPECTIVE|||||||
33965093|NCT00410592|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183586|NCT05609331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965094|NCT00961051|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34183587|NCT03975582|||COHORT||PROSPECTIVE|||||||
34183588|NCT01526304|||COHORT||PROSPECTIVE|||||||
34183589|NCT06507189|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Biospecimen investigators will be blinded from gender and age.|The overarching goal of this project is to determine factors contributing to response heterogeneity in outcomes key to healthy aging. The first phase of this two-phase trial will be focused on understanding the underlying biological mechanisms that explain/predict response heterogeneity and the second phase will test augmentation efforts to mitigate poor responsiveness while assessing whether the same or different mechanisms predict response when augmenting an individual's prescription in Phase II.|f|f|t|f
34183590|NCT06236269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183591|NCT00874510|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34183592|NCT02529969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183593|NCT04062786|||COHORT||PROSPECTIVE|||||||
34183594|NCT00724698|||COHORT||PROSPECTIVE|||||||
34183595|NCT06595875|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183596|NCT03235011|||COHORT||PROSPECTIVE|||||||
34183597|NCT01545492|||COHORT||PROSPECTIVE|||||||
34183598|NCT01324895|||CASE_CONTROL||RETROSPECTIVE|||||||
34183599|NCT04411498|||CASE_CONTROL||PROSPECTIVE|||||||
34183600|NCT06299046|||COHORT||RETROSPECTIVE|||||||
34183601|NCT00770419|||COHORT||PROSPECTIVE|||||||
34183602|NCT00335777|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183603|NCT03094325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Each of the 10 patients will have 4 measurements(OPIE \& TEE before cardiopulmonary bypass and OPIE \& TEE after cardiopulmonary bypass) in the septum using two techniques (TEE and OPIE Ultrasound Probe).|||||
34183604|NCT02656771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183605|NCT00512213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183606|NCT00742495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183607|NCT02575638|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183608|NCT04731558|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34183609|NCT00003523||||TREATMENT||||||||
34183610|NCT04137640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183611|NCT03918564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183612|NCT05445271|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34183613|NCT04069702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183614|NCT04782869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183615|NCT06473168|||COHORT||PROSPECTIVE|||||||
34183616|NCT01747876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183617|NCT00695773|||CASE_ONLY|||||||||
34183618|NCT03754621|||CASE_CONTROL||PROSPECTIVE|||||||
34183619|NCT03121053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183620|NCT01043419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183621|NCT04674423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"Two treatment groups: TAF group and control group~Treatment groups:~1. TAF treatment group (144 weeks)~2. Controlled group (144 weeks)"|||||
34183622|NCT04380285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant was blinded to the type of orthotic provided to the participant to prevent possible bias during administration of the post treatment questionnaire.|The study design was a randomized clinical trial.The study was completed when the target number of recruitments was reached. Prior to randomization to treatment groups, patients were stratified by age (younger adults: 18 - 64 years and older adults: 65 years and older) in blocks of four to ensure that there were an equal number of participants receiving soft versus hard orthotics in each age group.|f|f|f|t
34183623|NCT05251168|||OTHER||PROSPECTIVE|||||||
34183624|NCT05521308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183625|NCT03144154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are randomized into 2 groups: the experimental group receives the intervention immediately while the control group only receives usual care. When the control group has received the intervention and that evaluations have been done for all participants, the control group will receive the intervention (randomized controlled trial).||||
33965095|NCT01407575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965096|NCT05926336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965097|NCT04300777|||COHORT||PROSPECTIVE|||||||
33965098|NCT03364920|||COHORT||RETROSPECTIVE|||||||
33965099|NCT02823873|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965100|NCT01760694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965101|NCT02597283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753172|NCT03963674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753173|NCT05668533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. Interscalene group: Patients received ipsilateral ultrasound-guided interscalene nerve after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg).~2. PENG Block: Patients received ultrasound-guided PENG block after induction of general anesthesia using bupivacaine 0.25% (0.5 mL/kg)."|t|f|t|f
33753174|NCT01059175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753175|NCT00157781|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33753176|NCT05964478|RANDOMIZED|PARALLEL||PREVENTION||NONE|The laboratory technicians involved in the processing and analysis of the hand rinse samples will be masked and therefore do not know if the sample comes from the intervention or the control group|"The study is a multi-center Cluster Randomised Controlled Trial being conducted across two countries. Within each country, there will be two arms: an intervention arm and a control arm.~The intervention arm will receive a comprehensive multi-component intervention package. On the other hand, the control arm will not receive the intervention package during the data collection phase, serving as a comparison group.~However, It will receive the same intervention package (with potential improvements) once the data collection period concludes, specifically at the endline assessment after one year from the baseline"||||
33965102|NCT01134588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34183626|NCT03821402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded. The subject, Sponsor, and study site research personnel will be blinded to the identity of the subject's assigned treatment.|Eligible subjects will be randomized (1:1:1:1) to one of four treatment groups: Group 1: DAXI 250 U (N=32); Group 2: DAXI 375 U (N=32); Group 3: DAXI 500 U (N=32); Group 4: Placebo (N=32).|t|t|t|t
34183627|NCT01194856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183628|NCT06654375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183629|NCT03879161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183630|NCT00086632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183631|NCT03619382|||OTHER||CROSS_SECTIONAL|||||||
33753177|NCT01338025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753178|NCT00611000||||PREVENTION||SINGLE||||||
33753179|NCT04740489|||COHORT||CROSS_SECTIONAL|||||||
33753180|NCT03549650|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33753181|NCT04760093|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Pharmacists will assign participants to one of the research arms following a randomization schedule, and will maintain a study log not accessible to the investigators or care provider. Study coordinators will remain blinded when distributing the bottles of EVOO.|In this study, subjects will be randomized to one of two research arms. Subjects in the first research arm will be given low polyphenol concentration EVOO, followed by high polyphenol concentration EVOO for consumption. Subjects in the second research arm will be given high polyphenol concentration EVOO, followed by low polyphenol concentration EVOO for consumption. There will be a 14- day washout period in between administration of either low or high polyphenol concentration EVOO.|t|t|t|f
33753182|NCT05741216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753183|NCT05697094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33753184|NCT06648772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753185|NCT02795273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753186|NCT06164470|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33753187|NCT01469533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33753188|NCT00004827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33753189|NCT03059108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868532|NCT03625687|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33868533|NCT00000491|RANDOMIZED|||PREVENTION||DOUBLE||||||
33868534|NCT04101747|||COHORT||PROSPECTIVE|||||||
33868535|NCT00135239|RANDOMIZED|PARALLEL||||NONE||||||
33868536|NCT04735822|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1: Single center, open-label, randomized, 6-arm design to assess the taste profile of different novel belumosudil in bottle formations in 12 healthy male subjects.~Part 2: Single center, open-label, randomized, 3-arm, design to assess the relative bioavailability of a selected belumosudil suspension formulation compared to the oral belumosudil tablet reference and the effect of food on the selected belumosudil suspension formulation in 18 health male subjects"||||
33965103|NCT06542510|||OTHER||PROSPECTIVE|||||||
33965104|NCT02047058|||COHORT||PROSPECTIVE|||||||
33965105|NCT01138566|||COHORT||PROSPECTIVE|||||||
33965106|NCT06083896|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34183632|NCT02992795|||COHORT||PROSPECTIVE|||||||
34183633|NCT04237116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|The primary objective of this study was to demonstrate superiority of secukinumab compared to placebo in patients with moderate to severe chronic plaque-type psoriasis and non-alcoholic fatty liver disease (NAFLD) with respect to psoriasis area and severity index (PASI) 90 response at Week 12.|t|f|t|f
34183634|NCT03033095|NA|SINGLE_GROUP||SCREENING||NONE||||||
33965107|NCT05897762|NA|SINGLE_GROUP||OTHER||NONE||||||
33965108|NCT00175773|||COHORT||PROSPECTIVE|||||||
33965109|NCT01265888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965110|NCT01767545|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183635|NCT06175884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965111|NCT03318237|||CASE_ONLY||PROSPECTIVE|||||||
33965112|NCT03091894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33965113|NCT05504616|RANDOMIZED|PARALLEL||TREATMENT||NONE||Repeated measures randomized control pre-test/post-test design comparing an intervention group with a control group (usual care).||||
33965114|NCT02465307|||CASE_CONTROL||PROSPECTIVE|||||||
33965115|NCT04832165|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33965116|NCT04916860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965117|NCT00204932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965118|NCT02948478|||CASE_CONTROL||PROSPECTIVE|||||||
33965119|NCT06379022|||CASE_CONTROL||PROSPECTIVE|||||||
33965120|NCT04498052|NA|SINGLE_GROUP||SCREENING||NONE|no masking due to the nature of the intervention|interrupted time series||||
34183636|NCT01493739|||CASE_ONLY||PROSPECTIVE|||||||
34183637|NCT03980054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pyrotinib versus Placebo|t|t|t|t
34183638|NCT05204277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking was ensured as the baseline and follow-ups data were stored on a computer with a unique ID and the investigators were not disclosed about the participants' treatment protocol. Blinding of the participants was guaranteed as they didn't know each other, or the treatments received in other protocols||t|f|t|f
34183639|NCT03904914|||COHORT||PROSPECTIVE|||||||
34183640|NCT06087653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183641|NCT06217510|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study with a single group of 15 patients||||
34183642|NCT02153320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183643|NCT05812729|RANDOMIZED|PARALLEL||TREATMENT||NONE||Waitlist-control design||||
34183644|NCT03531346|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Subjects were masked with respect to the lens type.||t|f|f|f
34183645|NCT01973764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183646|NCT05859503|||CASE_ONLY||RETROSPECTIVE|||||||
34183647|NCT05952466|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34183648|NCT03470389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183649|NCT04387604|||COHORT||PROSPECTIVE|||||||
34183650|NCT02057016|||COHORT||RETROSPECTIVE|||||||
34183651|NCT00736762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34183652|NCT05953701|||OTHER||RETROSPECTIVE|||||||
33965121|NCT02969733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965122|NCT00065065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965123|NCT01838083|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33965124|NCT03630718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965125|NCT03579147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965126|NCT00003669||||TREATMENT||||||||
33965127|NCT03319381|||CASE_CONTROL||PROSPECTIVE|||||||
33965128|NCT00667433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965129|NCT05789680|||COHORT||RETROSPECTIVE|||||||
33965130|NCT00420290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965131|NCT04317729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183653|NCT03519633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34183654|NCT03979287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34183655|NCT05528315|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Placebo matches appearance of ABX-002|Double-Blind, Randomized, Placebo-Controlled Single and Multiple Ascending Doses in Healthy Adult Subjects|t|t|t|f
34183656|NCT00494793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183657|NCT00006461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183658|NCT04522232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34183659|NCT03631888|||COHORT||PROSPECTIVE|||||||
33965132|NCT04124978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965133|NCT01497574|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33965134|NCT02616679|||COHORT||CROSS_SECTIONAL|||||||
33965135|NCT04867967|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33965136|NCT02063698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33965137|NCT04613895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965138|NCT05332080|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, parallel-treatment trial||||
33965139|NCT01284244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183660|NCT02575157|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34183661|NCT00984217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183662|NCT05612477|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34183663|NCT03841604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183664|NCT00456222|||||PROSPECTIVE|||||||
34183665|NCT02877407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183666|NCT05565625|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183667|NCT06603688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183668|NCT00218868|||CASE_ONLY||PROSPECTIVE|||||||
34183669|NCT05385770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Single-blind Run-in period, Double-blind Treatment period||t|t|t|t
34183670|NCT05949333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183671|NCT01585376|||CASE_ONLY||RETROSPECTIVE|||||||
34183672|NCT05710237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, their families, the study investigator, study therapists, and research assistants carrying out assessments will be concealed from allocation.||t|t|t|t
34183673|NCT05393102|||COHORT||PROSPECTIVE|||||||
34183674|NCT01094847|RANDOMIZED|CROSSOVER||||NONE||||||
34183675|NCT03155906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Even though complete blinding is regarded as difficult, there will be some degree of blinding/masking. Randomisation will be disclosed to physician and other health care staff providing OST treatment, but not to research nurses conducting data collection for outcomes. Patients will be informed of the follow-up they will receive, but not on other follow-up alternatives that are used or the exact hypotheses for the study.|A multicentre, randomised controlled clinical trial.|t|f|t|t
33753190|NCT06579508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will be randomly distributed into 5 groups:~Control; Normoxia + placebo (Nor-P); Normoxia + taurine (Nor-T); Hypoxia + placebo (Hyp-P); Hypoxia + Taurine (Hyp-T). Control group is the only group without training"|Randomized clinical trial|t|f|f|f
34183676|NCT05651503|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Two random sequences will be obtained for each age group from www.random.org (2 for patients 12-18 yo and 2 for patients ≥18 yo), one for males and one for females in each age group. Each sequence will be a random ordering of a list of 30 'Ex's and 30 'Co's (Ex: Probiotic, Co: Placebo). The sequence values will be written on standard-sized pieces of paper using a pencil and sealed in opaque numbered envelopes (sequentially numbered from F1 to F30 (female group) and M1 to M30 (male group)) for each group by a person not involved in the project.~The different lozenges will be labeled 1 or 2 by the manufacturer. The packaging, appearance and taste of lozenges in both intervention and control groups will be identical.~Clinical measurements of plaque accumulation, gingival inflammation and VSCs levels will be conducted by an assessor blind to treatment allocation. Due to the nature of the intervention, participants and patients can be blinded to allocation."|"This trial is designed as a prospective, randomized, placebo-controlled, double (investigator and patient) blinded, with four parallel groups and an equal allocation ratio in all groups. In this dose study, the intervention consists of delivery of oral probiotics Lactobacillus Salivarius or placebo lozenges.~Equal number of males and females will be allocated to each group. In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two different groups:~Experimental group 1: patients, age 12-18, conventional brackets, Oral probiotics lozenges Experimental group 2: patients, age ≥18, Invisalign™ appliances, Oral probiotics lozenges Control group 1: patients, age 12-18, conventional brackets, placebo lozenges Control group 2: patients, age ≥18, Invisalign™ appliances, placebo lozenges"|t|f|t|f
33868537|NCT01235559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183677|NCT02690948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183678|NCT05166772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183679|NCT01228097|||COHORT||PROSPECTIVE|||||||
34183680|NCT06592456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868538|NCT01961401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183681|NCT04657393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomizing the study groups|prospective, randomized, parallel study|t|f|f|f
34183682|NCT05979246|NA|SINGLE_GROUP||TREATMENT||NONE||"40 patients who are planned to undergo implant installation will be enrolled in the study, at the department of Periodontology at the School of postgraduate dentistry in the Rambam Health Care Center.~The patients will be divided into 2 groups:~* Test group - 20 patients diagnosed with type 2 diabetes with 10\>HbA1C\>7.5% values~* Control group - 20 non-diabetic patients."||||
34183683|NCT03822117|NA|SINGLE_GROUP||TREATMENT||NONE||This study consists of 3 cohorts that will have study drug administered in parallel, Cohort A, Cohort B, and Cohort C. There is no difference in the treatment regimen between the cohorts.||||
34183684|NCT02847052|||OTHER||RETROSPECTIVE|||||||
33868539|NCT03823404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183685|NCT06555549|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34183686|NCT02264249|||COHORT||PROSPECTIVE|||||||
33868540|NCT04213105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized、double-blind、parallel-group、positive control|t|f|t|t
34183687|NCT03367663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183688|NCT06171243|||CASE_ONLY||PROSPECTIVE|||||||
34183689|NCT03258385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34183690|NCT04072900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868541|NCT00887120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183691|NCT02874378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34183692|NCT03002337|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34183693|NCT03308071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treating team including surgeons, anesthesiologists, pain consultants, hospitalists who are in charge of administering pain medication and documenting outcomes will be blinded to the intervention.||f|t|f|f
33868542|NCT00475722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965140|NCT03262233|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34183694|NCT05352503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34183695|NCT06088121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183696|NCT06651866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183697|NCT03023397|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183698|NCT02516761|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34183699|NCT04078906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965141|NCT01779531|||CASE_CONTROL||PROSPECTIVE|||||||
34183700|NCT04842812|NA|SINGLE_GROUP||TREATMENT||NONE||TILs treatment of solid cancers||||
34183701|NCT04237597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183702|NCT00629070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183703|NCT04346381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183704|NCT03074513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183705|NCT06174077|||CASE_ONLY||RETROSPECTIVE|||||||
34183706|NCT06655038|RANDOMIZED|PARALLEL||PREVENTION||NONE||Schools will be the target of an intervention. The 20 participating schools will be randomly assigned either to the intervention arm or to the control arm.||||
34183707|NCT00395031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183708|NCT04670978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868543|NCT02558114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868544|NCT00698724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33868545|NCT00790686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868546|NCT06243406|||CASE_ONLY||RETROSPECTIVE|||||||
33868547|NCT00733954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868548|NCT02613884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868549|NCT05247814|||COHORT||PROSPECTIVE|||||||
33868550|NCT02525055|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Cohort 1 (including 4 arms) is double blinded. Cohort 2 (including 1 arm divided in 2 separate age comparison groups) is open labelled. In order to allow for an age comparison between subjects aged 18 to 45 and subjects aged 56 to 64, data from Cohort 2 (Infectious Titre 5) will be presented in 2 separate reporting groups.||t|f|t|f
33868551|NCT05754567|||COHORT||PROSPECTIVE|||||||
33868552|NCT03968107|||COHORT||PROSPECTIVE|||||||
33868553|NCT05220397|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33868554|NCT04077541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33868555|NCT02451579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868556|NCT01624987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868557|NCT02016820|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33868558|NCT05741281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066273|NCT00489294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066274|NCT03888326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are aware of whether they are in one of the robotic treatment groups but are blinded to the type of tDCS they receive (true or sham). Assessor therapist is blinded to all group allocation.|Participants are assigned to one of 3 groups for the duration of the study (robotic rehabilitation plus anodal tDCS, robotic rehabilitation plus sham tDCS, standard of care rehabilitation)|t|f|f|t
34066275|NCT04688606|||COHORT||RETROSPECTIVE|||||||
34066276|NCT06018922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066277|NCT00116636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066278|NCT00520052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066279|NCT05890300|RANDOMIZED|PARALLEL||PREVENTION||NONE||"All participants will complete two test sessions: 1) a pre-test (baseline), and 2) a post-test conducted after the 24-week trial. Participants will be allocated to either an experimental group or a control group. The experimental group will conduct a 24-week intervention, while the control group will receive no intervention.~Participants are randomized to an experimental group (EXP) or a control group (CON) stratified for age, gender, and work experience. Participants allocated to the EXP will use a passive- back exoskeleton during more than 50 % of their working hours for 24 weeks. CON will be instructed to resume their normal working routine throughout the study period. Both groups will attend weekly meetings and will fill out questionnaires every fourth week."||||
34066280|NCT00164164|RANDOMIZED|PARALLEL||||SINGLE||||||
33868559|NCT00560742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868560|NCT05891340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized, prospective|f|f|f|t
33868561|NCT01671111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868562|NCT01595126|||CASE_ONLY||PROSPECTIVE|||||||
33868563|NCT04092296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33868564|NCT04526743|||CASE_CONTROL||PROSPECTIVE|||||||
34151490|NCT02373514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151491|NCT03716752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151492|NCT06256471|||OTHER||CROSS_SECTIONAL|||||||
34151493|NCT03247725|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be informed of the condition they have been assigned to.|Three conditions. Patients will be randomly assigned to one of the three conditions.||||
34151494|NCT05749393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151495|NCT02561221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868565|NCT05424172|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33868566|NCT01043276|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33868567|NCT05620147|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33868568|NCT04916028|||CASE_ONLY||RETROSPECTIVE|||||||
33868569|NCT01423851|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1: 75, 125, 200, 300, 400 mg QD and 100, 200, 250, 300, 400 mg BID Phase 2: 300 mg QD||||
33868570|NCT00682448|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868571|NCT01572675|||COHORT||PROSPECTIVE|||||||
34151496|NCT04594928|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34151497|NCT00309062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151498|NCT01177969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151499|NCT03907033|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This will be a blinded study where investigators, patients, and care providers will be blinded to treatment assignment.|Patients will be randomized to receive either the bupivacaine HCl injection at the time of surgery or bupivacaine HCl plus liposomal bupivacaine.|t|t|t|f
34151500|NCT03409341|||CASE_ONLY||PROSPECTIVE|||||||
34151501|NCT04999527|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34151502|NCT00541346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151503|NCT02189278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151504|NCT02458183|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Label|||||
34151505|NCT03649204|||COHORT||PROSPECTIVE|||||||
34151506|NCT03936751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151507|NCT00058682||||TREATMENT||||||||
34151508|NCT00003658||||TREATMENT||||||||
34151509|NCT06034353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be entertained as part of their regular appointment for prescription filling without any information of which group they are assigned in.||t|f|f|f
34151510|NCT00135109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151511|NCT00899158|||CASE_ONLY||CROSS_SECTIONAL|||||||
34151512|NCT01560455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151513|NCT01570049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151514|NCT03497364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34151515|NCT00953563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868572|NCT01925924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33868573|NCT00397033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868574|NCT00786747|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33868575|NCT00272064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868576|NCT00535275|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868577|NCT02723695|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33868578|NCT04553705|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33868579|NCT04556396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients are assigned to receive intraoperative cone beam CT if enrolled.||||
33868580|NCT02535715|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33868581|NCT05659784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868582|NCT00749476|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33868583|NCT01655420|||COHORT||PROSPECTIVE|||||||
33868584|NCT01372150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868585|NCT00943774|||COHORT||PROSPECTIVE|||||||
33868586|NCT00068211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868587|NCT06226311|||COHORT||PROSPECTIVE|||||||
33868588|NCT01943513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868589|NCT01750320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868590|NCT05163184|||CASE_ONLY||CROSS_SECTIONAL|||||||
33868591|NCT04937244|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33753191|NCT02425982|||COHORT||PROSPECTIVE|||||||
33753192|NCT02672787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753193|NCT01634542|||COHORT||PROSPECTIVE|||||||
33868592|NCT05901493|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be assigned to one of six training schedules to complete over 48 hours. All participants will complete the same amount of training. The investigators will examine retention of trained information at the end of the week.||||
33868593|NCT05161091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled trial|t|t|t|t
33868594|NCT00419146|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33868595|NCT02594969|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33868596|NCT01161355|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33868597|NCT01245387|||COHORT||PROSPECTIVE|||||||
33868598|NCT01345747|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33965142|NCT03603431|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33965143|NCT03374137|||COHORT||PROSPECTIVE|||||||
33965144|NCT01725074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753194|NCT02021838|||COHORT||PROSPECTIVE|||||||
33753195|NCT01274195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753196|NCT01355393|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33868599|NCT01599299|||CASE_ONLY||CROSS_SECTIONAL|||||||
33868600|NCT05799079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868601|NCT04234672|NA|SINGLE_GROUP||OTHER||NONE||||||
33868602|NCT06151912|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Morbidly obese patients will undergo sleeve gastrectomy, starting 3 cm cranial to the pylorus, under the guidance of a 36 F bougie. After gastrectomy, fibrin glue will be applied to the stapler line in one of the groups. In the other group, the staple line will be sutured with 3/0 prolene in an inverted manner.|t|f|f|t
33868603|NCT05767554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868604|NCT02475226|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33868605|NCT00616915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868606|NCT05604495|||CASE_ONLY||PROSPECTIVE|||||||
33965145|NCT03268031|||CASE_ONLY||RETROSPECTIVE|||||||
33965146|NCT03064633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965147|NCT06305637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965148|NCT04537702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following consent, the clinical research coordinator will randomize the patient to either the Traditional Group (TG) or Streamlined Group (SG). The randomization process will have occurred previously using blocks of ten randomly computer-generated numbers. These numbers will be kept in individual, ordered envelopes. When a subject requires randomization, the next envelope in the sequence will be opened and the subject will be randomized according to the number listed in the envelope.||||
33965149|NCT05394142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase 2 clinical trial with four subgroups|t|t|t|t
33965150|NCT05338554|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and assessors were blind to group assignment until the study was completed.|After 5 consecutive days of 10HZ rTMS or pcTBS intervention of previous study, patients were divided into responders and non-responders according to the change of pain intensity measured with VAS and both of them will receive different trial of interventions.|t|f|f|t
33965151|NCT02836340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965152|NCT00938600|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965153|NCT02692430|||COHORT||RETROSPECTIVE|||||||
33965154|NCT03725787|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33965155|NCT02177747|NA|SINGLE_GROUP||||||||||
33965156|NCT04311138|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965157|NCT04844996|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|the outcome assessors who measured the sizes of the post-treatment explants, and who histopathologically evaluated the explants were blinded to the groups|an experimental rat, randomized, drug versus placebo trial|f|f|f|t
33753197|NCT04732806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33753198|NCT06440148|||CASE_CONTROL||RETROSPECTIVE|||||||
33753199|NCT02621099|||CASE_ONLY||PROSPECTIVE|||||||
33753200|NCT04557072|||OTHER||OTHER|||||||
33753201|NCT06217367|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will be informed of the study interventions prior to experimental trials to ensure participants are able to provide informed consent. However, participants will blinded to the order of the arms (i.e., participants will not be informed which antihistamine/placebo pill they ingest for any trial). Data will remain blinded to researchers until after a third-party statistical analysis.|Each participant will be asked to ingest either i) 50mg of diphenhydramine, ii) 10 mg loratadine iii) 5 mg desloratadine, or iv) placebo (sugar pill) \~2 hours before heating protocol in a random pre-determined order over four separate experimental trials.|t|f|t|f
33753202|NCT01918735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753203|NCT05630183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753204|NCT00790010|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753205|NCT00520780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753206|NCT03195192|NA|SINGLE_GROUP||OTHER||NONE|Open-label|||||
33753207|NCT02744144|||COHORT||OTHER|||||||
33753208|NCT04319211|||CASE_ONLY||CROSS_SECTIONAL|||||||
33753209|NCT04840810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33753210|NCT06382012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753211|NCT05072080|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants will be randomized in a 2:2:2:1 ratio within each age stratum (12 to \<18, 18 to \<46, and 46 to \<65). This study will be conducted in the US, using up to 50 sites.|t|t|t|f
33753212|NCT04279223|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33753213|NCT01698684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753214|NCT00675389|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33753215|NCT04832828|||CASE_ONLY||PROSPECTIVE|||||||
33753216|NCT05492266|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753217|NCT03215732|||OTHER||CROSS_SECTIONAL|||||||
33753218|NCT03527225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Consented, eligible female subjects to be randomized to Music or No Music to evaluate pre and post treatment anxiety level via STAI and SDT anxiety questionnaire at their first radiotherapy treatment for cancer."||||
33753219|NCT00413387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753220|NCT04001673|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33753221|NCT00289354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33753222|NCT06578910|||CASE_CONTROL||OTHER|||||||
33753223|NCT01509222|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753224|NCT03872752|NA|SINGLE_GROUP||PREVENTION||NONE||This study includes a pre/post study||||
33753225|NCT00842140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753226|NCT06230289|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||f|t|t|t
33753227|NCT00189215|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33753228|NCT06191718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753229|NCT02320565|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|t|f
33753230|NCT01508429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753231|NCT06005805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753232|NCT02782169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753233|NCT02008890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753234|NCT06367192|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753235|NCT04443140|||COHORT||PROSPECTIVE|||||||
33753236|NCT06647810|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753237|NCT02181803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753238|NCT06386757|RANDOMIZED|PARALLEL||PREVENTION||NONE||These prospective, randomized, controlled clinical trials will be conducted at Aswan University Hospital on 62 patients who are scheduled for maxillofacial surgeries requiring nasal intubation.||||
33753239|NCT05410600|NA|SINGLE_GROUP||OTHER||NONE||||||
33753240|NCT00649558|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33753241|NCT03083587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753242|NCT05578963|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33753243|NCT04823377|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||In this prospective comparative study, the rate of systemic oncological treatment during the last month of life will be measured consecutively, over a period of usual management, followed by a period of systematic application of a process of optimization of the medical decision.||||
33753244|NCT03709355|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33753245|NCT02616874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868607|NCT03067571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868608|NCT02009345|||OTHER||OTHER|||||||
33868609|NCT06322836|NA|SINGLE_GROUP||TREATMENT||NONE||a pilot, non-controlled, non-randomised, single centre study. The Electra-1 pilot study is a prospective intervention feasibility study.||||
33868610|NCT04458662|||COHORT||CROSS_SECTIONAL|||||||
33753246|NCT01372306|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753247|NCT05460416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33753248|NCT06580795|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33753249|NCT03626155|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33753250|NCT02217930|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33753251|NCT04915573|||OTHER||CROSS_SECTIONAL|||||||
33753252|NCT06488378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753253|NCT02186522|||COHORT||PROSPECTIVE|||||||
33753254|NCT05368662|NA|SINGLE_GROUP||OTHER||NONE||||||
33753255|NCT01146509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753256|NCT05970627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753257|NCT04855422|||COHORT||PROSPECTIVE|||||||
33965158|NCT05703555|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, multi-cohort||||
33965159|NCT02868307|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33753258|NCT04278118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753259|NCT02782338|||CASE_ONLY||PROSPECTIVE|||||||
33753260|NCT01180855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33753261|NCT03683797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33753262|NCT06122714|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33753263|NCT00877825|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33753264|NCT01368965|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33753265|NCT04932122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the study team member who is performing the physical exam (including range of motion and grip/pinch strength testing) will be blinded to the randomization.||t|f|f|t
33753266|NCT01891149|||COHORT||CROSS_SECTIONAL|||||||
33753267|NCT03280173|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33753268|NCT00507000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33753269|NCT03953846|||COHORT||PROSPECTIVE|||||||
33753270|NCT02728557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33753271|NCT06732076|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33753272|NCT04437940|||COHORT||PROSPECTIVE|||||||
33753273|NCT01866228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33753274|NCT02252705|||COHORT||PROSPECTIVE|||||||
33753275|NCT01803308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753276|NCT03846648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be performed in a double-blind fashion. The investigator, study staff, subjects, sponsor, and monitor will remain blinded to the treatment until study closure. The investigational drug and its matching placebo are indistinguishable and will be packaged in the same way.|Randomized, placebo-controlled, double-blind phase I study|t|f|t|f
33753277|NCT01833338|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753278|NCT04598867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Double (Participant, Investigator) Dose blinding will be performed using Placebo. Patient will receive 2 vials labeled for study drug administration as follows: 1 capsule in the morning, and evening.~Package numbers were assigned via IWRS. Thus, during the Study Treatment period, neither the patient nor the Investigator knew the group to which the patient was allocated. Single blinding was performed during the Placebo Run-in and Follow-up periods."|This is a multicenter, randomized, double-blind, placebo- and active-controlled study to assess the efficacy and safety of CD-008-0045 in patients with GAD. The primary study objective is To assess the efficacy of CD-008-0045 at a dose 20 mg BID vs Placebo and Afobazol based on the change of the total score of the Hamilton Anxiety Rating Scale (SIGH-A) structured interview at Week 8 from baseline. Treatment response is considered the difference between group CD-008-0045 and Placebo is 5.5 points decrease of the Hamilton Anxiety Rating Scale (HARS) total score from baseline.|t|t|t|f
33753279|NCT05309278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be implemented for the outcome assessors. Specifically, all tests, assessments, and measurements will be performed by an investigator blinded to the group participants were assigned to. Because of the type of intervention (i.e., exercise intervention), the investigator(s) who will carry out the exercise sessions, as well as the participants, won't be blinded.|This is a randomized, single-blind, parallel, controlled, superiority trial. Older participants will be allocated into two groups, experimental and control, based on a randomization sequence that will be generated on a computer in a 1:1 ratio.|f|f|f|t
33753280|NCT02131779|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33753281|NCT02747238|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753282|NCT01297231|||COHORT||PROSPECTIVE|||||||
33965160|NCT03342326|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33753283|NCT04048824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753284|NCT05387941|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter interventional phase 1 trial||||
33753285|NCT00326131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753286|NCT02106299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753287|NCT04262544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Care providers (doctors and nurses) providing usual care to study participants will be blinded to the allocation of participants.~Data collectors and assessors of subjective outcomes (e.g. health beliefs, self-efficacy, self-care) will be blinded to the allocation. Study participants will be asked not to reveal to their provider and assessor which group they are assigned to. Data collectors/assessors will have restricted access to patient data in REDCap and will not share the same space with other study investigators."||f|t|f|t
33753288|NCT05515068|||CASE_ONLY||PROSPECTIVE|||||||
33868611|NCT05484479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868612|NCT04498208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33894012|NCT04180605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||200 patients selected for percutaneous LAA closure with an AmplatzerTM AmuletTM device will be enrolled in this study and randomized into the following two arms: the comparator (standard of care arm) for whom the procedure will be conducted following the standard of care of the center, and the computational simulation arm where the pre-procedural planning will include a careful analysis of the computational simulation results provided by the FEops HEARTguideTM platform.|f|f|f|t
33894013|NCT01033994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894014|NCT00206570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894015|NCT02043574|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are randomized to either stretching or treadmill training.||||
34183709|NCT00567099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183710|NCT03351452|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34183711|NCT05663658|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34183712|NCT05701995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183713|NCT04542317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The active treatment is REACH VN, a culturally adapted version of REACH VA, a multi-component dementia family caregiver support intervention that includes psychoeducation, stress reduction, problem-solving, and skill-building.|f|f|f|t
34151516|NCT04021212|||CASE_ONLY||PROSPECTIVE|||||||
34151517|NCT03605316|||COHORT||RETROSPECTIVE|||||||
34151518|NCT05670132|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894016|NCT02910440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33894017|NCT05386914|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The member of the study team carrying out the MRI imaging and image analysis will be blinded to the APOE genotype of the subject, subject's family history, and treatment category.||f|f|t|f
33894018|NCT03624569|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33894019|NCT01413269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894020|NCT05771428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894021|NCT00134914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34151519|NCT00510978|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34151520|NCT06267066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Experienced dermatologist blinded to the interventions done will assess the patients' at the end of the treatment period.|"Sixty patients will be divided randomly through closed envelop technique into 2 groups (Group A and B) each of 30 patients. Group A will be subdivided into 2 groups (1 and 2) each of 15 patients. All LSC lesions will be treated in any patient having multiple lesions.~Group 1 - A: Patients will receive 3 monthly laser sessions, in addition to the use of topical emollients only once daily in between the sessions.~Group 2 - A: Patients will receive 3 monthly laser sessions, in addition to topical steroids twice daily and topical emollient once daily in between the sessions.~Group B: Patients will be prescribed topical steroids twice daily and topical emollient once daily for 3 months."|f|f|f|t
34151521|NCT01799434|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151522|NCT04198675|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group 1: Supervised EMG Biofeedback Exercise Training Group; Posture training will be provided before intervention and ergonomic arrangements will be made in the workplace. Three sessions per week and six weeks of EMG biofeedback training will be carried out with electromyography-controlled video game combined with Proprioceptive Neuromuscular Facilitation (PNF) exercises.~Group 2: Home-Based Exercise Training Group; Posture training will be provided before interventions and ergonomic arrangements will be made in the workplace. Posture correction exercises, contains strengthening, stretching, mobility and relaxation exercises, will be given as a home exercises program for 6 weeks.~Group 3: Posture Training/Ergonomic Regulations Group Posture training will be provided before interventions and ergonomic arrangements will be made in the workplace."||||
34151523|NCT02270593|||CASE_CONTROL||PROSPECTIVE|||||||
34151524|NCT02636712|||CASE_ONLY||PROSPECTIVE|||||||
34151525|NCT02472236|NA|SINGLE_GROUP||OTHER||NONE||||||
34151526|NCT06416254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Crossover: Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study.|t|f|f|f
34151527|NCT04113551|||COHORT||RETROSPECTIVE|||||||
34151528|NCT00710463|||COHORT|||||||||
34151529|NCT03259815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Operator blinded pre and post PCI coronary physiology measurements will be performed in both arms of the study.~Post-PCI FFR results \<0.90 in the interventional arm will be disclosed to the operator to allow further intervention"|Randomised Controlled Trial|f|t|f|f
34151530|NCT03806075|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All patients with Peutz-Jeghers were enrolled and accepted second generation gene sequencing. Then all patients allocated into gene mutation group and no gene mutation group according to if the cases accompany with gene mutation of STK11.||||
34151531|NCT02399514|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34151532|NCT01165970|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34151533|NCT03187223|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective non-blinded clinical phase II trial investigating the drugs bendamustine hydrochloride and melphalan.||||
34151534|NCT02238093|||CASE_ONLY||RETROSPECTIVE|||||||
34151535|NCT01310829|||COHORT||PROSPECTIVE|||||||
34151536|NCT03083145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34151537|NCT04309058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151538|NCT01912690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151539|NCT04345172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blind|a randomized, prospective, non-inferiority comparative study|t|f|t|t
34151540|NCT05928416|||CASE_CONTROL||PROSPECTIVE|||||||
34151541|NCT04046250|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study will be partially blinded. The patient and investigator will be blinded as to whether TK112690 or placebo is administered. The clinical research organization, sponsor, and site pharmacist will know whether the patient was administered active drug or placebo.|A total of 22 patients will be enrolled into one of 2 different: TK112690 treated or placebo treated.|t|t|t|f
34151542|NCT04147546|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151543|NCT01326832|||COHORT||PROSPECTIVE|||||||
34151544|NCT05806866|||COHORT||PROSPECTIVE|||||||
34151545|NCT01666106|||CASE_ONLY||PROSPECTIVE|||||||
34151546|NCT03871972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151547|NCT01549873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151548|NCT03610373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessors do not have access to data regarding which arm each participant is in.|Participants are randomly assigned to receive a treatment planned primarily by the clinician (clinician guided) or planned collaboratively by the clinician, parent, and child (shared decision-making).|f|f|f|t
34151549|NCT04460846|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Randomized, double-blinded, placebo-controlled, cross-over trial|f|f|t|f
34151550|NCT02774655|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894022|NCT04804215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183714|NCT01649778|||OTHER||PROSPECTIVE|||||||
34183715|NCT05226806|||OTHER||PROSPECTIVE|||||||
34183716|NCT03595683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183717|NCT01075490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183718|NCT02960581|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183719|NCT05537662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183720|NCT06653179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183721|NCT02064023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183722|NCT00679900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183723|NCT01946230|||||PROSPECTIVE|||||||
34183724|NCT05895292|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Twelve patients will be randomly assigned to one of two groups (I or II) by a practitioner who will not be involved in patient selection or treatment but will be aware of the randomization sequence and have access to the randomization lists. This will be stored on a password-protected laptop, and the randomly generated codes will be placed in sequentially ordered, opaque, and sealed envelopes using a research randomizer (https://www.randomizer.org/). Participants were randomized to first receiving either Conventional CAD/CAM manufactured complete removable dentures Based on bone support concept or CAD/CAM neutral zone complete dentures will be designed based on the neutral zone concept and then after 3 months cross over to the other set. Patients and clinical practitioners are blinded to the type of prostheses at all study times.||t|t|t|f
34183725|NCT00035243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183726|NCT03873077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Group A receives standard treatment (intravenous analgesia). Group B received intravenous analgesia and a LIA.|t|f|t|t
34183727|NCT00199212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183728|NCT03387085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183729|NCT04948372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183730|NCT00453141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183731|NCT06299332|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label clinical study.||||
34183732|NCT00815061|||COHORT||RETROSPECTIVE|||||||
34183733|NCT05513534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be masked concerning the intervention provided.|We will compare Yoga and circuit resistance tarining impacts on mindfulness, anxiety, cognition, muscle structure, and physical performance in people with Parkinson's disease.|f|f|f|t
34183734|NCT00235274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183735|NCT00112619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183736|NCT05022576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183737|NCT04467684|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The assignment to either CB-0406 or placebo will be blinded to the participants, investigators and staff at the study site. The pharmacy team will be unblinded.||t|t|t|t
34183738|NCT05063058|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183739|NCT04763369|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1: Five (5) subjects will be treated by injecting UMSCs in sub-tenon space of eye.~Group 2: Five (5) subjects will be treated by suprachoroidal injection of UMSCs .~From two subjects in group 1 \& 2 will not be treated 24 hrs apart. Patients will be randomized in a 1:1 ratio (Sub-tenon injection of UMSCs : Suprachoroidal injection of UMSCs).~Note: In total, twenty five patients will be subjected to cell injection for each of group 1 \& 2."||||
34183740|NCT05008653|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34183741|NCT04053803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894023|NCT01841151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894024|NCT02140125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894025|NCT05026073|||CASE_CONTROL||PROSPECTIVE|||||||
33894026|NCT02265328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894027|NCT02195843|RANDOMIZED|PARALLEL||||NONE||||||
33894028|NCT02607527|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33894029|NCT03414879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894030|NCT04939155|||COHORT||RETROSPECTIVE|||||||
33753289|NCT03148223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be informed which group they belong to, intervention or control. Who will apply the treatment will not be blind, since during the treatment it will know if the points to be stimulated must contain seeds of mustard or just plaster, but will not have previous knowledge of the members of the groups. The evaluator, who is responsible for applying the pre- and post-treatment evaluation instruments, will be blind and not aware of the research intervention. The data analyst will also be early for the intervention group.||t|f|t|t
33753290|NCT04682548|||COHORT||PROSPECTIVE|||||||
33753291|NCT06580483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753292|NCT06360939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183742|NCT02965014|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34183743|NCT02778737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34183744|NCT03283501|||COHORT||RETROSPECTIVE|||||||
34183745|NCT05287620|||COHORT||PROSPECTIVE|||||||
34183746|NCT05533736|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34183747|NCT05808231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomised to be in Arm 1 or Arm 2 using pre-defined randomisation list; 1:1 for each arm.~Arm 1 receives Standard of Care Arm 2 receives Standard of Care+Quinine Sulfate"||||
34183748|NCT06048549|||OTHER||PROSPECTIVE|||||||
34183749|NCT03863158|||COHORT||RETROSPECTIVE|||||||
34183750|NCT01698398|RANDOMIZED|||||DOUBLE|||t|f|t|f
34183751|NCT00536419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183752|NCT00887536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183753|NCT02721329|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183754|NCT02558296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183755|NCT01244893|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183756|NCT02689661|||COHORT||PROSPECTIVE|||||||
34183757|NCT04347122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomized to one of four groups. One group is the bony tumor treated with TXA, second group is the bony tumor treated without TXA, third group is the soft tissue sarcoma treated with TXA, and the fourth group is soft tissue sarcoma treated without TXA.|t|f|f|f
34183758|NCT01732289|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34183759|NCT01123902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183760|NCT06177548|||COHORT||RETROSPECTIVE|||||||
34183761|NCT05183867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The groups will be randomized to one of three groups in a 2:2:1 ratio.|t|f|f|t
34183762|NCT00843596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183763|NCT06655844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183764|NCT03029871||SEQUENTIAL||TREATMENT||NONE||Nine subjects (3 cohorts, 3 subjects/cohort)||||
34183765|NCT04029402|||CASE_CONTROL||RETROSPECTIVE|||||||
34183766|NCT04818853|||COHORT||PROSPECTIVE|||||||
34183767|NCT01887535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183768|NCT04057326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34183769|NCT03530072|||COHORT||PROSPECTIVE|||||||
34183770|NCT02351076|||CASE_ONLY||PROSPECTIVE|||||||
34183771|NCT00380783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183772|NCT06654570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183773|NCT04077879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34183774|NCT06170047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Principal Investigator, Co-Investigators, Statistician, and the Clinical Research Coordinator conducting the caregiver-youth DPICS observation recording and coding will be blinded to study condition.|Parallel, two-arm, randomized controlled trial|f|f|t|t
34183775|NCT00735436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183776|NCT03531112|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will use a randomized clinical trial design. A sample of 40 black women who report at least weekly binge eating episodes will be randomized to 2 arms of a 6-month AAT intervention: AAT or a wait-list control group (delayed intervention group). AAT participants will receive an 8-week AAT program using a group format, and will be provided a smart scale (with bluetooth-connection for automatic data reporting) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessments will be conducted at 0, 2, and 6 months.||||
34183777|NCT00029484|RANDOMIZED|||||||||||
34183778|NCT00043316|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34183779|NCT03769519|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34183780|NCT06628830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34183781|NCT03244332|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"The investigators aim to start a prospective and observational study over a 2 years period.~First, the investigators will identify all children suffering from cirrhosis irrespective of underlying etiology and/or portal hypertension coming into the pediatric hepatogastroenterology unit at Saint-Luc University Clinics. Any patient with a congenital or acquired thrombophilia/haemorrhaegic disorder will be excluded."||||
34183782|NCT04221867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753293|NCT05768698|||COHORT||PROSPECTIVE|||||||
33753294|NCT02500862|||OTHER||OTHER|||||||
33753295|NCT00476216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753296|NCT00609687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753297|NCT05335512|||COHORT||PROSPECTIVE|||||||
33753298|NCT01368367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33753299|NCT01015157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753300|NCT04161508|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization and drug preparation are executed by a nurse anesthetist according to the body weight of the patients. The nurse anesthetist is not responsible for perioperative anesthetic care, and outcome assessemnt. The volume of drugs is adjusted to 10 ml with addition of normal saline to become undifferent in appearance|Participants are randomly allocated into one of the two group: neostigmine and sugammadex group for reversal of neuromuscular blockade|t|f|f|t
33753301|NCT03466294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753302|NCT03551574|||OTHER||PROSPECTIVE|||||||
33753303|NCT00676767|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33753304|NCT00584727|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33753305|NCT00384267|||||PROSPECTIVE|||||||
34183783|NCT04308291|||COHORT||PROSPECTIVE|||||||
33753306|NCT02607995|||COHORT||PROSPECTIVE|||||||
34183784|NCT01465919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753307|NCT02753049|NA|SINGLE_GROUP||OTHER||NONE||||||
33753308|NCT01436825|||COHORT||PROSPECTIVE|||||||
33753309|NCT01426165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753310|NCT04919265|||COHORT||PROSPECTIVE|||||||
33965161|NCT05066074|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Clinical Trial - Equivalence model (Two tailed) Based on a previous pilot study: SD 97 sec Allowable Diff: 90 sec, Patient loss 15%, Type I error 2.5%, Type II error 90% Mean Differences: 0||||
33965162|NCT05966870|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, before and after, cohort study||||
33965163|NCT01893983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33965164|NCT03456726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753311|NCT04917523|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753312|NCT03311412|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753313|NCT01255982|||COHORT||PROSPECTIVE|||||||
33753314|NCT04533854|||CASE_CONTROL||PROSPECTIVE|||||||
33965165|NCT01499342|||CASE_ONLY||PROSPECTIVE|||||||
33965166|NCT04009954|||CASE_CONTROL||RETROSPECTIVE|||||||
34183785|NCT02437344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183786|NCT05512156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183787|NCT04277338|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33753315|NCT00107003||||TREATMENT||NONE||||||
33753316|NCT04808804|||OTHER||CROSS_SECTIONAL|||||||
33753317|NCT04474002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33753318|NCT00220298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753319|NCT06490107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753320|NCT02291679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965167|NCT01424774|||COHORT||PROSPECTIVE|||||||
33965168|NCT01362959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183788|NCT04243720|||COHORT||PROSPECTIVE|||||||
34183789|NCT03533049|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34183790|NCT00651690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183791|NCT06128759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34183792|NCT03421483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34183793|NCT05267613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking only applies to the double-blind, randomized maintenance phase of 16 weeks.||t|t|t|t
34183794|NCT02765750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34183795|NCT06492642|NA|SINGLE_GROUP||TREATMENT||NONE||20 individuals with chronic low back pain. Will aim to recruit a socioeconomically diverse sample. No randomization or group assignment; analyses will be conducted using a pre-post design.||||
34183796|NCT01001325|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34183797|NCT06322628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183798|NCT06096467|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34183799|NCT04126005|||COHORT||OTHER|||||||
34183800|NCT04554680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183801|NCT04963647|||OTHER||CROSS_SECTIONAL|||||||
34183802|NCT00823017|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34183803|NCT01980537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183804|NCT00204178|||DEFINED_POPULATION||OTHER|||||||
34183805|NCT01715740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183806|NCT00624598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753321|NCT00447980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33894031|NCT05187117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessment collector will be blinded as to whether a participant is in the intervention or waitlist group|Waitlist Control Trial|f|f|f|t
33894032|NCT05300412|||OTHER||CROSS_SECTIONAL|||||||
33894033|NCT05877677|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34183807|NCT05556837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"The study will be double-blinded; the participants, those serving the participants and those doing the biochemical analysis, entering data, and performing the statistical analysis will be blinded to the nature of the test meals.~The codes identifying the test meals will be kept in a sealed opaque envelope at INQUIS and will be opened only if necessary to assist in the diagnosis and management of a serious adverse event. Test meal identity on study documents and blood tubes will be the code numbers on the test food packages. Thus, the identity of the test meals will be double-blinded. The codes will be broken once the database for plasma glucose and serum insulin has been cleaned, locked, and sent to the sponsor."|The study is a double-blinded, randomized, crossover design with all subjects completing all 3 tests.|t|f|t|t
34183808|NCT05342077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34183809|NCT03610269|NA|SINGLE_GROUP||OTHER||NONE||||||
34183810|NCT05033782|||COHORT||PROSPECTIVE|||||||
34183811|NCT00967070|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
34183812|NCT02885701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183813|NCT05079308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34183814|NCT01724099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183815|NCT06176079|||COHORT||PROSPECTIVE|||||||
34183816|NCT01369888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183817|NCT02989597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183818|NCT02926001|||||RETROSPECTIVE|||||||
34183819|NCT04489836|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34183820|NCT01448980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183821|NCT06194331|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|The assessor and the investigator will be blinded to whether or not the participant received the iCHART/cASAP intervention or if they are receiving treatment as usual.|This study will utilize a stepped wedge design in which 4 PROS practices start with usual care initially and are randomly chosen to transition to iCHART-cASAP at different times in such a way as half of the participants will receive TAU and half will receive iCHART-cASAP. All sites will be initially monitored for at least 3 months during TAU. This will be followed by a staggered adoption of iCHART-cASAP. At each time period, a new site will begin implementing the intervention. Block randomization determines the order each site begins the intervention phase. Each time period (approximately 3 months), a web-based system will be used to assign the next clinic to begin using iCHART-cASAP. Research staff will be available to assist with consenting participants and assisting with study procedures.|f|f|t|t
34183822|NCT05471310|||CASE_ONLY||RETROSPECTIVE|||||||
34183823|NCT00104286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183824|NCT04396418|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34183825|NCT01592357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183826|NCT02683577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183827|NCT01016392|||COHORT||PROSPECTIVE|||||||
34183828|NCT04441892|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34183829|NCT06120985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34183830|NCT00720915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183831|NCT02266888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183832|NCT05134428|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
34183833|NCT03127007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183834|NCT02444767|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183835|NCT03603353|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
34183836|NCT06591078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33894034|NCT05844384|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The investigators performing the vision assessment and measuring the intraocular pressure are masked.|Prospective, randomized, single-masked, active-controlled, crossover (AB:BA)|f|f|t|f
33894035|NCT02224430|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34183837|NCT03891108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183838|NCT01193244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183839|NCT00614432|||COHORT||PROSPECTIVE|||||||
34183840|NCT03486834|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183841|NCT03189004|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34183842|NCT02097264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753322|NCT00950066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183843|NCT03155841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183844|NCT03632473|||COHORT||PROSPECTIVE|||||||
34183845|NCT04015544|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||randomized||||
34183846|NCT01096069|||COHORT||PROSPECTIVE|||||||
34183847|NCT04600596|||COHORT||PROSPECTIVE|||||||
34183848|NCT05777252|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective clinic study with a single group||||
34183849|NCT06055270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study statistician|Double-Blinded, Placebo-Controlled Randomized Clinical Trial|t|f|t|f
34183850|NCT01460693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183851|NCT05336162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34183852|NCT00004169||||TREATMENT||||||||
34183853|NCT04057417|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Natural Experiment||||
34183854|NCT03705338|||CASE_CONTROL||PROSPECTIVE|||||||
34183855|NCT02024919|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34183856|NCT03278171|||COHORT||PROSPECTIVE|||||||
33753323|NCT04616261|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33753324|NCT01441102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183857|NCT04289935|NA|SEQUENTIAL||DIAGNOSTIC||NONE||multicenter, prospective, single arm, feasibility trial||||
33753325|NCT00591474|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33753326|NCT05186870|||COHORT||CROSS_SECTIONAL|||||||
33753327|NCT01602887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33753328|NCT04244890|||CASE_ONLY||PROSPECTIVE|||||||
33753329|NCT01398280|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753330|NCT05840432|||COHORT||PROSPECTIVE|||||||
33753331|NCT00729404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753332|NCT01315093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894036|NCT05591911|||COHORT||PROSPECTIVE|||||||
33894037|NCT03784378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894038|NCT03591887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183858|NCT04479670|||COHORT||PROSPECTIVE|||||||
34183859|NCT06274736|||COHORT||PROSPECTIVE|||||||
34183860|NCT00521404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183861|NCT04626908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183862|NCT01328132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34183863|NCT06523933|||COHORT||PROSPECTIVE|||||||
34183864|NCT04293068|||COHORT||PROSPECTIVE|||||||
34183865|NCT02509442|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34183866|NCT00252096|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183867|NCT01597804|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34183868|NCT03520855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34183869|NCT05093946|||COHORT||PROSPECTIVE|||||||
33753333|NCT00733538|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33753334|NCT05762133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|At 3- and 6-months postpartum, mothers and fathers will attend an observation that includes a 5-minute free play with their infant separately and a 5-minute free play together as co-parents. Parent-infant interactions will be videotaped and interaction quality will be coded by a blind evaluator.|We plan to enroll 50 parent dyads (100 individuals total, 25 romantic or non-romantic partners per arm). If we assume 5% attrition at each phase, we anticipate analyzable data for between 20-25 parent duos per arm.|f|f|f|t
33753335|NCT04920357|||CASE_CONTROL||PROSPECTIVE|||||||
33753336|NCT04162665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753337|NCT05381155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind waitlist randomized controlled trial|t|f|f|f
33753338|NCT00889902|||CASE_CONTROL||PROSPECTIVE|||||||
33753339|NCT00487266|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33753340|NCT05715996|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894039|NCT01379625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894040|NCT04863716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894041|NCT04225598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894042|NCT01898663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965169|NCT03126851|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34183870|NCT01035086|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34183871|NCT04449250|RANDOMIZED|CROSSOVER||OTHER||NONE||Subjects will be randomized to one of two sequences: Sequence 1) Fasted: Fed or Sequence 2) Fed: Fasted||||
34183872|NCT01527097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183873|NCT02664896|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34183874|NCT04016935|||CASE_ONLY||PROSPECTIVE|||||||
34183875|NCT05684172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183876|NCT00830440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183877|NCT05513404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This acute intervention study will have a randomised controlled crossover design where the volunteers will return for 4 stand-alone study sessions. All study procedures will be carried out at the Human Nutrition Unit (HNU) of the Rowett Institute.||||
34183878|NCT02668653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183879|NCT02877992|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34183880|NCT02802540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183881|NCT05705453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183882|NCT02947789|||COHORT||RETROSPECTIVE|||||||
34183883|NCT04762589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo-controlled, double-blind||t|t|t|t
34183884|NCT04425109|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|subject with random allocation Investigator do not know the group the analysator do not know the group|Group 1 : give tempeh steak Group 2 : give soybean steak washout 3 days Group 1 : give soybean steak Group 2 : give tempeh steak|t|f|t|f
34183885|NCT04427267|||CASE_CONTROL||PROSPECTIVE|||||||
34183886|NCT03276624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183887|NCT05704582|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Single-blind randomized controlled trial|f|f|f|t
34183888|NCT04572789|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183889|NCT03041181|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-Label|||||
34183890|NCT05194644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel assignment|f|f|f|t
34183891|NCT04743843|||CASE_ONLY||RETROSPECTIVE|||||||
34183892|NCT05027555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34183893|NCT02850926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34183894|NCT03921957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183895|NCT01323101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183896|NCT05348213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183897|NCT02738281|||COHORT||PROSPECTIVE|||||||
34183898|NCT01399541|||COHORT||PROSPECTIVE|||||||
34183899|NCT03511937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This trial uses incomplete disclosure to mask the purpose of the trial from participants.||t|f|f|f
34183900|NCT00767988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34183901|NCT00168857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34183902|NCT03488953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183903|NCT03525496|||COHORT||RETROSPECTIVE|||||||
34183904|NCT01628640|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183905|NCT03312634|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, open-label study. NHS data (study PVO-1A-001) will be used as an external control in the analysis.||||
34183906|NCT04698863|||OTHER||PROSPECTIVE|||||||
34183907|NCT03690687|||COHORT||CROSS_SECTIONAL|||||||
33753341|NCT05591508|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open labeled randomized controlled trial||||
33753342|NCT03258567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183908|NCT06351007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183909|NCT06515730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment of the primary outcome of thrombus resolution will be performed through review of images by researchers who are blinded to the treatment assignment|Investigator-initiated, multicenter, open-label, blinded outcome assessment, parallel arm, active comparator, randomized study|f|f|f|t
34183910|NCT00433420|RANDOMIZED|||TREATMENT||||||||
34183911|NCT04490070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34183912|NCT06001203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34183913|NCT04457297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183914|NCT04134208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183915|NCT02859571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183916|NCT05975606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants are blinded to their groups. Research assistant and physiotherapist who are responsible for conducting assessment sessions are also blinded to participants group.~All the participants will be randomized to groups using opaque envelopes blocked by four and stratified by AIS score."|This protocol involves two groups of participants: intervention group and control group. Intervention group will receive real rTMS and FES cycling and control group will receive sham rTMS and FES cycling. The results of these groups are then evaluated at several stages of the study.|t|t|f|t
34183917|NCT01173094|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183918|NCT05821777|NA|SEQUENTIAL||TREATMENT||NONE||Part 1 of the study will be non-randomized and Part 2 design will depend on results of Part 1.||||
34183919|NCT03597945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants were assigned to one of two groups in parallel for the duration of the study|t|t|t|t
34183920|NCT02681029|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183921|NCT01538095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965170|NCT02934386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183922|NCT06312904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183923|NCT04241419|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34183924|NCT05479019|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34183925|NCT04046120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183926|NCT04200846|RANDOMIZED|PARALLEL||TREATMENT||NONE||An interventional pilot trial will be performed with 21 randomized subjects who are aged 18-75 years who are frail according to the LFI to a 3-month exercise intervention (n=14) versus standard of care (n=7) with no change in activity.||||
34183927|NCT05053802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183928|NCT05458115|||CASE_ONLY||PROSPECTIVE|||||||
34183929|NCT01136161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34183930|NCT03614156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183931|NCT01263197|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34183932|NCT02824341|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34183933|NCT02109302|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
34183934|NCT00913640|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34183935|NCT01832246|||CASE_ONLY||PROSPECTIVE|||||||
34183936|NCT03187886|||COHORT||RETROSPECTIVE|||||||
34183937|NCT00318643|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34183938|NCT02061410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183939|NCT01276210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183940|NCT03681314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Neurodevelopmental providers will be blinded to the randomization of the toddler during the examination.|Neurodevelopmental assessments will be done at 2 years of age (22-26 months) for subjects who were randomized to receive either immediate cord clamping or umbilical cord milking as part of the MIDAB trial.|f|f|f|t
34183941|NCT02897271|||CASE_ONLY||RETROSPECTIVE|||||||
34183942|NCT00797641|||COHORT||RETROSPECTIVE|||||||
34183943|NCT03040544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183944|NCT05589467|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34183945|NCT03129217|||COHORT||PROSPECTIVE|||||||
34183946|NCT06073301|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible Subjects for this single center open label randomized study, will randomize eligible subjects to 2 groups, 15 in the treatment arm (Fish skin graft) and 15 in the control arm (cadaver graft). Randomization will be done electronically on day of surgery, enrollment.||||
34183947|NCT05217693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34183948|NCT00711061|||CASE_CONTROL||PROSPECTIVE|||||||
34183949|NCT02222623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183950|NCT05378191|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized to immediately receive or not a dose of COMIRNATY in a ratio of 2:1. If primary analysis at 14 days confirms the starting hypothesis, subjects randomized to no vaccination will be considered for administration of one dose of COMINARTY at day 28th according to Public Health Department of the Ministry of Health recommendations on heterologous vaccination.||||
34183951|NCT05429957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34183952|NCT03807206|||COHORT||CROSS_SECTIONAL|||||||
34183953|NCT06405191|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized cotrolled clinical trial|t|f|f|f
34183954|NCT04420312|||CASE_CONTROL||RETROSPECTIVE|||||||
34183955|NCT00760617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34183956|NCT05045495|||CASE_CONTROL||PROSPECTIVE|||||||
34183957|NCT04911452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data outcomes for growth and clinical data will be blind to group allocation|Single-site, single-blind, two-group (treatment and control), randomized pilot trial|f|f|f|t
34183958|NCT02722993|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34183959|NCT03705689|||CASE_CONTROL||PROSPECTIVE|||||||
34183960|NCT05324059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183961|NCT02518438|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34183962|NCT02527811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34183963|NCT02185508|||CASE_ONLY||RETROSPECTIVE|||||||
34183964|NCT00518765|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34183965|NCT02896803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183966|NCT02837770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34183967|NCT04951024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183968|NCT05469659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183969|NCT01338740|||CASE_ONLY||PROSPECTIVE|||||||
34183970|NCT00089752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34183971|NCT05650385|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34183972|NCT04389281|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group, Open Label||||
34183973|NCT04431440|||CASE_ONLY||PROSPECTIVE|||||||
34183974|NCT05880186|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Dietary Supplement: caffeine acute supplementation|t|t|t|t
34183975|NCT06092593|||COHORT||CROSS_SECTIONAL|||||||
34183976|NCT03903406|||COHORT||PROSPECTIVE|||||||
34183977|NCT00467116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183978|NCT01924338|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965171|NCT03395574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753343|NCT05744648|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a triple-blinded study in which the participant, care provider and outcome assessor will be masked.|In this study, participants will be allocated in two groups by Consecutive non-random sampling technique.|t|t|f|t
33753344|NCT01584765|||COHORT||RETROSPECTIVE|||||||
33753345|NCT03440931|||COHORT||PROSPECTIVE|||||||
33965172|NCT02649608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study comprised 5 cohorts (Cohorts 1 to 5), with each cohort consisting of 3 patients (men and/or women). The dosing regimen planned for Cohort 1 was a dose of 0.2 mg Lu AE04621 on Day 1 followed by a dose of 0.4 mg Lu AE04621 on Day 2, and a dose of 0.6 mg Lu AE04621 on Day 3. • The dosing regimen planned for Cohort 2 was 0.4 mg Lu AE04621 on Day 1 followed by a dose of 0.6 mg Lu AE04621 on Day 2, and a dose of 0.8 mg Lu AE04621 on Day 3. The dosing regimen planned for Cohort 3 was 0.2 mg Lu AE04621 on Day 1 followed by a dose of 0.4 mg Lu AE04621 on Day 2, a dose of 0.6 mg Lu AE04621 on Day 3, and a dose of 1.0 mg Lu AE04621 on Day 4. The dosing regimen planned for Cohorts 4 and 5 was 0.2 mg Lu AE04621 on Day 1 followed by a dose of 0.4 mg Lu AE04621 on Day 2, a dose of 0.6 mg Lu AE04621 on Day 3, and a dose of 1.2 mg Lu AE04621 on Day 4. The results are presented by dose groups and are based on the actual doses administered.||||
33965173|NCT06119646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33965174|NCT02139605|RANDOMIZED|PARALLEL||TREATMENT||NONE||Gastrectomy with D2 or D3 lymphadenectomy||||
33965175|NCT04337190|||COHORT||PROSPECTIVE|||||||
33965176|NCT03644602|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965177|NCT00821041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33965178|NCT01368679|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965179|NCT03233737|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
34183979|NCT04214938|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The caregiver administering the nasal spray, the subject, and the otolaryngologist carrying out nasendoscopy were all uninformed as to the type of spray employed.|A Double Blind, Randomized, Controlled Trial|t|f|t|f
34183980|NCT03879733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participating child-care centers, staff, parents and children are blind to the study conditions prior to consenting. After randomization the participants know if they get the intervention or not.|Participating childcare centers are randomized to either a wait list control- group or an intervention group. The wait-list control group will receive the intervention after 1 year.|t|f|f|f
34183981|NCT03559608|||COHORT||PROSPECTIVE|||||||
34183982|NCT00336596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34183983|NCT05851261|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34183984|NCT02601248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183985|NCT01591525|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34183986|NCT02615899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34183987|NCT00244569|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34183988|NCT04455256|||CASE_CONTROL||PROSPECTIVE|||||||
34183989|NCT04343742|||CASE_ONLY||PROSPECTIVE|||||||
34183990|NCT01753232|||COHORT||PROSPECTIVE|||||||
34183991|NCT05680402|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single Blind RCT in which only participants will not know about the type of treatment undergoing|Randomized Control Clinical Trial in which group 1 will be of experimental group and group 2 will be of control group|t|f|f|f
34183992|NCT00349544|||||CROSS_SECTIONAL|||||||
34183993|NCT05363748|||COHORT||PROSPECTIVE|||||||
34183994|NCT04275362|||CASE_CONTROL||OTHER|||||||
34183995|NCT00148317|NA|SINGLE_GROUP||TREATMENT||NONE||"Consolidation: All patients will receive 2 cycles of bortezomib (VEL) and dexamethasone (DEX). Patients who achieve a complete response after 2 cycles will receive 4 additional cycles of VEL/DEX before mobilization.~Patients who do not achieve at least a partial response after 2 cycles will receive 4 more cycles of VEL/DEX plus DOXIL.~Patients who achieve a partial response after 2 cycles on VEL/DEX, will continue this combination for 2 more cycles. Patients who achieve a complete response after 4 cycles will receive 2 additional cycles of VEL/DEX before mobilization. Patients who remain with a partial response after 4 cycles of VEL/DEX will receive 2 additional cycles of the combination of VEL/DEX plus DOXIL.~Mobilization: Patients who complete 6 cycles of consolidation will proceed to mobilization. Patients will receive one cycle of VEL plus high dose CYTOXAN followed by G-CSF beginning 24 hours after CYTOXAN given for a total of 10 daily doses."||||
34183996|NCT03307499|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34183997|NCT04193995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34183998|NCT01055431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34183999|NCT06119932|||COHORT||PROSPECTIVE|||||||
34184000|NCT00491842|||COHORT||RETROSPECTIVE|||||||
34184001|NCT05975684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized into one of two parallel groups in 1:1 ratio. The specific details of randomization sequence will be managed by investigational pharmacy. The participant, care provider, and research team are blinded to randomization.|Parallel groups of (a) baclofen or (b) placebo control|t|t|t|f
34184002|NCT05164991|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33753346|NCT00935376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753347|NCT06524349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study team member who obtains knee measurements will be blinded to study treatment.||f|t|f|f
33753348|NCT02837627|||COHORT||PROSPECTIVE|||||||
33753349|NCT03365024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753350|NCT03258749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184003|NCT03487237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066281|NCT06216405|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|A single-blind, randomised study. Patient is not informed of the arm he is assigned to.|"Patients will be randomized into the two groups:~* Experimental : AI-aided colonoscopy using GI Genius™ intelligent endoscopy system (Medtronic Inc., Minneapolis, Minnesota, USA)~* Control : Standard high-definition colonoscopy:~Randomization will be established according to a 1:1 ratio, balanced and per block of variable size, and stratified according to age (≤50 vs \>50 years-old) and on personal polyps or colorectal cancer history (yes vs no)"|t|f|f|f
34066282|NCT03387501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066283|NCT00072904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066284|NCT03015194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066285|NCT06156137|||CASE_ONLY||RETROSPECTIVE|||||||
34066286|NCT02750085|||CASE_ONLY||PROSPECTIVE|||||||
34066287|NCT02143167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066288|NCT02419794|||COHORT||PROSPECTIVE|||||||
34066289|NCT04656366|||COHORT||RETROSPECTIVE|||||||
34066290|NCT03406988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Each enrolled patient will be blind regarding the administered therapy (active and sham procedure).~Evaluation of primary and secondary outcomes will be performed by assessors blind regarding the administered therapy."|"Candidate SSc patients will have only one active DU of at least 6 mm in diameter, lasting for at least 6 weeks, despite conventional vascular therapy. Patients with severe visceral manifestations, diabetes and treated with immune-suppressors and endothelin inhibitors will be excluded. Active therapy: implantation of 0.5-1 ml of autologous AT at the base of the finger with DU. Autologous AT will be obtained by liposuction from abdominal fat.~SP will be blindly performed in the control group to simulate the AT-G. A false liposuction will be performed followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger. Basal therapy: weekly iloprost infusion (0.5-2 ng/Kg/min), and calcium-channel blockers (oral nifedipine 20 mg daily) will be continued during the entire observation time in all of the patients recruited in both arms of the study. The administration of analgesics to alleviate the DU-related pain will be also allowed for each patient."|t|f|f|t
34066291|NCT01294059|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34066292|NCT00478907|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34066293|NCT05905133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066294|NCT02623517|||COHORT||PROSPECTIVE|||||||
34066295|NCT01129804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066296|NCT03259906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066297|NCT05018988|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinded to participant and researcher|Observational study followed double blinded randomised control trial|t|f|t|t
34066298|NCT03081299|||OTHER||PROSPECTIVE|||||||
34066299|NCT03862092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066300|NCT04968522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The order of medications (placebo/active drug) will be masked to the participant, assessors and investigator. At the end of the trial, the order of medications will be unmasked, and compared with the parent and teachers' observations of the child's behaviour.|The N-of-1 trial has a four-period crossover design, comparing attention skills on active drug compared to placebo. The 8-week trial comprises four 2-week treatment blocks (each block consisting of 1 week active drug and 1 week placebo). Participants randomisation will be in the two-week pairs - so the order of treatment (A) and placebo (P) to be randomly assigned within each two-week cycle is randomly allocated.|t|t|t|t
34066301|NCT04489732|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, open-label, non-randomized, non-placebo controlled, single-group assignment, pilot study||||
34066302|NCT01558713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34066303|NCT02720159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066304|NCT00032630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066305|NCT02550925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Note: 139 individuals enrolled. 4 dropped out after consent, before baseline data collection, leaving 135 individuals with data.|||||
34184004|NCT02382705|||COHORT||PROSPECTIVE|||||||
34184005|NCT04207762|||COHORT||PROSPECTIVE|||||||
34184006|NCT00408057|||CASE_ONLY||PROSPECTIVE|||||||
34184007|NCT03350685|||COHORT||RETROSPECTIVE|||||||
34184008|NCT00478543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184009|NCT01925456|NA|SINGLE_GROUP||||NONE||||||
34184010|NCT02439437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184011|NCT03699514|||CASE_ONLY||PROSPECTIVE|||||||
34184012|NCT01104311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184013|NCT01528332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184014|NCT02085161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34184015|NCT00707889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184016|NCT04830332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184017|NCT00456040|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34184018|NCT01654302|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34184019|NCT04058964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184020|NCT04976400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184021|NCT01397214|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184022|NCT06276920|||OTHER||CROSS_SECTIONAL|||||||
34184023|NCT03405597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184024|NCT01759446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34184025|NCT01465555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184026|NCT00996398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753351|NCT00208416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066306|NCT05241444|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Escalating doses of CD4\^LVFOXP3 will be administered in 2-6 participants per dose in two age cohorts (Cohort A: ≥ 12 years of age; Cohort B: \< 12 years of age) using a 2+4 dose escalation design. Cohort B will be started at the second dose level.||||
34066307|NCT05559684|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomization will be achieved by using an online random number generator. Patient codes will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A medical doctor not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anesthesiologist who is expert in doing the ESPB in patients included within the block group. This expert anaesthesiologist will not be involved in collecting data but another anaesthesist blinded to the type of block will be responsible for patient management and collecting the intra-operative and postoperative data||f|f|t|f
34184027|NCT04843462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be immediately pseudonymized and stored as a master list at the internal server of the MUV (Medical University Vienna). The study staff will only have access to the master list and only the principal investigator and study director will have access to the pseudonymization list. This locked place will be located at the clinic (MUV). All non-personal pseudonymized research relevant data are stored in a master list on a server of the research group at the MUV, to which study staff has access.|"The interventional study consists of two parallel study arms. The interventional group receives treatment-as-usual with nasal esketamine spray and access to edupression.com®. The control group only receives treatment-as-usual."|t|f|f|f
34184028|NCT06154213|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184029|NCT01740882|||COHORT||RETROSPECTIVE|||||||
34066308|NCT00427427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066309|NCT03472521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization table will be used by the research pharmacy and study drug will be prepared in numbered bottles.|Double blind randomized|t|t|t|t
34066310|NCT05202015|||COHORT||PROSPECTIVE|||||||
34066311|NCT01530802|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34066312|NCT02603107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066313|NCT04393207|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34066314|NCT03570008|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|||||
34066315|NCT01146561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066316|NCT00502099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066317|NCT02131636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066318|NCT05746767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Comparing peer-supported delivery vs. unsupported delivery of dCBT|f|f|t|t
34066319|NCT03836456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data collected will be coded and codes will not be revealed to the investigators or outcome assessors until after data analysis is complete. The study participants will be told they are participating in an intervention to promote mental health but not told which of the 2 interventions is the active control.|Randomized controlled trial|t|t|t|t
34066320|NCT02599337|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34066321|NCT00650286|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34066322|NCT00865657|RANDOMIZED|CROSSOVER||||NONE||||||
34184030|NCT00072839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184031|NCT00454324|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184032|NCT02693366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184033|NCT03819530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Treatment group: receives baseline deworming medication and daily micronutrient supplementation for 4 months; Control group: receives baseline deworming medication only|f|f|f|t
34184034|NCT02191358|||OTHER||PROSPECTIVE|||||||
34184035|NCT00604799|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184036|NCT03827096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184037|NCT02647996|||CASE_CONTROL||PROSPECTIVE|||||||
34184038|NCT05463484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||"Three toothpastes will be included in the study; one with the composition including an olive product, betaine and xylitol, one with the same composition but without the olive product, betaine and xylitol, and one of a product marketed for gingivitis with and antimicrobial ingredient.~Subjects are randomnly assigned and products will have a white label so that nor subject nor researcher will know the composition to be tested."|t|t|t|t
34184039|NCT04891068|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, window of opportunity trial in which patient with previously untreated high risk early stage breast cancer will receive 5 consecutive days of azacitidine 50mg/m2 SC followed by standard of care therapy||||
34184040|NCT00813202|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184041|NCT05566106|||COHORT||CROSS_SECTIONAL|||||||
34184042|NCT00390143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184043|NCT05628376|||COHORT||PROSPECTIVE|||||||
34184044|NCT00335595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184045|NCT05790369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184046|NCT00687492|||CASE_ONLY||PROSPECTIVE|||||||
34184047|NCT04302077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184048|NCT00393692|||COHORT||PROSPECTIVE|||||||
34184049|NCT01472289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184050|NCT02170077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184051|NCT03611829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blind to their condition, but physicians and administrative staff were not blind to participant condition. Physicians were not blind to participant condition because they were responsible for delivering the ACT intervention or standard care. They were thus required to know the participant's condition in order to deliver the adequate treatment. Administrative staff was responsible for providing physicians with this information and organizing study paperwork and thus needed to be aware of participant condition as well.|The present study was a two-arm pilot randomized controlled trial.|t|f|f|f
34184052|NCT04286945|NA|SINGLE_GROUP||TREATMENT||NONE||PROSPECTIVE STUDY||||
34184053|NCT05430399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184054|NCT03405532|||CASE_CONTROL||PROSPECTIVE|||||||
34184055|NCT02873377|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study arms will be conducted simultaneously.||||
34184056|NCT01190462||||TREATMENT||NONE||||||
33965180|NCT02082262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965181|NCT01416142|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965182|NCT02501031|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34184057|NCT04805034|||COHORT||OTHER|||||||
34184058|NCT01544010|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34184059|NCT04017663|||OTHER||CROSS_SECTIONAL|||||||
34184060|NCT01233011|||CASE_ONLY||PROSPECTIVE|||||||
34184061|NCT03177655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184062|NCT01744977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184063|NCT06447714|||COHORT||PROSPECTIVE|||||||
34184064|NCT02315742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184065|NCT02074696|||COHORT||CROSS_SECTIONAL|||||||
34184066|NCT01196637|||CASE_CONTROL||PROSPECTIVE|||||||
34184067|NCT03192735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184068|NCT02504151|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34184069|NCT01896167|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34184070|NCT01877993|||COHORT||CROSS_SECTIONAL|||||||
34184071|NCT06125600|||COHORT||RETROSPECTIVE|||||||
34184072|NCT01736995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184073|NCT01588730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184074|NCT00899132|||CASE_ONLY||CROSS_SECTIONAL|||||||
33965183|NCT05482087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184075|NCT00248404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184076|NCT01635296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184077|NCT01551186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184078|NCT00813241|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34184079|NCT04210531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184080|NCT01427153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34184081|NCT02592798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184082|NCT01773720|||CASE_ONLY||PROSPECTIVE|||||||
34184083|NCT04035148|||CASE_ONLY||CROSS_SECTIONAL|||||||
34184084|NCT00288132|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184085|NCT05165940|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomized to receive care coordination as usual (i.e., TAU) through the VA or an experimental care coordination intervention.||||
34184086|NCT04846426|||CASE_CONTROL||PROSPECTIVE|||||||
34184087|NCT00531544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184088|NCT05035381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184089|NCT02899468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184090|NCT04961684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184091|NCT01424384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184092|NCT04706455|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Corneal topography and Biometry will be performed in individuals with age-relate cataract. Patients will be classified as dry eye or normal eye based on BUT. The tear film breakup (BUT) time of less than 5 seconds will be diagnosed as dry eyes. One of two artificial tear eye drops will be instilled in the eye, and corneal topography and biometry will be repeated after 5 minutes of application||||
34184093|NCT03241901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Due to the objectives of the study, the identity of test and control treatments will be known only to investigators, research staff, but NOT patients. The following study procedures will be in place to ensure single-blind administration of study treatments.~1. Access to the randomization code will be strictly controlled.~2. A taste-matching agent for the placebo.~3. Packaging and labeling of test and control treatments will be identical to maintain the blind.~During the study, the blind may be broken only in emergencies when knowledge of the patient's treatment group is necessary for further patient management. When possible, the Investigator should discuss the emergency with the Medical Monitor prior to un-blinding"||t|f|f|f
33753352|NCT00130533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965184|NCT01562431|RANDOMIZED|PARALLEL||||NONE||||||
33965185|NCT00944437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965186|NCT02828748|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965187|NCT04399096|||CASE_ONLY||OTHER|||||||
33965188|NCT04856579|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965189|NCT04238468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient, investigator, outcome assessor will be blinded for which side of the scar was injected with stromal vascular fraction. Only the surgeon will know which site was injected.||t|t|t|t
33965190|NCT01580020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965191|NCT05439759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33965192|NCT03723928|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34066323|NCT05926414|||CASE_ONLY||PROSPECTIVE|||||||
34066324|NCT00910117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066325|NCT01937715|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066326|NCT04698083|||CASE_ONLY||RETROSPECTIVE|||||||
34066327|NCT02111681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066328|NCT03706976|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34066329|NCT05376020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066330|NCT04272957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184094|NCT04128852|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, single-center, post market surveillance study.||||
34184095|NCT05006963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two researchers will be part of the protocol. One will be responsible for pre and post intervention assessments and will be blind to the type of intervention. The other will be responsible for the treatment phase: face-to-face and telerehabilitation. A third party collaborator will process and statistically analyze the collected data. Individuals will be randomized using the statistical program present at www.randomization.com , in two groups. Randomization and concealment of allocation will be made by a fourth external employee, not research participant, who will organize the allocation in individual opaque envelopesand keep it confidential. There will be 2 blocks of 25 envelopes: face-to-face (GA) and telerehabilitation (GB). With this process, participants will have the same probability of being allocated to one of the two treatment groups. Blinding of the evaluator will be maintained until the end of the research and data tabulation.||t|f|t|t
34184096|NCT04586439|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184097|NCT03726580|||CASE_CONTROL||PROSPECTIVE|||||||
34184098|NCT06128954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184099|NCT05044689|||CASE_CONTROL||PROSPECTIVE|||||||
34184100|NCT06081816|||OTHER||OTHER|||||||
34184101|NCT04640610|||COHORT||PROSPECTIVE|||||||
34184102|NCT05410184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||experimental model using randomized pretest and posttest with control group|t|f|t|f
34184103|NCT02846506|RANDOMIZED|CROSSOVER||||NONE||||||
34184104|NCT02538224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184105|NCT04859738|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||During the data collection, 120 individuals who met the inclusion criteria and were selected with the randomization list created on the computer constituted the sample of the study.|t|f|f|f
34184106|NCT04273737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184107|NCT00414336|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34184108|NCT04324411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184109|NCT04627402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Diabetic macular edema.|f|f|f|t
34184110|NCT01293734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184111|NCT01447459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34184112|NCT05642052|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||All participants will go through 10 days of control diet and 10 days of reduced carb diet.||||
34184113|NCT00926861|||COHORT||PROSPECTIVE|||||||
34184114|NCT04583241|||CASE_CONTROL||PROSPECTIVE|||||||
34184115|NCT04263155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184116|NCT01809340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184117|NCT06371781|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||Pregnant women who were given birth at Cumhuriyet University Faculty of Medicine Hospital Gynecology and Obstetrics Clinic between July 1, 2021 and July 1, 2022 and whose pregnancy follow-ups were performed in our hospital will be included in our prospectively designed study. Researchers will divide the study into two main groups. The first group will consist of pregnant women with above-normal weight gain during pregnancy, and the other group will consist of pregnant women with normal weight gain during pregnancy. It is estimated that 46 control and 44 pregnant women with overweight will be reached during this period. In the study, first a form containing demographic data such as age, education, height and weight will be filled out.|t|f|f|f
34184118|NCT00445926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184119|NCT00209612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184120|NCT02850913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184121|NCT01957995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184122|NCT00843700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184123|NCT03690297|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34184124|NCT04204525|||CASE_CONTROL||PROSPECTIVE|||||||
34184125|NCT04570137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Two-armed crossover trial|t|f|f|f
34184126|NCT01598506|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34184127|NCT02088476|||COHORT||RETROSPECTIVE|||||||
34184128|NCT03475095|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34184129|NCT06339801|||CASE_CROSSOVER||PROSPECTIVE|||||||
34184130|NCT05994755|||COHORT||PROSPECTIVE|||||||
34184131|NCT03978546|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||All participants will have the same examinations but in a randomised order, these examinations are: Humphrey Visual Fields Test (10-2 and 24-2, SITA Standard), OCT Scan (Cube scan, Wide angle and macula scan) and Smart Perimetry - Henson 9000.||||
34184132|NCT01100801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066331|NCT05096598|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||First human dose trial. A single-centre, placebo-controlled, double-blind (within cohorts), randomised single dose trial.|t|t|t|t
33753353|NCT01939548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753354|NCT03853668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33753355|NCT02136940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753356|NCT03899753|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Sealed envelop determining which arm the participant is assigned to|"\* Prospective Randomized Design~o After determining a participant's eligibility for inclusion, participant will be randomized to the OCA mesh group or monocryl with dermabond group. After surgery, both groups will be seen at the 2 week, 6 week, and 3 month appointments"|t|f|t|f
33753357|NCT05824065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753358|NCT03827122|NA|SINGLE_GROUP||TREATMENT||NONE||Single group with bruxism they will be injected in masster muscles bilaterally||||
33753359|NCT01826474|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753360|NCT03817996|||COHORT||PROSPECTIVE|||||||
33868613|NCT03880032|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|To maintain masking during the trial, intervention and assessment teams will not have any interaction during the trial, as they will be placed at separate locations within the Obstetrics Department of Holy Family Hospital (HFH). Furthermore, participants will be instructed not to disclose which type of treatment they are receiving to the assessment team. Fidelity of masking will be measured by having assessors guess the trial arm of each participant at the end of follow-up assessment. We hypothesize that assessors will only be able to correctly guess the condition of participants at a chance rate of nearly 50% at follow-up assessments, indicating that masking is maintained.|Women with at least mild anxiety but not depression will be enrolled simultaneously into an intervention or an enhanced usual care group during pregnancy. Women in the intervention group will receive individual-based cognitive behavioral therapy. Women in the control group with receive enhanced usual care.|f|f|t|t
33753361|NCT01743079|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753362|NCT01532115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33753363|NCT04022200|||COHORT||PROSPECTIVE|||||||
33868614|NCT00844155|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33868615|NCT06181942|||COHORT||CROSS_SECTIONAL|||||||
33868616|NCT02512809|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868617|NCT01391403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868618|NCT00747643|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33868619|NCT05097521|||COHORT||PROSPECTIVE|||||||
34066332|NCT04964167|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34066333|NCT02027857|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34184133|NCT01216826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753364|NCT03483987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who relapsed to prior treatment with one or two DAA will be retreated with second course of DAA regimen and ribavirin with or without pegylated interferon. The duration of treatment will be 24 weeks. The drugs will be chosen based upon their prior exposure to DAA, liver disease severity and virus genotype.||||
33753365|NCT00310232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33753366|NCT01384708|NA|SINGLE_GROUP||SCREENING||NONE||||||
33753367|NCT06097949|||COHORT||PROSPECTIVE|||||||
33868620|NCT01678989|||||PROSPECTIVE|||||||
33868621|NCT05374382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33868622|NCT04427150|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||120 participants (60 children with autism spectrum disorder and 60 typically developed children) will form three groups: Group 1 will contain 30 children with autism spectrum disorder (randomly selected) whom will partake in psychoacoustic intervention training. Group 2 will contain 30 children with autism spectrum disorder (randomly selected) whom will partake in non-psychoacoustic intervention training. Group 3 will contain 60 typically developed children whom will not partake in any training.||||
33868623|NCT06132165|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868624|NCT01978782|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33868625|NCT03256955|NA|SINGLE_GROUP||OTHER||NONE||||||
33868626|NCT00338754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868627|NCT04957550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR0302 tablets compared with placebo|t|t|t|t
33868628|NCT06049381|||CASE_CONTROL||PROSPECTIVE|||||||
33868629|NCT00366821|||||RETROSPECTIVE|||||||
33868630|NCT06254742|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33868631|NCT00050141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066334|NCT02007278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066335|NCT03927586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33753368|NCT03052738|||COHORT||PROSPECTIVE|||||||
33753369|NCT03719950|||OTHER||CROSS_SECTIONAL|||||||
33753370|NCT00248781|RANDOMIZED|PARALLEL||||NONE||||||
33753371|NCT04275466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753372|NCT00894231|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33753373|NCT05718375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753374|NCT03860233|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All study staff are masked except the pharmacist.||t|t|t|f
33753375|NCT06184672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"assesor in another isolated room with no possibility of seeing which subjects have been treated or not. Subjects will be informed that they cannot disclose whether they have been needled or not."|single-blind randomized clinical trial. two groups: intervention group and control group.|f|f|f|t
33753376|NCT03496155|RANDOMIZED|PARALLEL||OTHER||NONE||Treatment groups receive intervention and control groups receive usual care.||||
33753377|NCT05080946|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33753378|NCT03771976|||COHORT||RETROSPECTIVE|||||||
33753379|NCT06072534|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double blind|prospective randomized double blind|t|t|t|t
33753380|NCT00219076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33753381|NCT04437251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will not be informed about their group assignments while learning a leg task. The testers who are conducting neurological and walking assessments before and after training will also be blinded from the group assignments.|This study is a double-blinded, randomized controlled study in which participants will be randomly assigned into one of two brain stimulation groups (sham or real brain stimulation) while being evaluated for their ability of learning a leg task in a single session (phase I), and receiving a 12-session leg exercise training program.|t|f|f|t
33753382|NCT05678764|||CASE_CONTROL||PROSPECTIVE|||||||
33753383|NCT02262533|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33753384|NCT03907995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066336|NCT06509347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laser is a non-emission Laser||t|f|f|f
33753385|NCT01073423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753386|NCT00222651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753387|NCT05904951|||OTHER||PROSPECTIVE|||||||
33753388|NCT03583749|||CASE_ONLY||PROSPECTIVE|||||||
33753389|NCT02863068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753390|NCT00004122||||TREATMENT||||||||
33753391|NCT03364751|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|The Dentist (Investigator) or Dental Hygienist performing the periodontal assessments will be blinded to the arm allocation.||f|f|t|f
33753392|NCT06732843|||CASE_CROSSOVER||PROSPECTIVE|||||||
33753393|NCT02199028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753394|NCT03339323|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33753395|NCT00251862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33753396|NCT05942911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33753397|NCT04944433|||COHORT||PROSPECTIVE|||||||
33753398|NCT03498833|NA|SINGLE_GROUP||OTHER||NONE||All the domains and items in CKOAI will undergo reliability testing. Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability. Cronbach's alpha for internal consistency and Intra class correlation coefficient for test retest reliability will be used to determine the degree of consistency of items in the scale. MDC will be calculated using the formulae, SEM = SD x √ (1-reliability) and MDC95 = √2 x (1.9) x (SEM). Significant level will be set at p value less than 0.05 (p \< 0.05) to minimize the type-I error.||||
33753399|NCT00158665|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33753400|NCT01332227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184134|NCT06654206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this research project, the evaluators will be blinded, as none of them will know which group the participants belong to. Due to the nature of the study, the participants cannot be blinded. Additionally, the statistical analysis will be performed by an independent statistician who will not be aware of the intervention group, and thus will also be blinded.|"This is a double-blind, randomized controlled clinical trial with two parallel groups, in which patients diagnosed with Chronic Lymphocytic Leukemia (CLL) and undergoing active treatment will be recruited. Study participants will be assigned to one of two arms of the study: 1) Supervised Therapeutic Strength Exercise Intervention Group (GI); 2) Control Group without Supervised Exercise (GC). The study will last for 3 months. There will be 2 evaluation visits: one prior to the intervention (initial visit) and one at the end of the intervention (final visit). The intervention period will last for 8 weeks.~The trial will be conducted following the CONSORT (Consolidated Standards of Reporting Trials) guidelines, and the current treatment protocol is described according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) recommendations."|t|f|t|t
34184135|NCT01302990|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34184136|NCT02019095|||COHORT||PROSPECTIVE|||||||
34184137|NCT04099199|||OTHER||PROSPECTIVE|||||||
34184138|NCT06387836|||COHORT||PROSPECTIVE|||||||
34184139|NCT00309374|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34184140|NCT00446849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184141|NCT01764906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184142|NCT06650878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184143|NCT04580979|||CASE_ONLY||OTHER|||||||
34184144|NCT03755258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Multiple Ascending Dose, Multiple Groups, Multiple Centers|t|t|t|t
34184145|NCT03506152|||COHORT||CROSS_SECTIONAL|||||||
34184146|NCT04590521|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will be given Gardasil (Merck) HPV vaccine||||
34184147|NCT01055197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184148|NCT00751517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184149|NCT01939613|||CASE_CONTROL||PROSPECTIVE|||||||
33753401|NCT02134587|NA|SINGLE_GROUP||OTHER||NONE||||||
33753402|NCT03358563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753403|NCT03178006|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33753404|NCT02766569|||COHORT|||||||||
33753405|NCT03317002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753406|NCT06234410|||COHORT||PROSPECTIVE|||||||
34066337|NCT02731170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066338|NCT03519100|||COHORT||PROSPECTIVE|||||||
33868632|NCT01782573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868633|NCT01891500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184150|NCT05248152|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will receive either the actual drug or placebo. A separate investigator will be in charge of preparing the capsules and intravenous solutions that patients will receive before surgery in a way that it will not be possible to determine whether it is an actual drug or a placebo. That investigator will also write in which group the patient is on a piece of paper and insert it in the patient's inventory for safety purposes. The person that will measure the conditioned pain modulation and complete the pain questionnaires with patients will be a separate investigator. The anesthesiologist performing the axillary block will also be blinded, because the drugs/placebo will be prepared by a separate investigator. We will code the group to which the patients are allocated, so that the Outcomes Assessor will also be blinded.|Three groups of patients with three different treatment regimens|t|t|t|t
34184151|NCT03587623|||CASE_ONLY||PROSPECTIVE|||||||
34184152|NCT06490354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinding.||f|f|t|f
34184153|NCT03466814|||COHORT||PROSPECTIVE|||||||
34184154|NCT03533504|||CASE_ONLY||RETROSPECTIVE|||||||
34184155|NCT06421532|RANDOMIZED|PARALLEL||TREATMENT||NONE||pre-post study with additional randomisation||||
34184156|NCT05281302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34184157|NCT02628873|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Outcomes assessor does not know which procedure was received first or second.|Cross over study in which participants receive one diagnostic test (SSI or HSG), then receive the other.|f|f|f|t
34184158|NCT02572908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184159|NCT00404144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184160|NCT01464437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184161|NCT02740452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184162|NCT00121615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184163|NCT05517252|RANDOMIZED|PARALLEL||TREATMENT||NONE||Tele-Yoga and Control Group||||
34184164|NCT01453218|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34184165|NCT00446004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184166|NCT01392105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184167|NCT01577992|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34184168|NCT00734500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184169|NCT03183297|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||A Double-Blind, Placebo-Controlled, 4-Way Crossover Study|t|t|t|f
34184170|NCT00898417|||OTHER||RETROSPECTIVE|||||||
34184171|NCT04240496|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184172|NCT00781703|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34184173|NCT00750438|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34184174|NCT03311243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184175|NCT04708561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184176|NCT06038604|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184177|NCT03498898|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184178|NCT03054532|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label phase II study||||
34184179|NCT03288103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184180|NCT02650076||||TREATMENT||||||||
33753407|NCT03128996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753408|NCT01898468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868634|NCT05287074|||COHORT||PROSPECTIVE|||||||
33868635|NCT02512406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33868636|NCT01811745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868637|NCT04747834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be stratified into two Cohorts. Cohort 1 is comprised of eyes with mild-to- moderate cataracts only (Grade 1 to 2). Cohort 2 is comprised of eyes with moderate to more dense cataracts only (Grade 2+ to 3+).||||
33868638|NCT05752695|||CASE_ONLY||CROSS_SECTIONAL|||||||
34184181|NCT04800809|||COHORT||PROSPECTIVE|||||||
34184182|NCT01292629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184183|NCT02298582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184184|NCT05910437|||COHORT||RETROSPECTIVE|||||||
34184185|NCT00600080|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34184186|NCT05165771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184187|NCT01912170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184188|NCT00707811|||COHORT||PROSPECTIVE|||||||
34184189|NCT02909400|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33753409|NCT03234205|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33753410|NCT04643704|||CASE_CONTROL||PROSPECTIVE|||||||
33753411|NCT05828966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753412|NCT00006041||||TREATMENT||||||||
33753413|NCT05232695|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753414|NCT05191758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753415|NCT06224738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753416|NCT03952832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753417|NCT05817448|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753418|NCT05684081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|This is an unblinded study.|The intervention consists of direct cash payment to vaccination campaign health workers using government of Uganda Ecash platform on IFMIS||||
33753419|NCT04789096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753420|NCT01825213|||COHORT||RETROSPECTIVE|||||||
33753421|NCT06580314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753422|NCT00222534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753423|NCT04541810|||COHORT||PROSPECTIVE|||||||
34066339|NCT00275665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34066340|NCT04269824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753424|NCT00156065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753425|NCT02615574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753426|NCT03049410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753427|NCT04888390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study population will be randomized and separated in two groups, Intervention and Usual care group.||||
33753428|NCT03436888|||OTHER||CROSS_SECTIONAL|||||||
33753429|NCT02479230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753430|NCT01710176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184190|NCT00070967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868639|NCT04272840|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Control Trial||||
33868640|NCT03576599|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33868641|NCT02244320|||COHORT||PROSPECTIVE|||||||
33868642|NCT03294226|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33868643|NCT05875051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to treatment group allocation. The blinded assessor will collect all baseline and post-intervention measures and enter data.||f|f|f|t
33868644|NCT02013453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868645|NCT01622192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868646|NCT03390543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|participants, investicator, outcome assessors will be blinded for group allocation.|"1. sono with simple needle guide device group~2. sono only group"|t|f|t|t
34184191|NCT03550599|||COHORT||PROSPECTIVE|||||||
34184192|NCT00643903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184193|NCT04226742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be unaware of which condition they have been assigned.|Participants will be randomly assigned to receive either the treatment condition (ADAPT platform, iCBT platform comprised of didactic and interactive content), or a control condition (iCBT comparison platform comprised only of didactic content).|t|f|f|t
34184194|NCT06655623|NA|SINGLE_GROUP||TREATMENT||NONE|The participant and investigator are both blinded to condition at the initial baseline measurements, since randomization and assignment to treatment are only made after the baseline measurements have taken place.|This study is a multiple case study of three patients with difficult-to-treat depression. The patients are also part of a larger, randomized controlled trial with two treatment arms (which also includes a Treatment As Usual arm), in which they have been assigned to the schema therapy arm.||||
34184195|NCT03162263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184196|NCT03420352|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184197|NCT00936715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184198|NCT01670487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34184199|NCT01977989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33753431|NCT02211326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868647|NCT05746299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33868648|NCT05015192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868649|NCT01217398||||TREATMENT||NONE||||||
33868650|NCT01080248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868651|NCT04202770|NA|SINGLE_GROUP||TREATMENT||NONE||The present study is being undertaken as an open-label study to evaluate the safety and feasibility of exosomes and concurrent focused ultrasound as an intervention for patients with refractory depression, anxiety, and cognitive impairment due to a neurodegenerative disease (e.g., Alzheimer's).||||
33868652|NCT03999723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind masking (Participant, Care Provider, Investigator, (some) Outcomes Assessors)|A multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study|t|t|t|t
33868653|NCT06066372|||CASE_ONLY||PROSPECTIVE|||||||
33868654|NCT00034710|RANDOMIZED|||TREATMENT||DOUBLE||||||
33868655|NCT00002970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868656|NCT02704546|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33868657|NCT04239937|||COHORT||PROSPECTIVE|||||||
33868658|NCT01614938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868659|NCT04026178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868660|NCT01012102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868661|NCT04206748|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868662|NCT03625050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868663|NCT00975169|||CASE_CONTROL||RETROSPECTIVE|||||||
33868664|NCT01987960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868665|NCT02171962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868666|NCT05533879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868667|NCT03010306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066341|NCT04123379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066342|NCT05485233|||OTHER||PROSPECTIVE|||||||
33965193|NCT03876158|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This open-label, non-randomized, single-blind, multi-center study is designed to evaluate effects of a planned 20% dose reduction when converting to valve-gated from a peristaltic pump. Study participants will be blinded (single blind) to the dose reduction aspect of this trial and must remain blinded to this dose reduction information throughout the trial in an attempt to provide an unbiased assessment of the pain encountered by the patient with their pain pump medications used.|Prior Peristaltic Synchromed II intrathecal pump's data prior to crossover to valve-gated Flowonix Prometra® II Programmable Pump is recorded to compare.|t|f|f|f
33965194|NCT06133088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066343|NCT01072747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34066344|NCT03879551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066345|NCT01122459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33965195|NCT02955992|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066346|NCT02875717|||COHORT||RETROSPECTIVE|||||||
34066347|NCT04659317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066348|NCT01858025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066349|NCT01773018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066350|NCT01689753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066351|NCT04671355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965196|NCT01776619|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33965197|NCT02247583|||COHORT||PROSPECTIVE|||||||
33965198|NCT05668715|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965199|NCT03284073|NA|SINGLE_GROUP||TREATMENT||NONE||Human uterus transplantation from a live donor||||
34184200|NCT03710499|NA|SINGLE_GROUP||TREATMENT||NONE||After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted two months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 3 different timepoints (baseline, after 8 weeks of training, and after a 4-week washout period with no treatment); thus, he served as his own control. The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment. Throughout the application of the protocol, the patient regularly maintained his follow-up visits with the multidisciplinary team. Moreover, there was no change in pharmacological treatment throughout this period.||||
34184201|NCT00002150||||TREATMENT||DOUBLE||||||
34184202|NCT01567267|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184203|NCT00600262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184204|NCT01312740|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33965200|NCT03933319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184205|NCT03499990|||COHORT||PROSPECTIVE|||||||
33965201|NCT01170000|||FAMILY_BASED||PROSPECTIVE|||||||
33965202|NCT00921479|||COHORT||PROSPECTIVE|||||||
33965203|NCT02353429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965204|NCT00644605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965205|NCT03835975|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965206|NCT01187160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965207|NCT05587478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066352|NCT05905250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigative team will be masked except in the event interventionists or data collectors require input from the team that requires disclosure of identifying information. Participants will be randomized to the intervention or attention control.|Individual randomized control trial with 1:1 randomization|t|f|f|t
34066353|NCT03706469|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34066354|NCT02084433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066355|NCT03275389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The site staff will work in an observer-blind manner. As the vaccines appearance and preparation are different, two teams of study personnel will be set up:~* A team of unblinded personnel (responsible for the reception, preparation and administration of the vaccines).~* A team of blinded personnel (responsible for the clinical safety evaluation of the subjects)."||t|f|t|t
34066356|NCT04974606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34066357|NCT00701571|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34066358|NCT04344522|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||randomized controlled trial||||
34066359|NCT05363813|NA|SINGLE_GROUP||TREATMENT||NONE||Patient selection based on need for laparoscopic surgical treatment involving vessel or duct ligation.||||
34066360|NCT00893971|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34184206|NCT05188833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184207|NCT00099333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184208|NCT01907347|||COHORT||PROSPECTIVE|||||||
34184209|NCT00281242|||COHORT||PROSPECTIVE|||||||
34184210|NCT04301154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184211|NCT01743222|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34184212|NCT04648397|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34184213|NCT00163683|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34184214|NCT04252534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative, open label||||
33965208|NCT01683552|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965209|NCT00362856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|randomized, double-blind, placebo controlled, dose ranging, multicenter|t|f|t|f
33965210|NCT00184964|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753432|NCT00831779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753433|NCT06203106|||OTHER||PROSPECTIVE|||||||
34066361|NCT03947775|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This will be a randomized, open-label multicentre clinical trial consisting of two arms (immediate versus delayed vaccination) assessing the efficacy, safety and immunogenicity of the 9-valent recombinant HPV vaccine in HIV-positive males 18 years of age and older. The delayed arm will receive Gardasil-9 12 months after the immediate arm. Similarly, appropriate follow-ups and testing in the delayed arm will occur 12 months after the immediate arm.~Participants for the proposed study will be recruited from Canadian centres in Toronto, and Vancouver through ongoing projects making up our HPV-SAVE team grant. Other study sites may be added as the study progresses."||||
34066362|NCT04505306|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066363|NCT01051726|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34184215|NCT03585751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Every participant will grasp an opaque sealed envelop from a box after diagnosis of the case. Being opaque and sealed ensures allocation concealment. Envelopes have been assigned to RN who is not involved in neither the diagnosis nor the treatment phases of the cases.||t|f|f|t
34184216|NCT00378365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184217|NCT01147874|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34184218|NCT05488041|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34184219|NCT02991040|NA|SINGLE_GROUP||TREATMENT||SINGLE|The side of the face for each product was randomly assigned. The investigator performing the evaluations and the subject were blinded to the treatment; injections of the study product were performed by an unblinded injecting investigator.|Subjects were treated with Revanesse Ultra in the NLF on one side of the face and Revanesse Ultra+ in the NLF on the other side of the face. The side of the face for each study product was randomly assigned.|f|f|f|t
34184220|NCT03561805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184221|NCT06654674|||COHORT||RETROSPECTIVE|||||||
34184222|NCT03739203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184223|NCT05764785|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will know which condition they are assigned (mentors will know if they are using MentorPRO; students will know if they are using MentorPRO). Researchers will also know participant group allocation.|Participants assigned based on the timing of their courses in the summer program||||
34184224|NCT01655732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184225|NCT03527433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1:1 ratio|t|f|t|t
34184226|NCT06653387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184227|NCT04515316|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Each feasibility group is of 20 persons.||||
34184228|NCT04412629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184229|NCT05992753|||OTHER||CROSS_SECTIONAL|||||||
34184230|NCT01672580|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34184231|NCT05089825|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184232|NCT00154960|||CASE_CONTROL||PROSPECTIVE|||||||
34184233|NCT03386383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|4||f|f|t|f
34184234|NCT02932852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184235|NCT04320316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184236|NCT03250715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184237|NCT04809480|||COHORT||RETROSPECTIVE|||||||
34184238|NCT06112509|NA|SINGLE_GROUP||TREATMENT||NONE||Prognostic cohort study||||
34184239|NCT04377893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184240|NCT00577174|||CASE_CONTROL|||||||||
34184241|NCT06595394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184242|NCT04643613|NA|SINGLE_GROUP||TREATMENT||NONE|None, since treating cancer patients|Supplementation with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks||||
34184243|NCT01534702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184244|NCT05338619|NA|SINGLE_GROUP||TREATMENT||NONE||Lazertinib treatment group (open-label)||||
34184245|NCT01295255|||COHORT|||||||||
34184246|NCT03183869|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective, cross-over, open label, randomized 1:1 early versus delayed groups, interventional \[FMT\] versus no interventional \[no FMT\] controlled trial to explore the effects of FMT from a healthy donor to RMS patients and investigate whether this can influence disease activity based on a panel of biological markers.||||
34184247|NCT00080535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184248|NCT02624076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184249|NCT04475796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184250|NCT03629535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184251|NCT03529669|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34184252|NCT04675632|||CASE_CONTROL||PROSPECTIVE|||||||
34184253|NCT04871646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184254|NCT02720419|||COHORT||PROSPECTIVE|||||||
34184255|NCT05969158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184256|NCT01816035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184257|NCT04721886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184258|NCT00749255|||CASE_ONLY||PROSPECTIVE|||||||
34184259|NCT03568227|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34184260|NCT00768027|||COHORT||PROSPECTIVE|||||||
34184261|NCT04696965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The subjects enrolled will be informed the purpose of this study is to evaluate the inhaler step errors after add-on tiotropium with the other ICS+LABA inhaler and how the education improve patients to reduce the error rate. The subjects are not aware the different methods of study arm and control arm.|"Brief summary of protocol At visit 1, patients characteristics, lung function, cognition function, HRV, CRC and FeNo will be recorded. Randomization by stratification with cognition function will be done but both arms receive usual verbal instruction of inhaler steps.~At visit 2, inhaler step errors will be recorded 1 months after add-on Tiotropium with ICS+LABA and interventions of education start by correct/recheck strategy in study arm and usual verbal instruction in control arm.~At visit 3, inhaler step errors will be recorded 3 months after add-on Tiotropium with ICS+LABA as the primary endpoint. Heart rate variability (HRV), cardiopulmonary coupling (CRC) and FeNo will be checked.~Other endpoints, e.g. lung function, PEFR, exacerbation will be evaluated at V3 and V4 (6 months after V1), V5 (9 months after V1) and V6 (12month after V1)"|t|f|f|f
34184262|NCT05866315|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A trained anesthesiologist not involved in general anesthesia assessed clinically relevant and mechanically evoked pain using the Von-Frey filaments and secondary outcomes after surgery.|"1. Group RHR (Remimazolam- High doses of Remifentanil): Administer remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min.~2. Group DHR (Desflurane-High doses of Remifentanil): Administer desflurane at 1 MAC, adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min.~3. Group DLR (Desflurane-Low-dose of Remifentanil): Administer desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.025 µg/kg/min."|t|t|f|t
34184263|NCT03791814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184264|NCT00195104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184265|NCT04546672|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Assessor-blinded, randomized, controlled, single center, parallel design trial with patient masking|t|f|t|t
34184266|NCT02172885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184267|NCT05624970|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Sixty smokers male their age ranged from 40-50 years old will be selected from diabetic outpatient clinic Qasr AL-Einy Hospital. All patients will be carefully examined by the physicians of the hospital. They will be randomly assigned into two groups equal in numbers, as group (A) and group (B).~Group (A):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), aerobic training, tobacco cessation program and nutritional advices for 12 weeks.~Group (B):~This group will consist of 30 patients who will receive the medical treatment (oral hypoglycemic drugs), tobacco cessation program and nutritional advices for 12 weeks."||||
34184268|NCT03252431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33868668|NCT02663557|||COHORT||PROSPECTIVE|||||||
33753434|NCT00860379|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33753435|NCT01850914|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753436|NCT00863408|||||PROSPECTIVE|||||||
33868669|NCT05805384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868670|NCT00151970|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33753437|NCT06034548|RANDOMIZED|PARALLEL||OTHER||NONE||RCT with wait-listed control||||
33753438|NCT03855449|RANDOMIZED|PARALLEL||PREVENTION||NONE||A single group will be recruited to go through the in-person DECIDE problem-solving curriculum||||
33868671|NCT02798055|||OTHER||PROSPECTIVE|||||||
33868672|NCT03044782|||CASE_ONLY||CROSS_SECTIONAL|||||||
33868673|NCT03174418|||COHORT||PROSPECTIVE|||||||
33868674|NCT03779308|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after cohort study with sample size less than 20||||
33868675|NCT03858842|||COHORT||RETROSPECTIVE|||||||
33868676|NCT01693354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184269|NCT05876715|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.||||
33753439|NCT06579547|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The radiologists who perform the readout will be blinded to the reference low dose CT scan to avoid being primed for certain bony anatomy and pathology by evaluating the low dose CT first. The reference low dose CT scan will be read in a separate session.||f|f|f|t
33753440|NCT06732050|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33753441|NCT00725452|||COHORT||PROSPECTIVE|||||||
33753442|NCT05747222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33753443|NCT04934423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study design in question involves patients with MCI, submitted to an intervention protocol, which includes: G1) active vs. G2) tDCS sham. These participants will be assessed previously for eligibility, then randomized to receive tDCS sham or active. All researchers responsible for the evaluation before and after the interventions will be blinded to the type of treatment the patient will receive (active stimulation or sham). The effectiveness of the masking mechanism will be assessed at the time of the last interview with patients when they will be asked about their opinion as to whether the electric current producing system was on or off.|A randomized, double-blind, placebo-controlled clinical trial will be conducted with patients diagnosed with Mild Cognitive Impairment, submitted to Direct Current Transcranial Stimulation sessions in a primary clinical trial. Both studies are in accordance with the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (Moher \& Chan, 2014), which is considered a tool composed of minimal contents of a clinical trial protocol.|t|f|f|t
33753444|NCT01477125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184270|NCT01870518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33753445|NCT06061497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753446|NCT05756855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||open pilot clinical trial||||
33753447|NCT01121068|||COHORT||PROSPECTIVE|||||||
34184271|NCT02012413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753448|NCT03538470|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33753449|NCT05437458|||COHORT||RETROSPECTIVE|||||||
33753450|NCT06474221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The rater will be blind to the group status of the participant.|This is a multicentric, parallel arm, interventional randomized control trial. A total of 84 at each site will be enrolled, N = 168 would be adequate for both sites together.|f|f|f|t
33753451|NCT02527668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33753452|NCT01830608|||COHORT||PROSPECTIVE|||||||
33753453|NCT01164995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753454|NCT03215836|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"This is a cross sectional pilot study comparing specific metabolic pathways in bronchial airway epithelial cells and the nasal epithelium across the following patient groups:~1. Obese (BMI ≥ 30) asthmatics without metabolic syndrome,~2. Obese asthmatics with metabolic syndrome,~3. Obese non-asthmatics, and~4. Non - obese (lean \> 18 \<= 25, OW \> 25 - \<30) asthmatics."||||
33753455|NCT02549469|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184272|NCT05290714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868677|NCT00054704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33868678|NCT00543075|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33868679|NCT00785044|||OTHER||PROSPECTIVE|||||||
33868680|NCT00244270|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184273|NCT00509054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34184274|NCT02911584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184275|NCT03646552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184276|NCT03835806|RANDOMIZED|PARALLEL||TREATMENT||NONE|The treatments are visually dissimilar, therefore blinding for the investigator and subject is not possible.|This is a randomized control trial looking at a novel blister treatment intervention versus a traditional model.||||
34184277|NCT06201780|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34184278|NCT05005117|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized controlled multicenter trial||||
34184279|NCT02600234|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34184280|NCT00779350|RANDOMIZED|CROSSOVER||||NONE||||||
34184281|NCT03825406|||CASE_ONLY||PROSPECTIVE|||||||
34184282|NCT02103387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34184283|NCT04082793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, outcome assessors and care provider will be blinded in the study. This will be a triple blinded randomized controlled trial|Parallel assignment|t|t|f|t
34184284|NCT03713385|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34184285|NCT03739723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184286|NCT04086901|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial||||
34184287|NCT00753506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184288|NCT02124837|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34184289|NCT06118632|||OTHER||CROSS_SECTIONAL|||||||
34184290|NCT02871934|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34184291|NCT01208207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184292|NCT02379663|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34184293|NCT00461370|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34184294|NCT00002696|RANDOMIZED|||TREATMENT||||||||
34184295|NCT02215252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184296|NCT06009133|||CASE_CONTROL||RETROSPECTIVE|||||||
34184297|NCT04216056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184298|NCT02077452|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34184299|NCT04429256|||COHORT||RETROSPECTIVE|||||||
34184300|NCT05063799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184301|NCT03367520|NA|SINGLE_GROUP||TREATMENT||NONE||This project has two phases. Phase 1: Develop StayQuit materials and train the study interventionist. Phase 2: Implement StayQuit with 10-20 Veterans who are hospitalized on the inpatient psychiatric unit at the Baltimore VA Medical Center.||||
34184302|NCT03071926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184303|NCT00403520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184304|NCT04198688|||COHORT||PROSPECTIVE|||||||
34184305|NCT02453321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184306|NCT01116986|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34184307|NCT01807988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34184308|NCT01684761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184309|NCT01393392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184310|NCT02786394|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34184311|NCT05199077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|placebo group 2.5 % GM-XANTHO of cohort A 5 % GM-XANTHO of cohort B.|t|f|t|f
34184312|NCT05425472|NA|SINGLE_GROUP||TREATMENT||NONE||HR070803 for all enrolled subjects||||
34184313|NCT04273776|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|"Study sessions will be randomized prior to the study (e.g. Session 1 = placebo, Session 2 = zolpidem, etc.) and volunteers will be assigned a session (treatment group) when they are scheduled for their enrollment visit (Day 1). The randomization schedule will be generated using a random number generator by a person who is not involved in data collection prior to commencement of the study, with the following qualification (hence pseudo-random): that all volunteers participating in the same session be randomized or blocked together (i.e., assigned the same condition). This will help ensure double-blinding since it may be obvious to volunteers and staff within the same session if some volunteers receive placebo whereas others receive active drug. To help maintain confidentiality, each participant will also be given a unique numerical identifier (e.g., 01-120)."|"Randomization will occur at the level of the study session such that all volunteers participating in the same session will be blocked together (i.e., assigned the same condition)."|t|f|t|f
34184314|NCT02200406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184315|NCT01106690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184316|NCT00157677|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34184317|NCT04963010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184318|NCT02311244|||COHORT||PROSPECTIVE|||||||
34184319|NCT01047488|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34184320|NCT02999204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184321|NCT03131219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184322|NCT06393933|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33753456|NCT06732440|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Each participant enrolled will be randomly assigned to one of three intervention arms, and will remain in the arm until the end of the study.|t|t|t|t
33868681|NCT04209036|||CASE_CONTROL||PROSPECTIVE|||||||
33868682|NCT05815251|||COHORT||PROSPECTIVE|||||||
34184323|NCT00387504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184324|NCT01749332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184325|NCT05919173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||comparative study|t|f|f|t
34184326|NCT04569565|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184327|NCT02958917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184328|NCT03483402|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, one-arm, prospective clinical trial.||||
34184329|NCT02081781|||COHORT||RETROSPECTIVE|||||||
34184330|NCT00304551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184331|NCT04098718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066364|NCT03825185|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 100 patients with diagnosis of MG referred to our center for surgical treatment between 1993 and 2003 were invited to participate in the study. Software (Power and Precision, Biostat, NJ) was used for sample size calculation. Software (G\* Power 3.1) was used for sample size calculation. Sample size was calculated based on a 4.0% difference in the remission rate between TC (40%) and TS (44%). The calculated sample size was 26 patients in each group. Considering a 10 to 20% loss of follow up in the long term, a total of 50 patients per group were included.||||
34066365|NCT01110785||||TREATMENT||NONE||||||
34184332|NCT03449667|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All individuals will be masked to treatment with the exception of the anesthesiologist administering the procedure who will choose which probe to use: the functional or sham. Of note, this individual could not be masked to treatment since the cryoneurolysis ice ball is visualized on ultrasound; and, the practitioner would see a lack of ice ball formation for the sham probes.|The primary endpoint at 4 months following the initial treatment will utilize a parallel group study design; however, an optional crossover is offered to subjects following this time point.|t|f|t|t
34184333|NCT00613561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184334|NCT03997344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are randomly assigned to one of two arms||||
34184335|NCT00404469|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34184336|NCT01125592|NA|SINGLE_GROUP||||NONE||||||
34184337|NCT03754777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184338|NCT04406857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184339|NCT02891577|||CASE_ONLY||PROSPECTIVE|||||||
34184340|NCT02440282|||COHORT||RETROSPECTIVE|||||||
33753457|NCT06010472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753458|NCT04649866|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753459|NCT05885152|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753460|NCT04133233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled (2 active: 1 placebo), multicentre, 6-week, proof-of concept trial of add on low dose IL-2 therapy in patients with a depressive episode in the course of a bipolar disorder, hospitalized or not. The study will be an add-on study, with no wash-out period.|t|t|t|t
33753461|NCT04770922|||COHORT||RETROSPECTIVE|||||||
33753462|NCT00586911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753463|NCT06177665|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33753464|NCT04315168|||COHORT||PROSPECTIVE|||||||
33868683|NCT00612170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965211|NCT03571854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33965212|NCT03343977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965213|NCT00465504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965214|NCT04272736|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184341|NCT06212128|||CASE_CONTROL||PROSPECTIVE|||||||
34184342|NCT01987453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965215|NCT06013761|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965216|NCT01303588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965217|NCT01931891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965218|NCT05717283|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965219|NCT01566669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965220|NCT00486499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965221|NCT04716400|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled study. The randomization is at school level.||||
33965222|NCT01215682|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33965223|NCT00713245|||CASE_ONLY||PROSPECTIVE|||||||
33965224|NCT04921046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The test solutions were prepared in coded syringes and the observer was blinded to the groups as well as drugs .|two arm parallel assignment, two groups, receive two different drugs ;drug A and drug B to see the effect.|f|f|t|t
33965225|NCT04171388|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Masking of Azithro vs. Placebo arm only|2x3 factorial randomized controlled trial, with cluster randomization of nutrition interventions and individually randomized infection management interventions|t|t|t|t
33868684|NCT03662165|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants were not informed about the specific research question or the fact that they would be randomized to different HIV testing options in order to avoid bias.|We selected a sample of eligible truckers and randomized them on a 1:1:1 ratio to the three study arms. After completing the 2 month follow-up, we followed the same procedure with a sample of eligible female sex workers.|t|f|f|f
33868685|NCT05396079|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33868686|NCT06226350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868687|NCT04237727|||CASE_ONLY||PROSPECTIVE|||||||
33868688|NCT04173689|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33868689|NCT04188795|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This randomized controlled trial conducted at Gulhane Training and Research Hospital , Orthopedic and Traumatologic clinic between May 2018 and January 2019.The CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting randomized controlled trials (RCTs) has been used to describe the methods.|t|f|t|f
33868690|NCT00240981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184343|NCT03228823|RANDOMIZED|PARALLEL||TREATMENT||NONE||PVC suppression with either antiarrhythmic drugs or radiofrequency ablation||||
34184344|NCT01773213|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34184345|NCT02067286|||COHORT||PROSPECTIVE|||||||
34184346|NCT01006239|||COHORT||PROSPECTIVE|||||||
34184347|NCT02396199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184348|NCT00896896|||COHORT||RETROSPECTIVE|||||||
34184349|NCT00453219|||||PROSPECTIVE|||||||
34184350|NCT03279744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184351|NCT04780646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184352|NCT00615303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184353|NCT00871416|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184354|NCT02631590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184355|NCT04434456|||COHORT||PROSPECTIVE|||||||
34184356|NCT02986360|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34184357|NCT00846976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184358|NCT03257059|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomised, crossover study with two treatments||||
34184359|NCT02477982|||COHORT||PROSPECTIVE|||||||
34184360|NCT00067002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184361|NCT00354432|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34184362|NCT01065883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184363|NCT02497352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184364|NCT02331888|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|f|t
34184365|NCT03956654|||COHORT||PROSPECTIVE|||||||
34184366|NCT03754452|||COHORT||PROSPECTIVE|||||||
33868691|NCT00363324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868692|NCT02700997|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33868693|NCT00797199|||COHORT||PROSPECTIVE|||||||
33868694|NCT06401824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868695|NCT02214602|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965226|NCT02991833|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34184367|NCT00798993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184368|NCT04558034|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"There are 2 arms to the study.The Elasto-gel mitt and Rapid Relief slipper will be placed either on one hand/foot or both based on the patient's medical oncologist. All subjects will have a standardized onset/duration of therapy which includes the following :~* 15 minutes prior to the paclitaxel infusion,~* Continuously during the paclitaxel infusion,~* 15 minutes after completion of paclitaxel for a total of 90 minutes."||||
34184369|NCT03689621|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184370|NCT04059159|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184371|NCT03762317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184372|NCT04214158|||OTHER||CROSS_SECTIONAL|||||||
34184373|NCT04438148|||OTHER||CROSS_SECTIONAL|||||||
34184374|NCT05024032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184375|NCT02261701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184376|NCT02779946|||COHORT||PROSPECTIVE|||||||
34184377|NCT02275234|||COHORT||PROSPECTIVE|||||||
34184378|NCT01649206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184379|NCT00722943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34184380|NCT00553891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184381|NCT01455701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753465|NCT03583918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753466|NCT00151307|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33753467|NCT05817851|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups :~* Expérimental group~* Control group~Patient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days"||||
33753468|NCT05671562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33753469|NCT03035292|||CASE_CROSSOVER||PROSPECTIVE|||||||
33753470|NCT04752423|||OTHER||PROSPECTIVE|||||||
33753471|NCT00868855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753472|NCT00914329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753473|NCT06523530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, interventional, open label, non-randomized, parallel group||||
33753474|NCT00003214|RANDOMIZED|||TREATMENT||||||||
33753475|NCT03503266|NA|SINGLE_GROUP||OTHER||NONE||Open Label||||
33753476|NCT04210206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753477|NCT02955264|NA|SINGLE_GROUP||TREATMENT||NONE||Dietary Supplement: D-Galactose||||
33868696|NCT05501938|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention (cerclage) and control (no-cerclage) to reduce/prevent preterm delivery in those with a dilated cervix between 24w0d and 25w6d||||
33868697|NCT04035018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868698|NCT03562572|RANDOMIZED|PARALLEL||TREATMENT||NONE||It concerns an investigator initiated prospective 1:1 randomised clinical trial in non-STEMI patients with multivessel coronary artery disease amenable to treatment with PCI.||||
33868699|NCT01788033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066366|NCT02703896|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34066367|NCT01941251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066368|NCT03529708|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study of standard of care 3D conformal radiotherapy plus Stereotactic body radiotherapy (SBRT) boost||||
34184382|NCT03829644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of each intervention, blinding will not be feasible for participants. However, the MR technician, outcomes assessor, outcome adjudicators, and the statistician will be blinded to the actual allocation. The actual allocation will not be disclosed to the research assistant responsible for image processing, data entry, and the statistician.|This is a prospective, superiority, 1:1 parallel randomised control trial with concealed allocation. Superiority will be based on a minimally clinically significant difference of the Modic changes (our primary outcome measure).|f|f|f|t
34184383|NCT05959720|||COHORT||PROSPECTIVE|||||||
34184384|NCT03584789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184385|NCT04266145|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study anesthetic drugs both for adductor-canal-blockade and for intravenous infusion were prepared according to the group by an anesthetist who was not involved in its injection or the perioperative assessment||t|f|f|t
34184386|NCT04030871|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A Single-Center, Investigator-Initiated, Randomized, Pilot Study||||
34184387|NCT01230983|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34184388|NCT05136872|||COHORT||PROSPECTIVE|||||||
34184389|NCT04195373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184390|NCT01573689|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184391|NCT02725918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868700|NCT02709499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33868701|NCT04615754|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant and the endpoint-assessor will be masked to intevention|"Randomized cross-over I.e. Ketone infusion is compared to saline infusion in a randomised cross-ove design.~(Ketones are considered dietary supplement as glucose or lipids)"|t|f|f|t
33868702|NCT00907439|||COHORT||PROSPECTIVE|||||||
33868703|NCT01378858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868704|NCT03777995|||COHORT||CROSS_SECTIONAL|||||||
33753478|NCT02443948|||COHORT||PROSPECTIVE|||||||
33753479|NCT06641180|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Modified double-blind:~* Participants, Sponsor study staff\*, investigators, and study site staff will not know which study vaccine is administered during the study conduct~* Dedicated study site staff who prepare/administer the study interventions and are not involved in the safety evaluation will know which study vaccine is administered.~  * Select sponsor staff will be unblinded after the code break for primary completion analysis."||t|t|t|t
34184392|NCT02461134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184393|NCT05953623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184394|NCT05996718|NA|SINGLE_GROUP||OTHER||NONE||||||
34184395|NCT03591211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753480|NCT01896570|||CASE_CONTROL||PROSPECTIVE|||||||
34184396|NCT00807001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184397|NCT01871935|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33868705|NCT05151003|||COHORT||RETROSPECTIVE|||||||
33868706|NCT05376826|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Pre-test - Post test Control group design||||
33868707|NCT00532181|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965227|NCT05617859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965228|NCT03670407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965229|NCT02407028|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34184398|NCT01597596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184399|NCT01887483|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34184400|NCT03006003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184401|NCT04592887|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm prospective feasibility study||||
34184402|NCT02808117|||CASE_CONTROL||RETROSPECTIVE|||||||
33965230|NCT01222715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965231|NCT04293640|||COHORT||CROSS_SECTIONAL|||||||
33965232|NCT00773864|||CASE_ONLY||PROSPECTIVE|||||||
33965233|NCT03461315|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental study .||||
33965234|NCT02373969|||CASE_ONLY||PROSPECTIVE|||||||
33965235|NCT04449679|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"PHASE I: Patients participate in an audio-recorded focus group or one-on-one interview over 40 minutes either in-person, over the phone, or electronically. Patients receive sample text messages and questionnaires generated from the RT-CAMSS to generate reaction, discussion, and scenarios.~PHASE II: Patients receive RT-CAMSS over 2 months or until chemotherapy is discontinued, whichever is earlier. RT-CAMSS consists of text messages addressing knowledge about specific cancer type and chemotherapy, side-effect prevention, suggestions of lifestyle behavioral changes and emotional support, and preparation for surgery. Patients then record their symptoms through answering a series of questionnaires and receive tailored feedback according to their answers, including a consultation with a nurse."||||
33965236|NCT06338683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965237|NCT00490737|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753481|NCT05759325|||COHORT||PROSPECTIVE|||||||
33753482|NCT03876834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753483|NCT00349453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753484|NCT06106386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33868708|NCT05281107|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33868709|NCT03658265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868710|NCT01033890|||CASE_ONLY||PROSPECTIVE|||||||
34184403|NCT00420446|RANDOMIZED|PARALLEL||||DOUBLE||||||
34184404|NCT02566421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184405|NCT02231359|||COHORT||PROSPECTIVE|||||||
34184406|NCT03980704|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial||||
34184407|NCT00001027||||TREATMENT||||||||
34184408|NCT03650127|||COHORT||PROSPECTIVE|||||||
34184409|NCT02766023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34184410|NCT05477667|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34184411|NCT01610115|||CASE_ONLY||PROSPECTIVE|||||||
34184412|NCT02964182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34184413|NCT01057732|||CASE_CONTROL||PROSPECTIVE|||||||
34184414|NCT01281904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184415|NCT06359353|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33868711|NCT04404322|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients are referred to SCMC depression and suicide clinic through the ER, outpatient providers or are self-referred. They undergo an initial evaluation and risk assessment. Following initial evaluation, each subject is assigned to one of three study groups, based on clinical considerations. In this stratified randomization system, the most serious acute cases are generally referred to our ultra-short crisis intervention (IPT- A SCI) and the rest are randomized to either one of the three groups: IPT- A SCI, Treatment as usual (TAU) and waiting list (WL). All participants and their parents complete the questionnaires via a secure electronic interface, with the aid of a trained research assistant. Treatment drop-out rates, thus far, seem low and stand at about 11% for the IPT-A SCI and at about 16% for patients who receive TAU.||||
33868712|NCT02867865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868713|NCT01429818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868714|NCT00003073||||TREATMENT||||||||
33868715|NCT00538330|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33868716|NCT01733979|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33868717|NCT02181816|||COHORT||PROSPECTIVE|||||||
33868718|NCT03215550|||COHORT||PROSPECTIVE|||||||
33868719|NCT00395863|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33868720|NCT03357315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868721|NCT06372548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33965238|NCT04871178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A two-armed randomized, 8-week interventional and controlled (no intervention) feasibility study with two visits, one visit before (week 0) and one visit after intervention (week 10±1), with repeated measures||||
33965239|NCT05918666|||OTHER||OTHER|||||||
33965240|NCT03932747|RANDOMIZED|PARALLEL||OTHER||DOUBLE||CLINICAL TRIAL WITH THREE GROUPS: CONTROL GROUP, UREA GROUP 5% AND UREA GROUP 20%.|t|f|t|f
33965241|NCT05849909|||CASE_CONTROL||PROSPECTIVE|||||||
33965242|NCT05765045|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Intervention group and control group||||
33965243|NCT02777853|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33965244|NCT05875766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965245|NCT01987661|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965246|NCT01127386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965247|NCT04329650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965248|NCT05879900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blinding process will only be in relation to the evaluators of the pre- and post-intervention variables and those responsible for the tabulation and data analysis. Regarding the blinding of the sample and teachers participating in the intervention, it will not be possible to blind the process of clarity and understanding of the intervention in which the group will participate.|The research methodology consists of 230 participants, of which 115 subjects will be the Control Group with interventions to be carried out: pre and post-intervention measures and the other 115 subjects will be the Intervention Group with interventions of pre- and post-intervention measures, and participation of the study intervention.|f|f|f|t
34066369|NCT05396352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Within-subjects design (active, sham tDCS) with separate groups receiving tDCS targeting cerebellar right lobule VII and the posterior cerebellar vermis.|t|f|t|t
34184416|NCT03052062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066370|NCT00755950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34184417|NCT01734616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34184418|NCT04983446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.|Subjects will be randomized 1:1 to receive intranasal foralumab 100 µg (50 µg in 0.1 ml solution into each nostril) or placebo (0.1 ml vehicle solution into each nostril).|t|t|t|t
34184419|NCT02564835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research assistants at Time 2 and 3 are blinded to which arm the participant is in.||f|f|f|t
34184420|NCT02331212|||CASE_CONTROL||PROSPECTIVE|||||||
34184421|NCT05488444|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34184422|NCT00093626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868722|NCT00137228|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868723|NCT05132842|||OTHER||CROSS_SECTIONAL|||||||
33868724|NCT02035085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868725|NCT03936881|||CASE_ONLY||RETROSPECTIVE|||||||
33868726|NCT04594382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33868727|NCT01147744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868728|NCT01559493|||COHORT||PROSPECTIVE|||||||
33868729|NCT00000570|RANDOMIZED|||PREVENTION||||||||
33868730|NCT05956730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868731|NCT01568684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868732|NCT03021499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965249|NCT00267293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965250|NCT02479932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965251|NCT01276028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066371|NCT02242019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066372|NCT01997996|||COHORT||PROSPECTIVE|||||||
34066373|NCT05346185|||COHORT||PROSPECTIVE|||||||
34184423|NCT06273215|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34184424|NCT02000440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868733|NCT03211221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, the investigators and the outcome assessor will be blind to the type of intervention (TMS or SHAM). The TMS operator will be unblinded.|Patients will be randomized to receive 15 sessions of active rTMS or sham rTMS over the bilateral pre-SMA with a 1:1: ratio. After the randomized phase, all patients will undergo a 4 weeks washout phase. At the end of the wash phase each patient will be classified as responder, partial responder or non-responder. After the washout phase responder patients will enter a follow-up phase up to 12 months while partial responders or non-responders in both the active and sham rTMS groups, will undergo an open phase of 15 sessions of active rTMS over the bilateral pre-SMA. Partial responders and non-responders after the randomized phase who will choose not to go into the open phase will end the study.|t|f|t|t
34184425|NCT00483977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34184426|NCT04399785|NA|SINGLE_GROUP||TREATMENT||NONE||Combination of camrelizumab and stereotacic radiotherapy||||
34184427|NCT01045837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868734|NCT00359138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184428|NCT00976560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868735|NCT00768196|||CASE_ONLY||PROSPECTIVE|||||||
33868736|NCT06094751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868737|NCT04244630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868738|NCT04515225|||COHORT||PROSPECTIVE|||||||
33868739|NCT05542550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only patient is aware of treatment group|Randomized to one of two arms: no voice rest following injection and 48 hours voice rest following injection|f|t|t|t
34184429|NCT00477386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184430|NCT01841411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184431|NCT01989364|||COHORT||PROSPECTIVE|||||||
34184432|NCT00889720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184433|NCT03894683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184434|NCT01088867|NA|SINGLE_GROUP||||NONE||||||
33868740|NCT04896047|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33868741|NCT04341636|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33868742|NCT01205828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868743|NCT04429165|||CASE_CONTROL||RETROSPECTIVE|||||||
33868744|NCT05341479|||OTHER||PROSPECTIVE|||||||
33868745|NCT00290199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868746|NCT00097773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868747|NCT02897492|||CASE_ONLY||PROSPECTIVE|||||||
33868748|NCT06387654|||COHORT||PROSPECTIVE|||||||
33868749|NCT02295371|||CASE_ONLY||PROSPECTIVE|||||||
33868750|NCT04196075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33868751|NCT04598997|||COHORT||PROSPECTIVE|||||||
34184435|NCT03692624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cancer patients will be recruited from the Cancer Institute at Greenville Health System. Random assignment to the HRV-B or control group will occur after baseline assessment. During the baseline assessment, participants will be asked to fill out a questionnaire, including information about symptoms and feelings. Participant heart rate (pulse) and breathing will be measured for 15 minutes. Baseline heart rate will be measured with a sensor loosely attached to the wrist. Breathing will be monitored by another sensor attached around the abdomen by a belt. Each weekly HRV-B training session will last 30-45 minutes. In each session, heart rate and breathing will be monitored while the participant is viewing pleasant images on a computer screen. An Intervention professional will be present throughout the session. While viewing the images, the participant will be coached on how to control their pulse.||||
34184436|NCT00823693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184437|NCT01569607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184438|NCT04581213|||CASE_ONLY||PROSPECTIVE|||||||
34184439|NCT02750917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184440|NCT01539161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184441|NCT05481086|||COHORT||CROSS_SECTIONAL|||||||
34184442|NCT02382432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34184443|NCT02500797|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184444|NCT01354314|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34184445|NCT03517878|||CASE_CONTROL||PROSPECTIVE|||||||
34184446|NCT04840693|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33868752|NCT01805167|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33868753|NCT04982757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will be randomized to receive rTMS targeting the DMPFC or the LPFC. The treatment course will be 10 sessions per day hourly for 5 days. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area, enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.||||
33868754|NCT03668600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753485|NCT04716179|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Parallel groups, non-randomized:~1. - patients with COVID-19;~2. - healthy participants without COVID-19."||||
33753486|NCT05437133|||COHORT||PROSPECTIVE|||||||
33868755|NCT04342286|||CASE_ONLY||PROSPECTIVE|||||||
33868756|NCT04514120|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|This is not a blinded study|This mixed-methods clinical study of patients with CRS includes both a cross-sectional arm (single participant encounter with stable patients, n=100) and a second prospective aspect (3 participant encounters with patients experiencing CRS exacerbation, n=30)||||
33868757|NCT03803501|||COHORT||PROSPECTIVE|||||||
33868758|NCT06443164|RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional Group Control Group||||
33868759|NCT03314740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868760|NCT03721510|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965252|NCT03768219|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"SAD: Randomized, double-blind, placebo-controlled, sequential cohort-group study with a sentinel subject design~MAD: Randomized, double-blind, placebo-controlled, sequential cohort-group study~Psoriasis Expansion Cohort: Randomized, double-blind, placebo-controlled study~Ulcerative Colitis Expansion Cohort: Randomized, double-blind, placebo-controlled study"|t|t|t|t
34184447|NCT04266717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965253|NCT02598622|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184448|NCT00685191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184449|NCT03341702|||COHORT||RETROSPECTIVE|||||||
34184450|NCT04822116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||In the study group volume therapy is based on variables like stroke volume and/or diameter of vena cava inferior based on a goal directed haemodynamic optimization protocol.|f|f|t|f
34184451|NCT06056518|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184452|NCT02334904|||CASE_CONTROL||PROSPECTIVE|||||||
34184453|NCT06452576|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34184454|NCT01539421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753487|NCT06126354|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will be blinded to study group assignment.|All participants will undergo (i.e., cross over between) both pancreatic clamp protocols (MH, RE) separated by 2-4 weeks. The order of the clamp protocols (i.e., MH \> RE, RE \> MH) will be randomized.|t|f|f|f
33753488|NCT02475122|NA|SINGLE_GROUP||OTHER||NONE||||||
33753489|NCT05959993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33753490|NCT05305196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753491|NCT00057551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753492|NCT02030015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066374|NCT03688802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066375|NCT00423813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184455|NCT05012917|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This is a randomized cross-over study that involves a single interview where the primary analysis will involve the first period only.||||
34184456|NCT02928965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184457|NCT05448352|||CASE_ONLY||CROSS_SECTIONAL|||||||
34184458|NCT02314559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34184459|NCT04909385|||COHORT||PROSPECTIVE|||||||
34184460|NCT06035913|||OTHER||PROSPECTIVE|||||||
34184461|NCT03798769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184462|NCT03450122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184463|NCT02980393|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34184464|NCT04112719|||COHORT||PROSPECTIVE|||||||
34184465|NCT02405832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34184466|NCT03537404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33868761|NCT03653130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Parallel Interventional Study Model: Intervention participants (N=40) and usual care controls (N=40) will be eligible if they are residents of the Indianapolis VA Domiciliary who are eligible to participate in elective activities at the time of recruitment. Intervention participants will include eligible Veterans who agree to participate in the intervention. Usual Care Controls will include eligible Veterans who agree to complete the interviews and measures, but do not agree to participate in the participatory music program. Records for retrospective chart review (N=160) will be selected from past Domiciliary residents based on case-matching for gender and biological sex factors with intervention participants.||||
33868762|NCT06490796|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33868763|NCT05210881|||COHORT||RETROSPECTIVE|||||||
34184467|NCT01153932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184468|NCT01213628|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34184469|NCT00585026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34184470|NCT03868657|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34184471|NCT01127802|||COHORT||PROSPECTIVE|||||||
34184472|NCT04338386|||COHORT||PROSPECTIVE|||||||
34184473|NCT03713047|||COHORT||PROSPECTIVE|||||||
34184474|NCT05038982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-randomized study with two arms conducted in parallel: an arm of 10 Prurigo Nodularis (PN) patients, and an arm of 10 Chronic pruritus of unknown origin (CPUO) patients.||||
34184475|NCT04567992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184476|NCT04808440|||COHORT||PROSPECTIVE|||||||
34184477|NCT02453308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184478|NCT05795608|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration.|f|f|t|f
34184479|NCT05633758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184480|NCT02682524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184481|NCT00078546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184482|NCT03588585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184483|NCT01558804|||COHORT||PROSPECTIVE|||||||
33868764|NCT03967366|||COHORT||RETROSPECTIVE|||||||
34184484|NCT01820988|||||CROSS_SECTIONAL|||||||
34184485|NCT02224560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184486|NCT02051413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184487|NCT00531661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184488|NCT04230031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184489|NCT03548948|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||"1. Typical American Diet with high heme/non-heme iron (16 mg)~2. Typical American Diet with low iron (8 mg)~3. Plant-based Diet with high non-heme iron (16 mg)"||||
34184490|NCT00210912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34184491|NCT02168244|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34184492|NCT01717027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34184493|NCT00616759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184494|NCT03992248|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Due to the nature of this study, it is not possible to mask the intervention effect for the investigator or the participant. During randomisation, the intervention arms will be coded with 1 and 2 and the independent researcher will be unaware which intervention is assigned to which letter. With this approach, concealed allocation will be guaranteed. Additionally, the person in charge with the data quality check and the data analyses will be blinded for the interventions using this same randomisation codes to generate unbiased results.|Randomised controlled cross-over design with two 3-week arms and a 4-week wash-out period.|f|f|f|t
34184495|NCT03708276|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34184496|NCT03537521|||OTHER||PROSPECTIVE|||||||
34184497|NCT01658319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184498|NCT01523756|RANDOMIZED|CROSSOVER||||NONE||||||
34184499|NCT06229275|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34184500|NCT00530972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868765|NCT02230254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066376|NCT04418089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34066377|NCT01017757|||COHORT||PROSPECTIVE|||||||
34066378|NCT03518398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184501|NCT01690156|||CASE_CONTROL||PROSPECTIVE|||||||
34184502|NCT06654388|||COHORT||OTHER|||||||
34184503|NCT01876017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184504|NCT02130843|||CASE_ONLY||RETROSPECTIVE|||||||
34184505|NCT04664452|||COHORT||CROSS_SECTIONAL|||||||
34184506|NCT05824819|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective tertiary single-centre cohort study||||
34184507|NCT02416206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184508|NCT01837121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34184509|NCT04126941|||COHORT||RETROSPECTIVE|||||||
34184510|NCT00956319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184511|NCT01935778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184512|NCT03082521|||OTHER||PROSPECTIVE|||||||
34184513|NCT01326949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184514|NCT00385359|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184515|NCT01318460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066379|NCT01900899|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34066380|NCT06376539|||COHORT||RETROSPECTIVE|||||||
34066381|NCT05974228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184516|NCT06295484|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"The baby will be assigned to first go on traditional CPAP, NIPPV, or high CPAP, stay for 2 hours, switch to one of the other methods for 2 hours and then spend 2 hours supported by the remaining method. We will continue to record the Edi signals during the 3 methods.~Study duration will be 6 hours from the time of catheter insertion to fit into feeding and handling plans. Upon completion or termination of the study protocol, your baby will be put back to the originally prescribed breathing support.~Routine monitoring for oxygen saturation, heart rate, and respiratory rate will be continued as per the standard of practice in the NICU."||||
33868766|NCT05903729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatmaent.|It is a randomized control trial, used to compare conventional physiotherapt and neurodevelopmental therapy approaches on trunk control and upper extremity function in spastic diplegic cerebral palsy patients. subjects with spastic diplegic cerebral palsy meeting the predetermined inclusion and exclusion criteria will be divided into two groups using simple random sampling technique.|t|f|f|f
34184517|NCT01129596|||COHORT||PROSPECTIVE|||||||
34184518|NCT02751853|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34184519|NCT04198558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double-blind||f|f|t|f
34184520|NCT01216553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184521|NCT01352000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184522|NCT01887457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184523|NCT03297112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184524|NCT06519669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184525|NCT02180100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184526|NCT05969834|||COHORT||PROSPECTIVE|||||||
34184527|NCT04016623|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||This is a non-dispensing, double-masked, randomized, contralateral study design. Each subject will be randomized to wear the test lens in one eye and the control lens in the other eye.|t|f|t|f
34184528|NCT03294252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184529|NCT06209307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184530|NCT06008041|||COHORT||PROSPECTIVE|||||||
34184531|NCT05198596|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34184532|NCT05326490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184533|NCT04852926|||COHORT||PROSPECTIVE|||||||
34184534|NCT00933452||PARALLEL||||NONE||||||
34184535|NCT05506033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184536|NCT00867672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184537|NCT03698877|||COHORT||PROSPECTIVE|||||||
33868767|NCT02899689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184538|NCT05069493|||OTHER||PROSPECTIVE|||||||
34184539|NCT01376258|||COHORT||RETROSPECTIVE|||||||
34184540|NCT00071058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184541|NCT00533676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184542|NCT04987333|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34184543|NCT06480084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||cross-sectional study||||
34184544|NCT03071107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184545|NCT01040962|||COHORT||CROSS_SECTIONAL|||||||
34184546|NCT01432054|||OTHER||OTHER|||||||
34184547|NCT03254797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184548|NCT02374528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184549|NCT02717923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184550|NCT00286468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184551|NCT00545454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868768|NCT04316377|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, open label, pragmatic randomized controlled trial.||||
34184552|NCT05824234|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized controlled trial, with cluster randomization with sequential permutation or stepped wedge||||
34184553|NCT01814267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184554|NCT01635439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184555|NCT04355169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184556|NCT01502774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184557|NCT03767413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are two group of subjects: PNF group will receive only PNF training PNFMP group: will receive PNF training and mental pracice technique||||
34184558|NCT02270294|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34184559|NCT05386771|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomized double-blind|Double-blind, parallel-group, placebo-controlled intervention study|t|f|t|t
34184560|NCT01048619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184561|NCT02497170|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066382|NCT03153345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184562|NCT01035801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184563|NCT05694416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184564|NCT05744674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||HR18034 compared with active comparator|t|t|t|t
34184565|NCT01737437|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34184566|NCT06004427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||resistance training (RT), (3 days/wk, 3 sets/day, 8-12 repetitions/set)|f|f|f|t
34184567|NCT00427765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184568|NCT01198977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753493|NCT05894434|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The experimental and control paradigms are based on sensory stimulation and there is no practical way to mask the participant from its nature, although they are not informed as to what the expected results will be. The outcomes assessor will be blinded to which stimulation arm preceded the data collection.|There are two principal sub-studies: standard intervention and early intervention. Each sub-study contains a multisensory training group (experimental arm) and a unisensory training group (control arm). The unisensory training group crosses over to multisensory training at its completion. Thus, the model design is both factorial and crossover.|f|f|f|t
33753494|NCT04872764|||CASE_CONTROL||RETROSPECTIVE|||||||
33753495|NCT03331718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753496|NCT05310474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study includes 3 arms.|t|f|f|f
33753497|NCT01522417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184569|NCT01716234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184570|NCT00193661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184571|NCT02387502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184572|NCT04002102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34184573|NCT04157413|||OTHER||CROSS_SECTIONAL|||||||
34184574|NCT04205877|||CASE_ONLY||OTHER|||||||
34184575|NCT06589089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184576|NCT04248634|||COHORT||PROSPECTIVE|||||||
34184577|NCT00892476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184578|NCT04601961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34184579|NCT06473636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34184580|NCT02773810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753498|NCT05373498|||CASE_ONLY||PROSPECTIVE|||||||
33753499|NCT06068855|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33753500|NCT06078462|||OTHER||PROSPECTIVE|||||||
33753501|NCT04487093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled without disease progression were given neoantigen vaccine combined with EGFR-TKI therapy； Patients with disease progression were given neoantigen vaccine combined with anti-angiogenesis drug therapy. Patients received subcutaneous injection of individualized neoantigen vaccines at a dose of 200ug per peptide once a week for 5 weeks. The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance.||||
33753502|NCT00979836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753503|NCT04072510|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33868769|NCT04096027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laboratory personnel will not be informed of the subject's group assignment.||f|f|f|t
33868770|NCT04750876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184581|NCT06244160|RANDOMIZED|PARALLEL||PREVENTION||NONE||Feasibility randomised control trial||||
34184582|NCT01850212|||COHORT||CROSS_SECTIONAL|||||||
34184583|NCT03740672|||COHORT||PROSPECTIVE|||||||
34184584|NCT00925457|||CASE_CONTROL||RETROSPECTIVE|||||||
34184585|NCT05077748|||COHORT||PROSPECTIVE|||||||
34184586|NCT03081429|||COHORT||PROSPECTIVE|||||||
34184587|NCT06516029|||COHORT||RETROSPECTIVE|||||||
34184588|NCT05623917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184589|NCT04686669|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34184590|NCT02916368|||CASE_CONTROL||PROSPECTIVE|||||||
34184591|NCT03308929|||COHORT||PROSPECTIVE|||||||
34184592|NCT00003278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184593|NCT00044616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868771|NCT02243254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34184594|NCT00041561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184595|NCT02446574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184596|NCT00721383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184597|NCT05336591|||OTHER||CROSS_SECTIONAL|||||||
34184598|NCT01052337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184599|NCT02775500|||COHORT||PROSPECTIVE|||||||
34184600|NCT02740101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33753504|NCT05148377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The pharmaceutical presentation of the medication to be studied is: solution for injection packaged in 5ml vial and 0.25ml ampoule. All doses have been prepared prior to administration to patients by the LAL Clinic Pharmacy which knows the randomization of the study. It is preparation consisted of preparing the dose of each patient previously calculated based on the weight of each patient and the pharmaceutical presentation of the product randomized into standard 3 ml syringes.|Parallel clinical study, randomized, double-blind, systematic sampling that evaluated the safety of the sadistic Heparin tested.|t|f|t|f
33753505|NCT01838148|||OTHER||PROSPECTIVE|||||||
33753506|NCT06524466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184601|NCT03008369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868772|NCT05210283|||COHORT||PROSPECTIVE|||||||
33868773|NCT01094587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868774|NCT01628445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868775|NCT01133899|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33868776|NCT00004047||||TREATMENT||||||||
33868777|NCT00738153|||||PROSPECTIVE|||||||
33868778|NCT00692484|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33868779|NCT00596947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868780|NCT00906893|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33868781|NCT02148991|||OTHER||PROSPECTIVE|||||||
33868782|NCT06237543|||COHORT||PROSPECTIVE|||||||
33868783|NCT00766948|||COHORT||PROSPECTIVE|||||||
33868784|NCT04703673|||COHORT||PROSPECTIVE|||||||
33868785|NCT04489251|||CASE_CONTROL||PROSPECTIVE|||||||
33868786|NCT06125769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868787|NCT06044064|||OTHER||PROSPECTIVE|||||||
33868788|NCT02528370|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only data entry people and biostatisticians were masking||f|f|f|t
33868789|NCT02879227|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184602|NCT00045760||||TREATMENT||||||||
34184603|NCT00675272|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34184604|NCT00636493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184605|NCT04968275|RANDOMIZED|PARALLEL||PREVENTION||NONE|Group assignment will not be masked after randomization, but it will be at the data analysis stage.|two-arm parallel, open-labelled, pilot randomized controlled trial||||
34184606|NCT03584477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184607|NCT00606606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34184608|NCT02196844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184609|NCT06655428|NA|SINGLE_GROUP||TREATMENT||NONE||The study is prospective, single-arm and multi-center.||||
34184610|NCT03863769|||OTHER||OTHER|||||||
34184611|NCT00704236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066383|NCT04716036|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34184612|NCT02376153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34184613|NCT00750087|||COHORT||PROSPECTIVE|||||||
34184614|NCT01441076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184615|NCT05995106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184616|NCT03399552|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, two-stage study that will be conducted at Memorial Sloan Kettering Cancer Center Main Campus and regional sites.||||
34184617|NCT04349397|||COHORT||PROSPECTIVE|||||||
34184618|NCT06218966|NA|SINGLE_GROUP||TREATMENT||NONE||feasibility study||||
34184619|NCT06516978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184620|NCT02869464|||COHORT||PROSPECTIVE|||||||
34184621|NCT02734459|RANDOMIZED|CROSSOVER||||NONE||||||
34184622|NCT02797613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184623|NCT05427188|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34184624|NCT04667221|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and investigators are blinded according to the sham / active stimulation.|Randomized, balanced crossover design.|t|f|t|f
34184625|NCT05660499|||CASE_ONLY||RETROSPECTIVE|||||||
34184626|NCT06248996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184627|NCT04452084|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding is not feasible in this study and will not be performed.|||||
34184628|NCT03237455|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Reader of the MRI studies will be blinded to the patients diagnoses|case control study|f|f|f|t
34184629|NCT02546271|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34184630|NCT01526577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184631|NCT06275516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184632|NCT00404612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184633|NCT01070017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster randomization of sites assign individuals starting antiretroviral therapy to receive community-based directly observed therapy plus home visits / social support versus home visits / social support alone.|f|f|f|t
34184634|NCT06107309|||CASE_ONLY||RETROSPECTIVE|||||||
34184635|NCT02853058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33868790|NCT00805272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066384|NCT03200977|||COHORT||OTHER|||||||
34066385|NCT03289299|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles).||||
34184636|NCT05486377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184637|NCT02625857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184638|NCT00973804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184639|NCT04045028|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184640|NCT04219384|||COHORT||PROSPECTIVE|||||||
34184641|NCT00194428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184642|NCT06188767|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34184643|NCT03266510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184644|NCT05681767|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a 2-arm, randomized controlled clinical trial, in which participants are randomized to the study arms at an individual level. After the baseline data is collected, the study nurse (nurse 1), who conducts the baseline data collection, uses opaque capsules to randomize patients to the study arms.||||
33868791|NCT05568108|||COHORT||PROSPECTIVE|||||||
33868792|NCT02524522|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33868793|NCT03702504|||COHORT||PROSPECTIVE|||||||
33868794|NCT03932656|||COHORT||PROSPECTIVE|||||||
33868795|NCT04972474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are unaware of the changes that have been made to the app, and therefore are unaware of which arm they are randomised to.|Participants will be randomised to one of two arms, the app as usual or the adapted app.|t|f|f|f
33868796|NCT01923142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184645|NCT05950074|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34184646|NCT01982097|||COHORT||PROSPECTIVE|||||||
34184647|NCT02229669|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34184648|NCT02581410|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184649|NCT05677568|||CASE_ONLY||OTHER|||||||
34184650|NCT04035460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184651|NCT02979496|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33868797|NCT00290342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868798|NCT04981470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868799|NCT03371979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868800|NCT05549700|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33868801|NCT01713621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868802|NCT02597569|||COHORT||PROSPECTIVE|||||||
33868803|NCT01322750|||COHORT||PROSPECTIVE|||||||
33868804|NCT05496179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184652|NCT00891904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868805|NCT02091778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868806|NCT06396078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868807|NCT01688596|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33868808|NCT02875249|||||PROSPECTIVE|||||||
33868809|NCT06317818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, controlled study|t|t|t|t
34184653|NCT01931566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184654|NCT00082225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184655|NCT02268175|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184656|NCT02556840|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184657|NCT04085380|||COHORT||PROSPECTIVE|||||||
33753507|NCT05850832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"60 patients aged 20-65 years of both sexes, of American society of Anesthesiologists (ASA) physical status I and II planned for ambulatory laparoscopic cholecystectomy under general anaesthesia were engaged to this study.~* Group (E): (Esmolol group) received loading dose 1 mg/kg followed by maintenance dose of 30 μg/kg/min throughout the surgery.~* Group (M): (Magnesium sulphate group) received loading dose 40 mg/kg over a period of 15 mins and maintenance 15 mg/kg/h throughout the surgery."|t|f|t|f
33753508|NCT03253224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34184658|NCT02143388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184659|NCT03460249|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34184660|NCT00973635|RANDOMIZED|CROSSOVER||||NONE||||||
34184661|NCT05028543|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study design precluded neither participants nor the surgeons will be blinded, only data analyzer will be blinded to each allocation group single blinded study. However, the outcomes of the study are objective not subjective and will not be affected by lack of blinding."|A Randomized controlled Trial.|f|f|t|f
34184662|NCT01256138|||CASE_CONTROL||RETROSPECTIVE|||||||
34184663|NCT02395081|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34184664|NCT00493129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184665|NCT06411080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34184666|NCT03388164|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34184667|NCT04198714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled randomized controlled trial|t|t|t|t
34184668|NCT00522080|||||OTHER|||||||
34184669|NCT03906448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184670|NCT03881852|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34184671|NCT04292899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184672|NCT05982418|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 108 patients will be recruited prospectively, i.e. 54 patients for intervention arm 1 (3D printed models), and 54 patients for intervention arm 2 (3D virtual models). An additional set of 54 patients will be obtained retrospectively.|t|f|f|f
34184673|NCT00844961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184674|NCT05119881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher(s) who perform the outcome assessments will be blinded to the group allocation of the participants.|3 groups of different interventions|f|f|f|t
34184675|NCT00965172|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184676|NCT02175524|||CASE_CONTROL||PROSPECTIVE|||||||
34184677|NCT02578706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184678|NCT04264936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753509|NCT05656599|||CASE_CONTROL||PROSPECTIVE|||||||
34066386|NCT03435159|RANDOMIZED|PARALLEL||SCREENING||SINGLE||30 participants were divided into 2 groups. In the first group, participants were applied manual chiropractic manipulation, and in the second group, participants were applied instrumental chiropractic manipulation.|f|f|f|t
34184679|NCT02410226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184680|NCT06051149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Will be performed in a sterile operating room under appropriate sterile precautions with help of assistant nurse who will open catheter set before principal investigator enter the operating room and the patient will be blinded.|double-blinded, prospective study|t|t|f|t
34184681|NCT06272396|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34184682|NCT04057950|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|double blind study||t|t|t|t
33753510|NCT02184611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753511|NCT04964765|||COHORT||PROSPECTIVE|||||||
33753512|NCT00668954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33753513|NCT02302443|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753514|NCT03837912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Multi-centre, 12 month, two-arm, two-level cluster randomized controls trial (Primary Care professionals within Primary Care centres, with randomization at the centre level in a 1:1 ratio)||||
33753515|NCT04730622|||COHORT||PROSPECTIVE|||||||
33868810|NCT03583983|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomized to intervention or control groups using a minimization scheme which will adaptively weight probabilities of treatment assignment based on the distribution of age (\> 40 vs. \< 40), gender (male vs. female), and ethnicity (European/African/East Asian/South Asian/Latino/Other). This design has been adopted to minimize unintended covariate biases, which can plague smaller trials. Randomization will be implemented through a centralized database. The intervention will be delivered via automated e-mails, minimizing direct personal contact with the intervention group.||f|f|t|t
34184683|NCT05209971|||CASE_ONLY||RETROSPECTIVE|||||||
34184684|NCT03370978|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34184685|NCT04765891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184686|NCT05950711|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Feasibility Study of an Intervention Without a Control Group||||
34184687|NCT02086253|RANDOMIZED|CROSSOVER||||NONE||||||
34184688|NCT06189053|||COHORT||RETROSPECTIVE|||||||
34184689|NCT04512157|RANDOMIZED|PARALLEL||PREVENTION||NONE|There was no masking after random assignment of recruited schools to condition (intervention or waitlist control condition).|The design used was a cluster randomized controlled intervention trial, with a waitlist comparison group, with pre and post-testing.||||
34184690|NCT00811915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184691|NCT04326803|NA|SINGLE_GROUP||PREVENTION||NONE||A single group of subject will be offered to enroll in a study to assess the serological response to an accelerated schedule (0, 1 and 6 months) of recombinant hepatitis B vaccine||||
34184692|NCT00694642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868811|NCT05439486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded randomized controlled trial|Double blinded randomized controlled trial|t|f|t|t
33868812|NCT01866384||||TREATMENT||||||||
33868813|NCT05147272|NA|SEQUENTIAL||TREATMENT||NONE||Dose Escalation and Expansion||||
33868814|NCT01753128|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33868815|NCT04521023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868816|NCT04350385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33868817|NCT05207995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184693|NCT04999540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184694|NCT03950297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184695|NCT01042106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184696|NCT04803552|NA|SINGLE_GROUP||SCREENING||NONE||||||
34184697|NCT00588016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184698|NCT01600716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184699|NCT05400278|||CASE_ONLY||PROSPECTIVE|||||||
34184700|NCT02321020|||COHORT||PROSPECTIVE|||||||
34184701|NCT00279487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184702|NCT05971485|||CASE_CONTROL||PROSPECTIVE|||||||
34184703|NCT04856800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184704|NCT00831181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184705|NCT05816447|||COHORT||PROSPECTIVE|||||||
34184706|NCT03570710|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used.|Eligible participants were allocated to one of three groups. Group (I): patients received 110 ml normal saline IV just before skin incision Group (II): patients received 1 gm TA (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision. Group (III): patients received 2 gm topical TA (4 ampoules of Capron 500 mg/5 ml) applied on the placental bed after placental delivery.|t|t|t|t
34184707|NCT01875796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184708|NCT06655233|||OTHER||PROSPECTIVE|||||||
34184709|NCT03404700|RANDOMIZED|CROSSOVER||OTHER||NONE||"The proposed study will comprise of two parts: Part I: an observational study based on ecological momentary assessment, and Part II: a randomized partial crossover clinical trial. Same subjects will participate in both parts of the study.~In the observational study, the dietary intake of the subjects will be evaluated using an ecological momentary assessment approach for 7 days. In the randomized partial crossover clinical trial, four test breakfasts will be administered so that each subject will get exposed to only two out of the four diets (thus, partial crossover). Therefore, there will be six possible combinations of diets (i.e. 4! / 2! \[4-2\]!) and 12 possible ordered combinations (i.e. permutations; 4! / \[4-2\]!) of diets. Four subjects will be randomly assigned to each of these 12 possible ordered combinations of diets. Thus, the total sample size will be 48 (i.e. n = 4x12)."||||
34184710|NCT02506244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184711|NCT02189317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184712|NCT03035357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184713|NCT00693771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184714|NCT04048356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be anesthetized during the intervention and will not be informed of the arm of their randomization||t|f|f|f
34184715|NCT00439517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184716|NCT05293223|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The ratio of Geometric mean titers (GMTs) of SARS-CoV-2 neutralizing antibody in participants on Day 21 post-vaccination of Ad5-nCoV (previously received a 1st dose of Sputnik V) (Group A) and two doses of Sputnik V (Group B) is used for the evaluation of this hypothesis.||||
34184717|NCT02419001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184718|NCT04444453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184719|NCT04799912|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter open randomized controlled trial with 2 parallel arms||||
34184720|NCT03101761|||COHORT||RETROSPECTIVE|||||||
34184721|NCT06088784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Parts 1a and 2 are double-blind and Part 1b is open label.||t|t|t|t
34184722|NCT03430102|||COHORT||PROSPECTIVE|||||||
34184723|NCT02472470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184724|NCT04012957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184725|NCT00874094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184726|NCT00885170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184727|NCT02290249|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34184728|NCT03185377|||COHORT||PROSPECTIVE|||||||
34184729|NCT01112839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184730|NCT02763670|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184731|NCT03752437|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Randomisation by computer, different sheet for encoding data.|One arm will receive 300 IU of heparin based on real weight, and the other arm will receive 300 IU of heparin based on ideal weight.|t|t|t|f
34184732|NCT04931706|||COHORT||PROSPECTIVE|||||||
34184733|NCT05067725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective cluster randomized control study||||
34184734|NCT01632722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184735|NCT04168918|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Fifty per cent receive psychological intervention and fifty per cent receive treatment-as-usual||||
34184736|NCT00684918||PARALLEL||TREATMENT||NONE||||||
34184737|NCT02551887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34184738|NCT00382759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184739|NCT02973750|||COHORT||PROSPECTIVE|||||||
34184740|NCT02567812|||COHORT||PROSPECTIVE|||||||
34184741|NCT00680108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34184742|NCT04459650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184743|NCT01954446|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34184744|NCT05916079|||CASE_ONLY||PROSPECTIVE|||||||
34184745|NCT01206218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184746|NCT02643446|||COHORT||PROSPECTIVE|||||||
34184747|NCT03812757|||COHORT||PROSPECTIVE|||||||
34184748|NCT00445913|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34184749|NCT06390748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study employs a single-blind design where the participants are blinded to their treatment assignments. In this setup, the patients do not know whether they are receiving the intervention (Esmolol) or are in the control group receiving only standard sepsis care. This blinding is essential to mitigate placebo effects and bias in patient-reported outcomes. However, the care providers, as well as the investigators and outcomes assessors, are aware of the treatment assignments. This knowledge allows them to manage the care more effectively while maintaining a robust observational stance on the impact of the interventions. The single-blind design is chosen to ensure the integrity of the data collected, particularly in measuring clinical outcomes and patient responses, without influencing the patients' perceptions or expectations about the treatment they are receiving.|This study employs a parallel assignment model to investigate the effects of Esmolol on patients with sepsis. Participants are randomly assigned to one of two groups. The first group, the intervention group, receives Esmolol in addition to the standard sepsis care, which includes antibiotics, fluid resuscitation, and other supportive therapies. Esmolol dosing is adjusted to achieve and maintain specific heart rate targets, and cardiac monitoring through daily electrocardiograms is implemented to track QT interval changes. The second group, the control group, receives only the standard sepsis care without any additional interventions.|t|f|f|f
34184750|NCT05106400|RANDOMIZED|CROSSOVER||OTHER||NONE||Subjects will be randomized to ZTlido (Lidocaine Topical System) 1.8% or Salonpas (Lidocaine Patch 4%) or Aspercreme (Lidocaine Patch 4%) or IcyHot (Lidocaine 4% + Menthol 1% Patch). Subjects will crossover to each treatment after a wash out period.||||
34184751|NCT04612504|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34184752|NCT04671017|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"1. st phase is open-label~2. nd phase is double-blind randomized (Participant, Investigator )~3. rd phase is open-label phase"|"1. st phase Sequential (open-label phase)~2. nd phase Parallel Assignment (double-blinded randomized phase )~3. rd phase Parallel Assignment (open-label phase)"|t|t|t|t
34184753|NCT03630315|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34184754|NCT00637455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34184755|NCT00692432|||COHORT||PROSPECTIVE|||||||
34184756|NCT02874872|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184757|NCT06030024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184758|NCT01501565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184759|NCT03527459|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are masked as to the treatment arm to which they are assigned. Care providers in the control arm are masked to the interventions being tested in the experimental arm, so as to not inadvertently deliver aspects of SPARC B intervention to the SPARC A group. The outcomes assessor is not collecting primary outcome data, which is self-reported via online survey.|Half of the clients in the SPARC clinical program are enrolled into either the original program or SPARC B (which will overlap significantly with SPARC A but targets in some sessions specific negative cognitions of perceived burdensomeness). The program is already structured so that each patient consistently attends either a morning or an afternoon track, with different therapists running each track. This allows for separate programs in each track. Clinically justifiable innovations are routinely introduced into the program usually in a stepwise fashion in one or another part by one set of therapists at a time. We will assess relative impact of SPARC A and SPARC B on depressive symptoms and suicide ideation. Our investigation will allow us to assess whether this innovation is effective. Patients will not be randomized at the individual level, but rather their time slot (usually decided based on opening within the program) will place them into either SPARC A or SPARC B.|t|t|f|f
34184760|NCT02922647|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34184761|NCT05264922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The provider (PI) and team performing the injection will not care for the subject during follow up.|Subjects will be randomized 1:1 to SVF Cells \& Fibrin Glue or Fibrin Glue alone.|t|t|f|t
34184762|NCT03146416|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34184763|NCT01300507|||CASE_CONTROL||PROSPECTIVE|||||||
34184764|NCT04204889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184765|NCT05945342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184766|NCT01291732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34184767|NCT04664699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|next of kin were blinded to the allocated arm|This is a single centre, with equal randomisation, single blind, parallel group study conducted in Hospital Universiti Sains Malaysia|f|t|f|f
34184768|NCT03478709|||CASE_CONTROL||PROSPECTIVE|||||||
34184769|NCT03309735|||OTHER||PROSPECTIVE|||||||
34184770|NCT04672278|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34184771|NCT00583076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868818|NCT04404998|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33868819|NCT03280875|NA|SINGLE_GROUP||OTHER||NONE||||||
33868820|NCT04072289|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparative cohort trial||||
33868821|NCT04041986|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded to which tDCS group (real or sham) they are initially enrolled in; however, since only the sham group crosses over this will signal to subject that they are now getting real stimulation.|This is an incomplete crossover design where subjects randomized to the real tDCS group will end their participation but subjects randomized to the sham tDCS group will crossover into the real tDCS group.|t|f|f|f
33868822|NCT03016208|||COHORT|||||||||
33868823|NCT02355249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868824|NCT02743351|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868825|NCT00268437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868826|NCT03840512|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33868827|NCT03434340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33868828|NCT00275223|||||PROSPECTIVE|||||||
33868829|NCT03292809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868830|NCT03104894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patient will be assigned to the study/control group by randomization soft ware. The results will be documented and kept by the doctor who preforms the meibomian glands massage/ sham massage. All patients will receive study number. Follow up examination will be preformed by another doctor.||t|f|t|t
33868831|NCT06512012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868832|NCT02371226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33868833|NCT03135470|||COHORT||PROSPECTIVE|||||||
33868834|NCT02556502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868835|NCT01451008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868836|NCT00530751|||FAMILY_BASED||PROSPECTIVE|||||||
33868837|NCT00577109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868838|NCT01419951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868839|NCT00012220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753516|NCT06580457|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to either intervention or control group||||
33753517|NCT00493818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753518|NCT03719755|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participant masked to distention media||t|f|f|f
33868840|NCT05132374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study consists of the following main activities: (1) training and certification of early childhood mental health consultants from various agencies on the I-T CHILD Tool; (2) random assignment of child care providers into treatment (those receiving standard practice early childhood mental health consultation but enhanced with the I-T CHILD as a framework for consultation) and waitlist-control groups (no intervention until the end of the evaluation period); (3) provision of I-T CHILD resources to child care providers (user-friendly tips on how to strengthen their relationships with children and families); and (4) data collection (pre-test, post-test, 3-month follow-up).|f|f|f|t
34184772|NCT05727124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184773|NCT04000633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator will provide to the anesthesiologist 1 seringue containing either lidocaine or normal saline to be nebulized before induction of general anesthesia|2 groups comparaison between nebulized lidocaine versus placebo for prevention of cough at emergence from general anesthesia and post extubation sore throat|t|t|f|f
34184774|NCT00588107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34184775|NCT04970225|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34184776|NCT00578149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184777|NCT02407600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184778|NCT03174730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In order to control for expectancy or placebo effects, participants will be told that the study is designed to test the method of delivery of content (email vs. smartphone). They will not be aware that one group is getting something extra that the control group is not getting.|All participants will gain access to SmartQuit, a smartphone based app with tools for quitting smoking. In order to test whether the growth mindset intervention is effective, smokers will be randomly assigned to either an experimental group, where they will additionally get growth mindset content or to a control group.|t|f|f|f
34184779|NCT02094157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184780|NCT06517420|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Simple random sampling method was used to avoid bias in providing patients to be included in the study before the data collection phase. With the computer-based randomization method, patients were numbered in the order of arrival and divided into experimental and control. The study data will be analyzed by an independent statistician.|A randomized controlled prospective experimental study|t|f|f|t
34184781|NCT06589115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184782|NCT01807624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184783|NCT03040336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184784|NCT06188143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34184785|NCT03324087|||CASE_ONLY||PROSPECTIVE|||||||
34184786|NCT05152394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753519|NCT06579651|||CASE_ONLY||CROSS_SECTIONAL|||||||
33753520|NCT04960865|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants were not aware of the type of tape applied|Three-arm parallel group|t|f|f|t
33753521|NCT01385072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753522|NCT00002292|RANDOMIZED|||TREATMENT||||||||
33753523|NCT01206530||||TREATMENT||||||||
33753524|NCT06195540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Open label with blind assessment of study's outcomes||f|f|f|t
33753525|NCT03295487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868841|NCT02782520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066387|NCT02419651|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34066388|NCT02859519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066389|NCT02557516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34066390|NCT00609713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066391|NCT05546814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two cohorts; experimental and control||||
34184787|NCT01935206|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34184788|NCT02894684|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184789|NCT02863120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184790|NCT01209416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34184791|NCT01249079|||FAMILY_BASED|||||||||
34184792|NCT03847597|||COHORT||PROSPECTIVE|||||||
34184793|NCT06204640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184794|NCT06263413|||COHORT||OTHER|||||||
34184795|NCT05610137|||COHORT||PROSPECTIVE|||||||
34184796|NCT04926987|||COHORT||PROSPECTIVE|||||||
34184797|NCT00088088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34184798|NCT04883827|||CASE_ONLY||PROSPECTIVE|||||||
34184799|NCT06198582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184800|NCT00774891|||COHORT||PROSPECTIVE|||||||
34184801|NCT03387618|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184802|NCT05807620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184803|NCT00045617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184804|NCT03557034|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34184805|NCT00628108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184806|NCT02326701|||COHORT||PROSPECTIVE|||||||
34184807|NCT03848832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184808|NCT03333278|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre, Randomised, Open-label controlled Trial||||
34184809|NCT00783107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184810|NCT02823015|||COHORT||PROSPECTIVE|||||||
34184811|NCT02779101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184812|NCT03495089|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|A neurologist will be blinded to previous test results and will perform neurographyc test including sensory conduction study of the median, ulnar and sural nerves, and motor conduction study of the deep peroneal nerve.|consecutively there will be included patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care. We will also include the following two groups of patients matched by age and gender: one including patients with prediabetes (intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration and another including patients without glucose alterations (normal glucose tolerance) (control group)|f|f|t|f
33965254|NCT06389474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Adaptive design. IA will be done when approximately 50% of the enrollment is reached and the participants have completed 28 days of follow-up. This analysis will not be blinded and will be carried out to declare futility or re-estimate the sample size. The re-estimation of the sample size will allow a maximum of 300 randomized subjects in total, but a reduction in the initial item size of 220 subjects is not expected. In case of re-estimating the sample size, the smallest sample size under 300 will be selected, which allows a power of ≥ 80%. %. If with 300 subjects, a power of 80% is not reached, but it is ≥ 50%, then the sample size is re-estimated to 300 subjects, as long as the conditional power of the IA is ≥ 50% (promising results)|t|t|t|t
33965255|NCT00265083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965256|NCT00444288|||||OTHER|||||||
33965257|NCT00117585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184813|NCT04906902|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184814|NCT02608684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184815|NCT02869568|||COHORT||PROSPECTIVE|||||||
34184816|NCT03802292|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Single blind, placebo-controlled|Dose escalation study to determine the safe dose level.|t|f|f|f
34184817|NCT05679869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184818|NCT02064777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965258|NCT01726335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965259|NCT02383537|||CASE_CONTROL||PROSPECTIVE|||||||
33965260|NCT05578755|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are three arms: 1) smartphone-based intervention, 2) immersive virtual reality intervention, and 3) active, goal-setting, control group||||
34184819|NCT06151457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184820|NCT04783493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The random sequence will be generated by a computer program (randomization.com) using randomly exchanged blocks (size of four per block, active ratio / placebo 1: 1). Randomization will be stratified according to the severity of symptoms (TUG\> 33 seconds = severe group; TUG ≤ 33 seconds = light group). The researchers will be specifically instructed not to break the randomization schedule in any way. Different researchers will carry out randomization, clinical evaluation and stimulation. Patients will be blinded to randomization.|Study is a randomized, double-blind, placebo-controlled, parallel, phase II clinical trial|t|f|t|f
34184821|NCT02895893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184822|NCT00406484|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34184823|NCT03854097|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34184824|NCT05301790|||OTHER||PROSPECTIVE|||||||
33965261|NCT05898048|||COHORT||PROSPECTIVE|||||||
34184825|NCT03562026|||COHORT||PROSPECTIVE|||||||
34184826|NCT04761328|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients will receive treatment and be evaluated pre- and post-treatment||||
34184827|NCT01707199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184828|NCT06472232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184829|NCT05324514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Formalin embedded biopsies will be sectioned and the sections will be stained. Stained tissue sections will be graded by blinded dermato-pathologists.|Participants will have three wound sites that will be randomized to receive either the standard of care treatment, high density microscopic tissue skin columns, or low density microscopic tissue skin columns.|f|f|f|t
33753526|NCT03076099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|this investigation is a triple mask study. The patiens, the care providers and Outcome Assessor will not allowed to know the grouping information.|two parallel groups|t|t|f|t
33753527|NCT01922115|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33753528|NCT00228072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753529|NCT02175355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33753530|NCT00035672|||COHORT||RETROSPECTIVE|||||||
33753531|NCT04481737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33753532|NCT01400503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753533|NCT02212574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753534|NCT06185205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753535|NCT02330133|RANDOMIZED|PARALLEL||||NONE||||||
33753536|NCT00989768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753537|NCT04648189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753538|NCT05350943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753539|NCT03206320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33753540|NCT03443882|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33753541|NCT06580145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753542|NCT06643351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868842|NCT05246020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All tissue samples harvested during IDS will be subjected to H\&E expert pathological evaluation to confirm the diagnosis of high-grade serous ovarian cancer(HGSOC). Omental slides will be independently reviewed by two pathologists to determine those with the greatest amount of viable tumour, and one slide of each site will be selected. The two pathologists, who will be blinded to the written report and each other's results, will independently score each slide according to the CRS system.|The eligible patients will be randomised into an experimental group (NHIPEC +intravenous NACT) or a control group (intravenous NACT). Patients in the NHIPEC experimental group will receive NHIPEC and two cycles of intravenous NACT, while patients in the control group will receive three cycles of intravenous NACT. All patients will undergo IDS within 4weeks after the last cycle of NACT.|f|f|f|t
33868843|NCT03048539|||CASE_CONTROL||PROSPECTIVE|||||||
33868844|NCT01778439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184830|NCT04962308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184831|NCT03036202|||CASE_ONLY||PROSPECTIVE|||||||
34184832|NCT02546206|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34184833|NCT02753504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184834|NCT06442319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184835|NCT00369265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184836|NCT04442828|||COHORT||PROSPECTIVE|||||||
33753543|NCT05711641|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|This is a double blind study. The substances are produced by the same handling pharmacy and delivered in identical vials, only with the information: substance 1 and substance 2.|All patients will receive both lidocaine and placebo at an interval of 15 days and the order of application of the substances is randomized.|t|f|t|f
33753544|NCT02646228|||COHORT||PROSPECTIVE|||||||
33753545|NCT01925950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753546|NCT04639128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753547|NCT04437784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed opaque envelopes containing computer generated random numbers||t|f|t|f
33753548|NCT02231827|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33753549|NCT03565081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753550|NCT00642512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33753551|NCT05412641|NA|SINGLE_GROUP||OTHER||NONE||Fathers participate in and educational program designed to help them improve (1) healthy marriage/relationship skills, (2) conflict resolution skills, (3) financial management/economic stability, and (4) parenting skills.||||
33753552|NCT06209879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753553|NCT00803452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868845|NCT02166164|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33868846|NCT01770470|||CASE_ONLY||PROSPECTIVE|||||||
34184837|NCT02028273|||COHORT||CROSS_SECTIONAL|||||||
34184838|NCT00078598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184839|NCT03075514|RANDOMIZED|PARALLEL||TREATMENT||NONE||MKD and MCT ketogenic diets||||
33868847|NCT06148987|||OTHER||OTHER|||||||
33868848|NCT02982369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33868849|NCT03099954|||COHORT||CROSS_SECTIONAL|||||||
33965262|NCT06133699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965263|NCT04976049|||CASE_ONLY||PROSPECTIVE|||||||
33965264|NCT03165643|||CASE_CONTROL||RETROSPECTIVE|||||||
34184840|NCT05738642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184841|NCT03323424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965265|NCT00438685|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34184842|NCT04932486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184843|NCT00506974|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34184844|NCT00210743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184845|NCT03077841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184846|NCT00509119|||COHORT||PROSPECTIVE|||||||
34184847|NCT00002786||||TREATMENT||||||||
34184848|NCT04467372|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34184849|NCT01170169|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184850|NCT00074048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184851|NCT03846206|RANDOMIZED|PARALLEL||TREATMENT||NONE||. One hundred and two patients who will be randomized to continues usual diet or to a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months. Throughout the study a specialized dietician will monitor the patients. Blood samples will be collected to assess parameters of bacterial translocation, inflammation and immune activation. To assess compliances with diet, urine samples will be collected too, and stool samples to study changes in gut microbiota. All the samples will be collected at the beginning and 90 days after the inclusion in the study.||||
34184852|NCT00880919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184853|NCT00055913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184854|NCT03895749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|placebo-controlled study material|Phase II, randomized,double-blind, placebo-controlled 2 arm parallel|t|t|t|f
34184855|NCT02397161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184856|NCT00847210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184857|NCT02042963|||COHORT||PROSPECTIVE|||||||
34184858|NCT03705806|||CASE_ONLY||PROSPECTIVE|||||||
34184859|NCT05611320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184860|NCT01471288|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34184861|NCT05695508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Induction Treatment of Arms A, A1, B, D, E, E1, F, F1 contain 6 cycles of Tec-DRd \[Arm A, A1, D\] , Tec-DVRd \[Arm B\], Tal-DRd \[Arm E, E1\] or Tal-DVRd \[Arm F, F1\]. Enrollment will be staggered with Arm A opening first.~Induction therapy (except Arm D) is followed by HDT and a single ASCT according to local SoC. After ASCT, participants will receive maintenance treatment with Tec-D \[Arm A, A1, B, E. F\] or Tal-D \[E1, F1\] Arm C and C1 participants will enter the study at Maintenance Treatment with Tec-D or Tal-DR after induction, HDT, and ASCT according to local SoC (outside of the study).~All Arms will receive maintenance treatment for a max. of 18 cycles or until confirmed progressive disease, death, intolerable toxicity, loss to follow-up, or consent withdrawal, whichever comes first. An optional end of treatment is possible for those patients who have sustained MRD negativity of 12 months.~Periodic safety evaluations will be conducted to ensure that treatment is safe and tolerable."||||
34184862|NCT05965544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After each patient's eligibility has been assessed, numbered and sealed envelopes will be used to conceal assignment status. The same clinician (E.M.) will perform the patient's pre- and post-operative procedures. A researcher who does not know which method was applied to the patient in the perioperative and postoperative follow-ups will be included as double-blind.|The patients were equally randomized into two groups using a computer-generated random number table. In the preoperative period, according to whether FIBP was before or after spinal anesthesia, it was named as a separate group as Group PreS (Pre-Spinal) and Group PostS (Post-Spinal).|f|t|f|t
34184863|NCT03901872|||COHORT||PROSPECTIVE|||||||
34184864|NCT02641782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184865|NCT00003153||||TREATMENT||||||||
34184866|NCT06109636|||CASE_ONLY||PROSPECTIVE|||||||
34184867|NCT05858723|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34184868|NCT00350415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184869|NCT01318239|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184870|NCT02247986|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34184871|NCT02263027|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34184872|NCT02536963|||CASE_ONLY||PROSPECTIVE|||||||
34184873|NCT01378585|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34184874|NCT03659669|||COHORT||PROSPECTIVE|||||||
33753554|NCT03399422|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|One blinded|"Two Arms injectable platelet rich fibrin group: consisted of two subgroups~Experimental group : injectable platelet rich fibrin assisted upper canine retraction Control group: conventional upper canine retraction"|f|f|f|t
34184875|NCT03066947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184876|NCT00649207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753555|NCT02339961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753556|NCT04840550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33753557|NCT01473667|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965266|NCT04714684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33965267|NCT01864473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184877|NCT03562377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of tralokinumab/placebo will contain no evidence of their identity.~Since tralokinumab and placebo are visually distinct and not matched for viscosity, they will be handled and administered by a qualified, unblinded healthcare professional at the trial site who will not be involved in the management of trial subjects."||t|f|t|f
34184878|NCT00555698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184879|NCT01406782|||OTHER||RETROSPECTIVE|||||||
34184880|NCT03350672|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"1a) Ten healthy subjects will be given seven daily doses of TAF/FTC under direct observation to ensure adherence.~1b) Ten healthy subjects will be given one daily dose of TAF/FTC under direct observation to ensure adherence. Morning (not first morning) urine and plasma samples will be collected starting the day the dose is given (1 hr post-dose) and every day thereafter for 6 days.~2) Ten HIV-positive patients who have had undetectable viral loads for greater than 12 weeks (and a recent undetectable viral load in the previous 4 weeks) on an antiretroviral regimen containing TAF/FTC (i.e. Genvoya™, Odefsey™, or Descovy™ in combination with another HIV medication or medications) will have one-time pre-dose urine (early morning) and plasma samples drawn for tenofovir (TFV) concentration, as well as a comprehensive metabolic panel for measurement of creatinine clearance."||||
34184881|NCT02778789|||CASE_CONTROL||PROSPECTIVE|||||||
34184882|NCT04963439|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33753558|NCT04199858|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|A double-blind randomization list was created by an independent researcher to randomize participants into two counterbalanced conditions: participants either receive the nocebo sham medical gel in a blue or in a brown jar. Complete blinding of the researchers during the experiment is not possible due to the nature of conditioning/ suggestion paradigms. Participants are blind with respect to the conditioning/nocebo manipulation.|||||
33753559|NCT04796441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753560|NCT03156790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868850|NCT05217121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for lumbar disc herniation surgery will be included in the study. Patients will be randomly divided into two groups (Group Q = QLB group, Group M = mTLIP group) including 30 patients each, before entering the operating room.|t|f|f|t
33868851|NCT02066311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868852|NCT01650025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33868853|NCT05670769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33868854|NCT02456597|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33868855|NCT04673227|||CASE_ONLY||PROSPECTIVE|||||||
33868856|NCT02061670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868857|NCT05567575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers doing outcome assessments will be kept masked of the treatment allocation||f|f|f|t
33868858|NCT00086970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184883|NCT02009904|||CASE_CONTROL||PROSPECTIVE|||||||
34184884|NCT03666663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study|Randomized placebo controlled study|t|t|t|t
33868859|NCT00942175|RANDOMIZED|CROSSOVER||||NONE||||||
33868860|NCT00169689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33868861|NCT01444248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965268|NCT06087393|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This study is single cohort and plans to enroll a total of 30 patients.||||
33965269|NCT02902380|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33965270|NCT04784845|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"A single intervention cohort will receive one open label intervention (nasal inoculation with 10\^5 CFU N. lactamica).~If any naturally-occurring N. lactamica carriers are identified at screening, they will not attend for inoculation with N. lactamica, but will be invited to remain in the study. They (and their neonates) will undergo the same follow-up visits and sampling as inoculated volunteers. This observational cohort is not considered a separate study arm, and there is no recruitment target for this cohort."||||
33965271|NCT01318265|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34184885|NCT05295095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients under anaesthesia at randomization|Single-center, prospective, controlled, parallel, randomized, single-blind study comparing the conventional extubation technique to two positive pressure extubation techniques|t|f|f|f
34184886|NCT03809104|NA|SINGLE_GROUP||PREVENTION||NONE||elder residents in caring facilities, including nursing home and daycare center 15 participants in nursing home and 15 participants in daycare center||||
34184887|NCT06514014|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open Label Randomized Clinical Trial||||
34184888|NCT06185543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184889|NCT05660577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965272|NCT04496778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34184890|NCT06416384|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blind (outcomes assessor)|It is a randomized controlled, single-blind, experimental study.|f|f|f|t
34184891|NCT00719472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184892|NCT01153529|||||RETROSPECTIVE|||||||
34184893|NCT01039740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34184894|NCT04588571|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, open-label study. Group 1 (n=55): Femoropopliteal proximal bypass. Group 2 (n=55): Recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.||||
34184895|NCT02964143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All patients will undergo blood collection, whatever treatment they will receive. The day of each treatment session, a specially trained staff member, who won't be otherwise related to the study, will perform blood withdrawal and prepare the treatment according to the randomization code in a separate -but neighboring- room. This staff member will then deliver the treatment to the ward where the clinician will inject it into the patient's knee. To preserve patient's blindness, a screen will be placed in order to prevent him/her from seeing the whole procedure (from blood withdrawal to treatment injection).~Evaluation of primary and secondary endpoints will be performed by a blinded assessor who will not know which treatment (PRP/HA combination, HA alone, or PRP alone) was given to the patient. The blinded assessor will not perform any other study-related procedure."||t|f|f|t
34184896|NCT00131248|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34184897|NCT05056389|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study with 20 eligible patients with peritoneal metastases from colorectal cancer||||
33965273|NCT01205529|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All participants and investigators were blinded to the genetic sequencing results at the time of outcome ascertainment|||||
33965274|NCT03698318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33965275|NCT05089240|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33965276|NCT04463277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965277|NCT02775461|||CASE_ONLY||PROSPECTIVE|||||||
33965278|NCT02835599|||COHORT||PROSPECTIVE|||||||
33965279|NCT04192617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965280|NCT02230085|||COHORT||PROSPECTIVE|||||||
33965281|NCT06337630|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor types.||||
33965282|NCT06381427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965283|NCT03816800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33965284|NCT02444156|NA|SINGLE_GROUP||||NONE||||||
33965285|NCT06176859|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A prospective, interventional, and randomized study||||
33965286|NCT05691673|||CASE_CONTROL||PROSPECTIVE|||||||
33965287|NCT02615379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be given blinded data and pictures to enable unbiased assessment.||f|f|f|t
34184898|NCT06425900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184899|NCT01596010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34184900|NCT05021978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A: Open label Part B: Open label titration followed by quadruple-blind, randomized withdrawal|Part A: Single group Part B: Parallel group, randomized withdrawal|t|t|t|t
34184901|NCT01351181|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184902|NCT01896219|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33965288|NCT00958815|||COHORT||CROSS_SECTIONAL|||||||
33965289|NCT03150030|||OTHER||PROSPECTIVE|||||||
33965290|NCT01174641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965291|NCT02343016|||COHORT||CROSS_SECTIONAL|||||||
33965292|NCT06537518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965293|NCT00989040|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965294|NCT05329415|||CASE_CONTROL||PROSPECTIVE|||||||
33965295|NCT05003583|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965296|NCT04060654|NA|SINGLE_GROUP||TREATMENT||NONE||After an initial injection of 300mg SUBLOCADE, all subjects will receive SUBLOCADE doses of 100mg or 300mg based on the medical judgement of the Investigator||||
33965297|NCT02373735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33965298|NCT01540682|NA|SINGLE_GROUP||TREATMENT||||||||
33965299|NCT00363129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33965300|NCT02277795|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33965301|NCT02379832|||CASE_CONTROL||PROSPECTIVE|||||||
33965302|NCT04615676|||COHORT||PROSPECTIVE|||||||
33965303|NCT02639819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965304|NCT02537067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965305|NCT00738010|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33965306|NCT01145703|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33965307|NCT02170701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184903|NCT04042948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomized control parallel||t|f|f|f
33868862|NCT01519596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868863|NCT06385730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868864|NCT02307487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868865|NCT03278600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Tissue-of-origin test||||
33965308|NCT00261937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868866|NCT02218957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965309|NCT00372827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965310|NCT04168047|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33965311|NCT06536491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluators of efficacy study assessments will be masked. The injecting physician and the injection technician or clinical assistant preparing the IP for administration will be unmasked to the identity of the specific investigational product (IP)|Computer generated equal randomization|t|f|f|t
33965312|NCT00613678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34184904|NCT06462599|||CASE_CONTROL||PROSPECTIVE|||||||
33965313|NCT02930109|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33965314|NCT00507182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184905|NCT03780166||SEQUENTIAL||TREATMENT||NONE||||||
34184906|NCT00793897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184907|NCT01929746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34184908|NCT03758040|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34184909|NCT01327482|NA|SINGLE_GROUP||||NONE||||||
33868867|NCT06226909|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33868868|NCT03994328|||COHORT||PROSPECTIVE|||||||
33868869|NCT04624464|||COHORT||PROSPECTIVE|||||||
33868870|NCT06289244|||COHORT||PROSPECTIVE|||||||
33868871|NCT01969487|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|t|f|t
33868872|NCT05788744|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33868873|NCT03665389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965315|NCT04603937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For masking purposes, sham injections will be administered at every monthly visit if an active treatment is not administered. To preserve masking, two investigators are required for this study. The masked Investigator will be responsible for the examinations and safety assessments. The unmasked Investigator will perform the injections and post-treatment assessments.|Participants will be randomized 1:1 into one of two treatment arms: KSI-301 or aflibercept.|t|t|f|t
33965316|NCT02467088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965317|NCT01430104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965318|NCT00459589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965319|NCT03306784|||OTHER||PROSPECTIVE|||||||
33965320|NCT01693276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965321|NCT01488266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965322|NCT02453919|||COHORT||PROSPECTIVE|||||||
33965323|NCT01990898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965324|NCT01039571|||CASE_CONTROL||PROSPECTIVE|||||||
33965325|NCT00125476|RANDOMIZED|PARALLEL||||NONE||||||
33965326|NCT03575182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965327|NCT00293826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965328|NCT02204215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965329|NCT02762877|||OTHER||PROSPECTIVE|||||||
34184910|NCT01582269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868874|NCT05771064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868875|NCT03936283|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33868876|NCT04703036|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and the investigative team are masked. Only the biostatistician will be unmasked to the identity of the active and placebo groups.|Randomized controlled trial, placebo-controlled, double-blind design|t|f|t|f
33868877|NCT06011564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||RCT||||
33868878|NCT00326742|||DEFINED_POPULATION||OTHER|||||||
34184911|NCT03818321|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is randomized double-blinded placebo-controlled trial, and both patients and investigators are blinded. However, a research nurse will not be blinded to the group allocation, and the research nurse will order each patient's medication to the inpatient pharmacy based on the study randomization scheme.||t|t|t|t
34184912|NCT02654769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184913|NCT00045318||||TREATMENT||||||||
34184914|NCT02610114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184915|NCT03813927|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34184916|NCT00692835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184917|NCT06120374|||COHORT||PROSPECTIVE|||||||
34184918|NCT05403424|||OTHER||CROSS_SECTIONAL|||||||
34184919|NCT01260116|||CASE_CONTROL||PROSPECTIVE|||||||
34184920|NCT05204004|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients under investigation for OSA will use both devices (Sunrise solution and overnight polygraphy) simultaneously for a single overnight sleep study. They will be randomised to receive their treatment decision based on either the Sunrise solution or polygraphy. They will be unaware of which device their treatment decision was based on.|A prospective, randomised, blinded pilot study|t|f|f|f
34184921|NCT01577888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184922|NCT03232697|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Different populations including subjects with or without cognitive impairment will be used to determine the accuracy of a short version of the MOCA as compared to the full version of this scale.||||
34184923|NCT01143246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34184924|NCT05546632|||CASE_CONTROL||PROSPECTIVE|||||||
34184925|NCT03957642|||CASE_ONLY||RETROSPECTIVE|||||||
34184926|NCT02606110|||CASE_ONLY||PROSPECTIVE|||||||
34184927|NCT04378543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184928|NCT03986086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34184929|NCT00297258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184930|NCT05897203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A phase 2A open-label randomized controlled clinical trial|t|f|f|f
34184931|NCT03291496|||COHORT||PROSPECTIVE|||||||
34184932|NCT02773316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184933|NCT00290316|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34184934|NCT02484118|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34184935|NCT02528981|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34184936|NCT00485810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184937|NCT00030914|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34184938|NCT02503137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34184939|NCT04772274|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34184940|NCT04295720|NA|SINGLE_GROUP||TREATMENT||NONE||12 participants with PCCI will be recruited to participate in this trial.||||
34184941|NCT03141138|RANDOMIZED|PARALLEL||PREVENTION||NONE|This will be an open-label study. The laboratories in charge of testing will be blinded to the experimental arm, and codes will be used to link the subject and study (without any link to the experimental arm attributed to the subject) to each sample.|||||
33868879|NCT01978821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868880|NCT00992420|||COHORT||PROSPECTIVE|||||||
33868881|NCT01719315|||CASE_CONTROL||PROSPECTIVE|||||||
34184942|NCT01258686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184943|NCT06221306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753561|NCT01703026|||COHORT||PROSPECTIVE|||||||
33753562|NCT06172972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|t|f|f|f
33753563|NCT02453685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753564|NCT02668523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753565|NCT00871052|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33753566|NCT05081453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blind|Parallel controlled triple-blind randomized clinical trial.|f|t|t|t
33753567|NCT04560491|||CASE_CONTROL||RETROSPECTIVE|||||||
33753568|NCT02400138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753569|NCT04650555|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33753570|NCT06732453|NA|SINGLE_GROUP||OTHER||NONE||||||
33753571|NCT01279499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753572|NCT00345449|RANDOMIZED|PARALLEL||||SINGLE||||||
33753573|NCT02456168|||COHORT||CROSS_SECTIONAL|||||||
33868882|NCT06001112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868883|NCT00703001|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33868884|NCT00754481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868885|NCT01034735|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33868886|NCT03714191|||COHORT||PROSPECTIVE|||||||
33868887|NCT03383497|||COHORT||RETROSPECTIVE|||||||
33868888|NCT05259722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868889|NCT05111262|RANDOMIZED|PARALLEL||OTHER||NONE||Randomization will occur using a 1:1 ratio with random numbers generated using SAS 9.4||||
33965330|NCT02087228|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066392|NCT04091204|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, multicentre, open-label Phase 2 study||||
34066393|NCT05637190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753574|NCT05891847|||CASE_CONTROL||RETROSPECTIVE|||||||
33753575|NCT01342874|||CASE_CONTROL||PROSPECTIVE|||||||
33753576|NCT00174525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33868890|NCT00737191|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34066394|NCT02481180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066395|NCT01139671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34066396|NCT00364078|||||CROSS_SECTIONAL|||||||
34066397|NCT04625933|||COHORT||PROSPECTIVE|||||||
34066398|NCT02254798|||COHORT||PROSPECTIVE|||||||
34066399|NCT00892515|NA|SINGLE_GROUP||OTHER||SINGLE||||||
33868891|NCT05602038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomly allocated to the procedure through closed envelopes and so syringes and medication will be prepared and labelled by anesthetist other than the anesthetist giving the block|randomized control study|f|t|f|t
34184944|NCT04330404|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the interventionist, it is important to build relationships with participants through baseline interviews. The pre-test will be conducted by the interventionist. Assessors at post-intervention, and 3-month follow-up will be blind to the group allocation.|The experimental group will receive the Cognitive strategy training. The active control group will receive group interactive game.|f|f|f|t
34066400|NCT01317524|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34184945|NCT03498937|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34184946|NCT05429008|NA|SINGLE_GROUP||OTHER||NONE||||||
34184947|NCT00118417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34184948|NCT04818788|||COHORT||PROSPECTIVE|||||||
34184949|NCT05279677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184950|NCT04100252|||COHORT||PROSPECTIVE|||||||
34184951|NCT02426203|||CASE_ONLY||PROSPECTIVE|||||||
34184952|NCT00102817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184953|NCT01916954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184954|NCT02156622|||COHORT||PROSPECTIVE|||||||
34184955|NCT06383481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34184956|NCT05592717|||COHORT||PROSPECTIVE|||||||
34184957|NCT01021891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184958|NCT05586438|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34184959|NCT01562093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753577|NCT05441085|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184960|NCT01129856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34184961|NCT01321099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34184962|NCT06595719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753578|NCT05069090|||COHORT||PROSPECTIVE|||||||
33753579|NCT05426434|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo, or SP and DP) followed by one drug on days 2 and 3 (placebo or DP). One placebo that mimics the appearance of DP will be used. A randomization list will be computer generated by a member of the project who will not be directly involved in the conduct of the study. The randomization list will include consecutive treatment numbers with corresponding random treatment assignments. Randomized codes will correspond to the 2 treatment arms using permuted variable sized blocks.|Double blinded randomized controlled trial|t|t|t|t
33753580|NCT00253669|||CASE_CONTROL||PROSPECTIVE|||||||
33753581|NCT05938985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33868892|NCT01575106|NA|SINGLE_GROUP||OTHER||NONE||||||
33868893|NCT05184673|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Each group of participants will complete four different yoga classes - hatha thermo-neutral, flow thermo-neutral, hatha hot, and flow hot - in different orders, keeping the time of the class, the other participants in the class, the instructor, and the sequence of the moves the same.||||
33868894|NCT01830855|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33868895|NCT06367842|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33868896|NCT05678387|||CASE_CONTROL||PROSPECTIVE|||||||
33868897|NCT00966342|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33868898|NCT03023930|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Note: Care Providers and Research Associates are masked during Baseline Evaluation Period|||||
33868899|NCT04792567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868900|NCT03574857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868901|NCT02071212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868902|NCT03624933|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label intervention of contingent reinforcement and behavioral support to try to enhance cannabis abstinence for 28 days with people with Major Depressive Disorder. We will analyze data post hoc from this study as a function of subjects who attain abstinence versus those who do not.||||
33868903|NCT00592267|||CASE_ONLY||PROSPECTIVE|||||||
33868904|NCT03280654|||OTHER||CROSS_SECTIONAL|||||||
33868905|NCT05704764|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two group randomized design.||||
33868906|NCT03722342|NA|SEQUENTIAL||TREATMENT||NONE||This was mTPI design to start with optimal dose and next dose level is selected accroding to DLT occurrance||||
33868907|NCT03456648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single dose pharmacokinetics study||||
33868908|NCT04497896|||OTHER||PROSPECTIVE|||||||
33868909|NCT04983173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868910|NCT02130739|||COHORT||PROSPECTIVE|||||||
33868911|NCT04492098|||OTHER||CROSS_SECTIONAL|||||||
33868912|NCT04745039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868913|NCT02005991|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33868914|NCT05676684|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Prospective, randomised, open-label, two-treatment, two-period, cross-over trial|f|f|f|t
33868915|NCT03932370|||CASE_ONLY||PROSPECTIVE|||||||
33868916|NCT01040351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066401|NCT01881698|||COHORT||PROSPECTIVE|||||||
34066402|NCT03807622|||CASE_ONLY||PROSPECTIVE|||||||
34066403|NCT03054285|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention study model is a randomized block design using a 1:1 allocation scheme||||
34066404|NCT00224900|||COHORT||CROSS_SECTIONAL|||||||
34066405|NCT00634686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868917|NCT01966328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868918|NCT01015768|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
33868919|NCT02509182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33868920|NCT03827824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184963|NCT01408173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184964|NCT00065078|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184965|NCT06367140|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The evaluators were blinded to the intervention details of the participants.||f|f|f|t
34184966|NCT00801177|NON_RANDOMIZED|PARALLEL||||NONE||||||
33965331|NCT06526858|NA|SINGLE_GROUP||TREATMENT||NONE||The HyperQure RDN System consists of a Generator that generates RF(Radiofrequency) energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds. The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the RDN procedure by CTA.||||
34184967|NCT02688777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel: participants are assigned to one of two or more groups in parallel for the duration of the study.|f|f|f|t
34184968|NCT02926885|RANDOMIZED|PARALLEL||||NONE||||||
34184969|NCT01740648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184970|NCT01709084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184971|NCT04396639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184972|NCT04078425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34184973|NCT05109468|||OTHER||PROSPECTIVE|||||||
34184974|NCT05811663|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34184975|NCT05614596|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34184976|NCT01942837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184977|NCT06278714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the outcome assessor will not know in which group is each participant, and the investigator will receive the data without knowing which data is from which group||f|f|t|t
34184978|NCT00981110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184979|NCT05858307|||COHORT||PROSPECTIVE|||||||
34184980|NCT01385293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184981|NCT06373952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184982|NCT03559374|||COHORT||PROSPECTIVE|||||||
34184983|NCT05644158|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Prospective randomized controlled trial~1. Exercise group~2. Revascularization group~3. Healthy control group"||||
34184984|NCT00002002||||TREATMENT||DOUBLE||||||
34184985|NCT02399176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34184986|NCT00781313|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34184987|NCT00694941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34184988|NCT06080841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"A pilot study in adult women diagnosed with cervical cancer in locally advanced stages (IB3-IVA), who are selected to undergo treatment with concomitant QT-RT followed by BT, by the Functional Gynecology Oncology Unit of the National Cancer Institute.~The intervention will be supplementation with different doses of curcumin. Patients will eat a standard diet according to their requirements. The aim is to describe the expression of p53 protein levels and apoptosis in tumor cells from these patients. Patients will be monitored by a nutritionist and receive the corresponding care from the medical oncologist.~Sample size. Because this is a pilot study, the sample size will be at the researcher's convenience; 5 patients per group, 30 patients with locally advanced cervical cancer, who are candidates to receive standard treatment of concomitant chemoradiotherapy, followed by brachytherapy.~Blood, urine, fecal, and cervicovaginal cytology samples will be collected."||||
34184989|NCT04195841|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups were made one test and control. All the subjects required rehabilitation with implants.In the test group Z shaped incision was placed. in control group sulcular H shaped incision was placed.||||
34184990|NCT03286517|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|All the participants were told for injecting the kisspeptin.|All the groups were injected with exogenous IV kisspeptin according to the body weight.||||
34184991|NCT05952882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184992|NCT04502082|NA|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
34184993|NCT04786717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34184994|NCT04148365|||CASE_ONLY||CROSS_SECTIONAL|||||||
34184995|NCT00275509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34184996|NCT03382353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34184997|NCT06601764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34184998|NCT02978976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34184999|NCT01120964|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34185000|NCT04926714|||COHORT||PROSPECTIVE|||||||
34185001|NCT04577521|||COHORT||PROSPECTIVE|||||||
34185002|NCT01926457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34185003|NCT00473564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185004|NCT00489593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185005|NCT00000716||||TREATMENT||NONE||||||
34185006|NCT06591403|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34185007|NCT00544297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185008|NCT00000288||CROSSOVER||TREATMENT||DOUBLE||||||
34185009|NCT05136014|||COHORT||PROSPECTIVE|||||||
34185010|NCT04663282|RANDOMIZED|PARALLEL||TREATMENT||NONE||INS068 campared with Insulin degludec, both in Combination with One or Two Oral Antidiabetics||||
34185011|NCT04089995|||CASE_ONLY||RETROSPECTIVE|||||||
34185012|NCT00646880|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34185013|NCT05342714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34185014|NCT06238258|NA|SINGLE_GROUP||OTHER||NONE||||||
34185015|NCT02599246|||COHORT||PROSPECTIVE|||||||
34185016|NCT00043979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185017|NCT06214065|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34185018|NCT01955421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185019|NCT04593537|||COHORT||PROSPECTIVE|||||||
34185020|NCT02036814|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34185021|NCT05208099|||CASE_CONTROL||PROSPECTIVE|||||||
34185022|NCT06141525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868921|NCT01637220|||CASE_CONTROL||PROSPECTIVE|||||||
34185023|NCT01034332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185024|NCT01749215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185025|NCT00110448|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34185026|NCT06145620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34185027|NCT00658359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185028|NCT02551939|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34185029|NCT02056587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185030|NCT01162642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33868922|NCT04881071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34185031|NCT06398756|RANDOMIZED|PARALLEL||TREATMENT||NONE||assignment||||
33868923|NCT02431897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33868924|NCT03377842|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868925|NCT03236220|NA|SINGLE_GROUP||PREVENTION||NONE|Open Label|||||
33868926|NCT03887533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868927|NCT00829179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33868928|NCT02887404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868929|NCT03399981|||COHORT||OTHER|||||||
33868930|NCT00838292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33868931|NCT01567657|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33868932|NCT05279248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868933|NCT02428543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868934|NCT03357250|||COHORT||PROSPECTIVE|||||||
33868935|NCT00565526|||||PROSPECTIVE|||||||
33868936|NCT05687747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868937|NCT00830245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868938|NCT01518881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185032|NCT00664625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185033|NCT02392624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185034|NCT05275283|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34185035|NCT05889676|||COHORT||PROSPECTIVE|||||||
34185036|NCT00006086||||TREATMENT||||||||
34185037|NCT04379895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185038|NCT00757302|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185039|NCT04184089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34185040|NCT01339143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185041|NCT03652805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185042|NCT04400201|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34185043|NCT05932823|||COHORT||PROSPECTIVE|||||||
33868939|NCT01524198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868940|NCT04588662|||OTHER||PROSPECTIVE|||||||
34185044|NCT02633306|NA|SINGLE_GROUP||TREATMENT||NONE||This is a device study and therefore does not have a drug, biological/vaccine or combination product involved.||||
34185045|NCT01206725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185046|NCT01523106|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34185047|NCT05940480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors were blinded to the group allocation of the participants.|This study is a 16-week, randomized controlled trial. Individuals at-risk for COPD are randomized to either TCM Daoyin intervention group or health education control group.|f|f|f|t
34185048|NCT02318706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34185049|NCT01076361|||COHORT||PROSPECTIVE|||||||
34185050|NCT00892099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34185051|NCT00759941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185052|NCT04316013|RANDOMIZED|PARALLEL||OTHER||SINGLE|The propofol-TIVA/sevoflurane element of each arm will have a single blind (patient blinded), as the administering anesthesiologist cannot be blinded to allocation. The lidocaine infusion or no lidocaine infusion element of each ARM will be blinded to the patient . The anaesthetic team and research team caring for the patient will not be blinded to the lidocaine infusion/no lidocaine infusion element of the randomisation ARM|This is an event-driven, international multicentre, randomised controlled trial with a 2x2 factorial design. Patients with stage I-III colorectal cancer or stage I-IIIa NSCLC are eligible and will be randomised in the ratio of 1:1:1:1 using permuted block randomisation with stratification by cancer type (Colon, Rectal or NSCLC), and by site to receive either 1) sevoflurane maintenance anaesthesia and lidocaine infusion or 2) sevoflurane maintenance anaesthesia; or 3), propofol maintenance anaesthesia and lidocaine infusion or 4), propofol maintenance anaesthesia .|t|f|f|f
34185053|NCT00927953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185054|NCT02304367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185055|NCT00090207|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34185056|NCT06067360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185057|NCT02819804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185058|NCT02785523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185059|NCT01790724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185060|NCT01867671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34185061|NCT00599339|||COHORT||PROSPECTIVE|||||||
34185062|NCT02902562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185063|NCT06365632|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34185064|NCT03823742|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The proposed study is a randomized trial with a two group design. Children will be equally likely to be randomized to either CBT or a low FODMAP diet. There is no placebo treatment and no healthy controls are to be studied. Subjects will be stratified based on age (7-9 vs 10-12), sex, baseline pain (mean pain frequency: less than or equal to 50% of the rated intervals or \> 50% of the rated intervals, as reported on the baseline pain and stool diary) and PedsQL.||||
34185065|NCT05933850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34185066|NCT02868632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185067|NCT05488535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185068|NCT01660724|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34185069|NCT00594841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185070|NCT01083771|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34185071|NCT03461614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185072|NCT02041624|||||PROSPECTIVE|||||||
34185073|NCT01026480|||COHORT||PROSPECTIVE|||||||
34185074|NCT03229785|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34185075|NCT02154698|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34185076|NCT00735488|||COHORT||RETROSPECTIVE|||||||
34185077|NCT04773535|||COHORT||CROSS_SECTIONAL|||||||
34185078|NCT06118398|||COHORT||RETROSPECTIVE|||||||
34185079|NCT00722306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185080|NCT04259996|||COHORT||PROSPECTIVE|||||||
34185081|NCT05019911|||COHORT||PROSPECTIVE|||||||
34185082|NCT05741671|||CASE_CONTROL||PROSPECTIVE|||||||
34185083|NCT04542239|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34185084|NCT02233361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34185085|NCT05853536|||OTHER||RETROSPECTIVE|||||||
34185086|NCT00998296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185087|NCT02831972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185088|NCT00087841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185089|NCT04775628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Within subject design||||
33868941|NCT05506176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868942|NCT01973374|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33868943|NCT02441413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868944|NCT01214694|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33868945|NCT01651858|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33868946|NCT04183283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33868947|NCT04870411|||CASE_CONTROL||PROSPECTIVE|||||||
33868948|NCT04725695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33868949|NCT02601677|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868950|NCT01767675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868951|NCT06216379|||COHORT||CROSS_SECTIONAL|||||||
33965332|NCT00184431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965333|NCT05516420|||COHORT||RETROSPECTIVE|||||||
33965334|NCT04629183|||COHORT||PROSPECTIVE|||||||
34185090|NCT02535806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185091|NCT00261820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185092|NCT00970996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185093|NCT05747794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This trial consists of an open-label dose optimization lead-in component (phase 2) followed by a double-blinded, randomized, placebo-controlled phase 3 component.|t|f|t|f
34185094|NCT06438770|||COHORT||PROSPECTIVE|||||||
34185095|NCT03906019|||CASE_ONLY||RETROSPECTIVE|||||||
33868952|NCT05774925|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20).||||
33868953|NCT01936636|||||PROSPECTIVE|||||||
33868954|NCT05514990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868955|NCT01979159|NA|SINGLE_GROUP||TREATMENT||NONE||Single-case experimental design; multiple baseline design across behaviors and participants||||
33868956|NCT02689531|||COHORT||PROSPECTIVE|||||||
33868957|NCT02660203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33868958|NCT05692492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868959|NCT02017353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868960|NCT01508104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868961|NCT01434420|NA|SINGLE_GROUP||||NONE||||||
33868962|NCT04943081|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients with age group ≥ 18 years old with renal stones candidate for PCNL with pre-operative estimated GFR less than 90 ml/min/1.7 m2 and ≥ 15 ml/min/1.7 m2.||||
33868963|NCT02009436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868964|NCT04195854|||OTHER||RETROSPECTIVE|||||||
33868965|NCT03962738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868966|NCT01018628|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33868967|NCT00471705|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868968|NCT05449990|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||control group: 150 patients and one family member experimental group: 150 patients and one family member; 90 healthcare professionals (no intervention, convenience sampling. cross-sectional data collection)||||
34185096|NCT03352037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185097|NCT05652439|||COHORT||RETROSPECTIVE|||||||
34185098|NCT01140126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185099|NCT01164709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185100|NCT00541385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185101|NCT01792895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185102|NCT04913077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Submucosal gastric Tumors up to 2 centimeters of size||||
34185103|NCT02941601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185104|NCT04030910|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"All eligible patients will be recruited to receive the intervention (LIFEView)."||||
34185105|NCT00560352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185106|NCT03830541|||COHORT||RETROSPECTIVE|||||||
34185107|NCT05298956|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34185108|NCT05105204|||CASE_ONLY||PROSPECTIVE|||||||
34185109|NCT04740372|||OTHER||OTHER|||||||
34185110|NCT00422136|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34185111|NCT01699438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185112|NCT01921309|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34185113|NCT00000670||||TREATMENT||NONE||||||
34185114|NCT05805254|||OTHER||PROSPECTIVE|||||||
34185115|NCT00929695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868969|NCT03082105|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34185116|NCT00460083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34185117|NCT02765516|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34185118|NCT00555516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34185119|NCT04412980|||COHORT||PROSPECTIVE|||||||
34185120|NCT02327832|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185121|NCT02851472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|iNO vs nitrogen will be administered from tanks labeled with a code number that is known by the manufacturer and a campus safety officer but masked to investigators and to bedside personnel.|subjects are randomize into either of two groups: intervention or placebo|t|t|t|f
34185122|NCT00148083|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34185123|NCT05384652|||COHORT||PROSPECTIVE|||||||
34185124|NCT01850654|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34185125|NCT01635153|RANDOMIZED|PARALLEL||TREATMENT||NONE||Protein-calorie supplement plus micronutrient vs micronutrient alone||||
33868970|NCT05561361|||COHORT||PROSPECTIVE|||||||
33868971|NCT04688151|NA|SINGLE_GROUP||TREATMENT||NONE|This study will use the 3+3 design in the dose escalation phase.|Dose level 1,Dose level 2,3+3 design in the dose escalation.||||
33868972|NCT00239811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868973|NCT01180478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868974|NCT00050154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33868975|NCT00120861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868976|NCT03537144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33868977|NCT02726087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33868978|NCT01687075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33868979|NCT04425720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33868980|NCT01129362|||COHORT||CROSS_SECTIONAL|||||||
33868981|NCT00587002|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33868982|NCT00912847|||||PROSPECTIVE|||||||
33868983|NCT00860184|||COHORT||PROSPECTIVE|||||||
33868984|NCT00508079|||COHORT|||||||||
33868985|NCT02751762|||COHORT||PROSPECTIVE|||||||
33868986|NCT02984579|||OTHER||CROSS_SECTIONAL|||||||
33868987|NCT03885791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33868988|NCT02852603|||COHORT||RETROSPECTIVE|||||||
33868989|NCT05492695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33868990|NCT02073175|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066406|NCT01897792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34066407|NCT01146028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066408|NCT06052514|||COHORT||PROSPECTIVE|||||||
34066409|NCT03653312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One blinded outcome assessor (physiotherapists) will perform measurements of functional capacity, patient reported outcome, and cognition. Statistical analysis will be performed by a blinded statistician and a blinded interpretation of the results will be performed before breaking the randomization code.|Parallel group, assessor blinded, randomized controlled trial|f|f|f|t
34066410|NCT02983253|||COHORT||CROSS_SECTIONAL|||||||
34066411|NCT04178616|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study is single-group epidemiologic study, without any control group.||||
34185126|NCT05744817|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Due to the nature of the study groups, blinding is not possible.|All participants will perform training 5 days/week for 6 weeks. Participants will then be randomly allocated at a 1:1:1 ratio to stop training (control), or to perform training 1 or 3 days/week for the next 12 weeks.||||
34185127|NCT05788159|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.~Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH"||||
34185128|NCT00624182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185129|NCT04864093|||COHORT||PROSPECTIVE|||||||
34185130|NCT04342533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185131|NCT02757508|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34185132|NCT01483261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185133|NCT04955691|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34185134|NCT01289002|||COHORT||PROSPECTIVE|||||||
34185135|NCT02975375|||COHORT||RETROSPECTIVE|||||||
34185136|NCT00274729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185137|NCT05097963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185138|NCT02955173|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34185139|NCT01635504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185140|NCT02183649|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34185141|NCT01267500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185142|NCT01560832|||COHORT||PROSPECTIVE|||||||
34185143|NCT04295447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185144|NCT03418714|NA|SINGLE_GROUP||OTHER||NONE|Participants will not be aware of exact doses salvinorin A (i.e. they will be told they may receive placebo or up to a moderately high dose of of salvinorin A).|||||
34185145|NCT04477096|NA|SEQUENTIAL||OTHER||NONE||||||
34066412|NCT03609190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34066413|NCT05464082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185146|NCT04187781|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34185147|NCT06069375|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185148|NCT02283827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185149|NCT02592590|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34185150|NCT01173367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185151|NCT01838096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185152|NCT03181932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185153|NCT00165997|||||PROSPECTIVE|||||||
34185154|NCT03387397|||COHORT||OTHER|||||||
34185155|NCT05513781|||COHORT||PROSPECTIVE|||||||
34185156|NCT04152941|||COHORT||RETROSPECTIVE|||||||
34185157|NCT06029829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185158|NCT03770767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066414|NCT05479851|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34066415|NCT03307187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066416|NCT03996226|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34066417|NCT04229056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the nature of the intervention, masking participants and investigators is not possible. Outcome assessors will be masked to the group allocation of participants.|Two parallel groups will be included in this study|f|f|f|t
34185159|NCT00256568|||COHORT||PROSPECTIVE|||||||
34185160|NCT00905866|||CASE_ONLY||PROSPECTIVE|||||||
34185161|NCT05682196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185162|NCT03004937|NA|SINGLE_GROUP||SCREENING||NONE||||||
34185163|NCT02027441|||COHORT||PROSPECTIVE|||||||
33868991|NCT05378997|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part I: Multiple topical doses of TCP-25 will be administered in 3 sequential dose groups, each of 8 subjects. Within each cohort, the subjects will receive TCP-25 on one wound on each thigh and placebo on one wound on each thigh in a randomized fashion as topical treatment. In Part II: Multiple topical doses of TCP-25 will be administered to 6 patients with non-healing leg ulcers. In Part III: Up to 4 dose levels of TCP-25 will be administered in up to 5 patients with DEB by topical application of TCP-25 gel of two concentrations.|t|t|t|t
33868992|NCT01976520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066418|NCT03214549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34066419|NCT03776526|||COHORT||PROSPECTIVE|||||||
34185164|NCT03366077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||double-blinded, randomized, placebo-controlled, parallel-group|f|f|t|f
34185165|NCT03449290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185166|NCT01976091|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34185167|NCT01981382|||CASE_CONTROL||PROSPECTIVE|||||||
34185168|NCT01755182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185169|NCT01065987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185170|NCT02178345|||COHORT||PROSPECTIVE|||||||
34185171|NCT02607709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185172|NCT00951340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185173|NCT04840823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185174|NCT02102178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185175|NCT01582893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185176|NCT04254380|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects who meet the eligibility criteria will be centrally randomized 1:1 in an open-label fashion to receive either Gan \& Lee Insulin Lispro Injection or Humalog for 26 weeks. Randomization will be stratified by country.||||
34185177|NCT06204198|||COHORT||RETROSPECTIVE|||||||
34185178|NCT01764880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185179|NCT04315740|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The exposure was generated in small adjacent chamber and thereby led into the exposure chamber using a pipe connection and a small negative pressure. Thus, the exposure could not be observed.|A randomised double-blinded crossover study|t|f|t|t
34185180|NCT02465619|||CASE_ONLY||PROSPECTIVE|||||||
34185181|NCT04836780|RANDOMIZED|PARALLEL||PREVENTION||NONE|The study participants and the clinicians who will evaluate post-treatment outcomes will be known to group assignment. The clinical research team will not be blinded to group assignment|This is a prospective, multicentre, phase 3, parallel-group, randomized and controlled trial that is open-label to investigators, participants and clinical outcome assessors||||
33753582|NCT03531424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753583|NCT06336616|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33753584|NCT06733350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066420|NCT02334384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066421|NCT00003781||||TREATMENT||||||||
34066422|NCT02720861|||COHORT||CROSS_SECTIONAL|||||||
34066423|NCT04290377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Impossible to mask participants and care providers due to using a device that is so obvious.|Phase1 (chronic stroke): with-in group (one group) multiple measurements Phase2 (subacute stroke): Randomized controlled study. Control (OT plus OT) vs Experimental (OT plus BMI-assisted OT)|f|f|t|t
34066424|NCT04060771|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|Patients will be divided between two groups, Group P will receive single dose of palonosetron whereas Group D will receive a single dose of dexamethasone during general anesthesia.|t|f|t|f
34066425|NCT02508415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185182|NCT02129127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185183|NCT05740501|||COHORT||PROSPECTIVE|||||||
34185184|NCT02640287|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185185|NCT04941677|||CASE_ONLY||CROSS_SECTIONAL|||||||
34185186|NCT02152293|||COHORT||PROSPECTIVE|||||||
34185187|NCT03869047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185188|NCT04754048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Three different patient groups treated with the Avance Solo NPWT System||||
34185189|NCT02660372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34185190|NCT06002724|||OTHER||PROSPECTIVE|||||||
34185191|NCT02253862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185192|NCT02342028|||CASE_CONTROL||PROSPECTIVE|||||||
34185193|NCT02461758|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34185194|NCT06212726|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34185195|NCT04609176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185196|NCT06286488|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185197|NCT00198822|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34185198|NCT03370432|||OTHER||PROSPECTIVE|||||||
34185199|NCT02806102|||COHORT||PROSPECTIVE|||||||
34185200|NCT00105781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185201|NCT04790721|||COHORT||CROSS_SECTIONAL|||||||
33868993|NCT01686776|NON_RANDOMIZED|PARALLEL||OTHER||NONE||3 parallell Groups were measured regarding plasma volume and transcapillary escape rate of albumin where commercial 125I-iodinated human serum albumin was compared to hospital manufactured 123I- iodinated human serum albumin||||
34185202|NCT03599869|||CASE_ONLY||RETROSPECTIVE|||||||
34185203|NCT05174403|||CASE_CONTROL||PROSPECTIVE|||||||
34185204|NCT00132704|||COHORT||PROSPECTIVE|||||||
34185205|NCT01904994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185206|NCT02642016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185207|NCT03773276|NA|SINGLE_GROUP||PREVENTION||NONE||This is a feasibility (efficacy and safety) trial that tests the Norepinephrine boluses for the prevention of postreperfusion syndrome during liver transplantation operation.||||
34185208|NCT05133141|||COHORT||PROSPECTIVE|||||||
34185209|NCT02768584|||CASE_CROSSOVER||PROSPECTIVE|||||||
34185210|NCT00756613|||COHORT||PROSPECTIVE|||||||
34185211|NCT02350140|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34185212|NCT02306317|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185213|NCT05647148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled study||||
34185214|NCT05439915|||OTHER||CROSS_SECTIONAL|||||||
34185215|NCT01829906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185216|NCT01886066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an Investigator-Initiated Prospective Trial (not a clinical trial, as ICG not a novel drug that is being used as intervention).||||
33868994|NCT00381199|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34185217|NCT01902095|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34185218|NCT01853735|||COHORT||PROSPECTIVE|||||||
34185219|NCT00681278|||COHORT||RETROSPECTIVE|||||||
33868995|NCT01529177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33868996|NCT04002037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33868997|NCT00443807|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33965335|NCT02755545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965336|NCT04063384|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33965337|NCT05846828|||COHORT||RETROSPECTIVE|||||||
33965338|NCT04466774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965339|NCT04154566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).|They were assigned randomly into two equal groups. Group (A) the study group received aerobic exercise in addition to selected physical therapy program. And group (B) the control group received the same selected physical therapy program only. The treatment was conducted for one hour, three times / weak for three successful months.|f|f|f|t
33965340|NCT03108391|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parellel Assignment||||
33965341|NCT05409131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965342|NCT01289431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33965343|NCT05054166|||CASE_ONLY||RETROSPECTIVE|||||||
33965344|NCT02535052|||CASE_CONTROL||PROSPECTIVE|||||||
33965345|NCT06538324|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The principal investigator will have exclusive access to the randomization code, which specifies the order of administration (either starting with HOSO or omega-3). This code is generated by an external statistician. The PI will ensure that the identical boxes containing capsules (both HOSO and Omega-3) are marked only with an Identification (ID). The randomization code will remain unknown to the participant, care provider, and outcomes assessor until after the primary outcome data has been analyzed.|Randomized, controlled, double - blind, crossover study.|t|t|f|t
33965346|NCT04539509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome (recovery) is determined using a 3 step approach. Each assessor responsible for one of the three steps, will be blind to at least ONE other recovery determinant.||f|f|f|t
33965347|NCT04624061|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative effectiveness cluster-randomized trial||||
33965348|NCT04937751|||COHORT||PROSPECTIVE|||||||
33965349|NCT01150513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965350|NCT04005105|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965351|NCT02551003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066426|NCT00635986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066427|NCT03055494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066428|NCT02305524|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066429|NCT00653978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185220|NCT03891849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185221|NCT03586154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators were not allowed to know randomization codes and block size until all calculations and measurements had been entered into the database for all patients. All medical caregivers, investigators and patients were blinded to group allocation. One hour before the injection procedure of an enrolled patient, a nurse (not otherwise participating in the study) opened a sealed opaque envelope containing group allocation, and then filled the assigned drug injection for each patient according to the protocol of randomization.||t|t|t|f
34185222|NCT03455595|||OTHER||PROSPECTIVE|||||||
34185223|NCT00930046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34185224|NCT06523920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185225|NCT01241201|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34185226|NCT00988728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185227|NCT04615832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185228|NCT02870907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185229|NCT00713518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185230|NCT05854238|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||multicenter, open, single design, researcher-led, exploratory study||||
34185231|NCT02565108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33868998|NCT05571228|NA|SINGLE_GROUP||TREATMENT||NONE||Consultation with our lived-experience advisory group, consisting of service-users and family members, supports our decision to use a single-arm, non-randomized trial design. All participants recruited into the study will receive the intervention. Results of single arm interventions can provide rich data using data analytic techniques such as Reliable Change Index and will allow us to examine mediators of change from the intervention to continue to refine its efficacy.||||
33868999|NCT00917527|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34185232|NCT03490695|RANDOMIZED|PARALLEL||PREVENTION||NONE||"For the first 12-month of the study, the intervention will not be implemented as this is a stepped-wedged design. During this time period, primary outcome (adoption ratings) and secondary outcome (Systolic BP) data will be collected at the CHPS Zones following TASSH training and the PFOs will provide support to their assigned CHPS zones to prepare to implement the TASSH protocol.~Each CHPS zones will then be randomly assigned to one of the two intervention arms: Group A will receive the Practice Facilitation Strategy at 12 months and Group B will initially serve as a Usual Care comparison group. Group B will then receive Practice Facilitation beginning 24 months into the trial, as this is a stepped wedge design. Sustainability for groups A and B will be assessed one year after the end of the intervention."||||
34185233|NCT03513939|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, single arm||||
34185234|NCT03543878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be randomly assigned to one of two study arms. One group will receive the Flicker exposure for 8 weeks while the other group will receive the active exposure for 4 weeks.|t|f|f|t
34185235|NCT02740023|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34185236|NCT04529018|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Scans will be assessed by two independent nuclear medicine physicians, who will be blinded to patient identifiable data when analysing PET-CT scans.|Phase I single-centre, open-label, micro-dosing study|f|f|f|t
34185237|NCT02881606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding was done for the plastic surgeon (care provider) during lip repair and for the outcome assessor||f|t|f|t
34185238|NCT04287582|||OTHER||PROSPECTIVE|||||||
34185239|NCT02832115|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34185240|NCT04605809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185241|NCT00427453|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34185242|NCT05437406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185243|NCT01519921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185244|NCT02475694|||COHORT||PROSPECTIVE|||||||
34185245|NCT00654771|||CASE_ONLY||PROSPECTIVE|||||||
34185246|NCT00264732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185247|NCT05182749|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34185248|NCT04230811|||CASE_ONLY||CROSS_SECTIONAL|||||||
34185249|NCT02791672|||COHORT||PROSPECTIVE|||||||
34185250|NCT02073058|||COHORT||PROSPECTIVE|||||||
34185251|NCT01637441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185252|NCT05380817|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185253|NCT01039519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185254|NCT02434406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185255|NCT03461588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185256|NCT05811286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185257|NCT03963258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34185258|NCT00803569|NA|SINGLE_GROUP||TREATMENT||NONE||All patients received the same study treatment.||||
34185259|NCT06003894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||360 degree expanded diaphragm breathing|f|f|f|t
34185260|NCT04921072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Fifty participants will be randomly assigned to two groups: constant and variable practice condition group (CG and VG). The pretest-posttest design will be applied.~All participants will go through MRI scanning and EEG measurements. All participants will perform a pretest (baseline) consisting of 15 trials of SPSIC (1-3) and MRCP - motor related cortical potential, as the specific type of event related potential. The testing will start with MRCP, then SPSIC 1, then SPSIC 2, and will finish with SPSIC 3. The testing will be scheduled in blocked order. After completing the whole training program, each participant will perform a posttest analogically to the pretest."||||
34185261|NCT00843219|||CASE_ONLY||PROSPECTIVE|||||||
34185262|NCT02556359|||CASE_ONLY||PROSPECTIVE|||||||
34185263|NCT04995952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185264|NCT04855526|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34185265|NCT01817270|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34185266|NCT00712439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34185267|NCT03310918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185268|NCT02393378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185269|NCT01391546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185270|NCT02677883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34185271|NCT00919321|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34185272|NCT06190704|||COHORT||RETROSPECTIVE|||||||
34185273|NCT05654818|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34185274|NCT01378871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185275|NCT03352609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized double blind control using a sham rTMS system|Randomized, double blind, control|t|t|t|t
34185276|NCT04200599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185277|NCT04623632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34185278|NCT05484895|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Intervention involves demonstration of HIV self-testing and access to a mobile health application to promote HIV self-testing, HIV behavioral risk reduction, and linkage to care|f|f|f|t
34185279|NCT04468984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185280|NCT01046708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185281|NCT02198378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185282|NCT04327804|||CASE_ONLY||PROSPECTIVE|||||||
33869000|NCT02746133|||COHORT||PROSPECTIVE|||||||
33869001|NCT02032550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33965352|NCT03156517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the doctor who assesses the primary outcome measures at 3 and 6 months and the participant are unaware of which of the two targets is stimulated in the two randomization periods.|Randomized allocation of half the patients to be stimulated the first 3 months in the VIM-nucleus of the thalamus (VIM) and then 3 months in the posterior subthalamic area (PSA), and for the other half the first 3 months in the PSA and the next 3 months in the VIM|t|f|f|t
33965353|NCT05358561|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants will not know what type of bread to eat|Cross over|t|f|f|f
33965354|NCT06024902|||COHORT||RETROSPECTIVE|||||||
33965355|NCT01882231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965356|NCT04321733|||COHORT||PROSPECTIVE|||||||
33965357|NCT04670029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965358|NCT00005500|||COHORT||RETROSPECTIVE|||||||
33965359|NCT05697484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33965360|NCT03501199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185283|NCT05211843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant will know what group they are assigned to as they will see and taste the assigned beverage. The investigator who assigns participants to a treatment group will not administer the beverage or collect data. The investigator who administers the beverage will know the group assignment. The laboratory staff who assess the outcomes will not know the assignment.|Three randomly assigned groups, with randomization stratified by weight status, with measurements at baseline and post-intervention|f|f|f|t
33965361|NCT01230866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965362|NCT01837420|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34185284|NCT01035125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34185285|NCT04562428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185286|NCT02196636|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34185287|NCT01702649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869002|NCT05522179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869003|NCT03177616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869004|NCT02917681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869005|NCT05301868|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33869006|NCT05604820|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Due to the characteristics of the study, blinding cannot be applied to the participants. In order to eliminate the bias, the data of the study will be collected and recorded by an impartial researcher (assistant researcher) who does not know the groups trained by the researcher. The statistics of the research will be carried out by an independent statistician who does not know the groups. In this way, the prevention of bias will be ensured.|A Randomized Controlled Study|f|f|t|t
33869007|NCT00771134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869008|NCT02403362|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33869009|NCT04168073|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33869010|NCT06002308|||COHORT||RETROSPECTIVE|||||||
33869011|NCT01015651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33965363|NCT05620680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965364|NCT05712915|||COHORT||RETROSPECTIVE|||||||
33965365|NCT04862104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following recruitment, patient who underwent oncological surgery were divided into a study and a control group by randomization (1:1 randomization)||||
34185288|NCT03403283|||CASE_CONTROL||PROSPECTIVE|||||||
34185289|NCT05903768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185290|NCT04700644|||COHORT||RETROSPECTIVE|||||||
33869012|NCT01868256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185291|NCT04823247|||COHORT||PROSPECTIVE|||||||
34185292|NCT05104177|||COHORT||PROSPECTIVE|||||||
34185293|NCT01088724|NA|SINGLE_GROUP||TREATMENT||||||||
34185294|NCT04899986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753585|NCT03709368|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33753586|NCT02060851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753587|NCT06363929|||COHORT||PROSPECTIVE|||||||
33753588|NCT00037219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753589|NCT00163579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33753590|NCT05340881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized, double-blind, placebo-controlled trial design|t|t|f|t
34185295|NCT00425776|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34185296|NCT02767414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185297|NCT01166282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185298|NCT01462370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34185299|NCT00353483|||COHORT||PROSPECTIVE|||||||
33753591|NCT05586568|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753592|NCT03097705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753593|NCT02115633|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33753594|NCT03167307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo-controlled study|A 36-week, multi-centre, double-blind, placebo-controlled randomized superiority Study.|t|t|t|t
33753595|NCT06079905|||COHORT||PROSPECTIVE|||||||
33753596|NCT00744770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753597|NCT05186948|||COHORT||OTHER|||||||
33753598|NCT03776214|||COHORT||OTHER|||||||
33753599|NCT04460118|||COHORT||RETROSPECTIVE|||||||
33753600|NCT04618874|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial||||
33753601|NCT02254226|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753602|NCT01926730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753603|NCT06732362|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753604|NCT02452723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753605|NCT03918655|||COHORT||OTHER|||||||
33753606|NCT03392402|||COHORT||PROSPECTIVE|||||||
33753607|NCT03909126|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965366|NCT02946502|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34185300|NCT01023893|||CASE_ONLY||PROSPECTIVE|||||||
34185301|NCT02596932|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185302|NCT03365089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185303|NCT01525069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185304|NCT04773106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185305|NCT03903237|||COHORT||RETROSPECTIVE|||||||
34185306|NCT04569487|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective, multicentric, cohort study with 2 parallel groups (sarcopenic versus non-sarcopenic population)||||
34185307|NCT02444078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185308|NCT03570099|||CASE_CONTROL||PROSPECTIVE|||||||
34185309|NCT01102582|||COHORT||PROSPECTIVE|||||||
33753608|NCT06278103|||COHORT||OTHER|||||||
33753609|NCT04762381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded, results enteree into RedCap, logged and masked for participants|Randomized, double blinded trial|t|t|t|f
33753610|NCT04176627|||COHORT||CROSS_SECTIONAL|||||||
33753611|NCT05031364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment condition and timepoint will be masked for the outcomes assessors (independent evaluators \[IEs\]), who will administer the interview-based measures.||f|f|f|t
33753612|NCT02013622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753613|NCT05786248|NA|SEQUENTIAL||OTHER||NONE||||||
33753614|NCT06734026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753615|NCT01944865|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33753616|NCT02177110|||COHORT||PROSPECTIVE|||||||
34185310|NCT04355039|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753617|NCT05290831|NA|SINGLE_GROUP||OTHER||NONE||||||
33753618|NCT04431466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185311|NCT04204512|||COHORT||PROSPECTIVE|||||||
34185312|NCT05796934|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34185313|NCT06255431|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|double-blinded|A randomized, placebo-controlled, double-blinded, split face trial on women undergoing TCA 15% chemical peels.|t|t|t|t
34185314|NCT02192489|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34185315|NCT00018083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185316|NCT02668978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185317|NCT01832597|||COHORT||RETROSPECTIVE|||||||
34185318|NCT03170596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independant senior dermatologist who is blinded regarding the modality used for atrophic acne scarring in each half of the face, will be assessing the outcome scores.|Microneedling procedure will be done on one half of the face and patients will be instructed to apply tazarotene 0.1% gel on the other half of the face|f|f|f|t
34185319|NCT04355143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment to study arms in a 1:1 ratio||||
34185320|NCT00343460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33965367|NCT02444182|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34185321|NCT05442476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185322|NCT00904137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185323|NCT02844868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185324|NCT04833218|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34185325|NCT06039111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185326|NCT06117319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups with different learning modalities (individual feedback compared to collective feedback)||||
34185327|NCT02377817|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34185328|NCT00296621|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34185329|NCT00691834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185330|NCT01436435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185331|NCT04639258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185332|NCT06054074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants dont know the condition|||||
33753619|NCT05068817|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33753620|NCT00617578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753621|NCT02291731|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33753622|NCT03556111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753623|NCT02744222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753624|NCT03393000|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, controlled||||
33753625|NCT02939040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185333|NCT00120497|||CASE_CROSSOVER||PROSPECTIVE|||||||
34185334|NCT06239896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-arm, cluster randomized trial to compare the effectiveness of delivering PREPARE-PSH via facilitated groups versus one-on-one visits||||
34185335|NCT00357006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185336|NCT00938704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185337|NCT04057976|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185338|NCT00733668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185339|NCT04606602|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34185340|NCT01024413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185341|NCT05847816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The intervention and measurements will carried out by the TY (for hand manipulation standard) and the patients will discovered their own groups when intervention will applied to them. Because of the nature of the intervention, blinding will not be performed|This is a prospective, randomized controlled experimental study.||||
34185342|NCT02212782|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34185343|NCT04114318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753626|NCT01926756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33753627|NCT06262568|||OTHER||OTHER|||||||
34185344|NCT04033016|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185345|NCT03703427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185346|NCT04560673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185347|NCT03555448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185348|NCT01919567|||CASE_CONTROL|||||||||
34185349|NCT00682123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34185350|NCT00200369|||COHORT||PROSPECTIVE|||||||
34185351|NCT05050877|||COHORT||RETROSPECTIVE|||||||
34185352|NCT04226755|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34185353|NCT04427813|||OTHER||PROSPECTIVE|||||||
34185354|NCT02694016|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34185355|NCT00482053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185356|NCT03937570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185357|NCT05043662|||CASE_CONTROL||PROSPECTIVE|||||||
34185358|NCT02281916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185359|NCT01073111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185360|NCT01856959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185361|NCT06521333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Randomized Controlled Clinical Trial|t|t|f|t
34185362|NCT05142501|||OTHER||PROSPECTIVE|||||||
34185363|NCT01397968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185364|NCT04607018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking - all are taking the same products starting at different time points|The pilot-study evaluated the effect of the PMA-zeolite supplementation of 28 days (in accordance with the regulations of this medical device) on 2 groups of 15 subjects (males and females) all together. All subjects are healthy volunteers taking PMA-zeolite since years and the other one just started. No washout phase is planned, but if food-supplements are taken this will be protocolled. The diagnostics will be performed through the defined parameters at defined time-points.||||
34185365|NCT01746901|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34185366|NCT01374984|||CASE_ONLY||PROSPECTIVE|||||||
34185367|NCT04287790|||OTHER||PROSPECTIVE|||||||
34185368|NCT00766662|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34185369|NCT02445898|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34185370|NCT05612620|||CASE_CONTROL||PROSPECTIVE|||||||
34185371|NCT03754998|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Quasi experimental||||
34185372|NCT01298648|||COHORT||PROSPECTIVE|||||||
34185373|NCT04148846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be randomly divided into three groups according to the reduced distribution of use of the site www.randomization.com to be conducted prior to the commencement of surveys and data collection. Each patient is given an identification number following a search entry order, and this number is already available through prior randomization linked to one of the three intervention groups. The professional who administers as drugs will be external to the research group and may cause non-burdensome form. Researchers who perform the evaluations of the researched variables can obtain the following results for the intervention performed.|A prospective randomized clinical, analytical study will be conducted at the Obstetric Center of the Central Institute of the University of São Paulo School of Medicine Clinical Hospital (ICHC-FMUSP). Postpartum women undergoing neuraxial block for cesarean section, vaginal delivery or uterine curettage, and who later present with cerebrospinal fluid hypotension, will be studied after evaluation and diagnosis by anesthesiologist. The research will be submitted for evaluation by the Research Ethics Committees, according to resolution 196/96. Patients will be approached as to the eligibility of their participation in the study, and after the necessary clarifications, will authorize or not the proposed interventions and data collection, by signing the Informed Consent Form.|t|f|f|f
34185374|NCT03143062|||CASE_CONTROL||RETROSPECTIVE|||||||
34185375|NCT04922632|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 4-year, multi-site, four-arm parallel-group randomized clinical trial (RCT).||||
34185376|NCT02733640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33753628|NCT06533033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33753629|NCT03977519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33869013|NCT02383095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869014|NCT04223895|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185377|NCT05185869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185378|NCT01099462|||COHORT||PROSPECTIVE|||||||
34185379|NCT00981448|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34185380|NCT01821118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185381|NCT03651414|||CASE_CONTROL||PROSPECTIVE|||||||
34185382|NCT06020820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185383|NCT04883372|||COHORT||RETROSPECTIVE|||||||
34185384|NCT01765257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869015|NCT01944683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869016|NCT01543828|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33965368|NCT04290806|||COHORT||PROSPECTIVE|||||||
34185385|NCT06522100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Phase III, prospective, randomized, placebo controlled, superiority, double blinded trial with 2 parallel groups randomized in a 1:1 ratio.~Patients will be hospitalized in Cardiology or Intensive Care Unit for a suspicion of an acute myocarditis. They will have an 2D-TTE to confirm a left ventricular dysfunction (LVEF \< 50% and/or Global longitudinal strain \[GLS\] \< -16%) and a cardiac magnetic resonance imaging or an endomyocardial biopsy will be performed to prove acute myocarditis. Coronary artery disease will be excluded by coronary angiography or Cardiac CT Scan. Once diagnosis of complicated AM with left ventricular dysfunction done, investigators will have 48 hours to include the patients and randomize them. They will benefit of placebo or experimental treatment in addition of conventional treatment for 6 months. At M6, end of participation for each patients, they will benefit of cardiologist consultation with TTE and cardiac magnetic resonance imaging."|t|t|t|t
34185386|NCT04846738|||COHORT||OTHER|||||||
34185387|NCT00225732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185388|NCT00993967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185389|NCT03874988|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34185390|NCT03168776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185391|NCT00089869||||TREATMENT||||||||
34185392|NCT04475302|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||In this study, as we are employing a control group that is not vaccinated against the disease to be prevented, but some clinical data are available to support the likely efficacy of the candidate vaccine, we will use unbalanced randomization and enrol participants to control group in the ratio of 2:1, so that majority of the study participant will receive the vaccine||||
34185393|NCT04485390|||COHORT||RETROSPECTIVE|||||||
34185394|NCT05862649|NA|SINGLE_GROUP||OTHER||NONE||||||
34185395|NCT02689037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185396|NCT02109497|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185397|NCT00557713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185398|NCT04972903|||COHORT||PROSPECTIVE|||||||
34185399|NCT04446104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185400|NCT03943654|||OTHER||CROSS_SECTIONAL|||||||
33965369|NCT02282111|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34185401|NCT01541696|||COHORT||PROSPECTIVE|||||||
34185402|NCT02754440|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185403|NCT00165477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185404|NCT03480269|||CASE_ONLY||PROSPECTIVE|||||||
34185405|NCT06127849|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, placebo-controlled, double-blinded study|t|t|t|f
34185406|NCT05004441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185407|NCT06491485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185408|NCT04122716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The above-mentioned are masked in terms of Liraglutide/placebo, not in terms of exercise/non-exercise.~Statistical analysis of primary outcome will be blinded to the assessor."|After 8 weeks of weight loss the participants are randomized to receive a) Liraglutide 3mg/day sc or b) placebo sc or c) Exercise + placebo sc or d) Exercise + Liraglutide 3mg/d sc for 52 weeks.|t|t|t|t
34185409|NCT03452657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185410|NCT01619124|||COHORT||PROSPECTIVE|||||||
34185411|NCT05156034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185412|NCT04540913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965370|NCT05356351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185413|NCT00345358|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869017|NCT02554903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185414|NCT01735331|||CASE_CONTROL||PROSPECTIVE|||||||
34185415|NCT02217358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185416|NCT04961957|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective, randomized controlled trial involves the subject being randomized (similar to flipping a coin) by envelope to receive either waterproof padding or non-waterproof padding in their short leg walking cast. The study will take approximately three to seven weeks for the subject to complete (pending date of cast removal).||||
34185417|NCT02853617|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34185418|NCT00911456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185419|NCT02401789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185420|NCT00195364|||COHORT||RETROSPECTIVE|||||||
34185421|NCT02585518|||CASE_ONLY||PROSPECTIVE|||||||
34185422|NCT02532803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185423|NCT01279148|||CASE_CONTROL||PROSPECTIVE|||||||
34185424|NCT04625504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33869018|NCT04857801|||COHORT||RETROSPECTIVE|||||||
34185425|NCT02494323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185426|NCT02346162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185427|NCT03356041|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34185428|NCT05361707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185429|NCT00214890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a comparative, open-labeled study of a dual NRTI regimen, TDF + ABC, compared to ABC and TDF monotherapy administered for 7 days. Each patient will be randomized to a 7-day sequence of either ABC or TDF once-daily followed by a 35-day washout period. After completion of the monotherapy sequence all patients will then receive dual NRTI therapy of TDF + ABC for an additional 7 days. After completion of the dual NRTI sequence patients will enter the HAART treatment stage with the addition of EFV and continue on a once-daily regimen of EFV + ABC + TDF for an additional 14 days. At day 63, TDF will be stopped and 3TC will be substituted. Patients will then continue on a once-daily regimen of EFV + ABC + 3TC for an additional 46 weeks.||||
34185430|NCT04764422|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Unblinded study staff, including the site pharmacist, will be responsible for preparing study products (in accordance with the randomly determined assignment), administering the study vaccine, and handling all drug accountability procedures. These personnel will not participate in the other aspects of the clinical trial, to help ensure the integrity of the blind at the site. Unblinded staff will retrieve a subject's randomization assignment after being informed by the PI or designee that a subject is eligible for randomization. They will prepare the 0.5 ml dose of study product based on the subject's randomization||t|f|t|f
34185431|NCT06410196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|At the beginning of the study, the participants and experimenter are blind to the arm allocation. The experimenter's blindness is lifted upon administering the intervention while the participant's blindness is maintained until the end of their participation in the study.|80 participants to be enrolled in the study, with 40 in each arm (randomized arm allocation)|t|f|t|f
34185432|NCT05569278|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34185433|NCT05524597|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized controlled trial|t|t|t|f
34185434|NCT02874989|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Some patients will be randomized either to placebo or study drug and other patients will go into open label.||t|f|f|f
34185435|NCT06517693|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34185436|NCT01623453|||||PROSPECTIVE|||||||
34185437|NCT00478023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753630|NCT05353998|RANDOMIZED|PARALLEL||OTHER||NONE||Caregiver-child dyads with a child who meets criteria for further SDB evaluation will be randomly assigned (1:1) to either the intervention condition, which is the CDS and the Sleep Navigation program, or to a CDS only condition.||||
33753631|NCT04088019|||COHORT||PROSPECTIVE|||||||
33753632|NCT05028725|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753633|NCT06059222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753634|NCT04357327|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The rapid salivary test will provide results within 5-10 minutes, while the rRT-PCR performed on nasopharyngeal swab shows results only after 6 hours, thus the outcome assessor of the experimental test is blinded|Consecutive recruitment of both patients with COVID-19 like symptoms (i.e., cough, fever, dyspnea) and patients with low risk phenotype|f|f|f|t
33753635|NCT04250727|RANDOMIZED|PARALLEL||OTHER||SINGLE||30 current non-treatment seeking adult smokers will be randomized to either the 3mg or 6mg nicotine concentration ZYN condition.|t|f|f|f
33753636|NCT00363519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753637|NCT03298646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33753638|NCT00877331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753639|NCT02872701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753640|NCT05538780|||COHORT||PROSPECTIVE|||||||
33753641|NCT02816138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753642|NCT05591339|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be blinded to treatment. The investigators (or delegated vaccinator, e.g. nurse) administering the BCG vaccine or placebo (saline) will not be blinded. In case of serious adverse events, the participant can be unblinded after consultation with the coordinating PI.||t|t|f|t
33869019|NCT04603885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33869020|NCT05772754|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Partecipants with heart failure and pulmonary hypertension||||
33869021|NCT05572528|||CASE_ONLY||PROSPECTIVE|||||||
33869022|NCT05823415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965371|NCT02372682|||CASE_CONTROL||PROSPECTIVE|||||||
33753643|NCT00003038||||TREATMENT||||||||
33869023|NCT04533555|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is a randomized controlled trial among young adult cancer patients that will compare an investigational strategy for detecting genetic risk (universal testing of all eligible patients using a broad panel of cancer risk genes) vs. the standard strategy (referring the subset of patients who meet certain guideline criteria, based on age, cancer type, and family history, for genetic counseling and testing). We will test the hypothesis that the investigational strategy detects substantially more patients as having genetic risk than the standard strategy.||||
33869024|NCT01327820|||COHORT||PROSPECTIVE|||||||
34185438|NCT00396253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965372|NCT00253461|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965373|NCT00817466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965374|NCT02313116|||COHORT||PROSPECTIVE|||||||
34185439|NCT01054885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185440|NCT02784899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185441|NCT03873792|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34185442|NCT04857320|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Healthy Males, aged 20 to 60, Non-diabetic and Hemoglobin A1c test results of less than 6.||||
34185443|NCT05914337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185444|NCT02939443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185445|NCT06316050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open randomized controlled clinical trial.||t|f|f|f
34185446|NCT03487432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185447|NCT01405144|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34185448|NCT00218777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34185449|NCT04496583|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective controlled study of parallel groups||||
34185450|NCT06071689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185451|NCT06331143|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34185452|NCT05836896|NA|SEQUENTIAL||TREATMENT||NONE||||||
34185453|NCT04904614|NA|SINGLE_GROUP||OTHER||NONE||Open label trial||||
34185454|NCT05702606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185455|NCT01477970|||||PROSPECTIVE|||||||
34185456|NCT04147663|||COHORT||OTHER|||||||
34185457|NCT00685997|||COHORT||CROSS_SECTIONAL|||||||
34185458|NCT01376934||PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34185459|NCT00767832|||COHORT||PROSPECTIVE|||||||
34185460|NCT04595747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185461|NCT04202107|||COHORT||PROSPECTIVE|||||||
34185462|NCT00308490|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185463|NCT04469335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185464|NCT04937218|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors were masked to the intervention.|Longitudinal pre- post-evaluation of intervention and comparison group|f|f|f|t
34185465|NCT02579304|||COHORT||PROSPECTIVE|||||||
34185466|NCT04424719|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34185467|NCT06514768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185468|NCT01003769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185469|NCT02105181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185470|NCT00543413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185471|NCT04615377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965375|NCT06381596|NA|SINGLE_GROUP||OTHER||NONE||||||
33965376|NCT01873638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965377|NCT03836729||SEQUENTIAL||TREATMENT||NONE||This is a fixed-sequence 2-period, one-way drug interaction study||||
33965378|NCT00657397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185472|NCT03464591|||CASE_ONLY||PROSPECTIVE|||||||
34185473|NCT02390193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185474|NCT03714672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study used double-blind and double-dummy methods to guarantee the blinding of all personnel involved in the study. Participants, investigators, and all persons involved in the conduct, data management, and analysis of the study were fully blinded to the participant's treatment.||t|t|t|t
34185475|NCT01394003||SEQUENTIAL||TREATMENT||NONE||||||
34185476|NCT04913935|||CASE_CONTROL||PROSPECTIVE|||||||
34185477|NCT05185661|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|One school will be considered as an intervention group and another school control group to reduce the health education information bias between the intervention and control group participants through the coin toss simple randomization technique. Then computer-generated simple random sampling technique will be used to select anemic study participants for both the intervention and control group from the schools|Randomized control trial (RCT) study.||||
34185478|NCT04268381|||CASE_ONLY||CROSS_SECTIONAL|||||||
34185479|NCT00184301|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34185480|NCT04238897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||paired-eye design|t|t|t|t
34185481|NCT03742323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185482|NCT05676619|NA|SINGLE_GROUP||OTHER||NONE||||||
34185483|NCT03637738|RANDOMIZED|PARALLEL||TREATMENT||NONE||Medico-economic, National Multicentric, Prospective, Randomized, Comparative, Open study of a medical device||||
34185484|NCT03343899|||COHORT||PROSPECTIVE|||||||
34185485|NCT02858362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753644|NCT01970462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753645|NCT01911728|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753646|NCT03230227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||post open heart surgery pain alleviation|t|f|t|f
33753647|NCT00122226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33753648|NCT03508648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869025|NCT00095875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869026|NCT01369420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869027|NCT04123236|||COHORT||CROSS_SECTIONAL|||||||
33869028|NCT05606081|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The risk prediction model is being applied to patients who are awaiting surveillance colonoscopy at select KPNC service areas to help identify those at highest risk for colorectal cancer based on their risk scores. The prediction model is being used in 2-3 service area to identify about 60-80 patients per month who are at highest risk for colorectal cancer based on their risk scores. Risk scores represent one of a number of factors being considered for prioritizing patients for colonoscopy.||||
33869029|NCT06435091|||CASE_ONLY||OTHER|||||||
33869030|NCT03533972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869031|NCT05560373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869032|NCT05895682|NA|SINGLE_GROUP||OTHER||NONE||||||
33869033|NCT03078374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869034|NCT02763709|||COHORT||PROSPECTIVE|||||||
33869035|NCT01380379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185486|NCT05663632|||CASE_CONTROL||PROSPECTIVE|||||||
34185487|NCT04055077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesiologist who interviews and examines patients scheduled for PPV under analgo-sedation will enroll eligible participants and offer procedure explanation with possibility to sign uniformed written consent. Unique personal hospital admission number (UPHAN) will be assigned to all eligible participants. Participants will be randomized to control or intervention group by using random numbers generator. Anesthesiologist who implements anesthesia will receive nontransparent envelope with assigned intervention provided by independent investigator and will not decide which participant will receive LFNO or HFNO. However, attending anesthesiologist and participants will unavoidably be aware of type of oxygenation applied. Collected data are objective measures. Investigator who collects data after procedure will be unaware of study protocol and will enter data to formatted database. Participants' data will be noted under UPHAN. Outcome assessors will be unaware of intervention applied.|"Investigators plan to conduct prospective, parallel group, randomized controlled clinical trial.~In total, 126 participants will be included in this trial. These participants are patients scheduled for analgo-sedation for vitrectomy."|f|f|t|t
34185488|NCT03071419|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The interventionists will not be aware of whether participants are in the intervention or wait-list control group.||f|t|f|f
34185489|NCT05441748|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34185490|NCT00890123|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34185491|NCT05422898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185492|NCT00598793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185493|NCT04381754|||COHORT||PROSPECTIVE|||||||
34185494|NCT03859310|||COHORT||PROSPECTIVE|||||||
33753649|NCT04530448|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1 (control) will receive standard of care treatment for coronavirus according to institutional protocols.~Group 2 (treatment) will receive sodium bicarbonate 225 mEq (225 mL of an 8.4% solution) intravenously over 1 hour."||||
33753650|NCT02486484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753651|NCT01746342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869036|NCT01127659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869037|NCT00520728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869038|NCT03777540|||COHORT||RETROSPECTIVE|||||||
33753652|NCT03511833|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"Eligible patients will be randomized according to a blocked randomization scheme using www.sealedenvelope.com (site accessed Sep 10, 2017), which permits assignment of the participant to either group A or group B (the IN ketamine or IV morphine group). Only the pharmacy will have knowledge of which group is Ketamine and which group is Morphine. Eligible patients will be divided in equal proportions (58 in group A and 58 in group B). Both medications will be prepared by the pharmacy as coded kits, and will be stored in the ER safe with clear signage: For ketamine/morphine clinical trial only. Shelf life of the kits is 6 months. Each vial in a kit will be marked by the group name either A or B and by either IN or IV. The IV vials will either contain: morphine (10 mg of morphine in 10 ml saline) or 10 ml saline for IV administration, and the IN vials will either contain ketamine (100 mg in 2ml saline) or 2 ml saline for nasal administration."|t|t|t|t
33753653|NCT06579131|||CASE_ONLY||PROSPECTIVE|||||||
33753654|NCT01201148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753655|NCT02925611|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33753656|NCT05612074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Physiologic study in healthy volunteers||||
33869039|NCT04060082|||COHORT||CROSS_SECTIONAL|||||||
33869040|NCT05417607|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility trial||||
33753657|NCT02451527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753658|NCT05040009|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33869041|NCT05340361|||COHORT||PROSPECTIVE|||||||
33753659|NCT04041960|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33753660|NCT01235390|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33869042|NCT02429726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869043|NCT04252053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869044|NCT00845013|||COHORT||PROSPECTIVE|||||||
33869045|NCT01788384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869046|NCT02108860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869047|NCT03620890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869048|NCT00069927|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33869049|NCT05299775|||CASE_ONLY||PROSPECTIVE|||||||
33869050|NCT00105248|RANDOMIZED|PARALLEL||||SINGLE||||||
33869051|NCT02718924|||COHORT||PROSPECTIVE|||||||
33869052|NCT00129168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869053|NCT00101751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869054|NCT06089148|||CASE_ONLY||PROSPECTIVE|||||||
33869055|NCT02951286|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066430|NCT04938596|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Prospective, semi-experimental, controlled trial.~Two different health care areas of Santiago (and their corresponding TB clinics) will be allocated to control or intervention arm; after a baseline pre-intervention period."||||
33869056|NCT02925702|||COHORT||PROSPECTIVE|||||||
33869057|NCT03979690|NA|SINGLE_GROUP||OTHER||NONE||||||
33869058|NCT05899881|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot study in which participants are randomly assigned to either a yoga group or waitlist control group||||
33869059|NCT04428463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"two groups. In one we will use the conventional treatment strategy using tympanoplasty with fascia and cartilage.~in the intervention group we will use tachosil in closing the perforations."||||
33869060|NCT04265716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This is a double-blinded study. All study staff, including the Principal Investigator and the persons performing the subject assessments, will be blinded during the study. Sealed individual treatment code envelopes will be kept at the clinic to be able to break the code if any emergency occurs, as judged by the Investigator. Tubes with interventions has the same exterior appearence. Emollient are similar in consistency and odour|Randomized, double blind, placebo controlled trial, 2 parallel arms. Children with mild or moderate atopic dermatitis will be randomly selected at the Pediatric Dermatologic Clinic-Hospital General GEA-Mexico if they fulfill selectioncriteria.|t|t|t|t
33869061|NCT06295367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33965379|NCT03152227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965380|NCT00003583||||SUPPORTIVE_CARE||||||||
33965381|NCT04178317|||COHORT||PROSPECTIVE|||||||
33965382|NCT03066635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965383|NCT04218006|||FAMILY_BASED||PROSPECTIVE|||||||
33965384|NCT03143088|||CASE_CONTROL||PROSPECTIVE|||||||
34066431|NCT05193123|||OTHER||PROSPECTIVE|||||||
34066432|NCT01560715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185495|NCT01842217|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185496|NCT05120401|||CASE_ONLY||RETROSPECTIVE|||||||
34185497|NCT01666028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185498|NCT05178004|||CASE_CONTROL||PROSPECTIVE|||||||
34185499|NCT04117516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185500|NCT02532881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34185501|NCT02436629|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34185502|NCT05375760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185503|NCT00763880|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34185504|NCT05737953|||CASE_CONTROL||PROSPECTIVE|||||||
34185505|NCT05194735|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34185506|NCT05876897|||COHORT||CROSS_SECTIONAL|||||||
34185507|NCT06003049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind study|"This is an Investigator-initiated a clinical trial to determine the safety and preliminary efficacy of subcutaneous injections of BOTOX in participants with moderate COPD.~Participants will be treated with either one series of subcutaneous injections of BOTOX or of normal saline solution in the back in the T-1 to T-5 dermatome regions as indicated in Appendix A.~Participants' COPD status will be measured using the COPD Assessment Test (CAT), Pulmonary Function Test (Spirometry), and 6 Minute Walk Test (6MWT)."|t|f|t|t
34185508|NCT03224819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Bayesian Model||||
34185509|NCT05119361|||COHORT||PROSPECTIVE|||||||
34185510|NCT00811018|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34185511|NCT02177565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185512|NCT02683681|||COHORT||PROSPECTIVE|||||||
34185513|NCT05542719|||COHORT||PROSPECTIVE|||||||
34185514|NCT01803607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185515|NCT04458870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185516|NCT05928962|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1 With Recombinant Human Adenovirus Type 5 Injection||||
34185517|NCT05985252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185518|NCT01119378|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34185519|NCT04342325|NA|SINGLE_GROUP||TREATMENT||NONE||3 + 3 dose escalation study design||||
34185520|NCT03719859|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to one of two groups (surgeon directed home therapy or formal physical therapy). If subjects in either group are dissatisfied with the outcome of their rehabilitation process, they will be afforded the opportunity to cross-over to the other arm of the study.||||
34185521|NCT05474157|||CASE_CONTROL||PROSPECTIVE|||||||
33965385|NCT06263465|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33965386|NCT02795130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066433|NCT05058092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization in two groups of type: Immediate Solution vs. Delayed Solution|f|f|t|f
34066434|NCT05437016|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||monocentric, prospective, randomised, simple blind study (evaluators) with 2 intervention arms (1:1 ratio)|f|f|t|t
34066435|NCT03557814|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The investigator and outcome assessor are blinded to the study design|Split-mouth design in the same volunteer. Different quadrant receives different treatment.|f|f|t|t
34066436|NCT02773420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066437|NCT03501654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066438|NCT02584959|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34066439|NCT00830583|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066440|NCT03510429|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34185522|NCT04199988|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34185523|NCT02367833|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34185524|NCT02892448|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185525|NCT02964091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185526|NCT04186143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized|f|t|f|f
34185527|NCT01686399|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34185528|NCT03292367|||COHORT||PROSPECTIVE|||||||
34185529|NCT03186742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185530|NCT00475696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185531|NCT02289261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753661|NCT01892059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753662|NCT03311373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185532|NCT06523361|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single case experimental design, with sequential introduction of the intervention and comparison within subject (between phases) and between subjects||||
33753663|NCT01634126|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34185533|NCT04963868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185534|NCT05848999|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and 3+3 design dose escalation phase followed by dose expansion phase||||
34185535|NCT00787358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753664|NCT02058615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33753665|NCT04080050|||COHORT||PROSPECTIVE|||||||
33753666|NCT03676855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33753667|NCT02245958|||COHORT||RETROSPECTIVE|||||||
33753668|NCT00623090|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33753669|NCT01831622|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33869062|NCT03416270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study|Patients will be randomized to 15 mg (10mg + 5mg tablets) PO ertugliflozin daily or a matched placebo.|t|t|t|t
33869063|NCT01824511|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185536|NCT03417011|||COHORT||PROSPECTIVE|||||||
34185537|NCT05451901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753670|NCT06152133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Pilot|t|f|f|t
33753671|NCT05227833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blinded design|"The enrolled participants after having an endoscopic variceal ligation session will be randomly allocated to one of three interventions (for 14 days):~Vonoprazan 20 mg once before breakfast OR Pantoprazole 40 mg before breakfast OR Placebo (no treatment) at a 1:1 ratio."|f|f|t|f
33869064|NCT01966614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869065|NCT00458796|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33869066|NCT01093274|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34066441|NCT04136262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066442|NCT02414789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066443|NCT01938989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34066444|NCT00166049|RANDOMIZED|FACTORIAL||||NONE||||||
34066445|NCT02219386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34185538|NCT04220541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185539|NCT05108012|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will enroll 5 patients (3-60 year, both sex, -Lansky performance scale/Karnofsky performance scale: 70-100%) with recurrent Glioblastoma Multiform. A haploidentical donor will enter for each patient.||||
34185540|NCT04938154|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34185541|NCT02284243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066446|NCT03774394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753672|NCT06195982|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Overview: The overall study design will be a randomized, double-blind crossover comparison of ketone ester (KE) therapy vs. KE-free vehicle in 25 patients with established HF with reduced ejection fraction (HFrEF). The main outcomes will be measures of exercise performance (peak and submaximal exercise).|t|f|t|t
33753673|NCT05976282|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33753674|NCT01936480|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33753675|NCT03031587|NA|SINGLE_GROUP||OTHER||NONE||||||
33753676|NCT01976767|||COHORT||PROSPECTIVE|||||||
33753677|NCT00699959|||COHORT||CROSS_SECTIONAL|||||||
33753678|NCT04227015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869067|NCT04898920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* An anesthesia resident who will be blinded to the study groups and not participating in it will help in the preparation of uniform 10-ml syringes that contain normal saline in the control group and 16 mg dexamethasone in the other group to make the patient and care provider blinded to the group of the patient.~* An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in the collection of the data of measurements to make the outcomes assessor blinded to the group of the patient."||t|t|f|t
33869068|NCT00545597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869069|NCT03850600|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study design is a three-arm, prospective, pre-post intervention trial. Crohn's Disease (CD) patients at 27-29 weeks of pregnancy will self-select to Arm 1 or Arm 2. Controls will be in Arm 3.~1. Arm 1 (diet-CD): 8-10 weeks of dietary intervention (n=66)~2. Arm 2 (no-diet-CD): usual diet with no intervention (n=66)~3. Arm 3 (no-diet-control): unaffected controls at the same gestational stage will follow their usual diet and no intervention (n=66)."||||
34066447|NCT02445131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066448|NCT04895488|RANDOMIZED|CROSSOVER||TREATMENT||NONE|None (Open Label)|A two arm, Open-label, randomized, Cross-over Design and single-center clinical trial Phase II b /Phase III.||||
34066449|NCT01990716|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34066450|NCT06498726|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34066451|NCT03489200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34066452|NCT05049473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066453|NCT05900583|||COHORT||PROSPECTIVE|||||||
34066454|NCT03036982|||COHORT||PROSPECTIVE|||||||
33753679|NCT02539810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753680|NCT06579833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753681|NCT02794376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753682|NCT01918410|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33753683|NCT00048464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753684|NCT04216810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33753685|NCT03963908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blinded to group assignment.|This study involves a 2-group X 3 occasion randomized trial that will examine whether AtEase produces more significant improvements in PEG scores (which reflect total pain intensity and pain interference) than a comparison intervention (i.e., an existing online pain self-management intervention entitled Chronic Pain Education for Veterans).|t|f|f|f
33753686|NCT01485042|NA|SINGLE_GROUP||OTHER||NONE||||||
34066455|NCT04114656|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34066456|NCT02470663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34066457|NCT04881279|||COHORT||RETROSPECTIVE|||||||
34066458|NCT03066778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066459|NCT01096498|RANDOMIZED|CROSSOVER||||NONE||||||
33753687|NCT04508595|||OTHER||OTHER|||||||
33753688|NCT04846959|||CASE_CONTROL||PROSPECTIVE|||||||
33753689|NCT05741879|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33753690|NCT02919800|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34066460|NCT01348100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066461|NCT06275737|NA|SINGLE_GROUP||OTHER||NONE||Two-cohort, open-label, single-arm feasibility study||||
33869070|NCT03134742|||COHORT||PROSPECTIVE|||||||
33869071|NCT00051675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869072|NCT04358263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869073|NCT03754140|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm pilot study||||
33869074|NCT00527436|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, Double Blind, Placebo Controlled Trial|t|f|t|t
33869075|NCT03422562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomized clinical trial|f|f|f|t
33869076|NCT05414981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869077|NCT00003440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869078|NCT03361150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33869079|NCT02988180|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33869080|NCT00806247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066462|NCT03051373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066463|NCT06396299|||OTHER||PROSPECTIVE|||||||
34066464|NCT00123682|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34066465|NCT02074319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066466|NCT06209762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066467|NCT04284163|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33753691|NCT03722927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Women of all races and ethnicity who meet the above-described eligibility criteria are eligible to participate in this study. Approximately 5% of study participants to be Hispanic/Latino (N=5), 10% Black or African American (N=10), 1% American Indian/Alaska Native (N=1), and 5% Asian (N=5).|t|f|t|f
33753692|NCT02077179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869081|NCT04186975|||COHORT||PROSPECTIVE|||||||
33869082|NCT02559297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869083|NCT00277186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869084|NCT06490510|||COHORT||OTHER|||||||
33869085|NCT00665873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869086|NCT02039804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869087|NCT06389981|NA|SINGLE_GROUP||SCREENING||NONE||||||
33869088|NCT06293248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant)||t|f|f|f
33753693|NCT04547608|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Attending anesthesiologist knew which anesthetic agents were used. However Outcomes assessor didn't know which anesthetic agents were used.|One hundred patients, between 18-60 years of age were randomly assigned to one of the two groups; group PRi received immediate injection of rocuronium after propofol administration, and group PRd received rocuronium injection when bispectral index score became below 60 after propofol administration|f|f|f|t
33869089|NCT01771055|RANDOMIZED|PARALLEL||TREATMENT||NONE||Galactose versus standard care||||
33869090|NCT01520311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965387|NCT05099328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is unaware of the arm to which the child has been assigned and is also unaware of which of two targets are the treatment target.|Children are stratified based on treatment site. Then they are randomly assigned to receive treatment for 1 of 2 targets, using 1 of 4 methods of intervention. Each child is randomly assigned to parent or clinician delivered intervention using books or recast therapy (2x2 design). Then assignment to treatment targets is assigned so that it is evenly distributed within each condition.|f|f|f|t
33965388|NCT06529081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753694|NCT00003500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753695|NCT02186210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869091|NCT04592224|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869092|NCT02466867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869093|NCT01523496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869094|NCT00750698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869095|NCT01056510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869096|NCT04416555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single (Outcomes Assessor)|parallel assignment (one arm will receive the full immersive virtual reality experience and the other arm will receive a static presentation in the same device)|t|f|f|t
33965389|NCT00435201|||CASE_ONLY||PROSPECTIVE|||||||
33965390|NCT01004484|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33965391|NCT06406985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965392|NCT03210233|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753696|NCT03211286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be allocated into two groups based on randomized 20-block method by an independent assistant using computer generated randomization. Both patients and the treating surgeons will be blinded with regard to placebo vs. treatment until completion of the study|"Patients will be treated surgically with a long trochanteric femoral nail (TFN) or hemiarthroplasty The two patient groups will include: 1) Study group treated with tranexamic acid at the time of surgical incision; 2) Control group treated with placebo injection (saline solution).~Blood transfusion criteria will remain consistent with hospital standards. Deep vein thrombosis (DVT) prophylaxis will remain consistent with hospital standards (subcutaneous heparin from admission until 12 hours prior to surgery and beginning 6 hours after surgery). After discharge, .....~Patients will be followed at regular intervals (1mo, 3mo, and at least 6mo) and at each time point the patient will be asked to report any adverse events (DVT, PT, Stroke, myocardial infarction, infection, hospitalization). Diagnostic studies to assess for thromboembolic events (i.e. DVT, pulmonary embolism (PE), and stroke) will be ordered only if the patient develops clinical signs or symptoms that justify their use."|t|t|t|t
33753697|NCT03610087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753698|NCT02316795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753699|NCT04515459|NA|SINGLE_GROUP||OTHER||NONE||||||
33753700|NCT00885196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753701|NCT01506895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753702|NCT04499651|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869097|NCT00121433|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33965393|NCT00294320|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33965394|NCT02122510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33965395|NCT01377649|||COHORT||PROSPECTIVE|||||||
33965396|NCT04857827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study subjects, Investigators and their staff, and Sponsor personnel involved with the conduct and monitoring of the study will be masked to the investigational product (IP) identity until after the final database is locked. IPs will be provided in identical-appearing pouches to maintain masking.||t|f|t|f
33965397|NCT02209454|RANDOMIZED|CROSSOVER||||NONE||||||
33965398|NCT06375031|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study was designed as a multi-center, randomized, double-blind, three-cycle crossover, positive drug control (NovoRapid ®) To compare the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single injection of HR011408 or NovoRapid ® before or after a standard meal test in patients with type 1 or type 2 diabetes.|t|f|t|f
33965399|NCT00962182|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33965400|NCT03333681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965401|NCT05117086|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm pragmatic trial with pre- and post- assessments||||
33965402|NCT00447187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965403|NCT04266678|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965404|NCT03884595|||COHORT||PROSPECTIVE|||||||
33965405|NCT01330615|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34185542|NCT01239693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34185543|NCT01110902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185544|NCT03968562|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||This cross-sectional survey involves a single consecutive two day study visit.To assess the effect of topical doxycycline 2% emollient cream or control emollient on immediate hypersensitivity allergy skin tests responses, pruritus, and associated late phase skin swelling. We will use generic Aquaphor, a skin protectant, as the control emollient. The active ingredient in this cream is Petrolatum 42%. Inactive ingredients include ceresin, lanolin alcohol, microcrystalline wax, mineral oil, phenoxyethanol. Adults (18-75 yrs) with known respiratory (allergic rhinoconjunctivitis and/or asthma), and are allergen skin prick test (SPT) positive to common aeroallergens will, after 5 days of non-use of oral antihistamine therapy, undergo limited repeat SPT with the same allergens (up to 5 allergens per subject) with measurement of swelling, flare, and itch at 20 min, then after application of doxycycline cream or control emollient, at 30 min, 60 min, and 24 hrs post initial cream removal.|t|f|f|f
34185545|NCT01931293|NA|SINGLE_GROUP||SCREENING||NONE||||||
34185546|NCT04109261|||COHORT||RETROSPECTIVE|||||||
34185547|NCT01586572|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185548|NCT04543279|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185549|NCT06517589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185550|NCT02030652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185551|NCT02084407|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34185552|NCT03916913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185553|NCT01265537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185554|NCT01526733|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34185555|NCT04289974|||COHORT||RETROSPECTIVE|||||||
34185556|NCT03074240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixty subjects with be randomized to the TAPB or RSB arm upon enrollment, using randomized permutated blocks of six.||||
34185557|NCT04767919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to the Standard of Care treatment they receive for their kidney stone disease|Subjects will be assigned to one of two Standard of Care treatments for kidney stone disease and complete their treatment using one treatment modality.|t|f|f|f
33753703|NCT05853887|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|This intervention is directed towards physicians. Individuals will not be randomized.|This study employs a stepped-wedge cluster randomized clinical trial design. Randomization will occur at the group (site) level. Sites will be turned on according to the stepped-wedge cluster randomized design but will run in parallel.||||
33753704|NCT03869398|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be enrolled in the study during their pre-operative consultation with the surgeon once they have been cleared to undergo total thyroidectomy per the usual screening process. The attending surgeon or an IRB approved co investigator will perform the informed consent process (see designated co-investigators). This process will occur in the General Surgery clinic when potential subjects have their 30 minute scheduled preoperative appointment prior to going to the operating room. This process will be conducted in the same manner as the informed consent process for the operation. The nature of their condition will be discussed; the potential risks and benefits of the study will be explained to subjects. The options including not enrolling, enrolling now, and the option to withdraw from the study at any time for any reason will be explained to subjects as well. Once they have consented a consent form will be signed and the subject provided a copy.||||
33753705|NCT05073367|||COHORT||RETROSPECTIVE|||||||
33753706|NCT05049408|||CASE_CONTROL||RETROSPECTIVE|||||||
33753707|NCT04361565|||CASE_ONLY||RETROSPECTIVE|||||||
33869098|NCT03804736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomized by a closed envelope method in a 1: 1 ratio to either FMT-c (15 capsules every 12 h by 2 days) or a FMT-c and Lactobacillus (15 capsules every 12 h by 2 days)||t|f|f|f
33869099|NCT00793260|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33869100|NCT04269148|||OTHER||PROSPECTIVE|||||||
34185558|NCT02788552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869101|NCT06426251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185559|NCT00402402|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869102|NCT00928889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869103|NCT00089050||||TREATMENT||NONE||||||
33869104|NCT00196638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869105|NCT02554747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869106|NCT04183816|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33869107|NCT06473311|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33869108|NCT00209014|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869109|NCT00161187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869110|NCT02341638|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34185560|NCT01252498|||CASE_ONLY||PROSPECTIVE|||||||
34185561|NCT01815697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with benign prostatic hyperplasia are assigned to two groups in parallel for the duration of the study||||
34185562|NCT03460236|||COHORT||PROSPECTIVE|||||||
34185563|NCT06379815|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The allocation of lactate and placebo will be completed by a researcher not involved in data collection. Both the participant and the researchers collecting and analyzing the data will be blinded to the treatment allocation. This will be completed in a counter-balanced order.|Participants will consume a sodium lactate and sodium chloride placebo in a double-blind, crossover design.|t|f|t|t
34185564|NCT00741182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869111|NCT02802748|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33869112|NCT01553136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869113|NCT05103878|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33869114|NCT01677156|||COHORT||PROSPECTIVE|||||||
33869115|NCT04664361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized double-blind, placebo-controlled clinical trial conducted on 3 parallel groups|t|t|t|t
33869116|NCT04137120|||COHORT||PROSPECTIVE|||||||
33869117|NCT03450291|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Three parallel groups: those who have recovered from anorexia nervosa; those who worry a lot about eating, shape and weight; and healthy control participants will be included, and all will complete some questionnaires and two tasks.||||
33869118|NCT03913702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the treating physician nor the patient will have access to drug-related details. Data will only be retrieved by the coordinating institution's research coordinator.|Randomized clinical trial in which patients will be randomized to receive subacromial injection with either methylprednisolone or ketorolac.|t|f|t|f
33869119|NCT02386280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185565|NCT01715324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185566|NCT02841904|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34185567|NCT06393699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185568|NCT03788252|RANDOMIZED|PARALLEL||PREVENTION||NONE||Renamezin (AST-120) group or non-Renamezin group||||
34185569|NCT05288803|||COHORT||PROSPECTIVE|||||||
34185570|NCT03930082|||COHORT||PROSPECTIVE|||||||
34185571|NCT05724888|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be from 2 different locations. 1) Winnipeg, MB, Canada 2) St. Theresa Point First Nations, MB, Canada. 20 participants will be recruited from each location and then at each location participants will be randomized in a 1:1 fashion to one of two arms for 12 weeks: (A) A behavioural lifestyle intervention that supports increased PA or (B) a control group.||||
34185572|NCT05728957|||OTHER||PROSPECTIVE|||||||
34185573|NCT01630876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185574|NCT05779540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185575|NCT04730232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185576|NCT03327207|||COHORT||PROSPECTIVE|||||||
33869120|NCT02490475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869121|NCT05125055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869122|NCT06149390|||COHORT||RETROSPECTIVE|||||||
33869123|NCT04577729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965406|NCT03264079|NA|SINGLE_GROUP||TREATMENT||NONE||"All participants are placed into a one group to receive two interventions: one intervention during Period 1 and a second intervention during Period 2.~For Period 1, all qualified subjects shall receive a single oral dose of bardoxolone methyl (10 mg) on Day 1.~For Period 2, following a washout of 14 days, itraconazole (SPORANOX®) capsules (100 mg) will be administered as a 200-mg single daily dose on Study Days 15 through 27, with bardoxolone methyl (10 mg) administered on Day 18 (1 hour after itraconazole administration)"||||
33965407|NCT03096574|||OTHER||PROSPECTIVE|||||||
33965408|NCT01271933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965409|NCT04078815|||OTHER||PROSPECTIVE|||||||
33965410|NCT00108901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965411|NCT01217528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965412|NCT00443131|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34151551|NCT03990506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are not aware which eye will receive the Epi-off PiXL treatment and which eye will receive the Epi-on PiXL treatment.|Prospective, single-masked intraindividually comparing randomized controlled trial. Participants will be randomized to receive Epi-off PiXL in one eye and Epi-on PiXL in the other, which is masked to the participant. The participant can choose to treat in eye at a time or both eyes during the same visit.|t|f|f|f
34151552|NCT05288140|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A control group and an experimental group|t|t|t|f
34151553|NCT05611502|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants will be randomly assigned to receive each arm in counterbalanced order (AB or BA).|t|f|f|f
34185577|NCT03750123|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34185578|NCT00840112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185579|NCT04913038|||CASE_ONLY||PROSPECTIVE|||||||
34185580|NCT02052518|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185581|NCT05370677|||OTHER||CROSS_SECTIONAL|||||||
34185582|NCT06081270|||COHORT||PROSPECTIVE|||||||
34185583|NCT03153943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pragmatic randomized trial|f|f|f|t
34185584|NCT00589394|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185585|NCT01662570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185586|NCT02783807|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34185587|NCT02633202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753708|NCT05918705|||COHORT||PROSPECTIVE|||||||
33753709|NCT01552850|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33869124|NCT06189495|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33869125|NCT02470468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869126|NCT05201027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869127|NCT02453490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869128|NCT06428084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33869129|NCT06399523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869130|NCT03621332|||COHORT||PROSPECTIVE|||||||
33869131|NCT00546299|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33869132|NCT06118151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Open label (Sponsor) Blinded (Sites, except for those preparing/administering study intervention)||t|t|t|t
33869133|NCT06229106|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33869134|NCT04689204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869135|NCT04267770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869136|NCT06323603|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869137|NCT01274819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869138|NCT04861675|||COHORT||PROSPECTIVE|||||||
33869139|NCT03991806|||COHORT||PROSPECTIVE|||||||
33869140|NCT00461344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869141|NCT05675540|||COHORT||RETROSPECTIVE|||||||
33869142|NCT04092348|||OTHER||CROSS_SECTIONAL|||||||
33869143|NCT00094692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869144|NCT03371433|||COHORT||RETROSPECTIVE|||||||
33869145|NCT05907681|||COHORT||PROSPECTIVE|||||||
33869146|NCT04171479|||CASE_CONTROL||RETROSPECTIVE|||||||
33869147|NCT00159757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869148|NCT00770770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869149|NCT00821938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869150|NCT03209206|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective Randomized Phase II Trial||||
33869151|NCT01429584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869152|NCT03883191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Probiotic or placebo group|t|f|t|f
33869153|NCT04602806|||COHORT||PROSPECTIVE|||||||
33869154|NCT01329445|||COHORT||OTHER|||||||
33869155|NCT02106286|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33869156|NCT03945357|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design would be a registry-based RCT through the AHSQC to evaluate the effect of dual antibiotic irrigation at the time of mesh placement during open RM +/-TAR OVHR.||||
33869157|NCT03725579|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33869158|NCT05242731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Single center, randomized control, non inferiority trial||||
33869159|NCT01896674|||CASE_ONLY||RETROSPECTIVE|||||||
33869160|NCT06043115|||COHORT||RETROSPECTIVE|||||||
33869161|NCT03281668|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group assignment||||
33869162|NCT02755207|||OTHER||PROSPECTIVE|||||||
33869163|NCT00742248|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33869164|NCT03350295|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Group 1 ( Treatment A,B,C - 3 way cross-over), Group 2 ( Treatment D, E - 2 way cross over)||||
33869165|NCT00279019|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33869166|NCT04334707|||COHORT||PROSPECTIVE|||||||
33869167|NCT02484833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869168|NCT00001520||||TREATMENT||||||||
33753710|NCT02652988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753711|NCT06100133|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated measures design to register the changes before and after treatment. Non-randomized, non-blinded, multi center prospective interventional cohort trial.||||
33753712|NCT05365893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"20 patients diagnosed with resectable pancreatic cancer will be consented for blood and tissue prior to starting neoadjuvant therapy.~10 patients will be assigned to the experimental (PHL) arm (Arm A).~Treatment arm; N=10 (Consented for PHL the time of neoadjuvant therapy completion): Experimental therapy 4-8 weeks pre-op:~Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily~Control arm (Arm B); N=10 These patients have already signed consent for blood and tissue- will proceed to surgery at completion of neoadjuvant therapy."||||
34185588|NCT03829202|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185589|NCT05372172|||COHORT||PROSPECTIVE|||||||
33869169|NCT02193321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869170|NCT02209298|||COHORT||PROSPECTIVE|||||||
33869171|NCT00718445|||COHORT|||||||||
33869172|NCT01565915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869173|NCT01607424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869174|NCT06000995|||COHORT||PROSPECTIVE|||||||
33869175|NCT00263744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33869176|NCT05560542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33869177|NCT03651453|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|A controlled un-blinded pilot study.|A controlled un-blinded pilot study.||||
33869178|NCT01666509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185590|NCT01696539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34185591|NCT00332176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185592|NCT02178150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185593|NCT03389958|||CASE_ONLY||PROSPECTIVE|||||||
33869179|NCT02276781|||COHORT||PROSPECTIVE|||||||
33869180|NCT01274715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869181|NCT04417764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869182|NCT03782402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869183|NCT06155500|||OTHER||PROSPECTIVE|||||||
33869184|NCT03194386|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator / Outcomes Assessor||f|f|t|f
33869185|NCT03028051|||COHORT||PROSPECTIVE|||||||
33869186|NCT03853811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869187|NCT05058755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869188|NCT05546164|||OTHER||PROSPECTIVE|||||||
33869189|NCT03184233|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients undergoing elective cerebral aneurysm clipping surgery or arteriovenous malformation surgery will be asked to take part and give informed consent.~A control group of patients undergoing craniotomy without the use of RVP will be built in, having the same exclusion criteria. Both study groups receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care."||||
33869190|NCT00321347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869191|NCT06476210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869192|NCT01997762|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33869193|NCT04290663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869194|NCT04845321|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33869195|NCT02676999|||CASE_ONLY||OTHER|||||||
33869196|NCT05934747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33869197|NCT06245876|||CASE_CONTROL||PROSPECTIVE|||||||
33869198|NCT04643990|||COHORT||PROSPECTIVE|||||||
33869199|NCT06410365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33869200|NCT01150175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869201|NCT00113074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33869202|NCT04420520|||COHORT||CROSS_SECTIONAL|||||||
33869203|NCT00262522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185594|NCT05036733|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185595|NCT01459497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185596|NCT01235078|||CASE_ONLY||PROSPECTIVE|||||||
34185597|NCT01907035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185598|NCT04430816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants don't know the procedure they will undergo|two groups of patients with incisional hernia group A underwent double mesh modification of chevrel's technique, group B underwent onlay mesh hernioplasty|t|f|f|f
34185599|NCT06522022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185600|NCT00892346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185601|NCT03708614|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-randomized pilot intervention study||||
34185602|NCT04032093|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but the participant and all other study personnel, including the principal investigator, will be blinded.||t|t|t|t
34185603|NCT01064947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185604|NCT05076162|||COHORT||PROSPECTIVE|||||||
34185605|NCT06047418|||COHORT||RETROSPECTIVE|||||||
34185606|NCT01751620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185607|NCT01017198|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185608|NCT05744934|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33869204|NCT04312035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869205|NCT04187300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185609|NCT00903188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869206|NCT05088642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869207|NCT06108713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869208|NCT02201121|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33869209|NCT06455917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869210|NCT02107495|||COHORT||PROSPECTIVE|||||||
33869211|NCT03761511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869212|NCT03075813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33869213|NCT03896542|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33869214|NCT02139254|||COHORT||PROSPECTIVE|||||||
33869215|NCT05187442|||COHORT||CROSS_SECTIONAL|||||||
33869216|NCT01149889||CROSSOVER||TREATMENT||NONE||||||
34185610|NCT03831750|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Sealed envelopes||t|f|f|f
33869217|NCT00288249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869218|NCT02423551|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33869219|NCT05357690|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34185611|NCT05447884|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869220|NCT05287945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869221|NCT02572674|NA|SINGLE_GROUP||OTHER||NONE||||||
33869222|NCT02687542|RANDOMIZED|||TREATMENT||TRIPLE|||t|t|t|f
33869223|NCT00225979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869224|NCT05231499|||CASE_CONTROL||PROSPECTIVE|||||||
33869225|NCT00333671||CROSSOVER||BASIC_SCIENCE||NONE||||||
33869226|NCT05060263|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|open-label|dose-escalation study||||
33869227|NCT04993040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869228|NCT04791839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869229|NCT04310085|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the PfSPZ Challenge product. In cohort 1 parasitaemia will be allowed to develop until a threshold of 5000 parasites/mL blood or a malaria clinical score ≥6 is reached. In cohort 2 the threshold is 10 000/mL or a malaria clinical score of ≥6.||||
33869230|NCT05636657|||COHORT||PROSPECTIVE|||||||
33869231|NCT00038727|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label phase for metformin|||||
33869232|NCT03345823|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34185612|NCT02359097|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Radiologists will be blinded to the type of cerebral blood volume (CBV) maps (steady state \[SS\] and dynamic susceptibility contrast \[DSC\]) and patient information.||f|f|f|t
34185613|NCT02173899|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185614|NCT00976404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185615|NCT04273035|RANDOMIZED|PARALLEL||TREATMENT||NONE|digital block randomization|Group A: midazolam premedicated, standard of care Group B: IPAD, no midazolam premedication||||
34185616|NCT03262844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analysist do not know the group assignment.||f|f|f|t
34185617|NCT02143999|||COHORT||PROSPECTIVE|||||||
33965413|NCT05191225|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Rapid infusion group After the administration of intravenous premedication (usually dexchlorpheniramine 5 mg IV and paracetamol 1 g IV), rituximab will be administered at standard dose (375 mg/m2 diluted in 250 ml of saline) administered in one hour, divided into: 10 first minutes at 450 mg/hour, and 50 minutes later at 720 mg/hour.~* Ultrarapid infusion group After the administration of the premedication, the dose of rituximab will be administered at standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour.~* Ultrarapid plus infusion group After the administration of the premedication, the dose of rituximab will be administered at the standard dose administered in half an hour, divided into: 10 first minutes at 450 mg/hour, and 20 minutes later at 1800mg/hour."||||
33965414|NCT02996253|||COHORT||PROSPECTIVE|||||||
33965415|NCT02856451|||CASE_ONLY||RETROSPECTIVE|||||||
34185618|NCT04446884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185619|NCT04711226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965416|NCT01318941|||COHORT||PROSPECTIVE|||||||
34185620|NCT04294680|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185621|NCT05147259|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover Assigned to HR011408(formulation A) or HR011408(formulation B)|t|f|t|f
34185622|NCT00699114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185623|NCT01601548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185624|NCT03042819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185625|NCT00737672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185626|NCT06025968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be adiministered via a digital platform.|Randomized controlled trial|f|f|f|t
34185627|NCT05653869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185628|NCT04778137|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34185629|NCT00463515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869233|NCT04519411|NA|SINGLE_GROUP||OTHER||NONE||||||
33869234|NCT04335942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869235|NCT06402175|||COHORT||OTHER|||||||
33753713|NCT06732713|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about treatment|The current study will be randomized clinical. The study will include 32 patients aged between 8 to 13 years equally divided into two groups and randomly allocated trial. Group A will perform Frenkel exercises and group B will perform Swiss ball exercises along routine physical therapy. Before and after intervention period, Static and dynamic balance will be assessed by Pediatric Balance Scale, Timed Up and Go test and Romberg test.|t|f|f|f
33753714|NCT03633968|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|assessment of the effect of the antrostomy size in graftless lateral maxillary sinus floor elevation using AMBE (antral membrane balloon elevation) with simultaneous implant placement|assessment of the effect of the antrostomy size in graftless lateral maxillary sinus floor elevation using AMBE (antral membrane balloon elevation) with simultaneous implant placement|t|f|f|f
33965417|NCT01387438|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965418|NCT03374150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185630|NCT01434199|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185631|NCT03378271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185632|NCT01843816|||COHORT||CROSS_SECTIONAL|||||||
34185633|NCT00559819|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33753715|NCT01474096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185634|NCT03854279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185635|NCT06215261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185636|NCT01128283|||CASE_CONTROL||PROSPECTIVE|||||||
34185637|NCT03710161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34185638|NCT06400043|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185639|NCT03626909|||COHORT||PROSPECTIVE|||||||
34185640|NCT04242524|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34185641|NCT06071806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185642|NCT01077076|RANDOMIZED|CROSSOVER||||NONE||||||
34185643|NCT05641259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase 1 study with a dose escalation design and an expansion cohort.||||
33965419|NCT03866837|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Stratified randomization will be carried out by the Trial Statistician using computer-generated randomly permuted blocks of size 2, 4 or 6 with stratification by gender and assignment of eligible infants to one of the 4 intervention groups using 4 color codes. Allocation will be known solely by the Trial Statistician and the Clinical Trial Safety Officer and concealed from all other study personnel.|The study is a single-center, double-blinded, randomized, 9-month clinical trial with a 2X2 factorial design to determine the efficacy of galacto-oligosaccharides and bovine lactoferrin in preserving a beneficial gut microbiota during iron supplementation in Kenyan infants.|t|t|t|t
33965420|NCT01535846|RANDOMIZED|PARALLEL||||NONE||||||
33965421|NCT00054119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965422|NCT02219269|||COHORT||PROSPECTIVE|||||||
33965423|NCT03255031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33965424|NCT04242862|||CASE_ONLY||CROSS_SECTIONAL|||||||
33965425|NCT03810664|RANDOMIZED|CROSSOVER||OTHER||NONE||"This is a Phase 1, single-center, open-label randomized, 2×2 crossover (Ref Test \| Test Ref) study with a washout of two weeks to establish bioequivalence between single dose of somatrogon in a PEN to somatrogon in VIAL administered sc in healthy male volunteers."||||
33965426|NCT01990066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965427|NCT01673165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965428|NCT04891367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965429|NCT01309828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965430|NCT05599204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|Schroth exercise and postural correction group|f|f|t|t
33965431|NCT02496871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965432|NCT00907036||||TREATMENT||NONE||||||
33965433|NCT02620319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965434|NCT03229395|||OTHER||PROSPECTIVE|||||||
33965435|NCT01586767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066468|NCT06255600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The research includes the responsible researcher, assistant and collaborator. Collaborating Researcher is responsible for applying the technique to the patient, knowing which stimulus will be true or placebo. He must apply the research tools and fill out the forms. Alert the main researcher and assistant regarding signs and symptoms in patients resulting from adverse effects.~In this way, the patient and the collaborating researcher are blind."|"Experimental group: Experimental group: Patients allocated to this group will receive a current of 3mA for 20 minutes of anodal HD-tDCS (4x1) for 10 sessions (twice a week in five weeks) and/or Chlorella Pyrenoidosa (5g/day), receiving 10 tablets per day for five weeks.~Placebo/Sham Group: Patients allocated to this group will receive a simulated 3mA current with 30 seconds of acceleration and 30 seconds of deceleration minutes of anodal HD-tDCS (4x1) for 10 sessions (twice a week in five weeks) and/or Placebo with maltodextrin (5g/day) being 10 capsules per day for five weeks."|t|f|f|t
34066469|NCT01291264|||COHORT||CROSS_SECTIONAL|||||||
34066470|NCT00076401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066471|NCT02509078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066472|NCT01916070|||COHORT||PROSPECTIVE|||||||
34066473|NCT05077813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant||t|f|f|f
34066474|NCT01682018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066475|NCT00316407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066476|NCT02259829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066477|NCT02483494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34066478|NCT03078309|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Electrophysiology will be analyzed by a blinded investigator.|Arm 1 - healthy subjects. Arm 2 - subjects with retinitis pigmentosa All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.|f|f|f|t
34066479|NCT00841308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066480|NCT03900247|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066481|NCT02755974|||COHORT||PROSPECTIVE|||||||
34066482|NCT04940585|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066483|NCT05436353|||OTHER||PROSPECTIVE|||||||
34066484|NCT01068587|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066485|NCT04338243|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib: Glumetinib 300mg Combined With Osimertinib 80mg, Qd ,oral||||
34066486|NCT03140761|||CASE_ONLY||PROSPECTIVE|||||||
34185644|NCT01524055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185645|NCT06094582|||OTHER||PROSPECTIVE|||||||
34185646|NCT00193544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185647|NCT05552937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185648|NCT01671319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185649|NCT03931369|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185650|NCT02949791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185651|NCT05539898|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185652|NCT01859624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185653|NCT05064137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Double blinded ( participant and statistician )||t|f|f|f
34185654|NCT03755349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be blinded for allocation to the study group/side, but surgeons will not be. Patients will not be aware of the study group/side, since the operation takes place under general anesthesia. After surgery, it is not possible to see through the skin, whether or not a burr hole cover has been placed.~The fact that patients are blinded for the study group allocation will be mentioned in the discharge letter (in order to inform the family physician), and the neurosurgical team of nurses and physicians will also be informed not to unblind the patient.~Unblinding (and revealing a participant's allocated intervention) towards the patient is permissible only if the trial is suspended, prematurely terminated due to security concerns or completed."|"As the evacuation of a cSDH encompasses trepanation of the skull with 2 burr-holes per side (each one in the frontal and parietal skull region), we will perform the study as follows:~1. In patients with unilateral cSDH, we will cover either both (intervention group) or none of the burr holes with a burr hole cover (control group).~2. In patients with bilateral cSDH, we will cover one side with burr hole covers (intervention side), while on the other side no burr hole covers are applied (control side)."|t|f|f|f
33869236|NCT05111444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869237|NCT00977236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33869238|NCT01565044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33753716|NCT05728723|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33753717|NCT05629702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753718|NCT02248792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753719|NCT06731894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Every bottle will be labelled in a blinded fashion. IDS Pharmacy will obtain the unblinded key. The study team, including the physician, will remain blinded.||t|t|t|t
33753720|NCT06732219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753721|NCT03263429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753722|NCT02652481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753723|NCT01613157|||COHORT||PROSPECTIVE|||||||
33753724|NCT00236873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869239|NCT02114164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33869240|NCT03351751|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33965436|NCT05363852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy volunteers were included to the study.||||
33965437|NCT00304954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965438|NCT04972136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965439|NCT05085197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965440|NCT02084979|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869241|NCT02285920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869242|NCT02825355|||COHORT||PROSPECTIVE|||||||
33869243|NCT06065293|||OTHER||PROSPECTIVE|||||||
33869244|NCT02665052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded evaluator|Parallel: participants are randomized to one of 3 groups: delayed control, active clinic-based training or active home-based training for the initial phase of the study. The delay group is randomly assigned to receive either clinic-based or home-based training for the second phase of the study.|f|f|f|t
33869245|NCT05114395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869246|NCT02453373|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965441|NCT05085860|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a repeated measures randomized counter-balanced design. All participants will complete three conditions in a randomized order, with a wash-out week in between.||||
33965442|NCT02182960|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965443|NCT04583488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965444|NCT04296461|NA|SINGLE_GROUP||TREATMENT||NONE||A standard 3+3 trial design will be used Welgenaleucel(UWC19) dose escalation cohorts. The planned dose escalation cohort levels for Welgenaleucel (UWC19) are 4, 8, 12, 16 and 20 x10\^6 CAR-T cells/kg.||||
33965445|NCT06217978|||CASE_ONLY||RETROSPECTIVE|||||||
33965446|NCT03171506|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized clinical trial with a parallel arm design to evaluate the effects of 12 weeks of usual care plus AND or usual care plus KD on women with ovarian and endometrial cancer.||||
33965447|NCT01736137|||CASE_CONTROL|||||||||
33965448|NCT06121349|||OTHER||PROSPECTIVE|||||||
33965449|NCT03634631|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33965450|NCT03724916|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33965451|NCT01928654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965452|NCT02492295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965453|NCT03496532|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Different stimulation paradigm tested sequentially in every patient of the group|t|f|f|f
33965454|NCT01491490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965455|NCT01420835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965456|NCT02698631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965457|NCT02358954|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965458|NCT00829101|||COHORT||PROSPECTIVE|||||||
33965459|NCT00736333|||CASE_ONLY||PROSPECTIVE|||||||
33965460|NCT02226939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965461|NCT05131490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single blind pre-post test randomized controlled design|t|f|f|f
33965462|NCT01920373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33965463|NCT05837598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33965464|NCT02044276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965465|NCT00004328||||TREATMENT||||||||
33965466|NCT03351127|||CASE_CONTROL||PROSPECTIVE|||||||
33965467|NCT04106466|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|N/A. This is open label study.|All participants will be implanted with the study device and receive open label, active DBS stimulation||||
33965468|NCT00124566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965469|NCT06189352|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility||||
33965470|NCT04063618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185655|NCT00450268|||DEFINED_POPULATION||OTHER|||||||
33869247|NCT04912284|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34185656|NCT06023017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34185657|NCT05366062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185658|NCT00598910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185659|NCT04442282|||OTHER||PROSPECTIVE|||||||
34185660|NCT00337623|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34185661|NCT06169059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185662|NCT00359320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869248|NCT01866579|||CASE_ONLY||PROSPECTIVE|||||||
33869249|NCT04756700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869250|NCT01552291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33869251|NCT04641455|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33869252|NCT04832958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869253|NCT00113230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869254|NCT05742997|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869255|NCT05833048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965471|NCT02530879|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33965472|NCT04277676|||OTHER||PROSPECTIVE|||||||
33869256|NCT00753831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869257|NCT02640833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869258|NCT00660127|||CASE_ONLY||PROSPECTIVE|||||||
33869259|NCT01376778|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33869260|NCT06319313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185663|NCT04055623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study drugs for the first 6-months of the study are (1) Treg cell intravenous (IV) infusions or matching placebo / inactive infusion and (2) subcutaneous interleukin-2 (IL-2) injections or matching placebo / inactive injections; followed by 6-months of Treg infusions and IL-2 injections for all participants.|"Group 1 entered the first 6-months is the double-blind part of the study where participants are randomized to Treg cell infusions and low dose Interleukin-2 (IL-2) injections OR placebo (inactive) infusions and placebo IL-2 injections and then went into the open label second 6-months of ascending Treg infusions and IL-2 injections.~Group 2 went directly into the open label six month trial of ascending Tregs infusions. Group 2 was added due to the pandemic and limits on travel and funding."|t|t|f|t
33869261|NCT02545621|||OTHER||CROSS_SECTIONAL|||||||
33965473|NCT05153291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33965474|NCT04324385|||COHORT||PROSPECTIVE|||||||
33965475|NCT01986790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185664|NCT02820493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185665|NCT00084513||||TREATMENT||||||||
33753725|NCT06489535|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomization process will involve assigning participants to either the intervention or control group The Randomization ratio will be 2:1 to intervention and will be done after enrollment by a research assistant through an automated Redcap feature.||||
33753726|NCT02965365|||COHORT||PROSPECTIVE|||||||
33869262|NCT03598816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869263|NCT04858750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869264|NCT03883594|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33869265|NCT01582022|RANDOMIZED|||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33869266|NCT01460199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869267|NCT02760979|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34185666|NCT03139682|||COHORT||PROSPECTIVE|||||||
33869268|NCT04492462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869269|NCT02709694|||COHORT||CROSS_SECTIONAL|||||||
33869270|NCT01786096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185667|NCT00472030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185668|NCT01950130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753727|NCT04944641|RANDOMIZED|PARALLEL||OTHER||NONE||randomly group into two||||
33869271|NCT05856916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753728|NCT03621644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869272|NCT03388242|||COHORT||PROSPECTIVE|||||||
33753729|NCT04445636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be achieved by a statistician using an online random number generator. Patient codes will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. An anesthesia resident not involved in patient management will be responsible for opening the envelope. The anesthesia resident will prepare the study drug according to the instructions contained within each envelope and give it to the anesthesiologist.||t|t|t|t
33753730|NCT04955912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled clinical trial|t|t|f|f
33753731|NCT03510572|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753732|NCT03270449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33753733|NCT00293267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753734|NCT06463288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Randomized Clinical Trial|t|f|f|f
33753735|NCT03860584|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Both participants and key research personnel will be blinded between MFGM-enriched full-fat dairy milk (treatment) and milk with soy phospholipid/lecithin (control).|2-arm, double-blind, randomized controlled, crossover trial|t|f|f|t
33753736|NCT05485805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753737|NCT06733870|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33869273|NCT04674475|||CASE_CONTROL||PROSPECTIVE|||||||
33753738|NCT06244277|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33869274|NCT03210389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869275|NCT05837442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this double-blind study, the physician who performed the radiological evaluation was unaware of which group the individual belonged to, and the patients were unaware of which group they belonged to.|28 Patients were included. All of the patients included in the study were informed about the process. Voluntary consent was obtained from the patients participating in the study. 14 of the patients were randomly assigned to the osteopathic manual therapy group (OMTG) and 14 to the control group (CG).|t|f|t|f
33869276|NCT03666312|||COHORT||PROSPECTIVE|||||||
33869277|NCT01152684|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33869278|NCT02999867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33869279|NCT03041350|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33869280|NCT01048749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33869281|NCT01357655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869282|NCT00530283|||COHORT||PROSPECTIVE|||||||
34185669|NCT06361108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Double-blinded with regard to the study treatment that subjects receive,without the investigator, the sponsor, or the subjects being aware of wether YJ001 or the placebo is administered. All decisions concerning dose escalation will be made in a blinded manner by the safety review committee.~The Safety Review Committee (SRC), comprised of the Principal Investigator, Medical Monitor, and Sponsor's qualified designee, will convene after completion of each cohort to evaluate available safety, PK, and other relevant data.~The SRC will determine whether to proceed to the next planned dose level, continue with the study and add additional safety evaluations, expand the number of subjects at the current level, reduce the dose, or stop the study."||t|t|t|t
34185670|NCT05825378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185671|NCT01734018|||COHORT||PROSPECTIVE|||||||
34185672|NCT03419286|||CASE_ONLY||RETROSPECTIVE|||||||
34185673|NCT00645346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185674|NCT05843396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33869283|NCT02712151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33869284|NCT03333642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869285|NCT02171845|||CASE_ONLY||PROSPECTIVE|||||||
33869286|NCT02216721|||CASE_CONTROL||PROSPECTIVE|||||||
33869287|NCT02982590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965476|NCT05713214|||OTHER||PROSPECTIVE|||||||
34066487|NCT02032771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066488|NCT01487239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869288|NCT05987059|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||The proposed study will be a Type 2 hybrid effectiveness-implementation RCT with individual level randomization to two arms (standard and enhanced implementation strategy packages and control data captured at baseline. An expected 10 community-based organizations will participate in the study. A hybrid type 2 design is ideal because there are effectiveness studies conducted on preconception counseling conducted in clinical settings, but there is still a dearth of evidence on both effectiveness and implementation of preconception counseling in community-based settings and specifically with Black women and in Black-led organizations. The hybrid type 2 design would allow for continued evaluation of the effectiveness of the intervention and could capitalize on the implementation occurring to evaluate the impact of implementation strategies.||||
33869289|NCT05171348|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33869290|NCT00528580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869291|NCT05486520|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34066489|NCT05695820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed envelope|Randomized Parallel Groups Clinical Trial|t|f|f|f
34066490|NCT01687842|||FAMILY_BASED||PROSPECTIVE|||||||
34066491|NCT02929134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066492|NCT01858623|RANDOMIZED|CROSSOVER||||NONE||||||
34066493|NCT04663932|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is a prospective, multicenter, randomized, controlled, open-label clinical study.|Eligible patients with STEMI who meet the Inclusion/Exclusion Criteria will receive thrombolytic therapy, and then be transferred to the PCI center for coronary angiography (CAG). Patients having a target vessel with TIMI grade 3 flow as shown by CAG, and and ≥ 50% angiographic stenosis after thrombus aspiration, will be randomized in a 1:1 ratio to either an immediate stenting group or a deferred stenting group. Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions. Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.||||
34066494|NCT04754399|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066495|NCT03749408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066496|NCT05513755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34066497|NCT03145051|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34066498|NCT02910726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066499|NCT03103685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The dentist will be blind wheater the patient takes DAPT or not.||f|f|t|t
34066500|NCT02366403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066501|NCT01196377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066502|NCT04261010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomization 1:1:1||||
34066503|NCT01415375|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34066504|NCT00344656|||COHORT||PROSPECTIVE|||||||
34066505|NCT05136430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will not know condition assignment|Participants will be randomly assigned to one of the two study conditions at the group level after they have completed baseline assessment. The principal investigator, who is not involved in conducting assessments, will use a random number generator to determine assignment. Participants will learn their condition assignment during their first group session. The interventionist will use a detailed intervention manual to ensure standardization of treatment delivery.|f|f|f|t
34066506|NCT04875871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066507|NCT02283320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066508|NCT00003902||||TREATMENT||||||||
34066509|NCT03447106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066510|NCT01600599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34066511|NCT05387512|||CASE_CONTROL||RETROSPECTIVE|||||||
34066512|NCT00755885|NON_RANDOMIZED|||TREATMENT||NONE||||||
34066513|NCT00675337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34066514|NCT02332161|||COHORT||PROSPECTIVE|||||||
34066515|NCT03666949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066516|NCT01310244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066517|NCT01356329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066518|NCT01046357|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34066519|NCT04290325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185675|NCT03000660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185676|NCT03292796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* The patient is not masked as to treatment group and are aware of whether they are to continue or stop the PGA drops~* The care providers are not masked as to treatment group~* Outcome assessors are masked as to the patient's treatment group for their analysis of the OCT scans over the 4 week peri-operative period.~  * The scans are recorded with only the randomised identifier.~ * This is to reduce bias in the analysis of the scans~ * Unmasking of each patient will occur after their analysis of their week 4 OCT scan"|Randomised Control Trial|f|f|f|t
34185677|NCT05216354|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34185678|NCT00476853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185679|NCT00357903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185680|NCT06174415|NA|SINGLE_GROUP||TREATMENT||NONE||Comparing the data before and after treatment||||
34185681|NCT02058303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34185682|NCT05868616|||COHORT||PROSPECTIVE|||||||
34185683|NCT00397865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185684|NCT00825487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185685|NCT05710484|||OTHER||PROSPECTIVE|||||||
34185686|NCT06033404|||COHORT||PROSPECTIVE|||||||
34185687|NCT05459896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers who perform the outcome assessment and analysis will be blinded to the group allocations of participants.|A single-blinded, two-arm randomized controlled trial consisting of experimental and waitlist groups will be adopted to examine the effects of the Health Apps for Post-Pandemic Years (HAPPY) for alleviating people's physiological and psychosocial distress during the post-pandemic era.|f|f|f|t
34185688|NCT04006132|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The participants are blinded to the tested condition (unilateral vs bilateral)|||||
33869292|NCT01395875|||COHORT||RETROSPECTIVE|||||||
33869293|NCT04752176|||COHORT||RETROSPECTIVE|||||||
33869294|NCT05784636|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33869295|NCT01208584|||COHORT||PROSPECTIVE|||||||
33869296|NCT05888090|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Breastfed preterm neonates to be included in the study will be placed in 3 positions in a randomized crossover design. The order of the 3 positions that will be given to the babies in the research group will be determined by drawing lots and 3 intervention groups will be formed. Preterm newborns in each intervention group will be followed for two hours after feeding in all three positions: semi-elevated supine position, prone position, and right lateral position. Positions will be given to babies, taking into account the order of positions in each group. All positions will be applied once to each baby. Groups and position rankings according to the result of the draw:~1. st group: Prone, right lateral and semi-raised supine position~2. nd group: Semi-raised supine, prone and right lateral position~3. rd group: Right lateral, semi-raised supine and prone position~48 preterm newborns in the study group will be randomly assigned to these 3 intervention groups."||||
33869297|NCT02771509|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33869298|NCT01226459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869299|NCT04497129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869300|NCT00025220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869301|NCT01886339|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34066520|NCT05721183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The reserachers who evaluates the outcome of interest will be masked for the group allocation.|"The intervention is to implement NOST, which includes:~* observation and recording of compliance with hand hygiene recommendations~* identification of areas for improvement~* training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."|f|f|f|t
33869302|NCT01490450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869303|NCT01830751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869304|NCT02665169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869305|NCT01837030|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33869306|NCT05338177|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869307|NCT03163589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066521|NCT02501083|||CASE_ONLY||RETROSPECTIVE|||||||
34066522|NCT01560572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066523|NCT02453659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066524|NCT06366698|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients are initially randomized to either PO or IV iron, after the initial 4-week treatment patients in the PO iron group can switch to IV iron if labs continue to show persist iron deficiency anemia.||||
34066525|NCT05150080|||COHORT||PROSPECTIVE|||||||
34066526|NCT03209518|||COHORT||PROSPECTIVE|||||||
34066527|NCT01051258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066528|NCT04819750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34066529|NCT06291623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066530|NCT01141166|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34066531|NCT03580395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066532|NCT00595101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066533|NCT02986698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066534|NCT04203251|||COHORT||PROSPECTIVE|||||||
34066535|NCT02981563|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34066536|NCT01658254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34066537|NCT02121054|||COHORT||PROSPECTIVE|||||||
34066538|NCT04059341|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Sham LI-ESWT treatment.|Randomised, single-blinded, placebo-controlled trial|t|f|f|f
33753739|NCT04711915|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Healthy individuals and patients with major depressive disorder will participate in this study. Subjects will receive 0.1 mg/kg and 0.3 mg/kg DMT in a fixed order across 2 test days.||||
33753740|NCT03608930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753741|NCT01760850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965477|NCT06334978|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|The study was blinded: patients were unaware of the group to which they had been assigned. Patient evaluations at the start and end were performed by a physiotherapist different to the one performing the intervention, who was also unaware of the patient assignment. The same person performed all therapies for both the control and intervention groups and was unaware of the pre-intervention measurements. The statistician who analysed the data was also unaware of the group to which each patient belonged.|Randomised controlled clinical trial|t|f|t|t
33753742|NCT04331782|||CASE_ONLY||CROSS_SECTIONAL|||||||
33753743|NCT00002109||||TREATMENT||DOUBLE||||||
33753744|NCT04255628|||CASE_CONTROL||PROSPECTIVE|||||||
33753745|NCT01474733|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33753746|NCT05624177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A Staff member, not part of the study group will be assigned to distribute blinded samples. The investigator will not be are of the dose groups.|"Participants will be randomly assigned to one of two groups consuming chewing gum containing Streptococcus salivarius M18.~Group A: Probiotic Streptococcus salivarius M18 chewing gum (dose: 1 billion colony forming units per gum tablet) and chew for 5 minutes duration.~Group B: Probiotic Streptococcus salivarius M18 chewing gum (dose: 1 billion colony forming units per gum tablet) and chew for 10-20 minutes"|f|f|t|f
33753747|NCT03058211|||COHORT||PROSPECTIVE|||||||
33753748|NCT00446810|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33753749|NCT02432872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753750|NCT05980117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized to the intervention group receiving Remimazolam or to the control group receiving Midazolam.|t|f|f|f
33753751|NCT00854633|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33753752|NCT03490513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One of the investigators will be unblinded for safety purposes and to adjust the dose of medication|"Intervention: Subjects will be randomized to 2 groups: 1) placebo+weight loss, and 2) anastrozole+weight loss. Intervention will be conducted for 12 months.~Weight loss + placebo: Subjects will participate in a supervised dietary and exercise program plus a placebo.~Anastrozole + weight loss: Subjects will participate in a supervised dietary and exercise program plus the aromatase inhibitor, anastrozole at 1 mg daily.~All subjects will be provided supplements to ensure an intake of \~1500 mg of calcium/day and \~1000 IU vitamin D/day. We will maintain a serum 25-hydroxyvitamin D level of at least 30 ng/dl. Additional vitamin D supplements will be provided for those with level \<30 ng/dl.~Dosage adjustments and monitoring will be done by an unblinded investigator."|t|t|t|t
33965478|NCT06496594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965479|NCT01783730|||COHORT||PROSPECTIVE|||||||
33965480|NCT03833037|||COHORT||OTHER|||||||
33753753|NCT05031702|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753754|NCT02658864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753755|NCT02219022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753756|NCT06134349|||COHORT||PROSPECTIVE|||||||
33753757|NCT04899050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753758|NCT06381089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753759|NCT02767115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33753760|NCT00183703|||CASE_ONLY||CROSS_SECTIONAL|||||||
33753761|NCT00911534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753762|NCT01834755|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33753763|NCT06576271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double-blind study.||t|f|t|f
33965481|NCT05512715|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised into lithium or carbimazole arms in a 1:1 ratio||||
34066539|NCT01327560|||CASE_ONLY||RETROSPECTIVE|||||||
34066540|NCT04527978|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33753764|NCT06194123|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33753765|NCT05449951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are blinded towards treatment groups.|There are two groups.Group A experimental group which receive dry needling protocol along with conventional therapy.Group B is control group which receive sustained stretching protocol along with conventional therapy.|t|f|f|f
33869308|NCT04411420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The only blinded members of the project include the VA research and Duke Clinical Research Institute (DCRI) research staff members administering the consent and follow up survey data collection processes. All other team members will be unblinded due to the pragmatic design.|"This study is a 4-year cluster randomized pragmatic trial comparing the effectiveness of a sequenced, multi-modal integrated care pathway for lower back pain (LBP) to a care management by pain navigator program for LBP. The study target population is veterans seeking services for lower back pain in participating VA clinics.~We plan to enroll 16 VA clinics randomized in a 1:1 Ratio using a covariate constrained randomization."|f|f|f|t
33869309|NCT05102851|||CASE_CONTROL||PROSPECTIVE|||||||
33869310|NCT00383084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869311|NCT01713842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869312|NCT05517395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization will be performed by a research assistant with no access to participant information and who did not participate in the enrolment process. The person performing the intervention will be blinded to group allocation. Outcome data will be collected by another two blinded research assistants, one for the intervention group and one for the control group.|The randomized controlled trial design with one intervention arm (nutrition education and complementary feeding) and one control (usual care) arm (1:1 ratio).|t|t|t|f
33869313|NCT05526690|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869314|NCT05349851|||COHORT||PROSPECTIVE|||||||
33965482|NCT05020054|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|the participant did not know that the therapy was placebo|tecarterapia intervention and placebo|t|f|f|f
33965483|NCT00305110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965484|NCT01796431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965485|NCT01236053|||CASE_CONTROL||RETROSPECTIVE|||||||
33965486|NCT06217952|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34066541|NCT04393376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185689|NCT05887388|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This feasibility and acceptability study will use a single-arm, post-test-only trial design.||||
34185690|NCT05599867|||CASE_ONLY||PROSPECTIVE|||||||
34185691|NCT02566369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185692|NCT00967837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185693|NCT02716480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185694|NCT02565368|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185695|NCT03821727|||CASE_ONLY||OTHER|||||||
34185696|NCT02001259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34185697|NCT06284135|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185698|NCT04767529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185699|NCT06097715|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185700|NCT01001819|||COHORT||PROSPECTIVE|||||||
34185701|NCT00387985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185702|NCT06233396|||COHORT||PROSPECTIVE|||||||
33753766|NCT03256162|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33753767|NCT05263752|||OTHER||PROSPECTIVE|||||||
33753768|NCT05786690|||CASE_CONTROL||PROSPECTIVE|||||||
33869315|NCT03218098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33869316|NCT01072305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33869317|NCT00739011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869318|NCT02536313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869319|NCT03761875|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33869320|NCT02535884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||During the first 3 month the one group will be stimulated (pallidal DBS), thereafter 12 weeks open follow up, where patients in both groups are stimulated.|t|t|t|t
33869321|NCT02375152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965487|NCT04349176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965488|NCT02693600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965489|NCT00522327|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33965490|NCT00722111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965491|NCT00001803|||CASE_CONTROL||RETROSPECTIVE|||||||
33965492|NCT03367286|||COHORT||PROSPECTIVE|||||||
34066542|NCT01124370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066543|NCT03326232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066544|NCT05790642|||COHORT||PROSPECTIVE|||||||
34066545|NCT03525808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066546|NCT00350779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066547|NCT01318746|||COHORT||CROSS_SECTIONAL|||||||
34066548|NCT06327360|||COHORT||PROSPECTIVE|||||||
34066549|NCT02518841|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066550|NCT05112159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185703|NCT00946387|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185704|NCT03651297|RANDOMIZED|CROSSOVER||OTHER||NONE||The first group will complete two sessions of harnessed video gaming balance training. The second group will include older adults over the age of 50 with self-reported falls or the fear of falling. The second group of older adults will complete two sessions of a reactive (slip) training protocol. For both groups, the first session participants will be assigned randomly to use a standard fall-arrest harness or the new BWS harness system. At the second session, they will switch the harness used.||||
34185705|NCT02106858|||COHORT||PROSPECTIVE|||||||
34185706|NCT04712253|||COHORT||RETROSPECTIVE|||||||
33753769|NCT03982186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066551|NCT05418660|||COHORT||OTHER|||||||
34066552|NCT02748629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185707|NCT06147388|||COHORT||PROSPECTIVE|||||||
33869322|NCT00006151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869323|NCT04207450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869324|NCT03215420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869325|NCT06243042|||CASE_CONTROL||PROSPECTIVE|||||||
33869326|NCT04007575|||OTHER||RETROSPECTIVE|||||||
33869327|NCT02171611|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869328|NCT04297956|||COHORT||RETROSPECTIVE|||||||
33869329|NCT01252212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33965493|NCT01480908|NON_RANDOMIZED|PARALLEL||||NONE||||||
33965494|NCT03829449|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-comparative||||
33965495|NCT02657083|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33965496|NCT00158327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965497|NCT03352817|||OTHER||CROSS_SECTIONAL|||||||
33965498|NCT02881073|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33965499|NCT06416137|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869330|NCT01621230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double-blinded 2 arm|t|f|t|f
33869331|NCT03853720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869332|NCT05641870|||COHORT||PROSPECTIVE|||||||
33869333|NCT01398020|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33869334|NCT05043571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869335|NCT03988530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is double-blinded placebo controlled for all treatment arms on Treatment Day 1. All DPI-386 Nasal Gel and placebo nasal gel vials are opaque and indistinguishable. The DPI-386 Nasal Gel and placebo nasal gels are identical in color and viscosity, and without identifiable smell. Treatment Days 2-4 are open-label.||t|f|t|t
33869336|NCT01250340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869337|NCT01053299|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33869338|NCT01353196|||CASE_CONTROL||PROSPECTIVE|||||||
33965500|NCT04740112|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33965501|NCT03075657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The rating of PANSS and PSQI will be done by one Psychiatrist who will be blind to the groups and treatment alloted.||f|f|f|t
33965502|NCT06085482|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965503|NCT02981602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965504|NCT01089049|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33965505|NCT03621020|||COHORT||PROSPECTIVE|||||||
33965506|NCT00773981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185708|NCT05504785|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||"Twenty type 2 diabetic patients in the Control Group will be managed according to standard-of-care methods at TJUH using finger-stick blood glucose measurements in an attempt to maintain the patient's blood glucose levels in the desired target range (80 to 180 mg/dL).~Forty type 2 diabetic patients in the Investigational Group will be managed by the orthopedic floor nurses using the real-time DexCom G6 CGM trend data and an insulin dosing protocol to determine the appropriate therapy to maintain the patient's glucose levels in the desired target range (80 to 180 mg/dL). T~Glucose control will be compared between the two groups, and glucose control will be correlated with post-operative clinical adverse events (wound infection, deep vein thrombosis, pulmonary embolism, extended hospital LOS, hospital re-admission, emergency room visit)."||||
33965507|NCT01886170|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33965508|NCT04455594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965509|NCT02411656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965510|NCT02194166|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185709|NCT01093157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185710|NCT02745119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185711|NCT01216189|||COHORT||PROSPECTIVE|||||||
34185712|NCT05908019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34185713|NCT03077412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185714|NCT05098431|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185715|NCT06410092|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33869339|NCT01640652|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33869340|NCT02332395|||CASE_ONLY||PROSPECTIVE|||||||
33869341|NCT05911659|||COHORT||PROSPECTIVE|||||||
33965511|NCT02740933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965512|NCT00580333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965513|NCT01292460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965514|NCT00002484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965515|NCT03376984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965516|NCT03997331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33965517|NCT03012815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869342|NCT04623203|||COHORT||PROSPECTIVE|||||||
33965518|NCT05084534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965519|NCT00769678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965520|NCT05368233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965521|NCT03639961|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The integrated health system leading, managing and governing for results model is constructed from: leading practices, managing practice, and governing practices; moderating factors ; health services performance, and sustainable health outcomes and impact aligned with national health goals and Sustainable Development Goals (SDGs).||||
33965522|NCT01352559|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33965523|NCT00002777|RANDOMIZED|||TREATMENT||||||||
33965524|NCT01235858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965525|NCT05014425|||COHORT||RETROSPECTIVE|||||||
33965526|NCT02272582|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33965527|NCT04134832|||CASE_ONLY||RETROSPECTIVE|||||||
33965528|NCT01073683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965529|NCT04188769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185716|NCT02639221|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34066553|NCT00000613|RANDOMIZED|||PREVENTION||DOUBLE||||||
34066554|NCT04856397|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are four cohorts of patients in this study (please see below on study procedures). To be able to have meaningful data showing statistical significance, we will need at least 30 patients in each cohort of patients, accounting for There will be at least 30 patients in each cohort. We will need at least 100 patients enrolled in the study prior to randomization of the non-responders into early switch (\~30) or late switch (\~30) or non-switch (\~30). The estimated number also accounts for the estimated number of patients who will be lost to follow-up or may drop out.||||
34066555|NCT05529732|RANDOMIZED|PARALLEL||OTHER||SINGLE|After the researh report is written, a third person will assing an intervention and control group to the letters|Prospective, parallel, two-arm randomized controlled clinical trail|f|f|f|t
34185717|NCT02396121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869343|NCT00164073|||DEFINED_POPULATION||PROSPECTIVE|||||||
33869344|NCT01480999|||COHORT||PROSPECTIVE|||||||
33869345|NCT03975621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869346|NCT03286686|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33869347|NCT04933604|||COHORT||RETROSPECTIVE|||||||
33869348|NCT02524821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34066556|NCT06129786|||OTHER||PROSPECTIVE|||||||
34066557|NCT03634202|NA|SINGLE_GROUP||TREATMENT||NONE||Phase-1 study of escalade dose of radiation||||
34066558|NCT02966821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066559|NCT02777424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066560|NCT04260568|||OTHER||PROSPECTIVE|||||||
34066561|NCT03845400|||COHORT||PROSPECTIVE|||||||
34066562|NCT00698295|||CASE_CONTROL||PROSPECTIVE|||||||
34066563|NCT03905681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After computer-generated randomization, participants will either receive the active TENS treatment for 30 minutes, or receive the application of TENS pads and wear the device with no electrical stimulation. Both groups will have pre and post visual analogue scores assessed.|Using a sample population in a military treatment facility emergency department, this prospective, randomized controlled trial utilized forty-six total participants evenly divided to both a active and placebo group, were used to determine the efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) on acute back pain of ambulatory patients presenting for emergent care.|t|t|f|f
34066564|NCT00528073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066565|NCT04025125|||OTHER||OTHER|||||||
34066566|NCT05489549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066567|NCT04853966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066568|NCT04500678|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Metformin vs Observation|t|f|t|f
33869349|NCT03320928|||COHORT||RETROSPECTIVE|||||||
33965530|NCT00311571|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965531|NCT05787977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33965532|NCT02954120|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066569|NCT02105519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185718|NCT04207788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Activity-based intervention|t|t|t|t
34185719|NCT05969652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not know which group they belong to. Doctors examining patients will also be blinded to group information. Which group the patients are included in will be the primary investigator who only performs the exercises.|Two groups will be treated. The first group (experimental group) will be called the heavy slow resistance (HSR) group. The second group (control group) will be called the eccentric exercise (EE) group.|t|f|f|t
34185720|NCT00905801|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185721|NCT01605955|||||PROSPECTIVE|||||||
34185722|NCT05914974|||COHORT||PROSPECTIVE|||||||
34185723|NCT02281513|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33753770|NCT04616287|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33753771|NCT05773976|NA|SINGLE_GROUP||OTHER||NONE||||||
33753772|NCT05384626|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753773|NCT03657433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33753774|NCT02056080|||COHORT||RETROSPECTIVE|||||||
33753775|NCT04501510|||CASE_CROSSOVER||PROSPECTIVE|||||||
33753776|NCT02288468|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33753777|NCT00854022|||COHORT||PROSPECTIVE|||||||
33753778|NCT02191072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753779|NCT00660842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753780|NCT02068755|||COHORT||PROSPECTIVE|||||||
33753781|NCT00383487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753782|NCT00808275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753783|NCT03076970|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33753784|NCT03256773|||COHORT||PROSPECTIVE|||||||
33869350|NCT00820950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185724|NCT02415478|||||PROSPECTIVE|||||||
34185725|NCT01232023|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185726|NCT00516360|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185727|NCT06125717|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34185728|NCT01369537|||COHORT||PROSPECTIVE|||||||
34185729|NCT06383533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185730|NCT04161157|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34185731|NCT00487656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185732|NCT01370382|||COHORT||PROSPECTIVE|||||||
34185733|NCT00622440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34185734|NCT04795687|||CASE_CONTROL||PROSPECTIVE|||||||
34185735|NCT01554241|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34185736|NCT02963285|||COHORT||PROSPECTIVE|||||||
34185737|NCT02961829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185738|NCT02860767|||CASE_ONLY||PROSPECTIVE|||||||
34185739|NCT04691076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34185740|NCT00355966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185741|NCT03501108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher obtaining outcome measurements will be blinded to the group allocation of patient participants.|Comparison of application of explicit deprescribing criteria (STOPPFrail) with standard pharmaceutical care versus standard pharmaceutical care alone. The intervention is applied randomly at a single time point in hospitalized older people who will undergo a transition of care from the community to nursing home. The primary outcome measure is total number of daily prescription drugs.|f|f|f|t
34185742|NCT04816552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185743|NCT04257929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34185744|NCT01563809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753785|NCT05566223|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753786|NCT05119894|NA|SEQUENTIAL||TREATMENT||NONE||||||
33753787|NCT05111795|||COHORT||RETROSPECTIVE|||||||
33753788|NCT06074705|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753789|NCT00273312|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753790|NCT01641393|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33753791|NCT02593175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753792|NCT01587534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753793|NCT02434133|||OTHER||PROSPECTIVE|||||||
33753794|NCT03135483|||COHORT||PROSPECTIVE|||||||
33753795|NCT04683926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label, randomized, balanced, single-dose, four-treatment, four-period, four-sequence (using a Williams' square design) cross-over study.||||
33753796|NCT02164877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753797|NCT01314274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753798|NCT01712841|||CASE_CONTROL||PROSPECTIVE|||||||
33753799|NCT06371677|||COHORT||PROSPECTIVE|||||||
33753800|NCT06496178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869351|NCT03600142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869352|NCT01568775|NA|SINGLE_GROUP||||NONE||||||
33869353|NCT03401242|||COHORT||PROSPECTIVE|||||||
34066570|NCT01838772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066571|NCT04100590|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each volunteer will participate in two sessions in a cross-over fashion (active cannabis vs. inactive placebo cannabis)|t|f|t|t
34185745|NCT03289572|||CASE_ONLY||PROSPECTIVE|||||||
34185746|NCT00516516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185747|NCT06214234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient will be enrolled in one each group without masking|Two groups of patients present with variceal bleeding|f|f|t|f
34185748|NCT02035267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185749|NCT00426413|||COHORT||PROSPECTIVE|||||||
34185750|NCT00986856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185751|NCT04041414|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33869354|NCT04637607|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participants were randomly assigned to the treatment group and the control group. The Ear-Acupressure group received the seeds attached by 3M tap to the auricular acupoints. The Sham-Acupressure group received sham acupoint stimulation, on the same points, but only with 3M tap. The procedure was then switched to perform cross-over study design.|The study recruited the archery players in school teams among junior high, senior high schools, and colleges.|t|f|f|t
34185752|NCT06515600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Our Study was performed on sixty patients with VIDD from both genders. All patients will be referred by a physician. All patients were randomly assigned into two groups equal in number|Our Study was performed on sixty patients with VIDD from both genders. All patients will be referred by a physician. All patients were randomly assigned into two groups equal in number|t|f|f|f
34185753|NCT04298242|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34185754|NCT00417417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185755|NCT00670748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185756|NCT00002330||||TREATMENT||||||||
34185757|NCT02324192|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|f|t|t
34185758|NCT02022124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185759|NCT03566134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185760|NCT00985361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185761|NCT04291898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and outcome assessors will be blinded to the device they receive. Healthcare providers or site coordinators cannot be blinded due to clear differences between devices.|Patients will be randomly assigned to one of three arms for the duration of the study. The arms include: ASO, FSO, GAO/GSO which indicate the type of intervention they will be receiving.|t|f|f|t
34185762|NCT04103749|NA|SINGLE_GROUP||OTHER||NONE||||||
34185763|NCT01907711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34185764|NCT04785703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34185765|NCT00002630||||TREATMENT||||||||
34185766|NCT02170103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185767|NCT05724095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34185768|NCT04922385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185769|NCT02037399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185770|NCT00072709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34185771|NCT03604406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34185772|NCT02911168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34185773|NCT03678519|||OTHER||CROSS_SECTIONAL|||||||
34185774|NCT00891943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34185775|NCT05659186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869355|NCT00940979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185776|NCT00996333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185777|NCT01103752|||||PROSPECTIVE|||||||
34185778|NCT01523093|RANDOMIZED|CROSSOVER||||NONE||||||
34185779|NCT05073146|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34185780|NCT01647347|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34185781|NCT03651401|||CASE_CONTROL||PROSPECTIVE|||||||
34185782|NCT01926561|||CASE_CROSSOVER||PROSPECTIVE|||||||
34185783|NCT00553878|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34185784|NCT03922958|||COHORT||PROSPECTIVE|||||||
34185785|NCT03762993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Within Subject Design||||
34185786|NCT04178603|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Lean control subjects and obese insulin resistant subjects undergo two different trials (trial A and B). Trial A aims to investigate the effect of acute exercise and 2 hours recovery. Trial B aims to investigate insulin sensitivity for glucose uptake in recovery from exercise.||||
34185787|NCT06518408|||COHORT||PROSPECTIVE|||||||
33753801|NCT06359210|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE||"An adaptive design results in a final total of 4 possible subgroups, depending upon responder/non-responder status, and researchers plan to compare the proportion of participants achieving the minimum exercise guidelines for cancer survivors within the responders and incomplete responder subgroups. Admittedly however, it is not possible to fully elucidate the analyses the researchers will conduct, as researchers cannot predict the number of subgroups that participants will represent at the end of the trial (e.g., if there are no incomplete responders the design reduces to randomization to only two groups), nor the number of participants who will be in those subgroups"|f|f|t|t
33753802|NCT01981564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34185788|NCT01167413|||COHORT||PROSPECTIVE|||||||
34185789|NCT02982980|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34185790|NCT02321007|||CASE_CONTROL||PROSPECTIVE|||||||
34185791|NCT05779189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753803|NCT01624675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753804|NCT05092321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753805|NCT01165775|||COHORT||PROSPECTIVE|||||||
33753806|NCT01677273|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33753807|NCT06732518|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|In this clinical trial, masking involves several key roles to ensure unbiased results. The Participant, Care Provider, Investigator, and Outcomes Assessor are all masked in this triple-blind study. This means that the participants do not know which group they have been assigned to, the care providers administering the treatments are unaware of the specific products being used by each participant, the investigators conducting the study do not know the group assignments, and the outcomes assessors evaluating the results are blind to the treatment allocations. This comprehensive masking approach is designed to minimize any potential biases and maintain the integrity of the study results.|This is a Phase III, randomized, one-center, crossover group, triple blind, clinical study.|t|t|t|t
33753808|NCT06648642|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A 3-arm open label, adaptive randomized control trial||||
33753809|NCT06525493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||t|f|f|f
33753810|NCT02251327|||COHORT||PROSPECTIVE|||||||
33753811|NCT02803775|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33753812|NCT06386770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In our randomized controlled trial, we employed masking (also called blinding) to reduce bias. Participants were unaware of whether they were receiving the intervention or control. Caregivers were instructed not to reveal this information, and outcome assessors who evaluated results were kept separate from intervention delivery.|These prospective, randomized, controlled clinical trials will be performed in Aswan University Hospital on 75 patients who are scheduled for kidney exploration surgeries|t|t|t|t
34185792|NCT05396183|||COHORT||PROSPECTIVE|||||||
34185793|NCT05127863|NA|SINGLE_GROUP||TREATMENT||NONE||multiple single case study||||
34185794|NCT05556811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34185795|NCT03530124|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753813|NCT04834466|||CASE_ONLY||CROSS_SECTIONAL|||||||
33753814|NCT01222325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753815|NCT04905394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753816|NCT00973557|||COHORT||CROSS_SECTIONAL|||||||
33753817|NCT06429566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066572|NCT03479138|||COHORT||PROSPECTIVE|||||||
34066573|NCT02017652|||COHORT||PROSPECTIVE|||||||
34066574|NCT00651144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34185796|NCT03120897|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34185797|NCT00738933|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34185798|NCT03974568|||COHORT||PROSPECTIVE|||||||
34185799|NCT04029285|RANDOMIZED|PARALLEL||OTHER||NONE||Participants were assigned to either the control group (TGB) or the experimental group (exergaming) in parallel for the duration of the study.||||
34185800|NCT01718405|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
34185801|NCT04596384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185802|NCT01422343|||COHORT||PROSPECTIVE|||||||
34185803|NCT02861885|||COHORT||PROSPECTIVE|||||||
34185804|NCT03008057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34185805|NCT02572102|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33869356|NCT03585218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|When a participant is eligible, according to the inclusion criteria, she is allocated to one of the groups in a 1:1 ratio. The randomization assignment was placed in sealed envelopes and assigned before chemotherapy (CT).|On each moment of data collection, the researcher will apply the evaluation protocol to the participant regardless of the group and before chemotherapy treatment. Regarding the psychophysiological variable, each participant's saliva will be collected using salivettes®, while cortisol concentrations will be analyzed through ELISA kits. At the time of the sample collection, before the CT, the participant who accepted to participate and fulfilled the inclusion criteria will be provided with three salivettes and an explanatory leaflet so that, on the day before the 2nd Cycle, they can collect their own saliva, around 23h, and on the day of CT, on waking up and thirty minutes after, fasting. This process will be replicated throughout the remaining evaluation moments. Subsequently, it is also our goal to evaluate the cortisol levels to CT by performing one collection of saliva before and another thirty minutes after CT.|t|f|f|f
33869357|NCT00053092|RANDOMIZED|||TREATMENT||NONE||||||
33869358|NCT06295341|||CASE_CONTROL||OTHER|||||||
33869359|NCT03764891|||CASE_CONTROL||RETROSPECTIVE|||||||
33869360|NCT03648008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869361|NCT04206020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment Parallel-group study SkQ1 Ophthalmic Solution versus placebo (vehicle) solution|t|t|t|t
33869362|NCT00398671|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33869363|NCT00642395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869364|NCT05470920|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869365|NCT05018039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33869366|NCT03331861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869367|NCT03609138|||COHORT||PROSPECTIVE|||||||
33869368|NCT05395611|||CASE_CONTROL||PROSPECTIVE|||||||
34185806|NCT03895840|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an open-label study to determine the functional effects of IA injection of Zilretta into bilateral knees of 70 subjects with KL grade 2-4 symptomatic knee OA. Measurement of OARSI recommended physical performance measures, patient-reported physical function, quality of life and pain at baseline, 6, 12 and 24 weeks will allow assessment of short and long-term effects, consistent with OARSI and OMERACT recommendations||||
34185807|NCT04731545|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185808|NCT02910531|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34185809|NCT01020240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34185810|NCT01147510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185811|NCT01931319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185812|NCT02769585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185813|NCT01082068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185814|NCT03328091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185815|NCT01096355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185816|NCT01068496|||COHORT||PROSPECTIVE|||||||
34185817|NCT04298671|NA|SINGLE_GROUP||TREATMENT||NONE||Pre/Post||||
34185818|NCT01308177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185819|NCT00000426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869369|NCT04823572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185820|NCT05084950|||COHORT||PROSPECTIVE|||||||
34185821|NCT02484885|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185822|NCT05938400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185823|NCT04411667|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized into one of two groups: Standard of Care plus IVIG or Standard of Care.||||
34185824|NCT05240391|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185825|NCT03275649|||OTHER||PROSPECTIVE|||||||
34185826|NCT02559999|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185827|NCT00790842|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869370|NCT03512795|||OTHER||PROSPECTIVE|||||||
33869371|NCT04298775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33869372|NCT04860271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator did not know the respondent and did not come in contact. The outcome assessor consist of 4 person who are randomly assessing the respondent, so the assessor do not know the full data since the beginning of participation thus do not have any bias when assessing the respondent||f|f|t|t
33869373|NCT02251379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869374|NCT02213575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869375|NCT05602662|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34185828|NCT05234697|||COHORT||PROSPECTIVE|||||||
34185829|NCT04931043|||CASE_ONLY||PROSPECTIVE|||||||
34185830|NCT05945537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185831|NCT02352389|||COHORT||PROSPECTIVE|||||||
34185832|NCT02000869|||COHORT||PROSPECTIVE|||||||
34185833|NCT03193593|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34185834|NCT00419588|||CASE_CONTROL||PROSPECTIVE|||||||
34185835|NCT02713464|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34185836|NCT02064257|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34185837|NCT01131689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185838|NCT05220072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185839|NCT04685044|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185840|NCT06415136|||COHORT||RETROSPECTIVE|||||||
34185841|NCT05552989|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34185842|NCT01303367|||||RETROSPECTIVE|||||||
34185843|NCT02145377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34185844|NCT03710577|RANDOMIZED|CROSSOVER||OTHER||NONE||The proposed study is an acute, single group, crossover pilot study where participants will complete control and experimental conditions.||||
34185845|NCT04254172|||CASE_ONLY||PROSPECTIVE|||||||
34185846|NCT05510596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185847|NCT01287741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185848|NCT02538978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869376|NCT05043714|NA|SEQUENTIAL||TREATMENT||NONE||||||
34185849|NCT03913507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185850|NCT00636298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869377|NCT01612468|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34185851|NCT03613519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know the treatment at the time of randomization.|Eligible subjects will be randomly assigned to one of the 3 intervention groups; SHUTi-BWHS, SHUTi, or patient education (PE).|t|f|f|f
34185852|NCT04690361|||OTHER||CROSS_SECTIONAL|||||||
34185853|NCT00513916|RANDOMIZED|||PREVENTION||||||||
34185854|NCT03641586|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185855|NCT02622282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185856|NCT02297594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869378|NCT05458973|||CASE_ONLY||PROSPECTIVE|||||||
33869379|NCT02593162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869380|NCT05864742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869381|NCT03207711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blood tests at LabCorp and 24-hour dietary recall interviews are done by research assistants blinded to treatment assignment.||f|f|f|t
34185857|NCT04129008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185858|NCT03983811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185859|NCT05251324|||COHORT||PROSPECTIVE|||||||
34185860|NCT02581241|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185861|NCT06344221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185862|NCT04179669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185863|NCT00179192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185864|NCT02198768|||COHORT||PROSPECTIVE|||||||
34185865|NCT00328107|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34185866|NCT02289157|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Placebo Controlled Clinical Trial - Open Label||||
34185867|NCT00254839|||||OTHER|||||||
34185868|NCT02991976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33869382|NCT03029715|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34066575|NCT03917979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to fully mask participants to the treatment they receive since they will know whether their sessions start immediately or after 20 weeks and whether their sessions are individual or in a group. Similarly, it is not possible to mask the care provider to the participants' condition. However, participants will be masked to which condition is the experimental condition and which is the control condition, and all will receive a series of GIM sessions either in groups or as individuals. The outcome assessors will be masked to participants' group assignment during data collection since participants will complete data collection procedures by mailed packet of self-report measures. All self-report packets will be identified only by a unique client number.||f|f|f|t
34066576|NCT00362531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185869|NCT01181349|||COHORT|||||||||
34185870|NCT05740540|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34185871|NCT06395337|NA|SINGLE_GROUP||OTHER||NONE||||||
34185872|NCT03976219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185873|NCT05254704|||COHORT||PROSPECTIVE|||||||
34185874|NCT02865577|||OTHER||CROSS_SECTIONAL|||||||
34185875|NCT00753649|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185876|NCT05684393|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double blinded design: both the participant and the investigator have no information about the treatment group.|The performance with the CI is investigated over time in two groups of freshly implanted CI users. The first group is fitted using the standard frequency-band distribution as implemented in MAESTRO 9 fitting software. In the second group of users, an anatomy-based frequency distribution is used as per anatomy-based fitting in MAESTRO 9.|t|f|t|f
34185877|NCT01342016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185878|NCT03330301|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34185879|NCT04312724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185880|NCT04119531|||CASE_CONTROL||PROSPECTIVE|||||||
34185881|NCT02224001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185882|NCT03515330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients will be aware of which arm they are randomized to; thus, the study will not be blinded to practitioners or patients. However, study personnel performing data analysis will receive de-identified data that does not explicitly describe which group is intervention and which is control, but simply the code without a key. Only the PI and necessary personnel performing data extraction will have the key for the code to minimize bias in data analysis.|This is a single center, prospective, randomized control trial with two arms. Participants in the intervention arm will use the mHealth app to manage and track their immunosuppression medical regimen post-transplant, and participants in the control arm will receive the current standard of follow-up care post-transplant.|f|f|f|t
34185883|NCT06172309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185884|NCT05915910|||OTHER||PROSPECTIVE|||||||
34185885|NCT01165216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185886|NCT02268357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185887|NCT04129463|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1 SST with iris incarceration and group2 conventional trabeculotomy||||
34185888|NCT04665167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185889|NCT05086107|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||BV100 administered as a single intravenous infusion to subjects with varying degree of renal impairment and control volunteers with normal renal function.||||
34185890|NCT01463644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185891|NCT03318302|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33753818|NCT05808049|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Sequentially numbered, sealed, opaque envelopes|Randomized, Parallel Group, Placebo Controlled Trial|t|t|t|f
33753819|NCT06096051|||OTHER||RETROSPECTIVE|||||||
33753820|NCT02848248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753821|NCT04952506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753822|NCT01560039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34185892|NCT02305719|||CASE_ONLY||PROSPECTIVE|||||||
34185893|NCT04653077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185894|NCT01467960|||COHORT|||||||||
34185895|NCT00560001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185896|NCT00509704|||CASE_CONTROL||PROSPECTIVE|||||||
34185897|NCT02812342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753823|NCT04259450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753824|NCT02937961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753825|NCT02112188|||COHORT||PROSPECTIVE|||||||
33753826|NCT06440291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869383|NCT01129830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869384|NCT05001984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, open-label, blinded end-point study|f|f|t|t
33869385|NCT02060942|||COHORT||PROSPECTIVE|||||||
33869386|NCT03588182|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel design, nonblinded, randomized controlled superiority trial||||
33869387|NCT03886311|NA|SINGLE_GROUP||TREATMENT||NONE||Forty male and female patients with advanced sarcoma including desmoid tumor and chordoma will be treated with talimogene laherparepvec, nivolumab and trabectedin will be studied and evaluated for progression free survival at month 12.||||
33869388|NCT02577744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066577|NCT04618809|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34066578|NCT04607681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33753827|NCT02617004|||COHORT||PROSPECTIVE|||||||
33869389|NCT06433830|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33869390|NCT03422432|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869391|NCT00880659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185898|NCT01793324|||||RETROSPECTIVE|||||||
34185899|NCT03937934|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34185900|NCT00972062|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34185901|NCT06347120|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34185902|NCT00776074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185903|NCT06324513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34185904|NCT00256997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185905|NCT04642690|||COHORT||PROSPECTIVE|||||||
34185906|NCT04490876|||CASE_ONLY||RETROSPECTIVE|||||||
34185907|NCT01647217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185908|NCT04473313|||COHORT||PROSPECTIVE|||||||
34185909|NCT02886455|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34185910|NCT05039892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185911|NCT02106390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185912|NCT03599739|||COHORT||RETROSPECTIVE|||||||
34185913|NCT00829504|RANDOMIZED|CROSSOVER||||NONE||||||
34185914|NCT01999257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34185915|NCT01840982|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34185916|NCT02424877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185917|NCT00604773|||COHORT||PROSPECTIVE|||||||
33753828|NCT05117242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753829|NCT02937168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753830|NCT06562361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869392|NCT00512343|||COHORT||PROSPECTIVE|||||||
33869393|NCT04609228|||COHORT||RETROSPECTIVE|||||||
33869394|NCT00095082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869395|NCT00036075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869396|NCT05131984|||COHORT||RETROSPECTIVE|||||||
34185918|NCT01559857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185919|NCT02772367|||COHORT||PROSPECTIVE|||||||
34185920|NCT00578825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34185921|NCT00217607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185922|NCT05498714|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34185923|NCT02718144|NA|SINGLE_GROUP||OTHER||NONE||||||
34185924|NCT01678404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185925|NCT03089281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34185926|NCT05255315|||COHORT||RETROSPECTIVE|||||||
34185927|NCT02272439|||COHORT||PROSPECTIVE|||||||
34185928|NCT00365833|||COHORT||PROSPECTIVE|||||||
34185929|NCT00517244|||CASE_CONTROL||PROSPECTIVE|||||||
34185930|NCT02217202|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185931|NCT03317184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Expertise-based, single intuition, assessor-blinded, randomized clinical trial.|f|f|t|t
33869397|NCT04638972|||CASE_ONLY||PROSPECTIVE|||||||
33869398|NCT00003702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869399|NCT00003895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869400|NCT06082388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869401|NCT00175877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185932|NCT00541541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869402|NCT02549430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869403|NCT00906568|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869404|NCT04091490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869405|NCT02680132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869406|NCT02489643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869407|NCT00651417|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33869408|NCT00847145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869409|NCT04482218|||COHORT||PROSPECTIVE|||||||
34185933|NCT03677557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185934|NCT02645669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185935|NCT02185482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34185936|NCT03522896|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34185937|NCT01241227|||COHORT||PROSPECTIVE|||||||
34185938|NCT00585767|||CASE_CONTROL||PROSPECTIVE|||||||
34185939|NCT00040989||||TREATMENT||||||||
34185940|NCT05509140|||CASE_ONLY||RETROSPECTIVE|||||||
34185941|NCT05846854|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869410|NCT01196520|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34185942|NCT03946475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|participants did not know that they were in intervention group|Intervention group (4 schools) received nutrition education in the same time. Meanwhile, control group (4 schools) did not received anything except for baseline and endline data collection.|t|f|f|f
34185943|NCT04630496|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33869411|NCT04932850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical kits for active and placebo will be provided.||t|t|t|t
34185944|NCT05285046|||COHORT||PROSPECTIVE|||||||
34185945|NCT00005618||||TREATMENT||||||||
34185946|NCT05805917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185947|NCT01965574|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185948|NCT02495519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185949|NCT03423784|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34185950|NCT02395471|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34185951|NCT05542030|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Non-blinded, single center, non-randomized prospective pilot study||||
34185952|NCT00983658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34185953|NCT05465577|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34185954|NCT02369796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185955|NCT00802945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185956|NCT00604487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185957|NCT04506138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185958|NCT02287766|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34185959|NCT01442103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185960|NCT00087867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185961|NCT06514560|||COHORT||PROSPECTIVE|||||||
34185962|NCT01010646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185963|NCT05585450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34185964|NCT01209533|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33869412|NCT03670043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869413|NCT00777621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869414|NCT04046081|NA|SINGLE_GROUP||OTHER||NONE||||||
33869415|NCT05755295|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33869416|NCT02047253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869417|NCT04666779|||COHORT||PROSPECTIVE|||||||
33869418|NCT03901105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|PET scans were obtained in an open-label fashion.|Physician PET scan readers are participants, blinded to demographic and clinical data from the source PET scans.||||
33869419|NCT02774512|NA|SINGLE_GROUP||OTHER||NONE||||||
33869420|NCT05752877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869421|NCT04349982|||COHORT||PROSPECTIVE|||||||
34185965|NCT06226493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185966|NCT02873351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34185967|NCT04336878|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the nature of the trial, it will not be possible to blind participants or intervention facilitators to group allocation. Researchers involved in collecting outcome data will not have access to details of group allocation and we will attempt to retain this blinding throughout. Participants will be asked not to discuss their group allocation with the researchers. Fidelity of blinding will be assessed.||f|f|t|t
34185968|NCT03865095|||COHORT||PROSPECTIVE|||||||
34185969|NCT01512238|||||RETROSPECTIVE|||||||
34185970|NCT00663091|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34185971|NCT03498404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185972|NCT05611190|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34185973|NCT04147780|||COHORT||PROSPECTIVE|||||||
34185974|NCT02949284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185975|NCT06228313|||CASE_ONLY||CROSS_SECTIONAL|||||||
34185976|NCT02684825|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34185977|NCT04601649|RANDOMIZED|PARALLEL||PREVENTION||NONE|None; this is a feasibility study.|30 friendship dyads (N=60) will be assigned to a control group and 30 friends dyads (N=60) will be assigned to the intervention group to collect feasibility and acceptability data.||||
34185978|NCT03549767|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is testing the acceptability of the device (springfusor) in the administration of magnesium suphate||||
34185979|NCT03725891|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|both participants and researchers will be blinded to the intervention given|This will be a randomized control trial to estimate the efficacy of two doses (81 mg versus 162 mg) of aspirin for prevention of preeclampsia in healthy, nulliparous obese and overweight pregnant women identified in the first trimester.|t|t|t|t
34185980|NCT03811704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185981|NCT01290770|||CASE_ONLY||PROSPECTIVE|||||||
34185982|NCT02840461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34185983|NCT02079961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34185984|NCT00854399||PARALLEL||BASIC_SCIENCE||NONE||||||
34185985|NCT03384862|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All participants, field staff, and investigators will be blinded to the intervention status of participants.||t|t|t|f
34185986|NCT02002910|||CASE_ONLY||PROSPECTIVE|||||||
34185987|NCT02578693|||COHORT||OTHER|||||||
34185988|NCT04550884|||CASE_ONLY||CROSS_SECTIONAL|||||||
34185989|NCT03949803|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34185990|NCT05433519|||COHORT||PROSPECTIVE|||||||
34185991|NCT04085289|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34185992|NCT03370900|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|All analyses were blinded to group assignment|This was a four arm randomized control trial. All participants completed an 80-case deliberately practiced learning set of pediatric elbow radiographs followed by an immediate 20-case post-test. Following this, Group 1 had no testing until 12 months; Groups 2, 3, and 4 had testing (20 cases without feedback) every 2 months until 12 months, but Group 3 also had refresher education (20 cases with feedback) at six months while Group 4 had refresher education at two, six, and ten months.|f|f|f|t
34185993|NCT02503761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185994|NCT00156468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34185995|NCT00273494|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34185996|NCT05173753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||for both the intervention group and control group, the procedure and follow up will be done parallel to each other(same time).|t|f|f|t
34185997|NCT02945488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34185998|NCT01834911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34185999|NCT04563143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186000|NCT05394155|NA|SINGLE_GROUP||OTHER||NONE||Repeated measures study design.||||
34186001|NCT04306341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186002|NCT04530084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186003|NCT03326336|NA|SEQUENTIAL||TREATMENT||NONE||3 dose-escalation cohorts with 3 subjects per each cohort plus 1 extension cohort at the highest well-tolerated dose.||||
34186004|NCT00104923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186005|NCT02955849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186006|NCT00501917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186007|NCT02586740|||COHORT||RETROSPECTIVE|||||||
34186008|NCT02675634|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34186009|NCT00721968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186010|NCT02039141|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186011|NCT01543048|||COHORT||PROSPECTIVE|||||||
34186012|NCT03657082|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186013|NCT02462135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34186014|NCT03335670|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186015|NCT00201110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186016|NCT01852409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186017|NCT00172393|||DEFINED_POPULATION||OTHER|||||||
34186018|NCT00206817|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34186019|NCT05153096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869422|NCT03526770|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|only primary investigator will know the intervention done by the subject. The outcome investigator(assessor) will be unaware (blinded) to which intervention the subject is undertaken.||f|f|f|t
33869423|NCT00729482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869424|NCT01037660|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33869425|NCT00376090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33869426|NCT04856930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869427|NCT02197338|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33869428|NCT00636675|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33869429|NCT01166100|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869430|NCT00542464|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33869431|NCT01979536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186020|NCT03516968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186021|NCT00399815|||CASE_CONTROL||PROSPECTIVE|||||||
34186022|NCT01088698|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186023|NCT00002496||||TREATMENT||||||||
34186024|NCT01497223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186025|NCT03236636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||multicenter, randomized, double-blind, double-dummy, adaptive enrichment design|t|t|t|t
34186026|NCT01012440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186027|NCT02181088|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869432|NCT05645614|||COHORT||RETROSPECTIVE|||||||
33869433|NCT06348485|||CASE_CONTROL||RETROSPECTIVE|||||||
33869434|NCT02430142|||COHORT||PROSPECTIVE|||||||
34186028|NCT00633113|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34186029|NCT02379091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186030|NCT03636516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186031|NCT04145518|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34186032|NCT01226199|||COHORT||PROSPECTIVE|||||||
34186033|NCT04561765|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||A 1x3 pilot randomized control trial (RCT) (iCanCope-NF, iCanCope-NF +Contingency Management (CM), Control Group) will be conducted with 108 adults with NF1 who suffer from pain.|t|f|f|f
33869435|NCT05038462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34186034|NCT02302339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186035|NCT05419778|||CASE_CROSSOVER||PROSPECTIVE|||||||
34186036|NCT03060096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be stratified by baseline score ≥15 on the GAD-7 and/or on the PHQ-9, indicating severe significant anxiety or depressive symptom. Participants with moderate symptoms only (10-14 on the PHQ-9 and/or 8-14 on the GAD-7) will be block randomized to either the low-intensity stepped care or to the enhanced usual care (EUC control). Participants with moderate to severe symptoms will be block randomized to either the high-intensity stepped care intervention or the EUC control. Block sizes will be chosen randomly to ensure that future assignments cannot be inferred from previous ones.||||
34186037|NCT06096961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||There are two groups in the study: experimental and control groups. Mothers in the experimental group will be given baby clothes that their babies will wear for 12 hours and will be asked to smell these clothes during the milking process. The work will continue for four days. Mothers in the intervention group will smell their baby's scented diapers, and mothers in the control group will express their milk without any intervention and record the amount.|t|t|f|f
34186038|NCT04799093|||CASE_CONTROL||PROSPECTIVE|||||||
34186039|NCT04513197|||CASE_CONTROL||PROSPECTIVE|||||||
34186040|NCT06152393|||CASE_CONTROL||OTHER|||||||
34186041|NCT05486806|||COHORT||PROSPECTIVE|||||||
34186042|NCT00624169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186043|NCT04368637|||COHORT||CROSS_SECTIONAL|||||||
34186044|NCT01628666|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34186045|NCT02282514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186046|NCT02460419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753831|NCT06525324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753832|NCT00093834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753833|NCT04950374|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33869436|NCT04086004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869437|NCT06011343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After randomization and allocation each patient will receive a code that will be confidential.|CL patients will be allocated in 2 intervention groups.|t|f|t|f
33869438|NCT00825279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33869439|NCT05310643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869440|NCT03198520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869441|NCT00011908||||TREATMENT||||||||
33869442|NCT04973982|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open label, single centre, randomised parallel-group controlled trial||||
33869443|NCT04329351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869444|NCT00725881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869445|NCT02742064|||CASE_CONTROL||PROSPECTIVE|||||||
33869446|NCT06038240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33869447|NCT00937261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869448|NCT00185952|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34186047|NCT06450483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants were masked in regards to the group they are in|Random allocation of two groups|t|f|f|f
34186048|NCT01550224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186049|NCT02869880|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34186050|NCT02739061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33869449|NCT05785468|||COHORT||RETROSPECTIVE|||||||
33869450|NCT05140512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869451|NCT03387436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"As in most psychological interventions, care providers (psychologists) can not be blinded, because they are delivering the intervention.~Patients only know if they are in one of the intervention groups or in TAU. All other study personnel will be blinded."|"Participants will be allocated randomly to three arms:~1. palliative treatment as usual (TAU)~2. sham-intervention + (TAU)~3. study-intervention + (TAU)~Stratification will be carried out for sex, and availability of a care giver."|f|f|t|t
33869452|NCT00262210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869453|NCT00474396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||||||
33869454|NCT01661855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869455|NCT05691998|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869456|NCT03688399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869457|NCT06087250|||CASE_CROSSOVER||PROSPECTIVE|||||||
33869458|NCT00625495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186051|NCT06214273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double-blinded trial:~The outcome assessor and the statistician will be blinded. Participants can't be blinded because of the difference in intervention methods of application."|a three-arm head-to-head RCT assessing two of the promising studied interventions, low-level diode laser and topical chamomile, comparing them to each other's and to conventional therapy.|f|t|f|t
34186052|NCT03805282|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A study participant who will not participate during assessment of the main outcome will prepare the drug solutions to be infused at 10ml/h accordingly to the response of the previous patient and to the dose calculated for the next patient. The participant who will verify the main outcome during anesthesia emergence will not know the dose the patient is receiving. Participants will not be informed of the dose they will receive. The outcomes assessor will not handle individual data and statistical analysis plan was developed in advance.|"Four parallel groups will be studied:~* Female \> 60 years old~* Male \> 60 years old~* Female 18 to 60 years old~* Male 18 to 60 years old"|t|t|t|t
34186053|NCT03783832|||COHORT||OTHER|||||||
34186054|NCT05176405|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33965533|NCT03221439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical outcomes will be obtained in the evaluations carried out by a blinded assessor 3, 6 and 12 months after randomization. Both arms include active treatments, and participants will not know whether they are in the experimental group or control group.|Randomized controlled trial with concealed allocation, blinded assessor, blinded participants and intention to treat analysis. Patients will be evaluated at baseline, immediately after the end of the intervention (12 weeks), as in 6 and 12 months after randomization, to assess the maintenance of any effect of treatment. The patients in the CFT group will be treated by two physical therapists that attended twice the CFT workshops with two of the tutors of the method. They completed 106 hours of training including workshops, patient examinations and a pilot study with the supervision of a physical therapist with more than three years of clinical experience in CFT. Patients in MT-EX group will be treated by two physical therapists with more than 8 years of clinical experience in manual therapy and motor control exercises.|t|f|f|t
34186055|NCT04961411|||CASE_ONLY||RETROSPECTIVE|||||||
34186056|NCT00904592|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34186057|NCT04948359|||COHORT||PROSPECTIVE|||||||
34186058|NCT00060840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186059|NCT01695304|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an intervention trial of ceramic water filters, and as such cannot be masked. The intervention participants received the CWFs during the trial and the control group after the trial was over.|||||
34186060|NCT00865566|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34186061|NCT03162549|||COHORT||PROSPECTIVE|||||||
34186062|NCT04139213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186063|NCT02944487|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33965534|NCT02997956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965535|NCT00766506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965536|NCT05578417|||COHORT||RETROSPECTIVE|||||||
33965537|NCT04379440|||COHORT||OTHER|||||||
33965538|NCT05057234|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33965539|NCT03230968|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33965540|NCT04663269|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Anesthesia will know the randomization assignment. The surgeon and the patient will be blinded to randomization.||t|f|t|f
33965541|NCT02717338|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33965542|NCT06542549|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects in the experimental group received AK104 combined chemotherapy for 3-4 cycles (determined by the investigator) before surgery, and subjects in the control group received chemotherapy for 3-4 cycles (determined by the investigator) before surgery.||||
33965543|NCT00676026|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33965544|NCT01571635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965545|NCT02964052|||COHORT||PROSPECTIVE|||||||
33965546|NCT03630588|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33965547|NCT05470738|||COHORT||PROSPECTIVE|||||||
33965548|NCT05774873|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965549|NCT03100253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965550|NCT04324398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965551|NCT02783742|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33965552|NCT05607810|||OTHER||PROSPECTIVE|||||||
33965553|NCT02572180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965554|NCT03677778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965555|NCT03475940|||COHORT||RETROSPECTIVE|||||||
33965556|NCT00301431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965557|NCT04368325|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965558|NCT06517849|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will know whether they are offered the incentive or not. Care providers (i.e., counselors at Kindbridge Behavioral Health) will not know (and participants can access care regardless of whether they are in the treatment group or not).|Participants in the control group will take two (paid) surveys and have access to free cognitive behavioral therapy (CBT). Participants in the treatment group will be offered an additional payment (in the form of gift cards) to undergo a certain number of CBT sessions with Kindbridge Behavioral Health.|f|t|f|f
33965559|NCT04573179|||COHORT||PROSPECTIVE|||||||
33753834|NCT01642680|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965560|NCT04331652|NA|SINGLE_GROUP||OTHER||NONE||||||
33965561|NCT00067158||||TREATMENT||||||||
33965562|NCT01406873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965563|NCT01050166|||COHORT||PROSPECTIVE|||||||
33965564|NCT00894465|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34186064|NCT05991297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||classic rehabilitation group vs.deep sensory assisted rehabilitation group|t|t|f|t
34186065|NCT06250348|||OTHER||PROSPECTIVE|||||||
34186066|NCT01641185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186067|NCT03088956|||COHORT||PROSPECTIVE|||||||
34186068|NCT01424072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186069|NCT05716282|||COHORT||PROSPECTIVE|||||||
34186070|NCT01174719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186071|NCT02927561|||||RETROSPECTIVE|||||||
34186072|NCT04674761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186073|NCT01441232|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186074|NCT02640534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186075|NCT04347876|||CASE_CONTROL||PROSPECTIVE|||||||
33965565|NCT00821522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965566|NCT02046473|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33965567|NCT05541601|||COHORT||PROSPECTIVE|||||||
34186076|NCT04749992|||CASE_CONTROL||PROSPECTIVE|||||||
34186077|NCT04843657|||COHORT||PROSPECTIVE|||||||
34186078|NCT02224807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34186079|NCT00101673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186080|NCT03937622|||COHORT||PROSPECTIVE|||||||
34186081|NCT04944004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blinded||t|f|f|t
34186082|NCT04981483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186083|NCT00069615|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34186084|NCT06256796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186085|NCT00048074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186086|NCT01688349|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34186087|NCT01070485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186088|NCT01342211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186089|NCT02309242|NA|SINGLE_GROUP||SCREENING||NONE||||||
34186090|NCT04791332|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34186091|NCT05723003|||COHORT||PROSPECTIVE|||||||
33869459|NCT04350528|||COHORT||RETROSPECTIVE|||||||
33869460|NCT00193869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186092|NCT00538018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186093|NCT02321709|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34186094|NCT05378750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186095|NCT01529723|||COHORT||PROSPECTIVE|||||||
34186096|NCT05341141|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186097|NCT05513794|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34186098|NCT00244400|||DEFINED_POPULATION||OTHER|||||||
34186099|NCT01786577|||COHORT||PROSPECTIVE|||||||
34186100|NCT02018718|NA|SINGLE_GROUP||OTHER||NONE||||||
34186101|NCT02282098|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34186102|NCT00346697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186103|NCT04454918|NA|SINGLE_GROUP||OTHER||NONE||||||
34186104|NCT03727256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186105|NCT05576454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded design.|It's a randomized, double-blinded, single-dose, 3-arm parallel comparative study.|t|t|t|t
34186106|NCT05151276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34186107|NCT05793268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186108|NCT02406508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186109|NCT00649038|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34186110|NCT00171561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186111|NCT00888732|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186112|NCT02131506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186113|NCT02844309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186114|NCT04289064|||COHORT||PROSPECTIVE|||||||
34186115|NCT03941288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186116|NCT05374512|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a 1:1 ratio to one of two intervention groups.||||
34186117|NCT05593978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186118|NCT04982263|||COHORT||PROSPECTIVE|||||||
34186119|NCT03798353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization will be known exclusively by the cardiac surgery team and the study coordinator, and it will be blind to the patient and to the rest of the investigators team: clinical cardiologist who performs the follow-up, team that performs image tests, core lab that evaluates the imaging tests and the equipment that statistically analyzes the data.|"- Experimental group: The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.~In addition, the matrix-cell construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.~- Control group: The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed."|t|f|t|f
34186120|NCT03254758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186121|NCT03083834|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34186122|NCT01004991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869461|NCT00236769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186123|NCT03154411|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|open label|||||
34186124|NCT01175577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34186125|NCT04819178|||COHORT||PROSPECTIVE|||||||
34186126|NCT04127006|||COHORT||PROSPECTIVE|||||||
34186127|NCT00909298|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34186128|NCT02357368|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186129|NCT05513599|||COHORT||PROSPECTIVE|||||||
34186130|NCT02038933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186131|NCT03441815|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Blinding was carried out by using Placebo equivalent to XC8 tablets without active substance and the corresponding labeling of the study drug.|The dose cohorts were included into the study subsequently based on preliminary safety results evaluation performed by the Data Safety Monitoring Committee. 4 doses of XC8/placebo (2 mg, 10 mg, 50 mg and 200 mg) were used in the study.The duration of exposure to the study drug was 15 days in each cohort: Day 1, once, at the step of single administration, and then in 6 days, daily, 1 time a day for 14 days at the step of multiple administration.|t|f|t|f
34186132|NCT03753828|||COHORT||RETROSPECTIVE|||||||
34186133|NCT00331097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186134|NCT02357771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186135|NCT06654765|||OTHER||PROSPECTIVE|||||||
34186136|NCT00298558|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34186137|NCT03611153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only research pharmacy staff will be aware of randomization scheme and all study personnel and subjects will remain blinded.|Single Administration of study drug|t|f|t|f
34186138|NCT01301027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965568|NCT05828433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965569|NCT01826318|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33869462|NCT01640509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869463|NCT05860842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869464|NCT06466031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33869465|NCT03663426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869466|NCT01670539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869467|NCT03094351|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Parallel Assignment||||
33965570|NCT05066087|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|During the RCT data analysis, the researcher will be blinded (not knowing the participants treatment group).|Focus groups (n=16 patients and n=8 health care professionals); single-arm, iterative sprints with n=10 patients per sprint (total of n=40-60 patients); two-armed RCT with n=180 patients per arm; interviews with stakeholders (minimum of n=6 interviews)|f|f|f|t
33965571|NCT04737668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965572|NCT00838500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33753835|NCT01647490|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33753836|NCT05661955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753837|NCT04357262|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33753838|NCT00554879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33869468|NCT05421312|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"This explorative, low intervention study will be conducted in the Radboudumc Nijmegen and Sint Maartenskliniek (SMK) Nijmegen, The Netherlands.~Subject will receive the cefazolin antibiotic prophylaxis and clindamycin antibiotic therapy as standard of care. The study interventions will include blood sampling on baseline and perioperative sampling of serum, synovial fluid and bone for the concentration measurements of the antibiotic agents. For every participating subject 3 serum samples, 1 synovial fluid sample and 2 bone samples will be taken for concentration measurement of cefazolin and clindamycin. Samples will be taken at different timepoints during the procedure."||||
34186139|NCT05736068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient-Reported Outcome Measure (PROM) scores and radiographs will be evaluated by persons, who are blinded to treatment allocation and who are not otherwise involved in the study. Data analysis will be performed by an external biostatistician blinded to treatment allocation.||f|f|f|t
34186140|NCT00000285||PARALLEL||TREATMENT||DOUBLE||||||
34186141|NCT04075032|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled and crossover trial.|t|t|f|t
34186142|NCT05408442|||COHORT||PROSPECTIVE|||||||
34186143|NCT02351856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186144|NCT01377103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186145|NCT00584636|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34186146|NCT03952975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753839|NCT06545760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33753840|NCT01770054|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33753841|NCT01371773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186147|NCT01885741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186148|NCT04118959|||CASE_ONLY||PROSPECTIVE|||||||
34186149|NCT05271877|||COHORT||RETROSPECTIVE|||||||
34186150|NCT04980703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34186151|NCT06492746|NA|SINGLE_GROUP||OTHER||NONE||||||
34186152|NCT04843007|||CASE_ONLY||PROSPECTIVE|||||||
34186153|NCT00852852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34186154|NCT01072643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186155|NCT00001209||||TREATMENT||||||||
34186156|NCT02099955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186157|NCT02999672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186158|NCT00912795|RANDOMIZED|PARALLEL||||NONE||||||
34186159|NCT00997308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34186160|NCT05654532|NA|SEQUENTIAL||TREATMENT||NONE||||||
34186161|NCT06374628|||COHORT||RETROSPECTIVE|||||||
34186162|NCT03553303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186163|NCT03705143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186164|NCT01947140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186165|NCT04539795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186166|NCT03630445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33869469|NCT00143195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753842|NCT04003168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753843|NCT04266301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind|t|t|t|f
33753844|NCT02436265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753845|NCT05944523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869470|NCT01436084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869471|NCT01825291|||COHORT||RETROSPECTIVE|||||||
33869472|NCT06345430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869473|NCT00754793|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33869474|NCT06446245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Phase II, multi-center randomised controlled trial, parallel design of intervention versus placebo|t|t|t|t
33869475|NCT04986033|||COHORT||RETROSPECTIVE|||||||
33869476|NCT05974150|||OTHER||PROSPECTIVE|||||||
33869477|NCT04687332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective controlled monocentric observational study||||
33869478|NCT02369107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869479|NCT02639572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869480|NCT04918745|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE||Controlled clinical trial with a randomized single-blind 3-treatment 3-period crossover design|t|f|f|f
33869481|NCT03277742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869482|NCT06490744|||CASE_CONTROL||RETROSPECTIVE|||||||
33869483|NCT02512133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869484|NCT05107830|||CASE_CONTROL||RETROSPECTIVE|||||||
33869485|NCT04972240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869486|NCT05472467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869487|NCT06360250|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33869488|NCT03344952|||CASE_ONLY||RETROSPECTIVE|||||||
33965573|NCT01354262|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186167|NCT04814004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869489|NCT02821923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33869490|NCT01554644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186168|NCT00942227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33869491|NCT01417338|||COHORT||PROSPECTIVE|||||||
33869492|NCT03163251|NA|SINGLE_GROUP||OTHER||NONE||This is a single institution, single arm, prospective cohort study stratified by post-graduate training year||||
33869493|NCT05897723|NA|SINGLE_GROUP||TREATMENT||NONE|Independent blinded evaluator assessment of the surgical scar sites using the Global Aesthetic Improvement Scale (GAIS), comparing follow-up visit photographs for for both the treated and untreated sides.|Non-randomized, single-center, split-body, evaluator blinded||||
33869494|NCT00640718|||CASE_ONLY||PROSPECTIVE|||||||
33869495|NCT03715894|||CASE_ONLY||PROSPECTIVE|||||||
33869496|NCT02779959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869497|NCT06116604|||COHORT||PROSPECTIVE|||||||
33869498|NCT01490814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869499|NCT06299657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Raters completing the outcome assessments will be blind to condition.|Participants will be randomized to receive one of two possible interventions.|f|f|f|t
33869500|NCT01458912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869501|NCT04311892|||COHORT||RETROSPECTIVE|||||||
33869502|NCT00714675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869503|NCT05092542|RANDOMIZED|FACTORIAL||TREATMENT||NONE||By including 240 Latinx immigrants and 60 African refugees recruited from CBO partners who are randomly assigned to treatment-as-usual CBO involvement or the RIWP intervention and a random sample comparison group of 900 Latinx immigrants, this mixed methods longitudinal waitlist control group design study with five time points over 28 months will test the effectiveness of the RIWP intervention and engagement with CBOs to reduce psychological distress, daily stressors, and economic precarity and increase protective factors (social support, critical awareness of/access to resources, English proficiency, cultural connectedness, and mental health service use).||||
33869504|NCT00474734|||DEFINED_POPULATION||PROSPECTIVE|||||||
33869505|NCT05244291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind will be done in the study. Only parents will be blinded. Two weeks follow up will be done in both groups. Since the researcher should implement the intervention, evaluate and manage the process, it will not be blinded.|The study will be conducted as a single-blind, randomized controlled trial.|t|f|f|f
33869506|NCT02354222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965574|NCT00358774|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34186169|NCT03400839|||COHORT||PROSPECTIVE|||||||
34186170|NCT06212336|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participant, Investigator, Outcomes Assessor|"a) Arms~Intervention/ treatement~Arm 1: SCD: ribavirin Arm:2 Favirpiravir 1600 Arm 3: Favipiravir 1200+ribavirin Arm 4: Ribavirin + dexamethasone"|t|f|t|t
34186171|NCT04805398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186172|NCT05145101|||COHORT||PROSPECTIVE|||||||
34186173|NCT05635253|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34186174|NCT00953056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34186175|NCT05064592|||COHORT||RETROSPECTIVE|||||||
34186176|NCT00515762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34186177|NCT01411046|||CASE_CONTROL||PROSPECTIVE|||||||
33869507|NCT04100681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multi-centre, randomized, sham (placebo) device-controlled, double-blinded trial|t|t|t|t
33869508|NCT02724384|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965575|NCT06537882|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Attending physicians, investigators performing assessments in clinic visits and study participants will be blinded to the group allocation until study completion.|All subjects will be randomized into two groups to take SLP07 or placebo daily for 3 months with monthly assessment.|t|f|t|f
34186178|NCT02376920|||COHORT||PROSPECTIVE|||||||
34186179|NCT06516016|||COHORT||PROSPECTIVE|||||||
33753846|NCT04823260|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33753847|NCT00685958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753848|NCT03407794|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study investigators will be blinded to the treatment conditions and the outcome assessors will only have access to study ID numbers when conducting the lab analyses.|This is a randomized parallel-arm trial|f|f|t|t
33753849|NCT01636180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753850|NCT05875948|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Patients in Cohorts 4 and 5 will be blinded to study treatment. Patients randomized to Cohort 4 will receive terlipressin and R2R01. Patients randomized to Cohort 5 will receive terlipressin and R2R01-matching placebo in the same schedule as Cohort 4. Study staff and Investigators will not be blinded|"A. An Open-Label Safety Run-In Part with 3 Cohorts of patients, followed by~B. A Single-Blind Placebo-Controlled Randomized Part with two Cohorts of patients treated in parallel, and~C. An Open-Label Terlipressin Non-Responder Cohort."|t|f|f|f
33869509|NCT03062592|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Subjects complete three oral glucose tolerance test (OGTT) on different days, with a minimum of one week in between. First visit is a combined screening and baseline OGTT, with no supplementation. The second and third visit subjects are randomly assigned to either 1 g of non-hydrolyzed pine nut oil or 1 g of hydrolyzed pine nut oil.|t|f|f|f
33869510|NCT01537198|||CASE_ONLY||PROSPECTIVE|||||||
33869511|NCT04524702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869512|NCT01529099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869513|NCT02317211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869514|NCT00080028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869515|NCT02472041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869516|NCT04154670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869517|NCT00382720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869518|NCT02467283|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869519|NCT03406247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33869520|NCT00123292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869521|NCT03868540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869522|NCT01423942|||CASE_ONLY||PROSPECTIVE|||||||
33869523|NCT00257166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869524|NCT00424749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869525|NCT04552275|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894043|NCT03431012|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants were blinded to group assignment.|This study was a vignette-based randomised controlled trial, with a 2 (human vs virus agency assignment) x 2 (negative vs positive frame of antivirals side effects) between-participants factorial design. All participants were presented with a hypothetical pandemic flu scenario describing moderate health consequences (i.e. about 1 in 1000 infected people dying). The scenario: 1) in the initial scenario participants were told to imagine that their GP (although not confirming whether it was a pandemic case) had advised them to take antivirals as a precaution; 2) after measuring baseline intentions, participants were introduced to the second part of the scenario where they were asked to imagine being at their local pharmacy where a pharmacist provided them with some health messages and information about the antivirals. Participants were randomised to one of the four health messages described below. After reading the health messages their intentions to use antivirals were re-measured.|t|f|f|f
33894044|NCT03758937|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33894045|NCT02107144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33894046|NCT01740362|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186180|NCT01537705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186181|NCT02124785|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34186182|NCT05322382|NA|SINGLE_GROUP||OTHER||NONE||||||
34186183|NCT00659789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186184|NCT04838470|||COHORT||RETROSPECTIVE|||||||
34186185|NCT04093102|||CASE_CONTROL||PROSPECTIVE|||||||
34186186|NCT06147791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A (drainage) vs Group B (no drainage)||||
34186187|NCT04376866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186188|NCT04001322|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Local government area (LGA) is the unit of assignment. The study state (Kebbi) has 21 LGAs. Of these, 14 will be assigned to receive the intervention while the remaining seven will serve as control.||||
34186189|NCT05699928|||OTHER||CROSS_SECTIONAL|||||||
34186190|NCT00404196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186191|NCT01886053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186192|NCT00997646|||COHORT||PROSPECTIVE|||||||
34186193|NCT03586466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186194|NCT00140608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34186195|NCT01282762|||COHORT||PROSPECTIVE|||||||
34186196|NCT05369442|||COHORT||PROSPECTIVE|||||||
34186197|NCT05676177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186198|NCT02206633|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186199|NCT04067817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186200|NCT05482100|||COHORT||PROSPECTIVE|||||||
34186201|NCT00689858|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34186202|NCT04602780|||COHORT||RETROSPECTIVE|||||||
34186203|NCT00207480|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34186204|NCT03822845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186205|NCT01483521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186206|NCT01578369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186207|NCT00052117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186208|NCT06289907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Decentralized, double-blind, placebo-controlled, randomized|t|t|t|t
34186209|NCT04371159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33753851|NCT03065868|RANDOMIZED|PARALLEL||TREATMENT||NONE||open labelled randomized controlled trial. randomization : 2015 September||||
33753852|NCT06017219|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|single blind|single blind cross over study|t|t|t|t
33753853|NCT06338319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753854|NCT00696748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753855|NCT00789438|||CASE_CONTROL||PROSPECTIVE|||||||
33753856|NCT01444222|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753857|NCT05695638|||COHORT||PROSPECTIVE|||||||
33753858|NCT02144064|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33869526|NCT04957342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Twenty subjects (20) requiring mucogingival surgery and palatal graft harvest will be recruited into study.~The randomization will be achieved by preparing 20 envelopes, 10 envelopes containing materials for the palatal wound treatment #1 (empty packaging materials) and 10 envelopes containing materials for palatal wound treatment #2 (BioXclude membrane \& suture). A blinded study team member will randomly hand the designated cohort allocation materials to the periodontology resident preforming the palatal wound dressing treatment."|The primary purpose of this study is to determine patient-reported outcome measures (i.e., pain and satisfaction) during the immediate post-operative period. Participants will be randomly allocated into two study groups (see Study Design for the randomization process). The palatal wound treatment group #1 will not receive an allograft dressing. The palatal wound treatment group #2 will receive a thin bandage (BioXclude, Snoasis Medical) underneath the suture. At the time of the procedure and post-op days 14 and 60, a research team member will administer the survey, take an impression, photograph the surgical site, and collect extra measurements, probing depth (PD), recession (REC), \& clinical attachment level (CAL), of the participants' mouth. The subject will also be asked to remotely complete a brief survey twice per day for eight days after surgery.|t|f|f|f
33894047|NCT05059353|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study comprises three study populations: patients with MCI, cognitively normal subjects, and caregivers of the patients with MCI.||||
33894048|NCT04751643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894049|NCT03217760|||COHORT||PROSPECTIVE|||||||
33894050|NCT01689558|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33894051|NCT05200767|||COHORT||PROSPECTIVE|||||||
33894052|NCT06434168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066579|NCT03287011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Toothpaste tubes will be masked so the care provider would not know which tube he/she allocating to the participants as well the outcome assessor would be masked from both groups ( test and control) so data is assessed unbiased.|interventional preventive trial|f|t|f|t
34066580|NCT05454852|||COHORT||PROSPECTIVE|||||||
34066581|NCT02420483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066582|NCT06024707|||COHORT||PROSPECTIVE|||||||
34066583|NCT00719394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753859|NCT04020341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066584|NCT00530790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066585|NCT05149001|||COHORT||PROSPECTIVE|||||||
34066586|NCT00772187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066587|NCT04053244|NA|SINGLE_GROUP||TREATMENT||NONE||A Single-Centre, Open-Label Trial of Therapist-Assisted Internet-Based Cognitive Behaviour Therapy||||
34066588|NCT01410240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753860|NCT00924287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066589|NCT04879836|||CASE_CONTROL||PROSPECTIVE|||||||
34066590|NCT00671047|||COHORT||PROSPECTIVE|||||||
34066591|NCT04622072|NA|SEQUENTIAL||TREATMENT||NONE||||||
33753861|NCT06580171|NA|SINGLE_GROUP||SCREENING||NONE||Walking and Remembering Test Group||||
33753862|NCT03319979|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33753863|NCT02446301|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753864|NCT00956345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753865|NCT00002481||||TREATMENT||||||||
33753866|NCT01981694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33753867|NCT04402866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Pharmacist \& Sponsor are not blinded for Part 1. Sponsor is blinded for Part 2. Pharmacist is not blinded for Part 2.|Parallel group, randomized, double-blind, placebo-controlled|t|t|t|f
33753868|NCT03417167|||OTHER||PROSPECTIVE|||||||
33753869|NCT04745611|||COHORT||PROSPECTIVE|||||||
33753870|NCT02294890|||COHORT||RETROSPECTIVE|||||||
33753871|NCT00030693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753872|NCT06514144|||COHORT||RETROSPECTIVE|||||||
33869527|NCT04424160|NA|SINGLE_GROUP||TREATMENT||NONE||Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal route after the cessation of menstrual period. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day. On the second menstrual cycle after the procedure, the patients will be checked under ultrasound and will be started hormone replacement therapy for embryo transfer.||||
34186210|NCT04382352|NA|SINGLE_GROUP||TREATMENT||NONE||"Test staging: Phase I Design Type: Single Arm Test This study was a preliminary study of stage Ia, openness, dose escalation, pharmacokinetics, and efficacy.~To assess safety and tolerability in HER2-positive recurrent or metastatic breast cancer subjects, to determine dose-limiting toxicity (DLT) and to explore maximum tolerated dose (MTD); to evaluate pharmacokinetic characteristics, immunization Originality and preliminary exploration of efficacy.~The study was divided into the main trial period and the extended trial period. The subject trial completed the enrollment and DLT observations of all evaluable DLT subjects for the dose climbing phase; the PK expansion phase completed the enrollment required PK sample collection for the enrolled subjects.~The extension test is the completion of the subject test and the subject continues to take the drug to the stage of progression of the disease or intolerance.~Blind method: open Test range: Domestic test"||||
34186211|NCT02884713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186212|NCT03419559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753873|NCT00680511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753874|NCT06219317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753875|NCT03381560|||CASE_ONLY||CROSS_SECTIONAL|||||||
33753876|NCT06495619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753877|NCT05804773|||COHORT||PROSPECTIVE|||||||
33753878|NCT05253872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33753879|NCT01767558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869528|NCT05327920|||COHORT||PROSPECTIVE|||||||
33869529|NCT04344340|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869530|NCT01141114|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33869531|NCT01898572|||CASE_CONTROL||PROSPECTIVE|||||||
33869532|NCT00053924||||TREATMENT||NONE||||||
33869533|NCT03344419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869534|NCT01205230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186213|NCT02591966|||OTHER||PROSPECTIVE|||||||
33869535|NCT05780255|||COHORT||PROSPECTIVE|||||||
33869536|NCT05764382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869537|NCT02558920|||OTHER||PROSPECTIVE|||||||
33869538|NCT01186796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33869539|NCT01798368|NA|SINGLE_GROUP||||NONE||||||
34186214|NCT04558294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"Double-blind, placebo-controlled, random-order 2-period cross-over design with 2 treatment conditions:~1. 100 μg LSD + ketanserin (40 mg)~2. 100 μg LSD + placebo"|t|t|t|f
34186215|NCT04539132|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The participants will be divided into two groups (N = 20). One group will be the intervention group who will participate in the 6-month interdisciplinary comprehensive rehabilitation program whereas the non-intervention group or control group will have all of the same pre-tests administered as the intervention group, however, will not participate in the cognitive program."||||
34186216|NCT04235621|||COHORT||PROSPECTIVE|||||||
34186217|NCT01668589|||COHORT||PROSPECTIVE|||||||
34186218|NCT03032978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34186219|NCT04766840|NA|SEQUENTIAL||TREATMENT||NONE||||||
34186220|NCT01886846|||CASE_CROSSOVER||PROSPECTIVE|||||||
33869540|NCT01306799|||COHORT||PROSPECTIVE|||||||
33869541|NCT05160155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869542|NCT04383379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869543|NCT06284551|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869544|NCT01762215|NA|SINGLE_GROUP||||NONE||||||
34186221|NCT06001073|||COHORT||OTHER|||||||
34186222|NCT00569959||CROSSOVER||DIAGNOSTIC||NONE||||||
34186223|NCT00322660|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34186224|NCT06282978|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|This is an open label, multicenter, phase II study of Elranatamab as single agent. The primary aiming is to evaluate the efficacy of elranatamab monotherapy in participants with relapsed refractory multiple myeloma (RRMM) who had received prior treatment with immunomodulatory drugs, protease inhibitors, and anti-CD38 therapy and were refractory to the last line of therapy as evaluated with the rate of complete Response and Undetectable Measurable Residual Disease. Efficacy refers to the rate of Undetectable Measurable Residual Disease at 6 and 12 months as per International Myeloma Working Group (IMWG) criteria evaluated by the investigators.||||
34186225|NCT02350296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34186226|NCT01470326|||CASE_ONLY||PROSPECTIVE|||||||
34186227|NCT04782583|||CASE_CONTROL||PROSPECTIVE|||||||
34186228|NCT04258800|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34186229|NCT04563949|||OTHER||PROSPECTIVE|||||||
34186230|NCT03941470|||CASE_CONTROL||OTHER|||||||
34186231|NCT04777175|||COHORT||RETROSPECTIVE|||||||
34186232|NCT03739125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186233|NCT04588584|||CASE_ONLY||PROSPECTIVE|||||||
33869545|NCT05842369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869546|NCT04193020|||COHORT||PROSPECTIVE|||||||
33869547|NCT01353040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869548|NCT05280028|||CASE_CONTROL||PROSPECTIVE|||||||
33869549|NCT05214612|||COHORT||PROSPECTIVE|||||||
33869550|NCT00670436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869551|NCT02479100|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33869552|NCT03497728|||FAMILY_BASED||PROSPECTIVE|||||||
33869553|NCT02146508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869554|NCT02585219|||COHORT||PROSPECTIVE|||||||
33869555|NCT03378804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869556|NCT05341362|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33869557|NCT01729975|||COHORT||PROSPECTIVE|||||||
33869558|NCT05739565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869559|NCT05381142|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The study will be performed with a participant-blinded design.||t|f|f|f
33869560|NCT03099642|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34066592|NCT01043133|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34066593|NCT00840034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066594|NCT00309023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066595|NCT03872817|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Participants are assigned in two groups, an experimental group who will receive the psychoeducational intervention ProLiSMentAl and a control group who have usual intervention"|f|f|t|t
34066596|NCT04015752|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186234|NCT03193502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066597|NCT01100190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186235|NCT06119139|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parallel, randomized, clinical trial|t|f|f|t
34186236|NCT03729700|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186237|NCT04071288|||COHORT||PROSPECTIVE|||||||
34186238|NCT03644004|||COHORT||RETROSPECTIVE|||||||
34186239|NCT04249986|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34186240|NCT02194478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186241|NCT05377255|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186242|NCT01092546|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186243|NCT00634777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186244|NCT05103046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34186245|NCT05345899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186246|NCT05579613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and outcomes assessors will be blinded to the intervention the group wil receivee||t|f|f|t
34186247|NCT02751008|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34186248|NCT02461641|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186249|NCT00824577|||COHORT||CROSS_SECTIONAL|||||||
34186250|NCT03721003|||COHORT||PROSPECTIVE|||||||
34186251|NCT02230033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066598|NCT02417961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066599|NCT05735678|||COHORT||PROSPECTIVE|||||||
33869561|NCT00699465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33869562|NCT05442151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869563|NCT00304200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869564|NCT02863731|RANDOMIZED|CROSSOVER||||NONE||||||
33869565|NCT04328246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869566|NCT00603460|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33869567|NCT04378816|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34066600|NCT00097552|||COHORT||PROSPECTIVE|||||||
33869568|NCT03768180|||COHORT||RETROSPECTIVE|||||||
33869569|NCT05710120|||OTHER||OTHER|||||||
33869570|NCT00526409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869571|NCT02819635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869572|NCT05838079|||COHORT||PROSPECTIVE|||||||
33869573|NCT00689702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066601|NCT04092829|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized prospective analysis.||||
34186252|NCT04442802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186253|NCT02760953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186254|NCT01897688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186255|NCT05379998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a single blinded study. The data will be coded and the analyst will also be blinded.||t|f|f|f
34186256|NCT00327600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186257|NCT01683357|||COHORT||PROSPECTIVE|||||||
34186258|NCT00257985|NON_RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
34186259|NCT04818372|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation: Modified 3+3 dose escalation design: an accelerated dose titration design followed by traditional 3+3 dose escalation design||||
34186260|NCT02804113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869574|NCT00364520|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34186261|NCT06339372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33753880|NCT06220357|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|The indocyanine green (ICG) is added into the syringe by research assistant before operation ended. Each bottle contains 25 mg of lipophilic powder with the active ingredient being ICG. It is packaged with 5 ml of sterile distilled water for dilution, resulting in a solution of 5 mg/ml. The dilution process was carried out carefully to ensure the accuracy of the concentrations. The ICG was diluted into several concentrations using sterile distilled water. The patient didn't know which concentration were given to them. The injection to the patient was performed by anesthesiologist who didn't know about the concentration|The population were divided into three equal groups of indocyanine green concentration : 5 mg/mL, 2,5 mg/mL, and 0,5 mg/mL|t|t|t|t
33753881|NCT06205589|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33753882|NCT04222101|NA|SINGLE_GROUP||SCREENING||NONE||||||
33753883|NCT05874557|||COHORT||RETROSPECTIVE|||||||
33753884|NCT00845390|||CASE_CONTROL||OTHER|||||||
33753885|NCT04688242|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients were randomized to the treatment group (anal dilatation plus probiotics) or the control group.||||
33869575|NCT03974776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33869576|NCT00001075||||TREATMENT||||||||
33869577|NCT01651104|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33869578|NCT01121523|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869579|NCT02280395|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33869580|NCT03069352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869581|NCT01792349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869582|NCT03199040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869583|NCT03083704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869584|NCT00501007|||COHORT||PROSPECTIVE|||||||
33869585|NCT04602169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869586|NCT04066036|||COHORT||PROSPECTIVE|||||||
34066602|NCT02795468|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34186262|NCT00515619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186263|NCT02910882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186264|NCT03600077|||OTHER||OTHER|||||||
34186265|NCT01726439|||COHORT||PROSPECTIVE|||||||
34186266|NCT05569083|||COHORT||PROSPECTIVE|||||||
34186267|NCT00714870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186268|NCT02620748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186269|NCT02202941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186270|NCT01259414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186271|NCT00337480|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186272|NCT02932241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186273|NCT05335226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186274|NCT00072319||||TREATMENT||||||||
34186275|NCT05717543|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Exploratory pilot study||||
34186276|NCT00488917|||COHORT||PROSPECTIVE|||||||
34186277|NCT06384014|RANDOMIZED|PARALLEL||TREATMENT||NONE||İki farklı grupta farklı kanal dolum teknikleri uygulandıktan sonra apikal rezeksiyon yapılarak lezyon iyileşmesinin değerlendirilmesi||||
34186278|NCT00996853|||COHORT||PROSPECTIVE|||||||
34186279|NCT00203099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186280|NCT01541241|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186281|NCT06116370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186282|NCT04188561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Closed Opauqe Envelopes|This Prospective randomized study was conducted on (100) knees with mild to moderate osteoarthritis and scheduled for Intra articular injection or Genicular nerve radiofrequency at Tanta University Hospital (Intra articular injection was done in pain clinic and Radiofrequency was done in operating room|t|t|f|f
34186283|NCT05728125|||CASE_CROSSOVER||PROSPECTIVE|||||||
34186284|NCT02918214|||COHORT||PROSPECTIVE|||||||
34186285|NCT06654531|RANDOMIZED|PARALLEL||PREVENTION||NONE||"All patients will be assigned randomly into two groups :group 1 (the I.V group ) Patients in the I.V group (n = 25) received intrathecal hyperbaric bupivacaine 15 mg together with NSS 0.5 ml, followed by an I.V bolus dose of dexmedetomidine 0.5 μg/kg over 10 min and then an I.V infusion of a maintenance dose of 0.5 μg/kg/h (200 μg dexmedetomidine in 2 ml added to 48 ml NSS yielded dexmedetomidine 4 μg /ml) for the entire period of surgery.~intrathecal group (n = 25) patients received intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine 100 μg/ml diluted with normal saline solution (NSS) to 10 μg/ml), followed by an NSS I.V bolus and an I.V infusion of maintenance volume equivalent to that of the I.V group throughout the entire period of the surgery."||||
33869587|NCT04486248|||OTHER||CROSS_SECTIONAL|||||||
34066603|NCT02044900|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066604|NCT05709405|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple random baseline design||||
34186286|NCT02362282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186287|NCT00588835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186288|NCT00998361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066605|NCT04081857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066606|NCT04699370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, parallel-group, randomized clinical trial participants will be randomly assigned to the control group or intervention group.|f|f|f|t
33869588|NCT02645760|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33869589|NCT00843518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869590|NCT04240015|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869591|NCT04529681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869592|NCT06076837|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||(Part 1) Maximum Tolerated Dose (MTD) Safety Group; (Part 2) Expansion Cohort - Botensilimab MTD from Part 1||||
33869593|NCT06240221|||COHORT||PROSPECTIVE|||||||
33869594|NCT05857527|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||For this study we are making modifications to the taVNS stimulation (Soterix unit) system. These modifications include using Electromyography (EMG) muscle sensors to trigger stimulation instead of a manual button. We are also transitioning the manual stimulation option to Bluetooth to improve ease of use in the clinic with infants. The taVNS stimulation will be paired with constraint induced movement therapy (CIMt) an established rehabilitation intervention. The Soterix taVNS unit is FDA registered and is a custom version of an FDA cleared device.||||
34186289|NCT00131261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186290|NCT03018652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186291|NCT00770172|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33869595|NCT05418673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066607|NCT00927225|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34066608|NCT00869973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066609|NCT01955915|||COHORT||PROSPECTIVE|||||||
34186292|NCT02606513|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34186293|NCT00885534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186294|NCT03995602|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34186295|NCT00137072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186296|NCT05838898|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066610|NCT04066322|||COHORT||PROSPECTIVE|||||||
34186297|NCT00314535|||CASE_ONLY||RETROSPECTIVE|||||||
34186298|NCT05103137|||COHORT||PROSPECTIVE|||||||
34066611|NCT01249326|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34066612|NCT03590223|||COHORT||RETROSPECTIVE|||||||
34066613|NCT04059939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants and evaluators are not told which interventions individual participants have been assigned to||t|f|f|f
34066614|NCT01393106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066615|NCT06321497|||COHORT||PROSPECTIVE|||||||
34186299|NCT00332410|||OTHER||PROSPECTIVE|||||||
34186300|NCT04798404|||COHORT||PROSPECTIVE|||||||
34186301|NCT02849899|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34186302|NCT03440164|||OTHER||CROSS_SECTIONAL|||||||
34186303|NCT01237197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186304|NCT00995800|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34186305|NCT00706238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186306|NCT04423302|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|2 blinded arms (Active 3 intakes per day and Placebo 3 intakes per day) and 1 open arm (Active 2 intakes per day)||t|t|t|t
34186307|NCT00522808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186308|NCT04226196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will be masked to which axis the IOL will be implanted until a sealed envelope will be opened in the operating theater.||f|f|t|f
34186309|NCT03193099|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34186310|NCT06165393|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34186311|NCT05360680|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Dose Escalation and Expansion||||
34186312|NCT00213434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869596|NCT04474665|NA|SINGLE_GROUP||OTHER||NONE||||||
33869597|NCT05144750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869598|NCT02791984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066616|NCT04940689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066617|NCT06404515|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Subjects will participate in at least one telehealth session, lasting one hour, or up to five sessions lasting one hour each, over the course of 12 weeks.||||
34066618|NCT02028962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066619|NCT02748291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066620|NCT03086109|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34066621|NCT01538537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066622|NCT01351948|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066623|NCT05749406|||COHORT||RETROSPECTIVE|||||||
34066624|NCT00881283|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066625|NCT05302947|||COHORT||RETROSPECTIVE|||||||
34186313|NCT01470261|||COHORT||PROSPECTIVE|||||||
34186314|NCT03422094|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34186315|NCT03703180|||COHORT||PROSPECTIVE|||||||
34186316|NCT04522544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186317|NCT06170294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186318|NCT00330954|||CASE_CONTROL||PROSPECTIVE|||||||
34186319|NCT03349034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||The study is a double-blind prospective randomized placebo controlled trial wherein patients undergoing osseocutaneous free flap surgery are randomized to receive continuous infusion of Ropivacaine or normal saline (placebo) via local infusion catheter, which will be placed intraoperatively at the time of donor site closure. Outcomes are tracked and assessed for the first 48 hours post-operatively - median post-operative pain assessed via VAS every 8 hours, total analgesic used (all patients receive Tylenol 650 and dilaudid PCA post-operatively), physical therapy outcomes assessed on post-operative day two, and a patient satisfaction survey.|t|t|t|t
34186320|NCT02203968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186321|NCT01335672|||COHORT||RETROSPECTIVE|||||||
34186322|NCT02248246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186323|NCT06472843|||CASE_ONLY||PROSPECTIVE|||||||
34186324|NCT02132429|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33869599|NCT03747211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Concealed computer generated allocation via REDCap|Randomized, outcome assessor blinded, controlled trial|f|f|t|t
33753886|NCT05189808|||COHORT||PROSPECTIVE|||||||
33753887|NCT00981981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753888|NCT00432731|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33753889|NCT03565510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33869600|NCT01845012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869601|NCT01186575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869602|NCT00918801|||CASE_CONTROL||PROSPECTIVE|||||||
33869603|NCT01227499|||COHORT||PROSPECTIVE|||||||
33869604|NCT05539768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869605|NCT00542295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965576|NCT04812704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965577|NCT00042042|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34066626|NCT00230165|||CASE_CONTROL||PROSPECTIVE|||||||
34186325|NCT04379622|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34186326|NCT05224999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186327|NCT00055757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186328|NCT03080896|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34186329|NCT03108469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|At randomization (Visit 2), neither the subject nor the investigator will be aware to which treatment group the subject has been assigned. Investigational product will be drawn and administered in a double blind format. If needed, for safety and proper treatment of the subject, the investigator can unblind the subject's treatment assignment to determine which treatment has been assigned and institute appropriate follow-up care. When possible, Sponsor and Clinvest should be notified prior to unblinding study drug.||t|f|t|f
34186330|NCT05651061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186331|NCT00714727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186332|NCT00500513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186333|NCT02334462|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34186334|NCT02295618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186335|NCT02421835|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34186336|NCT04573582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186337|NCT01469611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186338|NCT05368246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186339|NCT05571332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186340|NCT05434416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186341|NCT00194506|RANDOMIZED|PARALLEL||ECT||NONE||||||
34186342|NCT03345784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186343|NCT06458881|||CASE_ONLY||PROSPECTIVE|||||||
34186344|NCT01271985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186345|NCT06367530|||COHORT||PROSPECTIVE|||||||
34186346|NCT02763501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186347|NCT02724618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33753890|NCT06369259|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753891|NCT06731920|||COHORT||PROSPECTIVE|||||||
33753892|NCT05356884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753893|NCT02718274|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753894|NCT03520764|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Intervention group: New infant formula with synbiotics; Control group: Standard infant formula with prebiotics|t|f|t|f
33753895|NCT04307004|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33753896|NCT04668885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869606|NCT03012087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869607|NCT05362422|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33869608|NCT05802654|NA|SINGLE_GROUP||TREATMENT||NONE||single fraction of ultra-high dose SBRT||||
33869609|NCT05342662|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be told that both pairs of glasses block blue light.|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses. Sleep and wake behaviors are the primary study outcome.|t|f|f|f
33869610|NCT05638542|||CASE_CONTROL||PROSPECTIVE|||||||
34066627|NCT01728571|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34066628|NCT03182491|||OTHER||PROSPECTIVE|||||||
34066629|NCT00496704||||TREATMENT||NONE||||||
34066630|NCT04112550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066631|NCT05420831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186348|NCT06009848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186349|NCT03473509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894053|NCT06352671|||COHORT||PROSPECTIVE|||||||
33894054|NCT05278234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894055|NCT04905862|||CASE_CONTROL||PROSPECTIVE|||||||
33894056|NCT02153840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894057|NCT01714921|||COHORT||PROSPECTIVE|||||||
34186350|NCT01771289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186351|NCT00658125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186352|NCT02182752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186353|NCT01117363|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34186354|NCT00004761|||NATURAL_HISTORY||OTHER|||||||
34186355|NCT00107913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186356|NCT00642083|NA|SINGLE_GROUP||TREATMENT||||||||
34186357|NCT01584440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869611|NCT03854929|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization will be 1:1 to either AZI or CIP. Block randomization with stratification by hospital of enrolment, and variable block sizes of 4 and 6, respectively, will be used to assign subjects to treatment. The randomization list will be generated according to standard operating procedures without our organization. In brief, the Research Biostatistician (RB) will generate a randomization list using an in-house statistical code and transfer it to the central Study Pharmacist (SP). The SP will change the random seed to blind the RB and then run the code to prepare the final randomization list for treatment preparation. The randomization list will be saved and stored on a secure server.~After enrolment, children will be randomly allocated to one of two treatment arms: in one arm, children will be treated with the current standard of care, oral CIP 15mg/kg BW /twice daily for 3 days, while those in the other arm will receive oral AZI 10mg/kg BW/daily for 3 days."||||
33869612|NCT01312038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869613|NCT05038020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869614|NCT00164112|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33894058|NCT00241267|||DEFINED_POPULATION||PROSPECTIVE|||||||
33894059|NCT01640847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894060|NCT04752280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894061|NCT00525252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186358|NCT00000258|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34186359|NCT01774396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34186360|NCT01982656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186361|NCT05000255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||an experimental group comparison is performed. For the first group, a psychological intervention for psychoeducational measures and psychosocial support, was designed according to the recommendations of the DGP - Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. for the rehabilitation of COVID-19 patients (DGP, 2020). The second intervention was designed after Cacioppo's intervention EASE, for processing loneliness. In this experiment, the psychological interventions will be applied to both groups of patients (non-Covid/post-Covid patients). . Patients who refuse to participate in one of the interventions but nevertheless agree to complete the questionnaires at the measurement time points are treated according to the standards of the complex treatment in early rehabilitation||||
34186362|NCT02970162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186363|NCT05526482|||CASE_ONLY||PROSPECTIVE|||||||
34186364|NCT01421719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186365|NCT01492335|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34186366|NCT06437041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186367|NCT04359316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.|t|t|t|f
34066632|NCT06488872|||COHORT||RETROSPECTIVE|||||||
34066633|NCT06180083|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34066634|NCT00752141|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34066635|NCT00780364|||COHORT||PROSPECTIVE|||||||
34066636|NCT01635309|||COHORT||PROSPECTIVE|||||||
33869615|NCT05288218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"This study will compare the efficacy of the standard commercially available adapter to the newly developed leak-free adapter. The intervention is considered the leak-free bronchoscope adapter. The study will be conducted as a randomized control trial in patients who require bronchoscopy. Once the participant has been randomized to either the leak free adapter vs. standard adapter group, the bronchoscope adapter will be spliced into the ventilator circuit. Bronchoscopy will then be performed by the primary critical care physician in the intensive care unit."|t|f|f|t
33869616|NCT02462668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869617|NCT01218464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33869618|NCT01027819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869619|NCT01684072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33869620|NCT02988570|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869621|NCT06265857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33869622|NCT02439996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869623|NCT03941678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel groups: creatine and placebo|t|t|t|t
33869624|NCT05931796|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33869625|NCT05376215|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects will be fit with two sets of identical devices. One set will be programmed to fitting method A and one set will be programmed to fitting method B. Subjects will be blinded as to which set they are sent on a home trial with. Outcomes will be assessed at return visits by a second sub-investigator who does not know which devices the subject is wearing.|This study is a prospective, repeated measures, within-subject, cross over design. Subjects will be assigned in random order to the two fitting methods. Subjects will be blinded as to which fitting method they are using during the home trials.|t|f|f|t
33869626|NCT04106882|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33869627|NCT01236690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186368|NCT02902861|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34186369|NCT02912689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186370|NCT03554564|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized, non-blinded crossover study||||
34186371|NCT02145013|||COHORT||PROSPECTIVE|||||||
34066637|NCT03497767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186372|NCT04847336|||OTHER||CROSS_SECTIONAL|||||||
34186373|NCT02453711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186374|NCT05666310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186375|NCT06522139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186376|NCT05510232|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized to each arm, with a target of 35 subjects in each arm.||||
34186377|NCT04441918|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34186378|NCT05756959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34186379|NCT05808829|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research data/output measurements, analysis and reporting||f|f|f|t
34186380|NCT05302726|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||All patients will be examinated after 3 months on oral estrogen, 3 months on transdermal estrogen and after 3 months without estrogen substitution||||
34186381|NCT03507569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186382|NCT01234389|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186383|NCT03229980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186384|NCT04517175|||COHORT||PROSPECTIVE|||||||
34186385|NCT00512915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34186386|NCT00455182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186387|NCT00277732|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186388|NCT03139591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186389|NCT00254384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186390|NCT05637580|||COHORT||RETROSPECTIVE|||||||
34186391|NCT02644421|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33869628|NCT00228995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869629|NCT05018247|RANDOMIZED|CROSSOVER||TREATMENT||NONE|"Study personnel and subjects will not be blinded. All core lab measurements, comparisons, and statistical analysis will be blinded to group assignment by blinded coding of PET images. Two volunteers who are not involved in the study in any way to create randomization envelopes with each arm. The study staff volunteers for randomization assignment will:~Create a randomization list with two arms (52 per arm). Create 104 sequential envelopes which will contain a paper with the assignment based on the randomization list.~The sequential randomization envelopes will be kept in the site PI's locked office thereby allowing for randomization immediately after consent is obtained. The randomization arm will be shared with the research team and the subject."|After randomization, patients will receive urgent revascularization combined with Optimal Medical Treatment or Optimal Medical Treatment with delayed revascularization. Following the initial PET scan, randomization and treatment, each group will undergo a second PET scan at the 3-4 month mark and a third PET scan at the one year mark. At their first follow-up visit (3-4 month mark), patients in the OMT with delayed revascularization group will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. Patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter.||||
33869630|NCT02685423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869631|NCT02679014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869632|NCT01797497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869633|NCT01465100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869634|NCT04858763|||COHORT||RETROSPECTIVE|||||||
34066638|NCT05741814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066639|NCT04273932|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, parallel group, open-label trial||||
34066640|NCT04578509|||COHORT||PROSPECTIVE|||||||
34066641|NCT05491395|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm Experimental: Post Mastectomy Hypofractionated Radiotherapy Arm No Intervention: Post Mastectomy Conventional Radiotherapy||||
34186392|NCT04040387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186393|NCT02449148|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186394|NCT00378157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186395|NCT01771224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186396|NCT04313062|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186397|NCT02356861|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|the design included double blind procedures for study staff and participants. study devices were be: 1) an active LED helmet that delivered therapeutic frequencies of light and 2) and identical helmet in all ways except it did not deliver therapeutic frequencies of light||t|f|t|t
34186398|NCT02506413|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study was part of a longitudinal implementation evaluation using an effectiveness-intervention hybrid (Type 2) design and a RE-AIM evaluation model.||||
34186399|NCT05738304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186400|NCT02549872|||COHORT||RETROSPECTIVE|||||||
34186401|NCT00248040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34186402|NCT04784572|NA|SINGLE_GROUP||OTHER||NONE||The group will have a first injection delay and then a second injection delay.||||
34186403|NCT04402567|||OTHER||RETROSPECTIVE|||||||
34186404|NCT05268913|||CASE_CONTROL||PROSPECTIVE|||||||
34186405|NCT01941186|RANDOMIZED|PARALLEL||||NONE||||||
34186406|NCT00380367|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34186407|NCT05235269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm, no placebo, no comparator||||
34186408|NCT06383728|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma receive osimertinib (80mg/d, ≥9 weeks)||||
34186409|NCT06259461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186410|NCT00532376|||||PROSPECTIVE|||||||
34186411|NCT01465360|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186412|NCT01939418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186413|NCT06416124|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186414|NCT05876000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186415|NCT04495920|NA|SINGLE_GROUP||SCREENING||NONE||||||
34186416|NCT02542319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled, parallel-group|t|f|t|t
33869635|NCT03440099|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34066642|NCT03127761|||COHORT||PROSPECTIVE|||||||
34066643|NCT02215499|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34066644|NCT05068011|||COHORT||PROSPECTIVE|||||||
34186417|NCT04632836|||COHORT||PROSPECTIVE|||||||
34186418|NCT02510508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186419|NCT03593746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186420|NCT04666220|||COHORT||RETROSPECTIVE|||||||
33869636|NCT06440785|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33869637|NCT00479284|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||||||
33869638|NCT01534247|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33869639|NCT00096785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869640|NCT01826799|||COHORT||PROSPECTIVE|||||||
33869641|NCT01434589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869642|NCT00923403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869643|NCT05837156|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34186421|NCT01685502|||CASE_ONLY||PROSPECTIVE|||||||
34186422|NCT04863469|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33869644|NCT05242055|||COHORT||PROSPECTIVE|||||||
34066645|NCT01741571|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
34066646|NCT05176613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151554|NCT06543680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized clinical trial will be performed. A number of 35 patients will be included in this study. Each patient will have at least three NCCLs. One of these lesions will be randomly restored with resin modified glass ionomer cement, the second lesion will be restored with self-adhesive Surefil One composite hybrid while the third lesion will be restored with self-adhesive flowable composite.|t|f|t|f
34186423|NCT03830307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186424|NCT01850758|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186425|NCT05808543|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised on a 1:1 ratio to either the BEARS or usual care intervention arm. The trial will be unblinded.||||
34186426|NCT01450332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186427|NCT02196662|RANDOMIZED|CROSSOVER||||NONE||||||
34186428|NCT04038996|||COHORT||PROSPECTIVE|||||||
34186429|NCT02668562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34186430|NCT00943618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186431|NCT05479357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient will be blinded to the drug to be used|Randomized Clinical Trial (Simple randomization)|t|f|f|f
34186432|NCT05892029|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186433|NCT06271746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment. Randomized, double-blind, sham-controlled|t|t|t|f
34186434|NCT05107726|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 20 dyads will be enrolled in this study. A dyad will consist of a parent and a child. Dyads will be randomized to one of two treatment groups: the time restricted eating (TRE) group or standard of care control group.||||
34186435|NCT01672671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186436|NCT01551511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186437|NCT05885399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186438|NCT02780752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of three treatment groups, each including up to 6 participants, with treatment over 4 days of different doses of oral hymecromone. Following a wash-out period, participants are allowed to re-enroll into different treatment groups to provide intra-patient dose comparisons.||||
34186439|NCT02447302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186440|NCT01240824|NA|SINGLE_GROUP||||NONE||||||
34186441|NCT04168606|||CASE_ONLY||RETROSPECTIVE|||||||
34186442|NCT02042274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186443|NCT00193271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186444|NCT00159887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869645|NCT03417908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869646|NCT04881825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869647|NCT04090710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible and consenting, newly diagnosed and histologically confirmed intermediate/poor risk metastatic renal cell carcinoma patients with primary disease in-situ will be randomized in a 2:1 fashion to either induction I/N followed by SBRT prior to the second cycle (experimental arm) versus I/N alone (standard arm). Patients will be stratified based on IMDC criteria (intermediate 1-2 versus poor 3-6).||||
34186445|NCT04749004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34186446|NCT06305832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869648|NCT03533647|||OTHER||PROSPECTIVE|||||||
33869649|NCT03081442|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33869650|NCT03105167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869651|NCT02265770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869652|NCT05888727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869653|NCT02913872|||OTHER||PROSPECTIVE|||||||
33869654|NCT01541189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151555|NCT05176756|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34151556|NCT05484323|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|double-blind both the participant and investigator were masked. A researcher not involved in data analyses was responsible for participant allocation and test food consumption|Crossover, double blind, randomized clinical trial|t|f|t|f
34151557|NCT02886871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151558|NCT04712552|||COHORT||PROSPECTIVE|||||||
34151559|NCT03909451|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34151560|NCT01302054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151561|NCT00483041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151562|NCT02593656|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151563|NCT01838018|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34151564|NCT01308229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151565|NCT05251038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151566|NCT05230485|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34151567|NCT05943197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869655|NCT05427409|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33869656|NCT00741247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869657|NCT03789461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965578|NCT03900845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study will use a within-subject crossover design to identify differences in adherence (slippage), expulsion of perspiration, residual limb health, and comfort that may exist between the three study prostheses. The three study prostheses include: (1) a perforated elastomeric liner intended to transport perspiration away from the residual limb, (2) a dynamic air exchange - rising edge design (DAE-RED) suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump that expels perspiration into a distal chamber, and (3) the participant's as-prescribed prosthesis. The order in which participants wear the perforated elastomeric liner and the DAE-RED systems will be randomized (first or third), but the as-prescribed prosthesis will always be worn second.||||
33965579|NCT04822961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, Double-Blinded, Placebo-Controlled|t|f|t|f
33965580|NCT03008629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186447|NCT05283941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34186448|NCT02728687|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34186449|NCT00809718|NA|SINGLE_GROUP||||NONE||||||
34186450|NCT02298010|||OTHER||RETROSPECTIVE|||||||
34186451|NCT00299169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186452|NCT03239106|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
34186453|NCT04084691|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34186454|NCT00077415||||TREATMENT||NONE||||||
34186455|NCT00880243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186456|NCT02564003|||CASE_CONTROL||PROSPECTIVE|||||||
34186457|NCT00026169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186458|NCT04151303|||COHORT||OTHER|||||||
34186459|NCT02731105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34186460|NCT02645019|||COHORT||PROSPECTIVE|||||||
34186461|NCT00509613|NA|SINGLE_GROUP||||NONE||||||
34186462|NCT06161389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186463|NCT06142929|||COHORT||PROSPECTIVE|||||||
34186464|NCT01193504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33753897|NCT04578990|RANDOMIZED|PARALLEL||TREATMENT||NONE|Analysis masking|Randomized longitudinal controlled trial, parallel, blinded to the analysis, with a sample of participants studied between 3 and 6 months after starting a physical exercise program. Participants will be randomly assigned to four groups. Intervention walking group: The intervention will consist of carrying out the walking training progression. The strength group will carry out a resistance training program. The concurrent training intervention group will carry out an exercise program that will alternate strength and endurance training in the same session. Both experimental groups will hold 36-72 sessions, with a frequency of 3 sessions per week and 60 minutes per session. The control group will receive standard advice consisting of the recommendation to perform aerobic exercise at the lower limbs level warning.||||
33753898|NCT02346305|||COHORT||PROSPECTIVE|||||||
33753899|NCT02436330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869658|NCT00139282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869659|NCT01656148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869660|NCT06462300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869661|NCT05182463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869662|NCT02013947|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33869663|NCT06292091|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33869664|NCT05678036|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33869665|NCT00003004||||TREATMENT||||||||
33869666|NCT04159142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869667|NCT05784779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869668|NCT03033173|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869669|NCT01379469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965581|NCT01245595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965582|NCT00771901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33965583|NCT01198119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965584|NCT04537325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965585|NCT04748094|||OTHER||PROSPECTIVE|||||||
33869670|NCT05340894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965586|NCT06538974|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients presenting lower limb weakness and / or deficiencies, regardless of the underlying causes||||
33965587|NCT05801354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and assessors involved in the study from randomization, allocation, bacteriological outcome, and data analysis will be blinded to which medicament group the patients belonged as all data will be coded.|Turmeric gel= interventional drug Formocresol= Control drug (standard drug)|t|f|f|t
33965588|NCT04571957|||CASE_CONTROL||RETROSPECTIVE|||||||
33965589|NCT02942173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965590|NCT02814669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965591|NCT03086668|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33965592|NCT03078842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants will get dispersible zinc tablets that, contain either 20 mg, 10 mg, or 5 mg of zinc. All tablets look and taste the same. Randomization and tablet package labelling was done in Geneva, and no-one at the trial sites knows the actual zinc content of tablets packaged for each participant number.||t|t|t|t
33965593|NCT06542848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965594|NCT04612205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965595|NCT04222322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186465|NCT01185080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186466|NCT03806764|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study consists of a retrospective and a prospective parts on patients developing CMV infection post allogeneic haematopoeitic stem cell transplant.||||
34186467|NCT00329355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186468|NCT03669341|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||All study participants will perform both techniques of suppression of respiratory motion at 4 weekly visits. They always start with the deep-inspiration-breath- hold (DIBH) technique, extended by prior hyperventilation while breathing 100% O2, followed by the high-frequency-percussive-ventilation (HFPV) technique. Inbetween the weekly visits, participants are requested to perform a daily, short breath-hold training at home.||||
34186469|NCT00529867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186470|NCT06041607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869671|NCT04452474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186471|NCT00067730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869672|NCT02177396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869673|NCT00488722|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33869674|NCT04667377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869675|NCT04305275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186472|NCT05438303|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34186473|NCT02369887|||COHORT||CROSS_SECTIONAL|||||||
34186474|NCT02141828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186475|NCT04106752|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34186476|NCT05606432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded study that conceals the group allocation from physical outcome assessors.||f|f|f|t
34186477|NCT03135964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186478|NCT02345993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186479|NCT00135343|RANDOMIZED|PARALLEL||||NONE||||||
34186480|NCT03057483|||COHORT||PROSPECTIVE|||||||
34186481|NCT01388335||CROSSOVER||OTHER||NONE||||||
34186482|NCT01516021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34186483|NCT05812872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186484|NCT02910791|||CASE_CONTROL||PROSPECTIVE|||||||
34186485|NCT02758184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186486|NCT05821062|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186487|NCT01297829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34186488|NCT04681950|||CASE_ONLY||OTHER|||||||
34186489|NCT01776216|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34186490|NCT00180336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186491|NCT02245217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186492|NCT00357552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186493|NCT05442788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186494|NCT00457457|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186495|NCT00214201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186496|NCT01421732|||CASE_ONLY||PROSPECTIVE|||||||
34186497|NCT04295278|||COHORT||PROSPECTIVE|||||||
33869676|NCT05422820|||COHORT||PROSPECTIVE|||||||
34186498|NCT03494998|||COHORT||PROSPECTIVE|||||||
33753900|NCT06198465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869677|NCT00699270|||COHORT||PROSPECTIVE|||||||
33869678|NCT06323564|||CASE_CONTROL||PROSPECTIVE|||||||
33869679|NCT04452045|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33869680|NCT04704830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|RCT|t|t|t|t
33869681|NCT03926975|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects are all non-scleral lens wearers. One eye (test) will be selected to wear a scleral lens, and the contralateral eye (control) will not wear any lens.||||
33869682|NCT05442099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869683|NCT02330575|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33869684|NCT00359021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869685|NCT04327765|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33869686|NCT02942914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34186499|NCT02983552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186500|NCT02431923|||COHORT||PROSPECTIVE|||||||
34186501|NCT04371458|NA|SINGLE_GROUP||TREATMENT||NONE||Intraoperative providone-iodine lavage during resection||||
34186502|NCT04256083|||COHORT||PROSPECTIVE|||||||
34186503|NCT03171571|NA|SINGLE_GROUP||OTHER||NONE||||||
34186504|NCT02196948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186505|NCT03182569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869687|NCT03690076|||CASE_CONTROL||PROSPECTIVE|||||||
33869688|NCT02398708|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965596|NCT05543070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965597|NCT02926183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151568|NCT00076349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186506|NCT04652037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186507|NCT00641667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186508|NCT05251883|||COHORT||PROSPECTIVE|||||||
34186509|NCT05902806|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm, open-label, multi-centre, multi-country, exploratory study||||
34186510|NCT04724993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186511|NCT03037177|||OTHER||RETROSPECTIVE|||||||
34186512|NCT05196295|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34186513|NCT04587427|||COHORT||RETROSPECTIVE|||||||
34186514|NCT02641288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869689|NCT06490549|||COHORT||PROSPECTIVE|||||||
33869690|NCT03924752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The model used is a repeated measures single arm study. Multiple conditions including using and not using the device will be tested on the same subjects to have multiple test points on a per subject basis.||||
33869691|NCT04699019|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869692|NCT04439604|||COHORT||RETROSPECTIVE|||||||
33869693|NCT04579562|||CASE_CONTROL||RETROSPECTIVE|||||||
33869694|NCT03974087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33869695|NCT03310450|||COHORT||PROSPECTIVE|||||||
33869696|NCT02075242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151569|NCT01278407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151570|NCT04107441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A first group of 10 participants will be enrolled in the Part 1 of the study (arm 1).~Based on the results of Part 1, a second group of 10 participants will be enrolled in Part 2 of the study (arm 2)."||||
34151571|NCT02166541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151572|NCT00821912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151573|NCT05017818|||OTHER||RETROSPECTIVE|||||||
34151574|NCT00052156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151575|NCT03392870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A researcher will be masked for group aleatorization (active, group) in order to unbiasedly evaluate outcomes which require subjective assesment of functionality.||f|f|f|t
34151576|NCT02769780|||CASE_ONLY||PROSPECTIVE|||||||
34151577|NCT04956588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor was blinded when evaluating the subject's imaging data (i.e., when calculating the deviation of the nail placement).||f|f|f|t
34151578|NCT05808010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151579|NCT02965885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151580|NCT00311909|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34151581|NCT06097546|||CASE_CONTROL||RETROSPECTIVE|||||||
34151582|NCT01196962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151583|NCT04372459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The current clinical trial is a multicenter Randomised Controlled Trial with 2 parallel groups. The effectiveness of the online integrated and stepped psychosocial care group will be compared with the usual psychosocial care group|f|f|t|t
34151584|NCT01273194|||||OTHER|||||||
34151585|NCT03645330|||COHORT||PROSPECTIVE|||||||
34151586|NCT00685737|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34151587|NCT03787992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151588|NCT03508232|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinding. Randomization will be done prior to the study and with binary encoding, for further blinding. Drug randomization (placebo or doxycycline) will be done by the Drug Development and Innovation Centre in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, with 50% allocated in the Placebo Control Group and 50% in the Doxycycline Group. The coding list will be generated and kept sealed by the PI. Patients will be randomized during recruitment, following a previously generated list with 50% of patients allocated to each group.|Randomized, double-blinded, placebo-controlled study|t|t|t|t
34151589|NCT01149902|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151590|NCT02784769|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34151591|NCT02797496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151592|NCT04664647|||COHORT||RETROSPECTIVE|||||||
34151593|NCT05318196|||COHORT||PROSPECTIVE|||||||
34151594|NCT06584084|NA|SINGLE_GROUP||OTHER||NONE||Each participant will undergo to the study intervention and the control intervention||||
34151595|NCT04724395|||COHORT||PROSPECTIVE|||||||
34151596|NCT03507075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151597|NCT01286363|||||CROSS_SECTIONAL|||||||
34151598|NCT02023047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151599|NCT05901103|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34151600|NCT04524624|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34151601|NCT03377933|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center exploratory study||||
34151602|NCT00616694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151603|NCT02264548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151604|NCT00619099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151605|NCT03677297|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34151606|NCT00911729|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186515|NCT03038880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186516|NCT02809001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186517|NCT03187392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186518|NCT01536886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34186519|NCT03619720|NA|SINGLE_GROUP||SCREENING||NONE||||||
34186520|NCT02360878|||COHORT||PROSPECTIVE|||||||
34186521|NCT00272311|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34186522|NCT03028519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186523|NCT05765578|||COHORT||PROSPECTIVE|||||||
34186524|NCT04408976|||COHORT||PROSPECTIVE|||||||
34186525|NCT06067152|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34186526|NCT03847896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186527|NCT01589042|||COHORT||PROSPECTIVE|||||||
34186528|NCT04163952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186529|NCT05497999|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34186530|NCT06519708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34186531|NCT01481818|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33753901|NCT01416870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753902|NCT02565043|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753903|NCT00898469|||COHORT||RETROSPECTIVE|||||||
33753904|NCT06731972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753905|NCT03152383|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Children with autism, typically developing children, and children with developmental disabilities will participate in the same intervention.||||
33753906|NCT01186029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33753907|NCT01196338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753908|NCT01982240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753909|NCT05732233|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Pathologist is blind to group assignment|Parallel trial design|f|f|f|t
33753910|NCT00134550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753911|NCT06188572|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33753912|NCT01081093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753913|NCT02495051|||COHORT||PROSPECTIVE|||||||
33753914|NCT04160715|||COHORT||PROSPECTIVE|||||||
33753915|NCT06732635|RANDOMIZED|PARALLEL||TREATMENT||NONE||A controlled, randomized, parallel-group, open-label, interventional, single-center clinical trial in which the intervention group will be managed according to the multimodal rehabilitation protocol (RICA clinical pathway), and the control group will receive traditional care that has been provided up to now.||||
33753916|NCT03130751|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33753917|NCT04477928|||OTHER||PROSPECTIVE|||||||
33753918|NCT01596582|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33753919|NCT03661411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753920|NCT05098093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753921|NCT04568135|||OTHER||PROSPECTIVE|||||||
33753922|NCT01903850|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33869697|NCT02015442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33869698|NCT00820911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869699|NCT01892163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869700|NCT04662658|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants are assigned to one of two groups in parallel for the duration of the study||||
33869701|NCT05149222|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a virtual, single-arm, pragmatic, non-significant risk study.~Study participants will receive 12 weeks of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia"||||
33869702|NCT01496729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869703|NCT05040802|||CASE_CONTROL||RETROSPECTIVE|||||||
33869704|NCT01440270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869705|NCT01043341|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34186532|NCT01288261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186533|NCT02986295|||COHORT||PROSPECTIVE|||||||
34186534|NCT03106311|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34186535|NCT02231905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186536|NCT05112029|||CASE_ONLY||PROSPECTIVE|||||||
34186537|NCT03715049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186538|NCT01315639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186539|NCT04230278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor is blinded to group assignment.||f|f|f|t
34186540|NCT03734380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186541|NCT02492763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186542|NCT05459883|||COHORT||RETROSPECTIVE|||||||
34186543|NCT05349071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186544|NCT02256709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186545|NCT03638037|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186546|NCT04585126|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participant, surgeons and outcomes assessor are blind Only the anesthesiologist taking care of the patient knows the allocation group|Prospective, randomized, double blinded, non inferiority study comparing general anesthesia combined with cervical nerve block vs general anesthesia alone in thyroid surgery|t|f|t|t
34186547|NCT04422158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Drinks will be prepared without subjects aware of which drink they are receiving.|Randomized, single-blind, placebo-controlled, cross-over with non-directional hypothesis regarding the potential differences between the two different dosages tested.|t|f|f|f
34186548|NCT00705952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186549|NCT01173237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186550|NCT00902096|||COHORT||PROSPECTIVE|||||||
34186551|NCT05267522|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|It will not be possible to blind participants to the diet being consumed, or the research dietician assisting the participants to comply with the diets. All other research staff involved in data collection will be blinded.|Counter-balanced, cross-over trial with randomization to the starting diet will be via minimization, based on the LDL-C concentration at screening and sex. Minimization will ensure balanced LDL-C and sex between the treatment groups at commencement of each of the three diets.|f|f|f|t
33753923|NCT01900782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33753924|NCT05451654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753925|NCT03496506|NA|SINGLE_GROUP||OTHER||NONE||Open-label, two-treatment, one-sequence, cross-over study||||
33753926|NCT04454658|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33753927|NCT05597254|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33753928|NCT06265077|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33753929|NCT00302796|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33753930|NCT02207010|NA|SINGLE_GROUP||OTHER||NONE||||||
33753931|NCT05721534|||CASE_ONLY||PROSPECTIVE|||||||
33753932|NCT01087268|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33753933|NCT03274869|||COHORT||PROSPECTIVE|||||||
33753934|NCT04306198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764664|NCT06333834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A pharmacist will be responsible for randomizing the patients and preparing the study medication in a blinded manner, so that the treatment is administered by the physician without the care provider or the participant being able to identify it. The pharmacist will keep the randomization results in a sealed envelope that will be opened at the end of the study.|Experimental Group: Patients with scorpion envenomation of any grade will receive scorpion antivenom therapy in a reduced regimen. The dosing regimen based on response will be one initial intravenous vial in patients with grade III scorpion envenomation, and two initial intravenous vials as the starting dose in patients with grade IV scorpion envenomation, according to the FDA classification of scorpion envenomation. In both scenarios, an additional vial can be administered every 30 minutes if symptoms persist, with no limit on vials. Control Group: Patients with scorpion envenomation of any grade will receive scorpion antivenom therapy according to the traditional regimen proposed in the Mexican Clinical Practice Guideline, where, according to the severity classification of scorpion envenomation, between one and six vials of anti-scorpion venom will be administered, and equal doses can be repeated every 30 minutes if necessary.|t|t|t|t
33764665|NCT00735865||PARALLEL||TREATMENT||NONE||||||
33764666|NCT03131635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764667|NCT02166437|||CASE_ONLY||PROSPECTIVE|||||||
33869706|NCT03127839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869707|NCT04134182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764668|NCT03296709|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split mouth design||||
33869708|NCT01638572|||COHORT||RETROSPECTIVE|||||||
33869709|NCT02329080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869710|NCT06489600|NA|SINGLE_GROUP||OTHER||NONE||open-label, interventional, prospective, safety in-use tolerability||||
33869711|NCT02801656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186552|NCT00670306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869712|NCT02164175|||CASE_ONLY||PROSPECTIVE|||||||
33869713|NCT02075489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869714|NCT03908320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186553|NCT04258267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The care provider and participant know the duration of the immobilization. The investigator and outcome assessor don't know the duration.|Prospective longitudinal study with randomised group allocation, based on length of immobilization.|f|f|t|t
33869715|NCT03750578|RANDOMIZED|PARALLEL||OTHER||NONE||"Interventions. When venipuncture (either for IV line insertion or diagnostic venipuncture) is prescribed by a physician, a topical anesthetic cream (Maxilene® 4 - Lidocaine 4%) will be proposed to the patient, as standard of care. Usual positioning will be used by the staff nurse.~A) Virtual reality: Patients in this group will be offered virtual reality distraction through the use of OR.~B) Control intervention (standard of care): Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse."||||
33869716|NCT02681679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869717|NCT06317675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869718|NCT01137825|||CASE_ONLY||PROSPECTIVE|||||||
34186554|NCT03682770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186555|NCT01413204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186556|NCT01981018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186557|NCT03840980|||COHORT||PROSPECTIVE|||||||
34186558|NCT03846908|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34186559|NCT02052388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186560|NCT01698580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34186561|NCT04557592|||COHORT||RETROSPECTIVE|||||||
34186562|NCT00510822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869719|NCT01589276|||CASE_CONTROL||PROSPECTIVE|||||||
33869720|NCT02219282|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34186563|NCT02653599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33753935|NCT01559844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753936|NCT00627484|||CASE_CONTROL||PROSPECTIVE|||||||
33753937|NCT03830593|||COHORT||RETROSPECTIVE|||||||
33753938|NCT02369055|||COHORT||PROSPECTIVE|||||||
33753939|NCT01955954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753940|NCT04803981|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33753941|NCT00809887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869721|NCT02426476|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33869722|NCT05301920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869723|NCT00053950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869724|NCT05897021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors will be independent from the Study Team and will be blind to participants' treatment condition.|"In Phase I, all sexual minority Veterans will receive EWMS, which will be iteratively refined based on qualitative interviews at end of treatment, consultation with experts in sexual minority health (Dr. Livingston and SMEs, Drs. Sloan and Pachankis) and discussion amongst mentors (Drs. Marx, Livingston, and Iverson).~In Phase II, sexual minority Veterans who are eligible (i.e., clinically significant depression and/or anxiety symptoms and a history of sexual minority stressor exposure that is reported by Veterans to be related to their distress) will be randomized to the EWMS condition or to the neutral control condition. Participants will complete the assigned intervention condition and will be assessed at baseline, post-treatment, and 3 month follow-up."|f|f|f|t
33894062|NCT03711383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33894063|NCT03247400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894064|NCT00469937|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34151607|NCT03883087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151608|NCT02396394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151609|NCT01879072|||COHORT||PROSPECTIVE|||||||
34151610|NCT06581172|||OTHER||PROSPECTIVE|||||||
34151611|NCT01862549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151612|NCT03974295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After informed consent signing and randomization using a computer generated randomization scheme, the Research Nurse will open a numbered, opaque, and sealed envelope, within which there will be a white sheet of paper labelled with the patient assigned group. The participant will be informed of their assigned group by the Research Nurse. Patients assigned to the study group will be handed a log to record the number of times the patient engages in unprotected vaginal intercourse. The fertility providers will be blinded to the patients assigned treatment group. Patients who do not consent to be part of the study will still undergo their planned frozen embryo transfer per protocol.||f|t|t|t
33753942|NCT06174714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753943|NCT02538731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33753944|NCT02131272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753945|NCT02413580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753946|NCT00571454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33753947|NCT03546881|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33753948|NCT00006352|RANDOMIZED|||TREATMENT||||||||
33753949|NCT05562882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753950|NCT03749564|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Design precludes blinding of patients or care providers. Research personnel conducting outcomes assessments and the principal investigator are blind to participants' group assignment throughout the study.|Factorial design examining the outcomes of SMT with varying combinations of co-interventions.|f|f|t|t
33753951|NCT01764165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33753952|NCT01229930|RANDOMIZED|||TREATMENT||DOUBLE||||||
33753953|NCT06580405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764669|NCT03928002|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||MRI 4DFlow Cardiac cathetherization||||
34151613|NCT00877370|NA|SINGLE_GROUP||||NONE||||||
34151614|NCT00209794|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34151615|NCT02924012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151616|NCT01443507|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34151617|NCT04721665|||COHORT||PROSPECTIVE|||||||
33894065|NCT03615092|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical parameters were screened by one single examiner that was not aware of the procedures|Controlled Split-mouth clinical trial|f|f|t|t
33894066|NCT04372264|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34186564|NCT01432730|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34186565|NCT03236376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be masked for treatment group|Randomized controlled Trial with two therapy groups ( experimental and control therapy) and one healthy control group|f|f|f|t
34186566|NCT05304533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186567|NCT03417154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186568|NCT04765319|||CASE_ONLY||RETROSPECTIVE|||||||
34186569|NCT00936923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186570|NCT03714958|NA|SINGLE_GROUP||TREATMENT||NONE||This study will utilize sequential and adaptive Bayesian design using the method of Time-to-event Continual Reassessment Method (CRM) to guide dose escalation and estimate the MTD||||
33764670|NCT05975502|||COHORT||RETROSPECTIVE|||||||
33764671|NCT05512429|||COHORT||RETROSPECTIVE|||||||
33894067|NCT02655484|NA|SINGLE_GROUP||||NONE||||||
34186571|NCT01472718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151618|NCT00301288|||||RETROSPECTIVE|||||||
34151619|NCT00056446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151620|NCT02651571|||COHORT||RETROSPECTIVE|||||||
34151621|NCT03693781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|placebo will be unrecognizable from active treatment (both in tablets)|Three arms of 18 patients each; in two arms two colchicine dosages will be tested compared to placebo in the control arm. The three arms will undergo treatment vs placebo in parallel|t|f|t|f
34151622|NCT02622646|||||PROSPECTIVE|||||||
34151623|NCT00240604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151624|NCT04357977|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34151625|NCT05578378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151626|NCT02383641|||COHORT||PROSPECTIVE|||||||
34151627|NCT02147769|||COHORT||PROSPECTIVE|||||||
34151628|NCT00126984|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151629|NCT05066308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34151630|NCT02263911|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34151631|NCT01055678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151632|NCT03091127|||COHORT||OTHER|||||||
34151633|NCT03853564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34151634|NCT02048033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151635|NCT01424566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151636|NCT02575703|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34151637|NCT00867555|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34151638|NCT02166827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151639|NCT03243175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|PROBE design|1:1:1|f|f|f|t
33753954|NCT04824482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All participants will be randomly assigned to two parallel intervention groups for the duration of study. Thirty patients from each intervention group will be randomized to multimodal MRI of brain.|f|f|t|t
33753955|NCT00343928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33753956|NCT00377403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753957|NCT01845740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753958|NCT00095706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753959|NCT03057353|||CASE_ONLY||RETROSPECTIVE|||||||
33753960|NCT03544892|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study uses 33 week randomized, powered study design to measure glycemic control with a low carbohydrate dietary pattern versus standard of care diabetes medical nutrition therapy. Each arm is 12 weeks with an 8 week washout between arms.||||
33753961|NCT05314036|NA|SINGLE_GROUP||OTHER||NONE||||||
33753962|NCT01763710|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753963|NCT00439712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753964|NCT01024426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33753965|NCT03369548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753966|NCT05675657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients will be divided randomly by a computer-generated randomization table into three equal groups.|f|t|f|t
33753967|NCT00288483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33753968|NCT05907824|||COHORT||RETROSPECTIVE|||||||
33753969|NCT05461222|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33753970|NCT05142592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753971|NCT00234052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753972|NCT01808950|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33753973|NCT00781391|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33753974|NCT03176420|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization to maximal medical therapy vs endovascular intervention||||
33753975|NCT05641558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33753976|NCT02514629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33753977|NCT00785291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33753978|NCT05236686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753979|NCT00554918|RANDOMIZED|||TREATMENT||||||||
33753980|NCT03375983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33753981|NCT01059981|||||RETROSPECTIVE|||||||
33753982|NCT03927469|||OTHER||RETROSPECTIVE|||||||
33753983|NCT01760239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33753984|NCT00968682|||COHORT||PROSPECTIVE|||||||
33753985|NCT04844515|||COHORT||PROSPECTIVE|||||||
33753986|NCT01789554|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33753987|NCT05382312|RANDOMIZED|PARALLEL||OTHER||SINGLE|All laboratory staff involved in analyzing and reporting the microbiological endpoints (logarithm to base10 \[log10\] colony forming units \[CFU\] counts and time to sputum culture positivity) will be unaware of treatment assignments.||f|f|f|t
33753988|NCT03393676|||COHORT||PROSPECTIVE|||||||
33753989|NCT02051647|||||PROSPECTIVE|||||||
33753990|NCT00298246|||COHORT||PROSPECTIVE|||||||
33753991|NCT02565914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151640|NCT02127177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151641|NCT02967601|||CASE_ONLY||CROSS_SECTIONAL|||||||
34151642|NCT05732883|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind, randomized, placebo-controlled trial|Multi-specialty, double-blind, randomized, placebo-controlled trial|t|t|t|f
34151643|NCT03948919|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34151644|NCT03048604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151645|NCT00175266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151646|NCT01338584|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34151647|NCT06277648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The orthopaedic surgeon responsible for the study was blinded to the study groups. This surgeon was the sole evaluator of postoperative pain scores and total analgesia consumption.|a double-blind, prospective, randomized, controlled study|t|f|f|t
34151648|NCT05718037|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34151649|NCT01760590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151650|NCT02821364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33894068|NCT04551443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The eligible patients were assigned randomly to each of two groups (WJMSCs or placebo control) in a 1:1 fashion using a computer-generated randomization of sequence numbers. Physicians and other clinical personnel remained blind to the treatment assignment throughout the study.|Placebo Comparator: Intravenous infusion WJMSCs +standard therapy Vs placebo+ standard therapy in patients with acute myocardial infarction|t|f|t|f
33894069|NCT01000103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066647|NCT05160298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will be under sedation during the block performance. Th nurse in charge to the patient will be absent during the block performance and the block will be realized by the practitioner who will not take care of the patient during his hospitalization|"* The ropivacaine group (42 patients): Echo-guided bilateral erector spinae block at the arrival in the intensive care unit. 20ml of Ropivacaine 2mg/ml for each side.~* The control group (42 patients): Sham block bilaterally."|t|t|f|t
34066648|NCT04971083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066649|NCT05854849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066650|NCT04151901|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34066651|NCT01733992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066652|NCT00715520|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34066653|NCT04882410|||COHORT||RETROSPECTIVE|||||||
34186572|NCT04287127|||COHORT||RETROSPECTIVE|||||||
34186573|NCT04416841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186574|NCT01273519|||COHORT||PROSPECTIVE|||||||
34186575|NCT05131737|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33753992|NCT00477230|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33753993|NCT00460187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33753994|NCT05832450|||COHORT||PROSPECTIVE|||||||
33753995|NCT00405626|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33753996|NCT04845113|||CASE_ONLY||RETROSPECTIVE|||||||
33894070|NCT04403867|||COHORT||RETROSPECTIVE|||||||
33894071|NCT01478555|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33894072|NCT03607370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186576|NCT02598583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186577|NCT04618107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186578|NCT02217826|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34186579|NCT04259099|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186580|NCT05014087|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single center, open label, randomized 1:1 controlled trial.||||
34186581|NCT06139367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186582|NCT06132867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34186583|NCT00598676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186584|NCT00606593|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34186585|NCT05411315|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pragmatic randomized trial||||
34186586|NCT02695563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34186587|NCT02026531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186588|NCT05062499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186589|NCT03527732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The parallel group trial will be double blinded (i.e. study participants and the trial team/researchers conducting the treatment and assessing the outcomes will be blinded) using repacked tablets including appearance-matched placebos while the dose-finding study will be single blinded (i.e. all outcome assessors except the investigators who provide the treatment and the study participants who get either active or placebo tablets matching in appearance will be blinded) due to the nature of this study (i.e. including ascending doses).||t|t|t|t
34066654|NCT04008264|||CASE_CONTROL||PROSPECTIVE|||||||
34186590|NCT01298986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186591|NCT02658396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186592|NCT06021704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||N=60 dyads of older adult patients with cognitive impairment up to mild-to-moderate ADRD and their familial care partners will be randomly assigned in 1:1 ratio (n=30 dyads per group) to receive home care services from one of 2 pools of HHAs: 1) HHAs who completed enhanced curriculum training or 2) HHAs who completed standard curriculum training. A block randomization strategy will be used to ensure balance of relative proportions of patients who receive HHA services from public versus private-based home care agencies.|t|t|t|t
34186593|NCT00839696|||COHORT||PROSPECTIVE|||||||
34186594|NCT00590265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186595|NCT03782506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34186596|NCT04616989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants in the intervention arm will receive leaflets about the mental health literacy while those in the control arm will receive COVID-19 leaflets||||
34186597|NCT00619710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186598|NCT01615536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186599|NCT01210404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186600|NCT04493788|||CASE_CONTROL||PROSPECTIVE|||||||
34186601|NCT00474591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186602|NCT05871632|||COHORT||PROSPECTIVE|||||||
34186603|NCT03622476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186604|NCT03244839|||CASE_ONLY||PROSPECTIVE|||||||
34186605|NCT03761368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded investigator, not involved in either CA or randomization procedure, performed assignment intervention.|After admission to the Department, patients were randomly assigned in 1:1 ratio to either control group or RIPC - group by means of a computerized randomization table.|f|f|t|f
34066655|NCT06147323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066656|NCT00912106|||CASE_CONTROL||PROSPECTIVE|||||||
34066657|NCT04390308|||COHORT||PROSPECTIVE|||||||
34151651|NCT00772109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151652|NCT04648514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151653|NCT00386321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151654|NCT03484390|RANDOMIZED|PARALLEL||TREATMENT||||||||
34151655|NCT06150794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151656|NCT01583660|||COHORT||PROSPECTIVE|||||||
34151657|NCT04110990|||CASE_ONLY||RETROSPECTIVE|||||||
34151658|NCT01073007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151659|NCT02438813|||COHORT||PROSPECTIVE|||||||
34151660|NCT01778426|||COHORT||PROSPECTIVE|||||||
34151661|NCT02816619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151662|NCT02168517|||CASE_CONTROL||RETROSPECTIVE|||||||
34151663|NCT03683888|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-label||||
34151664|NCT02215343|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34151665|NCT01984450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151666|NCT06484361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151667|NCT06221787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151668|NCT06054256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151669|NCT05474222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned, in a three to one ratio, to the intervention group, or the control group. All participants will complete a pretest questionnaire and have access to case management services. The intervention group will receive 40 hours of classroom instruction, then all participants will complete a posttest questionnaire. Following the posttest all participants will have access to workforce training. Six months after the posttest, all participants will complete a follow-up questionnaire.||||
34151670|NCT00244634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151671|NCT03413670|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34151672|NCT02145598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151673|NCT01822613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151674|NCT04006392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151675|NCT01720979|||COHORT||RETROSPECTIVE|||||||
34151676|NCT02321449|||CASE_ONLY||PROSPECTIVE|||||||
34151677|NCT02160145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151678|NCT05350189|||COHORT||PROSPECTIVE|||||||
34151679|NCT02372422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151680|NCT04770844|||COHORT||PROSPECTIVE|||||||
33753997|NCT05089617|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double Blinded|Single Ascending Dose and Multiple Dose|t|t|t|f
33753998|NCT04208516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"For study participants, the investigator placing the block will record in the narrative that this patient is a study participant and received Paravertebral block with ESP approach or this patient is a study participant and received TAP block with QL approach. By documenting blocks in this way, the research team member collecting the data will be blinded to whether the patient received continuous block with 0.5% ropivacaine, or single block with 0.5% ropivacaine, dexamethasone, and dexmedetomidine."|Two groups of patients will be studied simultaneously. One group will receive continuous peripheral nerve blocks and the other group will receive single blocks plus postoperative intravenous lidocaine infusion.|f|f|f|t
33753999|NCT04000295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754000|NCT06733168|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single center, ramdomized controlled trial||||
33754001|NCT02943057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754002|NCT01292876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754003|NCT05519579|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33754004|NCT02904408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754005|NCT05002569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754006|NCT02413164|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33754007|NCT03768479|NA|SINGLE_GROUP||OTHER||NONE||||||
33754008|NCT01159054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764672|NCT03595501|||COHORT||PROSPECTIVE|||||||
33764673|NCT04305808|||COHORT||PROSPECTIVE|||||||
33764674|NCT05619874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764675|NCT04281433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33764676|NCT00118625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894073|NCT01835444|||||PROSPECTIVE|||||||
33764677|NCT01754883|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764678|NCT05613101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Erector Plane Block Adductor Canal Block|f|t|f|t
33764679|NCT00750100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894074|NCT00847340|||CASE_ONLY||CROSS_SECTIONAL|||||||
33894075|NCT05220150|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open labelled feasibility study with a control group.||||
33894076|NCT06286722|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
34066658|NCT04691687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, nurses and treating physicians will be blinded to whether the subjects are receiving continuous IV furosemide (group 2) or continuous IV placebo (group 3). The pharmacist will not be blinded to help administer the appropriate medication. Because the trial will be double-blinded, safety laboratory tests will be performed for each subject for the duration of the trial, regardless of the treatment arm, and will be monitored by the research coordinator. Similarly, monitoring of potential side effects will be continuous and irrespective of treatment assignment. Outcomes assessor will be blinded.|A single center prospective randomized double-blind controlled trial|t|t|t|t
34066659|NCT03001466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34066660|NCT01863732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066661|NCT03463252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186606|NCT05844007|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34186607|NCT00487461|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33764680|NCT05721430|||OTHER||CROSS_SECTIONAL|||||||
33764681|NCT02961114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764682|NCT02597907|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33764683|NCT04844437|||CASE_CONTROL||PROSPECTIVE|||||||
34186608|NCT05824104|NA|SINGLE_GROUP||OTHER||NONE||||||
34186609|NCT05109143|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34186610|NCT03174600|||COHORT||PROSPECTIVE|||||||
34186611|NCT05766696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This study is a parallel-group, randomized, controlled non-inferiority trial with a 2-year follow up. School children (from 2 schools) in a township in South Africa are randomized to the ART group (class room) or Conventional group (mobile clinic).|f|f|f|t
34186612|NCT04445896|||OTHER||RETROSPECTIVE|||||||
34186613|NCT00560170|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34186614|NCT01663103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34186615|NCT00575731|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34186616|NCT06091683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186617|NCT03400761|||COHORT||RETROSPECTIVE|||||||
34186618|NCT04512612|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The participants will be randomised to one of the two groups. The first group will undergo colonoscopy evaluation using pan-colonic chromoendoscopy during withdrawal of endoscope. In the second group, colonoscopy evaluation will be performed using high-definition white light endoscopy during withdrawal|t|f|f|f
34186619|NCT06519474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186620|NCT02124317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186621|NCT02282605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186622|NCT00241436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186623|NCT02570048|||COHORT||RETROSPECTIVE|||||||
34186624|NCT02044640|||CASE_ONLY||RETROSPECTIVE|||||||
34186625|NCT06440681|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|There is nothing masked to study|"A 6-month lifestyle modification program will be launched at primary health centers in Arar, Saudi Arabia. 500 participants will be involved and all participants will be advised to: Reducing weight (5% of the basic weight), Exercise (4 hours/week), Moderate fat consumption (total fat 30% of total energy intake and saturated fat 10%). % of total energy consumed), A diet rich in fiber (15 g/1000 calories). Participants will receive individual, detailed, ongoing nutritional counseling by the study dietitian every two weeks. They will also be encouraged to participate in physical activities. The table below shows the detailed intervention for both groups.~Finally, the participants will be divided into two groups:~Lifestyle Modification Group (LMP): those who agreed and followed the previous instructions and advice. Control group (CG): those who did not receive health education or did not follow previous instructions or advice."|t|f|f|f
34186626|NCT03714880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869725|NCT06159387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A simple randomization are carried out in which the computer program generates a number (0 or 1) for each subject who enters the research. Zero is the the placebo group and 1 is the active drug group. Neither the evaluators nor the patients know which medication each research subject is taking. The laboratory provides identical solutions of active drug and placebo to ensure blinding of the research and only professionals in that laboratory know which is placebo or active drug.|After admission, 60 patients are randomly allocated into 2 groups. A simple randomization are carried out in which the computer program generates a number (0 or 1) for each subject who enters the research. Zero is the the placebo group and 1 is the active drug group. Neither the evaluators nor the patients know which medication each research subject is taking. The laboratory provides identical solutions of active drug and placebo to ensure blinding of the research and only professionals in that laboratory know which is placebo or active drug.|t|t|t|f
34066662|NCT04361097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Third party makes the aleatorization|Prospective, double blind, experimental|t|t|t|f
34066663|NCT00153725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066664|NCT01256580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066665|NCT04992624|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Some of the treatment phase will be blinded by the study team.|This is a single-site, 2x2 factorial double-blind, randomized clinical trial with 200 participants (160 completers).|t|f|t|f
34066666|NCT03236571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066667|NCT05080725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869726|NCT04828395|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066668|NCT04034316|NA|SINGLE_GROUP||TREATMENT||NONE||Open lable, single arm||||
34066669|NCT03337906|||COHORT||PROSPECTIVE|||||||
34066670|NCT02381925|||COHORT||PROSPECTIVE|||||||
34066671|NCT05786599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066672|NCT05112757|NA|SINGLE_GROUP||OTHER||NONE||||||
34066673|NCT04606667|NA|SINGLE_GROUP||PREVENTION||NONE||Quasi-experimental, test-retest, with one sample.||||
34066674|NCT05196477|||COHORT||RETROSPECTIVE|||||||
34066675|NCT01501032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066676|NCT04745507|||CASE_CONTROL||PROSPECTIVE|||||||
34066677|NCT01172808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34066678|NCT00464295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066679|NCT00025753|RANDOMIZED|||TREATMENT||||||||
34066680|NCT03964701|||COHORT||PROSPECTIVE|||||||
34066681|NCT03899012|||COHORT||CROSS_SECTIONAL|||||||
34066682|NCT05135793|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34066683|NCT04399538|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double-blind, Double-dummy, Placebo controlled|Dose-ranging of combination doses|t|t|t|t
34066684|NCT05127928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066685|NCT05158231|||COHORT||PROSPECTIVE|||||||
34066686|NCT00617513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066687|NCT00693615|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066688|NCT04591457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066689|NCT00946127|||COHORT||PROSPECTIVE|||||||
34066690|NCT00604422|||COHORT||PROSPECTIVE|||||||
34066691|NCT00441948|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34066692|NCT05202860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066693|NCT03811054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066694|NCT05679297|||CASE_CONTROL||PROSPECTIVE|||||||
34066695|NCT02148315|RANDOMIZED|PARALLEL||||NONE||||||
34066696|NCT00017680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066697|NCT05911672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and providers (nurses and clinicians) will be blinded on the type of intervention received.|patients will be randomized into three groups: Full Intervention; Partial Intervention and Control|t|t|f|f
34186627|NCT04995224|||OTHER||PROSPECTIVE|||||||
34186628|NCT02876549|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34186629|NCT06520774|NA|SINGLE_GROUP||OTHER||NONE||||||
34186630|NCT02567578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186631|NCT05755321|||COHORT||PROSPECTIVE|||||||
34186632|NCT02259088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066698|NCT02927496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066699|NCT04293172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066700|NCT06215144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind placebo controlled|t|t|t|t
34066701|NCT04752306|||OTHER||CROSS_SECTIONAL|||||||
34066702|NCT05023070|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||This is an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of cannabidiol.||||
33764684|NCT03931447|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33764685|NCT04242225|||COHORT||PROSPECTIVE|||||||
34066703|NCT04735796|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Dose level 1: 3mg/kg, enroll CLDN18.2 positive advanced solid tumors|t|f|f|f
34066704|NCT02797418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066705|NCT00170014|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34066706|NCT00878605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066707|NCT05872880|||COHORT||PROSPECTIVE|||||||
34066708|NCT05047614|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34066709|NCT04304261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066710|NCT04575532|||COHORT||PROSPECTIVE|||||||
34066711|NCT04118777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|this will be a double-blinded study. Study participants will be randomized into one of two study arms by the pharmacy staff after using a random number generator.||t|t|t|t
34066712|NCT00549601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066713|NCT03280316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066714|NCT03478761|||COHORT||OTHER|||||||
33965598|NCT06047366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A statistician will provide a two-product randomization scheme which will randomize each of the 60 subjects on the order of their entry into the study. The research assistants will be aware of and document this scheme, but the student researcher/PI will not know what type of anesthetic will be administered.|This study will be a single-center, controlled, randomized, double-blind (provider and subject), 2 treatment, 1 period, parallel study|t|t|t|f
33965599|NCT00150930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34066715|NCT04129125|NA|SINGLE_GROUP||TREATMENT||NONE|"Reperfusion will be graded by an independent core lab that is not an enrolling investigational site.~Neurological Outcome Assessors (NIHSS assessment): Neurological outcome assessors who will perform post-procedure 24-hour NIHSS assessments are NIHSS certified team members not performing the thrombectomy procedure and with no financial conflict of interest with Imperative Care, Inc.~Functional Outcome Assessors (mRS assessment): Functional outcome assessors who will perform post-procedure assessments are part of achieving unbiased study objectives. They will not have access to patient data."|Prospective, multicenter, open-label with independent outcome assessments.||||
34066716|NCT04006678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066717|NCT01741155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066718|NCT03761004|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066719|NCT00478088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066720|NCT03613688|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34066721|NCT01786031|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066722|NCT02171832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066723|NCT01123772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066724|NCT04347655|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Heart Failure Patients (with reduced and preserved ejection fraction) and Healthy Control Subjects will be studied with the same protocol||||
34066725|NCT04859309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34066726|NCT03149822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open-Label|||||
33965600|NCT05400837|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33965601|NCT04938401|||CASE_ONLY||CROSS_SECTIONAL|||||||
33965602|NCT03823365|NA|SINGLE_GROUP||TREATMENT||NONE|This study is a phase I open-label, single center study. The patient population will consist of adults diagnosed with indolent non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL) in need of first line treatment consisting of either FCR or BR as per investigator assessment. Chemotherapy treatment will consist of a minimum of 4 to a maximum of 6 cycles of standard FCR or BR.Patients will be enrolled in the study after the last planned cycle of chemo-immunotherapy and, if eligibility criteria are met, BET dose level will be assigned.|CD20+ Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Patients After First-line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab.||||
33965603|NCT00969059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965604|NCT00559884|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965605|NCT00896883|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33965606|NCT03068910|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Treatment allocation will be double-blinded. The blind will be broken in the event of substantial adverse effects that would also lead to study withdrawal. The blind for a given subject will be lifted after the subject completes the study and analysis is complete for that subject.|Randomized, placebo-controlled, crossover study|t|t|t|t
33965607|NCT04056507|||CASE_ONLY||RETROSPECTIVE|||||||
33965608|NCT06020105|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965609|NCT01200394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965610|NCT04451382|||COHORT||PROSPECTIVE|||||||
34066727|NCT02217800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066728|NCT05521113|||COHORT||PROSPECTIVE|||||||
34066729|NCT02686788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066730|NCT03371056|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||There are 4 pre-specified groups||||
34066731|NCT00441987|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34066732|NCT01634568|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34066733|NCT03001245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066734|NCT04808414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, placebo controlled ascending single- and multiple-dose|double-blind, placebo controlled ascending single and multiple dose|t|t|t|f
34066735|NCT02372942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33764686|NCT04396041|||COHORT||OTHER|||||||
33764687|NCT00638196||CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33764688|NCT01449240|||CASE_ONLY||PROSPECTIVE|||||||
33764689|NCT02180438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764690|NCT06333210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066736|NCT01464619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066737|NCT02815150|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34066738|NCT03850691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066739|NCT01796314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066740|NCT02175329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066741|NCT05849792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial|t|f|f|f
34066742|NCT02860416|||OTHER||RETROSPECTIVE|||||||
34066743|NCT01400906|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34066744|NCT06059729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066745|NCT00006087||||SCREENING||||||||
34066746|NCT04346771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066747|NCT02342600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066748|NCT02806830|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066749|NCT01234701|||COHORT||RETROSPECTIVE|||||||
34066750|NCT06292130|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, repeated measures (2 timepoints)||||
34066751|NCT05359198|||COHORT||PROSPECTIVE|||||||
34066752|NCT02682511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066753|NCT01922856|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066754|NCT02017626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066755|NCT04542278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled pilot study||||
34066756|NCT00770666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754009|NCT03185481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the titration phase, the allocation to treatment will be double blind to protect the blind of the parent study (B7601003). After completing the titration phase, the treatment assignment becomes open label.|"Depending on the actual treatment the subject received in B7601003, subjects will be randomized to one of 4 treatment groups (15 mg QD, 7 mg QD, 3 mg QD, or 1 mg QD group) and titrated up to 15 mg QD over a 3 week period, as appropriate.~All subjects who were blindly down-titrated during the parent study (B7601003) will remain at/or be titrated to 7 mg QD only and remain at that dose for the rest of the B7601017 study in order to protect the blind for the parent study. Subjects who successfully titrate to 15 mg QD will enter the Adjustment Period at that dose. Subjects who cannot tolerate 15 mg QD at any time during the study will be allowed to down-titrate to 7 mg QD (but not lower) and will stay at that dose for the rest of the study. Subjects who cannot remain at a stable dose (7 mg or 15 mg QD) will be discontinued."|t|t|t|f
33754010|NCT06301412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754011|NCT06130826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754012|NCT01054768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754013|NCT00003508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754014|NCT00998608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754015|NCT03102814|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Due to the nature of the study intervention, it is not possible to blind participants or the health care providers. However, the statistician who will perform the main statistical analyses will be blinded to group allocation.|"In order to evaluate the effects of the BRIDGE program, a stepped wedge cluster randomized controlled trial will be conducted. In the trial, participating centres switch from control (current rehabilitation program) to intervention phase (adding the BRIDGE program to the current program) in a randomized order. All centres start the trial simultaneously and act as controls until the point in time they are randomized to crossover from control to intervention, and all centres deliver the intervention by the end of inclusion.~The stepped wedge design is suitable for a phased evaluation approach, where it is difficult to deliver two parallel interventions."|f|f|t|f
33754016|NCT05042778|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33754017|NCT03436329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754018|NCT03270605|||COHORT||RETROSPECTIVE|||||||
33754019|NCT06579209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754020|NCT06012734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754021|NCT06723314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon performing the surgical technique as well as the patient cannot be blinded because the two surgical procedures are different and recognizable by both the surgeon and the patient after being well informed||f|f|t|t
33754022|NCT05581550|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754023|NCT00363675|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754024|NCT03611348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33754025|NCT05872568|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754026|NCT05588726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be conducted as a parallel, single-blinded pilot study for reducing insomnia among patients with opioid use disorder who are stabilized on buprenorphine maintenance therapy. All subjects will participate in some form of insomnia treatment over a fourteen-day period (either the mindfulness relaxation therapy with sleep hygiene or only sleep hygiene for controls). Consent and screening will occur on Day -7, and the sleep diary will be assigned for baseline measurement. Randomization and survey baseline measurements from eligible participants will occur on Day -1, and participants will be randomized into one of two arms: one arm consisting of only the sleep hygiene intervention and the other consisting of both the sleep hygiene and mindfulness interventions. On Day 28, two weeks post-intervention(s), surveys will be emailed to participants to track any changes in sleep quality, mean buprenorphine dose, and frequency of non-prescribed opioid use.|t|f|f|f
33754027|NCT02565654|||CASE_CONTROL||PROSPECTIVE|||||||
34186633|NCT04518358|NA|SINGLE_GROUP||TREATMENT||NONE||A multiple probe design across participants will be used. This design necessitates a minimum of three participants to demonstrate experimental control, however 8 will be recruited. The small-N design yields much higher power and inferential validity than a traditional between-subject design, allowing for a much smaller n. The eight adults with ASD/ID will be divided into two groups, with four participants per group, which creates two sets of multiple probe designs. Baseline data will be collected for all participants (fidelity of treatment implementation for DSPs and independent completion of steps for adults with ASD/ID) for a minimum of three-to-five sessions prior to implementation of the intervention. Baseline data collection will continue until stability is achieved through each data point not exceeding 20% of mean responding during baseline. The intervention will be implemented in a staggered manner within each group in order to assess the effects of the intervention.||||
33754028|NCT02938598|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34186634|NCT02189733|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186635|NCT02117661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186636|NCT04681183|||COHORT||PROSPECTIVE|||||||
34186637|NCT03524118|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE||Single ascending dose|t|t|t|f
34186638|NCT02577718|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34186639|NCT05727852|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34186640|NCT02114073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186641|NCT05726708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186642|NCT02149043|||CASE_CONTROL||PROSPECTIVE|||||||
33754029|NCT05766514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754030|NCT00049374||||TREATMENT||NONE||||||
33754031|NCT00837174|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754032|NCT04367350|||COHORT||PROSPECTIVE|||||||
33754033|NCT00392405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754034|NCT00722891|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33754035|NCT01215292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754036|NCT06444906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764691|NCT01298921|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764692|NCT01656837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764693|NCT00615862|||COHORT||PROSPECTIVE|||||||
33764694|NCT05767775|||CASE_CONTROL||PROSPECTIVE|||||||
34186643|NCT02447523|||COHORT||PROSPECTIVE|||||||
34066757|NCT02886884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pilot phase is open label. Randomized phase is blinded.||t|t|t|t
34066758|NCT00564317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34066759|NCT00386230|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33869727|NCT05584982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869728|NCT01660555|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869729|NCT06296238|||COHORT||PROSPECTIVE|||||||
33869730|NCT04483674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869731|NCT04312685|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|subject will be blinded to dosing decreases and increases|Open-Label, Non-Randomized, Single-Blind, Multi-Center|t|f|f|f
33869732|NCT01392677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869733|NCT04114292|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Open-label study. All patients will receive TUDCA.|Determine the effect of TUDCA treatment on colon inflammation including ER stress in colon biopsy tissues from subjects with symptomatic ulcerative colitis. Secondary: Measure the safety, tolerance and efficacy of TUDCA treatment in symptomatic ulcerative colitis.||||
33869734|NCT05782400|||OTHER||PROSPECTIVE|||||||
33869735|NCT02069470|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33869736|NCT06064942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869737|NCT05337579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34066760|NCT04848753|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34066761|NCT02424994|||COHORT||RETROSPECTIVE|||||||
34066762|NCT01309750|||COHORT||PROSPECTIVE|||||||
34186644|NCT02694289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186645|NCT01419288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186646|NCT01678235|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34186647|NCT00196313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186648|NCT02292589|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
34186649|NCT01898559|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34186650|NCT06045702|||OTHER||PROSPECTIVE|||||||
34186651|NCT00433082|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186652|NCT03532204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186653|NCT04300166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186654|NCT06001957|||CASE_ONLY||PROSPECTIVE|||||||
34186655|NCT02340364|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34186656|NCT02842489|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34186657|NCT02354053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186658|NCT01587924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186659|NCT03590821|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Administration of acetylsalicylic acid versus placebo will be masked|"Prospective study design, double-blinded and randomized by order for acetylsalicylic acid versus placebo, open for celecoxib.~In a prospective study each individual will undergo two treatment periods randomized by order (separated by 3 weeks of washout). In one period, placebo (matching aspirin for double-blinding) will be administered in the evening for 14 days. In the other period, aspirin (81 mg QD) will be administered in the evening for 14 days. Drug intake will be timed to occur within 1-2 hours prior to falling asleep. Celecoxib (200 mg BID) will be added openly for the final 7 days during each treatment period."|t|f|t|t
34186660|NCT05605886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|2 Cards will have sequential numbers one number for each card then these cards will be placed within opaque sealed envelopes. Then these envelops will be placed in a container (box), each participant will grasp one envelop the day of procedure|All patients involved in this study will be divided in to two different groups, one group will undergo zinc supplement then botulinum toxins injection in masseter and temporalis muscle while the other group will have botulinum toxins injection in masseter and temporalis muscle without previous zinc supplement|t|f|f|t
34186661|NCT01288885|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34186662|NCT00618267|||COHORT||PROSPECTIVE|||||||
34186663|NCT05842096|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective tertiary single-centre cohort study||||
34186664|NCT05291312|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34186665|NCT03807856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186666|NCT04727307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186667|NCT02905890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186668|NCT05237076|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Multi arm pre-post study||||
34186669|NCT03983356|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186670|NCT01052701|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34186671|NCT01168986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869738|NCT04053647|||CASE_CONTROL||PROSPECTIVE|||||||
33869739|NCT04311697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, placebo-controlled trial with identical drug and placebo infusion bags|Multicenter trial, initially conducted at a single center with a safety/futility assessment following enrollment of 30 patients, expanded to 196 total patients at 12 study sites|t|t|t|t
33869740|NCT04927286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869741|NCT01530425|||COHORT||PROSPECTIVE|||||||
33869742|NCT02142738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869743|NCT02787187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869744|NCT02499861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869745|NCT00130195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869746|NCT04866992|||COHORT||PROSPECTIVE|||||||
33869747|NCT01105676|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33869748|NCT02058030|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33869749|NCT02135211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869750|NCT02282150|NA|SINGLE_GROUP||TREATMENT||NONE||Cross over||||
33869751|NCT06174844|||COHORT||CROSS_SECTIONAL|||||||
33869752|NCT03691129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33869753|NCT02075359|||COHORT||CROSS_SECTIONAL|||||||
33894077|NCT03034941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066763|NCT01024361|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066764|NCT04957199|||OTHER||OTHER|||||||
34066765|NCT02510820|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34066766|NCT04352738|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066767|NCT02003989|||CASE_CONTROL||PROSPECTIVE|||||||
33869754|NCT05818553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Parallel group|t|t|t|f
33869755|NCT03514342|||COHORT||PROSPECTIVE|||||||
33869756|NCT00268632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869757|NCT00001545||||TREATMENT||||||||
33869758|NCT04093843|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33869759|NCT04515914|||CASE_CONTROL||RETROSPECTIVE|||||||
33965611|NCT04661566|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants will not know the exact intervention conditions (i.e., what all of the intervention components are and what all of the possible combinations of intervention components there are)|The MOST framework will be used. This study follows the optimization phase of the MOST framework where component selection experiments are conducted to experimentally evaluate the effectiveness of individual intervention components. Using a factorial design in this phase allows the effect of each intervention component to be evaluated and for observation of interaction effects while maximizing statistical power using a smaller sample size compared to an randomized controlled trial (RCT) powered similarly to explore individual components of an intervention. The optimization phase then allows for time and resources to be saved by ensuring only optimized components are retained after the RCT in the final intervention package.|t|f|f|f
33965612|NCT02816554|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066768|NCT02986347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|open label|||||
34066769|NCT06463379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186672|NCT02461277|NON_RANDOMIZED|PARALLEL||||NONE||||||
34186673|NCT04782479|||OTHER||PROSPECTIVE|||||||
34186674|NCT06385626|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Volunteers will be asked to consume 50 g of carbohydrate powder (sucrose and glucose) with or without 10 g of raspberry leaf tea, which will be dissolved in 300 mL of warm water during four visits (every month).||||
34186675|NCT03248206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34186676|NCT01708902|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34186677|NCT05853991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869760|NCT03251742|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a cross-sectional study designed to evaluate the immediate impact of negative pressure ventilation (NPV) in an ambulatory Fontan population using cardiovascular magnetic resonance imaging (CMR) for assessment of cardiovascular flows.||||
33869761|NCT03300895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869762|NCT01118273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869763|NCT03349775|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34186678|NCT03475836|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Double blind. Treatments were prepared and coded by a third party researcher who had no further involvement with the study.|Randomised, placebo controlled, crossover|t|f|t|t
33869764|NCT05533138|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Participants are blinded for allocation to perinatal extra support in addition to therapist-guided internet CBT treatment.~Outcome is assessed by an independent assessor who is blind for whether patient chose or was allocated to assessment modality and whether patient received extra-support or not."|Multiple Assignment Randomized Trial|t|f|f|t
34186679|NCT00872443|||COHORT||RETROSPECTIVE|||||||
34186680|NCT00602472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186681|NCT01482052|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34186682|NCT02210039|NA|SINGLE_GROUP||SCREENING||NONE||||||
34186683|NCT00888940|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34186684|NCT06216509|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186685|NCT00792220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34186686|NCT02796183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754037|NCT06273644|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinding is attempted by labeling the provided diet plans as A and B. The physician recording outcome variables and the researcher performing statistical analysis are blinded to the given diet.|The study is a crossover study involving 50 individuals with AIP. The study design was chosen to determine whether the treatment has an effect compared to baseline analyses and whether the sequence of treatment has an effect, as well as whether one of the interventions is more effective than the other.|f|f|t|t
34186687|NCT00515268|RANDOMIZED|PARALLEL||DIAGNOSTIC||||||||
33754038|NCT03491176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754039|NCT01811082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186688|NCT00693901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754040|NCT02085148|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34186689|NCT01956799|||COHORT||PROSPECTIVE|||||||
34186690|NCT04070872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186691|NCT04251403|NA|SINGLE_GROUP||SCREENING||NONE||This is a pilot feasibility study. High-risk individuals with known history of gastric precursor lesions (atrophic gastritis, intestinal metaplasia, dysplasia) who are presenting for routine surveillance endoscopy will undergo mucosal irrigation and collection of gastric aspirate for analysis, in addition to standard of care (visual inspection on endoscopy).||||
34186692|NCT02633020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186693|NCT03233581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34186694|NCT00336609|||DEFINED_POPULATION||PROSPECTIVE|||||||
34186695|NCT03061396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34186696|NCT01202032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186697|NCT01753934|||OTHER||PROSPECTIVE|||||||
34186698|NCT04420104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186699|NCT04695808|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34186700|NCT03792906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186701|NCT00655200|||COHORT||PROSPECTIVE|||||||
34186702|NCT03585738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients, care provides, investigators and outcome assessors are blinded for the treatment: Inositol + Folic acid versus Folic acid alone. The treatment allocation is identified by code number before the study start, and will be revealed only after data analysis.|Randomized multi centre double-blind controlled trial|t|t|t|t
34186703|NCT04433988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186704|NCT00126334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186705|NCT01145976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186706|NCT02094924|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186707|NCT00125177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186708|NCT05002296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186709|NCT03298035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186710|NCT03223441|||COHORT||PROSPECTIVE|||||||
34186711|NCT01847326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186712|NCT03137199|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||a first group of 3 patients will receive a lower dose of 20 million hMSCs, followed by a second group of 3 patients to receive a dose of 100 million hMSCs||||
34186713|NCT00684541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754041|NCT03974542|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33754042|NCT02609217|||COHORT||PROSPECTIVE|||||||
33754043|NCT00075062|||||PROSPECTIVE|||||||
33754044|NCT00738946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754045|NCT05338723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754046|NCT00997087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754047|NCT02489396|||OTHER||PROSPECTIVE|||||||
33754048|NCT04153227|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869765|NCT00871845|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants were divided into arms based upon BMI. Weight loss instruction/management provided only to overweight arm.|Both groups followed for same period of time||||
33869766|NCT00267683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869767|NCT00029874|RANDOMIZED|||TREATMENT||DOUBLE||||||
33965613|NCT02626182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965614|NCT05478005|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor who was blinded to the treatment group allocation and who was not involved in the interventions.||f|f|f|t
33965615|NCT03318328|||CASE_ONLY||OTHER|||||||
33965616|NCT04126733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965617|NCT03360526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965618|NCT02957682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965619|NCT00127764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965620|NCT01218737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869768|NCT00454259|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34186714|NCT02457143|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34186715|NCT04341870|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bayesian open labelled randomized clinical trial||||
34186716|NCT05303311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34186717|NCT04319588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869769|NCT05653622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186718|NCT05346419|NA|SINGLE_GROUP||TREATMENT||NONE||33 participants between 40 and 78 years old with a diagnosis of postmenopausal osteoporosis or osteopenia with associated hyperparathyroidism, hypovitaminosis or both conditions were selected. All participants were treated for 6 months with risedronate 35 mg and vitamin D 2800 IU once a week, with additional daily vitamin D supplementation of 4000 IU.||||
34186719|NCT03889522|||COHORT||CROSS_SECTIONAL|||||||
34186720|NCT03172416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186721|NCT04879251|||COHORT||OTHER|||||||
34186722|NCT03281200|||OTHER||RETROSPECTIVE|||||||
34186723|NCT03521440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186724|NCT06246461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754049|NCT03281525|||OTHER||OTHER|||||||
33869770|NCT04037748|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33869771|NCT02691754|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869772|NCT01912742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869773|NCT02671357|||COHORT||PROSPECTIVE|||||||
33869774|NCT06331442|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33894078|NCT06655077|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge cluster randomized trial||||
33894079|NCT01142830|||COHORT||PROSPECTIVE|||||||
33894080|NCT06487949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894081|NCT06587256|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label, non-randomized interventional clinical trial comparing each participant's baseline snoring or sleep apnea level to the participant's 3-month snoring or sleep apnea while using mouth tape during sleep.||||
33894082|NCT05781048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894083|NCT01564979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869775|NCT03561103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study includes an RCT with two randomized arms plus additional non-randomized arms.~In the RCT, 160 participants will be recruited. The RCT consists of an Intervention group that receives client-centered representative payee services in addition to standard of care; the control group receives standard of care only.~For the two additional non-randomized (Choice) arms, two arms have been added through which an additional 50 people will be recruited. The Choice Intervention arm (n=25) receives client-centered representative payee services in addition to standard of care. The Choice control group (n=25) receives standard of care. Participant in the choice arms are not randomized."||||
34186725|NCT04823013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants in HPPT-US 1 group received the HPPT-US treatment (n=52). The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. Participants in HPPT-US 2 group also received the HPPT-US treatment (n=57). The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times.Participants in IC group received ischemic compression therapy (n=44). The duration for each trigger points was 1 minute.|t|f|f|f
34186726|NCT03636100|||CASE_ONLY||PROSPECTIVE|||||||
34186727|NCT01099332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186728|NCT02415413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186729|NCT00110747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186730|NCT02198118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34186731|NCT01967576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186732|NCT04986267|||CASE_ONLY||CROSS_SECTIONAL|||||||
34186733|NCT00082797||||TREATMENT||NONE||||||
34186734|NCT04174326|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either immediate treatment group or delayed waitlist treatment group at baseline. Participants in both groups will receive the same CBT intervention program consecutively, once a week during a period of 6 weeks. Two in-between sessions practice assignments will be included in each therapy session in the program. Participants will be followed-up at 18 weeks from the beginning of the intervention.||||
34186735|NCT04531930|||COHORT||PROSPECTIVE|||||||
34186736|NCT05155267|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186737|NCT06103786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||This experiment utilized a high-intensity interval training methodology to intervene in the physical fitness, skills, and tactical performance of college athletes and compared it to traditional technical skill training methods.|t|f|t|t
34186738|NCT00505349|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186739|NCT01418690|||CASE_CONTROL||PROSPECTIVE|||||||
34186740|NCT01254422|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34186741|NCT02281383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186742|NCT04651062|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|participant, care provider, investigator and outcomes assessor know whether or not a endocuff has been used for the colonoscopy|this is a randomized controlled trial||||
34186743|NCT01391078|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34186744|NCT00046462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186745|NCT01574092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186746|NCT00005080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186747|NCT00225485|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34186748|NCT03332706|||COHORT||PROSPECTIVE|||||||
34186749|NCT04646044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186750|NCT01134055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186751|NCT00768456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34186752|NCT00709241|||COHORT||PROSPECTIVE|||||||
34186753|NCT00828204|NA|SINGLE_GROUP||||NONE||||||
34186754|NCT05510349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Sonographic measure of placental elasticity and viscosity||||
34186755|NCT04028219|||COHORT||PROSPECTIVE|||||||
34186756|NCT00614731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186757|NCT01209013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186758|NCT03584958|||COHORT||PROSPECTIVE|||||||
34186759|NCT00356304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186760|NCT02698553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186761|NCT01333930|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33869776|NCT04869345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34066770|NCT04084899|||COHORT||PROSPECTIVE|||||||
33869777|NCT00927654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869778|NCT06118983|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869779|NCT05071079|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This is a double-blinded study; volunteers, clinical investigators, and study staff who perform laboratory study endpoint will be blinded to inoculation arm allocation.|Controlled Plasmodium vivax human malaria infection through experimental inoculation of cryopreserved infected erythrocytes in healthy Thai adults, with a randomized double blind design.|t|t|t|f
33869780|NCT02680925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33869781|NCT03039400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33869782|NCT03562130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869783|NCT00868348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965621|NCT02516631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965622|NCT01440595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965623|NCT02131415|||COHORT||PROSPECTIVE|||||||
33965624|NCT03451331|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|||||
34186762|NCT03598686|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The HOSENG study is linked to a follow-up trial, the VIBRA study. Together they are called the GET ON (GETing tOwards Ninety) research project. The HOSENG study with its home-based HIV testing campaign provides the platform for the VIBRA study. The reasons for this interlinked design are: a) potential study participants for VIBRA trial (HIV-positive individuals not on ART) are recruited during the HOSENG study, b) this design allows us to assess the entire HIV/AIDS care cascade in one larger project, and c) both trials rely on interventions involving VHWs, who need to be randomized and specifically trained. Therefore, it is more efficient and feasible to run both trials parallel and randomize at one time point.~The HOSENG study is a cluster randomized, parallel-group (1:1:1:1 allocation), open-label, superiority, prospective clinical trial. Clusters are stratified by district, size of village, and village access to the nearest health facility."||||
34186763|NCT01956838|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33965625|NCT04608149|||COHORT||PROSPECTIVE|||||||
33965626|NCT00166374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869784|NCT06242379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869785|NCT03375398|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33869786|NCT01030159|||COHORT||PROSPECTIVE|||||||
33869787|NCT02623127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894084|NCT00872066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869788|NCT01922817|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|double blind|crossover trial between Saxaglipin and Placebo with 2 week washout in between|t|f|t|f
33869789|NCT01059240|||||PROSPECTIVE|||||||
33869790|NCT01469182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869791|NCT04860570|||CASE_CONTROL||RETROSPECTIVE|||||||
33869792|NCT05273034|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33869793|NCT04743921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965627|NCT00032370|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965628|NCT03705884|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients and healthy subjects will be allocated in a non-randomised fashion to either corticosteroid or control arms, for parallel comparison within the two groups. The corticosteroid is recognised treatment for the condition and is being used to observe the impact on diagnostic imaging; no treatment effects are being studied or are endpoints of the study (i.e. the study is not a clinical trial of treatment in cardiac sarcoidosis with corticosteroid).||||
33965629|NCT06156228|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|In order to generate evidence that reflects real-world circumstances and is generalizable to a broad patient population served by Federally Qualified Health Centers, Investigators will evaluate our proposed intervention in a single-blind, pragmatic, cluster randomized trial, whereby 10 clinics will be randomized at a ratio of 1:1 to one of two conditions. The first being standard clinical practice and the second being the intervention which will include motivational interviews where health educators can assist with scheduling their vaccine appointments should the clinic patient opt for that. The study participants will not know whether they are placed on the intervention or control group and their care providers will also be unaware. This will ensure balance across study conditions regarding clinic patient characteristics.|Investigators will implement a multilevel intervention in 10 clinics that will be randomized to either a Standard Clinical Practice consisting of standard clinic-based strategies to promote vaccine uptake among patients or a Multilevel Intervention consisting of an individualized/tailored intervention delivered by Health Educators working within the clinics plus a multi-component community intervention delivered by community promotores.|t|t|t|f
33965630|NCT01559831|NA|SINGLE_GROUP||||NONE||||||
33965631|NCT05288673|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Participants and on-site medical/nursing staff at the study site were blinded to study drug/dose assignment. The pharmacy staff who prepared ALXN1210 or placebo, however, was not blinded to study drug assignment, but all other site staff, including the Investigator and personnel administering study drug, was blinded. Sponsor staff was unblinded as needed (for example, to monitor the pharmacy), but did not share any information on study drug assignment with the site staff.||t|t|t|f
33965632|NCT02601911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965633|NCT03346031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33965634|NCT04938609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965635|NCT03687099|||OTHER||RETROSPECTIVE|||||||
33965636|NCT01208259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965637|NCT01400672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965638|NCT00000168|||COHORT||PROSPECTIVE|||||||
33965639|NCT05750979|||COHORT||PROSPECTIVE|||||||
33965640|NCT01424371|||CASE_CONTROL||PROSPECTIVE|||||||
33965641|NCT01092299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33965642|NCT03559010|NA|SINGLE_GROUP||OTHER||NONE||||||
33965643|NCT06197256|||COHORT||PROSPECTIVE|||||||
33965644|NCT06545682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965645|NCT00902291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965646|NCT01664273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965647|NCT04559165|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33965648|NCT02134691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965649|NCT02148783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965650|NCT02664766|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965651|NCT01802840|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33965652|NCT02683187|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33965653|NCT03970720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33965654|NCT01814995|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33965655|NCT00769015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965656|NCT02279576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965657|NCT04271683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965658|NCT01463683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33965659|NCT00897533|||OTHER||RETROSPECTIVE|||||||
33965660|NCT02593188|||COHORT||PROSPECTIVE|||||||
33965661|NCT03774927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33869794|NCT01068691|||CASE_ONLY||PROSPECTIVE|||||||
33869795|NCT04400370|||CASE_ONLY||PROSPECTIVE|||||||
33869796|NCT03509142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869797|NCT01471015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869798|NCT00674583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869799|NCT04204733|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33869800|NCT00995475|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33869801|NCT05376475|||COHORT||PROSPECTIVE|||||||
33869802|NCT04204187|||OTHER||PROSPECTIVE|||||||
33869803|NCT02783339|||COHORT||PROSPECTIVE|||||||
33869804|NCT03070925|||CASE_ONLY||PROSPECTIVE|||||||
33869805|NCT03880487|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33869806|NCT00006469|NA|SINGLE_GROUP||TREATMENT||||Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer||||
33965662|NCT00968396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965663|NCT00406822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965664|NCT06439615|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33965665|NCT01497873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754050|NCT05603468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754051|NCT06248619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754052|NCT04397042|||CASE_CONTROL||PROSPECTIVE|||||||
33754053|NCT05829655|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33754054|NCT05835128|||COHORT||PROSPECTIVE|||||||
33754055|NCT00378989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754056|NCT06038656|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33754057|NCT00345982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754058|NCT02264704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754059|NCT01049113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754060|NCT02195986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754061|NCT00262587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754062|NCT00141427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754063|NCT05237050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33754064|NCT05497440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754065|NCT03763422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754066|NCT01510275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33754067|NCT01618864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754068|NCT01346748|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33754069|NCT02087631||SEQUENTIAL||TREATMENT||NONE||||||
33754070|NCT02818712|||COHORT||PROSPECTIVE|||||||
33754071|NCT04198805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869807|NCT04778982|||COHORT||PROSPECTIVE|||||||
33869808|NCT02319187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869809|NCT05896488|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33869810|NCT00211848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965666|NCT04516694|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33754072|NCT01284426|||COHORT||PROSPECTIVE|||||||
33754073|NCT00975312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066771|NCT03046056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754074|NCT04739501|||COHORT||PROSPECTIVE|||||||
34066772|NCT00742027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754075|NCT03951454|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants are not informed as to whether they are in the experimental intervention or the control intervention.~Members of the Data Collection Team at New Mexico State University (NMSU) remain blind on the randomization status of study participants. Randomization will be handled centrally by the team's biostatistician, Griffith, at the University of Washington. She will be responsible for centralized random assignment using block randomization \[by recruitment sites, language of program delivery, and cancer types\] and will communicate that assignment only to Palacios, Lewis and the Project Manager."|"Experimental group: Experimental subjects will receive Conexiones, a program designed to help the cancer-diagnosed mother manage her child's cancer-related concerns by improving the mother's mood and anxiety and by equipping the mother with parenting and communication skills to assist the child in coping with the mother's cancer. The program involves 5 fully scripted telephone-delivered educational sessions delivered at 2-week intervals by patient educators.~Control group: Control subjects will receive an informational booklet published by NCI called, Taking Time. The booklet contains information on ways to manage emotional issues, including the importance of sharing feelings about the cancer with a trusted adult confidant, learning all you can about your cancer in order to regain control and talking with medical providers, and dealing with a new self-image. This group receives one scripted telephone-delivered session guiding the mother on how to obtain the most from the booklet."|t|f|f|t
33764695|NCT03395249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized in a 3:1 ratio of SPR994 to placebo. Study drug tablets, both active and placebo, are the same shape, weight and size. Those blinded to study drug assignment include the sponsor, the PI, clinical study personnel participating in subjects' care or clinical evaluations, and the subjects. Those unblinded to study drug assignment include the statisticians preparing the randomisation, pharmacy personnel, the unblinded study monitor, the bioanalytical laboratory, and the pharmacokineticist performing interim PK analysis.|Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose (SAD and MAD) trial|t|t|t|t
33764696|NCT00792103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066773|NCT04893187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066774|NCT02864329|||COHORT||RETROSPECTIVE|||||||
34066775|NCT03437161|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34066776|NCT05930405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764697|NCT05386563|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34066777|NCT01660802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33764698|NCT01892943|||CASE_ONLY||RETROSPECTIVE|||||||
33764699|NCT01683240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869811|NCT00702754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869812|NCT03697720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869813|NCT01710384|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869814|NCT00808236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33869815|NCT03735927|RANDOMIZED|PARALLEL||SCREENING||NONE||"In this study hospital departments will be randomized with respect to the time they will introduce the DeltaScan following a stepped wedge cluster randomization design. All departments apply 'usual care' in combination with a harmonized delirium treatment protocol during the control phase. After this first time period, each new time period a department switches to the intervention period.~Due to the first wave of the COVID-19 pandemic the stepped wedge planning was interrupted. Where possible the control period and/or intervention, whichever was affected, will be extended. We marked the first wave of the COVID-19 pandemic from the 15th of March until the 15th of May or longer for a few heavily effected sites with a maximum of 6 months. Data collected during this period will not be used for primary analysis, but may be used for specific sub analyses."||||
33869816|NCT04267419|||CASE_CONTROL||RETROSPECTIVE|||||||
33869817|NCT00427349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869818|NCT02667275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869819|NCT06463691|NA|SINGLE_GROUP||TREATMENT||NONE||Sonrotoclax, Zanubrutinib and CD20mab||||
33754076|NCT06580444|RANDOMIZED|PARALLEL||OTHER||TRIPLE|To minimize bias, a placebo drug is employed as the comparison group to active study drug doses and the study is conducted in a double-masked fashion in that both the participants and anyone assessing study outcomes are masked to treatment assignment. The only individuals at the site with access to treatment assignment information are the research pharmacists.|"At baseline, participants who meet eligibility criteria are randomized to placebo or 90, 60, or 30 mcg/kg/h doses of BREX along with the order/sequence of their stress and neutral lab sessions in a double-mask fashion for the duration of the study. The treatment allocation will be equal in each arm. Additionally, the order/sequence of stress and neutral laboratory sessions will be randomized for laboratory sessions (e.g., if stress on session #1 then neutral on session #2) in a manner that assures treatment balance within laboratory session.~Each participant will be randomized to receive a target dose of either 90, 60, 30 and 0 mcg/kg/h, titrated over the 20 hours; both the 90 and 60 doses have shown efficacy to target postpartum depressive symptoms and the 30 mcg/kg/h will test the lower limits of efficacy.~The sample size will have 10 participants in each group for doses 0, 30, 60 and 90 to equal 40 participants."|t|t|t|f
33754077|NCT05217342|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms with a standard care control group and a peripheral pressure guided intervention group||||
33754078|NCT03162575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754079|NCT02382198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754080|NCT03355638|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a prospective, randomized, pilot study in 60 patients with treatment-naïve choroidal neovascularization. Patients were randomized 1:1:1 into 3 groups: aflibercept monotherapy, aflibercept plus pranoprofen, or aflibercept plus nutraceutical tablets containing multivitamin antioxidant and mineral supplementation plus omega-3.||||
33754081|NCT00769548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754082|NCT04674241|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754083|NCT04979559|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The participant and care provider in each site are unaware of the group allocation.|Participants will be assigned to one of two arms: (1) a group that is used mobile health application intervention for screening and early intervention and (2) a group that receive standard care for screening and early intervention from PHCs regular practice.|t|t|f|f
33754084|NCT02123108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754085|NCT04818580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A random number generator will be used. Subjects will be blinded as to which side of the chest has the sutures.||t|f|f|f
33754086|NCT01206998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754087|NCT02481310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754088|NCT02366910|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33754089|NCT05524974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754090|NCT04862182|||COHORT||PROSPECTIVE|||||||
33754091|NCT02824133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869820|NCT04591730|||CASE_ONLY||PROSPECTIVE|||||||
34186764|NCT05017272|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Using a stepped wedge effectiveness design, evaluate OARS platform in 6 treatment programs (N=200 treated patients) data before and after implementation along MAT outcomes. Each clinic, once randomized to begin using OARS, will have a minimum of 4 months and a maximum of 12 months to collect baseline data on the number of PCPs who have DATA-2000 waivers, on the number of patients each PCP treats and on relevant patient outcomes to MAT (e.g., length of time in treatment, visits kept with PCP and psychosocial providers, number of drug-free urine tests). There will be four months of baseline data available for PCPs and patients defined as treatment as usual (TAU) for clinics 1 and 2, eight months of baseline data available for PCPs and patients defined as TAU for clinics 3 and 4 and 12 months of baseline data available for PCPs and patients defined as TAU for clinics 5 and 6. In the final 3 months, we will finish data analyses, prepare papers for dissemination in peer-reviewed journals."||||
34186765|NCT06137417|||COHORT||PROSPECTIVE|||||||
33869821|NCT05855057|||COHORT||RETROSPECTIVE|||||||
33869822|NCT01824992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869823|NCT03317470|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34186766|NCT03903588|||COHORT||PROSPECTIVE|||||||
34186767|NCT05336448|||COHORT||PROSPECTIVE|||||||
34186768|NCT02365337|||COHORT||PROSPECTIVE|||||||
34186769|NCT06048978|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34186770|NCT00888719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186771|NCT06093841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186772|NCT03616028|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a prospective, multicenter, open-label, first-in-human study aimed at examining the performance of the CLAAS device for LAA closure.||||
34186773|NCT00160901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186774|NCT02141204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186775|NCT04976543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186776|NCT05757544|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|All participating staff involved in the evaluation and execution of the study will remain blinded to the participant's treatment assignment during the double-blind phase.||t|t|t|f
34186777|NCT01744106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186778|NCT00175396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186779|NCT04349332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized trial||||
34186780|NCT00412919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186781|NCT01730482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186782|NCT01760733|||COHORT||PROSPECTIVE|||||||
34186783|NCT02321176|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33754092|NCT05330221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754093|NCT02481544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33754094|NCT03924375|||CASE_ONLY||RETROSPECTIVE|||||||
33754095|NCT04365764|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754096|NCT05016700|||COHORT||RETROSPECTIVE|||||||
33754097|NCT02571517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754098|NCT00387582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869824|NCT04994392|||COHORT||PROSPECTIVE|||||||
33869825|NCT00415857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869826|NCT00238550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869827|NCT04810182|||COHORT||PROSPECTIVE|||||||
34186784|NCT01995188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186785|NCT04421027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754099|NCT01080508|||CASE_CONTROL||PROSPECTIVE|||||||
33754100|NCT06079463|RANDOMIZED|CROSSOVER||OTHER||NONE||The experimental group consisted of 52 people (the group in which progressive movements exercises were applied) and the control group consisted of 52 people, a total of 104 people. Patients who meet the sample selection criteria are randomized using the Random Integer Generator method from the Random.org organelle Numbers sub-title. In the randomization, the 1-digit experiment will continue to represent the 2-digit control group.||||
33754101|NCT03371082|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects who meet the study eligibility criteria will be centrally randomized 1:1 in an open-label fashion to receive either Gan \& Lee Insulin Glargine Injection or Lantus® for 26 weeks. Randomization will be stratified by country.||||
33754102|NCT00474695|||||PROSPECTIVE|||||||
34186786|NCT05530564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"none of the participants knew at which pressure they will be operated on, nor the physicians who followed participants at floor or those analyzing blood samples, not the assigned physician to collect data, nor the personnel doing the analysis.~only the operating surgeon and circulating nurse were aware of the meaning of the participant assigned label at time of operation. The masking was revealed post completion of analysis."|participants were divided into two masked groups, labelled red and green; those operated at low-pressure pneumoperitoneum (green-label) and those operated at standard-pressure pneumoperitoneum (red-label).|t|t|t|t
33754103|NCT01786369|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33754104|NCT05560048|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33754105|NCT02839551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754106|NCT05782764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754107|NCT04332796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind controlled trial between participants, drug preparing team, doctors, investigators, and outcome assessors.||f|f|t|t
33754108|NCT01371214|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33754109|NCT02191267|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34186787|NCT01032252|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34186788|NCT03967444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186789|NCT00749853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186790|NCT00520806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186791|NCT03227120|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial with repeated measures pre and post-surgery. Consecutive patients which meet inclusion and exclusion criteria and consent to participate will be evaluated two months or more pre-operatively. After completion of office testing at the pre-surgery/pre-exercise time point, randomization will be completed using a gender stratified randomized sequence generated prior to subject recruitment.||||
33869828|NCT05753267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
34186792|NCT01421615|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34186793|NCT02625909|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186794|NCT05190497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The exercise group received inspiratory muscle training in addition to routine chest physiotherapy (group A).~The Control group received only routine chest physiotherapy (group B)."|t|f|f|f
34186795|NCT05305404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study is double blind, where participants and investigators are blind to the medication assignment|This is a two arm assignment where participants are randomized to a single dose dexamethasone (1.5mg) or placebo|t|f|t|f
34186796|NCT01412684|||COHORT||PROSPECTIVE|||||||
34186797|NCT02752282|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34186798|NCT05415917|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A chemotherapy cycle will constitute 28 days of treatment:~1. Gemcitabine: 1000 mg/m2 IV on days 1, 8, and 15 of each 28-day cycle~2. Capecitabine: 1660 mg/m2 per day orally on days 1 through 21 of each 28-day cycle."||||
34186799|NCT01387997|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34186800|NCT01271634|||CASE_ONLY||PROSPECTIVE|||||||
34186801|NCT00157989|RANDOMIZED|PARALLEL||ECT||NONE||||||
34186802|NCT04059380|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34186803|NCT03304158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186804|NCT03488017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186805|NCT05505617|||OTHER||CROSS_SECTIONAL|||||||
34186806|NCT05971082|||COHORT||OTHER|||||||
33754110|NCT00356954|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33754111|NCT01394900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754112|NCT02398929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754113|NCT05542940|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754114|NCT05273632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754115|NCT00512512|||COHORT||PROSPECTIVE|||||||
33754116|NCT02310529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754117|NCT01379833|||CASE_CONTROL||PROSPECTIVE|||||||
33754118|NCT03687190|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754119|NCT03585582|||COHORT||PROSPECTIVE|||||||
33754120|NCT04738526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754121|NCT00878098|||||PROSPECTIVE|||||||
33754122|NCT01174095|||CASE_ONLY||RETROSPECTIVE|||||||
33869829|NCT05803200|||CASE_ONLY||RETROSPECTIVE|||||||
33869830|NCT05094791|||COHORT||PROSPECTIVE|||||||
33869831|NCT05261763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869832|NCT05166629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial|f|f|f|t
33869833|NCT02953639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869834|NCT00528021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869835|NCT01961349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066778|NCT01734083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066779|NCT00703118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066780|NCT03765229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754123|NCT03432364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869836|NCT05584670|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33869837|NCT01304095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754124|NCT04329754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754125|NCT00108602||CROSSOVER||DIAGNOSTIC||SINGLE||||||
33754126|NCT03664869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754127|NCT05550142|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34186807|NCT02743104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186808|NCT05791604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754128|NCT01403896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754129|NCT02692326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754130|NCT03538951|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3-part, open-label, multi-center study||||
33754131|NCT05288010|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with cannabis via an inhalation device in addition to standard of care chronic pain treatment.||||
33754132|NCT05169034|||CASE_ONLY||PROSPECTIVE|||||||
33754133|NCT03204916|||CASE_ONLY||RETROSPECTIVE|||||||
33754134|NCT01792180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33754135|NCT03742700|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|Subjects were divided into 4 groups (n=30 each) based on their self-declared smoking status: control (C), tobacco cigarette smokers (T-Smokers), exclusive e-cigarette users (E-Smokers) and dual users (T/E-Smokers).|This was a laboratory-based intervention study: pre-post-post||||
33754136|NCT02566018|||COHORT||OTHER|||||||
33754137|NCT00916032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754138|NCT05900726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomised allocation to treatment or sham arm will be performed using sealedenvelope.com, the software will only be available to the study team. Participant ID's will be entered 001 - 036 randomisation tool on sealedenvelope.com where they will be assigned to group A (treatment) or group B (sham). A randomisation log will be kept in the site file. Participants will be blinded to which group they have been assigned too.|This protocol describes a single blinded, two-armed, parallel-group, randomised exploratory study with control arm, assessing the effect of pelvic floor magnetic neuromuscular stimulation (Pelvipower) versus sham stimulation, in patients with faecal incontinence.|t|f|f|f
33754139|NCT00244296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754140|NCT01803074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754141|NCT06497452|||COHORT||PROSPECTIVE|||||||
33754142|NCT01542606|NA|SINGLE_GROUP||OTHER||NONE||||||
33754143|NCT04207827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754144|NCT06289075|||COHORT||RETROSPECTIVE|||||||
33754145|NCT02934074|||||PROSPECTIVE|||||||
34186809|NCT03970317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186810|NCT04437134|||OTHER||OTHER|||||||
34186811|NCT01376804|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34186812|NCT02055118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186813|NCT01081106|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34186814|NCT05083286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754146|NCT01746004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754147|NCT06579924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754148|NCT00765596|||CASE_CONTROL||PROSPECTIVE|||||||
33754149|NCT01232608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754150|NCT05477758|||OTHER||OTHER|||||||
33754151|NCT02351219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754152|NCT04521855|||COHORT||PROSPECTIVE|||||||
33754153|NCT06362512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a single-blinded randomized controlled trial . The assessor will be blinded during assessments. The participants and investigators (trainers) are not possible to be blinded as it is an exercise intervention.|After stratification according to gender and walking speed, the participants will be randomly allocated to one of three groups: (1) dual-task training, (2) single-task training, and (3) control intervention, using a 1:1:1 allocation ratio.|f|f|f|t
33754154|NCT03599349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754155|NCT00010855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754156|NCT01620866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754157|NCT04462380|||CASE_ONLY||RETROSPECTIVE|||||||
33754158|NCT03246282|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33754159|NCT04605796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754160|NCT05906602|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be masked to the type of ischemic conditioning they receive (real or sham). Treatment arms/ session order (ischemic conditioning and sham ischemic conditioning) will be randomized.||t|f|f|f
33754161|NCT01197196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754162|NCT00677352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754163|NCT01686555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754164|NCT03098134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066781|NCT03230838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066782|NCT03278847|||COHORT||RETROSPECTIVE|||||||
34066783|NCT05828797|||CASE_CONTROL||PROSPECTIVE|||||||
34186815|NCT02433366|||COHORT||CROSS_SECTIONAL|||||||
34186816|NCT02454842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186817|NCT06328335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186818|NCT04282330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186819|NCT04791163|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34186820|NCT05247047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster||||
34186821|NCT05825573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186822|NCT01642589|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34186823|NCT03933085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186824|NCT06073561|NA|SINGLE_GROUP||TREATMENT||NONE||Every patient will be selected do underwater emr group.||||
34186825|NCT01811966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34186826|NCT01177397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186827|NCT04780997|NA|SINGLE_GROUP||SCREENING||NONE||||||
34186828|NCT05452343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186829|NCT03487705|NA|SINGLE_GROUP||OTHER||NONE||||||
34186830|NCT06428292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator administering the treatment and the investigator performing the evaluations will be different. The evaluator will not know about the interventions that the participants received.||f|f|f|t
34186831|NCT01649817|||COHORT||RETROSPECTIVE|||||||
34186832|NCT00433134|||COHORT||RETROSPECTIVE|||||||
34186833|NCT02877589|||CASE_ONLY||PROSPECTIVE|||||||
34186834|NCT04129996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186835|NCT05459818|||COHORT||RETROSPECTIVE|||||||
34186836|NCT01963078|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34186837|NCT00183482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and outcome assessors are masked to condition of participants.|Repeated measures ANCOVA design.|f|f|t|t
34186838|NCT05078840|||COHORT||PROSPECTIVE|||||||
34186839|NCT02447003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186840|NCT00255060|||COHORT||PROSPECTIVE|||||||
34186841|NCT05868122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754165|NCT04131608|||OTHER||CROSS_SECTIONAL|||||||
34186842|NCT06193668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34186843|NCT05653076|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|triple-blinded||t|f|t|t
33754166|NCT01950949|NA|SINGLE_GROUP||||NONE||||||
33754167|NCT03365882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754168|NCT03878732|||COHORT||CROSS_SECTIONAL|||||||
34186844|NCT03216226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186845|NCT04841083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186846|NCT04296838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186847|NCT00967421|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34186848|NCT00399906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186849|NCT03317015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186850|NCT04422483|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34186851|NCT06223984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34186852|NCT02512029|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34186853|NCT02271672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186854|NCT03823209|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34186855|NCT04737304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186856|NCT05812911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186857|NCT06418256|||OTHER||PROSPECTIVE|||||||
34186858|NCT01223781|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34186859|NCT02559024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186860|NCT00000596|RANDOMIZED|||TREATMENT||||||||
34186861|NCT05777356|||OTHER||PROSPECTIVE|||||||
34186862|NCT05597488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186863|NCT03793699|||CASE_CONTROL||PROSPECTIVE|||||||
33754169|NCT06485076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33754170|NCT00370630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33754171|NCT03553004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754172|NCT04205630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186864|NCT00938067|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34186865|NCT01209689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186866|NCT00499148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34186867|NCT03990727|||FAMILY_BASED||PROSPECTIVE|||||||
34186868|NCT06320262|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled drugs||||
34186869|NCT02268123|||OTHER||PROSPECTIVE|||||||
34186870|NCT00025519||||TREATMENT||NONE||||||
34186871|NCT06521931|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34186872|NCT00971815|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34186873|NCT04613037|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-blinded placebo-controlled cross-over study, among adult patients suffering from moderate-to-severe atopic dermatitis (AD), insufficiently responsive to topical and systemic treatment. All patients receive 2 placebo transplantations each 2 weeks apart followed by 4 fecal microbial transplantations (FMTs) from healthy donors each 2 weeks apart. Patients were allowed to continue with their baseline medical topical treatment, including moisturizers and glucocorticoids, during the study period, but no new therapy was commenced||||
34186874|NCT05221957|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Propensity score matched cohort study||||
33754173|NCT02960100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754174|NCT06461130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754175|NCT02377154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186875|NCT00408200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186876|NCT05601895|||COHORT||PROSPECTIVE|||||||
34186877|NCT00711191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186878|NCT04217304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186879|NCT00002999||||TREATMENT||||||||
34186880|NCT05022732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186881|NCT00946283|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34186882|NCT04923282|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34186883|NCT01443052|||CASE_CONTROL||PROSPECTIVE|||||||
34186884|NCT03369262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo.|A phase 2a, double-blind, parallel group, randomised, placebo controlled, added-on to atosiban.|t|t|t|t
34186885|NCT05669911|NA|SINGLE_GROUP||SCREENING||NONE||||||
34186886|NCT06072664|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34186887|NCT02797938|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34186888|NCT03501719|||COHORT||RETROSPECTIVE|||||||
34186889|NCT04667130|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34186890|NCT00030732|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34186891|NCT03638765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186892|NCT01312103|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34186893|NCT00275912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186894|NCT06442878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186895|NCT00985309|||COHORT||RETROSPECTIVE|||||||
34186896|NCT04129567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34186897|NCT00206908|||COHORT||RETROSPECTIVE|||||||
34186898|NCT02738385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34186899|NCT03860259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The only person unblinded to treatment allocation will be the Principal investigator or designee -- the individual performing cryopuncture||t|t|f|t
34186900|NCT03176706|||COHORT||CROSS_SECTIONAL|||||||
33754176|NCT00411593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754177|NCT03628287|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge design: To compare effects of the original and revised CCP contemporaneously for timely viral suppression, we will randomize (within matched pairs and one trio) 17 veteran CCP-implementing agencies to immediate or delayed implementation of the revised model, with delayed implementers providing services under the original model until their assigned start date 9 months later.||||
33754178|NCT04235335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754179|NCT06579001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34186901|NCT01707732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754180|NCT05131880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754181|NCT05298150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two interventions are dynamic cycling and forced cycling. Participants will randomly assigned to one of the two interventions, and they will be kept blinded. Outcome assessment, such as subjective rating scale, behavioral rating scales, and quality of life assessment will be done in blinded fashion.|Exercise intervention|t|t|f|t
33754182|NCT02603081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186902|NCT01157403|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34186903|NCT00882557|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34186904|NCT00452972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34186905|NCT01637129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186906|NCT03172988|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34186907|NCT02354430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34186908|NCT01281800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186909|NCT01137838|||COHORT||RETROSPECTIVE|||||||
34186910|NCT02560558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34186911|NCT01009216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34186912|NCT00804908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186913|NCT06208280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186914|NCT05171556|||OTHER||OTHER|||||||
34186915|NCT04276948|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34186916|NCT05401097|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34186917|NCT00526071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186918|NCT01130480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34186919|NCT06432218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34186920|NCT03553693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Comparative effectiveness cluster-randomized trial||||
34186921|NCT02824653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186922|NCT04876469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186923|NCT05256199|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34186924|NCT04510961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Measurements will be at three occasions: at randomization (T1), at 6th week (T2) and at 12th week (T3) of treatment. Evaluative procedures will be by a blind assessor|"Sixty patients with moderate to severe Chronic Hand eczema (CHE) will participate in the study. They will be classified randomly into two groups of equal number; paraffin group and the control group.~Interventions: Paraffin group will receive Paraffin Therapy for 5 days per week for 12 weeks in addition to routine skin care program while the control group will received routine skin care program"|f|f|f|t
34186925|NCT02348099|||CASE_ONLY||PROSPECTIVE|||||||
34186926|NCT01723319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186927|NCT01833247|||CASE_ONLY||PROSPECTIVE|||||||
34186928|NCT02324348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186929|NCT05034939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186930|NCT06292208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186931|NCT03163303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186932|NCT03622788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186933|NCT04555616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186934|NCT01684293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186935|NCT03702153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A study group submitted to abdominal wall repair with synthetic mesh in the contaminated/infected setting compared to a control group submitted to abdominal wall repair with synthetic mesh in the clean setting.||||
33754183|NCT00986206|||COHORT||PROSPECTIVE|||||||
34066784|NCT02634944|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34186936|NCT00306826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34186937|NCT01579929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186938|NCT02136069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754184|NCT01235780|||CASE_CONTROL||RETROSPECTIVE|||||||
33754185|NCT06370026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186939|NCT01180582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186940|NCT03008434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186941|NCT01308437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186942|NCT04945928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186943|NCT03247946|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||3 month old infants were recruited from 2 Mother-Child-Health clinics and followed for 12 months. Mothers from intervention group were instructed to feed their babies (88 infants) with their head in upright position. Mothers from control group (75 infants) fed their infant regularly without any instructions . Respiratory and ear morbidity were evaluated during the following 12 month period.||||
34186944|NCT02376699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754186|NCT00402181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754187|NCT03497455|||OTHER||PROSPECTIVE|||||||
33754188|NCT03700138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754189|NCT00561210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754190|NCT01146496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754191|NCT01777659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754192|NCT03195868|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, prospective cohort||||
33754193|NCT04979455|||COHORT||PROSPECTIVE|||||||
33754194|NCT05283967|||COHORT||PROSPECTIVE|||||||
34186945|NCT01804127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186946|NCT02792530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186947|NCT01038843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34186948|NCT04334967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analysts will be blinded to patient randomization; outcome data analyses will be conducted with patient identifiers removed.|Upon confirmation of positive nasopharyngeal test for SARS-CoV-2, eligible patients will be randomized 1:1 to either a treatment group or control group.|f|f|f|t
34186949|NCT05053646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34186950|NCT05752357|||CASE_ONLY||PROSPECTIVE|||||||
34186951|NCT03074838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A case Control study were patients undergoing two surgical Methods for aortic valve repair is compared||||
34186952|NCT01529567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186953|NCT00991016|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34186954|NCT02047032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34186955|NCT04887129|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34186956|NCT02248519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186957|NCT02817464|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34186958|NCT04299789|||COHORT||RETROSPECTIVE|||||||
34186959|NCT00004114||||TREATMENT||||||||
34186960|NCT02389153|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34186961|NCT00623142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34186962|NCT05029778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|we don´t know who receives the intervention and who receives the placebo|Clinical Trial open controlled parallel randomized simple|t|f|t|f
34186963|NCT05619172|NA|SINGLE_GROUP||TREATMENT||NONE||Two safety cohorts will be implemented in a 3+3 dose escalation design. The main cohort will start only after data from safety cohorts are assessed by an internal safety committee.||||
34186964|NCT06012552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186965|NCT03543917|NA|SINGLE_GROUP||TREATMENT||NONE||The new combination treatment is given to all consecutive patients and compared to literature and between groups (based on the time lapsed between CVA and treatment)||||
34186966|NCT04607538|||COHORT||PROSPECTIVE|||||||
34186967|NCT04619771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186968|NCT02193503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186969|NCT00379691|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34186970|NCT04386720|||CASE_ONLY||PROSPECTIVE|||||||
34186971|NCT02111304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34186972|NCT01399372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186973|NCT03192553|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to a doffing protocol chronologically starting with the double glove and ending with the control until 100 volunteers have participated. Only one volunteer with participate in each simulation session.||||
33754195|NCT00002507||||TREATMENT||||||||
33754196|NCT00844025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33754197|NCT05875519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33754198|NCT04753372|||COHORT||PROSPECTIVE|||||||
33754199|NCT04718428|||CASE_CONTROL||PROSPECTIVE|||||||
33754200|NCT03141424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754201|NCT01229631|RANDOMIZED|PARALLEL||TREATMENT||NONE||longitudinal, randomised, block stratified (for smoking), double-blind, 2-arm interventional study||||
33754202|NCT01844284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754203|NCT06011941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754204|NCT04540705|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754205|NCT04558255|||CASE_CONTROL||RETROSPECTIVE|||||||
33754206|NCT00994981|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33965667|NCT06274216|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Groups A and B were created out of all patients who had signed up. Patients in group A received 5000 IU of vitamin D3 orally every day for 12 weeks , whereas patients in group B received a placebo. Patients were blinded to the study medication. The implants were then allowed to cure adequately and submerged for a further three months. Patients were summoned back three months later to un-cover the implant.~The both groups were compared for the difference of osseo-integration at 3 months, as well as difference of osseo-integration were compared with respect to implant site (maxilla and mandible).~Additionally, change in vitamin D levels were also assessed pre-operatively and post-operatively at 3 months."|"The research commences through a self-administered questionnaire such as age, gender, weight, height, BMI, smoking habits, sun exposure, and employment status.~Prior to implant surgery, each participant undergoes a blood test to assess their vitamin D levels.~Detailed records are maintained concerning the anatomical position (molar, pre-molar, canine, and incisor) and implant site (maxilla and mandible) for every participant.~Group Formation: The participant pool is stratified into two distinct groups - Group A and Group B. This categorization is essential for implementing and comparing different interventions within the study. Group A undergoes a specific intervention wherein they receive a daily oral dose of 5000 IU of vitamin D3 for a duration of 12 weeks. In contrast, Group B receives a placebo.~Following the intervention period, the implants are allowed to cure adequately"|t|t|f|f
34186974|NCT03688594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869838|NCT00299962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869839|NCT05801328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blinded|this is a split mouth study. Participants teeth will be divided into left or right side and randomised into either control or intervention side.|t|f|f|f
33869840|NCT01752751|||COHORT||PROSPECTIVE|||||||
33869841|NCT04755075|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33869842|NCT04967079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869843|NCT06453811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After meeting the couples, their eligibility for inclusion in the study will be assessed. Subsequently, couples who meet the inclusion criteria will be asked to read the informed consent form and provide verbal and written consent. Pre-tests will be administered to eligible couples, who will then be assigned to either the experimental group (Self-Efficacy Theory-Based Spouse Participation Childbirth Preparation Program) or the control group according to the block randomization list.||||
33869844|NCT01329679|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33869845|NCT05788887|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Only investigator knew the type of meal, consumed by each participant|In the first trial period, participants in arm a consumed a meal containing 100g of white wheat bread and 80g of Italian Parmesan PDO cheese and arm b participants consumed a meal containing 100g of white wheat bread and 80g of Authentic Ladotyri Mytilinis PDO cheese. After a washout week participants consumed the meals, in reverse.|t|f|f|f
34186975|NCT05198440|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34186976|NCT04282603|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Eligible volunteers will be randomly assigned to one of two groups: Experimental Meal Replacement or Bariatrics Advantage Meal Replacement. Only the statistician will know to which group a subject is assigned. Identifying information with regard to randomization of participants to their assigned group will be stored in a binder with Case Report Forms. A master list linking participants to a number and their assigned group will be kept in a password protected file in the database by the study statistician. This process will ensure a high degree of scientific rigor.|The study design is a randomized, double blind, two arm study, where one arm receives a standard meal replacement (Bariatrics Advantage), and the other an enhanced one (ie., EMR) for 24 weeks, including a caloric restriction period of 12 weeks, and a maintenance period of 12 weeks.|t|f|t|f
34186977|NCT00002013||||TREATMENT||||||||
34186978|NCT03900091|||COHORT||PROSPECTIVE|||||||
34186979|NCT02207452|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34186980|NCT01673737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754207|NCT04977050|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups||||
33754208|NCT05327387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||In each patient, the investigators will test the decoders of the symptom level and the input-output models of the neural response to stimulation therapy.||||
33754209|NCT01579734|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33754210|NCT00762320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965668|NCT04856995|||CASE_CONTROL||PROSPECTIVE|||||||
33965669|NCT04677582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965670|NCT04379388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965671|NCT01954329|||COHORT||CROSS_SECTIONAL|||||||
33965672|NCT04130919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965673|NCT01880645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965674|NCT05834257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965675|NCT01922531|||CASE_CONTROL||PROSPECTIVE|||||||
33965676|NCT02996370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965677|NCT03768882|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33965678|NCT05472285|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||This study is designed as a multicentric, randomized, parallel arms, double-blind, placebo-controlled clinical trial.|t|t|t|t
33965679|NCT06157489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Active Comparator: Kinesiotape Group In active group, KT was applied in masseter muscle, orbicularis oris and infrahyoid muscles for facilitating suprahyoid muscle and oral sensorimotor exercise In sham group will receive the oral sensorimotor exercise only|t|t|f|f
33965680|NCT06370195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965681|NCT01595490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965682|NCT01268137|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33965683|NCT02666365|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33965684|NCT02149550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33965685|NCT06056700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965686|NCT03157310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965687|NCT05285332|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965688|NCT05203588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965689|NCT02113969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965690|NCT05935319|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33965691|NCT06159439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965692|NCT06045975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965693|NCT02541435|||COHORT||PROSPECTIVE|||||||
33965694|NCT00077402||||TREATMENT||NONE||||||
33965695|NCT04461652|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collected from the X-rays and the pain score evaluation will be masked and the outcomes assessor have no method to get randomized information.|The study is a prospective, randomized, non-inferiority trial, two different drainage strategy will be performed, and both were used routinely in clinical practice. One should be one thoracic tube (28fr drainage tube) was inserted through intercostal incision, and one microtubule (7fr × 20cm) was punctured through the middle line of clavicle, and another will be two conventional chest tubes (28fr or 24fr) were placed through intercostal incision.|f|f|f|t
33965696|NCT01218906|||COHORT||PROSPECTIVE|||||||
33965697|NCT05944770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The control air filtration device will have a filter that looks like the intervention filter but is much less effective. A cover shroud will be placed over the air filtration device so that differences in components will not be noticeable to participants."|Participants will be randomized to the intervention or control group.|t|f|f|f
33965698|NCT05251415|||COHORT||PROSPECTIVE|||||||
33965699|NCT05756088|||COHORT||PROSPECTIVE|||||||
34151681|NCT03489512|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will receive one or the other treatment depending on where and when they are treated and will continue the treatment until the end.||||
34151682|NCT03691363|NA|SINGLE_GROUP||TREATMENT||NONE||All youth will receive the intervention||||
34151683|NCT00123045|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34151684|NCT06299176|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|6 participants with end-stage heart failure (NYHA 3 or 4, LVEF \< 30%) with no other standard of care therapy options to receive whole heart radiation therapy.||||
34151685|NCT03565237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151686|NCT00257231|||COHORT||PROSPECTIVE|||||||
34151687|NCT04171232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151688|NCT05095415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to the knowledge of if they are receiving the typical pre-operative care or an additional individualized occupational therapy consult.|Participants will be randomly assigned to the experimental or control group in accordance with their diagnosis specific block. This will be continued until there is at least 5 participants in each diagnosis block.|t|f|f|f
34151689|NCT04816318|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34151690|NCT00135252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34151691|NCT05035433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34151692|NCT04204356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151693|NCT02080936|||COHORT||RETROSPECTIVE|||||||
34151694|NCT03979599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|all participant will be blinded to the study drugs.|Group A (control group): patients will receive levobupivacaine 0.25% . Group B (magnesium sulphate group): patients will receive levobupivacaine 0.25% + MgSo4 .|t|t|t|t
34151695|NCT04135846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151696|NCT01814670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151697|NCT06014281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151698|NCT00302757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186981|NCT05556044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186982|NCT02192411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34186983|NCT01908062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869846|NCT01086020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869847|NCT04536428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869848|NCT03451786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869849|NCT03169764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33869850|NCT03146000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869851|NCT02715375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869852|NCT03698942|||CASE_CONTROL||RETROSPECTIVE|||||||
33869853|NCT02330887|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869854|NCT04200053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Grup 1: Reflexology massage group Grup 2: Reflexology massage and pasiive music group Grup 3: Control group||||
33869855|NCT03791242|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33869856|NCT03589599|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33869857|NCT01463670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869858|NCT02311842|||CASE_CROSSOVER||PROSPECTIVE|||||||
33869859|NCT06097442|||COHORT||PROSPECTIVE|||||||
33869860|NCT04170803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study will be a randomized controlled trial. A convenience sample will be recruited from the Army Medical Department Center and School and the Brooke Army Medical Center (BAMC) Outpatient Physical Therapy Clinic using fliers and word of mouth. A computer-generated table of random numbers will be used to accomplish the group assignment. Thirty participants with shoulder pain will be randomized to receive either true or sham dry needling (Aim #1). An additional 15 participants will be recruited to receive true dry needling (Aim #2). Pre- and post-treatment and 1-week follow-up measurements will be recorded using the MyotonPRO and NIRS, in addition to measures of local hypoalgesia and self-reported pain and disability.|t|f|f|t
33869861|NCT02663453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34186984|NCT04989335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186985|NCT03557060|||CASE_ONLY||PROSPECTIVE|||||||
34186986|NCT05684211|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34186987|NCT03743636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34186988|NCT01877395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34186989|NCT01680471|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34186990|NCT05666167|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34186991|NCT02708667|||CASE_ONLY||RETROSPECTIVE|||||||
34186992|NCT03458819|||COHORT||PROSPECTIVE|||||||
34186993|NCT01189409|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Double blind using a dummy alternate treatment.|"The primary outcome will be treated as a binomial outcome, expressed as the number of successful trials out of a pre-defined number of trials n = 18. Given this, the primary outcome will be analysed via a generalized mixed effects model. The model will include: (i) fixed effects for treatment, treatment period and their interaction, (ii) fixed effects for the baseline characteristics and (iii) a random patient effect. Including the latter effect in the model will help capture the within-patient correlation among the values of the primary outcome collected in Period I and Period II for the same patient.~All statistical analyses will be conducted using the open-source statistical software package R."|t|t|t|t
34186994|NCT05766046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764700|NCT03187015|NA|SINGLE_GROUP||OTHER||NONE||||||
33869862|NCT05289570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869863|NCT03098849|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869864|NCT06078423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Similar vaccine control|t|t|t|t
33869865|NCT03566355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869866|NCT05777447|||COHORT||RETROSPECTIVE|||||||
33869867|NCT02277015|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33869868|NCT01971021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||open label pragmatic|f|f|t|t
33869869|NCT04300699|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single cohort intervention design with 12 month follow-up.||||
33869870|NCT05539729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research team will be blinded to the treatment group (placebo/vancomycin).|Placebo-controlled blinded trial|t|t|t|f
33869871|NCT02681328|||COHORT||PROSPECTIVE|||||||
34186995|NCT03214848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33869872|NCT04530773|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33869873|NCT04686747|||COHORT||RETROSPECTIVE|||||||
33869874|NCT02839057|||COHORT||PROSPECTIVE|||||||
33869875|NCT04956003|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34186996|NCT02790190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34186997|NCT04315064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34186998|NCT03088735|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34186999|NCT03644511|||COHORT||PROSPECTIVE|||||||
34187000|NCT04178785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187001|NCT03917953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Children with ADHD in the 2 groups were treated in separate treatment rooms and blinded on the intervention (i.e., true or sham TEAS). The TEAS operators could not be blinded to the treatment assignments. The data collectors, outcome assessors, and statisticians were blinded to group allocations.||t|t|f|t
34187002|NCT04048772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187003|NCT01993797|||COHORT|||||||||
34187004|NCT04087850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Some outcome measures are collected through interviewing children and their classmates, who would not be aware of the intervention condition of their classroom; this is because the intervention is delivered to the classroom teacher outside of class time.||f|f|f|t
34187005|NCT05071248|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"The present study is a monocentric, prospective intervention study designed to evaluate the feasibility and~* to evaluate the feasibility and integration in the setting of the intensive care unit.~* the behavior and experience of the mobilizing specialists of the robot-assisted VEM is to be evaluated longitudinally (three data collection points).~* to compare robot-assisted VEM in critically ill ICU patients with non-robot-assisted early mobilization according to the standard of care of a historical patient population."||||
34187006|NCT03881215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34187007|NCT03899922|||CASE_ONLY||CROSS_SECTIONAL|||||||
34187008|NCT02403648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34187009|NCT06330558|||COHORT||RETROSPECTIVE|||||||
34187010|NCT03468140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Five end-stage liver disease (ESLD) patients will be matched to 5 historical controls.||||
34187011|NCT02067481|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34187012|NCT02979548|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34187013|NCT00565292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187014|NCT04440904|||COHORT||RETROSPECTIVE|||||||
34187015|NCT01107158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187016|NCT03615443|||COHORT||OTHER|||||||
34187017|NCT01681719|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33754211|NCT05651854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients are assigned randomly in groups||t|f|f|f
33754212|NCT03942133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33869876|NCT05687331|||COHORT||PROSPECTIVE|||||||
33894085|NCT03717922|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will be blinded to exactly when the transducer is turned on, and to the region being targeted at each visit. The individual collecting the neuropsychological data will be blinded to which condition (amygdala, entorhinal cortex) the participant completed during the session. The statistical analysts for both the neuropsychological and neuroimaging data will also be blinded to condition.|Participants will be assigned to both study arms; the order in which they complete the arms will be randomized and counterbalanced. The two visits will be spaced apart by 2 weeks.|t|f|f|t
34187018|NCT05862168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187019|NCT00882817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187020|NCT03855059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The research pharmacist will randomize and prepare the necessary syringes for injection to look similar and have the same amount of solution as so the PI and anyone else does not know what is being given.|Double blind study|t|f|t|t
34187021|NCT01573052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754213|NCT00808379|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754214|NCT03377543|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33754215|NCT04096248|||OTHER||RETROSPECTIVE|||||||
33754216|NCT04815525|||COHORT||RETROSPECTIVE|||||||
33754217|NCT04168554|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754218|NCT05924542|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT with intervention and wait-list control group.||||
34187022|NCT02219425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187023|NCT00750776|||||PROSPECTIVE|||||||
34187024|NCT00296413|||COHORT||PROSPECTIVE|||||||
34187025|NCT03135496|||CASE_CONTROL||PROSPECTIVE|||||||
34187026|NCT03805152|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Complete blinded|Double Blind randomized controlled trial|t|t|t|t
34187027|NCT02458326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187028|NCT00294970|||COHORT||RETROSPECTIVE|||||||
34187029|NCT02682043|NA|SINGLE_GROUP||||NONE||||||
34187030|NCT03097809|||OTHER||PROSPECTIVE|||||||
34187031|NCT02622178|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187032|NCT02644499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187033|NCT06274918|||COHORT||PROSPECTIVE|||||||
33754219|NCT01821261|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33754220|NCT00445679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754221|NCT05552651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754222|NCT04605562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754223|NCT03536000|||COHORT||PROSPECTIVE|||||||
33754224|NCT06580418|||COHORT||PROSPECTIVE|||||||
33754225|NCT03689335|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no blinding possible in this study, as the presence or absence of a skin incision/surgical scar is obvious to both patient and clinician during follow-up assessment.|Randomised controlled trial, with 1:1 allocation into one of 2 treatment arms (operative or non-operative treatment). The randomisation is stratified by patient age (\<65 years old or ≥65 years old) to ensure approximately equal numbers by age in each treatment arm.||||
33754226|NCT03665610|||OTHER||PROSPECTIVE|||||||
33754227|NCT02453581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764701|NCT01629680|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34187034|NCT06317740|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The study was carried out as a randomized controlled trial using two-group pretest-posttest designs in which the intervention group received an intervention program, in contrast to the comparison group. The study design of the present work followed the CONSORT 2010statement|A randomized controlled trial using two-group pretest-posttest designs|t|f|f|f
34187035|NCT00343096|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34187036|NCT06131736|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Assessor who will take the readings is blind|Randomized clinical trial|f|f|f|t
34187037|NCT01917630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187038|NCT00577798|||CASE_ONLY||PROSPECTIVE|||||||
34187039|NCT04867304|||COHORT||PROSPECTIVE|||||||
34187040|NCT05402488|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|During data collection, participants will be blinded to the condition, i.e. sham or verum stimulation. All experimenters will be blind for processing and analysis of outcome measures.||t|f|f|t
34187041|NCT02200640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187042|NCT03208647|||CASE_CONTROL||RETROSPECTIVE|||||||
34187043|NCT05445791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34187044|NCT05391490|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP)||||
34187045|NCT00782847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187046|NCT01318980|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34187047|NCT05649436|||OTHER||CROSS_SECTIONAL|||||||
34187048|NCT00485784|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187049|NCT02864056|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34187050|NCT02096640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187051|NCT01564576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34187052|NCT06403969|NA|SINGLE_GROUP||TREATMENT||NONE||Single Case Experimental Design||||
34187053|NCT01320917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187054|NCT04641208|||COHORT||PROSPECTIVE|||||||
34187055|NCT05414058|RANDOMIZED|CROSSOVER||TREATMENT||NONE|An open-label fixed dose controlled cross-over trial is planned.|An open-label fixed dose controlled cross-over trial is planned. Participants will be randomized into one of two arms: 1) participants will receive four weeks of add-on methylphenidate ER 36 mg, or 2) participants will receive 4 weeks of treatment as usual (no-treatment control group). At 4 weeks, participants will switch arms for another 4 weeks.||||
34187056|NCT01106248|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187057|NCT01111799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187058|NCT02486185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187059|NCT00508196|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34187060|NCT03695367|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34187061|NCT02629900|NA|SINGLE_GROUP||||NONE||||||
34187062|NCT04794569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be instructed not to disclose their treatment to PTS assessors||f|f|f|t
34187063|NCT01921595|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187064|NCT01342159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34187065|NCT02013271|||COHORT||PROSPECTIVE|||||||
34187066|NCT04287517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187067|NCT03522311|||CASE_CONTROL||RETROSPECTIVE|||||||
34187068|NCT00232752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187069|NCT04655989|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Group A subjects will be assigned to 4 weeks of routine dialysis (control group) followed by 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group).~Group B subjects will be assigned to 4 weeks of treatment dialysis with the DBB-EXA ES Hemodialysis System (investigational group) followed by 4 weeks of routine dialysis (control group).~After completion of the initial 8-week treatment period, subjects were eligible for the Vascular Access Recirculation Rate Measurement (VARRM) sub-study."||||
34187070|NCT03459768|||COHORT||PROSPECTIVE|||||||
34187071|NCT02748083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187072|NCT06517355|||OTHER||PROSPECTIVE|||||||
34187073|NCT05803733|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
34187074|NCT06067217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Drug in concealed envelop which participant and care provider aren't see||t|t|t|f
34187075|NCT02629263|||OTHER||RETROSPECTIVE|||||||
34187076|NCT04292418|||CASE_CONTROL||PROSPECTIVE|||||||
34187077|NCT02076061|||COHORT||PROSPECTIVE|||||||
34187078|NCT00997776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187079|NCT02774629|||COHORT||PROSPECTIVE|||||||
34187080|NCT04917016|||COHORT||PROSPECTIVE|||||||
34187081|NCT05321277|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34187082|NCT06202820|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34187083|NCT04944199|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187084|NCT00753181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187085|NCT01119209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187086|NCT00302367|RANDOMIZED|PARALLEL||||SINGLE||||||
34187087|NCT01862237|NON_RANDOMIZED|PARALLEL||||NONE||||||
34187088|NCT05136924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated studyOC-01 (varenicline 1.2mg/ml) nasal spray Or Placebo (vehicle) nasal spray|OC-01 (varenicline 1.2mg/ml) nasal spray Or Placebo (vehicle) nasal spray|t|t|t|t
34187089|NCT02490865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187090|NCT01760252|NA|SINGLE_GROUP||OTHER||NONE||||||
34187091|NCT01574729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187092|NCT03390283|||CASE_CROSSOVER||PROSPECTIVE|||||||
33754228|NCT02657031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-Blind Randomized Clinical Control Trial|t|t|f|f
33754229|NCT01719835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066785|NCT06455345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the participants and the research coordinator will know which group (self-guided vs. psychologist-guided) an individual participant will be randomly assigned to.|The present study will evaluate whether the self-guided online ADOPT-TPS tool is a the feasible and efficacious intervention compared to the psychologist-guided group workshop.|f|t|f|t
34066786|NCT06316388|||OTHER||PROSPECTIVE|||||||
34066787|NCT00523523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066788|NCT05523921|||COHORT||CROSS_SECTIONAL|||||||
34066789|NCT04550000|||OTHER||PROSPECTIVE|||||||
34066790|NCT01313221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066791|NCT05837702|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34066792|NCT05442541|||OTHER||PROSPECTIVE|||||||
34066793|NCT02412878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066794|NCT01145794|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066795|NCT00908596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066796|NCT06188845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066797|NCT06009289|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34066798|NCT04282720|NA|SINGLE_GROUP||OTHER||NONE||||||
34066799|NCT03582514|NA|SINGLE_GROUP||TREATMENT||NONE||The study uses a Continual Reassessment Method (CRM) to inform dose escalation and determine the MTD and MTIV. This is a Bayesian statistics-based model. It uses all available data from previous doses to guide dose escalation.||||
34066800|NCT04455776|||COHORT||RETROSPECTIVE|||||||
34066801|NCT02197442|RANDOMIZED|CROSSOVER||||NONE||||||
34066802|NCT02313285|||COHORT||PROSPECTIVE|||||||
34066803|NCT01243177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066804|NCT06118333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066805|NCT01583270|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34066806|NCT04864223|||COHORT||RETROSPECTIVE|||||||
34066807|NCT04413942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Arm A: FB825 Arm B: Placebo|t|t|t|t
34066808|NCT01160380|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34187093|NCT03363490|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Assessor will not know which group the patients are enrolled when evaluate the baseline and follow-up situation|Patients of knee OA will be divided into A, B, C, D four parallel groups with fully informed, each group will enroll 100 patients, A for control group, B for neuromuscular exercise, C for self-management program, D for neuromuscular exercise and self-management program, respectively.|f|f|f|t
34187094|NCT04556799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187095|NCT01963949|||CASE_CONTROL||PROSPECTIVE|||||||
34187096|NCT06003270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization codes will be generated by a study statistician at the beginning of the study and is provided to research pharmacist who will be dispensing the study drugs. The study drug bottles will be numbered with no information about the study drug. The randomization codes will not be revealed until all the data is collected and analyzed. Both placebo and quercetin will be similarly packaged and will have similar color, taste and texture.|Double blinded placebo controlled study|t|t|t|t
34187097|NCT02422667|||COHORT||OTHER|||||||
34187098|NCT04526769|||CASE_ONLY||PROSPECTIVE|||||||
34187099|NCT01260077|||COHORT||CROSS_SECTIONAL|||||||
34187100|NCT01260402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187101|NCT04398927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187102|NCT04844398|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Using a non-controlled pre-/post-test design, the level of salivary cortisol and self-reported stress and mood will be measured before and after each clown visit on a weekly basis over four consecutive weeks.||||
34187103|NCT00309348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187104|NCT05949801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This trial is planned to be conducted simultaneously in multiple clinical study sites nationwide, including 198 subjects, 99 subjects in the treatment group and 99 subjects in the placebo group.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial|t|f|t|f
34066809|NCT02946489|NA|SINGLE_GROUP||TREATMENT||SINGLE|Open label single-blind trial, with participants given the impression they may get any of several medications.||t|f|f|f
34066810|NCT02114294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34066811|NCT02169388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34066812|NCT06174025|||CASE_ONLY||CROSS_SECTIONAL|||||||
34066813|NCT03472001|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34066814|NCT01412892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066815|NCT00502853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066816|NCT01956864|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34066817|NCT04641702|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will have the option of consenting for Aim 1(pharmacologic challenge ), Aim 2 (in the event they go for future myotomy) or both if they choose to be included in the study.||||
33869877|NCT04858451|NA|SINGLE_GROUP||OTHER||NONE||"Part 1a: Dose Finding Phase~Up to 48 eligible participants will be administered single ascending doses of RESP301 to determine the maximum tolerated dose, according to the following schedule:~* 8 participants to receive RESP301 at a dose of 1 ml~* 8 participants to receive RESP301 at a dose of 2 ml~* 8 participants to receive RESP301 at a dose of 3 ml~* 8 participants to receive RESP301 at a dose of 4 ml~* 8 participants to receive RESP301 at a dose of 5 ml~* 8 participants to receive RESP301 at a dose of 6 ml~Part 1b: Concomitant Medication Expansion Phase~• 8 participants to receive RESP301 at MTD with short-acting bronchodilator administered 10min prior to RESP301~Part 2: Expansion Phase~A minimum of 150 patients will be enrolled in to the Expansion Phase. These may include eligible participants from Part 1."||||
33869878|NCT05839275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869879|NCT03025230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33869880|NCT00721370|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33869881|NCT02285777|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33965700|NCT04874766|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"The participant will be blinded by wearing a sham mask during the no mask condition (i.e. they will wear a surgical mask with the covering for the mouth and nose cut out). The individual who will statistically analyze the data will be blinded to conditions"||t|f|t|f
34187105|NCT05298553|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34187106|NCT00031317||||TREATMENT||||||||
34187107|NCT05021861|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187108|NCT01405001|||CASE_ONLY||PROSPECTIVE|||||||
34187109|NCT05686369|||COHORT||OTHER|||||||
34187110|NCT03399188|NA|SINGLE_GROUP||TREATMENT||NONE||Inflammatory bowel disease patients in active stage.||||
34187111|NCT04527770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both drugs are the same colour and volume injected by a staff member not aware of study design|2 groups received hydrodissection sonar guided , one group received 50 mic/kg midazolam and the other received 8 mg dexamethasone|t|f|t|f
34187112|NCT00580307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187113|NCT00695097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187114|NCT00042419|||NATURAL_HISTORY||PROSPECTIVE|||||||
34187115|NCT01431872|||COHORT||PROSPECTIVE|||||||
34187116|NCT02595489|NA|SINGLE_GROUP||PREVENTION||NONE||single-arm dose escalation||||
34187117|NCT03085264|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
34187118|NCT03669783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187119|NCT05819151|||OTHER||CROSS_SECTIONAL|||||||
34187120|NCT05240027|NA|SINGLE_GROUP||OTHER||NONE||||||
34187121|NCT01652534|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34187122|NCT04724109|||COHORT||PROSPECTIVE|||||||
34187123|NCT03752567|||COHORT||PROSPECTIVE|||||||
34187124|NCT04285970|||CASE_CONTROL||PROSPECTIVE|||||||
34187125|NCT03766737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187126|NCT03544086|||COHORT||PROSPECTIVE|||||||
34187127|NCT01364844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187128|NCT03238430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187129|NCT04063007|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, non-randomized study||||
34187130|NCT04182828|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34187131|NCT03520504|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, prospective trial with 3+3 dose de-escalation and dose expansion cohort.||||
34187132|NCT03835364|||CASE_CONTROL||PROSPECTIVE|||||||
34187133|NCT02528552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187134|NCT05570669|RANDOMIZED|PARALLEL||SCREENING||SINGLE|the endoscopist analyzes the results and evaluates the cleaning without knowing the treatment followed by the patient|two groups randomized 1:1|f|f|f|t
34187135|NCT01056016|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869882|NCT02385149|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33869883|NCT01187563|||COHORT||PROSPECTIVE|||||||
33869884|NCT01806350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965701|NCT04153201|RANDOMIZED|PARALLEL||PREVENTION||NONE||1 intervention arm (Hydroxychloroquine plus standard care), 1 control arm (standard care) Patients randomized 1:1 using block size 2 randomization||||
33965702|NCT03963999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients undergoing myeloblative conditioning regimen as part of hematopoietic cell transplant or prior liver damage or other high risk factor will be consecutively studied||||
33965703|NCT01469988|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34066818|NCT04465656|||COHORT||RETROSPECTIVE|||||||
34187136|NCT03284580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187137|NCT05002712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34187138|NCT04259814|NA|SINGLE_GROUP||TREATMENT||NONE||Non-concurrent, multiple-baseline across participants||||
34187139|NCT05115149|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients rehabilitation outcomes will be assessed by blinded assessors. In Neva Arm some patients will receive sham tSCS, with gradient decrease of the stimulation intensity from threshold level to 0 during one minute, as described in PMID 29335430 and PMID: 31996455|Participants are categorised by the type of injury (spinal cord injury or stroke) and by the rehabilitation stage (early stage, later stage). Within those categories participants are randomly assigned to experimental and delay (control) groups.|t|f|f|t
34187140|NCT03646097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187141|NCT04061330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187142|NCT01515553|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34066819|NCT02020512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066820|NCT04606875|||COHORT||CROSS_SECTIONAL|||||||
34187143|NCT06176235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187144|NCT06064916|||CASE_CONTROL||PROSPECTIVE|||||||
34187145|NCT04598802|||COHORT||OTHER|||||||
34187146|NCT01915589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187147|NCT05612828|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||randomized control trial|t|f|t|f
34187148|NCT02577445|||COHORT||OTHER|||||||
34187149|NCT02336217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754230|NCT00314314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754231|NCT05777798|||COHORT||PROSPECTIVE|||||||
34187150|NCT05824780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor is blinded to participants group allocation|Randomized controlled trial with two arms|f|f|f|t
34187151|NCT04609670|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187152|NCT02207088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187153|NCT02462096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187154|NCT01022528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187155|NCT02062840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187156|NCT04441086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||3 group randomized control trial. Conditions include eMotion intervention, healthy living active control, and usual care.|f|t|t|t
34187157|NCT05242380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187158|NCT06259370|NA|SINGLE_GROUP||OTHER||NONE||||||
34187159|NCT00125164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187160|NCT00940953|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33869885|NCT01225731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187161|NCT00470275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187162|NCT02172690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187163|NCT05711212|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34187164|NCT04631250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The photographs of the patients were evaluated by two dermatologists blinded to the study protocol.|"Split Face design is a common model used in dermatology to study the difference between two treatments on a facial condition. The face was divided into two symmetrical contralateral treatment areas: the left was covered with a light-impermeable dressing, while the right face was exposed to sunlight. After 2 hours outdoors, the right side of the face was covered, and the left half was illuminated with red light."|f|f|f|t
34187165|NCT02373683|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187166|NCT05169489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187167|NCT02442388|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34187168|NCT02230995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187169|NCT00589199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187170|NCT00690781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187171|NCT01121770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187172|NCT03009396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Active||||
34187173|NCT04558840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187174|NCT02827929|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34187175|NCT05042414|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34187176|NCT03517397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187177|NCT02562677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187178|NCT06138496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754232|NCT01562210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754233|NCT05600348|RANDOMIZED|CROSSOVER||SCREENING||NONE||3 conditions, order randomly allocated||||
33754234|NCT04158050|||CASE_ONLY||RETROSPECTIVE|||||||
33754235|NCT01949779|||CASE_ONLY||PROSPECTIVE|||||||
33754236|NCT02315339|||COHORT||PROSPECTIVE|||||||
33754237|NCT03861013|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomized assigned to the intervention group or the wait-list control group. The measurements were taken at the same time for both groups: before and after the intervention, and two follow-up ( at 3 and 6 months)||||
33754238|NCT05019092|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33754239|NCT04684121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754240|NCT00526266|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33754241|NCT05391854|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754242|NCT05527379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754243|NCT04857931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754244|NCT00500942|||CASE_ONLY||PROSPECTIVE|||||||
33754245|NCT00994877|||COHORT||PROSPECTIVE|||||||
33754246|NCT00820833|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34187179|NCT06313918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, two-arm, parallel group, randomised trial, to compare standard and short HIT during 26 weeks of supervised exercise. The group will receive comprehensive follow-up to be able to carry out the 26 weeks exercise intervention program. Outcome measures will be taken at; baseline (T0), 4 weeks (T1), 12 weeks (T2), 26 weeks (T3), and 52 weeks (T4) post randomisation.||||
34187180|NCT04413461|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34187181|NCT02668393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187182|NCT01570946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187183|NCT03669497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187184|NCT06184893|||COHORT||PROSPECTIVE|||||||
33754247|NCT00224874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754248|NCT01655290|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33754249|NCT00095524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754250|NCT04367584|||OTHER||CROSS_SECTIONAL|||||||
33754251|NCT01345721|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754252|NCT01471054|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754253|NCT04487769|||COHORT||RETROSPECTIVE|||||||
33754254|NCT03493048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754255|NCT02651766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754256|NCT05454150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754257|NCT01326065|||COHORT||PROSPECTIVE|||||||
33754258|NCT01800968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754259|NCT01832428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754260|NCT00955669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754261|NCT04139564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869886|NCT00784381|||||PROSPECTIVE|||||||
33869887|NCT01981915|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869888|NCT04402684|||COHORT||PROSPECTIVE|||||||
33894086|NCT04746040|RANDOMIZED|CROSSOVER||OTHER||SINGLE||One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33894087|NCT03615222|||COHORT||PROSPECTIVE|||||||
33869889|NCT05369104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All persons will be blinded, except the pharmacist will be unmasking.|This is a pilot, randomized, non-comparative, double-blind study in patients with knee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SAT). A stratification will be performed on the affected area of arthroplasty: knee or hip and on study site.|t|f|t|f
33869890|NCT02668874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple:~Participants, Investigator, and Outcome assessors do not know the randomization. However, it was hard to blind the care provider."|Simple randomization will be used for assignment of the treatment groups. Randomization: Two application methods will be used in each subject in order to place sealants, one using the Isolite system and one using the cotton roll system.|t|f|t|t
33869891|NCT04368572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the investigator will blindly collect the subject's self-rated pain and anxiety scales.||f|f|t|f
33869892|NCT02595671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33869893|NCT05382247|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33869894|NCT05735730|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869895|NCT04519359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33869896|NCT00005757|||CASE_CROSSOVER|||||||||
33869897|NCT02604316|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33869898|NCT02958020|||COHORT||PROSPECTIVE|||||||
33869899|NCT05376813|NA|SINGLE_GROUP||OTHER||NONE||No comparative, no control study||||
33869900|NCT03852862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869901|NCT02792270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965704|NCT05270694|NA|SINGLE_GROUP||OTHER||NONE||150 participants will be enrolled into the cohort, with 15 participants from each of the 10 specific populations of interest (3 groups that access different health services for low-income/uninsured, unhoused individuals, and 6 different immigrant groups)||||
33965705|NCT06321666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965706|NCT02626065|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965707|NCT02316678|||COHORT||RETROSPECTIVE|||||||
33965708|NCT04384926|||COHORT||OTHER|||||||
33965709|NCT01818895|||COHORT||PROSPECTIVE|||||||
33965710|NCT02401893|||COHORT||PROSPECTIVE|||||||
33965711|NCT01354600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33965712|NCT06364579|||COHORT||OTHER|||||||
33965713|NCT04683887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data processing will be blinded||f|f|t|f
33965714|NCT05374772|||COHORT||RETROSPECTIVE|||||||
33965715|NCT03398655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066821|NCT06124105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||study group: patients who develop aki in sepsis||||
34066822|NCT04958161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187185|NCT03437616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Longitudinal controlled study: The intervention group (n=150) participates in Tulppa rehabilitation program and the control group (n=150) do not participate in Tulppa rehabilitation.||||
34187186|NCT02765646|||COHORT||PROSPECTIVE|||||||
34187187|NCT05367596|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open-label.||||
34187188|NCT04189887|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187189|NCT03085602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187190|NCT05440552|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33754262|NCT04058353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754263|NCT05380648|||COHORT||PROSPECTIVE|||||||
33869902|NCT01427998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869903|NCT04298736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded pathologist||f|f|f|t
33869904|NCT05092178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33869905|NCT05095220|||COHORT||PROSPECTIVE|||||||
33869906|NCT02043821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869907|NCT00362349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869908|NCT05488600|||CASE_CONTROL||PROSPECTIVE|||||||
33869909|NCT05787873|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869910|NCT02997527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869911|NCT04518215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33869912|NCT04267536|||COHORT||PROSPECTIVE|||||||
33869913|NCT03173131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33965716|NCT02008331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965717|NCT06074419|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The person analyzing the statistics will not know which group is the experiment and which is the control group.|The experimental group will be shown a nature video through virtual reality glasses. No action will be applied to the control group. The two groups will be compared in terms of sleep quality and mental well-being|f|f|f|t
34066823|NCT04861441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066824|NCT04599192|||COHORT||PROSPECTIVE|||||||
34066825|NCT00897975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066826|NCT00315484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066827|NCT04054726|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34066828|NCT02708797|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34187191|NCT05169008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34187192|NCT04004195|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187193|NCT00775190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34187194|NCT02987790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869914|NCT00827606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869915|NCT05039450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869916|NCT00050648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869917|NCT04232228|||COHORT||PROSPECTIVE|||||||
33869918|NCT03725124|||CASE_ONLY||CROSS_SECTIONAL|||||||
33869919|NCT06497348|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The evaluation of each group will be carried out in different rooms of the university, a team of 6 physiotherapists divided into two groups, where 3 will evaluate with knowledge of the pathology and the other 3 without knowledge of it.~The experimental group will receive mobilization treatment and exercises, while the control group will receive only exercises. Weekly one-hour sessions will be held, from Monday to Friday, with two times available for each patient. The experimental group, treated by physiotherapists who know the pathology, will be applied Maitland mobilization techniques, focused on passive neural and joint mobilizations. Flexion-extension, abduction-adduction, and external and internal rotation movements will be performed.~The control group, treated by physiotherapists who will blindly evaluate the patients, will only be prescribed exercises, the same as the experimental group."||||
33869920|NCT04251910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) This is a double-blind study. Due to the nature of the drug, the pharmacist and the drug administrator will both be aware of the treatment. They have no other responsibility in the trial||t|t|t|t
33869921|NCT05575479|||OTHER||CROSS_SECTIONAL|||||||
34187195|NCT04494802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187196|NCT00831480|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34187197|NCT02864459|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33869922|NCT04040075|NA|SINGLE_GROUP||TREATMENT||NONE||subjects under current treatment for HIV with the I84 I/V Mutation Resistance||||
33869923|NCT03553251|||CASE_ONLY||PROSPECTIVE|||||||
33869924|NCT01271192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869925|NCT03104699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869926|NCT06489730|||COHORT||PROSPECTIVE|||||||
33869927|NCT03388359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34187198|NCT00473239|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187199|NCT02900573|||COHORT||PROSPECTIVE|||||||
33869928|NCT03271398|||COHORT||OTHER|||||||
34187200|NCT03329638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187201|NCT00218842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187202|NCT05503823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will receive the same stimulations to analyze the effects of tACS on the brain.||||
34187203|NCT01059435|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34187204|NCT00785239|||CASE_ONLY||PROSPECTIVE|||||||
33754264|NCT01922726|||COHORT||PROSPECTIVE|||||||
33754265|NCT04029129|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants were not told the high, medium and low exposure context, however, some aspects of the sessions might have been apparent to them since filters were running during high, but not low exposure sessions.|Randomized cross over trial|t|f|f|f
33754266|NCT06354179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754267|NCT01959451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754268|NCT02642250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754269|NCT03001297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754270|NCT03154801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754271|NCT05460494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants will be blinded to which arm they are randomized to.|Modified cluster randomized controlled trial with randomization|t|t|f|f
33754272|NCT06305949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754273|NCT03406728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754274|NCT04419948|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Acute postprandial study with a randomized cross-over design|f|f|t|f
33754275|NCT00100451||||TREATMENT||||||||
33754276|NCT02002403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754277|NCT03104764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor have not met the patient before assessing the outcome. The assessor has no information about which surgical technique that is used.|Prospective, randomized, controlled, single-blind investigation|f|f|f|t
33754278|NCT04405518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants will be randomly divided into a group receiving concentrate of fibrinogen in the different phases of the liver transplant procedure, to achieve~* Thromboelastometry value (A10 FIBTEM) of 11mm (study group) or~* Thromboelastometry value (A10 FIBTEM) of 8mm (control group) The doses of fibrinogen will be calculated acording to the formula based on previous study (AJT2017), rounded to the higher value according to the presentation format of the drug. Study medication will be stored at the hospital pharmacy."|t|f|f|t
33754279|NCT04373538|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33754280|NCT06367205|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33754281|NCT02495025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants were randomized individually at the time of enrollment, to receive either telephone-based developmental screening and care coordination, through 2-1-1 Los Angeles, in addition to usual care, or usual care alone. Primary outcomes were measured at 6 months after enrollment.||||
33754282|NCT05806229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants will be masked as they will be under effect of anesthesia while the investigators resposible for pain scoring and clinical assesment are masked|prospective randomized controlled trial|t|f|f|t
33754283|NCT03148470|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33754284|NCT01172002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754285|NCT04239040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754286|NCT00575926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754287|NCT03212157|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33754288|NCT01821742|||COHORT||PROSPECTIVE|||||||
33754289|NCT03361436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754290|NCT03786731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754291|NCT02038530|||COHORT||PROSPECTIVE|||||||
33754292|NCT00559650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754293|NCT01298999|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754294|NCT01735890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754295|NCT01718925|||COHORT||CROSS_SECTIONAL|||||||
33754296|NCT04074538|||COHORT||PROSPECTIVE|||||||
33754297|NCT06384417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33754298|NCT02538185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754299|NCT01443819|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754300|NCT03810248|||COHORT||RETROSPECTIVE|||||||
33754301|NCT00606775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754302|NCT02979938|||COHORT||PROSPECTIVE|||||||
33754303|NCT00994357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754304|NCT02771743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754305|NCT04931927|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33754306|NCT00316082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754307|NCT05671874|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||stepped-wedge randomized trial (before-after study)|f|f|f|t
33754308|NCT05540925|||CASE_CONTROL||RETROSPECTIVE|||||||
33754309|NCT01676337|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33869929|NCT03385603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An investigator who will not interact with study participants will perform the random intervention assignment.|Participants will be randomized to receive one of two treatments.|f|f|t|f
33869930|NCT00143663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869931|NCT02203825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869932|NCT05743738|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33869933|NCT04948775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869934|NCT06111833|||COHORT||PROSPECTIVE|||||||
33754310|NCT01507805|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754311|NCT01535820|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754312|NCT00689221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754313|NCT04188977|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|OTPs are masked during their Pre-Implementation Phase.|Type 3 implementation-effectiveness type study using a modified stepped wedge design|f|t|f|f
33754314|NCT06497244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The first assessor will perform the digital models \& CBCT measurements blindly for each patient. The second assessor will perform the same measurements blindly to calculate the inter-observer error|Subjects will receive MOPs randomly to either the left or right maxillary molar buccal alveolar regions. MOPs will be performed at the first day of the distalization treatment (T0) and will repeated every 2 months.|f|f|f|t
33754315|NCT01688466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754316|NCT05422417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754317|NCT05009303|||COHORT||PROSPECTIVE|||||||
33754318|NCT01268748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33754319|NCT01698294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33754320|NCT04629703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754321|NCT01156948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754322|NCT01903538|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33754323|NCT01788865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754324|NCT00319748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754325|NCT04924231|||CASE_ONLY||RETROSPECTIVE|||||||
33754326|NCT03945188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754327|NCT06086327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754328|NCT06578897|||COHORT||RETROSPECTIVE|||||||
33965718|NCT05183399|||CASE_ONLY||PROSPECTIVE|||||||
33965719|NCT05972070|||COHORT||PROSPECTIVE|||||||
34066829|NCT00968188|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34066830|NCT05521152|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34187205|NCT05060029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to preserve the blinding, IP and placebo suppositories will be matched for size, shape, color, and texture. They will be packed in identical fashion in terms of size, color, as well as labelling. The blinding will be done at the CRO (Vedic Lifesciences Pvt. Ltd.). The participant IDs will be arranged in chronological order as per the randomization chart. This chart will be secured, saved and maintained in the electronic Trial Master File (TMF) under the respective project folder.|Randomized, double-blinded, placebo-controlled study|t|f|t|f
34187206|NCT02561832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187207|NCT00049868|||OTHER||OTHER|||||||
34187208|NCT00002080||||TREATMENT||||||||
33754329|NCT02199067|||CASE_ONLY||PROSPECTIVE|||||||
33754330|NCT04588961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will not be informed which type of prosthesis was used in particular patient.|Patients would be assigned randomly to 2 different groups|f|f|f|t
33754331|NCT03391674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754332|NCT04133727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754333|NCT06432517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754334|NCT02676102|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34066831|NCT01979237|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066832|NCT04099537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066833|NCT04438798|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34066834|NCT00954200|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34066835|NCT05812430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754335|NCT05330065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754336|NCT03156660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754337|NCT01067170|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33764702|NCT01849900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764703|NCT00337662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764704|NCT05507658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066836|NCT00006113||||TREATMENT||||||||
34066837|NCT03147807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066838|NCT06207760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187209|NCT04514653|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The vision examiners and central reading center (CRC) graders will be masked, meaning they will be unaware of the participants' treatment assignment. All other individuals affiliated with the study (investigators, all study center personnel apart from the vision examiners, the participants, all Sponsor staff, all staff affiliated with the contract research organization, and all CRC staff apart from the CRC graders) will have knowledge of the treatment assignment.||f|f|f|t
33869935|NCT04663789|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|It will be single blinded. Operator, first assistant and data collector could not be blinded. Whereas patients, nurses, data analyzer, and those who have the access to the primary predictor will be blinded.|"The study is a single-center, randomized controlled clinical trial. Grouping: the study group is set as staple line plus reinforcement group, in which a lock stitch will be placed after transecting the pancreas with stapler. While the control group is set as staple line with no reinforcement group, in which no additional reinforcement is used after transecting the pancreas with stapler."|t|f|f|t
33869936|NCT01785459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187210|NCT02193243|||COHORT||PROSPECTIVE|||||||
34187211|NCT01936870|||CASE_ONLY||PROSPECTIVE|||||||
34187212|NCT01310075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187213|NCT04988243|NA|SEQUENTIAL||TREATMENT||NONE||Retrospective subjects were subjects who had completed transcatheter aortic valve replacement at the beginning of the study. Previous data such as demography and treatment of subjects before the start of the study will be realized by reviewing medical records. Follow up data not traceable to medical records and follow-up data after the start of the study, Prospective subjects were those who were undergoing or planned to undergo transcatheter aortic valve replacement at the beginning of the study. Subjects were enrolled from the beginning of the first case to one year later. The demographic, treatment and follow-up data of subjects will be collected through clinical follow-up or telephone follow-up||||
34187214|NCT04016662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover trial with three 12-week crossover periods (HCL during one period, PLGS during one period, and SAP therapy (control) during one period) preceded by a run-in phase.||||
34187215|NCT05907057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187216|NCT00000921||||TREATMENT||DOUBLE||||||
34187217|NCT00686686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187218|NCT04478006|||COHORT||PROSPECTIVE|||||||
34187219|NCT02776397|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187220|NCT06219408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34187221|NCT00329589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187222|NCT03270501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187223|NCT01122797|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187224|NCT04515238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187225|NCT04957875|||COHORT||RETROSPECTIVE|||||||
34187226|NCT00166777|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
34187227|NCT00212368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187228|NCT00842491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187229|NCT02232906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187230|NCT02125669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187231|NCT04993157|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187232|NCT02731235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34187233|NCT01616095|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187234|NCT02633709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187235|NCT04830319|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34187236|NCT05413317|||COHORT||OTHER|||||||
34187237|NCT05353153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33869937|NCT02905929|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33869938|NCT06165848|||COHORT||PROSPECTIVE|||||||
33869939|NCT04508400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869940|NCT03755895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754338|NCT05685459|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The population of the study consisted of 112 second-semester nursing students who took the Nursing Fundamentals course in the spring semester of the 2021-2022 academic year, and the sample included volunteers who took the course for the first time. A power analysis was performed on the G\*Power (v3.1.7) software to determine the sample size. The power of a study is expressed as 1-β (β = probability of type II error), and in general, studies should have 80% power. According to Cohen's effect size coefficients, assuming that the evaluations between two independent groups would have a large effect size (d = 0.8), the sample size was calculated as 60 subjects. Students were randomly assigned to groups using computer software."|t|f|f|f
33869941|NCT01075412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869942|NCT03544372|||COHORT||CROSS_SECTIONAL|||||||
33869943|NCT01585272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869944|NCT03262454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869945|NCT01948336|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33869946|NCT04998838|NA|SINGLE_GROUP||PREVENTION||NONE||Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV||||
33869947|NCT03226145|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34066839|NCT05314179|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre and post intervention pilot study||||
34066840|NCT01308996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187238|NCT03046862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187239|NCT04943653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187240|NCT02575690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187241|NCT01247272|RANDOMIZED|CROSSOVER||||NONE||||||
34187242|NCT02253446|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34187243|NCT00110721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066841|NCT03642600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066842|NCT04485637|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34066843|NCT04965428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066844|NCT02230826|||COHORT||PROSPECTIVE|||||||
34066845|NCT03268512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869948|NCT04973475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869949|NCT01164774|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33869950|NCT05331040|||COHORT||RETROSPECTIVE|||||||
33869951|NCT00388973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869952|NCT03714321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized non-blinded controlled pilot study||||
33869953|NCT03385811|||COHORT||PROSPECTIVE|||||||
33869954|NCT04001075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869955|NCT03880175|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33869956|NCT02698670|||CASE_ONLY||PROSPECTIVE|||||||
33869957|NCT04852965|||COHORT||CROSS_SECTIONAL|||||||
33869958|NCT04896554|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33869959|NCT02278562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33869960|NCT01228370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869961|NCT04674514|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33869962|NCT04256460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187244|NCT02856672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34187245|NCT01823016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187246|NCT01872390|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187247|NCT04688008|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187248|NCT03722004|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187249|NCT04751006|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34187250|NCT03415542|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187251|NCT00065572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187252|NCT01444040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187253|NCT03200288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the course of the study only the physicians who will perform the intra-articular injection (injectors) will be unblinded. All the other physicians (assessors) and study participants will be blinded||t|t|t|t
34187254|NCT05679258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187255|NCT03651570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34187256|NCT01669681|||COHORT||PROSPECTIVE|||||||
34187257|NCT01486095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187258|NCT04016766|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187259|NCT00232427|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187260|NCT03238495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187261|NCT01107301|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187262|NCT02900040|||COHORT||PROSPECTIVE|||||||
34187263|NCT00145808|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34187264|NCT00662441|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187265|NCT05400382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187266|NCT02157883|NON_RANDOMIZED|||OTHER||NONE||||||
34187267|NCT01879098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34187268|NCT04545580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187269|NCT04079140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187270|NCT01463449|||CASE_CONTROL||PROSPECTIVE|||||||
34187271|NCT05430594|||COHORT||PROSPECTIVE|||||||
34187272|NCT00779155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187273|NCT05927155|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||A prospective, clinical, uncontrolled, single-blind, cross-over trial that included 2 visits over 2-3 days. Assessments were performed before and after long-acting bronchodilation (LABD): during the first visit, before, 30 minutes and 2 hours after inhalation of olodaterol (LABA); during the second visit, before, 40 minutes and 2 hours after the administration of 4 puffs of 2,5 µg of tiotropium (LAMA).|t|f|f|f
34187274|NCT02790411|NA|SINGLE_GROUP||OTHER||NONE||||||
34187275|NCT02062619|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33869963|NCT00163202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33869964|NCT02154360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869965|NCT04443543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869966|NCT04417179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33869967|NCT01871220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869968|NCT05304104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187276|NCT02842216|||CASE_ONLY||RETROSPECTIVE|||||||
34187277|NCT00668889|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187278|NCT01420952|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187279|NCT05761548|||COHORT||PROSPECTIVE|||||||
34187280|NCT01398306|||COHORT||CROSS_SECTIONAL|||||||
34187281|NCT04867096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187282|NCT02481661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187283|NCT02640456|||CASE_CONTROL||PROSPECTIVE|||||||
34187284|NCT00772317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869969|NCT02116777|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33869970|NCT02281032|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894088|NCT02186392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894089|NCT00384956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894090|NCT01879020|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33894091|NCT03910569|||COHORT||PROSPECTIVE|||||||
33894092|NCT01662089|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33894093|NCT04907851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894094|NCT03347214|||FAMILY_BASED||RETROSPECTIVE|||||||
33894095|NCT05659732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187285|NCT01796366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187286|NCT01253577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187287|NCT05046561|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Double-blind||t|t|t|f
34187288|NCT05275504|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965720|NCT03202511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This will be an open-label study.|Subjects will be randomly allocated to enter the study in either the control or treatment arm using a blocked design to ensure equal numbers of subjects in each sequence group (n=8, control to treatment; n=8, treatment to control). Following a washout period of at least 6 weeks, each individual will crossover to the next study phase. The randomization table will be constructed prior to subject enrollment by the Principal Investigator using the Statistical Analysis Software (SAS®) randomization procedure. In the event that an individual is withdrawn from the study, an alternate participant will replace that individual using an identical study sequence to maintain the block design. A total of 16 subjects will be initially enrolled in an effort to ensure that at least 14 subjects complete the entire study. If needed, additional subjects will be screened and enrolled until the target enrollment of n=14 subjects have completed the entire study.||||
34187289|NCT06232824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded participants and therapists were not implemented in our study. Before the intervention, an independent researcher communicated with the patient to inform the method of using the mobile application. Apart from the mobile application, no paper rehabilitation program materials will be distributed to participants. Admission, ACLR surgery, follow-up, and assessment of all participants were conducted separately and will not be arranged in the same ward room to avoid discussion and communication between participants. The ACLR surgery was performed by a senior surgeon who was blinded to the group allocation. In addition, we selected two assessors who were blinded to the group allocation to measure the baseline data and follow-up outcomes after the intervention. The collection and analysis of data were carried out by two independent researchers who were also blinded to the group allocation.|"Intervention Participants in the intervention group coud only view the rehabilitation content that needs to be carried out at the current phase every day and confirm whether to execute it on the application. Participants could communicate with therapists on the mobile phone application by sending text, voice, images, and videos throughout the entire experiment.~Control Participants in the control group could only receive a graphic and textual minimal postoperative rehabilitation plan on the mobile phone application. However, the participants was not informed the frequency and intensity of the rehabilitation items. They could not communicate with therapists online. Participants in the control group was expected to exercise unsupervised postoperatively."|f|f|t|t
34187290|NCT00248768|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754339|NCT02044991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to receive either an injection of methylprednisolone acetate plus lidocaine or to receive an injection of saline with lidocaine using a randomized block design with a 1:1 allocation.|t|t|t|t
33754340|NCT00109538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754341|NCT00530855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754342|NCT05134181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33754343|NCT03343223|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754344|NCT02191553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754345|NCT00002258||||TREATMENT||NONE||||||
33754346|NCT02579252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754347|NCT02693275|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open Label|||||
33754348|NCT05034523|||CASE_CONTROL||PROSPECTIVE|||||||
33754349|NCT05189366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764705|NCT05893199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965721|NCT00877266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187291|NCT03470298|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo ES just after finishing oocyte pick up and the other group undergo ES one week before starting COH. Manual Vacuum Aspiration (MVA) size 5 moved from below upwards with suction ,scratching anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly funds.|t|t|t|t
33965722|NCT03053622|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33965723|NCT03171675|||CASE_CONTROL||RETROSPECTIVE|||||||
33965724|NCT01706276|||COHORT||RETROSPECTIVE|||||||
34187292|NCT06441240|||CASE_ONLY||RETROSPECTIVE|||||||
34187293|NCT04366817|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34187294|NCT04664127|||COHORT||PROSPECTIVE|||||||
34187295|NCT04560699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator is masked to group assignment for study analysis. Outcome assessor is masked to group allocation|randomized 1:1 to intervention or control|f|f|t|t
34187296|NCT01356277|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187297|NCT02346721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187298|NCT03252925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34187299|NCT02256280|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34187300|NCT03751917|||COHORT||OTHER|||||||
34187301|NCT01415414|||COHORT||PROSPECTIVE|||||||
34187302|NCT01075542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187303|NCT01340846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187304|NCT01752777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34187305|NCT01704209|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34187306|NCT02306044|||COHORT||PROSPECTIVE|||||||
34187307|NCT01357525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187308|NCT00755183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187309|NCT00354978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187310|NCT02736578|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187311|NCT03858309|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34187312|NCT03636893|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomly assigned(1:1) either to FLOT or SOX group.||||
33869971|NCT05407233|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study was blinded to the professionals involved in the analyses of skin complications and the needle characterization test.|A randomized clinical trial will be carried out to compare the reuse or not of needles in diabetes patients who use insulin. The groups will be divided in two: a group that will not reuse the needles and a group that will reuse the needles five times. Primary outcomes as skin complications, local pain, glycemic control will be evaluated at baseline and after 4, 8 and 12 weeks and secondary outcomes will also be evaluated as quality of life, insulin application technique, frequency of capillary blood glucose tests, adherence to treatment, quality of needles, microbiological contamination and cost-utility analysis of after needle reuse|f|f|f|t
33869972|NCT00004414|RANDOMIZED|||TREATMENT||DOUBLE||||||
33965725|NCT04354337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965726|NCT02866019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965727|NCT04013022|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965728|NCT02662608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187313|NCT03103334|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187314|NCT02708186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187315|NCT03072108|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34187316|NCT05636670|||COHORT||OTHER|||||||
34187317|NCT05338814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187318|NCT02451709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187319|NCT05295069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All participants did not know which group they were in.||t|f|f|f
34187320|NCT04677283|||COHORT||RETROSPECTIVE|||||||
34187321|NCT05228951|NA|SINGLE_GROUP||TREATMENT||NONE||single arm study||||
34187322|NCT04845503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187323|NCT02003599|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34187324|NCT03108326|||COHORT||PROSPECTIVE|||||||
33764706|NCT04834778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965729|NCT01328054|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33965730|NCT04087083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965731|NCT06327321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187325|NCT01547078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34187326|NCT02753452|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187327|NCT02501577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34187328|NCT01565824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187329|NCT00027352|||||PROSPECTIVE|||||||
34187330|NCT03346980|||COHORT||PROSPECTIVE|||||||
34187331|NCT01558648|||COHORT||PROSPECTIVE|||||||
34187332|NCT01918306|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33764707|NCT02053545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187333|NCT01526681|||OTHER||OTHER|||||||
34187334|NCT02259335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187335|NCT02841852|||||PROSPECTIVE|||||||
34187336|NCT04176471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors of neurodevelopmental outcome at 12-14 months of age will be blinded to the allotted treatment group|A total of 68 neonates with mild HIE will be enrolled and randomized to therapeutic hypothermia (33.5°C ± 0.5°C for 72 hours plus 6 hours of rewarming) or normothermia (36.5-37.3°C for 72 hours ) with targeted temperature management. Each treatment group will have 34 patients. Participants randomized to normothermia who develop signs of moderate-severe HIE in the first 24 hours after birth will be crossed over to the treatment arm, as therapeutic hypothermia is the standard of care treatment for neonates with moderate-severe HIE.|f|f|f|t
34187337|NCT05961007|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Masking participant and investorgastor||t|f|t|f
34187338|NCT00507143|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187339|NCT00802256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187340|NCT05865119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187341|NCT02280343|||||CROSS_SECTIONAL|||||||
34187342|NCT03485378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33869973|NCT04097613|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
34066846|NCT02711020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066847|NCT02533297|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34066848|NCT01081496|||COHORT||CROSS_SECTIONAL|||||||
34066849|NCT01703559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066850|NCT02978612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066851|NCT05230199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parents will enroll in this study, understanding that they will be assigned to one of two types of sensory approaches. They will be masked from whether they are in the treatment (SENSE group) or control group (standard of care). After enrollment, the SENSE program will be described to those parents assigned to the SENSE group. The use of nurses and therapists to aid the parent in conducting sensory interventions at the bedside will be described to those parents assigned to the standard of care group. All assessments in the NICU will be conducted at the infant's bedside by a certified (when necessary) and trained evaluator who is blinded to treatment assignment. All assessments following NICU discharge will be conducted by a different blinded evaluator (to decrease bias), who is trained and experienced with standardized childhood assessment. The evaluators will not be involved in other study-related activities in order to maintain blinding.||f|f|f|t
34066852|NCT02992184|||CASE_CONTROL||RETROSPECTIVE|||||||
34066853|NCT01222663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066854|NCT01459393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066855|NCT02572960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066856|NCT05460078|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||stepped-wedge||||
34066857|NCT01942811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066858|NCT06187272|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|There was no masking|One group was a control, one group received the intervention|t|f|f|f
34187343|NCT04042636|||COHORT||RETROSPECTIVE|||||||
34187344|NCT01626872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764708|NCT05726682|NA|PARALLEL||TREATMENT||NONE||This is a parallel multicohort, phase 2, single-arm study.||||
33764709|NCT01395654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764710|NCT02057601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764711|NCT02150837|||COHORT||RETROSPECTIVE|||||||
33764712|NCT00790114|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33764713|NCT00352898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764714|NCT04195529|||CASE_ONLY||PROSPECTIVE|||||||
33764715|NCT04488562|||COHORT||PROSPECTIVE|||||||
33764716|NCT04649827|||CASE_ONLY||OTHER|||||||
33764717|NCT01500564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33869974|NCT03221491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33869975|NCT00823628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33869976|NCT03778528|||COHORT||PROSPECTIVE|||||||
33869977|NCT00683163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066859|NCT03910140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066860|NCT05994053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066861|NCT01462539|||COHORT||PROSPECTIVE|||||||
34066862|NCT01915550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066863|NCT04123249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066864|NCT02304380|||OTHER||OTHER|||||||
34066865|NCT05029245|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The 8-week, Prospective, Randomized controlled of IntraDermal administration of Comirnaty® 6 microgram compare to Intramuscular Comirnaty® 30 microgram by 28 days interval Efficacy Study in healthy volunteers.~There were flexible 8 arms recruitment up to type of immunological background of 1000 volunteers and availability of BNT162b2 vaccine ( initially estimated 125 volunteers. Per arm)"|t|f|f|f
34066866|NCT06486285|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066867|NCT02346695|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066868|NCT04616040|||OTHER||PROSPECTIVE|||||||
34066869|NCT02665923|||COHORT||PROSPECTIVE|||||||
34066870|NCT04474977|||CASE_ONLY||PROSPECTIVE|||||||
34066871|NCT01300156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066872|NCT03033927|||COHORT||PROSPECTIVE|||||||
34187345|NCT00663182|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187346|NCT01474252|NON_RANDOMIZED|PARALLEL||||NONE||||||
34187347|NCT02476461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187348|NCT01473901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187349|NCT04551209|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34187350|NCT00430404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187351|NCT01605799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187352|NCT02229162|||OTHER||OTHER|||||||
34187353|NCT00420771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187354|NCT05959356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187355|NCT02214134|||COHORT||PROSPECTIVE|||||||
34187356|NCT05796375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Health care delivery parallel trial with 1:1:1 randomization||||
34187357|NCT05210777|||COHORT||PROSPECTIVE|||||||
33869978|NCT00278642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187358|NCT03241368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187359|NCT00379964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187360|NCT00573300|||CASE_ONLY||PROSPECTIVE|||||||
34187361|NCT00857714|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187362|NCT00561509|||COHORT||PROSPECTIVE|||||||
34187363|NCT00912067|||COHORT||CROSS_SECTIONAL|||||||
34187364|NCT03854877|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized two group behavioral intervention||||
34187365|NCT04154813|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||There is no evidence for patients who fail to respond to fluoxetine therapy to choose further treatment. As the result of fact, this study is proposed to adopt a two-stage sequential study design.|f|f|t|t
34187366|NCT00080444|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34187367|NCT04717219|||CASE_CONTROL||PROSPECTIVE|||||||
34187368|NCT06357195|||OTHER||CROSS_SECTIONAL|||||||
34187369|NCT05494424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187370|NCT06464978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes assessors will be blinded to the group assignments. Surgeons will be aware of the group assignments but will not disclose this information to the participants or the outcomes assessors.|Participants will be randomly assigned to either the experimental group receiving the stapler reinforcement patches or the control group undergoing standard procedures without reinforcement patches.|t|f|f|t
34187371|NCT03453138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187372|NCT01885130|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187373|NCT05733117|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187374|NCT03828578|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34187375|NCT04873219|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|neither the patients, nor the operator knew which type of denture was inserted|double blind single center cross-over design|t|t|t|f
34187376|NCT01279161|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187377|NCT00731302|NA|SINGLE_GROUP||OTHER||NONE||||||
34187378|NCT03336112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187379|NCT00434785|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34187380|NCT04043858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187381|NCT05079243|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Triple blinded, randomized, paired study on healthy participants|t|f|t|t
34187382|NCT04515680|||COHORT||OTHER|||||||
34187383|NCT05418205|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187384|NCT06356896|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single (Participant) Single Blinded|Adult patients will be divided into two groups: experimental and control groups. Diaphragmatic breathing exercise will be explained to the patients in the experimental group in the preoperative period. In the preoperative period, the sleep, anxiety and symptom levels of the experimental and control groups will be evaluated.In the post-operative period, the experimental group was reminded to do diaphragmatic breathing exercises on the 2nd, 3rd and 4th days.On the 5th post-operative day, sleep, anxiety and symptom severity of the experimental and control groups will be evaluated.|t|f|f|f
34187385|NCT00659737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33869979|NCT04221763|NA|SINGLE_GROUP||TREATMENT||NONE||60 patients with heart failure, severe left ventricular systolic dysfunction and cardiac conduction abnormality (QRS \> 120ms) will be recruited and undergo an attempt at His bundle, left bundle pacing and biventricular pacing. Patients will have acute haemodynamic and electrical measurements.||||
33869980|NCT01942603|||CASE_CONTROL||PROSPECTIVE|||||||
33894096|NCT02037126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187386|NCT01574443|||CASE_ONLY||PROSPECTIVE|||||||
34187387|NCT00464191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187388|NCT02328638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187389|NCT02117297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187390|NCT02681978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187391|NCT00220285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187392|NCT05670691|||COHORT||PROSPECTIVE|||||||
34187393|NCT01528969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34187394|NCT00689507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187395|NCT06315816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data will be analyzed by a statistician blind to the groups.|The population will consist of children between the ages of 7-10 who presented to the pediatric dental clinic of an oral and dental health center Turkey. The sample size of the study was calculated as GPOWER 3.1 statistical analysis software, based on a significance level of 0.05, a power value of 80%, and an effect size of 0.15 (medium effect size). Considering 10% attrition, it will plan to sample a total of 80 children, including 40 in the experimental group and 40 in the control group. Eventually, a total of 120 children, 60 in the experimental group and 60 in the control group,will include in the study to reveal the relationship between the variables more clearly.|f|f|f|t
34187396|NCT02135926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187397|NCT00897819|||OTHER||RETROSPECTIVE|||||||
34187398|NCT01276054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187399|NCT05324852|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intramuscular loxapine versus intranasal midazolam||||
34187400|NCT00629343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187401|NCT05683613|||CASE_ONLY||PROSPECTIVE|||||||
34187402|NCT00993148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187403|NCT04338802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187404|NCT04250909|||COHORT||RETROSPECTIVE|||||||
34187405|NCT05701501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187406|NCT03639909|||COHORT||RETROSPECTIVE|||||||
34187407|NCT00926718|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34187408|NCT05626868|||COHORT||PROSPECTIVE|||||||
34187409|NCT00846092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187410|NCT00523302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33869981|NCT01819649|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||AMENDMENT TO STUDY DESIGN: Towards the end of the intervention period, it was decided to follow-up participants for an additional ten years via Danish public registries for data on morbidity and mortality.|t|t|t|f
33869982|NCT01508481|||COHORT||PROSPECTIVE|||||||
33869983|NCT01699477|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33869984|NCT03945526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Astaxanthin and Placebo|t|f|f|f
33869985|NCT00582218|||CASE_ONLY||PROSPECTIVE|||||||
33869986|NCT02354066|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187411|NCT04581694|NA|SINGLE_GROUP||PREVENTION||NONE||"Twenty-five patients who meet all inclusion criteria and without exclusion criteria will be submitted to TAVI using the zero contrast strategy.~Four imaging methods will be used to evaluate this new strategy: (1) multi-slice computed tomography (TCMS) without contrast, (2) aortoiliac angiography with CO2, (3) nuclear magnetic resonance (MR) of heart without contrast and (4 ) 3D transesophageal echocardiogram (3D TEE)."||||
33869987|NCT00677651|||CASE_ONLY||PROSPECTIVE|||||||
34187412|NCT01956929|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33869988|NCT03669432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869989|NCT02596477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869990|NCT05650489|||OTHER||CROSS_SECTIONAL|||||||
33869991|NCT03870659|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33869992|NCT02014389|||CASE_CONTROL||PROSPECTIVE|||||||
33869993|NCT04229433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multiple dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects|t|f|f|f
33869994|NCT05596682|||CASE_ONLY||PROSPECTIVE|||||||
33869995|NCT04286087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187413|NCT02784691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187414|NCT04660916|||CASE_CONTROL||PROSPECTIVE|||||||
33764718|NCT01979731|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33764719|NCT03601455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33869996|NCT06210698|||COHORT||PROSPECTIVE|||||||
33869997|NCT04485143|||COHORT||PROSPECTIVE|||||||
33869998|NCT01944293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33869999|NCT05915689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870000|NCT05636592|||COHORT||PROSPECTIVE|||||||
33870001|NCT05975164|||COHORT||RETROSPECTIVE|||||||
33870002|NCT04436536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870003|NCT02858908|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33870004|NCT05467956|||COHORT||RETROSPECTIVE|||||||
33870005|NCT03536975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Intervention group using the CAREGIVERSPRO-MMD platform versus control group"||||
33870006|NCT03880942|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33870007|NCT05679336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965732|NCT02459639|||COHORT||PROSPECTIVE|||||||
33965733|NCT03211091|||COHORT||PROSPECTIVE|||||||
33965734|NCT01644578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870008|NCT06427928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870009|NCT00595322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870010|NCT04035447|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||A two-arm, cluster RCT employing a wait-list control arm will be used. Six cohorts of YA survivors (n=10/cohort) will be randomized with equal allocation to the intervention or control arms.||||
34187415|NCT04583163|||COHORT||PROSPECTIVE|||||||
34187416|NCT00140582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187417|NCT04375085|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized||||
34187418|NCT06225713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The masking range includes participants, most researchers (including the study leader; subjects screening researchers; follow-up researchers; sonographers, MR scanners, members of the clinical endpoint identification committee, and etc.) except for the study statistical analysts and the therapy operators.|This is a randomized, blinded, and sham-control study. The ratio of the intervention group versus sham-control group is 1:1|t|t|t|f
34187419|NCT00946621|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187420|NCT05676840|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||three groups||||
34187421|NCT05355688|||COHORT||PROSPECTIVE|||||||
34187422|NCT00073476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187423|NCT01716052|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34187424|NCT05008406|||COHORT||CROSS_SECTIONAL|||||||
34187425|NCT03207061|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187426|NCT04374097|||OTHER||CROSS_SECTIONAL|||||||
34187427|NCT00158418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187428|NCT02814994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187429|NCT00004554|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34187430|NCT05322473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187431|NCT04615026|||CASE_ONLY||PROSPECTIVE|||||||
34187432|NCT02897440|||COHORT||PROSPECTIVE|||||||
34187433|NCT00051532|RANDOMIZED|||ECT||DOUBLE||||||
34187434|NCT04073979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187435|NCT05631613|||COHORT||PROSPECTIVE|||||||
34187436|NCT04565639|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34187437|NCT05724537|||COHORT||CROSS_SECTIONAL|||||||
34187438|NCT01119404|||||CROSS_SECTIONAL|||||||
33870011|NCT02889406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33965735|NCT01681043|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33870012|NCT03126695|RANDOMIZED|CROSSOVER||OTHER||NONE||A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall results.||||
33870013|NCT03667534|||COHORT||CROSS_SECTIONAL|||||||
33870014|NCT06125275|||OTHER||PROSPECTIVE|||||||
33965736|NCT03039374|||COHORT||PROSPECTIVE|||||||
33965737|NCT00655005|||CASE_ONLY||PROSPECTIVE|||||||
33965738|NCT04918537|NA|SEQUENTIAL||PREVENTION||NONE||3 weeks of observation 3 weeks of intervention||||
34066873|NCT02454868|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187439|NCT05592899|||COHORT||RETROSPECTIVE|||||||
33965739|NCT01195389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965740|NCT02535676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965741|NCT01131702|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965742|NCT05578300|||COHORT||PROSPECTIVE|||||||
34187440|NCT03810924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187441|NCT04978298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187442|NCT06009211|||CASE_CROSSOVER||PROSPECTIVE|||||||
34187443|NCT02161289|||COHORT||PROSPECTIVE|||||||
34187444|NCT02816385|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870015|NCT03622463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a multi-centers, phase IIa, double blind, randomized, placebo-controlled trial of Antroquinonol in patients with atopic dermatitis. Subjects with diagnosis of atopic dermatitis, using the Hanifin and Rajka Diagnostic Criteria, who meet inclusion/exclusion criteria will be randomized into 3 groups:~1. Antroquinonol 100 mg PO QD~2. Antroquinonol 50 mg PO QD~3. Placebo"|t|t|t|t
33870016|NCT04703556|NA|SINGLE_GROUP||TREATMENT||NONE||Single blinded study on patients with Parkinson's disease being treated with deep brain stimulation, who still experience severe therapy-resistant gait disorders.||||
33870017|NCT05097703|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participant randomly assigned to either an intervention arm or control arm. Intervention arm will receive the sleep resource and be asked to use it over a 4 week period where as the control group will not.||||
33870018|NCT00022867|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33965743|NCT01883999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066874|NCT01693185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066875|NCT04750278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS).|t|t|t|t
33870019|NCT06474949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient is asleep at time of injection|Randomized Control Trial|t|f|f|t
33965744|NCT05217056|||COHORT||PROSPECTIVE|||||||
33965745|NCT00616928|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33965746|NCT00135291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965747|NCT03218410|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric, randomized, open-label, controlled, clinical, non-inferiority trial.||||
33965748|NCT00626587|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33965749|NCT05016076|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33965750|NCT06191510|||CASE_CONTROL||PROSPECTIVE|||||||
33965751|NCT01664494|||COHORT||PROSPECTIVE|||||||
33965752|NCT00882986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33965753|NCT04470622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965754|NCT05086081|||COHORT||RETROSPECTIVE|||||||
33965755|NCT00590291|||FAMILY_BASED||RETROSPECTIVE|||||||
33965756|NCT03099967|||COHORT||PROSPECTIVE|||||||
33965757|NCT04036383|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965758|NCT03341598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33965759|NCT02869932|NA|SINGLE_GROUP||OTHER||NONE||||||
33965760|NCT00700869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965761|NCT05725707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two groups -~1. Group 1 - received a face-to-face based peer-led intervention~2. Group 2 - received an online based peer-led intervention"||||
33965762|NCT02095119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965763|NCT00932958|||COHORT||PROSPECTIVE|||||||
33965764|NCT03334916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870020|NCT04276389|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870021|NCT03556436|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965765|NCT05530642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The PSP PTSI Study uses a longitudinal prospective sequential experimental cohort design that engages each participant for approximately 16 months. Several practical constraints prohibited a randomized controlled trial, including resource limitations and probable interactions between PSP during and after training.||||
33965766|NCT00371488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965767|NCT02556632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33965768|NCT04412876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187445|NCT02223858|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|The statistician will seal PA and AC program workbooks in envelopes following the randomization scheme. To blind participants and staff during the baseline assessment, staff will take the next sealed envelope in the sequence to each baseline visit, to be opened after a patient has consented and completed the baseline assessment. The study staff that complete the baseline visits will be unblinded once a participant's envelope is opened; participants will not be told whether they are in the PA or AC program. Staff who conduct the weekly intervention calls in the 6 weeks following the baseline visit will also be unblinded. To maintain blinding for the collection of outcome measures, study staff members who did not complete the baseline visit or any weekly calls during the 6-week program period for a given participant will collect the 1, 3, and 6-month follow-up assessments.|Randomization will be at the patient level, stratified by study site and patient race, with a 1:1 allocation using random block sizes of 2, 4, 6, or 8.|t|f|f|t
34187446|NCT02394587|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187447|NCT04029077|||COHORT||PROSPECTIVE|||||||
34187448|NCT05824195|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34187449|NCT05573997|||COHORT||PROSPECTIVE|||||||
34187450|NCT06471335|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This research is descriptive and monocentric research.~* retrospective on the clinical description of the 182 Fetal Alcohol Spectrum Disorder patients~* prospective on the microRNAs part with 18 patients in Fetal Alcohol Spectrum Disorder group and 18 people in the control group"||||
34187451|NCT03529591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187452|NCT04473677|||COHORT||PROSPECTIVE|||||||
34187453|NCT02534740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34187454|NCT01029106|||||PROSPECTIVE|||||||
34187455|NCT01093235|RANDOMIZED|||TREATMENT||NONE||||||
34187456|NCT02379637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187457|NCT01962740|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187458|NCT01263847|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34187459|NCT04617704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187460|NCT05263778|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Pragmatic randomized clinical trial|t|t|t|t
34187461|NCT00075257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187462|NCT00703716|||COHORT||PROSPECTIVE|||||||
34187463|NCT00645996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187464|NCT04372940|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE||TXA would be randomized to one side with the other acting as a control|t|f|t|f
34187465|NCT05111730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (study group) and Group B ( control group).|Eighty children with tumors were enrolled in this study and were assessed for eligibility. Their aged ranged from eight and forty years. They were assigned randomly into two equal groups. Group (A) study group received the same medical care and shock wave, three times / weak for three successful months. And group (B) control group received medical care and standard chemotherapy only.Nerve conduction studies (NCS) and somatosensory-evoked potentials (SSEPs) were used to assess peripheral neuropathy pre and post intervention. All children were assisted before and after three months of intervention.|f|f|f|t
34187466|NCT03599089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187467|NCT01974219|||CASE_CONTROL||PROSPECTIVE|||||||
33870022|NCT01750931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187468|NCT02156934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187469|NCT03731676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187470|NCT03993106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187471|NCT05668052|||OTHER||CROSS_SECTIONAL|||||||
34187472|NCT05269667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870023|NCT00904800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33870024|NCT02895880|||CASE_CONTROL||PROSPECTIVE|||||||
33894097|NCT03728244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187473|NCT01011309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187474|NCT02812862|NA|SINGLE_GROUP||OTHER||NONE||||||
34187475|NCT03683459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187476|NCT01261221|||COHORT||CROSS_SECTIONAL|||||||
34187477|NCT05452694|||COHORT||PROSPECTIVE|||||||
33894098|NCT03808961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Only Pharmacists keep the log of the drug dispensed. Everyone else is blinded.|There are three arms, niacin, niacinamide and placebo. They are double blind and randomized.|t|t|t|t
33894099|NCT04342065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894100|NCT02397252|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||f|t|f|t
33894101|NCT02534649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894102|NCT04265612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|External evaluator: care provider||f|f|t|f
33894103|NCT04253093|||CASE_CONTROL||PROSPECTIVE|||||||
33894104|NCT05233995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894105|NCT06478953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pilot, randomized, controlled open-label trial|f|f|f|t
33894106|NCT06640114|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Allocation of patients into groups will be done by stratified 1:1 randomisation.~Stratification will be done by the patient's PASI index score (10 to 19, and more than 19)."||||
33894107|NCT01486589|||COHORT||PROSPECTIVE|||||||
33894108|NCT02485392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894109|NCT01670201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894110|NCT03735940|RANDOMIZED|PARALLEL||SCREENING||NONE||"In this study ICU departments will be randomized with respect to the time they will introduce the DeltaScan following a stepped wedge cluster randomization design. All departments apply 'usual care' in combination with a harmonized delirium treatment protocol during the control phase. After this first time period, each new time period a department switches to the intervention period.~Due to the first wave of the COVID-19 pandemic the stepped wedge planning was interrupted. Where possible the control period and/or intervention, whichever was affected, will be extended. We marked the first wave of the COVID-19 pandemic from the 15th of March until the 15th of May or longer for a few heavily effected sites with a maximum of 6 months. Data collected during this period will not be used for primary analysis, but may be used for specific sub analyses."||||
33894111|NCT02951273|||COHORT||PROSPECTIVE|||||||
34066876|NCT02208050|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34066877|NCT06266299|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34187478|NCT03279562|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, open label, non-randomized clinical trial||||
34187479|NCT04837378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In the study, patients will be stratified according to their gender (male and female) status and the blocking process will be performed. 46 patients will be included in each group by repeating the layers formed according to the specified variables 3 times. The stratified patients will be assigned to the experimental and control groups, and the research groups will be written on papers for the determined sets and a lot will be drawn.~Group 1: Abdominal Massage 2. Group: In-bed Exercise 3. Group: Control"|t|f|f|f
34187480|NCT03470844|||COHORT||PROSPECTIVE|||||||
34187481|NCT04065672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators and the study participants were masked to the allocation sequence and the intervention (study drug containing IL-2 or placebo). The study drug was packaged, labeled, and randomly assigned by an independent third party (Beijing Stemexel Technology Co).||t|t|t|t
34187482|NCT03005158|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34187483|NCT03931200|||OTHER||RETROSPECTIVE|||||||
34187484|NCT02186418|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Gamma Globin Lentivirus Vector||||
34187485|NCT02904954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187486|NCT06252688|NA|SINGLE_GROUP||OTHER||NONE||||||
34187487|NCT03775135|||COHORT||PROSPECTIVE|||||||
34187488|NCT03249116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34187489|NCT06035757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34187490|NCT01614392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34187491|NCT06308016|||COHORT||RETROSPECTIVE|||||||
34187492|NCT04769388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187493|NCT00296699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187494|NCT01523041|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34187495|NCT06227104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants don't know which kidney replacement therapy they would receive.|Patients with sepsis-associated AKI who need kidney replacement therapy in Ramathibodi Hospital will be divided into two arms. First convection base hemodiafiltration which basically removes solute by convection mode. Second is hemodialysis which the majority of clearance is the diffusion base method.|t|f|f|f
34187496|NCT03418818|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187497|NCT03519295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187498|NCT02998268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187499|NCT05244252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups of equal size will be included in study|t|f|f|f
34187500|NCT02505919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All study subjects and the study site follow-up team are blinded to the assigned treatment until the year 3 follow-up.||t|f|t|f
34187501|NCT02481128|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187502|NCT05700019|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187503|NCT00948441|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34187504|NCT06492525|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34187505|NCT03918876|||COHORT||CROSS_SECTIONAL|||||||
34187506|NCT06403332|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34187507|NCT01955330|||COHORT||PROSPECTIVE|||||||
34187508|NCT05974124|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomised to instill either povidone-iodine eye drops (35 patients) or chlorhexidine (35 patients) in the eye to be operated on. The contralateral eye was considered as control and received no antiseptic prophylaxis.||||
34187509|NCT02876562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187510|NCT03620461|||CASE_ONLY||RETROSPECTIVE|||||||
34187511|NCT00108199|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34187512|NCT03849508|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187513|NCT05242120|||OTHER||CROSS_SECTIONAL|||||||
34187514|NCT03215004|||CASE_ONLY||PROSPECTIVE|||||||
34187515|NCT03519711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187516|NCT05821881|||COHORT||PROSPECTIVE|||||||
34187517|NCT05529797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764720|NCT03748017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators, and data evaluators will be blinded to the treatment assignments.|Subjects will be enrolled and randomized, receiving either a streptococcus-containing probiotic supplement or a placebo-control supplement.|t|f|t|t
33764721|NCT05398146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187518|NCT02792829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187519|NCT06518746|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34187520|NCT03310853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34187521|NCT03339752|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34187522|NCT05216809|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Parallel Group Cohort Study~Twenty healthy young (18-35 years of age; 10 females and 10 males) and twelve healthy older adults (60-80 years of age; 6 females and 6 males), for a total of 32 individuals, will undergo 3 days (Days 1-3) of Habitual Activity in a free-living setting (Phase 1) followed by a metabolic trial (Day 4), where individuals will be subjected to a non-invasive 13CO2 breath-test. This will also serve as a lead-in period for the subsequent 3 days of step-reduction (\<2,000 steps/day; Days 4-6). Following the 3-days of reduced daily step count (Day 7), participants will undergo another metabolic trial day involving the non-invasive 13CO2 breath-test in order for us to determine changes in anabolic sensitivity."||||
33754350|NCT03362567|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study involved 47 patients with cervical radiculopathy which were purposively recruited from the Physiotherapy Department Outpatient Clinic of Usmanu Danfodio University Teaching Hospital, Sokoto for the study. Subjects were randomly allocated to Sustained Natural Apophyseal Glides (SNAGS)and Mechanical Cervical Traction (MCT) group. All the subjects were treated using cryotherapy for seven minutes. Subjects in SNAGS group were then treated with sustained natural apophyseal glides, twice weekly for six weeks while subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks. Visual analogue scale, neck disability index questionnaires and inclinometer were used to assess pain intensity, disability and cervical range of motion respectively at the beginning, 3rd and 6th week of treatment||||
33754351|NCT03594565|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33754352|NCT06313580|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The study coordinator and participants are unblinded due to the nature of the study design and intervention; however, the PI will remain blinded.|In a single blind crossover design, participants are randomized to 4 weeks of yogurt intake twice daily with or without added spices with a two-week washout period between study arms.|f|f|t|f
33754353|NCT03697902|||COHORT||CROSS_SECTIONAL|||||||
33754354|NCT02271256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There are 2 groups of subjects. One group receives the treatment of functional intimate apparel which is called FIA group while one group receives observation only, which is called control group.|t|f|f|f
33754355|NCT06111651|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754356|NCT02803268|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34187523|NCT04969302|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33754357|NCT02183987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33754358|NCT04983550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754359|NCT06015867|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33894112|NCT02475200|||CASE_ONLY||PROSPECTIVE|||||||
33965769|NCT03287479|RANDOMIZED|PARALLEL||OTHER||NONE||"Patients presenting ≥ 2 surplus regularly fertilized oocytes for cryoperservation on day 1 and patients undergoing elective cryopreservation of all available 2PN oocytes are are allocated to one of the two following procedures:~Study group: surplus or all 2PN-stage oocytes are vitrified/warmed using the semiautomated Gavi® protocol.~Control group: surplus or all 2PN-stage oocytes are vitrified/warmed using the manual Cryotop® protocol.~Randomization will be performed on day of fertilization check by lab staff by opening a numbered, opaque sealed envelopes. The random sequence will be software-generated and blocks will be used."||||
33965770|NCT00700310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965771|NCT03235583|NA|SINGLE_GROUP||OTHER||NONE||||||
33965772|NCT04401787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective study included 191 patients, randomly allocated into two arms of the study, Arm I is open anterior resection (OAR), this is the control and arm II, The LAR. Only 156 analyzed.|t|f|f|f
34187524|NCT00565084|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34187525|NCT05335278|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open label study||||
34187526|NCT01339052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187527|NCT05840757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187528|NCT00004428|RANDOMIZED|||TREATMENT||DOUBLE||||||
34187529|NCT05860309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||preoperative versus postoperative quadratous lumborum block in nephrectomy|t|f|f|t
34187530|NCT05940090|||COHORT||PROSPECTIVE|||||||
34187531|NCT05055206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187532|NCT03760861|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Open label pilot study||||
34187533|NCT02441595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34187534|NCT06079710|||COHORT||PROSPECTIVE|||||||
34187535|NCT00915616||||TREATMENT||||||||
33754360|NCT04949659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754361|NCT06167980|||CASE_CONTROL||RETROSPECTIVE|||||||
33754362|NCT02367755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754363|NCT01785303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754364|NCT06273098|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33754365|NCT05432076|||OTHER||OTHER|||||||
33754366|NCT00333164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754367|NCT06580236|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33754368|NCT05965011|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The single-blind design will involve that the assessors are unaware of the group assignments.|This study will be a pilot trial conducted as a two-arm, parallel, single-blind, randomized controlled trial.|f|f|f|t
33754369|NCT02123862|||COHORT||PROSPECTIVE|||||||
33754370|NCT04833387|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1||||
33894113|NCT01958567|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894114|NCT01783834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894115|NCT02914392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33894116|NCT01451515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894117|NCT02566512|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33894118|NCT00997074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894119|NCT02509208|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33894120|NCT04232449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|blinded patients, physicians and outcome assessors|multi-centre, 1:1 randomised, parallel-group, placebo-controlled, superiority trial with blinded patients, physicians and outcome assessors in a primary health care setting|t|t|t|t
34187536|NCT03995953|RANDOMIZED|PARALLEL||PREVENTION||NONE||Zones, with their respective clinics, will be randomized into three groups (zones with integrated wellness care (IWC) clinics and (Support for HIV Integrated Education, Linkages to care, and Destigmatization) SHIELD intervention, zones with only SHIELD intervention, and control zones with no intervention at the clinic or community levels) to assess the impact of offering IWC clinics coupled with the SHIELD intervention compared to the standard of care. In each clinic zone, the study team will use stratified random sampling, using age-group strata drawn from the sampling frame previously established, to select AGYW for the HIV-/u and HIV+ study cohorts. The sample size was calculated assuming conventional specifications (power = .80, alpha = .05, two-sided tests) and based on the primary endpoints.||||
34187537|NCT00528593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187538|NCT00451347|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34187539|NCT03972943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187540|NCT00067106|||COHORT||PROSPECTIVE|||||||
34187541|NCT04532320|||CASE_ONLY||RETROSPECTIVE|||||||
34187542|NCT04733859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187543|NCT04578236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187544|NCT01470950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187545|NCT04037696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34187546|NCT05536596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to maintain the blindness of subjects and the main surgeon, the drugs will be delivered in an identical brown non-translucent bag. The only one who will know about the assignament will be the second researcher.|The participants will be assigned into 4 groups. Groups A, B and C will receive the medication (Melatonin, Hydroxycobalamin and combination UTP/CMP/hydroxycobalamin), whereas the Group P will receive placebo.|t|t|f|f
34187547|NCT00156676|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187548|NCT03819114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187549|NCT04827680|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded evaluation of photographs taken at baseline and at 6, 12 weeks post final treatment by independent evaluators.|||||
34187550|NCT03216824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group will maintain a dressing on the CVAD exit site as per institutional practice. The second group will not cover the CVAD exit site with a dressing (i.e. no-dressing).||||
34187551|NCT05373914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187552|NCT00842296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187553|NCT04113421|||COHORT||PROSPECTIVE|||||||
34187554|NCT03656380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34187555|NCT02177149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34187556|NCT00240396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187557|NCT00563472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187558|NCT02789293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187559|NCT04395742|||OTHER||RETROSPECTIVE|||||||
34187560|NCT03436082|||COHORT||PROSPECTIVE|||||||
34187561|NCT06251843|||OTHER||PROSPECTIVE|||||||
34187562|NCT03668899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187563|NCT06083740|||COHORT||RETROSPECTIVE|||||||
34187564|NCT06326567|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34187565|NCT06255613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187566|NCT04549129|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187567|NCT02696967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187568|NCT00812019|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34187569|NCT01328067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187570|NCT02702791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187571|NCT05576636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|They did not know if they were in the control and intervention group at the time of randomization.||t|f|f|f
34187572|NCT02153749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187573|NCT02899429|||COHORT||PROSPECTIVE|||||||
33754371|NCT03984799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754372|NCT01391221|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754373|NCT03390205|||CASE_CONTROL||PROSPECTIVE|||||||
33754374|NCT02982694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754375|NCT00645164|NA|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33754376|NCT06060977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33754377|NCT00331643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754378|NCT05840172|RANDOMIZED|CROSSOVER||OTHER||NONE||The condom types will be tested in a 3-way cross-over design where subjects will be randomised to use each of the 3 condom types in a defined order, according to the randomisation schedule.||||
33754379|NCT04305314|||COHORT||PROSPECTIVE|||||||
33754380|NCT00712868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754381|NCT02327754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187574|NCT01096459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187575|NCT01267214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187576|NCT02354196|||COHORT||OTHER|||||||
34187577|NCT02252796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187578|NCT06005207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187579|NCT00666861|||COHORT||CROSS_SECTIONAL|||||||
34187580|NCT02948634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187581|NCT02211170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34187582|NCT00726011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187583|NCT04240548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187584|NCT05272501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34187585|NCT00238641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187586|NCT02611583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187587|NCT02612519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187588|NCT02469311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187589|NCT03888417|||COHORT||RETROSPECTIVE|||||||
34187590|NCT01021085|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754382|NCT00630110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754383|NCT06574815|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33754384|NCT00377325|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33754385|NCT00952822|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33754386|NCT06580977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754387|NCT01420848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754388|NCT03531320|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1 of the study comprises a sequential dose escalation to identify dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD), if any, of D07001-softgel in patients with unresectable locally advanced or metastatic GI cancer. Part 1 will follow a 3+3 dose escalation scheme at predefined dose levels. There will be sequential cohorts of 3 to 6 patients each with increasing doses of 40 mg, 60 mg, 80 mg, 120 mg, and 160 mg per cohort.~In Part 2 of the study, D07001-softgel will be administered at the 2 dose levels selected for expansion from Part 1 of the study."||||
33754389|NCT02115594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754390|NCT03190538|||COHORT||PROSPECTIVE|||||||
33754391|NCT03064516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two arms: Endocrowns vs partial ceramic restoration with post|t|f|f|t
33754392|NCT05047198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, vanguard non-inferiority, randomized controlled trial||||
33754393|NCT05691257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754394|NCT04679090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33754395|NCT06336668|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Randomizing the participants to either Bovine-HMF or Human Milk based-HMF will mask the Investigator|Prospective randomized-controlled crossover trial comparing 2 different HMFs and 2 intestinal rSO2S periods in random order: 6 hours while on B-HMF and 6 hours on H-HMF with at least 6 hours washing period|f|f|t|f
33754396|NCT05813353|||COHORT||PROSPECTIVE|||||||
33870025|NCT04796051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An external assessors would be invited to assess the study's participants before and after the treatment. The extensor assessor would be blind to which group he/she is assessing.|61 healthy individuals aged 18-65 are planned to participate in our study. Each case will fill out a questionnaire and will be subjected to a detailed examination by checking whether there have any factors that would cause the participant to be excluded from the study. Participants meeting the criteria will be divided into two groups according to their degrees of craniovertebral angle (CVA) after their participation in the study is approved. Neck Injury Index: The scale consists of 20 questions, the intensity of the pain; researches in terms of recreational, professional, social and daily life functions and emotional factors. Each question consists of a 10 cm long visual analog scale. CVA above 52 degrees will be considered as normal head posture, while less than 48 degrees will be considered as forward head posture.|f|f|f|t
33870026|NCT02245438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870027|NCT05075525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded to allocation and outcomes measures.||t|f|f|f
33870028|NCT02652338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870029|NCT02289430|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870030|NCT01314963|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The unit of study in this trial was sentinel lymph nodes (SLNs) rather individual participants. with the comparison conducted by evaluation of each SLN with the prototype intraoperative handheld gamma camera (pIHGC) and standard of care intraoperative gamma probes (GP).||||
33870031|NCT05032625|||COHORT||PROSPECTIVE|||||||
33870032|NCT06502613|||COHORT||PROSPECTIVE|||||||
33870033|NCT02877693|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870034|NCT05513937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870035|NCT00546767|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34187591|NCT01424215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187592|NCT02885025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187593|NCT05067699|||CASE_CONTROL||PROSPECTIVE|||||||
34187594|NCT05243732|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will be randomised into two groups, mindful music or music listening in a 1:1 ratio using a randomisation software (https://www.randomizer.org/) and block randomisation to ensure equal distribution of groups between age and number of years living with a visual impairment. The researchers who are managing and running the study will not be blinded to the assignment of the groups. The participants will not be blinded to their allocated group, as participants would clearly know if they listened to their own preferred music alone or with mindfulness instructions. However, the researchers will blind the participants from the study hypothesis and which listening group is the control condition to minimise risk of bias.|Feasibility and acceptability pre/post-test design|f|f|f|t
34187595|NCT04808661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187596|NCT03256916|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two study arms. If patient is randomized to standard arm patient will receive concurrent chemoradiation and brachytherapy. If patient is randomized to nelfinavir arm then nelfinavir will be started at the dose of 1250 mg bid 5-7 days prior to standard treatment||||
34187597|NCT02396095|||COHORT||PROSPECTIVE|||||||
34187598|NCT05982405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.||t|f|f|f
34187599|NCT02446119|||COHORT||PROSPECTIVE|||||||
33754397|NCT00009828||||TREATMENT||||||||
33754398|NCT00683644|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|placebo pill||t|f|t|f
33754399|NCT04273230|||OTHER||CROSS_SECTIONAL|||||||
33870036|NCT05171491|||COHORT||PROSPECTIVE|||||||
33870037|NCT05992870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870038|NCT04770389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablet made to resemble active|Placebo-Controlled, Double-Blind, Randomized|t|t|t|t
33870039|NCT00273975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870040|NCT01301950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870041|NCT04173676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The sentinel lymph nodes are observed by submucosal injection of ICG||||
33870042|NCT01391286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870043|NCT01171222|||COHORT||PROSPECTIVE|||||||
33870044|NCT03418129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870045|NCT01210807|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870046|NCT02884063|||COHORT||PROSPECTIVE|||||||
33965773|NCT02205866|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965774|NCT05998733|||COHORT||RETROSPECTIVE|||||||
34187600|NCT04858022|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|All perceptual ratings will be obtained from blinded, skilled clinician listeners recruited through online crowdsourcing. Following protocols refined in previous published research, binary rating responses (1=correct; 0=incorrect) will be aggregated over at least 9 unique listeners per token.|Children with residual speech errors (RSE) and typical perception will assigned to a randomized controlled trial measuring the efficacy of online visual-acoustic biofeedback treatment relative to a waitlist comparison condition. Treatment will last a total of 20 weeks. The investigators will randomly assign 20 children to receive 10 weeks of biofeedback training via video call followed by 10 weeks in a no-treatment phase; 20 children will receive the same phases in reverse order. Children with RSE may vary in pre-treatment severity, and the extent to which they can approximate /r/ may be an important indicator of subsequent treatment response. Therefore, a blocked randomization procedure will be used to protect against a situation where treatment groups are unbalanced with respect to pre-treatment severity.|f|f|f|t
34187601|NCT04788706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187602|NCT01324414|||COHORT||PROSPECTIVE|||||||
34187603|NCT02722083|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34187604|NCT02602210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34187605|NCT01993121|NA|SINGLE_GROUP||||NONE||||||
34187606|NCT00540085|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34187607|NCT05139004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187608|NCT04670367|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|t|f|t
34187609|NCT05322395|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"A two-arm parallel group, two-centre randomised controlled trial of 0-1-hour high sensitivity troponin T (hs cTnT) compared to a 0-3-hour pathway as rules for rapid discharge of suspected ACS. (both incorporating single presentation sample limit of detection (LOD) high sensitive troponin as a rule for discharge, or cut-off selected by manufacturer).~The power of the study is on safety rather than percent discharge achieved by 4 hours as this is the primary focus for clinicians and health care institutions. (By virtue of the earlier sampling the 0-1 hour troponin sampling is likely to allow greater discharges by 4 hours and the sample size for safety easily accommodates this aspect)."||||
34187610|NCT05243511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34187611|NCT01583296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187612|NCT05417919|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34187613|NCT02897856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187614|NCT04591353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Upon enrollment in the study, participants will be randomized 1:1 to either the investigational group (PENG Block group) or the control group (No Block group). Participants will be randomized using a random number generator. The randomization will be performed using computer-generated random numbers. The study will follow a 1:1 allocation ratio for the intervention (PENG) and control (No-PENG). A random permuted block will be used to reduce the predictability of allocation. The randomization sequence will be generated using computer software using a block randomization method where blocks are variable in size (minimum block size four). The study will use a sealed opaque envelope as method to comply with allocation concealment."||t|f|t|t
34187615|NCT02991872|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34187616|NCT05751603|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34187617|NCT02470650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187618|NCT00534482|RANDOMIZED|FACTORIAL||||NONE||||||
33870047|NCT05167682|||COHORT||PROSPECTIVE|||||||
33870048|NCT00809666|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33870049|NCT05172414|||CASE_ONLY||PROSPECTIVE|||||||
33870050|NCT03370120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870051|NCT02153528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965775|NCT04117152|||COHORT||PROSPECTIVE|||||||
33965776|NCT02807324|||COHORT||PROSPECTIVE|||||||
33965777|NCT02175654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965778|NCT06427330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33965779|NCT04495387|||COHORT||PROSPECTIVE|||||||
33965780|NCT05719610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066878|NCT05831709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066879|NCT03911947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||monitoring of treatment of patients with respiratory failure, the list of therapeutic measures which includes vibroacoustic therapy||||
34066880|NCT02839382|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34187619|NCT01940796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187620|NCT01469715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187621|NCT00241839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187622|NCT01033448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187623|NCT02127697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187624|NCT01538758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187625|NCT00675610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34187626|NCT03860493|||COHORT||PROSPECTIVE|||||||
34187627|NCT03535948|||COHORT||RETROSPECTIVE|||||||
34187628|NCT05675969|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A matching will be performed at inclusion between the two groups on gestational age according to two categories: 23-27+6 and 28-31+6 amenorrhoea weeks||||
34187629|NCT00558649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34187630|NCT05829226|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A Phase 1 open-label, multi-center study. The 4+2 algorithm-based dose-escalation design in single agent LYT-200 and in combination with venetoclax and/or HMAs will be used to help identify the recommended Phase 2 dose (RP2D). Up to 6 patients per single treatment Cohorts 1-5 will receive infusions of LYT-200 every week (QW). Up to 6 patients per combination Cohorts 1-4 will receive infusions of LYT-200 QW and oral venetoclax every day and/or HMAs for 7 days (azacitidine) or 5 days (decitabine) per cycle.||||
34187631|NCT04510441|||COHORT||RETROSPECTIVE|||||||
34187632|NCT01000792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187633|NCT02424604|||COHORT||RETROSPECTIVE|||||||
34187634|NCT00041743|RANDOMIZED|PARALLEL||TREATMENT||||||||
34187635|NCT04690452|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single|Medical students during academic year 2020-21 will be asked to participate in the present study. Once inclusion criteria are met, each participant will be randomly assigned to the experimental group or waitlist control. Randomization will be performed by using a computer-generated sequence|f|f|f|t
34187636|NCT03071042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187637|NCT04822506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187638|NCT06290570|||COHORT||PROSPECTIVE|||||||
34187639|NCT04919200|||COHORT||RETROSPECTIVE|||||||
34187640|NCT04670471|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34187641|NCT02676141|||COHORT||PROSPECTIVE|||||||
34187642|NCT03956446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187643|NCT05895812|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Parallel||||
34066881|NCT06011096|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34066882|NCT05880225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066883|NCT02003261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066884|NCT06137911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066885|NCT06363994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870052|NCT05631392|||OTHER||PROSPECTIVE|||||||
33870053|NCT02447055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870054|NCT06264882|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33870055|NCT05087355|||COHORT||RETROSPECTIVE|||||||
33870056|NCT01664988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187644|NCT05467969|||COHORT||PROSPECTIVE|||||||
33870057|NCT06305494|||OTHER||CROSS_SECTIONAL|||||||
33870058|NCT06340048|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870059|NCT01232543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870060|NCT04405687|||OTHER||RETROSPECTIVE|||||||
33870061|NCT05403320|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter cluster randomized controlled and open-label trial. Because intubation is an urgent intervention in critically ill patients patients with acute respiratory failure, individual randomization is considered too complex and we predetermined cluster of 9 consecutive patients, stratified by centers, with each cluster being assigned to one of the study groups.||||
33870062|NCT03597230|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870063|NCT02883023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33870064|NCT03327012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870065|NCT06422975|||OTHER||PROSPECTIVE|||||||
33870066|NCT00063141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870067|NCT05319184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34187645|NCT02019797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870068|NCT02861768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870069|NCT03778411|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870070|NCT01671540|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33870071|NCT05326009|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187646|NCT01506804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870072|NCT01943526|||CASE_ONLY||OTHER|||||||
33870073|NCT01543152|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870074|NCT06360991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870075|NCT01704586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870076|NCT01223170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33870077|NCT03305991|||COHORT||PROSPECTIVE|||||||
34187647|NCT02550834|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33870078|NCT02495155|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187648|NCT03016052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870079|NCT00653614|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33870080|NCT03803072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894121|NCT05718115|||CASE_ONLY||PROSPECTIVE|||||||
33894122|NCT03306537|||COHORT||PROSPECTIVE|||||||
33894123|NCT06219538|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The participants consist of women undergoing planned CD for reasons unrelated to this study.||||
33894124|NCT00235157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894125|NCT00934895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965781|NCT00004187||||TREATMENT||||||||
34187649|NCT01576900|||CASE_CONTROL||PROSPECTIVE|||||||
34187650|NCT03254589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187651|NCT02131649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187652|NCT01818011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187653|NCT04433416|||COHORT||PROSPECTIVE|||||||
34187654|NCT02353624|||||PROSPECTIVE|||||||
34187655|NCT00221117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187656|NCT05219552|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||20 participants recruited to the intervention group at one clinic. 20 participants simultaneously recruited to a control group at a different (but matched) clinic.||||
34187657|NCT04350762|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187658|NCT06411314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187659|NCT02560545|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34187660|NCT01792752|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187661|NCT02605460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187662|NCT01651637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187663|NCT06400381|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be conducted using a 1-month prospective quasi-experimental design. The participants in this study are Jordanian pediatric nurses from different pediatric departments four major hospital in northern and central Jordan. Based on G power a satisfactory sample size for two groups (experimental group and control group) with a power level of 0.8, significant alpha level of 0.05, and a moderate effect size of 0.25 will be at least 80 participants for each group and 160 in total. To count for potential attrition, the investigators added additional 30% of the total sample to the participant resulting in a total sample size of 208 (104 in each group).||||
34187664|NCT01483326|||COHORT||PROSPECTIVE|||||||
34187665|NCT00834093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187666|NCT03574012|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34187667|NCT01817803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187668|NCT01748513|||CASE_CROSSOVER||PROSPECTIVE|||||||
34187669|NCT02338271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187670|NCT00705549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187671|NCT01615913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187672|NCT04469764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187673|NCT01791712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066886|NCT06403202|||CASE_ONLY||PROSPECTIVE|||||||
34066887|NCT00546689|||CASE_ONLY||PROSPECTIVE|||||||
34066888|NCT00456820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066889|NCT05096962|||COHORT||PROSPECTIVE|||||||
34066890|NCT01135836|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34066891|NCT02087943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066892|NCT02110628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066893|NCT01983098|||||PROSPECTIVE|||||||
34066894|NCT00477204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066895|NCT02377128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066896|NCT02452814|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066897|NCT03268005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34066898|NCT02034760|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34066899|NCT06229899|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34066900|NCT03611101|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|The collaborator is responsible for the masking process.|Subjects will be enrolled and randomized via interactive response technology (IRT) to receive BMS-9860936 Dose Level 1 , BMS-986036 Dose Level 2, BMS-9860936 Dose Level 3 or matching placebo in a 1:1:1:1 ratio. in both Stage 3 liver fibrosis and cirrhosis cohorts.|t|t|t|t
34066901|NCT04962035|||COHORT||PROSPECTIVE|||||||
34066902|NCT01891903|||||PROSPECTIVE|||||||
34066903|NCT02882464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066904|NCT04849611|||OTHER||PROSPECTIVE|||||||
34066905|NCT00143468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870081|NCT04697238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects might be able to determine if they are in the control group or intervention group since it is difficult to mask the difference between a heavy and a light weight vest. Therefore, intervention in this study won't be masked for the participants. However, group affiliation will be masked for outcomes assessors.|A parallel study design will be used in which the control group is to be compared with the intervention group. To avoid the risk of carry-over effects, the investigators have decided to not use a crossover design. This could have decreased the variation of the measurement values and increased the power of the study. However, the investigators believe there could be a risk of a carry-over effect with a cross over design. As this is a new effect in clinical studies, the investigators have no information about the wash-out time needed to avoid this problem.|f|f|f|t
33870082|NCT06256315|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33870083|NCT02921074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870084|NCT00331695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870085|NCT04702802|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot, controlled, open, comparative, randomized clinical trial.||||
33870086|NCT01010698|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870087|NCT01439542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870088|NCT05905120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870089|NCT05498350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870090|NCT05691374|||COHORT||PROSPECTIVE|||||||
33870091|NCT04974554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study Biostatistician will conduct the randomization of 180 subjects, 90 subjects per condition (FIT vs. HBFS) using a 1:1 allocation ratio. Research Assistants collecting data will be kept blind to participants' randomization status to the extent possible in a behavioral clinical trial.|The proposed study follows a 2 (condition: FIT Families \[FIT\], and HBFS x 4 (time: baseline \[T1\], 3-month mid-treatment \[T2\], 6-month end of treatment \[T3\], and 12-months follow-up \[T4\]), with random assignment of 180 caregivers/youths to one of the two treatment conditions. Repeated measures of caregiver and youth percent overweight (primary outcome) and physical activity (secondary outcome) will be collected at baseline (T1), and each of the 3 post-randomization time points (T2-T4).|t|f|f|f
34066906|NCT04555252|||COHORT||PROSPECTIVE|||||||
34066907|NCT00384371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066908|NCT00731731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066909|NCT05601388|||OTHER||PROSPECTIVE|||||||
34066910|NCT01421745|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34066911|NCT02679456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34066912|NCT05318833|NA|SINGLE_GROUP||TREATMENT||NONE||The study was divided into two phases, the dose escalation phase and the dose extension phase of HRS7415 in subjects with advanced malignant tumors.||||
34066913|NCT03120494|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will receive same treatment with study drug||||
34066914|NCT02548715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34066915|NCT02500771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754400|NCT02822222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This study was a double-blind, placebo-controlled study. The Investigational Site pharmacist was not blinded and was responsible for dispensing the appropriate study drug based upon the randomization schedule and ensuring that the remaining Investigational Site personnel were blinded to the drug.~Total serum magnesium was used to monitor for magnesium toxicity and subjects with levels ≥ 5 mg/dL were to be discontinued. Thus, there was the potential for these measurements to unblind the Principal Investigator. Due to the pre-existing endogenous levels of total serum magnesium and urine magnesium and the relatively large variability in values between subjects, review of these numbers would not necessarily have suggested one treatment arm over the other. To minimize the impact of such potential unblinding on the ABPM endpoints, a centralized ABPM reader was used and the reader was blinded to the total serum magnesium and urine magnesium values."||t|f|t|t
33754401|NCT00825266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754402|NCT03157518|NA|SINGLE_GROUP||OTHER||NONE||||||
33754403|NCT03978234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066916|NCT03792607|||CASE_CONTROL||PROSPECTIVE|||||||
34066917|NCT03363308|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a cluster-randomized trial in phase I and interrupted time series in phase II||||
34066918|NCT02443272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066919|NCT01048099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066920|NCT04170101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||a continuous deep NMB (group A) versus a non deep NMB (group B) having a moderate to superficial block imitating common practice today as control group.|t|f|t|t
34066921|NCT05180565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066922|NCT05273099|||COHORT||RETROSPECTIVE|||||||
34066923|NCT05292612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34066924|NCT06352125|||OTHER||PROSPECTIVE|||||||
33754404|NCT04219605|||COHORT||PROSPECTIVE|||||||
33754405|NCT04578327|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Aim 1 - An experiment will take place grouped by the type of prosthesis used by upper limb amputees Aim 3 - An experiment will take place grouped by type of sensory restoration||||
33870092|NCT02198625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870093|NCT03181230|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870094|NCT05836142|NA|SINGLE_GROUP||TREATMENT||NONE||Pretest posttest of bilateral Flexor digitorum Brevis progressive pressure release intervention||||
34066925|NCT04849585|||COHORT||PROSPECTIVE|||||||
33870095|NCT05026281|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|No masking|H0 : blood analyse with Quantra® H0+30 min : blood analyse with Quantra® D0+30 : end of study||||
33870096|NCT05947994|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870097|NCT03839173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870098|NCT05377268|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The subject and the investigators will be blinded to the order of the two crossover protocols|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally and by written instruction (recorded on a standardized grid as in our lab's previous work, see Appendix)11 to inject insulin in sites of subclinical lipohypertrophy (LH protocol) or normal subcutaneous tissue (Normal protocol). During each protocol, each subject will have glycemic variability measured.|t|f|t|f
33965782|NCT04888741|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients eligible for entry into the trial will be randomised on a 1:1:1 ratio to receive either one of the experimental treatment arms or the control arm.||||
34066926|NCT05704283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34066927|NCT01016574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34066928|NCT04775719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Members of the care team and investigator will be blinded from knowing which study arm the patient is in and what their predicted functional ability is, to ensure standard of care is not influenced in any way.||f|t|t|f
34066929|NCT06155032|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Drug: Best medical management Procedure: Endovascular therapy|f|f|f|t
34066930|NCT05743647|||COHORT||PROSPECTIVE|||||||
34066931|NCT00288444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066932|NCT01387945|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34066933|NCT03518502|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sorafenib monotherapy vs. transarterial chemoembolization-sorafenib sequential therapy||||
34066934|NCT01590316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34066935|NCT01066871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066936|NCT04702997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34066937|NCT06433817|||COHORT||PROSPECTIVE|||||||
33754406|NCT01298960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965783|NCT03573115|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965784|NCT04212182|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33965785|NCT03223285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965786|NCT00527397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894126|NCT06033443|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The aim of the research was to reduce the bias by using a single-blind technique|Marmara Creative Thinking Disposition Scale and Self-Regulated Learning Scale for Clinical Nursing Practices will be administered to the students who have been informed about the research, after their individual consent has been obtained. Students participating in the research will take 4 hours of theoretical and 4 hours of clinical practice courses for 12 weeks, and a patient education plan will be created in clinical practices.||||
33894127|NCT05706714|||COHORT||CROSS_SECTIONAL|||||||
34066938|NCT03107533|||COHORT||PROSPECTIVE|||||||
34066939|NCT03927833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pragmatic randomized clinical trial addressing patient safety.|f|f|f|t
34066940|NCT06298578|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34187674|NCT04723277|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Complete double-blinding is not possible in this mental health intervention trial as trial participants and the intervention team will be aware of their status. However, to minimize bias and the risk of unmasking, the field team will be separated into intervention and data collection teams. The data collection team will be blinded to intervention allocation at the cluster-level and treatment status at the individual child level. Additionally, while over time it may be likely that children and caregivers are aware of the intervention delivered, they will not be explicitly informed of this allocation.|The study will be conducted as a stepped-wedge cluster randomized trial. Given the nature of the intervention, each school will be a cluster and each step will be an academic year. Randomization will occur at the school level. All schools will initially receive the control condition (EUC) and will be randomly and sequentially transitioned into the intervention arm. A qualitative exploration of context and process will be embedded within the framework of the randomized control trial. An embedded approach has been chosen to facilitate a high level of integration between the qualitative and quantitative components of the study.|f|f|f|t
34187675|NCT00915382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894128|NCT02201940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894129|NCT00932087|||CASE_CONTROL||PROSPECTIVE|||||||
34187676|NCT02584010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187677|NCT03385980|||OTHER||PROSPECTIVE|||||||
34187678|NCT05080335|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will not be aware of which of the four arms they will be assigned to|RCT of three different education / training approaches|t|f|t|f
34187679|NCT01368913|||COHORT||PROSPECTIVE|||||||
34187680|NCT01227993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965787|NCT03533530|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The Epilepsy Surgery Group make their decision about the surgical approach only with knowledge of the LD-EEG without ESI (and knowledge of non EEG investigations). Thereafter the LD ESI results are revealed and the clinical decision is revised. Finally the HD ESI results are revealed and the clinical decision is revised.|Evaluation of low-density (LD, 25 channels) and high-density (HD, 256 channels) electrical source imaging (ESI) in epilepsy surgery|f|f|f|t
34187681|NCT03862911|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is a phase III multicentre randomized trial. Subjects will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease.~Subjects will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis: histology (Group 1: prostate, breast, or renal; Group 2: all others), and disease-free interval (defined as time from diagnosis of primary tumor until first detection of the metastases being treated on this trial; divided as ≤2 years vs \>2 years)."||||
33965788|NCT01347879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965789|NCT04354402|||COHORT||RETROSPECTIVE|||||||
33965790|NCT00069160|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965791|NCT02309918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965792|NCT03438305|||OTHER||PROSPECTIVE|||||||
33965793|NCT01220089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965794|NCT02289027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33965795|NCT02194803|||COHORT||PROSPECTIVE|||||||
34066941|NCT01765608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066942|NCT02812225|||COHORT||PROSPECTIVE|||||||
34066943|NCT00179764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066944|NCT02888275|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34066945|NCT03577132|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective study||||
34187682|NCT01364168|||COHORT||PROSPECTIVE|||||||
34187683|NCT06107881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled non-inferiority trial|f|f|f|t
34187684|NCT01594788|||COHORT||PROSPECTIVE|||||||
34187685|NCT06042062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187686|NCT04926389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187687|NCT05172908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187688|NCT01103193|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34187689|NCT01524796|||COHORT||PROSPECTIVE|||||||
33894130|NCT01931514|RANDOMIZED|||||||||||
33965796|NCT01308983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965797|NCT05651529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor) Investigators, participants and outcome assessors will be fully blinded.|Crossover Assignment, Each participant will have to do the 2 Acute supplementation interventions|t|f|t|t
34187690|NCT04952948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34187691|NCT00594815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187692|NCT04793737|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II open-label multicenter trial||||
34187693|NCT04919798|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187694|NCT03869697|NA|SEQUENTIAL||TREATMENT||NONE||||||
34187695|NCT04553380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187696|NCT01463085|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34187697|NCT03179319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187698|NCT03749837|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187699|NCT04455815|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34187700|NCT02293317|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187701|NCT05136950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187702|NCT02052999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754407|NCT04727151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||In Phase 1, escalating doses of TAC01-HER2 will be evaluated to identify the RP2D of the monotherapy arm and the combination arm using the classic keyboard design. In Phase 2, dose expansion groups will further evaluate the safety, efficacy, and PK of the MTD or RP2D for TAC01-HER2 as a monotherapy and in combination with pembrolizumab in subjects with gastric and gastroesophageal adenocarcinoma.||||
33754408|NCT05944965|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|placebo is open-label and optional||t|t|t|t
33754409|NCT01241357|||||PROSPECTIVE|||||||
33754410|NCT01441739|||CASE_CONTROL||PROSPECTIVE|||||||
33754411|NCT01696487|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33754412|NCT04380922|||OTHER||PROSPECTIVE|||||||
33754413|NCT04512521|||COHORT||PROSPECTIVE|||||||
33870099|NCT05307484|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization sequence was prepared by the bio-statistician who was not involved in the enrollment of the participants. The outcome data was collected via a participant-administered questionnaire on an online secured platform, without contact with the study members. All data were de-identified and the statistical analysis was performed by the bio-statistician, who was blinded to group allocation, only after the completion of enrollment of all participants. The principal investigator was not involved in the enrollment or randomization process of participants in this study.|A randomized controlled trial was conducted among volunteer adults who were visiting a regional primary care clinic in Sengkang, Singapore. 400 participants were randomly allocated to receive information regarding dengue prevention from either playing a serious game (intervention) or visiting a dengue prevention website (control). Before and after receiving information on dengue prevention, participants completed a self-administered questionnaire within a 2-week interval to assess the knowledge, attitude and practice (KAP) score and their interest to vaccinate against dengue. Participants, who played serious game, evaluated the game with the Systems Usability Score (SUS).|f|f|t|t
33870100|NCT00018655|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33870101|NCT02407327|||COHORT||PROSPECTIVE|||||||
33870102|NCT00345228|||DEFINED_POPULATION||OTHER|||||||
33870103|NCT03454802|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33870104|NCT00538798||||TREATMENT||||||||
33870105|NCT02783443|||COHORT||PROSPECTIVE|||||||
34187703|NCT00750503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187704|NCT06405724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187705|NCT01262196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187706|NCT01755819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187707|NCT01449968|||COHORT||PROSPECTIVE|||||||
34187708|NCT03339219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754414|NCT02681913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754415|NCT03236298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754416|NCT00846872|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33754417|NCT01758354|NA|SINGLE_GROUP||SCREENING||NONE||||||
33754418|NCT05609084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754419|NCT01204801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754420|NCT01190696|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754421|NCT00381966|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33754422|NCT00962195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754423|NCT03369717|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754424|NCT03912844|||COHORT||PROSPECTIVE|||||||
33754425|NCT06292156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754426|NCT02985866|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33754427|NCT02881723|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754428|NCT03705208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754429|NCT00801008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754430|NCT00654810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754431|NCT00097331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754432|NCT02870140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754433|NCT02723864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754434|NCT06202326|||COHORT||PROSPECTIVE|||||||
33754435|NCT03520166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Type inclusion was consecutively type|Quasi-experimental, longitudinal, pre-/post-. Level of evidence II/III.||||
33754436|NCT00180726|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754437|NCT05941754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33754438|NCT05769985|||COHORT||PROSPECTIVE|||||||
33754439|NCT05638399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33754440|NCT05032209|||COHORT||PROSPECTIVE|||||||
33754441|NCT04064151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33754442|NCT05649111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"* Group A (FDA dose): will receive Difluprednate 4 times per day for 1 week, then twice per day for 1 week and then once per day for 5 days starting 24 hours after the operation~* Group B will receive Difluprednate 3 times per day for 4 days, then twice per day for 4 days and then once per day for 4 days starting 4 hours after the operation"|t|t|t|f
33754443|NCT04946968|NA|SINGLE_GROUP||TREATMENT||NONE||"Eligible subjects will be allocated to one of four cohorts based on tumour type and presence of specific biomarker. All subjects in cohorts 1 to 3 will have tumours that demonstrate low EGFR-AS1 lncRNA expression as determined through a companion diagnostic biomarker suite (consisting of three components - EGFR Q787Q AA genotype, low AS1 lncRNA levels and increased EGFR isoform D/A ratio).~* Cohort 1 will consist of squamous NSCLC patients with the presence of at least 1 out of 3 in the biomarker suite.~* Cohort 2 will consist of HNSCC patients with the presence of at least 1 out of 3 in the biomarker suite.~* Cohort 3 will consist of any other solid tumour with the presence of at least 1 out of 3 in the biomarker suite.~* Cohort 4 will have tumours that demonstrate the presence of a novel emerging biomarker including but not limited to NRG1 fusions and specific MET SNPs."||||
33754444|NCT06213948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33754445|NCT06457555|||OTHER||CROSS_SECTIONAL|||||||
33754446|NCT06560047|RANDOMIZED|PARALLEL||TREATMENT||NONE||The DanAblate-HF trial is a pragmatic, investigator-initiated, prospective, multicenter, open-labeled, randomized, controlled trial. Patients will be randomized 1:1 to either early catheter ablation or standard treatment.||||
33754447|NCT02522936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33754448|NCT03928080|||OTHER||CROSS_SECTIONAL|||||||
33754449|NCT02925676|NA|SINGLE_GROUP||OTHER||NONE||||||
33754450|NCT03818282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754451|NCT03833882|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33754452|NCT05138718|||CASE_ONLY||PROSPECTIVE|||||||
33754453|NCT03910413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754454|NCT01093612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754455|NCT05066464|||CASE_ONLY||PROSPECTIVE|||||||
33754456|NCT04171102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33754457|NCT01429129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33754458|NCT06063304|||OTHER||PROSPECTIVE|||||||
33754459|NCT04636970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33754460|NCT03836131|||COHORT||RETROSPECTIVE|||||||
33754461|NCT00744484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187709|NCT00404222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34187710|NCT04880252|||CASE_ONLY||RETROSPECTIVE|||||||
34187711|NCT03212144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Data collection staff is masked||f|f|t|f
34187712|NCT02185495|NA|SINGLE_GROUP||SCREENING||NONE||||||
34187713|NCT04922567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187714|NCT02721966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"498 patients were randomized in this Phase 3b trial. 5 (of 503) were mis-randomized, i.e. received randomization number but never received study medication.~This was a 52-week, randomized, double-blind, double-dummy, placebo-controlled, multicenter study to assess the efficacy of secukinumab 150 mg or 300 mg in patients with AxPsA who had an inadequate response to NSAIDs. The study had 2 treatment periods; a placebo-controlled period from Baseline to Week 12 followed by an active treatment period from Week 12 to Week 52.~At Week 12, patients randomized to placebo at Baseline were re-randomized (1:1) to active treatment with secukinumab 150 mg or secukinumab 300 mg."|t|t|t|t
34187715|NCT05210933|||COHORT||PROSPECTIVE|||||||
34187716|NCT05641480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187717|NCT03678220|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187718|NCT00643721|||COHORT||PROSPECTIVE|||||||
34187719|NCT02657967|||COHORT||PROSPECTIVE|||||||
34187720|NCT04509219|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, phase 1 study of methylprednisolone pulse therapy safety in treatment of aneurysm or coronary artery dilation of Kawasaki disease.||||
34187721|NCT03765034|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34187722|NCT03212781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187723|NCT03527823|||COHORT||PROSPECTIVE|||||||
34187724|NCT04682054|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187725|NCT00035932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187726|NCT05741749|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Clinical Trial|f|f|f|t
33754462|NCT06056375|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Since the study is a waitlisted control, all participants are aware of which condition they are in at any time.|Waitlist control design||||
33894131|NCT02717507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34066946|NCT05163730|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894132|NCT02302495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754463|NCT05482360|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||An interrupted-time series design will be used; this is a quasi-experimental design that compares data before an intervention is introduced to data after the intervention is introduced, and controls for time trends. Three rounds of interrupted-time series to evaluate three PrEP optimization interventions, identified by stakeholders based on qualitative information. Each of the three rounds of interrupted-time series evaluations will include 4 facilities receiving the intervention and 4 facilities serving as an ongoing concurrent comparator group; these 4 facilities will not receive any of the packages of interventions, but will undergo the same data collection procedures.||||
33754464|NCT04406948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"* Treatment with current antiepileptic therapy 28 days - Various combinations of anti-epileptic (AE) medications~* Add on treatment 42 days (6 weeks) - titration period - MGCND00EP1 or placebo in addition to AE medications.~* Add on treatment 42 days (6 weeks) Maintenance stable treatment period - MGCND00EP1 or placebo in addition to AE medications~* Add on treatment 14 days (2 weeks)- taper - down titration period - MGCND00EP1 or placebo in addition to AE medications~* Follow up 28 days - Standard/ previous AE treatment"|t|t|t|t
33754465|NCT01804920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870106|NCT04526236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The masking will be generated on a research laboratory computer and will be stored in an encrypted file. This information will be known exclusively to a member of the research team present during the surgery, who will hand over preparing the corresponding medicine in a 20 cc syringe and hand it over to the treating anesthesiologist.|Patients will be randomly divided into four groups according to the dose of intravenous methadone to be administered during anesthetic induction, for a total number of 60 patients.|t|t|f|f
33870107|NCT06400173|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870108|NCT01999569|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||f|t|t|t
34187727|NCT03117140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870109|NCT04717518|||COHORT||PROSPECTIVE|||||||
33870110|NCT00988143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187728|NCT04216264|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34187729|NCT00708617|||CASE_ONLY||PROSPECTIVE|||||||
34187730|NCT00183313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870111|NCT01496131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870112|NCT00376116|||||PROSPECTIVE|||||||
33870113|NCT06414525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187731|NCT01808833|||||CROSS_SECTIONAL|||||||
34187732|NCT05037227|||COHORT||PROSPECTIVE|||||||
34187733|NCT01436929|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187734|NCT00916331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187735|NCT01567540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187736|NCT00528034|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187737|NCT05652049|||OTHER||RETROSPECTIVE|||||||
34187738|NCT04115865|||COHORT||PROSPECTIVE|||||||
34187739|NCT05808361|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34187740|NCT01763840|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187741|NCT01710319|||CASE_CONTROL||PROSPECTIVE|||||||
34187742|NCT02670096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187743|NCT06112886|||OTHER||CROSS_SECTIONAL|||||||
34187744|NCT00006206|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34187745|NCT02902146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187746|NCT00851058|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34187747|NCT04433676|||COHORT||OTHER|||||||
34187748|NCT01259960|||COHORT||PROSPECTIVE|||||||
34187749|NCT02541604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870114|NCT00182312|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33870115|NCT02362620|||COHORT||PROSPECTIVE|||||||
33870116|NCT04474795|NA|SINGLE_GROUP||PREVENTION||NONE||Staff participants will complete surveys on diabetes knowledge, attitudes, and self-efficacy before and after completing online training modules on gestational diabetes.||||
33870117|NCT00004754||||TREATMENT||NONE||||||
33870118|NCT02302352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870119|NCT03719690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870120|NCT04512053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870121|NCT06006234|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33870122|NCT00530985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965798|NCT01058382|||COHORT||PROSPECTIVE|||||||
33965799|NCT02309554|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33965800|NCT01133444|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965801|NCT03978169|||CASE_CONTROL||PROSPECTIVE|||||||
33965802|NCT01591486|||CASE_CONTROL||PROSPECTIVE|||||||
33965803|NCT06536634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized controlled Bayesian phase II trial with a follow-up examination after 12 weeks mwas designed. The study participants will be recruited via the University Children's Hospital Bern and the Swiss Cerebral Palsy Registry.|f|f|t|t
33965804|NCT03355859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965805|NCT05078710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187750|NCT00005062|RANDOMIZED|||TREATMENT||||||||
34187751|NCT03067714|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187752|NCT02699424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187753|NCT00002127||||TREATMENT||DOUBLE||||||
34187754|NCT04629092|||OTHER||CROSS_SECTIONAL|||||||
34187755|NCT02350478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187756|NCT04859933|||COHORT||RETROSPECTIVE|||||||
34187757|NCT04628325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187758|NCT02901392|||COHORT||PROSPECTIVE|||||||
34187759|NCT03188419|||COHORT||RETROSPECTIVE|||||||
34187760|NCT06170099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187761|NCT03108443|||CASE_CONTROL||PROSPECTIVE|||||||
34187762|NCT01470118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187763|NCT00158496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187764|NCT05675488|||CASE_CONTROL||PROSPECTIVE|||||||
34187765|NCT00163696|||DEFINED_POPULATION||OTHER|||||||
34187766|NCT05246358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187767|NCT01869764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187768|NCT02009280|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34187769|NCT04976101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187770|NCT01851759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754466|NCT01263951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187771|NCT02162199|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34187772|NCT04365608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187773|NCT02483962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187774|NCT06344962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187775|NCT01576068|NA|SINGLE_GROUP||SCREENING||NONE||||||
34187776|NCT06434142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187777|NCT05595902|||COHORT||CROSS_SECTIONAL|||||||
34187778|NCT06519721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187779|NCT00078897|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187780|NCT05318352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187781|NCT06456502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Assignment to each group will be done by randomization software performed blindly by an external investigator who will not perform the interventions with the patients.~Assessment will be performed by two persons of the team, not involved in the treatment.~Participants will be blinded as they do not feel anything during the stimulation (whether within the active or placebo group), just the care provider will know if the cable is attached or not."|two armed parallel randomized clinical trial|t|f|t|t
34187782|NCT06519071|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187783|NCT03960996|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking will be used in the course of this study.|The patients will be randomized into two parallel groups.||||
34187784|NCT02903329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187785|NCT05259280|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187786|NCT00785642|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187787|NCT01295164|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187788|NCT06521307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The protocol contemplates triple blinding for the intervention. The inclusion and follow-up of patients will be carried out by the team of clinical investigators, who will remain blinded to the assigned group. Assignment to intervention groups will be carried out by an investigator independent of the team of clinical investigators and the clinical management team, who will remain blind to the information and follow-up of the patients. The medical team in charge of hospital treatment (surgery, cardiology, intensive care and nephrology), and the patient himself will remain blind to the assigned intervention group.|The evaluation of normality will be carried out by the Shapiro-Wilks and Kolmogorov-Smirnov tests. The change or delta in the creatinine value from preoperative to 48 hours postoperative will be calculated, said delta will be analyzed with a t-test between the intervention groups. Other variables will also be compared between groups with t-test or U-Mann-Whitney for quantitative variables. Qualitative variables will be analyzed with a Chi-square test between groups. In secondary objectives, biochemical measurements will be correlated with creatinine values with the Pearson or Spearman test as appropriate to the distribution. Statistical package= SPSS version 23. Statistical significance= alpha 0.05|t|t|t|f
34187789|NCT04421703|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187790|NCT03050385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187791|NCT03055130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187792|NCT01809743|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34187793|NCT03308370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187794|NCT03459885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187795|NCT03966638|||COHORT||RETROSPECTIVE|||||||
34187796|NCT00614068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187797|NCT01400880|||CASE_ONLY||PROSPECTIVE|||||||
34187798|NCT05457010|NA|SEQUENTIAL||TREATMENT||NONE||||||
34187799|NCT01607684|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34187800|NCT03079843|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34187801|NCT03416543|||COHORT||PROSPECTIVE|||||||
34187802|NCT01967329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187803|NCT04165694|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a pre-/post-test prospective intervention.||||
34187804|NCT01655004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187805|NCT03994848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187806|NCT05398913|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized crossover study with three arms|t|t|t|t
33754467|NCT04375748|||COHORT||PROSPECTIVE|||||||
33870123|NCT03434171|RANDOMIZED|PARALLEL||TREATMENT||NONE||What is the effect of aerobic exercises with diet modification on hot flushes, lutenizing hormone (L.H) and follicle stimulating hormone (F.S.H) in post-menopausal women||||
33870124|NCT04532476|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|It was determined in advance that the right side of the upper jaw was treated with laser, and the left side was placebo.Placebo side was treated the same way with the difference that the laser was switched off, but with the maintained sound signal, implying laser was working, so that partici-pants were blinded to the allocation of the group, only the operator knew whether the side is laser treated or placebo.|This is a single -blinded, placebo controlled, split-mouth study. The design was split-mouth to eliminate all components related to differences among subjects.|t|f|f|t
33870125|NCT04660513|||CASE_CONTROL||PROSPECTIVE|||||||
33870126|NCT06367075|NA|SINGLE_GROUP||TREATMENT||NONE||cadonilimab (AK104) with adriamycin||||
33870127|NCT01122732|||||PROSPECTIVE|||||||
33870128|NCT01884259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870129|NCT00005798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870130|NCT02422888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870131|NCT02971631|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33870132|NCT02241369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870133|NCT06044207|||COHORT||PROSPECTIVE|||||||
33870134|NCT02910947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33870135|NCT01534312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870136|NCT06024395|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965806|NCT03234582|||OTHER||PROSPECTIVE|||||||
33870137|NCT03331055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant is allocated randomly by staff A, and grouping situation is concealed; Technician (stuff B) or chargeing docotor operates PENS or TENS, or administers oral analgesic medication; Related datas are collected according to perdetermined forms by stuff C; Outcomes are assessed by stuff D.|patients with pancreatic cancer pain|t|t|t|t
33870138|NCT02963116|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33870139|NCT00399789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870140|NCT05122884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacist who does not involve in patient enrollment nor treatment will prepared milrinone or placebo in the identical container, before the study drug will be given to patients, according to their treatment arm.||t|t|t|t
33870141|NCT05471752|||COHORT||CROSS_SECTIONAL|||||||
33870142|NCT06029075|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34187807|NCT00687427|||COHORT|||||||||
34187808|NCT03045796|||COHORT||PROSPECTIVE|||||||
34187809|NCT02795403|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34187810|NCT02945904|||COHORT||PROSPECTIVE|||||||
34187811|NCT06296329|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187812|NCT01077050|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34187813|NCT04712630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187814|NCT04982185|||CASE_CONTROL||RETROSPECTIVE|||||||
34187815|NCT05368012|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive the active MIDCAB block.||||
34187816|NCT04236609|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The staff (i.e. research nurses, research coordinators and other practitioners) involved in the follow-up care of study subjects and the Clinical Events Committee (CEC) adjudicators will be blinded to the patient assignment;|"Target lesions should be treated in accordance with the randomization schedule after meeting the clinical and angiographic inclusion and exclusion criteria following the instruction for use of the study stent.~Additional lesions (other vessels) may be staged up to 45 days post-index procedure but must be treated with the same stent.~Dual antiplatelet therapy must be prescribed in alignment with the Instructions for Use of the DES and the guidelines"|f|t|f|t
34187817|NCT01079299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187818|NCT04960657|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, double-blind, cross-over, placebo-controlled design in healthy volunteers.|t|t|t|t
33870143|NCT02768090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870144|NCT02441049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187819|NCT04910997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187820|NCT01809119|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34187821|NCT00092443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34187822|NCT03082625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical delivery systems and appearance of the product|Randomised placebo-controlled|t|t|t|t
34187823|NCT05494164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants in both groups will be blinded to which treatment arms they will be assigned to till the end of the study.||t|f|f|f
34187824|NCT01684865|||COHORT||PROSPECTIVE|||||||
33754468|NCT04835155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The PIOMI was applied only by the trained researcher, and blind to the nursing staff in charge of care and feeding. No information about the PIOMI was shared with the general staff working in the NICU, and it was performed in the absence of the mothers, although no formal curtain was used for additional blinding.|"Sample The sample consisted of a total of 60 preterm infants all born after 26 weeks PMA with 30 each in the experimental and control group. Subjects were enrolled when they reached 29 or 30 weeks PMA and met inclusion criteria, and whose parents gave written consent.~Random assignment to groups was performed by a research assistant, who was not involved in the research but worked in the same unit as the researchers, using the online software at https://www.randomizer.org. The primary nurses were blinded to groups, and the parents stepped out during therapy to assist in blinding."|t|f|f|t
33754469|NCT06286150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754470|NCT02660710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754471|NCT01799564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33754472|NCT00616187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754473|NCT00970879|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754474|NCT01459510|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33754475|NCT02683850|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33754476|NCT06515379|||COHORT||RETROSPECTIVE|||||||
34066947|NCT01059019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33754477|NCT02813148|||COHORT||RETROSPECTIVE|||||||
33754478|NCT05361226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Forty participants were allocated to two study groups via the coin-tossing technique.|f|f|t|t
33754479|NCT05279781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participant will not be informed whether complete pulp removal or partial treatment was done.~Operator and investigator cannot be blinded due to differences in the procedure and it will be evident on the radiographs, so it cannot be masked during radiographic evaluation."|Two groups. One will receive root canal treatment t and the other will receive pulpotomy.|t|f|f|f
33754480|NCT00119548|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33754481|NCT01813474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754482|NCT03748290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo pills will be purchased from Trilog, which is licensed and licensed by the Ministry of Health to prepare random drug kits (the company has an agreement with Sheba). The drug will be used by the company that supplies the drug and placebo, so that the researchers in the study did not know which treatment was given to each patient. This information will be received at the end of the study, or if the subjects for any reason participate in the research||t|t|t|t
33754483|NCT01841346|||CASE_ONLY||PROSPECTIVE|||||||
33754484|NCT00824226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754485|NCT00144274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754486|NCT00014638||||TREATMENT||||||||
33754487|NCT04085783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754488|NCT01625351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066948|NCT04170036|||COHORT||CROSS_SECTIONAL|||||||
33754489|NCT03545867|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Static first arm with randomized remaining three arms.||||
34066949|NCT05187559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two study groups, 60 patients per group. Patients will be randomly assigned to first of second study group.||||
33754490|NCT01093118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754491|NCT01281644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066950|NCT00857961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066951|NCT04150653|||CASE_ONLY||PROSPECTIVE|||||||
34066952|NCT05176925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754492|NCT03032055|||COHORT||PROSPECTIVE|||||||
33754493|NCT02357251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34066953|NCT03630133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066954|NCT02673294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870145|NCT00082524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870146|NCT00002364||||TREATMENT||||||||
33870147|NCT03683277|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients will receive the same treatment until disease progression or end of study||||
33870148|NCT00077363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870149|NCT03640598|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870150|NCT02330978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870151|NCT01033825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870152|NCT02618655|||COHORT||PROSPECTIVE|||||||
33870153|NCT05429788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870154|NCT01059110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870155|NCT01330342|||CASE_CONTROL|||||||||
33870156|NCT03939845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870157|NCT02366559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870158|NCT00802204|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Lean who are age and sex similar to obese will complete baseline outcome measurements only.~Obese will complete baseline outcome measurements then the VLCD intervention with post outcome measurements ."||||
33870159|NCT01396174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34151699|NCT05979168|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will use a two-arm parallel-group, individually randomized control trial design to test the effectiveness of a TelTex4BP intervention compared to standard care at one year among diagnosed patients of HTN.||||
34151700|NCT04293302|||COHORT||RETROSPECTIVE|||||||
33870160|NCT00690989|||||RETROSPECTIVE|||||||
33870161|NCT04146740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870162|NCT00654914|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151701|NCT02789592|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33754494|NCT06526117|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33754495|NCT04125368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870163|NCT01023867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870164|NCT03889275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870165|NCT03283124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant and investigator are not blinded. outcome assessor who are in charge of follow-up assement is masked.||f|f|f|t
33870166|NCT02594423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870167|NCT02047682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33870168|NCT01838616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870169|NCT05458765|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Complete blinding is not possible, however, to the extent possible, clinicians or study staff who collect adverse event data will be blinded to the randomization assignments to limit bias.||f|f|t|t
34151702|NCT04855383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151703|NCT06523257|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34151704|NCT00892138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34151705|NCT04556422|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34151706|NCT01825941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151707|NCT00867906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151708|NCT04857411|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34151709|NCT03139617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151710|NCT00256516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34151711|NCT03323866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled trial comparing mometasone nasal spray to budesonide irrigations for treatment of chronic rhinosinusitis with nasal polyposis|f|t|t|t
34151712|NCT06338202|||COHORT||RETROSPECTIVE|||||||
34151713|NCT05633966|NA|SINGLE_GROUP||OTHER||NONE||||||
34151714|NCT00307554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34151715|NCT05273541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151716|NCT01897090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151717|NCT04838327|||COHORT||PROSPECTIVE|||||||
34151718|NCT05950620|||CASE_CONTROL||PROSPECTIVE|||||||
34151719|NCT04365933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151720|NCT01295424|||COHORT||PROSPECTIVE|||||||
34151721|NCT06226935|||COHORT||CROSS_SECTIONAL|||||||
34151722|NCT05231707|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34151723|NCT05546671|||COHORT||PROSPECTIVE|||||||
34151724|NCT06465745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151725|NCT04476875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Observation of clinical outcomes in two groups||||
34151726|NCT02880917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151727|NCT03881904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151728|NCT01858753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151729|NCT01964677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151730|NCT03316950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151731|NCT01922843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151732|NCT03519594|||COHORT||RETROSPECTIVE|||||||
34151733|NCT06422637|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34151734|NCT01869660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151735|NCT04025177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151736|NCT01699711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151737|NCT01009086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151738|NCT05890482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151739|NCT04635813|||CASE_CONTROL||RETROSPECTIVE|||||||
34151740|NCT05157139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151741|NCT01304407|NA|SINGLE_GROUP||OTHER||NONE||||||
34151742|NCT03944382|||COHORT||RETROSPECTIVE|||||||
34151743|NCT01579630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151744|NCT00468975|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34151745|NCT00771615|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34151746|NCT00355992|||COHORT||PROSPECTIVE|||||||
34151747|NCT00504374|||CASE_ONLY||PROSPECTIVE|||||||
34151748|NCT05271331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both arms will receive the same treatment (Wound infiltration and ESP block) after general anesthesia induction (Participant masked to intervention) Drugs will be prepared after randomization by a physician not involved in the care of the patients and not involved in the study, and labelled as WOUND INFILTRATION and ESP block. One syringe will contain local anesthetic, the other normal saline (Care Provider masked to intervention, Investigator masked to intervention) Outcome assessor will be not involved in other part of the study and will be not aware of the intervention (Outcome assessor masked to intervention)||t|t|t|t
34151749|NCT00884832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151750|NCT03193476|||OTHER||OTHER|||||||
34151751|NCT00212706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151752|NCT03083184|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34151753|NCT05587374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151754|NCT04787185|||COHORT||PROSPECTIVE|||||||
34151755|NCT05245188|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34151756|NCT01608373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151757|NCT04785599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151758|NCT05701046|||COHORT||PROSPECTIVE|||||||
34151759|NCT00431119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151760|NCT06506929|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study- single group pretest postest||||
33870170|NCT04942795|||COHORT||RETROSPECTIVE|||||||
33870171|NCT03085524|||CASE_ONLY||PROSPECTIVE|||||||
33870172|NCT05627414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187825|NCT05820191|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Double blinding analysis of PET images will be performed. Involved Radiologists will provide their independent opinions. In addition, blinding research strategy with withholding of patient information, with three independent people involved for data collection and analysis will be used.|3 patients, diagnosed with GBM, who underwent tumor resection surgery with concurrent chemo- and/or radiotherapy and developed enlarging tumor lesion, will be involved to the study. PET-CT with use of Amyvid radioisotope tracer will be performed for 3 study participants. Amyvid-PET images will be analyzed together with previously performed MRI, MRS and MRP images, to identify pattern of deposition in tumor and peri-tumoral areas of brain.Tissue specimens, separated from total tumor after planned surgical resection and prior Amyvid-PET analysis, will be analyzed to identify amyloid-β expression level, tumor phenotype and vascularization. Data will be correlated with PET images to determine whether Amyvid-positive patterns represent distinct tumor phenotype.||||
34187826|NCT04759326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be collected at Centre Hospitalier Sud Francilien (CHSF) Corbeil-Essonnes (https://www.chsf.fr/nos-service/medecine/neurologie/), Centre Hospitalier of Béziers (CHB) (https://www.ch-beziers.fr/services/neurologie) and Centre Hospitalier Universitaire of Grenoble-Alpes (https://www.chu-grenoble.fr/patients-et-accompagnants/offre-de-soin/neurologie). The data will be duly anonymized and handled blindly. Data will be centralized on a secure server at the external subcontractor (Contract Research Organization - CRO) facilities. Their processing and analysis will be carried out blindly by the private service provider (CRO).|We will use a randomized single-blinded prospective two-arms controlled clinical trial on the effectiveness of hippotherapy versus conventional outpatient rehabilitation alone. To ensure that patients in the two arms of the trial are as homogeneous as possible in all respects except for the planned intervention, randomization will be stratified by age (18-59 years, 60-74 years, and ≥ 75 years), stroke type (ischemic versus hemorrhagic) and degree of disability (Rankin score). Stratified sampling reduces potential confusion by selecting homogeneous subgroups. In this case, matching will ensure a similar distribution of variables that could introduce a major imbalance potentially rendering the results unusable. The study will be single-blinded in order to rule out any possible bias introduced by the experimenter. We will use a fixed randomization defined by the allocation of each treatment (hippotherapy or neurorehabilitation alone).|f|f|t|f
34187827|NCT03623529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187828|NCT01212341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187829|NCT02876601|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Subjects will be randomized to receive LPS (n=16) or placebo (n=4) first. In each group they will undergo two study periods (crossover trial): a placebo period and a defibrotide period. The placebo group (n=4) will only be analyzed descriptively.|t|t|t|t
34187830|NCT00111852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187831|NCT00891670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187832|NCT06369727|RANDOMIZED|PARALLEL||OTHER||NONE|NA- Safety study|||||
34187833|NCT04449263|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34187834|NCT04655352|||CASE_ONLY||PROSPECTIVE|||||||
34187835|NCT02149901|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34187836|NCT04021641|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34187837|NCT05060601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187838|NCT03358264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34187839|NCT04367818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34187840|NCT05411952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The sample of the study was consisted of 75 (male= 36, female= 39) children and adolescents in total, including Intervention 1 group (n=25), Intervention 2 (n=25) group and Control (n=25) group determined by double-blind, stratified, random method.|t|t|t|t
34187841|NCT04265105|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigators will compare the superiority of effectiveness and safety of fluticasone-vilanterol versus usual care. In this study, there is a random allocation of participants to usual care (Any ICS or SABA combination) or fluticasone-vilanterol single daily use for the relief of symptoms.||||
34187842|NCT02223845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187843|NCT04350957|NA|SINGLE_GROUP||SCREENING||NONE||This clinical trial has a single arm. All subjects will receive a low dose and standard dose on two separate days||||
34187844|NCT02747498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187845|NCT03414931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754496|NCT02328833|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33754497|NCT00005041||||TREATMENT||||||||
33754498|NCT01496833|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33754499|NCT01515748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754500|NCT04102202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754501|NCT04184193|||COHORT||RETROSPECTIVE|||||||
33754502|NCT02707354|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754503|NCT02154633|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33870173|NCT02384902|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870174|NCT05511974|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870175|NCT00319150|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965807|NCT03760107|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33870176|NCT06261073|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894133|NCT05095389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo is visually indistinguishable from Active Treatment. Every patient receives Standard Care, plus either Active Treatment or Placebo.|Randomized, Parallel-Group, Double-Blind, Placebo Controlled|t|t|t|t
33894134|NCT03050125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33894135|NCT04057183|||CASE_ONLY||PROSPECTIVE|||||||
33894136|NCT03593694|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33894137|NCT02010203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894138|NCT03530449|||COHORT||PROSPECTIVE|||||||
33965808|NCT01956682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965809|NCT02122159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965810|NCT03712228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|Subjects are assigned to 1 of 2 or more groups in parallel for the duration of the study|t|t|t|t
33870177|NCT05704894|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be carried out in approximately 10 participating Brazilian centers.~This is a multicenter, open-label, randomized, national study. Randomization will be performed in a 1:1 ratio, in which 160 participants will be allocated to the intervention arm (Erythropoietin 150UI/Kg/week, divided into 3 doses, IV) and 160 participants to the local institution's standard care arm: Iron, Vitamin B12 and Folic Acid. Doses should be prescribed at the physician's discretion.~Every week (1 to 12), the study medication will be administered 3 times, according to the proposed treatment, for those allocated in the intervention group. All evaluations, procedures and notes must be recorded in a source document and in a CRF (case report form) The use of Iron, Vitamin B12 and folic acid will be allowed both in the intervention arm and in the control arm. Doses should be prescribed at the physician's discretion."||||
33870178|NCT05919654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870179|NCT00005221|||||CROSS_SECTIONAL|||||||
33870180|NCT03944226|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Single group with no masking|Single Group: trials with a single arm||||
33870181|NCT01825057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research staff independently screen, assess and obtain consent from eligible substance using patients admitted to the general medical hospitalist service. Patients are included if they are assigned to a participating provider according to the hospital's usual clinical administrative procedures. Thus, patients followed the randomization condition of their assigned provider, but they do not know how their providers have been trained to deliver MI and the providers do not know which patients assigned to them have been enrolled in the study. This approach permits a naturalistic test of the providers' ability to identify and intervene using MI with patients who misuse substances without patients or research staff prompting providers to do so.|In this three-arm parallel assignment, study-eligible and consented provider participants are randomized to one of three conditions (See One, Do One, or Order One) in which they receive their respective motivational interviewing training in parallel with provider participants assigned to the other conditions.|t|f|f|f
33870182|NCT05230589|||COHORT||PROSPECTIVE|||||||
33870183|NCT03849417|||COHORT||PROSPECTIVE|||||||
33870184|NCT02486978|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33870185|NCT05891925|NA|SINGLE_GROUP||TREATMENT||NONE||This study will be conducted over 30 older adults who will use an audiobook mobile application for 4 weeks. Participants will be evaluated pre and post intervention through validated questionnaires on digital competences, usability, and perception of well-being.||||
33870186|NCT00538395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870187|NCT03700281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870188|NCT05459454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single-center prospective randomized open label pilot study||||
33870189|NCT01186120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870190|NCT03675035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870191|NCT01628757|||COHORT||PROSPECTIVE|||||||
33870192|NCT02605187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870193|NCT02056197|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33870194|NCT02700412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870195|NCT00071942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870196|NCT00222170|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870197|NCT05640024|||CASE_ONLY||PROSPECTIVE|||||||
33870198|NCT05796908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870199|NCT02691208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754504|NCT06088940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be randomized individually upon enrollment after completing baseline assessments into the probiotic or placebo condition in a 1:1 allocation ratio using a computer-generated stratified randomization strategy (to balance age and sex). Randomization sequence will be pre-determined by randomization software and sequential allocations prepared in sealed envelopes, only to be revealed to a research assistant after consent and baseline questionnaires are completed. Once randomized, a research assistant will be responsible for assigning the probiotic or placebo for each participant to their study package so that the study coordinator, who will have direct contact with patients, will remain blinded to participants' condition. A member of the study team who does not have contact with participants will also be provided a copy of the treatment allocation.|"Theoretical Framework: This line of research follows the NIH ORBIT model for intervention development. Briefly, the ORBIT model provides a generic, systematic framework that emphasizes using a set of studies to form a chain of evidence that ultimately indicates readiness for an efficacy trial.~Study Design. Consistent with the National Institutes for Health (NIH) clinical trial phases for drug development, this study will fit into phase II, where investigators are focused on examining treatment effectiveness. A placebo-controlled randomized double-blinded study design is the gold standard for intervention research involving medications or natural health products, such as probiotics."|t|f|t|f
33870200|NCT00215995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754505|NCT02889653|||COHORT||PROSPECTIVE|||||||
33754506|NCT03278015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754507|NCT05534347|||COHORT||PROSPECTIVE|||||||
33754508|NCT00225433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754509|NCT02943408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to participant intervention assignment.||f|f|f|t
33754510|NCT03653455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33754511|NCT04164992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754512|NCT01380951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754513|NCT01295450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754514|NCT01248832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187846|NCT01696188|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33754515|NCT03509649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants randomly assigned to one of 2 instructional sets (positive/ negative) and randomly assigned to one of 2 practitioner experience levels (experienced/ novice)||t|f|t|t
33754516|NCT00240487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754517|NCT00137566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754518|NCT00112268|RANDOMIZED|PARALLEL||ECT||NONE||||||
33754519|NCT06333054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33754520|NCT00728169|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33754521|NCT05224882|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754522|NCT00036881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33754523|NCT06057142|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a pilot pre-intervention trial without controls.||||
33754524|NCT00277953|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33754525|NCT03961789|||COHORT||CROSS_SECTIONAL|||||||
33754526|NCT01735565|||COHORT||PROSPECTIVE|||||||
33754527|NCT05779202|||COHORT||PROSPECTIVE|||||||
33870201|NCT01382797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870202|NCT03271814|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33870203|NCT02664272|||OTHER||PROSPECTIVE|||||||
33870204|NCT02799407|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870205|NCT02427451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870206|NCT03364244|||CASE_ONLY||PROSPECTIVE|||||||
33870207|NCT05069883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33870208|NCT03358199|||CASE_CONTROL||RETROSPECTIVE|||||||
33870209|NCT03173859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870210|NCT01795885|NA|SINGLE_GROUP||OTHER||NONE||||||
33870211|NCT01371019|||COHORT||PROSPECTIVE|||||||
33870212|NCT01365039|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33870213|NCT00545298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870214|NCT02371239|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33870215|NCT01699945|||||RETROSPECTIVE|||||||
33870216|NCT03022695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894139|NCT04661696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894140|NCT03835663|||CASE_ONLY||PROSPECTIVE|||||||
34187847|NCT00034268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187848|NCT04922541|||CASE_ONLY||RETROSPECTIVE|||||||
34187849|NCT02559804|||COHORT||PROSPECTIVE|||||||
34187850|NCT04781959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187851|NCT01694797|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34187852|NCT05191420|||CASE_ONLY||PROSPECTIVE|||||||
34187853|NCT01531569|NA|SINGLE_GROUP||||NONE||||||
34187854|NCT02668536|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34187855|NCT01724632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187856|NCT05828485|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34187857|NCT03959267|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will conduct a two-arm Randomized Controlled Trial (RCT) comparing Telephone Genetic Counseling in Spanish vs. Usual care.||||
34187858|NCT03171467|NA|SINGLE_GROUP||OTHER||NONE||||||
33870217|NCT03078075|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||During the study, participants may or may not be switched to another group due to the adaptive aspect of the study design. Participants appearing to respond well to their original treatment assignment will not be switched.|t|t|t|t
33870218|NCT04804514|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33870219|NCT00097747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870220|NCT02870049|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
34187859|NCT05785442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This study is designed to maintain blinding from participants, site investigators and their teams until completion of the study. At each center, there will be an unblinded pharmacist (and one substitute) who will be in charge of randomizing and preparing the study drug for each participant according to the randomized intervention assignment. These pharmacists will not be involved in data acquisition, collection, adjudication of outcomes or adverse events, or any other study procedures. They will not disclose the treatment assignment to the study team members unless it is via a formal process of early unblinding as described below.~Αn independent biostatistician will generate the assignment to blinding treatment.~Under normal circumstances, all the treatment assignments of participants will remain blinded until the completion of the trial (completion of enrollment and follow-up or early termination of the trial)."|Prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial.|t|t|t|t
34187860|NCT03714152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187861|NCT04339452|||COHORT||PROSPECTIVE|||||||
34187862|NCT03644472|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34187863|NCT04145232|||CASE_ONLY||CROSS_SECTIONAL|||||||
34187864|NCT05328349|||COHORT||PROSPECTIVE|||||||
34187865|NCT06248749|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open label, prospective, randomized \[1:1\] controlled, Phase III study of Iron Sucrose, Iron Gluconate or Iron Isomaltoside (Treatment group A) versus No Iron Infusion treatment (Control group B) in participants diagnosed with ovarian cancer and with iron deficiency anemia. The primary objective of the study is to assess the efficacy of iron infusion, as measured by the primary endpoint, of Group A versus Group B.||||
34187866|NCT05461534|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34187867|NCT04038021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187868|NCT06256380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187869|NCT00088764|RANDOMIZED|FACTORIAL||||NONE||||||
34187870|NCT00566696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187871|NCT00684008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187872|NCT04154189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870221|NCT00554359|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33870222|NCT04142775|||COHORT||RETROSPECTIVE|||||||
33870223|NCT05404399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870224|NCT01119742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870225|NCT01200550|||COHORT||PROSPECTIVE|||||||
33870226|NCT02834221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33870227|NCT02220842|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187873|NCT01610934|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34187874|NCT02213861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870228|NCT03397004|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33870229|NCT05961995|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33965811|NCT02267850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870230|NCT06124625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870231|NCT02437864|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870232|NCT00565253|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33870233|NCT00710879|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870234|NCT02769663|||CASE_CONTROL||PROSPECTIVE|||||||
33870235|NCT04051879|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870236|NCT05315960|||OTHER||CROSS_SECTIONAL|||||||
33870237|NCT03719703|||COHORT||PROSPECTIVE|||||||
33870238|NCT03871322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, placebo, same looking capsules|a prospective, three- month, randomized, double-blind, placebo-controlled, intervention trial (RDBPC),|t|f|t|t
33965812|NCT03637673|||OTHER||PROSPECTIVE|||||||
33965813|NCT03066154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965814|NCT03530033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965815|NCT02751086|||COHORT||PROSPECTIVE|||||||
33965816|NCT03778359|||OTHER||RETROSPECTIVE|||||||
33965817|NCT01684449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187875|NCT01938716|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34187876|NCT02411097|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34187877|NCT01006993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187878|NCT00056069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187879|NCT05009004|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-post evaluation study of the impact of the digital health intervention on hypertension medication adherence.||||
33754528|NCT03999879|||OTHER||PROSPECTIVE|||||||
33870239|NCT05402475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not be informed about which comparison condition to which she has been assigned|This is a parallel group randomized clinical trial with two active comparison conditions|t|f|f|f
33870240|NCT02667665|||OTHER||PROSPECTIVE|||||||
33870241|NCT03431376|||COHORT||PROSPECTIVE|||||||
33870242|NCT01141036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33870243|NCT03317041|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33754529|NCT00989248|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33754530|NCT04605848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870244|NCT00866450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33870245|NCT05774730|||CASE_CONTROL||PROSPECTIVE|||||||
33870246|NCT03996876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blind to the bias modification training they are assigned.|Participants will be assigned to either a threat attention bias modification training or a neutral attention training.|t|f|f|f
33754531|NCT05943457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, investigators, and analysts will remain blind to the identity of the treatment from the time of randomization until the time of unblinding. The identity of the treatment will be concealed by using placebo pills that are identical in appearance, color, odor and packaging. Unblinding will only occur in the case of a medical emergency and at the conclusion of the study.|Migraine subjects will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months.|t|t|t|t
33754532|NCT04189718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||wo groups were made one test and control. The control group were treated with conventional implant site preparation technique and the test group were treated with osseodensification technique.|t|f|f|t
33754533|NCT01489995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870247|NCT03366688|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33965818|NCT03101579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965819|NCT03259737|||COHORT||RETROSPECTIVE|||||||
33754534|NCT03198026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870248|NCT04244526|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870249|NCT04811404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870250|NCT01612182|||||RETROSPECTIVE|||||||
34187880|NCT04775836|||COHORT||PROSPECTIVE|||||||
34187881|NCT06422897|||CASE_ONLY||PROSPECTIVE|||||||
34187882|NCT00042315|RANDOMIZED|||||DOUBLE||||||
34187883|NCT03454360|||COHORT||PROSPECTIVE|||||||
34187884|NCT01497561|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34187885|NCT03001817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34187886|NCT03841201|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm, multicenter phase II trial||||
34187887|NCT01614483|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34187888|NCT00068419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187889|NCT02670811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187890|NCT04316988|||COHORT||PROSPECTIVE|||||||
34187891|NCT02713152|||CASE_CONTROL||PROSPECTIVE|||||||
34187892|NCT04101942|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33870251|NCT02433197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34187893|NCT01409941|||COHORT||PROSPECTIVE|||||||
34187894|NCT02970903|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34187895|NCT01933685|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34187896|NCT03607266|||OTHER||PROSPECTIVE|||||||
34187897|NCT06532149|||COHORT||PROSPECTIVE|||||||
34187898|NCT00792064|||COHORT||PROSPECTIVE|||||||
34187899|NCT03812276|||COHORT||PROSPECTIVE|||||||
33870252|NCT05357443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754535|NCT04725344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are 2 groups : an interventional group with ACTIV'DOS app ; and a control group with a standard procedure using a sheet of paper.||||
33754536|NCT03115892|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statistician only will be blind|two group one for intervention and one for control randomize control trail||||
33870253|NCT00449683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870254|NCT03159091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870255|NCT00105716|RANDOMIZED|FACTORIAL||||NONE||||||
33870256|NCT04778436|NA|SINGLE_GROUP||OTHER||NONE||an open-label, single-arm, pilot study||||
33870257|NCT02950090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870258|NCT04511832|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34187900|NCT06453889|NA|SINGLE_GROUP||TREATMENT||NONE||multimode thermal therapy||||
34187901|NCT02283762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34187902|NCT01036048|||||RETROSPECTIVE|||||||
34187903|NCT04411732|||CASE_CONTROL||PROSPECTIVE|||||||
34187904|NCT06444841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34187905|NCT04466670|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34187906|NCT03126513|NA|SINGLE_GROUP||TREATMENT||NONE||This a prospective study that evaluates G-POEM in a group of participants with diagnosis of refractory gastroparesis. Participants are sequentially recruited as diagnosed.||||
34187907|NCT02043808|||||RETROSPECTIVE|||||||
34187908|NCT03590041|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Blinding is not possible with the study design. Patients will not know that there is a difference in SMAs|"The two interventions are based in the Chronic Care Model, which emphasizes whole person care, addressing physical, mental health and psychosocial needs. The conceptual model underlying patient-driven diabetes Shared Medical Appointments is based on self-determination theory (SDT) and principles of whole person care. According to SDT, human motivation and behavior are a function of the social environment and the extent to which that environment supports basic psychological needs shown to enhance self-determined motivation."||||
34187909|NCT04417699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187910|NCT04473287|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34187911|NCT02061371|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34187912|NCT05330299|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive COMPASS as part of standard care.||||
34187913|NCT06165289|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187914|NCT02433470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34187915|NCT01966848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187916|NCT04460001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187917|NCT03078218|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Multicenter controlled before and after study conducted in Nouvelle Aquitaine, including types 1, 2 and 3 maternity wards.~The BEFORE period will be strictly observational in order to assess the current screening strategy as it is conducted in real life.~The AFTER period will be consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards as the BEFORE period."||||
33965820|NCT00751972|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33965821|NCT05409599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965822|NCT04567199|||COHORT||RETROSPECTIVE|||||||
33965823|NCT03777787|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, double-blind, placebo-controlled study|t|f|t|t
33965824|NCT04133480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965825|NCT04422015|||COHORT||PROSPECTIVE|||||||
33965826|NCT06058468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965827|NCT01111630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965828|NCT02627365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33965829|NCT06464237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965830|NCT00155441|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33965831|NCT06206499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965832|NCT00860574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965833|NCT03102203|||COHORT||PROSPECTIVE|||||||
33965834|NCT04039165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A group of participants, who will be randomized to wait-list control group, is assigned to a waiting list and receives intervention after the active treatment group.||||
33965835|NCT01676259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965836|NCT01408576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965837|NCT00459381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754537|NCT05240105|||OTHER||PROSPECTIVE|||||||
33754538|NCT06472596|||CASE_CONTROL||PROSPECTIVE|||||||
33965838|NCT04540120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized, blinded, placebo-controlled study. Treatment allocation (to active or placebo treatment groups) will be blinded to all study participants, personnel, and investigators. Only the drug labeling personnel, unblinded pharmacist and DMC members may be unblinded to the treatment assignment. Also, in the event of an emergency, an unblinding envelope can be opened unmasking the treatment assignment to the PI.|Subjects will be assigned to receive either dapansutrile capsules or placebo capsules in a 1:1 ratio.|t|t|t|f
33965839|NCT03344380|||COHORT||RETROSPECTIVE|||||||
33965840|NCT02864680|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151761|NCT05423912|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are 24 dyads of persons with MCI and their care partners who experience the same intervention.||||
34151762|NCT05604963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151763|NCT00328471|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151764|NCT06507475|||COHORT||RETROSPECTIVE|||||||
34151765|NCT03020017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151766|NCT03336385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"The randomization list was generated and provided by the Fibebiotics consortium (part of the EU framework 7 program) using unique study codes for participants.~All study product labels were coded by a third-party. All investigators and study participants remained blinded until final analysis"|The study participants were allocated through block randomization into three different intervention arms that ran in parallell throughout the study|t|t|t|t
34151767|NCT03514563|||COHORT||PROSPECTIVE|||||||
34151768|NCT03297125|||COHORT||PROSPECTIVE|||||||
34151769|NCT01981681|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34151770|NCT02841241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151771|NCT03550768|||COHORT||PROSPECTIVE|||||||
34151772|NCT04491760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870259|NCT04790136|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33870260|NCT00316355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870261|NCT02403336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870262|NCT04966520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965841|NCT05074563|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be blinded to group allocation and will complete self-reported surveys online. One of the study investigators not involved in the delivery of training or randomisation process and who will analyse the survey responses will be blinded to treatment assignment.||f|f|t|f
33965842|NCT03877237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965843|NCT02169583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965844|NCT05162885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33965845|NCT02651896|||COHORT||PROSPECTIVE|||||||
34187918|NCT04326283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|K-ALSFRS-R score will be measured by independent outcome assessors.|Patients will be randomly assigned 4:1 to receive SNR1611 (0.5, 1 mg) or riluzole as an active comparator. The study will initiate with the first group of patients who will receive SNR1611 (0.5 mg, 8 patients) or riluzole (100 mg, 2 patients), while the initiation of the next dose groups will be decided by the IDMC (Independent Data Monitoring Committee) through safety assessment of the first 4-week periods of prior dose groups.|f|f|f|t
34187919|NCT02400385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187920|NCT00654550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187921|NCT05392907|||CASE_ONLY||CROSS_SECTIONAL|||||||
34187922|NCT04014517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187923|NCT06254573|||COHORT||CROSS_SECTIONAL|||||||
34187924|NCT04160754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34187925|NCT04049149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34187926|NCT00449891|||||CROSS_SECTIONAL|||||||
34187927|NCT04328077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34187928|NCT03944317|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|The personnel involved in the data collection and laboratory staff analyzing the samples will all not be aware of which group of patient is taking SP or Azithromycin|The design is a randomized comparative controlled study. Candidates for the study will be recruited from the antenatal booking clinic of our institution after being duly informed that participation is voluntary. Consented eligible pregnant woman will be recruited and those enrolled will be alloted into the two groups A and B of SP and Azithromycin respectively using a computer program (SPSS software version 21, Armonk, NY:IBM) generated sequence of numbers. Sequentially numbered sealed envelope containing either SP or AZ labelled will be allotted one after the other to participants. The personnel involved in the data collection and laboratory staff analyzing the samples will all not be aware of which group of patient is taking SP or Azithromycin while the doctors involved in administering the medication and the patients will be aware of which is being administered.|f|f|f|t
34187929|NCT06437743|||COHORT||PROSPECTIVE|||||||
34187930|NCT04989868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187931|NCT03124004|||COHORT||PROSPECTIVE|||||||
34187932|NCT00387790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187933|NCT02941718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187934|NCT00229567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34187935|NCT04002492|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34187936|NCT03070964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187937|NCT02763280|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34187938|NCT02510560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187939|NCT00239330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187940|NCT03951662|||CASE_CONTROL||PROSPECTIVE|||||||
34187941|NCT02781259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34187942|NCT02087696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187943|NCT00392769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187944|NCT01160822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965846|NCT02295683|||OTHER||PROSPECTIVE|||||||
33870263|NCT04341220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33870264|NCT04700527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33870265|NCT02947672|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870266|NCT01417598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965847|NCT01291719|NA|SINGLE_GROUP||TREATMENT||NONE||Insulin and glucose infusion in closed loop control; intervention is glucose control with insulin and glucose infusion||||
34187945|NCT05775276|NA|SINGLE_GROUP||SCREENING||NONE||All adult patients aging above 21 years old, who presented with obstructed or strangulated hernia with viable bowel loops by clinical examination or detected by preoperative ultrasound or computed tomography CT imaging.||||
34187946|NCT03419923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34187947|NCT03212313|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34187948|NCT03031015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|blinded|Patients with proximal phalangeal fractures of fingers.|t|t|t|t
34187949|NCT05384431|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All Exerkine and University of Waterloo research staff will be blinded to the study.|Randomized, placebo controlled, parallel group design.|t|f|t|t
34187950|NCT04000854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187951|NCT06143904|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34187952|NCT02891135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187953|NCT00986037|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34187954|NCT00751608|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34187955|NCT03640611|||COHORT||PROSPECTIVE|||||||
34187956|NCT01164072|||COHORT||PROSPECTIVE|||||||
34187957|NCT04885777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34187958|NCT02052492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187959|NCT06013046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187960|NCT01607255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34187961|NCT03605485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187962|NCT06062342|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a stepped wedge trial and all zip codes cross over from pre-assessment period (control) to active intervention. The time/order in which zip codes enter the stepped wedge is the unity of randomization.||||
34187963|NCT03319758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187964|NCT05346666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind||t|t|t|f
34187965|NCT00351429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187966|NCT05639491|||CASE_ONLY||RETROSPECTIVE|||||||
34187967|NCT00123422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34187968|NCT02616796|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
34187969|NCT06015152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187970|NCT05270252|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were blinded in their group assignment; means were put in place to maintain blinding of students throughout the study.|"The study was designed following the framework of the Medical Research Council (MRC) (Craig et al., 2019), for complex interventions.~The sample size was estimated in at least 58 participants assuming a percentage of potential losses of 10%.~The recruitment period was from January-February 2021. After receiving permission of the University and approvals from the Ethics Committee (REF. 2020.161), the principal researcher presented the project to the students with a brief oral presentation supported by video. The students who agreed to participate scanned a QR code through which they could request information indicating a contact email.~Students who requested information, and who met the inclusion criteria, were sent a project information sheet, as well as a Doodle to sign up for the first session. Before the first session, they signed the informed consent and the sociodemographic data were collected through a Google Form questionnaire."|t|f|f|f
34187971|NCT04207632|||CASE_ONLY||PROSPECTIVE|||||||
34187972|NCT03931252|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34187973|NCT03131609|||COHORT||PROSPECTIVE|||||||
34187974|NCT01047553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187975|NCT01623050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187976|NCT04141436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34187977|NCT02425943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187978|NCT05053204|||CASE_CONTROL||PROSPECTIVE|||||||
34187979|NCT02518295|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34187980|NCT03766152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187981|NCT02745080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187982|NCT00235365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187983|NCT00215839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34187984|NCT04330092|||COHORT||PROSPECTIVE|||||||
34187985|NCT06016777|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients will be grouped by block randomization method (1:1:1) by a researcher who is unaware of the meaning of the group code. Patients will be stratified by ID numbers with a block of 6. Within each block, random sequences between 0 and 1 are generated. The group code (A, B or C) will be defined as the remainder of the serial number divided by three. The group code will be put in a light-proof envelope. Patients with the envelope will be transferred to the OR, unaware of the group assignment throughout the study. After induction, the anesthesiologist opens the light-proof envelope and get the group code. Group codes will be recorded in the CRF table with the cards destroyed. Only the principal investigator and the anesthesiologists know the intervention represented by the group code. The anesthesiologists will not involve in postoperative follow-ups or data collection. Neither doctors in charge of postoperative follow-ups nor the statisticians will know the specific interventions.|This will be a parallel-group, single-blind, randomized controlled trial. Patients are expected to be enrolled in the trial within 8 months. Participants will be randomly assigned to one of the three groups: ultrasound-guided paravertebral block (PVB+PCIA group), ultrasound-guided erector spinae block(ESB+PCIA group) , or intravenous patient-controlled analgesia pump group (PCIA group). Different nerve block operation schemes will be used in different groups.Except for different nerve block schemes, all the participants will have the same methods and choices of medicine for other kinds of rescue analgesia regimens.The participants and the follow-up evaluation doctors are not aware of the group assignment, and the surgeon and anesthesiologist will not know the grouping code until the beginning of the surgery. In this way, the analgesic effect of each subject can be fairly evaluated.|t|f|t|t
34187986|NCT01694407|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34187987|NCT05785676|||COHORT||PROSPECTIVE|||||||
34187988|NCT00026026|||||CROSS_SECTIONAL|||||||
34187989|NCT01039883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34187990|NCT06140862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
34187991|NCT06050057|||COHORT||PROSPECTIVE|||||||
34187992|NCT01976741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34187993|NCT05699694|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34187994|NCT03822559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34187995|NCT03433040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754539|NCT05559034|||OTHER||OTHER|||||||
33754540|NCT03589079|||COHORT||CROSS_SECTIONAL|||||||
33754541|NCT06473662|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomised twelve-week open-label study.||||
33754542|NCT03159026|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754543|NCT01616901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754544|NCT04262362|||OTHER||PROSPECTIVE|||||||
34187996|NCT03064061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34187997|NCT04730219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34187998|NCT02167139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34187999|NCT00850239|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34188000|NCT05985369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34188001|NCT03048578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomization will be 2:1 (drug:placebo) with stratification by gender and percent post-operative TBWL (25%, 25 - 49.9%).|t|t|f|f
34188002|NCT06413849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34188003|NCT01272063|||CASE_ONLY||PROSPECTIVE|||||||
34188004|NCT01994096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188005|NCT05997303|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34188006|NCT04722419|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870267|NCT01766128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34066955|NCT06201468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple-blinded clinical randomized trial|"Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks."|t|f|t|t
34066956|NCT00096759|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34066957|NCT04424030|||COHORT||PROSPECTIVE|||||||
34066958|NCT04017871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066959|NCT06194058|||CASE_ONLY||PROSPECTIVE|||||||
34066960|NCT05933694|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34066961|NCT03039608|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33870268|NCT04712721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Imaging study||||
33870269|NCT04935892|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Lab personnel processing cultures blinded to the study group|Randomized trial|f|f|f|t
33870270|NCT03118700|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33870271|NCT02021084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870272|NCT05543577|||OTHER||CROSS_SECTIONAL|||||||
33870273|NCT03680911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066962|NCT02033278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188007|NCT05613465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188008|NCT00254696|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34188009|NCT05475080|||COHORT||PROSPECTIVE|||||||
34188010|NCT01636518|||COHORT||PROSPECTIVE|||||||
34188011|NCT01280708|||COHORT||PROSPECTIVE|||||||
34188012|NCT05039983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188013|NCT04968769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled study|f|f|f|t
34188014|NCT04282408|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34188015|NCT03658681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Intervention with cross-over design. Two test meals will be tested.|t|f|t|t
34188016|NCT04600661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sixty Three patients of both genders with mild to moderate unilateral tibiofemoral OA, with age range from 45-60 years will be randomly assigned to 1 of 3 groups using opaque, sealed envelopes, each containing the name of one of the groups. Each patient will sign an informed consent before starting the study (Appendix III). All patients will be referred by the orthopedic surgeon who will diagnose knee OA based on clinical and radiological examination. The investigator will be blinded|"Sixty Three patients of both genders with mild to moderate unilateral tibiofemoral OA, with age range from 45-60 years will be randomly assigned to 1 of 3 groups control group (Traditional therapy group) (n=21): patients will receive traditional training exercises (high load resistance training) Experimental group I (BFR training group) (n=21): patients will receive LLRT with BFR.~Experimental group II (Neuromuscular training group) (n=21): patients will receive neuromuscular training exercises"|f|f|t|t
34188017|NCT01963416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34188018|NCT02554461|||COHORT||PROSPECTIVE|||||||
34188019|NCT03515655|||COHORT||RETROSPECTIVE|||||||
34188020|NCT03409224|||COHORT||PROSPECTIVE|||||||
34188021|NCT04462627|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188022|NCT04857164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188023|NCT01168037|||OTHER||PROSPECTIVE|||||||
34188024|NCT00574522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188025|NCT06237504|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34188026|NCT04456036|||COHORT||PROSPECTIVE|||||||
34188027|NCT02317367|||OTHER||CROSS_SECTIONAL|||||||
34188028|NCT04195893|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34188029|NCT01010867|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34188030|NCT06378216|||CASE_ONLY||OTHER|||||||
34188031|NCT00395668|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34188032|NCT04946981|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34188033|NCT06266832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188034|NCT02502617|||CASE_ONLY||PROSPECTIVE|||||||
34188035|NCT05326269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants are randomly assigned a number (generated using an online random number generator) and given an opaque envelope containing instructions for study drug or placebo administration. The envelope will be opened by a nurse who prepared the injection in a treatment room, separated from the Labour Suite. The doctors managing the cases, the surgeons who performed the surgeries, the anaesthetists and the patients themselves were blinded against the injection given||t|t|t|f
34188036|NCT06208943|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34188037|NCT01538667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188038|NCT00205452|||CASE_ONLY||PROSPECTIVE|||||||
34188039|NCT05577117|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34188040|NCT01630538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188041|NCT01493076|||COHORT||PROSPECTIVE|||||||
33870274|NCT05790382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study. Prior to dosing visit 4 for Cohort 2, a small team will be unblinded to treatment assignment in order to conduct lumbar punctures on subjects assigned to active IMP only|56|t|f|t|t
33870275|NCT06490341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870276|NCT01001468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870277|NCT03137589|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Stepped-Wedge-Design||||
33870278|NCT00714428|||COHORT||CROSS_SECTIONAL|||||||
33870279|NCT04641767|||COHORT||PROSPECTIVE|||||||
33870280|NCT04296214|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870281|NCT04578860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33870282|NCT02227732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870283|NCT01886573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754545|NCT01835210|||COHORT||RETROSPECTIVE|||||||
33754546|NCT02781402|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor who measured pre and post outcomes was blended and did not know participants belonged to which group.|Same intervention (4 weeks of aerobic training) was given to 2 different groups (Normal BMI group \& Overweight BMI group).|f|f|f|t
33754547|NCT04292249|||COHORT||RETROSPECTIVE|||||||
33754548|NCT02104622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754549|NCT06577636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, sham-controlled RCT|Two groups of participants will be randomized to either (a) Dream group, or (b) No-Dream group.|t|f|t|t
33754550|NCT02892812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33754551|NCT01769300|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33754552|NCT01733108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066963|NCT04350177|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||Sentinel dosing will be employed for each cohort in Part A, with one subject randomized to receive IkT-148009 and the other placebo on the first day. These two subjects in each cohort will be monitored for 48 hours after dosing before deciding to dose the remainder of the cohort. As such, the other six subjects in the first cohort will be dosed approximately 48 hours later. Each cohort will be monitored for at least 48 hours before deciding whether to sentinel pair in the next (higher dose) cohort, and each cohort will be dosed at approximately monthly intervals in order to allow adequate time for collection and review of safety and PK data. In Part B, 8 patients will be 3:1 randomized to placebo and dosed once per day for 7 days. In Part C, 8 patients will be 3:1 randomized to placebo and dosed once per day for 7 dayts.|t|f|t|f
34066964|NCT03564093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34066965|NCT01101256|||COHORT||PROSPECTIVE|||||||
34188042|NCT04287270|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Multiple system atrophy patients; Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure (SNIP) and maximal inspiratory mouth pressure (PImax). Expiratory muscle strength will be evaluated maximal expiratory mouth pressure (PEmax). Pulmonary function test will be performed.~Healthy Controls: Inspiratory muscle strength will be evaluated with sniff nasal inspiratory pressure (SNIP) and maximal inspiratory mouth pressure (PImax). Expiratory muscle strength will be evaluated maximal expiratory mouth pressure (PEmax). Pulmonary function test will be performed."||||
34188043|NCT04133688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188044|NCT06288100|||COHORT||RETROSPECTIVE|||||||
34188045|NCT04953728|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will receive all treatments including sham comparator in a randomized order. Participants will not be informed of which treatment they will be receiving or the treatment order to which they are assigned.|||||
34188046|NCT02231931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188047|NCT05404932|NA|SINGLE_GROUP||TREATMENT||NONE||Only one patient (and their family) with laboratory diagnosis of plasminogen deficiency and ligneous conjunctivitis will be enrolled in this study.||||
34188048|NCT00267566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188049|NCT02833467|||CASE_ONLY||PROSPECTIVE|||||||
34188050|NCT03164239|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188051|NCT04080167|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||nonrandomized, closed cohort, stepped-wedge cluster trial||||
34188052|NCT00568386|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34188053|NCT05343624|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34188054|NCT00124514|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34188055|NCT01539460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188056|NCT04194021|||COHORT||RETROSPECTIVE|||||||
34188057|NCT05225805|RANDOMIZED|CROSSOVER||OTHER||NONE||Open-label, Crossover Study||||
34188058|NCT00851227|NON_RANDOMIZED|PARALLEL||||NONE||||||
34188059|NCT06364488|NA|SINGLE_GROUP||OTHER||NONE||125 participants, of whom 12 will enter the initial 5-month within-study pilot phase aimed at understanding any device-related adverse events and usability issues.||||
34188060|NCT02597478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188061|NCT00839319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754553|NCT00859079|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870284|NCT04227366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870285|NCT01124903|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||single-sample pre-post design||||
34188062|NCT06230211|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34188063|NCT03838432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188064|NCT03959176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34188065|NCT04153396|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188066|NCT06051643|||COHORT||RETROSPECTIVE|||||||
34188067|NCT03820895|||COHORT||RETROSPECTIVE|||||||
34188068|NCT02795702|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34188069|NCT03261752|||CASE_CONTROL||PROSPECTIVE|||||||
33754554|NCT00852631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754555|NCT00253968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754556|NCT01204827|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33754557|NCT05199818|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870286|NCT02121600|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33870287|NCT05352997|||COHORT||RETROSPECTIVE|||||||
34188070|NCT00144638|||DEFINED_POPULATION||PROSPECTIVE|||||||
34188071|NCT02694692|||CASE_CONTROL||PROSPECTIVE|||||||
33754558|NCT06448351|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Personnel performing the assays will be blinded to the status of the sample.||t|f|f|t
33754559|NCT02160717|||COHORT||CROSS_SECTIONAL|||||||
33754560|NCT00553930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754561|NCT04629482|||CASE_CONTROL||PROSPECTIVE|||||||
34066966|NCT02109445|RANDOMIZED|||TREATMENT||NONE||||||
33754562|NCT06236750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066967|NCT01957943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34066968|NCT03765853|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066969|NCT02704559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066970|NCT05229627|||CASE_CONTROL||PROSPECTIVE|||||||
34066971|NCT02568371|||COHORT||PROSPECTIVE|||||||
34066972|NCT05968690|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, single institution, phase I study with a 3+3 design of dose escalated naltrexone in combination with propranolol 30 mg bid and ipilimumab 3 mg/kg plus nivolumab 1 mg/kg q3wk for up to 4 doses followed by NIVO monotherapy q4wk in participants with advanced melanoma.||||
34066973|NCT05237739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Simple randomisation will be completed using the online programme, Sealed Envelope. This will be completed by a member of the research team not involved in this specific study. Sealed Envelope will provide a randomisation schedule, patient numbering and a sequence of patient number assignment. This will all be safely stored and secured. The treatment allocation will be communicated to the study therapist/nurse and patient when booking the treatment appointment. It will not be possible to blind the participants or the clinician completing the study treatment. The study examiner will remain blind to treatment allocation.|This is a single-centre single-masked randomised controlled feasibility trial with SMART design to assess the response to treatment for degree III periodontal furcation involved molars (n=20).|f|f|t|t
34066974|NCT02493530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066975|NCT00942539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34066976|NCT02234336|||COHORT||PROSPECTIVE|||||||
34066977|NCT03477721|||CASE_CONTROL||PROSPECTIVE|||||||
34188072|NCT03221153|RANDOMIZED|PARALLEL||OTHER||SINGLE|Masking only at the level of outcome assessor as this is an educational intervention.|Randomized controlled trial of two educational interventions|f|f|f|t
34188073|NCT00863226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188074|NCT00345748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188075|NCT04182646|NA|SINGLE_GROUP||TREATMENT||NONE||The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year which have capability for decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required||||
34188076|NCT02519985|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188077|NCT04723797|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized control trial with a control group, a moderate-intensity intervention group, and a high-intensity intervention group|f|f|t|f
34188078|NCT00597324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188079|NCT00004366||||ECT||||||||
34188080|NCT02693132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188081|NCT01426685|||COHORT||PROSPECTIVE|||||||
34188082|NCT04539769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188083|NCT05155514|||COHORT||PROSPECTIVE|||||||
34188084|NCT02118441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33870288|NCT05060653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188085|NCT06310941|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, randomized, open label||||
34188086|NCT01339572|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188087|NCT01341613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188088|NCT04151576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experiment.|t|f|f|f
34188089|NCT02118961|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188090|NCT05475756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188091|NCT03339843|NA|SEQUENTIAL||TREATMENT||NONE||This is a two step, open-label, basket trial looking at 5 different tumour types.||||
34188092|NCT05791019|||CASE_CONTROL||PROSPECTIVE|||||||
34188093|NCT01881672|||COHORT||PROSPECTIVE|||||||
34188094|NCT04482452|||COHORT||PROSPECTIVE|||||||
34188095|NCT00224991|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34188096|NCT00343941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188097|NCT03053167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188098|NCT00647959|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34188099|NCT03401814|||COHORT||PROSPECTIVE|||||||
34188100|NCT03446404|||COHORT||PROSPECTIVE|||||||
33754563|NCT02716389|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33754564|NCT02808936|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33754565|NCT01722968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754566|NCT04356404|||COHORT||PROSPECTIVE|||||||
33754567|NCT03249415|||CASE_CONTROL||PROSPECTIVE|||||||
33754568|NCT01577576|||COHORT||CROSS_SECTIONAL|||||||
33754569|NCT01218126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754570|NCT03696017|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754571|NCT02062268|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33754572|NCT01570426|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754573|NCT04459390|||CASE_CONTROL||PROSPECTIVE|||||||
33754574|NCT03365076|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized control trial. Randomization 1:1||||
33754575|NCT00910923|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33754576|NCT02633800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754577|NCT00276471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754578|NCT04295005|||COHORT||RETROSPECTIVE|||||||
33754579|NCT06104033|||COHORT||PROSPECTIVE|||||||
34188101|NCT01781299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We are looking at 2 products called Acellular Dermal Matrix (ADM) implant to evaluate the outcomes of 2 specific ADM products: SurgiMend PRS and AlloDerm RTU.|t|f|f|f
34188102|NCT00557856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188103|NCT05357248|NA|SINGLE_GROUP||TREATMENT||NONE|open label|This single arm study of 20 patients is to evaluate the feasibility of using BT-NCBT-00x in the treatment of NAFLD and NASH||||
34188104|NCT01571518|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188105|NCT00556504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188106|NCT03478098|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34188107|NCT05731063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870289|NCT03650920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870290|NCT00456105|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188108|NCT03551561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188109|NCT03713346|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34188110|NCT03393988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188111|NCT05446064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188112|NCT01356251|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188113|NCT02225691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188114|NCT01867177|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188115|NCT04775940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34188116|NCT00742144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188117|NCT00419952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188118|NCT05949437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188119|NCT00679796|||CASE_CONTROL||PROSPECTIVE|||||||
34188120|NCT02392819|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34188121|NCT00633503|||COHORT||PROSPECTIVE|||||||
33870291|NCT01593293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870292|NCT03606993|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754580|NCT06456632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Intervention and Control group|f|f|f|t
33754581|NCT05304338|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33754582|NCT02250105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754583|NCT01433354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754584|NCT04858555|||COHORT||PROSPECTIVE|||||||
33754585|NCT02774070|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33754586|NCT06216522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754587|NCT04912648|||COHORT||PROSPECTIVE|||||||
33870293|NCT05755841|||COHORT||PROSPECTIVE|||||||
33965848|NCT06485037|RANDOMIZED|PARALLEL||PREVENTION||NONE||This was a randomized, controlled experimental study. The recruited participants will be randomized to follow one of two groups: i) TRE, during which the participants will have to restrict the daily time allocated to eating to a window of 10 hours per day but without any other diet modification (e.g., types of food or amount of energy consumed). The fasting period of participants assigned to this intervention must include between 11 p.m. and 6 a.m. Each participant can freely choose the starting time of their eating window. If a participant needs to make modifications to the start time of her feeding window, he/she may do so only once during the study, and the research team must be informed; ii) Control, during which the participants must continue with their usual eating pattern, without making any changes. The duration of the intervention will be 8 weeks. Randomization will be done using computer-generated random numbers.||||
33965849|NCT00380913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965850|NCT00391937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965851|NCT05950633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965852|NCT01909505|||COHORT||PROSPECTIVE|||||||
33965853|NCT00591487|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33965854|NCT06388668|||CASE_ONLY||PROSPECTIVE|||||||
33965855|NCT00345683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33965856|NCT02191956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965857|NCT04009473|NA|SINGLE_GROUP||TREATMENT||NONE||"Pre-post study design:~A study group receives the intervention, and the changes in parameters were measured and compared before and after the intervention."||||
33965858|NCT03893409|||COHORT||PROSPECTIVE|||||||
33965859|NCT05633537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965860|NCT00240864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965861|NCT06529224|||OTHER||CROSS_SECTIONAL|||||||
33965862|NCT00769080|||||PROSPECTIVE|||||||
34188122|NCT01906606|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34188123|NCT01875406|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33754588|NCT06457633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-blind, parallel-group, randomized controlled trial|f|f|t|t
34188124|NCT01255436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754589|NCT01952496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754590|NCT01437826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754591|NCT03227679|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Participant, Nurse, and RAs all blinded to random Arm assignment, none blinded to medication prescription|Parallel arm pilot trial with a single-arm crossover design|t|t|f|t
33754592|NCT06202833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blind for patients, blind for data processing personnel, not blind for acupuncture operators|For stroke patients with consciousness disturbance, the Glasgow coma score was between 3 and 9 points, the patient's vital signs were stable, and the onset time of consciousness disturbance caused by stroke was confirmed to be less than 6 months; Clinical and auxiliary examination confirmed that cerebral infarction or cerebral hemorrhage is the only factor causing consciousness disorder, excluding other diseases caused consciousness disorder patients; Aged between 18 and 85 years old; Family members or authorized clients are informed and sign informed consent; Did not enter other clinical studies at the same time.|t|f|t|t
33754593|NCT05347264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34066978|NCT02061423|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34188125|NCT00990197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188126|NCT00613275|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34188127|NCT02930018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188128|NCT04610593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188129|NCT03185962|||COHORT||PROSPECTIVE|||||||
34188130|NCT03702283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188131|NCT06414993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34188132|NCT00511368|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34188133|NCT01926262|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34188134|NCT05226637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This two-arm parallel randomized double blinded controlled trial design study is designed as a pilot study, with the intention of using the result to inform a larger study across multiple centers. The study will be interventional using an existing device for specialized indication.|t|f|t|t
34188135|NCT06516536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34188136|NCT02425852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188137|NCT04413617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188138|NCT00965861|||COHORT|||||||||
34188139|NCT05569070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34188140|NCT02433808|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34188141|NCT00734877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188142|NCT05548322|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants will take part in experiments that investigate the seven arms of the study. Participants with an amputation will only take part in arm 7. Healthy participants may take part in one to six arms (arms 1-6). However, this is dependent upon the recordings found in the experiment.|t|f|f|f
34188143|NCT04660565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188144|NCT05812313|||COHORT||PROSPECTIVE|||||||
34188145|NCT00126724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188146|NCT04683614|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34188147|NCT00845117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188148|NCT02482974|||COHORT||PROSPECTIVE|||||||
34188149|NCT02747836|||CASE_CONTROL||PROSPECTIVE|||||||
34188150|NCT01919983|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34188151|NCT01964820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34188152|NCT05669261|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|To ensure proper Randomization, the Sponsor has elected to use the NIH National Cancer Institute Clinical Trial Randomization tool|The proposed study is a randomized single-center, double-blinded, placebo controlled standard of care plus study. Once safety has been certified by IRB/ HRPP, the study will be unblinded and participants that received the placebo treatment will be offered the opportunity to crossover and receive 150 million cell ATCell™ autologous treatment with the same monitoring and clinical support afforded to the first treatment cohort|t|t|t|f
34188153|NCT03929380|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
34188154|NCT03920332|||COHORT||RETROSPECTIVE|||||||
34188155|NCT05453591|NA|SINGLE_GROUP||OTHER||NONE||||||
34188156|NCT02817568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34188157|NCT02050893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188158|NCT02025413|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34188159|NCT04239014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The olaparib and placebo arms will be double blinded, whereas the ceralasertib+olaparib arm will be open label.||t|f|t|f
34188160|NCT01847027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754594|NCT06481748|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33754595|NCT04369014|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33754596|NCT00372281|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754597|NCT05477082|||COHORT||PROSPECTIVE|||||||
33754598|NCT03175770|||COHORT||PROSPECTIVE|||||||
33754599|NCT06329492|NA|SINGLE_GROUP||TREATMENT||NONE||Single group cohort of 20 subjects||||
33870294|NCT03700320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870295|NCT05952440|||COHORT||OTHER|||||||
33870296|NCT03213964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870297|NCT05445401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870298|NCT03946137|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentric experimental study before-after with intervention of Chest physiotherapy and workshops of postural hygiene in 30 children from 0 to 6 years with chronic neurological diseases and respiratory complications.||||
34188161|NCT03898557|RANDOMIZED|PARALLEL||TREATMENT||NONE||HIV self-test kits will be distributed at fixed-point distribution sites in the Tshwane district of South Africa and will be grouped into clusters to randomly receive intervention or control. About 44 clusters with an average of 30 participants per cluster, will be selected for the study.||||
34188162|NCT06355232|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|A comparator vaccine (influenza) with an identical appearance will be used as the control.|Randomised, controlled cross-over study|t|f|t|t
34188163|NCT01130935|||COHORT||PROSPECTIVE|||||||
34188164|NCT05410873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188165|NCT00297518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34188166|NCT05266170|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188167|NCT04759443|||COHORT||PROSPECTIVE|||||||
34188168|NCT00000903||||TREATMENT||NONE||||||
33870299|NCT03856853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870300|NCT04308070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870301|NCT05462964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870302|NCT05988450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870303|NCT03231046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870304|NCT00006448|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33870305|NCT04185753|||COHORT||CROSS_SECTIONAL|||||||
33870306|NCT02566291|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33870307|NCT06466304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870308|NCT04326712|||CASE_ONLY||PROSPECTIVE|||||||
33870309|NCT00552175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870310|NCT02506595|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34188169|NCT00372593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188170|NCT01568242|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34188171|NCT01898260|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34188172|NCT01638871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34188173|NCT01521403|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34188174|NCT04587661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188175|NCT00000369|RANDOMIZED|||TREATMENT||||||||
34188176|NCT01113866|||COHORT||PROSPECTIVE|||||||
34188177|NCT02222948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188178|NCT00649909|||COHORT||PROSPECTIVE|||||||
34188179|NCT01955148|||CASE_ONLY||PROSPECTIVE|||||||
34188180|NCT02817009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188181|NCT03125616|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be an open label, phase IV study.||||
33870311|NCT03359291|NA|SINGLE_GROUP||OTHER||NONE||All subjects will receive rosuvastatin alone (treatment A) or with macitentan at steady state (treatment B). A fixed sequence design was selected to avoid a lengthy washout period and unnecessary prolongation of subjects' participation in the study.||||
33754600|NCT02361515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870312|NCT03739905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870313|NCT01994382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870314|NCT01490099|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33870315|NCT04777136|RANDOMIZED|PARALLEL||PREVENTION||NONE||Home visit from the geriatric team||||
33870316|NCT06443918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be informed during consent that they will have a 50-50 chance of receiving the intervention.|Half of families will be randomly assigned to the intervention group. The intervention will include family-based activities for improving child and family mental health and functioning delivered as psychoeducation and activities through the smartphone app. The intervention also includes real-time feedback and coaching of family interactions through a just-in-time adaptive intervention (JITAI).|t|t|t|t
33870317|NCT05548348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870318|NCT03862352|||COHORT||OTHER|||||||
33870319|NCT06489496|||OTHER||PROSPECTIVE|||||||
33870320|NCT02713542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870321|NCT03242265|NA|SINGLE_GROUP||SCREENING||SINGLE|NK cell activity not provided to investigator prior to biopsy; results of biopsy not provided to biochemistry lab||f|f|f|t
33870322|NCT02657161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870323|NCT00139347|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33870324|NCT02365220|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33870325|NCT04646785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized, multicenter, clinical trial with assessments at baseline, post treatment (3 months later) and follow-ups at 6, 9 and 12 months after baseline.||||
33870326|NCT00859599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870327|NCT01967355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870328|NCT04512443|||OTHER||PROSPECTIVE|||||||
33870329|NCT04140656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The study was planned as a randomized controlled clinical trial; by simple randomization method, cases will be divided into two groups. There are 40 elderly people in the nursing home to be studied. Study was planned as group 1 and group 2. 40 minutes / 3 days per week / 8 weeks long program will be applied to both groups. Four weeks after the first measurement, the second measurement was performed. After the second measurement, rehabilitation program was started in both groups. After the 8-week program is finished, the third measurements will be made. After the third measurements, the fourth measurement will be done 4 weeks later for late results. The measurements are as follows: Primary results: electronic pedobarography device for static and dynamic base pressure changes. Biodex balance test for measuring fall risk and static stability.~For secondary results; 30 second Chair stand test, Berg balance scale, Semmes weinstein monofilament test."|f|f|t|f
33870330|NCT02325115|||COHORT||PROSPECTIVE|||||||
33870331|NCT04828070|||OTHER||PROSPECTIVE|||||||
33870332|NCT02306109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870333|NCT00066768|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870334|NCT00003784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870335|NCT06448702|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870336|NCT02477657|||COHORT||PROSPECTIVE|||||||
33870337|NCT05005806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||100 participants will asses for eligibility and underwent randomized double blind placebo controlled clinical trial .in whom they meet inclusion criteria with informed consent from participants and will be held at out patient clinic of Rheumatology department at Erbil- Iraq.|t|t|t|f
33870338|NCT03565575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||matched-cluster randomized controlled trial|f|f|f|t
33870339|NCT00111280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188182|NCT04752904|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||randomized double blind controlled trial|t|f|t|t
34188183|NCT06445985|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients with DMD, show great variability in age and speed of deterioration. As such it is difficult to find matched controls for a short randomised intervention study. Instead, due to the progressive nature of DMD and the inherent variance within a mixed age and ability population, the participants will act as their own controls. This single-arm, non-crossover design where the participant acts as his own control, although not as robust as randomized control exercise trials, is advocated for longitudinal interventions in populations such as the present one.||||
34188184|NCT02386644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188185|NCT05480267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188186|NCT02112071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188187|NCT05631483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188188|NCT01576809|NA|SINGLE_GROUP||||NONE||||||
34188189|NCT04410952|||COHORT||RETROSPECTIVE|||||||
34188190|NCT00993330|||CASE_ONLY||PROSPECTIVE|||||||
33870340|NCT00861250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870341|NCT00002142||||TREATMENT||NONE||||||
33870342|NCT00974675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870343|NCT00619970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870344|NCT00997451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870345|NCT05192356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870346|NCT03010969|||COHORT||PROSPECTIVE|||||||
33870347|NCT03817554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870348|NCT02403570|||CASE_ONLY||PROSPECTIVE|||||||
33870349|NCT01242267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870350|NCT06541067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870351|NCT00540059|||DEFINED_POPULATION||PROSPECTIVE|||||||
33870352|NCT05798676|||COHORT||PROSPECTIVE|||||||
33870353|NCT03173729|||COHORT||PROSPECTIVE|||||||
33870354|NCT01395199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870355|NCT02285998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870356|NCT04897477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870357|NCT00645814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870358|NCT02603367|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33870359|NCT02408705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33870360|NCT02349399|||COHORT||RETROSPECTIVE|||||||
33870361|NCT01673711|||OTHER||PROSPECTIVE|||||||
33870362|NCT06039462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870363|NCT02867176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34188191|NCT00170859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188192|NCT03674905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188193|NCT05021068|||OTHER||CROSS_SECTIONAL|||||||
34188194|NCT03646461|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multi-center, randomized, controlled, clinical trial. Enrollment will be stratified by HPV status and randomized in a 1:1 ratio to either ibrutinib + cetuximab or ibrutinib + nivolumab||||
34188195|NCT03692299|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Clinical Trial||||
34188196|NCT00522769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188197|NCT04988581|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188198|NCT01776580|||COHORT||PROSPECTIVE|||||||
34188199|NCT04244916|||COHORT||PROSPECTIVE|||||||
34188200|NCT04669444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group, intervention||||
34188201|NCT02386540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188202|NCT06516094|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34188203|NCT05677113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188204|NCT00773214|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34188205|NCT03307876|||CASE_CONTROL||PROSPECTIVE|||||||
34188206|NCT01750229|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34188207|NCT02124993|||||PROSPECTIVE|||||||
34188208|NCT01885598|||CASE_ONLY||PROSPECTIVE|||||||
34188209|NCT04752241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188210|NCT01168076|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188211|NCT00495248|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188212|NCT05317741|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34188213|NCT05166200|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34188214|NCT05644522|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188215|NCT04673019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a partial crossover trial in which immediate treatment group participants receive the Nurse AMIE intervention in full for 3 months, then continue Nurse AMIE (without navigation) for 3 months, while the delayed intervention group will not receive an intervention for 3 months, followed by receiving the Nurse AMIE full intervention with navigation for 3 months. The primary comparisons will be between the immediate treatment and delayed treatment groups over the first 3 months.||||
33870364|NCT05609474|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33870365|NCT00589420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870366|NCT01362361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870367|NCT02558673|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870368|NCT00507949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870369|NCT04086082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870370|NCT04750759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870371|NCT03741114|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which was used.|The study was a double-blind randomized controlled trial carried out in a tertiary University Hospital|t|t|t|t
33870372|NCT03295877|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870373|NCT04170439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Women who will receive clomiphe citrate plus N acetyle cysteine rally in arm number 1 And women who will receive clomiphene citrate and chromoum in arm number 22|t|t|f|t
33870374|NCT02458521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870375|NCT01512836|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870376|NCT05957250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocenter, non-randomized, non-blinded, prospective observational study.||||
33870377|NCT01328951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754601|NCT05982769|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33754602|NCT04434560|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754603|NCT04535947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigation product (1% SDP-4 ophthalmic solution and vehicle) will be provided in single-use doses (SUDs) contained in foil pouches.|Subjects will be randomized to either 1% SDP-4 ophthalmic solution or vehicle in 1:1 ratio in parallel groups.|t|t|t|t
33754604|NCT04843930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants and care managers will be instructed not to reveal the group assignment to the member of the research team conducting assessments. Following the completion of recruitment, data analysts will be provided with the data for the arms simply labelled as Group A and Group B to avoid bias. These generic labels will be unmasked only after completion of all the planned statistical analyses described below. Participants in the waitlist control arm who begin the intervention at the end of the waitlist period will have different assessors for the initial 6-week control procedures and the subsequent 6-week intervention period so as to maintain the blind."|This study is a randomized clinical trial designed to compare efficacy of the AKL-T01 intervention relative to a waitlist control in patients who were infected with COVID-19. Participants will be randomized to the AKL-T01 or a waitlist control. We will use a waitlist design; at the end of the intervention period, participants in the control group will have the option to receive the 6-week AKL-T01 intervention.|f|f|t|t
33870378|NCT01841502|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33870379|NCT02324855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188216|NCT02964169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34188217|NCT03751930|||COHORT||PROSPECTIVE|||||||
34188218|NCT06146361|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster Randomized||||
34188219|NCT04163211|||COHORT||RETROSPECTIVE|||||||
34188220|NCT01469377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188221|NCT03532867|NA|SINGLE_GROUP||OTHER||NONE||To study the changes in choroidal thickness of the macular region during aerobic exercise inducing an increase in systolic and diastolic blood pressure in healthy subjects measured by Optical Coherence Tomography (OCT) provides cross-sectional imaging of the choroid and in vivo measurement of its thickness Patients are treated in the usual way but the study is an interventional study, with minimal risks and constraints, because of the imaging (OCT image in EDI mode)||||
34188222|NCT04056390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188223|NCT01662609|||CASE_ONLY||PROSPECTIVE|||||||
34188224|NCT02342236|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34188225|NCT03868813|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754605|NCT06136390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33754606|NCT00232492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754607|NCT04308564|||COHORT||PROSPECTIVE|||||||
33754608|NCT02909348|||COHORT||PROSPECTIVE|||||||
33754609|NCT02209584|||COHORT||PROSPECTIVE|||||||
33754610|NCT04791982|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754611|NCT01795430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754612|NCT02226913|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33754613|NCT04052464|||COHORT||CROSS_SECTIONAL|||||||
33754614|NCT02953301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870380|NCT02781142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870381|NCT01561950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870382|NCT02459327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33870383|NCT01258244|||OTHER||PROSPECTIVE|||||||
33870384|NCT02114320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870385|NCT02670070|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188226|NCT03445832|||CASE_ONLY||RETROSPECTIVE|||||||
34188227|NCT00702299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188228|NCT05593068|||COHORT||RETROSPECTIVE|||||||
34188229|NCT00746057|NA|SINGLE_GROUP||||NONE||||||
34188230|NCT00101452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188231|NCT03881527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188232|NCT05178797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician will also be masked.|Participants are assigned to one of groups (A and B) in parallel for the duration of the study|f|f|f|t
34188233|NCT04241562|||COHORT||PROSPECTIVE|||||||
34188234|NCT03078140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188235|NCT04436848|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34188236|NCT01072604|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188237|NCT03458104|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188238|NCT00728403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188239|NCT00135499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188240|NCT02336529|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34188241|NCT00351052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188242|NCT05939843|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33754615|NCT03113474|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33870386|NCT04450680|||COHORT||PROSPECTIVE|||||||
33870387|NCT05929716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870388|NCT02639611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188243|NCT00774566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870389|NCT04363528|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33870390|NCT03639103|||CASE_ONLY||PROSPECTIVE|||||||
33870391|NCT02839408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870392|NCT05327413|||COHORT||PROSPECTIVE|||||||
33870393|NCT02865018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188244|NCT02335788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188245|NCT02974543|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34188246|NCT03855488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Baseline (pre-intervention) outcome measures will be completed at the first visit to our lab at Ryerson University. Participants will then be randomly assigned to one of the following conditions: (1) imagery CBM-I, (2) standard CBM-I (i.e., no instruction to use imagery), or (3) a neutral control condition. The participants will then practice their respective training at home for 7 days (60 scenarios/day). During this at-home training period, participants will track their worry three times per day. All the outcome measures will be reassessed at post-intervention, and 2-week follow-up. Worry will also be assessed at 1-week follow-up.|t|f|f|f
34188247|NCT03007225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188248|NCT06245980|||COHORT||PROSPECTIVE|||||||
34188249|NCT02728167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188250|NCT00865280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188251|NCT03358524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188252|NCT05346068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prospective, randomized, multicenter, non-inferiority trial with blinded assessment of outcomes (PROBE design)||f|f|f|t
34188253|NCT04485351|||COHORT||CROSS_SECTIONAL|||||||
34188254|NCT06254885|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33870394|NCT02571127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870395|NCT04647474|||COHORT||PROSPECTIVE|||||||
33870396|NCT05401084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870397|NCT01846728|NA|SINGLE_GROUP||OTHER||NONE||||||
33870398|NCT02836028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870399|NCT00836043|||COHORT||PROSPECTIVE|||||||
33870400|NCT01887236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33870401|NCT05664542|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Procedure will be done after patient will undergo GA for surgery. Medications will be prepared by anesthetist not involved in the study. The nurse/doctor who will assess the outcome will not know the group allocation|2 groups, one with block and other with no block|t|t|t|t
33870402|NCT01877187|NA|SINGLE_GROUP||OTHER||NONE||||||
34188255|NCT05102032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188256|NCT00273793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188257|NCT01574183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870403|NCT00612950|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34188258|NCT00276341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188259|NCT00299390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188260|NCT03816293|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Randomized stepped wedge cluster but site||||
34066979|NCT04595084|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arms, one intervention (8-wk MBCT-R + CHA-MW) and two comparator arms (8-wk iCBT + CHA-MW or CHA-MW alone) which are randomly assigned at the same time and are implemented in parallel.||||
34066980|NCT01638195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34066981|NCT03731026|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||3-Group Study||||
34066982|NCT02392702|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34188261|NCT05741619|||COHORT||RETROSPECTIVE|||||||
34188262|NCT04159207|||COHORT||PROSPECTIVE|||||||
34188263|NCT02232568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34188264|NCT06251882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188265|NCT01614691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188266|NCT01411891|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188267|NCT02515721|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34188268|NCT03666364|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34188269|NCT00085176|||||PROSPECTIVE|||||||
34188270|NCT02790892|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34188271|NCT01600144|||OTHER||PROSPECTIVE|||||||
34188272|NCT02141503|||COHORT||OTHER|||||||
34188273|NCT05933382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188274|NCT03313037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34188275|NCT03463928|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188276|NCT02214394|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34188277|NCT01646489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188278|NCT00975780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188279|NCT04704596|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188280|NCT05814172|||COHORT||RETROSPECTIVE|||||||
34188281|NCT03105752|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34188282|NCT04618848|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188283|NCT00470886|||COHORT||PROSPECTIVE|||||||
34188284|NCT01147913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754616|NCT04830072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754617|NCT06347302|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870404|NCT00337909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870405|NCT04563780|||OTHER||RETROSPECTIVE|||||||
33870406|NCT01809951|||CASE_ONLY||PROSPECTIVE|||||||
33870407|NCT00217204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33870408|NCT02513849|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870409|NCT01436136|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33870410|NCT00548015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870411|NCT06341530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870412|NCT00993642|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870413|NCT05015075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870414|NCT00625209|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34066983|NCT01539928|||CASE_ONLY||PROSPECTIVE|||||||
34188285|NCT01723033|||CASE_CONTROL||PROSPECTIVE|||||||
34188286|NCT03843554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors will grade the oral mucositis.|Prospective, single blind, two arm, randomized, controlled trial|f|f|f|t
34188287|NCT03544177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures assessors, blinded to group allocation, will not have access to the randomization list and unblinding will not be possible for these researchers.|Single-center pilot randomized parallel group clinical trial|f|f|f|t
34066984|NCT02555930|||COHORT||CROSS_SECTIONAL|||||||
34066985|NCT02756598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34066986|NCT04437446|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study is a prospective multicentric and interventional trial that aims to compare the vascular density between patients with glaucoma and patients without glaucoma.||||
34066987|NCT04895332|||COHORT||RETROSPECTIVE|||||||
34066988|NCT01140412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34066989|NCT02814617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34066990|NCT06200272|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34066991|NCT02350699|||COHORT||PROSPECTIVE|||||||
34066992|NCT04114214|||COHORT||RETROSPECTIVE|||||||
34066993|NCT04125940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-Blind|Single-blind, pre-post ingestion, control|t|f|f|f
34066994|NCT03637530|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34066995|NCT05175820|||COHORT||CROSS_SECTIONAL|||||||
34188288|NCT06406296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Randomization assigned participants to 2 arms:~ACT group Waiting list"|t|f|f|f
34188289|NCT00923572|||COHORT||PROSPECTIVE|||||||
34188290|NCT00212589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34188291|NCT06246201|||CASE_ONLY||PROSPECTIVE|||||||
34188292|NCT00644800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188293|NCT00276523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188294|NCT03646396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Drug sof-Dakla"||||
34188295|NCT06156748|||COHORT||RETROSPECTIVE|||||||
34188296|NCT01500720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188297|NCT02223377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870415|NCT05949619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870416|NCT05929898|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33870417|NCT02100436|RANDOMIZED|PARALLEL||PREVENTION||||||||
33870418|NCT04278963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33870419|NCT04030221|||OTHER||PROSPECTIVE|||||||
33870420|NCT05217485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional single arm, prospective cohort||||
33870421|NCT05335499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870422|NCT00002400||||TREATMENT||||||||
33870423|NCT00657813|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870424|NCT06125912|NA|SINGLE_GROUP||OTHER||NONE||||||
34188298|NCT02794532|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188299|NCT05133310|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical randomized trial||||
34188300|NCT04271397|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188301|NCT02314819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188302|NCT04499924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965863|NCT04583839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There will be two cohorts. One cohort will be provided intensive, individualized patient navigation services through one year postpartum, with a focus on diabetes prevention. The second cohort will receive usual care.||||
33965864|NCT01335464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188303|NCT06213103|||COHORT||PROSPECTIVE|||||||
34188304|NCT01043367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188305|NCT04621149|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||This will be a randomized, blinded placebo-controlled study with respect to the active treatment vs placebo, and randomized open-label with respect to non-prescription medicine and supplements.|t|t|t|t
34188306|NCT06186843|NA|SINGLE_GROUP||TREATMENT||NONE|There will be no masking.|A single group of kidney transplant recipients will transition to a plant-based diet and be followed for 24 weeks.||||
34188307|NCT00976924|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188308|NCT06265662|NA|SINGLE_GROUP||PREVENTION||NONE||Single-arm quasi-experimental study for evaluating the effectiveness of a digital health program in weight reduction for the prevention of non-communicable diseases in the Thai workplace setting.||||
34188309|NCT01635426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34188310|NCT03037580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188311|NCT05036421|NA|SINGLE_GROUP||OTHER||NONE||open label, single-dose, one-period, design||||
34188312|NCT02689362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188313|NCT03083873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188314|NCT01691222|NA|SINGLE_GROUP||||NONE||||||
33965865|NCT02998788|||COHORT||PROSPECTIVE|||||||
33965866|NCT01588587|||COHORT||PROSPECTIVE|||||||
33965867|NCT00512356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33965868|NCT01501201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754618|NCT03603080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870425|NCT03836495|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33870426|NCT06547658|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870427|NCT04774731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870428|NCT04871269|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33870429|NCT04144374|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870430|NCT04658901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870431|NCT01213420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870432|NCT06178445|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients will receive SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab.||||
33870433|NCT04472520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870434|NCT04649632|||COHORT||RETROSPECTIVE|||||||
33870435|NCT00210392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870436|NCT04672564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870437|NCT00332254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965869|NCT03165266|||CASE_ONLY||PROSPECTIVE|||||||
33965870|NCT05640882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965871|NCT05888207|NA|SEQUENTIAL||OTHER||NONE||||||
33965872|NCT05151094|||COHORT||OTHER|||||||
34188315|NCT06079099|||OTHER||PROSPECTIVE|||||||
34188316|NCT05998057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group will be asked to continue the standard (routine) classical training training (5 days/12 weeks).|The intervention group will be given neuromuscular exercises 5 days a week for 12 weeks.|f|f|f|t
34188317|NCT05862103|||COHORT||PROSPECTIVE|||||||
34188318|NCT02431962|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34188319|NCT04149756|||COHORT||PROSPECTIVE|||||||
34188320|NCT04565704|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34188321|NCT02280408|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34188322|NCT04041167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870438|NCT00464321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870439|NCT02701452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870440|NCT03399136|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33870441|NCT03800784|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870442|NCT04653610|||COHORT||PROSPECTIVE|||||||
33870443|NCT04274855|||OTHER||CROSS_SECTIONAL|||||||
33870444|NCT03802383|||COHORT||PROSPECTIVE|||||||
33870445|NCT05688878|NA|SINGLE_GROUP||TREATMENT||NONE||An exploratory-descriptive qualitative study will be conducted . This study will be conducted with 10 stroke patients receiving threshold electrical stimulation therapy. Threshold electrical stimulation will be applied for 4 weeks, 3 days a week, for one hour. At the end of the 4th week, semi-structured focus group interviews will be held with the patients. . In the semi-structured focus group interviews, the same questions will be asked to all participants and the verbal answers to these questions will be recorded with voice recorders. Compared to taking notes by hand; It will be preferable to record the conversation with a voice recorder because it has advantages such as recording all the interviews and allowing the interviewer to focus on the interview. Thematic analysis method will be used in the evaluation of the data.||||
33870446|NCT04563273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33870447|NCT00867789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870448|NCT04931784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870449|NCT02079857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870450|NCT02036242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33870451|NCT04521829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870452|NCT03079206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|In terms of study inclusion there will be no masking. Only the food challenge itself will be masked.|The study intends to compare the outcome of food challenge with hazelnut and the in vitro basophile activation test using hazelnut extract and allergens||||
33870453|NCT00454103|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870454|NCT00906802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870455|NCT05797987|||COHORT||RETROSPECTIVE|||||||
33870456|NCT03938779|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participants do not know that there is a control group and an intervention group|Volleyball team will be evaluated in two moments, at the beginning and 4 months after the PFMT. After 4 months, to compare with the control group and to evaluate if there are differences between groups, namely muscle strength|t|f|f|f
33870457|NCT03598647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870458|NCT05843006|||COHORT||PROSPECTIVE|||||||
33870459|NCT05656768|NA|SINGLE_GROUP||OTHER||NONE||||||
33965873|NCT04551807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33965874|NCT04821440|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33965875|NCT06243081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This research is a randomized controlled experimental study. It was planned to divide the students into two groups as experimental and control groups. Simple random sampling method will be used to determine the experimental and control groups. To ensure randomization, each student will be numbered and data sets (experiment and control) will be created.||||
33965876|NCT01440647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965877|NCT00201929|RANDOMIZED|PARALLEL||||NONE||||||
33965878|NCT04052074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34066996|NCT04273867|||COHORT||PROSPECTIVE|||||||
33870460|NCT02389023|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870461|NCT01472770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870462|NCT03558984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Subjects will be blinded to the treatment arm assignment. The study site personnel present at the baseline procedure as well as the physician performing the procedure will be trained not to disclose the treatment arm to the subject, his/her family, to health care providers outside of the surgery department and to the study sponsor.~Two independent of the sponsor/investigator committees will be involved in the assessment of study outcomes."|"Eligible subjects will be randomized to either the treatment arm (D-PLEX + SOC prophylactic antibiotic treatment) or to control arm (SOC prophylactic antibiotic treatment only), in a 1:1 ratio.~Subjects will be blinded to the study arm."|t|f|f|t
33870463|NCT00254501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870464|NCT00587548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965879|NCT00920335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965880|NCT00548288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965881|NCT06536829|RANDOMIZED|PARALLEL||OTHER||SINGLE|single|Randomized Controlled Trial.|f|f|f|t
33965882|NCT01695798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33965883|NCT03941171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding|Randomized controlled trial|f|f|f|t
33965884|NCT05402761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965885|NCT02677610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33965886|NCT00688610|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965887|NCT06189183|NA|SINGLE_GROUP||TREATMENT||NONE||Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection||||
33965888|NCT01331083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965889|NCT00947765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965890|NCT04768829|RANDOMIZED|PARALLEL||TREATMENT||NONE||moringa extract ear drops||||
33965891|NCT05755633|||CASE_ONLY||RETROSPECTIVE|||||||
33965892|NCT01190826|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33870465|NCT05281133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A total of 80 children assigned by randomization method (experimental group=40, control group= 40) were included in the sample group. The Participant Information Form, the Practice Registration Form, the Wong Baker Pain Scale, the State Anxiety Inventory for Children, the After Splint Child's General Condition Evaluation Form, virtual reality glasses and pulse oximeter were used to collect data by outcomes assessor. Pain, anxiety and vital signs of the children in the experimental and control groups were recorded before, during and after the splint. The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes. In the control group, during the splint a video was not watched."|The study was carried out as a randomized controlled. In the study, two groups consisted of experimental group (n=40) and control group (n=40) were determined.|t|t|f|t
33870466|NCT00013208|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965893|NCT05755594|NA|SINGLE_GROUP||TREATMENT||NONE|The way of surgery.|||||
33965894|NCT00172302|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33965895|NCT03565666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33965896|NCT00978926|||COHORT||PROSPECTIVE|||||||
33965897|NCT00492388|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33965898|NCT00406432|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754619|NCT00550485|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33754620|NCT01799265|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33754621|NCT00845663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754622|NCT00361140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754623|NCT00107250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965899|NCT01357785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965900|NCT02058771|||COHORT||PROSPECTIVE|||||||
33965901|NCT00821990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965902|NCT02323295|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965903|NCT01560091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754624|NCT05626413|||COHORT||PROSPECTIVE|||||||
33754625|NCT04784702|||CASE_CONTROL||PROSPECTIVE|||||||
33754626|NCT04365582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754627|NCT03750006|NA|SINGLE_GROUP||TREATMENT||NONE||The goals of this proposal are to: 1) investigate the feasibility of recruiting and administering short session HIIT to frail, pre-frail, and non-frail older Veterans and 2) to characterize the physical performance benefits and serum microRNA (miRNA) profiles in those participants.||||
33754628|NCT05890443|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental and control groups were evaluated separately. There was no need for blinding.|A Randomized Experimental Study|t|f|f|f
33754629|NCT03498508|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754630|NCT05439902|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||One month of intervention of drug or placebo followed by one month wash-out period and then final one month intervention with the remaining treatment not received in the first cycle.|t|f|t|t
33754631|NCT04592445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject and HF Cardiologist providing care are blinded. Interventionalist who performs the Index procedure is not|Subjects randomized 1:1 (treatment to sham control); cross-over offered|t|f|f|t
33754632|NCT02923804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754633|NCT04932629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754634|NCT00416182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33754635|NCT04616508|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754636|NCT05807243|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33754637|NCT02605629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33754638|NCT04231708|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo (lactose) for pharmacological stressor, and sham for dlPFC rTMS|Double-blind, 10Hz left dlPFC rTMS (vs. sham) X pharmacological stressor (vs. placebo) within-subject, randomized crossover design.|t|f|f|t
33754639|NCT03993548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965904|NCT06445556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This pilot study is a two-arm, parallel randomized controlled trial. 12-16 parent-child dyads will be recruited||||
34188323|NCT05201300|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34188324|NCT05066048|||COHORT||PROSPECTIVE|||||||
34188325|NCT01957306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188326|NCT00552435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188327|NCT01153334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188328|NCT02506348|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34188329|NCT02835079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188330|NCT02186093|||CASE_ONLY||PROSPECTIVE|||||||
34188331|NCT02533453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188332|NCT06210139|||COHORT||CROSS_SECTIONAL|||||||
34188333|NCT03830619|||COHORT||PROSPECTIVE|||||||
34188334|NCT02838394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754640|NCT05030948|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33754641|NCT01877408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754642|NCT02329054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754643|NCT00789087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754644|NCT01245010|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33754645|NCT05321719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754646|NCT01263834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754647|NCT00104169|NON_RANDOMIZED|||TREATMENT||||||||
34188335|NCT03348059|||COHORT||RETROSPECTIVE|||||||
34188336|NCT00606437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870467|NCT02023775|||COHORT||PROSPECTIVE|||||||
33870468|NCT03568591|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Coded-analysis group allocation and database - blind to allocation.|A researcher-blind parallel-group controlled psychosomatic therapy intervention trial.|f|f|t|t
33870469|NCT01626898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33870470|NCT02937012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870471|NCT05003947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870472|NCT04059172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Ibuprofen, acetaminophen and placebo tablets have been prepared to look identical by a pharmacy. The appropriate tablets are placed in a blister pack to be delivered to the study participant. The number of tablets are the same for each blister in all blister packs.~The study participant, care provider, investigators and the outcomes assessor are all blinded to the groups."|Two investigational groups and a placebo group|t|t|t|t
33870473|NCT05105464|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870474|NCT04041089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870475|NCT05530720|||OTHER||CROSS_SECTIONAL|||||||
33870476|NCT00627887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870477|NCT00147056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870478|NCT03527134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two groups: one with amantadine treatment and the other with amantadine treatment.|t|t|f|t
33965905|NCT04656093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research coordinators (RCs) and Principal Investigator (Juan Wisnivesky) are blinded to study randomization and treatment arm for each participant.|The study team will use data from the observational component of the study to identify patients with COPD, Diabetes (DM) and/or Hypertension (HTN).|f|f|t|t
33965906|NCT01226875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965907|NCT03952936|NA|SINGLE_GROUP||TREATMENT||NONE||Case study||||
33965908|NCT03104088|||CASE_CONTROL||PROSPECTIVE|||||||
33965909|NCT03049137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double Blind (Subject, Outcomes Assessor)||f|f|f|t
33965910|NCT01632683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34188337|NCT02369172|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34188338|NCT01348516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188339|NCT04052152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870479|NCT03890783|||COHORT||RETROSPECTIVE|||||||
33870480|NCT04756505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870481|NCT05426512|||CASE_CONTROL||RETROSPECTIVE|||||||
33870482|NCT02583906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965911|NCT05113901|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33965912|NCT05033015|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Self applied||t|t|t|f
34188340|NCT01025518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33870483|NCT03821740|||COHORT||CROSS_SECTIONAL|||||||
33870484|NCT02688491|RANDOMIZED|PARALLEL||||NONE||||||
33870485|NCT05811182|||COHORT||PROSPECTIVE|||||||
33870486|NCT06383637|||OTHER||CROSS_SECTIONAL|||||||
33870487|NCT06239337|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870488|NCT04158076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870489|NCT03581266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study was carried out using a crossover design with a three-week washout period. The participants stayed overnight at the facility and had one out of two types of breakfast in the morning.||||
33870490|NCT00303147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188341|NCT00882297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34188342|NCT02911831|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188343|NCT05978843|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants will be randomized into one of three arms. Each arm will receive a different benefit amount during the 6-month intervention period, with benefit amounts determined by a percentage of the Thrifty Food Plan (TFP) - the USDA food plan used to calculate SNAP benefit rates. For ethical reasons, participants will each receive the same total benefit amount over the course of the study, with those randomized to the lower benefit arms receiving the difference between the value of the benefits issued to them and the value of the benefits issued to the highest dose group as a lump sum payment at the end of the study.|f|f|f|t
34188344|NCT03180918|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34188345|NCT03439384|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A stepped wedge trial design was used to cluster and randomize recruiting sites into a schedule as to when sites would enroll participants into the control or intervention group.||||
33754648|NCT05182879|||OTHER||CROSS_SECTIONAL|||||||
33754649|NCT03102723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754650|NCT04745481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188346|NCT05083117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754651|NCT05933031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754652|NCT06246604|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Enrolling centers are blinded to each others. Investigators are blinded to centers allocation.|"Multicenter trial, involving 2 intervention arms: screening and standard-of-care.~Centers are randomly allocated to provide the screening or the standard-of-care."|f|t|t|t
34188347|NCT01032122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188348|NCT06090136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188349|NCT04911608|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870491|NCT00219284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188350|NCT05013541|||COHORT||PROSPECTIVE|||||||
34188351|NCT01873534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870492|NCT02201420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870493|NCT02705924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870494|NCT04544475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188352|NCT00989872|RANDOMIZED|||TREATMENT||TRIPLE|||t|f|t|t
33870495|NCT01648790|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870496|NCT00659568|NON_RANDOMIZED|||TREATMENT||NONE||||||
33870497|NCT01674075|||CASE_ONLY||PROSPECTIVE|||||||
33870498|NCT00761306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870499|NCT04026698|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This intervention study has a single group of participants who will receive the intervention. There is no control group or randomization.||||
33870500|NCT02258789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870501|NCT02359630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894141|NCT03971981|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||a double-blind cross-over in vivo study was performed to measure the salivary concentration of Xylitol released from the two chewing gums containing different amount of the polyol. The study had a cross-over design: the first half of the sample used the chewing-gum with Xylitol as the only sweeteners (64.5% of chewing-gum weight) and the other half use the chewing-gum with Xylitol among the sweeteners (22% of chewing-gum weight), after a 7-days wash-out period, the two sub-groups inverted the chewing gums. Subjects were instructed to consume the products as they normally would be consumed.|t|t|t|t
33894142|NCT01262430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965913|NCT04208191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965914|NCT04881591|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Patients will be informed of the condition they have been assigned to.|One condition||||
33965915|NCT03232749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188353|NCT00074490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188354|NCT04650529|||COHORT||PROSPECTIVE|||||||
34188355|NCT00787267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188356|NCT02236936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188357|NCT04286048|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188358|NCT03915093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34188359|NCT02479646|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34188360|NCT05438472|||COHORT||PROSPECTIVE|||||||
34188361|NCT04405453|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|One physician who will be blind will examinade all patients for eligibility and will valuate the outcome measures although the physician who will performe all injections will not be blind.|Patients with myofasial pain syndrome will randomized into two group. TMI group will receive ultrasound guided trapezius muscle injection two times with one week interval. ESPB group in the 1th week will receive ultrasound guided trapezius muscle injection and in the 2nd week ultrasound guided erector spina plane block will receive. Pain severity of the patients will evaluate by visual analog scale. Datas will obtaine before (week 0) and after (week 1,2,3,4) the injections.|f|f|t|f
34188362|NCT02888119|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188363|NCT06057467|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188364|NCT05657808|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on sex at birth then randomized to one of the study arms|t|f|t|f
34188365|NCT06521762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188366|NCT04987788|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34188367|NCT00369980|||DEFINED_POPULATION||PROSPECTIVE|||||||
34188368|NCT05465252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894143|NCT04704180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In this study, stratified sampling was employed based on Gestational age. Two strata, \[35-(35+6 days)\] and \[36-(36+6 days)\], were generated to ensure even distribution in terms of Gestational age in each group. First, ninety-two preterm neonates were stratified into two groups (A and B), which were then stratified again into two: \[35-(35+6 days)\] and \[36-(36+6 days)\].~A scheme was developed to randomize the gestational weeks of \[35-(35+6 days)\] and \[36-(36+6 days)\] into two groups (A and B), resulting in the experimental and control groups stratified by the week of gestation and blocked into paired-groups of (2:2/\[35-(35+6 days)\]:\[36-(36+6 days)\]). Permutation was also used to strike a balance between the strata. Block sets were generated for each combination of the prognostic factors (gestational age). The experimental and control groups were then randomized into the strata using a random numbers table."|f|f|t|f
33894144|NCT05288088|||COHORT||PROSPECTIVE|||||||
33894145|NCT02072629|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33894146|NCT05909891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33894147|NCT03195101|NA|SINGLE_GROUP||TREATMENT||NONE||Incisional or excisional biopsy of orbital tumors via transconjunctival approach||||
33894148|NCT03183570|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965916|NCT00170261|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33965917|NCT02456051|||COHORT||PROSPECTIVE|||||||
33965918|NCT02267252|||OTHER||PROSPECTIVE|||||||
33965919|NCT05338710|NA|SINGLE_GROUP||TREATMENT||NONE||8-week single group intervention||||
33965920|NCT02425865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965921|NCT06190782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965922|NCT00003985||||TREATMENT||||||||
33965923|NCT02941237|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965924|NCT04249063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The patient (participant), physician (care provider), recovery nurse (outcomes assessor) and researcher team (investigator) will all be blinded to the intervention. Only the assisting nurse dedicated to procedural setup will be aware of the allocated intervention.||t|t|t|t
33965925|NCT02077751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188369|NCT04502680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188370|NCT04828317|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34188371|NCT04150861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34188372|NCT02591225|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188373|NCT04306861|||COHORT||PROSPECTIVE|||||||
34188374|NCT06322654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients and their parents will not be blinded by the nature of the therapeutic procedure used after random allocation to the treatment group. Study personnel will be divided into Blinded Team and Unblinded Team to ensure objectivity of the assessment of safety and effectiveness of both strategies.|"There are two research groups with 100 patients in each group.~1. Experimental: Robotically Assisted Locomotion~2. Comparison: Robotically Assisted Verticalization"|f|f|t|f
34188375|NCT00607490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754653|NCT01826227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188376|NCT06425692|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34188377|NCT01621802|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188378|NCT00999778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34188379|NCT03894813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754654|NCT02577666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870502|NCT03235830|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Following the initial visit where consent, demographic information, and the NVS were obtained, participants were randomly assigned, by computer, to one of two groups: (1) caregiver receives only enhanced standard of care documents (ESoC), or (2) caregiver receives text messages in addition to enhanced standard of care documents (ESoC + Text). Both research team members and participants were blind to group assignment at the time of consent and enrollment. Clinic staff and providers were not aware of group assignment unless revealed by the participant.|"Caregivers of newborns (0-10 weeks of age) whose child received primary care at an urban, academic primary care clinic were approached for participation. Inclusion required reliable cellular and text messaging service and the ability to speak English. At intake, caregivers completed a brief demographic survey and were given a researcher-administered health literacy test called the Newest Vital Sign (NVS).~Following the initial visit where consent, demographic information, and the NVS were obtained, participants were randomly assigned, by computer, to one of two groups: (1) caregiver receives only enhanced standard of care documents (ESoC), or (2) caregiver receives text messages in addition to enhanced standard of care documents (ESoC + Text). Both research team members and participants were blind to group assignment at the time of consent and enrollment. Clinic staff and providers were not aware of group assignment unless revealed by the participant."|f|t|t|t
33965926|NCT01307774|||||CROSS_SECTIONAL|||||||
33965927|NCT02431884|||CASE_CONTROL||PROSPECTIVE|||||||
34188380|NCT02329418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33965928|NCT05429853|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33965929|NCT04926961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants receive both sham TMS stimulation and real TMS stimulation in different sessions.|t|f|f|f
33965930|NCT03032588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965931|NCT01757366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965932|NCT06129487|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965933|NCT05274399|||OTHER||CROSS_SECTIONAL|||||||
33965934|NCT00796211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33965935|NCT04407195|||COHORT||PROSPECTIVE|||||||
33965936|NCT04472182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Dentin Hypersensitivity|t|f|f|t
33965937|NCT02796898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188381|NCT03257449|||OTHER||PROSPECTIVE|||||||
34188382|NCT02922049|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188383|NCT04277923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34188384|NCT00279864|||||PROSPECTIVE|||||||
34188385|NCT02399163|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34188386|NCT02559375|||COHORT||PROSPECTIVE|||||||
34188387|NCT02509026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188388|NCT04785469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188389|NCT02663037|||COHORT||PROSPECTIVE|||||||
34188390|NCT01794767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34188391|NCT00458978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188392|NCT00176917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188393|NCT02532738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188394|NCT05459857|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34188395|NCT00473096|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34188396|NCT02170415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34188397|NCT02302014|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34188398|NCT00285623|||CASE_ONLY||PROSPECTIVE|||||||
34188399|NCT04678219|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 subjects will be randomized onto either the Specific Carbohydrate Diet or the low-protein (vegan/low-sulfur) diet, with 10 subjects per diet.||||
34188400|NCT03839797|RANDOMIZED|PARALLEL||PREVENTION||NONE||Half of the squadrons of incoming cadets were randomized to the CHiPS intervention, the other half were randomized to the control condition||||
34188401|NCT06287099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188402|NCT00845897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188403|NCT02905227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188404|NCT02225002||||TREATMENT||||||||
34188405|NCT01149018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188406|NCT00452816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188407|NCT04475887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188408|NCT00364104|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34188409|NCT00226759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188410|NCT05242198|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
34188411|NCT00005035||||TREATMENT||||||||
33870503|NCT04417634|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study is a single-center, randomized superiority trial to compare two strategies for the assessment of the hemodynamic relevance of coronary lesions.||||
33870504|NCT03854136|||CASE_ONLY||RETROSPECTIVE|||||||
33870505|NCT01312454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870506|NCT00374686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188412|NCT02217761|||CASE_ONLY||PROSPECTIVE|||||||
34188413|NCT03429270|NA|SINGLE_GROUP||OTHER||NONE||||||
34188414|NCT04542018|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with diarrhea predominant IBS (IBS-D) will undergo 4 weeks of low FODMAP diet. Urine, blood, stool, and colon biopsies will be collected before and after the diet to assess changes in gut physiology.||||
34188415|NCT00010699|RANDOMIZED|||TREATMENT||DOUBLE||||||
34188416|NCT05271435|||COHORT||PROSPECTIVE|||||||
34188417|NCT04980339|||COHORT||PROSPECTIVE|||||||
34188418|NCT05063448|NA|SINGLE_GROUP||PREVENTION||NONE||Perinatal father support primary intervention is small group mentoring program (with pre/post test data) run by educators at The Women's Clinic (TWC). Participants who sign up for the program early enough will be provided surveys approximately 1 month prior to the intervention start to provide a non-randomized wait-list comparison. Participants will additionally have access to follow-up daddy/baby drop-in groups and a podcast series and may be provided satisfaction surveys for both.||||
33870507|NCT00480181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34066997|NCT04842552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Hydralazine hydrochloride was imported directly from a global supplier, packed in 90 tablet bottles with a specific batch number for drug and placebo not revealed to any of the above parties.|Two arms will be randomly allocated to either hydralazine hydrochloride 25mg TDS or placebo.|t|t|t|t
34188419|NCT03586557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessor was masked to avoid measured bias|a open-labeled randomized comparison study|f|f|f|t
34188420|NCT00990548|||COHORT||PROSPECTIVE|||||||
34188421|NCT02829567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188422|NCT00934362|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34188423|NCT05461508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188424|NCT04279626|||COHORT||RETROSPECTIVE|||||||
34188425|NCT05163899|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|For a surgical vs non-surgical trial, the investigator can not be masked thus only the evaluators will be unaware of the arm.|Subjects will be randomized to one of two arms: surgical untethering or medical management only. Symptom improvement and adverse events will be assessed and recorded for 1 year from initiation of treatment. After a minimum of 1 year, subjects who were randomized to the medical management arm may cross over to the surgical arm if the PI deems it is in the subject's best interest to do so.|f|f|f|t
33754655|NCT03683147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870508|NCT04099914|||CASE_ONLY||RETROSPECTIVE|||||||
33870509|NCT03679533|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind placebo-controlled parallel intervention|t|t|t|t
33870510|NCT05162027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870511|NCT03216096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870512|NCT04501627|||COHORT||PROSPECTIVE|||||||
33870513|NCT04489745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870514|NCT04245514|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, phase II trial with 1 single arm with 3 radiotherapy cohorts||||
33870515|NCT04493021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870516|NCT00956397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870517|NCT04735445|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33870518|NCT01832220|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870519|NCT02124278|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34188426|NCT03763877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754656|NCT03284788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754657|NCT05257772|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33754658|NCT01057238|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754659|NCT04640532|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754660|NCT02940366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754661|NCT02162784|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870520|NCT05795686|NA|SINGLE_GROUP||OTHER||NONE||"* Quantitative approach by monitoring the structure's operating indicators~* Qualitative approach by semi-structured interviews with professionals of the structure~For patients:~* At inclusion:collection of socio-demographic and medical data,Quality of life (QoL) questionnaires,anxiety and depression,autonomy in health,adherence to treatment~* At end of the program:QoL questionnaires,anxiety and depression,autonomy,autonomy in health,adherence to treatment,satisfaction,semi-structured interviews~* 6 months post-program:data on retention and re-hospitalization,QoL questionnaires,anxiety and depression,autonomy in health,adherence to treatment~For caregivers:~* At inclusion:collection of socio-demographic data,QoL questionnaires,anxiety and depression,perceived burden~* At the end of the program:QoL questionnaires,anxiety and depression,perceived burden,semi-structured interviews~* 6 months post-program:data about new support,QoL questionnaires,anxiety and depression,perceived burden"||||
33870521|NCT03491007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo (PBO)-controlled, randomized Phase 2 pilot study|This is a parallel-group, double-blind, placebo (PBO)-controlled, randomized Phase 2 pilot study using adjunctive dehydroxyepiandrosterone \[DHEA (400 mg)\] will be evaluated to establish Proof of Concept (POC) for this agent in Veterans with PTSD.|t|t|t|t
34188427|NCT02110043|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33870522|NCT04566770|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754662|NCT04081467|NA|SINGLE_GROUP||TREATMENT||NONE||One group of 10 will undergo 10 days of horizontal bed rest without countermeasures.||||
33870523|NCT01816061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870524|NCT01475175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870525|NCT01143727|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33870526|NCT01599520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33870527|NCT03274570|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870528|NCT02999542|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33870529|NCT04224675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33894149|NCT01583036|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894150|NCT05307471|||CASE_CONTROL||PROSPECTIVE|||||||
34188428|NCT00451633|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34188429|NCT00462397||||TREATMENT||NONE||||||
34188430|NCT06142214|||CASE_CONTROL||PROSPECTIVE|||||||
34188431|NCT04812717|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Perfusionists will not be blinded.||t|t|t|t
34188432|NCT01053780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188433|NCT03169725|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34188434|NCT02640508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188435|NCT04658199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188436|NCT03293368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188437|NCT03098004|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34188438|NCT02611089|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34188439|NCT05119634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||there will be two groups: control and case. case group will recepe whole body vibration and control group will recepe only breathing exercise and some physical exercises|t|f|f|t
33754663|NCT03222648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||single cohort pilot study||||
33754664|NCT05362890|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33754665|NCT01484548|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33754666|NCT00050180||||TREATMENT||||||||
33754667|NCT04310553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754668|NCT03330223|||COHORT||PROSPECTIVE|||||||
33754669|NCT05077150|||CASE_CONTROL||PROSPECTIVE|||||||
33754670|NCT04779970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754671|NCT03071055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754672|NCT00506259|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33754673|NCT02992990|NA|SINGLE_GROUP||OTHER||NONE||||||
33754674|NCT05199779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"To reduce bias in the assessments, none of the constructs of interest to this study (e.g., stress, self-compassion) will be included in the language used to describe the intervention or in any materials used to advertise the study. Study participants will be told they are participating in a study on fostering emotional well-being. No further information about the intervention will be provided."|Participants will be randomized to the SCI or AC control using the randomizer elements in Qualtrics.|t|f|f|f
33754675|NCT04719091|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Triple(Participant, Care provider, investigator)||t|t|t|t
33754676|NCT05925907|||COHORT||PROSPECTIVE|||||||
33754677|NCT03369379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, the subject of study and researcher.|Longitudinal, prospective, interventional, randomized.|t|t|t|t
34188440|NCT02279706|||COHORT||PROSPECTIVE|||||||
34188441|NCT02586649|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33754678|NCT04995679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754679|NCT06130150|||CASE_CONTROL||PROSPECTIVE|||||||
33754680|NCT04523896|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33754681|NCT00737555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754682|NCT05969574|||COHORT||PROSPECTIVE|||||||
33754683|NCT02668224|RANDOMIZED|PARALLEL||||NONE||||||
33754684|NCT04220164|||COHORT||OTHER|||||||
33754685|NCT00845741|||COHORT||PROSPECTIVE|||||||
33754686|NCT01313286|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33754687|NCT06449040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754688|NCT01273233|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754689|NCT02954523|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33965938|NCT05589610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965939|NCT05488652|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33965940|NCT02116491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965941|NCT02178449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188442|NCT03208985|NA|SINGLE_GROUP||OTHER||NONE||||||
34188443|NCT02921841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188444|NCT01733680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188445|NCT01347619|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34188446|NCT05890716|||COHORT||RETROSPECTIVE|||||||
34188447|NCT03959397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188448|NCT00161343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188449|NCT01773759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188450|NCT04162080|||COHORT||CROSS_SECTIONAL|||||||
34188451|NCT05092308|||FAMILY_BASED||PROSPECTIVE|||||||
34188452|NCT02516969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188453|NCT04754659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The type of stentgraft is masked for participants, investigators and outcome assessors as the journal chart and information about implanted device are made not accessible for the above mentioned individuals, and all data will be gathered in an Electronic Case Report Form (eCRF) with stentgraft information masked.|Randomized controlled, parallel group, partly blinded clinical study.|t|f|t|t
34188454|NCT04571567|NA|SINGLE_GROUP||TREATMENT||NONE||"Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1κ monoclonal antibody targeting IL-17A. Phase III studies have demonstrated the safety and efficacy of secukinumab in the treatment of moderate-to-severe psoriasis when dosed as 300mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300mg every 4 weeks.12 Secukinumab is FDA approved for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older.~The study treatment consists of secukinumab 300mg by subcutaneous injection. Each 300mg dose is given as two subcutaneous injections of secukinumab 150mg, 1mg liquid formulation in a pre-filled syringe. Secukinumab pre-filled syringes 150 mg will be supplied by Novartis."||||
34188455|NCT05454917|||COHORT||PROSPECTIVE|||||||
34188456|NCT06079970|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188457|NCT04861168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188458|NCT04323657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188459|NCT02037230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188460|NCT04986319|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34188461|NCT04805099|||CASE_ONLY||RETROSPECTIVE|||||||
34188462|NCT04200352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188463|NCT00385437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188464|NCT00004101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188465|NCT02569788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188466|NCT04151056|||COHORT||PROSPECTIVE|||||||
33754690|NCT03228056|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33754691|NCT00414817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754692|NCT02880800|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754693|NCT01273948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754694|NCT01494337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754695|NCT06127290|||COHORT||PROSPECTIVE|||||||
33754696|NCT02330718|||COHORT||OTHER|||||||
33754697|NCT02219048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754698|NCT05433870|||CASE_ONLY||RETROSPECTIVE|||||||
33754699|NCT00000126|||||OTHER|||||||
33754700|NCT00678314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754701|NCT02454101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33754702|NCT03810625|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754703|NCT01805492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754704|NCT04911790|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870530|NCT06189807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Group assignment will be randomized at the clinic level to intervention decision aid (N=2 clinics) or control (N=2 clinics). Nephrologists will be trained to deliver the intervention.||||
33870531|NCT00933179|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33870532|NCT03279614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870533|NCT04399330|||COHORT||OTHER|||||||
33870534|NCT00806195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870535|NCT04644939|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33894151|NCT02224950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965942|NCT03636542|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33965943|NCT05397600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33754705|NCT02348814|||CASE_CONTROL||PROSPECTIVE|||||||
33754706|NCT05564013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multi-center, prospective cohort study||||
33754707|NCT04851483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Study Groups 1 and 2: open-label~* Study Group 3: open-label~* Study Group 4: double-blind"|"* Study Groups 1 and 2 using a fixed sequence parallel group design~* Study Group 3 using a fixed sequence design~* Study Group 4 using a placebo-controlled parallel design"|t|t|t|t
33754708|NCT01316510|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33754709|NCT04846452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754710|NCT04434989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965944|NCT02971865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33965945|NCT06156410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188467|NCT03367637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"We will enroll 80 advanced cancer patients with moderate to severe pain needs (10 per month) with estimated 40% females. Following informed consent, study staff will administer baseline assessments, assess eligibility and obtain consent. Subsequently, eligible consenting patients, will be randomly assigned via computer-generated randomization, to standard palliative care (currently provided at Rwanda Palliative Care and Hospice Organization) or to the new smartphone intervention (with biweekly and SOS symptom assessment and response) plus standard care for 3 months. The probability of being assigned to either group will be equal (50%).~With 36 patients per group, we will have 85% power to detect a clinically significant difference of 1 point on the pain score \[SD=1.4\] between the two treatment groups at 3-months with an alpha of 0.05. Based on prior studies and assuming an attrition rate of no more than 10%, we increased our sample size to 40 patients per group."|f|f|f|t
34188468|NCT05181436|||COHORT||CROSS_SECTIONAL|||||||
34188469|NCT03748004|RANDOMIZED|PARALLEL||OTHER||SINGLE||72 clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC (control group).|f|f|t|f
34188470|NCT03391921|RANDOMIZED|PARALLEL||PREVENTION||NONE||After a first open label phase evaluating tolerability of Gardasil9 in HIV-positive women and where all patients (n=50) have received three doses (0,2 and 6 months) of the 9valent vaccine against HPV from June 2018 to end of December 2018, the study will randomize participants between two between two different doses schedules: in the first schedule (ARM A), women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule (ARM B) will be 3 doses at 0, 2 and 6 months.||||
34188471|NCT02537015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188472|NCT04516889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188473|NCT02146534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188474|NCT02896413|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34188475|NCT01545505|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188476|NCT06029855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188477|NCT03021343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188478|NCT00201188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188479|NCT01077414|||||PROSPECTIVE|||||||
34188480|NCT04183426|||COHORT||PROSPECTIVE|||||||
34188481|NCT06172062|||COHORT||RETROSPECTIVE|||||||
33965946|NCT06314984|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34188482|NCT01085006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33965947|NCT00842790|||COHORT||PROSPECTIVE|||||||
33754711|NCT02149251|||CASE_CONTROL||RETROSPECTIVE|||||||
33754712|NCT06472466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each participant will be assigned an identification code (ID-code) randomly generated by a computer. The outcome assessors will be blind to which group (intervention or control) conditions 1 and 2 will correspond to.|"Data collected throughout the first phase of the study, will allow to identify participants at high-risk for or with insomnia and/or eating disorder symptoms. Based on these data:~Participants with eating/insomnia disorder symptoms will be randomized to one of two conditions:~1. repeated exposure to the virtual kitchen/bedroom scenario respectively (intervention condition);~2. self-help written materials (control condition).~Participants allocated to the intervention condition will be asked to use the virtual reality scenario for one week, for a minimum of three times in total and to rate their level of perceived anxiety at the beginning and at the end of each exposure session. To evaluate the feasibility and acceptability of the virtual environments, they will be asked to complete a series of visual analogue scales, EMAs of eating and/or sleep behaviours, and will participate in a brief interview to collect qualitative data on their experience."|f|f|f|t
33754713|NCT01324271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965948|NCT02621827|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965949|NCT01492712|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33965950|NCT06526689|||OTHER||PROSPECTIVE|||||||
33965951|NCT02661282|NA|PARALLEL||TREATMENT||NONE||||||
33754714|NCT04901650|||COHORT||PROSPECTIVE|||||||
33965952|NCT01319071|||COHORT||PROSPECTIVE|||||||
34066998|NCT04542811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34066999|NCT03790618|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34067000|NCT03699878|||COHORT||PROSPECTIVE|||||||
33870536|NCT04272671|RANDOMIZED|PARALLEL||PREVENTION||NONE|As this is a pragmatic design, there will be no blinding for this study.|This trial uses a cluster-randomized pragmatic design wherein clinics are randomized into intervention and control, and all patients receiving care from those clinics are categorized into intervention or control based on their clinic's participation.||||
33870537|NCT01616420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870538|NCT02381405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870539|NCT01349868|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33870540|NCT01454375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33870541|NCT04222673|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.||||
34067001|NCT01019460|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|t|f|f
34067002|NCT02389374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067003|NCT01343108|||||PROSPECTIVE|||||||
34067004|NCT02924805|||CASE_CONTROL||RETROSPECTIVE|||||||
34067005|NCT06268496|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34067006|NCT02611765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067007|NCT06324526|||COHORT||RETROSPECTIVE|||||||
34067008|NCT05253118|NA|SINGLE_GROUP||TREATMENT||NONE|open|Tislelizumab (BGB-A317) 200mg will be administered on Day 1 of each 21-day cycle (once every 3 weeks) in combination with pemetrexed. And pemetrexed 500 mg/m2 will be administered on Day 1 of each 21-day cycle (once every 3 weeks).||||
34067009|NCT04710368|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study team will screen patients scheduled for elective PCI, who are receiving statin therapy for at least 4 weeks with acceptable LDL-C levels. Patients with non-obstructive lesion (30-50% stenosis) by angiography and lipid-rich plaque with lipid arc \>90° and minimal fibrous cap thickness ≤ 120 µm detected by OCT will comprise the final study population. Serial NIRS/IVUS and OCT imaging will be performed in a non-target lesions, first during PCI and subsequently after 26 weeks.||||
34067010|NCT01066793|||COHORT||PROSPECTIVE|||||||
34067011|NCT04118179|||CASE_CONTROL||PROSPECTIVE|||||||
34067012|NCT02599064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188483|NCT01742117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188484|NCT02405468|||CASE_CONTROL||PROSPECTIVE|||||||
33870542|NCT02516787|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34188485|NCT01520064|||COHORT||PROSPECTIVE|||||||
34188486|NCT03018262|||COHORT||PROSPECTIVE|||||||
34188487|NCT04310189|NA|PARALLEL||OTHER||NONE||||||
34188488|NCT01262989|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34188489|NCT01766258|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34188490|NCT04490096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870543|NCT01847482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870544|NCT05085639|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34188491|NCT01970098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188492|NCT00895206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188493|NCT04791306|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34188494|NCT01926496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188495|NCT04656327|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34188496|NCT01855646|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34188497|NCT03870243|RANDOMIZED|PARALLEL||TREATMENT||NONE|As it was an open-labeled randomized controlled clinical trial, there was no masking in any intervention.|Children aged 1-59 months with Severe Pneumonia in Ethiopia, divided in two arms; one arm will get bCPAP other arm will get WHO recommended low flow oxygen.||||
34188498|NCT06456996|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870545|NCT04643028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator who made the outcome measurements will not have any information about the group of participants.||f|f|f|t
33870546|NCT02785016|||COHORT||PROSPECTIVE|||||||
34067013|NCT02782754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067014|NCT06314412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067015|NCT03513783|NA|SINGLE_GROUP||OTHER||NONE||||||
34067016|NCT03749421|||OTHER||PROSPECTIVE|||||||
34067017|NCT04142684|||COHORT||RETROSPECTIVE|||||||
34067018|NCT00323843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067019|NCT05365334|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34067020|NCT00882661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067021|NCT00370422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34067022|NCT00157716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34188499|NCT04427982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants receive the dance and education interventions.||||
34188500|NCT03387722|||COHORT||PROSPECTIVE|||||||
34067023|NCT03207308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067024|NCT03236129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067025|NCT02474134|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067026|NCT02536274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067027|NCT01322698|||COHORT||PROSPECTIVE|||||||
34067028|NCT04292145|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be aware of the purpose of the study, thus they will not know if they are in the experimental or control group.|Participants will be randomly assigned to one of the two groups as they enter the study.|t|f|f|f
34067029|NCT02205294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067030|NCT04397549|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Patients will randomized into two groups cervical ESP and control.|f|f|f|t
34067031|NCT04150120|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Consecutive series of legal guardians to children fulfilling the inclusion criteria in each arm. The legal guardians will be asked to 1) be involved in the development of the eHealth application, 2) evaluate the eHealth application at home, or 3) serve as a control group receiving traditional follow-up after discharge.||||
34067032|NCT01030718||PARALLEL||TREATMENT||NONE||||||
34067033|NCT04157049|||COHORT||PROSPECTIVE|||||||
34067034|NCT05430685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The company (Gaia Herbs) prepared the intervention and placebo and had knowledge with Intervention A and B. Neither the investigators, coordinators, subjects or data analyst had knowledge of the group designation.|Two groups: one intervention, one placebo|t|t|t|t
34067035|NCT00817674|||CASE_CONTROL||PROSPECTIVE|||||||
34067036|NCT02336347|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34067037|NCT02836951|||CASE_ONLY||RETROSPECTIVE|||||||
34067038|NCT03699540|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Double-blind, double-dummy, placebo-controlled design|Within-subject, randomized, placebo-controlled, double-dummy, double-blind study|t|f|t|f
34151773|NCT05771038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* In first group: 20cc of venous blood is collected from the patient's forearm into silica-coated tube (10 ml) and 1 non coated vacutainer. Blood will be used to make injectable prf by spinning in centrifuge(2400-2700) for 2 minutes to produce autologous fibrin glue and then for 12 minutes+/- 2 minutes to obtain the concentrated growth factor layer. and sticky bone will be prepared then inserted into the socket.~* In second group: prepared sodium alendronate gel will be placed in defective extraction sockets."|t|f|f|f
34151774|NCT03030339|||COHORT||PROSPECTIVE|||||||
34151775|NCT05095168|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34188501|NCT05538715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are not aware of the randomly assigned flap design. Independent examiners are not aware of patient allocation during analysis of clinical and radiographic data.|"Test group: Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a full-thickness flap design in the posterior maxilla or mandible in partially edentolous patients.~Control group: Following randomization, horizontal guided bone regeneration utilizing Bio-Oss (Geistlich, Wolhusen, Switzerland) and autogenous bone in combination with Bio-Gide membrane (Geistlich, Wolhusen, Switzerland). Surgery is performed with a split-thickness flap design in the posterior maxilla or mandible in partially edentolous patients."|t|f|f|t
34188502|NCT02074683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188503|NCT02459483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188504|NCT01924949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188505|NCT02722304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188506|NCT04924881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188507|NCT04203186|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|double-blind, randomized, placebo-controlled trial|2 parallel test groups to directly compare clinical and laboratory characteristics|t|t|t|f
34188508|NCT03294837|||CASE_ONLY||OTHER|||||||
33754715|NCT02532673|||COHORT||RETROSPECTIVE|||||||
33754716|NCT00698490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754717|NCT03602651|||COHORT||PROSPECTIVE|||||||
33754718|NCT00279201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754719|NCT04014764|||OTHER||PROSPECTIVE|||||||
33754720|NCT06099067|||COHORT||RETROSPECTIVE|||||||
33754721|NCT04114734|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to get Park Rx or to receive care as usual.||||
33754722|NCT00259532|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33754723|NCT02368808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754724|NCT02535104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754725|NCT03175302|||COHORT||OTHER|||||||
34188509|NCT06380413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be implemented for the outcome assessors. All tests and questionnaires will be supervised by an evaluator blinded to the participant's group. Due to the type of intervention, the investigator conducting exercise sessions and participants will not be blinded.|This study is a randomized, single-blinded, two-arm, parallel, superiority trial. Forty healthy and physically inactive subjects, 60 to 75 years of age, are recruited. Participants are randomly allocated on a 1:1 ratio to a 12-week intervention of Tai Chi Chuan plus walking program twice a week, or an active-control group of walking twice a week.|f|f|f|t
34188510|NCT03962504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be unaware of participant conditions. Assessors will not have access to any study materials in which unmasking could occur. Participants will be instructed to not reveal their treatment condition to the assessors.|The study is a non-inferiority design to examine if a brief intervention for PTSD is non-inferior to a more time-intensive intervention.|f|f|f|t
34188511|NCT06521905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870547|NCT04277520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34188512|NCT03690752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188513|NCT00132470|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34188514|NCT03920319|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Matching placebo pills|Randomized, double-blind, before-after controlled trial|t|t|f|f
33754726|NCT02166424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754727|NCT04897984|NA|SINGLE_GROUP||TREATMENT||NONE||The study is designed as a clinical study involving one experimental study day.||||
33870548|NCT00259155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33870549|NCT03675945|||COHORT||PROSPECTIVE|||||||
33870550|NCT04020601|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blinded, randomized controlled, prospective|t|t|t|f
33870551|NCT01981655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33870552|NCT01188200|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870553|NCT05873920|||COHORT||PROSPECTIVE|||||||
33870554|NCT04262687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188515|NCT05461144|||COHORT||PROSPECTIVE|||||||
34188516|NCT00905177|||COHORT||PROSPECTIVE|||||||
33870555|NCT01793142|||COHORT||PROSPECTIVE|||||||
33754728|NCT01417689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754729|NCT00998179|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33754730|NCT02401581|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33754731|NCT02639260|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754732|NCT02258139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754733|NCT01121042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754734|NCT03502655|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Patient allocation to each arm will be based on the sequential opening of an opaque envelope containing an non-consecutive number indicating a track number of the recorded message (control or intervention). Randomization will be based on randomly mixed block of size 2 to 6 patients.|Each eligible patient will be randomized in a 1: 1 ratio between the two arms of the study, double-blind (patient, caregiver, investigator) in the first study and single-blind (patient) in the second study.|t|t|t|t
33754735|NCT02470546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754736|NCT00355420|||COHORT||PROSPECTIVE|||||||
33754737|NCT06097754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||1 group with ketone ester supplementation and 1 group with taste and viscosity matched placebo|t|f|t|f
33754738|NCT05961358|||COHORT||PROSPECTIVE|||||||
33754739|NCT02347020|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33754740|NCT01175915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754741|NCT06415357|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33870556|NCT03497481|||COHORT||PROSPECTIVE|||||||
33870557|NCT00591097|||CASE_ONLY||PROSPECTIVE|||||||
33870558|NCT06451445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870559|NCT02414399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870560|NCT00146315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870561|NCT01989403|||COHORT||PROSPECTIVE|||||||
33870562|NCT04206605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870563|NCT00836628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870564|NCT02878538|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34188517|NCT02637037|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870565|NCT04501770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870566|NCT02977650|||COHORT||PROSPECTIVE|||||||
33870567|NCT00501371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188518|NCT01260532|||COHORT||PROSPECTIVE|||||||
33870568|NCT01017003|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870569|NCT00929877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870570|NCT03291223|||COHORT||PROSPECTIVE|||||||
33870571|NCT02428855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870572|NCT00871182|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33870573|NCT03963414|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870574|NCT01908270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870575|NCT01498055|||CASE_CONTROL||PROSPECTIVE|||||||
33870576|NCT01162356|||COHORT||PROSPECTIVE|||||||
33870577|NCT00632658|||CASE_ONLY||PROSPECTIVE|||||||
33870578|NCT05937178|||COHORT||PROSPECTIVE|||||||
33870579|NCT00127725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33870580|NCT06354114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151776|NCT03372993|||COHORT||PROSPECTIVE|||||||
34151777|NCT02149017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188519|NCT05711563|||COHORT||OTHER|||||||
34188520|NCT02970942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188521|NCT00162019|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188522|NCT01377337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188523|NCT04036396|RANDOMIZED|PARALLEL||PREVENTION||NONE||The Mobile Enhanced Prevention Support (MEPS) intervention is designed to support, motivate, and facilitate engagement in preventive health care activities in the period of community reentry following jail. Three components: support from a selected Peer Mentor (PM), incentives, and a developed mobile application. Client-driven approach, in which participants are encouraged to address priorities and immediate needs for that they identify a client-centered needs assessment, prioritization, and wellness planning process, especially social determinants of health that may discourage or undermine preventive health measures.||||
34151778|NCT02133365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151779|NCT03468322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intra-individual comparison|t|t|t|t
34151780|NCT02125565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151781|NCT01013311|||COHORT||RETROSPECTIVE|||||||
34151782|NCT03908476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151783|NCT00594594|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34151784|NCT05141188|||CASE_ONLY||CROSS_SECTIONAL|||||||
34151785|NCT03403309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple-blinded||t|t|t|t
34151786|NCT01235299|||COHORT||PROSPECTIVE|||||||
34151787|NCT03519061|NA|SINGLE_GROUP||TREATMENT||NONE||Non randomized, single arm, prospective||||
34151788|NCT05533710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151789|NCT05298800|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34151790|NCT03399955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151791|NCT00658190|||CASE_ONLY||PROSPECTIVE|||||||
34151792|NCT04081272|||COHORT||PROSPECTIVE|||||||
34151793|NCT00300365|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Pioglitazone and placebo were overencapsulated||t|t|t|t
34151794|NCT04048447|||COHORT||PROSPECTIVE|||||||
34151795|NCT01158690|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34151796|NCT06306066|||COHORT||PROSPECTIVE|||||||
34151797|NCT04593407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151798|NCT01178424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151799|NCT01423916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151800|NCT00701805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151801|NCT01816555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151802|NCT03922165|||COHORT||PROSPECTIVE|||||||
34151803|NCT00931801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151804|NCT04450329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870581|NCT00881127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151805|NCT00556270|||CASE_ONLY||PROSPECTIVE|||||||
34151806|NCT05985096|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151807|NCT01657760|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34151808|NCT01919216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151809|NCT02964585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151810|NCT01543776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151811|NCT06065592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34151812|NCT05883254|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34151813|NCT00991406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151814|NCT05726474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151815|NCT06356688|NA|SINGLE_GROUP||TREATMENT||NONE||paclitaxel polymer micelles and cisplatin combined with Camrelizumab||||
34151816|NCT03933176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151817|NCT00278811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33754742|NCT06370988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|rTMS treatment will be delivered using the MagPro X100/R30 stimulator and use the Cool-B70 A/P coil (MagVenture, Farum, Denmark), a figure 8 coil with active cooling, in which both the sham and active coils are contained internally. Its symmetric design ensures there is no indication of which side is active or sham with only the side of the coil delivering the treatment differing. The sham coil has been designed in such a way that it produces a similar auditory experience as the active coil. To account for the tactile sensation of active stimulation, both treatment allocations will have scalp electrodes placed that deliver a weak electrical stimulation to mask this tactile sensation.|This trial will use a multi-centre randomized controlled trial for individuals with treatment-resistant Bipolar Depression comparing iTBS applied to the left DLPFC with sham treatment and examining differences in efficacy and safety outcomes between groups over 6 weeks of treatment.|t|t|t|t
33754743|NCT04766762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754744|NCT00828984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754745|NCT00202202|NA|SINGLE_GROUP||||NONE||||||
33754746|NCT01417507|||COHORT||PROSPECTIVE|||||||
33870582|NCT06240000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This current prospective randomized study was carried out in Ankara Bilkent City Hospital, Department of Physical Therapy and Rehabilitation. Total of 25 CLBP patients (12 patients underwent SCN RFA, 13 patients participated CPT) were enrolled. Patients who admitted to outpatient clinics with low back pain that lasts more than 3 months, aged ≥ 18 year-old and detected positive 'iliac crest sign' included in the study. Patients have pain score \<3 according to the Visual Analog Scale (VAS), INR \>1.2 in blood samples were excluded from the study.|f|f|f|t
33870583|NCT02830776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870584|NCT04101565|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 groups will be enrolled and randomized to receipt or not receipt of the intervention.||||
33870585|NCT05262699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Assessment, motor training, data analyzes, and group allocation are done by different persons. Participants as well as the assessor, the trainer and the investigator are blinded to the group allocation.||t|t|t|t
33870586|NCT00336219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870587|NCT05141370|NA|SINGLE_GROUP||OTHER||NONE||||||
33870588|NCT06538948|||COHORT||PROSPECTIVE|||||||
33870589|NCT06156683|||COHORT||RETROSPECTIVE|||||||
33870590|NCT06061315|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants will be allocated to either placebo or collagen peptide supplementation in a double blinded randomized design.~Only following completion of all participants will the blinding be removed"|A double blinded randomized controlled trial|t|f|t|f
33870591|NCT03863600|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870592|NCT02592551|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151818|NCT06546137|||FAMILY_BASED||PROSPECTIVE|||||||
34151819|NCT03602859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151820|NCT04552288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151821|NCT00119665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151822|NCT01344720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151823|NCT02666612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151824|NCT00758641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151825|NCT02180477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151826|NCT04059432|||COHORT||PROSPECTIVE|||||||
34151827|NCT00907166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151828|NCT05296993|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34188524|NCT04442061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188525|NCT03725618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188526|NCT06066632|||CASE_CONTROL||OTHER|||||||
34151829|NCT04572750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At follow-up interview, the interviewer will no know whether the individual was in the treatment or control condition.|The EMPOWER-ED intervention is an app that runs on a smart phone or computer. It will provide education about the risk of benzodiazepine, a tool to create a method of self-tapering, and information on how to succeed at reducing or quitting benzodiazepine use. Individuals in the treatment condition of the trial will be given access to EMPOWER-ED on any platform they wish to use.|f|f|f|t
34151830|NCT01276002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151831|NCT01761500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151832|NCT05827315|||COHORT||PROSPECTIVE|||||||
34151833|NCT04650425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34151834|NCT05737719|||CASE_CONTROL||OTHER|||||||
34151835|NCT00154882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188527|NCT02344524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188528|NCT06193226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188529|NCT02803580|||COHORT||PROSPECTIVE|||||||
34188530|NCT04187183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188531|NCT04579939|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34188532|NCT01145261|||CASE_CONTROL||PROSPECTIVE|||||||
34188533|NCT06307197|NA|SINGLE_GROUP||OTHER||NONE||||||
34188534|NCT06248723|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The patients are randomized 1:1 into active intervention and self-guided intervention parallel groups."||||
34188535|NCT05397158|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Endoscopist blind method.||f|f|f|t
34188536|NCT05762068|||OTHER||OTHER|||||||
34188537|NCT01497288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188538|NCT00005664|||OTHER||PROSPECTIVE|||||||
34188539|NCT03346694|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participant randomly assigned to either a control or one of two intervention groups||||
34188540|NCT00533936|RANDOMIZED|||TREATMENT||NONE||||||
34188541|NCT00630123|||COHORT||PROSPECTIVE|||||||
34188542|NCT01794286|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34188543|NCT02720731|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34188544|NCT06205368|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34188545|NCT02499757|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34188546|NCT00245752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870593|NCT04996173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33870594|NCT03793465|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Consumption - 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery||||
33870595|NCT04327687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a single-blind (outcomes assessor)|Prospective randomized clinical trial|f|f|f|t
34151836|NCT02160691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151837|NCT03708666|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151838|NCT03038854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34151839|NCT00206362|||COHORT||PROSPECTIVE|||||||
34151840|NCT03834935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|investigators and patients will be blinded to treatment||t|t|t|t
34188547|NCT00981058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188548|NCT03965390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188549|NCT00518089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188550|NCT01572285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188551|NCT06262126|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34188552|NCT06297811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188553|NCT02578303|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188554|NCT02382380|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188555|NCT02608671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188556|NCT03304938|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Lavender Essential oil as medication and almond oil as placebo put in similar dark buttle and the head of placebo bottle aromatized whit Lavender Essential oil and all of participants, care provider, investigator and outcomes assessor will be blind.|40 diabetic patients with sleep disorder with the inclusion criteria will enter into the crossover study and randomly assign to treatment or placebo groups.|t|t|t|t
34188557|NCT04947085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34188558|NCT01146795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188559|NCT02925299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188560|NCT05968729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34188561|NCT00409734|||CASE_CONTROL||RETROSPECTIVE|||||||
34188562|NCT02988895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188563|NCT01744080|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188564|NCT02188888|||COHORT||PROSPECTIVE|||||||
34188565|NCT05773170|||CASE_ONLY||RETROSPECTIVE|||||||
34188566|NCT02590224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34188567|NCT04199130|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Described in study description|t|f|f|f
34188568|NCT05648032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The syringe is covered.|Tennis elbow Supraspinatus calcific tendinitis|t|f|t|t
34188569|NCT03534180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188570|NCT04673396|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single center, open, non-randomized trial design||||
34151841|NCT01501552|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34151842|NCT03914677||SEQUENTIAL||PREVENTION||NONE||dose-escalation||||
34188571|NCT02765581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34188572|NCT01594216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188573|NCT03612752|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33870596|NCT06072521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"It is a randomized controlled clinical trial (Pilot study) that will be conducted on hepatic encephalopathy patients who will attend to National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt to receive the treatment regimen in concurrence with the Egyptian guidelines of treatment. Eligible patients will randomly assigned in a 1:1:1 ratio to receive lactoferrin (Pravotin@ sachets) as followings:~Group I: Patients receive standard care alone (control group) Group II: Patients receive 100mg lactoferrin orally (one sachet (100 mg), one time a day) plus standard care.~Group III: Patients receive 200 mg lactoferrin orally (one sachet (100mg), two times a day) plus standard care. Lactoferrin will be administrated in groups II and III for 15 days. The blood samples of all eligible participants and reported signs and symptoms will be collected after 15 days."||||
33870597|NCT01641328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870598|NCT01298752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870599|NCT02299037|||COHORT||PROSPECTIVE|||||||
33870600|NCT00362934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151843|NCT04108806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151844|NCT00575874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151845|NCT06475040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151846|NCT05235724|||COHORT||PROSPECTIVE|||||||
34151847|NCT00348894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188574|NCT03160235|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Magnetic resonance imaging|Methodological development of new MRI approaches||||
34188575|NCT03746158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188576|NCT01266187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870601|NCT00870220|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33754747|NCT05873608|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||For aim 4, each participant is assigned to watch a video and comprehension is tested using a pre and post method||||
33754748|NCT02980055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870602|NCT01378234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870603|NCT01722175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870604|NCT05863104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870605|NCT03515070|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33870606|NCT00377884|||COHORT||PROSPECTIVE|||||||
33870607|NCT00554567|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870608|NCT02712476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870609|NCT00199836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870610|NCT04202679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870611|NCT05376358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be masked to the intervention condition at follow-up assessment time points.|This study will use a parallel study design, where participants are randomized into two intervention groups (Usual Care or MoodRing) and will receive interventions in parallel.|f|f|f|t
33870612|NCT02569814|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870613|NCT05280184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870614|NCT01187966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870615|NCT03456375|||OTHER||PROSPECTIVE|||||||
33870616|NCT04459052|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This is an Open Label study. Randomization will occur via a 1:1 ratio of the NAC group and the waitlist control groups using the method of random permuted blocks with random block sizes without stratification.||||
33870617|NCT03039231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870618|NCT02853448|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33870619|NCT05885867|||OTHER||CROSS_SECTIONAL|||||||
33870620|NCT03610724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870621|NCT01269762|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870622|NCT04968977|||COHORT||CROSS_SECTIONAL|||||||
33870623|NCT02462356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870624|NCT06083441|||COHORT||PROSPECTIVE|||||||
33870625|NCT03590730|||COHORT||PROSPECTIVE|||||||
33965953|NCT03931057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A controlled, randomized, double blinded study Study group 1 (40 children) ADV6209 0.25 mg/kg p.o. Study group 2 (40 children) Midazolam (in orange flavoured syrup) 0.25 mg/kg p.o.|t|t|t|f
33965954|NCT02916160|NA|SINGLE_GROUP||OTHER||NONE||||||
33965955|NCT05840666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be unaware of the treatment group of study.|Participants will be randomized to three study arms and each study arm will be allocated a different intervention|f|f|f|t
34151848|NCT04903366|||OTHER||CROSS_SECTIONAL|||||||
34151849|NCT02999152|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754749|NCT01124760|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754750|NCT02923843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754751|NCT01267513|||CASE_ONLY||PROSPECTIVE|||||||
33754752|NCT02331862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870626|NCT00318214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870627|NCT01047371|||CASE_ONLY||PROSPECTIVE|||||||
33870628|NCT04523636|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each extremity was randomized to receive a custom or pre-fabricated resting hand splint.||||
33965956|NCT01890018|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33965957|NCT02872545|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34151850|NCT03331523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754753|NCT01107860|||COHORT||PROSPECTIVE|||||||
33754754|NCT02257268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33754755|NCT05753150|||OTHER||PROSPECTIVE|||||||
33754756|NCT05801211|||CASE_CONTROL||PROSPECTIVE|||||||
33754757|NCT00500877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151851|NCT00002580|RANDOMIZED|||TREATMENT||||||||
34151852|NCT02943616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151853|NCT00688272|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34151854|NCT01704456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188577|NCT04522700|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34188578|NCT00456170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188579|NCT05252091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188580|NCT01277380|||COHORT||PROSPECTIVE|||||||
34188581|NCT04112381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188582|NCT01855061|||COHORT||PROSPECTIVE|||||||
34188583|NCT01988285|||COHORT||PROSPECTIVE|||||||
34188584|NCT04066231|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A gastroprokinetic agent is administered to stimulate gastric motility.||||
34188585|NCT00295373|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34188586|NCT02053376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188587|NCT04761224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The surgeon cannot be blind to the treatment group. On the other hand, the treatment group will be masked for all the participants (doctors and nurses) in charge of collecting the judgement criteria.||f|t|f|f
34188588|NCT02721472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188589|NCT00842751|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188590|NCT05291715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double- blinded|Group 1: Will receive ozone therapy after harvesting a free gingival graft. Group 2: Following the harvesting of the free gingival graft; the palatal donor site will be protected by a periodontal pack.|t|f|f|t
34188591|NCT03101332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188592|NCT00482248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754758|NCT00745810|||CASE_ONLY||PROSPECTIVE|||||||
33754759|NCT00241527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754760|NCT04582474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754761|NCT04467554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pilot randomized controlled trial|f|f|f|t
33754762|NCT02946333|||COHORT||PROSPECTIVE|||||||
33754763|NCT04215042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754764|NCT04858958|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754765|NCT04278625|||CASE_CONTROL||PROSPECTIVE|||||||
33754766|NCT01207102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754767|NCT03093831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754768|NCT04648748|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33754769|NCT03701984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33754770|NCT00886340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754771|NCT01442948|||COHORT||PROSPECTIVE|||||||
33754772|NCT03376581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754773|NCT04658407|||COHORT||RETROSPECTIVE|||||||
33754774|NCT01423630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870629|NCT04060420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This study is a cluster-randomised trial, with a total of 20 clusters across two communities (10 clusters per community). Within each community, these 10 clusters have been randomised to intervention or control arm using restricted randomisation.|f|f|f|t
33870630|NCT01605279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870631|NCT04030728|||COHORT||PROSPECTIVE|||||||
33870632|NCT02384668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870633|NCT04550104|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is designed as a randomised Phase I dose escalation platform study, using the TiTE CRM design to find the RP2D of each DDRi with RT combination. At the time of patient identification the treating centre will be informed of the allocated study arm following a pre-specified prioritisation schedule. Consenting participants will be randomised between DDRi with RT or RT only. Patients are not randomised between experimental arms nor will endpoints be compared between experimental arms. RT only participants will be pooled across the platform to provide contemporary data on toxicity.||||
33870634|NCT00715026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870635|NCT04822649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with chest pain or ischemic symptoms with non-obstructive coronary artery disease (\<50% stenosis) in coronary angiography and preserved ejection fraction (\>50%) in echocardiography.||||
33870636|NCT04214379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870637|NCT00839384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870638|NCT03172832|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized comparative effectiveness trial||||
33870639|NCT02409849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870640|NCT02992340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870641|NCT06326580|||OTHER||OTHER|||||||
33870642|NCT02970604|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33870643|NCT06156436|||COHORT||PROSPECTIVE|||||||
33870644|NCT01652742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870645|NCT01651351|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33894152|NCT06596304|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Outcomes will be assessed by the same experts in every time point. Participants and evaluators will be blinded until arrival of the participant for the fist experimental condition.|Parallel group crossover randomized trial||||
33894153|NCT04488822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894154|NCT01144273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33754775|NCT01834885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754776|NCT02311530|RANDOMIZED|CROSSOVER||||NONE||||||
33754777|NCT00921752|||COHORT||PROSPECTIVE|||||||
33754778|NCT02553525|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33754779|NCT01850979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33754780|NCT04913844|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754781|NCT02918110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754782|NCT04802941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754783|NCT04320628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This protocol is double-blinded. Subjects will be randomized 1:1 to have their wound cleansed with either NSS or NaOCl. Unblinded staff will prepare the solutions for the two arms the morning of the day of enrollment. NSS and NaOCl will be placed in labeled containers consistent with the randomization scheme. NaOCl has a faint odor of chlorine. In order to maintain the blind the containers will have chlorine placed on the outside of bottom of the container and in the treatment room an open container of chlorine bleach will be safely positioned as to avoid injury to subjects and research personnel, but close enough to provide a mild chlorine smell in the room. Finally, the unblinded research staff will provide the subject with their 4-week supply of NSS or NaOCl to take home.|AnaSept® AnaSept® Antimicrobial Skin and Wound Cleanser is a clear liquid consisting of 0.057% sodium hypochlorite (NaOCl) in an isotonic saline.|t|f|t|f
33754784|NCT02821403|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33754785|NCT01691833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754786|NCT01803048|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754787|NCT02219126|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33754788|NCT04508439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"* Initially they will be randomized into two blocks, the first based on prophylactic Enoxaparin (Numbers 1 to 64) and the second (Numbers 65 to 128) will be assigned to the Enoxaparin therapeutic regimen arm at doses of 1mg / kg/dose twice up to date~* During hospitalization, the clinical evolution will be evaluated according to the requirements of mechanical ventilation, the reduction in D-Dimer levels and the clinical outcome (discharge or death).~* Those patients who are discharged will be Randomized in two following treatment arms~* The allocation of patients in the outpatient stage will be carried out randomly 1: 1 to receive Rivaroxaban 10mg PO every 24hrs or only clinical follow-up.~* Follow-up of adverse events will be carried out in the Hematology outpatient clinic with a first consultation 15 days after discharge and a second consultation 30 days after discharge. With dimer D, ferritin, protein C, blood count, ESR and on day 30 with CAT."|t|t|f|f
33754789|NCT02279043|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33754790|NCT05721131|||OTHER||OTHER|||||||
33894155|NCT04140487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894156|NCT05162157|||COHORT||CROSS_SECTIONAL|||||||
33894157|NCT05627245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894158|NCT03446677|NA|SINGLE_GROUP||SCREENING||NONE||||||
33894159|NCT02514538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33894160|NCT00967941|||CASE_CONTROL||PROSPECTIVE|||||||
33894161|NCT02351115|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33894162|NCT05377632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894163|NCT06457126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894164|NCT03308851|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A split mouth design will be used where the experimental subjects will receive one procedure on one side of the upper dental arch and another procedure on the other side.||||
33894165|NCT04771715|||COHORT||RETROSPECTIVE|||||||
33894166|NCT06521489|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894167|NCT02015819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894168|NCT03184870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894169|NCT06276387|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Physicians completing joint exams to assess clinical disease activity, including the principal investigator, will be blinded to participant assignment. It will not be possible for participants to be blinded to treatment condition.|Participants will be randomly assigned to participate in a mindfulness-based stress reduction (MBSR) course or treatment as usual (TAU). Randomization will be done using a program-tracking system.|f|f|t|t
33894170|NCT02568904|||OTHER||PROSPECTIVE|||||||
33894171|NCT04406038|||COHORT||PROSPECTIVE|||||||
33894172|NCT00762151||CROSSOVER||PREVENTION||NONE||||||
33894173|NCT01636037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894174|NCT04637451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894175|NCT02226484|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894176|NCT02017444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894177|NCT00794287|||COHORT||RETROSPECTIVE|||||||
33894178|NCT04902287|RANDOMIZED|PARALLEL||SCREENING||NONE||The current clinical trial involves two conditions (N=20 each): engagement condition or referral as usual||||
34188593|NCT05306756|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"The primary and perinatal secondary outcomes will be recorded from the computerised delivery record without knowledge of the allocation.~The principal investigator will play no role in the care of the patient or assessment of outcomes."|Patients in labor with CTG abnormalities that warrant second-line testing of fetal wellbeing - randomized to digital fetal scalp stimulation (dFSS) versus fetal blood sampling (FBS)|f|f|t|t
34188594|NCT06168916|||COHORT||PROSPECTIVE|||||||
34188595|NCT05353504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|People will be randomly assigned to the three arms and blinded towards receipt of dietary fibre supplement or placebo supplement. However, behavioural lifestyle intervention arm cannot be blinded to participants.||t|f|t|t
34188596|NCT00583895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754791|NCT05759416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Forty chronic periodontitis selected patients ,divided into two groups. Group I: included 20 chronic periodontitis patients, treated by conventional periodontal therapy SRP combined with intra- pocket application of Melatonin gel once weekly for 1 month begin application at the second week after initial therapy. Group II: included 20 chronic periodontitis patients, treated by SRP combined with the injection of placebo, weekly for one month.||||
33754792|NCT02413775|||COHORT||PROSPECTIVE|||||||
33754793|NCT03251638|||OTHER||PROSPECTIVE|||||||
33894179|NCT04017403|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894180|NCT01904487|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894181|NCT06073262|||OTHER||OTHER|||||||
33894182|NCT06480734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||multi-center prospective study||||
33894183|NCT00194350|||COHORT||RETROSPECTIVE|||||||
34188597|NCT06157138|||COHORT||PROSPECTIVE|||||||
34188598|NCT01802138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188599|NCT00409552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188600|NCT03464175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34188601|NCT02757417|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188602|NCT03320577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188603|NCT01163227|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34188604|NCT02751489|NA|SINGLE_GROUP||||NONE||||||
34188605|NCT04212962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Advance practice registered nurses provide care management and education to intervention group patients prior to discharge and during the 90 days after transitioning to home.||||
34188606|NCT04239612|NA|SINGLE_GROUP||TREATMENT||NONE||All patients attending open care units for psychosis will be invited to participate||||
34188607|NCT01067196|||COHORT||PROSPECTIVE|||||||
34188608|NCT00071630|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188609|NCT00942526|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34188610|NCT04996095|||COHORT||PROSPECTIVE|||||||
34188611|NCT05179356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188612|NCT05545540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188613|NCT02127957|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34188614|NCT02921178|||COHORT||RETROSPECTIVE|||||||
34188615|NCT01544335|||COHORT||PROSPECTIVE|||||||
34188616|NCT00932178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188617|NCT04980092|||COHORT||PROSPECTIVE|||||||
34188618|NCT05213767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188619|NCT03474419|||COHORT||PROSPECTIVE|||||||
34188620|NCT00503815|RANDOMIZED|PARALLEL||||SINGLE||||||
34188621|NCT02714972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Subjects are randomized on a per-night level for when the PHHM will be active or not.||t|t|t|f
34188622|NCT00272103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188623|NCT00611026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188624|NCT00342108|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188625|NCT02023697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188626|NCT00554632|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34188627|NCT02549365|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188628|NCT02358941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34188629|NCT04011696|||COHORT||PROSPECTIVE|||||||
34188630|NCT04509661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188631|NCT01519869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188632|NCT02295670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067039|NCT04796207|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study personnel will be kept blind to treatment assignments. The treatment assignment for each participant will be available to the investigator in a sealed envelope that may be opened only in the case of a serious adverse event which the investigator feels cannot be adequately treated without knowing the identity of the study medication. Code breakers will be collected and reviewed at the end of the study. If the blinding has been broken, then the investigator will provide documentation regarding the fact and indicate the other staff that received this information.|Participants will be randomized to treatment (3 grams DHA and EPA (2:1 weight ratio)) or placebo (3 grams high-oleic safflower oil) in a 1:1 allocation ratio based on their position on the football team and roster depth (starter vs. non-starter). Participants will be recruited as a single cohort. After screening, participants will be treated with DHA and EPA or matching placebo for 25 weeks (a full course of an American football season, including summer camp training sessions). A follow-up visit is scheduled 7 weeks after the final dosing at week 32 for recovery and adverse event evaluation.|t|t|t|t
34188633|NCT02592096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188634|NCT05374824|||COHORT||RETROSPECTIVE|||||||
34188635|NCT01685515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188636|NCT00002751||||TREATMENT||||||||
34188637|NCT05593562|NA|SINGLE_GROUP||OTHER||NONE||||||
34188638|NCT00607373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188639|NCT04640220|NA|SINGLE_GROUP||TREATMENT||NONE||Adhesive capsulitis patients who underwent breast cancer operation||||
33754794|NCT04777045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinding of treatment is ensured by using a double-blind technique. The diltiazem capsules and the respective placebo capsules will have the same look and feel. The bottles with the IMP will be labelled with unique identification numbers. No member of the study team, or anyone handling study data will have access to the randomization scheme during the study. In case of an adverse event (AE), the code should only be broken in circumstances when knowledge of the IMP is required for treating the patient. If possible, contact should be initiated with the principal investigator before breaking the code. Code breaking can be performed at any time by the investigator. A sealed emergency envelope per patient randomization number will be present per patient at the research department. If the blind is broken, the Investigator should document the date, time of the day and the reason for code breaking. If the code is broken, patient must discontinue IMP administration but continues the study.|"A clinical multi-center randomized with 1:1 ratio, double-blind, placebo-controlled study. Patients with chronic angina in the absence of CAD will be screened for study enrolment. Eligible patients will be asked for informed consent at the screening visit.~Within 8 weeks after screening, participants undergo coronary function testing. If this shows either a CFR ≤ 2.0, an IMR ≥ 25 and/or abnormal acetylcholine testing the patient will continue in the intervention arm and will be randomized to either diltiazem or placebo treatment for 6 weeks. After 6 weeks, coronary function testing will be repeated and the diltiazem/placebo treatment will be discontinued. Follow-up will be obtained 1 month, 1 year and 5 years after treatment discontinuation. If coronary function testing at baseline shows no signs of vascular dysfunction, patients will enter in the registration arm of the study. These patients will not receive any study medication. Follow-up will be obtained after 1 year and 5 years."|t|t|t|t
34067040|NCT04029259|||COHORT||PROSPECTIVE|||||||
34067041|NCT02933528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067042|NCT03578133|||OTHER||CROSS_SECTIONAL|||||||
34067043|NCT05921240|||CASE_ONLY||PROSPECTIVE|||||||
34067044|NCT01494701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067045|NCT00898326|||COHORT||PROSPECTIVE|||||||
34188640|NCT06311097|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"Two 4-week intervention periods separated by a washout period of at least 4 weeks.~The crossover intervention will include 60 participants. Another 40 participants will only complete the first (baseline) visit."|f|f|t|f
34188641|NCT03111186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients of either sex, greater than 18 years of age, scheduled to undergo elective outpatient soft tissue hand surgery for one of the following procedures: carpal tunnel release, Dupuytren contracture release, trigger digit release, ganglion cyst removal, De Quervain's release, whose primary language is English or Spanish||||
34188642|NCT05389540|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34188643|NCT02212951|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34188644|NCT00141791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188645|NCT02967783|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|six vaccination teams will be randomly assigned to administer the three different ID fIPV administration technique the campaign days|||||
34188646|NCT02422459|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188647|NCT01151904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188648|NCT03810105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188649|NCT05242627|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The post-partum OSCE is a regular assessment as part of the DGSOM curriculum. After completing their OSCE, student's will be consented to allow their OSCE to be viewed by the study team (all OSCEs are routinely recorded for assessment purposes) and will be presented with a post-OSCE survey to assess their attitudes and beliefs on firearms as well as their performance on the OSCE. Students in both arms are masked to the fact that their OSCE performance will be evaluated in a comparative study (in addition to evaluation as a part of the standard curriculum) while they are participating in the study. Informed consent for their OSCE to be included in the study will be obtained after the OSCEs have been completed. There will be no prompting about firearms prior to the OSCE. Study results regarding firearm screening and counseling will not factor into the student's grade on the OSCE.|Students in the DGSOM Classes of 2023 and 2024 will participate in the same Observed Structured Clinical Exam (OSCE) scenario during their second year of medical school, in which they virtually interview a standardized patient presenting with postpartum depression. The Class of 2023 received no specific training on firearm screening and counseling, while the Class of 2024 participated in an educational module on firearm safety counseling 6-months prior to the OSCE.|t|f|f|f
34188650|NCT04301804|RANDOMIZED|PARALLEL||OTHER||NONE||A total of 36 healthy volunteer subjects will be enrolled in this study. 12 subjects subjects will take a single dose of SHR6390 in each of the 3 dose cohorts||||
34188651|NCT00373997|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34188652|NCT00334113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188653|NCT00867815|NA|SINGLE_GROUP||OTHER||NONE||||||
34188654|NCT02138448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188655|NCT03048006|||COHORT||PROSPECTIVE|||||||
34188656|NCT00692263|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34188657|NCT02872935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754795|NCT05461781|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single-center, open-label, parallel randomized controlled trial||||
34188658|NCT03103477|||COHORT||PROSPECTIVE|||||||
34188659|NCT02692638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188660|NCT01942226|||COHORT||CROSS_SECTIONAL|||||||
34188661|NCT03578783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188662|NCT04970186|||OTHER||RETROSPECTIVE|||||||
34188663|NCT00006289|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34188664|NCT05592587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188665|NCT05111457|||COHORT||RETROSPECTIVE|||||||
34188666|NCT01091220|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34188667|NCT01880138|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34188668|NCT02309905|||CASE_CONTROL||RETROSPECTIVE|||||||
34188669|NCT03596411|||OTHER||RETROSPECTIVE|||||||
34188670|NCT02744404|||COHORT||RETROSPECTIVE|||||||
34188671|NCT02417506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188672|NCT02410564|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34188673|NCT06276504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754796|NCT01381796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33754797|NCT02173548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754798|NCT01673906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754799|NCT02248298|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33754800|NCT05988996|||COHORT||PROSPECTIVE|||||||
33754801|NCT01319266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754802|NCT03577587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33754803|NCT03831659|||COHORT||PROSPECTIVE|||||||
33754804|NCT02813070|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33754805|NCT05667220|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34067046|NCT05573464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754806|NCT06458205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34067047|NCT00031044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754807|NCT00838955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754808|NCT02073799|||COHORT||RETROSPECTIVE|||||||
33754809|NCT04893486|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33754810|NCT06072378|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754811|NCT04052204|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Combination A: Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck~Combination B: Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will enroll participants with DDR defect positive mCRPC.~Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC"||||
33754812|NCT06579521|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754813|NCT06579339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754814|NCT02605005|||CASE_CONTROL||PROSPECTIVE|||||||
34067048|NCT03340298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067049|NCT00770471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188674|NCT04638361|||COHORT||CROSS_SECTIONAL|||||||
34188675|NCT05007535|||COHORT||PROSPECTIVE|||||||
34188676|NCT02950467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188677|NCT03565198|||COHORT||PROSPECTIVE|||||||
34188678|NCT03313167|||COHORT||PROSPECTIVE|||||||
34188679|NCT00424541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188680|NCT00464776|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34188681|NCT00003439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188682|NCT03692104|||COHORT||PROSPECTIVE|||||||
34188683|NCT03365349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34067050|NCT02735473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188684|NCT05932667|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, multicentric phase II study designed to evaluate the efficacy and safety of milademetan-fulvestrant combination in patients with ER+ advanced breast cancer. The study treatment step is divided into two successive parts: a safety run-in part followed by a phase II part.||||
33754815|NCT00910442|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33754816|NCT03737838|||COHORT||PROSPECTIVE|||||||
34188685|NCT02918513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754817|NCT00691080|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33754818|NCT01826864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188686|NCT01229267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34188687|NCT06043869|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188688|NCT02901704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188689|NCT05739201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34188690|NCT05674305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188691|NCT02064101|||COHORT||PROSPECTIVE|||||||
34188692|NCT06462105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188693|NCT01608945|||CASE_CONTROL||PROSPECTIVE|||||||
34188694|NCT00899431|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188695|NCT02967224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188696|NCT00632606|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34188697|NCT06020989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188698|NCT02544516|RANDOMIZED|PARALLEL||||NONE||||||
34188699|NCT05936697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During each training session, a cap adjusted to the participant's head size will be used to mount the EEG and fNIRS sensors. The hardware setup will be the same for all groups to ensure that both the participant and the experimenter are blinded to the training group.|The participants will be randomly and equally assigned to one of three neurofeedback training groups: (1) sham, (2) EEG, and (3) fNIRS. Each participant will complete a neurophysiological assessment (1) before, (2) immediately after, and (3) 1 month after the intervention.|t|f|t|f
34188700|NCT05008965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188701|NCT04635540|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Every caregiver and patient dyad will complete the study tasks. The caregiver will receive a 1 month follow up call.||||
34188702|NCT03061006|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34188703|NCT03396263|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188704|NCT01630382|||CASE_CONTROL||PROSPECTIVE|||||||
34188705|NCT05360121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blinding will be used in which only the researcher doing the study knows which treatment or intervention the participant is receiving until the trial is over.|f|f|f|t
34188706|NCT01359085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34188707|NCT00992797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188708|NCT00617968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188709|NCT04743986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, assessors, and the PI were blinded to the assigned treatment allocation.|Two arm parallel randomized controlled trial|t|f|t|t
34188710|NCT02751190|||COHORT||PROSPECTIVE|||||||
34188711|NCT02644603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188712|NCT05389904|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34188713|NCT05915481|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will receive SBRT combined with Cadonilimab until disease progression or intolerable toxicities or death.|||||
34188714|NCT04348916|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188715|NCT04743778|NA|SINGLE_GROUP||TREATMENT||NONE||Initially, we intended to have a control group and an intervention group. However, due to low recruitment numbers and COVID-19 pandemic barriers, we decided to offer all participants virtual DSME/S.||||
34188716|NCT06278441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Due to the nature of the intervention, blinding could not be done for the participants, and the two researchers who collected the data, but the statistician and two other researchers who analyzed the results were unaware of group allocation.|This study is parallel-group, randomized controlled.|f|f|t|t
34188717|NCT03727308|||COHORT||PROSPECTIVE|||||||
34188718|NCT02004678|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34188719|NCT04550429|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Using block randomization to divide patients into two groups using two different levels of pressure on the hysteroscopic morcellator: experimental group (those receiving 60 mmHg of pressure) and control group (those receiving 80 mmHg of pressure)|f|t|t|f
34188720|NCT05938205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Single-center open-label randomized experimental study with 3 parallel arms with an allocation ratio of 1:1:1. Participants will be all involved in high intensity exercise (Exe-H). Participants will be further randomized into 3 groups to receive (double-blind) dietary supplementation with either placebo, low dose amino acid blend (AA-1) or full dose amino acid blend (AA-2).|t|f|t|f
34188721|NCT04003948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188722|NCT02877771|NA|SINGLE_GROUP||||NONE||||||
34188723|NCT05395559|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188724|NCT03452163|NA|SINGLE_GROUP||OTHER||NONE||||||
34188725|NCT03034070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754819|NCT05955703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754820|NCT02281799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754821|NCT01704313|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33754822|NCT04270214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754823|NCT06099301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754824|NCT02200913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33754825|NCT04207346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to one of two or more groups in parallel for the duration of the study: procedure vs. sham procedure|t|t|t|t
33754826|NCT03961620|||COHORT||PROSPECTIVE|||||||
33754827|NCT03004794|||CASE_ONLY||RETROSPECTIVE|||||||
33894184|NCT01154101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894185|NCT03437187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Information connecting the patients to the data are kept locked and will be destroyed after the end of the investigation||t|f|f|f
33894186|NCT00613314|||COHORT||PROSPECTIVE|||||||
33870646|NCT04912245|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a pragmatic pilot study where 300 patients with either mild cognitive impairment (MCI) or unrecognized dementia and their care partner (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of their primary care team in hopes of enrolling 94 patients. Patients are still eligible to participate in the study even if a care partner/loved one does not attend the ACP visit with them or if the patient does not have a care partner.||||
33754828|NCT04567108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor will be blinded to participants' beverage assignment at time of outcome assessment; Investigators will be masked to treatment arm assignments during primary analyses|Parallel randomization on a rolling basis to one of 4 interventions; After 9/1/2023 design is modified to 3 parallel interventions, with sucralose and aspartame interventions combined into one ASB substitution arm|f|f|t|t
33754829|NCT05674396|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754830|NCT00142727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754831|NCT04394390|||CASE_CONTROL||PROSPECTIVE|||||||
33870647|NCT00582335|||FAMILY_BASED||PROSPECTIVE|||||||
34067051|NCT00462449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34067052|NCT03576209|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"The described trial is a controlled before-and-after study. In this study, observations are made before and after the implementation of the intervention during 12 weeks, both in groups participating in the program (intervention group) and in groups who are not participating in the program (control groups).~Observations are made in intervention and control groups. Participants of the intervention group are registered for participation in this health promotion program 'Lekker Actief' prior to the start of this trial. The control groups are composed of participants who are not participating in the program (not receiving any intervention) or the controls are waitlist controls."||||
34067053|NCT05629676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067054|NCT00002073||||TREATMENT||DOUBLE||||||
33754832|NCT01604551|||||PROSPECTIVE|||||||
33754833|NCT02471092|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33754834|NCT00298480|||CASE_CONTROL||PROSPECTIVE|||||||
33754835|NCT03609567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754836|NCT00434382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33754837|NCT03733405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754838|NCT04118348|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE||Prospective randomized controlled trial.|t|t|f|f
33754839|NCT01631084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754840|NCT05895032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is impossible to blind those in receipt and those delivering the intervention as to group allocation. However, it will be possible, although perhaps challenging, to blind the assessor to group allocation. Consequently, we will attempt a single blind approach in which the participant and physiotherapists delivering the intervention will be encouraged to withhold their group allocation from the assessors collecting data.|A single-blinded, two-arm pragmatic randomised controlled trial|f|f|t|t
33754841|NCT04941040|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33754842|NCT06579612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled superiority trial in parallel arms (1:1 ratio) comparing personalized follow-up and support after a pulmonary rehabilitation program (experimental group) versus a control group receiving only usual care,||||
33754843|NCT02047045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754844|NCT02592382|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33754845|NCT04685902|||CASE_ONLY||PROSPECTIVE|||||||
33870648|NCT05151081|||CASE_CONTROL||PROSPECTIVE|||||||
33870649|NCT01450449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894187|NCT04990739|NA|SEQUENTIAL||TREATMENT||NONE||Initial dose escalation will use an accelerated titration scheme followed by a 3+3 dose escalation design.||||
33894188|NCT03650504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067055|NCT06111001|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants will be enrolled by the NHS Research Coordinator. Participants and their allocation to study groups will not be known to the Sponsor Investigators.||f|f|t|f
34067056|NCT01614106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067057|NCT04656678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067058|NCT02587754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2 arm study comparing acupuncture with sham|t|f|f|t
34067059|NCT03277911|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34151855|NCT04082286|NA|SINGLE_GROUP||TREATMENT||NONE|Yttrium-90 labelled monoclonal antibody against CD66|3+3 Dose escalation study, patient will receive 111In-labelled anti-CD66 MoAb (dosimetry) and 90Yttrium-labelled anti-CD66 MoAb (for therapy)||||
34151856|NCT04842305|||COHORT||CROSS_SECTIONAL|||||||
33754846|NCT06263621|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Entrees are offered in two different portion sizes at two cafes. The cafes were randomized to either receive the Standard portion label for the smaller size (Intervention) or the Small portion label for the smaller size (Control). The larger portion was labeled Large. Daily lunch transaction data will be provided by the cafes."||||
33754847|NCT03151005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754848|NCT04962425|||CASE_CONTROL||RETROSPECTIVE|||||||
33754849|NCT00710138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33754850|NCT05602636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188726|NCT00199303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188727|NCT03915652|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The investigators plan to newly enroll 40 lupus patients prospectively using a stepped wedge design starting first with 20 patients enrolled in Rheum-iCMP, and then with 20 additional patients enrolled 4 months later. For the second 20 patients, for the first 4 months, patients will receive educational material. Additionally, the investigators expect that 100 lupus patients within the Partners system are already enrolled in BWH iCMP. For this group, EMR and claims data pre and post standard of care iCMP enrollment will be examined for changes in utilization, but patients will not be newly enrolled for this observational component.||||
34188728|NCT00423917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188729|NCT02406534|||COHORT||PROSPECTIVE|||||||
34188730|NCT03124342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188731|NCT04239391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188732|NCT02726854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188733|NCT04916691|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34188734|NCT02985528|||CASE_ONLY||PROSPECTIVE|||||||
34188735|NCT02861001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188736|NCT05241548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188737|NCT00249899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188738|NCT01305993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188739|NCT00610480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188740|NCT06005064|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Supplements will be identical in look and taste|1:1 basis|t|f|t|t
34188741|NCT01179113|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
34188742|NCT03024099|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34188743|NCT01650597|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34188744|NCT00941590|||CASE_CONTROL||PROSPECTIVE|||||||
34188745|NCT01079052|RANDOMIZED|CROSSOVER||||NONE||||||
34188746|NCT02086500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754851|NCT02606903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754852|NCT01592370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754853|NCT02115880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754854|NCT00033358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754855|NCT04304664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant, therapists and outcome assesors are blind to the condition the individual participant was assigned to, by encrypting the names of the individual into a number-letter codes.~The therapists led the intervention group was not aware of the participants condition."|The current study is a randomized- Control Trial (RCT), 95 patients diagnosed with fibromyalgia syndrome were randomly assigned either to mindfulness-based intervention group (MBI) or to a wait-list control group (WL).|t|t|t|t
33754856|NCT04230044|||COHORT||PROSPECTIVE|||||||
33754857|NCT02406326|||OTHER||PROSPECTIVE|||||||
33754858|NCT01785680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754859|NCT02077166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33754860|NCT02863679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754861|NCT05327881|||COHORT||PROSPECTIVE|||||||
33754862|NCT04274673|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33754863|NCT04209075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33894189|NCT03702725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894190|NCT04548310|||CASE_CONTROL||PROSPECTIVE|||||||
33894191|NCT03071718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188747|NCT00338585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188748|NCT02352155|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188749|NCT02198404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188750|NCT05750446|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34188751|NCT03677453|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34188752|NCT01039376|RANDOMIZED|||TREATMENT||NONE||||||
34188753|NCT04816669|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34188754|NCT01732237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067060|NCT05012410|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Single blind allocation. Study interviewers will be masked to group allocation. Other research personnel (investigator, project manager, interventionist), may become aware of group allocation. Caregivers will be asked not to disclose to interviewers the group to which they are assigned.|Prospective randomized trial involving an immediate treatment group (Group A) and a 3-month waitlist control group (Group B). Also, groups will be randomized to different prompting conditions (email only, telephone and email) to remind participants to use the tool.|f|f|f|t
34151857|NCT03342092|||COHORT||PROSPECTIVE|||||||
34151858|NCT06347939|||COHORT||PROSPECTIVE|||||||
34151859|NCT02785419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151860|NCT02580786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894192|NCT05714930|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, national, two-armed cluster-randomized controlled trial||||
34188755|NCT02395159|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188756|NCT04240834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188757|NCT03843840|||CASE_CONTROL||PROSPECTIVE|||||||
34188758|NCT00388817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34188759|NCT05676021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomised control trial||||
34188760|NCT02347137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188761|NCT01610778|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34188762|NCT04981990|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patients will not know whether they are in the first or second group|Two equal groups: the first group undergoing lung surgeries with single lung ventilation by double lumen endotracheal tube, the second group undergoing lung surgeries with two lung ventilation using conventional single lumen endotracheal tube|t|f|f|f
34188763|NCT06246045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754864|NCT04833764|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective, single arm Phase 1/Phase 2 study of patients with lower extremity DVT. Phase 1 will assess safety and tolerability of xisomab 3G3 in patients with lower extremity DVT on standard rivaroxaban therapy in 12-18 subjects. Three doses of xisomab 3G3 (42, 126, or 252 mg IV) will be tested to determine the maximum tolerated dose (MTD) with the dose limiting toxicity as any major bleeding or serious adverse event. Phase 2 will assess the efficacy of xisomab 3G3 for the prevention of PTS and compare the 1 year incidence of PTS as determined by the Villalta score in patients with lower extremity DVT on standard rivaroxaban therapy in 30 study participants.||||
33754865|NCT06265545|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33754866|NCT01492023|||CASE_CONTROL||PROSPECTIVE|||||||
33754867|NCT01846793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754868|NCT03716609|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
33754869|NCT01437748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754870|NCT01951625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188764|NCT05743959|||COHORT||PROSPECTIVE|||||||
34188765|NCT00459732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188766|NCT00485095|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34188767|NCT01438736|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188768|NCT06517628|||COHORT||PROSPECTIVE|||||||
34188769|NCT00786591|||CASE_CONTROL||PROSPECTIVE|||||||
34188770|NCT04173494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the 24 week randomized treatment phase of the study, participants, investigators and sponsor and relevant vendor personnel (with the exception of specified unblinded personnel, for example clinical supply) will remain blinded to the participant's treatment assignment and to aggregate data that may lead to inadvertent unblinding. Participants who continue treatment with momelotinib or danazol after Week 24 in the extended treatment phase will receive unblinded treatment.||t|t|t|t
34188771|NCT04510818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188772|NCT02398435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188773|NCT01424878|||||RETROSPECTIVE|||||||
34188774|NCT01810536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188775|NCT02925884|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34188776|NCT06343519|||CASE_ONLY||PROSPECTIVE|||||||
34188777|NCT05196321|||COHORT||PROSPECTIVE|||||||
34188778|NCT02065258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188779|NCT00619814|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34188780|NCT05395598|||COHORT||PROSPECTIVE|||||||
34188781|NCT00732537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34188782|NCT00002317||||TREATMENT||NONE||||||
34188783|NCT00351871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188784|NCT01798108|NA|SINGLE_GROUP||OTHER||NONE||||||
34188785|NCT01526759|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34188786|NCT00990704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188787|NCT01777113|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33754871|NCT02118129|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33754872|NCT02245932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33894193|NCT05307744|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34188788|NCT01437566|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34188789|NCT04440527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34188790|NCT00310739|||NATURAL_HISTORY||PROSPECTIVE|||||||
34188791|NCT03704896|||COHORT||PROSPECTIVE|||||||
34188792|NCT05457803|||COHORT||PROSPECTIVE|||||||
34188793|NCT02301416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870650|NCT04822051|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"In this study, it is the same researcher who applied the intervention and evaluated the data.~For this reason, a one-way blinding was made by ensuring that only the individuals who agreed to participate in the study did not know the group they were in."||t|f|f|f
33870651|NCT04885803|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Full blinding protocols employed to mask all participants, all those engaging with participants, and the PI for the duration of the study period.||t|t|t|f
33870652|NCT00042120|||CASE_CONTROL||RETROSPECTIVE|||||||
34067061|NCT03942367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An unblinded sub-Investigator will preconfigure the patches to be active or sham, and pack them in 4 patches per box. The randomization will be carried out in accordance to the the instructions provided, keeping the Investigator's and Patient's blindness about the configuration of each patch.|This is a double-blind, multi-center clinical trial. Patients enrolled will be randomized in a 2:1 ratio to receive active vPatch device (Group A) or a Sham Device (Group B).|t|f|t|f
33870653|NCT00655382|||COHORT||PROSPECTIVE|||||||
33870654|NCT03147781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870655|NCT01840579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870656|NCT02775084|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33870657|NCT02751593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067062|NCT02150681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067063|NCT02801370|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34067064|NCT05111938|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Research assistants were masked to treatment condition|AB/BA crossover: participants were randomized to Arm A (Standard Care (SC) then F3A-App), or Arm B (F3A-App then SC)|f|f|f|t
34067065|NCT02446535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067066|NCT05194943|||COHORT||PROSPECTIVE|||||||
34067067|NCT02226848|RANDOMIZED|PARALLEL||TREATMENT||||||||
34067068|NCT05576519|||OTHER||RETROSPECTIVE|||||||
34067069|NCT02365038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067070|NCT04586465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Non|Dynamic PET-CT compared with RECIST to predict therapeutic response treated with neoadjuvant ICI combined with chemotherapy for stage Ⅱ-Ⅲ NSCLC.||||
34067071|NCT00514982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067072|NCT04091815|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34067073|NCT03734445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Vitamin Supplement and placebo will be packaged by others not including the investigators, code will be kept secret until the end of the trial or unless a secondary effect is registered and merits the opening of the code|Subjects will be randomly allocated to two groups (vitamin supplement or placebo), with a duration of 24 weeks. Dietary and compliance monthly follow-up and baseline, 12 and 24-week measurements.|t|f|t|f
34067074|NCT03460366|||CASE_ONLY||PROSPECTIVE|||||||
34067075|NCT00341549|||COHORT||PROSPECTIVE|||||||
34067076|NCT04100655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067077|NCT03420222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067078|NCT02867800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067079|NCT00719940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067080|NCT03748121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Therapists (Care Provider) could not be blinded according to the nature of the intervention. However, therapists will be blinded to allocation concealment as they do not be aware of the patients' group assignment at baseline assessment until they open the opaque randomization envelope, which contains the patient randomization number and group assignment. The random sequence generation and the envelopes were prepared by the study coordinator who is not involved patient recruitment. Patients received post intervention questionnaires from a study assistant/nurse of the respective outpatient department who is also blinded to the patients' group assignment. After completing the questionnaires, the study assistant will sent them to study coordinator so that the therapist could not influence the patients' answers.||f|f|t|t
34067081|NCT00549471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067082|NCT00661453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067083|NCT03728621|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, prospective, controlled study of 12 months a total of 170 children were consecutively recruited among those with diagnosis of obesity (in accordance with World Health Organization (WHO) criteria) by primary care pediatricians and admitted to the Department of Pediatrics, San Paolo Hospital, Milan, Italy, between January 2012 and June 2017. Inclusion criteria were: age at recruitment ≥6 years; weight at birth ≥2500 g and \<4000 g; gestational age 37-42 weeks; single birth; Caucasian race; family residing in Milan or neighborhood (≤30 km). Children having syndromic, organic and hormonal conditions besides obesity were excluded.||||
34067084|NCT02874833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067085|NCT00450853|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067086|NCT00402818|||COHORT||PROSPECTIVE|||||||
34067087|NCT03736070|||COHORT||PROSPECTIVE|||||||
34067088|NCT03571724|RANDOMIZED|PARALLEL||OTHER||NONE||Longitudinal ambulatory switching study||||
34067089|NCT05745753|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Creation within the data platform of the Cardiology Network of a database of studies containing relevant information on patients with cardiovascular diseases with and without COVID 19; Study the prevalence of cardiovascular risk factors by collecting patient information and analyzing data using conventional statistical analysis and machine learning techniques to develop multivariable models and identify those at greatest risk.||||
34067090|NCT05373030|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34067091|NCT00565175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067092|NCT05061433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34067093|NCT03753178|||CASE_CONTROL||OTHER|||||||
34067094|NCT06083545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34067095|NCT05409755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067096|NCT06351553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188794|NCT03145870|NA|SINGLE_GROUP||OTHER||NONE||||||
34188795|NCT04772612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188796|NCT06045156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188797|NCT06268977|||OTHER||PROSPECTIVE|||||||
34188798|NCT01915836|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34188799|NCT01869153|||COHORT||OTHER|||||||
33754873|NCT04120233|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Data from cohorts will be reviewed in a blinded manner.|Dose-escalation study.|f|f|f|t
33754874|NCT00500903|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754875|NCT04455789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33754876|NCT01189279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754877|NCT03548298|NA|SINGLE_GROUP||TREATMENT||NONE||Men and women with diagnosis of GERD confirmed by endoscopy or pHmetry, GERD questionnaire and that accept this new treatment.||||
33754878|NCT02341001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33754879|NCT04570436|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33754880|NCT00479245|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754881|NCT01667991|||CASE_ONLY||PROSPECTIVE|||||||
33754882|NCT00042679|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754883|NCT04719689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754884|NCT05445648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754885|NCT02559752|||CASE_ONLY||PROSPECTIVE|||||||
33754886|NCT03369522|||COHORT||PROSPECTIVE|||||||
33754887|NCT04159480|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes measures will be collected electronically|Randomized Clinical Trial|f|f|f|t
33754888|NCT04852016|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33754889|NCT00969475|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33754890|NCT00818961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870658|NCT00113776|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870659|NCT01414881|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33870660|NCT04116996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870661|NCT01610895|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33870662|NCT04798937|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||78 were screened and 66 youth were randomized to 2 groups of 33 each and followed for 6 months with data collection at time zero, 3 months and 6 months.|t|t|t|t
33894194|NCT00351715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894195|NCT00913146|||||PROSPECTIVE|||||||
33754891|NCT03412682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754892|NCT03439774|||COHORT||PROSPECTIVE|||||||
33754893|NCT04654364|||OTHER||OTHER|||||||
33754894|NCT00462215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754895|NCT06029309|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33754896|NCT00693251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754897|NCT02630134|NA|SINGLE_GROUP||OTHER||NONE||||||
33754898|NCT00291148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754899|NCT00276640|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754900|NCT03900702|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33754901|NCT04787601|RANDOMIZED|PARALLEL||OTHER||NONE||Individuals who meet the inclusion criteria, who volunteered to participate in the study and signed the informed consent form will be divided into two groups, the control group and the study group, by simple random randomization. Experimental group cognitive based neuromuscular exercises + classical training; the control group will only do the classic training. A total of 8-week exercise program will be applied.||||
33894196|NCT04036084|||COHORT||PROSPECTIVE|||||||
33894197|NCT02923271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894198|NCT00418288|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33894199|NCT02704104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33894200|NCT01383369|||||PROSPECTIVE|||||||
34067097|NCT06178562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outside of the research, all participating staff were required to avoid unnecessary contact with the patients enrolled and were instructed to strictly adhere to the confidentiality agreement regarding the study. The personnel responsible for data collection and assessment were not involved in other parts of the study and were unaware of the study design. Additionally, all assessments were conducted under the supervision of the principal investigator to ensure objectivity. All staff involved in the intervention underwent rigorous training to ensure that the implementation followed the protocol. Additionally, the principal investigator of the study regularly supervised the process of intervention to ensure compliance with the predetermined protocol.||f|f|f|t
34067098|NCT00884845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067099|NCT03884309|NA|SINGLE_GROUP||OTHER||NONE||||||
34067100|NCT03002532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067101|NCT03420287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067102|NCT06384235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067103|NCT04270695|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34067104|NCT03339557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be operated upon using the implant allocated in randomization. Participants are blinded to the implant design used for their operation. Staff at the ward is also blinded. And the physiotherapists conducting the follow-up visits (at 2-3 months, 1 year and 2 years, i.e. the outcome assessors) are also blinded to the allocation.|Patients will be recruited from Coxa outpatient clinic according to inclusion and exclusion criteria. The participating orthopedic surgeons will recruit patients along their out-patient work. The indications for the surgical treatment in the study will follow the routine clinical guidelines of the hospital. When TKR surgery is decided, the eligible patients will be informed and those willing to participate will be randomized into one of the three implant groups.|t|t|f|t
34067105|NCT00490672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067106|NCT03206840|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34067107|NCT02752711|||COHORT||PROSPECTIVE|||||||
34067108|NCT03958474|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Within-subjects design|t|f|f|t
34067109|NCT06227715|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34067110|NCT00441363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067111|NCT03594955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067112|NCT05961189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study will be a pre- post-testing study seeing if antibiotic administration (azithromycin) impacts the ability to exercise.||||
34067113|NCT04574375|||COHORT||PROSPECTIVE|||||||
34067114|NCT05610475|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34067115|NCT05618158|NA|SINGLE_GROUP||PREVENTION||NONE||Randomized stepped-wedge with four cohorts||||
33870663|NCT04341441|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Blinded randomization will be performed by the Henry Ford Hospital Public Health Sciences investigators once the participants are determined to be eligible for enrollment. Randomization will be stratified by study site and risk of exposure based on location of work and type of work.~Once enrolled, each Participant will be assigned a unique identifier (detailed in the full protocol). This number, along with the assigned site number, will constitute the Subject Identifier (Subject ID)."|"This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW) and first responders (FR) in southeast (SE) Michigan, can prevent the acquisition, symptoms and clinical COVID-19 infection.~The study will randomize a total of 3,000 Healthcare Workers and First Responders, age ≥18 years or older, through the Henry Ford Health System, Detroit COVID Consortium. The participants who meeting study entry criteria and are not on HCQ prior to study enrollment will be randomized in a 1:1:1 blinded comparison of daily or weekly oral hydroxychloroquine versus oral placebo for 8 weeks.~A fourth non-randomized comparator group will be enrolled in the study comprising of HCW who are chronically on HCQ as part of their standard of care for their autoimmune disease(s). This will be an open enrollment group and will provide information of chronic weight-based daily therapy of HCQ effectiveness as a prophylactic/preventive strategy."|t|t|t|f
34067116|NCT02362425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34067117|NCT02547896|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067118|NCT01885663|NA|SINGLE_GROUP||TREATMENT||NONE||UCB therapy for TBI patient||||
34067119|NCT00429975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067120|NCT02148016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067121|NCT00073645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067122|NCT01773356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34067123|NCT03085771|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blind study.|This is a randomised, double-blind, placebo-controlled, cross-over, single center study of patients with diabetes mellitus type 1 without chronic complications.|t|t|t|t
34067124|NCT00681265|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34067125|NCT03972241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To compare between experimental and control groups.|t|f|f|f
34067126|NCT02960477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34067127|NCT02844036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067128|NCT05029609|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This is a Phase 1b double blind, randomized, placebo controlled, dose escalating study evaluating multiple doses of Foralumab via intranasal administration for 14 days in patients with MS.|t|t|t|t
34067129|NCT05885776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067130|NCT00650728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067131|NCT05941624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067132|NCT06234826|||COHORT||PROSPECTIVE|||||||
34067133|NCT06553963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067134|NCT01758718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067135|NCT03484403|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized controlled trial. Blinding of the subjects is not possible because a back brace is a visibly obvious intervention. In addition, since we are evaluating the adherence of back brace wear, blinding of the investigator is also not possible. Therefore, this study will be an unblinded RCT.||||
34067136|NCT06465771|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067137|NCT04749537|||OTHER||CROSS_SECTIONAL|||||||
34067138|NCT01870167|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34067139|NCT01496417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067140|NCT01209273|||COHORT||PROSPECTIVE|||||||
34067141|NCT03471806|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34067142|NCT06452290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067143|NCT01210222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067144|NCT04605926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be blinded to all study staff that has direct access to the subjects and the sponsor.||t|t|t|t
34188800|NCT00504972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188801|NCT03546296|||CASE_CONTROL||PROSPECTIVE|||||||
34188802|NCT01785485|||CASE_CONTROL||PROSPECTIVE|||||||
34188803|NCT03111641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188804|NCT05513209|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188805|NCT04470076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188806|NCT01122121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188807|NCT02759367|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treating physicians and participants were not blinded to randomization. Investigators performing randomization and analysis of dietary intake were blinded.|||||
34188808|NCT01873976|||COHORT||PROSPECTIVE|||||||
34188809|NCT00673738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188810|NCT00629889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188811|NCT02299843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188812|NCT02859870|||COHORT||PROSPECTIVE|||||||
34188813|NCT01632618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188814|NCT05428397|||CASE_CONTROL||RETROSPECTIVE|||||||
34188815|NCT03711695|||CASE_ONLY||PROSPECTIVE|||||||
34188816|NCT05185713|||COHORT||CROSS_SECTIONAL|||||||
34188817|NCT02405377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34188818|NCT02835976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188819|NCT04413006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188820|NCT01586130|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34188821|NCT04607317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Due to the nature of the intervention, participants will not be blinded as to whether they are in the intervention or control group.~Blinded study staff will perform all pre-and post outcome assessments. The PI will also be blinded"|Subjects will be randomized to exercise intervention arm or control arm.|f|t|t|t
34188822|NCT02652858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188823|NCT01255683|||COHORT||PROSPECTIVE|||||||
34188824|NCT02685137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188825|NCT00808080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188826|NCT02139007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754902|NCT00262275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33870664|NCT03574675|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath trough a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia|t|f|f|f
33754903|NCT02568748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|||||
34188827|NCT03617224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754904|NCT02401568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33754905|NCT02081573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870665|NCT02332499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870666|NCT01427465|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34067145|NCT05777083|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34067146|NCT06364202|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34067147|NCT05538936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled experimental design with pretest-posttest experiment and control group||||
34067148|NCT00034047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067149|NCT01530711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067150|NCT05061082|||COHORT||PROSPECTIVE|||||||
34067151|NCT01415726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067152|NCT04046263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067153|NCT00937092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188828|NCT05289895|||OTHER||OTHER|||||||
34188829|NCT01171482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188830|NCT02780128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188831|NCT03210337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188832|NCT02296645|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34188833|NCT05434780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After getting the consent, baseline measurements will be taken by the assessor. An assessor performing the tests will be blind to the assigned intervention to avoid expectation bias.After taking baseline measurements, all twenty participants will be given a fictitious number and according to these numbers subjects will be allocated to two different groups using Goldfish Bowl randomization method. Ten participants will be allocated to group A in which facilitatory taping will be applied on the calf muscles and the other ten will be allocated in group B in which inhibitory K Tape will be applied to calf muscles and facilitatory K taping will be applied on Tibialis anterior muscle. KT will be applied by a physiotherapist who will be blind to the purpose of the study|20 consented subjects will be randomly divided into 2 equal groups using goldfish bowl method.|t|t|f|t
34188834|NCT05779618|||COHORT||CROSS_SECTIONAL|||||||
34188835|NCT05927649|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34188836|NCT02660983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188837|NCT00694148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188838|NCT01829152|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34188839|NCT04388254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo for the 6-month randomized period (Month 12 to Month 18)|Approximately two hundred (200) patients will be enrolled into the study. All participants will receive open-label simufilam 100 mg b.i.d. for a year. At Month12, participants will be randomized (1:1) to continue taking simufilam 100 mg b.i.d. or to be switched to placebo for 6 months. At Month 18, all participants will enter a final 6-month treatment period of open-label simufilam 100 mg b.i.d.|t|t|t|t
34188840|NCT05170880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34188841|NCT01162837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34188842|NCT00351858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188843|NCT05271773|||COHORT||PROSPECTIVE|||||||
34188844|NCT00641368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188845|NCT00701883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188846|NCT01075685|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34188847|NCT02527421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188848|NCT00114517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34188849|NCT02510677|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754906|NCT06579365|||COHORT||PROSPECTIVE|||||||
33754907|NCT03044483|||OTHER||CROSS_SECTIONAL|||||||
33754908|NCT02798510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754909|NCT03872921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33754910|NCT03382782|RANDOMIZED|PARALLEL||TREATMENT||NONE||The behavioral weight loss intervention (BWLI) consists of an 8-month intervention phase followed by a 4-month maintenance phase. The initial intervention phase comprises four types of contact: 1) One-hour to one and a half hour group weight management class led by facilitator (once per week); 2) 45-minute physical activity class led by facilitator (1-2 per week); 3) 20-minute, individual visit with facilitator (once per month); 4) Weigh-in (once each week). Persons are randomly assigned to peer navigators to begin simultaneously with BWLI and run concurrently across the eight months of the intervention. PNs may work with participants to partner on BWLI homework, meet with participant and BWLI facilitator individually, attend health care appointments, and partner on tasks that arise out of those appointments.||||
33754911|NCT02633137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754912|NCT04173455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188850|NCT03052426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188851|NCT04013659|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Split-mouth model design|f|f|f|t
34188852|NCT03736642|||OTHER||PROSPECTIVE|||||||
33870667|NCT04080947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870668|NCT04292808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870669|NCT00006047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870670|NCT05945186|NA|SINGLE_GROUP||OTHER||NONE||||||
33870671|NCT01850485|||||PROSPECTIVE|||||||
33870672|NCT04670497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|sealed opaque envelop|This study is comparing the effect of Lumbar plexus block and fascia iliaca block with general anesthesia to provide perioperative pain control and compare their effects on hemodynamics.|t|t|t|t
33870673|NCT03382158|||COHORT||OTHER|||||||
33870674|NCT03096951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870675|NCT04689581|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33754913|NCT04813627|||COHORT||PROSPECTIVE|||||||
33870676|NCT06031649|||COHORT||RETROSPECTIVE|||||||
33870677|NCT00907348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870678|NCT00577642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870679|NCT01199588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870680|NCT06017570|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965958|NCT06017765|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be assessed for psychiatric symptoms (primary objective) by blinded Independent Evaluators, who will not be involved in the mindfulness training sessions. Participants will be instructed to keep their evaluators blinded to the randomization. Blinded Independent Evaluators will be clinical psychologists who are fully trained in assessing the different measures.|The study model is a pilot randomized waitlist controlled trial of an 8-session mindfulness training program (i.e., Stress Management and Resiliency Training, SMART program) delivered weekly for Prolonged Grief Disorder, either within 4 weeks (immediate) or after 12 weeks (waitlist). After participants have completed the baseline assessment (V0), they will be randomly assigned (1:1 randomization) to either the immediate mindfulness training group or the waitlist control group. The waitlist control group will wait for 12 weeks (when the immediate intervention group finished all study procedures, including the follow-up assessment) before receiving the mindfulness training, which is the same intervention as employed in the immediate intervention group.|f|f|f|t
33965959|NCT01666925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33965960|NCT03856671|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking is to conducted in the current study.|||||
34067154|NCT04191343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188853|NCT00475956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188854|NCT01666041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188855|NCT05429385|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Double-blind, Placebo-Controlled||t|t|t|t
34188856|NCT00363480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188857|NCT00517088|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34188858|NCT05986396|||OTHER||RETROSPECTIVE|||||||
34188859|NCT01569893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34188860|NCT05688475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188861|NCT00253162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34188862|NCT05430997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34188863|NCT00644982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188864|NCT04429477|||COHORT||PROSPECTIVE|||||||
34188865|NCT03214666|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34188866|NCT04858048|||COHORT||PROSPECTIVE|||||||
34188867|NCT04454853|||COHORT||PROSPECTIVE|||||||
34188868|NCT01150188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34188869|NCT05833607|||COHORT||PROSPECTIVE|||||||
34188870|NCT01949818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188871|NCT02657603|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34188872|NCT04059588|NA|SEQUENTIAL||OTHER||NONE||Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels of 2141-V 11 using a standard 3+3 dose-escalation design.||||
34188873|NCT06048640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34188874|NCT03756324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the different numbers of interventions, the investigators can not blind the participants and the doctors. Thus, the CRF recorders, outcomes assessors and the statisticians will be blinded in the study.|Based on previous studies, considering the 20% expulsion rate, the investigators plan to recruit 306 participants with sample-size calculation formula. The sequence of randomization (1:1:1) will be generated by the statisticians with a computer program.|f|f|f|t
34188875|NCT06394141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188876|NCT00029770||||TREATMENT||||||||
34188877|NCT05205889|NA|SINGLE_GROUP||TREATMENT||NONE|No masking is required, as participants are fully informed about the purpose of the study. Since there is only one arm, masking of the investigators is also not necessary.|Single case analysis with 10-17 pre-measurement time points; 10 measurement time points during the intervention; and one post-measurement.||||
33754914|NCT00922285|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33965961|NCT05415982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965962|NCT04077528|||COHORT||PROSPECTIVE|||||||
33965963|NCT00505128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754915|NCT01760096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33965964|NCT00130000||||TREATMENT||||||||
34067155|NCT00302887|||DEFINED_POPULATION||PROSPECTIVE|||||||
34067156|NCT00149370|||DEFINED_POPULATION||PROSPECTIVE|||||||
34067157|NCT01075464|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067158|NCT01527708|||CASE_CONTROL||PROSPECTIVE|||||||
34188878|NCT01136980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188879|NCT00326859|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34188880|NCT01939769|RANDOMIZED|PARALLEL||TREATMENT||||||||
34188881|NCT03967353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188882|NCT01657240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754916|NCT03713554|||OTHER||PROSPECTIVE|||||||
33754917|NCT04473131|||COHORT||PROSPECTIVE|||||||
33754918|NCT04550988|||OTHER||PROSPECTIVE|||||||
33754919|NCT03584932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754920|NCT02432105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870681|NCT00767052|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33870682|NCT04638348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870683|NCT03335163|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-inferiority study to evaluate the pharmacokinetic effect of topiramate on serum ENG levels in contraceptive implant users||||
34188883|NCT05753696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188884|NCT04693624|||COHORT||PROSPECTIVE|||||||
34188885|NCT01965678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34188886|NCT03544762|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34188887|NCT06458478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188888|NCT03371043|||COHORT||RETROSPECTIVE|||||||
34188889|NCT03607019|||COHORT||PROSPECTIVE|||||||
34188890|NCT03495245|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870684|NCT04957576|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33870685|NCT01193439|||CASE_CONTROL||PROSPECTIVE|||||||
33870686|NCT01858532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870687|NCT01940198|||COHORT||RETROSPECTIVE|||||||
33870688|NCT01027611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870689|NCT01483742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870690|NCT04127253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33870691|NCT02475070|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870692|NCT01505790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188891|NCT04106076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754921|NCT00852748|||COHORT||PROSPECTIVE|||||||
33754922|NCT01936025|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33754923|NCT03973008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754924|NCT05748912|NA|SINGLE_GROUP||TREATMENT||NONE||FOCUS protocol A is a single-arm study which means all study participants will receive the same intervention.||||
33870693|NCT03497585|||COHORT||PROSPECTIVE|||||||
33870694|NCT00177749|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33870695|NCT01655342|||COHORT||PROSPECTIVE|||||||
33870696|NCT01102075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067159|NCT04933396|||COHORT||RETROSPECTIVE|||||||
34188892|NCT06268756|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188893|NCT04146636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"prospective diagnostic study in primary care. Evaluation of a simple blood test (e-LIFT) for the diagnosis of advanced liver fibrosis.~Reference for advanced liver diagnosis : composite criteria :~* Elastometry between 8 kPa and 15 kPa and histologic evaluation of fibrosis ≥ F3 (NASH CRN ) OR~* Elastometry ≥ 15 kPa"||||
34188894|NCT05425940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188895|NCT03347955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All of the above were masked. Only the neurosurgeon (Dr. Breeze) who did the implant and the person in charge of random assignment were aware of which participant received which treatment."|In this double-blind study, 20 participants were randomly assigned to the treatment group and 20 to the sham surgery group with the blind being maintained for 12 months.|t|t|t|t
34188896|NCT04651842|||OTHER||CROSS_SECTIONAL|||||||
33870697|NCT00803699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870698|NCT00496730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894201|NCT06118528|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33894202|NCT00596505|||CASE_CONTROL||PROSPECTIVE|||||||
34188897|NCT03677804|||COHORT||RETROSPECTIVE|||||||
34188898|NCT03990558|||COHORT||PROSPECTIVE|||||||
34188899|NCT03497312|||OTHER||OTHER|||||||
34188900|NCT04338776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188901|NCT02981615|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34188902|NCT06032325|||OTHER||PROSPECTIVE|||||||
33870699|NCT03382977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|None, open-label Allocation (FDAAA)|"3+ 3 Dose Escalation~Therapeutic Vaccine: VBI-1901~The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM."||||
33870700|NCT01500759|||COHORT||PROSPECTIVE|||||||
33870701|NCT00639691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870702|NCT01710995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870703|NCT04266184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870704|NCT01323725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870705|NCT01239095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188903|NCT03134703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188904|NCT02110836|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34188905|NCT01398709|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34188906|NCT03500224|NA|SINGLE_GROUP||OTHER||NONE||||||
34188907|NCT03893942|||COHORT||PROSPECTIVE|||||||
34188908|NCT03831906|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"The TB-Speed Pneumonia study is a stepped wedge cluster-randomised trial. Clusters, i.e.hospitals, will successively switch from control to intervention in an order randomly assigned, until all clusters are eventually exposed to the intervention.~The TB-Speed Pneumonia study will be implemented in 15 hospitals. At the start of the study, all hospital will be implementing the WHO SOC for severe pneumonia (control arm). One hospital will then switch to the TB-Speed strategy (intervention arm) every 5 weeks.~Randomisation will be stratified on the country estimated TB incidence rate (see Table 3): \<300/100,000 patients-years (Cameroon, Cote d'Ivoire and Uganda) vs. ≥300/100,000 patients-years (Cambodia, Mozambique and Zambia)."||||
34188909|NCT00858104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188910|NCT00770159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188911|NCT05406635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34188912|NCT05925868|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34188913|NCT06445114|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm multicenter clinical trial||||
34188914|NCT03331640|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34188915|NCT00633204|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34188916|NCT02901678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34188917|NCT04121663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34188918|NCT03222999|||CASE_ONLY||PROSPECTIVE|||||||
34188919|NCT00400972|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34188920|NCT03443570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188921|NCT00268853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188922|NCT00357682|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34188923|NCT05875506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34188924|NCT02969148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34188925|NCT03561467|||CASE_ONLY||PROSPECTIVE|||||||
34188926|NCT01580215|||COHORT||PROSPECTIVE|||||||
34188927|NCT01043913|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34188928|NCT04118738|||COHORT||PROSPECTIVE|||||||
33870706|NCT05233020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870707|NCT04754360|||OTHER||PROSPECTIVE|||||||
33870708|NCT04640272|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-comparative||||
33870709|NCT05267275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870710|NCT01695395|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870711|NCT01483781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870712|NCT01388660|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188929|NCT04150848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870713|NCT05613764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
33870714|NCT01330134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965965|NCT04221087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized to either intervention or control group upon admission if they meet inclusion/exclusion criteria and consent.|t|t|t|t
33965966|NCT05155631|RANDOMIZED|PARALLEL||TREATMENT||NONE||CBT||||
33965967|NCT04157634|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort study||||
33965968|NCT01637961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965969|NCT04825509|||COHORT||PROSPECTIVE|||||||
33965970|NCT01535157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965971|NCT04512027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188930|NCT01957046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34188931|NCT00746512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188932|NCT01823913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870715|NCT00912028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870716|NCT05068466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33965972|NCT01325857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33965973|NCT00520247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33965974|NCT04042974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34188933|NCT03944252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33965975|NCT05994443|||COHORT||PROSPECTIVE|||||||
33965976|NCT00558519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965977|NCT05187312|||COHORT||PROSPECTIVE|||||||
33965978|NCT04809038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque sealed envelope|this trial has three group; two experimental and one control|t|f|f|f
33965979|NCT05140018|||COHORT||PROSPECTIVE|||||||
33965980|NCT02451969|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33965981|NCT00137085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33965982|NCT04698057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067160|NCT00534417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067161|NCT05277389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067162|NCT05940766|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Double-blinded|Prospective interventional, multi-center, double-blinded, randomized controlled, multiple crossover superiority trial|t|f|t|f
34067163|NCT02288481|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34067164|NCT01090141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188934|NCT00706342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188935|NCT03655249|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Participants receive one of two interventions during the first day, and receive the alternative intervention the following day.~Interventions are : aerosoltherapy + autogenic drainage or aerosoltherapy alone"||||
34188936|NCT03925779|RANDOMIZED|PARALLEL||OTHER||DOUBLE|A blinded investigator that was not involved in the anaesthetic management of the patients, collected the intra-operative and postoperative data. The patients and colonoscopist were blinded to group allocation. For blinding purposes, two drug infusion pumps were used in every patient where the infusion pumps and i.v. connection lines were concealed to avoid identification.||t|f|f|t
34188937|NCT06182956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188938|NCT05059119|||CASE_ONLY||RETROSPECTIVE|||||||
34188939|NCT02865213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188940|NCT06342505|||COHORT||PROSPECTIVE|||||||
34188941|NCT02181244|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34188942|NCT03916900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel assignment|t|t|f|t
34188943|NCT05226494|NA|SEQUENTIAL||TREATMENT||NONE||3+3 Dose Escalation with option for cohort expansion||||
34188944|NCT05418543|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34188945|NCT01033799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34188946|NCT04106206|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34188947|NCT00643162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188948|NCT00773604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188949|NCT04233723|||OTHER||PROSPECTIVE|||||||
34188950|NCT01286051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188951|NCT05475730|NA|SINGLE_GROUP||OTHER||NONE||||||
34188952|NCT06248775|NA|SINGLE_GROUP||OTHER||NONE||||||
34188953|NCT01694498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188954|NCT04354636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188955|NCT04363424|||COHORT||CROSS_SECTIONAL|||||||
34188956|NCT01344525|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34188957|NCT03068585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188958|NCT05135078|||CASE_ONLY||CROSS_SECTIONAL|||||||
34188959|NCT05829369|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants are unable to be blinded to treatment they are receiving, but they will not be told interventions of other groups.~Investigators who perform measurements are blinded to intervention group."|Randomized control trial with an effectiveness-implementation hybrid design Type I|f|f|t|t
34188960|NCT04986514|||OTHER||PROSPECTIVE|||||||
34188961|NCT06423274|||COHORT||PROSPECTIVE|||||||
34188962|NCT04028401|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34188963|NCT01169818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870717|NCT04898075|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870718|NCT01247636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870719|NCT03819348|||CASE_ONLY||RETROSPECTIVE|||||||
33870720|NCT05235945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomised controlled trial|f|f|f|t
33870721|NCT01933633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870722|NCT03886753|||COHORT||PROSPECTIVE|||||||
33870723|NCT06166420|RANDOMIZED|PARALLEL||SCREENING||NONE||Two arms randomised controlled cluster trial||||
33870724|NCT00349167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870725|NCT02847455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870726|NCT06490276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33965983|NCT01700751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965984|NCT01935531|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33965985|NCT04026295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomized to either short-burst interval locomotor treadmill training (SBLTT) or traditional locomotor treadmill training (TLTT)|f|f|f|t
33965986|NCT01068873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965987|NCT04380324|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34188964|NCT03620877|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34188965|NCT00973232|RANDOMIZED|CROSSOVER||||NONE||||||
34188966|NCT05150899|||OTHER||PROSPECTIVE|||||||
34188967|NCT00947882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34188968|NCT00545259|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34188969|NCT03290599|||OTHER||PROSPECTIVE|||||||
33754925|NCT05759195|NA|SINGLE_GROUP||OTHER||NONE||||||
33870727|NCT02456844|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870728|NCT04607577|||COHORT||PROSPECTIVE|||||||
33870729|NCT03118232|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870730|NCT04501068|||COHORT||PROSPECTIVE|||||||
33870731|NCT02614365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33870732|NCT02753322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067165|NCT06165913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754926|NCT01249248|||COHORT||PROSPECTIVE|||||||
33754927|NCT02792465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Cohort A: Patients with advanced cancer. Treatment: Daily dose of 168 mg of CFI 402257.~Cohort B: Patients with advanced breast cancer Treatment: Daily dose of 168 mg of CFI 402257.~Cohort C: Patients with breast cancer tested positive for ER and/or PR, and HER2-negative. Treatment: Daily dose of 168 mg of CFI 402257 + Fulvestrant (standard hormonal treatment) on Day 1 and 15 of each 28 day cycle"||||
34188970|NCT03073941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34188971|NCT05214820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective pilot study||||
34188972|NCT00047164||||TREATMENT||NONE||||||
34188973|NCT02843516|||CASE_CONTROL||RETROSPECTIVE|||||||
34188974|NCT02239549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188975|NCT02820766|||COHORT||PROSPECTIVE|||||||
34188976|NCT04532606|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34188977|NCT04685889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188978|NCT01747291|||COHORT||PROSPECTIVE|||||||
34188979|NCT03436290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33754928|NCT02010125|||COHORT||PROSPECTIVE|||||||
33754929|NCT00976599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33870733|NCT04922840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial is single-blinded with investigator (KRN) masked for group allocation to reduce risk of bias. Patients are not blinded to treatment exposure nor study hypothesis.|Participants will be allocated 1:1 according to a computer-generated randomization scheme, stratified by sex|f|f|t|f
33870734|NCT00457886|||OTHER||PROSPECTIVE|||||||
33870735|NCT06014892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study is designed as a prospective randomized open-labeled study. We plan to enroll 152 trainees who are pregnant or immediately post-partum. Participants will undergo stratified randomization to an intervention or no intervention arm in a 1 to 1 ratio based on training specialty (either procedural or non-procedural) and training site (MGH, BWH, BCH, or BIDMC). Procedural specialties are defined as specialties that spend a significant portion of their training performing procedures: this includes all surgical specialties, anesthesiologists, gastroenterologists, obstetricians-gynecologists, interventional-radiologist, interventional-pulmonologists, interventional-cardiologists, emergency physicians. All other training programs are considered non-procedural specialties.||||
33870736|NCT01875783|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|Primary diabetes care specialists masked to results of OCT intervention||f|t|t|f
33870737|NCT04688775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34188980|NCT02736318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870738|NCT06351969|||COHORT||PROSPECTIVE|||||||
33870739|NCT02537886|||OTHER||OTHER|||||||
33870740|NCT01257815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870741|NCT01987687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34188981|NCT04615052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34188982|NCT05855148|||COHORT||PROSPECTIVE|||||||
34188983|NCT01317277|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34188984|NCT05363306|||COHORT||PROSPECTIVE|||||||
34188985|NCT06335563|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|AR glasses-assisted puncture localizing group versus CT-guided conventional pulmonary nodule puncture localizing group||||
34188986|NCT02212691|||OTHER||PROSPECTIVE|||||||
34188987|NCT05290285|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind RCT|"A 13-week randomized double-blind placebo-controlled study.~Patients will be randomized to EAA supplementation or placebo supplementation upon admission. Randomisation will be carried out by an independent external figure adopting the following stratification:~Group 1: BMI \<= 15.2 \& age \<= 20 Group 2: BMI \> 15.2 \& age \<= 20 Group 3: BMI \<= 15.2 \& age \> 20 Group 4: BMI \> 15.2 \& age \> 20"|t|t|t|t
34188988|NCT02824796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
34188989|NCT02528812|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34188990|NCT05835817|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34188991|NCT01360736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34188992|NCT00560196|||CASE_CONTROL||PROSPECTIVE|||||||
34188993|NCT03847051|||COHORT||PROSPECTIVE|||||||
34188994|NCT01319552|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34188995|NCT01415336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188996|NCT02624986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34188997|NCT00853632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34188998|NCT06327672|||COHORT||PROSPECTIVE|||||||
34188999|NCT04259619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The low-level laser and the placebo-laser cannot be differentiated visually. The lasers are marked with the names Geraet1 and Geraet2. The therapy is carried out identical in the way of application, duration and preventive measures. After the participant is randomized, the study nurse hands out the corresponding laser for the therapy."|prospective, randomized double-blinded study|t|t|t|f
34189000|NCT02617472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189001|NCT02178137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189002|NCT03251313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189003|NCT03200080|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34189004|NCT01195532|||CASE_CROSSOVER|||||||||
34189005|NCT01742286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189006|NCT04956107|||COHORT||PROSPECTIVE|||||||
34189007|NCT02544581|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34189008|NCT00540332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34189009|NCT00787618|NON_RANDOMIZED|PARALLEL||||NONE||||||
34189010|NCT03330249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189011|NCT02390505|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189012|NCT00210951|||COHORT||PROSPECTIVE|||||||
34189013|NCT05048095|||COHORT||PROSPECTIVE|||||||
34189014|NCT01243580|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189015|NCT00635999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189016|NCT05485649|||COHORT||PROSPECTIVE|||||||
34189017|NCT04972617|||COHORT||PROSPECTIVE|||||||
34189018|NCT00186134|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34189019|NCT06424652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189020|NCT00341146|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34189021|NCT02109185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189022|NCT05562219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189023|NCT00462813|RANDOMIZED|||PREVENTION||DOUBLE||||||
34189024|NCT04803396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is a double blind study. The analytical centre as well as the Investigator and the team and the subjects were in blind conditions.||t|t|t|f
34189025|NCT03603262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189026|NCT05366738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34189027|NCT04208971|||COHORT||PROSPECTIVE|||||||
34189028|NCT05179590|||COHORT||PROSPECTIVE|||||||
34189029|NCT01154257|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189030|NCT05115071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single blind pre-post test randomized controlled design|t|f|f|f
34189031|NCT00542282|||COHORT||PROSPECTIVE|||||||
34189032|NCT00786370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189033|NCT02328365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189034|NCT04462614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870742|NCT00833053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870743|NCT04309942|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentric, prospective, randomized controlled study||||
33870744|NCT03402984|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33870745|NCT00810004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870746|NCT02716051|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33870747|NCT06097000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870748|NCT02916849|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33894203|NCT02137668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894204|NCT02090543|||COHORT||PROSPECTIVE|||||||
34189035|NCT02914301|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189036|NCT04324164|||COHORT||RETROSPECTIVE|||||||
34189037|NCT03385772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a prospective interventional pilot study of the efficacy of the sphenopalatine ganglion block for treatment of post-dural puncture headache in post-partum women.||||
34189038|NCT04274946|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single-center, randomized study.||||
34189039|NCT01063283|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189040|NCT03313817|||CASE_ONLY||PROSPECTIVE|||||||
34189041|NCT04108637|RANDOMIZED|PARALLEL||SCREENING||NONE||Multicentre, two parallel-arm, open label, individually randomised pragmatic trial with a nested-pilot study||||
34189042|NCT00539864|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34189043|NCT02122757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189044|NCT02685267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189045|NCT05633017|||COHORT||PROSPECTIVE|||||||
34189046|NCT05708794|||COHORT||PROSPECTIVE|||||||
34189047|NCT00609037|||CASE_CONTROL||PROSPECTIVE|||||||
34189048|NCT03734913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189049|NCT00176267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189050|NCT00631943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189051|NCT05897489|||COHORT||OTHER|||||||
34189052|NCT01090661|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34189053|NCT00859911|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189054|NCT02644876|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189055|NCT02327663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189056|NCT01416324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34189057|NCT05381857|||COHORT||PROSPECTIVE|||||||
34189058|NCT01918618|||CASE_CONTROL||RETROSPECTIVE|||||||
34189059|NCT01069900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189060|NCT01432925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189061|NCT05471271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189062|NCT06044077|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189063|NCT03583385|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34189064|NCT06049485|||CASE_CROSSOVER||PROSPECTIVE|||||||
34189065|NCT01098513|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189066|NCT04052633|||COHORT||PROSPECTIVE|||||||
34189067|NCT00148096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189068|NCT02446899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189069|NCT01657916|||COHORT||PROSPECTIVE|||||||
33894205|NCT04226352|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894206|NCT00504257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189070|NCT05370937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189071|NCT01167244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189072|NCT01026324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189073|NCT05808569|||COHORT||PROSPECTIVE|||||||
34189074|NCT04761666|||CASE_ONLY||RETROSPECTIVE|||||||
34189075|NCT04909281|||COHORT||PROSPECTIVE|||||||
34189076|NCT00713297|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34189077|NCT04234412|NA|SINGLE_GROUP||TREATMENT||NONE|only case series of the treated patients|||||
33894207|NCT06656871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33894208|NCT02473796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894209|NCT04146753|||COHORT||OTHER|||||||
33894210|NCT02016950|||COHORT||RETROSPECTIVE|||||||
33894211|NCT03459040|NA|SINGLE_GROUP||PREVENTION||NONE||Open label single arm||||
33894212|NCT03822884|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33894213|NCT05116969|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
33894214|NCT05463133|NA|PARALLEL||TREATMENT||NONE||||||
34067166|NCT00679224|||OTHER||PROSPECTIVE|||||||
34067167|NCT05626075|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34067168|NCT02119806|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34067169|NCT05773339|||COHORT||RETROSPECTIVE|||||||
34067170|NCT04482738|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34067171|NCT04231968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067172|NCT03271099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34067173|NCT02399969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067174|NCT05210270|NA|SINGLE_GROUP||TREATMENT||NONE||Two-phase study Phase 1: Dose-escalation study using standard 3+3 design Phase 2: Single-arm clinical trial using Simon's two-stage design||||
34067175|NCT00106977|||COHORT||PROSPECTIVE|||||||
34067176|NCT04219839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized 1:1 to either receive intervention (usual care + videos) or no intervention (usual care only.)||||
34189078|NCT01890252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189079|NCT01262820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189080|NCT05680688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189081|NCT03283514|||OTHER||PROSPECTIVE|||||||
34189082|NCT05846737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189083|NCT03062540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189084|NCT00280748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189085|NCT03254511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189086|NCT04096599|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189087|NCT01369524|||COHORT||PROSPECTIVE|||||||
34189088|NCT04756908|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189089|NCT04816110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189090|NCT05095103|||COHORT||PROSPECTIVE|||||||
34189091|NCT04321707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective, explorative, single arm, non-randomized clinical trial||||
34189092|NCT04396561|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|sealed opaque envelopes prepared by an assistant blinded about the study targets and chosen by patient him/herself, allocated into two groups|Prospective randomized controlled double-blind study.|t|f|f|t
34189093|NCT00405600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189094|NCT01458041|||COHORT||PROSPECTIVE|||||||
34189095|NCT01429740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189096|NCT02670239|||COHORT||PROSPECTIVE|||||||
34189097|NCT06210321|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Patients in each group will be blinded, as CYP2C19 genetic information is not given until the study is completed.|This study consists of two groups, an intervention group using CYP2C19 genetic information to validate escitalopram prescriptions, and a control group without using CYP2C19 genetic information.|t|f|f|f
34189098|NCT00063843|RANDOMIZED|||PREVENTION||DOUBLE||||||
34189099|NCT01780220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189100|NCT00004669||||PREVENTION||||||||
34189101|NCT00152919|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189102|NCT00080899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189103|NCT06133062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189104|NCT00685568|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34189105|NCT01915069|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189106|NCT05252780|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189107|NCT02074410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189108|NCT03116152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189109|NCT05959148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The outcome assessor was blinded to the treatment assignment.|A prospective, randomized controlled clinical trial|f|f|f|t
34189110|NCT02210494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189111|NCT01901913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189112|NCT02840799|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34189113|NCT03173001|||COHORT||PROSPECTIVE|||||||
34189114|NCT05625997|||OTHER||PROSPECTIVE|||||||
34189115|NCT00724087|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34189116|NCT06458699|||COHORT||RETROSPECTIVE|||||||
34189117|NCT01518764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189118|NCT00120419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189119|NCT02083913|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189120|NCT00481299|||DEFINED_POPULATION||OTHER|||||||
34189121|NCT06293651|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34189122|NCT02153619|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189123|NCT01254760|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34189124|NCT04812392|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189125|NCT06362057|||OTHER||OTHER|||||||
34189126|NCT05114252|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The optometrists evaluating visual function will be blinded to the current treatment and the treatment order|Monocentric blinded crossover randomised controlled trial|f|f|f|t
34189127|NCT01657019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189128|NCT03110913|NA|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 4 levels of methionine provided as free amino acids, lentils, or lentils combined with rice for a total of 10 studies x 3 days per study.||||
34189129|NCT05428657|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will be experimental and one group will active control||||
34189130|NCT00393861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189131|NCT03823313|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189132|NCT00002076||||TREATMENT||||||||
34189133|NCT01474018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189134|NCT04216797|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will initially receive 6 weeks of pelvic floor PT. After these six weeks, qualifying participants will be randomized to one of two arms: rectal or oral diazepam administration. Participants will be dispensed 30, 10 mg diazepam tablets to take daily (oral or rectal) for 4 weeks.||||
34189135|NCT05147090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo pills will be manufactured in identical appearance to the study drug (empagliflozin)|Eligible subjects will be randomly allocated to either the empagliflozin group or placebo group (i.e. control group)|t|t|t|t
34189136|NCT00424892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870749|NCT03070470|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"This clinical study consists of 2 parts:~* 50 subjects in Part 1 will be randomized to receive one of four drugs (ranolazine, verapamil, lopinavir / ritonavir, chloroquine) or placebo over 3 days.~* 10 subjects in Part 2 will be randomized to receive one of two treatment sequences (1. dofetilide or 2. diltiazem combined with dofetilide) over 3 days, then after washout, the subjects will receive the other treatment sequence over 3 days. Thus, Part 2 will have a cross-over component.~A maximum of 14 additional replacement subjects may be enrolled."|t|t|t|t
33870750|NCT01487642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870751|NCT02308982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870752|NCT01815749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870753|NCT01014325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870754|NCT01730508|||COHORT||PROSPECTIVE|||||||
33870755|NCT02518997|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33870756|NCT02084264|||CASE_CONTROL||PROSPECTIVE|||||||
33870757|NCT00389792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870758|NCT03807349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870759|NCT01086891|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870760|NCT05505721|||CASE_ONLY||PROSPECTIVE|||||||
33870761|NCT00639275|||||PROSPECTIVE|||||||
33870762|NCT01397799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870763|NCT02631525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870764|NCT02870114|||COHORT||CROSS_SECTIONAL|||||||
33870765|NCT03630211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870766|NCT03762369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870767|NCT01241799|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33870768|NCT06158542|||COHORT||PROSPECTIVE|||||||
33870769|NCT04721470|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomized into three groups: 90 underwent TACE (Group 1); 95 underwent MWA (Group 2); and 93 underwent combined therapy (Group 3).||||
33870770|NCT02567253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870771|NCT06002399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33870772|NCT01397370|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33870773|NCT06476418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33870774|NCT06283264|||OTHER||CROSS_SECTIONAL|||||||
33754930|NCT05776030|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"H1) Single group assignment with crossover design where participant will be randomized which of 3 gear ratios they start with and then which is second, than the last one. n=18~H2) Two Groups for randomized assignment of which chair (geared or not) the participant starts with and then crosses over to second chair. n=12"||||
33754931|NCT02455648|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single assignment||||
33754932|NCT05989217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870775|NCT05992103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870776|NCT00627653|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870777|NCT02817971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894215|NCT03947294|||COHORT||PROSPECTIVE|||||||
33965988|NCT04892940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33965989|NCT00407433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33965990|NCT06203691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be assigned a number and by the care provider staff prior to providing collecting data.|One group will receive the supplements. The control group will not receive the supplements. All participants will undergo strength test - pre and post operatively.|f|t|f|f
33965991|NCT06518941|NA|SINGLE_GROUP||OTHER||NONE||||||
33965992|NCT01016821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965993|NCT05105477|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
33965994|NCT03359928|RANDOMIZED|CROSSOVER||OTHER||NONE||Using a randomised crossover trial design participants will be randomised computer assisted random sequence generation to sequences in which they are exposed to each experimental condition (exercise modality: stair stepping, stair climbing and non-contact boxing).||||
33965995|NCT00069407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33965996|NCT03526952|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33965997|NCT00248820|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33965998|NCT02545010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33965999|NCT02886481|||COHORT||PROSPECTIVE|||||||
33966000|NCT06354712|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33966001|NCT02748538|||CASE_CONTROL||PROSPECTIVE|||||||
33966002|NCT02104128|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966003|NCT02414425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966004|NCT00619086|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33966005|NCT02924103|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33966006|NCT03125824|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33966007|NCT04343911|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754933|NCT00026273|RANDOMIZED|||TREATMENT||NONE||||||
33754934|NCT03059901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33754935|NCT00135005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754936|NCT00252655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754937|NCT00379132|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754938|NCT03960905|||COHORT||RETROSPECTIVE|||||||
33754939|NCT04481490|||COHORT||PROSPECTIVE|||||||
33754940|NCT03208023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754941|NCT04097457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754942|NCT05347979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754943|NCT05888506|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33754944|NCT06338982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial with a test group and a control group.||||
33754945|NCT05418738|||CASE_ONLY||CROSS_SECTIONAL|||||||
33754946|NCT03113643|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754947|NCT04791761|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Experimental, open-label randomized control trial.||||
33754948|NCT00857207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754949|NCT02813837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754950|NCT01531166|||COHORT||PROSPECTIVE|||||||
33966008|NCT02726737|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33966009|NCT05323500|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi experimental Design||||
33966010|NCT05139654|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966011|NCT05882981|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966012|NCT05758935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754951|NCT04494893|||COHORT||PROSPECTIVE|||||||
33754952|NCT03994068|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33754953|NCT02230943|||COHORT||PROSPECTIVE|||||||
33754954|NCT01402141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33754955|NCT00540124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754956|NCT05038241|||COHORT||PROSPECTIVE|||||||
33754957|NCT05311202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33754958|NCT04530890|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33754959|NCT05786716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33754960|NCT04584905|||CASE_ONLY||PROSPECTIVE|||||||
33966013|NCT01153399|||CASE_ONLY||PROSPECTIVE|||||||
33966014|NCT04275661|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33966015|NCT04490083|||COHORT||PROSPECTIVE|||||||
33966016|NCT01335152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966017|NCT01230385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966018|NCT05185687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33966019|NCT01572831|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33966020|NCT01604382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33966021|NCT02133352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966022|NCT03236493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966023|NCT00382291|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33966024|NCT01204060|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33966025|NCT01119976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754961|NCT03786029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant will be blinded, the drug administrator will be blinded too, and the investigator who will give the treatment and explain the pain scale to the participant and ask him\\her to point to the face that fits the degree of his pain that associated with the drug administration will also be blinded.|Blinded, randomized placebo-controlled trial, comparing three groups.|t|f|t|f
33754962|NCT00210795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33754963|NCT01454206|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33754964|NCT02132364|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33754965|NCT05226455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754966|NCT04616131|||COHORT||PROSPECTIVE|||||||
34067177|NCT04308044|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34067178|NCT01229813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067179|NCT06314399|||COHORT||PROSPECTIVE|||||||
33754967|NCT03469323|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34067180|NCT00346567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33754968|NCT01732068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754969|NCT02396654|||COHORT||PROSPECTIVE|||||||
33754970|NCT01687257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754971|NCT02235350|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33754972|NCT03263884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33754973|NCT04373876|||COHORT||OTHER|||||||
33754974|NCT04465019|||COHORT||RETROSPECTIVE|||||||
33754975|NCT01605929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33754976|NCT05855330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33754977|NCT06211660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33754978|NCT00291993|||||PROSPECTIVE|||||||
34067181|NCT00467207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067182|NCT01937585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067183|NCT04624802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34067184|NCT03846128|||COHORT||PROSPECTIVE|||||||
34067185|NCT05207085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067186|NCT00440635|||||PROSPECTIVE|||||||
34067187|NCT02770768|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34067188|NCT02786706|||COHORT||PROSPECTIVE|||||||
34067189|NCT02844894|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34067190|NCT00093977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067191|NCT01962623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067192|NCT05332717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Participants will not be informed if they are receiving study drugs or placebo pills.~Placebos will be compounded to be identical to treatment drugs in shape, size, color, texture etc."|"This study will compare postoperative sleep quality in two groups of patients undergoing primary total knee arthroplasty (TKA):~* Group 1 will take melatonin during the 6 week postoperative period~* Group 2 will take a placebo during the 6 week postoperative period"|t|f|f|f
34067193|NCT04594109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067194|NCT02860507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Care Providers, Investigators, and Outcome Assessors are blinded from the type of NMBA reversal agent used prior to completion of data collection|Prospective Randomized Double Blinded|t|t|t|t
34067195|NCT03151213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded by closed envelops||t|t|f|f
34067196|NCT03183479|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|After randomization, the unblinded independent investigator will be in charge of fibrinogen concentrate (drug) or placebo preparation, which will be performed in a laboratory next to the operating room. When the patient meets the inclusion criteria and is enrolled in the study, the functional fibrinogen tests will be done in the same laboratory by the same researcher, and drug or placebo will be prepared in sterile bags with opaque covers afterwards. Fibrinogen concentrate will be diluted in 100mL of sterile water or an equivalent volume of 0.9% saline solution as placebo and will be delivered to the operating room by the investigator. The anesthesiologists, the surgical staff, and the patients will all be blinded.||t|t|f|t
34067197|NCT02457754|||COHORT||CROSS_SECTIONAL|||||||
34067198|NCT04539756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||This is a two-arm parallel study, such that participants are assigned to either an active control group or intervention group.|t|f|f|f
34067199|NCT05020704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34067200|NCT04611776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067201|NCT03014284|||CASE_ONLY||PROSPECTIVE|||||||
34067202|NCT05964127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067203|NCT04723056|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial comparing Zemedy CBT app vs. Treatment as usual||||
34067204|NCT02983461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067205|NCT03592784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067206|NCT02432144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067207|NCT01915771|NA|SINGLE_GROUP||OTHER||NONE||||||
34067208|NCT01096680|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34067209|NCT05296070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067210|NCT05831306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34067211|NCT04685096|||COHORT||PROSPECTIVE|||||||
34067212|NCT03231137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067213|NCT05392595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067214|NCT04657094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067215|NCT03637309|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067216|NCT03942926|NA|SINGLE_GROUP||TREATMENT||NONE||Ten lymphatic bronchitis patients are planned to be recruited for the study. Sirolimus will be administered for 6 months.||||
34067217|NCT02020837|NA|SINGLE_GROUP||TREATMENT||NONE||A lymphatic diversion with lymphaticovenous microanastomosis will be performed.||||
34067218|NCT01648192|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34067219|NCT01841034|||COHORT||PROSPECTIVE|||||||
34067220|NCT03538704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067221|NCT05337995|||CASE_CONTROL||PROSPECTIVE|||||||
34067222|NCT00452153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067223|NCT01026818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067224|NCT01142492|||COHORT||PROSPECTIVE|||||||
33754979|NCT01091155|NA|SINGLE_GROUP||||NONE||||||
33754980|NCT04962555|||COHORT||RETROSPECTIVE|||||||
33754981|NCT04134156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33754982|NCT01372657|||CASE_ONLY||PROSPECTIVE|||||||
34067225|NCT04598971|||CASE_ONLY||PROSPECTIVE|||||||
33754983|NCT03592511|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33754984|NCT05698446|||COHORT||PROSPECTIVE|||||||
33754985|NCT02026089|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33754986|NCT04157569|||CASE_ONLY||PROSPECTIVE|||||||
33754987|NCT04069000|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the intervention (i.e., classroom teachers both implement the program (or not) and provide ratings of students' behaviour, it is not feasible to have blinded conditions. Most school-based prevention programs of this type are not blinded.|Children within grade 3 classrooms will be evaluated in one of three conditions. One condition includes classrooms that will implement MindUP with students for the first time. A second condition includes classrooms that will implement MindUP, but has students who have largely been exposed to MindUP every year since kindergarten. The third condition is the comparison group wherein classroom teachers will deliver their usual curriculum and teaching strategies.||||
33754988|NCT02354664|||CASE_CONTROL||PROSPECTIVE|||||||
33754989|NCT03885960|||COHORT||PROSPECTIVE|||||||
33754990|NCT01919242|||COHORT||PROSPECTIVE|||||||
33754991|NCT02338154|||CASE_ONLY||PROSPECTIVE|||||||
33754992|NCT03067038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33754993|NCT06374446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33754994|NCT03776955|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo matched control||t|t|t|t
33754995|NCT01927432|||CASE_CONTROL||PROSPECTIVE|||||||
33754996|NCT02150980|||COHORT||PROSPECTIVE|||||||
33754997|NCT01592331|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33754998|NCT00011505||||TREATMENT||||||||
33754999|NCT03948048|||CASE_CONTROL||PROSPECTIVE|||||||
33755000|NCT03249155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34067226|NCT02624622|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067227|NCT06313554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067228|NCT02284386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755001|NCT03263754|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755002|NCT04184726|NA|SINGLE_GROUP||TREATMENT||NONE||MBCT-vision intervention||||
33755003|NCT00166296|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33755004|NCT01561001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755005|NCT05902832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||participant will be randomly divided to one of two groups: first group will take part in the intervention program and the second will be wait-listed and children will receive treatment as usual|t|t|f|t
33755006|NCT00310219|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755007|NCT05825027|||COHORT||PROSPECTIVE|||||||
33755008|NCT04584164|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study aims at comparing the sialendoscopy associated with a local injection of corticosteroids to the basic hygiene rules in the treatment of Xerostomia.||||
33755009|NCT04595448|||CASE_CONTROL||PROSPECTIVE|||||||
33755010|NCT01422408|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755011|NCT06280703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-Blind (Part A) and Open-Label (Part B and Part C)|Parallel (Part A) and Crossover design (Part B and Part C)|t|f|t|f
34067229|NCT01422746|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067230|NCT04478760|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34067231|NCT03283332|||COHORT||PROSPECTIVE|||||||
34067232|NCT05476640|||COHORT||PROSPECTIVE|||||||
34067233|NCT04588844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067234|NCT04659057|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34067235|NCT03404934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067236|NCT02716922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067237|NCT03125850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34067238|NCT04357938|||COHORT||PROSPECTIVE|||||||
34067239|NCT03353181|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33755012|NCT05017922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755013|NCT06185257|||COHORT||CROSS_SECTIONAL|||||||
33755014|NCT04341506|||COHORT||PROSPECTIVE|||||||
33755015|NCT01812655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33755016|NCT06490250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be performed by an investigator who is blinded to group allocation|Three groups with control group|f|f|f|t
33755017|NCT00303862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755018|NCT04565171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755019|NCT02935491|||COHORT||RETROSPECTIVE|||||||
33755020|NCT00985010|||CASE_ONLY||PROSPECTIVE|||||||
33755021|NCT01382628|||CASE_CONTROL||PROSPECTIVE|||||||
33755022|NCT00175825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755023|NCT00550914|||||PROSPECTIVE|||||||
33755024|NCT00914004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755025|NCT02297568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755026|NCT05989100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Favourate taste stimulation group, sour stimulation group and thermal stimulation group.|f|t|f|t
34067240|NCT03416010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||longitudinal, randomized block RCT with repeated measures||||
33755027|NCT03023592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755028|NCT01261026|||CASE_CONTROL||PROSPECTIVE|||||||
33755029|NCT06462911|NA|SINGLE_GROUP||OTHER||NONE||||||
33755030|NCT01337895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189137|NCT03710200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34189138|NCT05334212|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34189139|NCT02422199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189140|NCT00554216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34189141|NCT00971152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189142|NCT04228380|||COHORT||PROSPECTIVE|||||||
34189143|NCT05002075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189144|NCT06241391|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189145|NCT04373252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189146|NCT04159753|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189147|NCT00330967|||||PROSPECTIVE|||||||
34189148|NCT03372681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189149|NCT05156021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189150|NCT04851262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34189151|NCT01170572|||COHORT||PROSPECTIVE|||||||
34189152|NCT01561313|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34189153|NCT03464539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34189154|NCT06104436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34189155|NCT01099449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34189156|NCT06314828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189157|NCT00734539|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189158|NCT02627261|||COHORT||PROSPECTIVE|||||||
34189159|NCT01385527|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34189160|NCT03298659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||1:1 randomization to (A) an active treatment arm with complete, iFR-guided revascularization of every noninfarct coronary lesion \>50% and iFR ≤0.89; or (B) a deferred treatment arm, in which patients will undergo an adenosine stress perfusion CMR scan within 6 weeks after STEMI, with revascularization of the noninfarct coronary lesions with associated perfusion defects.||||
34189161|NCT04881253|||COHORT||PROSPECTIVE|||||||
34189162|NCT03566485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189163|NCT02093819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34189164|NCT04333719|||COHORT||PROSPECTIVE|||||||
34189165|NCT02677519|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189166|NCT01734603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189167|NCT01080365|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189168|NCT03112577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189169|NCT06519851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189170|NCT03039712|||COHORT||PROSPECTIVE|||||||
34189171|NCT00452192|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189172|NCT00324597||||TREATMENT||NONE||||||
34189173|NCT03665727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical assessors were masked at postoperative follow-up||t|f|f|t
34189174|NCT01214733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189175|NCT01134705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189176|NCT05042869|||COHORT||RETROSPECTIVE|||||||
34189177|NCT05825352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189178|NCT05296109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189179|NCT06070961|||COHORT||PROSPECTIVE|||||||
34189180|NCT04763148|||COHORT||PROSPECTIVE|||||||
34189181|NCT01620216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189182|NCT00955916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189183|NCT06370403|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The researchers who analyzed the venous blood samples were blinded.|||||
34189184|NCT03241719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189185|NCT02724748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34189186|NCT01867697|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34189187|NCT03699215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189188|NCT00578734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34189189|NCT02709382|NA|SINGLE_GROUP||||NONE||||||
34189190|NCT02135913|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189191|NCT04870489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients are treated with Isotretinoin for at least 2 months prior to starting Co2 laser treatment, then they receive laser treatment on one side of the face (randomized) while still taking Isotretinoin; 6 months after cessation of Isotretinoin or any other treatment they are then treated with Co2 laser only on the second side of the face||||
34189192|NCT00742261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755031|NCT05892068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design includes patient candidates for clinically indicated craniotomy in three parallel cohorts.||||
33755032|NCT03544346|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755033|NCT01512420|||COHORT||PROSPECTIVE|||||||
33755034|NCT00487409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755035|NCT05090709|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Mixed factor: between-subject, repeated measures (mobilisation intervention vs general massage).||||
33755036|NCT03076255|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755037|NCT02316587|||COHORT||PROSPECTIVE|||||||
34067241|NCT01401543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067242|NCT00404716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755038|NCT01843374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755039|NCT02965339|||COHORT||PROSPECTIVE|||||||
33755040|NCT05617690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33755041|NCT03489304|NA|SINGLE_GROUP||TREATMENT||NONE||6-week open-label study evaluating zaleplon for insomnia in HIV positive patients with comorbid depression||||
33755042|NCT00254332|||||PROSPECTIVE|||||||
33755043|NCT00056251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33755044|NCT04953390|NA|SINGLE_GROUP||TREATMENT||NONE|During lab testing, participants will be aware of the device they are wearing, but will not be aware of which microphone setting is being tested.|A single group of participants will be evaluating different directional microphone settings on commercially available hearing aids||||
33755045|NCT03355417|NA|SINGLE_GROUP||TREATMENT||NONE||This study will use a non-concurrent multiple baseline design (MBD) where subjects will serve as their own control||||
33755046|NCT00746590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755047|NCT06577623|NA|SINGLE_GROUP||TREATMENT||NONE||Open label feasibility and acceptability trial.||||
33755048|NCT05005780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755049|NCT00033696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755050|NCT04018326|||COHORT||PROSPECTIVE|||||||
33755051|NCT04844580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|In the study, patients will be randomized in a ratio of 1: 1 into two arms, standard medical therapy + placebo versus standard medical therapy + inhaled Aviptadil arms. Randomization will be carried out by the block randomization method.|t|f|t|f
33755052|NCT05391139|||CASE_CROSSOVER||PROSPECTIVE|||||||
33755053|NCT00990080|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33755054|NCT05979753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33755055|NCT01718327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755056|NCT06295770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067243|NCT03529799|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067244|NCT00072748|NON_RANDOMIZED|||TREATMENT||NONE||||||
34067245|NCT05382013|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067246|NCT03326518|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067247|NCT00433017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067248|NCT01109628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067249|NCT00154843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755057|NCT03357874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870778|NCT03789942|RANDOMIZED|PARALLEL||TREATMENT||NONE||"90 patients will be randomly divided into three groups of 30 patients each. They will be given a prior consent both of the procedures to be performed and of the sedation procedure to which they will be subjected, if that is the case, without knowing what dose they will be administered. In case of being sedated, they will be informed verbally of the details concerning the procedure.~Group 1, 30 patients treated by Oral Surgery procedures exclusively with Local Anesthesia.~Group 2, 30 patients treated by procedures of Oral Surgery with Local Anesthesia and Oral Sedation with Midazolam.~Group 3, 30 patients treated by Oral Surgery procedures with Local Anesthesia and Inhalation Sedation with a mixture of Nitrous Oxide / Oxygen."||||
33870779|NCT02938884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870780|NCT06047652|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|This study consists of 4 participant groups, of which 3 will conduct FGDs to investigate data and 1 will conduct Moodle e-CPD trials. The four categories of participants are nurses with experience implementing CPD, hospital management responsible for implementing CPD for nurses, members of the Indonesian nursing professional organization with the authority to manage CPD for nurses, and clinical nurses with at least level 1 certification. However, the Moodle e-CPD trial will only be conducted with a group of at least level 1 clinical nurse participants.|This study is a seven-stage exploratory action research, with stage 6 being the Moodle e-CPD trial for hospital nurses.||||
34067250|NCT02333422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067251|NCT00481013|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34067252|NCT03121794|||COHORT||PROSPECTIVE|||||||
34067253|NCT01441856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient, surgical ward physician and surgical ward nurses are blinded up and until postoperative day 4.||t|t|f|f
34067254|NCT02215746|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067255|NCT01375374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067256|NCT01962246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755058|NCT02450006|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33755059|NCT05038384|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870781|NCT04820972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870782|NCT03044249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870783|NCT02625233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870784|NCT05689970|||COHORT||PROSPECTIVE|||||||
33870785|NCT03763071|||CASE_ONLY||CROSS_SECTIONAL|||||||
33870786|NCT00974246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870787|NCT06438484|||COHORT||PROSPECTIVE|||||||
33870788|NCT00344721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The active ingredient and placebo softgels appear identical and are supplied in identical containers for masking purposes.~Study personnel performing study visit procedures are masked to group assignment."|Patients will be randomized to receive either omega-3 fatty acid or placebo soft-gel capsules.|t|f|f|t
33966026|NCT03654261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966027|NCT02232451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966028|NCT06547463|||COHORT||PROSPECTIVE|||||||
34067257|NCT01437371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067258|NCT03957902|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34067259|NCT05327088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067260|NCT00079651|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34067261|NCT02797678|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34067262|NCT05545085|||OTHER||PROSPECTIVE|||||||
34067263|NCT04116606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067264|NCT03690362|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study will enroll approximately 32 subjects assigned to treatment groups based on renal function.||||
34067265|NCT00373802|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34067266|NCT01089478|||CASE_ONLY||PROSPECTIVE|||||||
33755060|NCT03819140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755061|NCT04517396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755062|NCT00815295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966029|NCT06537752|||COHORT||PROSPECTIVE|||||||
33966030|NCT02839356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33966031|NCT05125679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966032|NCT01279590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966033|NCT04722016|||COHORT||RETROSPECTIVE|||||||
33966034|NCT05742854|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study intends to investigate oxytocin and carbetocin, which are uterotonic agents used during C-section, in terms of haemodynamic changes they cause, their effects on the uterine tone and on bleeding as well as their side effects (flushing, headache, back pain, hypertension and tachycardia, nausea-vomiting, etc.), to determine if there are any differences between them.||||
33966035|NCT00131430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966036|NCT05081076|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The randomisation of surface finishing treatment per side (mesial or distal) of each zirconia crown will be made at the laboratory fabrication step, and the treatment codes will be known only by the certified technician and Projec PI. The clinician, who is also the investigator and outcomes assessor, will not assess the codes until the final data analysis.|The study design is a randomized, prospective, paired, clinical trial with intra-subject comparison. Each zirconia crown to be placed over the dental implant has two sides (mesial and distal), which will receive a randomised surface finishing treatment in the laboratory fabrication procedure.|t|t|t|t
33966037|NCT01537549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966038|NCT04551352|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33966039|NCT02682433|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966040|NCT06053879|NA|SEQUENTIAL||TREATMENT||NONE|biofeedback stimulation for faecal incontinence post Posterior Sagittal Anorectoplasty|pretest post test||||
33966041|NCT02982447|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067267|NCT01731106|||COHORT||PROSPECTIVE|||||||
34067268|NCT04571385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067269|NCT03062397|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34067270|NCT01215604|||CASE_ONLY||PROSPECTIVE|||||||
34067271|NCT05579132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067272|NCT05003830|||CASE_CONTROL||PROSPECTIVE|||||||
34067273|NCT04617483|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The first part of the study is a double-blinded trial, the second part is a open-label research.||t|f|t|f
34067274|NCT03634813|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||2 cohort parallel|t|f|f|f
34189193|NCT06223165|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Recruiters and data collectors will be blind to the intervention condition. Teen-caregiver dyads will not know what intervention condition they are randomized into until they arrive on site for the first workshop session. Key study staff and intervention facilitators will be made aware of the intervention conditions for the purposes of delivering the workshop.|"We will run a 2 x 2 x 2 pilot factorial experiment. Small groups of Latina teen-female caregiver dyads will be randomized to one of eight conditions. All groups of dyads will receive the constant (i.e., the intervention session focused on foundations in sexual risk prevention). The remaining three intervention components are either delivered (i.e., on) or not delivered (i.e., off)."|f|f|f|t
34189194|NCT05386407|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"Our hypothesis is that, applying a strict standard operating procedure (SOP, attached), guided oropharyngeal + nasal (OP+N) self-sampling (GSS) is non-inferior to nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP), and that guided OP+N sampling is superior to unsupervised OP+N self-sampling (USS).~After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP.~The outcome assessors and the investigators will be blinded to the randomization to either OP+N GSS - or to OP+N US"|interventional randomized method comparison study|f|f|t|t
34189195|NCT00479427|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34189196|NCT00126490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189197|NCT00473213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34189198|NCT01579136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34189199|NCT00564668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189200|NCT06032793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189201|NCT00456859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189202|NCT00629369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34189203|NCT00426244|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34189204|NCT03929497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189205|NCT03008200|||COHORT||PROSPECTIVE|||||||
34189206|NCT03448913|||COHORT||PROSPECTIVE|||||||
34189207|NCT00551278|||CASE_ONLY||PROSPECTIVE|||||||
34189208|NCT01257477|||||PROSPECTIVE|||||||
34189209|NCT00050362||||TREATMENT||||||||
34189210|NCT03282214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34189211|NCT06445270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34076079|NCT04332068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind trial so the participants, their parents, guardians or carers, administering clinicians, attending nurses, the central research team, and independent outcome assessors will all be blinded.|"The trial will initially randomize 30 participants at each site to receive control (permethrin cream), ivermectin 200 or 400 µg/kg (10:10:10) and review this data before escalation to ivermectin 800 µg/kg. Once the initial 30 participants have been treated a DSMB consultation will be performed for each site. If deemed safe to escalate to ivermectin 800 µg/kg, then remaining participants at each site will be treated with control (permethrin cream), ivermectin 200, 400, or 800 µg/kg (15: 15: 15: 25).~The Brazil site will initially randomize 30 participants receive control (permethrin cream) or ivermectin 200 µg/kg (15:15) and review this data before escalation to ivermectin 400 µg/kg. Once the initial 30 participants have been treated a DSMB consultation will be performed. If deemed safe to escalate to ivermectin 400 µg/kg, then remaining participants at the site will be treated with control (permethrin cream), ivermectin 200 or 400 µg/kg (18: 18: 33)."|t|t|t|t
33870789|NCT06489587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research staff collecting data will be masked to intervention|Randomized study to two arms: 1) creatine supplementation, 2) glucose supplementation|f|f|f|t
33870790|NCT00853320|RANDOMIZED|CROSSOVER||||NONE||||||
33870791|NCT05286021|||COHORT||PROSPECTIVE|||||||
33870792|NCT00984971|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33870793|NCT06445946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870794|NCT04203732|||COHORT||RETROSPECTIVE|||||||
33870795|NCT01984372|||COHORT||PROSPECTIVE|||||||
34076080|NCT04839718|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34076081|NCT03436017|||OTHER||PROSPECTIVE|||||||
34189212|NCT00986687|||COHORT||PROSPECTIVE|||||||
34189213|NCT00922012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189214|NCT03275350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189215|NCT03858816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189216|NCT05463848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189217|NCT01185665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189218|NCT01347411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189219|NCT04896515|||COHORT||PROSPECTIVE|||||||
34189220|NCT02557880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189221|NCT04119466|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34189222|NCT04609462|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II, multicenter, randomized, open-label, controlled study of the use of high flow nasal cannula respiratory support vs. conventional oxygen therapy in patients with moderate/severe hypoxemic respiratory failure secondary to SARS-CoV-2 infection.||||
34189223|NCT03188497|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The initial dose was 25mg/m2 on d1,d22,d43 for 1 cycles; if no obvious toxicity was observed,follow 30mg/m2,35mg/m2,40mg/m2,45mg/m2, and 50mg/m2 gradients into the next dose group until the maximum tolerated dose or 50mg/m2|f|f|t|f
34189224|NCT00233064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189225|NCT01578876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189226|NCT06359444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The training will be given by the care provider, but in exercise therapy it is not possible to mask. The assessor will assess the patients without knowing in which group they will be randomized. Randomization will be done by an external person who is only involved for randomization. The investigator, who will be analysing data afterwords, will only see 1 or 2 as group number, but will not know which number is corresponding to which group.|Patients will be randomized in two groups: (a) combined aerobic and strength and (b) combined high intensity and strength.|f|f|t|t
34189227|NCT00806819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34189228|NCT04288284|||CASE_CONTROL||PROSPECTIVE|||||||
34189229|NCT04097574|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34189230|NCT00677989|||CASE_CONTROL||PROSPECTIVE|||||||
34189231|NCT01379508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189232|NCT02469545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189233|NCT06516419|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34189234|NCT06355700|NA|SINGLE_GROUP||OTHER||NONE||||||
33870796|NCT05840926|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870797|NCT06353100|||COHORT||PROSPECTIVE|||||||
33870798|NCT02032563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870799|NCT03855436|||COHORT||PROSPECTIVE|||||||
33870800|NCT02833012|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33870801|NCT04080570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870802|NCT01301443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870803|NCT04178759|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33870804|NCT05534425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All data collected, assayed, coded, and analyzed by researchers blind to study condition and participant identity|Randomized to Immediate GenX intervention vs. Waitlist Control delayed intervention|f|f|t|f
34189235|NCT05760469|NA|SINGLE_GROUP||SCREENING||NONE||Data for this study will be collected daily until you are discharged from the hospital, up to a maximum of 7 days. Study data will be collected by the nurses/research assistants during regular patient check-ins and will require minimal time to complete (15-20min maximum). Participants for the study will be identified by nursing staff from patients admitted to the Valley Regional Hospital. After informed consent, where possible, the primary care nurse will collect qualitative information from the patient based on the history of their skin condition, whether the rash is new or recurring for them, and their pain, irritation, and discomfort measures. All patients participating in the study will receive the standard of care for patients presenting with MASD as prescribed by their primary care physician.||||
33755063|NCT00572195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755064|NCT03595579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755065|NCT06215014|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33755066|NCT06240325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755067|NCT01911377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755068|NCT01235403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755069|NCT05681806|RANDOMIZED|PARALLEL||OTHER||NONE|This is an open label trial.|Participants will be randomized into three parallel groups: two treatment groups of differing Carnipure AAS doses and one active control consuming creatine monohydrate||||
33755070|NCT03191487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755071|NCT00176579|||CASE_CONTROL||PROSPECTIVE|||||||
33755072|NCT01652144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755073|NCT00428090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755074|NCT02858050|||COHORT||PROSPECTIVE|||||||
33966042|NCT06527235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This trial will be double-blind (patient and evaluator). Only the physician performing the infiltration will know the status of the group assigned to the patient (experimental or placebo).|Multicenter, randomized vs placebo, controlled, comparative, superiority, with 2 parallel groups compared (ultrasound-guided betamethasone infiltration vs. physiological serum (identical volume) of the meniscal wall).|t|f|t|t
33966043|NCT00981916|||COHORT||PROSPECTIVE|||||||
33966044|NCT04401319|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||We will perform a 3 arm crossover trial. Subsequently, we will perform a longer protocol using a 3 arm parallel design.|t|f|f|t
33966045|NCT01533272|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076082|NCT02589470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755075|NCT01123668|||CASE_CONTROL||PROSPECTIVE|||||||
33755076|NCT02686580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755077|NCT01213602|||COHORT||PROSPECTIVE|||||||
33755078|NCT04969484|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The trial will be implemented in 3 nursing homes to evaluate the feasibility and acceptability of the multi-component ImPAcTT intervention.||||
33755079|NCT02130310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755080|NCT01489579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33755081|NCT03964597|||COHORT||PROSPECTIVE|||||||
33755082|NCT06578988|||CASE_ONLY||RETROSPECTIVE|||||||
33755083|NCT06146491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755084|NCT00047801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076083|NCT03981146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076084|NCT00189163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076085|NCT03971006|||OTHER||PROSPECTIVE|||||||
34076086|NCT02302846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076087|NCT00338546|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33755085|NCT02697851|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33755086|NCT06296576|||COHORT||PROSPECTIVE|||||||
33755087|NCT01951638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755088|NCT05450315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33755089|NCT00770107|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755090|NCT06274255|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755091|NCT03326505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33755092|NCT02324218|||COHORT||RETROSPECTIVE|||||||
33755093|NCT06166693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33755094|NCT02474550|||COHORT||PROSPECTIVE|||||||
33755095|NCT03789682|||COHORT||PROSPECTIVE|||||||
33755096|NCT06346379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870805|NCT01972620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870806|NCT05878457|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||single group, open-label pilot investigation||||
34189236|NCT05911685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189237|NCT02722018|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189238|NCT02796313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189239|NCT02459834|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34189240|NCT03289585|||COHORT||PROSPECTIVE|||||||
34189241|NCT01018940|||CASE_CROSSOVER||PROSPECTIVE|||||||
34189242|NCT02014337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189243|NCT02411890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34189244|NCT05581524|NA|SINGLE_GROUP||TREATMENT||NONE||V.A.S.C. is a multicentric, prospective, open label, non-randomized PMCF study||||
33870807|NCT02286414|||COHORT||PROSPECTIVE|||||||
34189245|NCT02164708|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33870808|NCT03693625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870809|NCT00333398|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33870810|NCT02776189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870811|NCT00579865|||COHORT||PROSPECTIVE|||||||
34189246|NCT02223494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189247|NCT04298476|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34189248|NCT00992472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189249|NCT02015962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189250|NCT02543957|||COHORT||PROSPECTIVE|||||||
34189251|NCT06101589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|double blind study||t|t|t|f
34189252|NCT05525481|NA|SINGLE_GROUP||TREATMENT||NONE|One blood sample will be taken blindly and will be measured after the end of follow-up.|Non-randomized, single-center, single-arm, MIPD intervention study||||
34189253|NCT00309491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189254|NCT02163941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189255|NCT00380653|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The starting dose is (A) 75 mg twice daily x 7 days followed by 14 days of rest or, (B) 375 mg twice daily x 3 consecutive days per week for 2 weeks followed by 7days of rest.~Evaluated doses in schedule A: 75mg, 100mg, 125mg, 175mg, 225mg, 275mg, 325mg and 375mg Evaluated doses in schedule B: 375mg, 425mg and 475mg"||||
34189256|NCT03167632|||OTHER||CROSS_SECTIONAL|||||||
34189257|NCT01019083|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189258|NCT02920242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189259|NCT03240549|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Prospective cohort study||||
34189260|NCT01974635|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189261|NCT06208371|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants who meet the inclusion criteria will be grouped using a stratified block randomization method. The stratification factors include the entire RAS/BRAF gene (wild-type vs. mutated), the number of liver metastases (10-20 vs. \>20), and the location of the primary lesion (left vs. right). The random grouping of participants will be accomplished using our center's Interactive Web Response System (IWRS). The participants will be randomly assigned to either the liver-localized treatment group or the palliative chemotherapy group in a 2:1 ratio.||||
34189262|NCT02661334|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34189263|NCT04460170|||COHORT||PROSPECTIVE|||||||
34189264|NCT00002618|RANDOMIZED|||TREATMENT||||||||
33870812|NCT01643863|||COHORT||PROSPECTIVE|||||||
33870813|NCT03919279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870814|NCT01708070|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33870815|NCT00250250|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870816|NCT06042400|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm pilot trial: all participants will receive intervention||||
33870817|NCT03196076|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966046|NCT04256005|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will perform each of the three different conditions once over the duration of the study. The experimental conditions will be performed in random order, determined by WinPepi for Windows, with each of the experimental trials being separated by five days. The three conditions are; completing ten intervals at a work rate which equates to 105% of VO2peak with a 1:1 work rest ratio, completing ten intervals at a work rate which equates to 50% ∆ GET, with a 1:1 work rest ratio, and a Control (CON) session with no exercise.||||
33966047|NCT05740059|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients won't be aware of the assignment group|Multi-center, single-blinded, and randomized controlled trial.|t|f|f|f
33966048|NCT01652261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966049|NCT01785186|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966050|NCT02831725|||COHORT||PROSPECTIVE|||||||
33966051|NCT02022371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966052|NCT01532349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966053|NCT01363401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966054|NCT06156969|NA|SINGLE_GROUP||OTHER||NONE||||||
33966055|NCT01338285|||OTHER||CROSS_SECTIONAL|||||||
33966056|NCT05139407|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Individual trials cannot be made public before publication||t|f|t|t
33966057|NCT04592991|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||There will be two (2) groups in this study. We plan to recruit 5 patients with AAA and 3 patients with diagnosed non-aneurysmal (without aneurysm) aortoiliac occlusive disease.||||
34076088|NCT06178809|||COHORT||PROSPECTIVE|||||||
34076089|NCT02003144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076090|NCT01309321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076091|NCT02589080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076092|NCT01249417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076093|NCT02171429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076094|NCT00336934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076095|NCT05911477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33870818|NCT03471975|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33870819|NCT03108547|||COHORT||PROSPECTIVE|||||||
34189265|NCT04337918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Multi-center, prospective, randomized, controlled, phase II, parallel group|f|f|f|t
34189266|NCT02858505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755097|NCT03315143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33755098|NCT01921296|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755099|NCT01248273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755100|NCT04883307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||All participants (coaches and coachees) were required to complete a baseline questionnaire including an informed consent item, demographic characteristics, Professional Fulfillment Index (PFI), Positive Emotion, Engagement, Relationship, Meaning, and Accomplishment scale (PERMA), Intolerance of Uncertainty scale (IUS), and Hardiness Resilience Score (HRS).10-13 Region was determined using self-reported cities and states as laid out in the US Census Divisions.14 Field of specialty or prospective specialty was also noted. The participating surgical residents were then randomized to the intervention group or the control group based on PFI's burnout sub-scale's quartile scores at pre-survey. Residents in the intervention group were encouraged to meet with a trained faculty coach for a 1:1 coaching meeting 3 times over 9 months. Residents in the control group were emailed wellness resources.||||
33870820|NCT00992940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870821|NCT04879667|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study included patients who were admitted to investigators' center to do laparoscopic sleeve gastrectomy and complicated by gastro-cutaneous fistula . Cases were collected in the period from December 2019 to march 2021. the sample size was 30 patients divided into two equal groups. Group (1) included 15 patients managed by surgical intervention , group (2) included 15 patients managed by endoscopic intervention.||||
33755101|NCT04553341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755102|NCT06378892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755103|NCT06225167|||CASE_ONLY||RETROSPECTIVE|||||||
33755104|NCT06185933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870822|NCT04831489|||OTHER||RETROSPECTIVE|||||||
33870823|NCT06042777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870824|NCT00873340|||COHORT||PROSPECTIVE|||||||
33870825|NCT05738473|||COHORT||PROSPECTIVE|||||||
34076096|NCT02720276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189267|NCT02038361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189268|NCT06471348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189269|NCT01879124|||COHORT||PROSPECTIVE|||||||
33870826|NCT02997735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33870827|NCT01063075|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33870828|NCT02616549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870829|NCT02292030|||COHORT||PROSPECTIVE|||||||
33870830|NCT04342754|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"Phase 1: Open label phase. All patients are in the ON stimulation condition and will be followed for 6 months.~Phase 2: Blind phase. All patients will be randomized for ON stimulation or sham stimulation group for 3 months, followed for 1 month of washout and crossover for other group."|t|t|t|t
33870831|NCT00150826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870832|NCT01439555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870833|NCT03044938|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Randomized Clinical trial, controlled, double-blind and crossover|t|t|t|f
33870834|NCT02224716|||COHORT|||||||||
33870835|NCT01128127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870836|NCT00733148|||CASE_ONLY||RETROSPECTIVE|||||||
34189270|NCT02111759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189271|NCT02707822|||CASE_ONLY|||||||||
34189272|NCT00621348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189273|NCT04462588|||CASE_ONLY||PROSPECTIVE|||||||
34189274|NCT03460262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067275|NCT05276960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|For the blinding of the maneuver, supplementation will be done with cholecalciferol (vitD3) in dispersible tablets of the same size and color, with doses of 2000 IU (0.05 mg) for the control group and 4000 IU (0.1 mg) for the intervention group. The capsules should be dissolved in 30 ml of water. The dispensing of the medication according to the intervention group and vitamin D levels will be performed by the investigator assigned to blinding of the principal investigator, the containers of the tablets will be of the same color and size and only the investigators responsible for the dispensing will know the corresponding dose|"Pediatric CF patients will be recruited from the CF Integrated Care Clinic of the Federico Gomez Children's Hospital of Mexico. Once at the clinic they will be invited to participate in the study. Parents or guardians of patients under 8 years of age will be asked to sign the informed consent form before starting the studies, procedures and intervention. For those patients older than 8 years, in addition to parental consent, they will be given information and asked to sign the informed consent form before starting the studies, procedures, and intervention.~The restrictive randomization will be performed by blocks of 8,obtained through the web page https://www.randomizer.org/, and will be carried out by one of the investigators, who will also be responsible for its safekeeping. The concealment will be carried out by the same investigator in charge of the randomization, for which the treatment groups will be placed in metallic gray, non-transparent, previously labeled envelopes"|t|t|t|f
34067276|NCT00086398||FACTORIAL||TREATMENT||||||||
34067277|NCT02352376|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067278|NCT04862832|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067279|NCT01685385|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067280|NCT00843414|||COHORT||PROSPECTIVE|||||||
33870837|NCT04943575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34067281|NCT05656885|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All participants received Lens A and then Lens B in fixed-sequence order.|t|f|f|f
33870838|NCT00631020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076097|NCT00970489|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870839|NCT02527369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870840|NCT02055651|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33870841|NCT06265675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33870842|NCT04586543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870843|NCT01792921|||CASE_CROSSOVER||PROSPECTIVE|||||||
33870844|NCT04918277|||COHORT||PROSPECTIVE|||||||
33870845|NCT02533063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870846|NCT01147328|||COHORT||RETROSPECTIVE|||||||
33870847|NCT00483301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870848|NCT05726799|||CASE_CONTROL||RETROSPECTIVE|||||||
33870849|NCT04640350|||COHORT||PROSPECTIVE|||||||
33870850|NCT02571296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33870851|NCT02221531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870852|NCT06310681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33870853|NCT04160455|||COHORT||CROSS_SECTIONAL|||||||
33870854|NCT05786079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870855|NCT06490588|||COHORT||PROSPECTIVE|||||||
34189275|NCT04371393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized clinical trial, in which the patients and investigators are masked to treatment assignment.|This will be a randomized (1:1 ratio), double blind, parallel design, placebo controlled trial.|t|f|t|t
34189276|NCT03599219|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective case control||||
34189277|NCT01219283|||CASE_CONTROL||PROSPECTIVE|||||||
34189278|NCT01923272|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34189279|NCT01877252|||COHORT||PROSPECTIVE|||||||
34189280|NCT02238652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34189281|NCT04472832|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34189282|NCT05171517|||CASE_ONLY||PROSPECTIVE|||||||
34189283|NCT05091775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blind|two groups seventy patients aged 18 to 65 years with diarrhea and subsequent acute fissure (with symptoms less than 6 weeks)|f|t|f|f
34189284|NCT05053958|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34189285|NCT03526718|||COHORT||CROSS_SECTIONAL|||||||
34189286|NCT03753113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189287|NCT00939393|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34189288|NCT04681976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34189289|NCT04235751|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34189290|NCT04207619|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189291|NCT01549418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34189292|NCT04197219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189293|NCT03144349|||COHORT||PROSPECTIVE|||||||
34189294|NCT01519167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189295|NCT02228980|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870856|NCT06052163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"1. Bumetanide low dose, 15 participants~2. Bumetanide high dose, 15 participants~3. Placebo, 10 participants"|t|t|t|t
33870857|NCT05699889|||COHORT||PROSPECTIVE|||||||
33870858|NCT01786200|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33870859|NCT06243874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870860|NCT03955302|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33870861|NCT02691975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870862|NCT00625469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870863|NCT00711620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33870864|NCT03816150|||CASE_ONLY||PROSPECTIVE|||||||
33870865|NCT00039585||||TREATMENT||NONE||||||
33870866|NCT03333720|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33870867|NCT04162964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870868|NCT02267148|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33870869|NCT00530270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870870|NCT01169298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870871|NCT06277895|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33870872|NCT01125150|||CASE_CONTROL||PROSPECTIVE|||||||
33870873|NCT03234244|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34067282|NCT04295213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel study with two arms of 13 weeks in total per participant|t|t|t|t
34067283|NCT01533688|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34067284|NCT02501707|||COHORT||PROSPECTIVE|||||||
33870874|NCT04646096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067285|NCT00813436|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067286|NCT05610579|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870875|NCT01934686|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34067287|NCT03423147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067288|NCT01013389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067289|NCT06366438|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomized to one of the three arms upon allocation.||||
34067290|NCT01483456|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870876|NCT02446314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33870877|NCT01473238|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33870878|NCT02440360|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870879|NCT02777268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33870880|NCT06335095|||COHORT||PROSPECTIVE|||||||
33870881|NCT05687968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870882|NCT01498198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870883|NCT02986503|||||PROSPECTIVE|||||||
33870884|NCT00003281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067291|NCT04102332|||CASE_CONTROL||PROSPECTIVE|||||||
34067292|NCT00507065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34067293|NCT01281943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067294|NCT04185584|||CASE_ONLY||PROSPECTIVE|||||||
34189296|NCT03098732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Subjects will be masked with regard to treatment group. Imaging data will be evaluated by independent readers (2) blinded to treatment allocation.~Neurological outcomes will be measured at the 90 Day visit by evaluators blinded to treatment allocation."|Subjects will be randomized 1:1 to receive active treatment or sham. Enrollment will be stratified based upon age (\<75 or \>/=75) and location of the occlusion (M1, M2 or carotid terminus.)|t|f|f|t
34189297|NCT04772560|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34189298|NCT01934595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189299|NCT03572608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189300|NCT02424578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189301|NCT02037685|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34189302|NCT03800147|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be blinded regarding the composition of their nutrition. Investigators performing stool and blood analyses will be blinded to the group assignment of the participants.|randomized controlled crossover clinical study|f|f|t|f
34189303|NCT01518270|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34189304|NCT00757471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189305|NCT02285608|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34189306|NCT04159298|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189307|NCT02083562|||COHORT||PROSPECTIVE|||||||
34189308|NCT04270370|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189309|NCT02292836|||||PROSPECTIVE|||||||
34189310|NCT00710541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189311|NCT04335019|||COHORT||PROSPECTIVE|||||||
34189312|NCT01493167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189313|NCT02923297|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189314|NCT00271453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189315|NCT00339001|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34189316|NCT04121793|||CASE_ONLY||PROSPECTIVE|||||||
34189317|NCT00900952|||COHORT||PROSPECTIVE|||||||
34189318|NCT02279264|||COHORT||PROSPECTIVE|||||||
33870885|NCT03707548|NA|SINGLE_GROUP||TREATMENT||NONE||"Study design: The project follows the outline of a non-randomized evaluation of a weekly group BPT using a waiting-period comparator, with a nested randomized controlled trial (RCT) to evaluate the short-term efficacy of smartphone-triggered bodily interventions.~Measurement points:~* Patients will be surveyed at three points in time (initial consultation, pre- and post-intervention) to explore the effects of BPT on bodily disturbances and body image in post-treatment cancer patients.~* During the BPT Intervention group cohesion and bodily well-being will be assessed weekly.~* The smartphone-triggered bodily and control interventions will be provided over a period of 5 consecutive weeks on 6 days per week and will be assessed pre- and post intervention."||||
33870886|NCT05851742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870887|NCT00478582|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33870888|NCT05004636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33870889|NCT06219265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870890|NCT03672409|NA|SINGLE_GROUP||OTHER||NONE||||||
33870891|NCT04405115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"2 arms; 1:1 randomization;~Standard of care (control group) will receive routine care only and will not be scheduled for a Comprehensive Geriatric Assessments visit.~Comprehensive geriatric assessment ( intervention group) will be scheduled for a Comprehensive Geriatric Assessment visit that will take place with a geriatric nurse practitioner of a physician as soon as possible following enrollment and randomization (preferably within 2 weeks)."||||
33870892|NCT02781909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870893|NCT03853239|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33870894|NCT05188716|||COHORT||PROSPECTIVE|||||||
34067295|NCT02400892|||COHORT||PROSPECTIVE|||||||
34067296|NCT02247297|||COHORT||PROSPECTIVE|||||||
34067297|NCT01729221|||COHORT||PROSPECTIVE|||||||
34189319|NCT03859583|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34189320|NCT05235867|||CASE_CONTROL||PROSPECTIVE|||||||
34189321|NCT00653926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189322|NCT01161199|||COHORT||PROSPECTIVE|||||||
34189323|NCT05138952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067298|NCT04422964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking will be included|Patient will be randomized according to the interventional and control goup according to the day of surgery. The allocation between the groups will be 1:1||||
33870895|NCT00986544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870896|NCT03540784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870897|NCT00481286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870898|NCT01446432|||COHORT||PROSPECTIVE|||||||
33870899|NCT05780775|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870900|NCT01737918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870901|NCT01390766|||||PROSPECTIVE|||||||
33870902|NCT06032780|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Group allocation will be kept blinded to the assessor and to the treatment provider (trained physical therapist).||f|t|f|t
33870903|NCT04808570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966058|NCT02712385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The intervention groups will be getting access to a home-based rehabilitation, 'The Healthy Brain Rehabilitation Manual', telephone follow-up with either a GP or stroke nurse and a pedometer.|f|f|f|t
33966059|NCT03605537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966060|NCT00990561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33966061|NCT06290869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966062|NCT01927081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33966063|NCT00458718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966064|NCT02629965|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33966065|NCT06369337|||COHORT||PROSPECTIVE|||||||
33966066|NCT05943496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966067|NCT02617173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966068|NCT04006847|NA|SEQUENTIAL||TREATMENT||NONE||Phase I/II, open-label, single site study using a standard 3 + 3 statistical design to determine the MTD and the recommended Phase 2 dose for oral EPA when administered to subjects receiving on a TKI pre-study.||||
33966069|NCT03818919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33966070|NCT05659706|||OTHER||PROSPECTIVE|||||||
33966071|NCT02354365|||COHORT||PROSPECTIVE|||||||
33966072|NCT05178147|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||To assess the feasibility of using the new GraduCheck® device to enable experienced Tissue Viability Nurses to bandage legs with an optimal pressure profile beneath the bandage, without causing excessive time to be spent.||||
34067299|NCT00496587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067300|NCT01504672|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34067301|NCT05926466|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will compare the efficacy, safety of 3 experimental regimens with a comparator regimen administered over 16 weeks, in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.||||
34067302|NCT03747718|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Masking will be completed at the 1.5 month visit by the pharmacy.|The study will operate as a single group open label study until visit 6, at which point it will become a randomized trial.|t|t|t|f
34067303|NCT02349282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870904|NCT00173303|||DEFINED_POPULATION||OTHER|||||||
33870905|NCT00012779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870906|NCT03215771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870907|NCT00677820|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870908|NCT01071538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870909|NCT02484976|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870910|NCT00153712|||COHORT||PROSPECTIVE|||||||
33870911|NCT00839670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33870912|NCT06090370|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33870913|NCT00971165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870914|NCT01446406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067304|NCT02247232|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870915|NCT04305522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34067305|NCT01041274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067306|NCT06465628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870916|NCT01370720|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33870917|NCT05514379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are blinded to study hypothesis. Investigators are blinded to treatment group.|Prticipants are randomly assigned to either the experimental or the control group.|t|f|t|f
33870918|NCT00808795|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33870919|NCT06121427|||COHORT||PROSPECTIVE|||||||
33870920|NCT00772486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067307|NCT01267422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966073|NCT00328783|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067308|NCT00060372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067309|NCT05413941|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067310|NCT00220948|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34067311|NCT01778751|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34067312|NCT05979584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067313|NCT01125813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067314|NCT02626923|||CASE_ONLY||RETROSPECTIVE|||||||
34067315|NCT04727255|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled (two parallel groups)||||
34067316|NCT01755806|||CASE_CONTROL||RETROSPECTIVE|||||||
34067317|NCT02685878|||OTHER||PROSPECTIVE|||||||
34067318|NCT01158105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067319|NCT00394394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34067320|NCT04725890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067321|NCT06300944|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||parallel assignment|t|f|t|f
33966074|NCT00941252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966075|NCT01377961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189324|NCT00316043|RANDOMIZED|FACTORIAL||||NONE||||||
33966076|NCT02506010|||COHORT||PROSPECTIVE|||||||
33966077|NCT01225991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966078|NCT03560505|||CASE_CONTROL||PROSPECTIVE|||||||
33966079|NCT06381570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966080|NCT00852956|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33966081|NCT06246851|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"This is a phase 1 study exploring differences between the immunological responses to revaccination with intradermal-BCG and aerosol-inhaled BCG in healthy adults and those with pre-existing T2DM.~There will be three study groups with twelve volunteers in each group. Volunteers will be enrolled into groups based upon whether they have a diagnosis of T2DM. They will then be vaccinated with intradermal BCG (Groups A and C) or aerosolised BCG (Group B)."||||
33966082|NCT05824468|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: Zimberelimab, Drug: Lenvatinib||||
33966083|NCT04591418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966084|NCT00038519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966085|NCT01400854|||COHORT||PROSPECTIVE|||||||
33966086|NCT01604954|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33966087|NCT05537337|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33966088|NCT04906473|NA|SEQUENTIAL||TREATMENT||NONE||Single-arm, open, single/multiple dose escalation (100mg/d, 200mg/d, 350mg/d, 550mg/d, 750mg/d) and dose Extension||||
33966089|NCT01015911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966090|NCT06046079|||COHORT||PROSPECTIVE|||||||
33966091|NCT03320473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966092|NCT02227537|||COHORT||PROSPECTIVE|||||||
33966093|NCT05146869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966094|NCT00813501|||COHORT||PROSPECTIVE|||||||
33966095|NCT05848271|||COHORT||RETROSPECTIVE|||||||
33966096|NCT00588627|||CASE_CONTROL||PROSPECTIVE|||||||
33966097|NCT00732771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33966098|NCT00894985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33966099|NCT05535517|||OTHER||PROSPECTIVE|||||||
33966100|NCT01224756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966101|NCT02053571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189325|NCT02192281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34189326|NCT03803241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189327|NCT01032109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189328|NCT02587273|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189329|NCT05360797|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ramdomized||||
34189330|NCT01209325|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34189331|NCT02913456|||COHORT||PROSPECTIVE|||||||
34189332|NCT02404025||||TREATMENT||NONE||||||
34189333|NCT04190888|||COHORT||PROSPECTIVE|||||||
34189334|NCT04729023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189335|NCT00874419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189336|NCT02659891|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34189337|NCT04074408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The hUMSCs suspension and placebo solvent have different appearance so only the participants but not the researches can be masked.||t|f|f|f
34189338|NCT02758483|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34189339|NCT01406613|||COHORT||PROSPECTIVE|||||||
34189340|NCT05281042|||COHORT||PROSPECTIVE|||||||
34189341|NCT03481686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189342|NCT00329797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34189343|NCT00674713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34189344|NCT01984528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189345|NCT02659397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189346|NCT05828329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomly assigned with a code with which investigators and outcomes assessors will not be able to know from whom data are or the group to which participants belong.|Randomized controlled trial|f|f|t|t
34189347|NCT00776243|||CASE_CONTROL||PROSPECTIVE|||||||
34189348|NCT00695929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189349|NCT03507946|NA|SINGLE_GROUP||TREATMENT||NONE|"Randomization will be conducted by the study coordinator and will take place in a separate room away from the PI.~The Study coordinator will number the 2 plaques 1 and 2. The Study coordinator will draw a sequential envelope containing the randomization code for the control and test. The code will inform the study coordinator which plaque is control and which test.~The Study coordinator will complete the randomization coding worksheet which identifies the test and control plaque and location.~The randomization coding worksheet will be kept separate from the subjects' case report form."|Randomized, Blinded, Controlled Trial||||
34189350|NCT03926611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This was a global Phase 2b multicenter, randomized, double-blind, parallel-group, placebocontrolled study investigating the efficacy, safety and tolerability of 6 dosing groups of oral LOU064 in subjects with inadequately controlled CSU despite treatment with (second generation) H1-antihistamine. Study duration was 18 weeks (2 weeks of screening period; 12 weeks of treatment period and a 4 weeks follow-up period).~Study had 7 arms: 10 mg LOU064 q.d.; 35 mg LOU064 q.d.; 100 mg LOU064 q.d.; 10 mg LOU064 b.i.d.; 25 mg LOU064 b.i.d.; 100 mg LOU064 b.i.d.; and Placebo~Throughout study, subjects were treated with a 2nd generation H1-antihistamine at a locally approved licensed posology (background medication). Subjects could take an additional second generation H1-antihistamine that was eliminated primarily via renal excretion (e.g. cetirizine, levocetirizine or bilastine) as rescue medication. Eligible subjects could roll over to extension at Wk 12 or Wk 16"|t|f|t|t
34189351|NCT01452841|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34189352|NCT05941195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following recruitment, person who the substance use disorder were divided into a study and a control group by randomization (1:1 randomization)||||
34189353|NCT06050824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189354|NCT03472261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189355|NCT00593190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755105|NCT03221621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be treated with either the combination of adalimumab and surgery or adalimumab monotherapy for two years, both according to normal clinical practice. Patients on adalimumab monotherapy will be given the possibility to crossover into Group B when they do not achieve the HiSCR after 6 months of treatment. Additionally patients will be offered treatment with infliximab, according to clinical practice, until he last surgery.||||
33755106|NCT05563103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33755107|NCT00774579|||COHORT||PROSPECTIVE|||||||
33755108|NCT06567678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755109|NCT04360525|||OTHER||RETROSPECTIVE|||||||
33755110|NCT05349825|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755111|NCT01356355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755112|NCT04311606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-masked|"Three groups as follows:~Group 1: Sub-tenon's injection of saline followed by sub-tenon injection of aflibercept Group 2: Sub-tenon's injection of hyaluronidase (HA) followed by sub-tenon injection of aflibercept; and Group 3: Sub-tenon injection of HA injection alone"|t|t|f|f
33755113|NCT03495011|||COHORT||PROSPECTIVE|||||||
33755114|NCT06113601|||COHORT||PROSPECTIVE|||||||
33755115|NCT05632510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33755116|NCT05339048|||COHORT||PROSPECTIVE|||||||
33755117|NCT02143180|||||PROSPECTIVE|||||||
33755118|NCT01037361|||||PROSPECTIVE|||||||
33755119|NCT02240095|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
33755120|NCT02415426|||OTHER||PROSPECTIVE|||||||
33755121|NCT06199258|||COHORT||PROSPECTIVE|||||||
33755122|NCT06052241|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||prospective, single-center, pre-post comparative study||||
33870921|NCT01758796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Interpretation of data is blinded to treatment group allocation. More precisely, the interpretation of data is carried out without knowledge of the actual treatment given to the particular group, rather labelling groups as Group 1 and Group 2. Only then the randomization code is broken, correct data interpretation is chosen, and the draft of the manuscript is finalised."||f|f|t|f
33870922|NCT03151720|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33755123|NCT01936857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755124|NCT01944631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33755125|NCT02203474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755126|NCT01538732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755127|NCT02652741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755128|NCT03764332|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755129|NCT04303949|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33755130|NCT01578148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755131|NCT01695486|||CASE_ONLY||PROSPECTIVE|||||||
33755132|NCT03797521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, Placebo-controlled Study||t|t|t|t
33755133|NCT01299948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755134|NCT00003780|RANDOMIZED|||TREATMENT||||||||
33870923|NCT02122198|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33870924|NCT01481051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870925|NCT06316700|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33870926|NCT06389864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870927|NCT02876588|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|t|f
33870928|NCT00162864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33870929|NCT01857284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870930|NCT04207801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870931|NCT03936621|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|A computer will be used to select participants for each of the study groups.|participants are randomized into 2 study groups. Group 1 Omega 3 fatty acids for 6 months and then off omega 3 fatty acids for the next 6 months. Group 2. No Omega 3 fatty acids for the first 6 months followed by Omega 3 fatty acids for the next 6 months.|t|f|f|f
34067322|NCT02697734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34067323|NCT05867901|||COHORT||PROSPECTIVE|||||||
33870932|NCT04961151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067324|NCT04404829|NA|SINGLE_GROUP||TREATMENT||NONE||The study has a one-group pretest-posttest design.||||
33870933|NCT02698267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870934|NCT03837639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33870935|NCT04066491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870936|NCT03702764|||COHORT||PROSPECTIVE|||||||
33870937|NCT05002270|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33870938|NCT04821037|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870939|NCT00609986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870940|NCT04024033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870941|NCT03831971|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870942|NCT04597983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The company that performed the encapsulation of both the 2S-hesperidin and the placebo performed the randomization, therefore no one on the research team or the sponsors knew which group each study subject belonged to. The results of the randomization were sent to our laboratory after the end of the study to determine which subjects composed each group|A randomized parallel study was conducted, where 40 amateur cyclists were divided into 2 groups: one group took 500 mg of 2S-hesperidin (n= 20) and the other group took 500 mg of placebo (microcellulose) (n= 20). All participants completed the study.|t|f|t|t
33870943|NCT04032600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33870944|NCT05773521|||COHORT||RETROSPECTIVE|||||||
34067325|NCT03519919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189356|NCT05070715|||CASE_CONTROL||PROSPECTIVE|||||||
34189357|NCT04223219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study subjects will be blinded to the allocated groups. The outcome assessor (the investigator who will assess the primary and secondary outcomes) will be blinded to the allocated groups.||t|f|t|t
34189358|NCT02728492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189359|NCT05358769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34189360|NCT02841072|||CASE_ONLY||RETROSPECTIVE|||||||
34189361|NCT05048966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189362|NCT05298449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189363|NCT03462693|||COHORT||PROSPECTIVE|||||||
34189364|NCT04499352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189365|NCT02098668|||||PROSPECTIVE|||||||
34189366|NCT02331277|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34189367|NCT03755804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189368|NCT00477113|||COHORT||PROSPECTIVE|||||||
34189369|NCT04424264|NA|SEQUENTIAL||TREATMENT||NONE||||||
34189370|NCT02749084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189371|NCT02874976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34189372|NCT05532306|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, two-way crossover, open-label, laboratory blind, bioequivalence study||||
33870945|NCT04474769|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Longitudinal quasi-experimental intervention study||||
33870946|NCT01381302|||COHORT||PROSPECTIVE|||||||
34067326|NCT03246919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind: Obstetricians, Anesthesiologists and patients will be blinded. Only nurses will be aware of timing of oxytocin administration||t|t|t|f
34067327|NCT00214292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755135|NCT03494166|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Data collectors will be blinded to the arm of the study.|Following baseline, symptom management need (high versus low need) will be determined. The low need group will not receive interventions, but will be followed at week 4 for a brief symptom assessment and at week 13. The high need group will be randomly assigned to either: 1) SMSH alone or 2) TIP-C+SMSH for 8 weeks followed by continued 4 weeks of SMSH alone. We will mail the SMSH, printed in the survivor's preferred language, following randomization. All high need participants will receive weekly telephone contacts during weeks 1-12 to assess symptoms, deliver the assigned intervention, and assess intervention enactment and fidelity. After the initial 4 weeks, responders on depression will continue with the SMSH only. Non-responders will re-randomized to either continue with the SMSH alone or add TIP-C. Those initially randomized to TIP-C+SMSH will not be re-randomized. Total duration of each of the three intervention sequences is 12 weeks.|f|f|f|t
33755136|NCT02055131|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33755137|NCT06270654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755138|NCT02047500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755139|NCT06492824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33755140|NCT01409902|||COHORT||PROSPECTIVE|||||||
33755141|NCT00754338|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33755142|NCT04717726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants nor research staff working with them will know what supplement they are receiving.|6 armmed, placebo controlled RCT|t|f|t|f
33755143|NCT00335218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755144|NCT03364322|||COHORT||PROSPECTIVE|||||||
33755145|NCT04823429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33870947|NCT03924349|NA|SINGLE_GROUP||OTHER||NONE||Prospective single center open label early phase clinical trial||||
33966102|NCT06522516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||2 intervention groups.|t|f|f|t
33966103|NCT04728737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33966104|NCT04180254|NA|SINGLE_GROUP||OTHER||NONE||a group of normal hearing and hearing-impaired participants||||
34189373|NCT04444440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo|Patients will be randomized at a 1:1 allocation ratio to two parallel treatment arms - intervention versus placebo|t|t|t|t
33966105|NCT04806477|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34189374|NCT04213248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189375|NCT01417377|||COHORT||PROSPECTIVE|||||||
34189376|NCT01235741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189377|NCT03573271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189378|NCT03777891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189379|NCT06022692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189380|NCT00818701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34189381|NCT02169427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189382|NCT00500435|||CASE_ONLY||PROSPECTIVE|||||||
34189383|NCT04828343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a participant-blind and investigator-blind study.||t|f|t|f
34189384|NCT02681354|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34189385|NCT02464280|||CASE_ONLY||PROSPECTIVE|||||||
34189386|NCT02175030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189387|NCT00003013|RANDOMIZED|||TREATMENT||||||||
34189388|NCT03975478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher responsible for statistical analysis will be blinded to group allocation until data analysis is complete.||f|f|f|t
34189389|NCT00220636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189390|NCT03791957|||OTHER||CROSS_SECTIONAL|||||||
34189391|NCT02707575|||OTHER||PROSPECTIVE|||||||
34189392|NCT03768648|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34189393|NCT00541801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189394|NCT01920672|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34189395|NCT00958906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189396|NCT03323281|||OTHER||PROSPECTIVE|||||||
34189397|NCT02663713|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34189398|NCT05470023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|White tape over receptacle.|Subjects will be randomized to different treatments.|t|f|t|f
34189399|NCT04153552|NA|SINGLE_GROUP||OTHER||NONE||The present study will be a single site, prospective, one arm observational study of minimal risk consisting of at least 200 participants who suffer from symptoms of occasional indigestion and heartburn. Participants will begin taking the capsules at the onset of indigestion and heartburn symptoms. Onset is defined as the point in time the participant takes the test product for relief of symptoms.||||
34189400|NCT03593616|||COHORT||PROSPECTIVE|||||||
34189401|NCT06271954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34189402|NCT04341519|||COHORT||PROSPECTIVE|||||||
34189403|NCT00002272||||TREATMENT||||||||
34189404|NCT01851603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189405|NCT03245489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189406|NCT04625140|||COHORT||PROSPECTIVE|||||||
34189407|NCT00106899|||CASE_CONTROL||PROSPECTIVE|||||||
34189408|NCT03633539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189409|NCT04835506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189410|NCT04521504|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study considers participants divided in two groups: the control group and the experimental group.||||
34189411|NCT03572595|||OTHER||PROSPECTIVE|||||||
34189412|NCT01148979|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the study participant and the study investigators making evaluations are blinded to which treatment arm the participants are assigned to (i.e., whether they are receiving placebo or Vyvanse at any given point). Placebo and active medication capsules look identical.|This is a double-blind, placebo-controlled, crossover study in which each subject will act as their own control after being randomly assigned to placebo or Lisdexamfetamine Dimesylate (Vyvanse) for the first 4 weeks of study treatment, then receiving the other for the second 4 weeks of treatment. The two 4-week treatment periods are separated by a washout of 2 weeks.|t|f|t|f
33755146|NCT01276925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33870948|NCT05681000|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"At least 4 dose cohorts are planned, and 16-28 cases are expected.~1. Cohort 1: 2 subjects are planned to take 25 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.~2. Cohort 2: 2 subjects are planned to take 50 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.~3. Cohort 3: 3-6 subjects are planned to take 75 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.~4. Cohort 4: 3-6 subjects are planned to take 100 mg/m2/d by QD for 5 consecutive days in a 21-day cycle.~5. Cohort 5: 3-6 subjects are planned to take 100 mg/m2/d by QD for 7 consecutive days in a 21-day cycle.~6. Cohort 6: 3-6 subjects are planned to take 120 mg/m2/d by QD for 7 consecutive days in a 21-day cycle."||||
33870949|NCT00388700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870950|NCT01295528|||COHORT||RETROSPECTIVE|||||||
33870951|NCT02347098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33870952|NCT02651584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870953|NCT02829242|||CASE_ONLY||PROSPECTIVE|||||||
33870954|NCT04642196|||COHORT||RETROSPECTIVE|||||||
33966106|NCT04182139|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189413|NCT03196349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189414|NCT01017380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189415|NCT04783090|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This study will be double-blinded. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (MT1013 or placebo). Blinding will be maintained until at least the clinical phase of the study is completed。|Randomized, double-blind single-dose, sequential SAD|t|t|t|t
34189416|NCT05636449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34189417|NCT00509145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189418|NCT01350791|||COHORT||PROSPECTIVE|||||||
34189419|NCT04059315|||COHORT||PROSPECTIVE|||||||
34189420|NCT03399929|||COHORT||PROSPECTIVE|||||||
34189421|NCT04437667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189422|NCT00000955|NA|SINGLE_GROUP||SCREENING||NONE||||||
34189423|NCT01192685|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34189424|NCT02869737|||||PROSPECTIVE|||||||
34189425|NCT05405686|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||prospective randomized open-label cross-over study||||
33755147|NCT05590780|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755148|NCT05741684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755149|NCT04021810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755150|NCT01127867|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33755151|NCT00441701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755152|NCT05242328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34189426|NCT05357001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189427|NCT02814552|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34189428|NCT00517855|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34189429|NCT01644357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34189430|NCT01677377|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34189431|NCT02516852|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189432|NCT01757925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189433|NCT01186341|||COHORT||PROSPECTIVE|||||||
34189434|NCT00473382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189435|NCT04786535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189436|NCT01980667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755153|NCT03540654|||COHORT||RETROSPECTIVE|||||||
33755154|NCT03244072|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33755155|NCT05201573|||OTHER||PROSPECTIVE|||||||
33755156|NCT00753792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755157|NCT00166140|||||PROSPECTIVE|||||||
33755158|NCT03501433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|I single investigator will be responsible for blinding. All researchers involved in collection and evaluation of data will remain blinded to treatments.|Randomized, cross-over|t|f|f|t
33755159|NCT05241704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755160|NCT00286845|||CASE_ONLY||RETROSPECTIVE|||||||
33755161|NCT01696981|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34189437|NCT05345340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the type of intervention performed by the patient.|This is a single-blind randomized-controlled trial (RCT) with 2-parallel arms comparing the effects between the experimental group (EG) and control group (CG). After screening, a simple randomization list will be generated by a physician using an automated randomization system (www.randomization.com) (allocation ratio 1:1) to assign eligible patients to either the EG or the CG. Group allocation will be kept concealed.|f|f|f|t
34189438|NCT03181529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome measure (GRID-HAMD) will be assessed by raters blinded to randomization condition.||f|f|f|t
34189439|NCT03924167|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Families and CHRs will be blinded to the order they receive the intervention and notified a month in advance.|The proposed research will use a stepped-wedge trial design (SWTD) to test the efficacy of a culturally modified intervention that is facilitated by Tribally-based community health representatives (CHRs) and the consolidated framework for implementation research (CFIR) to examine the barriers and facilitators for intervention sustainability and implementation.|t|t|f|f
33870955|NCT05316402|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870956|NCT04178694|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870957|NCT04082403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33870958|NCT02520687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189440|NCT01885585|||CASE_ONLY||PROSPECTIVE|||||||
34189441|NCT06514495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189442|NCT00704119|NA|SINGLE_GROUP||||NONE||||||
34189443|NCT02100696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189444|NCT06338137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189445|NCT03494504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189446|NCT04564157|RANDOMIZED|PARALLEL||TREATMENT||NONE||Design: Open-label, randomised, two arm, phase III, multicentre clinical trial||||
34189447|NCT06341920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible - referrals/care providers know whether they/referral is involved in the intervention or not.|Intervention v control||||
34189448|NCT02238899|||||CROSS_SECTIONAL|||||||
34189449|NCT02029248|||CASE_ONLY||CROSS_SECTIONAL|||||||
34189450|NCT01774409|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189451|NCT06067672|||OTHER||PROSPECTIVE|||||||
34189452|NCT05868434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189453|NCT04440865|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Arm 1- Standard colonoscopy Arm 2- Colonoscopy assisted by Genius® system||||
34189454|NCT00737815|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34189455|NCT03650283|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34189456|NCT00272532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34189457|NCT06338969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189458|NCT02476539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189459|NCT02453672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189460|NCT04776655|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, randomized, open-label, comparative, multi-centre study||||
34189461|NCT01311141|NA|SINGLE_GROUP||||NONE||||||
34189462|NCT01711216|||||PROSPECTIVE|||||||
34189463|NCT00968513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189464|NCT01585506|||OTHER||PROSPECTIVE|||||||
34189465|NCT04535778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189466|NCT00124436|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34189467|NCT03348228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189468|NCT03439332|||CASE_ONLY||RETROSPECTIVE|||||||
34189469|NCT05615519|||COHORT||PROSPECTIVE|||||||
34189470|NCT00010829|RANDOMIZED|||TREATMENT||||||||
34189471|NCT05219370|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|the responsible pharmacist is un-blinded|each participant will be randomized to one of the 4 arms and will receive the treatment for 32 days. Follow up till 6 weeks from starting|t|t|t|t
34189472|NCT05181293|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189473|NCT02583737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189474|NCT00042003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189475|NCT06451198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189476|NCT04949152|||COHORT||PROSPECTIVE|||||||
34189477|NCT06444191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189478|NCT04267484|||COHORT||CROSS_SECTIONAL|||||||
33870959|NCT06075342|||OTHER||CROSS_SECTIONAL|||||||
33870960|NCT04673292|RANDOMIZED|PARALLEL||SCREENING||NONE||Each household will be randomized to one of three arms in the study: Fixed site SOC testing (Arm 1), community-based, mobile van testing (Arm 2), or self-collected, home-based testing (Arm 3).||||
33870961|NCT04026724|||COHORT||RETROSPECTIVE|||||||
33870962|NCT03351920|||COHORT||PROSPECTIVE|||||||
33870963|NCT02004431|||CASE_CONTROL||PROSPECTIVE|||||||
33870964|NCT01636973|NA|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33870965|NCT02170883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33870966|NCT04468542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33870967|NCT00111800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870968|NCT00883662|||COHORT||PROSPECTIVE|||||||
33870969|NCT01306448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870970|NCT05690854|||CASE_CONTROL||PROSPECTIVE|||||||
33870971|NCT00503594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870972|NCT01127685|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33870973|NCT02035189|||CASE_CONTROL||PROSPECTIVE|||||||
33870974|NCT04605302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Patient blinded to MCC results. EGD assessor blinded to MCC results.|Tandem study||||
33870975|NCT06211894|||CASE_ONLY||PROSPECTIVE|||||||
33966107|NCT02924571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189479|NCT04155580|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34189480|NCT03892304|||COHORT||CROSS_SECTIONAL|||||||
34189481|NCT02670148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189482|NCT02252939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189483|NCT02569749|||COHORT||PROSPECTIVE|||||||
33755162|NCT00419822|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33755163|NCT05276466|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group assignment||||
33755164|NCT01864239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755165|NCT03980444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients as random allocation were divided into two groups: A (control group, no basket of bases and group B (use of pneumatic synchronous buccal waist). The dividing person and the patients themselves were not aware of which group they were in. They were double-blind Was.|"Patients included in the study included the necessary tests U/A, K, Na, Cr, BUN, CBC, And U / C was checked and anesthesia counseling was done. The demographic and clinical data of the patients were recorded.~Then patients as random allocation were divided into two groups: A (control group) and group B (use of a pneumatic basket of wire). The dividing person and the patients themselves were not aware of which group they were in.~In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A, the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~In group B (using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the same as A group."|f|f|t|f
34189484|NCT01575626|RANDOMIZED|PARALLEL||||NONE||||||
34189485|NCT04024189|||COHORT||RETROSPECTIVE|||||||
34189486|NCT03770988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189487|NCT05942235|||COHORT||PROSPECTIVE|||||||
34189488|NCT03099278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189489|NCT00233883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189490|NCT00710580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189491|NCT05380401|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"There will be four arms of the trial encompassing the period from enrollment to 36 weeks' postmenstrual age: (a) DHA/ARA supplement throughout the duration of the protocol, d-on; (b) no DHA/ARA supplement throughout the duration of the protocol, d-off; (c) a cross-over arm of DHA/ARA supplement from enrollment to 31 6/7 weeks post-menstrual age (PMA) then no supplement from 32 to 36 weeks' PMA, x- on/off; and (d) a cross-over arm of no DHA/ARA supplement till 31 6/7 weeks' then long-chain polyunsaturated fatty acids (LCPUFA) supplement from 32 to 36 weeks PMA, x-off/on."||||
34189492|NCT00768313|RANDOMIZED|||OTHER||SINGLE|||t|f|f|f
34189493|NCT02969655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189494|NCT00887211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189495|NCT04951635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34189496|NCT02961101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189497|NCT03158285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189498|NCT00498771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189499|NCT02661776|||COHORT||PROSPECTIVE|||||||
34189500|NCT03581552|||COHORT||PROSPECTIVE|||||||
34189501|NCT01719497|||CASE_CONTROL||PROSPECTIVE|||||||
33755166|NCT02034708|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33755167|NCT05190250|||CASE_CONTROL||PROSPECTIVE|||||||
33755168|NCT00023153||||TREATMENT||||||||
33755169|NCT03530930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755170|NCT01708330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33870976|NCT04107415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomization; participants were divided into two groups by using simple random numbers table, and then the first group which was drawn by lot method was named as the experimental group.|f|f|t|f
33870977|NCT03525717|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870978|NCT00843388|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34189502|NCT01684813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189503|NCT04297527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments were made by another blind researcher three times at before, after and 6 month after treatment.||f|f|t|f
34189504|NCT00410098|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34189505|NCT00357669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189506|NCT05942495|NA|SINGLE_GROUP||TREATMENT||NONE||Single Case experimental design||||
34189507|NCT01534897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189508|NCT06400758|||OTHER||RETROSPECTIVE|||||||
33870979|NCT03008642|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33870980|NCT05099627|||COHORT||OTHER|||||||
33870981|NCT04021836|RANDOMIZED|PARALLEL||OTHER||SINGLE||Three dimensional evaluation of nasolabial changes following classic vs without alar base suture after Le Fort I osteotomy|f|f|t|f
33870982|NCT04331795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33870983|NCT03124771|NA|SINGLE_GROUP||OTHER||NONE||||||
33870984|NCT04649255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870985|NCT03556553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076098|NCT05468216|RANDOMIZED|PARALLEL||PREVENTION||NONE|Only an allocation concealment mechanism will be used to prevent clusters' selection bias|Randomized Controlled Trial||||
33870986|NCT01937533|||CASE_ONLY||PROSPECTIVE|||||||
33870987|NCT02025868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966108|NCT00634283|RANDOMIZED|PARALLEL||OTHER||TRIPLE|We compared EEG outcomes for those subjects who had been randomly assigned to blinded treatment with venlafaxine (antidepressant-experienced, n=2) vs. placebo (antidepressant-naive, n=4). All subjects received 1 week of placebo followed by 4 weeks of venlafaxine. Subjects were blinded to the treatment during both phases of the study using lookalike capsules. Outcomes assessors and the treating physician also were blinded to treatment condition.|Subjects are assigned to one of two groups (antidepressant-experienced and antidepressant-naive) and receive parallel treatment (1 week of placebo followed by 4 weeks of venlafaxine) for the duration of the study. Subjects and assessors were blinded to treatment condition.|t|t|f|t
33966109|NCT05760183|||CASE_CROSSOVER||PROSPECTIVE|||||||
33966110|NCT06042894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966111|NCT05737459|||COHORT||PROSPECTIVE|||||||
33966112|NCT03876288|||CASE_ONLY||OTHER|||||||
33966113|NCT01318733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076099|NCT04164368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189509|NCT05388292|NA|SINGLE_GROUP||PREVENTION||NONE|This is a quasi-experimental study with a single-group pre-test and post-test design.|||||
34189510|NCT02586558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189511|NCT01157689|||CASE_ONLY||PROSPECTIVE|||||||
34189512|NCT04128813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this clinical trial design strategy, the participants and the investigator do not know which participants have been assigned which interventions so there is a double-blind masking.|In this clinical trial design, three groups of participants receive different interventions. One group receives a training with a vertical whole body vibration plattform, another group receives a training with a rotational whole body vibration platform and the third one is the control group.|t|f|t|f
34189513|NCT05987995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189514|NCT04587765|RANDOMIZED|PARALLEL||PREVENTION||NONE||open,non-inferiority cluster randomized controlled trial||||
34189515|NCT03817697|||COHORT||PROSPECTIVE|||||||
34189516|NCT01740453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189517|NCT04146428|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34189518|NCT02679118|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34189519|NCT00312195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33870988|NCT01444079|||COHORT||PROSPECTIVE|||||||
33870989|NCT02348775|NA|SINGLE_GROUP||OTHER||NONE||||||
33870990|NCT05578859|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33870991|NCT02231164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33870992|NCT06369103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870993|NCT02152085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966114|NCT00217971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966115|NCT03582007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sponsor blinded||f|f|f|t
33966116|NCT01827371|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966117|NCT01484028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966118|NCT03220763|||COHORT||PROSPECTIVE|||||||
33966119|NCT01558531|||CASE_CONTROL||PROSPECTIVE|||||||
34067328|NCT05358977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|At the end of the intervention, both sides will receive 1 minute of pressure to mask the patient as to which side received treatment. Postoperative photographs will be assessed by two masked ophthalmic surgeons who will rate the degree of postoperative bruising. Upper and lower eyelids of each patient will be evaluated separately. Observers will assess each side for ecchymosis using a 10-point Likert scale (1, none; 10, severe) on postoperative days 1, 3 and 7.|Each participant in the study will receive a topical application of fibrin sealant (Tisseel) in one of their upper eyelid eyelid blepharoplasty closures in addition to standard blepharoplasty closure techniques. The other eyelid will receive standard blepharoplasty closure techniques alone, without fibrin sealant. Both sides will receive 1 minute of pressure, after application of Tisseel, to mask which side received treatment.|t|f|f|t
34067329|NCT05868278|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34067330|NCT00002267||||TREATMENT||DOUBLE||||||
34067331|NCT05005767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||twenty patients will be randomly be selected and equally divided into Group I: will receive SRP only, group II: will receive SRP and Frankincense extract the gel. Subgingival application of Frankincense extract gel will be performed following initial SRP )day 1) and at 7, and 14 days.|t|f|t|f
34067332|NCT02581033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067333|NCT05201378|||COHORT||RETROSPECTIVE|||||||
34067334|NCT03202732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067335|NCT05635422|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067336|NCT00629148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067337|NCT00012675|||||RETROSPECTIVE|||||||
34067338|NCT00638261|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067339|NCT04209907|NON_RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||f|t|t|t
34067340|NCT05393687|RANDOMIZED|PARALLEL||OTHER||NONE||In order to examine the effect of strengthening exercises on performance amongst competitive young swimmers, a randomized controlled trial was undertaken. Swimmers were divided into two groups: Exercise (n=13) and the control groups (n=13). Both groups were assessed for 5-metre underwater swim time and ankle muscle strength before and after 8 weeks of normal swimming training. The exercise group received eccentric ankle strengthening exercises with an elastic band, in addition to their regular swimming training. Participants completed 24 exercises over 8 weeks, with 3 non-consecutive training sessions per week. Dynamic (2 minutes) and static stretching (2 minutes) exercises were performed as before the training session.||||
34067341|NCT03827551|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067342|NCT04850378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, controlled, non-randomized, interventional clinical trial.||||
34189520|NCT00598000|||COHORT||PROSPECTIVE|||||||
34189521|NCT02890121|||COHORT||PROSPECTIVE|||||||
34189522|NCT04303039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189523|NCT00916929|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34189524|NCT03970915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189525|NCT03220321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189526|NCT02879188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189527|NCT02757716|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33966120|NCT00410852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966121|NCT00798824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966122|NCT04320459|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966123|NCT00014521||||TREATMENT||||||||
34189528|NCT04473469|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189529|NCT01196403|RANDOMIZED|||TREATMENT||NONE||||||
34189530|NCT00473733|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34189531|NCT01273753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189532|NCT01500681|||COHORT||PROSPECTIVE|||||||
34189533|NCT04894331|||COHORT||PROSPECTIVE|||||||
34189534|NCT00852553|||CASE_ONLY||PROSPECTIVE|||||||
34189535|NCT01306344|||||RETROSPECTIVE|||||||
34189536|NCT04580992|||COHORT||PROSPECTIVE|||||||
34189537|NCT03759353|RANDOMIZED|PARALLEL||TREATMENT||NONE||98 pregnant women with iron deficiency will be randomized into two groups: lactoferrin group or ferrous sulfate group||||
33870994|NCT02731261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33870995|NCT04701671|||CASE_CONTROL||OTHER|||||||
33870996|NCT05258773|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33870997|NCT03691025|||COHORT||PROSPECTIVE|||||||
33870998|NCT03119961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33870999|NCT03426956|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||10 gastric bypass patients|t|f|f|f
33871000|NCT05997862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966124|NCT05215041|||COHORT||PROSPECTIVE|||||||
33966125|NCT02345928|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33966126|NCT03994094|||COHORT||RETROSPECTIVE|||||||
33966127|NCT06530992|||CASE_CONTROL||PROSPECTIVE|||||||
33966128|NCT05771311|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966129|NCT01407328|||CASE_ONLY||PROSPECTIVE|||||||
34189538|NCT05904418|NA|SINGLE_GROUP||OTHER||NONE|No masking|All enrolled participants have to go through the previously mentioned interventions||||
33755171|NCT05308732|NA|SEQUENTIAL||PREVENTION||NONE||"The investigator will assign a unique number to the patient being evaluated to participate in the study. The patients included in the study will receive instructions on oral hygiene and the aqueous copaiba solution for mouthwash.~The recruitment and design of the study will be carried out according to the 3 + 3 design (modified Fibonacci design) with the planned inclusion of 6 successive cohorts (of 3 patients) with different patients. Each cohort of patients will be closely monitored for one week before moving on to a new cohort. There will be no dose escalation in the same patient.~The first 3 cohorts will use the mouthwash at 10%, 2, 3, and 4 times a day respectively. The last 3 cohorts will use the mouthwash at 15%, 2, 3, and 4 times a day respectively.~If radiotherapy is interrupted for any reason and the patient is benefiting from using the mouthwash with copaiba, the patient will continue to perform the mouthwash."||||
33755172|NCT03672994|||CASE_CONTROL||PROSPECTIVE|||||||
33755173|NCT06029101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755174|NCT02815462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33755175|NCT01792479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755176|NCT01379872|||||RETROSPECTIVE|||||||
33755177|NCT00689026|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33755178|NCT02635451|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755179|NCT03089437|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33755180|NCT03811964|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33755181|NCT05276830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind, Placebo controlled|Study will randomize subjects 1:1:1 to receive BXCL501 40 μg, BXCL501 60 μg, or matching placebo film|t|f|t|f
33755182|NCT04987762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871001|NCT03321227|RANDOMIZED|CROSSOVER||OTHER||NONE||A random and within subject repeated measures experiment to study the effects of egg consumption on cognitive performance in children and the underlying physiological mechanisms in this relationship.||||
33755183|NCT03531047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755184|NCT01139307|||COHORT||RETROSPECTIVE|||||||
33755185|NCT06016452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed phase II prospective study will be split into two strata: Stratum A (symptomatic RN) and Stratum B (asymptomatic RN).||||
33755186|NCT00306982|||||PROSPECTIVE|||||||
33755187|NCT00511875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755188|NCT00487617|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755189|NCT04814082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755190|NCT04886882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33755191|NCT00799643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755192|NCT04011774|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871002|NCT03506321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755193|NCT01043822|||CASE_CONTROL||RETROSPECTIVE|||||||
33755194|NCT00578084|||COHORT||PROSPECTIVE|||||||
33755195|NCT04893655|NA|SINGLE_GROUP||OTHER||NONE||||||
33755196|NCT05242640|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33755197|NCT01459861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33755198|NCT05458648|||COHORT||PROSPECTIVE|||||||
33755199|NCT01774513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755200|NCT02119910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755201|NCT03985891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755202|NCT00703690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755203|NCT06149793|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|double-blind|"This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period.~Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients with CFRD to support a future larger randomized controlled trial."|t|f|t|f
33755204|NCT00349479|RANDOMIZED|FACTORIAL||||NONE||||||
33755205|NCT02495480|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33755206|NCT01033357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755207|NCT05904665|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33755208|NCT05052086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Included patients will undergo magnetomotoric ultrasound in addition to conventional MRI. The results of MRI examination and magnetomotoric ultrasound will be compared with final histopathology.||||
33755209|NCT02905201|||COHORT||PROSPECTIVE|||||||
33755210|NCT04763057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755211|NCT02610738|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755212|NCT00329329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755213|NCT01961336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755214|NCT04779138|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755215|NCT06118268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755216|NCT00569582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755217|NCT02311205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755218|NCT00885092|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33755219|NCT03284034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755220|NCT05449964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755221|NCT02396745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755222|NCT00602056|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33871003|NCT05565716|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33871004|NCT01787942|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871005|NCT05723185|||COHORT||PROSPECTIVE|||||||
34067343|NCT01470144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871006|NCT00668070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067344|NCT06187649|||COHORT||RETROSPECTIVE|||||||
34067345|NCT05917483|||OTHER||PROSPECTIVE|||||||
34189539|NCT05755243|||CASE_ONLY||PROSPECTIVE|||||||
34189540|NCT04014868|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The nasal high-flow device will be out of sight of the patients and will not be switched ON. The oxygen connection at the exit of the device will be obstructed. If the patient needs supplementary oxygen during-exercise, it will be provided through the fitting located just before the nasal canula (see Arms, Experimental: Nasal high-flow).|Single-blind randomized cross-over study.|t|f|f|f
34189541|NCT01732718|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34189542|NCT01890603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34189543|NCT05066932|||CASE_CONTROL||PROSPECTIVE|||||||
34189544|NCT01512511|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34189545|NCT00433043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189546|NCT02427464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189547|NCT02578758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189548|NCT03723304|||COHORT||RETROSPECTIVE|||||||
34189549|NCT02615639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189550|NCT00089401||||TREATMENT||NONE||||||
33871007|NCT04066270|||CASE_CONTROL||PROSPECTIVE|||||||
33871008|NCT01735253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871009|NCT00862576|||CASE_CONTROL|||||||||
33755223|NCT01615874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33871010|NCT01534104|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871011|NCT04071847|||COHORT||PROSPECTIVE|||||||
34067346|NCT02858232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067347|NCT05920148|||COHORT||PROSPECTIVE|||||||
34067348|NCT02731547|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067349|NCT03668522|||CASE_ONLY||CROSS_SECTIONAL|||||||
34067350|NCT00934232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067351|NCT00290693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189551|NCT03565419|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||f|f|t|f
33871012|NCT02667210|||OTHER||RETROSPECTIVE|||||||
33871013|NCT00214448|||DEFINED_POPULATION||OTHER|||||||
33871014|NCT05467475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067352|NCT04372745|||OTHER||PROSPECTIVE|||||||
34189552|NCT05828056|||CASE_ONLY||PROSPECTIVE|||||||
34189553|NCT05770089|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34189554|NCT02436837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189555|NCT03465969|NA|SINGLE_GROUP||OTHER||NONE||||||
34189556|NCT00002771|RANDOMIZED|||TREATMENT||||||||
34189557|NCT02714322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189558|NCT03100552|||CASE_ONLY||PROSPECTIVE|||||||
33871015|NCT02230384|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34189559|NCT00038818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871016|NCT06015347|||CASE_ONLY||RETROSPECTIVE|||||||
33871017|NCT05224063|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33871018|NCT03677258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067353|NCT04032834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a three part, randomized, open-label, crossover, Phase 1 trial in adults. Parts 1 and 2 are comparative single dose, 6-treatment, 6-period crossover trials with a mouthpiece or facemask, respectively, in healthy adults. Subjects will receive 4 dose levels of VR647 Inhalation Suspension delivered by the VR647 Inhalation System (AKITA JET) (5, 10, 15 and 25 breaths, with a targeted doses of 30, 60 120 and 240 µg) and 2 dose levels of budesonide delivered by conventional jet nebulizer (PARI VIOS) (0.5 and 1 mg). Part 3 is a comparative single dose, 4-treatment, 4-period crossover trial in subjects with mild asthma. Subjects will receive doses of VR647 Inhalation Suspension (15 breaths, with a targeted dose of 120 µg) delivered by the VR647 Inhalation System (AKITA JET) with facemask or mouthpiece and budesonide (0.5 mg) delivered by conventional jet nebulizer (PARI VIOS) with facemask or mouthpiece.||||
34067354|NCT01463358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067355|NCT04457934|||COHORT||PROSPECTIVE|||||||
34067356|NCT02855177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34067357|NCT00670657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189560|NCT05633342|||COHORT||OTHER|||||||
34189561|NCT05586269|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Families will be randomized to one of two intervention sequences:~1. Meal kit intervention without delay followed by newsletter + pantry referral~2. Newsletter + pantry referral followed by meal kit intervention after a delay of 8 weeks"||||
34189562|NCT04549298|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34189563|NCT03152929|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to one of two interventional arms (paravertebral block versus pectoral nerve block).||||
34189564|NCT00991315|||CASE_ONLY||PROSPECTIVE|||||||
34189565|NCT06517004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189566|NCT00002271||||TREATMENT||||||||
34189567|NCT06318013|||CASE_CONTROL||OTHER|||||||
34189568|NCT04995367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189569|NCT00344578|||COHORT||RETROSPECTIVE|||||||
34189570|NCT05345652|||COHORT||PROSPECTIVE|||||||
34189571|NCT06254365|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34189572|NCT00012844|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34189573|NCT05313334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189574|NCT05249517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|f|t
34189575|NCT06117046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189576|NCT00006340||||TREATMENT||||||||
34189577|NCT02209532|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189578|NCT03090425|||COHORT||PROSPECTIVE|||||||
34189579|NCT00493051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34189580|NCT03882268|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||8 NGO-run urban health facilities in Dhaka will receive intensified MIYCN interventions, while another 8 NGO-run urban health facilities will serve as a comparison group. No randomization will take place. No randomization will take place. Health workers and clients at these facilities will be participants in the study.||||
34189581|NCT02139592|||COHORT||PROSPECTIVE|||||||
34189582|NCT02852616|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189583|NCT04276376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871019|NCT02997904|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34189584|NCT00416221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189585|NCT03360318|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34189586|NCT00388193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755224|NCT05872373|NA|SINGLE_GROUP||PREVENTION||NONE||This study is a community trial for better community engagement and creating awareness of the first aid management and prevention of snakebites through different IEC materials.||||
33871020|NCT01835015|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871021|NCT00763750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871022|NCT05610033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871023|NCT00102011|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33871024|NCT00090194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871025|NCT04899271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Appearance, including packaging and labelling, of the IMP (capsules, packaging) will not allow to recognize actual treatment (either ladarixin or placebo).||t|t|t|t
33871026|NCT05554484|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stage A (Sequential allocation): 6 for experimental group, 3 for control group Stage B (Randomized allocation): 9 for experimental group, 12 for control group||||
34189587|NCT02269267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189588|NCT03056508|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34189589|NCT02940314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189590|NCT00426452|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189591|NCT01612806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189592|NCT02453347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189593|NCT06520644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a randomized controlled trial (RCT) as the selected children were divided randomly by sealed envelopes into two groups of equal number 15 children for each group. The investigator prepared 30 closed envelopes, with each envelope containing a card labeled as either group A or B. Each child legal guardian was asked to draw a closed envelope that determined whether he/she was allocated to Children in group A (control group N=15, Female =8, Male=7) received specially designed physical therapy program. Children in group B (study group=15, Female =10, Male=5) received the same program given to (group A) in addition to Wii-based interactive training. The sample size for this study was calculated using the G\*power program 3.1.9 (G power program version 3.1, Heinrich-Heine-University, Düsseldorf, Germany) for one tailed test.|t|f|f|f
34189594|NCT03314922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189595|NCT03027882|||OTHER||OTHER|||||||
34189596|NCT04163172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189597|NCT05543993|||COHORT||PROSPECTIVE|||||||
34189598|NCT00528450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189599|NCT02665832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34189600|NCT01904838|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34189601|NCT01349400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Watchful waiting vs. surgical repair|f|f|f|t
34189602|NCT03502356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Control Group:~This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.~Study Group:~This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)"|t|f|f|f
34189603|NCT00499083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189604|NCT04211909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189605|NCT03456622|||COHORT||PROSPECTIVE|||||||
34189606|NCT05446818|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Intervention and placebo in same number and size of capsules|Series of Repeated Cross-over Randomized Controlled Double-blind N-of-1 Pilot Studies; each subject receives 4 times treatment and 4 times placebo|t|f|t|t
34189607|NCT00651729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189608|NCT03588884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189609|NCT01179685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189610|NCT03031080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Initial heath-care provider and participant are not masked as would be impossible to do so. Outcome assessor (a different health care provider) and investigators will be masked as to whether the patient is in the splinted or unsplinted cohort.|Randomised Controlled Trial - Block Randomisation|f|f|t|t
34189611|NCT05852613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The current study will include twenty patients with unilateral cervical radiculopathy caused by disc prolapse at the level of C5 - C6 or C6 - C7. Patients will be diagnosed on the basis of clinical (history and physical examination) and radiological examination (MRI). All subjects will be evaluated using the same procedures.~- Patients will be randomly assigned into two equal matched groups~Group (A) study group: (N=10) this group will receive high power laser therapy (HPLT) for 15 minutes in addition to selected physical therapy program (hot pack, US for 5 min, exercise for 20min) for 8 session two times weekly for 4 weeks.~Group (B) control group: (N=10) this group will receive the same selected physical therapy program only (hot pack,US for 5 min, exercise for 20 min) for 8 session.~All patients will attended the physical therapy clinic two times weekly for 4 weeks."|t|f|f|t
34189612|NCT03401619|||COHORT||OTHER|||||||
34189613|NCT01383148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189614|NCT01237769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189615|NCT02663401|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189616|NCT02403440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189617|NCT00436345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755225|NCT01102244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33755226|NCT04266379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755227|NCT04767607|||COHORT||PROSPECTIVE|||||||
33755228|NCT05633212|||COHORT||PROSPECTIVE|||||||
33755229|NCT01010594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871027|NCT04712877|||COHORT||PROSPECTIVE|||||||
33871028|NCT00833170|||COHORT||PROSPECTIVE|||||||
33871029|NCT01252745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871030|NCT01856244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871031|NCT00665899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33871032|NCT03011268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966130|NCT04217668|NA|SINGLE_GROUP||OTHER||NONE|The investigators are blinded to the case-control grouping of the participants.|Blinded case-control study||||
33966131|NCT06301633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966132|NCT05058144|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||3X3|t|f|t|f
33871033|NCT04031911|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This clinical study will be organized in 2 arms:~* Control group benefiting from standard support (AFU (Association Française d'Urologie) information sheet), but applied in a more supervised way (communication document, process studies, etc.).~* Study group benefiting from a short spa treatment (5 days) with hydroposturotherapy (HPT arm) in Vittel or Capvern: posturotherapy, lumbar percussion and controlled hyperdiuresis."||||
34189618|NCT06230237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189619|NCT00686114|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34189620|NCT01871740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189621|NCT05023668|||COHORT||PROSPECTIVE|||||||
34189622|NCT01252225|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34189623|NCT04105504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189624|NCT06433492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189625|NCT06522490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871034|NCT00938808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871035|NCT02710838|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34189626|NCT02928016|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34189627|NCT05526963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stepped-wedge cluster-randomized controlled trial||||
34189628|NCT02001636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33871036|NCT02340338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34189629|NCT02290678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189630|NCT06443567|||CASE_CONTROL||PROSPECTIVE|||||||
34189631|NCT04956913|||CASE_CONTROL||PROSPECTIVE|||||||
34189632|NCT04990804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Non-Blinded||||
34189633|NCT04892849|||COHORT||PROSPECTIVE|||||||
34189634|NCT00974480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189635|NCT01717924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189636|NCT02207426|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871037|NCT02727985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33871038|NCT03528343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871039|NCT01110616|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871040|NCT06186076|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33871041|NCT01568086|||COHORT||PROSPECTIVE|||||||
33871042|NCT01239550|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871043|NCT03625167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067358|NCT03051347|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34067359|NCT06033170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067360|NCT03574038|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Traditional 3+3 (rule-based, modified Fibonacci) dose escalation design|t|t|f|t
34067361|NCT05749497|||COHORT||PROSPECTIVE|||||||
33871044|NCT06466148|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871045|NCT05422560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871046|NCT02800889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067362|NCT04303468|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized placebo controlled double blind parallel study design|t|f|t|t
34067363|NCT03648138|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Although participants are not blinded to the study arm to which they are randomized, they are not told the true purpose of the study until after completing the study.|||||
34189637|NCT01587976|||COHORT||PROSPECTIVE|||||||
34189638|NCT01670916|||CASE_CONTROL|||||||||
34189639|NCT04143464|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34189640|NCT00973869||||PREVENTION||||||||
34189641|NCT02873702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189642|NCT03204240|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34189643|NCT02288455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189644|NCT01284335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189645|NCT06204835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189646|NCT05244135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189647|NCT04901780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The enumerator will not know about the interventions used for the side of the body|RCT|t|t|t|t
34189648|NCT01048632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189649|NCT00660634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189650|NCT02618070|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189651|NCT00311129|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189652|NCT04483388|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34189653|NCT00842322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189654|NCT00433004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34189655|NCT02028728|||OTHER||PROSPECTIVE|||||||
34189656|NCT02465827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189657|NCT03230370|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33755230|NCT01179204|||COHORT||PROSPECTIVE|||||||
33755231|NCT02275065|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33755232|NCT00833560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755233|NCT02865720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755234|NCT00000657||||TREATMENT||DOUBLE||||||
33755235|NCT05506748|||COHORT||PROSPECTIVE|||||||
33755236|NCT01499082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755237|NCT03192605|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33755238|NCT04781738|||CASE_ONLY||CROSS_SECTIONAL|||||||
33755239|NCT01032733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189658|NCT01918748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755240|NCT01186445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189659|NCT05436743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34189660|NCT04044001|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Laboratory staff, analysing and evaluating the sputum and safety blood samples of the participants will be blinded to the treatment cohort/arm.|"Stage 1: We will enrol patients sequentially in up to 8 cohorts of at least 3 patients to receive BTZ-043 in ascending doses. Patients in the first cohort will receive the lowest dose of 250mg of BTZ-043 for 14 days.~After each patient in a cohort has completed at least 7 days, a dosing recommendation for the next cohort will be made using the continual reassessment method (CRM) algorithm.~Stage 2: This will be a parallel group comparison of 4 treatment regimens. Patients will be randomized to receive either one of three doses of BTZ-043 within the therapeutic window defined in stage 1, or the control regimen of daily doses of Rifafour e-275®, adapted to body weight, for 14 days in the ratio 3:3:3:2."|f|f|f|t
34189661|NCT01125696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189662|NCT04033393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189663|NCT04072120|||COHORT||RETROSPECTIVE|||||||
34189664|NCT05844488|||CASE_ONLY||PROSPECTIVE|||||||
34189665|NCT04802577|||CASE_CONTROL||PROSPECTIVE|||||||
34189666|NCT05006001|||OTHER||RETROSPECTIVE|||||||
34189667|NCT00261261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34189668|NCT03378713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189669|NCT01094145|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34189670|NCT03005015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189671|NCT02895581|||CASE_ONLY||RETROSPECTIVE|||||||
34189672|NCT02162043|||OTHER||OTHER|||||||
34189673|NCT01989494|||COHORT||PROSPECTIVE|||||||
34189674|NCT04631211|RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose Ranging Multidose||||
34189675|NCT05915598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189676|NCT04252976|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"* 4 Treatment Conditions:~* Multiple-baseline design: 3 Baselines (7, 14, 21 days)"||||
34189677|NCT04893304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189678|NCT02840604|||COHORT||PROSPECTIVE|||||||
34189679|NCT05417763|||COHORT||PROSPECTIVE|||||||
34189680|NCT02455830|||CASE_CONTROL||PROSPECTIVE|||||||
34189681|NCT04119791|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189682|NCT05083585|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34189683|NCT04652219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189684|NCT03208296|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a dose escalation study to determine the safety and efficacy of ASN-002 in treatment of BCCs in BCNS patients.||||
34189685|NCT05408546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189686|NCT02658617|||COHORT||PROSPECTIVE|||||||
34189687|NCT00774267|||COHORT||RETROSPECTIVE|||||||
34189688|NCT05660018|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34189689|NCT06139770|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will receive the same treatment (FBT/MCT) including their parents, and by post treatment the patients will be randomised to two types of follow-up. One group of the patients will be allocated to active follow-up, receiving 3 booster sessions during the 12 months follow-up, and the second group will be followed-up as usual.||||
34189690|NCT01455636|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33871047|NCT06198803|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients who are already on KD and carnitine supplements.|All aged from 1 month till 16 years old with DRE on KD.|t|f|f|f
34189691|NCT02474069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This was a multicenter, double-blind, randomized study in 772 patients with moderate to severe chronic plaque-type psoriasis. Patients were enrolled at 89 study sites in Germany. The study was divided into 3 phases: screening, selection phase (SP), and comparative dosing phase (CDP). In the screening phase, inclusion and exclusion criteria were confirmed. Eligible patients rolled over into a selection phase (SP) where all patients received 300 mg s.c. open-label secukinumab at baseline, Weeks 1, 2, 3, 4, 8, and 12. At Week 16, PASI response was assessed as a basis for further treatment: 300 mg s.c. secukinumab treatment every 4 weeks vesus 300 mg s.c. secukinumab treatment every 2 weeks.~Patients who achieved at least clear or almost clear skin (≥ PASI 90) at Week 16 discontinued the study"|t|f|t|f
34189692|NCT01936441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189693|NCT01038999|||CASE_CONTROL||PROSPECTIVE|||||||
33755241|NCT00566579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755242|NCT00204295|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755243|NCT03386201|NA|SINGLE_GROUP||OTHER||NONE||||||
33755244|NCT06121154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755245|NCT02872987|||OTHER||PROSPECTIVE|||||||
33755246|NCT03371940|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study subjects were randomly assigned to one of the four groups: talk therapy, exercise, talk therapy + exercise, or usual care. Separate randomization lists were generated by the study statistician for use by each of the three study sites.||||
33755247|NCT01693068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189694|NCT01521793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189695|NCT05955781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A Single blinded study will be used in which data analyzer will be blind.|Prallel Group Randomized Control Trial|f|f|f|t
34189696|NCT00150904|||COHORT||PROSPECTIVE|||||||
34189697|NCT06204380|||CASE_ONLY||PROSPECTIVE|||||||
33755248|NCT05938257|NA|SINGLE_GROUP||TREATMENT||NONE||randomized controlled clinical trial||||
33755249|NCT04747730|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33755250|NCT00386503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755251|NCT04928105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755252|NCT01257841|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34189698|NCT00776516|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34189699|NCT03382444|||OTHER||PROSPECTIVE|||||||
34189700|NCT02182388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871048|NCT02969187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189701|NCT06167811|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755253|NCT01231529|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33755254|NCT04445480|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33755255|NCT06579560|||COHORT||RETROSPECTIVE|||||||
33871049|NCT00415415|||||PROSPECTIVE|||||||
33871050|NCT01136135|||COHORT||PROSPECTIVE|||||||
33871051|NCT04282395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All study participants receive a behavioral intervention that is aimed at managing their diabetes condition, either a standard diabetes self-management education intervention or the experimental resilience-based diabetes self-management education intervention. Due to the nature of behavioral interventions, we are only able to mask the participants, care providers, and dietary recall outcome assessors.|"The primary goal of the project is to test the efficacy of a resilience-based diabetes self-management education intervention (RB-DSME) using a longitudinal, randomized control group design. Thirty-two AA churches are randomly assigned to the RB-DSME experimental group or a standard diabetes self-management education (DSME) control group, run in 8 cohorts over a 5-year period. Each cohort includes 4 churches (2 intervention, 2 control) with 10 participants in each group, run concurrently. Experimental and control groups participate in 8 weekly 1.5-hour classes, followed by 8 bimonthly (every other week) 1.5-hour support group sessions, followed by 2 every other month 1.5-hour booster sessions. Data are collected at baseline and also at 6 and 12 months post study entry; the specific diabetes-related outcomes are also measured at 24 months.~During the in-person pause in research due to the pandemic, the intervention groups are held via Zoom and will continue in that format."|t|t|f|f
33871052|NCT03060044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871053|NCT04763642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966133|NCT01783925|||COHORT||PROSPECTIVE|||||||
33966134|NCT03536819|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive the treatment||||
33966135|NCT03438799|||COHORT||PROSPECTIVE|||||||
34189702|NCT06114667|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking non feasible|Participants are randomly assigned to either one of two groups of respiratory support (NIV or nasal high flow) in parallel. Randomization will be in a 1:1 ratio, and stratified by center, severity of hypercapnia and acidosis||||
34189703|NCT02931773|||CASE_CONTROL||PROSPECTIVE|||||||
34189704|NCT02671812|||COHORT||CROSS_SECTIONAL|||||||
34189705|NCT04113213|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"The study is an interventional controlled observational study based in the Primary Care setting. Control groups will be utilized through the mechanism of wait-listing the enrolment of recruitment centres into the study.~Mixed methods will be used for both data collection and analysis. Historical clinical participant data (pre-intervention - from 12months) will be collected by the PI. Data will be collected immediately after the consultation and at 3 months post-intervention."||||
34189706|NCT05523778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are kept blinded to participant group allocation. Objective clinical data are provided to independent assessors with blindness of allocation. With clear definition for each endpoints, assessors are able to make grading for complications in primary and secondary endpoints||f|f|f|t
34189707|NCT04320589|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34189708|NCT01123213|||CASE_ONLY||RETROSPECTIVE|||||||
34189709|NCT06385782|||COHORT||PROSPECTIVE|||||||
34189710|NCT03815266|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189711|NCT05817708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189712|NCT01417494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189713|NCT04562818|||OTHER||RETROSPECTIVE|||||||
34189714|NCT04423341|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34189715|NCT00384046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189716|NCT01330108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189717|NCT04096976|||COHORT||RETROSPECTIVE|||||||
34189718|NCT01213199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189719|NCT01642784|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34189720|NCT02216604|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34189721|NCT06416579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189722|NCT06085885|||COHORT||PROSPECTIVE|||||||
34189723|NCT00232726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189724|NCT01897818|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755256|NCT00300066|||CASE_ONLY||PROSPECTIVE|||||||
33755257|NCT01407081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755258|NCT00149305|||CASE_CONTROL||PROSPECTIVE|||||||
33871054|NCT06147479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcomes assessor will be blinded to group allocation where possible.|This will be a multi-center, parallel, single-blind, randomized trial of CS-ADL versus treatment as usual for people with mild-to-moderate dementia.|f|f|f|t
34067364|NCT06380972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the method of endpoint blind evaluation is adopted, that is, it's blinded for the evaluator.||f|f|f|t
34067365|NCT00544908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067366|NCT04110496|NA|SINGLE_GROUP||TREATMENT||NONE||Single Ascending Dose||||
33871055|NCT04076514|||CASE_ONLY||PROSPECTIVE|||||||
33871056|NCT05988788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33871057|NCT02305095|||COHORT||PROSPECTIVE|||||||
33871058|NCT00861120|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33871059|NCT03715699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871060|NCT00547872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871061|NCT03112889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871062|NCT02553265|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33871063|NCT03960775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator prepared the drug and participant and outcomes assessor were blind to the group allocation|Double blind randomized controlled trial|t|f|f|t
33871064|NCT01245504|||COHORT||PROSPECTIVE|||||||
33871065|NCT04188574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment allocation will not be disclosed to the site team or subject or the clinical Sponsor team.|Double-Blinded|t|f|t|f
33871066|NCT00820495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871067|NCT01590550|||CASE_ONLY||PROSPECTIVE|||||||
33871068|NCT02300948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871069|NCT02035176|||CASE_CONTROL||PROSPECTIVE|||||||
33871070|NCT00289380|||COHORT||PROSPECTIVE|||||||
33871071|NCT06491056|||COHORT||PROSPECTIVE|||||||
34189725|NCT01821560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189726|NCT01628185|||COHORT||PROSPECTIVE|||||||
34189727|NCT03807921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871072|NCT03163147|||COHORT||PROSPECTIVE|||||||
33871073|NCT03683940|NA|SINGLE_GROUP||SCREENING||NONE||||||
33871074|NCT05145998|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||5 x 5 crossover study with 4 treatments and one control||||
33871075|NCT00708123|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871076|NCT04072055|||COHORT||PROSPECTIVE|||||||
33871077|NCT01140945|||COHORT||PROSPECTIVE|||||||
33871078|NCT01035099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871079|NCT03182647|||COHORT||RETROSPECTIVE|||||||
33871080|NCT06082141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871081|NCT05044520|||COHORT||PROSPECTIVE|||||||
33871082|NCT05623930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871083|NCT00948363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871084|NCT01668732|||CASE_ONLY||CROSS_SECTIONAL|||||||
33871085|NCT01222455|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871086|NCT00434421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871087|NCT01540253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871088|NCT05256550|||OTHER||PROSPECTIVE|||||||
33871089|NCT04935099|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33871090|NCT00932204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871091|NCT04424654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871092|NCT05070975|||COHORT||RETROSPECTIVE|||||||
33871093|NCT01159028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871094|NCT05063721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871095|NCT02946242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871096|NCT02255409|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33871097|NCT02859181|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871098|NCT02672436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871099|NCT05894174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be performed by a investigator who was blinded to group allocation|Two groups with the intervention group in which the game was applied and the control group|f|f|f|t
33871100|NCT01645189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871101|NCT04266262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33871102|NCT01438489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067367|NCT00700050|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34067368|NCT06537050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Parallel Assignment|t|t|t|t
34067369|NCT01077102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067370|NCT02674126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34189728|NCT02810509|||COHORT||RETROSPECTIVE|||||||
34189729|NCT03675906|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34189730|NCT04083768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189731|NCT03924830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189732|NCT01643096|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34189733|NCT05568303|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189734|NCT03783624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|due to the nature of the treatment (Open label placebo, hypnosis)patients and care providers will be in an open label setting, however the investigators and outcomes assessors will be blinded to the conditions.||f|f|t|t
34189735|NCT03227640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755259|NCT05935917|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is an open-label, single-dose, randomized, two-period, crossover study to evaluate BE of BCV plasma PK parameters after administration of single 100 mg doses of BCV using the Form H (test tablet) and Form II (reference tablet) under fasting conditions in normal healthy adults. The study will also evaluate the safety of BCV following administration of two 100 mg single doses of BCV.~Eligible participants will be randomized in a 1:1 ratio to one of two treatment sequences, Treatment AB or Treatment BA."||||
33755260|NCT02029079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755261|NCT01237626|||COHORT||PROSPECTIVE|||||||
33755262|NCT00208143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966136|NCT06271421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|ANCHIALE is open-label study|"A prospective longitudinal study will be performed recurrent glioblastoma multiforme patients who:~1. are included for NanoTherm therapy (group A),~2. are included for standard Stupp protocol (surgery/chemo-radiotherapy) (group B)"||||
34067371|NCT03754972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Determine whether an objective metric for spinal stability will change the surgical treatment plan in a significant proportion of patients with lumbar spinal stenosis||||
34067372|NCT02273765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067373|NCT05584878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067374|NCT00057005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067375|NCT00840697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067376|NCT01651455|||COHORT||RETROSPECTIVE|||||||
34067377|NCT05843032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067378|NCT06074627|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on gender at birth, then randomized to one of the study arms|t|f|t|f
34067379|NCT02435056|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067380|NCT05491863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers who evaluated the participants were not informed of how the participants were grouped. Participants were informed that they would receive one of two different interventions without indicating which group should undergo trunk stability or conventional physiotherapy program.|". Participants were randomly assigned to the experimental group or control group after a baseline assessment with a lottery ticket and an opaque envelope containing the same number of folded papers labeled control or intervention. Each participant took a piece of paper that identified their group and gave it to the researchers without seeing what was written. Participants were not notified which group was assigned to"|t|f|f|t
34067381|NCT00611377|||COHORT||PROSPECTIVE|||||||
34067382|NCT03935334|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Blinding will be performed by an independent third party operator (nurse/pharmacist, unblinded), who will prepare undistinguishable syringes with patient's dosing and labelling.||t|t|t|t
34067383|NCT02085226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067384|NCT01358240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067385|NCT05033977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||supervised exercise group home exercise group|t|f|f|f
34189736|NCT05420259|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189737|NCT00861562|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34189738|NCT04176848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189739|NCT01646125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755263|NCT03475082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial -double blind|t|f|f|t
33755264|NCT02054767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755265|NCT00003125|RANDOMIZED|||TREATMENT||||||||
33755266|NCT03323333|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755267|NCT05207592|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33755268|NCT02433743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755269|NCT04843033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755270|NCT02075879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33966137|NCT02082912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966138|NCT06530160|||OTHER||CROSS_SECTIONAL|||||||
33966139|NCT06064981|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33966140|NCT01207401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966141|NCT02857725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33966142|NCT00467532|||COHORT||PROSPECTIVE|||||||
33966143|NCT00447018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966144|NCT02681107|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2 - Irradiation||||
34189740|NCT00853567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189741|NCT04518267|||COHORT||PROSPECTIVE|||||||
34189742|NCT05491668|||COHORT||PROSPECTIVE|||||||
34189743|NCT00936780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189744|NCT05283772|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34189745|NCT05866809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871103|NCT01986920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The three tests solutions and the placebo solution are each applied topically to 1 of 4 target lesions on the backs of each subject (determined by the randomization schedule). If needed a second treatment may be applied at Visit 5.|t|f|t|f
33871104|NCT00215800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871105|NCT04856787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871106|NCT03982836|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|All subjects involved with this study will be masked. The masking was revealed only after the analysis of the results obtained.|It is a cross-sectional study, where the volunteer should attend the study area on three different days with a minimum washout of 7 days, each day receiving a sandwich containing one of the modules studied in a randomized manner (Partially Hydrolyzed Guar Gum, Fructooligosaccharide or Maltodextrin) and will be instructed to ingest this sandwich in the maximum time of 10 minutes. The volunteers should on an 8-hour fast. Samples of blood will be collected in the fasting, 60 and 180 minutes after the injection of the sandwich for intestinal hormone dosage.|t|t|t|t
33966145|NCT01392859|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33966146|NCT02519972|NA|SINGLE_GROUP||SCREENING||NONE||||||
33966147|NCT04881422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966148|NCT01208922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966149|NCT00707915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966150|NCT04125966|||COHORT||PROSPECTIVE|||||||
33966151|NCT05102045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966152|NCT00838669|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966153|NCT01917903|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Assessments are performed by a clinician blinded to participant group (training vs. waitlist control) allocation.||f|f|t|f
33966154|NCT04036448|||COHORT||PROSPECTIVE|||||||
33966155|NCT06520436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966156|NCT02542163|||COHORT||PROSPECTIVE|||||||
33966157|NCT03473847|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Scans from 4 devices obtained on the same patient population for comparison||||
33966158|NCT01735877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966159|NCT00268554|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966160|NCT02236156|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33966161|NCT00591253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966162|NCT06146621|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966163|NCT05639569|||OTHER||PROSPECTIVE|||||||
34189746|NCT06464822|||COHORT||PROSPECTIVE|||||||
33966164|NCT05770401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34189747|NCT03667092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189748|NCT02984605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189749|NCT05500404|||COHORT||PROSPECTIVE|||||||
34189750|NCT05292157|||CASE_ONLY||OTHER|||||||
34189751|NCT01775618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189752|NCT05241093|NA|SEQUENTIAL||TREATMENT||NONE||"level 1: HYML-122 400mg bid (day1-day28) in combination with Cytarabine 100mg/m2 (day1-day7). each cycle is 28 days.~level2: HYML-122 600mg bid (day1-day28) in combination with Cytarabine 100mg/m2 (day1-day7). each cycle is 28 days."||||
34189753|NCT06367738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34189754|NCT03535298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189755|NCT04787536|||COHORT||PROSPECTIVE|||||||
34189756|NCT03327103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34189757|NCT00522899|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34189758|NCT04492332|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34189759|NCT04097964|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189760|NCT05550688|||COHORT||RETROSPECTIVE|||||||
34189761|NCT01908803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189762|NCT02791503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189763|NCT03641404|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigational compound and placebo coded by manufacturer. Codes provided in envelope will only be unsealed at the end of the study (data assessment) or in case of emergency.|Randomized, double-blinded, placebo-controlled study|t|t|t|t
34189764|NCT01146717|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34189765|NCT03111628|NA|SINGLE_GROUP||TREATMENT||NONE||Active therapy||||
34189766|NCT01765972|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34189767|NCT00538811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189768|NCT03643068|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189769|NCT00672503|||CASE_CONTROL||RETROSPECTIVE|||||||
34189770|NCT06272513|||OTHER||PROSPECTIVE|||||||
34189771|NCT03550352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189772|NCT03742752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189773|NCT00575640|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33966165|NCT06116487|||COHORT||PROSPECTIVE|||||||
34189774|NCT03266016|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Analysis Blinded|Randomized Controlled Trial|f|f|f|t
34189775|NCT06328413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Since the groups were formed on the same individual, only which side would be the PBM and which side would be the L-PRF group was determined by coin-flip method (simple randomization).|f|f|t|t
34189776|NCT05301114|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34189777|NCT00241189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189778|NCT04857632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189779|NCT03284307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189780|NCT00163813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189781|NCT05097040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189782|NCT04120519|NA|SINGLE_GROUP||TREATMENT||NONE||thalidomide combined with dexamethasone and cyclophosphamide||||
34189783|NCT00060619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34189784|NCT00793013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189785|NCT02525770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34189786|NCT04301505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189787|NCT05804617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34189788|NCT06252324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189789|NCT06441916|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34189790|NCT02191865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189791|NCT05987410|RANDOMIZED|PARALLEL||OTHER||NONE||This is a single-center, randomized controlled intervention study with three parallel arms (NW=Nordic Walking, SR=standard rehabilitation and CG=control group), open label.||||
34189792|NCT04011358|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||case-control comparison study||||
34189793|NCT06370429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The sample was divided into intervention and control groups||||
34189794|NCT00282308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189795|NCT02705066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189796|NCT05801341|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34189797|NCT01802996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189798|NCT01350401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189799|NCT00003560||||TREATMENT||NONE||||||
34189800|NCT05945836|||CASE_ONLY||CROSS_SECTIONAL|||||||
34189801|NCT03565497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189802|NCT01753648|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34189803|NCT06003348|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||In this double-blind, placebo-controlled, randomized, crossover study, each participant will undergo 4 phases of study, with the order randomized by a blocked randomization scheme. The 4 phases will be Placebo, Super CitriMax (OHCit) low dose, Super CitriMax (OHCit) standard dose, or Potassium Citrate. Randomization will be stratified based on sex, concomitant thiazide use, and concomitant alkali use.|t|t|t|t
34189804|NCT04229537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189805|NCT06146283|||CASE_ONLY||CROSS_SECTIONAL|||||||
34189806|NCT04860388|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34189807|NCT00027989||||TREATMENT||||||||
34189808|NCT06333119|||COHORT||CROSS_SECTIONAL|||||||
34189809|NCT05337839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were informed that they will be requested to do stretching, balance and strengthening exercises. None of the participants did know about the presence of another supervised/unsupervised group.|"Seventy-five person all of whom eligible and willing were allocated to supervised home exercise group (group 1) or home exercise group (group 2) using blocked randomisation method. Subjects who have not agreed to join the supervised home exercise group were not invited to join the home exercise group or vice versa."|t|t|f|t
34189810|NCT01520610|||CASE_CONTROL||PROSPECTIVE|||||||
34189811|NCT01917162|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34189812|NCT01814241|NA|SINGLE_GROUP||OTHER||NONE||||||
34189813|NCT01808105|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34189814|NCT02804152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189815|NCT01017913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189816|NCT05167643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189817|NCT02501395|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34189818|NCT03146299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189819|NCT05444491|||COHORT||PROSPECTIVE|||||||
34189820|NCT05709938|RANDOMIZED|PARALLEL||TREATMENT||NONE||34 in each Arm||||
34189821|NCT04066907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded research assistant will collect questionnaire data and perform NYHA assessment.||f|f|t|f
34189822|NCT03344770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189823|NCT02465099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189824|NCT00618228|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189825|NCT00080236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33755271|NCT03581812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33755272|NCT04800861|||COHORT||CROSS_SECTIONAL|||||||
33755273|NCT04028284|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33871107|NCT04391036|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The participants, clinicians, and assessors of the study outcomes will be blinded to Eudragit® content of the film.|Each participant will self-insert one low level Eudragit® and one high level Eudragit® formulation film. The sequence of insertion will be randomized in a 1:1 ratio.|t|t|f|t
33871108|NCT01089348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871109|NCT02681536|RANDOMIZED|PARALLEL||||NONE||||||
33871110|NCT01262768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34189826|NCT06518018|||COHORT||RETROSPECTIVE|||||||
34189827|NCT04413682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will randomly assign to the structured supervised exercise or structured home-based groups. Randomization are done using Microsoft Excel 'RAND()' function.||t|f|f|f
34189828|NCT00098813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189829|NCT02424721|||COHORT||PROSPECTIVE|||||||
33871111|NCT06503757|||CASE_ONLY||PROSPECTIVE|||||||
33871112|NCT06311045|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34189830|NCT04140513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871113|NCT00801645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871114|NCT05177653|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33871115|NCT03485248|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double- Blind||t|f|t|f
33755274|NCT04722445|||COHORT||PROSPECTIVE|||||||
33755275|NCT06057376|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33755276|NCT02322008|||CASE_ONLY||RETROSPECTIVE|||||||
33755277|NCT04342351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755278|NCT04777864|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33755279|NCT04354987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755280|NCT06140108|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33755281|NCT02883062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755282|NCT00700921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871116|NCT06264427|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants will be examined with whole genom sequencing, and diabetes treatment will be accommodated their diabetic fenotype.~'For the intervention, participants will be screened for obstructive sleep apnea (OSA). Participants with signs of OSA will be offered treatment with Continuos Positive Airway Pressure."||||
33871117|NCT06491108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755283|NCT01435811|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33755284|NCT03736603|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871118|NCT02324959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871119|NCT03599128|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33871120|NCT04347915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871121|NCT01578408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871122|NCT02374099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871123|NCT01066585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871124|NCT00213187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33755285|NCT02240433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755286|NCT02151266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33755287|NCT04731454|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33755288|NCT01278134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755289|NCT02961023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755290|NCT01610310|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33755291|NCT02382068|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755292|NCT00339612|||COHORT||PROSPECTIVE|||||||
33755293|NCT03673254|||COHORT||PROSPECTIVE|||||||
33755294|NCT00115115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755295|NCT02063152|||COHORT||PROSPECTIVE|||||||
33755296|NCT06221579|NA|SINGLE_GROUP||PREVENTION||NONE||Interviews with MCI patients to develop the intervention.||||
33755297|NCT01472705|||COHORT||PROSPECTIVE|||||||
33755298|NCT05719441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755299|NCT06580847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||12 week RCT exploring the benefits of group singing and an audiobook club (1.5 hours per week)|t|f|f|t
33755300|NCT00523159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755301|NCT05763069|||COHORT||PROSPECTIVE|||||||
33764722|NCT02798211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Study design displays results combined as two or more Arms/Groups. Patients assigned to Placebo arm in Treatment Period 1 (TP1) may have switched to Secukinumab 300mg in Treatment Period 2 (TP2). Summaries by group were performed cumulatively by actual treatment received (as follows) for every visit until Week 16 groups in Treatment Period 1: · Secukinumab 300mg (Group 1) · Secukinumab 150mg (Group 2) · Placebo (Group 3) For entire treatment period, summaries by treatment group were performed cumulatively by the actual treatment received (as follows) for every visit til Week 52, including patients who switched at Weeks 16, 28, 40. For safety variables · Any Secukinumab 150 mg (Group 2) · Any Secukinumab 300mg (Group 1) · Any Secukinumab (Group 3) Hence, participants who received Placebo in TP1 were combined with participants who received Any Secukinumab in Group 3 and Any Secukinumab 300mg in Group 1 in TP2. Safety is presented for the ENTIRE period, including TP1 and TP2"|t|f|t|f
33871125|NCT05635799|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871126|NCT04620551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871127|NCT00625989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33871128|NCT01334151|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871129|NCT02800070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871130|NCT01064674|||COHORT||PROSPECTIVE|||||||
33871131|NCT05872802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871132|NCT00258011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871133|NCT05138042|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Frozen glove was provided for dominant hand of breast cancer patients while receiving paclitaxel treat, and as the experimental group. In addition, another hand as a control group.||||
33871134|NCT02080442|||COHORT||CROSS_SECTIONAL|||||||
33871135|NCT00006507|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33871136|NCT03250260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised Controlled Trial||||
33871137|NCT06247436|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871138|NCT00851201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871139|NCT00585000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871140|NCT03829657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Open Label Extension followed by Randomized Parallel Assignment|t|t|t|f
33764723|NCT06235658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764724|NCT02508532|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation and Dose Expansion||||
33764725|NCT06624865|||COHORT||PROSPECTIVE|||||||
33871141|NCT00007839||||TREATMENT||||||||
33871142|NCT04491539|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Pilot stepped wedged cluster randomized controlled trial.||||
33871143|NCT02524470|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871144|NCT04599322|NA|SINGLE_GROUP||TREATMENT||NONE||Pretest posttest of bilateral Flexor digitorum Brevis dry needling intervention||||
33871145|NCT04111640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment, prospective, double-blind, randomized, controlled study|t|f|t|f
33871146|NCT03428763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The current trial is designed to assess whether the effectiveness of home-based disease activity monitoring via a home-based (eHealth) intervention is superior to standard clinical disease activity assessment in obtaining and maintaining a low(er) disease activity in patients with RA.|f|f|f|t
33871147|NCT04338009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871148|NCT00865397|||CASE_CONTROL||PROSPECTIVE|||||||
33871149|NCT02256514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871150|NCT00277511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966166|NCT02278731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966167|NCT00871598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966168|NCT03914144|||COHORT||PROSPECTIVE|||||||
33966169|NCT01389024|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33966170|NCT06541353|||COHORT||PROSPECTIVE|||||||
33966171|NCT01361906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966172|NCT00236782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966173|NCT00407459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966174|NCT00190320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189831|NCT02462915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966175|NCT06307600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966176|NCT05843838|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34189832|NCT05590858|||COHORT||RETROSPECTIVE|||||||
34189833|NCT03983317|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||All participants will have a one-week control period with no treatment followed by two weeks of twice daily Empower treatment.||||
34189834|NCT01525225|NA|SINGLE_GROUP||||NONE||||||
34189835|NCT00299429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189836|NCT01812278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189837|NCT06412614|||COHORT||RETROSPECTIVE|||||||
34189838|NCT06143137|||OTHER||PROSPECTIVE|||||||
34189839|NCT02212184|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34189840|NCT04630808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-masked||t|f|t|f
34189841|NCT01761240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189842|NCT00495014|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34189843|NCT05938699|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34189844|NCT00483769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189845|NCT02380469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871151|NCT05086536|||COHORT||RETROSPECTIVE|||||||
33871152|NCT03045679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|envelope randomization|prospective randomized controlled trial: RYGB (group A) vs OAGB/MGB (group B)|f|f|t|f
33871153|NCT02187172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A hybrid RCT (randomized controlled trial) crossover trial where all patients receive total of 52 weeks of active treatment following an RCT phase of 12 weeks (active treatment or placebo). Patients randomized to active treatment will receive additional 40 weeks of active treatment at end of RCT phase; patients randomized to placebo will receive 52 weeks of active treatment at end of RCT phase. Primary outcomes are assessed at end of the RCT phase (comparison of interventions in change from start of treatment) and at end of 52 weeks of active treatment (change from start of treatment).|t|t|t|t
33871154|NCT02820155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871155|NCT06489483|||COHORT||PROSPECTIVE|||||||
33966177|NCT03335709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966178|NCT02555618|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33966179|NCT03402178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966180|NCT02450760|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966181|NCT01682941|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33966182|NCT00962949|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966183|NCT00080288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966184|NCT04078139|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33966185|NCT00370669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33966186|NCT00404586|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33966187|NCT04312919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34189846|NCT01166880|||CASE_ONLY||PROSPECTIVE|||||||
34189847|NCT04130269|||COHORT||PROSPECTIVE|||||||
34189848|NCT01391052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189849|NCT04550598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34189850|NCT00093704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189851|NCT01133249|||COHORT||PROSPECTIVE|||||||
34189852|NCT02640196|RANDOMIZED|CROSSOVER||||NONE||||||
34189853|NCT04653597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189854|NCT05895019|||COHORT||PROSPECTIVE|||||||
34189855|NCT04408781|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34189856|NCT05490550|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two study arms (COAST-enhanced CBTI or insomnia care as usual) at the site level.||||
34189857|NCT02437708|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189858|NCT04910841|NA|SINGLE_GROUP||OTHER||NONE||||||
34189859|NCT04344561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189860|NCT03016000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189861|NCT06516523|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34189862|NCT00567398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189863|NCT03829306|||CASE_ONLY||PROSPECTIVE|||||||
34189864|NCT04069897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189865|NCT03629496|RANDOMIZED|PARALLEL||OTHER||NONE||Feasibility randomised controlled trial||||
34189866|NCT01585857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189867|NCT01146743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189868|NCT04846413|||COHORT||PROSPECTIVE|||||||
34189869|NCT01345357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067386|NCT06052644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To allocate participants to their respective groups, we will employ random sampling facilitated by the Epidat program. This grouping process will remain concealed, ensuring that the individuals responsible for enrolling patients into the intervention phase remain unaware of the group assignments. An independent researcher, uninvolved in the subsequent stages of assessment, intervention, data collection, or database creation, will perform this allocation in advance. The group assignments will be communicated via sealed and completely opaque envelopes. The subsequent analysis of the results will be conducted by a separate researcher who has no involvement in either the group assignment process or the intervention itself.||f|t|t|t
34067387|NCT00046540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067388|NCT05962827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067389|NCT01111682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067390|NCT04475770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067391|NCT00546312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067392|NCT02462109|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34189870|NCT03866876|||COHORT||RETROSPECTIVE|||||||
34189871|NCT01879358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189872|NCT05679895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189873|NCT04551872|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871156|NCT03425214|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33871157|NCT01843842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871158|NCT00638001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871159|NCT05344794|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33871160|NCT05160961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33871161|NCT00893633|||CASE_ONLY||PROSPECTIVE|||||||
33871162|NCT04090008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871163|NCT04178837|||COHORT||PROSPECTIVE|||||||
33871164|NCT03357731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871165|NCT02366442|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33871166|NCT03221751|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33871167|NCT04168866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871168|NCT04878770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Personnel involved assessing disease severity are blinded for the NMF biomarker result.|This is a partially-blinded randomized controlled trial that investigates if NMF-biomarker status has an effect on the effectiveness of systemic treatment with CsA in children with moderate-to-severe AD. It also investigates whether stratification on the NMF biomarker results in an improvement of efficiency in the use of systemic treatment with CsA in the treatment of moderate-to-severe AD.|f|f|f|t
33871169|NCT02694770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871170|NCT03732612|||COHORT||PROSPECTIVE|||||||
33871171|NCT02615483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871172|NCT03672279|||COHORT||PROSPECTIVE|||||||
33871173|NCT03784547|||COHORT||RETROSPECTIVE|||||||
33871174|NCT05735691|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Assessment will be done by a separate team from the trainers. The participant cannot be blinded as they will recognize the intensity of the exercise and whether the treadmill moves.|A 2x2 factorial design will be used. One factor will consist of high intensity vs moderate intensity. The second factor will be walking perturbations vs no perturbations.|f|t|t|t
33871175|NCT00234468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871176|NCT01722604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33871177|NCT06015139|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33871178|NCT05651165|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, parallel-group, randomized (1:1) clinical trial.||||
33871179|NCT04344470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871180|NCT00702364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871181|NCT01989312|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33871182|NCT03180099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871183|NCT06208787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33871184|NCT00652366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871185|NCT00927290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871186|NCT03268434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind (Investigator, Outcome Assessor)||f|f|t|t
33871187|NCT04885088|||COHORT||PROSPECTIVE|||||||
33871188|NCT02200354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894216|NCT06657469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and their parents were blinded to their group assignments within the intervention groups (AFT or EFT). However, participants and parents in the passive control group were aware of their assignment. Research assistants who conducted the assessments before, after, and at follow-up were blinded to all group assignments.|In this study, participants were randomly assigned to one of three parallel groups: Attention Functions Training (AFT), Executive Functions Training (EFT), or a passive control group. Each group received a different intervention or no intervention, with the results being compared across groups to evaluate the relative effectiveness of each training program on attention, executive functions, academic performance, and behavior in children with ADHD.|t|f|f|t
33894217|NCT00044447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894218|NCT00361530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067393|NCT00297050||||TREATMENT||||||||
34067394|NCT03185494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067395|NCT00926432|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067396|NCT02578459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067397|NCT02191046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067398|NCT03534739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants with neck pain will be randomly assigned to receive a pain inducing massage, pain free massage, or a coldpressor task.|f|f|t|f
34067399|NCT06279494|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067400|NCT03872765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189874|NCT05802121|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Both participants and investigators will be blinded to the intervention, either the apple cider vinegar pills vs. acetate.|This will be a single-institution, randomized placebo-controlled trial involving men ≥18 years of age with metastatic castration-sensitive prostate cancer. This study will require histologic confirmation of prostate adenocarcinoma and radiographic evidence of metastatic disease on conventional imaging (CT or BS). Patients will be randomized 1:1 to receive acetate supplementation or placebo. Our institution sees approximately 200 new metastatic prostate cancer patients each year, therefore, the investigators do not anticipate encountering difficulties with recruitment into this study over a period of 2 years.|t|t|t|t
34189875|NCT01233557|||CASE_ONLY||PROSPECTIVE|||||||
34189876|NCT01041755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189877|NCT00033267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189878|NCT02030236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871189|NCT04675164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|With an online tool, participants will be randomized to undergo ICSI with HOST and LAISS sperm selection arms with a 1:1 allocation ratio as per a computer-generated list, using permuted block sizes of 8, and 16, stratified for sites and fresh or cryopreserved sperm. Results of allocation will be in sealed opaque envelopes labeled with unique random codes. Clinicians, embryologists, and participants in all centers will have no access to allocation results. Upon consent, instructors will assign participants to the relevant group. Embryologists who will perform fertilization check and embryo grading will be unaware of the sperm selection method. Women will undergo only day 5 blastocysts transfer. This trial will also conceal the allocation from participants and clinical team.|"(LAISS) group: viable immotile testicular sperms will be selected before ICSI using laser assisted immotile sperm selection (study group).~(HOST) group: viable immotile testicular sperms will be selected before ICSI using hypo-osmotic swelling test (control group)."|t|t|f|t
33871190|NCT01756040|NA|SINGLE_GROUP||SCREENING||NONE||||||
33871191|NCT00440479|||CASE_ONLY|||||||||
33871192|NCT02582606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33871193|NCT01707043|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33871194|NCT01224626|||CASE_ONLY||RETROSPECTIVE|||||||
33871195|NCT02737852|NA|SINGLE_GROUP||OTHER||NONE|The new personal lubricant was used by all participants|||||
33871196|NCT02087956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871197|NCT05095870|||COHORT||RETROSPECTIVE|||||||
33871198|NCT00433914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33871199|NCT02821611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33871200|NCT01792804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871201|NCT00592371|||COHORT||PROSPECTIVE|||||||
33871202|NCT02328651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871203|NCT06248164|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33871204|NCT00891982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871205|NCT04329702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|PI and analysts blinded to allocation. Outcomes completed by participants via a mobile app and as such, outcomes assessors are blinded.|randomized control clinical trial|f|f|t|t
33871206|NCT05993936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33871207|NCT05774236|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|multicenter, randomized (1:1), open-label, 2-arm parallel group, controlled trial||||
33871208|NCT04926051|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33871209|NCT03631030|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, singe group cohort study||||
33871210|NCT03166566|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33871211|NCT04172714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871212|NCT04660461|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The masking of the drug to produce the cecum will be carried out by the Pharmacy on University Hospital Virgen de la Macarena accredited by the AEMPS. The medication for this clinical trial will be prepared by the Pharmacy on University Hospital Virgen de la Macarena in Seville ; the lansoprazole capsules and their placebo will be re-encapsulated in larger ones to maintain the cecum. The proposed doses used are those used in mild/moderate gastro-oesophageal diseases|Clinical trial, double blind, placebo controlled, randomized and crossed groups of patients in two stages, that receive a treatment with lansoprazole and placebo during 8 weeks with wash-ot period of 15 days|t|f|t|f
33871213|NCT01786603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871214|NCT05193253|||COHORT||RETROSPECTIVE|||||||
33871215|NCT04143009|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871216|NCT02695992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33871217|NCT06427200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067401|NCT05167331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34067402|NCT02774187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067403|NCT02958410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067404|NCT00006355||||TREATMENT||||||||
34067405|NCT00560703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067406|NCT04468113|||COHORT||PROSPECTIVE|||||||
34067407|NCT05717205|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067408|NCT00275015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067409|NCT01240395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067410|NCT01469598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067411|NCT01609088|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067412|NCT00966901|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
34067413|NCT03474146|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34189879|NCT02326857|||COHORT||PROSPECTIVE|||||||
34189880|NCT02010450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189881|NCT00884741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189882|NCT05591209|||COHORT||RETROSPECTIVE|||||||
33764726|NCT05239910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764727|NCT02336919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33764728|NCT02473861|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33871218|NCT04972396|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871219|NCT01977599|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33871220|NCT04880785|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IIa, open-label, single arm, multicentric study||||
33871221|NCT02833922|||COHORT||PROSPECTIVE|||||||
33871222|NCT06246565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871223|NCT05507775|NA|SINGLE_GROUP||TREATMENT||NONE||10 participants with radioiodine refractory metastatic or locally advanced non-medullary thyroid carcinoma will enroll in this study. All participants will be treated according to the same protocol.||||
33871224|NCT02904915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871225|NCT00130585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33871226|NCT02963545|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871227|NCT01833611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871228|NCT02004262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871229|NCT05074251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871230|NCT05964374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871231|NCT02072408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871232|NCT03587662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871233|NCT04781621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial. Patients are randomized into one of two groups: robotic exoskeleton gait training and usual care gait training.|f|f|f|t
33871234|NCT02336659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33871235|NCT05390112|||COHORT||PROSPECTIVE|||||||
33871236|NCT01990638|||CASE_CONTROL||PROSPECTIVE|||||||
33871237|NCT04391348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33871238|NCT00411359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871239|NCT00888550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871240|NCT05560256|NA|SINGLE_GROUP||OTHER||NONE|We asked participants to interact with the paper diary during a workshop.|||||
33871241|NCT01669161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871242|NCT01156272|||COHORT||RETROSPECTIVE|||||||
33871243|NCT01041482|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871244|NCT00870402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871245|NCT01130285|||COHORT||PROSPECTIVE|||||||
33966188|NCT00428194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966189|NCT05131997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966190|NCT01234090|||COHORT||PROSPECTIVE|||||||
33966191|NCT06537986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Stat Trek software will be adopted to randomize the patients. It is a computer-generated randomization technique. Numbering of the groups has been decided based on coin-flipping.~1. Intervention group~2. Control group"||t|f|f|t
34067414|NCT05339165|||COHORT||PROSPECTIVE|||||||
34067415|NCT00933985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067416|NCT02145637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067417|NCT03621839|||COHORT||PROSPECTIVE|||||||
34067418|NCT05433675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34067419|NCT00183508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067420|NCT00303472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067421|NCT02304354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067422|NCT02560623|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34067423|NCT03627715|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double-blind, Randomised, Placebo-Controlled, Crossover Study|t|t|t|t
34067424|NCT02400203|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34067425|NCT02387424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067426|NCT05995184|||OTHER||OTHER|||||||
34067427|NCT02530697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067428|NCT01684124|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067429|NCT04140084|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34067430|NCT04442698|||COHORT||RETROSPECTIVE|||||||
34067431|NCT00290654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067432|NCT00004306|||COHORT||PROSPECTIVE|||||||
33764729|NCT00021034||||TREATMENT||||||||
33764730|NCT00509418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764731|NCT02401373|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33764732|NCT06617104|||OTHER||CROSS_SECTIONAL|||||||
33764733|NCT01199159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764734|NCT06396754|||COHORT||PROSPECTIVE|||||||
33871246|NCT04424446|||CASE_ONLY||CROSS_SECTIONAL|||||||
33871247|NCT05997329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871248|NCT05787080|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|participant and outcomes assessor will not be in the control and experimental group.|Massage/experimental Group- control Group|t|f|f|t
33966192|NCT04688983|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33966193|NCT03185247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966194|NCT01450579|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33966195|NCT00763984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33966196|NCT04821050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067433|NCT01690299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067434|NCT02373137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067435|NCT00431899|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34067436|NCT04171856|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34189883|NCT04587609|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34189884|NCT05040503|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189885|NCT01754727|||||PROSPECTIVE|||||||
34189886|NCT03777748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189887|NCT05945719|||COHORT||PROSPECTIVE|||||||
34189888|NCT01495806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189889|NCT00652106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34189890|NCT05335421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All healthcare providers involved in the care of the participant following surgery (surgeon, physician's assistants, nurses, medical assistants, etc.) will be blinded to the group assignment of each participant.|single-blind, randomized controlled trial design|f|t|f|f
33871249|NCT00145028|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33871250|NCT05023408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871251|NCT00788372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871252|NCT02023645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33871253|NCT03545763|||CASE_CONTROL||PROSPECTIVE|||||||
33871254|NCT00432042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871255|NCT05947487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871256|NCT01289236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871257|NCT03913052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871258|NCT05843084|||COHORT||PROSPECTIVE|||||||
33871259|NCT03127384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871260|NCT03788720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Surgeons who perform the surgery will be not masked for the treatment allocation.~Evaluators (sonographers, data analyzers) will be blind for the treatment allocation."|Randomized Controlled Trial|t|f|t|t
33871261|NCT05685875|||CASE_ONLY||PROSPECTIVE|||||||
33871262|NCT03000907|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871263|NCT01422915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871264|NCT02613650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871265|NCT00002243||||TREATMENT||DOUBLE||||||
33871266|NCT03588351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871267|NCT04267341|||COHORT||PROSPECTIVE|||||||
33871268|NCT01160757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871269|NCT05442255|||COHORT||PROSPECTIVE|||||||
33871270|NCT06441942|||COHORT||PROSPECTIVE|||||||
34189891|NCT05949164|||OTHER||CROSS_SECTIONAL|||||||
34189892|NCT04606446|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The dose escalation parts and the dose finding parts of the study will be guided by a Bayesian analysis of Cycle 1 dose-limiting toxicity (DLT) data for PF-07248144 as monotherapy or in combination (Part 1B, Part 1C and Part 1D).~A traditional 2-parameter Bayesian Logistic Regression Model (BLRM) will be used to model the DLT relationship of PF-07248144 monotherapy and a more complex BLRM model specifically designed for combinations will be used to model the dose/DLT relationship of PF-07248144 given in combination with fulvestrant, with letrozole + palbociclib or with PF-07220060 + fulvestrant."||||
34189893|NCT06390306|||COHORT||PROSPECTIVE|||||||
34189894|NCT04483648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189895|NCT05261698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871271|NCT02595164|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33871272|NCT04227314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind study||t|t|t|f
33871273|NCT02913690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871274|NCT05874050|||COHORT||PROSPECTIVE|||||||
33871275|NCT03998111|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34189896|NCT02605122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A healthcare provider designated as a sub-investigator blinded to treatment allocation at the site documented clinical response at specified time points during the study.||f|f|f|t
33871276|NCT03574870|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34189897|NCT01955629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189898|NCT05083832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871277|NCT04784728|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189899|NCT05633316|RANDOMIZED|PARALLEL||OTHER||NONE||After the oocyte retrieval or thawing of donor oocytes, oocytes will be randomly assigned into equal groups: test and control. Test group oocytes will undergo ICSI via ICSIA (the investigational device), and control group oocytes will undergo manual ICSI as is routinely performed.||||
33871278|NCT02582320|||COHORT||RETROSPECTIVE|||||||
33871279|NCT01145690|||COHORT||RETROSPECTIVE|||||||
33871280|NCT01355484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871281|NCT02116556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871282|NCT05970341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Research staff responsible for biomedical data collection at the sites are blinded to the participant's allocation group. Surveys are primarily self-administered on an electronic mobile device (e.g., tablet, laptop). For participants who require help reading and/or using the device, survey data will be collected via structured interview.|Community-based randomized controlled trial stratified by self-reported diabetes diagnosis at baseline.|f|f|t|t
33871283|NCT06159920|||COHORT||RETROSPECTIVE|||||||
33871284|NCT00000225||||TREATMENT||DOUBLE||||||
33871285|NCT05100732|||CASE_CONTROL||RETROSPECTIVE|||||||
33871286|NCT00550680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871287|NCT03861936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871288|NCT03117075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871289|NCT03410433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871290|NCT04918030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871291|NCT01449461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871292|NCT05305781|||COHORT||PROSPECTIVE|||||||
33871293|NCT02908256|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33871294|NCT03015675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871295|NCT02676089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871296|NCT05024370|||OTHER||OTHER|||||||
33966197|NCT04292171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|pharmacy prepared sequentially numbered opaque bottles with identical capsules containing either placebo (vit c) or Gabapentin 600mg, block randomized|double-blind placebo-controlled randomized controlled trial|t|t|t|f
33966198|NCT05570968|||COHORT||PROSPECTIVE|||||||
33966199|NCT03549663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966200|NCT06097611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33966201|NCT02414854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966202|NCT05465330|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33966203|NCT04355871|||COHORT||RETROSPECTIVE|||||||
33966204|NCT05528289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966205|NCT04431531|RANDOMIZED|PARALLEL||OTHER||NONE||the first group is about EMDR treatment. The second group is about YOGATHERAPY||||
33966206|NCT01697995|||CASE_CONTROL|||||||||
33966207|NCT04364724|||COHORT||PROSPECTIVE|||||||
34189900|NCT05870943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and care providers will be blinded to the results of randomization. They will remain blinded until the end of the study, or if there is a medical or surgical safety concern.|1:1 allocation to experimental and control group using variable block randomization|t|t|f|t
34189901|NCT04595890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34189902|NCT06296316|||COHORT||PROSPECTIVE|||||||
34189903|NCT05882708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871297|NCT06290349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871298|NCT03478553|||FAMILY_BASED||PROSPECTIVE|||||||
33871299|NCT06385249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871300|NCT02921191|||COHORT||RETROSPECTIVE|||||||
33871301|NCT04461262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Urine samples will not state which arm the participant is in||f|f|f|t
33871302|NCT05211336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871303|NCT04346043|||CASE_ONLY||OTHER|||||||
33966208|NCT00096369|RANDOMIZED|||PREVENTION||DOUBLE||||||
33871304|NCT05449626|||CASE_ONLY||CROSS_SECTIONAL|||||||
33871305|NCT00173927|||||PROSPECTIVE|||||||
33871306|NCT02767440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871307|NCT01815047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33871308|NCT05796102|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34189904|NCT03284658|||COHORT||PROSPECTIVE|||||||
34189905|NCT00167219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189906|NCT05932212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871309|NCT03309085|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33871310|NCT04607070|||COHORT||RETROSPECTIVE|||||||
33871311|NCT05914636|||CASE_CONTROL||PROSPECTIVE|||||||
33966209|NCT05649982|RANDOMIZED|FACTORIAL||TREATMENT||NONE|The level of added guidance received will be open to the participants. The main outcome of Alcohol consumption will be self-rated.|2\*2 factorial experiment||||
33966210|NCT05779111|||COHORT||RETROSPECTIVE|||||||
33966211|NCT05419141|||COHORT||PROSPECTIVE|||||||
33966212|NCT00206622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34067437|NCT05693025|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study will use a 2x2 factorial randomized controlled trial to evaluate the combinations of two types of exercise prescription and two types of behavioral training. The exercise prescription factor evaluates the relative effectiveness of two implementation strategies for the group WWE format (Standard vs Enhanced). The behavioral training factor compares Standard content to Enhanced content focused on building habit formation. This feature will enable the simultaneous evaluation of strategies to promote compliance with exercise prescriptions, a main limitation of current physical therapy-based approaches to fall prevention.||||
34067438|NCT01889732|||COHORT||RETROSPECTIVE|||||||
34067439|NCT01943955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067440|NCT01717157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189907|NCT02453204|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34189908|NCT02703337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189909|NCT04950621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization is done by an investigator who is not involved in anesthesia and outcome assessment. Participants are unaware of the group allocation. Due to the different color of remimazolam and propofol, the care provider is not blinded to the group allocation. At the end of the surgery, anesthetics are removed before outcome assessment. And the outcome assessor is blinded to the grouping.||t|f|t|t
34189910|NCT04884178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189911|NCT03284541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Couples are randomized into an experimental condition or control (existing public health practice).|t|f|t|f
34189912|NCT03276091|NA|SINGLE_GROUP||OTHER||NONE||||||
34189913|NCT05862662|||COHORT||RETROSPECTIVE|||||||
34189914|NCT02140593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34189915|NCT00921518|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33871312|NCT05598593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067441|NCT00004176||||TREATMENT||||||||
33871313|NCT03716271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871314|NCT06470113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomly assigned to the active stimulation group and sham stimulation group, Patients，Care Provider and Outcomes Assessor did not know the patient grouping.|Patients were randomly assigned to the active stimulation group and sham stimulation group.|t|t|f|t
33871315|NCT00139776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871316|NCT03370536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871317|NCT05763797|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871318|NCT03120221|||CASE_ONLY||PROSPECTIVE|||||||
33894219|NCT02265913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067442|NCT00003513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067443|NCT05952791|||CASE_ONLY||RETROSPECTIVE|||||||
34067444|NCT06054958|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34067445|NCT05271097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189916|NCT02561468|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34189917|NCT01999517|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34189918|NCT02774915|||COHORT||PROSPECTIVE|||||||
34189919|NCT05550493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067446|NCT01471275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067447|NCT01254084|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34067448|NCT06174545|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34067449|NCT05816460|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-armed, parallel group open label randomised controlled trial. Participants will be randomised 1:1 to receive dCBT-I (intervention arm) or to sleep hygiene education (control arm).||||
33871319|NCT03834467|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be randomly assigned to receive one of two possible orders of administration. All subjects will first complete the Levenson Psychopathy Scale. Then Arm 1 presents the Moral Elevation stimulus after playing the first AlAn's Short Game v.2 (session 1), while Arm 2 presents the control stimulus (nature video). Subjects in both arms will then play AlAn's game again. After playing the game for a second time, subjects in both arms will fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.||||
34067450|NCT01309451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067451|NCT06232486|||COHORT||PROSPECTIVE|||||||
34067452|NCT02194725|||COHORT||CROSS_SECTIONAL|||||||
34067453|NCT06283407|||COHORT||CROSS_SECTIONAL|||||||
34067454|NCT05224180|||COHORT||PROSPECTIVE|||||||
34067455|NCT05190965|||COHORT||PROSPECTIVE|||||||
34189920|NCT02955043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34189921|NCT00790140|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33871320|NCT02614859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871321|NCT04654442|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33871322|NCT00281645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871323|NCT04360980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871324|NCT00951847|RANDOMIZED|CROSSOVER||||NONE||||||
33871325|NCT02888015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871326|NCT02263274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871327|NCT05283759|||COHORT||PROSPECTIVE|||||||
33871328|NCT01895907|||COHORT||PROSPECTIVE|||||||
34189922|NCT02871752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34189923|NCT00758199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34189924|NCT02695420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189925|NCT02672293|NA|SINGLE_GROUP||OTHER||NONE||||||
34189926|NCT06211959|RANDOMIZED|PARALLEL||OTHER||NONE||single-centre, randomised, superiority study||||
34189927|NCT01281332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189928|NCT05526404|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764735|NCT05453747|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Athletes included in the study; They were divided into two groups as those with ankle injury and those without. After the first measurements and evaluations were made, the athletes were given a program that included strength and stabilization exercises. After 8 weeks, the athletes were evaluated for the second time and the effects of the given exercise program on the athletes were examined.|f|f|t|f
33764736|NCT05029024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel-group, non-blinded, randomised control trial||||
33764737|NCT06302959|||CASE_CONTROL||PROSPECTIVE|||||||
33764738|NCT04704453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764739|NCT05003388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871329|NCT03761095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871330|NCT02088970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871331|NCT03592706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871332|NCT02589899|||||PROSPECTIVE|||||||
33871333|NCT04116086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||One investigator will interpret the PSMA PET-CT and another one will interpret MRI, both in a blinded and independent fashion and before the biopsy. At the end of the study, these 'blind' PSMA PET-CT and MRI reports will be compared to each other and to the actual fusion biopsy results. In the event that a high correlation is found between the diagnostic imaging results to those of the fusion biopsies, it would suggest that PSMA PET-CT could give the option to be performed instead of the need for biopsy in men who present with high levels of PSA and prompt treatment accordingly.||||
34067456|NCT03522207|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067457|NCT04990765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blinded, randomized, controlled|f|f|f|t
34067458|NCT04242485|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34067459|NCT03430492|||CASE_ONLY||PROSPECTIVE|||||||
34067460|NCT00348335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067461|NCT03795662|||COHORT||PROSPECTIVE|||||||
34067462|NCT00744406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067463|NCT03816007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded to which intervention is hypothesized to be superior, but are aware of the intervention they are assigned to. All assessments are self-report and do not require interpretation by study investigators.|Eligible participants will be randomized to either the enhanced yoga interventions or the (R/HE) comparison intervention. Assessments will occur at baseline, 12-weeks, and again 6-weeks after the intervention ends (18-weeks). The enhanced yoga intervention will consist of 1x weekly instructor-led yoga sessions lasting approximately 75 minutes, augmented by home practice of yoga for 20 minutes/day. The R/HE control intervention will be manualized and will meet weekly for 12 weeks for approximately 75 minutes per week. Short homework assignments will be included.|t|f|f|f
34067464|NCT02946021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067465|NCT06108583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067466|NCT04725123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067467|NCT04934982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067468|NCT05124483|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Single center, open-label, safety and efficacy study on the biological activity of a SP/RBD-Fc antigen booster vaccine (AKS-452X) against COVID-19.||||
34189929|NCT05860972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatments will be performed by an operator/technician who will not be blinded to the type of treatment that the subject is receiving. Objective assessment of clinical improvements such as starch-iodine tests will administered by blinded study personnel. The blinded evaluators will review photographs of the treatment areas that underwent the starch-iodine test and will be blinded as to which photos were taken at the baseline, 4-week follow-up, 12-week follow-up and 24-week follow-up visits. The HDSS, which is an objective assessment, will also be evaluated by a blinded study personnel. All subjects and study staff will be unblinded at the end of the study.|Study subjects will be consecutively screened and enrolled into the study. The study will consist of an active group that will receive 2 treatments with the InMode RF Pro System with the Morpheus8 Applicator (with the 24 pin tip) and a sham group that will receive 2 sham treatments with the same InMode RF Pro System and Morpheus8 Applicator (with a sham 24 pin tip). Treatment will be performed in a preheated controlled environment (T°≥22°C). Follow up visits will occur at 1 month, 3 months, and 6 months post treatment.|t|f|f|t
34189930|NCT00870519|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34189931|NCT06413082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double-blind with respect to the genetic analysis and open-label with an observer blind with respect to the primary endpoint.|single-center, nationwide, randomized, phase III prospective interventional outpatient study, in two arms, in parallel groups|t|f|t|f
34189932|NCT04056832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189933|NCT02752581|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33871334|NCT03518593|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871335|NCT02110368|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34189934|NCT00569517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871336|NCT01197521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189935|NCT03227419|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicentric, randomized, open-label, superiority trial.||||
34189936|NCT02174822|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34189937|NCT03279640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755302|NCT03434938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|After inclusion in the study and obtaining informed consent, participants will be randomized to intervention or control group in a concealed allocation manner. Centralized randomization will be conducted through a block randomization procedure, with random-varying block size, stratified by participating centre. Participants will be randomized after the baseline assessment, guaranteeing the blinded assessment. The 30 days and 3 months assessments will be conducted by an assessor blinded to participants' group allocation, who will ask the participants not to disclose their group allocation. Afterwards, the assessor will record whether he/she was made aware of the participant allocation.|"MI intervention will be associated to standard geriatric rehabilitation. MI will be structured in 4 sessions (within 72 hours from admission, within next 6 days after first MI session, at 1 week from the second session and pre-discharge), with the goals of reducing disability obtaining patients' collaboration, creating a shared tailored plan which would complement the individual approach established by the multidisciplinary team as part of routine geriatric rehabilitation unit, and reinforcing engagement and adherence at 3 months.~Standard rehabilitation and control includes a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments."|t|f|t|t
33755303|NCT01989026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33871337|NCT06018415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871338|NCT05642455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871339|NCT04628637|||CASE_CONTROL||PROSPECTIVE|||||||
33871340|NCT02634151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871341|NCT01345136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871342|NCT00253175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871343|NCT05558475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A pragmatic mixed-models hybrid type-2 effectiveness-implementation trial will be used. 1) the effectiveness of a bundled clinical intervention: Digital CBTi plus Virtual Coaching Support (Digital CBTi with Coaching); and 2) a scalable implementation strategy for Digital CBTi with Coaching (REP-DI). The setting will be five healthcare systems within VISN 1: VA Maine, VA Central Western Massachusetts, VA White River Junction, VA Connecticut, and the Manchester VA. Interested and appropriate participants will undergo patient-level 1:1 stratified randomization to receive either Digital CBTi with Coaching or Digital CBTi+ Contact (control). All organizations will receive implementation activities and all participants will receive usual medical care.|f|f|f|t
33871344|NCT01519804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871345|NCT01380730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871346|NCT06338904|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33871347|NCT02956954|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33871348|NCT01425827|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33871349|NCT05470751|||COHORT||PROSPECTIVE|||||||
33871350|NCT00595556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871351|NCT01476475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871352|NCT00873964|||||PROSPECTIVE|||||||
33871353|NCT05912777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871354|NCT05019898|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871355|NCT02113085|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871356|NCT06037551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871357|NCT02214966|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871358|NCT01702714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871359|NCT03028870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871360|NCT01867060|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871361|NCT05246436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33871362|NCT02284789|NA|SINGLE_GROUP||||NONE||||||
33871363|NCT00418990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871364|NCT01021956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871365|NCT00312624|||COHORT||PROSPECTIVE|||||||
33871366|NCT00234936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871367|NCT05140655|||COHORT||PROSPECTIVE|||||||
33871368|NCT04135339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34189938|NCT05658315|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A multiple baseline across participants, single case experimental design (SCED) will be used. Participants will be randomly assigned to either a 5-, 6-, or 7-week baseline phase. They will then complete training in the use of ApplTree and a 5-week intervention phase.||||
34189939|NCT04768608|NA|SEQUENTIAL||TREATMENT||NONE||Group A: 0.5×10\^6 cells / kg; Group B: 1.0×10\^6 cells / kg; Group C: 2.0×10\^6 cells / kg.||||
34189940|NCT01279785|||COHORT||PROSPECTIVE|||||||
34189941|NCT03110770|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|"Part A was open-label. For Part A, the participant, investigator and outcome assessor knew what the participant received.~Part B injections were prepared by an unblinded site pharmacist or designee who was not involved in any participant assessments and did not discuss randomizations with study clinicians. Participants, study personnel, site data entry personnel, and laboratory personnel performing immunologic assays were blinded to the treatment assignment of all product administrations. The investigational new drug (IND) Sponsor unblinded treatment assignments for Part B at the end of the study."|Part A participants (n=90) were randomized to study groups at a 1:1:1 ratio to receive a 4 mg or 8 mg dose of vaccine split between 2 or 4 injections. In Part B, participants (n=2338) were randomized to vaccine or placebo in a 1:1 ratio to receive a 4 mg (1 mL) dose of vaccine or 1 mL of placebo split between 2 injections. The vaccine dose and number of injections in Part B was determined by preliminary data from the Phase 1 trial and from Part A.|t|f|t|t
34189942|NCT05843266|||COHORT||OTHER|||||||
34189943|NCT01466582|||COHORT||PROSPECTIVE|||||||
34189944|NCT04287296|NA|SINGLE_GROUP||PREVENTION||NONE||A non-randomised feasibility trial with all participants receiving the intervention (the breakfast show) via app that is available for free to download on iOS and Android operating systems.||||
34189945|NCT04309097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871369|NCT03060135|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34189946|NCT04936087|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Longitudinal within-subject design||||
34189947|NCT03069404|||OTHER||PROSPECTIVE|||||||
34189948|NCT04464018|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled experimental study|t|f|f|f
34189949|NCT02642315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189950|NCT05063773|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled||||
34189951|NCT00610454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189952|NCT05054387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189953|NCT03727724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189954|NCT06327880|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34189955|NCT06520085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because the application relies on interaction between patient and clinical care team, both the patient and clinicians cannot be blinded. The researcher that will perform data analysis will be blinded to group allocation.|This study is a multicentre, single-blinded (assessor), two-armed, parallel-group RCT designed to evaluate the effectiveness of a an interactive mHealth application to standard care (non-interactive app) in the rehabilitation period of patients undergoing RSA.|f|f|f|t
34189956|NCT01314053|||CASE_ONLY||RETROSPECTIVE|||||||
34189957|NCT04980144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Masked examiner for all clinical assessments will not involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the two groups.|Prospective, comparative pilot study|f|t|t|t
34189958|NCT05585606|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"This is a Phase 2 randomized, placebo-controlled, double-blind study that will be conducted in 2 parts: sequential dose escalation in Part A, followed by dose expansion in Part B.~In Part A, approximately 40 evaluable subjects will be assigned 1:1:2 overall to Cohort 1, Cohort 2 or placebo.~Doses of scp776 will be tested sequentially in 2 cohorts, each in parallel with a volume-matched placebo randomized as 1:1 scp776:placebo within each cohort, to maintain the overall 1:1:2 ratio.~Subjects will receive doses of either normal saline (placebo) or scp776, approximately 24 hours apart.~* Cohort 1 dose regimen:~  - 1.9 mg/kg~* Cohort 2 dose regimen:~  * 3.8 mg/kg~The study will proceed into Part B (dose expansion), in which approximately 40 subjects will be randomized 1:1 to the chosen scp776 therapeutic dose from Part A or volume-matched placebo:~Cohort 3: Therapeutic dose scp776:placebo"|t|t|t|f
34189959|NCT00260104|||||RETROSPECTIVE|||||||
34189960|NCT00687375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189961|NCT00505401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34189962|NCT01278212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34189963|NCT04043156|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study compared with a historical cohort.||||
34189964|NCT06176911|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned at a 1:1 ratio to receive teriflunomide plus danazol or danazol. Each group requires 62 patients (considering a 10% drop-off).||||
34189965|NCT00925925|||CASE_CONTROL||PROSPECTIVE|||||||
34189966|NCT01996761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189967|NCT04599413|||COHORT||CROSS_SECTIONAL|||||||
34189968|NCT02966444|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34189969|NCT02167997|||COHORT||PROSPECTIVE|||||||
34189970|NCT06464783|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34189971|NCT00102583|RANDOMIZED|||TREATMENT||||||||
34189972|NCT04312646|||CASE_ONLY||CROSS_SECTIONAL|||||||
34189973|NCT01296672|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34189974|NCT02717806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34189975|NCT03743857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34189976|NCT02538913|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34189977|NCT02471599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189978|NCT06383312|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups; treatment group and sham group||||
33871370|NCT05666336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871371|NCT05415475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894220|NCT00673855|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33894221|NCT03191786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894222|NCT02868892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894223|NCT02715271|||COHORT||OTHER|||||||
33894224|NCT04520477|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894225|NCT05348551|||CASE_ONLY||CROSS_SECTIONAL|||||||
33894226|NCT01713062|||COHORT||PROSPECTIVE|||||||
34189979|NCT06159426|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34189980|NCT04179292|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Study||||
33755304|NCT05159622|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collector will not know if the participant received the intervention or control curriculum.|"Effect Evaluation: Using a pre- and post-evaluation design, the investigators will evaluate the effects of randomized controlled trial by comparing self-reported SSB intake (servings/day) among participants in the intervention vs. control groups. Data collection points are: baseline, follow-up (12-weeks after the start of the intervention), and a second follow-up (12 months after the start of the intervention) to explore the sustainability of behaviors and potential effect on anthropometric measures. The entire survey (lasting about 40 minutes) will be administered at home.~Primary Outcome (SSB intake) During the three data collection periods, the investigators will use the Beverage Intake Questionnaire a quantitative food frequency questionnaire that assesses habitual beverage consumption of 15 beverage categories in the past month."|f|f|f|t
33755305|NCT01835392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33755306|NCT05807802|||COHORT||PROSPECTIVE|||||||
33755307|NCT00736645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755308|NCT06220955|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33871372|NCT04898270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|"It is expected to be admitted to patients with schizophrenia who are over 20 years old and are being treated with MARTAs antipsychotics due to poor treatment efficacy or significant weight gain after use, poor blood sugar control, and other metabolic syndrome-related problems, but Patients who do not meet the medication standards for diabetes or hyperlipidemia, and are willing to accept additional use of Flupentixol after evaluation by the physician.~To compare whether the original MARTAs dose can be effectively reduced after additional use of Flupentixol for at least 12 weeks, whether the symptoms of psychosis have improved, and whether the various factors of metabolic syndrome have improved."|"It is expected to be admitted to patients with schizophrenia who are over 20 years old and are being treated with MARTAs antipsychotics due to poor treatment efficacy or significant weight gain after use, poor blood sugar control, and other metabolic syndrome-related problems, but Patients who do not meet the medication standards for diabetes or hyperlipidemia, and are willing to accept additional use of Flupentixol after evaluation by the physician.~To compare whether the original MARTAs dose can be effectively reduced after additional use of Flupentixol for at least 12 weeks, whether the symptoms of psychosis have improved, and whether the various factors of metabolic syndrome have improved."|t|f|f|f
33871373|NCT03870984|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized design. Two arms in parallel with blinded operator.|t|t|t|f
34067469|NCT02259699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067470|NCT00910546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067471|NCT04648527|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective before-and-after study||||
34067472|NCT02642783|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067473|NCT00833014|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067474|NCT05357885|||CASE_ONLY||PROSPECTIVE|||||||
34067475|NCT01043484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189981|NCT00492128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34189982|NCT00703248||||SUPPORTIVE_CARE||||||||
34189983|NCT04950478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189984|NCT06237478|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34189985|NCT04913883|||CASE_ONLY||PROSPECTIVE|||||||
34189986|NCT01211678|||COHORT||PROSPECTIVE|||||||
34189987|NCT00707941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189988|NCT05339997|||COHORT||RETROSPECTIVE|||||||
34189989|NCT04251026|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34189990|NCT00538668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34189991|NCT00479687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34189992|NCT03651024|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34189993|NCT06326333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755309|NCT05264025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755310|NCT01552954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755311|NCT05435781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients and all study personnel are blinded for study medication (hydrocortisone or placebo)|Double-blinded randomised placebo-controlled clinical trial|t|t|t|t
33755312|NCT06338657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755313|NCT04983381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755314|NCT03919136|||COHORT||PROSPECTIVE|||||||
33755315|NCT05788757|||COHORT||PROSPECTIVE|||||||
33755316|NCT06157242|NA|SEQUENTIAL||TREATMENT||NONE||Open-label, single dose design||||
33755317|NCT01530217|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33755318|NCT02276222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755319|NCT03141957|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755320|NCT04529668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|all will be masked||t|t|t|t
33755321|NCT04762862|||COHORT||RETROSPECTIVE|||||||
33755322|NCT06579027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33755323|NCT04451122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764740|NCT04665622|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A monocentric prospective, descriptive, comparative study.||||
33764741|NCT05910086|||COHORT||RETROSPECTIVE|||||||
33764742|NCT05217043|||COHORT||OTHER|||||||
34067476|NCT02744209|||OTHER||PROSPECTIVE|||||||
34067477|NCT04318275|||CASE_ONLY||PROSPECTIVE|||||||
34067478|NCT01461473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067479|NCT05964010|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Research staff collecting initial and follow-up assessment are blinded to study condition.|Standard adolescent-only approach to screening, brief intervention, and referral to treatment for adolescent substance use (SBIRT-A-Standard) versus a family-based approach (SBIRT-A-Family) in which caregivers are systematically included in screening, intervention, and referral activities.|f|f|f|t
34067480|NCT03029026|||COHORT||PROSPECTIVE|||||||
34067481|NCT05704179|||COHORT||PROSPECTIVE|||||||
34067482|NCT00597064|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34189994|NCT05721599|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34189995|NCT02653417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871374|NCT01423162|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34189996|NCT03652285|NA|SINGLE_GROUP||TREATMENT||NONE||As a proof of concept, feasibility study - First In Man Study (FIM). The study will enroll 10 patients and an additional 10% of patients to compensate for potential attrition during follow-up, resulting in a sample size of 11 patients.||||
34189997|NCT05033704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34189998|NCT02246413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34189999|NCT04082819|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34190000|NCT03714581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190001|NCT01041963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190002|NCT00580528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190003|NCT00003280|RANDOMIZED|||TREATMENT||NONE||||||
34190004|NCT01396070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190005|NCT00256672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190006|NCT01929811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190007|NCT04310371|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||participants receive an intervention throughout the protocol||||
34190008|NCT00250328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190009|NCT03783715|||COHORT||PROSPECTIVE|||||||
34190010|NCT02472067|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34190011|NCT04875143|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|From a pre-established randomization, on the first day of collection, volunteers will be allocated to group I (Placebo) or group II (Citrus aurantium L.). In the first intervention, the volunteers allocated to group I will take a capsule containing 500mg of starch, at the end of this, another capsule containing 500mg of Citrus aurantium L. will be provided for the second intervention. Conversely, the volunteers allocated to group II will ingest a capsule containing 500mg of Citrus aurantium L. in the first intervention, and at the end of the experiment, another capsule containing 500mg of starch will be provided.|One hour before the experimental procedures, the volunteers will ingest 500 mg of Citrus aurantium L. extract or starch (placebo) in capsules according to the selected protocol. Neither the researcher nor the volunteer will know if the capsule is a placebo or Citrus aurantium L. (double-blind and placebo-controlled) Before starting these protocols, a heart rate monitor (Polar RS800CX, Finland) will be placed on the volunteers to record the HR beat to beat during the entire collection. After ingestion of the capsules, the volunteers will remain in initial rest sitting for 15 minutes. During rest, HR, systolic blood pressure (SBP), diastolic blood pressure (DBP) and respiratory rate (RF) values will be recorded in the 15th minute.|t|f|t|t
34190012|NCT02334540|NA|SINGLE_GROUP||||NONE||||||
34190013|NCT03458195|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients aged 18 or more, for whom Crohn's disease diagnosis is confirmed and ileum or ileocecal Crohn's disease require surgical resection. in addition to usual practice, a bio-banking (blood samples, biopsies and surgical specimens) is collected.||||
34190014|NCT01464060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190015|NCT04484220|NA|SINGLE_GROUP||OTHER||NONE||||||
34190016|NCT02063191|||COHORT||PROSPECTIVE|||||||
34190017|NCT02909543|||COHORT||RETROSPECTIVE|||||||
34190018|NCT05214261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190019|NCT02291458|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34190020|NCT02802267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190021|NCT05857488|NA|SINGLE_GROUP||SCREENING||NONE||||||
34190022|NCT00857688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190023|NCT02306902|RANDOMIZED|CROSSOVER||||NONE||||||
34190024|NCT04941287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190025|NCT03482596|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190026|NCT01366157|||CASE_CONTROL||PROSPECTIVE|||||||
34190027|NCT00287378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190028|NCT05239780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190029|NCT06095713|||COHORT||OTHER|||||||
34190030|NCT06522542|||COHORT||RETROSPECTIVE|||||||
34190031|NCT05867498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190032|NCT00499590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871375|NCT01439321|||COHORT||RETROSPECTIVE|||||||
33871376|NCT00503646|RANDOMIZED|||||||||||
33871377|NCT04303130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871378|NCT04167046|||COHORT||PROSPECTIVE|||||||
34190033|NCT02656693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871379|NCT06185829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Single-center, prospective, randomized, open label study with two parallel groups of patients.~Maximum duration of patient participation = 3 days."||||
33871380|NCT02386436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871381|NCT02322125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871382|NCT05487898|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871383|NCT02450175|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871384|NCT04050670|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34190034|NCT04129281|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to surgery or active surveillance. Patients who refuse the randomization process will be followed according to the treatment choice according to clinical practice.||||
34190035|NCT03196362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190036|NCT02353845|||CASE_CONTROL||PROSPECTIVE|||||||
33871385|NCT00289146|||COHORT||PROSPECTIVE|||||||
33871386|NCT01617070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871387|NCT06367231|||COHORT||PROSPECTIVE|||||||
33871388|NCT00455390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33871389|NCT03184961|NA|SINGLE_GROUP||OTHER||NONE||||||
33871390|NCT00349856|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33871391|NCT00330876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871392|NCT04164836|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33871393|NCT04802525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33871394|NCT00880399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871395|NCT01924182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871396|NCT03437382|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, interventional, dose escalation study||||
33871397|NCT01399554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871398|NCT05555043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blinded study. Following randomization, the participant and treating clinician will not be blinded from the treatment. Reviewers of all data collected will be blinded to the treatment modality provided.|In this block-randomized, single-blinded, randomized control trial, 120 participants will be recruited with 40 participants allocated to the GentleWave System treatment group, 40 participants allocated to the Waterlase treatment group, and 40 participants allocated to a control group receiving commonly used passive ultrasonic irrigation treatment.|f|f|f|t
33871399|NCT00634634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190037|NCT01849731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871400|NCT02520375|RANDOMIZED|||||DOUBLE||||||
33871401|NCT05773794|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871402|NCT02701387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871403|NCT03785925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871404|NCT01573871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871405|NCT02603770|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871406|NCT04045288|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pragmatic Cluster Randomized Controlled Superiority Trial.||||
33871407|NCT05675878|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to either immediately start the intervention or to the wait-listed control group. The intervention group will be trained, and then will follow the diet for one month. The waitlisted controls will follow their normal diet for one month, and then will have the opportunity to be trained on the diet and follow the intervention for one month.||||
33871408|NCT03668886|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||intervention group: receive multimodal exercise program for half year control group: participate community activity||||
33871409|NCT03870438|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase III, Randomized Control Trial, parallel, open-label, multi-country and multi-centre trial||||
33871410|NCT03831867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871411|NCT01157754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871412|NCT05963958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Applicators were blinded to who was receiving active stimulation and who was receiving placebo. The study drug was prepared by the nurses or nursing technicians, or an otherwise uninvolved research associate so that investigators and clinicians were fully masked to allocation.||t|t|t|t
33871413|NCT03689153|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33871414|NCT05377788|||COHORT||OTHER|||||||
34190038|NCT04024813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Dose masking||t|t|t|t
34190039|NCT06120790|||CASE_ONLY||CROSS_SECTIONAL|||||||
34190040|NCT04735484|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190041|NCT02439502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190042|NCT04241055|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will not know what the conditions are or which they are in. Staff from the collaborating organization will not know which conditions participants are in, and most staff members will not know details of the study. Researchers will not know which condition participants are in if/when they interact with participants (e.g., through email).||t|t|f|t
34190043|NCT04392180|||COHORT||PROSPECTIVE|||||||
33966213|NCT04998253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A person outside the research group will randomize the patients through the simple selection of the two drugs, once their admission to the intensive care unit is requested. We will not carry out the blinding of the researchers since the use of sevoflurane requires an external computer that cannot be replicated for the control group.|"Target Population: Patients with ARDS secondary to COVID-19 on invasive mechanical ventilation.~Accessible population: Patients with ARDS secondary to COVID-19 on invasive mechanical ventilation admitted to the Temporary COVID-19 Citibanamex Unit.~7.3 Randomization Simple randomization will be carried out using an envelope containing each sedative with 2 treatment groups. Taking into account 5% losses, by the formula: Sample adjusted to losses = n (1/1 - R) n = number of subjects without losses R = expected proportion of losses A person outside the study will place the indicated therapy inside identical opaque envelopes numbered 1 to 82 and then in a closed box. We will use the envelopes consecutively with the indicated therapy. Neither the researcher nor the people related to the study or the treatment will know the therapy that each patient will receive."|f|t|f|f
33966214|NCT02276976|||CASE_CONTROL||PROSPECTIVE|||||||
33966215|NCT02413697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966216|NCT06237140|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Patients participating in the study will be blinded to which treatment group they will be included in. The evaluations of the patients participating in the study will be evaluated by a physiotherapist who is blind to group assignments. During treatment, physical therapists will be instructed not to communicate with patients about the possible goals or rationale for either treatment. A professional who is blind to the evaluation results of the groups will perform the statistical analysis.|Randomization order tracking will be done with sequentially numbered containers. Patients participating in the study will be blinded to which treatment group they will be included in.|t|t|t|t
33966217|NCT03716505|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Two parallel groups, gammaCore®-Sapphire (active treatment) and a gammaCore®-Sapphire sham (inactive) treatment.|Two parallel groups, gammaCore®-Sapphire (active treatment) and a sham (inactive) treatment.|t|t|t|t
33966218|NCT03456362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33966219|NCT03167814|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who fill our study ciriteria are asked to join in on the study and then they are randomized in to two groups, interventional and control group||||
33966220|NCT05301166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the randomized controlled study, blinding will be done in terms of statistician and reporting. The data regarding the pre-test and post-tests will be collected by another researcher who does not know who is in the experimental and control group, and the research data will be coded and transferred to the computer environment by another researcher without specifying the experimental and control groups. The analysis of the data coded in terms of groups will be done by a statistics expert. After the statistical analyzes are made and the research report is written, the assistant researcher will explain the coding for the experimental and control groups. In this way, a single blinding application was planned for the researcher.|Quasi-experimental pretest-posttest randomized controlled trial.|f|f|f|t
33966221|NCT04458779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966222|NCT05195554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blind assessment of the response variables.|The study design is a multicentric, randomized, controlled trial with two parallel groups, with blind assessment of the response variables, with a 12-months of follow-up.|f|f|f|t
33966223|NCT03263819|||CASE_CONTROL||PROSPECTIVE|||||||
33966224|NCT02359084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33966225|NCT05350254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966226|NCT04303494|||COHORT||PROSPECTIVE|||||||
33966227|NCT05531045|||COHORT||PROSPECTIVE|||||||
33966228|NCT03036995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34067483|NCT03102008|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Independent evaluators to conduct post-treatment evaluations.|Participants are randomly assigned to one of three baseline conditions (2, 3, or 4 week waitlist) and all participants are subsequently treated using the active study intervention (UP-A).|f|f|f|t
34067484|NCT01304290|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34067485|NCT05259618|||COHORT||PROSPECTIVE|||||||
34067486|NCT00695214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067487|NCT06074978|||COHORT||PROSPECTIVE|||||||
34067488|NCT00511654|RANDOMIZED|PARALLEL||TREATMENT||||||||
34067489|NCT03092791|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34067490|NCT00230984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067491|NCT01569373|||COHORT||PROSPECTIVE|||||||
34067492|NCT04721639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34067493|NCT03376126|||COHORT||PROSPECTIVE|||||||
34067494|NCT02974803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067495|NCT03246191|||OTHER||CROSS_SECTIONAL|||||||
34067496|NCT01554163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067497|NCT03170609|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34067498|NCT02870764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067499|NCT00792714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755324|NCT05085119|NA|SEQUENTIAL||OTHER||NONE|FiO2 steps will be conducted by study investigator. Participants, care providers and outcomes assessor will remain blinded of FiO2 steps.|Validation study of a non-invasive sensor-type medical device, with comparison to standard paraclinical parameters, with a stepwise modification test of FIO2, in normo- to moderate hyperoxic conditions.||||
33755325|NCT03570684|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||comparing the recent tie used patients with the previous respective data.|t|t|f|t
33755326|NCT05848648|||OTHER||PROSPECTIVE|||||||
33755327|NCT06489561|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33755328|NCT02230202|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755329|NCT03521596|||COHORT||OTHER|||||||
33755330|NCT02736695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755331|NCT01185626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33871415|NCT01592253|NA|SINGLE_GROUP||||NONE||||||
33871416|NCT00865059|RANDOMIZED|CROSSOVER||||NONE||||||
33871417|NCT04185103|||CASE_ONLY||PROSPECTIVE|||||||
33871418|NCT01947816|||COHORT||PROSPECTIVE|||||||
33871419|NCT03395548|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871420|NCT01108146|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33871421|NCT01147289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871422|NCT00817232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871423|NCT02524574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871424|NCT01845922|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871425|NCT00182195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871426|NCT04376320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871427|NCT04531696|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871428|NCT03495258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871429|NCT02464579|||COHORT||PROSPECTIVE|||||||
33871430|NCT05046470|||COHORT||PROSPECTIVE|||||||
33871431|NCT04033120|||COHORT||PROSPECTIVE|||||||
33871432|NCT03324906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871433|NCT00396201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871434|NCT00370227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871435|NCT02221453|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871436|NCT03885427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator will prepare the drug, and the out come assessor(the anesthesiologist not sharing in the study) will assess the primary, and secondary outcomes|this will be a double blind study, and utilize a convenience sample of pre-schoolers. 31 children recruited in In oral ketamine arm, and 31 children in nebulized ketamine arm|t|f|f|t
33871437|NCT05113160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data coders will be blinded to study condition.|Parallel groups with delayed treatment control group.|f|f|f|t
33871438|NCT01024010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871439|NCT05244759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067500|NCT00662987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067501|NCT01482299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755332|NCT03767166|||COHORT||PROSPECTIVE|||||||
33755333|NCT01394354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067502|NCT02187029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755334|NCT00633464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755335|NCT05542043|||COHORT||RETROSPECTIVE|||||||
33755336|NCT01621126|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755337|NCT02558582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755338|NCT04332913|||COHORT||PROSPECTIVE|||||||
33755339|NCT05582564|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33755340|NCT02525965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871440|NCT02718781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894227|NCT05147246|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755341|NCT04741308|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33755342|NCT02620917|||CASE_ONLY||CROSS_SECTIONAL|||||||
33755343|NCT03838926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755344|NCT02094508|||CASE_CONTROL||PROSPECTIVE|||||||
33755345|NCT02414048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894228|NCT05918510|||COHORT||PROSPECTIVE|||||||
33894229|NCT05666154|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33894230|NCT05779163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190044|NCT05812560|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Pregnant women will make 2 postural changes every 60 min throughout labor, preferably every 30 min.~The positions will be different depending on the phase of labor in which the pregnant woman is. Those that correspond to each period have been chosen based on the comfort of the woman. These positions are set out below, finding in annex 3 more details of them."||||
34190045|NCT02121119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190046|NCT03993652|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|schools were blinded to study arm|4-arm intervention. 3 interventions that received the same model but tailored to behavioural target. control group received no treatment|f|f|t|f
34190047|NCT03841916|||COHORT||PROSPECTIVE|||||||
34190048|NCT00452361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190049|NCT00158964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190050|NCT04528966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190051|NCT00918788|||CASE_ONLY||CROSS_SECTIONAL|||||||
34190052|NCT01798849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190053|NCT06081933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190054|NCT03901664|||COHORT||RETROSPECTIVE|||||||
34190055|NCT00155896|||DEFINED_POPULATION||OTHER|||||||
34190056|NCT02657408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190057|NCT04770441|||COHORT||PROSPECTIVE|||||||
34190058|NCT01839669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190059|NCT03444636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871441|NCT04264403|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The subjects and all study personnel taking BP measurements will be blinded to the randomization. Subjects will complete a blinding assessment prior to hospital pre-discharge and at 3 weeks, 6 months and 12 months FU.|RDN-CKD Study is a prospective, randomized (1:1, central randomization), double-blind (unblinded interventionalist and blinded study team at each center), sham controlled, multicenter feasibility study.|t|t|f|t
33871442|NCT02874456|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871443|NCT05572710|||COHORT||PROSPECTIVE|||||||
33871444|NCT02724254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871445|NCT02961621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871446|NCT01516970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871447|NCT06477874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871448|NCT02348892|||||PROSPECTIVE|||||||
33871449|NCT01853995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067503|NCT00270504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067504|NCT02298036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34067505|NCT01793350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067506|NCT06494618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor were blinded to patients who received shockwave therapy and who did not received.|Pediatric patients diagnosed with cerebral palsy who received botulinum toxin injection for lower extremity spasticity were randomized two groups. The first group will receive only conventional treatment after the injection, while the second group will receive extracorporeal shockwave therapy for injected muscles and their routine conventional therapy. The shock wave therapy is planned as 3 sessions per week, starting one week after the injection.|f|f|f|t
34067507|NCT00392756|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33755346|NCT06164925|||COHORT||PROSPECTIVE|||||||
33755347|NCT05777330|NA|SINGLE_GROUP||SCREENING||NONE||||||
33755348|NCT03948191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755349|NCT04025151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755350|NCT03640702|||COHORT||RETROSPECTIVE|||||||
33966229|NCT04262869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966230|NCT00597584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067508|NCT01048684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190060|NCT03115541|||COHORT||PROSPECTIVE|||||||
34190061|NCT04162691|||CASE_CONTROL||PROSPECTIVE|||||||
34190062|NCT04856813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||blind|t|f|f|f
34190063|NCT06178601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190064|NCT02152956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190065|NCT05161013|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Patients at high risk of developing pancreatic cancer||||
34190066|NCT03512938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190067|NCT00862082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190068|NCT03202615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966231|NCT06290700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33966232|NCT00464256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966233|NCT06529874|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Forty normal healthy children from primary governmental schools at Alexandria governate, and Forty children with sickle cell anemia from Alexandria University Students Hospitals.|An observational correlational study design.||||
33966234|NCT06129331|||COHORT||PROSPECTIVE|||||||
33966235|NCT05926219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33966236|NCT05588830|||COHORT||PROSPECTIVE|||||||
33966237|NCT04000828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966238|NCT06539819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966239|NCT00141284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871450|NCT06137924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomization will be performed using sealed envelopes stratified by the institution in blocks of six. The data manager will prepare these envelopes. The data manager will store the randomization list containing the final treatment assignments. Only the data manager will have access to the randomization list throughout the study. These sealed envelopes will be placed in the patient's chart and will not be opened until the patient is in the operating room and general anesthesia has been initiated. The patient and the independent investigator assessing and recording the patient's data will be masked to treatment arm assignments.|Three arms using different local anesthetic combinations: bupivacaine plus dexamethasone, bupivacaine plus dexamethasone and a plasma substitute and bupivacaine plus clonidine.|t|f|t|f
34190069|NCT02180776|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190070|NCT04570319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190071|NCT05768607|NA|SINGLE_GROUP||TREATMENT||NONE||Normally patients with stress urinary incontinence undergoes laparoscopic burch operation if transvaginal sling surgery was not planned. Here in our study group the assigned surgery type applied to study group is extraperitoneal ( modified) burch operation which is performed by not interfering with the abdominal cavity. By the way our study is an interventional study and it is planned to discuss both the anatomic and functional results of this technique.||||
34190072|NCT05125588|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34190073|NCT06435897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190074|NCT01619969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190075|NCT03200886|||CASE_CONTROL||RETROSPECTIVE|||||||
34190076|NCT02234895|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34190077|NCT01731418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871451|NCT02266667|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34067509|NCT04624607|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Individuals with Spinal Cord Injury will be assigned to receive robotic gait training with the Lokomat combined with paired non-invasive thoracolumbar transspinal stimulation and non-invasive brain stimulation.|t|t|f|f
34067510|NCT03190785|NA|SINGLE_GROUP||TREATMENT||NONE||Pre/post exposure comparison||||
34067511|NCT05913596|NA|SINGLE_GROUP||TREATMENT||NONE||Each patient received CD38 monoclonal antibody monotherapy||||
34067512|NCT03545633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067513|NCT00968357|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34067514|NCT01841801|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34067515|NCT01924104|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34067516|NCT00404833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190078|NCT01750749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190079|NCT03016494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34190080|NCT06098742|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34190081|NCT04205383|||COHORT||RETROSPECTIVE|||||||
34190082|NCT00003749|RANDOMIZED|||TREATMENT||||||||
34190083|NCT01942733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190084|NCT04944264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190085|NCT05276388|||COHORT||OTHER|||||||
34190086|NCT04011215|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34190087|NCT01281735|||COHORT||PROSPECTIVE|||||||
33755351|NCT04531189|||COHORT||PROSPECTIVE|||||||
33871452|NCT01231594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067517|NCT00521885|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34067518|NCT01520519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190088|NCT00612248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190089|NCT03698097|||COHORT||PROSPECTIVE|||||||
34190090|NCT00482066|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34190091|NCT01745549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190092|NCT00217178|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34190093|NCT05558202|||OTHER||PROSPECTIVE|||||||
34190094|NCT05250063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190095|NCT02703441|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190096|NCT04932408|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34190097|NCT02206971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190098|NCT06103188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190099|NCT02116205|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190100|NCT01757249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190101|NCT04030117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190102|NCT03198507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190103|NCT05349799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190104|NCT03565094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871453|NCT06482736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871454|NCT03804203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871455|NCT06185621|NA|SINGLE_GROUP||PREVENTION||NONE||Patients received oral 100mg aspirin, one tablet daily for 2 years||||
33871456|NCT01859832|||CASE_ONLY||PROSPECTIVE|||||||
33871457|NCT02871778|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33871458|NCT00914251|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33871459|NCT02331433|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33871460|NCT05564143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871461|NCT05426889|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33966240|NCT06529393|RANDOMIZED|PARALLEL||PREVENTION||NONE||"For the SHAC block, with the patient in a beach-chair position and with the arm in extension,With external rotation and abduction,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the space where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected By injecting the pericapsular space, we reach the terminal articular branches indistinctly from their origin.~For suprascapular nerve block :~Patients will be placed in lateral position until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected."||||
33966241|NCT01918709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871462|NCT03724188|||CASE_CONTROL||PROSPECTIVE|||||||
33966242|NCT04839237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190105|NCT05350397|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Groups with the same trait random, independent, random, application and separated as the control group. Intervention is applied to a group, others are not interfered with, the results are followed by are compared.~It was performed as a single-blind, pretest-posttest placebo, randomized, parallel-controlled experimental study."||||
34190106|NCT00588497|||||PROSPECTIVE|||||||
34190107|NCT02413151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190108|NCT00635297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190109|NCT01994824|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190110|NCT06140810|||COHORT||PROSPECTIVE|||||||
34190111|NCT03668301|||CASE_CONTROL||PROSPECTIVE|||||||
34190112|NCT01271296|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33871463|NCT06068270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparative 2-arm parallel single-blinded randomized controlled clinical trial|f|f|f|t
33871464|NCT05776121|NA|SEQUENTIAL||TREATMENT||NONE||||||
33871465|NCT06060964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33871466|NCT01517893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871467|NCT02854514|||COHORT||PROSPECTIVE|||||||
33871468|NCT03569579|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871469|NCT01999465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33871470|NCT00436800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871471|NCT02034942|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33871472|NCT01974492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871473|NCT01489670|||COHORT||PROSPECTIVE|||||||
33871474|NCT03377530|||COHORT||RETROSPECTIVE|||||||
33871475|NCT03338140|||COHORT||PROSPECTIVE|||||||
33966243|NCT02442752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966244|NCT01462500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966245|NCT01796860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966246|NCT02085707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33966247|NCT03227822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966248|NCT00897442|||COHORT||PROSPECTIVE|||||||
33966249|NCT04473794|||CASE_ONLY||PROSPECTIVE|||||||
34190113|NCT03328338|||CASE_ONLY||PROSPECTIVE|||||||
34190114|NCT01439828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190115|NCT00251043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190116|NCT04110288|||COHORT||PROSPECTIVE|||||||
34190117|NCT02250703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34190118|NCT02876536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755352|NCT05920980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Blinding of research personnel and patients will be maintained throughout the observation period. On the day of surgery, nurses who did not participate in the perioperative management will assign the standard configuration of the trial drugs, including intraoperative medication and the configuration of the postoperative analgesic pump, to the researchers before the induction of anesthesia. Throughout the study, the patients and researchers should not be unblinded until the statistical analysis of the study data is completed.~During the operation, an independent anesthesiologist will be responsible for the blood draw, and the postoperative blood samples will be collected together with the routine blood examination specimens. The investigators remained blinded throughout the observation period until the anesthesiologist or assessors observe significant adverse events of local general anesthesia toxicity."|Patients were randomized in a 1:1 lidocaine group, placebo control group using a computer-generated random number table. After the randomization scheme is written, use the opaque envelope, hide each group envelope into an opaque envelope, the envelope outside the code, is sealed to the researcher, when the study, if the inclusion criteria, then open the corresponding numbered envelope, and intervene according to the group scheme in the envelope.|t|f|f|t
33755353|NCT04576468|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients equally distributed into 4 groups||||
33755354|NCT05724979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755355|NCT01993225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755356|NCT04896268|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, prospective, therapeutic, comparative, parallel group, randomised controlled open-label, superiority, single-centre, national study.||||
33755357|NCT03697109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190119|NCT02037308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34190120|NCT03747666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190121|NCT04232293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190122|NCT00586417|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34190123|NCT03353506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|LFMT and LSFF capsules appear identical. Randomization is performed by lab staff not involved in any aspect of treatment administration or care|double blind randomized|t|t|t|t
33755358|NCT01501708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755359|NCT05088070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755360|NCT03839264|||COHORT||OTHER|||||||
33755361|NCT00906841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755362|NCT06102265|||COHORT||PROSPECTIVE|||||||
33755363|NCT02468401|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33966250|NCT00676988|||CASE_ONLY||CROSS_SECTIONAL|||||||
34067519|NCT03778060|NA|SINGLE_GROUP||TREATMENT||NONE|No other parties will be masked|||||
34067520|NCT01982799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34067521|NCT00343655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190124|NCT06329895|NA|SEQUENTIAL||OTHER||NONE||||||
34190125|NCT04254913|NA|SINGLE_GROUP||OTHER||NONE||||||
34190126|NCT01421355|NA|SINGLE_GROUP||||NONE||||||
34190127|NCT00186589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190128|NCT01380821|||COHORT||PROSPECTIVE|||||||
34067522|NCT00039481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067523|NCT03337048|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067524|NCT06172790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Our study was conducted as single (assessor) blind.|Two groups: training group and control group.|f|f|f|t
34190129|NCT01567709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190130|NCT04663659|||CASE_CONTROL||RETROSPECTIVE|||||||
34190131|NCT04468152|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34190132|NCT03980691|RANDOMIZED|PARALLEL||TREATMENT||NONE||The control arm includes HIV-infected patients without receiving cellar therapy combined with Chidamide whose HIV-1 has been successfully suppressed after cART.||||
34190133|NCT04418193|||COHORT||OTHER|||||||
34190134|NCT01012089|NA|SINGLE_GROUP||OTHER||NONE||||||
34190135|NCT04749056|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Non-randomized controlled evaluation study (cluster crossover design) to test a screening program to assess psychological burden and supportive care needs among cancer patients.~Patients undergoing the screening (intervention group) will be compared to patients without the screeninig (control group).~The study has three measurement points: T0 (before the intervention), T1 (3 months after the intervention) and T2 (6 months after the intervention). Care relevant outcomes which are not yet relevant at T0 (information level, use of psychosocial services, treatment satisfaction) will be assessed at T1 and T2."||||
34190136|NCT04795258|||COHORT||PROSPECTIVE|||||||
34190137|NCT01136083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190138|NCT04900727|||COHORT||CROSS_SECTIONAL|||||||
34190139|NCT02165098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190140|NCT03967613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190141|NCT06137495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190142|NCT05809297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34190143|NCT03519191|RANDOMIZED|CROSSOVER||OTHER||NONE||This socio-behavioral intervention project will randomly assign participants to the HRE-only or the HRE+Technology bootcamp arms, with a waitlist for accommodation of additionally interested youth, and a cross-over option||||
34190144|NCT04245683|||CASE_ONLY||PROSPECTIVE|||||||
34190145|NCT02852447|||COHORT||PROSPECTIVE|||||||
34190146|NCT06179381|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34190147|NCT00034580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190148|NCT00755638|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34190149|NCT03260751|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190150|NCT01227018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190151|NCT04112212|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"38 IBD patients were included in the study.~1. Dose escalation, including 3 dose groups.~2. Adding a blocking dose.~3. Patients included after \>14 weeks of therapy"||||
34190152|NCT05043142|||COHORT||RETROSPECTIVE|||||||
34190153|NCT02773576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190154|NCT01229293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190155|NCT06353555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190156|NCT02433951|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190157|NCT03398083|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34190158|NCT04077788|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190159|NCT02805829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190160|NCT00740857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190161|NCT01367990|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34190162|NCT03133416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190163|NCT05838482|||CASE_ONLY||CROSS_SECTIONAL|||||||
34190164|NCT00959985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190165|NCT00601393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755364|NCT04475549|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm study with daily dosing for up to 29 days.||||
33755365|NCT00988403|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33755366|NCT02036203|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33755367|NCT05639790|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33755368|NCT02462707||PARALLEL||TREATMENT||NONE||||||
33755369|NCT05860127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33755370|NCT01858467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755371|NCT03661138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755372|NCT03977090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755373|NCT05525273|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1, single arm, open label, multicenter.||||
33755374|NCT00268294|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755375|NCT03731689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755376|NCT01637779|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33755377|NCT01082094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755378|NCT02502201|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33755379|NCT00644397|||CASE_ONLY||PROSPECTIVE|||||||
33755380|NCT02084459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755381|NCT03235505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755382|NCT02622165|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755383|NCT01610427|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33755384|NCT00510094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755385|NCT01477853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755386|NCT05431075|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a multi-center, open-label, non-inferiority, randomized controlled trial.||||
33755387|NCT03377023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755388|NCT02934152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755389|NCT06539871|||COHORT||CROSS_SECTIONAL|||||||
33755390|NCT03021824|||COHORT||OTHER|||||||
33755391|NCT04414449|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33755392|NCT01549431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755393|NCT00491803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755394|NCT06078605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871476|NCT05467514|NA|SINGLE_GROUP||TREATMENT||NONE||Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus||||
33871477|NCT05843851|NA|SINGLE_GROUP||SCREENING||NONE||All newborns whose parents have agreed to participate in the pilot project will be tested for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.||||
33894231|NCT04711681|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study aimed to experimentally evaluate the impact of school wide Positive Behavior Interventions and Supports (SWPBIS) on early adolescent development through a randomized control trial involving 35 middle schools in the Pacific Northwest. The impact of two levels of SWPBIS training and technical assistance on school discipline practices and student behavior was evaluated.||||
34190166|NCT06291818|NA|SINGLE_GROUP||OTHER||NONE||temporary magnetic system for tarsorrhaphy (MST)||||
34190167|NCT00171262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190168|NCT04753151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The method for blinding the study will be carried out through the use of sealed envelopes and will include the blinding of the assisting anesthesiologists, patients, researchers, evaluators and those responsible for the statistical analysis.|Randomized parallel controlled trial.|t|t|t|t
34190169|NCT04354649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190170|NCT04133142|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patient randomized in Medical treatment group or Early block group~* medical treatment group will have standard pain medications and evaluation of pain relief at day 7~  * If pain reduce less or egal to VAS 4 medical treatment will continue it will be the control group~ * If no pain relief VAS more than 4 patient will be randomized to have~    * single block = Group late block single~   * or repeated blocks = Group late block repeated~* ealy block group will be randomized to have~  * single block = Group early block single~ * or repeated blocks = Group early block repeated"||||
34190171|NCT02254954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190172|NCT02230319|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34190173|NCT00476229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755395|NCT05698238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755396|NCT05071690|||CASE_CONTROL||RETROSPECTIVE|||||||
33755397|NCT04275700|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking|Each Ovary will be injected with A-PRP.||||
33755398|NCT02414269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755399|NCT06313801|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the control group, after diagnostic laparoscopy, 6 courses of PCT FLOT are carried out, examination every 3 courses with the performance of control diagnostic laparoscopy after 6 courses of PCT. In the study group, after diagnostic laparoscopy, FLOT PCT courses (1st, 3rd, 5th courses), mFLOT (2nd, 4th, 6th courses) are conducted, examination every 3 courses with dPIPAC sessions with docetaxel (excluding it from systemic administration) on the 2nd, 4th, 6th courses of PCT. In group 2, the function of control laparoscopy is performed by revision at the dPIPAC session of the 6th course of PCT. In both groups, with complete regression of foci along the peritoneum and Cy- in peritoneal lavage - dynamic observation or cytoreductive surgery, with incomplete response - dynamic observation before progression, with progression - the 2nd line of CT or optimal palliative care options.||||
33755400|NCT05448300|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|In two groups with blinding|Randomized Controlled Trial|t|f|f|f
34190174|NCT03543228|||CASE_ONLY||PROSPECTIVE|||||||
33755401|NCT06296836|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, parallel, prospective trial.||||
33755402|NCT01290406|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755403|NCT01274182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755404|NCT01391520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755405|NCT00796250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755406|NCT01764087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755407|NCT02269566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755408|NCT04243291|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33755409|NCT04040751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755410|NCT00508430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190175|NCT04495608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blinding procedure will be systematic thanks to the indistinguishable nature of the active product and placebo and their packaging.~Only the biostatistician in charge of the production of the randomization list, the Centre Anti-Poison of Lyon, and the main pharmacy (Pharmacy Department Groupement Hospitalier Centre - Edouard Herriot Hospital - Hospices Civils de Lyon (Lyon, France), responsible for packaging, labeling and dispatching of experimental drugs to the sites, will have access to a decoded list."||t|t|t|t
34190176|NCT03832049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||a randomized, open-label, single-centre, phase 3, noninferiority clinical trial of the Gardasil 9 vaccine|f|f|f|t
34190177|NCT05302336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190178|NCT01716403|||COHORT||PROSPECTIVE|||||||
34190179|NCT02945917|||COHORT||PROSPECTIVE|||||||
34190180|NCT02479308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190181|NCT00145158|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The protocol planned the inclusion of 2 cohorts, each of them including 14 patients, with metastatic cutaneous melanoma, with at least one detectable metastasis (grades AJCC 2002 III N2b to N3, grades IV M1a, M1b, and M1c without elevation of the LDH rate and without central nervous system toxicity).||||
34190182|NCT04963985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190183|NCT03767790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190184|NCT00031278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190185|NCT03446196|RANDOMIZED|PARALLEL||OTHER||NONE||Adult patients with end stage kidney disease undergoing single kidney transplantation from deceased donor. Two arms. One arm will undergo fluid replacement based on mostcare UP information, other arm will undergo fluid replacement based on clinician experience.||||
34190186|NCT05733767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190187|NCT01440192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190188|NCT01782248|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190189|NCT01986699|||||PROSPECTIVE|||||||
34190190|NCT05300763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190191|NCT01594528|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190192|NCT06245096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190193|NCT00272896|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34190194|NCT01118000|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190195|NCT03815318|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190196|NCT04279613|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple ascending dose trial with a sequential trial design. A total of 48 patients with T1D are planned to be studied in 4 cohorts of 12 patients (9 on active and 3 on placebo treatment).|t|t|t|f
34190197|NCT01783704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Study PI (Magaziner) and Co-PI (Craik) and members of the Clinical Coordinating Center (Orwig, Lewis) are blinded to treatment assignment.~Clinical site PIs and clinical site coordinators who are responsible for assigning work and/or assessing for treatment fidelity of PTs in both groups are unblinded.~Staff who perform evaluations (clinical site visits and telephone interviews) after randomization and the Independent Safety Monitor (ISM) who will be blinded to treatment assignment.~The PTs only know specific information about the intervention he/she is delivering. To minimize contamination of the interventions, each PT provides only one of the interventions and PTs do not have contact with participants in the other group or with PTs providing the intervention to the other group. As PTs are hired for the study, they are assigned at random to one of the interventions."||f|f|t|t
34190198|NCT04551534|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34190199|NCT04518579|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Group (EP) received epidural - propofol based anesthetic technique and postoperative analgesia through patient controlled epidural analgesia and Group (EH) received epidural- inhalational based anesthetic technique and postoperative analgesia through patient controlled epidural analgesia|t|f|f|f
34190200|NCT02550405|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190201|NCT03825861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755411|NCT05046054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."|TENS YW-5000 (YoungWon Medical Co, Korea)|f|f|t|f
33755412|NCT05167266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33871478|NCT03972787|RANDOMIZED|PARALLEL||OTHER||NONE||This study is a stratified, parallel, randomized waitlist control study that will be implemented at Baycrest and JSLG/UCSF, in which eligible, consented participants will be randomly allocated to the ElliQ (intervention) group or the waitlist control group following a 1:1 allocation ratio. In light of the potential benefits of ElliQ exposure, the waitlist control group will receive the ElliQ intervention after serving as a comparable contemporary control group for the ElliQ intervention group.||||
33871479|NCT02231151|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
33871480|NCT05435703|||CASE_ONLY||PROSPECTIVE|||||||
33871481|NCT00876187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871482|NCT04345289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Both convalescent plasma and placebo will be administered via a colored intravenous line with a colored sleeve disguising the fluid bag.~In order to achieve blinding of participants and treating personnel, patients randomized to active treatment will also receive placebo treatment."|"Adaptive multi-arm trial comparing convalescent plasma against control group. Interim analyses are included at 300 and 700 included participants to compare the effect and safety of the experimental treatment to control (placebo). The results of the interim analyses are used to decide if the treatments should be discontinued due to either futility or harm. The study is discontinued if either of the predefined stopping criteria are met.~Additional experimental treatments may be added as they become available. Any efficacious treatment identified in this or any other high-quality RCT may become the new SOC after consensus by national and international societies, and, thus, the control arm will change accordingly and in parallel."|t|t|t|t
33871483|NCT04268251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871484|NCT02215876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871485|NCT05750875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871486|NCT01753245|||COHORT||CROSS_SECTIONAL|||||||
33871487|NCT03633175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871488|NCT02730585|||CASE_ONLY||PROSPECTIVE|||||||
33871489|NCT03693664|||OTHER||PROSPECTIVE|||||||
33871490|NCT06296186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871491|NCT03789851|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871492|NCT02722538|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33871493|NCT05993624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871494|NCT04265885|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33871495|NCT01833442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33871496|NCT06461975|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|A dedicated clinical pharmacist placed the topical benoxinate HCL (Benox ®, Removed for facilitating the blinded review). and the artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops (Polyfresh ®, Removed for facilitating the blinded review) in identical bottles, each of them had a code that was changed every clinic and was not known to the examining ophthalmologist, the nurse in charge of swaddling the baby and putting the drops or the attending neonatologist monitoring the infant and recording the PIPP score. The clinical pharmacist would ensure that crossover was performed in the second examination of every study child.|Prospective, observational, double-blinded, cross-over|t|t|t|t
33871497|NCT00855985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871498|NCT03200366|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33871499|NCT00754676|||CASE_CONTROL||PROSPECTIVE|||||||
33871500|NCT05016115|||CASE_ONLY||PROSPECTIVE|||||||
33966251|NCT05725278|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|By nature of the intervention, the implementers or pro agents knew who the users and non-users are, and this was critical even in sampling. The data collectors did not know who were the users and non-users but a smart data collector / outcome assessor could figure out who were the users based on type of questions that were asked and answered. Investigators also knew who were users and non users as it was essential for analysis and setting up the data.|The study compares family planning, antenatal care and postnatal care related outcomes (multiple) for women who had registered on Tiko Platform between those who used the platform and those who did not access any services on the platform. The comparison is done ex-post with a single cross sectional survey in March-April 2021. Model uses fixed effects at Pro-Agent level who is a local health promoter of a small geographical area and recruits and serves women in that area so that confounders at agent and levels beyond are controlled. For women/household level confounder control, a few socio-economic and demographic variables at the woman level were included in the model, and sensitivity of the results with and without adjusting for these control variables was investigated.||||
33966252|NCT02440776|||CASE_ONLY||PROSPECTIVE|||||||
33966253|NCT04155697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34190202|NCT06159218|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Adult patients with Eosinophilic Oesophagitis will undergo a swallowed string test just prior to their scheduled endoscopy. No additional endoscopy will be requested than as per routine care. String test will be analysed for biomarkers and the microbiome to compare against disease severity and medical therapy.||||
34190203|NCT02049593|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190204|NCT02039024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190205|NCT04494997|||COHORT||CROSS_SECTIONAL|||||||
34190206|NCT02004041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190207|NCT00283335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755413|NCT06405503|||COHORT||PROSPECTIVE|||||||
33755414|NCT03851796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors and the PI will be blind to treatment group.|Randomized Control Trial|f|f|t|t
34190208|NCT00332722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190209|NCT05355883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are masked to group assignment (RLIC vs. Sham conditioning) and the assessor will be masked to group assignment of the participants.|Double blinded, randomized controlled trial|t|f|f|t
34190210|NCT01747395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755415|NCT02219984|||COHORT||PROSPECTIVE|||||||
33755416|NCT01457911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755417|NCT05895136|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients enrolled in the study will be divided in two cohorts:~Cohort 1 will receive standard medical treatment plus a combinatorial therapy of enoxaparin and human Albumin.~Cohort 2 (control) will receive only standard medical treatment."||||
33755418|NCT03953235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33755419|NCT00111670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755420|NCT06525194|NA|SINGLE_GROUP||OTHER||NONE||The program was based on the ARCS-V motivational design model, included three sessions and was hybrid.||||
33755421|NCT00466882|||OTHER||RETROSPECTIVE|||||||
33755422|NCT02200796|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33755423|NCT05303779|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33755424|NCT04118244|||CASE_ONLY||PROSPECTIVE|||||||
33755425|NCT04963127|||COHORT||OTHER|||||||
33755426|NCT01741519|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755427|NCT06393621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755428|NCT00705133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755429|NCT06400550|||CASE_ONLY||PROSPECTIVE|||||||
33755430|NCT03105674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33755431|NCT02964416|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33755432|NCT01552590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755433|NCT00243880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755434|NCT06150651|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention: PiggyBac transposon-mediated CD-19 CAR T-cells (1x10\^6 cells/kg)||||
33871501|NCT05895942|||COHORT||PROSPECTIVE|||||||
33871502|NCT05514314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871503|NCT03449498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|t|f|f|t
33871504|NCT05440162|||COHORT||PROSPECTIVE|||||||
33871505|NCT06135649|||COHORT||PROSPECTIVE|||||||
33871506|NCT05091463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871507|NCT01361243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871508|NCT03691233|||CASE_ONLY||PROSPECTIVE|||||||
33966254|NCT05383391|||CASE_ONLY||CROSS_SECTIONAL|||||||
33966255|NCT00926289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966256|NCT02217345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966257|NCT01283607|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33755435|NCT01340469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966258|NCT04098549|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33966259|NCT04825080|||COHORT||PROSPECTIVE|||||||
33755436|NCT01551732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755437|NCT01738984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33755438|NCT04051268|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigational Product and Active Comparator was masking Number of lot was masking|"Subjects 6 months - 45 years of age: Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine Subjects 46 - 60 years of age: Randomized, observer blind, lot to lot consistency, superiority to Vi polysaccharide vaccine.~Subjects 6 months - 60 years old: Randomized, observer blind, lot to lot consistency"|t|f|t|f
33755439|NCT01990846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755440|NCT02709005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755441|NCT06169514|||OTHER||OTHER|||||||
33871509|NCT02887287|||CASE_ONLY||PROSPECTIVE|||||||
33966260|NCT00162786|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33966261|NCT04647461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190211|NCT00946153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190212|NCT05522348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the outcome assessor will be blinded to the intervention, however the primary investigator will not be blinded as he performs the surgical procedure.|randomized clinical trial parallel study and control groups equal randomization positive controlled|t|f|f|t
34190213|NCT02549924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190214|NCT01048034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190215|NCT02871908|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33871510|NCT02319421|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33871511|NCT04374760|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized controlled clinical trial with a prospectively collected convenience sample of 1,460 women nonadherent with CC screening guidelines. Women aged 21-65 will be recruited from a high-volume urban ED and a low-volume rural ED, assigned to study conditions, and followed-up at 150 days to assess interval uptake of CC screening (primary outcome). Electronic Health Record (EHR) review will be conducted to assess screening results and subsequent clinical endpoints. A two-step randomization process will be used to achieve a 2 x 2 factorial design.||||
33871512|NCT05520697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention||||
33871513|NCT06310486|||COHORT||RETROSPECTIVE|||||||
33871514|NCT00800436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871515|NCT00787462|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871516|NCT03435237|||CASE_ONLY||PROSPECTIVE|||||||
33966262|NCT03275779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966263|NCT02226809|||COHORT||CROSS_SECTIONAL|||||||
33966264|NCT06155799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patient will be unaware of which group since during the surgical procedure patient eyes' will be covered.~Outcome assessor won't take part of the clinical process and will be blinded regarding which group is allocated each patient."||f|f|t|t
33966265|NCT00228540|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34190216|NCT00133068|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34190217|NCT02201264|||OTHER||PROSPECTIVE|||||||
33871517|NCT04245475|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Some of the instructions for the outcome measure will be presented to the participants via a computer.|"Within subjects crossover design, VR treatment order randomized (some participants receive Low Tech VR + High Tech VR, some participants receive High Tech VR + Low Tech VR) and some participants receive No VR in a side study to test the assumptions of our QST testing pain paradigm.~1. No Virtual Reality (no treatment control side data to test QST paradigm assumptions).~2. Low Tech/passive Virtual Reality for 1st pain stimulus+High Tech for 2nd pain stimulus~3. High Tech/interactive VR for 1st pain stimulus +Low Tech for 2nd pain stimulus."|f|f|f|t
34190218|NCT03204864|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1. Conventional CS lead placement~Phase 2. CS placement guided by RLD measurement"||||
34190219|NCT01721837|||COHORT||PROSPECTIVE|||||||
34190220|NCT00063765||||TREATMENT||||||||
34190221|NCT00243438|||COHORT||PROSPECTIVE|||||||
34190222|NCT01274689|||COHORT||RETROSPECTIVE|||||||
34190223|NCT03163797|||COHORT||PROSPECTIVE|||||||
33871518|NCT00841568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871519|NCT04906980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871520|NCT02086786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871521|NCT00863200|||CASE_ONLY||PROSPECTIVE|||||||
33871522|NCT04240444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871523|NCT00117429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871524|NCT00632099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190224|NCT05765513|NA|SINGLE_GROUP||TREATMENT||NONE|an open-label, single-arm clinical study comparing pre- and post-treatment effects|an open-label, single-arm clinical study comparing pre- and post-treatment effects||||
34190225|NCT00928993|||COHORT||PROSPECTIVE|||||||
34190226|NCT00262626|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33966266|NCT02964065|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33966267|NCT05841966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966268|NCT02827513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966269|NCT05502068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33966270|NCT03768609|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34190227|NCT01039272|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190228|NCT03801044|||COHORT||CROSS_SECTIONAL|||||||
34190229|NCT02249832|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects received 18 sessions (3 times per week for 6 weeks) of seated robotic ankle training. Upon analysis, subjects were stratified by average admission gait speed on the 10 Meter Walk Test at comfortable pace, according to clinically established gait speed performance groups: low (\<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (\>0.8m/sec) gait functioning.||||
34190230|NCT03311698|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755442|NCT04855032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755443|NCT06578975|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33871525|NCT00002284||||TREATMENT||||||||
33871526|NCT02092675|||CASE_CONTROL||PROSPECTIVE|||||||
33871527|NCT04793542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33871528|NCT01987206|RANDOMIZED|CROSSOVER||||NONE||||||
33871529|NCT02910297|||CASE_CROSSOVER||PROSPECTIVE|||||||
33966271|NCT05879445|||OTHER||OTHER|||||||
34190231|NCT00463567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190232|NCT04949321|NA|SINGLE_GROUP||OTHER||NONE|60 Meniere's Disease patients and 20 healthy volunteers (sample of 5 volunteers per MRI machine)|||||
34190233|NCT02469870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190234|NCT03241511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34190235|NCT01155518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190236|NCT00361777|||COHORT||PROSPECTIVE|||||||
34190237|NCT01818752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755444|NCT04124926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755445|NCT03105414|||COHORT||PROSPECTIVE|||||||
33755446|NCT01666951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755447|NCT05001724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871530|NCT04340713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33871531|NCT06490913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871532|NCT03658382|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871533|NCT03185364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||23 patients use placebo and 23 patients use sidenafil for 12 weeks' treatment|t|t|t|f
33871534|NCT02598375|||CASE_CONTROL||PROSPECTIVE|||||||
33871535|NCT03885310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871536|NCT01260012|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33871537|NCT03089593|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33871538|NCT02137512|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33871539|NCT06236295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067525|NCT04939844|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 2, investigator initiated, single arm, open-label, multicenter study of isatuximab in combination with bortezomib and lenalidomide (IVR) with minimal dexamethasone, in patients with newly diagnosed multiple myeloma (NDMM) in-eligible for high dose melphalan with autologous stem cell support (HD-ASCT).||||
34067526|NCT01713296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067527|NCT03601156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067528|NCT01556230|||COHORT||PROSPECTIVE|||||||
34067529|NCT03102749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755448|NCT02744833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755449|NCT05939154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755450|NCT04238364|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33755451|NCT04232514|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755452|NCT02618616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755453|NCT04648540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755454|NCT03515928|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33755455|NCT05365321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755456|NCT02469948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755457|NCT00683826|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33755458|NCT02659761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871540|NCT04043325|||CASE_ONLY||PROSPECTIVE|||||||
33871541|NCT01908023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871542|NCT02690857|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33871543|NCT05999370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871544|NCT02971579|||CASE_ONLY||PROSPECTIVE|||||||
33871545|NCT00159991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871546|NCT01182402|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067530|NCT01588405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067531|NCT01153789|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067532|NCT04864145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067533|NCT06311071|||COHORT||PROSPECTIVE|||||||
34067534|NCT00915265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871547|NCT04161820|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871548|NCT04631575|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871549|NCT01295021|||COHORT||CROSS_SECTIONAL|||||||
33871550|NCT03641872|||COHORT||PROSPECTIVE|||||||
33871551|NCT02092012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871552|NCT05749809|||CASE_ONLY||PROSPECTIVE|||||||
33871553|NCT00473343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871554|NCT06306625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871555|NCT03383484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871556|NCT01034007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067535|NCT00140036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067536|NCT03077100|||COHORT||RETROSPECTIVE|||||||
34067537|NCT06122467|NA|SINGLE_GROUP||OTHER||NONE||||||
33755459|NCT03442712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The effects of the treatment will be evaluated by another researcher (second RA) who is blinded to the type of treatment modality received by the participants.|This study is a three-arm randomised waitlist-controlled feasibility trial.|f|f|f|t
34190238|NCT02619162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755460|NCT05563194|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755461|NCT06048510|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755462|NCT02303353|||COHORT||RETROSPECTIVE|||||||
34190239|NCT01145599|||COHORT||PROSPECTIVE|||||||
33755463|NCT03897257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Five Arms:~* 3 Arms of Monotherapy : UHE-103A1 cream (Drug A low dose concentration) or UHE-103A2 cream (Drug A high concentration) or UHE-103B cream (Drug B comparator)~* 2 Arms of combination therapy: UHE-103A1B cream (Drug A low dose + Drug B), or UHE-103A2B cream (Drug A high dose + Drug B)"|t|t|t|t
34067538|NCT04121767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755464|NCT03833297|||CASE_ONLY||CROSS_SECTIONAL|||||||
34067539|NCT04460963|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067540|NCT04054674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067541|NCT00265408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067542|NCT06210815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067543|NCT00923832|||||PROSPECTIVE|||||||
34067544|NCT03275935|||COHORT||PROSPECTIVE|||||||
34190240|NCT05457439|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention will be carried out for 7 weeks, and a follow-up period of 7 weeks, in a sample of Mexican young adults (18 to 35 years) randomly divided into an experimental group (n=50) and a control group (n=50). The nutritional care process model will be used.||||
34190241|NCT05359848|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with cancer where SOC is represented by chemotherapy will be eligible for the study. After informed consent, eligible patients will be scheduled to the chemotherapy. Each cycle will be every 14, 21 or 28 days depending on the regimen. The diet intervention will commence 1 week prior to the first infusion (i.e. on Day -5 for regimens every 21-28 days, on Day-3 for regimens every 14 days) and will continue until the end of cycle 4 or 6 depending on the regimen in the neoadjuvant or adjuvant setting. For metastatic disease the dietary intervention will last until cycle 6 and not beyond||||
34190242|NCT00850421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190243|NCT06233513|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34190244|NCT03563118|||OTHER||PROSPECTIVE|||||||
34190245|NCT03773796|NA|SINGLE_GROUP||TREATMENT||NONE|None, open-label|open-label||||
34190246|NCT00951977|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190247|NCT01714245|||CASE_ONLY||PROSPECTIVE|||||||
34190248|NCT02448641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190249|NCT05983315|||COHORT||PROSPECTIVE|||||||
34190250|NCT01971086|||||PROSPECTIVE|||||||
34190251|NCT04159311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34190252|NCT01509053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190253|NCT00441064|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755465|NCT00388310|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755466|NCT02510430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755467|NCT02526654|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33755468|NCT00677833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755469|NCT04492527|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871557|NCT00873171|||CASE_CONTROL||PROSPECTIVE|||||||
33871558|NCT06116500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the study, data collection and measurement will be conducted with the investigator. However, it won't be possible to blind the operator (investigator) due to the appliance design/shape difference, making the study single-blinded. Each patient will not know which type of twin block appliance will be used for them.|The patients will be treated with twin block appliance|t|f|f|f
33871559|NCT00182156|||COHORT||CROSS_SECTIONAL|||||||
33871560|NCT00019188||||TREATMENT||||||||
33871561|NCT01317862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871562|NCT04518462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871563|NCT02373059|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871564|NCT02841397|NA|SINGLE_GROUP||OTHER||NONE||||||
33871565|NCT02613962|NA|SINGLE_GROUP||SCREENING||NONE||||||
33871566|NCT00402649|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33871567|NCT02839265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871568|NCT02076997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871569|NCT01737385|||CASE_ONLY||PROSPECTIVE|||||||
33871570|NCT03947489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871571|NCT05767177|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871572|NCT03027362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871573|NCT00393887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871574|NCT01991990|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34190254|NCT03719196|RANDOMIZED|PARALLEL||OTHER||SINGLE|The primary trial outcome was the between-group difference in change in income (self-reported in Bangladeshi taka over the past 4 weeks) between baseline and follow-up surveys. Investigators collecting this information were unaware of participant group assignment.Participant masking with sham glasses was not considered ethical.||f|f|t|f
34190255|NCT01621347|||CASE_ONLY||RETROSPECTIVE|||||||
34190256|NCT00333762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190257|NCT02672527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190258|NCT04162860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190259|NCT02103673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190260|NCT00646269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190261|NCT04917341|||CASE_ONLY||RETROSPECTIVE|||||||
34190262|NCT03144934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190263|NCT05231096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual who evaluates the outcomes was masked.|105 patients with chronic periodontitis were selected in this single-blinded Randomized control clinical trial. At recruitment non-surgical therapy i-e scaling and root debridement was performed. At baseline all clinical parameters, gingival index, plaque index, bleeding on probing and pocket depths were recorded. All the participants were then randomly divided in three groups, Group A: SRD \& Gingival massage with Aloe-vera gel, Group B: SRD \& Gingival massage with Sidr honey and Group C SRD only. On 30th day of trial all the patients were re-examined for all the clinical parameters.|f|f|f|t
34190264|NCT00097604|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190265|NCT02274909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190266|NCT03710083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190267|NCT01516086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190268|NCT04007757|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34190269|NCT05131724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190270|NCT04346719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190271|NCT04001959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single|A randomized, controlled study in which the variables were evaluated 1 week, 15 days, 1 and 2 months after the intervention. For the allocation of participants, a Randomization ratio of 1: 1 was performed.|t|t|f|f
34190272|NCT01209702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190273|NCT00846963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190274|NCT03204734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871575|NCT00210093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190275|NCT01696604|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34190276|NCT02064582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190277|NCT00876551|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190278|NCT03205449|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This study will use a randomised controlled trial design to test the effects of the Masayang Pamilya programme in comparison to participants allocated to a treatment as usual control group (N = 120 parents of children ages 2 to 6 years; 1:1 intervention to control group ratio).|f|f|t|t
34190279|NCT03231878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190280|NCT00003021||||TREATMENT||||||||
34190281|NCT06531928|||CASE_CONTROL||PROSPECTIVE|||||||
34190282|NCT00796419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190283|NCT01441362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190284|NCT05130515|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: Niraparib Niraparib 200mg po QD day1\~21 Drug: Anlotinib Anlotinib 10mg po QD day1\~14.||||
34190285|NCT02504216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34190286|NCT03515668|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Double-blinding of participant and investigator, with independent investigator in charge of placebo and drug.|Healthy males 18-30 years of age|f|f|t|f
34190287|NCT00160472|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190288|NCT03351283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34190289|NCT02125019|||COHORT||PROSPECTIVE|||||||
34190290|NCT03296319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34190291|NCT06181344|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This study will use a stepped wedge cluster randomized controlled trial design in which the intervention is introduced stepwise across study units. After obtaining the consent form from the five clinical care units, they will be randomized to one of the two roll-out schedules with a 4-month duration each. All the study units will start the trial in a control condition (i.e., no implementation strategies used), then sequentially cross over from the control condition to the intervention condition, until all sites are receiving the intervention.||||
34190292|NCT00756262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190293|NCT00661427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190294|NCT03398499|NA|SINGLE_GROUP||TREATMENT||NONE||Rehabilitation of patients after orthognathic procedures was performed, in which orthognathic surgery was performed - Bilateral Sagittal Split Osteotomy (BSSO). In the study it was used treatments a combination physicotherapies that combines two therapeutic physical factors - the electromagnetic field and the electromagnetic wave of red and infrared light in the form of led light therapy generated by the Viofor JPS device (Med\&Life, Poland). Treatments with a slow-changing electromagnetic field were carried out using ring and elliptic applicators. Treatments with magnetoledotherapy using elliptical magnetic applicators combined with light. For physiotherapeutic purposes, led lighttherapy was used, which is a combined use of Extremely Low Frequency Magnetic Field (ELF-MF) and light coming from high energy LEDs (Light Emitting Diode) in the range of red (R) and infrared (IR). Therapies were used once a day, doing three described applications for a period of 10 days.||||
34190295|NCT04521725|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34190296|NCT01712399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190297|NCT05834829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Sham application during a single randomized session (1 of 3 sessions).|three arm model, participants receive each intervention/sham (dPI, ACC, or Sham) one per study visit in a randomized order.|t|f|t|t
34190298|NCT04222010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190299|NCT05966688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||It is anticipated that participants will enroll one after another in each arm of this study.||||
34190300|NCT04458090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34190301|NCT03353519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The IPCAS Trial is a two-arm cluster randomised controlled trial with general practices as the unit of randomisation.|t|f|f|f
34190302|NCT03306316|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34190303|NCT00860548|||COHORT||PROSPECTIVE|||||||
34190304|NCT02303652|||COHORT||PROSPECTIVE|||||||
34190305|NCT03703193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34190306|NCT05584319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190307|NCT03383016|||COHORT||PROSPECTIVE|||||||
34190308|NCT01914341|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34190309|NCT00003518||||TREATMENT||||||||
34190310|NCT03091348|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190311|NCT06478394|||COHORT||PROSPECTIVE|||||||
34190312|NCT04121585|||COHORT||PROSPECTIVE|||||||
34190313|NCT00208871|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190314|NCT05681143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190315|NCT05094388|||COHORT||PROSPECTIVE|||||||
34190316|NCT04927624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190317|NCT03648567|||CASE_ONLY||RETROSPECTIVE|||||||
34190318|NCT03804437|||OTHER||CROSS_SECTIONAL|||||||
34190319|NCT00005683|||||RETROSPECTIVE|||||||
34190320|NCT05123794|||COHORT||RETROSPECTIVE|||||||
34190321|NCT05634668|||OTHER||CROSS_SECTIONAL|||||||
34190322|NCT05448885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190323|NCT01034748|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34190324|NCT05884827|||CASE_ONLY||PROSPECTIVE|||||||
34190325|NCT00929396|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190326|NCT01468116|||CASE_CONTROL||PROSPECTIVE|||||||
34190327|NCT05250388|||COHORT||PROSPECTIVE|||||||
34190328|NCT04522830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190329|NCT01858935|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34190330|NCT03382340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190331|NCT02197078|||COHORT||RETROSPECTIVE|||||||
34190332|NCT03616301|RANDOMIZED|CROSSOVER||OTHER||SINGLE|This study is an open-label study; the subjects and the investigator will not be blinded towards the identity of the study products. However, analysts will be blinded towards identity of the study products administered.||f|f|f|t
34190333|NCT05533580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34190334|NCT00486291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190335|NCT05747885|||COHORT||PROSPECTIVE|||||||
34190336|NCT01522937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190337|NCT02832362|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34190338|NCT05344378|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will use a stepped wedge cluster randomized hybrid Type I effectiveness-implementation design to test the effects of technology-enhanced FN on service and clinical outcomes while gathering information on FN implementation (feasibility and acceptability). This design will also facilitate the early identification of technology enhancements that may require redesign to allow for testing of the redesigned enhancements during the subsequent step.||||
34190339|NCT01315561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190340|NCT00002845||||TREATMENT||||||||
34190341|NCT02983201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190342|NCT05541796|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-comparative, interventional, phase 4 study||||
34190343|NCT05014867|||COHORT||PROSPECTIVE|||||||
34067545|NCT02455973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067546|NCT00999700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067547|NCT01954199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067548|NCT06033677|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Patients scheduled for elective surgery and requiring invasive arterial monitoring were divided into two groups.~Group 1: The patients who were to undergo forearm radial artery catheterization were positioned with wrist dorsifection up to 30° and forearm supination. Intervention was planned after ultrasonographic measurements were taken.~Group 2: The patients who will undergo distal radial artery catheterization were placed in the pronation position of the forearm with the anatomical snuffbox facing upwards. Intervention was planned after ultrasonographic measurements were taken."|t|f|f|f
34067549|NCT05200845|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34190344|NCT01608932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067550|NCT00823758|||CASE_ONLY||PROSPECTIVE|||||||
34067551|NCT02050750|||COHORT||PROSPECTIVE|||||||
34067552|NCT03832673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067553|NCT05284903|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34190345|NCT00079027|RANDOMIZED|||TREATMENT||||||||
34190346|NCT00178113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190347|NCT04040933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34190348|NCT00713167|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190349|NCT05349565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34190350|NCT06112106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who performs the statistical analysis will be masked to group assignment.||f|f|t|f
34190351|NCT05792241|||OTHER||CROSS_SECTIONAL|||||||
34190352|NCT00955201|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33871576|NCT02001961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190353|NCT00022022|RANDOMIZED|||TREATMENT||||||||
34190354|NCT04947982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34190355|NCT01721252|||COHORT||PROSPECTIVE|||||||
34067554|NCT00596063|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067555|NCT03052348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be given creams (containing either the intervention or control regimens - both white in color) in unlabelled opaque containers. Participants, investigators and the outcomes assessor evaluating the outcome of interest (SCORAD) will be blinded to the treatment allocations.|Fusidic acid, polyethylene glycol hexadecyl ether \& Betamethasone valerate cream 0.1%|t|f|t|t
34067556|NCT05790668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190356|NCT03739021|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized, open label study. A series of 60 sealed envelopes: 30 Exparel single shot and 30 Ropivacaine catheter will be blindly open for each of the 60 patients when collecting informed consent."||||
34190357|NCT02029898|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34190358|NCT05159336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190359|NCT05733312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34190360|NCT01419197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190361|NCT03912519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190362|NCT03508908|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This trial will use a modified stepped wedge design to evaluate the yield of the HIV-1 RNA testing intervention at 6 public or private health facilities in Kenya, before (1,375 patients) and after (1,500 patients) intervention delivery. This study will be conducted in two phases (observation phase and intervention phase) at each site.||||
34190363|NCT03282604|||COHORT||PROSPECTIVE|||||||
34190364|NCT04441541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871577|NCT01049685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067557|NCT00868751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190365|NCT01474239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190366|NCT02349217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190367|NCT02779556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190368|NCT00021918|||||RETROSPECTIVE|||||||
33871578|NCT06140004|||COHORT||PROSPECTIVE|||||||
33871579|NCT05883462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871580|NCT04986306|||CASE_ONLY||PROSPECTIVE|||||||
33871581|NCT00071695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871582|NCT01402609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33871583|NCT03631784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067558|NCT01967979|NON_RANDOMIZED|PARALLEL||||NONE||||||
34190369|NCT04090801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The medications will be provided in bottles which will be identical in shape and color, and will be coded by a third party. Both patients and investigator will be blinded to the medication. Disclosure of the codes will be done, by a third party, at the end of the study.|This study will be to compare the efficacy of topical minoxidil 5% solution in ethanol plus 5% propylene glycol (PG), as a vehicle, versus 5% minoxidil in ethanol alone in treatment of women with FPHL.|f|t|t|t
34190370|NCT03236662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190371|NCT02893956|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33871584|NCT03061032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871585|NCT03203044|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are separated into two diet arms. The regular diet arm remains on a self-reported regular diet for the duration of the study. The Soylent diet arm maintains a regular diet for two days, switches to an all Soylent and water diet for four days, and returns to a regular diet for four days.||||
33871586|NCT06087796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871587|NCT00800293|||COHORT||PROSPECTIVE|||||||
33871588|NCT02835001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871589|NCT00923130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871590|NCT04819152|||COHORT||PROSPECTIVE|||||||
33871591|NCT03380455|NA|SEQUENTIAL||OTHER||NONE||Fixed sequence||||
33871592|NCT00139945|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33871593|NCT00614887|||CASE_CONTROL||PROSPECTIVE|||||||
33966272|NCT03459781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All investigators will remain blinded, except for the study interventionists who will administ the CBCT® and CHE programs to participants and research coordinator who will inform participants about group assignment. Study interventionists and the study coordinator will not conduct data collection procedures or analyses of data that is collected.|Over the course of the study we will randomize 20 survivor-caregiver dyads to CBCT®, and 20 dyads to the CHE. We will conduct the study in several cohorts, with 4-10 dyads randomized to CBCT® and 4-10 dyads randomized with CHE in each cohort.|f|f|t|f
33755470|NCT03827057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The CAPS-5, the gold standard for PTSD diagnosis, will be administered and scored at baseline to confirm the diagnosis, and subsequently as the primary outcome measure at 2, 6, and 12 months, by expert administrators who will be blinded to treatment arm.|This is an interventional randomized controlled trial in which participants have an equal chance of receiving either the current best-evidenced PTSD treatment, prolonged exposure, or a novel approach, reconsolidation of traumatic memories, that has the potential to achieve a more rapid, durable and greater overall response rate.|f|t|f|t
33966273|NCT04317833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966274|NCT00168259|||COHORT||PROSPECTIVE|||||||
33966275|NCT03634332|NA|SINGLE_GROUP||TREATMENT||NONE||Single Treatment Arm for Second-Line treatment of Specific sub-set (HA high) of advanced pancreatic cancer patients||||
33966276|NCT03078803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755471|NCT01117272|||COHORT||RETROSPECTIVE|||||||
33966277|NCT06481384|||COHORT||PROSPECTIVE|||||||
33966278|NCT02926391|||COHORT||PROSPECTIVE|||||||
33966279|NCT01536691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33966280|NCT03292965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34190372|NCT04918043|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34190373|NCT01071798|||COHORT||PROSPECTIVE|||||||
34190374|NCT02442804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34190375|NCT03338127|||CASE_ONLY||RETROSPECTIVE|||||||
34190376|NCT00336648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190377|NCT06520605|||COHORT||PROSPECTIVE|||||||
34190378|NCT04724122|||OTHER||OTHER|||||||
34190379|NCT00354783|||CASE_CONTROL||PROSPECTIVE|||||||
34190380|NCT00137891||PARALLEL||TREATMENT||SINGLE||||||
34190381|NCT01678495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190382|NCT01389843|||COHORT||PROSPECTIVE|||||||
33755472|NCT00378352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871594|NCT05435404|||OTHER||RETROSPECTIVE|||||||
33871595|NCT01217632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871596|NCT04623684|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33871597|NCT01666431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871598|NCT00816426|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871599|NCT01485939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33871600|NCT05478798|||COHORT||PROSPECTIVE|||||||
33871601|NCT02278900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871602|NCT00257725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871603|NCT01403818|RANDOMIZED|CROSSOVER||||NONE||||||
33871604|NCT02952274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33871605|NCT06092554|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A numbered sealed envelope will be used to ensure blinding.|The present study will be a multicenter, randomized, double-blind, placebo-controlled trial. Allocation will rely on a computer-based random number generator provided in a sequentially numbered, sealed, opaque envelope.|t|t|t|t
33871606|NCT02716987|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871607|NCT04928859|||CASE_CONTROL||RETROSPECTIVE|||||||
33871608|NCT02011282|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33871609|NCT00099970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871610|NCT03329911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871611|NCT00737256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871612|NCT04973436|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33871613|NCT05486351|||COHORT||PROSPECTIVE|||||||
33871614|NCT00354770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871615|NCT00823498|||COHORT||PROSPECTIVE|||||||
33871616|NCT03436459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33871617|NCT05068570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871618|NCT03260088|||COHORT||PROSPECTIVE|||||||
33871619|NCT01560780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966281|NCT05992649|NA|SINGLE_GROUP||TREATMENT||NONE||Single group study||||
33966282|NCT03787108|||COHORT||PROSPECTIVE|||||||
34190383|NCT00706303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190384|NCT01013103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34190385|NCT01257061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190386|NCT01590888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190387|NCT04491513|||OTHER||RETROSPECTIVE|||||||
34190388|NCT05390619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190389|NCT04465838|||OTHER||PROSPECTIVE|||||||
34190390|NCT05767918|||OTHER||OTHER|||||||
34190391|NCT03879005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190392|NCT00889161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190393|NCT02861274|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34190394|NCT01888302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190395|NCT04117867|||COHORT||RETROSPECTIVE|||||||
34190396|NCT03156699|||COHORT||RETROSPECTIVE|||||||
34190397|NCT00768924|||COHORT||PROSPECTIVE|||||||
34190398|NCT02795897|||COHORT||PROSPECTIVE|||||||
34190399|NCT04394637|||COHORT||PROSPECTIVE|||||||
34190400|NCT05231512|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34190401|NCT03128125|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Case-control study, monocentric.||||
33755473|NCT02904876|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755474|NCT03918863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190402|NCT00532610|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34190403|NCT05306808|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants in the intervention group will attend a program combing 24 sessions of physiotherapy and 10 sessions of educational class over 12 weeks. Participants in the control group will be asked to exercise on their own.||||
33755475|NCT03977675|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33755476|NCT05194904|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||This is a prospective randomised clinical study designed to assess the effect of intravenous ketorolac versus intravenous dexmedetomidin on postoperative pain after hypospadias repair in children||||
33755477|NCT02096328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755478|NCT03493243|||COHORT||PROSPECTIVE|||||||
33755479|NCT03466086|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33755480|NCT00995072|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755481|NCT03865602|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871620|NCT00534339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871621|NCT03339206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871622|NCT04345536|||COHORT||PROSPECTIVE|||||||
33871623|NCT04558411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871624|NCT01389375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871625|NCT04349774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871626|NCT05325151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871627|NCT05489731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||In the dose escalation phase, a total of 2 groups were planned, and 6-12 patients were expected to be enrolled. In the expansion phase, two cohorts are planned, with each cohort expanding to 20-30 patients, and approximately 40-60 patients are expected to be enrolled. A total of 46 to 72 patients were enrolled in this phase I trial||||
33871628|NCT05739786|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33871629|NCT05455112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871630|NCT03483142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Intervention~All women will be randomly assigned to either:~Group A ( study group ) ( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.~Group B (control group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation"|t|f|f|f
33871631|NCT00881803|||COHORT||PROSPECTIVE|||||||
33871632|NCT00112671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871633|NCT05847101|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33871634|NCT06343948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871635|NCT03982004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871636|NCT01230242|NA|SINGLE_GROUP||TREATMENT||NONE||Mirena IUD placement||||
33871637|NCT05109065|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33871638|NCT06113900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33871639|NCT00389428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190404|NCT05432089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190405|NCT03206229|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This is double blind study so participat healthy subjects and investigators both would be blinded|This study is a Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study|t|f|t|f
34190406|NCT02952443|||COHORT||CROSS_SECTIONAL|||||||
34190407|NCT04762719|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Three groups of patients (diabetic; diabetic gastroparesis; healthy volunteers) will undergo PET-CT. The diabetic gastroparesis group will also undergo gastric muscle biopsy of the involved and uninvolved area to validate immune changes visualized on imaging.||||
34190408|NCT04506099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study participants will be blinded to the stimulation parameters of the TINS. The research assistant/investigator will apply the electrodes and the PI will be blinded the stimulation setting as well. Unblinding is expected to occur after the 2 month follow up, at which point both subject and PI will be made aware of their group assignment.|Randomized sham-controlled trial|t|f|t|t
34190409|NCT02383212|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190410|NCT04643652|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Stepped Wedge Cluster Randomised Model||||
34190411|NCT01254162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190412|NCT02641561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34190413|NCT00509483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190414|NCT02912858|NA|SINGLE_GROUP||OTHER||NONE||||||
34190415|NCT06333899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Feasibility||||
34190416|NCT03402464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190417|NCT03202771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34190418|NCT05212870|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190419|NCT03357588|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190420|NCT01295437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190421|NCT01322893|||OTHER||PROSPECTIVE|||||||
33755482|NCT05207514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755483|NCT04206189|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator and outcomes assessor are blinded to group assignment.|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery. In contrast, patients in the control group are fasted water 2 hours before surgery.|f|f|t|t
33755484|NCT00780858|||CASE_CONTROL||PROSPECTIVE|||||||
33755485|NCT02712034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33755486|NCT03959462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind design|Participants are allocated to one of 2 groups: real tDCS or sham.|t|f|t|f
33755487|NCT04548063|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33755488|NCT00406133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755489|NCT05638633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|blinded labelling of the study drug by the Hospital pharmacy of the Charité|"after Baseline, Randomization to 4 arms:~1. st arm (prednisolone and placebo)~2. nd arm (placebo an Vitamin B compound)~3. rd arm (prednisolone and Vitamin B compound)~4. th arm (placebo and placebo)"|t|t|t|t
33755490|NCT03232983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34190422|NCT02722499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34190423|NCT02340637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755491|NCT01649232|||CASE_CONTROL||PROSPECTIVE|||||||
33755492|NCT01409148|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755493|NCT00534131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755494|NCT01429480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33755495|NCT01869842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755496|NCT04141527|||CASE_CONTROL||RETROSPECTIVE|||||||
33755497|NCT04716348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755498|NCT00082173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755499|NCT01406626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755500|NCT05804045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755501|NCT02384759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755502|NCT01040260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755503|NCT02778100|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33755504|NCT00418808|||CASE_CONTROL||OTHER|||||||
33755505|NCT02690974|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755506|NCT05394025|||CASE_CONTROL||OTHER|||||||
34190424|NCT05620693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190425|NCT01006291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190426|NCT01766999|||CASE_ONLY||PROSPECTIVE|||||||
34190427|NCT05651685|||COHORT||PROSPECTIVE|||||||
34190428|NCT06029192|||COHORT||RETROSPECTIVE|||||||
34190429|NCT01490489|NA|SINGLE_GROUP||OTHER||NONE||||||
34190430|NCT04504552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190431|NCT00547443|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190432|NCT02860429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755507|NCT03534973|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34190433|NCT04374942|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This trial is fully-blinded, at the level of the participant, study coordinator, and investigator. Study drug and placebo will be identical in appearance and will be provided by the manufacturer. They will be packaged in identical bottles and dispensed by the Research Clinical Trials Pharmacy at UHN.|The HEROS study is a double-blind, randomized placebo controlled trial of oral HCQ 400 mg taken once daily for three months as PrEP to prevent COVID-19 in health care workers in the emergency department.|t|t|t|t
33755508|NCT01971723|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33755509|NCT00671931|RANDOMIZED|FACTORIAL||||NONE||||||
33755510|NCT06309108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In our study, patients who would undergo bariatric surgery were selected randomly.||||
33755511|NCT05165342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755512|NCT05514912|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33755513|NCT03356379|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||transcutaneous oximetry|t|f|f|f
33755514|NCT02089256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755515|NCT04620291|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33755516|NCT01569438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33755517|NCT04483310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755518|NCT06579287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755519|NCT05590455|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase II multicenter, open-label, randomized, proof of concept, comparative trial with a large alpha (type 1 error rate).~All HIV1-infected patients diagnosed with TBM will be started on standard TB therapy for the duration recommended by national guidelines (2 months intensive phase and 7 months maintenance phase) and high-dose dexamethasone up to 4 weeks.~As soon as possible during the first 3 days of the standard TBM treatment that includes antituberculosis treatment and high-dose steroids, consenting patients will be randomized to standard treatment alone or standard treatment + adalimumab. Randomization will be stratified on country and initial severity using the British Medical Research Council (MRC) score.~Adalimumab arm:~* Standard TBM treatment as described above~* Adalimumab 40 mg: one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids"||||
33755520|NCT04563221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755521|NCT00140504|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33755522|NCT00053989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755523|NCT02316964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755524|NCT01256411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755525|NCT05400551|||COHORT||PROSPECTIVE|||||||
33755526|NCT00032279|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755527|NCT06579313|||COHORT||CROSS_SECTIONAL|||||||
33755528|NCT05117138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755529|NCT00373399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind, placebo-controlled||t|f|t|f
33755530|NCT00568048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755531|NCT03813446|||COHORT||PROSPECTIVE|||||||
33755532|NCT05956288|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33755533|NCT02545777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755534|NCT03044964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755535|NCT03369275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33755536|NCT01034267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755537|NCT02541890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755538|NCT03424434|||OTHER||CROSS_SECTIONAL|||||||
33755539|NCT03326531|||CASE_CONTROL||RETROSPECTIVE|||||||
33755540|NCT01362439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755541|NCT03536546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Veteran peer research assistants will deliver alcohol brief advice in the ED and will initiate conversations with the participant for at least 6-sessions over 2 months post-ED visit. Strengths-based discussions will include a combination of scripted and open-ended content to best facilitate reductions in drinking and engagement across severity.||||
33755542|NCT05569746|NA|SINGLE_GROUP||TREATMENT||NONE||"A Phase II, multicenter, controlled study, with a prospective open treatment group (with INM004 added to Standard of Care) and a retrospective control group (only treated with Standard of Care)."||||
33755543|NCT04498130|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33755544|NCT04549363|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33755545|NCT06385743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755546|NCT01503632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755547|NCT05351255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33755548|NCT03389542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755549|NCT03066050|||OTHER||OTHER|||||||
33755550|NCT00895986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190434|NCT05493800|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"Part I: open label~Part II: double blind, randomized, and Placebo controlled"|"Part 1 was completed with 16 patients and open label design to to evaluate the pharmacokinetic characteristics, efficacy, and safety of MIT-001 on prevention effect of MIT-001 in combination with conditioning regimen in auto-HSCT. 5mg as low dose and 20mg as high dose of MIT-001 were determined as RP2D through steering comittee and optional group of 30mg was not needed at Part 1 because low level of MIT-001 was enough to show efficacy and safety of MIT-001.~In Part 2, it's to determine the optimal dose (recommended part 2 dose (RP2D)) of MIT-001 in combination with conditioning regimen in auto-HSCT."|t|t|t|t
34190435|NCT03485872|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34190436|NCT00933777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190437|NCT03257319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190438|NCT00441116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190439|NCT00002213||||TREATMENT||||||||
34190440|NCT04456855|||COHORT||RETROSPECTIVE|||||||
34190441|NCT02105961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190442|NCT00380380|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34190443|NCT04285619|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34190444|NCT02830685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190445|NCT03366519|||COHORT||PROSPECTIVE|||||||
34190446|NCT03546452|||CASE_ONLY||PROSPECTIVE|||||||
34190447|NCT00485134|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190448|NCT00982423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190449|NCT04247607|||CASE_ONLY||PROSPECTIVE|||||||
34190450|NCT04800172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
34190451|NCT06184568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190452|NCT03620786|||COHORT||PROSPECTIVE|||||||
34190453|NCT01175499|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34190454|NCT04088058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190455|NCT00634101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190456|NCT05028244|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The selected patients undergo an ultrasound of lower extremity to discard previous thrombosis episodes. Then they are randomized to an intervention group (serial screening of deep venous thrombosis in lower extremity 2 times per week) or control group (no other exploration or interventions are made).||||
34190457|NCT00043797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190458|NCT00401934|||||PROSPECTIVE|||||||
34190459|NCT00773318|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190460|NCT02657473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||". In present study the value of maintenance TIS will be investigated in patients with non-CF bronchiectasis colonized by different bacterial species sensitive for tobramycin.~Objective: The primary outcome of the study is a 50% reduction in exacerbation rate in patients using maintenance TIS (OD). Secondary outcome parameters are lung function (FEV1, FVC), QoL (QOL-B), LTRI-VAS, Leicester cough score, bacterial load in sputum and tobramycin resistant pathogens.~Study design: A randomised, double blind placebo controlled, multicenter study. Study population: Patients aged ≥ 18-year-old with confirmed bronchiectasis by (HR)CT and at least two exacerbations during previous 12 months."|t|t|t|f
34190461|NCT06517485|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, dose escalation to reach MTD. The MTD will be confirmed in parallel cohorts: patients with platinum-resistant ovarian cancer; patients with non-squamous NSCLC, adenocarcinoma subtype||||
34190462|NCT01956916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190463|NCT03238690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190464|NCT02452515|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34190465|NCT01646229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190466|NCT01034670|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190467|NCT02935439|RANDOMIZED|PARALLEL||||NONE||||||
34190468|NCT04602871|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34190469|NCT06275945|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, non-randomized first-in-man study||||
33966283|NCT02515357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755551|NCT02525848|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33755552|NCT02884297|NA|SINGLE_GROUP||OTHER||NONE||||||
33755553|NCT03856710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be unaware of the type of mesh received as the randomisation process will be carried out intraoperatively when the patient is under general anaesthesia. Subsequently, over the follow-up period every possible effort will be made to continue the blinding process in order to minimise any bias in patient reported outcomes. Similarly outcome assessors would be blinded as well.|This is a double blinded randomised controlled trial of ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM an absorbable strap fixation device in the laparoscopic treatment of inguinal hernias. Sample size is 47 patients per group.|t|f|f|t
33755554|NCT01046539|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755555|NCT00005057||||TREATMENT||||||||
33755556|NCT02281669|||COHORT||PROSPECTIVE|||||||
33755557|NCT01816750|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33755558|NCT02142933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755559|NCT02107209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755560|NCT03943784|||COHORT||OTHER|||||||
33755561|NCT02804568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755562|NCT02807636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755563|NCT03157609|NON_RANDOMIZED|CROSSOVER||OTHER||TRIPLE|use of a third person (blinded to study design, population and statistics) which will extract data blindly from the hospital anaesthesia electronic database||t|f|t|t
33755564|NCT03651167|||CASE_ONLY||CROSS_SECTIONAL|||||||
33755565|NCT06182306|||COHORT||PROSPECTIVE|||||||
33755566|NCT03129854|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group receive standard of care ADT continually. Another group receive ADT plus prostate cryotherapy||||
33966284|NCT06043999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966285|NCT01809795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966286|NCT06035705|||CASE_ONLY||PROSPECTIVE|||||||
33966287|NCT01512784|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966288|NCT04779385|||OTHER||RETROSPECTIVE|||||||
33966289|NCT01682473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190470|NCT01617746|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190471|NCT04797559|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Both groups will receive a small circular band-aid on their temples.|Patients in the interventional group will receive a total of 5 mL of local anesthetic bilaterally near their temples.|t|t|f|f
33966290|NCT02521454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33966291|NCT05487872|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34190472|NCT00785382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190473|NCT03089905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomisation 1:1 will be stratified by site and age at exposure (less than 12 months and greater than or equal to 12 months). Randomisation will be in blocks of variable size. The treating anaesthetist will not be blinded to treatment arm. The assessing neuropsychologist and parents will be blinded to treatment arm.|Participants will be randomised to receive either low-dose sevoflurane/dexmedetomidine/remifentanil OR standard dose sevoflurane anaesthesia.|f|f|f|t
34190474|NCT00136188|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33755567|NCT05534022|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a mono-centre, prospective, one-arm, unmasked clinical trial, which consists of 9 visits, across 24 months. The objective of this clinical trial is to compare the test myopia control spectacle lens to the single vision control spectacle lens from the previous clinical trial, otherwise termed as historical control group.~After obtaining informed consent and assent, a comprehensive eye examination will be conducted during the screening visit on all 40 myopic children between the age of 8 to 13 years old. Eligible children will return in a separate visit (baseline visit) to collect the study spectacles and the assessment of study spectacles, biometry and instructions to use study spectacles are established in the same visit. A follow up visit will be conducted in 3, 6, 12, 18 and 24 months time, where 24 months is the end of study. All of the eye examinations and assessments are non-contact and non-invasive to the eyes."||||
33966292|NCT04071366|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Part 1 is not masked (open label). Part 2 is double blinded (participant, investigator)|Part 1: Singe Group Assignment Part 2: Parallel Assignment|t|t|t|f
33966293|NCT04455425|||COHORT||RETROSPECTIVE|||||||
33966294|NCT05758779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomised controlled trial|t|f|f|t
33966295|NCT01073059|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33755568|NCT03223974|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34190475|NCT00244543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33755569|NCT00553696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966296|NCT00320593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966297|NCT01481831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966298|NCT04235231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research Randomizer||f|f|t|f
33966299|NCT04933669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966300|NCT04568369|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Patients will be randomized with a random number generator to receive either sham or rTMS. The research assistant administering the fNIRS and PTSD assessments, will be blinded to the treatment allocations. Once the study is completed, patients and all study personnel will be unblinded. Subjects in the sham group will be given the opportunity to cross over to the treatment group.|This study will be a double-blind, sham-controlled, concealed allocation, randomized, cross over clinical trial.|t|t|t|f
33755570|NCT02718703|NA|SINGLE_GROUP||||NONE||||||
33966301|NCT02746705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33755571|NCT00877643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755572|NCT05039372|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||experimental randomized controlled||||
33755573|NCT03449810|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|All eligible participants will be randomly be allocated to three groups using a random number generator by an independent person (third party). Two study assessors will take measurements of all outcomes at baseline, 6th and 12th week and 3 months follow-up, however, they will be blinded to group allocation. Group indication will be placed in a sealed envelope that will be opened after the study assessors have performed the initial assessments and the participants will be instructed not to disclose their study groups to the assessors. However, participants are expected to be unaware of their group procedure/intervention, therefore, the physiotherapists will be instructed not to disclose the name of their group procedure to the participants.|The Intervention Models Includes; Muscles Energy Technique plus Dynamic stabilization exercises which would be administered to participants in group A, Dynamic stabilization exercises to be administered to group B participants and group C which is the control will receive standard physiotherapy treatment.|t|f|f|t
33755574|NCT04739787|||OTHER||OTHER|||||||
33755575|NCT05047367|||COHORT||PROSPECTIVE|||||||
33966302|NCT04189419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase I: Multicenter in Korea, Non-Randomized, Open-label, Single arm, 3+3 design Phase II: Multicenter in Korea, Randomized, Double-blind, Placebo-controlled, 2-arm, Parallel Group|t|t|t|t
34190476|NCT04180124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34190477|NCT06035419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to avoid bias in the study, a nurse who was not involved in the study performed the LATCH scoring and evaluation of the suckling time and feeding style of the infants, without knowing which group the mothers were in. In addition, mothers to be included in the experimental and control groups were determined by simple randomization method in order to prevent selection bias in the study.|randomized-controlled and single-blind study|t|f|f|f
34190478|NCT05886348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190479|NCT00735267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190480|NCT00775593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190481|NCT01715012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190482|NCT03292172|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34190483|NCT03507387|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34190484|NCT04139993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190485|NCT01613898|||CASE_ONLY||PROSPECTIVE|||||||
34190486|NCT03346642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190487|NCT04603027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multicenter, randomized, double-blind, placebo-controlled, parallel-cohort, dose-ranging study of participants with mild to moderate plaque psoriasis|t|f|t|f
34190488|NCT06109961|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, multicenter, randomized open-label clinical trial and parallel registry.||||
34190489|NCT02609113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190490|NCT04314713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blinded, randomized, placebo-controlled||t|t|t|f
34190491|NCT00340873|||CASE_CONTROL||RETROSPECTIVE|||||||
34190492|NCT02697474|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190493|NCT03261427|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190494|NCT02496052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34190495|NCT05861167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190496|NCT01081964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190497|NCT02934100|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34190498|NCT00504647|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34190499|NCT04626167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755576|NCT06171373|||COHORT||PROSPECTIVE|||||||
33755577|NCT04028986|||COHORT||OTHER|||||||
33755578|NCT03934736|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755579|NCT06248918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33755580|NCT04162769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755581|NCT03590756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33755582|NCT00338884|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755583|NCT05772780|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33871640|NCT03262870|||CASE_CONTROL||PROSPECTIVE|||||||
33755584|NCT00036998|RANDOMIZED|||TREATMENT||NONE||||||
33755585|NCT06348784|||COHORT||PROSPECTIVE|||||||
33755586|NCT01686789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755587|NCT01020110|||CASE_CONTROL||PROSPECTIVE|||||||
33755588|NCT04086420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755589|NCT00340015|||COHORT||PROSPECTIVE|||||||
33755590|NCT00539851|||COHORT||PROSPECTIVE|||||||
33755591|NCT00002426||||TREATMENT||DOUBLE||||||
34190500|NCT06153797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is a single-site randomized efficacy trial of the PATH-C intervention in 80 caregivers of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. Participants will be recruited from the Dana-Farber Cancer Institute and randomized in a 1:1 fashion, stratified by transplant type (autologous versus allogeneic), to assign each participant to either PATH-C versus usual care.||f|f|f|t
33755592|NCT02784483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755593|NCT02565290|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|f|t|t
33755594|NCT06111222|NA|SINGLE_GROUP||TREATMENT||NONE||Patients scheduled for cataract or refractive lens exchange surgery requiring bilateral implantation of multifocal IOL||||
34190501|NCT00771953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755595|NCT04064879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755596|NCT05760001|RANDOMIZED|PARALLEL||OTHER||NONE|The investigators are not masked. Our recruitment team will be masked until cluster recruitment is complete. The outcomes assessor will be masked.|||||
33755597|NCT03455374|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective||||
33871641|NCT03988348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871642|NCT04729985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data evaluation group will be blinded as to which arm the data comes from|Prospective Randomized Trial|f|f|f|t
33755598|NCT04688424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755599|NCT05586152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755600|NCT03249051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755601|NCT05674760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The statistician assessing the outcomes will be blinded to the randomisation|Open Label Randomised Controlled Trial|f|f|f|t
33871643|NCT01090466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755602|NCT05858697|||COHORT||OTHER|||||||
33755603|NCT04789590|||CASE_ONLY||CROSS_SECTIONAL|||||||
33755604|NCT00981084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33755605|NCT01104610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33755606|NCT02386995|||COHORT||PROSPECTIVE|||||||
33755607|NCT03213275|||COHORT||PROSPECTIVE|||||||
33871644|NCT06068712|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-Subjects Design||||
33871645|NCT02614755|||COHORT||RETROSPECTIVE|||||||
33871646|NCT05218512|||CASE_ONLY||CROSS_SECTIONAL|||||||
33871647|NCT03769246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33871648|NCT05421936|||CASE_ONLY||RETROSPECTIVE|||||||
33871649|NCT02369848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871650|NCT02329964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33871651|NCT06468397|NA|SINGLE_GROUP||TREATMENT||NONE||First in human use of investigational device called iSeelr™ system for the treatment of Rhegmatogenous Retinal Detachment||||
34190502|NCT02869659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190503|NCT00531791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755608|NCT04285450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33755609|NCT01694732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755610|NCT05794438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755611|NCT01685138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755612|NCT00137930|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33755613|NCT02908373|||CASE_CONTROL||PROSPECTIVE|||||||
33755614|NCT04766268|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm||||
33755615|NCT02138630|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33755616|NCT05877300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190504|NCT05284526|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33755617|NCT04995185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755618|NCT03371875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871652|NCT05785156|||CASE_ONLY||PROSPECTIVE|||||||
33871653|NCT03178760|||COHORT||PROSPECTIVE|||||||
33871654|NCT05821764|||COHORT||PROSPECTIVE|||||||
33871655|NCT05865795|||CASE_ONLY||PROSPECTIVE|||||||
33871656|NCT05217199|||CASE_CONTROL||RETROSPECTIVE|||||||
33871657|NCT02960230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871658|NCT05984342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871659|NCT02159729|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33871660|NCT01407770|||OTHER||PROSPECTIVE|||||||
33871661|NCT05360459|||CASE_CONTROL||RETROSPECTIVE|||||||
33871662|NCT02085889|||COHORT||PROSPECTIVE|||||||
33871663|NCT06073015|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33871664|NCT00248755|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871665|NCT03662880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871666|NCT01643629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871667|NCT00603109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871668|NCT00825162|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33871669|NCT04047810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871670|NCT04841707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871671|NCT04013529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190505|NCT03828019|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unmasked treatment administration and outcome assessments (participants, study ophthalmologists, visual function examiners, and study coordinators are all unmasked). Masked assessment of baseline, 1-month, 3-month, and 6-month photographic images and OCT by the Reading Center (graders masked).|Randomized treatment assignment with allocation ratio: 1:1 and two stratification variables: (1) number of immunosuppressive drug patient is on at time of enrollment (zero vs. one); (2) Initial dose of prednisone patient will be on in trial (\<30 mg/day vs. ≥30 mg/day). The unit of randomization is the patient,||||
34190506|NCT02744040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190507|NCT02420015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190508|NCT03428035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34190509|NCT06445205|||OTHER||PROSPECTIVE|||||||
34190510|NCT02829190|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34190511|NCT00019201||||SCREENING||||||||
34190512|NCT02313961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190513|NCT04875000|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|None of the participants is aware of the remineralizing agent to be applied to his/her teeth after bleaching|Parallel interventional study model|t|f|f|f
34190514|NCT06164990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190515|NCT00838084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34190516|NCT04708314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190517|NCT00003690||||TREATMENT||||||||
34190518|NCT05884541|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors of PALS and REMA are masked to intervention status|Randomized clinical trial|f|f|f|t
34190519|NCT02569099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34190520|NCT01460043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34190521|NCT03114852|||FAMILY_BASED||PROSPECTIVE|||||||
34190522|NCT03904992|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"First, a baseline evaluation will be made to the participants, based on the indicators of interest.~During a period of 60 days, the caregivers of the intervention group had free access to the progressive web app Nutrinidos and received training for its use. On the other hand, nutritional counseling was available every 30 days for the participants assigned to the control group. They consisted of personalized sessions with a duration of 20 minutes in which parents and caregivers could resolve their doubts regarding the feeding of their children. In addition, they were offered physical education materials designed and adapted with content used in this study. The educational material addressed contains information about lunch boxes, eating habits, consumption of fruits and vegetables, prevention of anemia, and physical activity.~After 60 days of follow-up, the evaluation of results will be carried out."||||
34190523|NCT06014398|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190524|NCT04684238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190525|NCT02057081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871672|NCT01547169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871673|NCT05679128|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"randomised to either palpation or ultrasonography~The participants are thus arandomised to use either palpation or to use ultrasonography to DIAGNOSE the position of the cricothyroid membrane"||||
33871674|NCT06490640|||COHORT||RETROSPECTIVE|||||||
33871675|NCT04597736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871676|NCT04226690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo controlled, parallel group design||t|t|t|t
33871677|NCT03194282|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33871678|NCT01325922|RANDOMIZED|PARALLEL||OTHER||||||||
33871679|NCT03016325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871680|NCT04163796|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871681|NCT03443076|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33871682|NCT00003351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871683|NCT04592640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871684|NCT05380011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be single blinded study. The data will be coded and the analyst will also be blinded.||t|f|f|f
33966303|NCT02410070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34190526|NCT02800629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double blind clinical trial|t|t|t|t
34190527|NCT01686542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190528|NCT05113069|NA|SINGLE_GROUP||TREATMENT||NONE||single arm for SHR-A1912||||
34190529|NCT01864603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190530|NCT06523491|||COHORT||OTHER|||||||
34190531|NCT02862067|||COHORT||PROSPECTIVE|||||||
33871685|NCT04790877|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The investigator who prepares the beverages and the bread is not blinded but the investigator who manage the samples and is plan to analyze the results is blinded.|The overall study involved two sub-studies. The first one includes 4 arms and the second one includes 5 arms.|t|f|t|f
33871686|NCT03731858|||COHORT||PROSPECTIVE|||||||
33871687|NCT04146194|||COHORT||PROSPECTIVE|||||||
33871688|NCT03283826|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33871689|NCT02238704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871690|NCT05936684|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33871691|NCT04496622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871692|NCT05214300|||COHORT||RETROSPECTIVE|||||||
33871693|NCT01255644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871694|NCT00732277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871695|NCT03402529|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871696|NCT05957666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients will either recieve oral or vaginal misoprostol by envelope method ina dose of 50microgram.Total of 176 envelopes are placed in a concealed box.Neither the doctor nor the patient knows.|Total 176 patient included in this study.Patients will be randomised by envelop method to recieve either oral or vaginal misoprostol in a dose of 50microgram.|t|f|t|f
33871697|NCT03187431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871698|NCT02685241|||CASE_ONLY||PROSPECTIVE|||||||
33871699|NCT01294202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871700|NCT05051904|||COHORT||RETROSPECTIVE|||||||
33871701|NCT02159703|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33871702|NCT03847129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33966304|NCT03070431|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
33966305|NCT03850054|||COHORT||PROSPECTIVE|||||||
33966306|NCT03836274|NA|SINGLE_GROUP||OTHER||NONE||||||
33966307|NCT01162395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966308|NCT05591690|||COHORT||RETROSPECTIVE|||||||
33966309|NCT05911347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Test meals will have similar appearance and flavour|3 way cross-over|t|f|f|t
34190532|NCT04945057|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants previously followed in the AKTIBIPO study and newly admitted participants (DeNovo) are included. Participants are followed over 12 months in the programme, collecting primary outcome every 3 months. Some long-term secondary outcomes are compared to values from the equivalent amount of time in the preceding AKTIBIPO study. The newly admitted DeNovo participants are followed for additional 3 months prior to starting the digital programme to collect outcome data from a non-interventional comparison period.||||
34190533|NCT02791763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190534|NCT05190926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190535|NCT00001213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190536|NCT04721301|NA|SINGLE_GROUP||TREATMENT||NONE||Single Center Phase 1 trial||||
34190537|NCT00594243|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34190538|NCT02476266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34190539|NCT01039662|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34190540|NCT01050517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190541|NCT03198325|NA|SINGLE_GROUP||OTHER||NONE||||||
34190542|NCT04669626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190543|NCT00194532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34190544|NCT00006100||||TREATMENT||||||||
34190545|NCT02659046|||CASE_CONTROL||RETROSPECTIVE|||||||
34190546|NCT00267813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190547|NCT03658590|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33871703|NCT03411720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33871704|NCT00050609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871705|NCT00900458|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871706|NCT04992819|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled two groups (control group and experimental group)||||
33966310|NCT01572428|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34190548|NCT02538354|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190549|NCT03237286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190550|NCT04593264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190551|NCT03305497|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34190552|NCT04860778|NA|SINGLE_GROUP||OTHER||NONE||||||
34190553|NCT02409277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|We initially enrolled 327 randomized (at the clinic level) participants who received the e-AT interventions overall, including 267 participants receiving the standard intervention and 60 receiving the intensive intervention. We also included another set of 599 non-randomized matched controls of patients with persistent asthma retrieved electronically from non-participating clinics. This is why we stated that 926 subjects (327+599) overall were included.||t|f|f|f
34190554|NCT04856839|||COHORT||PROSPECTIVE|||||||
34190555|NCT05071768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190556|NCT05466617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-group Randomized Controlled Trial|t|f|f|f
34190557|NCT00572754|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190558|NCT03871218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|examiner blinded|After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. In the TG, HA was applied to the entire recipient bed before suturing the graft taken from the palatial mucosa to the recipient site. In the control group (CG), HA was not applied to the recipient or the donor site.|f|f|f|t
34190559|NCT02936921|||COHORT||PROSPECTIVE|||||||
33755619|NCT05556720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both study participants and investigators will be blinded to treatment allocation. Individual assignments will be delivered securely and confidentially to the identified site personnel administering the vaccines via a web-based portal.|"Study participants who have received three to six doses of Australian TGA approved COVID-19 vaccine will be randomised into one of up to three groups, who will be administered either one or two homologous doses of bivalent COVID-19 vaccines, e.g. bivalent Moderna mRNA vaccine OR bivalent Pfizer mRNA vaccine, using a central computer-generated random allocation algorithm, with random block sizes of 3 or 6.~Randomisation will be stratified by:~- Study subgroup (HIV, solid organ transplant, haematological malignancy)"|t|t|t|t
33755620|NCT03220243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966311|NCT05765929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966312|NCT04129034|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized||||
34190560|NCT04609644|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190561|NCT04412785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190562|NCT01043289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190563|NCT03540836|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34190564|NCT05359367|||COHORT||PROSPECTIVE|||||||
34190565|NCT02823067|||COHORT||CROSS_SECTIONAL|||||||
33755621|NCT01389830|||COHORT||PROSPECTIVE|||||||
33755622|NCT04102579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755623|NCT02514018|RANDOMIZED|PARALLEL||||NONE||||||
33755624|NCT04166253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant did not know the exact drug he is using.|2 arms one is a control arm recieving only doxorubucin adjuvant chemotherapy and another intervention arm recieving doxorubucin as well as vitamin D orally once daily for 3 months|t|f|f|f
33755625|NCT05620212|||OTHER||PROSPECTIVE|||||||
33755626|NCT03103243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755627|NCT04263597|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Eligible patients will be allocated into the following arms as determined by age at enrollment.~Arm 1: 0-5 years; Arm 2: 5.1-10 years; Arm 3: \>10 years"||||
33755628|NCT00908167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755629|NCT02853890|||||PROSPECTIVE|||||||
33755630|NCT03201016|||COHORT||PROSPECTIVE|||||||
33755631|NCT01111357|||CASE_CONTROL||PROSPECTIVE|||||||
33755632|NCT06324266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755633|NCT01050816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755634|NCT02674893||PARALLEL||||||||||
33755635|NCT01929733|||||RETROSPECTIVE|||||||
33755636|NCT03780348|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The caregivers of the children, the care provider linking the children to either of the groups and the investigator will not know which group each child is joining and which group is using which method.|Children will be assigned for nutrition status assessment to either of the two groups that use the 'new' or the 'existing' assessment method|t|t|t|f
33755637|NCT03982602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755638|NCT01914835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755639|NCT04474743|||OTHER||CROSS_SECTIONAL|||||||
33755640|NCT02350348|||COHORT||PROSPECTIVE|||||||
33755641|NCT01169675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755642|NCT00433303|||DEFINED_POPULATION||PROSPECTIVE|||||||
33755643|NCT01196455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755644|NCT02713802|RANDOMIZED|CROSSOVER||||NONE||||||
33966313|NCT02953197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067559|NCT03280745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl or 0.9% NaCl by infusion pump over 60 minutes. If necessary, fluid resuscitation will be performed with Ringer's lactate to normalize peripheral perfusion and to allow weaning of vasopressors.|t|t|t|t
33871707|NCT04564742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966314|NCT02772913|||COHORT||RETROSPECTIVE|||||||
33966315|NCT04681456|||OTHER||PROSPECTIVE|||||||
33966316|NCT03038178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966317|NCT05306080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067560|NCT04691167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single blind sham-controlled randomized clinical trial||t|f|f|f
34067561|NCT00084877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190566|NCT03746119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33871708|NCT03821025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871709|NCT03255681|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|No masking.|The study treatment group will have one half of their face treated with PRP filler and the other half of the face treated with PRP with CaCl2. Using a VectraH1 3D camera, the degree of volume achieved, measured in cm3 using VECTRA Capture Analysis module software, will be assessed at one, three and six and twelve month intervals and compared to the pre-procedure imaging. This is therefore a pilot study and results will need to be reviewed after performing this protocol on 50 subjects.||||
33871710|NCT03757286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because the two interventions used in this trial are easily recognized by the participants and the investigator, neither the investigator nor the participant can be blinded. But, assessor and the statistician will be blinded.||f|f|f|t
33871711|NCT04758442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871712|NCT01732302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33871713|NCT05939479|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33871714|NCT04283136|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||In Part 1 a single oral dose of padsevonil 200 mg for the 4 different product variants and the padsevonil reference tablet will be administered to all subjects in the fasted state in a randomized 5-way crossover design. In order to explore the food interaction with padsevonil, in Part 2 a single oral dose of a padsevonil reference tablet at dose levels of 200 mg and 400 mg (2x 200mg tablets) will be administered to all subjects in the fasted and fed state in a randomized 4-way crossover study.||||
33894232|NCT05654415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The patients will be subjected to two EEG recordings: in one they will receive the melatonin solution (5 mg), in the 'other they will undergo only partial sleep deprivation (about 50% of physiological sleep).||||
34067562|NCT05452291|||COHORT||PROSPECTIVE|||||||
34190567|NCT05909657|||OTHER||CROSS_SECTIONAL|||||||
34067563|NCT03370692|||COHORT||PROSPECTIVE|||||||
34067564|NCT05697159|||COHORT||PROSPECTIVE|||||||
34067565|NCT04012346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34067566|NCT05719025|||COHORT||CROSS_SECTIONAL|||||||
34190568|NCT06424314|||COHORT||PROSPECTIVE|||||||
34190569|NCT06208475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190570|NCT00742235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190571|NCT04738461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be able to be blinded due the inherent of interventions. Staff members who are responsible for statistical analysis, investigators and outcome assessors will be blinded.|Prospective, triple-blinding, randomized controlled and 3-arm parallel group design clinical study. 3 arms of the study were planned to consist of telerehabilitation group, standard physiotherapy group and home exercise group.|f|t|t|t
33755645|NCT04730050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894233|NCT05169671|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33894234|NCT00526201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894235|NCT03025412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067567|NCT06485011|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups included||||
34067568|NCT05172401|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, single-dose, open-label, multi-center clinical investigation||||
34067569|NCT01313013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34067570|NCT03797131|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067571|NCT01268189|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067572|NCT00860132|||COHORT||RETROSPECTIVE|||||||
34067573|NCT00842777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067574|NCT00994214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067575|NCT00828269|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34067576|NCT01270321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067577|NCT02891486|||OTHER||PROSPECTIVE|||||||
34067578|NCT01903759|NA|SINGLE_GROUP||||NONE||||||
34067579|NCT02142205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067580|NCT01017601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067581|NCT03840408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190572|NCT01950013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33894236|NCT01726361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966318|NCT03625817|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|There will be the necessary blinding during the conduct of the all laboratory and statistical analyses. At the start of the study, participants will be given a 2-digit code (10-60) - once the researchers have names of eligible participants, each name will be given a code. This will be participant's study ID that will accompany participant's answered questionnaires, diaries, urine vials and temperature measurement's files.|A 2 x 2 cross-over pilot study of healthy adults is proposed to prospectively describe the effect of ambient temperature gradient on metabolic hormonal secretion patterns. A total of 50-60 subjects will be followed for a period of 7 days firstly in an urban environment or in a village of the mountainous rural environment and later, for the same period, in the alternate setting, during the summer period in Cyprus. The two settings will allow for the comparison of the circadian patterns of hormones secreted by the adipose tissue among different gradient temperature changes. Continuous quantification of skin temperatures on one day in each setting will allow for characterization of how skin temperature is affected by ambient temperature. Collection of all urine voids in one day in each setting will allow for quantification of the hormone secretion by the adipose tissue.|f|f|t|t
33966319|NCT01190098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966320|NCT01951547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067582|NCT01390428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966321|NCT05627908|||OTHER||PROSPECTIVE|||||||
34067583|NCT00913770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34067584|NCT04437797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894237|NCT03748927|||COHORT||PROSPECTIVE|||||||
33894238|NCT05804331|||COHORT||PROSPECTIVE|||||||
34190573|NCT05805319|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-center randomized trial in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibition. Patients will receive standard-of-care immune checkpoint inhibitor (ICI) therapy alone or in combination with a dietary intervention.||||
34067585|NCT04957784|||OTHER||RETROSPECTIVE|||||||
34067586|NCT03652688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Groups assigned to experimental and control conditions were given a tablet on which either the experimental or control program was provided. Both groups were told that they would be viewing a program on safety while at the club. Both groups had to respond to some questions on the tablet about the program. Both groups were asked to interact as a group to answer these questions. Without a view of the tablet, it appeared as if both experimental and controls had the same condition.|Randomized Controlled Trial|t|f|f|f
34067587|NCT02913105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190574|NCT03404752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34190575|NCT04335734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894239|NCT02216695|||COHORT||RETROSPECTIVE|||||||
34190576|NCT05261529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants randomly assigned in a 1:1:1 ratio to each of the three groups established through a centralized method with computer support (OxMaR software).|Three-arm prospective randomized controlled 24-week clinical trial of patients diagnosed with SLE.|f|f|t|t
34190577|NCT01282619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34190578|NCT02894736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190579|NCT02397629|||COHORT||PROSPECTIVE|||||||
34190580|NCT04629066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190581|NCT06072456|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34190582|NCT01206088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894240|NCT01929252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190583|NCT04952935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient receives true or sham acupuncture, and patient is unaware of treatment assignment. Acupuncturist is aware of treatment assignment, as is the statistician who is aware of randomization assignment but not involved otherwise in the execution of clinical trial. Investigators, medical assistants, and patients' physicians are unaware of treatment assignment.|Randomized double-blinded sham-controlled clinical trial|t|f|t|t
34190584|NCT04711161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||GRN-300 single-agent and in combination with paclitaxel.||||
34190585|NCT01763996|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34190586|NCT06201806|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|The participant is unaware of the assigned breakfast intervention, but they were aware of consuming white bread as the standard.|The study follows FAO/WHO 2008 protocol for glycemic index in breakfasts with and without non-nutritive sweeteners. Participants prep with a similar diet, light dinner, and a 10-hour fast before the test. The experimental design, implemented three times independently for 7-14 days, employs a crossover approach with each DM1 individual serving as their own control. Interventions feature test breakfasts with or without sweeteners, providing 50g of CHO. A third intervention uses white bread as a standard for glycemic response. This design calculates the area under the curve, contrasts experimental and standard responses, and determines the glycemic index for both test breakfasts.|t|f|f|f
34190587|NCT04695717|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190588|NCT01508806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190589|NCT01423747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190590|NCT04563897|||OTHER||PROSPECTIVE|||||||
34190591|NCT01088048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190592|NCT00935922|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190593|NCT00637988|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190594|NCT00326430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34190595|NCT00947687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190596|NCT02436720|||COHORT||PROSPECTIVE|||||||
33894241|NCT00892437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894242|NCT05957640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894243|NCT06357286|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894244|NCT01295333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894245|NCT02976506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894246|NCT01213134|||||CROSS_SECTIONAL|||||||
33966322|NCT04534192|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, single arm||||
33966323|NCT00330200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190597|NCT04863911|||COHORT||CROSS_SECTIONAL|||||||
34190598|NCT00228111|||COHORT||PROSPECTIVE|||||||
34190599|NCT04463069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190600|NCT05191914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190601|NCT06060327|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"A randomized controlled clinical trial including 4 groups comprising of 111 each.~Group 1 will receive Oxytocin only, Group 2 will receive Oxytocin and Tranexamic acid, Group 3 will receive Oxytocin and Misoprostol and Group 4 will receive Oxytocin and Carbetocin."|t|t|f|f
34190602|NCT04846933|||COHORT||PROSPECTIVE|||||||
34190603|NCT05163626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34190604|NCT01553370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190605|NCT03903224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34190606|NCT01237015|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34190607|NCT00620529|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190608|NCT05181189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190609|NCT02164487|||CASE_CONTROL||PROSPECTIVE|||||||
34190610|NCT03859362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190611|NCT00122980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190612|NCT02831101|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34190613|NCT05310552|||COHORT||CROSS_SECTIONAL|||||||
34190614|NCT04006275|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|The sequence of sonovue or sonazoid is blind to participant. The data is blind to the radiologist who is plan to evalutaed the data using CEUS LIRADS version 2017 and the outcome assessor who calculated all data and do the statistical calculation.|included patients receive both SonoVue and Sonazoid with a randomized crossover design. The wash out period is at least 30min to make sure the fore-inject contrast agent is clear in blood.|t|f|t|t
34190615|NCT03173183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The research is designed by randomized, double-blind, placebo and parallel clinical control.|t|f|t|f
33755646|NCT05867004|||COHORT||RETROSPECTIVE|||||||
33755647|NCT02645981|RANDOMIZED|PARALLEL||TREATMENT||NONE|open-label|||||
33755648|NCT06031532|||CASE_CONTROL||PROSPECTIVE|||||||
33755649|NCT04879914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755650|NCT02108379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755651|NCT03094780|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755652|NCT02966756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755653|NCT00796692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755654|NCT03149068|||CASE_CONTROL||PROSPECTIVE|||||||
33755655|NCT00404365|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33755656|NCT06578936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"A biostatistician who is not involved in the study will be randomly assigned to groups A and B, which are formed by a biostatistician in the computer environment. As a result of the draw of lots, whether group A and B will be the study or control group will be determined by a coin toss at the beginning of the study. The information showing that the patients included in the research sample are assigned to groups A and B according to the randomization table will be placed in an opaque envelope. This envelope will be kept by the coordinator researcher (GAU), and when the researcher (AD) goes to the patient for the application, he/she will open the envelope after filling out the Informed Consent Form and learn which group the patient is in"|A prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
33755657|NCT01717781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755658|NCT02328885|NA|SINGLE_GROUP||TREATMENT||NONE||DLI||||
33755659|NCT03602417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755660|NCT03894852|||OTHER||CROSS_SECTIONAL|||||||
33755661|NCT03854968|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755662|NCT03633942|||COHORT||PROSPECTIVE|||||||
34190616|NCT06335004|||COHORT||PROSPECTIVE|||||||
34190617|NCT05032924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Participants are randomly into four group to receive either shockwave or PRP or sham (HA) treatment based on a computerized statistical randomization. Every participant will have Subacromial injection of 2.5 ml PRP form Regen Kit BCT 1 or HA (control)(HYAJOINT Synovial Fluid Supplement, active ingredient: Sodium Hyaluronate 25 mg, package: 2.5 mL per syringe) one week before ESWT or sham therapy.~Follow-up examinations are performed independently by one of the coauthors, who is blinded to patient treatment status at 1week, 2week, 1month, 3 months, 6 months, and 12 months after treatment. Peripheral blood (10cc) will be collected one week and 1 month after treatment and shoulder MRI will be checked 12 months after treatment. Participants who have persistent shoulder discomfort may be advised to undergo surgical intervention."|t|t|t|f
34190618|NCT01227174|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34190619|NCT03791099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871715|NCT05917561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double (Participant, Investigator) This is a double-blind study. To preserve the blinding of the study, a minimum number of sponsor personnel will see the randomization table and treatment assignments before the study is complete.~All study assessments will be performed by study personnel who are blinded to the patient's treatment group.~Except in clinical circumstances where unblinding is required, the patients, investigators, sponsor study team, and any personnel interacting directly with patients or investigative sites will remain blinded to Anifrolumab and placebo assignment until after completion of the Double-Blinded Treatment Period."|This is a multicenter, randomized, non-comparative, phase II proof-of-concept trial involved patients with progressive vitiligo and uses one of the most common regimens in this phase of study. Assessment of the experimental treatment efficacy will be estimated only on the results obtained in the experimental treatment arm (Anifrolumab 300mg/month + narrowband UVB TL01 arm).|t|f|t|f
33871716|NCT03113656|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33871717|NCT06153875|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The order of the interventions will be randomized by a third person not involved in the treatment, assessment or statistical analysis. Once the care provider has inserted the needle in each subject, another third person will choose the protocol assigned on the stimulator, previously programmed and codified. Another investigator will take measurements of the variables of interest. Thus, nobody (participant, care provider, investigator and the outcome assessor) will know what intervention is applied.|Randomised quadruple-blind clinical trial, with three intervention groups|t|t|t|t
33871718|NCT03200132|||CASE_ONLY||CROSS_SECTIONAL|||||||
33871719|NCT04707742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The hospital staff consecutively assigned each participant a code following the order from a previously randomly generated table.~The code were unknown to the personnel who processed the samples and to those that analyzed the data.~Participants were blinded by using identical tubes with the same volume for both mouthwashes and placebo."|A multicentre, randomized, blind, five-parallel-group, placebo-controlled trial.|t|f|t|t
33871720|NCT01598779|||CASE_ONLY||PROSPECTIVE|||||||
33871721|NCT06418607|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190620|NCT03554486|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blinded|Subjects will be randomly assigned to start with either Fiasp insulin or Novolog insulin. After 2 weeks, they will start the previously unassigned insulin and continue using it for another 2 weeks.|t|f|t|f
34190621|NCT03755128|||COHORT||PROSPECTIVE|||||||
34190622|NCT03795272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded placebo-controlled|This is a multicentre, phase 2, double-blind, placebo-controlled trial of maintenance rucaparib to obtain evidence of clinical benefit of rucaparib in locally advanced cervical cancer.|t|t|t|f
34190623|NCT03783078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871722|NCT02768337|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966324|NCT03875430|||COHORT||PROSPECTIVE|||||||
34190624|NCT04541459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomised double blind controlled study|t|f|t|t
34190625|NCT01516541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190626|NCT03166202|||COHORT||CROSS_SECTIONAL|||||||
33871723|NCT00842738|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871724|NCT00373139|||CASE_CONTROL||PROSPECTIVE|||||||
33871725|NCT05021250|NA|SINGLE_GROUP||TREATMENT||NONE||HCC patients treated with TACE and lipiodol marking, followed by SBRT with DIBH which was registrated with lipiodol.||||
33894247|NCT01121016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894248|NCT03832387|RANDOMIZED|PARALLEL||TREATMENT||NONE||STUDY GROUP: Non-invasive ventilation using BiPAP Vision and continuous positive airway pressure (CPAP) systems CONTROL GROUP: Oxygen therapy||||
33894249|NCT02687308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894250|NCT02441530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894251|NCT02112968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894252|NCT01492673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966325|NCT04948255|||COHORT||PROSPECTIVE|||||||
33966326|NCT00432783|||COHORT||PROSPECTIVE|||||||
33966327|NCT05398575|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966328|NCT01260571|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33966329|NCT00370396|RANDOMIZED|PARALLEL||PREVENTION||||||||
33966330|NCT01260480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966331|NCT00359554|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33966332|NCT01988428|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33966333|NCT01710878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966334|NCT02746159|||CASE_ONLY||PROSPECTIVE|||||||
33966335|NCT06452433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966336|NCT02144493|||CASE_CONTROL||RETROSPECTIVE|||||||
33966337|NCT04869488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fluzopali in combination with apatinib mesylate or fluzopali monotherapy with or without homologous recombinant repair-related gene mutations in metastatic castration-resistant prostate in subjects||||
33966338|NCT00769730|||CASE_CONTROL||PROSPECTIVE|||||||
33966339|NCT00513565|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33966340|NCT05057429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966341|NCT06447519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966342|NCT00820391|RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
33966343|NCT00566098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966344|NCT03682783|||CASE_ONLY||PROSPECTIVE|||||||
33966345|NCT02038985|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190627|NCT01697618|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34190628|NCT02841514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966346|NCT00037973|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190629|NCT05241613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190630|NCT05859191|||CASE_CONTROL||PROSPECTIVE|||||||
34190631|NCT05454072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190632|NCT05294289|||COHORT||PROSPECTIVE|||||||
34190633|NCT05024110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized controlled trial was used to investigate the effect of exercise intensity on vitamin D and PTH levels in children with Down's syndrome. The enrollment of the participants was done by telephone calls to their parents or legal guardians. A total of fifty male DS subjects were initially selected to participate in the study. Only forty-four subjects completed the interventional study because six children were excluded. three children did not meet the inclusion criteria, parents of two children refused to complete the study, and one lost to follow-up. Their age was ranged from 8-12 years. The participants were assigned randomly using sealed envelopes into two equal groups; group I (GI) and group II (GII) each contain twenty-two subjects. GI received the high-intensity T-AE and the GII received the moderate-intensity T-AE, three times per week for three months. All subjects were selected from hospitals in the Western area, Saudi Arabia.|t|f|f|t
34190634|NCT04030273|||COHORT||PROSPECTIVE|||||||
34190635|NCT02440841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190636|NCT00540852|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||||||||
33966347|NCT02533388|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33966348|NCT06317766|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966349|NCT05522933|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190637|NCT01625741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190638|NCT01358721|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34190639|NCT02269579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190640|NCT00272025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190641|NCT02507700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190642|NCT04010604|||COHORT||PROSPECTIVE|||||||
34190643|NCT00543530|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190644|NCT01014351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190645|NCT05603234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190646|NCT00267072|||COHORT||PROSPECTIVE|||||||
34190647|NCT04986761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor received only data without participant group assigned after the intervention was done by a investigator|Digital and conventional workflows for treatment of implant single crowns, and also the material used.|f|f|f|t
34190648|NCT05435443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190649|NCT01215097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190650|NCT01521312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190651|NCT03455231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190652|NCT00463723|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34190653|NCT05522491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190654|NCT01749189|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34190655|NCT03680326|||OTHER||RETROSPECTIVE|||||||
33755663|NCT04285008|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The Colonoscope will be prepared as per normal routine and the research assistant will cover the colonoscope before the patient enters the endoscopy room to keep him/her blinded to the study arm. This is uncovered once the patient is sedated.|Randomization to Intervention or Control arm will use stratification by site, endoscopist and blocking. Sites are expected to contribute approximately equal numbers of procedures, and no site will be allowed to contribute more than 50% of the target sample size. The randomization sequences will be provided in advance by the study's statistician using an online system to obtain the randomization assignment and the corresponding colonoscope will be prepared. Randomization assignment will be recorded for each subject.|t|f|f|f
33755664|NCT04932876|||CASE_CONTROL||PROSPECTIVE|||||||
33871726|NCT04788251|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||"This is a stepped-wedge cluster randomized trial in which there will be a sequential crossover of clusters from the waitlist control to the intervention period where the sequence of crossover is randomized. The clusters are defined as groups with at least 5 participants. Each of the North and Central regions will have 6 clusters.~The intervention will be sequentially rolled out to 12 clusters that are randomized to 6 time periods (sequences). Each sequence has 6 steps where one step has a duration of 8 weeks. The intervention will be rolled out sequentially to 2 clusters (1 North, 1 Central) at every step until all 12 clusters have received the intervention by the end of the study. Each cluster will have 1-3 community sites and minimum 5 participants. Outcome assessors will be blinded to sequence allocation."|f|f|f|t
33871727|NCT05023096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33871728|NCT00549939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871729|NCT01576770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871730|NCT03823066|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|not possible|a humanoid socially assistive robot will be tested for people with dementia||||
34190656|NCT05724511|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190657|NCT05126251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190658|NCT05796206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190659|NCT01302249|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33755665|NCT02976441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871731|NCT02238873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33871732|NCT03901079|||CASE_ONLY||PROSPECTIVE|||||||
33871733|NCT00366964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33871734|NCT00174031|||DEFINED_POPULATION||PROSPECTIVE|||||||
34190660|NCT02978599|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34190661|NCT05063656|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label treatment with gabapentin for 8 weeks||||
34190662|NCT05222776|||COHORT||RETROSPECTIVE|||||||
34190663|NCT02644109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190664|NCT04727372|||OTHER||CROSS_SECTIONAL|||||||
34190665|NCT00778661|RANDOMIZED|CROSSOVER||||NONE||||||
34190666|NCT00275548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190667|NCT02592057|||COHORT||PROSPECTIVE|||||||
34190668|NCT02369744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190669|NCT01171560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190670|NCT02796261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190671|NCT00202878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190672|NCT02049606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190673|NCT03202602|||COHORT||PROSPECTIVE|||||||
34190674|NCT02874703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190675|NCT05770323|||COHORT||PROSPECTIVE|||||||
34190676|NCT03142711|||CASE_ONLY||PROSPECTIVE|||||||
34190677|NCT01833156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190678|NCT00829192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190679|NCT01286909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190680|NCT00788177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190681|NCT05874193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190682|NCT03820687|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190683|NCT04086329|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34190684|NCT00379301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190685|NCT05158764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190686|NCT04606329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190687|NCT02895789|||COHORT||PROSPECTIVE|||||||
34190688|NCT04604769|||COHORT||CROSS_SECTIONAL|||||||
34190689|NCT03335696|||COHORT||PROSPECTIVE|||||||
34190690|NCT00950859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190691|NCT01462253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190692|NCT02294799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190693|NCT00004908||||TREATMENT||||||||
34190694|NCT00194493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190695|NCT02803983|||CASE_CONTROL||PROSPECTIVE|||||||
34190696|NCT02637492|||COHORT||PROSPECTIVE|||||||
34190697|NCT02129907|||CASE_ONLY||PROSPECTIVE|||||||
34190698|NCT00021801||||TREATMENT||NONE||||||
34190699|NCT01037777|||FAMILY_BASED||PROSPECTIVE|||||||
34190700|NCT01305798|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34190701|NCT01956721|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34190702|NCT05861349|||CASE_CONTROL||PROSPECTIVE|||||||
34190703|NCT03867318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190704|NCT01680042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190705|NCT00923611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190706|NCT04343235|RANDOMIZED|PARALLEL||TREATMENT||NONE|randomized open label|Randomized controlled trial||||
34190707|NCT03367078|||COHORT||OTHER|||||||
34190708|NCT00467753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190709|NCT04755686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34190710|NCT03542786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||100 patients will be included in this trial. Patients will be randomized 2: 2: 1 to one of the following 3 branches according to the use of integrase inhibitors (INI), protease inhibitors (PI) or non-nucleoside analogue reverse transcriptase inhibitors ( ITINAN) and according to the CD4 count nadir is greater or less or equal to 200 cells / mm3: Branch A: add probiotic i3.1 to the antiretroviral therapy Branch B: add probiotic i3.1 and ProSeed prebiotic to the antiretroviral therapy Branch C: add placebo to ART The treatment periods will be of 6 months and follow-up will be carried out at month, at 3 months and at 6 after the start of the study treatment, and a last visit will be made at 3 months after discontinuing it (wash-out period).|t|f|t|f
34190711|NCT04820140|||COHORT||PROSPECTIVE|||||||
34190712|NCT04293822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.||t|t|t|f
33755666|NCT03880838|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|Participants, care providers, and outcomes assessors will not know the participant's arm. Insurance claims data and medical health records will be used (after all identifying information is removed).|"One group of participants will not be contacted at all (n = 6200). One group will only received a letter promoting a plant-based diet (n = 2200). Twelve groups (n = 550 for each group) will receive the letter promoting a plant-based diet, along with the Forks Over Knives documentary. The documentary will be delivered through 3 different methods, and the accompanying letter will contain 4 different combinations of behavioral nudges.~* 1 primary control group (no contact)~* 1 group contacted by letter~* 3 groups (documentary distribution: online link, DVD, online link + DVD) x 4 groups (behavioral nudges in the letter: no nudge, commitment nudge, prevention nudge, commitment and prevention nudges)~Note: The control group size is an estimate of number of participants who match the eligibility criteria but were not randomly assigned to an experimental group."|t|t|f|t
33871735|NCT03705637|NA|SINGLE_GROUP||OTHER||NONE||||||
33871736|NCT04219176|||CASE_ONLY||RETROSPECTIVE|||||||
33871737|NCT00524342|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190713|NCT01452932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190714|NCT00590772|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190715|NCT00892216|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34190716|NCT01374503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190717|NCT04349800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34190718|NCT05591235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190719|NCT01098643|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
34190720|NCT06354816|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||prospective, randomized, double-blind, controlled trial|t|f|t|f
34190721|NCT04058132|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Exposures/interventions will be the same for healthy controls and participants with traumatic brain injury No blinding and no treatments.||||
34190722|NCT06030570|||CASE_ONLY||PROSPECTIVE|||||||
34190723|NCT00392067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190724|NCT06520293|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34190725|NCT01900717|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190726|NCT00960570|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34190727|NCT02865707|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33871738|NCT04441268|||COHORT||PROSPECTIVE|||||||
33871739|NCT00833950||PARALLEL||TREATMENT||NONE||||||
34190728|NCT04726969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The parallel group trial co-administered moxidectin/albendazole versus albendazole alone will be double blinded (i.e. study participants and the trial team/researchers conducting the treatment and assessing the outcomes will be blinded) using tablets including appearance-matched placebos, while the ivermectin/albendazole arm will be open label due to the nature of ivermectin (i.e. requiring bodyweight-dependent doses).||t|t|t|t
34190729|NCT00254345|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34190730|NCT01892839|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34190731|NCT03788772|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34190732|NCT04110535|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190733|NCT01563133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190734|NCT06332417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190735|NCT04677413|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective dose evaluation||||
34190736|NCT02098122|||COHORT||PROSPECTIVE|||||||
34190737|NCT05515497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190738|NCT00456391|||DEFINED_POPULATION||OTHER|||||||
34190739|NCT02784067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190740|NCT01032889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190741|NCT03883165|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Neither subjects nor the study team members responsible for performing the laboratory- or radiology-based assessment will be informed of group allocation status, although subjects will be aware of whether or not they are performing neck strengthening exercises during their exercise sessions. Subjects will be instructed not to reveal their group status during subsequent assessment sessions.||t|f|t|t
34190742|NCT01517425|||CASE_CONTROL||RETROSPECTIVE|||||||
34190743|NCT00684060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190744|NCT05170997|RANDOMIZED|PARALLEL||PREVENTION||NONE||There will be four parallel groups in this study, stratified by iodine supplementation and then randomised to milk or control group.||||
34190745|NCT02451384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190746|NCT05820906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190747|NCT05008900|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Feasibility||||
34190748|NCT00003182||||TREATMENT||||||||
34190749|NCT01119079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190750|NCT00003496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190751|NCT03722277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34190752|NCT03536416|RANDOMIZED|PARALLEL||OTHER||SINGLE|The schools will be randomised, and will not be told which group they have been randomised to.|The study will include three treatment arms. The first arm will receive the theatre workshop only; the second arm will receive the theatre workshop and the self-management workshops; the control group will receive usual care. Schools will be randomised to one of the groups.|t|f|f|f
34190753|NCT05750771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190754|NCT00494247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190755|NCT00006205|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34190756|NCT00267787|||CASE_ONLY||PROSPECTIVE|||||||
34190757|NCT03869008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Subjects randomized to the Experimental group will use the gammaCore Sapphire till the end of the study. Subjects in this group will become un-blinded in the open label phase of the study at 4 weeks after randomization.~Subjects randomized to the Sham group will use the Sham device for 4 weeks. Subjects in the Sham group will become un-blinded in the open label phase of the study at 4 weeks after randomization and be switch to the gammaCore Sapphire for the rest of the study."|"At randomization subjects are randomized to 2 groups, the Experimental group and the Sham group.~The Experimental group will use the study device from randomization to the end of the study.~The Sham group will use the Sham device for 4 weeks after randomization then be switched to the study device for the rest of the study."|t|f|f|f
34190758|NCT04988503|RANDOMIZED|PARALLEL||TREATMENT||NONE||bare platinum coils group versus second-generation hydrogel coil group||||
34190759|NCT05236088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871740|NCT05988775|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled trial (RCT)|t|f|f|f
33871741|NCT02217085|||COHORT||PROSPECTIVE|||||||
33871742|NCT04800562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871743|NCT02771704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871744|NCT00975299|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33871745|NCT03290833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871746|NCT00108394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871747|NCT02324920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871748|NCT00817882|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33871749|NCT00247000|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33871750|NCT05265078|||COHORT||RETROSPECTIVE|||||||
33871751|NCT02317861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966350|NCT03908112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be masked to the treatment assignment and at follow-up examinations the examiners will be masked to the treatment group assignment. Investigators providing the therapy will be unmasked.|To compare the effectiveness of SC, SC+, SC plus office-based vergence/accommodative therapy for improving a composite outcome measure of clinical findings (near point of convergence and positive fusional vergence at near) in children 11-17 years of age with concussion-related CI after 12 weeks of treatment.|t|f|t|t
34190760|NCT03193827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two hundred and sixty-eight patients undergoing surgery are randomised 1:1 to in-line filtration (study group) and standard care (control group). For patients randomize to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used during anaesthesia and the following 96 postoperative hours. Patients randomize to standard care (control group) are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient. The incidence and severity of phlebitis are evaluated using the Visual Infusion Phlebitis (VIP) Score23 every 12 hrs from the end of surgery until 96 hrs postoperatively in both groups. Time and severity of phlebitis and time and causes for venous cannula removal are all compared between groups.|f|t|t|f
33966351|NCT01076166|||COHORT||PROSPECTIVE|||||||
33966352|NCT00399490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966353|NCT04014101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966354|NCT00149435|||COHORT||PROSPECTIVE|||||||
33966355|NCT01528878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966356|NCT04365088|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33966357|NCT02798237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966358|NCT02434796|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33966359|NCT00361257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33966360|NCT05471219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190761|NCT01173289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190762|NCT01666795|||COHORT||RETROSPECTIVE|||||||
34190763|NCT03412240|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190764|NCT00888043|NA|SINGLE_GROUP||||NONE||||||
34190765|NCT02956200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871752|NCT03536988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871753|NCT05270070|||COHORT||PROSPECTIVE|||||||
33871754|NCT04858230|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33871755|NCT00507390|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871756|NCT05949775|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1/PD-L1 drug therapy benefits patients with secondary drug-resistant malignant solid tumors, including but not limited to gastric cancer, esophageal cancer, and other gastrointestinal tumors of MSI-H.||||
33871757|NCT04241211|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33871758|NCT03106246|||COHORT||PROSPECTIVE|||||||
33871759|NCT04581564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The intervention is administered using an app installed in a smartphone or tablet pc. It does not involve drug, etc.|t|t|f|f
33871760|NCT03770949|||COHORT||PROSPECTIVE|||||||
33871761|NCT02820792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33871762|NCT06115772|||COHORT||PROSPECTIVE|||||||
33871763|NCT01098552|||COHORT||PROSPECTIVE|||||||
33966361|NCT05295251|||COHORT||PROSPECTIVE|||||||
33966362|NCT02874638|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33966363|NCT06530420|||COHORT||RETROSPECTIVE|||||||
33966364|NCT00004158||||TREATMENT||||||||
33966365|NCT05578833|||CASE_CROSSOVER||PROSPECTIVE|||||||
33966366|NCT01584726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966367|NCT04878250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966368|NCT01001676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966369|NCT00303264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966370|NCT03830931|||COHORT||PROSPECTIVE|||||||
33966371|NCT02360410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33966372|NCT03951597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966373|NCT04600882|||CASE_ONLY||CROSS_SECTIONAL|||||||
33966374|NCT02680977|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33966375|NCT06025396|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind|sequential assignment|t|f|t|f
33966376|NCT02544945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966377|NCT00740467|NON_RANDOMIZED|||TREATMENT||NONE||||||
33966378|NCT02499549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966379|NCT06150911|||COHORT||PROSPECTIVE|||||||
34190766|NCT05687669|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Group(A): Glyceryl trinitrate (GTN) is labelled with Drug A on syringe pump. Group(B): Phentolamine is labelled with Drug B on syringe pump."|Prospective study will be done in Assiut university hospital obstetric ICU, 2 groups will be examined and randomly assigned: group A using glyceryl trinitrate (GTN) to emergency control of blood pressure and group B using phentolamine infusion to control blood pressure. Each group consists of 85patients:|t|f|f|f
34190767|NCT02648256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871764|NCT05895149|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Each participant will pull from a bag within equally number of folded papers with letter 1 to 50 and it will be handled to the investigator. The even numbers correspond to the control group and the odd numbers to the experimental group.||t|f|f|t
33871765|NCT05993650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.|Assessment|t|f|f|f
33871766|NCT01240603|||||PROSPECTIVE|||||||
33871767|NCT06261398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871768|NCT04960982|||COHORT||CROSS_SECTIONAL|||||||
34190768|NCT02405442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871769|NCT04944212|||OTHER||CROSS_SECTIONAL|||||||
33871770|NCT01168648|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871771|NCT03427047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871772|NCT01087775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966380|NCT01092702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966381|NCT03765684|||COHORT||PROSPECTIVE|||||||
34190769|NCT04401683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33966382|NCT05990205|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966383|NCT00323609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966384|NCT03166306|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigators propose to enroll 10 patients with known severe idiopathic or familial PAH, 10 individuals with exercise-associated PAH (EPAH), felt to be a milder and early stage of PAH, and 10 healthy volunteers with no evidence of cardiopulmonary disease. Baseline PET-CT scans will be obtained 7 days after the injection of \[89Zr\]-bevacizumab. Follow- up imaging will be obtained 12 months status post enrollment.||||
34190770|NCT04380246|||COHORT||PROSPECTIVE|||||||
34190771|NCT00620503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190772|NCT04802668|||COHORT||PROSPECTIVE|||||||
34190773|NCT03899467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190774|NCT03159039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will randomized in 2 groups: group CCP (conventional chest physiotherapy techniques) (n=22) , the technique will made during 5 minutes in each side and after that, endotraqueal aspiration will performed.or group PSE (prolonged slow exhalation technique) (n=21), the technique will made during 10 minutes, 2 times a day.At the end, endotraqueal aspiration will perfomed.~During the protocol the parameters will recorder: respiratory rate, heart rate and peripheral oxygen saturation, exhaled tidal volume, number of days under mechanical ventilation and number of fail times in extubation. In 5 diferent moments."|t|f|f|f
34190775|NCT05756075|||COHORT||PROSPECTIVE|||||||
34190776|NCT03373396|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||It is a case-control study. There will be two groups. The patient will be assigned to a group according to the Metavir classification. F0 patients will be in the control group.||||
34190777|NCT01623713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190778|NCT05453669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190779|NCT02465424|||CASE_ONLY||OTHER|||||||
34190780|NCT05495269|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single treatment||||
34190781|NCT02310204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190782|NCT01600170|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34190783|NCT02840591|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190784|NCT03482960|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190785|NCT03304249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190786|NCT00327197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190787|NCT02310867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190788|NCT01437904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190789|NCT01668862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190790|NCT01384149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190791|NCT01780064|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190792|NCT04991051|||OTHER||PROSPECTIVE|||||||
34190793|NCT03961009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190794|NCT05688124|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190795|NCT04860544|||COHORT||OTHER|||||||
34190796|NCT00767936|||COHORT||PROSPECTIVE|||||||
33871773|NCT01018433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871774|NCT00124059|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33871775|NCT04562207|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871776|NCT03449589|||COHORT||PROSPECTIVE|||||||
33871777|NCT03737383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871778|NCT06190652|||COHORT||RETROSPECTIVE|||||||
33871779|NCT05858021|||CASE_ONLY||CROSS_SECTIONAL|||||||
33871780|NCT03542006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871781|NCT01572116|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33871782|NCT01353820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33871783|NCT05228795|||OTHER||PROSPECTIVE|||||||
34190797|NCT04675008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190798|NCT03805113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755667|NCT04573465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned with equal likelihood to receive the online intervention with coaching delivered through weekly phone calls, the online intervention with coaching delivered through weekly text messages, or the online intervention with no coaching.||||
34190799|NCT00286598|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33755668|NCT02819765|||CASE_ONLY||PROSPECTIVE|||||||
33755669|NCT06414551|||OTHER||RETROSPECTIVE|||||||
33755670|NCT00305799|||COHORT||PROSPECTIVE|||||||
33755671|NCT02022969|||COHORT||PROSPECTIVE|||||||
33755672|NCT02154984|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755673|NCT06013254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33755674|NCT04996615|||COHORT||PROSPECTIVE|||||||
33755675|NCT00241579|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34190800|NCT02989428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755676|NCT00587964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755677|NCT04385368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double- Blind||t|t|t|t
33755678|NCT05790538|||COHORT||PROSPECTIVE|||||||
33755679|NCT04525495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755680|NCT04135157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The anesthesia doctor who will perform the peripheral nerve block will be informed with a sealed envelope by an independent assistant outside the study.|Randomization of the study will be done by a doctor who will not participate in patient follow-up with closed envelopes using computer generated generated random numbers.|f|t|t|t
33755681|NCT04216030|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Participant is non-blinded based on differences in meal option A and B, meal option A --\> B or B --\> A, is assigned through investigator randomisation.|Each woman consumes both high-iron Irish potato and a regular Irish potato variety.||||
33755682|NCT04499807|NA|SINGLE_GROUP||OTHER||NONE||||||
33755683|NCT04274400|||COHORT||RETROSPECTIVE|||||||
33755684|NCT04496726|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single site, single group prospective cohort study||||
33755685|NCT02182973|||CASE_ONLY||PROSPECTIVE|||||||
33755686|NCT02120508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33755687|NCT04032665|||COHORT||PROSPECTIVE|||||||
33755688|NCT02922348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755689|NCT06239155|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33871784|NCT02151955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871785|NCT04243590|||COHORT||PROSPECTIVE|||||||
33871786|NCT00094770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871787|NCT05688436|||COHORT||PROSPECTIVE|||||||
33871788|NCT05293834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871789|NCT03615677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190801|NCT04437121|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34190802|NCT05002751|||COHORT||PROSPECTIVE|||||||
34190803|NCT01709669|||COHORT||PROSPECTIVE|||||||
34190804|NCT00600418|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34190805|NCT04611490|||COHORT||PROSPECTIVE|||||||
34190806|NCT00690144|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33871790|NCT03186677|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33871791|NCT06119490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871792|NCT00129324|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34190807|NCT04132271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34190808|NCT06126198|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
33755690|NCT02417818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755691|NCT04899882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755692|NCT04853680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know about the use of anti-adhesion agents.|Treatment: Use of Anti-adhesion barrier on the thyroidectomy space Control: No use of anti-adhesion barrier|t|f|f|f
33755693|NCT02112981|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|BioMime Sirolimus Eluting Stent system compared to the Abbott XIENCE family (V, Xpedition or Prime) of Everolimus Eluting Stent system||||
33755694|NCT01753921|||COHORT||CROSS_SECTIONAL|||||||
33755695|NCT04020848|||COHORT||PROSPECTIVE|||||||
33755696|NCT05177458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755697|NCT00816881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33755698|NCT03153579|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|randomized, double-blind, placebo-controlled, crossover|randomized, double-blind, placebo-controlled, crossover|t|t|t|t
33755699|NCT03238300|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33871793|NCT00272142|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33871794|NCT02547350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871795|NCT04882306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871796|NCT06042218|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33871797|NCT03814486|||COHORT||RETROSPECTIVE|||||||
33871798|NCT04247061|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33871799|NCT01805531|||COHORT||PROSPECTIVE|||||||
33871800|NCT03481114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871801|NCT00003737||||TREATMENT||||||||
33871802|NCT02170233|||COHORT||PROSPECTIVE|||||||
33871803|NCT03802175|||COHORT||PROSPECTIVE|||||||
33871804|NCT02264483|||CASE_CONTROL||PROSPECTIVE|||||||
33871805|NCT00889265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871806|NCT04049838|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized control study||||
33871807|NCT00002106||PARALLEL||TREATMENT||||||||
34190809|NCT02216240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190810|NCT04078256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190811|NCT02812017|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34190812|NCT00592800|||||PROSPECTIVE|||||||
34190813|NCT06058000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190814|NCT04849559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||A single center, randomized, double-blind, placebo-controlled study to evaluate the effects of tradipitant on satiation, gastric volume, gastric accommodation and gastric emptying in healthy volunteers|t|t|t|t
34190815|NCT00837317|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34190816|NCT02467634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190817|NCT05366868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190818|NCT05473481|||COHORT||PROSPECTIVE|||||||
34190819|NCT05201664|||CASE_ONLY||PROSPECTIVE|||||||
34190820|NCT03565952|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33871808|NCT03753646|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Assessor who will measure children's cognitive development and behavor and other measurements will be masked|We will integrate ECD services to Bangladesh government lactating allowance to measure children's neurocognitive behavior in urban area of Bangladesh.|f|f|f|t
33871809|NCT05744765|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized controlled, single-blind|t|f|f|t
33871810|NCT05768451|||CASE_CONTROL||RETROSPECTIVE|||||||
33871811|NCT05468554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind / placebo controlled|Arm A - patients qualified to receive metformin and 131I treatment, arm B - patients receiving placebo and 131 I treatment. Arm C- observation group, patients undergoing thyroidectomy, characterized by low risk of disease progression, in this case, not qualified for the 131I treatment.|t|t|t|f
33871812|NCT00822731|NA|SINGLE_GROUP||||NONE||||||
33871813|NCT04056572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871814|NCT04694664|||COHORT||CROSS_SECTIONAL|||||||
33871815|NCT03844984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871816|NCT02735395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871817|NCT01940471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871818|NCT02349048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871819|NCT02943564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871820|NCT00502138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871821|NCT02725983|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33871822|NCT02404623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33871823|NCT02446431|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871824|NCT03015571|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33871825|NCT02240979|||COHORT||PROSPECTIVE|||||||
33871826|NCT01231659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190821|NCT04058184|||COHORT||PROSPECTIVE|||||||
34190822|NCT04716296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinded: The participant , the neurologist, the neurophysiologist and neuropsychologist treating the participant will be blinded to the randomization arm. The neurosurgeon and anesthesiologist assigned to the patient will be unblinded to the randomization arm||t|t|f|t
34190823|NCT01536067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190824|NCT03387878|NA|SINGLE_GROUP||OTHER||NONE||||||
34190825|NCT05838118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190826|NCT00310661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190827|NCT04202172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190828|NCT03894228|||OTHER||PROSPECTIVE|||||||
34190829|NCT00627276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190830|NCT01994889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190831|NCT00315653|||||PROSPECTIVE|||||||
34190832|NCT03595995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190833|NCT02439489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190834|NCT05613218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Oxygen-delivery will be given through a robot, which adjusts oxygen-flow towards a given oxygen-saturation target. The robots monitor will be turned of during the intervention and will only alarm in case of clinically relevant hypoxemia.|1:1 allocation|t|t|f|t
34190835|NCT02942459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190836|NCT01420211|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34190837|NCT06164340|||CASE_CONTROL||RETROSPECTIVE|||||||
34190838|NCT02888938|||COHORT||CROSS_SECTIONAL|||||||
34190839|NCT06120829|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34190840|NCT06096311|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33966385|NCT04345731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Several different studies within one large study to explore the use of over the counter medical labels and reducing adverse side effects. Each study is a repeated subjects design, with each participant receiving all label treatments to allow a within subjects analysis of label effectiveness.||||
33966386|NCT06242522|NA|SINGLE_GROUP||OTHER||NONE||Prospective and retrospective cohort||||
33966387|NCT00711867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966388|NCT05202613|||CASE_CONTROL||RETROSPECTIVE|||||||
33966389|NCT02267733|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966390|NCT04455074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966391|NCT04273152|||COHORT||PROSPECTIVE|||||||
33966392|NCT06383377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be informed of their randomization assignment until the 1 year post implant placement follow-up visit. At this timepoint, the primary endpoint will have been achieved (at the implant placement visit) as well as the majority of the secondary endpoints. After the bone grafting surgery, all patients will receive an identic implant cart that does not break the blinding of the study. 1 year after implant placement, the patients will receive their definitive implant cart.|The parallel group will be treated with the product Bio-Oss® in a 1:1 randomization. Bio- Oss® is a natural bone mineral of bovine origin. Bio-Oss® is available as granules of spongious bone. Sterilization of Bio-Oss® is carried out by irradiation. Bio-Oss® has a macro- and microporous structure similar to human spongious bone. Bio-Oss® supports the in-growth of new bone at the implantation site by serving as a stable scaffold for osteoblasts; over time it is subject to the physiological remodeling process. Bio-Oss® is slowly resorbable, depending on the physiological environment of the individual patient, or integrated into the host bone. The highly purified osteoconductive mineral structure is produced from natural bone in a multistage purification process, adhering to the strictest safety regulations.|t|f|f|f
33966393|NCT02169661|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33966394|NCT05238285|||OTHER||PROSPECTIVE|||||||
33966395|NCT01901211|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33966396|NCT04562584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966397|NCT00066807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966398|NCT01259518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190841|NCT01074593|RANDOMIZED|CROSSOVER||||NONE||||||
34190842|NCT00254189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966399|NCT00493363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966400|NCT00492466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190843|NCT00554710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966401|NCT04976608|||CASE_ONLY||CROSS_SECTIONAL|||||||
33966402|NCT04141995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966403|NCT05550558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966404|NCT03552354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966405|NCT05941468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33966406|NCT03532477|||CASE_ONLY||PROSPECTIVE|||||||
33966407|NCT06360900|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33966408|NCT02778763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34190844|NCT04985552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190845|NCT01805791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects were randomized according to a stratified blocked randomization schedule generated by an unblinded biostatistician. Stratification was by country/region and modified Mayo Score at screening using an interactive web-based response system (IWRS).||t|t|t|t
34190846|NCT00466596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966409|NCT01906099|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33966410|NCT00010933|RANDOMIZED|||TREATMENT||DOUBLE||||||
33966411|NCT01186874|||COHORT||CROSS_SECTIONAL|||||||
33966412|NCT04528303|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33966413|NCT03734679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966414|NCT04582097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966415|NCT06085742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190847|NCT02059291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190848|NCT00632788|||COHORT||RETROSPECTIVE|||||||
34190849|NCT01324401|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|The observational control arm (parallel for the first year) was then offered to cross over to active treatment||||
34190850|NCT00333099|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34190851|NCT03937999|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group compared to concurrent and historical control groups||||
34190852|NCT01449799|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34190853|NCT02983812|||COHORT||PROSPECTIVE|||||||
33966416|NCT05906784|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2x2 factorial trial|f|f|t|f
34190854|NCT06516926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966417|NCT04624269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966418|NCT04372212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966419|NCT02736643|||CASE_ONLY||OTHER|||||||
33966420|NCT00631683|||COHORT||PROSPECTIVE|||||||
33966421|NCT05836597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190855|NCT04793022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34190856|NCT00578292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190857|NCT02786420|||COHORT||PROSPECTIVE|||||||
34190858|NCT04343105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34190859|NCT00711477|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34190860|NCT06316024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190861|NCT05518578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190862|NCT00759538|||COHORT||PROSPECTIVE|||||||
34190863|NCT00527241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190864|NCT04984837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190865|NCT05407662|||COHORT||CROSS_SECTIONAL|||||||
34190866|NCT00354276||||TREATMENT||NONE||||||
34190867|NCT04296448|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Block randomization, pediatric trainees are exposed in 2-week blocks: 1 week with Cellscope available, 1 week with the traditional otoscope||||
34190868|NCT04508088|||CASE_CONTROL||PROSPECTIVE|||||||
34190869|NCT00006118||||TREATMENT||||||||
34190870|NCT02614599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34190871|NCT04103788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||open-label, crossover||||
34190872|NCT02004444|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190873|NCT01712724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190874|NCT01497366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190875|NCT00201513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34190876|NCT06291519|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
34190877|NCT04422678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190878|NCT02512835|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34190879|NCT06248190|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be a type 2 hybrid trial, testing the effect of the intervention in improving clinical outcomes, and also testing and observing the effects of the intervention on implementation processes and outcomes using the RE-AIM (reach, effectiveness, adoption, implementation, maintenance) framework. The trial will be a cluster randomised parallel arm trial with embedded process evaluation.||||
34190880|NCT02489305|||COHORT||PROSPECTIVE|||||||
34190881|NCT00836121|||CASE_ONLY|||||||||
34190882|NCT02400983|||CASE_ONLY||RETROSPECTIVE|||||||
34190883|NCT00498290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190884|NCT04625517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190885|NCT00504530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190886|NCT06436599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190887|NCT05069272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190888|NCT00715910|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190889|NCT03012048|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190890|NCT05118880|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The research was conducted in the pretest-posttest experimental research design with intervention-control group.||||
34190891|NCT00625430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190892|NCT01170247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190893|NCT06425042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
34190894|NCT01111578|||COHORT||PROSPECTIVE|||||||
34190895|NCT02497742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190896|NCT02807584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190897|NCT03707704|||COHORT||PROSPECTIVE|||||||
34190898|NCT05766878|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34190899|NCT00650676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34190900|NCT02904213|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190901|NCT01794143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190902|NCT02415036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190903|NCT05207800|||COHORT||PROSPECTIVE|||||||
34190904|NCT00000176|RANDOMIZED|||PREVENTION||DOUBLE||||||
34190905|NCT04728516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190906|NCT01028196|||CASE_ONLY||CROSS_SECTIONAL|||||||
34190907|NCT03995940|||COHORT||CROSS_SECTIONAL|||||||
34190908|NCT02604160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|single-blind participant only||t|f|f|f
34190909|NCT03966430|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||a single center prospective cohort study||||
34190910|NCT00148707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190911|NCT03795246|NA|SINGLE_GROUP||OTHER||NONE||||||
34190912|NCT04696614|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|singal blinding for the assessor|Participants will be randomized with 1:1 equal allocation at baseline to one of two first-stage interventions (8 weeks aerobic exercise (AE) or interval training). Those who exhibit early signs of nonresponse determined by a tailoring variable (reduced (visceral adipose tissue (VAT) \< 3%) will then be rerandomized to one of two second-stage interventions (AE + RE (resistance exercise) vs interval training or AE), also with 1:1 equal allocation, whereas those who have a significant response to the first-stage intervention will continue to receive the same exercise treatment until 16 weeks.|f|f|f|t
34190913|NCT00792168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34190914|NCT04074161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Semaglutide once weekly vs liraglutide once daily treatment will be open label, but each of the two active treatment arms will be double blinded against placebo administered at the same dosing frequency.~Sponsor staff involved in the clinical trial is masked according to company standard procedures."||t|t|t|t
34190915|NCT03518255|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|This study has no masking.|||||
34190916|NCT04815148|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Phase Ia is open label while Phase Ib is double blind.|||||
34190917|NCT05070351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34190918|NCT02101424|||COHORT||PROSPECTIVE|||||||
34190919|NCT04239378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871827|NCT04744207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871828|NCT00721474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966422|NCT00028730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190920|NCT02093195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190921|NCT01110148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34190922|NCT00555061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190923|NCT01191762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190924|NCT04059536|||COHORT||PROSPECTIVE|||||||
34190925|NCT04909918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34190926|NCT05423743|RANDOMIZED|PARALLEL||OTHER||NONE||This cluster-randomized trial will assess a novel quality improvement antibiotic stewardship strategy for empiric antibiotic selection.||||
34190927|NCT04527900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190928|NCT04944290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190929|NCT02039843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34190930|NCT02563067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190931|NCT00922948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190932|NCT01402102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34190933|NCT00277654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34190934|NCT05647603|||CASE_ONLY||CROSS_SECTIONAL|||||||
34190935|NCT02606201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190936|NCT04201808|NA|SINGLE_GROUP||TREATMENT||NONE||This is single-arm, multicenter cohort study evaluating the efficacy, safety, and tolerability of TAF monotherapy in Asian CHB adults with SOR to the nucleos(t)ide therapy by assessing the HBV DNA suppression over a duration of 48 weeks.||||
34190937|NCT04890041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190938|NCT00552188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190939|NCT00389987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34190940|NCT02571335|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34190941|NCT01640314|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190942|NCT00324259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190943|NCT04135287|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be randomized to receive for 6 months in an open label fashion GLP1RA||||
34190944|NCT03145688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34190945|NCT06140030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190946|NCT05262049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190947|NCT05944484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant,outcomes Assessor) Random generator|Visceral fat reduction vs total body fat reduction on obese female with stress urinary incontinence|t|f|f|t
34190948|NCT05233241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34190949|NCT02296983|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190950|NCT04279418|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34190951|NCT06363942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34190952|NCT02973438|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34190953|NCT05178719|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|"The clinical study started in a randomized, double-blinded, controlled study aimed to assess the effect of zeolite-intervention in osteoporotic patients on the bone mineral density and bone turnover in comparison to osteoporotic patients. In the rears 2-5 only receiving the study substance.~The study TOP 2 started with 81 patients with osteoporosis defined according BMD criteria: T score -2, 5 on the femoral neck, and, or T -2, 5 on L1-L5, who have not been treated before, or in whom privies treatment did not been successful, despite a gender or age.~Subjects were monitored at the start of the study and at the end of each study year. The surrogate markers of bone status are measured as follows: BMD, changes in levels of osteocalcin and beta-crosslaps CTx assay."||||
34190954|NCT00104520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190955|NCT01910935|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34190956|NCT05343728|||COHORT||PROSPECTIVE|||||||
34190957|NCT06290648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966423|NCT04423653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966424|NCT02328807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190958|NCT04588467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966425|NCT06526871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190959|NCT01120717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190960|NCT02512848|||OTHER||OTHER|||||||
34190961|NCT04960956|||COHORT||PROSPECTIVE|||||||
34190962|NCT03526029|||COHORT||OTHER|||||||
34190963|NCT03913338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized, intra-patient controlled, clinical trial|t|f|f|t
34190964|NCT00752804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34190965|NCT00886678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871829|NCT04247958|||CASE_ONLY||PROSPECTIVE|||||||
33871830|NCT02670824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871831|NCT04686175|NA|SINGLE_GROUP||TREATMENT||NONE||Study INZ701-101 is a Phase 1/2, multi-center, open-label, first-in-human (FIH), multiple ascending dose (MAD) study followed by a long-term open-label extension period conducted in adults with ENPP1 Deficiency. The study design during the Dose Evaluation Period is a MAD 3+3 with 3 dose cohorts.||||
33871832|NCT01779037|||OTHER||OTHER|||||||
33871833|NCT01262378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966426|NCT01503242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966427|NCT02174900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190966|NCT01367951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190967|NCT00782834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34190968|NCT04198051|NA|SINGLE_GROUP||OTHER||NONE||||||
34190969|NCT00862641|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34190970|NCT00811486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190971|NCT00000156|RANDOMIZED|||TREATMENT||DOUBLE||||||
34190972|NCT00796991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966428|NCT05694429|NA|SINGLE_GROUP||OTHER||NONE||||||
33966429|NCT03595709|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label||||
33966430|NCT04800107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized to a treatment or placebo group after completing both the TFI and THI surveys.||t|f|t|f
34190973|NCT05048576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966431|NCT00242775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966432|NCT02996435|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966433|NCT05898490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966434|NCT03413865|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34190974|NCT03136848|NA|SINGLE_GROUP||OTHER||NONE||A pilot study of procedural feasibility involving both device and drug (organ perfusate solution).||||
34190975|NCT02487017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34190976|NCT01895556|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34190977|NCT02199210|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34190978|NCT05274893|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34190979|NCT02428725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34190980|NCT04562051|||COHORT||PROSPECTIVE|||||||
34190981|NCT01397903|||CASE_ONLY||CROSS_SECTIONAL|||||||
34190982|NCT03328208|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The four tablets used in the study will be labeled A,B,C,D and will be preloaded with the app or white noise by the Hypnalgesics, LLC in randomized sequence. Personnel at TUSDM will not be aware which tablet presents test or control content. The opening screen and option screen of the white noise control app will use the same color scheme and lay-out as the one of the test Comfort Talk app. The statistical team will receive the encoded data entries and will not be informed about the content of the tablets until all analyses are completed. Since they also will not have direct contact with the study patients they are also not at risk of becoming unblinded during app use by the patients.~At the end of their visit, patients will receive a sealed envelope which according to their number will either contain a download coupon for the app for home use or a thank you note. To maintain blinding, all patients who send their diaries back will receive a download coupon."|This is a single-blind placebo-controlled trial comparing a Comfort Talk® calmative app (App Group) with a white noise app (Control Group).|f|t|t|t
34190983|NCT02032238|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
34190984|NCT02739971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants and study dietitian can not be blind to the assigned dietary intervention. However, the clinical testing and all data analysis are carried out blind to the intervention.|A randomized pilot trial|f|f|f|t
34190985|NCT03672890|||COHORT||PROSPECTIVE|||||||
34190986|NCT00480467|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34190987|NCT00687778|||COHORT||PROSPECTIVE|||||||
34190988|NCT06075355|||COHORT||RETROSPECTIVE|||||||
34190989|NCT01984658|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
34190990|NCT02049541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34190991|NCT00732446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34190992|NCT00908843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190993|NCT05744804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34190994|NCT01264705|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34190995|NCT02561338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34190996|NCT03544333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34190997|NCT01259232|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34190998|NCT02074462|||COHORT||PROSPECTIVE|||||||
34190999|NCT02640339|||COHORT||PROSPECTIVE|||||||
34191000|NCT06186193|||COHORT||PROSPECTIVE|||||||
34191001|NCT00442364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191002|NCT01374230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191003|NCT03865381|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191004|NCT03807375|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34191005|NCT01900418|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34191006|NCT01284036|NA|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34191007|NCT01819532|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33966435|NCT06530394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Independent blind researchers will analyze blood and data using masked participant codes.|Participants will be invited to participate in this 8-week study, with senior fit participants being randomly assigned into the control (NYEX) or the intervention exercising (GYEX) group and non-senior fit citizens from the Niagara community will be assigned to the intervention non-exercising group (GYNE).|f|f|f|t
33966436|NCT00350519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966437|NCT00854620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966438|NCT00409188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966439|NCT02577289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191008|NCT05749432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191009|NCT04978103|NA|SINGLE_GROUP||TREATMENT||NONE|Both the investigators and outcome assessors will be given codes of the participants for further analysis|Postmenopausal females are randomly selected to receive Gum Arabic treatment and intended outcomes will be measured before and after the intervention||||
34191010|NCT03578952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191011|NCT00539942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191012|NCT02880436|||COHORT||RETROSPECTIVE|||||||
34191013|NCT02067676|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191014|NCT04522284|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-centre, one-arm, prospective pilot study of participants diagnosed with either solid organ or haematological neoplasm.The participants will be enrolled for the duration of their treatment with the selected regimens, XELOX, XELIRI and single agent capecitabine regimens or single-agent ibrutinib . At 12-month mark, the decision on the patient engagement with the study will be made by the principal investigator in consultation with the study sponsors and treating physician.||||
34191015|NCT02734641|||COHORT||PROSPECTIVE|||||||
33966440|NCT00541294|||OTHER||PROSPECTIVE|||||||
33966441|NCT01454882|||||CROSS_SECTIONAL|||||||
33871834|NCT00114335|||COHORT||CROSS_SECTIONAL|||||||
34191016|NCT04208607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871835|NCT05023759|||COHORT||PROSPECTIVE|||||||
33871836|NCT00792194|RANDOMIZED|PARALLEL||||NONE||||||
33871837|NCT06307821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double（Participant,Investigator）||t|f|f|f
34191017|NCT03867370|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34191018|NCT00006117||||TREATMENT||||||||
34191019|NCT00314795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191020|NCT03672097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191021|NCT02978781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191022|NCT03492918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191023|NCT02666625|||COHORT||PROSPECTIVE|||||||
34191024|NCT03122951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191025|NCT03435783|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Randomized controlled trial where participants are assigned to either a treatment or control group.|f|f|t|f
34191026|NCT00166413|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191027|NCT02184624|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34191028|NCT00725062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191029|NCT02314637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191030|NCT03264729|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34191031|NCT04937465|||COHORT||OTHER|||||||
34191032|NCT00790088|||COHORT||PROSPECTIVE|||||||
34191033|NCT05065411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the central radiologist readers will be blinded to treatment assignments|Open Label two treatment arm|f|f|f|t
34191034|NCT03180840|NA|SINGLE_GROUP||TREATMENT||NONE||Switch over study in patients previously receiving either agalsidase alfa or agalsidase beta and switched to pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease.||||
34191035|NCT03122834|||COHORT||PROSPECTIVE|||||||
34191036|NCT02396472|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34191037|NCT02945709|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34191038|NCT01046838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191039|NCT05540587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191040|NCT04346355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191041|NCT03479164|NA|SINGLE_GROUP||OTHER||NONE||||||
34191042|NCT04455152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random assignment will not be made, nor known to anyone, until informed consent process and baseline assessment are completed.|Participants are randomly assigned to self-control vs. wait list for 2 weeks after baseline assessment and before all receive 10 weeks of web-based self-help.|f|f|t|f
34191043|NCT00064688|||COHORT||CROSS_SECTIONAL|||||||
34191044|NCT04981535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191045|NCT04452110|||COHORT||PROSPECTIVE|||||||
34191046|NCT01656655|||COHORT||CROSS_SECTIONAL|||||||
34191047|NCT03340324|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|open-label, single arm study||||
34191048|NCT01601652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191049|NCT06134141|||OTHER||PROSPECTIVE|||||||
34191050|NCT00635271|||||PROSPECTIVE|||||||
33871838|NCT01214928|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33871839|NCT04507542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A clinical researcher with expertise in stroke rehabilitation will perform the evaluations and will be blinded to participants' group allocation.|A parallel-group randomised controlled trial will be conducted with participants being randomised to either an enriched Music-Supported Therapy group or to a control treatment group receiving the Graded Repetitive Arm Supplementary Program (GRASP, Harris et al., 2009).|f|f|f|t
33871840|NCT02976714|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871841|NCT01650961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33871842|NCT01141842|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
33871843|NCT05567497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871844|NCT04101279|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled comparative study||||
34191051|NCT01146327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191052|NCT03458013|NON_RANDOMIZED|PARALLEL||OTHER||NONE||We are using a 2-cohort, nonrandomized comparative design focused on assessing feasibility and acceptability.||||
34191053|NCT01236976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191054|NCT03563183|||OTHER||RETROSPECTIVE|||||||
34191055|NCT03771170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will perform the assessment of primary, secondary efficasy and safety parameters|Assignment|f|f|f|t
34191056|NCT03407716|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34191057|NCT05085301|||COHORT||OTHER|||||||
34191058|NCT02176252|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34191059|NCT06425835|||COHORT||PROSPECTIVE|||||||
34191060|NCT05266833|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34191061|NCT03333772|NA|SINGLE_GROUP||OTHER||NONE||||||
34191062|NCT01658644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191063|NCT06205550|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191064|NCT05927337|RANDOMIZED|PARALLEL||TREATMENT||NONE|The nature of the intervention (Cognitive Behavioral Therapy) makes it impossible to mask interventions assigned.|||||
34191065|NCT04390204|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191066|NCT06457906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191067|NCT01358955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191068|NCT04820881|||CASE_CONTROL||PROSPECTIVE|||||||
34191069|NCT06273696|||COHORT||PROSPECTIVE|||||||
34191070|NCT05431270|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a first-in-human, Phase I, open-label, dose-escalation and expansion study.~The study will consist of 3 parts: Monotherapy Dose Escalation (Part A), Combination Therapy Dose Escalation (Part B), and Combination Dose Expansion (Part C). Patients may be eligible for intra-patient dose escalation as well as crossover from Monotherapy to Combination therapy."||||
34191071|NCT02384434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191072|NCT03308721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34191073|NCT04215497|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34067588|NCT05537285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be achieved via a sham rTMS coil (Cool-B65 A/P) used with the device. This coil can deliver either active or sham stimulation in a manner that is randomized by the system itself and therefore blinded to the treater. The sham setting on this coil looks and sounds identical to the active setting but has a hidden aluminum plate blocking actual stimulation. The MagVenture TMS device holds a blinded key code that is kept by the individual that holds the blind. During the rTMS setup, the operator is instructed to flip the coil to correspond with the key code, but the operator is not able to discern the active versus sham stimulation. Additional measures will be taken to ensure that the treater remains blinded during treatment administration.|Patients enrolled in the study will be evenly randomized into one of three treatment groups: Individualized Accelerated Intermittent Theta-Burst Stimulation (Ind-aiTBS), Standard aiTBS (Std-aiTBS). Treatments will last 1 week in all three arms.|t|t|f|f
34067589|NCT05035849|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067590|NCT03873311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067591|NCT01879202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871845|NCT04776733|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34067592|NCT03913871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An online randomizer software was used to assign participants into one of two arms.|This was a clinical trial (behavioral with no clinical assessments) in which two groups of participants receive different interventions. One group received a healthy eating program, and the other group received a physical activity program.|t|f|f|f
34067593|NCT06154421|||COHORT||RETROSPECTIVE|||||||
34067594|NCT01038752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067595|NCT00135356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067596|NCT05732077|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34191074|NCT04103580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized 2 arm study; control and intervention||||
34191075|NCT01837823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191076|NCT01293656|||COHORT||CROSS_SECTIONAL|||||||
34191077|NCT02706262|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191078|NCT03859297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"First two years. randomization to either rumination-focused cognitive behavioral therapy (RF-CBT) or Assessment only (AO) for a 10 week intervention period.~Last three years. randomization to either rumination-focused cognitive behavioral therapy (RF-CBT) or Relaxation therapy (RelaxT) for a 10 week intervention period."|t|f|f|t
34191079|NCT02173509|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191080|NCT02129088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191081|NCT05338424|||CASE_CROSSOVER||PROSPECTIVE|||||||
33871846|NCT01439464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191082|NCT06103253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191083|NCT03159793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191084|NCT00794313|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34191085|NCT01475617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191086|NCT01802073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191087|NCT00778843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191088|NCT05211583|||COHORT||PROSPECTIVE|||||||
34191089|NCT00283634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191090|NCT02230514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiologist will assess images in a blinded manner||f|f|f|t
34191091|NCT00936312|||COHORT||RETROSPECTIVE|||||||
34191092|NCT01316068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191093|NCT00481091|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34191094|NCT03799042|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34191095|NCT03135691|||CASE_ONLY||RETROSPECTIVE|||||||
34191096|NCT03548181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is a randomized controlled trial|The study is a prospective, randomized controlled trial comparing the effects of tele-rehabilitation and standard treatment in patients with IPF|t|f|f|t
34191097|NCT01632124|||COHORT||PROSPECTIVE|||||||
34191098|NCT04119518|NA|SINGLE_GROUP||OTHER||NONE||Prospective, method-comparison, proof of concept, single centre study||||
34191099|NCT04240132|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, observational and semi-experimental (mix method)||||
34191100|NCT06315790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191101|NCT02172417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191102|NCT01783756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191103|NCT02174484|||COHORT||PROSPECTIVE|||||||
34191104|NCT05433285|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Vaccine candidate and active comparator are masking, lot number is masking||t|f|t|f
33871847|NCT03601520|||COHORT||RETROSPECTIVE|||||||
33871848|NCT02902354|NA|SINGLE_GROUP||SCREENING||NONE||||||
33871849|NCT02361541|||COHORT||CROSS_SECTIONAL|||||||
33871850|NCT04449770|||COHORT||PROSPECTIVE|||||||
33871851|NCT03739398|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"LUTRONIC GENIUS Laser is performed on one side and LASEMD Laser is performed on the other. LUTRONIC GENIUS Laser is performed on the other side without energy irradiation. Laser treatment is performed after application of EMLA cream (2.5% lidocaine 2.5% and prilocaine 2.5%) for 30 minutes or more before local anesthesia.~Measurement of hydration, transepidermal water loss, skin pigmentation, redness, and elasticity were performed using a corneometer, a vapometer, a mexameter, and a cutometer before the procedure and on the 7th day after the first operation and 3 months after the last operation. Using an Antera 3D® camera, the skin texture, wrinkles, pores, volume of depressions / elevations, skin color, redness and pigmentation were measured. The change of skin surface and extent of wrinkle were measured using a visuometer, a high-resolution camera."||||
33871852|NCT03328702|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871853|NCT04467944|||COHORT||PROSPECTIVE|||||||
33871854|NCT04055714|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, non-significant risk, multi-center, non-controlled trial||||
33871855|NCT00662402|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33871856|NCT06535243|NA|SINGLE_GROUP||OTHER||NONE||"eligible candidates to be included in this cohort should be~* older than 18 yo~* French speaking~* with a diagnosis of complex PTSD as confirmed by 1/clinical interview with a trained psychiatrist and 2/ scores for the International Trauma Questionnaire (ITQ), clinical tool based on the ICM 11 criteria"||||
33871857|NCT06280131|||COHORT||PROSPECTIVE|||||||
34067597|NCT03013790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34191105|NCT03198624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A open label, Part B double blind.||t|t|t|f
34067598|NCT01298349|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34067599|NCT04086381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A double-blind, randomised, controlled, cross-over intervention trial.|t|f|t|f
33871858|NCT05886790|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In people aged 18 years and older, people were divided into in three groups and vaccinated using three kinds of vaccines:~1. Test vaccine 1: Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation~2. Test vaccine 2: Bivalent COVID-19 mRNA Vaccine~3. Control vaccine: Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation"||||
34067600|NCT00552890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191106|NCT04909073|||COHORT||PROSPECTIVE|||||||
34191107|NCT02897570|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34191108|NCT00972361|||CASE_ONLY||RETROSPECTIVE|||||||
34191109|NCT00363701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34191110|NCT05376332|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover model: Participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study||||
34191111|NCT01186172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191112|NCT01698034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191113|NCT02608801|||COHORT||PROSPECTIVE|||||||
34191114|NCT05649319|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective randomized open-labeled study||||
34191115|NCT02879201|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191116|NCT03290924|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34191117|NCT00930072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34191118|NCT00845767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34191119|NCT00373113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191120|NCT04133129|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are only assigned to one of 3 possible groups for the duration of the intervention.||||
34191121|NCT02202083|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||f|t|t|f
34191122|NCT00865540|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34191123|NCT02934503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191124|NCT01309282|||COHORT||PROSPECTIVE|||||||
34191125|NCT06257589|||COHORT||RETROSPECTIVE|||||||
34191126|NCT03891238|NA|SINGLE_GROUP||TREATMENT||NONE||To assess the activity of avelumab in patients with metastatic or locally advanced PD-L1 positive urothelial cancer not eligible for cisplatin-based chemotherapy.||||
34191127|NCT05217316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|20 primary schools in Riyadh, Saudi Arabia will be recruited to the trail. Schools are the unit of clustering will be randomly selected and allocated to groups. The schools who did not respond and refused to participate will be dropped and replaced randomly from the selected list. All data entry and management will be carried out by the study principal investigator. This will be applied by pseudo-anonymization, an artificial identifier (code) will be assigned to each subject as he enrolled in the study. All the study team members will deal with coded data while collecting or analyzing information.|This is a cluster randomized controlled trial comparing virtual supervised tooth brushing program against conventional oral hygiene program (lecture and tooth brushing demonstration). 1280 children in 20 primary schools in Riyadh, Saudi Arabia will be recruited to the trail. Schools are the unit of clustering. Schools will be randomly selected and allocated in two groups, intervention, and control group (10 schools for each group). Clinical assessment for dental caries will be conducted in four points (baseline, 6 months, 12 months, 18 months). Both groups will receive oral assessment and both will receive a videos five times a week that illustrate a unified toothbrushing technique and remind the child to brush their teeth. The intervention lies in which the intervention group will receive a supervised virtual toothbrushing performed once a week for each child.|f|f|t|f
34191128|NCT01291082|||CASE_ONLY||PROSPECTIVE|||||||
34191129|NCT03945604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191130|NCT01533350|||CASE_CONTROL||PROSPECTIVE|||||||
34191131|NCT02736370|||COHORT||PROSPECTIVE|||||||
34191132|NCT05101304|||COHORT||OTHER|||||||
34191133|NCT04976907|||COHORT||PROSPECTIVE|||||||
34191134|NCT03156296|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34191135|NCT06096571|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34191136|NCT00808652|||COHORT||PROSPECTIVE|||||||
34191137|NCT01040234|||COHORT||PROSPECTIVE|||||||
34191138|NCT01675167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871859|NCT00644774|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33871860|NCT00616122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191139|NCT00436514|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34191140|NCT04367623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191141|NCT00528697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191142|NCT00006119||||TREATMENT||||||||
34191143|NCT06471192|||COHORT||PROSPECTIVE|||||||
34191144|NCT01275807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191145|NCT04865900|||COHORT||PROSPECTIVE|||||||
34191146|NCT00318734|||COHORT||PROSPECTIVE|||||||
33871861|NCT00939783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871862|NCT03766529|||COHORT||PROSPECTIVE|||||||
33871863|NCT04782544|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33871864|NCT05645874|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33871865|NCT00606203|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33871866|NCT00052351|RANDOMIZED|||TREATMENT||||||||
33871867|NCT05074264|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33871868|NCT03523728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33871869|NCT00441974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191147|NCT03877328|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33755700|NCT05843916|NA|SINGLE_GROUP||TREATMENT||NONE||BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group, baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and previously stabilized with Fabrazyme®.||||
33755701|NCT04701151|RANDOMIZED|PARALLEL||TREATMENT||NONE||multi-center, multi-national, two-armed, randomized, open-label, investigator-initiated clinical controlled - phase IV trial.||||
33755702|NCT05597657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755703|NCT02163733|RANDOMIZED|||OTHER||NONE||||||
33755704|NCT02827604|||COHORT||PROSPECTIVE|||||||
33755705|NCT01973660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191148|NCT03391245|||COHORT||PROSPECTIVE|||||||
34191149|NCT04872140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The powder supplements are being administered in a blinded manner. An individual who is separate from the rest of the research team will generate the allocation schedule and prepare the supplement packages so that participants, investigators, and outcome assessors are blinded. Statistical analysis will be blinded by coding of groups|"Participants are being randomized to three groups for the 8-week intervention:~1. Pea power with high iron bio-availability~2. Regular pea powder~3. Placebo (maltodextrin)"|t|f|t|t
34191150|NCT01882608|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191151|NCT03337490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191152|NCT06046170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor is blinded|Randomized assignment to one of two conditions|f|f|f|t
34191153|NCT06099080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191154|NCT04161703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191155|NCT01962363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191156|NCT05354362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191157|NCT02427997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191158|NCT02529228|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34191159|NCT00459186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191160|NCT02273804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191161|NCT04145219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34191162|NCT05549752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191163|NCT01864382|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34191164|NCT00947193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191165|NCT02014701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191166|NCT04541771|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||participants will be divided in two groups. one is control group and the other Interventional group. control group will receive the drug under study and control will be given placebo for the period of until they complete 35 weeks of gestation or discharged.|t|t|f|f
34191167|NCT06523101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755706|NCT02203240|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33755707|NCT03289234|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33755708|NCT01472198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755709|NCT04233476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755710|NCT04202380|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755711|NCT01466985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755712|NCT04602533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755713|NCT00005600|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33755714|NCT00733603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755715|NCT05919693|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participant Care Provider Outcomes Assessor|"Part 1 is a multiple-dose escalation study and patients will be enrolled sequentially in ascending order through the dose levels until the highest level is reached or until a maximum tolerated dose is reached, whichever comes first.~Part 2 is randomized single-masked study where patients on all arms will be enrolled in parallel."|t|t|f|t
33755716|NCT06243718|||COHORT||CROSS_SECTIONAL|||||||
33755717|NCT05684406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755718|NCT05019248|||CASE_CONTROL||PROSPECTIVE|||||||
33755719|NCT05738187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755720|NCT02362048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755721|NCT02471651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755722|NCT01064206|||CASE_CONTROL||PROSPECTIVE|||||||
33755723|NCT00063050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755724|NCT05204225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755725|NCT01723722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755726|NCT00522301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871870|NCT03692000|||OTHER||OTHER|||||||
34191168|NCT05078762|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participants will not be blinded to the main investigator, as this is impossible due to the nature of the trial. The statistical analysis will be performed blinded and by someone other than the principal investigator.|Randomization is performed online using SealedEnvelope™ (Sealed Envelope ltd, London, UK) before the start of the trial. The participants are stratified by sex (man/woman) as this has been seen to influence skills acquisition during the early part of in the learning curve|t|f|f|t
34191169|NCT00865410|RANDOMIZED|CROSSOVER||||NONE||||||
34191170|NCT01588392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191171|NCT02238080|||COHORT||PROSPECTIVE|||||||
34191172|NCT05430633|||COHORT||RETROSPECTIVE|||||||
34191173|NCT02470000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191174|NCT03519529|||COHORT||RETROSPECTIVE|||||||
34191175|NCT01214096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191176|NCT02937324|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34191177|NCT02064413|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34191178|NCT00124553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191179|NCT02228837|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191180|NCT00858338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191181|NCT03038828|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34191182|NCT05311813|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Patients were randomized into four parallel equal groups using a computerized random number generator using simple randomization with an equal allocation ratio. Two hundred and twenty patients were eligible. Twenty patients were excluded due to not meeting the inclusion criteria (n=14) or the decline to be enrolled in the study (n=4). The sample size was calculated by G.power version 3.1 for windows (Faul et al., 2009). With a priori calculating the sample size based on the length of stay among the studied groups using one way ANOVA test (F-test group), at an effect size (0.306), alpha probability (0.05) and power (95%), the calculated sample size was 184 in the 4 groups that increased to 200 (with 6% increase) to overcome the missing of data and dropout or loss of follow up.||||
34191183|NCT05737199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191184|NCT01172717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191185|NCT03763097|||COHORT||PROSPECTIVE|||||||
34191186|NCT05282134|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34191187|NCT00892983|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34191188|NCT06214091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191189|NCT02441296|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34191190|NCT00823615|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33755727|NCT02096523|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34191191|NCT05519722|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomly distributed to the intervention group or the control group. The intervention group will receive a nonguided online-intervention to optimize expectations. The control group will receive no intervention at all.||||
34191192|NCT01587014|||CASE_ONLY||PROSPECTIVE|||||||
34191193|NCT03734640|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|Guardian consent for intervention as standard of care service provision. Outcome assessed by independent researcher blind to treatment allocation|stepped wedge cluster randomized|t|f|f|t
34191194|NCT02922296|||OTHER||PROSPECTIVE|||||||
34191195|NCT02121821|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191196|NCT05302648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191197|NCT03536117|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34191198|NCT05367089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191199|NCT02551549|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34191200|NCT03120195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191201|NCT00406562|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34191202|NCT04299932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191203|NCT03745599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34191204|NCT00244140|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34191205|NCT01354899|||CASE_CONTROL||PROSPECTIVE|||||||
34191206|NCT03605628|NA|SINGLE_GROUP||TREATMENT||NONE|Assessment of the quality of operation conditions by the obstretic surgeon without information with regard to the actual depth of the neuromuscular block or the drugs administrated for improvement of the block.|||||
34191207|NCT03536793|||COHORT||PROSPECTIVE|||||||
34191208|NCT05714800|||COHORT||PROSPECTIVE|||||||
34191209|NCT03669276|||CASE_ONLY||RETROSPECTIVE|||||||
34191210|NCT02498171|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191211|NCT01563653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191212|NCT05219916|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Descriptive physiopathological study||||
34191213|NCT01297491|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191214|NCT03309176|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stair step group: blind start ovulation induction (no progesterone induced withdrawal bleeding and stair step protocol in case of treatment failure.~Control: standard care; a progesterone induced withdrawal bleeding in case of no spontaneous menses before starting an ovulation induction cycle and in between anovulatory cycles."||||
34191215|NCT00541619|||COHORT||PROSPECTIVE|||||||
34191216|NCT03872778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I: dose finding to identify Recommended Phase II Dose Phase IIa: preliminary assessment of anti-tumor activity||||
34191217|NCT02584556|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191218|NCT04873960|||OTHER||CROSS_SECTIONAL|||||||
34191219|NCT03894397|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Both the patient and the psychiatrist are blinded during the cross-over phase, until the end of the study. The investigator who will evaluate behavior from the videorecordings, will also be blinded.~Unblinded are: the principal investigator (who has access to all data) and the technical staff in charge of stimulation settings."|We will evaluate the effect of unilateral and bilateral stimulation of the BNST. Four conditions will be evaluated: left BNST stimulation, right BNST stimulation, bilateral BNST stimulation or no stimulation (OFF). Note that the order of these conditions is stratified beforehand (www.random.org). Each condition takes around 15 minutes.|t|t|f|t
34191220|NCT04904393|||OTHER||PROSPECTIVE|||||||
34191221|NCT03005405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191222|NCT05689580|RANDOMIZED|CROSSOVER||TREATMENT||NONE||For Group 1, subjects will be educated by dietitian and receive two months of ketogenic diet. Then, followed by three months of washout period. Finally, they will receive dietary education and follow balanced diet for two months. For Group2, subjects will receive dietary education and follow balanced diet for two months first, then followed by three months of washout period. At last, they will receive dietary education of ketogenic diet and need to follow the ketogenic diet for two months.||||
34191223|NCT03742466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191224|NCT00157482|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33871871|NCT04688736|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither patients nor medical staff, including physicians and nurses participating in this study, will know the group assignment after allocation.||t|f|t|f
33871872|NCT01606267|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33871873|NCT05623579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871874|NCT00645593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871875|NCT04187638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, double-blind, placebo-controlled crossover trial.||||
33871876|NCT05502042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Our primary outcome, adherence to SAP, will be abstracted from copies of final Uganda Ministry of Health SAP booklets by a team member blinded to treatment allocation.|Case Managers and Peer Support Groups (CAMPS) will be a pragmatic randomized trial of two support strategies for rheumatic heart disease secondary antibiotic prophylaxis, integrated into routine care.|f|f|f|t
33871877|NCT04821466|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Cohort interrupted time series study||||
33871878|NCT02989831|NON_RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33871879|NCT00959036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191225|NCT01055067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871880|NCT05825703|||COHORT||RETROSPECTIVE|||||||
33871881|NCT03970694|RANDOMIZED|PARALLEL||TREATMENT||NONE||Research group: Neoadjuvant chemoradiotherapy group Control group: Neoadjuvant chemotherapy group||||
34191226|NCT02834793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191227|NCT05891574|||OTHER||CROSS_SECTIONAL|||||||
33871882|NCT03912142|||OTHER||PROSPECTIVE|||||||
33871883|NCT04169750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067601|NCT06485570|RANDOMIZED|PARALLEL||OTHER||SINGLE|2|50 first year nursing students, 25 experimental, 25 control|t|f|f|f
34067602|NCT02593955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191228|NCT00348881|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34067603|NCT01352897|||CASE_ONLY||RETROSPECTIVE|||||||
34067604|NCT01961167|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34067605|NCT05614583|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single site, randomized controlled trial research study||||
34067606|NCT06543420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191229|NCT05518747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Computerized randomization only known to the principal investigator, who are not directly involved in data collection or data analysis|Double blinded randomized clinical trial with a test and placebo group|t|t|t|t
34191230|NCT04215965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871884|NCT02644564|||COHORT||PROSPECTIVE|||||||
33871885|NCT00734799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871886|NCT04782362|||CASE_ONLY||PROSPECTIVE|||||||
33871887|NCT01969994|NA|SINGLE_GROUP||||NONE||||||
33871888|NCT01563770|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33871889|NCT01505348|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894253|NCT04373603|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|side of face for treatment is randomized and double blinded to the participant and physician|half face study where participant serves as own control, intervention on one side of the face, control on the other|t|f|t|f
34067607|NCT04413383|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34067608|NCT02499510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191231|NCT04254770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191232|NCT00838513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191233|NCT02352285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191234|NCT01338454|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34191235|NCT00552747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34191236|NCT02804841|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191237|NCT03013309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191238|NCT04249349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191239|NCT04254991|||COHORT||PROSPECTIVE|||||||
34191240|NCT05950386|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191241|NCT00824304|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191242|NCT05921136|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34191243|NCT03073837|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34191244|NCT04063306|||CASE_ONLY||PROSPECTIVE|||||||
34191245|NCT00849095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191246|NCT00165815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33871890|NCT04629820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study personnel assessing trial outcomes will be masked as to participants assignment, which will be simplified by the fact that there will be participants with and without glasses at both Intervention and Control. It is not ethical in this setting to provide Control participants with placebo treatment (glasses with zero power lenses), but participants will not be informed of either the overall design of the study or the explicit treatment intervention assignment.|800 textile workers aged 35 years and above with uncorrected presbyopia will be randomized to receive free glasses within one week of undergoing vision assessment, or free glasses at the end of the study assessment (3 months after vision assessment).|f|f|t|t
34191247|NCT01742819|||COHORT||PROSPECTIVE|||||||
34191248|NCT03848182|NA|SINGLE_GROUP||SCREENING||NONE||||||
34191249|NCT04724824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34191250|NCT00397917|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Random number assignments||t|t|t|t
34191251|NCT00929643|||||PROSPECTIVE|||||||
34191252|NCT00539188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191253|NCT03368690|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34191254|NCT04107025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191255|NCT02088138|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34191256|NCT00964210|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34191257|NCT02505828|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34191258|NCT03023813|RANDOMIZED|PARALLEL||PREVENTION||NONE|Only the 2 arm round(s) will be randomized.|Multiple round pilot testing. Some round(s) will have a single group with 1 arm. Other round(s) will be parallel with 2 arms.||||
34191259|NCT04013828|||COHORT||RETROSPECTIVE|||||||
34191260|NCT05818969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34191261|NCT00161772|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34191262|NCT03667456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871891|NCT03650816|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33871892|NCT03852290|||COHORT||PROSPECTIVE|||||||
33871893|NCT02094456|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871894|NCT04125550|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33871895|NCT04540146|||CASE_CONTROL||PROSPECTIVE|||||||
34067609|NCT04720625|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|After completing the screening, informed consent, and baseline data collection, study staff will enter the participant identification number and participant mobile phone number from the survey into an online system, and the system will assign allocation based on the randomization table. Using this technique, both smokers and the staff will be blinded to allocation during the initial session. Then, the research staff will be un-blinded to provide personalized training for intervention and control (note that staff who complete follow-up will be different and blinded to group assignment).||t|f|t|t
34067610|NCT02624128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067611|NCT00523809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067612|NCT05859282|||CASE_ONLY||PROSPECTIVE|||||||
34191263|NCT03719924|RANDOMIZED|PARALLEL||TREATMENT||NONE||"All initial characteristics will be described in the overall population and by treatment arm. Evaluation criteria related to efficacy and safety will be described by treatment arm. Initial characteristics of best response and toxicities will be evaluated using usual statistics: for quantitative variables: mean, standard deviation, median, interquartile interval and range and for qualitative variables: frequencies and percentages.~For the primary evaluation end point, a one-sided 95% confidence interval (CI) will be calculated in the experimental arm."||||
34191264|NCT01697514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191265|NCT01519193|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34191266|NCT05805267|||COHORT||RETROSPECTIVE|||||||
34191267|NCT01701232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191268|NCT01040117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34191269|NCT04137445|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34191270|NCT01616693|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34191271|NCT02246465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191272|NCT00373568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191273|NCT02451215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755728|NCT03350568|||COHORT||PROSPECTIVE|||||||
33755729|NCT01096992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871896|NCT05597475|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871897|NCT06022731|||CASE_ONLY||RETROSPECTIVE|||||||
34191274|NCT00006050||||TREATMENT||||||||
34191275|NCT06131060|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor who will take the readings is blind.|Randomized clinical trials|f|f|f|t
33755730|NCT04216680|||COHORT||CROSS_SECTIONAL|||||||
33755731|NCT03918746|NA|SINGLE_GROUP||OTHER||NONE||||||
33755732|NCT04043923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755733|NCT06184828|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot, single center, and a randomized 1:1 trial.||||
33755734|NCT02159131|NA|SINGLE_GROUP||||NONE||||||
33755735|NCT02427360|||COHORT||RETROSPECTIVE|||||||
33755736|NCT05279625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a randomized, multi-arm parallel and controlled intervention study.|f|f|t|t
33755737|NCT03132428|||COHORT||RETROSPECTIVE|||||||
33755738|NCT03840590|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||CSK endoscopic diagnosis and treatment system a new system of artificial intelligence. It is manufactured by Tianjin Yujin Limited in China. It is equipped with the endoscopic mainframe and has the access to the endoscopic video and image. When lesion-like objects appear in the real-time video, the system will alarm the examiners by sound.||||
33755739|NCT04432701|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33755740|NCT01123382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755741|NCT04225988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755742|NCT02529501|||COHORT||CROSS_SECTIONAL|||||||
33755743|NCT02984657|||COHORT||RETROSPECTIVE|||||||
33755744|NCT02671032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755745|NCT01252823|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755746|NCT03327766|||CASE_CONTROL||PROSPECTIVE|||||||
33755747|NCT03202706|||COHORT||PROSPECTIVE|||||||
33755748|NCT05089838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755749|NCT00412100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764743|NCT02460263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subjects will be enrolled in the trial for approximately 21 weeks according to the following schedule:~* Run-in, In-Center - Subjects undergo study staff administered dialysis treatment 4 times/week for 1 week~* Treatment Period 1, In-Center - Subjects undergo study staff administered dialysis treatment 4 times/week for 32 treatments (approximately 8 weeks)~* In-Home Transition - Subjects undergo device training for the study, perform self-care dialysis 4 times/week for approximately 4 weeks, and are assessed for stability in the new care environment.~* Treatment Period 2, In-Home - Subjects undergo self-care dialysis treatment 4 times/week for 32 treatments (approximately 8 weeks)"||||
33966442|NCT04952532|NA|SINGLE_GROUP||OTHER||NONE|This is an open-label pilot study. The clinician conducting the clinical assessments will be blind to how the participants are doing in the treatment intervention. i.e. one clinician will administer the treatment and another will do the outcome assessment.|This is a feasibility and acceptability pilot study which aims to collect preliminary data for a future grant application proposing a randomized clinical trial. This pilot study aims to collect feasibility data of this therapeutic intervention in Veterans. The Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed CR pus bridging session) intervention involves 20 90-minute sessions (2x/week for 10 weeks). Pre- and post-treatment assessments of neurocognitive, clinical, social, and real-world functioning will be conducted.||||
33966443|NCT00004739||||PREVENTION||||||||
33966444|NCT02069834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966445|NCT03454100|RANDOMIZED|PARALLEL||PREVENTION||NONE||Panel cluster randomized intervention trial||||
33966446|NCT06413654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966447|NCT02836197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33966448|NCT05837065|||COHORT||RETROSPECTIVE|||||||
33966449|NCT01999231|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966450|NCT01517334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966451|NCT03712137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966452|NCT03604354|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study will be participant and investigator blinded. Allocation concealment will be done by sequentially numbered sealed drug pouches.||t|t|t|t
33966453|NCT02118701|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33966454|NCT05350683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33966455|NCT05695235|||CASE_CONTROL||PROSPECTIVE|||||||
34191276|NCT05670938|||COHORT||PROSPECTIVE|||||||
34191277|NCT02837107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191278|NCT03935763|||COHORT||PROSPECTIVE|||||||
34191279|NCT05907213|NA|SEQUENTIAL||OTHER||NONE||MTD 3+3 design||||
34191280|NCT05526040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191281|NCT00145119|||COHORT||PROSPECTIVE|||||||
34191282|NCT01510769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191283|NCT00549003|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34191284|NCT02428283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34191285|NCT04974632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191286|NCT04375462|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966456|NCT05105087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966457|NCT01504867|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33966458|NCT03016663|||CASE_CONTROL||PROSPECTIVE|||||||
34067613|NCT05635500|RANDOMIZED|PARALLEL||OTHER||SINGLE|Computer generated randomisation, Patient under general anaesthesia during procedure|Computer generates randomisation in two groups middle insertion (n=92) and right insertion (n=92)|t|f|f|f
34067614|NCT01044589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067615|NCT01523327|||||CROSS_SECTIONAL|||||||
34191287|NCT00963118|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33871898|NCT04572984|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33871899|NCT02897700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871900|NCT01361035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33871901|NCT02121262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871902|NCT04462562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871903|NCT01189188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871904|NCT04221932|||OTHER||OTHER|||||||
33871905|NCT04001621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871906|NCT04113200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|On each study day, when the feed is administered, the Principle investigator (if present) and the research nurse administering the feed and obtaining blood samples are aware of which enteral feed will be given, but the MRI (magnetic resonance imaging) scanner, and researcher collecting outcome data will not be.|Participants will receive the control and intervention product according to randomised crossover design with a minimum washout period of 7 days.|t|f|f|t
33871907|NCT06020586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871908|NCT00649883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34067616|NCT06408350|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three randomly assigned arms.||||
34067617|NCT04857853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067618|NCT03701685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067619|NCT04037852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|prospective, non-randomized, non-masking, open label, 3 arms|prospective registry of R-NSM versus C-NSM or E-NSM in the management of breast cancer. 3 arms study for comparisons||||
34191288|NCT03133741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34191289|NCT03936790|NA|SEQUENTIAL||TREATMENT||NONE|Two anaesthetists are required to conduct the study: a study supervisor who sets the dose of the local anaesthetic for the next participant according to the sequential distribution algorithm and performs the technique and an anaesthetist responsible for recording the study parameters and for the clinical management of the parturient, blinded to the administered dose.|The sequential distribution methodology (up-down sequential allocation)||||
34191290|NCT05349006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind||t|t|t|t
34191291|NCT01856218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191292|NCT06164639|||COHORT||PROSPECTIVE|||||||
34191293|NCT05012384|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34191294|NCT03928977|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34191295|NCT05570461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191296|NCT00015834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191297|NCT03488264|||COHORT||CROSS_SECTIONAL|||||||
34191298|NCT04834622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191299|NCT01510470|||CASE_ONLY||PROSPECTIVE|||||||
34191300|NCT03855826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191301|NCT00747734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191302|NCT04748367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191303|NCT01931371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191304|NCT01433380|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34191305|NCT01696513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191306|NCT06339268|RANDOMIZED|PARALLEL||PREVENTION||NONE||"After setting the indication for operative treatment, patients who meet the criteria for inclusion in the study, after signing the informed consent, will be randomized into two groups:~1. The first group (intervention) where the patient will receive preoperative cognitive stimulation and physical therapy for one month before surgical treatment.~2. The second group (control) where patients receive standard treatment."||||
34191307|NCT06148454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191308|NCT03052400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191309|NCT04851405|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34191310|NCT02185924|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34191311|NCT06342193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34191312|NCT01182090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191313|NCT03387527|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191314|NCT02236117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871909|NCT03331770|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open-label, single-arm, multicenter, 12-week study||||
33871910|NCT00320008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871911|NCT04342000|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33871912|NCT06037733|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871913|NCT01035775|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33871914|NCT01361776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871915|NCT02690662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871916|NCT03728075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33871917|NCT00365456|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871918|NCT02287389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871919|NCT02515110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067620|NCT02529098|NON_RANDOMIZED|PARALLEL||||NONE||||||
34067621|NCT00374257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067622|NCT02222116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067623|NCT02155322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067624|NCT01108237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067625|NCT06549881|||COHORT||PROSPECTIVE|||||||
33966459|NCT04304235|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Due to the clinical pre-post intervention design, masking will not be possible.|This is a pre-post intervention study involving pediatric outpatients at Jinja Hospital in Jinja, Uganda, and Mbagathi Hospital in Nairobi, Kenya. The study has three phases: (I) Baseline Period: data is collected on key predictors and outcomes before implementation of the digital triage tool, (II) Interphase Period: model/technology development and usability testing, (III) Intervention Period: data is collected on key predictors and outcomes after implementation of the digital triage tool. Patients who present to the study hospitals in seek of medical care for an acute illness during Phase I will be part of the baseline cohort. Patients who present to the study hospitals in seek of medical care for an acute illness during Phase III will be part of the interventional cohort. A third hospital site, Kiambu Hospital in Nairobi Kenya, will serve as a control hospital, and will only participate in Phase I for the entire duration of the study.||||
33966460|NCT03439293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966461|NCT00449579|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33966462|NCT06466044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During clinical trials, subjects, evaluators, data managers, and statisticians are unaware of treatment assignments. After randomization and allocation by an independent data manager, it is handed over to the acupuncturist, who will not be involved in the results evaluation or data analysis. Neither the study participants nor the investigators had any effect on randomization and assigned hiding. The participants were told there were two treatment options. Two months after the study, patients were asked to complete a blind assessment and a perceived efficacy assessment, and were asked to guess which treatment they had received to test the success of the blind. All researchers will receive training on the methodological specifications of this study prior to the trial and strictly adhere to the principle of task separation.|the two groups affixed the auricular points with Vaccaria seed to the ear, the control group affixed to the ear lobe, and the experimental group affixed to the ear nail area. The ear compression treatment was performed, and the pressure was subject to the patient's gas state (acid, numbness, weight, swelling, etc.). Frequency: 3 times a day, press the ear point within half an hour after a meal, the press time is about 1-2 minutes, the press frequency is about 30 times, and the bilateral ear lobe is alternately pressed. The treatment lasted for 2 weeks. Go to the hospital once a week to change the ear patch.|t|f|t|t
33966463|NCT00403364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764744|NCT04341532|||COHORT||PROSPECTIVE|||||||
33966464|NCT01039285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966465|NCT00543582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966466|NCT00159666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966467|NCT02605083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966468|NCT00271999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966469|NCT01001663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966470|NCT06529523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot, open label to gather preliminary data on the use of PD-1 blockade therapy in patients with metastatic dMMR CRC (cohort 1) and patients with localized (stage II/III) dMMR rectal cancer (cohort 2).||||
33966471|NCT01480271|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33764745|NCT04998162|NA|SINGLE_GROUP||TREATMENT||NONE||30 patients with moderate to severe ankle osteoarthritis (Giannini grade 1-3) will be included in the study and the affected ankle will be treated with a single injection of SVF (Stromal vascular fraction). Each patient will sign an informed consent for the participation in the study.||||
34191315|NCT05306119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective cohort study||||
34191316|NCT00527839|||COHORT||OTHER|||||||
34191317|NCT01145677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191318|NCT00763698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191319|NCT03647852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191320|NCT00461474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34191321|NCT01280877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191322|NCT04319692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764746|NCT02415777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191323|NCT02558413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191324|NCT00220129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191325|NCT00885209|||COHORT||PROSPECTIVE|||||||
34191326|NCT04466202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34191327|NCT04666662|||COHORT||RETROSPECTIVE|||||||
34191328|NCT01541683|RANDOMIZED|PARALLEL||||NONE||||||
34191329|NCT05788016|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191330|NCT04105491|||OTHER||PROSPECTIVE|||||||
34191331|NCT01598129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191332|NCT00000400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764747|NCT01583244|||CASE_ONLY||PROSPECTIVE|||||||
33764748|NCT01215357|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33764749|NCT01433484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871920|NCT03111082|||COHORT||PROSPECTIVE|||||||
33871921|NCT01659242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871922|NCT00998894|||COHORT||PROSPECTIVE|||||||
33871923|NCT02407262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871924|NCT01756534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33871925|NCT06098612|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871926|NCT06120400|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33871927|NCT04580628|||COHORT||PROSPECTIVE|||||||
33871928|NCT03653273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871929|NCT02301182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33871930|NCT02754895|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33871931|NCT04411485|||CASE_CONTROL||PROSPECTIVE|||||||
33894254|NCT01645761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894255|NCT04972383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894256|NCT06435507|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33894257|NCT00775021|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34191333|NCT05479396|||COHORT||PROSPECTIVE|||||||
34191334|NCT00709865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191335|NCT02762370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966472|NCT00340535|||OTHER||CROSS_SECTIONAL|||||||
33966473|NCT02306603|||COHORT||PROSPECTIVE|||||||
33966474|NCT03541213|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||3 groups will be performed depending on the presence or absence of a pre-operative iron deficiency and whether they had an iron treatment preoperatively (before their inclusion in the study). However, patient management will not be different in the different groups from their inclusion in the study. Therefore we can consider that there is a single interventional group.||||
33966475|NCT03899974|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33966476|NCT03545737|||OTHER||PROSPECTIVE|||||||
34191336|NCT02280018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34191337|NCT02954172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191338|NCT01092117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191339|NCT05625555|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Participants will receive either a single infusion of IV Ketamine (KET; 0.5mg/kg over 40 minutes) or Midazolam (MID; 30μg/kg over 40 minutes). Investigators will randomize infusion sequences in a 1-to-1 ratio: KET followed by MID or vice versa. Infusions will be administered on Day 0 and Day 21, separated by a 20-day washout period.|t|t|t|t
34191340|NCT01883076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191341|NCT03338738|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191342|NCT01320137|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191343|NCT06175949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191344|NCT02704143|NA|SINGLE_GROUP||TREATMENT||NONE||stereotactic bodt radiation therapy plus sequential S-1 for locally pancreatic cancer||||
34191345|NCT02361632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34191346|NCT02433080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34191347|NCT01335737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34191348|NCT01526824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191349|NCT03194737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191350|NCT01765218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191351|NCT01920685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191352|NCT02267317|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participant, Care Provider, Investigator, Outcomes Assessor||t|t|t|t
34191353|NCT01387542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191354|NCT02084290|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191355|NCT04520438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the clinician who provided the treatment knew the treatment assigned. A different clinician performed all the evaluations.|A split-mouth, randomized controlled clinical trial enrolling 13 patients (8 males and 5 females, mean age 52.3 ± 9.4 years) was set-up. The periodontal pockets ≥ 6 mm were randomly treated with SRP + L-PRF (test group) or SRP alone (control group)|f|f|t|t
34191356|NCT02980913|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34191357|NCT03791944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34191358|NCT04102163|||COHORT||PROSPECTIVE|||||||
34191359|NCT01702493|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34191360|NCT02759718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191361|NCT05266885|||OTHER||PROSPECTIVE|||||||
34191362|NCT05989451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34191363|NCT01278472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191364|NCT02036853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191365|NCT04497623|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Enrolled patients receive mechanical ventilation using the Unisabana-Herons ventilator during 24 hours||||
34191366|NCT01426841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191367|NCT00068861|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34191368|NCT04336501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191369|NCT03114540|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Multiple-center, nonrandomized, open-label, parallel group study||||
34191370|NCT04812262|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part A - Cohorts A1, A2, A3, A4, A5, A6, A7 \& A8 Part B - Cohorts B2, B3, B4, B5, B6, B7 \& B8|t|t|t|t
34191371|NCT00084136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191372|NCT06033755|NA|SINGLE_GROUP||TREATMENT||NONE||A mixed methods design, which combined qualitative and quantitative research, was used. Data, including subjective experiences of respiratory distress, findings from physiotherapeutic body examinations and objective measurements of lung function and aerobic capacity were gathered before and after a five month intervention.||||
33755750|NCT05973448|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||"Each participating community will have approximately 8-12 enrolled residents with ADRD. The AL communities will be randomized to four treatment sequences over the course of one year that define the order of the lighting intervention delivered across four 3-month (90 day) periods (N=390 residents). This design requires that the lights be turned on or off some periods, which will be done by research staff during scheduled visits. The four treatment sequences are chosen such that each resident receives control (C) lighting in two periods and novel lighting (L) in two periods and no more than 2 lighting changes. The four sequences are: CCLL, CLLC, LCCL, LLCC. There are no washout periods between the lighting conditions."|f|f|t|f
33755751|NCT00504426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755752|NCT02077348|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33871932|NCT05502575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, research staff, and outcome assessors will be blind to condition assignment and to specific details of the intervention. Investigators will be blind to condition assignment until the conclusion of data collection.|A comparative trial of two stress management approaches for the improvement of stress responses, sleep, and physical activity in everyday life.|t|t|f|t
33871933|NCT00494754|||FAMILY_BASED||OTHER|||||||
33871934|NCT00356850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894258|NCT00648986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894259|NCT03787069|RANDOMIZED|PARALLEL||PREVENTION||NONE||Equal allocation||||
33894260|NCT00816036|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33755753|NCT05055102|||COHORT||RETROSPECTIVE|||||||
33755754|NCT02191696|||CASE_ONLY||PROSPECTIVE|||||||
33755755|NCT00538590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755756|NCT05288426|||CASE_ONLY||PROSPECTIVE|||||||
33755757|NCT01421251|||COHORT||RETROSPECTIVE|||||||
33755758|NCT04444167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755759|NCT03656705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755760|NCT06397131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755761|NCT06020222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors don't know groups||f|f|t|f
33755762|NCT02555540|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33755763|NCT06489873|RANDOMIZED|PARALLEL||OTHER||TRIPLE|A researcher not participating in the research randomized participants and packaged LZF and placebo supplements in the exact same bottle other than the participant number and delivered these to the PI for distribution. Only this person has the list of numbers associated with the supplements.|Participants will be randomly assigned to an LZF or placebo supplement group and asked to take the assigned supplement daily for six months.|t|f|t|t
33755764|NCT02421484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755765|NCT01118533|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34191373|NCT05273671|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|allocated children will be randomly assigned through computer-generated random numbers contained in sealed opaque envelopes to one of the three groups||t|t|t|f
34191374|NCT04286906|||COHORT||PROSPECTIVE|||||||
34191375|NCT02920099|||CASE_ONLY||PROSPECTIVE|||||||
34191376|NCT01961726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191377|NCT02230917|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34191378|NCT02761902|||ECOLOGIC_OR_COMMUNITY|||||||||
34191379|NCT01224990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191380|NCT00192634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191381|NCT04901689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191382|NCT04527393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191383|NCT02787629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191384|NCT05416710|||CASE_ONLY||PROSPECTIVE|||||||
34191385|NCT06371001|||CASE_ONLY||CROSS_SECTIONAL|||||||
34191386|NCT03059680|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treating physicians and participants were not blinded to randomization. Investigators performing randomization and analysis of dietary intake were blinded.|||||
34191387|NCT04165421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34191388|NCT05525806|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will enroll urologists practicing in the US. Participants are randomly assigned to either control, intervention 1, or intervention 2 arms upon enrollment. All eligible and consented participants will complete two rounds of three patient simulations.~The intervention 1 and intervention 2 arms only will receive educational material about the LynxDx test in between these two rounds. Intervention 1 arm participants only will receive the CDMT test results whether they select it or not, and Intervention 2 participants will receive the CDMT test results only if they select it in the second round of simulated cases"||||
34191389|NCT01148992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755766|NCT04669730|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|t|t|f
33764750|NCT04890795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764751|NCT01342692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966477|NCT02450409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33966478|NCT04364542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, and Outcomes Assessor)|2 groups of patients. Randomization into groups SSNB or ISB as per randomization list, for a total of 98 patients|t|f|t|t
33966479|NCT01477671|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33966480|NCT01047904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191390|NCT04596059|||CASE_ONLY||RETROSPECTIVE|||||||
34191391|NCT00254930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191392|NCT03897517|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Treatment and placebo will be matched closely in color and appearance administered in a double blinded fashion as provided by the material supplier.|Participants will receive both treatments in random order with a washout period of at least 1 week between the 2 study visits. Women will be measured during the follicular phase of the menstrual cycle.|t|f|t|f
34191393|NCT01396447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871935|NCT03121911|RANDOMIZED|PARALLEL||TREATMENT||NONE||54 patients will be included, divided into three groups with 18 participants each. All will be submitted to several exams applied to the monitoring of cardiac and pulmonary function. Then, groups 1 (IT) and group 2 (IT + IMT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. In addition, they will be monitored for a 6 month period after discharge, with returns every two months to measure the energy expenditure through an accelerometer, and at the end of this period they will repeat all the tests again. Group 3 (absence of CR), will consist of patients who do not live in the city or those who can not participate in the CR program for any other reason, and will only participate in the evaluations.||||
33871936|NCT05953142|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871937|NCT03959332|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966481|NCT02028702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966482|NCT03386149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966483|NCT03256383|||CASE_ONLY||CROSS_SECTIONAL|||||||
33966484|NCT05735782|||CASE_CONTROL||PROSPECTIVE|||||||
33966485|NCT00317083|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191394|NCT02377739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191395|NCT02897661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191396|NCT04779788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191397|NCT04651504|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped wedge trial where clusters of sites sequentially enter the intervention. Independent samples of patients are enrolled within a cluster at each set interval of time thus, it is analyzed as a repeated cross-sectional study.||||
34191398|NCT00888186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34191399|NCT05574413|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Repeated measures randomized counterbalanced crossover design||||
34191400|NCT01656265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191401|NCT05546203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized parallel designed two arm clinical study|f|f|f|t
33871938|NCT02441465|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33871939|NCT04945668|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33871940|NCT01733628|||CASE_ONLY||PROSPECTIVE|||||||
33871941|NCT01916876|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33966486|NCT03839888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966487|NCT01794871|||||RETROSPECTIVE|||||||
33966488|NCT00821613|||CASE_ONLY|||||||||
33966489|NCT05006183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966490|NCT04537819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871942|NCT05970198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871943|NCT06494696|||CASE_ONLY||PROSPECTIVE|||||||
33871944|NCT02216864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33871945|NCT02745587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871946|NCT06044662|||COHORT||PROSPECTIVE|||||||
33871947|NCT04716452|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33871948|NCT03641963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33871949|NCT05515250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966491|NCT00923195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966492|NCT06529198|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33966493|NCT00101205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966494|NCT03689140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966495|NCT01634022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966496|NCT00595049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966497|NCT02832427|||COHORT||PROSPECTIVE|||||||
34191402|NCT02767349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191403|NCT02879006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191404|NCT02460237|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33966498|NCT06221345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191405|NCT03315962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966499|NCT01824459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966500|NCT03779594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966501|NCT02769000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966502|NCT01884870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966503|NCT04892966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33966504|NCT05002400|||COHORT||PROSPECTIVE|||||||
33966505|NCT02577042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966506|NCT05814419|||COHORT||PROSPECTIVE|||||||
33966507|NCT04601662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33966508|NCT05480527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191406|NCT01589991|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33966509|NCT03958669|||COHORT||PROSPECTIVE|||||||
33966510|NCT01823484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966511|NCT02580188|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33966512|NCT04287452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966513|NCT03739359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Nebulization will be offered in a one room and pulmonary function test will be performed in the other room. Both patients and the pulmonary function test technician will be masked to the group.||t|t|f|f
33966514|NCT05260151|||CASE_CONTROL||PROSPECTIVE|||||||
33966515|NCT02938910|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966516|NCT03054961|||COHORT||PROSPECTIVE|||||||
33966517|NCT02355795|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33966518|NCT06527300|NA|SEQUENTIAL||TREATMENT||NONE||||||
33966519|NCT01706770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191407|NCT03966339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191408|NCT01590758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191409|NCT02137915|||CASE_ONLY||PROSPECTIVE|||||||
34191410|NCT03310346|||CASE_ONLY||PROSPECTIVE|||||||
34191411|NCT03961438|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomised in a 1:1 ratio between two treatment groups with a different dosing regimen. The randomisation will be stratified for gender.||||
34191412|NCT04841642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34191413|NCT04357223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191414|NCT01940172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191415|NCT01705509|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191416|NCT06240416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A split mouth randomized clinical trial|t|f|t|t
33966520|NCT04346290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966521|NCT01433952|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33966522|NCT00029406|||COHORT||PROSPECTIVE|||||||
33966523|NCT03670537|||COHORT||PROSPECTIVE|||||||
33966524|NCT01613131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966525|NCT01357031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33966526|NCT06013020|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966527|NCT00078468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966528|NCT05612737|NA|SINGLE_GROUP||TREATMENT||NONE||"All subjects undergo the same type of horizontal bone augmentation using sticky bone (combination of xenograft and autologous platelet rich concentrate) and tenting screws."||||
33966529|NCT03405337|||COHORT||OTHER|||||||
33966530|NCT05948293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to arm allocation. The research team will also be blinded, with the exception of the data coordinator. The medical team, with the exception of the ones assigned to care for the participants, will also be blinded to arm allocation. The embryology laboratory team will also be blinded.||t|f|f|t
33966531|NCT02108613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966532|NCT02328261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191417|NCT02164461|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34191418|NCT05906290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34191419|NCT04688099|||COHORT||PROSPECTIVE|||||||
34191420|NCT02780011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191421|NCT01708785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191422|NCT00013416|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191423|NCT02506803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191424|NCT02865876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34191425|NCT02685982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191426|NCT00001062||||TREATMENT||||||||
34191427|NCT02664948|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34191428|NCT05937932|||CASE_CROSSOVER||PROSPECTIVE|||||||
34191429|NCT05910190|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||prospective, single arm, open label||||
34191430|NCT04971317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191431|NCT01707784|||COHORT||CROSS_SECTIONAL|||||||
34191432|NCT04335136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966533|NCT01213355|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33966534|NCT02741362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966535|NCT00933660|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33966536|NCT03151499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966537|NCT02841540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966538|NCT02734615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966539|NCT05669196|||COHORT||PROSPECTIVE|||||||
33966540|NCT01511900|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33966541|NCT00839020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966542|NCT04904432|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33966543|NCT04370652|||CASE_CONTROL||RETROSPECTIVE|||||||
33966544|NCT05460026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single blinded in which the assessor will be unaware of the treatment intervention.||f|f|f|t
33966545|NCT02778568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966546|NCT05388188|||CASE_CONTROL||OTHER|||||||
33966547|NCT03062865|||COHORT||PROSPECTIVE|||||||
33966548|NCT01137409|||COHORT||PROSPECTIVE|||||||
33966549|NCT06039787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||In a cross-over design, we will compare cerebral response from before to after intranasal insulin administration after a single bout of HIIT or MICT compared to a control condition without exercise.|t|f|f|f
33966550|NCT02087579|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966551|NCT00367666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966552|NCT03665571|||CASE_CONTROL||PROSPECTIVE|||||||
33966553|NCT03808220|||COHORT||PROSPECTIVE|||||||
33966554|NCT03627195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966555|NCT04723485|||COHORT||RETROSPECTIVE|||||||
33966556|NCT00343811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966557|NCT02768142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966558|NCT00686790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966559|NCT01583751|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33966560|NCT02442882|||COHORT||PROSPECTIVE|||||||
33966561|NCT04857216|||COHORT||PROSPECTIVE|||||||
33966562|NCT05309837|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, double-blind, placebo-controlled, parallel study.|t|f|t|f
33966563|NCT03908983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966564|NCT02020733|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33966565|NCT00720733|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966566|NCT02328547|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33966567|NCT04310748|RANDOMIZED|PARALLEL||SCREENING||SINGLE||This study is a randomized controlled prospective study to be performed in 60 patients ASA 1 between the ages of 18-55 who will undergo elective rhinoplasty. History of smoking, alcohol, and drug use, who had a BMI\>30 are excluding from the study. BIS and TOF monitoring are performing in all patients undergoing standard anesthesia induction. Patients divided into two groups with closed envelope method; TIVA(Group1) and inhalation anesthesia(Group2). In both, MAP target is determining to be in the range of 50-65 mmHg. Blood sample is collecting and storing to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters, before induction and 5, 30, 60 and 120 minutes after induction. The extubation time is recording. The surgical field opinion and satisfaction assessment and the survey presented to the surgeon, respectively. The patients by following up in the recovery unit for 30 minutes; numerical pain scores and nausea-vomiting scores is recording.|t|f|f|f
33966568|NCT00984906|RANDOMIZED|CROSSOVER||||NONE||||||
33966569|NCT00047489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966570|NCT01700920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966571|NCT05864352|||COHORT||CROSS_SECTIONAL|||||||
33966572|NCT04452500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The investigators propose a two-site parallel group, randomized, double-blind, placebo-controlled Phase IIa clinical trial to test the efficacy and safety of CORT108297- 180mg daily for 7 days for PTSD symptoms in Veterans.|t|t|t|t
33966573|NCT00916422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966574|NCT01270373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966575|NCT04225273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966576|NCT00476684|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34191433|NCT06078943|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191434|NCT04611399|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study can be defined as a controlled and randomized clinical trial, single-blind and monocentric, aimed at studying the efficacy of the intervention with virtual reality contents in reducing stress and anxiety in healthcare personnel involved in the care of COVID-19 patients. The study will be conducted according to the indications of Good Clinical Practices. The clinical efficacy of the intervention will be assessed at two different time distances (T0, T1).||||
34191435|NCT00753246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191436|NCT01913496|RANDOMIZED|PARALLEL||||NONE||||||
33966577|NCT06188481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33966578|NCT05737888|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective research with 3 independent research arms.||||
33966579|NCT06336889|||COHORT||PROSPECTIVE|||||||
33966580|NCT00528879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966581|NCT00168337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966582|NCT00482287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966583|NCT02024698|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33966584|NCT00846196|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34191437|NCT00367614|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191438|NCT01454258|||COHORT||CROSS_SECTIONAL|||||||
34191439|NCT02121080|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34191440|NCT06022523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191441|NCT03074552|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A numbered sealed envelope will be used to ensure blinding. Only the pharmacist responsible for the sealed envelopes preparation will be aware of its content, with no further involvement in the study protocol.|The present study will be a multicenter, randomized, double-blind, placebo-controlled trial including data collected from 9 ICUs. Patients will be randomly assigned in a 1:1 ratio to receive probiotic or placebo treatment according to a computer-based table blinded to study investigators and physicians in charge.|t|t|t|t
34191442|NCT04980742|||CASE_CONTROL||RETROSPECTIVE|||||||
34191443|NCT04380272|||CASE_CROSSOVER||PROSPECTIVE|||||||
33755767|NCT04900129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Methods: Case control study Population: Adult patients with RT-PCR +ve mild to moderate COVID 19. Severe and critical disease patients had been excluded from the study.~Duration: One month Study Place: Corona unit, Sher-E-Bangla Medical College Hospital, Barishal. Sample Size: Total 43 patients (N). Among them study group (SG) had 27 respondents and control group (CG) had 16 respondents Materials: Suitable vapor producing electric teapot, medicine, pulse oximeter and a structured questionnaire"|t|f|t|f
33755768|NCT05394662|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Subjects won't be told which group they were assigned. Primary outcome reviewed by blinded independent central review.|Juveena Hydrogel vs No Hydrogel|t|f|f|t
33755769|NCT01861184|||CASE_CONTROL||PROSPECTIVE|||||||
33871950|NCT00019708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871951|NCT02340585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871952|NCT06540781|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm pretest-posttest interventional study||||
33871953|NCT05654597|||CASE_ONLY||PROSPECTIVE|||||||
33755770|NCT05225623|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants of the Small Changes BWLT will attend 16 2-hour group-based weekly sessions (in a virtual format using Zoom teleconferencing). Sessions will be facilitated by a senior master's level interventionist rigorously trained in the program's delivery. The empirically validated ASPIRE BWLT will be adapted for a PsA population with obesity based on the results of a qualitative study that is currently underway. After the 16 weekly sessions are complete, patients will attend bi-weekly follow-up sessions for an additional 8-weeks via Zoom. Follow-up sessions will also be group-based. In total, patients will be provided 16+8 (24) group BWLT sessions across the treatment and follow-up period.~Participants in the control group will continue to receive their treatment as usual from the Balfour Medical Clinic and be put on a waitlist for the BWLT. This group will receive the same treatment as the intervention group after the intervention group has received treatment."||||
33755771|NCT05550116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755772|NCT01825681|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33755773|NCT01757626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755774|NCT00255931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755775|NCT06162650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755776|NCT03640351|RANDOMIZED|PARALLEL||TREATMENT||NONE||Methods: The subjects are randomly divided into three groups. Group 1 uses preservative diquafosol ophthalmic solution, Group 2 uses preservative containing diquafosol ophthalmic solution, and Group 3 uses preservative free sodium hyaluronate after cataract surgery. Before surgery, all patients underwent a detailed ophthalmological examination that included slit-lamp examination (Haag-Streit, Köniz, Switzerland), and dry eye parameters including tear breakup time (TBUT), schirmer test, ocular surface disease index (OSDI), and MGD staging. Corneal wavefront aberrations were measured using i-Trace (Tracey Technologies Corp. Houston, TX). All examinations were repeated at 1, and 3 months after surgery.||||
33755777|NCT03297515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755778|NCT05841979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755779|NCT05168891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study design, neither the patient nor the operator will be blinded. On the other hand, two blinded investigators will collect and record all the clinical and radiological measurements, respectively.|This is a prospective, single-blinded, randomized, controlled clinical trial with 1-year follow-up.|f|f|t|f
33755780|NCT01368133|||COHORT||PROSPECTIVE|||||||
33755781|NCT00875004|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755782|NCT02110901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871954|NCT05896254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871955|NCT04648605|NA|SINGLE_GROUP||OTHER||NONE||||||
33871956|NCT02088112|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871957|NCT05241392|NA|SEQUENTIAL||TREATMENT||NONE||"a 3+3 design is used to determine Maximum Tolerated Dose (MTD) and the recommended phase 2 dose (RP2D)"||||
33871958|NCT02988453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871959|NCT01432873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871960|NCT06096402|||COHORT||PROSPECTIVE|||||||
33871961|NCT01545479|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33871962|NCT01870427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871963|NCT02068742|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||First arm of the study considers patients from the operating room with general anesthesia; Second arm of the study considers patients from geriatric regular general ward, without any anesthesia.||||
33871964|NCT02866279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871965|NCT02113436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33871966|NCT04967300|||COHORT||RETROSPECTIVE|||||||
33871967|NCT02877368|||CASE_ONLY||RETROSPECTIVE|||||||
33871968|NCT05808933|||OTHER||PROSPECTIVE|||||||
33871969|NCT00428909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33871970|NCT04231149|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33871971|NCT02147600|||COHORT||CROSS_SECTIONAL|||||||
33871972|NCT05275374|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33871973|NCT00562952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33871974|NCT04944511|NA|SINGLE_GROUP||TREATMENT||NONE||one group of HLH patients with mixed chimerism (80%-95%), PD-1 antibody will be used to improve the chimerism||||
33871975|NCT01012375|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33871976|NCT05120895|||COHORT||PROSPECTIVE|||||||
34191444|NCT05857696|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective study on the evolution of spatial-temporal parameters of walking for each mode of medullary neurostimulation.||||
34191445|NCT03372902|||COHORT||PROSPECTIVE|||||||
33871977|NCT04449055|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized order of TMS site stimulated first||||
33871978|NCT02242578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33871979|NCT04096209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871980|NCT02385981|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33871981|NCT05775640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|32 control +32 intervention group|Single blind pre-post test randomized controlled design|t|f|f|f
33871982|NCT03529721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871983|NCT02014350|||COHORT||CROSS_SECTIONAL|||||||
33871984|NCT02534688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871985|NCT04103684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191446|NCT03956238|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34191447|NCT01137604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871986|NCT00282334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191448|NCT02935283|||COHORT||PROSPECTIVE|||||||
33871987|NCT04503499|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34191449|NCT01380626||PARALLEL||BASIC_SCIENCE||NONE||||||
34191450|NCT00082862||||TREATMENT||NONE||||||
34191451|NCT04021693|RANDOMIZED|PARALLEL||OTHER||NONE||Intern physicians were randomized 1:1 to receive personal access to a handheld ultrasound device vs. no device. The groups did not cross over in which intervention they received.||||
34191452|NCT01786772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191453|NCT03780296|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single group pre-test/post-test design||||
34191454|NCT01745822|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34191455|NCT00429728|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34191456|NCT02697149|||COHORT||RETROSPECTIVE|||||||
34191457|NCT05157308|||CASE_ONLY||RETROSPECTIVE|||||||
34191458|NCT03590964|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because the two interventions used in this trial are clearly different and easily recognized by the participants and investigators, neither the investigators nor participants can be blinded.|"* A Randomized controlled trial.~* Parallel group study.~* A trial will be carried out in hospital of Oral and Maxillofacial surgery department- Faculty of Oral and Dental Medicine Cairo University~* Equal randomization: participants with equal probabilities for intervention.~* Positive controlled: Both groups receiving treatment."||||
34191459|NCT06327841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34191460|NCT06039865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191461|NCT04509349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191462|NCT04075734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191463|NCT02906176|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34191464|NCT03510741|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|Double-blind placebo controlled trial|This will be a 2x2 factorial design trial|t|t|t|t
34191465|NCT03226197|NA|SINGLE_GROUP||OTHER||NONE||||||
34191466|NCT05310175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191467|NCT04415671|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|SAD Part A in HVs- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) MAD Part B in HVs- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34191468|NCT01627288|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191469|NCT01454817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33871988|NCT01982474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33871989|NCT02302976|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33871990|NCT03908385|||COHORT||PROSPECTIVE|||||||
33871991|NCT03156920|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33966585|NCT03346928|||COHORT||RETROSPECTIVE|||||||
33966586|NCT06392737|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33966587|NCT03957278|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, multi-center, prospective study where all eligible subjects are treated with the study device after enrollment.||||
34191470|NCT00800254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871992|NCT04854434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871993|NCT01417195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871994|NCT00871520|||COHORT||PROSPECTIVE|||||||
33871995|NCT00545727||CROSSOVER||TREATMENT||NONE||||||
33871996|NCT00198380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33871997|NCT03193697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33871998|NCT06398548|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||3 group randomized controlled trial. 1 control group, 2 exercise groups.||||
33871999|NCT01922687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872000|NCT01424111|||CASE_CONTROL||PROSPECTIVE|||||||
34191471|NCT02042872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872001|NCT05521230|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872002|NCT01251848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34191472|NCT03253861|||CASE_CONTROL||RETROSPECTIVE|||||||
34191473|NCT01727024|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191474|NCT00843284|||OTHER||PROSPECTIVE|||||||
34191475|NCT01396057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191476|NCT02824406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191477|NCT00750152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191478|NCT06110637|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34191479|NCT02522663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191480|NCT03005899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872003|NCT05216679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872004|NCT03704142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant will be tested with one of the models of devices.||||
33872005|NCT05067322|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Test group and a control group||||
33872006|NCT02004496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33872007|NCT01104038|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|f|t
33872008|NCT03642756|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33872009|NCT01131533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33872010|NCT00451802|||CASE_CONTROL||OTHER|||||||
33872011|NCT05505162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872012|NCT06490458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33872013|NCT03189823|||COHORT||PROSPECTIVE|||||||
33872014|NCT03115736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872015|NCT00480818|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33872016|NCT02793440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872017|NCT06503575|||CASE_CONTROL||PROSPECTIVE|||||||
33872018|NCT04383873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872019|NCT01352832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33872020|NCT05540002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the principal investigator, the co-investigators, the research assistant, or the subjects will know if they are given the high intensity Quell device or the low intensity Quell device.|Participants will be equally randomized to one of the two treatment groups: the High Intensity Quell group or the Low Intensity Quell group. All groups will receive the same questionnaires and undergo quantitative sensory testing.|t|f|t|f
33872021|NCT00017342||||TREATMENT||NONE||||||
33872022|NCT00607386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872023|NCT06469996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872024|NCT04719650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872025|NCT02218281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33872026|NCT03549156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each food will be randomized to two colors with the study coordinator, nurse, caregivers blinded to the which color is which food.||t|t|t|t
33872027|NCT05725070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872028|NCT00272909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872029|NCT04719143|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33872030|NCT00917150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872031|NCT01944475|||CASE_ONLY|||||||||
33966588|NCT01860885|||COHORT||RETROSPECTIVE|||||||
33966589|NCT01312142|||COHORT||PROSPECTIVE|||||||
33966590|NCT03583463|||OTHER||PROSPECTIVE|||||||
33966591|NCT02402426|||COHORT||PROSPECTIVE|||||||
33966592|NCT06322810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966593|NCT04888260|||CASE_CONTROL||PROSPECTIVE|||||||
33966594|NCT06460987|||COHORT||RETROSPECTIVE|||||||
33966595|NCT04641572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The researcher will use the simple randomize technique ( lottery withdrawal) to give the participants the right to pick up one of these positions through three letters will be written in three folded papers and put in an envelope, each letter will refer to a certain method. As soon as chosen of the letter the research will apply the chosen method and explain the benefits of that position/ technique for the participant.|Random selection based on the woman's preference for certain positions during her first stage of labor.|t|t|f|f
33966596|NCT04698564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966597|NCT01405105|||COHORT||CROSS_SECTIONAL|||||||
33966598|NCT01630265|RANDOMIZED|PARALLEL||||NONE||||||
34191481|NCT00984997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191482|NCT04824651|||COHORT||PROSPECTIVE|||||||
34191483|NCT01145586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34191484|NCT06170411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872032|NCT03956914|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34191485|NCT03277339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191486|NCT02711709|||OTHER||PROSPECTIVE|||||||
34191487|NCT06436677|||COHORT||OTHER|||||||
34191488|NCT00277875|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34191489|NCT00496938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872033|NCT02015884|||||PROSPECTIVE|||||||
33872034|NCT02173860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872035|NCT02692365|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872036|NCT05284370|||CASE_ONLY||PROSPECTIVE|||||||
33872037|NCT03187938|||COHORT||PROSPECTIVE|||||||
33872038|NCT06281470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872039|NCT01975740|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33872040|NCT06320691|||COHORT||RETROSPECTIVE|||||||
33872041|NCT01889485|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33872042|NCT05003622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872043|NCT05086328|||COHORT||CROSS_SECTIONAL|||||||
33872044|NCT00141024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872045|NCT01785160|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872046|NCT05046405|NA|SINGLE_GROUP||OTHER||NONE||Feasibility studies aim to inform large RCT studies. Thus, for the feasibility study, the investigators aim to inform the practicality of the future Phase-III RCT and to unveil threats to the validity of the efficacy outcomes. Within a users'-centred approach and co-designed methodology, the investigators will assess safety, feasibility of the intervention, and feasibility of procedures for outcomes' assessment. Additionally, the investigators will estimate recruitment/retention and sample size. A consequent underpowered pilot study will be conducted following the achieved static protocol, based on the assumption that the procedures are well defined, serving the purpose of gathering preliminary information and testing the study protocol. Both the feasibility and the pilot studies will be open-label, single arm, single-site longitudinal studies.||||
33872047|NCT04438083|NA|SEQUENTIAL||TREATMENT||NONE||||||
33872048|NCT00131469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966599|NCT02995837|||CASE_CONTROL||PROSPECTIVE|||||||
33966600|NCT01894113|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33966601|NCT02502409|||OTHER||PROSPECTIVE|||||||
33966602|NCT05692466|||CASE_CONTROL||PROSPECTIVE|||||||
33966603|NCT00012155||||TREATMENT||||||||
33966604|NCT00990626|||COHORT||PROSPECTIVE|||||||
33966605|NCT03884933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33966606|NCT03828656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966607|NCT02308657|||COHORT||PROSPECTIVE|||||||
33966608|NCT05815719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966609|NCT04477083|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The first 20 consecutive patients (group A) will be treated by oral antibiotics, supportive treatment and inhalable hydroxychloroquine (HCQ). (In day 1, an inhaled hydroxychloroquine sulfate dose of 12 mg will be taken via nebulization three times/day (TID) as a loading dose. Then, starting from day 2, same dose of 12 mg of inhaled hydroxychloroquine will be taken twice/day (BID) as maintenance dose for 5 days. The subsequent 20 consecutive patients (group B) will receive the same treatment of group A but without inhalable hydroxychloroquine (HCQ). At day 7, all patients of both groups will be evaluated by clinical, laboratory and chest CT parameters. Patients of group B who still show no clinical, laboratory or radiological improvement will continue treatment by adding inhalable hydroxychloroquine (HCQ). for another 7 days and re-evaluated at day 14. Patients of group A who still show no significant improvement at day 7 only will be re-checked at day 14.|f|f|f|t
33966610|NCT04393155|||COHORT||PROSPECTIVE|||||||
33966611|NCT01940237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966612|NCT00545181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966613|NCT05379569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966614|NCT01965535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966615|NCT02766387|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33966616|NCT03889457|||COHORT||PROSPECTIVE|||||||
33966617|NCT00606671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966618|NCT02065791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966619|NCT00946452|||CASE_ONLY||PROSPECTIVE|||||||
33966620|NCT01693107|||COHORT||PROSPECTIVE|||||||
33966621|NCT01005264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966622|NCT04498156|||COHORT||PROSPECTIVE|||||||
33966623|NCT02818478|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33966624|NCT00764998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33966625|NCT01843907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33966626|NCT02431403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966627|NCT01829945|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966628|NCT01638793|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33966629|NCT01537965|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966630|NCT00001951||||TREATMENT||||||||
33966631|NCT02999373|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33966632|NCT00186433|||CASE_CONTROL||PROSPECTIVE|||||||
33966633|NCT01010074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966634|NCT03788798|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33966635|NCT00388479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966636|NCT03337737|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33966637|NCT00004582||||TREATMENT||NONE||||||
33966638|NCT03746301|||COHORT||PROSPECTIVE|||||||
33966639|NCT01405885|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966640|NCT00612833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966641|NCT06039527|||COHORT||PROSPECTIVE|||||||
33966642|NCT05064488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966643|NCT01703338|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34191490|NCT02917642|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34191491|NCT04229407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind||t|t|t|f
34191492|NCT04137939|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34191493|NCT04079309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33872049|NCT03709238|||COHORT||PROSPECTIVE|||||||
33872050|NCT06144476|||COHORT||PROSPECTIVE|||||||
33872051|NCT02572726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33872052|NCT02947152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966644|NCT01996176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966645|NCT04494178|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33966646|NCT04396483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33966647|NCT04711122|||CASE_CONTROL||PROSPECTIVE|||||||
33966648|NCT03472833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966649|NCT00384358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191494|NCT05106699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191495|NCT00942097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191496|NCT01962961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191497|NCT05696093|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre randomized non-inferiority trial comparing cotrimoxazole to standard antibiotic therapy for enterobacterial VAP.||||
34191498|NCT06110169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191499|NCT03263702|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191500|NCT01158599|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34191501|NCT00635219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191502|NCT00010452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191503|NCT00402740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191504|NCT05295667|||COHORT||PROSPECTIVE|||||||
34191505|NCT00229385|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34191506|NCT02922686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191507|NCT01430052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191508|NCT03849118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||diagnostic, confirmatory, prospective, multi-centre||||
34191509|NCT01532492|||COHORT||PROSPECTIVE|||||||
34191510|NCT03994653|||CASE_CONTROL||RETROSPECTIVE|||||||
34191511|NCT00045461|RANDOMIZED|||TREATMENT||NONE||||||
34191512|NCT04552249|||OTHER||CROSS_SECTIONAL|||||||
34191513|NCT05552417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191514|NCT03790033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872053|NCT02869282|||COHORT||PROSPECTIVE|||||||
33872054|NCT02794324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872055|NCT05693636|||COHORT||PROSPECTIVE|||||||
33872056|NCT05877053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34191515|NCT03493217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191516|NCT00349115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191517|NCT06373133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191518|NCT01599988|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34191519|NCT00547833|||CASE_CONTROL||PROSPECTIVE|||||||
34191520|NCT05561556|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The member of the study team performing data analysis will be blinded when performing data analysis and unblinded after the final statistical analysis|The intervention is to give participants an 8-week supplementation of one capsule (20 mg) of either a mitochondrial antioxidant (MitoQ) or a placebo (dextrin and silica), in a randomized order. Followed by a two-week washout, then another 8-week supplementation of a 20 mg capsule.|f|f|f|t
34191521|NCT06136585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A single-center, Assessor-Blinded, parallel group randomized trial||t|f|f|t
34191522|NCT05688722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care provider and investigator were not blinded.|Patients were divided into 4 groups by random sampling each with different intervention|t|f|f|f
34191523|NCT03265652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects in the study arm will receive a series of IPL pulses using the M22 IPL handpiece. In subjects of the control arm, the device will be disabled. The subject will feel the lightguide on the skin, will hear clicking sounds, but no light will be actually produced by the M22 device. Since during treatment both eyes of the subject will be fully occluded, no subject will be able to see if the treatment is actual or sham. There is no way to completely mask the subjects, since the IPL generally causes slight redness of the skin, and in some patients is may also cause some discomfort|Subjects will be randomized 1:1 to a study arm and a control arm. Subjects in the study arm will be treated with IPL and meibomian gland expression. Subjects in the control arm will be treated with sham and meibomian gland expression.|t|f|f|f
34191524|NCT03220906|||CASE_ONLY||PROSPECTIVE|||||||
34191525|NCT05933239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191526|NCT01475149|||COHORT||PROSPECTIVE|||||||
34191527|NCT01596361|||COHORT||RETROSPECTIVE|||||||
34191528|NCT01388985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191529|NCT03085797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191530|NCT02481453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191531|NCT03036215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The pilot study design is a 2-arm randomized clinical trial to test the methods that will be used in a future proposal for a full-scale multi-site clinical trial. The two aims include: 1) evaluate the feasibility of methods to conduct a full-scale multi-site randomized clinical trial comparing the PACT self-management with usual self-care for TMD and, 2) estimate the parameters needed to plan for a larger multi-site trial including the effect size and standard deviation for primary outcomes of pain and function. A traditional self-care control arm is added to determine the acceptability of randomization and the feasibility of collecting baseline and follow-up data from a traditional care control arm for the full-scale study.||||
34191532|NCT05433844|RANDOMIZED|SEQUENTIAL||OTHER||NONE||A randomized, open, single-dose, 2x2 crossover-design clinical trial||||
34191533|NCT02054104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191534|NCT04845711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and medical personnel collecting data and conducting follow-up will be blinded to the group of the patient. All blocks will be performed by one anesthesiologist who will not participate in data collection or analysis.||t|f|f|t
34191535|NCT02543060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34191536|NCT04269798|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34191537|NCT03161444|NA|SINGLE_GROUP||OTHER||NONE||A blood sample collection for the study will be taken to each participant. Each subject enrolled must have previously participated in the study CHIKVIH.||||
34191538|NCT03126318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|randomized, double-blind, placebo-controlled - 4 cohorts of 4 patients each with a dosing regimen of 3:1 (active:placebo)|t|t|t|t
34191539|NCT06226220|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multi-center, randomized, non-inferiority trial||||
33872057|NCT03846986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33872058|NCT03095794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872059|NCT02290873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191540|NCT04702919|||OTHER||PROSPECTIVE|||||||
34191541|NCT03170180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872060|NCT00573989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872061|NCT04095650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191542|NCT06325592|||COHORT||RETROSPECTIVE|||||||
34191543|NCT02883218|||OTHER||PROSPECTIVE|||||||
33872062|NCT01268358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872063|NCT05645497|||CASE_CONTROL||PROSPECTIVE|||||||
33872064|NCT02164929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872065|NCT00254462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872066|NCT06379737|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34191544|NCT02375334|||COHORT||PROSPECTIVE|||||||
33872067|NCT02672670|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33872068|NCT05259865|||COHORT||PROSPECTIVE|||||||
33966650|NCT05334602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|Randomized clinical trial|t|f|f|t
33966651|NCT02784860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33966652|NCT00297479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191545|NCT05764447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent randomizer will prepare a computer-generated list of random assignments in sealed, sequentially numbered opaque envelopes. To aid allocation concealment, permuted blocks of varying sizes with an allocation weight of 1:1 will be used. The randomizer will keep a secure copy of the randomization list, which will be concealed from all research personnel and participants. The statistician performing data analysis will be blinded. Although it is not feasible to blind the participants or intervention personnel to the group assignments, the outcome assessors will be blinded.||f|f|f|t
33966653|NCT04168762|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be masks from the specific details of the type of TUMS stimulation they are receiving.|Participants are randomized into two groups. Group A will receive a two part Transcranial Ultrasound Magnetic Stimulation (TUMS) on two visits and Group B will receive a one part TUMS on two visits.|t|f|f|f
33966654|NCT05522517|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966655|NCT01674842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966656|NCT01281579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966657|NCT02204683|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33966658|NCT01665859|||COHORT||PROSPECTIVE|||||||
33966659|NCT00170170|||||RETROSPECTIVE|||||||
33966660|NCT01017029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966661|NCT04708405|||COHORT||PROSPECTIVE|||||||
34191546|NCT03584880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191547|NCT05299632|||OTHER||PROSPECTIVE|||||||
34191548|NCT02364635|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34191549|NCT00455728|||COHORT||PROSPECTIVE|||||||
34191550|NCT06122311|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention and control groups||||
34191551|NCT02894268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966662|NCT05615129|||COHORT||RETROSPECTIVE|||||||
33966663|NCT00004871||||TREATMENT||||||||
33966664|NCT04826185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966665|NCT05154422|||COHORT||CROSS_SECTIONAL|||||||
33872069|NCT03803462|||COHORT||CROSS_SECTIONAL|||||||
33872070|NCT00091104||||TREATMENT||NONE||||||
33872071|NCT01035385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872072|NCT02589691|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872073|NCT05861479|||COHORT||RETROSPECTIVE|||||||
33872074|NCT00185744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872075|NCT00960843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872076|NCT05138016|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Within-subject design||||
33872077|NCT01001000|||COHORT||PROSPECTIVE|||||||
33872078|NCT02060682|||CASE_ONLY||PROSPECTIVE|||||||
33872079|NCT00641550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872080|NCT00375336|||COHORT||PROSPECTIVE|||||||
33872081|NCT03300674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33872082|NCT05018832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191552|NCT05928546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group(I): 10 sites will receive non-surgical periodontal therapy (scaling and root planing) . Group(Ⅱ): 10 sites will receive non-surgical periodontal therapy followed by the application of quercetin nanoemulgel local delivery 2 times one at the day of non-surgical periodontal therapy and after 2 weeks.||||
33872083|NCT02227602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191553|NCT05863208|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33872084|NCT00670670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872085|NCT04050982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized control trial||||
33872086|NCT03096730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double Blind||f|f|t|t
34191554|NCT04091607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1 will listen to Music during the procedure. Group 2 will not hear any music during the procedure||||
34191555|NCT02709538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872087|NCT01868880|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191556|NCT03611257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center prospective randomised clinical trial||||
33872088|NCT00004138|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872089|NCT01556139|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33872090|NCT04714242|||CASE_CONTROL||PROSPECTIVE|||||||
33872091|NCT04936360|||OTHER||CROSS_SECTIONAL|||||||
33872092|NCT02953353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872093|NCT02799823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966666|NCT05784506|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966667|NCT06208761|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33966668|NCT06452823|||COHORT||PROSPECTIVE|||||||
33966669|NCT02589769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966670|NCT06120010|||COHORT||CROSS_SECTIONAL|||||||
33966671|NCT05953285|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||The study is a within-subjects, randomized crossover experimental design.|t|f|f|f
33966672|NCT02483481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966673|NCT05493033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966674|NCT05519020|||COHORT||OTHER|||||||
34191557|NCT02361840|||COHORT||PROSPECTIVE|||||||
34191558|NCT02024789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191559|NCT04521049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191560|NCT00161161|||CASE_CONTROL||OTHER|||||||
34191561|NCT01287312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191562|NCT02975557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191563|NCT00737945|||COHORT||PROSPECTIVE|||||||
34191564|NCT02385643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191565|NCT00666016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191566|NCT00419445|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34191567|NCT00775008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34191568|NCT02001753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34191569|NCT05617456|||COHORT||PROSPECTIVE|||||||
34191570|NCT04583098|||COHORT||PROSPECTIVE|||||||
34191571|NCT06520410|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34191572|NCT04098484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191573|NCT05998746|||COHORT||PROSPECTIVE|||||||
34191574|NCT00482989|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34191575|NCT05246267|||CASE_CONTROL||PROSPECTIVE|||||||
34191576|NCT02185859|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34191577|NCT01757353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34191578|NCT03456310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191579|NCT00942994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191580|NCT05977244|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34191581|NCT02932371|NA|SINGLE_GROUP||||NONE||||||
34191582|NCT06099730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191583|NCT00438568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191584|NCT04052256|||COHORT||PROSPECTIVE|||||||
34191585|NCT00959725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872094|NCT01048762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872095|NCT03805945|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33872096|NCT01984385|||COHORT||PROSPECTIVE|||||||
33872097|NCT01607736|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33872098|NCT04438161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (study personnel blind to intervention allocation status)||t|f|f|f
33872099|NCT00932347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872100|NCT02075372|||CASE_ONLY||PROSPECTIVE|||||||
33872101|NCT02734836|NA|SINGLE_GROUP||OTHER||NONE||||||
33872102|NCT00382746|||||PROSPECTIVE|||||||
33872103|NCT05437003|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33872104|NCT01349465|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33872105|NCT01587911|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33966675|NCT00512187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34191586|NCT01550848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191587|NCT05478525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191588|NCT00324961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191589|NCT00947167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191590|NCT06382376|||COHORT||CROSS_SECTIONAL|||||||
34191591|NCT04064216|||COHORT||PROSPECTIVE|||||||
34191592|NCT05507112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191593|NCT01383343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191594|NCT01874340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191595|NCT01744535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191596|NCT00004368||||TREATMENT||||||||
34191597|NCT00260962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191598|NCT01543633|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34191599|NCT01991613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191600|NCT02117622|||COHORT||PROSPECTIVE|||||||
34191601|NCT01710813|||COHORT||PROSPECTIVE|||||||
34191602|NCT01132781|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34191603|NCT00831493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191604|NCT05276440|||CASE_ONLY||RETROSPECTIVE|||||||
34191605|NCT00213538|||COHORT||PROSPECTIVE|||||||
33872106|NCT04046432|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|a randomized, double-blind, placebo-controlled clinical study|a randomized, double-blind, placebo-controlled clinical study|t|f|f|f
34191606|NCT01057589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191607|NCT03730090|||COHORT||PROSPECTIVE|||||||
34191608|NCT01030926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34191609|NCT01575535|||||RETROSPECTIVE|||||||
34191610|NCT03092362|||COHORT||PROSPECTIVE|||||||
34191611|NCT06083064|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||1:1:1||||
34191612|NCT03521778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872107|NCT01433146|||COHORT||PROSPECTIVE|||||||
33872108|NCT01077648|||COHORT||RETROSPECTIVE|||||||
33872109|NCT05371977|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872110|NCT00349375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872111|NCT04701138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872112|NCT01286428|||CASE_ONLY||PROSPECTIVE|||||||
33872113|NCT02428842|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872114|NCT04456179|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33872115|NCT05245331|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872116|NCT02031497|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33872117|NCT00029692|RANDOMIZED|||TREATMENT||DOUBLE||||||
34191613|NCT00295880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191614|NCT04161248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191615|NCT01318005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34191616|NCT02949895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191617|NCT05575323|RANDOMIZED|PARALLEL||TREATMENT||NONE|According to the TwiCs design, patients allocated to the control group are not informed about their role as a control in the trial.|||||
34191618|NCT04359901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872118|NCT00103974|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33872119|NCT05354011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872120|NCT01244555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872121|NCT01971073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872122|NCT05809778|||OTHER||CROSS_SECTIONAL|||||||
33872123|NCT06503718|||CASE_ONLY||RETROSPECTIVE|||||||
33872124|NCT04077307|NA|SEQUENTIAL||TREATMENT||NONE||"First part of the study - 3 different dose cohorts with escalating doses are planned.~Extension part of the study - 20 patients with diagnosis of Relapsed, Refractory or Progressive AML and MDS to be enrolled and treated with RP2D."||||
33872125|NCT01529437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872126|NCT03677830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention (intravenous acetaminophen) and placebo (saline) will be distributed by the pharmacy and are visually indistinguishable.||t|t|t|t
33872127|NCT00967551|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33872128|NCT02355899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872129|NCT06238167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872130|NCT05758675|||COHORT||PROSPECTIVE|||||||
33872131|NCT02411162|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872132|NCT06179758|NA|SINGLE_GROUP||OTHER||NONE||||||
33872133|NCT05587855|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a 6-week randomized controlled intervention. Participants with hypertension will be assigned to an eCulinary medicine group (E-group) or control that will receive recipes without the eCulinary intervention (C-group).||||
33872134|NCT01342835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872135|NCT06148376|||COHORT||PROSPECTIVE|||||||
33872136|NCT00351013|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33872137|NCT01431196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872138|NCT04983407|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872139|NCT00885027|||||PROSPECTIVE|||||||
34191619|NCT05751564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, providers, investigators and outcome assessments will be blind to randomization except in need to open code for security reasons|Prospective Double blind Randomized Controlled Trial|t|t|t|t
34191620|NCT00243269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34191621|NCT02065206|||COHORT||PROSPECTIVE|||||||
34191622|NCT03803319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Investigators will be blinded to the fibre provided over the 8-week intervention period.|multi-centre, 3 treatment, placebo-controlled trial|t|f|t|f
34191623|NCT03475420|||COHORT||RETROSPECTIVE|||||||
33872140|NCT05489835|||COHORT||PROSPECTIVE|||||||
33872141|NCT00455689|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872142|NCT01509495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872143|NCT02311153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872144|NCT04095364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872145|NCT06075836|||COHORT||RETROSPECTIVE|||||||
33872146|NCT01528111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872147|NCT02438514|||COHORT||PROSPECTIVE|||||||
33872148|NCT00779480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872149|NCT04565886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised placebo controlled monocentric trial|t|f|f|t
34191624|NCT05317117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191625|NCT05132322|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34191626|NCT04838080|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191627|NCT02467686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191628|NCT04765228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191629|NCT06220942|||CASE_CONTROL||PROSPECTIVE|||||||
34191630|NCT01988584|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33872150|NCT03203057|||COHORT||PROSPECTIVE|||||||
33872151|NCT04114149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872152|NCT00455988|||||OTHER|||||||
33966676|NCT05332626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trail|t|f|t|f
33966677|NCT00455533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966678|NCT01268800|||COHORT||PROSPECTIVE|||||||
33966679|NCT00360867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966680|NCT03615079|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33966681|NCT01881529|||COHORT||CROSS_SECTIONAL|||||||
33966682|NCT01047085|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067626|NCT05390723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A single-centre proof-of-principle RCT will be conducted using a scripted video-design. Four different information-videos about chemotherapy's side effects are created in which specific communication is manipulated to assess their effect on patient (psychological/cognitive/physical outcomes. (The investigators cannot yet reveal the manipulation as it would influence our participants)|t|t|f|f
33872153|NCT04271059|||CASE_CONTROL||PROSPECTIVE|||||||
33872154|NCT04464395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872155|NCT00844753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872156|NCT06119867|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33872157|NCT00331045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872158|NCT06098365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised Controlled Trial|t|f|f|f
33872159|NCT01378507|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872160|NCT02039375|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single arm study||||
33872161|NCT01427985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872162|NCT01057407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872163|NCT05884203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants: Subjects will be blinded. Each subject will participate in both residual limb shape capture methods during the first study visit (order randomly assigned), but only one study socket (either the study helper assisted socket with digital methods, or the prosthetist made socket with traditional methods) will be used for outcomes testing (randomly assigned and blinded to the participant).~Care Provider: The prosthetist will fabricate the prosthetist socket using traditional methods, thereby knowing study socket and participant randomization. However, the investigators will apply apply a fabric cover to the sockets (both sensorized as-prescribed and study sockets) during visits 3 and 4. This method blinds the prosthetist during the distal end residual limb pressure measurements.~Outcomes Assessor. The study staff collecting patient reported outcomes will also be blinded, as they will not know which socket the participant received."|The shape of the participants' residual limb will be captured with both study helper assistance and digital methods, and also by a prosthetist using traditional methods. However, only one study socket, randomly assigned, will be manufactured and used for outcomes testing.|t|t|f|t
33872164|NCT01833637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966683|NCT03003533|NA|SEQUENTIAL||TREATMENT||NONE||||||
33966684|NCT04896359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33966685|NCT03610178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Women with GDM are randomised to 2 treatment groups: group 1 - treatment group with very tight glycemic targets (\<5.1 mmol / L fasting glucose and \<7.0 mmol / l hour after a meal) and group 2 - treatment group with tight-moderate glycemic targets (\<5.3 mmol / L fasting glucose and \<7.8 mmol / l in an hour after a meal).|f|f|t|f
33966686|NCT02340078|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Split-face design. Subjects were decided by randomization which side of the face would be injected with the test device. According to this randomization result, the other side would be determined to be injected with a comparator. It was determined just by one randomization.|t|f|t|t
33966687|NCT05322265|||CASE_CONTROL||RETROSPECTIVE|||||||
33966688|NCT02330250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33966689|NCT05798858|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33966690|NCT04093726|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||f|t|t|t
33966691|NCT00875368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966692|NCT01298596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966693|NCT03974984|||COHORT||PROSPECTIVE|||||||
34067627|NCT02411981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191631|NCT00029146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191632|NCT00977119|||COHORT||PROSPECTIVE|||||||
34191633|NCT02906605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191634|NCT03849625|||COHORT||PROSPECTIVE|||||||
34191635|NCT05756257|||COHORT||PROSPECTIVE|||||||
34191636|NCT04641884|||COHORT||RETROSPECTIVE|||||||
34191637|NCT02974699|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34191638|NCT02636361|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34191639|NCT00117494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191640|NCT02860832|||||CROSS_SECTIONAL|||||||
34191641|NCT00448604|||COHORT||PROSPECTIVE|||||||
34191642|NCT02961738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191643|NCT01776307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191644|NCT02377661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191645|NCT04571931|||OTHER||CROSS_SECTIONAL|||||||
34191646|NCT01491984|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34191647|NCT05331404|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Patient and control||||
34191648|NCT01251341|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34191649|NCT03697915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Thirty hospitalized patients who were immobile more than 1 week were randomised into two groups. Each group had received 15 sessions of physical therapy (ROM exercises and electrotherapy) regularly.||||
34191650|NCT01330251|||CASE_CONTROL||PROSPECTIVE|||||||
34191651|NCT06043193|||COHORT||PROSPECTIVE|||||||
34191652|NCT05101850|||CASE_CROSSOVER||PROSPECTIVE|||||||
34191653|NCT02056262|||COHORT||CROSS_SECTIONAL|||||||
34191654|NCT06492863|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34191655|NCT06226389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191656|NCT04699136|NA|SINGLE_GROUP||OTHER||NONE||||||
33872165|NCT00533832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872166|NCT05732090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33872167|NCT03614754|||COHORT||PROSPECTIVE|||||||
33966694|NCT00469534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872168|NCT00867321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872169|NCT03535467|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33872170|NCT03077685|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose-escalating, Phase IIa trial.||||
33872171|NCT01982032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872172|NCT03007368|RANDOMIZED|CROSSOVER||||NONE||||||
33966695|NCT00606879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872173|NCT00456352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894261|NCT01591980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894262|NCT01531725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894263|NCT03604666|||COHORT||OTHER|||||||
33894264|NCT01664026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966696|NCT01410695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966697|NCT00904059|RANDOMIZED|CROSSOVER||||NONE||||||
34191657|NCT02905851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191658|NCT02639416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191659|NCT02538393|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34191660|NCT04710472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34191661|NCT03223519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191662|NCT04838977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will not be aware of study assignment.|Study comparing treatment to usual care.|f|f|t|f
34191663|NCT03637439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191664|NCT02923440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191665|NCT03601117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"A small pilot study (n=22) will be an open-label study in which all participants receive stimulation to the L-DLPFC to demonstrate feasibility of delivering this accelerated protocol on an inpatient unit.~For participants who do not respond to L-DLPFC stimulation, we will offer an alternative site, the ACC.~If patients are enrolled that have a psychiatric diagnosis other than MDD, scales measuring symptoms related to their other diagnosis/(es) will also be collected in addition to measuring change in depressive symptoms (see 'other pre-specified outcome measures' for a list of measures used to measure symptoms related to psychiatric diagnoses other than depression)."||||
34191666|NCT00063440|||COHORT||PROSPECTIVE|||||||
34191667|NCT05037799|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191668|NCT01221311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191669|NCT06373289|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The PI will perform bedside echocardiography precluding masking to group allocation. All echocardiograms will be further reviewed by a cardiologist masked to group allocation with additional cardiologist review in instances of disagreement. Inter-rater reliability testing will also be performed.|Single center, randomized cross-over pilot study with a 1:1 parallel allocation of infants to SpO2 targets of 92-95% (control) and 95-98% (intervention) using a stratified permuted block design. Following 2 weeks of exposure A, infants will cross over to exposure B for 2 weeks with a 1-week washout period.|f|f|f|t
34191670|NCT02513927|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34191671|NCT03725241|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind||t|f|t|f
34191672|NCT03071250|||COHORT||RETROSPECTIVE|||||||
34191673|NCT03794830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191674|NCT02565784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191675|NCT03617328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191676|NCT04721080|||OTHER||CROSS_SECTIONAL|||||||
34191677|NCT03060980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191678|NCT02011724|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191679|NCT00430976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191680|NCT00488683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191681|NCT04140578|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191682|NCT03812822|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34191683|NCT01785992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191684|NCT05301478|NA|SINGLE_GROUP||OTHER||NONE|No masking|Wear custom foot orthotics during in laboratory testing for up to four hours||||
34191685|NCT04110197|||CASE_CONTROL||PROSPECTIVE|||||||
34191686|NCT04713397|||CASE_CONTROL||RETROSPECTIVE|||||||
34191687|NCT04158934|||COHORT||PROSPECTIVE|||||||
34191688|NCT02887118|||COHORT||PROSPECTIVE|||||||
34191689|NCT01192009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191690|NCT06341985|||COHORT||PROSPECTIVE|||||||
34191691|NCT03663621|||COHORT||PROSPECTIVE|||||||
34191692|NCT00001272||||TREATMENT||||||||
34191693|NCT01859520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191694|NCT00580671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894265|NCT04048577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894266|NCT04937699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894267|NCT01330290|||COHORT||CROSS_SECTIONAL|||||||
33894268|NCT05548634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966698|NCT02437890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966699|NCT01561118|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966700|NCT06110585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966701|NCT01823315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966702|NCT03953781|||CASE_ONLY||PROSPECTIVE|||||||
33966703|NCT00240084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966704|NCT05514028|||COHORT||PROSPECTIVE|||||||
33966705|NCT03101293|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33966706|NCT02061150|||COHORT||RETROSPECTIVE|||||||
33966707|NCT05928728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966708|NCT01272193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755783|NCT04016948|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33755784|NCT02178748|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755785|NCT06580613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755786|NCT05821738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872174|NCT03257670|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to two treatment cohorts (each with 35 patients): (1) treatment with the CO2RE laser or; (2) treatments of 4% aqueous lidocaine applied to the vulvar vestibule for 3 minutes before vaginal penetration. Both cohorts will have four follow-up assessments following initiation of treatment: (1) One-week post treatment initiation; (2) 1-month post treatment initiation; (3) 3-months post treatment initiation and; (4) 6-months post laser-only treatment initiation. At the 3-month assessment, subjects in the lidocaine arm will be allowed to try the CO2RE laser therapy. In doing this, an imbedded crossover trial is included that will allow assessment of subject decision-satisfaction between the two therapy approaches. The primary outcome will be the overall and lubrication, satisfaction, and pain domain scores on the Female Sexual Function Index instrument. Secondary outcomes will be other validated pain and pelvic floor symptom instruments.||||
33872175|NCT03029143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872176|NCT00889148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872177|NCT01315860|||COHORT||PROSPECTIVE|||||||
33755787|NCT02671448|NA|SINGLE_GROUP||SCREENING||||This pilot trial will be the first attempt at developing a homebound hematopoietic stem cell transplant (HSCT) program at MSK.||||
33755788|NCT02802800|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33755789|NCT04991467|RANDOMIZED|FACTORIAL||TREATMENT||NONE||3 interventions: Care \& Valera, Care only, and Valera only.||||
33755790|NCT03468556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo|test drug|t|t|t|t
33755791|NCT00285610|||COHORT||PROSPECTIVE|||||||
33755792|NCT05502705|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33755793|NCT02548767|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33755794|NCT02008604|||CASE_CONTROL||PROSPECTIVE|||||||
33755795|NCT05686005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33755796|NCT01348061|||CASE_CONTROL||PROSPECTIVE|||||||
33755797|NCT01129388|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33755798|NCT01533493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755799|NCT06049875|||CASE_CONTROL||PROSPECTIVE|||||||
33755800|NCT06486532|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872178|NCT03628053|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase III, open label, multinational, randomized trial. Eligible patients will be randomized 1:1 to Tisagenlecleucel treatment strategy (tisagenlecleucel after optional bridging chemotherapy and lymphodepleting chemotherapy) or control arm treatment strategy (blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy).~The randomization will be performed stratifying for the number of prior salvage therapies (0 vs. 1) and prior allogenic stem cell transplant (yes vs. no)."||||
33872179|NCT03383536|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966709|NCT05896332|NA|SINGLE_GROUP||TREATMENT||NONE||We propose to conduct an open-label Phase I trial of accelerated iTBS-rTMS for AUD+MCI. We propose to recruit 35 treatment-seeking individuals ages 60-85 years, with AUD and cognitive impairment, specifically those meeting criteria for AUD with DSM-5 Mild Neurocognitive Disorder. Individuals will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total). All will undergo clinical assessments and brain MRI at pre-treatment and at 1-week post-treatment, and clinical assessments at 4-weeks post-treatment. Weekly post-treatment online self-report assessments will be collected up to four weeks. Resting-state parcellations of pre- and post-fMRI will be completed for personalized targeting and network parcellations.||||
33966710|NCT04681274|||OTHER||RETROSPECTIVE|||||||
33966711|NCT00615771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966712|NCT01114542|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33966713|NCT04246190|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872180|NCT03186690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were not aware of type of capping material used.|This prospective longitudinal, parallel-design, randomized clinical trial was set up and is reported according to CONSORT statement|t|f|f|f
33966714|NCT01377233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067628|NCT06139705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After baseline measurements, the patients will be randomly assigned to either walking outdoors (OUT) or walking indoors (IN) groups. OUT group will walk in the parke. IN group will walk in a gym on a treadmill. During both interventions, the patient will be supervised by researchers. The order and sequence of measurements within each trial will be the same.||||
34067629|NCT03307460|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872181|NCT06255704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067630|NCT04765670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067631|NCT03642444|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||N-of-1 series||||
33872182|NCT02410668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872183|NCT01718561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33872184|NCT01230541|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33872185|NCT05896085|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872186|NCT01731379|||CASE_ONLY||CROSS_SECTIONAL|||||||
33872187|NCT06005870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872188|NCT00061542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872189|NCT00351832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872190|NCT01887067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872191|NCT03820414|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33872192|NCT02751203|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33872193|NCT02431702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872194|NCT00297609|||DEFINED_POPULATION||PROSPECTIVE|||||||
33872195|NCT03433872|NA|SINGLE_GROUP||TREATMENT||NONE||The goal of the field test is to evaluate use of the We Grow Together system by typical early childhood professionals working in a variety of care settings serving infants and toddlers. The field test will take place in 8 to 12 geographic areas across the country. This study will include only centers and FCC settings that already have local PD providers-the investigators will exclude ECE settings without established PD providers. The field test will include a purposive sample of 175 center-based classrooms (approximately half will be affiliated with Early Head Start \[EHS\], and half will be community-based child care programs). The field test sample will also include 125 FCCs, including those operating under EHS and in community-based settings.||||
33872196|NCT05676359|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872197|NCT02164695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|CMR results will be interpreted by observers blinded to randomization|"* Control group: PPCI only~* Study group: PPCI + RIPC"|f|f|f|t
33872198|NCT05771220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized controlled trial, single blinded, placebo|t|f|f|f
33872199|NCT03270189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872200|NCT04625621|||COHORT||RETROSPECTIVE|||||||
33872201|NCT05248568|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34067632|NCT05456854|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34067633|NCT01955577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067634|NCT03628716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067635|NCT02041780|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067636|NCT00251498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067637|NCT03313310|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm longitudinal pre/post study||||
34067638|NCT02030886|NA|SINGLE_GROUP||OTHER||NONE||||||
34067639|NCT01602679|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomized, placebo-controlled, crossover study|t|t|t|t
34067640|NCT02588092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067641|NCT03034135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067642|NCT00100152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755801|NCT02820220|||||PROSPECTIVE|||||||
33755802|NCT03676179|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|unicompartment knee arthroplasty without patella denervation|unicompartment knee arthroplasty with patella denervation|f|f|t|t
33755803|NCT05101629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755804|NCT01778348|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755805|NCT02139722|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33755806|NCT02306655|||CASE_ONLY||RETROSPECTIVE|||||||
33755807|NCT00975845|||COHORT||PROSPECTIVE|||||||
33755808|NCT03401684|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872202|NCT01023633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872203|NCT02424032|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33872204|NCT00894062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872205|NCT05700305|||COHORT||PROSPECTIVE|||||||
33872206|NCT06148688|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33872207|NCT05312853|||CASE_ONLY||PROSPECTIVE|||||||
33872208|NCT01486849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872209|NCT04455763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755809|NCT04997954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755810|NCT05586594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755811|NCT06174311|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to which condition they are assigned to. Participants will be assigned codes so that the care provider is also blinded to which condition the participants are in.|"Condition 1: Cognitive Bias Modification for active group~Condition 2: Cognitive Bias Modification for waitlist control group"|t|t|f|f
33755812|NCT00696410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755813|NCT06136975|||COHORT||RETROSPECTIVE|||||||
33755814|NCT02489955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755815|NCT05195073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755816|NCT05350241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blinded to the treatment allocation.|A prospective, randomized controlled clinical trial|f|f|f|t
33755817|NCT00035529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755818|NCT03086330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755819|NCT04614233|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||We are testing the hypotheses that high fat diet consumers will show the greatest benefit from supplementation with oleoylethanolamide (OEA) in terms of weight loss maintenance, because OEA targets brain adaptations that are related to high fat diet.|t|t|t|t
33755820|NCT04462861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872210|NCT04944654|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm study||||
33872211|NCT03144245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872212|NCT06114784|||COHORT||PROSPECTIVE|||||||
33872213|NCT05630248|||OTHER||PROSPECTIVE|||||||
33872214|NCT00294359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872215|NCT05963789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872216|NCT05404464|||COHORT||PROSPECTIVE|||||||
33872217|NCT05576389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872218|NCT00861068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33872219|NCT03817775|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be recruited from the coronary angiography patient pool of the American Hospital of Paris and assigned to one of 2 groups in a non-randomized manner: Control or music intervention.||||
33872220|NCT02993874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872221|NCT00472264|||CASE_CONTROL||PROSPECTIVE|||||||
33872222|NCT01347554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872223|NCT00169455|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33872224|NCT00229879|||||RETROSPECTIVE|||||||
33872225|NCT04046107|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33872226|NCT03413189|||COHORT||PROSPECTIVE|||||||
33872227|NCT04194528|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33872228|NCT02431091|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33872229|NCT04852328|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33966715|NCT04058678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the first visist to the doctor, women will be selected according to the selection criteria. Those who seem to have a low ovarian reserve by ultrasound will be informed of the trial, and if they decide to participate, blood will be taken to analyze AMH values. On the second visit, women with low ovarian reserve will be randomized 1:1 for either inactive substance or Danazo, accordint to a computer-generated randomization list prepared by associated statistic. This way, the assigned group will be blind until the momento of executing the randomization procedure. Moment in which, the assigned group will be revealed.~Those with normal ovarian reserve will not be randomized and will just be included as controls.~To maintain the blinding of the trial, Danazol and placebo will be provided in boxs with blisters (PVC opaque and aluminium sealed).~Only the trial medication delegate(s) at the site will dispense the IMP and will know the treatment allocation."|A control group composed of women with normal ovarian reserve to compare telomeric and fertility parameters with the group with compromised ovarian reserve.|t|t|t|t
33966716|NCT04895969|||OTHER||CROSS_SECTIONAL|||||||
34067643|NCT00487097|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067644|NCT04365673|||CASE_CONTROL||RETROSPECTIVE|||||||
34067645|NCT04886752|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067646|NCT02769312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067647|NCT03089853|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot, randomized controlled study where subjects will be randomized in a 2:1 ratio to either receive remote tele pulmonary rehabilitation intervention and NMES or usual care.||||
33872230|NCT06475833|||OTHER||CROSS_SECTIONAL|||||||
33872231|NCT01530204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33872232|NCT02225470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872233|NCT02498015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872234|NCT02031562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872235|NCT00954720|||COHORT||PROSPECTIVE|||||||
33872236|NCT05626998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872237|NCT00143312|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33872238|NCT06170138|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."||||
33872239|NCT04360109|||COHORT||PROSPECTIVE|||||||
33872240|NCT03860675|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33872241|NCT02461550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872242|NCT06453096|||COHORT||RETROSPECTIVE|||||||
33872243|NCT02838966|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33755821|NCT04639674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755822|NCT03233243|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|t|f|t
33872244|NCT05425615|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participant and outcomes assessor will both be blinded to intervention modalities.|Multiple studies will be conducted in parallel. But within a study, the interventional assignment will be set to cross-over with 3-4 arms.|t|f|f|t
33872245|NCT01508702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872246|NCT05110703|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This will be a 3-arm randomized, double-blinded (for the two meal replacement arms), placebo-controlled study|t|t|t|f
33872247|NCT03134599|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33872248|NCT00766038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872249|NCT04636827|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33872250|NCT01923285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872251|NCT04628338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872252|NCT06001658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872253|NCT03516526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872254|NCT01236573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872255|NCT03765138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872256|NCT00802542|||CASE_ONLY||PROSPECTIVE|||||||
33872257|NCT05397626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each participant fill out online outcome forms that involve no interaction with the principal investigator or study staff, thus avoiding any staff-specific influence on online outcome forms.|This clinical study involves three active intervention groups: group 1 receiving heart rhythm biofeedback alone, group receiving hydrogen water alone, and group 3 receiving both heart rhythm biofeedback and hydrogen water.|f|f|f|t
33872258|NCT00957528|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33872259|NCT04591275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872260|NCT02250274|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872261|NCT04152577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872262|NCT03075800|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pilot, cluster randomized controlled trial was conducted in which ACT teams were randomized to provide either IMR within ACT (ACT+IMR) or standard ACT treatment (ACT-only). The impact of ACT+IMR vs. ACT-only on illness management and recovery outcomes was based on assessments conducted on a subset of randomly selected clients from each team, conducted at baseline, six months, and one year. Randomization to ACT+IMR or ACT-only was stratified by state and by team size, resulting in one large team and one small team assigned to each condition in each state.||||
33872263|NCT06071507|||COHORT||PROSPECTIVE|||||||
33872264|NCT00755274|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872265|NCT00788281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872266|NCT01131676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872267|NCT00574288|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872268|NCT05169151|||COHORT||PROSPECTIVE|||||||
33872269|NCT00006451|RANDOMIZED|PARALLEL||TREATMENT||||||||
33872270|NCT01497470|NA|SINGLE_GROUP||||NONE||||||
33872271|NCT01651624|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33872272|NCT00633906|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33872273|NCT02505503|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33872274|NCT04354480|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33872275|NCT06275763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872276|NCT01863940|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872277|NCT00840086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872278|NCT02718742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872279|NCT03129087|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The proposed study is a randomized, cross-over, clinical trial involving the comparison of two treatments (A and B) separated by a wash-out period (W). The patient participants will be randomized to one of the following two treatment orders: AWB or BWA.|f|f|f|t
33872280|NCT06254911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872281|NCT02097615|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33872282|NCT03300999|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33872283|NCT02346032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872284|NCT00079404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067648|NCT04513899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067649|NCT00098462||||TREATMENT||NONE||||||
33872285|NCT00637520|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872286|NCT03450005|||CASE_ONLY||PROSPECTIVE|||||||
33872287|NCT01193855|RANDOMIZED|||TREATMENT||DOUBLE||||||
33872288|NCT04702776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After signing the informed consent form (ICF), every subject will receive a coded patient number and will be assigned randomly to one of the investigation products.|Phase IV, non inferiority, controlled, open, comparative, multicenter clinical study|t|f|t|f
33872289|NCT04244656|NA|SEQUENTIAL||TREATMENT||NONE||||||
34067650|NCT01514890|||COHORT||OTHER|||||||
34067651|NCT03747913|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participant enrolled in the study will be part of the supplementation and control condition group in a non-randomized order||||
34067652|NCT04386161|NA|SINGLE_GROUP||TREATMENT||NONE||Children, aged between 8 and 11 years, with clinical dyslexia diagnosed by a child and adolescent psychiatrist||||
34067653|NCT06330675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067654|NCT04321941|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Blinded evaluation of MRE and CTE images respectively|Within patient comparison of diagnostic methods|f|f|f|t
34067655|NCT04052516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872290|NCT00236015|RANDOMIZED|PARALLEL||||DOUBLE||||||
33872291|NCT05479253|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33872292|NCT00728975|||COHORT||RETROSPECTIVE|||||||
33872293|NCT05649085|||COHORT||PROSPECTIVE|||||||
34067656|NCT01204918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067657|NCT01343966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067658|NCT03610321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067659|NCT05810610|||COHORT||OTHER|||||||
34067660|NCT03072251|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34067661|NCT00974038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872294|NCT03234387|||COHORT||CROSS_SECTIONAL|||||||
33872295|NCT04658758|||COHORT||PROSPECTIVE|||||||
33872296|NCT00490451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872297|NCT06201897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872298|NCT03426371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||multicenter, double-blind, randomized, controlled phase III trial|t|t|t|f
33872299|NCT04186494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872300|NCT01467843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872301|NCT05800184|||COHORT||PROSPECTIVE|||||||
33872302|NCT04835636|||COHORT||PROSPECTIVE|||||||
33872303|NCT06290375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872304|NCT04423874|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067662|NCT00724802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067663|NCT01905774|||COHORT||RETROSPECTIVE|||||||
34067664|NCT06043492|RANDOMIZED|CROSSOVER||SCREENING||NONE||The same participants will participate in three different conditions||||
33966717|NCT03351218|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups study : patients versus healthy controls||||
33966718|NCT02348619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966719|NCT05126914|||COHORT||PROSPECTIVE|||||||
33872305|NCT01737476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966720|NCT06547203|NA|SINGLE_GROUP||TREATMENT||NONE||To investigate the objective response rate (ORR) of cetuximab combined with toripalimab and irinotecan in right-sided mCRC patients with negative ultraselected RAS/BRAF wild-type who have progressed after previous treatments with bevacizumab, irinotecan, oxaliplatin, and 5-fluorouracil.||||
33872306|NCT00929175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966721|NCT01077349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966722|NCT01335178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33966723|NCT05319340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966724|NCT03551678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872307|NCT03957265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966725|NCT06259929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966726|NCT01440478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966727|NCT05751083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872308|NCT02887664|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872309|NCT03898375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872310|NCT05445375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34067665|NCT04234594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067666|NCT04377841|||COHORT||PROSPECTIVE|||||||
34067667|NCT00909220|||CASE_CONTROL||PROSPECTIVE|||||||
34191695|NCT05025436|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|A total of 64 subjects were admitted, and they were randomly assigned into a control group and an experimental group by a crossover test, with 32 persons in each group. Random Allocation Software is used to randomly allocate 64 cases with random serial numbers generated by the computer. The 64 cases are divided into two groups with 32 people in each group. Randomly assigned serial numbers will be stored in consecutively numbered opaque sealed envelopes.|The intervention time of the study was 2.5 months. The cross-over test was adopted. There were 2 kinds of intervention measures. Each subject in the experimental group was given the main acupoints (5 acupoints) and the physical acupoints (1-2 acupuncture points). Acupoints) Intervene in low-energy laser (Erger laser pen) acupoint stimulation, set wavelength 810nm +/-10%, power 200mW, select Bahr parameter (B2: 1199 Hz; B3: 2398 Hz) module according to the acupuncture point for treatment The time is 30 seconds per acupoint, and the therapeutic dose is 3 joules per acupoint; each subject in the control group is given the same main acupoints and physical matching acupoints without energy acupoint care (therapeutic dose is 0 joules per acupoint), three times a week, for a period of 4 Weeks later, after a 2-week suspension, the two groups crossed over for another 4 weeks of intervention.|t|f|f|f
34191696|NCT01738646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191697|NCT01069380|||COHORT||CROSS_SECTIONAL|||||||
34191698|NCT02606149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34191699|NCT00637780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191700|NCT02086396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34191701|NCT02829801|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34191702|NCT02165267|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34191703|NCT06067620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191704|NCT02456363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191705|NCT05856136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34191706|NCT06222788|NA|SINGLE_GROUP||OTHER||NONE||||||
34191707|NCT02641340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34191708|NCT02845167|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
34191709|NCT04455464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191710|NCT01145092|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34191711|NCT01652469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191712|NCT05369182|||COHORT||PROSPECTIVE|||||||
34191713|NCT02046759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34191714|NCT00696917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34191715|NCT01237899|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34191716|NCT05539300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191717|NCT05622253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191718|NCT00250289|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34191719|NCT01500499|||COHORT||RETROSPECTIVE|||||||
34191720|NCT06372236|NA|SINGLE_GROUP||TREATMENT||NONE||UTAA06 injection||||
34191721|NCT01901250|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34191722|NCT01330004|||COHORT||RETROSPECTIVE|||||||
33872311|NCT04700839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872312|NCT02898532|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872313|NCT00127738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872314|NCT02808000|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33872315|NCT04053868|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966728|NCT02880163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966729|NCT03809013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966730|NCT03426319|||COHORT||CROSS_SECTIONAL|||||||
33966731|NCT02162030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966732|NCT02103322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966733|NCT02023502|||CASE_CONTROL||PROSPECTIVE|||||||
33966734|NCT05760378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966735|NCT01771861|||COHORT||PROSPECTIVE|||||||
33966736|NCT05769088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||6 Weeks of resistance training (alternate days), with a Pre-workout or Maltodextrin intake.|t|t|t|t
33966737|NCT00185211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966738|NCT00946465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966739|NCT04655482|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Patients diagnosed with type 3 neovascularization Patients treated with treat-and-extend regimen using aflibercept||||
33966740|NCT02625415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34067668|NCT03409484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33872316|NCT04738812|RANDOMIZED|PARALLEL||TREATMENT||NONE||DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial.||||
33872317|NCT06170424|||COHORT||RETROSPECTIVE|||||||
33872318|NCT04754880|||OTHER||RETROSPECTIVE|||||||
33872319|NCT01967628|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33872320|NCT01759550|||CASE_ONLY||PROSPECTIVE|||||||
33872321|NCT01439672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872322|NCT03807804|RANDOMIZED|PARALLEL||TREATMENT||NONE||【ARDS caused by pneumonia cohort】Parallel Assignment 【ARDS caused by COVID-19 cohort】Single group||||
33872323|NCT03761615|||COHORT||PROSPECTIVE|||||||
33872324|NCT04500782|||OTHER||CROSS_SECTIONAL|||||||
33872325|NCT01022242|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33872326|NCT03518879|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a single-arm proof of concept study to evaluate the impact of the ASTHMA-Educator on process and clinical outcomes||||
33872327|NCT03688880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966741|NCT01559961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966742|NCT00242450|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33966743|NCT00652379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966744|NCT01098240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966745|NCT00355069|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34067669|NCT02671617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34067670|NCT00485186|||FAMILY_BASED||PROSPECTIVE|||||||
33872328|NCT01430455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872329|NCT05312177|||CASE_CONTROL||PROSPECTIVE|||||||
33872330|NCT04484298|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33872331|NCT04049591|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Cluster crossover||||
33966746|NCT04590469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention is a care home/nursing home training programme/coaching and a digital platform. The research assistants collecting data will do so using virtual platforms and will not be told the randomization of participating care homes. Participating care homes will be told not to disclose treatment allocation, and this will be reinforced by the research assistant at the start of each research assessment to maintain the blind.|4 month, randomized, parallel group cluster RCT comparing the WHELD nursing home programme with virtual coaching and digital support with treatment as usual|f|f|f|t
33966747|NCT03047954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33966748|NCT05900609|RANDOMIZED|PARALLEL||PREVENTION||NONE|This study is partially blinded, study participants in the fiber and fermented group will be informed about their intervention after randomization. However, the control group will remain blind throughout the intervention period. Furthermore, participants are not made aware of the different types of intervention before start or during the intervention period. This is done to prevent any adjustments of their diets based on the advices in the other groups and to ensure that the control group stays blinded.|The study applies a randomized, parallel design of 8 weeks (+ follow-up after 3 months)||||
33966749|NCT01689974|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966750|NCT05491564|||CASE_ONLY||PROSPECTIVE|||||||
33966751|NCT06312085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067671|NCT04424914|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||To determine global prevalence of transthyretin amyloid cardiomyopathy in participants diagnosed with heart failure with preserved ejection fraction. No study treatment will be dispensed however, participants will undergo scintigraphy.||||
34067672|NCT03605472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191723|NCT03072004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"We will analyze leprosy patients with neuropathy. These patients will be randomly divided in: (a) Control: who will receive simulated application sham of LLLT; and (b) LLLT: who will receive LLLT (830 nm, continuous emission, 100mW output power and 3J power density). Treatments will occur in 12 sessions (3 times per week) on the nerves: a)ulnar: around the ulnar nerve at the elbow region, and b)common peroneal: surrounding fibular head. For the inclusion criteria will be selected leprosy patients (tuberculoid and borderline tuberculoid forms) with focal demyelinating neuropathy of the ulnar and common peroneal nerves by electroneuromyography (ENMG); patients without leprosy reactions and corticoid use. We will perform measurements of the following parameters before and after the LLLT protocol application: ENMG Muscle Strength; Tactile Sensitivity measured; Pain Intensity; Incapacity grade; Infrared thermography; Screening of Activity Limitation and Safety Awareness scale."|t|f|t|f
34191724|NCT01419652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191725|NCT02741973|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191726|NCT01787721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191727|NCT01322841|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34191728|NCT00306319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191729|NCT03679832|||COHORT||PROSPECTIVE|||||||
34191730|NCT01454141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34191731|NCT04229134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191732|NCT02668211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191733|NCT01050894|||CASE_ONLY||PROSPECTIVE|||||||
34191734|NCT01521104|||COHORT||PROSPECTIVE|||||||
34191735|NCT03476590|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized (1:1), open-label and controlled, parallel group study||||
34191736|NCT03386916|||CASE_ONLY||RETROSPECTIVE|||||||
34191737|NCT05246345|||COHORT||RETROSPECTIVE|||||||
34191738|NCT01254708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191739|NCT06522126|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191740|NCT00466570|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34191741|NCT00644891|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34191742|NCT05571319|NA|SINGLE_GROUP||TREATMENT||NONE||We will enroll 30 participants in an open-label study of metformin treatment for 12 weeks with a 4-week washout period and a final evaluation. The 4-week washout period was chosen to assess the post-treatment effect of metformin on peripheral markers of endothelial function, with expectation that those measurements will trend toward the baseline values.||||
34191743|NCT03794336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191744|NCT00900588|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34191745|NCT04474574|||CASE_ONLY||PROSPECTIVE|||||||
34191746|NCT00077090|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34191747|NCT02613026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191748|NCT02122003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191749|NCT00222664|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34191750|NCT01599624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191751|NCT00329524|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34191752|NCT00218218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34191753|NCT04122469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191754|NCT03878641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191755|NCT01182844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191756|NCT00568165|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34191757|NCT04009811|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191758|NCT05773378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34191759|NCT00904033|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34191760|NCT00600977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191761|NCT00357279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191762|NCT05797389|||CASE_ONLY||PROSPECTIVE|||||||
33966752|NCT00955188|||CASE_ONLY||PROSPECTIVE|||||||
33966753|NCT01281878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966754|NCT01351987|||CASE_ONLY|||||||||
33966755|NCT02357550|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33966756|NCT05093179|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966757|NCT01315483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34191763|NCT06044701|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||"The randomization method:~Children who meet the sample selection criteria will be randomly assigned to three groups: bubble machine group (n=55), hologram fan group (n=55) and control group (n=55). The assignment of individuals to the study groups will be carried out by block randomization method and the blocks will be formed according to age groups (3-7 years / 8-12 years: 2 blocks). The confidentiality of assigning to groups will be ensured by a table of numbers created on the computer by a person independent of the research."|f|f|f|t
34191764|NCT02052076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34191765|NCT04045002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Respondents and investigators will aware the intervention received by respondents. The data analysers who assess research outcomes will be blinded as they would not know respondents belongs to intervention or control group as each respondent will be labelled as numbers.|Intervention group receive 'MyPinkMom' educational intervention and routine antenatal care. Control group receive routine antenatal care only|f|f|f|t
34191766|NCT02849730|||CASE_CONTROL||RETROSPECTIVE|||||||
34191767|NCT02175199|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34191768|NCT03847506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34191769|NCT01161745|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191770|NCT03228329|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34191771|NCT05896267|NA|SEQUENTIAL||OTHER||NONE||||||
34191772|NCT02750241|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34191773|NCT01095198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191774|NCT02948036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191775|NCT03463642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191776|NCT01082549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191777|NCT00612807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191778|NCT01367067|||COHORT||PROSPECTIVE|||||||
34191779|NCT01490424|||CASE_CONTROL||PROSPECTIVE|||||||
34191780|NCT01086358|RANDOMIZED|CROSSOVER||OTHER||NONE||This was a randomized, open-label, 6-attack (3-attacks per arm) crossover design in which subjects were randomized to threat their first 3 workplace migraines with sumatriptan/naproxen sodium or with their usual triptan monotherapy before treating their subsequent 3 workplace migraines with the opposite medication.||||
34191781|NCT00995293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191782|NCT04476004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191783|NCT03073733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects, their family members and clinical staff performing key efficacy assessments will be masked to the randomization assignment of subjects. Due to the nature of some safety assessments and the sham treatment, not all personnel can be masked.||t|f|f|t
34191784|NCT01613846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191785|NCT04826549|||OTHER||PROSPECTIVE|||||||
34191786|NCT00108940|||FAMILY_BASED||PROSPECTIVE|||||||
34191787|NCT00390819|||DEFINED_POPULATION||PROSPECTIVE|||||||
34191788|NCT05979142|||COHORT||PROSPECTIVE|||||||
34191789|NCT05056844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191790|NCT00004930||||TREATMENT||||||||
34191791|NCT05758636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34191792|NCT00702715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191793|NCT06319950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191794|NCT01934920|||OTHER||PROSPECTIVE|||||||
34191795|NCT01897129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191796|NCT04586842|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191797|NCT02035254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191798|NCT01600534|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34191799|NCT02756416|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191800|NCT04988360|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33872332|NCT03707067|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Randomization carried out and compression garments allocated by a third party. All testing will be completed once athletes have removed their garments, without the knowledge of outcomes assessors or primary investigator|Crossover RCT|t|f|t|t
33872333|NCT05083728|||OTHER||PROSPECTIVE|||||||
33872334|NCT04029870|||COHORT||PROSPECTIVE|||||||
34191801|NCT02964013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191802|NCT02500940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191803|NCT03336437|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blind||t|f|f|f
34191804|NCT06113679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded|Randomized, 1:1 Sham Control|t|t|t|t
34191805|NCT03449641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191806|NCT00194649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191807|NCT02535156|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34191808|NCT05682222|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blind|This is a single-center, randomized, double-blind, placebo-controlled, platform trial to evaluate the effects of EDP1815 and EDP2939 on the systemic immune system, using intradermal KLH and topical IMQ skin challenges. A total of at least 72 healthy volunteers will be divided into 4 cohorts.|t|f|t|f
34191809|NCT06087627|||COHORT||PROSPECTIVE|||||||
34191810|NCT05377801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34191811|NCT00492635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191812|NCT01097005|||COHORT||PROSPECTIVE|||||||
34191813|NCT06155396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191814|NCT05113238|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||single group of patients will be conducted into sibling-oocyte-split design|t|t|f|f
34191815|NCT00704652|||CASE_CONTROL||PROSPECTIVE|||||||
34191816|NCT04431921|||CASE_CONTROL||PROSPECTIVE|||||||
34191817|NCT04803240|||OTHER||PROSPECTIVE|||||||
34191818|NCT01443624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34191819|NCT03679507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A Study Administrator will assign subjects to a treatment group randomly, and keep this information strictly confidential. Subjects and investigators will be blinded. The Study Administrator will assign each participant a randomly generated Patient ID number to be used in the collection of data.|This clinical trial will investigate the safety and efficacy of a new hand-held, low-intensity therapeutic ultrasound (LIPUS) device to treat chronic knee pain in osteoarthritis patients. Osteoarthritis of the knee is painful condition, and a leading cause of disability \[11\]. Two meta-analyses of this application indicate its efficacy in controlling pain \[7,10\]; one in improving function \[10\]. Three randomized, double blind, placebo-controlled studies have been published recently. Two demonstrate the ameliorative effects of low-intensity ultrasound therapy on pain, function and quality of life in patients with knee osteoarthritis \[12,13\]; one showed no significant difference from placebo \[9\]. Significantly, no adverse event was reported in any of these clinical trials. However subjects will have 24 hours phone access and email access to study administrator and study investigator for reporting any type of adverse event and seeking guidance if needed.|t|t|t|f
33872335|NCT04674020|NA|SINGLE_GROUP||OTHER||NONE|Open-label|||||
33872336|NCT05758519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872337|NCT05798442|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with cardiovascular disease risk factors will be blindly randomized into two groups in a ratio of (1:1); mHealth app-based intervention group and a traditional mainstream face-to-face consultation group. The app-based intervention group will be given access to a mHealth app that will be specifically designed to motivate the users to increase their physical activity and healthy diet intake while reducing smoking and alcohol intake. The app provides the patients with standardized dietary and exercise guidelines and sends them frequent advice and reminders to follow the guidelines. Changes in the CVD risk factors of the participants will be assessed based on blood biochemical and anthropometric measurements collected every 4 months over a period of 20 months. The app will be designed to include interactive functions which allow the patients to insert their daily caloric intake and exercise, biometric data, track the improvement in their CVD risk factors and CVD risk score.||||
33872338|NCT05254431|RANDOMIZED|PARALLEL||OTHER||SINGLE||Exercise trial of 12 weeks moderate intensity interval exercise in Veterans with COPD and OSA that compares exercise group to standard of care control group|f|f|f|t
33872339|NCT04278339|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33872340|NCT02512224|||||RETROSPECTIVE|||||||
33872341|NCT05536310|||CASE_CONTROL||OTHER|||||||
33872342|NCT01237834|||||CROSS_SECTIONAL|||||||
33872343|NCT06084520|||OTHER||PROSPECTIVE|||||||
33872344|NCT00794599|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33872345|NCT01334528|||COHORT||PROSPECTIVE|||||||
33872346|NCT04228042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872347|NCT01603953|||COHORT||PROSPECTIVE|||||||
33872348|NCT06478069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872349|NCT04760964|||CASE_ONLY||PROSPECTIVE|||||||
33872350|NCT01669070|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872351|NCT05754385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191820|NCT05387434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two rural KSRE local units will be randomized in a 1:1 ratio to either DPP-FB or DPP-R.|The proposed 2-arm trial will compare the feasibility and effectiveness of Facebook or remote-delivery of the DPP in rural adults with prediabetes both delivered through the KSRE. The CES is a non-formal educational program, implemented in the U.S. through each state's designated land grant university, to help people use research-based knowledge to improve their lives. The KSRE maintains local units which are comprised of single counties or multi-county districts. Two KSRE local units serving rural counties will be identified by our partners at KSRE and randomized to the Facebook or remote delivery arms. Members of the KUMC research team will recruit and consent participants and will train KSRE personnel to deliver the 30 core-sessions of the DPP protocol over 12 mos. Outcomes will be assessed by the research team at the local CES offices at baseline, 3 mos. 6 mos. and 12 mos.|t|f|f|f
34191821|NCT03973060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant was blinded not knowing the treatment to which he was submitted and outcome assessor responsible for collecting the results, without commenting on the group from which the patient came. Only the principal investigator knew the group to which the patient belonged.||t|f|f|t
33872352|NCT05703971|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1: 3+3 dose selection to identify RP2D. Phase 2: open label, non-randomized treatment with quaratusugene ozeplasmid at RP2D in combination with atezolizumab.||||
33872353|NCT05548621|||COHORT||PROSPECTIVE|||||||
33872354|NCT06398847|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a combination device of virtual software developed by the study team to be inserted into an off the shelf virtual reality headset.||||
33872355|NCT02054897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872356|NCT05073614|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||patients with chronic gastritis will undergo upper endoscopy, punch biopsies will be obtained and tissue sections will be prepared from each specimen. sections will be stained by H\&E to establish diagnosis of chronic gastritis. others will be stained by Giemsa staain to detect H.pylori, still others will be stained immunohistochemically by anti Heparanase antibody.||||
33872357|NCT01518218|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872358|NCT03220542|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33872359|NCT01418807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33872360|NCT06047340|RANDOMIZED|PARALLEL||SCREENING||NONE||Interventional study with three study arms (mild cognitive impairment, mild AD-related dementia, healthy controls).||||
33872361|NCT04425291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191822|NCT03383341|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Recipes containing cricket powder were matched for taste, color, and texture to creat placebo intervention foods. All foods were prepared by study personnel and then blinded by a third party individual that was not directly associated with the study.|Randomized, placebo controlled crossover dietary intervention|t|f|t|t
34191823|NCT00845793|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34191824|NCT03192358|||COHORT||CROSS_SECTIONAL|||||||
34191825|NCT03253341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872362|NCT06100822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872363|NCT01035554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872364|NCT03113240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872365|NCT00838773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191826|NCT03497013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a randomized, double-blind, sham-controlled clinical trial.All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment). All evaluations were performed at baseline, the end of 3rd weeks, 5th weeks, and 7th weeks by 2 psychiatrists blinded to the treatment assigned. Inter-rater reliability was satisfactory(ka=0.86).|The aim of the study was to evaluate the efficacy, safety, and cognitive function of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD).|t|f|f|t
34191827|NCT06384118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34191828|NCT05663138|||CASE_ONLY||RETROSPECTIVE|||||||
34191829|NCT00291044|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34191830|NCT04536103|||OTHER||PROSPECTIVE|||||||
34191831|NCT02870478|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34191832|NCT04818567|||COHORT||RETROSPECTIVE|||||||
34191833|NCT01707576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34191834|NCT00934440||SEQUENTIAL||TREATMENT||NONE||||||
34191835|NCT06169267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34191836|NCT01947855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34191837|NCT02644616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191838|NCT03636464|||CASE_ONLY||PROSPECTIVE|||||||
34191839|NCT05081297|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191840|NCT01322282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34191841|NCT04381546|NA|SINGLE_GROUP||OTHER||NONE|FES-based control of knee joint to reduce stance phase asymmetry during gait in patients with post-stroke hemiplegia|Feasibility study||||
34191842|NCT02643134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872366|NCT02827864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872367|NCT00058812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191843|NCT04248283|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single arm, non-randomized, multicenter, prospective case-series trial.||||
34191844|NCT03192371|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be stratified into age subsets of equal numbers within each age cohort (children: 6 to11 years of age and 12 to 17 years of age). Within each age subset, subjects will be assigned randomly in a 1:1 ratio, to one of the two regimens: Zagreb (2-1-1) Group and Essen (1-1-1-1-1) Group.||||
34191845|NCT03376295|||COHORT||RETROSPECTIVE|||||||
34191846|NCT03470064|||COHORT||PROSPECTIVE|||||||
34191847|NCT03835949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191848|NCT05962567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Supra and subgingival scaling will be performed on all patients. Oral Hygiene measures will be instructed following treatment and follow up after 3 months||||
34191849|NCT05854498|NA|SINGLE_GROUP||TREATMENT||NONE||This is a nonrandomized, single arm, open-label study of the combination of liposomal irinotecan with TAS102 and bevacizumab in patients with treatment refractory metastatic colorectal cancer.||||
34191850|NCT00275340|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34191851|NCT06116513|||COHORT||RETROSPECTIVE|||||||
34191852|NCT03620864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191853|NCT03163017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191854|NCT01227135|RANDOMIZED|||TREATMENT||NONE||||||
34191855|NCT02270372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872368|NCT04428021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Only the two experimental arms are masked. COVID-19 convalescent plasma (CP) and standard plasma (SP) will be masked and delivered to the wards in identical bags; a tag printed as PLASMA TRIAL will cover the actual name of the product"|Three arms randomized trial, partially blinded|t|t|f|t
33872369|NCT02941016|NA|SINGLE_GROUP||OTHER||NONE||||||
34191856|NCT03427580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34191857|NCT05227040|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34191858|NCT04995458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191859|NCT04948983|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention group will access a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group will access a webpage, answers a set of questionnaires at baseline, and then receive standardised information given by the healthcare system. Both groups will complete the questionnaires two weeks later.||||
33872370|NCT01691573|||COHORT||PROSPECTIVE|||||||
33872371|NCT06043232|||OTHER||OTHER|||||||
34067673|NCT03489122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a behavioral intervention such that participants cannot be blinded. Participant questionnaires are fill out by participants without staff involvement. Outcome assessors: Clinicians completing the depression scales will be blinded to group assignment. Individuals analyzing magnetic resonance spectroscopy (MRS) and electrocardiogram (ECG) data will receive blinded data for analysis|Participants will be randomized to a Iyengar yoga and coherent breathing or walking intervention. Two interventions a week for 12 weeks are prescribed|f|f|f|t
34067674|NCT04064255|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34191860|NCT03801057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The provider of the dietary supplement deliver the supplement prepared and packed in equal bags (active/placebo) that we hand out to the participants in an randomized order.|A parallel group randomized, controlled clinical trial for six weeks|t|t|t|f
34191861|NCT01982188|||COHORT||PROSPECTIVE|||||||
34191862|NCT03733886|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"N-of-1-study.~Each patient will go through three treatment cycles each consisting of two weeks of active treatment and two weeks of sham in randomised order. In total the study period will be 12 weeks."|t|t|t|t
34191863|NCT00136513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191864|NCT04247867|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, interventional, two parallel arm study.||||
34191865|NCT03500562|||COHORT||PROSPECTIVE|||||||
34191866|NCT05902052|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34191867|NCT05048524|NA|SINGLE_GROUP||TREATMENT||NONE||Two cohorts: unresectable and resectable||||
34191868|NCT06342778|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34191869|NCT03844204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Nurses who will measure the temperature at NICU admission are blind to treatment arm in the delivery room||f|f|f|t
34191870|NCT03445949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191871|NCT04387240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the pharmacy will do the randomization of the labeled drug and placebo|double blind controlled trial|t|t|t|f
34191872|NCT03945552|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Approximately 600 potential infant/parent dyads screened for inclusion and exclusion criteria.|f|f|f|t
34191873|NCT02555904|||COHORT||PROSPECTIVE|||||||
34191874|NCT04599764|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34191875|NCT06034639|||CASE_ONLY||RETROSPECTIVE|||||||
34191876|NCT03151902|||CASE_ONLY||PROSPECTIVE|||||||
34191877|NCT05799248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||role of rhPSMA-7.3 in PET/CT||||
34191878|NCT04796090|||CASE_CONTROL||PROSPECTIVE|||||||
34191879|NCT00979485|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191880|NCT05150119|||OTHER||PROSPECTIVE|||||||
34191881|NCT02120183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34191882|NCT04662515|||COHORT||PROSPECTIVE|||||||
34191883|NCT03985969||SEQUENTIAL||BASIC_SCIENCE||NONE||Open-label, one sequence crossover, single-centre, single group assignment Phase 1 study in healthy male Caucasians volunteers, aged between 18-50 years old (inclusive)||||
34191884|NCT03564704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191885|NCT05255809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Parallel|f|f|f|t
34191886|NCT02707263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191887|NCT02090842|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34191888|NCT01864005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191889|NCT05861713|NA|SINGLE_GROUP||TREATMENT||NONE|Since the Hydrating Cream is applied to the subjects' hands and therefore masking is difficult to be done, the investigators adopt open-label design for this study|Evaluation of the efficacy of Hydrating Cream on Tug-of-war player with repeated hands injury by using a single arm, open-label, split-hand crossover design clinical study||||
34191890|NCT00587496|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191891|NCT03374852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191892|NCT02147561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191893|NCT06153719|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34191894|NCT01035411|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34191895|NCT01282060|||COHORT||PROSPECTIVE|||||||
34191896|NCT01305577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191897|NCT00575146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191898|NCT00013156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191899|NCT04643717|||COHORT||PROSPECTIVE|||||||
34191900|NCT03723967|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, prospective, single arm phase II study (a run-in tolerance study will be first performed on a limited number of patients: maximum 9)||||
34191901|NCT05368701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The allocation sequence will be concealed from the researcher by using a centralised service (e.g., trial coordination centre) to ensure that selection remains unbiased. Thus, the trial will be double-blind.|Participants will be randomly allocated to one of three conditions. Patients will be randomised to the control group or the interventions in a 1:1:1 using a computer-generated random allocation sequence with block sizes of 3, 6, and 9.|t|f|t|f
34191902|NCT03386838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191903|NCT06282133|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial||||
34191904|NCT00230867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34191905|NCT02933684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34191906|NCT05842161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191907|NCT06002334|||CASE_ONLY||CROSS_SECTIONAL|||||||
34191908|NCT03586570|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34191909|NCT03497351|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34191910|NCT00648960|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191911|NCT05731349|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not feasible given the study design|Stepped-wedge, cluster-randomized trial||||
34191912|NCT05161364|||COHORT||PROSPECTIVE|||||||
34191913|NCT06218498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191914|NCT02529553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191915|NCT04424953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients who have consented for the operation will not know which laryngoscope (either McGrath videolaryngoscope or direct laryngoscope) was used for their intubation. The outcomes assessor will not know which group the patients and the anesthetists are in when analysing the results.|Randomized controlled trial. Prior to a consented patient turning up for his/her operation, randomization will be done to determine who from the selected group of anesthetists will be doing the intubation. The randomly selected anesthetist will wear the PAPR and intubate the patient using either a DL or McGrath VL that he/she is randomized to.|t|f|f|t
34191916|NCT04264624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel-Arm, Examiner-Blinded, RCT||||
34191917|NCT02609867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191918|NCT00133003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191919|NCT00880971|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191920|NCT02082756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191921|NCT04530136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34191922|NCT01671878|RANDOMIZED|CROSSOVER||||NONE||||||
34191923|NCT03745859|||CASE_ONLY||PROSPECTIVE|||||||
33872372|NCT01911442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872373|NCT06466915|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33872374|NCT02242084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872375|NCT04620044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872376|NCT01373203|||CASE_ONLY|||||||||
33872377|NCT00621478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872378|NCT02532894|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33872379|NCT02227628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33872380|NCT05617833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872381|NCT03247270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|t|f|f|t
33872382|NCT06490627|RANDOMIZED|PARALLEL||TREATMENT||NONE||in this study three groups have been made. one is control group which received no intervention and on transfusion only. whereas other two groups are interventional both received thalidomide. one received thalidomide at 5-6mg/kg/day and second at 7-8 mg/kg/day.||||
33872383|NCT02851381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872384|NCT06356298|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33872385|NCT03440528|||CASE_ONLY||PROSPECTIVE|||||||
34191924|NCT01146587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34191925|NCT00234754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191926|NCT02616588|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34191927|NCT04744987|||CASE_CONTROL||RETROSPECTIVE|||||||
34191928|NCT05650359|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|This is a prospective, randomized, controlled, open-label, multicenter PMCF study.||||
33755823|NCT05166044|||CASE_ONLY||RETROSPECTIVE|||||||
33872386|NCT04016480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872387|NCT06395831|||FAMILY_BASED||PROSPECTIVE|||||||
33872388|NCT05970874|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191929|NCT01076439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872389|NCT06295939|RANDOMIZED|PARALLEL||OTHER||SINGLE||"1. The researcher provided information about a research project involving pregnant women diagnosed with fetal demise or abnormalities, who are recommended to undergo pregnancy termination at the third trimester abortion clinic.~2. Pregnant women voluntarily consent to participate in the research by signing the informed consent form.~3. Volunteer participants providing consent will be randomly divided into two groups using the randomization technique with Excel program.~4. Divide into groups of 45 individuals each, totaling 90 participants in the entire sample."|f|f|f|t
33872390|NCT02093806|||CASE_ONLY||RETROSPECTIVE|||||||
34191930|NCT00708487|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33872391|NCT02140697|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33966758|NCT05509634|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||HR20013 for injection + dexamethasone compared with fosaprepitant dimeglumine for injection + palonosetron hydrochloride injection + dexamethasone|t|t|t|t
33966759|NCT00245622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966760|NCT01745471|||CASE_CONTROL||PROSPECTIVE|||||||
33966761|NCT03558997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966762|NCT05369988|||COHORT||PROSPECTIVE|||||||
33966763|NCT01313390|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872392|NCT00128479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966764|NCT03244995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966765|NCT03483181|||COHORT||PROSPECTIVE|||||||
33966766|NCT04405193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Matching placebo|Randomised, parallel, 4 week-treatment of N-acetylcysteine versus matching placebo|t|f|t|t
33966767|NCT03793075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double -blinded ( masking of both participant and care provider)|Participating subject will be divided equally and randomly into two groups.The first group is propofol group while the second is the ketamine group|t|t|f|f
33872393|NCT05362903|||COHORT||PROSPECTIVE|||||||
33872394|NCT02520323|||COHORT||PROSPECTIVE|||||||
33872395|NCT03745274|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33966768|NCT01458119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966769|NCT03437460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33966770|NCT03338049|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966771|NCT03542318|||COHORT||PROSPECTIVE|||||||
33966772|NCT00001633||||TREATMENT||||||||
33966773|NCT05466513|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Two arms parallel (Experimental and control group) design.|t|f|f|t
34191931|NCT02591498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191932|NCT02022943|||OTHER||OTHER|||||||
34191933|NCT01516034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191934|NCT00268255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755824|NCT01523054|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33755825|NCT04746573|||CASE_ONLY||PROSPECTIVE|||||||
34191935|NCT03841630|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33755826|NCT02434094|||CASE_CONTROL||PROSPECTIVE|||||||
33755827|NCT04138589|||CASE_ONLY||PROSPECTIVE|||||||
33755828|NCT03343197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191936|NCT03948945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34191937|NCT04343664|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34191938|NCT00811096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191939|NCT06279208|||COHORT||PROSPECTIVE|||||||
34191940|NCT01919281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755829|NCT04143841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33764752|NCT00577538|||CASE_CONTROL||RETROSPECTIVE|||||||
33872396|NCT04933331|||COHORT||PROSPECTIVE|||||||
33872397|NCT00521261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872398|NCT02905370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966774|NCT02431481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966775|NCT03940326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966776|NCT03759769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966777|NCT06355960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966778|NCT02868281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966779|NCT01956227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33966780|NCT02264457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966781|NCT03853083|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966782|NCT03807882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966783|NCT01722266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966784|NCT06363201|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33966785|NCT00472706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966786|NCT01913873|NA|SINGLE_GROUP||SCREENING||NONE||||||
34067675|NCT00930267|||COHORT||PROSPECTIVE|||||||
34067676|NCT02156063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191941|NCT05870696|||COHORT||PROSPECTIVE|||||||
34191942|NCT01974063|||CASE_CONTROL||PROSPECTIVE|||||||
34191943|NCT04039009|||COHORT||PROSPECTIVE|||||||
34191944|NCT03195309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant do not know which formula they are receive. Nor do the daily care providers.|All patients were received epidural anesthesia with 2% Lidocaine and patient-controlled epidural analgesia (PCEA) for post- operative pain control. PCEA randomly allocated into three groups. Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl, Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl, and Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl. Dermographic data, dosage of PCEA during first 48 hours post-operation，NRS scores, patient satisfaction and the intensity of motor block will be recorded and analyzed.|t|t|t|f
34191945|NCT03535727|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34191946|NCT01629446|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34191947|NCT05311878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191948|NCT04994002|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33755830|NCT05050201|NA|SINGLE_GROUP||TREATMENT||NONE|Participation is not masked - any service users who would like to participate may do so and their keyworker will be notified as a mandatory condition of consent|All service users who would like to trial the Sleepio intervention will be able to do so.||||
33755831|NCT02683564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872399|NCT01070732|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33872400|NCT03990064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||musicotherapy versus waiting list||||
33872401|NCT01148199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067677|NCT02343432|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34067678|NCT00055510||||TREATMENT||||||||
34067679|NCT06004323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a single-blinded, randomized controlled trial that outcome assessors will be prevented from having knowledge of the interventions assigned to individual participant||f|f|f|t
34067680|NCT04051814|||COHORT||OTHER|||||||
34191949|NCT00056797|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34067681|NCT00285766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067682|NCT02553798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067683|NCT02313805|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34067684|NCT00555776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067685|NCT01777139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067686|NCT02570230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067687|NCT04839432|||CASE_CONTROL||RETROSPECTIVE|||||||
34191950|NCT06320652|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||First, all willing patients who are offered cardiac rehabilitation will comprise the control group. Following a period of implementing the adapted co-created cardiac telerehabilitation intervention. Patients in the control group have access to standard care at the cardiac outpatient clinic program comprising standard center-based cardiac rehabilitation. Patients in the intervention group will, in addition to standard care, be offered an individually tailored family-focused cardiac telerehabilitation developed through a co-creative process.||||
34191951|NCT04520646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191952|NCT02560025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191953|NCT06017037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34191954|NCT05744843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755832|NCT06380218|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33755833|NCT04631263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755834|NCT05724355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755835|NCT05548101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will be blinded to use of ICSI versus conventional insemination|prospective randomized controlled clinical trial|t|f|f|f
33755836|NCT00895401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872402|NCT00867399|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33872403|NCT01880671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872404|NCT05913570|NA|SINGLE_GROUP||TREATMENT||NONE|Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy.|||||
33872405|NCT04194359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067688|NCT01905592|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be 2:1 (treatment:control) in at least 215 patients with germline BRCA mutations.||||
34067689|NCT00624364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067690|NCT04951713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067691|NCT06039605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants and Research Assistants will be blinded to the groups/treatment conditions unless the participant is a control. The investigator and/or research administration team will screen, enroll and assign participants to groups."|Participants will be assigned to one of 4 groups: control, tDCS1, tDCS2, or tDCS3.|t|t|f|f
34067692|NCT02324699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067693|NCT05205629|||OTHER||PROSPECTIVE|||||||
34191955|NCT00856518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34191956|NCT05424289|||COHORT||PROSPECTIVE|||||||
33872406|NCT01517529|||CASE_ONLY||PROSPECTIVE|||||||
34067694|NCT00594074|RANDOMIZED|PARALLEL||||NONE||||||
34067695|NCT02126124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067696|NCT03704506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067697|NCT01502488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067698|NCT00312052|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34067699|NCT02653898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067700|NCT05270278|||OTHER||PROSPECTIVE|||||||
34067701|NCT05366114|||CASE_ONLY||CROSS_SECTIONAL|||||||
34067702|NCT05440721|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34067703|NCT06435078|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34067704|NCT03173495|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34067705|NCT02788318|||COHORT||PROSPECTIVE|||||||
34067706|NCT03165084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067707|NCT01194193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067708|NCT01607346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067709|NCT02509793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067710|NCT04525209|||COHORT||PROSPECTIVE|||||||
33966787|NCT03555890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is 2-way crossover 2 part study. In Part 1, comparison of bioavailability of levocetirizine ODT and levocetirizine IRT taken with water in the fasted state will be done and In Part 2, comparison of bioavailability of levocetirizine ODT without water and levocetirizine IRT with water in the fasted state will be done.||||
33966788|NCT04128878|||COHORT||PROSPECTIVE|||||||
33755837|NCT00446381|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755838|NCT00892112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755839|NCT03703466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755840|NCT05061316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872407|NCT01357096|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33872408|NCT04339907|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||"5 groups will be compared:~* participant needing cataract surgery without glaucoma~* participant needing glaucoma filtration surgery without prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)~* participant needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma~* participant needing intraocular surgery (cataract, retina or glaucoma) with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)~* participant needing glaucoma filtration surgery with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)"||||
33872409|NCT00933673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872410|NCT06475066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872411|NCT00128856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872412|NCT02234479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872413|NCT04272658|||COHORT||PROSPECTIVE|||||||
33966789|NCT03197805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cohort longitudinal follow up||||
34067711|NCT02252926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067712|NCT05668572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Sponsor, investigators and biostatisticians will remain blinded to subject allocation.||t|f|t|f
34067713|NCT03029845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067714|NCT06543082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067715|NCT00802958|||COHORT||PROSPECTIVE|||||||
34067716|NCT00581061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34191957|NCT00022646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191958|NCT01911962|||CASE_CONTROL||PROSPECTIVE|||||||
33872414|NCT01083355|||CASE_CONTROL||PROSPECTIVE|||||||
33872415|NCT00015054||||TREATMENT||NONE||||||
33872416|NCT00679510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly allocated either rosuvastatin (crestor) 10 mgs or placebo. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd. Computerised randomisation was done by an independent person from Tayside pharmacy and both patients and doctors were unaware of drug allocation. In order to blind the trial drugs during the study period, the blood tests for cholesterol were checked by research nurse who was not involved in the clinical assessment of patients.||t|f|t|f
33872417|NCT02628236|NA|SINGLE_GROUP||OTHER||NONE||||||
33872418|NCT05592912|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33966790|NCT04949867|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|. For dual-hormone control, the study pumps will be filled with FiAsp® and GlucaGen®. For single-hormone control, the study pumps have been filled with FiAsp® and isotonic saline. Pump filling is conducted before the participant arrives at the research facility. The glucagon/saline pump and the insulin pump are clearly marked and cannot be confused. The participants are blinded to the treatment, as isotonic saline by its looks is indistinguishable from GlucaGen®. The placebo pump ('dummy' pump) will not infuse the saline and cannot be detected by the participant.|A randomized, single-blinded, cross-over study of glycemic control during dual-hormone therapy compared with single-hormone therapy in adolescents with type 1 diabetes.|t|f|f|f
33966791|NCT04150783|||COHORT||PROSPECTIVE|||||||
33966792|NCT05649631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966793|NCT05489679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966794|NCT01228396|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33966795|NCT04651283|RANDOMIZED|PARALLEL||TREATMENT||NONE||study group and control group||||
34191959|NCT05382949|||OTHER||OTHER|||||||
34191960|NCT01886989|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34191961|NCT05423561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191962|NCT04781751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34191963|NCT04332458|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|none of the participants are blinded in the focus group interview|Focus group interviewing a cohort of patients with stroke (one group with previous exercise experience and a group without)||||
34191964|NCT03698591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Neither the lead experimenter nor the subject will know which arm they will complete first. The secondary experimenter will use a randomized counter-balanced log to determine the order of sequences will take place. The secondary experimenter will set up the device while the lead experimenter is out of the room to preserve blindness to the intervention.||t|f|t|f
34191965|NCT03325101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191966|NCT01114399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34191967|NCT01338298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191968|NCT01896791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34191969|NCT02565667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191970|NCT02449343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191971|NCT00541814|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34191972|NCT01612832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34191973|NCT02086513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191974|NCT02633696|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191975|NCT00885222||PARALLEL||TREATMENT||NONE||||||
33755841|NCT00696384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755842|NCT03030222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755843|NCT01530230|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33755844|NCT03791073|||COHORT||RETROSPECTIVE|||||||
33755845|NCT04918784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will remain blinded to the randomization assignment from the time of randomization assignment to the end of the treatment.||t|f|f|f
33755846|NCT05307848|||COHORT||PROSPECTIVE|||||||
33755847|NCT02026323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872419|NCT04133792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872420|NCT02471703|||CASE_ONLY||PROSPECTIVE|||||||
33872421|NCT01305642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872422|NCT03686436|||CASE_ONLY||PROSPECTIVE|||||||
33872423|NCT04723121|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755848|NCT01132326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872424|NCT04462094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Only care providers involved directly with the subjects in the operating room are not masked.|This is a double-blind, randomized control trial. It provides a controlled care comparison between low-dose ketamine given at anesthesia induction and at the end-of-surgery.|t|f|t|t
33872425|NCT02195024|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872426|NCT05554419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872427|NCT00524602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872428|NCT06218095|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33872429|NCT04613323|||CASE_ONLY||RETROSPECTIVE|||||||
33872430|NCT00821639|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33966796|NCT06069765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"One member of the research team responsible for carrying out the evaluations of the dependent variables and the collection of data carried out by the participant himself and/or his families, will remain blinded to the assignment of the participants to the study groups.~In this sense, it is worth saying that the person responsible for carrying out the evaluations will do so only for the main variable, that is to say, he will be the one who will carry out the registration of the compensatory movements of the proximal part of the upper limb and trunk through the DLC . The secondary response variables are evaluated through self-administered scales and this same evaluator will be in charge of collecting the data provided by the families."||f|f|f|t
33755849|NCT05854225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872431|NCT00366275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872432|NCT05453058|||COHORT||PROSPECTIVE|||||||
33966797|NCT02667496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872433|NCT00309309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966798|NCT05881200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966799|NCT01968681|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33966800|NCT02888925|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966801|NCT03289637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participant, nor the care provider will be informed if active supplementation or placebo will be given, nor will blood sample results be open for care provider|Double blind, parallel, placebo controlled study|t|t|f|f
34067717|NCT04324515|RANDOMIZED|PARALLEL||OTHER||NONE||Patients who meet the inclusion criteria will be randomized according to a randomization list generated by the CRC of the University Hospital of Geneva. The randomization envelops will be opened by the study staff at the appropriate time prior to the scheduling of gastric bypass after subject selection. The randomization assignment insert will contain information specifying whether the cholecystectomy will be performed or not during gastric bypass procedure.||||
34067718|NCT04165135|||COHORT||PROSPECTIVE|||||||
34067719|NCT03495115|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34067720|NCT02374619|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34067721|NCT01360047|||COHORT||RETROSPECTIVE|||||||
34067722|NCT02857621|||OTHER||CROSS_SECTIONAL|||||||
34067723|NCT02083302|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067724|NCT02840227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067725|NCT00164502|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33872434|NCT03539055|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective single arm intervention of dabigatran etexilate with aspirin for 90 days following Watchman LAA device closure to prevent device related thrombus (DRT)||||
33872435|NCT01270308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872436|NCT00405067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872437|NCT05291676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872438|NCT03804333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872439|NCT06190067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872440|NCT00964535|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33872441|NCT00601536|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872442|NCT00490178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872443|NCT05931237|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34067726|NCT06320353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067727|NCT05753540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067728|NCT01508390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067729|NCT02530918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sequential Assignment with 3 cohorts in Part 1, Parallel Assignment with 3 arms in Part 2, and Parallel Assignment with 2 arms in Part 3||||
34067730|NCT00372398|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755850|NCT02011152|||CASE_CONTROL||PROSPECTIVE|||||||
33755851|NCT06150365|NA|SINGLE_GROUP||TREATMENT||NONE||KSX01-TCRT cell therapy||||
33755852|NCT05148325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755853|NCT01621698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33755854|NCT00254033|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33755855|NCT00468221|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33755856|NCT01176487|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755857|NCT05361655|||COHORT||RETROSPECTIVE|||||||
33872444|NCT04145362|||CASE_ONLY||PROSPECTIVE|||||||
33872445|NCT03521375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872446|NCT02392650|||COHORT||OTHER|||||||
33872447|NCT06033573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872448|NCT02316340|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872449|NCT03503877|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||sibling embryo study|t|t|f|t
33872450|NCT02603120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872451|NCT03317795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872452|NCT04543071|NA|SINGLE_GROUP||TREATMENT||NONE||The study will use a Simon optimal 2-stage design. The study will enroll 10 participants in the first stage. If 3 or more participants meet the endpoint in the first stage, the study will be expanded to a total of 40 participants. If a total of 14 or more participants achieve CR or PR by 16 weeks weeks, the agents will warrant further study.||||
33872453|NCT02363140|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33872454|NCT03506711|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33872455|NCT03191890|||COHORT||PROSPECTIVE|||||||
33872456|NCT00507299|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Pediatric residents were trained to screen for and help address prevalent psychosocial problems, such as parental depression and substance abuse, that are risk factors for child maltreatment (CM). The SEEK model included a project social worker and use of community resources.||||
33872457|NCT03173794|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33966802|NCT02775227|RANDOMIZED|PARALLEL||PREVENTION||||||||
33966803|NCT04149899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part 1 - not masked; Part 2 - Double-masked - neither investigator, study staff nor study participant were aware of treatment assignment|Part 1 - Open-labelled, single dose, 3-period dose escalation; Part 2 - Double-masked, randomized, parallel comparison|t|f|t|t
33966804|NCT04744896|RANDOMIZED|PARALLEL||TREATMENT||NONE||cryolipolysis treadmill cryolipolysis + treadmill||||
33966805|NCT06293690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966806|NCT05872607|||OTHER||PROSPECTIVE|||||||
33966807|NCT02787226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966808|NCT00091182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966809|NCT02739802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966810|NCT02077192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067731|NCT06020248|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Smoke exposure is impossible to mask and team is too small to mask data analysis until later stages.|Dermal uptake, metabolism and excretion of nicotine in participants with high and low levels of dermal melanin will be compared.||||
34067732|NCT05956405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34067733|NCT01633970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067734|NCT01897519|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34067735|NCT01842906|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34067736|NCT06026839|||COHORT||PROSPECTIVE|||||||
34067737|NCT05435560|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34067738|NCT06344117|||CASE_CONTROL||PROSPECTIVE|||||||
34067739|NCT05326256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants in the training groups and the statistical assessor will not be informed about which group the individuals belong to.||t|f|f|t
34067740|NCT03340467|NA|SINGLE_GROUP||OTHER||NONE||||||
34067741|NCT00815503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067742|NCT05682729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34067743|NCT03187717|||CASE_CONTROL||RETROSPECTIVE|||||||
34067744|NCT05415514|NA|SINGLE_GROUP||OTHER||NONE||instrumented evaluations||||
34067745|NCT00415324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067746|NCT06337227|||COHORT||PROSPECTIVE|||||||
34067747|NCT00548249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067748|NCT00564291|||CASE_ONLY||PROSPECTIVE|||||||
34067749|NCT00857467|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34067750|NCT05445388|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34067751|NCT02107313|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966811|NCT01917578|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33966812|NCT03980327|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized trial||||
33966813|NCT01575119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34191976|NCT04183543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The proposed study is a single-centre, double-blinded randomised controlled trial. Multivariate matching based on gender, age, race and BMI will be carried out before randomisation of one subject in each pair into control or treatment group (matched pairs design). Participants will be excluded if they do not meet all inclusion criteria and/ or meet at least one exclusion criterion. Participants will be randomised 1:1 to either the standard of care/ placebo group (no exposure to fields) or the treatment group (PEMF exposure). The research personnel who are not directly involved in the patient care will prepare a randomisation table. Study research personnel, physicians, dieticians and physiotherapists will be blinded to the randomisation assignment.|t|t|t|f
34191977|NCT00540410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191978|NCT02600039|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34191979|NCT04248491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sham Emsella treatment will provide sensation without active HIFEM technology. The sham treatment amplitude setting will be limited to below the therapeutic level.|Patients who meet all the eligibility criteria will be enrolled in the study and randomized (1:1) to receive Emsella chair or sham treatments. The subject and biostatistician will be blinded to the group allocation throughout the study. The initial analysis of data, performed by the biostatistician will not include group assignment.|t|f|f|t
34191980|NCT03041506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872458|NCT00970853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34191981|NCT01898351|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872459|NCT00968084|||||OTHER|||||||
33872460|NCT01170520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872461|NCT01303042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872462|NCT02655965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872463|NCT02847195|NA|SINGLE_GROUP||OTHER||NONE||||||
33966814|NCT05738564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomised, prospective trial performed on 2 equal groups|f|t|f|f
33966815|NCT00451932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33966816|NCT02354976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966817|NCT01754181|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33966818|NCT06540092|||COHORT||PROSPECTIVE|||||||
33966819|NCT06292910|||COHORT||PROSPECTIVE|||||||
33966820|NCT05549128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be performed for the application of the ILIB during the clinical session. An operator will be trained who will be the one who will perform the application. Another operator, in this case the researcher (blind), will be in charge of collecting the parameters to be evaluated.|2 groups: experimental group (G1), control group or placebo (G2) where ILIB and placebo will be applied respectively.|t|f|f|t
33966821|NCT02972151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966822|NCT03596918|||COHORT||PROSPECTIVE|||||||
33966823|NCT02529566|||COHORT||PROSPECTIVE|||||||
33966824|NCT03077828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966825|NCT01690481|||COHORT||PROSPECTIVE|||||||
33966826|NCT06528028|RANDOMIZED|PARALLEL||TREATMENT||NONE|A non-blind study|Treatment group and control group||||
33966827|NCT02917616|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966828|NCT05060952|||COHORT||PROSPECTIVE|||||||
33966829|NCT03109522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191982|NCT01847729|||OTHER||PROSPECTIVE|||||||
33755858|NCT05806749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872464|NCT00901771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872465|NCT04340986|||COHORT||PROSPECTIVE|||||||
33872466|NCT03230552|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized control trial||||
33872467|NCT00814892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872468|NCT03501667|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Data collected by an RA, PI and outcome assessment (I.e., data analyst) are blinded to which arm the participant was assigned to. Given use of software, the participant cannot be blinded to the arm he/she was assigned|Comparing use of deision support group (intervention group) to use of common literature (control group) among pediatric trainees treating patients with possible rheumatologic disorder|f|f|t|t
33872469|NCT01392911|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33872470|NCT04818736|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Controlled Trial|f|f|t|t
33872471|NCT06094634|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33872472|NCT04216459|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872473|NCT02947035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872474|NCT00906087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872475|NCT04398342|||COHORT||RETROSPECTIVE|||||||
33872476|NCT02025907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872477|NCT04694495|||COHORT||PROSPECTIVE|||||||
33755859|NCT03116048|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33755860|NCT02428322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33755861|NCT04415450|NA|SINGLE_GROUP||OTHER||NONE||Pregnant women who were on their first and second trimester of pregnancy||||
33872478|NCT00575198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872479|NCT03624699|NA|SINGLE_GROUP||TREATMENT||NONE||Historic control (before vs. after intervention).||||
33872480|NCT02176070|||COHORT||CROSS_SECTIONAL|||||||
33872481|NCT02424942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872482|NCT05823675|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33872483|NCT02244567|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33872484|NCT03172845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33872485|NCT00350948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872486|NCT04905303|||CASE_ONLY||PROSPECTIVE|||||||
33872487|NCT02325284|||CASE_ONLY||PROSPECTIVE|||||||
33872488|NCT03535259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872489|NCT02953340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34191983|NCT00899392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33872490|NCT02422420|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966830|NCT05720676|||CASE_ONLY||PROSPECTIVE|||||||
33966831|NCT05386745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966832|NCT01026688|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33966833|NCT05485857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966834|NCT06180811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966835|NCT03724669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33966836|NCT00004699||||TREATMENT||||||||
33966837|NCT06205199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants, the surgeon, the surgical nurse, the data collector, and the anesthesiologist administering anesthesia were not aware of the patient groups||t|t|f|f
33966838|NCT01149616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966839|NCT05198115|RANDOMIZED|PARALLEL||OTHER||NONE||Eight Weeks of Aerobic Exercise||||
33966840|NCT02803723|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33966841|NCT04181996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind Placebo controlled trial||t|t|t|t
34191984|NCT00796978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191985|NCT05360862|||CASE_ONLY||PROSPECTIVE|||||||
34191986|NCT03248791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34191987|NCT00558168|||||PROSPECTIVE|||||||
34191988|NCT04790110|||COHORT||PROSPECTIVE|||||||
34191989|NCT01766505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872491|NCT01931657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872492|NCT03596489|||COHORT||PROSPECTIVE|||||||
33872493|NCT05086731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872494|NCT04442945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872495|NCT00748280|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872496|NCT00210808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872497|NCT03711656|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal, prospective, interventional study||||
33872498|NCT01916928|||COHORT||PROSPECTIVE|||||||
33872499|NCT05957991|||COHORT||PROSPECTIVE|||||||
33872500|NCT00524407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872501|NCT01741675|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872502|NCT05944315|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|injury prevention knowledge being assessed in comparison to control group|Cluster randomized controlled trial|t|f|f|f
33966842|NCT01311297|||COHORT||PROSPECTIVE|||||||
33966843|NCT04575038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Randomized 1:1 brequinar 100 mg or placebo|t|t|t|t
33966844|NCT01999387|||COHORT||CROSS_SECTIONAL|||||||
33966845|NCT00333333|||COHORT||PROSPECTIVE|||||||
33966846|NCT00285415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966847|NCT00553033|||COHORT||PROSPECTIVE|||||||
33966848|NCT03418077|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33966849|NCT05983237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966850|NCT04487145|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an open-label prospective pharmacokinetic and safety study of DP and 3 different ART regimens (EFV-, LPV/r- and DTG-based ART) in non-malaria-infected 1) HIV-infected children and 2) HIV uninfected children not on ART (controls).||||
34191990|NCT01019200|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34191991|NCT01768403|||COHORT||PROSPECTIVE|||||||
34191992|NCT00000659||||TREATMENT||NONE||||||
34191993|NCT04599634|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34191994|NCT00530816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34191995|NCT02181725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34191996|NCT06515808|||COHORT||RETROSPECTIVE|||||||
34191997|NCT06132139|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34191998|NCT02292069|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34191999|NCT01124006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755862|NCT06524674|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33872503|NCT04302194|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755863|NCT00530595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755864|NCT00331747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755865|NCT02678130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755866|NCT06579729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872504|NCT04070859|||CASE_ONLY||PROSPECTIVE|||||||
33872505|NCT03573427|||COHORT||PROSPECTIVE|||||||
33872506|NCT00576459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872507|NCT06037798|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872508|NCT06407167|||COHORT||PROSPECTIVE|||||||
33872509|NCT00176605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872510|NCT04412850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872511|NCT00244387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872512|NCT06266728|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective, one-month, three-visit study will refit all participants into TOTAL30 for Astigmatism contact lenses.||||
33872513|NCT00960336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872514|NCT04848558|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33872515|NCT02749773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872516|NCT03089827|||COHORT||PROSPECTIVE|||||||
33872517|NCT01290874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872518|NCT00520884|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33966851|NCT06424925|||COHORT||RETROSPECTIVE|||||||
34192000|NCT04181125|||CASE_CONTROL||PROSPECTIVE|||||||
34192001|NCT00852488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192002|NCT01958489|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192003|NCT05926518|||CASE_ONLY||PROSPECTIVE|||||||
34192004|NCT03933891|||CASE_ONLY||PROSPECTIVE|||||||
34192005|NCT05741554|||COHORT||RETROSPECTIVE|||||||
34192006|NCT03671850|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34192007|NCT02541396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192008|NCT06084871|||CASE_CONTROL||PROSPECTIVE|||||||
33872519|NCT02458963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872520|NCT02234284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34067752|NCT02535377|||COHORT||PROSPECTIVE|||||||
34067753|NCT02182830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34067754|NCT03996122|||COHORT||PROSPECTIVE|||||||
34192009|NCT00573144|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34192010|NCT02460796|||COHORT||PROSPECTIVE|||||||
34192011|NCT00530504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192012|NCT02130791|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192013|NCT04500262|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34192014|NCT02657785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192015|NCT04267913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192016|NCT04193644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33872521|NCT04964427|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Study participants will receive the three conditions in random order:~* a single dose of immediate release MPH (Ritalin®) administered according to the AIFA and NICE guidelines for ADHD;~* a single 1 mA anodal tDCS session over the DLPFC for 20 min~* a single session of sham tDCS over the DLPFC for 30s at the beginning and end of the tDCS session.~The order of administration of the conditions will be counterbalanced between the participants and the conditions will be spaced apart from an interval of 24 hours."|t|f|f|t
33872522|NCT00912002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872523|NCT00400881|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33872524|NCT03278184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966852|NCT01915381|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33966853|NCT01462695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966854|NCT06542328|||OTHER||CROSS_SECTIONAL|||||||
34192017|NCT06190197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized non-inferiority trial.|f|f|f|t
34192018|NCT03418961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34067755|NCT03014141|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34192019|NCT06071585|||COHORT||RETROSPECTIVE|||||||
34192020|NCT00407056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067756|NCT01241331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192021|NCT00139477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34192022|NCT04746066|||OTHER||RETROSPECTIVE|||||||
34192023|NCT04765267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34192024|NCT06149468|||COHORT||CROSS_SECTIONAL|||||||
34192025|NCT03233984|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192026|NCT03278353|NA|SINGLE_GROUP||OTHER||NONE||Prospective cases series||||
34192027|NCT01403597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192028|NCT00473304|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34192029|NCT03613961|||COHORT||PROSPECTIVE|||||||
34192030|NCT01677000|||CASE_ONLY||PROSPECTIVE|||||||
34192031|NCT01898481|||CASE_ONLY||CROSS_SECTIONAL|||||||
34192032|NCT00551057|||COHORT||PROSPECTIVE|||||||
34192033|NCT01838980|NA|SINGLE_GROUP||SCREENING||NONE||||||
34192034|NCT06519045|||COHORT||PROSPECTIVE|||||||
34192035|NCT01311024|||COHORT||CROSS_SECTIONAL|||||||
34192036|NCT02089893|||COHORT||CROSS_SECTIONAL|||||||
34192037|NCT02048319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192038|NCT03883841|||OTHER||CROSS_SECTIONAL|||||||
34192039|NCT04806555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192040|NCT03919578|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigational product was masking with control|Experimental, randomized, double blind, four arm parallel group study|t|t|t|t
34192041|NCT04692636|||COHORT||PROSPECTIVE|||||||
34192042|NCT01324037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192043|NCT03093571|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34192044|NCT04986436|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34192045|NCT04009733|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33755867|NCT03676426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients will be blinded to the comparison being made, but not to the intervention in their arm.|||||
33872525|NCT01781715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872526|NCT00385957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872527|NCT04320732|||COHORT||PROSPECTIVE|||||||
33872528|NCT01794611|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34192046|NCT06343480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966855|NCT04316897|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966856|NCT04087382|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33966857|NCT00415961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966858|NCT00003070|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE||||||
33966859|NCT02691806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966860|NCT04863456|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966861|NCT04341818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966862|NCT02309632|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33966863|NCT00180869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966864|NCT01418261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33966865|NCT00188071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33966866|NCT02181374|||CASE_CONTROL||PROSPECTIVE|||||||
34192047|NCT00484757|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
34192048|NCT01689532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192049|NCT00243841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192050|NCT04076098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192051|NCT03405961|||CASE_CONTROL||PROSPECTIVE|||||||
33872529|NCT03462576|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The collaborator is responsible for the masking process.|"The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48. All subjects will continue treatment until the last subject in the study reaches 48 weeks in the study. At least 30% of subjects randomized should have baseline MELD score ≥15 and ≤20.~For each subject, the study will consist of:~* Screening period of up to 4 weeks~* Randomized, double-blind treatment period of at least 48 weeks~* A follow-up visit 2 weeks after completion of study drug treatment The duration of each subject's participation will be at least 54 weeks for those completing the entire study."|t|t|t|f
33872530|NCT00950768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872531|NCT04123782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872532|NCT05358756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Each of the following treatments were given to subjects in a randomized sequence:~Treatment A: SACT-1, 150 mg rilpivirine oral suspension (30.0 mg of rilpivirine \[equivalent to 33.0 mg of rilpivirine hydrochloride\] in each mL), fasted Treatment B: SACT-1, 150 mg rilpivirine oral suspension (30.0 mg of rilpivirine \[equivalent to 33.0 mg of rilpivirine hydrochloride\] in each mL), fed Treatment C: Edurant, 150 mg (6 × 25 mg rilpivirine, oral tablets), fed"||||
33872533|NCT04030923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192052|NCT06465407|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Single blind repeated measures design. Participants will be blinded to the intervention while research team will not be blinded and will be mixing supplements.|This is a single blind repeated measures study design. There will be an intervention group and a control group. Intervention group is sub-divided into those who receive collagen (n=12) and those who receive placebo (n=12). The intervention group will perform every assessment including a standardized exercise routine focused on eccentric movements. Control group (n=12) will receive no supplement. Control group participants will do all the assessments that the intervention participants are performing, except for the standardized exercise routine focused on the eccentric movements. Randomization will be performed via www.randomizer.org website.|t|f|f|f
34192053|NCT05582928|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33872534|NCT02860364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34192054|NCT00975689|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34192055|NCT05376033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872535|NCT05352204|||CASE_CONTROL||RETROSPECTIVE|||||||
34067757|NCT05282589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded means that the participants have no idea of what treatment they are receiving and to which group they belong.|parallel assignment|t|f|f|f
34192056|NCT04122352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Individuals included in the study were randomized into two groups ; Group 1 : Exercises + ischemic compression Group 2 : Exercises~Rocabado's 6x6 jaw exercises are shown to be applied to both groups for 4 weeks. After 1 week, posture exercises are added to the exercise programs of the patients.~In addition to the exercises, Group 1 is given a total of 4 sessions of trigger point treatment after the initial evaluation, 1 week later, 2 weeks later and 4 weeks later."|t|f|f|f
34192057|NCT00641641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192058|NCT04661787|||OTHER||PROSPECTIVE|||||||
34192059|NCT04832568|||COHORT||PROSPECTIVE|||||||
34067758|NCT00142272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067759|NCT00043563|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067760|NCT01586702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192060|NCT01659476|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192061|NCT03622918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34192062|NCT02509117|RANDOMIZED|||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34192063|NCT06163508|||COHORT||PROSPECTIVE|||||||
34192064|NCT05170932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||chlorhexidine gel, Biological drug|t|f|f|t
34192065|NCT00139789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34192066|NCT02627976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755868|NCT00787657|||COHORT||PROSPECTIVE|||||||
33755869|NCT01494428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872536|NCT02103998|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34067761|NCT00095459||||TREATMENT||||||||
34067762|NCT01154205|||CASE_ONLY||PROSPECTIVE|||||||
34067763|NCT00623857|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34067764|NCT03240185|||COHORT||PROSPECTIVE|||||||
34067765|NCT03264534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067766|NCT05057858|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067767|NCT03244267|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34067768|NCT04049305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label) Retrospective, non-randomized, non-masking, open label, 3 arms|"Retrospective, multi-centers pooled data analysis of R-NSM versus C-NSM or E-NSM in the management of breast cancer.~3 arms study for comparisons"||||
34067769|NCT02540161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067770|NCT03544281|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label study; therefore, no blinding of treatment identity will be done for both treatments.|||||
34067771|NCT04998383|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either high-velocity nasal insufflation or noninvasive positive-pressure ventilation therapy and they will be enrolled if they met the inclusion criteria.||||
34067772|NCT05912985|||COHORT||PROSPECTIVE|||||||
33755870|NCT04183270|||COHORT||PROSPECTIVE|||||||
33755871|NCT00976352|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open label study|||||
33764753|NCT04041050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764754|NCT00460720|||COHORT||PROSPECTIVE|||||||
34067773|NCT00759655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067774|NCT03585972|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors do not know which arm participants were assigned to.||f|f|f|t
34067775|NCT01741350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067776|NCT02368275|||COHORT||PROSPECTIVE|||||||
34067777|NCT05461989|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34067778|NCT02651688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067779|NCT03876496|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067780|NCT04622202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33966867|NCT04421885|RANDOMIZED|CROSSOVER||OTHER||NONE||Open-Label, Randomized, Single-Dose, Semi-Replicate, 4-Period, Crossover||||
33872537|NCT04639856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872538|NCT03133689|||COHORT||PROSPECTIVE|||||||
33872539|NCT01439282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872540|NCT05156970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872541|NCT01386359|||COHORT||OTHER|||||||
33872542|NCT00527475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872543|NCT00199550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192067|NCT05826171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|t|f|f|t
34192068|NCT02806583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192069|NCT03647891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192070|NCT04667884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192071|NCT04618432|||COHORT||PROSPECTIVE|||||||
34192072|NCT02371915|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34192073|NCT03181737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192074|NCT06086340|||COHORT||RETROSPECTIVE|||||||
34192075|NCT00762697|||CASE_CONTROL||PROSPECTIVE|||||||
34192076|NCT03569345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192077|NCT05788471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192078|NCT06160648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The primary investigator and the participants are masked.|Participants are randomly allocated to one of two treatment groups.|t|f|t|t
34192079|NCT04504409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192080|NCT05740878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34192081|NCT05504642|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm, monocenter phase II trial||||
34192082|NCT06518395|||OTHER||CROSS_SECTIONAL|||||||
34192083|NCT05590078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192084|NCT03792828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192085|NCT03258528|RANDOMIZED|PARALLEL||PREVENTION||NONE||2||||
34192086|NCT03189238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a single center study with 40 female patients; twenty placebo and twenty active treatment patients.|t|t|f|f
34192087|NCT04230135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192088|NCT03976648|NA|PARALLEL||TREATMENT||NONE||||||
33872544|NCT02826642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872545|NCT00143715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192089|NCT01812668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192090|NCT04135976|||CASE_ONLY||CROSS_SECTIONAL|||||||
34192091|NCT01572987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192092|NCT00982059|||CASE_ONLY||RETROSPECTIVE|||||||
34192093|NCT03078829|||OTHER||PROSPECTIVE|||||||
34192094|NCT04535453|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34192095|NCT02562664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192096|NCT05466201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192097|NCT02267798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192098|NCT03293901|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34192099|NCT01680029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192100|NCT01693978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192101|NCT02842190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192102|NCT04181814|||OTHER||PROSPECTIVE|||||||
34192103|NCT02082119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872546|NCT05551715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872547|NCT06054191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192104|NCT01386866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192105|NCT03574519|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34192106|NCT03914222|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192107|NCT01638182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192108|NCT04370119|||COHORT||PROSPECTIVE|||||||
34192109|NCT01866085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192110|NCT04109677|||COHORT||RETROSPECTIVE|||||||
34192111|NCT01640392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192112|NCT00994968||||TREATMENT||NONE||||||
34192113|NCT03539549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872548|NCT04216277|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Procalcitonin will be measured on all participants but none of the participants will be informed about the results of the procalcitonin value or the randomisation and thus remain unaware of allocated group status (intervention or control).||t|f|f|f
33872549|NCT05023356|||CASE_CONTROL||PROSPECTIVE|||||||
33872550|NCT02538874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34192114|NCT00000991||||TREATMENT||NONE||||||
34192115|NCT02370108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872551|NCT02268279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966868|NCT04051632|||CASE_ONLY||RETROSPECTIVE|||||||
33966869|NCT03292783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966870|NCT06458686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966871|NCT01399021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33966872|NCT05979051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A single-arm/randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 clinical study.||||
33966873|NCT02086526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33966874|NCT00004483|||NATURAL_HISTORY||OTHER|||||||
33966875|NCT05715606|NA|SEQUENTIAL||TREATMENT||NONE||||||
33966876|NCT00700284|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33966877|NCT06457464|||COHORT||CROSS_SECTIONAL|||||||
33966878|NCT00068237|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33966879|NCT01438333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34192116|NCT04880291|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34192117|NCT02514993|||CASE_CONTROL||RETROSPECTIVE|||||||
34192118|NCT02724397|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34192119|NCT03233321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192120|NCT00409357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755872|NCT06109792|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Group I: Ten overdentures with locator retentive caps and blue inserts were picked up by the indirect method.~Group II: Ten overdentures with locator retentive caps and pink inserts were picked up by the indirect method.~Group III: Ten overdentures with locator retentive caps and blue inserts were picked up by the direct method.~Group IV: Ten overdentures with locator retentive caps and pink inserts were picked up by the direct method."|t|f|f|f
33755873|NCT02201914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755874|NCT01514214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755875|NCT06240585|||CASE_CONTROL||RETROSPECTIVE|||||||
33755876|NCT03638895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Practitioner) Energy expenditure information (resting energy expenditure \& respiratory quotient) is withheld from participant and practitioner providing care to participants in the control group.|Parallel assignment|t|t|f|f
34192121|NCT01587898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192122|NCT04514380|||COHORT||PROSPECTIVE|||||||
34192123|NCT00822549|||||CROSS_SECTIONAL|||||||
34192124|NCT01932437|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|The investigator, clinical research unit staff, and subjects will be blinded to treatment assignment. The randomization list will be made available to the pharmacist preparing study drug.|Dose escalation study|t|t|t|f
34192125|NCT01751945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192126|NCT00400270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192127|NCT06278818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neurophysiologist and neuroradiologist will be blinded to the type of rehabilitation treatment (experimental group vs. control).||f|f|f|t
34192128|NCT00036842||||TREATMENT||||||||
34192129|NCT00795119|NA|SINGLE_GROUP||SCREENING||NONE||||||
34192130|NCT04177576|||COHORT||PROSPECTIVE|||||||
34192131|NCT05726084|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34192132|NCT04534816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pending patient acceptance all are eligible for inclusion||||
34192133|NCT02105662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192134|NCT00373893|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34192135|NCT03291366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755877|NCT02551081|||COHORT||PROSPECTIVE|||||||
33755878|NCT06466850|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755879|NCT01161979|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33755880|NCT01269996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755881|NCT02001766|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33755882|NCT02241122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755883|NCT04839965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755884|NCT00238433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755885|NCT05305287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Patients with T2D and NAFL or NASH will be randomly assigned to receive placebo or pioglitazone treatment groups.|t|f|f|f
33755886|NCT05853679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization of patients is done by using sealed envelope technique at the end of the Baseline visit. During the Baseline visit, participants, care providers, and investigators do not know to which group the participant will be allocated.||t|t|t|f
33755887|NCT02332720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755888|NCT03124979|NA|SINGLE_GROUP||OTHER||NONE||||||
33872552|NCT04863846|||OTHER||PROSPECTIVE|||||||
33872553|NCT04276428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872554|NCT02861209|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872555|NCT01030770|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33872556|NCT01511276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Analyses of the blood assays and MRI data were masked.||f|f|f|t
33872557|NCT06324006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a Phase I, double-blind, parallel-group, placebo-controlled, randomized first-in-human trial.|t|t|t|t
33872558|NCT03119714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33872559|NCT02989415|||COHORT||PROSPECTIVE|||||||
33872560|NCT05270590|||COHORT||PROSPECTIVE|||||||
33872561|NCT03147716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blind masking|Participants are randomly assigned to one of five conditions: 1) enrollment flyer only; 2) enrollment flyer + testimonial booklet; 3) enrollment flyer + teacher endorsement; 4) enrollment flyer + provider engagement call; or 5) all four engagement strategies.|t|f|f|f
33872562|NCT02693561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872563|NCT01234974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872564|NCT00002375||PARALLEL||TREATMENT||||||||
33872565|NCT02084303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755889|NCT02414542|||CASE_CONTROL||PROSPECTIVE|||||||
33755890|NCT00900068|||COHORT||RETROSPECTIVE|||||||
33755891|NCT06412627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33755892|NCT00135369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755893|NCT00439205|||CASE_ONLY||PROSPECTIVE|||||||
34192136|NCT04383418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Dexmedetomidine hydrochloride nasal spray compared with placebo|t|t|t|t
33755894|NCT01171326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755895|NCT03215368|||COHORT||PROSPECTIVE|||||||
33755896|NCT00269035|RANDOMIZED|PARALLEL||TREATMENT||||||||
33755897|NCT02126501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755898|NCT03338894|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33755899|NCT05676580|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33755900|NCT06073730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755901|NCT03119324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33755902|NCT01829438|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33755903|NCT06579859|||COHORT||OTHER|||||||
33755904|NCT03037450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755905|NCT01291368|||COHORT||PROSPECTIVE|||||||
33755906|NCT03905330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755907|NCT04584229|||OTHER||CROSS_SECTIONAL|||||||
33755908|NCT01514448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755909|NCT00945464|||COHORT|||||||||
33755910|NCT02239393|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755911|NCT00365391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755912|NCT06059105|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized into two groups. The test group (n=15) will be treated with the Inverta Co-Axis 12º implant (Southern Implants). In the control group (n=15) the Internal Conical implants (Southern implants) will be used. The difference between both implants lies in the fact that the Inverta Co-Axis 12º implant presents two different variants to the classic implant with parallel walls (Internal Conical)||||
33755913|NCT00814294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755914|NCT01766622|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755915|NCT05388500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755916|NCT01024608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755917|NCT04489043|NA|SINGLE_GROUP||PREVENTION||NONE||Patients with prediabetes beyond 12 months after transplantation will be included. Prediabetes will be diagnosed based on fasting glucose levels and oral glucose tolerance tests (OGTT). Patients will be treated with a stepped training intervention, starting with an aerobic exercise training (brisk walking, swimming and cycling) 5 times per week, 30 min/day. Aerobic exercise training will gradually increase to 60 min/day or in combination with anaerobic exercise training in case of persistent prediabetes. The reversibility/persistence of prediabetes will be measured with fasting glucose and OGTTs at every 3 months.||||
33755918|NCT01002872|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33755919|NCT01876316|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33755920|NCT00718003|||CASE_ONLY||CROSS_SECTIONAL|||||||
33755921|NCT02329548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33755922|NCT03404310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded placebo controlled||t|f|f|f
33755923|NCT04721925|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34192137|NCT03853278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The randomization procedure was handled by an independent research assistant. Participants, care providers, investigator and outcomes assessors are blind to the group assignment.|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables. The control group will receive health education leaflets.|t|t|t|t
34192138|NCT01305980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192139|NCT03691194|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34192140|NCT01933568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872566|NCT02690870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872567|NCT02226107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192141|NCT02854930|||||PROSPECTIVE|||||||
34192142|NCT03048513|||CASE_ONLY||RETROSPECTIVE|||||||
33755924|NCT01304030|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33755925|NCT00826306|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33755926|NCT05773118|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33755927|NCT01313702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755928|NCT04710082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755929|NCT02885987|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33872568|NCT01433848|||COHORT||PROSPECTIVE|||||||
33872569|NCT02613936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872570|NCT01443520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33755930|NCT04502576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755931|NCT05079074|||COHORT||RETROSPECTIVE|||||||
33755932|NCT05559502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33755933|NCT06579898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755934|NCT01029119|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33755935|NCT04169308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755936|NCT04818554|||COHORT||RETROSPECTIVE|||||||
33755937|NCT05488132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872571|NCT00728676|||CASE_CONTROL||PROSPECTIVE|||||||
33872572|NCT06039124|||COHORT||RETROSPECTIVE|||||||
33872573|NCT03362970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Data extractors and Investigators will be unaware of allocation assignment.||f|f|t|t
33872574|NCT02409589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872575|NCT01514487|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33872576|NCT03371615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192143|NCT06089551|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized study with two study groups||||
34192144|NCT06311877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192145|NCT04172818|NA|SINGLE_GROUP||OTHER||NONE||||||
33872577|NCT02808754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33872578|NCT02104986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872579|NCT02998775|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872580|NCT01631136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872581|NCT04071574|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||comparative protocols||||
33872582|NCT02742428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872583|NCT02902250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872584|NCT01432249|||COHORT||PROSPECTIVE|||||||
33872585|NCT05354583|||COHORT||PROSPECTIVE|||||||
33872586|NCT00376870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872587|NCT03891264|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33966880|NCT00845026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872588|NCT01439204|RANDOMIZED|PARALLEL||||NONE||||||
33872589|NCT01438164|||COHORT||PROSPECTIVE|||||||
33872590|NCT04712110|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872591|NCT00918034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872592|NCT00631774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872593|NCT04530942|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study starts with a longitudinal open-label phase followed by a randomized, double blind crossover phase. In the crossover phase, patients are randomized to active DBS for 2 weeks, followed by sham DBS for 2 weeks, or vice versa. The patients' post-surgery duration need to be more than 6 months when they entered the randomized cross-over phase.|t|f|f|t
33872594|NCT02703311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872595|NCT00691002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872596|NCT05762380|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a double-blind study|Dietary Supplement: FeSO4 Dietary Supplement: Ao iron|t|f|t|f
33872597|NCT02810665|||CASE_ONLY||CROSS_SECTIONAL|||||||
33872598|NCT03516682|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Investigator and Analyst will stay blinded to the randomization arm throughout the trial.||f|f|t|t
33872599|NCT03009032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872600|NCT00449462|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33872601|NCT03059238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872602|NCT01879995|||COHORT||CROSS_SECTIONAL|||||||
33872603|NCT04444999|NA|SINGLE_GROUP||TREATMENT||NONE||carbon dioxide (CO2) digital subtraction angiography (DSA) to guide endovascular aneurysm repair (EVAR(||||
33872604|NCT05709964|||COHORT||PROSPECTIVE|||||||
33872605|NCT03705728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective randomized|t|t|f|f
33872606|NCT03211702|||COHORT||PROSPECTIVE|||||||
33966881|NCT02176174|||COHORT||PROSPECTIVE|||||||
33966882|NCT05955170|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multicenter, phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.||||
33966883|NCT04927819|||COHORT||PROSPECTIVE|||||||
33966884|NCT04261933|||COHORT||PROSPECTIVE|||||||
33966885|NCT04454970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded|Randomised controlled trial|t|f|f|f
33966886|NCT02899052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067781|NCT01768923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067782|NCT00002823|RANDOMIZED|||TREATMENT||||||||
34067783|NCT03079973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|t|t|f
34067784|NCT00591019|RANDOMIZED|||TREATMENT||SINGLE|||t|f|f|f
34067785|NCT01950156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067786|NCT00284154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067787|NCT02528617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067788|NCT01331135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067789|NCT01227239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067790|NCT05215353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The proposed MELODY trial is a two-arm, parallel group, randomized clinical trial (RCT) to compare the effectiveness of music therapy (M) versus cognitive behavioral therapy (CBT) for anxiety and co-morbid symptoms in a diverse, heterogeneous sample of 300 cancer survivors.|f|f|t|t
34067791|NCT05308849|NA|SINGLE_GROUP||OTHER||NONE||||||
34067792|NCT03909698|||COHORT||PROSPECTIVE|||||||
34067793|NCT05497817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be randomly assigned to two different arms of the study: one where the algorithm matches individuals and one where matches are randomly assigned.|t|f|t|f
34067794|NCT01639924|||COHORT||PROSPECTIVE|||||||
34067795|NCT01994564|||COHORT||PROSPECTIVE|||||||
34067796|NCT00332306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067797|NCT03126123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067798|NCT05128097|||CASE_ONLY||PROSPECTIVE|||||||
34067799|NCT01066702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067800|NCT01612078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192146|NCT02432755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192147|NCT03235232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34192148|NCT01205867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192149|NCT05297981|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"This randomized prospective study will be carried out in Ain shams university hospitals for 6 months on 82 adult patients with American Society of Anesthesiologists (ASA) Physical Status Class I and II, aged between 30 and 60 years, and scheduled for laparoscopic abdominal surgery after approval by local ethical committee. Written and informed consent will be taken from each patient. Every patient will receive an explanation to the purpose of the study and will have a secret code number to ensure privacy to participant and confidentiality of data.~Patients will be randomly allocated into two equal groups:~* Group E (41 patients): Each patient will receive general anesthesia plus bilateral ESP block.~* Group Q (41 patients): Each patient will receive general anesthesia plus bilateral posterior QLB."|t|t|f|f
34192150|NCT00001113||||TREATMENT||NONE||||||
34192151|NCT01670305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872607|NCT04750642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34192152|NCT03665519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192153|NCT02948517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192154|NCT01997918|||COHORT||RETROSPECTIVE|||||||
34192155|NCT03415711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34192156|NCT02536417|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192157|NCT03156985|||COHORT||PROSPECTIVE|||||||
34192158|NCT05118659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34192159|NCT00136097|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34192160|NCT05613062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192161|NCT05300204|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are not aware of the assigned intervention group|Participants are assigned to two intervention groups in parallel for the duration of the study|t|f|f|f
34192162|NCT02350764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192163|NCT03506893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192164|NCT00534599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192165|NCT03448484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of the intervention package compared to the control package prevents a double-blind study design and thus, only the outcome assessors (data collectors) and the study statistician can be blinded to the group assignment|Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study|f|f|f|t
34192166|NCT05403216|||COHORT||PROSPECTIVE|||||||
34192167|NCT04593199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192168|NCT00054340||||SUPPORTIVE_CARE||NONE||||||
34192169|NCT04655794|||COHORT||PROSPECTIVE|||||||
34192170|NCT01707238|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34192171|NCT05155189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three Groups Assignment||||
34192172|NCT06132815|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34192173|NCT00196092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192174|NCT03816709|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192175|NCT02766985|||COHORT||PROSPECTIVE|||||||
34192176|NCT05143372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192177|NCT04771091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192178|NCT02872285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192179|NCT05396599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34192180|NCT00980967|NA|SINGLE_GROUP||||NONE||||||
34192181|NCT03504176|||COHORT||PROSPECTIVE|||||||
34192182|NCT03599232|RANDOMIZED|PARALLEL||OTHER||SINGLE|The staff who participated in the summative-OSCE(outcome assessor) were unaware of the group assignment and the two-teaching staff who participated in the intervention (Formative-OSCE) did not participate in the summative exam.|"Students in the intervention group (first-arm) attended a formative-OSCE on the first day of their pediatric module to assess the competencies they gained from previous modules. The formative-OSCE design involved a blueprint development which served as a guideline for the development and face-validation of the 8 stations, which were both interactive and static.~The formative-OSCE examiners consisted of 2 teaching staff and 11 postgraduate pediatric board trainees, who were trained by the researcher using role model and audiovisual aids. The formative-OSCE was carried out following the exact same process of the summative-OSCE. It composed of stations assessing same competencies with standardized mark sheets and feedback. Students received feedback on their performance in the formative-OSCE on the day the results were released on a one-to-one basis.~at the end of pediatric module both groups undergo summative OSCEassessment"|f|f|f|t
34192183|NCT01290796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192184|NCT01760785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192185|NCT00561548|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192186|NCT04827667|||COHORT||PROSPECTIVE|||||||
34192187|NCT00581880|||CASE_ONLY||PROSPECTIVE|||||||
34192188|NCT01338779|||COHORT||PROSPECTIVE|||||||
34192189|NCT02230670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192190|NCT02123472|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34192191|NCT00257270|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34192192|NCT03138980|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33872608|NCT03496428|NA|SINGLE_GROUP||SCREENING||NONE|Altough it is a single arm two different techniques will be used and obtained STL files will be identified as A and B and the outcomes assessor will not be informed which group corresponds to intra-oral scanner and extra-oral scanner|"To describe the soft tissues dimensional changes (based on STL files) occurred between an intra-oral scanner and standartized scan-body and a extra-oral scanner of stone cast poured from silicone impression with a customized impression coping~12 months after implant placement and simultaneous regeneration with L-PRF and bovine bone graft in the aesthetic zone of atrophic maxillae in full arch implant supported rehabilitations"||||
33872609|NCT03478514|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma.||||
33872610|NCT04804787|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"1 experimental group composed of patients with multiple sclerosis~1 control group composed of volunteers matched in gender, age, and education's level with the experimental group"||||
33872611|NCT04555824|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Dose Escalation for 7 Cohorts.|t|t|t|t
34192193|NCT06053125|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192194|NCT01909011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34192195|NCT02423369|NA|SINGLE_GROUP||SCREENING||NONE||||||
34192196|NCT05107869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34192197|NCT02024490|||COHORT||PROSPECTIVE|||||||
34192198|NCT01373957|||COHORT||PROSPECTIVE|||||||
34192199|NCT00918736|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34192200|NCT05224804|||OTHER||CROSS_SECTIONAL|||||||
34192201|NCT01552421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192202|NCT03986593|NA|SINGLE_GROUP||TREATMENT||NONE||open, single-arm group, prospective||||
34192203|NCT05905978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34192204|NCT00243165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33764755|NCT06624566|NA|SINGLE_GROUP||TREATMENT||NONE|As a quasi-experimental observational study, there is no masking.|"Study design Quasi-experimental single-group study with pre-post design. Participants:~Inclusion/exclusion criteria o Inclusion criteria: adult patients \&amp;amp;amp;amp;gt; 18 years diagnosed with spinal cord injury below C3 admitted to the Neurorehabilitation ward of the Miguel Servet University Hospital.~Exclusion criteria: Patients with tetraplegia with level C3."||||
33764756|NCT02235467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872612|NCT05386901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This experiment adopts a single-blind scheme. Only the researcher understands the grouping situation, and the research subjects do not know whether they are the experimental group or the control group. The researcher can better observe and understand the research subjects, and can timely and appropriately deal with possible occurrences of the research subjects when necessary. Unexpected problems, so that the safety of the research object is guaranteed.|Patients were randomly assigned to lung dynamic compliance-guided individualized PEEP group and traditional PEEP group.The traditional lung protective ventilation experimental group kept PEEP at 5cmH2O, and the lung dynamic compliance-oriented individualized PEEP group passed the incremental PEEP (0-14cmH2O). lung dynamic compliance==Vt/(Pplat-PEEP).The initial PEEP is set to 0cmH2O, and the PEEP is increased by 2cmH2O every 2 minutes. Observe the PEEP value corresponding to the maximum lung dynamic compliance during the process. After the incremental PEEP process is completed, set the PEEP value for ventilation until the end of the operation.|t|f|f|f
33872613|NCT01123499|||COHORT||PROSPECTIVE|||||||
33872614|NCT02162836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872615|NCT04117243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872616|NCT01513538|||CASE_ONLY||PROSPECTIVE|||||||
33872617|NCT02467738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872618|NCT02975895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872619|NCT03053700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Physicians will perform assessment of clinical outcome, using clinical photographs .These physicians will be blinded to which half of the face was treated with intense pulsed light.|This is an interventional, prospective single blinded study. Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. In addition half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.|f|f|f|t
33872620|NCT04094753|||COHORT||PROSPECTIVE|||||||
33872621|NCT05650814|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34192205|NCT04854447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192206|NCT05330247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The endocrinologists responsible for the pharmacological regulations during the study will be blinded to the allocation of the participants.~In addition, the bio-analysts performing laboratory analyses, the MR physicist responsible for evaluating MRI/MRS scans, and the individual performing DXA scans, handgrip strength and 30-second chair-stand tests will also be blinded to the allocated diet group."||f|t|f|f
34192207|NCT00973011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192208|NCT06533436|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"A total of 170 patients will be included over two distinct 6-month periods (85 patients per period). Each period corresponds to the study of one fixation device: cord fixation or fixation with the AnchorFastTM medical device.~The caregivers will also be included as a population since the workload with the two types of device will be evaluated and compared."||||
34192209|NCT00369291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192210|NCT03058328|||OTHER||PROSPECTIVE|||||||
34192211|NCT00859456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192212|NCT03298971|||COHORT||CROSS_SECTIONAL|||||||
34192213|NCT00301613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192214|NCT02683603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192215|NCT04304638|||COHORT||RETROSPECTIVE|||||||
34192216|NCT02766582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872622|NCT04798599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|One researcher, who will not participate in teleconsultations (intervention), will be responsible for the questionnaires before the intervention and will randomize the patients. This same researcher will distribute the patients randomly among the dentists responsible for teleconsultations. Dentists will also be blind as to the allocation of the patient to the groups. Also, to the patients/families, it will be not mentioned which group participants are part of. An external operator will be responsible for collecting information about the outcome (questionnaire after the interventions) will also not know which group the patient was allocated. As only the researcher responsible for randomization will know which group the patient belongs to and coordinate all operational parts of the teleconsultations, investigators can ensure the other operators and participants' blinding.|"This protocol refers to a randomized, patient-controlled study on a waiting list, nested to a before-after type study to be conducted in a cell unit, simulating a basic dental health unit. Next, a modelling study was idealized, prospecting the situation found for the reality and integral demand of the Unified Health System.~The before-after study was designed to measure the positive and negative effects resulting from telecare implementation in primary care for children. The randomised controlled study evaluates the impact of teleservice implementation from the patient´s and parents perception and allows comparison with a reference. For that, children potentially eligible for the study will initially be randomized to one group (intervention vs waiting list). On the waiting list, participants will receive the intervention (standardized telecare) and will be evaluated for outcomes of interest two weeks later."|t|t|f|t
34192217|NCT00838032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872623|NCT02371447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872624|NCT01152320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34192218|NCT06224374|||OTHER||PROSPECTIVE|||||||
34192219|NCT06367712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192220|NCT02980861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192221|NCT05231213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will be a double-blind, randomized, placebo (sham) controlled feasibility study. Thirty-eight Veteran inpatients in the Minneapolis VA Psychiatric unit will be recruited. Each participant will be randomly assigned to receive either active or sham tDCS, both paired with executive function cognitive training tasks. Training/tDCS sessions will occur twice a day for five days, for a total of 10 sessions. tDCS (2mA current), with anode over left prefrontal cortex and cathode over right prefrontal cortex, will be applied concurrently with cognitive training. Training/tDCS sessions last approx. 45 min, with tDCS applied during the first 20 min of training.|t|t|t|t
34192222|NCT00792493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192223|NCT04156633|||CASE_CONTROL||RETROSPECTIVE|||||||
34192224|NCT01731938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192225|NCT02909608|||CASE_CONTROL||PROSPECTIVE|||||||
34192226|NCT05983081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"group A: intra-articular glenohumeral joint injections with HA, 60mg, once per week for 3 consecutive weeks.~group B: physical therapy"|t|f|f|t
34192227|NCT00147069|||CASE_CONTROL||PROSPECTIVE|||||||
34192228|NCT02637349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192229|NCT02061839|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34192230|NCT03688256|||COHORT||PROSPECTIVE|||||||
34192231|NCT05664568|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized-controlled early bactericidal activity trial||||
34192232|NCT00004802|RANDOMIZED|||TREATMENT||DOUBLE||||||
34192233|NCT00163254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192234|NCT00422864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192235|NCT03156998|||COHORT||PROSPECTIVE|||||||
34192236|NCT03211052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192237|NCT00615901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192238|NCT02078960|NA|SINGLE_GROUP||OTHER||NONE||||||
34192239|NCT01623557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192240|NCT06143930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192241|NCT00801619|||COHORT||PROSPECTIVE|||||||
34192242|NCT00830895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192243|NCT04519242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192244|NCT00217659||||TREATMENT||NONE||||||
34192245|NCT02782156|||||RETROSPECTIVE|||||||
34192246|NCT01540955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192247|NCT02467426|||CASE_CONTROL||PROSPECTIVE|||||||
34192248|NCT04491071|||COHORT||PROSPECTIVE|||||||
34192249|NCT00262054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192250|NCT01420094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34192251|NCT04313413|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34192252|NCT01490905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966887|NCT05157607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Control Trial, efficacy Study|t|f|t|f
33872625|NCT03962101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872626|NCT00525993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33966888|NCT04699643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872627|NCT03820648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is an RCT, single-blinded, conducts in patients with cancer submitted to PD (1:1). In the experimental group, we will use the dual-ring WP Alexis (Applied Medical, Rancho Santa Margarita, California, USA), while in the control group we will use the standard 3M™ Steri-Drape 2. There is planned a clinical visit of follow-up on the 30th day from the operation day (as in clinical practice).|t|f|f|f
34067801|NCT03579121|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will not be aware of which arm of the study they are enrolled.|All subjects meeting inclusion/exclusion criteria will undergo pharmacogenomic testing. A pharmacist will review the pharmacogemic report and make recommendations for patients in the interventional group. The anesthesiologist and orthopedic surgeon will use that information for preoperative clinical decisions related to anesthesia and analgesia.|t|f|f|f
34067802|NCT00791700||PARALLEL||TREATMENT||NONE||||||
34067803|NCT05717621|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial with a single arm (one-group), all eligible patients will receive treatment with VTD-101 ointment.||||
34067804|NCT06154720|||CASE_CONTROL||PROSPECTIVE|||||||
34067805|NCT02851212|RANDOMIZED|CROSSOVER||||NONE||||||
34067806|NCT00489437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067807|NCT02610530|||CASE_CONTROL||RETROSPECTIVE|||||||
34067808|NCT01515735|||CASE_CONTROL||PROSPECTIVE|||||||
34067809|NCT02977806|||COHORT||PROSPECTIVE|||||||
34067810|NCT02502695|||COHORT||PROSPECTIVE|||||||
34067811|NCT01447719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067812|NCT04271345|||COHORT||PROSPECTIVE|||||||
34067813|NCT02751619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067814|NCT01958398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34067815|NCT00638287|||COHORT||PROSPECTIVE|||||||
34067816|NCT01908582|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192253|NCT00528554|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34192254|NCT02298660|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192255|NCT03111862|||COHORT||PROSPECTIVE|||||||
34192256|NCT04323579|||CASE_CONTROL||PROSPECTIVE|||||||
34192257|NCT01699516|||CASE_CONTROL||PROSPECTIVE|||||||
34067817|NCT00343629|RANDOMIZED|||PREVENTION||||||||
34067818|NCT04825925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872628|NCT05533528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872629|NCT00133991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872630|NCT04858477|NA|SINGLE_GROUP||OTHER||NONE||||||
33872631|NCT03921424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872632|NCT02483663|||FAMILY_BASED||PROSPECTIVE|||||||
33872633|NCT04177277|||OTHER||PROSPECTIVE|||||||
33872634|NCT03592940|||COHORT||CROSS_SECTIONAL|||||||
33872635|NCT04539210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872636|NCT05379348|||COHORT||PROSPECTIVE|||||||
33872637|NCT02431065|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872638|NCT04548726|||COHORT||RETROSPECTIVE|||||||
33872639|NCT04539639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872640|NCT03015259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872641|NCT01199029|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872642|NCT05206942|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966889|NCT03198637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966890|NCT00165854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966891|NCT03769181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966892|NCT04582448|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966893|NCT03061760|||CASE_CONTROL||PROSPECTIVE|||||||
33966894|NCT04854980|||OTHER||PROSPECTIVE|||||||
33966895|NCT00931853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966896|NCT04541888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966897|NCT02182258|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34067819|NCT01282905|||CASE_CONTROL||PROSPECTIVE|||||||
34067820|NCT03349489|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34067821|NCT05460637|NA|SINGLE_GROUP||PREVENTION||NONE||This study uses a single-arm study with all participants receiving the intervention||||
34192258|NCT05171062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose levels will be escalated to determine maximum tolerated dose (MTD) in participants with non-small cell lung cancer (NSCLC) eligible for standard of care pembrolizumab treatment. MTD will be determined based on occurence of dose limiting toxicities (DLTs) by standard 3+3 escalation.||||
34192259|NCT02249897|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Prescription of 6 g oral cholestiramine in 7 patients with type 2 DM, to study changes in neuroophtalmologic variables (electroretinogram and optic nerve conduction)||||
34192260|NCT03303261|||COHORT||PROSPECTIVE|||||||
34067822|NCT05050422|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34067823|NCT03013192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192261|NCT04382014|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Neither the participant nor the research nurse will know the administration order of the different treatments administered. All plasma samples collected during the research project will be anonymized. Also, it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.|Double-blind controlled-randomized pharmacokinetic (PK) study with crossover design (15 men and 15 women), with a minimum of 6 days between treatments|t|t|t|t
34067824|NCT03370185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067825|NCT00109941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067826|NCT04283110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067827|NCT00925197|RANDOMIZED|||||NONE||||||
34067828|NCT03274752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067829|NCT05263297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34067830|NCT02877121|||COHORT|||||||||
34067831|NCT06171568|||COHORT||PROSPECTIVE|||||||
34067832|NCT01385956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067833|NCT00508157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067834|NCT02324621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067835|NCT04183569|||COHORT||RETROSPECTIVE|||||||
34067836|NCT02945696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34192262|NCT00653939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192263|NCT05935189|||COHORT||PROSPECTIVE|||||||
34192264|NCT00575484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192265|NCT00673530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192266|NCT01549639|||CASE_ONLY||PROSPECTIVE|||||||
34192267|NCT02735135|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34192268|NCT05260684|||COHORT||RETROSPECTIVE|||||||
34192269|NCT04734470|||CASE_CONTROL||RETROSPECTIVE|||||||
34192270|NCT03063320|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Person assessing the outcome measures will be blinded to participant allocation|3 period randomized cross over|f|f|f|t
33872643|NCT00707928|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33872644|NCT01127568|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33872645|NCT01669655|||FAMILY_BASED||PROSPECTIVE|||||||
34067837|NCT03251482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Double Blinded|t|f|t|f
34067838|NCT00102154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872646|NCT00709982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872647|NCT04739254|||COHORT||PROSPECTIVE|||||||
33872648|NCT01119300|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34067839|NCT00004892||||TREATMENT||||||||
34067840|NCT02163317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067841|NCT06380933|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||two-group crossover design trial and block randomly assigns groups after gender stratification. The experimental group first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days; the control group first received routine care for 3 days, then rested for 3 days, and then received lavender essential oil 41-42C warm water foot bath for 20 minutes for 3 days.|t|t|t|t
34067842|NCT05642416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The only people who will know the treatment arm that has been assigned to the participant are the research coordinator who randomized them and the regional anesthesia team. The patient, nursing team, and research coordinator performing outcomes assessments will all be blinded to the treatment group.|Patients will be randomized to one of two treatment groups (one with continuous infusion of drug and the other with bolus via ESP catheter)|t|t|f|t
33872649|NCT06175403|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872650|NCT05203497|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33872651|NCT02963389|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872652|NCT00505440|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33872653|NCT00449501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872654|NCT04989114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872655|NCT03212053|NA|SINGLE_GROUP||SCREENING||NONE||||||
33872656|NCT01326182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872657|NCT06050174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872658|NCT04340375|NA|SINGLE_GROUP||OTHER||NONE||||||
33872659|NCT03532594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The randomisation ratio will be 1:1 in the first instance but the trial uses an adaptive design and an interim analysis will be conducted after 100 patients have been randomised.|t|f|f|f
33872660|NCT02193399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872661|NCT00864994|||CASE_CONTROL||PROSPECTIVE|||||||
34067843|NCT00329095|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34067844|NCT00080483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067845|NCT04384198|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||PROBE|f|f|f|t
34067846|NCT03142256|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067847|NCT00269828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067848|NCT01644760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872662|NCT02666339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33872663|NCT04117971|||OTHER||CROSS_SECTIONAL|||||||
33872664|NCT03962374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067849|NCT00618852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966898|NCT05078281|||CASE_ONLY||RETROSPECTIVE|||||||
33966899|NCT05919459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192271|NCT04659213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study subjects will not know which treatment arm they were randomized to. Additionally, the gastroenterologist performing the endoscopy post-procedure will also be blinded to the treatment arm.|This is a prospective, multicenter, randomized controlled, double blinded clinical study to assess a reduction of esophageal lesions attributable to radiofrequency (RF) ablation with use of esolution (esophageal retractor) in comparison to conventional therapy (no use of an esophageal retractor). The randomization is with a 1:1 randomization scheme assigning consecutive patients who meet inclusion and exclusion criteria to either: placement of a luminal esophageal temperature probe(LET) (control group); or, to placement of a LET and insertion of esolution esophageal retractor (intervention group). In the control group, there will not be deviation of the esophagus and in the intervention group, esolution will be utilized to deviate the esophagus during RF catheter ablation. All randomized subjects will be included in the intent-to-treat population, which will be used in the primary study analysis.|t|f|f|t
34192272|NCT01292018|||COHORT||CROSS_SECTIONAL|||||||
34192273|NCT03952949|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34192274|NCT00501904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192275|NCT05172583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be triple-blind, since the participants and their relatives, the research assistant who measures the outcome variables, and who performs the information analysis process, will not know the assignment of the study, control and intervention groups, due to They will be named by categories coded by the research assistant who performs the randomization.|Participants will be recruit upon admission to the ICU, patients and family members are asked to sign the informed consent and confidentiality agreement. The Assignment to the groups will be random. All interventions will be performed and will be adjusted according to the patient's condition. If the patient is recruited while under the effects of sedation, they will be asked to sign the informed consent when she is conscious; if she does not wish to participate, the withdrawal will be completed, and she will be excluded from the study. Follow-up will be done each shift, where the outcome variables will be measured and recorded in an established format.|t|t|t|t
34192276|NCT00466141|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34192277|NCT03030976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192278|NCT03217253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192279|NCT04798651|NA|SINGLE_GROUP||OTHER||NONE||||||
34192280|NCT02600780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192281|NCT01221935|||||RETROSPECTIVE|||||||
34192282|NCT03153722|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34192283|NCT04942977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The characteristics of the interventions do not allow the study to be blinded either for the patient or for the professional. However, the analyses, stress tests and shuttle tests will be performed in a masked manner without the assigned group being identified by the investigators who carry out the examinations.|Phase III clinical trial, feasibility, controlled and randomized, with two arms: cardiac telerehabilitation (intervention group) and centre-based cardiac rehabilitation (control group)|f|t|f|f
34192284|NCT02034409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants in this double-blind, randomized, sham-controlled trial will be randomly assigned to receive either sham or PLIUS device for 48 weeks.|t|t|t|t
34192285|NCT05533229|||COHORT||PROSPECTIVE|||||||
34192286|NCT02537158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192287|NCT02073409|||CASE_ONLY||PROSPECTIVE|||||||
34192288|NCT05963737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34192289|NCT05437497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Care provider(anesthesiologist) cannot be blinded for different appearance of propofol and remimazolam.|The experimental group was sedated with remimazolam, and the control group was sedated with propofol;|t|f|t|t
34192290|NCT02902484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192291|NCT00764764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192292|NCT00228553|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34192293|NCT00759564|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34192294|NCT00591318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192295|NCT00239252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192296|NCT01401309|||COHORT||CROSS_SECTIONAL|||||||
34192297|NCT05480111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34192298|NCT02267993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872665|NCT00761007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872666|NCT03488173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872667|NCT03371446|||CASE_CONTROL||OTHER|||||||
33966900|NCT03634670|||COHORT||PROSPECTIVE|||||||
33872668|NCT01577901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872669|NCT03727477|||COHORT||RETROSPECTIVE|||||||
33872670|NCT01300169|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33872671|NCT02304107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872672|NCT04278209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|Randomized, controlled, balanced incomplete crossover design||||
33872673|NCT00708149|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33872674|NCT04772040|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized controlled trial, parallel design.||||
33872675|NCT04035551|||OTHER||PROSPECTIVE|||||||
33872676|NCT05155202|||COHORT||PROSPECTIVE|||||||
33872677|NCT06466447|||CASE_ONLY||RETROSPECTIVE|||||||
33872678|NCT03076385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33872679|NCT00996268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872680|NCT06394011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966901|NCT02305420|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomised control trial comparing EmbryoGen/ BlastGen media use with standard media in IVF|t|t|t|t
33966902|NCT04519489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192299|NCT04655170|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participating patients with AECOPD will be randomized 1:1 to either a standard bronchodilator protocol with nebulized Albuterol and Ipratropium every 6 hours or nebulized Revefenacin 175 μg once per day and Formoterol 20 μg twice per day. Each patient will have a single randomization number indicating the allocated treatment. The treatment assignments will be generated with the use of a pseudo-random-number generator with stratification for age groups (\<50, 50-69, \>70) that will be used to ensure balance of these factors in the numbers of subjects assigned to each of the two treatments. The allocation to~treatment arms will be according to a predetermined computer-generated randomization schedule that will not be disclosed to the clinical investigators."||||
33966903|NCT02128867|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192300|NCT01792544|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33966904|NCT02805374|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33966905|NCT03804801|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study participants will be randomized into 2 groups, one of which will receive the intervention and the other will not receive the intervention||||
34192301|NCT03063034|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34192302|NCT00781885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192303|NCT04556383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, investigators and site personnel, and the Sponsor will be blinded to individual subject treatment assignments.||t|f|t|t
34192304|NCT05571566|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34192305|NCT05027724|||COHORT||CROSS_SECTIONAL|||||||
34192306|NCT03696459|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34192307|NCT05067218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of the operator and the patients will not be applicable due to the difference between the used techniques, however, the statistician will be blinded.|split mouth|f|f|f|t
34192308|NCT04302909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34192309|NCT03396952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192310|NCT05767268|||COHORT||PROSPECTIVE|||||||
34192311|NCT00886847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192312|NCT01106716|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34192313|NCT00004567||||TREATMENT||||||||
34192314|NCT01009619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192315|NCT04540016|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, single-dose, non-randomized, open-label design.||||
34192316|NCT00279526|||NATURAL_HISTORY||OTHER|||||||
34192317|NCT03332849|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34192318|NCT04927169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unblinded Pharmacist will prepare blinded syringes of colorless drug or placebo|randomized controlled of treatment vs placebo|t|t|t|t
34192319|NCT03774719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192320|NCT01238484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192321|NCT05203900|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||The number of anticipated participants is 60 mother-infant pairs. The 30 first enrolled mother-infant pairs are assigned to the investigational formula group, and the next 30 enrolled mother-infant pairs are assigned to the control formula group.||||
34192322|NCT03323567|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and care providers had no knowledge about the substance prepared for the injection. The information for the main investigator was the number of patient and the number of injection|patients were divided into the three groups and examination and therapy was performed after 7 and 14 days|t|t|f|f
34192323|NCT03272776|||COHORT||PROSPECTIVE|||||||
34192324|NCT02344199|||||PROSPECTIVE|||||||
33872681|NCT04405154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872682|NCT02718755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872683|NCT01925690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872684|NCT04998435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33872685|NCT05214859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this trial, neither the staff, participants, nor care provider can be masked to allocation. The data analyst will be blinded during the data analysis process.||f|f|t|f
33872686|NCT01290861|||COHORT||PROSPECTIVE|||||||
33872687|NCT06042153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization and each dispensation will be performed by blinded study staff using an electronic system coded with the randomization code, to ensure all study personnel remains blinded.|This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled, trial comparing semaglutide subcutaneously weekly versus matched placebo|t|t|t|t
33872688|NCT03514628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data analysis and determination of primary outcome will be done blind to allocation|1:1 randomisation to VAD or standard care|f|f|t|t
33872689|NCT00268489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872690|NCT05607368|||COHORT||PROSPECTIVE|||||||
33966906|NCT04819347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966907|NCT04777773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966908|NCT01021137|||COHORT||CROSS_SECTIONAL|||||||
33966909|NCT00540709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764757|NCT05496621|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Our work will be carried out in two stages. 1st stage Keele start msk tool translated into Turkish and its cultural adaptation, 2nd stage statistical analysis of the reliability and validity of the Turkish Keele start msk tool. Permission was obtained from Keele University, the developer of the scale, before starting the study.||||
33966910|NCT02350530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966911|NCT01848652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966912|NCT01623232|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33966913|NCT06169657|||COHORT||PROSPECTIVE|||||||
33966914|NCT01321112|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966915|NCT05354245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966916|NCT01971931|||CASE_ONLY||PROSPECTIVE|||||||
33872691|NCT00491348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872692|NCT01246570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872693|NCT05959395|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33872694|NCT05259371|NA|SINGLE_GROUP||TREATMENT||NONE||• Experimental: Transcutaneous Pulsed Electrical Stimulation Treatment Patients wear our clinical trial device 30mins once a day for 16weeks. Device: Nu eyne M02||||
33872695|NCT00483561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872696|NCT04145167|||COHORT||PROSPECTIVE|||||||
33872697|NCT03475745|||COHORT||PROSPECTIVE|||||||
34067850|NCT05739175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192325|NCT04435717|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Patients eligible to be included in the study will be randomized in a 1: 1: 1 ratio to receive:~* TCZ 8 mg / kg (with a maximum of 800 mg) in single dose + usual treatment~* TCZ 8 mg / kg in two doses at 0 and 12 hours (with a maximum of 800 mg per dose) + usual treatment~* Usual / standard care treatment"||||
33872698|NCT02602782|||CASE_ONLY||PROSPECTIVE|||||||
34192326|NCT02366884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192327|NCT01895621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192328|NCT03515915|||COHORT||PROSPECTIVE|||||||
34192329|NCT05680441|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34192330|NCT05179200|RANDOMIZED|PARALLEL||OTHER||SINGLE|The statistical analyses will be blinded with regard to group identity.|Participants/blood donors will be randomized into three donor groups in a 1:1:1 ratio and donate for a 16 week donation period. Group 1 will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis three times every 2 weeks, group 2 will donate 650 ml plasma (excluding anticoagulant) by plasmapheresis once every 14 days and group 3 will donate 450 ml (405-495 ml) whole blood every 3 months.|f|f|f|t
34192331|NCT00461071|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34192332|NCT00451464|||CASE_CONTROL||OTHER|||||||
34192333|NCT05032469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Single (Investigator)|||||
34192334|NCT00992589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192335|NCT03515317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192336|NCT02238067|||COHORT||CROSS_SECTIONAL|||||||
34192337|NCT00246545|RANDOMIZED|PARALLEL||||NONE||||||
34192338|NCT01649089|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34192339|NCT04377347|||COHORT||OTHER|||||||
34192340|NCT01966718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192341|NCT04099264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34192342|NCT03645434|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This study will be performed in a double-blind manner. Each investigational product (IP) and its placebo will be supplied in identical packaging to enable double-blind conditions.||t|f|t|f
34192343|NCT03665025|RANDOMIZED|PARALLEL||TREATMENT||NONE||jumping gap area in aesthetic area||||
34192344|NCT02231099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192345|NCT05401578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both subjects and investigators will be blinded. A nurse independent of the research group will be responsible for treatment blinding and preparation of trial drugs throughout the study.|National, multicenter, 1:1 randomized, placebo-controlled, parallel-group, double-blind superiority trial|t|f|t|f
34192346|NCT04813367|||COHORT||RETROSPECTIVE|||||||
34192347|NCT00160667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192348|NCT02141737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192349|NCT03264053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192350|NCT04334083|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33764758|NCT01069081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764759|NCT06029556|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33764760|NCT04714801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Double-blind placebo-controlled dose titrating study|t|t|t|t
33872699|NCT02729142|NA|SINGLE_GROUP||OTHER||NONE||||||
33872700|NCT01662674|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872701|NCT03019042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872702|NCT02934984|||COHORT||PROSPECTIVE|||||||
33872703|NCT02334449||PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872704|NCT06504537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the study would be single blinded as the assessor of the study would be kept blind.||f|f|f|t
33872705|NCT00440206|||DEFINED_POPULATION||PROSPECTIVE|||||||
33872706|NCT05648994|NA|SEQUENTIAL||TREATMENT||NONE||||||
33872707|NCT00842426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33872708|NCT01547533|||COHORT||PROSPECTIVE|||||||
33872709|NCT01775735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872710|NCT02081040|||COHORT||CROSS_SECTIONAL|||||||
33872711|NCT02595476|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33872712|NCT03886051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872713|NCT04168944|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled in the study were randomly allocated in the lenvatinib group (54 patients) and the control group (54 patients) after stable condition.||||
33872714|NCT05721703|||COHORT||OTHER|||||||
33872715|NCT01227044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872716|NCT05348148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent researchers will carry out the digital image analyze.||f|f|f|t
33872717|NCT06141369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872718|NCT01443104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067851|NCT01214460|||COHORT||PROSPECTIVE|||||||
34067852|NCT03713996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067853|NCT02192853|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|intervention was blinded for the participant and the investigator||t|f|t|f
34067854|NCT05239546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067855|NCT06405802|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34067856|NCT05943184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33764761|NCT00640237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872719|NCT06174623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872720|NCT05290155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872721|NCT05699161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872722|NCT06442579|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872723|NCT01502709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872724|NCT03381716|||COHORT||RETROSPECTIVE|||||||
34067857|NCT02242370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192351|NCT04645719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A professional will arrange the electronic draw, allocate the groups and prepare the opaque envelopes. Another professional will prepare the covert solution, the prescription of which will be inside the opaque envelope. The third professional will administer the anesthesia. Another team member will collect the data and organize it in a spreadsheet. The data will be analyzed by an independent statistician. Participants and performers for each stage will be covered for each participant's group.|Prospective, controlled, randomized and covered clinical trial|t|t|t|t
34192352|NCT04013061|||CASE_CONTROL||PROSPECTIVE|||||||
34192353|NCT04660097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192354|NCT01461109|NA|SINGLE_GROUP||||NONE||||||
34192355|NCT02223702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34192356|NCT05553301|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a parallel-group prevention study with up to 5 arms that will be blinded to participants, investigators / sub-investigators, outcomes assessors, and laboratory personnel (with the exception of the sentinel safety portion of the study, which will be open-label). The Sponsor study staff will be unblinded (except laboratory testing personnel).|"Sentinel Cohort: Open label~Main Cohort:~* Open label (Sponsor, except laboratory testing personnel)~* Blinded (Sites, except for those preparing/administering study intervention)"|t|f|t|t
33764762|NCT02760329|||COHORT||PROSPECTIVE|||||||
33764763|NCT02190513|||COHORT||RETROSPECTIVE|||||||
33764764|NCT04887948|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple||t|f|t|t
33872725|NCT04359628|||COHORT||OTHER|||||||
33872726|NCT01433575|RANDOMIZED|CROSSOVER||||NONE||||||
33872727|NCT05096923|||COHORT||PROSPECTIVE|||||||
33872728|NCT04395664|||COHORT||PROSPECTIVE|||||||
33872729|NCT06480916|||COHORT||RETROSPECTIVE|||||||
33872730|NCT01823042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872731|NCT06306521|NA|SINGLE_GROUP||SCREENING||NONE||||||
33872732|NCT05454371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872733|NCT05648890|||CASE_ONLY||PROSPECTIVE|||||||
33872734|NCT03655184|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872735|NCT06433609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192357|NCT04351789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the intervention, the RCT trial is not blinded, but the outcome measures are masked for health professionals and staff until the end of the study|Randomized 1:1 to either intervention group or control group|f|f|f|t
34192358|NCT04832269|||OTHER||RETROSPECTIVE|||||||
34192359|NCT05816499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192360|NCT06234241|||COHORT||PROSPECTIVE|||||||
34192361|NCT00221468|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34192362|NCT05155891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192363|NCT03805659|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"An unblinded member of the study team will randomize participants to the treatment conditions. Study Group assignment will be based on random number generation (in blocks of 4) followed by the creation of numbered envelopes.~Participants and the study team members involved in language training, tDCS delivery, and assessment of outcomes will be blind to the treatment received."|This is a randomized, double-blind, sham-controlled trial in which stimulation or sham will be administered to 20 subjects over the age of 45 years, with the order of treatments counterbalanced in a within-subject crossover design. Stimulation and sham sessions last 20 minutes and occur for 10 days over a 2-week period.|t|t|t|t
34192364|NCT04316091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192365|NCT05361447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192366|NCT03081936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33872736|NCT05473403|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a multicenter, prognostic, non-randomized, comparative, longitudinal, prospective, external validation cohort, which aims to evaluate a decisional score previously developed in a retrospective cohort.||||
34192367|NCT00732719|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872737|NCT04400812|||OTHER||CROSS_SECTIONAL|||||||
33872738|NCT04851587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872739|NCT01063374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872740|NCT05144035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872741|NCT01952561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872742|NCT02832973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872743|NCT06090214|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The subjects will be included in the 3 following groups :~Group 1 : Patients: n=14 Group 2 : Controls, exposed to the same occupational risks n=14 Group 3 : unexposed controls n=14"||||
33872744|NCT02909075|||COHORT||PROSPECTIVE|||||||
34067858|NCT02318654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067859|NCT04321551|NA|SINGLE_GROUP||OTHER||NONE||||||
34192368|NCT05856695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192369|NCT01159431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192370|NCT02711228|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192371|NCT00943072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192372|NCT00795587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192373|NCT05800301|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 130 eyes of 80 RP patients who could be checked regularly, mean 36 months of the follow-up period, were included in this study. Four different groups with similar demographic characteristics were created in the cohort||||
34192374|NCT00427817|||CASE_CONTROL||PROSPECTIVE|||||||
34192375|NCT05344404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both participants and all investigators are blinded during the trial and during data analysis.|Randomized double-blinded study. 20 participants randomized in 1:1 ratio to either vitamin supplementation or placebo.|t|t|t|f
34192376|NCT01481194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192377|NCT01363739|||COHORT||PROSPECTIVE|||||||
34192378|NCT00854113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192379|NCT05650918|NA|SEQUENTIAL||OTHER||NONE||open-label, dose-finding, single-center phase I study||||
34192380|NCT00932061|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34192381|NCT00876408|||CASE_ONLY||RETROSPECTIVE|||||||
34192382|NCT01063413|||CASE_CONTROL||PROSPECTIVE|||||||
34192383|NCT05056584|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192384|NCT05637528|||COHORT||PROSPECTIVE|||||||
34192385|NCT03051867|||COHORT||PROSPECTIVE|||||||
34192386|NCT01127828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34192387|NCT02753439|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34192388|NCT01597180|||COHORT||PROSPECTIVE|||||||
33872745|NCT00886535|||COHORT||PROSPECTIVE|||||||
33872746|NCT02093013|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872747|NCT01441479|||||PROSPECTIVE|||||||
33872748|NCT04075474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33872749|NCT00120991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872750|NCT02813694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872751|NCT00442780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872752|NCT03832491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192389|NCT04734899|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial: Two parallel treatment groups; The control group will only receive exercise therapy, while the other group will receive foot core training in addition to exercise therapy||||
34192390|NCT03011021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192391|NCT00826462|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33872753|NCT03912675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The study includes 20 patients with 24 post-surgical defect in any site of the body with a size range 4-400 cm2. The acute post-surgical soft tissue loss is considered the experimental unit of the study irrespective of the number of wounds per patient. Each unit is randomized to be treated either with Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol (group A - RigeneraTM protocol - 12 units) or with Integra® dermal substitute only (group B - Control - 12 units). The expected endpoint is a spontaneous re-epithelialization higher than 25% of the total wound area in group A at 4 weeks. The secondary endpoint is the comparison of the re-epithelialization rate at 4 weeks after the first surgical stage between the group A and the controls. The re-epithelialization rate in the wounds is assessed through digital photography with the software Image J."|t|f|f|f
34192392|NCT06135298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients in the study group and the control group will be blind to the group they are assigned to until the end of the trial. As intervention is performed during the surgery, blinding will not be possible for the surgical team. Investigators will be blinded during all evaluations, however due to radio-opaque nature of CERAMENT™ BVF, detection of intervention group is possible in CT, DEXA and X-ray evaluations.|A total of 20 eligible patients with osteoporotic per trochanteric fractures, that are scheduled to be treated with proximal femoral nail (PFN), will be included in the study after informed and approved consent and will be randomized into two groups. Randomization will be performed by the principal investigator, by sealed envelopes, after determining if the patient fulfills the inclusion criteria.|t|f|t|f
34192393|NCT00294086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34192394|NCT02120040|NA|SINGLE_GROUP||OTHER||NONE||||||
34192395|NCT05819489|||COHORT||PROSPECTIVE|||||||
34192396|NCT04708977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to randomization and surgical technique will not be evident based on postoperative radiographs. Research coordinators, surgeons, principal investigator (assisting with randomization) and other co-investigators will not be blinded to the type of surgical procedure performed.|This is a single-center, prospective, randomized controlled trial.|t|f|f|f
34192397|NCT01741740|||COHORT||RETROSPECTIVE|||||||
34192398|NCT04502173|||CASE_ONLY||PROSPECTIVE|||||||
33872754|NCT06072326|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multicenter, open-label randomized cross-over trial||||
33872755|NCT05279144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|It is known by the researcher which group the participants belong to. 1 week VL, 1 week VG application will be done.|Comparison of vastus lateralis (VL) and ventrogluteal (VG) region applications in terms of pain and fear in safe and evidence-based intramuscular injection application in children.||||
33872756|NCT03521024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patient will receive a restoration with superior function, esthetics, and quality.|t|f|f|t
33966917|NCT02883673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966918|NCT06543225|||COHORT||CROSS_SECTIONAL|||||||
33966919|NCT01483222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33966920|NCT04934514|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34192399|NCT03613142|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34192400|NCT04655651|||COHORT||PROSPECTIVE|||||||
34192401|NCT04641988|||COHORT||RETROSPECTIVE|||||||
34192402|NCT02081326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34192403|NCT04168736|||COHORT||PROSPECTIVE|||||||
34192404|NCT06429553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34192405|NCT01404936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192406|NCT01738477|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192407|NCT04334395|||COHORT||RETROSPECTIVE|||||||
34192408|NCT00401232|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||||||||
34192409|NCT05034822|NA|SINGLE_GROUP||TREATMENT||NONE|Images will be taken and masked for privacy|||||
34192410|NCT00700141|||COHORT||PROSPECTIVE|||||||
34192411|NCT03843008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|At discharge, the patient will be assessed via a blinded-physician for NIHSS and this value will be recorded.|Patients will receive 3mg of melatonin or no melatonin for up to seven days or for the duration of his or hospital stay for a maximum total of 21mg of melatonin.|t|f|t|f
34192412|NCT04171492|||COHORT||PROSPECTIVE|||||||
34192413|NCT03739034|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are being treated with established lifestyle medicine modalities, tailored to the individual patient need and situation.||||
34192414|NCT04665089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blind randomized clinical trial comparing 2 arms: erythromycin versus a placebo|t|f|f|f
34192415|NCT05960630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192416|NCT01771341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34192417|NCT03764293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192418|NCT03689686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192419|NCT00484848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34192420|NCT01324141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192421|NCT02692391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192422|NCT03993067|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34192423|NCT06421103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Dose escalation with backfilling.||||
34192424|NCT04423198|||COHORT||PROSPECTIVE|||||||
34192425|NCT02664571|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34192426|NCT02546700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192427|NCT02873117|||COHORT||RETROSPECTIVE|||||||
34192428|NCT05300438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192429|NCT06027645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192430|NCT04154527|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34192431|NCT01701050|||COHORT||PROSPECTIVE|||||||
34192432|NCT01411813|||CASE_ONLY||RETROSPECTIVE|||||||
34192433|NCT02988284|||||CROSS_SECTIONAL|||||||
34192434|NCT01047605|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33872757|NCT02511730|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33966921|NCT01545219|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34192435|NCT02152917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192436|NCT06046300|||CASE_CONTROL||PROSPECTIVE|||||||
34192437|NCT04367909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192438|NCT04463459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192439|NCT02883868|||COHORT||RETROSPECTIVE|||||||
34192440|NCT05488496|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34192441|NCT05764707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192442|NCT05072613|||OTHER||PROSPECTIVE|||||||
34192443|NCT03381638|||CASE_ONLY||PROSPECTIVE|||||||
34192444|NCT03662581|NA|SINGLE_GROUP||TREATMENT||NONE||This study evaluates the effect of the intervention using a single group, before-after study model. The subjects will be evaluated at baseline and followed longitudinally, until study completion and a long-term followup.||||
34192445|NCT01508533|||COHORT||PROSPECTIVE|||||||
34192446|NCT00579384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33872758|NCT06475417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872759|NCT03227900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Masking of participant and investigator|Double blind randomized cross over trial|t|f|t|f
33872760|NCT05959135|||CASE_CONTROL||PROSPECTIVE|||||||
33872761|NCT04751890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to patients' allocation||f|f|f|t
33872762|NCT05501561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872763|NCT01246583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872764|NCT02577146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872765|NCT00476411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872766|NCT02448602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872767|NCT02167750|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33872768|NCT02255422|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33872769|NCT02238275|||COHORT||PROSPECTIVE|||||||
33872770|NCT01392534|||COHORT||PROSPECTIVE|||||||
33966922|NCT04024579|||OTHER||PROSPECTIVE|||||||
33966923|NCT03872700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966924|NCT01878747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192447|NCT00945828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192448|NCT06344897|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|"The research is in a parallel group, single-blind randomized controlled experimental design.~Simple randomization will be applied to children who have had open appendicitis surgery and meet the inclusion criteria, without any stratification in the study.~In order to determine which group the 68 children who meet the sample selection criteria in the study group will be included in, numbers from 1 to 68 will be randomly distributed to 2 groups through a computer program (https://www.randomizer.org/) without number repetition. 34 patients will be assigned to the experimental group and 34 patients to the control group. Since the person who will actively apply the taping in the study is the researcher, only the children will be blinded, therefore a single blind design will be applied."|The effect of kinesio taping on pain in children aged 6-12 years who had open appendicitis surgery.|t|f|f|f
33764765|NCT04791202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical assessor is blinded to the baseline evaluations and to the administered treatments. Information about the medications used in the study will be given to the participants, but they will be blinded to their group allocation.||t|f|f|t
33764766|NCT05046522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764767|NCT03492736|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized, double-blind, placebo-controlled, parallel|t|t|t|f
33764768|NCT05542563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All healthcare providers involved in the care of the participant following surgery (surgeon, physician's assistants, nurses, medical assistants, etc.) will be blinded to the group assignment of each participant.|a single-blind, randomized controlled trial design to evaluate the effects of a remotely-delivered 8-week mindfulness intervention on patient-reported outcomes following ACL reconstruction surgery|f|t|f|f
33764769|NCT02254408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764770|NCT05714605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872771|NCT01389167|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33872772|NCT00234689|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33872773|NCT03910829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33966925|NCT06527976|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33966926|NCT03447483|NA|SINGLE_GROUP||OTHER||NONE||||||
34192449|NCT05326854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34192450|NCT01151293|||COHORT||PROSPECTIVE|||||||
34192451|NCT04640662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192452|NCT03835832|||OTHER||CROSS_SECTIONAL|||||||
34192453|NCT02045641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764771|NCT00854516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764772|NCT02761655|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33764773|NCT01455025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764774|NCT01964521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966927|NCT02745457|||COHORT||PROSPECTIVE|||||||
33966928|NCT03083054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966929|NCT04465383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33966930|NCT01538030|||COHORT||PROSPECTIVE|||||||
33966931|NCT00740064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192454|NCT05140720|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"This will be an open label, prospective, bridging study. Pneumococcal conjugate vaccine (PCV)-native subjects in three pre-defined age groups will be recruited into the study.~Age group 1: From 6 weeks - 6 months Age group 2: From 7 months - 11 months Age group 3: From 12 months - 24 months~Study subjects will be vaccinated with the primary doses. The dose of 0.5 ml of study vaccine has been selected based on the results from previous clinical studies and in compliance with the approval for marketing authorization in India."||||
34192455|NCT02741518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192456|NCT01846767|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34192457|NCT01290913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192458|NCT02527603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192459|NCT03893461|||COHORT||PROSPECTIVE|||||||
33872774|NCT04156971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the parents/caregivers completed the consent form, the participants were age matched and randomized using a permuted block method, with a block size of four, into either IG or CG. To guarantee allocation concealment, we had the recommendation the randomization carried out by an independent third party.|A parallel study is a type of clinical study where two groups of treatments. The intervention group (IG) received stage-based lifestyle modification intervention and fish oil supplement, while the control group (CG) received stage-based lifestyle modification intervention only.|t|t|f|f
34192460|NCT01622309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192461|NCT01446783|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34192462|NCT03865043|||COHORT||PROSPECTIVE|||||||
34192463|NCT00773539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192464|NCT01410916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192465|NCT00743106|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34192466|NCT04450381|NA|SINGLE_GROUP||OTHER||NONE||||||
34192467|NCT03892278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34192468|NCT05543772|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192469|NCT00025480||||TREATMENT||||||||
34192470|NCT02594020|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34192471|NCT02445794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192472|NCT03555019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Double-blind, randomized-controlled. Parallel group, single center trial|t|t|t|t
34192473|NCT00724867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192474|NCT06205680|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE||Participants are not randomized. A randomization (paper) strategy will be applied to determine which drug will be applied in which nostril|t|t|f|f
34192475|NCT01787162|||COHORT||PROSPECTIVE|||||||
34192476|NCT02284698|||||PROSPECTIVE|||||||
34192477|NCT04447469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192478|NCT02302612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34192479|NCT05164419|||COHORT||RETROSPECTIVE|||||||
34192480|NCT04052178|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34192481|NCT05339776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192482|NCT01168869|||||RETROSPECTIVE|||||||
34192483|NCT05742308|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33872775|NCT03332823|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872776|NCT01079897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872777|NCT03045770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872778|NCT03891173|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part I includes a brief initial dose escalation phase, followed by Part II, which includes a randomized treatment phase.||||
33966932|NCT03155828|||COHORT||PROSPECTIVE|||||||
33966933|NCT05049889|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|The investigator who will be in charge of the physiological examination will not know the subject's group.|"The model includes 2 groups:~* 1 group of divers with a history of immersion pulmonary edema~* 1 group of matched divers without a history of immersion pulmonary edema"|f|f|f|t
33966934|NCT00939133|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33872779|NCT05431400|||COHORT||OTHER|||||||
33966935|NCT02535000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33966936|NCT06105619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192484|NCT04329338|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|This is an open label study|In this case each participant served as control as we collected sample before and after intervention||||
34192485|NCT01839604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966937|NCT02350010|||COHORT||PROSPECTIVE|||||||
33966938|NCT00293670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872780|NCT02281643|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33872781|NCT01841242|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 randomized groups||||
33872782|NCT02480270|||CASE_ONLY||PROSPECTIVE|||||||
33872783|NCT03831841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872784|NCT00440947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872785|NCT00695448|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192486|NCT04834089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Stage C of this study was designed as double-blind to avoid the bias introduction in the efficacy and adverse events evaluation. The clinical care team, the responsible professional for administering the serum and the participant will not know which product under investigation will be administered. Only the pharmacists or nurses responsible for the randomization of the study, separation and blinding of the product under investigation will have access to unblinded information. The allocation of the product under investigation will only be revealed after the completion of the participants' following up and database closing to guarantee a long-term safety evaluation of the product. The sponsor's operational team will also remain blind.~If necessary, independent scientists not involved with the clinical or laboratory evaluation of the participants, who analyze the unblinded data of laboratory results."|"Phase I/II Clinical Trial, randomized, multicentric, on three stages (A, B and C) to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 serum and dose escalation. The study will be in three stages:~Stage A: 30 kidney transplanted participants (very high risk), where 15 will received 1 vial (5 mL) and 15 will received 2 vials (10 mL) of serum; Stage B: 30 immunocompetent participants with at least 2 risk factors for severe disease (high risk) who will receive the dose selected by stage A; Stage C: 558 participants, of very high risk and high risk, compared with placebo in allocation 2:1."|t|f|t|f
33872786|NCT04577950|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective phase 2 study comparing three injection sites to detect sentinel lymph nodes in endometrial cancer.||||
33966939|NCT00444132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33966940|NCT05876416|||COHORT||OTHER|||||||
33966941|NCT01377454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33966942|NCT05483920|RANDOMIZED|PARALLEL||PREVENTION||NONE||There will be two arms of the study including intervention and a control group.||||
33966943|NCT06297499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will be unaware of their grouping allotment. The outcomes assessor will be unaware of the patient grouping allotment.|Randomized double-blinded trial|t|f|t|t
33966944|NCT06112457|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33966945|NCT01106937|||COHORT||PROSPECTIVE|||||||
33966946|NCT05311241|||CASE_ONLY||CROSS_SECTIONAL|||||||
34192487|NCT01676779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192488|NCT05646849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192489|NCT04588454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764775|NCT03320798|||CASE_ONLY||RETROSPECTIVE|||||||
33872787|NCT03199820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The trial statistician will be blinded to group allocation.|A randomised controlled trial of feasibility|f|f|f|t
33872788|NCT03119909|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872789|NCT04234906|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"Patients will be randomized within each participating center, not by center, into study groups:~Stage 1: Group 1 - Dexmedetomidine vs. Group 2- Magnesium Sulfate + Dexmedetomidine~Stage 2: If clinically significant arrhythmias in need of treatment develop, patients will be randomized to Group 1 - amiodarone vs. procainamide.~Randomization will occur through a module in Redcap."|"Two staged, prospective randomized clinical trial:~Stage 1 targets prevention of post-operative arrhythmias.~Stage 2 allows for re-randomization to secondary treatment for those subjects failing Stage 1, i.e. those patients that develop and require treatment of clinically significant post-operative cardiac arrhythmias with antiarrhythmic medication."||||
33872790|NCT02817321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33872791|NCT05174468|||COHORT||PROSPECTIVE|||||||
33872792|NCT03484767|||COHORT||PROSPECTIVE|||||||
33872793|NCT00202787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966947|NCT06136845|||OTHER||RETROSPECTIVE|||||||
33966948|NCT02291107|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33966949|NCT00162435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33966950|NCT04050800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33966951|NCT02332135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966952|NCT05401331|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33966953|NCT06541392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33966954|NCT01947556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966955|NCT01416649|||COHORT||PROSPECTIVE|||||||
33966956|NCT05642611|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192490|NCT02977962|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34192491|NCT02069860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192492|NCT01210859|||CASE_CONTROL||PROSPECTIVE|||||||
34192493|NCT05018208|||COHORT||PROSPECTIVE|||||||
34192494|NCT00335764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192495|NCT03021993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192496|NCT03297905|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Multiple Assignment Randomized Trial (SMART)||||
34192497|NCT02980575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192498|NCT00572130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192499|NCT02410889|||CASE_ONLY|||||||||
34192500|NCT04847713|||CASE_CONTROL||PROSPECTIVE|||||||
33872794|NCT06460402|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, parallel-group controlled trial comparing the effects of cryotherapy versus warm water sitz baths on post-hemorrhoidectomy wound care. Eligible participants (N=128) will be 1:1 randomized to receive either ice pack applications (cryotherapy group) or warm water sitz baths (control group) after undergoing surgical hemorrhoid excision. The primary outcomes of postoperative pain levels and analgesic consumption, as well as secondary outcomes of wound separation incidence and swelling, will be assessed at various time points. This parallel-group design allows direct comparison of the two interventions to determine if cryotherapy is superior to the current standard of care (sitz baths) in promoting recovery after hemorrhoidectomy.||||
33966957|NCT04331119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966958|NCT05445752|||COHORT||PROSPECTIVE|||||||
33966959|NCT06198985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33966960|NCT02076191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966961|NCT04755218|||OTHER||PROSPECTIVE|||||||
33966962|NCT03385187|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33966963|NCT02996006|||CASE_ONLY||CROSS_SECTIONAL|||||||
33966964|NCT02662322|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34192501|NCT00013702||||TREATMENT||||||||
34192502|NCT04877951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192503|NCT05974059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192504|NCT00475982|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34192505|NCT02646241|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192506|NCT02299791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34192507|NCT05686044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized|t|t|t|t
34192508|NCT05172934|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive intra-arterial Tenecteplase after achieving mTICI 2b or 2c reperfusion with standard of care mechanical thrombectomy.||||
34192509|NCT00367367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192510|NCT04388462|||OTHER||PROSPECTIVE|||||||
34192511|NCT01559740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34192512|NCT02794675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192513|NCT01843946|||||PROSPECTIVE|||||||
34192514|NCT03098615|NA|SINGLE_GROUP||TREATMENT||NONE||Topical application of Jublia (Efinaconazole 10% Topical Solution) to patients with distal lateral subungual onychomycosis with dermatophytoma.||||
33966965|NCT04714099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is prospective randomized comparative clinical study that included 80 eyes of 40 patients with moderate to severe DED. Patients were divided into two groups; group A received topical CsA 0.05% for 3 months, and group B were controls.|t|f|f|f
34192515|NCT04780919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants don't know which group (either treatment or placebo) they are in.|Participants are divided into two groups - treatment and placebo.|t|f|f|f
34192516|NCT02312193|||CASE_CONTROL||PROSPECTIVE|||||||
34192517|NCT00000303|RANDOMIZED|||TREATMENT||DOUBLE||||||
34192518|NCT03690635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34192519|NCT02452788|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33966966|NCT02269215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34067860|NCT04611282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067861|NCT03331705|||CASE_ONLY||PROSPECTIVE|||||||
34192520|NCT05328557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192521|NCT00037089||||TREATMENT||||||||
34192522|NCT05208840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192523|NCT04035434|NA|SEQUENTIAL||TREATMENT||NONE||||||
34192524|NCT05713149|||COHORT||PROSPECTIVE|||||||
34192525|NCT00985699|||||RETROSPECTIVE|||||||
34192526|NCT02260180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192527|NCT05659160|||COHORT||PROSPECTIVE|||||||
34192528|NCT05426603|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34192529|NCT00122551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192530|NCT00051662|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34192531|NCT05218291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34192532|NCT01292824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192533|NCT03423199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192534|NCT03565328|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192535|NCT01483417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192536|NCT00147836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192537|NCT05189041|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34192538|NCT00127465|RANDOMIZED|FACTORIAL||||NONE||||||
34192539|NCT02817932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192540|NCT00700388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192541|NCT03338712|||COHORT||PROSPECTIVE|||||||
34192542|NCT05541536|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34192543|NCT01214395|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872795|NCT04417036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966967|NCT04109378|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Our study was designed as a two-arm prospective randomized trial where all cases will be executed unblindly. As an experimental clinical trial the cases have been managed independently where the applied measures were computer based randomization.~In addition clustering effect has been examined within the two groups. The statistical power will be calculated for a sample size.~Randomization: Blinding in our study is not feasible.~Assignment of a patient to conventional or NOSE-colorectal resection is based on a randomization list using the simple randomization method. In order to determine the allocation sequence a computer based (www.random.org) coin flipping is carried out by a staff member with no clinical involvement in the study. The randomization will start after the patient had completed all baseline assessments and had given written consent to be enrolled in the trial."||||
33966968|NCT02931565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966969|NCT03629847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966970|NCT06079086|RANDOMIZED|PARALLEL||OTHER||NONE||velvet/silicone foam envelope silicone with textured envelope||||
34192544|NCT03171181|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||Longitudinal case-control study. Accidental sampling. Single - centre study (Hospital Universitario Miguel Servet, Zaragoza. Spain)|f|f|f|t
34192545|NCT04409860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192546|NCT05503238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192547|NCT00571168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192548|NCT01924416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33764776|NCT02775422|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764777|NCT06056622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention group will receive combined exercise program and the control group will receive a sham exercise using reaction time games. Outcome assessment will be performed by an investigator who was unaware of group allocation|Two groups with a sham control. Assessments will be performed before intervention, and four months after the last session.|t|f|f|t
33872796|NCT02987036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192549|NCT01409811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192550|NCT02948088|||COHORT||PROSPECTIVE|||||||
34192551|NCT02586779|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34192552|NCT02618499|RANDOMIZED|PARALLEL||||NONE||||||
34192553|NCT02944006|||CASE_ONLY||PROSPECTIVE|||||||
33764778|NCT03317223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764779|NCT03402880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764780|NCT03454425|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33764781|NCT00975052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33764782|NCT05646199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872797|NCT04279275|||COHORT||CROSS_SECTIONAL|||||||
33872798|NCT01549002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872799|NCT03831594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872800|NCT02431936|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33872801|NCT00676390|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872802|NCT03978507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Prior to randomization, all participants will be informed that the goal of the study is to compare the effects of two types of feedback about physical activity on freezing of gait. By withholding information about the cueing intervention, we hope that the participants in the control group will not realize that they are in the control group, in order to avoid a lack of motivation in this group. The intervention group will probably become unmasked after group allocation, as the cueing therapy was not mentioned in the informed consent.~During the post-assessment, the FOG provoking protocol will be performed with and without cueing. This induces the risk of the investigator/outcome assessor becoming unmasked, as patients in the control group may mention that this cueing option is something they haven't experienced during the intervention period. In order to prevent this, the therapist will ask patients in the intervention group to also act surprised to the cueing modality."|This is an interventional study with a parallel design, consisting of pre- and post-assessments, 2x (pre- and post) 7 days of free-living gait monitoring and an intervention/control period of 4 weeks. The pre-assessment and first week of free-living gait monitoring will take place prior to randomization.|f|f|t|t
33872803|NCT06494293|||COHORT||RETROSPECTIVE|||||||
34192554|NCT05361213|||OTHER||CROSS_SECTIONAL|||||||
34192555|NCT06426706|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34192556|NCT00951197|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34192557|NCT02404090|||COHORT||PROSPECTIVE|||||||
33966971|NCT02122211|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33966972|NCT05123027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966973|NCT00307619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34192558|NCT06443931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients undergoing minimally invasive mitral valve surgery while on cardiopulmonary bypass will be randomized into two groups:~1. Patients receiving cryoablation of intercostal nerves (CryoINB) as a method of pain relief.~2. Patients who will undergo a standard pain management protocol."|f|f|f|t
34192559|NCT00188383|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
34192560|NCT05957471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192561|NCT05611333|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34192562|NCT05149885|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872804|NCT02670863|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34192563|NCT04425213|||COHORT||PROSPECTIVE|||||||
34192564|NCT00906633|||CASE_ONLY||PROSPECTIVE|||||||
34192565|NCT02508818|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192566|NCT03084783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192567|NCT01756170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764783|NCT03833180|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohorts of 3 to 6 subjects will be sequentially enrolled at progressively higher dose levels within each dose schedule of zilovertamab vedotin using a 3+3 dose-escalation design.||||
33872805|NCT00635479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872806|NCT02860312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872807|NCT00330395|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872808|NCT03066128|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33872809|NCT01100515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872810|NCT02263079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872811|NCT04162821|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872812|NCT02474212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872813|NCT04928755|||COHORT||PROSPECTIVE|||||||
33872814|NCT00714285|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33872815|NCT01140451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This extension study was not blinded. The investigators and participants remained blinded to the Study 009 treatment assignments throughout participation in Study PTC124-GD-009e-CF.|||||
33872816|NCT00319774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872817|NCT05559489|RANDOMIZED|PARALLEL||TREATMENT||NONE||hybrid type 1 effectiveness-implementation study of a randomized trial of enteral-based resuscitation (intervention arm) vs. IV fluid resuscitation (standard-of-care arm) for moderate-sized burn injuries.||||
33872818|NCT00873977|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33872819|NCT03095742|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Interventions are considered emergency procedures and study blood pressure measurement using the study blood pressure modules should be commenced as soon as possible after sustained ROSC, screening and randomisation. Study target blood pressure will be blinded.|Single center randomized trial with allocation of 60 comatose out-of-hospital cardiac arrest patients undergoing TTM, to normal or high blood pressure target during ICU stay. Secondary a descriptive prospective cohorte study, measuring LP ratio obtained by microdialysis (MD) of the cerebral venous outflow, during the peri-cardiac arrest period|t|t|t|f
33872820|NCT03412175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33872821|NCT05062876|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33872822|NCT03729232|||CASE_ONLY||PROSPECTIVE|||||||
33872823|NCT01142401|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33872824|NCT03418428|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33872825|NCT03523481|||COHORT||RETROSPECTIVE|||||||
33872826|NCT00002152||||TREATMENT||DOUBLE||||||
33872827|NCT05288738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33872828|NCT06171451|||COHORT||PROSPECTIVE|||||||
33872829|NCT04046003|NA|SINGLE_GROUP||TREATMENT||NONE||24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks.||||
33872830|NCT02289742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33966974|NCT04741503|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33966975|NCT04595227|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34192568|NCT01688531|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34192569|NCT04192383|||COHORT||PROSPECTIVE|||||||
34192570|NCT01368328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192571|NCT02110459|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192572|NCT02752893|||COHORT||PROSPECTIVE|||||||
33872831|NCT04044300|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:1 to one of two treatment arms||||
33872832|NCT03024970|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33872833|NCT00002279||||TREATMENT||NONE||||||
33872834|NCT03894670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is a randomized cross-over study including 15 healthy normal-weight individuals. On two separate test days participants ingest the SmartPill™ in combination with a SmartBar™ (standard procedure, reference) or a standard mixed breakfast meal.||||
33872835|NCT02011659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872836|NCT05311124|NA|SINGLE_GROUP||TREATMENT||NONE|The study design is a single-arm prospective pilot study with all patient receiving the IDRT wound care device.|The study will be a single-arm prospective pilot study. Target of 10 enrolled patients at one study site under Joshua Choo, MD. Enrollment duration is 10 months - 1 year. Patients will have follow-up for 6 months per each patient.||||
33872837|NCT05285241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two arms parallel design|f|f|f|t
33872838|NCT04266275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33966976|NCT05909306|RANDOMIZED|SEQUENTIAL||OTHER||NONE||The complete randomization technique was used to assign students to groups. Following recruitment, the midwifery students were divided into an education and a control group by randomization. The first half of the list consisting of numbers produced randomly showed the students to be assigned to the education group and the other half indicated the students to be assigned to the control group.||||
33966977|NCT00001428||||TREATMENT||||||||
34192573|NCT00000771||PARALLEL||TREATMENT||||||||
33764784|NCT02304016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764785|NCT00365560|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33764786|NCT06155578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research products will be prepared in pediatric cold cream (water in oil emulsion) at a concentration of 25% or placebo, with identical packing and labeling, each identified by an exclusive number ID which will be assigned by a researcher not involved with the trial.|Randomized placebo-controlled trial with subjects allocated to topical 25% sodium metabisulfite or placebo cream twice daily.|t|t|t|t
33872839|NCT03459911|RANDOMIZED|CROSSOVER||OTHER||NONE|This study is an open label study; the subjects and the investigator will not be blinded towards the identity of the investigational products. However, analysts will be blinded towards identity of investigational product administered.|||||
34192574|NCT06259656|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Thai term pregnant women are recruited at labor room, after informed consent was done. Characteristic data (such as vaccination type and time) and Maternal Blood was collected then cord blood was collected after birth. All blood was sent to test Anti SARs CoV antibody level. Then all data and 80 test result will analyzed.||||
34192575|NCT02936648|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192576|NCT04291989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study aims to compare lactate levels from the same patient at the same time with blood samples taken from three locations - fingertip, earlobe and forearm venepuncture||||
34192577|NCT02490670|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33872840|NCT05608174|||CASE_ONLY||PROSPECTIVE|||||||
34192578|NCT06083922|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This trial will include a safety run-in-stage that will enroll patients from either cohort, which purpose is to test the safety of the combination. The run-in-stage will be followed by:~A Simon-two-stage phase II study that will enroll patients with cast nephropathy (cohort A), A pilot study that will enroll patients with all other MGRS excluding AL amyloidosis (cohort B)."||||
34192579|NCT06267352|||COHORT||PROSPECTIVE|||||||
34192580|NCT01548833|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34192581|NCT03609606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34192582|NCT02385422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192583|NCT01467219|NA|SINGLE_GROUP||||NONE||||||
34192584|NCT03263949|||COHORT||PROSPECTIVE|||||||
34192585|NCT00284453|||COHORT||PROSPECTIVE|||||||
34192586|NCT01343381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192587|NCT05322668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192588|NCT04235296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192589|NCT00115583|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34192590|NCT06521528|||COHORT||PROSPECTIVE|||||||
34192591|NCT04166240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|VBTS participants, providers, and outcome assessors know about the intervention and in which conditions sites are in and when.|It's a cluster randomized control trial where 12 sites are randomized in groups of 4 in 3 clusters each.||||
34192592|NCT06462092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192593|NCT04036188|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Subjects, investigators and blinded research staff will be masked until subjects start the open label part of the study.||t|f|t|f
34192594|NCT04185285|||COHORT||PROSPECTIVE|||||||
34192595|NCT03702413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192596|NCT00223080|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34192597|NCT03471416|||COHORT||PROSPECTIVE|||||||
34192598|NCT03486626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192599|NCT04043741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|this study is randomized control trail, participants are randomly allocated through sealed envelope method||t|f|f|f
34192600|NCT03705013|||COHORT||RETROSPECTIVE|||||||
34192601|NCT04661059|||CASE_ONLY||PROSPECTIVE|||||||
33872841|NCT01206062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872842|NCT03716401|||COHORT||CROSS_SECTIONAL|||||||
33872843|NCT00073723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872844|NCT03286062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multi dose Phase I study with injection of VM110 at 5 dose levels||||
33872845|NCT02738983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872846|NCT04261790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872847|NCT05482464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single group assignment||||
33872848|NCT05060822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo-controlled (double-blind design), active comparator-controlled (open-label design)，parallel-group||t|t|t|t
33872849|NCT04836975|||COHORT||RETROSPECTIVE|||||||
33872850|NCT02174471|||COHORT||PROSPECTIVE|||||||
33872851|NCT02600832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872852|NCT01720342|||COHORT||PROSPECTIVE|||||||
33872853|NCT06223659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872854|NCT00562354|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872855|NCT00522353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872856|NCT04571411|||COHORT||OTHER|||||||
33872857|NCT02189161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872858|NCT03853681|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872859|NCT05227638|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33966978|NCT02346981|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33966979|NCT01914315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33966980|NCT05910710|||COHORT||PROSPECTIVE|||||||
33966981|NCT03543033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Control Trial with randomization ratio 1:1|t|f|f|f
34192602|NCT01105767|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34192603|NCT05589558|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"The blinded urologist performed TRUS-guided and cognitive biopsy without prior knowledge about MRI results"|"First step: the unblinded urologist №1 performed a fusion and transpeineal template mapping biopsy. Second step: the blinded urologist №2 performed TRUS-guided and cognitive biopsy. All specimens were obtained within a single procedure."||||
34192604|NCT01716416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192605|NCT04734561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double-blind randomized controlled clinical trial|t|f|f|t
34192606|NCT05690867|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34192607|NCT03024749|||COHORT||PROSPECTIVE|||||||
33872860|NCT02707783|||COHORT||PROSPECTIVE|||||||
33872861|NCT00007085||||DIAGNOSTIC||||||||
33872862|NCT02288936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872863|NCT03076203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872864|NCT02738970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872865|NCT03023527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872866|NCT01556425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872867|NCT01265797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33872868|NCT04291443|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|The GCF measures were coded by a clinician who bonded the appliance using patient ID number and the side of the arch (either right or left sides) to which orthodontic force (either heavy or light force) was allocated blindly for the investigator and outcomes assessor because the clinician could know the type of force from the shape of archwires. The surgeon who extract the teeth was also blinded. The extracted premolars were coded to be masked to the investigator who measured the root resorption areas. All outcome assessors of proteomic analysis as well as the statistician was blinded.|Adult orthodontic patients|t|t|t|t
33872869|NCT01705171|||CASE_CONTROL||PROSPECTIVE|||||||
33872870|NCT00343473|||OTHER||OTHER|||||||
33872871|NCT01118442|||OTHER||PROSPECTIVE|||||||
33872872|NCT03882970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872873|NCT03197844|||COHORT||PROSPECTIVE|||||||
34067862|NCT04242407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sponsor, the investigator, personnel at the clinical study unit who are directly involved with monitoring and/or performing study procedures and assessments, and the subjects will be blinded to treatment assignment.|Subjects will be randomized in 1:1 ratio to receive DMTS or matching placebo.|t|t|t|t
34192608|NCT04180540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192609|NCT04509622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192610|NCT03284892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To maintain allocation concealment, the investigators ensured that only the intervention nurse had access to the random sequence. Physicians and staff at the study sites were aware of a pending nursing-intervention study but were blinded with respect to the hypothesis, group allocation, specific SOC protocols, and study endpoints. Moreover, outcome assessors were blinded to the group assignments, ensuring an unbiased evaluation.|Qualified participants will receive a two-item screening and FEES examination within 48 hours postextubation. Then participants will be randomly assigned, on a 1:1 ratio, to an intervention, SOC group or a control group (receiving usual care). A research nurse will provide the SOC program for seven days or until death or hospital discharge. All outcomes, including resumption of oral feeding, incidence of pneumonia, and incidence of penetration and aspiration, will be evaluated by an independent outcome assessor.|f|t|t|t
34192611|NCT02567162|||COHORT||PROSPECTIVE|||||||
34192612|NCT05583578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192613|NCT06094491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Type I hybrid effectiveness-implementation cluster randomized trial among adult patients with T2DM across 9 intervention sites and 9 control sites||||
33764787|NCT02489266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764788|NCT01966315|||CASE_CONTROL||PROSPECTIVE|||||||
33872874|NCT02594306|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872875|NCT01311050|||CASE_CONTROL||PROSPECTIVE|||||||
33872876|NCT00326352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872877|NCT00490438|||||PROSPECTIVE|||||||
34192614|NCT05520554|||CASE_ONLY||PROSPECTIVE|||||||
33872878|NCT00919100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33872879|NCT00823407|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33872880|NCT01852994|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33872881|NCT02170285|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33872882|NCT02797340|NA|SINGLE_GROUP||OTHER||NONE||||||
34067863|NCT03009175|||OTHER||PROSPECTIVE|||||||
34067864|NCT04812834|||CASE_ONLY||PROSPECTIVE|||||||
34067865|NCT04636671|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized controlled trial||||
34067866|NCT02547701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067867|NCT03267459|||CASE_ONLY||PROSPECTIVE|||||||
34067868|NCT01071434|||COHORT||PROSPECTIVE|||||||
33764789|NCT01316341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34067869|NCT01636648|||COHORT||PROSPECTIVE|||||||
33764790|NCT05347966|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192615|NCT01189019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192616|NCT04589026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192617|NCT03010488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872883|NCT03134170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients are randomized to the control or intervention group. After 12 months patients in the control group who do not have well controlled diabetes may be crossed over to the interventiobn gorup||||
33872884|NCT05065502|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will conduct a series of three trials to test two implementation strategies designed for sustained change. Each trial will be a two-arm, cluster-randomized trial. The results of these trials will be pooled together in a single cross-trial analysis using a dichotomous outcome for each trial. Each trial will also be analyzed independently. Two of the trials will use the same dichotomous primary outcome and the third trial will use a different primary outcome (CBTI). The two arms will both include use of clinical population health dashboards. Unit of analysis is clinic. Clinics will be randomized to one of two implementation strategies described below. Implementation strategies will be tested for effectiveness of sustained use of practices to address documented quality gaps related to (1) potentially inappropriate medications, (2) use of direct oral anticoagulation medications (DOACs), and (3) cognitive behavioral therapy as first-line treatment for insomnia (CBTI).||||
33872885|NCT02232373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872886|NCT01359709|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33872887|NCT06177964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872888|NCT00760019|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33872889|NCT02554019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872890|NCT01668251|||CASE_CONTROL||PROSPECTIVE|||||||
33764791|NCT04284839|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33872891|NCT04124913|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33872892|NCT01848288|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33872893|NCT01925573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872894|NCT01203540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33872895|NCT04841421|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33872896|NCT04542759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33872897|NCT05127837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872898|NCT01908764|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33872899|NCT04866693|||OTHER||OTHER|||||||
33872900|NCT03986385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872901|NCT06035653|||COHORT||RETROSPECTIVE|||||||
33872902|NCT00606320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872903|NCT00058786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872904|NCT03459209|||COHORT||PROSPECTIVE|||||||
33872905|NCT00004998||||TREATMENT||||||||
33872906|NCT04988412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872907|NCT01086462|NA|SINGLE_GROUP||OTHER||NONE||||||
34192618|NCT03499535|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants blinded to condition.|Study 1: Participants randomly assigned to one of two conditions. Study 2: Participants randomly assigned to one of three conditions.|t|f|f|f
34192619|NCT00946985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192620|NCT05290571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192621|NCT01641419|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34192622|NCT02270944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192623|NCT00710216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192624|NCT00933556|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192625|NCT01745497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872908|NCT04092712|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872909|NCT01908179|||||PROSPECTIVE|||||||
33872910|NCT05352126|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Multicentre prospective cross-over, randomised, double-blind placebo-controlled trial|f|t|f|f
33872911|NCT01309542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872912|NCT03784079|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double blind study. Subjects and investigator will be blinded.|Eligible subjects will be randomized to receive two active doses of GSK3640254 along with placebo in Part 1 of the study. In Part 2, subjects will receive three active doses of GSK3640254 along with placebo depending upon the data obtained in Part 1.|t|f|t|f
34192626|NCT02059096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192627|NCT05241977|||CASE_ONLY||PROSPECTIVE|||||||
34192628|NCT03408704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel group randomized controlled trial. Primary health care clinics are randomized. The enrolment number refers to included clinics.||||
34192629|NCT03269188|||COHORT||PROSPECTIVE|||||||
33764792|NCT06227962|||COHORT||CROSS_SECTIONAL|||||||
33764793|NCT05810051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764794|NCT04330365|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33966982|NCT03112993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The surgeon, anesthesiologist, operating room staff, patients, personnel in the postanesthesia care unit (PACU) as well as the investigators collecting the postoperative data will be blinded to the group allocation.|Participants will receive (per a randomization schedule) either sugammadex, or neostigmine/glycopyrrolate to reverse neuromuscular blockade at the end of the surgery. The reversal agent will be prepared in a blinded fashion.|t|t|t|t
33966983|NCT02012205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872913|NCT05921994|||COHORT||PROSPECTIVE|||||||
34192630|NCT05025956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigator or properly trained and delegated study team member (research PA) will write the prescription for the study medication. The subject's randomization block and within-block random number will be communicated directly to the Vail Health pharmacy. The Vail Health pharmacy will maintain an unblinded, de-identified randomization spreadsheet that documents group allocation for each subject. The Vail Health Pharmacy oversees and manages drug disbursement for research.|pilot, prospective, randomized, double-blind, placebo control clinical trial|t|t|t|t
34192631|NCT05563155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blinding The patient, all personnel attending in treatment and care of the patient, the investigators and the sponsor will all be blinded to the study-drug allocation, until all data processing is finished.~The randomization-sequence will be stored in a sealed envelope at the Pharmacy at Lillebaelt Hospital who carried out the packaging-process. The randomization personnel have no contact to the patient."|"A double-blind randomization will be carried out, 5:5 block-randomization, half of which will be allocated to the CG and the other half to RDG.~Group 1: Postoperative placebo tablet on day 1 after surgery.~Group 2: Postoperative dexamethasone 24 mg tablet on day 1 after surgery."|t|t|t|t
34192632|NCT06396104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physiotherapist who will apply the evaluation methods to be used in our study will be blind to the group distribution of the patients. Additionally, patients will be blind to the procedure.|A Parallel, double blind, randomised controlled trial|t|f|f|t
34192633|NCT02637830|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34192634|NCT04046614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192635|NCT00093379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192636|NCT01456897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192637|NCT06140953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872914|NCT03676621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33872915|NCT05149898|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study||||
34192638|NCT04613427|||CASE_CONTROL||PROSPECTIVE|||||||
34192639|NCT02751385|NA|SINGLE_GROUP||OTHER||NONE||||||
34192640|NCT04095429|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This cluster-randomized school-based study will examine the effectiveness of a support group-based teen dating violence (TDV) and sexual violence (SV) prevention program on the primary prevention of serious (and potentially lethal) violence perpetration among middle school students (both male and female-identified) already exposed to violence. The study will be located in western Pennsylvania across 36 middle schools (anticipated number of 'clusters'), randomized either to receive the Expect Respect program (i.e., intervention schools, n=18) or to an enhanced usual care condition (n=18 schools)."||||
34192641|NCT03352908|||COHORT||CROSS_SECTIONAL|||||||
34192642|NCT02560077|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34192643|NCT01486498|||CASE_CONTROL||PROSPECTIVE|||||||
34192644|NCT05839158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192645|NCT04497051|||COHORT||PROSPECTIVE|||||||
34192646|NCT02507167|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34192647|NCT02055222|||CASE_CONTROL||PROSPECTIVE|||||||
33872916|NCT06241092|||COHORT||CROSS_SECTIONAL|||||||
33872917|NCT04191330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872918|NCT00255970|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33872919|NCT03235648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872920|NCT02970825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Two experimental arms: physical training and relaxation program, including social activities. Both programs are conducted in parallel with adolescents and young people.~A first study was conducted among schoolchildren and was published. The second study was conducted in a clinical population of Area + -Fond'Roy psychiatric hospital in Brussels. Both studies were performed in a parallel order and randomized at the beginning of the study."|t|f|t|t
33872921|NCT00837941|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33872922|NCT01222676||||TREATMENT||NONE||||||
33872923|NCT01821651|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33872924|NCT05914142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872925|NCT04384562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All participants will receive the same instructions, and neither they nor the experimenters are informed which drug is used. Participants must take the drug in front of the investigator, to ensure correct intake and compliance.|This is a double-blind, randomized, placebo-controlled, between-participant study. In this experiment. Participants will receive a preferential dopamine reuptake inhibitor, a selective noradrenaline reuptake inhibitor, a natural nicotinic acetylcholine receptor agonist, or placebo under double-blind conditions.|t|f|t|f
33872926|NCT02094690|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33872927|NCT03638154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33872928|NCT01336582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966984|NCT05436691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33966985|NCT04911920|NA|SINGLE_GROUP||OTHER||NONE||||||
33966986|NCT05651620|||CASE_CONTROL||OTHER|||||||
34192648|NCT02723565|||COHORT||PROSPECTIVE|||||||
34192649|NCT01241045|||ECOLOGIC_OR_COMMUNITY|||||||||
33966987|NCT00543790|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33966988|NCT06214026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A1, B1, B2, A2 crossover design||||
33966989|NCT04452799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized double-blind controlled Parallel study|Randomized double-blind controlled Parallel study|t|t|f|f
33966990|NCT01015612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966991|NCT05484271|||CASE_ONLY||RETROSPECTIVE|||||||
33966992|NCT06351137|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33966993|NCT00699634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33966994|NCT03996265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33966995|NCT04427696|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33966996|NCT06356376|||COHORT||PROSPECTIVE|||||||
33966997|NCT03208933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33966998|NCT00095199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192650|NCT04237142|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Results of the biological tests are masked for the clinician and the patient and therefore do not modify the current management. Results will be given after delivery in order to not influence the current medical care of the patient.|||||
34192651|NCT03219970|||COHORT||RETROSPECTIVE|||||||
34192652|NCT05858424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomization will be performed according to a minimization algorithm of the Ennov Clinical software. The ratio will be 1:1 by stratifying on the criterion: management service (CLB vs IHOPe).|"This study is a monocentric open-label clinical research with 2 parallel groups. Patients will be 1:1 randomly assigned in both groups.~* Group A : former patients with multidisciplinary day hospitalization~* Group B : former patients without multidisciplinary day hospitalization"|t|f|t|f
34192653|NCT06264804|||OTHER||PROSPECTIVE|||||||
34192654|NCT02408757|||COHORT||PROSPECTIVE|||||||
34192655|NCT00814060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34192656|NCT02133690|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192657|NCT04548869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192658|NCT03207035|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34192659|NCT00945295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192660|NCT04072406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192661|NCT06226857|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomize and compare contol and experimental groups||||
34192662|NCT00586781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872929|NCT04319575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872930|NCT01109914|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872931|NCT02529787|RANDOMIZED|CROSSOVER||||NONE||||||
33872932|NCT02894853|||OTHER||PROSPECTIVE|||||||
33872933|NCT01550146|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33872934|NCT00075985|||||PROSPECTIVE|||||||
33872935|NCT06363214|||COHORT||RETROSPECTIVE|||||||
33872936|NCT03743311|||OTHER||PROSPECTIVE|||||||
33872937|NCT00621699|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33872938|NCT02331082|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33872939|NCT06054685|||COHORT||PROSPECTIVE|||||||
33872940|NCT00846300|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33872941|NCT00972673|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33872942|NCT04501185|||COHORT||PROSPECTIVE|||||||
33872943|NCT05546125|||CASE_ONLY||PROSPECTIVE|||||||
33872944|NCT00761514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872945|NCT00397813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872946|NCT03546530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872947|NCT05054114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872948|NCT05774379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33872949|NCT04075838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872950|NCT03014778|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33872951|NCT02075099|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33872952|NCT06189599|||CASE_ONLY||PROSPECTIVE|||||||
33872953|NCT01121315|||||RETROSPECTIVE|||||||
33872954|NCT02192203|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33872955|NCT04035070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872956|NCT04782271|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Interventional, observer-masked, parallel groups, time-lagged trial to study safety, tolerability and PK of SYL1801 sodium in healthy volunteers.|f|f|f|t
33872957|NCT01161264|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872958|NCT05447468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33872959|NCT04248101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33966999|NCT06526130|||COHORT||RETROSPECTIVE|||||||
34192663|NCT04174404|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"The investigators will firstly generate certain sets of random numbers from 1 to 6 by using Research Randomiser (Research Randomiser, 2019). Each number represents one combination of the allocations, e.g. 1 - \[I I C C}, 2 - {I C I C}, 3 - {I C C I}, 4- {C I C I}, 5- {C I I C} and 6 - {C C I I} where I and C represent the allocation to the intervention and control group, respectively. Such randomly generated sequences will be used to allocate participants, who will be assigned in successive order according to the sequence. Opaque, sealed envelopes with cardboard inside indicating the randomly assigned group will be prepared by the PI. Through these processes, randomisation and allocation concealment will be ensured (Doig \& Simpson, 2005; Schulz \& Grimes, 2002).~One research assistant will recruit participant, collect baseline data, conduct randomisation, and deliver the intervention, while another research assistant who is blind from group allocation will collect post-test data."|"This study will be a two-group pretest and repeated posttest pilot randomised controlled trial followed by a qualitative process evaluation. A randomized controlled trial design was chosen as it has been the gold standard in testing effectiveness of a new intervention or treatment. A qualitative process evaluation is incorporated into this study design to explore the experiences of the participants' use of the applications.~A total of 80 dyads of parents and their primary school-aged children (7-12 years old) will be randomly assigned into the intervention group which will receive the ICory-Circumcision plus routine care, whereby the parents will receive the BuddyCare application while the child will receive the Triumf game application, and the control group, who will just receive routine care provided by the hospital."|f|f|f|t
34192664|NCT04784442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192665|NCT05780424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764795|NCT04740203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764796|NCT02812472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872960|NCT02921620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33872961|NCT01767454|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33872962|NCT02141685|||COHORT||PROSPECTIVE|||||||
33872963|NCT01187186|NON_RANDOMIZED|PARALLEL||||NONE||||||
33872964|NCT00812058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872965|NCT03812640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33872966|NCT00005039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872967|NCT06120335|||OTHER||OTHER|||||||
33872968|NCT04171375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967000|NCT02619071|NA|SINGLE_GROUP||||NONE||||||
33967001|NCT03273127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single-blind with regard to treatment (abediterol or placebo).||t|f|f|f
33967002|NCT03066440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The intravenous fluids administered will all have generic labeling making the study arm assignment unknown to all providers, study personnel and participants. Only the pharmacist filling the orders will known arm assignment.|Single-center randomized double-blinded control trial|t|t|t|f
33872969|NCT00547170|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33872970|NCT03554876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872971|NCT05753072|||OTHER||RETROSPECTIVE|||||||
33872972|NCT03045861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872973|NCT00617500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872974|NCT05192291|||CASE_ONLY||PROSPECTIVE|||||||
33872975|NCT03024554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33872976|NCT01914874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33872977|NCT04647591|NA|SINGLE_GROUP||SCREENING||NONE||||||
33872978|NCT04427007|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33872979|NCT01464411|||COHORT||PROSPECTIVE|||||||
33872980|NCT03731650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33872981|NCT05020171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33967003|NCT05009628|RANDOMIZED|PARALLEL||OTHER||NONE||interventional study with 4 paralel arms ; randomization is realised according to a centralized and balanced 2x2 factorial design||||
33967004|NCT05165511|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label one-arm pilot study.||||
33967005|NCT05145296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967006|NCT04116294|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Before after. During the before period, standard of care. During the after period, computer-assisted prescription for plain abdominal radiography (reminding the indication for this procedure).|f|f|f|t
33967007|NCT02817854|||CASE_ONLY||PROSPECTIVE|||||||
33967008|NCT00914797|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34192666|NCT03391739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967009|NCT06049667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967010|NCT01556178|||COHORT||PROSPECTIVE|||||||
33967011|NCT05644912|NA|SINGLE_GROUP||OTHER||NONE||Proof of concept investigation with subjects experienced in using transanal irrigation with a balloon catheter.||||
33967012|NCT02289924|||COHORT||PROSPECTIVE|||||||
33967013|NCT02436395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967014|NCT03578276|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants' eyes are assigned to one of two groups.||||
33967015|NCT03349918|NA|SINGLE_GROUP||OTHER||NONE||||||
34067870|NCT03135574|||CASE_ONLY||CROSS_SECTIONAL|||||||
34192667|NCT06133504|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a phase III randomized clinical trial at a single center with two patient groups, early arm (EA) and late arm, assigned through stratified randomization. Allocation concealment uses sealed envelopes. EA includes intubated patients receiving early multimodal therapy, while the late arm starts therapy during ventilatory support weaning. Blinding isn't feasible, but final assessments at 90 days are blinded to intervention groups. Statisticians analyze data blinded. The study is intention-to-treat based, ensuring a comprehensive evaluation of intervention effectiveness"||||
34192668|NCT03726229|||COHORT||PROSPECTIVE|||||||
34192669|NCT05536271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192670|NCT01499277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192671|NCT02649751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34192672|NCT02219867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192673|NCT05409534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|İn this context, individuals included in the study will be assigned to the control and intervention groups respectively, randomized by an expert statistician and received in closed envelopes|26 for intervention 1 (Backward Walking Exercise) group and 26 for intervention 2 (Forward Walking Home Exercise) group|f|f|f|t
33872982|NCT01590940|||COHORT||PROSPECTIVE|||||||
33872983|NCT06236477|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 parallel-group, superiority randomized controlled trial||||
33872984|NCT02427074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33872985|NCT02548325|||COHORT||RETROSPECTIVE|||||||
33872986|NCT01283074|||COHORT||PROSPECTIVE|||||||
33872987|NCT04514523|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33872988|NCT01748175|||COHORT||PROSPECTIVE|||||||
33967016|NCT03063489|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33967017|NCT00125931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967018|NCT00515073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967019|NCT05938452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967020|NCT04384341|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33967021|NCT03968900|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967022|NCT03885492|||COHORT||PROSPECTIVE|||||||
33967023|NCT05415319|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All children will experience brief standardized laboratory tasks according to the same protocol.||||
33967024|NCT05131503|||OTHER||PROSPECTIVE|||||||
33967025|NCT03654911|||CASE_ONLY||PROSPECTIVE|||||||
34067871|NCT01358578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067872|NCT03141034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067873|NCT00560898|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067874|NCT02600364|||COHORT||PROSPECTIVE|||||||
34067875|NCT05211908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067876|NCT01768221|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067877|NCT00855699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067878|NCT00802672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067879|NCT06196697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067880|NCT03406624|||COHORT||PROSPECTIVE|||||||
34067881|NCT02643706|||CASE_CONTROL||PROSPECTIVE|||||||
34067882|NCT04897035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067883|NCT02004314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192674|NCT06165315|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33967026|NCT04272177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33967027|NCT00174759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967028|NCT00436527|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34192675|NCT06134024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967029|NCT03621085|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34067884|NCT06288542|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192676|NCT05741606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33872989|NCT03107520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The surgeon and musculoskeletal radiologist administering the contrast-enhanced ultrasound will not be blinded at the time of the intervention; however, they will be blinded when comparing the results of the CEUS to standard-of-care perfusion MRI and 3-years postop radiographs.|||||
34192677|NCT04037332|||COHORT||CROSS_SECTIONAL|||||||
34192678|NCT06153303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192679|NCT01282580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192680|NCT04027478|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34192681|NCT01105546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192682|NCT06136767|||COHORT||PROSPECTIVE|||||||
34192683|NCT00049985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34192684|NCT00892736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192685|NCT06125080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192686|NCT05166837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192687|NCT03425760|||COHORT||PROSPECTIVE|||||||
34192688|NCT04228029|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34192689|NCT05235490|||COHORT||RETROSPECTIVE|||||||
34192690|NCT00171834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192691|NCT05283512|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients are allocated to either oral- or IV-hydration|f|f|f|t
34192692|NCT00194870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192693|NCT00152269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192694|NCT04141904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants will be randomly allocated to one of two groups (tofacitinib or placebo) and take the assigned medication for 7-10 days|t|t|t|t
33872990|NCT03972176|||FAMILY_BASED||PROSPECTIVE|||||||
33872991|NCT05627375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33872992|NCT01515761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33872993|NCT04720235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33872994|NCT05790109|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33872995|NCT04490863|NA|SINGLE_GROUP||OTHER||NONE||||||
33872996|NCT02134483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192695|NCT03695770|NA|SINGLE_GROUP||OTHER||NONE||before/after study design||||
34192696|NCT00125528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192697|NCT05593263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Candidates will be randomly divided into two groups, OCCE group \& LRI group before their cataract surgery.|t|f|f|f
34192698|NCT01580501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192699|NCT02813577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192700|NCT06228677|||COHORT||PROSPECTIVE|||||||
34192701|NCT00575939|||CASE_CONTROL||PROSPECTIVE|||||||
33872997|NCT04344938|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33872998|NCT02350972|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33872999|NCT03034564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873000|NCT01550159|||COHORT||PROSPECTIVE|||||||
33873001|NCT04451577|||CASE_CONTROL||OTHER|||||||
33873002|NCT05382650|||COHORT||PROSPECTIVE|||||||
33873003|NCT06020677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967030|NCT01260428|||CASE_ONLY||PROSPECTIVE|||||||
33967031|NCT03392961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3 Cohorts Cohort 1: 5 periods, 4 treatments and 5 sequences with a partial replicate crossover design Cohort 2: 6 periods, 6 treatments and 6 sequences in a cross-over design Cohort 3: 6 periods, 6 treatments and 6 sequences in a cross over design||||
33873004|NCT05898100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873005|NCT03126942|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33873006|NCT02132208|||COHORT||PROSPECTIVE|||||||
33873007|NCT04941950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33873008|NCT00677014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873009|NCT06194136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967032|NCT02191579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967033|NCT02301962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967034|NCT01427803|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967035|NCT01824069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192702|NCT03899181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192703|NCT02940041|||OTHER||PROSPECTIVE|||||||
34192704|NCT05567718|||COHORT||PROSPECTIVE|||||||
34192705|NCT01141413|||COHORT||RETROSPECTIVE|||||||
34192706|NCT01895478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192707|NCT03412565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192708|NCT05707039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192709|NCT01579851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192710|NCT04939142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192711|NCT00970684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192712|NCT01156337|||COHORT||PROSPECTIVE|||||||
34192713|NCT04048330|||COHORT||PROSPECTIVE|||||||
34067885|NCT02692131|||COHORT||PROSPECTIVE|||||||
34067886|NCT02770846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067887|NCT00431145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067888|NCT02322333|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34067889|NCT04677387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34067890|NCT00898495|||OTHER||RETROSPECTIVE|||||||
34067891|NCT05050500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34067892|NCT05012774|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In Aim 1, which is sentence lipreading training, the intervention compares the provision of three different types of feedback for lipreading. The three types are consonant-level, word-level, or sentence-level feedback. A no-training wait-list control is included.~In Aim 2, novel word training, the intervention has one arm in which novel word learning via lipreading the words is supported by allowing the participants to read the consonants in the novel words before lipreading them.~In Aim 3, the most effective feedback with sentence training will be compared with novel word training using training stimuli that are audiovisual speech in speech-shaped noise.~The interventions are all delivered individually via the web. Finally, all pre- and post-training results will be compared across groups including the wait-list controls."||||
34067893|NCT01379105|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067894|NCT00029978|||DEFINED_POPULATION||CROSS_SECTIONAL|||||||
34067895|NCT03630029|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34067896|NCT04876313|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with muscle-invasive urothelial bladder carcinoma, not eligible or denying standard neoadjuvant therapy||||
34192714|NCT05099367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective, monocentric, pathophysiological study, comparing 3 parallel groups: healthy controls; patients with diabetes and without DFU; patients with diabetes and with DFU. To address secondary objectives , samples from a fourth group (patients with diabetes, neuropathy and DFU undergoing lower-limb amputation) will be collected.||||
33873010|NCT00822757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33873011|NCT04624711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873012|NCT05705609|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||randomized controlled trial conducted with experimental and control groups.|t|f|f|f
33873013|NCT00634309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33873014|NCT01724840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873015|NCT04632758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873016|NCT04039893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873017|NCT01692275|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33873018|NCT01236300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873019|NCT01628471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873020|NCT00073216|RANDOMIZED|FACTORIAL||PREVENTION||||||||
34067897|NCT00305422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34192715|NCT03156387|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study, designed as a randomized prospective controlled clinical trial, was conducted to compare the clinical outcomes of frenectomies performed using conventional surgery or a diode laser.||||
34192716|NCT04835675|||CASE_CONTROL||PROSPECTIVE|||||||
34192717|NCT00830297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192718|NCT01739062|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34192719|NCT05151029|||COHORT||PROSPECTIVE|||||||
34192720|NCT04004871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192721|NCT02384798|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34192722|NCT06109818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192723|NCT00543959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192724|NCT03846518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups: control group (Hyrax) and experimental group (mini Hyrax)|f|f|f|t
34192725|NCT00523445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192726|NCT03844945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192727|NCT03675854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192728|NCT00554489|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34192729|NCT01051154|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192730|NCT02080819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192731|NCT03028454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34192732|NCT04044170|NA|SINGLE_GROUP||TREATMENT||NONE||"Each treatment cycle is 28 calendar days in duration. There will be two patient cohorts and eligible patients will be enrolled into each cohort in parallel based on EGFR or HER2 exon 20 mutation status:~* Cohort 1 : Previously treated patients with EGFR exon 20 insertion mutation positive NSCLC~* Cohort 2 : Previously treated patients with HER2 exon 20 insertion mutation positive NSCLC"||||
34192733|NCT06250361|||COHORT||PROSPECTIVE|||||||
34192734|NCT00807560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192735|NCT06196671|NA|SINGLE_GROUP||TREATMENT||NONE||Oncolytic virus plus PD-1 inhibitor||||
34192736|NCT00870428|||CASE_ONLY||PROSPECTIVE|||||||
34192737|NCT02619383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873021|NCT02443363|||COHORT||CROSS_SECTIONAL|||||||
33873022|NCT00767091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873023|NCT01076049|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization methodology was controlled by a biostatistician at the site.||||
34067898|NCT02226120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067899|NCT02702232|||CASE_CONTROL||PROSPECTIVE|||||||
34067900|NCT05045404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067901|NCT02932605|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34067902|NCT01467193|||COHORT||PROSPECTIVE|||||||
34192738|NCT02929407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873024|NCT00868062|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33873025|NCT05073107|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||To investigate the feasibility of the usage of a mobile dental application in the self-administration of plaque control in a two (2) parallel arm study with 52 subjects (n = 52). The study will take place over 2 visits (within 35 days): Visit 1 and 2.|f|f|t|f
33873026|NCT05142475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873027|NCT03023020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873028|NCT00442052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873029|NCT05779137|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The involved researchers will not be blinded to the treatment allocation, because this would not be feasible with the current design. Patients receiving MBCT need to be allocated to a specific treatment group, which requires extensive communication between the patient, mindfulness center and researcher. Also, patients receiving the treatment will perform different questionnaires in the course of the study, which makes it impossible for the researcher to be blinded for group allocation. We do not expect any bias on our primary outcome measure (self-report questionnaire). Secondary outcome measures (MRI, blood serum, hair cortisol) are unlikely to be biased by the researcher. UPDRS-III performance will be video recorded to allow blinded ratings by independent researchers after collecting the data (hence blinded outcome assessor). Patients will be informed about their intervention after randomization.||f|f|f|t
33873030|NCT00985803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873031|NCT02967081|||OTHER||PROSPECTIVE|||||||
33873032|NCT05106322|||COHORT||PROSPECTIVE|||||||
33967036|NCT00517374|||COHORT||PROSPECTIVE|||||||
33967037|NCT05571085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967038|NCT03675191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The placebo pill is given to participants who are randomly assigned to the control group.~Double-blinded"|"Randomized placebo-controlled clinical trials (12 weeks)~* orlistat (120mg, three times a day, within 1hour after meal) + phentermin (37.5mg, once a day, within 1hour after meal)~* placebo (120mg, three times a day, within 1hour after meal) + phentermin (37.5mg, once a day, within 1hour after meal) The patients were divided into two groups: orlistat (120mg, three times a day), phentermine (37.5 mg, once a day) combined Group (N = 57), placebo (placebo, three times a day) and phentermine (37.5 mg, once a day) Group (N=57)"|t|t|t|f
33967039|NCT05680207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967040|NCT05028686|||COHORT||PROSPECTIVE|||||||
34192739|NCT01229696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967041|NCT01986595|||||CROSS_SECTIONAL|||||||
33967042|NCT05693857|||CASE_ONLY||PROSPECTIVE|||||||
33967043|NCT00780715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067903|NCT03469999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067904|NCT00300846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34067905|NCT01265004|||CASE_ONLY||PROSPECTIVE|||||||
34192740|NCT06519695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34192741|NCT04749511|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34192742|NCT02269085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192743|NCT06436807|||COHORT||PROSPECTIVE|||||||
34192744|NCT00337675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192745|NCT06392399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34192746|NCT00550641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192747|NCT01977872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34192748|NCT05189353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single randomized clinical trial||t|f|f|f
34192749|NCT04202419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192750|NCT05086614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There is no masking for participants or investigators. The outcomes assessors will be blind for the allocation.|Patients with pathological high-risk stage II and stage III colorectal cancer after radical resection were randomly allocated to receive thymosin-alpha 1 or not in a 1:1 ratio.|f|f|f|t
34192751|NCT03583619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192752|NCT02177071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192753|NCT00280384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34192754|NCT04331743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192755|NCT05371756|||CASE_CONTROL||PROSPECTIVE|||||||
34192756|NCT03345290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192757|NCT05787548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192758|NCT04215419|||COHORT||RETROSPECTIVE|||||||
34192759|NCT01363349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192760|NCT00246740|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34192761|NCT00131053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192762|NCT05200234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192763|NCT04303676|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This trial will investigate the superiority from an effectiveness perspective of: a) a virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions utilizing alcohol use e-learning modules to guide and focus the process and content, compared to b) a virtual practice facilitation intervention, with a practice facilitator working with practices in virtual one-on-one or group sessions without utilizing alcohol use e-learning modules.||||
34192764|NCT02273596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192765|NCT02730013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192766|NCT00447785|||CASE_CONTROL||PROSPECTIVE|||||||
34192767|NCT01501877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192768|NCT04075253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192769|NCT00526916|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34192770|NCT01067092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34192771|NCT06405308|||COHORT||RETROSPECTIVE|||||||
34192772|NCT06076967|RANDOMIZED|PARALLEL||TREATMENT||NONE||Students with ADHD will be randomized to a group-based mindfulness intervention or Services-As-Usual (SAU; standard support services provided by the universities).||||
34192773|NCT01039103|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33764797|NCT01457105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873033|NCT04419610|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33967044|NCT02891265|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192774|NCT05591313|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The present study adopted a counterbalanced design. All participants were instructed to complete four counterbalanced treatments: a) longer duration (LI-40), b) moderate-intensity with 30 min (MI-30), c) high-intensity with shorter duration (HI-16), and d) control treatments.||||
34192775|NCT02873494|||COHORT||PROSPECTIVE|||||||
33873034|NCT04994951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873035|NCT05706896|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will take place by eye, each patient will have one eye treated and the contralateral subjected to sham. The treated eye will receive CB-PRP injections modulated differently over time in each of the sub-studies, i.e. monthly, bimonthly or quarterly, while the contralateral eye will receive a SHAM injection.||||
33873036|NCT06438978|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33873037|NCT05222373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873038|NCT05930600|||CASE_ONLY||CROSS_SECTIONAL|||||||
33873039|NCT05775185|||CASE_ONLY||PROSPECTIVE|||||||
33873040|NCT06030388|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-armed randomised trial where participants are randomised to 1) strength training, 2) high-intensity aerobic training or 3) untreated control group.||||
33873041|NCT01294579||||TREATMENT||NONE||||||
33873042|NCT04375202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873043|NCT06132386|||COHORT||PROSPECTIVE|||||||
33873044|NCT00355173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873045|NCT04652323|||CASE_CONTROL||PROSPECTIVE|||||||
33873046|NCT06159868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study outcome assessors will be blinded to group allocation.|A mixed-methods, multicentre, randomised controlled feasibility study.|f|f|t|t
33873047|NCT05241730|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873048|NCT02657395|NA|SINGLE_GROUP||TREATMENT||NONE||Bovine collagen matrix -PriMatrix||||
33967045|NCT01773174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967046|NCT04668222|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"According to the assessment of Self-test for classification and judgment of body constitution by TCM theory, participants with the body constitution of deficiency of Qi and Yin or deficiency of Qi and Yin will be included into this study."|t|t|t|t
33967047|NCT00948025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967048|NCT02477904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067906|NCT05865093|||COHORT||OTHER|||||||
34192776|NCT02326480|||CASE_ONLY||PROSPECTIVE|||||||
34192777|NCT02023333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192778|NCT02551042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34192779|NCT02928263|||COHORT||RETROSPECTIVE|||||||
33873049|NCT05115838|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33873050|NCT02281370|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33873051|NCT01667770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873052|NCT05559190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873053|NCT05035615|||COHORT||CROSS_SECTIONAL|||||||
33873054|NCT05564975|||CASE_CONTROL||OTHER|||||||
33873055|NCT06210074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873056|NCT01555528|||COHORT||OTHER|||||||
33873057|NCT02648802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873058|NCT02700724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873059|NCT06359873|||OTHER||CROSS_SECTIONAL|||||||
33873060|NCT06287970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873061|NCT05413486|||CASE_CONTROL||PROSPECTIVE|||||||
33873062|NCT04565964|NA|SINGLE_GROUP||OTHER||NONE||||||
33873063|NCT03260504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873064|NCT04006886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967049|NCT01360632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967050|NCT04242966|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967051|NCT06092645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192780|NCT05953233|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Sham cleaners are constructed by removing the filters from air cleaners and adding a sound generator rendering them indistinguishable from active HEPA cleaners.|Classrooms will be randomized in a 1:1 ratio using a random number generator to active vs sham HEPA arms|t|t|f|t
34192781|NCT05086029|||CASE_CONTROL||PROSPECTIVE|||||||
33873065|NCT04169880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The author who did not perform evaluation or treatment of the patients assessed participants for eligibility and assigned them to one of the two groups; HILT (n=15) and HILT\&Exercise (n=15) (Figure 1) by a computerized random number generator (Random.org; Randomness and Integrity Services Ltd, Dublin, Ireland; httpp://www.random.org). Participants did not know there were two groups and which group they were in.|Our study is a parallel group randomised comparison trial comparing two interventions with a 1:1 ratio.|t|f|f|f
33873066|NCT03591640|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34192782|NCT04344964|||CASE_CONTROL||PROSPECTIVE|||||||
34192783|NCT02499133|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192784|NCT01755000|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873067|NCT05513989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873068|NCT01579448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873069|NCT01632995|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33873070|NCT05265312|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873071|NCT06294886|||COHORT||PROSPECTIVE|||||||
33967052|NCT03678961|||CASE_CROSSOVER||PROSPECTIVE|||||||
33967053|NCT01344395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967054|NCT02565082|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33967055|NCT05559216|NA|SINGLE_GROUP||SCREENING||NONE||||||
33967056|NCT03197961|NA|SEQUENTIAL||OTHER||NONE||This is a biphasic steady state pharmacokinetic and pharmacodynamic study of healthy women to evaluate the concentrations and activity of tenofovir and emtricitabine in different compartments before and after the administration of DMPA. Each participant will receive the study medications in the same order, i.e. TDF/FTC alone for 14 days followed by TDF/FTC for 14 days after having received DMPA.||||
33967057|NCT00947518|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33967058|NCT05463458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33967059|NCT01086215|||CASE_ONLY||PROSPECTIVE|||||||
33967060|NCT00136019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967061|NCT06545058|||COHORT||RETROSPECTIVE|||||||
33967062|NCT01234688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967063|NCT04130945|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33967064|NCT00634582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067907|NCT02437188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34192785|NCT06415500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192786|NCT03432806|||COHORT||PROSPECTIVE|||||||
34192787|NCT04986956|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Blinding information will be held by the study sponsor, VDF FutureCeuticals, Inc. The study will be conducted in a double-blind fashion such that both the investigators and the participants are unaware of their assignment. Unblinding will only occur once the study has been completed.|Participants will be randomly assigned to one of two groups - study materials (whole coffee cherry extract (WCCE) or placebo).|t|f|t|t
34192788|NCT00207285|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34192789|NCT00616785||||TREATMENT||NONE||||||
34192790|NCT03624010|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34192791|NCT03243292|||CASE_ONLY||PROSPECTIVE|||||||
34192792|NCT04226768|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34192793|NCT02806141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192794|NCT03227783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Parallel, Sham-controlled, single-blinded study|t|t|f|t
34192795|NCT01690676|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34192796|NCT03934099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192797|NCT01339520|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34192798|NCT01934270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192799|NCT03595228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192800|NCT03514810|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34192801|NCT00835562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192802|NCT02661009|||COHORT||RETROSPECTIVE|||||||
34192803|NCT01373541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34192804|NCT06259006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be achieved by over-encapsulation of tablets so that placebo cannot be distinguished from dexamethasone|Participants will be randomised and allocated 1:1 to blinded dexamethasone or placebo groups.|t|t|t|t
34192805|NCT00158015|||||PROSPECTIVE|||||||
34192806|NCT06396910|||CASE_ONLY||RETROSPECTIVE|||||||
34192807|NCT03229694|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192808|NCT05917782|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34192809|NCT02405338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192810|NCT06144580|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34192811|NCT04306796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873072|NCT05595187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33873073|NCT00413647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873074|NCT00554242|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34192812|NCT05256004|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34192813|NCT06069895|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34192814|NCT05547204|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34192815|NCT00003497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192816|NCT06142578|NA|SINGLE_GROUP||OTHER||NONE||||||
34192817|NCT04796194|NA|SINGLE_GROUP||TREATMENT||NONE||LTX-315 in Combination With Pembrolizumab||||
34192818|NCT04349904|||COHORT||PROSPECTIVE|||||||
34192819|NCT04461067|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192820|NCT02675673|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34192821|NCT06523413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34192822|NCT02863536|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192823|NCT03307655|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Semen and FF samples will be obtained from donors and patients by masturbation after 2-7 days of sexual abstinence and they will be analyzed according to WHO guidelines (2010). FF samples will be obtained during the oocyte pick up procedure. After oocyte removal, the FF will be centrifuged for 10 min at 2000g and stored at -20°C until evaluation. NO concentration will be determined in the FF samples with the help of ion selective electrodes.~Sperm will be capacitated in the presence and absence of FF. In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined. The same treatment will be performed on all semen samples regardless of whether they come from patients or donors."||||
34192824|NCT03680118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192825|NCT04231370|NA|SINGLE_GROUP||TREATMENT||NONE||treatment with lenalidomide in combination with sintilimab for relapsed/refractory ENKTCL patients||||
33873075|NCT05601375|||COHORT||PROSPECTIVE|||||||
33873076|NCT04457050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192826|NCT03069105|||COHORT||PROSPECTIVE|||||||
34192827|NCT03558880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34192828|NCT04497038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192829|NCT00791817|RANDOMIZED|CROSSOVER||||NONE||||||
34192830|NCT06092268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192831|NCT00225810|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34192832|NCT01827423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192833|NCT02745015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192834|NCT02091557|||COHORT||PROSPECTIVE|||||||
34192835|NCT00654433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873077|NCT02820285|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873078|NCT05251181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this double-blind study, the subject and all relevant personnel involved with the conduct and interpretation of the study (including investigator, investigational site personnel, and the sponsor or designee's staff) will remain blinded to the identity of the Investigational Product (IP) assigned and the randomization codes. The final randomization list will be kept strictly confidential, filed securely by the independent biostatistician, and accessible only to authorized persons as per the sponsor's standard operating procedures until the completion of the study.|"This is a multi-centric, randomized, double-blind, placebo-controlled phase-III clinical study to assess the safety and efficacy of centhaquine therapy in patients with hypovolemic shock with systolic arterial blood pressure ≤ 90 mmHg at presentation and continue to receive standard treatment of shock.~This protocol is designed to develop a novel first-in-class treatment for use in critical care and life-threatening condition of hypovolemic shock with unmet need and is of national interest."|t|t|t|t
33873079|NCT05698082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192836|NCT00019383||||TREATMENT||||||||
33873080|NCT06276361|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33873081|NCT04550091|||OTHER||PROSPECTIVE|||||||
33873082|NCT04362969|||COHORT||RETROSPECTIVE|||||||
33967065|NCT00565370|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967066|NCT03216200|NA|SINGLE_GROUP||TREATMENT||NONE||single center open-label study||||
33967067|NCT02115685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967068|NCT00647166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967069|NCT02619331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967070|NCT03553277|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33967071|NCT05639673|||COHORT||RETROSPECTIVE|||||||
33967072|NCT05570929|||COHORT||PROSPECTIVE|||||||
34067908|NCT06188676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873083|NCT03295370|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33873084|NCT00237432|||COHORT||PROSPECTIVE|||||||
33873085|NCT05404620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967073|NCT04745780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873086|NCT04754698|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Study consisting of 3 arms, all of which will receive CoronaVac: patients with rheumatic diseases, PLWHA, and healthy controls. Also, in an exploratory, post hoc, substudy nested within the trial, 2 other arms will receive exercise or no intervention 1 hoour before the third dose.||||
33873087|NCT04933851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873088|NCT01515137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067909|NCT02356107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067910|NCT03850990|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A single group will be assessed for change in body weight across time.||||
34067911|NCT03853291|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34067912|NCT03577314|||CASE_CONTROL||PROSPECTIVE|||||||
34067913|NCT04884971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967074|NCT02751060|||COHORT||PROSPECTIVE|||||||
33873089|NCT01921751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967075|NCT04609527|NA|SINGLE_GROUP||OTHER||NONE||All women with placenta praevia and previous scar in the uterus. Surgical management and follow up will be defined||||
33873090|NCT05768945|||COHORT||RETROSPECTIVE|||||||
33967076|NCT02856997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967077|NCT04843176|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|. Both radiologists will be blinded to the clinical characteristics and subsequent management of participants, with any discordance in assessment resolved by consensus before reaching a final decision.|Scanned images are randomized individually 1:1 to either the prototype AI algorithm or LI-RADS criteria interpretation by two specialist gastrointestinal radiologists|f|f|t|f
33967078|NCT01878656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33967079|NCT06009900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967080|NCT03551366|RANDOMIZED|PARALLEL||OTHER||NONE||Schools are randomly assigned to either a control (usual practice), linear PE pedagogy or nonlinear PE pedagogy arm. Both linear and nonlinear arms will receive 15 weeks of physical education lessons from trained coaches, whereas the control group will carry on with PE lessons as usual.||||
33967081|NCT05699837|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The stimulation is delivered via a smartphone application. Each participant will receive one of two versions, which are identical apart from the order in which the two types of stimulation are given. The participant and the investigator enrolling participants and conducting questionnaire and interview outcome assessment, will be masked as to which version they are using. The record of which version was allocated to which participant will be held centrally by co-investigators with no direct participant contact, until results are analysed.|Following a baseline period each participant will use two types of sensory stimulation for two weeks, in a randomised order, with a 1 week washout period.|t|f|t|t
33967082|NCT01526915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967083|NCT06078085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||One intervention group that receive a postoperative rehabilitation programme. One control group that can train freely.|f|t|t|t
33967084|NCT04904900|||COHORT||PROSPECTIVE|||||||
33967085|NCT03520335|||CASE_ONLY||PROSPECTIVE|||||||
33967086|NCT00409578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33967087|NCT02037373|||COHORT||PROSPECTIVE|||||||
34192837|NCT05323058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator and participant will be blinded as the treatment preparations will be identical in color, odor, and consistency and they will be placed in identical bottles|Allocation ratio (1:1)|t|f|t|f
33873091|NCT00823355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873092|NCT05153083|||COHORT||PROSPECTIVE|||||||
33873093|NCT03339011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33873094|NCT03222206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind|Salsalate (2g/d), Place (2g/d)|t|f|t|f
33873095|NCT01419912||CROSSOVER||||||||||
33873096|NCT00577785|||CASE_ONLY||PROSPECTIVE|||||||
33967088|NCT02878278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873097|NCT00950664|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33873098|NCT04149015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873099|NCT02184195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873100|NCT05179447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873101|NCT04315675|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a quantitative intervention study that tests and compares outcomes of three interventions and a control group. The subjects are randomly assigned to one of four study groups.||||
33873102|NCT04017520|||COHORT||PROSPECTIVE|||||||
33873103|NCT06459154|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment of Randomized Control Trial||||
33873104|NCT06353828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873105|NCT03435848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873106|NCT06272474|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group is receiving the two interventional arms||||
33873107|NCT04238975|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33873108|NCT03312959|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33873109|NCT05503173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873110|NCT01390272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873111|NCT01274975|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873112|NCT03803059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967089|NCT03083132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo-controlled delayed start|t|t|t|t
33967090|NCT05890326|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33967091|NCT02729194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192838|NCT05448443|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"Patients who meet the eligibility criteria will be randomized equally to receive AD981 or matching placebo.~After 14 days of treatment and a washout period, the patients crossover to the other treatment arm for 14 days."|t|t|t|t
34192839|NCT02036970|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34192840|NCT01831583|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192841|NCT05262829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192842|NCT02160899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192843|NCT03603678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192844|NCT01667419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192845|NCT05416918|||COHORT||PROSPECTIVE|||||||
34192846|NCT06088472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967092|NCT04273672|||COHORT||CROSS_SECTIONAL|||||||
33967093|NCT00299728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967094|NCT02103647|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967095|NCT02199652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967096|NCT00005583|RANDOMIZED|||TREATMENT||NONE||||||
33967097|NCT01718054|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34192847|NCT03007641|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34192848|NCT01828151|||COHORT||RETROSPECTIVE|||||||
34192849|NCT01316198|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192850|NCT01401660|||COHORT||PROSPECTIVE|||||||
34192851|NCT00077129||||TREATMENT||NONE||||||
33873113|NCT02064530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873114|NCT00807742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873115|NCT00964743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873116|NCT02029859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873117|NCT02107638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873118|NCT03710174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not know to which group the participants belong.||f|f|f|t
33873119|NCT00676676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873120|NCT02151474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873121|NCT02225080|||CASE_ONLY||RETROSPECTIVE|||||||
33873122|NCT01787682|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33873123|NCT02994433|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33873124|NCT01305538|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33873125|NCT03519763|||CASE_CONTROL||PROSPECTIVE|||||||
33873126|NCT06360263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967098|NCT02893852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967099|NCT00274144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967100|NCT04264299|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967101|NCT06527729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were randomly assigned to use either topical 5% minoxidil gel or topical 1% sildenafil-loaded liposomes twice daily for a period of 8 weeks.|t|f|f|f
33967102|NCT01880099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967103|NCT00176683|||COHORT||PROSPECTIVE|||||||
33967104|NCT04166669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967105|NCT01313000|||CASE_ONLY||PROSPECTIVE|||||||
33967106|NCT01473758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967107|NCT05339828|||COHORT||RETROSPECTIVE|||||||
33967108|NCT02015923|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967109|NCT02746458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967110|NCT01840475|||COHORT||PROSPECTIVE|||||||
33967111|NCT05296122|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33967112|NCT01386879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34067914|NCT06004830|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
34067915|NCT03022487|||COHORT||PROSPECTIVE|||||||
34192852|NCT02862340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34192853|NCT02252744|||CASE_ONLY||PROSPECTIVE|||||||
34192854|NCT04380519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192855|NCT02340351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192856|NCT03482934|||COHORT||CROSS_SECTIONAL|||||||
34192857|NCT05067309|||CASE_CONTROL||PROSPECTIVE|||||||
34192858|NCT00170378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34192859|NCT04158843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192860|NCT04680182|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority randomised study.||||
33873127|NCT00099411|||COHORT||PROSPECTIVE|||||||
33873128|NCT01973712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192861|NCT05483218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873129|NCT00810056|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33967113|NCT00534092|||COHORT||OTHER|||||||
33967114|NCT06011473|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33967115|NCT06110884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33967116|NCT04021901|||COHORT||PROSPECTIVE|||||||
33967117|NCT04023994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967118|NCT06040957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To ensure the blinding of the health care personnel who will perform the checks (single-blind), follow-up visits will be performed by physicians not involved in the treatment procedures.|This is a randomized trial with 1:1 allocation.|f|f|f|t
34067916|NCT05388422|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067917|NCT00994799|||COHORT||PROSPECTIVE|||||||
34067918|NCT06005090|||CASE_CONTROL||RETROSPECTIVE|||||||
34067919|NCT03157596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34192862|NCT00697138||CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34192863|NCT05996913|NA|SINGLE_GROUP||OTHER||NONE||||||
34192864|NCT00922727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067920|NCT03492905|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Outcome assessment is automatic, pre-programmed, on-line|||||
33873130|NCT05988658|||COHORT||PROSPECTIVE|||||||
33873131|NCT06220370|||COHORT||PROSPECTIVE|||||||
33873132|NCT03868592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Study insulin action and adipose function before and after weight loss from gastric sleeve surgery||||
33873133|NCT02774382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873134|NCT01538823|||COHORT||PROSPECTIVE|||||||
33873135|NCT03297736|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33873136|NCT03139812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research optometrists conducting eye examinations and technicians conducting fluorometry measurements did not know whether a given subject was in the treatment (irrigating) or control (non-irrigating) group.|161 non-contact lens wearers were fit with silicone hydrogel (SiH) contact lenses and randomized to either a treatment (n = 81) or control (n = 80) group for 30-day continuous wear (CW). Subjects in the treatment group irrigated every morning and whenever dryness symptoms occurred; subjects in the control group did not.|f|f|t|f
33873137|NCT00622674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873138|NCT04018430|||CASE_CONTROL||PROSPECTIVE|||||||
33873139|NCT03200327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873140|NCT03040375|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33873141|NCT06363721|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The proposed study is a 12-week pilot study of PerioPull™. Eligible participants will be recruited from within the clinical practice of the periodontist. All study outcomes will be measurements and testing during three dental visits spaced 6 weeks apart. These are typical assessments in routine clinical practice. All study outcomes are described in detail in an ensuing section.||||
33873142|NCT00806936|||CASE_ONLY||PROSPECTIVE|||||||
33873143|NCT05925296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873144|NCT02124564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873145|NCT06384209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873146|NCT06066827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was a single-blind clinical trial, masking the investigator and outcomes assessor|Each subject will receive an injection of the secretome from ADCS's, topical minoxidil, or both.|f|f|t|t
33873147|NCT06537713|||CASE_CONTROL||PROSPECTIVE|||||||
33873148|NCT04383860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873149|NCT04155255|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873150|NCT06379386|||COHORT||PROSPECTIVE|||||||
33873151|NCT05319171|||COHORT||OTHER|||||||
33873152|NCT06494852|||CASE_ONLY||CROSS_SECTIONAL|||||||
33873153|NCT03650842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873154|NCT03332498|NA|SEQUENTIAL||TREATMENT||NONE||||||
33873155|NCT06436651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33873156|NCT03081520|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873157|NCT06126302|||OTHER||RETROSPECTIVE|||||||
33873158|NCT04179734|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33873159|NCT05241990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873160|NCT05995288|||OTHER||RETROSPECTIVE|||||||
33967119|NCT04271150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967120|NCT03509051|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33967121|NCT06072690|||COHORT||PROSPECTIVE|||||||
34192865|NCT05710445|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomly assigned to one of two groups. In the first group intravenous catheters will be placed per standard of care. In the second group, the catheter will be placed while the physicians utilizes augmented reality.||||
34192866|NCT05041608|||COHORT||RETROSPECTIVE|||||||
34192867|NCT02671604|||CASE_CONTROL||PROSPECTIVE|||||||
34192868|NCT02265159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192869|NCT01808092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192870|NCT04389541|||COHORT||OTHER|||||||
34192871|NCT03712085|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34192872|NCT00487890|||OTHER||OTHER|||||||
34192873|NCT06408753|||COHORT||PROSPECTIVE|||||||
34192874|NCT03702881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192875|NCT04708249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192876|NCT00597597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192877|NCT06517030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A randomization list will be generated in blocks: patients will be divided in 3 blocks according to the study center and the treatment will be assigned at random in each block to ensure a balanced distribution of the tested interventions, with a ratio test:control=1:1. The investigator who will generate the allocation sequence will not be the person who will determine eligibility and entry of patients. The assignments (A or B group) will enclose in serially numbered, opaque, sealed envelopes, each bearing on the outside only the letter corresponding to the name of the center (M, B, S) and a number (from 1 to 10).|The present research is a national multicentric prospective parallel double-blinded (both the patient and the investigator who will perform the measurements are blind) randomized controlled clinical trial. It is a superiority comparative study on a medical device CE marking, used according to the intended use subject to the CE marking.|t|f|f|t
34192878|NCT03502551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192879|NCT02857634|||CASE_ONLY||CROSS_SECTIONAL|||||||
34192880|NCT00635258|||CASE_CONTROL||PROSPECTIVE|||||||
34192881|NCT02899767|||COHORT||RETROSPECTIVE|||||||
34192882|NCT00495898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192883|NCT04339244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873161|NCT05418400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873162|NCT00522145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873163|NCT00540137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873164|NCT02012621|||COHORT||PROSPECTIVE|||||||
33873165|NCT04832997|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Every patient will receive the same diagnostic test (MRI and Micro-US) in a randomized sequence||||
33873166|NCT02393638|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33873167|NCT02455570|||COHORT||PROSPECTIVE|||||||
34067921|NCT06015919|NA|SINGLE_GROUP||TREATMENT||NONE||dash diet and acupuncture on post menopausal hypertention||||
34192884|NCT03568656|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The RP2D/MTD dose will be determined in Part A. Parts B-H will run in parallel after the completion of Part A.||||
34192885|NCT01485172|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34192886|NCT04230252|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34192887|NCT04340271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. The patients didnot know whether it is included in the experimental group and control group~2. Outcome measurements and data analyses were performed by a trained and blinded outcome assessor who was not involved in the intervention."|The patients' burn scars had re-epithelialized after split-thickness skin graft (STSG). We included patients aged ≥18 years with a deep partial-thickness (second-degree) burn or a full thickness (third-degree) burn to their upper extremities, having been transferred to the rehabilitation department after acute burn treatment, and less than 6 months since the onset of the burn injury.|t|f|f|t
34192888|NCT03288142|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial with randomization stratified by age and baseline systolic blood pressure.||||
33873168|NCT05063227|||CASE_ONLY||PROSPECTIVE|||||||
33873169|NCT04507685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||24-week parallel arm, randomized controlled trial (RCT)|f|f|t|t
33873170|NCT01388673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873171|NCT06420778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873172|NCT00885274|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33873173|NCT02431351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873174|NCT03703102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||subcutaneous administration|t|t|t|t
33873175|NCT00514514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873176|NCT04080193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873177|NCT04539561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873178|NCT06136377|NA|SINGLE_GROUP||OTHER||NONE||||||
33873179|NCT05759754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873180|NCT00582140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873181|NCT01763619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873182|NCT01473082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873183|NCT00404690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873184|NCT04878003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873185|NCT03325725|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33873186|NCT03046485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873187|NCT04687579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873188|NCT04697459|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"* Acute phase : standard HD versus HD with acute intradialytic exercise (in HD-EX group only);~* Chronic phase : before and after an exercise training program of 16 weeks (HD-EX group) as well as before and after 16 weeks of standard HD (HD group)"|f|f|t|f
33873189|NCT06434415|||COHORT||RETROSPECTIVE|||||||
33873190|NCT01765920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873191|NCT03458221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Targeted therapy based on functional signal transduction pathway activation in patients with recurrent ovarian cancer.||||
33873192|NCT01469338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33873193|NCT00025051|RANDOMIZED|||PREVENTION||DOUBLE||||||
33873194|NCT01717209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873195|NCT01408992|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
33873196|NCT01527864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873197|NCT01582425|NA|SINGLE_GROUP||||NONE||||||
33873198|NCT05041751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873199|NCT04445675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind (researchers are not blind) randomization will be provided since the mothers will be provided with support for breastfeeding and the feeding of infants' with breast milk by the researchers. The statistician was also blinded for the data analysis purpose.|Randomized Controlled Trial|f|f|f|t
33873200|NCT00440908|||||PROSPECTIVE|||||||
33873201|NCT00361270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873202|NCT00811616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873203|NCT01586884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873204|NCT05009771|||COHORT||PROSPECTIVE|||||||
33873205|NCT00885703|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 was the dose escalation phase which used a sequential model. Phase 2 was the dose validation phase which used a parallel model. Analyses combine arms from Phase 1 and Phase 2, as appropriate, for validation.||||
33873206|NCT01827670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33873207|NCT04434963|||CASE_ONLY||PROSPECTIVE|||||||
33873208|NCT06006260|||COHORT||PROSPECTIVE|||||||
33873209|NCT00407095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873210|NCT06470256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873211|NCT03560856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873212|NCT00781911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873213|NCT05443841|||COHORT||PROSPECTIVE|||||||
33873214|NCT02351505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873215|NCT03949933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873216|NCT01796587|||COHORT||PROSPECTIVE|||||||
33873217|NCT00113828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873218|NCT03695575|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33873219|NCT05170906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33873220|NCT00350142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873221|NCT00883207|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33873222|NCT04343625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873223|NCT00715585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873224|NCT03446222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873225|NCT04086394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinded randomized control trial in which patient was unaware of treatment arm||t|f|f|f
33873226|NCT05123833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873227|NCT04722575|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will be conducted according to an open-label, randomized, not comparative phase II design. Three arms for a total of 88 patients will be considered.~BRAF mutated patients will be randomized in two arms: Arm A and Arm B (27 patients per arm). BRAF WT patients will be included in Arm C (34 patients)."||||
33873228|NCT02853942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873229|NCT00772642|||||OTHER|||||||
33873230|NCT04451356|||COHORT||PROSPECTIVE|||||||
33873231|NCT00314184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894269|NCT06091501|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is designed as a parallel-group, 2-arm pragmatic RCT. The primary outcome is diabetes competences measured by The Perceived Competence in Diabetes scale (PCD) before and after 8 weeks of interventions. The trial sites are to deliver either (1) Lev Livet or (2) Lev Livet + HiiT. Within each trial site the participants will be randomly allocated (2:1) to intervention or a control group.||||
33894270|NCT00803556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067922|NCT01054313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067923|NCT05872659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067924|NCT06080165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
34067925|NCT00190112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067926|NCT05735405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34067927|NCT01121536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067928|NCT02315664|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34067929|NCT02863653|||||CROSS_SECTIONAL|||||||
34067930|NCT03564132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067931|NCT03724019|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34067932|NCT03464474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Colonic biopsies from 28 patients with ulcerative colitis will be endoscopically acquired. These biopsies will be examined by digital holographic microscopic and by analysis due to an experienced histopathologists using an established scoring system (Goldstandard).||||
34067933|NCT02346214|||OTHER||CROSS_SECTIONAL|||||||
34067934|NCT02886013|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34067935|NCT02118259|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34067936|NCT05131347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067937|NCT00370435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34067938|NCT04721366|||COHORT||PROSPECTIVE|||||||
34067939|NCT00421109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067940|NCT00038311|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34067941|NCT04163926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessor will not know the study group assignment of participants.|Randomised control trial (RCT) control versus usual care|f|f|f|t
34067942|NCT02779270|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34067943|NCT04609449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34067944|NCT00797407|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067945|NCT00161967|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067946|NCT02535754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34067947|NCT00562731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192889|NCT01110642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192890|NCT01874769|||COHORT|||||||||
34192891|NCT01779258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192892|NCT00929448|||COHORT||PROSPECTIVE|||||||
34192893|NCT04363541|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The application of an electric chest pad. The use of an electric cushion was chosen because it is designed to be used in human thermal therapy. The electric cushion provides continuous 90 minutes of regulated heat, with enough penetration to raise the external temperature of the area to 40-42 ° C.~It is a therapy designed to detain disease progression. It is not expected to have an effect on concomitant microorganisms such as bacteria or opportunists such as Candida albicans, so that when the concomitant infection is suspected, the antibiotic of choice should be given or continued, depending on the nature of the infection."||||
34192894|NCT00475943|||||PROSPECTIVE|||||||
34192895|NCT01840917|||CASE_CROSSOVER||PROSPECTIVE|||||||
34192896|NCT01900210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192897|NCT02163603|||CASE_CONTROL||PROSPECTIVE|||||||
34192898|NCT00030459|RANDOMIZED|||TREATMENT||||||||
34192899|NCT05094778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192900|NCT00693082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192901|NCT00476008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192902|NCT01634191|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34192903|NCT06332456|||CASE_CONTROL||PROSPECTIVE|||||||
34192904|NCT04281134|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."|At the end of month 8 after DBS implant, all subjects will enter a one-month delayed onset withdrawal period in which the subject and Independent Evaluators are blinded to timing of discontinuation. See description below.|t|f|f|t
34192905|NCT06073145|||COHORT||PROSPECTIVE|||||||
33873232|NCT03550482|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Study multicenter open-label nonrandomized clinical trial in two parallel groups with a 20-day treatment period. No follow-up period was intended. Following visits were scheduled: Visit 1 - the first day of 2nd and further course of ACT before ACT drugs administration; Visit 2 - 7±1 days before next course of ACT; Visit 3 - the day of next course of ACT before ACT drugs administration (21±3 days after Visit 1).~It is expected, that the proportion of patients with MCID improvement in total SDS ESAS was 50% in ONCX group and 20% in control group (with baseline total SDS ESAS of 30 points). Based on patients' allocation as 2:1 in comparison groups for the ONCX and control groups, respectively, alpha 0.05 and power not less than 0.9 data of 120 patients has to be analyzed. With the dropout of 25% 150 patients has to be included in the study (100 ONCX/50 controls)."||||
33967122|NCT04525157|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|In the first half of the study, the Participant and Investigator are masked. In the second half of the study, the study is single arm, Open Label Study.|A Two-Arm, Randomized, Double-Blind Study and a Single-Arm, Open Label, Phase IIb Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants plus Narrow-Band Ultraviolet B (NBUVB) Light Source in the Treatment of Nonsegmental Vitiligo.|t|f|t|f
33967123|NCT04550715|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|t|f|f
33967124|NCT04438681|||COHORT||PROSPECTIVE|||||||
33967125|NCT02731833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34192906|NCT01350193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34192907|NCT04517890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized controlled trial|double blind randomized controlled trial|t|t|t|t
34192908|NCT00502203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192909|NCT02155478|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34192910|NCT03043105|NA|SINGLE_GROUP||TREATMENT||NONE|open-labeled|This will be a single center, single arm, phase-II pilot study.||||
33873233|NCT04426877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34192911|NCT02739685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192912|NCT02150434|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34192913|NCT05439785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34192914|NCT02995824|||COHORT||RETROSPECTIVE|||||||
34192915|NCT05279573|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33764798|NCT04811599|||OTHER||PROSPECTIVE|||||||
33873234|NCT03734835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873235|NCT03103802|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33873236|NCT04763577|||COHORT||PROSPECTIVE|||||||
33873237|NCT01888029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873238|NCT01539967|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33873239|NCT05182775|NA|SINGLE_GROUP||TREATMENT||NONE||Case study||||
33873240|NCT01212081|||||PROSPECTIVE|||||||
33873241|NCT01594515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33873242|NCT01088776|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33873243|NCT03151863|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|"The nurse administers to the patient both subcutaneous and intranasal dose, however, one of the two is a placebo. The subcutaneous placebo and the subcutaneous opioids have the same packaging. Similar procedure is done for the intranasal compounds.~Neither medical staff nor patient knows which analgesia is administered before this nursing care."|"This two-sided, superiority, cross-over trial is based on a clinically relevant reduction (≥20%) of primary outcome (ECPA pain score \>5) with the Dexmedetomidine treatment versus standard active control (opioids). It requires a sample size of 52 patients for a paired analysis with an intra-patient correlation of 50%.~Type I error: 0.05 and type II error: 0.20. 25% of drop-out are expected. In consequence, 66 patients are required for the study."|t|t|t|f
33873244|NCT01166022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967126|NCT03250650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All the questionnaires (OABV-8, King´s Health, Anamnesis), Function Avaliation of Pelvic Floor Muscles, before and after treatment will be conduced by other person who is not the responsable for the research.|Group 1: will be treated receiving Transcutaneous Tibial Electric Stimulation Group 2: will be treated receiving TTNS and Transvaginal Electric Stimulation|f|f|f|t
33967127|NCT02314273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967128|NCT03736395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All data collectors will be masked.|A portion of participating schools will receive the Idaho Rural Implementation Model (I-RIM) intervention, designed to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). All other participating schools will only receive basic training session about SWPBIS. The process to determine which schools receive the intervention is random. Intervention is at the school level. Outcomes are at the school level, staff level, and student level (anonymous).|f|f|f|t
34192916|NCT02650908|||||RETROSPECTIVE|||||||
34192917|NCT01421472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192918|NCT04801056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single Ascending Dose|t|f|t|f
34192919|NCT03438071|||OTHER||PROSPECTIVE|||||||
34192920|NCT02873429|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34192921|NCT05867771|NA|SEQUENTIAL||TREATMENT||NONE||||||
34192922|NCT04554121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192923|NCT00647270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192924|NCT00492713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34192925|NCT06044051|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34192926|NCT03563924|||COHORT||OTHER|||||||
34192927|NCT00748904|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764799|NCT03324659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873245|NCT03455491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will carried out by using Placebo equivalent to XC221 tablets without active substance and the corresponding labeling of the study drug.||t|f|t|f
34192928|NCT00522938|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34192929|NCT06197919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants of both group are informed about possible risk and potential benefits but don't know which group they are placed in. assessors are also masked. concealment will be done via sealed opaque method.||t|f|f|t
34192930|NCT01433289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192931|NCT01008423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34192932|NCT01645943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192933|NCT05250453|||COHORT||PROSPECTIVE|||||||
34192934|NCT01125488|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192935|NCT01930578|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34192936|NCT04166799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients receiving chest wall radiation or patients with large breast size (bra size 36 in and/or C cup or greater) will be randomized 2:1 to receive either Mepitel Film or the institutional standard of care skin treatments.||||
34192937|NCT05620121|||CASE_CONTROL||RETROSPECTIVE|||||||
34192938|NCT05676268|||COHORT||PROSPECTIVE|||||||
34192939|NCT03334786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967129|NCT00035165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192940|NCT01204008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192941|NCT03706248|||CASE_CONTROL||PROSPECTIVE|||||||
34192942|NCT02230852|||COHORT||PROSPECTIVE|||||||
34192943|NCT00152100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967130|NCT06219382|||OTHER||PROSPECTIVE|||||||
34192944|NCT00687141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34192945|NCT00040300|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192946|NCT05926115|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34192947|NCT02803346|||COHORT||PROSPECTIVE|||||||
34192948|NCT03181256|||CASE_ONLY||PROSPECTIVE|||||||
34192949|NCT02267876|||COHORT||PROSPECTIVE|||||||
34192950|NCT01305590|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment.~The study also included 70 individuals in a passive control (PC) arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period."||||
34192951|NCT01041534|||COHORT||PROSPECTIVE|||||||
34192952|NCT03010293|||COHORT||RETROSPECTIVE|||||||
34192953|NCT06426589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34192954|NCT01783691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192955|NCT05675644|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||3x3 adaptive dose-finding design||||
34192956|NCT01732601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192957|NCT05878262|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient, parents, surgeon and pain assessor were all blinded to the study. Only investigator, anesthetist and the nurse delivering the analgesic to the child were not blinded.|The patients were randomly assigned into either the pre-emptive analgesia group or the control group|t|f|f|t
34192958|NCT03637088|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath through a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia.|t|f|f|f
34192959|NCT02585336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34192960|NCT02408159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34192961|NCT03754478|||CASE_ONLY||PROSPECTIVE|||||||
34192962|NCT03735524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192963|NCT03018483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873246|NCT00567970||||TREATMENT||||||||
33873247|NCT04389762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873248|NCT04979442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873249|NCT02211729|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873250|NCT06443866|||CASE_CONTROL||PROSPECTIVE|||||||
33873251|NCT06414811|||COHORT||PROSPECTIVE|||||||
33873252|NCT01833286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873253|NCT03742180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33873254|NCT01178450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873255|NCT05377047|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomisation 2:1 (systemic treatment + SABR vs systemic treatment)||||
33873256|NCT01322464|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33873257|NCT03448068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873258|NCT05097482|||CASE_ONLY||CROSS_SECTIONAL|||||||
33873259|NCT04126863|||CASE_ONLY||PROSPECTIVE|||||||
34192964|NCT00640224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34192965|NCT00500214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34192966|NCT04243382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization will be done by external source and the assignment will disclosed to cord bank bank only. They will produce either a cord blood or placebo unit which will be completely covered. Each unit will have its own index number that will be documented by the research coordinator. Neither the researcher or the family will know the nature of the unit.||t|t|t|t
34192967|NCT03811860|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34192968|NCT01343264|||COHORT||PROSPECTIVE|||||||
34192969|NCT00636363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34192970|NCT01763008|||CASE_ONLY||PROSPECTIVE|||||||
34192971|NCT00161538|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34192972|NCT05168111|||CASE_CONTROL||PROSPECTIVE|||||||
34192973|NCT04280237|||COHORT||PROSPECTIVE|||||||
34192974|NCT02895867|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34192975|NCT03225508|||OTHER||PROSPECTIVE|||||||
34192976|NCT05160064|||COHORT||PROSPECTIVE|||||||
33873260|NCT03359512|NA|SINGLE_GROUP||OTHER||NONE||||||
33873261|NCT02509416|||COHORT||PROSPECTIVE|||||||
33873262|NCT02626897|RANDOMIZED|CROSSOVER||||NONE||||||
33873263|NCT06267651|||COHORT||PROSPECTIVE|||||||
33873264|NCT01680822|||COHORT||RETROSPECTIVE|||||||
33873265|NCT03652038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33873266|NCT05650801|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967131|NCT02896868|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33967132|NCT01363609|RANDOMIZED|CROSSOVER||||NONE||||||
34067948|NCT04708496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|study physicians and laboratory technicians will be blinded to treatment group assignments.|A three arm single blind randomized trial. Study participants will be randomized to one of the 3 arms. Standard dose, double dose or 5 day course of Artemether-lumefantrine|f|f|t|f
34192977|NCT03616808|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"A case-control study. Conventional management patients are considered as controls whereas goal-directed management patients will be considered cases."||||
34192978|NCT03939741|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants will be placed in a single group. Those having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) above 1 x 10\^6 will be included in the study and they will be studied for Phase I/ Phase II trial by the proposed outcome measures over the stipulated time frame.~Those having a harvested total Adipose Derived Stem Cell (ADSC) count (in 5 ml SVF solution) less than 1 x 10\^6 will be excluded from the study."||||
34192979|NCT05072067|NA|SINGLE_GROUP||OTHER||NONE||||||
34192980|NCT06227793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34192981|NCT01657461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192982|NCT02343549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192983|NCT01015638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34192984|NCT01343693|||CASE_ONLY||PROSPECTIVE|||||||
34192985|NCT04050280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192986|NCT03736772|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33873267|NCT04227262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).|The children were assigned randomly into two equal groups. Group (a) control group received traditional physical therapy program. And group (b) study group received the same traditional physical therapy program in addition to mirror therapy three times / weak for three successful months.|f|f|f|t
33873268|NCT05599542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873269|NCT00916188|RANDOMIZED|PARALLEL||||NONE||||||
33873270|NCT04639973|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34192987|NCT00512980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34192988|NCT00799214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192989|NCT00508664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34192990|NCT04214964|||CASE_ONLY||OTHER|||||||
34192991|NCT00891540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34192992|NCT06044597|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized study with 2 groups: control group (Traditional biventricular stimulation), study group (biventricular stimulation + SyncAV feature)||||
34192993|NCT00749112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34192994|NCT03922113|||COHORT||PROSPECTIVE|||||||
34192995|NCT01640834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34192996|NCT06531551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34192997|NCT01681355|NA|SINGLE_GROUP||||NONE||||||
34192998|NCT01090323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34192999|NCT06438510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193000|NCT02305810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193001|NCT05343767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization was done using interactive response technology (IWRS).|"This was a double-blind, double dummy, randomized, active-controlled, three-arm, parallel-group, interventional phase II clinical trial to investigate efficacy and safety of a herbal medicinal product of (NW Low-Glu) in patients newly diagnosed with type II diabetes mellitus.~Study duration: 3 months of recruitment and 3 months of treatment. Sample Size: It was planned to enroll 68 patients per arm, 204 in total. Participants were patients between 18 and 65 years of age, newly diagnosed with type II diabetes mellitus and consenting to participate in this study.~Eligible patients were randomized in a 1:1:1 allocation ratio, into one of the three treatment groups, to receive either Metformin or one of the two doses of NW Low-Glu."|t|t|t|t
34193002|NCT02661048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193003|NCT00913952|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193004|NCT01937832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193005|NCT01334619|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34193006|NCT03753945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective cohort study that will enroll patients who have already undergone DBS electrode placement for a variety of disorders including, but not limited to Parkinson's disease, essential tremor, dystonia, depression, epilepsy, neuropathic pain and Alzheimer's disease. This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician.||||
34193007|NCT00496925|||COHORT||CROSS_SECTIONAL|||||||
34193008|NCT04241900|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34193009|NCT01128660|||COHORT||RETROSPECTIVE|||||||
34193010|NCT03179904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193011|NCT05127746|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193012|NCT06287177|||COHORT||PROSPECTIVE|||||||
34193013|NCT00003206||||TREATMENT||||||||
34193014|NCT02543424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193015|NCT03364270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pilot study||||
34193016|NCT01614678|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34193017|NCT01347216|||COHORT||PROSPECTIVE|||||||
34193018|NCT02005861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193019|NCT05317325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193020|NCT01094522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193021|NCT05162937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|A total of 160 patients were enrolled in the planned trial, and after passing the screening period of 2 weeks, they were randomly assigned to the 100mg group, 200mg group, 300mg group or placebo group according to 1:1:1:1. After the completion of the 16-week administration period, the follow-up period (\~24 weeks) was initiated.|t|t|t|t
34193022|NCT03890042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193023|NCT01863836|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193024|NCT02073344|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193025|NCT03238014|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
34193026|NCT05680532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34193027|NCT05224193|||COHORT||PROSPECTIVE|||||||
34193028|NCT02211677|||COHORT||PROSPECTIVE|||||||
34193029|NCT05173116|||COHORT||OTHER|||||||
34193030|NCT04096768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34193031|NCT00173641|||DEFINED_POPULATION||OTHER|||||||
34193032|NCT04930341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant) Self-Acupressure and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
34193033|NCT05412602|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||parallel-arm randomized control trial|f|f|f|t
34193034|NCT00967980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193035|NCT01801228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193036|NCT03615040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A or B|Single-centre, double-blinded, placebo-controlled, parallel group, randomised controlled trial|t|t|t|t
33873271|NCT00550602|||OTHER||PROSPECTIVE|||||||
33967133|NCT03700528|NA|SINGLE_GROUP||TREATMENT||NONE||The psychological treatment which we will use is called Acceptance and Commitment Therapy (ACT). The ACT treatment includes treatment processes of acceptance, cognitive defusion, mindfulness, and values-based action. Methods will include practice to deal with painful experiences, to improve awareness, to identify and work on goals, and to better stick to commitments.||||
33967134|NCT00410566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967135|NCT05944549|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193037|NCT06092281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34193038|NCT05194423|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multi-center single-arm trial in eight centers in China. A minimum of 150 subjects will be enrolled in this study and followed-up at discharge (≤ 10 days post operation), 30 days, 6 months, 1, 2, 3, 4, 5 years.||||
34193039|NCT01175083|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193040|NCT00617799|||COHORT||PROSPECTIVE|||||||
34193041|NCT00200343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34193042|NCT02411864|||COHORT||PROSPECTIVE|||||||
34193043|NCT00512057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34193044|NCT01504646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34193045|NCT06161298|||COHORT||PROSPECTIVE|||||||
33873272|NCT03092102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873273|NCT01903707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873274|NCT04729673|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33873275|NCT02970214|||COHORT||PROSPECTIVE|||||||
33873276|NCT01826110|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873277|NCT03087630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873278|NCT00279825|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33873279|NCT04808531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple blinding||t|t|t|t
33873280|NCT05277545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33873281|NCT03723707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33873282|NCT04851028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873283|NCT06466629|||COHORT||PROSPECTIVE|||||||
33873284|NCT04136873|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33873285|NCT02275078|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33967136|NCT05209061|||COHORT||PROSPECTIVE|||||||
33967137|NCT02708732|||COHORT||CROSS_SECTIONAL|||||||
33873286|NCT04751032|||COHORT||PROSPECTIVE|||||||
33967138|NCT06540378|||COHORT||RETROSPECTIVE|||||||
33967139|NCT01633749|NA|SINGLE_GROUP||||NONE||||||
33967140|NCT05841381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967141|NCT00689663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967142|NCT03000868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967143|NCT00005960||||TREATMENT||||||||
33967144|NCT00124176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967145|NCT04446832|||COHORT||PROSPECTIVE|||||||
33967146|NCT00235833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967147|NCT01806883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967148|NCT06234800|||COHORT||RETROSPECTIVE|||||||
33967149|NCT02378506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967150|NCT01077115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967151|NCT04976140|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33967152|NCT00192751|RANDOMIZED|PARALLEL||ECT||NONE||||||
33967153|NCT05621200|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34193046|NCT00504946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193047|NCT01786070|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34193048|NCT05129033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193049|NCT02027090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193050|NCT00678756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193051|NCT01571687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34193052|NCT05815875|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study will be conducted using a 1-month prospective quasi-experimental design.~The study sample will be 70 neurosurgical patients at King Abdullah University Hospital. The study sample will be non-randomly divided into a control group (35 patients) and an intervention group (35 patients)."||||
34193053|NCT01521754|||COHORT||OTHER|||||||
34193054|NCT01715441|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193055|NCT03989505|||COHORT||PROSPECTIVE|||||||
34193056|NCT01313741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193057|NCT02753257|||COHORT||PROSPECTIVE|||||||
34193058|NCT05098262|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193059|NCT06246006|||CASE_ONLY||RETROSPECTIVE|||||||
34193060|NCT04228133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193061|NCT06063603|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34193062|NCT04342507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Prospective comparative pilot study with two groups randomly divided|f|t|t|t
34193063|NCT03854994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873287|NCT03621514|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is a prospective cohort study.Participants,Care Provider, and Investigator all know the grouping situation. The Investigator collect the information and observation indicators of the two groups of participants and send to the Outcomes Assessor . The Outcomes Assessor does not know the grouping situation of each participant.|This study is a prospective cohort study.The main study content is the feasibility and advantages of painless indwelling catheter in perioperative period of uniportal video-assisted thoracoscopic surgery in lobectomy of lung cancer,divided into exposed and non-exposed groups.The exposed group was painless indwelled urethral catheter, the non-exposed group was indwelled urethral catheter routinely.|f|f|f|t
33873288|NCT02662621|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873289|NCT06005727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873290|NCT06392568|||COHORT||PROSPECTIVE|||||||
33967154|NCT06267261|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33967155|NCT00786110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967156|NCT00219557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193064|NCT00602758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193065|NCT04326426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193066|NCT00300547|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193067|NCT06027957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193068|NCT03436602|||COHORT||RETROSPECTIVE|||||||
34193069|NCT06148324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967157|NCT03984136|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967158|NCT04964622|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|drug will be put in sealed envelop and assistant supervisor will generate random sequence|patient with symptomatic irriversible pulpitis|t|t|f|f
33967159|NCT04115176|||CASE_CONTROL||PROSPECTIVE|||||||
33967160|NCT05895981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193070|NCT06284824|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193071|NCT00133549|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34193072|NCT05877742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193073|NCT01060280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193074|NCT04259918|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|enrolled groups ares only selected and applied in the operating room and participants, care giver and outcomes accessor could not know the group assignment||t|t|f|t
33764800|NCT05667779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A participant and investigator-blinded, randomized, placebo-controlled design will be used to minimize bias in this study.|This study will be a randomized, double-blind, placebo-controlled single ascending dose (SAD) study in healthy participants with the primary goal of evaluating the safety and tolerability of QRL-101.|t|f|t|f
33764801|NCT03047122|||CASE_ONLY||PROSPECTIVE|||||||
33764802|NCT01654081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764803|NCT01068314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764804|NCT04199312|NA|SINGLE_GROUP||OTHER||NONE||||||
33764805|NCT04307706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193075|NCT04162561|||COHORT||PROSPECTIVE|||||||
34193076|NCT04633044|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized placebo-controlled study with maternal dietary supplementation (betaine or placebo) for 3 months starting at infant birth and follow-up until 12 months of age.|t|t|t|t
34193077|NCT01695759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34193078|NCT03951350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193079|NCT02068716|||CASE_ONLY||PROSPECTIVE|||||||
34193080|NCT01790997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193081|NCT04254328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193082|NCT02651129|||CASE_ONLY||PROSPECTIVE|||||||
34193083|NCT00381290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193084|NCT05952128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193085|NCT04027608|||COHORT||PROSPECTIVE|||||||
34193086|NCT06087861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193087|NCT01675544|||COHORT||PROSPECTIVE|||||||
34193088|NCT00229515|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34193089|NCT00079365|RANDOMIZED|||TREATMENT||||||||
34193090|NCT01172132|||COHORT||PROSPECTIVE|||||||
34193091|NCT05165693|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34193092|NCT05391789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193093|NCT06044441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34193094|NCT05044299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study has two arms comparing device with and without resistance load over equal period of operation|t|f|f|f
34193095|NCT01068600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193096|NCT02967341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193097|NCT03291964|||COHORT||PROSPECTIVE|||||||
34193098|NCT00669123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193099|NCT00776919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193100|NCT04215302|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33764806|NCT04903457|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33764807|NCT01975220|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764808|NCT00110253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764809|NCT01615575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33764810|NCT05670002|NA|SINGLE_GROUP||OTHER||NONE||||||
33764811|NCT02213328|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33967161|NCT01348542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967162|NCT03782649|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33967163|NCT05295602|||CASE_ONLY||PROSPECTIVE|||||||
33967164|NCT05496114|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants (emergency physicians) will be allocated to performing the scenario with or without checklist in a randomized fashion on a 1:1 ratio. Computerized randomization will take place using an online randomization module.||||
33967165|NCT04816188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193101|NCT00448643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193102|NCT00530387|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34193103|NCT00856232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193104|NCT01650116|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193105|NCT03060161|NA|SINGLE_GROUP||PREVENTION||NONE||The present project corresponds to a longitudinal study. Intervention will be performed soon after the initial diagnosis, through nutritional monitoring and individual guidance on regular physical exercise for a period of 12 weeks. Participants will be evaluated for weight loss, body fat reduction, changes in laboratory parameters and eating habits and in relation to the routine of physical activities immediately after the intervention period, and will be retested after six months.||||
34193106|NCT01269242|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34193107|NCT01301898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193108|NCT04345367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764812|NCT03383562|||COHORT||PROSPECTIVE|||||||
33764813|NCT03104647|NA|SINGLE_GROUP||OTHER||NONE||||||
34193109|NCT02931669|||OTHER||PROSPECTIVE|||||||
34193110|NCT03010644|||COHORT||PROSPECTIVE|||||||
34193111|NCT04176484|||OTHER||PROSPECTIVE|||||||
34193112|NCT01586754|||COHORT||CROSS_SECTIONAL|||||||
34193113|NCT04726540|||OTHER||OTHER|||||||
34193114|NCT00093249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34193115|NCT02693158|||CASE_ONLY||PROSPECTIVE|||||||
33873291|NCT03639870|NA|SINGLE_GROUP||TREATMENT||NONE||The iStent infinite Trabecular Micro-Bypass System Model iS3 is a sterile, single-use injector system that is pre-loaded with three G2-W stents, and is designed to deliver the stents into Schlemm's canal. The three G2-W stents are heparin-coated and manufactured from implant grade titanium.||||
33873292|NCT06288620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873293|NCT03149081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873294|NCT02395926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873295|NCT04170322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled trial|t|t|f|t
33873296|NCT02512471|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873297|NCT03439202|NA|SINGLE_GROUP||OTHER||NONE|No drug and no arm are used for this study. This is a clinical study, because subjects are exposed to hypoxic conditions.|Crossover randomized study||||
34193116|NCT03353337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193117|NCT04744090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193118|NCT01775397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873298|NCT02866474|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34193119|NCT01903980|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34193120|NCT04783558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Women will be randomized 1:1 to the intervention or TAU conditions.|Pregnant women in the Treatment-as-Usual (TAU) condition will receive care as usual that involves continued enrollment in treatment and continued obstetric care. Participants will also be provided with a printed handout containing information on NAS and local resources. Pregnant women in the Adapted NAS tool Intervention will receive the adapted mobile-based NAS instructional tool and TAU. Women in this condition will go through the NAS instructional tool at least once during pregnancy, with their choice of going through the modules gradually while waiting at the OAT clinic to receive their dose, or by scheduling a time to review the modules. Participants will have free online access to the tool throughout their third trimester as well as through 12-weeks postpartum so they can access the modules at any time, and as many times as desired, including after giving birth. Women will be randomized 1:1 to the intervention or TAU conditions.||||
34193121|NCT01578850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193122|NCT02333617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193123|NCT04364984|||COHORT||PROSPECTIVE|||||||
33873299|NCT03568474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, care provider, outcomes assessor and statistician will be masked|parallel two arm groups with 1:1 allocation ratio|t|t|f|t
33873300|NCT02347683|||COHORT||PROSPECTIVE|||||||
33873301|NCT00630656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873302|NCT05329376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33873303|NCT03978455|||CASE_ONLY||PROSPECTIVE|||||||
33873304|NCT00976222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873305|NCT03040440|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33873306|NCT06097117|||OTHER||CROSS_SECTIONAL|||||||
33873307|NCT03587714|||COHORT||CROSS_SECTIONAL|||||||
33873308|NCT03381235|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193124|NCT02785796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34193125|NCT04019756|||OTHER||OTHER|||||||
33873309|NCT00159900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33873310|NCT05309798|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study design is a randomised, controlled, crossover design in which participants undertake three conditions in a randomised order with at least one week in between trials.||||
33873311|NCT00431340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873312|NCT02573870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873313|NCT03413111|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33873314|NCT04816929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873315|NCT04980482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873316|NCT04225130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33873317|NCT05240911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873318|NCT00507559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873319|NCT04169360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873320|NCT03583151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873321|NCT05915572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873322|NCT03594227|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33873323|NCT03080298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873324|NCT00736255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873325|NCT02936583|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33873326|NCT00247026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873327|NCT01155362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873328|NCT04058340|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33873329|NCT04911036|||COHORT||PROSPECTIVE|||||||
33873330|NCT05145907|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm||||
33873331|NCT03394144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873332|NCT02434848|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873333|NCT03448250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873334|NCT01356082|||CASE_ONLY||PROSPECTIVE|||||||
33873335|NCT04549870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873336|NCT05776836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193126|NCT00967824|RANDOMIZED|||||||||||
34193127|NCT05111015|||COHORT||OTHER|||||||
34193128|NCT02303132|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764814|NCT03629860|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Assessment of ascending ramus cortical plate for reconstruction of atrophic maxillary ridges versus chin cortical plates (Randomized clinical trial)|Assessment of ascending ramus cortical plate for reconstruction of atrophic maxillary ridges versus chin cortical plates (Randomized clinical trial)|t|f|f|f
33764815|NCT06527664|||COHORT||PROSPECTIVE|||||||
33764816|NCT01423981|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764817|NCT03791502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Subjects will be randomized into three groups, two intervention groups and one group will be the control. The randomization process will be done by a person who does not participate in the survey, at random.org, and concealment of the allocation will occur using opaque and sealed envelopes.|f|f|t|t
33764818|NCT06511999|||CASE_ONLY||PROSPECTIVE|||||||
33764819|NCT00245401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764820|NCT03842462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873337|NCT00081237||||TREATMENT||NONE||||||
33873338|NCT02247895|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|t|f
33873339|NCT01087905|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33873340|NCT03058042|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Protocol of group I (Outpatient training): Patients will perform 24 outpatient sessions of pelvic floor muscle (PFM) strength training and home training. At the end of one month, the patients will perform PFM evaluation and training progression~Group II protocol (home training): Patients will perform strength training of the pelvic floor muscles daily at home. At the end of one month, the patients will return for consultation, in which the PFM evaluation and training progression will be performed."||||
33873341|NCT03930719|||CASE_CONTROL||PROSPECTIVE|||||||
33873342|NCT02587650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873343|NCT02345954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873344|NCT01690078|||COHORT||PROSPECTIVE|||||||
33873345|NCT00074321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873346|NCT03080844|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Primary investigator was blinded to intervention assignment||f|f|t|f
33873347|NCT05916027|RANDOMIZED|CROSSOVER||SCREENING||NONE||Stepped-wedge cluster randomized controlled trial.||||
33873348|NCT05382832|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|In order to have a double-blinded RCT, the investigators will not be aware of the trial branch of the participants. Injections will be performed either with Botulinum Toxin or with Normal Saline and Spinal Cord Stimulators will be configured in order to use high-frequency stimulation or a sham treatment.|Double-Blinded, Randomized, Controlled Trial|t|f|t|f
34067949|NCT05223166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193129|NCT04384081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193130|NCT06171477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34193131|NCT02902341|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193132|NCT00771862|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34193133|NCT05606471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193134|NCT05657574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193135|NCT04420936|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomized clinical Trial with percent weight change at 24 months||||
34193136|NCT01713101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193137|NCT03310489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193138|NCT00984113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193139|NCT04416360|NA|SINGLE_GROUP||OTHER||NONE||||||
34193140|NCT05861817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193141|NCT00994344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193142|NCT02771613|||OTHER||PROSPECTIVE|||||||
34193143|NCT02996279|||COHORT||PROSPECTIVE|||||||
34193144|NCT02351427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193145|NCT05344196|NA|SINGLE_GROUP||TREATMENT||NONE||Several cohorts of people with prediabetes will be given the treatment and tracked with respect to outcomes from before to after treatment and follow-up||||
34193146|NCT05988606|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants completed all trials and were compared to themselves.||||
34193147|NCT01660438|||COHORT||PROSPECTIVE|||||||
34193148|NCT00685256|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33873349|NCT03061175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067950|NCT01483599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193149|NCT03179605|NA|SEQUENTIAL||TREATMENT||NONE||In the first stage, subjects who are at least 12 years of age and not more than 16.9 years (16 years and 11 months) of age with moderate to severe plaque psoriasis will be treated with DFD-06 (at least 20 completed subjects). In the second stage subjects who are at least 6 years of age and not more than 11.9 years (11 years and 11 months) of age with moderate to severe plaque psoriasis will be treated with DFD-06 (at least 20 completed subjects).||||
34193150|NCT02101710|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193151|NCT03425253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193152|NCT04078646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"Twenty four male individuals from or living in the region of Luxembourg will be recruited for this study. The number of participants is based on a randomized block design, constituting of 6 blocks of 4 subjects, each will be served different sequences of test meals (A, B, C/A, C, B/B, C, A/B, A, C/C, A, B/C, B, A) in order to cancel out any potential effect of sequence of meals.~Thus, each subject will act has his/her own control. Test meal intake will be separated by 1 week."|t|f|f|f
34193153|NCT00646854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193154|NCT00474279|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34193155|NCT05519540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193156|NCT02282241|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873350|NCT03957772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and all care providers will be blinded to the patient assignment.|Parallel assignment|t|t|f|f
34193157|NCT05969847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193158|NCT06408961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34193159|NCT03647813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only one researcher knew in which group the patients were allocated and performed all the treatments. A blinded researcher performed all the evaluations after the procedures. The patient was also blinded to the treatment as the laser was turned off, simulating the treatment.||t|f|t|f
34193160|NCT02737891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193161|NCT04009564|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34193162|NCT00379704|||CASE_CONTROL||PROSPECTIVE|||||||
34193163|NCT01546623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193164|NCT03297411|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both participants and the outcome assessor will be blinded.|Each participant will be randomly allocated to a sequence of treatments using designs for crossover studies with fewer periods (3) than treatments (4) involving two sets of ECT electrode placements and two sets of pulse width.|t|f|f|t
34193165|NCT00360321|||DEFINED_POPULATION||PROSPECTIVE|||||||
33873351|NCT01471782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873352|NCT06199609|||COHORT||RETROSPECTIVE|||||||
33873353|NCT02267694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873354|NCT03295162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873355|NCT00177775|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33873356|NCT04227509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873357|NCT01664559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873358|NCT06496282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33873359|NCT01173224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873360|NCT00823823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873361|NCT03527121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873362|NCT04995055|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33873363|NCT03479996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967166|NCT04188223|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Double blind.|This Study is sequential age de-escalation. To be conducted in heathy adults (18-40 years old) and followed by children (10-17 years old) )|t|f|t|f
33967167|NCT05050513|||CASE_CONTROL||RETROSPECTIVE|||||||
33967168|NCT01040013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967169|NCT05837559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967170|NCT04298125|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33967171|NCT02391883|||CASE_CONTROL||RETROSPECTIVE|||||||
33967172|NCT06306027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33967173|NCT01993420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33967174|NCT00442585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967175|NCT06481826|||COHORT||PROSPECTIVE|||||||
33967176|NCT02609737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967177|NCT04313283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967178|NCT04692220|||COHORT||RETROSPECTIVE|||||||
33967179|NCT00879515|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33967180|NCT05373433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967181|NCT05792410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open, multicenter, dose-finding and dose expansion investigational Phase IB/II clinical trial||||
33967182|NCT05853510|||CASE_ONLY||RETROSPECTIVE|||||||
33967183|NCT05585619|||COHORT||PROSPECTIVE|||||||
33967184|NCT05271201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967185|NCT02360657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967186|NCT02278952|||COHORT||PROSPECTIVE|||||||
33967187|NCT02170129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33967188|NCT06168305|||CASE_ONLY||PROSPECTIVE|||||||
33967189|NCT00145756|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33967190|NCT03640000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067951|NCT00005872||||TREATMENT||||||||
33755938|NCT04749732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible participants will be randomly assigned to three groups in blocks of multiples of five and will be stratified according to i) age; and ii) mean walking distance at the baseline. This procedure will be performed using an online random number generator, by a researcher external to the team involved in the execution of this study, in order to ensure the concealment of the allocation of participants by the different groups. The participants will be blinded as to the group where they were allocated. After this procedure, it will not be possible to hide the group to which the patient belongs from the researcher who will carry out the psychological intervention and from the informatics engineer who will define the route of the walking plan. However, the outcome assessors (doctors, researchers, the clinical physiologist, and the exercise specialist) will be blinded to the allocation group.|This is a single-center three-arm parallel prospective, randomized controlled and superiority trial, with stratified random allocation, aiming to test the effectiveness of a Home-based Exercise Therapy (HbET) for claudicant patients to increase the Maximum Walking Distance (MWD), the Pain-free Walking Distance (PFWD) and the Functional Walking Distance (FWD). Patients will be assigned to one of three groups: an active control group (ACG); an experimental group 1 (GE1) and an experimental group 2 (EG2). All groups will have in common the prescription of a walking plan on a route defined by one of the team members through WalkingPAD web-platform and customized to the patient's home area. Participants from all three groups will undergo standard treatment for PAD and IC, according to the guidelines of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.|f|f|f|t
33755939|NCT03645759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|No other parties will be masked|Behavioral treatment intervention that focuses on enhancing stroke self-management, psychological distress and social functioning that will be provided to two groups (treatment and education plus usual care).|t|f|t|f
33755940|NCT04128644|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755941|NCT00558311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755942|NCT00136955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755943|NCT00099892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34193166|NCT03808259|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34193167|NCT03500445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193168|NCT03083990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193169|NCT04448028|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinding is reached through over-encapsulation of the IMP, as well as identical drug packaging in both study arms.|Study participants are randomized 1:1 to either discontinue their previous PPI therapy and replace it with placebo (intervention group) or continue pre-existing PPI therapy with esomeprazole 20mg/day. Details for the dose tapering phase are described below.|t|t|t|t
34193170|NCT01131013|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34193171|NCT04765085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193172|NCT01037764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755944|NCT05374226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755945|NCT06145243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33755946|NCT03949166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are 2 arms - fasting and eating||||
33755947|NCT04472286|||COHORT||PROSPECTIVE|||||||
33755948|NCT00746122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873364|NCT03489408|||CASE_ONLY||PROSPECTIVE|||||||
33755949|NCT01811212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873365|NCT01810185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873366|NCT02550184|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33873367|NCT01918007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33873368|NCT06248281|||CASE_CONTROL||PROSPECTIVE|||||||
33873369|NCT01549275|||CASE_ONLY||PROSPECTIVE|||||||
33873370|NCT04509375|||COHORT||PROSPECTIVE|||||||
33873371|NCT01589471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873372|NCT02012985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873373|NCT04012554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a randomized controlled trial.Partcipants,Care Provider, and Investigator all know the grouping situation.The Investigator collect the information and observation indicators of the two groups of participant and send the outcomes.|This is a randomized controlled trial.The main study content is the feasibility and safety of avoiding chest tube placement after VATS of the lung,participants were divided into experimental group and control group.Avoiding chest tube placement after VATS of the lung in the experimental group.Indwelling thoracic drainage tube after VATS of the lung in the control group.|f|f|f|t
34193173|NCT01710137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873374|NCT02971462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967191|NCT03586830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967192|NCT00931567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967193|NCT01712230|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34067952|NCT04627948|||COHORT||PROSPECTIVE|||||||
34193174|NCT03946696|||COHORT||PROSPECTIVE|||||||
34193175|NCT05751018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193176|NCT02523144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193177|NCT01331213|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34193178|NCT02817425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193179|NCT04170985|||COHORT||PROSPECTIVE|||||||
34193180|NCT00416039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873375|NCT04081636|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||"Randomized 1:1 to either trans-rectal needle biopsy (TR-Bx) or Trans-perineal biopsy (TP-Bx) of the prostate.~Both arms, either with or without MRI guided biopsy"|f|f|t|t
33873376|NCT00089362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873377|NCT02642445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873378|NCT05195294|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33873379|NCT04507555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193181|NCT03873090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873380|NCT01727674|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34067953|NCT05938322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34067954|NCT01796275|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193182|NCT01499706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193183|NCT03369080|||COHORT||PROSPECTIVE|||||||
34193184|NCT03033550|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34193185|NCT04408222|||COHORT||RETROSPECTIVE|||||||
34193186|NCT02603731|||COHORT||RETROSPECTIVE|||||||
34193187|NCT02972567|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34193188|NCT00754637|||COHORT||PROSPECTIVE|||||||
34067955|NCT03446209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and patient will be masked. There' ll be one qualified person in each center who s not going to be masked to prepare study treatment|Multi-center, phase II, randomized, placebo-controlled, double blind proof of concept trial|t|f|t|f
34193189|NCT05984550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193190|NCT02713074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34067956|NCT03290183|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193191|NCT03785223|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34193192|NCT03162367|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067957|NCT02985021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193193|NCT04093024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193194|NCT06391632|||COHORT||PROSPECTIVE|||||||
34193195|NCT06531785|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193196|NCT02183740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193197|NCT01208753|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34193198|NCT00603694|||CASE_CONTROL||PROSPECTIVE|||||||
34193199|NCT01639729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34193200|NCT01504906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34193201|NCT02234518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34193202|NCT00207064|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34193203|NCT02078856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193204|NCT01609829|||COHORT|||||||||
34193205|NCT04468997|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34193206|NCT00835211|RANDOMIZED|CROSSOVER||||NONE||||||
34067958|NCT00983541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067959|NCT02624154|||CASE_ONLY||RETROSPECTIVE|||||||
34193207|NCT05798000|||COHORT||PROSPECTIVE|||||||
34193208|NCT05149521|||CASE_ONLY||PROSPECTIVE|||||||
33873381|NCT05088486|||OTHER||PROSPECTIVE|||||||
33873382|NCT02886143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873383|NCT00494611|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873384|NCT03672019|||COHORT||PROSPECTIVE|||||||
33873385|NCT00005832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873386|NCT05079945|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193209|NCT05371808|||COHORT||PROSPECTIVE|||||||
34193210|NCT06349889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193211|NCT00970619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193212|NCT01836978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34193213|NCT02687191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193214|NCT06131099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment.|Its a randomized control trail, used to compare the effects of Dohsa hou exercises on functional mobility in children with Down syndrome. Subjects with Down syndrome meeting the predetermined inclusion and exclusion criteria will be divided into two groups using simple random sampling technique.|t|f|f|f
34193215|NCT03869463|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34193216|NCT02914002|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193217|NCT01497054|||COHORT||PROSPECTIVE|||||||
34193218|NCT04363788|||COHORT||PROSPECTIVE|||||||
34193219|NCT04321135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to either a guided or self-guided lifestyle intervention||||
34193220|NCT02851355|||COHORT||RETROSPECTIVE|||||||
34193221|NCT00549068|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193222|NCT00171522|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193223|NCT03112083|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||two parallel groups (placebo and Krill oil), intervention trial (56 days)|t|t|t|t
34193224|NCT01028300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193225|NCT04709627|||OTHER||PROSPECTIVE|||||||
34193226|NCT03758300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34193227|NCT04270240|||COHORT||PROSPECTIVE|||||||
34193228|NCT01804738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34193229|NCT04204551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193230|NCT02942732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193231|NCT00961909||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193232|NCT00381576|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34193233|NCT05790278|||COHORT||PROSPECTIVE|||||||
34193234|NCT05148195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755950|NCT01919203|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33873387|NCT00579371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873388|NCT00793637|||CASE_ONLY||PROSPECTIVE|||||||
33873389|NCT03711578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873390|NCT05374252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873391|NCT01372384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967194|NCT01222871|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients will be randomized into 2 study groups, experimental and control.||||
33967195|NCT04411719|||COHORT||PROSPECTIVE|||||||
33967196|NCT00179452|NA|SINGLE_GROUP||OTHER||NONE||||||
33967197|NCT02361190|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33967198|NCT01691365|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33967199|NCT01110499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967200|NCT04493268|||COHORT||PROSPECTIVE|||||||
33967201|NCT00557973|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33967202|NCT06344702|||COHORT||PROSPECTIVE|||||||
33967203|NCT02726217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33967204|NCT02784717|||CASE_ONLY||PROSPECTIVE|||||||
33967205|NCT02604069|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967206|NCT00229450|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33967207|NCT04356573|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Biological samples were coded and code list password protected until all data was analyzed.|Subjects crossed over between ingesting 2 different types of kiwifruit for 2 weeks prior to each stable isotope metabolic study.|t|t|t|t
33967208|NCT00478361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967209|NCT04978285|||COHORT||RETROSPECTIVE|||||||
33967210|NCT02598193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967211|NCT03175783|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33967212|NCT02685761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33967213|NCT03229993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967214|NCT02457728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967215|NCT04793503|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|the patient doesn't recognise the type of complete denture that he use|To reduce the effect of order of treatment on MBF, were successively given the following prosthesis i) complete dentures fabricated by the conventional technique ii) 3D printed complete dentures iii) milled complete dentures in a random order.|t|f|f|f
33967216|NCT05952427|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873392|NCT04966377|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
33967217|NCT05599906|||COHORT||PROSPECTIVE|||||||
33967218|NCT00693784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967219|NCT00971204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967220|NCT02799316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967221|NCT00139386|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967222|NCT04336267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Transcranial direct current stimulation (tDCS) was delivered by a technician that was not otherwise involved in the management of patients. The managing physician and the patient were instead blind to the type of stimulation.|Pilot randomized sham-controlled trial|t|t|f|f
33967223|NCT01866683|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33967224|NCT05934279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The participants will be randomized to one of 2 groups: RT and control (no exercise). The participants' muscle strength under dynamic condition, balance (especially fall risk), body composition and quality of life will be assessed pre- and post-intervention.|t|f|f|f
33967225|NCT03180983|RANDOMIZED|PARALLEL||OTHER||NONE||CLUSTER RANDOMIZED STUDY||||
33967226|NCT03401645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967227|NCT01967888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967228|NCT00876733|||COHORT||PROSPECTIVE|||||||
33967229|NCT00802750|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33967230|NCT04339088|||COHORT||PROSPECTIVE|||||||
33967231|NCT05664750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized and receive a single intramuscular injection (IM) gluteal injection of TNM002 or human tetanus immunoglobulin (HTIG).|t|f|t|f
33967232|NCT00038129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967233|NCT01401478|||||PROSPECTIVE|||||||
33967234|NCT02464878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967235|NCT03057288|NA|SINGLE_GROUP||OTHER||NONE||Prospective study with one single group of 40 patients||||
33873393|NCT02230059|||COHORT||RETROSPECTIVE|||||||
33873394|NCT03321136|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33873395|NCT00492752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873396|NCT05326945|RANDOMIZED|PARALLEL||PREVENTION||NONE||an experimental clinical study||||
34193235|NCT05090774|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34193236|NCT02237222|||CASE_ONLY||PROSPECTIVE|||||||
34193237|NCT02658071|||CASE_ONLY||PROSPECTIVE|||||||
34067960|NCT00202891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193238|NCT06225479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This will be a 2-arm, partially-blinded, attention-controlled RCT. The randomization scheme will be computer-generated by the study statistician without participant contact. Participants will be randomized 1:1 in randomly permuted block sizes (2 or 4) to the exercise intervention or health education control arm stratified by recruitment site and any BPH medication use (yes/no). The randomization scheme is uploaded to University of California San Francisco (UCSF) REDCap and the study coordinator will randomize participants in UCSF REDCap. Assessors (for urinary and physical function testing), data analysts, and investigators will remain blinded to participants' randomization arm.~Primary outcomes will be collected using self-administered questionnaires without risk of unblinding. Intervention status and any variables related to intervention status will be recorded and stored in a separate database by unblinded Clinical Research Coordinator (CRC)."|Single-center 2-arm pilot randomized control trial (RCT) of a 12-week remote exercise intervention and a health education control among 68 physically inactive older men with LUTS/BPH.|f|f|t|t
34193239|NCT00834080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193240|NCT05089786|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-arm, non-randomized, feasibility trial with no control group seeks to evaluate the safety and efficacy of using the Exablate 4000 Type 1 or 1.1 System with Echo-focusing in patients with Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Essential Tremor (ET), Post Traumatic Stress Disorder (PTSD), anorexia nervosa (AN).||||
33873397|NCT00492167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873398|NCT03992508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873399|NCT00035022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873400|NCT00766532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873401|NCT01867281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33873402|NCT01238016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873403|NCT03861754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873404|NCT04905121|NA|SINGLE_GROUP||TREATMENT||NONE||An exploratory open-label phase 1b, ascending dose study||||
33873405|NCT03923426|||CASE_ONLY||RETROSPECTIVE|||||||
33873406|NCT03930654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be assigned to either an intervention or usual care||t|f|f|f
33873407|NCT00894556|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34067961|NCT04350164|||COHORT||RETROSPECTIVE|||||||
33967236|NCT05238506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The drug or placebo(normal saline) will be placed in a syringe by the principal investigator. Only principal investigator will be aware of the participants allocation. The principal investigator will not be involved in the process of: recruitment, providing an intervention, or outcomes assessment.||t|t|t|t
33967237|NCT03703739|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33967238|NCT01783769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967239|NCT06381726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients immediately candidate for resection will be assessed neurologically, neuropsychologically and by functional MRI. Extent of resection will be assessed on \<48hrs and 2-month MRI. Neurological and neuropsychological assessment will be performed during regular follow-up. Patients not requiring an adjuvant treatment according to tumor board meeting will be submitted to functional MRI at 4-8 and 12 months from surgery. Patients not immediately eligible for resection will be submitted to biopsy for histomolecular definition. Patients not requiring radiation therapy will be submitted to neurological, neuropsychological, and functional MRI evaluation. Upon clinical context, patients will undergo motor rehabilitation and/or chemotherapy. After 3-6 months, patients will undergo functional MRI and evaluated for surgery. Neurological and neuropsychological evaluation will be performed at treatment initiation, every month during treatment, at admission for surgery and 1 month after surgery.||||
34193241|NCT00423202|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34193242|NCT00474305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193243|NCT04407949|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Every enrolled patient underwent a CPAP - Titration under PSG with predefined pressure steps. Afterwards breathing events are scored manually based on AASM Criteria by a trained study member. The events will be compared with the readout from the CPAP Device.||||
34193244|NCT01760642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193245|NCT02121613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193246|NCT02993172|||COHORT||PROSPECTIVE|||||||
34193247|NCT05881070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193248|NCT02917564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193249|NCT06337019|||COHORT||PROSPECTIVE|||||||
34193250|NCT00490529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193251|NCT02401425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193252|NCT05842356|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants (parents) will not know which communication technique group they are in until after their participation.||t|f|f|f
34193253|NCT00012597|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193254|NCT05167006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34193255|NCT04119830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193256|NCT05202340|||COHORT||CROSS_SECTIONAL|||||||
33873408|NCT04511247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible subjects will be randomised via a secure online system to a labelled device and to receive either Magic Touch sirolimus drug coated balloon in addition to standard balloon angioplasty or standard balloon angioplasty and placebo balloon.|t|t|t|t
33873409|NCT00782951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873410|NCT06012370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873411|NCT05140538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873412|NCT01834274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873413|NCT01708642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873414|NCT06252064|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873415|NCT00769184|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33873416|NCT02956603|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873417|NCT05158738|||CASE_ONLY||OTHER|||||||
33873418|NCT02381639|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873419|NCT00712699|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33873420|NCT05486559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, parallel-group, randomized pilot trial||||
33873421|NCT03943875|RANDOMIZED|PARALLEL||OTHER||SINGLE|Vials submitted for assay will be de-identified and labeled only with the study ID number.||f|f|f|t
33873422|NCT03888937|||COHORT||PROSPECTIVE|||||||
33873423|NCT01920880|||CASE_CONTROL||PROSPECTIVE|||||||
33873424|NCT06216639|||COHORT||PROSPECTIVE|||||||
33873425|NCT02541279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873426|NCT00356928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873427|NCT02681172|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33873428|NCT02404259|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33873429|NCT05137548|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33873430|NCT00982865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873431|NCT00554502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873432|NCT04594967|||COHORT||PROSPECTIVE|||||||
33873433|NCT01332357|||COHORT||RETROSPECTIVE|||||||
33873434|NCT05815407|||CASE_CONTROL||RETROSPECTIVE|||||||
33873435|NCT02124239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873436|NCT03910907|||COHORT||PROSPECTIVE|||||||
33873437|NCT02081534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873438|NCT05012956|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Group 1: pelvic organ prolapse patients~Group 2: patients assigned to gynecologic laparoscopic surgery, other than pelvic organ prolapse, at UZ Leuven."||||
33873439|NCT02807480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873440|NCT02829307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193257|NCT04375540|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study casts and cephalometric analysis were performed by different person (D. T.) who did not know to which group the patient belongs. Records were given numbers.|Group 1: upper first premolars extraction (24 patients) Group 2: upper second premolars extraction (26 patients) and Group 3: no orthodontic intervention was performed (happy with their teeth) (26 subjects).|f|f|f|t
33873441|NCT00518037|||OTHER||PROSPECTIVE|||||||
34193258|NCT03701035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193259|NCT02933450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873442|NCT00379652|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873443|NCT01675635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873444|NCT03724071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193260|NCT01155128|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193261|NCT05208970|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193262|NCT03745885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193263|NCT02736890|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34193264|NCT05460091|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Graduate student and PI were double-blinded|Pilot RCT. We had a test group and a control group|f|t|t|t
34193265|NCT00263185|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34193266|NCT04316832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation will be implemented using a random numbers generator, https://www.random.org/lists/. The allocation ratio will be 1:1.|This will be a two-arm, randomized controlled trial exploring whether a single-session of MBIs could improve task-related scores of attention, mood and CVC in children and adolescents with ADHD/ADD referred to a Romanian Child and Adolescent Psychiatric Unit. Outcomes assessment will be conducted at baseline, immediately after the session of training (T1) and 4 weeks after the intervention (T2)|t|t|t|t
34193267|NCT03137069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193268|NCT05998889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193269|NCT03223168|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34193270|NCT01944852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193271|NCT04799808|||COHORT||PROSPECTIVE|||||||
33755951|NCT02448251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755952|NCT04158011|||COHORT||RETROSPECTIVE|||||||
33873445|NCT05809414|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||All patients will receive all possible combinations (TMS+placebo, TMS+amantadine, TMS sham+amantadine, TMS sham+placebo), the only difference being the sequence in which they are administered.|t|f|t|t
33873446|NCT02031770|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873447|NCT04346589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873448|NCT05254184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873449|NCT04350775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873450|NCT02176473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873451|NCT02757599|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873452|NCT05230121|||CASE_ONLY||RETROSPECTIVE|||||||
33873453|NCT05347186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873454|NCT04116385|||COHORT||PROSPECTIVE|||||||
34193272|NCT02398006|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33873455|NCT05049096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The masking range includes participants, most researchers (including the study leader; subjects screening researchers; follow-up researchers; sonographers; MR scanners, members of the clinical endpoint identification committee,and etc.) except for the study statistical analysts and the therapy operators|This is a ramdomized, double-blinded, and sham-control study. The ratio of the intervention group versus sham-control group is 1:1|t|t|t|f
33873456|NCT03737058|||COHORT||RETROSPECTIVE|||||||
33873457|NCT00042887|RANDOMIZED|||TREATMENT||||||||
34193273|NCT04581707|||COHORT||OTHER|||||||
34193274|NCT06523829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants were not informed of which group they were in when they agreed to participate in the study. Similarly, caregivers and hospital staff were not informed about the groups. Only the researcher knew which group the participants were in.|This study was conducted as a randomized controlled trial.|t|t|f|f
34193275|NCT00460291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193276|NCT04816968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193277|NCT05783557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193278|NCT05805618|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Parallel Assignment|t|t|t|t
34193279|NCT03479333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193280|NCT03535246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193281|NCT05518318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193282|NCT04561726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The volunteers were numbered according to the order of their application. At the end of the applications, small papers were numbered from 1 to 40, and among these papers, the first 20 people selected by the lottery method were included in the study group, and the rest were included in the exercise group.|The sample size was calculated before starting to study by the G\*Power 3.1.9.2. In order to find a meaningful difference between the pre-treatment and post-treatment Biodex Balance System (BBS) measurements, study group should include at least 18 individuals when the type I error was 0.5 and 95% power value (1-β = 0.95). Considering the data loss that may occur during the study period, 20 volunteers were planned for each group (40 voluntary university students in total).|t|f|f|f
34193283|NCT03753789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193284|NCT04565743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled study. 40 clusters with an estimated cluster size of 90 participating individuals in each cluster.||||
34193285|NCT04276909|NA|SINGLE_GROUP||OTHER||NONE||||||
34193286|NCT05005104|||CASE_CONTROL||OTHER|||||||
34193287|NCT02922478|||COHORT||PROSPECTIVE|||||||
34193288|NCT02889367|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34193289|NCT01876004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193290|NCT02055638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193291|NCT06144099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193292|NCT02215980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873458|NCT00777101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873459|NCT03068442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a diagnostic-interventional cohort study in patients undergoing carotid endarterectomy for atherosclerotic disease.||||
33873460|NCT02149940|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33873461|NCT00961220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873462|NCT06365203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873463|NCT04893642|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Masking was done for outcome assessor concerning the answers for questionnaires that were the primary endpoint. Masking of arms were not done concerning recurrence of rectal prolapse.|This was a multicenter randomized trial with a 2 x 2 factorial design conducted in 13 sites in Sweden. Randomization was performed with randomly assigned envelopes, stratified for each participating center. Patients were randomized between perineal and abdominal approach (A). The perineal group was further randomized to Delorme's or Altemeier's procedure (B) and the abdominal group to suture rectopexy or resection rectopexy (C). Patients who were considered unsuitable for random allocation to a perineal or an abdominal procedure were included only in (B) or (C).|f|f|f|t
33873464|NCT02257372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873465|NCT02522702|||COHORT||PROSPECTIVE|||||||
33873466|NCT02534402|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873467|NCT04445571|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33873468|NCT04812132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873469|NCT02762162|||COHORT||PROSPECTIVE|||||||
33873470|NCT01245582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873471|NCT01263821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873472|NCT05500209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873473|NCT05973929|||CASE_ONLY||CROSS_SECTIONAL|||||||
33873474|NCT02662257|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33873475|NCT01157975|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873476|NCT05017207|||COHORT||PROSPECTIVE|||||||
33873477|NCT02641145|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873478|NCT03048903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients were randomly divided into two groups ,using rheum palmatum or placebo|t|t|t|t
33873479|NCT01565733|||COHORT||PROSPECTIVE|||||||
33873480|NCT01382992|||CASE_ONLY||RETROSPECTIVE|||||||
34193293|NCT03480724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome accessor will have no patient contact and will not have access to the information on the type of intervention study patients were given.|3 groups of patients One group with no VR One group with Oculus rift VR One group with google cardboard box VR|f|f|f|t
34193294|NCT04001530|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34193295|NCT00332735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34193296|NCT00644085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193297|NCT05827198|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"The products will be labelled with a code and participants will not be informed which test meal is which. However, since the portion sizes of some of the treatments differ, some information about them may be available to participants and study coordinators; that is why we have termed the study single blind. Single blinding will be achieved by identifying the treatments by code on the case report forms and in the database, so that those doing the statistical analysis and the study sponsor will be unaware of the treatment assignments."|In a 4-way cross-over, there is a set of 4 balanced sequences to which participants will be randomly assigned (ABCD, BADC, CDAB, DCBA). Blocks of 2, 3, or 4 sets of sequences were randomly ordered to create a balanced sequence for n=60 participants. Orders will be assigned to participants in the order they attended for the first visit after being recruited.|f|f|f|t
34193298|NCT05220475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193299|NCT04338061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193300|NCT00420043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193301|NCT00146848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193302|NCT03927378|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34193303|NCT05569590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (participant, Outcome assessor) It is double blinded study in which participant will be blinded. the assessor who will assess the post operative sensitivity of the participant will also be blinded regarding the intervention.|Subjects are randomly placed into one of the groups: Control, Propolis and Propolis mixed with bleaching agent. In Propolis group Propolis paste will be applied for 10 minutes. Post operative sensitivity will be assessed for 7 days by using visual analogue and Shiff's scale.|t|f|f|t
34193304|NCT04301310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193305|NCT01252732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193306|NCT05828537|||COHORT||PROSPECTIVE|||||||
34193307|NCT02873949|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34193308|NCT05573048|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34193309|NCT03730142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193310|NCT03564483|||COHORT||PROSPECTIVE|||||||
33755953|NCT02120027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193311|NCT02113254|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873481|NCT03858673|||COHORT||RETROSPECTIVE|||||||
34067962|NCT04394663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will not know the assigned treatment.|The patients with successful endoscopic hemostasis in peptic ulcer bleeding were equally randomized to either high-dose oral PPI or standard IV PPI for 3 days|f|f|f|t
34067963|NCT02904395|||||CROSS_SECTIONAL|||||||
34067964|NCT05919355|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There are no other parties.|"Intention-to-treat (ITT)"||||
34067965|NCT03428399|||COHORT||PROSPECTIVE|||||||
34193312|NCT01285011|||COHORT||PROSPECTIVE|||||||
34193313|NCT04424277|||CASE_ONLY||OTHER|||||||
34193314|NCT05152537|||COHORT||PROSPECTIVE|||||||
34193315|NCT06131164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193316|NCT01964755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193317|NCT02215811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193318|NCT05995067|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34193319|NCT05724706|||CASE_CONTROL||PROSPECTIVE|||||||
33873482|NCT00002753||||TREATMENT||||||||
34067966|NCT03276845|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33873483|NCT02701868|||COHORT||CROSS_SECTIONAL|||||||
33873484|NCT01901575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873485|NCT04481984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Randomized Controlled, Single-blind, Clinical Study|f|f|f|t
33873486|NCT02651168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873487|NCT04085679|||OTHER||PROSPECTIVE|||||||
33873488|NCT05120479|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The forearm that is being evaluated will be hidden by a medical curtain so that the participants do not know the tape application that is being carried out.||t|f|f|f
34193320|NCT02372227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873489|NCT02679898|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33873490|NCT02270619|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34067967|NCT01993641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067968|NCT00568568|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34067969|NCT05634642|||COHORT||CROSS_SECTIONAL|||||||
34067970|NCT02756364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067971|NCT04213833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and endoscopist||t|f|f|t
34067972|NCT04779710|||COHORT||CROSS_SECTIONAL|||||||
34067973|NCT00888290|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34067974|NCT03549065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34067975|NCT03167255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Low Dose cohort of 40 mg/kg and High Dose cohort of 80 mg/kg||||
34067976|NCT00201318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067977|NCT04652518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34067978|NCT01480817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193321|NCT03120351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34193322|NCT01379144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193323|NCT01870076|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34193324|NCT05755061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193325|NCT04491604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||An intra-subject parallel study. Primary wounds are randomized within each subject, such that one wound receives B-VEC and the other wound receives placebo. Secondary wounds are selected to receive B-VEC only.|t|t|t|t
34193326|NCT05312307|||OTHER||PROSPECTIVE|||||||
34193327|NCT02428478|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34193328|NCT04036370|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomised Controlled|t|f|f|f
34193329|NCT05873218|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34193330|NCT00409669|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34067979|NCT02783313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34067980|NCT04540731|||COHORT||PROSPECTIVE|||||||
34067981|NCT01002248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193331|NCT04911985|||COHORT||PROSPECTIVE|||||||
34193332|NCT04900532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34193333|NCT03890666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193334|NCT04022395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193335|NCT05722444|NA|SINGLE_GROUP||OTHER||NONE||||||
34193336|NCT04855084|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A non-randomized one-control group study|t|f|f|t
34193337|NCT04228159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized control trial. Older adults at moderate and high risk of falling will be recruited among Clalit patients referred to one of three physical therapy clinics, or other clinics nearby, neither by physician referral due to gait abnormality or following the physiotherapist diagnosis. Potential participants fulfilling the inclusion criteria and not meeting the exclusion criteria will sign informed consent and continue with baseline assessment. Those not wishing to participate will continue with routine care. Once the baseline assessment is completed, participants will be randomized into one of two intervention groups using computer random allocation software. Participants in both groups will attend physical therapy clinics twice a week for a total of 14 sessions. Each session will last 30 minutes. General information regarding fall prevention will be delivered to all participants using Clalit brochures and electronic prescriptions|f|f|f|t
34193338|NCT00177827|||CASE_ONLY||PROSPECTIVE|||||||
34193339|NCT03443583|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Only the participant does not know which treatment is used on which teeth. The care provider and investigator have to know because different treatment protocol steps that have to be taken.|A split mouth clinical trial comparing ceramic restorations cemented with either IDS or DDS after one year of three years of clinical service.|t|f|f|f
34193340|NCT02328378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193341|NCT01962324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193342|NCT04182802|||COHORT||PROSPECTIVE|||||||
34193343|NCT00156429|||COHORT||PROSPECTIVE|||||||
34193344|NCT04848857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193345|NCT04694924|||COHORT||PROSPECTIVE|||||||
34193346|NCT06244290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193347|NCT02149667|||COHORT||PROSPECTIVE|||||||
34067982|NCT01615159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34193348|NCT00863213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193349|NCT04285281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34193350|NCT01282463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193351|NCT04496570|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33873491|NCT01251653|||COHORT||PROSPECTIVE|||||||
33873492|NCT04933175|NA|SINGLE_GROUP||TREATMENT||NONE||Fluzopali combined with anlotinib for extensive stage small cell lung cancer after failure of first-line platinum-containing chemotherapy||||
33873493|NCT05349929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34193352|NCT03549832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873494|NCT01324258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873495|NCT03242421|||OTHER||PROSPECTIVE|||||||
33873496|NCT04233697|NA|SINGLE_GROUP||OTHER||NONE||||||
33873497|NCT03666832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873498|NCT06281860|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, non-randomised monocentric Phase I clinical trial study with cisplatin dose escalation administered by PITHAC.||||
33873499|NCT01342068|||CASE_CONTROL||RETROSPECTIVE|||||||
33873500|NCT01500278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873501|NCT05192135|||COHORT||RETROSPECTIVE|||||||
34193353|NCT03893695|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, Open label,Two stage study||||
34193354|NCT04291404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873502|NCT05818592|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Eligible participants will be randomized to either the intervention group or control group.||||
33873503|NCT06110507|||CASE_ONLY||RETROSPECTIVE|||||||
33873504|NCT06152445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33873505|NCT05791500|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873506|NCT03173833|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33873507|NCT03363321|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33873508|NCT06489444|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873509|NCT04940104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33873510|NCT02120014|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873511|NCT05894590|||COHORT||RETROSPECTIVE|||||||
33967240|NCT03317145|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Patients who have had a total hip replacement will be randomised to wear either a foot compression (IPC) device or a neuromuscular electrostimulation (NMES) device (gekoTM) first. Blood flow will be measured using both devices on the same patient in sequence. The blood flow measurements will be done by ultrasound. Each ultrasound assessment will take approximately 30 minutes in total. Baseline blood flow measurements will be taken initially. The first device will then be fitted and allowed to operate for 10 minutes before ultrasound measurements are taken. After a rest period of 30 minutes, the second device is then fitted and allowed to operate for 10 minutes, following which blood flow measurements are repeated. Patients will then be asked to complete a questionnaire to assess the comfort of each device.||||
33967241|NCT01286337|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967242|NCT06276179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967243|NCT01434706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967244|NCT03671265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067983|NCT03494049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067984|NCT03884270|NA|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized observational study designed||||
34193355|NCT02459288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193356|NCT00863811|||CASE_ONLY||PROSPECTIVE|||||||
34193357|NCT04065737|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34193358|NCT04404933|||OTHER||PROSPECTIVE|||||||
34193359|NCT01115322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34193360|NCT00119678|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34193361|NCT02935426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873512|NCT00856921|||CASE_ONLY||RETROSPECTIVE|||||||
33873513|NCT05428891|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants do not know which method will apply.|Randomized prospective|t|f|f|f
33873514|NCT00427076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873515|NCT06080828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873516|NCT03866135|||COHORT||CROSS_SECTIONAL|||||||
33873517|NCT05513248|||CASE_ONLY||RETROSPECTIVE|||||||
33764821|NCT05733962|NA|SINGLE_GROUP||TREATMENT||NONE||interventional single-arm open-label before/after multicentric national study||||
33764822|NCT01502995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873518|NCT01783080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193362|NCT05960721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193363|NCT00674596|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
33873519|NCT06059768|||OTHER||CROSS_SECTIONAL|||||||
34193364|NCT01743859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193365|NCT05212818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193366|NCT01256632|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34193367|NCT03838458|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873520|NCT05470127|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The two biopsy needle sets will be used in the same patient during the procedure.||||
34193368|NCT00618085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193369|NCT03541395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873521|NCT02514616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873522|NCT05348174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, care providers and investigators will be blinded. Randomization will be done via REDCap software|"This prospective, 2x2 randomized controlled trial will be conducted with participants from Prisma Health, a tertiary level health care center based in South Carolina, USA. We evaluate the effects of two two-level factors: Guided imagery and VR immersion and based on the presence and absence of these factors, the study will have 4 arms."|t|t|t|f
33764823|NCT05101135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193370|NCT03671317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants are randomized to either receive medical clowning intervention or no intervention. The total length of subject participation is the participant's one visit to the blood draw clinic. Data collection involves pre then post surveys to measure anxiety and pain levels for comparison.~After screening, consent, and randomization, the participants and legal guardians assigned to both arms will complete a survey. Once completed, the intervention arm is introduced to two medical clowns who accompany the participant through the blood draw process. The non intervention arm will continue with usual care. Audio recording begins when participants of both arms enter the blood draw room. Once the nurse leaves the room after venipuncture, all participants and legal guardians complete a second questionnaire.~At the conclusion of the study, the medical staff are asked to answer a questionnaire rated on the Likert Scale."||||
34193371|NCT05253261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193372|NCT01686997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193373|NCT02299102|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34193374|NCT04618796|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34193375|NCT04458480|||COHORT||PROSPECTIVE|||||||
34193376|NCT05815979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician who performs the analysis of the data will not know which group the students are in, so statistics will be blinded.||f|f|f|t
34193377|NCT04306484|||COHORT||RETROSPECTIVE|||||||
34193378|NCT05701319|||CASE_ONLY||PROSPECTIVE|||||||
34193379|NCT04289233|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193380|NCT00749047|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193381|NCT00375609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873523|NCT01995682|||||CROSS_SECTIONAL|||||||
33873524|NCT04535349|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33873525|NCT05873582|||CASE_ONLY||PROSPECTIVE|||||||
33873526|NCT01531309|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873527|NCT06466226|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is possible considering the intervention.|||||
33873528|NCT01505634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873529|NCT05113875|||CASE_ONLY||CROSS_SECTIONAL|||||||
33873530|NCT01897285|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
33873531|NCT04314921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873532|NCT01199042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873533|NCT00914927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873534|NCT02290899|||OTHER||OTHER|||||||
33873535|NCT04759976|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873536|NCT05073497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873537|NCT01748279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873538|NCT04066582|||CASE_ONLY||PROSPECTIVE|||||||
33873539|NCT00982085|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33873540|NCT02965521|RANDOMIZED|CROSSOVER||OTHER||NONE|Statistician who analyzes the data will be masked to intervention/control status.|||||
34067985|NCT02741115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067986|NCT00743847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067987|NCT01133496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34067988|NCT01181947|||COHORT||PROSPECTIVE|||||||
34193382|NCT04620876|NA|SINGLE_GROUP||OTHER||NONE||||||
33764824|NCT01583439|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764825|NCT02918500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764826|NCT03182140|||COHORT||PROSPECTIVE|||||||
34193383|NCT00047645|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34193384|NCT02727439|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34193385|NCT01523847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193386|NCT04114617|||COHORT||CROSS_SECTIONAL|||||||
34193387|NCT05140824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193388|NCT02090751|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34193389|NCT04966663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193390|NCT03093662|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34193391|NCT02173067|||||PROSPECTIVE|||||||
34193392|NCT00470834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764827|NCT01948180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873541|NCT03341962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873542|NCT00911352|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33873543|NCT05530265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873544|NCT03591250|||COHORT||PROSPECTIVE|||||||
33873545|NCT05530603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are unaware of which group they have been assigned to.|2 arms randomized clinical trial with control and intervention group|t|f|f|f
33873546|NCT02845570|NA|SINGLE_GROUP||OTHER||NONE||||||
33873547|NCT00650702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34067989|NCT02662270|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34193393|NCT00664001|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34193394|NCT00833664|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34193395|NCT02921334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193396|NCT04161326|||COHORT||PROSPECTIVE|||||||
34193397|NCT01529138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193398|NCT02395432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873548|NCT04788121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193399|NCT00323011|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34193400|NCT00000722||PARALLEL||TREATMENT||||||||
34193401|NCT04050202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193402|NCT00443963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34193403|NCT05952609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33873549|NCT04618159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||helipyl is given to patients with non symptomatic helicobacter pylori infection||||
33873550|NCT00075400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873551|NCT00542256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34067990|NCT03116724|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34067991|NCT05487820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|None (Open Label)|Prospective, interventional. Hundred-and-sixty (56) patients will receive tissue CO2 monitoring in a reconstructed flap after reconstructive flap surgery.||||
34193404|NCT00271713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193405|NCT05865041|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"Approximately 60 participants will be randomized in into one of two treatment sequences:~* Sequence one: Farudodstat 100mg twice daily for 12 weeks followed by placebo twice daily for 12 weeks~* Sequence two: Placebo twice daily for 12 weeks followed by farudodstat 100mg twice daily for 12 weeks"|t|t|t|t
34193406|NCT03718780|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34193407|NCT05883241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193408|NCT03956537|||COHORT||OTHER|||||||
34193409|NCT05901740|||OTHER||CROSS_SECTIONAL|||||||
33873552|NCT05432882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873553|NCT01250600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873554|NCT01610180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873555|NCT00821080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873556|NCT05775471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873557|NCT03284671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873558|NCT02263898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34067992|NCT03447964|||COHORT||CROSS_SECTIONAL|||||||
34067993|NCT06123793|||COHORT||PROSPECTIVE|||||||
34067994|NCT03436069|||COHORT||OTHER|||||||
34193410|NCT00388583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193411|NCT04028544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193412|NCT02989454|||CASE_ONLY||RETROSPECTIVE|||||||
34193413|NCT01658306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873559|NCT00377377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873560|NCT03615196|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33873561|NCT01278745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873562|NCT04458298|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33873563|NCT05412056|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873564|NCT00381342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193414|NCT02133703|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34067995|NCT04719195|||CASE_ONLY||PROSPECTIVE|||||||
34067996|NCT00312767|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193415|NCT03506230|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to the intervention group and the control group. The randomization will be in blocks of 6. In addition, the randomization will be in strata according to the level of HbA1c: 8.5% \<HbA1c\> 9.5%, 9.6%\> HbA1c\> 11%.||||
34193416|NCT00062803|RANDOMIZED|||TREATMENT||NONE||||||
34193417|NCT04325841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193418|NCT02535390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193419|NCT06349759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193420|NCT04175847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193421|NCT01573234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193422|NCT04600271|||COHORT||PROSPECTIVE|||||||
34193423|NCT00327067|||||PROSPECTIVE|||||||
34193424|NCT02654717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193425|NCT00924859|||CASE_ONLY||PROSPECTIVE|||||||
34193426|NCT04038216|||CASE_CONTROL||PROSPECTIVE|||||||
34193427|NCT02874144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193428|NCT03079960|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The main part of the proposed study has a duration of 2 years and will include up to 20 PD patients who are eligible to receive treatment with STN DBS. This is the interventional arm, this patient group is termed PG-O here onwards.~An extension phase of the study, starting in August 2019, will consider two additional groups of patients as controls for the PG-O patient group. Firstly, patients treated chronically with DBS, who underwent DBS implantation surgery months to years ago, termed PG-chronic. Secondly, patients scheduled for DBS implantation but who have not yet been implanted, termed PG-pre.~It is intended to recruit approx. n=50 patients into each control group, thus resulting in an overall study cohort size of approx. 20+50+50=120 patients."||||
34193429|NCT04650867|||COHORT||CROSS_SECTIONAL|||||||
34193430|NCT02238184|||COHORT||PROSPECTIVE|||||||
34193431|NCT00611403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193432|NCT06118788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193433|NCT05243693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193434|NCT01250145|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33873565|NCT00731575|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873566|NCT03007056|||COHORT||RETROSPECTIVE|||||||
33873567|NCT05020873|||COHORT||PROSPECTIVE|||||||
33873568|NCT01803984|||COHORT||CROSS_SECTIONAL|||||||
33873569|NCT01602770|||COHORT||PROSPECTIVE|||||||
33873570|NCT03799250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873571|NCT04670614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873572|NCT02676492|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873573|NCT00407524|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33873574|NCT01568398||||TREATMENT||||||||
33873575|NCT04398875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects randomly assigned to either ASC group or SSC group will be blinded to their group assignment||t|f|f|f
33873576|NCT06439212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873577|NCT04031742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 \[ Time Frame: Baseline and Week 12 \]||||
33873578|NCT00962572|||CASE_CONTROL||RETROSPECTIVE|||||||
33873579|NCT04413253|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33873580|NCT00433108|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33873581|NCT00947180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873582|NCT01411943|||COHORT||PROSPECTIVE|||||||
33873583|NCT04425187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873584|NCT00626691|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33873585|NCT02019576|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase II study, single arm study, open-label, safety and efficacy study||||
33873586|NCT01367535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873587|NCT01811875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873588|NCT00531752|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33873589|NCT02145286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873590|NCT05928195|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, placebo-controlled, double-blind, crossover study|t|t|t|t
33873591|NCT05617976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873592|NCT00530894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873593|NCT03010124|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873594|NCT01290380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873595|NCT01445821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873596|NCT03424785|||COHORT||RETROSPECTIVE|||||||
33873597|NCT02775396|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873598|NCT05069181|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33873599|NCT01497639|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33873600|NCT06412250|||OTHER||PROSPECTIVE|||||||
33873601|NCT02509806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34067997|NCT01498042|||COHORT||PROSPECTIVE|||||||
34067998|NCT04685356|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34067999|NCT01756248|||COHORT||PROSPECTIVE|||||||
34068000|NCT00073008|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068001|NCT01711008|RANDOMIZED|CROSSOVER||||NONE||||||
34068002|NCT02314312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068003|NCT02491580|||CASE_CONTROL||RETROSPECTIVE|||||||
34068004|NCT02727309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068005|NCT00943501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068006|NCT05987943|NA|SINGLE_GROUP||TREATMENT||NONE||patients||||
34068007|NCT05325723|||COHORT||PROSPECTIVE|||||||
34068008|NCT03293446|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967245|NCT01179282|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33967246|NCT02029261|||COHORT||PROSPECTIVE|||||||
33764828|NCT00876460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873602|NCT02734160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873603|NCT00485602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873604|NCT05464303|||CASE_CONTROL||RETROSPECTIVE|||||||
33873605|NCT01462435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873606|NCT03578471|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33873607|NCT01950000|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33873608|NCT05365542|||COHORT||PROSPECTIVE|||||||
33873609|NCT04031651|||COHORT||PROSPECTIVE|||||||
33967247|NCT02530632|RANDOMIZED|PARALLEL||||NONE||||||
33967248|NCT05620381|||CASE_ONLY||RETROSPECTIVE|||||||
33967249|NCT05037682|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Dissemination and Implementation Research (D\&I): Involves assisting primary care practices to address pain and opioid management in older adults. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.||||
34193435|NCT06193551|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial with a single arm of patients undergoing elective repair of paraesphageal hiatal hernia repair or large hiatal henia repair with implant of Ovitex-LPR.||||
34193436|NCT06258616|||COHORT||PROSPECTIVE|||||||
34193437|NCT06356480|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34193438|NCT05857475|RANDOMIZED|PARALLEL||TREATMENT||NONE||To compare pulmonary function of COPD-OSA overlap subjects who using and not using (waiting list for PAP therapy) in the period of 2 months.||||
34193439|NCT01852396|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34193440|NCT05068882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physician is unaware of the type of the intervention. The type of intervention is given by the independent person to dietitian instructing the patient how to use the product.|4 arm randomized study|f|f|t|t
34193441|NCT02129504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193442|NCT04291170|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34193443|NCT03567343|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34193444|NCT01981551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193445|NCT02807675|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34193446|NCT02079272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193447|NCT01917253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193448|NCT02547363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193449|NCT01112306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193450|NCT02433275|||CASE_CONTROL||PROSPECTIVE|||||||
34193451|NCT05972057|||COHORT||PROSPECTIVE|||||||
34193452|NCT00870376|||COHORT||PROSPECTIVE|||||||
34193453|NCT02460601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193454|NCT02669485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193455|NCT06111118|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects who are qualified to enter the investigation will be randomized in a 2:2:1 ratio to one of the following 3 treatment groups, respectively:~* Group 1: Immediate ThermaCare HeatWraps application (approximately 40 subjects)~* Group 2: Delayed ThermaCare HeatWraps application (starting 24 hours after exercise; approximately 40 subjects)~* Group 3: No treatment (approximately 20 subjects)"||||
34193456|NCT05147233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193457|NCT03968133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, triple-blind, placebo-controlled study|t|t|t|t
34193458|NCT06123234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|different batch code assigned to products, same labeling|Randomized double blind verum vs placebo|t|t|t|t
34193459|NCT01451437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193460|NCT04952155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193461|NCT00219895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193462|NCT02200809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193463|NCT00178776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193464|NCT02871037|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33764829|NCT06439823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873610|NCT05677555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873611|NCT05872750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||theta burst stimulation|t|t|f|t
33873612|NCT03328650|||COHORT||PROSPECTIVE|||||||
33873613|NCT03865173|||COHORT||PROSPECTIVE|||||||
33873614|NCT03308838|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873615|NCT03255707|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients of the study will be recruited from the ophthalmology outpatient clinic of Ain Shams University Hospital.100 patients of both sexes with amblyopia will be enrolled. Informed consents will be obtained from adult patients and children's parents.~Patients will be assigned randomly:~Group A:50 patients will receive the gold standard occlusion therapy while playing a video game (Lazy Eye Tetris games such as Lazy Eye Blocks ®).Group B:50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Tetris games such as Lazy Eye Blocks ®) while wearing a red/green goggle.Each group will be subdivided according to age:~1)4 to 7 years. 2)\>7 to 12 years. 3)\>12 to 30 years.~Hours of occlusion /dichoptic treatment will be classified according to the degree of amblyopia:~* Mild to moderate amblyopia (Best corrected visual acuity (BCVA)\< 0.2) : 2-4 hours~* Severe (BCVA\> 0.2) : 4-6 hours~All patients will undergo full ophthalmological examination"||||
33873616|NCT00003535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873617|NCT02758340|RANDOMIZED|PARALLEL||||NONE||||||
33873618|NCT06320587|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33873619|NCT02838498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873620|NCT04554160|||COHORT||PROSPECTIVE|||||||
33873621|NCT02289950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967250|NCT03163095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research members in the laboratory will be blinded with participants' clinical data.|Randomization by blocks on a website.|f|f|f|t
33967251|NCT04257240|||COHORT||RETROSPECTIVE|||||||
34193465|NCT04459208|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigator-initiated, single-center, prospective, open-label randomized controlled trial||||
33873622|NCT01053390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193466|NCT00742833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193467|NCT03642132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193468|NCT01629225|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34193469|NCT00644007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193470|NCT03614208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind RCT with two parallel group|f|f|t|f
34193471|NCT02809222|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34193472|NCT01258322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193473|NCT00651248|||COHORT|||||||||
34193474|NCT02559492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193475|NCT00918931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193476|NCT04136847|NA|SINGLE_GROUP||TREATMENT||NONE||At least twenty three (23) qualified and consenting subjects treated with 4 Skinpen microneedling treatments.||||
34193477|NCT04152564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193478|NCT02215941|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34193479|NCT02899572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193480|NCT06092918|||COHORT||PROSPECTIVE|||||||
34193481|NCT04188444|||CASE_CONTROL||PROSPECTIVE|||||||
34193482|NCT06248580|||OTHER||PROSPECTIVE|||||||
34193483|NCT04193618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193484|NCT00230555|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34193485|NCT00097656|NA|SINGLE_GROUP||TREATMENT||SINGLE||||||
34193486|NCT00832624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193487|NCT06357676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193488|NCT04327193|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34193489|NCT04494568|NA|SINGLE_GROUP||TREATMENT||NONE||INTERVENTIONAL, PROSPECTIVE, MULTICENTRIC, NON-RANDOMIZED AND NON-CONROLLED STUDY||||
34193490|NCT05547009|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor was blinded to the participants interventions.|An assessor-blinded two-armed randomized trial|f|f|f|t
34193491|NCT02575547|||CASE_ONLY||PROSPECTIVE|||||||
34193492|NCT06427434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193493|NCT05282953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193494|NCT00575393||||TREATMENT||||||||
34193495|NCT00451503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193496|NCT02194985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193497|NCT02471326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193498|NCT01137201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193499|NCT00973817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193500|NCT01700387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193501|NCT06092814|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The proposed study is a within-subject, double-blind \& sham-controlled|t|t|t|f
34193502|NCT04007354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193503|NCT00975897|RANDOMIZED|||DIAGNOSTIC||NONE||||||
34193504|NCT01158170|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193505|NCT03050229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193506|NCT05484544|||COHORT||PROSPECTIVE|||||||
34193507|NCT00257257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193508|NCT01411735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873623|NCT04162574|||CASE_ONLY||PROSPECTIVE|||||||
34193509|NCT01765010|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34193510|NCT00741845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193511|NCT01217333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873624|NCT05909982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193512|NCT03241030|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34193513|NCT03801031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34193514|NCT02936531|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193515|NCT02368561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193516|NCT00197548|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34193517|NCT05419193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|f|f|f|t
34193518|NCT01788215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193519|NCT01307644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34193520|NCT03000439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193521|NCT01627730|NON_RANDOMIZED|PARALLEL||||NONE||||||
34193522|NCT04124679|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34193523|NCT04951661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193524|NCT02925338|||COHORT||PROSPECTIVE|||||||
34193525|NCT01588470|NA|SINGLE_GROUP||TREATMENT||NONE||"this study includes single arm intervention with pioglitazone. T2DM individuals will be studied at baseline and after 6 months treatment.~as a reference group, healthy subjects will be studied in cross sectional fashion. Because healthy subjects will not be treated nor restudied at 6 months, they can not be considered a separate arm in the study but rather a reference group"||||
34193526|NCT03236155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873625|NCT06011148|||COHORT||OTHER|||||||
34193527|NCT03828071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193528|NCT00002069||||TREATMENT||||||||
34193529|NCT02113137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34193530|NCT00744042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193531|NCT03159260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Product has come in identical bottles from manufacturer. Both the investigators and statistician will remind blind until the conclusion of the study.||t|t|t|t
33873626|NCT04777487|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of GCF were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20).||||
33873627|NCT06024642|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33873628|NCT00715832|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193532|NCT05711082|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|double dummy, placebo-controlled|MORDOR study will use a randomized, double dummy, placebo-controlled, three-arm crossover design.|t|f|f|f
34193533|NCT05515185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193534|NCT05909488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193535|NCT00437008|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34193536|NCT03903315|||COHORT||RETROSPECTIVE|||||||
34193537|NCT03838471|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193538|NCT05499299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34193539|NCT03779490|||COHORT||PROSPECTIVE|||||||
34193540|NCT05693012|||CASE_CONTROL||PROSPECTIVE|||||||
34193541|NCT05646524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||12 (18) patients will be divided into two cohorts of 6 (9) patients each. Patients will be dosed in parallel with either a 20 mg/kg NM8074 dose every two weeks for the entire duration of the treatment period or with an initial dose of 10 mg/kg NM8074 weekly for the first four weeks followed by the 20 mg/kg dose for the remainder of the treatment period.||||
34193542|NCT02891070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34193543|NCT04453553|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking will be used as the study arms have different testing patterns|randomised cluster trial of care homes||||
34193544|NCT02894697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193545|NCT04707482|||COHORT||PROSPECTIVE|||||||
34193546|NCT03542396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193547|NCT04502940|||CASE_CONTROL||PROSPECTIVE|||||||
34193548|NCT02298439|||COHORT||PROSPECTIVE|||||||
34193549|NCT04825730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193550|NCT01311167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193551|NCT02796417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193552|NCT02766140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193553|NCT02990624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193554|NCT00921167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193555|NCT02549599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34193556|NCT05739084|||COHORT||OTHER|||||||
34193557|NCT00301184|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34193558|NCT02730780|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34193559|NCT02778113|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34193560|NCT04760743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34193561|NCT01764919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873629|NCT05827939|||COHORT||PROSPECTIVE|||||||
33873630|NCT02846532|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873631|NCT05121480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Cohorts 1, 2 \& 3 will be run concurrently, and Cohort 4 recruitment will commence after enrollment for Cohorts 1, 2, \& 3 are completed. Randomization to Cohort 4 will not start before randomization to Cohorts 1, 2 \& 3 have completed.|t|t|t|t
33873632|NCT02350907|||OTHER||CROSS_SECTIONAL|||||||
33873633|NCT06268743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel group, single blinded, randomized trial|f|f|t|f
33873634|NCT01651715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873635|NCT00453726|||COHORT||PROSPECTIVE|||||||
33873636|NCT00718276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873637|NCT03344744|||CASE_CONTROL||PROSPECTIVE|||||||
33873638|NCT00258336||||TREATMENT||NONE||||||
33873639|NCT00336453|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34193562|NCT00658164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193563|NCT00544700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193564|NCT06138860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|strain counter strain technique and physical therapy exercises|f|f|t|t
34193565|NCT01502215|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34193566|NCT01155011|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34193567|NCT03799302|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34193568|NCT05194579|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34193569|NCT03975244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193570|NCT06409156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participant and Outcomes Assessor will be blinded to the patient's allocation.|Single center randomized control trial|t|f|f|t
34193571|NCT02999438|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873640|NCT05671432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193572|NCT02957214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193573|NCT02884505|||OTHER||PROSPECTIVE|||||||
34193574|NCT03347370|||COHORT||PROSPECTIVE|||||||
34193575|NCT04530760|||COHORT||PROSPECTIVE|||||||
34193576|NCT05511077|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34193577|NCT02161900|RANDOMIZED|PARALLEL||TREATMENT||NONE||Yogic exercises are being evaluated for better supportive care over standard exercises for the breast cancer patients under treatment||||
33873641|NCT00236808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33873642|NCT02244216|||COHORT||PROSPECTIVE|||||||
33873643|NCT02854423|||CASE_CONTROL||RETROSPECTIVE|||||||
33873644|NCT02109900|||CASE_CONTROL||PROSPECTIVE|||||||
33873645|NCT04451421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873646|NCT06082700|||COHORT||CROSS_SECTIONAL|||||||
33873647|NCT00358865|||||PROSPECTIVE|||||||
33873648|NCT03051360|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, Double blind, Multi-center, Randomized clinical trial|t|t|t|t
34068009|NCT03162328|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are randomized to two different therapies: Sham or Stimulation. Sites are masked as they are randomized to: Therapy A or Therapy B|randomized, double-blind, placebo-controlled cross-over study|t|f|t|f
33873649|NCT00675922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873650|NCT03669458|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||A minimum of 10 patients will be enrolled for treatment of BTK disease||||
33873651|NCT01783275|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33873652|NCT06076421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Cluster randomised cross-sectional controlled trial with a 2x2-design with the between-subjects factors: format (usual care plus evidence-based fact box vs. usual care), health educator (cluster unit medical practice vs. cluster unit outreach work settings) taking into account various factors of disadvantage (e.g., low education).|t|t|t|f
33873653|NCT04512040|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are assigned a treatment group for the duration of the study||||
33873654|NCT02411539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873655|NCT01576549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873656|NCT03319875|||OTHER||RETROSPECTIVE|||||||
33873657|NCT05497596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068010|NCT00714155|||COHORT|||||||||
34068011|NCT00240656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068012|NCT02278705|||CASE_CONTROL||RETROSPECTIVE|||||||
34068013|NCT03947502|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre (5 nodes) randomized clinical trial, Pain neuro education based on 6 weekly classes of 2 hours for patients affected by fibromyalgia, taught by a multidisciplinary group. Controlled with usual therapies treated group.||||
34068014|NCT04888858|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The force of the maternal push when performing Valsalva maneuver will be compared before and after administration of epidural analgesia.||||
34068015|NCT00845676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068016|NCT06006637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and their caregivers will be held blind to group assignment. The PI will also remain blind to participant group assignment and conduct the pre- and post-assessment batteries (i.e., CARS-2, SRS, and CGI-I). Two clinical research assistants and co-investigator, will randomly assign participants to groups and have knowledge of their assignment. A third research assistant will also be held blind to group assignment and complete weekly interviews with caregivers.|This is a Randomized, Sham-controlled, Double Blind, Mixed-Design study|t|t|t|t
34068017|NCT01362023|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068018|NCT00600314|||COHORT||PROSPECTIVE|||||||
34068019|NCT01753414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068020|NCT03541447|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34068021|NCT00707642|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34068022|NCT05574829|||COHORT||PROSPECTIVE|||||||
34068023|NCT03016468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068024|NCT06454643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34068025|NCT02698709|||CASE_CONTROL||RETROSPECTIVE|||||||
34068026|NCT02488967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068027|NCT04202536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068028|NCT00419159|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068029|NCT05508880|||COHORT||OTHER|||||||
34068030|NCT02710552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068031|NCT04649970|||CASE_CONTROL||RETROSPECTIVE|||||||
34068032|NCT01198535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068033|NCT02102672|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34068034|NCT06468163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068035|NCT01742715|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068036|NCT02202889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068037|NCT00729300|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34068038|NCT04013152|||OTHER||PROSPECTIVE|||||||
34068039|NCT03040349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068040|NCT03573570|RANDOMIZED|PARALLEL||TREATMENT||NONE||This project (implementation and accompanying evaluation) will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12 months apart in the same individuals. In the interim, 110 Treatment Fair Price Shops (FPS) will be assigned randomly to receive rice fortified with iron and other micronutrients, and another 110 Control FPS will be assigned randomly to conventional Public Distribution System (PDS) rice. The control arm therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.||||
34068041|NCT03369873|RANDOMIZED|PARALLEL||OTHER||SINGLE|The profissional that evaluated the patients, was not informed if the patients were of the control or intervention group. The outcomes assessor was not informed if the group 1 and 2 was control or intervention group.|The patients were randomized to one of two groups (control or intervention), according to the sequence determined by the Random System|f|f|f|t
34068042|NCT03470623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068043|NCT04125225|||OTHER||PROSPECTIVE|||||||
34068044|NCT05683951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068045|NCT00621517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068046|NCT00012389|RANDOMIZED|||TREATMENT||NONE||||||
34068047|NCT03983434|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068048|NCT05249621|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34068049|NCT02446847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068050|NCT00755261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068051|NCT00191802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068052|NCT01125085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193578|NCT05025319|||COHORT||RETROSPECTIVE|||||||
34193579|NCT02620527|||OTHER||OTHER|||||||
34193580|NCT03079102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Gas canisters will be marked with a bar code which will be recorded by the study coordinator and available to the study team. Only the respiratory therapy directors will be aware of the canister content (placebo vs. active drug). Treatment assignment will be revealed upon opening a sealed opaque envelope after enrollment has been confirmed.|Subjects will be randomized 1:1 to either placebo or active study drug (iNO). This will be stratified within blocks of 8 subjects at each center.|t|t|t|t
33755954|NCT06472401|RANDOMIZED|PARALLEL||OTHER||DOUBLE|This study will adopt a double-blind approach. The exchange of information between the students who will compose the Experimental and Control groups is already expected, that is, the contamination effect, which causes a tendency to underestimate the true effect of the intervention. In this sense, throughout the duration of the simulated scenarios, a flow will be established in which each group (intervention and control) of students will be kept in different environments, to guarantee confinement, a condition that will prevent contact between the different groups. The main researcher will be blinded, that is, he will not have knowledge about the distribution of groups (randomization) and who will receive the Integrated Learning Support System (ILSS). The statistician responsible for data analysis will also be blinded, as he will receive and analyze coded data, without knowing the identity of the participants and the intervention allocated to each one.||f|f|t|t
34193581|NCT03572205|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33755955|NCT06268158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33755956|NCT01977300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755957|NCT05307380|||COHORT||PROSPECTIVE|||||||
33755958|NCT04573621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessor will not know whether the patient received a drain or not||f|f|f|t
34068053|NCT00104793||||TREATMENT||NONE||||||
33755959|NCT02038894|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33755960|NCT01143688|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755961|NCT03715205|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755962|NCT01722942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873658|NCT05931887|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33873659|NCT03496220|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Clustered randomized cross over trial||||
33873660|NCT02300701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873661|NCT02055820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873662|NCT06494670|||OTHER||CROSS_SECTIONAL|||||||
33873663|NCT02037295|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33873664|NCT04141384|RANDOMIZED|PARALLEL||OTHER||NONE||"Stage 1-NO intervention~Stage 2-To explore the possibility of enhancing the balance of stroke patients by stimulating the modular robotic brick system.~Control group-General rehabilitation Study group-General rehabilitation+Modular Interactive Tiles System(MITS)"||||
33873665|NCT03915015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068054|NCT01810744|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193582|NCT03395236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193583|NCT04371588|||CASE_CONTROL||PROSPECTIVE|||||||
34193584|NCT00856414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193585|NCT02482038|NA|SINGLE_GROUP||OTHER||NONE||||||
34193586|NCT00367783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34193587|NCT05981053|||CASE_ONLY||PROSPECTIVE|||||||
34193588|NCT03891797|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193589|NCT02527772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193590|NCT01319604|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193591|NCT03339154|NA|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 4 levels of methionine provided as free amino acids, chickpeas, or chickpeas combined with rice for a total of 10 studies x 3 days per study.||||
34193592|NCT05500144|||OTHER||OTHER|||||||
34193593|NCT00003745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873666|NCT05865236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33873667|NCT02142777|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33873668|NCT01756131|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33873669|NCT05752253|NA|SINGLE_GROUP||SCREENING||NONE||||||
33873670|NCT03373097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068055|NCT03894761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068056|NCT01759394|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068057|NCT00538512|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34068058|NCT02097771|RANDOMIZED|||||||||||
34068059|NCT01383252|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34068060|NCT06525974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068061|NCT01119846|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34068062|NCT02074085|||CASE_ONLY||RETROSPECTIVE|||||||
34068063|NCT05008445|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34068064|NCT06307171|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068065|NCT06450093|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34068066|NCT00226525|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34068067|NCT06494228|||CASE_ONLY||RETROSPECTIVE|||||||
34068068|NCT01601067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068069|NCT05827588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068070|NCT05911698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068071|NCT03461302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068072|NCT00560911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068073|NCT04017117|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Clinical Trial. A trial will be carried out in hospital of Oral and Maxillofacial surgery department,Faculty of Oral and Dental Medicine Cairo University Equal randomization parallel group study positive controlled||||
34068074|NCT02415231|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34068075|NCT05450406|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34068076|NCT00048165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068077|NCT03627650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|2 skin zones per participant, A and B, 1 is treated, 1 is placebo coin toss determines which zone will be treated, this information is kept in sealed envelope|randomised controlled trial|t|f|f|t
34193594|NCT05857865|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit caregivers with young children who have a neurodevelopmental disorder and who are currently on the waitlist for relevant services. Eligible caregivers (mothers, fathers, guardians) will be randomly assigned to either participate in one 90-minute single session intervention (SSI) in which a strategy will be developed to address a primary mental health concern or receive community family support services as usual.||||
34193595|NCT03919097|||COHORT||RETROSPECTIVE|||||||
34193596|NCT05254977|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34193597|NCT03048487|||OTHER||RETROSPECTIVE|||||||
34193598|NCT00846950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34193599|NCT00539968|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193600|NCT01417013|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34193601|NCT00196846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193602|NCT04295824|||COHORT||CROSS_SECTIONAL|||||||
34193603|NCT01235650|||CASE_ONLY||RETROSPECTIVE|||||||
34193604|NCT00488553|||CASE_CONTROL||PROSPECTIVE|||||||
34193605|NCT00888199|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193606|NCT06010043|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193607|NCT03007251|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34193608|NCT01302145|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34193609|NCT05693961|NA|SINGLE_GROUP||OTHER||NONE||||||
34193610|NCT00457106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34193611|NCT02402998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193612|NCT05532293|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Both the Investigator and study participants will remain blinded to the treatment administered (drug or placebo) till the final results of the study are obtained.~The placebo will identical to the investigational medicinal product in smell, taste, and appearance."|Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of the Investigational Product in Healthy Adult Volunteers|t|f|t|f
34193613|NCT06312475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193614|NCT04997356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded to study condition.||t|f|f|f
34193615|NCT00115921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193616|NCT00001378||||TREATMENT||||||||
34193617|NCT00749567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193618|NCT05618691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a multicenter, double-blinded, randomized, placebo-controlled study, to evaluate the safety/tolerability and efficacy in three paralleled dose groups of GFH312 compared with placebo in patients with PAD and IC.||t|f|t|f
34193619|NCT04264481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator blinded to intervention||f|f|t|f
34193620|NCT04636216|NA|SINGLE_GROUP||TREATMENT||NONE||Open, single-group trial||||
34193621|NCT00967954|NON_RANDOMIZED|||TREATMENT||||||||
34193622|NCT04545853|||COHORT||CROSS_SECTIONAL|||||||
34193623|NCT03074019|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, placebo-controlled, 3-arm, parallel, dose ranging study|t|t|t|f
34193624|NCT03743935|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193625|NCT00238342||||DIAGNOSTIC||||||||
34193626|NCT02224248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193627|NCT03145818|||OTHER||PROSPECTIVE|||||||
34193628|NCT05249478|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34193629|NCT04657666|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34193630|NCT02047721|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193631|NCT02365844|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193632|NCT00983008|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34193633|NCT04126278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193634|NCT01788358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193635|NCT00358540|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34193636|NCT02381483|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34193637|NCT02740803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34193638|NCT02532699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34193639|NCT00036608||||TREATMENT||||||||
34193640|NCT02492607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193641|NCT02878798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193642|NCT03868644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193643|NCT02371941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193644|NCT01724554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193645|NCT05079113|||OTHER||OTHER|||||||
34193646|NCT03635658|RANDOMIZED|PARALLEL||TREATMENT||NONE|because the two interventions used in this trial are clearly different and easily recognized by the investigator and the participants. neither the participant nor the investigator could be blinded|the participants are divided into two groups one control and the other is the intervention||||
34193647|NCT04708236|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Patients will be allocated into 1 of 3 sequential escalating dose cohorts and randomized to ORTD-1 treatment versus vehicle control within each cohort.|t|t|t|t
34193648|NCT02145650|||CASE_ONLY||CROSS_SECTIONAL|||||||
34193649|NCT02384915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34193650|NCT00003897||||TREATMENT||||||||
34193651|NCT02471612|||COHORT||RETROSPECTIVE|||||||
34193652|NCT04814199|||COHORT||PROSPECTIVE|||||||
34193653|NCT04614402|||COHORT||PROSPECTIVE|||||||
34193654|NCT04129437|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34193655|NCT04876300|||COHORT||RETROSPECTIVE|||||||
34193656|NCT04109885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193657|NCT03180632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193658|NCT04297722|||OTHER||CROSS_SECTIONAL|||||||
34193659|NCT05466864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193660|NCT04096378|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193661|NCT05404672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193662|NCT03147157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755963|NCT00735995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755964|NCT04841941|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068078|NCT02918097|NA|SEQUENTIAL||TREATMENT||NONE||This is a pragmatical clinical trial. The patients follow a pre-established algorithm About the participant flow the results the table to indicate the number of participants who received treatment in the whole algoritm, not in each step.||||
34068079|NCT02724566|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33873671|NCT06183840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34068080|NCT01908309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34068081|NCT00674895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068082|NCT02696174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34193663|NCT05529095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193664|NCT05243901|||COHORT||PROSPECTIVE|||||||
34068083|NCT02009423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068084|NCT03727516|||COHORT||PROSPECTIVE|||||||
34068085|NCT02741466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068086|NCT02010541|||CASE_CONTROL||PROSPECTIVE|||||||
34068087|NCT01811290|||OTHER||PROSPECTIVE|||||||
34193665|NCT02642055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34193666|NCT04909983|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193667|NCT02987062|||COHORT||RETROSPECTIVE|||||||
34193668|NCT00732407|RANDOMIZED|CROSSOVER||||NONE||||||
34193669|NCT03285022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor and participant will be blinded to the type of material||t|f|f|t
34193670|NCT02133300|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34193671|NCT05180396|||COHORT||PROSPECTIVE|||||||
34193672|NCT01640717|||OTHER||RETROSPECTIVE|||||||
34193673|NCT01727440|||CASE_CONTROL||RETROSPECTIVE|||||||
34193674|NCT01912313|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193675|NCT03171909|||COHORT||PROSPECTIVE|||||||
34193676|NCT00132548|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34193677|NCT05089851|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Subjects left and right face (split face) will be randomly assigned to one of the following treatment arms: peptide antiaging serum vs placebo serum. The active and placebo will be placed in the same container and labelled Right and Left. Double blinded study, where the investigator, study subject, and other study personnel involved in the evaluation of the efficacy or safety are blinded to treatment during the twelve week randomization study. The investigational product will be identical in appearance to placebo and both will be packaged in the same container, which will be labelled Right and Left corresponding to the randomization.|Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Split-Face|t|f|t|f
34193678|NCT04655937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"* Participants attend the group if they agree to invitation and accept.~* Staff / Care providers are trained and cannot be masked~* Key outcomes are provided through self-report data from participants and therefore cannot be masked.~Other outcomes - related to acceptability and feasibility - are collected by the research team. The research team is small and funding is minimal so we cannot mask the research team."|"* Eligible Stroke Survivors are recruited and asked to a) provide self-reports on their wellbeing every 3 months for up to 12 months; b) opt in or out of invitation to group-based support.~* Those who consent only to a) form our COHORT arm who do not receive treatment.~* Those who consent to both a) and b) form our INTERVENTION group. When sufficient numbers are recruited, they are offered the intervention (Acceptance and Commitment Therapy group) Groups are delivered over 9 weekly sessions and involve homework.~This description was updated in May 2023 but to confirm: no active comparator / attention control arm (as originally plan) was included in the actual study"||||
34193679|NCT05348278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34193680|NCT05280834|||CASE_ONLY||PROSPECTIVE|||||||
34193681|NCT05822765|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34193682|NCT05006300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193683|NCT01682304|||CASE_CONTROL||PROSPECTIVE|||||||
34193684|NCT06110832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the research, the researcher is involved in the implementation of the mindfulness-based meditation and yoga program, data collection and data entry into the system. At the same time, the women in the experimental group had to be informed about the research. Therefore, researcher and participant blinding could not be performed. The data obtained from the research were coded as Group 1 and Group 2 by the researcher and transferred to the analysis program. The statistical expert who performed the analysis had no knowledge about the groups. Thus, it was aimed to control statistical bias, control bias and detection bias.|2-arm study with experimental control groups|f|f|f|t
34193685|NCT00093405||||TREATMENT||NONE||||||
34193686|NCT02277561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193687|NCT06141356|||COHORT||PROSPECTIVE|||||||
34193688|NCT01868542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193689|NCT06065085|NA|SINGLE_GROUP||OTHER||NONE||||||
34193690|NCT02765009|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193691|NCT04472507|||CASE_ONLY||PROSPECTIVE|||||||
34193692|NCT05835102|||COHORT||RETROSPECTIVE|||||||
34193693|NCT00271284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193694|NCT05887596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34193695|NCT05509868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34193696|NCT05674097|||COHORT||OTHER|||||||
34068088|NCT02353221|||COHORT||PROSPECTIVE|||||||
34068089|NCT01608191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068090|NCT06148493|||COHORT||RETROSPECTIVE|||||||
34068091|NCT05712837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068092|NCT00528372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068093|NCT02102594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068094|NCT03152266|||COHORT||PROSPECTIVE|||||||
34193697|NCT03820700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34193698|NCT05802953|||OTHER||PROSPECTIVE|||||||
34193699|NCT00985777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193700|NCT05913037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193701|NCT06321380|||CASE_CONTROL||PROSPECTIVE|||||||
34193702|NCT00932828|NA|SINGLE_GROUP||TREATMENT||NONE|For exploratory analysis, subjects will be randomized 1:1 to high (3000mg) and low dose (300mg) OIT to potentially look for a dose response. Low dose will be masked by adding oat flour to provide a dose equal to high dose with respect to flour but with lower peanut protein content|For the purposes of the primary outcome, all subjects will receive peanut OIT and represent a single group. For exploratory analysis, subjects will be randomized to high and low dose OIT to potentially look for a dose response.||||
34193703|NCT01788436|NON_RANDOMIZED|PARALLEL||||NONE||||||
34193704|NCT00577616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193705|NCT05157828|||OTHER||CROSS_SECTIONAL|||||||
33967252|NCT04703725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects.|Randomized Controlled Experimental Design|t|f|f|f
33967253|NCT00665197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755965|NCT01975896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33967254|NCT05244824|||OTHER||OTHER|||||||
33967255|NCT05926882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967256|NCT02092233|||CASE_ONLY||PROSPECTIVE|||||||
33967257|NCT02351973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967258|NCT01963819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967259|NCT01562470|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33967260|NCT05995145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967261|NCT01724398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967262|NCT03457025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967263|NCT02390219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967264|NCT03648333|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967265|NCT02012179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967266|NCT05354531|NA|SINGLE_GROUP||SCREENING||NONE|Those previously mentioned cases should be assessed clinically and radiologically|One group of 20 cases should be managed by INFIX for their pelvic ring disruption||||
34068095|NCT00147511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068096|NCT04786366|||COHORT||PROSPECTIVE|||||||
34068097|NCT01758042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068098|NCT02928601|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34068099|NCT04872738|||COHORT||PROSPECTIVE|||||||
34193706|NCT04185116|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34193707|NCT02102204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193708|NCT04730661|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34193709|NCT00004845|RANDOMIZED|||TREATMENT||DOUBLE||||||
34193710|NCT00147368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068100|NCT02609373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068101|NCT05957185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34193711|NCT02789930|||CASE_ONLY||PROSPECTIVE|||||||
34193712|NCT04194385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34193713|NCT03485300|||COHORT||CROSS_SECTIONAL|||||||
34068102|NCT03430856|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label Trial|Study is conducted in two parts. Part I has 3 arms and Part 2 has 2 arms.||||
34068103|NCT01914965|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34068104|NCT04728984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068105|NCT05593328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068106|NCT02546596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068107|NCT03090503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068108|NCT05674409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068109|NCT02350088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068110|NCT01138527|||COHORT||PROSPECTIVE|||||||
34068111|NCT06224296|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects are self-controlled in each group.||||
33755966|NCT04697277|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A computer-generated random numbers table and sealed envelopes will be used to ensure randomization. The gynecologist performing the surgery, the anesthesiologist and the patients will not know the Group allocation. The medications will be prepared by the anesthesia technician responsible for the study. Prophylactic antibiotic and placebo will be prepared in 10 ml in the syringe and labeled as study drug.||t|f|t|t
33873672|NCT00746980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068112|NCT03975725|NA|SINGLE_GROUP||OTHER||NONE||||||
33755967|NCT01315834|||CASE_CONTROL||PROSPECTIVE|||||||
33755968|NCT04512066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33755969|NCT01059630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755970|NCT06341725|||CASE_ONLY||PROSPECTIVE|||||||
33873673|NCT00784654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873674|NCT04455646|||COHORT||RETROSPECTIVE|||||||
33873675|NCT05352815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873676|NCT00884273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873677|NCT04147000|||COHORT||PROSPECTIVE|||||||
33873678|NCT02228291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873679|NCT01032915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873680|NCT00625833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873681|NCT05606367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873682|NCT01157312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873683|NCT00708500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068113|NCT02780960|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068114|NCT00198809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068115|NCT06389383|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34068116|NCT02911558|||COHORT||RETROSPECTIVE|||||||
34068117|NCT02963272|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193714|NCT06275633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|There will be a blinded assessment of videos of participants with Parkinson's Disease ON and OFF medication|This is a prospective patient with Parkinson's Disease cohort. After acute levodopa challenge test patients with Parkinson's Disease are divided due to measured levodopa response and their self-rated medicine effect.||||
34193715|NCT04032509|||COHORT||PROSPECTIVE|||||||
34193716|NCT02233270|||COHORT||PROSPECTIVE|||||||
34193717|NCT01064375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193718|NCT00766350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873684|NCT01097278|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Phase 2 study|t|f|t|f
33873685|NCT02684604|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873686|NCT05348057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33873687|NCT04360551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo controlled trial||t|t|t|f
33873688|NCT02085382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873689|NCT03992976|||CASE_ONLY||CROSS_SECTIONAL|||||||
33873690|NCT02148965|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873691|NCT00635037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873692|NCT03816930|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873693|NCT02907385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873694|NCT04522089|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33873695|NCT01888640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873696|NCT06356961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193719|NCT02587182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193720|NCT05352633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193721|NCT02106819|||CASE_CONTROL||PROSPECTIVE|||||||
34193722|NCT05429736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193723|NCT02633865|||||CROSS_SECTIONAL|||||||
34193724|NCT02859584|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193725|NCT04585061|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Randomized Intervention Model: Split-mouth assignment|t|f|f|f
34193726|NCT06150118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34193727|NCT01660958|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||"* The infant phase is a factorial design.~* The preschool phase is a cluster-randomized trial (MNP/placebo nested within high/low-quality preschools)."|t|t|t|t
33755971|NCT05780489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective multicentric study,||||
33755972|NCT06276270|NA|SEQUENTIAL||TREATMENT||NONE||||||
33755973|NCT01367509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33755974|NCT04870710|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33755975|NCT04663022|||CASE_CONTROL||PROSPECTIVE|||||||
33755976|NCT01755442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33873697|NCT03853603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33873698|NCT05078294|||CASE_ONLY||PROSPECTIVE|||||||
33873699|NCT01422122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873700|NCT05348512|||COHORT||PROSPECTIVE|||||||
33873701|NCT03084536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873702|NCT03562013|||COHORT||PROSPECTIVE|||||||
33873703|NCT02831413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873704|NCT00085956|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33873705|NCT06104852|||CASE_ONLY||PROSPECTIVE|||||||
33873706|NCT05234970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to one of two apps and will be blinded to which is the intervention app and which is the control.||f|f|t|f
33873707|NCT01997736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873708|NCT03473574|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment Arm A: Combination of Durvalumab, Tremelimumab (Regimen 1) and Gemcitabine Treatment Arm B: Combination of Durvalumab, Tremelimumab (Regimen 1), Gemcitabine and Cisplatin Treatment Arm C: Gemcitabine and Cisplatin Treatment Arm D: Combination of Durvalumab, Tremelimumab (Regimen 2), Gemcitabine and Cisplatin Treatment Arm E: Combination of Durvalumab, Gemcitabine and Cisplatin||||
33873709|NCT03168880|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will test platinum based chemotherapy against the standard taxane based chemotherapy in the neo adjuvant setting as below:~Arm A: Paclitaxel (weekly \*8) + AE/EC 3 weekly \*4 followed by Surgery + RT Arm B: Paclitaxel+ Carboplatin (weekly \*8) + AE/EC 3 weekly \*4 followed by Surgery+ RT"||||
33873710|NCT03722615|||COHORT||PROSPECTIVE|||||||
33873711|NCT05591664|||CASE_CONTROL||PROSPECTIVE|||||||
33873712|NCT02936427|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33873713|NCT03570931|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Single arm open-label study||||
34193728|NCT01539044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34193729|NCT00170534|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34193730|NCT02738788|||COHORT||PROSPECTIVE|||||||
34193731|NCT02193906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193732|NCT04330313|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are paralel groups, each has 15 participants. Different electrotherapy applications will be applied to each group.||||
34193733|NCT02087007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193734|NCT02249000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193735|NCT01781468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34193736|NCT03810872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193737|NCT03209739|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Endoscopists will be masked if the patients have received WhatsApp reminder prior colonoscopy||f|f|f|t
34193738|NCT01915303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193739|NCT00773838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193740|NCT05478031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193741|NCT05839418|||COHORT||PROSPECTIVE|||||||
34193742|NCT00585598|||||PROSPECTIVE|||||||
34193743|NCT00912184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193744|NCT03263663|||CASE_CONTROL||PROSPECTIVE|||||||
34193745|NCT02801812|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34193746|NCT01494623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193747|NCT04742582|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34193748|NCT04881942|RANDOMIZED|CROSSOVER||OTHER||NONE||This is an open-label, 4-way crossover study designed to estimate the nicotine, glycerin, propylene glycol, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during use of four MarkTen® XL e-vapor products.||||
34193749|NCT04894877|||COHORT||PROSPECTIVE|||||||
34193750|NCT02663544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193751|NCT04314297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193752|NCT04719806|||COHORT||RETROSPECTIVE|||||||
34193753|NCT05215548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193754|NCT03484793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34193755|NCT06317545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193756|NCT04708457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34193757|NCT00572767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33755977|NCT01463722|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33755978|NCT03825783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755979|NCT00724152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873714|NCT02848378|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34068118|NCT02552953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151909|NCT04721548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will be adopted in this study, in which the experimental products under evaluation will be provided in a masked way, that is, one group will receive an experimental drug (Minoxidil 5%) and another group will receive a placebo (product without the active ingredient) in identical primary and secondary packaging to avoid potential bias, so neither the researcher nor the research participant will know what is being applied.|Participants will be randomized at a 2: 1 ratio to receive new pharmaceutical form Minoxidil 5% and placebo, respectively. The primary objective of the MINOX study is to demonstrate the superiority of a new topical 5% pharmaceutical form of minoxidil (experimental drug) in treating men with androgenetic alopecia (Hamilton-Norwood scale IIIv, IV or V) compared to placebo when administered for 180 days.|t|f|t|f
34151910|NCT03897595|||COHORT||PROSPECTIVE|||||||
34193758|NCT04812600|||COHORT||PROSPECTIVE|||||||
34193759|NCT00296205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193760|NCT05916443|||COHORT||PROSPECTIVE|||||||
34193761|NCT02864654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193762|NCT00109980|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34193763|NCT03887702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34193764|NCT01203085|||CASE_ONLY||PROSPECTIVE|||||||
34193765|NCT00606905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193766|NCT00233454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193767|NCT06280742|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873715|NCT01479179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873716|NCT03057106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873717|NCT00123006|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33873718|NCT00450723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873719|NCT00541320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33873720|NCT01745770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873721|NCT02590120|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34193768|NCT03353233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34193769|NCT04941170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded||t|f|t|f
34193770|NCT06126211|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34193771|NCT06471283|NA|SINGLE_GROUP||OTHER||NONE||||||
34193772|NCT06225869|||COHORT||PROSPECTIVE|||||||
34193773|NCT01440257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193774|NCT06193109|||COHORT||PROSPECTIVE|||||||
34193775|NCT03248349|||COHORT||PROSPECTIVE|||||||
34193776|NCT04157673|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will not be informed of the group that they are randomly assigned until the completion of the study.|This study is a multiple-baseline single subject design; participants will be randomized to intervention at 6-week, 8-week, or 10-week.||||
34193777|NCT06220760|||COHORT||PROSPECTIVE|||||||
33755980|NCT03630822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33755981|NCT02891057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33755982|NCT03391609|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blinding||t|t|t|f
33755983|NCT01763879|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33755984|NCT06033248|||CASE_CONTROL||PROSPECTIVE|||||||
33755985|NCT03546517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and assessor are blinded but the physiotherapist giving the treatment is not blinded||t|f|f|t
33755986|NCT03349801|||COHORT||PROSPECTIVE|||||||
33873722|NCT06289712|||COHORT||RETROSPECTIVE|||||||
33755987|NCT01341665|||COHORT||PROSPECTIVE|||||||
33755988|NCT03295890|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33755989|NCT01907191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33755990|NCT00258258||||TREATMENT||NONE||||||
33755991|NCT04794231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The laboratory microbiologist was blinded to the study groups. The two dressings were visibly different, and consequently, it was not possible to blind the patients, PICU staff or the investigators who collected data in the PICU.||f|f|f|t
33755992|NCT05925933|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33873723|NCT04788979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|self investigator|"The subjects included in the study were the following:~1-control group:20 subjects (healthy) 2-30 obese periodontitis patients.dont take melatonin 3-30 obese periodontitis patients taking melatonin"|f|f|t|f
33873724|NCT03412656|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33873725|NCT00363948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873726|NCT03518788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873727|NCT02636582|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33873728|NCT03322189|||OTHER||OTHER|||||||
33873729|NCT05335460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873730|NCT03138434|||COHORT||CROSS_SECTIONAL|||||||
33873731|NCT03917823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Cryoneurolysis probes are available for a console neurolysis device (PainBlocker, Epimed, Farmers Branch, Texas) that either (1) pass nitrous oxide to the tip inducing freezing temperatures; or, (2) vent the nitrous oxide at the base of the probe so that no gas reaches the probe tip, resulting in no temperature change. The latter is a sham procedure since without the temperature change, no ice ball forms and therefore the target nerve is not affected.|Randomized, double-masked, sham-controlled, parallel-arm human subjects clinical trial|t|t|f|t
33873732|NCT02336490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873733|NCT03223480|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|All patients recruited will receive EUS-guided gastrojejunostomy using the double balloon occluder||||
33873734|NCT02761304|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33873735|NCT04022915|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects with acute pulmonary embolism meeting the inclusion criteria will be enrolled.||||
33873736|NCT04759651|||COHORT||PROSPECTIVE|||||||
33873737|NCT04282447|||COHORT||PROSPECTIVE|||||||
33873738|NCT01263483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076100|NCT06439108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and physicians allocated to each intervention group were aware of the allocation; however, the data analysts and the outcome assessors were kept blinded to the allocation.|An independent doctor created the randomization sequence using Excel 2016 (computerized random numbers) with a 1:1 allocation via random block sizes of 2, 4, and 6; he assigned the sample numbers equally to each group and assigned the block. Patients and physicians allocated to each intervention group were aware of the allocation; however, the data analysts and the outcome assessors were kept blinded to the allocation. The investigators prospectively carried out this study on 30 patients with APC III pelvic ring injuries between March 2022 and May 2023 that met our inclusion criteria. The independent doctor allocated the 30 cases to two groups: Group A (15 cases): single superior symphyseal plate, group B (15 cases): double superior \& anterior symphyseal plate|f|f|t|t
33873739|NCT03219242|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873740|NCT01188889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873741|NCT04378530|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33873742|NCT02868073|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873743|NCT01081912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193778|NCT04023734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34193779|NCT00701662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193780|NCT00655174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193781|NCT01407380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193782|NCT03830892|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to their condition (power level and nicotine concentration) used in each session, except during their 'own brand' session.|"We will recruit two populations of e-cigarette users: exclusive e-cigarette users and dual users of e-cigarettes and tobacco cigarettes.~All participants complete 5 within-subject laboratory conditions that each last 4 hours. Conditions (sessions) differ by the tobacco product used: 1) e-cigarette with low device power, low nicotine mg/ml; 2) e-cigarette with low device power, high nicotine mg/ml; 3) e-cigarette with high device power, low nicotine mg/ml; 4) e-cigarette with high device power, high nicotine mg/ml; and 5) own brand e-cigarette/cigarette.~The first four sessions are latin-square-ordered and the last session for all participants will be their own brand cigarette/e-cigarette depending on the population. For dual users, we will counter-balance own brand condition product assignment (cigarette vs. e-cigarette). Conditions will differ in the presentation of primary outcomes (task order) which will be counterbalanced."|t|f|f|f
34193783|NCT00662467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193784|NCT00667108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193785|NCT02466659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193786|NCT00502411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193787|NCT02890641|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34193788|NCT01478048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193789|NCT06297278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34193790|NCT02317744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193791|NCT05331859|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193792|NCT05366504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193793|NCT05089422|NA|SINGLE_GROUP||OTHER||NONE||||||
34193794|NCT01589653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33755993|NCT06364657|||CASE_CONTROL||PROSPECTIVE|||||||
33755994|NCT04322721|||OTHER||RETROSPECTIVE|||||||
33755995|NCT05021510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33755996|NCT01185067|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33755997|NCT04182100|NA|SINGLE_GROUP||TREATMENT||NONE||Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of P1101 (ropeginterferon alfa-2b) once every 2 weeks||||
33755998|NCT03941275|||OTHER||PROSPECTIVE|||||||
33873744|NCT01285115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193795|NCT04341428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193796|NCT04825470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193797|NCT03300596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193798|NCT04696887|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will be screened and assigned to the same condition in a phased/rolling enrollment.||||
34193799|NCT05427617|||CASE_CONTROL||RETROSPECTIVE|||||||
34193800|NCT04264832|||OTHER||CROSS_SECTIONAL|||||||
34193801|NCT02204475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873745|NCT04216745|||COHORT||PROSPECTIVE|||||||
34193802|NCT02720029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193803|NCT02706964|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193804|NCT03316989|||CASE_CONTROL||PROSPECTIVE|||||||
34193805|NCT04042090|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned (1:1) to either the intervention group or the control group. Both intervention and control group are placed on the waiting list (approximate time of waiting is 6 weeks) to receive treatment. Meanwhile, our study will be executed. Intervention group: use of virtual reality intervention at home over a period of 28 days (with a maximum of 35 days) at least ten minutes a day (excluding day 1, in which the participants should do the entire education module of 25 minutes) and in addition, when participants feel the need. The control group: no intervention, patient is waiting to receive normal chronic pain treatment. Randomisation is not blinded: both researchers and participants know which participants are part of the intervention and control group. Randomisation will take place using a computerised randomisation list with variably sized blocks, directly after providing oral informed consent.||||
34193806|NCT06020872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34193807|NCT02250729|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193808|NCT02500056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193809|NCT04139889|||CASE_CONTROL||PROSPECTIVE|||||||
34193810|NCT03288233|||OTHER||CROSS_SECTIONAL|||||||
33873746|NCT06518122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"\[PART A\] 6 x 3 Crossover~\[PART B\] Single Arm (Three periods)"||||
33873747|NCT04916509|||COHORT||RETROSPECTIVE|||||||
33873748|NCT04261075|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33873749|NCT02327637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873750|NCT00376610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873751|NCT04327583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076101|NCT00003494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076102|NCT05128591|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873752|NCT01055600|NA|SINGLE_GROUP||||NONE||||||
33873753|NCT04249687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873754|NCT00983177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873755|NCT04273828|||COHORT||PROSPECTIVE|||||||
33873756|NCT06490016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|There are 2 groups: 2 interventional group||||
33873757|NCT04322851|||COHORT||PROSPECTIVE|||||||
33873758|NCT00947336|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33873759|NCT03152019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873760|NCT02919878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873761|NCT02244502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873762|NCT00117598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873763|NCT03217006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The endpoint assessors will be blinded to treatment allocation (PROBE).|Patients undergoing coronary artery bypass surgery will be in one of two groups. One group will receive a single arterial graft and the second group will receive two or more arterial grafts.|f|f|f|t
33873764|NCT00419575|||CASE_ONLY||PROSPECTIVE|||||||
33873765|NCT00309543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076103|NCT00053209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076104|NCT03175926|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34151911|NCT01032824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151912|NCT03874039|||COHORT||PROSPECTIVE|||||||
34151913|NCT01265303|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151914|NCT02258724|||COHORT||PROSPECTIVE|||||||
34151915|NCT02870088|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34151916|NCT04876612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151917|NCT06100874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151918|NCT05087719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151919|NCT04421209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151920|NCT00012168||||DIAGNOSTIC||||||||
34151921|NCT01639755|NA|SINGLE_GROUP||OTHER||NONE||||||
34151922|NCT00205816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151923|NCT05808517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151924|NCT02392936|||COHORT||PROSPECTIVE|||||||
34151925|NCT03053869|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34151926|NCT04057690|||OTHER||RETROSPECTIVE|||||||
34151927|NCT00049894|||||RETROSPECTIVE|||||||
34151928|NCT01851785|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34151929|NCT00258466|RANDOMIZED|||TREATMENT||||||||
34151930|NCT03861156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151931|NCT05794828|NA|SINGLE_GROUP||TREATMENT||NONE||Single group open label assignment||||
34151932|NCT02266212|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34151933|NCT05714137|RANDOMIZED|PARALLEL||PREVENTION||NONE||two groups||||
34151934|NCT05701436|RANDOMIZED|PARALLEL||TREATMENT||NONE||The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on 3D-HDRA results, and the control group received postoperative conventional treatment combined with Empirical transarterial chemoembolization.||||
34151935|NCT02603848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151936|NCT00219960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34151937|NCT06284330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873766|NCT05793671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Closed letters will be provided in cath-lab , inside of each letter , there is a paper with decision written --\> either go for stent ( for immediate stenting ) or don't go for stent ( for non-deferred stenting)||t|f|f|f
33873767|NCT04659265|RANDOMIZED|PARALLEL||OTHER||SINGLE|participants not aware of the study goal||t|f|f|f
33873768|NCT01059669|||CASE_CONTROL||PROSPECTIVE|||||||
33873769|NCT02089399|RANDOMIZED|CROSSOVER||||NONE||||||
33873770|NCT02410304|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33873771|NCT05347888|||COHORT||PROSPECTIVE|||||||
33873772|NCT04944160|||COHORT||RETROSPECTIVE|||||||
33873773|NCT03001089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873774|NCT02514915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873775|NCT04500535|||COHORT||PROSPECTIVE|||||||
33873776|NCT05601648|NA|SINGLE_GROUP||TREATMENT||NONE||Open label treatment study, no placebo.||||
33873777|NCT02714920|NA|SINGLE_GROUP||SCREENING||NONE||||||
33873778|NCT04098770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873779|NCT04352959|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33873780|NCT02907294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873781|NCT00001014||PARALLEL||TREATMENT||||||||
34193811|NCT01754402|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation with 3+3 cohort design plus Dose expansion at the Maximum tolerated dose.||||
34193812|NCT01531855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33967267|NCT03306602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The cavity in an individual will be randomly assigned to either the experimental or the control restoration, according to a predetermined scheme of randomization. If the participants have two cavities, they will not know in which cavity the experimental and control restoration were placed. All the restorations will be analyzed by using Modified United States Public Health Services (USPHS) criteria. The investigators and outcome assessors evaluating the restorations will not know which tooth has been restored with the experimental or control restoration|All the participants will receive both the experimental and control restoration. In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps. The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.|t|f|t|t
33967268|NCT01864720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967269|NCT05045235|||CASE_ONLY||PROSPECTIVE|||||||
33967270|NCT02094937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967271|NCT05692752|||CASE_ONLY||PROSPECTIVE|||||||
34151938|NCT01890668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151939|NCT06106269|||COHORT||PROSPECTIVE|||||||
34151940|NCT06007261|||CASE_ONLY||PROSPECTIVE|||||||
34151941|NCT06246812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193813|NCT00464971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193814|NCT00127270|RANDOMIZED|PARALLEL||||NONE||||||
34193815|NCT01626937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193816|NCT02712047|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34193817|NCT03020940|||CASE_ONLY||RETROSPECTIVE|||||||
34193818|NCT04790565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193819|NCT06176105|||COHORT||RETROSPECTIVE|||||||
33755999|NCT03065270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756000|NCT02456402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756001|NCT01180348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873782|NCT02318862|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33873783|NCT00004420|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33873784|NCT01758939|||COHORT|||||||||
33873785|NCT03155581|RANDOMIZED|PARALLEL||PREVENTION||NONE|Women under are those recruited in the intervention targeting women. In addition, 40 GP centers were recruited|One intervention targeting women, the other one targeting health professionals.||||
33873786|NCT04906850|||COHORT||RETROSPECTIVE|||||||
33873787|NCT00406510|RANDOMIZED|PARALLEL||||SINGLE||||||
33873788|NCT00087828|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873789|NCT01227486|||||PROSPECTIVE|||||||
33873790|NCT02709564|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33873791|NCT00265538|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33873792|NCT01918839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873793|NCT01487252|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33873794|NCT02575768|||CASE_CONTROL||PROSPECTIVE|||||||
33873795|NCT03972969|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33873796|NCT04678570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The same nurse, who will perform the insertion of the orogastric tube, will be blinded to the control and the intervention groups.~Another nurse, who will take the measurements of the heart rate and the saturation, will be blinded to the control and the intervention groups.~2 observers, independent from the study, who will assess the pain will be blinded to the intervention and control groups."||f|t|f|t
33873797|NCT01676675|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33873798|NCT02840695|||COHORT||PROSPECTIVE|||||||
33873799|NCT01339806|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33873800|NCT01525784|||COHORT||PROSPECTIVE|||||||
34151942|NCT03370562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study medication provided in blinded syringe labeled with study number||t|t|t|t
34151943|NCT05098509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151944|NCT04394650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151945|NCT01848470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151946|NCT00901810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34151947|NCT06285123|||OTHER||PROSPECTIVE|||||||
34151948|NCT05653817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151949|NCT03436823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151950|NCT01477112|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34151951|NCT00946907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151952|NCT00054028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076105|NCT04308863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Thirty permanent mandibular molars of patients with signs and symptoms of irreversible pulpitis will be selected. They will be randomly allocated into two groups, Group 1(Chitosan scaffold/ MTA pulp dressing materials), Group 2 (MTA pulp dressing material).|f|f|f|t
34076106|NCT05594147|||COHORT||RETROSPECTIVE|||||||
34076107|NCT01178125|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34193820|NCT05575050|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Patients were divided into 2 groups depending on the oral care procedure:~1. Standard oral procedure (cleaning and moisturizing of oral cavity, suction of excess fluid)~2. Extended oral procedure (cleaning and moisturizing of oral cavity, teeth brushing, suction of excess fluid) The procedures were performed twice daily in each patient. The detailed information on these procedures is included in the Appendix 1. The allocation protocol was based on patients' location in the ward. Each room was assigned with one type procedure (standard- even number or extended - uneven number of room), that was permanent during the study period."|t|f|f|f
34193821|NCT00121043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193822|NCT00851162|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34193823|NCT00680641|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34193824|NCT03679520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Individual participant information will state that different ways of providing antenatal parental preparation will be evaluated, but will not reveal any specific information about the different types of antenatal parental preparation. Individual participants will therefore have no knowledge of allocation to control group or intervention group.|Antenatal clinics randomised to control group provide antenatal parental preparation as usual (regular programme) to expectant parents and antenatal clinics randomised to intervention group provide a new programme of antenatal parental preparation to expectant parents.|t|f|f|f
34193825|NCT04360382|||CASE_CONTROL||PROSPECTIVE|||||||
34193826|NCT03900325|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34193827|NCT01676636|||COHORT||PROSPECTIVE|||||||
34193828|NCT03480087|||COHORT||PROSPECTIVE|||||||
34193829|NCT05461274|||CASE_CROSSOVER||PROSPECTIVE|||||||
34193830|NCT01505764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193831|NCT03316495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34193832|NCT01243242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193833|NCT01039129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193834|NCT04884464|||CASE_CONTROL||PROSPECTIVE|||||||
34193835|NCT00675467|||COHORT||PROSPECTIVE|||||||
34193836|NCT03597204|NA|SINGLE_GROUP||OTHER||NONE||selected high risk group of individuals for CRC screening by using FIT||||
34193837|NCT04220476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193838|NCT03904056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193839|NCT01620320|||COHORT||PROSPECTIVE|||||||
34193840|NCT05413434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician who referred patients to the study and the participants were blind to the study.|randomized controlled|t|f|f|f
34193841|NCT05146947|NA|SINGLE_GROUP||SCREENING||NONE||||||
34193842|NCT04681352|NA|SINGLE_GROUP||TREATMENT||NONE|While there was only one arm, Outcome Assessors were masked to pre- vs post-treatment images.|||||
34193843|NCT00995059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193844|NCT03917407|RANDOMIZED|PARALLEL||TREATMENT||NONE|Dur-28 treated moderate AH: 7 Dur-28 treated severe AH: 12 Observational AH: 8 Steroid Treated AH: 16|An Open-Label, Dose Escalation Study to Assess the Safety, and Pharmacodynamics signals of DUR 928 in Patients with AH. DUR-928 will be administered in 100 mL 5% dextrose or 0.9% sodium chloride by slow intravenous infusion over 2 hrs (50mL/h) until entire dose is given at Day 1 and Day 4. If a patient meets the hospital discharge criteria prior to the 2nddose, the patient will receive only one dose of DUR-928 instead of 2 doses.||||
34193845|NCT03811236|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34193846|NCT01105065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193847|NCT05919836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193848|NCT02193464|||COHORT||PROSPECTIVE|||||||
34193849|NCT06160934|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized into one of two groups: the T1D Parent Check-in Intervention group or the Treatment as Usual Group (TAU). Participants in the intervention and TAU groups will be yoked by age group (e.g., parent of an 8-12-year-old child will be yoked to another parent of an 8-12-year-old child) to minimize variability in effects due to differences in parenting by child age. Matching participants by clinic location (e.g., child receiving care at MGH will be yoked to another child receiving care at MGH) will serve as a natural control for differences in practice between clinic locations.||||
34193850|NCT06049901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193851|NCT00637702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193852|NCT02103296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967272|NCT05257603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are not told the outcomes the investigators are seeking to reduce, but are told participants are assigned to either a Health and Lifestyle intervention (Health Education control) or Managing High Risk intervention (RPCW).|Half of participants will be assigned to the intervention (RPCW) condition designed to reduce hazardous drinking and increase awareness of risk cues for sexual assault and implementation of safe drinking and dating behaviors. Half of participants will be assigned to the Health education control designed to control for time and attention.|t|f|f|f
33967273|NCT02971514|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33756002|NCT02080468|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33967274|NCT02998333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967275|NCT03411642|||COHORT||CROSS_SECTIONAL|||||||
33967276|NCT05385029|||CASE_CONTROL||PROSPECTIVE|||||||
33967277|NCT05187403|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33967278|NCT05164848|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33967279|NCT02831348|||COHORT||CROSS_SECTIONAL|||||||
33967280|NCT00744887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967281|NCT05881265|NA|SINGLE_GROUP||TREATMENT||NONE||Chi-Ven treatment||||
33967282|NCT00211783|||CASE_CONTROL||PROSPECTIVE|||||||
33967283|NCT06141382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756003|NCT02899325|||COHORT||PROSPECTIVE|||||||
33756004|NCT02150018|||||CROSS_SECTIONAL|||||||
33756005|NCT02115555|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873801|NCT06548256|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Drug: Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year, then stopped for 1 year Drug: observed for 1 year and then Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year||||
33756006|NCT03996850|||COHORT||PROSPECTIVE|||||||
33873802|NCT05462847|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33873803|NCT04200729|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Stepped-wedge cluster randomized trial (SW-CRT). After a period of baseline data collection, clusters will be randomized to cross over from control to intervention in a stepwise fashion until all clusters have been exposed.||||
33873804|NCT03581227|||CASE_ONLY||PROSPECTIVE|||||||
33873805|NCT00001788|||COHORT||RETROSPECTIVE|||||||
33873806|NCT02410135|||COHORT||PROSPECTIVE|||||||
33873807|NCT00971451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873808|NCT02849561|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
33873809|NCT02205203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33873810|NCT03175900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873811|NCT00350051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873812|NCT02389803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873813|NCT06534450|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33873814|NCT06154369|RANDOMIZED|PARALLEL||OTHER||SINGLE|Given the nature of this trial, it will not be possible to blind participants to their allocation. As measures are self report, blinding of outcome measures is also not possible. Protect against bias will occur by blinding investigators to condition (i.e., only staff directly managing participants will be unblinded).|A pragmatic, randomized controlled trial will be used. Participants will be randomly allocated in a 1:1 ratio to the control (no intervention) or intervention (JoyPop) condition. Block randomization (block size of 8) will be used to randomly assign participants to each condition.|f|f|t|f
33873815|NCT01441531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873816|NCT03893968|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigator is blinded to group allocation.|Patients are assigned to either a group informed by doctors or assistance nurses in parallel.|f|f|t|f
33873817|NCT02026895|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873818|NCT05993221|||COHORT||CROSS_SECTIONAL|||||||
33873819|NCT00267137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33873820|NCT00295711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33873821|NCT02189213|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33873822|NCT00208221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873823|NCT00071071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873824|NCT03415295|||CASE_CONTROL||RETROSPECTIVE|||||||
33873825|NCT00346073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33873826|NCT01097746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873827|NCT03269045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873828|NCT03574090|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|In the operating room area we will keep a notebook with the random number sheet and a box with the numbered envelopes and containing the treatment to follow: physiological saline alone or physiological saline with antibiotic. At the end of the surgery and before closing the abdominal wall, it is definitively informed to the nurse whether or not to recruit them, a case number is assigned chronologically and in the random number sheet corresponds to an envelope containing one of the two treatments. Dilution is performed with 10cc of physiological saline solution with or without antibiotic in the outside of the operating room and then it is incorporated into the 500cc bottle of physiological saline once opened in a sterile way. We used according to the usual protocol.||t|t|t|f
33873829|NCT05433571|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33873830|NCT00003283||||TREATMENT||||||||
33873831|NCT06361732|||CASE_ONLY||OTHER|||||||
33873832|NCT04867473|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will attend teleyoga sessions once per week, with assessments at beginning and end of treatment||||
33873833|NCT00997100|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33873834|NCT00177333|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33873835|NCT05590286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873836|NCT03115567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873837|NCT05972200|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33873838|NCT03027531|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33873839|NCT01394042|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33967284|NCT05826249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967285|NCT01778582|||OTHER||PROSPECTIVE|||||||
33967286|NCT05175495|||COHORT||PROSPECTIVE|||||||
33967287|NCT03295539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967288|NCT03786510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A single-blinded randomized controlled pilot study|f|f|f|t
33967289|NCT06478446|||COHORT||OTHER|||||||
33967290|NCT00065897|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33967291|NCT04303052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|On the intervention day, the patient is randomly assigned to one of the two study arms through envelope (145 cm vs 70 cm)|Depending on randomization, the Power-PICC implantation occurs either with Seldinger over-the-wire technique or with Seldinger modified technique. All related substances, measures or procedures are performed according to the clinical routine.|t|f|f|f
33967292|NCT00936884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967293|NCT05827900|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective||||
34076108|NCT03012932|NA|SINGLE_GROUP||SCREENING||NONE||||||
34076109|NCT01566604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076110|NCT05451277|||COHORT||PROSPECTIVE|||||||
34076111|NCT01751321||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076112|NCT04634188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076113|NCT03137277|||CASE_CONTROL||PROSPECTIVE|||||||
34076114|NCT03059732|||CASE_ONLY||RETROSPECTIVE|||||||
34076115|NCT06158204|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34076116|NCT04505852|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756007|NCT03428425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873840|NCT03536871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The nutritional supplement will be delivered to a 3rd party contract research organization and the allocation will only be un-blinded after data lock.||t|t|t|t
33873841|NCT05219942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients of both groups know that they will receive crystalline insulin infusion.However they are not told whether they receive glargine insulin or not.||t|t|f|t
33873842|NCT04500977|NA|SINGLE_GROUP||PREVENTION||NONE||Training of community members in leadership and community-based health promotion skills||||
33873843|NCT01114503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873844|NCT01028092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873845|NCT05989906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research study assistant collecting self-report outcomes and Principal Investigators will be masked to participant's study group.|"Participants will be randomly assigned to one of four treatment conditions:~* Usual care~* Sprint Interval Training~* SIT + Home Ergometer~* SIT + Home Ergometer + Motivational Interviewing"|f|f|t|t
33873846|NCT04706676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873847|NCT04106648|||OTHER||PROSPECTIVE|||||||
33873848|NCT03065907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873849|NCT00294060|||COHORT||PROSPECTIVE|||||||
33873850|NCT02445807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873851|NCT00226109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873852|NCT00271596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873853|NCT01599403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873854|NCT06156982|||COHORT||OTHER|||||||
33873855|NCT05927051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873856|NCT05745220|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignment||||
33873857|NCT03314974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873858|NCT05176119|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33873859|NCT02744443|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33873860|NCT04739085|||COHORT||PROSPECTIVE|||||||
33873861|NCT01734577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33873862|NCT03754075|||COHORT||PROSPECTIVE|||||||
33873863|NCT03379272|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873864|NCT04885725|||COHORT||CROSS_SECTIONAL|||||||
33873865|NCT05722119|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33873866|NCT03351621|||OTHER||CROSS_SECTIONAL|||||||
33873867|NCT04752709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Device looks identical. A third person masks which software is coded.|Randomized between two active groups|t|t|t|t
33873868|NCT05261958|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single|Two groups with randomization Assignment: High knee with mini hurdles, agility ring hops, 30 yard sprint, depth jumps, overhead ball drop|t|f|f|f
33873869|NCT03471039|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33873870|NCT03820622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873871|NCT00897663|||COHORT||CROSS_SECTIONAL|||||||
33873872|NCT02682628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873873|NCT01570504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873874|NCT01255527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873875|NCT03357679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator is blinded to the initial laryngeal exposure during the sniffing position, but is unblinded during assessment of laryngeal exposure in either the bed up head elevated position or glidescope assisted tracheal intubation||f|f|t|f
33873876|NCT02634853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873877|NCT01803321|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33873878|NCT04551937|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double blind (participant and investigative team)|Participants will pass through 2 arms, control and prebiotic, in a randomized, counterbalanced order.|t|t|t|t
33873879|NCT03852251|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33873880|NCT00658476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873881|NCT04919642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873882|NCT04161430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873883|NCT02581202|||COHORT||PROSPECTIVE|||||||
33873884|NCT03581786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076117|NCT02938117|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34076118|NCT02824627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076119|NCT02862145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076120|NCT06298955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193853|NCT03675009|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and education providers will be unaware whether they are in an early or late delivery of education randomization group.|stepped wedge|t|t|f|f
34193854|NCT01043939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193855|NCT00614770|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193856|NCT00864695|||COHORT||PROSPECTIVE|||||||
34193857|NCT01149148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34193858|NCT02264145|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34193859|NCT01075594|||||PROSPECTIVE|||||||
34193860|NCT04049877|||CASE_ONLY||OTHER|||||||
34193861|NCT02009540|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34193862|NCT04617496|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34193863|NCT05666050|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcome assessors will be masked about which group is intervention and control to avoid bias.|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and continued up to 6 weeks of post partum period for 4 months. Three intervention worker female nurses/midwifes will be recruited and trained to do the intervention based on the protocol After this end line data will be collected from both intervention and control group.|f|f|f|t
34193864|NCT01121809|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193865|NCT05692336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193866|NCT04030156|||CASE_ONLY||PROSPECTIVE|||||||
34193867|NCT00448318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34193868|NCT03719833|||COHORT||PROSPECTIVE|||||||
34193869|NCT05831683|||COHORT||PROSPECTIVE|||||||
34193870|NCT00116298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193871|NCT02540278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34193872|NCT02900989|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34193873|NCT03490812|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193874|NCT05915156|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34193875|NCT03716154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split mouth|t|f|f|f
34193876|NCT01809093|||CASE_ONLY||PROSPECTIVE|||||||
34193877|NCT01087736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193878|NCT05216744|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each subject will receive one of two combination regimens including regimen A (Doxycycline plus Cefixime) or regimen B (Doxycycline plus Ceftriaxone).||||
34193879|NCT00875693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193880|NCT05014932|||COHORT||RETROSPECTIVE|||||||
33873885|NCT00872651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873886|NCT00370279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873887|NCT04916457|||OTHER||PROSPECTIVE|||||||
33873888|NCT03445871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873889|NCT04290832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33873890|NCT00930761|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873891|NCT03709654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Randomized Double Blind Vehicle Controlled Trial, dual arm with 2:1 treatment to vehicle assignment|t|f|t|f
33873892|NCT04158622|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Assignment|f|f|f|t
33873893|NCT02122328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873894|NCT01307215|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33873895|NCT01986413|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873896|NCT00317109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873897|NCT05114200|||CASE_ONLY||PROSPECTIVE|||||||
33873898|NCT00925015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873899|NCT02770547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873900|NCT05597085|||COHORT||RETROSPECTIVE|||||||
33873901|NCT00706251|||COHORT||RETROSPECTIVE|||||||
33873902|NCT01042015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873903|NCT01732497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873904|NCT04749823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873905|NCT03096964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873906|NCT04691193|||CASE_CONTROL||PROSPECTIVE|||||||
33873907|NCT01179464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873908|NCT04038788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA.|In active tRNS condition, random noise was delivered by a battery-operated device (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) via 5 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), with 2 mA amplitude, offset at 1 mA, frequency 100-640 Hz, for 20 min with 15 s ramp-in/ramp-out. The combined impedance of all electrodes was kept below 15 kΩ, as measured by NeuroConn DC stimulator Plus device, using electrolyte gel. The anode was placed over International 10-10 electrode position AF3 (a point midway between F3 and Fp1), with cathodes (reference electrodes) at AF4, F2, F6 and FC4. Stimulation was applied at an intensity of 2 milliampere (mA) for 20 min, twice-daily on 5 consecutive weekdays.|t|t|t|t
33873909|NCT04368728|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33873910|NCT01012791|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873911|NCT01102647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33873912|NCT03478111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33873913|NCT01485627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33873914|NCT05909956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873915|NCT03978195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873916|NCT04817644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967294|NCT00856778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967295|NCT01326702||SEQUENTIAL||TREATMENT||NONE||||||
33967296|NCT02092961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967297|NCT00922792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967298|NCT00005091||||TREATMENT||||||||
33967299|NCT01447329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967300|NCT00773526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193881|NCT03289624|RANDOMIZED|PARALLEL||OTHER||SINGLE|No other parties will be masked in the trial|Persons with chronic conditions and their family caregivers will be randomly assigned to a treatment or control group|t|f|f|f
33967301|NCT01252238|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34193882|NCT00881868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33967302|NCT01361607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967303|NCT02305368|||COHORT||PROSPECTIVE|||||||
33967304|NCT03501342|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomize controlled study||||
33967305|NCT06525441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This trial is an open-label study. Given that dietary intervention will be administered to all participants, it is challenging to implement blinding for the participants. However, throughout the study, the individuals involved in the preparation and distribution of meals, along with those conducting the statistical analysis, will remain blind to the group assignments of the participants.||f|f|f|t
33967306|NCT01325532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967307|NCT05775458|||COHORT||PROSPECTIVE|||||||
33873917|NCT02872740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33873918|NCT04354714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873919|NCT05876052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873920|NCT01457209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873921|NCT06424938|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was designed as a prospective randomized study. Patients with ASA II-III between the ages of 30 and 70 who will undergo major gynecological cancer surgery will be included in the study. They will be randomized into 2 groups: the group in which epidural block is applied for postoperative analgesia (Group Epidural) and the group in which erector spinae plane block is applied (Group ESP).|t|f|f|f
33873922|NCT05569707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873923|NCT02471495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873924|NCT04347707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit a group of mother-child dyads in which the mother meets the current criteria for depression. Those mothers will participate in a 20-week group therapy intervention that incorporates Dialectical Behavior Therapy (DBT) and parent skills training. A control group of mother-child dyads who will be income and child age-matched to the intervention sample will also be recruited. These mothers will not meet the criteria for depression and will not receive the group therapy intervention.||||
33873925|NCT02055105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873926|NCT05365503|NA|SINGLE_GROUP||OTHER||NONE||||||
33873927|NCT03328546|||COHORT||PROSPECTIVE|||||||
33873928|NCT06424028|||COHORT||PROSPECTIVE|||||||
33873929|NCT05427552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be informed of the stimulation intensities.|Healthy volunteers will receive iTBS three times with three different intensities separated by one week to investigate the prefrontal hemodynamic response to different stimulation intensities.|t|f|f|f
33873930|NCT01221220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33873931|NCT01972867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873932|NCT02237521|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33967308|NCT03210259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967309|NCT00770315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967310|NCT04846218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967311|NCT03938298|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
33967312|NCT04316598|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The subjects, Investigators and designees involved in the conduct of the study will be blinded to the identity of the treatment administered during the study.~The following precautions will be taken to ensure the integrity of the study blinding during the trial:~* The monodose capsules containing the treatment conditions will be prepared by an unblinded technician who will not be involved in any study assessment. The unblinded technician will also maintain records for drug accountability.~* Treatment will not be unblinded for an individual subject except for a medical emergency."|Prospective, monocentric, double-blind, randomized, placebo-controlled, parallel group study. Subjects will be randomly assigned in a 2:1 ratio to study arms.|t|t|t|f
33967313|NCT03406130|RANDOMIZED|PARALLEL||TREATMENT||||||||
34076121|NCT04754815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single arm open label with 2 treatment options||||
34193883|NCT03241147|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193884|NCT05114642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Head posture on lateral cephalometric radiographs taken before and after the application of the rapid maxillary expansion device with hooks to the upper dental arch and the Petit type face mask treatment applied after the skeletal class III patients due to maxillary retrognathia, whose growth development continues, for treatment to the Orthodontics Department of the Faculty of Dentistry, cervical posture, pharyngeal airway, and hyoid bone positions are determined.||||
33873933|NCT06264700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators will be blinded to prevent the possibility of any differential treatment that could affect the ability of the study team to evaluate the impact of VDOT on hydroxyurea adherence. As such, a statistician will create a randomization model and study staff will facilitate communication with participants as well as between participants and the VDOT team.|After completing a one to three-month run-in period, participants will be randomized to receive six months of either VDOT or attention control. All participants will then complete six months of ongoing monitoring during which VDOT patients will receive intermittent communication to encourage adherence and both groups will continue to use their electronic adherence monitors.|f|f|t|f
33873934|NCT02268903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873935|NCT01865409|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193885|NCT01715857|||CASE_ONLY||PROSPECTIVE|||||||
34193886|NCT05600777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193887|NCT05483829|NA|SINGLE_GROUP||OTHER||NONE||||||
34193888|NCT04013685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193889|NCT02715440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193890|NCT03288051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193891|NCT02042716|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756008|NCT04196426|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Three communities receive the nutrition intervention while three other communities do not. After 1 month, the first 3 communities do not receive the intervention while the later 3 communities receive the same nutrition intervention. Baseline, post intervention data are collected.||||
33756009|NCT03610295|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Retrospective,consecutive,nonrandomized comparative trial with historical control||||
33873936|NCT01735487|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33873937|NCT00960661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873938|NCT05331521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873939|NCT00971178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873940|NCT01337856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33873941|NCT01239602|||CASE_CONTROL||PROSPECTIVE|||||||
33873942|NCT04255446|||COHORT||PROSPECTIVE|||||||
33873943|NCT06240832|NA|SINGLE_GROUP||TREATMENT||NONE||One group of children ages more than 6ys will recruited and assessed pre and post of study completion for 12week||||
33873944|NCT03548935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33873945|NCT05345964|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33873946|NCT04276714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single Case Experimental Design : multiple N of 1 trial||||
33873947|NCT03399877|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Children who meet the inclusion criteria and no exclusion criteria are assigned to perform one of the three test protocols in order of registration according to a computer gererated randomization list. Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again. Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry. Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.||||
33873948|NCT03569709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|f|t|t|t
33873949|NCT01170403|||COHORT||PROSPECTIVE|||||||
33873950|NCT04746352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873951|NCT05941975|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33873952|NCT03401515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33873953|NCT04200261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873954|NCT02828553|||COHORT||PROSPECTIVE|||||||
33873955|NCT02912572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873956|NCT02194751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967314|NCT05450666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment and evaluation in the study were performed by different physiotherapists.|Evaluation was made before the exercise application, after the eight-week application.|f|f|t|f
33967315|NCT05569733|||COHORT||PROSPECTIVE|||||||
33967316|NCT01805310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33967317|NCT00230633|||COHORT||PROSPECTIVE|||||||
33967318|NCT06147219|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967319|NCT01203319|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34076122|NCT00441285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193892|NCT01138917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193893|NCT02013258|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34193894|NCT03390842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34193895|NCT05204693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873957|NCT04971291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873958|NCT06003114|||OTHER||RETROSPECTIVE|||||||
33873959|NCT01611974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33873960|NCT01483391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33873961|NCT04911803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33873962|NCT04643912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Measuring the effectiveness of vibration fracture analysis against standard radiographs.||||
33873963|NCT00006476||||TREATMENT||||||||
33873964|NCT00798850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873965|NCT04133467|||CASE_CONTROL||RETROSPECTIVE|||||||
33873966|NCT02584842|||COHORT||RETROSPECTIVE|||||||
33967320|NCT05527119|||CASE_ONLY||RETROSPECTIVE|||||||
33967321|NCT02125578|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33967322|NCT00782236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967323|NCT00874900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076123|NCT02212119|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34193896|NCT02711267|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34193897|NCT05439005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33873967|NCT00426257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873968|NCT01956903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33873969|NCT05007951|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Outcome assessors are unblinded after Stage1 interim analysis||t|t|t|t
33873970|NCT03698435|||CASE_ONLY||PROSPECTIVE|||||||
33873971|NCT00530114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33873972|NCT02543463|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33873973|NCT02954367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873974|NCT00535132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873975|NCT03951675|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33873976|NCT01157364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873977|NCT01509196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33873978|NCT05339295|RANDOMIZED|CROSSOVER||OTHER||NONE||A single center, open Label, Randomized, Two Way Cross over, Two Period, Two Treatment, two Sequence Bioequivalence Study||||
33873979|NCT02180555|||COHORT||PROSPECTIVE|||||||
33873980|NCT04818684|||COHORT||PROSPECTIVE|||||||
33873981|NCT02401828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873982|NCT05376865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873983|NCT01956513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33873984|NCT00845650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873985|NCT02755311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33873986|NCT04918199|||COHORT||RETROSPECTIVE|||||||
34193898|NCT03113890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No Masking|The investigators will enroll 200 inpatient subjects over 2 years who will donate saliva/undergo a cheek swab to collect DNA for the Genecept assay. For 100 patients in the assay-guided group (AGG), study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management. For the additional 100 inpatients, treating clinicians will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Study Doctors will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period. Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making.||||
33873987|NCT00865150|||COHORT||PROSPECTIVE|||||||
33873988|NCT00067028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193899|NCT04191200|||COHORT||PROSPECTIVE|||||||
33873989|NCT03900403|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open-arm study, comparing the effects of 12 weeks of 40g of walnut intake to 6 weeks of the study participant's habitual diet.||||
33873990|NCT06156956|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open label, observational study with intervention (Fecal Microbiota Transplantation)||||
33873991|NCT00409084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33873992|NCT06082986|||COHORT||RETROSPECTIVE|||||||
33967324|NCT01710852|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33967325|NCT02856867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33967326|NCT00872391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967327|NCT02588131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076124|NCT00849069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34193900|NCT05213728|NA|SINGLE_GROUP||PREVENTION||NONE|Open Label|||||
34193901|NCT03129399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193902|NCT02916537|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34193903|NCT04636983|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
34193904|NCT03537300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193905|NCT00095940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193906|NCT00747357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193907|NCT06327724|||COHORT||PROSPECTIVE|||||||
34193908|NCT05622760|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The randomization code is only known to a collaborator who fills the envelopes according to said code. The envelopes are distributed in order of arrival at the study, the researcher in charge of distributing them and recording the information does not know the randomization code. At the end of the study and registering all the data, the collaborator who has the code will deliver it to the principal investigator of the study.~In all the envelopes there is some type of information so that the patients are also blind. The experimental group is given a sheet with the links to the videos and the other group is given written information, which is available on the health organization's website. In this way, no group feels that it does not receive information and we control said bias."|Clinical trial on quality of life where there are 2 groups. After signing the informed consents and completing the anxiety surveys, each participant is randomized and given the corresponding envelope.|t|t|t|t
34193909|NCT05726188|||COHORT||RETROSPECTIVE|||||||
34193910|NCT03089164|||COHORT||PROSPECTIVE|||||||
33873993|NCT05429827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33873994|NCT06470139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33873995|NCT05973604|||CASE_ONLY||PROSPECTIVE|||||||
33873996|NCT03906097|RANDOMIZED|PARALLEL||TREATMENT||NONE||Before randomization, 80 children were performed the tests (TVPS-3 and DOTCA-Ch) and questionnaires (BRIEF and EFORTS) were given to their parents and teachers. Then, SPSS 24.00 was randomized with the program and the control group was divided into 2 equal groups (intervention group n = 40; control group n = 40). The intervention group was received cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program (Figure 3.1). Both groups were evaluated three times at baseline, at the end of the 10th week and at the end of the third month (follow up).||||
33873997|NCT02595151|||CASE_CONTROL||PROSPECTIVE|||||||
33967328|NCT04242186|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33967329|NCT00601328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967330|NCT04340700|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33967331|NCT05348590|||COHORT||PROSPECTIVE|||||||
33967332|NCT00971672|||COHORT||PROSPECTIVE|||||||
33967333|NCT06325982|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33967334|NCT01888328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967335|NCT01340950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967336|NCT04451265|||CASE_ONLY||PROSPECTIVE|||||||
33967337|NCT05959369|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||description study||||
34193911|NCT00336856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193912|NCT06420609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study proposes a randomized controlled clinical trial (RCT) with a stepped-wedge design, in which 6 palliative care units from second and third level hospitals in Spain will collaborate. The six units will contribute with both experimental and control participants, starting with the recruitment of the control group participants and subsequently starting the intervention group. The time at which they will transition to the intervention will be chosen at random. The centers will be randomized to know at what point in the study they should begin the intervention and each center will be informed of the number of patients they should include in each of the groups. The clusters correspond to the different palliative care units that participate in the study. Six sequences will be carried out, seven periods with 4 patients in each period. Patients will be different in each of the periods.||t|f|f|f
34193913|NCT01523977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193914|NCT03571698|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34193915|NCT00123253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34193916|NCT04135586|RANDOMIZED|PARALLEL||OTHER||SINGLE||Physical exercise intervention (24 weeks)|f|f|f|t
34193917|NCT05453149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34193918|NCT02482818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34193919|NCT03338413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193920|NCT00006409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193921|NCT05236699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193922|NCT02801019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34193923|NCT06073483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193924|NCT01643772|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193925|NCT03998839|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33873998|NCT03966742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients||||
33873999|NCT02184078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967338|NCT03779516|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33967339|NCT00071409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967340|NCT06321237|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34193926|NCT05350696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34193927|NCT03381976|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34193928|NCT02682862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34193929|NCT05224167|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
34193930|NCT03294564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34193931|NCT00914108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34193932|NCT05032170|||COHORT||CROSS_SECTIONAL|||||||
34193933|NCT00028652||||TREATMENT||||||||
33874000|NCT00259883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967341|NCT03859609|||COHORT||RETROSPECTIVE|||||||
33967342|NCT06447454|||COHORT||PROSPECTIVE|||||||
33967343|NCT00388882||||TREATMENT||||||||
33967344|NCT02611999|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33967345|NCT06238492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967346|NCT05997485|||COHORT||RETROSPECTIVE|||||||
34193934|NCT02587377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193935|NCT02468245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34193936|NCT04900740|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No masking will be used in the study.|The patients will be enrolled into one of two study groups, depending on the decision of the attending physician.||||
34193937|NCT03554343|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34193938|NCT06190769|||OTHER||CROSS_SECTIONAL|||||||
34193939|NCT00638183|||COHORT||PROSPECTIVE|||||||
33874001|NCT06537960|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874002|NCT04553120|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single case, multiple-baseline AB design||||
33874003|NCT05778058|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||90 healthy young individuals were included in the study. Participants were randomly divided into 3 groups as unilateral (n=30, 15 female, 15 male), bilateral (n=30, 15 female, 15 male) and bilateral sham (n=30, 15 female, 15 male) groups. ). The cycling exercise was performed at maximum performance for 30 minutes under the same wattage load. Non-invasive ear stimulation was performed with the Vagustim device according to the participant groups. Pulse, systolic and diastolic blood pressure, distance, pain, fatigue, lactic acid level and autonomic nervous system were evaluated before, after and at the end of cycling exercise. Oneway Anova test and Kruskal Wallis test were used between groups. Dunn's test was used to determine the group that caused the difference. Analysis of variance was used for repeated measurements, Bonferroni test and Friedman test were used for in-group comparisons. Significance was evaluated at the p\<0.05 level.|t|f|f|t
33874004|NCT02376270|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874005|NCT04891094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874006|NCT04070742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967347|NCT01297192|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967348|NCT00826631|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967349|NCT00253097|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33967350|NCT00397319|||CASE_CONTROL||PROSPECTIVE|||||||
33967351|NCT05093283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33967352|NCT04080882|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33967353|NCT03198988|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34193940|NCT00236704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34193941|NCT01210547|||CASE_ONLY||PROSPECTIVE|||||||
34193942|NCT01318824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33756010|NCT01037855|||COHORT||PROSPECTIVE|||||||
33967354|NCT05705440|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33967355|NCT05835206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967356|NCT04535583|||CASE_ONLY||PROSPECTIVE|||||||
33967357|NCT01405170|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33967358|NCT01792856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967359|NCT02118753|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967360|NCT05970601|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33967361|NCT03370484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33756011|NCT02297022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756012|NCT00671203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756013|NCT06256133|||COHORT||RETROSPECTIVE|||||||
33756014|NCT05795101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||two parallel cohorts||||
33756015|NCT05539092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33756016|NCT05382182|||CASE_ONLY||RETROSPECTIVE|||||||
33756017|NCT06579066|RANDOMIZED|PARALLEL||TREATMENT||NONE||"One hundred twenty three patients who will fit the inclusion criteria will be randomly divided into 3 groups:~Group 1 (Probiotics group): 41 Patients will administer Linex®(one capsule daily) orally along with the standard care of therapy for duration of 4 weeks.~Group 2 (activated charcoal): 41 Patients will administer Charclone® 1000MG Tab (Tablet three times daily) orally along with the standard care of therapy for duration of 4 weeks.~Patients will take activated charcoal dose at least 2 hours before taking other drugs.~Group 3 (Control group) : 41 Patients will administer standard care of therapy alone (fexofenadine) TELFAST®120mg tablet once daily"||||
33756018|NCT01866943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756019|NCT04496102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756020|NCT03451734|||COHORT||PROSPECTIVE|||||||
33756021|NCT02529826|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756022|NCT06311279|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|randomized comparative clinical trial|Comparison between end to end and side to end anastomosis after anterior resection of cancer rectum and compare the outcomes of both surgical techniques. The main outcomes were bowel functional outcomes and QoL. Bowel functional outcomes mainly included three indexes: stool frequency, urgency, incomplete defecation, and incontinence. The secondary outcomes were surgical outcomes including operative time, postoperative hospital stay, postoperative complications, reoperation, and mortality|t|f|f|t
33756023|NCT01654432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756024|NCT05333406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756025|NCT00384904|NON_RANDOMIZED|PARALLEL||||NONE||||||
33756026|NCT02879812|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756027|NCT04042155|||COHORT||PROSPECTIVE|||||||
33756028|NCT03940820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756029|NCT00232830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756030|NCT02314624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874007|NCT01536600|||COHORT||PROSPECTIVE|||||||
33874008|NCT06402708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874009|NCT02960828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874010|NCT02526342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874011|NCT03580252|||COHORT||PROSPECTIVE|||||||
33874012|NCT04255264|||COHORT||PROSPECTIVE|||||||
33874013|NCT01747642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874014|NCT00868777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874015|NCT04523311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193943|NCT03930264|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34193944|NCT01795170|||COHORT||PROSPECTIVE|||||||
33874016|NCT05294055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874017|NCT01438580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874018|NCT04945070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874019|NCT04081350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33874020|NCT06282042|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicentre, randomised, open-label, comparative effectiveness clinical trial for the treatment of clinically significant functional mitral regurgitation within 60 days after acute myocardial infarction, who are treated per standard of care and who have been determined by the site's local heart team as inappropriate or too high risk for mitral valve surgery.||||
33967362|NCT04160949|||CASE_ONLY||PROSPECTIVE|||||||
33967363|NCT06382779|||CASE_CONTROL||RETROSPECTIVE|||||||
33967364|NCT02591979|||OTHER||PROSPECTIVE|||||||
34193945|NCT02070913|||CASE_ONLY||PROSPECTIVE|||||||
33874021|NCT06262958|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clients are randomized into two groups: 1) those receiving TAU and 2) those receiving a mini-intervention for substance and alcohol use an add-on treatment.||||
33874022|NCT02111161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874023|NCT04071821|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, Open-Label, Single-Dose, Five-Period Crossover||||
33874024|NCT02821507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874025|NCT04254068|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized case series trial||||
33874026|NCT02260115|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874027|NCT00338039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874028|NCT02005809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756031|NCT03230773|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomised study with volunteers randomised to use one of six different defibrillator designs.||||
33756032|NCT01224301|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874029|NCT04451980|||COHORT||CROSS_SECTIONAL|||||||
33756033|NCT00134290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33756034|NCT06580873|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm, open-label, prospective interventional cohort study.||||
33756035|NCT02185625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756036|NCT05189951|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33756037|NCT06291610|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Patients are recruited anonymous|Pre- and post-intervention measures in two consecutive groups.||||
33756038|NCT01261702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874030|NCT03767023|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874031|NCT05378256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874032|NCT01358864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874033|NCT01620242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874034|NCT00000421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33967365|NCT06000189|||CASE_CONTROL||PROSPECTIVE|||||||
33967366|NCT02371967|||COHORT||PROSPECTIVE|||||||
34193946|NCT06057961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Controlled Study|t|f|f|t
34193947|NCT02028208|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Biologic||||
33967367|NCT05045794|RANDOMIZED|PARALLEL||TREATMENT||NONE|A centralized radiologist who evaluates imaging (MRCP) for one of the secondary endpoints (ischemic cholangiopathy) will be blinded to treatment assignment. The study is otherwise open label.|This is a randomized, controlled, open-label, sequential assignment, non-inferiority design comparing two treatment arms (HOPE, static cold storage)||||
34193948|NCT00344487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193949|NCT00129844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193950|NCT02373085|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874035|NCT02191254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874036|NCT02383732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874037|NCT01880931|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874038|NCT02115009|||CASE_CONTROL||PROSPECTIVE|||||||
33874039|NCT00004873|RANDOMIZED|||TREATMENT||||||||
33874040|NCT00328315|||OTHER||PROSPECTIVE|||||||
33874041|NCT04195152|||CASE_CONTROL||PROSPECTIVE|||||||
34193951|NCT03329014|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33874042|NCT02225249|||COHORT||PROSPECTIVE|||||||
33874043|NCT02069405|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33874044|NCT00116350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874045|NCT05908682|||CASE_ONLY||OTHER|||||||
33874046|NCT03617991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967368|NCT03229031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized, Double-blind||t|f|t|t
34193952|NCT03141294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34193953|NCT01475240|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34193954|NCT00531427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34193955|NCT05176171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193956|NCT03550521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193957|NCT01814709|RANDOMIZED|PARALLEL||||NONE||||||
34193958|NCT03089385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34193959|NCT01685151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193960|NCT00000797|||COHORT||PROSPECTIVE|||||||
34193961|NCT04211675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193962|NCT03113136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34193963|NCT05879094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193964|NCT04017845|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34193965|NCT06174090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double|The intervention group will watch a 12-minute video-education about pre-post surgical process and care in bypass surgery, for once the day before surgery. Video-education was created by the researcher based on the literature. Expert opinion was provided related to content. The control group will receive standard verbal education lasting 12-minute about the issue.|t|f|f|t
33756039|NCT00147940|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756040|NCT02714335|||CASE_ONLY||RETROSPECTIVE|||||||
33756041|NCT05049759|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility trial to establish acceptability and feasibility of the developed intervention.||||
33756042|NCT05323539|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33756043|NCT02036957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33756044|NCT03383770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The selection of the puncture cannula for regional anaesthesia is not up to the performing anaesthetist, as is usual in the clinical standard, but is made randomly on the basis of a random list. The blockade is carried out by two anaesthetists experienced in regional anaesthesia, who have the principle of dual control. The ultrasound image acquired during the blockade is recorded in the form of an ultrasound video for subsequent evaluation. The recorded ultrasound videos are stored pseudonymously on the server of the Klinik für Anästhesiologie m. S. operativ Intensivmedizin reported to the data protection department.|t|f|f|f
33756045|NCT02265302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33756046|NCT01836705|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33756047|NCT04450602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study agents will have randomized codes. Supplement capsules, shampoo, conditioner and scalp serum will all be similar in look and scent to the active products. The placebo shampoo, conditioner and serum will have the same base materials as their counterparts but will not contain active ingredients, and will therefore be similar in viscosity and color.|Subjects will be randomized into 1 of 2 parallel groups. There will be one (1) treatment group and one (1) placebo group. Subjects will receive either the ALRV5XR treatment regimen or placebo regimen.|t|t|t|t
33756048|NCT01137474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874047|NCT02463409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874048|NCT02216032|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33874049|NCT01870102|RANDOMIZED|CROSSOVER||||NONE||||||
33874050|NCT03603860|||CASE_ONLY||PROSPECTIVE|||||||
33874051|NCT01535170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874052|NCT03914794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874053|NCT01709149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874054|NCT05479942|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34193966|NCT03030846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193967|NCT05303402|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34193968|NCT02909816|||COHORT||PROSPECTIVE|||||||
34193969|NCT00468962|RANDOMIZED|PARALLEL||||DOUBLE||||||
34193970|NCT00616538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34193971|NCT01300013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34193972|NCT05909501|||COHORT||PROSPECTIVE|||||||
34193973|NCT04512755|||COHORT||PROSPECTIVE|||||||
34193974|NCT02511223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193975|NCT04516954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193976|NCT02575027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193977|NCT02299583|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34193978|NCT00499616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193979|NCT01362478|||CASE_CONTROL||PROSPECTIVE|||||||
34193980|NCT01077921|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34193981|NCT05667337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Once qualified, subjects will be enrolled to receive a CLP-PEG-MPC implant by DALK. DALK surgery requires the precise dissection of the central 8 mm of the corneal stroma from the underlying posterior corneal layers (Dua layer, Descemet membrane and endothelium, approximately 30 microns thick). The dissection performed during DALK may perforate the posterior corneal layers, requiring conversion to full-thickness penetrating keratoplasty (PKP). Subjects who require conversion to PKP will receive a full-thickness human donor cornea as a safety measure and will be followed per protocol as a comparison group.||||
34193982|NCT00817310|||CASE_CONTROL||PROSPECTIVE|||||||
34193983|NCT02925949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34193984|NCT06171841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193985|NCT01511120|NA|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34193986|NCT02677233|||CASE_CONTROL||RETROSPECTIVE|||||||
34193987|NCT03419585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomized to one of two arms: an intervention light group or a comparison light group. Both the participant and the investigator will be blind to the light assignment.||t|f|t|f
34193988|NCT05784272|||COHORT||CROSS_SECTIONAL|||||||
34193989|NCT05971576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34193990|NCT02784639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34193991|NCT03963271|||COHORT||PROSPECTIVE|||||||
34193992|NCT04578821|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes Assessor|Prospective randomized controlled clinical trial|f|f|f|t
34193993|NCT02375061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193994|NCT02127099|||COHORT||PROSPECTIVE|||||||
34193995|NCT01298908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34193996|NCT04442035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34193997|NCT04308967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34193998|NCT03268655|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind|Pilot. Double-blind placebo-controlled randomized trial|t|f|t|f
34193999|NCT04073524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The municipality of Svendborg has the superior responsibility for the 'Wild man programme'. Participation in the intervention as well as participation in the study is voluntary. All information collected in the study will be treated confidentially, and participation requires a signed consent form.|The study is a matched control study where the intervention group receives a nine-week nature-based intervention and is compared to a matched control group receiving case management as treatment as usual in the municipalities (see figure 1). All primary and secondary outcomes are measured at baseline (T1), post treatment (T2), and at follow-up 6 months post intervention (T3).||||
34194000|NCT03229642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194001|NCT00874939|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34194002|NCT05630963|||CASE_CONTROL||PROSPECTIVE|||||||
34194003|NCT00609531|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34194004|NCT00003590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194005|NCT01192802|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34194006|NCT01651962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194007|NCT02878187|||CASE_CONTROL||PROSPECTIVE|||||||
34194008|NCT06126250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner-blind only, subjects will receive treatment assignment and instructions in a room separate from the examiner and exam area.|Parallel Assignment|f|f|f|t
34194009|NCT03047824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33756049|NCT06412653|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm, open-label pilot trial||||
33874055|NCT00472433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874056|NCT00081159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874057|NCT04940858|||COHORT||PROSPECTIVE|||||||
33874058|NCT00000761||||TREATMENT||NONE||||||
34194010|NCT03287518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind, placebo-controlled|Randomized, double-blind, placebo-controlled, parallel-group study|t|t|t|t
34194011|NCT04508218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194012|NCT00262938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194013|NCT02949479|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34194014|NCT02045043|||COHORT||PROSPECTIVE|||||||
34194015|NCT01757990|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34194016|NCT05862506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194017|NCT00263289|||||OTHER|||||||
34194018|NCT00783484|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34194019|NCT02907632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194020|NCT02527044|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|FFR values are collected by a member of the research staff. The treating physicians, the patient, and the outcome assessor will be blinded to the pre-operative FFR values.||t|t|f|t
33967369|NCT04719897|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34194021|NCT04623853|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34194022|NCT00271505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194023|NCT02888678|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||f|f|t|t
34194024|NCT05192447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34194025|NCT06105905|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34194026|NCT03400605|||COHORT||PROSPECTIVE|||||||
34194027|NCT01349049|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34194028|NCT02628080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194029|NCT05189821|||COHORT||PROSPECTIVE|||||||
34194030|NCT01801267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194031|NCT01278940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194032|NCT01703182|||COHORT||PROSPECTIVE|||||||
34194033|NCT00582075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194034|NCT03945617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded regarding treatment allocation|This is randomized controlled trial involving a before-after design with an intervention group that receives immediate access to treatment and a waitlist-control group.|f|f|f|t
34194035|NCT06192199|||COHORT||RETROSPECTIVE|||||||
34194036|NCT00346424|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34194037|NCT01078818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194038|NCT05826561|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
34194039|NCT05777291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The masking procedure will involve blinding the outcome assessors to the treatment allocation of the patients. This means that the outcome assessors will be kept unaware of whether the patients are wearing the device or not.|unblinded randomized trial with blinded outcome assessors|f|f|f|t
34194040|NCT00444561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194041|NCT01222728|||||PROSPECTIVE|||||||
34194042|NCT03713905|NA|SEQUENTIAL||TREATMENT||NONE||1 mg per kg, Q2W; 4 mg per kg, Q2W; 10 mg per kg, Q2W; 240 mg fixed dose, Q2W||||
34194043|NCT02345564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194044|NCT03680846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194045|NCT02817529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194046|NCT04169932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194047|NCT00349050|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34194048|NCT01835509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194049|NCT04313140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194050|NCT04155242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967370|NCT05064865|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33967371|NCT02457624|||COHORT||PROSPECTIVE|||||||
33967372|NCT00581659|||COHORT||CROSS_SECTIONAL|||||||
33967373|NCT03017599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967374|NCT06531200|||COHORT||PROSPECTIVE|||||||
33967375|NCT01596816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967376|NCT06177379|||COHORT||PROSPECTIVE|||||||
33967377|NCT01270841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194051|NCT02190565|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34194052|NCT03196492|||COHORT||PROSPECTIVE|||||||
34194053|NCT03687944|||OTHER||OTHER|||||||
34194054|NCT00004005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194055|NCT02604901|RANDOMIZED|FACTORIAL||||NONE||||||
34194056|NCT02720042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194057|NCT02422368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34194058|NCT01071018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194059|NCT05949502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194060|NCT06348290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194061|NCT01748240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194062|NCT06230601|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194063|NCT00973713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194064|NCT06394882|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster Randomized controlled clinical trial to test the efficacy of a family-centered healthy lifestyle program on adiposity and weight status in mother-child dyads with overweight or obesity.||||
33874059|NCT06182982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33874060|NCT02250820|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33874061|NCT05744089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874062|NCT04967937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194065|NCT05486624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||1 control group, 1 intervention group||||
34194066|NCT04661579|RANDOMIZED|PARALLEL||OTHER||NONE||Three groups (Groups 1, 2, and 3) will be administered RTS,S/AS01E on a 0, 1, 7 month schedule with Dose 3 delivered as a 1/5th fractional dose. Two groups (Groups 4 and 5) will be administered a comparator vaccine on a 0, 1, 7 month schedule.||||
34194067|NCT04876690|||COHORT||CROSS_SECTIONAL|||||||
34194068|NCT02262208|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34194069|NCT03438370|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster Randomized Trial comparing three different antiretroviral therapy (ART) dispensing strategies.||||
34194070|NCT03405233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patients do not know which group will they belong the duplex operator will not know the details of operative data||t|f|f|t
34194071|NCT05237089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the acupuncturists in this study will know about the group assignment of patients. All other relevant parties will be blinded to the intervention. Participants will be informed that they will be randomly allocated to the electroacupuncture group or the superficial acupuncture group before study participation.|All eligible participants will be randomly assigned into two group at a ratio of 1:1, the Electroacupuncture group and the Sham acupuncture group (the control group).|t|f|t|t
34194072|NCT00638638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194073|NCT00464880|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34194074|NCT03424941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194075|NCT03562988|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34194076|NCT04202042|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34194077|NCT00625664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194078|NCT02619916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194079|NCT03601884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To reduce performance bias after the randomization process, blinding is adopted. However, due to the conflicting requirements of ethical and methodological aspects in designing a randomized controlled trial with a psychosocial intervention, double blinding and randomizing each individual participant posits a huge challenge. Patients, the attending doctors and the co-author involved in randomly assigning the group will be blinded in a way that none of them will know which group is considered the experimental group and the control group.|"This study is a Randomised Controlled Trial. The sampling frame will be patients with diabetes registered in all the government health clinics located in Putrajaya. Patients are screened at the beginning and later interviewed using a structured questionnaire and intake interview. All four Health Clinics in Putrajaya will participate in the study, randomization will be conducted at the facility level.~This study is a two arm - experimental vs. control group RCT. Participants are randomly allocated at facility level. All four health clinics will be randomly assigned to the OHP and TAU (experimental group) or TAU (control group), with two health clinics randomly allocated in the experimental group and another two the control group."|t|f|f|f
34194080|NCT03664596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194081|NCT02567604|||OTHER||PROSPECTIVE|||||||
34194082|NCT02716012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194083|NCT04480970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194084|NCT04085900|||COHORT||PROSPECTIVE|||||||
34194085|NCT01123551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194086|NCT02992197|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194087|NCT05917678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants with deformational head shapes start with repositioning strategies, then some will change to the orthotic intervention (custom remolding helmet). Healthy infants will only be followed, no intervention performed. All infants will be followed until 12 months of age.||||
33874063|NCT01505842|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34194088|NCT04500561|NA|SINGLE_GROUP||TREATMENT||NONE||YY-20394 combined with GEMOX was used as a cycle for 21 days. The dose of YY-20394 was 80mg/ day as recommended in phase 2, and the dose of GEMOX was treated according to clinical standards||||
34194089|NCT02083861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194090|NCT00375206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34194091|NCT03236324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194092|NCT00809302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194093|NCT04582253|||COHORT||RETROSPECTIVE|||||||
34194094|NCT00899353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194095|NCT01284491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194096|NCT00264459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194097|NCT01346995|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34194098|NCT03697889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194099|NCT04466579|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking is being used in this study.|The study subjects will be randomized into two study arms.||||
34194100|NCT04870580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194101|NCT05555420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194102|NCT06522594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194103|NCT02184052|||COHORT||PROSPECTIVE|||||||
34194104|NCT03303508|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study will include patients with suspected diagnosis of autoimmune rheumatic diseases referred to the Laboratory of Clinical Immunology, Clinical Pathology Department, Assiut University Hospital for anti-dsDNA test. Patients will be recruited into the study within period of one year.~Also, apparently healthy subjects (at least 25 subjects; according to international method verification guidelines) will be included as a control group."||||
34194105|NCT03218618|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34194106|NCT02501187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194107|NCT05648045|||OTHER||CROSS_SECTIONAL|||||||
34194108|NCT04487119|||COHORT||RETROSPECTIVE|||||||
34194109|NCT02646371|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34194110|NCT01761162|||CASE_ONLY||PROSPECTIVE|||||||
34194111|NCT05473650|||COHORT||PROSPECTIVE|||||||
34194112|NCT01536392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194113|NCT03144609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194114|NCT04732078|||COHORT||RETROSPECTIVE|||||||
34194115|NCT01250444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194116|NCT02938715|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194117|NCT01074385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194118|NCT06326983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194119|NCT04529486|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The children with Cerebral Palsy included in this study consisted of 2 groups, the study group and the control group. No application was made to the control group. The same participant group was included as the experimental group after 1 week of rest. The assessments were done three times for each group (beginning - 45min later - 1 week later)||||
34194120|NCT03269929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34194121|NCT00852839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194122|NCT02843152|||CASE_CONTROL||PROSPECTIVE|||||||
34194123|NCT01672177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34194124|NCT06426524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194125|NCT05950646|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194126|NCT01948856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194127|NCT06194045|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Interventions are given as 1g bovine capsules of equal size, weight and appearance, and provided in identical bottles with a coded label.||t|t|t|t
34194128|NCT01488851|||COHORT||PROSPECTIVE|||||||
34194129|NCT02438475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874064|NCT04584528|NA|SEQUENTIAL||TREATMENT||NONE||Multi-site pre-post study design, with a core set of mandatory patient and provider intervention strategies for each participating site, and optional strategies to allow for intervention adaptation to local needs and resources.||||
33874065|NCT01859728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874066|NCT04527302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
33874067|NCT05260619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874068|NCT05029635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874069|NCT01692964|||COHORT||PROSPECTIVE|||||||
33874070|NCT04534478|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel clinical trial with therapeutic intervention, randomized, open and controlled, of non-inferiority||||
33874071|NCT06500351|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33967378|NCT00480220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076125|NCT03932461|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multicentre randomized non-blinded clinical trial comprising of \> 4 centres. In total there will be included 320 patients.||||
34076126|NCT06086938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194130|NCT03762096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34194131|NCT00199719|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194132|NCT02576145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194133|NCT06409416|||COHORT||PROSPECTIVE|||||||
34194134|NCT06418139|||COHORT||CROSS_SECTIONAL|||||||
34194135|NCT03287206|||COHORT||PROSPECTIVE|||||||
34194136|NCT03472170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194137|NCT06231771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Dosage · Dosing of IMP is based on ulcer size. The recommended dose is 1 million cells/cm2 of ulcer. Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients) Dosage · Dosing of placebo is based on ulcer size. the volume will be same as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)|t|t|t|t
34194138|NCT03300102|||COHORT||PROSPECTIVE|||||||
34194139|NCT05003297|||CASE_ONLY||RETROSPECTIVE|||||||
34194140|NCT06332872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194141|NCT00643084|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
34194142|NCT03826368|||COHORT||RETROSPECTIVE|||||||
34194143|NCT01873612|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34194144|NCT05437302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194145|NCT03859947|||COHORT||PROSPECTIVE|||||||
33756050|NCT06579664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This trial is a double-blind design using simulants to ensure blinding. Participants will be randomly assigned to the iTBS and sham group according to the randomization codes that were generated by a computer program.|This trial was a randomized, single-center, double-blind, sham-controlled parallel trial. Participants were randomly assigned to receive iTBS stimulation or sham stimulation for 3 weeks in 1:1 ratio.|t|t|t|t
33756051|NCT01175525||PARALLEL||||||||||
33756052|NCT01168193|NA|SINGLE_GROUP||||NONE||||||
33874072|NCT03446950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be blinded to their intervention group. Investigators following up with participants at 6 weeks will be blinded to the group allocation of the participants|To compare patient positioning during vaginal surgery we plan to conduct a single site single blinded randomized controlled trial where patients planning elective vaginal surgery will be randomized to be positioned in Candy cane or Boot stirrups|t|f|f|t
33874073|NCT01053871|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33874074|NCT01791348|NA|SINGLE_GROUP||||NONE||||||
33874075|NCT02136030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194146|NCT03704636|NA|SINGLE_GROUP||OTHER||NONE||||||
34194147|NCT02855918|NA|SINGLE_GROUP||OTHER||NONE||||||
34194148|NCT05317091|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194149|NCT01758536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194150|NCT04903743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194151|NCT05437705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The study will use a single-blind design.|All subjects will receive TMS using the optimized and least optimized frequencies, but the order is randomized and counterbalanced.|t|f|f|f
34194152|NCT03373331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194153|NCT04483401|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The occupational therapist assessing the filming of child performing their 3 goals at week 1 and 10 will be blinded to which week the the goals were performed.|"Participants are either recruited from the Trajectories Study at their 8-year follow-up visit where the Neonatal Follow-Up Team has determined that the child has DCD and meets inclusion criteria for the study, or participants may contact the research coordinator after seeing a recruitment flyer for this study.~Both groups will receive occupational therapy once weekly for 10 weeks using the published protocol for the CO-OP approach."|f|f|f|t
34194154|NCT01484886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874076|NCT01794572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874077|NCT03844165|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant and study team will not be blinded to this allocation, although the scientist and radiology team will be blinded when analysing samples/scans.|This is two-arm dietary interventional study that will be conducted through the Population Health and Research Institute, Trivandrum, India. Participants will be randomised to one of two study arms: diet change with yoga or yoga. We will aim to recruit 42 participants to each arm.|f|f|t|f
33874078|NCT00424424|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33967379|NCT03560622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Ten adults with refractory ET (ET cohort) and 20 healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.||||
33967380|NCT04158479|||COHORT||PROSPECTIVE|||||||
33967381|NCT00332137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967382|NCT02226692|||COHORT||PROSPECTIVE|||||||
33967383|NCT02939638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967384|NCT01888471|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33967385|NCT00124449|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34194155|NCT06311318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were randomly assigned, using concealed block of four randomization, to either the experimental group receiving lower eyelid massage or the control group receiving standard care. While the authors, acting as massage trainers, were unblinded, an independent plastic surgeon, serving as the assessor, remained blinded to the study interventions.|A randomized controlled trial enrolled patients with traumatic facial fractures slated for subciliary approach repair. Patients were randomly allocated to the lower eyelid massage (experimental) or standard care (control) groups. The massage group received post-operative instructions. Data on demographics, injury profiles, lower eyelid scar contracture (graded by GLESCO criteria), eyelid malpositioning, comfort scores, and complications were gathered over a 6-month follow-up.|f|f|f|t
34194156|NCT03542032|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34194157|NCT01876329|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34194158|NCT01523275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076127|NCT01454011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874079|NCT06186960|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple Method Design||||
33874080|NCT03243383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874081|NCT04257825|RANDOMIZED|CROSSOVER||OTHER||NONE|There was no masking in this study.|In the four week study, participants were randomized into multiple arms, and asked to not use their device for 1 week, and then use it the next. Arms alternated back and forth.||||
33874082|NCT05939024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be unaware of the treatment group.||f|f|f|t
33874083|NCT00256737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194159|NCT01810614|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33874084|NCT00639483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874085|NCT01964014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874086|NCT04052451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open label study with one arm for subjects diagnosed with major depression disorder and one arm for subjects diagnosed with generalized anxiety disorder||||
33874087|NCT02898259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874088|NCT01411436|||CASE_ONLY||PROSPECTIVE|||||||
33874089|NCT00547846|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33874090|NCT04185688|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874091|NCT00300664|RANDOMIZED|PARALLEL||||SINGLE||||||
33967386|NCT03568500|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967387|NCT05977751|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33967388|NCT05693181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants in the experimental group will obtain 4 systemic (i.v.) infusions of allogenic group- and rhesus-compatible non-related mononuclear cord blood cell samples (500 +/- 50 x 10'6 cells each).~Participants in the control group will obtain the similar volume of vehicle (sterile saline).~Participant's devision will be performed in a randomized manner. Randomization will be performed using standard randomization computer table.~All participants will be blinded concerning the therapy mode."||t|f|f|f
33967389|NCT00362570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967390|NCT02460874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076128|NCT06108908|||COHORT||PROSPECTIVE|||||||
34076129|NCT02976610|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076130|NCT01704807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34076131|NCT04531423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The investigators adopted randomized design to test placebo-controlled antidepressant augmentation.Participants were randomized (1:1) into one of the following 2 groups: SSRI +golimumab, or SSRI +placebo."|f|f|f|t
34076132|NCT04978701|||COHORT||PROSPECTIVE|||||||
34076133|NCT03157076|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients are randomized in two different pacing modes (CLS versus intrinsic rhythm) after one month after enrollment. The cross-over takes place after one month after the randomization.|t|f|t|f
34194160|NCT00123669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194161|NCT05069870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194162|NCT05776095|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, two-center interventional study||||
34194163|NCT02659748|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34194164|NCT03409887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967391|NCT06047782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967392|NCT05351385|||COHORT||PROSPECTIVE|||||||
34076134|NCT00889941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076135|NCT04273516|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33874092|NCT03775954|||COHORT||PROSPECTIVE|||||||
33874093|NCT06060262|||COHORT||PROSPECTIVE|||||||
33874094|NCT00047060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874095|NCT03205462|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The current Phase I clinical trial has been developed to assess the safety and tolerability of the Fluorothyazinone drug used as a single-dose administration and a treatment course in healthy volunteers. This dose-escalation trial will be conducted with sequential enrollment of volunteers||||
33874096|NCT06001060|||COHORT||RETROSPECTIVE|||||||
33874097|NCT01489007|||COHORT||PROSPECTIVE|||||||
33874098|NCT05218330|||COHORT||PROSPECTIVE|||||||
33874099|NCT01437852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874100|NCT02316535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874101|NCT04671277|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874102|NCT04608227|||COHORT||PROSPECTIVE|||||||
33874103|NCT04064502|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33874104|NCT01761084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33874105|NCT05373654|NA|SINGLE_GROUP||OTHER||NONE||||||
33874106|NCT05030870|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33874107|NCT05032612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33874108|NCT01819051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874109|NCT01379274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874110|NCT04963556|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blinded to verum or placebo drink||t|f|f|f
33874111|NCT03308305|||COHORT||PROSPECTIVE|||||||
33874112|NCT04687787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be kept blind of the treatment provided.|There will be two groups which will receive physical therapy interventions. one will be experimental and other will be control group.|t|f|f|f
33874113|NCT01187953|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874114|NCT03923972|||OTHER||CROSS_SECTIONAL|||||||
33874115|NCT02534701|||COHORT||PROSPECTIVE|||||||
33874116|NCT00003625||||TREATMENT||NONE||||||
33874117|NCT01761292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874118|NCT00391573|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33874119|NCT02396134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34194165|NCT04590846|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a quasi-experimental design study, which will enroll students in the 3rd to 6th grades of two primary schools and their parents in Yunlin. There will be 200 children in the experimental group and 200 in the control group; with a total of 400 students and their parents. Parents in the experimental group will receive health educational leaflets every week. No intervention will be given to the control group. The 4-weeks intervention is scheduled to be from September to November 2020. Both the experimental and control groups will be asked to fill up a questionnaire at the before and after the intervention. The questionnaire includes the defecation and constipation situation of children, physical activity, dietary behavior, life pressure, and parents' knowledge and attitude toward constipation. Both groups of children have to fill out the Stool diary record sheet once a week, including the intervention period and the follow-up period for a total of 8 weeks.||||
34194166|NCT03870594|||COHORT||CROSS_SECTIONAL|||||||
34194167|NCT05102305|||COHORT||PROSPECTIVE|||||||
34194168|NCT04954651|||COHORT||PROSPECTIVE|||||||
34194169|NCT02319629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34194170|NCT00017329||||TREATMENT||NONE||||||
34194171|NCT02815722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194172|NCT04193696|NA|SINGLE_GROUP||TREATMENT||NONE||This stuy has only one arm.||||
34194173|NCT04626401|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blinded||t|f|t|f
34194174|NCT06060938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756053|NCT04759690|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cross-sectional sampling / Randomized controlled trial||||
33756054|NCT01984684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756055|NCT01954355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756056|NCT06535841|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33756057|NCT06495671|NA|SINGLE_GROUP||TREATMENT||NONE|Primary outcome assessed by blinded imaging core laboratory. Day 90 modified Rankin scale assessed by central blinded clinician.|Bayesian optimal phase 2 trial||||
34076136|NCT01442662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076137|NCT03150329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076138|NCT05686447|||CASE_CONTROL||OTHER|||||||
34076139|NCT03035565|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34194175|NCT00842868|||COHORT||PROSPECTIVE|||||||
34194176|NCT00700167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194177|NCT00145977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194178|NCT00536913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194179|NCT02086006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194180|NCT04788368|||CASE_ONLY||OTHER|||||||
34194181|NCT02567058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34194182|NCT03032380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194183|NCT02885064|||COHORT||PROSPECTIVE|||||||
34194184|NCT04976582|RANDOMIZED|PARALLEL||TREATMENT||NONE|Researcher and participants both are familiar with the procedure of interventions.|"Participants will be divided into two groups Group 1: control group in which kinesiotaping with conventional physical therapy treatment (modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered.~Group 2: experimental group in which dry needling with conventional physical therapy treatment modalities including transcutaneous electrical nerve stimulation (TENS); electrical muscle stimulation (EMS); and interferential current (IFC). Physical agents including ultrasound, hot packs, and cold packs. Exercise including McKenzie exercises) will be administered."||||
34194185|NCT04232618|||COHORT||PROSPECTIVE|||||||
34194186|NCT03216434|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34194187|NCT01862692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194188|NCT03684369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194189|NCT00927914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194190|NCT03737526|||CASE_ONLY||RETROSPECTIVE|||||||
34194191|NCT03666533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||transcranial Direct Current Stimulation|t|t|t|t
34194192|NCT04264897|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Subjects assigned to the placebo group will receive visually identical pills (silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate). Only the study statistician and pharmacist will know the metformin versus placebo assignment.|This is a randomized, controlled clinical trial of healthy older male and female subjects 40-75 years of age. Subjects will be randomized into one of two groups (metformin or placebo) for a 12-week intervention. The study is double-blinded on placebo versus metformin. The randomization sequence will be stratified by study center (OUHSC or UWM) and baseline insulin status (HOMA-IR \<=2.2 \[sensitive\] versus \>=2.5 \[resistant\]) and will be created using randomly chosen block sizes of four or six. At each center, there will be four groups: insulin sensitive (IS) placebo, IS metformin, insulin resistant (IR) placebo, and IR metformin.|t|f|t|t
34194193|NCT00488306|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194194|NCT00597168|||CASE_ONLY||PROSPECTIVE|||||||
34194195|NCT02135003|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34194196|NCT02136888|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34194197|NCT04012164|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||2 types of participants. Human subjects participating in microbiological and anthropological study. Human subjects participating in historical and anthropological study, providing a larger context for those from whom we will collect biological samples and anthropological data||||
34194198|NCT05549921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194199|NCT03528499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194200|NCT00548652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194201|NCT02937402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194202|NCT04398095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194203|NCT01886599|NON_RANDOMIZED|PARALLEL||||NONE||||||
34194204|NCT01368562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194205|NCT03860818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective, cluster-randomized controlled clinical trial at 10 sites, randomizing 5 sites to standard clinical care and 5 to the intervention.||||
34194206|NCT01049542|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34194207|NCT05561205|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194208|NCT05094310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194209|NCT01947413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194210|NCT06149247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194211|NCT00718653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34194212|NCT01042041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194213|NCT03728283|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomised, parallel-group, controlled clinical trial (Altman et al. 2001) with allocation ratio 1:1,||||
34194214|NCT05481476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194215|NCT01368224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194216|NCT06047119|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34194217|NCT02903459|||CASE_ONLY||RETROSPECTIVE|||||||
34194218|NCT03301116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|N/A (there are no other parties who will be masked in the clinical trial)|Home care aide-client pairs will be randomly assigned to one of two groups in parallel for the duration of the study. Home care aides will not be allowed to have multiple participating clients assigned to different groups to prevent group contamination.|f|f|f|t
34194219|NCT02019485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194220|NCT00184951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756058|NCT03017079|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33756059|NCT01030861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756060|NCT02063074|||COHORT||PROSPECTIVE|||||||
34076140|NCT04910334|||COHORT||PROSPECTIVE|||||||
34076141|NCT01932697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076142|NCT04990193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34076143|NCT00347178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076144|NCT00116961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076145|NCT05002556|||COHORT||PROSPECTIVE|||||||
34076146|NCT01116037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874120|NCT03100045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects will be enrolled sequentially in each treatment cohort.||||
33874121|NCT00575627|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874122|NCT00004471||||TREATMENT||||||||
33874123|NCT00114049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874124|NCT06171321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874125|NCT05654389|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874126|NCT00466466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874127|NCT05168800|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874128|NCT04899700|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||"Colonoscopy will be performed in tandem by two different endoscopist.~Patients will be randomized to two groups:~* WLE-LCI~* LCI-WLE"|t|f|f|f
33874129|NCT06490835|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874130|NCT01227187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874131|NCT02499679|||CASE_ONLY||PROSPECTIVE|||||||
33874132|NCT00553709|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874133|NCT04539340|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34194221|NCT03663660|||COHORT||RETROSPECTIVE|||||||
33874134|NCT03476499|NA|SINGLE_GROUP||OTHER||NONE|The physician taking the images will be blinded to the images until the end of the study.|"KENT CAMERA MULTISPECTRAL IMAGING DEVICE Health Canada Medical device Licence: 99281 First Issue Date: 2017/06/07 Device class 2 Handheld near infrared multispectral imaging device with custom software. A new commercially available imaging technology uses NIR spectroscopy to measure regional tissue hemoglobin oxygenation, StO2. These images are processed to produce a colour coded StO2 image of a large tissue area (\~6 by 4). Since the image device doesn't contact the skin the depth of measurement is \~2mm instead of \~10mm with a point system. Compared to dye based angiography methods, StO2 NIR imaging does not require the injection of a dye. The advantage of the NIR imaging device over point NIR systems is a lack of patient contact. Thus StO2 NIR imaging is completely non-invasive, non-contact. Images can be captured and displayed in less than 5 seconds therefore imaging can be repeated as needed with no risk to the patient and no cost for disposables."||||
33874135|NCT00978211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874136|NCT03746704|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33874137|NCT04486092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874138|NCT03370783|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33874139|NCT02544711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874140|NCT05998421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34194222|NCT00077467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194223|NCT03284281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194224|NCT01893034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874141|NCT04989283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194225|NCT04843683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194226|NCT05260918|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34194227|NCT01829880|||COHORT||PROSPECTIVE|||||||
34194228|NCT02158429|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34194229|NCT02942225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874142|NCT02263157|||CASE_CONTROL||PROSPECTIVE|||||||
33874143|NCT05790122|||COHORT||RETROSPECTIVE|||||||
33874144|NCT05956951|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33874145|NCT03490643|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33874146|NCT01399788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33874147|NCT00091806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967393|NCT03479385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967394|NCT00840359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967395|NCT02943681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967396|NCT00489931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967397|NCT04261296|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled study||||
33967398|NCT03635684|NA|SINGLE_GROUP||OTHER||NONE||||||
33967399|NCT04894994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967400|NCT00694499|||COHORT||RETROSPECTIVE|||||||
33967401|NCT04388033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967402|NCT01950754|NON_RANDOMIZED|PARALLEL||||NONE||||||
33967403|NCT01140269|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34194230|NCT04583137|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Both solutions will be kept in identical syringes with an atomization tip (Teflex, MAD Nasal™ Intranasal Mucosal Atomization Device). Each product has a randomized serial number. Both the investigator and the participant are masked. The solutions are made by a different investigator who is not part of the clinical examination, questionnaire filling, patients selection, and recruitment.|"trial containing two groups. The first group receives an intranasal solution of lidocaine combined with bicarbonate. The second group receives intranasal plain lidocaine. After a measured time of 5 minutes, all patients will attend a TFL examination. The patients will fill the first questionnaire immediately after the procedure, a second questionnaire by telephone after one hour, and the third questionnaire by telephone after a one-month follow-up.~Sample size was calculated using data from a previous publication of local soft tissue injection with buffered lidocaine5. This estimation power analysis showed that for VAS average and standard deviation were 3.5±1.4 for the lidocaine group and 2.5±1.4 for the second group given lidocaine with bicarbonate. In order to achieve a statistical power of 90% and significance of p\<0.05 a sample of 40 patients is needed for each group, 80 patients in total. The comparison will be made using Mann-Whitney U-test."|t|f|t|f
34194231|NCT00335179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756061|NCT04465357|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756062|NCT01440426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756063|NCT04928820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756064|NCT03371810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Observer-blinded assessment of the primary outcome measure|Prospective, randomized, observer-blinded, controlled, multi-centre, pilot phase-IIa parallel-group design with three arms (two treatment groups and one control group); three trial phases: baseline assessment, 10 weeks of treatment versus treatment as usual; 12 weeks post-treatment observation period.|f|f|f|t
33756065|NCT03508843|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756066|NCT04127838|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756067|NCT05400343|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single-blind (participant) study||t|f|f|f
33756068|NCT01614626|||COHORT||PROSPECTIVE|||||||
33756069|NCT02586025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756070|NCT03642925|NA|SINGLE_GROUP||TREATMENT||NONE|it's a Open-label clinical trial|To evaluate the impact of a nutritionally balanced conventional meal replacement diet (rich in soy/pea protein and soluble fibers) with caloric restriction in Taiwanese obese subjects.||||
33756071|NCT00566683|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33756072|NCT04335045|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Single-center, randomized, double-blind, placebo-controlled, single ascending dose study|t|t|t|t
33756073|NCT03940599|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33756074|NCT01353222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194232|NCT00447070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34194233|NCT01651806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33756075|NCT02621580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194234|NCT01442844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756076|NCT03613311|||CASE_ONLY||RETROSPECTIVE|||||||
34194235|NCT00232791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756077|NCT05380843|||OTHER||CROSS_SECTIONAL|||||||
33874148|NCT02170402|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33874149|NCT01166737|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33874150|NCT04800289|||COHORT||PROSPECTIVE|||||||
33874151|NCT03380260|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33874152|NCT05873998|||COHORT||PROSPECTIVE|||||||
33874153|NCT02076789|||COHORT||PROSPECTIVE|||||||
33874154|NCT02763176|||OTHER||PROSPECTIVE|||||||
9957946|NCT06361849|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33874155|NCT05415995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874156|NCT04100889|||CASE_ONLY||PROSPECTIVE|||||||
33874157|NCT05706974|||CASE_CROSSOVER||PROSPECTIVE|||||||
33874158|NCT03537027|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874159|NCT03116074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874160|NCT02528903|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33874161|NCT03458208|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|four-way crossover||||
33874162|NCT04269174|||OTHER||CROSS_SECTIONAL|||||||
33874163|NCT01553630|RANDOMIZED|PARALLEL||||NONE||||||
34194236|NCT01687725|||COHORT||PROSPECTIVE|||||||
34194237|NCT00149318|||CASE_ONLY||PROSPECTIVE|||||||
34194238|NCT03920644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blinded|The study will include 120 subjects per arm, for a total of 360 subjects (n=360). A double-dummy design will be used to mask the treatment assignment. All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or TDS patch + placebo nasal gel.|t|t|t|f
33874164|NCT01685463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874165|NCT00710476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874166|NCT03655808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The opaque sealed envelope method was used to conceal the allocation sequence. Both patients and investigators, except for the bronchoscopy operators, remained masked to the treatment assignment for the duration of the study. Only the investigators who performed the bronchoscopy were unblinded. The non-blinded investigators should not disclose any blind information to other investigators, participants, care providers, or outcomes assessors.|Eligibility patients were randomly assigned in a 1:1 ratio to receive either autologous cell transplantation therapy (cell treatment group) or bronchoscopic airway clearance treatment (B-ACT therapy, control group).|t|t|f|t
33874167|NCT03529266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874168|NCT01513421|||COHORT||PROSPECTIVE|||||||
33874169|NCT04265183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874170|NCT04459182|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756078|NCT05941130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33756079|NCT02440633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967404|NCT03168685|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33967405|NCT00923494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194239|NCT04787419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Both placebo and probiotics have the exact same packaging. batch production numbers are printed, ended with either 0 or 1. code will be revealed by third party (production and packaging team) upon study completion (following data analysis)"||t|t|t|t
33874171|NCT04572477|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Group A (acute stroke/TIA patients), n=200 Group B (chronic stroke/TIA patients), n=200 Group C (healthy elderly controls), n=30|f|f|t|f
34194240|NCT00605787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194241|NCT04727489|||CASE_CONTROL||PROSPECTIVE|||||||
34194242|NCT03495778|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34194243|NCT00422513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194244|NCT01717599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34194245|NCT06123351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded study where the participants will be blinded to the study different groups and the study hypothesis.|Permuted block randomization to ensure an equal number of allocations in each of the three groups (traditional, Denneroll cervical traction orthodontic and dental treatment). Each random block was stored in opaque sealed envelopes consecutively numbered with a third researcher. Once each participant officially joins the study the researcher will open the subsequent envelop.|t|f|f|f
34194246|NCT05704569|||COHORT||PROSPECTIVE|||||||
34194247|NCT02711917|RANDOMIZED|PARALLEL||||NONE||||||
34194248|NCT00574236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194249|NCT01410344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194250|NCT05715112|||COHORT||OTHER|||||||
34194251|NCT01906996|||CASE_CONTROL||PROSPECTIVE|||||||
34194252|NCT04193072|||CASE_CONTROL||PROSPECTIVE|||||||
34194253|NCT03142685|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective pilot randomized control study||||
34194254|NCT03278054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194255|NCT00181597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194256|NCT06460740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the patients will be blind its a single blind study||t|f|f|f
34194257|NCT00901732|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34194258|NCT04683783|||COHORT||PROSPECTIVE|||||||
34194259|NCT02389556|||COHORT||PROSPECTIVE|||||||
34194260|NCT04972045|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Subjects will be given test preparation (A) or control preparation (B) on the first day of the first cycle. After a 7-day washout period, on the 8th day of the second cycle, subjects will be cross-administered with the control preparation (B) or test preparation (A)||||
34194261|NCT00040560|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194262|NCT04211246|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34194263|NCT04939350|||COHORT||PROSPECTIVE|||||||
34194264|NCT01986556|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34194265|NCT05246085|||CASE_CONTROL||PROSPECTIVE|||||||
33874172|NCT00545883|||COHORT||PROSPECTIVE|||||||
33874173|NCT03854864|||COHORT||CROSS_SECTIONAL|||||||
33874174|NCT02043535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194266|NCT05274295|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33874175|NCT02335775|||COHORT||PROSPECTIVE|||||||
33967406|NCT04204486|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomised control trial. Participants will be stratified by shift pattern and by role, and will be randomised to one of three intervention arms using permuted blocks of 3 and 6.||||
33967407|NCT05717829|NA|SINGLE_GROUP||TREATMENT||NONE||prospective case series study||||
33967408|NCT01403454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967409|NCT04295460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967410|NCT01448031|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34194267|NCT02760225|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194268|NCT00004042||||TREATMENT||||||||
34194269|NCT03041129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34194270|NCT03708887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194271|NCT02457104|||COHORT||PROSPECTIVE|||||||
33874176|NCT03241953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874177|NCT04111211|||COHORT||PROSPECTIVE|||||||
33874178|NCT02854644|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33874179|NCT02324075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967411|NCT06526715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967412|NCT03786913|||COHORT||PROSPECTIVE|||||||
33967413|NCT04443283|||COHORT||PROSPECTIVE|||||||
33967414|NCT05499494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967415|NCT01944189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967416|NCT00353938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33967417|NCT05775809|||COHORT||PROSPECTIVE|||||||
33967418|NCT04942041|||CASE_CONTROL||OTHER|||||||
33967419|NCT00751153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967420|NCT06477315|||OTHER||PROSPECTIVE|||||||
33967421|NCT02544061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967422|NCT00625001|||COHORT||PROSPECTIVE|||||||
34194272|NCT05813041|NA|SINGLE_GROUP||OTHER||NONE||Clinical investigation of the safety and performance of a medical device. Single site, single arm, open label, healthy volunteer.||||
33874180|NCT01881464|||COHORT||PROSPECTIVE|||||||
33874181|NCT05965349|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874182|NCT02599701|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33874183|NCT04153864|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Investigators and outcome assessors are independent from type of treatment delivery and allocation status.|"The intervention modules include:~1. Brief BA psychological treatment delivered by a non-specialist provider~2. Brief BA psychological treatment delivered through telemedicine"|f|f|t|t
33874184|NCT03027986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874185|NCT00343889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33874186|NCT00003715|RANDOMIZED|||TREATMENT||||||||
33967423|NCT06282588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase 3 trial: blinded Phase 2 trial: open label|Phase 2: non randomised, 1 treatment arm, open label Phase 3: randomized 1:1 between two treatment arms, blinded|t|t|t|t
33967424|NCT05316103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967425|NCT04139551|||COHORT||PROSPECTIVE|||||||
33967426|NCT04579497|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33967427|NCT04962126|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase II study with addition of involved site radiotherapy treatment in participants who achieve only PR/SD at first response assessment||||
34194273|NCT04242641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the which arm the participants have been allocated.|Participants will be randomised on a 1:1 ratio to either the intervention arm (WW programme) or to the control group.|f|f|f|t
33967428|NCT04783259|NA|SINGLE_GROUP||OTHER||NONE||||||
33967429|NCT02050490|||CASE_CONTROL||PROSPECTIVE|||||||
34076147|NCT04464746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are not knowledged whether they are allocated to the control group or to the interventional group|Interventional, prospective, randomized, controlled, parallel groups, open study|t|f|f|f
34194274|NCT03833193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194275|NCT02997306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194276|NCT05197660|||COHORT||PROSPECTIVE|||||||
34194277|NCT00000144|RANDOMIZED|||TREATMENT||||||||
34194278|NCT02199717|||COHORT||PROSPECTIVE|||||||
34194279|NCT03711240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194280|NCT04721587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194281|NCT06243562|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be an intervention and control group in the study.||||
33967430|NCT02311426|||COHORT||PROSPECTIVE|||||||
33967431|NCT00446264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194282|NCT06055543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194283|NCT02864862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194284|NCT02263352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194285|NCT04321447|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34194286|NCT04157309|||COHORT||OTHER|||||||
34194287|NCT00505076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194288|NCT00347620|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194289|NCT04741126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194290|NCT02853201|||COHORT||PROSPECTIVE|||||||
33874187|NCT04084574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874188|NCT03551223|||COHORT||PROSPECTIVE|||||||
33874189|NCT01302951|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874190|NCT02552719|||OTHER||OTHER|||||||
33874191|NCT01155804|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33874192|NCT01838109|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874193|NCT04296370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874194|NCT05209503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874195|NCT05437120|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33874196|NCT04897464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967432|NCT04684784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967433|NCT03922659|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33967434|NCT04162392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967435|NCT02009956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967436|NCT01669044|||CASE_CONTROL||PROSPECTIVE|||||||
33967437|NCT01132287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33967438|NCT00606268|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967439|NCT04987177|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33967440|NCT00804349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967441|NCT01484990|NA|SINGLE_GROUP||OTHER||NONE||||||
34076148|NCT01983215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076149|NCT05758818|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34076150|NCT03631069|||COHORT||RETROSPECTIVE|||||||
34076151|NCT00845403|||||PROSPECTIVE|||||||
33874197|NCT05072509|||COHORT||RETROSPECTIVE|||||||
33874198|NCT03782376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874199|NCT04966546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only research pharmacist is unblinded.|Pilot parallel RCT|t|t|t|t
33874200|NCT04342871|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Because this is a pilot study, all participants will receive the same intervention and no blinding will take place||||
33874201|NCT03889314|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Patients will serve as their own controls in this study whereby they will receive randomly allocated 28-day packets of statin and placebo.|t|t|t|f
33874202|NCT00500019|||||PROSPECTIVE|||||||
33967442|NCT05081752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded as to which study arm they are in, in order to avoid any bias they may have.||t|f|f|f
33967443|NCT06429761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076152|NCT00000173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34076153|NCT01563328|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194291|NCT00999193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194292|NCT03658096|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||patients and healthy controls|t|f|f|f
34194293|NCT03365843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, study coordinator and care-givers are blinded to the assigned treatment arm. Participants may be able to guess which treatment group they have been assigned. This will be assessed at the end of the study by asking participants to identify the group to which they think they have been assigned.|Randomized, single centre, double-blind clinical study|t|t|f|t
34194294|NCT01812447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194295|NCT05916599|||CASE_CONTROL||PROSPECTIVE|||||||
34194296|NCT00299611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194297|NCT00718588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194298|NCT04918134|||OTHER||CROSS_SECTIONAL|||||||
34194299|NCT06308705|NA|SINGLE_GROUP||OTHER||NONE||||||
34194300|NCT02437110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194301|NCT01571544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194302|NCT01311284|RANDOMIZED|CROSSOVER||||NONE||||||
34194303|NCT06163378|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34194304|NCT01429025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194305|NCT02870933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194306|NCT00645437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194307|NCT00409370|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194308|NCT01233232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194309|NCT06119750|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Subjects act as their own control. They each receive all three study treatment via patch application.||||
33874203|NCT00595998|||COHORT||RETROSPECTIVE|||||||
33874204|NCT02589444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33874205|NCT01428284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874206|NCT00750737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967444|NCT05610605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967445|NCT01557491|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33967446|NCT02270983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967447|NCT06530563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967448|NCT01033864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967449|NCT04905719|||COHORT||PROSPECTIVE|||||||
33967450|NCT04848350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194310|NCT04384133|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34194311|NCT01453062|||COHORT||RETROSPECTIVE|||||||
34194312|NCT04709133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194313|NCT05082597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194314|NCT03545425|||COHORT||CROSS_SECTIONAL|||||||
34194315|NCT03135119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All individuals collecting and/or handling data will be masked.||f|f|f|t
34194316|NCT04760171|||COHORT||PROSPECTIVE|||||||
33874207|NCT03141736|RANDOMIZED|PARALLEL||PREVENTION||NONE||Assignment||||
33967451|NCT01902134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967452|NCT02314520|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33967453|NCT01543815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967454|NCT04852991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967455|NCT04602390|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34076154|NCT00919633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34076155|NCT00284843|||||PROSPECTIVE|||||||
34076156|NCT05460299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076157|NCT04195061|||COHORT||CROSS_SECTIONAL|||||||
34076158|NCT05890417|NA|SINGLE_GROUP||OTHER||NONE||||||
34076159|NCT05927168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076160|NCT02133430|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34194317|NCT05525598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194318|NCT05971706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194319|NCT01056302|||CASE_ONLY||RETROSPECTIVE|||||||
34194320|NCT05500222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194321|NCT00522236|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34194322|NCT03546868|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34194323|NCT05573269|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194324|NCT04347187|||COHORT||PROSPECTIVE|||||||
34194325|NCT00724711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194326|NCT02030899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||ACDF with plate and autologous bone|t|f|f|t
34194327|NCT00150917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194328|NCT04646434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874208|NCT06232070|||COHORT||PROSPECTIVE|||||||
34151953|NCT05607706|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"This research; It was planned as a Randomized Controlled Experimental Study. In the study, the effect of kangaroo care and maternal odor, which are independent variables, on the toxic stress level of preterms, which is the dependent variable, was tried to be determined. The study was carried out NICU at Anka Hospital, in Gaziantep, Turkey. The sample calculation of the research was made using the Jamovi 1.8 program. The significance level was taken as 0.05 according to the power analysis performed to determine the sufficient sample size, and it was calculated that at least 30 patients should be included in each patient group in order to have a minimum theoretical power of 0.7. The study was planned to be conducted with a total of 135 patients, with 45 patients in each group."||||
33874209|NCT04010214|||COHORT||PROSPECTIVE|||||||
33874210|NCT04696432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874211|NCT04294875|NA|SEQUENTIAL||TREATMENT||NONE||||||
33874212|NCT00751595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874213|NCT01517048|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874214|NCT03069430|||COHORT||CROSS_SECTIONAL|||||||
33874215|NCT01217671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874216|NCT02816307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874217|NCT01301339|||||PROSPECTIVE|||||||
33874218|NCT04600245|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used||||
33874219|NCT04649476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874220|NCT04891042|||COHORT||PROSPECTIVE|||||||
33874221|NCT02053168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874222|NCT04499443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967456|NCT05842577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a multicentre, single-blind (evaluator), Randomized Controlled Trial (RCT)|f|f|f|t
33967457|NCT00244088|||CASE_CONTROL||PROSPECTIVE|||||||
33967458|NCT06524778|NA|SINGLE_GROUP||TREATMENT||NONE||Single dose high-dose （10Gy）implantable brachytherapy||||
33967459|NCT02117479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967460|NCT01773278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967461|NCT00665522|||COHORT||PROSPECTIVE|||||||
33967462|NCT04229797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967463|NCT03294278|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967464|NCT00318344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967465|NCT04057755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967466|NCT05015881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized, 2-way crossover trial in 10 individuals with AUD and 10 Healthy controls||||
33967467|NCT05182398|||OTHER||PROSPECTIVE|||||||
33967468|NCT01268449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967469|NCT02032290|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967470|NCT00538187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967471|NCT01484171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967472|NCT02984683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967473|NCT03727464|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33967474|NCT02614937|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967475|NCT00058617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967476|NCT01287780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33967477|NCT01063725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967478|NCT00303316|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33967479|NCT04128449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967480|NCT00591422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967481|NCT00036582||||TREATMENT||||||||
33967482|NCT06362876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967483|NCT06036654|NA|SINGLE_GROUP||TREATMENT||NONE||Local hyperthermia for the Treatment of Onychomycosis||||
33967484|NCT01335282|||COHORT||PROSPECTIVE|||||||
34151954|NCT03590951|||CASE_ONLY||RETROSPECTIVE|||||||
34194329|NCT04136015|||CASE_CROSSOVER||PROSPECTIVE|||||||
34194330|NCT00163917|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34194331|NCT02926521|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194332|NCT06449196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194333|NCT00363545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194334|NCT04944108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194335|NCT05282745|||COHORT||PROSPECTIVE|||||||
34194336|NCT04672382|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34194337|NCT05768022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A Pretest posttest control group||||
34194338|NCT01486082|||COHORT||PROSPECTIVE|||||||
34151955|NCT03271905|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The participant is blind about the procedures. The investigator is blind about order of procedure and outcomes assessor is blind about procedures.||t|f|t|t
33756080|NCT01118364|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33756081|NCT00229814|||CASE_ONLY||RETROSPECTIVE|||||||
33756082|NCT02827006|RANDOMIZED|PARALLEL||TREATMENT||NONE||the standard treatment is a corrective osteotomy with bone graft. The intervention in parallel group is a corrective osteotomy and use of CaP bone cement||||
33756083|NCT05087082|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Masking of participants is not possible due to the nature of the study|The study is a clinical feasibility study. We anticipate to enroll 20 participants. Participants are admitted patients with a lower respiratory infection are 18 years of age or older and have been admitted at the hospital for at least 24 hour. additionally they must be and are considered suitable for home admission according o the inclusion- and exclusion criteria. The participants will be a part of the study until discharge or withdrawal of consent. If a next-of-kin is identified as primary informal caregiver this person is offered to take participate in the study as well. Follow-up questionnaires will be sent to all participants, and follow-up interviews will be performed after discharge.||||
33756084|NCT01269879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756085|NCT01844752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756086|NCT03458884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1 prospective randomized open-label trial with blinded evaluators (PROBE-design)|f|f|f|t
33756087|NCT00236301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756088|NCT02879266|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756089|NCT06451120|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This is a randomized, double-blind, placebo-controlled trial with a secondary crossover phase at the end of the initial trial to ensure all subjects receive one PRP injection. The randomization will be stratified by two age groups (ages 18-45 yrs. and 46-70 yrs).|t|f|t|t
34151956|NCT01909765|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34151957|NCT02355444|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34151958|NCT04268745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151959|NCT06013189|||COHORT||PROSPECTIVE|||||||
33756090|NCT03977558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756091|NCT06323733|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756092|NCT05917639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33756093|NCT05909514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756094|NCT01615328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151960|NCT04382417|||COHORT||PROSPECTIVE|||||||
34151961|NCT02249468|||CASE_CONTROL||PROSPECTIVE|||||||
34151962|NCT02610803|||COHORT||RETROSPECTIVE|||||||
34151963|NCT00002517|RANDOMIZED|||TREATMENT||||||||
34151964|NCT00172042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151965|NCT00398203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151966|NCT04919837|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34151967|NCT03802045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Prior to the first treatment session, the random allocation sequence will be implemented by a researcher not involved in the patient recruitment or evaluation, and will be generated through the randomization.com program, where each number will match one of five study groups.~After the numbers are generated, they will be placed in sealed, brown envelopes and numbered in series, then given to the acupuncturist. This person will open them according to the numerical sequence, prior to the first session.~Patients will remain blind regarding the category of their allocation throughout the data collection period of the study. Additionally, the evaluators responsible for the data collection and the outcomes assessor will be blinded to the patient allocation. The acupuncturist, being responsible for the interventions, will be the only person not blind to the type of treatment to be performed."|The individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF) with 2Hz, high frequency EA (HF) with 100Hz, alternating frequency EA (AF) with 2 and 100Hz for 3 seconds each, control group (C) and placebo group (P), each containing 25 participants. The LF, HF and AF groups will be submitted to the treatment protocol, which will consist of the bilateral application of electroacupuncture using NKL® portable electrostimulator. The C and P groups will follow exactly the same protocol as the electroacupuncture groups, however the C group will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient. In the P group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it. In addition, as in group C, the electrodes will be connected to the needles, however, no electrical current will be applied.|t|f|t|t
34151968|NCT01612208|||COHORT||PROSPECTIVE|||||||
34151969|NCT00440830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874223|NCT05922462|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will use a randomized controlled parallel design, where participants will be randomly assigned to either to consume greek yogurt or whey protein for 16 weeks.||||
33874224|NCT02839980|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33874225|NCT04086823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874226|NCT04884321|||OTHER||OTHER|||||||
33874227|NCT01624662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874228|NCT02097914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874229|NCT03002584|||COHORT||PROSPECTIVE|||||||
33967485|NCT02175407|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33967486|NCT05017376|||COHORT||RETROSPECTIVE|||||||
34194339|NCT03087617|RANDOMIZED|FACTORIAL||OTHER||SINGLE|University of Minnesota Office of Measurements Services will administer follow up calls to assess outcomes. Callers will be blinded to the arm to which the patients were assigned.||f|f|f|t
34194340|NCT01533740|||COHORT||PROSPECTIVE|||||||
34194341|NCT04531709|||COHORT||PROSPECTIVE|||||||
34194342|NCT05611294|RANDOMIZED|PARALLEL||TREATMENT||NONE||Contralateral Eye to Eye Comparison||||
34194343|NCT04444856|||COHORT||RETROSPECTIVE|||||||
34194344|NCT00618345||||TREATMENT||NONE||||||
34194345|NCT06443645|||COHORT||PROSPECTIVE|||||||
34194346|NCT02668471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194347|NCT04123691|||COHORT||PROSPECTIVE|||||||
34194348|NCT00103350|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34194349|NCT02750020|||COHORT||CROSS_SECTIONAL|||||||
34194350|NCT04679415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194351|NCT00993226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194352|NCT06466018|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34194353|NCT02526030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194354|NCT05176132|||COHORT||PROSPECTIVE|||||||
34194355|NCT00064064||||TREATMENT||NONE||||||
34194356|NCT01279941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967487|NCT01488019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967488|NCT02544100|||CASE_ONLY||RETROSPECTIVE|||||||
33967489|NCT04180189|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33967490|NCT06531265|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967491|NCT01208402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967492|NCT02678897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967493|NCT04302428|||COHORT||CROSS_SECTIONAL|||||||
33967494|NCT06217133|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"The researchers will compare the conventional CPAP and bubble CPAP group according to randomization.~The participant selected for conventional CPAP will receive conventional CPAP for 24 hours, then receive bubble CPAP for 24 hours the following day. The opposite will be done for the participant drawn for CPAP bubbles.All participants will be evaluated on two different days, on one day data collection will be carried out using conventional CPAP and on the other day bubble CPAP according to randomization. The days will be consecutive and premature babies will remain on each type of CPAP for 24 hours."||||
33967495|NCT03010085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967496|NCT03474705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967497|NCT04887545|||COHORT||PROSPECTIVE|||||||
33967498|NCT02288689|||COHORT||PROSPECTIVE|||||||
34194357|NCT04795336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194358|NCT00336830|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34194359|NCT03389048|NA|SINGLE_GROUP||OTHER||NONE||||||
34194360|NCT00878761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194361|NCT06043544|RANDOMIZED|PARALLEL||TREATMENT||NONE||80 consecutive patients with glenohumeral OA degree II or III were prospectively enrolled in our clinic from May 2021 to March 2022. The study was approved by Concordia Hospital Ethical Committee (02/2021) and performed according to ISO14155:2020 and Declaration of Helsinki.||||
34194362|NCT03406091|||CASE_ONLY||PROSPECTIVE|||||||
33967499|NCT00062556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967500|NCT00379587|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33967501|NCT05213507|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967502|NCT02157233|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34194363|NCT02722057|||COHORT||OTHER|||||||
34194364|NCT03761862|||OTHER||RETROSPECTIVE|||||||
33967503|NCT05756699|||COHORT||PROSPECTIVE|||||||
33967504|NCT01155063|||CASE_CONTROL||PROSPECTIVE|||||||
33967505|NCT06156787|||CASE_ONLY||CROSS_SECTIONAL|||||||
33967506|NCT02323659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967507|NCT03301519|||COHORT||PROSPECTIVE|||||||
33967508|NCT06366672|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be vaccinated with MVA-BN according to the FDA-approved labeling and immune responses in the blood, lung mucosa, skin, and bone marrow will be monitored prior to and following vaccination using phlebotomy, research bronchoscopy, skin punch biopsy, and bone marrow aspiration procedures.||||
33874230|NCT05288400|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a phase III, multicenter, randomized, open-label, controlled study, over a 12-week treatment period with a single-capsule of fixed dose combination (FDC) of Amlodipine 5 mg/ Bisoprolol fumarate 5 mg / Perindopril arginine 5 mg and free monocomponents of Amlodipine 5 mg, Bisoprolol Fumarate 5 mg and Perindopril arginine 5 mg given concomitantly, in 150 patients with uncontrolled essential HT.||||
33874231|NCT00004340|RANDOMIZED|||TREATMENT||||||||
33874232|NCT04875546|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33874233|NCT02620696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874234|NCT06383273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked|Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study|t|t|t|t
33874235|NCT06548919|||COHORT||PROSPECTIVE|||||||
33874236|NCT01418183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874237|NCT04639583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study will be a prospective observational study, in which any infant consented to participate in the study will have the NIRS applied for the first 96 hours of life.||||
33874238|NCT00953368|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874239|NCT05133011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874240|NCT02995486|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34194365|NCT03558568|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||"The study initially recruited 18 patients with idiopathic PD who underwent DBS surgery for movement disorders caused by PD at Mustafa Kemal University Medical Faculty Neurosurgery Department.~Inclusion criteria:~* Idiopathic PD responsive to L-Dopa treatment,~* Between 40-75 years of age,~* Having received bilateral STN DBS surgery at least six months prior to the investigation to ensure stable stimulation parameters,~* Mentally normal patients that could understand and respond to a directives."|f|f|f|t
33874241|NCT00669058|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34194366|NCT00775047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874242|NCT02302508|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33874243|NCT05141760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874244|NCT01784770|||CASE_ONLY||RETROSPECTIVE|||||||
33874245|NCT01739985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33874246|NCT03005795|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874247|NCT01003275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34194367|NCT03625843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34194368|NCT02310334|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34194369|NCT00201552|RANDOMIZED|PARALLEL||||NONE||||||
34194370|NCT02152280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194371|NCT03060551|NA|SINGLE_GROUP||TREATMENT||NONE||Systemic sclerosis patients with hand disability, planning 24 weeks of follow-up period Autologous adipose tissue-derived stromal vascular fraction(SVF) injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles.||||
34194372|NCT00682578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874248|NCT02366611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194373|NCT00296296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194374|NCT00200356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194375|NCT01848041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194376|NCT03319745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194377|NCT04455490|||CASE_ONLY||RETROSPECTIVE|||||||
34194378|NCT04466709|||COHORT||PROSPECTIVE|||||||
34194379|NCT00947960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33874249|NCT01609946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874250|NCT05462015|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194380|NCT05401942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34194381|NCT00588068|||COHORT||PROSPECTIVE|||||||
34194382|NCT06153004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked (blinded) field-based assessors will conduct all outcome assessments|Fluoxetine versus a contextually adapted version of behavioral activation called the Healthy Activity Program (HAP) delivered by non-specialists for the treatment of depression|f|f|f|t
34194383|NCT03594240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients were randomly assigned into two groups; intervention group who received vitamin B complex once daily orally and control group who did not receive B complex|t|t|t|f
34194384|NCT03921645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34194385|NCT04525885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants with refractory or unexplained chronic cough will be randomized to 1 of 3 treatment groups: gefapixant 45 mg twice daily (BID), gefapixant 15 mg BID, or placebo.|t|f|t|f
33874251|NCT05807360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874252|NCT01195727|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874253|NCT04219345|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blind|This randomized, double-blind, placebo-controlled clinical trial will analyze patients with a confirmed diagnosis of chronic migraine by a neurologist who were subjected to tDCS associated with mindfulness practices.|t|t|t|f
33874254|NCT01630473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874255|NCT01407705|||CASE_CONTROL||PROSPECTIVE|||||||
33874256|NCT06077604|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33874257|NCT00643266|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33874258|NCT00877812|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874259|NCT05554848|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874260|NCT05313451|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33874261|NCT02691442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194386|NCT00792571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194387|NCT06313385|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||QUADRUPLE|The participants didn't know about indocyanine green (ICG) drug groups as well as the concentration that they received. The ICG was added into the syringe by research assistant without any label near the end of operation time. The ICG injection to the patient was performed by anesthesiologist who didn't know about the concentration at all. Outcome assessor didn't know about the given concentration.|The population were divided into three equal groups of indocyanine green concentration : 5 milligram per milliliter (mg/mL), 2,5 mg/mL, and 0,5 mg/mL|t|t|t|t
34194388|NCT02878161|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967509|NCT03279484|NA|SINGLE_GROUP||TREATMENT||NONE||"NAVIGO 4LV LV leads are available as S shaped(NAVIGO 4LV 2D) , U shaped (NAVIGO 4LV ARC) and straight( NAVIGO 4LV Pilot) models. All the models are available in 78 cm and 88 cm long versions. All models are designed for multipolar pacing (4 electrodes) and all of them have a quadripolar IS4 connector (IS4_LLLL).~The NAVIGO 4LV leads are steroid eluting to avoid adverse effects due to inflammation reaction of the myocardium after positioning of the lead, and therefore to limit the acute pacing threshold peak. The steroid collar design is the same as the one used in all other LIVANOVA leads"||||
33967510|NCT01814137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967511|NCT06019130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase-II optimum Simon design with alpha=0.1 and beta=0.2 will be used.||||
33967512|NCT03700710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967513|NCT00748813|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33967514|NCT00851266|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33967515|NCT04315012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The data were collected to with face to face and/or telephone interviews at 2 time points: prior to the initiation (T0) and after the completion (T1) of mobile app-based education. Mobile application was including information about breast cancer definition, treatment process, symptoms management, adequate nutrition, regular physical activity and coping with stress. In this process, the control group patients were provided with standard care|t|f|t|f
33967516|NCT00828490|||||RETROSPECTIVE|||||||
33967517|NCT05589935|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
33967518|NCT01423565|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33967519|NCT01055444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068119|NCT05808270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each participant belonging to this institution has the same probability of being selected for the study. On this occasion, a numbered list of the subjects candidates to participate in the study will be needed. Subsequently, by means of a raffle with balls numbered from 1 to 2, the subjects will be assigned to each of the interventions, number 1 corresponds to the intervention with the nutrition care process and number 2 to the conventional nutritional intervention.|There will be two groups in which one group will be given a conventional intervention, a second group will use the nutrition care process (NCP). A nutritional clinical history will be applied to each of the older adults to know general data, body composition, biochemical and clinical parameters, nutritional evaluation (considered step 1 of the NCP), then a nutritional diagnosis will be given (step 2) , to give a dietary prescription, objectives, action plan, intervention and nutritional education to the patient for a period of 8 weeks (step 3) to monitor adherence to the nutritional prescription, which will be monitored at 3 , 6 and 12 months (step 4).|t|f|f|f
34068120|NCT05194241|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34068121|NCT00886964|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068122|NCT05326126|NA|SINGLE_GROUP||OTHER||NONE|Patients will be assigned a univocal identification code. Medical personnel in charge of baseline, in-hospital and follow-up data acquisition will be allowed to know each patient identity.|TAVI's intervention will be performed as per current clinical indications and according to the hospital's clinical practice. To this will be added the evaluation of coronary physiology using Pressure Eire X and Coroventis software, which, although performed in accordance with the IFU of the aforementioned devices, is considered an experimental procedure. Adenosine will be required to complete the measurement of coronary physiology||||
34068123|NCT01775683|||CASE_CONTROL||RETROSPECTIVE|||||||
34068124|NCT00055497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068125|NCT00516490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068126|NCT05393297|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
34068127|NCT00966355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068128|NCT01090297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34068129|NCT05589220|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068130|NCT03594318|||COHORT||PROSPECTIVE|||||||
34194389|NCT06428071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be double-blinded consequently neither the assessor nor the data analyzer will be aware of the allocation sequence. Each participant will be coded using special numbers that refer to the correct allocation. The interpretation of these code numbers will be kept with the senior author who will not be involved in the treatment or assessment. The therapist will only be allowed to get the code number interpretation after the end of the allocation process and at the beginning of the study. In this study, the participants and the therapist will be blind.|3 arm parallel randomized controlled trial|f|f|t|t
34194390|NCT03800420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194391|NCT04469998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194392|NCT05132114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware of their treatment allocation in order not to influence patient reported outcomes|Prospective randomized trial with 2 groups (use vs not use of Lugol's iodine during LLETZ)|t|f|f|f
34194393|NCT03472846|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33874262|NCT02364089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874263|NCT01826279|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34194394|NCT03720652|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"In Aim 1, the 8-week MSC program was conducted with nursing assistants from 1 nursing home to test for feasibility and practicality.~After receiving feedback from participants of Aim 1, in Aim 2, the MSC program will be conducted in 2 nursing homes. Both nursing homes in Aim 2 will receive a shortened 6-week, 1 hour version specific to health care staff, in order to test the feasibility and practicality."||||
34194395|NCT04020861|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33874264|NCT03050242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33874265|NCT04338035|||COHORT||RETROSPECTIVE|||||||
34194396|NCT05813808|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874266|NCT04135430|||COHORT||PROSPECTIVE|||||||
33874267|NCT05455853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874268|NCT02501265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study (N=300) is a double-blinded randomized placebo-controlled trial designed to compare biochemically-confirmed abstinence rates in smokers randomized to Varenicline Adaptive Protocol vs. Varenicline (N=150) and for comparison, Nicotine Patch Adaptive Protocol vs. Nicotine Patch (N=150).|t|t|t|t
33874269|NCT04272684|NA|SINGLE_GROUP||OTHER||NONE||||||
34194397|NCT03354507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874270|NCT00254748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194398|NCT01014910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194399|NCT01234935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194400|NCT02763683|||CASE_CONTROL||PROSPECTIVE|||||||
34194401|NCT01945918|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34194402|NCT03230019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194403|NCT04565808|||COHORT||PROSPECTIVE|||||||
34194404|NCT00961818|||CASE_CONTROL||PROSPECTIVE|||||||
34194405|NCT03630770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194406|NCT02704390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194407|NCT04596436|||CASE_ONLY||RETROSPECTIVE|||||||
34194408|NCT01061255|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34194409|NCT01503411|||COHORT||PROSPECTIVE|||||||
34194410|NCT00950820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194411|NCT01181986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34194412|NCT03820739|||COHORT||PROSPECTIVE|||||||
34194413|NCT03012126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Children were randomized to either: 1) federally qualified health center-based Healthy Weight Clinic, or 2) YMCA community-based Healthy Weight and Your Child Program.~A comparison sample of children receiving care in eight demographically similar FQHCs serve as a comparison group."|f|f|f|t
34194414|NCT03303664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34194415|NCT04494100|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194416|NCT02809040|||COHORT||PROSPECTIVE|||||||
34194417|NCT02885467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874271|NCT01628588|||CASE_ONLY||PROSPECTIVE|||||||
34194418|NCT05482750|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34194419|NCT02284425|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34194420|NCT01832584|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34194421|NCT00536497|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194422|NCT00453414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874272|NCT05904977|||COHORT||CROSS_SECTIONAL|||||||
33874273|NCT05087290|||CASE_CONTROL||PROSPECTIVE|||||||
33874274|NCT03452592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874275|NCT03719274|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874276|NCT06051682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33874277|NCT05216042|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each participant will be enrolled into one of the two groups based on their genotype.||||
33874278|NCT05196126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874279|NCT02241759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874280|NCT02199938|||COHORT||PROSPECTIVE|||||||
33874281|NCT06095661|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874282|NCT03275194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The data will be evaluated for a external person with the groups labeled as A and B for all outcomes."||f|f|f|t
33874283|NCT04876170|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33874284|NCT03383445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 fashion to either TAVR or SAVR||||
33874285|NCT03263962|||COHORT||RETROSPECTIVE|||||||
33874286|NCT04506008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874287|NCT05040594|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34194423|NCT06182228|||CASE_CONTROL||PROSPECTIVE|||||||
34194424|NCT00847509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194425|NCT01987336|||CASE_ONLY||PROSPECTIVE|||||||
34194426|NCT02103153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194427|NCT03598517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194428|NCT03453788|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective cohort study with reference group.||||
34194429|NCT01184950||||OTHER||||||||
34194430|NCT03336593|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study for subjects 9-40 years of age is randomized, double blind study. While the study for subjects 6 months-8 years of age is open labeled study.|Subjects 9- 40 years of age: Experimental, randomized, double blind bridging study Subjects 6 months - 8 years of age: Experimental, open labeled bridging study|t|f|t|f
34194431|NCT03543787|RANDOMIZED|PARALLEL||TREATMENT||NONE||PRECEDE-PROCEED implementation research framework; 2-arm cluster randomized controlled trial||||
34194432|NCT05262062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194433|NCT01352403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194434|NCT00229424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194435|NCT02160041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874288|NCT05076383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194436|NCT02323100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194437|NCT01386970|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194438|NCT03708783|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with locally advanced upper and middle third gastric cancer will receive laparoscopic total gastrectomy with D2 lymphadenectomy including No. 10 lymph node dissection.||||
34194439|NCT04067570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194440|NCT00920010|||COHORT||PROSPECTIVE|||||||
34194441|NCT03614052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34194442|NCT03632408|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Alcohol not masked Zopiclone and placebo capsulated, identical in weight and appearance Third party generated code only available to pharmacy and in case of emergency||t|f|t|t
34194443|NCT03158662|||CASE_ONLY||CROSS_SECTIONAL|||||||
34194444|NCT00477516||CROSSOVER||BASIC_SCIENCE||NONE||||||
34194445|NCT00576329|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34194446|NCT06365970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874289|NCT04474756|RANDOMIZED|PARALLEL||TREATMENT||NONE|open, multicenter study in 90 obstructive sleep apnea (OSA) patients|Prospective, randomized, controlled, comparative, open, multicenter study. 90 patients, randomized into two parallel groups, comparing the efficacy of 2 different custom-made mandibular advancement devices: NarvalTM versus TALITM, in the treatment of obstructive sleep apnea (OSA).||||
33874290|NCT00597480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874291|NCT04845100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study is a single blind randomized controlled study designed in a pretest, posttest and follow-up design.|t|f|f|f
33874292|NCT01068171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194447|NCT05647161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194448|NCT03065972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874293|NCT03829319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194449|NCT03014232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194450|NCT02561767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194451|NCT03835793|||COHORT||CROSS_SECTIONAL|||||||
34194452|NCT06180187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"group I (Osseo Densification group) Patients in this group will have sinus floor elevation using osseodensification burs then application of PRF membrane through the socket to protect schneiderian membrane and application of sticky bone (xeno graft and i-PRF) to augment alveolar ridge to receive dental implant~group II (electrical mallet group) Patients in this group will have sinus floor elevation using electrical mallet then application of PRF membrane through the socket to protect schneiderian membrane and application of sticky bone (xeno graft and i-PRF) to augment alveolar ridge to receive dental implant"|f|f|f|t
34194453|NCT05011370|||COHORT||PROSPECTIVE|||||||
34194454|NCT06179342|||CASE_CONTROL||PROSPECTIVE|||||||
34194455|NCT00645450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194456|NCT02791568|||CASE_CONTROL||PROSPECTIVE|||||||
34194457|NCT04484571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Indipendent assessor blinded on treatment provided|Randomized Clinical Trial|f|f|f|t
34194458|NCT05652088|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects receiving therapies with the potential for HIV cure who agree to participate in this study, will undergo a colonoscopy to obtain tissue samples for research assays before and after receiving such treatment.||||
33874294|NCT01652183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874295|NCT05522075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33874296|NCT06053255|NA|SINGLE_GROUP||TREATMENT||NONE||10 participant feasibility study||||
33874297|NCT02337374|||CASE_ONLY||PROSPECTIVE|||||||
33874298|NCT01776879|||CASE_CONTROL||PROSPECTIVE|||||||
33874299|NCT03461328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Intra-operative intravenous infusion of magnesium sulphate in patients with chronic obstructive pulmonary diseases undergoing total laryngectomy and assess the influence on arterial oxygenation and pulmonary Mechanics in|t|f|f|t
33874300|NCT03326076|||COHORT||PROSPECTIVE|||||||
33874301|NCT01685827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874302|NCT00684255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874303|NCT01579188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874304|NCT03201458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874305|NCT04894500|||COHORT||PROSPECTIVE|||||||
33874306|NCT02361502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874307|NCT00841802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874308|NCT03997435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874309|NCT03611192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33874310|NCT02198703|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874311|NCT03094234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33756095|NCT04010071|NA|SINGLE_GROUP||TREATMENT||NONE||Patients were confirmed with advanced hepatobiliary malignancies by imaging and histological examination and meet with the inclusive criteria, including hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, gallbladder carcinoma, and mixed cancer).||||
33756096|NCT02348450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756097|NCT01806987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33756098|NCT00330174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756099|NCT05802368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756100|NCT04679181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756101|NCT04151225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double blind study where participants, investigator and sponsor will be blinded.|This is a parallel group treatment study.|t|t|t|f
33756102|NCT05346003|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756103|NCT01410474|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33756104|NCT03016767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756105|NCT02657616|||COHORT||RETROSPECTIVE|||||||
33756106|NCT00760149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756107|NCT03523468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33756108|NCT04888091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant masking: Embryo transfer is done while the patient is lying in lithotomy position in accordance with gynecological examination. The patient is informed about the preparations before the embryo transfer and then the examination is completed. The patient will not be informed about the method used for removal of the cervical mucus. The patient's lying position also does not allow observation of the material used to remove cervical mucus.|It is a parallel model interventional study. The sample size is calculated as 180 patients. Sixty patients will be assigned to each study arm by randomization. It is planned to use random computerized numbers for randomization. İn arm 1, cervical mucus will be removed with a cotton swab before embryo transfer. In arm 2, cervical mucus will be removed with a canula before embryo transfer. In arm 3, cervical mucus will not be removed.|t|f|f|f
33756109|NCT01094925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756110|NCT05009342|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric, randomized, non-inferiority, without blinding, controlled trial with 2 parallel groups||||
33756111|NCT05154383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756112|NCT00686140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756113|NCT05471648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Trial of EirGenix' Pertuzumab and Perjeta® (Pertuzumab) sourced from US and EU Administered to Healthy Male Volunteers|t|t|t|t
33756114|NCT02204995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756115|NCT02615964|||CASE_ONLY||PROSPECTIVE|||||||
33756116|NCT01011621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756117|NCT01314040|RANDOMIZED|CROSSOVER||||NONE||||||
33756118|NCT03917667|||COHORT||PROSPECTIVE|||||||
33756119|NCT03956472|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33756120|NCT01572779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756121|NCT01963325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756122|NCT06048770|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||f|f|f|t
33756123|NCT03121157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756124|NCT02954354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756125|NCT06418555|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33756126|NCT05282797|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33756127|NCT01285622|||COHORT||PROSPECTIVE|||||||
33756128|NCT05596305|NA|SINGLE_GROUP||OTHER||NONE||quasi experimental ( pre-post ) study evaluating the outcomes of anti-stigma educational intervention||||
33756129|NCT05576584|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33756130|NCT02426788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756131|NCT03742024|||COHORT||PROSPECTIVE|||||||
33756132|NCT03294330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874312|NCT02577614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874313|NCT05143892|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into avatrombopag group or supportive care group at the ratio of 1:1.||||
33874314|NCT06334289|||COHORT||PROSPECTIVE|||||||
34194459|NCT03278704|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is an exploratory randomized controlled trial. Participants will complete a parallel designed study, in which they will be randomly assigned to a resistance exercise (RE) only or concurrent RE and high-intensity interval training (RE + HIIT) group.||||
34194460|NCT04034667|||CASE_CONTROL||PROSPECTIVE|||||||
34194461|NCT03736902|||OTHER||OTHER|||||||
34194462|NCT02820948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34194463|NCT01029860|||CASE_CROSSOVER||PROSPECTIVE|||||||
34194464|NCT05253391|||COHORT||PROSPECTIVE|||||||
34194465|NCT00597896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194466|NCT06092944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194467|NCT00094484|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34194468|NCT00548184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756133|NCT00817180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756134|NCT00627380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756135|NCT02255357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874315|NCT05227521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874316|NCT03587220|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33874317|NCT02249143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874318|NCT02707120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874319|NCT04159220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33874320|NCT05464888|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34194469|NCT03211572|NA|SINGLE_GROUP||OTHER||NONE||The clinical trial will be a prospective, two-strata, non-blinded, single institution Health Canada approved window of opportunity trial with 2 weeks of pre-surgical endocrine therapy using either anastrozole or tamoxifen.||||
34194470|NCT02840617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194471|NCT03399201|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33874321|NCT00952497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194472|NCT05761717|NA|SEQUENTIAL||TREATMENT||NONE||12\~18 participants in Cohort . C1:50 ug of PCV; C2: 100 ug of PCV ; C3: 150 ug of PCV.Extended research phase:49 participants in Cohort.||||
33874322|NCT03717909|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34194473|NCT06362733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194474|NCT03653559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are only aware of the study condition in which they are allocated.|"Randomised controlled trial. The model tests a new dietary recommendation (home meals condition) against a standard dietary recommendation (healthy meals condition)"|t|f|f|f
34194475|NCT00125606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194476|NCT02291016|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34194477|NCT01018810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194478|NCT01012219|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34194479|NCT00475306|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34194480|NCT02125591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194481|NCT00845091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194482|NCT02173093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194483|NCT02807415|||CASE_ONLY||PROSPECTIVE|||||||
34194484|NCT00439738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194485|NCT02611596|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34194486|NCT05594745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized|Multiple group, single unmasked randomized trial|f|f|t|f
34194487|NCT01224951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194488|NCT03117452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants will be assessed on outcomes of interest by trained clinical interviewers who are blind to the treatment condition in which participants are assigned.|Half of the participants will be randomized to receive the computerized visual training, which will be delivered in small groups over a period of 12-14 weeks, and the other half will be assigned to the control condition, which consists of standard Partial Hospital care without visual training.|f|f|f|t
34194489|NCT02883257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194490|NCT05785819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194491|NCT00946140|||COHORT||PROSPECTIVE|||||||
34194492|NCT05677685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double-blind study and therefore participants and clinical staff are not aware of the treatment group assigned to each participant.|Eligible patients who meet the study inclusion criteria will be randomized in a 1:1 assignment ratio to the study group or control group in a double-blind manner.|t|t|t|t
34194493|NCT03196609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This cohort will consist of 55 patients as described below:~* non-small cell lung cancer (NSCLC)~* hepatocellular cancer:~* colorectal cancer~* breast cancer~* prostate cancer~* glioblastoma"||||
34194494|NCT03309033|||COHORT||PROSPECTIVE|||||||
34194495|NCT00640211|||COHORT||PROSPECTIVE|||||||
34194496|NCT02987777|||CASE_ONLY||RETROSPECTIVE|||||||
34194497|NCT00689117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194498|NCT01454778|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34194499|NCT05519592|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34194500|NCT05659537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194501|NCT01068964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194502|NCT00185198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194503|NCT02356900|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194504|NCT02559700|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33874323|NCT04558866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874324|NCT02864368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874325|NCT00400673|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874326|NCT03703882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874327|NCT00271817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874328|NCT03632733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware of the drug they are given|Three antimicrobials ( two single and one in combination form) and a placebo will be provided in patients randomly|t|f|f|f
33874329|NCT02688595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33874330|NCT03440814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874331|NCT01890642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194505|NCT01296399|||CASE_CONTROL||RETROSPECTIVE|||||||
34194506|NCT00915499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194507|NCT04332861|||COHORT||PROSPECTIVE|||||||
34194508|NCT01784822|||COHORT||PROSPECTIVE|||||||
34194509|NCT02291653|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194510|NCT03868527|||COHORT||RETROSPECTIVE|||||||
34194511|NCT02218892|||COHORT||PROSPECTIVE|||||||
34194512|NCT05738681|RANDOMIZED|PARALLEL||PREVENTION||NONE||Tuberculosis patients who had standard regimen treatment, non-HIV, no severe co-morbidity, no chronic hepatitis B or C were randomized to using NAC-long 1,200 mg/day for 8 weeks (NAC long group) or using anti-TB alone (non-NAC group). Genetic test, CBC, Cr, coagulogram were assessed at baseline. LFT were assessed at baseline, 2 weeks, 8 weeks and 24 weeks.||||
34194513|NCT05382767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194514|NCT02102711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194515|NCT03029988|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE|Open Label|Injection and imaging will begin with Cohort 1. Cohort 1 and Cohort 2 will receive tilmanocept intravenously.||||
34194516|NCT02862353|||COHORT||PROSPECTIVE|||||||
34194517|NCT04134546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194518|NCT04273906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194519|NCT03232333|||COHORT||PROSPECTIVE|||||||
34194520|NCT04395053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"* Experimental: Treatment group TR Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.~* Experimental: Treatment group RT Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation."||||
33756136|NCT04417998|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants are assigned to two groups in parallel for the duration of the study. Aim 1 involves the prospective data collection of subjects who are already enrolled in Mayo Clinic Rochester research study 08-005553 (PI: Dr Val Lowe) and are scheduled to be scanned on the Siemens Biograph Vision 600 PET/CT system (hereafter referred to as the V600-R1) in the PET/CT Molecular Imaging Research Center on Charlton 6 of Mayo Clinic Rochester. Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1.||||
33756137|NCT00077064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33756138|NCT00708240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756139|NCT04826601|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756140|NCT06239363|||COHORT||PROSPECTIVE|||||||
33756141|NCT00265174|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33756142|NCT05064852|||COHORT||PROSPECTIVE|||||||
33874332|NCT04879043|NA|SINGLE_GROUP||TREATMENT||NONE||"Eligible patients will be enrolled and treated with intravenous HDP-101 every 3 weeks. In Phase 1 dose-escalation part from Cohort 6 additional treatment arms are introduced for dose-optimization purposes with dosing every 3 weeks, split dosing weekly or split dosing in the first cycle on Day1 and Day8.~A Bayesian logistic regression model will be used to guide dose-escalation during Phase 1 and select the best dose for the Phase 2a of the study."||||
33874333|NCT03983577|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33874334|NCT02603874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33874335|NCT03836391|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant-time point is randomized between intervention message or no intervention message||||
33874336|NCT05112536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874337|NCT04945603|||COHORT||OTHER|||||||
33874338|NCT03496246|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||It is a Clinical trial with three arms||||
33874339|NCT02705651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874340|NCT01026831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874341|NCT05980624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33874342|NCT00170287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874343|NCT01452763|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068131|NCT05438758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent trained individual will not be aware of which treatment arm the participant is in. The Montgomery Asberg Depression Rating Scale (MADRS) assessor will have no other contact with participant apart from remotely assessing the MADRS|Participants who have received Almond Therapy in study ZYL-730-01 will continue to have this in the extension study Participants who received Treatment as Usual in study ZYL-730-02 will continue to have this in the extension study.|f|f|f|t
34068132|NCT04089501|||CASE_ONLY||PROSPECTIVE|||||||
34068133|NCT00977691|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34068134|NCT02187861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068135|NCT04748393|||COHORT||PROSPECTIVE|||||||
34194521|NCT06458816|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a prospective cohort study the utility of a non-invasive distractor during arthroscopy. We hypothesize that the non-invasive distractor in conjunction with the DeMayo leg holder will provide superior medial and lateral compartment distraction with greater stability of the operative leg compared to standard manual arthroscopy techniques.||||
34194522|NCT03589937|||COHORT||PROSPECTIVE|||||||
34194523|NCT02894502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34194524|NCT02365480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34194525|NCT00593476|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194526|NCT02872844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34194527|NCT00566384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194528|NCT04863508|||COHORT||PROSPECTIVE|||||||
34194529|NCT00817596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194530|NCT03247452|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only the endoscopists in charged of rating cleansing quality during colonoscopy will be masked.||f|f|t|f
34194531|NCT01821976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874344|NCT06493773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"There is follow-up for each individual participant conducted by personnel blinded to the randomization and consisting of: 1) telephone contact with interview about alcohol consumption using the time-line follow-back method conducted at three time points after 1, 3 and 6 months, 2) measurement of phosphatidyl ethanol after 6 months, and 3) electronic health records after 6 months.~Care providers will not be informed about the study.~Analyses will be performed in a blinded data set with treatment allocation labeled A and B. Prior to this, the statistical analysis plan will be completed, signed, and uploaded at clinicaltrials.gov, and the data set will be locked. Unblinding will not occur until all analyses are performed (expected spring 2027). This means that apart from data on long-term follow-up, all analyses will be finalized collectively."||f|t|t|t
34194532|NCT05827536|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study products will be self-administered at home according to the assigned randomization sequences, AB or BA where A=standard of care and B=PKU GOLIKE.~Patients will be randomized in a 1:1 ratio to one of the following two sequences:~* AB: patients will receive 3 daily self-administrations of their usual standard of care for 2 consecutive days in the first period followed by 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the second period.~* BA: patients will receive 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the first period followed by 3 daily self-administrations of their usual standard of care for 2 consecutive days in the second period. Patients that are not compliant or need to be excluded for other clinical reasons from the treatment schedule will be replaced in order to ensure 20 subjects completing both treatment sequences."||||
34194533|NCT00190151|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33874345|NCT02526706|NA|SINGLE_GROUP||||NONE||||||
33874346|NCT05389163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874347|NCT02286700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874348|NCT06169007|||CASE_CONTROL||PROSPECTIVE|||||||
33874349|NCT06494631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874350|NCT02353156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874351|NCT00385502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874352|NCT03209102|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33874353|NCT03009214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874354|NCT01191073|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874355|NCT04971876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967520|NCT03568825|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"The study is a RSP designed multicenter study with two interventional- and one response variable. The two-interventional variable were Number of OMTs and Interval in days between each treatment. The GERD variables were degrees of Heartburn, Chest pain, Acid in mouth, Epigastric pain and Thoracic pain. The response variable were percent reduction in sum of the GERD variables from baseline in 4 categories. Each of the two RSP designs consisted of three dose levels. Three GERD patients were allocated to the first design level given six OMT with five days' interval. Based on the results obtained from the first design level, five patients were subsequently included to the second design level. The number of OMT's and interval between each treatment was separately determined. Seven patients were included to the third design level and given number of OMT's and interval between treatments calculated based on results obtained from the second design level."||||
33967521|NCT03311009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194534|NCT05615025|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34194535|NCT00250198||||TREATMENT||||||||
34194536|NCT06089096|||OTHER||CROSS_SECTIONAL|||||||
34194537|NCT04499313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194538|NCT04904224|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized multicentric open-label study in cooperation with local gastroenterological specialist practices. A comparison is made of pan-intestinal capsule endoscopy versus colonoscopy.||||
34194539|NCT03039946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874356|NCT03480100|||OTHER||PROSPECTIVE|||||||
33874357|NCT05566951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the research, it was planned to blind the participant and outcome evaluation.||f|f|f|t
33874358|NCT02604277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874359|NCT00820677|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33874360|NCT00563186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33874361|NCT02954497|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Jarvik 2015||||
33874362|NCT05663762|||COHORT||RETROSPECTIVE|||||||
33874363|NCT04772495|||CASE_CONTROL||PROSPECTIVE|||||||
33967522|NCT02879747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967523|NCT01324063|RANDOMIZED|||TREATMENT||||||||
33967524|NCT03354156|||CASE_CONTROL||PROSPECTIVE|||||||
33874364|NCT01303094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874365|NCT00671021|||COHORT||PROSPECTIVE|||||||
33874366|NCT02375230|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
34068136|NCT00632632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874367|NCT00002689||||TREATMENT||||||||
33874368|NCT01999803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874369|NCT01141504|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33874370|NCT04705194|||COHORT||PROSPECTIVE|||||||
33874371|NCT00959868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874372|NCT03869528|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Group allocation by opaque sealed envelopes. Participant and bronchoscopist shall be unaware of the number of sprays administered.|Randomized Controlled Trial|t|t|t|t
33874373|NCT03075527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874374|NCT00251940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874375|NCT01750385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33874376|NCT04724564|||COHORT||PROSPECTIVE|||||||
33874377|NCT03114176|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33874378|NCT02855528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874379|NCT00558870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33874380|NCT01423409|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33874381|NCT05142527|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874382|NCT00314522|||CASE_ONLY||RETROSPECTIVE|||||||
33874383|NCT04199637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33874384|NCT02888093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874385|NCT02810756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874386|NCT02572752|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874387|NCT04012047|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33874388|NCT06450652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874389|NCT03825874|||OTHER||PROSPECTIVE|||||||
33874390|NCT03572985|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33874391|NCT00923390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874392|NCT04718974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"2 groups one on intervention of Call for life mHealth with standard of care and other on standard of care only.~mHealth Call for life Tool using interactive voice response"||||
33967525|NCT00212771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967526|NCT00973778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967527|NCT02611206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967528|NCT03382210|||COHORT||PROSPECTIVE|||||||
33967529|NCT01217203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967530|NCT03105115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967531|NCT06059742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33967532|NCT06090747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A controlled trial design was adopted in which patients were assigned to two intervention groups according to the nutritional, psychological, or rehabilitation risk at baseline or according to their geographical localization. The first group will receive a hybrid multidisciplinary lifestyle education intervention (control), whereas the second group will receive an individualized hybrid multidisciplinary lifestyle intervention. The study aims to evaluate the effect of both interventions on the internal exposome of young patients with breast cancer and their effect on quality of life. To do this, changes over time in biochemical, inflammatory, and metabolomic indicators will be measured, and validated questionnaires will be applied to assess lifestyle components such as level of physical activity, sleep hygiene, emotional distress, and quality of life (so baseline, during and after treatment).||||
33874393|NCT05284942|NA|SINGLE_GROUP||TREATMENT||||Mycophenolate mofetil combined with stand of care of oral prednisone 5mg-15mg/day||||
33874394|NCT01858077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874395|NCT02970890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194540|NCT00740610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194541|NCT06342206|||CASE_CONTROL||PROSPECTIVE|||||||
34194542|NCT02492932|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34194543|NCT01951040|||COHORT||RETROSPECTIVE|||||||
34194544|NCT01136785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194545|NCT00386919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194546|NCT02773953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194547|NCT00380042|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34194548|NCT04379128|||CASE_CONTROL||PROSPECTIVE|||||||
34194549|NCT03370172|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33756143|NCT02520167|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34194550|NCT03373617|||COHORT||PROSPECTIVE|||||||
34194551|NCT02082340|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194552|NCT01232036|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34194553|NCT05907941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194554|NCT04740138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874396|NCT04827784|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants whose Temporomandibular disorders (TMD)-related complaints continued despite occlusal stabilization splint, NSAIDs and centrally acting muscle relaxant treatments were administered a total of 3 doses of Auriculotemporal Nerve Block (ATNB).||||
33874397|NCT03043716|||COHORT||PROSPECTIVE|||||||
33874398|NCT01577186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874399|NCT05435651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The present study will be carried out using a parallel randomized study design. Each participant will be randomly assigned either to Multitask game-based digital therapy or to Schulte Grid digital game control group.|f|f|t|t
33874400|NCT03685266|||CASE_ONLY||PROSPECTIVE|||||||
33874401|NCT01698164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874402|NCT05347160|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Evaluate the effect of different pulpotomy medicaments on permanent molars with immature root clinically and radiographically:~1. Calcium Hydroxide~2. Biodentine~3. Platelet Rich Fibrin"||||
33874403|NCT02115204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874404|NCT02323269|||COHORT||PROSPECTIVE|||||||
33874405|NCT03609697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All outcome assessors will be blinded to group allocation|"It is a 12-month 2-arm randomised controlled trial, RCT (the lifestyle intervention group and the SMS intervention group) with a 3 year follow up. The programme will proceed in two phases: the intensive intervention phase (0-6 months) and the maintenance phase (7-12 months). During the intensive intervention phase, participants in the lifestyle intervention group will attend 7 group-based interventions plus two sessions of individual face-to-face dietician consultation. During the maintenance phase, participants will receive monthly phone call from the research team.~The SMS intervention group will receive regular SMS during both the intensive intervention and the maintenance phases."|f|f|f|t
33874406|NCT04762537|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The proposed study is an open-label, multi-center, stepped-wedge cluster randomized trial. As part of the stepped-wedge design proposed for this trial, one site, randomly chosen, will start implementing the Rapid procedure (RP) and will remain in this arm for the rest of the study. The next 4 sites randomly chosen will first implement the Standard procedure (SP), to establish the within-site comparison condition, and then at selected staggered time-points (steps) will switch to implementing only the RP. The 6th site (after 5 sites have been randomized to RP) will remain in the SP procedure arm throughout the whole duration of the study. Implementation of RP at study sites will be staggered by 14 weeks and the order in which sites will cross-over from SP to RP will be randomly chosen.||||
33874407|NCT03854708|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33874408|NCT06073600|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|In this bioequivalence study, the bioanalysis, the pharmacokinetics and the statistical analysis will be blind.|This study is an open label, randomized, fed, single oral dose, two-treatment, two-sequence, and two-period crossover study with a washout interval of at least one week between dosing.|f|f|f|t
33874409|NCT01346033|||COHORT||CROSS_SECTIONAL|||||||
33874410|NCT04004637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967533|NCT01559974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967534|NCT05720728|||COHORT||PROSPECTIVE|||||||
33967535|NCT04663893|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33967536|NCT04917900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967537|NCT02531230|||COHORT||PROSPECTIVE|||||||
33967538|NCT03183271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967539|NCT04797156|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The patient, surgeon, and anesthesiologist in the case will be blinded|"Patients will be assigned randomly using a computer-generated table of numbers to one of the three groups:~1. High Dose Intravenous TXA (hTXA group)~2. Low Dose Intravenous TXA (lTXA group)~3. Combined Intravenous and Topical TXA group (cTXA group)."|t|t|f|t
33967540|NCT02360397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967541|NCT01505595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967542|NCT02041585|||COHORT||PROSPECTIVE|||||||
33967543|NCT01690520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967544|NCT00395200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967545|NCT06223022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34194555|NCT00272662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194556|NCT01325337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194557|NCT05887583|RANDOMIZED|PARALLEL||PREVENTION||NONE||Schools will be randomized to receive either the intervention or control group condition.||||
34194558|NCT02221713|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34194559|NCT05653453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194560|NCT05807165|||COHORT||PROSPECTIVE|||||||
34194561|NCT02414256|||COHORT||PROSPECTIVE|||||||
34194562|NCT05730803|||OTHER||CROSS_SECTIONAL|||||||
34194563|NCT02689921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194564|NCT02084251|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34194565|NCT00155675|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33967546|NCT02921347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874411|NCT04307992|NA|SINGLE_GROUP||TREATMENT||NONE||The current study is a follow-up study on the previous feasibility study where ACP-T5 was used. After increasing the % tantalum in ANEUFIX to make the product more detectable under X-ray, the current study is a pilot study that (1) evaluates the technical feasibility of the prophylactic use of AneuFix during EVAR implentation and (2) assesses the rate of endoleaks after EVAR in 5 patients.||||
33967547|NCT02235961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874412|NCT00892385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967548|NCT04410341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967549|NCT00618397|NA|SINGLE_GROUP||||NONE||||||
33967550|NCT00654043|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33967551|NCT02309203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068137|NCT01872806|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34068138|NCT06386159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068139|NCT06040671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking is used in the study.|The study subjects will be divided into two groups.||||
34068140|NCT00333632|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34068141|NCT00575471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068142|NCT00930527|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068143|NCT03876847|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34068144|NCT03057717|NA|SINGLE_GROUP||OTHER||NONE||||||
34068145|NCT01687855|||CASE_CONTROL||PROSPECTIVE|||||||
34068146|NCT01047111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068147|NCT03153683|||OTHER||PROSPECTIVE|||||||
34068148|NCT00671099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068149|NCT00647036|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34068150|NCT03488602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research staff responsible for measuring outcomes will be blinded to participants' randomization.||f|f|f|t
34194566|NCT01389661|NA|SINGLE_GROUP||TREATMENT||NONE||MSV-H autologous transplantation: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal||||
34194567|NCT05772585|||COHORT||PROSPECTIVE|||||||
34194568|NCT06032013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194569|NCT04609007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194570|NCT01789398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194571|NCT02686008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874413|NCT02536989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194572|NCT00421941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34194573|NCT01643421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874414|NCT04192487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874415|NCT01383577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874416|NCT00916266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874417|NCT02783703|NA|SINGLE_GROUP||OTHER||NONE||||||
33874418|NCT04870242|||COHORT||RETROSPECTIVE|||||||
33874419|NCT01851681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874420|NCT01265550|RANDOMIZED|PARALLEL||TREATMENT||NONE|Partial Double Blind (Medical Treatment Groups)|||||
34194574|NCT01089517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194575|NCT04580641|||CASE_ONLY||CROSS_SECTIONAL|||||||
34194576|NCT05379010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874421|NCT04755361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33874422|NCT03268044|||COHORT||RETROSPECTIVE|||||||
33967552|NCT03827785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33967553|NCT01684722|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33967554|NCT05548218|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33967555|NCT05862259|||COHORT||PROSPECTIVE|||||||
33967556|NCT04929171|||CASE_ONLY||PROSPECTIVE|||||||
34068151|NCT00600158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068152|NCT03604705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068153|NCT04124328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068154|NCT03051438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068155|NCT00718016|||COHORT||CROSS_SECTIONAL|||||||
34068156|NCT04786171|||CASE_CONTROL||PROSPECTIVE|||||||
34068157|NCT00391742|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34068158|NCT06075043|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34068159|NCT05068479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34068160|NCT06034132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068161|NCT00669851|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068162|NCT01459835|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34068163|NCT01957839|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34068164|NCT00076999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194577|NCT05673798|||COHORT||RETROSPECTIVE|||||||
34194578|NCT06288464|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Cohort||||
33874423|NCT03666455|NA|SINGLE_GROUP||TREATMENT||NONE||Study Design: Mixed methods, intervention trial, feasibility study, with sequential and concurrent quantitative and qualitative data collection before, during, and after the intervention.||||
33874424|NCT06250803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|For enhanced objectivity in data analysis, the project statisticians will be blinded to the arm allocation.||t|f|t|t
33874425|NCT03129659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967557|NCT03230032|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||There participants will be randomized to two groups: PAL (pacifier and mother's voice provided contingently on sucking behavior) or Sounds of Love (listening to mother's voice not contingent upon sucking behavior on the pacifier, but pacifier available, per standard of care). To allow for high repetitiveness of the treatment, participants in both groups will receive 2 daily 15-min sessions of the intervention or control treatments for a total of 20 sessions. Sessions occur 15-30 min prior to feeding.|f|t|f|t
33967558|NCT01082198||||TREATMENT||NONE||||||
33967559|NCT06173895|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33967560|NCT06328634|||COHORT||RETROSPECTIVE|||||||
33967561|NCT00853931|NA|SINGLE_GROUP||||NONE||||||
33967562|NCT01625845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33967563|NCT00562692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194579|NCT00827138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967564|NCT00325429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874426|NCT04289337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33967565|NCT06326268|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33967566|NCT04601064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967567|NCT01933828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33967568|NCT01663714|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967569|NCT05547893|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33967570|NCT05178589|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a randomized cross-over design over the course of 3 menstrual cycles. Each menstruation phase begins on the first day of menstruation until the last day of menstruation (disappearance of bleeding). Each participant will participate in 3 randomized conditions: control (no TENS), one-unit TENS, and two-unit TENS.||||
33967571|NCT00789178|||COHORT||PROSPECTIVE|||||||
33967572|NCT03330028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967573|NCT02713503|||COHORT||PROSPECTIVE|||||||
33967574|NCT01265966|||CASE_CONTROL||PROSPECTIVE|||||||
33967575|NCT03525665|||COHORT||RETROSPECTIVE|||||||
33967576|NCT01052805|||CASE_ONLY||PROSPECTIVE|||||||
34151970|NCT05685056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Both groups (control and intervention) will be informed that the main aim of the study is to assess the impact of food guidance on the micronutrient intake in pregnant women. The intervention group will receive texts with detailed information focusing on nutrition and iodine rich foods specifically. The information sheet will have information on all the study procedures but the focus on iodine will remain discreet, to avoid unintended bias in response from participants. At the end of the study, participants will be debriefed on the deception.||t|f|f|f
34151971|NCT00634790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194580|NCT03840434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO.||||
33874427|NCT03254420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874428|NCT00024115||||TREATMENT||||||||
33874429|NCT03838302|||CASE_CONTROL||PROSPECTIVE|||||||
33874430|NCT03317938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874431|NCT02785250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874432|NCT02424253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874433|NCT05574595|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33874434|NCT01136655|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33874435|NCT04212455|||COHORT||PROSPECTIVE|||||||
33874436|NCT02560376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874437|NCT01321710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874438|NCT00475683|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33874439|NCT03413501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874440|NCT01466920|||COHORT||PROSPECTIVE|||||||
33967577|NCT06526845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967578|NCT05509322|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Patients will be blinded in the sense that they will be offered the consult at a particular price, and may be informed of the expected list price of the consult (i.e. what the price would be without the subsidy offered to the patient), but patients will not be aware that others are being offered different levels of subsidy.~Independent raters will be blinded as to the level of subsidy the patient has received; reasonable effort will be made to maintain investigator blinding; however, nothing will prevent the patient from proactively mentioning to the investigator the price they are paying or considering paying for the consult."|Prospective, interventional, multi-arm real-world study|t|f|f|t
33967579|NCT04102228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to one of two groups for the duration of the study (Multi-modality aphasia therapy plus inhibitory rTMS or multi-modality aphasia therapy plus sham rTMS).|t|t|t|t
33967580|NCT03295058|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||severe aplastic anemia patients will receive two different conditioning regimens before doing allogenic stem cell transplantation||||
33967581|NCT00651547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967582|NCT04133519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Randomized, Double-Blind, Comparator-Controlled, Parallel-Group Study|t|t|t|f
33967583|NCT00512174||FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|t|f
33967584|NCT04878874|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33967585|NCT05521490|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33967586|NCT04650607|||COHORT||PROSPECTIVE|||||||
33967587|NCT02156349|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33967588|NCT03379246|||COHORT||RETROSPECTIVE|||||||
33967589|NCT06356870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel assignment|t|f|f|t
33967590|NCT06120881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967591|NCT01764854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967592|NCT03172260|||CASE_CONTROL||PROSPECTIVE|||||||
33967593|NCT00630682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34151972|NCT01700010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151973|NCT03239015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874441|NCT04001023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874442|NCT01056627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874443|NCT00239798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874444|NCT01412476|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874445|NCT02728830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874446|NCT02389127|||CASE_CONTROL||PROSPECTIVE|||||||
33874447|NCT05535348|NA|SINGLE_GROUP||OTHER||NONE||We ran two groups of a resiliency intervention.||||
33874448|NCT05029206|||COHORT||RETROSPECTIVE|||||||
33874449|NCT03358719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194581|NCT04143308|RANDOMIZED|PARALLEL||OTHER||SINGLE||We will conduct a single-blinded, randomized controlled study. Ninety participants will be randomly assigned to: simultaneous training of walking and cognitive group, the cognitive training group, and treatment as usual group.|f|f|f|t
33874450|NCT03227263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151974|NCT06128122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Dextrose curve production from a single individual||||
34151975|NCT00072774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151976|NCT03795181|||COHORT||PROSPECTIVE|||||||
34151977|NCT00659503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151978|NCT05115513|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34194582|NCT03495856|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group, mixed methods repeated measures design (pre and post assessments)||||
34194583|NCT04511377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194584|NCT04664764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194585|NCT02921464|||COHORT||PROSPECTIVE|||||||
34194586|NCT00888264|||COHORT||PROSPECTIVE|||||||
34194587|NCT02198001|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34194588|NCT01460511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194589|NCT02919358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34194590|NCT00199043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194591|NCT03608358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194592|NCT01896206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874451|NCT04105374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194593|NCT02192333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194594|NCT03234569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874452|NCT03276000|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34194595|NCT04162782|||CASE_ONLY||CROSS_SECTIONAL|||||||
34194596|NCT01696682|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33874453|NCT04990089|||COHORT||PROSPECTIVE|||||||
33874454|NCT06475859|||CASE_CROSSOVER||PROSPECTIVE|||||||
33874455|NCT01316861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874456|NCT01179009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874457|NCT03222791|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33874458|NCT01020864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874459|NCT05080023|||COHORT||PROSPECTIVE|||||||
33874460|NCT06188884|||CASE_ONLY||PROSPECTIVE|||||||
33874461|NCT06493968|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33874462|NCT03177421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Midway through the study, participants from the control group will be folded into the intervention group.|t|t|f|f
33874463|NCT00578305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967594|NCT05056337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967595|NCT05565183|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151979|NCT05891158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151980|NCT04212689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194597|NCT05083858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194598|NCT01699867|||COHORT||PROSPECTIVE|||||||
34194599|NCT04691414|||COHORT||RETROSPECTIVE|||||||
34194600|NCT00483756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194601|NCT06491901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, non-blinded, randomized controlled trial|f|f|f|t
34194602|NCT00796523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34194603|NCT04048564|||COHORT||OTHER|||||||
34194604|NCT01370252|||CASE_CONTROL||PROSPECTIVE|||||||
34194605|NCT05847985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34194606|NCT02756429|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34194607|NCT05473078|||OTHER||CROSS_SECTIONAL|||||||
34194608|NCT03034551|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34194609|NCT01952808|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33874464|NCT03051555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874465|NCT03586128|||COHORT||PROSPECTIVE|||||||
33874466|NCT05656677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The six NICU nurses involved were blinded to the purpose of the study, whereas the clinical nurse specialist (CNS) was not. Always three members of this research team conducted the pain assessment during the facilitated tucking or the observing by the parents. The other three members of the research team focused on the nurses' group.~The CNS or the neonatologist provided information about the study to the parents, without stating its specific aim, instead referring in principle to the increased involvement of parents in pain management."|A three-arm pilot study using mixed methods of data collection (questionnaires, SCA, interviews) was designed to test the feasibility of the intervention encompassing parents' active and passive involvement in procedural pain management of extremely and preterm infants hospitalised at a neonatal intensive care unit (NICU).|t|t|t|f
33874467|NCT00066703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874468|NCT05632887|||COHORT||PROSPECTIVE|||||||
33874469|NCT01433237|||CASE_CONTROL||RETROSPECTIVE|||||||
33874470|NCT04132362|||CASE_ONLY||PROSPECTIVE|||||||
33874471|NCT04577235|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33874472|NCT02690155|||COHORT||RETROSPECTIVE|||||||
33874473|NCT02237300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33874474|NCT06223282|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874475|NCT02079103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874476|NCT05021107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967596|NCT03049956|NA|SINGLE_GROUP||DIAGNOSTIC|||Blinded diagnostic accuracy study (index test vs. reference standard).|||||
33967597|NCT05214157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34151981|NCT04542174|||CASE_ONLY||RETROSPECTIVE|||||||
34151982|NCT01943006|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34151983|NCT01482481|||COHORT||PROSPECTIVE|||||||
34151984|NCT02939768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151985|NCT00447122|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34194610|NCT05654077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194611|NCT03068351|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33756144|NCT03286374|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the study intervention, it is not possible to blind the participants. Some of the participants will give a focus group interview and their identity will be known for the other participants in the group. The health care providers will not get information about who will participate or not.|The study is a Clinical cohort trial with a pseudo prospective, parallel mixed methods design. Questionnaires and register data at baseline, T1, and T2. Focus group interviews at T3, and register data at T4.||||
33756145|NCT06282679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756146|NCT01187979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756147|NCT01430260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756148|NCT05981859|||COHORT||PROSPECTIVE|||||||
33756149|NCT02804464|||CASE_ONLY||PROSPECTIVE|||||||
33756150|NCT04419090|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33756151|NCT04621110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756152|NCT04861857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756153|NCT03450902|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33874477|NCT03448237|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional comparative study over 9 months, of three modes of care: Speech-language, or proprioceptive, or combined (speech therapy or proprioceptive); In view of the lack of recruitment of dyslexic children who had stopped speech therapy, we decided to keep only two comparative arms to our study: of two modes of care: Speech-language, or combined (speech therapy or proprioceptive)||||
33874478|NCT04304716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874479|NCT06402266|||CASE_ONLY||CROSS_SECTIONAL|||||||
33874480|NCT01375842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874481|NCT05618600|||COHORT||PROSPECTIVE|||||||
33874482|NCT02835183|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874483|NCT06023160|||COHORT||RETROSPECTIVE|||||||
33874484|NCT01248351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874485|NCT03138538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874486|NCT02006342|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33874487|NCT03114514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874488|NCT03896516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33874489|NCT02132481|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33874490|NCT03861559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874491|NCT02579070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874492|NCT05075070|NA|SINGLE_GROUP||PREVENTION||NONE||subjects infected with HIV receive two doses inactivated COVID-19 vaccine||||
33874493|NCT00881400|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874494|NCT03920189|||COHORT||PROSPECTIVE|||||||
33874495|NCT04807907|RANDOMIZED|PARALLEL||OTHER||NONE||"The treatment groups are randomly assigned, as follows:~* Infant Directed Speech (IDS) Video (Treatment; 50%): The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.~* Control (50%): No intervention. The participant will receive a regular wall calendar."||||
33874496|NCT03866044|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874497|NCT00129766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874498|NCT04027400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants never told which group they were in.|two groups with different treatment|t|f|f|f
33874499|NCT01231100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151986|NCT02345330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151987|NCT04936373|||COHORT||CROSS_SECTIONAL|||||||
33756154|NCT03298451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756155|NCT00765349|||COHORT||PROSPECTIVE|||||||
33756156|NCT03182335|||COHORT||PROSPECTIVE|||||||
33756157|NCT05437081|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Though most assessments were conducted by participants themselves online, in a few cases, study assessors conducted telephone interviews with parent participants. In these cases, the assessor was kept blind to the participant's study condition.|Latino emerging adults (EAs)and Latino parents of EAs were recruited in Oregon and Florida. Participants were then randomly selected into either the intervention or the control condition. Participants randomized to the control condition received referrals to community agencies for mental health, substance abuse, and health issues commonly experienced by EAs. Participants randomized to the intervention condition were invited to attend four family-focused sessions (for parents) or four identity development-focused sessions (for EAs).|f|f|f|t
33756158|NCT05608850|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33756159|NCT00541450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756160|NCT05263466|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756161|NCT04355351|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756162|NCT02717312|||COHORT||PROSPECTIVE|||||||
33756163|NCT04073602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756164|NCT00464815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874500|NCT02372474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874501|NCT01886365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194612|NCT00469742|||||RETROSPECTIVE|||||||
34194613|NCT04122651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomised into one of two groups.|Rayone Toric intraocular lens (for cataract surgery)|t|f|f|f
34194614|NCT05358613|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either receive the treatment now (10 working days, experimental group) or in 3 months (control group).||||
34194615|NCT03207763|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34194616|NCT00536393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194617|NCT04493892|NA|SINGLE_GROUP||OTHER||NONE||||||
34194618|NCT01567449|||CASE_CONTROL||RETROSPECTIVE|||||||
34194619|NCT01103024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194620|NCT00432549|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34194621|NCT01075308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194622|NCT05346822|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A two-site, two-arm, parallel-group controlled trial of integrated rehabilitation program||||
34194623|NCT02265588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756165|NCT03081390|NON_RANDOMIZED|PARALLEL||OTHER||NONE||There are four total groups of participants, stratified according to migraine status (yes/no) and obesity status (yes/no). All undergo the same experimental phenotyping procedures.||||
33756166|NCT01181726|RANDOMIZED|CROSSOVER||||NONE||||||
33756167|NCT00994838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756168|NCT05035472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33756169|NCT01479387|||CASE_ONLY||PROSPECTIVE|||||||
33874502|NCT05639907|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|There will be random allocation established, such that as a study participant is enrolled the clinician will receive a numbered envelope that contains the information for which TAD placement site will receive a TAD coated with solution A or B. The identification of Solution A or B is kept secret in an envelope stored in the office of the Chair of the Orthodontic Department (U Colo, Sch Dent Med). The patient, clinical operator, Investigator and Outcomes assessor is not aware which solution (A or B) is the experimental or placebo.|Split mouth|t|t|t|t
33874503|NCT05644028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874504|NCT02024542|||COHORT||PROSPECTIVE|||||||
33874505|NCT05504733|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||This study will be a single blinded, randomized clinical trial.|t|f|f|t
33874506|NCT05269485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There are two parallel group with each of 18 patients. One group would receive high-dose hypofraction radiotherapy of 60-68Gy/15-17f and the other group would receive low-dose hypofraction radiotherapy of 48Gy/12f.|f|f|t|f
33874507|NCT00413426|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874508|NCT02327364|||COHORT||PROSPECTIVE|||||||
33874509|NCT01121133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874510|NCT02396186|||COHORT||PROSPECTIVE|||||||
33874511|NCT02701543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874512|NCT02386228|||||PROSPECTIVE|||||||
33874513|NCT02895464|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33874514|NCT03651284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874515|NCT05171257|||COHORT||RETROSPECTIVE|||||||
33874516|NCT01803243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874517|NCT00390754|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967598|NCT03618082|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomization in 2 groups 1- control group : patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, desflurane, remifentanil (curare or not) for the maintenance, the dosage of the anesthetic agents will be decided by the anesthesiologist responsible for the patient based on the usual practice. 2- experimental group : patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, desflurane, remifentanil (curare or not) for the maintenance, administered according to a specific algorithm. In this group, the remifentanil administration will be piloted by the ANI (50 to 80), as well as the prophylactic administration of morphine at the end of the intervention. Administration of 2mg of morphine immediately before the extubating if ANI\<50. And, desflurane will be administered with a targeted purpose of 0.8 to 1.2 MAC.|t|f|f|f
33967599|NCT06385977|||CASE_CONTROL||RETROSPECTIVE|||||||
33967600|NCT04959110|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33967601|NCT02884661|||COHORT||RETROSPECTIVE|||||||
33967602|NCT02707432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33967603|NCT06092606|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33967604|NCT01710826|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33967605|NCT01456702|RANDOMIZED|PARALLEL||||NONE||||||
33967606|NCT05476679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967607|NCT05463783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Interventional, open-label, parallel-group, randomized trial||||
33967608|NCT04277819|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33967609|NCT04723771|||COHORT||PROSPECTIVE|||||||
33967610|NCT01720940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967611|NCT01248312|||COHORT||PROSPECTIVE|||||||
33967612|NCT00049634||||TREATMENT||NONE||||||
33967613|NCT01051622|NON_RANDOMIZED|PARALLEL||||NONE||||||
33967614|NCT04536233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967615|NCT03900611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33967616|NCT04351191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective double blind randomized superiority clinical trial.|t|t|t|t
33967617|NCT00096382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967618|NCT04304326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Outcomes Assessor)||f|f|f|t
33967619|NCT04614974|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Experimental, open-label randomized control trial||||
33967620|NCT05163379|||CASE_ONLY||CROSS_SECTIONAL|||||||
33967621|NCT05723627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33967622|NCT00628394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967623|NCT02277873|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33967624|NCT02961452|||CASE_ONLY||RETROSPECTIVE|||||||
33967625|NCT05358873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Tolerability and safety of the study product will be evaluated when given 3 times a day for 7 days in 36 healthy volunteers.|t|t|t|t
33967626|NCT05423691|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm study consisting of a safety run-in (3+3+3 design) followed by an expansion cohort after completion of safety run-in data is evaluated for tolerability in the safety.||||
33967627|NCT05636033|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33967628|NCT01914822|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33967629|NCT05992545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967630|NCT01489878|||COHORT||PROSPECTIVE|||||||
33967631|NCT02963298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756170|NCT00466635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874518|NCT02199080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874519|NCT04938583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874520|NCT04319133|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Overall, this research will run for ± 10 weeks; 1 week of preparation, 8 weeks of intervention and 1 week of evaluation of the final results of the study.~This research will involve an interview, physical examination and laboratory examination.~This research is a clinical trial research with interventions in the form of fasting. There will be divided into two groups: the intervention group (fasting) and the control group (not fasting). The fasting group will fast every Monday and Thursday, while the fasting group consumes daily food as usual. Both groups will be given education about balanced nutrition."||||
33874521|NCT01353027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874522|NCT00003462||||TREATMENT||||||||
33874523|NCT03709173|||OTHER||CROSS_SECTIONAL|||||||
33874524|NCT04897373|||COHORT||PROSPECTIVE|||||||
33874525|NCT05382637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874526|NCT04686721|||CASE_CONTROL||PROSPECTIVE|||||||
33874527|NCT03512600||SEQUENTIAL||OTHER||NONE||||||
34194624|NCT03463005|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study subjects were voluntarily assigned to royal gel and IUI groups. In royal gel group, 5 grams of royal gel was used after menstruation and every other night before and after intercourse. IUI group received 75 units of FSH from the second day of the cycle.||||
33874528|NCT05359120|||COHORT||CROSS_SECTIONAL|||||||
33874529|NCT01530984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874530|NCT01226550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874531|NCT05802719|NA|SINGLE_GROUP||OTHER||NONE||Exploratory pathophysiological cohort study, with a prospective 6-months follow-up||||
33967632|NCT04624022|||CASE_ONLY||PROSPECTIVE|||||||
33967633|NCT06242730|||COHORT||PROSPECTIVE|||||||
33967634|NCT04270526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All subjects will be randomized 1:1 at the first intervention visit to one of the two protocols using a random block design|t|t|t|f
33967635|NCT04505514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194625|NCT00511394|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34194626|NCT02850640|||COHORT||PROSPECTIVE|||||||
34194627|NCT02380768|RANDOMIZED|PARALLEL||||NONE||||||
34194628|NCT06427135|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized controlled study divided into intervention and control groups.||||
34194629|NCT02226445|||COHORT||PROSPECTIVE|||||||
34194630|NCT03496714|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be told of the specifications only of the condition to which they are assigned.|Immediately after baseline assessment, each participant will be automatically randomized into one of three study conditions. Randomization will be stratified based on number and severity of safety behaviors used and level of Acute Stress Disorder symptoms reported at baseline. Once randomized, participants in the two psychoeducation conditions will immediately receive psychoeducation materials, and all participants will receive rationale for their study condition, as specified above. All three conditions will complete the same schedule of assessments.|t|f|f|f
34194631|NCT00662298|NA|SINGLE_GROUP||OTHER||NONE||||||
34194632|NCT03399396|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the intervention, it is not possible to blind the practices or study staff to study arm allocation. To minimize bias, allocation will be masked until after baseline data collection of outcome measures, when it is time for each practice to initiate the intervention.|"Using a two-group, cluster randomized control trial (RCT) design, with the clusters being pediatric practices, practices will be randomized to two study arms representing two delivery modalities of the intervention: In-Person Coaching Arm and Web-Based Coaching Arm.~The intervention targets the providers and staff in the pediatric practices to make changes aimed to improve their quality of care, and the study participants are the providers and staff (not patients). Individual patients will not be recruited or enrolled in the study, since the intervention is focused on QI and all patient vaccination outcome data will be collected via aggregated reports from the EHR or other clinical data systems (no individual patient-level private health information (PHI)). The study practices include approximately 190 providers (physicians, nurse practitioners, physician assistants) and 275 other staff (nurses, clinical support staff, administrative staff)."||||
34194633|NCT01733303||CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34194634|NCT03367468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194635|NCT01437475|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34194636|NCT03171753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34194637|NCT01326338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194638|NCT00961129|||COHORT||PROSPECTIVE|||||||
34194639|NCT01872767|||COHORT||PROSPECTIVE|||||||
34194640|NCT05282303|||CASE_ONLY||RETROSPECTIVE|||||||
34194641|NCT01117909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194642|NCT05984498|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34194643|NCT03050411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874532|NCT01040455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874533|NCT00153114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874534|NCT03443908|||CASE_ONLY||PROSPECTIVE|||||||
33874535|NCT04431570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967636|NCT01876199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967637|NCT00995332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967638|NCT03016078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967639|NCT03960918|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is prospective (for stroke), randomized, parallel-group (for exercise) design with a 1:1 allocation ratio.||||
33967640|NCT03120702|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33967641|NCT05105139|||COHORT||RETROSPECTIVE|||||||
33967642|NCT00285350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34194644|NCT04772677|RANDOMIZED|PARALLEL||TREATMENT||NONE||This pilot study will include two arms. The first arm will enroll 30 mothers with children aged 6-17 months (i.e., infant cohort). The second arm will enroll 30 mothers with children aged 18-36 months (i.e., preschool cohort). The postpartum cohort will receive access to the online psychoeducation and social-connection platform and the preschool cohort will be randomized to the program or a services as usual control group. Analyses will be performed separately per each arm.||||
34194645|NCT00121862|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34194646|NCT01317459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967643|NCT04347590|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33967644|NCT00446654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194647|NCT04276324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194648|NCT00578760|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194649|NCT05087992|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1a non randomized, Phase 1b randomized.||||
33874536|NCT03171207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874537|NCT04481542|||COHORT||RETROSPECTIVE|||||||
33874538|NCT06387407|||OTHER||CROSS_SECTIONAL|||||||
33874539|NCT02202876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874540|NCT05572047|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, multi-center||||
33874541|NCT03238859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874542|NCT02915523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874543|NCT01118351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874544|NCT00644787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874545|NCT02950298|||OTHER||PROSPECTIVE|||||||
33874546|NCT04420637|||COHORT||RETROSPECTIVE|||||||
33874547|NCT06355765|||CASE_CONTROL||PROSPECTIVE|||||||
33874548|NCT01279577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874549|NCT06227299|||COHORT||OTHER|||||||
33874550|NCT01862042|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874551|NCT05289635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874552|NCT06244758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized (1:1), prospective, double-blind, placebo controlled, parallel-group, single centre study|t|t|t|f
33874553|NCT04071184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967645|NCT05341557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33967646|NCT02112812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967647|NCT06521034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967648|NCT05880563|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This is a controlled, open-label, first in man study to evaluate the regional distribution and brain-kinetics of \[18F\]RoSMA-18-d6 in ALS patients (n=20) and healthy volunteers (n=10).~ALS patients will get two imaging sessions with \[18F\]RoSMA-18-d6 PET/CT and MRI-scans one year apart. Healthy volunteers will get only one pair of \[18F\]RoSMA-18-d6 PET/CT and MRI scans"||||
33967649|NCT03875391|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33967650|NCT00448682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967651|NCT01489956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967652|NCT03372369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967653|NCT01960933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967654|NCT04726917|||COHORT||RETROSPECTIVE|||||||
34194650|NCT05184829|RANDOMIZED|PARALLEL||OTHER||NONE|open label|systemic or selective lymph node dissection group||||
34194651|NCT03124927|NA|SINGLE_GROUP||OTHER||NONE||||||
34194652|NCT03629314|NA|SINGLE_GROUP||OTHER||NONE||Educational-Interventional Pilot study||||
34194653|NCT06455046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194654|NCT00553722|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34194655|NCT01332799|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194656|NCT02601261|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34194657|NCT00305461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874554|NCT04156295|||COHORT||PROSPECTIVE|||||||
33874555|NCT04737655|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study population will consist of one cohort of patients admitted in our hospital (CHU DE LIEGE) for acute exacerbation of COPD. The COPD has to be diagnosed based on the international recommendations (GOLD recommendations). The patient has to suffer from an acute severe exacerbation requiring an ICU stay of at least 24hours.~Patients will be separated in 2 randomized groups (Trimbow + SOC versus SOC) 1:1.~A total of 200 patients will be randomized in this study following the inclusion and exclusions criteria."||||
33874556|NCT00360594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874557|NCT04061421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874558|NCT02980224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874559|NCT05595824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874560|NCT00258674|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874561|NCT00137111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874562|NCT00549172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874563|NCT02544685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33967655|NCT01551550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967656|NCT00654303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967657|NCT04898023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756171|NCT02640378|||CASE_ONLY||CROSS_SECTIONAL|||||||
33756172|NCT00993655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756173|NCT02470130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756174|NCT00311038|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756175|NCT03731754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756176|NCT01774357|||COHORT||PROSPECTIVE|||||||
33756177|NCT04008810|||COHORT||PROSPECTIVE|||||||
33756178|NCT00500864|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33756179|NCT01063101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33756180|NCT04430751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756181|NCT03664505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient receives two different burn garments and does not know which one was produced based on the scan data and which one on the manual measuring.||t|f|f|f
33756182|NCT02425332|NA|SINGLE_GROUP||OTHER||NONE||||||
33756183|NCT00385580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756184|NCT03133026|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33756185|NCT00941993|NA|SINGLE_GROUP||OTHER||NONE||||||
33756186|NCT02507648|RANDOMIZED|CROSSOVER||||NONE||||||
33756187|NCT03281148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756188|NCT06319417|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Nor participant and care provider knew the treatment given.|"28 days of treatment: one group with HT treatment and the other with placebo treatment.~2-weeks washout period. The treatment will be switched between groups for another 28 days: those who initially consumed HT will the switch to the placebo treatment, and vice versa."|t|t|f|f
33874564|NCT05297942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking not possible due to the nature of the intervention.|||||
33874565|NCT00083031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874566|NCT03061981|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
33874567|NCT00096707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874568|NCT00309634|RANDOMIZED|PARALLEL||PREVENTION||||||||
33874569|NCT00323232|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874570|NCT00619073|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33874571|NCT02284126|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874572|NCT05860075|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM01 in subjects with relapsed or refractory lymphoma.||||
33874573|NCT00000742||||TREATMENT||||||||
33874574|NCT01824277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33874575|NCT03073980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874576|NCT05288283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967658|NCT06407895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|t will be Randomized control trial in which non probabilty convenient sampling will be used. Two groups of 6-10 age will be formed in which participants will be randomly divided. Group A will only receive Lower Limb Fitness Program and group B will receive Routine Therapy|t|f|f|f
33967659|NCT01347398|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34194658|NCT04189185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An envelope deciding the treatment modality is drawn while the patient is anesthetized. Post operative follow-up is performed by blinded assessors. The treatment will be revealed after one year, or if the patient is excluded from the study.|Two study arms. One arm is treated with k-wire tension band wiring and one leg is treated with suture fixation|t|f|t|t
34194659|NCT01059708|||COHORT||PROSPECTIVE|||||||
33874577|NCT02882633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874578|NCT03362424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeon and patients not blinded|Randomized controlled trial|f|f|f|t
33874579|NCT04185090|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33874580|NCT01841944|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33874581|NCT01539590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874582|NCT02106052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874583|NCT06145555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874584|NCT01201161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33874585|NCT00867373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967660|NCT05750225|||CASE_CONTROL||OTHER|||||||
33874586|NCT03506035|||CASE_CONTROL||PROSPECTIVE|||||||
33874587|NCT01323426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874588|NCT04772937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient is anesthetized during surgery and will not recognize type of surgery.|Prospective randomization, 1:1 allocation, group 1: LLETZ, group 2: LEEP|t|f|f|f
33874589|NCT05183607|NA|SINGLE_GROUP||TREATMENT||NONE||Study sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely while in the comfort of their own residence or where it is deemed to be comfortable and safe.||||
33874590|NCT01365260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33874591|NCT00949546|||COHORT||PROSPECTIVE|||||||
33874592|NCT00641589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874593|NCT03036137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874594|NCT01208350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874595|NCT01501305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33874596|NCT00859378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967661|NCT03242577|||OTHER||CROSS_SECTIONAL|||||||
33967662|NCT04942379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34194660|NCT04441580|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34194661|NCT03800940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Enrolled patients will be randomly assigned in a 2:1 ratio to receive trans-drain occlusion followed by gradual drain withdrawal or gradual drain withdrawal.|t|t|t|t
34194662|NCT01450852|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194663|NCT04316533|||COHORT||PROSPECTIVE|||||||
34194664|NCT02802917|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34194665|NCT02917018|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34194666|NCT03218800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194667|NCT05254847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194668|NCT04343924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194669|NCT04354597|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Subjects who are enrolled in the study will be randomly assigned to any of the study arms, A or B.~Study Arm A (HCQ \& AZ)~Study Arm B (No treatment)"||||
34194670|NCT00642785|||CASE_ONLY||PROSPECTIVE|||||||
34194671|NCT04316819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194672|NCT00907179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194673|NCT01767142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194674|NCT02766556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34194675|NCT02502656|||COHORT||PROSPECTIVE|||||||
34194676|NCT01168219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194677|NCT01630993|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34194678|NCT02463253|||CASE_CONTROL||PROSPECTIVE|||||||
34194679|NCT06286189|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34194680|NCT03842878|||COHORT||PROSPECTIVE|||||||
34194681|NCT00439816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194682|NCT05996302|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Patients living permanently \>2500m around Quito (Equador) will be assessed at 2850m and after relocation to sea level||||
34194683|NCT05902650|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34068165|NCT05683925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Noninvasive electrostimulation will be applied to the left ear. taVNS will be applied to the cyma conchae and sVNS will be applied to the earlobe - participants will not be told which is the active and which is the sham condition. Both taVNS and sVNS were applied through the Nemos® electrode. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment. For each condition, the electrode will be placed in the ear by a third person and the ear will be covered by cotton pads and an EEG cap to hide the electrode position from the experimenter. The order of stimulation will not be revealed until the automated data and statistical analysis.|Participants and study overview In this randomised placebo controlled trial, the investigators will include 30 PD patients with HY\>2 and L-dopa unresponsive gait characteristics. Each participant will complete 1 visit, during which the instrumented stand and walk test will be repeated 16 times. The baseline measurement will be followed by three different stimulation conditions sham VNS (sVNS), taVNS at 25Hz (taVNS25) and taVNS a 100Hz (taVNS100). sVNS, taVNS25 and taVNS100 in a randomized order. To enhance gait disturbances, the participants will preform iSAW during each condition twice in silence and twice while simultaneously performing calculations around.|t|t|t|t
34068166|NCT04740996|||OTHER||PROSPECTIVE|||||||
33764830|NCT04591977|NA|SINGLE_GROUP||SCREENING||NONE||Participants who enroll in the study will be asked to complete an HPV self-sampling test in addition to attending their well-woman visit and receiving a clinician-sampled Pap Smear/HPV test. Participants will collect the sample at home and mail it back to the Penn State Health clinical laboratory, where the results will be compared to those obtained from the Pap Smear/HPV test at their clinic appointment. Participants will also complete a follow up survey over the phone after their sample is collected.||||
34068167|NCT05742113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|no masking|||||
34068168|NCT00678964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068169|NCT00351559|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34068170|NCT02425423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068171|NCT05294809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in all categories will be announced that they have received a mobile intervention aimed at distress reduction, without knowing the the rationale and specifics of each intervention. Outcomes will be assessed only by online questionnaires, so no assessor is involved.|Participants will be randomly assigned to one of three conditions: 2 experimental conditions and an active control group.|t|f|f|f
33764831|NCT05827874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764832|NCT03126864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874597|NCT01677533|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874598|NCT04833088|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874599|NCT03257007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants are blind to study hypotheses.|Participants will be assigned in equal numbers using block randomization to the mindfulness intervention or usual care. The course curriculum for the mindfulness intervention is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.||||
34068172|NCT04918472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068173|NCT02715102|||COHORT||PROSPECTIVE|||||||
34068174|NCT04627311|||COHORT||RETROSPECTIVE|||||||
34068175|NCT06028386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068176|NCT02940236|||CASE_ONLY||PROSPECTIVE|||||||
34068177|NCT04949204|||COHORT||PROSPECTIVE|||||||
34068178|NCT04633291|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34068179|NCT05118763|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|Randomised double blind placebo controlled parallel arm|t|t|t|t
34068180|NCT03048071|||CASE_CONTROL||RETROSPECTIVE|||||||
34068181|NCT06081491|||OTHER||RETROSPECTIVE|||||||
34068182|NCT00949871||||||NONE||||||
34068183|NCT04608890|||CASE_ONLY||CROSS_SECTIONAL|||||||
34068184|NCT00693485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34068185|NCT00500253|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34068186|NCT04648839|||COHORT||RETROSPECTIVE|||||||
34068187|NCT05266859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068188|NCT01863719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194684|NCT02162147|||COHORT||PROSPECTIVE|||||||
34194685|NCT03123406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||CKD Hemodialysis Patients with SHPT||||
34194686|NCT05646017|||COHORT||RETROSPECTIVE|||||||
34194687|NCT02697344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194688|NCT04040322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194689|NCT06445452|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34194690|NCT04339842|||CASE_ONLY||CROSS_SECTIONAL|||||||
34194691|NCT05786742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective comparative cohort study with non inferiority analysis UH-IMRT combined to 15 Gy HDR Brachytherapy will considerably reduce the treatment fraction delivered while maintaining b-DFS and Side-effects at comparable levels to our actual reported prostate cancer patient population, without lymph nodes involvement (risk being less than 15%). We believe that this therapeutic regime will show to be non-inferior to our actual standard therapeutic regime||||
34194692|NCT01610999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194693|NCT04232332|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34194694|NCT05382442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194695|NCT04510428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764833|NCT03311425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33764834|NCT01001481|||COHORT||PROSPECTIVE|||||||
33764835|NCT00111124||||TREATMENT||||||||
33764836|NCT02374632|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33874600|NCT02725723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874601|NCT02413112|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34194696|NCT03181646|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194697|NCT04439435|||COHORT||PROSPECTIVE|||||||
34194698|NCT01568619|||||PROSPECTIVE|||||||
34194699|NCT06530173|||CASE_ONLY||CROSS_SECTIONAL|||||||
33967663|NCT02245282|||COHORT||PROSPECTIVE|||||||
33967664|NCT00879970|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33967665|NCT00790075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967666|NCT01537575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194700|NCT04687514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants, health-care providers and data collectors are blinded to treatment allocation. Excluded from the blinding are defined study nurses administrating the injections as injection devices (dulaglutide/ placebo) are not identical. The unblinded study nurses are otherwise not involved in the trial. During the injection participants are blindfolded such as the injection device and the injection site is not visible for them.|randomized, double-blind, placebo-controlled trial with crossover design: Dulaglutide or placebo weekly subcutaneously for 4 weeks; in random order, separated by washout period of at minimum 28 days.|t|t|t|f
34194701|NCT05912790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194702|NCT00003076||||PREVENTION||||||||
34194703|NCT01642615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194704|NCT03433612|NA|SINGLE_GROUP||OTHER||NONE|The estimation marks from each technique (two total) will be on the back of the patient (one on the left flank, one on the right flank), therefore the patient does not know where the marks are. Additionally, each mark will be covered with a taped on gauze pad to conceal it so that the two investigators are blinded to each others assessment. The ultrasound clinician will be masked to the two estimations. The marks will still remain covered while the interspace is determined by the third assessor using lumbar ultrasound.|All patients will undergo estimation of the L4-L5 interspace using the classic and novel technique, followed by identification of the interspace using lumbar ultrasound.||||
34194705|NCT03936231|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34194706|NCT06317129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194707|NCT03162913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34194708|NCT00561626|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34194709|NCT01481532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764837|NCT04490135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||a quasi-experimental design with a convenience sample and a non-randomized wait-list control group||||
33764838|NCT02659917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33764839|NCT03926793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Clinical site investigators, study personnel, and study subjects will be blinded to treatment assignment; however, the Sponsor will be unblinded.||t|t|t|f
33764840|NCT04647422|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764841|NCT05130255|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 dose-escalation single-arm, open-label, non-randomized, multi-center trial||||
33764842|NCT03159897|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study aims to compare the efficacy of two alternative ABVD-based strategies, the first one (Comparator arm) based on a PET-2-adaptation, the second (Experimental arm) relying on a straight dose- and time-intensified schedule, devoid of any PET-adaptation.||||
33874602|NCT05780307|NA|SINGLE_GROUP||TREATMENT||NONE||This study is to observe the dose-limiting toxicity (DLT) of the patients and to determine the maximal tolerance dose(MTD) and recommended dose for expansion (RDE)||||
33874603|NCT03179332|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33874604|NCT01661907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33874605|NCT02287623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33874606|NCT03391271|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33874607|NCT00115609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874608|NCT06033742|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33874609|NCT05897853|||CASE_ONLY||PROSPECTIVE|||||||
33874610|NCT05743452|NA|SINGLE_GROUP||TREATMENT||NONE||Device: GBR with CS@Mg The patient was treated by GBR with magnesium calcium silicate scaffold for alveolar bone defect.||||
33874611|NCT01308970|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33874612|NCT03641066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874613|NCT03553043|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the intervention, it will not be possible to blind participants or research staff to the different conditions.|Participants were randomly assigned (1:1:1:1 ratio, stratified by ethnicity and alcohol use) by computer to view on-line one of four label conditions.||||
33874614|NCT01774578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874615|NCT05394064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Maintain masking to all but those are perform the actual procedure|3 Cohorts, each with active treatment and 1 with imitation procedure|t|t|t|t
33874616|NCT00445419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33874617|NCT04065555|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874618|NCT05214729|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33874619|NCT06444139|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874620|NCT03175666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874621|NCT02517164|||COHORT||PROSPECTIVE|||||||
33874622|NCT02656485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874623|NCT02011321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874624|NCT04778046|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33874625|NCT05284123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not know prior to their study participation that there are three different study conditions, and they will not find out which condition they were randomized to until the end of their study participation.|1/3 of the study participants (anticipated n=100) will be randomly assigned to the self-compassion intervention group, 1/3 of the participants (anticipated n=100) will be placed into the mental health literacy intervention group, and 1/3 of the study participants (anticipcated n=100) will be placed into the control group.|t|f|f|f
33874626|NCT03472157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874627|NCT00138788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874628|NCT04585464|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34068189|NCT01754766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068190|NCT05682274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34068191|NCT06041282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068192|NCT02734225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068193|NCT02137226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874629|NCT01042860|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34194710|NCT05867329|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be randomized to stage 1 and then be evaluated day 3. If patients are non-responders (defined by protocol) re-randomization for the second stage will take place. Patients that are responders at day 3 will continue with stage 1 treatment. Response to the second-stage of treatment will be calculated 72 hours after initiation of second-stage treatment and on every day up to day 10. If a patient meets any of the second-stage treatment failure criteria (per protocol) on day 6 through day 10, the patient will be considered to have failed second-stage therapy and will be referred for colectomy. If a patient does not meet criteria for second-stage treatment failure or criteria for safe discharge (see the protocol) the patient will be permitted to continue second-stage treatment for a maximum of 7 days (day 10 of intervention). Physicians care for patients enrolled in our study will be interviewed to evaluate acceptability and feasibility.||||
33874630|NCT00584155|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33874631|NCT03646851|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33874632|NCT01950871|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874633|NCT06346678|||COHORT||CROSS_SECTIONAL|||||||
34194711|NCT03035487|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33874634|NCT03101228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the intervention, masking of the participants is not possible. Analyzing of the obtained data will be masked.|A parallel-group randomised controlled trial|f|f|f|t
33874635|NCT00150254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874636|NCT06388655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33874637|NCT05627063|NA|SEQUENTIAL||TREATMENT||NONE||||||
33874638|NCT00956670|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874639|NCT04155749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874640|NCT04891315|||COHORT||PROSPECTIVE|||||||
33874641|NCT03958162|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33874642|NCT00714220|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874643|NCT01320670|||COHORT||PROSPECTIVE|||||||
33874644|NCT03917173|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase III randomized, multicenter study with two different arm:~* experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin~* comparator: standard surgery"||||
34068194|NCT02439788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068195|NCT03887156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194712|NCT00621062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194713|NCT05506241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194714|NCT03238170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194715|NCT03774056|NA|SEQUENTIAL||TREATMENT||NONE||||||
34194716|NCT03068091|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will undergo CT and pulmonary function testing.||||
34194717|NCT00756535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34194718|NCT05546580|NA|SINGLE_GROUP||TREATMENT||NONE||Escalation/extension open label study||||
34194719|NCT06292611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34194720|NCT05706051|NA|SINGLE_GROUP||OTHER||NONE|Ech individual is its proper control|Prospective study, with analysis of posturography parameters variation before and after hearing aid fitting in age-related hearing loss affected population aged 55 to 80 years old.||||
34194721|NCT04402255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874645|NCT05785663|||COHORT||PROSPECTIVE|||||||
33874646|NCT06423573|||COHORT||PROSPECTIVE|||||||
33874647|NCT00732511|RANDOMIZED|PARALLEL||||NONE||||||
33874648|NCT04096274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Clinicians and caregivers of youth were naïve to condition; however, masking of clinic leaders was not possible due to the nature of the LOCI strategy (which entails leadership training and consultation).||t|t|f|f
33874649|NCT00457015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874650|NCT01553981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194722|NCT05901753|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|"Randomization will be done by computer generated numbers and concealed by serially numbered, opaque and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside.~This study will be performed by 2 investigators; the first one (implementing doctor) who will insert supra glottic airway device based on patients' weight as per the manufacturers' size recommendations and according to a computer-generated sequence of random numbers and sealed envelope. The second anesthetists (planning doctor) will be blinded to the technique performed, and will monitor the patients intra and postoperatively."||t|t|t|t
34194723|NCT02416622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194724|NCT02814903|||COHORT||PROSPECTIVE|||||||
34194725|NCT02678559|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34194726|NCT02706990|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34194727|NCT02686723|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34194728|NCT02177799|||||PROSPECTIVE|||||||
34194729|NCT01328405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34194730|NCT01430169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874651|NCT01220453|||||PROSPECTIVE|||||||
34194731|NCT06272903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34194732|NCT02568891|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194733|NCT03941704|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Crossover: 1. Pulse-based diet; 2. Regular diet|f|f|t|t
34194734|NCT05504239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194735|NCT04862221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194736|NCT04408560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34194737|NCT02889029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874652|NCT05303545|||COHORT||CROSS_SECTIONAL|||||||
33874653|NCT03991130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194738|NCT05744245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194739|NCT00450125|||CASE_ONLY||PROSPECTIVE|||||||
34194740|NCT02296372|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194741|NCT02290743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194742|NCT05364359|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34194743|NCT04566887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194744|NCT00529607|||COHORT||PROSPECTIVE|||||||
34194745|NCT03222882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194746|NCT00005642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194747|NCT06247189|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34194748|NCT03347292|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34194749|NCT01604356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194750|NCT01809639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194751|NCT05061056|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34194752|NCT06233929|||COHORT||PROSPECTIVE|||||||
34194753|NCT04599530|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A within Subject Design||||
34194754|NCT02340871|||||PROSPECTIVE|||||||
34194755|NCT03896256|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
34194756|NCT05829785|||COHORT||PROSPECTIVE|||||||
34194757|NCT02936661|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194758|NCT04865367|||COHORT||PROSPECTIVE|||||||
34194759|NCT05606029|||CASE_ONLY||RETROSPECTIVE|||||||
34194760|NCT05884164|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34194761|NCT02205840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194762|NCT01711502|||COHORT||RETROSPECTIVE|||||||
34194763|NCT06157788|||CASE_CONTROL||PROSPECTIVE|||||||
34194764|NCT01702636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194765|NCT03464292|||CASE_CONTROL||PROSPECTIVE|||||||
34194766|NCT04520529|NA|SINGLE_GROUP||OTHER||NONE||||||
34194767|NCT02776618|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34194768|NCT00605007|||||RETROSPECTIVE|||||||
33874654|NCT00678873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874655|NCT05917574|||OTHER||OTHER|||||||
33874656|NCT02125227|RANDOMIZED|CROSSOVER||||NONE||||||
33874657|NCT03099187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874658|NCT01468584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967667|NCT03757585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967668|NCT01188954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34194769|NCT01142804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34194770|NCT05289518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967669|NCT00778271|RANDOMIZED|CROSSOVER||||NONE||||||
33967670|NCT01557270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33967671|NCT04447833|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, dose escalating safety study of the advanced therapy investigational medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced severe acute respiratory distress syndrome (ARDS).||||
33967672|NCT02525029|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34194771|NCT01149668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194772|NCT02356367|||COHORT||PROSPECTIVE|||||||
34194773|NCT02984930|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34194774|NCT01601600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194775|NCT02005952|||COHORT||PROSPECTIVE|||||||
34194776|NCT02147119|||COHORT||PROSPECTIVE|||||||
34194777|NCT05498415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be randomly assigned to group A (control) or group B (treatment) but will not be told which group they are receiving.||t|f|f|f
33967673|NCT04808245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194778|NCT03393247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194779|NCT02543749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194780|NCT01170533|RANDOMIZED|CROSSOVER||||NONE||||||
34194781|NCT02150538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194782|NCT03011944|||CASE_CONTROL||PROSPECTIVE|||||||
34194783|NCT02156271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194784|NCT04650451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194785|NCT01978938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Except for the responsible study site pharmacist or designee and separate unblinded clinical research associates to monitor drug supply and adherence to study drug blinding and randomization procedures, all study staff and participants were blinded to treatment assignment.||t|f|t|t
33967674|NCT05683314|||COHORT||PROSPECTIVE|||||||
34194786|NCT02052713|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34194787|NCT01600625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194788|NCT00120757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34194789|NCT01093703|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34194790|NCT00536445|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34194791|NCT03661567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194792|NCT05412446|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Diagnostic Test: ADAPT6-SPECT Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes||||
34194793|NCT04591678|||COHORT||PROSPECTIVE|||||||
34194794|NCT06386016|||COHORT||PROSPECTIVE|||||||
34194795|NCT03522623|||COHORT||CROSS_SECTIONAL|||||||
34194796|NCT01049009|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34194797|NCT03481179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194798|NCT02748382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194799|NCT05468047|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is an observational study following clinicians enrolled in a psychedelic-assisted therapy training program. It will investigate changes in measures of therapeutic efficacy and competency following those who choose to undergo a personal ketamine-assisted therapy experience and those who do not.||||
34194800|NCT03084380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194801|NCT01542164|||OTHER||CROSS_SECTIONAL|||||||
34194802|NCT05011201|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants will take part in the same interventional model. Participants will undergo several gait retraining bouts using two variants of the DJVF system. The order of bouts during the gait retraining will be block randomized.||||
34194803|NCT00137878|RANDOMIZED|||TREATMENT||||||||
33756189|NCT05443165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be divided into groups according to the randomization list created to assign each patient to a group. Two independent researchers will conduct the assignment of participants to the intervention and control groups and the evaluation of outcome measurement data. Researchers will not be blinded as they make the interventions. However, participants will be blinded because they do not know the study's hypotheses and which group they are in.|"NHL patients meeting the sampling criteria will be assigned to the intervention and control groups by block randomization (1:1). NHL patients in the intervention group will be introduced to the decision support system regarding symptom self-management in face-to-face interviews. The decision support system will be asked to use it for three months on the 3rd, 7th, and 10th days of the 3rd, 4th and 5th chemotherapy cycles. A short SMS message will be sent to the patients on the 3rd, 7th, and 10th days of the 3rd, 4th and 5th chemotherapy courses. Participants will be able to contact researchers via the 24/7 contact button or by phone.~In the control group, SMS will be sent to the control group on the 3rd, 7th, and 10th days after each chemotherapy to remind them about the frequency and severity of symptoms during the three-month follow-up. The Lymphoma Patient Guide link on the Turkish Society of Hematology page for the symptom management system will be sent to the patients via SMS."|t|f|f|f
33756190|NCT02306759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756191|NCT01843192|||COHORT||PROSPECTIVE|||||||
33756192|NCT01271348|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33756193|NCT01865786|||COHORT||RETROSPECTIVE|||||||
33967675|NCT00381056|RANDOMIZED|PARALLEL||ECT||NONE||||||
33967676|NCT00003533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967677|NCT03723590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967678|NCT00677924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967679|NCT01659632|||CASE_ONLY||RETROSPECTIVE|||||||
33967680|NCT05207319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34194804|NCT04659811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194805|NCT05424640|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34194806|NCT02322853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194807|NCT05863000|||CASE_ONLY||CROSS_SECTIONAL|||||||
34194808|NCT02756806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194809|NCT00846183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194810|NCT00263445|||CASE_ONLY||RETROSPECTIVE|||||||
34194811|NCT02867644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34194812|NCT01112449|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34194813|NCT01802164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194814|NCT03964428|||COHORT||CROSS_SECTIONAL|||||||
34194815|NCT03876392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967681|NCT02557594|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194816|NCT00374829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194817|NCT01124864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194818|NCT02720354|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194819|NCT04352972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the nature of the intervention, it is not feasible to blind participants or the treating physiotherapists. To reduce bias, the outcome assessor will be blinded to treatment allocation. Participants will also be instructed not to reveal details about their group assignment to the outcome assessor.||f|f|f|t
34194820|NCT06019442|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The on-site researcher responsible for recruitment will not be blind to treatment assignment; the participating women self-completing baseline assessment, intervention, immediate post-intervention and 4-week follow-up assessments will be blinded to treatment assignment. The researcher who oversees follow-up assessment data collection will be blinded to treatment assignment.|"Randomised controlled trial (2 arms) + pilot of modified active arm~The pilot group does not form part of the planned randomised controlled trial or power and sample size calculation, but is included based on findings from the previous phase of this research (e.g. women not having time to complete the intervention onsite). Therefore n\~20 women who cannot participate on the day of breast screening will be offered to participate in the modified active arm offsite."|t|f|f|t
34194821|NCT01632267|||COHORT||RETROSPECTIVE|||||||
34194822|NCT00183417|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194823|NCT02998957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194824|NCT04347668|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial, VR will be compared to usual care for residents with moderate to severe dementia.||||
34194825|NCT01057641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194826|NCT02200198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34194827|NCT01337037|||CASE_CONTROL||PROSPECTIVE|||||||
34194828|NCT00777153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194829|NCT05316935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194830|NCT03817086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194831|NCT05420909|||COHORT||RETROSPECTIVE|||||||
34194832|NCT03449524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||CXA-10|t|t|t|t
34194833|NCT01569217|||COHORT||PROSPECTIVE|||||||
34194834|NCT02473146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194835|NCT05213819|NA|SEQUENTIAL||TREATMENT||NONE||||||
34194836|NCT04516785|||COHORT||PROSPECTIVE|||||||
34194837|NCT04377113|||COHORT||PROSPECTIVE|||||||
34194838|NCT00665808|||||PROSPECTIVE|||||||
34194839|NCT02604979|||OTHER||PROSPECTIVE|||||||
34194840|NCT03085914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194841|NCT03725228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33756194|NCT01665664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756195|NCT04072094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756196|NCT00654901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764843|NCT05461105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068196|NCT01578499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194842|NCT06275542|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Upon arrival in the recovery room, all subjects were fitted with SpO2, EKG, NIBP monitors, and the TOF monitoring device. TOF values were measured by a second researcher who was unaware of the type of intervention.|"The study was conducted through a randomized clinical trial with blinding of observers. Two parallel groups were selected to compare the incidence of paralysis in the recovery room. The research samples were collected using non-probability sampling method through consecutive enrollment over a specific period. This study consisted of 3 comparisons distinguished based on the type of volatile anesthetic gas maintenance and neuromuscular blockade agent, namely:~* Comparison 1: The volatile anesthetic gas used was sevoflurane and the muscular blockade agent used was rocuronium.~* Comparison 2: The volatile anesthetic gas used was isoflurane and the muscular blockade agent used was rocuronium.~* Comparison 3: The volatile anesthetic gas used was sevoflurane and the muscular blockade agent used was atracurium."|t|f|f|t
34068197|NCT01627795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068198|NCT02614508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068199|NCT02301845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068200|NCT00348465|||COHORT||PROSPECTIVE|||||||
34068201|NCT03140865|||COHORT||PROSPECTIVE|||||||
34068202|NCT02411344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068203|NCT01399281|||COHORT||PROSPECTIVE|||||||
34194843|NCT01361204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34194844|NCT04090372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194845|NCT06335745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068204|NCT05431114|||CASE_CONTROL||PROSPECTIVE|||||||
34194846|NCT03053206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194847|NCT04475042|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34194848|NCT01081418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194849|NCT03255083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194850|NCT04797624|||OTHER||RETROSPECTIVE|||||||
34194851|NCT01131819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194852|NCT03471624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194853|NCT02664623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34194854|NCT03855670|||COHORT||PROSPECTIVE|||||||
34194855|NCT05111418|||COHORT||PROSPECTIVE|||||||
34194856|NCT00366067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34194857|NCT05942781|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34194858|NCT00003472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874659|NCT04536688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohorts will be enrolled and treated sequentially. Dosing decisions will be made based on prior cohort's safety and biomarker data. Six to 9 subjects will be enrolled in each cohort based on the magnitude and/or variability of the increase in PC1 and PC2 or to allow for replacement of subjects that do not complete the study. The highest dose (1 mg/kg) will be administered in cohort 1. If the Sponsor determines that the increase in PC1 and PC2 from baseline for cohort 1 is inadequate, the study may be stopped for futility. If the Sponsor determines that the increase from baseline for cohort 1 is adequate, then 0.3 mg/kg will be administered in cohort 2. Based on the increase of PC1 and PC2 from baseline in cohort 2, Sponsor may determine a higher dose needs to be evaluated, then 0.5 mg/kg will be administered in cohort 3. If the Sponsor determines that lower dose needs to be evaluated, then 0.1 mg/kg will be administered in cohort 3.||||
33874660|NCT02385630|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874661|NCT00655031|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874662|NCT03080246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33874663|NCT00827021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874664|NCT02757560|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33874665|NCT02601339|||COHORT||PROSPECTIVE|||||||
33874666|NCT00670319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068205|NCT05041777|||COHORT||PROSPECTIVE|||||||
34068206|NCT02336009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068207|NCT05692804|||COHORT||PROSPECTIVE|||||||
34068208|NCT00162097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068209|NCT02708030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068210|NCT04726774|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34068211|NCT06613308|||COHORT||PROSPECTIVE|||||||
34068212|NCT00413933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068213|NCT04854941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068214|NCT06344689|||CASE_ONLY||RETROSPECTIVE|||||||
34068215|NCT00263471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34194859|NCT02886403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34194860|NCT05002244|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194861|NCT04628455|NA|SINGLE_GROUP||TREATMENT||NONE||Both SGDs were used to invert the hernia sac by gradual sustained alternating traction on the round ligament. Each SGD hands to the other one till complete inversion occurs, this is known by the hernial sac hanging from internal ring without retracting-back inside the inguinal canal. . SGD-C passed inside the loop of MPS and re-catches the hernial sac, which is then twisted around its neck several times. MPS is closed tightly at the proper neck and coagulation diathermy current is applied.Detached sac was then pushed antigradely out through the umbilical port.||||
33764844|NCT06365021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068216|NCT05977556|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34068217|NCT00849290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068218|NCT05591534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068219|NCT03592849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068220|NCT00423358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068221|NCT02169297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34068222|NCT01474161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068223|NCT00149032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068224|NCT00621998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068225|NCT04137341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34068226|NCT02088398|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34068227|NCT03323970|||OTHER||CROSS_SECTIONAL|||||||
34068228|NCT04077710|||COHORT||PROSPECTIVE|||||||
33756197|NCT04238026|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two randomized groups, one receiving traditional radial access and the other receiven distal radial access||||
33756198|NCT03177668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756199|NCT00324584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33756200|NCT04575168|||COHORT||CROSS_SECTIONAL|||||||
33756201|NCT05521854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756202|NCT06156423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756203|NCT05933759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33874667|NCT00371865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874668|NCT03553342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068229|NCT00151164|NON_RANDOMIZED|PARALLEL||||DOUBLE||||||
34194862|NCT05732519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34194863|NCT00580775|||COHORT||PROSPECTIVE|||||||
34194864|NCT05825157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients will be blinded and be randomized via a blocked randomization design. Approximately 60 patients will be randomized in a 4:1 ratio to the intervention arm (VLNT + BioBridge): control arm (VLNT alone). Randomization will be done within blocks (of size 5) so that the balance between treatments is preserved throughout the trial.|VLNT or VLNT with BioBridge placement|t|f|f|f
34194865|NCT01368640|||CASE_ONLY||CROSS_SECTIONAL|||||||
34194866|NCT05250544|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34194867|NCT03213171|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||Stepped-wedge cluster randomized trial|t|f|f|t
34194868|NCT04150367|||OTHER||PROSPECTIVE|||||||
34194869|NCT01457352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194870|NCT00386542|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194871|NCT03512457|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|study arm not disclosed||f|f|t|f
34194872|NCT03977311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756204|NCT05902962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756205|NCT03462732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||assignment|t|t|t|t
33874669|NCT02466152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874670|NCT03043248|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34068230|NCT01500655|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34068231|NCT06356324|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants assigned to one of three groups: music listening, tv viewing, or control (waiting with ambient noise)|t|t|t|f
34068232|NCT01439490|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34068233|NCT05373563|||CASE_ONLY||CROSS_SECTIONAL|||||||
34068234|NCT01990768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194873|NCT02782858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194874|NCT06351384|||COHORT||PROSPECTIVE|||||||
34194875|NCT03361683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194876|NCT02215018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34194877|NCT04772833|||COHORT||PROSPECTIVE|||||||
34194878|NCT04279899|||CASE_ONLY||PROSPECTIVE|||||||
34194879|NCT00640692|||CASE_CONTROL||PROSPECTIVE|||||||
34194880|NCT00124046|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33874671|NCT02611856|||COHORT||RETROSPECTIVE|||||||
33874672|NCT04452981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874673|NCT04914208|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33874674|NCT04952298|||COHORT||RETROSPECTIVE|||||||
33874675|NCT03853785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874676|NCT02757183|||CASE_ONLY||PROSPECTIVE|||||||
33874677|NCT01006265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874678|NCT00004887|RANDOMIZED|||TREATMENT||||||||
33874679|NCT03410173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967682|NCT00772252|||COHORT||PROSPECTIVE|||||||
33967683|NCT05681377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34194881|NCT03079713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34194882|NCT04430595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194883|NCT00485797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194884|NCT04989153|||COHORT||PROSPECTIVE|||||||
34194885|NCT03278067|||OTHER||PROSPECTIVE|||||||
34194886|NCT01755026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34194887|NCT02323607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194888|NCT03789279|||COHORT||PROSPECTIVE|||||||
33756206|NCT04272580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756207|NCT06525948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756208|NCT03695302|||OTHER||CROSS_SECTIONAL|||||||
33756209|NCT02428465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33756210|NCT03802864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study model is a randomized double blind control trial.|t|t|f|t
33756211|NCT00156793|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756212|NCT03610425|||COHORT||CROSS_SECTIONAL|||||||
33756213|NCT00811382|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking.|||||
33756214|NCT03634124|NA|SINGLE_GROUP||OTHER||NONE||||||
33967684|NCT06528223|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The study divides enrolled patients into three groups based on PANDA's output results: nonPDAC, PDAC, and normal.|t|f|f|f
33967685|NCT03994588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded to the study group allocation.||t|f|f|f
33967686|NCT03845478|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33967687|NCT04376489|RANDOMIZED|FACTORIAL||OTHER||NONE||Micro-Randomized Trial (MRT) in the development of data-driven behavioral interventions.||||
33967688|NCT01280864|||CASE_CONTROL||PROSPECTIVE|||||||
33967689|NCT04339491|||COHORT||PROSPECTIVE|||||||
33967690|NCT01122472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967691|NCT02057510|||COHORT||PROSPECTIVE|||||||
33967692|NCT03503656|||CASE_ONLY||RETROSPECTIVE|||||||
34194889|NCT05330104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34194890|NCT03137264|||COHORT||PROSPECTIVE|||||||
33967693|NCT01127191|||COHORT||PROSPECTIVE|||||||
33967694|NCT03071133|||COHORT||PROSPECTIVE|||||||
34068235|NCT01893268|||COHORT||PROSPECTIVE|||||||
34194891|NCT06193122|||CASE_ONLY||PROSPECTIVE|||||||
34194892|NCT00835029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194893|NCT05315895|||COHORT||PROSPECTIVE|||||||
34194894|NCT00680394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34194895|NCT03730792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34194896|NCT04221776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874680|NCT03489382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All data linkage and analyses will be conducted by statisticians who are blind to the study site allocations.|Multi-Centre Cluster Randomized Controlled Trial|f|f|f|t
34194897|NCT03373903|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34194898|NCT05514808|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194899|NCT00601042|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194900|NCT05354440|||OTHER||PROSPECTIVE|||||||
34194901|NCT00605956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33874681|NCT03203239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single group study in which the subject undergoes a single exposure to red light.||||
33874682|NCT04288154|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34194902|NCT02941172|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34194903|NCT02671513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194904|NCT00906737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194905|NCT02943304|||COHORT||PROSPECTIVE|||||||
34194906|NCT05414357|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34194907|NCT02834754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34194908|NCT01256294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34194909|NCT06478381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194910|NCT05605938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind placebo-controlled randomized|t|t|t|t
34194911|NCT02105051|||COHORT||PROSPECTIVE|||||||
33874683|NCT03147937|||COHORT||PROSPECTIVE|||||||
34194912|NCT03180619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194913|NCT05380479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194914|NCT05090319|||COHORT||RETROSPECTIVE|||||||
34194915|NCT01111396|||CASE_ONLY||PROSPECTIVE|||||||
34194916|NCT02856152|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34194917|NCT05781880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes indexes will be assessed by trained neurologists or neuroradiologists who are blinded to the research content or patient grouping.||f|f|f|t
34194918|NCT01143701|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34194919|NCT04608539|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is primarily open label. It includes, however, a short period (from the 1. to the 4. postoperative day) of participant, care provider and investigator masking. The aim is to reduce differences in transfusion practices.|||||
33874684|NCT01277549|||CASE_ONLY||PROSPECTIVE|||||||
33874685|NCT02279459|||COHORT||PROSPECTIVE|||||||
33874686|NCT00711984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874687|NCT01627899|NA|SINGLE_GROUP||OTHER||NONE||||||
33874688|NCT05386355|RANDOMIZED|PARALLEL||OTHER||NONE||The study will use a 1:1 parallel design at the caregiver level to assign caregivers to the intervention (Vaccine Uptake app) or the control (General Health app) arm. The study team will stratify randomization by participating clinic and in varying block of participants using a permuted design. Randomization will occur after enrollment and before the baseline assessment.||||
33874689|NCT00315744|RANDOMIZED|PARALLEL||TREATMENT||||||||
33874690|NCT05639127|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single group||||
33874691|NCT01211600|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33874692|NCT02989064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874693|NCT04342221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874694|NCT02194127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874695|NCT00535561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33874696|NCT01262690|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33874697|NCT00841594|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874698|NCT05778500|||OTHER||CROSS_SECTIONAL|||||||
33874699|NCT06169475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants who under deep sedation are blinded to the grouping.||t|f|f|f
33874700|NCT00283075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874701|NCT04186741|||COHORT||PROSPECTIVE|||||||
33874702|NCT01448460|||COHORT||PROSPECTIVE|||||||
33874703|NCT00677274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874704|NCT02326454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874705|NCT04923659|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Healthy Controls 18-80 years|||||
33874706|NCT02874807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874707|NCT03116698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967695|NCT04104711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||During the first home visit, the participants in the intervention group were applied the data collection tools, and then nursing interventions in accordance with the subscales of the Health Belief Model by taking into account the individual differences of the participants. The nursing interventions were performed within the scope of the basic dimensions of diabetes management such as nutrition, exercise, medication management, etc. was also explained. Home visits were paid 3 times at 3-month intervals. After the home visits started, reminder messages supporting the home visit process were sent at two-week intervals. The participants in the control group were contacted 3 times at 3-month intervals through telephone calls, and were applied the data collection tools. At the end of the study, the participants in the control group were given health training and booklet was distributed to them.|t|f|f|f
33967696|NCT02958878|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33967697|NCT01565382|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33967698|NCT06267547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874708|NCT03740971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967699|NCT05456828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967700|NCT00879554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967701|NCT02749682|||CASE_CONTROL||PROSPECTIVE|||||||
33967702|NCT01714505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967703|NCT03877874|||COHORT||CROSS_SECTIONAL|||||||
33967704|NCT02262949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967705|NCT01710306|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34194920|NCT06173700|NA|SINGLE_GROUP||OTHER||NONE||||||
34194921|NCT02037555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874709|NCT03801850|NA|SINGLE_GROUP||OTHER||NONE||||||
33874710|NCT02448030|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34068236|NCT03038776|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068237|NCT05203679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068238|NCT05152199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068239|NCT04187716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068240|NCT00963846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068241|NCT06323213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068242|NCT00631163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068243|NCT03006263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068244|NCT06150729|||COHORT||PROSPECTIVE|||||||
34068245|NCT03633916|RANDOMIZED|CROSSOVER||OTHER||NONE||Stepped-wedge cluster randomized controlled trial||||
34068246|NCT06002256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068247|NCT01392456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068248|NCT01543737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068249|NCT01065298|||CASE_CONTROL||PROSPECTIVE|||||||
34068250|NCT02951793|||COHORT||PROSPECTIVE|||||||
34068251|NCT05401487|||COHORT||PROSPECTIVE|||||||
34068252|NCT05309330|||COHORT||PROSPECTIVE|||||||
34068253|NCT05034835|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This research is part of a Research Involving the Human Person of the interventional type (RIPH1) and relates to a class I medical device (MD).~This is a single-center, controlled, randomized, open-label, superiority study."||||
34068254|NCT06371937|||OTHER||PROSPECTIVE|||||||
34068255|NCT05624216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068256|NCT02495818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068257|NCT00988819|||CASE_CONTROL||PROSPECTIVE|||||||
34068258|NCT01033708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194922|NCT02082938|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34194923|NCT05711758|||COHORT||PROSPECTIVE|||||||
34194924|NCT02781389|||CASE_CONTROL||PROSPECTIVE|||||||
34194925|NCT02076425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194926|NCT00202475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194927|NCT00266058|RANDOMIZED|PARALLEL||||NONE||||||
34194928|NCT02117557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194929|NCT01923779|||COHORT||PROSPECTIVE|||||||
34194930|NCT02922699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194931|NCT00783198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194932|NCT02495038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068259|NCT00978341|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34068260|NCT02540122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068261|NCT05262855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068262|NCT06274502|||COHORT||RETROSPECTIVE|||||||
34068263|NCT01146015|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34068264|NCT02801981|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34194933|NCT06533761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194934|NCT00107484|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34194935|NCT03843671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both groups compressed in a hyperbaric chamber. Patients will be unaware of the compression gas or degree of pressurization as references to each are obscured|Randomized sham-controlled, with allocation concealment and blinded patients and assessors|t|f|f|t
34194936|NCT06269939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194937|NCT06120270|||COHORT||PROSPECTIVE|||||||
34194938|NCT03635450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The first cohort of three patients will receive a single dose in the first 48 postnatal hours. If there are no safety concerns, the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.||||
34194939|NCT02882750|||COHORT||PROSPECTIVE|||||||
34194940|NCT03159962|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective 3-arm parallel group randomized clinical trial with a 1:1:1 allocation ratio||||
34194941|NCT02184572|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194942|NCT05065723|||COHORT||PROSPECTIVE|||||||
34194943|NCT03574181|||OTHER||PROSPECTIVE|||||||
34194944|NCT06247956|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34194945|NCT02499445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34194946|NCT03717870|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34194947|NCT00905645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194948|NCT02600819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194949|NCT05973721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194950|NCT02857348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194951|NCT05520892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068265|NCT00652808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068266|NCT04351477|RANDOMIZED|CROSSOVER||OTHER||NONE|"1. Randomization by allocation concealment~2. Open label, cross-over design"|Randomized, open-label, cross-over study||||
34068267|NCT02427243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068268|NCT03947593|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34068269|NCT05624736|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34068270|NCT05274087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34068271|NCT03285165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|this study will be accomplished to investigate the effect of dexmedetomidine sedation on the cerebral blood flow in intubated mechanically ventilated trauma patients with and without traumatic brain injury, in comparison with propofol.|t|f|f|t
34068272|NCT03949738|||CASE_ONLY||PROSPECTIVE|||||||
34068273|NCT04668872|||COHORT||PROSPECTIVE|||||||
34068274|NCT03556397|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No roles in the study will be marked.|The patients will be divided into four groups, according to the stage of the disease prior to neoadjuvant therapy.||||
34068275|NCT04309487|||COHORT||CROSS_SECTIONAL|||||||
34068276|NCT03301935|||COHORT||PROSPECTIVE|||||||
34068277|NCT04037293|||COHORT||PROSPECTIVE|||||||
34068278|NCT01343784|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34068279|NCT02940015|||OTHER||PROSPECTIVE|||||||
34194952|NCT03234283|NA|SINGLE_GROUP||OTHER||NONE||A prospective, open label, non-randomized, safety and feasibility study.||||
34194953|NCT04958460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194954|NCT00427115|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34194955|NCT04270279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194956|NCT02366091|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|t|f
34194957|NCT01689194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874711|NCT01997411|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|IM and NG arms are open labeled. NG cohorts, 2mg and 3mg, are quadruple blinded.||t|t|t|t
34194958|NCT03712371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194959|NCT02280798|||||PROSPECTIVE|||||||
34194960|NCT00630383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194961|NCT01782391|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34194962|NCT02470988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194963|NCT03911687|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34194964|NCT02717832|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34194965|NCT01209182|NA|SINGLE_GROUP||TREATMENT||NONE||2 phase study: Phase 1 - Validation of safety and accuracy when used ex-vivo to image excised breast surgery specimens Phase 2 - To guide surgeon's decision to re-excise additional margins during primary operation||||
33874712|NCT04182373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874713|NCT04697680|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33874714|NCT03169985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The obtained intravascular ultrasound(IVUS) data will be stored through the storage device in the core lab of Heart Center of Heart Vascular Stroke Institute in Samsung Medical Center, and the treatment group to which the patient belongs would not be known. Subsequent baseline and follow-up IVUS data will be analyzed together by independent experts without knowledge of the patient's treatment group.|Prospective, open label, two-arm, randomized controlled trial|f|f|f|t
33874715|NCT00794677|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33874716|NCT00664833|RANDOMIZED|FACTORIAL||||NONE||||||
33874717|NCT04414800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874718|NCT01834092|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874719|NCT02210065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874720|NCT04077996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcomes assessor will mask to do statistical analisis|Patients will be randomly through table of random numbers, and divided to form two treatment groups with 51 patients per group. One of which will be a APD and the other a CAPD. The initial antibiotic scheme will be applied to both groups continuously based on: ceftazidime (1500-2000mg/day) and vancomycin (20mg/kg every 3 days) according to current management guidelines;|f|f|f|t
33874721|NCT06091215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|PI will assess subject after a single treatment and decide if a second treatment is necessary.|Subjects will receive 1-2 combination treatments.||||
33894271|NCT04578210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Phase I/II escalating-dose clinical trial, randomized study to determine safety, tolerability, alloreactivity and efficacy of cell therapy with adoptive cell therapy of NK cells or memory T cells in patients affected by COVID-19 Donors will be patients recovered from COVID-19 Will be 2 arms~* A: allogeneic T memory cells~* B: allogeneic NK cells~Two consecutive phases:~* The first dose escalation focuses on determining safety and the recommended dose for the phase II Phase I: Patients with SARS-CoV-2+ pneumonia and/or lymphopenia and O2Sat ≤ 94% on room air at screening, with no oxygen required or with an oxygen need of ≤ 2.5 lpm in nasal cannula, will be selected This phase has a single ascending dose design with up to 3 planned dose levels for each arm.~* The second phase extends the safety study Phase II: Patients with SARS-CoV-2+ pneumonia and/or lymphopenia and O2Sat ≤ 94% on room air at screening, requiring or not oxygen supplementation"|t|t|t|f
33894272|NCT01956981|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894273|NCT01748383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894274|NCT01997073|||COHORT||PROSPECTIVE|||||||
33894275|NCT01217606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894276|NCT06497738|||COHORT||PROSPECTIVE|||||||
33967706|NCT01387971|||CASE_ONLY||PROSPECTIVE|||||||
33967707|NCT01984281|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33967708|NCT01181661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33967709|NCT00459082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33967710|NCT03559764||SEQUENTIAL||TREATMENT||NONE||||||
33967711|NCT05745064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Sponsor, Investigators and study staff will be masked during the randomization process and throughout the study. The study site will have the capacity to unmask participants in an emergency.~Following completion of the study, the randomization code will be unmasked once all data has been entered into the Study database for every subject and the database has been locked."|"In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID.~The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment."|t|t|t|t
33967712|NCT04929197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967713|NCT05380830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly distributed into 3 groups: Control (Gcon), Hypoxia (GHyp) and Normoxia (GNor). Those in Ghyp and GNor won't be able to know which group they are.|Randomized clinical trial.|t|f|f|f
33967714|NCT05206136|||OTHER||PROSPECTIVE|||||||
33967715|NCT05687656|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible subjects will be treated with a weekly application for 12 weeks of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading||||
33967716|NCT00636428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33967717|NCT00644371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967718|NCT05824299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34194966|NCT03663400|||COHORT||PROSPECTIVE|||||||
34194967|NCT02194374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194968|NCT01250496|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194969|NCT00241462|||CASE_ONLY||PROSPECTIVE|||||||
34194970|NCT01612923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194971|NCT04178278|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34194972|NCT01395290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34194973|NCT04704947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194974|NCT02663791|||COHORT||PROSPECTIVE|||||||
33756215|NCT04367857|||COHORT||PROSPECTIVE|||||||
33756216|NCT03758963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In this study, double-blinding will be applied for subjects and independent efficacy evaluators. It is difficult to apply blinding to the practitioner who handles the products used for therapy because of difference in the procedure of the treatment and sham, but the information related to the medical device shall not be released to subjects and independent efficacy evaluators. For blinding of independent efficacy evaluators, an independent evaluator shall conduct efficacy evaluation tests (OCT, BCVA test, contrast sensitivity test, FA).~Subjects and independent efficacy evaluators will not know which group the subjects are assigned to and whether SRT or sham procedure is used. The blinding on the test device will be maintained until the data for statistical analysis are opened."||t|f|f|t
33756217|NCT06243705|RANDOMIZED|PARALLEL||OTHER||NONE||The study will be used a parallel-group randomized controlled trial design. Children fulfilling the inclusion criteria will be randomized to three group. Fissure sealants will be applied to the children using the distraction technique determined by randomisation.||||
33756218|NCT04557930|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|A hospital's treatment assignment was masked during analysis.|A stepped wedge crossover trial randomizing physician participants at the group level (i.e., hospital). Each hospital group 'crossed over' from control to intervention at a randomized time point.|f|f|f|t
33756219|NCT02006082|||COHORT||RETROSPECTIVE|||||||
33756220|NCT06545981|||CASE_CONTROL||PROSPECTIVE|||||||
34194975|NCT03476005|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Incidence of wrong blood in tube in interns provided with proficiency based progression training supported by technology enhanced learning in 2017 will be compared with historical controls from the same period in 2016||||
34194976|NCT00926029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194977|NCT04334577|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34194978|NCT04950296|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomized, double-blind, placebo-controlled, parallel group|t|t|t|t
33756221|NCT03210155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blocked randomization method will be used to assign participants to active and sham groups. Participants will be assigned to CES treatment or sham CES using a 1:1 ratio. Electromedical Products International, Inc. (EPI) will randomize the assignment of appropriate devices to active or sham groups by using a random list of computer generated numbers (1 for active and 2 for sham) in randomly selected block sizes. The PI and participants are blinded to which participants have Alpha-Stim® CES active or sham devices until data analysis is complete. After the completion of data analysis, blinding will be broken.|The design for the proposed study is a matched-pair, quasi-experimental, 1:1 randomized, double-blind, sham-controlled clinical trial with a longitudinal component. The analytic technique employed to answer the research questions will be repeated measures analysis of covariance.|t|t|t|t
33874722|NCT03593252|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The patient's records will mention he/she is part of a study and will mention the study number, while the actual medications received (group allocation) will not be mentioned. The outcome detector, assessing the patient from day 1 in the hospital to the end of the study, will not have access to information on the study group allocation. The statistician analyzing the data will have a coded and de-identified version, and will be blinded to study groups to ensure unbiased analysis.~For the purpose of blinding the data analyst, data on bowel prep diary will be withheld until analysis for all other outcomes is done and finalized.~The principle investigators and the research coordinator will be involved in prescribing the prep regimen preoperatively and will not be blinded. The patient and family will be aware of the medications used and will not be blinded either. Also, the pharmacist will have access to the treatment allocation list, and cannot be blinded."|"Patients will be randomized to the following study arms:~1. Combination bowel prep: Mechanical preparation and oral non-absorbable antibiotics + standard care.~2. Oral antibiotics + standard care.~3. No preparation, with standard care. \*Standard care (all groups):~   * Nil per os (NPO) prior to general anesthesia~     * Solids until 8 hours prior to surgery, formula until 6 hours, breast milk until 4 hours, clear fluids until 2 hours~  * Prophylactic IV antibiotics~     * Cefazolin (30mg/kg) and metronidazole (15mg/kg) within 60 minutes of incision~    * Re-dosing if procedure exceeds 4 hours~    * In case of beta-lactam allergy allergy, clindamycin 5mg/kg and gentamicin 7mg/kg will be used."|f|f|f|t
33874723|NCT02073864|||COHORT||PROSPECTIVE|||||||
33874724|NCT05341960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967719|NCT00525031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967720|NCT00368329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194979|NCT03543072|||COHORT||PROSPECTIVE|||||||
34194980|NCT01798160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194981|NCT01212380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194982|NCT04267224|||CASE_ONLY||PROSPECTIVE|||||||
34194983|NCT06089785|||OTHER||CROSS_SECTIONAL|||||||
34194984|NCT03291093|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34194985|NCT02282293|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194986|NCT00611754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34194987|NCT04056377|||COHORT||PROSPECTIVE|||||||
33967721|NCT03157063|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33874725|NCT05558280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34194988|NCT06505772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Anesthesiologists, graduate students, anesthesiologists, patients and their families will not know if a child is taking the drug or not.~Also, the person who will conduct the survey will not know either, all will be hidden.~Depending on the volume in ml, to mask the medical team from the substance of the drug..."|Parallel Assignment|t|t|t|t
34194989|NCT06431867|||OTHER||PROSPECTIVE|||||||
33874726|NCT02474433|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34194990|NCT01515644|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34194991|NCT02212600|||COHORT||PROSPECTIVE|||||||
34194992|NCT01494493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34194993|NCT05860556|||OTHER||CROSS_SECTIONAL|||||||
33874727|NCT02732769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33874728|NCT01366547|RANDOMIZED|CROSSOVER||||NONE||||||
33874729|NCT04284202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874730|NCT00309231|||CASE_ONLY||PROSPECTIVE|||||||
33874731|NCT03699176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874732|NCT03992040|||COHORT||RETROSPECTIVE|||||||
33874733|NCT06464250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the study, participant blinding was performed by ensuring that the participants did not know which group they were in|In the study, there are two parallel groups as control and intervention groups.|t|f|f|f
33874734|NCT00822965|||CASE_ONLY||RETROSPECTIVE|||||||
33874735|NCT01230307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33874736|NCT05800548|||COHORT||CROSS_SECTIONAL|||||||
34194994|NCT03035474|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34194995|NCT00920803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34194996|NCT01717833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34194997|NCT06365762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34194998|NCT04466878|||COHORT||RETROSPECTIVE|||||||
34194999|NCT04143178|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Five days after the transplant, to the expressive writing group participants has been asked to write for 3 consecutive days, for 20 minutes a day, their deepest emotions, thoughts and concerns about the disease and the transplant. They wrote in a silent room that guaranteed their privacy. The instructions followed the standard task of Pennebaker, creator of the technique (1986), translated and adapted for the specific hospital situation already proposed in a study on urological patients by Solano et al, 2007.~Similarly, five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it."||||
34195000|NCT01051518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34195001|NCT02010151|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34195002|NCT00224185|||CASE_ONLY||PROSPECTIVE|||||||
34195003|NCT02746224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34195004|NCT04583722|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34195005|NCT05604378|||COHORT||RETROSPECTIVE|||||||
34195006|NCT05005039|||CASE_CONTROL||PROSPECTIVE|||||||
34195007|NCT04750616|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34195008|NCT03208582|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34195009|NCT05611918|||CASE_CONTROL||PROSPECTIVE|||||||
34195010|NCT04136782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34195011|NCT03618290|||COHORT||PROSPECTIVE|||||||
34195012|NCT01615276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34195013|NCT03348436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 100 patients with persistent，in whom successful RF ablation of slow pathway or accessory pathway was performed. Patients with atrial fibrillation, structural heart disease, ventricular arrhythmias, impaired left ventricular systolic function or on antiarrhythmics were excluded. All the patients had echocardiographic study before ablation 、1 day and 1 months after ablation.|t|f|f|t
34195014|NCT01569542|||CASE_CONTROL||PROSPECTIVE|||||||
34195015|NCT02779322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34195016|NCT03596749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34195017|NCT04153708|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either call or mail invitation||||
33874737|NCT04776382|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34195018|NCT01700309|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34195019|NCT02206789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34195020|NCT05086211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34195021|NCT02897297|||COHORT||CROSS_SECTIONAL|||||||
34195022|NCT04354506|||COHORT||PROSPECTIVE|||||||
34195023|NCT00927004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34195024|NCT06515795|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34195025|NCT02122913|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34195026|NCT05266729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874738|NCT01480336|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33874739|NCT04271436|NA|SINGLE_GROUP||OTHER||NONE||||||
33874740|NCT01152021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874741|NCT03688932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874742|NCT04013035|||COHORT||PROSPECTIVE|||||||
33874743|NCT04401176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967722|NCT03569163|||COHORT||RETROSPECTIVE|||||||
33967723|NCT05168059|||CASE_ONLY||RETROSPECTIVE|||||||
33967724|NCT00689403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967725|NCT04221581|||COHORT||PROSPECTIVE|||||||
33967726|NCT01975090|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33967727|NCT02700802|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33967728|NCT01508156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967729|NCT04199780|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33967730|NCT03520621|||OTHER||CROSS_SECTIONAL|||||||
33967731|NCT01004692|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33967732|NCT02101320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967733|NCT00436878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33967734|NCT01294878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967735|NCT00864487|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967736|NCT03659968|NA|SINGLE_GROUP||OTHER||NONE||||||
33967737|NCT03806322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33967738|NCT01503359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967739|NCT05700357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967740|NCT03826485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967741|NCT02429401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967742|NCT03469271|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33967743|NCT05744661|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE|This is a triple-blinded study. Participants will be unaware of the intervention they will recieve. All interventions will be performed by Single Care Provider (Clinician). Due to the nature of intervention, care provider cannot be masked. Data collector (Investigator) and Data Analyst(Outcome Assessor) both will be blinded.|This is a Parallel type, Non-random Consecutive Sampling Technique. Patients reporting to the Department of Operative Dentistry \& Endodontics, School of Dentistry with Necrotic teeth will be filtered. All participants who fulfil the Inclusion and Exclusion criteria will be enrolled in this study.|t|f|t|t
33967744|NCT01792284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967745|NCT03119064|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33967746|NCT03269175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967747|NCT05961254|||CASE_ONLY||CROSS_SECTIONAL|||||||
33967748|NCT06206733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967749|NCT06319391|||COHORT||RETROSPECTIVE|||||||
33967750|NCT00707174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967751|NCT03221946|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 arms with 3 groups of 30 patients each evaluated for diclofenac sodium oral tablets, transdermal patch and injection of same drug for dental pain disorders||||
33967752|NCT01890187|||CASE_ONLY||PROSPECTIVE|||||||
33967753|NCT00323674|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967754|NCT06186167|||COHORT||PROSPECTIVE|||||||
33967755|NCT02602340|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33967756|NCT06417502|||COHORT||PROSPECTIVE|||||||
33967757|NCT01716754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967758|NCT06527053|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||patients with maxillary defects had received two types of obturators|f|t|f|f
33874744|NCT05710471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are randomised and masked from the treatment|Parallel interventional arms with option of rescue treatment|t|f|f|f
33874745|NCT02833974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874746|NCT03870542|||COHORT||PROSPECTIVE|||||||
33874747|NCT02422212|NON_RANDOMIZED|PARALLEL||||NONE||||||
33874748|NCT05885100|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Patients aged 18 years old and above Body mass index of above 25 kg/m2 Patients Undergoing Elective/emergency surgery in UKMMC with an expected duration of 1 hour|t|f|t|f
33967759|NCT03145610|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This investigation was designed as double-blind, randomized, crossover study|t|f|t|t
33967760|NCT01811797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967761|NCT06360731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the study, patients do not know which group they were in. Therefore, blinding is performed among the participants. To prevent bias in the study, blinding is also performed between the researchers. Researchers (S.B. and A.O. from both clinics) make the pre- and post-test evaluations without knowing which group the patients are in.|This study employs a parallel group randomised controlled trial design.|t|f|t|f
33967762|NCT01637025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34195027|NCT03820440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study protocol is started during a period of intraoperative hemodynamic stability, as previously defined (change in mean arterial pressure of less than 10% during 5 minutes). The study protocol is the following: 1) a set of measurements is recorded (T0) at a baseline ventilation of 7 ml/Kg and then the EEOT is performed by using the software function, expiratory hold, to interrupt mechanical ventilation; 2) after one minute a set of measurements was recorded (T1); 3) the LRM is then performed; 4) after one minute another set of measurements is recorded (T2) and then a fluid challenge of 4 mL/Kg of crystalloid solution is infused over 10 minutes. The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment. The sequence of application of EEOT and LRM on the same patient (EEOT_LRM or LRM_EEOT) is randomly generated."||||
34195028|NCT02679963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34195029|NCT01264601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34195030|NCT01542567|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34195031|NCT01245569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34195032|NCT03374319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34195033|NCT04786834|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33874749|NCT02503228|||COHORT||PROSPECTIVE|||||||
33874750|NCT03008850|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33874751|NCT03729674|||COHORT||PROSPECTIVE|||||||
33874752|NCT01586351|||CASE_ONLY||PROSPECTIVE|||||||
33874753|NCT01486927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874754|NCT00870051|||COHORT||PROSPECTIVE|||||||
33967763|NCT02750527|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33967764|NCT06462001|RANDOMIZED|PARALLEL||TREATMENT||NONE||an open label, randomised, stratified, 2-arm multicentre phase 3 clinical trial||||
34195034|NCT02360683|||COHORT||PROSPECTIVE|||||||
34195035|NCT01588418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34195036|NCT00285389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34195037|NCT06233669|||COHORT||PROSPECTIVE|||||||
34195038|NCT02205489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34195039|NCT00662675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34195040|NCT04928898|||COHORT||PROSPECTIVE|||||||
34195041|NCT05946356|||OTHER||CROSS_SECTIONAL|||||||
34195042|NCT01299545|||COHORT||CROSS_SECTIONAL|||||||
34195043|NCT02595632|||CASE_ONLY||PROSPECTIVE|||||||
34195044|NCT00784342|||COHORT||PROSPECTIVE|||||||
34195045|NCT03332680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In terms of blinding, the physician and/or nurses as well as the patients will be blinded and will not know what arm of the study the participant has been allocated too. The embryologists however will be unblinded (as they provide intervention and will have to be aware).|This study is a positive control study with a single site two arm parallel design|t|f|t|t
34195046|NCT03071757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34195047|NCT00264758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34195048|NCT06437444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental pre-post cluster trial with control group||||
34195049|NCT01528202|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34195050|NCT03667898|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34195051|NCT03557840|NA|SINGLE_GROUP||OTHER||NONE||All patients will be simultaneously studied (disregarding the nature of their infection or the dose/schedule of temocillin)||||
34195052|NCT06467136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research assistant will be blind to study condition and time point||f|f|f|t
34195053|NCT04084119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants don't know to which intervention group they belong to||t|f|f|f
34195054|NCT03209128|||COHORT||PROSPECTIVE|||||||
34195055|NCT05311644|||COHORT||CROSS_SECTIONAL|||||||
34195056|NCT04473742|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34195057|NCT05834387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756222|NCT02840357|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33874755|NCT05417724|NA|SINGLE_GROUP||TREATMENT||NONE||Recruitment of veterans with chronic pain who are interested in being treated with Battlefield Acupuncture (BFA).||||
33874756|NCT04560595|RANDOMIZED|PARALLEL||TREATMENT||NONE||Caffeine consumption and secondary measures will be examined before, during, and after the caffeine reduction intervention and compared between immediate and delayed treatment groups.||||
33874757|NCT03916211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874758|NCT03487575|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874759|NCT04071743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874760|NCT00772954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874761|NCT04404387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874762|NCT03511963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967765|NCT02281188|||COHORT||PROSPECTIVE|||||||
33874763|NCT05093400|||COHORT||PROSPECTIVE|||||||
33967766|NCT01072019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967767|NCT05059782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A (drug treatment group) : Patients accept paclitaxel + platinum or paclitaxel single drug chemotherapy of which paclitaxel 135-175mg/m2, carboplatin AUC=5, cisplatin 40-60mg/m2. The treatment should be repeated every 3 weeks. Other second-line and third-line chemotherapy regimens (dose is not specified) are also allowed. Targeted, immunological or PARPi drugs can be added based on pathological and genetic test results until disease progression, unacceptable toxicity or informed consent withdrawal. Group B (radiotherapy group): IFRT, IMRT or SBRT is applied. Radiotherapy regimen: Involving field PGTV 60Gy-70Gy, 2-3Gy/f,5 times/week. External irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent. Group C (radiotherapy + drug group) : IFRT is the same as group B;Drug therapy: same as group A.||||
33967768|NCT04304950|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two groups: Evening Time or Morning Time. Participants are used as their own control. The evening time group will take their medication in the evening and the morning time group will take the medication in the morning.||||
34068280|NCT03402425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The result of the PET scan is masked until a treatment plan for the patient has been decided by the treatment responsible clinicians based on the MRI findings.|We aim to include all patients that fullfil the inclusion criteria.||||
34068281|NCT02437643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068282|NCT00030966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068283|NCT00332774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068284|NCT04350931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A block-randomization scheme will be generated by computer software. Participants will be randomized between 0.10 mL intradermal injection of BCG vaccine or placebo normal saline in a 2:1 ratio (600 will receive BCG \& 300 will receive placebo saline). In Egypt, the available BCG vaccine is the Copenhagen (Danish strain).|t|f|f|f
34068285|NCT06197477|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34068286|NCT01085240|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34068287|NCT04858867|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34068288|NCT03323697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind controlled trial|t|t|t|f
34068289|NCT00316329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34068290|NCT00154375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068291|NCT05430113|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-arm, open-label study performed to quantify variables that are predictive of the efficacy of spinal cord stimulation to improve motor control.||||
34068292|NCT02869893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068293|NCT01109134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068294|NCT03616392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068295|NCT03838029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068296|NCT03685500|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase IV, multicentre, randomised, open-label, pilot clinical trial.||||
34068297|NCT03326115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34068298|NCT03488563|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Each participant scheduled to receive investigational product (IP) will receive a randomization number at the time of randomization. The randomization number will be used to identify the study medication kit assigned to the participant and indicate the treatment to be administered to that participant.|Randomization will be 1:1:1 so that equal number of subjects will be treated in each arm of the study.|t|t|t|t
34068299|NCT03992677|||COHORT||RETROSPECTIVE|||||||
34068300|NCT00559663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068301|NCT01607853|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34068302|NCT02849171|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068303|NCT01209247|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874764|NCT03134352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874765|NCT01701570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874766|NCT02328430|||COHORT||PROSPECTIVE|||||||
33967769|NCT04918615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967770|NCT05278585|||COHORT||PROSPECTIVE|||||||
33967771|NCT00164203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33967772|NCT05293587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Fitbit data will be analyzed by Kansas State University personnel masked to group assignment.|Waitlist control group|f|f|f|t
33967773|NCT03453502|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33967774|NCT03093545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967775|NCT03473834|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Only patients with PD who meet the inclusion and exclusion criteria will be invited to participate in the study. All participants will be assessed for daily activity and motor skill using the Unified Parkinson's Disease Rating Scale (UPDRS). At pre- and post- assessments, eye movement and turning characteristics will be assessed using xIMU sensors and EOG.||||
33967776|NCT04090684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967777|NCT01730690|||COHORT||PROSPECTIVE|||||||
33967778|NCT05443555|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33967779|NCT05516212|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33967780|NCT06531291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967781|NCT00703378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967782|NCT01724476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068304|NCT02360748|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068305|NCT04247451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764845|NCT03204084|||CASE_CONTROL||PROSPECTIVE|||||||
33874767|NCT02250352|||COHORT||PROSPECTIVE|||||||
33874768|NCT06367257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33874769|NCT02567149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874770|NCT02140814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874771|NCT00484653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874772|NCT02756728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874773|NCT00364507|||CASE_CONTROL||OTHER|||||||
33874774|NCT01647451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874775|NCT02700490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874776|NCT01008683|||||PROSPECTIVE|||||||
33874777|NCT05200078|||COHORT||PROSPECTIVE|||||||
33874778|NCT02261194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874779|NCT03077347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Sham Stimulation followed by Direct Current Stimulation or Vice-Versa|t|f|t|f
33874780|NCT00003398||||TREATMENT||||||||
33874781|NCT01743755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874782|NCT02829138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33874783|NCT06070259|||CASE_CROSSOVER||PROSPECTIVE|||||||
33874784|NCT05411159|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874785|NCT06399627|||COHORT||RETROSPECTIVE|||||||
33967783|NCT04993781|RANDOMIZED|PARALLEL||PREVENTION||NONE||The design is a cluster randomized, parallel group superiority trial with practices stratified by healthcare system and patients nested within practices. The unit of randomization is the practice.||||
33967784|NCT04191512|||COHORT||PROSPECTIVE|||||||
33967785|NCT02758093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967786|NCT04157270|||COHORT||PROSPECTIVE|||||||
33756223|NCT04523987|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, pilot study evaluating the addition of Ciprofloxacin (study drug) to standard-of-care gemcitabine and nab-paclitaxel chemotherapy in treatment-naïve metastatic PDAC patients.||||
33874786|NCT04029974|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subject repeated measures design||||
33874787|NCT01526161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756224|NCT01194570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874788|NCT03957564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756225|NCT05338099|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33756226|NCT05120089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874789|NCT00518154|NA|SINGLE_GROUP||OTHER||NONE||||||
33756227|NCT03890822|||COHORT||PROSPECTIVE|||||||
33756228|NCT01236079|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33756229|NCT01345630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33756230|NCT04499573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874790|NCT06065852|||COHORT||OTHER|||||||
33874791|NCT04795232|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33874792|NCT02318667|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967787|NCT04275219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967788|NCT05603078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967789|NCT02763735|||COHORT||CROSS_SECTIONAL|||||||
33967790|NCT06541275|||CASE_ONLY||OTHER|||||||
33967791|NCT06545734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967792|NCT01301131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967793|NCT04190238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||case-control study|f|t|f|f
33967794|NCT02196506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967795|NCT01974570|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33967796|NCT05842083|RANDOMIZED|PARALLEL||OTHER||NONE||Oncologists will be randomized between the intervention and usual practice.||||
33874793|NCT00000299|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33967797|NCT04670822|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33967798|NCT02587156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33967799|NCT02569840|NA|SINGLE_GROUP||OTHER||NONE||||||
33967800|NCT05399719|||CASE_ONLY||RETROSPECTIVE|||||||
33967801|NCT03935659|RANDOMIZED|PARALLEL||PREVENTION||NONE|As this intervention necessitated the use of an external negative wound therapy device, masking is not possible|Patient fulfilling the inclusion criteria will be randomized into a standard gauze therapy group or a negative pressure wound therapy group.||||
33967802|NCT02880215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33967803|NCT01708876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967804|NCT03476915|||COHORT||CROSS_SECTIONAL|||||||
33967805|NCT05024071|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33967806|NCT04634721|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33967807|NCT00012584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967808|NCT01795456|||CASE_CONTROL||PROSPECTIVE|||||||
33967809|NCT03998228|||COHORT||CROSS_SECTIONAL|||||||
33967810|NCT03995303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967811|NCT04697355|NA|SINGLE_GROUP||OTHER||NONE||Case study in a single human subject||||
33967812|NCT04552496|||COHORT||RETROSPECTIVE|||||||
33967813|NCT02768740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967814|NCT06530082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967815|NCT00592020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967816|NCT04749186|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33967817|NCT01965652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967818|NCT04314427|||COHORT||PROSPECTIVE|||||||
33967819|NCT01042496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967820|NCT02102490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967821|NCT05337683|||CASE_ONLY||RETROSPECTIVE|||||||
33967822|NCT06469346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967823|NCT00002273||||TREATMENT||DOUBLE||||||
33967824|NCT01222806|RANDOMIZED|PARALLEL||TREATMENT||||||||
33967825|NCT02476552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967826|NCT01730859|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33967827|NCT05704218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||the final diagnosis will be judged by the pneumologist on plural results: imagery, BALF cytology. The final diagnosis will be used to make 2 groups proven / non proven domestic forms||||
33967828|NCT06090578|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a pragmatic cluster randomized trial. 26 primary care clinics will be randomized in two 18-month waves to receive either the TabCAT-BHA paradigm or usual care. The first wave will include six intervention practices and the second wave will include seven intervention practices.||||
33967829|NCT00684879|||||PROSPECTIVE|||||||
33874794|NCT03798964|||COHORT||PROSPECTIVE|||||||
33874795|NCT02350556|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874796|NCT03028571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Subjects will be studied twice, randomly assigned to star on the intact day (saline) or the blocked day (trimethaphan) and after 1 month cross to the other arm|t|f|f|f
33874797|NCT04267874|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33874798|NCT05386992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874799|NCT01825707|NA|SINGLE_GROUP||||NONE||||||
33967830|NCT04499456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33967831|NCT02132741|||COHORT||PROSPECTIVE|||||||
33967832|NCT02903576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967833|NCT02033876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967834|NCT00160030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967835|NCT01872689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967836|NCT01478633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068306|NCT04144868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||High-flow oxygen is delivered through the facemask at a rate of 8 L/min, once a hour, every 4 hours to the ICH patient.|t|t|f|f
34068307|NCT03561051|||COHORT||PROSPECTIVE|||||||
33967837|NCT03582371|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients will be scored Mini-Balance evaluation System Test by blinded investigators, before and after AquaSup or Physiotherapy|Proof of concept. Study of non-inferiority, prospective, monocentric, randomized, controlled (Aqua SUP vs physiotherapy), in blind treatment compared to applied treatment.|f|f|f|t
33967838|NCT02088528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967839|NCT05723822|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33967840|NCT05349331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967841|NCT03101423|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33967842|NCT00618423|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33967843|NCT06290414|||OTHER||CROSS_SECTIONAL|||||||
33967844|NCT03695133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33967845|NCT01735591|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33874800|NCT03620227|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The preparation and coding of the liquids will be performed by a third party so that the researchers and participants will not know which liquid is being consumed.|The volunteers will do 2 days of intervention in random order with 7 days of wash out. In one of the days will consume 350ml of concentrated beet juice and in the other 350ml of placebo made with the juice itself denitratized by an anionic resin that does not alter taste, smell or color.|t|f|t|f
33874801|NCT05870267|||COHORT||CROSS_SECTIONAL|||||||
33874802|NCT03804294|||COHORT||PROSPECTIVE|||||||
33874803|NCT05139186|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33874804|NCT03237104|||CASE_CONTROL||PROSPECTIVE|||||||
33874805|NCT02229500|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33874806|NCT02598843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874807|NCT04338750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Principal Investigator and Outcomes Assessors are blinded to randomization sequence and randomization assignments for the duration of the study.|Caregivers of adults with Alzheimer's disease or related dementias (N = 60) will be randomly assigned in equal numbers to Acceptance and Commitment Therapy delivered by telephone (TACTICs) or minimally-enhanced usual care (mEUC) using a block randomization scheme.|f|f|t|t
33874808|NCT03044535|||OTHER||PROSPECTIVE|||||||
33874809|NCT01178489|||COHORT||PROSPECTIVE|||||||
33874810|NCT00663988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874811|NCT00501787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874812|NCT01486836|||CASE_ONLY||PROSPECTIVE|||||||
33874813|NCT00750958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874814|NCT01083303|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33874815|NCT01620931|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33874816|NCT01326546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874817|NCT00773812|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33874818|NCT05952245|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33874819|NCT06087744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33874820|NCT03121404|||CASE_CONTROL||PROSPECTIVE|||||||
33874821|NCT01796327||CROSSOVER||BASIC_SCIENCE||NONE||||||
33874822|NCT05884931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874823|NCT04103073|||CASE_ONLY||PROSPECTIVE|||||||
33874824|NCT02185404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874825|NCT05229302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Outcome Assessor will be unaware of which treatment arms participants have been assigned to El evaluador será ciego a la pertenencia de los participantes al grupo control o de intervención|Cluster randomized controlled trial|f|f|f|t
33874826|NCT06493474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33874827|NCT03449095|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33874828|NCT04055792|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single-arm, Phase II study||||
33874829|NCT02336204|||COHORT||PROSPECTIVE|||||||
33874830|NCT04035811|||CASE_ONLY||PROSPECTIVE|||||||
33874831|NCT02541981|||CASE_ONLY||RETROSPECTIVE|||||||
33874832|NCT01714687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874833|NCT06004843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33874834|NCT00794157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068308|NCT00921206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068309|NCT04605718|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33967846|NCT00769899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068310|NCT05792137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33967847|NCT00002119||||TREATMENT||||||||
33967848|NCT03974581|||COHORT||PROSPECTIVE|||||||
33967849|NCT02151461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967850|NCT00017030||||TREATMENT||||||||
33967851|NCT02273206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967852|NCT00796159|||CASE_ONLY||CROSS_SECTIONAL|||||||
34068311|NCT00571753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068312|NCT00287521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874835|NCT01280825|||COHORT||PROSPECTIVE|||||||
33874836|NCT04180293|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874837|NCT01788254|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33874838|NCT06475456|||COHORT||OTHER|||||||
33874839|NCT05555784|||CASE_ONLY||RETROSPECTIVE|||||||
33874840|NCT03143140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874841|NCT03303742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874842|NCT03926663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33874843|NCT04351984|||COHORT||PROSPECTIVE|||||||
33874844|NCT02952157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874845|NCT02967874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874846|NCT01930136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874847|NCT00629291|||CASE_CONTROL||PROSPECTIVE|||||||
33874848|NCT05754502|||OTHER||OTHER|||||||
33874849|NCT01601028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874850|NCT03842423|||COHORT||RETROSPECTIVE|||||||
33874851|NCT00000580|RANDOMIZED|||PREVENTION||DOUBLE||||||
33874852|NCT05252364|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33874853|NCT03269435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double dummy design with IV placebo and placebo nerve block||t|t|t|t
33874854|NCT02228590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874855|NCT01963312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874856|NCT02394873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874857|NCT01991340|||COHORT||PROSPECTIVE|||||||
33967853|NCT04591561|||COHORT||PROSPECTIVE|||||||
33967854|NCT01938300|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33967855|NCT01491659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33967856|NCT02693678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967857|NCT00767689|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33967858|NCT03526107|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Dietary intervention study in healthy young adult males|t|t|t|t
33967859|NCT04214951|||COHORT||PROSPECTIVE|||||||
33967860|NCT02427906|||COHORT||PROSPECTIVE|||||||
33967861|NCT03378349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967862|NCT02432261|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33967863|NCT01735045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967864|NCT01484665|NA|SINGLE_GROUP||SCREENING||NONE||||||
33967865|NCT02722824|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33967866|NCT04809428|||COHORT||PROSPECTIVE|||||||
33967867|NCT05058937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967868|NCT05686278|||COHORT||OTHER|||||||
33967869|NCT03189264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33967870|NCT02415361|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967871|NCT02356081|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33967872|NCT02189395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967873|NCT03792971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967874|NCT05940883|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33967875|NCT03706677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blinded; participants will be blinded to the treatment group. Investigators will be blinded on study specific diagnostics used in the trial; Endpoint Review Committee will be blinded to the treatment group.|Randomization 1:1 between Cryoballoon ablation and Radiofrequency ablation|t|f|t|t
33967876|NCT01398592|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33967877|NCT03500965|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33967878|NCT04684810|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33967879|NCT01004666|||COHORT||PROSPECTIVE|||||||
33967880|NCT03111888|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33967881|NCT02685956|||OTHER||PROSPECTIVE|||||||
33874858|NCT02982343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874859|NCT00610987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874860|NCT01951820|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33874861|NCT04661709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It's a double-blind trial and includes two levels of blinding.|Parallel Assignment|t|f|t|t
33874862|NCT05970900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874863|NCT00913900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874864|NCT00004231||||TREATMENT||||||||
33874865|NCT04315181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a randomized, double-blind, double-dummy, placebo- controlled design||t|f|t|f
33874866|NCT00529997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33874867|NCT00886600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33874868|NCT04882592|NA|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33874869|NCT02487420|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874870|NCT01528514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874871|NCT03857490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization will be programmed with SAS Proc Plan and implemented via a user friendly web-based interface using REDCap. The biostatistician will be responsible for randomization; however, he/she will not have any contact with the patients and will not be involved in outcome measures. All investigators, except the research nurses, will be blinded to the group status of the patient during 8-week treatment and post-treatment testing. The research nurses will not be involved in data analysis and interpretation.|This is a randomized, placebo-controlled study. Older women with hypertension will randomly be assigned to either an intervention group or a control group (1:1 ratio). Patients in the intervention group will be required to perform 8 weeks of home-based lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 min per session), whereas patients in the control group will immerse their legs in a thermoneutral water bath (33°C) at the same frequency and duration.|f|f|f|t
33874872|NCT03382665|||COHORT||PROSPECTIVE|||||||
33874873|NCT02713958|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874874|NCT04526561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874875|NCT00545064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874876|NCT00163332|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33874877|NCT02249650|NA|SEQUENTIAL||TREATMENT||NONE||||||
33874878|NCT01181011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33874879|NCT01970189|||COHORT||PROSPECTIVE|||||||
33874880|NCT00270517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874881|NCT06496815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874882|NCT03002415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33874883|NCT04919980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874884|NCT04203524|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Randomized controlled study|t|f|f|f
33874885|NCT05843734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874886|NCT03923543|||CASE_ONLY||PROSPECTIVE|||||||
33874887|NCT00573573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874888|NCT03600779|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33874889|NCT03290235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874890|NCT02223260|NA|SINGLE_GROUP||||NONE||||||
33874891|NCT05939310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874892|NCT04438473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33874893|NCT04543643|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
33874894|NCT06220331|||OTHER||RETROSPECTIVE|||||||
33874895|NCT02891655|||OTHER||CROSS_SECTIONAL|||||||
33874896|NCT06254729|||COHORT||PROSPECTIVE|||||||
33874897|NCT04423809|||COHORT||RETROSPECTIVE|||||||
34068313|NCT02598778|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33874898|NCT05697601|||COHORT||RETROSPECTIVE|||||||
33874899|NCT04546477|NA|SINGLE_GROUP||TREATMENT||NONE||Peripheral Stent placement at the location of the initially stenosed or occluded femoropopliteal lesion after proper (1:1 to the reference vessel diameter) vessel preparation without the use of adjunctive debulking devices. Proper vessel preparation should result in ≤20% residual stenosis (as per operator's assessment).||||
33874900|NCT05882448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|At the end of the operation, two dressings will be placed on the child's abdomen to ensure the blindness of the health professionals performing the postoperative care and the parents.|parallel assignment|t|f|f|t
33874901|NCT03284684|||CASE_ONLY||PROSPECTIVE|||||||
33874902|NCT00232102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874903|NCT00742768|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33874904|NCT01934556|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33874905|NCT05926700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874906|NCT03420690|||COHORT||RETROSPECTIVE|||||||
33874907|NCT02021045|||CASE_ONLY||PROSPECTIVE|||||||
33874908|NCT03298581|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single treatment arm study||||
33874909|NCT02554123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33874910|NCT00948571|||COHORT||PROSPECTIVE|||||||
33874911|NCT00779649|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33874912|NCT03924609|||COHORT||RETROSPECTIVE|||||||
33874913|NCT04324359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874914|NCT00853671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874915|NCT00860210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874916|NCT05477121|||COHORT||PROSPECTIVE|||||||
33874917|NCT01725555|RANDOMIZED|CROSSOVER||||NONE||||||
33874918|NCT03563378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33874919|NCT05177120|||CASE_ONLY||CROSS_SECTIONAL|||||||
33874920|NCT03129321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874921|NCT02882659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874922|NCT02279680|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874923|NCT02941627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874924|NCT04457804|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be assigned to the same intervention.||||
33874925|NCT02215356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874926|NCT00203853||FACTORIAL||TREATMENT||NONE||||||
33874927|NCT02829840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874928|NCT00000270||||TREATMENT||||||||
33874929|NCT05533983|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.||||
33874930|NCT06180200|||COHORT||PROSPECTIVE|||||||
33874931|NCT06235073|||CASE_CONTROL||RETROSPECTIVE|||||||
33874932|NCT01916837|||||PROSPECTIVE|||||||
33874933|NCT01308008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874934|NCT05779475|||COHORT||PROSPECTIVE|||||||
33874935|NCT03426085|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33874936|NCT02270242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33874937|NCT03024489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874938|NCT04978909|||CASE_ONLY||PROSPECTIVE|||||||
33874939|NCT02616289|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical Trial in two treatment arms||||
33874940|NCT04165707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967882|NCT03121781|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Randomization will be done by sealed envelopes, ready for use once consent is obtained.Each envelope will contain a card with the assigned treatment group: protocol 1 or protocol 2.~Protocol 1: we start the study on CPAP with binasal prongs. Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.~Protocol 2: we start the study on CPAP with RAM cannula. Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours."||||
33874941|NCT06279767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874942|NCT05388461|||COHORT||PROSPECTIVE|||||||
33874943|NCT04247633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874944|NCT04563494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874945|NCT00658554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33874946|NCT06402864|RANDOMIZED|PARALLEL||TREATMENT||NONE||"It is an open label phase III randomized controlled clinical trial comparing 2 arms:~* Control arm A consists in TNT regimen, with an induction chemotherapy Modified FOLFIRINOX (mFOLFIRINOX) 6 cycles over 12 weeks, followed by nCRT 50 Gy over 5 weeks with concomitant capecitabine (CAP50 Gy).~* Experimental arm B consists in addition of three fractions of CXB every two weeks between end of mFOLFIRINOX and nCRT."||||
33874947|NCT05184608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874948|NCT00054067|RANDOMIZED|||TREATMENT||||||||
33874949|NCT00484497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33874950|NCT05193110|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33874951|NCT01541475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33874952|NCT01356407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33874953|NCT00770614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874954|NCT03343496|||CASE_ONLY||PROSPECTIVE|||||||
33874955|NCT04326335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967883|NCT04605523|||COHORT||PROSPECTIVE|||||||
33967884|NCT02100566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33967885|NCT05687929|||COHORT||PROSPECTIVE|||||||
33967886|NCT06529991|NA|SINGLE_GROUP||TREATMENT||NONE||This study will utilize a pretest-posttest design which will measure changes in the following in response to a 5-minute self-myofascial release intervention: muscle biomechanical properties, plantar pressure distribution, pain pressure threshold, ankle range of motion. Investigators will correlate subjective measures of stress, anxiety, sleep, and pain experience with treatment response and evaluate changes in these subjective measures after 1 treatment.||||
33967887|NCT03855319|NA|SINGLE_GROUP||PREVENTION||NONE||no randomized, no controlled||||
33967888|NCT00251628|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967889|NCT01555281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967890|NCT01170260|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33874956|NCT05593250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1905 compared with placebo|t|t|t|t
33874957|NCT06220539|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756231|NCT05543850|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is a monocenter, randomized cross-over trial. The total duration of the study will be three months: two weeks open loop control and 4-6 training days followed by a two-week closed-loop period, or vice versa, with at least 2 weeks in between.||||
33756232|NCT01067248|||COHORT||CROSS_SECTIONAL|||||||
33756233|NCT05673226|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Randomized, controlled, cluster, crossover, trial|t|f|f|t
33874958|NCT03134872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874959|NCT01131377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874960|NCT02588976|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874961|NCT01050270|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33874962|NCT00750633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874963|NCT04225923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33874964|NCT04502485|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33756234|NCT06082245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||TLIP block group, ESP block group and control group|t|f|f|f
33756235|NCT03050970|||COHORT||PROSPECTIVE|||||||
33756236|NCT05210855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874965|NCT00312988|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33874966|NCT02291120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33874967|NCT06479421|||COHORT||PROSPECTIVE|||||||
33874968|NCT00404014|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33874969|NCT02681237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874970|NCT04621864|||COHORT||PROSPECTIVE|||||||
33874971|NCT00790907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874972|NCT06118684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single centre, open label trial to assess the impact of CYP3A4 and Pgp inhibition on the PK of EP395 (Part A); and, to assess the impact of EP395 on the PK of a CYP3A4 substrate and a Pgp substrate (Part B). Parts A and B of the trial may be conducted concurrently.||||
33874973|NCT01081249|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33874974|NCT00879645|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967891|NCT05329428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33967892|NCT01433900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967893|NCT03214458|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33756237|NCT02256215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756238|NCT00903526|||COHORT||RETROSPECTIVE|||||||
33756239|NCT05004987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the study staff and the subjects will be blind to the study assignment.||t|f|t|f
33756240|NCT05182567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756241|NCT02044185|||CASE_CONTROL||PROSPECTIVE|||||||
33756242|NCT00800839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756243|NCT03362450|||COHORT||RETROSPECTIVE|||||||
33756244|NCT05280418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756245|NCT05408806|||CASE_CONTROL||PROSPECTIVE|||||||
33756246|NCT00003617|RANDOMIZED|||TREATMENT||||||||
33756247|NCT01484639|RANDOMIZED|PARALLEL||||NONE||||||
33874975|NCT03488875|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Participants cannot be made blind to study assignment due to the nature of the intervention.~Baseline (T1) measures will be collected prior to treatment assignment. Every effort will be taken to minimize knowledge of group assignment by the study team, in particular the PI and other individuals involved in data analysis; however, the small size of the study team and overlapping roles of team members may preclude masking of group assignment for all members of the study team."|Participants are randomized to an active treatment group and a waitlist control group.||||
33874976|NCT03953066|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33874977|NCT05113576|||COHORT||RETROSPECTIVE|||||||
33874978|NCT02488369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33874979|NCT00689468|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33874980|NCT04876014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874981|NCT01660360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33874982|NCT00893724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33874983|NCT04784182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|One study staff member will be responsible for randomization and allocation of intervention supplement or placebo, which will be appear to be identical|Placebo controlled randomized controlled trial|t|f|t|t
33874984|NCT01674101|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33874985|NCT03374189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33874986|NCT02343159|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33874987|NCT02258451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874988|NCT05580133|||COHORT||PROSPECTIVE|||||||
33874989|NCT00864643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874990|NCT02989558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874991|NCT02639000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874992|NCT04122794|||COHORT||CROSS_SECTIONAL|||||||
33874993|NCT01441830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33874994|NCT01892358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33874995|NCT02175732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33874996|NCT04496401|NA|SINGLE_GROUP||OTHER||NONE||||||
33874997|NCT01973777|NA|SINGLE_GROUP||PREVENTION||NONE||intrauterine contraceptive device IUB||||
33874998|NCT00543426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33874999|NCT01588795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756248|NCT05925374|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will pilot test a substance use training that aims to reduce professional stigma towards patients who use drugs. Participants will be professionals working in primary care settings, and all participants will receive the intervention (training). Their stigmatizing attitudes and intended/planned behaviors will be assessed immediately prior to the training and immediately after the training.||||
33756249|NCT00403624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967894|NCT02629133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967895|NCT06460428|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"In order to prevent selection bias and to ensure similarity between groups; simple randomization will be used to assign the couples in the sample group to the experimental and control groups.~In this study, researcher and participant blinding will not be performed. Because the researcher will do the intervention himself/herself and placebo will not be used in the intervention.~Data collection forms to prevent detection bias will be applied online through Google Forms® independently of the researcher.~The data obtained from the research to prevent reporting bias will be transferred to the SPSS program by an independent researcher. Analysis of the data will also be done by an independent statistician."|This research is a randomized controlled experimental study with a pretest-posttest control group.|t|f|f|t
33967896|NCT04229316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967897|NCT03299530|||CASE_ONLY||CROSS_SECTIONAL|||||||
33967898|NCT05500495|||COHORT||RETROSPECTIVE|||||||
33967899|NCT04539002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind, randomized, controlled|The first 44 participants with spinal cord injury related to multiple sclerosis (MS) will be randomized in a 1:1 ratio to a 24-week aerobic exercise intervention on a stationary ergometer or an MS education control group.|f|f|t|t
33967900|NCT03056326|RANDOMIZED|||TREATMENT||QUADRUPLE||"Part 1: alternating cross-over design~Part 2: parallel design"|t|t|t|t
33967901|NCT02106169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33967902|NCT03413527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967903|NCT05771831|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label treatment. Only statistician performing the data analysis will be blinded|Parallel groups, patients entering in either intervention arm or standard treatment||||
33967904|NCT03655899|||OTHER||PROSPECTIVE|||||||
33967905|NCT04948307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967906|NCT02218359|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33967907|NCT02657590|||COHORT||PROSPECTIVE|||||||
33967908|NCT00146289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967909|NCT00740259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151988|NCT04303299|RANDOMIZED|PARALLEL||TREATMENT||NONE|"The study is described as 'open' unblinded, however all clinical, virological and laboratory data, as well as adverse events were reviewed by two independent physicians, and all radiological images were reviewed by two independent radiologists who were blinded to the treatment assignments.~The study outcomes assessed blinded to randomized group ( PROBE design - prospective randomised open blinded evaluation)"|||||
34151989|NCT03197909|||CASE_CONTROL||RETROSPECTIVE|||||||
34151990|NCT01614171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151991|NCT03968185|||OTHER||RETROSPECTIVE|||||||
34151992|NCT05822050|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33756250|NCT00698594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756251|NCT00765843|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33756252|NCT06020092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875000|NCT02070029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875001|NCT05180942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875002|NCT05938192|||COHORT||PROSPECTIVE|||||||
33875003|NCT06424184|NA|SINGLE_GROUP||TREATMENT||NONE||Open label trial||||
33875004|NCT02060578|NA|SINGLE_GROUP||||NONE||||||
33875005|NCT05913661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875006|NCT00890032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875007|NCT03150771|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875008|NCT05075811|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single|Crossover Assignment|t|f|f|f
33875009|NCT04831970|||COHORT||PROSPECTIVE|||||||
33875010|NCT06090734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33875011|NCT03253588|||CASE_CONTROL||RETROSPECTIVE|||||||
33875012|NCT04270110|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875013|NCT05234606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875014|NCT03744351|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33875015|NCT04322773|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33967910|NCT03179475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151993|NCT03943745|||CASE_ONLY||PROSPECTIVE|||||||
34151994|NCT03067376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33967911|NCT03563027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Investigator and Outcomes assessor will be masked until the trial is completed and all analyses are finished.|Parallel 3-arm randomized, controlled trial|f|f|t|t
33967912|NCT03932084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967913|NCT00637442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33967914|NCT03557710|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Quantify the degree to which cognitive and behavioral interventions alter the valuation of cancer-risk foods relative to an active control. We will recruit 300 overweight/obese adults who are at risk for eating- and obesity-related cancers and randomize them to a (a) behavioral response training toward low cancer-risk foods and away from high cancer-risk foods, (b) cognitive reappraisal intervention focused on cancer-risk foods (experimental arms), or (c) non-food inhibitory control training (active control arm). Valuation, our primary mediating process as implicated in the incentive sensitization model, will be measured using behavioral economics tasks and functional magnetic resonance imaging (fMRI) of the vmPFC at pre- and posttraining. Proximal, intervention-specific mediators will also be indexed with fMRI. A final analysis will compare the potency of the intervention-specific neural systems to alter valuation via connectivity to vmPFC.||||
33967915|NCT04132739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967916|NCT00583869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967917|NCT01862328|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33967918|NCT00366379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967919|NCT03250910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967920|NCT06373406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967921|NCT04261478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label, blinded endpoint (PROBE)|A multi-centre, prospective, randomized, open-label, blinded endpoint (PROBE) controlled trial (1:1 allocation).|f|f|f|t
33967922|NCT04766294|||OTHER||CROSS_SECTIONAL|||||||
33967923|NCT05256732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33967924|NCT05357794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967925|NCT00003637|RANDOMIZED|||TREATMENT||||||||
33967926|NCT04696562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This single-centered, randomized controlled study will be held in Ankara city hospital in Turkey. The investigators used the G\*Power (Version 3.1.9) test to determine the sample size. Participants included patients who treated in hospital for covid-19 who fulfilled the inclusion criteria and agreed to participate.~Randomized block assignment was used to assign 44 patients to the intervention group (n = 22) and the control group (n = 22). The investigators did block randomization, via a computer program (sealed envelope, https://www.sealedenvelope.com/ , randomization code: 34780089372265)."||||
33967927|NCT01212783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967928|NCT00040859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967929|NCT00094783||||TREATMENT||||||||
33967930|NCT00002582|RANDOMIZED|||TREATMENT||||||||
33967931|NCT04363736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967932|NCT01581983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967933|NCT02348970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967934|NCT00560547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967935|NCT04926896|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental group:~Minimally invasive bone harvesting surgery group.~Control group:~Traditional iliac crest bone harvesting surgery group."||||
33967936|NCT02050464|||CASE_CONTROL||PROSPECTIVE|||||||
33967937|NCT04576793|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33967938|NCT04267796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33967939|NCT01082445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967940|NCT01704183|||COHORT||PROSPECTIVE|||||||
33967941|NCT05935800|||COHORT||RETROSPECTIVE|||||||
33967942|NCT02235428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33967943|NCT05528926|RANDOMIZED|PARALLEL||OTHER||SINGLE|In the RESIST trial, independent evaluators will be blinded to the type of program received by the parents; this aspect will be monitored throughout the study and parents will be instructed before every assessment to avoid disclosing the type of therapy received.|"3 parallel groups to compare:~* Non-Violent Resistance parent training (NVR)~* Parent Management Training (PMT)~* Treatment As Usual (TAU)"|f|f|f|t
33967944|NCT00635388|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33967945|NCT02974374|RANDOMIZED|||TREATMENT||DOUBLE|||t|t|f|f
33967946|NCT02386254|||CASE_ONLY||PROSPECTIVE|||||||
33967947|NCT04860635|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33967948|NCT01677559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967949|NCT04366388|||COHORT||PROSPECTIVE|||||||
33967950|NCT02947061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151995|NCT05173701|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34151996|NCT03836677|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34151997|NCT05124379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151998|NCT02073669|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34151999|NCT03496766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152000|NCT03712488|||COHORT||PROSPECTIVE|||||||
34152001|NCT00958737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152002|NCT02971150|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152003|NCT03299361|||CASE_ONLY||PROSPECTIVE|||||||
34152004|NCT02517372|NON_RANDOMIZED|PARALLEL||||NONE||||||
33756253|NCT00762450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33756254|NCT04060875|||CASE_ONLY||RETROSPECTIVE|||||||
33756255|NCT04065750|||CASE_CONTROL||RETROSPECTIVE|||||||
33756256|NCT03706118|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, longitudinal, monocentric, interventional study||||
33756257|NCT00981890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756258|NCT03587246|||COHORT||PROSPECTIVE|||||||
33756259|NCT00389883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756260|NCT06222515|||COHORT||RETROSPECTIVE|||||||
33756261|NCT03470779|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a randomized, wait-list controlled pilot study. A parallel group study design will be used to compare a treatment group and a wait-list control group. This study design will be effective for addressing the gap in literature by examining both the initial treatment estimates related to health and functioning and the feasibility of performing a similar study on a larger scale.||||
33756262|NCT01032655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756263|NCT05340959|||CASE_ONLY||PROSPECTIVE|||||||
33756264|NCT05805995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The exercise group received vertebral derotation with posterior correction in addition to routine chest physiotherapy (group A).~The Control group received only posterior correction with routine chest physiotherapy (group B)."|t|f|f|f
33756265|NCT04475432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment assignment will be unknown to the study participant, investigators and site staff performing study assessments.|"Active arm: TP-03 0.25%~Control arm: Vehicle of TP-03"|t|t|t|t
33756266|NCT00447148|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756267|NCT01211990|||||PROSPECTIVE|||||||
33756268|NCT01939704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33756269|NCT01256853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756270|NCT04905615|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33756271|NCT05899842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756272|NCT00542880|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33756273|NCT03078088|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33756274|NCT01945151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756275|NCT00032474|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34152005|NCT00129467|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33756276|NCT05947929|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33756277|NCT03458455|||COHORT||PROSPECTIVE|||||||
33756278|NCT00137540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756279|NCT00762944|||COHORT||PROSPECTIVE|||||||
33756280|NCT00643058|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33756281|NCT03260868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756282|NCT01996579|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756283|NCT01531452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875016|NCT06162299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875017|NCT05949905|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|"The researchers will use two groups (study and control) in which participants will be randomly selected and assigned in each of the study and control groups using simple random sampling.~The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."||t|f|f|f
34152006|NCT01471210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152007|NCT00485966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152008|NCT05067803|||OTHER||PROSPECTIVE|||||||
34152009|NCT05024136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34152010|NCT02830620|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152011|NCT05633264|||COHORT||PROSPECTIVE|||||||
34152012|NCT02713659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756284|NCT01633879|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756285|NCT04511455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756286|NCT01867931|||CASE_CONTROL||PROSPECTIVE|||||||
33756287|NCT02270151|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33756288|NCT03063294|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152013|NCT00016549||||TREATMENT||||||||
34152014|NCT04787991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152015|NCT00438594|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33875018|NCT06494046|||CASE_CONTROL||PROSPECTIVE|||||||
33875019|NCT01970995|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33875020|NCT01351935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152016|NCT03189836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875021|NCT04094571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34152017|NCT05755659|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34152018|NCT02492282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152019|NCT02895945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152020|NCT01147848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152021|NCT04022980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34152022|NCT06254924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152023|NCT06258096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind RCT|t|t|t|t
34152024|NCT04036929|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34152025|NCT00826670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34152026|NCT02024126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152027|NCT00684827|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34152028|NCT02533895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152029|NCT04093986|||CASE_ONLY||RETROSPECTIVE|||||||
34152030|NCT04246723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152031|NCT06076070|||CASE_ONLY||PROSPECTIVE|||||||
34152032|NCT03225924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152033|NCT00895453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152034|NCT03946085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel treatment group participants will be randomly assigned either the experimental intervention, Lumega-Z, or the AREDS2 supplement. An observational, control group will be included for further comparison.|t|f|f|f
34152035|NCT00075738||||TREATMENT||NONE||||||
34152036|NCT06056856|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm parallel assignment. The first arm will be operated using penile skin grafts, The second arm will be operated using buccal mucosal grafts.||||
34152037|NCT04477057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152038|NCT00812565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152039|NCT03131882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152040|NCT04364620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152041|NCT06407102|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152042|NCT03134183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computer-generated randomization will be utilized to assign treatment arms and the vaginal misoprostol and buccal placebo and buccal misoprostol and vaginal placebo will be prepared according to randomization scheme by the research pharmacy in opaque-sealed envelopes as to blind participants and providers.||t|t|t|f
34152043|NCT03623009|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34152044|NCT00837603|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34152045|NCT00518297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152046|NCT00000643||||PREVENTION||DOUBLE||||||
34152047|NCT05476523|||COHORT||PROSPECTIVE|||||||
34152048|NCT05964595|||COHORT||PROSPECTIVE|||||||
34152049|NCT00514462|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34152050|NCT00028574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34152051|NCT00667667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152052|NCT00300352|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34152053|NCT02868138|||COHORT||PROSPECTIVE|||||||
34152054|NCT03549559|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34152055|NCT03589222|NA|SINGLE_GROUP||TREATMENT||NONE||This is an investigator-sponsored, open-label, non-randomized Phase 2 study to evaluate the efficacy and safety of this combination for a total of 62 patients with refractory or relapsed/refractory MM patients. The treatment will be given until progression of the disease or inacceptable toxicity. This trial will be conducted in approximately 15-centers in Spain||||
34152056|NCT03255746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34152057|NCT02402283|RANDOMIZED|CROSSOVER||||NONE||||||
34152058|NCT03793491|||CASE_ONLY||PROSPECTIVE|||||||
34152059|NCT00908102|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34152060|NCT06303466|||COHORT||RETROSPECTIVE|||||||
34152061|NCT06334874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34152062|NCT03583827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eighty unilaterally brain injured right-handed patients, with lesion time of 6 months or more, aged 70 years or younger, 40 with left-brain and 40 with right-brain injury, will take part in the study. They will be randomly divided into a control group (GC), which will undergo conventional therapy and an experimental group (EG), which will be submitted to conventional and virtual reality training using the game virtual. The study will also include 40 healthy individuals matched for age, sex, schooling and hand laterality.|f|f|f|t
34152063|NCT00910169|||COHORT||PROSPECTIVE|||||||
34152064|NCT01722656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152065|NCT02258113|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34152066|NCT03740568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152067|NCT00067782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152068|NCT02348307|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34152069|NCT03887858|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152070|NCT06113536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a diagnostic, open-label, single-center interventional study.||||
34152071|NCT05715515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152072|NCT04964596|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||patients who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1:1 ratio into 3 groups|t|f|f|f
34152073|NCT06145958|||CASE_CONTROL||RETROSPECTIVE|||||||
34152074|NCT04311463|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|A single-dose, randomized, balanced, open-label, two-sequence, two-treatment, two-period, crossover bioequivalence study under fasting condition.||||
34152075|NCT04882787|NA|SINGLE_GROUP||TREATMENT||NONE||2 groups based on hearing aid gain needs; one similar intervention||||
34068314|NCT03250247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blinded Clinical assessments for PTS will be obtained at baseline (pre-randomization) and at the 6- month follow-up visits. Examining clinicians will complete PTS training to ensure accuracy across all Clinical Centers. The examiners for PTS must be blinded to the subjects' treatment allocation. Subjects will be reminded not reveal to clinic staff which therapy they received (EVT or No-EVT). Subjects should be examined in the afternoon (the later the better) to allow the symptoms and signs of PTS to manifest. The assessment is performed as follows:~1. The subject should be asked to rate the 5 symptoms on the Villalta PTS scale for each leg, record his/her ratings on the CRF.~2. The subject's legs should be unclothed and he/she should be seated facing the blinded clinician (nurse or physician).The 5 signs of PTS and VCSS measures will be recorded by the blinded clinician. Leg ulcers (if present) will be assessed and measured."|This is an NIH-funded, Phase III, multicenter, randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial.|f|f|f|t
33875022|NCT06474754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-blinded Phase IV diagnostic clinical trial study design||||
34068315|NCT03621241|||OTHER||PROSPECTIVE|||||||
34152076|NCT05055310|||COHORT||PROSPECTIVE|||||||
34152077|NCT05268029|||COHORT||CROSS_SECTIONAL|||||||
34152078|NCT02517320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875023|NCT04486950|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33875024|NCT03456921|NA|SINGLE_GROUP||OTHER||NONE||"This project uses an evidence-based and effective intervention--an end-of-life conversation game called Hello--to engage and activate participants to perform advance care planning. Quantitative data will be collected before and after immediately playing the game. Focus groups also will be held immediately after the game. Three months to nine months after playing the game, participants will complete surveys and also engage in semi-structured interviews about the game and about their ACP activities."||||
33875025|NCT04027114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33875026|NCT05363475|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort with comparison to retrospective cohort||||
33875027|NCT00829907|NON_RANDOMIZED|PARALLEL||||NONE||||||
34152079|NCT04043078|NA|SINGLE_GROUP||OTHER||NONE||||||
34152080|NCT02209623|||OTHER||PROSPECTIVE|||||||
34152081|NCT05020002|||COHORT||PROSPECTIVE|||||||
34152082|NCT02095509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152083|NCT02387008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152084|NCT03009318|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152085|NCT01107613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34152086|NCT06025409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875028|NCT01647971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875029|NCT00242827|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875030|NCT05413382|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33875031|NCT04510233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875032|NCT04677959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875033|NCT00214370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33875034|NCT00464334|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34152087|NCT04348396|||CASE_ONLY||PROSPECTIVE|||||||
33875035|NCT03631732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875036|NCT05428787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875037|NCT01168362|||COHORT||PROSPECTIVE|||||||
33875038|NCT04479579|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cohort study||||
33875039|NCT01701739|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33875040|NCT00075023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875041|NCT02611388|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33875042|NCT02966509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33875043|NCT02330159|||COHORT||PROSPECTIVE|||||||
33875044|NCT00935480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875045|NCT03814070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875046|NCT01744600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875047|NCT03641664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33875048|NCT04467424|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33967951|NCT06371547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interventions and assessment will be performed by separate researchers.||f|f|f|t
33967952|NCT03998085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875049|NCT03266042|||OTHER||OTHER|||||||
33875050|NCT02662036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33875051|NCT03682523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A senior statistician will use a computer-generated random sequence to determine whether each patient is allocated to the control or intervention group. To minimize risk of bias, the RA who collects assessment data will remain blinded to the study group, with separate RAs assisting with the intervention. Only the statistician will hold the key to the control/intervention group.|"Participants will be classified into three strata based on their baseline mobility measured with the HABAM. Within each strata, patients will be randomly allocated to the control (n=25) and intervention (n=25) groups in temporal blocks. In the event of Covid-19 related interruptions to the study, temporal blocks aim to keep the number of participants in the intervention and control groups similar at all times.~This stratified, block randomised control trial design will ensure a similar distribution of patient characteristics in the control and intervention groups and will safeguard against possible interruptions due to Covid-19."|f|f|t|t
33875052|NCT00238251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875053|NCT00491699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33967953|NCT05682794|||COHORT||PROSPECTIVE|||||||
33967954|NCT04804332|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Design : RCT~* Multicenter~* Randomized controlled~* Parallel group design~* Superiority trial~* Non-blinded"||||
33967955|NCT02418910|||COHORT||PROSPECTIVE|||||||
33967956|NCT04433845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967957|NCT02917954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Stepped-wedge randomized trial. Group 1: 3 month control period followed by a 12 month intervention period. Group 2: 6 month control period followed by a 9 month intervention period.||||
33967958|NCT02889328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967959|NCT00680576|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34152088|NCT04186507|||OTHER||OTHER|||||||
34152089|NCT01502163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152090|NCT06124794|NA|SINGLE_GROUP||TREATMENT||NONE||A Multicenter, Single group, Open, Extension Study of Phase III Clinical Trial||||
34152091|NCT04692142|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The outcomes assessor and the statistical analyst will be masked|The trial is designed as a cross-over clustered randomized trial (each group would be a cluster), so that each group will act as their own control for their learning performance and perception.|f|f|f|t
34152092|NCT00236756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152093|NCT06412913|||COHORT||RETROSPECTIVE|||||||
33967960|NCT06204172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To minimize the effect of selection bias (or even selection distortion), subject enrollment in the respective study arms (experimental or control) will be carried out through simple randomization sampling, i.e., randomly. Randomization is achieved by extracting numbers from a list, referred to as the 'sampling list,' which includes all individuals in the study population|The study adopts a Randomized Controlled Pilot design, an interventional, non-pharmacological, monocentric approach, aiming to explore cognitive-motor effects using advanced multisensory stimulation, the Neurowave system. Enrollment of at least 20 eligible subjects will occur consecutively at the Neurorehabilitation Unit of Piedmont Hospital. The study entails comprehensive baseline assessments (T0), succeeded by a one-month intensive cycle of advanced multisensory training. The experimental group will undergo Neurowave (INES) stimulation, while the control group will receive conventional multisensory stimulation (ISES - Intensive Sensorial Emotional Stimulation) without the advanced technological tool. Evaluations after each training cycle (T1) and a one-month follow-up (T2) will yield insights into short-term and long-term outcomes encompassing clinical-psychometric, neurophysiological, and metabolic-nutritional dimensions.|t|f|t|f
33875054|NCT04294719|||OTHER||PROSPECTIVE|||||||
33875055|NCT02477059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875056|NCT05129059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33875057|NCT01916330|||CASE_ONLY||PROSPECTIVE|||||||
33875058|NCT00455234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33875059|NCT00780247|||COHORT||CROSS_SECTIONAL|||||||
33875060|NCT04169373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875061|NCT00106275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875062|NCT04956835|||COHORT||PROSPECTIVE|||||||
33967961|NCT05715710|||COHORT||PROSPECTIVE|||||||
33875063|NCT03332563|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||This study will employ a stepped wedge cluster randomized design in which clinic sites are randomized sequentially to initiate the intervention. Prior to initiating patient recruitment, each of the 8 clinics will be randomized to one of two waves in the stepped wedge design. During the non-exposure periods, patients will receive usual care from the clinic.|f|t|t|t
33875064|NCT02813551|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33875065|NCT05726500|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875066|NCT01441037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875067|NCT00073489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875068|NCT01988064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875069|NCT03009266|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875070|NCT05298891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875071|NCT02942745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875072|NCT01106170|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33875073|NCT01070472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875074|NCT02457637|||COHORT||PROSPECTIVE|||||||
33875075|NCT01910259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875076|NCT03446066|||CASE_CONTROL||PROSPECTIVE|||||||
33875077|NCT02721680|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33875078|NCT04640467|||COHORT||PROSPECTIVE|||||||
33875079|NCT04754503|||CASE_ONLY||PROSPECTIVE|||||||
33875080|NCT01111851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875081|NCT02756507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33967962|NCT05521750|||COHORT||OTHER|||||||
33967963|NCT00794326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33967964|NCT04905654|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33967965|NCT03676959|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33967966|NCT01218620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875082|NCT02922374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875083|NCT03424707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33967967|NCT04956406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician will be blinded to avoid evaluator bias.||t|f|f|f
33875084|NCT06497205|||COHORT||CROSS_SECTIONAL|||||||
33875085|NCT02466711|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33875086|NCT01537562|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875087|NCT06183723|NA|SINGLE_GROUP||OTHER||NONE||||||
33875088|NCT01202656|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33875089|NCT00574275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875090|NCT03734796|||COHORT||PROSPECTIVE|||||||
33875091|NCT01885611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33875092|NCT03656861|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33875093|NCT03971201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875094|NCT02610595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875095|NCT00142467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875096|NCT03366298|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875097|NCT00713128|||CASE_ONLY||PROSPECTIVE|||||||
33875098|NCT02458755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875099|NCT06062186|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33967968|NCT05701267|||CASE_CONTROL||PROSPECTIVE|||||||
33967969|NCT00457379|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33967970|NCT02867020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967971|NCT00756119|||CASE_ONLY||PROSPECTIVE|||||||
33967972|NCT00580983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152094|NCT03414294|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Masking for Part A (SAD) , Part B (MAD), Part E (MAD) open for Part C (FE) and Part D (FE)|Sequential Assignment/Crossover (for food effect)|t|f|t|f
34152095|NCT03806608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152096|NCT02316886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152097|NCT03034902|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34152098|NCT02239965|||CASE_ONLY||PROSPECTIVE|||||||
34152099|NCT02553538|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34152100|NCT02772627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152101|NCT01493856|RANDOMIZED|CROSSOVER||||NONE||||||
34152102|NCT02288988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152103|NCT01789606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152104|NCT03961412|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34152105|NCT06175156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34152106|NCT03625713|||COHORT||PROSPECTIVE|||||||
34152107|NCT00391612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152108|NCT04119102|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
34152109|NCT02411929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152110|NCT03855683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967973|NCT06278402|NA|SINGLE_GROUP||TREATMENT||NONE||This study includes patients with moderate to severe Alopecia Areata, totalis and universalis. The efficacy of JAK 1/3 inhibitor, Tofacitinib will be assessed by using SALT score (Severity of Alopecia Tool) at Baseline, 06 weeks, 12 weeks and 24 weeks. Oral Tofacitinib given at a dose of 5 mg twice daily after relevant investigations. The data will be analyzed in SPSS version 23.||||
33967974|NCT02791659|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33967975|NCT00660790|||COHORT||PROSPECTIVE|||||||
33967976|NCT05817526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33967977|NCT03658278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33967978|NCT05619042|||COHORT||PROSPECTIVE|||||||
33967979|NCT02945280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967980|NCT00300092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967981|NCT02048397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967982|NCT04203706|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33967983|NCT00830063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33967984|NCT01676584|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33967985|NCT03365921|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33967986|NCT06537492|NA|SINGLE_GROUP||OTHER||NONE||||||
33967987|NCT02177097|||COHORT||RETROSPECTIVE|||||||
33967988|NCT05947552|||CASE_CONTROL||PROSPECTIVE|||||||
33967989|NCT06048328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||parallel randomized controlled trial, with individual randomization to receive the intervention or wait-list control|f|f|f|t
33967990|NCT00586300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967991|NCT04854694|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will try on both the FaceView Mask™ and the conventional surgical N95 respirator in quasi-random order from participant to participant and provide feedback via survey afterward.||||
33967992|NCT02971605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33967993|NCT00111189|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33967994|NCT05478811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group1: NaOCl, Er,Cr:YSSG will be activated by laser during the final irrigation; Group2 (control): Routine final irrigation procedure will be done, NaOCl will not be activated by any method) teeth will be divided into two main groups (n:15).|t|f|f|f
33967995|NCT00001622||||TREATMENT||||||||
33967996|NCT03843437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Fifty children age 6 months to 6 years with moderate to severe eczema will be recruited from the Johns Hopkins pediatric dermatology clinic and randomized (1:1) to be treated with Tencel vs. cotton therapeutic garments in addition to standard eczema care. Randomization will be computer-generated and parents will be blinded to whether the children receive Tencel vs. cotton garments.|t|f|f|t
33967997|NCT05326087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33967998|NCT04409002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33967999|NCT00461500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33968000|NCT03113058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968001|NCT05452538|||COHORT||RETROSPECTIVE|||||||
33875100|NCT01899833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients receive typical imaging agent for rest and stress imaging then receive investigational imaging agent for rest and stress imaging||||
33875101|NCT04002635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875102|NCT01663597|||COHORT||PROSPECTIVE|||||||
33875103|NCT00326209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968002|NCT03465228|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|The participants will be not informed if the LED appliance will be on or off, and the outcomes will be numbers for identification.|The first day, will be explanation of the project and signing of the Informed Consent Term. The participants will go to collect blood samples for analysis creatine kinase and cortisol levels. They will be submitted an anthropometric evaluation, psychometric questionnaires and perform functional tests, and perform of a continuous submaximal exertion test. All these procedures will be performed again at the end of the intervention, and the pain intensity scale will be applied in all meetings with participants (beginning and end of each session). After the evaluations, the participants will be randomized into three experimental groups with 15 participants in each: the first group will be the training group that will perform interval training sessions in addition to continuous training sessions. The second group will perform the same training model, and before the training sessions the LED will be applied. And the third group will only receive the LED application.|t|f|f|t
33968003|NCT02958540|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33968004|NCT04088578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968005|NCT04878978|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single centre open labelled randomised study.||||
33968006|NCT01614613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968007|NCT02370784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968008|NCT00059995||||TREATMENT||NONE||||||
33968009|NCT01916564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33968010|NCT03049150|||COHORT||PROSPECTIVE|||||||
33875104|NCT04209751|||COHORT||PROSPECTIVE|||||||
33875105|NCT03452696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Women||t|f|f|f
33875106|NCT02565030|||COHORT||RETROSPECTIVE|||||||
33875107|NCT01535456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875108|NCT02335827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33875109|NCT04455880|RANDOMIZED|PARALLEL||OTHER||NONE||Group 1 (n= 79, GDM with insulin therapy), Group 2 (n=90, GDM with only diet), Group 3 (n= 150, healthy controls) All patients were above 36 gestational weeks with anterior placenta.||||
33875110|NCT03500900|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33968011|NCT02005640|||||RETROSPECTIVE|||||||
33968012|NCT00097019||||TREATMENT||||||||
33968013|NCT01569503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968014|NCT01698320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968015|NCT02888132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968016|NCT01261520|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33875111|NCT00331474|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875112|NCT03256500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33875113|NCT05158374|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33875114|NCT00905736|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875115|NCT04778254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875116|NCT00975156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875117|NCT04812873|||OTHER||CROSS_SECTIONAL|||||||
33968017|NCT06307808|||COHORT||PROSPECTIVE|||||||
33968018|NCT05470790|||OTHER||CROSS_SECTIONAL|||||||
33968019|NCT04405206|||COHORT||PROSPECTIVE|||||||
33968020|NCT03770169|||CASE_ONLY||PROSPECTIVE|||||||
34152111|NCT05042102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152112|NCT05153213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875118|NCT03294785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875119|NCT03171220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875120|NCT01119170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875121|NCT02365714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875122|NCT05146921|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33875123|NCT03422315|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875124|NCT03729063|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is designed to compare one group of patients who had morning (6-8 am) and evening (5-7 pm) measurements of expired carbon monoxide (COexp) every day during their hospitalization (the twice-daily COexp group) versus a second group who had COexp measurements only the first morning following admission and the morning just prior to discharge (control group). A high potential for arm-contamination led the investigators to exclude a randomised design. The frequent COexp intervention was therefore deployed throughout months 1 and 3 of the four-month inclusion period, while the control intervention was deployed on months 2 and 4.||||
33875125|NCT01505569|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33875126|NCT01183559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875127|NCT05914168|NA|SINGLE_GROUP||OTHER||NONE||||||
33875128|NCT05372302|||CASE_ONLY||PROSPECTIVE|||||||
33875129|NCT00851539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33875130|NCT03841071|||COHORT||PROSPECTIVE|||||||
33875131|NCT03670212|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Double-blinded study. Subjects, the experimenter, research assistants, and MRI technician did not know if the oral doses were active (acute stress condition) or inert (placebo session).|Double-blind, placebo-controlled, and randomized cross-over study design. Each subject completed both the placebo and acute stress experimental sessions.|t|f|t|f
33875132|NCT02131558|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875133|NCT04729036|||COHORT||CROSS_SECTIONAL|||||||
33875134|NCT00223028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875135|NCT03710109|||COHORT||PROSPECTIVE|||||||
33875136|NCT00542269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875137|NCT06337071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33875138|NCT01740375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875139|NCT03422107|||COHORT||PROSPECTIVE|||||||
33875140|NCT01002235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33875141|NCT01394627|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33875142|NCT06090942|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875143|NCT04193007|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33875144|NCT00642915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875145|NCT01202929|||CASE_CONTROL||PROSPECTIVE|||||||
33875146|NCT05537597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The figure-of-eight coils used for active or sham stimulation are similar, including the emitted sound and the scalp tapping sensation.|Patients will be randomised to receive either active or sham-rTMS according to a 2:1 ratio.|t|t|f|t
33875147|NCT03961815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875148|NCT02763202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33875149|NCT06281184|||COHORT||PROSPECTIVE|||||||
33875150|NCT04360070|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33875151|NCT01360554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875152|NCT05084911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33875153|NCT00764595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875154|NCT04253795|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33875155|NCT04059770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968021|NCT06391905|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: Advanced Treatment combined with PCSK9 inhibitor Control: Advanced Treatmentcombined without PCSK9 inhibitor||||
33968022|NCT00686374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968023|NCT06529835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will occur to the subject and the blinded assessor. The blinded assessor will remain blinded from the device that was implanted. For subjects, blinding will be accomplished by informing subjects during the consent process that they may or may not also receive a secondary procedure in which they could have an incision in their leg that is not dependent on the device in which they are randomized to receive. Blinding will be assessed by the use of blinding assessment to both the assessor at the patient at the 12 month follow-up visit.|A total of 80 subjects will be enrolled and randomized using a 1:1 ratio.|t|f|f|t
33875156|NCT02268721|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875157|NCT02285621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33875158|NCT06007300|||COHORT||PROSPECTIVE|||||||
33875159|NCT05627284|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33875160|NCT04052685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968024|NCT06536712|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968025|NCT02367079|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33968026|NCT00648856|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33968027|NCT05658614|RANDOMIZED|PARALLEL||PREVENTION||NONE|open label|"Main objective: to compare the immunological quality of the new vaccination schedule (amplitude and duration) versus the vaccination schedule used in the previous trials, by studying the Sm14 specific antibody response induced both quantitatively and qualitatively. The hypothesis is to obtain a mean response quantitatively higher with the new vaccine schedule.~Secondary objective: safety profile of the two vaccine schedules studied."||||
33968028|NCT05366556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single Blinded|The adult patients will be divided into two as the experimental and control group. Patients in the experimental group will be informed about the using virtual reality glasses during the taking blood. During this process, their anxiety and pain will be assesed. Patients in the study group will be evaluated 2 times, before the intervention and after the intervention, through data collection tools.|t|f|f|f
34152113|NCT04877236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152114|NCT01802307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152115|NCT02040896|||COHORT||PROSPECTIVE|||||||
34152116|NCT04503824|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34152117|NCT01059383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152118|NCT00513721|||CASE_CONTROL||RETROSPECTIVE|||||||
34152119|NCT00859157|||CASE_CONTROL||PROSPECTIVE|||||||
34152120|NCT05875493|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open-label,randomized, 2-cycle,2-period crossover,food effect study||||
34152121|NCT04054271|||OTHER||CROSS_SECTIONAL|||||||
34152122|NCT01843270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152123|NCT03015038|||COHORT||PROSPECTIVE|||||||
34152124|NCT01694836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152125|NCT05017532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152126|NCT00547521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152127|NCT01517581|||COHORT||RETROSPECTIVE|||||||
34152128|NCT02219503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152129|NCT00979225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152130|NCT05079477|RANDOMIZED|PARALLEL||PREVENTION||NONE||This randomized, controlled online study will capture beverage and snack purchases from an online store. These products will be mailed to participants for each of the 4 shopping weeks. Participants' consumption will be measured at the beginning and end of the study. As this is a within-participant study, consumption for each arm will be compared to baseline for that participant (Week 1 shopping).||||
34152131|NCT00961194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34152132|NCT00048100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152133|NCT06459336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152134|NCT02966470|||COHORT||PROSPECTIVE|||||||
34152135|NCT00837226|||||PROSPECTIVE|||||||
34152136|NCT03794674|||COHORT||OTHER|||||||
34152137|NCT00519662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152138|NCT00015951||||TREATMENT||||||||
34152139|NCT05051943|||COHORT||PROSPECTIVE|||||||
34152140|NCT02997982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152141|NCT01854268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152142|NCT00320463|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34152143|NCT01438177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152144|NCT06583577|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|The post-operative soma care nurses and statistician will be blinded to group allocation.|Participants are randomly assigned to two treatment groups. The experimental group will receive preoperative hands on education on stoma care using a new 3D model. The comparator group will receive standard preoperative education.|f|t|f|t
34152145|NCT00870298|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34152146|NCT05529329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Clinical Trial|t|t|f|t
34152147|NCT02607228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152148|NCT04518488|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34152149|NCT04238169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152150|NCT02189681|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34152151|NCT04288700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152152|NCT00098306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152153|NCT05774847|||COHORT||PROSPECTIVE|||||||
34152154|NCT00307866|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756289|NCT04099043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756290|NCT01315509|||CASE_ONLY||PROSPECTIVE|||||||
33756291|NCT03114826|||COHORT||RETROSPECTIVE|||||||
33756292|NCT03399032|||COHORT||PROSPECTIVE|||||||
33756293|NCT01825668|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33756294|NCT00822133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756295|NCT05085626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756296|NCT05943405|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875161|NCT04811456|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875162|NCT04265846|||COHORT||PROSPECTIVE|||||||
33875163|NCT04122014|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875164|NCT05547451|||COHORT||CROSS_SECTIONAL|||||||
33875165|NCT05461612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875166|NCT04914689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33875167|NCT02821871|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875168|NCT04117464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are simple randomized to three experimental conditions (Behavioral activation, Acceptance and commitment therapy and Cognitive-behavior therapy) and a Wait List control group|t|t|f|t
33875169|NCT05288790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a two-arm randomized double blind clinical trial study design.|t|t|t|t
33875170|NCT05789030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875171|NCT05932940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||detection of incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.||||
33968029|NCT06025175|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups Group (A) and group(B)||||
33968030|NCT05213078|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968031|NCT05684250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756297|NCT04110002|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 arm: randomized to injury prevention protocol or control group||||
33756298|NCT01487317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33875172|NCT04555356|||CASE_ONLY||RETROSPECTIVE|||||||
33875173|NCT00910793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894277|NCT03420638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using sealed envelope assignment, the participant will be placed in study Arm 1 or 2. The PI will not be masked because the PI will administer the adjunct treatment or the standard of care only. The outcome assessor will be masked to study group assignment for gathering data from trial participants.|Randomized clinical trial|t|f|f|t
33875174|NCT04176263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessors will be single blinded. Participants will be semi-blinded. The participants will be told that they can be assigned to one of the two forms of treadmill training.They do not know the exact content of the training they would receive and what training is given in the other arm.|Overground turning speed during single and dual-task will be compared between a group who will receive 4 weeks of SBT 3 times a week and a group who will receive TBT in the same dose. Participants will be randomized (1:1) to either the SBT or TBT groups by an independent researcher who is not involved in the measurements of any of the studies using a computerized random number generation technique. The randomization will be stratified based on H\&Y stage and freezing status (freezer/non-freezer).|t|f|f|t
33875175|NCT02295527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875176|NCT01169155|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33875177|NCT06455956|||COHORT||PROSPECTIVE|||||||
33875178|NCT02984527|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33875179|NCT02526459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875180|NCT01820364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875181|NCT05590260|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Study participation will be individually randomized and allocated 1:1 to one of two arms stratified by site. A computer algorithm generated by the data coordinating center (DCC) will create the random assignment to one of the treatment arms based on randomly permuted block design with randomly varied block sizes. Randomization will be stratified based on delivery mode (Cesarean section vs. vaginal birth) and site. The block sizes will be known only by the Data Coordinating Center's personnel.||||
33875182|NCT01696526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33875183|NCT01539681|||COHORT||PROSPECTIVE|||||||
33875184|NCT01770132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875185|NCT01744665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875186|NCT02563847|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33875187|NCT02951871|||||RETROSPECTIVE|||||||
33875188|NCT05479214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33875189|NCT02282943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875190|NCT05209633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded study||t|t|t|t
33875191|NCT00355433|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33875192|NCT01616407||CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33875193|NCT00337870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875194|NCT03997955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875195|NCT00595179|||||RETROSPECTIVE|||||||
33875196|NCT06150235|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875197|NCT01970501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875198|NCT03198052|NA|SINGLE_GROUP||TREATMENT||NONE||Use engineered CAR-T cells to kill cancer cells with certain targets.||||
33875199|NCT02232802|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33875200|NCT04289844|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875201|NCT05438823|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33875202|NCT03507920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875203|NCT05326542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875204|NCT06366802|||COHORT||RETROSPECTIVE|||||||
33875205|NCT00841789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Approximately 200 subjects will be randomized in a 1:1 ratio to receive Etanercept or Placebo. Subjects are randomized after hospital admission and diagnosis of Kawasaki Disease at eight participating sites. The primary analysis time-point is visit 5 (day 44). Sample size calculation is based on initial IVIG refractory rate at Seattle Children's. Assuming a 17.4% refractory rate in the control group and a 4.3% refractory rate in the Etanercept group, 200 subjects will provide 80% power at a 5% 2-sided type I error rate. Analyses will be based on a modified intention to treat population, including all subjects who were randomized and received at least 1 dose of study drug. Efficacy analyses will be based on randomization assignment, and safety analyses will be based on the treatment actually received. The statistical analysis plan will be finalized prior to database lock and study unblinding.|t|t|t|t
33875206|NCT00002300||||TREATMENT||DOUBLE||||||
33875207|NCT01183143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875208|NCT04395339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875209|NCT02955615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875210|NCT03966521|||COHORT||PROSPECTIVE|||||||
33875211|NCT04503954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875212|NCT06407037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875213|NCT03296085|||COHORT||PROSPECTIVE|||||||
33875214|NCT02337400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875215|NCT01263171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875216|NCT00861952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33875217|NCT03001050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875218|NCT04472585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Empty capsule will sub-cutaneous injection of ivermectin will be used|randomized, controlled, multi-armed, open-label, interventional study|t|t|t|t
33875219|NCT03388411|||COHORT||PROSPECTIVE|||||||
33875220|NCT04983914|||COHORT||RETROSPECTIVE|||||||
33875221|NCT00985335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875222|NCT00343668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875223|NCT00163774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875224|NCT01251107|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875225|NCT00072735||||TREATMENT||||||||
33875226|NCT00698243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875227|NCT03577730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a single-center, quadruple-blinded, pilot randomized controlled trial at the University of Michigan Health System.||t|t|t|t
33875228|NCT00639249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875229|NCT02531581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875230|NCT00767650|||||PROSPECTIVE|||||||
33875231|NCT00053417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875232|NCT04203615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A two parallel group, randomized, placebo controlled design will be used. Twenty PD patients will be stimulated in a two weeks long therapeutical sessions (10 sessions). Other twenty PD patients will be stimulated with the same protocol using sham stimulation.|t|t|f|t
33875233|NCT04670185|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875234|NCT05094700|NA|SINGLE_GROUP||OTHER||NONE||||||
33875235|NCT03285737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind|Parallel group design (with repeated measurements within each group)|t|f|f|t
33875236|NCT01142102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875237|NCT00805480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875238|NCT04921735|||COHORT||PROSPECTIVE|||||||
33968032|NCT04193722|RANDOMIZED|PARALLEL||TREATMENT||NONE||Trial within cohorts design||||
33756299|NCT02030782|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33756300|NCT03051971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756301|NCT00637208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756302|NCT00637286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875239|NCT00763815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875240|NCT03971279|||COHORT||PROSPECTIVE|||||||
33875241|NCT03963011|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Infants randomized to the AXR only arm will obtain an AXR as per standard of care. Repeat AXR, if any, will be left to the discretion of the treating neonatologist. In this arm, no BUS study will be performed unless the attending neonatologist decides it is clinically indicated. This situation is expected to be exceedingly rare, as BUS is not part of the standard of care for NEC evaluation. Infants randomized to the AXR and BUS arm will also get an AXR, with repeat AXR left to the discretion of the treating neonatologist. In addition to this standard of care, infants randomized to this arm will receive a BUS as the intervention. This BUS will be ordered at the same time as the initial AXR and will be performed within six hours of the order being placed.||||
33875242|NCT04499261|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875243|NCT05099861|||CASE_CONTROL||PROSPECTIVE|||||||
33875244|NCT00427609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875245|NCT02302482|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33875246|NCT04599777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875247|NCT04840043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind trial|A double-blind, placebo-controlled, randomized study|t|t|t|t
33968033|NCT06331078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968034|NCT03952910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33968035|NCT01956279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968036|NCT00401882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968037|NCT01846247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33968038|NCT05127603|NA|SINGLE_GROUP||TREATMENT||NONE||"Single Case methodology with a baseline (phase A), intervention (phase B) and intervention withdrawal phase (A')~This multiple case study has three phases: (A) A baseline phase of two weeks with no intervention, (B) a treatment phase with 5-7 consultations (offered weekly) and (A') a follow-up 3 months after the last treatment consultation.~The participants are seen as single systems in both the qualitative as the quantitative analyses in an experimental design, using a tailored care physiotherapy intervention, in which the participants act as their own controls."||||
33968039|NCT00003633||||TREATMENT||||||||
33968040|NCT00670878|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33968041|NCT03446274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968042|NCT01802983|||CASE_CONTROL||RETROSPECTIVE|||||||
33968043|NCT01986842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33968044|NCT06353035|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|The research subjects were not randomized or masked to the intervention and control group, because the control group needs volunteers who have no intention of following the yard management instructions advised to the intervention group.|Intervention-control study in which intervention study subjects private yards are rewilded and control receives no treatment.||||
34152155|NCT03238118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and caregivers will be blinded to the intervention and control groups. They will not be blinded to the psychoeducation group.|"A) The first sub-group (n=60) will participate in the intervention group (the attention bias modification training) and will receive psychoeducation; B) The second sub-group (n=60 children) will participate in the attention control condition and will receive psychoeducation; C) The third sub-group (n= 20) will receive only psychoeducation. Children will be randomly assigned to one of these three groups. Both children and parents will be blind to group assignment.~Parents will provide written informed consent for children's participation. This study was approved by the Ethics Committee of Hospital de Clinicas de Porto Alegre."|t|t|f|t
33875248|NCT01923597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875249|NCT03319485|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33875250|NCT02256540|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33875251|NCT04447521|||CASE_ONLY||PROSPECTIVE|||||||
33875252|NCT05476159|||CASE_ONLY||RETROSPECTIVE|||||||
33875253|NCT02812277|||COHORT||RETROSPECTIVE|||||||
33875254|NCT01545856|||COHORT||RETROSPECTIVE|||||||
34152156|NCT00289328|||||PROSPECTIVE|||||||
34152157|NCT01297582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152158|NCT02478528|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756303|NCT00526630|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33756304|NCT00003796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875255|NCT06205888|||CASE_CONTROL||RETROSPECTIVE|||||||
33875256|NCT01381432|||||PROSPECTIVE|||||||
33875257|NCT00178152|||CASE_CONTROL||RETROSPECTIVE|||||||
33875258|NCT01239342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875259|NCT05482685|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33875260|NCT04865328|||COHORT||PROSPECTIVE|||||||
33875261|NCT03332602|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33875262|NCT03681119|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33875263|NCT04292509|RANDOMIZED|CROSSOVER||OTHER||NONE||open-label cross-over RCT||||
33875264|NCT05062863|||COHORT||PROSPECTIVE|||||||
33875265|NCT05622526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33875266|NCT04714333|||COHORT||PROSPECTIVE|||||||
33875267|NCT00330902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875268|NCT00250835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875269|NCT04317495|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875270|NCT00156364|||COHORT||PROSPECTIVE|||||||
33875271|NCT00002788||||TREATMENT||||||||
33875272|NCT06364111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875273|NCT00718783|||CASE_ONLY||PROSPECTIVE|||||||
33875274|NCT02162524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875275|NCT00088374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875276|NCT03456752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875277|NCT03673774|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33875278|NCT02443883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875279|NCT00556452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875280|NCT05940779|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33875281|NCT05217745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875282|NCT05491356|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33875283|NCT03473288|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33875284|NCT01826253|||COHORT||RETROSPECTIVE|||||||
33875285|NCT04715061|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Each participant performed 3 experimental conditions (rest, moderate continuous training and interval training).||||
33875286|NCT01982929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875287|NCT04082871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This single-blind parallel randomized controlled trial|"Following recruitment, participants were randomized into two groups (1:1 randomization), active and control, using the computer-generated randomization program (www.randomization.com). The researcher generated the allocation sequence, and assigned the participants to their group. Participant who came into the clinic during the clinic's working hours (Sunday to Thursday, from 9 am to 1 pm) were approached consecutively and allocated to the active or control group. Participants were not aware of which study group they were assigned to; only the researcher was aware of each patient's group assignment.~Participants in the active and control groups completed a baseline and follow-up (3 months from baseline) visits at the same outpatient psychiatric clinic with the researcher conducting the interview using the study tool to complete the MMR process."|t|f|f|f
33875288|NCT02343172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875289|NCT00257179|||NATURAL_HISTORY||OTHER|||||||
33875290|NCT04852107|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33875291|NCT02948465|||CASE_ONLY||PROSPECTIVE|||||||
33875292|NCT01083004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875293|NCT00428142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875294|NCT05309187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875295|NCT05523037|||COHORT||PROSPECTIVE|||||||
33875296|NCT04594590|||CASE_ONLY||OTHER|||||||
33875297|NCT05923632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Who will be assigned to the experimental or control group will be determined by using the https://www.randomizer.org/ site. Blinding will be done at the beginning of the research when assigning groups and in the statistics and reporting part. At the end of the study, measures will be taken to prevent bias in the measurement in the coding of the data and the evaluation of the statistician. The statistician will not be informed whether the groups are experiments or controls. To avoid bias in the evaluation of data; It is thought that the statistical analyzes of the coded data in the prepared database will be done by a statistics and operations expert independent of the researcher. Data entries will be entered with A and B codes without specifying the experimental or control group, and the analysis of the data will be done by coding as A and B groups. After the statistical analysis, the coding of the experimental and control groups will be explained."|Parallel Assignment Randomized Controlled Trial|t|f|f|t
33875298|NCT04610021|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||prospective randomized with intervention study.||||
33875299|NCT04668859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875300|NCT04106700|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial with a single arm||||
33875301|NCT06029621|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|RATS versus VATS||||
33875302|NCT05000385|||OTHER||CROSS_SECTIONAL|||||||
33875303|NCT00500526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875304|NCT02309229|||COHORT||PROSPECTIVE|||||||
33894278|NCT01967225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894279|NCT00278629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894280|NCT02541630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894281|NCT04457440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894282|NCT03268798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875305|NCT04870528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants are suffering from lower limb burn with second-degree burn ( Partial thickness of thermal injury) and total body surface area (TBSA) from 20% to 35%.The care provider are burn center stuff. The investigator is a physical therapist(myself).|"In this study, the patients will be assigned into two equal groups :~study group which will receive (Pulsed Electromagnetic Field therapy and quadriceps strengthening exercises), control group which will receive (Quadriceps strengthening exercises)."|t|t|t|f
33875306|NCT01154374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875307|NCT05578729|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single surgical mask group (n=30) Double surgical mask group (n=30) N95 mask group (n=31)|f|f|f|t
33875308|NCT02271828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875309|NCT06494189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875310|NCT04342975|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"This study is a single-center, prospective, randomized, double-blinded, placebo-controlled phase II clinical trial to evaluate the efficacy of NAD+ supplementation with Basis™ (Nicotinamide Riboside and Pterostilbene) in preventing acute kidney injury (AKI) in patients undergoing complex aortic aneurysm repair and open aortic arch reconstruction."|t|f|t|f
33875311|NCT00396175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875312|NCT05243264|NA|SINGLE_GROUP||TREATMENT||NONE||The purpose of this research project is to assess the feasibility, acceptability, and preliminary effects of a novel internet-based cognitive behavioral therapy (iCBT) program called Empower@Home. The program is intended to decrease depression in participants by encouraging them to participate in meaningful and enjoyable activities while challenging problematic thinking patterns.||||
33875313|NCT02830100|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33756305|NCT05554068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875314|NCT04503239|||CASE_CONTROL||PROSPECTIVE|||||||
33875315|NCT06503939|||COHORT||RETROSPECTIVE|||||||
33875316|NCT01527214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33875317|NCT00579852|||CASE_ONLY||PROSPECTIVE|||||||
33875318|NCT05941078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756306|NCT00919074|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33756307|NCT05011994|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756308|NCT03384173|||COHORT||PROSPECTIVE|||||||
33756309|NCT05311800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data collected on the volunteers will be made anonymous.|2 groups : running vs cycling|t|f|f|f
33756310|NCT01273025|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33756311|NCT01342705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756312|NCT02450266|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33756313|NCT03313518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756314|NCT01547897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756315|NCT00868465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33756316|NCT06347094|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Metabotypes will also be masked to participants and investigators, while the dietary treatment will not.||f|f|f|t
33756317|NCT00428467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33756318|NCT01435863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756319|NCT00178425|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756320|NCT02508467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875319|NCT04793256|RANDOMIZED|PARALLEL||PREVENTION||NONE|No one is blinded ( unfortunately) as fissure sealant will be obvious|"The study will be randomized, allocation-blinded, two-arm, parallel-group trial.~The participants will be randomized on a 1: 1 allocation ratio to receive one of the following interventions:~* Resin-based fissure sealant FS.~* Fluoride varnish FV"||||
33894283|NCT05207150|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33875320|NCT03998046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients will be randomized to either Basic Resources and Services or the C3PO intervention arm. Although patients will be aware of the specific forms of support they are receiving throughout the trial, each individual will not be aware that they are part of a randomized experiment and will not know that other patients may be receiving different levels of support. For this reason, the non-concealed nature of the behavioral support intervention for participating patients should not introduce bias. Investigators and outcome assessors will not be aware of intervention assignment during the study conduct or evaluation phase.|"The active intervention C3PO involves enhanced use of pragmatic electronic health record system technologies and members of the primary care workforce to increase supportive accountability and problem solving support for weight loss goals and behavior, which in turn will lead to routine self-weighing, increased take up into intensive community programs, and increased adoption and maintenance of healthy eating and physical activity behaviors that collectively lead to greater weight loss at a population level."|f|f|t|t
33875321|NCT00920673|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875322|NCT00283114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875323|NCT06098768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875324|NCT04460976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking at baseline of both participant and care-provider.||t|t|f|f
33875325|NCT04957264|||COHORT||PROSPECTIVE|||||||
33875326|NCT06267196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875327|NCT00729456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875328|NCT02180360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875329|NCT01073332|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33875330|NCT04986397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875331|NCT02181829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875332|NCT04994899|||OTHER||CROSS_SECTIONAL|||||||
33875333|NCT04318899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875334|NCT05344521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind study where the participant will not know which area is covered with Integra®-SC.|Integra®-SC will be applied to one area of the body and acellular Integra® will be applied to another. Determination of the location of the Integra® control or Integra®-SC application will be assigned using simple randomization. The wound areas will be appropriately matched for body surface area and depth of the wound.|t|f|f|f
33875335|NCT05666427|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33875336|NCT01520935|||||RETROSPECTIVE|||||||
33875337|NCT00330382|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33968045|NCT03090009|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Both patient and investigator will blinded to the identity of the medication given.|The study design is random controlled double blind clinical trial|t|f|t|f
33968046|NCT06374381|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Outcome assessors will be masked to randomization condition.||f|f|f|t
33968047|NCT00002189||||TREATMENT||||||||
33968048|NCT01007981|||COHORT||PROSPECTIVE|||||||
33968049|NCT04664608|||COHORT||PROSPECTIVE|||||||
33968050|NCT01987700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968051|NCT02189694|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068316|NCT05527899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|We will conduct a double-blind, randomized, and controlled trial (RCT) in elderly NH residents with low serum Zn levels (\< 70 μg/dL ) to evaluate the efficacy of 1 y of 30 or 60 mg/d Zn supplementation on serum and T cell Zn levels, and T cell number and function. There will be a placebo group. Neither participants, nor Investgators or Outcome Assessors will be aware of treatment group. Masking will be done over RedCap Software and participants will be assigned to groups A, B, or C.|We will conduct a randomized, double-blind, placebo-controlled trial (RCT) in elderly NH residents with low serum Zn levels to evaluate the efficacy of 1 y of Zn supplementation (dose to be determined during R34 planning grant) in the prevention of PNA. Eligible subjects will be randomly assigned to one of two groups: both groups will receive a capsule containing ½ Recommended Dietary Allowance (RDA) of all the essential micronutrients, including 5 mg of elemental Zn; the Zn-supplemented group's capsule will contain an additional mg Zn gluconate (total equiv. of dose to be determined during R34 grant). Suppl. duration will be 12 mo to account for seasonal variations in the incidence of PNA.|t|t|t|t
34068317|NCT03992898|||COHORT||RETROSPECTIVE|||||||
34068318|NCT00441038|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34068319|NCT04511000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068320|NCT05395533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068321|NCT05987592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"The study PI, statistician, co-investigators, and all personnel who are involved in endpoint assessments, will be blinded.~In addition, blinded reports will be provided to the Wake Forest Data and Safety Monitoring Board (DSMB) for safety monitoring."|Two-arm parallel assignment in which one group receives treatment A and the other group receives treatment B|t|t|t|t
34068322|NCT02851316|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34068323|NCT02612545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068324|NCT05037890|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Colour-coded margarin tubs|Randomized, placebo-controlled, double blinded study with a run-period of 2 weeks, an intervention period of 6 months and a wash-out period of 1 month.|t|f|t|t
34068325|NCT00826150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068326|NCT00565890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068327|NCT04501016|NA|SINGLE_GROUP||TREATMENT||NONE||All tobacco users will receive a tailored pharmacological and behavioral intervention. The specific counseling protocol will vary depending upon their response to treatment and initial success with quitting.||||
34068328|NCT04271176|||OTHER||RETROSPECTIVE|||||||
34068329|NCT02483325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068330|NCT00255840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068331|NCT02121353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756321|NCT01223157|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756322|NCT03143725|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33756323|NCT00279669|||CASE_ONLY||CROSS_SECTIONAL|||||||
33756324|NCT01417429|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33756325|NCT02001194|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33756326|NCT03685591|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33756327|NCT06088524|||OTHER||CROSS_SECTIONAL|||||||
33968052|NCT04618835|||COHORT||PROSPECTIVE|||||||
33968053|NCT03764410|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33968054|NCT03654690|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants are not informed of their condition assignment, but may infer it via the procedures they are provided. Both investigators and staff assessing outcomes are blinded to participants' group assignments.||t|f|t|t
33968055|NCT06371716|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|pathologists (two different pathologist blinded about the power of RFA applied and respect to the other pathologist) will evaluate the effect of ablation (coagulative necrosis at microscopic evaluation)|"15 resected PDAC without neoadjuvant treatment 15 resected PDAC with neoadjuvant treatment 15 resected neuroendocrine tumors~Each group (15 patients each) Subgroup A: 10 W (5 patients) Subgroup B: 30 W (5 patients) Subgroup C: 50 W (5 patients)"|t|f|f|t
33968056|NCT03951870|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Both participants and study personnel (Investigators and outcomes assessor) in the two active experimental arms (Mesolimbic NF and Control NF) will be blinded to group allocation.|"1. Experimental arm: fMRI neurofeedback to mesolimbic system (the ventral tegmental area, and bilateral ventral striatum).~2. Active control arm: fMRI neurofeedback to a control network.~3. Natural history arm: assessment of immunological response to Hepatitis B without neurofeedback manipulation."|t|f|t|t
33968057|NCT02891564|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Randomized Control Trial|f|f|f|t
33968058|NCT04733352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968059|NCT01548950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875338|NCT06377787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875339|NCT04707157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875340|NCT02706821|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33875341|NCT03875898|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33875342|NCT02774837|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm parallel study||||
33875343|NCT03046875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33875344|NCT06494722|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33875345|NCT01114074|||||CROSS_SECTIONAL|||||||
33875346|NCT01584973|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33875347|NCT01086800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894284|NCT05087030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind design will be used during the main and transition periods.||t|t|f|f
33894285|NCT01241539|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33894286|NCT01050621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894287|NCT03449888|||COHORT||PROSPECTIVE|||||||
33894288|NCT00543647|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33894289|NCT04237649|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33894290|NCT03456479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968060|NCT00198978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968061|NCT00662714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968062|NCT02838290|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33968063|NCT05031871|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968064|NCT02678221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875348|NCT04233190|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the first study period (Period 1), patients with moderate to severe persistent asthma according to GINA criteria, with or without COPD, will be randomized at a 1: 1 ratio to receive formoterol 12mcg / budesonide 400mcg Eurofarma or Alenia® 12mcg / 400mcg during 12 weeks Participants who maintain asthma control at the end of this treatment period (no more than one exacerbation during this period) will be included in Period 2, in which the dose of each investigational product will be reduced (step-down), and the patients will receive formoterol 6mcg / budesonide 200mcg Eurofarma or Alenia® 6mcg / 200mcg, respectively, for an additional 12 weeks. The primary non-inferiority assessment will be performed at the end of 24 weeks of treatment, with intermediate assessment at the end of week 12.||||
33875349|NCT02177968|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875350|NCT02592239|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875351|NCT01007578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875352|NCT04432883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33875353|NCT01389752|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875354|NCT01227733|||COHORT||RETROSPECTIVE|||||||
33875355|NCT00583362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968065|NCT03455023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968066|NCT03706326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968067|NCT04318652|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968068|NCT00967200|||COHORT||RETROSPECTIVE|||||||
33968069|NCT04928911|||COHORT||PROSPECTIVE|||||||
33968070|NCT05127811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968071|NCT02448472|||CASE_ONLY||PROSPECTIVE|||||||
33968072|NCT01919957|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968073|NCT02767622|||CASE_CONTROL||PROSPECTIVE|||||||
33968074|NCT04323007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968075|NCT03973996|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33968076|NCT00270699|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33968077|NCT04134975|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33968078|NCT05482672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study pharmacist that prepared the randomization schedule will meet with the pre-specified unblinded study personnel prior to the site initiation visit. The unblinded personnel will then prepare sealed envelopes that contain each subject's group assignment.~The investigators will designate, a priori, study personnel that will be unblinded. These unblinded personnel will be directly involved with maintaining the drug log and communicating with participants to schedule virtual mind-body sessions. The unblinded pharmacist/coordinator will access the actual treatment assignment but both blinded study personnel and the patient will not know the patient's treatment assignment. The Investigator, participant, patient assessors, laboratory personnel, and statistician will remain blinded throughout the study."||t|t|t|t
33968079|NCT01810926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968080|NCT01107080|||COHORT||PROSPECTIVE|||||||
33968081|NCT06232863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968082|NCT01305317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968083|NCT03622333|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968084|NCT01574599|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33968085|NCT04362033|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Patients will be submitted to two different fluid responsiveness maneuvers in a cross over randomization.||||
33968086|NCT01513785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968087|NCT01418729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968088|NCT00103103||||TREATMENT||NONE||||||
33968089|NCT00437281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068332|NCT04848246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessor for tuberculosis outcomes at the study site were blinded in terms of intervention allocation|A total of three groups, two intervention and one control|f|f|f|t
33875356|NCT01682135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875357|NCT03994939|RANDOMIZED|PARALLEL||OTHER||SINGLE|A computer random number generation program was used to create a randomly permutated scheme that assigned specific subject identification numbers to either the experimental or passive control group in a one-to-one ratio. An allocation sequence was generated by the principal investigator. Each experimental/control group allocation sequence was placed in a sealed envelope which remained concealed until after participants had enrolled into the study. After the baseline was completed, the sealed envelope was opened with the family's allocation tied to their specific ID. Data collectors administering the immediate and delayed follow-up surveys were blinded to the condition of participants.|Two-arm parallel RCT designed to test the efficacy of a teen pregnancy prevention program conducted in the Rio Grande Valley from 2013-2018. Parent-adolescent dyads were randomly assigned to either a passive control group that received no intervention or an experimental group which received the promotor delivered family-based SRH prevention program Families Talking Together (FTT) with added Affordable Care Act (ACA) module.|f|f|f|t
33875358|NCT05618821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875359|NCT04091529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875360|NCT02821702|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875361|NCT01040559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968090|NCT04728087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed, blinded envelopes will be provided by the Sponsor (Hemostasis LLC). The Investigator/designee only opens the randomization envelope after the subject has been deemed eligible for the study and an eligible TBS has been identified in order to reduce potential bias.||t|f|f|f
34068333|NCT00463125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068334|NCT00683761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068335|NCT00004832|RANDOMIZED|||TREATMENT||DOUBLE||||||
34068336|NCT04844983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. All subjects, investigators, and site staff (except unblinded pharmacist or designated site staff) in the study will be blinded to the treatment assignment.|"Part 1: 40 subjects randomized in a 1:1:1:1 ratio to receive 6 weeks of treatment of placebo, 30 ug, 60 ug, or 90 ug of STP705. Enrollment will be temporarily stopped after the 40th subject. Interim Analysis will be done for dose response assessment and selection of the 2 doses for Part 2 of the study.~Part 2: 60 additional subjects will be randomized in a 1:1:1 ratio to receive placebo or one of the 2 selected STP705 doses."|t|f|t|f
34068337|NCT04498039|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE||"The study is a within-subject blinded randomized control design. Twenty chronic MS subjects with an identified gait disturbance were assigned to either an active or control group. Both groups completed a 14-week intervention program using a standardized combination of exercise and a device that provided electrical stimulation to the tongue. Those in the active group received electrical stimulation on the tongue that they could perceive.~Those in the control group used a device that did not provide a physiologically significant stimulus and was not perceivable. Subjects were assessed with the Dynamic Gait Index (DGI)."|t|t|f|t
34068338|NCT02550080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34068339|NCT05446220|RANDOMIZED|PARALLEL||PREVENTION||NONE||Follow-up study on healthy lifestyle intervention during pregnancy (randomized controlled trial - TOP study) 12 years after the intervention.||||
33875362|NCT01250015|||||PROSPECTIVE|||||||
33875363|NCT01793155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875364|NCT05447494|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Phase 2 is blinded to dose group. Except for the non-blind team, no other participants associated with this study should attempt to learn the treatment group assignment or which study treatment they are receiving. The unblinding of all subjects will take place after database lock.||t|t|t|t
33875365|NCT00339391|||COHORT||OTHER|||||||
33875366|NCT02054026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875367|NCT00549458|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33875368|NCT01854619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875369|NCT05461911|||CASE_CONTROL||PROSPECTIVE|||||||
33968091|NCT06544772|NA|SINGLE_GROUP||OTHER||NONE||||||
33968092|NCT00310778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968093|NCT06426758|||COHORT||PROSPECTIVE|||||||
33968094|NCT00475852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968095|NCT05017493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968096|NCT04351282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968097|NCT00911859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968098|NCT01306461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068340|NCT01197209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068341|NCT00459368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068342|NCT04641533|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The random allocation list was generated by a periodontist (EEA), a clinical staff enrolled patients according to their reference date. The first allocation on the list was assigned to the right mandibular molar for each patient by the oral surgeon (SÇ).|Prospective within person randomised split-mouth study. Left and right surgical sites for each participant were randomized using an online generated list to determine test and positive control LM3. (http://www.randomization.com). LM2s and LM3 extraction sockets were divided into two groups: a test group (extraction sockets filled with L-PRF membranes + DPSCs) and a control group (extraction sockets filled with L-PRF membranes).|f|f|t|t
34068343|NCT04385004|||CASE_ONLY||OTHER|||||||
34068344|NCT06186596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068345|NCT02113007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068346|NCT03792542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068347|NCT01378715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068348|NCT00903578|||||PROSPECTIVE|||||||
34068349|NCT05208268|||COHORT||PROSPECTIVE|||||||
34068350|NCT00043277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875370|NCT02872766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875371|NCT00482430|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33875372|NCT02613390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875373|NCT01358409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875374|NCT00473707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875375|NCT05782621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|Acupoint Focused Ultrasound and Laserpuncture|f|f|t|t
33875376|NCT03045562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875377|NCT03775421|NA|SINGLE_GROUP||TREATMENT||NONE||The study is designed as an open-label (OL), single-arm, multicenter long-term trial in which all adolescent (≥ 12 years) and adult male and female subjects who had previously completed in the parent RUBATO DB study (AC-055H301, NCT03153137) will enroll. The primary objective of the study is to assess the long-term safety and tolerability of macitentan. All efficacy endpoints including the ones listed below are considered as exploratory in nature.||||
33875378|NCT02390011|||COHORT||PROSPECTIVE|||||||
33875379|NCT00665457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875380|NCT04220957|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33875381|NCT00562588||PARALLEL||TREATMENT||||||||
33875382|NCT04036968|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|Study drug administration will be concealed from all study staff and participants to prevent bias in outcomes.|Within-subject study|t|f|t|t
33875383|NCT06155370|||OTHER||CROSS_SECTIONAL|||||||
33875384|NCT03976011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875385|NCT04716790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinician who performs the cures, photographs and data collection is different from the clinician who performs the application of ultrasound debridement. Therefore, the evaluator will be blinded.|A randomized and controlled parallel clinical trial|f|f|t|f
33875386|NCT05517642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Observer-blind clinical trial|Subjects will be randomized in a ratio of 1:1 to receive a second booster dose of IH Convidecia vaccine (treatment arm), or a second booster dose of mRNA vaccine BNT162b2 (Pfizer).|f|f|t|f
33875387|NCT00301951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875388|NCT05430035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968099|NCT03016182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33968100|NCT04031287|||CASE_ONLY||PROSPECTIVE|||||||
33968101|NCT03569254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment randomized controlled clinical trial with preterm or low birth weight infants who have low risk hyperbilirubinemia requiring phototherapy||||
33968102|NCT03645070|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33968103|NCT01255228|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33875389|NCT00631371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875390|NCT03894930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33875391|NCT00205855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875392|NCT03283189|||OTHER||CROSS_SECTIONAL|||||||
33875393|NCT02312635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756328|NCT04334226|||COHORT||PROSPECTIVE|||||||
33756329|NCT03527394|||COHORT||PROSPECTIVE|||||||
33756330|NCT05980182|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756331|NCT06258018|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The 3+3 method will be followed in the safety run-in."||||
33756332|NCT01446666|||COHORT||PROSPECTIVE|||||||
33756333|NCT00707265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756334|NCT01797679|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33756335|NCT03026790|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33756336|NCT06208748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756337|NCT02365519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756338|NCT03655795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756339|NCT05696210|||CASE_CONTROL||RETROSPECTIVE|||||||
33756340|NCT03319537|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is a single institution trial with two cohorts to test the efficacy of the NEDD8 inhibitor, pevonedistat as a single agent in patients with NF2 mutant MM (Cohort 1), and also to test the safety of pevonedistat in combination with standard chemotherapy, pemetrexed/cisplatin (Cohort 2).||||
33756341|NCT03248375|NA|SINGLE_GROUP||TREATMENT||NONE||Individuals with the targeted medical condition is given the experimental therapy and then followed over time to observe their response.||||
33756342|NCT01418274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756343|NCT04241094|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial||||
33756344|NCT04023864|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33756345|NCT00112879||||TREATMENT||||||||
33756346|NCT01782443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756347|NCT01201057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756348|NCT02244255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756349|NCT05183022|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective, one-month, three-visit study will refit all participants into Total30 Sphere contact lenses.||||
33756350|NCT01550198|||COHORT||PROSPECTIVE|||||||
33756351|NCT06132555|||CASE_ONLY||RETROSPECTIVE|||||||
33756352|NCT03033654|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756353|NCT06380335|||OTHER||PROSPECTIVE|||||||
33756354|NCT04791501|||COHORT||PROSPECTIVE|||||||
33756355|NCT00203359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756356|NCT06246786|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single arm, non-randomized, pre-surgical clinical trial||||
33756357|NCT01385345|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33756358|NCT01357616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756359|NCT00611858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756360|NCT02375295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756361|NCT02978755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* phase 1 escalation GM102 single agent~* phase 1 escalation GM102 combined with paclitaxel and carboplatin~* phase 1b: 3 parallel expansion cohorts at the recommended dose of GM102 single agent"||||
33875394|NCT02806297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875395|NCT00599040|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33875396|NCT02586675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875397|NCT05468268|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor) We will implement a randomized, non-pharmacological study, with a double-blind certified medical device (neither the patient nor the clinician / researcher who will carry out the evaluations will be aware of the group to which the patient has been assigned).|"Factorial Assignment 40 patients with pAD. Patients randomly assigned to 1 of 2 rTMS protocols (20 pAD participants real rTMS and 20 sham rTMS). Patients will be balanced using MoCA and age matching to create homogeneous groups.~Protocols:~1. 20 Hz rTMS~1. Sham rTMS Patients will undergo a clinical, neuropsychological, and neurophysiological evaluation before the start of treatment (baseline, t0), at the end of the rTMS stimulation phase (t1), after 3 (t2) and 6 months (t3) from the end of treatment."|t|t|f|t
33875398|NCT04791774|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33875399|NCT05599334|||COHORT||RETROSPECTIVE|||||||
33875400|NCT01314677|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875401|NCT05744999|||CASE_ONLY||RETROSPECTIVE|||||||
33875402|NCT00731900|||CASE_ONLY||PROSPECTIVE|||||||
33756362|NCT01445652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756363|NCT04365595|||CASE_ONLY||PROSPECTIVE|||||||
33756364|NCT00979979|||CASE_ONLY||CROSS_SECTIONAL|||||||
33756365|NCT02145221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33756366|NCT03084666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In this study, patients undergoing live donor kidney transplantation will be allocated to the control group or remote ischemic preconditioning group (RIPC). RIPC is the utilization of short periods of ischemia to provide protection of the myocardium or other organ (i.e. kidney) from a subsequent ischemic event.|t|f|f|f
33756367|NCT05128643|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756368|NCT02009670|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33756369|NCT04172155|||COHORT||PROSPECTIVE|||||||
33875403|NCT04217187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875404|NCT05296187|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33875405|NCT03233555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875406|NCT05030012|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This study is unblinded, as there is a distinct difference in modality control between automated and manual modes. Clinical staff are instructed to perform FiO2 adjustments as required, regardless of the study arm.|This study will be a prospective, multi-center, randomized, crossover trial evaluating automated oxygen titration versus manual titration in maintaining oxygen saturation levels in preterm infants requiring noninvasive ventilatory support via high velocity nasal insufflation (HVNI).||||
33875407|NCT04096196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875408|NCT00015977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875409|NCT06096597|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|At time of surgery, the surgeon will be given a sealed envelope containing a sterile syringe of either 10 mL of 0.9% preservative-free sodium chloride or 100 mg of commercially available micronized AM (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride||t|t|t|f
33875410|NCT01696240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875411|NCT03162770|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Behavioral: Mindfulness meditation practice This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in hemodialysis session. It will last for 12 weeks, with trainings of 15 to 25 minutes, three times a week.~No Intervention: Control App This group will observe their psychological and physical condition (levels of stress and well-being) during their daily activities and social interactions."||||
33875412|NCT01252901|||COHORT||RETROSPECTIVE|||||||
33756370|NCT06517667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|0.20% Cross-linked hyaluronic acid tear substitute and 0.15% hyaluronic acid tear substitute are transparent, with no special smell and the bottles were identical in appearance such that patients, investigators and care provider were masked to treatment assignment.|Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid tear substitute or 0.15% hyaluronic acid A tear substitute into each eye 3 times per day for 3 months.|t|t|f|f
33756371|NCT03824379|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled open label study||||
33756372|NCT00004339|RANDOMIZED|||TREATMENT||DOUBLE||||||
33756373|NCT01342224|NA|SINGLE_GROUP||OTHER||NONE||||||
33756374|NCT02889133|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33756375|NCT00596739|||COHORT||PROSPECTIVE|||||||
33756376|NCT02178605|||COHORT||PROSPECTIVE|||||||
33756377|NCT05522725|NON_RANDOMIZED|CROSSOVER||PREVENTION||||We conducted a clustered crossover trial at Shamir medical center from October 20, 2016 to January 19, 2018. Clusters were randomly assigned to use either single-use quaternary ammonium-based wipes (Clinell®; Watford, UK) or standard practices (reusable cloths, buckets and bleach (hypochlorite 1,000-5,000 ppm)) for cleaning of high-touch surfaces. Six-month intervention periods were implemented in alternating sequence, separated by a 4-week washout period. Five high-touch surfaces were monitored by fluorescent markers (EvaluClean®; Watford, UK), and for the presence of MDRO. Study outcomes were compared between periods using generalized estimating equations, Poisson regression and Cox proportional hazards models.||||
33756378|NCT01930357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33756379|NCT01104740|||COHORT||PROSPECTIVE|||||||
33756380|NCT04202939|||COHORT||CROSS_SECTIONAL|||||||
33756381|NCT02080780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756382|NCT02098980|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33756383|NCT06275152|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Only Research Assistant will be unblinded. Participant, clinical team, PI, etc. will all be blinded to the randomization group.|randomized controlled pilot study|t|t|t|t
33756384|NCT04686786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756385|NCT04334473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants are assigned to the same interventions. All will undergo pre- \& postoperative assessment, cataract surgery.||||
33756386|NCT01619202|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875413|NCT03334890|||CASE_ONLY||PROSPECTIVE|||||||
33875414|NCT04671706|||OTHER||OTHER|||||||
33875415|NCT03239366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is double blind, randomized and placebo controlled. The clinical and operational teams from both MHI and BioK+ are blinded. Treatment codes will be available at the research pharmacy from the MHI.|This study will evaluate the effects of Bio-K+50B® at a dosage of 100 billion (B) colony forming units (CFU) daily for 12 weeks in improving glycemic control in patients with Type 2 diabetes (T2D) population when compared to placebo.|t|t|t|t
33875416|NCT01320488|||COHORT||PROSPECTIVE|||||||
33968104|NCT04468087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study for participants of the same active drug and researchers. Both participant and investigator can know, after randomization, which medication they were allocated to. However, none will know whether the capsule to be administered is active or placebo, ensuring blinding within that specific group to which the participant was allocated.|"Randomized, multicenter, multi-arm, multi-stage, study. Adults, COVID-19 confirmed by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) or SARS-Cov2 Antigen hospitalized patients with ≤ 9 days duration of symptoms and SpO2\<=94% will be randomly assigned to receive antivirals with potential effectiveness for SARS-CoV-2.~The study is planned to be an adaptive phase II / III study. The phase II will be divided into 2 stages: first and second stages. First stage will allocate patients into a 3:3:3:1:1:1 allocation ratio (5 for each treatment group and 1 for placebo) and second stage will allocate into 2:2:1:1 (2 for each treatment group and 1 for placebo). The phase 3 study will then proceed in a 2:1 allocation (2 treatments for each placebo)."|t|t|t|t
33968105|NCT00657878|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968106|NCT04675060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968107|NCT03187483|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33968108|NCT00440375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875417|NCT05817877|||OTHER||PROSPECTIVE|||||||
33875418|NCT02520232|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875419|NCT00814775|RANDOMIZED|PARALLEL||||NONE||||||
33875420|NCT03067883|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, cohort, open label trial||||
33875421|NCT00248859|||COHORT||PROSPECTIVE|||||||
33875422|NCT00544895|||COHORT||PROSPECTIVE|||||||
33968109|NCT02207647|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33968110|NCT01502345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33968111|NCT02947282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968112|NCT05529771|||COHORT||OTHER|||||||
33968113|NCT05729256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Trial procedures designed so that the post-intervention assessor is blind to condition|Participants randomly assigned to either intervention or control|f|f|f|t
33875423|NCT05972811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The application will be made by the researcher. However, pain assessment will be done by the nurse who cares for the patient.|Prospective, parallel randomized controlled clinical trial|f|t|f|f
33875424|NCT02132507|||COHORT||PROSPECTIVE|||||||
33875425|NCT04646642|||COHORT||PROSPECTIVE|||||||
33875426|NCT00435838|||||RETROSPECTIVE|||||||
33875427|NCT04739514|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875428|NCT02193074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068351|NCT05472571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068352|NCT00119483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33756387|NCT03616184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756388|NCT00777374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756389|NCT04218448|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33756390|NCT01602406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756391|NCT05613738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756392|NCT00990717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875429|NCT01014689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875430|NCT01263600|||COHORT||PROSPECTIVE|||||||
33875431|NCT01888185|||CASE_CONTROL||PROSPECTIVE|||||||
33968114|NCT04733235|||COHORT||PROSPECTIVE|||||||
33968115|NCT00190307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33875432|NCT05071950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875433|NCT00576043|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33875434|NCT01197404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968116|NCT01991977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968117|NCT02292433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34068353|NCT03581955|RANDOMIZED|CROSSOVER||OTHER||NONE||The present project is a randomized, controlled, crossover study with 12 subjects. A cross-over design has been selected as each subject can serve as his/her own control thereby minimizing variations. The intervention order was randomized. The study design does not allow blinding as intervention is the ingestion of different foods.In this study, we assessed the metabolomic profiles of human biofluids after consumption of two different foods: banana (240g peeled fruit) and tomato (300g fresh fruit) in order to identify novel biomarkers for each food. As a control diet, a high energy high protein drink, Fresubin ® 2kcal fiber (Fresinius kabi) was used. The study comprised three dietary interventions of 4 days each and a wash-out period no shorter than 3 days.||||
34068354|NCT00329745|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34068355|NCT00335855|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756393|NCT03233802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators are blind to treatment conditions|3 Group randomized clinical trial with parallel treatments|f|f|t|f
33756394|NCT06490757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756395|NCT04679402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The only person who will know the breathing gas is the trial coordinator. Since carbon monoxide is a colorless, tasteless gas, the subject will be unaware of the group they are in. The gas labeling will be blinded.|Mixed model with repeated measures|t|f|t|t
33756396|NCT02342886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756397|NCT05399680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756398|NCT06217757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756399|NCT04444037|||CASE_CONTROL||RETROSPECTIVE|||||||
33875435|NCT01659008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875436|NCT05807061|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33875437|NCT00003642||||TREATMENT||||||||
33875438|NCT03724864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33875439|NCT04823104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875440|NCT01202331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875441|NCT01033734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968118|NCT05547815|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068356|NCT01137656|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34068357|NCT06478368|||COHORT||PROSPECTIVE|||||||
34068358|NCT04805164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068359|NCT00581984|||CASE_ONLY||PROSPECTIVE|||||||
34068360|NCT02703376|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756400|NCT03751631|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|There were no differences in the presentation of drug administered and all study personnel conducting ophthalmic assessments after drug administration were masked to treatment assignment.|This trial was a double-masked, active-controlled, cross-over superiority study evaluating the efficacy of the fixed combination drug vs. the drug's 2 individual components. All participants in the trial were to receive each of the 3 drugs.|t|f|f|t
33756401|NCT02316522|||COHORT||PROSPECTIVE|||||||
33756402|NCT03509974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756403|NCT03778879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756404|NCT05864664|RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, prospective, therapeutic, comparative, randomized controlled ?||||
33756405|NCT05174663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The dietary interventions in this proposed study prevent blinding as it is impossible to mask the participant and investigators to whether the participants are consuming whole almonds or not. The requirements to report the quantity of almonds consumed also precludes blinding for both the participant and investigator. The statistician will be blinded for the duration of the study and throughout all analysis and reporting. The preclusion of blinding in this study is not a limitation given the objectivity of the primary and most secondary endpoints. This is a well-controlled study design that provides a real-world assessment of the dietary interventions that bolsters the resulting data to withstand scientific and regulatory scrutiny."||f|f|f|t
33756406|NCT04487067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756407|NCT00010179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756408|NCT02264522|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756409|NCT02748187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756410|NCT01826240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756411|NCT06068452|||OTHER||RETROSPECTIVE|||||||
33756412|NCT04609267|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|The study will be counterbalanced with no masking components|This study will be a repeated measure, mixed methods design (i.e., it will contain both qualitative and quantitative components). Newly admitted patients will be asked to complete the questionnaires (i.e., PHQ-9 and the UEQ) at two different time points (i.e., Baseline and 1-month follow-up). In order to reduce or control for order effects, the procedure will be counterbalanced.||||
33756413|NCT05541016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756414|NCT01293058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756415|NCT04517864|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33756416|NCT00444691|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756417|NCT02007005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756418|NCT03118024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756419|NCT02445040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756420|NCT02172625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33756421|NCT03323619|||COHORT||PROSPECTIVE|||||||
33756422|NCT04793919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756423|NCT05679011|||COHORT||CROSS_SECTIONAL|||||||
33756424|NCT06083025|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, single group, single center, open label study. Each study subject will be implanted bilaterally with IOL of surgeon's choice (same IOL in both eyes) and CleaRing device in one eye.||||
33756425|NCT00101933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756426|NCT00816738|||COHORT||RETROSPECTIVE|||||||
33756427|NCT00045305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875442|NCT00903175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756428|NCT00279292|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33756429|NCT01238055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756430|NCT04167605|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875443|NCT04017481|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Final outcomes evaluators are blinded. Clinical evaluation is performed using videotaped neurological examination. Neurophysiological evaluation is done with the raw data recorded during the sessions.|Each study participant is assigned to one of the arms. Four intervention groups are defined as rTMS only, NFB only, both TMS and NFB, or neither TMS or NFB|f|f|f|t
33756431|NCT01189968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756432|NCT04818294|||COHORT||PROSPECTIVE|||||||
33756433|NCT03218202|||COHORT||PROSPECTIVE|||||||
33756434|NCT02057874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756435|NCT00047476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33756436|NCT05455905|||COHORT||CROSS_SECTIONAL|||||||
33756437|NCT04123067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756438|NCT01931280|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33756439|NCT05508230|NA|SINGLE_GROUP||OTHER||NONE||||||
33756440|NCT00811343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756441|NCT00505141|||CASE_CONTROL||OTHER|||||||
33756442|NCT00784394|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33756443|NCT05184257|||CASE_CONTROL||OTHER|||||||
34068361|NCT00061750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756444|NCT05065489|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33756445|NCT00972348|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756446|NCT04886492|||COHORT||PROSPECTIVE|||||||
33756447|NCT02578979|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33756448|NCT06442618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756449|NCT05084417|||COHORT||PROSPECTIVE|||||||
33875444|NCT03669302|RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals with Spinal Cord Imjury will be randomly assigned to receive robotic gait training with the Lokomat, and/or Lokomat gait training combined with non-invasive thoracolumbar transspinal stimulation at 0.3 or at 30 Hz.||||
33875445|NCT02568813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968119|NCT03342508|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Each patient will have a Fetal Pillow inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow if the patient has been randomized into the Fetal Pillow Inflated (FPI) group. In the Fetal Pillow Not Inflated (FPNI) group, the device will remain, not inflated, in the vagina. The obstetrician will therefore be blinded to the intervention.||t|t|t|f
34068362|NCT06262022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was planned as a prospective, parallel, two-arm (1:1) randomized controlled trial (RCT).||||
33968120|NCT02725671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968121|NCT01344408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968122|NCT03574246|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33968123|NCT00889785|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33968124|NCT02962882|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968125|NCT00202072|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33968126|NCT04014400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968127|NCT02237352|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34068363|NCT03538691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068364|NCT03718234|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized crossover study design.||||
34068365|NCT02018770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968128|NCT04360603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968129|NCT02808806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33968130|NCT02145403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968131|NCT03065283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The sample was randomly divided by electronic draw in two groups, the intervention group (GI), where two techniques were performed, one for diaphragmatic release and another for relaxation of the diaphragm pillars. In the control group (CG) the same techniques were applied, but in a placebo form.|t|f|f|f
33968132|NCT04440345|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33968133|NCT06204926|||OTHER||CROSS_SECTIONAL|||||||
33968134|NCT00328237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968135|NCT01569555|||CASE_CONTROL||PROSPECTIVE|||||||
33968136|NCT06502041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of either patient or clinician is not possible. However, blinding was ensured during analyzing the data. All digital models and x-rays were coded and shuffled before they were evaluated and measured.||f|f|f|t
33968137|NCT03286647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968138|NCT00602550|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068366|NCT05739656|||COHORT||PROSPECTIVE|||||||
34068367|NCT04281628|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34068368|NCT02740335|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34068369|NCT03780972|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34068370|NCT03735745|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34068371|NCT04933864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068372|NCT03734809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068373|NCT02523404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968139|NCT01936168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968140|NCT03978702|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968141|NCT04252352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intra-person split-face trial|f|f|f|t
33968142|NCT03139747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968143|NCT05189561|NA|SINGLE_GROUP||SCREENING||NONE||||||
33968144|NCT00276874|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33968145|NCT01151787|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33968146|NCT01132716|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968147|NCT03765671|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33968148|NCT04147728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968149|NCT05313620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968150|NCT00955747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968151|NCT00544557|||COHORT||PROSPECTIVE|||||||
33968152|NCT00732329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968153|NCT00204750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968154|NCT03294161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968155|NCT04861896|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968156|NCT05692921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Comparing 2 interventional groups: 1) Virtual Remote Home Monitoring and 2) Rapid Response Nursing care||||
33968157|NCT02278549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968158|NCT04837625|||COHORT||PROSPECTIVE|||||||
33968159|NCT01792258|||CASE_ONLY||PROSPECTIVE|||||||
33968160|NCT06152159|||CASE_ONLY||CROSS_SECTIONAL|||||||
33968161|NCT05001490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Control Trial|f|f|f|t
33968162|NCT03779399|||CASE_CONTROL||PROSPECTIVE|||||||
33968163|NCT02555709|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33968164|NCT02501109|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968165|NCT01470794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968166|NCT01786811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34068374|NCT02984644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968167|NCT00683150|||CASE_ONLY||PROSPECTIVE|||||||
33968168|NCT02925065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to early-start or late start guitar groups. Following baseline assessment week, the early-start group will receive twice-weekly non traditional guitar instruction for 6 weeks. The late-start guitar group will receive same intervention after the early-start group complete their 6 week instruction. Study assessments will be conducted during week 7 and week 14. Follow up assessment will be conducted in week 20.|f|f|t|f
33968169|NCT05818020|||COHORT||PROSPECTIVE|||||||
33968170|NCT05925322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33968171|NCT01020305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968172|NCT01675908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968173|NCT03387410|NA|SINGLE_GROUP||OTHER||NONE||||||
33968174|NCT01266382||||TREATMENT||||||||
33968175|NCT00443352|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33968176|NCT01512979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33968177|NCT04800055|RANDOMIZED|PARALLEL||PREVENTION||NONE||An open-label two-arm cluster randomized controlled trial (CRCT) design will be used comparing ATSB + universal coverage with a WHO core vector control intervention vs universal coverage with VC alone (standard of care). Universal VC (mainly LLIN) will be ensured in both arms prior to start of the study and will serve as the standard of care. Arm 1 will receive ATSBs for up to two years. Arm 2 will receive the standard of care of universal vector control coverage.||||
33968178|NCT03790085|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33968179|NCT03244397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups: Experimental group and Control group|f|f|t|t
33968180|NCT04697511|NA|SEQUENTIAL||OTHER||NONE||||||
33968181|NCT01588106|||CASE_CONTROL||PROSPECTIVE|||||||
33968182|NCT05450497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968183|NCT03746028|||COHORT||PROSPECTIVE|||||||
33968184|NCT02154113|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968185|NCT03276910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"3 different conditions:~* Eprex 20 UI/kg~* Eprex 50 UI/kg~* Placebo"|t|f|t|t
33968186|NCT06130865|||COHORT||PROSPECTIVE|||||||
33968187|NCT03334487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968188|NCT00435695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968189|NCT03582293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Double-blind, placebo-controlled, multicentre, randomized clinical trial.|t|t|t|t
33968190|NCT00756847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968191|NCT00796289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968192|NCT02344134|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968193|NCT03372499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33968194|NCT02693184|||CASE_CROSSOVER||PROSPECTIVE|||||||
33968195|NCT06539299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968196|NCT02675426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968197|NCT01050231|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33968198|NCT00306631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968199|NCT02720315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968200|NCT01195870|||COHORT||PROSPECTIVE|||||||
33968201|NCT03986749|NA|SEQUENTIAL||DIAGNOSTIC||NONE||prospective observational case-series||||
33968202|NCT00600288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968203|NCT00609778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968204|NCT00775983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968205|NCT01165242|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968206|NCT04456465|||CASE_ONLY||PROSPECTIVE|||||||
33968207|NCT02001428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968208|NCT01859702|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968209|NCT03564899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are randomized, using a 1:1:1 allocation, into one of three groups: 1) the control group (no physical activity intervention), 2) the lighter intensity physical activity intervention or 3) the higher intensity physical activity intervention.||||
33968210|NCT06546436|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33968211|NCT05377333|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33968212|NCT04886570|||COHORT||CROSS_SECTIONAL|||||||
33968213|NCT01740492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968214|NCT02481479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968215|NCT02957786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33968216|NCT02580890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968217|NCT02799732|||COHORT||PROSPECTIVE|||||||
33968218|NCT03785483|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||3 groups: motivation, mindfulness, and treatment as usual||||
33968219|NCT01841359|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Participants in this study were asked to complete 4 study visits.~Arm/Phase 1: Baseline: Study V1 was a screening visit. Participants kept a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms. At V2, a baseline mixed meal tolerance test (MMTT) was performed. Glucose, hormonal responses, and satiety were assessed. Glucose and symptom logs were reviewed.~Arm / Phase 2: Pramlintide treatment Pramlintide was prescribed at the end of visit 2 (following MMTT), with instructions for titration from minimal to maximal dose (15 to 120 µg). During treatment, the participants kept a record of all hypoglycemic symptoms and blood glucose measurements at those times.~Study visit 3 occurred at week 4 of treatment and focused on evaluation of symptoms and side effects. Participants again completed a food and glucose diary for 3 days. During study visit 4 (week 8 of treatment), participants underwent a repeat MMTT."||||
33968220|NCT04101474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756450|NCT02213562|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33968221|NCT04344054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants will receive vaccine as per the assigned treatment to the arm to which he/she has been randomized.|The study will enroll infants in six arms divided into two cohorts enrolling infants at birth (0-6 days) or at approximately 6 weeks of age. Within each cohort, the enrolled infants will be randomized to the three arms in a ratio of 6:6:5.|t|t|t|t
33968222|NCT02401854|||COHORT||PROSPECTIVE|||||||
33968223|NCT04656951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968224|NCT06168071|NA|SINGLE_GROUP||OTHER||NONE||||||
33875446|NCT03673007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875447|NCT06330389|||CASE_CONTROL||RETROSPECTIVE|||||||
33875448|NCT02414386|||CASE_CONTROL||PROSPECTIVE|||||||
33875449|NCT00001003||||TREATMENT||||||||
33875450|NCT00610831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875451|NCT02788942|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33875452|NCT04588779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know which treatment techniques are given in the specified groups.|Both groups were treated simultaneously with their specified treatment techniques within given duration.|t|f|f|f
33875453|NCT01554137|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33875454|NCT02358642|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33875455|NCT06392646|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33968225|NCT03256175|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Both medical air and oxygen were supplied in compressed liquid form and available throughout the hospital. During the study, the medical gas cylinders shielded using an opaque temporary cover. Similarly the oxygen saturation was not displayed, but instead monitored by an independent third party.||t|f|f|t
33968226|NCT01188928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968227|NCT02506725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|statistician and qualitative researchers||f|f|f|t
33968228|NCT05610930|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33968229|NCT01507831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068375|NCT03942003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875456|NCT03587454|NA|SEQUENTIAL||DIAGNOSTIC|||Investigators in teleglaucoma and conventional glaucoma clinics are masked to one another|Prospective sequential enrolment in teleglaucoma then conventional glaucoma clinical care||||
33875457|NCT01797575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875458|NCT00429403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875459|NCT04634500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875460|NCT04840108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33875461|NCT00408694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875462|NCT00912249|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33875463|NCT01743911|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33875464|NCT03428971|||COHORT||RETROSPECTIVE|||||||
33875465|NCT05013762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will be done by a blinded and standardized clinical researcher||f|f|f|t
33875466|NCT01760668|||COHORT||CROSS_SECTIONAL|||||||
33875467|NCT03237377|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33968230|NCT00927888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068376|NCT04592796|||CASE_ONLY||PROSPECTIVE|||||||
33968231|NCT00776633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968232|NCT01504828|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34068377|NCT01859871|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34068378|NCT03615820|RANDOMIZED|PARALLEL||TREATMENT||NONE||Volunteers will be divided into two groups; each group contained 12 volunteers who will receive one formula of the selected formulae||||
33968233|NCT06177041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968234|NCT00868114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968235|NCT03974152|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33968236|NCT02922959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068379|NCT03963778|||CASE_ONLY||OTHER|||||||
34068380|NCT03743844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068381|NCT02036541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968237|NCT01652118|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
33968238|NCT03892148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968239|NCT04645238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968240|NCT04166981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessors are blinded for treatment allocation.||f|f|t|t
33968241|NCT04033133|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||People with Multiple Sclerosis and healthy controls will receive tDCS at different intensities while in the PET scanner.|t|f|t|f
33968242|NCT00520351|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33968243|NCT03760510|RANDOMIZED|PARALLEL||PREVENTION||NONE||The endotracheal tube securement study was a pragmatic, single center, open-label, randomized trial comparing the effect of adhesive tape versus endotracheal tube fastener (Hollister AnchorFast Guard) among critically ill adults requiring intubation and mechanical ventilation for at least 24 hours.||||
33968244|NCT01276483|||COHORT||PROSPECTIVE|||||||
33968245|NCT05642559|||COHORT||PROSPECTIVE|||||||
33968246|NCT04460989|||COHORT||PROSPECTIVE|||||||
33968247|NCT01400269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968248|NCT00274014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068382|NCT00497341|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34068383|NCT01888250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068384|NCT05294965|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Open-label, cross-over trial in healthy volunteers with random sequence of the two study interventions||||
34068385|NCT02258906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34068386|NCT05992688|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34068387|NCT02849210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968249|NCT00274755||||DIAGNOSTIC||NONE||||||
33968250|NCT02880904|||COHORT||OTHER|||||||
33968251|NCT03825952|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33968252|NCT02832908|NA|SINGLE_GROUP||||NONE||||||
33968253|NCT01032681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968254|NCT03208959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968255|NCT04866485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756451|NCT05934968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756452|NCT05211388|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A total of 12 subjects is anticipated, providing sufficient statistical power for estimation of an overall ROC curve assessing the capability of decorrelation-controlled RFA to reliably ensure complete ablation in human liver tumors, while also providing sufficient power to estimate a separate ROC curve for prediction of local ablation in generator-controlled RFA.~The first subjects undergoing the treat-and-resect procedure (at least 2 subjects, or more at discretion of the PI) will be assigned to arm 1 (generator-controlled ablation), and will undergo RFA following manufacturer-specified algorithms. This will allow confirmation of appropriate echo decorrelation thresholds for use as treatment end points.~Remaining subjects will be randomly assigned to arm 1 or arm 2 (echo decorrelation imaging-controlled ablation), up to a total of 6 treat-and-resect procedures in each arm."||||
33756453|NCT03368820|||COHORT||PROSPECTIVE|||||||
33756454|NCT05070247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33756455|NCT05838807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In addition to the participants being blinded to the treatment they are receiving, the outcome assessors will also be blinded to the treatment assignment. This will ensure that the assessors are unbiased when measuring the outcome measures of pain intensity, functional status, and nerve conduction studies.|The study will be a level II randomized controlled trial with a parallel group design. Participants will be randomized to receive one of four interventions: thermal ultrasound, pulsed ultrasound, a combination of both, or a placebo treatment. Participants will receive their assigned treatment for 10 minutes, three times per week, for 4 weeks.|t|f|f|t
33756456|NCT05100290|||CASE_CONTROL||PROSPECTIVE|||||||
33756457|NCT03901196|||CASE_ONLY||RETROSPECTIVE|||||||
33756458|NCT05461976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756459|NCT00652158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756460|NCT01922492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756461|NCT06509126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875468|NCT05290025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Even though complete blinding is regarded as difficult and infeasible, patients will be informed of the follow-up they will receive but not on other follow-up alternatives that are used or the exact hypotheses for the study. Outcomes assessor will be blinded.|"Participants randomised to the intervention arm will receive an individually tailored plan for smoking cessation or reduction of number of cigarettes smoked. Smoking cessation treamtent consist of brief behavoiural interventions and provision of prescription-free nicotin patches, nicotine lozenges or nicotine gum.~Participants will collect the medication for smoking cessation once a week in parallel with delivery of OAT medication. Medication is individually packed for each patient and one week's use. Staff handing out the medication will give the patients a brief intervention asking about how they are progressing in their smoking cessation attempt, how much the patient smoked the day before and if they took the medication as planned. At mid of the intervention period around week 16 (12-20 weeks after intervention initiation), treatment effect measures will be collected"|f|f|f|t
33875469|NCT00416962|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875470|NCT05660720|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33875471|NCT00573430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875472|NCT00872807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875473|NCT02500680|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33875474|NCT05492929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875475|NCT04456309|||COHORT||RETROSPECTIVE|||||||
33968256|NCT04468776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking of participants and providers is not possible given two very different treatment types. The Prime Principal Investigator and a statistician at the Data Coordinating Center will be masked to individual treatment assignment.|This study is a randomized (1:1:1) comparative effectiveness trial of medication preference (zolpidem or trazodone), CBT-I, and the combination for the treatment of insomnia in 155 men and women aged 18-80 years living in rural areas.|f|f|t|t
33968257|NCT05866133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968258|NCT02382978|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33968259|NCT05061667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068388|NCT00973284|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068389|NCT00758329|||COHORT||RETROSPECTIVE|||||||
34068390|NCT05061381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068391|NCT04303234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single ( participant ) because the two interventions used in this trial are easily recognized by the investigator but the participant and the statistician will be blinded.||t|f|f|f
34068392|NCT03695328|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34068393|NCT03439891|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33875476|NCT04570553|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Subjects are randomized to one of two groups in parallel: V-care uterine manipulator group or sponge stick group||||
33875477|NCT05504954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Adolescent girl and young women-female caregiver (AGYW-FC) dyads will be randomized to the IMARA-SA intervention arm or a health promotion control arm matched in time and intensity. IMARA-SA and the health promotion program will be delivered as group interventions.|f|f|f|t
33875478|NCT06260254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants will be aware that in any given study night they can be exposed to railway vibration and noise. They will not be informed what exposure condition will occur in any given night, but they can become unblinded to the exposure if they are awake, as they will may hear the noise or feel the vibration.~Study investigators responsible for analysing cognitive performance variables and physiological sleep data will be be blind to which vibration and noise interventions were introduced on which study nights."|"All participants will be exposed to each of the different vibration conditions. Each study night is treated as a separate arm of the crossover study. The order of the vibration exposure conditions will be be randomly assigned across participants using a Latin square design to avoid first-order carryover effects. Each subject will be exposed to one night of each of the following:~Quiet night: No noise or vibration will be played, serving as a control night to assess individual baseline sleep, metabolic profile, and cognitive performance; Three railway vibration nights to determine consequences of noise-disrupted sleep. The vibration level in these three nights will be 0.5 mm/s, 0.7 mm/s and 0.9 mm/s respectively, so that exposure-response relationships can be derived."|t|f|f|t
33875479|NCT05514626|||COHORT||PROSPECTIVE|||||||
33875480|NCT02671136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875481|NCT04676997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068394|NCT05334459|||COHORT||PROSPECTIVE|||||||
34068395|NCT00488137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068396|NCT00284011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068397|NCT02147392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875482|NCT02017327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33875483|NCT00978315|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33875484|NCT00446511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875485|NCT00805831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875486|NCT02497209|||COHORT|||||||||
33875487|NCT05361772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875488|NCT05626270|NA|SINGLE_GROUP||OTHER||NONE||||||
33875489|NCT00001287||||TREATMENT||||||||
33875490|NCT03682679|||COHORT||CROSS_SECTIONAL|||||||
33875491|NCT00333359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875492|NCT03505021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875493|NCT03742414|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a randomized, controlled, parallel design trial designed for children (total n = 312) who have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) or moisturizer and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).|t|f|t|f
33875494|NCT05427773|||COHORT||CROSS_SECTIONAL|||||||
33875495|NCT00848861|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33875496|NCT05022329|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33875497|NCT06046144|||COHORT||RETROSPECTIVE|||||||
34068398|NCT00001119||||TREATMENT||||||||
34068399|NCT01575002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34068400|NCT05989971|||COHORT||PROSPECTIVE|||||||
34068401|NCT03411902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both participant and research associate charged with administering medication or placebo capsules will be blinded.|This pilot study is a RCT, involving 24 sleeve gastrectomy patients randomized to Risedronate or placebo capsules for 24 weeks|t|t|f|f
34068402|NCT02393235|||CASE_CONTROL||PROSPECTIVE|||||||
34068403|NCT03746379|||OTHER||CROSS_SECTIONAL|||||||
34068404|NCT02072070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068405|NCT00019656||||TREATMENT||||||||
34068406|NCT02875873|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34068407|NCT05392777|||CASE_ONLY||PROSPECTIVE|||||||
34068408|NCT02788669|||COHORT||RETROSPECTIVE|||||||
34068409|NCT00529178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068410|NCT05889208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068411|NCT04755738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875498|NCT05711004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Eligible participants with uncontrolled HTN will be randomly assigned to experiment (SMS) or control (routine care) groups at a 1:1 ratio.|f|f|t|t
33875499|NCT06373809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective an open label||||
33875500|NCT03223428|||COHORT||PROSPECTIVE|||||||
33875501|NCT02114437|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33875502|NCT06300658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875503|NCT03321695|||COHORT||PROSPECTIVE|||||||
33875504|NCT02102321|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33875505|NCT01705600||PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875506|NCT03797586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756462|NCT05842226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33756463|NCT05589870|||OTHER||RETROSPECTIVE|||||||
33756464|NCT03300791|||OTHER||PROSPECTIVE|||||||
33756465|NCT05886400|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33756466|NCT01201395|||COHORT||PROSPECTIVE|||||||
33756467|NCT00453986|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33756468|NCT06181864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756469|NCT04837300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants|Randomized controlled trial|t|f|f|f
33756470|NCT00742638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875507|NCT03270735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875508|NCT05304702|||CASE_CONTROL||RETROSPECTIVE|||||||
33875509|NCT03741829|||CASE_ONLY||PROSPECTIVE|||||||
33875510|NCT05511272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875511|NCT00155909|||DEFINED_POPULATION||PROSPECTIVE|||||||
33875512|NCT05875259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875513|NCT02858414|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875514|NCT06076512|||COHORT||PROSPECTIVE|||||||
33875515|NCT05314608|||COHORT||PROSPECTIVE|||||||
33875516|NCT03186170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.|t|f|f|f
33875517|NCT03443674|NA|SEQUENTIAL||TREATMENT||NONE||||||
33875518|NCT03278470|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33875519|NCT02656095|||COHORT||PROSPECTIVE|||||||
34068412|NCT02128334|||COHORT||PROSPECTIVE|||||||
34068413|NCT01234064|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33875520|NCT05735431|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Enrolled participants will be randomized to one of the following treatment groups:~Investigational Group: Formoterol 6 mcg/fluticasone 125 mcg Eurofarma. Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.~Comparator Group: Alenia® 6 mcg/200 mcg. Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks."||||
33875521|NCT03287219|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|None. Open label|Open label, staining efficacy exploratory study.||||
33875522|NCT00150657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875523|NCT03958227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875524|NCT00094055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875525|NCT00934570|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33875526|NCT03245073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875527|NCT01595152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875528|NCT05810064|||OTHER||RETROSPECTIVE|||||||
33875529|NCT04291950|||COHORT||CROSS_SECTIONAL|||||||
33875530|NCT02823691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875531|NCT00325026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875532|NCT04389021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33875533|NCT05992389|||CASE_CONTROL||PROSPECTIVE|||||||
33875534|NCT00035282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875535|NCT05988060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In this study a TwiCs design will be used. The TwiCs design consists of an experimental intervention study within an observational longitudinal cohort. This design uses a staged-informed consent. Patients will be asked to participate in an observational longitudinal cohort study and will be informed about the design with the probability to be randomly invited for an experimental intervention which they can accept or refuse. When patients are willing to participate in the observational longitudinal cohort, an informed consent (IC) will be signed. Directly after cohort enrollment, all patients will be randomized.||||
33875536|NCT00011921|RANDOMIZED|||TREATMENT||||||||
33875537|NCT03430921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875538|NCT04608812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875539|NCT02562456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875540|NCT06022952|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33875541|NCT04450121|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Randomization will be done using computer generated number and concealed using sequentially numbered, sealed opaque envelope.|"Comparison between the two airways regarding:~1. Time to Glottic view.~2. Grade of bronchoscopic view.~3. Success of intubation from 1st trial."|t|f|t|f
33875542|NCT05044208|||COHORT||PROSPECTIVE|||||||
33875543|NCT01664728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875544|NCT00931359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875545|NCT05266378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All researchers other than the anesthesiologist who manage the randomization table and the medical staff in charge of the patient must keep the group assignment blinded until the end of the study.|"1. Control arm: Conventional Anesthesia~2. Interventional arm: Conventional Anesthesia with pectoralis nerve block."|t|t|f|t
33875546|NCT05999188|||COHORT||OTHER|||||||
33875547|NCT05442970|||COHORT||PROSPECTIVE|||||||
33875548|NCT02820428|NA|SINGLE_GROUP||||NONE||||||
33875549|NCT02562924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33875550|NCT00784420|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875551|NCT04350853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875552|NCT06539910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Randomized controlled study|t|f|f|t
33875553|NCT03269071|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33875554|NCT04961788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875555|NCT02474732|NA|SINGLE_GROUP||OTHER||NONE||||||
33875556|NCT06465797|||OTHER||PROSPECTIVE|||||||
33875557|NCT04621955|||COHORT||PROSPECTIVE|||||||
33875558|NCT02120105|||CASE_ONLY||PROSPECTIVE|||||||
33875559|NCT03718286|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized, double-blind, sham-controlled parallel group clinical trial.|t|f|t|t
33875560|NCT00500084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875561|NCT06073496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|asessor||f|f|f|t
33875562|NCT03006510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33875563|NCT06333509|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|N/Ap|Phase 1; Dose escalation followed by dose expansion Phase 2; Single group of each indication will be dosed at the recommended dose level from Phase 1.||||
33875564|NCT03551444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875565|NCT03307889|||CASE_ONLY||PROSPECTIVE|||||||
33875566|NCT01049594|||COHORT||PROSPECTIVE|||||||
33875567|NCT06129266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33875568|NCT03801655|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33875569|NCT02868697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875570|NCT02788747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875571|NCT00754832|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33875572|NCT04517747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875573|NCT01741649|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875574|NCT06145295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33875575|NCT05880446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Quality of life questionnaires and dietician advice before and at the end of treatment.||||
33875576|NCT03362021|||COHORT||PROSPECTIVE|||||||
33875577|NCT01533376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33875578|NCT00429208|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33875579|NCT01745250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875580|NCT04818593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875581|NCT02878954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875582|NCT04136223|||COHORT||PROSPECTIVE|||||||
33875583|NCT02742285|NA|SINGLE_GROUP||OTHER||NONE||||||
33875584|NCT02788097|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33875585|NCT02409654|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33875586|NCT01808300|RANDOMIZED|CROSSOVER||||NONE||||||
33875587|NCT00513500|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34068414|NCT04040465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will place patients into 3 different groups based on BMI, and within those groups patients will be randomly assigned to an aspirin dose (81mg, 325mg, or 500mg)||||
34068415|NCT04154839|||CASE_CONTROL||PROSPECTIVE|||||||
34068416|NCT03158610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068417|NCT01675388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068418|NCT04456400|||COHORT||CROSS_SECTIONAL|||||||
34068419|NCT00305565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068420|NCT01233310|||COHORT||PROSPECTIVE|||||||
33875588|NCT03609021|||COHORT||PROSPECTIVE|||||||
34068421|NCT00523055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34068422|NCT04150536|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33875589|NCT01107678|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875590|NCT00996944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875591|NCT03530865|||OTHER||RETROSPECTIVE|||||||
33875592|NCT03778619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875593|NCT00183274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875594|NCT04229745|||COHORT||PROSPECTIVE|||||||
33875595|NCT02595723|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Each participant receives three treatments: phenytoin + megestrol, placebo + megestrol, or placebo + placebo|t|t|t|t
33875596|NCT04631146|||OTHER||RETROSPECTIVE|||||||
33875597|NCT00322283|NON_RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33875598|NCT03792815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875599|NCT04743102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875600|NCT00579397|||COHORT||PROSPECTIVE|||||||
33875601|NCT04245007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875602|NCT01109875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875603|NCT05821803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875604|NCT04622007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In all cohorts, investigational product (IP, tomivosertib or placebo) will be blinded and pembrolizumab will be open label. On Cohort C, pembrolizumab and pemetrexed will be open label.|In each Cohort approximately 60 eligible Subjects were targeted to be randomized to receive tomivosertib or matching placebo in combination with pembrolizumab (and pemetrexed, Cohort C). Cohorts A and C were closed to enrollment early due to recruitment challenges. In Cohort B, 54 subjects received blinded IP (tomivosertib or matching placebo) in combination with pembrolizumab as first line therapy.|t|t|t|t
33875605|NCT02821715|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33875606|NCT00977951|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33875607|NCT03655756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875608|NCT00174109|||NATURAL_HISTORY||PROSPECTIVE|||||||
33875609|NCT00153686|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875610|NCT02127437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875611|NCT01208714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875612|NCT04540042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part 1 of the study will enroll patients in two arms in a 1:1 ratio to receive either SelK2 or placebo. Part 2 of the study will enroll patients in two arms in a 2:1 ratio to receive either SelK2 or placebo, respectively.|t|t|t|t
33875613|NCT02211027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875614|NCT05458076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875615|NCT02115464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068423|NCT06330571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875616|NCT01732809|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33875617|NCT00136630|||FAMILY_BASED||PROSPECTIVE|||||||
33875618|NCT05266937|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II, multicentre, single-arm study||||
33875619|NCT02998346|||COHORT||PROSPECTIVE|||||||
33875620|NCT01489839|||COHORT||PROSPECTIVE|||||||
33875621|NCT06378814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||two arms parallel randomized clinical trial|t|f|f|t
33875622|NCT02486198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875623|NCT04075721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875624|NCT03999762|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33875625|NCT01319409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875626|NCT05690529|||COHORT||PROSPECTIVE|||||||
33875627|NCT05555537|||CASE_CONTROL||RETROSPECTIVE|||||||
33875628|NCT04309240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968260|NCT03618966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All the electrophysiological experiments will be performed in double-blind fashion.|Patients will be randomized in two groups by receiving a sequential number according to a from a computer-generated random list. A first group will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm; a second group received a rNMMS of the left arm and a sNMMS of the right arm. Every cycle of stimulation will last two weeks. All patients will undergo a medial nerve conduction study (NCS) and a clinical evaluation before and at the end of the treatment and another evaluation after two weeks after the end of treatment. Clinical examination will include i) handgrip strength test for the measure of maximal isometric strength of hand and flexor forearm muscles; ii) MRC Muscle Scale for manual muscular testing of the upper limbs. At the end of the stimulation procedure, a needle muscle biopsy under a local anesthetic will be performed bilaterally from flexor carpi radialis muscle for histological, physiological and molecular studies.|t|t|t|f
33968261|NCT00744510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33968262|NCT02238977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968263|NCT00134888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33968264|NCT04520035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968265|NCT00161174|||COHORT||PROSPECTIVE|||||||
33968266|NCT03162952|||COHORT||OTHER|||||||
33968267|NCT02280421|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33968268|NCT02609282|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33968269|NCT00789802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34068424|NCT00895934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068425|NCT00002030||||TREATMENT||NONE||||||
34068426|NCT05119686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068427|NCT04163315|NA|SINGLE_GROUP||OTHER||NONE||||||
34068428|NCT01759719|||CASE_ONLY||PROSPECTIVE|||||||
34068429|NCT02693899|||COHORT||PROSPECTIVE|||||||
34068430|NCT04174365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068431|NCT03940443|||COHORT||RETROSPECTIVE|||||||
34068432|NCT03013712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068433|NCT05727150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068434|NCT03110081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34068435|NCT06070675|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Mixed methods, randomized 2x2 crossover trial||||
34068436|NCT04657575|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34068437|NCT01911793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875629|NCT00114582|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875630|NCT01387243|||COHORT||PROSPECTIVE|||||||
33875631|NCT03430115|||COHORT||RETROSPECTIVE|||||||
33894291|NCT04535063|NA|SINGLE_GROUP||TREATMENT||NONE||patients with severe COVID19 pneumonia will be recruited to a single arm therapy group with convalescent plasma from recovered patients||||
33894292|NCT02591615|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33894293|NCT00227357|||||PROSPECTIVE|||||||
33894294|NCT00811629|||||PROSPECTIVE|||||||
33756471|NCT04511754|RANDOMIZED|PARALLEL||OTHER||SINGLE|Both trainee and researcher will be blinded to training condition assignment prior to randomization, and follow-up assessment will be blinded.|Participants will be randomized at a 1:1 ratio to either the standard training or the experiential training condition.|f|f|f|t
33875632|NCT05899244|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor is blind to participant group allocation. After the first evaluation participant are conduct in another room where a second investigator allocate them to a subgroup and give them instructions concerning the intervention. After a month the re-avaluation takes place and patient are told to keep secret their affiliation group until the end of the re-evaluation in order to keep the outcomes assessor blind.||f|f|f|t
33875633|NCT01066364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875634|NCT06336252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome (accelerometer data) blinded for the investigator and assesor.|1/1 allocation|f|f|f|t
33875635|NCT05223946|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33875636|NCT03001674|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875637|NCT06503172|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875638|NCT03579784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875639|NCT01271283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875640|NCT05815108|||COHORT||RETROSPECTIVE|||||||
33875641|NCT00940589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875642|NCT06375109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875643|NCT03302845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33875644|NCT02479009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875645|NCT02765568|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33875646|NCT05988671|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33875647|NCT04435509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Single (Participant)|t|f|f|f
33875648|NCT03263507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875649|NCT02956551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875650|NCT00964327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875651|NCT06213090|||CASE_CONTROL||PROSPECTIVE|||||||
33875652|NCT00015288||||TREATMENT||DOUBLE||||||
33756472|NCT03623087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756473|NCT02635048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756474|NCT01064297|||COHORT||PROSPECTIVE|||||||
33756475|NCT01134146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756476|NCT04769726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875653|NCT06206759|||CASE_CONTROL||RETROSPECTIVE|||||||
33875654|NCT00985062|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33875655|NCT02248727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33875656|NCT04155671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875657|NCT05967702|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875658|NCT03711500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33875659|NCT06183658|||COHORT||PROSPECTIVE|||||||
33875660|NCT00414102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875661|NCT02530528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875662|NCT01849471|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33875663|NCT01714271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33875664|NCT01319695|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875665|NCT03723382|||COHORT||OTHER|||||||
33875666|NCT03557892|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875667|NCT04392518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor does not know the group of the patient|There will be two group. The first group will perform the exercises in the hospital under the supervision of a physiotherapist (Group 1: Hospital based rehabilitation group) and the second group will perform the exercises at their home under remote supervision of a physiotherapist via internet connection (Group 2: Telerehabilitation group).|f|f|f|t
33875668|NCT04684446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blinded study||t|f|f|f
33875669|NCT04006964|||COHORT||PROSPECTIVE|||||||
33875670|NCT01201239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875671|NCT01914380|||COHORT||PROSPECTIVE|||||||
33875672|NCT05747456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary endpoint is assessed through objective measures of facial volume, obtained using standardized, three-dimensional (3D), digital photographic images. Measurement will be made by an independent expert who will be blinded, as image files will not reveal subject treatment randomization, or the time point at which the image was taken.|"Prospective, Randomized, No-Treatment Controlled Trial. Subjects will be randomized (5:1 ratio) to the IPN-21-SENSE (treatment) arm or the no-treatment control arm.~After 24 weeks, the no-treatment control arm (delayed treatment group) will receive their first treatment and will then follow the same schedule as the initial treatment group. After the no-treatment control group receives treatment, data from both groups will be pooled."|f|f|f|t
33875673|NCT00368511|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33875674|NCT02201407|||COHORT||PROSPECTIVE|||||||
33875675|NCT05839873|||COHORT||PROSPECTIVE|||||||
33875676|NCT00599495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875677|NCT04730843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33875678|NCT01798589|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33875679|NCT01905280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875680|NCT02400788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875681|NCT05967637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875682|NCT00421356|||OTHER||PROSPECTIVE|||||||
33875683|NCT03757533|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34068438|NCT05979207|NA|SEQUENTIAL||TREATMENT||NONE||MMV367 will be administered as a single oral dose, with different doses to be tested across and within cohorts. The highest dose of MMV367 administered in this study will be no more than 1500 mg, to determine the maximum parasite killing rate of MMV367. Doses to be tested in Cohort 1 will be 20mg, 90mg and 1500mg. Parasite regrowth following initial parasite clearance is required to effectively characterise PK/PD parameters such as the half maximum effective concentration of MMV367.The Safety Data Review Team will review all safety, PK, and PD data. Doses to be tested in Cohort 2 will be informed by the results obtained in Cohort 1, and will be selected to refine the PK/PD parameter estimates. The SDRT will meet following the completion of Cohort 2 to review all safety, PK, and PD data. If the SDRT deems sufficient data has been obtained to achieve the primary endpoint, a third cohort of participants will not be enrolled.||||
33875684|NCT01309503|||COHORT||CROSS_SECTIONAL|||||||
33894295|NCT00004829|RANDOMIZED|||TREATMENT||DOUBLE||||||
33894296|NCT01999673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068439|NCT02954588|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34068440|NCT00357890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068441|NCT01583283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068442|NCT03818009|||COHORT||PROSPECTIVE|||||||
34068443|NCT04593355|||COHORT||PROSPECTIVE|||||||
34068444|NCT00939744|||CASE_ONLY||PROSPECTIVE|||||||
33875685|NCT04601948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The intervention will include an activity monitor and access to the mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.||||
33968270|NCT02552381|||COHORT||PROSPECTIVE|||||||
33968271|NCT00989079|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33968272|NCT06330311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator will be blinded to the randomization, patient assessment, and data analysis.|The participants will be randomly allocated to experimental or control group|f|f|t|f
33875686|NCT06539013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875687|NCT05416762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875688|NCT01967537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875689|NCT04733690|||OTHER||CROSS_SECTIONAL|||||||
33875690|NCT00707070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875691|NCT03413280|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33968273|NCT05249010|||CASE_CROSSOVER||PROSPECTIVE|||||||
33968274|NCT03567915|||CASE_CONTROL||PROSPECTIVE|||||||
33968275|NCT04876833|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968276|NCT01745978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875692|NCT00390546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875693|NCT04654494|||COHORT||RETROSPECTIVE|||||||
33968277|NCT06340542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants' allocation was concealed by using lottery method whether there are in exercise group or manual therapy group. Accessors was blinded which means they were not aware about the treatment or therapy which was obtained by the participants|This study is a Randomized Control Trial, Double- Blinded study. Participants and accessors was blinded. Participants were allocated randomly in to two groups which are experimental group which will receive thoracic mobility exercises and control group which will receive myofascial release and joint mobilization treatment by using lottery method.|t|f|f|t
33968278|NCT03967483|||COHORT||PROSPECTIVE|||||||
33968279|NCT06530485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968280|NCT03652961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968281|NCT02447510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968282|NCT00125567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875694|NCT05778006|||COHORT||PROSPECTIVE|||||||
33875695|NCT01940029|||COHORT||PROSPECTIVE|||||||
33875696|NCT04015453|||COHORT||RETROSPECTIVE|||||||
33875697|NCT01794130|||CASE_ONLY||PROSPECTIVE|||||||
33875698|NCT02678481|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875699|NCT01028664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33894297|NCT06188832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894298|NCT05505422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894299|NCT03069573|||COHORT||PROSPECTIVE|||||||
33968283|NCT04719364|||OTHER||CROSS_SECTIONAL|||||||
33968284|NCT01816971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968285|NCT02324985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068445|NCT03974529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment will be taken by three blinded assessors (one occupational therapist, a registered research nurse and a research assistant) at baseline, at completion of the training and 6 months after, at Prince of Wales Hospital.|"This is a prospective randomized controlled single-blinded study. 30 patients will be included and randomized to intervention arm or control arm in a ratio of 2 to 1. Informed consent will be signed after the patient is fully informed about the procedures and prior to the baseline assessments.~Intervention arm~* Number of participants: 20~* Venue: Shatin playground~* Supervisors: licensed coaches (2 to 4 per session)~* Training session: 30 minutes of warm-up stretching + 60 minutes supervised progressive aerobic endurance track running~* Targeted intensity: 60-75% of maximum heart rate (HR max = 220 - age) OR 40-50% heart rate reserve (HRR= HR max - HR rest)~* Frequency and training period: 2 sessions per week, for 24 weeks~Control arm~* Number of participants: 10~* Venue: Indoor gymnasium~* Supervisor: a physiotherapist~* Training session: 60 minutes of physical stretching~* Frequency and training period: 1 session per week, for 24 weeks"|f|f|f|t
33756477|NCT04848428|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||2-arm pilot RCT|f|t|t|t
33756478|NCT04035057|RANDOMIZED|PARALLEL||OTHER||SINGLE|Therapist participants who are completing the training intervention are blind to the other training condition|Two phases: Phase I is a case-series analysis to determine the necessary dosage to engage the training intervention target (i.e., therapist negative beliefs). Phase II is a randomized trial of a behaviorally-enhanced training versus standard didactic training.|t|f|f|f
33756479|NCT03055143|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33875700|NCT05648279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In patients in the routine management group, the treating anesthesiologists will be blinded to data of preoperative baseline cardiac output measurements to avoid performance bias. Participants and outcome assessors are blinded to group allocation.||t|f|f|t
33875701|NCT06044480|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33875702|NCT01755715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875703|NCT03216473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875704|NCT03766048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33875705|NCT01612260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875706|NCT00002000||||TREATMENT||||||||
33875707|NCT02246569|||||PROSPECTIVE|||||||
33875708|NCT02189642|||COHORT||PROSPECTIVE|||||||
34068446|NCT04418622|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33875709|NCT00893321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875710|NCT04391699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875711|NCT03569527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875712|NCT00157976|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33875713|NCT03080909|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Double-blind|A double-blind, randomized crossover design with five arms including four experimental conditions and placebo|t|t|t|t
33875714|NCT03760575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875715|NCT05736900|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33875716|NCT03368170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, placebo controlled|t|t|t|t
33875717|NCT03791788|||CASE_ONLY||RETROSPECTIVE|||||||
33875718|NCT02305355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875719|NCT06188156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875720|NCT05107856|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33875721|NCT06297668|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33875722|NCT04842201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068447|NCT00985933|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34068448|NCT03270033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068449|NCT05351593|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068450|NCT01427543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068451|NCT01671098|||CASE_ONLY||PROSPECTIVE|||||||
34068452|NCT04869852|RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy postmenopausal women aged 50 - 70, Fitzpatrick skin type I, II, or III||||
34068453|NCT02021110|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875723|NCT04893772|||COHORT||PROSPECTIVE|||||||
33875724|NCT00650910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875725|NCT03031275|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|All investigators (radiologist, neuropsychologist, physiotherapist) were masked from all patient details other than the fact that they were treated with ECMO (ie did not know when the patient was treated, for what condition, if any side effects were seen and so on).||f|f|t|f
33875726|NCT02463175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875727|NCT04091633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Study investigators and outcome assessors will be blind to the allocations status of participants. To ensure blinding, participants will be instructed to not disclose their allocation during assessment.~Fidelity of masking will be ensured by having assessors guess the allocation status of participants at the end of assessments."|Single blind, two arm, cluster randomized controlled trial|f|f|t|t
33875728|NCT06519786|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875729|NCT01003496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875730|NCT00119535|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33875731|NCT04509778|||COHORT||PROSPECTIVE|||||||
33968286|NCT04418427|RANDOMIZED|PARALLEL||TREATMENT||NONE|"From May 2020 through April 2021: Double-masked study Subjects, outcomes assessors and the designated masked study personnel will be masked to subject's treatment assignment throughout the study. There must be a minimum of two physicians per site to fulfill the masking requirements of the study. A masked and unmasked investigator are required to be present for administration of the preceding dose of aflibercept or sham and following dose of ADVM-022 or sham visits, thereafter only the masked investigator is required to be present.~Starting May 2021: Open label study, study was unmasked for enhance safety monitoring."|||||
33968287|NCT00509210|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968288|NCT06462157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968289|NCT06129552|||COHORT||CROSS_SECTIONAL|||||||
33968290|NCT05165251|RANDOMIZED|PARALLEL||TREATMENT||NONE||After screening and run-in period, eligible patients will be randomly assigned into amlodipine/atorvastatin group (amlodipine/atorvastatin 5mg QD) or amlodipine group (amlodipine 5mg QD) or lifestyle intervention only group.||||
33875732|NCT04636619|NA|SINGLE_GROUP||TREATMENT||NONE|"Patients are blinded to know which group their endoscopist belongs to. Pathology is blinded to know which group of endoscopists performed each polypectomy.~A centralized research nurse, blinded to procedure and groups, will made the telephonic follow up."|Non-pharmacological clinical trial evaluating the incomplete resection rate in colonic cold snare polypectomy in two phases, before and after receiving a polypectomy online course.||||
34068454|NCT04792060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875733|NCT03031301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875734|NCT00005070||||TREATMENT||||||||
33875735|NCT04839380|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33875736|NCT05054972|||COHORT||RETROSPECTIVE|||||||
33875737|NCT05965284|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized, open-label, control, pilot study||||
33875738|NCT04840160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants supplied with treatment or placebo in a plastic container|Randomised controlled trial|f|f|t|f
33875739|NCT03629457|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068455|NCT00264290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875740|NCT01860924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875741|NCT04814251|||COHORT||PROSPECTIVE|||||||
33875742|NCT02550886|||COHORT||PROSPECTIVE|||||||
33894300|NCT00420914|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
33968291|NCT04698122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968292|NCT05763511|||COHORT||PROSPECTIVE|||||||
33968293|NCT00382330|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33968294|NCT01040325|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968295|NCT06527482|||COHORT||PROSPECTIVE|||||||
33968296|NCT00263081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968297|NCT06468683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968298|NCT04340414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968299|NCT01070394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968300|NCT03522740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968301|NCT05684133|||COHORT||OTHER|||||||
33968302|NCT00502541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968303|NCT03989115|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a dose escalation study followed by dose expansion.||||
34068456|NCT01971515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068457|NCT03896178|||CASE_ONLY||OTHER|||||||
34068458|NCT06274242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068459|NCT05313646|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and investigators will be kept blinded.|Subjects in adults cohort and elderly cohort will be randomized in a 1:1:1 ratio to receive one of three consecutive batches of Convidecia, respectively.|t|f|t|t
34068460|NCT04966819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, it is not possible to mask the participant nor the care provider. However, outcome assessor will be blinded to the treatment allocation when analyzing primary and secondary outcomes.||f|f|f|t
34068461|NCT02669043|NA|SINGLE_GROUP||OTHER||NONE||||||
34068462|NCT04885790|||OTHER||PROSPECTIVE|||||||
33968304|NCT06529640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968305|NCT01456052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968306|NCT04485286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Eligible subjects planning on receiving radiation for lung cancer or pancreatic cancer will be enrolled to undergo imaging with the PET Probe \[68Ga\]CBP8.||||
33968307|NCT04514029|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33968308|NCT01696383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968309|NCT04478071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968310|NCT02905721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968311|NCT03282305|||COHORT||PROSPECTIVE|||||||
33968312|NCT01259401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968313|NCT04837755|||CASE_ONLY||PROSPECTIVE|||||||
33875743|NCT04925609|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Phase 1:~* To estimate the MTD/RP2D regimen of brigatinib monotherapy when administered in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~* To characterize the PK of brigatinib administered as monotherapy in pediatric and AYA patients with ALK+ ALCL or ALK+ solid tumors.~Note that:~* If the MTD is not reached at the highest proposed test dose, no further dose-escalation will be performed.~* Pediatric PK data, compared to exposure in adults, and cumulative toxicity, will be taken into consideration to determine the RP2D regimen.~Phase 2:~• B1, ALK+ IMT: To establish the activity (ORR by RECIST 1.1) of single agent brigatinib when administered to children with ALK+ IMT.~• B2, ALK+ ALCL: To establish the efficacy (EFS) of single agent brigatinib when administered to children with ALK+ ALCL for a duration of 2 years, without SCT in consolidation."||||
33875744|NCT06430281|||COHORT||CROSS_SECTIONAL|||||||
33875745|NCT01749943|||COHORT||CROSS_SECTIONAL|||||||
33875746|NCT04248439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875747|NCT04295161|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875748|NCT00811135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875749|NCT02188875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33875750|NCT02079571|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875751|NCT01671852|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33875752|NCT05213377|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Unblinded||f|f|t|t
33875753|NCT01632514|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875754|NCT01677806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875755|NCT03739632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875756|NCT04643951|||OTHER||OTHER|||||||
33875757|NCT03398577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is designed as a single-center, double-blinded, placebo controlled, 2-arm clinical trial to provide evidence on the effects of Dapagliflozin on key biomarkers of athero-thrombosis, inflammation and ventricular loading conditions (NT ProBNP).|t|t|t|f
33875758|NCT03361397|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33875759|NCT04990466|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All vaccinations will be prepared by a single, unblinded research pharmacist in a site removed from the clinical immunization site|Randomized, double-blind, comparator-controlled non-inferiority trial|t|t|t|t
33875760|NCT03002155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875761|NCT06078969|RANDOMIZED|CROSSOVER||TREATMENT||NONE||If the diseae progression in the control group is confirmed, the patient is allowed to transferred to the test group (Oral prednisone).||||
33875762|NCT00481650|||||PROSPECTIVE|||||||
33875763|NCT02007174|||COHORT||PROSPECTIVE|||||||
33875764|NCT00719927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875765|NCT06264895|NA|SINGLE_GROUP||TREATMENT||NONE||single -arm longitudinal cohort study||||
33875766|NCT01816009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875767|NCT06017596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875768|NCT04778098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875769|NCT03576937|||COHORT||PROSPECTIVE|||||||
33875770|NCT01676714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756480|NCT04814836|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was carried out to investigate different etching methods used for application modes of universal adhesive on clinical performance of non-carious cervical lesions. The 35% phosphoric acid (K-ETCHANT) or Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc.) etching was applied to the tooth before these application modes in order to bond the universal adhesive, Clearfil Universal Bond Quick. Accordingly, the restorations were completed with 5 different application methods to five different teeth. The allocation of etching method and application mode on each tooth was determined in an order that was assigned by Biostatistics Department. This randomization was blinded to participants and evaluators. It was not known which etching method and application mode was applied to which teeth of the participants.||||
33756481|NCT03713528|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter, single arm, retrospective/prospective clinical trial||||
33875771|NCT03851900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects will blind to the agent being used. At each recall the investigator used blank sheets with patients' names only to avoid bias relative to previous assessments|For each patient, selected teeth will be randomly assigned to TM, SE or placebo by the lottery method. The subjects will blind to the agent being used. All applications will be performed by the same examiner.|t|f|t|f
33875772|NCT01974544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875773|NCT04856553|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33875774|NCT04194099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875775|NCT01996800|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33875776|NCT01401738|||||RETROSPECTIVE|||||||
33875777|NCT01384227|NA|SINGLE_GROUP||SCREENING||NONE||||||
33875778|NCT06247709|||COHORT||RETROSPECTIVE|||||||
33875779|NCT02705638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875780|NCT00285727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875781|NCT04160702|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Individuals will be randomly assigned to complete either a motivational interviewing intervention to increase bystander behaviors or an assessment only control condition. The outcome variables are post-treatment bystander behaviors, measured through both self-report measures and a virtual realty assessment of bystander behaviors. The primary analyses will consist of a series of multiple regressions with intervention group (0 = control, 1 = MI training) interacting with each of the moderators to predict post-treatment bystander behaviors (self-reported and B-SAVE).||||
33875782|NCT03048669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The intervention will be implemented at the health facility level by the health facility staff under the supervision of health districts supervisors and investigators. As such, care providers nor investigations cannot be masked from the intervention. however, participant will not be told about the intervention or which study group they are in.||t|f|f|t
34068463|NCT02557685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756482|NCT04816513|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33756483|NCT01588626|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33756484|NCT05816070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875783|NCT02803021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875784|NCT06033079|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will conduct a randomized controlled trial comparing our prognostic tool (intervention arm) to usual care (control arm) over a period of 24 months. Randomization will occur at the patient level. Allocation to intervention or control will be based on medical record number (even vs. odd) or similar strategy and will be assigned automatically once a provider confirms the diagnosis of pneumonia. Importantly, all standard of care treatment options will be available and decision-making will not be restricted in any way in either group.||||
33875785|NCT03849378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875786|NCT04089007|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34068464|NCT00000888||||TREATMENT||||||||
34068465|NCT01613079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068466|NCT05299762|||COHORT||PROSPECTIVE|||||||
34068467|NCT02574936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068468|NCT00548483|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34068469|NCT03739801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968314|NCT03833453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments will be performed by allocation-blind assessors. Upon seeing a participant for an assessment, assessors are instructed to immediately state that participants are not allowed to discuss aspects of the treatment.|"A randomized controlled trial comparing PTSD-treatment (EMDR) to integrated PTSD-PD-treatment (DBT-EMDR) in patients with PTSD and comorbid BPD.~The PTSD treatment (EMDR) specifically address the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in a maximum period of 6 months. Integrated PTSD-PD-treatment consist of a PTSD treatment (EMDR) interwoven in a PD treatment (DBT) that takes at least one group- session per week, and one individual coaching session every two weeks, for the duration of one year."|f|f|t|t
33968315|NCT00756028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968316|NCT06180967|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33968317|NCT02599883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968318|NCT03336632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968319|NCT04352491|||CASE_ONLY||CROSS_SECTIONAL|||||||
33968320|NCT02935075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968321|NCT04905979|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33968322|NCT04148183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prior to detailed information and signature of informed consent by patients, it was randomized forming three treatment groups, a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks|t|f|f|t
33968323|NCT02565485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33968324|NCT01498419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068470|NCT04063605|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups will receive different exercise program for 8 weeks.||||
34068471|NCT06114771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34068472|NCT00013923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068473|NCT02842008|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968325|NCT05181137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968326|NCT03780933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33968327|NCT02220140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33968328|NCT03281434|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind|Parallel group design (with repeated measurements within each group)|t|f|f|t
33968329|NCT00500409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968330|NCT05268731|||COHORT||RETROSPECTIVE|||||||
33968331|NCT01467609|||COHORT||PROSPECTIVE|||||||
33968332|NCT02163811|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33968333|NCT04262310|||COHORT||PROSPECTIVE|||||||
33968334|NCT03242122|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34068474|NCT05202535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068475|NCT04653155|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34068476|NCT02759835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968335|NCT00384696|||COHORT||PROSPECTIVE|||||||
33968336|NCT06075914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double-blind (investigator and participants)|Double-blind, random allocation, balanced 3-arm study.|t|f|t|t
33968337|NCT01623830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968338|NCT03707483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968339|NCT00463892|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33968340|NCT04486183|NA|SINGLE_GROUP||PREVENTION||NONE||This was a quasi-experimental study with a single group and simultaneous (matched) sample conducted with the purpose of examining whether or not there is a difference between venous and capillary blood samples in blood glucose level measurements and the effects of different methods used in skin cleaning before collecting blood samples on measurement results||||
33968341|NCT04791735|RANDOMIZED|PARALLEL||TREATMENT||NONE||the intervention group is Laparoscopic approach for liver resection of HCC The standard arm is the open approach for liver resection of HCC. Both this standard arm and the laparoscopic arm are in the realm of usual care.||||
33968342|NCT04053881|||COHORT||PROSPECTIVE|||||||
33968343|NCT03028194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756485|NCT03240731|NA|SINGLE_GROUP||OTHER||NONE||Haploidentical Marrow Transplants||||
33968344|NCT02512770|NON_RANDOMIZED|PARALLEL||||NONE||||||
33968345|NCT04366466|RANDOMIZED|PARALLEL||PREVENTION||NONE||Controlled, randomized and prospective study of a cohort of suicide victims comparing an experimental (interventional) group to a control group (usual treatment)||||
33968346|NCT05081674|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients are treated in one of 4 different arms based on biomarker testing. There is no randomization or cross-over||||
33968347|NCT00949390|||COHORT||PROSPECTIVE|||||||
33968348|NCT00871169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968349|NCT03935581|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33968350|NCT01114113|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33968351|NCT05028101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968352|NCT02140489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968353|NCT06282796|||CASE_CONTROL||PROSPECTIVE|||||||
33968354|NCT06175702|||COHORT||PROSPECTIVE|||||||
33968355|NCT01643083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968356|NCT05131009|||COHORT||PROSPECTIVE|||||||
33968357|NCT01499927|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33968358|NCT06298279|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Participants cannot be blinded to condition because ICBT (like other psychotherapies) cannot be both provided to and concealed from a participant. However, the difference between the four conditions (i.e., presence or absence of social learning resources, tunneled versus personalized course navigation) will be concealed from all participants. Because outcomes will be assessed via self-report questionnaire measures, outcomes assessor masking is not applicable.|Factor 1: Tunneled or Personalized Course Delivery Factor 2: Standard or Enhanced Social Learning Resources Participants will be randomly assigned to one of four treatment conditions (tunneled delivery of ICBT with standard resources, tunneled delivery of ICBT with enhanced social learning resources, personalized delivery ICBT with standard resources, personalized delivery of ICBT with enhanced social learning resources)||||
33968359|NCT02006966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33968360|NCT01110733|||CASE_ONLY||PROSPECTIVE|||||||
33756486|NCT04879290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756487|NCT06294496|||COHORT||PROSPECTIVE|||||||
33968361|NCT04961229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968362|NCT06541782|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participating dyad will be randomized into one of two groups.||||
33968363|NCT02754791|NON_RANDOMIZED|PARALLEL||||NONE||||||
34068477|NCT04794673|||CASE_CONTROL||OTHER|||||||
34068478|NCT06239181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study included 2 groups, experimental and control. The patients in the experimental group were administered the beck anxiety scale before coronary angiography. the patients in the experimental group were given breathing exercises by the researcher for 15-20 minutes. the beck anxiety scale was reapplied after the procedure. the patients in the control group were not administered any application and the beck anxiety scale was reapplied after the procedure.||||
34068479|NCT05319262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants will be aware that in any given study night they can be exposed to traffic noise and/or pink noise. They will not be informed what noise condition will occur in any given night, but they can become unblinded to the exposure if they are awake, as they will hear the noise.~Study investigators responsible for analysing cognitive performance variables and physiological sleep data will be be blind to which noise interventions were introduced on which study nights."|"All participants will be exposed to each of the different noise exposure conditions. Each study night is treated as a separate arm of the crossover study. The order of the noise exposure conditions will be be randomly assigned across participants using a Latin square design to avoid first-order carryover effects. Each subject will be exposed to one night of each of the following:~Quiet night: No noise will be played, serving as a control night to assess individual baseline sleep, metabolic profile, and cognitive performance; Traffic noise night to determine consequences of noise-disrupted sleep; Pink noise night: To determine impact of continuous pink noise on sleep; Traffic + pink noise night: simultaneous traffic and pink noise at the same sound pressure levels as in the traffic-only and pink noise-only nights, to determine sleep-protecting effects of pink noise in the face of traffic noise."|t|f|f|t
34068480|NCT05583786|||CASE_ONLY||PROSPECTIVE|||||||
34068481|NCT01882803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756488|NCT06084858|NA|SEQUENTIAL||DIAGNOSTIC||NONE||This is a single-center, prospective, proof-of-priciple, pilot study. Bicarbonate for dialysis will be modified step-by-step from 27 mmol/l to 37 mmol/l.||||
33756489|NCT00567190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756490|NCT00303199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756491|NCT06468319|||COHORT||PROSPECTIVE|||||||
33756492|NCT01162681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756493|NCT00324181|||COHORT||PROSPECTIVE|||||||
33756494|NCT04723823|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be asked to imagine movements or sensensations while brain activity is measured with fMRI||||
33756495|NCT03536286|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"As part of the encouragement intervention, participants (households) will be randomly assigned to the opportunity or encouragement arm, where they will be incentivized to participate in the Asili intervention, but are allowed to choose whether or not they actually participate.~Families will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes, supervised by a community outreach liaison. Control households will not receive an individualized home visit.~Due to numerous factors, including political instability and program implementation delays, our local research team was unable to deploy encouragement as planned."||||
33756496|NCT00990639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756497|NCT02758353|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33756498|NCT02320292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756499|NCT02200874|||CASE_CONTROL||PROSPECTIVE|||||||
33756500|NCT06454032|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756501|NCT00644631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756502|NCT04274920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756503|NCT06174584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756504|NCT05228899|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Neither the patients nor the researchers know who is getting a placebo and who is getting the treatment.|This is a phase I/II randomized, double blinded and placebo control. The ratio between groups is 1:1 for total 30 subjects. Each subject will be randomized to receive either treatment or placebo.|t|t|t|f
33875787|NCT04091087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875788|NCT00345176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875789|NCT02970292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875790|NCT01348997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875791|NCT03747250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The allocation to the group will be randomized in located in closed envelope, that will be opened in the operating theater before anesthesia induction|Randomized controlled trial|t|f|f|f
33875792|NCT00747851|||OTHER||PROSPECTIVE|||||||
33875793|NCT00622648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875794|NCT03787498|NA|SEQUENTIAL||TREATMENT||NONE||||||
33875795|NCT04358835|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, open-label, clinical trial designed to determine whether a ketogenic diet improves gas exchange and reduces ventilator requirements in patients with coronavirus disease intubated for respiratory failure. The study team will prospectively enroll 15 intubated patients with COVID-19 infection and administer a 4:1 ratio enteral ketogenic formula within 48 hours of intubation. This study will compare outcomes to a retrospective cohort of intubated patients with COVID-19 who did not receive ketogenic diet. As other clinical trials begin, co-administration of other therapies as well as standard care treatments will be recorded. In addition, the study will compare clinical outcomes with patients receiving exclusively standard clinical care.||||
33875796|NCT03057925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875797|NCT05630079|||COHORT||RETROSPECTIVE|||||||
33875798|NCT04454190|||COHORT||PROSPECTIVE|||||||
33875799|NCT02195388|||COHORT||PROSPECTIVE|||||||
33875800|NCT05376228|||CASE_ONLY||PROSPECTIVE|||||||
33764846|NCT05885919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Subjects with AIS who met the criteria for inclusion were stratified 1:1 from onset to use of the investigational drug: early (\< 3 hours) and late (3-6 hours).~Each layer was then randomly assigned to two groups in a 1:1 ratio: the right group and the placebo group.~Test group:~Edaravone dextronicol concentrated solution for injection, 15ml / time (37.5mg / time, of which edaravone 30mg, (+)-2-camphol 7.5mg), that is, 3 bottles / time, 2 times a day, for 12±2 days;~Control group:~Equal dose of placebo, 15 ml / time, that is, 3 sticks / time, 2 times a day for 12±2 days."|t|t|t|f
33764847|NCT04244396|||OTHER||PROSPECTIVE|||||||
33764848|NCT00000230||||TREATMENT||||||||
33875801|NCT02500121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875802|NCT02195752|||COHORT||PROSPECTIVE|||||||
33968364|NCT03254719|NA|SINGLE_GROUP||OTHER||NONE||Chiropractic care will be administered by licensed DCs who are current employees of the Iowa City VA Health Care System (ICVAHCS). Participants will receive chiropractic care at a frequency of 1-2 visits per week for a duration up to 10 weeks, with the frequency and duration of care individualized within established VA parameters. For this trial, the minimum treatment dose is 1 visit to the DC, while the maximum treatment dose is 12 visits.||||
33968365|NCT02991261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968366|NCT04523415|||COHORT||RETROSPECTIVE|||||||
33968367|NCT03351413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, two group randomized pilot trial. Randomization is 2:1 (27 intervention, 13 control). Participants have a chance of being in the LIVE-LiFE group or the control group.|f|f|t|f
33764849|NCT04479280|||CASE_CONTROL||PROSPECTIVE|||||||
33875803|NCT03561571|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33968368|NCT05077306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968369|NCT04170959|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective multicentre trial, consisting of an observational lead-in phase and a randomized phase II using a 1:1 ratio. All patients willing to participate will receive definitive radiotherapy either in combination with metformin (arm C) or without metformin (arm B).||||
33968370|NCT00206466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764850|NCT00351897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875804|NCT06087055|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33875805|NCT01452152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875806|NCT05121974|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Pilot study for efficacy and pharmacokinetics for Tebipenem:~Two arms for children (24-59 months) with shigellosis~1. Oral Tebipenem-pivoxil~2. Oral Azithromycin~Main trial:~Two arms for children (24-59 months) with shigellosis:~1. Oral Tebipenem-pivoxil~2. IV Ceftriaxone"||||
33875807|NCT05381818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875808|NCT03937180|RANDOMIZED|PARALLEL||TREATMENT||NONE||cluster randomized controlled trial||||
33875809|NCT06470269|||COHORT||CROSS_SECTIONAL|||||||
33968371|NCT02229266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968372|NCT04901754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968373|NCT03079362|||COHORT||RETROSPECTIVE|||||||
34068482|NCT02206399|||CASE_ONLY||CROSS_SECTIONAL|||||||
34068483|NCT04671056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068484|NCT00565097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068485|NCT04063995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068486|NCT05411601|||COHORT||PROSPECTIVE|||||||
33875810|NCT03902509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875811|NCT01771770|||COHORT||PROSPECTIVE|||||||
33875812|NCT01805622|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33875813|NCT01689298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875814|NCT06302907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875815|NCT02561598|||CASE_CONTROL||RETROSPECTIVE|||||||
33875816|NCT05605600|||OTHER||PROSPECTIVE|||||||
33875817|NCT05364242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33875818|NCT03302715|NA|SINGLE_GROUP||PREVENTION||NONE||Consecutive cohort study with mucosal samples during colonoscopy||||
33875819|NCT05800314|||COHORT||PROSPECTIVE|||||||
33875820|NCT05468632|||OTHER||RETROSPECTIVE|||||||
34068487|NCT01370616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068488|NCT04525326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068489|NCT06138717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068490|NCT00193557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068491|NCT05694273|||COHORT||RETROSPECTIVE|||||||
34068492|NCT04030637|||CASE_CONTROL||PROSPECTIVE|||||||
34068493|NCT03658642|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel cluster randomized||||
34068494|NCT01797588|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33756505|NCT05164575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"ReDI@Home will be a randomized, parallel-arm, single-blind (clinical assessor) feasibility trial with participants randomized to eRP-HI or eRP-LO. An uneven block randomization sequence will be computer-generated with a 1:1 group allocation. Randomization will occur after the pre-intervention visit.~The research coordinator will randomize participants after the equipment/software set-up and the pre-intervention assessment has been completed. The assigned intervention PT will contact participants to review the eRP and set up appointments as required based on group assignment. We will use one PT for all eRP-LO participants and up to 2 PTs to provide the eRP-HI intervention. Participants will have the same PT throughout, with visits scheduled during the day or early evening at PT and participant preference/availability, as per our previous COACH study."|eRP-LOw Intensity (eRP-LO) will be an 8-week intervention that includes FOUR virtual visits with a physiotherapist (PT) while eRP-HIgh Intensity (eRP-HI) will be an 8-week intervention with EIGHT virtual weekly visits with a PT. Both interventions will include a progressive resistance exercise program and self-management strategies. Participants will be provided with Theraband to progress exercise intensity, a FitBit to monitor physical activity, an audio-journal to promote self-reflection, and educational materials provided as part of usual OA care.|f|f|f|t
33756506|NCT00430248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756507|NCT02487810|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33756508|NCT04492579|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756509|NCT04425005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756510|NCT02609165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756511|NCT02709668|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33756512|NCT02483897|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33756513|NCT06181110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756514|NCT05673239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756515|NCT03382964|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33756516|NCT00558064||PARALLEL||TREATMENT||||||||
33968374|NCT05936736|NA|SINGLE_GROUP||TREATMENT||NONE||"According to the optimal design of Simon, 13 pts will be enrolled for the first phase of the study. Hypothesis: the proportion of pts free from acute cumulative G ≥3 toxicity (CTCAE v5.0 scale) 1 month after the end of treatment must be \< 85% to suspend treatment and \> 95% to consider the treatment as safe. The treatment will be interrupted if G3-G4 toxicities and/or biochemical recurrences are recorded within a month in 2 or more pts, otherwise the study will continue with the second phase enrolling another 52 pts for a total of 65 pts. A single fraction SBRT of 24 Gy with the urethral sparing HDR like technique will be delivered. Assuming a minimal drop-out, 5 more pts will be enrolled, thus reaching a total number of 70 pts (65 necessary + 5 for any drop-outs). In the absence of worse subsequent toxicity and with a biochemical control comparable to that in the literature as well as historical treatments of our department, the scheme will be considered as safe and effective."||||
33968375|NCT01535248|||COHORT||CROSS_SECTIONAL|||||||
33968376|NCT03222167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756517|NCT03788538|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33756518|NCT01000168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756519|NCT03505281|||COHORT||PROSPECTIVE|||||||
33756520|NCT03639701|NA|SINGLE_GROUP||TREATMENT||NONE||Open label treatment with thymidine and deoxycytidine||||
33756521|NCT05012800|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756522|NCT06580535|||CASE_CONTROL||RETROSPECTIVE|||||||
33756523|NCT02119260|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33756524|NCT00281710|RANDOMIZED|CROSSOVER||||SINGLE||||||
33756525|NCT02278068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756526|NCT01925833|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33756527|NCT05580848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756528|NCT00743769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756529|NCT00815282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756530|NCT00502255|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756531|NCT06561178|||CASE_ONLY||PROSPECTIVE|||||||
33756532|NCT00768820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756533|NCT00960180|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33756534|NCT00022412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756535|NCT02082535|||COHORT||PROSPECTIVE|||||||
33756536|NCT04356833|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||phase II, open label, single centre, uncontrolled, repeated dose, pilot trial||||
33756537|NCT06430840|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33756538|NCT04392505|NA|SINGLE_GROUP||TREATMENT||NONE||open, exploratory, multinational, phase 2 trial||||
34068495|NCT06321185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subcostal TAP block and port-site infiltration will be applied after the patient has general anesthesia, so the patient will not know the allocated group. The healthcare providers who work in the ward and are responsible for the analgesic treatments will be blinded to the patient's group. The outcomes assessor who will question the QoR-15 scale at the 24th hour will also be blinded.|The patients will be allocated randomly into three groups. Two groups will receive subcostal TAP block or port site local anesthetic infiltration, and the third group will not receive any intervention.|t|t|f|t
34068496|NCT00696995|||COHORT||PROSPECTIVE|||||||
34068497|NCT00946062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068498|NCT03189069|||COHORT||RETROSPECTIVE|||||||
34068499|NCT03534544|||CASE_ONLY||CROSS_SECTIONAL|||||||
33756539|NCT01559454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756540|NCT03568266|||CASE_ONLY||PROSPECTIVE|||||||
33756541|NCT06200103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756542|NCT05334498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756543|NCT04457505|||COHORT||PROSPECTIVE|||||||
34068500|NCT04993703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968377|NCT02872181|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33968378|NCT04364165|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33968379|NCT03349177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968380|NCT04229303|RANDOMIZED|CROSSOVER||OTHER||NONE||Safety, tolerability and PK will be assessed following either single ascending (SAD) or multiple ascending (MAD) dosing of ZP-059; Part 1 and Part 2, respectively. Part 1 will comprise 4 separate cohorts planned to receive single doses of ZP-059; part 2 will comprise 3 separate cohorts planned to receive daily doses of ZP-059 on Day 1 to 10; part 3 is a 2-period, randomised crossover study in subjects with mild to moderate stable asthma to assess the safety, tolerability and PK of single doses of ZP-059 and single doses of oral voriconazole.||||
33968381|NCT04528628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968382|NCT04650100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34068501|NCT01570842|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34068502|NCT00280696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33968383|NCT03751020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33756544|NCT01786928|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756545|NCT02629991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968384|NCT04711629|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Smoker COPD Ex Smoker COPD||||
33968385|NCT01381822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968386|NCT00032708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33968387|NCT04965610|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patients will be divided into two groups by lot.|Two groups of patients. One receiving preoxygenation via High Flow Nasal Cannula and one group receiving preoxygenation via face mask||||
33968388|NCT04283747|||COHORT||PROSPECTIVE|||||||
33968389|NCT05751395|||COHORT||PROSPECTIVE|||||||
33968390|NCT06232356|||COHORT||CROSS_SECTIONAL|||||||
33968391|NCT04127591|||CASE_ONLY||PROSPECTIVE|||||||
33968392|NCT06530290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968393|NCT04281056|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33968394|NCT04335110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068503|NCT05597449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants (caregivers) blinded to the intervention and outcomes and care providers blinded to the study group assignments|Families randomized by urologic surgery type to receive access to YouTube video link|t|t|f|f
34068504|NCT02496741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764851|NCT03311230|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33764852|NCT03149016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764853|NCT00191360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968395|NCT02775253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968396|NCT02947373|NA|SINGLE_GROUP||OTHER||NONE||||||
33968397|NCT02977442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756546|NCT04063774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Samples were coded and laboratory personnel were unaware of algorithm results, the participant did not know what algorithm prototype was tested.|Algorithms were developed and validated in silico, those with the highest sensitivity were tested in consecutive eligible subjects and their performance compared to dengue reference tests (gold standard combination of tests). Algorithms were modified according to intermediate analysis of performance planned in advance||||
33756547|NCT05000567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33968398|NCT02451670|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinics have been randomized into a treatment and a control arm.||||
33968399|NCT05185427|||CASE_ONLY||CROSS_SECTIONAL|||||||
33968400|NCT02410837|||COHORT||PROSPECTIVE|||||||
33968401|NCT05967312|||CASE_CONTROL||PROSPECTIVE|||||||
33968402|NCT06547879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Blinding of Participants:~Blinding of participants means that the individuals taking part in the study are not aware of which group they have been assigned to, whether it is the intervention group or the control group. This helps to prevent bias in their behavior and responses, as they do not know if they are receiving the actual treatment or a placebo.~Blinding of Outcome Assessors:~Blinding of outcome assessors involves keeping the individuals who are measuring and assessing the results of the study unaware of which participants belong to the intervention or control group. This is done to ensure that the data collected and the evaluations made are not influenced by any preconceived notions or expectations about the effectiveness of the intervention."|The study has a parallel two-group, randomized controlled intervention design.|t|f|f|t
33756548|NCT02450331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756549|NCT00618254|RANDOMIZED|||TREATMENT||NONE||||||
33756550|NCT05949970|||COHORT||RETROSPECTIVE|||||||
33756551|NCT03948750|||CASE_CONTROL||RETROSPECTIVE|||||||
33756552|NCT06495788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968403|NCT01423838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968404|NCT04072978|||COHORT||PROSPECTIVE|||||||
33968405|NCT01557452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875821|NCT06501742|||CASE_ONLY||RETROSPECTIVE|||||||
33875822|NCT04502251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blinded study, in which the participants and the outcomes assessor, who is the same as the investigator and the care provider, are blinded|A randomized, double-blinded, parallel, controlled with placebo and sham stimulation, clinical trial.|t|t|t|t
33875823|NCT02722863|||CASE_ONLY||PROSPECTIVE|||||||
33875824|NCT04370080|NA|SINGLE_GROUP||TREATMENT||NONE||Case series, consecutive||||
33875825|NCT03837470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875826|NCT02984046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875827|NCT05110053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Following surgery with implantation of Spinal cord stimulator (SCS), participants will be randomized to either active or placebo stimulation. The patient will have no knowledge of group, as the stimulation protocol is designed to be subperceptional. Further, the primary investigators and outcome assessors will be blinded to group assignment. Imaging analysis will likewise be blinded to group assignment.|Double blinded, placebo-controlled intervention study with six month voluntary, active extension.|t|t|t|t
33875828|NCT04553965|||COHORT||RETROSPECTIVE|||||||
33875829|NCT04453046|NA|SINGLE_GROUP||TREATMENT||NONE||This trial will evaluate the use of the Hemopurifier in combination with pembrolizumab (Keytruda) in patients with advanced and/or metastatic head and neck cancer. The Hemopurifier is a blood filtration device similar to a kidney dialysis cartridge which is designed to remove small particles called exosomes from the blood. Exosomes are believed to be involved in suppression of the immune system in cancer patients. The study will evaluate whether pretreatment with the Hemopurifier before administration of pembrolizumab is safe and well tolerated and results in lower numbers of exosomes in the blood.||||
33875830|NCT04155138|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Naida Hearing Aid Naida CROS Device||||
33875831|NCT05746221|||COHORT||PROSPECTIVE|||||||
33875832|NCT03464994|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33875833|NCT04703075|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Arm A (n=250): Experimental arm. Rifapentine 600 mg daily and isoniazid 300 mg daily for 4 weeks.~Arm B (n=250): Control arm. Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks."||||
33875834|NCT00077792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33875835|NCT00522431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968406|NCT00691145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968407|NCT00764803|||COHORT||RETROSPECTIVE|||||||
33968408|NCT00903890|||CASE_ONLY||RETROSPECTIVE|||||||
33968409|NCT00133315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968410|NCT01768078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068505|NCT01173900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068506|NCT03457844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068507|NCT00585325|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33875836|NCT01830504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968411|NCT01388686|||COHORT||RETROSPECTIVE|||||||
33968412|NCT02039310|||COHORT||PROSPECTIVE|||||||
33875837|NCT03767075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|no masking is used. All involved know the identity of the intervention assignment|"* Part A includes a molecular profiling program for subjects with advanced solid tumors (iPROFILER) and a molecular tumor board to select the most appropriate treatment based on the molecular alterations found in the iPROFILER.~* Part B includes iBASKET, a modular investigator initiated basket study for subjects with selected molecular alterations."||||
33875838|NCT05374538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose Escalation Phase followed by Expansion Phase. A total of 24 subjects are anticipated in Dose Escalation Phase, Cohort 1a. A total of 12 subjects are anticipated in Dose Escalation Phase, Cohort 1b. A total of 29 subjects are anticipated in Expansion Phase, Cohort 2a. A total of 29 subjects are anticipated in Expansion Phase, Cohort 2b. A total of 46 subjects are anticipated in Expansion Phase, Cohort 2c.||||
33875839|NCT02246062|RANDOMIZED|PARALLEL||||NONE||||||
33875840|NCT04141228|||COHORT||RETROSPECTIVE|||||||
33756553|NCT05654896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756554|NCT00814424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875841|NCT04829851|||COHORT||CROSS_SECTIONAL|||||||
33875842|NCT05536765|||OTHER||PROSPECTIVE|||||||
33875843|NCT03846752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875844|NCT02892474|||CASE_CONTROL||PROSPECTIVE|||||||
33875845|NCT01437397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875846|NCT05057169|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33875847|NCT04707898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled clinical trial|t|f|f|f
33875848|NCT05862181|||COHORT||RETROSPECTIVE|||||||
33875849|NCT03987503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875850|NCT03373305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875851|NCT03569800|||CASE_ONLY||PROSPECTIVE|||||||
33875852|NCT01614314|RANDOMIZED|PARALLEL||||NONE||||||
33875853|NCT04286061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875854|NCT01094431|||COHORT|||||||||
33875855|NCT02082509|||CASE_CONTROL||PROSPECTIVE|||||||
33875856|NCT05931146|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894301|NCT03815890|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Separate cohorts will be opened in this trial. LumB and TNBC tumors will be divided in separate cohorts.More cohorts, e.g. combining nivolumab and novel IO, can open after the start of this trial.||||
34068508|NCT00657995|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068509|NCT05787743|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34068510|NCT03952026|||COHORT||PROSPECTIVE|||||||
33756555|NCT04649502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|randomized controlled trial|t|t|t|t
33756556|NCT01235546|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756557|NCT04237506|NA|SINGLE_GROUP||TREATMENT||NONE||Children and adults with cerebral palsy||||
33756558|NCT06495203|||COHORT||RETROSPECTIVE|||||||
33756559|NCT02937272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756560|NCT04503525|||OTHER||PROSPECTIVE|||||||
33756561|NCT01016080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756562|NCT03721575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756563|NCT02408575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756564|NCT00119405|||COHORT||PROSPECTIVE|||||||
33756565|NCT04967235|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The researcher performing the heart rate variability and heart rate recovery data filtering will be blinded, and the researcher performing the data analysis will also be blinded. All data will be handled in a coded datasheet and all volunteer's names will be replaced by a confidential ID.|The study consists of one group of women who will be submitted to one dance-based cardiac rehabilitation session and after that will be submitted to one conventional exercise-based cardiac rehabilitation session|f|f|t|t
33756566|NCT05666453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756567|NCT06206928|||CASE_ONLY||PROSPECTIVE|||||||
33756568|NCT03881306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756569|NCT02063334|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33756570|NCT05025969|||COHORT||RETROSPECTIVE|||||||
33756571|NCT00936442|||COHORT||PROSPECTIVE|||||||
33756572|NCT03968432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33756573|NCT04834791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756574|NCT03887338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All the subjects will receive the same intervention, and they will be examined both prior to the intervention, one month after and three months after the intervention. They will act as they own controls.||||
33756575|NCT03344679|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33756576|NCT03580889|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33756577|NCT00207584|RANDOMIZED|PARALLEL||||DOUBLE||||||
33875857|NCT04226820|NA|SINGLE_GROUP||OTHER||NONE|There is no masking because the participant knows his diagnosis. Besides, the investigator checks the blood sugar at different times during the examinations, so also the investigator is not blinded. In this study, blinding would have no additional value.|Participants are divided into 3 groups based on their diagnosis: diabetes mellitus type 1, diabetes mellitus type 2, and healthy persons. Each participant (independent of group) will have the same examinations. There is no retesting of the same participant in other conditions.||||
33875858|NCT01401725|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875859|NCT02027142|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875860|NCT06079450|||OTHER||OTHER|||||||
33875861|NCT00768521|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33875862|NCT04174781|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase II Single-arm, Open-label Study||||
33875863|NCT02157675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33875864|NCT02972255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875865|NCT05664087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875866|NCT00001386||||TREATMENT||||||||
33875867|NCT02298829|||COHORT||PROSPECTIVE|||||||
33875868|NCT03725878|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a single-blind randomized controlled trial, participants are blinded from their preconceptional folate nutrition status.|cluster rondomization with average cluster size =100 pregnancies.|t|f|f|f
33875869|NCT01708109|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33875870|NCT03182270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875871|NCT00385255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875872|NCT04505241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not be informed of their assigned condition, though may infer it through the types of texts that they receive.~The principal investigator and outcomes assessor will each be blinded to a participant's assignment while the participant is enrolled in the study, and will be unblinded at the conclusion of the study prior to performing statistical analyses."|Half of participants will be randomized to receive text message-delivered adaptive goal-setting (goals change each day) for 6 weeks, and half will receive static goal-setting (goals are fixed) for 6 weeks.|t|f|t|f
33875873|NCT06408740|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875874|NCT01703013|||COHORT||PROSPECTIVE|||||||
33875875|NCT05015088|||OTHER||PROSPECTIVE|||||||
33875876|NCT04010396|||OTHER||OTHER|||||||
33875877|NCT05785143|||COHORT||PROSPECTIVE|||||||
33875878|NCT02185950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875879|NCT04156880|||COHORT||RETROSPECTIVE|||||||
33875880|NCT05803395|||CASE_ONLY||PROSPECTIVE|||||||
33875881|NCT03042507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875882|NCT03951623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875883|NCT01757678|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|No Masking|prospective, multicenter study to evaluate the diagnostic performance of cCTA plus FFRCT employing ≥64-detector row CT scanners for the detection and exclusion of significant obstructive CAD, as defined by invasively-measured FFR, the reference standard||||
33968413|NCT01797419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968414|NCT02281071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33968415|NCT00227656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968416|NCT06467500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968417|NCT03400371|||CASE_CONTROL||OTHER|||||||
33968418|NCT06530836|||COHORT||PROSPECTIVE|||||||
33968419|NCT06171997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple|36 baby in experimental group and 36 baby in control group, a total of 72 bany will be included in the study.|t|f|t|t
33756578|NCT01144026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756579|NCT03089892|||COHORT||RETROSPECTIVE|||||||
33756580|NCT05499390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764854|NCT06225414|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33968420|NCT03990389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968421|NCT04733131|||COHORT||OTHER|||||||
33968422|NCT00912418||PARALLEL||TREATMENT||NONE||||||
33968423|NCT03953365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33968424|NCT00280787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968425|NCT00947011|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33968426|NCT03503708|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068511|NCT02824562|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33968427|NCT00133107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968428|NCT05291728|||OTHER||CROSS_SECTIONAL|||||||
33875884|NCT03825770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Study participants will be blinded as to which educational program is the active treatment under study. Patient study materials and communications will only describe the study as being about an educational program for adults on hemodialysis with fatigue."|1:1 pilot randomized controlled trial. Participants will be randomized to intervention (energy conservation education) or active control (general information about kidney disease).|t|f|f|f
33875885|NCT06229795|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33875886|NCT00849732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33875887|NCT01157221|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33875888|NCT03445455|||CASE_ONLY||PROSPECTIVE|||||||
33968429|NCT06010056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, nurses who cared for the patients, the anesthetist who performed the anesthesia and the investigators who gathered the data were blinded to patients' group allocation.|"Participants were randomly allocated into either Group A or Group B by computer-generated randomization a day before planned surgery.~Group A will receive PCA ketamine-morphine 0.5 mg/ml in 1:1 ratio while group B will receive PCA morphine 1mg/ml."|t|t|t|f
33968430|NCT01333176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968431|NCT03618459|||COHORT||PROSPECTIVE|||||||
33968432|NCT05418478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
33968433|NCT05215704|||COHORT||PROSPECTIVE|||||||
33968434|NCT03080194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968435|NCT01783496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875889|NCT03652662|RANDOMIZED|PARALLEL||OTHER||NONE||This is a randomized longitudinal controlled observational study. The study will recruit 30 participants and utilize a control group experimental design with dependent pretest and posttest to derive data regarding (1) feasibility and (2) within-participant effect size of the RESP-FIT intervention in terms of satisfaction, use and adherence, technical issues and acceptability, and self-reported symptom severity (dyspnea and fatigue). When completed, 30 adults (15 in each group) will have used SAMS for 6 weeks.||||
33875890|NCT05858905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875891|NCT01836432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875892|NCT00432614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33875893|NCT03464656|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, prospective, comparative study||||
33875894|NCT01531608|||COHORT||PROSPECTIVE|||||||
33875895|NCT05916365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875896|NCT04170361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875897|NCT01418885|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875898|NCT00599482|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33875899|NCT05957289|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33875900|NCT03320759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33875901|NCT06308042|||OTHER||CROSS_SECTIONAL|||||||
33875902|NCT01490437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875903|NCT01653548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33875904|NCT01924455|||COHORT||PROSPECTIVE|||||||
33875905|NCT05686200|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Two-group Parallel Assignment|t|t|f|t
33875906|NCT05317520|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients were divided into intervention and control groups using a simple randomized control method.||||
33875907|NCT04863300|NA|SINGLE_GROUP||PREVENTION||NONE||The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from two types of NGOs (aged care or mental health service units) according to level of risks, symptom severity, and intervention response of the clients. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.||||
33875908|NCT02586935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33875909|NCT05373927|||OTHER||PROSPECTIVE|||||||
33875910|NCT00993928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875911|NCT02833259|||COHORT||RETROSPECTIVE|||||||
33875912|NCT01959711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875913|NCT00710528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875914|NCT05725616|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33875915|NCT01273051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894302|NCT06488781|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study participants, clinical personnel, and members of the research team responsible for collecting clinical outcomes will be blinded to the treatment group allocation. The research pharmacist at each site and the research analyst generating the randomization scheme will be the only study team members to know the treatment group allocation.|Patients will be randomly assigned 1:1 to receive either the prophylactic antibiotic regimen or placebos during labor induction.|t|t|t|f
33894303|NCT06152887|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33894304|NCT03180853|||COHORT||PROSPECTIVE|||||||
33894305|NCT03794986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized comparative||||
33968436|NCT05791942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel-arm randomized control trial|t|t|f|f
33968437|NCT03423706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968438|NCT04881890|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33968439|NCT04133571|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33968440|NCT04476732|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968441|NCT02647554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968442|NCT04074213|||CASE_ONLY||CROSS_SECTIONAL|||||||
33968443|NCT02659878|||CASE_ONLY||PROSPECTIVE|||||||
33968444|NCT03796299|||CASE_CONTROL||PROSPECTIVE|||||||
33968445|NCT06140511|||COHORT||PROSPECTIVE|||||||
33968446|NCT04136197|||COHORT||PROSPECTIVE|||||||
33968447|NCT02086656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968448|NCT00376779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34068512|NCT05300659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinded research nurse will take upper limb measurements at baseline, after 10 therapy sessions and at 6 months follow up, without knowing which of the two groups participant had been randomized to .||f|t|f|f
33756581|NCT03300947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase One: Double blind (both participant AND researchers (In room Care Provider, Investigators, Blinded Outcomes Assessor) Phase Two: Single blind (Participant and Blinded Outcomes Assessor)|All participants will be randomly assigned to administration of low dose (100 µg/kg) psilocybin, High dose (300 µg/kg) psilocybin, or Lorazepam (1 mg). Eight different sessions divided in two phases will ensure all subjects are exposed to psilocybin at some point during the study in a blinded fashion.|t|t|t|t
33756582|NCT02380625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756583|NCT04799626|||COHORT||PROSPECTIVE|||||||
33756584|NCT05505877|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33756585|NCT03012464|||COHORT||PROSPECTIVE|||||||
33968449|NCT06410040|||COHORT||RETROSPECTIVE|||||||
33968450|NCT02540707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968451|NCT00188695|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968452|NCT03058978|||COHORT||PROSPECTIVE|||||||
33968453|NCT05255133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968454|NCT04638855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Evaluator-blinded|Pivotal study (Determine effectiveness and adverse effects)|f|f|f|t
33968455|NCT00884130|||COHORT||PROSPECTIVE|||||||
33968456|NCT02555059|||COHORT||PROSPECTIVE|||||||
34068513|NCT00104806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068514|NCT01608672|||CASE_ONLY||CROSS_SECTIONAL|||||||
34068515|NCT05137002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756586|NCT05897567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756587|NCT02898779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33756588|NCT04675450|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756589|NCT00915031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894306|NCT05718362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups will be formed as study and control. A simple random distribution will be made when creating groups.||||
33894307|NCT00805207|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894308|NCT00824564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894309|NCT05244772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894310|NCT01449825|||COHORT||RETROSPECTIVE|||||||
33894311|NCT00458471|NON_RANDOMIZED|||PREVENTION||||||||
33894312|NCT03481530|||COHORT||PROSPECTIVE|||||||
33894313|NCT03366389|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33894314|NCT03672318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894315|NCT03792503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894316|NCT01162525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894317|NCT03978650|||COHORT||PROSPECTIVE|||||||
33894318|NCT03156530|RANDOMIZED|SINGLE_GROUP||OTHER||NONE|The subjects were randomized between the groups and the auricular stimulation was performed unilaterally, the motor preference side being standardized as the stimulated side|This study is a randomized controlled clinical trial to analyze the influence of auricular points on lower limbs on the equilibrium response assessed by static stabilometry||||
33894319|NCT03394222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|One research assistant was tasked to give the interventional medication in indentical containers to the anesthesiologists(care provider) in charge of the participants for preoperative preparations.Both the participants and care providers were blinded.||t|t|f|f
33894320|NCT05859854|||OTHER||PROSPECTIVE|||||||
33894321|NCT06656273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894322|NCT00219908|RANDOMIZED|PARALLEL||||NONE||||||
33894323|NCT04654507|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894324|NCT06056973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894325|NCT05514665|||COHORT||PROSPECTIVE|||||||
33894326|NCT00789126|RANDOMIZED|||||DOUBLE||||||
33894327|NCT05041738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968457|NCT03862625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In our clinical study, the person who performed radiographic evaluations before and after treatment did not know about the treatments received by the participants.|There are two groups in this study. In the first group, there is home exercises program for scoliosis and a modular adaptive seating system. In the second group there is only home exercises program for scoliosis. The nonambulatory children between the ages of 6-15 with cerebral palsy and scoliosis were randomly grouped according to the order of Pediatric Rehabilitation Unit of Istanbul University, Istanbul Faculty of Medicine, Physical Medicine and Rehabilitation Department.|f|f|f|t
34068516|NCT00351936|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34068517|NCT06168747|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||They were divided into two groups: research and sham mobilization. Participants in the study group had mediolateral wrist glide, anteroposterior 1st MCP glide, and anteroposterior and mediolateral glide. Applications were performed to the wrist, first metacarpal, and CMC joints in three sets of six repetitions. The patient in the sham mobilization group remained in the same posture for the same amount of time without gliding. The Nelson Hand Reaction Test was used to assess hand reaction before and after application. A 50 cm ruler was used, and the average of five measurements in cm was recorded and interpreted to sec.|t|f|f|f
34068518|NCT02227368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068519|NCT02374437|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34068520|NCT00747253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068521|NCT04677452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068522|NCT01171469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068523|NCT03890978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34068524|NCT05582759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068525|NCT02008032|NA|SINGLE_GROUP||SCREENING||NONE||||||
34068526|NCT02247271|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068527|NCT00690586|||CASE_ONLY||PROSPECTIVE|||||||
34068528|NCT03510897|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068529|NCT02641405|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34068530|NCT01575730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068531|NCT03816111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068532|NCT03247881|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
34068533|NCT06277713|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The outcome assessor will be blinded to the allocation of participants as samples will be code labeled.|"Participants will follow three regimes of 2 days each including a sedentary control, a sedentary with exercise and a standing breaks with exercise regimen. The sequence of the regimens will be randomised. Each regimen will be followed by a minimum wash-out period of 7 days during which subjects will continue their normal lifestyle.~We will use a balanced design with 6 randomisation blocks (ABC, ACB, BAC,BCA, CAB, CBA). The randomisation will be computer-generated and allocation will be determined by a member of the research team drawing a sealed, non-translucent envelop with herein written the scheme."|f|f|f|t
34068534|NCT03178851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068535|NCT03147976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068536|NCT03364621|||COHORT||PROSPECTIVE|||||||
34068537|NCT06000553|NA|SINGLE_GROUP||OTHER||NONE||the patient takes specific blood samples for the study||||
34068538|NCT04910737|||CASE_ONLY||RETROSPECTIVE|||||||
34068539|NCT06609031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068540|NCT01796301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068541|NCT05524727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
34068542|NCT04819477|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34068543|NCT00619125|||COHORT||RETROSPECTIVE|||||||
34068544|NCT02726984|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34068545|NCT00099177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068546|NCT04295369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068547|NCT03250338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068548|NCT01398358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068549|NCT02005237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34068550|NCT04389307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068551|NCT00815477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34068552|NCT03042910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068553|NCT04250428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Given the in-person nature pf both interventions, masking of subjects will not be possible. Interviewers conducting the final assessment will however be blinded to the treatment condition.|This study is designed as a 3-arm parallel trial|f|f|f|t
34068554|NCT04455737|||COHORT||RETROSPECTIVE|||||||
34068555|NCT03395847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068556|NCT03574688|NA|SINGLE_GROUP||PREVENTION||NONE||All participants of this pilot intervention study had the intervention of 1.5 Liters of increased daily water intake per day during 6 weeks.||||
34068557|NCT03025074|||COHORT||CROSS_SECTIONAL|||||||
34068558|NCT04769492|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068559|NCT02306421|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34068560|NCT03711136|||COHORT||RETROSPECTIVE|||||||
34068561|NCT01129271|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34068562|NCT05287854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068563|NCT00405847|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34068564|NCT00211432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068565|NCT04217642|||COHORT||PROSPECTIVE|||||||
34068566|NCT01979601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068567|NCT05388084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will recruit pregnant women to be randomized to: 1) the intervention arm (peer father phone call) or 2) the delayed intervention arm, standard of care standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay. Women in both arms will receive an HIVST kit from the ANC clinic per standard of care guidelines. In the delayed intervention arm, men who have not HIV tested after 3 months of female partner enrollment will receive the intervention of a peer father phone call.||||
34068568|NCT02328937|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34068569|NCT05578677|RANDOMIZED|FACTORIAL||DIAGNOSTIC||QUADRUPLE||2x2 factorial design|t|t|t|t
33875916|NCT03284736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the participant and primary investigator are blinded in the study until whole surgical procedure is completed and before suturing the flap.|A total number of 15 patients in each group were selected. Patients were randomly allocated by computer program into two group. Clinical and radiographic examinations were performed every 3, 6 and 12 months by assessing the same parameters as baseline except that PD, CAL, and GMP were measured until 12 months. Routine examination procedure were used to evaluate any evidence of signs and/or symptoms. Jig radiographs were taken at 3, 6 and 12th month of follow up. Inter and intra observation of data will be analyzed by distribution of data. Categorical data will be analyzed by chi square test. Regression analysis will be done to observe any association between independent and dependent variables. Interobserver/intraobserver reliability with cohen kappa analysis.|t|f|t|f
33875917|NCT02524509|||CASE_ONLY||PROSPECTIVE|||||||
33875918|NCT05011929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomised, assessor-blind, parallel group controlled trial|f|f|t|t
33875919|NCT02010164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875920|NCT04589273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Neither the researcher or the participant will know which arm of the trial they are part of.|Double blind, randomised, placebo controlled trial|t|f|t|f
33875921|NCT05950087|||COHORT||PROSPECTIVE|||||||
33875922|NCT04850053|||CASE_CONTROL||PROSPECTIVE|||||||
33875923|NCT05326984|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The patients are randomized assigned to one of two groups. One group (control group) will receive conventional chemotherapy during remission induction, the other group will receive conventional chemotherapy plus metformin 1000mgm2 per day during the remission induction.||||
33875924|NCT02752516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875925|NCT05069246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33875926|NCT05194540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875927|NCT03919526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875928|NCT00966537|||COHORT||PROSPECTIVE|||||||
33875929|NCT05082103|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33875930|NCT01251809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875931|NCT00004259|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I (sequential) followed by phase III (parallel)||||
33875932|NCT05070221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875933|NCT01258504|||CASE_CONTROL||PROSPECTIVE|||||||
33875934|NCT02918383|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875935|NCT04252430|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Open label, Parallel-group, Single oral dose|t|t|t|t
33875936|NCT05618665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875937|NCT05488587|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875938|NCT02388438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875939|NCT04314856|NON_RANDOMIZED|PARALLEL||OTHER||NONE||15 male subjects with FXS will be compared to 5 healthy volunteers who will be the control group.||||
33875940|NCT06279156|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33875941|NCT05068336|||OTHER||PROSPECTIVE|||||||
33875942|NCT01050309|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33875943|NCT05382975|RANDOMIZED|PARALLEL||PREVENTION||NONE||Schools will be randomized to start the intervention at different time points||||
33875944|NCT05777200|||CASE_ONLY||CROSS_SECTIONAL|||||||
33875945|NCT00651066|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875946|NCT04240327|||COHORT||PROSPECTIVE|||||||
33875947|NCT04068480|||CASE_ONLY||PROSPECTIVE|||||||
33875948|NCT05609890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the investigator who will provide the intervention and collect the data will be masked about interventions.|Parallel assignment|t|f|t|f
33875949|NCT00082888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875950|NCT05220826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome will be assesed by a blinded external core lab||f|f|f|t
33875951|NCT04599556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875952|NCT00510926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875953|NCT03785990|||COHORT||PROSPECTIVE|||||||
33875954|NCT05883891|||CASE_ONLY||RETROSPECTIVE|||||||
34068570|NCT03928379|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34068571|NCT04592679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875955|NCT02559440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33875956|NCT03949920|||COHORT||PROSPECTIVE|||||||
33875957|NCT01740115|||COHORT||PROSPECTIVE|||||||
33875958|NCT01632462|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33875959|NCT02350270|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875960|NCT02715037|||CASE_CONTROL||PROSPECTIVE|||||||
33875961|NCT05517941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|active cycle breathing and incentive spirometer|t|f|f|t
33875962|NCT00645957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756590|NCT00512148|NA|SINGLE_GROUP||TREATMENT||NONE|Note: Tengion no longer exists following Chapter 7 bankruptcy in 2014. No further information is available. No data are available to be reviewed or re-analyzed.|Note: Tengion no longer exists following Chapter 7 bankruptcy in 2014. No further information is available. No data are available to be reviewed or re-analyzed.||||
33756591|NCT04154202|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756592|NCT05771909|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33756593|NCT05599009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756594|NCT01216930|||COHORT||PROSPECTIVE|||||||
33756595|NCT03280134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study based on prospective cohort method and concerning on the two groups (whether ALND or not) by predictive model nSLN results.||||
33756596|NCT01220700|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756597|NCT01981733||||BASIC_SCIENCE||NONE||||||
33756598|NCT02763514|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33756599|NCT00004070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomize phase I/II where patients are directly assigned treatment.||||
33756600|NCT03144414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756601|NCT06469710|||CASE_ONLY||OTHER|||||||
33875963|NCT04503278|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33875964|NCT00446602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875965|NCT00273104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875966|NCT03655613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||(Phase 1) 3+3 dose escalation (Phase 2) Simon two-stage Minimax design||||
33875967|NCT06067737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and study team will be masked/blinded to intervention.|The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care outpatient buprenorphine induction|t|t|t|t
33875968|NCT02868008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894328|NCT01588223|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068572|NCT05180981|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34068573|NCT05719298|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068574|NCT01216917|||COHORT||CROSS_SECTIONAL|||||||
34068575|NCT01456143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068576|NCT04019886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068577|NCT01782352|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34068578|NCT06073509|||COHORT||OTHER|||||||
34068579|NCT01694901|||COHORT||PROSPECTIVE|||||||
34068580|NCT05969587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756602|NCT02993445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33756603|NCT05706766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33756604|NCT05482048|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm randomised, pilot trial with an embedded qualitative component||||
33756605|NCT01326858|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33756606|NCT04437238|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|Consenting participants will be randomly allocated to the intervention (KeepWell) or control (usual care) using a random number generator; allocation will be concealed. Consenting participants will be assigned a login and password by the research coordinator, which they can use to access the KepWell tool. Each individual login and password will be randomly allocated into intervention or control using a 1:1 ratio; participants will be the unit of randomization. The research coordinator will have the master list of logins and allocation. Allocation will thus be concealed because this list will not be shared with the research team. To protect against sources of bias, investigators, outcome assessors and data analysts will be blinded to the randomization sequence. Blinding of older adults will not be possible given that the intervention is a standalone, web-based tool and the control condition is usual care.||f|f|t|t
33894329|NCT01745003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894330|NCT03904927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894331|NCT00349297|||||PROSPECTIVE|||||||
34068581|NCT03440970|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34068582|NCT04763616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068583|NCT00936676|||COHORT||PROSPECTIVE|||||||
33756607|NCT06108375|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||monocentric study utilizing a prospective repeated measures design||||
34068584|NCT01763203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34068585|NCT01981070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068586|NCT02301819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764855|NCT04163887|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective multicenter, open-label and pragmatic, controlled randomized (minimization procedure) superiority trial in 2 parallel groups comparing the rates of 90 days postoperative complications between patients undergoing laparoscopic and open liver resection for colorectal liver metastases.||||
34068587|NCT02130700|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068588|NCT00799799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068589|NCT04521842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients qualified to undergo total hip arthroplasty due to the end-stage osteoarthritis will be randomly allocated to receive either standard femoral head size implants nor large ones. Pre- and postoperatively they will undergo gait analysis. To avoid risk of bias assessor will be blinded in terms of used implants in every participants case.|t|f|t|t
34068590|NCT01651754|NA|SINGLE_GROUP||||NONE||||||
33764856|NCT04609124|||CASE_CONTROL||PROSPECTIVE|||||||
33764857|NCT00928759|||CASE_ONLY||PROSPECTIVE|||||||
33764858|NCT05264610|||COHORT||RETROSPECTIVE|||||||
33894332|NCT00995371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33764859|NCT05822336|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Single blind masking|Repeated measure|t|f|f|f
33764860|NCT02607657|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33764861|NCT03290157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33764862|NCT00445198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764863|NCT01907139|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33764864|NCT00970125|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33875969|NCT05106309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Part A is an open-label, randomized, 4-period, 4-sequence, crossover design to investigate the PK, relative bioavailability, safety, and tolerability of single doses of CVL-231 IR/MR formulations in healthy participants. The following treatments, administered under fasted conditions are: 1) 10mg CVL-231 as IR formulation, 2) 30mg CVL-231 as slow release MR formulation, 3) 30mg CVL-231 as medium release MR formulation, 4) 30mg CVL-231 as fast release MR formulation.~Part B is an open-label, randomized, 2-period, 2-sequence, crossover design to investigate the effect of food on CVL-231 PK following a single dose of the CVL-231 MR formulation in healthy participants. After completion of Part A, a target release formulation (MR formulation with acceptable PK characteristics) may be selected and effect of food on CVL-231 PK from the target release formulation may be evaluated. Based on Part A data, if a target release formulation cannot be selected, Part B of the trial may be canceled."||||
33875970|NCT06166186|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33756608|NCT05523414|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Only the Principal investigator and study coordinator will have access to identifying information. They will de-identify the data and then send this de-identified data (sequencing data and the other clinical, demographic and behavioral data) into an easily accessible set of files for further analysis by the remaining team members. They will also make sure there are no medical record numbers, intervention type, or other identifying information in this dataset, and that the data is blinded in this respect. The files will be stored behind a secure firewall, so that it can only be accessed with permission by the members of the study group. The data will denote the SKY and control groups as Arm 1 \& Arm 2 without indicating whether they refer to SKY or the control groups.|Participants are assigned to either the SKY arm or the control arm, that practices the HEP.|f|f|t|f
33756609|NCT06579495|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, experimental group 1 involved peer participation in a Competitive Exergame; that is, the participants were accompanied by peers to complete the experiment. Experimental group 2 completed the task on their own using the Single-player Competitive Exergame. The control group did not undergo any intervention and simply continued with their normal school routine.|t|f|t|t
33756610|NCT04398212|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33756611|NCT00617292|||CASE_CONTROL||PROSPECTIVE|||||||
33756612|NCT01774747|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33756613|NCT02745665|||COHORT||OTHER|||||||
33756614|NCT04620187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756615|NCT05651776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756616|NCT04775914|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"2x2 factorial~As a second randomization to the iPOST2 trial (ID: H-180512561,NCT03787745) patients are randomized 1:1 to either a) receiving ultrasound guidance before and after stent placement or b) no ultrasound, independently of randomization in the iPOST2 trial. The iPOST2 trial was initiated February 2019."||||
33756617|NCT04245280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blind|Prospective, randomized controlled, triple blind|t|t|f|t
33756618|NCT02561494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33756619|NCT03214367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756620|NCT01896882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756621|NCT03325244|||COHORT||PROSPECTIVE|||||||
33756622|NCT05340855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This is a single arm study where every participant in Phase 3 will receive the same single intervention.|All study participants in Phase 3 beta test will be in the same Facebook group intervention and will view the same content.||||
33756623|NCT02753855|NA|SINGLE_GROUP||||NONE||||||
33756624|NCT03008967|||COHORT||PROSPECTIVE|||||||
33756625|NCT05291780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756626|NCT06579820|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33756627|NCT01047592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756628|NCT00173901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33756629|NCT06049264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756630|NCT05258786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will collect the data from the files without knowing the participant's groups (intervention/control/standard care)|Randomized controlled study|f|f|f|t
34068591|NCT01648998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068592|NCT00040144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33756631|NCT04636489|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.|placebo-controlled, randomized clinical trial|t|t|t|t
33756632|NCT06200844|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756633|NCT04021303|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33756634|NCT00586404|||COHORT||PROSPECTIVE|||||||
33756635|NCT00244790|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34068593|NCT05887960|||COHORT||CROSS_SECTIONAL|||||||
34068594|NCT00037778|||FAMILY_BASED||RETROSPECTIVE|||||||
34068595|NCT02632370|||COHORT||PROSPECTIVE|||||||
33756636|NCT02276885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756637|NCT05306041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756638|NCT00957294|||COHORT||PROSPECTIVE|||||||
33756639|NCT00002587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875971|NCT05595083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33875972|NCT01981590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894333|NCT02676258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33894334|NCT04980547|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multi-centre, non-randomized, and non-blinded follow-up study.||||
33894335|NCT02580162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894336|NCT02561897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894337|NCT00390832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068596|NCT03231397|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||"Eligible subjects in this study will have either a known abdominal aortic aneurysm (AAA) or because they do not have an AAA (control group).~The purpose of this research study is to further study, through FEA, changes that occur in the mechanical properties of the aortic wall. The investigator will compare two radiotracers, 18F-FDG and 11C-PBR28 to determine if one provides more useful and reliable information about inflammation. 18F-FDG and 11C-PBR28 are radioactive drugs that will be used for imaging during the PET-CT scan. The investigator will also compare the results describing the mechanical properties of the AAA wall to the degree of inflammation in that wall as determined by PET-CT imaging to define new and better predictors of AAA growth and/or rupture."||||
34068597|NCT04282616|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures assessors will be blinded to group allocation|End-stage kidney disease patients will be proposed to choose between one of the three organizational models of exercise (counselling; home-based prescription; supervised) or to take part in the project as a control group (no exercise).|f|f|f|t
34068598|NCT02900664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068599|NCT00096187||||TREATMENT||NONE||||||
34068600|NCT01549340|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34068601|NCT00645671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068602|NCT01894971|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34068603|NCT05091996|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
34068604|NCT05831150|||CASE_CROSSOVER||PROSPECTIVE|||||||
34068605|NCT01765816|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34068606|NCT02186899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34068607|NCT04536298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068608|NCT05597878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068609|NCT05887362|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34068610|NCT04318262|||CASE_CONTROL||PROSPECTIVE|||||||
34068611|NCT03548350|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068612|NCT00292916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34068613|NCT04750941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068614|NCT00495989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068615|NCT03234920|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34068616|NCT03747783|||COHORT||RETROSPECTIVE|||||||
34068617|NCT02022735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34068618|NCT03142776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068619|NCT00493506|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068620|NCT00593606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068621|NCT00547417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068622|NCT03425994|||COHORT||PROSPECTIVE|||||||
34068623|NCT00898872|||||RETROSPECTIVE|||||||
34068624|NCT05130645|||OTHER||PROSPECTIVE|||||||
34068625|NCT03405571|||CASE_ONLY||PROSPECTIVE|||||||
34068626|NCT02992756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068627|NCT01917461|||COHORT||PROSPECTIVE|||||||
33875973|NCT05261022|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be unmasked to their group assignment as they will be told their group assignment, by virtue of the psychosocial intervention. There is no care provider (the intervention is participant-directed and fully online). Participants report on their own outcomes and thus outcomes are not masked. Feasibility outcomes are masked. Study team investigators, including data analysts, will be masked. The research coordinator will be the only unmasked member of the research team.|The current study is a two-arm (intervention vs. waitlist) design with pre-, 1-week post-, and 1- and 3-month follow-up assessments. The first 120 interparental couples who meet eligibility criteria and consent will be included in the study. The entirety of the study will be conducted online (via mobile or computer). The writing assignments (intervention vs. inactive-control task) will commence approximately one week following baseline surveys, which will include three writing sessions over the course of 12 weeks (one session every 4 weeks). Following the 3 month follow-up, couples randomised to the waitlist control condition will be invited to participate in the writing program (i.e., three writing sessions over the course of 12 weeks).|f|f|t|f
33875974|NCT02126709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33875975|NCT02370615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875976|NCT00032565|||||CROSS_SECTIONAL|||||||
33875977|NCT03603821|||COHORT||PROSPECTIVE|||||||
33875978|NCT01883635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875979|NCT05687071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33875980|NCT05006469|NA|SINGLE_GROUP||TREATMENT||NONE||Relapsed and refractory MM received bendamustine combined with liposomal adriamycin (or adriamycin) and dexamethasone (BAd) for treatment||||
33875981|NCT02037932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875982|NCT00713427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33875983|NCT04133532|RANDOMIZED|CROSSOVER||TREATMENT||NONE||We will enroll 50 patients and divide them into two arms. Initially, arm A will be given metoprolol and arm B will not. We will evaluate the two groups after a sufficient time period (three months) and after that, patients will cross-over to the other treatment strategy for three months followed by a final evaluation.||||
33875984|NCT06542055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875985|NCT01253655|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33875986|NCT02358070|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33875987|NCT04753827|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three different strategies for true bifurcation||||
33875988|NCT04459780|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Monocentric, open-label, comparative, parallel group and intra-individual patho-physiological study :~* Group 1 : 20 subjects with plaque psoriasis~* Group 2 : 10 subject with atopic dermatitis"||||
33875989|NCT01697735|NON_RANDOMIZED|PARALLEL||||NONE||||||
33875990|NCT02937818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875991|NCT05056532|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34068628|NCT05158842|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34068629|NCT05546320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756640|NCT03111056|RANDOMIZED|PARALLEL||TREATMENT||NONE|The intervention and assessments are all completed online and therefore masking is not necessary.|||||
34068630|NCT02178358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068631|NCT00565227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068632|NCT00258193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068633|NCT00006244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068634|NCT00845273|||CASE_ONLY||PROSPECTIVE|||||||
34068635|NCT00639392|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34068636|NCT04672876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068637|NCT04363138|||COHORT||PROSPECTIVE|||||||
34068638|NCT00691652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068639|NCT03087383|||COHORT||OTHER|||||||
34068640|NCT02079441|||COHORT||PROSPECTIVE|||||||
34068641|NCT03824366|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068642|NCT06010628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068643|NCT03701152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068644|NCT04096001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068645|NCT00888498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068646|NCT04969588|||CASE_ONLY||PROSPECTIVE|||||||
34068647|NCT02156440|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33756641|NCT02068495|||COHORT||PROSPECTIVE|||||||
33756642|NCT05047055|||COHORT||PROSPECTIVE|||||||
33756643|NCT00733980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756644|NCT03660579|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756645|NCT01071564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756646|NCT06425328|||COHORT||CROSS_SECTIONAL|||||||
33756647|NCT03381755|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33756648|NCT05858138|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33875992|NCT01221064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33875993|NCT01310894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33875994|NCT05444595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33875995|NCT03685539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33875996|NCT03940859|||COHORT||PROSPECTIVE|||||||
33875997|NCT03424252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33875998|NCT05651295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33875999|NCT04519385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blind|dexamethsone group Tocilizumab group|t|f|f|t
33876000|NCT01713023|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33876001|NCT04131335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876002|NCT02972073|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876003|NCT02646982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876004|NCT06460090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All outcomes will be administered blind and the investigator team analysing parent videos will be blind to time and treatment arm.|"The design is a parallel cluster randomised trial of a 12-week manualised intervention delivered in pre/school settings serving socially disadvantaged communities, over two academic years in Ireland. Following baseline data and scoring, randomization will take place at the level of the setting whereby pre/schools will be allocated to either a treatment or a business as usual control group, stratified for geographical region."|f|f|t|t
33876005|NCT01605526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876006|NCT01058096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876007|NCT00801879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876008|NCT04689529|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876009|NCT02787863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876010|NCT02362958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876011|NCT04793178|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The investigator and assessor are blinded to study arms.||f|f|t|t
33876012|NCT01748539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876013|NCT03608176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876014|NCT00393107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876015|NCT00600574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876016|NCT03223064|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876017|NCT00586495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876018|NCT01489566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876019|NCT04191382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876020|NCT02785926|||COHORT||PROSPECTIVE|||||||
33876021|NCT06275360|NA|SINGLE_GROUP||TREATMENT||NONE||Carboplatin, paclitaxel, and nivolumab for three cycles followed by radiotherapy followed by nivolumab (for squamous cell lung cancer) OR Carboplatin, pemetrexed, and nivolumab for three cycles followed by radiotherapy followed by nivolumab (for lung adenocarcinoma)||||
33876022|NCT02567890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33876023|NCT04936295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068648|NCT05633589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068649|NCT00621725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068650|NCT04713293|||COHORT||PROSPECTIVE|||||||
34068651|NCT00313586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068652|NCT06012526|||CASE_ONLY||CROSS_SECTIONAL|||||||
33876024|NCT06476067|||CASE_CONTROL||RETROSPECTIVE|||||||
33876025|NCT05769335|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The OMIT study will be a parallel, single-blinded, 3-arm randomised controlled trial.||||
33876026|NCT01425008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876027|NCT05256407|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective case/control intervention study||||
33876028|NCT00000874|||COHORT||PROSPECTIVE|||||||
33968458|NCT04405934|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Superiority model:~1. Baseline/control phase 1 Sample collection and genomic sequencing from Covid-19 positive participants suspected of acquiring infection in hospital (suspected nosocomial Covid-19 infection where tested positive \>48 hours after hospital admission) where sequencing reports not interpreted/actioned by Infection Prevention Control (IPC) site teams~2. Site intervention phase Sample collection and genomic sequencing from Covid-19 positive participants suspected of acquiring infection in hospital where sequencing reports generated both rapid or standard and received by site IPC teams for interpretation and action~3. Control phase 2 (prospective) Sample collection and genomic sequencing from Covid-19 positive participants suspected of acquiring infection in hospital where sequencing reports not interpreted/actioned by IPC site teams - where deemed ethical and approved by oversight committees i.e. DMEC."||||
33968459|NCT05245773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic randomized controlled trial with intervention and control arm||||
33968460|NCT05890105|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33876029|NCT03053479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876030|NCT04578795|NA|SINGLE_GROUP||OTHER||NONE||||||
33876031|NCT04509921|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33876032|NCT03064737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876033|NCT00290485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968461|NCT02748005|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34068653|NCT04965337|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34068654|NCT02993965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34068655|NCT05390385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Supplement packaging will be labeled with an alphanumeric code that is only understood by an individual who is not involved in the study. The participants and study team will both be blinded to the supplement being given.|Participants will each undergo all five treatments, in randomized order. The five treatments include the control placebo, 5g of KE1, 10g of KE1, 5g of KE4, and 10g of KE4. There will be a minimum of two days washout period between treatments.|t|f|t|f
34068656|NCT04591392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068657|NCT04414423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eighteen patients will be divided into two equal groups. Each group comprises nine patients.|f|f|f|t
34068658|NCT06133959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will only know that they will be assigned to one of the two comparable behavioral and educational programs and they will not know which program is the intervention. Outcome assessors will not know the participants' assigned program throughout the study.|Intervention and control arms|t|f|f|t
34068659|NCT05643209|NA|SEQUENTIAL||TREATMENT||NONE||||||
34068660|NCT00708474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756649|NCT04497792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756650|NCT00180635|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33756651|NCT06054659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756652|NCT02434510|||COHORT||PROSPECTIVE|||||||
33756653|NCT00687921|||COHORT||PROSPECTIVE|||||||
33756654|NCT01256567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756655|NCT00835848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756656|NCT03651648|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33756657|NCT03684148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This was a randomized, controlled, parallel-group intervention trial to evaluate the benefits of adding MI practice to CPT postoperative rehabilitation program. Eligible patients were randomly assigned to either an intervention group in which MI practice was combined with CPT (MIp), or to a control group which received CPT alone (CON).|t|t|f|f
33756658|NCT03631446|||CASE_ONLY||PROSPECTIVE|||||||
33756659|NCT02220894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756660|NCT00800969|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33756661|NCT06134830|||COHORT||RETROSPECTIVE|||||||
33756662|NCT02832206|||COHORT||PROSPECTIVE|||||||
33756663|NCT05176275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756664|NCT04569630|NA|SINGLE_GROUP||OTHER||NONE||||||
33756665|NCT02731248|||||PROSPECTIVE|||||||
33756666|NCT00353587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876034|NCT00870961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33876035|NCT03344315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Observer: Another periodoncist outside the intervention, would be in charge of recording the clinical parameters.~Analyst: The statistician does not know which treatment corresponds to each variable."|split mouth|f|f|f|t
33876036|NCT01982292|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33876037|NCT03129490|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Open label|Cluster randomized cross-over study.|f|f|f|t
33876038|NCT05773001|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33876039|NCT03465189|||COHORT||PROSPECTIVE|||||||
33876040|NCT04720482|||COHORT||PROSPECTIVE|||||||
33876041|NCT06320769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876042|NCT06256510|NA|SINGLE_GROUP||OTHER||NONE||||||
33876043|NCT00991523|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33876044|NCT04268121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II and prospective cohort||||
33876045|NCT01072214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876046|NCT05723705|||COHORT||PROSPECTIVE|||||||
33876047|NCT06320561|||COHORT||PROSPECTIVE|||||||
33876048|NCT06077266|||COHORT||OTHER|||||||
33876049|NCT02661412|||COHORT||RETROSPECTIVE|||||||
33876050|NCT01445951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894338|NCT01161225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33894339|NCT02341664|||COHORT||CROSS_SECTIONAL|||||||
33756667|NCT00763958|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33756668|NCT00002155||||TREATMENT||DOUBLE||||||
33756669|NCT06111209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756670|NCT00778128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756671|NCT06395610|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33756672|NCT01451879|||CASE_ONLY||PROSPECTIVE|||||||
33756673|NCT01405625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33756674|NCT01429636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756675|NCT01528384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756676|NCT04031144|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients with reduced clot strength before applying ultrafiltration (patients with MCF in ROTEM-EXTEM less than the cut-off value which will be determined by preliminary analyses, n=30).~ROC analysis of the preliminary data was performed and the cut-off values was 50.5 mm.~The sample size of the present study is determined by using these data. The minimum sample size to detect the observed difference by applying ultrafiltration was 25, with a 2-sided significance level of 0.05 and a statistical power of 0.80. Considering 10% of the possible loss, 28 patients will be recruited for the present study.~Patients who scheduled for elective cardiac surgery with cardiopulmonary bypass are recruited first, and the data of patients with MCF \<50.5 mm will be included to the final analysis."||||
33756677|NCT03006770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756678|NCT03987841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756679|NCT03381768|NA|SINGLE_GROUP||TREATMENT||NONE||Fixed dose safety study||||
33756680|NCT00145015|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33756681|NCT00653458|RANDOMIZED|CROSSOVER||||NONE||||||
33756682|NCT01520740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756683|NCT00002974||||TREATMENT||||||||
33756684|NCT04079348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization to treatment groups will be performed using a computer system to randomly assign subjects to treatment arms. Sealed envelopes numbered 1-40 will be provided to the study site. Patients will be assigned an envelope number upon providing informed consent. The envelope will be opened during the treatment procedure to minimize the risk of bias in patient assignment to the treatment group.|"A patient is suitable for inclusion in the study if the patient meets the following criteria, based on known information at the time of enrolment:~1. Has a split thickness skin graft (STSG) donor site wound no greater than 14 x 20 cm in size requiring placement of a covering material."|f|f|f|t
33756685|NCT00766233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756686|NCT02116348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756687|NCT02388802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756688|NCT03278938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||treatment in this study was determined by treatment received in prior study; i.e., those who had received escitalopram then receive escitalopram + bupropion; those initially taking bupropion then receive escitalopram + bupropion||||
33756689|NCT05488626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756690|NCT02680548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756691|NCT03014674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756692|NCT03574064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33756693|NCT00268827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756694|NCT03670667|||COHORT||RETROSPECTIVE|||||||
33876051|NCT06463613|NA|SINGLE_GROUP||TREATMENT||NONE||This pivotal investigational study is designed to evaluate the safety and efficacy of a skin tag removal (STR) study device. This is a non-significant risk interventional clinical study that will be conducted by a Clinical Research Organization (CRO) with a licensed dermatologist(s) to serve as Principal Investigator. There are two arms of the study that are only differentiated by the type of STR study device used; arm 1 will be conducted using the manual version, and arm 2 will use the automatic version.||||
33876052|NCT04713865|||CASE_CROSSOVER||PROSPECTIVE|||||||
33876053|NCT02033564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756695|NCT00755040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756696|NCT04137692|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33756697|NCT05874765|||CASE_ONLY||CROSS_SECTIONAL|||||||
33756698|NCT06165783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756699|NCT01269580|||CASE_CONTROL||PROSPECTIVE|||||||
33756700|NCT03840603|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||This is an open label, prospective, single-center, randomized interventional trial with 2 arms (FilmArray-guided arm versus usual care).|t|f|f|f
33876054|NCT03884738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||randomization into three groups and measurement before and after intervention||||
33876055|NCT01526902|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33876056|NCT00177944|||COHORT||PROSPECTIVE|||||||
33756701|NCT02963974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756702|NCT06447584|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764865|NCT02090335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33876057|NCT02177201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33876058|NCT00743951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33876059|NCT00578682|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33876060|NCT04194255|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33876061|NCT02154282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876062|NCT04286204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33876063|NCT04073771|||COHORT||RETROSPECTIVE|||||||
33876064|NCT04213612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876065|NCT03098784|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33876066|NCT00245362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876067|NCT03363815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968462|NCT06078488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will not be blinded to group allocations due to the nature of the study, which is not a placebo-controlled trial, but rather, a real-world pragmatic study. Subjects, research dietitian and nursing staff will be aware that they are in a study to examine the effects of nutritional intervention on pressure injury healing rates. The nursing personnel responsible for measuring wounds and gathering data will not be blinded, given their role in conducting follow-up with the participants as a component of clinical care. However, they will be randomized to ensure that they do not attend to both the intervention and control groups. The research dietitian will be blinded to the measurement and health outcomes. The trial statistician will be blinded to the group allocation.||f|f|t|t
33968463|NCT01380314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968464|NCT04821882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968465|NCT03491605|||COHORT||PROSPECTIVE|||||||
34068661|NCT01872650|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34068662|NCT03859648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068663|NCT00564395|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068664|NCT02829385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068665|NCT06304298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068666|NCT06054945|||COHORT||RETROSPECTIVE|||||||
34068667|NCT03482908|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A multi-site, randomized controlled trial (RCT) to test that hypothesis that an individually tailored responsive parenting obesity prevention intervention that coordinates care provided by WIC nutritionists and primary care providers will be effective to ultimately reduce/prevent obesity in infants.||||
34068668|NCT00048997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756703|NCT04917133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||controlled randomized trial with two parallel arms||||
33756704|NCT00778479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33876068|NCT00623428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876069|NCT04922476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876070|NCT01617980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876071|NCT00456989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876072|NCT00193063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876073|NCT01972048|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876074|NCT00879697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876075|NCT01206959|||||PROSPECTIVE|||||||
33876076|NCT01527773|||COHORT||PROSPECTIVE|||||||
33876077|NCT05852535|||CASE_ONLY||RETROSPECTIVE|||||||
34068669|NCT01247389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068670|NCT00222014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876078|NCT06203561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33876079|NCT01481038|||COHORT||PROSPECTIVE|||||||
33876080|NCT04285021|||COHORT||PROSPECTIVE|||||||
33756705|NCT04232683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33756706|NCT03834233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756707|NCT00260143|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33756708|NCT06122740|||OTHER||CROSS_SECTIONAL|||||||
33756709|NCT02243410|||COHORT||PROSPECTIVE|||||||
33756710|NCT05043051|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33756711|NCT00083057||||TREATMENT||||||||
33756712|NCT03393195|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial. Participants will randomly assigned to one of two diet interventions for the duration of the 12-week study.||||
33756713|NCT04878835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756714|NCT00227617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756715|NCT00680927|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33756716|NCT01091948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33756717|NCT03699579|||COHORT||RETROSPECTIVE|||||||
33756718|NCT02497287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756719|NCT00294983|||||RETROSPECTIVE|||||||
33756720|NCT03074227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients will be randomised by a computerised random-number generator to one of the following two treatment arms:~1. allogeneic faecal infusions at t=0 and t=6.~2. autologous faecal infusions at t=0 and t=6.~Randomisation and preparation of the faeces will be performed by one of the research assistants. He/she is the only person who will know which treatment the patient will be given and will have no role in further parts of the study.~The randomisation list will be kept under secured access by the Clinical Research Unit of the AMC Amsterdam, who will perform the randomisation. In case of an emergency the study medication can be unblinded after consultation of the principal investigator."|Double-blind, randomised, placebo-controlled pilot study as well as a reversed translational part.|t|t|t|t
33968466|NCT06455189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neurosurgeons and participants will not be masked to the treatment group assignment, but the team members looking at outcome assessment will be blinded.|Participants will be randomly allocated in a one-to-one ratio to undergo either tumor resection with intraoperative MRF/MRI infiltration mapping guidance or with standard of care neurosurgical techniques. The investigators who assess eligibility of participants and schedule surgeries (neurosurgeons, residents, research nurse) will be masked to treatment group assignment by use of a sealed-envelope design. The treatment group assignments will be disclosed after surgery is scheduled and after written consent is obtained, usually on the day before the operation.|f|f|f|t
33968467|NCT04391556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968468|NCT03361956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968469|NCT04281368|||COHORT||RETROSPECTIVE|||||||
33968470|NCT02025582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968471|NCT03874078|||CASE_ONLY||PROSPECTIVE|||||||
33968472|NCT02578810|||CASE_CONTROL||PROSPECTIVE|||||||
33968473|NCT05709106|||COHORT||PROSPECTIVE|||||||
33756721|NCT00002611||||TREATMENT||||||||
33756722|NCT04026165|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Participants received Run-in and Randomized treatments sequentially and in the Randomized Phase, the treatments were assigned in parallel.|t|f|t|f
33756723|NCT05040555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756724|NCT05011474|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical trial is a Phase 1/2a, open and researcher-led clinical trial. Subjects will be enrolled in succession, signed informed consent, and administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 to each eligible subject meeting all selection criteria.||||
33756725|NCT00522626|||COHORT||PROSPECTIVE|||||||
33756726|NCT05076630|||OTHER||PROSPECTIVE|||||||
33968474|NCT00077688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968475|NCT05624359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33968476|NCT06272851|||COHORT||PROSPECTIVE|||||||
33968477|NCT04053478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968478|NCT06316947|NA|SINGLE_GROUP||OTHER||NONE||a feasibility pilot of the new CHW-delivered intervention to reduce home shisha SHS exposure with n=15 Somali families.||||
33968479|NCT03575559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Friendship dyads are assigned to the 4 conditions without being informed that 4 conditions exist.||t|f|f|f
33968480|NCT01993433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968481|NCT01893502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968482|NCT04182932|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33968483|NCT04780100|||CASE_ONLY||RETROSPECTIVE|||||||
33968484|NCT03780894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Single-center, non-randomized, open-label, two-arms, controlled pilot clinical trial.~The experimental and control arms will be determined according to the SEM units with RBC, TXA and FC administration capacity (i.e. helicopter unit, rapid intervention ambulance or advanced life support ambulance). The emergency SEM units are activated according current protocols based on distance, severity and weather conditions."||||
33968485|NCT02801448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968486|NCT03526367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968487|NCT06045416|||COHORT||PROSPECTIVE|||||||
33968488|NCT04800445|||CASE_CONTROL||PROSPECTIVE|||||||
33968489|NCT02416037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968490|NCT02673671|||COHORT||PROSPECTIVE|||||||
33756727|NCT05979831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756728|NCT03087565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756729|NCT05293561|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33756730|NCT01440400|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33756731|NCT00795457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756732|NCT02128464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33756733|NCT03625401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the double-blind period, all of the study personnel, including Investigators, site personnel,the Sponsor's staff (eg, clinical research associate \[CRA\]/monitor), and study subjects will be blinded to treatment assignment. Placebo and AD-35 will be identical in appearance and packaging to preserve blinding.|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet; Placebo group: 3 placebo tablets.|t|f|t|f
33756734|NCT01814748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756735|NCT06223412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33756736|NCT05590208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756737|NCT04274452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756738|NCT00789815|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756739|NCT04450537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876081|NCT05430763|||CASE_CONTROL||PROSPECTIVE|||||||
33876082|NCT00800332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876083|NCT01991782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876084|NCT01588977|||CASE_CONTROL||PROSPECTIVE|||||||
33876085|NCT02519933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876086|NCT03809611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-mask(Investigator, patient)||t|f|t|f
33876087|NCT01123746|||COHORT||PROSPECTIVE|||||||
33876088|NCT02263716|||COHORT||PROSPECTIVE|||||||
33876089|NCT05178238|||CASE_ONLY||PROSPECTIVE|||||||
33876090|NCT01223703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876091|NCT02879565|NA|SINGLE_GROUP||||NONE||||||
33968491|NCT06281119|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968492|NCT01434056|||COHORT||PROSPECTIVE|||||||
33756740|NCT02563496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756741|NCT03433989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, prospective, epidemiological, descriptive and analytical study.||||
33756742|NCT06579053|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33756743|NCT00212992|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33756744|NCT01825629|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33756745|NCT02336243|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756746|NCT06328764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756747|NCT00066482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756748|NCT04152902|||COHORT||PROSPECTIVE|||||||
33756749|NCT02773550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756750|NCT01474213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33756751|NCT00009802||||TREATMENT||||||||
33756752|NCT00335452|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33876092|NCT04765800|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-Inferiority Trial (NI margin: d = 0.46, required N = 152, α = 0.025, 1-β = 0.80)||||
33876093|NCT01621633|NON_RANDOMIZED|PARALLEL||||NONE||||||
33876094|NCT05985031|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Group I. Spinal cord injuries Group II. Healthy Control||||
33876095|NCT06399887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876096|NCT02152852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876097|NCT00533442|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33876098|NCT02915081|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33876099|NCT02739607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876100|NCT03048929|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33876101|NCT05026398|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participant, Data Collectors, Outcomes Assessor|Participants will be randomly allocated to one of two groups (fenfluramine or placebo), stratified on group allocation, gender and cognitive task version administered. Participants in the fenfluramine group will receive oral solution of fenfluramine 15mg twice daily (BID) for seven days. Participants in the placebo group will receive a placebo oral solution 15mg twice daily (BID) for seven days. The study is assessing the effects of fenfluramine on cognitive ability, it is not an efficacy or safety study.|t|f|t|t
33876102|NCT02588053|||OTHER||PROSPECTIVE|||||||
33876103|NCT05286970|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33876104|NCT02034890|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33968493|NCT03335020|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756753|NCT05072457|NA|SINGLE_GROUP||OTHER||NONE||||||
33756754|NCT04050774|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756755|NCT00921986|||CASE_CONTROL||PROSPECTIVE|||||||
33756756|NCT02252419|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33756757|NCT03983187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756758|NCT01053195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756759|NCT05676632|||OTHER||CROSS_SECTIONAL|||||||
33756760|NCT02221167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756761|NCT04656379|||COHORT||RETROSPECTIVE|||||||
33756762|NCT02623322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876105|NCT00776607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876106|NCT02702765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876107|NCT00069498|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33876108|NCT06338839|||CASE_CONTROL||OTHER|||||||
33876109|NCT06103201|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876110|NCT01500109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876111|NCT04523077|||CASE_CONTROL||PROSPECTIVE|||||||
33876112|NCT00094978||||TREATMENT||||||||
33876113|NCT02707367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33876114|NCT01836783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968494|NCT04078230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||resectable intrahepatic cholangiocarcinoma|t|f|f|f
33968495|NCT01653483|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33968496|NCT00468923|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33968497|NCT00814658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968498|NCT05707429|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968499|NCT03955666|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, multiple ascending dose study|t|t|t|t
33968500|NCT04621942|RANDOMIZED|PARALLEL||OTHER||NONE||the study finally included 24 women after mastectomy (age, 66.2 ± 10.6 years, range 43-82 years; body mass, 72.7 ± 10.6 kg; height, 159 ± 5.2 cm), 17 after simple mastectomy and 7 after breast conserving therapy. The participants were randomly allocated into two groups: a training group (T; n = 12) and a control group (C; n = 12) using chit method. The T group participated in 6 weeks of inertial training while the control group maintain their normal daily activity. All women still participated in rehabilitation gymnastics twice a week.||||
33968501|NCT00229112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756763|NCT01328301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876115|NCT01432691|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33876116|NCT05372523|||COHORT||PROSPECTIVE|||||||
33876117|NCT04989920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Evaluator was blinded to group membership|Two group (treated vs waitlisted) crossover design.|f|f|f|t
33756764|NCT04894201|||COHORT||RETROSPECTIVE|||||||
33756765|NCT05867810|||OTHER||CROSS_SECTIONAL|||||||
33756766|NCT03250884|||COHORT||PROSPECTIVE|||||||
33756767|NCT01887080|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33756768|NCT00590902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756769|NCT01012232|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33756770|NCT03209323|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The EEGs recorded before and during the general anaesthesia induction analysed offline by a neurophysiologist with an expertise in anaesthetic EEGs, the recording technique, and the anaesthetic agent used unaware of group allocation of the participant.||t|f|f|f
33756771|NCT05171751|||OTHER||RETROSPECTIVE|||||||
33756772|NCT03163355|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|f|t
33756773|NCT05016154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756774|NCT06580379|||OTHER||RETROSPECTIVE|||||||
33756775|NCT00417352|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33756776|NCT05030779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764866|NCT03461848|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33876118|NCT06123065|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Delayed cross-over design, with a Waitlist control. This study was a quasi-randomization to Active or Waitlist and Waitlist individuals were then moved to the Active group after assessment.||||
33876119|NCT03784976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33876120|NCT04943991|NA|SINGLE_GROUP||SCREENING||NONE||||||
33876121|NCT01564186|||CASE_CONTROL||PROSPECTIVE|||||||
33876122|NCT05754814|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33876123|NCT05186142|||COHORT||PROSPECTIVE|||||||
33876124|NCT01243710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876125|NCT04627272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a study to determine the accuracy of AutoDX. All eligible study participants will have a retinal fundus image taken which is then uploaded to the RetinaVue Network. Subjects will also undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera.||||
33876126|NCT05619198|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||A two-period, cross-over, clinical trial with between and within cohort comparisons of two different exercise modalities in adolescents with type 1 diabetes||||
33876127|NCT00751400|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33876128|NCT02951715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876129|NCT04766021|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33756777|NCT05099926|NA|SINGLE_GROUP||PREVENTION||NONE||The intervention involves home-based psychoeducation, interoceptive exposure (walking), and interoceptive counseling administered by research personnel via video visits. Participants also complete weekly physical activity journals throughout the intervention.||||
33968502|NCT05270187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|By sealed envelopes, the allocation concealment will be achieved. Patient randomization is performed simply by computer number generator for each patient using GraphPad software. All eligible participants will be evaluated by independent physician and will be treated by the same therapist. The physician conducts the processes of participant enrollment, and allocation. The same assessors will measure the measured outcome. Both the therapist and the assessor will be blinded (masked) from patient's enrollment into the three study groups.|A total of 60 recruited patients will be randomly assigned into three groups of 20 patients in each. Group one will receive MLS laser therapy with 10 J/cm2 in scanning mode to the affected side plus facial massage and exercises. Group two will receive MLS laser therapy to predetermined eight motor points to facial muscles plus facial massage and exercises. Group three will receive placebo laser plus facial massage and exercises.|t|f|t|t
33968503|NCT00736619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968504|NCT02419859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968505|NCT03705169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068671|NCT03732222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the masking of the evaluator has been obtained, measuring the association between the response variables at baseline and the intervention group, by means of the variance analysis (ANOVA), for each response variable separately. We have verified that there are no differences between the means of the responses at the baseline level in each assigned intervention group, so that masking at the level of the evaluator has been carried out correctly||t|f|f|t
34068672|NCT05823974|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Phase 2 of this study will be observer blind.||t|t|t|t
33756778|NCT05627102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A specialist physician will be diagnosed the supraspinatus tendinopathy.|f|f|f|t
33756779|NCT01578811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756780|NCT01783418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34068673|NCT01041677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068674|NCT01752062|||CASE_ONLY||PROSPECTIVE|||||||
34068675|NCT03041467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068676|NCT02800915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068677|NCT04235816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple: (Participant, Care Provider, Investigator, Outcomes Assessor)|2-arm individually randomized placebo-controlled clinical trial of AZi administration in young children from Sierra Leone.|t|t|t|t
34068678|NCT04551235|||CASE_ONLY||PROSPECTIVE|||||||
34068679|NCT01709864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068680|NCT06439472|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Dual (participant, outcome assessor). Participants will be assigned codes, these codes will be randomized via the website https://www.invertexto.com/numeros-aleatorios, and randomly distributed into two groups, a control group and an experimental group, where only the principal investigator and the care provider will have access.~The outcome assessors will also have no contact with the researcher and the participant during the intervention."||t|f|f|t
33968506|NCT04458337|||COHORT||PROSPECTIVE|||||||
33968507|NCT03575039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968508|NCT01718210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968509|NCT03867227|||COHORT||PROSPECTIVE|||||||
33968510|NCT03524937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968511|NCT03208348|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single group will pilot test a virtual reality system that is designed to support mental health treatment.||||
33968512|NCT02130206|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33968513|NCT02785835|||COHORT||OTHER|||||||
33968514|NCT02804269|||COHORT||PROSPECTIVE|||||||
33756781|NCT04111003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756782|NCT02080429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756783|NCT03019926|||COHORT||PROSPECTIVE|||||||
33756784|NCT00455975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756785|NCT00694005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756786|NCT00292435|RANDOMIZED|PARALLEL||||DOUBLE||||||
33968515|NCT05209490|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33968516|NCT02706002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968517|NCT00787566|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33968518|NCT03717285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068681|NCT06228495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33756787|NCT05072925|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34068682|NCT01281956|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34068683|NCT03958942|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34068684|NCT03585712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068685|NCT02732015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068686|NCT05483465|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All data will be unmasked upon completion of the trial, or during performance of data review if requested by the data safety and monitoring board.|Randomized, double-blinded, placebo-controlled, parallel study design|t|f|t|t
34068687|NCT02007655|||CASE_ONLY||PROSPECTIVE|||||||
34068688|NCT04652947|||COHORT||RETROSPECTIVE|||||||
34068689|NCT01522131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068690|NCT04046822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068691|NCT04600609|||CASE_ONLY||PROSPECTIVE|||||||
34068692|NCT03899402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a two-center, randomized, open-label then double-blind, parallel group, placebo and standard of care controlled prospective study in type 1 diabetes.|This will be a two-center, randomized, open-label then double-blind, parallel group, placebo and standard of care controlled prospective study in type 1 diabetes.|t|f|t|f
34068693|NCT00004794||||TREATMENT||||||||
34068694|NCT05745233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068695|NCT00774072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068696|NCT00615810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068697|NCT04964583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068698|NCT03928964|||COHORT||RETROSPECTIVE|||||||
34068699|NCT01858220|||CASE_ONLY||PROSPECTIVE|||||||
34068700|NCT03990779|||COHORT||PROSPECTIVE|||||||
34068701|NCT04024566|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34068702|NCT05950165|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 sequential cohort design||||
34068703|NCT05041660|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants and investigators will not be aware who is receiving the sham ICT and who is receiving the real ICT.|The study is a 2x2 factorial design with the factors being VR (VR/non-VR) and ICT (ICT/Sham).|t|f|f|f
34068704|NCT00940186|||CASE_CONTROL||PROSPECTIVE|||||||
34068705|NCT00030485||||TREATMENT||||||||
34068706|NCT04202965|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Study||||
34068707|NCT02663765|||COHORT||CROSS_SECTIONAL|||||||
34068708|NCT06397209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068709|NCT00633490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756788|NCT01768130|||COHORT||PROSPECTIVE|||||||
33756789|NCT05050149|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study||||
33756790|NCT02095275|||COHORT||PROSPECTIVE|||||||
33756791|NCT00785408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756792|NCT05711979|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756793|NCT02080975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756794|NCT04790058|||COHORT||PROSPECTIVE|||||||
33756795|NCT05200130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756796|NCT05452655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study is designed as a Randomized Controlled Trial (RCT). Subjects with a diagnosis of PD in accordance of MDS criteria will be randomly allocated to the experimental (EXP) or control group (CTR).~Clinical, kinematic, blood samples and MRI data will be collected before (T0) at the end of treatment (T1) and 3 months after the end of treatment (T2)."|f|f|t|t
33756797|NCT06286605|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized controlled trial of parallel-group design.||||
33756798|NCT02604290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756799|NCT01254123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33756800|NCT03604536|||COHORT||PROSPECTIVE|||||||
33756801|NCT02771444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is an imaging study. All participants will be imaged using two modalities. All participant data will be deidentified.|||||
33756802|NCT03222193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756803|NCT03084926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756804|NCT04922346|||CASE_CROSSOVER||PROSPECTIVE|||||||
33756805|NCT02672254|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33756806|NCT05907382|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33876130|NCT01318109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876131|NCT06474559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33876132|NCT02369614|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33876133|NCT00549367|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33876134|NCT05637918|||COHORT||PROSPECTIVE|||||||
33876135|NCT05640778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876136|NCT04418076|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876137|NCT00264238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876138|NCT00865826|||COHORT||PROSPECTIVE|||||||
33876139|NCT04334980|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33876140|NCT04655443|||COHORT||PROSPECTIVE|||||||
33876141|NCT05482230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||double-lumen tube or bronchial blocker in lateral position|t|f|f|f
33876142|NCT01250379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876143|NCT04906174|||COHORT||RETROSPECTIVE|||||||
33968519|NCT05933525|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Consenting, eligible participants will be randomized in a 1:1 ratio to receive either the test article Travelan® or placebo. Once enrolled into the study (subject meets all eligibility criteria and is selected by the investigator for inclusion in the study), subjects will be assigned a randomization number. The subject will receive the study treatment regimen assigned to the corresponding randomization number. Subjects will receive the test article/placebo in containers bearing their assigned identification numbers. This number will be linked to the randomization code list securely maintained throughout the clinical phase of the study by the designated study staff. Investigators and participants will remain blinded to group assignments until completion of the clinical phase of the trial and validation of the clinical and immunological data.|60 healthy volunteer participants will be randomized to receive Travelan investigational product or placebo. The study is a double-blind randomized study.|t|t|t|t
33968520|NCT00122850|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33968521|NCT00708630|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33968522|NCT06528002|||COHORT||PROSPECTIVE|||||||
33968523|NCT03082456|NA|SINGLE_GROUP||SCREENING||NONE||||||
33968524|NCT01314326|||OTHER||PROSPECTIVE|||||||
33968525|NCT00037466|||COHORT||PROSPECTIVE|||||||
33968526|NCT05451043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968527|NCT06503042|||COHORT||PROSPECTIVE|||||||
33968528|NCT00003782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968529|NCT01154153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968530|NCT01146730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968531|NCT05261425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968532|NCT05654610|||COHORT||PROSPECTIVE|||||||
33968533|NCT00919971|||COHORT||RETROSPECTIVE|||||||
33968534|NCT06440083|||COHORT||PROSPECTIVE|||||||
33968535|NCT01168115|||CASE_ONLY||CROSS_SECTIONAL|||||||
33968536|NCT02168075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33968537|NCT00595426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33876144|NCT01246440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876145|NCT04995276|||COHORT||RETROSPECTIVE|||||||
33968538|NCT01032161|||COHORT||PROSPECTIVE|||||||
33968539|NCT04882111|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33968540|NCT06012591|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Before-after study||||
33968541|NCT03984071|||COHORT||PROSPECTIVE|||||||
33968542|NCT02036528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968543|NCT04545632|||COHORT||PROSPECTIVE|||||||
33968544|NCT05064202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968545|NCT05252078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876146|NCT03561909|NA|SINGLE_GROUP||OTHER||NONE||||||
33876147|NCT01508871|||COHORT||PROSPECTIVE|||||||
33876148|NCT05210530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876149|NCT05541809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33876150|NCT02940509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33876151|NCT01203384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876152|NCT04163250|||COHORT||PROSPECTIVE|||||||
33876153|NCT01604265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876154|NCT04338503|||COHORT||PROSPECTIVE|||||||
33876155|NCT04411264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876156|NCT01337128|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876157|NCT04246879|NA|SINGLE_GROUP||OTHER||NONE||||||
33876158|NCT01566773|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33876159|NCT04004650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968546|NCT03108079|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Female patients seen at the Pelvic Floor Institute will be offered participation in the study. The study will consist of a pelvic floor MRI at no cost to them or their payors. Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (A and B above) in sequence. During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.||||
33876160|NCT04687800|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label prospective randomized comparative investigator -initiated study||||
33876161|NCT04087525|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876162|NCT00414453|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33876163|NCT00837109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968547|NCT05618483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized 1:1 to receive the Xylitol Based Nasal Spray or a matching saline base placebo. This is a double blinded study. The Nasal Spray Kits will be randomized and allocated to patients in chronological order.|Randomization to Nasal Spray or Placebo|t|t|t|t
33968548|NCT04484922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756807|NCT05159089|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The trial has an open design with a blind assessment of outcomes. Researchers conduction the baseline assessments will be blind to group allocation. The statistician (RMV) will also be blind to group allocation until the completion of the statistical analysis. Participants will be asked not to reveal group allocation when undergoing follow-up measurements. To assess the extent to which blinding has been preserved, researchers will record the number of cases in which allocation was revealed.|A mixed methods research model will be used. A prospective and longitudinal three-arm randomized control trial with blinded evaluators will be needed to compare the efficacy of the interventions. Outcomes will be assessed at baseline, month three (end of intervention), and at months 12 and 24 (9 and 21-month post-intervention), which will be the main outcome assessment. The study protocol has been developed based on the Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) guidelines. On the other hand, a qualitative analysis using semi-structural interviews should help to understand both the reasons for the (un)efficacy and the patients' and HCP's perceptions about the intervention. Qualitative outcomes will be assessed at month three (end of intervention) and at month 24 (21-month post-intervention).|f|f|t|t
33756808|NCT00173108|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33756809|NCT04274894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756810|NCT01543243|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33756811|NCT00452387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756812|NCT00346021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876164|NCT00401375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876165|NCT01806363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876166|NCT00762892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876167|NCT04473378|||COHORT||PROSPECTIVE|||||||
33876168|NCT00945776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876169|NCT00416000|||COHORT||PROSPECTIVE|||||||
33968549|NCT03492073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33876170|NCT04066972|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 'proof-of-principle/feasibility' within group repeated measures study.||||
33876171|NCT06192901|||COHORT||PROSPECTIVE|||||||
33876172|NCT03981237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876173|NCT02062788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876174|NCT02877173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876175|NCT00851851|||CASE_ONLY||PROSPECTIVE|||||||
33876176|NCT02510027|||COHORT||PROSPECTIVE|||||||
33876177|NCT05407584|NA|PARALLEL||TREATMENT||NONE||||||
33876178|NCT03294031|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33876179|NCT04719182|||COHORT||RETROSPECTIVE|||||||
33876180|NCT01074190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876181|NCT03057236|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to Standard of Care group or the Intervention (CBCS) group.||||
33876182|NCT02286180|||CASE_ONLY||CROSS_SECTIONAL|||||||
33876183|NCT03716869|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33876184|NCT06179771|RANDOMIZED|PARALLEL||TREATMENT||NONE||Consecutive study participants would be assigned using block randomisation into the intervention arm or the standard of care arm. Patients in the intervention arm would be treated with the HA380 column. The outcomes would be compared with patients who received standard ICU care .||||
33876185|NCT05791656|||COHORT||PROSPECTIVE|||||||
33876186|NCT02486731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33876187|NCT00811772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876188|NCT03403114|||OTHER||CROSS_SECTIONAL|||||||
33876189|NCT05567237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This is a randomised, balanced, double-blind parallel-group between-participants design. The participants will not know whether they receive sham or live microcurrent. Both devices (microcurrent and sham) will look exactly the same in terms of appearance, colour, size and weight. The current transmitted from the microcurrent device is insufficient to stimulate sensory nerve fibres, so participants will not be able to feel it, and due to the fact that the devices will have the same appearance, neither participants nor researchers will be able to identify those participants allocated to the MC or the SH groups. Only one researcher who will not be involved in the assessments and training supervision will know the participant allocation during the intervention (unblinded researcher).|"Randomised, double-blind parallel-group between-participants design, which will analyse the effects of microcurrent on health-related parameters. Once considered eligible, the participants will be randomly assigned to the following two groups:~1. Microcurrent (MC)~2. Sham (SH) Thereafter, all of the participants will be offered to take part in a supervised resistance training (RT) programme which will be combined with either the MC or SH intervention.~The participants who do not accept to undergo the resistance training programme will integrate a non-exercise group involving a 6-week intervention period using the microcurrent (MC) or the sham (SH) device. Those participants who accept to perform the resistance training programme (regardless of being previously allocated to MC + RT or SH + RT) will perform a 2-session familiarization before the beginning of the study. Then, they will follow the exercise programme of 2 training sessions per week for 6 weeks (12 sessions in all)."|t|f|t|t
33876190|NCT01783119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876191|NCT00385632|||COHORT||PROSPECTIVE|||||||
33876192|NCT03376568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33876193|NCT00240409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876194|NCT03600662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968550|NCT01252628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968551|NCT02468986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968552|NCT00689429|||CASE_ONLY||RETROSPECTIVE|||||||
33756813|NCT04838990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33876195|NCT00586261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33876196|NCT03969121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876197|NCT02018731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968553|NCT04846556|||COHORT||RETROSPECTIVE|||||||
33968554|NCT02308111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968555|NCT04511351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968556|NCT03518710|NA|SINGLE_GROUP||OTHER||NONE||||||
33968557|NCT05499156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both the patient and the assessor are blind to the contents of injectibles|This study includes two arms. The first one is the cases that are treated with MSC-derived exosomes and the controls do not receive exosomes and are treated with placebo|t|f|f|t
33968558|NCT01916785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968559|NCT02600169|||COHORT||RETROSPECTIVE|||||||
33756814|NCT06449131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756815|NCT00642187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33968560|NCT03911609|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are masked to the primary hypothesis of the study.|All subjects will participate in two randomized sessions (exercise session and cognitive task session). Experimental pain assessment will be performed before after both tasks.|t|f|f|f
33968561|NCT06503341|||COHORT||PROSPECTIVE|||||||
33968562|NCT02758366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968563|NCT02447484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33968564|NCT04449159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068710|NCT06217445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|DOUBLE BLIND|parallel study is type of clinical study in which two or more groups of participants receive different interventions.|t|f|f|t
34068711|NCT00781924|||COHORT||PROSPECTIVE|||||||
34068712|NCT02758197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33756816|NCT05605054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756817|NCT06008574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A prospective randomized pilot study||||
33756818|NCT05717556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33756819|NCT01265355|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756820|NCT01750606|||COHORT||CROSS_SECTIONAL|||||||
33756821|NCT04392466|||CASE_CONTROL||PROSPECTIVE|||||||
33756822|NCT01410058|||CASE_CROSSOVER||PROSPECTIVE|||||||
33756823|NCT01382394|||COHORT||PROSPECTIVE|||||||
33756824|NCT04189692|||OTHER||CROSS_SECTIONAL|||||||
33756825|NCT04394364|||COHORT||PROSPECTIVE|||||||
33968565|NCT03754816|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33968566|NCT01681771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968567|NCT02960815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968568|NCT04412499|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968569|NCT04976868|||COHORT||PROSPECTIVE|||||||
33968570|NCT04078919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068713|NCT02431104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068714|NCT01084538|||||PROSPECTIVE|||||||
33756826|NCT02579954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756827|NCT05596175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to blind either the participant or care providers to their study arm, however the outcome analysis will be undertaken blinded to study arm|Patients randomized to Usual Care or Super Rehab plus Usual Care|f|f|f|t
33756828|NCT05493774|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized control trial|f|f|f|t
33756829|NCT01896869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756830|NCT02218827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756831|NCT02360319|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33756832|NCT03220490|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33756833|NCT00498979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756834|NCT02479568|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33756835|NCT02159248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756836|NCT02608866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876198|NCT02459795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756837|NCT05478980|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33756838|NCT01974167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756839|NCT01922076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756840|NCT00598026|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876199|NCT03927274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876200|NCT06403527|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Investigator-initiated, prospective, randomized, interventional, multicenter trial|t|f|t|f
33876201|NCT06185153|||CASE_CONTROL||RETROSPECTIVE|||||||
33876202|NCT03914807|RANDOMIZED|PARALLEL||PREVENTION||NONE||Superiority cohort embedded 2 arm pragmatic randomized controlled trial||||
33876203|NCT00796276|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968571|NCT00863057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33756841|NCT04349280|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study.|This is a single arm study.||||
33756842|NCT04107922|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33756843|NCT03293576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34068715|NCT04747665|||OTHER||RETROSPECTIVE|||||||
33756844|NCT02695355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756845|NCT02465840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33756846|NCT04954599|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A modular, multi-arm, multi-part, first time in patient study||||
33756847|NCT05100186|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756848|NCT02403180|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33756849|NCT05862922|||OTHER||PROSPECTIVE|||||||
33756850|NCT01291498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756851|NCT05835830|||CASE_ONLY||PROSPECTIVE|||||||
33756852|NCT04788901|NA|SINGLE_GROUP||SCREENING||NONE||||||
33756853|NCT03434327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756854|NCT00147680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876204|NCT04962022|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a Phase I, fixed sequence, 2-period study to evaluate the effect of the strong CYP3A4 inhibitor, itraconazole, on the PK of PF-07321332 and ritonavir in healthy participants. A total of 12 healthy participants will be enrolled into this study.||||
33876205|NCT00323440|||CASE_CONTROL||PROSPECTIVE|||||||
33876206|NCT02243085|||COHORT||RETROSPECTIVE|||||||
33876207|NCT05458388|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33876208|NCT04043546|NA|SINGLE_GROUP||TREATMENT||NONE||Patients enrolled in the study receive a novel physiotherapy program.||||
33876209|NCT01417715|||CASE_ONLY||PROSPECTIVE|||||||
33876210|NCT05680909|||CASE_ONLY||PROSPECTIVE|||||||
34068716|NCT03582319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized clinical trial, double blinded using split mouth technique.|t|f|f|t
34068717|NCT04926506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068718|NCT02634632|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34068719|NCT04856059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||cardiac MRI||||
33756855|NCT06188793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756856|NCT05452928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|We will use a centralised internet-based computer-generated randomisation schedule prepared and overseen by an experienced statistician. Patients will be randomised in a 1:1 ratio in permuted blocks of two to six and stratified by country, sex, and adjunctive dexamethasone treatment (yes/no).|Investigator initiated, double-blind, 2-arm (1:1 allocation), international, multicentre, parallel group, randomised, placebo controlled, superiority trial.|t|t|t|t
33756857|NCT03285126|||CASE_ONLY||PROSPECTIVE|||||||
33756858|NCT05980208|||COHORT||PROSPECTIVE|||||||
33756859|NCT06580366|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33756860|NCT01093105|||COHORT||PROSPECTIVE|||||||
33756861|NCT05978245|||COHORT||PROSPECTIVE|||||||
33756862|NCT01410955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756863|NCT04023240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756864|NCT03063697|||COHORT||PROSPECTIVE|||||||
33876211|NCT04575558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876212|NCT05194085|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33876213|NCT00725400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876214|NCT04683250|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation phase followed by a dose expansion phase (Phase 1), then followed by a Phase 2 at the recommended dose||||
33876215|NCT01609907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876216|NCT05779462|||COHORT||PROSPECTIVE|||||||
33876217|NCT03269708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33894340|NCT06037954|RANDOMIZED|PARALLEL||OTHER||NONE||This protocol aims to refine and pilot test a brief telehealth intervention, Open Door for Cancer (OD-C), that addresses individual barriers to mental health service initiation in depressed older adults with cancer (OACs) without requiring in-person appointments.||||
33894341|NCT05008328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894342|NCT03932240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894343|NCT01672892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756865|NCT02508987|||||CROSS_SECTIONAL|||||||
33756866|NCT00975910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33756867|NCT05239130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, open-label, non-randomized clinical investigation||||
33756868|NCT02785341|RANDOMIZED|CROSSOVER||||NONE||||||
33756869|NCT00438880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756870|NCT00652782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756871|NCT05093049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33756872|NCT00579280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756873|NCT01089374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756874|NCT02054806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876218|NCT05715970|NA|SINGLE_GROUP||SCREENING||NONE||"The ITAMA_CAP project, designed as a prospective, multicenter study \[U.O.C. of Geriatrics (21.01) of the University Hospital of Palermo and the Mater Dei Hospital of Malta), provides for the enrollment of about 25,000 subjects, divided between Sicily and Malta. Approximately 10,000 students aged between 12 and 18 will be enrolled in Malta and approximately 15,000 adults (\>18 years) will be enrolled in Sicily. These numbers are dictated by the need to obtain heterogeneous samples comparable with the subjects diagnosed in the previous ITAMA project (20,000). In Sicily, screening will be carried out in the GPs (Italian takers) clinics."||||
33876219|NCT00736346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876220|NCT02141269|||COHORT||PROSPECTIVE|||||||
33876221|NCT01859442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33876222|NCT03167996|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group A Control Group B HealthPals||||
33876223|NCT01926288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876224|NCT05087550|||OTHER||OTHER|||||||
33876225|NCT04304443|||COHORT||RETROSPECTIVE|||||||
33876226|NCT04261673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756875|NCT01090570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756876|NCT00140205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756877|NCT05606757|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33876227|NCT02844556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876228|NCT01779973|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33756878|NCT00520858||PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756879|NCT00693173|||CASE_ONLY||RETROSPECTIVE|||||||
33756880|NCT01312870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876229|NCT03770585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876230|NCT05512546|||CASE_CONTROL||RETROSPECTIVE|||||||
33876231|NCT00261430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068720|NCT00627926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068721|NCT05565885|||CASE_ONLY||PROSPECTIVE|||||||
33756881|NCT01830114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756882|NCT05996666|||CASE_CONTROL||PROSPECTIVE|||||||
33756883|NCT06580522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33756884|NCT05695781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double Masking|t|f|t|f
33756885|NCT00999466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756886|NCT00372008|RANDOMIZED|CROSSOVER||||NONE||||||
33756887|NCT03069092|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33756888|NCT00006018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756889|NCT01085838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756890|NCT05929469|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This initial pilot and feasibility study uses a sequential, multiple assignment, randomized trial (SMART) design to test digital, behavioral weight loss approaches, with or without human support. Sequential randomization will occur at baseline and at the end of 4 weeks. At baseline, participants will be randomized to receive a standard mHealth program and either a a) Fully Automated Kick-Off session, or b) Human-Enhanced Kick-Off session. Using an a priori decision rule after 4 weeks, those for whom the intervention is not effective will be re-randomized and receive one of two doses of human support. The final assessment will be at 3 months.||||
33756891|NCT00440869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756892|NCT05260996|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756893|NCT00209924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33756894|NCT00131014|||FAMILY_BASED||PROSPECTIVE|||||||
33756895|NCT00977665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756896|NCT05024851|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33756897|NCT02037048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756898|NCT05751512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756899|NCT04114838|||COHORT||RETROSPECTIVE|||||||
33756900|NCT00929162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756901|NCT03758976|||COHORT||PROSPECTIVE|||||||
33756902|NCT01127282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756903|NCT05699330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756904|NCT04806295|||COHORT||RETROSPECTIVE|||||||
33756905|NCT02701985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33756906|NCT03488368|||OTHER||RETROSPECTIVE|||||||
33756907|NCT02673398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756908|NCT05592054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756909|NCT02335073|||COHORT||PROSPECTIVE|||||||
33756910|NCT02616887|||COHORT||PROSPECTIVE|||||||
33764867|NCT03555825|RANDOMIZED|PARALLEL||OTHER||NONE||Group 1: 60 minutes of Armeo treatment, 3 times per week for 6 weeks. (Half the patients will be assigned to 1:1 therapy and the other half to 2:1 therapy) Group 2: 30 minutes of Armeo treatment, 3 times per week for 6 weeks. (Half the patients will be assigned to 1:1 therapy and the other half to 2:1 therapy)||||
33764868|NCT00856661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764869|NCT02617277|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876232|NCT04314271|||COHORT||PROSPECTIVE|||||||
33764870|NCT05967182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764871|NCT00594971|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33764872|NCT02716038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764873|NCT06534905|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33764874|NCT01320423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764875|NCT06396416|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double: Double (Investigator, Outcomes Assessor)||f|f|t|t
33876233|NCT03008356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876234|NCT05231382|RANDOMIZED|PARALLEL||TREATMENT||NONE|Oxaliplatin Fluorouracil|Oxaliplatin retitrexed||||
34068722|NCT02751164|||COHORT||RETROSPECTIVE|||||||
33764876|NCT03592030|||COHORT||PROSPECTIVE|||||||
34068723|NCT05762809|NA|SINGLE_GROUP||SCREENING||NONE||||||
33764877|NCT02629055|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764878|NCT00605943|||||PROSPECTIVE|||||||
33764879|NCT03027063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876235|NCT03964961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapist who assesses the outcomes is blinded.||f|f|f|t
33876236|NCT04788654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876237|NCT00441597|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33876238|NCT05125237|||COHORT||RETROSPECTIVE|||||||
33876239|NCT05378451|||CASE_ONLY||PROSPECTIVE|||||||
33876240|NCT05033470|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center prospective pilot study||||
33876241|NCT03053297|||COHORT||PROSPECTIVE|||||||
33876242|NCT01251367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894344|NCT03797560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894345|NCT04444570|||COHORT||PROSPECTIVE|||||||
33894346|NCT03487224|||COHORT||CROSS_SECTIONAL|||||||
33894347|NCT05145465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33894348|NCT01671904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894349|NCT02707029|||COHORT||PROSPECTIVE|||||||
33894350|NCT02216565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894351|NCT05718102|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33894352|NCT06656585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894353|NCT00310310|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33894354|NCT00201539|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33968572|NCT00006721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968573|NCT02967133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968574|NCT01072032|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33968575|NCT01670461|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756911|NCT03619460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sequentially sealed opaque envelopes will be opened by a nurse not involved in the treatment of the patient and a number will be assigned to the patients included in the study. The randomization code will be disclosed at the end of the statistical analysis. The doctor who will evaluate the complications, the duration of the procedure and the healing will be not aware of the type of treatment provided to the patients, nor will be the patients.|"All patients will take amoxicillin + clavulanic acid and Ibuprofen 600mg . Mepivacain with 1:100.000 adrenalin will be used for anesthesia. Local infiltration of Desamethasone 4mg and intraoral disinfection of the surgical area with povidone iodine will be done.~A full thickness flap will be raised after a sulcular incision from the mesial buccal aspect of the second molar to the distal aspect of the third one where a releasing incision begins describing an open V shape.~In the Piezoelectric group Piezoelectric tools will be used. In the conventional group manual tools and burs with a straight handpiece will be used. The flap will be sutured using a 3/0 suture. Levobupivacaine hydrochloride 5mg will be injected at the end of the procedure in the site of the operation"|t|t|t|t
33756912|NCT01349920|||COHORT||PROSPECTIVE|||||||
33756913|NCT03651050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756914|NCT02470494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756915|NCT03963154|NA|SEQUENTIAL||TREATMENT||NONE||Open-label study||||
33756916|NCT01534325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756917|NCT04284345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756918|NCT05085587|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Laboratory blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33756919|NCT05969457|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33894355|NCT06011486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968576|NCT02638857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968577|NCT04857385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968578|NCT01004081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968579|NCT04597762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33968580|NCT00022425||||PREVENTION||||||||
33968581|NCT01766011|NA|SINGLE_GROUP||||NONE||||||
33968582|NCT01078623|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33968583|NCT02005354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33876243|NCT03225053|NA|SINGLE_GROUP||TREATMENT||NONE||After the initial evaluation, the investigator 2 will conduct the experimental procedures in the different groups, which will be submitted to the following protocols: G1 (n = 15) called LMF will be submitted to the myofascial release technique consisting of: , Deep sliding, pumping-kneading, thumb and four-finger rubbing, and sliding) applied to the musculature of the most painful region for 15 minutes. G2 (n = 15) will be applied to the MEP® technique, in which needles will be introduced on three occasions during each session, at different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will be performed the two techniques above, being applied first Miofascial Release and later to MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.||||
33968584|NCT04611035|||OTHER||PROSPECTIVE|||||||
33968585|NCT03515850|||CASE_ONLY||PROSPECTIVE|||||||
33968586|NCT01369251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968587|NCT00803946|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968588|NCT01428024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968589|NCT03074279|||CASE_CONTROL||RETROSPECTIVE|||||||
33968590|NCT04156191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968591|NCT00685971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968592|NCT03287466|RANDOMIZED|PARALLEL||OTHER||SINGLE|Clinicians and other healthcare providers will not be blinded to treatment allocation, nor will the clinical research team. This is because knowing the patient's blood oxygen level is an essential component of the study. Those members of the research team analysing data after the recruitment phase of the study will be blinded to group allocation. Participants will not be blinded but are unlikely to be aware to their allocation due to the severity of their illness.|feasibility, multi-centre, randomised controlled trial|f|f|f|t
33968593|NCT01608633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33968594|NCT04586790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968595|NCT01306253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968596|NCT03058497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968597|NCT01034137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968598|NCT04312659|||CASE_ONLY||PROSPECTIVE|||||||
33968599|NCT04671602|||COHORT||PROSPECTIVE|||||||
33968600|NCT06540729|NA|SINGLE_GROUP||TREATMENT||NONE||we are initiating this clinical study aimed at evaluating the efficacy and safety of vedolizumab (HER2-targeted ADC) in combination with AK104 (anti-PD-1 and CTLA4) and bevacizumab (anti-angiogenesis) in recurrent and persistent OCCC patients (vedolizumab 2.5 mg/kg + AK104 10 mg/kg + bevacizumab 15 mg/kg, every 3 weeks), with the aim of providing new treatment options for these refractory gynecologic malignancies.||||
33968601|NCT01323998|||COHORT||RETROSPECTIVE|||||||
33876244|NCT02146612|||||PROSPECTIVE|||||||
33968602|NCT00367406|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968603|NCT03988725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968604|NCT03539315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968605|NCT00130481|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33968606|NCT06240845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968607|NCT05250349|||COHORT||PROSPECTIVE|||||||
33968608|NCT05491174|RANDOMIZED|PARALLEL||OTHER||NONE||Participants are assigned to either the intervention arm (DBT-informed skills group) or a wait-list control.||||
33968609|NCT03518697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968610|NCT02415010|||COHORT||PROSPECTIVE|||||||
33968611|NCT06481696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33968612|NCT02573428|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968613|NCT04607642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded as well as use of blinded assessors.||t|f|f|t
33876245|NCT00000522|RANDOMIZED|||TREATMENT||||||||
33876246|NCT04187768|||OTHER||PROSPECTIVE|||||||
33876247|NCT01499420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876248|NCT02481388|||||CROSS_SECTIONAL|||||||
33876249|NCT05979298|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a prospective randomized multi-center study with two arms. Gemcitabine 1000 mg/m2 days 1,8 every 3 weeks) was administered in both arms: In the Chemo arm (n = 20) GEM was the only treatment, and in the ELENAGEN arm (n = 20) GEM was supplemented with ELENAGEN (2.5 mg i.m. weekly).||||
33876250|NCT04009863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||group 1 is for HIFU treatment, group 2 is for RAI treatment||||
33876251|NCT01272700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33876252|NCT00933075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876253|NCT03111446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876254|NCT01564355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876255|NCT00710073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876256|NCT06421558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed by clinicians at Hands on Diagnostics locations. Assessors will be blinded to which intervention participant has received.|Study will be divided into two randomly assigned groups - control and experimental. Control group will receive traditional e-stim treatment with TENS plus physical therapy. Experimental group will receive direct current e-stim treatment with the Neubie device plus physical therapy.|f|f|f|t
33876257|NCT02639585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876258|NCT00513409|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33876259|NCT00274027|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33968614|NCT01510665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968615|NCT02557672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968616|NCT00653653|||COHORT||PROSPECTIVE|||||||
33968617|NCT03125057|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33968618|NCT03187054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968619|NCT05907200|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968620|NCT02152787|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968621|NCT04108481|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration design with an expansion phase once MTD is determined to treat up to a total of 18 patients.||||
33968622|NCT02561988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968623|NCT00718965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968624|NCT03824210|||OTHER||PROSPECTIVE|||||||
33968625|NCT00872560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968626|NCT04324879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968627|NCT01226147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968628|NCT01159769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968629|NCT02198677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068724|NCT00359177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068725|NCT01519973|NA|SINGLE_GROUP||OTHER||NONE||||||
34068726|NCT05208580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34068727|NCT03419143|||COHORT||PROSPECTIVE|||||||
34068728|NCT02834832|||COHORT||PROSPECTIVE|||||||
34068729|NCT06345391|||COHORT||OTHER|||||||
34068730|NCT05376072|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34068731|NCT03745248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will know that the participant has received balance or aerobic training, but will not be aware of which group the participant belonged|Single blind randomized control trial|f|f|f|t
34068732|NCT04692272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068733|NCT01404897|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34068734|NCT04476498|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participants don't know which arm they were allocated to.|This study is a randomised prospective monocentric study with a one to one allocation in two different treatment arms.|t|f|f|f
33968630|NCT02525328|||FAMILY_BASED||PROSPECTIVE|||||||
33968631|NCT04460352|RANDOMIZED|PARALLEL||TREATMENT||NONE||NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the three co-primary endpoints i) Overall survival and superiority for the experimental intervention definitive chemoradiotherapy; ii) Global health related quality of life (HRQOL) one year after randomisation; iii) Eating restictions one year after randomisation.||||
33968632|NCT05898282|||OTHER||CROSS_SECTIONAL|||||||
33968633|NCT06318481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Care provider and investigator are same so both are blinded in the trial.||t|t|t|f
33876260|NCT03611855|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Study Population in 2 groups: Group 1 participates in MRI before treatment, at crossover, and at study completion. Group 1 participants either receive rehabilitation via BCI device then cross over to a standard range-of-motion program, or start with a range-of-motion program then crossover to receive BCI rehabilitation. A balanced number of participants will be assigned to the different orders within Group 1.~Group 2 receives no MRI, and is not assigned a range-of-motion program. Thus, Group 2 only receives BCI rehabilitation and does not cross over."||||
33876261|NCT02321436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876262|NCT04925232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876263|NCT03927001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876264|NCT01650636|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33876265|NCT05598099|||COHORT||PROSPECTIVE|||||||
33876266|NCT00940082|||COHORT||PROSPECTIVE|||||||
33876267|NCT00479791|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876268|NCT00357500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876269|NCT01560000|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33876270|NCT02217605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33876271|NCT03389282|||COHORT||PROSPECTIVE|||||||
33876272|NCT00080509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876273|NCT06035900|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The aim of the study is to assess the bioavailability and pharmacokinetic parameters and to monitor the safety and tolerability of a formulation in healthy subjects under fasting conditions after a single oral dose of L-130 Capsules containing 2 mg of psilocin as its Mucic Acid Salt or Conjugate.||||
33876274|NCT03539250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876275|NCT02976870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876276|NCT05222256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876277|NCT00641251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876278|NCT04034862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876279|NCT05632185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||one group will receive Equine assisted intervention, and a control group to receive the regular care used in the setting|t|t|f|t
33876280|NCT02498639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876281|NCT03627260|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33876282|NCT03353571|NA|SINGLE_GROUP||OTHER||NONE||"Safety and efficacy of the Catheter Science C3 Umbrella Catheter in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days.~The reduction in Catheter Acquired Urinary Tract Infection (CAUTI)~A single arm study design was chosen because there is no alternative treatment to serve as an appropriate control. The C3 catheterizes the bladder with engagement into the bladder neck under the control of the patient or care giver. A Foley catheter, a pre- amendment device, was considered for a control treatment. However, although a Foley catheter is used to establish urinary drainage with close to 100% efficacy, it does not restore voiding function like the C3, and severely impairs activities of daily life."||||
33968634|NCT03564756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded|Randomized Parallel Group, Placebo Controlled Trial|t|t|t|f
33968635|NCT05639387|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each participant will complete 2 sessions at least one week apart, one with active tVNS and one with sham tVNS.|t|f|f|f
33968636|NCT04164485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068735|NCT05770349|||COHORT||PROSPECTIVE|||||||
33968637|NCT03574883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Study will be double-blind : neither participant nor the investigator will know which stimulation type (in-phase active, anti-phase active or sham) is on.|This study is composed of two independent sub-studies, one exploring the effects of tACS and the other the effects of tDCS, with different participants assigned to the two sub-studies. There will be 3 arms in tACS group and 2 arms in tDCS group. Among each sub-study, all participants will participate in all arms (hence the cross-over design).|t|f|t|f
33968638|NCT03569319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968639|NCT00062309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968640|NCT01127698|||COHORT||PROSPECTIVE|||||||
33968641|NCT05299229|||COHORT||PROSPECTIVE|||||||
33968642|NCT01361399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968643|NCT05557578|NA|SINGLE_GROUP||TREATMENT||NONE||Patients of Resectable ICC With High-risk Factors of Recurrence||||
33968644|NCT00495118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968645|NCT03010202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968646|NCT05126875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968647|NCT01804764|||CASE_ONLY||PROSPECTIVE|||||||
33968648|NCT04890275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968649|NCT06463938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968650|NCT03016585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33968651|NCT00305370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33968652|NCT04897971|||COHORT||PROSPECTIVE|||||||
33968653|NCT05455970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33968654|NCT00902824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968655|NCT02110706|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33968656|NCT06447220|||COHORT||PROSPECTIVE|||||||
33968657|NCT02362854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968658|NCT04908722|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33968659|NCT00609895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968660|NCT05514847|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized into 1 of 4 groups based on their results of two screening tests for preeclampsia.||||
33968661|NCT03704779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data collectors will be masked to participant group assignment.|"Intervention will be implemented over 8 consecutive weeks and will consist of experiential mindfulness activities that can be accessed in-person and online. In-person mindfulness activities will be available twice per week and last approximately 40 minutes in length. Mindfulness meditation videos posted online will be available 24/7 and last 10-45 minutes. Students will be asked to participate in one 40-minute in-person and four 10-minute online mindfulness activities per week (total of 1 hour and 20 minutes per week).~Week 1. Progressive muscle relaxation, mindfulness meditation, guided imagery.~Week 2. Mindfulness: Zen garden, painting, craftwork.~Week 3. Active Meditation: yoga, Tai Chi.~Week 4. Aromatherapy.~Week 5. Addiction Information and Management Strategies.~Week 6. Positive Psychology Strategies: cognitive reframing techniques.~Week 7. Self-Compassion Strategies: walking meditation, nutritious snacks, self-massage.~Week 8. Pet Therapy."|f|f|f|t
33968662|NCT03900546|||COHORT||PROSPECTIVE|||||||
33968663|NCT01773694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33968664|NCT00147264|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33968665|NCT01742325|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33968666|NCT02017483|||CASE_CONTROL|||||||||
33968667|NCT04189094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968668|NCT02496260|||CASE_ONLY||PROSPECTIVE|||||||
33968669|NCT01261325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968670|NCT04694040|||CASE_ONLY||RETROSPECTIVE|||||||
34068736|NCT05693324|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study employs a single-case experimental design with randomized waiting period lengths (4, or 6 weeks) as well as randomization to three treatment arms (same content, different progress through the three modules). Included in the design is also standardized pre- and post measurement allowing for single group analysis of change. In addition, we collect qualitative data from participants, detailing how the intervention is experienced.||||
34068737|NCT02328794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068738|NCT04959292|||COHORT||PROSPECTIVE|||||||
34068739|NCT00939237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068740|NCT02383355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068741|NCT00316914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33968671|NCT00701766||PARALLEL||TREATMENT||||||||
33968672|NCT06529029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968673|NCT00551486|||||PROSPECTIVE|||||||
33968674|NCT06052878|||COHORT||OTHER|||||||
33968675|NCT03358394|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33968676|NCT00231049|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33968677|NCT06021262|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33968678|NCT04387110|||COHORT||PROSPECTIVE|||||||
33968679|NCT02450942|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968680|NCT04807127|||COHORT||PROSPECTIVE|||||||
34068742|NCT01937884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068743|NCT06307834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068744|NCT02625246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068745|NCT05867680|RANDOMIZED|PARALLEL||PREVENTION||NONE||Random assignment to the control or treatment group using a 1:1 parallel assignment.||||
34068746|NCT06414876|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068747|NCT05644990|||CASE_ONLY||PROSPECTIVE|||||||
34068748|NCT02843165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068749|NCT01584700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068750|NCT00018421|RANDOMIZED|PARALLEL||TREATMENT||||||||
34068751|NCT01737242|||CASE_ONLY||PROSPECTIVE|||||||
34068752|NCT00456781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068753|NCT03264014|||OTHER||RETROSPECTIVE|||||||
34068754|NCT01004432|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33876283|NCT05424653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876284|NCT00252343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876285|NCT05573074|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33876286|NCT03724565|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33876287|NCT05858619|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33876288|NCT04179825|||COHORT||CROSS_SECTIONAL|||||||
33876289|NCT05352152|||COHORT||CROSS_SECTIONAL|||||||
33876290|NCT05342675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Interpreting radiologists of the post-biopsy CTs and radiographs will be blinded to whether the patient is in the control or intervention group.|Randomized controlled trial. Eligible patients will be randomized into either the control group (standard protocol CT-guided lung biopsy) or the rapid rollover group (immediate reposition with biopsy site down).|f|f|t|f
33876291|NCT03033875|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomly assigned in a 2:2:1 ratio to the Tele-Savvy intervention, Healthy Living intervention, or usual care condition. Participants in the Healthy Living and usual care arms can take part i the Tele-Savvy intervention after a delay of 6 months.||||
33876292|NCT03586414|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33876293|NCT02090322|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33876294|NCT03108313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A participant will generate the random allocation sequence. The researcher will enroll the patients but an unbiased participant will assign the intervention/Control identification procedures .The participants will be blinded to intervention/control assessment methods. Also, it will not be allowed among the examiners to exchange any information throughout the entire study period.||f|f|f|t
33876295|NCT05459831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876296|NCT06338956|||COHORT||RETROSPECTIVE|||||||
33876297|NCT04820894|||COHORT||PROSPECTIVE|||||||
33876298|NCT02408471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968681|NCT04155788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968682|NCT00661674|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"There were three treatment arms to the study: Placebo, Palonosetron, and Palonosetron + Hydroxyzine (Combo). Participants were not randomized in between these arms, all participants completed each arm of the study in a cross-over study methodology (Placebo, Palonosetron, Palonosetron + Hydroxyzene (combo). Participants were individually randomized into the order in which they participated in each arm.~Per sequence each individual participant underwent the following randomization schedule:~Participant 1: Placebo, Combo, Palonosetron Participant 2: Palonosetron, Combo, Placebo Participant 3: Palonosetron, Combo, Placebo Participant 4: Combo, Placebo, Palonosetron Participant 5: Placebo, Palonosetron, Combo Participant 6: Combo, Palonosetron, Placebo Participant 7: Combo, Placebo, Palonosetron Participant 8: Combo, Palonosetron, Placebo Participant 9: Palonosetron, Placebo, Combo Participant 10: Placebo, Combo, Palonosetron"|t|t|f|t
33968683|NCT05969795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33968684|NCT02060656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968685|NCT06200389|||CASE_ONLY||PROSPECTIVE|||||||
33968686|NCT03037684|||COHORT||PROSPECTIVE|||||||
33968687|NCT03272867|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33968688|NCT01312779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968689|NCT00424814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756920|NCT02552628|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33756921|NCT02679040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756922|NCT05735574|||CASE_CONTROL||RETROSPECTIVE|||||||
33756923|NCT00545961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756924|NCT02340741|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33756925|NCT01155154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756926|NCT05857787|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33968690|NCT01306149|||COHORT||PROSPECTIVE|||||||
33968691|NCT02505698|||CASE_CONTROL||PROSPECTIVE|||||||
33968692|NCT02910310|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968693|NCT06523088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is an open-label study at first dose level, and switched to double-blind study starting from the second dose level.||t|t|t|f
33968694|NCT00276705|NON_RANDOMIZED|||TREATMENT||NONE||||||
33968695|NCT02938806|||COHORT||CROSS_SECTIONAL|||||||
33968696|NCT02624518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968697|NCT04706871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968698|NCT00706706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968699|NCT02658682|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33968700|NCT03813485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33756927|NCT02612987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756928|NCT02073695|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876299|NCT00365521|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33876300|NCT00439946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756929|NCT03850652|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33876301|NCT02484911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876302|NCT01014832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876303|NCT00847912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33968701|NCT02439606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33968702|NCT04253925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968703|NCT04932733|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33756930|NCT03394521|||COHORT||RETROSPECTIVE|||||||
33756931|NCT06119984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33756932|NCT01867801|||COHORT||PROSPECTIVE|||||||
33756933|NCT01969110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756934|NCT01393782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876304|NCT02762474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876305|NCT02022488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33968704|NCT04270669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968705|NCT00000452|RANDOMIZED|||TREATMENT||DOUBLE||||||
33968706|NCT05600179|||COHORT||PROSPECTIVE|||||||
33968707|NCT02058810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968708|NCT02809534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968709|NCT02368522|||COHORT||OTHER|||||||
33968710|NCT04503252|||COHORT||PROSPECTIVE|||||||
33876306|NCT03528512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization list created by an online randomization tool will be used to assign participants to a treatment arm (in random blocks of 4, 6, and 8). As participants are enrolled in the study, they will be assigned to the next available sequential treatment arm.|Randomized double blinded control trial|t|t|t|t
33876307|NCT06321107|||CASE_CONTROL||OTHER|||||||
33876308|NCT03246737|||COHORT||PROSPECTIVE|||||||
33876309|NCT05182957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876310|NCT04996121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876311|NCT02595450|||COHORT||CROSS_SECTIONAL|||||||
33876312|NCT00295984||||TREATMENT||DOUBLE||||||
33876313|NCT03976037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968711|NCT02544633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968712|NCT01475656|||COHORT||PROSPECTIVE|||||||
33968713|NCT01362114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968714|NCT01182714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968715|NCT00686478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968716|NCT04426071|||COHORT||PROSPECTIVE|||||||
33968717|NCT04296383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968718|NCT01121900|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968719|NCT04283760|||OTHER||PROSPECTIVE|||||||
33968720|NCT00140998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968721|NCT02685605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968722|NCT04543045|||OTHER||RETROSPECTIVE|||||||
33968723|NCT05326152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968724|NCT06189261|||CASE_ONLY||PROSPECTIVE|||||||
33968725|NCT00303992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968726|NCT01186783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968727|NCT05727293|||CASE_ONLY||RETROSPECTIVE|||||||
33968728|NCT02140073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968729|NCT01422733|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968730|NCT00569283||||TREATMENT||||||||
33968731|NCT02162329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968732|NCT05809583|||COHORT||PROSPECTIVE|||||||
33968733|NCT02364466|||COHORT||PROSPECTIVE|||||||
33968734|NCT02967900|||COHORT||RETROSPECTIVE|||||||
33968735|NCT01672372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968736|NCT00384891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968737|NCT05903599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968738|NCT05946642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33968739|NCT05474612|RANDOMIZED|PARALLEL||TREATMENT||NONE||36 participants were recruited in study and divided into two groups. Group A is given intervention with kinesiology taping and group B is given Instrument Assisted Soft Tissue Mobilization treatment.||||
33968740|NCT01538706|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968741|NCT00072033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968742|NCT03872271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968743|NCT02832297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968744|NCT01494220|||COHORT||PROSPECTIVE|||||||
33968745|NCT00912470|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968746|NCT01207063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968747|NCT04036578|NA|SINGLE_GROUP||TREATMENT||NONE||A 12-week PFMT bio-assisted surface electromyographic program in group 1(Pelvic Floor Dysfunction Without POP Stage I\~II) and group 2(Pelvic Floor Dysfunction With POP Stage I\~II)||||
33968748|NCT03493698|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33968749|NCT04525690|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The principal study investigator and data analyst will not have knowledge of when the hospital sites are randomized to the intervention.|Hospital sites will be cluster randomized to the intervention in 3 month blocks over 6 months, after which both sites will receive the default intervention.|f|f|t|t
33968750|NCT01860482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968751|NCT00548990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33968752|NCT05479968|||COHORT||PROSPECTIVE|||||||
33968753|NCT01724359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968754|NCT02436135|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33968755|NCT00686803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968756|NCT04656522|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm, pre-test/post-test trial design will be used to evaluate the effectiveness of a participatory comic intervention on changes in PEP knowledge and acceptability, sexual violence stigma, and bystander beahviour with displaced/refugee youth and health care providers in Bidi Bidi Refugee Settlement, Uganda.||||
33968757|NCT04116346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigating physician performing the interventional procedure and evaluating the safety judgment criteria will not be informed of the patient's randomization arm|Our study is a prospective, monocentric, controlled, single-blind, randomized trial in two parallel arms|f|f|t|t
33968758|NCT00747747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968759|NCT00595660|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33968760|NCT03716102|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33968761|NCT03628352|NA|SINGLE_GROUP||OTHER||NONE||||||
34068755|NCT03280706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator and outcomes assessor will not know to which group each woman was allocated||f|f|t|t
33968762|NCT04101136|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Subjects with undetectable HIV-RNA, positive anti-CMV, having Framingham Risk Score above 10% with LDL \< 130 or under 10% with LDL \<160 will undergo thorough medical history and anthropometric examination as the initial data. Patient will be seen for regular clinical follow up as standard of care in the clinic (monthly/ bimonthly). Follow up visit will include clinical and laboratory procedure. At week 24, blood collection procedures and neurocognitive examination procedures will be repeated. At week 48, blood collection procedures, CIMT, FMD, transient elastography with CAP, and neurocognitive examination procedures will be repeated.|Atorvastatin tablets in generic form. The placebo tablets will be prepared by Cipto Mangunkusumo hospital pharmacist, were composed of starch and were similar to atorvastatin tablets in size, shape, and colour. The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month.|t|t|f|f
34068756|NCT03414398|||COHORT||PROSPECTIVE|||||||
34068757|NCT05761457|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm and multicenter study||||
34068758|NCT06523972|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34068759|NCT00624832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068760|NCT00892814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068761|NCT04088539|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33876314|NCT01695473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876315|NCT02805777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876316|NCT02325219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876317|NCT04145011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is a participant-blinded trial and deliberate action, utilizing a physical barrier, will be needed to ensure the blind remains intact.||t|f|f|f
33876318|NCT00498173|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"At the end of the 8-week double-blind, placebo-controlled study, participants randomized to placebo who are not responders at the end of 8 weeks will be treated with atomoxetine for 8 weeks during an open-label trial. All participants who are rated much improved or very much improved on the CGI-I following treatment with atomoxetine (i.e., atomoxetine responders) during either the 8-week placebo-controlled trial or the 8-week open-label phase for placebo nonresponders will be eligible to enter the 10-month open-label extension phase of the study."|t|t|t|f
33876319|NCT00450476|||||OTHER|||||||
33876320|NCT05318456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876321|NCT05561517|RANDOMIZED|CROSSOVER||OTHER||NONE||12 athletes with T1D and 12 healthy athletes are included in a prospective experimental randomized, cross-over study.||||
33876322|NCT03318146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a prospective, open-label, controlled non-randomized study, comparative split body-design study comparing unilateral Latanoprost-loaded punctual plug in patients with open angle early visual field defects glaucoma or ocular hypertension with Xalatan © eye drops treatment in the second eye."||||
33876323|NCT02076971|||CASE_ONLY||PROSPECTIVE|||||||
33876324|NCT05910866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33876325|NCT02197676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876326|NCT01262521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33876327|NCT06063109|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A two-arm, open-label, single-sequence, multiple oral dosings, crossover clinical trials~THP-00101 (Dapagliflozin) 10mg (18 Subjects): Tx A (5 days) -\> Tx B (5 days) Treatment A: THP-00101 (Dapagliflozin) 10mg/5 days Treatment B: THP-00101 (Dapagliflozin) 10mg/5 days + THP-00102 (Telmisartan) 80mg/5 days~THP-00102 (Telmisartan) 80mg (32 Subjects): Tx C (5 days) -\> Tx B (5 days) Treatment C: THP-00102 (Telmisartan) 80mg/5 days Treatment B: THP-00102 (Telmisartan) 80mg/5 days + THP-00101 (Dapagliflozin) 10mg/5 days"||||
33876328|NCT02072811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876329|NCT01311037|||CASE_CONTROL||PROSPECTIVE|||||||
33876330|NCT00607308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33876331|NCT02335996|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876332|NCT01220895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876333|NCT02890810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876334|NCT02690311|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33876335|NCT03829930|NA|SEQUENTIAL||TREATMENT||NONE||3+3 Design||||
33876336|NCT01962571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876337|NCT00434564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876338|NCT02626507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968763|NCT02513459|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with clinical response or remission at the end of Study NCT02031276 (Boehringer Ingelheim trial 1311.6/AbbVie M15-993) or at screening for this study were rolled over directly into this study and received maintenance therapy of risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who lost response or remission between the completion of Study NCT02031276 and enrollment in this study received open-label intravenous (IV) re-induction treatment with risankizumab consisting of 3 infusions of 600 mg IV every 4 weeks (q4w), after which eligibility was assessed if clinical response was re-gained. If clinical response or remission was achieved, participants continued with maintenance treatment of risankizumab 180 mg SC q8w beginning at Visit 5.||||
33968764|NCT01785875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968765|NCT05510713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876339|NCT03712397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876340|NCT00248183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33968766|NCT04988945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068762|NCT05491681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose finding study||||
34068763|NCT00913302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068764|NCT02291003|||OTHER||OTHER|||||||
34068765|NCT02670421|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068766|NCT05437614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068767|NCT02741232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068768|NCT00456261|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068769|NCT04261647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876341|NCT04933929|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .||||
33876342|NCT04505098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Pragmatic randomized clinical trial|f|f|f|t
33876343|NCT03113500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876344|NCT01750112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968767|NCT03455179|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|For masking the participants, the investigators will not inform participants of what group they will be in. For outcome assessor, data collectors and data analysts independent people will be use, and if this is not possible, a random code will be created for each participant so that it is not possible to identify which group belongs to.|This is a randomized, duoble-blind (participant-outcome assessor), 4 arms prospective parrallel desing clinical trial. The older adults will be recruited from the Municipal Activity Centers for Older People located in Valencia and will be randomized in a prospective clinical trial study with a 4 parallel arms study design to a slow-speed traditional resistance training, high-speed resistance training, multicomponent training or control over a 20 weeks period.|t|f|f|t
33968768|NCT03944785|||COHORT||PROSPECTIVE|||||||
33968769|NCT02307409|||CASE_CONTROL||PROSPECTIVE|||||||
33968770|NCT02052128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876345|NCT04671849|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33968771|NCT03280537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876346|NCT02586168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33876347|NCT02597946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968772|NCT01179633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968773|NCT00002196||||TREATMENT||||||||
33968774|NCT04549259|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33968775|NCT05664191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33968776|NCT04648293|||COHORT||PROSPECTIVE|||||||
33968777|NCT03107949|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||LIVE Catheter is temporarily insertied into the left subclavian vein and connected to the LCU for DPTS to be delivered daily. The DPTS includes the LIVE Catheter, LCU and intermediate cable.||||
33968778|NCT04727944|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968779|NCT03729752|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33968780|NCT02571725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968781|NCT03233282|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33968782|NCT02926378|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968783|NCT01671384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968784|NCT05337319|||COHORT||PROSPECTIVE|||||||
33968785|NCT04513340|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968786|NCT02687477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968787|NCT06530381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068770|NCT05744297|||COHORT||PROSPECTIVE|||||||
34068771|NCT03323645|||COHORT||OTHER|||||||
33876348|NCT04317274|RANDOMIZED|FACTORIAL||OTHER||NONE||Subjects were randomly assigned to one of the two clinical conditions (colorectal cancer screening or high cholesterol) then randomly assigned to view the two videos in one of two orders. Participants either viewed the good shared decision making video first (and the poor shared decision making video second) or the poor shared decision making video first (and the good shared decision making video second). Thus we used a 2 (clinical condition; colorectal cancer screening v. high cholesterol) x 2 (video; good v. poor) x 2 (order; good first v. poor first) factorial design.||||
33876349|NCT00939900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876350|NCT05773196|||COHORT||PROSPECTIVE|||||||
33968788|NCT02042690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||After 1 year of enrollment, randomization was terminated because of the patients's intention to crossover between the two intervention groups (total enrolled n=16). The sample size was recalculated in July 2015, and the ethics committee agreed to modify the randomization scheme to intention-to-therapy (ITT). Patients who met the recruitment criteria after the second consolidation participated fully in discussions with their doctors and then made decisions on their own regarding their intention to receive haplo-SCT. For each patient, informed consent was obtained from that patient or his/her guardian in accordance with the Declaration of Helsinki.||||
33876351|NCT03106623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876352|NCT00185003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876353|NCT06021080|||CASE_CROSSOVER||PROSPECTIVE|||||||
33968789|NCT02595333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968790|NCT01531348|NA|SINGLE_GROUP||OTHER||NONE||||||
33968791|NCT04563078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33876354|NCT02317120|||OTHER||PROSPECTIVE|||||||
33876355|NCT01962233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876356|NCT06020456|||COHORT||RETROSPECTIVE|||||||
33968792|NCT02521948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876357|NCT03685786|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) treatment for the Patients with Minimal Residual Disease (MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT).||||
33876358|NCT04697485|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a proof-of-concept, non-randomized, pilot study of patients with HFpEF and diabetes mellitus to receiving polydiuretic therapy (bumetanide 0.5 mg + eplerenone 25 mg + dapaglifozin 5 mg) on top of background therapy||||
33876359|NCT03707600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33876360|NCT03826550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study products are blinded and provided to the patients in the same packaging.|Randomized, double-blind, placebo-controlled, three-arm, parallel group, multiple-site bioequivalence study with clinical endpoints.|t|t|t|t
33876361|NCT05385861|NA|SINGLE_GROUP||TREATMENT||NONE||an investigator-initiated, single-arm phase 1/2 study||||
33876362|NCT06417021|RANDOMIZED|PARALLEL||OTHER||SINGLE|A clip of the ultrasound procedure will be saved and reviewed by a blind assessor that will value the quality of the procedure||f|f|f|t
33876363|NCT03313076|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Double-blind|2x2 Factorial design|t|t|t|t
33876364|NCT01081795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876365|NCT03405259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33876366|NCT02261727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876367|NCT03420950|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The nurse administering the drug is not blinded, but the outcome assessor and physician performing the intubation are blinded to drug order.||t|t|t|t
33876368|NCT06144905|||COHORT||CROSS_SECTIONAL|||||||
33876369|NCT03828591|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876370|NCT01133587|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876371|NCT05285293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968793|NCT03171714|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1 - Pilot Trial:~As this device has never been used on humans, the investigators will first deploy a pilot, uncontrolled trial of 10 subjects to assess for safety, and further refine outcome measures. The same protocol will be followed as the controlled trial, except the randomization.~Phase 2 - Controlled Trial: 25 patients in each arm:~1. Novel silicon packing device~2. Usual Care, cotton gauze packing"||||
33968794|NCT04009967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968795|NCT01169649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968796|NCT05938153|||CASE_ONLY||PROSPECTIVE|||||||
33968797|NCT04805281|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33968798|NCT02514187|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34068772|NCT03191825|RANDOMIZED|PARALLEL||PREVENTION||NONE|The recruitment procedure and the treatment is fully automated and delivered by web, e-mail and SMS-textmessages - i.e., the participant is not contacted by any care providers, investigators or assessors during recruitment or treatment - and data are collected by means of web-based questionnaires. However, non-responders to the questionnaires will be contacted by phone for telephone interview.|All participants receive one out of three versions of a web-based smoking cessation program. Two of the versions includes a lapse management system that are based on a day-to-day logging of target behavior. In one version the logging is done on the web, while on the other version, logging is done by SMS-textmessages.||||
33876372|NCT00838331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876373|NCT05376254|||COHORT||PROSPECTIVE|||||||
33876374|NCT00835237|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876375|NCT00927095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876376|NCT05120882|||COHORT||CROSS_SECTIONAL|||||||
33876377|NCT06475638|||OTHER||PROSPECTIVE|||||||
33876378|NCT01868048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33876379|NCT03757208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876380|NCT03178227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876381|NCT03313427|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33876382|NCT05007275|NA|SINGLE_GROUP||PREVENTION||NONE||This is a Phase I, open label non-randomised dose escalation study in healthy adults aged 30-55 years recruited in the UK. AZD1222 will be administered by inhalation via vibrating mesh nebuliser. The study will assess safety and immunogenicity of AZD1222 with blood and respiratory tract samples. The dose evaluation will be conducted in a single centre supervised by the Chief Investigator and senior clinician experienced in first-in human studies in a cohort of 30 individuals. Approximately 14 days before vaccination, participants will undergo bronchoscopy to sample their lower airways, obtaining bronchoalveolar lavage (BAL), bronchial lining fluid and bronchial tissue. This will be repeated at day +21 and day +182 post-vaccination.||||
33876383|NCT02288507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876384|NCT01972555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876385|NCT01201135|||||PROSPECTIVE|||||||
33876386|NCT05526833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Schizophrenia patients with AVH who have completed protocol #8116 will be recruited, and allocated to one of three arms based on their treatment responsiveness from protocol #8116 which included 10 low-frequency TMS treatment sessions using the TPJ target. Their treatment responsiveness is assessed by the Auditory Hallucination Rating Scale (AHRS) at pre- and post-TMS session. Non-responders will be offered 10 daily sessions of 1-Hz rTMS delivered to the rSTS region instead. Partial responders will be offered 10 additional daily sessions of 1-Hz rTMS delivered to the same original left TPJ target used in protocol #8116. Full responders will be offered followup clinical assessments at 1,2,4, and 8 weeks to assess sustainability of their response.||||
33876387|NCT02092194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968799|NCT01429402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33876388|NCT00871312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876389|NCT05919979|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33876390|NCT03461757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Participant|Randomized Controlled Trial|t|t|t|f
33876391|NCT02019914|||COHORT||PROSPECTIVE|||||||
33876392|NCT01600443|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876393|NCT06448403|||COHORT||PROSPECTIVE|||||||
33876394|NCT04319978|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 100 patients will be considered in this study which will be equally divided into two groups; group A and group B (50 in each group).Group A will receive dexamethasone 1 hour pre-operatively while group B will receive the same post-operatively.||||
33876395|NCT05704478|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|double-blind, both participant and provider. Blinding to be coordinated by research coordinator|Randomized clinical trial|t|f|t|f
33876396|NCT01512303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876397|NCT06353451|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups, non blinded, randomized controlled trial||||
33876398|NCT01343433|||COHORT||PROSPECTIVE|||||||
33876399|NCT03345108|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33876400|NCT05996172|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33876401|NCT02236520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876402|NCT00470600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876403|NCT04469296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876404|NCT05772260|||COHORT||PROSPECTIVE|||||||
33876405|NCT00109707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876406|NCT01547455|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876407|NCT02231554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876408|NCT04417894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876409|NCT02189135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876410|NCT01297335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876411|NCT01401634|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876412|NCT02670135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876413|NCT00720109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876414|NCT00332995|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33876415|NCT04298983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876416|NCT00586209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876417|NCT01889290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876418|NCT06426355|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33876419|NCT01240161|||CASE_ONLY||PROSPECTIVE|||||||
33876420|NCT05098795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876421|NCT04430244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876422|NCT01395394|NON_RANDOMIZED|PARALLEL||||NONE||||||
33756935|NCT02660723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756936|NCT05025657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33756937|NCT04613908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the person in charge of performing the statistical analysis was blind, by coding the interventions in the database.|"3 Groups Group 1 (GR-STD) received the standard or usual rehabilitation treatment used in our ICU as intervention.~Group 2 (GR-NMES) received neuro muscular electro stimulation sessions in addition to the standard treatment.~Group 3 (GR-EM) received an early mobilization protocol as intervention."|f|f|f|t
33756938|NCT05808738|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33756939|NCT00559299|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33876423|NCT06199388|||COHORT||RETROSPECTIVE|||||||
33876424|NCT02247323|||CASE_ONLY||RETROSPECTIVE|||||||
33876425|NCT01478035|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876426|NCT03339921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876427|NCT02266992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33876428|NCT05531175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33756940|NCT03281473|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33756941|NCT01089231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33756942|NCT04000152|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876429|NCT01232829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876430|NCT03687151|||COHORT||PROSPECTIVE|||||||
33876431|NCT00199563|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33876432|NCT01648127|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33876433|NCT01437774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876434|NCT05044156|||CASE_CONTROL||PROSPECTIVE|||||||
33876435|NCT01135498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876436|NCT05224583|||CASE_ONLY||RETROSPECTIVE|||||||
33876437|NCT01984268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876438|NCT00999531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876439|NCT01535729|||COHORT||PROSPECTIVE|||||||
33876440|NCT06536660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968800|NCT04236310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968801|NCT01365845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968802|NCT01783483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33968803|NCT01753479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756943|NCT05152732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876441|NCT00634829|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33876442|NCT00717938|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876443|NCT02606422|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33876444|NCT02111642|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876445|NCT01335763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876446|NCT05392686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876447|NCT02202629|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33876448|NCT04586283|NA|SINGLE_GROUP||TREATMENT||NONE|As the study involves examination of cardiorespiratory indices in different maternal positions investigators cannot be blind to the participants' position.|Cohort study||||
33876449|NCT05070767|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Prospective randomized double masked two arm|Prospective randomized double masked two arm|t|t|t|f
33968804|NCT04063566|NA|SINGLE_GROUP||SCREENING||NONE||Single site screening study to assess the feasibility of MRI as a screening tool for prostate care and determine the prevalence of MRI defined suspicious lesions and cancer in men across a spectrum of PSA results.||||
33968805|NCT01189240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756944|NCT01054417|||COHORT||PROSPECTIVE|||||||
33764880|NCT04232046|RANDOMIZED|PARALLEL||TREATMENT||NONE||Case and control group||||
33764881|NCT00728962|||COHORT||PROSPECTIVE|||||||
33764882|NCT00877981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764883|NCT01576718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764884|NCT04047511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968806|NCT06417957|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group 1: Experimental group (Education group) Goup 2: Control group|t|f|f|f
33968807|NCT05826106|||CASE_ONLY||PROSPECTIVE|||||||
33968808|NCT03601247|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33968809|NCT02509871|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968810|NCT06527495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968811|NCT06338228|||COHORT||OTHER|||||||
33968812|NCT01396759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764885|NCT06422702|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33764886|NCT01750736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764887|NCT04143334|||OTHER||CROSS_SECTIONAL|||||||
33764888|NCT00380016||||TREATMENT||||||||
33764889|NCT03993236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764890|NCT03013218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876450|NCT01973582|||COHORT||PROSPECTIVE|||||||
33876451|NCT00659204|RANDOMIZED|FACTORIAL||SCREENING||QUADRUPLE|||t|t|t|t
33876452|NCT06126432|NA|SINGLE_GROUP||TREATMENT||NONE||Single intervention arm with trial treatment||||
33876453|NCT00674050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876454|NCT03559855|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876455|NCT04647500|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Depending on medication history and current psychostimulant medication, participants are included either in the consumer group (composed of participants with ongoing methylphenidate treatment) or in the naïve group (composed of participants naïve to the molecule)||||
33876456|NCT04889729|||COHORT||RETROSPECTIVE|||||||
33876457|NCT01548339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876458|NCT04320238|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876459|NCT06494137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|gels given in opaque plastic bag|randomised placebo controlled crossover study|t|f|t|t
33876460|NCT00034658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764891|NCT00150995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876461|NCT02300298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876462|NCT05711290|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33876463|NCT02056483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876464|NCT04766307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876465|NCT00143455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876466|NCT00075504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876467|NCT05912842|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigative team will conduct a clustered-randomized small-scale trial in two HIV treatment services organizations in Philadelphia. One agency will be randomized to the OPAHL intervention, consisting of integrated legal support (n=100 PLWH) and one agency will be randomized to the standard of care, legal aid referral (n=100 PLWH).||||
33764892|NCT02066402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764893|NCT03352934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876468|NCT01471457|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33968813|NCT00293969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33968814|NCT05987657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968815|NCT01567371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968816|NCT04368052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33968817|NCT04497324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876469|NCT05875675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34068773|NCT04436653|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multi-center single-arm trial in seven centers in China. A minimum of 150 subjects will be enrolled in this study and followed-up at discharge (≤ 10 days post operation), 30 days, 6 months, 1, 2, 3, 4, 5 years.||||
33876470|NCT02965807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876471|NCT00890565|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33876472|NCT05464225|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort of 60 individuals with Parkinson's will be randomly assigned (please read 'Participant Randomization' below) to either exercise using the COSD or to standard of care using tongue depressors, as per the request of the funding source.||||
33876473|NCT03976960|NA|SINGLE_GROUP||OTHER||NONE||||||
33876474|NCT05085080|||COHORT||PROSPECTIVE|||||||
33876475|NCT01968135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876476|NCT04003233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded to the medical device till the surgery. After the surgery participants are able to see which medical device is implanted on X-rays.|Participants will be randomized and assigned to either SDS or MID-C.|t|f|f|f
33876477|NCT03692728|||OTHER||CROSS_SECTIONAL|||||||
33876478|NCT04052659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876479|NCT04034160|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33876480|NCT05315921|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||This is a phase 1, single-center, placebo-controlled, double-blind, randomized study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of OsrhAAT by a single ascending dose (SAD) design in healthy adults.|t|f|t|f
33876481|NCT01891487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876482|NCT01634555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876483|NCT03640923|NA|SINGLE_GROUP||OTHER||NONE||||||
33876484|NCT04940910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33876485|NCT03452371|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876486|NCT00732303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876487|NCT00963001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876488|NCT03116932|||CASE_ONLY||PROSPECTIVE|||||||
33876489|NCT05966883|||CASE_ONLY||PROSPECTIVE|||||||
33876490|NCT06230536|||COHORT||OTHER|||||||
33876491|NCT02204150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068774|NCT02151214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876492|NCT02551159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876493|NCT03743870|||COHORT||PROSPECTIVE|||||||
33876494|NCT05914909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876495|NCT03241914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876496|NCT00602108||||TREATMENT||NONE||||||
33876497|NCT04989855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876498|NCT03834428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876499|NCT02789904|||CASE_ONLY||PROSPECTIVE|||||||
33876500|NCT02069899|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876501|NCT05093738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This prospective studies that measure the effectiveness of a cognitive rehabilitation intervention. Randomized controlled trials (RCT) are prospective studies that measure the effectiveness of a new intervention or treatment. Participants are recruited and randomly assigned to either the intervention or the comparator group. It is important to ensure that at the time of recruitment there is no knowledge of which group the participant will be allocated to; this is known as concealment. It is examined whether there is any difference in the results of the study intervention and also the intervention and control group are compared.|t|f|f|f
33876502|NCT06495086|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|In this single-blind study, we assigned the participants randomly to one of three treatment groups using a computer-generated randomization program (SAS Institute, 1990). Each participant was assigned an identification number indicating their treatment group. An experienced clinician, who was blinded to the null hypothesis and did not participate in the evaluation of results, administered the treatments and recorded patient data on a pre-prepared case data form.|Single center|f|f|t|t
33876503|NCT00848055|NON_RANDOMIZED|||TREATMENT||NONE||||||
33876504|NCT00637884|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33876505|NCT05946369|||COHORT||PROSPECTIVE|||||||
33876506|NCT03239821|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||A single-blinded, monocenter, randomized crossover investigation in healthy volunteers.|t|f|f|t
33876507|NCT00832507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876508|NCT04243863|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33968818|NCT01203774|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968819|NCT04262375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968820|NCT06481553|||COHORT||RETROSPECTIVE|||||||
33968821|NCT03952156|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33968822|NCT00287287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968823|NCT03348982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968824|NCT06530069|||CASE_CONTROL||RETROSPECTIVE|||||||
33968825|NCT05483439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968826|NCT06089135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876509|NCT05398315|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Participants will be randomly assigned to a condition by a computer program. The entire study will take place online. Participants will not be aware of the condition they are in until after the study ends. Investigators/outcome assessors will only see de-identified data and will have no contact with participants.|Four intervention components will be manipulated in a full factorial design, such that each participant either does or does not receive each intervention component.|t|f|t|t
33876510|NCT05703815|||OTHER||RETROSPECTIVE|||||||
33876511|NCT00005071|RANDOMIZED|||DIAGNOSTIC||||||||
33876512|NCT03286842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876513|NCT01024374|||CASE_ONLY||PROSPECTIVE|||||||
33876514|NCT04193163|||COHORT||PROSPECTIVE|||||||
33876515|NCT00218491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876516|NCT02287727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876517|NCT03378076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876518|NCT04947670|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Unblinded interventionist, unblinded intervention team and blinded study team at each center, blinded patient.|Prospective, randomized, double-blind, sham-controlled, multicenter, feasibility study. Patients will be screened for meeting eligibility and centrally randomized to receive either renal denervation or sham procedure. Best medical therapy will be provided to all patients. Optional cross-over after 12 months for sham-group patients. Thus, there is an intra-individual control in patients of the control group and all of the randomized patients are entitled to receive study treatment.|t|f|t|t
33876519|NCT01617278|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33876520|NCT00505999|||CASE_CONTROL||PROSPECTIVE|||||||
33876521|NCT06208592|||COHORT||PROSPECTIVE|||||||
33876522|NCT03301493|||OTHER||OTHER|||||||
33876523|NCT01217021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876524|NCT03033537|||CASE_CROSSOVER||PROSPECTIVE|||||||
33876525|NCT03279380|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33876526|NCT00418353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876527|NCT06475014|||COHORT||PROSPECTIVE|||||||
33876528|NCT02317666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33876529|NCT01849302|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33876530|NCT02587533|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33876531|NCT04347200|||COHORT||PROSPECTIVE|||||||
33876532|NCT05761028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876533|NCT06053515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876534|NCT02419560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876535|NCT00919035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876536|NCT01125280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876537|NCT04642339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33876538|NCT01866007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876539|NCT00366587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33876540|NCT05243927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876541|NCT02227693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876542|NCT03382795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876543|NCT03469765|||COHORT||PROSPECTIVE|||||||
33876544|NCT05207826|||CASE_ONLY||PROSPECTIVE|||||||
33876545|NCT00716755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876546|NCT05093088|||COHORT||PROSPECTIVE|||||||
33876547|NCT03948828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876548|NCT00864435|RANDOMIZED|CROSSOVER||||NONE||||||
33876549|NCT01739179|||CASE_ONLY||PROSPECTIVE|||||||
33876550|NCT00092846|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33764894|NCT00299000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764895|NCT00003305||||TREATMENT||||||||
33876551|NCT03499028|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876552|NCT03232086|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"Clean Air~Concentrated PM2.5"|t|f|t|f
33876553|NCT00369356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876554|NCT03174132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876555|NCT03730155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876556|NCT02611986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876557|NCT03334331|||OTHER||CROSS_SECTIONAL|||||||
33876558|NCT00102206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968827|NCT03032991|||CASE_CONTROL||PROSPECTIVE|||||||
33968828|NCT02100449|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33764896|NCT06397274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33876559|NCT00847483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876560|NCT00037180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876561|NCT00817531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876562|NCT00000879||||PREVENTION||DOUBLE||||||
33876563|NCT05801835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876564|NCT03506243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33876565|NCT03869359|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The randomization was done by employees of the hospital that were otherwise not involved in the study by drawing concealed envelops. The interventions were concealed plastic bags marked A or B.|Randomized, Double-blind, Placebo-controlled, Cross-over Trial|t|f|t|f
33876566|NCT03358888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33876567|NCT03882814|||CASE_CONTROL||PROSPECTIVE|||||||
33876568|NCT02476721|||COHORT||RETROSPECTIVE|||||||
33876569|NCT00861744|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33876570|NCT00774462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876571|NCT00286273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876572|NCT02699892|||COHORT||PROSPECTIVE|||||||
33876573|NCT04799886|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33876574|NCT00006456|NON_RANDOMIZED|||TREATMENT||NONE||||||
33876575|NCT00452751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876576|NCT00086203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876577|NCT02601521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876578|NCT00525395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876579|NCT00172965|||DEFINED_POPULATION||OTHER|||||||
33876580|NCT02457455|||||RETROSPECTIVE|||||||
33876581|NCT01055158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876582|NCT05312034|NA|SINGLE_GROUP||PREVENTION||NONE||"A predictive model to identify patients at risk of Gram-positive infection. This model will be embedded in an app and a web page to provide real-time guidance on the predicted probability of infection due to Gram-positive agents.~The intervention will be implemented in two selected hospitals, aiming at monthly decreasing the use of broad-spectrum antibiotics while maintaining or reducing the ICU standardized mortality ratio and the standardized resource use."||||
33876583|NCT02018822|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33876584|NCT02997761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876585|NCT00505011|||CASE_CONTROL||OTHER|||||||
33876586|NCT03204656|||OTHER||PROSPECTIVE|||||||
33876587|NCT02109484|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876588|NCT03784066|RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary objective is to evaluate the biological response in the tumor upon treatment with Durvalumab, and in parallel, with combination of Durvalumab and Tremelimumab.||||
33876589|NCT00387400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876590|NCT03563469|||CASE_ONLY||CROSS_SECTIONAL|||||||
33876591|NCT00236834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876592|NCT01273883|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33876593|NCT00631748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876594|NCT00014456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876595|NCT01234272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876596|NCT04704232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876597|NCT01156584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876598|NCT00336973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968829|NCT02277314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876599|NCT06017804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
33876600|NCT00290433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876601|NCT05089968|||COHORT||RETROSPECTIVE|||||||
33876602|NCT02702037|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33876603|NCT05173064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876604|NCT00585507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876605|NCT01618942|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33876606|NCT00741416|||CASE_CONTROL||PROSPECTIVE|||||||
33876607|NCT02731209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876608|NCT02642133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876609|NCT02258828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968830|NCT03453359|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Patients will be randomly assigned to one of the two study groups. The anesthesiologist who records the information knows which group they belong to, according to a randomization table provided in collaboration with the Research Unit, but the patients do not know it.|We compared the results of two groups of patients. Experimental group, in which sedation is adjusted using as main parameters the information obtained by the bispectral index monitor. Control Group, with sedation based on subjective monitoring using the Ramsay scale as a reference.|t|t|f|f
33968831|NCT00994032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968832|NCT02659267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876610|NCT03369964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968833|NCT03310203|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33756945|NCT04920864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Sham rTMS will consist of inactive figure of 8 coil. The participant, rTMS administrator, and assessors will all be blind to coil type.|A mixed design study will be used to examine the effects of active rTMS vs. sham (within subject) over one of two locations: 10 Hz dlPFC rTMS (group 1) or 1 Hz mPFC rTMS (group 2) in subjects receiving methadone treatment for OUD. The general rTMS treatment protocol will be the same for both groups and will consist of 2 stimulation sessions per day, separated by \~30min, for 5 days (10 total stimulation sessions per treatment protocol). The sham protocol will be the same except the sham rTMS coil will be used. Participants will be randomly assigned to groups and complete the 2 conditions (active vs. sham rTMS) in random order.|t|f|t|t
33756946|NCT00778583|RANDOMIZED|CROSSOVER||||NONE||||||
33756947|NCT03513757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients and their parents/guardians as well as the blinded observer or investigator who participates in outcomes assessment will be blinded to the drug or drugs administered.|observer blinded comparison of propofol with low-dose propofol and dexmedetomidine for pediatric MRI sedation|t|f|t|t
33756948|NCT05307770|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33876611|NCT05758259|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33876612|NCT02072655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33756949|NCT05180708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876613|NCT05279547|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two arms randomized cross-over trial||||
33756950|NCT02418247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756951|NCT02944084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33756952|NCT05504226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756953|NCT04160325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33756954|NCT04563468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment with inspiratory muscle training will be presented to both groups of patients as active interventions (intentional deception) to increase compliance. Participants in the intervention group will be informed that they are performing a 'strength training' while participants in the control group that they are performing an 'endurance training'. Participants in the control group will be offered the active treatment upon completion of the study.|Single blind, parallel group RCT with 2:1 allocation ratio|t|f|f|f
33756955|NCT02647606|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33756956|NCT03504163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase II trial of Pembrolizumab (MK-3475) in combination with Bacillus Calmette-Guérin (BCG) as first-line therapy in patients with high-risk T1 bladder cancer and also in an exploratory cohort of patients with high-grade NMI-UTUC.||||
33756957|NCT01787448|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33756958|NCT05670379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756959|NCT04989127|||COHORT||RETROSPECTIVE|||||||
33756960|NCT04610931|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Random-sized block randomization, stratified on the number of previous relapses, will be performed for the inclusions of patients within the cybertherapy group or Treatment as usual group"||||
33876614|NCT02663388|||COHORT||PROSPECTIVE|||||||
33876615|NCT04468165|||COHORT||PROSPECTIVE|||||||
33756961|NCT03432923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind design. Placebo indistinguishable to active in appearance and dosing schedule.||t|t|t|t
33756962|NCT03189784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled trial|f|t|t|t
33756963|NCT04992351|||CASE_CONTROL||PROSPECTIVE|||||||
33756964|NCT01972529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764897|NCT01919996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764898|NCT00813696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876616|NCT02728193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876617|NCT00678405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33876618|NCT01212302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876619|NCT03945708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33876620|NCT00706134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876621|NCT04247178|||COHORT||PROSPECTIVE|||||||
33876622|NCT03624322|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups over 3 cohorts Period 2 (n=36) assignment to 1 of 3 IP treatment groups over 3 cohorts|t|t|t|t
33876623|NCT04077658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial with intervention arm and waitlist control arm||||
33876624|NCT00236977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876625|NCT04804254|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33876626|NCT02354937|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33968834|NCT01001897|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33968835|NCT02099968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968836|NCT00957957|||COHORT||PROSPECTIVE|||||||
33968837|NCT04621890|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be 3 arms to this study. Two of these will involve behavioral interventions - LOAN2DOSE and COIN2DOSE. The remaining arm will be the control group.||||
33968838|NCT03001609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968839|NCT03720795|NA|SINGLE_GROUP||TREATMENT||NONE|The rater is unaware of treatment status, that is if the child continues to receive treatment after Step 1 (versus being in maintenance).|Single group observational.||||
33876627|NCT03264300|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876628|NCT02105402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33876629|NCT03288909|||CASE_CONTROL||PROSPECTIVE|||||||
33876630|NCT06126237|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33876631|NCT01116908|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876632|NCT01464502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876633|NCT02243215|RANDOMIZED|PARALLEL||||NONE||||||
33876634|NCT03030430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876635|NCT05893927|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will be recruited to participate in the study, and then randomized to one of two arms.||||
33876636|NCT04042779|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33876637|NCT05480748|||CASE_CONTROL||PROSPECTIVE|||||||
33876638|NCT01032811|||CASE_ONLY||PROSPECTIVE|||||||
33876639|NCT04160130|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876640|NCT05197192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876641|NCT06359509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876642|NCT01150539|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876643|NCT00199862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876644|NCT00882609|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33876645|NCT03733223|||COHORT||RETROSPECTIVE|||||||
33876646|NCT01710449|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876647|NCT02730884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876648|NCT01219010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876649|NCT01661140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876650|NCT05044676|||OTHER||PROSPECTIVE|||||||
33876651|NCT04369365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33876652|NCT03428893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876653|NCT04772261|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876654|NCT05543564|||COHORT||PROSPECTIVE|||||||
33876655|NCT05378438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33876656|NCT02820129|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33876657|NCT00657891|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33876658|NCT03454022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Participants (patient-caregiver dyads) will be randomized to receive either usual care education (a pamphlet published by the National Kidney Foundation, Choosing a Treatment for Kidney Failure, or usual care education plus DART."|f|f|f|t
33876659|NCT01455688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876660|NCT03166033|||CASE_CONTROL||RETROSPECTIVE|||||||
33876661|NCT05195008|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33876662|NCT06294457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The device will be placed with no current. This type of neuromodulation gives no feeling at all to the patient while administred, so there is no way for the patient to know if the apparatus is connected or not.||t|f|f|t
33876663|NCT00705211|||OTHER||PROSPECTIVE|||||||
33876664|NCT04153188|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects randomized at baseline to either 3 monthly treatments with PDL and daily oxymetazoline 1.0% cream (Arm 1) or oxymetazoline cream alone (Arm 2).||||
33876665|NCT04055155|||COHORT||PROSPECTIVE|||||||
33876666|NCT06500143|||OTHER||CROSS_SECTIONAL|||||||
33876667|NCT06458803|||CASE_ONLY||PROSPECTIVE|||||||
33876668|NCT02464384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876669|NCT02447588|RANDOMIZED|PARALLEL||||NONE||||||
33876670|NCT05550311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blind to group allocation.|Randomized controlled study|f|f|f|t
33876671|NCT02433652|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876672|NCT02504021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876673|NCT04238390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876674|NCT05532774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876675|NCT04757272|||COHORT||RETROSPECTIVE|||||||
34068775|NCT04818723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||During the study period, adopting non-probability consecutive sampling method, patients were assigned into two groups; 53 in Case Group (given montelukast 5mg at bed time) and 53 in Control Group (given no montelukast).||||
34068776|NCT03691506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068777|NCT03387657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068778|NCT04305860|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study of nutritional intervention, randomized, and controlled||||
33876676|NCT05433506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Part 2 is an open-label study of up to 4 single, ascending dose levels.||||
34068779|NCT03454386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756965|NCT05700084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Study design: Part 1 is a dose-escalation trial, and it's an open design; Part 2 is for pharmacokinetic comparison and food effect study, and it's an open, controlled design. Part 3 is expansion test of utidelone capsule combined with capecitabine.~In the Part 1 dose-escalation trial, there is no control; in the Part 2 pharmacokinetic comparison and food effect study, utidelone injection is chosen as the control drug in Cycle 0 and 1; in Cycle 2 day1, high-fat postprandial dosing is served as the control.Part 3: expansion test of utidelone capsule combined with capecitabine dosage administered."||||
33756966|NCT03172702|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33756967|NCT00162695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756968|NCT02844699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33756969|NCT03484598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33756970|NCT03440749|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comparative monocentric physiopathological study with 2 groups of children : children with cerebral palsy and children age-matched for the control group||||
33756971|NCT05189626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is a single blinded study.|There are two groups Group 1 and 2.Group 1 is treated with Muscle energy techniques and Group 2 is treated with kaltenborn mobilizations for 30 minutes per session,3 days per week for 4 weeks.|t|t|f|f
33756972|NCT06296095|NA|SEQUENTIAL||TREATMENT||NONE||||||
33876677|NCT01709435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876678|NCT05846685|||OTHER||PROSPECTIVE|||||||
33876679|NCT04453982|||COHORT||PROSPECTIVE|||||||
33876680|NCT03379090|||CASE_ONLY||CROSS_SECTIONAL|||||||
33876681|NCT05148923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33876682|NCT01639677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876683|NCT02425826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756973|NCT02836223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33756974|NCT01881139|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33756975|NCT00409682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756976|NCT06384248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756977|NCT01494584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756978|NCT02877511|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33756979|NCT00441090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33756980|NCT05782257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756981|NCT03804710|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33756982|NCT05011968|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study were designed by two cohorts The control group and the interventional group. The intervention lasted for 10 days and 100gr of lettuce per day was consumed.||||
33876684|NCT01006421|||CASE_CONTROL||PROSPECTIVE|||||||
33876685|NCT01515384|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876686|NCT04995081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects, investigators and study staff will be blinded to the assigned treatment.|A parallel study is a type of clinical study where two groups of treatments, A (allogeneic HB-adMSCs) and B (Placebo), are given so that one group receives only A while another group receives only B.|t|t|t|t
33876687|NCT01457807|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33876688|NCT04640688|||OTHER||PROSPECTIVE|||||||
33876689|NCT02566980|||COHORT||PROSPECTIVE|||||||
33876690|NCT04153721|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968840|NCT01847183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968841|NCT02025309|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
33968842|NCT03646253|||CASE_ONLY||RETROSPECTIVE|||||||
33968843|NCT02608359|||COHORT||PROSPECTIVE|||||||
33968844|NCT00376142|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33968845|NCT06482710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33968846|NCT01753531|||COHORT||PROSPECTIVE|||||||
33968847|NCT00955032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968848|NCT00077428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968849|NCT04038151|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33968850|NCT06370299|||COHORT||RETROSPECTIVE|||||||
33968851|NCT03548714|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Apart from the Research Pharmacists, all others engaged with this study (participants and study team) will be masked to alcohol challenge order.|t|t|t|t
33968852|NCT04873674|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968853|NCT04155944|||COHORT||RETROSPECTIVE|||||||
34068780|NCT04243226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"1. Traumatic brain injury patients with GCS 8-13 and GCS 14-15~2. Discharged within 3 months~3. Can communicate and conversation with Mandarin Chinese or Taiwanese~4. Agree to join the research~5. Can walk and communicate individually and live in big Taipei area."|Randomized controlled trial|t|f|f|f
34068781|NCT04860024|||CASE_CONTROL||PROSPECTIVE|||||||
34068782|NCT00852280|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34068783|NCT02800395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068784|NCT02524626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068785|NCT04348500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded IP (clazakizumab or placebo) will be given initially, followed by the option of an open label dose of clazakizumab within the first 14 days of initial IP administration.|We propose the administration of a blinded dose of an investigational product (IP) (clazakizumab or placebo \[0.9% saline\]) in patients with COVID-19 disease and signs of pulmonary involvement who have not yet required mechanical ventilation and/or ECMO. If a patient progresses to mechanical ventilation and/or ECMO or develops clinical signs of deteriorating COVID-19 disease, and there are no treatment related serious adverse events (SAEs), within the initial 14 day period after the first dose of the IP, at the discretion of the investigator or treating physician, open-label clazakizumab 25mg IV x 1 dose may be administered. A minimum of 24 hours should elapse between the first dose of IP and this dose of open-label clazakizumab. The patient will remain blinded as to the identity of the IP administered in the first dose.|t|t|t|t
34068786|NCT04554381|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|t|f
34068787|NCT04852211|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with hepatocellular carcinoma which undergone major hepatectomy will be randomized to either laparoscopic or open surgery group||||
34068788|NCT03756597|||CASE_CONTROL||PROSPECTIVE|||||||
33876691|NCT05841823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation sequence is concealed in opaque, sequential numbered envelope. The randomization will be carried out by the research assistant which is not involved in the study. The data collection will also be carried out by the research assistant who did not know about the objective of the study. Hence, this is a three-armed parallel group single blind randomized controlled trial. The subjects are not blinded as they would have known which intervention they are in as the intervention procedures are different.|multicenter, three-armed, parallel, single blind randomized control trial|f|t|t|t
34068789|NCT02025270|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34068790|NCT04208672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068791|NCT04160637|||COHORT||PROSPECTIVE|||||||
34068792|NCT05007171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068793|NCT03717649|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||A single centre, prospective, randomised, double-blind trial|t|t|t|f
34068794|NCT06055153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068795|NCT02547909|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068796|NCT03188523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068797|NCT05689788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34068798|NCT00877539|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34068799|NCT05042986|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34068800|NCT04217824|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33756983|NCT05952635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33756984|NCT04803110|RANDOMIZED|PARALLEL||TREATMENT||NONE||10 receiving immediate implant placement with Socket-Shield Technique and 10 receiving immediate implant placement with complete extraction of the tooth. (n=20)||||
34068801|NCT05700331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068802|NCT02065518|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34068803|NCT00200941|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33756985|NCT03166943|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876692|NCT01192958|||CASE_ONLY|||||||||
33876693|NCT06434311|||OTHER||CROSS_SECTIONAL|||||||
33876694|NCT00820521|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33876695|NCT06149780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876696|NCT04082754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876697|NCT05304351|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33876698|NCT05288270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This randomized, double-blind, single center trial will recruit subacute hemiplegic patients of any age with hemiparesis of the arm after stroke. The trial is designed as prospective, exploratory, interventional study without drug. The study does not request the use of drugs. This study protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist.|f|f|f|t
33876699|NCT04495309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756986|NCT01872533|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33756987|NCT05597501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33756988|NCT00276692||||TREATMENT||NONE||||||
33968854|NCT05863156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was conducted in a pregnant follow-up outpatient clinic of a maternity hospital in Istanbul, between December 2021 and January 2023, in a randomized controlled experimental study design with two interventions and a control group. In the study, 60 participants were placed in the right side lying position (intervention 1), 60 participants in the semi-sitting position (intervention 2) and 120 participants in the left side lying position (control group), and the study was completed with a total of 240 pregnant women. Research data were collected through the Information Form and the General Comfort Scale-Short Form.|t|f|f|f
33968855|NCT01280799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968856|NCT05053178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33968857|NCT01428726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068804|NCT03105856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34068805|NCT05459558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34068806|NCT00102856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34068807|NCT06145113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each participant will not be aware of which arm to which they have been assigned. The on-site investigator will be responsible for randomization, so they will not be able to be blinded.||t|f|f|f
34068808|NCT04660786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068809|NCT06265571|||COHORT||RETROSPECTIVE|||||||
34068810|NCT01687283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34068811|NCT02626000|NA|SINGLE_GROUP||TREATMENT||NONE|For Phase 1b there are no 'maskings' as it's open-label.|||||
34068812|NCT00355511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068813|NCT03060291|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of three conditions: a web/mobile-only condition, a web/mobile + coach condition, or a wait list control group who will receive the web/mobile-only treatment one year after enrolling in the study.||||
34068814|NCT04722536|||COHORT||RETROSPECTIVE|||||||
34068815|NCT01044368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876700|NCT00746135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33876701|NCT04889300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Positive affect and optimism will be induced through the Best Possible Self (BPS) Intervention. Subjects will be randomly assigned to either the optimism or the control condition. In the optimism intervention, participants will be asked to imagine a future in which everything went well and in which all their wishes are fulfilled. After, it will be tested if selective learning can be increased through higher degrees of positive affect/optimism.||||
33876702|NCT01681264|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33876703|NCT02723500|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33876704|NCT00337064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876705|NCT01920347|||COHORT||PROSPECTIVE|||||||
33876706|NCT03957837|||COHORT||PROSPECTIVE|||||||
33876707|NCT00515801|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33876708|NCT06036862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876709|NCT05981833|||CASE_CONTROL||PROSPECTIVE|||||||
33876710|NCT05656209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876711|NCT05307029|||COHORT||RETROSPECTIVE|||||||
33876712|NCT04940143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068816|NCT02570035|||COHORT||PROSPECTIVE|||||||
34068817|NCT04646811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068818|NCT03007498|||||PROSPECTIVE|||||||
34068819|NCT02112877|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Thirty (30) patients will be enrolled at approximately 7 centers (feasibility cohort). These patients will not be included in the pivotal study population, but will be evaluated separately for the primary safety and efficacy endpoints as well as for all secondary endpoints. When these 30 feasibility patients have completed their 30-day follow-up, a Data Safety Monitoring Board (DSMB) will review the safety data and will determine if the study can proceed with enrollment of the 170 pivotal subjects.||||
34068820|NCT03315494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876713|NCT01082432|||CASE_ONLY||CROSS_SECTIONAL|||||||
33876714|NCT06396000|||COHORT||RETROSPECTIVE|||||||
33876715|NCT03720431|NA|SEQUENTIAL||TREATMENT||NONE||||||
33876716|NCT04485364|||OTHER||PROSPECTIVE|||||||
33876717|NCT02500524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876718|NCT00879229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876719|NCT00295334|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33876720|NCT02645357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33876721|NCT00005613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876722|NCT03841929|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33876723|NCT06433336|||COHORT||PROSPECTIVE|||||||
33968858|NCT03476356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One hundred and six opaque envelopes will be numbered serially and, in each envelope, there will be the corresponding letter which denotes the allocated group according to the randomization table. Then all of the envelopes will be closed and they will be placed in one box. When the first woman arrives, the first envelope will be opened and she will be allocated according to the letter inside, and this step will be repeated until the 106 envelopes are finished.|"A total of 106 women with the diagnosis of PCOS based on the European Society of Human Reproduction and Embryology/ American Society for Reproductive Medicine (ESHRE/ASRM) guidelines criteria (Rotterdam Criteria, 2003) will be randomly assigned using a computer-generated randomization sheet and they will be distributed into two groups:~Group L (53 patients):~This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.~Group C (53 patients):~This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle."|t|t|f|f
33968859|NCT02881476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968860|NCT03770871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded|Parallel group with 1:1 allocation ratio|t|f|t|t
33968861|NCT05926284|||COHORT||PROSPECTIVE|||||||
33876724|NCT00689715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876725|NCT04353180|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients and method :~This study will performed on 10000 patients tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection will randomly divided into 5 equal groups"||||
33876726|NCT04372277|NA|SINGLE_GROUP||TREATMENT||NONE||open-label||||
33876727|NCT02590588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876728|NCT02234154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876729|NCT00006130|RANDOMIZED|||TREATMENT||||||||
33876730|NCT06297746|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33876731|NCT01173991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876732|NCT05001321|||CASE_ONLY||RETROSPECTIVE|||||||
33876733|NCT03410888|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33876734|NCT05022797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876735|NCT03066102|NA|SINGLE_GROUP||OTHER||NONE||||||
33876736|NCT04907760|RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, prospective, randomized, controlled, two arms, multicentric study||||
33876737|NCT04027933|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes Assessor does not know which group the data belongs to.|Two parallel group pretest-poshest randomized control trial|f|f|f|t
33876738|NCT01077843|||COHORT||RETROSPECTIVE|||||||
33876739|NCT00000625||||TREATMENT||DOUBLE||||||
33876740|NCT00120458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876741|NCT04667351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33876742|NCT04584580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33876743|NCT03659682|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||delayed start design|t|t|t|t
33876744|NCT01094769|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33876745|NCT05386615|||OTHER||OTHER|||||||
33876746|NCT01652885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876747|NCT03239574|NA|SINGLE_GROUP||OTHER||NONE||||||
33876748|NCT04148131|||CASE_CONTROL||PROSPECTIVE|||||||
33876749|NCT02363686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876750|NCT03793712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876751|NCT01811251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968862|NCT06112535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968863|NCT00613847|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33756989|NCT03283579|||COHORT||PROSPECTIVE|||||||
33756990|NCT04322123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33756991|NCT04130568|||COHORT||PROSPECTIVE|||||||
33756992|NCT01113502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33756993|NCT00957892|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33756994|NCT04667312|||COHORT||RETROSPECTIVE|||||||
33756995|NCT06571448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33756996|NCT03070496|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33876752|NCT00234611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876753|NCT01688154|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33876754|NCT00123214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33876755|NCT01032304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876756|NCT05858671|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study will be single blind as the participants will not know to what treatment they have been allocated until the end of the study. However, as the Postdoctoral Research Fellow will be conducting study visits and allocating participants to their treatment group it will not be possible for them to be blinded.|This will be a randomised controlled trial. 114 participants will be randomized into two groups (57/group) to receive either fenugreek seed tea or a control black tea, respectively.|t|f|f|f
34068821|NCT05897827|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an unblinded study. This is an educational intervention that cannot be blinded because study participants will be able to tell which condition they are in based on the content they receive.|This is a two-armed cluster-randomized controlled pilot trial of the PLANTS intervention versus an active control group, the EMAILS intervention. The investigators will randomize schools in an equal 1:1 ratio, stratified by large versus small schools, into intervention or active control conditions. The investigators will use block randomization with block sizes of 2, which will be stratified by large schools versus not, where large is ≥1000 students. The investigators use block size of 2 because there are only 4 schools in this pilot trial.||||
33876757|NCT00709215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876758|NCT02480127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876759|NCT01967550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876760|NCT00003437|RANDOMIZED|||TREATMENT||||||||
33876761|NCT05234632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876762|NCT02745275|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33876763|NCT05185271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756997|NCT03399643|||COHORT||PROSPECTIVE|||||||
33756998|NCT04042857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33756999|NCT05114655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33757000|NCT00444808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757001|NCT01043432|||COHORT||CROSS_SECTIONAL|||||||
33757002|NCT04584034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Individually randomised, placebo-controlled, multicentre, parallel group trial|t|t|t|t
33757003|NCT04851548|RANDOMIZED|PARALLEL||TREATMENT||NONE||test group use membrane and hyaluronic acid ,control group use membrane without hyaluronic acid||||
33757004|NCT04115111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757005|NCT03883815|||COHORT||CROSS_SECTIONAL|||||||
33757006|NCT06059027|||COHORT||PROSPECTIVE|||||||
33757007|NCT01309529|||CASE_ONLY||PROSPECTIVE|||||||
33876764|NCT00977821|RANDOMIZED|PARALLEL||||NONE||||||
33876765|NCT01403012|||COHORT||PROSPECTIVE|||||||
33876766|NCT02982954|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876767|NCT05002023|||COHORT||PROSPECTIVE|||||||
33876768|NCT05607875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33876769|NCT03157427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will be treated on the randomized hand, the other hand is the comparator/control.~Comparison between the treated hand and the control hand will be performed."|f|f|f|t
33876770|NCT01391000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876771|NCT02766738|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33757008|NCT03726255|||COHORT||RETROSPECTIVE|||||||
33757009|NCT03346811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757010|NCT05389579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||As a parallel group, randomized controlled trial with repeated measures to test the following hypothesis: the average body temperature of patients who use an electric blanket along with a woolen blanket reaches a normal value at least one timeframe (15 minutes) before that of patients who use a woolen blanket. It was used electric blankets for the patients in the experimental group in addition to the routine practices in the clinic and did the routine practice in the clinic for the patients in the control group by the researcher.||||
33757011|NCT01078857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757012|NCT03802123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757013|NCT04110405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876772|NCT02263183|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33876773|NCT01329211|||COHORT||PROSPECTIVE|||||||
33876774|NCT05332158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Researcher will be blinded to participants with pseudonymised data being collected for analysis.|||||
33876775|NCT04110457|||CASE_ONLY||PROSPECTIVE|||||||
33876776|NCT00820651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876777|NCT04313127|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33876778|NCT02549209|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
33876779|NCT02589262||||TREATMENT||||||||
33876780|NCT01023971|||COHORT||PROSPECTIVE|||||||
33757014|NCT05256108|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|To ensure blinding to the treatment, subjects will receive 6 identically looking capsules that will contain one of the 5 assigned treatments. Subjects will be randomized 1:1:1:1:1 and will receive one of 2 cebranopadol doses: oxycodone IR: tramadol IR: placebo in each of the 5 treatment periods.|Randomized, single site, double-blind, placebo- and active-controlled, crossover, single oral dose, Phase 1 trial, in non dependent recreational opioid users|t|f|t|f
33757015|NCT01093950|||CASE_ONLY||PROSPECTIVE|||||||
33757016|NCT06219564|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Two radiologists with at least ten years of experience, independently of each other, evaluated p-MRI scans of pregnant women diagnosed with t-PP without prior knowledge of the original reports.|277 singleton pregnancies that met the inclusion criteria and were diagnosed with total placenta previa (t-PP) in the third trimester were divided into two groups according to whether a placental-MRI (p-MRI) was performed. Nevertheless, we explored whether pregnant women diagnosed with total placenta previa (t-PP), with or without a placental-MRI (p-MRI), needed to undergo peripartum-total abdominal hysterectomy (p-TAH) during cesarean section (C/S) due to the placenta accreta spectrum (PAS).|f|f|f|t
33757017|NCT03868865|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757018|NCT05604924|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757019|NCT00243542|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33757020|NCT00282893|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33876781|NCT03670953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double dummy, blinded drug|Multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study.|t|t|t|t
33876782|NCT03808727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876783|NCT00799123|||COHORT||PROSPECTIVE|||||||
33876784|NCT00135668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876785|NCT00661115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876786|NCT02363062|||COHORT||CROSS_SECTIONAL|||||||
33876787|NCT02925156|||COHORT||PROSPECTIVE|||||||
33876788|NCT01267851|||OTHER||RETROSPECTIVE|||||||
33876789|NCT00620412|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876790|NCT03142802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients diagnosed with testicular germ cell cancer will undergo both standard and low dose CT scan of the abdomen and pelvis.||||
33876791|NCT02192827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876792|NCT06495034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876793|NCT04952064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876794|NCT03921021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876795|NCT05450198|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33876796|NCT00892307|||||PROSPECTIVE|||||||
33876797|NCT00858858|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33876798|NCT06539767|||COHORT||PROSPECTIVE|||||||
33876799|NCT04042103|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm study||||
33876800|NCT05372029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will occur using a code corresponding to intervention arm. Participant and provider will not know the number-condition link.|Two group randomized controlled trial of AAT versus comparator|t|f|f|t
33876801|NCT01049841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876802|NCT04601987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33876803|NCT06101056|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be cluster-randomized at the level of the squadron to one of two conditions.||||
33876804|NCT00472524|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876805|NCT05511168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876806|NCT04845828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876807|NCT02182687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876808|NCT03961503|||COHORT||RETROSPECTIVE|||||||
33876809|NCT00841685|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876810|NCT01452334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876811|NCT06190171|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be assigned to active or sham respiratory strength training using block randomization and will be blinded to their assigned treatment. Researchers performing evaluations and data analysis will also be blinded.|randomized, sham controlled clinical trial|t|f|f|t
33876812|NCT03471702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876813|NCT02995109|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33876814|NCT04956380|RANDOMIZED|FACTORIAL||OTHER||NONE||2x2 factorial randomized controlled trial||||
33876815|NCT01946321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876816|NCT02820311|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33876817|NCT03304015|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876818|NCT00639405|||CASE_ONLY||PROSPECTIVE|||||||
33876819|NCT03656679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be provided with de-identified data for analysis|Parallel Assignment|f|f|f|t
33968864|NCT00133302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968865|NCT06450600|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is an observational, descriptive, and analytical research without a control group, aimed at assessing the impact of a specialized therapeutic education program on the quality of life of patients with multiple sclerosis. Participants will receive individual sessions to assess their needs, followed by targeted educational workshops on various aspects of disease management. The effectiveness of the program will be primarily measured using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire, with secondary outcomes assessed by the Urinary Handicap Measure (M.H.U) scale.||||
33968866|NCT03103009|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment Plan for an individual patient with pasireotide for Hyperinsulinemic Hypoglycemia (Compassionate Use Protocol for Pasireotide)||||
33876820|NCT00000414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876821|NCT00039793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876822|NCT05712044|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Quasi-experimental study, pretest-posttest design with no control group. equivalent, in subjects with substance abuse and healthy subjects. The intervention will consist of administration of 15 mg of folic acid divided into 3 doses per day. Mucosal samples will be taken orally in duplicate to each participant to determine the frequency of micronuclei (MN), bursts cells (NBUD), binucleated cells (BN), condensed chromatin (CC), karyorrhexis (CR), pyknosis (PIC) and caryolysis (CL) at different time events: pre-treatment, 15 days and 30 days. So as a survey to determine consumption patterns of psychoactives, sociodemographic data, dietary and exposure to known cytogenotoxic agents.|t|f|f|f
33876823|NCT05951608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876824|NCT02429414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876825|NCT01534533|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876826|NCT04241445|||OTHER||PROSPECTIVE|||||||
33876827|NCT05149482|||CASE_ONLY||RETROSPECTIVE|||||||
33876828|NCT02128230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876829|NCT00452205|||COHORT||PROSPECTIVE|||||||
33876830|NCT04824508|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33876831|NCT05667896|||COHORT||PROSPECTIVE|||||||
33876832|NCT04454463|||COHORT||PROSPECTIVE|||||||
33876833|NCT01409785|||CASE_CONTROL||PROSPECTIVE|||||||
33876834|NCT05209100|||CASE_CONTROL||OTHER|||||||
33757021|NCT03659448|RANDOMIZED|PARALLEL||OTHER||NONE||"Two parallel arms consisting of a treatment arm of patients who will receive the study drug and subsequently undergo surgical resections under both standard white light conditions and then NIR, and a no treatment arm to whom the study drug will not be administered and who will undergo surgical resections under standard white light conditions only."||||
33876835|NCT00730639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757022|NCT04123678|||COHORT||PROSPECTIVE|||||||
33876836|NCT04382170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will be a randomized, controlled, 2-arm, double-blinded trial.|t|t|t|t
33876837|NCT00673166|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33876838|NCT00949832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757023|NCT05675046|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter prospective single-arm trial of subjects with symptomatic CTS treated with CTR-US in an office-based setting.||||
33757024|NCT02313857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757025|NCT03295318|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Observer blind wherein the pharmacist and other study staff involved in vaccine administration will be aware of the treatment allocation.~The other study staff involved in safety assessments will be masked to treatment arm. The laboratory involved in immunogenicity analysis will also be blinded to the treatment allocation."||t|t|t|t
33876839|NCT05530226|NA|SINGLE_GROUP||TREATMENT||NONE||single arm study||||
33876840|NCT06290050|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33876841|NCT02215720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876842|NCT06548984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876843|NCT01430039|||COHORT||CROSS_SECTIONAL|||||||
33876844|NCT05936450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757026|NCT00255957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876845|NCT01258764|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33876846|NCT04950257|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The analysis team members will be blind to the randomisation process and group allocation of participants|The trial design is of a superiority two-arm parallel-group single-blind randomised controlled trial comparing usual practice plus up to 6 weeks of using the repetitive negative thinking-targeting digital self-help app versus usual practice and waiting list control. The primary hypothesis is that the rumination-targeting digital self-help app will reduce rumination and worry significantly more than waiting list control at 6 weeks follow-up.|f|f|f|t
33876847|NCT03610061|NA|SEQUENTIAL||TREATMENT||NONE||Dose Escalation||||
33876848|NCT03659019|||COHORT||PROSPECTIVE|||||||
33876849|NCT04479111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876850|NCT05796635|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33757027|NCT05841355|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||Compare intervention effects on BC screening among 400 non-adherent Latinas in a 1:1 empower/educate ratio (n=200 per group)|f|t|t|t
33757028|NCT04237805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757029|NCT06335264|||COHORT||PROSPECTIVE|||||||
33757030|NCT02921529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Inventions were given by an investigator who is not involved in patient care. The anesthetists, surgeons,staff in the ward, the one who record the outcomes, and data analyzer were all blinded to the group allocation.||f|t|t|t
33757031|NCT01928355|||||PROSPECTIVE|||||||
33876851|NCT01588717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876852|NCT05272800|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized open label controlled parallel-group trial aims to compare spectroscopy bioimpedance (BIS) guided DW estimation with clinical evaluation alone.||||
33876853|NCT02750540|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33876854|NCT04156451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876855|NCT00343174|RANDOMIZED|PARALLEL||||DOUBLE||||||
33876856|NCT02264990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876857|NCT02351570|||||CROSS_SECTIONAL|||||||
33876858|NCT04817111|NA|SINGLE_GROUP||OTHER||NONE||Open Label, 14 Days (+/- 2 Days)||||
33876859|NCT04854837|||CASE_CONTROL||PROSPECTIVE|||||||
33876860|NCT01409135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876861|NCT01290692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876862|NCT04434391|||COHORT||PROSPECTIVE|||||||
33876863|NCT03887897|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33876864|NCT00092430|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33876865|NCT00656955|||CASE_ONLY||PROSPECTIVE|||||||
33876866|NCT01075555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876867|NCT02213809|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876868|NCT06177756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876869|NCT06182332|NA|SINGLE_GROUP||SCREENING||NONE||||||
33876870|NCT05813912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876871|NCT01258907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876872|NCT06087354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876873|NCT05008107|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876874|NCT02919436|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33876875|NCT04814394|||CASE_CONTROL||RETROSPECTIVE|||||||
33876876|NCT04398563|||COHORT||RETROSPECTIVE|||||||
33876877|NCT06106464|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33876878|NCT02981680|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876879|NCT03462407|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized prospectively into one of three possible groups following initial assessments and screening (e.g., eligibility), 1) 15 participants in an experimental (DAID intervention), 2) 15 control participants (dog walking), 3) 15 waitlisted control participants (true control, waitlisted for DAID one-year after post-assessment 1 of the project).||||
33876880|NCT05776862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33876881|NCT04357821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757032|NCT05692622|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The participants will not be blinded to group allocation as both the groups will receive the same intervention, just at different time points. The principal investigator will not be blinded to the group allocation either as they will be the lead contact with the participants, monitoring their progress and engagement. The physiotherapist who will be carrying out outcome assessments will be blinded to the group allocation and not be made aware of the different timelines and structure of the trial|A delayed start design will be used in this study|f|f|f|t
33757033|NCT03826290|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinic randomized trial||||
33757034|NCT02999828|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33757035|NCT03014765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757036|NCT02982525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33757037|NCT02430402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757038|NCT04296487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757039|NCT03663686|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33757040|NCT02674217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757041|NCT04692402|NA|SINGLE_GROUP||TREATMENT||NONE|Investigator initiated multicentre open label prospective feasibility trial.|||||
33757042|NCT00790283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757043|NCT02782702|NA|SINGLE_GROUP||OTHER||NONE||||||
33757044|NCT00002568|RANDOMIZED|||TREATMENT||||||||
33757045|NCT02089230|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33757046|NCT01514526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757047|NCT05779865|||COHORT||PROSPECTIVE|||||||
33757048|NCT00825422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757049|NCT03915639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757050|NCT00289887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757051|NCT00424125|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33757052|NCT02845401|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33757053|NCT00708916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757054|NCT06141330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33876882|NCT03803098|||OTHER||CROSS_SECTIONAL|||||||
33757055|NCT06022835|NA|SINGLE_GROUP||PREVENTION||NONE||"The recruitment period was from October 2019 to August 2022. All incident PD patients aged between 21-99 years were screened. Patients allergic to chlorhexidine and Tegaderm dressing were excluded from the study. One hundred thirty-eight patients initiated PD and were screened between October 2019 and April 2022.~A historical cohort of incident PD patients from November 2016 to October 2017 with the same inclusion and exclusion criteria were also recruited and compared to the CHG dressing group."||||
33757056|NCT00551798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757057|NCT03658564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33757058|NCT05381935|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33757059|NCT03329287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757060|NCT00549757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757061|NCT06231238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33757062|NCT01992510|||CASE_CONTROL||PROSPECTIVE|||||||
33757063|NCT04001179|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757064|NCT01325285|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757065|NCT02764710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33757066|NCT01726881|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876883|NCT02037737|||OTHER||RETROSPECTIVE|||||||
33876884|NCT04639180|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Camrelizumab Combined with Rivoceranib (Apatinib) Versus Active Surveillance||||
33757067|NCT04497402|||COHORT||PROSPECTIVE|||||||
33757068|NCT05470114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757069|NCT03766022|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33757070|NCT05475067|||CASE_ONLY||RETROSPECTIVE|||||||
33757071|NCT02726802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33876885|NCT05826756|||COHORT||PROSPECTIVE|||||||
33757072|NCT02447822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757073|NCT06064084|||CASE_CONTROL||OTHER|||||||
33757074|NCT01291979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876886|NCT02625935|||COHORT||PROSPECTIVE|||||||
33876887|NCT01391507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068822|NCT05861206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The inclusion criteria was as follows: presence of all primary teeth without a restoration, except the third molars; papillary bleeding index of 2 or 3 in at least 30% of papillae; no clinical attachment loss; being systemically healthy; and being normal weight according to body-mass index (BMI, 18,5-24,9 kg/m2). The exclusion criteria was as follows: usage of non steroidal anlgesics or antibiotics in last 6 months; usage of fixed or removable orthodontic appliance; presence of a intraoral soft tissue pathology; mouth breathing; smoking; a physical or mental disability that could prevent daily plaque control; and usage of any mouthwash in last 6 months.Chronic gingivitis patients aged 18-32 years whose mechanical plaque control was supported with different mouthwashes were randomly assigned into 4 groups of 28 people each: CHX-MW group (0.12% CHX, as a positive control group), EO-MW group (Listerine mouthrinse), GT-MW group (5% Green tea), and WT-MW group (5% White tea).|t|t|t|f
33757075|NCT05273125|||COHORT||PROSPECTIVE|||||||
33757076|NCT05217238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757077|NCT04602312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||4 x (2) mixed design, with training (mindfulness vs specific sham mindfulness vs general sham mindfulness vs book listening control, between subjects) and time (pre-treatment vs post-treatment, within-subjects) as factors.|t|t|t|t
34068823|NCT05231070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial, in which patients will be randomly assigned either to one of the two arms (1:1): intervention (TeleSPC) or control group (standard care). Assessment will occur at inclusion (baseline) and after 2 weeks, 4 weeks, 8 weeks, and 6 months. sample will be composed by 87 patients in each group and their informal caregiver (1 informal caregiver per patient) .||||
33757078|NCT04805060|NA|SEQUENTIAL||TREATMENT||NONE||||||
33757079|NCT01733732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757080|NCT03758170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All intervention drugs will be blinded by a nurse who is not a participant in the study or in the treatment of the patient in any way.~The Patient, the administrator of the drug(nurse or doctor), the assessor, the investigator and the care team will all be blinded."|A randomized doubleblinded controlled trial.|t|t|t|t
33757081|NCT00314548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757082|NCT02737800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757083|NCT03509740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757084|NCT01008267|||CASE_CONTROL||PROSPECTIVE|||||||
33757085|NCT01520818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757086|NCT05333354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757087|NCT01247402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757088|NCT05257330|||CASE_ONLY||PROSPECTIVE|||||||
33757089|NCT04704518|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative, controlled, parallel group, open, randomized multicenter study||||
33757090|NCT05773560|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The researcher analyzing the final outcomes is blinded from the personal information and execution of the rehabilitation of the patients.|Patients after a major amputation would received at least 10 days of rehabilitation with the assistance of virtual reality. Before the operation, patients consent, life quality, pain score and motivation score were be evaluated. The rehabilitation with virtual reality started on the second postoperative day. The pain score would be evaluated everyday before and after the rehabilitation. On the fifth and tenth day, motivation, life quality and functional index would be carried out again as the evaluation of the outcome of training.||||
33757091|NCT06509256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33757092|NCT05360641|||COHORT||RETROSPECTIVE|||||||
33757093|NCT06346314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757094|NCT00198484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757095|NCT03155789|||COHORT||PROSPECTIVE|||||||
33876888|NCT01281566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876889|NCT04753073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876890|NCT05479500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be divided into three groups using block randomization method. Participants will be randomly allocated into 3 blocks of 12 participants in each group using a random number generation technique by computer. All assessments will be done by researcher who were not in the study.|There will be three groups in this study. Each group will consist of 12 patients aged 30-60 years with plantar fasciitis. A total of 36 participants will take part in the study. Conventional physiotherapy will be applied to the group 1 and, local release technique addition to conventional physiotherapy will be applied to the group 2, while myofascial release techniques will be applied to the experimental group in addition to conventional physiotherapy.|f|f|f|t
33876891|NCT05841043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876892|NCT03954535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34068824|NCT01917695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068825|NCT01215435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068826|NCT02707172|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34068827|NCT02935296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068828|NCT02057432|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34068829|NCT03148067|||COHORT||PROSPECTIVE|||||||
34068830|NCT00561535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068831|NCT00312117|RANDOMIZED|PARALLEL||||NONE||||||
34068832|NCT00466050|||CASE_ONLY||PROSPECTIVE|||||||
34068833|NCT06612918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|high-intensity laser acupuncture and exercise therapy program|t|f|f|t
34068834|NCT03039465|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single group of patients undergoing the insertion of the prosthesis would be evaluated for voice quality and fluid leak as a measure of success of the intervention.||||
34068835|NCT06222814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068836|NCT03662035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068837|NCT03635008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An investigator who applies the tDCS to the participants will not be masked. However, other investigators including outcome assessors and participants will be masked. The other care providers in our department (e.g. other physio- or occupational therapists) will be masked.|Randomized, double-blind, sham-controlled, parallel group design|t|t|t|t
34068838|NCT04755894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068839|NCT04198142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757096|NCT06451900|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blinded controlled trial|"full-term (37 to 41 weeks),Appropriate for gestational age weight between 2500 to 3500 gm infants with neonatal hyperbilirubinemia not reaching thel evel of phototherapy.The participants in our study will be divided in to three groups: Group A: full term neonates received a single oral dose of 10 mg/kg of non- micronized fenofibrate Group B: full term neonates received two oral doses of 10 mg/kg of non - micronized fenofibrate.~Group C: full term neonates received equivalent amount of distilled water."|t|t|t|t
33757097|NCT02459730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757098|NCT00526279|||COHORT||PROSPECTIVE|||||||
33757099|NCT02027402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757100|NCT03169803|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33757101|NCT05665933|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||randomized controlled trial with pretest posttest, experimental and control groups|f|f|f|t
34068840|NCT01257308|||||PROSPECTIVE|||||||
33876893|NCT03571646|RANDOMIZED|PARALLEL||SCREENING||SINGLE|During the study Phase I, the alarms of both devices will be silenced and the screen information blinded, as is the current clinical practice. During the study Phase II, the screen information will be available and the nursing staff will be instructed to respond to both devices' alarms based on a pre-defined hospital protocol.|"The occurrence of at least one of the following RC markers will be considered as primary endpoint for patients monitored by Capnostream 20p during both study Phases: (1) SpO2 ≤ 90% for ≥ 3 minutes.(2) RR ≤ 8 or ≥ 22 bpm for ≥ 3 minutes. (3) etCO2 ≤ 15 or ≥ 60 mmHg for ≥ 3 minutes. (4) Apnea episode lasting \> 30 seconds.~The occurrence of at least one of the following RC markers will be considered as primary endpoint for patients monitored by PM1000N-RR during both study Phases:~(1) SpO2 ≤ 90% for ≥ 3 minutes. (2) RR ≤ 8 or ≥ 22 bpm for ≥ 3 minutes."|f|t|f|f
33757102|NCT03595332|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33757103|NCT02611739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757104|NCT01949311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757105|NCT00404664|RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
33757106|NCT03791580|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will randomly assign each of the 3 participating pilot practices to 1 of 3 arms: (1) commitment nudge, (2) justification nudge, or (3) both commitment and justification nudges. Randomization will be at the practice level, without replacement, thus assigning exactly 1 practice to each arm. All participating clinicians within a given practice will receive the same nudges. Northwestern-affiliated practices that do not participate in the pilot will constitute a fourth arm of this pilot study.||||
33757107|NCT04051164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757108|NCT02925910|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33757109|NCT02703350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33757110|NCT01826812|||CASE_CONTROL||PROSPECTIVE|||||||
33757111|NCT02863484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757112|NCT04873648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757113|NCT05845268|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not practically possible|||||
33757114|NCT05541055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33757115|NCT04137848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33876894|NCT04396171|||OTHER||CROSS_SECTIONAL|||||||
33876895|NCT03259009|||COHORT||PROSPECTIVE|||||||
33876896|NCT03847675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||An experimental double blinded parallel arms randomized controlled trial with pre and post-intervention assessment over a period of 12 months with a follow up plan at 2 and 3 years of age|t|f|t|t
33876897|NCT02173574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757116|NCT06578884|||CASE_CONTROL||PROSPECTIVE|||||||
33757117|NCT03288610|||COHORT||PROSPECTIVE|||||||
33757118|NCT05180292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068841|NCT05522946|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Group 1: Parents and children without disabilities Group 2: Parents and adolescents with mild to moderate cognitive or physical disability Group 3: Parents and adolescents with moderate to severe cognitive and/or physical disability||||
34068842|NCT05774002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068843|NCT01548768|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068844|NCT04544839|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34068845|NCT04161105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator will gather data using a force platform and computer software. It will be anonymised and group allocation will be concealed by a second investigator before being individually analysed by the principal investigator. The second investigator will be given the individually analysed data and he/she will sort the individual data into relevant groups for group analysis.|Participants with latent trigger points in rectus femoris (RF) and gluteus maximus (GM) muscles will be stratified evenly into 3 groups (RF dry needling, GM dry needling or control) based on baseline strength. Treatment, data collection and data analysis of all participants will be conducted concurrently.|f|f|f|t
34068846|NCT00031772|RANDOMIZED|PARALLEL||||NONE||||||
34068847|NCT02591030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068848|NCT04131582|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Assigned treatments will be delivered to the patients in identical envelopes by a person not involved in the trial; persons who evaluate the follow-up and outcomes will be masked to the treatment allocation||t|t|t|t
34068849|NCT02494648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068850|NCT02883621|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34068851|NCT03396822|||COHORT||PROSPECTIVE|||||||
34068852|NCT01386944|||COHORT||PROSPECTIVE|||||||
34068853|NCT04186221|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, continued access protocol||||
34068854|NCT00998205|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34068855|NCT03011437|||CASE_ONLY||PROSPECTIVE|||||||
34068856|NCT00272844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068857|NCT05216640|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34068858|NCT00534105|||COHORT||PROSPECTIVE|||||||
34068859|NCT04240522|||COHORT||PROSPECTIVE|||||||
34068860|NCT05061901|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34068861|NCT04235842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the study intervention the participants were submitted.|Randomized clinical trial, single blinded.|f|f|f|t
34068862|NCT01664507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968867|NCT03873519|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Patients will be allocated into four conditions (Group A: Cold North, Group B: Cold South C: Warm North D: Warm South), and they will be assigned a new condition at each next visit. The sequence will be assigned randomly to each patient. During each of the four visits, the patients will be treated per standard of care during their chemotherapy sessions. Outcome variables will be assessed before and after each visit.|t|t|f|f
33968868|NCT05953922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||intervention study|f|f|f|t
33968869|NCT02756000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968870|NCT02179684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968871|NCT00824460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968872|NCT00036777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968873|NCT03040076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968874|NCT03231527|||COHORT||RETROSPECTIVE|||||||
33968875|NCT01990885|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Systemic Exposure Of Single Escalating Administrations And Repeated Administration Of Bl-7010 In Well-Controlled Celiac Patients|t|f|t|t
33968876|NCT02708290|||COHORT||PROSPECTIVE|||||||
33968877|NCT02762565|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33876898|NCT00716651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876899|NCT04772729|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A cross-over, open-label, randomized study.||||
33876900|NCT03524859|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33876901|NCT05454215|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Single center non-blinded randomized crossover trial||||
33876902|NCT04002011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876903|NCT03165097|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33876904|NCT01556607|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33876905|NCT02493595|||COHORT||PROSPECTIVE|||||||
33876906|NCT03630328|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33876907|NCT00896207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876908|NCT02750033|||CASE_ONLY||PROSPECTIVE|||||||
33876909|NCT03889977|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33876910|NCT03223545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33876911|NCT04559958|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33876912|NCT02282644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876913|NCT03607838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33876914|NCT05968573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Participants will be told during consent that they will be randomized and assigned to a group. Participants will be told that the two groups are to watch a video or listen to a health educator. Therefore, participants are not prevented from having knowledge of the interventions assigned to them.|"This study has two parts:~Part A: Modification of the PHCI with the assistance of current and former people who inject drugs (PWID) ED patients.~Part B: Randomized Controlled Trial - this will only be conducted after completion of Part A."||||
33876915|NCT03173092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876916|NCT06291389|||COHORT||PROSPECTIVE|||||||
33876917|NCT01312246|NA|SINGLE_GROUP||OTHER||NONE||||||
33876918|NCT04362280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876919|NCT00115154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33876920|NCT03339661|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876921|NCT03754426|||COHORT||PROSPECTIVE|||||||
33876922|NCT01765101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33968878|NCT02792413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968879|NCT04036227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study will be conducted in double-blind fashion and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.~GS-248 and the placebo are identical in appearance, taste and smell."|"Part I (SAD) Within each cohort, subjects will be randomised in a 3:1 ratio to receive either GS 248 (n=6) or placebo (n=2) in a blinded fashion.~Part II (MAD) Within each cohort, subjects will be randomised in a 3:1 ratio to receive GS-248 (n=6) or placebo (n=2) in a blinded fashion."|t|f|t|f
33968880|NCT00254397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876923|NCT04795557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|"Patients will be randomized in a manner of 1:1 for study drug (ADAPT-232) and Standard of Care to Placebo and Standard of Care.~Patient treatment period will last 2 weeks. During this time, patients will be monitored for adverse events.~There will be a follow up period in order to check adverse events and study drug efficacy"|t|t|t|t
33876924|NCT05275907|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33876925|NCT01871974|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33968881|NCT05197010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator responsible for randomization was independent from the assessors, assuring blindness to treatment allocation and randomization procedures. The blinded assessor performed the baseline and post-treatment assessments.|Prospective, single-center, single-blinded, two-armed randomized controlled trial|f|f|t|t
33968882|NCT01039220|NA|SINGLE_GROUP||OTHER||NONE||||||
33968883|NCT01483976|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33968884|NCT06482866|||CASE_CONTROL||RETROSPECTIVE|||||||
33968885|NCT01102777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33968886|NCT01336010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968887|NCT05954078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968888|NCT05300932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968889|NCT00581594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968890|NCT01955603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968891|NCT00347347|||COHORT||PROSPECTIVE|||||||
33968892|NCT00206206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968893|NCT06547905|NA|SINGLE_GROUP||OTHER||NONE||||||
33968894|NCT02914366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968895|NCT01402583|||COHORT||RETROSPECTIVE|||||||
33876926|NCT02573363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876927|NCT00916357|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33876928|NCT03730337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968896|NCT04070456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33968897|NCT00216944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33968898|NCT04372433|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation and Expansion||||
33968899|NCT03826381|||COHORT||CROSS_SECTIONAL|||||||
33968900|NCT00001128||||TREATMENT||DOUBLE||||||
33968901|NCT04823000|NA|SINGLE_GROUP||TREATMENT||NONE||Single Center, Open phase study||||
34068863|NCT05979480|||COHORT||PROSPECTIVE|||||||
33876929|NCT06036732|||CASE_ONLY||PROSPECTIVE|||||||
33876930|NCT04623983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876931|NCT02014636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876932|NCT00633659|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33876933|NCT06108895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single researcher who will be blinded to groups will be responsible for all measurements and data collection.|Ninty parturients who had normal singleton pregnancy scheduled for elective lower segment cesarean section through a Pfannensteil incision under spinal anesthesia will be recruited in the study. They will be randomly divided into three equal groups; Group C, control group who will receive spinal anesthesia; Group M who will receive spinal anesthesia with intrathecal morphine, and group I who will receive spinal anesthesia and IINB|f|f|f|t
34068864|NCT03720405|||COHORT||CROSS_SECTIONAL|||||||
34068865|NCT02937636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34068866|NCT01891240|||CASE_CONTROL||PROSPECTIVE|||||||
34068867|NCT00619372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068868|NCT05054205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized controlled experimental study was conducted between March and May 2018 with 39 intervention and 39 control groups, a total of 78 patients in the Chest Diseases Clinic of Chest Diseases Hospital who were treated with COPD. In data collection; ''Patient Data Form'', ''Medical Research Council (MRC) Dyspnea Scale'', ''COPD Self Efficacy Scale (CSES)'' were used.To the experimental group; motivational interview based self-management education was given for 30-45 minutes with groups of 5-8 people, COPD education guide was given, questions were shared with the question-answer method and group interaction was provided. After the self-management education, 3 motivational interviews were conducted 3 days apart with 30-45 minutes. Normal care was continued in the control group. The data were collected in three stages as pre-test, post-test and follow-up.||||
34068869|NCT02143934|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34068870|NCT03714776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068871|NCT03788980|||CASE_ONLY||PROSPECTIVE|||||||
34068872|NCT03729791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All researchers will conduct research with only the encrypted subject number. A separate third-party researcher will participate to encrypt the subject and adjust the active/sham direction of the tDCS device during the actual research.|"Randomized controlled trial~1 arm is active tDCS and 1 arm is sham tDCS"|t|t|t|t
34068873|NCT00964405|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34068874|NCT03072823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068875|NCT00994227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068876|NCT01812616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068877|NCT00472485|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068878|NCT06232746|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label single-center study enrolling up to 10 subjects in the Czech Republic||||
34068879|NCT02107677|||CASE_ONLY||RETROSPECTIVE|||||||
34068880|NCT01637883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34068881|NCT00741598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068882|NCT00673374|||COHORT||PROSPECTIVE|||||||
34068883|NCT04616820|||COHORT||PROSPECTIVE|||||||
33876934|NCT02858674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33876935|NCT04083482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876936|NCT01815307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876937|NCT02901808|||COHORT||RETROSPECTIVE|||||||
33876938|NCT06070103|||CASE_ONLY||CROSS_SECTIONAL|||||||
33876939|NCT01295216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876940|NCT06437808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876941|NCT04269226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33876942|NCT05175833|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Oral probiotics and placebo were physically identical and were revealed after statistical analysis|Randomized trial of oral probiotics versus placebo|t|t|t|t
33876943|NCT06194890|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33876944|NCT03260387|||COHORT||PROSPECTIVE|||||||
33876945|NCT00176995|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33876946|NCT00225472|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33876947|NCT06501404|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33876948|NCT02369276|||COHORT||PROSPECTIVE|||||||
33876949|NCT00577252|||COHORT||CROSS_SECTIONAL|||||||
33876950|NCT01359475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33876951|NCT05098496|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33876952|NCT04742088|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33876953|NCT02881632|||COHORT||PROSPECTIVE|||||||
33876954|NCT02004080|||COHORT||PROSPECTIVE|||||||
33876955|NCT00252057|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33876956|NCT04403581|||COHORT||CROSS_SECTIONAL|||||||
33876957|NCT01079182|||CASE_ONLY||PROSPECTIVE|||||||
33876958|NCT01706107|||COHORT||PROSPECTIVE|||||||
33876959|NCT02189850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876960|NCT01857661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33876961|NCT04411355|RANDOMIZED|CROSSOVER||PREVENTION||NONE||controlled semi-experimental design in matched groups||||
33876962|NCT01372904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876963|NCT04697875|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33876964|NCT02666573|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33876965|NCT04538027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876966|NCT04873752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876967|NCT04234711|||COHORT||PROSPECTIVE|||||||
33876968|NCT01146873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876969|NCT05138081|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|single blinding|parallel assignment|t|f|f|f
33876970|NCT02129959|||COHORT||PROSPECTIVE|||||||
33876971|NCT06050044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876972|NCT00326807|RANDOMIZED|||TREATMENT||DOUBLE||||||
33876973|NCT01550562|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33876974|NCT01069822|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33876975|NCT01099852|||COHORT||PROSPECTIVE|||||||
33876976|NCT05346705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33876977|NCT03467464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876978|NCT00316680|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33876979|NCT00105651|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33876980|NCT05562544|||CASE_CROSSOVER||PROSPECTIVE|||||||
33876981|NCT06072885|||COHORT||PROSPECTIVE|||||||
33876982|NCT01014741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33876983|NCT02386150|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33876984|NCT00822107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33876985|NCT01485757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876986|NCT06022263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33876987|NCT01425151|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33876988|NCT02092571|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33876989|NCT02035995|||CASE_CROSSOVER||PROSPECTIVE|||||||
33876990|NCT00601068|||CASE_ONLY||RETROSPECTIVE|||||||
33876991|NCT04697628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876992|NCT02386488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876993|NCT03764852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33876994|NCT03922009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||50 people in the control group 50 people in the experimental group||||
33876995|NCT01309659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33876996|NCT04599283|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33876997|NCT04515693|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33876998|NCT05517876|||COHORT||RETROSPECTIVE|||||||
33876999|NCT02849366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877000|NCT05670587|NA|SINGLE_GROUP||OTHER||NONE||||||
33877001|NCT00605423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877002|NCT03120286|||CASE_CONTROL||RETROSPECTIVE|||||||
33877003|NCT00436371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757119|NCT05130879|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Research assistants and participants will be blinded to the conditions until baseline assessments (referring to the set of questionnaires they have to complete before starting the training) are completed, at which time a random number sequence in a excel file will be opened to reveal whether they will be in the intervention or waitlist condition. Participants will not be explicitly told of participants' study condition; however, they need to participate in the intervention, so full blinding is not possible||f|t|t|t
33757120|NCT03255824|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33757121|NCT05204810|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877004|NCT06323109|||COHORT||PROSPECTIVE|||||||
33877005|NCT02791061|||CASE_CONTROL||PROSPECTIVE|||||||
33877006|NCT04499872|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877007|NCT03895866|||COHORT||PROSPECTIVE|||||||
33877008|NCT01946607|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33877009|NCT01262365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877010|NCT00845455|||COHORT||PROSPECTIVE|||||||
33877011|NCT00800501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877012|NCT02922062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33877013|NCT05382351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33877014|NCT00216411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877015|NCT04081363|NA|SINGLE_GROUP||TREATMENT||NONE||All the participants received only centanafadine but divided into 2 arm groups based on administration (as capsules or drug sprinkled onto applesauce).||||
33877016|NCT01222546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877017|NCT00520364|||CASE_CONTROL||RETROSPECTIVE|||||||
33877018|NCT00290615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877019|NCT05839054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Children were identified by a single investigator. He referred the child to the other investigator by noting the FLACC and MYPAS score, as well as the RR, SpO2, and HR values, which he determined to establish his criteria, including the first investigator. The second investigator divided the child into groups using the randomization method, with the double chronometer during the treatment, the duration of the crying and the effective treatment time were desired. He was re-directed to the first investigator, not telling the first investigator to group the treatment ending families and groups. Thus, before and after the first investigator's examination, when filling in the FLACC and MYPAS score and determining SpO2, RR and HR, the groups did not know which group they belonged to.|"The children randomize 3 different groups. A computer-generated block method divided children into 3 groups (VR glasses roller coaster, VR glasses wild dolphins, and control).~Based on 45 randomly sorted sets (1, 2, 3) (eg Set 1 Group 2, Set 2 Group 3, Set 3 Group 1), a total of 135 unique codes were generated and then randomly placed in a blocking box. protected. Only the second researcher knew the group value of the sets."|f|f|t|t
33968902|NCT05737329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Women with POI taking standard-dose estradiol hormone replacement therapy (E2/dydrogesterone (oral) (2.0/10 mg)) were invited to the study. We conducted a pilot study designed to compare the effectiveness of oral estradiol (2mg/ day) and Transdermal estradiol gel 0.1% (Gel sachet 1.0mg/ day) as standard-dose estradiol hormone replacement therapy. The obtained results on the absence of a significant difference in the effect of the above therapy made it possible to justify the prescription of higher doses of estrogens without prior switching from oral to transdermal therapy in equivalent doses in all study participants. Study participants will consistently receive Transdermal estradiol gel 0.1% (Gel sachet 1.5mg/ day) and Transdermal estradiol gel 0.1% (Gel sachet 2.0mg/ day) (both with 200mg micronized progesterone administered vaginally for 14days per cycle) with an outcome assessment at each stage of the study.|t|f|f|f
33968903|NCT05583175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968904|NCT06183775|||COHORT||PROSPECTIVE|||||||
33968905|NCT05678985|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33968906|NCT02854683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968907|NCT01545687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33968908|NCT00526773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968909|NCT04269278|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877020|NCT04359303|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|With a randomization table, nurses will treat the patients in treatment groups. Each patient will be in individual rooms.|Control group with WHO recommended treatment. Treatment group with WHO recommended treatment + systemic ozone therapy.|t|f|t|f
33877021|NCT05383027|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33877022|NCT00775632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877023|NCT05810220|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877024|NCT04017260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877025|NCT01093027|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33877026|NCT01779024|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33877027|NCT03813537|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomized to two arms:~1. Intervention: post operative phone call with protocol driven follow up pathway.~2. Control: Current standard post operative follow up practice at our institution."||||
33877028|NCT05448911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068884|NCT00079885|RANDOMIZED|||TREATMENT||DOUBLE||||||
34068885|NCT02394184|||COHORT||PROSPECTIVE|||||||
34068886|NCT05206383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double (Participant, Outcomes Assessor)|The study participants will be randomly qualified (allocated via a computer program) to the tree groups: A - positive message - placebo, B - negative message - nocebo, C - neutral message|t|f|f|t
34068887|NCT01640886|||CASE_CONTROL||PROSPECTIVE|||||||
34068888|NCT03354052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068889|NCT06387446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068890|NCT01592123|||COHORT||PROSPECTIVE|||||||
34068891|NCT00869583|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34068892|NCT02857036|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34068893|NCT01692522|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34068894|NCT00106158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068895|NCT04238338|||COHORT||PROSPECTIVE|||||||
34068896|NCT05513768|||CASE_CONTROL||OTHER|||||||
34068897|NCT02923401|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068898|NCT04829617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and treating study staff will be aware of the participant's treatment condition. However, follow-up assessments will be performed by a study staff member that is masked to the participant's treatment condition.|Randomized, single-blinded, controlled trial|f|f|f|t
34068899|NCT00408551||||TREATMENT||NONE||||||
34068900|NCT02688764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068901|NCT01168609|||COHORT||PROSPECTIVE|||||||
34068902|NCT02452255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068903|NCT03237052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068904|NCT05000736|||COHORT||RETROSPECTIVE|||||||
34068905|NCT00504543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068906|NCT05509101|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33877029|NCT03344302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33877030|NCT03267121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877031|NCT00003022||||TREATMENT||||||||
33877032|NCT03522870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877033|NCT04027998|||CASE_CONTROL||PROSPECTIVE|||||||
33877034|NCT02154386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877035|NCT04349527|||COHORT||PROSPECTIVE|||||||
33877036|NCT00936208|||COHORT||PROSPECTIVE|||||||
33877037|NCT01714427|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33877038|NCT00003362|RANDOMIZED|||TREATMENT||||||||
33877039|NCT04204278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877040|NCT02655432|||CASE_ONLY||RETROSPECTIVE|||||||
33877041|NCT04802993|||COHORT||OTHER|||||||
33757122|NCT00134979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33757123|NCT02219893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757124|NCT05374902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Single (investigator)|||||
33757125|NCT04748302|||COHORT||PROSPECTIVE|||||||
33757126|NCT01258634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757127|NCT05181852|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33757128|NCT02732379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757129|NCT03786861|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757130|NCT01490502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757131|NCT06459648|||COHORT||PROSPECTIVE|||||||
33757132|NCT05753787|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33757133|NCT04519086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757134|NCT01151800|RANDOMIZED|||TREATMENT||||||||
33877042|NCT02678390|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33877043|NCT05681507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33877044|NCT04147104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068907|NCT05834478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757135|NCT03813238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757136|NCT04389450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757137|NCT00783731||||TREATMENT||||||||
33757138|NCT02601989|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33757139|NCT04431193|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre||||
33757140|NCT03392584|||COHORT||PROSPECTIVE|||||||
33757141|NCT06272422|||COHORT||PROSPECTIVE|||||||
33757142|NCT05114317|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877045|NCT01780662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877046|NCT01380431|RANDOMIZED|CROSSOVER||||NONE||||||
33877047|NCT06488131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757143|NCT03346603|||CASE_ONLY||PROSPECTIVE|||||||
33757144|NCT03351855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757145|NCT04710745|||CASE_ONLY||PROSPECTIVE|||||||
33757146|NCT03099993|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757147|NCT01377272|||||RETROSPECTIVE|||||||
33757148|NCT04852874|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, open-label, interventional study||||
33757149|NCT02650050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757150|NCT05365750|||CASE_CONTROL||PROSPECTIVE|||||||
33757151|NCT04864574|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Childcare centers were randomly assigned to one of three groups: Group 1, intervention (5 centers); Group 2, wait list control (5 centers); Group 3, no-intervention control (5 centers).~In Year 1 (Spring), baseline data was collected from Groups 1 and 2. Group 1, initial intervention centers, received the garden intervention in the summer of Year 1 and both groups were assessed in the Fall, post intervention. No further data was collected from Group 1.~In Year 2, Groups 2 and 3 were assessed in the Spring. Group 2, the wait-list control centers, received the garden intervention in the summer of Year 2, and both Groups 2 and 3 were assessed in the Fall of Year 2.~No further data was collected."||||
33757152|NCT06070155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Aerobic exercises and no intervention|t|f|t|f
33757153|NCT02572557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877048|NCT04426110|||OTHER||PROSPECTIVE|||||||
33877049|NCT01681433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877050|NCT04993404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068908|NCT06129097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical outcome assessor (A.A) will not be aware of which treatment will be being administered, thus yielding a single-blind controlled study.|"Treatment protocol (for the intervention group):~* Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse.~The control group (placebo):~Patients in the control arm followed the same protocol with normal saline rinses.~All patients will receive a course of motivation, oral hygiene instructions (emphasizing proper tooth brushing technique, flossing, interdental brush, and mouthwash usage), scaling, polishing and root debridement with an ultrasonic scaler and Gracey curettes."|f|f|f|t
34068909|NCT05905081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Two group comparison, before and after intervention|f|f|t|t
34068910|NCT00255164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068911|NCT01960062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068912|NCT04229771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomization will be performed by the primary investigator who will have no participant interaction during the performance of the procedure and obtainment of the survey responses. A random number generator will be used to obtain either an even or odd number. Odd numbers mean the left eye receives Proparacaine hydrochloride 0.5% ophthalmic solution, even numbers mean the right eye does. The chief investigator will instruct clinic personnel as to which syringe should be labeled L or R depending on randomization results.Two identical 1 ml syringes will be prepared. One syringe containing control BSS, and the other containing Proparacaine hydrochloride 0.5% ophthalmic solution. Each syringe will be labeled by clinical assistants with either left (L) or right (R) as randomized."|A double-blinded, randomized, controlled clinical trial with one eye of each participant receiving the experimental treatment and one eye acting as control, receiving placebo|t|t|f|f
33757154|NCT03087344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All the above, the patient, provider and investigator and outcome assessor will not know the result of the biopsy to know if the participant does or does not have cirrhosis at the time of the study|Cross sectional diagnostic study of Chronic liver disease patients who have had a liver stiffness measurement performed that is discordant with clinical impression either clinically the patient appears to have cirrhosis but liver stiffness measurement is less than 10 kPa or clinically there is no evidence of cirrhosis but there liver stiffness measurement is more than 15 kPa or the patients liver stiffness measurement is in the grey zone which means patients' liver stiffness measurement is between 10 and 15 kPa to investigate the utility of postprandial postprandial liver and spleen stiffness measurements in the noninvasive diagnosis of cirrhosis||||
33757155|NCT03126825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757156|NCT05132608|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757157|NCT05096819|||CASE_ONLY||PROSPECTIVE|||||||
33757158|NCT04858698|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757159|NCT00652223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757160|NCT06562894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757161|NCT05428605|NA|SINGLE_GROUP||OTHER||NONE||To compare in vitro the effect of different immunomodulators on Th17/Treg lymphocyte balance in a cohort of relapsed MN patients to determine the best therapeutic approach.||||
33877051|NCT02469285|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33877052|NCT02683200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877053|NCT02137564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877054|NCT05920876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877055|NCT01583595|||COHORT||PROSPECTIVE|||||||
33877056|NCT04252846|||COHORT||PROSPECTIVE|||||||
33877057|NCT04623242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Interventional|t|t|t|t
34068913|NCT01090050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068914|NCT00160342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068915|NCT01247675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068916|NCT02650492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877058|NCT05405400|||CASE_CONTROL||PROSPECTIVE|||||||
34068917|NCT01482234|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33877059|NCT04057274|RANDOMIZED|CROSSOVER||PREVENTION||NONE|It is not possible to blind participants nor investigators. Investigators will be blind to allocation order until after the first blood sample is drawn.|This is a randomised, counterbalanced, crossover study whereby all participants will complete an exercise assessment and a resting assessment in a randomised order.||||
33877060|NCT01484626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877061|NCT02554097|||COHORT||PROSPECTIVE|||||||
33877062|NCT05099471|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877063|NCT05198271|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877064|NCT01972750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757162|NCT00614081||PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33757163|NCT04332523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757164|NCT05682911|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding was maintained by keeping identical packaging of the ginger and simvastatin drugs with different codes, and no aroma was detected from either; the participants and their care giver were blinded to the treatment allocation.|A two-arm parallel assignment involves two groups of participants. One group receives simvastatin 20mg OD, and the other group receives 500mg Ginger extract tablet BD.|t|t|f|f
33877065|NCT00511550|||||PROSPECTIVE|||||||
33877066|NCT02086539|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33877067|NCT06047691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be blinded as to participant treatment condition during follow-up assessments.|Randomized controlled trial with parallel group design|f|f|f|t
33877068|NCT05298007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877069|NCT02933034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877070|NCT00291408|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33877071|NCT03336021|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Enumerators will be blinded (to the extent possible) to the treatment assignment of farmers.||f|f|f|t
33877072|NCT04966533|||CASE_ONLY||RETROSPECTIVE|||||||
33877073|NCT04617951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877074|NCT04595903|NA|SINGLE_GROUP||TREATMENT||NONE||This trial will evaluate the use of the Hemopurifier in patients with SARS-CoV-2 Virus Disease (COVID-19). The Hemopurifier is an extracorporeal device device that combines plasma filtration, size exclusion and affinity binding of mannosylated structures including enveloped viruses and exosomes. The study will evaluate whether the device is safe in COVID-19 patients along with clearing virus and improving outcomes in infected patients. Subjects will receive a four to six hour treatment with the Hemopurifier® extracorporeal therapy daily for up to four days until discontinued because of clinical improvement or deterioration or upon decision of the Principal Investigator.||||
33877075|NCT01665183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877076|NCT02360020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877077|NCT01225484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877078|NCT02913937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33877079|NCT03467646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877080|NCT01192022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877081|NCT05682027|||COHORT||PROSPECTIVE|||||||
34068918|NCT04282837|||CASE_CONTROL||RETROSPECTIVE|||||||
33757165|NCT03577067|||COHORT||RETROSPECTIVE|||||||
33757166|NCT03205228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877082|NCT03074487|||CASE_ONLY||PROSPECTIVE|||||||
33877083|NCT03124563|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants are aware of the nature of the intervention. They are not aware if they are the experimental or control group.||t|f|f|f
33877084|NCT00353197|||OTHER||OTHER|||||||
33877085|NCT01799070|||COHORT||PROSPECTIVE|||||||
33877086|NCT05816135|||COHORT||PROSPECTIVE|||||||
33757167|NCT04670133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The intervention packages will be labelled with a unique code and there will be enough packages to account for the required number of participants. A member of the research team, not involved in providing the treatment, will be responsible for the randomization and labeling of the intervention packages, as well as creating a master list by matching the unique code to the treatment arm. The patient and care provider will be masked to the treatment arm.|Subjects will be randomized to receive one of the two treatments. They will be required to take one sachet per day (half in the morning; half in the evening) of the assigned intervention beginning 4 weeks before their scheduled sanative therapy appointment and remain on the intervention until 10 weeks after their sanative therapy appointment.|t|t|f|f
33757168|NCT01670981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757169|NCT05387824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757170|NCT00596843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757171|NCT03799068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757172|NCT05339932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757173|NCT01648270||SEQUENTIAL||OTHER||NONE||||||
33757174|NCT06076720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757175|NCT01638325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33757176|NCT04604002|||COHORT||PROSPECTIVE|||||||
33757177|NCT00338598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757178|NCT03376815|||CASE_CONTROL||PROSPECTIVE|||||||
33757179|NCT01751555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757180|NCT03577639|||COHORT||PROSPECTIVE|||||||
33757181|NCT04252742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33757182|NCT05203484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757183|NCT05936931|NA|SINGLE_GROUP||SCREENING||NONE||||||
33757184|NCT04201457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757185|NCT05899686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each participant will receive three tetanic stimuli. They are applied to the same three anatomical locations in each subject, but the order at which they are delivered to these locations will be random.||||
33877087|NCT02982135|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33877088|NCT00630266|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757186|NCT01822587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33757187|NCT03496519|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757188|NCT03883867|||CASE_CONTROL||RETROSPECTIVE|||||||
33757189|NCT02355028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757190|NCT04866615|||COHORT||PROSPECTIVE|||||||
33757191|NCT04284449|||CASE_ONLY||PROSPECTIVE|||||||
33757192|NCT01719484|||CASE_CONTROL||PROSPECTIVE|||||||
33877089|NCT01327157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33877090|NCT02590380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877091|NCT02285725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877092|NCT01988610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877093|NCT02977195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877094|NCT01362036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877095|NCT05487105|||COHORT||CROSS_SECTIONAL|||||||
33877096|NCT01409733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877097|NCT04543994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877098|NCT00517829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877099|NCT00087009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877100|NCT05850221|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial (waitlist control)||||
33877101|NCT02474342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877102|NCT04853784|||COHORT||PROSPECTIVE|||||||
33877103|NCT03027700|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33877104|NCT01385787|||COHORT||PROSPECTIVE|||||||
33877105|NCT05047809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877106|NCT00097344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877107|NCT02543567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33877108|NCT02544308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877109|NCT04640337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants don't know to which intervention group they belong to. The outcomes assessor doesn't know to which intervention group the patient belongs to.||t|f|f|t
33877110|NCT00471302|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877111|NCT02214238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877112|NCT00001498||||TREATMENT||||||||
33877113|NCT01998828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877114|NCT02776488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Dose ranging and then RCT|t|t|t|f
33877115|NCT03147729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877116|NCT03070847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Blinded (participant, care provider, investigator). Computer block randomisation tool will be used (randomisation.com 1 block, 50 subjects per block), 50 notes with '5 mg/kg' or '10 mg/kg' will be put into sealed envelopes.||t|t|t|f
33877117|NCT04760561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Experimental research design|f|f|f|t
33877118|NCT02735369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877119|NCT03760900|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877120|NCT03183193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The participants are randomly assigned to Control or FLiO strategy.|t|f|f|f
33877121|NCT04405869|||COHORT||OTHER|||||||
33877122|NCT01565070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877123|NCT00636766|RANDOMIZED|FACTORIAL||||NONE||||||
33877124|NCT00896922|||OTHER||RETROSPECTIVE|||||||
33877125|NCT00188643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33877126|NCT00371293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877127|NCT06471400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877128|NCT01292642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877129|NCT06493955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||comparative, multicenter, interventional, superiority study, randomized in two unblinded parallel groups. Randomization will be 1:1.||||
33757193|NCT03367039|RANDOMIZED|PARALLEL||TREATMENT||NONE||648 DDD patients (age from 20 to 70) from several hospitals matching the inclusion criteria will be randomly assigned to two groups (324 patients in each group). One group will be treated with ProDisc-C vivo disc replacement. The other groups will be treated with ACDF.||||
33877130|NCT06273332|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877131|NCT01538654|||COHORT||PROSPECTIVE|||||||
33968910|NCT03031899|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33968911|NCT04546906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968912|NCT02449603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968913|NCT01835132|NA|SINGLE_GROUP||TREATMENT||NONE||Subcutaneous injection of 60 mg gevokizumab||||
34068919|NCT05857800|||COHORT||PROSPECTIVE|||||||
34068920|NCT01875263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068921|NCT05034289|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34068922|NCT01680952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757194|NCT03087955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757195|NCT01281202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757196|NCT01899313|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757197|NCT00863252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757198|NCT00554008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757199|NCT05997264|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33877132|NCT06280482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877133|NCT01809574|||COHORT||PROSPECTIVE|||||||
33877134|NCT05506189|||CASE_ONLY||PROSPECTIVE|||||||
33877135|NCT01426139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877136|NCT00896675|||CASE_ONLY||RETROSPECTIVE|||||||
33877137|NCT06006793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877138|NCT04015895|||COHORT||PROSPECTIVE|||||||
33877139|NCT05343286|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33877140|NCT00015223||||TREATMENT||DOUBLE||||||
33968914|NCT02730065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33968915|NCT01634984|||CASE_CONTROL||RETROSPECTIVE|||||||
33968916|NCT03459326|||COHORT||PROSPECTIVE|||||||
33968917|NCT00200395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968918|NCT00336427|||||OTHER|||||||
33968919|NCT06543823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An interventional group with the application of the SupraTHEL 250 membrane and the control group with no membrane applied on the wound bed|f|f|t|f
33968920|NCT00425659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33968921|NCT04390139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968922|NCT00510549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968923|NCT03392376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33968924|NCT03107351|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE||Double blind randomized crossover active vs placebo|t|f|f|t
33968925|NCT01119729|||COHORT||PROSPECTIVE|||||||
33968926|NCT00778440|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33968927|NCT03124381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluator-blind||f|f|t|t
33968928|NCT02400710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968929|NCT05641272|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"During the trial, both the investigator and the subjects included will be unaware of the treatment each subject is receiving.~Blinding is intended to minimize potential biases resulting from differences in treatment or assessment of subjects. It is also intended to reduce as much as possible the interpretation of the results that could arise as a consequence of the investigator or the subject knowing the assigned treatment.~The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.~So that neither the subject nor the investigator will know which treatment each subject is receiving, all trial medication will be identical in outer packaging and appearance."|Prospective, randomised, double-blind, placebo-controlled clinical trial.|t|f|t|t
33968930|NCT00189397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33877141|NCT02222207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877142|NCT01978288|||CASE_ONLY||PROSPECTIVE|||||||
33877143|NCT06247943|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33877144|NCT01806779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33877145|NCT02505880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33877146|NCT04774835|RANDOMIZED|PARALLEL||SCREENING||NONE||Cluster randomized controlled trial||||
33877147|NCT02931721|||CASE_CONTROL||PROSPECTIVE|||||||
34068923|NCT06378203|NA|SINGLE_GROUP||TREATMENT||NONE||"Each patient will carry out a series of evaluation and training sessions (15 sessions) with a physiotherapist for the drafting of a personalized treatment plan which will subsequently be carried out independently at domicile.~The home therapeutic proposal will include the use of the tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA) which allows to perform personalized games at home"||||
33757200|NCT03913598|||COHORT||CROSS_SECTIONAL|||||||
33757201|NCT06425549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757202|NCT02996084|||COHORT||PROSPECTIVE|||||||
33757203|NCT02423681|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757204|NCT01122082|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33877148|NCT01076855|||COHORT||PROSPECTIVE|||||||
33877149|NCT01143753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877150|NCT02198781|||COHORT||PROSPECTIVE|||||||
33877151|NCT04938128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877152|NCT02342002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968931|NCT02688127|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34068924|NCT05011578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068925|NCT02915250|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33877153|NCT03565627|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will complete a baseline assessment (1 week), followed by the randomisation to using 1 of the 2 apps (3 weeks' follow up), and crossover (5 weeks' follow up).||||
33877154|NCT02949180|||CASE_CONTROL||PROSPECTIVE|||||||
33877155|NCT02008682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877156|NCT00708578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877157|NCT00288756|||DEFINED_POPULATION||OTHER|||||||
33877158|NCT01029132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877159|NCT02751502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877160|NCT02305862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877161|NCT04532060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33877162|NCT03166293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to receive 3 months of intervention or 3 months of observation. Participants in the observation group will be offered the intervention once the observation period is complete|f|f|f|t
33877163|NCT06548061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877164|NCT03325673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877165|NCT05559229|||CASE_ONLY||RETROSPECTIVE|||||||
33877166|NCT03963635|||CASE_CONTROL||PROSPECTIVE|||||||
33877167|NCT05046509|||CASE_ONLY||PROSPECTIVE|||||||
33877168|NCT03170297|||CASE_CONTROL||PROSPECTIVE|||||||
33877169|NCT05232500|||COHORT||RETROSPECTIVE|||||||
33877170|NCT05572762|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|the participant is going to have regional ophthalmic anesthesia, by either the atraumatic or the needle technique without being informed by which technique he is going to receive the block||t|f|f|f
33877171|NCT03311711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877172|NCT03428178|NA|SINGLE_GROUP||TREATMENT||NONE||20 patients of Leber Hereditary Optic Neuropathy (LHON) onset within 3 months,20 between 3 to 6 months,20 between 6 to 12 months,20 between 12 to 24 months,20 between 24 to 60 months,and 20 over 24 months.||||
33877173|NCT04888273|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single Group Assignment||||
33877174|NCT04408690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33877175|NCT04268485|||COHORT||PROSPECTIVE|||||||
33877176|NCT04319107|||COHORT||PROSPECTIVE|||||||
33877177|NCT02481921|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to either usual care group or the MEDIC-HF group in parallel for the duration of the study.||||
33968932|NCT05574582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|observer-blinded RCT, union is assessed by a blinded musculoskeletal radiologist. QDASH is a patient-reported survey, without the involvement of surgeons or research staff. Other secondary outcomes will be measured by an independent observer. The study will not be blinded to the operating theatre staff, surgeons, physiotherapists, or patients.|"1:1 observer-blinded randomized controlled, superiority trial. The main objective is to compare open C graft with arthroscopic assisted C chips graft reconstruction for scaphoid fractures with delayed/non-union.~Based on the sample size calculation, a total of 88 patients with scaphoid delayed/non-union are randomized to either:~1. Group A - Arthroscopic assisted C chips graft reconstruction (intervention group), n=44~2. Group O - Open C graft reconstruction (control group), n=44~The randomization is done in the outpatient clinic and the patients will be informed about the operative treatment. The randomization application, Research Electronic Data Capture (REDCap), will allocate patients in a 1:1 ratio, stratified for proximal pole fracture (yes /no), dislocation (\>/\< 2mm), and smoking (yes/ no). A statistician will generate a randomization sequence for REDCap."|f|f|t|t
33968933|NCT06497023|||COHORT||RETROSPECTIVE|||||||
34068926|NCT03099226|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34068927|NCT04826835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34068928|NCT05334563|||OTHER||RETROSPECTIVE|||||||
33968934|NCT02850523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducted assessments of symptoms and overall functioning at baseline, 6-weeks post-baseline, and (for participants assigned to CBGT) at 3-months post-treatment. Assessors were unaware of participants' assigned condition.|A single-blind, randomized controlled trial was conducted to evaluate the effectiveness of a new group-based cognitive-behavioural therapy (CBGT) for women with anxiety during pregnancy or in the early postpartum.|f|f|f|t
33968935|NCT03668028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33968936|NCT02529800|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968937|NCT00006170|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33968938|NCT01871987|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33968939|NCT06377358|NA|SINGLE_GROUP||TREATMENT||NONE||Tecar Theraty was applied to 20 obese patients in order to assess the effect on the body fat loss, serum adipocytokines and imflammation. It was an interventional study in one group of patients. No controls. No masking.||||
33968940|NCT05093777|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinded evaluation by independent researchers at baseline, at 12 months and at 24 months.|Randomized controlled trial (RCT) with blinded evaluation by independent researchers at baseline, at 12 months and at 24 months. A stepped-wedge design will be applied so that all study participants eventually will be offered the intervention program. Those who are randomized to control group in the first year of study, will be offered intensive training during the second year, and vice versa.|f|f|f|t
33968941|NCT03651661|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33968942|NCT03417622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968943|NCT05515809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968944|NCT06528587|||COHORT||PROSPECTIVE|||||||
33968945|NCT05079893|||CASE_CONTROL||PROSPECTIVE|||||||
33968946|NCT05802095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomised Controlled Clinical Trial|t|t|f|t
33968947|NCT00273195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33968948|NCT03641118|||COHORT||PROSPECTIVE|||||||
33968949|NCT06178679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968950|NCT04376723|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968951|NCT01353924|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33968952|NCT04050332|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757205|NCT03062722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757206|NCT04668196|||COHORT||RETROSPECTIVE|||||||
33757207|NCT03792854|||COHORT||PROSPECTIVE|||||||
33757208|NCT04220177|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Open-label, Multicenter, Non-randomized||||
33757209|NCT00617981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757210|NCT04049630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757211|NCT04488263|||COHORT||PROSPECTIVE|||||||
33968953|NCT04525742|NA|SINGLE_GROUP||SCREENING||NONE|No masking will be done|One study group will be researched- only disabled children's parents, in one arm -way||||
33757212|NCT06252103|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Total 40 females from 14 to 35 weeks of pregnancy with Hemoglobin level between 8.5 to 10.5 gm/dl, recruited from the obstetric inpatient/outpatient clinic at Ain Shams University, Maternity hospital.~This study included two groups:~Group I: 20 patients were given ferrous gluconate 300 mg (Ferrous-Gluconate®, tab.300mg glucofer, Egypt) two times daily.~Group II: 20 patients were given lactoferrin 100mg (Pravotin-sachets®,100mg, Hygint, Egypt) with ferrous gluconate twice daily.~hematological parameters (rise in hemoglobin) and the adverse effects of both drugs were studied at registration and after 4 weeks"||||
33757213|NCT00869921|||OTHER||PROSPECTIVE|||||||
33757214|NCT01901107|||COHORT||PROSPECTIVE|||||||
33757215|NCT03664466|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind||t|t|t|f
33757216|NCT04796116|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757217|NCT03086304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomised Controlled Trial||f|f|t|t
34068929|NCT06063161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A blinded study coordinator will assess the primary outcome (Confusion Assessment Measure) to reduce bias.||f|f|f|t
34068930|NCT01912053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068931|NCT05343299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will be blinded to his or her anesthesia protocol. The investigating physician who performs the anesthesia and surgery will be different from the evaluators (IDE, hospital CRA, evaluating physician) who will be blinded to the patient's assignment group.|"This is a single-center, prospective, randomized, single-blind superiority study comparing two management modalities in WALANT-type anesthesia for ambulatory hand surgery: addition of ropivacaine to lidocaine (experimental group) versus lidocaine alone (control group).~Jardé Law Research Involving Human Persons category 1"|t|f|t|f
33757218|NCT04131569|||CASE_CONTROL||PROSPECTIVE|||||||
34068932|NCT01891682|||COHORT||PROSPECTIVE|||||||
34068933|NCT02522793|||COHORT||PROSPECTIVE|||||||
34068934|NCT03993977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants do not know which group he/she is randomized into. They are under general anaesthesia, thus not knowing which protocol is used. When assessing outcomes, two groups are labeled only by number: the assessor does not know which arm is number 1 or 2 until whole data is analyzed.|60 patients having a potentially curative abdomino-oncological surgery and reaching an active blood loss of more than 1500 ml are randomized into two groups. One will be treated conventionally, ie. using MTP if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm. Randomization (ratio 1:1 in blocks of 10) between the two groups will be done beforehand. Each paper containing the treatment protocol in question will be put into a closed envelope. The envelopes are numbered from 1 to 60 and are placed in a box in the operative department.|t|f|f|t
33757219|NCT05139875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"1. Participant and Care Provider will not know which drug is injected to the investigated knee because the opaque syringe is used to inject.~2. Investigator and outcomes assessor will not known the group of participants because randomization, they only know the number of the participants."|Participants are randomized and assigned to betamethasone (Diprospan) group or Triamcinolone acetonide group in parallel for the duration of the study|t|t|t|t
33757220|NCT05439798|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||prospective, randomized, double-blind, controlled|t|t|t|t
33757221|NCT02943850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757222|NCT00251095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757223|NCT00486421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068935|NCT05761119|NA|SINGLE_GROUP||OTHER||NONE||||||
33757224|NCT03031964|||COHORT||PROSPECTIVE|||||||
33757225|NCT00877279|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33757226|NCT06369779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757227|NCT00117676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757228|NCT03925701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757229|NCT04924283|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33757230|NCT03388567|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||study protocol for a multicenter, cluster-randomized controlled trial.||||
33757231|NCT06022757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757232|NCT00282022||||TREATMENT||NONE||||||
33757233|NCT06435104|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The research model consists of two arms#~1. armA:neoadjuvant chemotherapy~2. armB:neoadjuvant chemotherapy+aromatherapy"||||
33757234|NCT01833143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757235|NCT04370925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877178|NCT04799392|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877179|NCT00514956|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33877180|NCT02562560||||DIAGNOSTIC||||||||
33877181|NCT06368713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877182|NCT03899779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877183|NCT04675866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877184|NCT03011346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877185|NCT03899766|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877186|NCT03694496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|.An experienced fieldworker will facilitate the survey process, and she will be blind to our group allocation. Two experienced dentists will conduct the dental examinations who don't know the group allocation.||f|f|t|t
33877187|NCT00803075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877188|NCT03115307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877189|NCT03224429|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33877190|NCT03891940|||COHORT||PROSPECTIVE|||||||
33877191|NCT03623607|||COHORT||PROSPECTIVE|||||||
33877192|NCT03658486|NA|SINGLE_GROUP||OTHER||NONE||||||
33877193|NCT02534142|||CASE_CONTROL||PROSPECTIVE|||||||
33877194|NCT01224184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877195|NCT03074474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877196|NCT00717171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877197|NCT06063200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33877198|NCT06164379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877199|NCT00376298|||CASE_ONLY||RETROSPECTIVE|||||||
33877200|NCT05182151|||COHORT||PROSPECTIVE|||||||
33877201|NCT03098823|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33877202|NCT02967471|||COHORT||PROSPECTIVE|||||||
33877203|NCT06061861|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877204|NCT00684788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877205|NCT04203849|||COHORT||PROSPECTIVE|||||||
33877206|NCT03960515|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877207|NCT04542187|||COHORT||PROSPECTIVE|||||||
33877208|NCT04320407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877209|NCT01178775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877210|NCT02567487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33877211|NCT02209077|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877212|NCT03500432|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33877213|NCT04212676|RANDOMIZED|PARALLEL||TREATMENT||NONE||The type of study is experimental. A computer-based randomization program (random.org) will be used to identify patients to be assigned to the experimental and control groups. All patients in the experimental and control groups will receive a 30-minute Pulmonary Rehabilitation (PR) program every day of the week for 8 weeks. In addition to the PR program, the BAQ will be administered to the experimental group by the physiotherapist. At the end of the eight weeks, all initial assessments will be repeated. All patients will be supervised physiotherapy sessions for 8 weeks and checked how they implement the program.||||
33757236|NCT01599052|||CASE_CONTROL||PROSPECTIVE|||||||
33877214|NCT03475459|NA|SINGLE_GROUP||TREATMENT||NONE|This study is a single-arm, open label, dose escalation study. QT interval will be evaluated by blinding outcome assessor in this study.|||||
33877215|NCT03482414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3-arm randomized controlled trial|t|f|f|f
33877216|NCT06061549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877217|NCT03490305|||COHORT||PROSPECTIVE|||||||
33877218|NCT02883946|||COHORT||RETROSPECTIVE|||||||
33877219|NCT06428578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877220|NCT02879175|||OTHER||PROSPECTIVE|||||||
33877221|NCT04517487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877222|NCT02777671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877223|NCT05138809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877224|NCT03991351|||COHORT||CROSS_SECTIONAL|||||||
33877225|NCT05314205|||CASE_ONLY||PROSPECTIVE|||||||
33877226|NCT00964977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877227|NCT00464412|RANDOMIZED|PARALLEL||||NONE||||||
33877228|NCT02803944|||COHORT||RETROSPECTIVE|||||||
33877229|NCT03072056|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33877230|NCT00343421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33877231|NCT06168032|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877232|NCT03380689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877233|NCT01960621|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33877234|NCT02585505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877235|NCT05956795|||COHORT||PROSPECTIVE|||||||
33877236|NCT04469413|||COHORT||RETROSPECTIVE|||||||
33877237|NCT03014401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877238|NCT04605354|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33877239|NCT06206174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877240|NCT01531920|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33877241|NCT05059314|RANDOMIZED|PARALLEL||OTHER||SINGLE|According to study|Parallel assignment|t|f|f|f
33877242|NCT01595776|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33877243|NCT04699487|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877244|NCT01060085|||COHORT||PROSPECTIVE|||||||
33877245|NCT00832728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877246|NCT05405179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877247|NCT04962360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877248|NCT04360902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877249|NCT00745563||CROSSOVER||TREATMENT||NONE||||||
33877250|NCT05543473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877251|NCT06296862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877252|NCT00276172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877253|NCT01443793|||COHORT||PROSPECTIVE|||||||
33877254|NCT03786445|||COHORT||RETROSPECTIVE|||||||
33877255|NCT00872105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877256|NCT02173743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33877257|NCT00202735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33877258|NCT03828929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacist who prepares the medication is in charge of blinding randomization.|Study is performed with 2 arms, interventional arm with thiamine and vitamin C, and the control arm with placebo in a 1:1 ratio.|t|t|t|t
33877259|NCT01266863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877260|NCT05837637|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877261|NCT02755857|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877262|NCT04686630|||OTHER||PROSPECTIVE|||||||
33877263|NCT02877342|||COHORT||PROSPECTIVE|||||||
33877264|NCT00000858|||NATURAL_HISTORY|||||||||
33877265|NCT03821857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877266|NCT00281398|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33877267|NCT00385645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877268|NCT03068364|||COHORT||RETROSPECTIVE|||||||
33968954|NCT03086239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757237|NCT03426202|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33757238|NCT02580708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757239|NCT05584852|||CASE_CONTROL||RETROSPECTIVE|||||||
33757240|NCT04547010|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Pre-post Quasi experimental study design.||||
33757241|NCT03204955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A double-blinded-double-dummy design, where each dose of hypertonic solution will be administered along with a balanced solution in order to mask the difference in the volume between the two solutions.|Once consented to the study, patients' serum chloride will be followed daily. Patients who will have a chloride concentration of 109mg/dL or above will be randomized to receive the blinded hypertonic solutions.|t|t|t|t
33877269|NCT05182554|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are four arms in the study which geographic areas are assigned to in parallel. The geographic areas in the three treatment arms will receive a Facebook ad campaign over the same time period to one another.||||
33877270|NCT03373604|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877271|NCT03044340|NA|SINGLE_GROUP||OTHER||NONE||||||
33877272|NCT05011708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Part 1 of the study will be double-masked (both investigator and participant are masked).~Part 2 will not involve masking."||t|f|t|f
33877273|NCT00283595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877274|NCT00397826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877275|NCT00338871|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33877276|NCT01891331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877277|NCT00000859||PARALLEL||TREATMENT||||||||
33877278|NCT05183750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877279|NCT01796405|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877280|NCT05220527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33877281|NCT05337254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877282|NCT02692066|||CASE_CONTROL||PROSPECTIVE|||||||
33877283|NCT03119792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877284|NCT01431664||||TREATMENT||NONE||||||
33877285|NCT02107586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877286|NCT01197326|||COHORT||PROSPECTIVE|||||||
33877287|NCT01051427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877288|NCT01121393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877289|NCT00878371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968955|NCT01597895|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33968956|NCT03684759|||CASE_ONLY||PROSPECTIVE|||||||
33757242|NCT00242372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33757243|NCT03872479|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33757244|NCT06324929|NA|SINGLE_GROUP||OTHER||NONE||"Mixed methods research during Aim 1 will include 4 different components. They are:~1. Convene working group of Native American stakeholders.~2. Collect data using a 35-minute survey of demographics, AEP risk, device use, recommendations for recruitment methods, and interest in subsequent trial with 300 Native women respondents, targeting approximately 100-150 per region (rural Great Northern Plains), urban Denver and mountain West, and other Native communities..~3. Conduct Iterative prototyping of existing and proposed CARRII components with 60 Native women across 10 focus group discussions. Content will be informed by Components 1 and 2, and will be added via modification request~4. Conduct User Testing of existing CARRII and candidate components with Think-Aloud methods among 20 Native women."||||
33757245|NCT05407454|||OTHER||CROSS_SECTIONAL|||||||
33757246|NCT04547374|||CASE_CONTROL||PROSPECTIVE|||||||
33757247|NCT04749589|||CASE_CONTROL||PROSPECTIVE|||||||
33757248|NCT00114179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757249|NCT01155752|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33757250|NCT00980070|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33757251|NCT01865955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757252|NCT05768685|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757253|NCT03363152|||OTHER||PROSPECTIVE|||||||
33877290|NCT03824808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The surgeon, anesthesiologist, operating room staff, participant, personnel in the postanesthesia care unit (PACU) as well as the investigators collecting the postoperative data will be blinded to the group allocation. Study medication is prepared and masked by an unblinded investigation drug pharmacist who is not involved in clinical care.|Participants will receive either intraoperative 0.8% lidocaine or normal saline at 1 mg/kg/h when younger than 65 years and 0.5 mg/kg/h when greater than or equal to the age of 65 to be delivered by continuous infusion for 24 hours.|t|t|t|t
33757254|NCT03657498|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||The trial includes a study group of patients receiving orthognathic surgery. It is divided into two subgroups. Subgroup I including bimaxillary surgical patients with Le-Fort I osteotomy for the upper jaw and sagittal split ramus osteotomy for the lower jaw. Subgroup II including patients receiving mandibular surgery only. Finally, two control groups were applied. Control group I including no treatment subjects and Control group II including standard orthodontic treatment subjects||||
33757255|NCT02529150|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
33877291|NCT00525655|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33877292|NCT04464161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877293|NCT06042803|||COHORT||PROSPECTIVE|||||||
33757256|NCT05522374|||COHORT||PROSPECTIVE|||||||
33757257|NCT02753595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757258|NCT03139422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757259|NCT03765840|||CASE_CONTROL||PROSPECTIVE|||||||
33757260|NCT04803448|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All participants respond to a request to take an online survey about health. Participants are blind to the purpose of the study and do not know what intervention group they are randomly assigned to by the survey software. Participants intervention is numerically coded so during analysis it is not evident what intervention statement the participant saw.|Participants are randomly assigned one of 1 intervention statements and then asked health care questions. This is a between subject 6 cell study, the dependent variable is the amount of lying as measured by answer adjustment and biometric mouse-movement under each intervention statement.|t|f|f|f
33757261|NCT05364775|||CASE_ONLY||PROSPECTIVE|||||||
33757262|NCT02548455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757263|NCT04586725|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be blinded to the level of encouragement they will receive during the tests||t|f|f|f
33757264|NCT00824096|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33757265|NCT03247790|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Multi-center, open-label study with 2 study periods.||||
33757266|NCT01620567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33757267|NCT05877950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757268|NCT00249106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757269|NCT06471634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The technicians analysing the accelerometer data and blood analysis will be blinded as to which arm the participant is from, no other masking is possible.||f|f|f|t
33757270|NCT02969525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757271|NCT04257266|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant will be blinded to which ice pack will be used during the intervention.|Participants receive two alternative interventions: 1) cryothermic cooling pack and 2) commercially available ice pack.|t|f|f|f
33877294|NCT04356560|||COHORT||PROSPECTIVE|||||||
33968957|NCT02909725|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968958|NCT02048254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968959|NCT04663880|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, double blind, cross-over study including two study groups|t|t|t|t
33968960|NCT04636749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968961|NCT05548933|||COHORT||PROSPECTIVE|||||||
33968962|NCT06529718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757272|NCT05385458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One investigator who will have no contact with participants will generate a randomization sequence. The research assistant who enrols participants in the studies will be blinded to the randomization sequence. They will contact the investigator to be told what group the participant is allocated. It is not possible to mask participants. Investigators will be blinded to groups when assessing and comparing outcomes.|Two group randomized controlled trial|f|f|t|t
33757273|NCT00665574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757274|NCT01862705|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33757275|NCT00387673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757276|NCT03995108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757277|NCT04657744|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33757278|NCT06413836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants will receive conventional endodontic treatment. The study group will receive antimicrobial photodynamic therapy with methylene blue application followed by active diode laser illumination. The control group will receive methylene blue solution and a simulation of laser application, which will be achieved by using an aluminum foil barrier placed at the tip of the equipment to block light in the control group. During this process, the participant will receive googles which aid eye protection and helps masking. The operator will wear protective glasses, which will aid in protection. Pre-irradiation and irradiation times will be the same at both groups.|"Control Group (1): Mechanized endodontic treatment with CaOH (calcium hydroxide) medication between sessions. This medicine is the most commonly used in all conventional endodontic treatments.~Study Group (2:) Mechanized endodontic treatment with CaOH (calcium hydroxide) medication following application of photodynamic therapy with methylene blue applied in surfactant medium."|t|f|f|t
33757279|NCT02070484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757280|NCT03944525|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will be performed as a randomized controlled non-inferiority trial. The study site is the Department of Emergency Medicine (ED) at the Vienna General Hospital, a leading academic research center for emergency medicine at a large, tertiary care hospital. Around 90,000 patients are being treated at the department each year, approximately 150-200 of them suffering from hypercapnic respiratory failure, and requiring non-invasive ventilation support. The department features its own ICU and intermediate-care unit, with 7 positions each, for a total of 14 positions capable of providing CPAP therapy.~The HFA-device is also at regular use at the department."||||
33757281|NCT00005810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757282|NCT00881179|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757283|NCT06350890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757284|NCT03050658|||COHORT||PROSPECTIVE|||||||
33757285|NCT06185998|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Single blind||t|f|f|f
33757286|NCT04296695|RANDOMIZED|PARALLEL||TREATMENT||NONE|randomized, multicentered, open-lable RCT, one arm with B/F/TAF and one arm with TDF/3TC/EFV|Non-inferioty or advantage of B/F/TAF comparing with the first line TDF/3TC/EFV for later presenters in China||||
33757287|NCT05592795|||CASE_CONTROL||PROSPECTIVE|||||||
33757288|NCT02465281|||CASE_ONLY||PROSPECTIVE|||||||
33757289|NCT00772590|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33757290|NCT01573936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757291|NCT06472817|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757292|NCT02526043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757293|NCT02974790|||COHORT||PROSPECTIVE|||||||
33757294|NCT01888393|NON_RANDOMIZED|PARALLEL||||NONE||||||
33757295|NCT03275025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968963|NCT01901991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968964|NCT02660385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968965|NCT00000531|RANDOMIZED|||TREATMENT||||||||
33968966|NCT01084603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968967|NCT00000759|||NATURAL_HISTORY|||||||||
33968968|NCT00481247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968969|NCT03000400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33968970|NCT03999346|||COHORT||RETROSPECTIVE|||||||
33968971|NCT03392090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33968972|NCT01605461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968973|NCT04379661|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757296|NCT05834114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||blinding|t|f|t|f
33757297|NCT00049933|||COHORT||PROSPECTIVE|||||||
33757298|NCT06200454|||CASE_CONTROL||RETROSPECTIVE|||||||
33757299|NCT04959058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Measurements will be made in 3 different positions for a participant||||
33877295|NCT02742038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33877296|NCT06044688|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|Clinical site staff are masked to VisionCheck results. Participants are masked to VisionCheck and phoropter refraction measurements. The eyecare professionals performing Visit 2 refraction readings are masked to Visit 1 screening refraction readings.||t|f|t|t
33877297|NCT02698735|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Ointments were formulated by an independent pharmacy and masked before receipt by investigators and delivered to participants as such. Intradermal injections were blinded by clinic staff (unrelated to the study) before injection.|Each participant will receive gentamicin ointment, and placebo ointment to treat two separate matched wounds (each ointment used exclusively on one wound) for 14 days as well as receive a intradermal injections of gentamicin and placebo at two intact skin sites (one site for each treatment).|t|f|t|t
33877298|NCT01445028|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877299|NCT00723970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33877300|NCT02019407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877301|NCT02428257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33877302|NCT00375726|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33877303|NCT02911480|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33877304|NCT05874973|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877305|NCT04670640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968974|NCT06401200|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33968975|NCT05986071|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I : we will examine the safety and determine the recommended phase II dose (RP2D) of the combination of M1774 with Fulvestrant in ER+/HER2- ABC with progressive disease under or after CDK4/6 inhibitor and aromatase inhibitor.~Phase II: Administration of M1774 ar RP2D with fulvestrant"||||
33968976|NCT02741271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|1:1 randomization to double-blinded MF/F MDI 100/10 mcg BID and MF MDI 100 mcg BID||t|t|t|f
33968977|NCT00174044|||DEFINED_POPULATION||OTHER|||||||
33968978|NCT05125783|||COHORT||PROSPECTIVE|||||||
33968979|NCT02189876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33968980|NCT05023954|||COHORT||PROSPECTIVE|||||||
33968981|NCT06231797|||OTHER||PROSPECTIVE|||||||
33968982|NCT01879800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33968983|NCT02887612|||CASE_ONLY||PROSPECTIVE|||||||
33968984|NCT00698178|||COHORT||CROSS_SECTIONAL|||||||
33968985|NCT01612156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968986|NCT01352247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33968987|NCT06458725|NA|SINGLE_GROUP||OTHER||NONE||||||
33968988|NCT06047158|||COHORT||PROSPECTIVE|||||||
33968989|NCT01097161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33968990|NCT01563432|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33968991|NCT01555606|||CASE_ONLY||PROSPECTIVE|||||||
33968992|NCT00629486|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33968993|NCT00131196|||COHORT||PROSPECTIVE|||||||
33968994|NCT02109926|||CASE_CONTROL||RETROSPECTIVE|||||||
33968995|NCT00851045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33968996|NCT01951183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33968997|NCT00140556||PARALLEL||TREATMENT||NONE||||||
33968998|NCT00418782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33968999|NCT05305183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969000|NCT02804828|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Parallel Design study is followed by Crossover to open label treatment.|t|t|t|t
33969001|NCT02915510|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33877306|NCT02983500|||COHORT||PROSPECTIVE|||||||
33969002|NCT01556685|NON_RANDOMIZED|||TREATMENT||||||||
33969003|NCT04147481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969004|NCT00205075|||COHORT||PROSPECTIVE|||||||
33969005|NCT04999228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969006|NCT01455545|||||CROSS_SECTIONAL|||||||
33757300|NCT05519280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33757301|NCT00000822||||TREATMENT||DOUBLE||||||
33969007|NCT00103870|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969008|NCT06182007|||COHORT||RETROSPECTIVE|||||||
33969009|NCT01475188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33969010|NCT04916171|||COHORT||PROSPECTIVE|||||||
34068936|NCT00003367|RANDOMIZED|||TREATMENT||||||||
33757302|NCT01982149|||CASE_CONTROL||PROSPECTIVE|||||||
33757303|NCT03979196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757304|NCT01177423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757305|NCT04211922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757306|NCT00801801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757307|NCT01735201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33757308|NCT06423755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomised comparative trial design||||
33757309|NCT05056779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757310|NCT02216344|||CASE_ONLY|||||||||
33757311|NCT03716310|||COHORT||PROSPECTIVE|||||||
33757312|NCT03798067|||COHORT||PROSPECTIVE|||||||
34068937|NCT03699072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757313|NCT06072703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking: Double (participants and principal investigator and co-investigator)|Intervention Model: 2:1 active: sham assignment, with an optional OLE phase|t|f|t|t
33757314|NCT03077490|||CASE_CONTROL||RETROSPECTIVE|||||||
33757315|NCT04357314|||COHORT||RETROSPECTIVE|||||||
33757316|NCT01323530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33757317|NCT02283281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757318|NCT00460005|||||PROSPECTIVE|||||||
33757319|NCT03814798|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757320|NCT01060202|||CASE_ONLY||PROSPECTIVE|||||||
33877307|NCT00751777|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33877308|NCT03519893|||CASE_ONLY||PROSPECTIVE|||||||
33969011|NCT02002156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068938|NCT05096611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34068939|NCT03286660||SEQUENTIAL||DIAGNOSTIC||NONE||||||
34068940|NCT01249729|||CASE_ONLY|||||||||
33757321|NCT01558479|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33757322|NCT02334566|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33757323|NCT05831111|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33757324|NCT06511336|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33757325|NCT00654719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757326|NCT05523622|NA|SINGLE_GROUP||OTHER||NONE||We are comparing the accuracy of eye pressure measurements with a Tono-Vera device compared to the current gold standard, Goldmann Applanation Tonometry.||||
33757327|NCT05968001|||COHORT||PROSPECTIVE|||||||
33757328|NCT02274389|||COHORT||PROSPECTIVE|||||||
33757329|NCT05712694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial|This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.|t|t|t|f
34068941|NCT02629042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757330|NCT02265614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877309|NCT01420237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877310|NCT03645993|||COHORT||PROSPECTIVE|||||||
33877311|NCT01383837|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|f|t
33877312|NCT01872520|||COHORT||PROSPECTIVE|||||||
33877313|NCT05422807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969012|NCT01527539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969013|NCT02885935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33969014|NCT06539221|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969015|NCT03237611|NA|SINGLE_GROUP||TREATMENT||NONE||Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive 125mg of oral aprepitant or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting||||
33969016|NCT01847196|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33969017|NCT03368495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068942|NCT03866278|||COHORT||PROSPECTIVE|||||||
34068943|NCT05414916|||COHORT||CROSS_SECTIONAL|||||||
34068944|NCT05665426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The eligible patients will be given a sequential study number by research staff. Subsequently, their basic information will be entered into an internet-based and password-protected clinical research management system (ResMan Research Manager, supported by West China Hospital, Sichuan University, China), which will automatically generate a research code and randomly allocate participants to one of four groups (Acu-BL40 group, Acu-LU5 group, Mox-BL40 group or Mox-LU5 group) at a ratio of 1:1:1:1. Given the nature of the intervention, the participants and acupuncturists will be aware of the assignment. The research assistants responsible for data collection, biostatisticians and data analysis will be masked to study group allocation. Precise documentation of therapy will be recorded in the case report forms (CRFs) in an exclusive computer as well as on paper.|2×2 factorial design|f|f|t|t
34068945|NCT01114295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877314|NCT01175109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877315|NCT03111784|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi Experimental / non-randomised trial||||
33877316|NCT05266235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877317|NCT05378386|||COHORT||PROSPECTIVE|||||||
33877318|NCT02840968|||COHORT||RETROSPECTIVE|||||||
33877319|NCT03881514|||COHORT||RETROSPECTIVE|||||||
33877320|NCT03065348|NA|SINGLE_GROUP||OTHER||NONE||First step: pilot study including 20 patients (intervention ) Second step: inclusion of 11 additional patients. Comparison of the intervention group (n=31) with a historical similar population (control group, n=31)||||
34068946|NCT04482608|||COHORT||RETROSPECTIVE|||||||
34068947|NCT05882383|||COHORT||CROSS_SECTIONAL|||||||
33969018|NCT04027010|RANDOMIZED|PARALLEL||PREVENTION||NONE||The treatment condition involves participation in a teen pregnancy prevention program, Healthy U (formally known as Virtual Student Health Center). The comparison condition for the study is treatment as usual.||||
33969019|NCT01201954|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33969020|NCT04235647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969021|NCT04985214|||COHORT||PROSPECTIVE|||||||
33969022|NCT02257632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969023|NCT03031457|||COHORT||PROSPECTIVE|||||||
33969024|NCT01956357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969025|NCT02494245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33969026|NCT03196791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969027|NCT00421785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969028|NCT04969952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Only investigator know|Shared decision making (SDM) process through Advance Care Planning (ACP) consultation with cancer patients|t|t|f|f
33969029|NCT03465657|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33969030|NCT02622074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969031|NCT00313053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969032|NCT00728559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969033|NCT02732587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969034|NCT03111147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969035|NCT01430182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969036|NCT00412815|RANDOMIZED|PARALLEL||OTHER||SINGLE||||||
33969037|NCT00122902|||||PROSPECTIVE|||||||
33969038|NCT01606137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969039|NCT00831090|||COHORT||PROSPECTIVE|||||||
33969040|NCT00468533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969041|NCT06107088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969042|NCT03201471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969043|NCT01677910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants were randomized to one of three treatment arms in the double-blind treatment period. After completion of the double-blind treatment period, participants entered an open-label treatment period.|t|t|t|t
33969044|NCT00877682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068948|NCT00568217|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34068949|NCT04452552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent person randomly assigned to all participated subjects to either group (A) or group (B)|Fifty overweight primipara women at 6 months postnatally aged from 20-35 years, BMI (25-29.9) kg/m2 and have waist hip ratio (WHR) \> 0.8. They were assigned randomly into 2 equal groups: Group (A) received ultra-sound cavitation40 KHz applied for 30 min, once time weekly for 8 weeks. Group (B) received radiofrequency multi-polar 5MHZ applied for 30 min, once time weekly for 8 weeks. Both groups received the same diet program throughout the treatment period. All females in both groups were assessed through weight scale for body weight, tape measurement for waist/hip ratio and ultra-sonography for fat thickness of abdominal region before and after treatment|t|f|f|t
34068950|NCT01760213|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34068951|NCT03485703|RANDOMIZED|PARALLEL||PREVENTION||NONE||for a period of 5 days, a group of infants will receive azithromycin EV at a dose of 10 mg / kg / day and another group will receive placebo (SF 0.9%) in the same volume, every 24 hours.||||
34068952|NCT02627482|||COHORT||PROSPECTIVE|||||||
33969045|NCT02922114|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068953|NCT02086955|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068954|NCT01207011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068955|NCT04264754|||CASE_CONTROL||PROSPECTIVE|||||||
34068956|NCT01359020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068957|NCT00634296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068958|NCT02273128|||CASE_CONTROL||RETROSPECTIVE|||||||
34068959|NCT05054816|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34068960|NCT03071016|||COHORT||PROSPECTIVE|||||||
34068961|NCT05307003|||COHORT||PROSPECTIVE|||||||
34068962|NCT01515696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34068963|NCT02657824|||||PROSPECTIVE|||||||
34068964|NCT01643486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34068965|NCT02840773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068966|NCT00860080|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33969046|NCT06544577|||COHORT||PROSPECTIVE|||||||
33969047|NCT03876756|||CASE_CONTROL||RETROSPECTIVE|||||||
33969048|NCT05175456|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33969049|NCT04177810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969050|NCT01501383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969051|NCT04725526|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969052|NCT03787485|||CASE_CONTROL||PROSPECTIVE|||||||
33969053|NCT01875445|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33969054|NCT05767255|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized 1:1 to continue the basal bolus ( insulin glargine and aspart ) or IDegLira ( insulin glargine and aspart ) or IDegLira ) on an outpatient basis by means of a system of random number generation through a mobile application ( Random Number Generator ) that will be centralized ( by a member of the independent group ) and to which the rest of the investigators will not have access.||||
33969055|NCT02454972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969056|NCT01737177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068967|NCT01394341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34068968|NCT02743845|||FAMILY_BASED||PROSPECTIVE|||||||
34068969|NCT04656184|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33877321|NCT02824705|||COHORT||PROSPECTIVE|||||||
33877322|NCT06416904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877323|NCT05540795|||CASE_CONTROL||RETROSPECTIVE|||||||
33877324|NCT04141332|||CASE_CONTROL||RETROSPECTIVE|||||||
33877325|NCT02431572|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877326|NCT05766995|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33877327|NCT02398591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877328|NCT03431155|RANDOMIZED|PARALLEL||OTHER||SINGLE|"* Data were collected by a nurse (not researher) who did not know anything about participants of experiment and control group.~* Data recorded on the computer by another nurse (without specifying the experiment and control group)~* The experimental and control groups codified by the co-investigator.~* The analysis of the data encoded by the groups was done by a statistical expert. Data collectors, statistical analyzes and report writing were blinded."||f|f|f|t
33877329|NCT05095207|NA|SINGLE_GROUP||TREATMENT||NONE||For the Phase 1 portion of the trial Bayesian optimal interval (BOIN) design is being used. a minimum of 3 and a maximum of 12 patients enrolled to determine RP2D. The 3-9 patients evaluated at the RP2D of the Phase I part of the trial will be enrolled and included in the Phase II part of the trial. If 2 or fewer among 12 patients in the first stage of Phase II have disease control, the trial will stop. However, if at least 3 have disease control in the first stage, then an additional 33 patients will be enrolled in the second stage, for a total of 46 patients. If among the 46 patients, 12 or fewer achieved complete response, partial response or stable disease, the treatment regimen under investigation in this trial will be rejected; or if at least 13 out of the 46 patients respond, the treatment regimen will be considered worthy of further study. The total sample size for Phase I and II portions combined is a minimum of 3 and a maximum of 60.||||
33877330|NCT00685503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877331|NCT06089642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877332|NCT00746252|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877333|NCT03102905|||COHORT||RETROSPECTIVE|||||||
34068970|NCT02131116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757331|NCT03251625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants divided into two groups by randomization software, consisting of 200 in each group.|a randomized, double-blind, placebo-controlled clinical trial|t|f|t|f
33757332|NCT00734630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757333|NCT05030831|NA|SINGLE_GROUP||TREATMENT||NONE||Study INZ701-201 is a Phase 1/2, multicenter, open-label, multiple ascending dose (MAD) study followed by a long-term open-label extension period conducted in adults with ABCC6 Deficiency manifesting as PXE. The study design during the Dose Evaluation Period is a MAD 3+3 with 3 dose cohorts.||||
33757334|NCT04887025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757335|NCT01232010|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757336|NCT01267292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33757337|NCT02003508|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33757338|NCT04026529|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Cross-sectional design||||
33757339|NCT03403348|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33757340|NCT02355743|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33757341|NCT03426384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757342|NCT02557841|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34068971|NCT01883661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757343|NCT01946542|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33757344|NCT03848403|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33757345|NCT04589533|||OTHER||RETROSPECTIVE|||||||
33757346|NCT00948779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33757347|NCT02009202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757348|NCT05115448|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33757349|NCT02132845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757350|NCT01559948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33757351|NCT02708979|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33757352|NCT05810168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757353|NCT00892502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757354|NCT00765232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757355|NCT03479697|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study will compare acoustic stimulation linked to brainwave activity (HIRREM, along with continued current care, HCC), with continued current clinical care alone (CCC). Both groups will continue their other current care throughout, including non-pharmacological, and lifestyle modification therapies. The participants in the CCC group will be offered the opportunity to crossover and receive a course of HCC.||||
33757356|NCT05417880|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized controlled trial||||
33757357|NCT03547843|RANDOMIZED|CROSSOVER||OTHER||NONE||Pilot randomized clinical trial||||
33757358|NCT01690091|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33757359|NCT02239380||PARALLEL||TREATMENT||NONE||||||
33757360|NCT05019664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757361|NCT00217646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757362|NCT06550336|NA|SINGLE_GROUP||TREATMENT||NONE||"Chidamide tablets,the medication is to be taken at a dose of 20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25. It should be administered orally 30 minutes after meals.~Treatment Duration: Each 4-week period constitutes one treatment cycle. Throughout the trial, all participants will continue to receive treatment until any of the following occurs: disease progression, intolerable adverse reactions, or the participant decides to withdraw."||||
33757363|NCT05596643|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757364|NCT01086748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757365|NCT01941732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757366|NCT02834156|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33757367|NCT04774302|||COHORT||PROSPECTIVE|||||||
33757368|NCT04889001|NA|SINGLE_GROUP||OTHER||NONE||Before and after intervention comparison. The students will be trained in simulation enhanced HBB. Simulation enhanced HBB is a one-day course delivered using a format of Explain, Demonstrate and Facilitate practice. Compared to the standard HBB training, the simulation enhanced HBB course is designed with increased peer-to-peer feedback and scripted expert facilitator feedback at HBB practice exercises.||||
33757369|NCT01770158|||OTHER||PROSPECTIVE|||||||
33757370|NCT04667299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757371|NCT02563457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877334|NCT02289222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877335|NCT02004665|||COHORT||PROSPECTIVE|||||||
33877336|NCT03713164|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33877337|NCT01464307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34068972|NCT00323076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068973|NCT00479115|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33877338|NCT05561660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877339|NCT00634153|||COHORT||OTHER|||||||
33877340|NCT00730938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33877341|NCT04986462|||OTHER||RETROSPECTIVE|||||||
33877342|NCT05700162|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33877343|NCT04480177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33877344|NCT02257983|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33877345|NCT00261872||||TREATMENT||||||||
33877346|NCT03425032|||COHORT||PROSPECTIVE|||||||
33877347|NCT02636088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877348|NCT02108431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877349|NCT02698488|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33877350|NCT03389971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877351|NCT05091398|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33877352|NCT01678729|||COHORT||RETROSPECTIVE|||||||
33877353|NCT05799456|||CASE_CONTROL||PROSPECTIVE|||||||
33877354|NCT01505621|||CASE_CONTROL||PROSPECTIVE|||||||
33877355|NCT04309227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator responsible for outcomes assessment and evaluation will be blinded. The investigator performing statistical analysis will not be involved with any interventions or assessments prior to being provided data.||f|f|t|t
33877356|NCT02733666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757372|NCT03372122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The two study products will be assigned to opposite forearms per a computer-generated randomization schedule. Additionally, the location for baseline and post-product samples will be randomly assigned to the two longitudinally-arranged sites per forearm.|t|f|f|t
33757373|NCT01172769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757374|NCT06579482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|coated tablets|Randomized, non-inferiority, double-blind ,comparative study|t|t|t|f
33757375|NCT03061565|||CASE_CONTROL||PROSPECTIVE|||||||
33757376|NCT03077191|||COHORT||PROSPECTIVE|||||||
33757377|NCT03500614|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33877357|NCT04994119|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33877358|NCT04607200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877359|NCT01178060|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33877360|NCT02779374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877361|NCT01773109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877362|NCT04621370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757378|NCT02381054|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757379|NCT06370364|||COHORT||CROSS_SECTIONAL|||||||
33757380|NCT05697874|||COHORT||PROSPECTIVE|||||||
33877363|NCT03033355|||COHORT||PROSPECTIVE|||||||
34068974|NCT02283580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34068975|NCT02253381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34068976|NCT00839748|||COHORT||PROSPECTIVE|||||||
34068977|NCT04891926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068978|NCT05964829|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34068979|NCT04736095|||OTHER||PROSPECTIVE|||||||
34068980|NCT02076815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34068981|NCT01593449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34068982|NCT02890563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068983|NCT04406116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068984|NCT04779281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Ultra-endurance athletes with at least one gastrointestinal symptoms will be administered oral rehydration salts supplemented with L. Rhamnosus GG or oral rehydration salts only for 4 weeks|t|f|t|t
34068985|NCT01724944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34068986|NCT02148081|||COHORT||PROSPECTIVE|||||||
34068987|NCT02644447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34068988|NCT04687865|||COHORT||PROSPECTIVE|||||||
34068989|NCT05180890|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34068990|NCT02889146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34068991|NCT06342856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34068992|NCT02868736|||COHORT||PROSPECTIVE|||||||
34068993|NCT00640406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34068994|NCT00176514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34068995|NCT05972642|NA|SINGLE_GROUP||TREATMENT||NONE|"As this is a single-arm study, there will be no separate randomization and blinding procedures. However, to minimize bias to the efficacy assessor, an imaging assessor independent of the investigator will be assigned to assess the percentage reduction in uterine fibroid volume.~The independent assessor will use MR imaging to assess the volume of the uterine fibroids at screening versus the volume of the uterine fibroids at 24 weeks post-procedure and the volume of the nonperfused area immediately post-procedure. In addition, the independent assessor's assessment notes will be kept secure for the duration of the study and will not be accessible to anyone other than the independent assessor. Once all assessments are completed for a subject, they will be forwarded to the Data Controller in batches."|This is a single-arm study.||||
34068996|NCT00071149|||DEFINED_POPULATION||OTHER|||||||
34068997|NCT06331975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34068998|NCT00603928|||CASE_ONLY||PROSPECTIVE|||||||
34068999|NCT05495529|||COHORT||RETROSPECTIVE|||||||
34069000|NCT00973427|||COHORT||PROSPECTIVE|||||||
34069001|NCT04385979|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069002|NCT00986323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069003|NCT04561986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069004|NCT03967808|||COHORT||PROSPECTIVE|||||||
34069005|NCT04625413|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Evaluate the usability and feasibility of a patient-centered communication tool (UR-GOAL)||||
34069006|NCT02517021|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069007|NCT00560482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069008|NCT04393857|||COHORT||CROSS_SECTIONAL|||||||
34069009|NCT03802734|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized control trial||||
34069010|NCT03860766|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34069011|NCT02548949|||CASE_ONLY||PROSPECTIVE|||||||
34069012|NCT00193739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069013|NCT01167725|RANDOMIZED|||TREATMENT||NONE||||||
34069014|NCT05126173|||COHORT||PROSPECTIVE|||||||
34069015|NCT03534999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with Hip Arthroplasty, one group was on TENS other group was a control||||
34069016|NCT00463008|NON_RANDOMIZED|||TREATMENT||||||||
34069017|NCT04769973|||OTHER||OTHER|||||||
34069018|NCT05505695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069019|NCT00166998|||DEFINED_POPULATION||OTHER|||||||
34069020|NCT02858024|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34069021|NCT01911702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069022|NCT02652559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069023|NCT02044562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069024|NCT01043094|NON_RANDOMIZED|PARALLEL||||NONE||||||
34069025|NCT00000809||||PREVENTION||||||||
33969057|NCT06285721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969058|NCT04479657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969059|NCT03100578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877364|NCT06461260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969060|NCT05716191|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33969061|NCT04797715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877365|NCT00418197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877366|NCT04116112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877367|NCT05694351|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877368|NCT04864665|NA|SINGLE_GROUP||OTHER||NONE||interventional with breastfed reference group||||
33877369|NCT03730116|||OTHER||PROSPECTIVE|||||||
33877370|NCT04008407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Selective treatment algorithm of ESD or EMR according to risk stratification.||||
33877371|NCT02553512|||COHORT||PROSPECTIVE|||||||
33877372|NCT02474966|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33877373|NCT04197115|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective longitunal experimental||||
33877374|NCT03132337|||COHORT||PROSPECTIVE|||||||
33969062|NCT01308281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969063|NCT06382181|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants were assigned to three groups in parallel for the duration of the study||||
33969064|NCT05949281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969065|NCT00754195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969066|NCT04562025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969067|NCT06213623|||COHORT||PROSPECTIVE|||||||
33969068|NCT02046785|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33969069|NCT05425108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969070|NCT06252194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969071|NCT04716959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969072|NCT00752856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969073|NCT05605028|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention will take 1 year to recruit all the patients. The investigators expect to have the 75 patients in the group intervention and 25 patients in the dietitian-led group. With these numbers, our preliminary power analysis suggests there will be a difference in the two groups with an alpha of .05 and 80% power. The investigators will add 3 tests to both arms of the study, 9-question Patient Health Questionnaire (PQ-9), Generalized Anxiety Disorder (GAD), and the Depression and Anxiety Assessment Test, in the POWER Obesity group at 0, 3, 6 months and 12 months of intervention.||||
33877375|NCT00915681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877376|NCT00546052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069026|NCT02736708|||COHORT||PROSPECTIVE|||||||
34069027|NCT00124722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069028|NCT00768287|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Study Part 1 only|Study Part 1: Randomized, double-blind, cross-over study of pharmacokinetics; Study Part 2: Non-randomized, open-label study of safety and efficacy; Surgical sub-study: Non-randomized, open-label study of safety and efficacy during major surgery|t|t|t|t
34069029|NCT01641471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069030|NCT04901234|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II open label randomized controlled trial||||
33757381|NCT04167501|||CASE_CONTROL||RETROSPECTIVE|||||||
33877377|NCT02975544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877378|NCT05088304|||COHORT||RETROSPECTIVE|||||||
34069031|NCT02039323|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34069032|NCT02782377|||COHORT||PROSPECTIVE|||||||
34069033|NCT02697591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069034|NCT05421806|||COHORT||RETROSPECTIVE|||||||
33877379|NCT04423497|||OTHER||CROSS_SECTIONAL|||||||
34069035|NCT01134393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069036|NCT04663854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069037|NCT01041339|||CASE_CONTROL||PROSPECTIVE|||||||
34069038|NCT04175041|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33757382|NCT03166150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757383|NCT03578003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757384|NCT06308679|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33757385|NCT02832479|||COHORT||RETROSPECTIVE|||||||
33877380|NCT00209378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069039|NCT00797940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069040|NCT03450408|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The individual or individuals responsible for assessing outcome data will be blinded to group assignment.||f|f|f|t
34069041|NCT02956707|||COHORT||PROSPECTIVE|||||||
34069042|NCT05499871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069043|NCT02134392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069044|NCT05436171|||COHORT||RETROSPECTIVE|||||||
34069045|NCT06526325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069046|NCT04039425|||COHORT||PROSPECTIVE|||||||
33757386|NCT02136472|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757387|NCT03958084|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33757388|NCT04381520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757389|NCT00975559|||CASE_CONTROL||PROSPECTIVE|||||||
33757390|NCT02693938|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33757391|NCT00041730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757392|NCT02798731|||COHORT||PROSPECTIVE|||||||
33877381|NCT01347151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877382|NCT03326843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877383|NCT04434495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877384|NCT00186550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877385|NCT02342015|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877386|NCT02284282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877387|NCT00362089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894356|NCT05303493|NA|SINGLE_GROUP||TREATMENT||NONE||"Cohort 1. For patients with advanced NSCLC, treatment will consist of ICI in combination with CamuCamu.~Cohort 2. For patients with advanced cutaneous melanoma, treatment will consist of single-agent anti-PD-1 either nivolumab or pembrolizumab at the discretion of the treating physician in combination with investigational CC capsules Cohort 3. For patients with advanced melanoma receiving standard-of-care ICI who exhibit either an ORR of SD or PD during the first 3 months of ICI initiation, their current regimen will continue unchanged and they will receive Camu C and will be continued for 18 weeks or upon progression."||||
34069047|NCT00157001|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069048|NCT06212570|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069049|NCT01065571|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34069050|NCT00639925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069051|NCT00761371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069052|NCT06294158|||COHORT||PROSPECTIVE|||||||
34069053|NCT01179932|||COHORT||PROSPECTIVE|||||||
34069054|NCT01326013|||CASE_ONLY||PROSPECTIVE|||||||
34069055|NCT00311870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34069056|NCT05573178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34069057|NCT02794506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877388|NCT04887493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants and the investigators will not be masked; however, outcome assessor (statisticians) will be masked because they will not know anything about the drugs received by sublingual or per vaginal routes as their role will be to analyze the outcome only.|Pregnant mothers at term (37 - 42 weeks of gestation) and post term (\>42 weeks of gestation) admitted to gynecology ward for induction of labour will be recruited to the study. The enrolled pregnant mothers will be randomly assigned to two groups by lottery method. Group 1- will be receive misoprostol 25µg by sublingual route for induction of labour; Group 2- will receive misoprostol 25µg by per vaginal route.|f|f|f|t
33877389|NCT02562742|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33877390|NCT01298115|||CASE_ONLY||PROSPECTIVE|||||||
33877391|NCT04937556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877392|NCT01514227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877393|NCT01069562|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33877394|NCT02870309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877395|NCT00753870|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877396|NCT04476303|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33877397|NCT00825500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877398|NCT00489567|||CASE_ONLY||PROSPECTIVE|||||||
33877399|NCT06330038|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33877400|NCT03477760|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33877401|NCT05683444|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Neither the participant nor investigator nor outcomes assessor was aware of whether saline or octreotide was infused on the day of investigation and data analysis.|Double-blinded cross over study|t|f|t|t
33877402|NCT01584479|||COHORT||RETROSPECTIVE|||||||
33877403|NCT05080465|NA|SINGLE_GROUP||OTHER||NONE||As the primary objective of the study is to assess safety of MSC infusion, a single arm non-blinded study design has been adopted.||||
33877404|NCT05534360|||COHORT||OTHER|||||||
33877405|NCT00873522|||COHORT||RETROSPECTIVE|||||||
33969074|NCT06091774|||CASE_CONTROL||PROSPECTIVE|||||||
33969075|NCT01402115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34069058|NCT01027377|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069059|NCT02217670|RANDOMIZED|CROSSOVER||||NONE||||||
33877406|NCT05990673|NA|SEQUENTIAL||TREATMENT||NONE||||||
33877407|NCT05024955|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877408|NCT05568511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33877409|NCT03246048|||COHORT||PROSPECTIVE|||||||
33877410|NCT01509963|||COHORT||PROSPECTIVE|||||||
33877411|NCT00166608|||||PROSPECTIVE|||||||
33877412|NCT02916940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877413|NCT04788355|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Patients and outcome assessors will not know which groups the patients belong to|Clinical study that will evaluate the action of drugs combined or not to reduce complications of patients with covid 19|t|f|f|t
33877414|NCT03637933|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33877415|NCT02905474|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969076|NCT02023632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33969077|NCT03763331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants were informed that there were two different categories of heat therapy, low heat and high heat, and that both might be beneficial for claudication symptoms."|Patients were randomized (blocked and stratified by sex) using assignments generated from PROC PLAN in SAS Version 9.4 by the study statistician into one of two groups: those receiving leg heat therapy or those receiving the sham treatment.|t|f|f|f
33969078|NCT03812068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969079|NCT02123459|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33969080|NCT01475669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969081|NCT03534596|||COHORT||RETROSPECTIVE|||||||
33969082|NCT04898985|||CASE_CONTROL||PROSPECTIVE|||||||
33969083|NCT02683733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069060|NCT05557617|||COHORT||RETROSPECTIVE|||||||
34069061|NCT01210014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069062|NCT05720195|||COHORT||PROSPECTIVE|||||||
33757393|NCT05321680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|anonimized data|A clinical, pragmatic, unicentric, open trial with blinded assessors. We will use a parallel randomized design (1:1) that will evaluate the effect of maintaining pharmacological treatment versus treatment withdrawal.|f|f|f|t
33877416|NCT00153582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877417|NCT00005112|RANDOMIZED|||TREATMENT||||||||
33877418|NCT00866307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877419|NCT06275503|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Cluster randomized trial|f|f|f|t
33877420|NCT03021642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877421|NCT00883376|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33877422|NCT05028400|NA|SINGLE_GROUP||TREATMENT||NONE||Laser speckle contrast imaging (LSCI)||||
33877423|NCT05712512|||COHORT||PROSPECTIVE|||||||
33877424|NCT03355300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877425|NCT01895322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877426|NCT02868242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877427|NCT00308217|||||PROSPECTIVE|||||||
33877428|NCT05061173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877429|NCT04312490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective study||||
33877430|NCT04683965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069063|NCT05205200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069064|NCT05163938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||REThink mobile therapeutic game intervention group and Treatment-as-usual group which receives the trial version of the app.|f|f|t|t
34069065|NCT00703326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069066|NCT05633628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069067|NCT01100632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069068|NCT00920413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069069|NCT04193553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069070|NCT01131390|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069071|NCT00694356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069072|NCT03579823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single blind. Operators are open to treatment allocation. Subjects are blinded to the treatment allocation. In order to keep the blind, subjects are masked during the subcutaneous injection.|Single Centre, Randomised, Single-Blind, Pilot Study|t|f|f|f
34069073|NCT05471427|||COHORT||PROSPECTIVE|||||||
34069074|NCT05461352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069075|NCT04477967|||COHORT||PROSPECTIVE|||||||
34069076|NCT01089452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069077|NCT05249387|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34069078|NCT02290925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Randomization code (A or B) was made using a computer and inserted in a sealed, serially numbered, opaque envelopes. Participants were given a serial number after run-in period. Assistant opened the envelope and assigned the patient to either biscuit A or B. The manufacturers held randomization code. Investigators, patients and those assessing the analysis were masked to the group outcome. Both Kothala Himbutu (KH) and placebo biscuits are identical in size, wrapped in same cover, and packed in identical boxes. The investigators tasted both biscuits and KH biscuits were slightly darker with the same taste. The study product is available in the market. Patients participating in the trial were asked about prior consumption of KH biscuits bought from the market (to exclude contamination). At the end of each period patients were asked whether they could assume the type of biscuit (KH biscuit or placebo) given to them and their preference for the type.|Patients with diabetes were screened and Type I Diabetes was excluded. The minimum run-in period was eight weeks and if the variability of HbA1c is more than 20%, excluded, to exclude patients with fluctuating glycaemia. As this is a crossover trial some degree of stability of the glycemic control is necessary to prevent excessive variation of HbA1c interfering with the study outcome. Participants were randomized to receive the KH or placebo biscuit. Oral hypoglycemic was continued and adjusted. Participants consumed KH or placebo biscuit for a period of 3 months as mid-morning and afternoon snack. Subsequently in the washout period of 1 month the participants did not consumed any biscuits. After, crossing over they continued biscuits for another 3 months. HbA1c was done at recruitment, after run-in period, at 3 months and on completion of the study. When there was deterioration of the glycaemic control patient was prescribed insulin, and withdrawn from the study.|t|t|t|t
34069079|NCT00878579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069080|NCT01830907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069081|NCT02707900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069082|NCT06106672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069083|NCT02898636|||OTHER||PROSPECTIVE|||||||
34069084|NCT01720485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069085|NCT02799810|||COHORT||PROSPECTIVE|||||||
34069086|NCT02118350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069087|NCT05742191|||OTHER||PROSPECTIVE|||||||
34069088|NCT03333486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069089|NCT04276077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069090|NCT06323395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|As the clinical trial will be conducted in a double-blind way, both investigators and patients will be blind with respect to the treatment administered. For the purpose of individual unblinding of a patient's treatment the investigator will receive a sealed emergency envelope for each patient containing the treatment code (Only in case of medical emergency it is permitted to open the emergency envelope).|Multi-centre, randomised, parallel-group, controlled (placebo), double-blind study|t|t|t|f
34069091|NCT06485622|||COHORT||PROSPECTIVE|||||||
33877431|NCT02922140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877432|NCT02914262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877433|NCT00415207|||COHORT||RETROSPECTIVE|||||||
33877434|NCT00589446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877435|NCT04806607|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective randomized trial comparing the biopsy specimen adequacy of 19G versus 22G core needles in subjects undergoing an EUS-LB.||||
33877436|NCT00217815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877437|NCT00525538||PARALLEL||||NONE||||||
33877438|NCT00105937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877439|NCT04755634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877440|NCT06417619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant (Major depression patients)|This study is a randomized controlled experimental study (Interventional Study Model)|t|f|f|f
33877441|NCT05966285|||COHORT||RETROSPECTIVE|||||||
33877442|NCT01459458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877443|NCT04957771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877444|NCT03194373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877445|NCT03535753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877446|NCT00953758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33877447|NCT02918864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877448|NCT01528917|||COHORT||RETROSPECTIVE|||||||
33877449|NCT05291494|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participants, the anesthesiologist, data collectors, the physicians performing the follow-up, and data analysts will be blinded to the group allocation. Blinding will maintain until the completion of the final analyses.|The experimental group will watch science videos through WeChat and regular preoperative visits before the surgical procedures. The regular group only received regular preoperative visits and education by ward nurses.|t|t|t|t
33757394|NCT05288660|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Participants and on-site medical/nursing staff at the study site were blinded to study drug/dose assignment. The pharmacy staff preparing the investigational products, however, were not blinded to ALXN1210 study drug assignment, but all other site staff, including the Investigator, were blinded. Sponsor staff was unblinded as needed (for example, to participate in the Safety Review Committee and to determine reportability of serious adverse events \[AEs\]), but was to refrain from sharing any information on study drug assignment with the site staff.||t|t|t|f
33757395|NCT04156165|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||2x2 factorial intervention trial with two and two arms|f|f|t|t
33757396|NCT01791920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757397|NCT02023528|||COHORT||PROSPECTIVE|||||||
33757398|NCT05950334|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The initial dose escalation stage of the study is nonrandomized; the dose optimization stage is randomized; the dose expansion stage is nonrandomized.|Participants will be enrolled first into a dose-escalation stage, followed by a dose optimization stage, and a dose-expansion stage.||||
33757399|NCT01448564|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33757400|NCT04805255|||COHORT||PROSPECTIVE|||||||
33757401|NCT05792904|||COHORT||PROSPECTIVE|||||||
33757402|NCT06180304|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33757403|NCT05204589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757404|NCT00003260|RANDOMIZED|||TREATMENT||||||||
33757405|NCT04702633|||CASE_CONTROL||PROSPECTIVE|||||||
33757406|NCT01982435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757407|NCT03574597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33757408|NCT02507518|NA|SINGLE_GROUP||OTHER||NONE||||||
33757409|NCT01974115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757410|NCT03169218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
33877450|NCT03468855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877451|NCT00583921|||COHORT||PROSPECTIVE|||||||
33877452|NCT03353870|||OTHER||PROSPECTIVE|||||||
33877453|NCT02887391|||COHORT||PROSPECTIVE|||||||
33877454|NCT03439865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877455|NCT06036719|||COHORT||PROSPECTIVE|||||||
33877456|NCT03807713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877457|NCT03728309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877458|NCT04642755|||COHORT||CROSS_SECTIONAL|||||||
33969084|NCT01025193|NA|SINGLE_GROUP||TREATMENT||NONE|There was no masking in this single group trial. The patients, providers and investigators were all aware that the patient were on belimumab therapy.|There was only one group in this trial. All participants received belimumab.||||
33969085|NCT05585502|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The first part of the project is a cross-sectional design to test the association between: diabetic condition -\> increase in muscle and tendon stiffness -\> impairment of muscle-tendon function -\> increase in the energy expenditure of locomotion (walking).~The second part of the project is an intervention study that aims to test the effects of a stretching training program on muscle and tendon stiffness, muscle function and locomotor (walking) capacity."||||
33969086|NCT02971410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969087|NCT04890600|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33969088|NCT04873349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33969089|NCT01850069|||COHORT||PROSPECTIVE|||||||
33969090|NCT03215485|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||There is one intervention group and one comparison group.||||
33969091|NCT00354510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969092|NCT03615456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969093|NCT00003102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33969094|NCT00739479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969095|NCT00334620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969096|NCT03872960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969097|NCT04639687|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A is randomized to intermediate intervention, and change in measured outcomes is changed to that of Group B, which is a wait-list control group. Group B gets intervention later, but data contributes to follow-up up data rather than randomized controlled trial data.||||
33969098|NCT03348046|||COHORT||PROSPECTIVE|||||||
33969099|NCT04193059|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|"PANSY-1:~Arm 1: EC-T: 4 cycles of EC (epirubicin + cyclophosphamide), followed by 4 cycles of T (docetaxel) .~Arm 2: PCb: 6 cycles of weekly PCb (paclitaxel + carboplatin).~PANSY-2:~Arm 1: EC-TH(P): 4 cycles of EC (epirubicin + cyclophosphamide), followed by 4 cycles of TH TH(P) (docetaxel + trastuzumab, with pertuzumab for participants receiving dual-targeted therapy). After completing chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab, with pertuzumab for participants receiving dual-targeted therapy.~Arm 2: PCbH(P): 6 cycles of weekly PCbH(P) (paclitaxel + carboplatin + trastuzumab, with pertuzumab for participants receiving dual-targeted therapy. After completing chemotherapy, patient will continue to complete 1 year of adjuvant trastuzumab, with pertuzumab for participants receiving dual-targeted therapy."||||
33969100|NCT00325494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969101|NCT05448859|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969102|NCT02081170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969103|NCT02352740|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34069092|NCT03184779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants (including the teachers and students) will not be told by the research team if the video assigned to their class is the control or intervention. During the consent process though, they will be made aware that they are going to be randomly assigned to either the control or intervention video.~Furthermore, when the two observers go to the ski hill to collect data on observed unsafe behaviours, they will be blinded to the intervention/control status of the school at the ski area that day to prevent observer bias."|Schools will be stratified by grade and half of the schools in each stratum will be randomly assigned to the intervention and the other half will be assigned to the control group. Stratification by grade is necessary to ensure that groups are similar enough to ensure less biased comparisons. The research team will also ensure that schools going on their outing to COP on the same day are assigned to the same group. This is to ensure that research assistants can assume that all students observed on the hill for that particular day have the same intervention or control status since it may be challenging to distinguish which school group each student belongs to strictly through observation. That way the research team can accurately ascertain the intervention and control status of each student for the behavior observation component of the study.|t|f|f|t
34069093|NCT02504047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757411|NCT05995028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757412|NCT05453825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757413|NCT05660200|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking procedure will be applied|Single-dose, open-label, randomized, double-arm cross-over study||||
33969104|NCT04400695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969105|NCT03312829|||COHORT||PROSPECTIVE|||||||
33969106|NCT04678453|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33969107|NCT04582227|||CASE_CONTROL||PROSPECTIVE|||||||
33969108|NCT00135642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969109|NCT05508451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969110|NCT02150486|||COHORT||PROSPECTIVE|||||||
33969111|NCT01016860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969112|NCT03521999|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Post-treatment assessors and a co-investigator in charge of randomization will be blind to condition assignment|376 Veterans who are referred for a PTSD evaluation through the Charleston VAMC PTSD Clinic Team (PCT) and Telehealth Programs and are recommended for PTSD specialty care will be randomized to receive an online peer-to-peer digital storytelling resource \[AboutFace\] or an educational brochure for PTSD \[enhanced Usual Care; eUC\]|f|f|f|t
33969113|NCT04086706|||COHORT||PROSPECTIVE|||||||
33969114|NCT05989282|||COHORT||PROSPECTIVE|||||||
33969115|NCT01090128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969116|NCT02059733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969117|NCT02260765|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33969118|NCT01882400|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33969119|NCT02232503|||||CROSS_SECTIONAL|||||||
33969120|NCT03476447|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators and data evaluators will be blinded to the treatment assignments.|Subjects will be enrolled and randomized 1:1:1:1 to the following treatment arms (daily dose of B. infantis EVC001): high dose, medium dose, low dose, and placebo.|t|f|t|t
33969121|NCT00796484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877459|NCT00034372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969122|NCT06334926|||COHORT||OTHER|||||||
33969123|NCT06547749|||CASE_CONTROL||PROSPECTIVE|||||||
33969124|NCT04200703|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969125|NCT03681106|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Randomization list has been already generated but will not be available to the recruiters to avoid allocation bias.~Statistician that will handle the data analysis will not know which group is the interventional and which group is the control.~We were not able to mask the using of tape to the patients or the investigators because it is an evident treatment."|||||
33969126|NCT02607761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33969127|NCT01223196|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33969128|NCT05824312|||COHORT||PROSPECTIVE|||||||
33877460|NCT01180660|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33877461|NCT05399537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894357|NCT01750918|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The original intention of the study was to include a randomized phase 2 portion of the study as a Part 3; however, a preliminary analysis did not meet predetermined criteria for efficacy. As a result, Part 3 of the study was not initiated."||||
33894358|NCT03921112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894359|NCT05415579|||OTHER||PROSPECTIVE|||||||
33969129|NCT03909321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33969130|NCT00299585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969131|NCT01723787|||FAMILY_BASED||PROSPECTIVE|||||||
33969132|NCT02143206|||COHORT||PROSPECTIVE|||||||
33969133|NCT04211298|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33969134|NCT03213561||SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33969135|NCT02951663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33969136|NCT00217412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969137|NCT03251183|||COHORT||PROSPECTIVE|||||||
33969138|NCT05151978|||COHORT||PROSPECTIVE|||||||
33969139|NCT01492257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33969140|NCT02102581|||CASE_CONTROL||PROSPECTIVE|||||||
33969141|NCT01585233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969142|NCT01264393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969143|NCT04965220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969144|NCT05362058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969145|NCT00798083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969146|NCT04106596|||CASE_CONTROL||RETROSPECTIVE|||||||
33969147|NCT01577537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969148|NCT04450290|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||First-in-human, single-arm, exploratory, open-label, prospective, longitudinal, monocentric study||||
33969149|NCT00811200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969150|NCT06440811|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969151|NCT00583596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969152|NCT00563303|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33969153|NCT05357560|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969154|NCT01203683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969155|NCT00194818|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33969156|NCT05692674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969157|NCT06263309|||COHORT||RETROSPECTIVE|||||||
33969158|NCT04705909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894360|NCT00826514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969159|NCT03821324|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded evaluation of photographs taken at baseline and at 6, 12 weeks post final treatment by independent evaluators.|||||
33969160|NCT05752305|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33969161|NCT01928914|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33969162|NCT05823311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33969163|NCT01705210|||COHORT||CROSS_SECTIONAL|||||||
33969164|NCT00373685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969165|NCT03052166|||COHORT||PROSPECTIVE|||||||
33969166|NCT03840811|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33969167|NCT05844683|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33969168|NCT02982382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969169|NCT04746014|||CASE_ONLY||PROSPECTIVE|||||||
33969170|NCT02383147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969171|NCT00373724|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33969172|NCT00632320|||||PROSPECTIVE|||||||
33969173|NCT05881109|||COHORT||PROSPECTIVE|||||||
33969174|NCT02141386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969175|NCT01830413|||COHORT||PROSPECTIVE|||||||
33969176|NCT01545063|||OTHER||PROSPECTIVE|||||||
33969177|NCT06286566|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|centralized radiographic assessor, outcome assessors(when possible), and the statistical advisors will be blind to the used implants|Multicenter prospective cohort study|f|f|f|t
33969178|NCT01724970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969179|NCT06405776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33969180|NCT05551728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, it is not possible to blind participants to the allocation received. Outcome assessors and statisticians will be blinded to participant group.|The study design will be an individually randomized group treatment RCT with a delayed treatment control group. 150 children, ages 18-72 months, with a DSM-5 diagnosis of autism spectrum disorder (ASD) and their caregivers will be recruited on a rolling basis, with arm allocation (coaching vs. delayed treatment control) conducted using a minimization approach with child sex balanced across groups. The intervention will be offered to the delayed treatment control group immediately after follow-up assessment (6-months after baseline). Offering the intervention to both groups is of ethical importance in an environment with few services and will enhance retention. Once control dyads have completed the intervention, the degree to which the trend in the control group is consistent with any treatment effect detected in the main trial comparison will be assessed. Note that a total of 320 participants will be enrolled in the study (150 caregiver-child dyads and 20 Aim 2 participants).|f|f|f|t
33969181|NCT01279642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969182|NCT06530537|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33969183|NCT04997538|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33969184|NCT05617820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969185|NCT05447585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969186|NCT03058939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969187|NCT01748500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969188|NCT03058536|RANDOMIZED|PARALLEL||PREVENTION||NONE||312 twin pregnant women with short cervix between 16 and 27 weeks and 6 days of gestacional age will be randomized in four groups: daily 400mg vaginal progesterone combined with insertion of cervical pessary; isolated use of daily 400mg vaginal progesterone, isolated insertion of cervical pessary or expectant management (no intervention).||||
33969189|NCT01806597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969190|NCT01017679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969191|NCT00800098|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969192|NCT02499354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969193|NCT01432132|||COHORT||PROSPECTIVE|||||||
33969194|NCT02159859|NA|SINGLE_GROUP||OTHER||NONE||||||
33969195|NCT05087394|||COHORT||OTHER|||||||
33969196|NCT05842395|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All participants and the consultants making definite treatment decisions and the researcher assistant collecting participants' data will be unaware of allocation until the completion of the study.||t|t|f|t
33969197|NCT00852085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33969198|NCT01690065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969199|NCT03676374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969200|NCT04274192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969201|NCT04383002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969202|NCT00950833|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969203|NCT01547832|||||PROSPECTIVE|||||||
33969204|NCT04434859|||COHORT||PROSPECTIVE|||||||
33969205|NCT02947932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969206|NCT04189276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969207|NCT05077852|||CASE_CONTROL||RETROSPECTIVE|||||||
34069094|NCT00505856|||||PROSPECTIVE|||||||
34069095|NCT04325165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069096|NCT02727179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069097|NCT05143606|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessors are blinded to each participant's group allocation. The assessors will be provided with video clips of the participants performing FOI. The identity and group allocation of each participant will not be revealed during the assessment.||f|f|f|t
33969208|NCT02212431|NA|SINGLE_GROUP||||NONE||||||
33969209|NCT02580578|||CASE_ONLY||PROSPECTIVE|||||||
33969210|NCT03154528|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34069098|NCT00004763|RANDOMIZED|||TREATMENT||||||||
34069099|NCT02002871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069100|NCT01031004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069101|NCT05331105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069102|NCT05056441|||COHORT||RETROSPECTIVE|||||||
34069103|NCT03000023|||COHORT||PROSPECTIVE|||||||
33969211|NCT01243749|||CASE_ONLY||PROSPECTIVE|||||||
33969212|NCT02158910|||CASE_ONLY||PROSPECTIVE|||||||
34069104|NCT06178718|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34069105|NCT02139774|||COHORT||PROSPECTIVE|||||||
34069106|NCT05985330|||COHORT||PROSPECTIVE|||||||
34069107|NCT04186858|||CASE_CONTROL||PROSPECTIVE|||||||
33969213|NCT01893866|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34069108|NCT00082186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069109|NCT01603199|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069110|NCT03700918|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||First in human||||
34069111|NCT04184596|||OTHER||PROSPECTIVE|||||||
34069112|NCT04274075|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34069113|NCT00338221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34069114|NCT04396145|||COHORT||PROSPECTIVE|||||||
33877462|NCT05912465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The overall model of this study involves enrolling a total of 150 patients from three different sites. These patients will undergo baseline PET/CT imaging to assess their metabolic changes, as well as provide clinical information through medical history review and physical examinations. Additionally, blood samples will be collected for laboratory tests, and patients will complete questionnaires to evaluate psychological stress levels. This comprehensive approach aims to gather a range of data including imaging, clinical information, blood biomarkers, and psychological assessments to investigate the relationship between cancer cachexia, stress, and metabolic changes in lung cancer patients.||||
33877463|NCT02289183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877464|NCT05574205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"The participant will not know which condition they are under due to the contribution of animal and plant based elements within the diet, the conditions are not immediately obvious. Further, the higher and lower quality supplemental drinks have been made so the taste and texture of which are not discernible.~The randomisation and counterbalancing will be done by a researcher separate to the project, using anonymised participant codes. The condition participants are under will be also completed before inducting participants. Researchers will be blinded to the condition and which leg was exercised during the analysis."|Participants will be randomly assigned to either the high-quality or low-quality condition. Within both conditions single-leg resistance exercise will be undertaken meaning the other non-exercise leg for each participant will act as their own internal control.|t|f|f|f
33877465|NCT04473456|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Participants, care providers, and outcomes evaluator are masked.|Patients are randomly assigned to non-intervention and intervention (simultaneous EGD and colonoscopy) arms|t|t|f|t
33877466|NCT06193590|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33877467|NCT05207007|||CASE_ONLY||PROSPECTIVE|||||||
33877468|NCT05409261|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877469|NCT02436876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877470|NCT04315519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877471|NCT00820898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877472|NCT02065752|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877473|NCT04210609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877474|NCT02764827|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33877475|NCT05733871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized stratified controlled clinical study|t|t|f|f
33877476|NCT00387114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877477|NCT05301946|||COHORT||CROSS_SECTIONAL|||||||
33877478|NCT00425386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877479|NCT00971945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877480|NCT05360056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877481|NCT00014183||||TREATMENT||||||||
33877482|NCT01876407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877483|NCT03922698|||CASE_ONLY||PROSPECTIVE|||||||
33877484|NCT00661531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877485|NCT01537757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877486|NCT02055144|||CASE_ONLY||PROSPECTIVE|||||||
33877487|NCT01944514|||CASE_CONTROL||PROSPECTIVE|||||||
33877488|NCT02695628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877489|NCT00875745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877490|NCT04069065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877491|NCT03183895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877492|NCT03286985|||COHORT||PROSPECTIVE|||||||
33877493|NCT03124823|NA|SINGLE_GROUP||OTHER||NONE||||||
33877494|NCT03202966|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877495|NCT02187471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877496|NCT03970187|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigators evaluating the (external) performance in the in vivo Public Speech Test (PST) will be blinded (unaware of group assignment of participants, single-blind).|Randomized controlled single-blind study design.|f|f|t|f
33877497|NCT03320122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The proposed program will target MTUs and patients in counties were pediatric physiatrists and other multidisciplinary team members are underrepresented. In this proposed model, the investigators will randomly select at least 350 patient encounters: approximately 175 children will receive care using tele-physiatrist medical direction; 101 children will receive care from a pediatric physiatrist who travels to the MTU to provide in-person care; and 74 children will receive care under a non-pediatric specialist's medical directorship. Once the care model has been created at each site, patients from each cohort will be selected using a clustered, clinic based randomization scheme.||||
33877498|NCT02071407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877499|NCT01028846|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33877500|NCT06131879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assessor were blinded to groups|Randomized double arm controlled study|f|f|t|t
33877501|NCT01594853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877502|NCT02280460|||CASE_CONTROL||OTHER|||||||
33877503|NCT05813080|RANDOMIZED|PARALLEL||PREVENTION||NONE||The aim of risk-adapted treatment (RAB) arm is to reduce the number of patients with an increased clinical risk for psychosis (ICD-10: schizophrenic disorders F2x.x, affective disorders F3x.3) to actually develop a manifest psychosis.||||
33877504|NCT06543108|||COHORT||PROSPECTIVE|||||||
34069115|NCT04708899|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Rehabilitation of dyslexic children with (cental) auditory processing disorder.~The first group will receive the proposed program the arabic version of differential processing training program and the control group will receive the computer based auditory traing program (CBAT)."||||
33877505|NCT04422860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877506|NCT05716880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization in 1:1 ratio with stratification by the type of glomerular disease (podocytopathy versus other type) and investigational site||||
33877507|NCT00290966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877508|NCT04020250|||COHORT||PROSPECTIVE|||||||
33877509|NCT03389035|NA|SEQUENTIAL||TREATMENT||NONE||||||
33877510|NCT03823469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877511|NCT05230186|||COHORT||PROSPECTIVE|||||||
33877512|NCT04475055|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34069116|NCT01119820|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877513|NCT03699007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Adolescents will be randomized to either GET Living or TPM and stratified on fear (moderate/high; FOPQ-C: moderate \[35-49\] high \[50-96\]) and disability (moderate/high; moderate \[13-29\] severe \[30-60\]), to minimize the possibility of imbalance between the two treatment arms. To allow the use of small blocks while minimizing the probability of a blinded staff member predicting the next assignment we will use blocks of size two and four and randomly choose block sizes.|f|f|f|t
33877514|NCT04293861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877515|NCT04388150|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757414|NCT00187226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757415|NCT02232308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33757416|NCT00168038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757417|NCT05885698|||COHORT||PROSPECTIVE|||||||
33757418|NCT00361439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757419|NCT00772785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757420|NCT03617744|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization to group a or group b||||
33757421|NCT01017354|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757422|NCT01966003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757423|NCT04895865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to allocation|Intervention group receives alternative treatment Control group receives traditional treatment|t|f|f|f
33877516|NCT06317194|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33877517|NCT05800249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877518|NCT06340932|||COHORT||PROSPECTIVE|||||||
33877519|NCT02949752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757424|NCT01791764|||COHORT||PROSPECTIVE|||||||
33757425|NCT02170025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757426|NCT04536246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||multi-site study 15 subjects on each group analysis||||
33877520|NCT04509310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069117|NCT01206023|||CASE_ONLY||CROSS_SECTIONAL|||||||
34069118|NCT06389552|||OTHER||PROSPECTIVE|||||||
34069119|NCT00042653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069120|NCT04475627|||OTHER||CROSS_SECTIONAL|||||||
33877521|NCT04674592|||COHORT||PROSPECTIVE|||||||
33969214|NCT04898725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33969215|NCT02785133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877522|NCT05395065|||OTHER||PROSPECTIVE|||||||
33877523|NCT01421550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877524|NCT04655664|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33877525|NCT01219387|||||PROSPECTIVE|||||||
33877526|NCT02849795|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877527|NCT00646542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877528|NCT04951037|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33877529|NCT05097456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33877530|NCT00480610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877531|NCT06216665|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Participants receive insulin delivered continuously or every five minutes during the hyperinsulinemic euglycemic clamp test||||
33969216|NCT01074021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969217|NCT03741218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|GRAP and PLA will have the same aspect, so neither the participant and the care provider will know the received treatment at each stage.|GRAP: dried and milled grape pomaces. PLA: control period. All the subjects will pass the two periods: one half will receive the acute PLA supplementation followed by the acute GRAP supplementation, and the other half will do it inversely. The assignment to each order will be done randomly. Both period will be separated by a two weeks washing period.|t|t|f|f
33969218|NCT03645083|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33969219|NCT03982056|||COHORT||PROSPECTIVE|||||||
33969220|NCT04246970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969221|NCT02770716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969222|NCT05527210|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33969223|NCT00123383|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33969224|NCT05631899|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969225|NCT05443490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33969226|NCT03492983|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33877532|NCT05547178|||COHORT||RETROSPECTIVE|||||||
33877533|NCT00004348|||COHORT||PROSPECTIVE|||||||
33877534|NCT04734912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||all patients with indication für gastroscopy in transnasal techique are included.||||
33877535|NCT05860062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Each month the treatment will be given in equal bottles that will be marked on the label with a color (red, blue, green), the green color corresponding to placebo, red to vitamin D3+calcium and blue to calcium, only the doctors in charge of applying the questionnaires will know the group to which each patient belongs, in this way the double blind is not broken.~The placebo will be used to evaluate the effect that produced the feeling of being benefited from a new treatment, the foregoing to avoid bias and have greater reliability of the results, when compared with the gold standard."|The patients selected as the study population will be randomly distributed using a random number table, giving them the number 1, 2 or 3, according to the treatment group they will belong to.|t|f|t|f
33877536|NCT00786578|||CASE_CONTROL||PROSPECTIVE|||||||
33877537|NCT05656924|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants will be randomized to one of two groups: group 1 will use the digital prosthetic interface technology developed by Bionic Skins and group 2 will use a traditional socket-liner technology (i.e., study participants will use their own liner and socket system).||||
33877538|NCT04828057|||COHORT||PROSPECTIVE|||||||
33877539|NCT03579355|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"A quasi-experimental, controlled trial design was utilized to evaluate the effectiveness of a school-based tobacco program, Dentists Fighting Nicotine Dependence (DFND), to prevent the initiation of tobacco use among middle school students (grades 7-9) in Jeddah, Saudi Arabia.~Eight middle schools were selected from the regional education registry; four allocated to treatment arm (n=379) and four to control arm (n=255). The treatment arm received the new tobacco prevention program (DFND) whereas the control arm received only the regular tobacco prevention program administered by the Department of Education. DFND was delivered by trained health educators over 5 weeks, two sessions per week."||||
33877540|NCT01309074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877541|NCT03442543|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33877542|NCT01903512|||CASE_ONLY||PROSPECTIVE|||||||
33877543|NCT04956159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877544|NCT03762759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877545|NCT06141278|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33877546|NCT05779826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877547|NCT01707472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877548|NCT02298764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877549|NCT04063371|||COHORT||RETROSPECTIVE|||||||
33877550|NCT04204252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877551|NCT05873244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877552|NCT00783094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877553|NCT01731652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969227|NCT02040428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969228|NCT05567757|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, nonrandomized, single-arm, single-center, open-label, initial safety study||||
33969229|NCT01521728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969230|NCT06253468|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969231|NCT04967716|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969232|NCT00114712|||COHORT||PROSPECTIVE|||||||
33969233|NCT06286839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969234|NCT01360450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969235|NCT02468557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969236|NCT04868409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized study|t|t|f|t
33969237|NCT04573400|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757427|NCT03365154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757428|NCT05061875|||CASE_ONLY||PROSPECTIVE|||||||
33757429|NCT03823781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757430|NCT04608175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33877554|NCT04640883|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Investigating the effects of including sprints during low-intensity training sessions during a 14-d training camp with increased training load on performance and muscle/blood biology||||
33877555|NCT03826732|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the nature of the intervention, and self-report as a main strategy for outcome assessment, nor masking is possible or necessary.|Randomization into active treatment versus a wait-list control group||||
33877556|NCT02965495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877557|NCT01368835|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33877558|NCT04590092|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877559|NCT02686515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877560|NCT03127371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33877561|NCT06195800|||CASE_CONTROL||PROSPECTIVE|||||||
33877562|NCT05393609|||COHORT||PROSPECTIVE|||||||
33877563|NCT02393729|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877564|NCT03718507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33877565|NCT04100330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757431|NCT01066325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33757432|NCT01408355|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33757433|NCT06168812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757434|NCT01939873|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33757435|NCT01839006|||COHORT||RETROSPECTIVE|||||||
33877566|NCT03713944|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Therapeutic study using historical controls||||
33877567|NCT02833103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877568|NCT01680900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877569|NCT01280136|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877570|NCT06454253|||COHORT||RETROSPECTIVE|||||||
33877571|NCT03691792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes are rated on a semi-structured interview by raters blind to treatment assignment.|head-to-head RCT|f|f|f|t
33877572|NCT01686620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877573|NCT02294240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877574|NCT00810979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877575|NCT00896376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877576|NCT01858181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877577|NCT05087069|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33877578|NCT05331014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877579|NCT00164294|RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
33877580|NCT00874978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877581|NCT00334022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877582|NCT06425003|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877583|NCT02566746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877584|NCT03843411|||CASE_CROSSOVER||PROSPECTIVE|||||||
33877585|NCT01406834|||CASE_CONTROL||PROSPECTIVE|||||||
33877586|NCT05021783|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757436|NCT05134766|||CASE_CONTROL||RETROSPECTIVE|||||||
33757437|NCT00246116|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33877587|NCT00957008|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877588|NCT04821427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877589|NCT04361591|||COHORT||PROSPECTIVE|||||||
33877590|NCT06296732|||COHORT||PROSPECTIVE|||||||
33877591|NCT02141711|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33894361|NCT04007614|||COHORT||PROSPECTIVE|||||||
33894362|NCT05374343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894363|NCT02063529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069121|NCT01760447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants enrolled in protocol MK-0431A-170 were aware that they would receive either sitagliptin and metformin, or metformin. Participants in protocol MK-0431A-289 were aware that they would receive either sitagliptin and metformin XR, or metformin XR.|"Participants enrolled in protocol MK-0431A-170 were randomized between the arms Sitagliptin/Metformin and Metformin. Participants enrolled in protocol MK-0431A-289 were randomized between the arms Sitagliptin/Metformin XR and Metformin XR."|t|t|t|t
34069122|NCT04396522|||COHORT||PROSPECTIVE|||||||
34069123|NCT03420001|||CASE_CONTROL||RETROSPECTIVE|||||||
33757438|NCT00511017|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757439|NCT03967431|RANDOMIZED|PARALLEL||OTHER||SINGLE||The participants were divided into experimental and control groups through block randomization.|t|f|f|f
33757440|NCT06069050|NA|SINGLE_GROUP||TREATMENT||NONE||SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver.||||
33757441|NCT05095805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757442|NCT01756950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757443|NCT06292338|||OTHER||CROSS_SECTIONAL|||||||
33757444|NCT00817492|||CASE_CONTROL||PROSPECTIVE|||||||
33757445|NCT06083870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757446|NCT05711537|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Any patient admitted to Atrium Health Wake Forest Baptist for which our chronic pain/addiction medicine service is consulted||||
33757447|NCT03339479|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||self-control method||||
33757448|NCT06566326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757449|NCT00072761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757450|NCT03767179|||CASE_CONTROL||PROSPECTIVE|||||||
33757451|NCT01245465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877592|NCT03064477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients (participants) will know the treatment they have been assigned to, but they will not know whether that treatment is considered TAU or experimental (UP). Healthcare professionals and researchers will know the condition each patient has been assigned to (mandatory to provide a given type of intervention).|All consecutive patients with emotional disorders attending any of the collaborating centers will be asked to participate in the present study. Once inclusion criteria are met, each patient will be randomly assigned to one of the two experimental groups: TAU or UP. Randomization will be performed by a researcher unrelated to the study using a computer-generated sequence (Randomizer). Randomization will be stratified according to the severity of the primary measures of depression and anxiety, using the recommended cutoff in the manuals. Stratification will be made to ensure a comparable proportion of severely depressed and anxious individuals in each group. For each subgroup (i.e., severe or less severe depression and/or anxiety), participants will be randomly assigned to the UP or to TAU.|t|f|f|f
33877593|NCT06345677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877594|NCT03303950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877595|NCT02987621|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33877596|NCT01496066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Phase 3 medical device study|f|f|f|t
33877597|NCT00002953||||TREATMENT||||||||
33877598|NCT02560675|||COHORT||PROSPECTIVE|||||||
33877599|NCT01242449|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33877600|NCT00987038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969238|NCT01907737|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
33969239|NCT05863988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969240|NCT00571922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877601|NCT04179383|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33877602|NCT02078687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877603|NCT04677712|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877604|NCT02100878|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33877605|NCT05076539|NA|SINGLE_GROUP||OTHER||NONE||||||
33877606|NCT04992520|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33877607|NCT04186078|||COHORT||PROSPECTIVE|||||||
33877608|NCT05808400|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33877609|NCT03678480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877610|NCT01928381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877611|NCT00505466|||CASE_CONTROL||PROSPECTIVE|||||||
33877612|NCT05461950|||COHORT||PROSPECTIVE|||||||
33877613|NCT04583033|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969241|NCT04398394|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Group 1: 20 to 30 individuals with healthy retina, 18 to 50 years old. Group 2: 20 to 30 individuals with healthy retina and presenting with myopia, 18 to 50 years old.~Group 3: 20 to 30 individuals with healthy retina, over the age of 50. Group 4: 25 to 50 patients with early and intermediate AMD, over the age of 50. Group 5: 25 to 50 patients with other retinopathies than AMD, over the age of 18."||||
33969242|NCT03676023|||CASE_ONLY||OTHER|||||||
33969243|NCT02763579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969244|NCT05776966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969245|NCT01779947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969246|NCT02381509|||COHORT||PROSPECTIVE|||||||
33969247|NCT05779319|||COHORT||PROSPECTIVE|||||||
33969248|NCT04202900|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33969249|NCT06524024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969250|NCT03818490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757452|NCT05789654|||CASE_ONLY||OTHER|||||||
33757453|NCT04684225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757454|NCT05840848|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||double-blind crossover|t|f|t|f
33757455|NCT02846090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757456|NCT03322280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757457|NCT02231177|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33757458|NCT01509781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757459|NCT03409666|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 assignment of treatment||||
33757460|NCT00954148|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33877614|NCT05152550|||COHORT||PROSPECTIVE|||||||
33877615|NCT05137327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Teachers are unaware of the consultation condition to which they are assigned.|Within a given school building, teachers will be stratified on three characteristics prior to randomization: (1) grade bands (K-2 and 3-5), (2) Global Classroom Management Competencies based on baseline observations and (3) teacher beliefs based on baseline ratings. This will ensure that similar numbers of teachers with these characteristics are in each condition.|t|f|f|f
33877616|NCT03308656|||COHORT||PROSPECTIVE|||||||
33877617|NCT05026307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877618|NCT01472497|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33877619|NCT05699096|||CASE_ONLY||RETROSPECTIVE|||||||
33877620|NCT02798536|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33877621|NCT05117775|||OTHER||RETROSPECTIVE|||||||
33877622|NCT04427215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The participants will be randomized|5 intervention groups (music therapy, art therapy, dance-movement therapy, physical activity, bibliotherapy) and 1 control group.|f|t|t|t
33877623|NCT00278993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877624|NCT00326365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33877625|NCT06253156|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33877626|NCT04368156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877627|NCT02931058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877628|NCT06463600|RANDOMIZED|PARALLEL||TREATMENT||NONE||One part feasibility and one part randomised.||||
33877629|NCT00604604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33877630|NCT04434521|||COHORT||PROSPECTIVE|||||||
33877631|NCT05208151|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33877632|NCT01632566|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33877633|NCT06446440|||OTHER||PROSPECTIVE|||||||
33877634|NCT04011020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All recruited T1D subjects will receive the treatment with Stem Cell Educator therapy.|Treatment group receive Stem Cell Educator therapy, control group receive conventional insulin therapy.|f|t|t|f
33877635|NCT04255056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877636|NCT00980200|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33877637|NCT05865678|||OTHER||CROSS_SECTIONAL|||||||
33877638|NCT04916873|||OTHER||OTHER|||||||
33877639|NCT03357627|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33877640|NCT00502762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877641|NCT06076655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877642|NCT05940792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757461|NCT04700501|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||implementation study||||
33757462|NCT05205902|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757463|NCT00990964|||||PROSPECTIVE|||||||
33757464|NCT01223482|||COHORT||RETROSPECTIVE|||||||
33757465|NCT02157779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757466|NCT01965405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757467|NCT04827485|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33757468|NCT01756352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757469|NCT05684627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757470|NCT01414621|||CASE_ONLY||PROSPECTIVE|||||||
33757471|NCT00941226|||COHORT||PROSPECTIVE|||||||
33757472|NCT03613805|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33757473|NCT00877084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757474|NCT04604080|||OTHER||RETROSPECTIVE|||||||
33757475|NCT02493296|||COHORT||PROSPECTIVE|||||||
33757476|NCT00200304|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33757477|NCT04000568|||CASE_CROSSOVER||PROSPECTIVE|||||||
33757478|NCT04119895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind randomized controlled trial|t|f|f|t
33969251|NCT02539095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969252|NCT03717610|NA|SINGLE_GROUP||OTHER||NONE||||||
33969253|NCT02373475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33757479|NCT01070901|||COHORT||PROSPECTIVE|||||||
33757480|NCT02592538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757481|NCT02475252|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877643|NCT01549236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877644|NCT03956095|||COHORT||PROSPECTIVE|||||||
33877645|NCT03470415|||OTHER||CROSS_SECTIONAL|||||||
33877646|NCT05382507|||COHORT||PROSPECTIVE|||||||
33877647|NCT03757910|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877648|NCT06180954|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a 2-part study.||||
33877649|NCT03098329|NA|SINGLE_GROUP||SCREENING||NONE||Community based screening of young men for chlamydia and gonorrhea, expedited treatment for positive subjects and their sexual partners||||
33877650|NCT02052271|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33877651|NCT05319392|||CASE_ONLY||PROSPECTIVE|||||||
33877652|NCT01344876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877653|NCT01320865|||COHORT||PROSPECTIVE|||||||
33877654|NCT03798158|||OTHER||PROSPECTIVE|||||||
33877655|NCT05562375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877656|NCT03189446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877657|NCT01415427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877658|NCT02121457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877659|NCT04041882|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877660|NCT02961985|||COHORT||PROSPECTIVE|||||||
33877661|NCT05572775|||COHORT||RETROSPECTIVE|||||||
33877662|NCT02302898|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877663|NCT06308276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial|f|f|f|t
33877664|NCT04223934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient blinded to assignment \[intervention versus control\].|Randomized, intervention versus control.|t|f|f|f
33877665|NCT05069857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877666|NCT06310980|NA|SINGLE_GROUP||OTHER||NONE||||||
33877667|NCT03946709|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33877668|NCT00419380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33877669|NCT05558839|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||This study adopted a quasi-experimental study design involving single-group pretest-posttest. The research participants were 41 community-dwelling older adults with mild or moderate dementia.||||
33877670|NCT02958488|NA|SINGLE_GROUP||OTHER||NONE||||||
33877671|NCT00220012|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33877672|NCT06130267|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33877673|NCT02150577|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877674|NCT02224859|NA|SINGLE_GROUP||||NONE||||||
33877675|NCT03864653|NA|SINGLE_GROUP||OTHER||NONE||Participants who have already enrolled in the methamphetamine outpatient treatment program, and who are still within their first two weeks of treatment, will be offered the chance to co-enroll in a low-intensity depression intervention.||||
33877676|NCT00806559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33877677|NCT02127190|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33877678|NCT04865068|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877679|NCT03847701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Each diet will be labelled Diet A or Diet B"|Each participant will be allocated to an intervention arm in a parallel design for 3 months of intervention|t|f|f|t
33877680|NCT01061814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877681|NCT00128544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33877682|NCT02326415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33757482|NCT01534026|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33757483|NCT05245890|||COHORT||PROSPECTIVE|||||||
33757484|NCT00604032|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33757485|NCT02969720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33757486|NCT05982184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757487|NCT04211064|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The participants were blinded to group allocation, as the measurements were performed after induction of general anesthesia. The investigator measuring the optic nerve sheath diameter was blinded to the group assignment.|Patients will be randomly divided into 2 groups. In the first group (Group 1), patients undergoing intraabdominal insufflation pressure 12 mmHg and deep neuromuscular block (TOF -- PTC 1-5), in the second group (Group 2) patients undergoing intraabdominal insufflation pressure 12 mmHg and moderate neuromuscular block (TOF 1-3) It would be classified.|t|f|t|f
33757488|NCT00853164|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33757489|NCT01560325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757490|NCT05098054|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33757491|NCT04082299|||COHORT||PROSPECTIVE|||||||
33757492|NCT03419364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All participants will receive study agent. 2.5 gm nicotinamide given orally in 3 divided doses (1000 in morning, 500 in afternoon, 1000 at bedtime).||||
33757493|NCT06433531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757494|NCT02899494|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757495|NCT03211364|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients do not know what are the intervention techniques or what is the control technique.||t|f|f|f
33757496|NCT02701010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757497|NCT04732091|||CASE_CONTROL||PROSPECTIVE|||||||
33757498|NCT04697264|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective analytical study||||
33757499|NCT03866941|||OTHER||PROSPECTIVE|||||||
33757500|NCT02599415|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757501|NCT05297955|||COHORT||RETROSPECTIVE|||||||
33757502|NCT00808587|||OTHER||PROSPECTIVE|||||||
33757503|NCT03418116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757504|NCT01995487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a Drug-Device combination Product.|t|f|f|f
33757505|NCT05727410|NA|SINGLE_GROUP||TREATMENT||NONE||single-center trial||||
33757506|NCT01878929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757507|NCT03861910|||COHORT||PROSPECTIVE|||||||
33969254|NCT04022070|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with fasciitis plantar pain||||
33757508|NCT06186141|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will not be blinded due to the need for opioid syringes to be readily identifiable on the ward.|This is a single site randomised embedded trial comparing the side effects of two standard intravenous opioid PCAs, namely morphine and oxycodone. There are two treatment arms, namely morphine and oxycodone, with patients randomised to each arm. Apart from the consent and randomisation process there will be no change to current pre-existing practices for PCAs and patient care.||||
33757509|NCT01559233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757510|NCT01751126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757511|NCT02929433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757512|NCT05294796|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, multicenter, non-inferiority, open labelled, randomized trial comparing different durations of antibiotherapy in osteosynthesis material infections after long bone fractures treated with debridement and material retention (see design algorithm and inclusion criteria). The CONSORT extension for pragmatic designs will be used.||||
33757513|NCT04188379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757514|NCT01964326|NA|||TREATMENT||NONE||||||
33757515|NCT04382105|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757516|NCT02694705|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33969255|NCT02532777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969256|NCT00900809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969257|NCT06247722|||COHORT||PROSPECTIVE|||||||
33757517|NCT04843787|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blind|Multiple Ascending Dose (MAD)|t|t|t|t
33757518|NCT03224182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized, multicenter, two-arm, double-blind, placebo-controlled study of Qapzola in participants with low- to intermediate-risk NMIBC.|t|t|t|f
33757519|NCT03768258|||COHORT||RETROSPECTIVE|||||||
33757520|NCT01367028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757521|NCT01270269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757522|NCT03769779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Envelopes that contain information regarding the coding of treatment and placebo will be provided to Sponsor, Site, and PI and kept in a secure location. Envelopes will be readily available for the investigator or site to open in the event that it becomes necessary to know which product a participant is taking for the sake of the participant health care. The sponsor must be notified of any unblinding by the site within 24 hours.|Randomized, Double-Blind, Placebo-Controlled, Parallel Study|t|t|t|t
33757523|NCT00673309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757524|NCT03511911|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33757525|NCT00717639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757526|NCT05736341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33757527|NCT00209573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877683|NCT04336631|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33877684|NCT02336828|||COHORT||PROSPECTIVE|||||||
33877685|NCT02423915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877686|NCT06391671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877687|NCT05034965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877688|NCT06110130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877689|NCT00264706|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33877690|NCT01259609|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877691|NCT01733472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33757528|NCT03171701|||COHORT||OTHER|||||||
33757529|NCT01876290|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757530|NCT04234880|||COHORT||CROSS_SECTIONAL|||||||
33757531|NCT03493230|NA|SINGLE_GROUP||OTHER||NONE||||||
33757532|NCT04467385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757533|NCT04995848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Mixed method randomised control trial||||
33757534|NCT00529490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757535|NCT00316173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757536|NCT06525766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757537|NCT04526535|||COHORT||PROSPECTIVE|||||||
33757538|NCT04050241|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33757539|NCT00350974|||CASE_CONTROL||PROSPECTIVE|||||||
33757540|NCT00648128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757541|NCT02062359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877692|NCT03106038||SEQUENTIAL||DIAGNOSTIC||NONE||beginning at the estimated target dose, the dosage was increased and decreased to confirm the near-optimal dose.||||
33877693|NCT03289650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877694|NCT06116825|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877695|NCT02025335|||COHORT||PROSPECTIVE|||||||
33894364|NCT04194229|||CASE_CONTROL||PROSPECTIVE|||||||
33894365|NCT05574153|||CASE_CONTROL||PROSPECTIVE|||||||
33894366|NCT02126488|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33894367|NCT01186432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894368|NCT01774916|NON_RANDOMIZED|PARALLEL||||NONE||||||
33894369|NCT05878509|||COHORT||PROSPECTIVE|||||||
33894370|NCT05975710|||COHORT||RETROSPECTIVE|||||||
33894371|NCT00687453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757542|NCT03027648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757543|NCT01116492|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33757544|NCT05374564|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed study will be a single-arm open-label longitudinal study of 18F-flutemetamol cardiac imaging before/after six months of tafamidis treatment in 12 patients with treatment naïve ATTR cardiac amyloidosis.||||
33757545|NCT03346720|||COHORT||PROSPECTIVE|||||||
33757546|NCT02464813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33757547|NCT03570398|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33757548|NCT03297203|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33757549|NCT04493931|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Cohort 1 to 3 are open-label cohorts. Cohort 4 is a double-blind cohort which contains blinded treatment of gepotidacin and placebo.|Cohort 1 and 2 are open-label, fixed sequence DDI cohorts. Cohort 3 is an open-label, 2-sequence, 2-period crossover randomized DDI cohort. Cohort 4 is a double-blind, placebo-controlled, randomized sequence study to investigate the safety and PK of gepotidacin.|t|f|t|f
33757550|NCT01613638|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969258|NCT04422847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking will be included|Patient will be randomized according to the interventional and control goup according to the day of surgery. The allocation between the groups will be 1:1||||
33969259|NCT01190306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969260|NCT06542042|||CASE_ONLY||PROSPECTIVE|||||||
33757551|NCT00265980|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Randomized, single-blind, crossover study: half of the subjects had placebo first and half had leptin first. The order does not affect data analysis.|t|f|f|f
33757552|NCT02745821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757553|NCT03637543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757554|NCT01266850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757555|NCT04757987|||CASE_CONTROL||PROSPECTIVE|||||||
33757556|NCT06332079|NA|SINGLE_GROUP||TREATMENT||NONE||"Two cohorts of patients will be included according to the two main prognostic populations in mCRC (left sided, RAS/BRAF wild-type and, right-sided and/or RAS mutated tumors) treated with different maintenance therapy (fluoropyrimidine plus anti-EGFR or bevacizumab).~A total of 23 patients will be enrolled in each cohort."||||
33757557|NCT00000279||||TREATMENT||||||||
33757558|NCT05382260|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757559|NCT02685644|||COHORT||PROSPECTIVE|||||||
33757560|NCT03682835|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized, parallel, single-blind, placebo-controlled|t|f|f|f
33877696|NCT04519892|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Over the study period, investigators will be blinded to participants' group status. The survey firm interviewers who conduct randomization, will not be involved in follow-up interviews. The interviewers who conduct the follow-up interviews in Ottawa will not have access to participants' group status. The coaches will not be involved in follow-up assessments. Given our description of study objectives, some participants may know their group status. Therefore, it is possible that some participants in the control group may try to find more information about the PDRC. At the follow-up assessments, participants will be asked if they have used any risk prediction tools over the study period. At the follow-up assessments, if participants develop a MDE, they will be encouraged to contact their family doctors and information about local mental health resources will be provided.|This is a randomized controlled trial with two arms. After screening and baseline assessment, participants will be randomized into: (1) Control group: Receiving PDRC only, and (2) Intervention group: Receiving PDRC + coach guidance. The trial was designed to compare the costs and effectiveness between the groups to inform future implementation. The randomization will be conducted in males and females separately because the MVRPs are sex-specific and the thresholds of high-risk differ by sex. Participants will be assessed at baseline and 3-month.|t|f|t|t
33877697|NCT00395564|||COHORT||RETROSPECTIVE|||||||
33877698|NCT03868332|||CASE_CONTROL||PROSPECTIVE|||||||
33877699|NCT02796846|||COHORT||PROSPECTIVE|||||||
33877700|NCT01783327|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33969261|NCT03575429|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|The investigator and diagnosticians for all measures will be kept blind to group assignment to treatment arm.|This study uses a 2-stage sequential multiple assignment randomized trial (SMART) design to optimize a menu of interventions by comparing the order and dose that best meet the needs of families. In stage 1, families will be randomly assigned to one of two study arms for 3 months. Stage 2 interventions will be for another 3 months and will be adapted based on the primary tailoring variable. Early responders will continue the same intervention and slow responders will be re-randomized to an adapted intervention for the next 3 months. The adaptations in stage 2 for slow responders include continuing the treatment arm, adding the other treatment arm, or increasing the dose of the treatment arm. Due to extenuating circumstances associated with COVID-19 from 2020-22, unplanned changes were necessary for slower recruitment than anticipated. Recruitment for the 2-stage SMART ended to allow completion of intervention and outcome measures. Recruitment continued for just stage 1 intervention.|f|f|t|t
33969262|NCT00162383|NA|SINGLE_GROUP||OTHER||NONE||||||
33969263|NCT00623025|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33877701|NCT00027339|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069124|NCT03445403|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|During offset analgesia testing, participants will be exposed to 3 heat pain paradigms: a constant heat stimulus, the offset analgesia paradigm, and a control paradigm. The participants will not be aware of the direction/pattern of temperature changes or which paradigm is being applied. Participants will not be allowed to view the computer screen so that it would not influence their response. The statistician will be unaware of the participants allocation of children with chronic pain vs. control|Response to a moderate heat pain \[defined as a heat stimulus producing pain rated at 50mm on a scale of 0-100 mm\] applied the the skin of the forearm using a paradigm known as offset analgesia will be compared in children with chronic pain disorders and healthy, age and sex matched controls.|t|f|f|t
33969264|NCT02934269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969265|NCT02793063|||COHORT||PROSPECTIVE|||||||
33969266|NCT03202628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969267|NCT03740100|NA|SINGLE_GROUP||TREATMENT||NONE||Oral administration||||
33969268|NCT05803278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969269|NCT01849939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969270|NCT06267599|||COHORT||RETROSPECTIVE|||||||
33969271|NCT03724721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969272|NCT01998685|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33969273|NCT04256993|||COHORT||RETROSPECTIVE|||||||
33969274|NCT03158428|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33969275|NCT03899337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969276|NCT01129154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969277|NCT04421794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This randomised controlled trial is in single blind. Participants will be informed about their treatment group after termination of the study.|Participants will be allocated to the intervention or control group using permuted block randomization with blocks of 4 or 6 patients on a 1:1 ratio.|t|f|f|f
33969278|NCT05806333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969279|NCT00213954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969280|NCT00650559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969281|NCT02393534|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33969282|NCT06226454|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33969283|NCT01357356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969284|NCT00007241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33969285|NCT02619994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969286|NCT04605952|||COHORT||RETROSPECTIVE|||||||
33969287|NCT02613065|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33969288|NCT06016933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969289|NCT05774106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A randomization of participating case managers will be performed. One intervention group will carry out the participatory action process and the other (control group) will carry out their professional activity normally.|First, a participatory intervention with nurses through the recording of four focus groups with the aim of understand, plan, change and maintain the practices surrounding the relationship therapy with their patients. Second, this intervention will be measured by administering scales to patients linked to the mental health case management program that provides service to different areas of the Barcelona Metropolitan Area. The variables to measure will be the quality of the therapeutic relationship, the recovery of the person and the overall functionality. These variables will be measured before and after finishing the participatory intervention.|t|t|f|f
33969290|NCT05907395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33969291|NCT00003966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969292|NCT03985501|||COHORT||RETROSPECTIVE|||||||
33969293|NCT02528578|NA|SINGLE_GROUP||OTHER||NONE||||||
33969294|NCT05446090|||COHORT||PROSPECTIVE|||||||
33969295|NCT03607006|RANDOMIZED|PARALLEL||TREATMENT||NONE|None because the two interventions requires different preoperative preparations , both the participants and the investigator can't be blinded .|"* A randomized clinical trial.~* Parallel group study.~* A trial will be carried out in hospital of Oral and Maxillofacial surgery department - Faculty of Oral and Dental Medicine - Cairo University .~* Equal randomization : participants with equal probabilities for intervention.~* Positive controlled : Both groups receiving treatment."||||
33969296|NCT02287337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969297|NCT03047382|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33969298|NCT06526897|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33969299|NCT05148546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label three-arm randomized phase II trial||||
33969300|NCT06270030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969301|NCT05141578|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33969302|NCT04119583|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33877702|NCT05204264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized according to the score on the Acceptance and Action Questionnaire-II (blocking factor) without knowing the treatment they were allocated to.||t|f|f|f
33877703|NCT05284760|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33877704|NCT05135650|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877705|NCT00405197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33877706|NCT04318860|||COHORT||PROSPECTIVE|||||||
33877707|NCT00916253|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33877708|NCT06499987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969303|NCT01244815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757561|NCT05849779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be followed up for primary and secondary endpoints by members of the research staff who will be unaware of the trial group allocation. Information on whether the primary and secondary outcomes occur will be collected and entered into the electronic web-based case report form (eCRF) by trial or clinical trained personal (clinical research associate), blinded to the allocation group, under the supervision of the local principal investigator (PI) or designee who will also be unaware of the trial group allocation.~Finally, the independent trial statistician and the members of the data monitoring and safety committee (DMSC) will also remain blinded for the allocation during analysis. However, the observation of differences in serious adverse events between the two groups will allow, for safety reasons may the DMSC deem necessary, to unblind allocation groups."|Investigator-initiated, single-center, prospective, randomized, stratified, parallel-group clinical trial with blinded outcome assessment and concealed allocation of patients at risk of developing the ARDS to a strategy of inhaled sedation with sevoflurane or to a strategy of current intravenous sedation practice.|f|f|f|t
33757562|NCT05738993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757563|NCT03921814|NA|SINGLE_GROUP||TREATMENT||NONE|Periodic photographs are taken of the treatment areas. The photos are labeled with a randomized bar code label. Hair counters will review the photos and count the hairs|All enrolled subjects will be treated with the investigation device.||||
33757564|NCT02432989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757565|NCT03026023|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33757566|NCT01055548|||COHORT||RETROSPECTIVE|||||||
33757567|NCT03474302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will not know the group randomization of the participants.|The randomized controlled trial will assign insufficiently active African American adults aged 65-85 to an intervention or successful aging control group|f|f|f|t
33757568|NCT06344390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757569|NCT00512772|||COHORT||PROSPECTIVE|||||||
33757570|NCT04717414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757571|NCT04279314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757572|NCT01351298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757573|NCT03475849|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757574|NCT01742377|||CASE_ONLY||PROSPECTIVE|||||||
33757575|NCT06579638|||CASE_ONLY||PROSPECTIVE|||||||
33757576|NCT02083016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757577|NCT04750967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757578|NCT01160848|RANDOMIZED|PARALLEL||||NONE||||||
33757579|NCT04076410|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants will be recruited among those patients (both males and females) from 5 to 18 years with suspected or confirmed diagnosis of generalised epilepsy with photosensitivity or photosensitive epilepsy (PSE) who comply with the established inclusion criteria.~No control patients will be required, since each patient will be tested with the different lenses in a specific order and will be, in turn, his/her own control. No randomisation will be carried out in our study."||||
33757580|NCT05429970|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757581|NCT05959343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757582|NCT02017054|||COHORT||PROSPECTIVE|||||||
33757583|NCT00431587|||||PROSPECTIVE|||||||
33757584|NCT01185444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757585|NCT02492854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757586|NCT05085925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757587|NCT01989143|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33757588|NCT00001507||||TREATMENT||||||||
33757589|NCT02139098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757590|NCT05001360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757591|NCT04334265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757592|NCT02403102|||COHORT||PROSPECTIVE|||||||
33757593|NCT02298361|||||PROSPECTIVE|||||||
33757594|NCT01334749|||COHORT||PROSPECTIVE|||||||
33757595|NCT06453655|RANDOMIZED|PARALLEL||OTHER||SINGLE|Experienced endoscopists, who were unaware of the instructions given to the subjects, performed the colonoscopies. The endoscopist who performed the procedure added the visual assessment score to the patient's colonoscopy report, regardless of their participation in the study.||f|f|f|t
34069125|NCT03216369|||CASE_ONLY||CROSS_SECTIONAL|||||||
34069126|NCT02006433|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34069127|NCT02445742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757596|NCT02751684|||OTHER||OTHER|||||||
33757597|NCT05742828|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969304|NCT04460599|||COHORT||RETROSPECTIVE|||||||
33969305|NCT02314533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969306|NCT01741480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34069128|NCT03365518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969307|NCT02912013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969308|NCT00665210|||CASE_ONLY||PROSPECTIVE|||||||
33969309|NCT05245981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969310|NCT04835766|||COHORT||PROSPECTIVE|||||||
33969311|NCT05608590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969312|NCT03154333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757598|NCT03846102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Syringes with either placebo or levobupivacaïne will be prepared under aseptic conditions and blinded by the hospital pharmacy. A supply of at least six syringe packs will be kept in the emergency department. Each pack will contain three different doses of either levobupivacain or placebo, of which one will be used according to the weight of the patient. When medication is used, the nurse, physician or researcher will inform the pharmacy, so new medication can be prepared. The hospital pharmacy will keep track of randomisation and register the allocation to either treatment or placebo. Allocation will remain blinded until all patients are included and all data is included.|double-blinded randomized placebo-controlled trial|t|t|t|t
33757599|NCT00002892|RANDOMIZED|||TREATMENT||||||||
33757600|NCT01844271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33757601|NCT02658630|NA|SINGLE_GROUP||TREATMENT||NONE|The outcomes assessor is masked as to the prediction model and to particulars of performance during the intervention, but knows that there is a single group design.|||||
33894372|NCT05837754|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Stratified block randomization, Sequentially numbered, sealed, opaque envelopes|Randomized, double blind, placebo controlled, parallel group|t|t|t|f
33894373|NCT03553173|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized open-label parallel-group trial.||||
33894374|NCT01349738|||CASE_CONTROL||PROSPECTIVE|||||||
33894375|NCT05635708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894376|NCT00070447||||TREATMENT||NONE||||||
33894377|NCT01068561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969313|NCT05378087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-randomized controlled concurrent trial. According to the patients' voluntary choice, they are enrolled on the surgery staging group or image staging group. All patients are evaluated by CT(≥32 slices) or MRI(≥1.5T) or PET/CT. The criteria for positive pelvic or para-aortic lymph nodes (one of the following): ① CT or MRI show more than one positive lymph node with a short diameter ≥ 15mm; ② PET/CT shows more than one positive lymph node with SUV ≥ 2.5; ③ If CT or MRI show positive lymph node with a short diameter between 10mm and 15mm, PET / CT should further verify that it is a positive lymph node with SUV ≥ 2.5.||||
33969314|NCT02807766|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33969315|NCT04756141|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969316|NCT02103803|||COHORT||PROSPECTIVE|||||||
33969317|NCT05202691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"To participants: the intervention applied to both groups is the same Physical Therapy Treatment protocol and the use of the same magnetic field therapy device during the same time (for the sham group: the device is disconnected and the sound is simulated with a recording).~The investigator assessing the outcomes is blinded to the group assignments"|This study is a randomized controlled trial evaluating clinical effects in people with low back pain who are divided into 2 groups of treatment, where the interventions are conducted in 3 sessions provided during 3 weeks.|t|f|t|t
33877709|NCT06076915|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The outcome evaluator of the pre- and post-measurement was blinded to group allocation.|The study is designed as a two-arm crossover pilot trial. The 12-week lasting study includes three assessment points (T0, T1, T2). After signing informed consent, participants will be randomly allocated to either group 1 (G1) or group 2 (G2), using simple (unrestricted) randomization based on a random-number table. All participants perform baseline assessments at T0. Depending on their random allocation to group 1 (G1) or group 2 (G2), they will either continue with their usual daily work life (G2), or they will start the intervention period (G1) , where they will implement the exergame training plan in their working schedule. After six weeks, both groups will perform the T1 assessments, and the program will be switched, meaning G2 will perform the exergame training and G1 will have their control period. After completing the intervention at week 12, both groups will perform the final assessments (T2).|f|f|f|t
33877710|NCT04791046|||COHORT||RETROSPECTIVE|||||||
33877711|NCT00406302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969318|NCT05272098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969319|NCT06172010|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled open label trial with a non-inferiority design||||
33969320|NCT02208583|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33969321|NCT04426526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969322|NCT05058859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969323|NCT04881526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind||t|f|t|f
33757602|NCT02606279|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757603|NCT04791280|||COHORT||PROSPECTIVE|||||||
33757604|NCT03021356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757605|NCT04181970|||CASE_ONLY||OTHER|||||||
33757606|NCT00290862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757607|NCT05446324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757608|NCT03893721|||CASE_CONTROL||RETROSPECTIVE|||||||
33757609|NCT01705496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757610|NCT00406003|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757611|NCT01774864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757612|NCT05391750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757613|NCT04439643|||COHORT||RETROSPECTIVE|||||||
33757614|NCT02591134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33877712|NCT00287625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877713|NCT05822687|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33757615|NCT02184754|||COHORT||PROSPECTIVE|||||||
33757616|NCT01525316|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757617|NCT06579274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This clinical trial will be double-blind, with participants and investigators unaware of which treatment arm they have been assigned to.~Blinding will be done automatically by code assignment via the RedCap electronic database. Only the investigating physician can assign the code to the patient and unblind the patient at the same time. The data manager will have a list of codes for possible unblinding.~Unblinding the patient for any reason is considered a protocol deviation. The reason for unblinding will be described in the source documentation and recorded in the eCRF. In an emergency, the investigator may perform unblinding himself according to ICH GCP E6(R2) paragraph 4.7."|The clinical trial is planned as a multicenter, prospective, randomized, double-blind, placebo-controlled Phase II clinical trial, a so-called therapeutic exploratory study. This is an investigator-initiated, academic clinical trial to evaluate the safety and efficacy of parecoxib in hospitalized patients with spontaneous SAH.|t|t|f|f
33757618|NCT05145387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757619|NCT03984370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blinded, randomised, 3-period, 3-treatment, crossover study comprising 3 separate treatment days|t|f|t|f
33757620|NCT01259050|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757621|NCT00415610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open treatment assignment was employed because it is not safe to conceal SBP measurement. Patient data routinely entered by clinical staff were used to evaluate safety.|Staged intensity levels of rapid intravenous antihypertensive control for elevated SBP in patients with intracerebral hemorrhage were implemented in 3 sequential treatment arms to assess the feasibility and tolerability (safety) of this treatment.||||
33757622|NCT06326827|||COHORT||PROSPECTIVE|||||||
33757623|NCT01250990|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33757624|NCT06011772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877714|NCT01052298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877715|NCT03354754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A blinded evaluator performed the safety and efficacy assessments||f|f|f|t
33877716|NCT03346460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757625|NCT06576882|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 assignment.||||
33877717|NCT04448587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877718|NCT02706730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877719|NCT04422249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Two different treatments are conducted on the participant base on the randomized choices||f|f|t|t
33877720|NCT02899039|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877721|NCT06493994|||OTHER||PROSPECTIVE|||||||
33877722|NCT03615183|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33877723|NCT01797211|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33877724|NCT02236052|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33877725|NCT01778361|||COHORT||PROSPECTIVE|||||||
33877726|NCT02355561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877727|NCT05299437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877728|NCT04455373|||COHORT||RETROSPECTIVE|||||||
33877729|NCT05598372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33969324|NCT00146237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969325|NCT00202553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969326|NCT01403142|||CASE_ONLY||PROSPECTIVE|||||||
33969327|NCT04646122|||CASE_CONTROL||RETROSPECTIVE|||||||
33969328|NCT06070285|||CASE_CROSSOVER||PROSPECTIVE|||||||
33969329|NCT02903433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969330|NCT03013166|||COHORT||RETROSPECTIVE|||||||
33969331|NCT05118282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969332|NCT04283383|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||quasi-experimental study,||||
33969333|NCT00285545|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34069129|NCT00493311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069130|NCT01319487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877730|NCT03183882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33877731|NCT05913453|||COHORT||RETROSPECTIVE|||||||
33877732|NCT04854681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877733|NCT03393767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877734|NCT05269758|||CASE_ONLY||PROSPECTIVE|||||||
34069131|NCT00298363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757626|NCT02987075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757627|NCT03702842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized to receive either 16 sessions of locomotor training with lower or higher dosage tsDCS, but will be unaware of the stimulation dosage level.||t|f|f|f
33757628|NCT03757221|NA|SINGLE_GROUP||TREATMENT||NONE||We plan a single-arm non-randomized open label phase II study with a Fleming one stage hypothesis testing for the primary endpoint of VGPR (Very Good Partial Response) + CR (Complete Response) Rate during the twelve months follow-up. The efficacy of Daratumumab plus Ixazomib will be evaluated in comparison to a minimally effective lower threshold level of VGPR + CR.||||
33757629|NCT05272566|||COHORT||PROSPECTIVE|||||||
33757630|NCT06218225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Different batch code assigned to products, same labeling|Randomized double blind verum vs placebo|t|t|f|f
33757631|NCT05602051|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33757632|NCT04027348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757633|NCT00855062|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33757634|NCT03924479|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33757635|NCT00598494|||CASE_ONLY||PROSPECTIVE|||||||
33757636|NCT06236867|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The patients did the pain scoring without knowing which group they were in. Patients are blinded.~In order to prevent the groups from being affected by each other, a inspection curtain was placed between the dialysis machines during the applications.~The data were coded as A, B and C groups and sent for statistical analysis. The outcomes assesor doing the analysis here is blinded."|"After obtaining the necessary permissions for the research, the patients who were followed up in the hemodialysis unit of X,Y, Z Hospitals were randomly divided into three groups (Kaleidoscope application, ice application and control group).~Patients were made to sign written voluntary consent forms by the researchers.After the patients were transferred to the randomized program for the arrival days and TC numbers for the dialysis session, they were assigned to the experimental and control groups.~The patients' pain levels were evaluated during 3 dialysis sessions. The pain level was evaluated without the procedure on the first day. 2 and 3. on the other hand, pain levels were evaluated after the interventions per day.~The data in the research are; Patient Diagnosis Form, Numerical Rating Scale and Life Signs Follow-up Form and Kaleidoscope Application Patient Experience Form, It was collected using the Patient Experience Form Related to Ice Application."|t|f|f|t
33757637|NCT03062462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877735|NCT02271503|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33877736|NCT06471868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877737|NCT01776073|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757638|NCT02379182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757639|NCT01519492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757640|NCT05308550|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Two cohorts, the second with a modified version of the test.||||
33757641|NCT04398537|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33757642|NCT04457557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only investigator who prepared the local anesthetics knows the group. Nerve block performer and outcome assessor are applied masking.|Randomized controlled trial One group received interscalene block with 0.15% of ropivacaine One group received interscalene block with 0.5% of ropivacaine|t|t|f|t
33757643|NCT03958838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention group and Control group||||
33969334|NCT04520854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The Specific Aims will be addressed using a single-blind, parallel-am randomized control trial. The independent variables will be group (Telehealth, usual care) and time (baseline, post-intervention, 1-month follow-up). Participants assigned to the Telehealth group will complete a 2-week intervention consisting of 5 live-video sessions. A 2-week intervention will be used to allow for the normal recovery of acute symptoms and account for the average number of supervised physical rehabilitation visits (5 sessions) currently recommended. The usual care group will be instructed to follow their physicians' orders during the two-week intervention period. The dependent variables for will be assessed on the injured limb only for both groups. A Co-I will collect all dependent variables and will be blinded to group assignment.|f|f|t|t
33757644|NCT03154489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33757645|NCT00995982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757646|NCT05473754|||CASE_CONTROL||PROSPECTIVE|||||||
33757647|NCT01620905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877738|NCT02057783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877739|NCT04258943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877740|NCT05105490|||COHORT||PROSPECTIVE|||||||
33877741|NCT01700556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33877742|NCT05051774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants and outcomes assessors only will be blinded in this study.|A single-blind parallel randomized control trial|t|f|f|t
33877743|NCT02797236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33877744|NCT02161679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877745|NCT05616260|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, cross-over trial.|t|t|t|t
33877746|NCT02875639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33877747|NCT02329769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877748|NCT01477242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877749|NCT04402190|||COHORT||PROSPECTIVE|||||||
33877750|NCT05754346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877751|NCT04793295|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Open Label||||
33877752|NCT01586585|||COHORT||PROSPECTIVE|||||||
33877753|NCT03740256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877754|NCT05680363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877755|NCT02370875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33877756|NCT04312009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757648|NCT01458470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757649|NCT02803554|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33757650|NCT06452056|||COHORT||PROSPECTIVE|||||||
33877757|NCT04441229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877758|NCT04145414|NA|SINGLE_GROUP||OTHER||NONE||||||
33877759|NCT05472727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877760|NCT04517188|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33877761|NCT00881777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33877762|NCT06198673|||COHORT||PROSPECTIVE|||||||
33877763|NCT01826552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877764|NCT03466177|||COHORT||PROSPECTIVE|||||||
33877765|NCT04245020|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33877766|NCT03156400|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877767|NCT06047548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3b|t|f|t|f
33877768|NCT05880342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33877769|NCT05080010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877770|NCT03042208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969335|NCT02759952|||COHORT||PROSPECTIVE|||||||
33969336|NCT06528483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969337|NCT01042977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969338|NCT04011085|||COHORT||CROSS_SECTIONAL|||||||
33969339|NCT03145883|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969340|NCT00377026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069132|NCT05647720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors will be blind. The patients name will be sealed from the pre- and post-radiographs and study models. Then two assessors will carry out, blindly and independently, the measurements and analysis of the study||f|f|f|t
33757651|NCT02327962|||COHORT||PROSPECTIVE|||||||
33877771|NCT06162039|||COHORT||RETROSPECTIVE|||||||
33877772|NCT05149690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33877773|NCT01210339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33877774|NCT01307475|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877775|NCT01148446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877776|NCT02435355|RANDOMIZED|PARALLEL||||NONE||||||
33877777|NCT00304889|||COHORT||RETROSPECTIVE|||||||
33894378|NCT04971590|||COHORT||PROSPECTIVE|||||||
33894379|NCT05087888|||COHORT||PROSPECTIVE|||||||
33877778|NCT05136937|NA|SEQUENTIAL||TREATMENT||NONE||Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 5×10\^8 TCID50/mL||||
33877779|NCT04650373|||COHORT||RETROSPECTIVE|||||||
33877780|NCT02148380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877781|NCT00486408|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33877782|NCT00006142||||PREVENTION||||||||
33877783|NCT00485212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969341|NCT06527989|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Preoperative: IV administration of prophylactic antibiotic 2gram ceftriaxone 30 to 60 min before surgical incision Intraoperative: if there is blood loss~Postoperative:~* Group A : Single dose 2grams of ceftriaxone in 1st 24 hr~* Group B: Multiple doses 2 grams of ceftriaxone every 24 hrs for 5 days Follow up assessment of surgical wound 2 weeks after surgery for both groups then lately after 3 months"||||
33969342|NCT04365283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969343|NCT00171782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969344|NCT01179178|||CASE_CONTROL||PROSPECTIVE|||||||
33969345|NCT01167855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33969346|NCT01795703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877784|NCT01751308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877785|NCT06309459|||COHORT||RETROSPECTIVE|||||||
33877786|NCT01324232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877787|NCT01029067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877788|NCT01703416|||COHORT||PROSPECTIVE|||||||
33877789|NCT01056146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877790|NCT02238444|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877791|NCT02905786|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33877792|NCT01210274|||CASE_ONLY||PROSPECTIVE|||||||
33877793|NCT03258112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877794|NCT04051437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877795|NCT03516760|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation scheme; Single patient cohorts on the first three dose levels, 3+3 afterwards.||||
33877796|NCT01727609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969347|NCT04719247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33969348|NCT04115449|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blinded randomized control study|This is a prospective, randomized double blinded control study which will be conducted in department of anesthesia and surgical Intensive care unit at Theodor Bilharz Research Institute after approval by research ethics committee and patient informed consent. 40 patients will be enrolled in the study and divided into two groups either (Dexa group (D) or Control group (C).|t|t|t|t
33969349|NCT05481060|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33969350|NCT04182750|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33969351|NCT04317781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969352|NCT03028883|||COHORT||RETROSPECTIVE|||||||
33969353|NCT03456869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969354|NCT02657720|NA|SINGLE_GROUP||||NONE||||||
33877797|NCT01018498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877798|NCT05218785|||COHORT||PROSPECTIVE|||||||
33877799|NCT02278172|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33877800|NCT02098174|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877801|NCT04222166|||COHORT||OTHER|||||||
33877802|NCT00401752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33877803|NCT02420873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877804|NCT00307151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877805|NCT01725009|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33877806|NCT01864538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877807|NCT01081067|||COHORT||PROSPECTIVE|||||||
33877808|NCT01653288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33877809|NCT02830880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877810|NCT06394713|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33877811|NCT05933369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor assessing patient outcomes will be blind. The participants and the intervention providers (Clinical pharmacists) will not be blind for patient assignment to one of the trial groups.||f|f|f|t
33877812|NCT06203990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877813|NCT04677244|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||prospective monocentric study||||
33877814|NCT05958472|||CASE_CROSSOVER||PROSPECTIVE|||||||
33877815|NCT01018875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877816|NCT02179333|||COHORT||PROSPECTIVE|||||||
33877817|NCT01957358|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33877818|NCT05706389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants|t|t|t|t
33877819|NCT06492096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877820|NCT04220996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877821|NCT00299832|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877822|NCT03776175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877823|NCT04793425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877824|NCT05099692|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877825|NCT01000662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877826|NCT02556398|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33877827|NCT04336761|||COHORT||PROSPECTIVE|||||||
33877828|NCT04978207|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A culturally-religiously tailored COVID-19 testing and linkage to care arm versus a standard COVID-19 education arm in African American churches||||
33877829|NCT00886301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877830|NCT01817309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877831|NCT05779072|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33877832|NCT01369914|||CASE_CONTROL||PROSPECTIVE|||||||
33877833|NCT01931358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33877834|NCT02286947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877835|NCT03937856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who choose the intervention arm will be asked to use the Calm application for 30 days.||||
33877836|NCT03900871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33877837|NCT04797143|||CASE_ONLY||RETROSPECTIVE|||||||
33877838|NCT04004884|||COHORT||RETROSPECTIVE|||||||
33877839|NCT01452399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877840|NCT00744874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877841|NCT01591512|||COHORT||PROSPECTIVE|||||||
33877842|NCT01803360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877843|NCT04440995|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33877844|NCT05721235|NA|SINGLE_GROUP||TREATMENT||NONE||The primary objective is to determine the safety and tolerability for up to 12 months of treatment with Azstarys based on incidence of adverse events||||
33877845|NCT06500364|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877846|NCT00630630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33877847|NCT05073809|||COHORT||CROSS_SECTIONAL|||||||
33877848|NCT01578733||CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33877849|NCT05376176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757652|NCT06214845|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre, randomised, controlled, superiority clinical trial. Participants will be randomly assigned to one of the two groups of the study (manual or automated REX) with a 1:1 allocation as per a computer generated randomisation list stratified by site and type of respiratory support as follows: low flow-oxygen vs noninvasive respiratory support (i.e., high low oxygen or continuous positive airway pressure or noninvasive ventilation) vs invasive ventilation.||||
33757653|NCT04147039|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33757654|NCT02273830|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33877850|NCT04001361|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Sham laser means laser not turned on. Sham marrow means incision in skin made but no marrow drawn. Patient under conscience sedation. MRI and outcomes measures independently measured.|Blinded trial. Three groups. Sham, laser only, laser plus marrow. Stage 2 and 3 OA of one or both knees|t|t|f|t
33877851|NCT02997579|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33757655|NCT00869479|||||CROSS_SECTIONAL|||||||
34069133|NCT03066583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069134|NCT02425462|||COHORT||PROSPECTIVE|||||||
33877852|NCT01544946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069135|NCT02259686|RANDOMIZED|CROSSOVER||||NONE||||||
34069136|NCT00369772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069137|NCT03679819|||CASE_ONLY||PROSPECTIVE|||||||
34069138|NCT05719272|||CASE_ONLY||CROSS_SECTIONAL|||||||
34069139|NCT04956939|||CASE_CONTROL||PROSPECTIVE|||||||
34069140|NCT05541913|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34069141|NCT03801577|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects are screened for eligibility and on consent, historical data from liver fat measurements With CAP scores, will be collected from the previous 6 months. Only subjects With no, or poor response to lifestyle recommendations will be enrolled.||||
34069142|NCT03438864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069143|NCT03825822|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinding will only be possible for the data analysts because no identifiable information about the sites, including the infants in the NICUs, will be available in the database or data extracted from the database. The code associating units with the data will be securely stored by the lead site, kept separate from the data, and only made available to the lead site Research Team for analyses purposes.||f|f|f|t
34069144|NCT04835883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069145|NCT02173379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069146|NCT00000256|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34069147|NCT00551525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069148|NCT00664365|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34069149|NCT02799121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877853|NCT03783390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||To assess the effectiveness of a physical activity intervention on eating behavior in adolescents; OW/OB inactive adolescents will be randomly assigned to a 3-month exercise intervention (Exercise +Newsletter), or a control condition (Newsletter).||||
33877854|NCT02626195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877855|NCT03638232|||COHORT||PROSPECTIVE|||||||
33877856|NCT01029366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877857|NCT00083993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33877858|NCT03603496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877859|NCT02135692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877860|NCT05687461|||COHORT||OTHER|||||||
33877861|NCT00428974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877862|NCT02634723|||COHORT||RETROSPECTIVE|||||||
33877863|NCT05446545|||COHORT||PROSPECTIVE|||||||
33877864|NCT05453331|||COHORT||PROSPECTIVE|||||||
33877865|NCT01665144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877866|NCT01113827|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33877867|NCT06479655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized control trial, two arms||||
33877868|NCT01263639|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33877869|NCT05104580|||CASE_CONTROL||PROSPECTIVE|||||||
33877870|NCT02884778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877871|NCT05319639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877872|NCT03261622|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Alle patients are stimulated sub-sensory in (3x4 weeks) and will be blinded. The investigators will not participate in the randomization, and setting of the stimulation amplitude.|Patients will be randomized to either control group (Stimulation amplitude at 90% of sensory threshold) or intervention arm (different stimulation amplitude - 0.05 V, 50 and 90% of sensory threshold)|t|f|t|f
33877873|NCT03449212|||CASE_CONTROL||PROSPECTIVE|||||||
33877874|NCT00689871|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33877875|NCT01068028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877876|NCT05259982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877877|NCT03801668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877878|NCT02733770|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877879|NCT03691974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877880|NCT02171585|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877881|NCT00005870|RANDOMIZED|||TREATMENT||||||||
33877882|NCT00381264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877883|NCT02103569|NA|SINGLE_GROUP||||NONE||||||
33877884|NCT06407180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33877885|NCT05376514|||COHORT||PROSPECTIVE|||||||
33877886|NCT05903846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Massage was applied to the Oketani massage group by a midwife working in the clinicThe outcome assessor does not know who the groups are.|"Oketani massage,The part between the breast and the base of the lower pectoral muscle is called the oketani. It is a manual massage technique developed to encourage breastfeeding in breastfeeding problems such as insufficient milk production and mastitis. It is a massage that stimulates the breast, relaxes it and is painless. There are 8 different stages in massage. Each set lasts 1 minute, the massage continues for 15-20 minutes."|f|f|f|t
33877887|NCT00715533|||COHORT||PROSPECTIVE|||||||
33877888|NCT02426216|||||PROSPECTIVE|||||||
33877889|NCT02902952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877890|NCT04712929|||CASE_CONTROL||PROSPECTIVE|||||||
33877891|NCT04307290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomization sequence was created using Stata 9.0 (Stata Corp, College Station, TX, USA) statistical software and was stratified by center with a 1:1 allocation using random block sizes of 4. Assignments were concealed in sealed envelopes. Participants were randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups: DEX group (n = 40) received intravenous dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery), and CON group (n = 40) received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.~Patients, attending anesthesiologists responsible for patient care, and nurses were all blinded to the anesthetic agent during the study period."|dexmedetomidine (0.5 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg/h infusion from 10 min before the start of surgery to the end of surgery), and CON group (n = 40) received an equivalent volume of normal saline bolus and infusion as placebo until the end of surgery.|t|f|f|t
33877892|NCT00928551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33877893|NCT05324046|||COHORT||PROSPECTIVE|||||||
33877894|NCT04270474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The principle investigator and all outcome assessor will be blinded to the arm assignment of the subjects. No access to unblinded data will be provided to blinded staff.|This cluster-randomized trial will randomize at the level of physicians. Physicians agreeing to participate in the trial will be randomized to intervention or usual care in blocks of two or four. Physician randomization status will determine participants' study group. Physicians randomized to usual care will not have access to the intervention. Study outcomes will be collected directly from participants; no outcomes will be collected from physicians.|f|f|t|t
33969355|NCT01402661|||COHORT||PROSPECTIVE|||||||
33969356|NCT01328392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757656|NCT06532318|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|All participants will have the same assessment and have blood drawn for CBC. Opaque tape masking of the syringes will be done so that care giver and patients are not aware of interventional drug given.||t|t|f|f
33757657|NCT06105242|||COHORT||PROSPECTIVE|||||||
33757658|NCT06352372|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, open label study comparing 15 individuals with active seizures and 15 individuals with EEG abnormalities before and after treatment with, near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)||||
33757659|NCT03376867|||COHORT||PROSPECTIVE|||||||
33757660|NCT00900874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877895|NCT01227330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877896|NCT03433014|RANDOMIZED|PARALLEL||OTHER||SINGLE||The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The control group will not receive any local infiltrative agent.|f|f|t|f
33877897|NCT02442973|||COHORT||PROSPECTIVE|||||||
33877898|NCT03119519|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized phase II trial of first line chemotherapy or targeted therapy plus local definitive radiotherapy or not for patients with synchronous oligometastatic non-small cell lung cancer||||
33877899|NCT03375450|||COHORT||RETROSPECTIVE|||||||
33877900|NCT05540197|||COHORT||PROSPECTIVE|||||||
33877901|NCT04609852|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33877902|NCT02813200|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33877903|NCT00812214|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33877904|NCT03621371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894380|NCT04392986|NA|SINGLE_GROUP||PREVENTION||NONE||Single group parallel study||||
33894381|NCT00003554||||TREATMENT||||||||
33969357|NCT03422783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Pilot study||||
33969358|NCT01224210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969359|NCT03536676|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969360|NCT04616690|||COHORT||PROSPECTIVE|||||||
33969361|NCT02274467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877905|NCT05915442|NA|SEQUENTIAL||TREATMENT||NONE||Simon Two-Stage design: In the first stage, trial will enroll 14 patients. If two or more patients show progression at 6 months, the study is terminated at the end of stage I. However, if 13 of the 14 remain free from progressive disease at 6 months, then the study would move onto the second stage. In this stage, n=9 additional patients will be enrolled, for a total of 23 total. If 21 of the 23 patients remain progression-free at 6 months, then the null hypothesis is rejected, and we will consider the addition of quemliclustat, etrumadenant, and zimberelimab to SBRT worthy of further study.||||
33877906|NCT03986489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877907|NCT00172848|||DEFINED_POPULATION||OTHER|||||||
33877908|NCT04096911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877909|NCT06463496|||COHORT||CROSS_SECTIONAL|||||||
33877910|NCT04942925|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Subjects will receive treatment based upon the randomized treatment sequence assignment|t|f|t|f
33877911|NCT01948687|||CASE_ONLY||PROSPECTIVE|||||||
33877912|NCT03086733|NA|SINGLE_GROUP||TREATMENT||NONE||single center, open label, single arm Phase II study of a pre-operative window of metformin treatment in stages I - IIIA NSCLC||||
33877913|NCT04695964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a non-randomised prospective cohort study design.||||
33877914|NCT03837080|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|The whole group will be randomized (cluster randomization) to either Intervention or Control arm. Each group consists of 8 to 12 patients.|Cluster randomization (groups of patients will be randomly assigned to the Intervention or the Control arm)||||
33877915|NCT00653003|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33877916|NCT03473496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877917|NCT01993693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877918|NCT00973076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877919|NCT03502993|||CASE_CONTROL||PROSPECTIVE|||||||
33877920|NCT02823977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877921|NCT04251637|||COHORT||PROSPECTIVE|||||||
33877922|NCT01422655|||COHORT||PROSPECTIVE|||||||
33877923|NCT00561197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877924|NCT00779376|RANDOMIZED|CROSSOVER||||NONE||||||
33877925|NCT02911922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877926|NCT06100341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877927|NCT04360759|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, multi-centre, open label, randomised controlled trial||||
33877928|NCT02549703|||COHORT||PROSPECTIVE|||||||
33877929|NCT00899184|||OTHER||RETROSPECTIVE|||||||
33877930|NCT03759535|||CASE_ONLY||PROSPECTIVE|||||||
33877931|NCT04381910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877932|NCT05300178|||COHORT||PROSPECTIVE|||||||
33877933|NCT06083974|||COHORT||RETROSPECTIVE|||||||
33877934|NCT00096863|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33877935|NCT04901143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877936|NCT01339559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877937|NCT04800198|||CASE_ONLY||PROSPECTIVE|||||||
33877938|NCT04325542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Hepatitis B prevalence study of woman attending antenatal care||||
33877939|NCT04901299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877940|NCT05018234|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33877941|NCT05417854|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33877942|NCT01440621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33877943|NCT05787262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33877944|NCT02455531|||COHORT||PROSPECTIVE|||||||
33877945|NCT03445091|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33877946|NCT04242082|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877947|NCT06424782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877948|NCT00211146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877949|NCT01332539|||COHORT|||||||||
33877950|NCT01902290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877951|NCT06301880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All surgical procedures and measurements were carried out by a single surgeon (MBI) who was blinded to the topical agent which was applied.||t|t|t|t
33877952|NCT00457327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877953|NCT04363775|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33877954|NCT01606111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877955|NCT04429178|||COHORT||PROSPECTIVE|||||||
33877956|NCT00978029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877957|NCT03269123|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial with a single arm||||
33894382|NCT01770184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33877958|NCT04345744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|After surgery, patients will be randomly assigned to study groups corresponding to mouth rinse prescription. The mouth rinse will be assigned by an experimenter not involved in the following steps of the study, in order to maintain the examiner blind. The patient will receive a non-labelled mouth rinse to avoid biases both of the examiner and the patient|Single-centre randomized, parallel design, clinical trial with a 2 week follow-up|t|t|t|t
33877959|NCT04807348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33877960|NCT04780620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research personnel involved in data collection will be blind to participants' treatment condition (single blind). In addition, coders for the interaction task and speech sample will be blind to treatment condition (intervention versus control) and measurement time point (baseline vs. posttreatment).||f|f|f|t
33969362|NCT03263520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The outcomes assessor and investigator does not have contact with the patient or care provider at the moment of randomization and the study purpose. The investigator just apply the bioelectrical impedance analysis and helps the patient about doubts on the Quality of Life questionnaire of EORTC ( QLQ-C30)|"Randomization will be made at the time of study enrollment by , where patients randomly selected as even number will be included in group 1 and those selected as odd number in group 2Group 1 (G1): the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily for both sexes.~Group 2 (G2): The patient will use corticosteroids (dexamethasone) at a dose of 4 mg daily."|f|f|t|t
33969363|NCT02801591|||COHORT||PROSPECTIVE|||||||
33969364|NCT02424565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33969365|NCT01181856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969366|NCT00568269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969367|NCT00326885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877961|NCT01784861|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33877962|NCT00704782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877963|NCT04319328|||OTHER||PROSPECTIVE|||||||
33877964|NCT01762852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33877965|NCT00062335||||TREATMENT||NONE||||||
33877966|NCT06115187|||CASE_ONLY||CROSS_SECTIONAL|||||||
33877967|NCT05903183|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33877968|NCT02105532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877969|NCT06154057|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969368|NCT02568995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969369|NCT04249206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969370|NCT02625766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969371|NCT04206852|||COHORT||PROSPECTIVE|||||||
33877970|NCT03401528|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This study has two portions: a single ascending dose (SAD) portion consisting of 4 sequential dose escalation cohorts, and a repeat dose (RD) portion. In both study portions, subjects are randomized to receive either a study intervention (AVB-S6-500) or a placebo.|t|f|f|f
33877971|NCT03436862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877972|NCT01849874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877973|NCT04110847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33877974|NCT02891304|||COHORT||PROSPECTIVE|||||||
33877975|NCT01687764|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33877976|NCT02905565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877977|NCT00248248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33877978|NCT00683033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877979|NCT00206531|||DEFINED_POPULATION||PROSPECTIVE|||||||
33877980|NCT02608021|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33877981|NCT05672342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33877982|NCT03449823|||CASE_CONTROL||PROSPECTIVE|||||||
33877983|NCT02205749|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33877984|NCT04558814|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33877985|NCT01140360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877986|NCT00940407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877987|NCT06495632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33877988|NCT02961335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969372|NCT05161104|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33969373|NCT02166242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969374|NCT00424606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969375|NCT03705351|NA|SEQUENTIAL||TREATMENT||NONE||The study is an open-label pilot study. Following surgery, eligible patients will start tumor treating fields therapy with the Optune device less than 2 weeks prior to radiation and temozolomide given at a dose and schedule conforming to routine treatment.||||
33969376|NCT00203671|||||RETROSPECTIVE|||||||
33877989|NCT06407310|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|Single Group Assignment||||
33877990|NCT03976973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33877991|NCT03695003|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double blind. Randomized by a disinterested third party. Placebo and active capsules matched for aesthetics.|The study will follow a randomised, double-blind, placebo-controlled, parallel groups design.|t|f|t|t
33877992|NCT03389854|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Objective outcomes including penile length and curvature will be masked for the investigator and outcome assessor by obtaining photographs of the penis in the lateral and dorsal planes. Curvatures will also be assessed by a clinician in the case where photographs are not able to be obtained or if the participant refuses photographs. These will be assessed without any knowledge as to which grouping the patient is located by two independent reviewers. If there are differences \>5 degrees (curvature), or 0.5 cm (length), a 3rd individual will mediate the difference.|Men will be randomized into one of four groups: no traction therapy, penile traction 30 minutes once daily, penile traction 30 minutes twice daily, and penile traction 30 minutes three times daily. This treatment will continue for 3 months, after which men will enter an open label phase for 3 months. Primary and secondary outcomes will be evaluated at the completion of the 3 month and 6 month time points. Additional AEs will be assessed at 9 months after study initiation.|f|f|t|t
33877993|NCT02091570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33877994|NCT03259074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Participant, Care Provider, Investigator and Sponsor are blinded to Secukinumab dose|Study was partially blinded. Subjects, investigators, site personnel, persons performing the assessments, monitors and the Sponsor remained blinded to the dose group of secukinumab (150 mg versus 300 mg)|f|f|f|t
33969377|NCT01142297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969378|NCT03339791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33969379|NCT00472498|||CASE_CONTROL||PROSPECTIVE|||||||
33969380|NCT02468479|||COHORT||PROSPECTIVE|||||||
33877995|NCT06046261|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33877996|NCT04392115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33877997|NCT04163809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33877998|NCT01314716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33877999|NCT03054376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel randomized to training or no training of non-immobilized leg during immobilization of the other leg||||
33878000|NCT03670875|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study groups. Agave inulin: 2.3 g twice a day by mouth during 3 months plus recommendations to decrease calories intake an do exercise.~Curcumin: 600 mg (turmeric 600 + black pepper 5 mg) by mouth daily during 3 months plus recommendations to decrease calories intake an do exercise.~Omega-3 fatty acids 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth during 3 months plus recommendations to decrease calories intake an do exercise.~Control group with no intervention. Recommendations to decrease calories intake an do exercise.~Dietary recommendations to ingest 1600 calories per day Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)"||||
33878001|NCT03220828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33878002|NCT04458142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878003|NCT05823597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were unaware that another condition existed.|Cluster-randomized controlled trial|t|f|f|f
33878004|NCT03651596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878005|NCT04248413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI who will be performing the analysis will be blinded to patients who underwent routine physical rehabilitation vs those who underwent routine rehabilitation plus blood flow restriction therapy.|The purpose of the study is to 1) evaluate patient reported outcomes and return to play in baseball athletes undergoing rehabilitation with blood flow restriction (BFR) therapy for shoulder injury and 2) evaluate changes in blood biomarkers to assess the mechanism of action of BFR therapy in injured athletes.|f|f|t|t
33878006|NCT05875870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33878007|NCT03673683|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge, cluster randomized stepped wedge clinical trial||||
33878008|NCT03156088|||COHORT||OTHER|||||||
33878009|NCT06494995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878010|NCT02412800|||COHORT||RETROSPECTIVE|||||||
33878011|NCT05564065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups: 1. intraarticular steroid injection of hip joint; 2. Radiofrequency thermocoagulation of femoral and obturator nerve terminal sensory branches of hip joint||||
33878012|NCT05541965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33878013|NCT03731962|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33878014|NCT06347237|||COHORT||PROSPECTIVE|||||||
33878015|NCT00210210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878016|NCT06329583|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878017|NCT00118014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878018|NCT00769002|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878019|NCT05450146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878020|NCT06420505|||COHORT||PROSPECTIVE|||||||
33878021|NCT02658123|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878022|NCT01436539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878023|NCT06168838|||CASE_ONLY||RETROSPECTIVE|||||||
33878024|NCT04036708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33878025|NCT05101603|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33878026|NCT03189875|||COHORT||PROSPECTIVE|||||||
33878027|NCT00506883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878028|NCT03716349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The statistician will prepare a randomization list of A-B and B-A pairs to be applied sequentially as subjects receive restorations. The first system listed in the randomization pair will be placed on first tooth (#4-#13), and the second system on 2nd tooth (#4-#13). The random sequence will be individually placed in opaque, consecutively numbered and sealed envelopes, which should be opened by the operator immediately before the intervention.|Simple randomization will be used for assignment of the treatment groups. Randomization: Two restorations will be placed in each subject, one using system A and one using system B.|t|f|t|t
33878029|NCT00160459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878030|NCT02961556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878031|NCT00797823|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33878032|NCT01100437|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33878033|NCT00372502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878034|NCT01535781|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33878035|NCT06426069|||COHORT||CROSS_SECTIONAL|||||||
33878036|NCT01423799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33878037|NCT04839731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The three groups will include the following: Group 1 will be divided into 1- and 2-week treatment groups (5 patients in each group) and will apply placebo cream, Nourivan base cream from Pure Science Rx, twice per day for their designated time. Group 2 will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 7 days, and Group 3 will apply combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream twice per day for 14 days. Patients will undergo randomization via an online randomization generator tool.|t|f|f|f
33878038|NCT01070264|NA|SINGLE_GROUP||||||||||
33878039|NCT03910556|||COHORT||PROSPECTIVE|||||||
33878040|NCT01412593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878041|NCT01294670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878042|NCT02592850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878043|NCT03393273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878044|NCT06319105|||OTHER||PROSPECTIVE|||||||
33878045|NCT00757250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878046|NCT03991689|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878047|NCT05442307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized placebo controlled study||||
33878048|NCT06128460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878049|NCT00950508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969381|NCT06234046|RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking|This randomized controlled trial was performed on two groups of Egyptian patients diagnosed with cirrhotic liver disease and ascites just recovered from SBP attack, group (1) included 40 patients were administered Rifaximin as 550 mg twice daily dosage for six months and group (2)included 40 patients were administered Ciprofloxacin as 750 mg once weekly dose for 6 months. All patients of the two groups were followed up for recurrence of SBP for 6 months.||||
33969382|NCT01196481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969383|NCT04647344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969384|NCT01002157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969385|NCT03172585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969386|NCT04767490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969387|NCT06480994|||COHORT||PROSPECTIVE|||||||
33969388|NCT04370626|||COHORT||OTHER|||||||
33969389|NCT05921084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a single-blind design, where the outcome assessors will be masked from the assignment of the participants.|This is a two-arm parallel design, with one arm being the control arm (usual medical care) and the other being the intervention arm (MIND diet intervention + usual medical care).|f|f|f|t
33969390|NCT05923177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969391|NCT00676585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969392|NCT05044403|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069150|NCT04552171|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All key study personnel will be blinded to participants' condition assignments. Since participants are encouraged to complete both STI self-testing and follow-up online surveys via automated emails linking to a web-based survey system, no members of the study staff will be serving as outcomes assessors. As such, outcomes assessment is also blinded to study condition.|Participants will be randomly assigned 1:1 to one of two conditions: (1) a 24-hour helpline providing free standard post-test counseling and referral, or (2) the 24-hour helpline plus the Game Plan app. In both conditions, participants will be encouraged to use these services via a large postcard included in each test kit and via email, and so, can use them after each test.|f|f|t|t
34069151|NCT02738411|||COHORT||PROSPECTIVE|||||||
34069152|NCT06427629|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069153|NCT03990311|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"BP, weight, IDH (as defined by an intra-or post dialysis BP \<90 mmHg) will be recorded per usual clinical care by the dialysis unit staff.~Patients will be blinded to the salinity of the salt solutions used to test taste perception and preference."||f|f|f|t
34069154|NCT00004500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069155|NCT05363956|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Patients were not told which dentifrice they will be given|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique. The technique will be demonstrated to the patient and an image of the technique provided to the participants.|t|f|f|f
34069156|NCT02822833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069157|NCT02917655|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069158|NCT00814593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069159|NCT00007995||||TREATMENT||NONE||||||
34069160|NCT01118663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069161|NCT02871284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069162|NCT06613321|||CASE_CONTROL||RETROSPECTIVE|||||||
34069163|NCT04453410|||COHORT||PROSPECTIVE|||||||
34069164|NCT03934840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069165|NCT01168622|||OTHER||CROSS_SECTIONAL|||||||
34069166|NCT01308463|||COHORT||PROSPECTIVE|||||||
34069167|NCT05963932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969393|NCT06382467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969394|NCT00177112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969395|NCT02186808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969396|NCT02907008|||CASE_CONTROL||PROSPECTIVE|||||||
34069168|NCT00021645||||TREATMENT||||||||
34069169|NCT00005263|||CASE_CONTROL||PROSPECTIVE|||||||
34069170|NCT02838875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969397|NCT06417606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069171|NCT02333994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069172|NCT02150252|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34069173|NCT06435546|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34069174|NCT03731208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069175|NCT02190123|||CASE_ONLY||RETROSPECTIVE|||||||
34069176|NCT00403026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878050|NCT03248401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069177|NCT04331093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069178|NCT02583412|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34069179|NCT01080976|||COHORT||PROSPECTIVE|||||||
34069180|NCT00002478||||TREATMENT||||||||
34069181|NCT00893529|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34069182|NCT05563623|||COHORT||PROSPECTIVE|||||||
34069183|NCT06476938|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069184|NCT00914498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069185|NCT00134758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069186|NCT05795972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34069187|NCT03585517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069188|NCT04745871|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||TEP-PSMA||||
34069189|NCT00328445|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069190|NCT03047564|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Randomization to one of two implants||||
34069191|NCT01388283|||CASE_CONTROL||RETROSPECTIVE|||||||
33878051|NCT02057315|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33878052|NCT05988476|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878053|NCT00152542|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878054|NCT01430273|||COHORT||PROSPECTIVE|||||||
33878055|NCT00018265|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33878056|NCT00411554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878057|NCT00641498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878058|NCT02061865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878059|NCT00262873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878060|NCT01856881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878061|NCT00003338||||DIAGNOSTIC||||||||
33878062|NCT03608943|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33878063|NCT05980442|||CASE_CONTROL||PROSPECTIVE|||||||
33878064|NCT01617460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878065|NCT04672759|||COHORT||PROSPECTIVE|||||||
33878066|NCT04693962|||COHORT||PROSPECTIVE|||||||
33878067|NCT03377907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33878068|NCT00305981|||DEFINED_POPULATION||OTHER|||||||
33878069|NCT02113059|||COHORT||PROSPECTIVE|||||||
33878070|NCT00934986|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33878071|NCT00568646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878072|NCT00085761|RANDOMIZED|||TREATMENT||DOUBLE||||||
33878073|NCT02303379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878074|NCT03451773|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33878075|NCT02242955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878076|NCT03306732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878077|NCT05318391|||COHORT||RETROSPECTIVE|||||||
33878078|NCT00002655||||TREATMENT||||||||
33878079|NCT03958448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A statistician not involved in the study performed the randomization in blocks of four and the assignments have been sealed in coded and opaque envelopes that will be opened at the time of the enrollment of each patient in the study. The surgeon will be blinded about the assignment until the time of the surgery. The outcome assessor will be blinded about the protocol|Two groups will be randomly prepared. The Short group, one 4 mm long and 4.1 mm in diameter implant (Short implant) will be installed in each side of the posterior region of the maxilla. The standard group, bilateral sinus floor elevations will be performed. After 4 months of healing, one 10 mm long and 4.1 mm in diameter implant (Standard implant) will be installed into each augmented sinus.|f|t|t|t
33878080|NCT04434274|||COHORT||PROSPECTIVE|||||||
33878081|NCT02277509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33878082|NCT05832281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, placebo-controlled trial|t|f|t|t
33878083|NCT04442230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind||t|f|t|f
33878084|NCT03632421|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation.|||||
33878085|NCT03217838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878086|NCT04160507|||OTHER||OTHER|||||||
33878087|NCT06171438|||COHORT||PROSPECTIVE|||||||
33878088|NCT01598038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069192|NCT00932386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069193|NCT02309723|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34069194|NCT02080338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069195|NCT05867225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34069196|NCT06395519|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34069197|NCT05676424|||OTHER||PROSPECTIVE|||||||
34069198|NCT04089878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069199|NCT00106834|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34069200|NCT03139409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34069201|NCT00000267||||TREATMENT||||||||
34069202|NCT01916421|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34069203|NCT00559169||CROSSOVER||TREATMENT||NONE||||||
34069204|NCT01728441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069205|NCT04945564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069206|NCT00000548|RANDOMIZED|||PREVENTION||DOUBLE||||||
34069207|NCT06179043|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Between-subjects intervention: label type (4 arms); Within-subjects intervention: regular or weight-neutral version of label (2 versions).||||
34069208|NCT00709527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069209|NCT06611488|||OTHER||CROSS_SECTIONAL|||||||
34069210|NCT05977101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069211|NCT01693770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069212|NCT01834664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069213|NCT04610996|||||PROSPECTIVE|||||||
34069214|NCT02731989|||CASE_CONTROL||PROSPECTIVE|||||||
33878089|NCT01437020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878090|NCT01575067|||||PROSPECTIVE|||||||
33878091|NCT05712187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878092|NCT01732887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878093|NCT03397407|||COHORT||CROSS_SECTIONAL|||||||
33878094|NCT05345600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878095|NCT04737577|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33878096|NCT00371930|RANDOMIZED|PARALLEL||||SINGLE||||||
33878097|NCT06288087|RANDOMIZED|PARALLEL||OTHER||SINGLE|the group trained with VR Based Training with Machine Guidance will be referred as MG group and the group trained with VR Based Training with Educators Guidance in Metaverse will be referred as EG group.|Randomized Controlled Trial|t|f|f|f
33878098|NCT02492503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878099|NCT04842084|||CASE_ONLY||PROSPECTIVE|||||||
33878100|NCT00179309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878101|NCT02834468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878102|NCT05700695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Placebo Controlled|Prospective interventional cohort study|t|t|t|t
33878103|NCT03592446|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33878104|NCT01738334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878105|NCT00782769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878106|NCT05939895|||OTHER||OTHER|||||||
33878107|NCT05639855|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33878108|NCT04892836|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||3 intervention groups and one control group, assessed in 4 different times (baseline, 4th, 8th, and 12th weeks of intervention)|t|f|f|f
33878109|NCT04755049|||CASE_ONLY||PROSPECTIVE|||||||
33878110|NCT01137773|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33878111|NCT04899232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878112|NCT03300466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878113|NCT03877887|||COHORT||PROSPECTIVE|||||||
33878114|NCT02555670|||CASE_ONLY||PROSPECTIVE|||||||
33878115|NCT04048915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878116|NCT01923129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878117|NCT02757664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878118|NCT06202170|||OTHER||CROSS_SECTIONAL|||||||
33878119|NCT05858970|||OTHER||PROSPECTIVE|||||||
33878120|NCT00313209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878121|NCT03245931|||COHORT||PROSPECTIVE|||||||
33878122|NCT01187641|||COHORT||RETROSPECTIVE|||||||
33878123|NCT00941265|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33878124|NCT05448872|||COHORT||RETROSPECTIVE|||||||
33878125|NCT05729412|||COHORT||RETROSPECTIVE|||||||
33878126|NCT04041284|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878127|NCT01897636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878128|NCT03344003|||COHORT||OTHER|||||||
33878129|NCT00606086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878130|NCT03612687|||COHORT||PROSPECTIVE|||||||
33878131|NCT04029012|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878132|NCT02135718|||||PROSPECTIVE|||||||
33878133|NCT04788628|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33878134|NCT05583929|||COHORT||PROSPECTIVE|||||||
33878135|NCT04223310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878136|NCT00159861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33878137|NCT04087473|||COHORT||PROSPECTIVE|||||||
33878138|NCT03988556|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33878139|NCT00301340||||TREATMENT||||||||
33878140|NCT02565407|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878141|NCT03108950|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878142|NCT01278498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878143|NCT05190003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878144|NCT00107237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878145|NCT01123863|||COHORT||PROSPECTIVE|||||||
33878146|NCT04007783|||COHORT||PROSPECTIVE|||||||
33878147|NCT02869386|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878148|NCT01462266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069215|NCT05315648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the investigator and the outcomes assessor doing follow-up interviews and extracting data from the electronic medical records will be blinded to group allocation and treatment interventions. The patients know the allocation, cause patients in group NGA will not receive any sedation.|Patients will be randomized in a 1:1 ratio into two groups, group GA and group NGA, using a random number generator. This allocation will be written and stored in an opaque, secure envelope. Patients in group GA will receive general anesthesia followed by femoral nerve block. Patients in group NGA will receive combined spinal-epidural anesthesia followed by femoral nerve block.|f|f|t|t
34069216|NCT05709912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069217|NCT03675529|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34069218|NCT03401632|||CASE_ONLY||PROSPECTIVE|||||||
34069219|NCT05411991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878149|NCT03652532|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878150|NCT04232579|||COHORT||CROSS_SECTIONAL|||||||
33878151|NCT00937300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878152|NCT02870361|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33878153|NCT00862264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878154|NCT05662423|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33878155|NCT02526004|RANDOMIZED|PARALLEL||TREATMENT||||||||
33878156|NCT03867578|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33878157|NCT04431713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878158|NCT02161211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878159|NCT04479163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878160|NCT03020732|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878161|NCT03933865|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Masking: Participant, Investigator, and Outcomes Assessor. The identity of study medication conditions will not be known to investigators, research staff, or patients.|This is an outpatient randomized within subject placebo-controlled human laboratory investigation of analgesia (as assessed with quantitative sensory testing) from ketamine alone and in combination with hydromorphone in buprenorphine maintained participants.||||
33878162|NCT01019382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878163|NCT06307912|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33878164|NCT04864730|||OTHER||RETROSPECTIVE|||||||
33878165|NCT04749459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878166|NCT05469347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878167|NCT00640172|||COHORT||PROSPECTIVE|||||||
33878168|NCT03755648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878169|NCT04019730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33878170|NCT03264469|||CASE_ONLY||PROSPECTIVE|||||||
33878171|NCT01465906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878172|NCT03595553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In both arms patients receive the same number of doses per day. Placebo tablets are included to maintain same number and appearance of IP in both arms.||t|t|t|t
33878173|NCT02826109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878174|NCT04417478|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A double-blind, controlled, clinical trial was conducted. The sampling method was probabilistic stratified and the sample size 27 subjects in total, divided in 3 groups of: 9 normal weight patients, 9 class I Obesity patients and 9 class II Obesity patients and history of moderate to severe periodontitis, who met the inclusion and exclusion criteria and signed an informed consent. All patients received SRP and clinical monitoring at baseline and 3 months post-therapy by the same examiner.Serum levels of leptin were evaluated by enzyme-linked immunosorbent assay at baseline and 3 months post SRP by one trained examiner.|t|t|f|t
33878175|NCT01040052|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878176|NCT00091832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33878177|NCT05801380|||COHORT||PROSPECTIVE|||||||
33878178|NCT01195129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878179|NCT04500327|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33878180|NCT04797065|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33878181|NCT05598918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients were randomized into two groups as active and passive rehabilitation groups by computer program. Patients, shear wave elastography practitioner and data evaluator were blinded to the treatment administered to the patient.|The patients were divided into two groups as early active and passive mobilization groups. The angles of the dorsal orthoses of the active and passive groups were different. In the home exercise program in the active group, in addition to the exercises in the passive group, flexion was continued for 3-5 seconds at the end of passive flexion. The rehabilitation program was similar apart from these distinctions.|t|f|t|t
33878182|NCT00257803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33878183|NCT01986543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878184|NCT01942057|||COHORT||CROSS_SECTIONAL|||||||
33878185|NCT01076582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878186|NCT04016311|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention and wait list control groups with rolling admission.||||
33878187|NCT04344587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878188|NCT03130244|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878189|NCT05748093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will involve two cohorts, which will both receive PK-boosting, but for different purposes, and with different primary outcomes. The cohorts will not be compared, and there will be no cross-over between cohorts.||||
33878190|NCT00356941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878191|NCT01497015|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33878192|NCT00832559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878193|NCT03548558|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The study will have separate teams for collection of surveys and program implementation. Due to the nature of the intervention, the participants and delivery agents will not be blinded to their study allocation as part of the program implementation team. Data collectors of surveys for the research team will, however, be blinded to the intervention allocation status of participants and villages. (Baseline surveys will be collected prior to randomization.) Likewise, data analysis will be blinded to the intervention status of participants and villages.|The evaluation design is conducted in two phases. During phase 1, a clustered Randomized Control Trial (cRCT) across 60 community health volunteers (CHVs) and their associated villages are randomly assigned to one of three equally-sized treatment arms: group meetings for 16 biweekly sessions over 8 months (Arm 1), 12 group meetings plus 4 home visits over 8 months (Arm 2), and a control group (Arm 3). Within half of villages assigned to Arms 1 and 2, fathers will also be invited to the sessions (a 2x2 factorial design among the 40 villages assigned to receive the intervention). After a first follow-up survey immediately after the end of the biweekly sessions, in phase 2 we stratify by Arms 1 and 2 and re-randomize villages so that 20 total receive booster group sessions every 2 months over another 2 years (10 each from Arms 1 and 2). The other 20 villages from Arms 1 and 2 do not receive extended boosters.|f|f|f|t
33878194|NCT05840744|||COHORT||PROSPECTIVE|||||||
33878195|NCT03193398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878196|NCT00373204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878197|NCT04332588|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33878198|NCT01394588|||COHORT||PROSPECTIVE|||||||
33878199|NCT03687216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878200|NCT03235258|||COHORT||PROSPECTIVE|||||||
33878201|NCT06264570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33878202|NCT00630955|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33878203|NCT03926897|||OTHER||CROSS_SECTIONAL|||||||
33878204|NCT03901950|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study. Open-label means that subjects and the study doctor will know exactly what tablets subjects are taking.|There will be 5 different doses of the study drug that will be tested. The dose of study drug that you will take will depend on when you enter the research project. The first few participants who enter the research project early will take lower doses of the study drug. Participants entering the research project at a later time will take higher doses of the study drug only if the lower doses that have been tested are well tolerated. You will be closely monitored after you take the study drug.||||
33878205|NCT01171846|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33878206|NCT01162434|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33878207|NCT00439582|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33878208|NCT01791192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878209|NCT05788809|||OTHER||CROSS_SECTIONAL|||||||
33878210|NCT00003683||||TREATMENT||||||||
33878211|NCT02556255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878212|NCT00779662|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33878213|NCT05686174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878214|NCT05166694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878215|NCT00731250|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33878216|NCT03955133|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Use of the intervention could not be blinded.|All participating care homes will receive the intervention at the same time. Residents' records and medicines charts will be reviewed sequentially.||||
33878217|NCT05427266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blinded randomised control trial|Multi centre Single blinded randomised control trial.|t|f|f|t
33878218|NCT03759626|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33878219|NCT02575521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33878220|NCT01329393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878221|NCT04299295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878222|NCT02368054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878223|NCT01340209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894383|NCT05072405|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Open-label, single-dose, randomized, three-phase (no herbs, with green tea, with soy isoflavones), once with rosuvastatin and once with simvastatin.||||
33894384|NCT02347293|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34069220|NCT03956030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized controlled trial in which the intervention group will receive an educational handout on contraception and the control group will receive a handout on nutrition.|t|t|t|t
34069221|NCT02797860|||CASE_CONTROL||PROSPECTIVE|||||||
34069222|NCT03332095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069223|NCT06058273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069224|NCT06467539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069225|NCT00214656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34069226|NCT01525160|||CASE_CONTROL||PROSPECTIVE|||||||
33878224|NCT03912077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to the study conditions; while participants and facilitators will be aware of the study conditions.|It is a randomized, parallel-group trial that enroll Syrian refugee women with psychological distress, according to the Hopkins Symptom Checklist - 25 (HSCL-25) who will be randomly assigned to the Culturally Adapted Cognitive Behavioural Therapy (CA-CBT) intervention or to treatment as usual (TAU).|f|f|f|t
34069227|NCT03181685|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This is randomized, controlled, prospective, crossover, open-label, two-treatments, two-period trial|f|f|t|f
34069228|NCT04041492|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|randomization simple, double blind.|Controlled clinical trial, with randomization simple, double blind.|t|t|t|f
34069229|NCT00121290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069230|NCT03815435|NA|SINGLE_GROUP||TREATMENT||NONE|The physician performing the surgery and assessing the surgical field clarity will be masked as to the value of the blood pressure in the individual patient.|The study subjects will be enrolled into one arm.||||
34069231|NCT05184387|||COHORT||PROSPECTIVE|||||||
34069232|NCT03058471|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34069233|NCT01905332|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33878225|NCT05501353|||CASE_ONLY||PROSPECTIVE|||||||
33878226|NCT00648375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069234|NCT04403165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069235|NCT05347693|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|"This is a Phase 4, randomised, controlled, open-label, parallel-group, multicentre study in participants with CKD treated for HK whilst in hospital.~* During the in-hospital phase, participants will be treated with SZC as per local label~* At discharge, NK participants who have been treated with SZC for between 1 and 21 days whilst in hospital and are started on SZC maintenance dose will be randomised in a 1:1 ratio to one of the following arms:~  * Arm A: Participants discharged with SZC, as per local label, to manage HK until the end of the outpatient phase~ * Arm B: Participants discharged with SoC, as per local practice, to manage HK until the end of study. Note: Participants intended to be discharged with a K+ binder (as per the site routine medical practice) will not be randomised and will be discontinued from the study.~* The total duration of the study for each participant will be up to approximately 6 months."||||
34069236|NCT05937516|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|After intubation was completed, bleeding was evaluated by the other investigator who did not know the patient's group.||t|f|t|t
34069237|NCT06486051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878227|NCT01936532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878228|NCT04348409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to receive either nitazoxanide or placebo (1:1).|t|t|t|t
33878229|NCT02540486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878230|NCT02776800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878231|NCT00429858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878232|NCT04878822|||COHORT||OTHER|||||||
33878233|NCT02103530|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878234|NCT02224378|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33878235|NCT02101723|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878236|NCT00777010|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel groups, randomized controlled nutritional intervention.||||
33878237|NCT01330238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878238|NCT05405283|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33878239|NCT06130293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878240|NCT04851951|||OTHER||PROSPECTIVE|||||||
33969398|NCT04450498|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study will be carried out in an observer blind fashion until database is locked with data collected until Day 30 (Visit 3) after vaccination. The clinical study material, i.e. vaccine packs, will be packaged and encoded according to the randomization list (see Appendix B for example of vaccine labels). At study site, the investigator will assign unblinded designated person(s) responsible for vaccine handling, administration (Vaccinator) and accountability to ensure that blinding is protected throughout the study procedures and that no other site personnel involved in the conduct of the study has access to the information. After assessment of eligibility of a new subject, the investigator will complete a form that the subject will take to the vaccinator. The vaccinator will administer the vaccine according to the randomization list to the subject without informing neither the subject nor the investigator of the randomization group, i.e. the nature of the vaccine."|At Day 0, eligible subjects will be randomized in a 1:1 ratio into either Walvax MPV ACYW® vaccine group (130 subjects) or Sanofi Pasteur Menactra ® vaccine group (130 subjects). A randomization list containing subject numbers and vaccine group assignments will be provided to the investigator. Each participant will receive a single intramuscular injection of one of the two vaccines either MPV ACYW® vaccine or Menactra ® vaccine according to the vaccine group assignment and will be followed up for one month for immunogenicity evaluation and for 6 months for safety evaluation.|f|f|t|f
33969399|NCT02182011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969400|NCT05840003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The reading of the images from the ULD scanner acquisition will be performed blinded to the patient's clinical record, the diagnosis made by the radiologist in charge of the patient on the basis of the standard dose conventional scanner, the result of the reading of the standard dose conventional scanner study and the reading of the other evaluator.|Monocentric study of the subject as his/her own control||||
33969401|NCT02986152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969402|NCT03408600|||COHORT||PROSPECTIVE|||||||
33969403|NCT00624403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969404|NCT01294592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969405|NCT00139204|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969406|NCT02791165|||CASE_ONLY||PROSPECTIVE|||||||
33969407|NCT05438290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969408|NCT05559554|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33969409|NCT02858856|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33969410|NCT00756132|||CASE_CONTROL||PROSPECTIVE|||||||
33969411|NCT05080777|RANDOMIZED|PARALLEL||OTHER||NONE||Three Tele-Savvy programs, with 10 caregivers in each Tele-Savvy program cohort, will be held sequentially at each health care system site, for a total of 60 caregivers in 6 Tele-Savvy cohorts. Recruitment will occur in three waves, whereby caregivers will be randomly assigned at a 3:2 ratio to either Tele-Savvy or the attention control group until the first Tele-Savvy cohort is filled (first wave), followed by the same randomization procedure until the second and third Tele-Savvy cohorts are filled.||||
33969412|NCT04382456|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969413|NCT03110952|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33969414|NCT01172886|||CASE_CONTROL||RETROSPECTIVE|||||||
33969415|NCT01877759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878241|NCT00540189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878242|NCT05211479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled and quasi-experimental research||||
33878243|NCT02418416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878244|NCT01698346|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878245|NCT06027359|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33878246|NCT06349395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 parallel groups randomized controlled study||||
33878247|NCT02419287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878248|NCT02308683|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878249|NCT01849861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878250|NCT02326805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878251|NCT01656031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878252|NCT01966133|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069238|NCT06062095|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Recruited asymptomatic subjects will be randomized in a 1:1 ratio to undergo either AI or CC group. Randomization will be done upon caecal intubation. The randomization sequence will be generated in a concealed allocation fashion in block sizes of 10 for the participating centres. Patient recruitment and group assignment will be done independently by the study team members of each participating centre. Randomization will be stratified by endoscopist's colonoscopy experience (non-expert vs expert). Group assignments will be contained in sealed, opaque envelopes. This is a single-blinded randomization with enrolled patients being blinded to the result of their randomization while endoscopists are not blinded to the group assignment. Colonic polyp specimens will be evaluated by pathologists who are also blinded to the study group allocation and they are not aware of the diagnosis by AI.||t|f|f|f
34069239|NCT00045734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878253|NCT02380196|||COHORT||PROSPECTIVE|||||||
33878254|NCT04243330|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Sequential Multiple Assignment Randomized Trial||||
33878255|NCT06063421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a pragmatic, open label, parallel design RCT.|f|f|f|t
33878256|NCT04739046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878257|NCT02206646|||COHORT||PROSPECTIVE|||||||
33878258|NCT00193895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878259|NCT04481529|||CASE_ONLY||PROSPECTIVE|||||||
33878260|NCT03631836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878261|NCT00222183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878262|NCT04804189|RANDOMIZED|PARALLEL||PREVENTION||NONE||"We will enroll up to 60 4-H Shooting Sports communities nationwide to participate in a Type I Hybrid Effectiveness Trial. All Clubs will receive standard national-level training and curricula. Clubs randomized to Guardians 4 Health intervention will add additional training to enable Club Leaders to integrate Guardians 4 Health methods into their standard activities. We will provide ongoing technical support to all intervention Clubs. In all enrolled communities, we will measure 1) short- and intermediate-term outcomes among both Club-level adult and teen leaders and the Club's youth participants and their primary caregivers, and 2) injury incidence."||||
34069240|NCT01429441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069241|NCT01756339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878263|NCT04639622|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33878264|NCT03740750|RANDOMIZED|PARALLEL||TREATMENT||NONE||6 different interventions will be tested in parallel on 6 equivalent groups of subjects||||
33878265|NCT02269527|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069242|NCT03577379|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|Patients will be randomized to either the treatment or control group using an automated randomization program using a research electronic data capture (REDCap) system prior to surgery.||t|t|f|t
33878266|NCT05627219|||COHORT||PROSPECTIVE|||||||
33878267|NCT06372964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878268|NCT00267748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878269|NCT03077672|||COHORT||PROSPECTIVE|||||||
33878270|NCT00352651|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33878271|NCT03343587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33878272|NCT04495738|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33894385|NCT00488631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894386|NCT05831215|||OTHER||PROSPECTIVE|||||||
34069243|NCT05903638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Single-blinded pilot randomized control trial with control arm and intervention (virtual MBSR course).|f|t|t|t
34069244|NCT03667443|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33878273|NCT02706873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Participants were to be randomized in a 1:1:1 ratio to treatment Groups 2, 3, and 4 below, except for participants from Japan, who were to be randomized in a 2:1:1:1 ratio to Groups 1, 2, 3, and 4:~Group 1: Upadacitinib 7.5 mg QD monotherapy (Japan only)~Group 2: Upadacitinib 15 mg QD monotherapy (43 countries, including Japan)~Group 3: Upadacitinib 30 mg QD monotherapy (43 countries, including Japan)~Group 4: MTX monotherapy (43 countries, including Japan)"|t|t|t|t
33878274|NCT03797625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878275|NCT00584480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878276|NCT01411982|||CASE_ONLY||PROSPECTIVE|||||||
33878277|NCT00596089|||COHORT||CROSS_SECTIONAL|||||||
33878278|NCT05713097|||COHORT||RETROSPECTIVE|||||||
33878279|NCT01238458|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33878280|NCT06457386|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33878281|NCT02239939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878282|NCT03703973|||CASE_CONTROL||PROSPECTIVE|||||||
33878283|NCT01334034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878284|NCT01493453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878285|NCT03328663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878286|NCT05134961|||COHORT||RETROSPECTIVE|||||||
33878287|NCT00416247|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878288|NCT02355288|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33878289|NCT00278421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878290|NCT03747601|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33894387|NCT00013884||||TREATMENT||||||||
34069245|NCT06432907|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069246|NCT02380170|||CASE_ONLY||PROSPECTIVE|||||||
34069247|NCT02448745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069248|NCT02963129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069249|NCT02853071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069250|NCT01342783|||CASE_ONLY||RETROSPECTIVE|||||||
34069251|NCT02865629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069252|NCT02263729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069253|NCT05039125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757661|NCT03151681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization to 'mismatch group' or 'no-mismatch group' will be done prior to the first treatment session by a third party unrelated to the study, and blind to participant outcome. Participants will also be blind to which group they are randomized to. The randomization scheme will use the permuted-block method with a block size of four, stratified by gender (male and female) and event type (infidelity and other), and a group allocation probability of 50% (Fleiss, 1986).|"Experiment 1: Repeated measures open-label clinical trial with time-series analysis.~Experiment 2: Randomized clinical trial (mismatch vs. no mismatch) with within-group wait-list."|t|f|t|t
33757662|NCT02296554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069254|NCT00939588|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34069255|NCT01375452|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069256|NCT03577197|||COHORT||PROSPECTIVE|||||||
34069257|NCT01441245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069258|NCT04120909|||COHORT||PROSPECTIVE|||||||
34069259|NCT03107559|||CASE_CONTROL||PROSPECTIVE|||||||
34069260|NCT03596515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069261|NCT01055353|||COHORT||CROSS_SECTIONAL|||||||
34069262|NCT02102347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069263|NCT04279990|||COHORT||PROSPECTIVE|||||||
34069264|NCT06408779|||COHORT||RETROSPECTIVE|||||||
34069265|NCT05492747|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069266|NCT02965508|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34069267|NCT00779987|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34069268|NCT04281043|||COHORT||PROSPECTIVE|||||||
34069269|NCT02496039|NA|SINGLE_GROUP||OTHER||NONE||||||
34069270|NCT03297021|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Random allocation by opaque envelope and random number generator. Investigator will draw up study medication and give to care-providers. Outcome assessor not present for drawing up of medications.||t|t|f|t
34069271|NCT05273229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Clinical Trail|t|f|f|t
34069272|NCT01284751|||COHORT||CROSS_SECTIONAL|||||||
34069273|NCT02497430|||CASE_ONLY||PROSPECTIVE|||||||
34069274|NCT05295199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34069275|NCT06351085|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Biostatistician created a randomized table to allocate patient in either intervention 1 or 2.|Patients of the intervention clinics will be assigned one of two interventions: 1) Pre Visit Planner (PVP) or 2) PVP + patient education delivered via the MyUCDHealth patient web portal.|t|f|f|f
34069276|NCT03336814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878291|NCT04583397|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33878292|NCT01568606|NA|SINGLE_GROUP||SCREENING||NONE||||||
33878293|NCT04813471|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label Randomized Controlled Trial||||
33878294|NCT03075566|||CASE_CONTROL||PROSPECTIVE|||||||
33878295|NCT04069845|||COHORT||PROSPECTIVE|||||||
33878296|NCT05219188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33878297|NCT05435456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33878298|NCT03580421|RANDOMIZED|PARALLEL||TREATMENT||NONE||a multicentre, prospective and randomised study||||
33878299|NCT06081907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878300|NCT00951730|||CASE_ONLY||PROSPECTIVE|||||||
33878301|NCT00919503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878302|NCT03506555|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33878303|NCT04044131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A total of 60 Alzheimer's and 60 Parkinson's disease patients will be randomized on a 2:1 basis to the cofactor mixture or placebo.|t|t|t|t
33878304|NCT03329235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878305|NCT03094871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878306|NCT04901208|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33878307|NCT02564315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878308|NCT04455529|||CASE_ONLY||RETROSPECTIVE|||||||
33878309|NCT06329037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|f
33878310|NCT04547205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878311|NCT06501664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878312|NCT03512678|||CASE_ONLY||PROSPECTIVE|||||||
33878313|NCT03530371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878314|NCT01622881|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878315|NCT04489966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878316|NCT01355939|||COHORT||PROSPECTIVE|||||||
33878317|NCT04344678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069277|NCT00702026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069278|NCT00240578|||COHORT||RETROSPECTIVE|||||||
34069279|NCT00124085|RANDOMIZED|PARALLEL||||SINGLE||||||
33878318|NCT06293612|||COHORT||RETROSPECTIVE|||||||
33878319|NCT02031705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878320|NCT03091309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878321|NCT05477290|||COHORT||PROSPECTIVE|||||||
33969416|NCT04121000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be a two-arm parallel assignment. One group will receive erector spinae block and the other will receive PCA.|t|f|f|f
34069280|NCT05885061|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34069281|NCT00170391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069282|NCT05556941|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Before and after intervention|f|f|t|t
34069283|NCT02609984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878322|NCT02966691|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34069284|NCT01331707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069285|NCT02394119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069286|NCT03866629|||CASE_ONLY||PROSPECTIVE|||||||
34069287|NCT02775292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069288|NCT04156386|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34069289|NCT02534519|||CASE_CONTROL|||||||||
34069290|NCT00784589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069291|NCT02700425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069292|NCT03782571|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34069293|NCT01424241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069294|NCT04671940|||COHORT||OTHER|||||||
34069295|NCT02824211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069296|NCT00527124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069297|NCT05327595|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34069298|NCT05759065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069299|NCT02038309|||COHORT||PROSPECTIVE|||||||
34069300|NCT00564278|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34069301|NCT02651493|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069302|NCT00082095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069303|NCT05942521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069304|NCT02210325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069305|NCT03812263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878323|NCT05655338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The blindness of the examiner was ensured by restriction of access to the patients' data. Only the supervisor (MP) had access to the allocation data and therefore knew which patients received additional aPDT treatment.~Periodontal examinations of 5 randomly selected individuals were carried out twice by the same examiner, and the second measurements were repeated after two weeks. The reproducibility of assessing all periodontal parameters was tested. Intra-examiner calibration scores were 0.95."||f|t|f|f
33878324|NCT00544609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969417|NCT00411697|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33969418|NCT03307512|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, open-label, cross-over design||||
33969419|NCT01671683|||CASE_ONLY||PROSPECTIVE|||||||
33969420|NCT03504332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969421|NCT04534647|||CASE_CONTROL||PROSPECTIVE|||||||
33969422|NCT03495193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The proposed study is a randomized, controlled, interventional study to investigate the impact of a novel exercise intervention on executive dysfunction (Aim 1) and objective sleep outcomes (Aim 2) in patients with PD. Thirty participants with idiopathic PD will be recruited from the University of Alabama at Birmingham (UAB) Movement Disorders Center and randomized (1:1) to one of two groups (15 per group): exercise intervention (Ex) group or no-exercise (no-Ex) control group.||||
33969423|NCT01004120|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33969424|NCT00593333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069306|NCT03550547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069307|NCT05784402|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33878325|NCT00207051|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894388|NCT00761215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894389|NCT06390605|||COHORT||PROSPECTIVE|||||||
33969425|NCT03309410|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969426|NCT01899157|||||CROSS_SECTIONAL|||||||
33969427|NCT04986696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34069308|NCT01571336|||CASE_ONLY||PROSPECTIVE|||||||
34069309|NCT05466851|||COHORT||PROSPECTIVE|||||||
34069310|NCT03637790|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
34069311|NCT06410417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069312|NCT01602497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069313|NCT05327751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069314|NCT04889170|||CASE_CONTROL||PROSPECTIVE|||||||
34069315|NCT06027255|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||To enroll up to 150 patients, 50 POTS without Long-COVID, 50 POTS with Long-COVID and 50 controls with history of COVID-19 infection without sequelae||||
33878326|NCT05144607|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be randomized to one of two groups: control group or Pmus group. The control group will watch recorded ventilator waveforms (pressure and flow), and the Pmus group will watch, in addition to pressure and flow, estimated muscle pressure curves based on artificial intelligence. For each of 49 scenarios recorded from simulated conditions using the ASL-5000 simulator, participants will have to select among multiple choices if there was patient-ventilator asynchrony.||||
33878327|NCT06162910|NA|SINGLE_GROUP||SCREENING||NONE||||||
33878328|NCT03920670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878329|NCT01103674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878330|NCT05934500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969428|NCT04596449|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969429|NCT01386476|||||OTHER|||||||
33878331|NCT02421445|||COHORT||PROSPECTIVE|||||||
33878332|NCT06258070|NA|SINGLE_GROUP||TREATMENT||NONE||A retrospective cohort study of two samples of participants ( group with long-standing for more than one year, group with recent symptoms for less than one year), with a single-arm trial (all the participants had the same treatment).||||
33878333|NCT05595044|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Two study groups. One group receiving vitamin D plus habilitation and the other group receiving habilitation only||||
33878334|NCT04513431|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878335|NCT03594188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878336|NCT00935168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878337|NCT05470907|||CASE_ONLY||PROSPECTIVE|||||||
33878338|NCT05040516|||CASE_ONLY||CROSS_SECTIONAL|||||||
33878339|NCT06241040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878340|NCT03668483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878341|NCT00767377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878342|NCT03798821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878343|NCT00303251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878344|NCT06260371|||CASE_ONLY||RETROSPECTIVE|||||||
33878345|NCT02415712|||COHORT||PROSPECTIVE|||||||
33878346|NCT00944164|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33878347|NCT05186207|||COHORT||PROSPECTIVE|||||||
33878348|NCT05986526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878349|NCT04800536|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33878350|NCT02851004|NA|SINGLE_GROUP||TREATMENT||NONE||"\[Phase Ib\] 6 to 9 patients~\[Phase II\] Cohort A (MSI-H): 10 patients Cohort B (MSS): 40 patients Including patients with metastatic CRC treated at the recommended dose (RD) level in the Phase Ib part who meet criteria for the full analysis set (FAS)~\[Additional cohort to the Phase II part\]~1. st stage: CMS 1 or 4, MSS right-side colon cancers\*: 10 patients~2. nd stage:~   1. : If no patient shows a partial or complete response in the 1st stage, the study will be prematurely terminated.~  2. : If 1 or 2 patients show a partial or complete response in the 1st stage, 19 patients with CMS 1 or 4, MSS right-side colon cancers will be enrolled additionally.~  3. : If 3 or more patients show a partial or complete response in the 1st stage, 19 patients with CMS 1 or 4, MSS right-side colon cancers and 10 patients with CMS 1 or 4, MSS left-side colon cancers\* will be enrolled additionally."||||
33878351|NCT00180245|||COHORT||PROSPECTIVE|||||||
33878352|NCT03155594|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients in the hospital receiving 4-5 glucometer checks per day||||
33878353|NCT01602692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894390|NCT05650957|||COHORT||RETROSPECTIVE|||||||
33894391|NCT05735054|||COHORT||RETROSPECTIVE|||||||
33969430|NCT03807154|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three conditions: Internet-based Cognitive behavioral therapy, Internet-based Interpersonal psychotherapy, and a wait-list during the primary treatment phase. The wait-list will be allocated to the two active conditions once the primary treatment phase has finished.||||
33969431|NCT01496027|||CASE_ONLY||PROSPECTIVE|||||||
33969432|NCT05765383|||COHORT||PROSPECTIVE|||||||
33969433|NCT03376074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969434|NCT06529822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969435|NCT00837083|||||PROSPECTIVE|||||||
33969436|NCT02265952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969437|NCT05004857|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878354|NCT05294744|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open trial.|Clinical, randomized, controlled, multicenter, parallel and open trial.||||
33878355|NCT00042861||||TREATMENT||||||||
33878356|NCT00003460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878357|NCT06194591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A sham device is used. The sham device is visually identical to the NephrospecTM device but disposes of a metal bar that prevents the shockwaves to be transmitted to the patient.|The medical device used to administer Low-intensity extracorporeal shockwave therapy (Li-ESWT) is the NephrospecTM device from Curespec (manufacutred by Medispec). This device is CE-marked, has been used in previous studies, and will be used according to its instructions of use.|t|t|t|t
33878358|NCT00272974|RANDOMIZED|PARALLEL||ECT||NONE||||||
33878359|NCT01479543|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33969438|NCT00308373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969439|NCT01208142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757663|NCT04928963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a pilot, double arm prospective trial assessing feasibility and safety of a 5-day fasting-mimicking diet in pre-frail elderly patients who are going to be vaccinated against flu. Patients will be randomized for FMD or for placebo diet and both of the groups will recieve flu vaccine.|t|f|f|f
33757664|NCT05666219|NA|SINGLE_GROUP||TREATMENT||NONE||An Open Label Non-randomized Clinical Trial||||
33757665|NCT04481295|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33757666|NCT02926248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757667|NCT06371131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Experimental group: right stellate ganglion block 30 minutes before anesthesia induction.Control group: No treatment was given 30minutes before anesthesia induction.Data was recorded at the corresponding time points.|t|f|t|t
33757668|NCT04744857|NA|SINGLE_GROUP||TREATMENT||NONE||Preliminary data from the TaurusOne® clinical trial show good safety and efficacy in this trial without altering the artificial aorta To evaluate the safety and effectiveness of a transporter with a recoverable function. Take TaurusOne® in a clinical trial of compounding Endpoint event incidence was used as a target control.||||
33757669|NCT00063284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757670|NCT04876222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized|f|f|f|t
33757671|NCT01100554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878360|NCT00127907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878361|NCT03919708|||COHORT||PROSPECTIVE|||||||
33878362|NCT01017393|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33878363|NCT01347034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878364|NCT01451710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878365|NCT04943705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878366|NCT01182428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878367|NCT02465073|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33878368|NCT04103437|||COHORT||PROSPECTIVE|||||||
33878369|NCT03597048|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes were self-reported and completed on lap top computers without interaction with assessors. Research staff conducting home visits were not aware of which arm participants received.|A two by two by two cluster randomized fully -crossed factorial design|f|f|f|t
33878370|NCT00084123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878371|NCT00185978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33878372|NCT05522439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study|t|t|t|t
33757672|NCT03431402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33757673|NCT06579976|||COHORT||PROSPECTIVE|||||||
33878373|NCT00187421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33878374|NCT05133635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757674|NCT00489333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33757675|NCT05602649|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind, placebo controlled|All participants will complete all dose conditions in a randomized order.|t|f|f|t
33878375|NCT03872986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878376|NCT03578120|||COHORT||PROSPECTIVE|||||||
33878377|NCT02457871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878378|NCT04482335|||COHORT||PROSPECTIVE|||||||
33894392|NCT01567436|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894393|NCT02848547|||COHORT||CROSS_SECTIONAL|||||||
33757676|NCT01952184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757677|NCT04358003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757678|NCT05815654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned to the experimental group (EG), or the placebo control group (CG) at a ratio of 5:5 stratified by recruitment site. Stratified block randomization will be used according to probability theory. An independent statistician will generate random sequences using R software version 4.2.1 (R Project for Statistical Computing, Vienna, Austria), in which the TCM syndrome type, duration, and the severity of dysmenorrhea will be used as indicators, after a patient's qualification is confirmed, a randomization number and its corresponding sticker will be provided to the assistant by the PI. Then the assistant will give the specific sticker to the subjects to ensure that both the assistant and the subjects will not know which type of sticker they get.|200 participants will be divided into experimental group and control group.|t|f|t|f
33757679|NCT03323879|NA|SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation design||||
33757680|NCT06574802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33757681|NCT05970965|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33757682|NCT05970081|||COHORT||PROSPECTIVE|||||||
33757683|NCT05557331|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Although neither the participants nor the study investigators can be blinded to the intervention, both will be blinded to the results of the study until their final analysis by the statistician. Participants will be informed only of the overall purpose of the study, which is to evaluate the effects of the app on quality of care, but not about the aim of reducing the time to access laboratory results to minimize bias. The statistician will remain blinded to allocation until the final analysis.|A single center, non-equivalent comparison group, pre-post study.|f|f|f|t
33757684|NCT04979975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757685|NCT05871710|||OTHER||PROSPECTIVE|||||||
33757686|NCT05598801|||COHORT||PROSPECTIVE|||||||
33757687|NCT02697279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757688|NCT00002402||||PREVENTION||||||||
33757689|NCT05334303|||OTHER||RETROSPECTIVE|||||||
33757690|NCT00608010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757691|NCT01649830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757692|NCT00328432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33757693|NCT02945384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33757694|NCT02435368|||CASE_ONLY||CROSS_SECTIONAL|||||||
33757695|NCT05543291|||COHORT||CROSS_SECTIONAL|||||||
33757696|NCT04999878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757697|NCT00836082|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33757698|NCT01444157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33757699|NCT05549401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757700|NCT05618548|||COHORT||PROSPECTIVE|||||||
33757701|NCT06015815|||COHORT||PROSPECTIVE|||||||
33969440|NCT05158491|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33757702|NCT03050502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069316|NCT05588934|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|"Participants will not have any knowledge of which of the five condition groups they are apart of during or after the study.~The investigator will not have any knowledge of which of the five condition groups the participant is apart of during or after the study.~A third party will prepare the caffeine dosing and not participate in the administration to avoid knowledge of what participants are in what categories."|"There are four different experimental conditions and one control condition that determines the ratio of caffeine gum to placebo gum that is administered to participants.~1. Standard Caffeine Dose Both Nights (200mg/2 hr. up to 800mg/24 hr.)~2. Optimized Caffeine Dose Both Nights (0-300mg/2 hr. up to 800mg/24 hr.)~3. Placebo Dose 1st Night/Standard Caffeine Dose 2nd Night (0mg) / (200mg/2 hr. up to 800mg/24 hr.)~4. Placebo Dose 1st Night/Optimized Caffeine Dose 2nd Night (0mg) / (0-300mg/2 hr. up to 800mg/24 hr.)~5. Placebo Dose Both Nights (0mg) Participants will be randomly assigned to 1 of the 5 conditions, so 20% of the study population will be in each condition."|t|f|t|f
34069317|NCT05255445|||COHORT||PROSPECTIVE|||||||
34069318|NCT00499343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878379|NCT03224897|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The tDCS device was placed at the back of the participants, so they could not see the parameters of stimulation. The participants of the sham stimulation group received anode stimulation for 30s, and then the device was turned off. The participants feel the initial itching in all conditions, so the are not able to distinguish to which condition of stimulation they are submitted.|The 60 participants will be divided into 3 groups: anodal, cathodal and sham stimulation. While receiving the transcranial direct current (tDCS) stimulation, participants will perform a reappraisal task. Four series of 15 IAPS pictures will be randomly passed on a computer screen. 3 of the 4 sets of pictures contain negative pictures, matched according to valence and arousal of the IAPS norm ratings (p\<0.05) and were assigned to one of instruction condition (upregulate, downregulate or maintain). The other set will contain neutral pictures with the instruction maintain. Participants will be asked to apply the instruction assigned to each picture and then rank the intensity of negative emotional arousal felt after using the reappraisal strategy, varying from 1 (weak) to 7 (strong). ANOVA will be used to compare the median subjective emotion intensity evaluation for each strategy intra-subjects and inter-groups.|t|f|f|t
33878380|NCT06409676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878381|NCT03664999|||COHORT||PROSPECTIVE|||||||
33878382|NCT04648384|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33878383|NCT02095535|||CASE_ONLY||CROSS_SECTIONAL|||||||
33878384|NCT01596998|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33878385|NCT02573155|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33757703|NCT04923113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878386|NCT04485520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33878387|NCT04884230|||CASE_CONTROL||PROSPECTIVE|||||||
33878388|NCT00097760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878389|NCT06539923|||COHORT||RETROSPECTIVE|||||||
33878390|NCT05701332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878391|NCT04321759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized cluster design with 19 service centers assigned to one of the two treatments.|f|f|f|t
33757704|NCT05228548|||OTHER||PROSPECTIVE|||||||
33757705|NCT03308825|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, Open-label, Phase IV Study||||
33878392|NCT00590590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878393|NCT00702663|||||CROSS_SECTIONAL|||||||
33878394|NCT05520983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessors at Wellesley Centers for Women B.E.S.T. Call Center (BCC) will be blinded to conditions and the assessment measures that they complete do not involve collecting any measures of the intervention.|Comparative-effectiveness study of two different care coordination models|f|f|f|t
33878395|NCT05945953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878396|NCT03682497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878397|NCT04079270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878398|NCT01930305|||CASE_CONTROL||PROSPECTIVE|||||||
33878399|NCT03298022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878400|NCT04937088|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|Placebo and ASA 150 will be labeled to maintain blinding. The Principal Investigator and one Biostatistician will remain blinded to prevent any bias. Study staff/healthcare providers distributing the treatments to study subjects will be blinded to treatment assignment. Subjects will also be blinded to their treatment assignment.|Phase 2, proof of concept study|t|f|t|t
33878401|NCT00467454|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33878402|NCT00548496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878403|NCT00691431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878404|NCT00823290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878405|NCT01965262|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33878406|NCT03303794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878407|NCT06374823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878408|NCT03402607|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33878409|NCT01829256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33878410|NCT05047757|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33878411|NCT05453617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878412|NCT06302218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33878413|NCT00868946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878414|NCT02200380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878415|NCT04687696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878416|NCT05997641|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Each enrolled participant will be assigned a randomization code generated with a computer program. Once generated, the randomization code will be final and will not be modified.~The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical phase of the study has been completed. The treatment assignment will not be known by the study participants. Furthermore, the randomization code will not be available to the physician and clinical staff involved in the collection, monitoring, revision, or evaluation of adverse events, as well as clinical staff who could have an impact on the outcome of the study.~The preparation and/or administration of the drug products will be done by designated personnel that are not directly involved in the clinical aspects of the trial."|The study will include 2 parts: 1) Single ascending dose phase with optional food effect (FE) assessment, and 2) multiple ascending dose phase.|t|f|t|f
33878417|NCT02150590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33878418|NCT03127033|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33878419|NCT04523506|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878420|NCT03268915|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The investigators want to test the reproductibility of a 3 minutes sit-to-stand test in patients with idiopathic pulmonary fibrosis.~For this, patient perform the test during 2 visits and the investigators are going to compare the results of the two visits."||||
33878421|NCT03480373|||COHORT||PROSPECTIVE|||||||
33878422|NCT01256073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878423|NCT06239987|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||It is planned to give a care-oriented applied training program to intensive care nurses in groups of 13-15 people for 2 hours. The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.||||
33878424|NCT05820425|||COHORT||PROSPECTIVE|||||||
33878425|NCT00898560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878426|NCT03991078|||COHORT||PROSPECTIVE|||||||
33878427|NCT05843552|||CASE_CONTROL||PROSPECTIVE|||||||
33878428|NCT03741998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878429|NCT01733017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969441|NCT05972850|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||40 rural-living older adults (60-80 years) with a history of cardiovascular disease (prior myocardial infarction, angina, or coronary procedure) who are medically cleared for exercise by their cardiologist.||||
33969442|NCT03925831|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33757706|NCT00005801||||TREATMENT||||||||
33878430|NCT03185390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All cases admitted in Assuit university hospital with periampullary lesions detected by ERCP with ERCP guided biopsy or brush cytology within the period of the study.||||
33878431|NCT05988801|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33878432|NCT04515732|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||As described. Only part 3 of the study is considered interventional.||||
33878433|NCT03242837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878434|NCT02705989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878435|NCT04235556|||COHORT||CROSS_SECTIONAL|||||||
33878436|NCT03027739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878437|NCT04821869|||COHORT||PROSPECTIVE|||||||
33878438|NCT03277495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be stratified by sex and randomly assigned with a 1:1 allocation ratio to one of two conditions: 1) to receive SREC pods in their usual flavor (N = 60); and 2) to receive SREC pods in their choice of flavor (N = 60).||||
33878439|NCT04373031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878440|NCT05058833|||COHORT||PROSPECTIVE|||||||
33878441|NCT05313061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878442|NCT01086709|||||PROSPECTIVE|||||||
33878443|NCT01240460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878444|NCT04710342|NA|SINGLE_GROUP||TREATMENT||NONE||If crossing the CTO is not successful with a conventional guidewire, the CapBuster system will be used to try to cross the occlusion||||
33878445|NCT02814630|NA|SINGLE_GROUP||OTHER||NONE||||||
33878446|NCT01382693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878447|NCT06434480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878448|NCT02483312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878449|NCT00921700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878450|NCT04726878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The patient: The primary intervention (erector spinae plane block) will be provided under general anesthesia.~The investigator and outcome assessor will be not aware of the allocation."|Patients will be randomized 1:1:1|t|f|t|t
33878451|NCT01849172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878452|NCT02065154|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878453|NCT02281695|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878454|NCT01618214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878455|NCT05831397|||CASE_CONTROL||PROSPECTIVE|||||||
33878456|NCT04918329|||COHORT||PROSPECTIVE|||||||
33878457|NCT03970902|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33878458|NCT03915223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|Solumedrol (steroidal anti-inflammatory drug) injection|t|f|t|f
33878459|NCT06475144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To maintain randomness, participants will draw lots to determine whether they belong to the control or experimental group before the course starts.|This study employs a quasi-experimental design with a two-group pre-test and post-test design.|t|f|f|f
33878460|NCT04324372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878461|NCT01910714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878462|NCT02167932|||COHORT||PROSPECTIVE|||||||
33878463|NCT03177772|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33878464|NCT04406909|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878465|NCT01185405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878466|NCT04624165|||COHORT||PROSPECTIVE|||||||
33878467|NCT03739450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be ensured by allocating to group assignment after baseline assessment is complete, having different staff performing assessments vs delivering the intervention, scheduling meetings with assessors and interventionists separately, and instructing participants to not discuss the intervention with the person calling to complete follow-up assessments.|Participants are randomized and allocated after baseline assessment to PST + Education or Education only via stratified, blocked randomization. Randomization is stratified by participating center and then based on whether a single care partner or multiple care partners are participating for the same patient by participating TBIMS Center. The investigators used a block size of four to ensure equal numbers across groups and to account for potentially small numbers of participants at any given TBIMS Center. Randomization is computer-generated and maintained by the TBI Model Systems National and Statistical Data Center. Allocation assignments for each center are distributed to the site PI and maintained in a password-protected electronic file. Outcome assessors are blinded to intervention allocation.|f|f|f|t
33878468|NCT00516737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878469|NCT01449331|||COHORT||PROSPECTIVE|||||||
33878470|NCT02917889|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33878471|NCT02222259|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33878472|NCT04980612|RANDOMIZED|PARALLEL||OTHER||NONE||"The intervention and MBPR manual will be refined iteratively in 4 courses with 10 participants. The last of these 4 MBPR classes will be about 10 of 20 participants randomly assigned to either participate in standard MBSR or MBPR.~The first part of the study is single-arm, the last randomized to assess acceptability of randomization."||||
33878473|NCT02778490|||COHORT||PROSPECTIVE|||||||
33878474|NCT04395794|||COHORT||PROSPECTIVE|||||||
33878475|NCT06299527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878476|NCT04580381|||CASE_CONTROL||RETROSPECTIVE|||||||
33878477|NCT00749996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878478|NCT01780831|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878479|NCT00501813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878480|NCT02416284|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33878481|NCT03911765|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Stepped wedge|t|f|f|f
33878482|NCT06287320|||COHORT||PROSPECTIVE|||||||
33878483|NCT02467530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969443|NCT01777425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969444|NCT02297906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969445|NCT01446913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33878484|NCT01052311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878485|NCT03283800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|All stockings are marked with an 'L' for the left or 'R' for the right foot. The manufacturer has randomly marked the copper stockings with an 'L' or 'R' and paired these with a non-copper stocking. A closed envelope will contain the unique numbers of all the pairs of stockings and the information on which stocking contains the copper. This envelope will remain closed for the whole recruitment period and throughout analysis of the results.|All participants will be asked to wear compression stockings. One of the pair will have copper oxide ions permanently attached to the nylon fibres and these stockings will contain 2-3% copper ions. The participants will wear a copper stocking on one leg (study leg) and a non-copper stocking on the other (control leg).|t|t|t|t
33878486|NCT01730235|||CASE_CONTROL||PROSPECTIVE|||||||
33878487|NCT00938756||||DIAGNOSTIC||NONE||||||
33969446|NCT00891683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969447|NCT03323632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969448|NCT03983707|||COHORT||PROSPECTIVE|||||||
33969449|NCT05559294|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33969450|NCT02201433|||COHORT||PROSPECTIVE|||||||
33969451|NCT02175966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969452|NCT00048971|||CASE_ONLY||PROSPECTIVE|||||||
33969453|NCT01403883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969454|NCT05956197|||COHORT||PROSPECTIVE|||||||
33969455|NCT06504108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969456|NCT01206712|||CASE_CONTROL||PROSPECTIVE|||||||
33969457|NCT05924971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to study arms.|Patients with preeclampsia will be randomized after delivery to receive either standard blood pressure control plus aspirin 81 mg or standard blood pressure control alone.|f|f|f|t
33878488|NCT05033496|||CASE_ONLY||RETROSPECTIVE|||||||
33878489|NCT02554539|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878490|NCT03601286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878491|NCT05122234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069319|NCT01502033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069320|NCT00809094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878492|NCT03797469|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33878493|NCT05459623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878494|NCT03099486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878495|NCT05498324|||COHORT||RETROSPECTIVE|||||||
33878496|NCT00089908|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33878497|NCT04900597|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33878498|NCT01781221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878499|NCT02486055|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878500|NCT03597932|||COHORT||PROSPECTIVE|||||||
33878501|NCT03237065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878502|NCT05102955|||OTHER||PROSPECTIVE|||||||
33878503|NCT02240654|||OTHER||CROSS_SECTIONAL|||||||
33878504|NCT04644809|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33878505|NCT03033186|||COHORT||PROSPECTIVE|||||||
33878506|NCT05160259|||COHORT||PROSPECTIVE|||||||
33878507|NCT05787405|||COHORT||PROSPECTIVE|||||||
34069321|NCT06399991|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069322|NCT05369143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069323|NCT04063722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969458|NCT03063632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969459|NCT03760133|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969460|NCT01840683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069324|NCT03762681|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34069325|NCT04233437|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be assigned to either CYP or Transporter cohort in ratio of 1:1.||||
34069326|NCT00349193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069327|NCT05401409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069328|NCT03872141|||COHORT||PROSPECTIVE|||||||
34069329|NCT04175236|||COHORT||RETROSPECTIVE|||||||
34069330|NCT04251416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069331|NCT06379529|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pragmatic evaluation of a clinical service using a prospective cohort comparison of intervention vs propensity matched controls.||||
34069332|NCT02969083|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069333|NCT04515277|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double-blind, randomized, controlled, three-way cross-over design, monocentric nutritional study|t|t|t|t
34069334|NCT01317004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069335|NCT00823485|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34069336|NCT02108899|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069337|NCT05765071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the treatment they received until after the 24-week visit is completed. The physiatrist administering the injection and the physiatrist performing the manual muscle power assessments will be blinded to treatment allocation.|Participants receiving botulinum toxin will be compared to those receiving normal saline.|t|f|f|t
34069338|NCT04627558|||OTHER||PROSPECTIVE|||||||
34069339|NCT02776670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069340|NCT00660595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069341|NCT00470561|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34069342|NCT01619072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969461|NCT02903927|RANDOMIZED|PARALLEL||TREATMENT||||||||
33969462|NCT05586620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969463|NCT02904200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969464|NCT01113710|||COHORT||PROSPECTIVE|||||||
33969465|NCT04517006|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33969466|NCT00770991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069343|NCT03725826|||COHORT||PROSPECTIVE|||||||
34069344|NCT00003328|RANDOMIZED|||TREATMENT||||||||
33878508|NCT00793650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878509|NCT05747911|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33878510|NCT01090882|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33878511|NCT04869085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data Collectors will be blinded to the intervention. Study participants will be asked to not disclose their treatment condition.||f|f|f|t
33878512|NCT00143585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878513|NCT02565979|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878514|NCT03538509|||CASE_ONLY||OTHER|||||||
33878515|NCT01657409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not aware how many injections were performed|Patients were randomized to receive different injection number of onabotulinumtoxinA|t|f|f|f
33878516|NCT02723123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33878517|NCT06320483|||OTHER||PROSPECTIVE|||||||
33894394|NCT05413681|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective study in two arms: a group of patients referred for metabolic exploration during exercise as part of their care and a group of control subjects who will perform the same explorations as the patients.|f|f|f|t
33894395|NCT03322800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894396|NCT00181298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894397|NCT03633331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894398|NCT03885921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894399|NCT01120626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894400|NCT03016611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894401|NCT02607215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894402|NCT02426606|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33894403|NCT03087214|||COHORT||PROSPECTIVE|||||||
33969467|NCT04033939|RANDOMIZED|PARALLEL||TREATMENT||NONE|Following Screening, subjects who meet the inclusion/exclusion criteria will be assigned a subject number in the order in which they are enrolled in the study. The subject number will determine the allocation of treatment as per the randomization list which will be generated by INCResearch Australia Pty Ltd and provided to the pharmacist. Cohorts 1 and 2 are a placebo controlled design, with open-labelling for the sentinel subjects and double-blind thereafter. Cohorts 3 to 8 are an open-label, positive controlled design.|||||
33894404|NCT04617288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants randomly assigned to group A receiving conventional Physiotherapy plus SNAGs and group B receiving conventional Physiotherapy plus ultrasound.|t|f|t|f
33969468|NCT02659202|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969469|NCT04467333|||COHORT||PROSPECTIVE|||||||
33969470|NCT00748007|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33969471|NCT05852782|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All subjects will participate in four conditions on separate days||||
33969472|NCT00469820||||TREATMENT||NONE||||||
33969473|NCT02687282|||COHORT||CROSS_SECTIONAL|||||||
33894405|NCT00765765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894406|NCT04057443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel design||||
33894407|NCT05182736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Students in comparison arm received intervention as usual. Students in the comparison schools (as well as those in the intervention condition) receive the normal ninth grade health curriculum, Reproductive and Health Safety Education, which is intended to cover three essential standards 1) Healthy and effective interpersonal communication and relationships, 2) Abstinence from sexual intercourse as a positive choice for young people, and 3) Strategies that develop and maintain reproductive and sexual health. All schools in North Carolina provide sex education in accordance with the 2009 Health Youth Act in seventh, eighth, and ninth grades"||t|f|f|f
33894408|NCT01823211|||COHORT||PROSPECTIVE|||||||
33894409|NCT02999503|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969474|NCT03404206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969475|NCT02657993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33969476|NCT01038583|||COHORT||PROSPECTIVE|||||||
33969477|NCT04809779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969478|NCT05994456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969479|NCT00224250|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33969480|NCT02799654|||COHORT||PROSPECTIVE|||||||
33969481|NCT02387814|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969482|NCT01993394|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33969483|NCT04292574|||COHORT||RETROSPECTIVE|||||||
33969484|NCT01138150|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33969485|NCT00996554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33969486|NCT05278754|||CASE_CONTROL||RETROSPECTIVE|||||||
33969487|NCT02531022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33969488|NCT02443428|||COHORT||PROSPECTIVE|||||||
33969489|NCT03360201|NA|SINGLE_GROUP||TREATMENT||NONE||The study will follow a single case (N of 1) series design. Pre-post changes will be measured, and repeated measures will be administered before, during, and following the intervention to track change over time. The timing of entry into the study and the numbers of repeated measures data points are randomized across families. Data analysis will aim to (a) identify patterns of change over the course of the intervention and (b) relate change trajectories to theorized mechanisms of action.||||
33969490|NCT02517359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969491|NCT02330679|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33969492|NCT00497367|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33757707|NCT02781948|||COHORT||PROSPECTIVE|||||||
33757708|NCT03349164|||OTHER||OTHER|||||||
33757709|NCT00983086|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33757710|NCT04789265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878518|NCT04513002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|"Once all required screening assessments are completed and eligibility is confirmed, participants will be registered with the Sponsor. Upon approval of registration, participants will be assigned a unique participant number that will remain consistent for the duration of the study.~Participants will be randomised (RandoWeb) into one of the following three groups on a 1:1 ratio:~1. Group 1: 10%, 20%, 35%, 35%, 35%,35%.~2. Group 2: placebo, 10%, 20%, 35%, 35%,35%.~3. Group 3; placebo, placebo, 10%, 20%, 35%,35%.~Our study pharmacist will ensure the groups are blinded in terms of dose increases, volumes, colour and taste of liquid dispensed in triheptanoin and placebo (medium chain triglyceride oil)."|"1. Primary objective A combined phase 2A/B trial will be undertaken to determine optimal dose, demonstrate tolerability, and to examine efficacy and safety of triheptanoin in participants with A-T.~2. Secondary objectives~   * Determine to what extent the beneficial effects of triheptanoin on epithelial cells in culture translate to clinical efficacy in patients with A-T. Clinical endpoints will include ataxia rating; MRI imaging; lung function; eye movement changes and speech assessment.~  * Provide validation of our primary and secondary endpoints to plan a phase 3 trial and form the basis of future trials."|t|t|t|t
33757711|NCT00306033|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33757712|NCT04811430|||COHORT||CROSS_SECTIONAL|||||||
33757713|NCT06437379|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|nurse working in urology department|To evaluate the effect of implementing teaching protocol on nurse's knowledge and practice regarding infection control measures for patients undergoing Percutaneous Nephrolithotomy.||||
33878519|NCT03697187|||COHORT||PROSPECTIVE|||||||
33878520|NCT00927836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878521|NCT00700271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878522|NCT04082195|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33878523|NCT03285997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878524|NCT03076983|||COHORT||PROSPECTIVE|||||||
33894410|NCT00644592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33894411|NCT01723189|||CASE_CONTROL||PROSPECTIVE|||||||
33894412|NCT04286932|||COHORT||CROSS_SECTIONAL|||||||
33757714|NCT05741580|||COHORT||RETROSPECTIVE|||||||
33757715|NCT00627848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33757716|NCT03379831|||CASE_ONLY||PROSPECTIVE|||||||
33878525|NCT04534660|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This FDA approved feasibility study model includes 2 single groups, one for each indication (Cheek augmentation N=15; Nasolabial Fold Correction N=15). Both will receive the same treatment (SMI-01). Findings from the feasibility study will be used to inform study design for the Pivotal study.||||
33878526|NCT02555514|||CASE_CROSSOVER||PROSPECTIVE|||||||
33969493|NCT04158830|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Subjects will be randomized in consecutive order, entering their basic information (name, date of birth, medical record number, date/time of randomization, randomization number) on a master log.~Group 1- (total of up to 450 subjects) designated by odd numbers in the randomization pattern \[1-001, 1-003, 1-005, etc. to 899\] oral dose: 81 mg aspirin daily: Rx 81 mg ASA, 1 tablet daily (1 bottle of 200 tablets/patient)~Group 2-(total of up to 450 subjects) designated by even numbers in the randomization pattern \[2-002, 2-004, 2-006, etc. to 900\] oral dose: 162 mg aspirin daily: Rx 81 mg ASA, 2 tablets daily (1 bottle of 400 tablets/patient)"||||
33969494|NCT05554510|||COHORT||PROSPECTIVE|||||||
33969495|NCT02546284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969496|NCT03964454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those who are providing home visitations on a monthly basis will be blinded to which condition a participant gets randomized.|This is a two-group parallel randomized controlled trial testing the efficacy of health incentives to increase breastfeeding duration among low income WIC eligible mothers.|f|f|f|t
33969497|NCT00785122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878527|NCT05325905|||OTHER||CROSS_SECTIONAL|||||||
33878528|NCT00603915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757717|NCT05122390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The experimental group is divided into two groups, one group that gets access to the application Contraction Coper only and one group gets Contraction Coper Plus, both the application and additional support of the midwife through blended care. The third group is standard care only.||||
33878529|NCT04577443|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33878530|NCT00643695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878531|NCT04015154|||COHORT||PROSPECTIVE|||||||
33878532|NCT02802891|||CASE_CONTROL||PROSPECTIVE|||||||
33878533|NCT05741255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33878534|NCT01724658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878535|NCT02490514|||COHORT|||||||||
33878536|NCT01514032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069345|NCT06345014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Background treatment - Xatral® XL Tab. 10 mg (alfuzosin hydrochloride): With the treatment of the investigational product, it will be administered for the first 13 weeks (Administration of the placebo will be continued to maintain the treatment compliance and blinding for the rest 13 weeks).~After week 13, Background treatment will be blinded for subject only until end of treatment period(Week 26)."|"Once a subject voluntarily gives written consent to participate in this study, a screening test will be conducted to evaluate their eligibility. Subjects determined to be eligible to participate in the study on Visit 2 (baseline) will be enrolled, randomized 1:1 either to the test group (OM-89 \[Uro-Vaxom® Capsule\]) or the control group (placebo of OM-89) and administered the investigational product for 26 weeks.~In parallel, an alpha blocker (alfuzosin 10 mg) will be administered for the first 13 weeks as a background treatment, followed by the placebo of alfuzosin until Week 26. The efficacy and safety will be checked until Week 52 from the start of the treatment for all subjects."|t|t|t|t
34069346|NCT03309345|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33878537|NCT00737659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878538|NCT03648697|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label, single dose phase I/II study of safety and efficacy.||||
33878539|NCT02223572|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878540|NCT01508728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878541|NCT00845728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878542|NCT04181138|||COHORT||PROSPECTIVE|||||||
33878543|NCT00756145|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878544|NCT04437355|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33878545|NCT00921232|NA|SINGLE_GROUP||||NONE||||||
33878546|NCT01476657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878547|NCT03881397|RANDOMIZED|PARALLEL||PREVENTION||NONE|This will be an online intervention with interventions pre-determined by tracks, so no masking is needed|Track A will be our intervention group receiving the Family Media Use intervention Track B will serve as control group at Time 2, and then receive an awareness intervention at that time to compare that intervention at Time 3 to Track A at Time 2||||
33878548|NCT00274521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878549|NCT02555735|||COHORT||RETROSPECTIVE|||||||
33878550|NCT06207136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Diet groups will be labelled without reference to the specific diet allocation (example: Yellow cooking group or Blue cooking group) for all participant communication.~Random assignment to either:~1. the active intervention diet group, or~2. the standard-of-care diet."|Intervention diet versus standard diet|t|f|t|f
33878551|NCT05758961|||COHORT||OTHER|||||||
33878552|NCT04395911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878553|NCT01339546|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33878554|NCT01265524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878555|NCT05119712|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Subjects will receive either terbinafine 500 mg or placebo for 16 weeks and then crossed over to the opposite therapy for another 16 weeks.|t|f|t|f
33878556|NCT02287974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878557|NCT06001138|||COHORT||PROSPECTIVE|||||||
33878558|NCT05113836|||COHORT||PROSPECTIVE|||||||
33878559|NCT05603715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878560|NCT04732741|||OTHER||CROSS_SECTIONAL|||||||
33878561|NCT06187376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878562|NCT00566930|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33878563|NCT02341092|||||PROSPECTIVE|||||||
33878564|NCT03432078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878565|NCT04708275|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arms, waitlist-controlled, randomized, single masked (outcomes assessor), single-center trial||||
33878566|NCT03096600|||CASE_ONLY||PROSPECTIVE|||||||
33878567|NCT00514865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878568|NCT02042937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878569|NCT00465595|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33878570|NCT03967548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878571|NCT03905993|||COHORT||CROSS_SECTIONAL|||||||
33878572|NCT02027103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878573|NCT00740350|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33878574|NCT03083340|NA|SINGLE_GROUP||TREATMENT||NONE||Deprexis consists of 10 content modules representing different psychotherapeutic approaches, plus one introductory and one summary module, each of which can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program (Meyer, et al., 2009).||||
33757718|NCT04644042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969498|NCT06358313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Our study was single-blinded to the investigators; an independent statistician generated a computer-generated randomization chart with a block size of four in a one-to-one ratio, and participants were randomly assigned to receive either atorvastatin or rosuvastatin by a specially trained and qualified nurse. None of the investigators included in the study knew the patients' assignments. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included atorvastatin bills, and Drug B included rosuvastatin bills. The statistical analysis was performed by an independent statistician.|The study will be composed of 2 arms atorvastatin arm, which consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and the rosuvastatin arm consisted of 300 patients who received 20 mg rosuvastatin daily for 3 months, All the patients in the two groups received open-label aspirin at a loading dose of 75 to 300 mg and then 75 mg daily till the end of the 3 months and an open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.|f|f|t|t
33969499|NCT03666182|||COHORT||CROSS_SECTIONAL|||||||
33969500|NCT00207714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969501|NCT03120585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069347|NCT05961605|||COHORT||RETROSPECTIVE|||||||
34069348|NCT04733625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069349|NCT00160264|RANDOMIZED|PARALLEL||||DOUBLE||||||
34069350|NCT01955317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069351|NCT00765947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069352|NCT04651166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069353|NCT05475834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069354|NCT05186051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069355|NCT01557192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069356|NCT06364436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069357|NCT04168320|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Starting two weeks prior to the initiation of radiotherapy serial, 7x blood samples will be taken every two days, excluding the weekend (for example, if starting on a Monday: Monday-Wednesday-Friday-Monday-Wednesday-Friday and Monday), but also on the day of the first radiotherapy treatment, to define the serial high-sensitivity C-reactive protein (hs-CRP) test, LDH and white cell differential count (leucocytes: neutrophils, basophils, eosinophils, lymphocytes, monocytes).~Data from the assays will be assembled in a spreadsheet and analyzed for levels and cyclical fluctuations to determine each patient's idiosyncratic immune cycle's periodicity and then each patient's time-position of initiation of treatment and response to therapy. Radiotherapy will be administered to the arm 1 (13 patients) at an estimated less favorable time-position, while it will be administered to the arm 2 (13 patients) at an estimated most favorable time-position in immune cycle."|t|f|f|t
33757719|NCT02662725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757720|NCT00816465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969502|NCT04275947|||COHORT||PROSPECTIVE|||||||
33969503|NCT03406689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33969504|NCT01094366|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33878575|NCT03627221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A licensed sleep technician, blinded to group assignment, visually analyzed sleep polygraphs by applying standard procedures.|The intervention is social networking and music listening. The outcome variables are sleep quality, sleep knowledge, and sleep hygiene. The control variables are participants' demographic data.|f|f|t|t
33878576|NCT03607760|||CASE_CONTROL||RETROSPECTIVE|||||||
33878577|NCT00476879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878578|NCT02555943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878579|NCT00110565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878580|NCT06268379|||OTHER||PROSPECTIVE|||||||
33878581|NCT05842187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878582|NCT06170515|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Arm 1: Evaluation of BGM's (listed below)~* CareSens N-Eco (i-Sens)~* CareSens N-Premier (i-Sens)~* CodeFree (SD Biosensor)~* GlucoNavii GDH (SD Biosensor) Comparator BGMs: Ascensia Contour Next One and Nova Statstrip Xpress (BG); using strip lots meeting CLSI POCT12 acceptance criteria as validated at an experienced laboratory using traceable analysers~Arm 2: HbA1c evaluation (listed below)~* Affinion (Abbott)~* HbA1c 501 (HemoCue)~* A1Care (iSens)~* DCA Vantage (Siemens)~Reference: NGSP-certified HbA1c laboratory method, validated with ERL reference samples"||||
33878583|NCT03721666|||OTHER||RETROSPECTIVE|||||||
33878584|NCT00722150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878585|NCT05167942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878586|NCT04388995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878587|NCT01857713|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878588|NCT04394533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, parallel group, double-blind, randomised, controlled, superiority trial|t|t|t|t
33878589|NCT00685126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878590|NCT00571350|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33878591|NCT05667714|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33878592|NCT02347176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878593|NCT06033820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878594|NCT01617330|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33878595|NCT05815303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878596|NCT06369012|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33878597|NCT05749380|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33878598|NCT03840655|||COHORT||PROSPECTIVE|||||||
33878599|NCT04451954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878600|NCT05157815|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind: The relationship between the randomisation number and the group assignment will be unknown to the clinical research team, the sponsor, trial site staff, and the participants, i.e. the trial will be double-blinded.||t|f|t|t
33878601|NCT05616936|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Factorial Assignment||||
33878602|NCT04159038|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Parents in the immediate intervention arm sign a study consent that is integrated into the Women, Infants, \& Children (WIC) Referral Form. They also complete a brief demographic survey. No consent is necessary in the delayed intervention arm as only aggregate information will be reported to the study team by Early Intervention/Early Childhood Special Education. EI/ECSE referrals are tracked from clinics in both arms for 6 months in ecWeb. At the end of the data collection period, the study team will meet to refine the intervention based on the experience with the immediate intervention group. Qualitative Interviews will take place with WIC staff, parents who indicate interest, EI/ECSE staff, and primary care providers during and after the post-intervention data collection period.||||
33878603|NCT05059496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878604|NCT01536860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33878605|NCT02488122|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33878606|NCT03354663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878607|NCT01971125|||CASE_ONLY||PROSPECTIVE|||||||
33878608|NCT03355508|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33878609|NCT02716610|RANDOMIZED|CROSSOVER||||NONE||||||
33878610|NCT01117636|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33878611|NCT00166205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969505|NCT02542306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969506|NCT00936975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969507|NCT03300193|||COHORT||PROSPECTIVE|||||||
33969508|NCT05012137|NA|SINGLE_GROUP||TREATMENT||NONE||This is a dosing exploratory study.||||
33969509|NCT03774979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969510|NCT01324245|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33969511|NCT03109873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33969512|NCT02271815|||CASE_ONLY||PROSPECTIVE|||||||
33969513|NCT04352842|||COHORT||PROSPECTIVE|||||||
33969514|NCT00567944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969515|NCT04195984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969516|NCT00170885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969517|NCT06042712|||CASE_CONTROL||PROSPECTIVE|||||||
33969518|NCT03139565|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33969519|NCT02373384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969520|NCT05676333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969521|NCT04025970|||COHORT||PROSPECTIVE|||||||
33757721|NCT04035213|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878612|NCT00692211|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33878613|NCT03405948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878614|NCT03616678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878615|NCT03677700|||CASE_ONLY||PROSPECTIVE|||||||
33878616|NCT02111993|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33878617|NCT00130403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878618|NCT01509352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878619|NCT03513003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878620|NCT02889796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757722|NCT05372770|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two groups of transgender women who have undergone surgery plus a group of healthy cisgender women who have not undergone surgery||||
33757723|NCT03642041|||COHORT||PROSPECTIVE|||||||
33757724|NCT03968757|||CASE_ONLY||PROSPECTIVE|||||||
33757725|NCT03350334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know whether they take placebo or Duloxetine|Prospective randomised|t|f|f|f
33757726|NCT03182699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Radiologist investigating the cMRI and physician performing the echocardiography will be blinded.~Patients will also be blinded"||t|f|f|t
33757727|NCT06276933|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33757728|NCT00969384|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33757729|NCT04061434|||COHORT||PROSPECTIVE|||||||
33757730|NCT05151068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757731|NCT03045406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757732|NCT00492609|||COHORT||PROSPECTIVE|||||||
33757733|NCT04137601|||COHORT||PROSPECTIVE|||||||
33757734|NCT02256670|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757735|NCT02216773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878621|NCT04405011|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33878622|NCT00201487|||COHORT||PROSPECTIVE|||||||
33878623|NCT04149067|||COHORT||RETROSPECTIVE|||||||
33878624|NCT05216965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878625|NCT04276675|||COHORT||PROSPECTIVE|||||||
33878626|NCT01376635|||CASE_CROSSOVER|||||||||
33878627|NCT00541554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878628|NCT04971304|||COHORT||RETROSPECTIVE|||||||
33878629|NCT00401271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878630|NCT01554280|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878631|NCT02452580|||COHORT||PROSPECTIVE|||||||
33878632|NCT03524248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878633|NCT02989792|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33878634|NCT01146106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878635|NCT05972460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878636|NCT04864444|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a two-arm cluster randomized controlled trial. A total of 60 villages will be randomized to receive the intervention (three rounds of MDA with DHA-PPQ + SLD-PQ) or control (standard malaria control measures, including SMC) at a ratio of 1:1||||
33878637|NCT00645983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878638|NCT01358656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33878639|NCT02368717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878640|NCT02013180|||CASE_CONTROL||PROSPECTIVE|||||||
33878641|NCT00223496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969522|NCT00580359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069358|NCT00429650|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069359|NCT05109208|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34069360|NCT03457623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069361|NCT00599742|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34069362|NCT05904678|||COHORT||RETROSPECTIVE|||||||
33878642|NCT00726687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878643|NCT05173454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The intervention will be single-blinded. The outcome assessors will be masked.|The study will have two arms, i.e., intervention and control groups. The intervention group will receive antenatal and postnatal breastfeeding education and support and control group will receive routine care.|f|f|f|t
33878644|NCT02392273|||CASE_ONLY||PROSPECTIVE|||||||
33878645|NCT02475811|||COHORT||PROSPECTIVE|||||||
33878646|NCT04938258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878647|NCT00000848||||TREATMENT||||||||
33878648|NCT03458390|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||HyGIeaCare colon irrigation procedure and PillCam COLON procedure||||
33878649|NCT00368771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878650|NCT04760925|||COHORT||OTHER|||||||
33878651|NCT06197828|||CASE_CONTROL||RETROSPECTIVE|||||||
33878652|NCT02066272|||COHORT||PROSPECTIVE|||||||
33878653|NCT01568593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33878654|NCT01376947|||CASE_CONTROL||PROSPECTIVE|||||||
33878655|NCT06539572|||CASE_CONTROL||RETROSPECTIVE|||||||
33878656|NCT05334186|NA|SINGLE_GROUP||OTHER||NONE||||||
33878657|NCT02138032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33878658|NCT06221475|NA|SINGLE_GROUP||OTHER||NONE||This is a single-arm open-label, single dose study in healthy male participants||||
33878659|NCT00037609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878660|NCT02274103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878661|NCT01495442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33757736|NCT01505387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878662|NCT01314300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878663|NCT04253275|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33878664|NCT05810545|||COHORT||PROSPECTIVE|||||||
33878665|NCT01678183|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33878666|NCT01394146|NA|SINGLE_GROUP||||NONE||||||
33878667|NCT02501044|||COHORT||RETROSPECTIVE|||||||
33878668|NCT00156312|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33878669|NCT06222151|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized into the intervention or control group. To assess the effect of the two interventions separately and independent of each other and to avoid inequality at the starting point of intervention 1 and 2, the patients will at the starting point be randomized into four different groups: A) Intervention 1/Intervention 2, B) Intervention 1/Control 2, C) Control 1/ Intervention 2 D) Control 1/Control 2 (Figure 1). This procedure will enable evaluation of one intervention group versus one control group who are different at each time point.||||
33878670|NCT05250375|||COHORT||PROSPECTIVE|||||||
33878671|NCT01726348|||CASE_ONLY||PROSPECTIVE|||||||
33878672|NCT02424526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878673|NCT01768455|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069363|NCT03999528|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34069364|NCT01742754|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069365|NCT02176109|||COHORT||PROSPECTIVE|||||||
34069366|NCT01789801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069367|NCT00069823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069368|NCT05601180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069369|NCT03466723|||CASE_CONTROL||PROSPECTIVE|||||||
34069370|NCT04686825|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757737|NCT04179721|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Nonrandom preliminary efficacy trial comparing 2 groups, intervention and control|f|f|t|t
33757738|NCT04632602|RANDOMIZED|CROSSOVER||OTHER||SINGLE||"Each patient will be his own control. The order of the experimental periods will be:~1. arm A: prone position followed by dorsal decubitus~2. arm B: dorsal decubitus followed by ventral decubitus A 30-minute wash-out period is set between the end of sequence 1 and the start of sequence 2."|t|f|f|f
33878674|NCT01931800|||COHORT||PROSPECTIVE|||||||
33878675|NCT02229552|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Children completed measurements of body weight, habituation to food, questionnaires and cognitive assessments in a repeated assessment prospective study.||||
33878676|NCT05797324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878677|NCT00723164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878678|NCT02825095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878679|NCT05166304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878680|NCT04018911|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each participant will be treated with each sound changing principle (Noise Reduction principle (NR)) in a randomized order.|t|f|f|f
33878681|NCT01569685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878682|NCT04113772|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33878683|NCT01562548|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33878684|NCT04758585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878685|NCT00176111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878686|NCT01926483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878687|NCT02469090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878688|NCT01168661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878689|NCT00920660|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33894413|NCT05662644|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients with esophageal cancer who are considered candidates for esophagectomy present to NCI in the period starting fromDecember 2022||||
33894414|NCT03476239|NA|SINGLE_GROUP||TREATMENT||NONE||"Evaluate the efficacy and safety of blinatumomab in Chinese subjects with relapsed/refractory B-precursor ALL, The study will consist of a screening period, a treatment period, and a follow-up period.~Treatment will consist of up to 5 cycles of blinatumomab"||||
33757739|NCT04413292|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757740|NCT06292988|||COHORT||RETROSPECTIVE|||||||
34069371|NCT01663857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757741|NCT06580288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757742|NCT01865708|NA|SINGLE_GROUP||OTHER||NONE||||||
33757743|NCT06221202|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Joining 12-week, 1 hour/week dance intervention online on Zoom.||||
33757744|NCT04618666|NA|SINGLE_GROUP||TREATMENT||NONE||single group in which half of them will be operated open and the other half laparoscopic||||
33757745|NCT04419844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757746|NCT04671979|||OTHER||CROSS_SECTIONAL|||||||
33757747|NCT02723942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757748|NCT00004549||||TREATMENT||||||||
33757749|NCT03440684|NA|SINGLE_GROUP||TREATMENT||NONE||Participants were included group exercise programme. The programme had been performed for 6 weeks. And participants were evaluated after exercise training programme.||||
33757750|NCT05152173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757751|NCT04756557|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The study will be double-blinded (blinded for the study subjects as well as for the investigators). The blind must not be broken throughout the study. Only after study end, study subjects will be informed on the toothpaste received, if requested by the subject.|Multicenter, double-blind, randomized, active-controlled parallel-group study.|t|t|t|t
33757752|NCT01980407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757753|NCT02080871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757754|NCT02770781|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757755|NCT05565729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33757756|NCT05934812|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33757757|NCT00758238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757758|NCT04484974|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The two treatments are pecan nuts or tortilla chips as snacks, therefore masking of treatment conditions is not possible.|Randomized, two period crossover with two treatment conditions||||
33894415|NCT03289689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069372|NCT04028323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34069373|NCT03795883|||COHORT||PROSPECTIVE|||||||
34069374|NCT06472687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomised controlled trial.|t|f|t|f
34069375|NCT01456546|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34069376|NCT02245035|||CASE_ONLY||PROSPECTIVE|||||||
34069377|NCT03389880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33757759|NCT00578955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757760|NCT03020225|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894416|NCT03282396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894417|NCT01025635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757761|NCT04835818|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33757762|NCT06094530|||CASE_CONTROL||PROSPECTIVE|||||||
33757763|NCT01938651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894418|NCT00184587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894419|NCT01829048|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33757764|NCT01948635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757765|NCT05900284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All parties are blinded by participant group.|One 500mg or 1,000mg tablet will be administered twice a day for the first (5) days of study treatment. One inactive tablet will be administered twice a day for the first (5) days of study treatment|t|t|t|t
33757766|NCT02241941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894420|NCT00969579|||||PROSPECTIVE|||||||
33894421|NCT06653218|||COHORT||PROSPECTIVE|||||||
33894422|NCT00284115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757767|NCT01383265|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
33757768|NCT04834310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be performed prior to surgery, and an assigned coordinator will generate group assignments. Patients and surgeons will be blinded to the study before randomization takes place. However, surgeons will have access to information following medication dispensation in case any complications arise so that the provider can carry out appropriate interventions.|The study will be designed as a non-inferiority trial with two parallel groups: the experimental group will receive an intraoperative dose of antibiotics followed by oral antibiotics for 5 days postoperatively (Cephalexin 500 mg QID or Clindamycin 300 mg QID, if Penicillin allergic) while the control group will receive an intraoperative dose of antibiotics (Cefazolin 1 g or 2 g, or Clindamycin 600 mg or 900 mg, if Penicillin allergic, higher doses provided if BMI \> 30 kg/m2) followed by a placebo for 5 days postoperatively.|t|t|t|f
33757769|NCT04523155|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33757770|NCT01529125|||CASE_CONTROL||PROSPECTIVE|||||||
33757771|NCT04386525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894423|NCT02588456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894424|NCT01663441|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33894425|NCT01009411|||COHORT||CROSS_SECTIONAL|||||||
33894426|NCT00968266|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33894427|NCT00121823|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33894428|NCT03352440|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894429|NCT01576211|||CASE_CONTROL||RETROSPECTIVE|||||||
33757772|NCT03457519|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Intervention Group A - Community Health Workers (CHWs) (Basic training in CHW curriculum, ChARM training and 8-month application of the ChARM device, self-monitoring, direct observation and review of CHW routine monthly reports and drug supply sheets): 8 months, March- November 2018.~Intervention Group B - Community Health Workers (Basic training in CHW curriculum, ChARM training and 4-month application of the ChARM device, self-monitoring, direct observation and review of CHW routine monthly reports and drug supply sheets): March- November 2018.~Control Group C - Community Health Workers (Basic training in CHW curriculum, direct observation and CHW routine monthly reports and drug supply sheets): 8 months, March- November 2018."||||
33757773|NCT06575777|||OTHER||CROSS_SECTIONAL|||||||
33757774|NCT06580431|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Saliva and serum of periodontitis and smoking patients collected for analyzing TMAO levels||||
33757775|NCT02992587|||COHORT||PROSPECTIVE|||||||
33757776|NCT02124382|||COHORT||RETROSPECTIVE|||||||
33757777|NCT01274052|||COHORT||PROSPECTIVE|||||||
33757778|NCT03829124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757779|NCT04180644|||COHORT||CROSS_SECTIONAL|||||||
33757780|NCT00018135|RANDOMIZED|SINGLE_GROUP||PREVENTION||||||||
33757781|NCT05423925|||CASE_CONTROL||RETROSPECTIVE|||||||
33757782|NCT00079001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757783|NCT04299880|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Individual patients will continue to be treated with napabucasin (monotherapy or combination) in accordance with the parent study under which they were enrolled.||||
33757784|NCT04376554|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects will be randomized by gender to 1:1 ratio to receive TBPM-PI-HBr or amoxicillin-clavulanate using a SAS ® generated randomization code and the treatment allocation will be performed using a block randomization algorithm.|Single-Center, Open-Label, Randomized, Parallel-Group, Active Control, Phase 1 Study||||
33757785|NCT03390868|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Intervention arm: web-based training for staff working with people with intellectuall disabilities and challenging behaviour Other: control arm||||
33757786|NCT02178566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757787|NCT06454760|||OTHER||PROSPECTIVE|||||||
33757788|NCT06457828|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33757789|NCT04806828|||COHORT||PROSPECTIVE|||||||
33757790|NCT03513796|||CASE_ONLY||RETROSPECTIVE|||||||
33757791|NCT03403868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757792|NCT02536365|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33757793|NCT02070068|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33757794|NCT03224013|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Interventional prospective consecutive comparative case control series of cases; 50 eyes of 25 patients with mean age 35.7 ± 12.4 (Range 18-61years) with hyperopia or hyperopic astigmatism underwent customized LASIK with concurrent prophylactic high-fluence cross-linking in right eye (group 1) and customized LASIK only in left eye (group 2). Cases with hyperopia +1D to +6D or hyperopic astigmatism up to 4D were included in the study. Patients with previous intraocular or corneal surgery, active corneal disease were excluded from the study.~Main outcome measures were uncorrected visual acuity (UCVA), manifest refractive spherical equivalent (MRSE), cycloplegic refractive spherical equivalent (CRSE), keratometric measurments and spherical aberrations at 4 mm and maximum pupilnand their ecolution along 6 months postoperatively."||||
33894430|NCT00877838|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33969523|NCT05343949|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Random order of the delivery of the HIIT protocol|"Patients will once screened will attend on 3 visits and will perform in a random order all of below protocols:~A - High-intensity duration and intensity: 5 seconds Rest duration: 40 seconds Number of Repetitions: 54 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds) B - High-intensity duration and intensity: 10 seconds Rest duration: 80 seconds Number of Repetitions: 27 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds) C - High-intensity duration and intensity: 30 seconds Rest duration: 240 seconds Number of Repetitions: 9 Total duration of HIIT protocol: 2,430 seconds (40 minutes, 30 seconds)"|t|f|f|f
33894431|NCT06657664|RANDOMIZED|PARALLEL||TREATMENT||NONE|all participants have an equal chance to be enrolled in any of the study groups. This pattern was the most suitable way to ensure the balance of the anonymous prognostic factors in the participants between the three groups thus, eliminating the selection or allocation bias|This is a randomized clinical study.||||
33894432|NCT05029622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894433|NCT03319199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894434|NCT01144754|||COHORT||PROSPECTIVE|||||||
33894435|NCT04273984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33969524|NCT02281630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969525|NCT03945344|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33969526|NCT06527313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research was designed as a double-blind randomized controlled study in which the participant and the evaluator were blinded.|. The study will be planned as a parallel research with 3 groups.|t|f|f|t
33969527|NCT06410937|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33894436|NCT05966818|RANDOMIZED|PARALLEL||TREATMENT||NONE|90 opaque envelopes will be numbered serially and the corresponding letter which denotes the allocation will be put according to the electronic randomization table. Then all envelopes will be closed and put in one box. When the first patient arrives, the envelope will be opened and the patient will be allocated according to the letter inside.|The study is a Prospective, Randomized, Interventional, Parallel, Open Label study.||||
33894437|NCT05440825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894438|NCT02175550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894439|NCT04363216|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33894440|NCT01760434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894441|NCT00499265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894442|NCT04314687|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33894443|NCT00054470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757795|NCT03791164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigator and the outcome assessor are blinded as to which intervention the participants have been allocated until after data collection and evaluation|This is a randomised controlled trial, with a nested qualitative element|f|f|t|t
33757796|NCT03116984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757797|NCT04387630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757798|NCT01572389|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757799|NCT04510675|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|The trained skin evaluator and Investigator was blinded to the identity of the test materials. Test/control sites were randomized within participants.|The study design is based on a Modified Draize Human Repeat Insult Patch Test.||||
33757800|NCT05320055|||COHORT||RETROSPECTIVE|||||||
33757801|NCT03359122|||CASE_ONLY||RETROSPECTIVE|||||||
33757802|NCT02216266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878690|NCT03496090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient data will be delivered to the investigator/s of the study of each hospital, who will fill out the Data Collection Notebook (DCN) of each patient and program their controls without information of the group to which the patient has been assigned, as such In this way, the consultations are carried out with blinding of the evaluator (the investigator who will do the controls will not know to which group the patient has been assigned).~The person in charge of carrying out the statistical analysis will not be able to know to which group the patient has been assigned due to the coding done in the DCN."|The study is a randomized, multicentric, controlled with active comparator, parallel group, blind to the evaluator, to demonstrate the non-inferiority in the efficacy and therapeutic and safety of the free diet (group 1) compared to the progressive diet (group 2) in the treatment of uncomplicated acute diverticulitis. This study will be carried out on 134 patients with uncomlpicated acute diverticulitis. The subjects will be randomized in a 1: 1 ratio to receive treatment with progressive diet or diet at free demand. The main analysis will take place two months after the start of treatment.|f|f|t|t
33878691|NCT00004262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878692|NCT02684214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878693|NCT06044116|||COHORT||RETROSPECTIVE|||||||
33878694|NCT04433650|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Arm 1: Treatment 1 is control and treatment 2 is intervention. Arm 2: Treatment 1 is intervention and treatment 2 is control.||||
33878695|NCT00317798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878696|NCT03534427|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||exercise intervention group, control group||||
33878697|NCT03725748|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33878698|NCT04381611|||COHORT||OTHER|||||||
33878699|NCT00097461|||||PROSPECTIVE|||||||
33969528|NCT02134574|||COHORT||PROSPECTIVE|||||||
33878700|NCT00643643|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33878701|NCT06092073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878702|NCT06084377|||OTHER||CROSS_SECTIONAL|||||||
33878703|NCT00326898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878704|NCT00737867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878705|NCT00264875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878706|NCT05692037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878707|NCT02321254|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33878708|NCT03464500|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33894444|NCT04357171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33894445|NCT04126148|||OTHER||PROSPECTIVE|||||||
33969529|NCT03874806|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33878709|NCT03161756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Trial design updated from randomised allocation of patients to physician's choice as per version 2.2 of protocol, there will be a pre-specified number of patients with stage IV M1c disease in each arm (approximately 60%).||||
33878710|NCT05373147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878711|NCT00649532|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33878712|NCT04280900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969530|NCT03847883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Cohort A double blind Randomized controlled trial 0.6 or 0.7 or 0.9 mg/Kg Ateplase in78 patients (preliminary) Cohort B single arm standard dose 0.9 mg/kg Ateplase in 330 patients|t|f|t|t
33878713|NCT00419328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878714|NCT01896375|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969531|NCT06279897|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants are blinded to the skin temperature control.|Participants will complete trial 1 at the beginning of the study. Participants will then complete trials 2 through 5 in a random, counterbalanced order.||||
33969532|NCT01381900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33969533|NCT04645290|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding of people in charge of both initial and final measurements, and of those who perform data analysis|Double-blind controlled clinical trial-type experimental design , with a mixed approach (QUAN + qual), with an intervention group and a control group.|f|f|t|t
33969534|NCT03712969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969535|NCT05344066|RANDOMIZED|PARALLEL||TREATMENT||NONE|Non blinded (statistician and laboratory staff will remain blinded).|Randomised two-arm feasibility trial||||
33969536|NCT01478503|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33969537|NCT03549130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969538|NCT01974271|||COHORT||PROSPECTIVE|||||||
33969539|NCT04131361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969540|NCT01857791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969541|NCT02247570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969542|NCT05678920|||OTHER||PROSPECTIVE|||||||
33878715|NCT02724995|||COHORT||PROSPECTIVE|||||||
33878716|NCT05679141|||CASE_ONLY||PROSPECTIVE|||||||
33878717|NCT00193765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878718|NCT00902785|||CASE_CONTROL||PROSPECTIVE|||||||
33878719|NCT04760665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878720|NCT05740228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, triple-blind, placebo-controlled, parallel-group study|t|t|f|t
33878721|NCT05581914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878722|NCT03602872|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33878723|NCT00194545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878724|NCT03604965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878725|NCT04064775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were informed they were in a study about snacking behaviour but were not told that we were attempting to reduce their portion sizes.|Intervention 2 used a parallel design where participants were either allocated to an intervention or a control group in a between-subjects repeated measures design.|t|f|f|f
33878726|NCT06445868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33878727|NCT02741102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878728|NCT04190225|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||1:1 treatment: control|f|f|f|t
33878729|NCT03343132|||CASE_CONTROL||PROSPECTIVE|||||||
33878730|NCT01716910|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33878731|NCT01801956|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33878732|NCT01297270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878733|NCT06339528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Stimulation of trigger zones according to Vojta's therapy was applied to 20 of them by a team of licensed physiotherapists while a control group received a sham stimulation carried out by physicians. Cardiotocographic (CTG) recordings were conducted right before and immediately after stimulation. CTG recordings were subsequently blindly evaluated by 2 independent obstetricians. Patients did not know if clinician have skills to stimulate properly according to the Vojta's Reflex Locomotion.|A total of 40 pregnant patients between 40+0 to 41+0 weeks of gestational age were randomly selected for this study. Stimulation of trigger zones according to Vojta's therapy was applied to 20 of them by a team of licensed physiotherapists while a control group received a sham stimulation carried out by physicians. Cardiotocographic (CTG) recordings were conducted right before and immediately after stimulation. CTG recordings were subsequently blindly evaluated by 2 independent obstetricians.|t|t|f|t
33878734|NCT00679705|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33878735|NCT03524261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
33878736|NCT02841215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878737|NCT01312935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878738|NCT03524339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878739|NCT05872776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878740|NCT03824847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33878741|NCT01902550|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33878742|NCT01975415|||COHORT||PROSPECTIVE|||||||
33878743|NCT04847973|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878744|NCT05625828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33878745|NCT01914562|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33878746|NCT05170243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878747|NCT02936141|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878748|NCT04198415|||COHORT||PROSPECTIVE|||||||
33878749|NCT03434405|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open-label, prospective, non-randomized, single-group, clinical trial. The experimental arm will receive TAU (both drug and psychosocial therapy) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team.||||
33878750|NCT03878511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Active and inactive tablets were identical. The tablets were packed and labelled by the manufacturer. The key to identity was retained and was disclosed after recruiting all patients. After informed consent, eligible patients drew a closed opaque envelope from a set of envelopes numbered 1-40 and placed in random order. The envelope contained both number labels for medical data-related documents and sample vials and a closed opaque container holding tablets labelled with the sample number.||t|t|t|f
33878751|NCT06276803|||COHORT||PROSPECTIVE|||||||
33878752|NCT06081556|||COHORT||RETROSPECTIVE|||||||
33878753|NCT04000685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Parallel Assignment|f|f|f|t
33878754|NCT05825508|||COHORT||PROSPECTIVE|||||||
33757803|NCT01257776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878755|NCT03096509|||COHORT||PROSPECTIVE|||||||
33878756|NCT02936700|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33878757|NCT04880200|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"For the aim #3 RCT, we will randomize participants 1:1 to the POC NAT intervention arm and to standard of care. The intervention will include a SAMBA test and adherence counseling intervention developed by the study team to accompany delivery of test results. The study team will train participating primary care providers (PCPs) in delivery of the adherence counseling intervention.~Study staff will discuss the study, obtain informed consent, and, for participants randomized to POC NAT, perform SAMBA and provide results to the PCP. Study staff will perform venipuncture, ensure that individual laboratory NAT is performed, and administer a brief CASI. PCPs will deliver the POC NAT result and adherence counseling intervention to patients during their visit. Participants will be asked to sign an ROI that allows the study to share POC NAT results with the PCP and allows the study staff to obtain outcomes measures from clinical patient data for longitudinal follow up."||||
33878758|NCT01614587|||CASE_CONTROL||PROSPECTIVE|||||||
33878759|NCT04247425|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33878760|NCT01899235||||TREATMENT||||||||
33878761|NCT02811692|||OTHER||RETROSPECTIVE|||||||
33878762|NCT02322060|||CASE_ONLY||PROSPECTIVE|||||||
33878763|NCT00179582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33878764|NCT05138835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878765|NCT05691855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878766|NCT04901910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878767|NCT05278195|||OTHER||RETROSPECTIVE|||||||
33878768|NCT02950220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878769|NCT04697407|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878770|NCT04011865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969543|NCT01818570|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33757804|NCT04227574|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33757805|NCT06070402|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental design with two groups: the control group and the experimental group, using pre and post evaluations by means of a randomized controlled trial.||||
33757806|NCT01010425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757807|NCT03248765|||CASE_CONTROL||PROSPECTIVE|||||||
33969544|NCT02524106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757808|NCT03305523|NA|SINGLE_GROUP||OTHER||NONE||"Short and long-term complications of male circumcisions using thermocautery was examined during 2 years period.~Complications were classified as perioperative (bleeding during the circumcision or under observation at the hospital after circumcision that required knotting or cauterization, scrotum or penile injury), early postoperative (first 10 days after being discharged) and long-term (late postoperative = after 10 days) (skin-mucosal bridge, delayed wound healing, secondary phimosis, meatitis)."||||
33757809|NCT02059967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757810|NCT05008783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757811|NCT01867099|||COHORT||PROSPECTIVE|||||||
33878771|NCT02534259|||CASE_ONLY||PROSPECTIVE|||||||
33878772|NCT04467307|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33878773|NCT04931992|||COHORT||RETROSPECTIVE|||||||
33878774|NCT06194773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969545|NCT05871879|||COHORT||RETROSPECTIVE|||||||
33969546|NCT04466449|||OTHER||CROSS_SECTIONAL|||||||
33969547|NCT00672022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969548|NCT06433349|||FAMILY_BASED||PROSPECTIVE|||||||
33969549|NCT04303845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969550|NCT03639428|||CASE_ONLY||RETROSPECTIVE|||||||
33969551|NCT01166971|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33969552|NCT01567215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969553|NCT01590433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969554|NCT04028583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969555|NCT00873210|||COHORT||PROSPECTIVE|||||||
33969556|NCT04506528|||COHORT||OTHER|||||||
33969557|NCT00493753|RANDOMIZED|FACTORIAL||||SINGLE||||||
33757812|NCT05080062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||50 patients who are in painrehabilitation will also receive the intervention. The control Group will be based on patients from 2017 and 2018 who has underwent rehabilitation. This data will be extracted from the National register of pain rehabilitation in Sweden.||||
33757813|NCT02460692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33757814|NCT03537079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|this is a single blind study patients don't know if they are breathing normal air (normoxia) or hypoxic air (hypoxia).||t|f|f|f
33969558|NCT04980521|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33757815|NCT05296499|||COHORT||PROSPECTIVE|||||||
33878775|NCT03958552|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre-post design where control data will be collected prior to intervention being implemented||||
33878776|NCT02454166|||CASE_ONLY||PROSPECTIVE|||||||
33878777|NCT06222840|||CASE_CONTROL||RETROSPECTIVE|||||||
33878778|NCT05828693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878779|NCT02852512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878780|NCT02085434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969559|NCT04363411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33969560|NCT05773690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969561|NCT01598649|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33969562|NCT01735058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969563|NCT05221606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33969564|NCT00618774||PARALLEL||TREATMENT||||||||
33969565|NCT01624831|||COHORT||PROSPECTIVE|||||||
33969566|NCT03266549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969567|NCT04382157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969568|NCT04665479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One group pre- and post-test clinical trial design||||
33969569|NCT00910858||PARALLEL||TREATMENT||NONE||||||
33969570|NCT00939705|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33969571|NCT03920436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969572|NCT04403100|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"The investigational medical product will be packaged in similar bottles by a third party who will keep the allocation confidential until the end of the study. The bottles will be sealed and identified as Research Product A, B and C and with different colored labels. They will be randomly allocated among the participants. The research subjects, medical assistance, administrative and health staff will not have access to the contents of the bottles. The Arm Lopinavir/ ritonavir plus hydroxychloroquine will receive two of such bottles.~At the end of the study, after the statistical analysis and DMSB meeting, it will then be requested from third party documentation on content of each bottle and then have arms identified."|"Patients will be randomly allocated to one of four treatment arms in a 1:1:1:1 ratio:~1. Lopinavir / Ritonavir~2. Hydroxychloroquine~3. Lopinavir / Ritonavir + Hydroxychloroquine~4. Placebo.~We will use a centralized random allocation schedule, generated by computer and implemented using an online remote access system. Randomization will be stratified by participating basic health unit."|t|t|t|t
33969573|NCT02266706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969574|NCT01140178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969575|NCT01880710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969576|NCT04897100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969577|NCT01851590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969578|NCT06528756|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective block-randomized experimental longitudinal analytical clinical trial~Patients will be stratified into two arms according to the Bianchi Martinoli classification (I or II/III) and will subsequently be included in groups based on the treatment received, US-PICT or ESWT . The decision to treat with one or another therapy will be made randomly 1:1, based on the treatment assigned to the previous patient. An initial consultation and 3 reviews (1 month, 3 months and 6 months) will be carried out after completing the therapy."||||
33969579|NCT04387747|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969580|NCT02615327|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33969581|NCT02642627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969582|NCT06543784|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969583|NCT05747365|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969584|NCT00055874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969585|NCT01360957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969586|NCT04146220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969587|NCT04503798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The study personnel who conduct screening and send pre/post-test surveys to participants are all blinded.~Randomizer is blinded to all participant pre-test outcomes. Care providers know what their participants are doing, but not aware of the full study design, including details of the other conditions or outcome test characteristics."|Participants are screened, undergo a battery of tests at pre-test, and then are randomly assigned to one of two conditions: online GMT intervention or treatment-as-usual control group. After the intervention, the participants take the same test battery and complete it once more at 6 week follow-up.|t|f|t|t
33969588|NCT03103659|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33969589|NCT04841239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969590|NCT02500017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969591|NCT00180830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969592|NCT00063960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969593|NCT00408876|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34069378|NCT03706716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Arm A - intervention /consultation with use of decision aid Arm B - Controls / consultation without use of decision aid||||
33969594|NCT00443950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969595|NCT03381885|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33969596|NCT04782115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969597|NCT01239147|RANDOMIZED|PARALLEL||||NONE||||||
33969598|NCT05036915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069379|NCT02116725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069380|NCT03102671|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34069381|NCT00623298|NON_RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
34069382|NCT05607121|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34069383|NCT00906854|||COHORT|||||||||
33878781|NCT01981642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878782|NCT04385654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878783|NCT04849039|||COHORT||PROSPECTIVE|||||||
33878784|NCT06266143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878785|NCT04740476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878786|NCT01140386|||COHORT||RETROSPECTIVE|||||||
33878787|NCT00909558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878788|NCT02836067|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878789|NCT03847987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878790|NCT02448407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878791|NCT06409312|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33878792|NCT05009719|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The patients in this study will be divided into 2 groups: prophylactic and preventive depending on indications. Patients without signs of disease with high risk of relapse will be included into prophylactic group. Patients with persistence minimal residual disease or cytogenetic relapse will be included into preventive group. Also, patients will move from the first group to second group, if the clinical status changes.||||
33878793|NCT04993365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878794|NCT03682978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|AIMS2-CT-01 is a double-blind study where participants and parent(s)/legal guardians as well as research staff will be unaware of the treatment allocation, with the exception of a dedicated unblinded pharmacist at each individual site. Blinding of the remainder of the study team members will be maintained by utilizing identical tablets, blistercards and boxes containing either Arbaclofen or placebo. Unblinded study drug and placebo supplies will be stocked at each study site pharmacy. An online randomization system will be used, by this unblinded pharmacist, to assign the study treatment. Based on the outcome of the randomisation, the pharmacist prepares the boxes containing the applicable treatment and releases these (blinded) boxes to the investigator for dispensing to the patient. In order to maintain the study blind, the dosing regimen will be consistent whether participants are randomized to Arbaclofen or placebo.||t|t|t|t
33878795|NCT04567212|||CASE_CONTROL||PROSPECTIVE|||||||
33878796|NCT06218719|||CASE_CROSSOVER||PROSPECTIVE|||||||
33878797|NCT01169077|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33969599|NCT04728113|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969600|NCT01901315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33969601|NCT05122585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969602|NCT04524481|||COHORT||PROSPECTIVE|||||||
33969603|NCT01743677|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33969604|NCT01403350|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33969605|NCT03548376|NA|SINGLE_GROUP||TREATMENT||NONE|the scoring of repeated evaluations was blinded regarding order. To do so, the scores of all of the instruments were calculated without the knowledge of which was the evaluation (T1, T2 or T3) or access to the previous scores of the same child. The GMFM-88 score was made by an examiner who did not participate in the data collection (evaluations and intervention). This examiner watched the videos and was blinded to the child's descriptive information and the order of the evaluation. The ECAB test score was calculated by two other external examiners who watched the videos and were also blinded regarding the same information.|Before-after trial (6 months of follow-up; one group with three repeated measurements)||||
33969606|NCT01317732|NA|SINGLE_GROUP||OTHER||NONE||||||
33969607|NCT05211050|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33969608|NCT01513057|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878798|NCT00716105|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33878799|NCT05929690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878800|NCT04899297|||COHORT||CROSS_SECTIONAL|||||||
33878801|NCT01778114|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33969609|NCT02541695|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33969610|NCT04835298|||CASE_ONLY||PROSPECTIVE|||||||
33969611|NCT02334956|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969612|NCT01696474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969613|NCT01997528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969614|NCT00833781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069384|NCT03843320|||COHORT||PROSPECTIVE|||||||
34069385|NCT05034380|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Investigators conducting molecular analysis were blinded to study samples/groups.|All participants underwent the same exact study protocol on random days throughout the study period.|f|f|f|t
34069386|NCT05176639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069387|NCT01042392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069388|NCT03180931|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969615|NCT00231296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069389|NCT01616758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069390|NCT05326438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069391|NCT03850015|||CASE_CONTROL||PROSPECTIVE|||||||
34069392|NCT05667168|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|The participants and care providers will not know the checking data.|intervention study|t|t|f|f
34069393|NCT03672344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969616|NCT00514995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069394|NCT00417521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069395|NCT05258032|||CASE_ONLY||PROSPECTIVE|||||||
34069396|NCT04739592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069397|NCT03675971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
33969617|NCT02112903|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33969618|NCT00618969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969619|NCT03902756|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33969620|NCT02327520|||CASE_ONLY||RETROSPECTIVE|||||||
33969621|NCT02131896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969622|NCT06038188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969623|NCT06338020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment.|A prospective, dual-arm, randomized controlled trial|f|f|f|t
33969624|NCT02922803|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969625|NCT02531828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969626|NCT05935774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969627|NCT03654534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969628|NCT05126381|||CASE_CONTROL||PROSPECTIVE|||||||
33969629|NCT00362401|||COHORT||RETROSPECTIVE|||||||
33969630|NCT04597606|||COHORT||PROSPECTIVE|||||||
33969631|NCT02006147|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33969632|NCT00411047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969633|NCT05454423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Aquatic Exercise and traditional physical therapy are effective methods of treatment for gout and hypertension in menopausal women.|t|f|f|f
33969634|NCT01238822|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33969635|NCT02558426|||COHORT||PROSPECTIVE|||||||
33969636|NCT00439764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969637|NCT04496089|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||open-label, safety, pharmacokinetic, diagnostic, prospective, multi-center||||
33969638|NCT04035837|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33969639|NCT01853007|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34069398|NCT00843011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069399|NCT03696199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069400|NCT01981811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069401|NCT00545935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069402|NCT03937674|NA|SINGLE_GROUP||TREATMENT||NONE||"At each decision time-a time point when an intervention component can be delivered-each day of the study each participant is randomized between intervention or no intervention (delivery of a contextually tailored activity suggestion or no suggestion; morning motivational message or no motivational message)"||||
34069403|NCT00498810|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069404|NCT01510964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34069405|NCT05805020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069406|NCT02303197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069407|NCT03172377|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized controlled, open label non-inferiority trial||||
34069408|NCT04813107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069409|NCT02204436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069410|NCT05643729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be double blinded such that neither the patients nor the researchers will know who is getting a placebo and who is getting the treatment. Only product manufacturing staff will be un-blinded.|This is a phase I/II randomized, double blinded and placebo control. The ratio between groups is 1:1 for total 20 subjects. Each subject will be randomized to receive either treatment or placebo.|t|t|t|f
34069411|NCT05552742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069412|NCT04876131|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be recruited when they present to the emergency department with a complicated UTI. Once they have been consented to the study they will then be randomised into one of the treatment arms, these treatment arms will run parallel to one another.||||
34069413|NCT04723589|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking will not be used. Participants randomized to standard care will not receive a sham treatment.|Group 1: Standard care for COVID-19 Group 2: Standard care plus non-convalescent plasma infusion||||
34069414|NCT06271161|||OTHER||PROSPECTIVE|||||||
34069415|NCT06612931|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34069416|NCT05948137|||COHORT||PROSPECTIVE|||||||
34069417|NCT02364076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069418|NCT04930705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878802|NCT00557219|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33878803|NCT04134962|||COHORT||PROSPECTIVE|||||||
33878804|NCT06351995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878805|NCT00562549|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33878806|NCT05042310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33878807|NCT05848154|||COHORT||PROSPECTIVE|||||||
33878808|NCT05066490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||40 obese children who suffered from vitamin d deficiency were randomly assigned into three groups. group I (15 children) received endurance exercises and group II (15 children) received endurance exercises preceded by resistance exercises which have a stronger lipolytic effect. group III (10 children) acted as a control group.|t|t|f|t
33878809|NCT04485312|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33878810|NCT05725356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878811|NCT02002975|||COHORT||PROSPECTIVE|||||||
33878812|NCT05618379|||OTHER||PROSPECTIVE|||||||
33878813|NCT01365559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878814|NCT05341271|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33878815|NCT01692301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878816|NCT00663065|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33878817|NCT03557281|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open label study. Hence, there will be no masking.|Eligible subjects in each cohort will be randomized to receive sequential doses of either GSK3036656 or standard-of-care (RIFAFOUR) regimen. This study will employ dose escalation, where the decision to proceed to each subsequent dose level will be made based on safety, tolerability and preliminary pharmacokinetic data from the prior cohort.||||
34069419|NCT01397149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069420|NCT04835961|||OTHER||PROSPECTIVE|||||||
34069421|NCT05546840|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34069422|NCT02264938|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34069423|NCT02168777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069424|NCT01453790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34069425|NCT01662856|RANDOMIZED|PARALLEL||TREATMENT||||||||
34069426|NCT05397340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069427|NCT04428528|||COHORT||PROSPECTIVE|||||||
34069428|NCT03953599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069429|NCT02352961|||||CROSS_SECTIONAL|||||||
34069430|NCT03397602|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34069431|NCT00888797|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069432|NCT03973398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34069433|NCT05999591|||COHORT||RETROSPECTIVE|||||||
33878818|NCT00371878|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33878819|NCT01272999|||CASE_ONLY||PROSPECTIVE|||||||
33878820|NCT04273178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33878821|NCT04833283|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33878822|NCT00379860|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33878823|NCT00664235|||||PROSPECTIVE|||||||
33878824|NCT02767648|||COHORT||PROSPECTIVE|||||||
33878825|NCT05648435|||CASE_CONTROL||PROSPECTIVE|||||||
33878826|NCT05537805|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study in a tertiary referral center. Investigators evaluated the procedure on a group of 30 participants that were referred to our unit for proximal tubal occlusion demonstrated by hysterosalpingo-foam sonography or hysterosalpingography.||||
33878827|NCT04326608|||COHORT||PROSPECTIVE|||||||
33878828|NCT03711643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33878829|NCT01158482|||CASE_ONLY||PROSPECTIVE|||||||
33878830|NCT06318910|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Participants will be allocated to the control (CFO without wedge) or experimental (CFO with W1 or W2) groups according to the seal-envelop randomization technique. Then, they will be assessed all outcomes for the baseline including pain intensity, foot function, lower-extremity muscle activity during gait and standing by the 2nd physical therapist. And the participants will receive the assigned treatment by the 1st physical therapist.|The present study will use a randomized controlled trial (RCT) to determine the effectiveness of CFO for the treatment of patients with PHP. Three treatment groups including the CFO without wedge, the CFO with W1, and the CFO with W2 will be randomly assigned to each participant by a computer-generated randomization. The opaque-sealed envelopes will be used to allocate the groups of participant.|f|f|f|t
33878831|NCT03530410|||CASE_CROSSOVER||PROSPECTIVE|||||||
33878832|NCT03960281|||COHORT||RETROSPECTIVE|||||||
33878833|NCT04623450|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34069434|NCT00662311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069435|NCT02044653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069436|NCT00242047|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33757816|NCT04596202|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Crossover Design Model|f|f|t|f
33757817|NCT02026180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878834|NCT02517775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33878835|NCT02084277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878836|NCT03799393|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33878837|NCT02692495|||COHORT||RETROSPECTIVE|||||||
33878838|NCT02229071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878839|NCT00724997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878840|NCT03041285|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|There is no masking.|Group 1 (6 participants) will receive 400mg of Idronoxil (NOX66) daily in the form of one suppository. Group 2 (6 participants) will receive 800mg of Idronoxil daily (two suppositories). Group 2 will only commence once all group 1 participants have completed their treatment course and have experienced no toxicity greater than grade 2 according CTCAE version 4.03 for adverse events assessment.||||
33878841|NCT02030743|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33878842|NCT05560958|||OTHER||PROSPECTIVE|||||||
34069437|NCT00311922|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34069438|NCT01956760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757818|NCT00026143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757819|NCT05415800|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33757820|NCT01648348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757821|NCT03535064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757822|NCT03687567|||COHORT||RETROSPECTIVE|||||||
33757823|NCT01701986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757824|NCT02573402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757825|NCT05087381|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, multiarm, prospective, randomised controlled trial||||
33757826|NCT04420468|||COHORT||RETROSPECTIVE|||||||
33878843|NCT04727762|||COHORT||RETROSPECTIVE|||||||
34069439|NCT04302207|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||non-randomized controlled trial of ROUTT-B using a parallel experimental and control interrupted time series study design extending over baseline, intervention, and post-intervention period.|t|f|f|f
34069440|NCT02861430|||COHORT||PROSPECTIVE|||||||
34069441|NCT00003896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069442|NCT05527795|||OTHER||PROSPECTIVE|||||||
34069443|NCT00287729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069444|NCT04159441|||CASE_ONLY||PROSPECTIVE|||||||
34069445|NCT04690335|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069446|NCT02417558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069447|NCT01994707|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34069448|NCT03848897|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069449|NCT03418597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069450|NCT01396551|NA|SINGLE_GROUP||OTHER||NONE||||||
34069451|NCT05009134|||COHORT||PROSPECTIVE|||||||
34069452|NCT05447026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An examiner, who was blinded for the patient group assignment, performed clinical measurements, and sample collections.|The present study is a parallel design randomized controlled clinical trial evaluating four different treatment approaches.|f|f|t|f
34069453|NCT05509998|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Controlled Trial||||
34069454|NCT04404348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069455|NCT05325372|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Randomization will be done by computer-generated numbers and concealed by serially numbered, opaque, and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in a set of sealed envelopes each bearing only the case number on the outside.~This study will be performed by 3 anesthetists; one anesthetist who is experienced in performing the blocks will be allocated to perform either the axillary or infraclavicular block according to a computer-generated sequence of random numbers and sealed envelope, and the other two anesthetists will be blinded to the technique performed, and they will monitor the patients intra and postoperatively. Assessment of brachial plexus blockade will be carried out every 10 mins until 30 min by one of these two blinded observers. The infraclavicular and axillary areas will be covered to maintain the blinding of investigators."||t|t|t|t
34069456|NCT05028205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069457|NCT04136002|||COHORT||PROSPECTIVE|||||||
34069458|NCT06239545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of this trial, it will not be possible to blind participants to their allocation. As measures are self report, blinding of outcome measures is also not possible. Protect against bias will occur by blinding investigators to condition (i.e., only staff directly managing participants will be unblinded).|A pragmatic, parallel arm randomized controlled superiority trial will be used. Participants will be randomly allocated in a 1:1 ratio to the control (usual practice; UP) or intervention (UP + JoyPop) condition. Stratified block randomization (block size of 10) will be used to randomly assign participants to each condition.|f|f|t|f
34069459|NCT02905357|||COHORT||PROSPECTIVE|||||||
34069460|NCT05251636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069461|NCT03011398|||CASE_CONTROL||PROSPECTIVE|||||||
34069462|NCT01183507|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34069463|NCT03376113|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34069464|NCT05767164|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34069465|NCT00799357|||OTHER||CROSS_SECTIONAL|||||||
34069466|NCT05316571|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Researchers and participants will be blinded to the condition until each day of testing, and the statistician and any technicians processing outcome data will be blinded to the condition.|Each participant will complete four, 4-hour SB bouts with the following conditions: (i) one 5-minute walk break per hour; (ii) one 15-minute standing break per hour; (iii) two breaks per hour, alternating between 5 minutes of walking and 15 minutes of standing; and (iv) SB with no breaks (control). The order of intervention will be assigned in a randomized, crossover manner with 24 potential unique sequences of intervention assignment.|f|f|t|t
33757827|NCT03704155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluator 1: triage, random draw of treatments to be performed; Evaluator 2: BoNT-A application; Evaluator 3: assessment data collection; Evaluator 4: physical therapy treatment. Evaluator 3 was blinded in relation to the groups.|A randomized controlled clinical trial|t|f|f|t
33757828|NCT03577860|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33757829|NCT04351503|||OTHER||RETROSPECTIVE|||||||
33969640|NCT03673384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The sampling method is purposive sampling. The inclusion criteria are adults between 20 and 50 year-old with a definite clinical diagnosis of allergic rhinitis. Subjects were randomly divided into experimental and control groups. Thirty persons in the experimental group received both medical and infrared-C irradiation as intervention. On the other hand, twenty persons in the control group received only medical treatment. Patients in experimental group received anti-histamine, steroid nasal spray and infrared-C irradiation by hot compress for 40 minutes per time, and more than three times per week. The regions of hot compress included head, neck and shoulder, back and lower back, which covered many acupuncture points frequently used by traditional Chinese medicine for the treatment of allergic rhinitis. In addition, patients also received hot compress over face, eyes and nose during acute stage of allergic rhinitis.|t|f|f|f
33969641|NCT00996528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969642|NCT00721682|||CASE_CONTROL||PROSPECTIVE|||||||
33969643|NCT01445132||||TREATMENT||||||||
33757830|NCT01732848|||COHORT||CROSS_SECTIONAL|||||||
33757831|NCT03202381|NA|SINGLE_GROUP||OTHER||NONE||||||
33757832|NCT00667472|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33757833|NCT03532802|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33757834|NCT00677235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757835|NCT02565563|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33757836|NCT02334696|||COHORT||PROSPECTIVE|||||||
33757837|NCT03852043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757838|NCT02138045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757839|NCT03682874|||COHORT||PROSPECTIVE|||||||
33757840|NCT02915848|||COHORT||PROSPECTIVE|||||||
33757841|NCT05840861|||CASE_CONTROL||PROSPECTIVE|||||||
33757842|NCT00543595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757843|NCT02745548|||CASE_ONLY||PROSPECTIVE|||||||
33757844|NCT02159599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757845|NCT03420781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757846|NCT04088370|||COHORT||PROSPECTIVE|||||||
33757847|NCT01574768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878844|NCT05846776|NA|SINGLE_GROUP||OTHER||NONE||||||
33757848|NCT02190292|||OTHER||OTHER|||||||
33757849|NCT01965210|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33757850|NCT06103825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757851|NCT02612064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757852|NCT03688061|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Each group will be sequentially recruited over a period of two months to allow for safety review.||||
33878845|NCT02772432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are assigned to the immediate or wait-list control intervention group.||||
33878846|NCT04856709|NA|SINGLE_GROUP||TREATMENT||NONE||"* Study design: Randomized Controlled clinical Trial~* Study Setting: Ain Shams maternity hospital.~* Study Population: The study included 80 women divided into 2 groups:~Group A: 40 women underwent abdominal pectopexy. Group B: 40 women underwent abdominal sacral hysteropexy."||||
33878847|NCT06096558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878848|NCT05474300|||COHORT||PROSPECTIVE|||||||
33878849|NCT03702998|||COHORT||RETROSPECTIVE|||||||
33878850|NCT02577861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878851|NCT03607864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878852|NCT02227680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33878853|NCT04612010|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||SINGLE|Each arm involves real stimulation but only one is consistent with the hypothesis of desynchronization. The participant will not be aware of which administration is providing the target frequency of stimulation.|The participants will be in an n-of-1 design with each participant receiving each frequency of stimulation in a randomized blinded order.|t|f|f|f
33878854|NCT01941407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878855|NCT02097147|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33878856|NCT00455598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878857|NCT06098235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33878858|NCT01039337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878859|NCT03504878|||COHORT||CROSS_SECTIONAL|||||||
33878860|NCT02230631|||COHORT||PROSPECTIVE|||||||
33878861|NCT01573715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878862|NCT00292825|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33878863|NCT00529256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757853|NCT02013492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878864|NCT02615444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33878865|NCT01758250|||CASE_CONTROL||PROSPECTIVE|||||||
33878866|NCT03231462|||COHORT||PROSPECTIVE|||||||
33878867|NCT06240884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878868|NCT06195722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33878869|NCT01536054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878870|NCT04770051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878871|NCT03066427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878872|NCT01389011|||CASE_ONLY||PROSPECTIVE|||||||
33878873|NCT06088238|||OTHER||PROSPECTIVE|||||||
33878874|NCT00486057|||||RETROSPECTIVE|||||||
33878875|NCT00609479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878876|NCT00679497|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878877|NCT00852995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878878|NCT04794712|||COHORT||PROSPECTIVE|||||||
33878879|NCT01312597|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33878880|NCT01923792|||COHORT||PROSPECTIVE|||||||
33878881|NCT02122237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757854|NCT00663325|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757855|NCT01800773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878882|NCT03236558|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33878883|NCT01031914|NA|SINGLE_GROUP||||NONE||||||
33878884|NCT00001133||||TREATMENT||||||||
33878885|NCT05204966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878886|NCT01564862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878887|NCT06118060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33878888|NCT06222125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Sequential Assignment This study will enroll 20 subjects at 10mg/kg and 20mg/kg respectively every 2 weeks (Q2W)to compare the safety and efficacy, and will be extended to the group with better efficacy and tolerance.||||
33878889|NCT00864955|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878890|NCT01580488|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
33878891|NCT01200901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757856|NCT05421338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757857|NCT05786222|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757858|NCT05399745|||CASE_CONTROL||PROSPECTIVE|||||||
33757859|NCT05700188|||COHORT||RETROSPECTIVE|||||||
33757860|NCT02719990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757861|NCT00948298|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33757862|NCT04972448|||COHORT||PROSPECTIVE|||||||
33757863|NCT00000605|RANDOMIZED|||PREVENTION||DOUBLE||||||
33878892|NCT06016426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33969644|NCT01337154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969645|NCT02241681|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969646|NCT03799978|RANDOMIZED|CROSSOVER||OTHER||NONE||Two way crossover||||
33969647|NCT02987595|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33969648|NCT00682383|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33969649|NCT03184103|||CASE_ONLY||PROSPECTIVE|||||||
33969650|NCT00318552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969651|NCT02785172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757864|NCT05995314|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|To achieve the blinded placebo situation, a researcher not associated with the study will be performed the blinding and prepared identical capsules containing placebo or the corresponding dose of caffeine. This researcher will be assigned an alphanumeric code to each trial to blind participants and investigators||t|f|t|t
33757865|NCT05295966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757866|NCT01843543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757867|NCT05887505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757868|NCT05030402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33757869|NCT04849286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757870|NCT03128424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757871|NCT02489786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757872|NCT02681848|||COHORT||PROSPECTIVE|||||||
33757873|NCT02787707|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33757874|NCT04209478|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33757875|NCT01904864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757876|NCT00560612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757877|NCT00992667|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33757878|NCT05179967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757879|NCT04069325|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||72 subjects will be randomized to two parallel groups (36 subjects per group) to receive simiaowan 6g twice daily or placebo. All subjects will be given febuxostat 40mg once daily as background therapy. Placebo will be administered to individuals randomized to that treatment group in a form identical to the simiaowan. The first investigational medicinal product dose will be administered the day after the randomization.|t|f|t|t
33757880|NCT00885248|||CASE_ONLY||PROSPECTIVE|||||||
33757881|NCT04107831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757882|NCT00173979|||DEFINED_POPULATION||OTHER|||||||
33757883|NCT02077764|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757884|NCT00552292|||COHORT||PROSPECTIVE|||||||
33757885|NCT05775588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757886|NCT01005342|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33757887|NCT05797064|||COHORT||PROSPECTIVE|||||||
33757888|NCT00018434|||||PROSPECTIVE|||||||
33757889|NCT04471155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled trial|t|t|t|f
33757890|NCT00742092|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33757891|NCT05362565|||COHORT||PROSPECTIVE|||||||
33757892|NCT04186013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757893|NCT03227211|||COHORT||PROSPECTIVE|||||||
33757894|NCT02546934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757895|NCT05374954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33757896|NCT01869790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757897|NCT02686034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757898|NCT01953393||||BASIC_SCIENCE||||||||
33757899|NCT01633554|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757900|NCT01639937|||COHORT||PROSPECTIVE|||||||
33757901|NCT04845048|||COHORT||PROSPECTIVE|||||||
33757902|NCT04225533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757903|NCT02908308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical team responsible for the participant (physicians, nurses and others) and involved with direct patient care will not be blinded to allocation group due to the inherent difficulty in blinding the intervention and as temperature is a vital sign required for clinical care. Measures will be taken to ensure that the information about allocation will not disseminate beyond the immediate group of caregivers responsible for patient care. A blinded physician will evaluate the patient at 96 hours after randomisation and make a statement on neurological prognosis.||t|f|t|t
33757904|NCT02858141|||COHORT||PROSPECTIVE|||||||
33757905|NCT03839342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757906|NCT00644202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757907|NCT06176599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757908|NCT06395181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757909|NCT02979002|||COHORT||PROSPECTIVE|||||||
33757910|NCT01730885|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33969652|NCT04076306|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Each child with haemophilia will undertake both the iSTEP exercise test and a modified shuttle walk test (10m-MSWT) in a randomised order on the same day with a washout period of at least 1 hour. This data will then be compared to previously collected normative data for the iSTEP test from healthy school age children from the original iSTEP development and validation study (Rand et al, 2015).~The second component will include the feasibility of collecting standardised lower limb clinical muscle myometry measurements. The third component will be to explore the viability of collecting physical activity level data, in this population over a 7 day period using an accelerometer. This will be evaluated by monitoring the adherence to accelerometry wear. The value of the data will also be used to determine if it is useful at informing other aspects of fitness for boys with haemophilia."||||
33969653|NCT04810195|||COHORT||PROSPECTIVE|||||||
33969654|NCT06544213|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Participants and investigators are aware of the groups distribution|Volunteers are divided in three groups (8 volunteers each), one control group, one group with supine bike as countermeasure, one group with artificial gravity and supine bike as countermeasure||||
33969655|NCT03535883|||COHORT||CROSS_SECTIONAL|||||||
33969656|NCT01263899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969657|NCT03428659|||CASE_ONLY||PROSPECTIVE|||||||
33969658|NCT03804125|||OTHER||PROSPECTIVE|||||||
33969659|NCT04555525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969660|NCT02815904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969661|NCT01023269|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33969662|NCT01332110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969663|NCT05778149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969664|NCT01109459|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33969665|NCT05571761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Random assignment will not be disclosed to the participants. The participants in the intervention arm will be contacted first, and once this is completed, the participants in the waiting list control arm will be contacted for the intervention.|A pilot randomized clinical trial will be conducted with HIV+ participants randomised in a 1:1 ratio to a study group that will receive the neuropsychological intervention and a second control group that will remain waiting until the study group finishes the intervention and after that can receive the intervention.|t|f|f|f
33969666|NCT00979628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757911|NCT01044576|||COHORT||PROSPECTIVE|||||||
33969667|NCT00857025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969668|NCT03786289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969669|NCT00004797||||TREATMENT||||||||
33969670|NCT04611659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be informed as to which group they are in. They will be randomized at the point of intake and assigned to one of two groups described above.|One group will receive a behavioral intervention using motivational interviewing, and educational training on long acting reversible contraceptives, the other group will receive an educational flier on medication assisted treatment and contraception. The participants will be randomly assigned to one or the other condition, and both groups will consist of women, ages 18-44 with a current opioid use disorder that are currently being treated using medication assisted treatment.|t|f|f|f
33969671|NCT00549198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969672|NCT00929903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969673|NCT05555082|NA|SINGLE_GROUP||OTHER||NONE||50 health care professionals will receive massage monthly during 12 months. Massage will not be given during summer holiday. Thus, 30 minutes of massage will be given 10 times.||||
33969674|NCT05063019|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969675|NCT03686800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969676|NCT01066481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969677|NCT01637311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969678|NCT02972411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33969679|NCT02880072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969680|NCT04532541|||COHORT||PROSPECTIVE|||||||
33969681|NCT05334654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and Outcome assessors will not take part in the care of patients. Data will be provide in anonymous form without any indication to the assigned treatment.||t|f|t|t
33969682|NCT00819650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969683|NCT02139306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969684|NCT03124485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study protocol aims to test the hypothesis that endoscopic sleeve gastroplasty (ESG) IS NOT inferior to conventional laparoscopic surgical sleeve gastrectomy (LSG) in terms of weight loss and improvement of glycemic control for Asian obese patients. It also investigates and compares the safety profile, improvement of co-morbidities, functional outcomes and changes in gut hormone profiles between the two bariatric procedures.||||
33969685|NCT01548469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969686|NCT06066385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors of previous radiological imaging and imaging created during our Long-term follow up will be blinded to the assigned randomization arm.|A Long-term follow-up with Outcome Assesor blinding of a parallel assigned double blinded (Participant, Investigator) Randomised Controlled trial|f|f|f|t
33969687|NCT01832090|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33969688|NCT04176640|||COHORT||PROSPECTIVE|||||||
33969689|NCT05777265|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A prospective clinic study with single group||||
33969690|NCT05391269|||COHORT||RETROSPECTIVE|||||||
33969691|NCT04632420|||COHORT||RETROSPECTIVE|||||||
33969692|NCT00248339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757912|NCT00546780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757913|NCT01103310|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33757914|NCT03546894|||COHORT||PROSPECTIVE|||||||
33757915|NCT04734548|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33757916|NCT06510582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757917|NCT05278780|NA|SINGLE_GROUP||SCREENING||NONE||Case series study||||
33757918|NCT04108000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||30 pairs of patients and their caregivers (surrogates) will be randomized to either receive the SPIRIT intervention or standard of care.||||
33757919|NCT05018884|||COHORT||PROSPECTIVE|||||||
33757920|NCT02137525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33757921|NCT01947465|||COHORT||PROSPECTIVE|||||||
33757922|NCT03535142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33969693|NCT06365827|||CASE_CONTROL||PROSPECTIVE|||||||
33757923|NCT06524011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757924|NCT01910168|||CASE_CONTROL||PROSPECTIVE|||||||
33757925|NCT00509834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33757926|NCT05267392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757927|NCT01373762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33757928|NCT03388749|NA|SEQUENTIAL||TREATMENT||NONE||||||
33757929|NCT00683709|||COHORT||PROSPECTIVE|||||||
33757930|NCT03115294|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|video analysts do not get information of the clinical data or procedure phase|Patients undergo medication intervention (w/intravenous theophylline) and ventilator volume adjustements, and serial ventricular function parameters are compared (pre-and post-intervention measurements).||||
33757931|NCT03286751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33969694|NCT01873768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757932|NCT05322148|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, prospective, randomized controlled, open label study of the efficacy of cyclosporine 0.1% / loteprednol 0.2% in improving higher order aberrations, and TBUT in patients with dry eye. Patients will be randomized to receive treatment with either cyclosporine 0.1% / loteprednol 0.2% BID for 4 weeks or cyclosporine 0.05% BID for 4 weeks and will be evaluated at baseline (before treatment), 14 days, and 28 days of treatment.||||
33757933|NCT05514002|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33757934|NCT04477187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757935|NCT05202483|||OTHER||RETROSPECTIVE|||||||
33757936|NCT02701127|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33757937|NCT05256979|||CASE_ONLY||PROSPECTIVE|||||||
33757938|NCT05139667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|oral lichen planus|treatment of oral lichen planus|f|f|f|t
33757939|NCT03610464|NA|SINGLE_GROUP||TREATMENT||NONE||This was an open-label, single-site, single-dose one-period, one-treatment study in 5 pediatric subjects diagnosed with ADHD, otherwise healthy. Subjects received a single, 1 mL dose of AMPH EROS 2.5 mg/mL, from which PK was assessed over a 28 hour period.||||
33757940|NCT05760157|||COHORT||PROSPECTIVE|||||||
33757941|NCT03485326|||COHORT||PROSPECTIVE|||||||
33757942|NCT02370433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33757943|NCT00597948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33757944|NCT03396029|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A computer programme designed by the research team IT developer carried out the randomization. The recruitment and the contact between the investigators and the participants was mailed. There was no face-to-face contact.||f|f|t|f
33757945|NCT02233933|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33757946|NCT06085274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757947|NCT02244905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33757948|NCT01019044|||COHORT||PROSPECTIVE|||||||
33757949|NCT02044848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757950|NCT05734963|||COHORT||PROSPECTIVE|||||||
33757951|NCT02259738|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33757952|NCT03357263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33757953|NCT03497650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor only was masked.|Pilot Randomised Controlled Trial|f|f|f|t
33757954|NCT02381522|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33969695|NCT00208910|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33969696|NCT05232578|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A balanced design is used for the 1:1 randomization into two arms A and B:"||||
33969697|NCT03440281|||COHORT||PROSPECTIVE|||||||
33969698|NCT05544383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757955|NCT03599154|||COHORT||PROSPECTIVE|||||||
33757956|NCT03479021|||COHORT||PROSPECTIVE|||||||
33969699|NCT05206032|||COHORT||PROSPECTIVE|||||||
33969700|NCT01401920|||CASE_ONLY||PROSPECTIVE|||||||
33969701|NCT00721461|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878893|NCT05979610|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects who meet all criteria for enrollment will be randomly assigned to receive Reiki therapy (Arm 1) or usual care (Arm 2) using block randomization. Subjects will be randomized through the OnCore system in a 1:1 ratio to Arm 1 or Arm 2 and stratified by treatment type (multichannel vaginal cylinder (MCVC) and vaginal cylinder vs. all other treatment modalities). Randomization will not be blinded.||||
33878894|NCT02014012|||CASE_ONLY||PROSPECTIVE|||||||
33878895|NCT02058680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969702|NCT02831530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878896|NCT03260959|||OTHER||PROSPECTIVE|||||||
33878897|NCT03881150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33878898|NCT04520672|||COHORT||PROSPECTIVE|||||||
33969703|NCT04597580|||OTHER||PROSPECTIVE|||||||
33969704|NCT06294171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969705|NCT01538316|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33878899|NCT03934450|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be able to know the sequence of the drug adminstration|"This study is a single center, prospective, cross-over phase 1 trial. Thirty-six participants will be enrolled into a two Cohort pharmacokinetic study evaluating the metabolism, pharmacokinetic behavior and tolerability of two dose levels (low/high) of primaquine enantiomers (and placebo) over the course of 7 days.~Placebo will be added in order to assess tolerability of enantiomers. Placebo control is needed in non-drug related clinical responses."|t|f|f|f
33878900|NCT03834415|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Blinding process will be structured centrally. The oil drops of active are contained in an ambar flask. Placebo consistency, smell, flavor and container are identical to active product|RCT two arms to evaluate the safety and efficacy of L. reuteri vs. placebo to modulate the microbiome gut profile in newborn babies delivered by C-section|t|t|t|t
33878901|NCT00006565|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878902|NCT05722665|||OTHER||RETROSPECTIVE|||||||
33878903|NCT04428424|||COHORT||RETROSPECTIVE|||||||
33878904|NCT00424827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969706|NCT04801602|||COHORT||PROSPECTIVE|||||||
33969707|NCT04602351|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969708|NCT02415166|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33969709|NCT04393805|||COHORT||RETROSPECTIVE|||||||
33969710|NCT01088152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969711|NCT02056730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969712|NCT01026610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969713|NCT03947047|||CASE_CONTROL||PROSPECTIVE|||||||
33969714|NCT02630745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33969715|NCT05214807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969716|NCT04674176|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33969717|NCT00528437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969718|NCT01391182|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33969719|NCT02172716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969720|NCT03501550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969721|NCT03491878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33969722|NCT01131728|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33969723|NCT03085082|||OTHER||PROSPECTIVE|||||||
33969724|NCT01909583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33969725|NCT05004818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969726|NCT01892995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969727|NCT06528678|||COHORT||PROSPECTIVE|||||||
33969728|NCT02317354|||COHORT||PROSPECTIVE|||||||
33969729|NCT05687045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969730|NCT01563471|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33969731|NCT01314703|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
33969732|NCT01907659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969733|NCT02184494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969734|NCT05285098|||COHORT||RETROSPECTIVE|||||||
33969735|NCT04289220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969736|NCT03435432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33969737|NCT00950183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969738|NCT00249457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969739|NCT02632656|||COHORT||PROSPECTIVE|||||||
33969740|NCT01907087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969741|NCT02600806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969742|NCT01527825|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33878905|NCT00252707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878906|NCT03038425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33878907|NCT04090112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study based on a sequentially numbered list were prepared in the same way. Participant and outcome assessor were blined to the computer generated lists|The randomized controled trial was conducted. the investigator allocated patient into two arms. Group A received four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet whereas Gr. B received 15 mg/kg of 2% lidocaine intravenous injection prior to extubation|t|f|f|t
33878908|NCT06410560|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33878909|NCT03003208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33878910|NCT06503705|||CASE_ONLY||PROSPECTIVE|||||||
33878911|NCT03554915|||COHORT||PROSPECTIVE|||||||
33878912|NCT00512798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878913|NCT00836212|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878914|NCT05776433|||CASE_ONLY||CROSS_SECTIONAL|||||||
33878915|NCT00099190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878916|NCT05992246|||CASE_CROSSOVER||PROSPECTIVE|||||||
33878917|NCT02064387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878918|NCT02895061|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33878919|NCT05797701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878920|NCT02665507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33878921|NCT00554125|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33878922|NCT02579655|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33878923|NCT06377878|||CASE_CONTROL||OTHER|||||||
33878924|NCT00281879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878925|NCT00253630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878926|NCT01240642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969743|NCT06093256|||COHORT||PROSPECTIVE|||||||
33969744|NCT01859390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969745|NCT05278377|||CASE_CONTROL||PROSPECTIVE|||||||
33969746|NCT05953428|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The study participants, surgeons and PACU nurses will be blinded.|"Patients undergoing laparoscopic hiatal hernia repairs will be randomized to:~Experimental Group: Opioid Sparing Anesthesia Protocol vs. Control Group: Opioid Based Anesthesia Protocol"|t|t|f|f
33969747|NCT01160575|||||PROSPECTIVE|||||||
33969748|NCT04928833|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33969749|NCT00272337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878927|NCT00896311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33878928|NCT03431571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878929|NCT02342795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33878930|NCT06343675|||COHORT||CROSS_SECTIONAL|||||||
33878931|NCT01411085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878932|NCT01697176|||COHORT||PROSPECTIVE|||||||
33878933|NCT00033410||||TREATMENT||||||||
33969750|NCT01078415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969751|NCT03846921|||CASE_CONTROL||PROSPECTIVE|||||||
33878934|NCT04620460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878935|NCT01525004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33878936|NCT05779982|||COHORT||RETROSPECTIVE|||||||
33878937|NCT02797808|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33878938|NCT02510768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33878939|NCT02482129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878940|NCT01759758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33878941|NCT04659460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Only Research Assistant will be unblinded. Participant, clinical team, PI, etc. will all be blinded to the randomization group.|Single-centre, randomized controlled pilot study|t|t|t|t
33878942|NCT01206205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878943|NCT04516928|||COHORT||PROSPECTIVE|||||||
33878944|NCT03544827|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants and main investigator will be blinded to the allocation concealment||t|f|t|f
33878945|NCT01703780|||||PROSPECTIVE|||||||
33757957|NCT04535674|RANDOMIZED|PARALLEL||TREATMENT||NONE||Asunercept/APG101 will be tested in three parallel intervention arms and compared with Standard of Care (SoC). The study will compare treatment efficacy of SoC to that of weekly intravenous infusions of Asunercept at three different doses. Patients will be randomised into four groups.||||
33757958|NCT00799292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757959|NCT02021175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878946|NCT04011280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Everyone, with the exception of the study pharmacist, will be blinded to which arm participants will be randomized into.|This pilot trial is a Phase IV, 12-week, single center, randomized, double blind, parallel group comparison of low (0.5 mg twice daily with slower titration over one full week) versus standard dose (1.0 mg twice daily with standard titration) varenicline in individuals with DSM-V BD or SSD with a 12-week, post-treatment follow-up.|t|t|t|t
33878947|NCT05235035|||COHORT||CROSS_SECTIONAL|||||||
33878948|NCT04754451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33878949|NCT00065728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878950|NCT01060059|||COHORT||PROSPECTIVE|||||||
33878951|NCT00705783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878952|NCT04703790|||OTHER||PROSPECTIVE|||||||
33878953|NCT02948621|||CASE_ONLY||PROSPECTIVE|||||||
33878954|NCT05685186|||COHORT||PROSPECTIVE|||||||
33878955|NCT03124784|NA|SINGLE_GROUP||OTHER||NONE||||||
33878956|NCT00246428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878957|NCT02106312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878958|NCT00748579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969752|NCT01210183|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33969753|NCT02856074|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33969754|NCT04202302|||COHORT||PROSPECTIVE|||||||
33969755|NCT05874869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969756|NCT02833857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969757|NCT01093859|NA|SINGLE_GROUP||||NONE||||||
33969758|NCT01234259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969759|NCT02478593|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33878959|NCT02670642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878960|NCT01168089|||CASE_ONLY||CROSS_SECTIONAL|||||||
33878961|NCT06392581|||COHORT||PROSPECTIVE|||||||
33878962|NCT05852756|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Single (Participant) preventing malnutrition|pecha kucha training|t|f|f|f
33878963|NCT04138485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33878964|NCT04082585|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33878965|NCT03370939|||CASE_ONLY||PROSPECTIVE|||||||
33878966|NCT01738971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33878967|NCT05801770|||CASE_CROSSOVER||PROSPECTIVE|||||||
33878968|NCT04561154|NA|SINGLE_GROUP||OTHER||NONE||||||
33969760|NCT01708928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969761|NCT00813371|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069467|NCT04647513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips). To this end, subjects in whom a correction of at least one of the studied zones is sought, will be included. The aesthetic correction will be appreciated at 3 weeks. Subjects will be followed over 18 months. The persistence of the correction will be evaluated at 3, 6, 9, 12, 15 and 18 months.~Around 200 subjects aged more than 19 years old with following distribution:~* Art Filler Fine Lines~* Forehead wrinkles~* Upper lip wrinkles~* Cheek folds~* Crow's feet wrinkles~* Art Filler Universal~* Volume of the lips (for soft volumizing effect)~* Nasolabial folds alone or with marionette lines~* Art Filler Lips~* Volume of the lips (for plumped lips)~* Very deep Nasolabial folds alone or with marionette lines"||||
34069468|NCT01761929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069469|NCT05168618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069470|NCT05475899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34069471|NCT06529159|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Two-arm, randomized, pilot, single-center, prospective clinical study||||
34069472|NCT05411380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069473|NCT04246528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment||||
34069474|NCT06271343|||CASE_CONTROL||PROSPECTIVE|||||||
34069475|NCT05134779|||COHORT||PROSPECTIVE|||||||
34069476|NCT04364412|||COHORT||PROSPECTIVE|||||||
34069477|NCT04617405|||CASE_CONTROL||PROSPECTIVE|||||||
34069478|NCT06297551|||COHORT||PROSPECTIVE|||||||
34069479|NCT03934918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparing the duration from admission to delivery in nulliparous women between outpatient cervical ripening and those who were admitted for induction of labor||||
34069480|NCT04252963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069481|NCT05567471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069482|NCT01232088|||COHORT||PROSPECTIVE|||||||
34069483|NCT02711358|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34069484|NCT04730752|||COHORT||PROSPECTIVE|||||||
34069485|NCT03307837|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34069486|NCT05511259|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Intervention group: 3-month community based exercise program (square stepping exercise)|f|f|t|t
34069487|NCT00572455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069488|NCT03964259|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The study uses a prospective randomized controlled crossover study design.||||
34069489|NCT01557868|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
34069490|NCT06025201|NA|SINGLE_GROUP||OTHER||NONE||All participants will complete all interventions.||||
33878969|NCT02842411|||COHORT||PROSPECTIVE|||||||
33878970|NCT05244850|||OTHER||OTHER|||||||
33878971|NCT00798746|||CASE_ONLY||PROSPECTIVE|||||||
33878972|NCT05269407|||COHORT||PROSPECTIVE|||||||
33878973|NCT01677715|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33878974|NCT00023374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33878975|NCT00865072|RANDOMIZED|CROSSOVER||||NONE||||||
33878976|NCT02312492|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33878977|NCT05913414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33878978|NCT05932550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878979|NCT01283165|||COHORT||PROSPECTIVE|||||||
33878980|NCT00181181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33878981|NCT06548906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878982|NCT04849780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33878983|NCT05661773|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Each patient will act as their own control. By applying the vacuum assisted warmer to one hand, results can be compared to the contralateral hand. In this way, patient outcomes can be assessed between patients and indexed to each patient.||||
33878984|NCT04775329|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomised, placebo-controlled study||t|t|t|f
33878985|NCT00900770|||COHORT||CROSS_SECTIONAL|||||||
33757960|NCT00386022|RANDOMIZED|SEQUENTIAL||OTHER||NONE||The study will is considered sequential as participants were studied at baseline and after one month of low-dose estrogen. Randomization refers to randomization of the order of doses of GnRH between participants.||||
33757961|NCT03151980|RANDOMIZED|PARALLEL||OTHER||SINGLE||Each participant will be randomized to receive Hamam on either the left or the right side of the back. The other side will be left untreated. Each individual will thereafter receive a sun exposure of both the Hamam-treated skin and the untreated skin.|f|f|f|t
33969762|NCT05360433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969763|NCT01232257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969764|NCT02277821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969765|NCT03591978|||COHORT||PROSPECTIVE|||||||
33969766|NCT02533999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33969767|NCT05481580|||COHORT||CROSS_SECTIONAL|||||||
33969768|NCT03947788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969769|NCT01657487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757962|NCT01868295|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33757963|NCT02048072|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33757964|NCT00969501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33757965|NCT00752843|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33757966|NCT02822625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33757967|NCT05892315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757968|NCT00490282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33757969|NCT05416957|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33757970|NCT04047043|||COHORT||PROSPECTIVE|||||||
33757971|NCT03072940|||CASE_CONTROL||PROSPECTIVE|||||||
33878986|NCT01175902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33878987|NCT04619485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, sham-controlled trial|t|t|t|t
33878988|NCT06106854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33878989|NCT00466648|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33878990|NCT01576692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878991|NCT01916538|||CASE_CONTROL||RETROSPECTIVE|||||||
33878992|NCT02490293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969770|NCT01261533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757972|NCT01593202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33878993|NCT01908101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33878994|NCT02104583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33878995|NCT02188316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34069491|NCT03399305|||COHORT||RETROSPECTIVE|||||||
33878996|NCT04864431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither do investigator nor participants will not know the random allocation|Intervention group: vitamin D 2000 IU ; Control group: placebo|t|f|t|f
33878997|NCT03042715|||COHORT||PROSPECTIVE|||||||
33878998|NCT04589104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33969771|NCT06449079|||OTHER||RETROSPECTIVE|||||||
34069492|NCT05496465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069493|NCT02103348|||COHORT||CROSS_SECTIONAL|||||||
34069494|NCT03019029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants with biopsy proven peripheral nerve amyloidosis will undergo an F-18 Florbetapir PET/MR scan||||
34069495|NCT00253006|||DEFINED_POPULATION||OTHER|||||||
33757973|NCT00320775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069496|NCT02974348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33757974|NCT00381069|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33757975|NCT04821479|NA|SINGLE_GROUP||TREATMENT||NONE||Single center open label study||||
33878999|NCT03150225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will have a double-blind blindness, performed in the process of randomization of the participants, who will not be informed about the allocation of the groups, and in the period of data collection and application of the concurrtent training protocol, in which the Researchers who will carry out the data collection will not participate in the application of the protocol, and vice versa.|The randomization of the men who will participate in the study will be carried out through a computer program; In the four groups that will compose the study: exercise group + supplementation - intervention with application of a concurrent training protocol for six months and supplementation with eurycoma longifolia, 200mg once daily; exercise group + placebo intervention with application of a concurrent training protocol for six months and administration of starch capsules; control group + supplementation - monthly will be contacted via telephone and will be encouraged to maintain their daily activities and supplementation with eurycoma longifolia, 200mg once daily; control group + placebo - monthly will be contacted via telephone and will be encouraged to maintain their daily activities and administration of starch capsules.|t|f|t|t
34069497|NCT01718587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069498|NCT02693717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069499|NCT04322097|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069500|NCT06399016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the process of assignment of children into groups, randomization is achieved in the computer by stratifying them in terms of sex and age variables (https://www.randomizer.org/).|"During the preoperative period, children who meet the inclusion criteria of the study will be determined from the list of children who will undergo surgery. Before the research, children who will undergo surgery and their parents will be informed on the morning of the surgery, approximately 1 hour before the surgery, and their written and verbal consent will be obtained. On the morning of the surgery day, the Child and Family Introductory Data Form will be filled out by children in the 7-12 age group and their parents who meet the inclusion criteria and agree to participate in the research. The child himself/herself will be asked to score the level of surgery-related anxiety using the CAS score, and the child, the parent, and the researcher will be asked to score the child's fear level regarding the surgery using the CFS score.~The application material to be used in the research is the story book titled 'One Child, One Miracle', which includes an augmented reality application."|t|f|f|t
34069501|NCT04844008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33757976|NCT05756972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33757977|NCT04253327|||CASE_CONTROL||PROSPECTIVE|||||||
33757978|NCT05245578|NA|SINGLE_GROUP||TREATMENT||NONE|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|||||
33757979|NCT02304276|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33757980|NCT01348750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757981|NCT02623010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757982|NCT04605978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33757983|NCT00432757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33757984|NCT00593567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33757985|NCT03764839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33757986|NCT04226222|||COHORT||PROSPECTIVE|||||||
34069502|NCT00869310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879000|NCT04049045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There will be two trial medications, the licensed medicinal product empagliflozin, trade name Jardiance®, 25 mg and matching placebo tablets. The placebo tablets will be indistinguishable by appearance, taste, smell, weight from the investigational product. Both will be stored in plastic containers containing 30 tablets each.|Single-center, prospective, double-blind, placebo-controlled, randomized and interventional exploratory study|t|t|t|f
33879001|NCT04858165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879002|NCT06424093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879003|NCT04195321|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879004|NCT01309178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879005|NCT01784965|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33879006|NCT03732300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Monocenter, open-label, randomized parallel two study arms (ASSIP vs control)|f|f|f|t
33879007|NCT04868084|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-randomised before and after pilot feasibility study||||
33879008|NCT05564169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Computerized central randomization system using an external provider.|Randomized, Double-blind, Placebo-controlled, Parallel group (1:1), Multicenter, Comparative study over 24 weeks with a 24-week extension period (all patients can enter the extension phase until week 48).|t|t|t|t
33879009|NCT01492608|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33969772|NCT01799733|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The principal investigator and clinical rater will remain blind to treatment condition until completion or discontinuation of participant from study. As patients will be coded, one statistician and technician and supervisor running assays also will be blind to patient name and treatment condition. Members of the Data Safety Monitoring Committee will review records in which patient names are coded, unless the code needs to be broken in the event of an adverse outcome. All other lab personnel will not be blind to treatment as the study coordinator and research associate prepare patient equipment and instruct patients on proper completion of the treatment protocol, the data manager and quality assurance officer enter all data into the database (including treatment condition). Due to the nature of the treatment (sleep, light intervention), patients will not be blind to condition.|40 women with Premenstrual Dysphoric Disorder ages 18-45 will be randomized to a cross-over design contrasting one night of Late Wake Therapy followed by 7 days of morning Bright-White Light (LWT+AM BWL) vs. one night of Early Wake Therapy followed by evening Bright-White Light (EWT+PM BWL) administered in the luteal phase of two separate menstrual cycles, with one month of no intervention (washout) between treatments to prevent carry-over effects. Treatment will be preceded by 2 evaluation months to determine diagnosis and collect baseline mood, sleep, actigraphy and endocrine measures. To lessen the patient's burden, the 1-night EWT or LWT and the following 7-day BWL interventions will be conducted at home, given at a fixed point in each menstrual cycle, from the day of mid-cycle LH surge to 7 after the LH surge.|f|f|t|t
33969773|NCT04950283|||COHORT||CROSS_SECTIONAL|||||||
33969774|NCT04951388|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33969775|NCT04882683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969776|NCT06476444|||COHORT||CROSS_SECTIONAL|||||||
33969777|NCT01084005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969778|NCT00005615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969779|NCT05012228|||OTHER||RETROSPECTIVE|||||||
33969780|NCT06527183|||CASE_CONTROL||PROSPECTIVE|||||||
33969781|NCT00774332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969782|NCT02988752|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33969783|NCT02462070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969784|NCT01271699|||COHORT||RETROSPECTIVE|||||||
33969785|NCT05142436|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969786|NCT00736528|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33969787|NCT02798068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969788|NCT02217137|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969789|NCT05426122|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double (Participant, Investigator)|Crossover Assignment|t|t|t|t
33969790|NCT02257359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969791|NCT03510247|||COHORT||RETROSPECTIVE|||||||
33969792|NCT00463866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969793|NCT04954079|||COHORT||CROSS_SECTIONAL|||||||
33969794|NCT03619161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33757987|NCT05864638|||CASE_ONLY||OTHER|||||||
33969795|NCT04988659|||OTHER||CROSS_SECTIONAL|||||||
33757988|NCT06115330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33879010|NCT02765074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879011|NCT04381390|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33879012|NCT00857727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879013|NCT05506761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879014|NCT05411419|||CASE_ONLY||RETROSPECTIVE|||||||
33879015|NCT05969509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the cholecystectomy group will be given exercise sessions and the result evaluations will be performed by a researcher who is blind to the group allocation|two groups consisting of experimental and control groups performed cholecystectomy.|f|f|f|t
33969796|NCT04900506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Outcome assessors are blinded to allocation by not having access to patients study protocol and by examining patients covering their operated hip with clothing.~Patients are attempted blinded by using wound dressings to cover their operated hip and are, unless expressing specific interest in knowing the surgical approach, not informed of the randomization result. To evaluate the blinding of patients we will record their knowledge of which surgical approach they were operated with at their 12-month follow-up."|Patients are allocated to either an anterior approach or a posterior approach after inclusion. Both groups are operated with a cemented hemiarthroplasty|t|f|t|t
33969797|NCT05472610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969798|NCT03005470|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants have uncontrolled hypertension under on pharmacological treatment. They will be requested not to change drugs and medicine doses during the trial.|This is a factorial randomized controlled trial (Figure 1) of effectiveness of the use of technologies - smartphones and blood pressure monitoring - to reduce systolic blood pressure and change lifestyle.|f|f|t|t
33969799|NCT03077633|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups: Cerclage + Progesterone vs. Progesterone alone||||
33969800|NCT04140006|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33969801|NCT05226156|||COHORT||RETROSPECTIVE|||||||
33969802|NCT04371783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969803|NCT01410383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969804|NCT02060461|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Contralateral eye study||||
34069503|NCT04262011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to the group to which the patient belongs, whether immediate or late.|The study will have two groups, one receiving immediate periodontal treatment and the other receiving late periodontal treatment.|f|f|f|t
33879016|NCT02497859|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879017|NCT06263569|||OTHER||OTHER|||||||
34069504|NCT04598308|||OTHER||PROSPECTIVE|||||||
34069505|NCT02400619|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34069506|NCT00160121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879018|NCT02981758|||COHORT||RETROSPECTIVE|||||||
33879019|NCT05337332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879020|NCT01666327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879021|NCT00412750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879022|NCT01179958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33879023|NCT05946473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33879024|NCT00421668|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33879025|NCT05626530|NA|SINGLE_GROUP||PREVENTION||NONE||Open label trial of letermovir given to eligible patients||||
33879026|NCT04349423|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to social media usage groups to assess if reduction social media will improve mood and in turn lower depressive and anxiety symptoms. The groups include 0 minutes, 30 minutes, 1 hours of use a day.||||
33879027|NCT04103801|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33879028|NCT01659320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879029|NCT04797832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is blinded to whether the patient received IV Iron.|Single blinded randomized control trial.|f|f|f|t
33879030|NCT00317525|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33879031|NCT00364312|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879032|NCT01148537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879033|NCT00452699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879034|NCT00106171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879035|NCT01147146|RANDOMIZED|||PREVENTION||||||||
33879036|NCT01503255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879037|NCT00010361||||TREATMENT||||||||
33879038|NCT02519166|NA|SINGLE_GROUP||||NONE||||||
33879039|NCT00185081|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33879040|NCT00149578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879041|NCT01870401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969805|NCT06528353|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33969806|NCT01620489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969807|NCT01976390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969808|NCT04307927|||COHORT||PROSPECTIVE|||||||
33969809|NCT02878291|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969810|NCT02039479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969811|NCT03552120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969812|NCT05101499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969813|NCT00004316|RANDOMIZED|||TREATMENT||||||||
33969814|NCT06324214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969815|NCT03094806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969816|NCT03334565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33969817|NCT03655210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded||t|f|t|t
33969818|NCT02416583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969819|NCT02874963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969820|NCT03994445|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33879042|NCT03700307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879043|NCT06255457|||COHORT||PROSPECTIVE|||||||
33879044|NCT03628014|NA|SINGLE_GROUP||OTHER||NONE||||||
33879045|NCT00002278||||TREATMENT||||||||
33879046|NCT02188030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33879047|NCT04709783|NA|SINGLE_GROUP||OTHER||NONE||||||
33879048|NCT00047138|RANDOMIZED|||TREATMENT||||||||
33879049|NCT00299208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879050|NCT04349020|||COHORT||PROSPECTIVE|||||||
33879051|NCT00258921|||||PROSPECTIVE|||||||
33879052|NCT03375190|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879053|NCT00985205|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33879054|NCT01961700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879055|NCT02500628|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879056|NCT05240755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879057|NCT03270865|NA|SINGLE_GROUP||OTHER||NONE||||||
33879058|NCT03773042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879059|NCT03250403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33879060|NCT05396742|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33879061|NCT02849132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879062|NCT02952222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879063|NCT03099928|||OTHER||OTHER|||||||
33879064|NCT02070614|||COHORT|||||||||
33969821|NCT04193631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969822|NCT03910803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969823|NCT00337805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879065|NCT04603573|RANDOMIZED|PARALLEL||PREVENTION||NONE|No one is blinded ( unfortunately) as fissure sealant will be obvious|"The study will be randomized, allocation-blinded, two-arm, parallel-group trial. The participants will be randomized on a 1: 1 allocation ratio to receive one of the following interventions:~* Resin-based fissure sealant FS.~* Fluoride varnish FV"||||
33879066|NCT00152425|RANDOMIZED|PARALLEL||||DOUBLE||||||
33879067|NCT01958801|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33879068|NCT02469766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069507|NCT03681782|||COHORT||PROSPECTIVE|||||||
34069508|NCT06477640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879069|NCT03961087|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with liver cirrhosis and frequent hepatic encephalopathy (HE)||||
33879070|NCT05578742|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Fifty patients will be enrolled, divided into 2 groups (n=26 each) according to a dynamic balanced sampling based on normalized respiratory system elastance (ERS) measured at PEEP 5 cmH2O with Vt 6-7 ml/kg PBW (\<2 cmH2O.mL-1.kg-1 vs. ≥2 cmH2O.mL-1.kg-1). Enrolment into each study group will be closed at 26 patients.~Then, patients will be randomized and allocated to one of the following strategies:~* Strategy A: PEEP 15 cmH2O → PEEP 5 cmH2O~* Strategy B: PEEP 5 cmH2O → PEEP 15 cmH2O~A parallel study will be conducted in Italy, to reach 50 more patients. Data will be shared between these two studies."||||
33879071|NCT06185673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879072|NCT00891605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879073|NCT00517595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879074|NCT04652271|||COHORT||PROSPECTIVE|||||||
34069509|NCT00651300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879075|NCT01942642|||CASE_ONLY||PROSPECTIVE|||||||
33879076|NCT01861405|||CASE_CONTROL||PROSPECTIVE|||||||
33879077|NCT05226065|||CASE_ONLY||CROSS_SECTIONAL|||||||
33879078|NCT00399165|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33879079|NCT00207454|RANDOMIZED|FACTORIAL||ECT||NONE||||||
33879080|NCT02026609|||COHORT||PROSPECTIVE|||||||
33969824|NCT02847533|NON_RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
33969825|NCT03295799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33969826|NCT01732965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969827|NCT02002013|||COHORT||CROSS_SECTIONAL|||||||
33969828|NCT02143947|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33969829|NCT03382678|||CASE_ONLY||CROSS_SECTIONAL|||||||
33969830|NCT00116415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969831|NCT05524987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Randomization will be done at the conclusion of the study|A randomized, two-arm intervention individually randomized trial with parallel assignment|f|f|t|t
33969832|NCT02970669|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33969833|NCT03999281|||CASE_CONTROL||RETROSPECTIVE|||||||
33969834|NCT05153356|||COHORT||PROSPECTIVE|||||||
33969835|NCT01155583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069510|NCT03457324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069511|NCT01226017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069512|NCT06124651|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|f|t
33757989|NCT03548883|||CASE_CONTROL||PROSPECTIVE|||||||
34069513|NCT03065153|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33757990|NCT01314989|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33757991|NCT01815788|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33757992|NCT04482543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34069514|NCT05276752|||COHORT||RETROSPECTIVE|||||||
34069515|NCT02442206|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34069516|NCT05576961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|RX-af01 and toripalimab||||
34069517|NCT04598295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double||t|t|t|t
34069518|NCT06223308|NA|SEQUENTIAL||TREATMENT||NONE||A single-subject cohort will be enrolled at the protocol starting dose of HB0028 every 3 weeks (Q3W). Dose escalation will proceed to the next main dose level according to the 3+3 dose-escalation procedure until the MTD/OBD is reached. Phase II of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose-escalation phase.||||
33879081|NCT00251537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33879082|NCT03140137|||COHORT||RETROSPECTIVE|||||||
33757993|NCT00939484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33757994|NCT05968222|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33757995|NCT02526355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33757996|NCT04236193|||COHORT||PROSPECTIVE|||||||
33757997|NCT00770926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33757998|NCT02582346|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33757999|NCT03083314|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study is a 2-arm (1:1 allocation) prospective randomised trial. The control arm consists of patients randomized to ALND, the study arm is patients randomized to SAD.||||
33758000|NCT00681642|||CASE_CONTROL||PROSPECTIVE|||||||
33758001|NCT00964834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758002|NCT00034255|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33758003|NCT02621957|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758004|NCT06081764|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758005|NCT04356326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treatment will be administered double blind. Pouches or tablets and caskets will be indistinguishable, prepared in advance and made available to pharmacies in participating hospitals by the sponsor. The treatment boxes are given as the monthly visits to the patient, a reassignment box will be required on the server at each visit to obtain a new cabinet number. The cabinet number (detachable label) used at each visit will be reported in the patient's file.|Prospective multicentric randomized double-blind superiority trial, placebo-controlled, on two parallel arms|t|t|t|f
33758006|NCT02579876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758007|NCT05101525|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33879083|NCT02468791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879084|NCT01453855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879085|NCT03110900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879086|NCT00793481|||CASE_ONLY||PROSPECTIVE|||||||
33879087|NCT02537171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879088|NCT01459250|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34069519|NCT01744158|||COHORT||CROSS_SECTIONAL|||||||
33879089|NCT01493336|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879090|NCT03106103|||CASE_ONLY||PROSPECTIVE|||||||
33879091|NCT05393466|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879092|NCT01317433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879093|NCT01054742|||COHORT||PROSPECTIVE|||||||
33879094|NCT02630758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069520|NCT03131687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069521|NCT02215889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758008|NCT02887079|||COHORT||PROSPECTIVE|||||||
33758009|NCT04988802|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33758010|NCT06457074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879095|NCT04529759|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33879096|NCT03022773|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879097|NCT00264433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879098|NCT00270530|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33879099|NCT01787357|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33879100|NCT00623480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879101|NCT04457427|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34069522|NCT03668340|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069523|NCT01290575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758011|NCT04792697|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33758012|NCT01445925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758013|NCT03011723|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33758014|NCT01798394|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33758015|NCT04434807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome of Modified Rankin scale (mRS) and secondary outcomes including National Institutes of Health Stroke Scale (NIHSS) are assessed by a blinded clinician.|Patients will receive either minimally invasive hematoma evacuation or standard medical therapy|f|f|f|t
33758016|NCT04174248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33758017|NCT00791206|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33758018|NCT05559957|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758019|NCT02093325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758020|NCT00122642|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758021|NCT06491251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069524|NCT02561546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069525|NCT01288651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758022|NCT01217008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758023|NCT04196218|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33758024|NCT03921203|||CASE_CONTROL||OTHER|||||||
33758025|NCT05964608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758026|NCT02331381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758027|NCT05539417|||COHORT||RETROSPECTIVE|||||||
33758028|NCT03238898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blind|randomized, double-blind and placebo-controlled study|t|f|f|f
34069526|NCT06121531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069527|NCT04297696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758029|NCT02953938|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IV, randomized, open-label, active-controlled, 2-arm, multicenter study||||
33758030|NCT02641392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758031|NCT03005509|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33758032|NCT01287130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758033|NCT00832767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758034|NCT04994496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are not aware of the assigned intervention group|Participants are assigned to two groups in parallel for the duration of the study|t|f|f|f
33758035|NCT05226182|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"The patient population in this pilot study consists of two cohorts. All inclusions start from the GP, based on well-defined inclusion criteria. The reason for working with two parallel cohorts is based on the premise that different patient characteristics will confound the results and provide a distorted conclusion if not separated. One group is anticipated to consist of patients capable of using the application independently, while the other group is expected to have patients that will likely be more dependent on others for help with digital applications. This discrepancy could impact the usability and evaluation of the application.~Literature shows that in similar pilot studies numbers of participants can vary a lot. Taking into regard the inclusion criteria, labor intensity and limited resources of this study investigators aim to include 15-30 patients for cohort 1 and 5-15 patients for cohort 2."||||
33758036|NCT05753722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33758037|NCT02924896|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33758038|NCT01820559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758039|NCT04290351|||COHORT||PROSPECTIVE|||||||
33758040|NCT05202925|NA|SINGLE_GROUP||OTHER||NONE||||||
33758041|NCT00716092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758042|NCT03295513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Patient will receive a restoration with superior function, esthetics, and quality.|t|f|f|t
34069528|NCT06435039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069529|NCT02983175|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34069530|NCT02280733|||OTHER||PROSPECTIVE|||||||
33758043|NCT03826095|||CASE_CONTROL||PROSPECTIVE|||||||
33758044|NCT02043691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758045|NCT01455935|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33758046|NCT03945539|NA|SINGLE_GROUP||OTHER||NONE||||||
33758047|NCT04309045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758048|NCT03395405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758049|NCT00606190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758050|NCT04013100|||COHORT||PROSPECTIVE|||||||
33758051|NCT06495931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758052|NCT01644734|NA|SINGLE_GROUP||||||||||
33758053|NCT00464646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758054|NCT02651935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879102|NCT04847661|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will be assigned randomly (locally in each center) in a 1:1 ratio to receive either Mefloquine (1100-1650 mg according to body weight), orally, or to receive the same number of placebo tablets (control group).Patients will be sequentially assigned a randomization number that was generated by an independent statistician. Randomization sequence will be provided in pre-sealed envelopes by the central co-ordination committee of the study. Individuals involved in randomization and masking will have no involvement in the rest of the trial.|open-label, randomized, placebo controlled trial|t|f|f|f
33879103|NCT00247754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33879104|NCT05491993|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The purpose of this study is to validate the performance of the SARS-CoV-2 Antigen Test bioassay for rapid detection of infection when using a nasopharyngeal swab. A prospective randomized and blinded study to evaluate a rapid point of care bioassay for the detection of virus particles compared with the currently validated RT-PCR detection standard. Nasopharyngeal samples will be collected along with the current standard of care collection.||||
33879105|NCT06542913|||COHORT||PROSPECTIVE|||||||
33879106|NCT00291005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879107|NCT04569721|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33879108|NCT05196659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Individual randomized parallel-group feasibility trial||||
33879109|NCT02790151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879110|NCT00887237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879111|NCT05056025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879112|NCT03048422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758055|NCT01210430|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33758056|NCT03262610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758057|NCT05158296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subject, site staff (study coordinator, imaging technician, etc) and Investigator will be completely masked. Physician performing IVT and post-IVT monitoring will know if subject is receiving sham or treatment, but will be masked to the dose level. Pharmacist is the only site staff that will be completely unmasked.|"Double-masked, randomized, controlled, multiple-dose study. Subjects will be randomized to one of three treatment groups:~1. Group 1: Ultevursen 180/60 µg (180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter)~2. Group 2: Ultevursen 60/60 µg (60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter; n = 27)~3. Group 3: Sham-procedure (administered on Day 1, Month 3 and every 6 months thereafter; n = 27)"|t|t|t|t
33758058|NCT03611244|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33758059|NCT00123032|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758060|NCT06463444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758061|NCT00000155|||||PROSPECTIVE|||||||
33758062|NCT04132843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879113|NCT00743379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879114|NCT02164981|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33879115|NCT03714945|||COHORT||PROSPECTIVE|||||||
33879116|NCT00733707|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33879117|NCT02953535|RANDOMIZED|CROSSOVER||||NONE||||||
33879118|NCT01233973|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33879119|NCT03926221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879120|NCT05287009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879121|NCT04029519|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|multicenter, open-label clinical study of retreatment of subjects seeking lip augmentation||||
33879122|NCT02542761|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This was a repeated measures cross-over trial whereby only the prosthetic foot was changed. Each subject was tested using their current carbon-fiber prosthetic foot (CFPF), and the fiberglass prosthetic foot (FPF). Half of the subjects began the study on the CFPF while the other half began on the FPF. Each subject was given an acclimation period of 4 weeks before testing.||||
33879123|NCT05199259|||OTHER||PROSPECTIVE|||||||
33879124|NCT01299714|||COHORT||PROSPECTIVE|||||||
33879125|NCT00336947|RANDOMIZED|||TREATMENT||||||||
33879126|NCT06173193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879127|NCT00687362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879128|NCT00777569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33879129|NCT00488982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758063|NCT03917784|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, double-blind, placebo-controlled clinical trial.|t|f|t|t
33758064|NCT00583986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758065|NCT02007434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758066|NCT02111525|||COHORT||PROSPECTIVE|||||||
33758067|NCT04638998|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758068|NCT02320422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758069|NCT00873418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33879130|NCT01107431|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33758070|NCT01258192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879131|NCT03098836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879132|NCT02944630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879133|NCT01127165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879134|NCT04968457|||CASE_ONLY||PROSPECTIVE|||||||
33879135|NCT02686593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879136|NCT04934787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33879137|NCT02199197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879138|NCT04170517|||COHORT||PROSPECTIVE|||||||
33879139|NCT06437678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879140|NCT05754840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33879141|NCT05593900|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879142|NCT01965132|||COHORT||PROSPECTIVE|||||||
33879143|NCT02069171|||CASE_ONLY||CROSS_SECTIONAL|||||||
33879144|NCT05954442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879145|NCT02806323|NA|SINGLE_GROUP||OTHER||NONE||||||
33879146|NCT03428165|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879147|NCT04001816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879148|NCT04462952|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33879149|NCT02918773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879150|NCT04091997|||CASE_CONTROL||PROSPECTIVE|||||||
33879151|NCT02706808|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33894446|NCT06167161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||This investigation will incorporate a within-subject, randomized, crossover study design in which all study participants will complete two different study arm conditions. During the first visit, subjects will be randomly allocated to study arm A (clinician-fitting) or study arm B (self-fitting). Following the initial two-week take-home field trial, the research participants will be assigned to the opposite study arm such that a complete two-sequence crossover design (AB/BA design) will be followed. The same within-subject crossover design will be followed in both clinical sites and for all individuals who will be enrolled in the study.|f|f|f|t
33879152|NCT03938805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded (PI). The randomization is performed by a study team member who was blinded to screening and baseline data. The physician who assessed the patients had access to them in a random sequence. Patients were randomized 1.1 to nine-week internet-based cognitive behavioral therapy (intervention group) or online 3 weeks sleep hygiene (control group) generated by an independent researcher using a block size of two. Masking of patients was not possible since the interventions is a internet-based cognitive behavioral therapy program. Outcome measures were not necessary to mask since these were automatically collected via the study platform.|Randomized controlled trial. The intervention group participated in a nine-week internet-based cognitive behavioral therapy program. The initial parts of the program, focusing on cardiovascular disease was initially tailored to fit patients with heart failure and has undergone pilot testing. The intervention program used in the current study was adapted to fit also patient with other cardiovascular diagnoses (i.e., heart failure, myocardial infarction, atrial fibrillation) and comprise 1-week of introduction, 2 weeks psycho education on cardiovascular diseases/insomnia, 6 weeks of sleep hygiene, stimulus control and sleep restriction. The Control Group receive 3 weeks of internet-based sleep hygiene education.|f|f|t|f
33879153|NCT00603759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879154|NCT05067842|||CASE_CONTROL||PROSPECTIVE|||||||
33969836|NCT04147715|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Parts 1 and 2 were blinded studies. Part 3 was an open-label study and, therefore, did not include blinding.||t|f|t|f
33969837|NCT00756964|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33969838|NCT01486706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969839|NCT06254209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33969840|NCT05008237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969841|NCT04377178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33969842|NCT02917200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969843|NCT06312332|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||cluster-randomized stepped-wedge design with two or more sites assigned at each of four steps||||
33758071|NCT03088592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879155|NCT05102643|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||Subjects will be enrolled into 2 cohorts and each subject will receive 2 vaccinations at one of the 2 dose levels or matching placebo. Each subject will only participate in one cohort. A Safety Review Committee (SRC) will be set up to review safety data and make decision on dose escalation.|t|t|t|t
33879156|NCT01992783|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33879157|NCT04010500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The participants will articulate phonemes with plosive sounds (/p/, /b/, /d/ and /t/) for the following conditions in a pre-determined sequence: (i) not using mouthguard; (ii) using a 'boil and bite' mouthguard; and (iii) using a custom-fitted mouthguard. A washout interval of one hour will be implemented between conditions.||||
33758072|NCT03735264|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib and Docetaxel||||
33758073|NCT02919722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758074|NCT01941290|||OTHER||PROSPECTIVE|||||||
33758075|NCT03209141|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758076|NCT04240184|||COHORT||PROSPECTIVE|||||||
33758077|NCT03688984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to randomization condition.||f|f|f|t
33758078|NCT04166825|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33758079|NCT01176721|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33758080|NCT05670483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33758081|NCT03233568|||CASE_CONTROL||RETROSPECTIVE|||||||
33758082|NCT04413630|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Intervention group||||
33758083|NCT02456766|||COHORT||CROSS_SECTIONAL|||||||
33758084|NCT06185348|||COHORT||RETROSPECTIVE|||||||
33758085|NCT05907434|||COHORT||PROSPECTIVE|||||||
33758086|NCT05284864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758087|NCT01355588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33758088|NCT06508047|||COHORT||PROSPECTIVE|||||||
33758089|NCT06481033|NA|SINGLE_GROUP||OTHER||NONE||"The goal of this study is to collect feasibility and acceptability data regarding the utility of using real-time functional magnetic resonance imaging neurofeedback in veterans experiencing suicide-specific rumination defined as a repetitive mental fixation on one's suicidal thoughts and intentions. Veterans will be provided neurofeedback signals from the brain to identify mental strategies for altering brain connectivity to reduce rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected."||||
33758090|NCT00266825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758091|NCT02436811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33758092|NCT01241695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33758093|NCT05996289|||COHORT||RETROSPECTIVE|||||||
33758094|NCT06171334|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II open-label, single-center, single-arm futility trial. The study will follow the Simon-2-stage MiniMax design for futility studies.||||
33879158|NCT00239876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879159|NCT01469858|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879160|NCT02349698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879161|NCT01060358|||CASE_ONLY||CROSS_SECTIONAL|||||||
33879162|NCT00191594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879163|NCT05970263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879164|NCT03546075|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33879165|NCT06392880|RANDOMIZED|CROSSOVER||OTHER||NONE||This study features a balanced cross-over design.||||
33879166|NCT02123485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879167|NCT04986709|||COHORT||PROSPECTIVE|||||||
33879168|NCT05265533|||OTHER||CROSS_SECTIONAL|||||||
33879169|NCT05988151|||CASE_CONTROL||RETROSPECTIVE|||||||
33879170|NCT01504217|||COHORT||CROSS_SECTIONAL|||||||
33879171|NCT01489514|||||PROSPECTIVE|||||||
33879172|NCT06344078|||COHORT||PROSPECTIVE|||||||
33879173|NCT00085371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879174|NCT05654129|NON_RANDOMIZED|PARALLEL||OTHER||NONE||people with stage F1-F2 NAFLD versus people with stage F3-F4||||
33879175|NCT02926209|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33879176|NCT05449600|RANDOMIZED|FACTORIAL||OTHER||SINGLE||Tegaderm™ tape, Kind™ tape, and Thermotape will be applied to both forearms for 24 hours. Afterwards, one forearm will have the tapes removed normally, without any intervention. The other forearm will have the tapes removed after heat is applied, using a heatpack.|t|f|f|f
33879177|NCT01016639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879178|NCT01920204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879179|NCT03330886|||COHORT||PROSPECTIVE|||||||
33879180|NCT01687712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33879181|NCT04231383|||CASE_CONTROL||PROSPECTIVE|||||||
33879182|NCT02937350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879183|NCT01489527|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33879184|NCT02158780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879185|NCT00006112||||TREATMENT||||||||
33879186|NCT02800200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879187|NCT01819779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33879188|NCT00144183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879189|NCT02190851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879190|NCT03178487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879191|NCT04208477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879192|NCT04492683|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33879193|NCT04824586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study was a parallel-group, randomized, controlled trial with 1:1 allocation ratio.|t|t|t|f
33879194|NCT02686086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758095|NCT06293209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Population~The sample group comprises 30 patients admitted for treatment in the male orthopedic surgery department, female orthopedic surgery department, and accident orthopedic surgery department at Sunpasitthiprasong Hospital, Ubon Ratchathani from August 2023 to January 2024. ."|f|f|t|t
33758096|NCT03909984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Phase 1: Usual care (2 months), Phase 2: Intervention with monitoring true different devices (2 months), Phase 3: Optional phase with continued use of Nightwatch or tailoring.||||
33758097|NCT01561859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33758098|NCT03350425|||OTHER||PROSPECTIVE|||||||
33758099|NCT00353236|||CASE_CONTROL||PROSPECTIVE|||||||
33758100|NCT02167763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33879195|NCT03453983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not be informed of the stimulation group to which they are randomized. Both stimulation groups produce similar transient scalp sensations in participants and the sham protocol that will be used has been shown to be valid and ensures that participants are naïve to their assigned treatment group \[9\]. Participants will be asked which stimulation group they felt they took part in to ensure adequate blinding.~Outcomes assessors will be blinded. Offline video analysis will be used to score motor assessment performance. These videos will exclude all identifying information including the participant's face and their stimulation group."|The currently proposed study is a randomized, sham controlled clinical trial that includes 30 adolescents diagnosed with DCD. Participants will be randomized to one of two tDCS treatment groups.|t|f|f|t
33879196|NCT04669834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional physical therapy treatment, but group (B) will receive additional core stability exercise.|t|t|t|t
33879197|NCT02669017|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879198|NCT03368651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879199|NCT02901288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879200|NCT03927105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879201|NCT02204696|||COHORT||PROSPECTIVE|||||||
33879202|NCT01425203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879203|NCT02651363|||COHORT||PROSPECTIVE|||||||
33879204|NCT04953312|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33879205|NCT00468780|||CASE_ONLY||PROSPECTIVE|||||||
33879206|NCT01637233|||||PROSPECTIVE|||||||
33879207|NCT02859935|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33879208|NCT00533975|||DEFINED_POPULATION||PROSPECTIVE|||||||
33879209|NCT03252483|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33879210|NCT00653822|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33879211|NCT00415779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879212|NCT05512533|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879213|NCT00381771|||CASE_ONLY||PROSPECTIVE|||||||
33879214|NCT06149858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879215|NCT02672566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879216|NCT01736579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879217|NCT01635114|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879218|NCT00940355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879219|NCT02133989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758101|NCT06384950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research uses a Randomized Controlled Trial (RCT) methodology, dividing patients into a control group undergoing the conventional patient education routine, and an experimental group that leverages both the chatbot and traditional education. By comparing selected outcomes between the two groups, the experiment's effectiveness will be determined.|To compare the educational effectiveness of a chatbot integrated with health education information to traditional health education methods. This comparison encompassed aspects such as the patient's health literacy and clinical satisfaction. Based on the findings, recommendations and improvements would be proposed to promote the application and development of large language models in the medical field.|t|f|f|f
33758102|NCT03039595|||COHORT||OTHER|||||||
33758103|NCT03721640|||OTHER||PROSPECTIVE|||||||
33758104|NCT01921816|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879220|NCT04111874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758105|NCT02063230|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33758106|NCT04433234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758107|NCT05341258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758108|NCT06341608|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33758109|NCT02510144|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33758110|NCT04493216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study treatment assignments was not blinded (GSK3640254 versus Dolutegravir control arm). However, the dose level of GSK3640254 in each of the treatment arms containing GSK3640254 was blinded to the research participants and all study personnel during the study. The Sponsor personnel remained blinded until the database lock for the Week 24 analysis.|This is a randomized, multicenter, parallel group study.|t|t|t|t
33758111|NCT01003457|||COHORT||PROSPECTIVE|||||||
33758112|NCT03935230|||COHORT||RETROSPECTIVE|||||||
33758113|NCT04620967|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Group allocation is concealed to participants as well as investigators until all participants have completed the study. The allocation for a participant may be revealed in a medical emergency if knowledge about the treatment allocation would influence the treatment of the person.|A randomized, double-blind, cross-over study with two 16-week intervention periods separated by a 3-week washout period comparing Fiasp with Iasp in adults with type 1 diabetes treated with insulin pump and CGM.|t|t|t|f
33758114|NCT01054261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758115|NCT01762150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758116|NCT01855217|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33758117|NCT01292551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33758118|NCT01828580|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33758119|NCT02640872|||COHORT||PROSPECTIVE|||||||
33758120|NCT01525602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758121|NCT00005791||||TREATMENT||||||||
33758122|NCT00975832|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758123|NCT01737957|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33758124|NCT02013310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758125|NCT01197508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879221|NCT05120310|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||There will be two groups: first is the intervention group and the other is a waitlist-control and will receive the intervention after the control portion of the study.||||
33879222|NCT03351257|||CASE_CONTROL||PROSPECTIVE|||||||
33879223|NCT04596475|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879224|NCT02569762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33879225|NCT03299920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879226|NCT04732507|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Depending on assignment, one group will receive 1-2 needle passes at each trigger point, the other will receive 10 and the third will receive 20.||||
33879227|NCT00813423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879228|NCT01148277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879229|NCT03585335|||OTHER||PROSPECTIVE|||||||
33879230|NCT02870855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879231|NCT04104438|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||To assess the efficacy and safety of basiliximab, delayed dose tacrolimus plus mycophenolate mofetil, and SOC corticosteroids versus basiliximab, delayed dose tacrolimus plus mycophenolate mofetil, and SOC corticosteroids and addition of delayed everolimus/mycophenolate minimization at one month post OLT compared to standard triple immunosuppression (tacrolimus, mycophenolate mofetil and corticosteroids) for prevention of acute organ rejection in liver transplant recipients with a high risk of developing renal dysfunction following OLT or with concomitant renal dysfunction prior to OLT.||||
33879232|NCT00954044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33879233|NCT01654055|||COHORT||PROSPECTIVE|||||||
33879234|NCT04369066|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33879235|NCT04740047|||COHORT||PROSPECTIVE|||||||
33758126|NCT03291743|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758127|NCT02088151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758128|NCT02532556|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33758129|NCT03879746|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33758130|NCT01566331|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33758131|NCT02770651|||CASE_CONTROL||PROSPECTIVE|||||||
33758132|NCT02365675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758133|NCT01373931|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33758134|NCT02539043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33758135|NCT02260453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758136|NCT02218879|||COHORT||PROSPECTIVE|||||||
33758137|NCT03298230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758138|NCT03190551|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34069531|NCT03862872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subject Code Numbers assigned to subjects using 400 randomly generated numbers ranging from 1-1000 are associated with all data generated in place of the subject name.~Product Code Numbers on Test Materials, using 90 randomly generated numbers ranging from 1-99, are assigned by a Data Manager. All subsequent documentation will be labelled with the Product Code Number. Test material identity will not be shared with any participants within the trial \[i.e. Subjects, Principal Investigator (PI), Clinical Research Monitor (CRM), Test Material Controller (TMC), Study Site Monitor \& Quality Specialist (SM\&QS), Data Analyst\]. The only person who will be aware of the test material identity relative to any Product Code Number will be the Data Manager.~Unmasking of the Product Code Numbers will be by the Data Manager, once statistical analysis is complete."|Phase IV, randomized, double-blind, placebo-controlled, three-arm, parallel intervention study|t|f|t|t
34069532|NCT00574093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069533|NCT05406271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069534|NCT00622583|||OTHER||PROSPECTIVE|||||||
34069535|NCT06341062|||COHORT||PROSPECTIVE|||||||
34069536|NCT01677182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069537|NCT02640898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|open label||t|f|f|f
34069538|NCT03278236|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34069539|NCT00013377|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34069540|NCT05253144|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III||||
34069541|NCT00003832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069542|NCT01679028|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34069543|NCT01913522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069544|NCT03895450|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Allocation will be concealed through the use of sequentially numbered, opaque envelopes.||f|f|t|f
33758139|NCT01318057|||COHORT||RETROSPECTIVE|||||||
33758140|NCT06097676|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33758141|NCT04715516|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomised controlled trial|t|f|f|t
33758142|NCT05435924|||OTHER||PROSPECTIVE|||||||
33879236|NCT01962051|||CASE_ONLY||PROSPECTIVE|||||||
33879237|NCT03067272|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879238|NCT06519019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879239|NCT01834729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879240|NCT04204174|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879241|NCT02929264|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33758143|NCT02031367|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33758144|NCT05749848|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758145|NCT02913664|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33758146|NCT03754179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758147|NCT04074421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33758148|NCT04590534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758149|NCT01756911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758150|NCT02638311|||||PROSPECTIVE|||||||
33879242|NCT01061463|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879243|NCT01356914|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33758151|NCT05388721|||CASE_CONTROL||PROSPECTIVE|||||||
33879244|NCT01286246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879245|NCT05997875|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879246|NCT03224273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879247|NCT04926272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879248|NCT05051007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33969844|NCT03246568|RANDOMIZED|PARALLEL||TREATMENT||NONE||Research on the Basis of Earlier Theory Renal artery sympathetic denervation (RND) by catheter ablation has been shown in a preliminary study to improve outcome of electrical isolation of the pulmonary vein (PVI) in patients with paroxysmal and/or persistent AF with concomitant refractory hypertension and the same group later showed renal sympathetic denervation improved outcome of PVI in the cohort of paroxysmal and/or persistent AF patients with moderate hypertension. In patients with renal impairment, RND also conferred benefit in reducing AF recurrence after PVI.The initial indication for catheter-based RND is for blood pressure control in patients with resistant hypertension. Early data from clinical trials without sham controls was promising - demonstrating large blood pressure reductions in patients with treatment-resistant hypertension.||||
33969845|NCT03502421|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Prospective Clinical Trial||||
33969846|NCT03895593|||CASE_ONLY||RETROSPECTIVE|||||||
34069545|NCT03412292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069546|NCT02961387|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33879249|NCT06193512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and Investigator will be specifically blinded to oral care management whereas the care provider will be unblinded to the oral care management.|randomized controlled study|t|f|t|f
33879250|NCT04690400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be implemented for outcome assessor. The questionnaires and functional tests will be supervised remotely by an investigator blinded to the participant's group. Due to the type of interventions, the investigator conducting exercise sessions as well as participants are not blinded.|This is a randomized, single-blinded, parallel, superiority, controlled trial. Participants, women with fibromyalgia, will be allocated to two groups, experimental and control, based on randomization sequence. Sequence will be generated by computer, with 1:1 ratio and blocks of random sizes that are not disclosed to ensure concealment. Allocation concealment will be implemented through a central randomization routine conducted by the same investigator that will generate the sequence. The allocation of participants will occur after the completion of baseline outcomes evaluations.|f|f|f|t
33879251|NCT05280678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||200 Absoanchor® miniscrews (Dentos, South Korea) in two sizes: SH2018-10 (length 10 mm, ø 18-20 mm) and SH1514-08 (length 8 mm, ø 14-15 mm) were inserted in the mandibular buccal shelf of 100 Caucasians aged 20-50 years, diagnosed with Class III malocclusion that required en-masse distalization of the mandibular dentition. We designed our project as a split-mouth study, therefore each patient received both SH2018-10 and SH1514-08 miniscrews. The same orthodontist (M.S.) inserted the screws near the muco-gingival junction, following one surgical protocol. Miniscrews were loaded with orthodontic force (NiTi coil springs) of approximately 200 g, two weeks after the surgery. On the same visit patients were surveyed upon pain incidence lasting longer than 48 hours. Then TISAD stability and soft tissue condition were closely examined at each appointment. Miniscrews were considered long-term stable if they served as an anchorage until completion of distalization of the mandibular teeth.|t|f|f|f
33879252|NCT06501287|||CASE_CONTROL||PROSPECTIVE|||||||
33879253|NCT00634491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33879254|NCT01271205|||CASE_ONLY||RETROSPECTIVE|||||||
33879255|NCT00378170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33879256|NCT05409339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||The project adopted a double blind, placebo-controlled, randomized within-subjects design. Screenings took place at the Centre for Chronobiology at the Psychiatric University Hospital Basel (UPK, single center). Data collection took place at Clinical Trial Unit, Department of Clinical Research, University of Basel and University Hospital of Basel. Each participant went through three study sessions, i.e. caffeine, placebo, withdrawal. Each of the session consisted of 9 days of pre-ambulatory part, 2 days of laboratory visit, and 7 days of post-ambulatory part.|t|f|t|t
33879257|NCT00670592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879258|NCT02406807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33879259|NCT04032990|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33879260|NCT01050400|||OTHER||PROSPECTIVE|||||||
33879261|NCT04882891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||all patients undergo clinical evaluation and wear Actimyo device in daily living to assess their gait and its evolution.||||
34069547|NCT05699525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33879262|NCT01058343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879263|NCT05979571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879264|NCT03947814|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879265|NCT00670332|||||RETROSPECTIVE|||||||
33879266|NCT01345331|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33879267|NCT04053738|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants were not informed prior to going to bed whether the night would be an intervention night or not||t|f|f|f
33879268|NCT01356589|||COHORT||RETROSPECTIVE|||||||
33879269|NCT00907400|RANDOMIZED|CROSSOVER||||NONE||||||
33969847|NCT00003747||||TREATMENT||||||||
33969848|NCT01140984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069548|NCT03521752|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34069549|NCT00734461|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34069550|NCT00625183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069551|NCT02362191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879270|NCT00938314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879271|NCT00880815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879272|NCT05738850|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33879273|NCT01285908|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069552|NCT05867966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The WP1 is observational only (N = 440) In the WP2, 60 other participants will be randomized into an intervention group and a control group.||||
34069553|NCT02066727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069554|NCT01900847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069555|NCT01739504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069556|NCT02020135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069557|NCT06174194|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879274|NCT03051113|||COHORT||PROSPECTIVE|||||||
33879275|NCT05993637|||COHORT||PROSPECTIVE|||||||
33879276|NCT06449638|RANDOMIZED|PARALLEL||TREATMENT||NONE||CAMPSTIM employs a novel modified platform clinical trial design. CAMPSTIM will evaluate several CAMPs, specifically (4) placental-based CAMPs and Standard of Care (SOC) versus SOC alone in the treatment of nonhealing diabetic foot ulcers. The initial plan is to evaluate the four CAMPs identified in this protocol; however, the platform design allows for the inclusion of additional products which will be added following an interval analysis.||||
33879277|NCT06095856|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"Double blinded study:~* Blinding of the operator is not applicable.~* Blinding of the participants is not applicable.~* Outcome assessors and biostatistician will be blinded. Participants' identity and their corresponding study group will be concealed by assigning an identification number to all lab communications, data files and reports for the transfer of data to and from assessors."|"The trial will be a Cross-Over clinical trial, with a wash-out period of 24 hours between investigated interventions, to set superiority, using 3 randomized groups of participants, and an allocation ratio of 1:1:1."|f|f|f|t
33879278|NCT04673786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879279|NCT04080622|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879280|NCT00713700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069558|NCT03584425|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The investigators will enroll a total of 30 chronic stroke patients and 30 neurologically healthy controls matched for age and with at least 2 cardiovascular risk factors||||
34069559|NCT05848544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069560|NCT03074461|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking in the CSAR Trial|Study participants will be randomized in two parallel study arms regarding their neorectal reconstruction in low anterior resection, the experimental arm using the side-to-end anastomosis and the control group using the transverse coloplasty technique.||||
34069561|NCT05059925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879281|NCT04751162|||COHORT||PROSPECTIVE|||||||
34069562|NCT00270621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069563|NCT02745938|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34069564|NCT02963519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069565|NCT06128681|||COHORT||PROSPECTIVE|||||||
34069566|NCT00482482|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34069567|NCT00835523|||COHORT||PROSPECTIVE|||||||
34069568|NCT03253536|||COHORT||PROSPECTIVE|||||||
34069569|NCT03750994|||CASE_ONLY||PROSPECTIVE|||||||
34069570|NCT01599481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34069571|NCT03627078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069572|NCT04551365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two-block, each with 2 arms; a total of 4 arms|t|t|t|t
34069573|NCT01928199|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069574|NCT05687409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069575|NCT05345366|||CASE_ONLY||PROSPECTIVE|||||||
34069576|NCT00957489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879282|NCT02797886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879283|NCT03105570|NA|SINGLE_GROUP||TREATMENT||NONE||Single Armed, prospective, open label study||||
33879284|NCT03406065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879285|NCT04146610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879286|NCT03652142|||COHORT||PROSPECTIVE|||||||
33879287|NCT02179957|||COHORT||RETROSPECTIVE|||||||
33879288|NCT03979274|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33879289|NCT02090400|RANDOMIZED|PARALLEL||||NONE||||||
33879290|NCT01775241|||COHORT||PROSPECTIVE|||||||
33879291|NCT01034995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879292|NCT05490420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant will be masked.|randomized controlled trial|t|f|f|f
33879293|NCT02693587|||COHORT||PROSPECTIVE|||||||
33879294|NCT05088707|RANDOMIZED|PARALLEL||TREATMENT||NONE|an open-label randomized controlled study|an open-label randomized controlled study||||
33879295|NCT02975843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879296|NCT06367296|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33969849|NCT00318266|||COHORT||PROSPECTIVE|||||||
33969850|NCT06118359|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The intervention will target UW Health accepting providers. Referring providers do not receive the intervention. Patients have waiver of informed consent.||||
33969851|NCT01339195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969852|NCT00376428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969853|NCT03137082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969854|NCT01844934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 arms, one intervention, one control|f|f|f|t
33969855|NCT03555721|||OTHER||PROSPECTIVE|||||||
33969856|NCT02010580|||COHORT||PROSPECTIVE|||||||
33969857|NCT01416376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33969858|NCT00490061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969859|NCT05425966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069577|NCT02779075|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34069578|NCT03606057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069579|NCT02706145|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069580|NCT02829502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879297|NCT02028195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879298|NCT05841095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879299|NCT04634214|||CASE_CONTROL||RETROSPECTIVE|||||||
33879300|NCT01829854|||||PROSPECTIVE|||||||
33879301|NCT00413361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33879302|NCT00432978|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33879303|NCT02867761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879304|NCT00388908|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33969860|NCT01005550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969861|NCT06225583|||CASE_CONTROL||PROSPECTIVE|||||||
33969862|NCT01331785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969863|NCT05583890|||CASE_CONTROL||PROSPECTIVE|||||||
34069581|NCT01006590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069582|NCT02628158|||CASE_CONTROL||RETROSPECTIVE|||||||
34069583|NCT01679444|NA|SINGLE_GROUP||||NONE||||||
33758152|NCT03197012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Main study: All participants will receive a single administration of intra-arterial 90Y-DOTA-TOC.~There will be a sub-study involving 10 patients from the main study who will undergo additionally correlative imaging to compare IA vs IV administration (intra-arterial 68Ga-DOTA-TOC administration and subsequent PET imaging)."||||
33758153|NCT04983563|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758154|NCT02636270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758155|NCT04021017|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in this study will be randomized 1:1 into 2 groups. One group will receive treatment with a transdermal estrogen patch and the other group will not.||||
33879305|NCT01844895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879306|NCT01890421|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879307|NCT05006885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879308|NCT03317756|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|intervention and control arms|||||
33879309|NCT03923569|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2 compared groups (Alzheimer's Disease patients vs controls)||||
33879310|NCT06033235|||CASE_ONLY||RETROSPECTIVE|||||||
33879311|NCT01843218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879312|NCT03865693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879313|NCT02692209|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33879314|NCT00294307|||COHORT||PROSPECTIVE|||||||
33879315|NCT05792215|||OTHER||CROSS_SECTIONAL|||||||
33879316|NCT04270097|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758156|NCT03460028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879317|NCT06484790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879318|NCT03690765|||COHORT||PROSPECTIVE|||||||
33879319|NCT00955630|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879320|NCT03335332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758157|NCT00461357|||||PROSPECTIVE|||||||
33758158|NCT04876079|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758159|NCT04162093|NA|SINGLE_GROUP||TREATMENT||NONE||the new technique was observed in a group of patients for effectiveness and complications.||||
33758160|NCT06370910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized clinical trial||||
33879321|NCT05524350|||COHORT||PROSPECTIVE|||||||
33879322|NCT03678402|NA|SINGLE_GROUP||PREVENTION||NONE||single arm prospective non-randomized study||||
33879323|NCT01325428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879324|NCT05853614|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879325|NCT04977180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879326|NCT05151055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879327|NCT02090712|||COHORT||PROSPECTIVE|||||||
33879328|NCT01569802|||COHORT||RETROSPECTIVE|||||||
33879329|NCT05552911|||COHORT||PROSPECTIVE|||||||
33879330|NCT02268058|RANDOMIZED|PARALLEL||||NONE||||||
33879331|NCT04222452|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969864|NCT03546582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969865|NCT01907724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969866|NCT05798403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the study, except for acupuncturists, other people involved in the trial, including participants, study supervisors, efficacy evaluators, data analysts, prescription drug prescribers and statistical analysts, will all be blinded to patients group assignment.||t|f|t|t
33969867|NCT05429710|||OTHER||RETROSPECTIVE|||||||
33758161|NCT04088201|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33758162|NCT01592903|||CASE_ONLY||PROSPECTIVE|||||||
33879332|NCT04218253|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33879333|NCT03477708|||CASE_CONTROL||PROSPECTIVE|||||||
33879334|NCT02971670|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879335|NCT03407989|||COHORT||PROSPECTIVE|||||||
33879336|NCT02474082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879337|NCT06364085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879338|NCT02979665|||COHORT||PROSPECTIVE|||||||
33879339|NCT03378908|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Glycemic profile will be collected with a blind-sensor during the study.|||||
33879340|NCT04890210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33879341|NCT01118468|||OTHER||PROSPECTIVE|||||||
33969868|NCT01288833|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33969869|NCT01987804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758163|NCT00116844|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33879342|NCT01112046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879343|NCT04930055|||COHORT||PROSPECTIVE|||||||
34069584|NCT04427046|||COHORT||RETROSPECTIVE|||||||
33879344|NCT01119248|||CASE_ONLY||PROSPECTIVE|||||||
33879345|NCT05793931|||OTHER||PROSPECTIVE|||||||
33879346|NCT02387580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879347|NCT02260843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879348|NCT01394939|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879349|NCT02535533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879350|NCT02365168|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33879351|NCT00083083||||DIAGNOSTIC||NONE||||||
33879352|NCT00782457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879353|NCT05804708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879354|NCT01446419|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33969870|NCT00058357|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33969871|NCT06378983|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33969872|NCT05307263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969873|NCT03207659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969874|NCT02058433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758164|NCT03879408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Post-operative dental pain following third molar extraction.|t|t|t|t
33758165|NCT02417779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34069585|NCT05754671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34069586|NCT03539484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069587|NCT03531476|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069588|NCT00580749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069589|NCT01489852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069590|NCT02094313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069591|NCT00596453|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33758166|NCT05255432|||COHORT||PROSPECTIVE|||||||
33758167|NCT01035164|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758168|NCT04780373|||COHORT||PROSPECTIVE|||||||
33758169|NCT00739375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758170|NCT02055157|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879355|NCT01849770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879356|NCT00847366|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879357|NCT05222217|||CASE_ONLY||RETROSPECTIVE|||||||
33879358|NCT00870064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879359|NCT03721094|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and the principal investigators were blinded to performance metrics by the simulator during the supervised procedure and the three test procedures. Participants and the data collector could not be blinded to the allocation/intervention. The investigator in charge of the statistical analysis was blinded to participants' group allocation.|A single-center randomized trial was designed according to the CONSORT statement||||
33879360|NCT00662103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33879361|NCT06400888|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879362|NCT00868283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879363|NCT00595712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879364|NCT05700903|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33879365|NCT01482364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879366|NCT06302244|||COHORT||RETROSPECTIVE|||||||
33879367|NCT05815589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879368|NCT05671939|||COHORT||RETROSPECTIVE|||||||
33879369|NCT05588570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758171|NCT00002558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758172|NCT03649230|||COHORT||PROSPECTIVE|||||||
33758173|NCT03920228|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|During the open-label period, there is no masking. During the randomized, double-blind, placebo-controlled period the participant and Investigator are masked.|"This study consists of 2 treatment periods:~* Open-Label~* Randomized, Double-Blind, Placebo controlled"|t|f|t|f
33758174|NCT04417686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758175|NCT04799379|||COHORT||PROSPECTIVE|||||||
33758176|NCT00956566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758177|NCT04706702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758178|NCT05518656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33758179|NCT04352478|||OTHER||RETROSPECTIVE|||||||
33758180|NCT05527366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758181|NCT03252080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758182|NCT02472210|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33758183|NCT00867438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758184|NCT06387290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators, study staff, and statistician will be blinded to treatment condition.|Hybrid implementation-effectiveness trial|f|f|t|t
33758185|NCT03058341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will not be informed about what type of anaesthesia they will receive. A separate investigator assessing the patients for data collection after the operation will be blinded. The anaesthetist providing general anaesthesia will not be involved in data collection.|Patients in the first group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. The patients in the second group (P) will be anaesthetized using total intravenous propofol.|t|t|t|t
33758186|NCT04023071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758187|NCT02484157|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33758188|NCT05801731|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The randomization list will be prepared by an independent staff who is not part of the current study. A non-speaking code will be used for each of the snack types. The study team members will be kept blinded to the order of snack given to the participant|The study will be carried out according to a decentralized, randomized, placebo controlled, double-blind, cross-over design.|t|f|t|f
33758189|NCT04858919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The sonographers will be blinded to all images obtained from the initial pelvic ultrasound and from the images obtained by the alternative sonographic modality. Also All sonographic images will be concealed from the physicians performing the vaginoscopy procedure .|A diagnostic test accuracy study that will be conducted at Ain-Shams University Maternity Hospital ,the patients will be recruited from women admitted from gynecologic clinic or from emergency room and from patients following up in outpatient clinic patients will be recruited to this study All Patients recruited must have suspected uterine, cervical or vaginal lesion by history, examination and Pelvic ultrasound||||
33758190|NCT02543658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758191|NCT05655676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758192|NCT00061802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758193|NCT02486289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758194|NCT02741401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879370|NCT06303934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33879371|NCT01221428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758195|NCT03353064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Statisticians will be receiving de-identified data|Randomized Controlled Trial|f|f|f|t
33758196|NCT02130934|||CASE_ONLY||PROSPECTIVE|||||||
33758197|NCT02133599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758198|NCT00715650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879372|NCT03264430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33879373|NCT04560088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879374|NCT05522166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Because the initiative of the study is based on the type of education. While obtaining informed consent, the purpose and content of the study were explained to the participants. For this reason, trainees know whether they will receive basic life support with digital storytelling or face-to-face applied.|The sample group determined by the stratified sampling method from the departments of the education faculty will be selected according to the simple random sampling method and distributed to the groups as 38 digital storytelling and 38 face-to-face applied training groups. In this pretest-posttest experimental study, data will be collected by using the student descriptive characteristics form, Basic Life Support Information Form and Basic Life Support Skills Evaluation Form in the pre-test. After the pre-test, BLS training will be carried out with digital storytelling for one group and face-to-face applied to the other group. The initiatives of both groups will last two months according to the program. After the training, post-test applications will be given to both groups. A permanence test will be given to both groups 1 month after the post-test.||||
33879375|NCT01564615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33879376|NCT01954693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879377|NCT00035880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879378|NCT01936545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33879379|NCT02155998|||COHORT||PROSPECTIVE|||||||
33879380|NCT00511355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879381|NCT01934283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879382|NCT01745146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879383|NCT01384578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33879384|NCT02070042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879385|NCT02876887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969875|NCT05114226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The degree of the skin injury during the radiotherapy was assessedaccording to the radiation morbidity scoring criteria of the Radiation Therapy Oncology Group (RTOG).After the start of radiotherapy, the degree of the damage to the patient's skin was assessed every week. BH4 was applied when skin damage≥ Grade I occurred. A sterile gauze was soaked with BH4 solvent, wringed out, and applied to the treated skin area for 15 minutes. It was applied three times a day (morning, noon, and evening), until three months after the end of treatment.~BH4 gradient: 50, 100, 200, 400, 600, 800, and 1,000 ug/ml."||||
33969876|NCT01952574|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||In the DBTP participants were randomized to one of four arms. In the optional CHU substudy participants were randomized into one of two treatment groups.|t|f|t|t
33969877|NCT04765033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Double-blind Placebo-controlled trial|t|t|t|t
33969878|NCT04023630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069592|NCT02566499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069593|NCT06500650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33879386|NCT05344456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069594|NCT06402877|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20).||||
33879387|NCT05244265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Open feasibility study: no masking. RCT: during the screening, assessment of eligibility and completion of T1 (baseline), the allocation to a specific study arm is masked. After T1, all participants, care provider and investigators know which arm (group or treatment as usual) was allocated.|First study is an open feasibility study, and the second one is a RCT with two parallel group study arms.|t|t|t|t
34069595|NCT00568737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069596|NCT03816618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||PROSPECTIVE|t|f|f|f
33879388|NCT00973960|||COHORT||PROSPECTIVE|||||||
33879389|NCT00913029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879390|NCT05558956|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34069597|NCT01025102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34069598|NCT04465084|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.|t|f|f|f
33879391|NCT04094220|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients included in this study are with degenerative lumbar stenosis and Schizas's stenosis grades C. Patients who suffered from significant lumbar scoliosis, grade 2 spondylolisthesis, lumbar fracture and prior lumbar surgery are excluded from this study.||||
33879392|NCT03750266|||COHORT||PROSPECTIVE|||||||
33879393|NCT04884048|||CASE_CONTROL||RETROSPECTIVE|||||||
33879394|NCT04554550|||COHORT||PROSPECTIVE|||||||
33879395|NCT00691483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879396|NCT06440460|||COHORT||PROSPECTIVE|||||||
33879397|NCT03692936|||CASE_CONTROL||PROSPECTIVE|||||||
34069599|NCT02330172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069600|NCT03998371|||CASE_CONTROL||PROSPECTIVE|||||||
34069601|NCT02166281|||CASE_ONLY||PROSPECTIVE|||||||
34069602|NCT03917277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069603|NCT00768573|||OTHER||PROSPECTIVE|||||||
34069604|NCT02331784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34069605|NCT01399398|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069606|NCT03373357|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"All the patients will have sampling blood specific to the protocol:~* Insulinémie~* US CRP(TEACHERS' CENTRE)~* Implementation of a sérothèque"||||
34069607|NCT05979896|NA|SINGLE_GROUP||PREVENTION||NONE||Cohort||||
34069608|NCT00003190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069609|NCT06046131|NA|SINGLE_GROUP||OTHER||NONE||Any patient with a histologically confirmed incident case of prostate cancer will be included in the study||||
34069610|NCT04862936|||OTHER||OTHER|||||||
34069611|NCT02567097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33758199|NCT06131580|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center (four sites in Canada), open-label study to evaluate the long term safety of osilodrostat in 7 patients currently being treated in a Global Recordati-sponsored study (LCI699C2X01B) and who are judged by their doctor as benefiting from the current study treatment. The study is expected to remain open for approximately 2 years from EOT (end of trial) visit for each patient in roll-over study. Patients will continue to be treated in this study until they are no longer benefiting from their osilodrostat treatment as judged by the Investigator, until one of the protocoldefined discontinuation criteria is met. Additionally, Company (RRD) agrees to provide osilodrostat for investigational use through the study until patients can transition to commercially available and reimbursed drug in patients' province, as long as there is a path, as determine by RRD Canada Inc., to reimbursement.||||
33758200|NCT01355458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758201|NCT02192970|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33879398|NCT02112370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879399|NCT00328770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879400|NCT02415738|||COHORT||PROSPECTIVE|||||||
33879401|NCT01764074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879402|NCT00711100|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open label trial|||||
34069612|NCT04188886|||OTHER||PROSPECTIVE|||||||
33879403|NCT05926726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879404|NCT02447848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879405|NCT03372031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized members of dyads (formed by residential treatment facility personnel) in to therapy order conditions. Two weeks piano therapy for one while the other listened followed by two week in reversed roles. Half the participants played first and listened second and the other half did the reverse.||||
33879406|NCT00701545|||CASE_ONLY||PROSPECTIVE|||||||
33879407|NCT04538794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879408|NCT03470493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879409|NCT03824665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Patients were grouped randomly using sealed envelopes prepared by an assistant who was blinded to the grouping and envelops were chosen by patient him/her self or by the nearest relative All patients received 8 ml of LAM which consisted of: 3 ml of mepivacaine 3%,~1 ml of hyaluronidase containing 150 IU, 2 ml of bupivacaine 0.5%, 1 ml of lidocaine 2%.Patients were categorized into three groups according to the type of additive used with the LAM as follows:~1. Group C (Control group): included patients assigned to receive 1 ml normal saline.~2. Group F: 1 ml saline containing 20 μg fentanyl was used instead of normal saline.~3. Group N:1 ml saline containing 4mg nalbuphine was used instead of normal saline."|Evaluation of the analgesic and hemodynamic outcome of nalbuphine or fentanyl versus a control group for peribulbar block (PBB) during posterior chamber surgery.|t|f|t|f
33879410|NCT02018627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879411|NCT00435968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33879412|NCT01934088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879413|NCT01558661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879414|NCT03195907|||CASE_CONTROL||PROSPECTIVE|||||||
33879415|NCT02230280|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33879416|NCT06471270|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34069613|NCT01089010|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33758202|NCT03911648|||COHORT||RETROSPECTIVE|||||||
33758203|NCT02522858|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758204|NCT00184548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879417|NCT01816243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879418|NCT01084070|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879419|NCT01088074|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879420|NCT01097863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879421|NCT03064139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879422|NCT00853697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879423|NCT03424447|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Ambispective cohort study||||
33879424|NCT00640471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879425|NCT04033835|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33879426|NCT03116646|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879427|NCT04163445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will be randomized to one of 2 treatment arms using a random number generator. The care provider will not be blinded as he will be implanting the device and following the patients' progress in clinic postoperatively, including radiographs which will show the implants. He will be blinded, however, to the results of the KOOS score and the data derived from the force plate analysis. The research assistants performing those assessments will be blinded to which treatment arm the patient belongs to.||f|f|t|t
33879428|NCT04743947|||COHORT||PROSPECTIVE|||||||
33879429|NCT01353742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879430|NCT03754244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879431|NCT02467933|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879432|NCT02911532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969879|NCT05975021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Trial treatment will be blinded to the trial staff. Istaroxime and placebo are both lyophilized powders and are put into identical vials. Each trial box will be numbered with a unique identifier, which will not allow the trial staff to ascertain which treatment is being used.|This is a pilot, multinational, multicenter, randomized, double-blind, placebo-controlled, safety and efficacy trial. Participants will consist of males or females 18 to 85 years of age hospitalized for acute decompensated heart failure (ADHF) with persistent hypotension (systolic blood pressure \[SBP\] 70 to 90 mmHg for two readings with concomitant signs of hypoperfusion), and mild to moderate renal impairment.|t|t|t|f
33969880|NCT06399419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969881|NCT06142656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969882|NCT00863369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069614|NCT03867968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969883|NCT04537247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069615|NCT01473225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33969884|NCT03104205|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A single arm pilot intervention||||
33879433|NCT03899662|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33879434|NCT03232515|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-randomized pre-test / post-test clinical trial||||
33879435|NCT00180310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879436|NCT02674438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33879437|NCT01269710|||CASE_ONLY||PROSPECTIVE|||||||
33879438|NCT02216461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33879439|NCT03060070|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33879440|NCT00272038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879441|NCT03234530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33969885|NCT02382471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969886|NCT01268475|||CASE_ONLY||PROSPECTIVE|||||||
34069616|NCT02018432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069617|NCT01148459|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069618|NCT00259428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069619|NCT01506687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069620|NCT05677958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|randomised controlled, open label, parallel-group, multi-centre and multicountry study|Test group: receiving daily 2 servings of a low volume, energy dense and high protein oral nutritional supplement (ONS) Control group: not receiving any study product. These subjects will be receiving standard of care.||||
34069621|NCT01104987|||COHORT||PROSPECTIVE|||||||
34069622|NCT00571116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069623|NCT03992833|NA|SINGLE_GROUP||SCREENING||NONE||||||
34069624|NCT01454219|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34069625|NCT01023425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069626|NCT02772146|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069627|NCT04444336|||OTHER||CROSS_SECTIONAL|||||||
34069628|NCT00818740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33879442|NCT06489132|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879443|NCT03406221|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879444|NCT06093061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879445|NCT00312910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33879446|NCT06195020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879447|NCT04756037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879448|NCT03444285|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups. One realize an static warm-up and the other a dynamic warm-up.||||
33879449|NCT02417272|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969887|NCT01035320|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33969888|NCT00603343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969889|NCT04923529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969890|NCT05765110|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33969891|NCT04362774|||COHORT||PROSPECTIVE|||||||
33969892|NCT00256542|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33969893|NCT04607603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind placebo-controlled||t|t|t|f
33969894|NCT06111456|||OTHER||CROSS_SECTIONAL|||||||
33969895|NCT04780737|||COHORT||OTHER|||||||
33969896|NCT00494806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33969897|NCT05730777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969898|NCT06546280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969899|NCT01439841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969900|NCT01088217|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33969901|NCT03283865|NA|SINGLE_GROUP||TREATMENT||NONE|"Single blinded prospective trial in which all patients serve as their own clinical control group.~Provider doing the procedure will be blinded to intervention"|Single blinded prospective trial in which all patients serve as their own clinical control group.||||
33879450|NCT00848354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879451|NCT02937714|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879452|NCT01261156|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879453|NCT01708759|||CASE_CONTROL||PROSPECTIVE|||||||
33879454|NCT02969668|||COHORT||PROSPECTIVE|||||||
33879455|NCT04564586|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33969902|NCT05170425|||COHORT||PROSPECTIVE|||||||
33969903|NCT01286142|||COHORT||PROSPECTIVE|||||||
33969904|NCT01589003|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33969905|NCT03080181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969906|NCT05934032|||COHORT||PROSPECTIVE|||||||
33969907|NCT01303991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969908|NCT03108105|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879456|NCT04779359|||COHORT||CROSS_SECTIONAL|||||||
33879457|NCT02626039|||CASE_ONLY||RETROSPECTIVE|||||||
33879458|NCT05465356|||COHORT||RETROSPECTIVE|||||||
33879459|NCT00781456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33879460|NCT04074928|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The trial is designed as an observer-blind study. During the treatment period of the study designated unblinded nurse(s), physician(s), or other qualified health care professional will be responsible for administering the study vaccine to the subjects.||t|f|t|t
33879461|NCT05419089|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized non-inferiority||||
33879462|NCT02499068|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879463|NCT05246137|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879464|NCT03917602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879465|NCT00593398|||CASE_ONLY||PROSPECTIVE|||||||
33879466|NCT05798260|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879467|NCT03800654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group Randomized Controlled Trial|t|f|f|f
33879468|NCT05079607|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879469|NCT02098564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879470|NCT00288093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879471|NCT05300516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33969909|NCT06277791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969910|NCT04669899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969911|NCT03770845|||COHORT||PROSPECTIVE|||||||
33969912|NCT05743283|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel-group, comparator-controlled interventional study to assess clinical efficacy of SynEx Wound Cleanser.||||
33969913|NCT02393196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33969914|NCT01173159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969915|NCT01506583|||OTHER||PROSPECTIVE|||||||
33969916|NCT05950724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969917|NCT01483872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969918|NCT00003833|||CASE_ONLY||PROSPECTIVE|||||||
33969919|NCT00526890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069629|NCT03363893|RANDOMIZED|PARALLEL||TREATMENT||NONE||Modular design||||
34069630|NCT02514200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069631|NCT04231240|||COHORT||PROSPECTIVE|||||||
34069632|NCT01681095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069633|NCT04513171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969920|NCT05893212|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Care provider recommended participation in either group, based on discussion with participant. All data is anonymized and stored at the Finnish Institute for Health and Welfare and outcomes assessor has access to this data, however, it includes knowledge of group participation.|This is a controlled pilot study on parallel groups in a real life, intention-to-treat setting.||||
33969921|NCT05436158|||OTHER||CROSS_SECTIONAL|||||||
33969922|NCT02942251|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069634|NCT01468571|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33758205|NCT00863694|||COHORT||PROSPECTIVE|||||||
34069635|NCT00507858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069636|NCT06406166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969923|NCT00163410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969924|NCT04052399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33969925|NCT03567057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969926|NCT03397563|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33969927|NCT05724433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33758206|NCT04479436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758207|NCT02489032|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758208|NCT04562961|NA|SINGLE_GROUP||OTHER||NONE||||||
33758209|NCT06118034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758210|NCT04752449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be informed after their first assessment whether they were randomized to CBTp or TAU. Those in TAU are offered CBTp at the end of the study period. Assessors remain blind throughout the study and therefore do not partake in the treatment intervention. Due to the nature of the study, the treatment providers cannot be blinded as those they treat have clearly been randomized to the CBTp condition. The investigator is not blind to any of the randomization outcomes.|Participants will be randomized to receive either Virtual Cognitive Behavioural Therapy or to Treatment as Usual. All participants who receive Treatment as Usual will be offered CBT at the end of the study period.|f|f|f|t
33758211|NCT00192309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758212|NCT06020690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758213|NCT05138445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758214|NCT05580666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded placebo-controlled|Double blinded placebo-controlled randomized trial|t|t|t|t
33758215|NCT02090634|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879472|NCT03777683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|On enrolment, study nutritionist or clinicians take a consecutive sealed opaque envelope containing the unique patient identifier but not the study group, to which they remain masked. A paired set of sealed envelopes are kept in a locked cabinet in the study laboratory, label with the unique patient identifier and containing the study group allocation. These are opened by the nutritionist. Investigators, all study staff hospital attending clinical teams, and patients were masked to the study group allocation.||t|t|t|t
33879473|NCT06156085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879474|NCT03662425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879475|NCT00651092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879476|NCT04700176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879477|NCT01641406|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969928|NCT02370966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33969929|NCT00762671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34069637|NCT03151083|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will employ a hybrid type 3 implementation-effectiveness study design through which the investigator will primarily test the effectiveness of the experimental implementation strategy the investigators are developing and secondarily evaluate the clinical effectiveness of the internet-based self-help program for insomnia. The investigators will use a quasi-experimental pre-/post-cohort design whereby the program will initially be implemented using an enhanced usual care (control) strategy, followed by implementation using the experimental implementation strategy. The program's association with clinical response will be evaluated in an uncontrolled pre-/post-format.||||
34069638|NCT02310880|||CASE_CONTROL||PROSPECTIVE|||||||
34069639|NCT04296578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose-finding||||
34069640|NCT00504738|||CASE_ONLY||PROSPECTIVE|||||||
34069641|NCT00822328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33879478|NCT06211231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only principal investigator is blinded, as neither participants nor care providers can be feasibly blinded, since both parties will know if a video consultation is provided or not. The study includes only patient-reported outcomes, hence, the outcome assessors are the participants.|Participants are randomized to one of three groups: 1) self-guided digital intervention, 2) therapist-guided digital intervention, or 3) no-treatment control group (waiting list)|f|f|t|f
33879479|NCT00612638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879480|NCT01450033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879481|NCT00781716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879482|NCT02631330|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879483|NCT03039842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879484|NCT00791271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879485|NCT06311474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be performed by assessors who are blind to group status. Investigators will be kept blind to study outcomes until data collection for the primary outcome is complete.|The clinical trial portion of this study uses a waitlist control design with random assignment to group. Randomization is stratified by age (3-4 years old, 5-6 years old).|f|f|f|t
33879486|NCT02461992||||BASIC_SCIENCE||NONE||||||
33879487|NCT05571787|RANDOMIZED|CROSSOVER||OTHER||NONE||Open-label, 4-Period, Randomized 6-Sequence Study||||
33879488|NCT00001193||||TREATMENT||||||||
33879489|NCT02682901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879490|NCT02200185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33879491|NCT06159595|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33879492|NCT05583266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879493|NCT00993811|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879494|NCT05847998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879495|NCT05347433|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879496|NCT01316172|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33879497|NCT05728580|||COHORT||PROSPECTIVE|||||||
33879498|NCT02207933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33879499|NCT05946408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879500|NCT02981875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879501|NCT04086550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879502|NCT05273827|||COHORT||PROSPECTIVE|||||||
33879503|NCT06485154|NA|SINGLE_GROUP||PREVENTION||NONE|Age ≥ 15 years, inclusive, at the time of signing the informed consent.|Oral - 1 tablet (300/300/50 mg TDF/3TC/DTG) daily||||
33879504|NCT01078831|||CASE_ONLY||PROSPECTIVE|||||||
33879505|NCT01212042|||CASE_ONLY||PROSPECTIVE|||||||
33879506|NCT06395727|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Anaesthesia will be provided according to the hospital protocol in respect to preoperative investigations, fasting hours and intra-operative monitoring and drugs.~All patients will be monitored by ECG, pulse oximeter and non-invasive blood pressure monitoring before receiving 2 mg midazolam for sedation before radial artery catheter insertion. After arterial catheter insertion, patients will be allocated to two groups, the first one (TBA group) will receive fentanyl traditional dose 3-5 mic/kg during induction. The second group will sit and receive lidocaine 2% nebulizer and then lidocaine 10 % oral application till achieving difficult swallowing. Then patient will lie, and induction will be done by fentanyl at a dose max 1 mic/kg. Then, both groups will receive general anaesthesia induction. Hemodynamic parameters will be recorded before induction, before intubation, 30 seconds, 1 minute and 2 minutes after intubation then every 5 minutes till skin incision."|f|f|f|t
33879507|NCT03655964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758216|NCT02174432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879508|NCT01149265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879509|NCT02211274|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33879510|NCT04660162|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33879511|NCT00428532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879512|NCT05505266|||OTHER||CROSS_SECTIONAL|||||||
33879513|NCT04904289|||COHORT||RETROSPECTIVE|||||||
33879514|NCT02627820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879515|NCT04720326|RANDOMIZED|PARALLEL||PREVENTION||NONE||A dynamic allocation technique allocates participants in a 1:1 ratio to one of two treatment arms: Envarsus® tablets (test IMP) or Advagraf® capsules (comparator IMP). Pre-treatment with immediate-release tacrolimus, as well as trial site, are used as stratification factors in the treatment allocation in order to minimise sources of treatment bias.||||
33879516|NCT00987363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879517|NCT04173429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879518|NCT00962832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879519|NCT06131970|||COHORT||PROSPECTIVE|||||||
33879520|NCT01098071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879521|NCT05915312|||CASE_CONTROL||OTHER|||||||
33879522|NCT00006366|RANDOMIZED|||TREATMENT||||||||
33879523|NCT03439150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879524|NCT02687399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879525|NCT03891589|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The intervention groups consisted of promotion of optimized complementary feeding (CF) with taburia (P1, n=51), optimized CF (P2, n=54) and taburia home fortification (P3, n=47). Control groups will not receive intervention or placebo but will receive only a standardized primary health care education program related to complementary feeding practices for infants and children. Also, the nutritional status of all groups will be measured every month.||||
33879526|NCT03302754|NA|SINGLE_GROUP||OTHER||NONE||||||
33879527|NCT01913392|||CASE_ONLY||PROSPECTIVE|||||||
33969930|NCT04482010|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Participants in the control group (HIV positive people at the artisanal gold-mining site in Diassa) will not be aware of the existence of the community-based HIV care services provided by ARCAD Santé PLUS at the Kofoulatiè artisanal gold-mining site.~The distance between these sites is around 400km. However they share similar characteristics in terms of geographical localisation, size and healthcare supply."|"ARCAD Santé PLUS NGO will offer community-based activities of HIV prevention and screening during 5 months. 8833 people will be tested for HIV in the two artisanal gold-mining sites. Thus, 265 HIV-positive individuals will be enrolled:~* Control group: 129 (Diassa), 30% of attrition and 5% of discordant HIV screening and confirmatory tests;~* Intervention group: 136 (Kofoulatiè), 30% of attrition; 5% of people accepting the study but refusing the community-based HIV care; and 5% of discordant HIV screening and enrolment tests.~This is the minimum number required to verify the primary endpoint of the study. The intervention consists in the provision of community-based healthcare services for HIV provided by ARCAD Santé PLUS's members in the Kofoulatiè site. People in the Diassa site (control group) will be referred to the public healthcare centers for classic HIV care. A quantitative survey with follow-up at M1, M3, M6, M9 and M12 after HIV diagnosis."|t|f|f|f
33969931|NCT04876898|||COHORT||PROSPECTIVE|||||||
33969932|NCT05242159|||CASE_ONLY||PROSPECTIVE|||||||
33969933|NCT03129737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33969934|NCT02878850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33969935|NCT05222815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969936|NCT03480828|||COHORT||PROSPECTIVE|||||||
33969937|NCT03492151|||COHORT||PROSPECTIVE|||||||
33969938|NCT00437151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879528|NCT00155155|||||PROSPECTIVE|||||||
33879529|NCT02576743|||CASE_CONTROL||PROSPECTIVE|||||||
33879530|NCT01380457|RANDOMIZED|CROSSOVER||||NONE||||||
33969939|NCT05447611|||COHORT||PROSPECTIVE|||||||
33969940|NCT01374399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969941|NCT02956720|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single arm||||
33969942|NCT01983956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33969943|NCT05445115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects are blinded as to which arm they are participating in|Treatment arm and sham arm|t|f|f|f
33969944|NCT03588156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||11 dose groups within 62.5 mg \~ 4000 mg for single-dose tolerability study to carried out from low-dose group to high-dose group|t|t|t|f
33969945|NCT03104153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879531|NCT05730465|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study protocol includes a cross-over component by which, at the 3 month mark, all study participants will have access to a home blood pressure cuff. This portion of the study will be open-label and observational.||||
33879532|NCT03477864|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879533|NCT06101615|RANDOMIZED|PARALLEL||TREATMENT||NONE||Concurrent Parallel Randomized Clinical Trial||||
33879534|NCT02841371|||COHORT||PROSPECTIVE|||||||
33879535|NCT02025387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879536|NCT02516748|||COHORT||PROSPECTIVE|||||||
33879537|NCT05416853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879538|NCT01789814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879539|NCT06459245|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33879540|NCT02122978|RANDOMIZED|PARALLEL||||NONE||||||
33879541|NCT01227902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879542|NCT02191943|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33879543|NCT00003345||||TREATMENT||||||||
33879544|NCT00800631|||COHORT||PROSPECTIVE|||||||
33879545|NCT00044577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879546|NCT03887351|||COHORT||PROSPECTIVE|||||||
33879547|NCT05386329|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional study without concurrent control||||
33879548|NCT02491255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879549|NCT03575858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study examiner who will be doing the clinical examination and collecting the study data will be blinded to the group allocation; however it is not possible to blind the study subjects to the group allocation. The clinician, who will be performing the treatment and providing oral hygiene instructions, will open the envelope containing the subject's group allocation after non-surgical periodontal therapy but before giving the oral hygiene instructions.|Participants will be randomly assigned into the barrel shaped (test) and tapered (control) interdental brushes groups|f|f|f|t
33879550|NCT01120496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879551|NCT05089500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879552|NCT05146570|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33879553|NCT04545346|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33879554|NCT04336995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||small pilot study to test technical feasibility||||
33879555|NCT02986230|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879556|NCT03789227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879557|NCT06391138|||COHORT||PROSPECTIVE|||||||
33879558|NCT04646759|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned to capecitabine plus pyrotinib or fulvestrant plus pyrotinib||||
33879559|NCT00113542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879560|NCT02983682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879561|NCT01524354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879562|NCT04365465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Among participants who receive a device, both the participant and care providers/investigators will be blinded to whether the device is active or placebo. There is no blinding among participants who do not receive a device.|This study is a randomized control trial with the following arms: 1) active device; 2) placebo device; 3) non-intervention (active control).|t|t|t|t
33879563|NCT06549374|||COHORT||PROSPECTIVE|||||||
33879564|NCT01679210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33894447|NCT06430892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be an open-label study, however, the outcome assessment will be blinded. A de-identified CD and post-PCI ECG with a unique tracking ID will be evaluated by the team of independent consultants, who will be blinded to the stent placement approach, and primary outcome variables i.e. TIMI flow, slow-flow/no-reflow, and ST-segment resolution will be assessed|Participants will be randomized into two groups in 1:1 , one arm will be treated with POP protocol and the other arm will be treated with conventional method.|f|f|f|t
33894448|NCT05809310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894449|NCT02609399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894450|NCT06432777|||CASE_ONLY||RETROSPECTIVE|||||||
33879565|NCT03109171|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|"The allocation sequence, determining which rater (expert vs non-expert) intervenes first or second, will be concealed using the SNOSE strategy (sequentially numbered opaque sealed envelopes). One of the authors (ARB), who has not competing interests will generate the allocation sequence and conceal it in envelopes. While the first rater measures the sensory thresholds (ST) the second rater will be at a different room for blinding purposes. There will be no communication about the testing results between the two raters nor the staff who are helping the testing performance.~To mask the values of the ST, air pulses will be identified by a random combination of three letters instead of by the intensity levels corresponding to the air pulses. The raters will not know the intensity corresponding to each letter combination. At the end of the test, an assistant will replace the letters corresponding to the ST values by the intensity levels of the air pulses in units of force (millinewtons)"|"Subjects participating in the inter-rater reliability evaluation will be evaluated by two raters, an expert and a non-expert rater, each rater performing two measurements of laryngopharyngeal sensory thresholds (ST) two times at each side (right and left) of the corresponding laryngopharyngeal structure. All other subjects, participating in the accuracy evaluation, will be evaluated by only one expert rater who will perform three measurements of laryngopharyngeal ST per subject. The varying degrees of rater experience aims to reproduce common scenarios when a new technique (like the measurement of laryngopharyngeal mechanosensitivity) is introduced to clinical practice.~The two raters will measure the ST sequentially and in a randomized cross-over design in each subject (the order in which each rater intervenes will be randomized) aiming that the sensory tests be started an equal number of times by an expert rater and non-expert rater."|t|t|t|t
33758217|NCT02234544|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33758218|NCT04230421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758219|NCT00070746|||||PROSPECTIVE|||||||
33758220|NCT05740202|NA|SINGLE_GROUP||TREATMENT||NONE||The study was divided into three phases, the dose escalation phase and the dose extension phase and therapeutic effect extension of SHR-7367 in subjects with advanced malignant tumors.||||
33758221|NCT00804401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758222|NCT03471169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758223|NCT02837640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758224|NCT05001438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758225|NCT04999982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758226|NCT03067454|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomised controlled trial to compare operation and treatment with early mobilisation for metacarpalfractures||||
33758227|NCT04436315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758228|NCT05918497|||OTHER||PROSPECTIVE|||||||
33879566|NCT00846014|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879567|NCT05148975|||COHORT||PROSPECTIVE|||||||
33879568|NCT04333901|||COHORT||PROSPECTIVE|||||||
33879569|NCT03353857|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879570|NCT01031446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879571|NCT06312072|||COHORT||OTHER|||||||
33879572|NCT01568814|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33879573|NCT00903149|||COHORT|||||||||
33879574|NCT06008990|||COHORT||PROSPECTIVE|||||||
33879575|NCT06537115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879576|NCT03548051|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33879577|NCT01675960|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33879578|NCT02956993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758229|NCT02428296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758230|NCT05048927|||COHORT||PROSPECTIVE|||||||
33758231|NCT03731702|||CASE_ONLY||CROSS_SECTIONAL|||||||
33758232|NCT01209065|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758233|NCT06075420|||CASE_ONLY||PROSPECTIVE|||||||
33758234|NCT06380699|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33758235|NCT05328687|||COHORT||PROSPECTIVE|||||||
33758236|NCT04755101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33758237|NCT01264276|||COHORT||PROSPECTIVE|||||||
33758238|NCT00136786|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33758239|NCT00654563|||CASE_ONLY||PROSPECTIVE|||||||
33758240|NCT06150703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758241|NCT02710279|NA|SINGLE_GROUP||OTHER||NONE||||||
33758242|NCT05118633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758243|NCT04670900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient instructed not to reveal treatment and to wear long sleeves.|Randomized non-inferiority multicenter|f|f|t|t
33758244|NCT03219385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758245|NCT01188109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758246|NCT01161368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758247|NCT06118723|||COHORT||PROSPECTIVE|||||||
33758248|NCT06413251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be recruited from the University of Texas at El Paso and its surroundings. They will be identified by a preliminary blood pressure screening and a health questionnaire. The inclusion criteria will consist on: (1) ≥18 years old, (2) SBP between 120-139 mmHg or DBP between 80-89 mmHg obtained from 2 different days, (3) an estimated 10-year risk of CVD ≤10%, calculated by the ACC/AHA Pooled Cohort Equations, and (4) no current participation in 3 or more days per week of endurance or resistance exercise training. Exclusion criteria will include non-controlled cardiac, pulmonary, or metabolic diseases, smoking, consumption of nutritional supplements containing antioxidants, and any physical impairment to exercise.|t|t|f|f
33758249|NCT04965350|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33758250|NCT00939874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758251|NCT01278355|||COHORT||PROSPECTIVE|||||||
33758252|NCT05604625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758253|NCT00316810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758254|NCT03274635|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33758255|NCT04591028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758256|NCT06358625|||COHORT||PROSPECTIVE|||||||
33758257|NCT01920282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758258|NCT04885556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects to be placed into one of two study groups, 1) immediate use and 2) 1 hour use||||
33758259|NCT01299090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758260|NCT05096156|NA|SINGLE_GROUP||OTHER||NONE||||||
33758261|NCT02161302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758262|NCT04010240|||COHORT||RETROSPECTIVE|||||||
33758263|NCT00953264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758264|NCT02064543|||COHORT||PROSPECTIVE|||||||
33758265|NCT00177060|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33758266|NCT00035074||CROSSOVER||TREATMENT||||||||
33758267|NCT05650164|||COHORT||RETROSPECTIVE|||||||
33758268|NCT04182711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758269|NCT05465057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled study|t|f|f|t
33758270|NCT04419402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758271|NCT03889626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879579|NCT04377737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758272|NCT00118716|RANDOMIZED|PARALLEL||TREATMENT||||||||
33758273|NCT05277675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758274|NCT05176470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758275|NCT01938248|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879580|NCT01315262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879581|NCT05348655|||COHORT||RETROSPECTIVE|||||||
33879582|NCT02178488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879583|NCT01477931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758276|NCT03603210|||COHORT||RETROSPECTIVE|||||||
33758277|NCT04259086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758278|NCT04204200|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33758279|NCT01452633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33758280|NCT03205657|||OTHER||RETROSPECTIVE|||||||
33758281|NCT01183663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758282|NCT01557387|||CASE_ONLY||PROSPECTIVE|||||||
33758283|NCT03011632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33758284|NCT00678743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758285|NCT01040858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758286|NCT03994302|||CASE_ONLY||CROSS_SECTIONAL|||||||
33758287|NCT01730898|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33758288|NCT06579456|RANDOMIZED|PARALLEL||OTHER||SINGLE||A single-center, single-blind, randomized educational intervention clinical trial was carried out to compare the use of formaldehyde free solution cadaver training in laparoscopic surgery with other traditional simulation surgery options. The trial was approved by our Institutional Research Board, prior to the beginning of the study (Act. No.201910224). Written informed consent was obtained from each participant and the CONSORT statement was followed.|f|f|t|f
33879584|NCT03814980|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33879585|NCT03602287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33879586|NCT06095765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Double-blind|Colchicine versus placebo (1:1)|f|f|f|t
33879587|NCT01521273|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33969946|NCT06542926|||COHORT||OTHER|||||||
33969947|NCT03500939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758289|NCT06218849|||COHORT||PROSPECTIVE|||||||
33969948|NCT05342090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33969949|NCT02058628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33969950|NCT00235859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33969951|NCT03170505|||COHORT||PROSPECTIVE|||||||
33758290|NCT00155389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758291|NCT04167241|||COHORT||PROSPECTIVE|||||||
33969952|NCT02621515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33969953|NCT02711150|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33969954|NCT01006668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758292|NCT00464802|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33758293|NCT00246480|||||PROSPECTIVE|||||||
33758294|NCT02519101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33758295|NCT02238379|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33758296|NCT02701712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758297|NCT02720939|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758298|NCT03820856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758299|NCT02434679|||COHORT||PROSPECTIVE|||||||
33758300|NCT03649620|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33758301|NCT01857882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758302|NCT00621543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758303|NCT06199557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This a two-part, open-label phase 1/2 study that will include clinical sites in Norway and other Nordic countries. The study consists of part A and part B.||||
33758304|NCT04285255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|only the anaesthetist is one aware of the study groups||t|t|f|t
33758305|NCT01631630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33758306|NCT02624544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758307|NCT02792361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969955|NCT01070966|||OTHER||PROSPECTIVE|||||||
33969956|NCT05960851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33758308|NCT03584620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants who meet the study inclusion criteria and complete the baseline assessments were randomly allocated into one of the two groups: namely Pulmonary Rehabilitation plus Inspiratory Muscle Training Group (IMT+PR) or Pulmonary Rehabilitation Group (PR).||||
33758309|NCT00484003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758310|NCT02333214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33758311|NCT04549610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758312|NCT05987033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758313|NCT05796856|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33969957|NCT04813822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33969958|NCT03773094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33969959|NCT06190847|||COHORT||PROSPECTIVE|||||||
33969960|NCT04654728|RANDOMIZED|PARALLEL||TREATMENT||NONE|None(Open Label)|Patients will be equally randomized into two groups using sealed envelope system. For anterior sector venous drainage, ePTFE vascular grafts (straight or bifurcated) in group 1, and Dacron grafts(straight or bifurcated) in 2 will be used as conduit.||||
33969961|NCT05687305|RANDOMIZED|PARALLEL||OTHER||SINGLE||"This study is a single-center parallel-group randomized controlled clinical trial.~Participants who accepted to participate in the study and met the inclusion criteria will be assigned to the intervention (n=30) or control group (n=30) according to the computer-based randomization table."|f|f|f|t
33758314|NCT01674374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33758315|NCT02650219|||CASE_CONTROL||PROSPECTIVE|||||||
33758316|NCT02946918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758317|NCT01499732|||COHORT||PROSPECTIVE|||||||
33758318|NCT03891121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33758319|NCT06016530|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||One group; all participants will undergo identical measurements, including: 1) Baseline assessment, 2) Sleep Deprivation, and 3) Dexamethasone Supplementation.||||
33758320|NCT06519279|||CASE_CONTROL||PROSPECTIVE|||||||
33758321|NCT02802163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758322|NCT04209946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758323|NCT00307749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758324|NCT00898040|||OTHER||RETROSPECTIVE|||||||
33758325|NCT04108455|||CASE_CONTROL||RETROSPECTIVE|||||||
33758326|NCT03406546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758327|NCT01699022|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33758328|NCT00024492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758329|NCT01138670|||COHORT||PROSPECTIVE|||||||
33758330|NCT00000881||||TREATMENT||||||||
33758331|NCT00394355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33969962|NCT05837364|||COHORT||RETROSPECTIVE|||||||
33758332|NCT06267885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758333|NCT03706625|||COHORT||PROSPECTIVE|||||||
33758334|NCT03764072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758335|NCT01579604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758336|NCT00530062|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758337|NCT03525548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758338|NCT04205318|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758339|NCT06181721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758340|NCT05751122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33758341|NCT04540874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758342|NCT03716284|||COHORT||PROSPECTIVE|||||||
33758343|NCT02309788|||COHORT||RETROSPECTIVE|||||||
33758344|NCT04933734|||COHORT||PROSPECTIVE|||||||
33758345|NCT00883506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758346|NCT00480701|NA|SINGLE_GROUP||||NONE||||||
33758347|NCT03159520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Not possible to mask due to nature of intervention except for outcome assessor|Randomised parallel clinical trial|f|f|f|t
33758348|NCT01719822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33758349|NCT02383199|||CASE_ONLY||RETROSPECTIVE|||||||
33758350|NCT04248647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758351|NCT03477279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33879588|NCT06208020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879589|NCT00142701|RANDOMIZED|||PREVENTION||||||||
33879590|NCT00394459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879591|NCT02247193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879592|NCT02344888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879593|NCT06264115|||COHORT||PROSPECTIVE|||||||
33879594|NCT03278132|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879595|NCT00495651|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34152159|NCT06524232|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||STUN II is a 48-site randomized 2x2 factorial trial to evaluate the comparative effectiveness of implementation strategies, including practice facilitation (PF), PF + learning collaborative (LC), PF + performance incentives (PI), and PF+LC+PI, on implementation of screening for and delivery of evidence-based interventions for substance use disorders (SUD) in primary care. We will use a stratified block randomization strategy with a block size of 12 practices to ensure a high degree of balance between study arms. The implementation phase will last for 12 months, and we will conduct 12-month post-implementation assessments to assess sustainment. The 2x2 design will allow us to assess the improvement in rates of screening and delivery of evidence-based interventions for SUDs in primary care with PF alone and the incremental benefit of LC, PI, or their combination, to inform primary care practices and health systems about optimal implementation strategies.||||
33879596|NCT05269290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879597|NCT00612443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33879598|NCT00855114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879599|NCT00887393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33879600|NCT04799587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not know whether the pressure point is correct or sham location.|Two group, sham vs actual location of pressure point.|t|f|f|f
33879601|NCT05460039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758352|NCT04227743|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758353|NCT04035967|||FAMILY_BASED||RETROSPECTIVE|||||||
33758354|NCT00103766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758355|NCT01786902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758356|NCT01459432|||COHORT||PROSPECTIVE|||||||
33758357|NCT00418236|||||RETROSPECTIVE|||||||
33758358|NCT05347758|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||HRS-7535 tablet compared with placebo|t|t|t|f
33758359|NCT01562730|||COHORT||PROSPECTIVE|||||||
33758360|NCT03018964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879602|NCT03175549|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Parallel Assignment, Double Blind, Randomized|t|t|t|t
33879603|NCT01441752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879604|NCT02307370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879605|NCT01785134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879606|NCT03152682|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33879607|NCT00581295|||CASE_ONLY||PROSPECTIVE|||||||
33879608|NCT01136265|||CASE_ONLY||PROSPECTIVE|||||||
33758361|NCT02129855|||OTHER||CROSS_SECTIONAL|||||||
33758362|NCT06202560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758363|NCT06439355|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758364|NCT02146313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758365|NCT06408324|||COHORT||RETROSPECTIVE|||||||
33758366|NCT02114151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758367|NCT03988075|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized to one of two study groups||||
33758368|NCT02124265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758369|NCT03931681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758370|NCT03056482|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will be allocated to an intervention via a sealed, opaque envelope system to be opened by an unblinded nurse not otherwise involved in patient care or research procedures will prepare the intervention. The Attending physician, Research personnel and Investigator(s) will all remain blinded to the allocation.|This is a double-blinded, randomized, cross-over clinical trial that will allocate subjects in a 1:1:1 fashion into one of three treatment groups: high- or low-dose haloperidol, or ondansetron, with a minimum 7-day washout period between treatments.|t|t|t|t
33758371|NCT04594499|||COHORT||PROSPECTIVE|||||||
33758372|NCT00415792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758373|NCT05687955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758374|NCT01747564|NA|SINGLE_GROUP||||NONE||||||
33758375|NCT02390531|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||8 bevacizumab doses were evaluated in this dose de-escalation study in the following dosage amounts: 0.250mg, 0.125mg, 0.063mg, 0.031mg, 0.016mg, 0.008mg, 0.004mg, 0.002mg. Each dose was planned to be used in up to 14 infants to ensure at least 10 infants with 4-week outcomes|t|t|t|t
33758376|NCT04504656|||COHORT||PROSPECTIVE|||||||
33758377|NCT00421720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758378|NCT04395573|||OTHER||PROSPECTIVE|||||||
33758379|NCT00214305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758380|NCT02657317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33758381|NCT00668902|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879609|NCT02001376|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33879610|NCT02872623|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879611|NCT01405261|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33879612|NCT06377826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879613|NCT01487759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33879614|NCT03849131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879615|NCT01065688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879616|NCT05639972|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm feasibility study.||||
33879617|NCT06045338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879618|NCT04093531|NA|SINGLE_GROUP||TREATMENT||NONE||Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.||||
33879619|NCT00584194|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879620|NCT00314600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33969963|NCT01992289|||OTHER||PROSPECTIVE|||||||
33969964|NCT00350857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969965|NCT01337050|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33969966|NCT04605419|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Barrett's esophagus high-grade dysplasia will get calcium electroporation||||
34152160|NCT05876234|||COHORT||RETROSPECTIVE|||||||
34152161|NCT02257203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758382|NCT02333279|||COHORT||PROSPECTIVE|||||||
33758383|NCT06356025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879621|NCT00640328|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33879622|NCT04161131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969967|NCT01709097|||CASE_CONTROL||PROSPECTIVE|||||||
33969968|NCT01299038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33969969|NCT03753854|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33969970|NCT04439851|||COHORT||PROSPECTIVE|||||||
33969971|NCT05021627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879623|NCT00006089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879624|NCT01002378|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33879625|NCT03861676|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm||||
33879626|NCT00163787|||NATURAL_HISTORY||OTHER|||||||
34152162|NCT00444340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152163|NCT02516319|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152164|NCT01270256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152165|NCT02654938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152166|NCT02237261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152167|NCT06508008|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34152168|NCT01850355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152169|NCT03462381|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will perform three endurance training sessions weekly for 12 weeks. All participants will be randomly assigned to the protein supplementation group or the placebo (iso-caloric carbohydrate) group. During the 12 weeks endurance training program participants allocated to the protein group (30 g protein per beverage) will receive a protein drink after exercise and prior to sleep at night on training days. On non-training days participants will only receive a protein drink before sleep. Participants allocated to the carbohydrate group (30 g carbohydrates) will receive a carbohydrate drink instead of a protein drink.|t|f|t|f
34152170|NCT01633177|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34152171|NCT05517694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double blind (both participants and assessor blinded)|62 participants will randomly divided into two groups.|t|f|f|t
34152172|NCT03574428|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34152173|NCT00119964|RANDOMIZED|PARALLEL||||NONE||||||
34152174|NCT04228094|||COHORT||PROSPECTIVE|||||||
34152175|NCT06065891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152176|NCT03779074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152177|NCT04367090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152178|NCT01141478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152179|NCT01467830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152180|NCT03824587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152181|NCT03395951|||COHORT||PROSPECTIVE|||||||
34152182|NCT00731471|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33758384|NCT02259179|RANDOMIZED|CROSSOVER||||NONE||||||
33969972|NCT00240357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758385|NCT03769402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
33758386|NCT04637334|||OTHER||RETROSPECTIVE|||||||
33969973|NCT00767325|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33969974|NCT05686733|NA|SINGLE_GROUP||TREATMENT||NONE||First In Human (FIH), prospective, single-arm, multicenter, interventional study. Patients presenting with evidence of a single unruptured or ruptured aneurysm requiring treatment will be enrolled into the study and treated using the SEAL™ System.||||
33969975|NCT03164590|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33969976|NCT03717766|||CASE_ONLY||PROSPECTIVE|||||||
33969977|NCT00864942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969978|NCT00511563|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33969979|NCT02070848|||CASE_ONLY||PROSPECTIVE|||||||
33969980|NCT01078090|||CASE_ONLY||PROSPECTIVE|||||||
33969981|NCT04570410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33969982|NCT00200005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152183|NCT06337708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34152184|NCT00955513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34152185|NCT05407350|||COHORT||PROSPECTIVE|||||||
33758387|NCT00854282|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758388|NCT02998762|||CASE_ONLY||PROSPECTIVE|||||||
33758389|NCT00870857|||COHORT||PROSPECTIVE|||||||
33758390|NCT02388503|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33758391|NCT02660801|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33758392|NCT02243280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758393|NCT04810117|||COHORT||PROSPECTIVE|||||||
33758394|NCT05766917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33758395|NCT06006988|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33758396|NCT04028349|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33758397|NCT00580814|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33758398|NCT01925664|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33758399|NCT03627884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879627|NCT03413020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879628|NCT06394687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Protein powders are identical in appearance and tase|This is a randomized, single-blind, crossover, clinical study in healthy participants comparing the effect of a single ingestion of MPC/FP vs MCI/SP protein powder formulations on small intestinal proteomic profile and gastric emptying. The study will enroll up to 20 healthy participants who will consume both MCP/FP and MCI/SP products in randomized order with a washout period in between. Randomization will occur in blocks of 4, with two participants per product.|t|f|f|f
33879629|NCT00465959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33879630|NCT02799069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879631|NCT01992887|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33879632|NCT06212245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879633|NCT03448588|||CASE_CONTROL||RETROSPECTIVE|||||||
33758400|NCT05810246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879634|NCT01428817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879635|NCT02751840|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33879636|NCT01411748|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33879637|NCT01816581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879638|NCT00003580||||SUPPORTIVE_CARE||||||||
33879639|NCT00554203|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33879640|NCT01780025|||CASE_CONTROL||PROSPECTIVE|||||||
33879641|NCT03686397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879642|NCT02822066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879643|NCT03640039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* A Radomized clinical trial.~* Parallel group study.~* A trial will be carried out in hospital of oral and maxillofacial surgery department - faculty of dentistry cairo university.~* Equal randomization: participants with equal probabilities for intervention.~* Positive controlled: both groups receiving treatment."|f|f|f|t
33969983|NCT05574426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will not be aware of group allocation and statistics performed on data with group identity blinded.|Participants will be randomized (1:1 allocation ratio) into Mobility or Cardiovascular movement break groups for 12-weeks. Both groups will perform 3-4 movement breaks on at least 3 days of the week.|f|f|f|t
33969984|NCT01193517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33969985|NCT06306495|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33969986|NCT06104930|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective Explorative Biomarker Study / Investigator-Initiated Trial||||
33969987|NCT04771819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34152186|NCT00123604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879644|NCT01929408|||COHORT||PROSPECTIVE|||||||
33879645|NCT04741724|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34152187|NCT00619307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879646|NCT06233071|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33879647|NCT02085993|||CASE_ONLY||PROSPECTIVE|||||||
33879648|NCT03023943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879649|NCT05105178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34152188|NCT00426543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152189|NCT02212769|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34152190|NCT01649024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152191|NCT04732949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be patient and investigator-blinded with regard to SNG001 or placebo but not the dose.||t|f|t|f
34152192|NCT01332747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758401|NCT05842902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized waitlist design: AYAs will be randomized 1:1 to psychosocial Usual Care (UC) or UC plus mPRISM. mPRISM will be provided to UC arm at 3-month follow-up.||||
33758402|NCT03912454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758403|NCT00700726|||COHORT||PROSPECTIVE|||||||
33758404|NCT02317926|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33879650|NCT05381246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33879651|NCT05043467|||CASE_CONTROL||RETROSPECTIVE|||||||
33879652|NCT04358679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879653|NCT05489978|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33879654|NCT01212185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33879655|NCT00316563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879656|NCT01515774|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879657|NCT00697567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33879658|NCT00528762|||CASE_CONTROL||PROSPECTIVE|||||||
33879659|NCT03187665|||CASE_ONLY||PROSPECTIVE|||||||
33879660|NCT03025958|NA|SINGLE_GROUP||TREATMENT||NONE||Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.||||
33879661|NCT04124146|||COHORT||OTHER|||||||
33879662|NCT02518009|||COHORT||PROSPECTIVE|||||||
34152193|NCT03942939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34152194|NCT01363115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152195|NCT00528996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152196|NCT02733965|RANDOMIZED|PARALLEL||||NONE||||||
34152197|NCT02937766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152198|NCT03596450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152199|NCT01507480|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34152200|NCT03134781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152201|NCT03277365|NA|SINGLE_GROUP||OTHER||NONE||||||
34152202|NCT04519853|NA|SINGLE_GROUP||TREATMENT||NONE||Single dietary treatment arm with run-in period as a control||||
34152203|NCT05889078|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33879663|NCT03034395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879664|NCT02618304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879665|NCT01870154|RANDOMIZED|PARALLEL||||NONE||||||
33879666|NCT00042380||||TREATMENT||||||||
33879667|NCT01096563|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33879668|NCT00028990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152204|NCT03003507|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33879669|NCT05838391|NA|SINGLE_GROUP||OTHER||NONE||||||
33879670|NCT01999283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879671|NCT01573273|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33879672|NCT00005648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879673|NCT03885128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33879674|NCT00809770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879675|NCT05901818|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33879676|NCT03583190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessor will be blinded the treatment group. The clinician providing treatment will be blinded to outcomes.||f|t|f|t
33879677|NCT00004900||||TREATMENT||||||||
33879678|NCT05707923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879679|NCT01047774|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879680|NCT05677074|NA|SINGLE_GROUP||OTHER||NONE||||||
33879681|NCT05428150|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152205|NCT00951405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33879682|NCT04735094|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879683|NCT00524823|||DEFINED_POPULATION||PROSPECTIVE|||||||
33879684|NCT03047980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969988|NCT04945720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969989|NCT00000372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33969990|NCT04641481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"All vaccine and placebo formulations are at a volume of 0.5mL per dose filled into a single-use glass vial. The appearance, color, and viscosity are identical across all vaccine and control formulations.~Participants, investigators, study coordinators, study-related personnel, and the sponsor will be blinded to the treatment group allocation (excluding an unblinded CRO, who is tasked with the dispatch and labeling of vaccine vials and the generation of the master randomization code). Participants will be assigned a computer-generated randomization code that maintains blinding. The blinded study nurse is responsible for vaccine preparation and administration. Each vial contains a unique code that ensured appropriate blinding."||t|t|t|t
33969991|NCT00840983|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33969992|NCT06379399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33969993|NCT06189755|||CASE_CONTROL||PROSPECTIVE|||||||
33969994|NCT05702359|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|double blind (both the investigator and the participant was not aware of the treatment)|Crossover assignment|t|f|t|f
33969995|NCT00630669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33969996|NCT02452060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33758405|NCT02272725|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33969997|NCT03306056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors involved in data analysis will not be aware of the arm to which the participants were allocated (single-blinded masking).|parallel-group, randomized-controlled study|f|f|f|t
33969998|NCT05138198|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33969999|NCT04175327|||COHORT||PROSPECTIVE|||||||
33970000|NCT04570020|||COHORT||PROSPECTIVE|||||||
33970001|NCT00752661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970002|NCT04933578|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34152206|NCT02666105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152207|NCT00188006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33879685|NCT03771742|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33879686|NCT03483480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879687|NCT03527563|RANDOMIZED|PARALLEL||OTHER||NONE||The study is a multi-center, randomized, open, and parallel study. Approximately 958 subjects will be enrolled in 16 sites. The random number table will be adopted to conduct cluster randomization per township hospital/community health service center. Patients will be randomized 1:1 to receive blood pressure management in Internet medical model or Conventional medical model. After follow-ups of 3 months and 6 months, the blood pressure in each group will be observed and compared||||
33879688|NCT06420973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879689|NCT06413862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879690|NCT03874377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879691|NCT01084733|||CASE_ONLY||PROSPECTIVE|||||||
33879692|NCT03605680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879693|NCT05506059|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The doctor's doing the ultrasounds will be blinded to each other's measurements and to the patient's past medical history||f|f|t|f
33879694|NCT00302965|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33879695|NCT00184678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879696|NCT04717674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879697|NCT05855265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879698|NCT03705715|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33879699|NCT03612986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879700|NCT06103032|||COHORT||RETROSPECTIVE|||||||
33879701|NCT01225679|||CASE_ONLY||RETROSPECTIVE|||||||
33879702|NCT03729492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879703|NCT04714541|NA|SINGLE_GROUP||TREATMENT||NONE||The 5 Participants Undergo A Sequenced Treatment of Adopting A Ketogenic Diet For at Least 4 Weeks, Followed by A Series of Intravenous Ketamine Infusions||||
33879704|NCT00903929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879705|NCT02558374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879706|NCT01106846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879707|NCT02524353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879708|NCT03186235|||OTHER||OTHER|||||||
34152208|NCT04684992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152209|NCT01306383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152210|NCT05480709|||CASE_ONLY||PROSPECTIVE|||||||
33879709|NCT05321979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879710|NCT00324285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879711|NCT04161833|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879712|NCT06151171|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33879713|NCT01049763|RANDOMIZED|CROSSOVER||||NONE||||||
33879714|NCT02677155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879715|NCT04772768|||COHORT||PROSPECTIVE|||||||
33879716|NCT03636243|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879717|NCT01464476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33970003|NCT05873777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects with malignant diseases (either FAP or SSTR2 positive expression) undergo contemporaneous 68Ga-FAPI-LM3 and 18F-FDG PET/CT for diseases assessment. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.||||
33970004|NCT00717210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970005|NCT01892423|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879718|NCT02743832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33970006|NCT00417027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879719|NCT04139876|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Study||||
33970007|NCT01904383|||COHORT||PROSPECTIVE|||||||
33970008|NCT03604926|||CASE_CONTROL||PROSPECTIVE|||||||
33970009|NCT01271764|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33970010|NCT04120220|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33970011|NCT00101465|||COHORT||PROSPECTIVE|||||||
33879720|NCT02079987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the ED, a sealed envelope contains the research participants' study assignment. The envelope remains sealed until completion of informed consent and all baseline study procedures after which unmasking occurs.||f|f|t|f
33879721|NCT02972164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970012|NCT02061085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970013|NCT04627220|||CASE_CONTROL||PROSPECTIVE|||||||
33970014|NCT03164863|||COHORT||PROSPECTIVE|||||||
33970015|NCT04427709|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Randomization will be maintained by the research pharmacist and by an independent individual not affiliated with the data collection or outcome evaluation|Randomized, double blind, crossover study. Each participant will receive Oxytocin 25 micrograms and placebo via intramuscular injection|t|f|t|t
33970016|NCT02754323|NA|SINGLE_GROUP||OTHER||NONE||||||
33970017|NCT05685706|||COHORT||PROSPECTIVE|||||||
33970018|NCT04523142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970019|NCT04775433|||OTHER||CROSS_SECTIONAL|||||||
33970020|NCT05171803|||COHORT||RETROSPECTIVE|||||||
33970021|NCT02760550|||COHORT||RETROSPECTIVE|||||||
33970022|NCT01913730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970023|NCT03903640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970024|NCT01223456|||||PROSPECTIVE|||||||
33970025|NCT01787370|||COHORT||PROSPECTIVE|||||||
33970026|NCT02444533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970027|NCT02780661|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33970028|NCT01643369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970029|NCT03650933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970030|NCT02579330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970031|NCT03367026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33970032|NCT06484192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970033|NCT04093947|||COHORT||PROSPECTIVE|||||||
34069642|NCT03453957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participating therapists will be aware of their group (Professional development training vs no training control); however, their participating patient/clients will not know which experimental group their therapists belongs to.|This will be a 2-arm, parallel, prospective, single-blind cluster RCT with 1-1 allocation comparing: (a) therapists who receive the professional development intervention to identify and repair alliance tensions at the study outset versus (b) therapists who receive the intervention after participation is complete (no training control). Therapists will be randomized to study condition and patients will be clustered within therapists. Randomization will control for: (a) the effect of therapist variables (age, gender, theoretical orientation, experience, differing initial skill level) on competence, therapeutic alliance, or patient outcomes; (b) potential biases caused by pre-treatment patient variables (symptom severity, co-morbidity, chronicity, psychoactive medications); and (c) treatment or study factors (e.g. frequency of sessions, time to complete the study sessions, treatment received after the study sessions). Patients will be blind to therapist study arm allocation.|t|f|f|f
34069643|NCT00187278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069644|NCT02025933|||CASE_CONTROL||PROSPECTIVE|||||||
34152211|NCT03217214|||CASE_CONTROL||PROSPECTIVE|||||||
34152212|NCT03968263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It will not be possible to prevent clinicians and their interventions.|Routine orthodontic treatment procedures will be applied to patients|t|f|f|t
34152213|NCT05500326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152214|NCT06540989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||One group of 42 participants with PD will be recruited and randomly assigned to either immediate treatment or deferred treatment. Twenty-one participants will receive treatment immediately after their second pre-treatment assessment. The other 21 participants will receive treatment one month after their second pre-treatment assessment. All participants will receive the same treatment.|f|t|f|t
34152215|NCT02554981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152216|NCT03762447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152217|NCT00562562|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152218|NCT01174394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152219|NCT03320330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152220|NCT06528912|||COHORT||PROSPECTIVE|||||||
33879722|NCT01972893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879723|NCT05170711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879724|NCT02126735|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970034|NCT02057952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970035|NCT02947113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758406|NCT01738620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33758407|NCT00059644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758408|NCT00692094|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758409|NCT05535049|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970036|NCT04823871|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Case control study in two patient population (AIM 1 in average risk population, AIM 2 in high risk population)||||
33758410|NCT01146314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758411|NCT01560858|||CASE_ONLY||RETROSPECTIVE|||||||
33758412|NCT03808779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758413|NCT03178279|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study will take place in 2 community mental health teams and have 3 main stages. Stage 1: The investigators will undertake focus groups with service users and staff to test out the assumptions in the Theory of Change. Stage 2: The PHP will be available as a paper version and on iPad and smartphone. Each team will be asked to work with all of the people on their caseload to complete the PHP. Service users will be encouraged to complete the PHP whilst waiting for their appointment with their care co-ordinator. The completed PHP will then be emailed to the service user and to their care co-ordinator and they will then be asked to develop an action plan to address any gaps in the completed PHP. Each action plan and the progress made with the action plan will be recorded. This exploratory trial will last six months. Stage 3 The investigators will evaluate the experience of using the PHP using interviews with a random selection of service users and clinical staff.||||
33758414|NCT02533869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758415|NCT02386657|||COHORT||PROSPECTIVE|||||||
33758416|NCT02855307|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33758417|NCT01922050|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33758418|NCT05795413|||COHORT||PROSPECTIVE|||||||
33758419|NCT05807113|RANDOMIZED|PARALLEL||OTHER||SINGLE||intra-individual comparison|t|f|f|f
33758420|NCT05519384|NA|SINGLE_GROUP||TREATMENT||NONE||"They were divided into three dose groups: 10\^6, 5x10\^6 and 3x10\^7 JK500 cells injection /kg/ time, three times a week, a total of 6 times.~According to the principle of dose escalation, 3 patients were assigned to each dose group. After completing the treatment of 3 patients in each dose group, the Safety Review Committee (SRC) discussed whether to enter the next dose group."||||
33879725|NCT01530750|||COHORT||PROSPECTIVE|||||||
33879726|NCT06437873|||COHORT||RETROSPECTIVE|||||||
33879727|NCT03787472|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33879728|NCT02940275|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879729|NCT03534700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879730|NCT02343471|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33879731|NCT01035905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879732|NCT01357369|||COHORT||PROSPECTIVE|||||||
33879733|NCT02510287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33879734|NCT02499432|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33970037|NCT01044147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970038|NCT05321810|||COHORT||RETROSPECTIVE|||||||
33970039|NCT00440154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970040|NCT03806894|||COHORT||PROSPECTIVE|||||||
33970041|NCT00865982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970042|NCT01725477|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33970043|NCT06334523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970044|NCT01809249|||COHORT||PROSPECTIVE|||||||
33970045|NCT03805204|||COHORT||OTHER|||||||
33970046|NCT01740856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970047|NCT03944486|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33970048|NCT02919137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33758421|NCT03357614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758422|NCT01629914|NA|SINGLE_GROUP||OTHER||NONE||||||
33879735|NCT02975908|||CASE_ONLY||PROSPECTIVE|||||||
33879736|NCT02907736|||OTHER||CROSS_SECTIONAL|||||||
33879737|NCT01916265|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33879738|NCT04099303|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879739|NCT06372132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879740|NCT02085603|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33970049|NCT03679754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970050|NCT05085964|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible participants from previous QR-421a study can be enrolled into this extension study to receive continuous dosing of QR-421a for 24 months or until treatment becomes available (whichever is longer). Subject who receive follow up only, will be in this study for 12 months.||||
33970051|NCT00192127|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33970052|NCT03859661|NA|SINGLE_GROUP||OTHER||NONE||||||
33970053|NCT01006837|||COHORT||PROSPECTIVE|||||||
33970054|NCT05774509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970055|NCT01318174|||CASE_ONLY||PROSPECTIVE|||||||
33970056|NCT02089542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970057|NCT03685019|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33970058|NCT05030857|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33970059|NCT04883398|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970060|NCT01080105|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33970061|NCT06093828|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective single-arm, multicenter pre-market study.||||
33879741|NCT04451915|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879742|NCT01827033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879743|NCT06163612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879744|NCT00969449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879745|NCT05205551|||CASE_ONLY||PROSPECTIVE|||||||
33879746|NCT00892411|||COHORT||PROSPECTIVE|||||||
33758423|NCT04646655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758424|NCT05349279|||COHORT||OTHER|||||||
33758425|NCT02052310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758426|NCT05362981|RANDOMIZED|PARALLEL||OTHER||NONE|The patients will be recruited from the active files of the four centers participating in the study. In order to avoid the disappointment bias, they will be randomized into three groups, according to a procedure adapted from the Zelen method, in two stages. After verification of the inclusion criteria, eligible patients will receive initial information detailing the follow-up methods, but not the intervention. If patients agree to participate, they will be randomized to three groups: CAT, MBCT or usual management. Patients in the CAT and MBCT groups will then be informed of the group in which they have been randomized, will sign a new consent form and the corresponding intervention will be offered to them.|The patients will be recruited from the active files of the four centers participating in the study. In order to avoid the disappointment bias, they will be randomized into three groups, according to a procedure adapted from the Zelen method, in two stages. After verification of the inclusion criteria, eligible patients will receive initial information detailing the follow-up methods, but not the intervention. If patients agree to participate, they will be randomized to three groups: CAT, MBCT or usual management. Patients in the CAT and MBCT groups will then be informed of the group in which they have been randomized, will sign a new consent form and the corresponding intervention will be offered to them.||||
33758427|NCT03309839|||COHORT||PROSPECTIVE|||||||
33758428|NCT00656604|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758429|NCT01287611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758430|NCT06328530|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Participant will be blinded about application of pruritogens.|The participants will randomly receive applications of cowhage and histamine.|t|f|f|f
34069645|NCT04010084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participant will be randomized through a raffle without knowing which group has the active intervention or placebo.||t|f|f|f
34069646|NCT03925181|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||In total, 12 ICU survivors will be recruited along with their 12 caregivers. Once participants have been recruited, they (and their caregivers) will be randomly assigned to 2 arms: intervention or no intervention (waitlist control). The waitlist control group will receive the intervention in the second arm after the first intervention arm is complete.||||
34069647|NCT03140098|||CASE_CONTROL||PROSPECTIVE|||||||
33758431|NCT04813380|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758432|NCT02274454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758433|NCT00394784|||OTHER||RETROSPECTIVE|||||||
33758434|NCT04767867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758435|NCT04859582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069648|NCT02837302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758436|NCT02964676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33758437|NCT05323461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879747|NCT04065529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Interventional, randomized, controlled, double blind, multicenter phase III clinical trial.|t|t|t|f
33879748|NCT03485833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879749|NCT01908660|||COHORT||PROSPECTIVE|||||||
33879750|NCT02579980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879751|NCT02645175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879752|NCT03505229|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|non randomised-single arm phase II||||
33879753|NCT05121532|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879754|NCT03649399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970062|NCT01815411|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33970063|NCT03506009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970064|NCT02277223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33970065|NCT06201481|||OTHER||PROSPECTIVE|||||||
33970066|NCT01275313|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33970067|NCT02541656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970068|NCT00097123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33970069|NCT03308617|||COHORT||PROSPECTIVE|||||||
33970070|NCT00367185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758438|NCT03547401|||COHORT||PROSPECTIVE|||||||
34069649|NCT03365960|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34069650|NCT03671785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069651|NCT00966732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069652|NCT03678675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subjects, care providers, and investigators will be blinded to the assignments of groups.|Randomized controlled trial|t|t|t|f
34069653|NCT03514056|||COHORT||PROSPECTIVE|||||||
34069654|NCT05248906|||COHORT||PROSPECTIVE|||||||
33758439|NCT01959425|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758440|NCT02344043|||COHORT||PROSPECTIVE|||||||
33879755|NCT01373983|NA|SINGLE_GROUP||||NONE||||||
33879756|NCT04880577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879757|NCT01826747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879758|NCT05066243|||COHORT||PROSPECTIVE|||||||
34069655|NCT01521468|||COHORT||PROSPECTIVE|||||||
34069656|NCT03061578|||CASE_CONTROL||PROSPECTIVE|||||||
34069657|NCT03210012|||CASE_ONLY||PROSPECTIVE|||||||
33879759|NCT02691780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879760|NCT01520571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33879761|NCT03959722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|t|f
33879762|NCT04925895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Other than the principal investigator, another physiotherapist will work as outcomes assessor who will blind to the intervention type given to the patient who will be assessed.|"A single blinded randomized control trial in which total 48 patients will be enrolled and randomly allocated into 2 interventional groups equally. The randomization will be carried out through an open source software research randomizer by statistician."|f|f|f|t
33879763|NCT01407783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879764|NCT00689949|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069658|NCT05056155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970071|NCT05849428|NA|SINGLE_GROUP||OTHER||NONE||||||
33970072|NCT05403632|||COHORT||PROSPECTIVE|||||||
33970073|NCT00909077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970074|NCT03564925|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups, group one is for Wide Area Circumferential Ablation With Contact Force catheter, group two is for Cryoballoon Ablation||||
33970075|NCT06114433|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33970076|NCT00503126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970077|NCT04165278|NA|SINGLE_GROUP||TREATMENT||NONE||a self-control study||||
33970078|NCT02519426|||COHORT||PROSPECTIVE|||||||
33970079|NCT06016855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970080|NCT03350022|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33970081|NCT02361021|||||CROSS_SECTIONAL|||||||
33970082|NCT02132299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33970083|NCT04551482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970084|NCT00057447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970085|NCT05208411|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34069659|NCT04170946|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation based on the maximum tolerated dose from each previous cohort within the study.||||
34069660|NCT01180023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069661|NCT01589588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34069662|NCT01306214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34069663|NCT04687189|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34069664|NCT06613243|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A randomized, double-blind, pilot trial|t|t|t|t
34069665|NCT01490840||PARALLEL||TREATMENT||NONE||||||
34069666|NCT06613256|||COHORT||PROSPECTIVE|||||||
34069667|NCT03319810|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center, open label, proof of concept, out-patient study.||||
34069668|NCT01640860|||||PROSPECTIVE|||||||
34069669|NCT02192983|||COHORT||PROSPECTIVE|||||||
34152221|NCT01403116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152222|NCT01567995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758441|NCT00336739|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33758442|NCT06497218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will undergo investigational diagnosis for ASD. Results will be compared to formal diagnosis by healthcare specialists.||||
34152223|NCT01631097|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152224|NCT03968848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152225|NCT04254120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152226|NCT02794545|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152227|NCT03007095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152228|NCT05327361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152229|NCT02728297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152230|NCT02792023|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34152231|NCT00371982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152232|NCT03464149|||COHORT||PROSPECTIVE|||||||
34152233|NCT06526910|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This is a multiple baselines single case series study. Each participant will complete 4 sequential phases of the study. Phase 1 is standard of care dysphagia exercise (baseline), Phase 2 is wash-out (no exercise, Phase 3 is standard of care + motor imagery practice OR continued standard of care exercise only, and Phase 3 is a second wash-out period (no exercise).|f|f|f|t
34152234|NCT06463054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34152235|NCT03792568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152236|NCT06500260|||COHORT||PROSPECTIVE|||||||
34152237|NCT06342596|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34152238|NCT02733653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152239|NCT01753401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152240|NCT03876665|||OTHER||CROSS_SECTIONAL|||||||
34152241|NCT05367128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152242|NCT03731078|||COHORT||PROSPECTIVE|||||||
34152243|NCT02305238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152244|NCT04232436|||COHORT||RETROSPECTIVE|||||||
34152245|NCT03555682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The dietary supplement will be delivered to the Clinical Research Center by the Investigational Pharmacy at Vanderbilt University Medical Center. Staff nurses and participants will be blinded to the capsule content.|Participants will be randomly assigned in a blinded fashion to 2-HOBA or placebo. A computer-generated randomization sequence with a block of size 3 will be used to assign participants at the ratio of 1:2 (placebo:2-HOBA) at each dose level of the treatment. All participants receiving the lower dose regimen will be completed before enrolling participants in the higher dose group.|t|t|t|f
34152246|NCT04672421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Evaluator-blinded||f|f|f|t
33879765|NCT03881995|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33879766|NCT06541054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33879767|NCT06322875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879768|NCT02235532|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33879769|NCT01418976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879770|NCT05687084|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, parallel arms, open-label, randomized controlled trial.||||
33879771|NCT06220734|||COHORT||PROSPECTIVE|||||||
33879772|NCT00294112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879773|NCT02438709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879774|NCT04420598|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial.~After confirmed eligibility, patients will be assigned to one of the following five study cohorts:~* Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.);~* Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM;~* Cohort 3: HER2-positive BC with progressing BMs after local treatment;~* Cohort 4: HER2-low expressing BC with progressing BMs after local treatment;~* Cohort 5: HER2-positive or HER2-low expressing BC with LMC"||||
33879775|NCT03657251|||OTHER||PROSPECTIVE|||||||
33879776|NCT04539730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and study team members involved in data collection and data processing will be blinded to the intervention.||t|f|f|t
33879777|NCT05500625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879778|NCT03995615|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"* Group I (Control) - 15 periodontally healthy patient with probing depth\< 3mm~* Group II - 15 systemically healthy chronic periodontitis patient who had \>25% of sites with gingival bleeding and an absence of probing depth ≥ 4mm and clinical attachment level ≥3mm~* Group III - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28\[DAS-28\] ≥3.2 to ≤5.1with out scaling and root planing.~* Group IV - 15 chronic periodontitis patient with a probing depth ≥ 5mm and relative attachment loss of ≥8mm and ≥ 10% sites with bleeding on probing present with radiographic evidence of bone loss and Rheumatoid arthritis with diseases active score 28\[DAS-28\] ≥3.2 to ≤5.1 with scaling and root planing. Periodontal clinical parameters will be assessed."|t|f|f|t
33879779|NCT01387893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879780|NCT00006121||||TREATMENT||||||||
33879781|NCT01902966|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879782|NCT06062862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group A (study group): 30 patients (15 males and 15 females) will receive respiratory training using incentive spirometer in addition to traditional chest physiotherapy, 3 sessions per day, for 2 weeks.~Group B (study goup): 30 patients (15 males and 15 females) will receive respiratory training using the breather in addition to traditional chest physiotherapy, 3 sessions per day, for 2 weeks."|t|f|f|f
33879783|NCT00023387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33879784|NCT04453293|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant and the laboratory (endpoint measurement) will be masked|Randomized, controlled trial of BCG (Tokyo 172) vaccine single dose given intradermally compared to placebo vaccine (diluent) given intradermally single dose|t|f|f|f
33879785|NCT05628220|NA|SINGLE_GROUP||TREATMENT||NONE||one cohort of patients suffering from motion sickness||||
33879786|NCT00825565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879787|NCT02005757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879788|NCT05086471|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879789|NCT04654208|||COHORT||RETROSPECTIVE|||||||
33879790|NCT02073773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879791|NCT01515787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894451|NCT02415725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894452|NCT00460993|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33894453|NCT01079767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894454|NCT01172314|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33758443|NCT02449668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758444|NCT03498638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758445|NCT03313843|||CASE_ONLY||PROSPECTIVE|||||||
33758446|NCT05241964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758447|NCT03043079|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758448|NCT00410033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758449|NCT02975570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758450|NCT05044013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894455|NCT01571713|||CASE_ONLY||PROSPECTIVE|||||||
33894456|NCT01651923|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33894457|NCT06488950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894458|NCT05194319|||CASE_CONTROL||PROSPECTIVE|||||||
33894459|NCT00322114|RANDOMIZED|||PREVENTION||||||||
33894460|NCT05319964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894461|NCT05227352|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33894462|NCT02602067|NA|SINGLE_GROUP||TREATMENT||NONE||Tenatumomab infusion||||
33894463|NCT02399748|||CASE_ONLY||PROSPECTIVE|||||||
33894464|NCT04298411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894465|NCT05903664|||OTHER||CROSS_SECTIONAL|||||||
33894466|NCT03574207|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33894467|NCT05388357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894468|NCT03802721|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Deidentified samples will be analyzed by AMS at Lawrence Livermore National Laboratory and the pharmacokinetics determine at Pacific Northwest National Laboratory.||f|f|f|t
33894469|NCT00326820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894470|NCT06182631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33970086|NCT01774006|||COHORT||PROSPECTIVE|||||||
33970087|NCT02579083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970088|NCT01573247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970089|NCT00720642|||CASE_ONLY||PROSPECTIVE|||||||
33970090|NCT04526678|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The assessor of outcomes are blinded to group allocation.|The intervention group will ingest 27 mg iron supplement per day for three months while the control group will not ingest iron supplements.|f|f|f|t
33970091|NCT00633152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970092|NCT01745328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970093|NCT05566379|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33970094|NCT00860106|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33970095|NCT03764059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970096|NCT01889862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970097|NCT03562299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970098|NCT01249339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33970099|NCT04676932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|participant women, care provider and Outcomes Assessor|Type of intervention, testing the comfort and components of women undergoing Hysterosalpingography with Nursing Care Based on Kolcaba's Comfort Theory|t|t|f|t
33970100|NCT02328599|||COHORT||PROSPECTIVE|||||||
33970101|NCT04689958|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Eligible subjects were randomly allocated to receive any of the following regiments: standard therapy consists of pregabalin, gabapentine, or amitriptyline (control group) or standard therapy and vitamin D 5000 IU tablet once daily (experimental group).||||
33970102|NCT06422611|||COHORT||CROSS_SECTIONAL|||||||
33970103|NCT00626483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970104|NCT00735683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970105|NCT01266395|||||CROSS_SECTIONAL|||||||
33970106|NCT00154037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33970107|NCT01371578||PARALLEL||TREATMENT||NONE||||||
34069670|NCT05240703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The same dentist examiner conducted all of the follow-up examinations, being unaware of the group status of the patients.||f|f|t|t
34069671|NCT04709497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069672|NCT02390713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069673|NCT00220883|||||PROSPECTIVE|||||||
34069674|NCT00077155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758451|NCT06579079|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33758452|NCT05413980|||COHORT||PROSPECTIVE|||||||
34069675|NCT05779787|||COHORT||PROSPECTIVE|||||||
34069676|NCT00190398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069677|NCT03743727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069678|NCT02685332|NA|SEQUENTIAL||TREATMENT||NONE||||||
34069679|NCT00915603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069680|NCT04788186|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, randomized pilot comparison||||
34069681|NCT03994237|||CASE_ONLY||PROSPECTIVE|||||||
34069682|NCT01009255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069683|NCT04230772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069684|NCT01476800|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34069685|NCT05916053|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34069686|NCT05223790|||CASE_ONLY||PROSPECTIVE|||||||
34069687|NCT04442152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Note that we are collecting new data from participants previously randomly assigned to intervention and control arms.|f|f|f|t
34069688|NCT00399711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069689|NCT06439693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069690|NCT03115593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879792|NCT04955392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible and recruited patients will be Randomized using OxMaR software (Oxford Minimization and Randomization).|SIngle-centre interventional single-blinded randomized contsubjectsrolled trial, with random assignment of the subjects in two groups (intervention and control, 1: 1 ratio)|t|f|f|t
34069691|NCT05840549|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trial||||
34069692|NCT06101888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758453|NCT02437656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758454|NCT03205371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study had an open-label design; however, as per the protocol, the laboratory technicians who were responsible for performing the serological testing remained blinded to the participants' group allocations throughout the study to avoid any bias.|Phase III, open-label, randomized, parallel-group, active-controlled, multicenter study|f|f|f|t
33758455|NCT04699955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants were randomly assigned to 1 of 3 parallel conditions. After assignment, they received a brief intervention and were then followed for the next 12 months.|t|f|f|f
33758456|NCT02157480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758457|NCT02344446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758458|NCT05208684|NA|SINGLE_GROUP||OTHER||NONE||||||
33879793|NCT02531646|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33879794|NCT00393575|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33879795|NCT02326558|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879796|NCT05551832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months|t|t|t|t
33879797|NCT06267833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34069693|NCT04409977|||CASE_CONTROL||PROSPECTIVE|||||||
34069694|NCT06337734|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34069695|NCT05689567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069696|NCT05498142|||COHORT||PROSPECTIVE|||||||
34069697|NCT04539548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069698|NCT01301079|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069699|NCT02414217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069700|NCT02092649|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34069701|NCT00816257|||||PROSPECTIVE|||||||
34069702|NCT00173797|||DEFINED_POPULATION||PROSPECTIVE|||||||
34069703|NCT00717795|||COHORT||PROSPECTIVE|||||||
34069704|NCT06145997|||COHORT||PROSPECTIVE|||||||
34069705|NCT03668977|RANDOMIZED|FACTORIAL||PREVENTION||NONE||2 x 2 factorial design.||||
33879798|NCT04124588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879799|NCT06538883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879800|NCT03594890|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|This study will be an observer-blind study with the subject-blind and the investigator-blind.|Phase I, single center, randomized, observer-blind, placebo-controlled study.|t|f|t|f
33879801|NCT04066075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879802|NCT00705939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879803|NCT03640871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879804|NCT02543528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33879805|NCT05048875|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The subject, investigator, and clinical staff will not know which treatment group the subject has been assigned. In addition, other personnel assigned to monitor the study will not know the treatment assignment of the subject. The pharmacist will be unblinded as the study drug will be provided as bulk supplies.|"There are two cohorts and three groups in each cohort. Cohort 1 consists of Group 1a, Group 1b and Group 2. Cohort 2 consists of Group 3, Group 4, and Group 5. Within each group, participants will either be randomized to receive study drug or placebo.~Four participants were enrolled in Group 1a before enrolling the remaining participants to Group 1b (12 participants) and Group 2 (14 participants) in Cohort 1. Based on the interim analysis results of Cohort 1, three groups for Cohort 2 were created.~Each group in Cohort 2 will enroll 8 participants (24 participants total). The goal of Cohort 2 is to evaluate the efficacy of different dosing regimens (daily vs. weekly dosing)."|t|t|t|f
33879806|NCT00870753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879807|NCT05485948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879808|NCT00826124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879809|NCT04868812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879810|NCT01171456|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33879811|NCT04469478|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Exploratory Study||||
33879812|NCT05174000|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33879813|NCT03215966|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33758459|NCT06384586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33758460|NCT01094132|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758461|NCT05255510|||COHORT||RETROSPECTIVE|||||||
33758462|NCT06524726|||OTHER||PROSPECTIVE|||||||
33758463|NCT01631890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758464|NCT04654702|||COHORT||PROSPECTIVE|||||||
33879814|NCT05185609|||CASE_CONTROL||RETROSPECTIVE|||||||
33879815|NCT00003955||||TREATMENT||NONE||||||
34069706|NCT02419391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34069707|NCT02016911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069708|NCT02521727|||COHORT||PROSPECTIVE|||||||
33879816|NCT03695068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are not aware of intervention assignment.|Participants are randomly assigned to one of two arms: (1) the reading instruction for students who are English learners with reading difficulties (RISE) intervention or (2) a business as usual comparison condition.|f|f|f|t
33879817|NCT03616938|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|study participant had no insight on the simulator or a cardio-monitor display||t|f|f|f
33879818|NCT06419140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879819|NCT04604808|||COHORT||PROSPECTIVE|||||||
33879820|NCT02788864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33879821|NCT00521846|||COHORT||OTHER|||||||
33879822|NCT06241612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879823|NCT03718143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879824|NCT01281462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879825|NCT01446354|||COHORT||RETROSPECTIVE|||||||
33879826|NCT05134272|||COHORT||PROSPECTIVE|||||||
33879827|NCT00502216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879828|NCT01583621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33879829|NCT02200315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879830|NCT00038350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879831|NCT03979092|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33879832|NCT00184145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879833|NCT02963532|||COHORT||PROSPECTIVE|||||||
33879834|NCT05012293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970108|NCT05585359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The investigator will not be blinded due to the natural of the intervention and control which require blood withdrawal from the patient or to be mixed with the Vitamin C.~* The patients and the outcome assessors are blinded to the intervention.~* The patients will not be informed which technique of treatment will be used.~* Data analyst will be blinded, he/she will receive data excel sheets with group A and group B"|Parallel Randomized controlled blinding trail|t|f|f|t
33879835|NCT03992937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879836|NCT03988335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33879837|NCT05528627|NA|SINGLE_GROUP||OTHER||NONE||||||
33879838|NCT05248438|||COHORT||PROSPECTIVE|||||||
33879839|NCT00934349|||CASE_CONTROL||PROSPECTIVE|||||||
33879840|NCT05512741|||CASE_CONTROL||PROSPECTIVE|||||||
33879841|NCT01378026|||CASE_CONTROL||RETROSPECTIVE|||||||
33879842|NCT04429620|||CASE_CONTROL||OTHER|||||||
33879843|NCT02435849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879844|NCT04193917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A conjunctival swab will be taken from healthy volunteers||||
33879845|NCT05689411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the database of the research will be created by a university graduate statistician working in a statistical center independent of the research, apart from the researcher.|randomized controlled experimental|f|f|f|t
33879846|NCT05765539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Midwife 'A' will begin by using either the echOpen probe or the classic US machine (in a random order, via sealed envelopes), and will then carry out the other type of examination. The results book will be filled in and validated after each examination, and it will not be possible to modify the results after the 2nd examination has been carried out. Another midwife (midwife 'B') will examine with the echOpen probe (blind to the first midwife's result). The alternation between midwife 'A' and midwife 'B' will also be random.|A single group, comparative, non-randomized, controlled study. Each patient represents her/his own control: the patient is examined consecutively with the echOpen probe, then with the probe used in the department.||||
33879847|NCT05506449|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized, controlled, open-label two-arm trial with an adaptive design||||
33879848|NCT05832294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded sham-controlled between-subjects design with two arms.|Single-blinded sham-controlled between-subjects design with two arms.|t|f|f|f
33879849|NCT05315466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients affected by lumbar spinal stenosis who are designated to surgical or conservative treatment||||
33879850|NCT05497466|||COHORT||PROSPECTIVE|||||||
33879851|NCT01381783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879852|NCT03551743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This study has four modules with a total of 21 cohorts, each module was reported and submitted separately.~Module 1, NCT01758432 (54 subjects with 7 cohorts including placebo); Module 2, NCT03578146 (48 subjects with 6 cohorts including placebo); Module 3, NCT03551730 (27 subjects with 4 cohorts including placebo); Module 4, NCT03551743 (28 subjects with 4 cohorts including placebo)"|t|t|t|t
33879853|NCT03643874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||2-way cumulative dose crossover||||
33879854|NCT06233370|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Participants will complete two single bouts of walking exercise. One bout of walking exercise involves walking at a moderate intensity over ground, and the other bout of walking exercise involves walking at a moderate intensity on a treadmill. The order of walking exercise bouts will be randomly determined and counterbalanced across participants. Before and after each bout of walking exercise, participants will complete an MRI scan to measure brain connectivity and brain blood flow.|t|f|f|f
33970109|NCT04132232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Will not discuss percent fetal carboxyhemoglobin to control group versus disclosing percent fetal carboxyhemoglobin to intervention group.|Randomized controlled trial|t|f|f|f
33970110|NCT02307474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970111|NCT03314129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33970112|NCT04471870|||COHORT||PROSPECTIVE|||||||
33970113|NCT00692926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970114|NCT01081028|||COHORT||PROSPECTIVE|||||||
33970115|NCT03417349|||COHORT||PROSPECTIVE|||||||
33970116|NCT02152020|||||PROSPECTIVE|||||||
33970117|NCT03154879|||COHORT||PROSPECTIVE|||||||
33970118|NCT00924066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970119|NCT02564991|||CASE_CONTROL||PROSPECTIVE|||||||
33970120|NCT02116686|||COHORT||RETROSPECTIVE|||||||
33970121|NCT05976542|||COHORT||PROSPECTIVE|||||||
33970122|NCT00638157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970123|NCT00030173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970124|NCT03846271|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind within-subject design|t|f|t|t
33970125|NCT02884206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970126|NCT01075139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970127|NCT02963753|||CASE_CONTROL||RETROSPECTIVE|||||||
33970128|NCT00686920|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33970129|NCT01536756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970130|NCT03588325|||COHORT||PROSPECTIVE|||||||
33970131|NCT00645775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970132|NCT06479759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970133|NCT03532256|||COHORT||PROSPECTIVE|||||||
33970134|NCT03803722|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single Blind: investigator masked|Approximately 80 patients globally: 40 per arm with a 1:1 ratio including an expected dropout rate of 15%. Single masked. Medical Device|f|f|t|f
33970135|NCT03096613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970136|NCT01854788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970137|NCT03624270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970138|NCT00094133|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33970139|NCT00541281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069709|NCT04480996|||CASE_ONLY||CROSS_SECTIONAL|||||||
34069710|NCT00315614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069711|NCT01949142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34069712|NCT01324921|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069713|NCT01516736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34069714|NCT03374163|RANDOMIZED|PARALLEL||TREATMENT||NONE||"To evaluate the effect ofempiricintralipidinfusion therapy on pregnancy outcomes in patient withunexplained recurrentimplantation failure (RIF) undergoIntracytoplasmic sperm injection (ICSI).~A total of 142 patients with history of unexplained RIF3 or more cycles were included in the study. Patient were randomized into two groups, study group (n=71) and control group (n=71). The study groupreceivedintralipid 20%infusionon the day of embryo transfer (ET) and a second dose on the day of pregnancy test. The control group underwent ET without intralipidinfusion.Allpatientswereclosely monitored for any side effectsincluding allergic reactions."||||
34069715|NCT02897466|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34069716|NCT06006598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069717|NCT01541072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069718|NCT01310582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34069719|NCT01007383|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34069720|NCT05671159|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34069721|NCT00287209|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34069722|NCT04204304|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34069723|NCT01961024|||COHORT||CROSS_SECTIONAL|||||||
34069724|NCT04502784|||CASE_CONTROL||PROSPECTIVE|||||||
34069725|NCT04564105|NA|SINGLE_GROUP||OTHER||NONE||||||
34069726|NCT01142505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069727|NCT03724045|NA|SEQUENTIAL||PREVENTION||NONE||||||
34069728|NCT04529317|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study was a cross-over pilot clinical study consisting of two periods. The first period was only an observational and monitoring phase where participants just continued with their regular diet (RD), for this reason all participants initiated this period and wash-out term was no needed. Subsequently, with the data of the first phase obtained, the subjects began the second period in which they had to undergo a nutritional intervention with a quinoa diet (QD).||||
34069729|NCT05726513|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
34069730|NCT00824629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069731|NCT01285479|||COHORT||PROSPECTIVE|||||||
34069732|NCT06087705|||COHORT||PROSPECTIVE|||||||
34069733|NCT05622643|||COHORT||PROSPECTIVE|||||||
34069734|NCT02347072|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34069735|NCT01887678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069736|NCT05206396|||COHORT||CROSS_SECTIONAL|||||||
34069737|NCT06397053|||CASE_CONTROL||RETROSPECTIVE|||||||
34069738|NCT04926285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069739|NCT02434159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069740|NCT01272505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069741|NCT05912075|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative phase 1b trial with randomization||||
34069742|NCT01048944|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34069743|NCT00029861|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34069744|NCT04356599|NA|SINGLE_GROUP||OTHER||NONE||||||
34069745|NCT03638830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In order to minimize subjectivity, block randomization will be carried out in treatment groups without stratification in the center. Randomization will be carried out by the method of envelopes.~To minimize the subjectivity of clinical study of the efficacy and safety of the drug Ftortiazinon will be conducted with the use of a placebo, which will not differ in appearance, shape, color, and will fully simulate the investigated product.~To distribute the drug to patients, taking into account the need to observe the blinding, a special authorized person (an unblided research pharmacist) will be appointed in each medical organization."|randomized, blind, placebo-controlled study|t|f|t|f
34069746|NCT04719845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
34069747|NCT01447641|||CASE_CROSSOVER||PROSPECTIVE|||||||
34069748|NCT01015105|||CASE_ONLY||PROSPECTIVE|||||||
34069749|NCT02333500|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069750|NCT01727362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069751|NCT03959488|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069752|NCT00559143|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34069753|NCT04110899||SEQUENTIAL||PREVENTION||NONE|Participant: masked because the intervention is applied after anesthesia induction Care provider who inserts an esophageal stethoscope under a certain paratracheal force: masked. The amount of applied paratracheal force is not shown to this investigator|Paratracheal force for occluding the upper esophagus is evaluated using the up-and-down sequential method.||||
33879855|NCT00130832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879856|NCT02851173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879857|NCT05557760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879858|NCT03825965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879859|NCT03070158|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||The assignment of the mothers to each group will be like that: First at all, mother will be assignment to control group. They will received usual care when achieve the total of 74 mothers, the mothers will be assigned to intervention group.|t|f|f|f
33879860|NCT01877083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879861|NCT06182488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A single center randomized controlled trial|t|f|f|t
33879862|NCT00046774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879863|NCT05650983|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33879864|NCT04682080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879865|NCT03382847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879866|NCT01110200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879867|NCT03529773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind|Parallel|t|t|t|t
33879868|NCT02195505|||COHORT||RETROSPECTIVE|||||||
33879869|NCT04764760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients with confirmed inguinal hernias of all types||||
33758465|NCT03375502|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758466|NCT03476629|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33758467|NCT03784040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879870|NCT01134965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879871|NCT06536738|||CASE_ONLY||CROSS_SECTIONAL|||||||
33879872|NCT01727895|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879873|NCT04917211|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879874|NCT03954600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758468|NCT05405959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758469|NCT04524754|||CASE_ONLY||RETROSPECTIVE|||||||
33879875|NCT03414580|||COHORT||PROSPECTIVE|||||||
33879876|NCT01951469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879877|NCT01655537|||CASE_ONLY||PROSPECTIVE|||||||
33879878|NCT03105687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33879879|NCT03506295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Primary bronchoscopist will perform localization of biopsy spot, after biopsy is determined to be in the control or intervention group. He/she will then perform the cryobiopsy per protocol. A bedside assistant will assist in managing the endobronchial blocker at all times. Secondary bronchoscopist will be stationed outside the operating room during initial part of the procedure. He will be prompted to enter the room by research coordinator to take control of the bronchoscope and assess post cryobiopsy bleeding. He will hence be blinded to the use or non-use of radial probe ultrasound. Research coordinator will be present at all times and will coordinate the switching process between proceduralists. Reference image of the radial USG determining the biopsy location on fluoroscopy monitor will be erased before secondary bronchoscopist enters the room. Patient will be blinded as he/she will be sedated. Four biopsies will be planned per procedure, two each from control \& intervention arm.||t|t|f|f
33879880|NCT06144983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879881|NCT02611154|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879882|NCT04132791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||parallel double blinded placebo controlled randomized clinical trial design|t|f|t|t
33879883|NCT05327465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879884|NCT02129946|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33879885|NCT04283695|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879886|NCT04395833|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34069754|NCT04630782|||COHORT||PROSPECTIVE|||||||
34069755|NCT05247346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069756|NCT05816850|||COHORT||RETROSPECTIVE|||||||
34069757|NCT03910881|NA|SINGLE_GROUP||OTHER||NONE||Using a one-group pre-post design, evaluate the effect of the adapted technology-assisted PSS on patient-reported outcomes (PROs).||||
34069758|NCT05943431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069759|NCT00086606||||TREATMENT||||||||
34069760|NCT01654263|RANDOMIZED|PARALLEL||PREVENTION||||||||
34069761|NCT01327092|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33879887|NCT04356183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized|f|f|f|t
33879888|NCT04702646|||COHORT||PROSPECTIVE|||||||
33879889|NCT00927771|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33879890|NCT06074874|||COHORT||RETROSPECTIVE|||||||
33879891|NCT04754100|NA|SEQUENTIAL||TREATMENT||NONE||||||
33879892|NCT01073566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879893|NCT04872114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879894|NCT02281019|||CASE_ONLY||PROSPECTIVE|||||||
33879895|NCT01019447|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33879896|NCT00763139|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33879897|NCT05744362|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33879898|NCT03884582|||COHORT||RETROSPECTIVE|||||||
33879899|NCT05355142|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33879900|NCT06301178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069762|NCT04146857|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34069763|NCT05243069|NA|SINGLE_GROUP||SCREENING||NONE||||||
34069764|NCT02652702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970140|NCT04859855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It will not be feasible to mask the assigned transfusion strategy from health care providers. Information regarding frequency of outcome measures will not be available to the study investigators or health care providers, to minimize comparison of outcomes between study groups. Trial statistician will be blinded for the allocation during analysis. The members of the DMSC will remain blinded unless they request otherwise after the interim analysis provides strong indications of one intervention being beneficial or harmful.|"Transfusion of RBCs according to allocation in two arms: Restrictive strategy (arm A): transfusion if Hb ≤7,0g/dL with the aim of maintaining Hb levels between 7,0-9,0g/dL. Liberal strategy (arm B): transfusion if Hb≤9,0g/dL, with the aim of maintaining Hb levels between 9,0-10,0g/dL. In both arms patients should receive one unit of RBC per time, and Hb should be monitored after 3 hours to check for the need of additional transfusion.~The strategy should be maintained during the entire ICU stay, for a maximum of 90 days. In case of permanence in the ICU for a period longer than 90 days or if the patient is discharged from the ICU, the transfusional support will be determined by the assisting physicians, independently of the study. If the patient returns to the ICU during the 90 days of randomization, then he should go back to receiving transfusions according to the liberal or restrictive strategy in use previously. Patients will receive pre-storage leukodepleted and irradiated RBCs."|f|f|f|t
33970141|NCT00647608|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33970142|NCT05660057|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will read a short story and watch moving images for 30 minutes or until any of their persisting concussion symptoms will arise on the standard computer monitor and the newly designed computer monitor in two visits.|t|f|f|f
34069765|NCT00675077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069766|NCT02330224|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34069767|NCT01134263|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An observer-blind procedure was followed for the three injections with CYD dengue vaccine or placebo. Neither the observer, Investigator, Sponsor, nor the participant knew which product was administered.||t|f|t|t
34069768|NCT00960973|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879901|NCT02956382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879902|NCT04354350|||COHORT||RETROSPECTIVE|||||||
33894471|NCT06509061|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The participants were told that they were in one of two informational sessions; they were not told if they were in the intervention or the control group. Researchers sending the surveys to participants' emails were also blinded to the condition. Intervention facilitators who were presenting the material were necessarily aware of the condition.||t|f|t|t
33970143|NCT03967132|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33894472|NCT01562119|||CASE_CONTROL||RETROSPECTIVE|||||||
33894473|NCT05495464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894474|NCT02659449|||CASE_CROSSOVER||PROSPECTIVE|||||||
33894475|NCT05895513|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Placebo (tablets identical to active drug)||t|t|t|t
33970144|NCT02818283|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33970145|NCT06021548|||CASE_ONLY||PROSPECTIVE|||||||
33970146|NCT04480099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970147|NCT02019979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894476|NCT02079727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894477|NCT02835729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894478|NCT02427061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970148|NCT06539364|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were obtained from 50 systemically healthy individuals with periodontitis and after the initial treatment repeat measurements were taken at the control session to evaluate participation in the surgical treatment group.||||
33970149|NCT00163930|||DEFINED_POPULATION||OTHER|||||||
33970150|NCT00086879|RANDOMIZED|||TREATMENT||NONE||||||
33970151|NCT03214757|||COHORT||PROSPECTIVE|||||||
33970152|NCT00719654|||CASE_CONTROL||PROSPECTIVE|||||||
33970153|NCT03339635|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33970154|NCT02008110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970155|NCT02627014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970156|NCT01075620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970157|NCT04718220|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective study that will enroll two cohorts of pregnant women: 1) exposed (SARS-CoV-2 positive), and 2) unexposed (SARS-CoV-2 negative as defined by antibody testing at the beginning of pregnancy, every trimester, and at delivery). Women who initially enroll as unexposed but later test positive for SARS-CoV-2 antibodies will cross over to the exposed cohort. Outcomes will be compared between the two cohorts.||||
33970158|NCT04109612|||CASE_ONLY||PROSPECTIVE|||||||
33970159|NCT04179071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970160|NCT02990832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970161|NCT00289458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970162|NCT00374543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970163|NCT00470444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970164|NCT03961776|||COHORT||PROSPECTIVE|||||||
33970165|NCT00425789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970166|NCT01127854|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970167|NCT02049359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970168|NCT04345471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970169|NCT06329596|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, data collectors (i.e. dental officers, study staff members, clinical officers), and data analysts will be blinded (triple-blinded) to group allocation throughout the study.||t|t|f|t
33970170|NCT03918551|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department.||f|f|f|t
33970171|NCT04046042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A team of assessors, different from the researchers implementing the exercise, will record all dependent variables. A blind researcher will randomize participants|Participants will be randomized into one of two exercise groups, during the first two hours of hemodialysis or during the last two hours of hemodialysis|f|f|t|t
33970172|NCT00365625|||||PROSPECTIVE|||||||
34069769|NCT03528382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069770|NCT05201443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069771|NCT00146549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069772|NCT04705532|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34069773|NCT05873868|||CASE_ONLY||PROSPECTIVE|||||||
34069774|NCT02447770|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33879903|NCT03290495|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The patients well be randomized to one of the two groups by closed envelope technique. After opening the envelope, the study drug (ketamine 100µg/kg total body weight (Isoket group)) or normal saline ((Isonly) or control group) will be prepared, made up to 10 ml and administered by an assistant in the proper timing. The patient identification will be written on a slip and put back into an envelope and sealed. The person doing the procedure and monitoring along with the patient will be blinded to the dose and nature of solution. The equal volume test solution will be given intravenously by an assistant who was not involved in the administration of anesthesia and monitoring|"An intravenous catheter was placed and normal saline (0.9%) will be infused. Spinal anesthesia will be given. The stability of spinal anesthesia will be assured before propofol injection and at the end of procedure.~Propofol will be given to facilitate isoflurane inhalation which will be varied between 0.8-1.2percent to keep (BIS) in the range 40-60. Anesthesia will be kept as so for 30 minutes. Then the test drug (either ketamine or saline) will be given slowly, to pressor response in case of ketamine. Anesthesia will be maintained for another 30 minutes then isoflurane is discontinued. Recovery from anesthesia will then be tested.. No other drugs will be routinely given. Development of complications or signs of inadequate anesthesia will cause drop of the case from study and any measures will be taken to insure patient safety and comfort.The patient will be let to recover from anesthesia then transferred to postoperative care unit."|t|f|t|t
33879904|NCT04852120|||COHORT||PROSPECTIVE|||||||
33879905|NCT05162482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879906|NCT03868683|RANDOMIZED|CROSSOVER||OTHER||NONE||Crossover randomized controlled Trials||||
33879907|NCT03305107|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33879908|NCT00986700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879909|NCT04834583|||COHORT||PROSPECTIVE|||||||
33879910|NCT05847894|||COHORT||CROSS_SECTIONAL|||||||
33879911|NCT02296398|||CASE_ONLY||RETROSPECTIVE|||||||
34069775|NCT00510055|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34069776|NCT05383066|||COHORT||PROSPECTIVE|||||||
33879912|NCT05241080|||OTHER||CROSS_SECTIONAL|||||||
33879913|NCT04989101|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33879914|NCT04378608|NA|SINGLE_GROUP||TREATMENT||NONE||100 Egyptian naive patients infected with HCV GT4 was allocated and administered orally OBV/PTV/r with RBV which given as oral tablets based on patient tolerability||||
33879915|NCT04916405|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33879916|NCT04201925|||COHORT||PROSPECTIVE|||||||
33879917|NCT01720537|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33879918|NCT01594021|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33879919|NCT02712515|||COHORT||CROSS_SECTIONAL|||||||
33879920|NCT00362011|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33879921|NCT05055193|||COHORT||PROSPECTIVE|||||||
33970173|NCT05442983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970174|NCT03277183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome is the progression of carotid plaque. John Forder, PhD, who will read the MRIs will be blinded to the subject and treatment group.|Patients will be randomly assigned two different erythropoietin dosing strategies. One group will be given more frequent, low-doses of EPO and the other group will be given the same, cumulative dose given every 2 weeks.|f|f|f|t
33970175|NCT00626925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970176|NCT03822962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, cohort study||||
33970177|NCT03270137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Investigator)|Parallel Assignment|f|f|t|f
33970178|NCT03139071|||OTHER||CROSS_SECTIONAL|||||||
33970179|NCT05584527|||CASE_CROSSOVER||PROSPECTIVE|||||||
33970180|NCT05353374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation sequence was generated by a statistician with a computer and it was concealed from the researchers and participants. The ointment was prepared and packaged by a pharmacist. Each pot was numbered in accordance with the allocation sequence.||t|t|t|t
33970181|NCT02558933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970182|NCT02319681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879922|NCT00345670|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33879923|NCT05877482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group assignment and short foot exercises training was conducted by the second physical therapist to provide blindness.||t|f|t|f
33879924|NCT04769011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33879925|NCT00244023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879926|NCT01302808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33879927|NCT04993378|||COHORT||PROSPECTIVE|||||||
33879928|NCT04466800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multicenter, randomized, comparative, parallel-group trial||||
33879929|NCT02349178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069777|NCT05080738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1) Intervention Group:~The patients in the intervention group will be asked to practice upper extremity home exercises including stretching, mobility and strengthening, as home exercises, 5 days a week for 8 weeks, which will be taught by the physiotherapist. The exercises will be performed as follows:~1. Stretching exercises: It will be applied in the form of 10 seconds\*10 repetitions for fingers, wrists, elbows and shoulders.~2. Strengthening exercises: It will be applied as 2 sets\*10 repetitions for fingers, wrists, elbows and shoulders.~Patients will be instructed to perform the exercises according to their pain tolerance. The compliance of the patients with the exercise will be checked during this process and the evaluations will be repeated at the end of 8 weeks.~2) Control Group: The patients in the control group will be taught the principles of joint protection and evaluations will be made again after 8 weeks."|t|f|f|t
33879930|NCT01515657|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33879931|NCT06037330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069778|NCT01421147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069779|NCT00833404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069780|NCT02484768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069781|NCT04416919|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34069782|NCT04919148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34069783|NCT00463489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069784|NCT02104167|||COHORT||OTHER|||||||
34069785|NCT00004533|RANDOMIZED|||TREATMENT||DOUBLE||||||
34069786|NCT00475293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879932|NCT02544932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879933|NCT05536180|||COHORT||PROSPECTIVE|||||||
33879934|NCT03340610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879935|NCT02575287|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33879936|NCT00280761|||CASE_ONLY||PROSPECTIVE|||||||
33879937|NCT00739154|||COHORT||CROSS_SECTIONAL|||||||
33879938|NCT04187885|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33879939|NCT03552341|||COHORT||PROSPECTIVE|||||||
33879940|NCT02105454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879941|NCT06152822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879942|NCT00996099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879943|NCT02511652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33879944|NCT02012478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33879945|NCT06075693|||COHORT||PROSPECTIVE|||||||
33879946|NCT02990442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879947|NCT05958511|||OTHER||PROSPECTIVE|||||||
33879948|NCT00756873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879949|NCT03177083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879950|NCT01641614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879951|NCT01978093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33879952|NCT00004001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879953|NCT01352806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33879954|NCT00225511|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33879955|NCT04656873|||COHORT||PROSPECTIVE|||||||
33758470|NCT03337646|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-Center Open Label||||
33970183|NCT01891591|||COHORT||PROSPECTIVE|||||||
33758471|NCT05809206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758472|NCT00604526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758473|NCT04272502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758474|NCT01353781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758475|NCT03724487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758476|NCT05782049|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||It's a cross-sectional case-control study. The study will include patients with rheumatoid arthritis compared to patients with Sjögren's syndrome or Sicca, Asthenia, Polyalgia syndrome (SAPS).||||
33758477|NCT05648162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758478|NCT04643925|NA|SINGLE_GROUP||TREATMENT||NONE||Women will undergo two identical consecutive IVF/ICSI treatments: a Control cycle including blastocyst culture and freeze-all and a subsequent identical Study cycle, separated by eight weeks of androgen priming by daily hCG-injections. Both IVF/ICSI cycles are performed in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and the GnRH antagonist (Fyremadel 0.25 mg) from stimulation day 5-6.||||
33758479|NCT00699439|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33758480|NCT03613675|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Participants will be asked to play 4 video games on asthma.||||
33758481|NCT00724581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758482|NCT00116896||||TREATMENT||NONE||||||
33758483|NCT01280838|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758484|NCT00695630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758485|NCT00742079|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33758486|NCT06298851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33758487|NCT02228070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758488|NCT00620750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758489|NCT03774901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758490|NCT02267005|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33758491|NCT05009108|||COHORT||PROSPECTIVE|||||||
33758492|NCT03741101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758493|NCT04284527|||OTHER||PROSPECTIVE|||||||
33758494|NCT04793906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758495|NCT01714804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758496|NCT05840484|||CASE_ONLY||PROSPECTIVE|||||||
33758497|NCT06218758|||COHORT||RETROSPECTIVE|||||||
33758498|NCT05993845|||COHORT||PROSPECTIVE|||||||
33758499|NCT01690884|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33758500|NCT04979039|||COHORT||PROSPECTIVE|||||||
33758501|NCT03076268|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be aware of which condition they are enrolled in.|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.|t|f|f|f
33758502|NCT05047874|||COHORT||RETROSPECTIVE|||||||
33758503|NCT04536090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758504|NCT06304350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758505|NCT06491771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758506|NCT01903421|RANDOMIZED|PARALLEL||PREVENTION||NONE||The proposed study will be a prospective, multicenter, cluster randomization clinical trial comparing two different anesthetic techniques in elderly patients (\> 65 years of age) undergoing urology/orthopedic/general surgery. The study will follow a cluster design; patients undergoing orthopedic or vascular surgery will have spinal anesthesia, where standard practice. Patients undergoing urology or general surgery will receive general anesthesia, also where it is standard practice. Patients with severe dementia will be excluded.||||
33758507|NCT01637103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758508|NCT01302431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758509|NCT02565238|||CASE_ONLY||PROSPECTIVE|||||||
33758510|NCT01856530|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33758511|NCT01479998|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758512|NCT06159010|||OTHER||PROSPECTIVE|||||||
33970184|NCT01079676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970185|NCT04676191|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970186|NCT00673790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970187|NCT03618979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970188|NCT05832606|NA|SINGLE_GROUP||PREVENTION||NONE||The FORX interventional trial will be a monocentric single arm dietary intervention trial in 60 patients starting immune checkpoint inhibitor therapy for different types of cancer in both the adjuvant and metastatic setting.||||
33970189|NCT04648579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758513|NCT03775200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758514|NCT00651053||CROSSOVER||DIAGNOSTIC||NONE||||||
33758515|NCT01873430|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33758516|NCT05032001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758517|NCT00295022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758518|NCT01169714|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33970190|NCT00225082|||CASE_ONLY||PROSPECTIVE|||||||
33970191|NCT01302314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970192|NCT05539183|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33970193|NCT00460473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33758519|NCT01494844|NA|SINGLE_GROUP||||NONE||||||
33758520|NCT00686452|||CASE_CONTROL||PROSPECTIVE|||||||
33758521|NCT06148220|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758522|NCT04716699|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758523|NCT05146050|||COHORT||PROSPECTIVE|||||||
33758524|NCT01552564|||CASE_ONLY||PROSPECTIVE|||||||
33758525|NCT04602130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33758526|NCT04435041|||OTHER||OTHER|||||||
33879956|NCT03847610|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33879957|NCT05707091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879958|NCT04549701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"CAVAL US will be performed on all patients, and patients will be blinded to the assigned group.~The treating medical team will be blind to the CAVAL US results of the control group.~Independent clinicians adjudicating 90-day events will not participate in patient follow-up, and will be blind to the assigned group."||t|t|f|t
33879959|NCT05840081|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomized crossover design|t|t|t|t
33879960|NCT02133859|||COHORT||PROSPECTIVE|||||||
33879961|NCT03188952|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The assessors will not be blind to intervention/control assessment methods. However it will not be allowed amongst the examiners to exchange any information throughout the entire study period||f|f|f|t
33879962|NCT00005783||||TREATMENT||||||||
33879963|NCT03987854|NA|SINGLE_GROUP||TREATMENT||NONE|Laboratory results will be assessed by a lab not associated with the study team.|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. Behavioral: positive affect informational materials. They will also be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths, in addition to information about mindfulness and mindful eating techniques.||||
33879964|NCT02852317|||COHORT||PROSPECTIVE|||||||
33879965|NCT03838679|||COHORT||PROSPECTIVE|||||||
33879966|NCT05196945|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879967|NCT05181527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894479|NCT02913625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33894480|NCT01547338|||CASE_ONLY||CROSS_SECTIONAL|||||||
33894481|NCT00820105|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33894482|NCT04438655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970194|NCT04504864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33970195|NCT00851032|||CASE_ONLY||RETROSPECTIVE|||||||
33970196|NCT01564758|||COHORT||PROSPECTIVE|||||||
33970197|NCT03411590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970198|NCT03218735|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970199|NCT05480878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970200|NCT02181257|RANDOMIZED|PARALLEL||TREATMENT||NONE||"REFRACTORY BOS - Participants are electronically assigned to either ECP Treatment or Observation (Standard Immunosuppression Therapy)~NEW BOS Participants are randomized to ECP Treatment or Control (Standard Immunosuppression Therapy"||||
33970201|NCT06074120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970202|NCT01216111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970203|NCT00845585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970204|NCT00377728|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33970205|NCT03750474|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970206|NCT05535712|NA|SINGLE_GROUP||TREATMENT||NONE||clinical lung cancer who receive Da Vinci sp robotic surgery||||
33970207|NCT02829489|||COHORT||PROSPECTIVE|||||||
33970208|NCT04436328|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized (1:1), controlled, multicentre explorative trial||||
33970209|NCT04780659|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33970210|NCT01713153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970211|NCT06182683|RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding process, open label design|Prospective, randomized open-label clinical trial||||
33970212|NCT03958981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970213|NCT06427265|||COHORT||PROSPECTIVE|||||||
33970214|NCT02843074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970215|NCT00277680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758527|NCT04699435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758528|NCT04658641|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Blinded design|Randomized, crossover, blinded design|t|f|f|f
33758529|NCT04336735|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||45 triads of parents, primary care physicians and subspecialists of children awaiting heart, liver and kidney transplantation will be enrolled to use a novel immunization tool (app).||||
33758530|NCT01431001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758531|NCT02395861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758532|NCT00863655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758533|NCT05471037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33758534|NCT00188955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758535|NCT02915094|||COHORT||PROSPECTIVE|||||||
33758536|NCT02831257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879968|NCT04711707|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Data analysts will be blind to the group allocation. Group allocation will be concealed until the final data analysis is performed. Families, research staff and clinical staff will not be blinded to the group allocation.|Participants who screen positive for social needs will be randomized to receive one of two possible interventions. An allocation ratio of 1:1 with random permuted blocks of varying size will be used. Random block size will help to ensure that investigators or outcome assessors will not be able to decipher the block size and anticipate future allocations. Allocation concealment is the process that prevents any trial participant or investigator from knowing in advance the treatment to which subjects will be assigned and seeks to prevent selection bias.|f|f|f|t
33879969|NCT06367881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33879970|NCT02735447|||CASE_ONLY||CROSS_SECTIONAL|||||||
33879971|NCT03368261|NA|SINGLE_GROUP||OTHER||NONE||||||
33970216|NCT01561183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970217|NCT06543368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970218|NCT00418873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970219|NCT05539573|||COHORT||PROSPECTIVE|||||||
33970220|NCT04502758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The use of the MagVenture Cool-B70 A/P coils facilitates blinding of the operator and subjects receiving aTBS or sham treatments. The study team members completing clinical rating scales will also not be allowed in the treatment suite during TBS treatment sessions and will be blinded to treatment assignment. A pre-post treatment expectancy and experience form will ask subjects and parents to make a guess regarding treatment arm (active or sham). Blinded study team members will also be asked to guess treatment assignments for each subject.|Randomized Controlled Trial|t|t|t|t
33970221|NCT05235594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33970222|NCT00217828|RANDOMIZED|||TREATMENT||||||||
33970223|NCT00197756|||COHORT||PROSPECTIVE|||||||
33970224|NCT02410512|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33970225|NCT05896059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970226|NCT06543602|||CASE_CONTROL||PROSPECTIVE|||||||
33970227|NCT01156571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33879972|NCT05060588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33879973|NCT03650192|NA|SINGLE_GROUP||OTHER||NONE||||||
33879974|NCT05402423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33879975|NCT05183503|||COHORT||PROSPECTIVE|||||||
33879976|NCT02671643|||COHORT||PROSPECTIVE|||||||
33879977|NCT01348646|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33879978|NCT05498688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33879979|NCT03803644|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33879980|NCT02481973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879981|NCT01028807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879982|NCT00751868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879983|NCT03049904|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33879984|NCT01479712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33879985|NCT05332483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33879986|NCT04963257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879987|NCT06466889|||COHORT||PROSPECTIVE|||||||
33879988|NCT01367522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33879989|NCT03951818|||CASE_ONLY||RETROSPECTIVE|||||||
33879990|NCT04728685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three-arm parallel groups|t|f|f|t
33879991|NCT02559466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33879992|NCT01514682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33879993|NCT03158870|||COHORT||RETROSPECTIVE|||||||
33879994|NCT00215605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33879995|NCT01977781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33879996|NCT05726344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind (endoscopist, researchers and statistician) randomized clinical assay.|An analytical, experimental, prospective study, specifically a triple blind randomized clinical assay (endoscopist, researchers and statistician) in which a bowel preparation is compared for colonoscopy with lactulose vs. Polyethylene Glycol.|f|t|t|t
33879997|NCT01820390|||COHORT||PROSPECTIVE|||||||
33879998|NCT04595214|||COHORT||PROSPECTIVE|||||||
33879999|NCT05537922|||COHORT||OTHER|||||||
33880000|NCT04196868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|placebo-controlled trial||t|f|f|f
33880001|NCT05688943|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This a a randomized control trail that will have 2 groups. One will be the control group and will receive the standard of care, general anesthesia. The other group will be the experimental group which will receive spinal anesthesia in place in general anesthesia.|t|t|t|f
33880002|NCT05010356|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33880003|NCT01609842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880004|NCT01932957|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880005|NCT00703638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880006|NCT04492280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33880007|NCT06458933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880008|NCT02001233|||CASE_CONTROL||PROSPECTIVE|||||||
33880009|NCT00490568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880010|NCT04819737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants (embedded within the currently ongoing Swiss MS Cohort (SMSC) study) will undergo a single visit including a clinical interview, neurological examination and MRI.||||
33880011|NCT04680611|||COHORT||PROSPECTIVE|||||||
33880012|NCT00359775|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33880013|NCT03733392|||OTHER||PROSPECTIVE|||||||
33880014|NCT03592095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880015|NCT05320900|||COHORT||PROSPECTIVE|||||||
33880016|NCT00915343|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880017|NCT04608695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880018|NCT01938144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880019|NCT00487539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880020|NCT01088035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880021|NCT02727335|||COHORT||RETROSPECTIVE|||||||
33880022|NCT03772626|NA|SINGLE_GROUP||TREATMENT||NONE||Single group non-randomized open label study of efficacy and feasibility. Comparison will be to historical controls.||||
33880023|NCT00001570||||TREATMENT||||||||
33880024|NCT04565678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880025|NCT01394081|RANDOMIZED|PARALLEL||SCREENING||NONE||Prospective randomized control trial||||
33880026|NCT00119522|||COHORT||PROSPECTIVE|||||||
33880027|NCT03786549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33764899|NCT04381936|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"RECOVERY participants are randomly allocated between one or more treatment arms. Not all treatments are available in all countries.~COVID-19:~Parts A to D, and the arm for children with PIMS-TS, have been discontinued.~Part E: randomisation between no additional treatment vs high dose corticosteroids~Part F: discontinued~Part J: randomisation between no additional treatment vs sotrovimab~Part K: discontinued~Part L: discontinued~Influenza:~Part G: randomisation between no additional treatment vrs baloxavir marboxil~Part H: randomisation between no additional treatment vrs oseltamivir~Part I: randomisation between no additional treatment vrs Low-dose corticosteroids: Dexamethasone~Community-acquired pneumonia:~Part M: randomisation between no additional treatment vrs Low-dose corticosteroids: Dexamethasone"||||
33970228|NCT01196182|||COHORT||PROSPECTIVE|||||||
34069787|NCT02936089|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with newly diagnosed AML1/ETO-positive AML took risk-directed stratification therapy based on c-KIT and ASXL1 mutations and measurable residual disease (MRD). low risk (LR) group (KIT-ASXL1- with main molecular response (MMR)) was recommended to chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT). Intermediate risk (IR) group (KIT+/ASXL1+ with MMR) was suggested for auto-HSCT or HLA-matched HSCT. High risk (HR) group (KIT+ASXL1+ or without MMR) was treated with allogeneic (allo-) HSCT.||||
33970229|NCT00342264|||COHORT||RETROSPECTIVE|||||||
34069788|NCT01532258|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069789|NCT04611139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970230|NCT06251128|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group study||||
33970231|NCT04156074|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double Blind|Parallel Randomized Controlled Trial|t|f|t|f
33970232|NCT02189616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069790|NCT03010241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970233|NCT05058742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970234|NCT03467412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970235|NCT06346236|||COHORT||RETROSPECTIVE|||||||
33970236|NCT02343887|RANDOMIZED|PARALLEL||||NONE||||||
33970237|NCT03483285|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33970238|NCT00624871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970239|NCT01284595|NA|SINGLE_GROUP||||NONE||||||
34069791|NCT06438887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinding|Double-blind, randomized controlled trial|t|f|t|t
34069792|NCT03961750|NA|SINGLE_GROUP||TREATMENT||NONE||Pre Post test single cohort feasibility study||||
33758537|NCT05771779|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is a open-label, randomized controlled, non-inferiority study. Study investigators along with study staff involved in safety evaluation and laboratory analysis will be blinded regarding the assigned treatment of the participant. The vaccine administration team will be un-blinded to the treatment assignment list. The vaccine administrator team members will not be involved in the evaluation of vaccine safety and laboratory analysis. The DSMB will be responsible for un-blinding the randomization number codes in the event of severe putative vaccine reactions. Otherwise, the codes will not be revealed until the end of the trial and until the computerized dataset has been frozen. If the intervention assignment is un-blinded, all study collaborators will be notified immediately. If deemed necessary, the DSMBs will recommend unblinding to the IRB and contact the study statistician responsible for providing information on the vaccine received by the individual in question.|An open-label, randomized controlled, non-inferiority study of co-administration of OCV, TCV and MR vaccines among children 12 to 59 months of age in Dhaka, Bangladesh will be conducted. Children who did not receive any of the aforementioned vaccines will be included in the study.||||
34069793|NCT00004088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069794|NCT05111639|||COHORT||PROSPECTIVE|||||||
34069795|NCT00347230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069796|NCT02888561|||COHORT||PROSPECTIVE|||||||
34069797|NCT04626661|||COHORT||PROSPECTIVE|||||||
34069798|NCT04210739|NA|SINGLE_GROUP||TREATMENT||NONE||chronic non bacterial prostatitis||||
34069799|NCT02155088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069800|NCT06144541|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33758538|NCT02287584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069801|NCT05988346|||COHORT||PROSPECTIVE|||||||
34069802|NCT00003703||||TREATMENT||||||||
34069803|NCT04760106|||COHORT||PROSPECTIVE|||||||
34069804|NCT02338115|||COHORT||PROSPECTIVE|||||||
34069805|NCT05273905|||CASE_ONLY||PROSPECTIVE|||||||
34069806|NCT02756819|||COHORT||PROSPECTIVE|||||||
34069807|NCT02348008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069808|NCT03232216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069809|NCT05614401|||COHORT||PROSPECTIVE|||||||
34069810|NCT02469012|NA|SINGLE_GROUP||SCREENING||NONE||||||
34069811|NCT01597297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069812|NCT05844072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The investigator setting up the goniometer will be masked to the outcome measures||f|f|f|t
34069813|NCT04177966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Women will be recruited for research at the time of admission preoperatively According to randomization women will be divided into two groups - intervention and control|f|t|f|f
34069814|NCT03809325|||COHORT||CROSS_SECTIONAL|||||||
34069815|NCT03826966|NA|SINGLE_GROUP||TREATMENT||NONE|"N/A at this time. This trial is a pilot study seeking an N of 15 participants. All participants will be assigned the treatment, which is accessing an mobile app, re-SET, for cognitive behavioral therapy extension that is to be used with MAT (Buprenorphine only at this time)."|||||
34069816|NCT06458777|||COHORT||RETROSPECTIVE|||||||
34069817|NCT01537380|NA|SINGLE_GROUP||OTHER||NONE||||||
34069818|NCT04973709|||COHORT||RETROSPECTIVE|||||||
34069819|NCT02226263|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34069820|NCT05868239|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069821|NCT01597492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069822|NCT01915901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069823|NCT06308900|NA|SINGLE_GROUP||SCREENING||NONE||||||
34069824|NCT05060107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069825|NCT04668443|||CASE_ONLY||CROSS_SECTIONAL|||||||
33970240|NCT00029185|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33970241|NCT01283633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970242|NCT00622141|RANDOMIZED|CROSSOVER||||NONE||||||
34069826|NCT01216332|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34069827|NCT05754541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069828|NCT02494557|||CASE_CONTROL||PROSPECTIVE|||||||
33880028|NCT00173823|||DEFINED_POPULATION||OTHER|||||||
34069829|NCT06101537|||COHORT||PROSPECTIVE|||||||
34069830|NCT06349915|NA|SINGLE_GROUP||PREVENTION||NONE||The first 6 participants will serve as a brief pilot to validate outcomes and the acceptability of the intervention. The study team may make slight changes to the intervention (e.g., time of day the suicide recovery narratives are administered, or which narratives are presented) before recruiting the remaining 40 participants.||||
33758539|NCT06510049|||CASE_CONTROL||RETROSPECTIVE|||||||
33880029|NCT03501030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single center, parallel group non-blinded, prospective, interventional non-pharmacologic, no profit, randomized and controlled trial|f|f|f|t
33880030|NCT04118816|||COHORT||PROSPECTIVE|||||||
33970243|NCT06150378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|At the time of blood collection, patients will be placed in a hemotherapy extraction chair with a screen that will prevent the patient from seeing their arm at the time of blood collection.|Randomized Controlled Double Blind Clinical Trial|t|t|t|t
34069831|NCT05472805|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34069832|NCT03403452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069833|NCT05346354|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069834|NCT04529707|NA|SINGLE_GROUP||TREATMENT||NONE||The overall objective of this project is to conduct an early phase single-group repeated measures design project examining the implementation and within-subjects effects of a 10-week parent-mediated TranS-CY program to improve sleep health in young boys with DMD.||||
34069835|NCT02209818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880031|NCT00754910|||CASE_CONTROL||RETROSPECTIVE|||||||
33880032|NCT02137954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880033|NCT00767897|||OTHER||PROSPECTIVE|||||||
33880034|NCT05075538|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880035|NCT03875144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880036|NCT03408795|NA|SINGLE_GROUP||OTHER||NONE||||||
33880037|NCT06425575|||COHORT||RETROSPECTIVE|||||||
33880038|NCT04870879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will compared survival in patient enrolled in the MELODIC trial with the OS in a matched cohort of patients treated with chemotherapy||||
33894483|NCT03739970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33758540|NCT03164980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758541|NCT04377932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758542|NCT06518421|||COHORT||PROSPECTIVE|||||||
33758543|NCT00876538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758544|NCT04534257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758545|NCT05897476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Prospective single-center interventional diagnostic~H1: inclusion interview then :~Medical interrogation (retrospective collection if already done / but additional requests if missing data).~Clinical examination (complementary if missing data).~Ultrasound with 3 ultrasound sections to be performed: parasternal long axis, supra-sternal and abdominal, looking for the following signs:~Direct signs: presence of an intimal flap, intramural aortic hematoma \> 5mm, penetrating aortic ulcer.~Indirect signs: pericardial effusion, aortic dilatation ≥ 4 cm, tamponade (1). H4: retrospective collection of the results of complementary examinations if any, biological and radiological, and collection of the final diagnosis retained."||||
33758546|NCT03916432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758547|NCT01507636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758548|NCT06096701|||COHORT||PROSPECTIVE|||||||
33758549|NCT05440370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758550|NCT01742364|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33758551|NCT06239870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758552|NCT01711762|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33758553|NCT01595893|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33758554|NCT03776825|||COHORT||PROSPECTIVE|||||||
33758555|NCT03171779|||COHORT||PROSPECTIVE|||||||
33758556|NCT06229132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758557|NCT02411799|||OTHER||PROSPECTIVE|||||||
33880039|NCT04732182|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes Assessor will not be told which group the participant is part of, so not be biased in evaluations.|Pilot RCT. Participants are randomized equally into the experimental group and a wait-list control group. Randomization will be based on a randomization table prepared by a contracted bio-statistician.|f|f|f|t
33880040|NCT00992316|||COHORT||PROSPECTIVE|||||||
33880041|NCT05112055|||COHORT||PROSPECTIVE|||||||
33880042|NCT05984238|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|In this study, both the study team and the study subjects are blinded to the treatment through the 24 week follow-up visit. While the endoscopist is not blinded to individual treatments, he or she is blinded to cohort level data and is not responsible for patient follow-up. At the 24 week visit, the subject and study team are unblinded. The subjects who received the sham treatment undergo ReCET.|This study is a single-center, double-blind, sham-controlled trial.|t|t|t|t
33970244|NCT06388291|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double Blind|"All participants will have electrodes implanted in the globus pallidus interna and connected to a subcutaneous pulse generator.~This will be followed by a 6 months open-phase period of stimulation for electrical parameter adjustment.~Following these 6 months, participants will be randomised into two groups by the order of treatment condition (ON/OFF-stimulation vs OFF/ON-stimulation): one group will be kept with the stimulation on (ON-stimulation) and the other switched off (OFF-stimulation) for up to two weeks. Tic severity will be assessed and all participants will enter a 2-day interval, in the ON state, before switching to the other treatment condition for another two weeks."|t|t|f|t
33970245|NCT02625545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970246|NCT04061564|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The use of the device in a location which will not stimulate the vagal nerve|Proof of concept randomised, placebo controlled, single blinded, cross over study|t|f|f|f
33970247|NCT01819766|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970248|NCT02408406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970249|NCT00501774|||CASE_CONTROL||OTHER|||||||
33970250|NCT01186978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970251|NCT00655421|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33970252|NCT05494775|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970253|NCT03165890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758558|NCT04044222|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33758559|NCT01078480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758560|NCT01595568|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33758561|NCT03340402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758562|NCT05321550|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758563|NCT05988021|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33758564|NCT00801541|||COHORT||PROSPECTIVE|||||||
33758565|NCT03917368|NA|SINGLE_GROUP||OTHER||NONE||||||
33758566|NCT03581084|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm study which means all study participants will receive the same treatment||||
33758567|NCT04126408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33970254|NCT04784481|RANDOMIZED|PARALLEL||TREATMENT||NONE|Each of the health centers (cluster of health centers) was randomly assigned to receive or not the intervention under study. The conglomerate of outpatients randomly assigned to the Experimental Group (EG) and Control Group (CG) belongs to the urban and peri-urban areas from Tucumán, and the selection of the centers was carried out considering a homogeneous socioeconomic profile in relation to the operating areas in which it is organized the Public Health Systems. Participants were recruited prior to cluster randomisation. Staff of each assistance center knew what intervention was being implemented as well as patients. Data processing group was blind to analyze the database.|Cluster-randomised trials.||||
33970255|NCT02069678|||COHORT||PROSPECTIVE|||||||
33970256|NCT06185712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970257|NCT01736553|||COHORT||PROSPECTIVE|||||||
33970258|NCT00740727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970259|NCT03410381|NA|SINGLE_GROUP||OTHER||NONE||||||
33970260|NCT05661877|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33970261|NCT00182221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970262|NCT01731483|||CASE_ONLY||PROSPECTIVE|||||||
33970263|NCT01785784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970264|NCT00576199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970265|NCT02628340|||||CROSS_SECTIONAL|||||||
33970266|NCT02268045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970267|NCT06527820|NA|SINGLE_GROUP||TREATMENT||SINGLE|Participants will receive usual care in all encounters.|Before and after trial. ED patients will be enrolled and followed before and after the intervention is delivered to clinicians. Clinicians at one site will receive the intervention and clinicians at control sites will complete outcome collection without receiving the intervention.|t|f|f|f
33970268|NCT02427373|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33880043|NCT01052584|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880044|NCT05292105|||COHORT||PROSPECTIVE|||||||
33880045|NCT06228222|||COHORT||PROSPECTIVE|||||||
33880046|NCT01664780|||COHORT||PROSPECTIVE|||||||
33880047|NCT03937583|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880048|NCT01378312|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880049|NCT05493943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random, at time of enrollment|3 arms, 2 have PEMF devices, 1 Control with sham devices|t|t|f|f
33880050|NCT02973737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880051|NCT04979507|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Cross-over within-subject, between-group||||
33880052|NCT01112098|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33880053|NCT03441178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880054|NCT02383914|||COHORT||PROSPECTIVE|||||||
33880055|NCT01926782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study was conducted in 2 separate populations concurrently: subjects receiving concomitant statin therapy and subjects not receiving concomitant statin therapy. Subjects receiving concomitant statin were to receive stable daily doses of rosuvastatin, atorvastatin, or simvastatin for at least 4 weeks. Background treatment with other lipid-modifying therapy (LMT) was allowed for all patients, provided they had been on a stable dose for at least 4 weeks (6 weeks for fenofibrate) prior to study entry.|t|t|t|t
33880056|NCT04421625|NA|SINGLE_GROUP||SCREENING||NONE||||||
33880057|NCT04314440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33880058|NCT00907101|NA|SINGLE_GROUP||OTHER||NONE||||||
33970269|NCT01373892|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Sleeve or gastric bypass operation for obese|||||
33970270|NCT00218686|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33970271|NCT03857685|||COHORT||PROSPECTIVE|||||||
33970272|NCT01996878|||CASE_CONTROL||PROSPECTIVE|||||||
33970273|NCT02304575|||CASE_CONTROL||PROSPECTIVE|||||||
33970274|NCT03387059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970275|NCT05168956|||COHORT||RETROSPECTIVE|||||||
33970276|NCT05796622|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33970277|NCT01199432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970278|NCT02340156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970279|NCT04598672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970280|NCT01759537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This was a split mouth study design in which the same patient was used for both arms.|f|f|t|f
33880059|NCT03613948|||CASE_ONLY||CROSS_SECTIONAL|||||||
33880060|NCT06005961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880061|NCT04788043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880062|NCT05743465|||COHORT||RETROSPECTIVE|||||||
33880063|NCT02190773|||CASE_CONTROL||PROSPECTIVE|||||||
33880064|NCT00019409|RANDOMIZED|||TREATMENT||||||||
33880065|NCT03216356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970281|NCT01780727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Arm 1 receives normal saline per the standard of care determined by the anesthesiologist.~Arm 2 receives normal saline or furosemide per the results of the intraoperative echocardiogram."|f|f|f|t
33970282|NCT05743790|RANDOMIZED|CROSSOVER||OTHER||NONE||We originally enrolled 196 participants and collected saliva samples for screening to participate in the intervention. Then we enrolled 76 participants in the intervention study. These participants were randomly assigned to one of two parallel arms in the intervention study.||||
33970283|NCT04052100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33970284|NCT05499364|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to the control or intervention groups randomly.||||
33970285|NCT01532882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970286|NCT03742739|||COHORT||PROSPECTIVE|||||||
33970287|NCT00624481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970288|NCT02363751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970289|NCT00416403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970290|NCT00604110|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33970291|NCT06186440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970292|NCT04758871|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled trial||||
33970293|NCT01388647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970294|NCT01063179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970295|NCT05494554|||COHORT||PROSPECTIVE|||||||
33970296|NCT06302855|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970297|NCT04155983|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study Design: Prospective RCT~Study Groups:~US Guided, Anesthesia Administered Adductor Canal Block (High ACB) Intra-Operative, Surgeon Administered Adductor Canal Block (Low ACB)~Model- Cluster Randomization There will be two surgeons collecting data for this study; Dr. Mann (principal investigator) \& Dr. Moskal. Each surgeon will begin collecting data on opposite arms of the study. Surgeon A will perform 35 consecutive High-ACB knees while Surgeon B performs 35 Low-ACB knees. After performing 35 knees under either the High-ACB or Low-ACB protocol, Surgeon A and Surgeon B will switch arms and perform an additional 35 consecutive knees in the opposite arm. At trial's end, each surgeon will have performed 35 TKAs using the High-ACB and Low-ACB protocol yielding a total of 70 patients in each arm."||||
33970298|NCT00120159|||||RETROSPECTIVE|||||||
33970299|NCT05295693|||COHORT||PROSPECTIVE|||||||
33970300|NCT00988234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33970301|NCT03599310|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33970302|NCT03409679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970303|NCT05464732|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33970304|NCT01438554|NA|SINGLE_GROUP||OTHER||NONE||||||
33970305|NCT06091410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||prospective, randomized clinical cohort study||||
34069836|NCT06538857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a single-blind trial in which investigators, and investigators' staff, will be aware of the treatment allocation (CEB-01 or not, but only once the tumour/s removal has/have been completed). The participants, medical staff of the sponsor or data analysts will remain blinded to each participant's assigned study treatment from the time of randomisation until database lock.|Participants will be allocated in a 2:1 ratio to two treatment arms: (Arm 1) standard surgery and CEB-01 implant after surgery, or (Arm 2) standard surgery without implant.|t|f|f|t
34069837|NCT00196248|||DEFINED_POPULATION||PROSPECTIVE|||||||
34069838|NCT00479830|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33880066|NCT06010966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970306|NCT01944228|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33970307|NCT06011421|||CASE_CONTROL||PROSPECTIVE|||||||
33970308|NCT00004110||||TREATMENT||NONE||||||
33758568|NCT05900856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||ultrasound cavitation and low caloric diet regimen|t|f|f|t
33758569|NCT04177680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758570|NCT04824079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880067|NCT05697458|||COHORT||PROSPECTIVE|||||||
33880068|NCT05268926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880069|NCT03622827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880070|NCT03443154|||COHORT||PROSPECTIVE|||||||
33880071|NCT04470700|||COHORT||PROSPECTIVE|||||||
33880072|NCT04476238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33880073|NCT02432768|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33880074|NCT03726645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|FMT type (donor/own feces) randomization is done by a study nurse.||t|t|t|f
33880075|NCT00288080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880076|NCT01487512|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880077|NCT01175798|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880078|NCT01246791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880079|NCT04726371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will employ a cluster-randomized trial design with \~200 group homes randomized to the implementation of Tailored Best Practices (TBP) compared to \~200 group homes randomized to Generic Best Practices (GBP). Randomization will occur at the level of the group home stratified by group home type (SMI versus ID/DD), incident COVID-19 infection in the staff and residents (high incidence versus low incidence), and race/ethnicity (proportion non-Hispanic Caucasian versus other). TBP and GBP will be delivered within each agency as part of routine training activities. TBP sites will receive coaching specific to the setting, staff, and residents. The best practice implementation fidelity (i.e. staff and residents participating in recommended screening, isolating, contact tracing, PPP protocols, and vaccine acceptance), and COVID-19 incidence are co-primary outcomes with group home as the unit of analysis. The outcomes will be assessed at baseline, 3, 6, 9, 12, and 15 months."||||
33880080|NCT01069497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880081|NCT02163018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970309|NCT04207086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880082|NCT00066079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880083|NCT04195828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880084|NCT02570633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33880085|NCT05493020|||COHORT||PROSPECTIVE|||||||
33970310|NCT04576806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will be blinded during analysis but unblinded during study performance.|RCT, unblinded|f|f|f|t
33880086|NCT00250783|||CASE_CONTROL||PROSPECTIVE|||||||
33880087|NCT03355183|NA|SINGLE_GROUP||SCREENING||NONE||||||
33970311|NCT04402749|||OTHER||RETROSPECTIVE|||||||
33970312|NCT03670979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880088|NCT05269394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Interventional|t|t|t|t
33880089|NCT05493319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessments before and after the intervention will be performed by a physical therapist blinded to the allocation of participants in each group.|Single-blind randomized clinical trial: interventional group and usual care group|f|f|f|t
33880090|NCT01345071|||COHORT||PROSPECTIVE|||||||
33880091|NCT04082000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)|Double-blind|t|f|t|t
33880092|NCT04450485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and outcomes assessor are blinded to the type of surgical approach.|Patients planned for fast track protocol applied total knee arthroplasty randomized into two groups by a computer program to generate random numbers and assign participants to either to mini mid-vastus or medial para-patellar surgical approach group|t|f|f|t
33880093|NCT05713643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880094|NCT05534932|RANDOMIZED|FACTORIAL||TREATMENT||NONE|No blinding between arms|Subjects will be randomized at baseline into one of two arms for the purposes of the sub-study. One arm will receive the GDMP, which includes the RPM program. The other arm will not receive the GDMP and will continue thier usual standard of care course per thier treating physician.||||
33880095|NCT02956668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880096|NCT02542475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880097|NCT04750551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880098|NCT04152096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will perform the assessment of primary, secondary efficasy and safety parameters||f|f|f|t
33880099|NCT03225300|NA|SINGLE_GROUP||TREATMENT||NONE||A prospectively single arm in single institution.||||
33880100|NCT03665285|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 will utilize a 3 + 3 design to explore escalating dose levels. Phase 2 Dose Expansion will further evaluate the safety, tolerability, preliminary efficacy, and PK/PD activity of NC318 at the RP2D utilizing a Simon 2-stage design.||||
33880101|NCT03665402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880102|NCT01787916|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33880103|NCT03046355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880104|NCT00191451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880105|NCT06383923|||COHORT||PROSPECTIVE|||||||
33880106|NCT00176280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970313|NCT00669578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970314|NCT05794399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The radiologist who will assess the presence or absence of left ventricular (LV) thrombus will be blinded.|1:1 parallel study design|f|f|f|t
33970315|NCT06045585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970316|NCT04511364|NA|SINGLE_GROUP||OTHER||NONE||||||
33970317|NCT03715595|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33970318|NCT04551079|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33970319|NCT03119532|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33970320|NCT06438783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758571|NCT00141739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758572|NCT02225730|||COHORT||PROSPECTIVE|||||||
33758573|NCT05848479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758574|NCT03970239|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758575|NCT00496899|||COHORT||CROSS_SECTIONAL|||||||
33758576|NCT00263718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758577|NCT04560166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758578|NCT00261989|||||RETROSPECTIVE|||||||
33758579|NCT03974659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Prospective Randomized, Double-Blind Clinical Trial|t|f|t|t
34069839|NCT02461056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069840|NCT04551768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069841|NCT04714645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be an external assessor, who will be blinded during the clinical assessments.||f|f|f|t
34069842|NCT03571178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069843|NCT04009161|||COHORT||PROSPECTIVE|||||||
34069844|NCT01526434|||COHORT||PROSPECTIVE|||||||
33758580|NCT03026218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758581|NCT05541562|||CASE_CONTROL||RETROSPECTIVE|||||||
33758582|NCT04860947|||CASE_ONLY||PROSPECTIVE|||||||
33758583|NCT03051503|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33758584|NCT02640248|||COHORT||PROSPECTIVE|||||||
33758585|NCT05282043|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33758586|NCT04857203|||COHORT||PROSPECTIVE|||||||
33758587|NCT00340457|||CASE_CONTROL||RETROSPECTIVE|||||||
33758588|NCT05987306|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pre and posttest design.||||
33758589|NCT01473693|||COHORT||PROSPECTIVE|||||||
34069845|NCT06307405|||CASE_ONLY||RETROSPECTIVE|||||||
34069846|NCT02075008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758590|NCT01497522||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758591|NCT03980925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758592|NCT02459366|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758593|NCT05403164|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758594|NCT00142779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758595|NCT05827952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069847|NCT01314027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069848|NCT02481752|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33758596|NCT05498506|||COHORT||RETROSPECTIVE|||||||
33758597|NCT02475785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758598|NCT05078151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758599|NCT03083938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758600|NCT01221948|NA|SINGLE_GROUP||TREATMENT||NONE||Boston Scientific Vercise Deep Brain Stimulation system will be implanted and each patient will serve as its own control.||||
33758601|NCT00006364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758602|NCT05460923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758603|NCT01857401|||CASE_ONLY||PROSPECTIVE|||||||
33758604|NCT00309530|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33758605|NCT05527067|||COHORT||PROSPECTIVE|||||||
33758606|NCT02962479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880107|NCT06351943|||OTHER||CROSS_SECTIONAL|||||||
33880108|NCT00669045|||COHORT||PROSPECTIVE|||||||
33758607|NCT05688748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758608|NCT01551199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758609|NCT02142647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33758610|NCT02826200|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33758611|NCT05378243|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Randomized crossover trial||||
33764900|NCT03060564|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33764901|NCT02909036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880109|NCT04466982|||COHORT||PROSPECTIVE|||||||
33894484|NCT02365428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34069849|NCT01716520|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34069850|NCT02855710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069851|NCT01038154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069852|NCT05667818|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd.~Reference preparation (R): amlodipine besylate tablets (trade name: Norfloxacin ®） Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd."||||
34069853|NCT02461680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069854|NCT00997347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34069855|NCT01050335|||COHORT||PROSPECTIVE|||||||
34069856|NCT04078854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants do not know that there are two types of presentations. When a potential enrollee has been identified, while still inpatient, one research associate from a group of trained residents or medical students will spend 15 to 30 minutes with the patient to enroll and give one of the two education video presentations. The patients will be randomized to one of the two presentations.|The patients will be randomized to one of the two presentations. Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.|t|f|f|f
34069857|NCT02051335|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34069858|NCT03454451|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34069859|NCT00550576|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34069860|NCT05911035|||COHORT||PROSPECTIVE|||||||
34069861|NCT00177645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069862|NCT03221179|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34069863|NCT00845936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069864|NCT00029783|RANDOMIZED|||TREATMENT||||||||
34069865|NCT03005639|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34069866|NCT00004464||||TREATMENT||||||||
34069867|NCT04231201|||COHORT||PROSPECTIVE|||||||
34069868|NCT03545620|||CASE_ONLY||PROSPECTIVE|||||||
34069869|NCT06322277|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880110|NCT02948803|RANDOMIZED|PARALLEL||PREVENTION||NONE||pre, post, follow up measurements with an intervention and control group||||
33880111|NCT00737451|||CASE_CONTROL||PROSPECTIVE|||||||
33880112|NCT02105415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880113|NCT01357486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880114|NCT04141709|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomized allocation to intervention (local ablative radiotherapy) or standard of care||||
33764902|NCT01790360|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33764903|NCT06438653|||COHORT||CROSS_SECTIONAL|||||||
33880115|NCT00739414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764904|NCT00538174|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33764905|NCT02504437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880116|NCT04830670|||CASE_CONTROL||PROSPECTIVE|||||||
33880117|NCT05210179|RANDOMIZED|PARALLEL||PREVENTION||NONE||National, Open-Label, Two Arms, Multi-Centered, Phase 2b Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination (TURKOVAC) Against SARS-CoV-2||||
33880118|NCT00488891|||COHORT||RETROSPECTIVE|||||||
33880119|NCT00273377|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33880120|NCT03025438|||CASE_ONLY||RETROSPECTIVE|||||||
33880121|NCT05430100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"A total of 4 groups will be involved in our research. These are; - Breast milk pacifiers group, - Sucrose pacifiers group, - Pacifiers group, - Control group. The numbers to be given to the groups will be determined by lot method. In the research, the assignment of the participants to the groups will be made using the block randomization method. Randomization will be provided by the researcher using microsoft excel. By typing the numbers from 1 to 100 in cell A, adding the RAND() operation to cell B, the number will be generated in all rows from 1 to 100. Then, the sorting process will be performed on the numbers in cell B and a random list will be created in column A. After evaluating the inclusion criteria and obtaining consent from the participants, it will be determined which group the preterm newborn will be in."|f|f|f|t
33880122|NCT03429192|||COHORT||RETROSPECTIVE|||||||
33880123|NCT01109784|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33880124|NCT06501755|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33880125|NCT00049673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880126|NCT05392491|||COHORT||RETROSPECTIVE|||||||
33880127|NCT00028912||||TREATMENT||||||||
33880128|NCT01850056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880129|NCT03639714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33880130|NCT03011957|||COHORT||PROSPECTIVE|||||||
33880131|NCT04427631|NA|SINGLE_GROUP||TREATMENT||NONE|It is too difficult to blind the assessor in thsi instance.|single arm study offering all children with glue ear currently waiting on grommet operation lists, an invitation to be involved in this research study for hearing support (bone conduction headphones, a microphone and an app which can be delivered remotely)||||
33880132|NCT00174083|||DEFINED_POPULATION||OTHER|||||||
33880133|NCT06267027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RANDOMIZED CONTROLLED STUDY|f|f|t|f
33880134|NCT05714683|||COHORT||PROSPECTIVE|||||||
33880135|NCT03709381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||At t=0, 9 ml of blood will be collected for measurement of VEGF, ACTH, and cortisol levels. Then, 1 mcg of cosyntropin (a synthetic ACTH analog) will be administered intravenously (IV). Samples for measurement of cortisol and VEGF levels will be obtained at t=30 and 60 minutes (6 ml of blood collected at both times). After the 60 minute blood draw, 250 mcg of cosyntropin will be administered IV. At t=90, 120, 150 , and 180 minutes, samples for measurement of cortisol and VEGF levels will be obtained (6 ml of blood collected at each time).||||
33880136|NCT03943212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel-Group, Randomized Controlled Trial|t|f|f|f
33880137|NCT00658151|||CASE_CONTROL||PROSPECTIVE|||||||
33880138|NCT01317589|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880139|NCT02447315|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33880140|NCT00699517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894485|NCT01835522|||COHORT||CROSS_SECTIONAL|||||||
33894486|NCT01059149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894487|NCT03582449|||COHORT||PROSPECTIVE|||||||
33894488|NCT06263712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894489|NCT02718820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894490|NCT00481481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880141|NCT05785312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded|Since this a comparative study, therefore after recruiting patients, the patients will be randomly allocated parallelly to the two arms. Arm One will will be Face-to-Face EMDR Therapy, in which the patients will receive standard EMDR therapy in a face-to-face meeting with the therapist. Arm two will be the online EMDR Therapy, in which the patients will receive EMDR therapy online via video conferencing. The patient will be randomly selected assigned to each arm with 1:1 allocation.|t|f|f|f
33880142|NCT02364128|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33880143|NCT06133283|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will utilize a randomized controlled design||||
33880144|NCT01535573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880145|NCT01002807|RANDOMIZED|CROSSOVER||||NONE||||||
33894491|NCT02424149|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34069870|NCT00162084|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34069871|NCT04711343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069872|NCT01088711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069873|NCT03528460|||COHORT||RETROSPECTIVE|||||||
34069874|NCT00642954|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069875|NCT03636048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069876|NCT00779753|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069877|NCT05576428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069878|NCT02404129|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34069879|NCT05695963|NA|SINGLE_GROUP||OTHER||NONE||||||
34069880|NCT05689853|NA|SEQUENTIAL||TREATMENT||NONE||||||
34069881|NCT04628000|||COHORT||RETROSPECTIVE|||||||
34069882|NCT06462170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069883|NCT05769478|NA|SINGLE_GROUP||TREATMENT||NONE||before-after study that will measure neuromuscular jitter before and after administration of amifampridine||||
34069884|NCT05177549|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069885|NCT05424354|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Prospective, Multi-Center, Open Label, Comparison, Human, Interventional||||
34069886|NCT04272983|||OTHER||PROSPECTIVE|||||||
34069887|NCT06097871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the subject and the investigator will be blinded to the subject's group allocation. All outcomes will be assessed by the blinded investigator.|1-1 randomization to placebo or active treatment|t|f|t|t
34069888|NCT04325867|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All patients with severe cardiovascular disease benefit from this project||||
34069889|NCT02350062|||COHORT||PROSPECTIVE|||||||
34069890|NCT00623961|||COHORT||PROSPECTIVE|||||||
33758612|NCT03496662|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A: 16 patients will be randomized to 1:1 to control or experimental arm through block randomization without stratification factors. After 8 evaluable patients have been enrolled and treated on the control arm, subsequent patients are enrolled only into the experimental arm.||||
33758613|NCT01886911|RANDOMIZED|PARALLEL||||NONE||||||
33758614|NCT03766256|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33758615|NCT04049318|||COHORT||PROSPECTIVE|||||||
33758616|NCT01210833|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758617|NCT03829163|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized prospective, parallel, voluntary study to test the effectiveness of a newly designed stair-climbing walker on post-acute care patients with hip fractures. Consecutive patients participating in the study will be given participant numbers 1- 40 (odd numbered participant numbers = conventional walker, even numbered participant numbers = HAW) to protect their privacy and to eliminate selection bias. They each will receive training on each assistive device via their assigned inpatient physical therapist. The HAW should not be kept in a vehicle overnight or in temperatures below 45 degrees due to possible hydraulic system failures. A standard walker will be offered along with the HAW to the even numbered patients to ensure that the patient will have an assistive device after the study is completed or if there was an issue with the HAW during the study and needed to be discontinued.||||
33758618|NCT02295839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33758619|NCT00491985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758620|NCT02339883|||COHORT||CROSS_SECTIONAL|||||||
33758621|NCT04864002|||OTHER||CROSS_SECTIONAL|||||||
33758622|NCT01938833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758623|NCT05059379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758624|NCT01184365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758625|NCT00946439|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33758626|NCT05847179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758627|NCT02617225|||COHORT||CROSS_SECTIONAL|||||||
33758628|NCT02614495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758629|NCT05079022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758630|NCT02335190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758631|NCT04065100|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||pregnant women with and without PCOS will be recruited in mid pregnancy. the newborn will be examined for sebum production and the two groups compared with each other and with and maternal testosterone levels.||||
33758632|NCT02775955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758633|NCT03680625|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel/2 groups||||
33758634|NCT04617132|||CASE_CONTROL||PROSPECTIVE|||||||
33758635|NCT00089141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758636|NCT02292017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758637|NCT03721120|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758638|NCT03446014|||COHORT||PROSPECTIVE|||||||
33758639|NCT05874908|||COHORT||PROSPECTIVE|||||||
33758640|NCT03656601|||COHORT||CROSS_SECTIONAL|||||||
33970321|NCT02400905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970322|NCT01277328|||COHORT||PROSPECTIVE|||||||
33970323|NCT05781477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069891|NCT00921635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758641|NCT03533426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the data collector will be blinded to the study groups||f|f|f|t
33758642|NCT06285513|||CASE_ONLY||PROSPECTIVE|||||||
33758643|NCT05772975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33758644|NCT04984707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33758645|NCT02927548|||COHORT||RETROSPECTIVE|||||||
33880146|NCT03961282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are 3 types of door alterations in a simulated residential setting being tested: Standard (conforms to conventional residential building practices); Enhanced (conforms to Americans with Disabilities Act or ADA residential building practices or recommendations); and Co-design.||||
33880147|NCT00556660|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33880148|NCT05968781|||COHORT||PROSPECTIVE|||||||
33880149|NCT00017862||||TREATMENT||||||||
33880150|NCT01762280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880151|NCT02357498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880152|NCT06107075|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)- Treatment will be blinded according to the randomisation schedule by a researcher who has no other involvement in the study.|Randomised, placebo-controlled, double-blind, parallel groups design|t|f|t|t
33880153|NCT05838638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to either an intervention or control group.||||
33880154|NCT05812989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880155|NCT06063187|||COHORT||CROSS_SECTIONAL|||||||
33880156|NCT05112783|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33880157|NCT01717365|||COHORT||RETROSPECTIVE|||||||
33880158|NCT01789970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880159|NCT00150592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880160|NCT00293579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880161|NCT03726684|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single center, single-armed, parallel design with four laboratory sessions for CI subjects||||
33880162|NCT00229307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880163|NCT04609189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33880164|NCT04192578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33880165|NCT00935558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880166|NCT04828408|||COHORT||PROSPECTIVE|||||||
33880167|NCT01898065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880168|NCT01507272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880169|NCT00699907|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880170|NCT01975168|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33880171|NCT01353703|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880172|NCT00163228|||||PROSPECTIVE|||||||
33880173|NCT04775277|||CASE_CONTROL||PROSPECTIVE|||||||
33880174|NCT01262846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880175|NCT06095739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880176|NCT00353418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880177|NCT02979431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880178|NCT01056250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880179|NCT04732286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880180|NCT00002778||||TREATMENT||NONE||||||
33880181|NCT02117765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880182|NCT00809107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880183|NCT04606459|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the nature of the intervention, there is not possibility to use a blinded design|In the current randomized, controlled, parallel-groups trial, patients will be randomized to guideline-directed optimal medical therapy with coronary sinus Reducer (Neovasc Reducer™ System) implantation or guideline-directed medical therapy alone.||||
33880184|NCT03187769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758646|NCT05635578|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Single (Participant) sleep, life quality|reiki|t|f|f|f
33758647|NCT02598986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33758648|NCT02769026|||COHORT||PROSPECTIVE|||||||
33758649|NCT03310073|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33758650|NCT05852132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33758651|NCT05521425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After completion of written consent, participants were randomly assigned to either intervention or control group. Outcomes assessors (and facilitators for phone interview for follow-up action) were independent, not knowing the condition of participants.|Non-inferiority, Paralleled, Randomized Controlled Trial|f|f|f|t
33758652|NCT06356194|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758653|NCT04390984|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All the subjects will administrated with apatinib and gefitinib following the same sequence to assess the effect of gefitinib on the pharmacokinetics of apatinib in NSCLC patients||||
33758654|NCT06579170|||COHORT||PROSPECTIVE|||||||
33758655|NCT05095272|NA|SINGLE_GROUP||OTHER||NONE||||||
33758656|NCT02522143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758657|NCT02300857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33880185|NCT02236780|||COHORT||RETROSPECTIVE|||||||
33880186|NCT00911989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880187|NCT04674631|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880188|NCT03839459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880189|NCT03506542|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomized and have phacotrabeculectomy augmented with either OLO (Ologen) or MMC (Mitomycin C).||||
33758658|NCT00312793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758659|NCT00490256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880190|NCT03665142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly divided into 2 groups. A randomized list is prepared in a computer environment by a statistician for randomization. In this list, the odd numbers for the control group and the KT group were given double numbers. The group identification is printed on sequentially numbered cards placed in sealed envelopes. After enrollment, the numbered envelope was opened by the patient and the blind investigator.||||
33880191|NCT01119456||SEQUENTIAL||TREATMENT||NONE||||||
33880192|NCT05261620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880193|NCT06282120|||CASE_CONTROL||PROSPECTIVE|||||||
33880194|NCT04797845|NA|SINGLE_GROUP||OTHER||NONE||||||
33880195|NCT00883714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33880196|NCT03299647|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880197|NCT05813509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880198|NCT03294018|||CASE_ONLY||PROSPECTIVE|||||||
33880199|NCT02072590|||COHORT||PROSPECTIVE|||||||
33880200|NCT01780883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880201|NCT01848535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069892|NCT05469620|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||2 by 2 factorial design, consisting of nutrition education and meal kit prescription.||||
34069893|NCT04970407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069894|NCT06212284|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34069895|NCT04105842|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will be masked to the lens type (brand) they will be wearing during the study in order to reduce bias towards or against this product|||||
34069896|NCT03692923|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069897|NCT01066663|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34069898|NCT02228018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069899|NCT00640731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880202|NCT05771298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880203|NCT01665118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880204|NCT03563937|||COHORT||RETROSPECTIVE|||||||
33880205|NCT00667615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880206|NCT04057625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758660|NCT03579329|||COHORT||PROSPECTIVE|||||||
33758661|NCT01265602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758662|NCT00831064|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33880207|NCT01571115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880208|NCT06345300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880209|NCT03622099|||CASE_ONLY||PROSPECTIVE|||||||
33880210|NCT03279003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880211|NCT03093038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880212|NCT05495893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880213|NCT05066256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pre-experimental study||||
33880214|NCT06431061|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single||t|f|f|f
33880215|NCT03847142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Through the randomized controlled trial component, there will be 2 arms, which include the ASTHMAXcel intervention and usual care delivered through the outpatient primary care setting.||||
33880216|NCT03550066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33880217|NCT02848196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880218|NCT00798226|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880219|NCT00538720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880220|NCT00000896||||TREATMENT||NONE||||||
33880221|NCT00271323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880222|NCT03082365|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33880223|NCT04219150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880224|NCT05381064|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33880225|NCT06216444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069900|NCT00821197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34069901|NCT02950038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069902|NCT01210482|||CASE_ONLY||PROSPECTIVE|||||||
34069903|NCT03377062|||COHORT||PROSPECTIVE|||||||
34069904|NCT00844779|||CASE_CONTROL||PROSPECTIVE|||||||
34069905|NCT00632125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069906|NCT03885245|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34069907|NCT04035122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization list is blind to anyone involved in informing potential study participants.|The study is a parallel-group randomized clinical trial using a double-blind study design. The enrolled patients will be randomly assigned to the 2 groups using an automated computerized randomization program. Patients will be informed about the research and will be asked to fill in the informed consent form. The patient's basic characteristics (age, sex, duration of the illness, marital status and educational background) will be recorded. Randomization will be performed using a randomization list, so patients will be randomized in a 1:1 ratio in the intervention or control group.|t|t|t|t
34069908|NCT03286621|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34069909|NCT04671394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients in the control group are treated by the same operator and received a sham laser treatment in which, after pocket irrigation with the photosensitizer solution, the laser tip is inserted in the pockets but the laser unit is kept off.||t|f|f|t
34069910|NCT00005069||||TREATMENT||||||||
34069911|NCT00635921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069912|NCT03352505|||CASE_ONLY||PROSPECTIVE|||||||
33880226|NCT00527579|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880227|NCT01799915|||COHORT||PROSPECTIVE|||||||
33880228|NCT06438172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880229|NCT00626938|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880230|NCT02501278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758663|NCT01060553|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758664|NCT03619590|||COHORT||PROSPECTIVE|||||||
33758665|NCT02159443|||COHORT||PROSPECTIVE|||||||
33758666|NCT01412801|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880231|NCT06093139|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33880232|NCT04188184|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33880233|NCT05350826|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33880234|NCT01090401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880235|NCT04329195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880236|NCT00207467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758667|NCT03043001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758668|NCT03500055|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Only the primary investigators will be able to be blinded for this study. The surgeon is unable to be blinded and since the patient is awake during c-sections, blinding will be impossible.|Single center, randomized controlled trial|f|f|t|t
33758669|NCT02642198|||CASE_ONLY|||||||||
33758670|NCT02498405|||CASE_ONLY||PROSPECTIVE|||||||
33880237|NCT01662895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758671|NCT03495388|||OTHER||PROSPECTIVE|||||||
33880238|NCT02472132|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880239|NCT04446364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880240|NCT04597879|||CASE_CONTROL||PROSPECTIVE|||||||
33880241|NCT05409547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880242|NCT06148558|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, 12-week study. 39 female subjects were recruited, 35 to 60 years, Fitzpatrick Skin Type I-VI, with moderate-severe overall facial photodamage.||||
33880243|NCT05143073|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33880244|NCT05813197|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33880245|NCT01178658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880246|NCT04934761|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33880247|NCT06268691|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomised trial for the application of a new vector control tool (insecticide coating of water containers) was conducted in the metropolitan area of Cúcuta, Colombia. Each cluster comprising approximately 2,000 dwellings.||||
33880248|NCT06277388|||COHORT||RETROSPECTIVE|||||||
33880249|NCT00772668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880250|NCT00622986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880251|NCT01393197|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33880252|NCT05354986|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|test and placebo toothpastes would be identical|Two consecutive parallel, double-blind, randomized, placebo-controlled, 2-week, clinical trials|t|t|t|t
33880253|NCT03570112|||CASE_CONTROL||PROSPECTIVE|||||||
33880254|NCT03308396|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Phase Ib/II||||
33880255|NCT02301403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880256|NCT01692548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880257|NCT04831333|||OTHER||CROSS_SECTIONAL|||||||
33880258|NCT04036409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880259|NCT04894656|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970324|NCT02468661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The study started as a non-randomized study, and was to move into randomized part in phase II. However the study was stopped after cohort #3 in the phase I part and so never moved into phase II.|The study started as a single assignment study which was to move to a parallel design (3 arms) but the study was stopped after cohort #3 in the phase I part and so never moved into phase 2.||||
33970325|NCT06442683|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Multicentered randomized controlled trial.|f|t|f|t
33970326|NCT01821027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970327|NCT04653870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970328|NCT04008342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluations were performed by a blind investigator.|An experimental pre- and postintervention design was used. The participants were recruited from philanthropic LTC institutions for aged people and allocated in experimental group and control group.|f|f|f|t
33970329|NCT03429296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Zelen : patients will be randomized according to the Zelen randomization design (as described in Zelen M. Randomized consent designs for clinical trials: An update. Stats in Med. 1990;9:645-656)"||||
33970330|NCT03515785|||CASE_ONLY||OTHER|||||||
33970331|NCT00737321|||CASE_ONLY||PROSPECTIVE|||||||
33970332|NCT05906264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Compared to control group, interventional group will be provided tele-intervention every week, checking compliance and encouraging the rehabilitation.||||
33970333|NCT03357432|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A crossover design where subject are randomized to consume all 3 intervention doses.||||
33970334|NCT00548353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970335|NCT02472977|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069913|NCT05157555|||CASE_ONLY||CROSS_SECTIONAL|||||||
34069914|NCT02309450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758672|NCT00308256|RANDOMIZED|PARALLEL||||NONE||||||
33758673|NCT01239667|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33758674|NCT01635608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33880260|NCT02678858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880261|NCT06370455|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33880262|NCT06247891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880263|NCT05956106|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants groups|Case-Control Study||||
33880264|NCT01662583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33880265|NCT04081194|||CASE_CONTROL||PROSPECTIVE|||||||
33880266|NCT04481776|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33880267|NCT05195697|||COHORT||RETROSPECTIVE|||||||
33880268|NCT04451629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Parallel Assignment a experimental design with pre test and post test|Parallel Assignment a experimental design with pre test and post test|f|f|f|t
33758675|NCT02010476|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880269|NCT06391697|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33880270|NCT04057339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33880271|NCT03653065|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33880272|NCT04947488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880273|NCT03099889|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participant in intervention arm signed an informed consent umasking the exercise intervention, participants in the control arm have already consented to ongoing outcomes assessment and yearly surveys regarding physical activity and other lifestyle activities|randomized consent design|f|t|t|t
33880274|NCT05261269|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33758676|NCT03612648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758677|NCT01991366|||CASE_CONTROL||RETROSPECTIVE|||||||
33758678|NCT04044456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||participants meeting inclusion criteria will be randomized to either treatment (Goal management training and attention training) or control (Brain Health Workshop and national geographic movies).|f|f|f|t
33880275|NCT05069987|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomly assigned, in a 1:1 ratio, to either procedural VR-immersion or non-VR control.||||
33880276|NCT01317810|||COHORT||PROSPECTIVE|||||||
33880277|NCT03201185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open-label|f|f|f|t
33880278|NCT00513032|||CASE_CONTROL||PROSPECTIVE|||||||
33880279|NCT06202300|||COHORT||PROSPECTIVE|||||||
33880280|NCT03671031|||COHORT||RETROSPECTIVE|||||||
33880281|NCT04304027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880282|NCT04871529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880283|NCT02865382|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33880284|NCT05097807|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants know their intervention because they are informed to use their smartphone as expected.|Four parallel group, each with a different intervention, of which two are shallow reading in social media (different type), the other two are common use of smartphone.|f|t|t|f
33880285|NCT02315365|||COHORT||PROSPECTIVE|||||||
33880286|NCT03783520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33880287|NCT00993031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758679|NCT04492358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758680|NCT00455585|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880288|NCT00209339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880289|NCT04505228|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880290|NCT02834637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880291|NCT00586573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880292|NCT01550497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880293|NCT02462473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880294|NCT02037659|||CASE_ONLY||PROSPECTIVE|||||||
33880295|NCT04397094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880296|NCT03589404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|investigator|prospective, cohort,double blind||||
33880297|NCT05537714|||OTHER||CROSS_SECTIONAL|||||||
33880298|NCT02085499|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33880299|NCT01617837|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880300|NCT04084886|||CASE_CONTROL||PROSPECTIVE|||||||
33880301|NCT04503577|||COHORT||PROSPECTIVE|||||||
33880302|NCT01789450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880303|NCT04145401|||COHORT||PROSPECTIVE|||||||
33880304|NCT05898958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33880305|NCT01338415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880306|NCT04407559|||COHORT||RETROSPECTIVE|||||||
33880307|NCT06539234|||COHORT||PROSPECTIVE|||||||
33880308|NCT03403205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is rater-blinded for the Unified Wilson Disease Rating Scale (UWDRS) assessment only.||f|f|f|t
33880309|NCT06042933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33880310|NCT03756038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomly assigned to either the experimental condition (lorazepam) or the control condition (placebo).|t|t|t|t
34069915|NCT04985227|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled Trial. One group has no intervention. Second group will be provided with a weighing scale and ask to report the infant's weight back to the provider.||||
34069916|NCT00459719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880311|NCT03473431|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomized, double-blind, dose-controlled follow-up study|t|t|t|t
33880312|NCT00928538|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33880313|NCT03598166|RANDOMIZED|PARALLEL||SCREENING||NONE||Eligible patients will be randomized 1:1 to the intervention or control group||||
33880314|NCT02381119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880315|NCT05399459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880316|NCT00383045|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33880317|NCT01188083|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33970336|NCT03534297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized, blinded, placebo-controlled study. Treatment allocation (to active or placebo treatment groups) will be blinded to all study participants, personnel, and investigators. Only the randomization statistician, drug labeling personnel and the medical monitor will be unblinded to the treatment assignment (in the event of an emergency, a scratch off label can be removed unmasking the treatment assignment to the PI and Medical Monitor).|Subjects will be assigned to receive either dapansutrile capsules or placebo capsules in a 4:1 ratio within each Cohort.|t|t|t|f
33970337|NCT05124756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970338|NCT01148290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970339|NCT03216733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970340|NCT04788589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970341|NCT01694511|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33970342|NCT01434459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069917|NCT01605825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34069918|NCT06329986|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34069919|NCT06612710|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34069920|NCT00461097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069921|NCT03386188|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069922|NCT01305707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34069923|NCT00658892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880318|NCT00713583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069924|NCT03290391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880319|NCT04293770|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective Clinical Trial||||
34069925|NCT01808261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069926|NCT00383370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880320|NCT05339672|||CASE_CROSSOVER||PROSPECTIVE|||||||
34069927|NCT06137820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069928|NCT01863342|||COHORT||PROSPECTIVE|||||||
33880321|NCT03726164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880322|NCT04327388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880323|NCT04607083|||COHORT||PROSPECTIVE|||||||
33880324|NCT03649295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880325|NCT00015600|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33880326|NCT03315767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880327|NCT01841333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880328|NCT02837315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880329|NCT01030510|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33880330|NCT03283176|||COHORT||PROSPECTIVE|||||||
33880331|NCT03887754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Children were divided into four groups.Twenty autistic children in each group. They followed up for 2 years.|f|f|f|t
33880332|NCT00132132|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880333|NCT05072132|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33880334|NCT02816918|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33880335|NCT03285750|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880336|NCT00243659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880337|NCT03536455|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880338|NCT00993746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880339|NCT02921971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880340|NCT00513760|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33970343|NCT03799887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069929|NCT01064362|||COHORT||RETROSPECTIVE|||||||
34069930|NCT01821274|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34069931|NCT01962194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069932|NCT03033160|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
34069933|NCT03291028|||COHORT||RETROSPECTIVE|||||||
33970344|NCT02245191|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33970345|NCT02415959|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33970346|NCT00905489|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970347|NCT06441565|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Participants will be randomly assigned in a 1:1 ratio to either the fruquintinib monotherapy group (control group) or the fruquintinib plus HAI-FOLFOX treatment group (experimental group)||||
33970348|NCT04648761|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will have their biological treatment titrated via the OPTIMAL algorithm and a control group will continue their biological treatment unchanged.||||
34069934|NCT02728284|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880341|NCT02977169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880342|NCT02896595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33880343|NCT01527474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880344|NCT01875965|||CASE_CONTROL||PROSPECTIVE|||||||
33880345|NCT05132244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in Group 1 can view their glucose data in real-time from the continuous glucose monitor (CGM) whereas participants in Group 2 cannot. Participants in Groups 1 and 2 will NOT be masked to the anti-cancer or anti-hyperglycemic treatment they receive.||t|f|f|f
33880346|NCT02991092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33880347|NCT01197287|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33880348|NCT00942474|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33880349|NCT04693000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880350|NCT01375764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069935|NCT04886297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34069936|NCT02460432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069937|NCT00001013||PARALLEL||TREATMENT||||||||
34069938|NCT03843450|||OTHER||PROSPECTIVE|||||||
34069939|NCT00428428|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
34069940|NCT05089812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split-mouth study|t|f|f|f
33758681|NCT05029505|||COHORT||RETROSPECTIVE|||||||
33758682|NCT04030858|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial with an intervention and control group comparison.||||
33758683|NCT03444233|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33758684|NCT03740308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded study (Patients blinding \& Outcome-assessor blinding).||t|f|f|t
33758685|NCT02352597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758686|NCT04224324|||COHORT||PROSPECTIVE|||||||
33758687|NCT03933475|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and post intervention study||||
33758688|NCT00834106|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33758689|NCT05830994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and researchers will be blinded to allocation in the trial.|Patients will be allocated to either the group receiving G-POEM or to the control group where a sham procedure consisting of a gastroscopy with biopsy during general anaesthesia will be done. The randomization will be carried out per-operatively. A computer-generated bloc randomization with sizes of four will be applied.|t|t|t|f
33758690|NCT04012684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758691|NCT05777148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970349|NCT04188925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description||t|f|t|f
33970350|NCT05353556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study was designed as a prospective and experimental study. Participants were randomly divided into two groups; a study group and a control group. The study group will perform inspiratory muscle training at 50% of maximal inspiratory pressure (MIP), and the control group received sham training for 8 weeks.|t|f|f|t
33970351|NCT04184375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33970352|NCT05588206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970353|NCT02011594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970354|NCT04524533|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Research assistants who are collecting outcome data will be masked.||t|t|t|t
33970355|NCT00544583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970356|NCT02141178||||TREATMENT||||||||
33970357|NCT01132599||||DIAGNOSTIC||NONE||||||
33970358|NCT00697112|||COHORT||PROSPECTIVE|||||||
33970359|NCT05092334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970360|NCT05720481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or Full-Mouth Scaling and Root Planing|t|f|t|f
33970361|NCT05740670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970362|NCT02873481|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970363|NCT05137808|||COHORT||PROSPECTIVE|||||||
33970364|NCT03511859|||COHORT||PROSPECTIVE|||||||
33970365|NCT03094208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34069941|NCT00334165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34069942|NCT04892199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, Double-blinded, Parallel, Placebo-controlled, clinical trial|t|t|t|f
34069943|NCT03020277|NA|SINGLE_GROUP||OTHER||NONE||||||
34069944|NCT05266482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34069945|NCT03228940|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label exploratory||||
34069946|NCT02976402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069947|NCT03995459|||OTHER||RETROSPECTIVE|||||||
33758692|NCT01222169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758693|NCT00929825|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33764906|NCT00116402|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34069948|NCT01408901|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34069949|NCT02020889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069950|NCT03313531|||OTHER||OTHER|||||||
34069951|NCT05980897|NA|SINGLE_GROUP||TREATMENT||NONE||Alternating treatment single-subject experimental design||||
33758694|NCT05063708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a randomised double blind controlled study|t|t|f|f
33758695|NCT06193265|||COHORT||RETROSPECTIVE|||||||
33758696|NCT05867654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758697|NCT05613790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study|Participants are allocated to one of two conditions: Active or Sham.|t|t|f|t
33758698|NCT05375474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758699|NCT01619501|||COHORT||RETROSPECTIVE|||||||
33758700|NCT02230956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758701|NCT00096694|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33758702|NCT03852563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758703|NCT02785640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33758704|NCT01665703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758705|NCT02613819|NA|SINGLE_GROUP||TREATMENT||NONE||"Radiotherapy;~* Fraction schedule 1: 26Gy in 1 fraction, for tumours \< 4cm in size~* Fraction schedule 2: 42Gy in 3 fractions, for tumours \> 4cm in size"||||
33758706|NCT05323617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758707|NCT05861128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880351|NCT04750538|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34069952|NCT05041803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069953|NCT03448172|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34069954|NCT05680428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069955|NCT05298436|||COHORT||PROSPECTIVE|||||||
33758708|NCT01728519|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33880352|NCT04926974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880353|NCT03213873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Investigator and outcome assessors are masked to group allocation at baseline assessment. Care providers are masked to results of the assessments.~Participants are masked to the studied intervention/treatment."||t|t|t|t
33880354|NCT03405623|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33880355|NCT03678805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880356|NCT00448188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880357|NCT02474329|||COHORT||PROSPECTIVE|||||||
33880358|NCT06221163|||OTHER||OTHER|||||||
33880359|NCT06538701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880360|NCT01698528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880361|NCT05168358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880362|NCT03269760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880363|NCT04992728|||COHORT||PROSPECTIVE|||||||
33880364|NCT03715283|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33880365|NCT02394977|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33894492|NCT00540215|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33894493|NCT04294758|||OTHER||PROSPECTIVE|||||||
33894494|NCT03431610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069956|NCT01317498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069957|NCT05307679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069958|NCT01058291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880366|NCT03784014|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"MULTISARC is a randomized multicenter study assessing whether high throughput molecular analysis (next generation sequencing exome - NGS) is feasible in advanced soft tissue sarcoma participants.~In parallel, MULTISARC aims to assess efficacy of an innovative treatment strategy guided by high throughput molecular analysis, in participants with advanced soft-tissue sarcomas.~Randomization 1:1 with 1 participant randomized in experimental Arm NGS (treatment strategy based on NGS) and 1 participant randomized in standard Arm No NGS (treatment strategy not based on NGS).~At the end of first-line treatment, participant's tumor profile of experimental Arm NGS will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant. Participants for whom a targetable genomic alteration has been identified will be proposed to enter in one of the subsequent phase II single-arm sub-trial."||||
34069959|NCT01342445|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34069960|NCT04070248|||OTHER||CROSS_SECTIONAL|||||||
34069961|NCT03126383|||COHORT||RETROSPECTIVE|||||||
34069962|NCT03461783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069963|NCT02872909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34069964|NCT05095883|||COHORT||CROSS_SECTIONAL|||||||
34069965|NCT00985660|RANDOMIZED|CROSSOVER||||NONE||||||
34069966|NCT05846568|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind|1200 patients aged 18 and above with WHO Category III rabies exposure should be enrolled as planned and randomly assigned to the GR1801 injection group and the HRIG group based on a ratio of 3: 1. The random stratification factors include time of exposure (within or beyond 24 hours), bite location (above or below the neck), and number of bites (1 or more).|t|t|t|t
34069967|NCT03831919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34069968|NCT01785017|||CASE_CONTROL||PROSPECTIVE|||||||
33880367|NCT04886687|||COHORT||PROSPECTIVE|||||||
33880368|NCT01216436|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34069969|NCT01491841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation, 3+3 design||||
33880369|NCT03315923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880370|NCT03790683|RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective, randomized interventional study||||
33880371|NCT03923205|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three groups ; healthy volunteers, individuals with T2D controlled by medication and individuals with T2D controlled by diet and lifestyle only. All groups follow same interventions assigned randomly.||||
33880372|NCT04223960|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33880373|NCT04222595|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open-label study of healthy and immunocompetent children aged 4 to 6 years||||
34069970|NCT02036684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34069971|NCT05911789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069972|NCT00495690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34069973|NCT01884545|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34069974|NCT03260114|RANDOMIZED|FACTORIAL||TREATMENT||NONE||We aim to recruit 30 persons who meet the eligibility criteria. Eligible participants will be randomized 1:1:1 to usual care (control group), to two different PAI eHealth Programs (PAI ≥ 100 and PAI = 50 to \<100) (N = 10). To provide balance across the trial arms for sex, and age groups (\<40, 40-55, \>55 years), participants will be allocated remotely by concealed minimisation.||||
33758709|NCT03266770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758710|NCT00000986||||TREATMENT||NONE||||||
33758711|NCT02181608|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758712|NCT04433364|||COHORT||PROSPECTIVE|||||||
33758713|NCT00170560|||||PROSPECTIVE|||||||
33758714|NCT02121925|||COHORT||PROSPECTIVE|||||||
33758715|NCT02323750|||COHORT||PROSPECTIVE|||||||
33758716|NCT05749055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758717|NCT03248258|||OTHER||PROSPECTIVE|||||||
33758718|NCT01127646|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33758719|NCT02366650|||COHORT||PROSPECTIVE|||||||
33880374|NCT02228863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880375|NCT03089073|||CASE_ONLY||PROSPECTIVE|||||||
34069975|NCT04729751|NA|SINGLE_GROUP||TREATMENT||NONE||Single group with 2 cohorts - ≥ 6 participants each from ALGS and PFIC.||||
34069976|NCT02298088|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinded adjudication|||||
34069977|NCT02874716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34069978|NCT03769701|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34069979|NCT00041600|||FAMILY_BASED||OTHER|||||||
33758720|NCT05024669|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33758721|NCT02801539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33758722|NCT02096172|||COHORT|||||||||
33758723|NCT01779726|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33758724|NCT02255032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758725|NCT05505630|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33758726|NCT03638206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758727|NCT02932046|||CASE_ONLY||PROSPECTIVE|||||||
33758728|NCT01928420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758729|NCT05700500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33758730|NCT01738880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33758731|NCT05414539|NA|SINGLE_GROUP||OTHER||NONE||A non-randomised single-arm feasibility study using a pre-test: post-test design.||||
33880376|NCT03618511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880377|NCT02113631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880378|NCT02163473|||CASE_CONTROL||PROSPECTIVE|||||||
33880379|NCT05086445|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33880380|NCT03011333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880381|NCT04415476|RANDOMIZED|PARALLEL||PREVENTION||NONE||Paralled Assignment||||
33758732|NCT02274857|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758733|NCT05324969|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|No marking intended given low budget and fewer research assistants available.|intervention group will receive 9 intervention sessions (via zoom or phone call) every other week and 3 texts/week to motivate lifestyle changes. Three times of rescheduling is allowed. Attention control group will receive 9 biweekly emails about other health related topics.|t|f|f|f
33758734|NCT00303056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758735|NCT04468269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758736|NCT00822081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33758737|NCT05692505|||COHORT||PROSPECTIVE|||||||
33758738|NCT05318924|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Neither participants nor investigators will know whether the participant receives a ghrelin or saline infusion, which will be prepared by independent members of the university hospital.|"The investigators will assess the effects of intravenous administration of ghrelin on dopamine signaling using a double-blind randomized cross-over design. To this end, 26 healthy participants will be infused with ghrelin (vs. saline) while we determine dopamine release (via PET imaging) and assess cerebral blood flow and functional connectivity at rest (via concurrent MR imaging).~These 26 healthy participants will be drawn from a larger sample of 100 participants (including 50 patients with major depressive disorders), who will complete a reward task battery that will be associated with fasting blood levels of ghrelin."|t|f|t|t
33758739|NCT00529750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34069980|NCT01994421|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33758740|NCT02583425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758741|NCT00992680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758742|NCT06347510|||CASE_ONLY||PROSPECTIVE|||||||
33758743|NCT04437433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758744|NCT03664479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33758745|NCT06491836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758746|NCT05166941|RANDOMIZED|PARALLEL||OTHER||NONE||it was planned in a quantitative design as a randomized controlled intervention study and in a mixed method in qualitative design in order to examine students' views on the method.||||
33758747|NCT02521662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758748|NCT03859258|||COHORT||PROSPECTIVE|||||||
33758749|NCT03521726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||20 participants receive intraluminal eradication of H. pylori. Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with High-dose PPI-amoxicillin dual therapy (rabeprazole 20 mg and amoxicillin 750 mg 4 times/day) for 14 days.||||
33758750|NCT02521402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758751|NCT01977014|||COHORT||OTHER|||||||
34069981|NCT03491787|||CASE_CONTROL||RETROSPECTIVE|||||||
33758752|NCT00552084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758753|NCT03360708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758754|NCT02400762|||COHORT||PROSPECTIVE|||||||
33758755|NCT01589172|||COHORT||PROSPECTIVE|||||||
33758756|NCT03340480|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33758757|NCT03138096|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758758|NCT00664937|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33758759|NCT02722512|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758760|NCT01566175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758761|NCT06414486|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Comparative, randomized, placebo-controlled, double-blind, monocentric interventional study in parallel groups|t|t|t|t
33758762|NCT00031486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758763|NCT00850889|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33758764|NCT03523312|NA|SINGLE_GROUP||TREATMENT||NONE||This phase II trial.||||
33758765|NCT00733499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894495|NCT04681131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894496|NCT06116383|||OTHER||PROSPECTIVE|||||||
33894497|NCT04662593|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33894498|NCT06112925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study participants and attending healthcare providers were blinded of participants' treatment group.|There were two groups of study population.|t|t|f|f
33894499|NCT00838487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894500|NCT03128463|||COHORT||PROSPECTIVE|||||||
33894501|NCT04543500|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33894502|NCT03707561|||COHORT||PROSPECTIVE|||||||
33894503|NCT05846633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants will be randomly assigned to 2 groups for intervention, none of them knows which arm will be for intervention||t|f|f|f
33894504|NCT03916068|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894505|NCT01731015|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894506|NCT03301857|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894507|NCT00332904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894508|NCT04740957|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758766|NCT05758831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation code transmitted to the pharmacy preparing the treatment. Blind labelling of treatments|multicenter, prospective, comparative (non inferiority), randomized, double blinded phase III/IV study|t|t|t|t
33758767|NCT04371146|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All participants will receive the same instructions, and neither the participants nor the experimenters are informed which drug is used. Participants must take the drug in front of the investigator, to ensure correct intake and compliance.|The investigators implement a randomized, double-blind, placebo-controlled between-subjects design, using one factor (pharmacological intervention) with three levels (reboxetine, methylphenidate and placebo).|t|f|t|f
33758768|NCT02003079|||COHORT||CROSS_SECTIONAL|||||||
33758769|NCT04762693|||COHORT||PROSPECTIVE|||||||
33758770|NCT02474290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758771|NCT04653402|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label randomised control trial||||
33758772|NCT05970822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758773|NCT02357030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758774|NCT00451165|||CASE_CONTROL||PROSPECTIVE|||||||
33758775|NCT04251884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized|t|f|f|t
33758776|NCT04421482|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a prospective study, with each infant serving as their own control. The order of each condition will be randomized to control for fatigue||||
33758777|NCT03738202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758778|NCT06100419|NA|SINGLE_GROUP||PREVENTION||NONE||case series||||
33758779|NCT05994209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758780|NCT03311282|RANDOMIZED|PARALLEL||OTHER||NONE|This was a prospective, open-label, monocentric, interventional clinical study.|"Treatment groups: bottle-fed infants~* Group 1: 10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle~* Group 2: 10 infants aged 4 months (+/- 10 days): 4-6 m bottle~* Group 3: 10 infants aged 6-10 months (+/- 10 days): 6m+ bottle Control groups: exclusively or prevalently breast-fed infants~* Group 4: 10 infants aged 0-4 weeks (+/- 7 days)~* Group 5: 10 infants aged 4 months (+/- 10 days)~* Group 6: 10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)~Number of subjects enrolled and allocated: 61 healthy infants, both male and female as follows:~Treatment groups: bottle-fed infants~* Group 1: 11 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle~* Group 2: 10 infants aged 4 months (+/- 10 days): 4-6 m bottle~* Group 3: 10 infants aged 6-10 months (+/- 10 days): 6m+ bottle Control groups: exclusively or prevalently breast-fed infants~* Group 4: 10 infants aged 0-4 weeks (+/- 7 days)~* Group 5: 10 infants aged 4 months (+/- 10 days)"||||
33758781|NCT01093144|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069982|NCT01220726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880382|NCT04278612|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The study evaluated 27 clinics in four sub-districts using a stepped-wedge design. Each sub-district received the intervention sequentially in a randomly selected order. Five waves of data collection were conducted in all participating clinics||||
33880383|NCT03017053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880384|NCT05370859|||COHORT||PROSPECTIVE|||||||
33880385|NCT01473797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880386|NCT03771365|||COHORT||PROSPECTIVE|||||||
33880387|NCT04690972|||COHORT||PROSPECTIVE|||||||
33880388|NCT01770925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880389|NCT03136315|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880390|NCT02184871|||COHORT||PROSPECTIVE|||||||
33880391|NCT00974987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880392|NCT00725075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880393|NCT06436378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33880394|NCT03938493|||OTHER||PROSPECTIVE|||||||
33880395|NCT01845038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880396|NCT06269445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880397|NCT04983160|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33880398|NCT00857870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880399|NCT02116166|||COHORT||CROSS_SECTIONAL|||||||
33880400|NCT03115151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880401|NCT04111029|||COHORT||PROSPECTIVE|||||||
33880402|NCT02555423||||SUPPORTIVE_CARE||||||||
33880403|NCT01903837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880404|NCT04951687|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33880405|NCT02096341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880406|NCT00128869|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33880407|NCT03891901|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33880408|NCT04094935|||CASE_ONLY||PROSPECTIVE|||||||
33880409|NCT00695565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880410|NCT01678144|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-national, multi-center, open-label, single-arm||||
33880411|NCT02177760|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880412|NCT00875355|RANDOMIZED|||TREATMENT||||||||
33880413|NCT04493827|||COHORT||RETROSPECTIVE|||||||
33880414|NCT02482454|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33880415|NCT03842826|||COHORT||CROSS_SECTIONAL|||||||
33880416|NCT00540878|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880417|NCT01055054|||COHORT||PROSPECTIVE|||||||
33880418|NCT00006465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880419|NCT02758158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880420|NCT05821283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880421|NCT01490619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069983|NCT01269099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069984|NCT02099383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34069985|NCT06309836|||COHORT||OTHER|||||||
34069986|NCT03682289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34069987|NCT01651975|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34069988|NCT00547924|||CASE_ONLY||PROSPECTIVE|||||||
34069989|NCT03122873|||CASE_CONTROL||PROSPECTIVE|||||||
34069990|NCT04060160|||COHORT||PROSPECTIVE|||||||
34069991|NCT03190980|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34069992|NCT05691777|||COHORT||PROSPECTIVE|||||||
33758782|NCT06090916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758783|NCT00921063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758784|NCT04123925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758785|NCT05063214|||COHORT||PROSPECTIVE|||||||
33758786|NCT04280653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758787|NCT03672838|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758788|NCT01065350|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758789|NCT02676401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758790|NCT03014063|||COHORT||PROSPECTIVE|||||||
33758791|NCT02087982|||COHORT||PROSPECTIVE|||||||
34069993|NCT00715871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758792|NCT03681574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A pharmacist will prepare the drugs under codes of numbers 1, 2 or 3. The nursing team and anesthesiologists will not know the drug formula used. Drugs will only be revealed after the statistical assessment.|Parallel Assignment|f|f|f|t
33758793|NCT03125005|NA|SINGLE_GROUP||OTHER||NONE||||||
33758794|NCT05745142|||COHORT||RETROSPECTIVE|||||||
33758795|NCT01837160|||COHORT||PROSPECTIVE|||||||
33758796|NCT00840723|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880422|NCT06170398|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880423|NCT03984305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subjects will remain blinded to treatment group throughout the life of the trial. Investigator and research staff will be unblinded to the treatment group as they will or will not have access to the PKG results to be incorporated into their standard of care practice.|Eligible subjects will be randomized using the Electronic Data Capture (EDC) system in a 1:1 ratio to the PKG- Group (standard of care clinical assessments without use of PKG data) or the PKG+ Group (standard of care clinical assessments plus use of PKG data).|t|f|f|f
33880424|NCT03949270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880425|NCT01166230|||OTHER||RETROSPECTIVE|||||||
33880426|NCT01610765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880427|NCT03296046|||COHORT||CROSS_SECTIONAL|||||||
33880428|NCT05047276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880429|NCT01888042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880430|NCT06500247|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental group:Dalpicilib+Abiraterone Acetate (II) +ADT+Prednisone||||
33880431|NCT03729388|||COHORT||PROSPECTIVE|||||||
33880432|NCT05511116|||COHORT||RETROSPECTIVE|||||||
33880433|NCT04467580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient with stenosing CD and for which the surgical resection of one or more stenosis (s) of the terminal ileum is programmed as part of the treatment.||||
33880434|NCT05229146|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880435|NCT03777644|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33880436|NCT01496885|||OTHER||PROSPECTIVE|||||||
33880437|NCT01914276|||COHORT||PROSPECTIVE|||||||
33758797|NCT01757834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33758798|NCT04978714|||COHORT||RETROSPECTIVE|||||||
33758799|NCT03859882|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33758800|NCT06206967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33758801|NCT00259064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758802|NCT06142136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33758803|NCT02856113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758804|NCT00091247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33758805|NCT03419416|||CASE_ONLY||PROSPECTIVE|||||||
33758806|NCT03569384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is a prospective randomized controlled trial comparing the effects of tele-rehabilitation and conventional rehabilitation in patients with COPD.|t|t|f|t
33758807|NCT03347916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33758808|NCT05125575|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33758809|NCT02288754|||COHORT||PROSPECTIVE|||||||
33758810|NCT03648112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||crossover design||||
33758811|NCT02262286|||CASE_CONTROL||PROSPECTIVE|||||||
33758812|NCT05634044|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33758813|NCT02656810|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33758814|NCT05836948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758815|NCT03144895|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33758816|NCT03092284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970366|NCT03238027|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Initially in both phases, 3 patients will receive axatilimab at 1 mg/kg IV on C1D1 and again on C1D15 of a 28-day cycle. Phase 1b only will also receive a fixed dose of 1500mg durvalumab IV on C1D1. If no DLTs are noted, 3 more patients will be treated at the next higher dose level (3 mg/kg). If 1 DLT is observed in 1 of 3 patients, 3 more patients will be treated at that starting dose level (1 mg/kg). If 2 or more DLTs are observed in 3-6 patients at the starting dose, the study will be terminated, or a lower dose will be considered. If the safety profile is acceptable, escalation to axatilimab doses of 3, 6 and 10mg/kg are planned for the 1a and for the 1b, doses of 3 and 6 mg/kg of axatilimab in combination with a fixed dose of 1500mg of durvalumab are planned. The MTD will be considered to have been exceeded if 2 or more patients in a dose group experience a DLT; in this case, the next lower dose group which has been evaluated will be considered as the MTD.||||
33970367|NCT02532010|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34069994|NCT01709409|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33970368|NCT00410722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880438|NCT04369898|||COHORT||RETROSPECTIVE|||||||
33970369|NCT04854720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was performed by a computer-generated random sorting sequence (sealed in opaque envelopes that sequentially numbered randomly selected through).|randomized controlled, three-arm parallel, single-blinded, split-mouth clinical trial|t|f|f|t
33758817|NCT05865743|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970370|NCT01191255|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33970371|NCT06531096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970372|NCT01968616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970373|NCT05581186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33970374|NCT06388161|||COHORT||PROSPECTIVE|||||||
33880439|NCT03790254|||OTHER||RETROSPECTIVE|||||||
33970375|NCT03209830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, randomised, placebo-controlled study|t|f|t|f
33970376|NCT00002185||PARALLEL||TREATMENT||||||||
33970377|NCT01261481|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880440|NCT05321836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two groups|t|f|f|f
33880441|NCT05272033|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33880442|NCT03130088|||COHORT||PROSPECTIVE|||||||
33894509|NCT04227691|RANDOMIZED|PARALLEL||TREATMENT||NONE||Twenty patients are enrolled. Each patient is randomized to receive treatment in left or right axilla with either IPL or Nd:YAG. Thus, it is a within-person randomised trial, where patients receive one treatment in one axilla and the opposite axilla serve as a control.||||
33894510|NCT04670705|||COHORT||CROSS_SECTIONAL|||||||
33894511|NCT01451333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970378|NCT05517512|||CASE_CONTROL||PROSPECTIVE|||||||
33970379|NCT03932487|||OTHER||CROSS_SECTIONAL|||||||
33970380|NCT02702206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970381|NCT02098356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34069995|NCT02649517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34069996|NCT02344771|||COHORT||PROSPECTIVE|||||||
34069997|NCT06415474|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"For all patients, lymphocyte phenotyping will be performed on biological samples taken on D0, D7 and the day of discharge. In case of infection, phenotyping will also be performed on the day of infection diagnosis and on the day corresponding to half the duration of antibiotic therapy.~For phenotyping, only 1.5 mL (0.5 mL per analysis) will be used (if no infection). In case of infection, an additional 1mL will be collected (0.5mL on the day of inclusion diagnosis and 0.5 mL on the day corresponding to half the duration of antibiotic therapy). Blood is collected during sampling, which takes place several times a day as part of the standard management of these patients."||||
34069998|NCT04581018|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970382|NCT02419638|||COHORT||PROSPECTIVE|||||||
33894512|NCT01160731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970383|NCT05941091|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33970384|NCT02742181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970385|NCT05512325|||CASE_ONLY||PROSPECTIVE|||||||
33764907|NCT01007240|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33764908|NCT05243381|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33880443|NCT05788939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants in the study do not know whether they are in the experimental or control group.|"The sample of this cluster randomized controlled experimental study consisted of 2nd year university students (n=116) training in Faculty of Economics and Administrative Sciences (FEAS) and Hasan Ferdi Turgutlu Faculty of Technology (HFTFT) from the faculties of Manisa Celal Bayar University (MCBU) between February-Semptember 2019. Among the faculties in MCBU, simple random sampling was used to draw lots, with the first lot being assigned to FEAS as the intervention group (IG), and the second lot being assigned to HFTFT as the control group (CG) . Among seven departments in FEAS and four departments in the HFTFT, simple random sampling was used to draw lots again. The Department of Econometrics from the FEAS was assigned as the IG and Mechatronics Engineering from HFTFT was assigned as the CG.~58 students for the CG and 58 students for the IG were recruited for the sample. Power of the study was calculated as post hoc at α=0.05 with a significance of 0.95."|t|f|f|f
33880444|NCT01526512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880445|NCT06128447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective, randomized, double-blind, placebo-controlled study|t|t|t|f
33880446|NCT03434977|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880447|NCT01047657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880448|NCT05594173|||COHORT||PROSPECTIVE|||||||
33880449|NCT01510678|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33880450|NCT00423163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33880451|NCT05118256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although this is an open study for participants and clinicians, professionals in charge of molecular and cellular analysis, HRCT and PET will be blind to the arm that each subject is assigned.||f|f|f|t
33880452|NCT00036179|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880453|NCT02989519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33880454|NCT01785212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880455|NCT00874120|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33880456|NCT04421495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880457|NCT02326779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880458|NCT00002356||||TREATMENT||NONE||||||
33880459|NCT00122265|||CASE_ONLY||RETROSPECTIVE|||||||
33970386|NCT05485181|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Two cohorts of 8 subjects each will receive psychological assessments initially.~First cohort will have brain scan followed by 9 week intervention and post-intervention repeat scan and repeat assessments.~2nd cohort serves as its own control, will receive repeat assessments and brain scan after Cohort 1 is done, and again after 9 week intervention."||||
33970387|NCT00570856|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33970388|NCT05426252|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized phase I/II trial||||
33970389|NCT01881399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970390|NCT02449291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970391|NCT00087061||||TREATMENT||NONE||||||
33970392|NCT01789281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970393|NCT01246128|||||OTHER|||||||
33970394|NCT06153524|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the interventions, no blinding can be involved|A three-arm randomised controlled trial||||
33970395|NCT01405976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970396|NCT06527092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33970397|NCT02109133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33970398|NCT05073900|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33970399|NCT00406198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970400|NCT04872426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33970401|NCT03043274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970402|NCT04572620|||COHORT||RETROSPECTIVE|||||||
33764909|NCT03102125|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33764910|NCT04266288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970403|NCT00593996|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970404|NCT03158259|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|Clinical tests and recordings will not be performed by investigator invested in the study.|Prospective controlled intervention study||||
33970405|NCT04867161|||COHORT||PROSPECTIVE|||||||
33970406|NCT05340556|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33970407|NCT05778370|||CASE_CONTROL||PROSPECTIVE|||||||
33970408|NCT02193984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970409|NCT00008099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764911|NCT02740855|||OTHER||PROSPECTIVE|||||||
33764912|NCT01624649|||CASE_ONLY||PROSPECTIVE|||||||
33880460|NCT01972074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880461|NCT03379662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880462|NCT01175291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880463|NCT04612998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the recovery room, Visual analogue scale (VAS, 0 cm= no pain, 10 cm= worst pain) scores for pain severity, anesthesia-related side effects (e.g., nausea, vomiting and headache), sensory block time (from the spinal injection to the recovery of T10 dermatome), and the time requiring supplemental analgesics was recorded by an independent observer blinded to the group assignment at 30 min and 1st and 2nd hours post-operatively.|Comparator group consisted of patients performing CSEA in the left lateral decubitus position. Active control group consisted of patients performing CSEA in the sitting position.|f|f|f|t
33880464|NCT01294800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34069999|NCT04769674|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline design across participants||||
33880465|NCT02237430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880466|NCT00300638|||OTHER||CROSS_SECTIONAL|||||||
33880467|NCT02216838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880468|NCT01665963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33880469|NCT00305656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880470|NCT05559827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880471|NCT04763070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880472|NCT04411550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880473|NCT02933697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880474|NCT02432235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33970410|NCT02561390|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970411|NCT01023906|||COHORT||CROSS_SECTIONAL|||||||
33970412|NCT00663910|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970413|NCT01506089|RANDOMIZED|PARALLEL||||NONE||||||
33970414|NCT04468971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multi-center, prospective, double-blinded, placebo controlled Phase 1 randomized clinical trial.|t|t|t|t
33970415|NCT02459613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970416|NCT06479694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070000|NCT06065189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070001|NCT03414827|||COHORT||PROSPECTIVE|||||||
34070002|NCT03328442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970417|NCT02323906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970418|NCT01087879|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764913|NCT03528174|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33758818|NCT03785574|RANDOMIZED|PARALLEL||TREATMENT||NONE||"lung nodule ≥1.0cm were randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). A:B=1:2，the sample size of group A and group B was 30 in total.~Lung nodule \<1.0cm will be directly treated as group C: follow up until hCG level met FIGO diagnostic criteria of GTN (C1) or hCG level declined to normal spontaneously (C2), it is an observation study and the sample volume depends on the enrolling time of group A and B."||||
33758819|NCT00973661|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758820|NCT03187990|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||In both arms PET/MR is compared to mpMRI for diagnostic accuracy for PCA detection.||||
33758821|NCT03685838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758822|NCT01720290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758823|NCT00589355|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758824|NCT01746095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758825|NCT03042455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758826|NCT00986076|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33758827|NCT03662932|NA|SINGLE_GROUP||TREATMENT||NONE||All the included participants receive the intervention||||
33758828|NCT04209816|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758829|NCT00141154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758830|NCT01007656|NA|SINGLE_GROUP||||NONE||||||
33758831|NCT00541918|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33758832|NCT03107078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758833|NCT03178786|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33758834|NCT04384263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33758835|NCT05797831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758836|NCT00003006|||CASE_ONLY||PROSPECTIVE|||||||
33758837|NCT05639179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758838|NCT00002420||||TREATMENT||NONE||||||
33758839|NCT04113954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant will be masked to the drug being provided in the nerve blocks (0.375% mepivacaine or 1.5% mepivacaine)|Our patients will be randomized to one of six arms.|t|f|f|f
33758840|NCT04506957|||CASE_ONLY||PROSPECTIVE|||||||
33880475|NCT01082315|||CASE_ONLY||PROSPECTIVE|||||||
33880476|NCT01913483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880477|NCT06252272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Biopsy sample in an area of liver macroscopically free from parenchymal alterations|Non-pharmacological study of a biological nature, low level interventional prospective intervention for the preparation of cultures of organotypic liver slices (hLSC)||||
33880478|NCT04600908|||COHORT||CROSS_SECTIONAL|||||||
33880479|NCT02838849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880480|NCT05827029|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|f|t|t
33880481|NCT00246532|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33880482|NCT05864976|||COHORT||PROSPECTIVE|||||||
33880483|NCT04668352|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33880484|NCT02853994|||COHORT||PROSPECTIVE|||||||
33758841|NCT04082884|NA|SEQUENTIAL||TREATMENT||NONE||Following enrollment, participants will follow a standard carbohydrate diet for 2 weeks. They will then undergo a 1 week transition followed by 2 weeks on a higher protein very low carbohydrate diet that is then followed by 2 weeks on a higher fat very low carbohydrate diet.||||
33758842|NCT02623855|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33880485|NCT02926950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880486|NCT04840680|||COHORT||PROSPECTIVE|||||||
33880487|NCT05206526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880488|NCT05816980|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are enrolled according to protocol criteria for hyperfractionated IMRT re-irradiation.||||
33880489|NCT00022529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880490|NCT00608985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880491|NCT04665830|RANDOMIZED|PARALLEL||PREVENTION||NONE||all renal transplant recipients who are followed up in Hamed Al-Essa organ transplant center of Kuwait for 6 months duration. Cardio-vascular risk score will be estimated using the Framingham score. Patients with scores higher than 10 will be randomized in this prospective controlled study to receive either the evolocumab (group 1, n=100 patients) or the conventional group (group 2, n=100 patients).||||
33880492|NCT03232476|NA|SINGLE_GROUP||OTHER||NONE||||||
33880493|NCT03183674|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33880494|NCT01008280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880495|NCT02381665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880496|NCT05841758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880497|NCT02844114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880498|NCT02213601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880499|NCT03365466|||COHORT||PROSPECTIVE|||||||
33880500|NCT01434771|||COHORT||PROSPECTIVE|||||||
33880501|NCT01430442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880502|NCT00002350||||TREATMENT||NONE||||||
33880503|NCT02918019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880504|NCT01306227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970419|NCT00401856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970420|NCT01249105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970421|NCT03232528|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33970422|NCT00877175|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33758843|NCT04343586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758844|NCT00845884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758845|NCT01291784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758846|NCT00827541|||COHORT||PROSPECTIVE|||||||
33880505|NCT00144482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880506|NCT02585011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880507|NCT05396274|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33880508|NCT03521505|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33880509|NCT02780882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880510|NCT00976066|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33880511|NCT03239717|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33880512|NCT01972230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880513|NCT00758745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970423|NCT01983059|||COHORT||PROSPECTIVE|||||||
33758847|NCT06107595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758848|NCT01265199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758849|NCT06443502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758850|NCT05947214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758851|NCT04386434|NA|SINGLE_GROUP||OTHER||NONE||||||
33758852|NCT03427684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758853|NCT00228605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758854|NCT02753309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880514|NCT01394107|||CASE_CONTROL||PROSPECTIVE|||||||
33970424|NCT05580926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors of the variables of interest will be blinded to the allocation group. The person responsible for randomization will be external, not involved in recruitment, study measurements and intervention.||f|f|f|t
34070003|NCT04927923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Pre-test will be applied to all individuals determined according to the inclusion and exclusion criteria. After the pre-test application, the envelope method will be used to determine the individuals who will form the experimental and control groups. 1 for the experimental group in 22 envelopes and 2 for the control group in the other 22 envelopes and all of them will be stored in a box. After each patient pulls the envelope, their group will be determined and the envelope will not be thrown back into the box. The researcher who will apply the intervention and evaluate the data in this planned study is the same person. It will be ensured that only the individuals involved in the research do not learn the group they are in, and one-way blinding will be made.|randomized controlled, pretest-posttest control group|t|f|f|f
34070004|NCT03945071|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34070005|NCT04936178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758855|NCT04558190|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33758856|NCT01556126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758857|NCT03606356|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Open-label, single-arm, prospective multicentre, clinical study||||
33758858|NCT01111123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758859|NCT04508608|||CASE_CONTROL||PROSPECTIVE|||||||
33758860|NCT02498834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758861|NCT04036461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758862|NCT02813187|||CASE_ONLY||PROSPECTIVE|||||||
33758863|NCT04022967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758864|NCT01048814|||CASE_ONLY||RETROSPECTIVE|||||||
33758865|NCT01891448|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33758866|NCT05711862|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33758867|NCT05531279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758868|NCT02940574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758869|NCT02393287|||COHORT||OTHER|||||||
33758870|NCT03716375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758871|NCT03019874|||COHORT||PROSPECTIVE|||||||
33758872|NCT04707625|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All patients will receive the same standard of care treatment.||||
33758873|NCT00501189|||COHORT||PROSPECTIVE|||||||
33758874|NCT05780294|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33758875|NCT00845338|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758876|NCT03529357|||COHORT||PROSPECTIVE|||||||
33758877|NCT02742298|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|t|f
33758878|NCT03017417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33758879|NCT04836702|||COHORT||RETROSPECTIVE|||||||
33758880|NCT03462615|||CASE_ONLY||CROSS_SECTIONAL|||||||
33758881|NCT05435274|NA|SEQUENTIAL||TREATMENT||NONE||||||
33758882|NCT02168530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758883|NCT04846088|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33758884|NCT05306366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758885|NCT01818674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758886|NCT00792896||PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880515|NCT03959280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicentric, randomized controlled trial||||
33880516|NCT04776590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880517|NCT01700933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880518|NCT01726751|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Spinal cord stimulation|t|f|f|f
33970425|NCT05188040|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking.|Participants at the Commonwealth Hand and Physical Therapy clinic with the 3 included arm and hand injury diagnoses will be offered the opportunity in a flyer at the clinic to participate in the VR study. Those consented will complete the pre and post outcome measures outlined within this document with the research team member. For intervention, the participants will be instructed by the treating therapist in standard of care rehabilitation and utilize Virtual Reality with the Oculus Quest 2 system as the active exercise component of their rehabilitation over approximately approximately 4 sessions, totally \~ 1-hour. The specific virtual reality games within the Oculus Quest 2 VR system will be selected by the therapist providing interventions each session. The virtual reality game allows for augmented visual feedback and will be directly supervised by the treating therapists.||||
33970426|NCT02047942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970427|NCT01239420|||CASE_CONTROL||PROSPECTIVE|||||||
33970428|NCT04091542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970429|NCT02600728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970430|NCT03673189|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Prospective, monocentric, with healthy volunteers and patients||||
33880519|NCT04316585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study where sponsor will be unblinded|Participants will randomized in ratio of 2:1 to receive either 960 mg GSK2982772 or placebo|t|f|t|f
33880520|NCT01445678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880521|NCT05244681|NA|SINGLE_GROUP||OTHER||NONE||||||
33880522|NCT02945631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880523|NCT02824744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880524|NCT06322771|||COHORT||PROSPECTIVE|||||||
33880525|NCT00030342||||TREATMENT||||||||
33880526|NCT05937945|||CASE_CROSSOVER||PROSPECTIVE|||||||
33880527|NCT05389878|||COHORT||PROSPECTIVE|||||||
33880528|NCT05040308|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33970431|NCT02588625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970432|NCT01257854|||COHORT||OTHER|||||||
33758887|NCT01148654|||COHORT||PROSPECTIVE|||||||
33758888|NCT01691625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758889|NCT01174420|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758890|NCT02862379|NA|SINGLE_GROUP||OTHER||NONE||||||
33880529|NCT05438316|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33880530|NCT05593887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880531|NCT04951258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880532|NCT01392820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33880533|NCT05531669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880534|NCT05357300|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluation of the pain reduction in patients treated with peripheral nerve stimulation compared to best medical treatment||||
33880535|NCT01871454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880536|NCT05462431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880537|NCT04123899|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880538|NCT01463098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880539|NCT03404011|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33880540|NCT01791608|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880541|NCT03754309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Primary analysis up to day 113. Long term follow up to day 253 (dependent on response).|t|f|t|t
33880542|NCT03445078|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|All participants will be blinded. Both the selenium-rich corn powder and the ordinary corn powder (placebo) have the same smell, color and taste.|20 participants with selenium deficiency (confirmed in previous phase (ID: Liuyanping3)) will be recruited to receive selenium-rich corn powder (20g/d, offering selenium 100μg/d) and ordinary corn powder (20g/d, offering selenium \< 0.5μg/d ) in two different sequences (10 subjects each) with a four-week washout period.Plasma samples were obtained at different time points before and after administration of the selenium-rich corn powder and ordinary corn powder.|t|f|f|f
33880543|NCT00529074|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880544|NCT04536883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880545|NCT05665270|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized, controlled study to assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert when utilized in conjunction with topical steroids as part of an extended taper steroid regimen following cataract surgery in patients with a history of epiretinal membrane, diabetic retinopathy, or non-exudative macular degeneration Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8).~Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week."||||
33880546|NCT04555122|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33880547|NCT04696588|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The responsible investigator is blinded .|It is a non randomized controlled trial|f|f|t|f
33880548|NCT01100944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880549|NCT00948870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880550|NCT02995616|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33880551|NCT02361216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880552|NCT01889979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880553|NCT04248738|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33880554|NCT05592405|||COHORT||PROSPECTIVE|||||||
33880555|NCT00142883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880556|NCT02236455|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33970433|NCT00479310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33880557|NCT01200836|||||PROSPECTIVE|||||||
33880558|NCT02339493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33880559|NCT02491164|NA|SINGLE_GROUP||OTHER||NONE||||||
33880560|NCT06344845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880561|NCT01913080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33880562|NCT04230863|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, open label design; All analyses are pre-post, with participants serving as their own controls.||||
33880563|NCT02325908|||CASE_CONTROL||PROSPECTIVE|||||||
33880564|NCT02796378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33880565|NCT03198208|||COHORT||PROSPECTIVE|||||||
33880566|NCT02861040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880567|NCT05507866|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Matched-pairs cluster-randomized trial||||
33970434|NCT00896285|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33970435|NCT00521898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970436|NCT03201783|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking because of the nature of the intervention|||||
33970437|NCT02614703|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34070006|NCT01087203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758891|NCT02280239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880568|NCT01716572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880569|NCT06000293|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33880570|NCT04971005|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised to control (ocrelizumab or alemtuzumab) or intervention (aHSCT).||||
33880571|NCT01244880|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33880572|NCT02639897|||COHORT||PROSPECTIVE|||||||
33880573|NCT05178875|||COHORT||CROSS_SECTIONAL|||||||
33880574|NCT02198807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880575|NCT05355350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880576|NCT00701753|||CASE_ONLY|||||||||
33880577|NCT03628170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880578|NCT04431115|||OTHER||CROSS_SECTIONAL|||||||
33758892|NCT03953963|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be experimental subjects, they will serve as their own controls by comparing their pre-op status to their post-op status in the parameters of investigation which include insulin status assessment (resistance versus sensitivity, as determined by hyperinsulinemic euglycemic clamp), measurements of glycemic control of T2D, and body weight measurements.||||
33970438|NCT04914793|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study design is an open cohort stepped wedge cluster randomized controlled trial (SW-CRT) in six central/provincial hospitals across Laos. SW-CRT is appropriate in the Lao context because it requires fewer sites than a parallel cluster trial, but has similar observational periods for reference and intervention phases. As the interventions are delivered by one team travelling to each cluster in turn, implementing in stages is more practical. In addition, all participating hospitals have access to the novel interventions at the end of the study. Prescribers are allowed to move in and out of clusters during the trial.||||
33970439|NCT03239275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758893|NCT03168568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880579|NCT05167773|||OTHER||PROSPECTIVE|||||||
33880580|NCT06434831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880581|NCT01986478|||COHORT||PROSPECTIVE|||||||
33880582|NCT01394705|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880583|NCT04019132|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880584|NCT03138876|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|There will be blinded EEG assessment in terms of the EEG readers.|Subjects may be treated for NCSE based on EEG cap findings, but only following standard practice. The study is designed to identify NCSE, not to assess treatment of NCSE.||||
33880585|NCT00428597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880586|NCT02448732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880587|NCT04823949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Control arm: will be scheduled an in-office blood pressure check 7-10 days postpartum Intervention arm: will receive a blood pressure cuff and app with which to monitor their blood pressures at home for 16 days postpartum||||
33880588|NCT02225678|||CASE_CONTROL||PROSPECTIVE|||||||
33880589|NCT04460235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880590|NCT05514964|NA|SINGLE_GROUP||PREVENTION||NONE||"Feasibility study:~* An online psychological intervention program (six weeks);~* Measurement points: Pre-Intervention and Post-Intervention;"||||
33880591|NCT02288338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880592|NCT01708460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880593|NCT05172739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Administration of a multimodal anaesthetic opioid-free strategy that includes pregabalin, ketamine, dexmedetomidine, lidocaine, dexamethasone, magnesium sulphate, paracetamol and dexketoprofen is expected to affect the inflammatory and stress response, measured by levels of inflammatory markers and haemodynamic stability, when compared to conventional opioid based techniques. An Opioid-Free Anaesthesia-Analgesia strategy, is expected to also lead to an attenuated immunosuppression, due to the avoidance of opioids, whose administration has been corelated with immunosuppressive effects. An overall decreased inflammatory and stress response as expressed by reduced levels of inflammatory biomarkers and hemodynamic stability, is expected to decrease peripheral and central sensitization, contributing to better postoperative analgesia.|t|t|t|t
33880594|NCT04970251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880595|NCT01839864|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33880596|NCT02905175|||COHORT||PROSPECTIVE|||||||
33880597|NCT05568342|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33880598|NCT02883751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880599|NCT01826682|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33880600|NCT03359876|||COHORT||RETROSPECTIVE|||||||
33880601|NCT03556930|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33880602|NCT03638349|||OTHER||CROSS_SECTIONAL|||||||
33880603|NCT00941460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880604|NCT00666458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880605|NCT04479566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880606|NCT03447626|||CASE_CONTROL||PROSPECTIVE|||||||
33880607|NCT00503165|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880608|NCT01985672|||COHORT||PROSPECTIVE|||||||
33880609|NCT00361595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880610|NCT06541873|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970440|NCT05127382|||COHORT||OTHER|||||||
33970441|NCT03830047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||applying laser for treatment of vulval warts|t|t|t|t
33970442|NCT00359229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970443|NCT05433337|NA|SINGLE_GROUP||TREATMENT||NONE||This is a virtual, single-arm, pragmatic, non-significant risk device study. Study participants will continue to have access to Digital Acceptance and Commitment Therapy (ACT) after the original 12-week study (PROSPER-FM, NCT05243511), in addition to their standard care for fibromyalgia||||
33970444|NCT02755337|||||RETROSPECTIVE|||||||
33970445|NCT04652921|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33970446|NCT04820959|NA|SINGLE_GROUP||OTHER||NONE||||||
33970447|NCT03091530|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33970448|NCT03607630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multiple Baseline Case Series - randomization for how long participants wait pre-intervention||||
33970449|NCT05085054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970450|NCT03136783|NA|SINGLE_GROUP||OTHER||NONE||||||
33970451|NCT00314379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33970452|NCT00588575|||COHORT||PROSPECTIVE|||||||
33970453|NCT01247896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970454|NCT00000606|RANDOMIZED|||TREATMENT||||||||
33758894|NCT06362980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758895|NCT00089089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758896|NCT02880592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758897|NCT03438695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880611|NCT00959816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880612|NCT00923117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880613|NCT04848922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33880614|NCT04405050|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective, 2-arm parallel assignment, randomized clinical trial to compare Restrata and NPWT in patients with complex diabetic foot ulcers.||||
33880615|NCT03912129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880616|NCT06213909|||COHORT||RETROSPECTIVE|||||||
33880617|NCT00356278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880618|NCT04509466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880619|NCT00522587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970455|NCT04094194|||OTHER||PROSPECTIVE|||||||
33970456|NCT05330845|NA|SINGLE_GROUP||OTHER||NONE||||||
33970457|NCT01166854|||CASE_ONLY||PROSPECTIVE|||||||
33970458|NCT04221555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970459|NCT00947856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970460|NCT05994781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970461|NCT03745625|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970462|NCT01898910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970463|NCT00006031|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970464|NCT04845022|||COHORT||CROSS_SECTIONAL|||||||
33970465|NCT05660083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970466|NCT02826603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970467|NCT03421652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970468|NCT01977326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970469|NCT02684695|||COHORT||PROSPECTIVE|||||||
33970470|NCT05102799|||COHORT||RETROSPECTIVE|||||||
33970471|NCT00477828|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||||||
33970472|NCT05092711|||COHORT||PROSPECTIVE|||||||
33970473|NCT03602898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970474|NCT02269202|RANDOMIZED|||TREATMENT||SINGLE||||||
33970475|NCT03032497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970476|NCT05448703|||COHORT||PROSPECTIVE|||||||
33970477|NCT06324253|RANDOMIZED|PARALLEL||OTHER||NONE||"Group A: will receive bilateral Erector Spinae Block after induction of anesthesia.~Group B: will receive Thoracic Epidural Block before induction of anesthesia."||||
33970478|NCT04110275|RANDOMIZED|PARALLEL||TREATMENT||NONE|observers are masking|||||
33970479|NCT00669955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970480|NCT02100956|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33970481|NCT04194905|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33970482|NCT01953159|||CASE_CONTROL||RETROSPECTIVE|||||||
33970483|NCT01207128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970484|NCT06024863|||COHORT||PROSPECTIVE|||||||
33970485|NCT02629952|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970486|NCT04922398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||60 patients with premature ovarian failure will be divided into 2 groups. The group A consists of 30 patients, who will receive a PRP (autologous platelet-rich plasma injection) with activation with calcium chloride. The group B consists of 30 patients, who will receive a normal saline inj. 0.9% Nacl.|t|f|f|t
33970487|NCT04380571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The current prospective randomized controlled study included 93 children with FNRFI who were randomly divided and allocated into 3 groups. were managed by conventional methods through Kegal exercises and dietetic regulation where they had received bulky food including vegetables, fruits bran and cereals. Fast foods, spicy drinks and caffeine should be limited in child's diet. Local hygiene and zinc oxide application to the perianal skin were advised to prevent skin excoriation.Biofeedback group treated by biofeedback therapy in addition to traditional treatment, while the third group is the electrical stimulation group received bilateral (TPTNS) in addition to the traditional treatment. Initial manometric findings including resting pressure (mm hg), squeeze pressure (mm hg), 1st sensation (cm water), 1st urge (cm water), and intense urge (cm water) were recorded and repeated after 3 and 6 months together with incontinence score recorded in using St' Mark's (Varizey).|t|f|f|t
33970488|NCT05578573|RANDOMIZED|CROSSOVER||TREATMENT||NONE||multi-center, prospective, interventional study||||
33970489|NCT01269983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970490|NCT02917447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970491|NCT04566783|||OTHER||CROSS_SECTIONAL|||||||
33970492|NCT04902339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33970493|NCT01060774|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33970494|NCT00799006|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33970495|NCT03260036|||COHORT||PROSPECTIVE|||||||
33970496|NCT04108169|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33970497|NCT05442333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33970498|NCT02517710|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33970499|NCT03263195|||COHORT||PROSPECTIVE|||||||
33970500|NCT06222463|RANDOMIZED|CROSSOVER||TREATMENT||NONE||non-blinded, randomized, cross-over, controlled trial||||
33970501|NCT01412671|||CASE_ONLY||PROSPECTIVE|||||||
33970502|NCT05091814|||COHORT||CROSS_SECTIONAL|||||||
33970503|NCT03979677|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible participants will receive information on food/beverage triggers to avoid, restful sleep tips, simple exercise tips, and eating regularly at the same time. Participants will return after 60 days and both pre- and post-intervention measures will be obtained.||||
33970504|NCT00101972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970505|NCT04119661|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33970506|NCT03321747|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This trial is a Phase I/II study designed to determine the maximum tolerated radiation dose and evaluate the efficacy of dose escalated SABR for early stage lung squamous cell carcinoma.~\*The Phase l portion of this study was completed. However; the trial will not continue into Phase II as originally planned."||||
33970507|NCT05216614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded, both participants and investigators will be blinded. Intervention will be packaged in blinded fashion by pharmacist before being shipped to participants by research assistant|Double-blinded, randomized, placebo-controlled trial|t|f|t|t
33970508|NCT01424982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970509|NCT04032678|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a prospective randomized trial (alternating design) where eligible patients will be randomized to treatment with two different defibrillators. Following the order of patient admittance in ICCU-NCH, the attending cardiologist will assign the odd and even eligible patients to the defibrillators in arm 1 and arm 2, respectively. The cardiologist cannot control the order of patient admittance in ICCU-NCH. The alternative randomization design will equalize the number of subjects on each treatment. This study is not designed to control for sex, age, comorbidity, type of device used for cardioversion, cumulative energy delivered during shocks, number of shocks administered. Randomization is performed to limit these and any other confounding factors.||||
34070007|NCT04687540|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Only subjects will be masked regarding order of saline and tocilizumab infusion|The study is designed in a placebo-controlled crossover manner, consisting of a screening visit and two study visits. Due to the 4-week wash out period of the IL-6 receptor antibody tocilizumab, the order of study visits will be identical in all subjects; hence, study visits will not be randomized. Subjects will be infused with tocilizumab at the end of study visit 1. This will allow us to study the effect of tocilizumab on study visit 2.|t|f|f|f
34070008|NCT06584812|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34070009|NCT03418142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070010|NCT05869396|||COHORT||PROSPECTIVE|||||||
34070011|NCT06218342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070012|NCT01299896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070013|NCT05695118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070014|NCT05443074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070015|NCT02603510|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070016|NCT04462874|||COHORT||PROSPECTIVE|||||||
34070017|NCT00652717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070018|NCT04636411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study participants will be randomized into 2 groups (intervention and control group) to be studied simultaneously|f|f|t|t
34070019|NCT03363685|||COHORT||PROSPECTIVE|||||||
33970510|NCT00229541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970511|NCT03182920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||2 Groups: Group 1 - Double-blind Randomized 2-Period Crossover, Group 2 - Open-label single dose|t|f|t|f
33970512|NCT05242419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33880620|NCT04520191|||COHORT||PROSPECTIVE|||||||
33970513|NCT02139345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator who assesses KSS score is blinded to the subject's treatment.|Subject was randomized to receive the treatment of investigational device or the comparator.|f|f|f|t
33970514|NCT03282435|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33970515|NCT02099266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970516|NCT01707459|||COHORT||PROSPECTIVE|||||||
33880621|NCT00318760|RANDOMIZED|PARALLEL||TREATMENT||||||||
33970517|NCT02261571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33880622|NCT04600895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970518|NCT05062109|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33880623|NCT05336071|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial.||||
33880624|NCT00813397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880625|NCT03630731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880626|NCT05275062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880627|NCT01347736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880628|NCT04874987|||COHORT||PROSPECTIVE|||||||
33880629|NCT06379581|||CASE_ONLY||PROSPECTIVE|||||||
33880630|NCT02448511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880631|NCT01831960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880632|NCT04675541|||COHORT||PROSPECTIVE|||||||
33880633|NCT03680495|||CASE_CONTROL||OTHER|||||||
33880634|NCT04779203|||CASE_CONTROL||PROSPECTIVE|||||||
33880635|NCT01456676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880636|NCT00269529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880637|NCT00464178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880638|NCT01964352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33880639|NCT02841969|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33880640|NCT05387811|||COHORT||PROSPECTIVE|||||||
33880641|NCT04995393|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Also masked: Biomedical Laboratory Scientist||t|t|f|t
33880642|NCT05429138|||COHORT||PROSPECTIVE|||||||
33880643|NCT01545700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880644|NCT03068156|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880645|NCT06496555|||COHORT||PROSPECTIVE|||||||
33880646|NCT05942287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880647|NCT03363633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33880648|NCT01282229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33880649|NCT01337076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880650|NCT02570269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880651|NCT03747146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880652|NCT03090126|||COHORT||PROSPECTIVE|||||||
33880653|NCT03287258|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33880654|NCT03804684|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880655|NCT02454920|||OTHER||PROSPECTIVE|||||||
33970519|NCT02222142|||CASE_CONTROL||RETROSPECTIVE|||||||
33970520|NCT04093180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33970521|NCT02376985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970522|NCT06528574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33970523|NCT04098874|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33970524|NCT04660942|||COHORT||PROSPECTIVE|||||||
33880656|NCT02708953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970525|NCT04763837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will not be informed of which type of ureteral stent will be used.|This study will be a prospective, randomized controlled, single-blinded trial. The subjects will include up to 140 patients (about 70 subjects per group) from ages 1-100 years old that are to undergo stent placement for nephrolithiasis, hydronephrosis, and urological cancer. They will be randomized to one of two groups: intraureteral stent or conventional double-J stent. Upon removal of the stent, migration distance will be measured via fluoroscopy using a calibrated x-ray system.|t|f|f|f
33970526|NCT01157728|||COHORT||PROSPECTIVE|||||||
33970527|NCT05625711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970528|NCT03099395|||COHORT||OTHER|||||||
33970529|NCT03316079|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33880657|NCT03618108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical placebo capsule dosing||t|t|t|t
33880658|NCT05029154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the intervention (i.e. exercise training), participants and study team members cannot be blinded. However, outcomes assessment will be carried out in a blinded fashion.|Two-arm randomized control trial|f|f|f|t
33880659|NCT03678597|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33880660|NCT03183362|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33880661|NCT03589378|RANDOMIZED|PARALLEL||TREATMENT||NONE||a Multicenter,Randomized and Controlled Clinical Trial||||
33880662|NCT00529971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880663|NCT03041558|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33880664|NCT03698006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880665|NCT03067909|||COHORT||PROSPECTIVE|||||||
33880666|NCT01942759|||CASE_ONLY||CROSS_SECTIONAL|||||||
33880667|NCT06099587|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective single-center||||
33880668|NCT03391947|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Split-mouth design, i.e. the right side will receive the first intervention, whereas the other side (the left side) will receive the second intervention.|t|f|f|f
33880669|NCT02566304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880670|NCT04240977|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study utilizes a single-arm pre/post experimental design with an additional 3-month maintenance assessment.||||
33880671|NCT02062658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880672|NCT00924937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33880673|NCT02681016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880674|NCT05697510|NA|SEQUENTIAL||TREATMENT||NONE||||||
33880675|NCT04201483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Ultrasound measurements will be performed by the rater responsible of performing ultrasound measurements who will be blinded to the assigned group|"This will be a randomized clinical trial, with parallel groups and a blinded assessor performed in accordance with CONSORT guidelines. Participants will be randomized into two exercise groups: DCE exercise without RUSI feedback (DCE) and DCE exercise with RUSI feedback (DCE+RUSI). Randomization will be conducted using computer-generated random numbers (Epidat® version 3.1). Allocation concealment will be ensured using opaque and sealed envelopes"|f|f|f|t
33880676|NCT03396965|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Patients randomized to fluoroscopically-aided reduction of fracture, versus no fluoroscopic guidance|f|f|f|t
33880677|NCT04352439|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880678|NCT01877135|||COHORT|||||||||
33880679|NCT03430648|||COHORT||PROSPECTIVE|||||||
33880680|NCT05495555|||COHORT||PROSPECTIVE|||||||
33880681|NCT02475642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880682|NCT03386175|||COHORT||PROSPECTIVE|||||||
33880683|NCT00132067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880684|NCT01608412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880685|NCT03939507|RANDOMIZED|PARALLEL||OTHER||TRIPLE||In the randomized assessment, patients meeting eligibility were randomized to two groups. In the intervention group, AEP score results were made available to the treating physician at each assessment visit, while in the other group AEP scores were only made available at the end of follow-up.|f|t|t|t
33880686|NCT01612533|||COHORT||PROSPECTIVE|||||||
33880687|NCT02988583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880688|NCT01659645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880689|NCT03823755|||COHORT||PROSPECTIVE|||||||
33970530|NCT02965820|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33970531|NCT00536055|||DEFINED_POPULATION||PROSPECTIVE|||||||
33970532|NCT04473352|||OTHER||PROSPECTIVE|||||||
33970533|NCT05821179|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970534|NCT01952028|||COHORT||CROSS_SECTIONAL|||||||
33970535|NCT03779191|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, single arm trial assessing Alectinib in combination with Bevacizumab in untreated and previously treated patients with Advanced or Metastatic Non-Squamous ALK-rearranged NSCLC||||
33970536|NCT01812083|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970537|NCT03501784|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is an exploratory, comparative, self-controlled, single blind study|t|f|f|f
33970538|NCT05074589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, single-dummy, parallel-controlled, multicentre study|t|t|t|t
34070020|NCT03173456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A pharmacist working in an area inaccessible to ED staff will ensure blinding of the study by masking the medication and inserting it into identical unmarked gel capsules, filling any void with small amounts of lactose. Randomization will be performed in blocks of 10 determined by a sequence generated at http://www.randomization.com. The pharmacist will make up numbered research packets based on the random allocation list, each with 5 tablets containing the masked investigational medication. Research packets will be removed sequentially by the nurse from the Pyxis automated medical dispensing system and administered to the study patients in the ED.|Randomized controlled trial|t|t|t|t
34070021|NCT05446532|||COHORT||RETROSPECTIVE|||||||
34070022|NCT05977868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome of cure at 3 months will be adjudicated by a 2 ID faculty blinded to study arm.||f|f|f|t
34070023|NCT04474054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070024|NCT03193333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be performed by the personnel assigned by the Laboratorios Sophia S.A. de C.V. Clinical Operations Management. The blinding will consist in the elimination of the primary label (commercial) for Krytantek Ofteno® and the triple concomitant therapy and the placement of a label identical to those of the other interventions. Since the bottles in which Krytantek Ofteno® and the concomitant therapies are different in color and cap shape to the ones used for the placebo and the PRO-122, a masking will be performed in the primary packaging, which shall be identical for all three interventions.|A non-inferiority, phase III, double-blind, randomized, controlled, parallel, clinical trial|t|f|t|f
34070025|NCT03955588|||COHORT||PROSPECTIVE|||||||
34070026|NCT02999841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070027|NCT05955144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880690|NCT01777152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880691|NCT05279846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880692|NCT01290965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880693|NCT03509350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33880694|NCT02302963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880695|NCT03370497|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomised, double-blind crossover|t|f|t|t
33880696|NCT02850237|||||PROSPECTIVE|||||||
33880697|NCT01731678|NA|SINGLE_GROUP||TREATMENT||NONE|Open label rTMS|||||
33880698|NCT03322059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33880699|NCT04975061|||CASE_ONLY||OTHER|||||||
33880700|NCT01318044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880701|NCT03730805|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Randomized Controlled Trial|f|t|t|t
33880702|NCT05152797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880703|NCT05941598|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33880704|NCT05401305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33880705|NCT03375060|||CASE_ONLY||RETROSPECTIVE|||||||
33880706|NCT01673321|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33880707|NCT04976894|||COHORT||PROSPECTIVE|||||||
33880708|NCT01617941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880709|NCT04009044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880710|NCT05111587|||COHORT||PROSPECTIVE|||||||
33880711|NCT00803179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880712|NCT01625754|||COHORT||PROSPECTIVE|||||||
33880713|NCT03313245|||COHORT||CROSS_SECTIONAL|||||||
33880714|NCT05037110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880715|NCT01126775|||COHORT||PROSPECTIVE|||||||
33880716|NCT00918151|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33880717|NCT00785330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880718|NCT05298137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators propose a prospective, parallel group, open-label randomized controlled trial.||||
33880719|NCT02059200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880720|NCT01355705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880721|NCT00782366|||COHORT||PROSPECTIVE|||||||
33880722|NCT01162330|||COHORT||PROSPECTIVE|||||||
33880723|NCT04930575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33880724|NCT00268242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970539|NCT05121181|||OTHER||OTHER|||||||
33970540|NCT00534625|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33970541|NCT03294083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970542|NCT01322932|||CASE_ONLY||PROSPECTIVE|||||||
33970543|NCT06162403|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33970544|NCT04488471|||COHORT||PROSPECTIVE|||||||
33880725|NCT05020600|||COHORT||PROSPECTIVE|||||||
33880726|NCT01318330|NA|SINGLE_GROUP||||NONE||||||
33880727|NCT03310970|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33880728|NCT00799877|||COHORT||PROSPECTIVE|||||||
33880729|NCT06076577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880730|NCT06501651|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Controlled, Multicenter Study||||
33880731|NCT02560610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880732|NCT03714529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880733|NCT04663958|||OTHER||PROSPECTIVE|||||||
33880734|NCT03400800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33880735|NCT05697575|||CASE_ONLY||OTHER|||||||
33880736|NCT03849339|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880737|NCT04850209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The interventions are blind to follow-up personnel who collect and analyze compliance and the incidence of adverse events. The interventions are also blind to the UBT personnel.|There are two randomized parallel groups in this study, control group and Wechat group.|f|f|f|t
33970545|NCT05699707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-arm pilot study||||
33970546|NCT01297647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970547|NCT04495777|||CASE_ONLY||CROSS_SECTIONAL|||||||
33970548|NCT02577081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970549|NCT05694988|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be randomized stratified 1:1. The stratification criterion is the patient's SOFA index score.||||
33970550|NCT02175849|||COHORT||PROSPECTIVE|||||||
33970551|NCT03343106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970552|NCT06503744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970553|NCT02514590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970554|NCT01093742|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33970555|NCT02592694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970556|NCT04931628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970557|NCT04198181|||COHORT||PROSPECTIVE|||||||
33970558|NCT04011969|||CASE_ONLY||CROSS_SECTIONAL|||||||
33970559|NCT02242513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970560|NCT04966897|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Single center, randomized, double-blind, cross-over trial with a single blind stage evaluation assessing the GBNS for safety, tolerability and blood lipid levels compared to a standard nutritional supplement with PERT. Phase 1: After an overnight fast, subjects in Arm 1 administered PERT placebo with the GBNS and those in Arm 2 will be administered standard nutritional supplement with PERT. Blood samples collected at baseline and hourly over 6 hours for all subjects. Subjects will return for crossover treatment no fewer than 4 days and no more than 14 days after with the same steps as the above but with patients switching treatment arms. Phase 2: Starting the day following the 2nd treatment the 6 day, single-blind safety stage begins with subjects randomized to GBNS with PERT-placebo or the standard nutritional supplement with PERT. One week after the end of the Home Trial (+/- 3 days) patients will return for an end of study visit.|t|t|t|f
33970561|NCT06157281|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||3 lower-retention clinics will receive the intervention. Outcomes will be compared to those at all other lower-retention clinics of the same type within the same health system.||||
33970562|NCT05896293|NA|SINGLE_GROUP||OTHER||NONE||||||
33880738|NCT06454331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880739|NCT05416294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880740|NCT02175680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070028|NCT06359197|RANDOMIZED|PARALLEL||OTHER||TRIPLE||An external party will prepare an equal number of kits (n=18) containing all the required materials for the participants, both in the placebo and caffeine group. They will assign a unique random number to each of the packages; each number will correlate to either the placebo or caffeine group. When a participant agrees to the study, they will be given a unique participant ID number ranging from 0-36. Then, the external party will use a random number generator to pick the kit given to that participant. They will record the number associated with that kit, and link the kit number to the participant ID for tracking purposes. At the end of the study, the investigators will determine which participants received caffeine vs placebo based on the assigned random numbers.|t|f|t|t
34070029|NCT06107855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070030|NCT01945476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34070031|NCT00190164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070032|NCT06463197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers who will collect data from participants will be blinded||f|f|f|t
34070033|NCT04087369|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34070034|NCT00948922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070035|NCT03038711|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33880741|NCT01908647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070036|NCT02831946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070037|NCT00362622|||COHORT||PROSPECTIVE|||||||
34070038|NCT02182154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070039|NCT04073290|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34070040|NCT03369626|NA|SINGLE_GROUP||TREATMENT||NONE||evaluation of pre/post measures of a single group||||
34070041|NCT03852498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070042|NCT02906579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070043|NCT00168155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070044|NCT02253576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070045|NCT04074330|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070046|NCT04938921|||CASE_ONLY||PROSPECTIVE|||||||
34070047|NCT01716611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880742|NCT03350217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Investigator is blinded to the randomization process but can be unblinded after the product has been dispensed if the patient has a medical issue that requires it.||f|f|t|f
33880743|NCT00968851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880744|NCT03008395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880745|NCT06030843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880746|NCT00430508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880747|NCT02025426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880748|NCT03872804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880749|NCT05980520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880750|NCT03273166|NA|SINGLE_GROUP||OTHER||NONE||||||
33880751|NCT01182831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880752|NCT02041377|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33880753|NCT04814693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects in this study will be included in either the intervention arm (EndoRotor) of control arm (conventional procedures).|f|f|f|t
33880754|NCT01478854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880755|NCT03841357|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880756|NCT01420146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880757|NCT00575809|||OTHER||PROSPECTIVE|||||||
33880758|NCT05069584|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880759|NCT00280007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880760|NCT00398463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880761|NCT02282592|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33880762|NCT06196086|||COHORT||PROSPECTIVE|||||||
33880763|NCT04593654|||COHORT||RETROSPECTIVE|||||||
33880764|NCT05196854|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised Control Trial||||
33880765|NCT01141595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880766|NCT03206697|||COHORT||PROSPECTIVE|||||||
33880767|NCT06339879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel assignment||||
33880768|NCT00835315|||||PROSPECTIVE|||||||
33880769|NCT00961883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33880770|NCT00380328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880771|NCT02440815|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33880772|NCT03875261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880773|NCT00003385||||TREATMENT||||||||
33880774|NCT01079481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880775|NCT00939198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970563|NCT05971121|||CASE_CONTROL||PROSPECTIVE|||||||
34070048|NCT06171516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070049|NCT05833867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070050|NCT04336475|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34070051|NCT05362149|||COHORT||RETROSPECTIVE|||||||
34070052|NCT04753333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Experimental: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training along with patellar taping~No Intervention: Control: Participants in this group will receive Sham EMG-BF guided strength training without patellar taping"|t|f|f|t
33758898|NCT03817892|RANDOMIZED|FACTORIAL||OTHER||NONE|The participants being in cardiac arrest at the time of the performance of the study, they are not aware of the arm of randomization in which they are initialy and they are inform as soon as their clinical status allow it.|This is a randomized, multicenter, open-label study using a 2x2 factorial design comparing (i) the rhythm of External Chest Compression relays every 4 minutes versus every 2 minutes on the Chest Compression Fraction; (ii) the use of real-time guidance of the External Chest Compression via a feedback device (CPRmeter®) versus no guidance on the quality of the External Chest Compression (correct compression score).||||
34070053|NCT05361135|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33758899|NCT03076476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070054|NCT03549052|||COHORT||PROSPECTIVE|||||||
34070055|NCT04879706|||COHORT||PROSPECTIVE|||||||
33758900|NCT00521703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33758901|NCT02976142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758902|NCT02740049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758903|NCT01444859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758904|NCT01120249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33758905|NCT06329726|||COHORT||PROSPECTIVE|||||||
33758906|NCT00766675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758907|NCT03257332|||COHORT||PROSPECTIVE|||||||
33758908|NCT05897255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of the type of the intervention they would be receiving.|Parallel Group Randomized Control Trial|t|f|f|f
33758909|NCT01226901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758910|NCT05396989|||COHORT||PROSPECTIVE|||||||
33758911|NCT01984697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758912|NCT06201130|||OTHER||PROSPECTIVE|||||||
34070056|NCT01256099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070057|NCT04537013|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070058|NCT06224686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070059|NCT02841358|NA|SINGLE_GROUP||||NONE||||||
34070060|NCT00386074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33758913|NCT03455452|||COHORT||PROSPECTIVE|||||||
33758914|NCT00980369|||CASE_CONTROL||PROSPECTIVE|||||||
33758915|NCT04791072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758916|NCT00256503|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758917|NCT03469284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758918|NCT02386384|||CASE_CONTROL||PROSPECTIVE|||||||
33758919|NCT03258216|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33758920|NCT06579586|||FAMILY_BASED||PROSPECTIVE|||||||
33758921|NCT00253344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758922|NCT04646239|||COHORT||PROSPECTIVE|||||||
33758923|NCT01900600|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33758924|NCT05438654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|In light of final diagnosis, an adjudication committee will evaluate the best diagnostic approach, blind to intervention for each patient.|One group of patients suffering from right upper quadrant abdominal pain will undergo the intervention (Point of care ultrasound of the right upper quadrant). Diagnostic approach will be registered on a case report form (part 1 and part 2) before and after the intervention on a patient. In light of final diagnosis, an adjudication committee will then evaluate the best diagnostic approach, blind to intervention for each patient.||||
33758925|NCT02660814|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758926|NCT05503589|||COHORT||PROSPECTIVE|||||||
33758927|NCT06059976|||COHORT||OTHER|||||||
33758928|NCT04688125|||COHORT||RETROSPECTIVE|||||||
33758929|NCT00989092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758930|NCT03075384|||CASE_ONLY||PROSPECTIVE|||||||
33758931|NCT06018792|||COHORT||PROSPECTIVE|||||||
33758932|NCT00859963|||COHORT||PROSPECTIVE|||||||
33758933|NCT06139757|||COHORT||PROSPECTIVE|||||||
33758934|NCT04569110|||COHORT||RETROSPECTIVE|||||||
33758935|NCT05373355|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33758936|NCT04975269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind randomized trial.|t|t|t|t
33758937|NCT03760536|||CASE_ONLY||PROSPECTIVE|||||||
34070061|NCT02081014|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34070062|NCT01509664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070063|NCT02082769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070064|NCT03083808|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34070065|NCT03881202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070066|NCT03891355|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a prospective, multicenter, single arm, phase II trial designed to evaluate the safety and efficacy of the combination of Carfilzomib (K), Lenalidomide (R) and Dexamethasone (D) in patients with mantle cell lymphoma (MCL) relapsed/refractory (R/R) or intolerant to BTK inhibitor (BTKi) monotherapy or BTKi containing regimens.~The primary endpoint will be assessed 12 months after the start of treatment of the last patient. However, responsive patients (CR, PR, SD) may continue to receive K up to a maximum of 24 cycles and RD up to a maximum of 24 cycles. Patients who will interrupt therapy (for any reason) will be followed up to 12 months after the end of the treatment.~After checking inclusion and exclusion criteria and signing written informed consent, the patient will be enrolled with an identification numeric code."||||
33880776|NCT01407094|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||"Patients were entered into Stage 1, treated with sertraline (Treatment A) or placebo (Treatment B), and used for the primary analysis which included the identification of potential mediators and moderators of response for these two treatments.~In stage two, responders to Treatment A remained on sertraline, and non-responders were switched to bupropion (Treatment C). Responders to Treatment B remained on placebo, and non-responders were switched to sertraline (Treatment D)."|t|t|t|t
33880777|NCT03146572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33880778|NCT00185393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880779|NCT00796315|NA|SINGLE_GROUP||||NONE||||||
33758938|NCT00045708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758939|NCT03115684|||OTHER||PROSPECTIVE|||||||
33758940|NCT03123146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758941|NCT02833688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33758942|NCT00710606|NON_RANDOMIZED|PARALLEL||||NONE||||||
33758943|NCT00681304|||CASE_ONLY||PROSPECTIVE|||||||
33758944|NCT04606277|||OTHER||RETROSPECTIVE|||||||
33880780|NCT02491814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33880781|NCT05449678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880782|NCT02164656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880783|NCT01604070|||CASE_CONTROL||PROSPECTIVE|||||||
33880784|NCT05744739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880785|NCT01517477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880786|NCT00778037|RANDOMIZED|CROSSOVER||||NONE||||||
33880787|NCT05019131|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880788|NCT01238809|||COHORT||CROSS_SECTIONAL|||||||
33880789|NCT02229344|||COHORT||PROSPECTIVE|||||||
33880790|NCT02889432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880791|NCT04423250|||COHORT||OTHER|||||||
33880792|NCT03639090|||COHORT||PROSPECTIVE|||||||
33880793|NCT06501443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880794|NCT04851600|||COHORT||PROSPECTIVE|||||||
33880795|NCT04632498|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33880796|NCT01408147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970564|NCT03480711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"participants are going to be randomly assigned into two groups outcomes assessor will asses~1. visual acuity and BCVA~2. IOP using Goldmann applanation tonometry~3. slit-lamp and fundus examination of cup-disc ratio,~4. Ultrasound Biomicroscopy (UBM) to assese ostium patency and extent of bleb area will be done once after 6 weeks post-operatively.~5. Colored photography of the filtering blebs will be performed for grading. Bleb grading will be classified according moorfields grading scale~6. Perimetry will be performed at the end of follow up."|Randomized non-controlled comparative prospective interventional study|t|f|f|t
33758945|NCT01359670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33758946|NCT01180543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758947|NCT01572025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970565|NCT00415532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970566|NCT01767441|||COHORT||PROSPECTIVE|||||||
33758948|NCT06078579|||CASE_CONTROL||OTHER|||||||
33758949|NCT03170011|NA|SINGLE_GROUP||TREATMENT||NONE||This cohort design study will examine the effects of a six week training program using the Biodex Sit2Stand Trainer.||||
33758950|NCT05605210|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33758951|NCT01965938|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33758952|NCT04653441|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The proposed multimodal Child Caregiver-Advocacy-Resilience intervention (ChildCARE) will include three integrated components: the individual child (peer-group activities), family (caregiver parenting skill training), and the local community (community advocacy)."||||
33970567|NCT05895084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970568|NCT00423800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970569|NCT05885360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070067|NCT02472262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34070068|NCT01344694|||||RETROSPECTIVE|||||||
34070069|NCT01887288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070070|NCT04330222|||COHORT||PROSPECTIVE|||||||
34070071|NCT06082726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34070072|NCT03845244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34070073|NCT01183416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070074|NCT05762640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758953|NCT02093767|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34070075|NCT03846544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34070076|NCT01115387|||CASE_CONTROL||PROSPECTIVE|||||||
34070077|NCT00005049||||TREATMENT||||||||
34070078|NCT04638556|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34070079|NCT01184612|RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
34070080|NCT02112019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33758954|NCT03301012|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants in the control and experimental condition will have access to post treatment recovery support services as usual.~Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-A mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle."||||
33758955|NCT02721576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758956|NCT03790761|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33758957|NCT02942602|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33758958|NCT05272332|||CASE_ONLY||PROSPECTIVE|||||||
33758959|NCT06259383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758960|NCT03781921|||COHORT||CROSS_SECTIONAL|||||||
33758961|NCT05672979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758962|NCT01385358|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758963|NCT01075932|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33758964|NCT05547243|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33758965|NCT05574725|||COHORT||PROSPECTIVE|||||||
33758966|NCT02319226|||COHORT||PROSPECTIVE|||||||
33764914|NCT03776994|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Subjects will be blinded to receiving the non-adjuvanted versus adjuvanted vaccines, but will not be blinded to the vaccine dosage. Vaccines will be brought into the subject rooms in a concealed container, and subjects will be asked to turn away from the dosing arm so that the SRI Clinical Trials' Unit (CTU) staff can prepare and administer the dose. Subjects may be unblinded if subject experiences a Serious Adverse Event (SAE) and upon notification to the data review team, called Protocol Safety Review Team (PSRT).|To assess the safety and immunogenicity of a monovalent Venezuelan Equine Encephalitis (VEE) Virus-like Particle (VLP) Vaccine in healthy adults for protection against exposure to VEE virus (VEEV).|t|f|f|f
33764915|NCT00709748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764916|NCT06512103|||CASE_CONTROL||PROSPECTIVE|||||||
33764917|NCT01023568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33764918|NCT03353259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880797|NCT03276195|||FAMILY_BASED||PROSPECTIVE|||||||
33880798|NCT01442883|||COHORT||PROSPECTIVE|||||||
33880799|NCT02077088|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33880800|NCT04239625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880801|NCT02270203|||COHORT||PROSPECTIVE|||||||
33880802|NCT02956161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33880803|NCT04206449|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33880804|NCT00009971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880805|NCT03978559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880806|NCT00704964|||CASE_ONLY||PROSPECTIVE|||||||
33880807|NCT01864278|||CASE_ONLY||PROSPECTIVE|||||||
33880808|NCT00758355|||COHORT||PROSPECTIVE|||||||
33880809|NCT01555203|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33880810|NCT01157039|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970570|NCT04721457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocated mouth rinses will be concealed in opaque sealed envelopes. Each envelope contains a 15 ml sterile amber test tube filled with the assigned mouth rinse, a 120 ml sterile empty specimen container for expectoration of the mouth rinse, and four identical empty 50 ml sterile test tubes for collecting saliva samples, each labeled with the allocated number and time point (T0, T1, T2, or T3), and a biohazard bag.|This randomizeda, single-center, randomized, double-blind, six-parallel-group, placebo-controlled trial compares the efficacy of four commercially available mouth rinses povidone-iodine (PVP-I), hydrogen peroxide (H2O2), cetylpyridinium chloride (CPC), sodium hypochlorite (NaOCl) on the salivary SARS-CoV-2 viral load at four-time points (baseline and 5-, 30-, and 60-min post rinsing) relative to two control groups (distilled water and no-rinse) in a cohort of positive COVID-19 patients.|t|f|t|f
33880811|NCT03433170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880812|NCT05599490|NA|SINGLE_GROUP||TREATMENT||NONE|The Investigators and Assessors will be blinded to the previous treatment assignment of participants from the Phase II study.|||||
33880813|NCT01781494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880814|NCT01526668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880815|NCT02911428|||COHORT||PROSPECTIVE|||||||
33880816|NCT00717600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880817|NCT04025827|||COHORT||PROSPECTIVE|||||||
33880818|NCT04583371|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a randomized crossover clinical trial in which the individuals selected for the study will be randomized to receive isolated tracheal aspiration (Control Group) and pulmonary hyperinflation through the mechanical ventilator associated with tracheal aspiration (Intervention Group). Randomization will be performed through the randomization.com website by a 1: 1 crossed block, allocating the patient to one of the groups and, after 24 hours, another technique will be performed. In addition, a control aspiration will be performed 2 hours before both techniques.|t|f|f|f
33880819|NCT06287034|||COHORT||PROSPECTIVE|||||||
33880820|NCT03742037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants randomized to the 4 mg arm who are still on treatment at month 6 will be re-randomized in a 1:1 ratio to placebo or cenerimod 2 mg to enter Treatment Period 2 and will continue study treatment for a total maximum of 12 months.|t|t|t|t
33970571|NCT02886975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764919|NCT04502056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880821|NCT05154695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.~They are randomly assigned into two groups (40 subjects in each group): A. therapeutic ultrasound group; B. prolotherapy group. The same physician (the principal investigator) injects all participants to avoid inter-physician variability. No other medication or physical modality was given to avoid efficacy interference in both groups.~Rescue therapy (cross-over treatment): If the participant does not satisfy with their first round treatment and the improvement of VAS is less than 1.0, then they are eligible to receive the rescue therapy-the treatment in the other group"||||
33880822|NCT04517084|||COHORT||RETROSPECTIVE|||||||
33880823|NCT01887977|NA|SINGLE_GROUP||||NONE||||||
33970572|NCT02042911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970573|NCT04186390|||COHORT||PROSPECTIVE|||||||
33970574|NCT03720483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970575|NCT01164033|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970576|NCT04251182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug packaging and labeling will maintain the double-blind design of the study. T3D-959 and placebo capsules will be identical in appearance. Therefore, the subject's treatment assignment will not be known to the subject or the study site personnel. None of the persons directly involved in the conduct of the study will have access to the treatment code. The DSMB and persons involved with reporting to the DSMB (as outlined within the DSMB Charter) will have access to the treatment code. The treatment code will be released to the study team after the study database has been locked.|A randomized, double-blind, placebo-controlled design evaluating three dose levels (15 mg, 30 mg, 45 mg) of T3D-959 in subjects with mild-to-moderate Alzheimer's Disease. Subjects will be stratified by ApoE4 genotype and assigned to one of four dose groups (1:1:1:1 ratio) in a randomized fashion.|t|t|t|t
33970577|NCT00095290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970578|NCT04109157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970579|NCT03786666|||COHORT||PROSPECTIVE|||||||
33970580|NCT05332561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Umbrella||||
33970581|NCT06529315|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33970582|NCT02765828|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970583|NCT00001089|||NATURAL_HISTORY|||||||||
33764920|NCT02430363|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764921|NCT04718558|||CASE_CONTROL||PROSPECTIVE|||||||
33764922|NCT06625268|||COHORT||CROSS_SECTIONAL|||||||
33764923|NCT02895022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764924|NCT04886427|||COHORT||CROSS_SECTIONAL|||||||
33764925|NCT03717402|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33764926|NCT02424591|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33764927|NCT02576158|||OTHER||PROSPECTIVE|||||||
33880824|NCT00563342|NA|SINGLE_GROUP||TREATMENT||||||||
34070081|NCT04470479|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This was a placebo-controlled, crossover study that involved patients with Sjögren's syndrome to use 20mg/day of oral pilocarpine or placebo for ten weeks and after two weeks of medication withdrawal, to invert the treatment for the same period of time. The assessments applied were the Ocular Surface Disease Index, NEI-VFQ-25 questionnaire, non-invasive break-up time, traditional break-up time, evaluation of the cornea and ocular surface with fluorescein and rose bengal dyes, Schirmer test, tear ferning test, osmolarity and the activity of lysozyme. R|t|f|t|f
34070082|NCT03737799|||COHORT||PROSPECTIVE|||||||
34070083|NCT05233215|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33880825|NCT00417586|||COHORT||PROSPECTIVE|||||||
33764928|NCT00771303|||COHORT||PROSPECTIVE|||||||
33764929|NCT00041756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764930|NCT03498222|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33880826|NCT04421274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880827|NCT01091701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880828|NCT03609307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33880829|NCT05877976|NA|SINGLE_GROUP||OTHER||NONE||||||
33880830|NCT04762628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880831|NCT02962050|||COHORT||PROSPECTIVE|||||||
33880832|NCT04789486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880833|NCT00654862|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33880834|NCT02798796|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880835|NCT05532410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070084|NCT01831271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970584|NCT00306384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970585|NCT04316052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970586|NCT03237585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970587|NCT00594633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970588|NCT00548210|||||PROSPECTIVE|||||||
33970589|NCT04378010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970590|NCT01942798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970591|NCT02814292|||COHORT||PROSPECTIVE|||||||
33970592|NCT00796237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970593|NCT03210675|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, comparative, open label, multi-center study||||
33970594|NCT03293927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764931|NCT03203694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to either a walking, a lower body heating, or no intervention.||||
33764932|NCT04479722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764933|NCT04089098|||COHORT||PROSPECTIVE|||||||
33764934|NCT06625957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764935|NCT03193671|||COHORT||PROSPECTIVE|||||||
33880836|NCT01042600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880837|NCT01602445|||COHORT||PROSPECTIVE|||||||
33880838|NCT02113735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880839|NCT01332071|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33880840|NCT01699555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880841|NCT01400451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880842|NCT01512264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880843|NCT03132181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880844|NCT05410288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To maintain assessor blinding, all interventions will be delivered by the part-time research assistant with health-related education background. All assessments and data entry will be performed by an independent full-time research assistant. In addition, the treatment and assessment will be conducted at different sites. Any analysts or statisticians involved in data management will also be blinded to the identification of each treatment group until the final efficacy analysis for each treatment group has been completed.||t|t|t|t
33880845|NCT02072031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880846|NCT04409873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Study participants will be blinded to the solutions to the extent possible (i.e., similar packages with identification number bar codes).~The lab technician who evaluates the SARS-CoV-2 load in samples will be blinded to the solutions and study groups."|A blinded randomized controlled parallel group design trial|t|f|f|t
33880847|NCT03965559|||COHORT||RETROSPECTIVE|||||||
33880848|NCT04702165|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33880849|NCT03899454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||two arm treatment|t|f|t|f
33880850|NCT05256498|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33880851|NCT01654510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880852|NCT04372927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880853|NCT01418001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880854|NCT06549569|||CASE_ONLY||PROSPECTIVE|||||||
33880855|NCT03981783|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comprehensive Health Informatics Engagement Framework for Pulmonary Rehabilitation (CHIEF-PR) will facilitate PR referrals, initial assessments, completion rates, and PR maintenance using multi-pronged approach at the healthcare, provider and patient levels that addresses current barriers for PR uptake and completion.||||
33880856|NCT01763450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880857|NCT03602079|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33880858|NCT02799680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880859|NCT05530993|||COHORT||PROSPECTIVE|||||||
33880860|NCT03770065|||CASE_ONLY||PROSPECTIVE|||||||
33880861|NCT04783636|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33880862|NCT01635478|||CASE_ONLY||PROSPECTIVE|||||||
33880863|NCT01975012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880864|NCT02490085|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880865|NCT04682886|||COHORT||PROSPECTIVE|||||||
33880866|NCT02163174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880867|NCT00393874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880868|NCT03584867|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study. Experimental group would receive a refresher training at six months wherease the control receive not training.||||
33880869|NCT04927728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880870|NCT00702078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880871|NCT00931398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880872|NCT03870555|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33758967|NCT06065566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A third person, the cardiothoracic surgery floor nurse, will assign the patients to the study group or control group by means of a sealed envelope. Registration will be carried out by this single person until the final results are revealed.|"1. Once the candidate patients undergo surgery for cardiac surgery with and without cardiopulmonary bypass, the inclusion criteria will be verified. Once their inclusion in the study has been accepted, the patient must sign their informed consent letter and will be randomly assigned by closed envelope, to a study group or to a control group. The patient's weight and height will be taken once he accepts inclusion in the study and the data collection notebook will be filled.~A. Study group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the dipeptide L-alanyl-L-glutamine, at a dose of 0.4 g / kg of weight 6 hours before the surgical intervention.~B. Control group: patients undergoing cardiac surgery with and without cardiopulmonary bypass, who will receive the placebo in the form of saline solution in a volume similar to the control 6 hours before the surgical intervention."|f|t|f|f
33758968|NCT04670692|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33758969|NCT03373526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial, with only statistical analysis blinded|f|f|f|t
33758970|NCT03684122|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33758971|NCT02577055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33758972|NCT05147948|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial with waitlist control.||||
33758973|NCT00002488||||TREATMENT||||||||
33758974|NCT01361425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970595|NCT00585091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970596|NCT01345409|||COHORT||PROSPECTIVE|||||||
33970597|NCT00539539|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970598|NCT01696864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758975|NCT02073825|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33758976|NCT02454192|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970599|NCT05673187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970600|NCT01199601|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33970601|NCT00004451|RANDOMIZED|||TREATMENT||DOUBLE||||||
33970602|NCT01162499|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33970603|NCT05989360|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970604|NCT02797964|NA|SEQUENTIAL||TREATMENT||NONE||||||
33970605|NCT03305432|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33970606|NCT00000616|RANDOMIZED|||PREVENTION||||||||
33970607|NCT02974413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970608|NCT03136692|||COHORT||RETROSPECTIVE|||||||
33758977|NCT02028026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758978|NCT03160989|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33758979|NCT05232864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758980|NCT04065503|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33758981|NCT04292782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33758982|NCT02324556|||CASE_CONTROL||PROSPECTIVE|||||||
33758983|NCT06391710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758984|NCT00691938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758985|NCT02805426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758986|NCT02123602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33758987|NCT02623465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33758988|NCT03359070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33758989|NCT05994144|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||For all participants who are randomised into VOT arm or traditional DOTS arm. Control group : Patients allocated into the traditional DOTS arm will follow the usual protocol as all other patients assigned to DOTS under Ministry of Health Malaysia Intervention group : Patient will be observed on their daily TB medication consumption via teleconference by using WhatsApp video call.||||
33758990|NCT02635802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33758991|NCT04176380|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking|||||
33758992|NCT01277055|||COHORT||PROSPECTIVE|||||||
33880873|NCT00060346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880874|NCT03719157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880875|NCT01857869|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33880876|NCT03984058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33880877|NCT00866138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880878|NCT02740478|||CASE_ONLY||CROSS_SECTIONAL|||||||
33880879|NCT04072458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880880|NCT04340973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Everyone is blinded, codes are selected by a third party not involved in any step of the study|5 groups, each group receives one of four treatments or the sham treatment. Double-blinded, sham controlled study|t|t|t|t
33880881|NCT06025435|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33894513|NCT06656546|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|During the endotracheal intubation procedure, the intubation itself and associated interventions will be performed by the patient's attending physician and healthcare team. The ultrasound operator, who will be blinded to the intubation process and its outcomes, will wear soundproof headphones to ensure no external auditory cues influence their assessment. The ultrasound operator will determine the intubation placement solely based on their ultrasound findings, and only the operator will have access to the ultrasound images. The rest of the team will remain blinded to the ultrasound results. Additionally, a designated individual will record the duration of the procedures for both the intubation and ultrasound teams to ensure accurate time tracking.||f|t|t|f
33894514|NCT01854177|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33758993|NCT05570643|RANDOMIZED|PARALLEL||OTHER||NONE|LPS is a non-investigational product and will only be used as a challenge agent to induce systemic inflammation. Since the effects op LPS-induced systemic inflammation are profound, no masking will be required.|An pilot study to explore the effects of a LPS-challenge on functional capacity and gene expression of human stem and hematopoietic progenitor cells and blood leukocytes. Subjects will be allocated to a LPS group (n=8 healthy volunteers) that will be challenged with endotoxin twice, or to a placebo group (n=4) who will undergo the same study procedures but receive a placebo challenge (NaCl 0.9%).||||
33758994|NCT02253355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33758995|NCT01677143|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33758996|NCT00156143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33758997|NCT06454617|||COHORT||PROSPECTIVE|||||||
33758998|NCT01669798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33758999|NCT02294578|||CASE_CONTROL||PROSPECTIVE|||||||
33759000|NCT06405399|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were blinded in their group assignment.||t|f|f|f
33759001|NCT01207570|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33759002|NCT02422602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33759003|NCT04309916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759004|NCT04204369|NA|SINGLE_GROUP||OTHER||NONE||One group receiving intervention. Assessement prior to intervention, immediately after, and at 6 months.||||
33759005|NCT04663451|||COHORT||RETROSPECTIVE|||||||
33759006|NCT04930692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759007|NCT05029258|||COHORT||PROSPECTIVE|||||||
33759008|NCT05129943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participants will carry the controller with a box to hide the controller (to keep the outcomes assessor blinded) and wear the VR device by an assistant ( to keep investigator blinded).|the participants will be divided into ( active distraction group) and ( passive distraction group )|f|f|t|t
33759009|NCT05224258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759010|NCT05493592|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prescription of a standardized 24-week physical activity protocol alone or accompanied by the consumption of 100 grams of pigeon peas (Cajanus cajan) per meal three times a week.||||
33759011|NCT00709462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759012|NCT02355067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970609|NCT06073795|||COHORT||PROSPECTIVE|||||||
33970610|NCT05822700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970611|NCT01536678|RANDOMIZED|CROSSOVER||||NONE||||||
33970612|NCT06107361|RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective, parallel, non-blinded, two-arm randomized (like the flip of a coin) controlled trial of catheter failure evaluating the impact of a built-in guide wire. This study plans to enroll 360 participants (two equally sized groups of 180 participants in each arm)||||
33880882|NCT04568226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to ConquerFear or control arms.~The participants are masked in terms of not knowing that one intervention (i.e. Conquer fear) is hypothesized to yield larger effects than the other (i.e. control)."|"We will use a block randomization structure with randomly permuted block sizes of 2,4, and 6 to ensure a close balance of the numbers in each arm. Randomization (by a statistician) occurs prior to eligible patients attending the clinic to minimize opportunities for selection bias.~We will also use a block randomization structure with randomly permuted block sizes of 4 and 8 to ensure an equal case allocation to each therapist.~We will also use a block randomization structure with randomly permuted block sizes of 2,4, and 6 to ensure an equal case allocation to each dietitian."|t|t|t|t
33880883|NCT02942667|||OTHER||PROSPECTIVE|||||||
33880884|NCT01558362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970613|NCT02429700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970614|NCT00000910|||||PROSPECTIVE|||||||
33970615|NCT01772368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33970616|NCT03619499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970617|NCT06479044|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33970618|NCT01798485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970619|NCT06419348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970620|NCT06528041|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||13 week, 2 arm parallel, double blind, randomised, placebo-controlled trial|t|t|t|t
33970621|NCT01231061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970622|NCT05606692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33970623|NCT05139966|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The products have a serial number and different colors|A randomized, triple-blind crossover clinical trial study was performed to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of mouthwash with experimental fluoride for one week, with wash-out periods between them|f|t|f|f
33970624|NCT04091269|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||PSV+ Automatic adjustmen of inspiratory triger and cycling-off based on waveform PSV with fixed inspiratory and expiratory NAVA||||
33970625|NCT02613637|||OTHER||PROSPECTIVE|||||||
33970626|NCT02384226|||COHORT||PROSPECTIVE|||||||
33970627|NCT03843177|||CASE_CONTROL||PROSPECTIVE|||||||
33970628|NCT00164606|RANDOMIZED|FACTORIAL||PREVENTION||||||||
33970629|NCT02911883|||COHORT||PROSPECTIVE|||||||
33970630|NCT05274503|||CASE_ONLY||PROSPECTIVE|||||||
33970631|NCT02611752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970632|NCT04866797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970633|NCT01007916|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33970634|NCT05364099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970635|NCT03355378|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970636|NCT05025423|NA|SEQUENTIAL||TREATMENT||NONE||Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.||||
33970637|NCT03035838|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33970638|NCT04359992|||COHORT||PROSPECTIVE|||||||
33970639|NCT03878355|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned 1:1:1 to receive FESS, RESS and RESS plus Draf 3 surgery.||||
33970640|NCT00564369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33970641|NCT02561312|||CASE_CROSSOVER||PROSPECTIVE|||||||
33970642|NCT03801096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research Assistant collecting data will be blinded to condition|Two-group randomized controlled trial (RCT) design|f|f|f|t
33970643|NCT05816733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33970644|NCT06316271|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33970645|NCT03815357|||COHORT||PROSPECTIVE|||||||
33970646|NCT04921683|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A single group model is when a group of subjects is administered treatment/exposure to device. Then it is measured and observed using behavioral and diagnostic tools over a specified amount of time throughout the study.||||
33970647|NCT02268513|||COHORT||PROSPECTIVE|||||||
33970648|NCT05778279|||COHORT||PROSPECTIVE|||||||
33970649|NCT02684500|||CASE_ONLY||PROSPECTIVE|||||||
33759013|NCT03835325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759014|NCT00367965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759015|NCT04547725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Arm-A: resectable advanced gastric adenocarcinoma with limited PC (PCI ≤ 10) Arm-B: resectable advanced gastric adenocarcinoma with positive peritoneal wash cytology (CY1/P0)|Complete cytoreductive surgery followed by intraperitoneal and systemic chemotherapies||||
33759016|NCT03203655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759017|NCT02330432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33759018|NCT01227122|||CASE_ONLY||PROSPECTIVE|||||||
33759019|NCT05129267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759020|NCT00948974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759021|NCT04978155|||CASE_CONTROL||PROSPECTIVE|||||||
33759022|NCT00421434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759023|NCT03794622|||CASE_CONTROL||PROSPECTIVE|||||||
33759024|NCT01058304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759025|NCT00980317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759026|NCT00551252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759027|NCT02227875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759028|NCT01972633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759029|NCT04258956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759030|NCT01807364|||COHORT||CROSS_SECTIONAL|||||||
33759031|NCT02749357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759032|NCT02003352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759033|NCT00261495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759034|NCT00808574|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33759035|NCT06434948|RANDOMIZED|PARALLEL||PREVENTION||NONE|This study will not be blinded as there is no suitable placebo for omega-3 ethyl esters available at this time.|Arm 1: 4 grams of Omega-3 Ethyl Esters Arm 2: 2 grams of Omega-3 Ethyl Esters Arm 3: Standard of care||||
33759036|NCT00325364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759037|NCT00404495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759038|NCT03045848|||COHORT||PROSPECTIVE|||||||
33759039|NCT03279835|||OTHER||PROSPECTIVE|||||||
33759040|NCT02094443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759041|NCT00218881|RANDOMIZED|FACTORIAL||ECT||NONE||||||
33880885|NCT06539546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880886|NCT01237366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880887|NCT04031703|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1：6 cycles of PC (Paclitaxel 80 mg/m2 ivgtt d1,8,15+ Carboplatin Auc = 2 ivgtt d1,8,15, 28 days per cycle).~Arm 2：3 cycles of FEC (epirubicin100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)"||||
33894515|NCT05541315|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33894516|NCT03116113|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33894517|NCT05430867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970650|NCT01787214|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33970651|NCT00977964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070085|NCT03793959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Twenty eligible athletes (baseline Hgb:12.3±0.9g/dL; sFer:18.1±9.2µg/L) were then randomized to receive either a daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis) or placebo, along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks using a double-blind design.|t|f|t|t
34070086|NCT05680662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070087|NCT05823103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970652|NCT05544851|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."|"Inclusion Criteria / Patient~Women of reproductive age (range 18-49 years) No history of STD, literate, Ability to understand and answer questions Those who have not received training on STDs before,~Exclusion Criteria from Research~Getting training on STDs before Absence from education for at least two sessions, Women with a history of STD (HIV, HPV, etc.) disease will be excluded from the study."|t|f|f|f
33759042|NCT03684486|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33759043|NCT00003092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970653|NCT01534975|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||randomized cohort into 4 groups - each group with a different contrast agent (omnipaque, visipaque 280, visipaque 320, isovue)|t|t|t|f
34070088|NCT02436499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070089|NCT05489107|||COHORT||PROSPECTIVE|||||||
34070090|NCT04831996|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Open Label|||||
34070091|NCT04664907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070092|NCT06551298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759044|NCT02571270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070093|NCT03485079|||COHORT||PROSPECTIVE|||||||
33759045|NCT00676182|||CASE_ONLY||PROSPECTIVE|||||||
33759046|NCT06144424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759047|NCT04581655|||COHORT||PROSPECTIVE|||||||
33759048|NCT02961530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759049|NCT04193839|||COHORT||PROSPECTIVE|||||||
33759050|NCT05584891|||COHORT||PROSPECTIVE|||||||
33759051|NCT04997707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33759052|NCT04882774|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||32 week study in 30 subjects. Those who meet certain hemodynamic criteria at Week 16 will begin study drug and continue diuresis protocol while the remaining participants continue with the diuresis protocol only.||||
33759053|NCT00019539||||TREATMENT||||||||
33759054|NCT04418635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33759055|NCT01518855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070094|NCT01358786|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|f|t
33759056|NCT03831321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind placebo controlled||t|t|f|f
33759057|NCT00435279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759058|NCT03358056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759059|NCT03403322|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The person that performed data analysis was blind to all conditions.||f|f|f|t
33759060|NCT02605564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759061|NCT06320886|||CASE_ONLY||OTHER|||||||
33759062|NCT02481284|||||PROSPECTIVE|||||||
33759063|NCT03362359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759064|NCT04896632|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33759065|NCT04031482|||COHORT||PROSPECTIVE|||||||
33759066|NCT01875185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759067|NCT02551523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759068|NCT01713725|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33759069|NCT01330602|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33759070|NCT05666284|||CASE_ONLY||RETROSPECTIVE|||||||
33759071|NCT04550325|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase 1/2 Open Label, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients with Pneumonia||||
33759072|NCT01488916|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33759073|NCT00571961|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34070095|NCT00797394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070096|NCT02069106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070097|NCT02447341|||CASE_ONLY||RETROSPECTIVE|||||||
34070098|NCT02624635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070099|NCT01225926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070100|NCT00828061|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34070101|NCT02098395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070102|NCT04704271|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34070103|NCT03969615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070104|NCT06252155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Before starting the research, two groups of mothers will be randomly formed. As a randomization method, mothers who meet the sampling inclusion criteria determined in the research will be identified and listed. Individuals to be taken into two groups will be determined by randomization method from the random numbers table. (http://www.stattrek.com/statistics/randomnumber-generator.aspx).|t|f|f|t
33759074|NCT00628797|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33880888|NCT03423342|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|Randomization and dispensing of matching placebo will be performed by Investigational Drug Services at the University of Washington|2:1 randomization to nicotinamide riboside vs. matching placebo|t|t|t|f
33880889|NCT04743557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880890|NCT02173795|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33880891|NCT01228123|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33880892|NCT05558540|NA|SINGLE_GROUP||TREATMENT||NONE|Due to the nature of the intervention, masking is not possible. All participants will receive a SCS.|All women participating in the trial will receive a SCS. Women will first undergo a trial period of 14 days. If succesful (\>50% pain reduction), women will receive a permanently implanted SCS. The follow-up period will enclose 12 months. There is an aimed sample size of 15 participants. However, due to financial limitations, inclusion will stop after 10 women have been succesfully implanted with a permanent SCS.||||
33880893|NCT06260280|||COHORT||PROSPECTIVE|||||||
33880894|NCT06405464|||COHORT||PROSPECTIVE|||||||
33880895|NCT03321097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880896|NCT04277845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880897|NCT02897895|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33880898|NCT06549829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880899|NCT00526682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33880900|NCT05439499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880901|NCT03982095|||OTHER||CROSS_SECTIONAL|||||||
33880902|NCT00599859||PARALLEL||BASIC_SCIENCE||NONE||||||
33880903|NCT02068547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33880904|NCT02485145|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33880905|NCT05117359|||COHORT||RETROSPECTIVE|||||||
33880906|NCT00327522|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33880907|NCT04307108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880908|NCT05624060|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33880909|NCT02494531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880910|NCT02014064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880911|NCT02290795|||CASE_CONTROL||PROSPECTIVE|||||||
33880912|NCT01578980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880913|NCT00274365|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33880914|NCT02792842|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33880915|NCT02757170|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33880916|NCT02700737|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33880917|NCT00892632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880918|NCT03277976|||COHORT||PROSPECTIVE|||||||
33880919|NCT03390062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070105|NCT01815502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070106|NCT05327205|||COHORT||RETROSPECTIVE|||||||
34070107|NCT06045611|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34070108|NCT02950922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880920|NCT02436850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880921|NCT01906177|||COHORT||PROSPECTIVE|||||||
33880922|NCT02407678|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is designated as Open Label with no masking. However, in order to minimise bias evaluation of the treated eye and untreated fellow eye (control eye), the ophthalmic assessments (visual acuity, microperimetry, fundus autofluorescence, etc.) will be conducted by an appropriately qualified masked observer once the participant's treated eye has had time to heal after the surgical procedure and has regained its normal appearance and function.|"The decision about which eye to treat will be made on clinical grounds and will generally be the worse eye affected in cases where BCVA differs between the two eyes by 2 lines or more of ETDRS letters. The eye to be treated will be randomised in cases where the degeneration is relatively symmetrical between the two eyes, defined as:~* a difference in BCVA of no more than 1 line of ETDRS letters, and~* no more than 25% difference in the area of surviving RPE as measured by fundus autofluorescence.~Prospective participants having non-symmetrical retinal degeneration will be allocated to the non-randomised arm. The treated eye will generally be the worse eye. Prospective participants having relatively symmetrical retinal degeneration will be allocated to the randomised arm."||||
33880923|NCT04949100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880924|NCT02266693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880925|NCT05556499|||COHORT||PROSPECTIVE|||||||
33970654|NCT00772577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880926|NCT06189937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be blinded to their study arm due to the nature of the intervention, but outcome assessors will be blinded.|A pilot randomized control trial involving 60 participants will be conducted. 30 randomly allocated participants will receive CA-CBT and 30 randomly allocated participants will receive Enhanced Care as Usual (E-CAU) as the control group. One week after the completion of the sessions, all participants including control group participants will have post-assessments consisting of the same questionnaires as baseline assessment with assessors. One month after the post-assessment, with the assessors, all participants including control group participants will have follow-up assessments consisting of the same questionnaires as baseline and post-assessments. After completing all assessments, CA-CBT will be offered to control group participants.|f|f|f|t
33880927|NCT05483530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880928|NCT01249352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880929|NCT01726946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970655|NCT04822662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blinded (Participant, Outcomes Assessor)|In this study, stratified sampling was employed based on age and sex. Two strata, \[12-14 age, girl\] and \[15-18 age, boy\], were generated to ensure even distribution in terms of age and sex in each group. First, thirty-six adolescent were stratified into two groups (A and B), which were then stratified again into two: \[12-14 age, girl\] and \[15-18 age, boy\]. A scheme was developed to randomize the age and sex of \[12-14, girl\] and \[15-18 age, boy\] into two groups (A and B), resulting in the experimental and control groups stratified by the age and sex and blocked into paired-groups of (2:2/\[12-14 age, girl\]:\[15-18 age, boy\]). Permutation was also used to strike a balance between the strata. Block sets were generated for each combination of the prognostic factors (age and sex). The experimental and control groups were then randomized into the strata using a random numbers table.|t|f|f|f
33880930|NCT03063580|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33970656|NCT02996903|||OTHER||PROSPECTIVE|||||||
33970657|NCT04579328|RANDOMIZED|PARALLEL||OTHER||SINGLE|enumerators interviewing/testing the participants on their understanding of the messages will not know whether or not the participants have been exposed to the growth mats (intervention).|Participants are assigned to intervention and control groups. At the end of a 3-month intervention, differences in comprehension of messages on stunting will be measured. Additionally, focus groups in the general community will collect information on perceptions of the messages and growth mats.|f|f|f|t
33970658|NCT01945099|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970659|NCT04749524|||CASE_CONTROL||OTHER|||||||
33970660|NCT03035227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970661|NCT05383274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970662|NCT00919958|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33880931|NCT04438174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Wound digital images will be assessed and evaluated by two University Staff members blinded to both the control and treatment group (one primary and one secondary).||f|f|f|t
33970663|NCT01692158|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970664|NCT03054025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33970665|NCT02243020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970666|NCT00773877|||||PROSPECTIVE|||||||
33970667|NCT03414164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33880932|NCT03064841|||COHORT||CROSS_SECTIONAL|||||||
33970668|NCT04342403|||COHORT||PROSPECTIVE|||||||
34070109|NCT03928275|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be randomized to first stage treatment and allocated to 1) IL-2 or 2) IL-2/BCG treatment. First stage treatment patients receive 4 treatments of 1) IL-2 or 2) IL-2 and BCG. Patient response will be determined for treatment groups following iRECIST guidelines as; 1) complete responder, 2) partial responder, or 3) stable disease. In second stage treatment, patients who completely respond to first stage treatment will be randomized to 1) discontinue treatment and followed every 3 mos for 2 yrs and then every 6 mos from yrs 3-5, or 2) will receive 2 additional treatments and then followed every 3 mos for 2 yrs and then every 6 mos from yrs 3-5. Patients that do not completely respond to first stage treatment, will be re-staged using a PET/CT scan. Patients not requiring escalation to systemic therapy will be randomized and advance to second stage treatment (IL-2, IL-2 and BCG, or BCG).||||
33880933|NCT03830710|||OTHER||PROSPECTIVE|||||||
34070110|NCT00088309||||TREATMENT||||||||
33880934|NCT03861143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter study with an optional open label extension (OLE) period. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 compared to placebo in subjects with UC. This study includes 3 periods: induction, maintenance, and an optional OLE period.|t|f|t|t
33880935|NCT06286748|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33880936|NCT03766880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33880937|NCT04163068|||OTHER||OTHER|||||||
33880938|NCT05304507|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An independent statistician, blinded to group allocation, will analyze data|Non-randomized pilot study|f|f|f|t
33880939|NCT01088581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33880940|NCT02978092|||||RETROSPECTIVE|||||||
33880941|NCT05878652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33880942|NCT02750787|NA|SINGLE_GROUP||OTHER||NONE||||||
33880943|NCT02527980|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33880944|NCT02561091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880945|NCT04808856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880946|NCT02750163|||CASE_ONLY||PROSPECTIVE|||||||
33880947|NCT00104546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33880948|NCT02613598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880949|NCT01179074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880950|NCT05276479|||COHORT||CROSS_SECTIONAL|||||||
33880951|NCT02650037|||COHORT||PROSPECTIVE|||||||
33880952|NCT01414257|||CASE_ONLY||PROSPECTIVE|||||||
33880953|NCT00789529|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33880954|NCT04067063|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33880955|NCT00883337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759075|NCT05655754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization of the study drug will be done using the software www.meduniwien.ac.at/randomizer according to consecutive CRF numbers. Stratification according to baseline HAMD17 scores (3 groups: HAMD 23-30, HAMD 30-40, HAMD\>40), age and previous ECT (yes/no) will be performed Participants and treating psychiatrists will be unaware or the anesthetic used; anesthetists will know the substance that it aministered during ECT|Depressive patients, that are eligible for ECT, will be randomized to receiving either ECT with esketamine plus propofol or methohexital anesthesia for the whole series (min. 8 treatments). Participants and treating psychiatrists will be unaware or the anesthetic used; anesthetists will know the substance that it aministered during ECT. Both drugs will be compared in terms of safety, recovery time and clinical outcome.|t|f|t|t
33970669|NCT03720756|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The efficacy of treatment methods will be assessed by comparing GERD-Health Related Quality of Life (HRQL) questionnaires before and after implementation of a nickel-free diet.|Patients will undergo a patch test to determine if they are hypersensitive to nickel among other metabolites. Regardless of the results of the patch test, patients will be placed on a nickel-free diet for 8 weeks.|t|f|f|f
33970670|NCT02967198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970671|NCT03989960|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970672|NCT06544317|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33970673|NCT00076323|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33970674|NCT00827827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970675|NCT04889183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized placebo controlled double-blind two arm parallel clinical trial|t|t|t|t
33970676|NCT02961920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970677|NCT05269719|||COHORT||CROSS_SECTIONAL|||||||
33970678|NCT02509728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33970679|NCT01427920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970680|NCT05977270|NA|SINGLE_GROUP||OTHER||NONE||Single Case Experimental Design with multiple baselines across individuals||||
34070111|NCT04776577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Results from simultaneous measurements with two wires will be graphically showed using the Bland-Altman plot and reported in terms of intraclass correlation coefficient (ICC). Also, whether a theoretical correction for the expected hydrostatic pressure error (0.77 mmHg per cm height difference) at the distal pressure measurement site (Pd) accounts for the difference in FFR during simultaneous measurements will be explored, and a corrected ICC reported. A two-sided p-value of \<0.05 will be considered to be significant, when applicable.~The Pearson's correlation coefficient will be also calculated considering the Wirecath FFR value in comparison to the FFR value made with the regular wire with and without correction for hydrostatic error.~For the CFR values, the Pearson's correlation coefficient will be used to determine the relation between the bolus-thermo CFR, absolute-flow CFR, Echo CFR and the pressure-derived CFR in the LAD."||||
34070112|NCT05195099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070113|NCT02064699|||COHORT||PROSPECTIVE|||||||
34070114|NCT02194894|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070115|NCT01018745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070116|NCT00999622|||CASE_CONTROL||PROSPECTIVE|||||||
34070117|NCT01440985|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33759076|NCT01389193|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33759077|NCT00002864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970681|NCT01091376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970682|NCT03430700|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive treatment||||
33970683|NCT00003860||||TREATMENT||||||||
33970684|NCT00643110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970685|NCT02883829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33970686|NCT00441584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970687|NCT06259942|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|women undergoing elective caesarean section|randomized controlled trial|t|f|f|f
33970688|NCT00084539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970689|NCT01786720|||COHORT||RETROSPECTIVE|||||||
33970690|NCT02144584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970691|NCT02423174|||CASE_ONLY||PROSPECTIVE|||||||
33970692|NCT01040221|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33970693|NCT04849026|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33970694|NCT04574310|||COHORT||RETROSPECTIVE|||||||
33970695|NCT05926908|||COHORT||PROSPECTIVE|||||||
33970696|NCT01860391|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
34070118|NCT02117609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34070119|NCT01340742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34070120|NCT02250456|||COHORT||PROSPECTIVE|||||||
34070121|NCT02051088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070122|NCT04953741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070123|NCT02065401|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34070124|NCT00813878|||CASE_ONLY||PROSPECTIVE|||||||
34070125|NCT02190721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070126|NCT06349707|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34070127|NCT01737879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070128|NCT05223816|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070129|NCT03883776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070130|NCT00699400|||COHORT||PROSPECTIVE|||||||
34070131|NCT03123003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970697|NCT05465915|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blocked randomization is used to divide patients into blue and red group via an allocator. ECT practitioners are aware which patient belongs to which group but are blinded to block size. Testers, patients and attending psychiatrists are blinded to what group the patients belong to and what ECT parameters are used.|Subjects are randomized into two groups (blue and red) where crossover titration of ECT is used. From the 3. application and onwards, subjects continue either with 0.15ms or 0.30ms pulse width.|t|f|t|t
33880956|NCT02318472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33880957|NCT05397990|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33880958|NCT01131000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970698|NCT03770000|NA|SEQUENTIAL||TREATMENT||NONE||||||
33970699|NCT02066584|||COHORT||RETROSPECTIVE|||||||
33880959|NCT00291447|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label, single dose escalation Phase I trial of ch806 in patients with advanced tumors expressing the 806 antigen.||||
33880960|NCT06038786|RANDOMIZED|PARALLEL||PREVENTION||NONE||Waitlist controlled design||||
33880961|NCT01823679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880962|NCT06099938|||CASE_CONTROL||PROSPECTIVE|||||||
33970700|NCT03381066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970701|NCT04437069|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Parents randomized using simple randomization into two conditions: one group receives the patient decision aid, and one group receives the patient decision aid and the values clarification exercise. There is no stratified randomization. There are 4 survey time points: 1) Baseline, 2) Post-Viewing of the Decision Aid (or Decision Aid and Values Clarification Exercise), 3) Post-Decision, and 4) Three Months Post-Decision.||||
33970702|NCT04927754|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33970703|NCT03594877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970704|NCT04561310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070132|NCT01385540|||CASE_CONTROL||PROSPECTIVE|||||||
34070133|NCT00235248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070134|NCT02776540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34070135|NCT01179438|NA|SINGLE_GROUP||||NONE||||||
34070136|NCT03282591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070137|NCT03966820|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34070138|NCT06136260|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomization will occur after a medical examiner or coroner (ME) case is referred to Missing Pieces. Participants and MEs will be blinded to participants' treatment arm; Missing Pieces and study staff will be aware of intervention assignments. Missing Pieces will randomize all referred ME cases, (except cases referred from Lake County where the intervention has already been adopted into practice) to CRx-B or GBSI using the method of permuted blocks and the uniform random number function in Stata V17. To ensure balance of intervention arms by ME office, randomization will be stratified by ME office.||t|f|f|f
33880963|NCT05868850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33880964|NCT02997995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880965|NCT03667066|||COHORT||CROSS_SECTIONAL|||||||
33880966|NCT02059083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880967|NCT05322239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Therefore, the proposed approach will be to measure the cumulative effect of TBS on resting state functional connectivity in healthy volunteers before and 24 hours after each of 3 identical doses (5 sessions/dose; 600 pulses/session) of cTBS or iTBS. Stimulation will be delivered to the left dlPFC; targeting will be individualized based on fMRI data collected during the Sternberg Working Memory (WM) paradigm.||||
33880968|NCT05994378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33880969|NCT03644238|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33759078|NCT01650493|||OTHER||PROSPECTIVE|||||||
33759079|NCT01387555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759080|NCT01991652|||COHORT||PROSPECTIVE|||||||
33759081|NCT02707692|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33759082|NCT04513613|||COHORT||PROSPECTIVE|||||||
33759083|NCT03761303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomization of the patients is carried out by a non-medical employee. This co-worker maintains a randomly generated randomization list, indicating to the particular study code (e.g., TMS-PSD-001; TMS-PSD-002), whether to perform an active or sham treatment. The employee pulls a number from an envelope before beginning the intervention of each enrolled patient and then looks at the list to identify the particular group assignment. There will always be randomization packages of ten patients each. Once these are used up, a new list and a new envelope with study codes are prepared.~In addition, the real and the placebo coils are coded before starting studies (eg A and B). Only the uninvolved employee is the assignment to the real - or placebo coil known. The uninvolved employee randomly assigns the study code containing the information on which coil to use (A or B). In this way a blinding of performing physician, patient and the evaluating scientist is guaranteed."|"All patients will receive standard antidepressant therapy with 15 mg escitalopram (Selective Serotonin Reuptake Inhibitor) per day during the study. The dose of escitalopram is increased in all included patients from 5mg/day (day 1-3), over 10mg/day (day 4-6) to 15mg/day (from day 7).~Patients in the experimental group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions). The comparison group receives a duration of equal long sham-stimulation.~For transcranial magnetic stimulation, the Stimulator PowerMAG Research 100 (Mag \& More, Munich, Germany) is used with a cooled double coil (PMD70-pCool)."|t|f|t|f
33759084|NCT03019510|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33759085|NCT01111838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759086|NCT00605202|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759087|NCT01218880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759088|NCT05215067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759089|NCT02165332|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33759090|NCT04260230|NA|SINGLE_GROUP||OTHER||NONE||Single arm open label device tolerability study.||||
33759091|NCT02776332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759092|NCT02390934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759093|NCT04025853|||OTHER||RETROSPECTIVE|||||||
33759094|NCT02347657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759095|NCT00375154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759096|NCT00352482|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33759097|NCT03264651|NA|SINGLE_GROUP||TREATMENT||NONE||A single armed group of premenopausal women receiving open labeled medication||||
33759098|NCT00169559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759099|NCT05097846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759100|NCT00736307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894518|NCT01439958|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894519|NCT06314750|||CASE_CONTROL||RETROSPECTIVE|||||||
33894520|NCT06027801|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33894521|NCT01021111|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894522|NCT05639764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894523|NCT04948021|||COHORT||RETROSPECTIVE|||||||
33894524|NCT02252861|||COHORT||PROSPECTIVE|||||||
33894525|NCT00730236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894526|NCT06498141|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33894527|NCT02945592|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33894528|NCT00937235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894529|NCT01175928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33894530|NCT00319527|||COHORT||RETROSPECTIVE|||||||
33894531|NCT02391610|||COHORT||PROSPECTIVE|||||||
33894532|NCT01244737|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33894533|NCT06314230|||COHORT||PROSPECTIVE|||||||
33894534|NCT01355406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894535|NCT00365235|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33894536|NCT03885284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880970|NCT04377451|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, two-phase dose escalation trial of metformin in overweight/obese patients with dengue compared to standard of care||||
33759101|NCT03117595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|a double blinded study. The participant and the Physician giving the treatment who would also evaluate the participant during the duration of the study are masked. However, the Assistant who is in charge of the randomization process and has the code and so would prepare the drugs is not blinded. The non-blinded Assistant would be available to break the code in the event of any adverse reactions.|2 groups that would remain with the randomly picked intervention throughout the study duration|t|f|t|t
33759102|NCT04077619|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||The other trial (NCT03239938) will randomize patients with chronic WAD to the experimental (modern neuroscience approach) or the control treatment (usual care physiotherapy). The WAD patient sample for the present MRI study will be a subsample recruited from this larger RCT. After inclusion in the large RCT, participants will be asked about the possibility of participating in the additional MRI study.|t|f|t|t
33759103|NCT05838261|||COHORT||PROSPECTIVE|||||||
33759104|NCT01530932|||COHORT||PROSPECTIVE|||||||
33880971|NCT05328037|||CASE_CONTROL||PROSPECTIVE|||||||
33880972|NCT04418700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880973|NCT01307969|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33880974|NCT04651387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880975|NCT00878280|||CASE_CONTROL||PROSPECTIVE|||||||
33880976|NCT00445133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33880977|NCT00002559||||TREATMENT||||||||
33880978|NCT00540254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33880979|NCT00598416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33880980|NCT02232386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880981|NCT03400722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880982|NCT02903680|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33880983|NCT04582578|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-centre randomized controlled trial with a prospective randomized open blinded endpoint trial (PROBE) design.||||
33880984|NCT03962205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33880985|NCT03428646|||CASE_ONLY||PROSPECTIVE|||||||
33880986|NCT00079859|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33880987|NCT03238287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33880988|NCT06398041|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Interventional study with the aim to asses the feasibility of this intervention||||
33880989|NCT06467890|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33880990|NCT05408754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33880991|NCT01317342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33880992|NCT03017170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33880993|NCT05178732|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33880994|NCT05458414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33880995|NCT04593069|NA|SINGLE_GROUP||OTHER||NONE|masking is not applicable for this study|All patients enrolled in the study will be contacted to answer additional questions regarding cognitive impairment||||
33880996|NCT00441857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33880997|NCT01660074|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33880998|NCT03582670|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33880999|NCT00865865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881000|NCT01751217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881001|NCT03934983|||COHORT||PROSPECTIVE|||||||
33881002|NCT01233778|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33881003|NCT02916420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881004|NCT01665807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881005|NCT04638569|RANDOMIZED|PARALLEL||OTHER||TRIPLE||group 1; Ultrasound-guided obturator nerve block group 2; obturator nerve block with anatomical signs|t|t|f|t
33894537|NCT01167608|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34070139|NCT06513832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study team and participants will not be blinded but statistical analyses will be performed in a blinded fashion using allocations of Intervention A and Intervention B. Randomization will be implemented 2:1, in blocks of 6, via a computer algorithm to minimize unintentional imbalances between groups."||f|f|f|t
33970705|NCT03623256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will be blinded. The investigators will not be blinded because they are the same care providers. In addition, the volume of intrathecal anesthetic is different when bupivacaine plus fentanyl is used in comparison with only one medication used.|"Patients will be randomly assigned to one of four groups:~Group A: Spinal dose of preservative-free fentanyl 25 mcg. Group B: Spinal preservative-free 0.25% bupivacaine. Group C: Spinal combination of preservative-free 0.25% bupivacaine and fentanyl 25 mcg.~Group D: Spinal preservative-free 0.25% bupivacaine and epidural fentanyl 100 mcg.~After the procedure, we will monitor the fetal heart rate and tocometry tracings for 30 min. Thereafter, an epidural infusion with a solution containing 0.125% bupivacaine and 2mcg/mL of fentanyl will be started. We will record demographic variables (age, and BMI), obstetric variables (parity, gestational age, cervical dilation, oxytocin infusion) and anesthetic variables (level of insertion of epidural catheter). We will also record level of insertion, blood pressure every 5 minutes, dermatomal level, pain level, patient satisfaction level and pruritus."|t|f|f|f
33759105|NCT01942681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759106|NCT04209725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759107|NCT06427655|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|single|Participants were randomized into two groups. One group utilizing the SALAD technique and the other employing intermittent suction during intubation on a manikin.|t|f|f|f
33759108|NCT02563470|||COHORT||RETROSPECTIVE|||||||
33759109|NCT01171092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759110|NCT00615732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759111|NCT00101530|||COHORT||PROSPECTIVE|||||||
33759112|NCT01576822|RANDOMIZED|PARALLEL||||NONE||||||
33759113|NCT02384564|RANDOMIZED|PARALLEL||||NONE||||||
33759114|NCT02462525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759115|NCT01760421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759116|NCT01061333|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33759117|NCT03320616|RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects will be randomized to 1 of 4 treatment sequences.||||
33759118|NCT06265272|||COHORT||PROSPECTIVE|||||||
33759119|NCT05961852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759120|NCT02659787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33759121|NCT00335582|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759122|NCT03138174|||OTHER||OTHER|||||||
33759123|NCT05713201|||CASE_ONLY||RETROSPECTIVE|||||||
33759124|NCT05135416|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||crossover assignment||||
33759125|NCT02817035|NA|SINGLE_GROUP||||NONE||||||
33759126|NCT02608398|||COHORT||PROSPECTIVE|||||||
33759127|NCT04635579|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33759128|NCT03559101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The ingredients-list is masked on the bottles of beverage. Test beverages are coded. The research nurse logs the code, administers the test beverage, and discards the empty bottle prior to the experiment and in the absence of the investigator and outcomes assessor. The investigator and outcomes assessor do not have access to the log. Subjects do not discuss the beverages with the investigator and outcomes assessor.|Two groups of subjects (young, older) participate in five experiments, one for each of five beverage pretreatments. Pretreatments are consumed immediately prior to the experiment. The experiments are conducted in randomized order. The trials are identical and separated by at least five days.|f|f|t|t
33759129|NCT00791843|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33759130|NCT02389257|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759131|NCT02131870||CROSSOVER||BASIC_SCIENCE||||||||
33759132|NCT01722760|||COHORT||PROSPECTIVE|||||||
33759133|NCT00414739|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33759134|NCT06155708|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33759135|NCT06170164|||COHORT||RETROSPECTIVE|||||||
33759136|NCT03471663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070140|NCT01187277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070141|NCT04999449|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pharmacokinetic study followed by double-blind, placebo-controlled, dose-ranging design||||
34070142|NCT04962087|RANDOMIZED|PARALLEL||TREATMENT||NONE||This project consists of two independent but related randomized controlled trials. Trial 1 will focus on people who are not currently prescribed BZRA medications. Trial 2 will focus on people who have been taking BZRA medications and are initiating gradual tapering of these medications as recommended and supervised by their primary health care provider. Both have 2 parallel arms (Health enSuite Insomnia or psychoeducation control). Eligible participants will be randomized to either treatment group in a 1:1 ratio using a gender and age stratified randomization procedure with permuted blocks.||||
34070143|NCT02186158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881006|NCT03188237|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||AfyaJamii is a group care model in pregnancy facilitated by Government of Kenya (GOK) Community Health Volunteers (CHVs) and Ministry of Health (MOH) nurses. Pregnant women are assigned to specific care groups according to their Expected Date of Delivery (EDD) and meet 3 times antenatally and 4 times postnatally. These groups are meant to provide women with antenatal and postnatal care, peer support, and knowledge to improve their health outcomes and the health outcomes of their infants. This model of group prenatal and postnatal care is being evaluated as an alternative to the existing policy of focused antenatal care that individualizes care to a single woman at a time.||||
33881007|NCT02172859|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33881008|NCT04507984|||COHORT||OTHER|||||||
34070144|NCT00399698|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34070145|NCT04424472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The sonographer for the additional ultrasound will be blinded as will be the blinded radiology who will compare the US to the most recent negative CT/MRI to determine if recurrence is visualized by US|||||
34070146|NCT06202274|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34070147|NCT02903953|||COHORT||PROSPECTIVE|||||||
34070148|NCT01449864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070149|NCT01408719|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34070150|NCT06236113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacist prepares medications for patients. Medication or placebo appear identical and are released to bedside nurse with weight based infusion instructions.|prospective, randomized, double-blinded, placebo-controlled study comparing saline infusion with low-dose ketamine versus saline infusion alone.|t|t|t|t
34070151|NCT00884260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881009|NCT03017560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881010|NCT05561790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33881011|NCT00637260|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33881012|NCT04434144|||CASE_ONLY||PROSPECTIVE|||||||
33881013|NCT02439125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34070152|NCT06336811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Before blood collection, the Emotional Appreance Scale for Children was evaluated by a non-researcher nurse. Pediatric patients between the ages of 6 and 12, from whom blood would be collected, were distributed to groups according to the randomization scheme."||f|f|t|f
34070153|NCT01393418|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070154|NCT03478085|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070155|NCT05930171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881014|NCT00726466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894538|NCT01646710|NA|SINGLE_GROUP||||||||||
33759137|NCT00004902||||TREATMENT||||||||
33881015|NCT06194396|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 groups 50 neonates / group||||
33881016|NCT01442259|NA|PARALLEL||OTHER||NONE||||||
33881017|NCT02568046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33881018|NCT04502407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881019|NCT03355989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The participant allocation sequence will be concealed from the study staff responsible for screening and enrolling participants through the use of real time phone based randomization sequence.|This is an individually randomized, twelve-arm parallel group design randomized control trial. The study has a cross-cutting design where one experiment (1) will investigate (1a) sharply increasing versus slowly increasing payouts; (1b) high incentive versus low incentive and (1c) simple SMS reminder vs no reminder. A second experiment (2), orthogonal to the first, will also test lottery payouts vs non-lottery payouts and we will cross-cut (1a), (1b) and (1c) with (2). The first experiment would enrol 1600 participants with the second distributing these participants to 900 participants each in the lottery vs non lottery payout. There will also be an SMS only arm and a control arm each enrolling 1600 participants.||||
33881020|NCT03782935|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pregnant women assigned to 1) over-the-counter approved prenatal multivitamin mineral supplement alone provided by the study at time of enrollment, 2)over-the-counter approved prenatal multivitamin mineral supplement with additional over-the-counter approved 750 mg choline supplement provided by the study at the time of enrollment, or 3) standard of care which is recommendation to take over-the-counter prenatal multivitamin mineral supplements||||
33881021|NCT04461470|||COHORT||PROSPECTIVE|||||||
33881022|NCT01765673|||COHORT||PROSPECTIVE|||||||
33881023|NCT00917449|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33881024|NCT01256437|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881025|NCT05586633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881026|NCT02353533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881027|NCT03233854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881028|NCT04863703|||OTHER||PROSPECTIVE|||||||
33881029|NCT04077905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970706|NCT06461923|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33970707|NCT02702752|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970708|NCT06546683|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators, and personnel involved in data analyses are blinded to the intervention. Unblinding occurs after all data has been collected and analysed.||t|f|t|t
33970709|NCT03778047|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33970710|NCT03873779|NA|SINGLE_GROUP||OTHER||NONE||||||
33970711|NCT02827903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970712|NCT04888650|||CASE_ONLY||PROSPECTIVE|||||||
33970713|NCT04699981|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970714|NCT04193943|||COHORT||PROSPECTIVE|||||||
33970715|NCT00757666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970716|NCT03449043|||COHORT||RETROSPECTIVE|||||||
33970717|NCT05562336|||COHORT||OTHER|||||||
33970718|NCT02273674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970719|NCT00737230|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||||||||
34070156|NCT00567424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070157|NCT04818203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881030|NCT05583942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial will be double-blinded to the investigators and participants.|Randomized double blind sham controlled clinical trial|t|t|t|t
34070158|NCT02393131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881031|NCT04219423|NA|SINGLE_GROUP||TREATMENT||NONE|Small study staff precludes blinding of assessors and instructors.|This is a small, prospective pre/post evaluation study to determine feasibility for a larger clinical trial. Participants will be recruited from an electronic medical record search and from primary care providers. Recruitment, retention and adherence will be determined. Baseline and post intervention outcomes on physical function and quality of life will be determined for preliminary estimates of change.||||
33881032|NCT06365073|||CASE_CONTROL||RETROSPECTIVE|||||||
33881033|NCT03283683|||COHORT||PROSPECTIVE|||||||
33881034|NCT05771610|||COHORT||PROSPECTIVE|||||||
34070159|NCT04923932|NA|SINGLE_GROUP||TREATMENT||NONE||locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with measurable lesions OR with no measurable lesions but have evaluable lesions.||||
34070160|NCT00835835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070161|NCT04773821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070162|NCT04064515|||COHORT||OTHER|||||||
34070163|NCT02878200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759138|NCT04577677|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33759139|NCT04647032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759140|NCT05194306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759141|NCT03720938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759142|NCT01288274|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759143|NCT06279884|||COHORT||PROSPECTIVE|||||||
33759144|NCT04737902|||COHORT||PROSPECTIVE|||||||
33759145|NCT02438943|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33759146|NCT02662062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759147|NCT04393298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Modular design, escalation \& expansion modules. Depending on emerging data, not all modules may open||||
33759148|NCT05747963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, multicenter, parallel, randomized controlled trial|f|f|f|t
33759149|NCT01944202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33759150|NCT00220974|RANDOMIZED|PARALLEL||||DOUBLE||||||
33759151|NCT02681614|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759152|NCT01870193|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33759153|NCT06423040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33759154|NCT03945838|||COHORT||PROSPECTIVE|||||||
33759155|NCT03888664|NA|SINGLE_GROUP||TREATMENT||NONE||1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks||||
33759156|NCT01122381|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759157|NCT00432081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33881035|NCT04422080|||COHORT||RETROSPECTIVE|||||||
33894539|NCT00135421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894540|NCT06235996|RANDOMIZED|PARALLEL||TREATMENT||NONE||Primary Purpose: Treatment Allocation: Randomized Interventional Model: Parallel Assignment Masking: Not applicable||||
33759158|NCT02681302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070164|NCT02328482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070165|NCT02742025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34070166|NCT03715452|||COHORT||PROSPECTIVE|||||||
34070167|NCT03634527|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants and outcome assessor will be masked for the treatment that participants received (actual treatment vs sham treatment).||t|f|f|t
33759159|NCT05545982|NA|SINGLE_GROUP||TREATMENT||NONE||one-group pretest-posttest study||||
33759160|NCT00810836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759161|NCT05957926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759162|NCT04309084|NA|SEQUENTIAL||TREATMENT||NONE||The study will utilize a 3+3 open label design, and will enroll up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.||||
33759163|NCT01622010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759164|NCT01083654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759165|NCT05100043|||CASE_CONTROL||PROSPECTIVE|||||||
33759166|NCT04692792|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33759167|NCT06496217|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33759168|NCT00153998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759169|NCT01067209|||CASE_ONLY||PROSPECTIVE|||||||
33759170|NCT03917004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33759171|NCT04152265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759172|NCT01558310|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33759173|NCT03551275|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33759174|NCT01383889|RANDOMIZED|PARALLEL||||NONE||||||
33759175|NCT00917163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759176|NCT02417103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33759177|NCT03975699|||CASE_CONTROL||PROSPECTIVE|||||||
33759178|NCT04454398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759179|NCT04773795|NA|SINGLE_GROUP||OTHER||NONE||||||
33759180|NCT04654988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070168|NCT00777062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34070169|NCT06492382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070170|NCT04972422|NA|SEQUENTIAL||TREATMENT||NONE||||||
34070171|NCT02814383|||COHORT||PROSPECTIVE|||||||
34070172|NCT04862975|||OTHER||PROSPECTIVE|||||||
34070173|NCT05309239|||COHORT||PROSPECTIVE|||||||
34070174|NCT05430477|||COHORT||PROSPECTIVE|||||||
34070175|NCT05599347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind masking|All consenting adults that fulfil the inclusion criteria will be randomized in a 1:1 ratio and allocated to the azithromycin or placebo arms|t|t|t|t
34070176|NCT03864003|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34070177|NCT02844270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759181|NCT05100264|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Randomization will be computer generated. Allocation concealment will be ensured by opaque sealed envelopes. Blinding of outcomes assessor, principal as well as other investigators will be ensured as randomization will be performed by an external investigator that will not participate in the clinical process of the study or the statistical analysis. The ward midwife will open the randomization envelope after patient enrollment and different types of vaginal washing will be applied as per randomization. Participant as well outcomes assessor (physician that will evaluate the progress of labor as well statistician involved in the analysis) will be blinded to the procedure.||t|t|t|t
33759182|NCT03154502|||COHORT||CROSS_SECTIONAL|||||||
33759183|NCT00626730|NON_RANDOMIZED|||TREATMENT||||||||
33759184|NCT01080014|||COHORT||PROSPECTIVE|||||||
33759185|NCT02091479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759186|NCT04436666|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33759187|NCT01128803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759188|NCT01245946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759189|NCT05616364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759190|NCT04777812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759191|NCT04000841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759192|NCT03626779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33759193|NCT03834103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759194|NCT03030443|||COHORT||PROSPECTIVE|||||||
33759195|NCT01870362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759196|NCT01981525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759197|NCT03430193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759198|NCT05151536|||OTHER||RETROSPECTIVE|||||||
33759199|NCT04960605|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analyses will be masked.|Prospective study|f|f|f|t
33894541|NCT03267355|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34070178|NCT00812500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070179|NCT01648920|||CASE_ONLY||PROSPECTIVE|||||||
34070180|NCT06148155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070181|NCT02078596|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34070182|NCT04037800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070183|NCT01439984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070184|NCT06053632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34070185|NCT00460746|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070186|NCT00807612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070187|NCT03968913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blinded|Randomized, placebo controlled study with 2 treatment groups: 1) to doses of placebo only and 2) two doses of study medication|t|f|f|t
34070188|NCT00830635|NA|SINGLE_GROUP||||NONE||||||
34070189|NCT01404949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070190|NCT03923049|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070191|NCT02830334|||COHORT||PROSPECTIVE|||||||
34070192|NCT01569698|||OTHER||PROSPECTIVE|||||||
34070193|NCT00667914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070194|NCT03472937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070195|NCT03271593|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34070196|NCT04268758|||COHORT||PROSPECTIVE|||||||
33881036|NCT05562986|RANDOMIZED|PARALLEL||PREVENTION||NONE||Thirty patients were randomly divided into two equal groups; patients using OI in addition to manuel brushing (OI-group), patients using IB in addition to manual brushing (IB-group). Study was planned as randomized, single-blind, parallel-design. Periodontal indexes were recorded clinically and interleukin (IL)-1β, IL-10, matrix metalloproteinase (MMP)-1, MMP-8 levels in gingival crevicular fluid were evaluated biochemically. After baseline examinations \[Silness-Löe plaque index(PI), Löe-Silness gingival index(GI), probing pocket depth(PPD), clinical attachment level(CAL), bleeding on probing(BOP)\], initial periodontal therapy was completed using full-mouth disinfection method. The data was collected in the baseline, 2nd, 4th and 8th weeks.||||
33759200|NCT00967382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070197|NCT02032615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070198|NCT01228812|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881037|NCT05582642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070199|NCT02616198|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34070200|NCT05447455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33881038|NCT03622697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33881039|NCT03694925|||CASE_CONTROL||PROSPECTIVE|||||||
33970720|NCT05494905|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The therapist who conducts the assessments will be blinded with the intervention these children receive.|For the first six weeks of intervention, children will be randomly assigned to receive either VR or FST. After being determined as a respondent or non-respondent by the end of the first 6 weeks of the intervention, non-respondent children will be re-randomized to either receive the combination of FST and VR or switch to the other intervention (i.e., children who receive VR in the first 6 weeks will switch to FST; and verse versa).|f|f|f|t
33970721|NCT04523493|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33970722|NCT06288165|||COHORT||PROSPECTIVE|||||||
33970723|NCT01110980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970724|NCT03198702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"First group or toxin group: the babies will receive BOTOX injections at the age of 12 months in the shoulder muscles.~Second group or sham group:the babies receive the same procedure but no injection."|t|f|t|f
33970725|NCT06546397|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The eligible population who underwent induced abortion were divided into two groups using block randomization. The experimental group received estrogen and progesterone therapy after surgery, while the other group served as a blank control group. Twenty-one days after surgery, a follow-up examination was conducted to assess the recovery of the endometrium and measure the endometrial thickness. Twenty-one days after the first post-operative menstrual cycle, blood samples were taken for laboratory tests to evaluate the recovery of ovarian function.|t|t|t|t
33970726|NCT00430157|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33970727|NCT00394745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970728|NCT03308110||CROSSOVER||OTHER||NONE||||||
33970729|NCT01810796|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881040|NCT00555100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881041|NCT02433600|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33881042|NCT03099720|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881043|NCT05598892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881044|NCT02022982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881045|NCT00784966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881046|NCT04735055|||COHORT||RETROSPECTIVE|||||||
33881047|NCT01918670|||COHORT||PROSPECTIVE|||||||
33894542|NCT01057121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894543|NCT04321343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881048|NCT05043415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient undergoing procedure and research coordinator assessing outcome measures during follow-up will be blinded to the treatment group to which the patients are randomized.||t|f|f|t
33881049|NCT03107793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881050|NCT05122416|NON_RANDOMIZED|PARALLEL||OTHER||NONE||There will be 6 different groups of patients depending on the spleen to skin distance and the presence or absence of splenomegaly. Every patient in every group will do an ultrasound and 2 FibroScan exams. The differences between Group 1 (1a and 1b), Group 2 (2a and 2b) and Group 3 (3a and 3b) are the probes that will be used to do the FibroScan.||||
33881051|NCT01251328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881052|NCT00613457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881053|NCT03677180|||COHORT||PROSPECTIVE|||||||
33881054|NCT05290701|||COHORT||PROSPECTIVE|||||||
33881055|NCT02916355|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33881056|NCT03098147|||CASE_CONTROL||PROSPECTIVE|||||||
33881057|NCT01772615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881058|NCT01704352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881059|NCT05484960|||CASE_ONLY||PROSPECTIVE|||||||
33881060|NCT00264056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881061|NCT01331356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881062|NCT01127724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33881063|NCT02392182|||CASE_ONLY||PROSPECTIVE|||||||
33881064|NCT03627845|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33881065|NCT03643380|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33881066|NCT00797732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33881067|NCT05855447|||CASE_ONLY||PROSPECTIVE|||||||
33881068|NCT02847130|||CASE_ONLY||RETROSPECTIVE|||||||
33881069|NCT03936504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33881070|NCT05882955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33881071|NCT04092127|||COHORT||PROSPECTIVE|||||||
33881072|NCT05746663|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881073|NCT03511131|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33881074|NCT05090839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881075|NCT01895127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881076|NCT02740088|||COHORT||PROSPECTIVE|||||||
33881077|NCT00144898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881078|NCT03424759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970730|NCT03366285|||COHORT||PROSPECTIVE|||||||
33970731|NCT04550468|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33970732|NCT01208558|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33970733|NCT03804099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070201|NCT03584230|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"The investigator will receive a randomized list of sequence orders for each age and gender group. Within the sequence orders, one third of them are for participants in the positive condition, one third are for participants in the negative condition, and one third are for participants in the no cues condition. The experimenter will not know which sequences relate to each condition.~The nonverbal behavior coders will also be blind to the participants' condition. They will view videos where only the participant is visible but the teacher is not."|Three conditions will be tested: assignment to a group that receives positive nonverbal teacher behaviors, assignment to a group that receives negative nonverbal teacher behaviors, and assignment to a group that receives no teacher behaviors.|f|f|t|t
34070202|NCT05409716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients enrolled to the study were randomized into TR Band or compressive dressing groups. Care providers operated on patients and investigators collected their data during and after the operation. The independent variable - Hemostasis technique (TR Band or compressive dressing ) - was coded into X or Z groups, then data was sent to the outcomes assessor.||f|f|f|t
34070203|NCT00202943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881079|NCT02450578|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881080|NCT05179317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881081|NCT02866825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881082|NCT01905358|||COHORT||PROSPECTIVE|||||||
33881083|NCT05980715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970734|NCT03740698|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||"This is a 3-way crossover open-label randomized controlled trial. Description of the three interventions for comparison are as follows:~1. Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)~2. Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator~3. Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)~The intervention in each arm will be assessed over 6 weeks with a minimum 2-week break in between each intervention. During the break participants will revert back to usual pump therapy."||||
33970735|NCT03309891|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|A Phase 2, randomized, open-label, active controlled, dose finding study||||
33970736|NCT03522584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970737|NCT02044978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070204|NCT03077425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Research Assessment- at 6, 12, and 18 months will be conducted by RAs. Data collected include a computerized 24 hour recall: MySmileBuddy (see below); and questionnaires. The T2 interview, in addition, will include the Intra-oral Camera Caries Assessment. Study identifiers will not include indication of group assignment. The REDCap database will include group assignment in a field that is not accessible to RAs~Caries Outcomes- Intra-oral camera images will be transmitted electronically to the University of Rochester; no group assignment identifier will be included.~Obesity Outcomes- RAs will obtained weight and length measures in the home- see above."|randomized controlled clinical trial|f|f|f|t
33881084|NCT05231148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881085|NCT05201833|||COHORT||PROSPECTIVE|||||||
33881086|NCT05928455|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open label, positive control (Stage Ⅰ); Single-arm, open-label (Stage Ⅱ)||||
34070205|NCT05644678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070206|NCT02927678|||COHORT||PROSPECTIVE|||||||
34070207|NCT00003522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070208|NCT04536675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070209|NCT05977790|||COHORT||PROSPECTIVE|||||||
34070210|NCT05100303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070211|NCT06137066|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Supplements will be coded as either 'A', 'B', 'C', or 'D'. A third-party researcher not involved in data collection will store the code key and only reveal the information after the data has been analyzed to maintain the double-blinded nature of the trial.|Four-arm study. All participants receive all acute nutritional interventions: placebo (microcrystalline cellulose with 5mg magnesium stearate and 5mg silicon dioxide), 200mg GCE +200mg ALA, 200mg GCE + 400mg ALA, 200mg GCE + 200mg dihydroberberine.|t|t|t|t
34070212|NCT04388124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Modification of the pharmaceutical form, removal from the primary packaging and repackaging-\> tablet of Bosentan will be encapsuled. The pharmaceutical form of placebo and bosentant will be identical||t|f|t|f
34070213|NCT04171362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070214|NCT05951036|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34070215|NCT04137809|NA|SINGLE_GROUP||OTHER||NONE||||||
34070216|NCT03187184|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single arm proof of concept trial. Sequential boundaries will be used to monitor late PGx test returns (failure to receive OneOme RightMed® pharmacogenomic test results before initiating chemotherapy). The concept will be considered a failure if excessive numbers of late PGx test returns are seen, that is, if the number of late PGx test returns is equal to or exceeds bn out of n patients (see table below). This Pocock-boundary is based upon the probability of early failure when the rate of late PGx test returns is equal to the acceptable rate \[event probability θ\]. In this trial crossing the boundary will not result in early stopping, because chemotherapy treatment is not dependent upon receipt of PGx test results prior to treatment initiation, but may be used to revise future protocol methodology.||||
34070217|NCT02975531|NON_RANDOMIZED|PARALLEL||||NONE||||||
34070218|NCT06461689|||COHORT||RETROSPECTIVE|||||||
34070219|NCT05612269|||COHORT||RETROSPECTIVE|||||||
33881087|NCT00493870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881088|NCT04270929|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single institution, single-arm, dose-escalation phase 1 study, designed to assess the feasibility, safety, and efficacy of oxaliplatin PEDD-PRVI with systemic FOLFIRI followed by FOLFIRINOX therapy for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma||||
33881089|NCT02118688|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33881090|NCT02838407|NA|SINGLE_GROUP||OTHER||NONE||||||
33881091|NCT01025986|||COHORT||PROSPECTIVE|||||||
33881092|NCT04908839|||CASE_CONTROL||PROSPECTIVE|||||||
33881093|NCT01688024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33881094|NCT06121414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881095|NCT04867798|||OTHER||PROSPECTIVE|||||||
33881096|NCT05749614|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881097|NCT05096988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881098|NCT04812652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33881099|NCT01382732|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33881100|NCT00282503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881101|NCT03707535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881102|NCT03313674|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970738|NCT04642573|||CASE_CONTROL||RETROSPECTIVE|||||||
33970739|NCT04636528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of investigators and patients regarding allocation arm will not be possible, given the nature of the intervention. Analysis of study results will be performed by an independent statistician at UCSF.|single-center, prospective, randomised, controlled study, with two parallel groups|f|f|f|t
33970740|NCT02124109|||COHORT||CROSS_SECTIONAL|||||||
33970741|NCT01607138|||COHORT||RETROSPECTIVE|||||||
33970742|NCT00312000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970743|NCT03956433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind|Five treatment groups, no placebo.|t|f|t|f
33970744|NCT00525967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33970745|NCT03325647|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
33970746|NCT00564174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970747|NCT04480411|NA|SINGLE_GROUP||OTHER||NONE||||||
33970748|NCT01518452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970749|NCT04766918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970750|NCT05965193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970751|NCT03055533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33970752|NCT03036033|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single group, open feasibility study of use of a CE marked and available device.||||
33970753|NCT05644691|||CASE_CONTROL||PROSPECTIVE|||||||
33970754|NCT00015106||PARALLEL||TREATMENT||||||||
33970755|NCT01312610|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33970756|NCT01554761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970757|NCT02482805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970758|NCT06545136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759201|NCT04960826|||CASE_CONTROL||PROSPECTIVE|||||||
33759202|NCT03013023|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33759203|NCT05632835|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33970759|NCT03719183|||CASE_ONLY||CROSS_SECTIONAL|||||||
33970760|NCT02493725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970761|NCT03169777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970762|NCT03179683|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was planned as randomized controlled split-mouth clinical study. Bilateral sinus bone augmentation and dental implant surgeries were done simultaneously. Low level laser therapy (LLLT) was (λ= 630-660 nm, 25 mw / cm², 6 mins) applied for just one operation side at first, third, fifth and seventh days. Treatment side were randomly selected by another surgeon who applied LLLT and no treatment were applied to other group(control group)||||
33970763|NCT00832078|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33970764|NCT02404740|||COHORT||PROSPECTIVE|||||||
33970765|NCT05305521|||COHORT||PROSPECTIVE|||||||
33759204|NCT00524914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33759205|NCT01670448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759206|NCT04235907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759207|NCT04922151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881103|NCT02661425|||CASE_CONTROL||RETROSPECTIVE|||||||
33881104|NCT05461638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759208|NCT03717090|||COHORT||PROSPECTIVE|||||||
33759209|NCT00908089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759210|NCT05725252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759211|NCT04350710|||COHORT||PROSPECTIVE|||||||
33759212|NCT01080222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759213|NCT05009524|RANDOMIZED|PARALLEL||TREATMENT||NONE||"participants are randomly assigned to either iPACES (pedal-to-play) or PACE (pedal-while-play) exergaming interventions to be completed 3-5x/wk for 6 months, then PACE crosses over to iPACES and all followed out to 1-year mark"||||
33759214|NCT06150781|||COHORT||PROSPECTIVE|||||||
33759215|NCT01949870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759216|NCT01807806|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33759217|NCT03223532|RANDOMIZED|PARALLEL||PREVENTION||NONE||A Prospective, Randomized, Open Label Trial.||||
33759218|NCT03645902|||CASE_ONLY||PROSPECTIVE|||||||
33759219|NCT02427789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759220|NCT00908401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759221|NCT01153139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33759222|NCT03811184|||COHORT||PROSPECTIVE|||||||
33759223|NCT03995784|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759224|NCT04372628|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Lopinavir/Ritonavir tablets or unmatched placebo tablets|Blinded, multicenter, placebo-controlled randomized clinical trial|t|t|t|f
33759225|NCT03040284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|open|||||
33759226|NCT01984580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33759227|NCT03782311|||COHORT||PROSPECTIVE|||||||
33759228|NCT06500494|||COHORT||PROSPECTIVE|||||||
33759229|NCT05873374|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The treatment will be masked to the participants and site staff (including the investigators and the care providers which are blinded site staff).||t|t|t|f
33759230|NCT00452686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759231|NCT03681210|||COHORT||PROSPECTIVE|||||||
33759232|NCT02440347|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33759233|NCT01654601|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33759234|NCT02264184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759235|NCT04224064|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759236|NCT03075579|||CASE_ONLY||PROSPECTIVE|||||||
33759237|NCT05732441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1.Conventional treatment group 2. Conventional treatment group combined with Huange capsule|t|f|f|f
33759238|NCT02977559|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33881105|NCT03473392|||COHORT||RETROSPECTIVE|||||||
33881106|NCT02638454|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33881107|NCT02326870|NA|SINGLE_GROUP||||NONE||||||
33881108|NCT01538485|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881109|NCT01265459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881110|NCT05229107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This will be a single site, open label, randomized, wait-list controlled, pilot clinical trial. This study will enroll up to 24 adults, age 18 or older, who have symptoms of chronic nausea (due to gastroparesis and who are not taking medications or supplements for management of symptoms) with a goal of 20 to complete the intervention. Participants will be randomly assigned to either an Early Intervention (EI) group which will receive 6 CR sessions over 4 weeks of audible tones echoing current brainwave activity, following enrollment, or a Delayed Intervention (DI) group which will continue current care only and will serve as a control group. Participants in both groups will continue their other current care throughout the study.||||
33881111|NCT02697383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881112|NCT01394445|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33881113|NCT00868881|||||RETROSPECTIVE|||||||
33881114|NCT05824754|NA|SINGLE_GROUP||OTHER||NONE||||||
33759239|NCT00053495|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759240|NCT03711526|||COHORT||PROSPECTIVE|||||||
33759241|NCT00982930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759242|NCT03179644|NA|SINGLE_GROUP||OTHER||NONE||Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant, the objective is to To assess the correlation between the mean pleural pressure and esophageal pressure||||
33881115|NCT03592914|||COHORT||PROSPECTIVE|||||||
33881116|NCT05250661|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|Parallel group, two arm, prospective randomized controlled clinical trial||||
33881117|NCT00835471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881118|NCT05462210|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants and statistician are blinded.||t|f|f|f
33881119|NCT05553080|||CASE_ONLY||PROSPECTIVE|||||||
33881120|NCT06355570|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||12-patient participants will be submitted to the study intervention.||||
33881121|NCT01024998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881122|NCT05998109|||OTHER||PROSPECTIVE|||||||
33881123|NCT05720780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881124|NCT00531804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881125|NCT03280004|||COHORT||PROSPECTIVE|||||||
33881126|NCT00205478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33881127|NCT02009644|NA|SINGLE_GROUP||TREATMENT||NONE||AAA Device||||
33881128|NCT04792931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||diagnosis and follow up of adult autoimmune myopathies||||
33881129|NCT04932811|||COHORT||PROSPECTIVE|||||||
33881130|NCT01874691|||CASE_ONLY||PROSPECTIVE|||||||
33881131|NCT05930262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33881132|NCT01443533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33881133|NCT06073392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking: Single-blinded, where participants are unaware of the type of intervention given to them (in which combination and either 1 topics, 2 topics or 3 topics)|"Model is multiple-arm parallel group. There are multiple-arm trials, four experimental are versus single-control arm.~Four experimental arms intervention are:~1. effective toothbrushing technique (1 topic)~2. effective toothbrushing technique, effects of sugary diet (2 topics)~3. effective toothbrushing technique, and dental caries (2 topics)~4. effective toothbrushing technique, effects of sugary diet, and dental caries (3 topics)~Single placebo arms is topic on tooth anatomy and eruption"|t|f|f|f
33881134|NCT06460116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two phase feasibility pilot. Consistent with the community engaged approach, the first study phase is interviews with at least 30 stakeholders to enhance the school-based community health worker (SB-CHW) intervention and the enhanced usual care (EUC) arms. The second study phase is a feasibility trial to assess the feasibility of the SB-CHW condition across 38 students and 38 parent/guardians and the EUC condition across 10 students and their 10 parents/guardians.||||
33881135|NCT03262415|||COHORT||CROSS_SECTIONAL|||||||
33881136|NCT02067039|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33881137|NCT00941876|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33881138|NCT02108405|||CASE_ONLY||PROSPECTIVE|||||||
33881139|NCT05628714|||OTHER||PROSPECTIVE|||||||
33881140|NCT06269003|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881141|NCT06213727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881142|NCT02237287|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33881143|NCT06463067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759243|NCT02685722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759244|NCT02082925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759245|NCT01395108|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33881144|NCT03666962|||CASE_CONTROL||OTHER|||||||
33881145|NCT04418687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the study it was not possible to blind the participant to the treatment being received.|"Group 1: Physiotherapy with Orthoglide~Group 2: Physiotherapy only"||||
33881146|NCT01157078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881147|NCT02011165|||CASE_CROSSOVER||PROSPECTIVE|||||||
33881148|NCT04032210|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33881149|NCT04393922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33881150|NCT04852848|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881151|NCT05808244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881152|NCT06348108|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759246|NCT03652779|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33759247|NCT02179502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881153|NCT01084265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881154|NCT06384885|||COHORT||PROSPECTIVE|||||||
33881155|NCT00671255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881156|NCT01587079|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33881157|NCT04338958|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, non-randomized||||
33970766|NCT03139214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The intervention involved 7 parenting sessions with mothers and their children that taught nurturant parenting techniques, effective communication skills, and about the importance of developing and following household rules.|f|f|f|t
33970767|NCT00164879|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970768|NCT03917628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970769|NCT00270374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33970770|NCT02870712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970771|NCT04822766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970772|NCT00088777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970773|NCT03840746|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|soups in plain tins and labelled A or B. Code held by person not part of study team.|This intervention study will be carried out using a parallel design, with three arms (foods containing polyphenol+NDC, foods with polyphenol alone, and habitual diet control)|t|f|t|f
33970774|NCT00268710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970775|NCT00003390||||TREATMENT||||||||
33970776|NCT00129779|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33881158|NCT00510627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970777|NCT05551078|||COHORT||RETROSPECTIVE|||||||
33970778|NCT03111979|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33970779|NCT03773328|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm study using a Simon 3 + 3 design. Study will utilize 3 dose cohorts with a minimum of 3 patients in each cohort.||||
33970780|NCT02666430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970781|NCT03135379|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|A heat-resistant glove, ULine Terry Cloth Glove (Appendix F), will be used by the investigators to handle the ultrasound gels.||f|f|t|f
33970782|NCT00419926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970783|NCT01654146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881159|NCT05150379|||CASE_CONTROL||RETROSPECTIVE|||||||
33881160|NCT02280278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881161|NCT04078698|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-centre, open-label, non-comparative, interventional study||||
33881162|NCT06386939|||OTHER||OTHER|||||||
33881163|NCT03431987|||OTHER||OTHER|||||||
33881164|NCT01213212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881165|NCT01788007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881166|NCT02740634|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881167|NCT04625127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881168|NCT05503381|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, multicenter, noninferiority clinical study||||
33881169|NCT01819909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970784|NCT02044471|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33970785|NCT02788123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970786|NCT01847573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970787|NCT02537132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881170|NCT03674151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881171|NCT05001347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894544|NCT01472276|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970788|NCT04108377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970789|NCT04090996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970790|NCT05427565|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||One healthy participant will undergo four weeks of concurrent TBS/fNIRS to investigate the cortical hemodynamic variability||||
33970791|NCT01836718|||CASE_CONTROL||PROSPECTIVE|||||||
33894545|NCT00495027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894546|NCT00262704|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894547|NCT02919306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894548|NCT05459597|||COHORT||PROSPECTIVE|||||||
33970792|NCT00746668|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33970793|NCT01672346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970794|NCT00005042||||TREATMENT||||||||
33970795|NCT02565342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970796|NCT00151294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33970797|NCT04515823|||OTHER||RETROSPECTIVE|||||||
33970798|NCT02400320|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33881172|NCT05541614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The selected sites will be randomly assigned to test and control groups using an online software for randomization. The therapist will be kept unaware of treatment allocation until the treatment. The outcomes assessor will be unaware of the treatment allocation.|Patients will be randomly allocated at a 1:1 ratio to either subgingival debridement and flapless application of EMD (test group) into the affected furcation defect or to periodontal surgery in combination with EMD application (control group). The selected sites will be randomly assigned to test and control groups using an online software for randomization. The therapist will be kept unaware of treatment allocation until the treatment.|t|f|f|t
33881173|NCT00257439|||COHORT||PROSPECTIVE|||||||
33881174|NCT01049035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881175|NCT00366522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33881176|NCT03572556|||COHORT||PROSPECTIVE|||||||
33881177|NCT04168424|||COHORT||CROSS_SECTIONAL|||||||
33881178|NCT02239263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881179|NCT02316405|NA|SINGLE_GROUP||||NONE||||||
33881180|NCT02507362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881181|NCT04838873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881182|NCT00002508||||TREATMENT||||||||
33881183|NCT04743180|||COHORT||PROSPECTIVE|||||||
33881184|NCT01028625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33881185|NCT03312660|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Both groups will receive fermented dairy products with similar color, flavor and nutritional composition, except the prebiotic components, which will only be administered to the intervention group.|Cluster randomized controlled trial|t|t|t|t
33970799|NCT05070520|NA|SINGLE_GROUP||TREATMENT||SINGLE||"This surveillance study is a prospective one-arm evaluation of clinical and parasitological responses to treatment of uncomplicated malaria with direct observation of treatment. Individuals with uncomplicated malaria, who meet the study inclusion criteria, will be recruited and treated at the sites by AL. They will be monitored for 28 days. Follow-up will consist of a series of fixed-date monitoring visits and corresponding clinical examinations and laboratory tests. Based on the results of these assessments, patients will be classified as having treatment failure (early or late) or adequate response. The proportion of patients with treatment failure during follow-up will be used to assess the efficacy of the study drugs.~PCR analysis will be used to distinguish between true recrudescence due to treatment failure and episodes of re-infestation. A proportion of 10% of the slides read in the field will be submitted for quality control."|t|f|f|f
33970800|NCT02303561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970801|NCT04853810|||COHORT||CROSS_SECTIONAL|||||||
33970802|NCT00809809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970803|NCT00727168|||COHORT||CROSS_SECTIONAL|||||||
33970804|NCT00301106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759248|NCT01682213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759249|NCT01356680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759250|NCT00150579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759251|NCT06397599|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33759252|NCT00812279|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881186|NCT02441504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881187|NCT01065974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881188|NCT05836337|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study is a single-center prospective, randomized and quasi double blinded pilot study. The study includes 2 parallel arms||||
33881189|NCT04634058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759253|NCT03595930|||COHORT||PROSPECTIVE|||||||
33881190|NCT04506294|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33881191|NCT02059590|NA|SINGLE_GROUP||||NONE||||||
33881192|NCT01128829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33881193|NCT03032276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881194|NCT02934438|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33881195|NCT04831281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970805|NCT02639208|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33970806|NCT05267574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970807|NCT05999981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881196|NCT02925130|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33881197|NCT00001550||||TREATMENT||||||||
33881198|NCT05525117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial with two arms: (i) online intervention in addition to treatment-as-usual versus (ii) treatment-as-usual|f|f|f|t
33881199|NCT01084187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881200|NCT00289679|NON_RANDOMIZED|PARALLEL||||NONE||||||
33881201|NCT03828279|||COHORT||PROSPECTIVE|||||||
33881202|NCT05879783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881203|NCT01384214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881204|NCT00101257||||TREATMENT||||||||
33881205|NCT01563887|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33881206|NCT00884104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881207|NCT03146533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881208|NCT00802243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881209|NCT02498626|||CASE_ONLY||PROSPECTIVE|||||||
33881210|NCT02025296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881211|NCT01871961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881212|NCT06401161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881213|NCT02170272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33881214|NCT02841410|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33970808|NCT03192683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970809|NCT02524028|||CASE_CONTROL||PROSPECTIVE|||||||
33970810|NCT05144620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33970811|NCT03717389|||OTHER||CROSS_SECTIONAL|||||||
33970812|NCT04485000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the research coordinator cannot be blinded to group condition, but staff making reminders and data analysts will not be aware of group status. Therapists delivering groups will be randomly assigned to workshops and not notified of group status.||f|t|f|t
33970813|NCT03131999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970814|NCT02855047|||COHORT||PROSPECTIVE|||||||
33970815|NCT01200082|||COHORT||PROSPECTIVE|||||||
33970816|NCT06054906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970817|NCT06135285|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33970818|NCT02480010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970819|NCT01211847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33970820|NCT05621538|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The PI will prospectively assign treatment groups with blind codes and so will not be blind to treatment type. Other staff, who are the individuals primarily working with the patients and who will be conducting follow-up interviews, will be blind to treatment type. It is not possible to blind the 5th condition (treatment as usual with a brief check-in).||t|t|f|t
33970821|NCT04385810|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33970822|NCT01683253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970823|NCT02122094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970824|NCT01522833|||COHORT||RETROSPECTIVE|||||||
33970825|NCT01954875|||OTHER||PROSPECTIVE|||||||
33970826|NCT00788957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970827|NCT03814109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881215|NCT03244033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33759254|NCT06004414|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881216|NCT00676715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759255|NCT04426643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759256|NCT03513406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881217|NCT05738239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Active PBMT|t|t|t|t
33881218|NCT02205060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881219|NCT03667703|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Prospective, double-blinded randomized placebo-controlled pilot feasibility trial|t|t|t|t
33881220|NCT00527605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881221|NCT05388539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881222|NCT00330473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881223|NCT02549768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881224|NCT02596412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881225|NCT04477681|||COHORT||PROSPECTIVE|||||||
33881226|NCT01083056|||COHORT||PROSPECTIVE|||||||
33881227|NCT05086146|||COHORT||PROSPECTIVE|||||||
33881228|NCT00774345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881229|NCT05099640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881230|NCT01537211|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33881231|NCT04848961|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881232|NCT05019001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070220|NCT04642482|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants receive the synbiotic in the form of fine powder and taken orally and packed with similar packages. Care provider (Research assistants) distribute the unlabeled formulation to the participants. Outcome assessors (laboratory technician) will not be informed regarding the allocation. Investigators are blinded from allocation and will not be informed until the final analysis. Only the statistician will perform and aware of the allocation. A propensity matching score (PSM) is preferred to allocate the participants.|A multiple-arm study involves three different groups receiving synbiotic (probiotic + prebiotic) and placebo. Observation of intestinal microbiota and insulin resistance is observed in repeated measurement|t|t|t|t
34070221|NCT04839666|||COHORT||RETROSPECTIVE|||||||
34070222|NCT03256357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070223|NCT06002659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881233|NCT02275338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34070224|NCT00492700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070225|NCT00098007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070226|NCT01408082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070227|NCT03117361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881234|NCT02689830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881235|NCT03004378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881236|NCT04146077|||COHORT||PROSPECTIVE|||||||
33881237|NCT00323557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881238|NCT02680379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881239|NCT02170662|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33881240|NCT01956812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881241|NCT02684981|||COHORT||PROSPECTIVE|||||||
33881242|NCT01476787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881243|NCT00064818|||DEFINED_POPULATION||OTHER|||||||
33881244|NCT02665286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881245|NCT06318533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881246|NCT03800875|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881247|NCT02095743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881248|NCT03347071|||CASE_CONTROL||PROSPECTIVE|||||||
33881249|NCT00714792|||COHORT||PROSPECTIVE|||||||
33881250|NCT01604005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881251|NCT02868346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881252|NCT00671385|||COHORT||PROSPECTIVE|||||||
33881253|NCT01760161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881254|NCT00946855|||COHORT||PROSPECTIVE|||||||
33881255|NCT05520801|||COHORT||OTHER|||||||
33881256|NCT04493801|||CASE_CONTROL||PROSPECTIVE|||||||
33881257|NCT03535623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881258|NCT01707693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33881259|NCT00250614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881260|NCT03484468|||COHORT||RETROSPECTIVE|||||||
33881261|NCT00152152|||||PROSPECTIVE|||||||
33881262|NCT00121212|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33881263|NCT01948843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894549|NCT03384056|||COHORT||PROSPECTIVE|||||||
33894550|NCT00655720|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33881264|NCT05572034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|all patients will go for intervention, however they will not know which group they were randomized to|randomized, prospective, sham controll, on a 1:1:1 basis to group A (Sham - 15 patients); group B (right sided denervation - 15 patients); and group C (bilateral denervation - 15 patients)|t|f|f|f
33881265|NCT06448208|||COHORT||PROSPECTIVE|||||||
33881266|NCT04989582|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33881267|NCT01070160|||COHORT||PROSPECTIVE|||||||
33881268|NCT02652897|||COHORT||PROSPECTIVE|||||||
33881269|NCT05718986|||FAMILY_BASED||OTHER|||||||
33881270|NCT04786600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881271|NCT01532531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881272|NCT05562154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881273|NCT04306432|||COHORT||PROSPECTIVE|||||||
33881274|NCT03285243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After enrollment and consent, each patient will be randomized to either placebo or intervention group. 110 sealed envelopes randomizing patients to the exposure group A (monochromatic light) or bulb B (placebo) white light bulb with blue outer coating. The recover room nursing staff will evaluate the patient using the PAED standard emergence delirium scale unaware of which light is monochromatic.|This is a double blinded randomized control trial. The placebo arm will serve as the control group. After enrollment and consent, each patient will be randomized to either placebo or intervention group. 110 sealed envelopes randomizing patients to the exposure group A (monochromatic light) or bulb B (placebo) white light bulb with blue outer coating.|t|t|f|f
33881275|NCT02346760|NA|SINGLE_GROUP||OTHER||NONE||||||
33881276|NCT06175858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881277|NCT02828800|||CASE_ONLY||PROSPECTIVE|||||||
33881278|NCT02930993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881279|NCT02187952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881280|NCT02011035|||COHORT||PROSPECTIVE|||||||
33970828|NCT01178359|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33970829|NCT03867903|||COHORT||CROSS_SECTIONAL|||||||
33881281|NCT00242476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881282|NCT03767322|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind clinical trial||t|f|t|f
33881283|NCT01549769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881284|NCT02094144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881285|NCT02635971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881286|NCT05964283|||OTHER||CROSS_SECTIONAL|||||||
33881287|NCT06281483|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33970830|NCT01918111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970831|NCT05205785|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33970832|NCT03626610|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cohort-controlled|f|t|f|f
33970833|NCT04736979|||COHORT||PROSPECTIVE|||||||
33970834|NCT01190683|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33970835|NCT01133392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970836|NCT03584737|||COHORT||CROSS_SECTIONAL|||||||
33970837|NCT04915586|NA|SINGLE_GROUP||TREATMENT||NONE|The radiologists were blinded to patient identity and intervention timing|||||
33970838|NCT03114189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970839|NCT06528262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970840|NCT04979130|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33970841|NCT03016559|NA|SINGLE_GROUP||OTHER||NONE||||||
33970842|NCT04569955|||COHORT||CROSS_SECTIONAL|||||||
33970843|NCT03709498|||COHORT||PROSPECTIVE|||||||
33970844|NCT04559295|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent Observer was blinded as to wether a subject received treatment or was in the control group.|A prospective evaluation of a cohort of patients with a specific characteristic over time to see if they develop a particular endpoint or outcome based on a stated hypothesis.|f|f|f|t
33970845|NCT05821712|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33970846|NCT03962933|||CASE_CONTROL||PROSPECTIVE|||||||
33970847|NCT04582773|||COHORT||PROSPECTIVE|||||||
33970848|NCT05030090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970849|NCT01106872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970850|NCT05431283|||CASE_ONLY||PROSPECTIVE|||||||
33970851|NCT03848585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The analysis is blinded. The statistician will not have access to the affiliation of the users until the statistical analysis of the study data is finalised.||f|f|f|t
34070228|NCT00980733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070229|NCT05473793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Subjects not receiving the intervention product will consume a placebo (rice puff particles). Neither the investigator, nor the participants, nor the outcome assessor will know who received what. No Care Provider is included in this trial.|A randomized, placebo-controlled, parallel, double-blind trial with three intervention arms and one control (placebo) arm.|t|f|t|t
34070230|NCT05499806|||COHORT||OTHER|||||||
34070231|NCT02501161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881288|NCT01863511|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881289|NCT02263833|||COHORT||PROSPECTIVE|||||||
33881290|NCT04887831|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment (1:1) to one of two treatment arms||||
33881291|NCT00084201|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881292|NCT01937650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33881293|NCT04732754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||f|f|t|t
33881294|NCT00958204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970852|NCT05480917|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The IRIS trial will be a prospective clinical trial in which patients attending the PsoPlus for the first time will be followed during a period of 1 year. The focus will lie on patients with no prior experience with PsoPlus. The study will run for 24 months, of which 12 months will serve as an inclusion period. Both outcomes (VOS) and costs will be collected. The VOS is normally measured on a biannual basis. For this trial these time points are called T0, T1, and T2. Additionally, screening for comorbidities is performed to account for the integrated way of working. Patient as well as disease characteristics are also captured in a standardized way. This is all considered to be standard of care within PsoPlus. Cost data is collected using TD-ABC over the full cycle of care.||||
33881295|NCT05125250|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33881296|NCT05731180|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The subject will be assigned a unique screening/enrolment number.|The 140 students will be randomised into CNT and EXP groups. Both of the groups will do a test after 3 days. There will be an introductory presentation (30-35 min) for both groups. The EXP group receive access to the SAITI website with 16 questions to practice and home in their skills. The recommendation for practice will be 45- 90 min per day. Students' diagnostic accuracy will be assessed on the 4th day via 9 questions. Tests will be repeated at intervals of 10, 34, and 184 days. The exam format will be kept the same during all assessments with no additional training. Though students will not discourage from participating in auscultations, they will be asked to inform investigators if they did so. This will allow the assessment of pathological sound recognition skills degradation over a period of time. Data will be collected on a spreadsheet, analysed via JASP and SPSS.|f|f|t|t
33970853|NCT01764620|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33881297|NCT05649293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881298|NCT00876083|||COHORT||PROSPECTIVE|||||||
33881299|NCT01634438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881300|NCT04623476|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot study||||
33881301|NCT03418532|NA|SINGLE_GROUP||TREATMENT||NONE||The trial was intended to be a Phase 1/2 trial. Trial was terminated before Phase 2 commenced.||||
33881302|NCT02235194|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33970854|NCT06080984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970855|NCT04656015|||OTHER||PROSPECTIVE|||||||
33970856|NCT06101121|||COHORT||PROSPECTIVE|||||||
33970857|NCT03324126|||COHORT||PROSPECTIVE|||||||
33970858|NCT00974883|||COHORT||PROSPECTIVE|||||||
33881303|NCT01882946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881304|NCT00213785|||||PROSPECTIVE|||||||
33881305|NCT03371797|||OTHER||PROSPECTIVE|||||||
33881306|NCT01014117|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33881307|NCT03657043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881308|NCT00755833|||COHORT||PROSPECTIVE|||||||
33881309|NCT04929184|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881310|NCT04690010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881311|NCT04001868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Simple blind with evaluator blinded strategy.||t|f|t|f
33970859|NCT03511352|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33970860|NCT01858246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970861|NCT05655702|NA|SINGLE_GROUP||SCREENING||NONE||||||
33970862|NCT01617564|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33970863|NCT01664052|NON_RANDOMIZED|PARALLEL||||NONE||||||
33970864|NCT00593138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33970865|NCT05219396|||CASE_CONTROL||PROSPECTIVE|||||||
33970866|NCT00704223|||COHORT||PROSPECTIVE|||||||
33970867|NCT02655172|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070232|NCT04953806|NA|SINGLE_GROUP||TREATMENT||NONE||Assess the feasibility of Step-CBT in a proof-of -concept, single-arm trial in Veterans (N=25) with COPD, low physical activity, and clinically significant depression and/or anxiety symptoms.||||
33881312|NCT03123133|||COHORT||PROSPECTIVE|||||||
33881313|NCT02439658|||CASE_CONTROL||PROSPECTIVE|||||||
33881314|NCT06501560|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33970868|NCT03170206|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 is a single group standard 3+3 dose escalation||||
33970869|NCT06347757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970870|NCT01877928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881315|NCT04588324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33881316|NCT03368183|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||In alternating months providers will be given the SCAMP vs. a shorter forms that does not include clinical decision support|f|f|f|t
33894551|NCT02739919|||CASE_ONLY||PROSPECTIVE|||||||
33970871|NCT01117064|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970872|NCT03144037|||COHORT||PROSPECTIVE|||||||
33970873|NCT00323583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970874|NCT00398359|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970875|NCT03772639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970876|NCT05084690|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomized, two arm parallel experimental and control groups|f|f|f|t
33970877|NCT05482984|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The investigators used a two-group pretest and post-test quasi-experimental design.||||
34070233|NCT03310632|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I~Run-in DDI and dose escalation:~Six patients will be enrolled in the run-in DDI cohort of the dose-escalation part of the study (ie, Cohort 1) and 3 to 6 patients may be enrolled in Cohort 2. The total number of patients to be entered in the dose-escalation part of this study will depend on the emergence of DLTs at each dose level, but will be up to 12 if no replacement occurs at the 2 predefined dose levels.~Phase II~Cohort expansion:~Up to an additional 40 patients may be enrolled at the MTD or MFD/RD. A power calculation was not employed to determine the sample size of the study, as this is aproof of concept study with a preliminary assessment of anti-tumor activity of antroquinonol in combination with nab-paclitaxel + gemcitabine in metastatic pancreatic cancer patients."||||
34070234|NCT03264612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070235|NCT01544647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070236|NCT02746094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070237|NCT01696656|||COHORT||RETROSPECTIVE|||||||
34070238|NCT00003115||||SUPPORTIVE_CARE||||||||
34070239|NCT04365075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070240|NCT04742881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070241|NCT00957099|||COHORT||PROSPECTIVE|||||||
34070242|NCT03070275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor is not aware of the treatment modality|Prospective, randomised, single blind, control clinical trial|f|f|f|t
34070243|NCT00043849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070244|NCT06491017|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34070245|NCT06344546|||CASE_CONTROL||PROSPECTIVE|||||||
34070246|NCT04298879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070247|NCT01974856|||COHORT||PROSPECTIVE|||||||
34070248|NCT01968499|||COHORT||PROSPECTIVE|||||||
34070249|NCT05984173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|Randomized clinical trial two groups|t|t|t|t
34070250|NCT03678194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||200 patients with a DSM-V diagnosis of depression are recruited. Patients are randomly assigned to receive either a 6 weeks smartphone application with daily evaluations, or no application.|f|f|f|t
34070251|NCT00688025|||||CROSS_SECTIONAL|||||||
33970878|NCT06544018|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Multicenter, prospective, interventional, comparative, open-label, controlled study with 2 parallel arms.||||
33970879|NCT00600626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970880|NCT01991587|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33970881|NCT00132431|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970882|NCT01688037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070252|NCT06187233|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All elective colonoscopies were performed by an experienced endoscopists who were unaware of the group assignments.||f|t|f|f
34070253|NCT00616447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070254|NCT00407342|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070255|NCT00459771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070256|NCT00582426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070257|NCT00451113|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34070258|NCT00003974||||TREATMENT||||||||
34070259|NCT02757625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070260|NCT03942887|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, 1:1 randomized, prospective study between RTX with cyclophosphamide and RTX alone.||||
34070261|NCT02916953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070262|NCT02648464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34070263|NCT04931771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070264|NCT05309694|NA|SINGLE_GROUP||OTHER||NONE||Single arm and open-label design||||
34070265|NCT01831427|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34070266|NCT06163014|||CASE_ONLY||PROSPECTIVE|||||||
34070267|NCT00232206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070268|NCT01201447|||COHORT||CROSS_SECTIONAL|||||||
34070269|NCT03547258|||COHORT||OTHER|||||||
34070270|NCT00298883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070271|NCT06598137|||COHORT||PROSPECTIVE|||||||
33881317|NCT03907332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The independent assessors will not know which women received the intervention or not. It is impossible to blind participants, persons conducting the visits or the researcher in this home visit intervention.|One arm will receive the usual care and in addition, three home visits as the intervention compared to a control group, another arm, receiving only usual care|f|f|f|t
33881318|NCT03591380|NA|SINGLE_GROUP||TREATMENT||NONE||This study is proposed to be an open-label, single-arm, pilot study to test whether the addition of belimumab, to inhibit the B cell survival factor BLyS at the time of kidney transplantation, to standard or care therapy (alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression) will prevent the prevent the generation of de novo DSA||||
33881319|NCT05359978|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Approximately 250 patients will be screened to achieve 240 participants, divided in two cohorts (120 each), furthermore each cohorts was divided in other two groups (experimental group (60 each) and control group (60 each) the first one followed up by private centres in Spain endowed with Occupational Therapy and the second by public centres in the region of Modena|It's a pretest-posttest non-equivalent control group experimental design study comparing two cohorts of patient with different types of dementia|t|f|f|f
33881320|NCT00954278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881321|NCT00502190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070272|NCT00178646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881322|NCT01277133|||COHORT||PROSPECTIVE|||||||
33881323|NCT02148237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881324|NCT05751356|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation and expansion||||
34070273|NCT01770808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070274|NCT01790802|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34070275|NCT01727830|||CASE_CONTROL||PROSPECTIVE|||||||
34070276|NCT02401698|||CASE_ONLY||PROSPECTIVE|||||||
34070277|NCT05872061|||COHORT||CROSS_SECTIONAL|||||||
34070278|NCT04855331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070279|NCT00156091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070280|NCT00802321|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|t|f|f
34070281|NCT00551174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070282|NCT02763917|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34070283|NCT05903755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070284|NCT03382405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34070285|NCT01719159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070286|NCT02373423|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070287|NCT04613440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070288|NCT05826340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070289|NCT00805129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070290|NCT04875572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881325|NCT06361043|||COHORT||PROSPECTIVE|||||||
33881326|NCT04035317|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The capsules will be identical in appearance and will be labelled only with patient's name.|Patients will be randomized to receive Aesculus hippocastanum or placebo for 4 months, followed by 4 weeks of washout and crossover.|t|t|t|t
33881327|NCT05392348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881328|NCT04116398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881329|NCT02640417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881330|NCT01123252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33881331|NCT02507011|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33881332|NCT01164085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881333|NCT05331885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a double-blind, randomized, controlled trial.|This is a Phase 3, randomized, placebo-controlled, single-dose study.|t|t|t|t
33881334|NCT01276171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881335|NCT00124111|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33759257|NCT06099457|RANDOMIZED|PARALLEL||TREATMENT||NONE||"One intervention and two arms (intervention and waitlist control group, treatment-as-usual).~Randomly assign 80 parent participants to a treatment condition and 80 to waitlist control group, treatment-as-usual. Conduct an 8-week intervention among the treatment condition participants. At the conclusion of post-intervention testing, deliver the SIBTime intervention to the treatment-as-usual condition participants."||||
33759258|NCT02415179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759259|NCT03620630|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|End of study visit to be completed by a blinded team|Randomised controlled Feasibility study|f|f|f|t
33759260|NCT04241458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759261|NCT03344224|||COHORT||RETROSPECTIVE|||||||
33759262|NCT01705743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759263|NCT03487536|||CASE_ONLY||PROSPECTIVE|||||||
33759264|NCT01344668|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33759265|NCT00454571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759266|NCT04040309|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The first group of patients will receive 1 ml PRGF 2nd fraction injections into the myofascial trigger point in the masseter muscle.~The second group of patients will receive 1 ml 2% Lidocaine injections into the myofascial trigger point in the masseter muscle."||||
33759267|NCT03118921|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33759268|NCT04177550|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33759269|NCT06243185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759270|NCT06350929|||COHORT||PROSPECTIVE|||||||
33759271|NCT05965830|||COHORT||PROSPECTIVE|||||||
33759272|NCT04158414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759273|NCT05882110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881336|NCT04616469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33881337|NCT01614132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881338|NCT06317480|||COHORT||RETROSPECTIVE|||||||
33881339|NCT02323698|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Balanced design|t|t|t|t
33881340|NCT03778112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881341|NCT00003426||||TREATMENT||||||||
33881342|NCT03324997|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33881343|NCT04125355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33970883|NCT04682275|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33881344|NCT02437162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881345|NCT03576560|||OTHER||RETROSPECTIVE|||||||
33881346|NCT02249910|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881347|NCT00609596|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881348|NCT06411795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and providers will not be blinded to the analgesic technique||f|f|t|t
33881349|NCT00956254|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33881350|NCT00662792|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33970884|NCT04193891|||CASE_CONTROL||PROSPECTIVE|||||||
33881351|NCT02584491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881352|NCT00148746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33881353|NCT03572127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One group will consume a non-animal derived high protein diet, whilst the other group will consume a more traditional animal protein based diet.||||
33970885|NCT00260325|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33970886|NCT04288050|||COHORT||PROSPECTIVE|||||||
33970887|NCT02854566|||CASE_ONLY||RETROSPECTIVE|||||||
33970888|NCT00130520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970889|NCT05235308|||COHORT||RETROSPECTIVE|||||||
33970890|NCT01618305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33970891|NCT01152281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33970892|NCT04767789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33970893|NCT05661929|||OTHER||CROSS_SECTIONAL|||||||
33970894|NCT02351128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970895|NCT03782857|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomized 1:1 to intervention or control group||||
33970896|NCT05731102|||COHORT||OTHER|||||||
33970897|NCT00892827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970898|NCT05678621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Infectious outcomes and adverse events will be adjudicated by an independent, blinded outcome adjudication committee.||f|f|f|t
33970899|NCT06436924|||CASE_ONLY||PROSPECTIVE|||||||
33759274|NCT03773458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759275|NCT01333735|||COHORT||PROSPECTIVE|||||||
33759276|NCT02710448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759277|NCT05003102|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Sleep study interpreters will not know which night had dexmedetomidine preferentially increased|randomized crossover trial|f|f|f|t
33759278|NCT01111916|||CASE_ONLY||PROSPECTIVE|||||||
33759279|NCT05081869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Fifty women with primary dysmenorrhea will be divided into two groups as study and control. The working group will be subjected to informative training and an online exercise program of 16 sessions. The control group will only receive information training.|t|f|f|f
33759280|NCT02461095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759281|NCT02347644|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33759282|NCT04545996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759283|NCT05701514|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, controlled, multicentre superiority trial. Randomisation will take place as blocked randomisation with stratification by centre, with a 1:1 allocation.||||
33759284|NCT00257140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759285|NCT01875380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759286|NCT02958592|||COHORT||PROSPECTIVE|||||||
33759287|NCT02535728|||COHORT||PROSPECTIVE|||||||
33759288|NCT03637244|NA|SINGLE_GROUP||PREVENTION||NONE||H1: PrEP decision support increases decision quality in both LDQ and HDQ groups, H2: HDQ + decision-support group more likely to initiate PrEP than HDQ control, H3: HDQ PrEP initiators are more likely than LDQ initiators to have serum levels consistent with adherence at 60-days. Investigators supply one smartphone/ participant,each registered to St. Mike's Hospital to protect participant privacy. The decision support aid will be a pre-programmed bookmark, an RA will give participants a brief tutorial on its use. Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.||||
33759289|NCT04247659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33759290|NCT02459262|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33759291|NCT03066401|||COHORT||PROSPECTIVE|||||||
33759292|NCT04909580|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre post study||||
33759293|NCT00002947||||TREATMENT||||||||
33759294|NCT02597426|||COHORT||CROSS_SECTIONAL|||||||
33881354|NCT04318405|||COHORT||PROSPECTIVE|||||||
33881355|NCT00493038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881356|NCT01490658|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33881357|NCT00147524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881358|NCT02831673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881359|NCT01422239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881360|NCT03988907|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759295|NCT04088721|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759296|NCT04184323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Drug and placebo will be prepared in color coded capsules. Randomization will be performed using computer-generated lists assigned sequentially upon recruitment.|Double blind, placebo controlled comparison of SirT1 inhibitor treatment for implantation failure associated with endometriosis|t|t|t|f
33881361|NCT05728294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two groups: femoral nerve block or sciatic nerve block with ropivacaine|t|f|t|t
33881362|NCT02273583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881363|NCT00488384|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33881364|NCT01275482|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33881365|NCT01099072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881366|NCT01844882|||||RETROSPECTIVE|||||||
33881367|NCT01142726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881368|NCT00686647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881369|NCT01109030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970900|NCT02300025|NON_RANDOMIZED|PARALLEL||||NONE||||||
33970901|NCT00653497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33970902|NCT02916381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33970903|NCT00876278|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33970904|NCT02248337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970905|NCT04183790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970906|NCT04832074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, Double-Blinded, Placebo-Controlled Trial|t|f|f|t
33970907|NCT01847313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970908|NCT01653574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970909|NCT04312555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970910|NCT04123041|RANDOMIZED|CROSSOVER||OTHER||NONE|The study is open label; however, subjects will be masked to the percentage of nicotine in JUUL products.|||||
33970911|NCT00001564||||TREATMENT||||||||
33970912|NCT06144359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33970913|NCT02394132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970914|NCT03109990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33970915|NCT00542516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970916|NCT02957409|||COHORT||PROSPECTIVE|||||||
33970917|NCT05729750|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|All participants whatever study or control gruops will get the headphone which may turn on the music in study gruop only that mean investigator will not known who are in listening to music.|the participants were purpostive sampling, and devided into two groups. The study group listening to music before and suring the assessment while the control gruop will not listening to music.|f|f|t|f
33970918|NCT03834584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970919|NCT06168955|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33970920|NCT03462329|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Patients will evaluate their pre-treatment expectations about treatment outcome of erythema migrans.~Nonspecific symptoms will be assessed in patients and control subjects."||||
33970921|NCT04948190|||CASE_CONTROL||OTHER|||||||
33970922|NCT01021150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970923|NCT01816152|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33970924|NCT02207621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970925|NCT05825118|||COHORT||PROSPECTIVE|||||||
33970926|NCT01413256|||COHORT|||||||||
33970927|NCT04998643|||COHORT||PROSPECTIVE|||||||
33970928|NCT05172856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970929|NCT01823549|||COHORT||PROSPECTIVE|||||||
33970930|NCT04948684|||COHORT||RETROSPECTIVE|||||||
33970931|NCT02345278|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33759297|NCT05008952|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||3 study groups: control (normal body mass index, low body fat percentage), normal-weight obesity ((normal body mass index, high body fat percentage), and metabolic syndrome||||
33759298|NCT02546830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759299|NCT02914132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759300|NCT04159974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759301|NCT03979170|||COHORT||PROSPECTIVE|||||||
33759302|NCT02022579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759303|NCT05177445|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Patients will receive information about both treatments, but won't have knowledge about which treatment is applied.|Interventional study, single blinded, convenience sampling.|t|f|f|f
33759304|NCT05960825|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33759305|NCT01230255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759306|NCT00005584|RANDOMIZED|||TREATMENT||NONE||||||
33759307|NCT03785067|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|Main Study: Participants are double-blinded. Sub-Study: No blinding to neuropsychological assessments|"Main Study: Multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial.~Sub-Study: Multicentre, international, single-arm trial"|t|t|t|t
33759308|NCT02129101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759309|NCT03659422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759310|NCT00041782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759311|NCT00815867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759312|NCT03502863|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759313|NCT05094531|RANDOMIZED|PARALLEL||PREVENTION||NONE|none since it is an open label|||||
33759314|NCT00640627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759315|NCT00514683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33881370|NCT03569995|NA|SINGLE_GROUP||TREATMENT||NONE||"\[Induction phase\]~① After induction therapy (R-M) 2 times, first evaluation~* Complete, partial response or stable disease-\> next step~* Progressive disease-\> eliminated~  ② After Induction therapy (R-M) was added 3 times (total 5 times), 2nd evaluation~* Complete response -\> consolidation therapy progress~* Partial response or stable disease-\> R-M 2 additional administrations~* Progressive disease-\> eliminated~  ③ After Induction therapy (R-M) was added twice (7 times in total), 3rd evaluation~* Complete, partial response or stable disease-\> consolidation therapy~* Progressive disease-\> eliminated"||||
33759316|NCT04424862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759317|NCT01666808|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759318|NCT06041984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33759319|NCT04863625|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention will be a peer education process on substance use (smoking, drinking and chewing) prevention based on the Theory of Planned Behavior (TPB). This program is a Level I, primary prevention; thus, it is an early intervention program. The program is targeting students with all substance experience (non-user, current user, and ever users).~The intervention aims to encourage anti-substance attitudes and beliefs; foster perceptions of normative support for anti-substance behavior; increase perceptions of control/self-efficacy to resist substance use, increase knowledge and risk perceptions on substance and decrease in intention to use substance and actual substance use behaviors."||||
33881371|NCT03704870|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33881372|NCT00865020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970932|NCT05396820|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|A randomized number is allocated for all participants.|Cross sectional study||||
33881373|NCT03343275|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Adults attending urology/nephrology consultation whom have been recently implanted a double J stent or have its implantation programmed and are able of taking care in urinary pH self-control.|t|f|t|f
33970933|NCT00439608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970934|NCT04283578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970935|NCT00621179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970936|NCT04565782|||COHORT||CROSS_SECTIONAL|||||||
33970937|NCT04624971|||COHORT||RETROSPECTIVE|||||||
33970938|NCT02260492|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33970939|NCT06175195|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial design would be used in this study. It would be two arm study and there would be two groups an experimental and wait-list control group. Experimental group will receive intervention and another group would be placed in waitlist. In this research, parallel group design would be used. We will give treatment to all participants in a parallel way. Allocation ratio and framework would be equivalence i.e., treatment group and control group would be equal number of participants.||||
33881374|NCT05721508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34070291|NCT03442088|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label pilot study of the impact of treatment with standard dosing of APM for 16 weeks on AM-endotype psoriasis patients, identified by elevated (\>150% of normal): 1.) Intermediate (CD14++CD16+) monocytes % of cells in circulation, or 2.) circulating monocyte doublets % of adherent monocyte-monocyte pairs, or 3.) circulating monocyte-platelet aggregates (MPA) % monocytes adherent to platelets.||||
34070292|NCT06573619|||OTHER||PROSPECTIVE|||||||
34070293|NCT01104714|||COHORT||PROSPECTIVE|||||||
33881375|NCT02254031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881376|NCT05818657|||OTHER||CROSS_SECTIONAL|||||||
33881377|NCT00505258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970940|NCT02918838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33970941|NCT01606566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970942|NCT05258812|||CASE_CONTROL||RETROSPECTIVE|||||||
33970943|NCT03306108|||COHORT||PROSPECTIVE|||||||
33970944|NCT00903383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970945|NCT01773577|||COHORT||PROSPECTIVE|||||||
33970946|NCT05743296|||CASE_ONLY||CROSS_SECTIONAL|||||||
33970947|NCT03433001|||COHORT||PROSPECTIVE|||||||
33970948|NCT00006425|||COHORT||CROSS_SECTIONAL|||||||
33881378|NCT00851071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881379|NCT06549205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881380|NCT01017952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881381|NCT05421910|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||One group will receive robotic training as soon as possible, another group will receive robotic training 3-5 weeks, after submission to the rehab center. Normal rehabilitation will also carry on.||||
33881382|NCT00983047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881383|NCT02377375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33970949|NCT03640936|||CASE_CONTROL||PROSPECTIVE|||||||
33970950|NCT03445559|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||The proposed behavioral intervention will be implemented according to a stepped wedge cluster-randomized design. This is a single direction cross-over randomized trial where every site serves, at some point, as both a control and an intervention site. The first time point will be a baseline measurement, where none of the study sites have yet received the intervention. At subsequent time points, study sites initiate the intervention. The time at which each site initiates implementation of the intervention is randomized.|f|f|f|t
33970951|NCT05542537|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070294|NCT05236855|||COHORT||PROSPECTIVE|||||||
34070295|NCT02497404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881384|NCT01660932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881385|NCT02872454|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33881386|NCT05094687|||OTHER||OTHER|||||||
33881387|NCT01750892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881388|NCT00674388|||OTHER||PROSPECTIVE|||||||
33881389|NCT01378286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881390|NCT00524992|||||PROSPECTIVE|||||||
33881391|NCT03858959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33881392|NCT00687284|||COHORT||RETROSPECTIVE|||||||
33881393|NCT00460330|||DEFINED_POPULATION||OTHER|||||||
33759320|NCT01636999|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33881394|NCT02179229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881395|NCT06123052|||OTHER||PROSPECTIVE|||||||
33881396|NCT04691583|NA|SINGLE_GROUP||OTHER||NONE||"1. Normal diet：Starting from May 20, 2018, the subjects will eat a normal diet for 4 days, with no restriction on calories and food types. The subjects are required to record their daily diet and dietary intake of calories.~2. Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~3. Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."||||
33881397|NCT05549115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759321|NCT02891720|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33881398|NCT01082185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881399|NCT02217566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881400|NCT02317562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881401|NCT04510363|||CASE_CONTROL||PROSPECTIVE|||||||
33881402|NCT05786092|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881403|NCT01254279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881404|NCT01792908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881405|NCT01582308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881406|NCT04621695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881407|NCT02771132|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881408|NCT00738478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881409|NCT03877172|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33881410|NCT01999582|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881411|NCT05791279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881412|NCT02591745|||CASE_ONLY||PROSPECTIVE|||||||
33881413|NCT05088278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881414|NCT02175056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759322|NCT05461703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The person in charge of the allocation of the schools will be blinded. The outcome assessors will also be blinded to the group allocation of the schools.|This is a cluster randomized controlled trial. The study will be conducted in two phases. The first will be a 6-month pilot study with a follow-up at 8 months (after the summer holidays) and the second a definitive study of 6 months with a follow-up at 8 and 12 months. The study will consist of three parallel, three-arm groups with a 1:1:1 allocation ratio.|f|f|t|f
33759323|NCT03918434|||COHORT||PROSPECTIVE|||||||
33759324|NCT04606784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759325|NCT00908492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759326|NCT00995501|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33881415|NCT04913129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881416|NCT02549755|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881417|NCT02851914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881418|NCT04507659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881419|NCT02488395|||CASE_CONTROL||PROSPECTIVE|||||||
33881420|NCT00002827|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33970952|NCT00236327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881421|NCT01815229|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33970953|NCT05431309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33759327|NCT04799132|||COHORT||RETROSPECTIVE|||||||
33759328|NCT03191695|||CASE_ONLY||PROSPECTIVE|||||||
33759329|NCT03671174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759330|NCT05421455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759331|NCT04959890|||COHORT||RETROSPECTIVE|||||||
33759332|NCT01375270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33759333|NCT05682092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33759334|NCT02026830|||COHORT||PROSPECTIVE|||||||
33759335|NCT00658567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759336|NCT01343602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759337|NCT03046615|||CASE_ONLY||PROSPECTIVE|||||||
33759338|NCT05016583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759339|NCT03022201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759340|NCT04990843|||CASE_ONLY||PROSPECTIVE|||||||
33881422|NCT00954109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881423|NCT05999318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881424|NCT04997057|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental study: post-treatment versus baseline comparison||||
33881425|NCT02547480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881426|NCT06457581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881427|NCT04494932|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881428|NCT00311467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881429|NCT05053295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881430|NCT03243994|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All patients had Chronic Obstructive Lung Disease. Those with additional Cor pulmonale was compared to those without||||
33970954|NCT05957718|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33970955|NCT03896490|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33881431|NCT01944956|||||PROSPECTIVE|||||||
33759341|NCT01330433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759342|NCT01573806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759343|NCT03882879|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||This is a randomized, single-blinded, study of a novel intervention, namely, non-contact karate, for early to middle stage PD.|f|f|t|t
33759344|NCT03243422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759345|NCT05562479|||COHORT||RETROSPECTIVE|||||||
33881432|NCT01577485|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33881433|NCT06335550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881434|NCT01358903|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881435|NCT01317680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970956|NCT05730985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970957|NCT00624767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759346|NCT00969397|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759347|NCT01407159|||COHORT||PROSPECTIVE|||||||
33759348|NCT04470245|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759349|NCT01313143|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33759350|NCT03988166|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, multicenter, single-arm, intent-to-treat, literature-controlled clinical study.||||
33759351|NCT01370525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759352|NCT01767168|||COHORT||PROSPECTIVE|||||||
33759353|NCT00679328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881436|NCT03697096|RANDOMIZED|PARALLEL||OTHER||NONE||This cluster-randomized trial will assess a novel quality improvement antibiotic stewardship strategy for empiric antibiotic selection.||||
33881437|NCT03314545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881438|NCT01133171|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881439|NCT02860351|||CASE_ONLY||PROSPECTIVE|||||||
33881440|NCT05634863|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of the participants (kidney transplant patients) to the outcome of the randomisation will not be possible due to the nature of the intervention. Similarly, the healthcare professionals (clinicians and nurses) taking care of the patients and collecting the data postoperatively cannot be blinded. However, the Southwest transplant team acts in the best interest of the kidney transplant patients and declares no conflict of interest with the device.|"Intervention group: kidney transplant patients with the vascular monitoring device):~The kidney transplant patients will receive the Implantable continuous vascular monitoring device surveillance for the first 72 hours in addition to the standard care clinical observation as part of their postoperative care.~Control group (kidney transplant patients with standard care clinical observation):~The kidney transplant patients will receive the standard care clinical observation as part of their postoperative care.~The results of the study will be determined by comparing the surgical outcomes in both the intervention and control group."||||
33881441|NCT00131846|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33881442|NCT03172429|||CASE_CONTROL||PROSPECTIVE|||||||
33881443|NCT03238820|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group, open study.||||
33881444|NCT03240146|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Devices will be coded, the placebo device is Identical to the active device in all ways except emitting the electromagnetic field. The energy emitted causes no sensation so can not be unmasked by user.||t|t|t|t
33881445|NCT05155501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors (i.e., pathologists) will be blinded to randomization.||f|f|f|t
33881446|NCT00931216|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881447|NCT02300454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881448|NCT05058508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881449|NCT04931004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomized to one of four arms. Type of mouthwash will not be disclosed to participant. Laboratory personnel and investigators performing the outcome measurements and analysis will be blinded to intervention.||t|f|f|t
33881450|NCT03903510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881451|NCT02538068|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881452|NCT04546685|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33881453|NCT01722500|||COHORT||CROSS_SECTIONAL|||||||
33881454|NCT01150240|||COHORT|||||||||
33881455|NCT03180775|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33881456|NCT01138956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33881457|NCT03504410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881458|NCT03706287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881459|NCT02813616|||COHORT||PROSPECTIVE|||||||
33881460|NCT06374017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33881461|NCT06146725|||COHORT||PROSPECTIVE|||||||
33881462|NCT06038331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881463|NCT01990287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881464|NCT03013062|||COHORT||PROSPECTIVE|||||||
33881465|NCT01385085|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33881466|NCT04563429|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33881467|NCT02761083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881468|NCT04904458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881469|NCT00057473|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881470|NCT01459705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759354|NCT00240292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759355|NCT01069354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759356|NCT04636372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759357|NCT03333798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33881471|NCT00880893|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An observer-design for the first vaccination and a single-blind design for the second and third vaccination were chosen to minimize the bias of the vaccine evaluation. The Investigator in charge of safety evaluation, the Sponsor, and the participants/parents did not know which vaccine was administrated at the first visit. For the second and third vaccinations, the participants/parents did not know which vaccine was administered.||t|f|t|t
33881472|NCT04874792|||CASE_ONLY||RETROSPECTIVE|||||||
33881473|NCT04986800|NA|SINGLE_GROUP||TREATMENT||NONE||A service delivery model and telehealth methodology to deliver a combination of mental health evaluation of the child, motivational interviewing, transdiagnostic and evidence-based skills training (ST), and parent training (PT) to parents.||||
33881474|NCT02597621|||COHORT||PROSPECTIVE|||||||
33759358|NCT00252538|||COHORT||PROSPECTIVE|||||||
33881475|NCT00762515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881476|NCT03856255|NA|SINGLE_GROUP||SCREENING||NONE||||||
33881477|NCT04711772|||COHORT||PROSPECTIVE|||||||
33881478|NCT00887757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881479|NCT06211010|||COHORT||CROSS_SECTIONAL|||||||
33881480|NCT03509519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This clinical trial will use a pre-test - post-test randomized experimental design. Subject will be randomly assigned to the treatment group or the sham group. Study outcomes will be measured pre- and post-intervention.|t|f|f|f
33881481|NCT00321230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881482|NCT00135122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881483|NCT01669954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881484|NCT05048719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881485|NCT05629325|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|A randomization list will be prepared by the laboratorium Wolfs (Zwijndrecht, Belgium) and the trial medication will be labeled by the laboratorium Wolfs based on the randomization list. The randomization list is prepared separately from study investigators or coordinators. The participant, investigator and study team are blinded to the allocated treatment arm in both intervention periods (buspirone/placebo). Each study patient will be assigned a subsequent randomization number. If a medical emergency occurs and a decision about the subject's condition requires knowledge of the treatment assignment, the investigator will immediately notify the laboratorium Wolfs to break the blind for this individual subject.|Patients with IEM or absent contractility and symptoms of dysphagia will participate in this study. They will be randomized on a 1:1 basis: Patients will be randomized to take buspirone for 4 weeks or placebo for 4 weeks. After a 2-week washout period the randomized groups will cross over into the alternate treatment.|t|t|t|t
33894552|NCT01595217|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Two experienced professors of radiology observed and analyzed the images separately. They were not involved in image acquisition and were blinded to the patients' clinical, surgical and histological information. Conventional MR sequences were qualitatively analyzed in the first reading session, including T2WI, FIESTA, 2D MRCP and 3D MRCP sequences, and after one week, DWI under three different b values with ADC map combined with the preceding conventional sequences were analyzed respectively as the second reading session.||t|t|t|t
33894553|NCT01225354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894554|NCT00343902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894555|NCT00507715|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33894556|NCT02240706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894557|NCT02489370|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759359|NCT06040190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894558|NCT03950323|NA|SINGLE_GROUP||OTHER||NONE||||||
33970958|NCT05621083|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The principal investigator will have access to the randomization code containing the order of the oils (starting with HOSO or starting with fish oil), which is generated by an external statistician. The PI will make sure that the identical boxes with capsules (both HOSO and fish oil) will be marked only with Identification (ID) number and period number (cross over 1 and 2). The participant, the care provider and the outcomes assessor will not know the randomization code before after the data of the primary outcome has been analyzed.|Start with control oil (HOSO) or start with fish oil, and then change after 12 weeks of wash out.|t|t|f|t
33881486|NCT04293679|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants in the first cohort will attend the study center once weekly for an injection of STP705 into the isSCC lesion. The participants will receive injections of STP705 once a week for up to 6 weeks. The clinician will evaluate the tumor for clinical changes and reduction in size at each treatment visit for up to 6 weeks. If during the 6 weeks of treatment there is Complete Clinical Clearance of the tumor, the treatments will end. At the End of Treatment visit, the residual tumor, or former tumor location, will be excised for analysis. In the absence of dose limiting toxicities (DLT), the subsequent cohorts will receive increasing doses of STP705, following the same schedule of administration as the first cohort.||||
33881487|NCT05331534|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33970959|NCT00681408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33970960|NCT05868057|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33970961|NCT05226520|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Unique coding|Exploratory, randomized, placebo-controlled, 2-arms, double-blinded, parallel|t|t|t|t
33970962|NCT00786071|||||CROSS_SECTIONAL|||||||
33970963|NCT05287984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|||||
33970964|NCT03877055|NA|SEQUENTIAL||TREATMENT||NONE||This is a two stage protocol comprised of a single institution phase I dose escalation trial using standard 3+3 design and a phase II two stage Simon mini-max clinical trial.||||
33970965|NCT00548977|||CASE_CONTROL||PROSPECTIVE|||||||
33970966|NCT03759327|||CASE_ONLY||OTHER|||||||
33970967|NCT04877392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33881488|NCT04267211|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33970968|NCT04735237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each patient will be given a code by the main researcher and the raters will be blind to which group this case belongs. Patients, raters and statistician will be blinded|"* A randomized controlled clinical trial.~* The trial will be carried out in the clinic of Oral and Maxillofacial Surgery Department- Faculty of Dentistry-Cairo University \& Pediatric Plastic Surgery Department (clinic \& operative theatre), Cairo University.~* Equal randomization: participants with equal probabilities for randomization.~* Parallel group study: Each group of patient receives a single treatment simultaneously."|t|f|f|t
33970969|NCT01868009|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33970970|NCT04434313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970971|NCT05871697|||CASE_CONTROL||PROSPECTIVE|||||||
33970972|NCT06454500|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33881489|NCT02750462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881490|NCT00650754|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33881491|NCT00993707|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33970973|NCT01760278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970974|NCT00333957|||||PROSPECTIVE|||||||
33970975|NCT01264211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33970976|NCT02254733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33970977|NCT02223975|||CASE_ONLY||OTHER|||||||
33970978|NCT01593527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33970979|NCT04138849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759360|NCT00941798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759361|NCT01537302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759362|NCT05508503|||CASE_CONTROL||PROSPECTIVE|||||||
33759363|NCT01870388|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33759364|NCT00337272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759365|NCT00360503|||CASE_ONLY||PROSPECTIVE|||||||
33759366|NCT06129864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070296|NCT06553482|RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistical Analysis will be conducted without knowledge of gropus allocation.|The subjects assigned to each group will participate in a randomized clinical trial, with a duration of 16 weeks of intervention. Measurements of all variables will be taken on the first day of the evaluation (considered the basal state) and at the end of 16 weeks of the intervention according to the group in which they were randomized, to be followed by sta-tistical analysis of the data. The variables contemplated involve assessments of body composition and physical capacities, biochemical variables, epigenetic variables and alternate variables.|f|f|f|t
33759367|NCT03113292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor won't have any knowledge about the study purposes and will be unaware of the group allocation. The statistical analysis will also be performed blinded for group allocation.|This is a randomized controlled clinical trial, characterized by the application of therapeutic exercises, in which subjects will be randomly allocated into two groups: Pilates Method and Home-Based Exercises. The participantes will be individuals with non-specific chronic low back pain. The study will be reported following the recommendations of the CONSORT Statement. For the present study, chronic non-specific back pain was defined as uninterrupted low back pain for more than 12 weeks, with unknown causes.|f|f|f|t
33759368|NCT02701894|||||RETROSPECTIVE|||||||
33759369|NCT04701463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759370|NCT03895554|||CASE_ONLY||PROSPECTIVE|||||||
33970980|NCT05886699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33970981|NCT03397628|RANDOMIZED|PARALLEL||PREVENTION||||||||
33970982|NCT06483958|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33970983|NCT00533520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970984|NCT04960475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33970985|NCT00942032|||CASE_ONLY||RETROSPECTIVE|||||||
33970986|NCT00927459|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33970987|NCT06547593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33970988|NCT05473156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070297|NCT05446142|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34070298|NCT03130933|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|There was 400 participiants, patients and the same oral surgeon|A RANDOMIZED CONTROLLED TRIAL|t|t|t|t
33970989|NCT02165228|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070299|NCT02634801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759371|NCT01048892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759372|NCT06037460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759373|NCT06246500|||COHORT||RETROSPECTIVE|||||||
33759374|NCT01701414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759375|NCT02313987|||CASE_CONTROL||PROSPECTIVE|||||||
33759376|NCT06225102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|While it is known by the researchers that the students are in the experimental and control groups, it is not known by the students.|The sample of the study consisted of 89 nursing students with primary dysmenorrhea (45 experimental group and 44 control group)|t|f|f|f
33759377|NCT03817138|||COHORT||RETROSPECTIVE|||||||
33759378|NCT05727722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759379|NCT01078155|||||PROSPECTIVE|||||||
33759380|NCT04285658|||COHORT||PROSPECTIVE|||||||
33759381|NCT04109014|NA|SINGLE_GROUP||PREVENTION||NONE||Quasiexperimental, single group pretest-posttest study design and qualitative interviews to evaluate feasibility, acceptability and effect.||||
33759382|NCT04176939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33970990|NCT00390156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970991|NCT05547230|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34070300|NCT01829997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759383|NCT01906671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759384|NCT02626832|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759385|NCT01591382|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33759386|NCT00433901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759387|NCT01030445|||COHORT||PROSPECTIVE|||||||
33759388|NCT04581525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759389|NCT05015816|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33759390|NCT05369715|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|To blind this study is not possible due to the studied conditions: morning and evening. Only data assesors can be blinded.||f|f|f|t
33759391|NCT00314925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759392|NCT03468959|||COHORT||PROSPECTIVE|||||||
33970992|NCT01211574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970993|NCT03723291|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, parallel group, randomised controlled trial in 50 patients with radiotherapy-induced fibrosis of the head and neck.||||
33759393|NCT06398483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759394|NCT01132625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33970994|NCT05464290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33970995|NCT03101163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33970996|NCT01814761|||CASE_ONLY||PROSPECTIVE|||||||
33970997|NCT02168270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759395|NCT03949790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759396|NCT03871088|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33970998|NCT06528834|||COHORT||PROSPECTIVE|||||||
33970999|NCT01943461|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33971000|NCT01680731|||CASE_CONTROL||RETROSPECTIVE|||||||
34070301|NCT01050322|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759397|NCT00331344||SEQUENTIAL||TREATMENT||NONE||||||
33759398|NCT02754102|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33759399|NCT00991341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759400|NCT03467932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Single-Blind Placebo Run-in (Masking will be with Participant):~During the placebo run-in period, subjects will self-administer blinded placebo study medication at night prior to bedtime (@10 PM ± 90 min. each night, no sooner than 2 hrs. after dinner). Outpatient glycemic levels and adverse events will be measured using self-monitored blood glucose (SMBG) and recorded in a diary. Treatment Period (Masking: Participant, Care Provider, Investigator, Outcomes Assessor) There are 2 Cohorts, A and B.~Part 1 In the first 2 weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS (bedtime), BID (2 X / day) or TID.~Part 2 Subjects will remain on fixed doses of ORMD-0801 or matched placebo for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia. Treatment arms will consist of subjects receiving ORMD-0801 QHS, BID, and TID versus placebo."||t|t|t|t
33759401|NCT00846105|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33759402|NCT05254548|NA|SEQUENTIAL||OTHER||NONE||Four-period, fixed-sequence drug-drug interaction study.||||
33759403|NCT03329898|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33759404|NCT01606527|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33759405|NCT01463956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759406|NCT01635257|||COHORT||PROSPECTIVE|||||||
33759407|NCT06525844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759408|NCT00661739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759409|NCT04934579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759410|NCT01489943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759411|NCT05028426|||COHORT||RETROSPECTIVE|||||||
33759412|NCT04859634|||COHORT||PROSPECTIVE|||||||
33759413|NCT06526221|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Based on NIH definitions, this is considered a clinical trial given that there is prospective assignment of an intervention (i.e., urine isoniazid testing) to evaluate medication adherence. As such, this could be considered a single group/arm study with prospective assignment of the intervention to all study participants.||||
33759414|NCT04812366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881492|NCT01466400|||||PROSPECTIVE|||||||
33881493|NCT02878980|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33881494|NCT04884555|||COHORT||PROSPECTIVE|||||||
33881495|NCT04677348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33881496|NCT00040755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881497|NCT05469971|||CASE_CONTROL||RETROSPECTIVE|||||||
33881498|NCT05160935|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Planning the Simple Randomization Method; Since the individuals in the sample group will share the same environment, it is created by separating different days for the experimental group and different days for the control group. It is planned to divide the sample as the control group on odd days and the experimental group on even days. In the selection of both groups, attention will be paid to the similarity of individual characteristics such as age, gender and educational status.|||||
33971001|NCT06400849|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Open-label, single-centre, randomised (1:1), stratified, self-controlled cohort study||||
33881499|NCT05866055|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33881500|NCT01207557|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33971002|NCT04755322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971003|NCT00001683||||TREATMENT||||||||
33971004|NCT03730324|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Study subjects will be randomized in a 1:7 fashion between~1. Standard biopsies + biomarkers and~2. Biomarkers + mpMRI and Standard / mpMRI targeted biopsies."||||
33971005|NCT04485247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971006|NCT02934828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971007|NCT05072691|||COHORT||PROSPECTIVE|||||||
33971008|NCT02144259|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971009|NCT03004690|RANDOMIZED|PARALLEL||||NONE||||||
33971010|NCT05555589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971011|NCT03729765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971012|NCT04449042|||COHORT||PROSPECTIVE|||||||
33759415|NCT00379522|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33971013|NCT01988311|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971014|NCT02789111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971015|NCT05760014|||CASE_CONTROL||PROSPECTIVE|||||||
33971016|NCT00652873|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33971017|NCT01507896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971018|NCT06290583|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33971019|NCT05610501|||COHORT||PROSPECTIVE|||||||
33971020|NCT01387100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33971021|NCT02386059|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33971022|NCT01682161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971023|NCT02872402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33971024|NCT03969459|||CASE_ONLY||PROSPECTIVE|||||||
33971025|NCT01480856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971026|NCT02345486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971027|NCT05085314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971028|NCT03496454|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971029|NCT05381259|NA|SINGLE_GROUP||OTHER||NONE||Part of the group having agreed to participate in the study will carry out the horticultural workshop while the other group will benefit from the workshop usually offered.||||
33971030|NCT03746678|||COHORT||PROSPECTIVE|||||||
33971031|NCT04051138|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE||randomized, double blind, prospective|t|t|t|f
33971032|NCT03645226|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33971033|NCT01978106|||COHORT||RETROSPECTIVE|||||||
33971034|NCT03089632|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after clinical trial.||||
33971035|NCT02296606|||COHORT||PROSPECTIVE|||||||
34070302|NCT00103662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070303|NCT02538406|||COHORT||PROSPECTIVE|||||||
34070304|NCT04787614|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33971036|NCT01254045|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34070305|NCT04508647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070306|NCT01963091|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33971037|NCT02570165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971038|NCT06126042|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33971039|NCT00729196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971040|NCT04277195|||COHORT||RETROSPECTIVE|||||||
33971041|NCT02648373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971042|NCT04083339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971043|NCT05705583|||COHORT||PROSPECTIVE|||||||
33971044|NCT06123403|||COHORT||PROSPECTIVE|||||||
33971045|NCT06200961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Case Control||||
33971046|NCT04111133|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33971047|NCT02619604|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33971048|NCT04510220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971049|NCT04625920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971050|NCT04633759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971051|NCT04568928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971052|NCT04574778|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Only those performing postoperative assessments and the participants will be blinded.||t|f|f|t
33971053|NCT04596501|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33971054|NCT01824771|||CASE_ONLY||PROSPECTIVE|||||||
33971055|NCT06051396|||CASE_CROSSOVER||PROSPECTIVE|||||||
33971056|NCT01004770|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33971057|NCT04079842|NA|SINGLE_GROUP||OTHER||NONE||||||
34070307|NCT06222177|||COHORT||RETROSPECTIVE|||||||
34070308|NCT02797509|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34070309|NCT05768529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070310|NCT01860716|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34070311|NCT03279601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070312|NCT04184011|||COHORT||PROSPECTIVE|||||||
34070313|NCT01817166|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34070314|NCT02781818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070315|NCT02370056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070316|NCT01277432|||COHORT||CROSS_SECTIONAL|||||||
34070317|NCT02721914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34070318|NCT00209950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070319|NCT00726258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971058|NCT01859325|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33971059|NCT02501239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971060|NCT04370145|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cholangitis patients post-kasai Portoenterostomy were grouped by cholangitis severity score, according to the severity was divided into mild, moderate, severe cholangitis, all levels of cholangitis patients were divided into subgroups by age and post-kasai Portoenterostomy jaundice matching design of experiment, then they were randomly divided into control group and experimental group.||||
33971061|NCT04847609|||COHORT||PROSPECTIVE|||||||
33971062|NCT04228302|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33971063|NCT02333409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33971064|NCT01677455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971065|NCT01583387|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971066|NCT06234852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971067|NCT03369756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070320|NCT03795285|||CASE_CONTROL||PROSPECTIVE|||||||
33881501|NCT05698680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"There are 2 active and effective treatments (colchicine vs. prednisolone). The allocation to the treatment arms is 1:1, and study participants are randomised to either group. Randomisation is intended to reduce selection and allocation bias.~As both drugs have different dosing regimens, the investigators provide identical blisters for both drugs including the active substance and corresponding placebos. This way, all study participants receive the same number of tablets and the possibility of drug prediction is more difficult. This is achieved by using tablets that are identical in taste and appearance (double-dummy design). Participants randomised to the colchicine arm will receive colchicine plus prednisolone placebo. Participants randomised to the prednisolone arm will receive prednisolone plus a colchicine placebo. The prednisolone placebos contain a bittering agent due to the bitter taste of prednisolone to ensure a similar taste."|"This clinical trial is a two-arm multicentre, pragmatic, prospective, randomised, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design (phase IV).~According to the guidelines of the German Society of General Medicine (DEGAM), the decision to start gout treatment is made clinically. As this is a pragmatic study, eligibility will be determined during a routine clinical examination. The clinical diagnosis is made without new laboratory tests, joint puncture with synovial analysis or imaging.~314 patients with an acute gout attack are going to be recruited in 60 General Practitioner's practices across 3 university sites (Greifswald, Göttingen, and Würzburg). All study participants receive active treatments, but are randomised into either the prednisolone group (treatment group) or the colchicine group (comparison group). The study lasts 4 weeks for each participant."|t|t|t|t
33881502|NCT01580397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881503|NCT04114435|||COHORT||PROSPECTIVE|||||||
33971068|NCT05485428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blinded to group allocation|Randomised controlled feasibility study with mechanistic, physiological and clinical sub components|f|f|f|t
33971069|NCT01706198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971070|NCT02217722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971071|NCT04066179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971072|NCT04224779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971073|NCT05163002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971074|NCT02523365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971075|NCT01525706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971076|NCT02945462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971077|NCT00551122|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971078|NCT06544486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The materials were visually different from each other, which allowed the investigators to identify each material. As a result, masking could only be performed with the participants.||t|f|f|f
33971079|NCT04900233|||COHORT||OTHER|||||||
33971080|NCT06161597|RANDOMIZED|PARALLEL||PREVENTION||NONE|Study personnel and participants are informed of what condition participants are assigned to.|All participants will receive the primary intervention: The Family Check-Up Online. Participants will then be randomly assigned to a specific coaching condition.||||
33971081|NCT02888769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33971082|NCT04996810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971083|NCT04657510|||COHORT||RETROSPECTIVE|||||||
33971084|NCT02749019|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971085|NCT01584778|||CASE_CONTROL||PROSPECTIVE|||||||
33971086|NCT00006081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971087|NCT03982758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971088|NCT05031481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971089|NCT06480448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33971090|NCT00881959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759416|NCT05225064|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcome assessor will be blind to study arm assignment. Due to the nature of the intervention, participants and care providers will not be blind to intervention assignment; however they are likely to be unaware of intervention components because they are not expect to communicate with those who are assigned to a different intervention arm|There are five arms. Arm 1: Control; Arm 2: Village-level vaccine clinics with monetary, non-monetary, or no incentive; Arm 3: Household-level vaccination with monetary, non-monetary, or no incentive; Arm 4: Mask promotion; Arm 5: Village-level vaccine clinics and mask promotion|f|f|t|t
33759417|NCT01321554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759418|NCT04318184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759419|NCT06491472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759420|NCT00978510|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33881504|NCT00458731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881505|NCT01648231|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881506|NCT00091910|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33881507|NCT04040777|||OTHER||PROSPECTIVE|||||||
33881508|NCT00824122|||CASE_CONTROL||PROSPECTIVE|||||||
33881509|NCT04442841|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881510|NCT05154292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Clinical Trial|t|t|f|f
33881511|NCT02342405|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33881512|NCT01292057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881513|NCT03979157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881514|NCT05453643|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881515|NCT02655081|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881516|NCT03195478|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33881517|NCT05835479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881518|NCT01300182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881519|NCT01828931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881520|NCT03249571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Flavonoid or placebo in capsules|Randomized, parallel group design|t|f|t|f
33881521|NCT02009527|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33881522|NCT01405053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881523|NCT00429585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881524|NCT03824860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881525|NCT02981771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33881526|NCT02542709|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33881527|NCT03993184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881528|NCT06023979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33881529|NCT02668718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881530|NCT06549257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971091|NCT01541462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33881531|NCT00836433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33881532|NCT04870476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881533|NCT02559687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759421|NCT05741957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881534|NCT03512145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881535|NCT03948178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881536|NCT03515109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|they will not be aware of the procedure they are going to perform or have.|prospective randomised|t|f|t|f
33881537|NCT04682405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33881538|NCT04264533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33881539|NCT01667471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881540|NCT02541773|||COHORT||PROSPECTIVE|||||||
33881541|NCT01547325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881542|NCT01656863|||CASE_ONLY||PROSPECTIVE|||||||
33881543|NCT00006255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881544|NCT02348515|||COHORT||PROSPECTIVE|||||||
33881545|NCT04490837|||CASE_CONTROL||PROSPECTIVE|||||||
33881546|NCT01783678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971092|NCT02223026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971093|NCT04305223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators assessing outcome measures will be blinded to participants' group assignment.|single-blinded randomized clinical trial|f|f|f|t
33971094|NCT02439242|||COHORT||PROSPECTIVE|||||||
33971095|NCT01900873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971096|NCT03804645|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|open-label, randomized, four-way crossover single oral dose||||
33971097|NCT06205303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971098|NCT00891774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971099|NCT02265887|||COHORT||PROSPECTIVE|||||||
33971100|NCT00075894||||TREATMENT||NONE||||||
33971101|NCT04813900|NA|SINGLE_GROUP||OTHER||NONE||||||
33971102|NCT01080430|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33971103|NCT02300376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971104|NCT01097356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971105|NCT05296512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759422|NCT01291914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759423|NCT05161299|||COHORT||OTHER|||||||
33759424|NCT01426971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759425|NCT06196450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Vivomixx and Placebo (Crystalline maltose)|Multi-site phase II randomised controlled trial (Proof of concept study)|t|t|t|t
33759426|NCT06184711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759427|NCT01115257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759428|NCT05797103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label, two arm clinical study|||||
33759429|NCT03320018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33759430|NCT00223626|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33759431|NCT04136886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759432|NCT06492980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759433|NCT03390387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759434|NCT03407690|||FAMILY_BASED||PROSPECTIVE|||||||
33759435|NCT05775055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Double-blind, randomised, crossover design|t|f|t|f
33759436|NCT04815044|||COHORT||PROSPECTIVE|||||||
33759437|NCT04825158|||COHORT||PROSPECTIVE|||||||
33759438|NCT00432003|||||PROSPECTIVE|||||||
33759439|NCT03245138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759440|NCT00118898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759441|NCT02654990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759442|NCT03871634|||COHORT||PROSPECTIVE|||||||
33759443|NCT00914277|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33759444|NCT01896401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759445|NCT01568268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759446|NCT02346019|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33759447|NCT00152464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759448|NCT03907319|||COHORT||RETROSPECTIVE|||||||
33759449|NCT00914784|||CASE_CONTROL||PROSPECTIVE|||||||
33759450|NCT05182645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Waiting Control Group Design|f|f|f|t
33759451|NCT03079310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759452|NCT06491849|||COHORT||PROSPECTIVE|||||||
33759453|NCT03152084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759454|NCT04372836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Primary and secondary outcomes are compared between study group and control group 6 months and 12 months after intervention during surgery for unilateral endometrioma.||||
33881547|NCT01571583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881548|NCT06134154|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33881549|NCT01814163|||CASE_ONLY||PROSPECTIVE|||||||
33881550|NCT03434379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881551|NCT01751971|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants were not informed whether they were breathing supplemental inspired oxygen or sham (air) on the study night. Technicians and investigators performing the study were not masked in order to carefully ensure delivery of treatment.||t|f|f|f
33881552|NCT03376672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881553|NCT01175044|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33881554|NCT03002025|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33881555|NCT02254889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881556|NCT01693315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881557|NCT05632679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Single-blind randomized clinical trial|f|t|t|t
33881558|NCT04536597|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881559|NCT04995146|||COHORT||RETROSPECTIVE|||||||
33759455|NCT04911309|RANDOMIZED|CROSSOVER||OTHER||NONE||This study is designed as a two-armed crossover intervention study with two intervention phases lasting 12 weeks each and three measurement points.||||
33759456|NCT00489710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759457|NCT02221401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759458|NCT05818150|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrolled subjects will be randomized 1:1 to either geniculate artery embolization or corticosteroid injection for treatment of symptomatic knee osteoarthritis.||||
33759459|NCT03040713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759460|NCT01077544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971106|NCT02788331|||COHORT||RETROSPECTIVE|||||||
33971107|NCT02727140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33971108|NCT02024828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971109|NCT04443322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971110|NCT02448628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971111|NCT00325533|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971112|NCT00621686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759461|NCT00115141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33759462|NCT01154569|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33881560|NCT04067947|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|The Investigator or designee, study coordinator(s), subjects, the Sponsor study team and its representatives, will be blinded to the treatment assignment.||t|t|t|f
33881561|NCT03843476|||COHORT||OTHER|||||||
33759463|NCT01819246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759464|NCT02080884|||CASE_ONLY||PROSPECTIVE|||||||
33759465|NCT02448940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759466|NCT00262795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759467|NCT02859402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759468|NCT02445313|||CASE_CONTROL||PROSPECTIVE|||||||
33759469|NCT00221910|RANDOMIZED|PARALLEL||||SINGLE||||||
33881562|NCT04547595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33881563|NCT04211207|||CASE_ONLY||PROSPECTIVE|||||||
33881564|NCT05792735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881565|NCT00338507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33881566|NCT02403609|NA|SINGLE_GROUP||||NONE||||||
33881567|NCT00232401|||||PROSPECTIVE|||||||
33881568|NCT01534676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881569|NCT00615615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881570|NCT00003063|RANDOMIZED|||TREATMENT||||||||
33881571|NCT03936374|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881572|NCT03597425|||COHORT||RETROSPECTIVE|||||||
33881573|NCT01920711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881574|NCT01707407|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33881575|NCT03721926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33759470|NCT06318325|||COHORT||PROSPECTIVE|||||||
33759471|NCT04325438|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge design trial||||
33759472|NCT04304352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759473|NCT02331602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881576|NCT00430170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881577|NCT04522674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881578|NCT06385132|||COHORT||PROSPECTIVE|||||||
33971113|NCT01702350|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33759474|NCT02341508|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33759475|NCT03953339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971114|NCT06106503|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33971115|NCT01129999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971116|NCT06480617|||CASE_CONTROL||RETROSPECTIVE|||||||
33971117|NCT03252288|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A random event (scheduled vaccination date for a child based on date of birth) will determine whether a women does not receive an intervention (before a certain calendar date) or receives an intervention (after a certain calendar date).||||
33971118|NCT05145777|||CASE_ONLY||PROSPECTIVE|||||||
33971119|NCT03432299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971120|NCT00195806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971121|NCT00560183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759476|NCT02803125|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070321|NCT04676724|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a ratio of 1:1 to one of two treatment arms: 24 weeks GSK3228836 followed by up to 24 weeks PegIFN, or 12 weeks GSK3228836 followed by up to 24 weeks PegIFN.||||
33971122|NCT01227668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971123|NCT02371083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971124|NCT04659733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971125|NCT03754491|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigators will enroll 204 naïve papilla with a body temperature ≥37 °C who was diagnosed with mild or moderate cholangitis associated with choledocholithiasis for one-stage procedure to remove CBD stone.||||
33971126|NCT03929224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971127|NCT02751333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070322|NCT02802696|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070323|NCT03450616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects and treating physician will be blinded to treatment.|All subjects will receive both treatment arms at the same time.|t|t|f|f
34070324|NCT03315598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070325|NCT04786236|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Patients are blinded to their current control mode.|Patients undergo testings in constant speed mode and physiologically controlled mode on the same day. the sequence is randomized. The number of patients was chosen due to the fact (experience in clinical care of the patients) the anatomical situation, the pump position due to surgical implant and the patient condition can vary to a high extent.|t|f|f|f
34070326|NCT04349540|||CASE_ONLY||PROSPECTIVE|||||||
33759477|NCT02475603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33759478|NCT02945332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971128|NCT00125996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33971129|NCT01809314|||COHORT||PROSPECTIVE|||||||
33971130|NCT01664195|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070327|NCT04728698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070328|NCT02711566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070329|NCT00497055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070330|NCT05447156|RANDOMIZED|PARALLEL||PREVENTION||NONE||Aim 2: All participants in this aim will use the tailored QuitGuide app Aim 3: Participants will be randomized to either the tailored QuitGuide app or the standard version of the QuitGuide app for 5 weeks.||||
33971131|NCT02181452|||CASE_ONLY||RETROSPECTIVE|||||||
34070331|NCT03130270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881579|NCT00539695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881580|NCT04855994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33881581|NCT04282772|||OTHER||RETROSPECTIVE|||||||
33881582|NCT03573453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881583|NCT03638505|||COHORT||PROSPECTIVE|||||||
33881584|NCT00931489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881585|NCT01570673|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881586|NCT01211379|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33881587|NCT04703894|NA|SINGLE_GROUP||OTHER||NONE||||||
33881588|NCT06057363|||COHORT||PROSPECTIVE|||||||
33881589|NCT03840538|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33881590|NCT01976923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881591|NCT02863809|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33881592|NCT03944239|NA|SINGLE_GROUP||OTHER||NONE||||||
33881593|NCT01396343|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881594|NCT05789017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881595|NCT00929071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881596|NCT01531114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881597|NCT00157612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881598|NCT04991766|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881599|NCT04740073|||COHORT||PROSPECTIVE|||||||
33971132|NCT04014959|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects receive active TMS to their individualized fMRI-guided target. Participants will first receive TMS in the MRI scanner, then over the course of 3-Day TMS Intervention Regimen, and lastly in a final MRI scan.||||
33971133|NCT06243978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759479|NCT02708225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759480|NCT04423822|||COHORT||RETROSPECTIVE|||||||
33759481|NCT02138266|||COHORT||PROSPECTIVE|||||||
33971134|NCT03175237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971135|NCT02081261|||COHORT||RETROSPECTIVE|||||||
34070332|NCT05886907|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Subjects will wear the products (test and comparator) in a predetermined order.|t|f|f|f
34070333|NCT00000589|RANDOMIZED|||PREVENTION||DOUBLE||||||
34070334|NCT01121263|||COHORT||PROSPECTIVE|||||||
33881600|NCT06548893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the team member who will apply the questionnaires/scales will be masked.|Randomized controlled trial|f|f|f|t
33759482|NCT06168292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881601|NCT06403085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881602|NCT01298492|NA|SINGLE_GROUP||TREATMENT||||||||
33881603|NCT02116010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881604|NCT04017143|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Two-Arm Randomized Clinical Trial|t|f|f|f
33881605|NCT00426894|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33881606|NCT04676737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881607|NCT03786367|||CASE_CONTROL||PROSPECTIVE|||||||
33881608|NCT01753908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33971136|NCT06483672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971137|NCT02610049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971138|NCT02817711|||COHORT||PROSPECTIVE|||||||
34070335|NCT02739659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070336|NCT00293800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070337|NCT00282685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070338|NCT05772611|||COHORT||CROSS_SECTIONAL|||||||
34070339|NCT00543673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759483|NCT01493505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759484|NCT02512523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759485|NCT04595721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070340|NCT01784926|RANDOMIZED|PARALLEL||TREATMENT||NONE|Investigator masked for group affiliation during image analysis|||||
34070341|NCT01466075|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070342|NCT05114564|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34070343|NCT04812314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971139|NCT05496088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The study is a prospective, randomized, open-label, blinded endpoint, multi-center study to compare the efficacy of adding additional ablation step (targeting areas of complex, continuous electrical activity in LA) beyond Re-PVI during catheter ablation of Atrial Fibrillation (AF) in patients undergoing 2nd ablation procedure.~Trial flow Patients fitting the enrollment criteria and signing the informed consent form will be included and will undergo the Redo procedure for catheter ablation of pers. AF. After Re-PVI only patients with ongoing or inducted AF will be randomized. Patients, who do not fulfill this intraprocedural criteria for randomization will not be randomized but be treated as dropouts.~Randomization is based on a 1:1 ratio into two study arms:~1. RePVI only: Re-PVI (followed by cardioversion if AF persists)~2. RePVI + substrate ablation: Re-PVI followed by ablation of areas of complex, continuous activity (followed by cardioversion if AF persists)."|f|f|f|t
33971140|NCT03605615|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a randomized open-label trial with the objective of evaluating the effect of vocalization as a perineal protection maneuver during the second stage of labor. Paerturients will be randomized to receive standard care, which in the ward is already a humanized approach, with freedom of position, and to push, ou to, toguether with all this standard prodedure, receive orientation about vocalization techniques.||||
33971141|NCT06389279|||CASE_ONLY||PROSPECTIVE|||||||
33971142|NCT01464359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759486|NCT01298505|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33881609|NCT03561584|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Participants and Providers will be masked until Week 14. If a subject continues past week 14, the study becomes Open-Label and participants are given the option to continue on the active drug for an additional 8 weeks. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.|There are two arms in this trial: active drug and placebo. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.|t|t|f|f
33881610|NCT02815839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881611|NCT03170141|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with GBM will be treated with tumor targeting IgT cells expressing immune modulatory genes||||
33881612|NCT04323904|||CASE_CONTROL||RETROSPECTIVE|||||||
33881613|NCT04196660|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study sample included 160 pregnant women who had the following characteristics: i) those who were admitted to the Ministry of Health Urla State Hospital for labor ii) those who met the inclusion criteria, and iii) those who had received labor dance training by attending Prenatal Training with their spouses/partners in the prenatal period. The Dance Practitioner Spouse/Partner Group (DPSG) (Experimental) included 40 pregnant women who signed the Informed Consent Form, the Dance Practitioner Midwife Group (DPMG) included 40 pregnant women and midwives who had received labor dance training, and the Control Group included 80 pregnant women who were subjected to routine treatment without dance. The sample size was calculated using a power analysis. The optimum sample size was found to be 160 as Type 1 error α = 0.05 and Type 2 error β = 0.2 (power = 80%).||||
33971143|NCT00226694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33971144|NCT00092079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971145|NCT04497610|||COHORT||PROSPECTIVE|||||||
33971146|NCT04661462|||OTHER||CROSS_SECTIONAL|||||||
33971147|NCT02229032|||COHORT||CROSS_SECTIONAL|||||||
33971148|NCT04604483|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective non-randomized trial||||
33971149|NCT00377052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971150|NCT02743442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971151|NCT00887003|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33759487|NCT03943966|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single centre prospective pilot study||||
33759488|NCT06130046|||COHORT||PROSPECTIVE|||||||
33759489|NCT04186780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be informed to which group they belong, intervention or control. Who will do the randomization will not be blind, because during treatment she will know which group is eating the bars with Shiitake. The researcher responsible for the pre- and post-treatment evaluation will be blind and will not know the research intervention.|Prospective, randomized, double blind and placebo-controlled|t|f|t|t
33759490|NCT04945148|NA|SINGLE_GROUP||TREATMENT||NONE||Metformin (1500 to 3000mg/day) in addition to Stupp protocol, starting 7 days before the start of the standard radiotherapy (RT, 60Gy/6 weeks), concomitant Temozolomide (TMZ) chemotherapy (75mg/m²/day), and adjuvant TMZ (150-200 mg/m2/ 5 days) + metformin will follow onwards until the 12th cycle of TMZ||||
33759491|NCT00269802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759492|NCT06200337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants: They did not know about acupuncture, meridian theory, and acupoints. The investigator informs the information about the specific location of the acupoints used and the purpose of the study. The investigator provided a questionnaire to assess the participants' knowledge of meridian and acupressure theory, expectations, and motivation to participate.~Infrared image analyst: The person analyzing the infrared images is not familiar with acupuncture methods. We trained them for two weeks on using FLIR Thermal Studio software and identifying experimental skin areas. After analysis, the infrared image analyst encodes the data and sends it back to the data analyst.~Data analyst: The investigator analyzed the data and was not involved in the randomization and data collection stages."||t|f|f|t
33759493|NCT05332457|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcome assessor are blinked to participants' allocation group.|This is a prospective, single-centered, crossover, randomized (1:1) study.|f|f|f|t
33759494|NCT01016301|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881614|NCT02611635|||OTHER||CROSS_SECTIONAL|||||||
33881615|NCT04834531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881616|NCT02643004|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33881617|NCT02750358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881618|NCT02988765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881619|NCT06549387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881620|NCT01935401|||CASE_CONTROL||PROSPECTIVE|||||||
33881621|NCT01399580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881622|NCT03542201|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33881623|NCT01448200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881624|NCT05550155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881625|NCT02165384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881626|NCT04894929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It has been explained to the patient that the exercises that they are going to perform are going to serve for their functional improvement, but the exercises are different depending on the group to which they have been assigned randomly.|set of interventions can be carried out by making an initial diagnosis of pre-frailty or frailty using instruments and simple validated tests. This is indicated or thus recommended in the guidelines from national and international societies (24-25). In this sense, we can use a comprehensive assessment of the VALINTAN (computerized) tool, a VGI-type assessment, whose axis is function, focusing on predefined diagnoses associated with effective documented interventions or with functional fragility or loss. Currently the tool is open and freely accessible (26).|t|f|f|f
33881627|NCT01543087||||OTHER||NONE||||||
33881628|NCT03723629|||COHORT||PROSPECTIVE|||||||
33881629|NCT02020486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881630|NCT05300191|||COHORT||PROSPECTIVE|||||||
33881631|NCT02463578|||||PROSPECTIVE|||||||
33881632|NCT04269109|||COHORT||RETROSPECTIVE|||||||
33881633|NCT02450487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33881634|NCT05509478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759495|NCT00246233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759496|NCT01077830|||COHORT||RETROSPECTIVE|||||||
33881635|NCT03971110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881636|NCT05931809|||COHORT||PROSPECTIVE|||||||
33881637|NCT05557058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881638|NCT06518460|||COHORT||PROSPECTIVE|||||||
33881639|NCT02102763|||COHORT||CROSS_SECTIONAL|||||||
33881640|NCT01637545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33881641|NCT05284682|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881642|NCT03987087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881643|NCT05361720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881644|NCT01306734|||COHORT||PROSPECTIVE|||||||
33881645|NCT06447610|||COHORT||RETROSPECTIVE|||||||
33881646|NCT04961606|||OTHER||CROSS_SECTIONAL|||||||
33881647|NCT00523991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33881648|NCT01281410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881649|NCT03245450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881650|NCT05153057|||COHORT||PROSPECTIVE|||||||
33881651|NCT05110976|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Part A of the study is single-blind, and Part B of the study is double-blind||t|t|t|t
33881652|NCT02074852|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881653|NCT04370327|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33881654|NCT04013594|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33881655|NCT00469950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881656|NCT02288585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33881657|NCT03642678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33971152|NCT06367556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Quantitative outcome assessors and data analysts will be blinded to participant treatment group. Blinding is not possible for trial participants, intervention providers, or pediatric oncology teams, as assignment cannot be hidden from these individuals.||f|f|f|t
33971153|NCT06103526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971154|NCT06546306|||COHORT||PROSPECTIVE|||||||
33971155|NCT01271114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971156|NCT06109662|||COHORT||PROSPECTIVE|||||||
33971157|NCT04487756|NA|SINGLE_GROUP||TREATMENT||NONE||single arm Phase Ib/II multicenter open label study, with translational sub-study||||
33971158|NCT01869322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971159|NCT01234571|||CASE_ONLY||PROSPECTIVE|||||||
33971160|NCT05875415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971161|NCT04044846|NA|SINGLE_GROUP||PREVENTION||NONE||The pilot evaluation will have a quasi-experimental pre-test/post-test design and investigators will collect self- reported data from frail older adults on the perceived benefit of exercise using the Vitality Plus Scale (VPS) (Myers et al., 1999).||||
33971162|NCT04372498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971163|NCT03720184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patient and neurocognitive examinator does not know the arm assigned, as well as the anaesthesiologist, surgeon and ICU team. Only the perfusionist has access to de randomization sheet before choosing and set up of the extracorporeal circuit.~In order to guarantee the blinding, the perfusionist must be hidden during the possible HAR performance, using a field blanket to isolate the oxygenator´s area. Anestesiologist´s proceed in every case as if HAR is assigned maintaining a mean arterial pressure over 60 mmHg."|"In a preliminary phase, patients are randomly assigned to 4 branches, regarding to two conditions: oxygenator´s deairing type and HAR exposure. This phase is designed as pilot study with 100 patients in order to determine precisely the sample size needed depending on the observed effects.~If there are no clinical differences between oxygenators behaviour, during the second stage, sample will be only divided in 2 groups due to HAR exposure."|t|t|t|t
33971164|NCT00632671|||CASE_ONLY||PROSPECTIVE|||||||
33971165|NCT06102889|||COHORT||PROSPECTIVE|||||||
33971166|NCT03256513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971167|NCT00717977|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33971168|NCT01247688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971169|NCT02099461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971170|NCT01465776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971171|NCT00410410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971172|NCT05110755|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33971173|NCT02370706|NA|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33881658|NCT01976598|||COHORT||PROSPECTIVE|||||||
33881659|NCT02444273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881660|NCT01868100|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33881661|NCT04455555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and investigator||t|f|t|f
33881662|NCT01243736|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33881663|NCT00814229|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33881664|NCT00940264|||COHORT||PROSPECTIVE|||||||
33971174|NCT03718156|RANDOMIZED|PARALLEL||PREVENTION||NONE|Long-term care facilities (LTCFs) cannot be blinded, as trial arm allocation will be obvious (those in the intervention group will undergo delirium prevention protocol training before their respective follow-up periods, and those in the control group will not). Similarly, research assistants (RAs) tasked with conducting resident assessments cannot be blinded to group allocation, as they will be constantly exposed to the everyday workings of participating LTCFs. However, RAs will be blinded to resident cognitive scores. All researchers analyzing the data will be blinded to group allocation, as LTCF names will be anonymized and randomization statuses will be concealed prior to data analysis.|The PREPARED Trial is a 4-year cluster randomized intervention study. A cluster design was adopted in order to prevent contamination across the intervention and control arms by nursing staff who may provide replacement hours of employment at different units/floors within their long-term care facilities (LTCFs). Participating LTCFs (clusters) will be assigned to either the PREPARED Trial intervention or the control (usual care) arm of the study using a covariate constrained randomization procedure. In addition, given the need to assess each resident weekly for a follow-up period of 18 weeks and logistical limitations (large geographical coverage, 40-50 LTCFs included, and limited work force), the investigators will employ a sequential approach whereby sets of clusters (LTCFs) will be randomized into the two study arms in consecutive 'waves' of follow-up lasting 18 weeks each. It is estimated that 4 waves of trial follow-up, comprised of 10-12 clusters each, will be completed.||||
33881665|NCT00494897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881666|NCT01055535|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881667|NCT05439187|||COHORT||RETROSPECTIVE|||||||
33881668|NCT02777216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881669|NCT01309035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881670|NCT06244238|||OTHER||CROSS_SECTIONAL|||||||
33881671|NCT01995071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881672|NCT03228966|||COHORT||CROSS_SECTIONAL|||||||
33881673|NCT02245139|||CASE_ONLY||PROSPECTIVE|||||||
33881674|NCT05341414|||COHORT||RETROSPECTIVE|||||||
33881675|NCT03418012|RANDOMIZED|PARALLEL||PREVENTION||NONE|due to the nature of the intervention (placement of a cervical pessary) a masking is not possible|"parallel groups:~* Controll group with management as usual~* Pessary group with insertion of cervical pessary at 12+0-16+0 weeks of gestation"||||
33881676|NCT03413150|||COHORT||RETROSPECTIVE|||||||
33881677|NCT04336098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881678|NCT00391222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881679|NCT02055066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881680|NCT01219231|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881681|NCT03144466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881682|NCT05879042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881683|NCT01367795|||COHORT||PROSPECTIVE|||||||
33881684|NCT05654831|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33881685|NCT01072370|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33881686|NCT03686787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Healthy, non-smoking||||
33881687|NCT01218607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881688|NCT05480813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The one participant of the study is an orthopaedic surgeon. He will execute 48 THA procedures during 4 study days. 24 THA procedures will be executed using the automated KINCISE™ impaction system and 24 THA procedures will be executed using a traditional handheld mallet. He will undergo physical and cognitive tests before the OR day, during lunch breaks and after the OR day. Next to that, operational efficiency and ergonomic impaction will be analysed.||||
33881689|NCT02135887|||OTHER||PROSPECTIVE|||||||
33881690|NCT01272310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881691|NCT00296088|||COHORT||PROSPECTIVE|||||||
33881692|NCT06342531|NA|SINGLE_GROUP||SCREENING||NONE||A pre-post design (quasi-experimental), a cluster design||||
33881693|NCT02245828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881694|NCT01928160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881695|NCT04476888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881696|NCT06538506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessor and investigator will be blinded to participant allocation.|Participants are assigned to one of two groups for the duration of the study (BCI therapy or standard physiotherapy employing active and passive range of motion exercises).|f|f|t|t
33881697|NCT02646527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881698|NCT05456477|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33881699|NCT01162421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881700|NCT01481311|||CASE_ONLY||CROSS_SECTIONAL|||||||
33881701|NCT03708055|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971175|NCT05108883|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33971176|NCT00349895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971177|NCT04413747|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|identifier number (ID) without any refer to clinical assessment or to patients|Prospective cohort study based on clinical assessment. Model- based adjusted outcome via hierarchical comparison of control curves using COVID19 national epidemic data with cyber layer algorithm of population||||
33971178|NCT03892681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971179|NCT01671787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971180|NCT05127083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971181|NCT04958083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971182|NCT02501850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971183|NCT00497471|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33971184|NCT03522779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33971185|NCT01347710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971186|NCT06044558|||COHORT||RETROSPECTIVE|||||||
33881702|NCT04761211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The patients who were going to receive double breast ultrasound and molybdenum target in the breast surgery clinic and ward were enrolled into the group (disease-free: benign: malignant = 1:1:1). The patients were put on the device for about 3 minutes, and the breast was photographed at 5 sites. After that, the artificial intelligence learning was carried out on the photos of the training group. For the photos of the verification group, the algorithm obtained by the training group was compared with the existing artificial intelligence algorithms of ultrasound and molybdenum target.||||
33971187|NCT02406833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971188|NCT00395707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881703|NCT01404299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33881704|NCT04324177|||COHORT||PROSPECTIVE|||||||
33881705|NCT04173897|RANDOMIZED|PARALLEL||OTHER||NONE|Open label|"Parallel group, two-arm randomised model using a waiting list control design.~\[A separate single arm study (non-randomised, pre-post design) will run in parallel, recruiting via online channels.\]"||||
33881706|NCT05967663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881707|NCT06149598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881708|NCT05217771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881709|NCT01991132|NA|SINGLE_GROUP||||NONE||||||
33881710|NCT03842020|NA|SINGLE_GROUP||OTHER||NONE||||||
33881711|NCT03998358|||CASE_CONTROL||PROSPECTIVE|||||||
33881712|NCT01355536|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881713|NCT05824429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881714|NCT05079503|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
33881715|NCT04744337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881716|NCT03084640|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33881717|NCT00002553||||TREATMENT||||||||
33881718|NCT03541005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881719|NCT05957172|||COHORT||PROSPECTIVE|||||||
33971189|NCT05723640|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33971190|NCT01765556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971191|NCT05198128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Calcium for Prevention of Ovarian Hyperstimulation Syndrome (OHSS)|t|t|t|t
33971192|NCT06220461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971193|NCT00545337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971194|NCT05772299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The outcome assessor, in this case the dental hygienist performing the registrations/measurement, is blinded during the whole study~The principal investigator, in this case the periodontologist performing all the treatments, and is therefore not blinded."|"Test group: will be treated using the Er:Yag laser device (AdvErL EVO, Morita Corporation, Japan). The tip is placed in the pocket mesially, lingually, distally and buccally.~Control group: will be treated using an ultrasonic device with PEEK coated tips (EMS, Switzerland). The tip is placed in the pocket mesially, lingually, distally and buccally."|f|f|f|t
33971195|NCT01475383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33881720|NCT05853770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33881721|NCT03188692|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881722|NCT01392729|||COHORT||PROSPECTIVE|||||||
33881723|NCT05207878|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|During TMS, participants will be masked to whether they receive effective or sham stimulation on a given trial.|"The only intervention is the movement task. All participants receive the same task."||||
33881724|NCT04856514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881725|NCT02250014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881726|NCT02969057|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33971196|NCT04373109|||COHORT||PROSPECTIVE|||||||
33971197|NCT00403286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971198|NCT01961791|||COHORT||RETROSPECTIVE|||||||
33971199|NCT03281421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33971200|NCT00386724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971201|NCT00782002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070344|NCT03865719|NA|SINGLE_GROUP||TREATMENT||NONE||"An 11 session, 6 month healthy lifestyle program comprised of 30 to 45 minute sessions run by a dietician.~Session 1 Getting Started/ anthropometric measures (weight, height, blood pressure and waist circumference)~Session 2 Healthy Eating Habits/ anthropometric measures~Session 3 Healthy Snacking Habits/anthropometric measures~Session 4 Healthy Portions \& Servings Habits/ anthropometric measures~(BI-WEEKLY MEETINGS)~Session 5 Healthy Shopping Habits/ anthropometric measures~Session 6 Healthy Cooking \& Mealtime Habits/ anthropometric measures .~Session 7 Healthy Dining Out Habits/ anthropometric measures~Session 8 Healthy Physical Activity Habits/ anthropometric measures~(MONTHLY MEETINGS)~Session 9 Healthy Eating Behavior Habits/ anthropometric measures~Session 10 Healthy Problem Solving Habits/anthropometric measures~Session 11 Maintaining a Healthy Lifestyle/ anthropometric measures"||||
34070345|NCT00456469|||DEFINED_POPULATION||PROSPECTIVE|||||||
34070346|NCT01238341|||CASE_ONLY||PROSPECTIVE|||||||
34070347|NCT03302507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070348|NCT00038870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070349|NCT06283433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34070350|NCT04979533|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||There will be a single group of participants in which all receive oxygen insufflation to see if oxygen insufflation is adequate in microlaryngoscopy airway surgery.||||
34070351|NCT01488747|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34070352|NCT01372540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070353|NCT02784288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070354|NCT02683239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070355|NCT04854070|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomization in a 1:1 fashion to IVUS-guided PCI versus angio-guided PCI||||
34070356|NCT00368459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070357|NCT00385827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070358|NCT05799898|||COHORT||PROSPECTIVE|||||||
34070359|NCT05535426|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, objective performance criteria study||||
34070360|NCT03743025|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective placebo controlled randomized study||||
34070361|NCT05635877|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34070362|NCT00396474|||CASE_CONTROL||PROSPECTIVE|||||||
33881727|NCT01825031|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34070363|NCT01954953|||COHORT||PROSPECTIVE|||||||
34070364|NCT00202098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34070365|NCT04718805|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34070366|NCT01662271|||COHORT||PROSPECTIVE|||||||
34070367|NCT03058718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070368|NCT05624190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070369|NCT04069143|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34070370|NCT02660437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34070371|NCT05891717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881728|NCT01363869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881729|NCT04453579|||CASE_ONLY||PROSPECTIVE|||||||
33881730|NCT00011453|||||PROSPECTIVE|||||||
33881731|NCT00794209||CROSSOVER||||NONE||||||
33881732|NCT00742339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881733|NCT02766829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881734|NCT01266486|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881735|NCT02695511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33881736|NCT05078125|||CASE_ONLY||PROSPECTIVE|||||||
33881737|NCT05976191|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Single (Participant) Identity information of the patients was concealed and verbal and written consents were obtained.|Crossover Assignment This research was designed in a pretest posttest randomized controlled experimental type|t|f|f|f
33881738|NCT01747057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881739|NCT01963065|||COHORT||PROSPECTIVE|||||||
33881740|NCT03567070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881741|NCT00525759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070372|NCT03945318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Parts 1 and 2 will be performed in a double-blind manner, for clinical research personnel interacting with study participants. An unblinded pharmacist will prepare the doses of investigational study drugs.|Part 1 (SAD-HV) is a randomized, placebo-controlled single ascending dose design in HVs. Part 2 (MAD-HV): is a randomized, placebo-controlled multiple ascending dose design in HVs. Part 3 (MD-IgAN) is an open-label multiple dose design in participants with IgAN. Part 4 (IgAN) is open-label retreatment for Part 3 participants.|t|t|t|f
33881742|NCT04368949|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33881743|NCT00131625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881744|NCT03083028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor were masked to the treatment allocation of participants|Randomised Controlled Trial with an Observational Cohort|f|f|f|t
33881745|NCT01441570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881746|NCT02659566|||COHORT||PROSPECTIVE|||||||
33881747|NCT02154087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881748|NCT04275622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881749|NCT06191237|||COHORT||PROSPECTIVE|||||||
33881750|NCT03227705|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized, controlled clinical trial.||||
33881751|NCT02623738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881752|NCT02488863|||CASE_CONTROL||PROSPECTIVE|||||||
33881753|NCT04747171|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33881754|NCT01046877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881755|NCT01702610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881756|NCT03778164|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study uses a cross sectional stepped wedge cluster randomized design||||
33881757|NCT01146678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881758|NCT03061266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33881759|NCT04803838|||OTHER||CROSS_SECTIONAL|||||||
33881760|NCT02655250|||COHORT||PROSPECTIVE|||||||
33881761|NCT00244595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881762|NCT01847885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881763|NCT06205108|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33881764|NCT02396810|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33881765|NCT01683201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33881766|NCT00416988|RANDOMIZED|||PREVENTION||||||||
33881767|NCT03640429|||COHORT||PROSPECTIVE|||||||
33881768|NCT03731286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34070373|NCT02651337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070374|NCT02144077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34070375|NCT01619098|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34070376|NCT04825756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070377|NCT00696319|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070378|NCT02401035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881769|NCT01629147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33881770|NCT03380299|||OTHER||CROSS_SECTIONAL|||||||
33881771|NCT02867995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33881772|NCT03281980|RANDOMIZED|PARALLEL||OTHER||SINGLE|The testers of the participants will not have the information about type of intervention of the children||f|f|f|t
33881773|NCT00720928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881774|NCT04117776|||COHORT||PROSPECTIVE|||||||
33881775|NCT00023530|RANDOMIZED|||PREVENTION||DOUBLE||||||
33881776|NCT04272931|NA|SINGLE_GROUP||TREATMENT||NONE||"Multicenter, international, prospective, multi-center trial to test enrolment capacity of participants and safety of Portal and Hepatic Vein Embolization (PVE/HVE): DRAGON 1 will form the basis of a planned subsequent trial (DRAGON 2) that will compare PVE with PVE/HVE. In DRAGON 1 every center has to demonstrate the ability to enroll 3 patients in 12 months safely"||||
33881777|NCT02526550|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881778|NCT02532270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33881779|NCT05558878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881780|NCT06165614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881781|NCT05429294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881782|NCT01888458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881783|NCT02525159|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33881784|NCT01949363|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881785|NCT05985811|||COHORT||PROSPECTIVE|||||||
33881786|NCT05090293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881787|NCT02007707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070379|NCT02070445|||COHORT||PROSPECTIVE|||||||
34070380|NCT02830074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070381|NCT04525040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34070382|NCT05416723|||OTHER||RETROSPECTIVE|||||||
34070383|NCT04075669|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34070384|NCT05356650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070385|NCT04994808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881788|NCT01552460|||COHORT||CROSS_SECTIONAL|||||||
33881789|NCT00796471|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881790|NCT01469897|||COHORT||CROSS_SECTIONAL|||||||
33881791|NCT04731935|NA|SINGLE_GROUP||TREATMENT||NONE||This study is designed as a pilot, single-center, non-randomized, uncontrolled, clinical trial in which subjects will be consented, receive a baseline assessment and receive tAN treatment and assessment every day during their 3 to 5-day detox treatment.||||
34070386|NCT04211558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070387|NCT02748759|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070388|NCT03163316|||OTHER||OTHER|||||||
34070389|NCT00078845|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34070390|NCT06127758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34070391|NCT03336931|||COHORT||PROSPECTIVE|||||||
34070392|NCT04035525|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Neither the participant nor the research nurse will know the administration order of the different treatments administered. All plasma samples collected during the research project will be anonymized i.e. it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.|Double-blind controlled-randomized pharmacokinetic (PK) study with crossover design (15 men and 15 women), with a minimum of 6 days between treatments|t|t|t|t
34070393|NCT03758235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Partecipants, investigators and outcomes assessor|Participants are assigned to the 4 groups (Incobot/A Group different dosages, or Onabot/A Group different dosages ) in parallel for the duration of the study.|t|f|t|f
34070394|NCT04987931|||COHORT||RETROSPECTIVE|||||||
34070395|NCT02990871|||CASE_CONTROL||RETROSPECTIVE|||||||
34070396|NCT00734656|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
34070397|NCT03192124|||COHORT||PROSPECTIVE|||||||
34070398|NCT04003376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070399|NCT01861002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070400|NCT00198523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881792|NCT01531283|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33881793|NCT02313779|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33881794|NCT01465659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881795|NCT00684957|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33881796|NCT04537689|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"To evaluate the real-life effectiveness of ixekizumab as first-line systemic treatment in participants with moderate to severe PsO, the investigators would recruit a pragmatic control arm.~⦁ Intervention arm: Eligible participants will be offered ixekizumab as first-line systemic treatment for PsO. Standard dose of subcutaneous ixekizumab for moderate to severe PsO will be given at 160 mg at week 0, followed by ixekizumab 80mg at weeks 2, 4, 6, 8, 10 and 12, then 4 weekly thereafter, for a total duration of 6 months.~Ixekizumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care.~⦁ Pragmatic control arm~Eligible participants will be recruited to pragmatic control arm in these circumstances:~* Patient disagree to ixekizumab for personal reasons.~* The quota for ixekizumab is exhausted.~* The management of PsO in this pragmatic control arm will be the same as that in the standard care."||||
33881797|NCT02154412|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33971202|NCT02768623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971203|NCT00146770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971204|NCT03480503|||CASE_CONTROL||RETROSPECTIVE|||||||
33971205|NCT05937113|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33971206|NCT01211769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971207|NCT00225199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971208|NCT05338086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971209|NCT01930084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971210|NCT01467063|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33971211|NCT04505410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881798|NCT03811509|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||All patents receive aromatase inhibitors Patients without osteoporosis receive only calcium and vitamin D Patients with osteoporosis receive antiresorptive treatment||||
33881799|NCT06385015|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33881800|NCT04638491|NA|SINGLE_GROUP||TREATMENT||NONE||Lurbinectedin for injection(PM01183)||||
33881801|NCT04682470|||COHORT||PROSPECTIVE|||||||
33881802|NCT01583374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33971212|NCT00634179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971213|NCT01452529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971214|NCT03980795|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded Statistical Analysis||f|f|f|t
33971215|NCT05745090|||CASE_ONLY||PROSPECTIVE|||||||
33971216|NCT02981797|||CASE_ONLY||PROSPECTIVE|||||||
33971217|NCT01830556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971218|NCT01073020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971219|NCT02469974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971220|NCT00319449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33971221|NCT01577095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971222|NCT04929496|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33971223|NCT01573923|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971224|NCT02896660|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971225|NCT06528444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971226|NCT03400345|||COHORT||PROSPECTIVE|||||||
33971227|NCT06113523|||COHORT||RETROSPECTIVE|||||||
33971228|NCT05497011|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized, controlled, parallel-groups||||
33971229|NCT03216330|||CASE_CONTROL||PROSPECTIVE|||||||
33971230|NCT05925101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971231|NCT00002806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070401|NCT01315522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070402|NCT06580340|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34070403|NCT01008813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33971232|NCT01252654|||CASE_CONTROL||PROSPECTIVE|||||||
33971233|NCT00119977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971234|NCT05261113|||CASE_CONTROL||PROSPECTIVE|||||||
33971235|NCT00788528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971236|NCT01592799|NA|SINGLE_GROUP||OTHER||NONE||||||
33971237|NCT03562403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971238|NCT00698022|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33971239|NCT04938206|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33971240|NCT01518491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971241|NCT00943800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070404|NCT04917705|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34070405|NCT04218279|RANDOMIZED|PARALLEL||OTHER||NONE|Unblinded|||||
33881803|NCT05688787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The participants in intervention group will be received 4 sessions of perineural injection~1 week a part with optional additional sessions per the physician recommadation and the patient preference. other group, will be received standard of care treatment of fibromyalgia"||||
33881804|NCT00794560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33881805|NCT01767883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33881806|NCT05307315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33881807|NCT05547490|||COHORT||RETROSPECTIVE|||||||
33881808|NCT01402297|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33881809|NCT03333070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881810|NCT00159289|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33881811|NCT01251783|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881812|NCT01748344|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33881813|NCT05026788|||COHORT||PROSPECTIVE|||||||
33881814|NCT06325488|||CASE_CONTROL||PROSPECTIVE|||||||
33881815|NCT02963805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881816|NCT05702528|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will use a waitlist design.||||
33881817|NCT02765360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881818|NCT02050269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881819|NCT05155254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised 1:1 to receive either dual-antigen IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone||||
33881820|NCT06222905|||COHORT||PROSPECTIVE|||||||
33881821|NCT04895761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881822|NCT00278681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971242|NCT03639597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971243|NCT00034515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971244|NCT01768000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971245|NCT01736410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881823|NCT04088344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
33881824|NCT00039988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33881825|NCT01145066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33881826|NCT06304454|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (outcomes assessor and participants)|Cluster RCT|t|f|f|t
33881827|NCT03027752|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33881828|NCT04192409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971246|NCT05958277|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971247|NCT01858714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971248|NCT01962883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971249|NCT00831727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971250|NCT02232048|||COHORT||PROSPECTIVE|||||||
33971251|NCT02739984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33971252|NCT03220230|||COHORT||CROSS_SECTIONAL|||||||
33971253|NCT02658409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33971254|NCT01167920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971255|NCT03863275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971256|NCT04013256|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover assignment||||
33971257|NCT00671671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971258|NCT04047212|||COHORT||PROSPECTIVE|||||||
33881829|NCT06549491|RANDOMIZED|PARALLEL||TREATMENT||NONE||First, foster parents will fill out the child sleep questionnaire, which will screen for behavioral and medical sleep issues. Foster parents will then complete introductory modules focused on general sleep hygiene and education. Next, they will access tailored sleep strategy modules determined by an automated algorithm based on sleep challenges identified in the sleep screening. Participants will be notified to alert the child?s pediatrician if the screening indicates the presence of a medical sleep disorder, such as sleep disordered breathing. Participants will be asked to follow recommended sleep strategies for 2 weeks, and complete short morning daily diaries on the child?s sleep from the night prior within the Sleep Wizard platform. To reinforce intervention content and enhance adherence and integrity, participants will receive appropriately timed tailored text message reminders of strategies they should be utilizing.||||
33881830|NCT01646632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881831|NCT00911846|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881832|NCT04381195|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881833|NCT00002744|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33881834|NCT02482584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971259|NCT02002247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971260|NCT02585258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971261|NCT03867591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study; the sponsor representative involved in the study, the investigator, the participants or site personnel involved in participant management or outcome assessment will remain blinded. Blinding to intervention will be used to reduce bias during data collection and evaluation of outcomes. At the investigational site, the randomization codes will remain secure at all times, but may be accessed in the event of an emergency.||t|f|t|f
33971262|NCT03871400|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33971263|NCT03818737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know if they are receiving the MSC or corticosteroid injection.|The study will include a parallel design using a blocked central randomization scheme of 1:1:1:1. Participants will first be randomized to have MSCs derived from either bone marrow, adipose tissue, or umbilical cord tissue. Then they will be further randomized to receive either an injection of MSCs (from bone marrow, adipose, or umbilical cord tissue, depending on the first randomization) or a corticosteroid injection.|t|f|f|f
33971264|NCT04417790|||COHORT||PROSPECTIVE|||||||
33971265|NCT02902731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971266|NCT02779582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971267|NCT05237700|||COHORT||PROSPECTIVE|||||||
33971268|NCT06542107|||COHORT||PROSPECTIVE|||||||
33971269|NCT01814579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971270|NCT02705079|||CASE_CONTROL||RETROSPECTIVE|||||||
33971271|NCT04936620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, some care providers (ie: physiotherapists) and outcome assessor will be blinded.|"Phase III clinical trial: randomised, controlled, double blind, multi-centre, superiority~+ Optional mechanistic study"|t|f|f|t
33881835|NCT02267590|||||PROSPECTIVE|||||||
33881836|NCT02638701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971272|NCT06429098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971273|NCT06019325|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The patients will be under general anesthesia and will not be aware if they receive a block procedure or not.~The investigator, the data collector and the outcome assessor will be completely blind to the study groups. Only the care provider who will perform the block procedures will know the study groups, but she will not involve in data collection."|Prospective, randomized, controlled study|t|f|t|t
33971274|NCT02275988|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33971275|NCT00673361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971276|NCT00878345|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33971277|NCT02973412|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070406|NCT02815267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070407|NCT02469233|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34070408|NCT02432209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881837|NCT03861637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|INVESTIGATOR|comparison of partially corrected vs. fully corrected PTA in renal transplant recipients|t|f|f|f
33881838|NCT04631029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881839|NCT01315379|||CASE_CONTROL||PROSPECTIVE|||||||
33881840|NCT03190200|||COHORT||PROSPECTIVE|||||||
33881841|NCT03591445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We hypothesized incidence rate that bronchoscopic findings would have changed the rate of established surgical plans as less than 2.0% (P0), then preoperative bronchoscopy examination would have limited impact on the surgical plan for GGO featured lung cancer; If bronchoscopic findings would have changed the rate of established surgical plans as more than 4.0% (P1), then bronchoscopy examination would be regarded as one routine preoperative work-up. Null hypothesis: H0: P≤P0; Alternative hypothesis: HA: P ≥ P1. α = 0.05, 1-β = 0.9. Using Simon's two-stage approach, the first phase enrolled 612 patients. If ≥18 patients supported the alternative hypothesis, they entered the second phase, otherwise the trial was terminated; the second phase enrolled 451 patients. If the patient number who eventually changes the surgical plan is ≤27, the null hypothesis is accepted, that preoperative bronchoscopy examination would be unnecessary for GGO featured lung cancer.||||
33881842|NCT01592981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881843|NCT02618447|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33881844|NCT05835869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881845|NCT01158521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881846|NCT00958139|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881847|NCT03736512|||CASE_ONLY||PROSPECTIVE|||||||
33881848|NCT02303626|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881849|NCT03741166|||COHORT||PROSPECTIVE|||||||
33881850|NCT03047070|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33881851|NCT04683510|RANDOMIZED|PARALLEL||OTHER||NONE||"AMPLIFI recruitment process, 1600 AA cancer survivors will be randomized to one of 8 conditions that vary by type of strategy, type of information, and type of perspective (survivor or researcher voice) and 400 randomized to the basic recruitment strategy"||||
33881852|NCT01077973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881853|NCT03712579|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33881854|NCT02482675|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33881855|NCT01238601|||CASE_ONLY||CROSS_SECTIONAL|||||||
33881856|NCT00804115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971278|NCT05757492|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase 1, open-label, multiple-phase, multiple phase study. Participants within the advanced solid tumor dose optimization phase will be assigned to one of two dosing arms. After one CHS-006 dose has been selected from Phase 1, Phase 2 participants will be dosed with that dose in combination with toripalimab.||||
33971279|NCT05887128|||COHORT||CROSS_SECTIONAL|||||||
33971280|NCT01626885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881857|NCT02362503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33881858|NCT03005054|NA|SINGLE_GROUP||TREATMENT||NONE||See detailed description||||
33881859|NCT04429061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster randomised. Randomization at the school level defines a school as receiving arm one or arm two.||||
33881860|NCT04467775|||CASE_ONLY||RETROSPECTIVE|||||||
33881861|NCT03924986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881862|NCT01511770|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881863|NCT04393610|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33881864|NCT01305759|||COHORT||PROSPECTIVE|||||||
33881865|NCT02809287|||COHORT||PROSPECTIVE|||||||
33881866|NCT01980797|||COHORT||PROSPECTIVE|||||||
33881867|NCT02466061|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33881868|NCT03286855|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective feasibility open-label randomised controlled trial||||
33881869|NCT03090594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33881870|NCT00453271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881871|NCT02789865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881872|NCT03133845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881873|NCT00367042|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33881874|NCT06500767|||CASE_CONTROL||PROSPECTIVE|||||||
33881875|NCT02535182|||CASE_CONTROL||PROSPECTIVE|||||||
33881876|NCT01851850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881877|NCT00713362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881878|NCT04004598|NA|SINGLE_GROUP||PREVENTION||NONE||Phase I, Feasibility and Safety Trial||||
33881879|NCT02258360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881880|NCT04221880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881881|NCT03517631|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Infusion of autologous CD34+ cells transduced with shRNAs targeting CCR5 and HIV genome||||
33881882|NCT00352105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881883|NCT01114529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881884|NCT03042936|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881885|NCT01821495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881886|NCT04642014|NA|SINGLE_GROUP||TREATMENT||NONE||The study is going to recruit 300 convalescent plasma donors and 200 recipients||||
33881887|NCT01022190|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33881888|NCT02114580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881889|NCT05896020|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of SHR-A1811||||
33881890|NCT00328627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33881891|NCT00003887||||TREATMENT||||||||
33881892|NCT02792803|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33881893|NCT00896610|||COHORT||PROSPECTIVE|||||||
33881894|NCT02671331|||CASE_ONLY||PROSPECTIVE|||||||
33881895|NCT06201052|||COHORT||RETROSPECTIVE|||||||
33881896|NCT04256161|||COHORT||PROSPECTIVE|||||||
33881897|NCT01419431|||COHORT||PROSPECTIVE|||||||
33881898|NCT05624008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881899|NCT05565469|NA|SINGLE_GROUP||OTHER||NONE||||||
33881900|NCT01614093|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||All participants will receive both active drug and placebo, differences between treatment conditions will be analyzed due to small sample order effects will not be analyzed|t|t|t|t
33881901|NCT05580029|NA|SINGLE_GROUP||TREATMENT||NONE||Hurley stage I or stage II disease||||
33881902|NCT04519645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881903|NCT01184482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881904|NCT02456428|||COHORT||RETROSPECTIVE|||||||
33881905|NCT01436773|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881906|NCT00002909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881907|NCT01504282|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881908|NCT04431830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to an intervention or a standard care control condition.||||
33881909|NCT05464355|||COHORT||PROSPECTIVE|||||||
33881910|NCT02193958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881911|NCT03636139|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33881912|NCT01543516|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881913|NCT04230174|NA|SINGLE_GROUP||OTHER||NONE||24 multiple sclerosis patients||||
33881914|NCT04147351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881915|NCT01447108||CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33881916|NCT04121247|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|parents and care provider|"the type of initiative tests to determine the effectiveness of education provided to parents in both countries.~However, it tests the non-pharmacological approaches used by parents between the two countries."|t|t|f|f
33881917|NCT00151671|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33881918|NCT04902846|||CASE_CONTROL||PROSPECTIVE|||||||
33881919|NCT03496909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881920|NCT04947176|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33881921|NCT02704533|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971281|NCT05962177|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33971282|NCT01541956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971283|NCT02041494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070409|NCT02383303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881922|NCT05789095|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881923|NCT01477385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33881924|NCT03826927|||COHORT||PROSPECTIVE|||||||
33881925|NCT00138736|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33881926|NCT00066898|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33881927|NCT02458807|||COHORT||PROSPECTIVE|||||||
33881928|NCT00963274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881929|NCT02471547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881930|NCT01457742|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33881931|NCT01137383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881932|NCT00278278|RANDOMIZED|||TREATMENT||NONE||||||
33881933|NCT05407259|RANDOMIZED|CROSSOVER||OTHER||NONE|Blinding (masking) and controlling risk of bias Because of the nature of exercise interventions, the blinding of participants and experimenters is not applicable to our study. To reduce the threat of the placebo effect, we will ask participants for their expectations on cognitive performance, and these will be incorporated into our statistical analysis. Blinding of the outcome assessors is also not possible. However, all measurements of cognitive performance will be computerized and not involve human judgment. The data analyzers will not be blinded but will follow a pre-specified statistical analysis plan. These procedures will reduce the risk of bias arising from the lack of blinding of participants, experimenters, assessors, and data analyzers and the threat from researchers' degrees of freedom.|||||
33881934|NCT00037479|RANDOMIZED|||TREATMENT||||||||
33881935|NCT02843620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33881936|NCT05044052|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Cluster Randomized Control Trial|f|f|t|t
33881937|NCT02282683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881938|NCT05122637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881939|NCT03604445|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33881940|NCT06528275|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881941|NCT00006479||||TREATMENT||||||||
33881942|NCT04955561|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33881943|NCT02627495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881944|NCT06162208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||f|f|t|t
33881945|NCT02445586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881946|NCT01459614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881947|NCT04895150|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881948|NCT05119478|||COHORT||RETROSPECTIVE|||||||
33881949|NCT05358379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation in Phase 1 part||||
33881950|NCT05769179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881951|NCT03166332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Care provider will not know the arm of randomization|Randomized controlled trial with 3 arms of intervention|f|t|f|f
33881952|NCT00003160||||TREATMENT||||||||
33881953|NCT01699087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881954|NCT05103345|NA|SINGLE_GROUP||TREATMENT||NONE||"This study will be conducted in 2 parts: Part 1 is a phase I open-label, dose escalation study phase. Part 2 is as a part of a phase Ib/IIa study, which is a specific Tumor-type expansion study.~The standard 3+3 dose escalation algorithm will be applied to explore dose limiting toxicity (DLTs) in at least 4 sequential cohorts with 3- 6 patients and identify the maximally tolerated dose (MTD).~When the cohort is completed in Part 1, the Part 2 study could be started according to the SMC evaluation."||||
33881955|NCT04080895|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open-label pharmacokinetic study in 16 healthy Thai subjects. Subjects will be admitted in the inpatient ward and will be randomized to group A or group B to receive 3 drug regimens (Regimen 1 Artemether-lumefantrine; Regimen 2 Amodiaquine ; Regimen 3 Artemether-lumefantrine + Amodiaquine) on Day 0, 1, and 2. Every subject will have 1 screening and 3 admissions in the hospital.||||
33881956|NCT01695889|||CASE_CONTROL||RETROSPECTIVE|||||||
33971284|NCT04776174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Children will be initially scanned with a telerobotic ultrasound system. Within 3 hours after the telerobotic examination, patients will be scanned by a different sonographer with similar experience and qualifications using the conventional ultrasound, who will be blinded to the findings of the telerobotic examination.||||
33971285|NCT04912466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971286|NCT01517724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070410|NCT06611670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Interventional single-masked pair-eye design clinical trial, single-center, single-surgeon. Eyes will be block-randomized as to which surgery they will receive first (high vs low IOP phacoemulsification). 76 eyes of 38 patients will be included in this study. For each patient, one eye will be randomized to receive phacoemulsification with high IOP (Group 1), and the other eye will receive phacoemulsification with physiological IOP (Group 2). This way, each patient will receive both treatments, one for each eye, which will allow us to do paired analyses.|t|f|t|t
34070411|NCT01310127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070412|NCT00050635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33881957|NCT03759665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The primary evaluation of the Clinical Impression of Change in Severity (CI-CS; Primary Endpoint) will be performed by two independent neurologists whose assessments are based on videos of patient's performance on either the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or the 8 Meter Walk Test (8MWT) taken at each visit.|In both the Parent Study and Extension Phase, patients will be assessed during three study phases: a baseline period (with or without a study run-in), a treatment period, and a washout period.|f|f|f|t
33881958|NCT02642094|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33881959|NCT02429362|||CASE_ONLY||PROSPECTIVE|||||||
33881960|NCT04136431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33881961|NCT00020540||||TREATMENT||||||||
33881962|NCT05892809|NA|SINGLE_GROUP||PREVENTION||NONE||A Pretest-Posttest Repeated Measures Design||||
33881963|NCT06205849|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IA is a limited dose-escalation study. We will use an interval 3 + 3 dose escalation design, which allows rapid dose escalation and de-escalation while maintaining good overdose control. The starting intratumoral dose of mitazalimab in the first-in-human study was 22.5 µg/kg, but no serious adverse events were observed until the third dose level (200 µg/kg). As such, we conservatively propose to start at the second dose level (75 µg/kg) with a single dose escalation to 200 µg/kg, and de-escalation to 25 µg/kg if dose-limiting toxicities are encountered at 75 µg/kg. Phase IB will be an expansion cohort at the recommended phase II dose to establish preliminary evidence of efficacy.||||
33881964|NCT03073473|||CASE_CONTROL||PROSPECTIVE|||||||
33881965|NCT03299803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881966|NCT04170595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33881967|NCT02633683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881968|NCT05039359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo controlled|t|t|t|t
33881969|NCT02609360|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33881970|NCT03714490|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized phase II trial design||||
33881971|NCT00553163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33881972|NCT06233526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881973|NCT06436885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881974|NCT05679635|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||prospective, open, clinical trial||||
33881975|NCT05987111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881976|NCT01564927|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33881977|NCT00004156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881978|NCT05991856|||COHORT||OTHER|||||||
33881979|NCT01615848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881980|NCT05519345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881981|NCT04428931|||COHORT||PROSPECTIVE|||||||
33881982|NCT02788214|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33881983|NCT03473561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881984|NCT02341378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33881985|NCT03253146|||CASE_ONLY||PROSPECTIVE|||||||
33881986|NCT06501092|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33881987|NCT00274131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33881988|NCT02793232|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33881989|NCT03906500|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will employ a cluster-randomized controlled study design: investigators plan to include a random sample of at least 12 high schools randomly 1:1 allocated to either intervention or control group.||||
33881990|NCT01407549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33881991|NCT01997879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881992|NCT05894343|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to the follow-up or active treatment group based on the group to which they were randomized in Study MGT-GAD-025.||||
33971287|NCT05480618|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study will be a small prospective cohort (N= 20) study with a one-time unblinded intervention of 4 differing breathing techniques/ratios compared to spontaneous breathing. Patients will receive instruction on D1 and on D7 lasting about 45 minutes and a diary for self-practice. On D14 the participant will be asked to sequentially perform the directed breathing frequencies and ratios. The lab visit will last approximately 1.5 hours, during which beat-by-beat cardiovascular variables and breath-by-breath respiratory variables will be recorded. The total in-person time commitment (\~4 hours) over the 14 days.||||
33971288|NCT05851235|NA|SINGLE_GROUP||OTHER||NONE||||||
33971289|NCT03946215|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33971290|NCT03787745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study personell involved in outcome assessment will be blinded to the treatment employed|Prospective, randomized, placebo controlled|f|f|f|t
33971291|NCT01280370|||COHORT||PROSPECTIVE|||||||
33971292|NCT05887830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971293|NCT03140306|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|the reader of the ct is blinded to the clinical presentation|Split dose CT||||
33759497|NCT04721379|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be randomized into two groups.~1. Group 1 participants with unguided session simply close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be asked to relax with eyes closed for 30 minutes. After finishing the session, they fill out meditation depth questionnaire.~2. Group 2 participants with guided sessions close their eyes for 10 minutes while EEG and EKG recordings are performed. Following 10 minutes, after briefly opening their eyes, they will be guided through relaxation and meditation session for 30 minutes with a Heartfulness trainer with continued recording. After finishing the session, they also fill out meditation depth questionnaire."||||
33759498|NCT00929084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759499|NCT03445065|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759500|NCT01738750|RANDOMIZED|PARALLEL||||NONE||||||
33759501|NCT03967769|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"At each participating center, patients will be followed up for primary and secondary endpoints by members of the research staff who will be unaware of the trial group allocation. Information on whether the primary and secondary outcomes occur will be collected and entered into the electronic web-based case report form (eCRF) by trial or clinical trained personal (clinical research associate), blinded to the allocation group, under the supervision of the local principal investigator (PI) or designee who will also be unaware of the trial group allocation.~Finally, the independent trial statistician and the members of the data monitoring and safety committee (DMSC) will also remain blinded for the allocation during analysis."|"Monocentric prospective, randomized, stratified, parallel-group clinical trial with concealed allocation to 3 groups of Apnoeic Oxygenation during Airway management for general anesthesia in elective surgery.~All participants will receive French actual standard of care of surgery and anesthesia."|t|t|t|f
33759502|NCT03294889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759503|NCT00674622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759504|NCT05104528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759505|NCT01970605|||COHORT||PROSPECTIVE|||||||
33759506|NCT02525614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759507|NCT05673629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759508|NCT02591550|||CASE_CONTROL|||||||||
33759509|NCT00571701|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33759510|NCT05439954|||CASE_CONTROL||OTHER|||||||
33759511|NCT06064864|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In this study, CD (Crohn's disease) patients who achieved clinical response at week 30 after to Remsima (CT-P13, a biosimilar of infliximab) SC (subcutaneous formulation) will be randomly (1:1) assigned to intravenous infliximab (Remsima) group (Arm 2) or to continued infliximab (Remsima) SC group (Arm 3). The primary endpoint of the study is the non-inferiority of Arm 3 compared with Arm 2 in terms of deep remission rate at week 54. Non-responder at week 30 will be allocated to Arm 1 (intravenous infliximab \[Remsima\] 10 mg/kg) and the secondary endpoint is the non-inferiority of Arm 3 compared with Arm 1 in terms of deep remission rate at week 54. Through this study, the investigators aim to provide the clinical evidence for selecting the most optimal formulation of infliximab according to therapeutic response among Korean patients with CD.||||
33759512|NCT04509895|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33759513|NCT03256825|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33881993|NCT00953693|||CASE_ONLY||PROSPECTIVE|||||||
33881994|NCT00005059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33881995|NCT03938961|||COHORT||PROSPECTIVE|||||||
33881996|NCT00002693||||TREATMENT||||||||
33881997|NCT02743260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33881998|NCT00971386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33881999|NCT01548495|||COHORT||PROSPECTIVE|||||||
33882000|NCT03362775|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|EEG will be electronically recorded and anonymised. The outcome assessor will analyse the EEG without knowledge of the propofol concentration.|Every subject will have an EEG recording in the absence of propofol, or during light sedation with propofol at an effect-site target concentration of 0.5 µg/mL and 1.0 µg/mL. Each subject will be his own control.||||
33882001|NCT01227551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882002|NCT06378086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-face design|t|t|t|f
33882003|NCT00477126|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33882004|NCT01009476|||||PROSPECTIVE|||||||
33882005|NCT00161252|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33971294|NCT00631111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971295|NCT01689610|||COHORT||PROSPECTIVE|||||||
33971296|NCT03940313|||COHORT||PROSPECTIVE|||||||
33971297|NCT02413073|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33971298|NCT02976012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971299|NCT03220685|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33971300|NCT03363282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33971301|NCT02019771|||CASE_ONLY||CROSS_SECTIONAL|||||||
33971302|NCT03070210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33971303|NCT05751655|||COHORT||RETROSPECTIVE|||||||
33971304|NCT02778178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971305|NCT00865553||||HEALTH_SERVICES_RESEARCH||||||||
33971306|NCT06039670|||COHORT||PROSPECTIVE|||||||
33971307|NCT04543981|||COHORT||CROSS_SECTIONAL|||||||
33971308|NCT03787446|||COHORT||CROSS_SECTIONAL|||||||
33971309|NCT01104233|||||PROSPECTIVE|||||||
33971310|NCT03776851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971311|NCT05668871|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-labelled clinical trial, no masking involved.|"Target population: Patients with multiple gallbladder polyps.~Intervention and comparison:~1. Test Group (N=168): Under lifestyle intervention, Danning Tablets will be taken orally 3 times each day, 5 tablets each time, from baseline to weeks 12±1.~2. Controlled Group (N=168): Only in treatment of lifestyle intervention.~Clinical Outcomes:~1. Efficacy on shrinkage of gallbladder polyps and alleviation of clinical symptoms of gallbladder polyps.~2. Safety in treatment of gallbladder polyps.~Follow-up cycle: The length of follow-up cycle is 24 weeks, 5 visit windows (baseline, weeks 4±1, weeks 8±1, weeks 12±1, weeks 24±1) are set."||||
33759514|NCT00783380|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33759515|NCT04957862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882006|NCT03767608|||COHORT||CROSS_SECTIONAL|||||||
33882007|NCT00091715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882008|NCT03317769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882009|NCT03331809|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33882010|NCT05833672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882011|NCT00347828|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33882012|NCT04747925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882013|NCT04647955|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33882014|NCT03413930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882015|NCT02147483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882016|NCT00105443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882017|NCT05255328|NA|SINGLE_GROUP||TREATMENT||NONE||Glutamine oral supplementation||||
33882018|NCT05452278|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33882019|NCT06443905|||COHORT||RETROSPECTIVE|||||||
33882020|NCT02685540|||||RETROSPECTIVE|||||||
33882021|NCT03650998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882022|NCT01612429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882023|NCT00883246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882024|NCT04301141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882025|NCT02755272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882026|NCT05309863|||COHORT||PROSPECTIVE|||||||
33882027|NCT03302273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882028|NCT00983983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882029|NCT00788346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882030|NCT03333031|NA|SINGLE_GROUP||OTHER||NONE||||||
33882031|NCT01396005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882032|NCT02083380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882033|NCT03143231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882034|NCT03682172|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||It is a blinded, randomized, placebo controlled study where 15 participants receive three different 4 hour intravenous infusions of either saline (placebo), low GLP-2 (at a rate of 1pmol/kg/min) or high GLP-2 (at a rate of 10pmol/kg/min) on three different study days.|t|f|t|f
33882035|NCT00876135|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33882036|NCT06537843|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort 1: Newly diagnosed, induction-ineligible AML patients Cohort 2: Relapsed-refractory AML patients||||
33882037|NCT03852394|||COHORT||PROSPECTIVE|||||||
33971312|NCT00038883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971313|NCT03355742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971314|NCT02933983|||CASE_CONTROL||PROSPECTIVE|||||||
33971315|NCT02026661|||CASE_CONTROL||RETROSPECTIVE|||||||
33971316|NCT04619433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1210 in combination with Famitinib plus chemotherapy.|t|t|t|t
33971317|NCT01313728|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33882038|NCT01623271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882039|NCT00693160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33882040|NCT05792085|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Stepped Wedge Design|f|f|f|t
33882041|NCT00119158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882042|NCT03055975|||COHORT||CROSS_SECTIONAL|||||||
33882043|NCT06251232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prednisone medication and its placebo will be identical in appearance and in organoleptic properties.|Controlled with placebo|f|f|f|t
33882044|NCT01411969|||CASE_CONTROL||PROSPECTIVE|||||||
33971318|NCT02224521|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33971319|NCT00783679|NA|SINGLE_GROUP||||NONE||||||
33971320|NCT00835601|||CASE_ONLY||PROSPECTIVE|||||||
33971321|NCT02346539|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33971322|NCT01497938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971323|NCT02397200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33971324|NCT05296681|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to receive NBT-NM108 or no microbiome support in a 2:1 ratio||||
33971325|NCT05941533|||COHORT||OTHER|||||||
33971326|NCT05801796|||CASE_CROSSOVER||PROSPECTIVE|||||||
34070413|NCT06477380|NA|SINGLE_GROUP||SCREENING||NONE||This is a small size feasibility study. There is no control arm and the aim of the study is to assess the feasibility and acceptability of the intervention in a community mental health setting. Findings from this study will be used to optimise the intervention.||||
33882045|NCT04994106|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|This study is single blind with regard to treatment (AZD5462 or placebo). This means that the Principal Investigator, all clinical staff involved in the clinical study (except for the unblinded Pharmacist), the participants, and the site monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.|This is randomized single-blind, and placebo-controlled study|t|t|t|f
33882046|NCT01538238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882047|NCT06500091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882048|NCT01777581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882049|NCT02004873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882050|NCT00933049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882051|NCT04110665|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Evaluation of the treatment based on QoR40 survey every 20 patients||||
33882052|NCT04584463|||COHORT||PROSPECTIVE|||||||
33882053|NCT01392807|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882054|NCT00533078|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882055|NCT05642910|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Patients who meet inclusion criteria will be randomized into the Azvudine group (treatment group) and Paxlovid group (control group).||||
33971327|NCT05025332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971328|NCT00472446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33971329|NCT00275028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971330|NCT06302712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882056|NCT00847327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882057|NCT04506983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971331|NCT02783391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971332|NCT00647049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971333|NCT03011463|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33971334|NCT00623623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971335|NCT01162083|||COHORT||PROSPECTIVE|||||||
33971336|NCT03349606|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||\[C-11\]FLB 457 d-amphetamine||||
33882058|NCT02981433|||CASE_ONLY||PROSPECTIVE|||||||
33882059|NCT01650090|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882060|NCT03011658|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33882061|NCT02160392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33971337|NCT03205514|||COHORT||PROSPECTIVE|||||||
33971338|NCT02036281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971339|NCT01723956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759516|NCT05767684|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patient will receive DCs monotherapy initially on day 1, 8, 15 and 29 as safety run-in. Safety and efficacy (1st CT evaluation) will be conducted at day 43. On the 1st CT evaluation, patient met randomization criteria and without progression disease/safety concern will be randomized to either observation or booster of lenvatinib and nivolumab during day 43 to 77.||||
33759517|NCT05105802|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind study|Double-blind randomized clinical trial with 2 groups|t|f|t|t
33759518|NCT01159743|||COHORT||CROSS_SECTIONAL|||||||
33759519|NCT05762991|||OTHER||OTHER|||||||
33882062|NCT02180893|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971340|NCT05612347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971341|NCT03797976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33971342|NCT03418883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33971343|NCT00362700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971344|NCT00004498||||TREATMENT||||||||
33971345|NCT06484023|||COHORT||PROSPECTIVE|||||||
33971346|NCT01172353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33971347|NCT03315156|||CASE_ONLY||PROSPECTIVE|||||||
33971348|NCT03158337|NA|SINGLE_GROUP||OTHER||NONE||||||
33971349|NCT03502629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971350|NCT02473991|||COHORT||PROSPECTIVE|||||||
33971351|NCT00000112|||DEFINED_POPULATION||OTHER|||||||
34070414|NCT03883477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070415|NCT06075550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882063|NCT06444672|NA|SINGLE_GROUP||TREATMENT||NONE|Home-based rehabilitation program We used ASIA-scale to evaluate sensory function and voluntary movement7. The HBRP included whole-body training with various exercises for stretching, strength, endurance, and aerobic fitness. The treatment sessions were performed three times per week and had a 50-120-min duration. The exercises were modified based on individual progress and included the use of a rubber ball for balance and strength as well as trunk flexibility, static balance, stability, and standing exercises. Participants who could stand with assistive devices (such as knee-ankle-foot orthoses, KAFO) performed walking exercises.|Serial case study in a quasi-experimental design||||
33882064|NCT04598373|||COHORT||PROSPECTIVE|||||||
33882065|NCT00191516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882066|NCT00110773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882067|NCT02890550|||COHORT||PROSPECTIVE|||||||
33882068|NCT05791292|RANDOMIZED|PARALLEL||OTHER||NONE||Case control study||||
33882069|NCT01284166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882070|NCT00731172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882071|NCT04753398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33882072|NCT04594291|||COHORT||PROSPECTIVE|||||||
33882073|NCT00006070||||TREATMENT||||||||
33882074|NCT01395992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882075|NCT06536400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882076|NCT04933266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients in both study groups will not be able to know the dosage they will receive during the block and therefore will be blinded to group allocation. The outcome assessor (research nurse) will not be presented in the procedure room during block placement and thus will also be blinded to group allocation. The anesthesiologist (principal investigator) performing the allocated block will take no further part in the study after block placement."|Patients will be randomly assigned to received either 10ml of 0.25% levobupivacaine (Group LD) or 20ml of 0.25% levobupivacaine (Group HD). The randomization sequence will be generated using an online randomization software (www.randomization.com). The randomization sequence will be assigned as 1=low dose 10ml (Group LD) and 2=high dose 20ml (Group HD). The group allocation will be prepared by a computer officer (third party) in the Department of Anaesthesia \& Intensive Care of the Chinese University of Hong Kong.|t|f|f|t
33882077|NCT05070377|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33882078|NCT01482910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882079|NCT03462056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882080|NCT05412680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882081|NCT02387359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882082|NCT02257190|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33882083|NCT04178980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blinded|t|t|f|f
33882084|NCT06256822|||OTHER||OTHER|||||||
33882085|NCT00126087|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33882086|NCT04046679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking will be done by throwing a coin|Scars or scarring areas will be randomized. Some scars or areas of scars will be infused with Bleomycin by tattoo machine and other scars or areas of scars will be infused with saline also by tattoo machine.|t|t|t|t
33882087|NCT05526027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882088|NCT00874250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882089|NCT01033409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33882090|NCT04706039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070416|NCT05185635|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This project is an initial cross-sectional study of 40 Spanish-speaking subjects to generate pilot normative neuropsychological performance data that will be used in the future in grant submissions and as an initial feasibility platform for larger scale research projects.||||
34070417|NCT04464252|||COHORT||RETROSPECTIVE|||||||
34070418|NCT01150903|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34070419|NCT00704951|||COHORT||PROSPECTIVE|||||||
33882091|NCT04607733|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882092|NCT02508194|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33882093|NCT05664984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who evaluated the cases was blinded from the study.|single blind randomized controlled trial|f|f|f|t
33882094|NCT01354483|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33882095|NCT03657615|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||within subject|f|f|f|t
33882096|NCT01163071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882097|NCT03032952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070420|NCT00819481|||COHORT||PROSPECTIVE|||||||
34070421|NCT00152243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070422|NCT03061487|||CASE_CONTROL||PROSPECTIVE|||||||
34070423|NCT00632645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070424|NCT02080208|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33882098|NCT06411275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070425|NCT06078644|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33882099|NCT03340844|RANDOMIZED|PARALLEL||OTHER||NONE||"Prospective, randomized (1:1) to 2 study groups according to duodenopancreatectomy surgical approach: No-Touch group (NT) or Artery First group (SMA) in patients with pancreatic and periampullary tumors, to evaluated circulating tumor cells (CTCs) levels during the surgery. Sample size = 86"||||
33882100|NCT01843855|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33882101|NCT06114979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882102|NCT02164422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882103|NCT00678145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33882104|NCT01401504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882105|NCT02634580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882106|NCT04224805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882107|NCT05499065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882108|NCT03796468|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882109|NCT05196763|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-arm, intervention and control, parallel design, randomized trial||||
33882110|NCT01842503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33882111|NCT05167448|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33882112|NCT04313907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||group 1:active laser+topical clonazepam, group 2:inactive laser+topical clonazepam, group 3:active laser+placebo clonazepam|t|t|t|t
33882113|NCT00363038|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33882114|NCT04123977|||CASE_ONLY||RETROSPECTIVE|||||||
33882115|NCT04610528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882116|NCT02666014|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33882117|NCT00129064|NON_RANDOMIZED|PARALLEL||||NONE||||||
33882118|NCT06103903|||FAMILY_BASED||PROSPECTIVE|||||||
33882119|NCT03962985|NA|SINGLE_GROUP||OTHER||NONE||||||
33882120|NCT02744157|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33882121|NCT00049088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882122|NCT06464146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882123|NCT01207622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882124|NCT01797900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882125|NCT03029975|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This study will consist of two groups: one group will be asked to consume 2x the RDA of protein during the 10 week intervention, while the other group will be asked to consume the RDA for protein. Both groups will receive 10 weeks of the same resistance training intervention.|f|f|t|t
33882126|NCT04203485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882127|NCT01032551|RANDOMIZED|PARALLEL||||NONE||||||
33882128|NCT05010460|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33882129|NCT02658812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070426|NCT04560868|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34070427|NCT00620646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070428|NCT01888653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070429|NCT04284384|||COHORT||PROSPECTIVE|||||||
34070430|NCT05063084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070431|NCT05008471|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34070432|NCT03374488|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will be unblinded after the last participant completes Week 9 imaging assessment for efficacy analysis and after appropriate EC/IRB approvals have been received.|||||
34070433|NCT04412798|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34070434|NCT06611852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070435|NCT04421157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments were undertaken at baseline, and after the 10 week treatment period for each patient by the investigator, who was blind to the allocation of the participants.|Each patient selected a number in a closed envelope, which was sorted via the 'Research Randomiser' program for the randomisation process, and the patients were separated into the following two groups; Schroth group (n=14) and stabilization group (n=14)|f|f|f|t
33971352|NCT00947427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33971353|NCT00945425|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33971354|NCT03025854|||COHORT||PROSPECTIVE|||||||
33971355|NCT05890456|RANDOMIZED|PARALLEL||PREVENTION||NONE||Students and their families will be randomly assigned to the SWIFT Program or SAU conditions. A blocked design will be used where randomization will occur at the individual level within each school once a family has agreed to study participation. This way variation between schools (blocks) will not affect the standard errors of treatment effect estimates. Key outcomes will be tested at Time 1 (T1, baseline), Time 2 (T2, 6 months post-baseline), Time 3 (T3, 12 months post-baseline), and Time 4 (T4, 18 months post-baseline).||||
33971356|NCT03603236|||CASE_CONTROL||PROSPECTIVE|||||||
34070436|NCT06060340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070437|NCT05733845|NA|SINGLE_GROUP||OTHER||NONE||||||
34070438|NCT02154958|||COHORT||PROSPECTIVE|||||||
34070439|NCT03613792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34070440|NCT02588729|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34070441|NCT00841009|||CASE_CROSSOVER||PROSPECTIVE|||||||
34070442|NCT05803759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34070443|NCT01761643|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Group 1: PrEP daily, HIV/STI screening, adherence and risk behavior counseling, and safety monitoring Group 2: PrEP daily, HIV/STI screening, adherence and risk behavior counseling, and safety monitoring as well as iTAB text adherence reminders|The purpose of this study is to evaluate a promising method of reinforcing PrEP adherence using text message. In this study, we will hope to learn if text message reminders increase PrEP adherence.||||
34070444|NCT05803577|||COHORT||PROSPECTIVE|||||||
34070445|NCT00225108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070446|NCT04553770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882130|NCT00428675|||OTHER||PROSPECTIVE|||||||
33882131|NCT03164382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882132|NCT03762070|||CASE_ONLY||CROSS_SECTIONAL|||||||
33882133|NCT00577993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882134|NCT06221982|||COHORT||PROSPECTIVE|||||||
33882135|NCT05893849|||OTHER||OTHER|||||||
33882136|NCT04858945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33882137|NCT00117468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882138|NCT05760443|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882139|NCT00250510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882140|NCT02881268|||CASE_CONTROL||PROSPECTIVE|||||||
33882141|NCT01045980|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33882142|NCT02434198|||COHORT||PROSPECTIVE|||||||
33882143|NCT05204043|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33971357|NCT02649231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882144|NCT00406146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33882145|NCT00116766|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33882146|NCT00000785|||||CROSS_SECTIONAL|||||||
33882147|NCT04461990|||COHORT||PROSPECTIVE|||||||
33882148|NCT05529914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882149|NCT04302532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33882150|NCT02747030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882151|NCT02865330|||COHORT||OTHER|||||||
33882152|NCT06345456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882153|NCT04186026|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will not be informed of the nature of the infusion they are administered on any of the study days. The investigator will be provided with an infusion (either isotonic saline with humane serum albumine (HSA) or isotonic saline with HSA + neurotensin or isotonic saline with HSA + GLP-1) prepared by a designated colleague|Participants will be studied on multiple occasions (4 days) in a randomised and double blinded fashion.|t|f|t|f
33882154|NCT01020760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971358|NCT02495597|||CASE_CONTROL||PROSPECTIVE|||||||
33971359|NCT02231320|||COHORT||PROSPECTIVE|||||||
33971360|NCT02073955|||||CROSS_SECTIONAL|||||||
33971361|NCT00681863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971362|NCT02505776|||COHORT||PROSPECTIVE|||||||
33971363|NCT01165814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971364|NCT00814320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971365|NCT06057298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971366|NCT01923246|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33971367|NCT02758054|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34070447|NCT01832883|||CASE_CONTROL||PROSPECTIVE|||||||
34070448|NCT02081001|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34070449|NCT00320697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070450|NCT03632070|||OTHER||RETROSPECTIVE|||||||
34070451|NCT03646942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882155|NCT05346614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the treatment allocations. It is not possible to blind participants or care providers who will be providing the intervention, as this is a lifestyle intervention. Controls receive usual care.|This a randomized intervention study. Subjects will be randomly allocated using a 5:1 ratio between the control and intervention groups.|f|f|f|t
33971368|NCT02742779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33971369|NCT02245776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971370|NCT04160078|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971371|NCT01982383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971372|NCT06503796|RANDOMIZED|PARALLEL||TREATMENT||NONE||the antiviral group and the control group||||
33971373|NCT01423435|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33971374|NCT03154320|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio to standard or same-day treatment||||
33971375|NCT03945565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971376|NCT03015142|||COHORT||PROSPECTIVE|||||||
33971377|NCT01752920|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33971378|NCT02462421|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971379|NCT00667927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971380|NCT00728806|||CASE_CONTROL|||||||||
33882156|NCT02727283|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33971381|NCT02543333|||COHORT||PROSPECTIVE|||||||
33971382|NCT02892656|||COHORT||PROSPECTIVE|||||||
33971383|NCT01214330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971384|NCT06259110|||CASE_ONLY||CROSS_SECTIONAL|||||||
33971385|NCT02104518|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33971386|NCT01045499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971387|NCT04638985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33971388|NCT05042336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971389|NCT05048732|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34070452|NCT06613035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070453|NCT02406963|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34070454|NCT04877418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070455|NCT05350813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070456|NCT04441632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070457|NCT05960175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070458|NCT03961516|||COHORT||CROSS_SECTIONAL|||||||
34070459|NCT05048615|NA|SINGLE_GROUP||TREATMENT||NONE|This is an Open label study|A consecutive sample of 15 patients with newly diagnosed AML will be prospectively included in this study.||||
33971390|NCT06354244|||COHORT||PROSPECTIVE|||||||
33971391|NCT01566292|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33971392|NCT05558722|NA|SINGLE_GROUP||TREATMENT||NONE|Check all roles that are masked or check None.|Assigned to receive chemotherapy plus oral Anlotinib (12 mg qd, d1-14; 21 days per cycle; total 5 cycles)，chemotherapy comprised of pirarubicin at 50 mg/m2 and cyclophosphamide at 500 mg/m2 and albumin-bound paclitaxel at 200 mg/m2, (d1, 21 days per cycle; both total 6 cycles), which was then followed by surgery.||||
33971393|NCT05511285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomisation and facilitation of the intervention will be performed by a research assistant, and the person analysing the data will be blinded to group allocations.|A randomised controlled trial with two parallel study arms: (1) digital cognitive behavioural therapy for insomnia (experimental condition), and (2) treatment as usual (control condition). Randomisation will be using a 2:1 ratio (experimental:control), within minimisation of between group differences in age, sex, baseline Sleep Condition Indicator score and time since stroke.|f|f|f|t
33971394|NCT00051428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070460|NCT03782129|||COHORT||PROSPECTIVE|||||||
34070461|NCT06423794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070462|NCT05340296|NA|SINGLE_GROUP||TREATMENT||NONE|There is only one arm. No masking will be attempted.|All subjects will receive Acute Youth Connect plus treatment as usual.||||
34070463|NCT05485714|||COHORT||RETROSPECTIVE|||||||
34070464|NCT01931397|||COHORT||PROSPECTIVE|||||||
33882157|NCT00471432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882158|NCT01937455|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971395|NCT00001427||||TREATMENT||||||||
34070465|NCT05028387|||CASE_ONLY||PROSPECTIVE|||||||
34070466|NCT05573256|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.|f|f|f|t
34070467|NCT02942121|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34070468|NCT03798548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Brief Bedside CBT versus Treatment As Usual|f|f|t|t
34070469|NCT06153017|||COHORT||PROSPECTIVE|||||||
33882159|NCT00758472|||COHORT||PROSPECTIVE|||||||
33882160|NCT04311086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882161|NCT02011009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882162|NCT04102033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882163|NCT01770600|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882164|NCT01986062|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33882165|NCT04002310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33882166|NCT04813185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882167|NCT03390738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882168|NCT05707780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882169|NCT06447467|||COHORT||PROSPECTIVE|||||||
33882170|NCT01017107|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33882171|NCT05087537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882172|NCT02793037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882173|NCT05638048|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33882174|NCT00041093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882175|NCT03751865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882176|NCT06282003|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A crossover design should be utilized in addition to the randomization procedure to properly address outcome variability. This study was a prospective, single-center, randomized controlled, patient- and evaluator-blinded clinical investigation with a two-arm parallel design to assess the advantage of the protective (optimized) ventilation procedure (PV group of patients) compared to the conventional (standard) method of lung ventilation (CV) during general anesthesia.||||
33882177|NCT01486199|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882178|NCT00384787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882179|NCT04257994|||CASE_ONLY||RETROSPECTIVE|||||||
33882180|NCT04023955|||CASE_ONLY||PROSPECTIVE|||||||
33882181|NCT06032442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882182|NCT00854828|RANDOMIZED|PARALLEL||TREATMENT||NONE||There were 2 cohorts: Randomized and Observational, each with an operative and non-operative arm.||||
33882183|NCT05350462|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33882184|NCT01465126|||CASE_ONLY||RETROSPECTIVE|||||||
33882185|NCT00379795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882186|NCT03451188|||COHORT||PROSPECTIVE|||||||
33882187|NCT02140671|||COHORT||PROSPECTIVE|||||||
33882188|NCT05066789|RANDOMIZED|FACTORIAL||TREATMENT||NONE||multi-center, open label, two-by-two factorial, randomized, noninferiority trial||||
33882189|NCT01938365|||COHORT||PROSPECTIVE|||||||
33882190|NCT05654493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882191|NCT04409938|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882192|NCT06460571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882193|NCT03723187|RANDOMIZED|PARALLEL||OTHER||NONE||"1. Cancer patients in need of chemotherapy~2. Newly accepted Port-A Implant~3. port maintenance:Catheter irrigation with 20 ml N/S,10 ml N/S sealing tube"||||
33882194|NCT02902120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882195|NCT02653768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882196|NCT03269214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither patients nor investigators were unaware about treatment and control groups.|Patients who had bisphosphonate-related osteonecrosis of the jaw of the mandible randomly allocated in 2 groups. Group 1 underwent debridement of necrotic bone and the involved area closed primary and in group 2 ,patients received topical Phenytoin 5%+ Tetracycline|t|f|t|f
33882197|NCT01681550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882198|NCT00496314|||CASE_ONLY||PROSPECTIVE|||||||
33882199|NCT00573794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882200|NCT05156827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971396|NCT02056899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971397|NCT05710302|||COHORT||PROSPECTIVE|||||||
33971398|NCT00571311|||||PROSPECTIVE|||||||
33971399|NCT06343051|||COHORT||PROSPECTIVE|||||||
33971400|NCT01426256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971401|NCT03999125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel, multi-arm trial|t|f|f|t
33971402|NCT01612000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971403|NCT01725815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971404|NCT02355145|||COHORT||PROSPECTIVE|||||||
33759520|NCT05180266|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||"After the preliminary test is applied to the experimental groups, therapeutic touch will be applied to one group by the researcher and music listening will be applied to the other group.~Once a week for four weeks after the preliminary test data Therapeutic Touch Group; Therapeutic Touch application will be performed by the researcher at the appointed time. Each therapeutic touch will take 15 minutes, in accordance with the literature information. At the end of the fourth week, the final test data will be obtained.~Music Listening Group: After the preliminary test data, women will be asked to listen to relaxation music every day for four weeks for 30 minutes before bedtime in a comfortable environment at home. At the end of the fourth week, the final test data will be obtained.~To the Control Group; no intervention will be made to women after the preliminary test data.At the end of the fourth week, the final test data will be obtained."|f|t|f|f
33759521|NCT00169000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759522|NCT03402516|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial||||
33759523|NCT00895700|RANDOMIZED|PARALLEL||||NONE||||||
33759524|NCT02350712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759525|NCT01068808|||CASE_ONLY||CROSS_SECTIONAL|||||||
33759526|NCT02049723|||CASE_ONLY||PROSPECTIVE|||||||
33759527|NCT05160324|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33759528|NCT02281448|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759529|NCT05284825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882201|NCT03112174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882202|NCT05354323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971405|NCT05297747|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33971406|NCT00631176|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33971407|NCT02950753|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33759530|NCT00539279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759531|NCT05140330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759532|NCT03645967|NA|SINGLE_GROUP||PREVENTION||NONE||Intervention in the standard of care for indwelling urinary catheter care and maintenance.||||
33759533|NCT04156490|||COHORT||RETROSPECTIVE|||||||
33882203|NCT04036279|||COHORT||PROSPECTIVE|||||||
33882204|NCT04617158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882205|NCT02615990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882206|NCT04186455|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33882207|NCT02889458|||CASE_CONTROL||PROSPECTIVE|||||||
33882208|NCT06036589|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33882209|NCT05075356|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will follow the same protocol (single arm).||||
33882210|NCT03463590|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive bilateral surgical implantation of DBS system||||
33882211|NCT01350856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882212|NCT04391959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882213|NCT03198494|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33882214|NCT05242250|||COHORT||PROSPECTIVE|||||||
33882215|NCT05246332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"The investigators use a grounding wire and a sham grounding wire to create grounding and sham-grounding groups. The patients are blinded to the grounding because they do not know which one has a grounding effect according to the exterior of the mat.~The investigators who do the evaluation of questionnaire and electrochemical analyzer and the outcomes assessor who interpret the data do not know which wire has grounding effect, too."||t|f|t|t
33882216|NCT02899143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33882217|NCT03994510|NA|SINGLE_GROUP||OTHER||NONE||"During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.~First visit (Baseline) only: Sociodemographic data, Clinical evaluation, family history~At Baseline and 5 years after baseline only:~* Blood sample~* BPD diagnosis (using the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM) Disorders (SCID II))"||||
33882218|NCT02606994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33882219|NCT02458196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882220|NCT05365165|||COHORT||PROSPECTIVE|||||||
33882221|NCT00168961|RANDOMIZED|PARALLEL||||NONE||||||
33971408|NCT01572961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33971409|NCT03919955|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33971410|NCT03179982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single Blind||f|f|f|t
33971411|NCT03876522|||COHORT||PROSPECTIVE|||||||
33971412|NCT06352320|||COHORT||OTHER|||||||
33971413|NCT02891200|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33971414|NCT06122259|||COHORT||PROSPECTIVE|||||||
33971415|NCT04259411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971416|NCT00566709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971417|NCT02818556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971418|NCT01897597|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971419|NCT05658042|||OTHER||PROSPECTIVE|||||||
33971420|NCT04818021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34070470|NCT06538259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070471|NCT05599386|||COHORT||PROSPECTIVE|||||||
33882222|NCT03412773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882223|NCT02426177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882224|NCT01743482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882225|NCT03242109|||COHORT||PROSPECTIVE|||||||
33882226|NCT01341327|||COHORT||PROSPECTIVE|||||||
33882227|NCT03170674|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882228|NCT02500186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882229|NCT01964001|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33882230|NCT05781828|||COHORT||CROSS_SECTIONAL|||||||
33882231|NCT04109495|RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective cohort study designed to investigate the usefulness of the Noom smartphone application on nutrition management of pancreatic cancer patients. We randomly assigned patients with first diagnosed pancreatic cancer to Noom user group or non-Noom user group. A total of 40 participants were included for randomization. All patients underwent nutritional assessments (PG-SGA), laboratory test and quality of life assessments (EORTC QLQ) at enrollment, 4, 8, and 12 weeks. During study period, Noom user group voluntarily record meals and get feedback.||||
33882232|NCT02950233|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Patients, health care providers, data collectors, outcome adjudicators, and Investigators (e.g., Steering Committee Members) will all be blind to treatment allocation.|We will randomize patients in a 1:1:1:1 fashion to receive; 1) NMDA active + dexamethasone placebo, 2) dexamethasone active + NMDA placebo, 3) NMDA active + dexamethasone active, and 4) NMDA placebo + dexamethasone placebo.|t|t|t|t
33882233|NCT05343065|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33882234|NCT04069052|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Single-centre, double-blinded, crossover study|t|t|t|f
33882235|NCT01500837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882236|NCT01409603|RANDOMIZED|CROSSOVER||||NONE||||||
33882237|NCT01284699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882238|NCT00280995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882239|NCT02496949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882240|NCT02427347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882241|NCT06196866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882242|NCT04746768|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882243|NCT04845412|||COHORT||PROSPECTIVE|||||||
33882244|NCT01935050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882245|NCT03473093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882246|NCT05776849|RANDOMIZED|PARALLEL||OTHER||SINGLE|The person assessing the outcomes was blind.|the experimental group will be given the teaching materials before the lesson, while the control group will be given them during the lesson|f|f|f|t
33882247|NCT01500057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882248|NCT04800731|||OTHER||RETROSPECTIVE|||||||
33882249|NCT06429995|||COHORT||PROSPECTIVE|||||||
33882250|NCT00221884|RANDOMIZED|PARALLEL||||DOUBLE||||||
33882251|NCT06423079|||COHORT||RETROSPECTIVE|||||||
33882252|NCT00836134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882253|NCT01526109|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33971421|NCT01754259|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.|t|f|t|f
33971422|NCT01798459|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33971423|NCT00287027|||DEFINED_POPULATION||PROSPECTIVE|||||||
33971424|NCT04330300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971425|NCT03449056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971426|NCT01565083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971427|NCT01466686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971428|NCT06546605|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33971429|NCT01465542|||CASE_ONLY||RETROSPECTIVE|||||||
33971430|NCT05455749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971431|NCT06031311|||COHORT||PROSPECTIVE|||||||
33971432|NCT05806359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971433|NCT01038557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33971434|NCT00228462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971435|NCT03657199|||OTHER||RETROSPECTIVE|||||||
33971436|NCT04281069|||OTHER||CROSS_SECTIONAL|||||||
33971437|NCT02330081|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33971438|NCT04117308|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective, single-center, randomized, open-label study evaluating the use of fetal active movements counts on the perinatal morbidity score in patients with prolonged pregnancy.||||
34070472|NCT03594799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33882254|NCT03664128|||COHORT||PROSPECTIVE|||||||
33882255|NCT02503904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882256|NCT02669472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33882257|NCT03318965|||CASE_ONLY||CROSS_SECTIONAL|||||||
33882258|NCT00000511|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34070473|NCT01698944|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070474|NCT05140252|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34070475|NCT02796521|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33882259|NCT01708980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882260|NCT01870739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882261|NCT00161629|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34070476|NCT05022888|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective||||
34070477|NCT03272347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking in Part 1, including matching placebo. Masking only to dose in Part 2. No masking in Parts 3 and 4.||t|f|t|f
34070478|NCT01208597|||CASE_CONTROL||PROSPECTIVE|||||||
33882262|NCT05845346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070479|NCT06609642|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070480|NCT05194683|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of the participants will not be valid for the nature of the study and for therapists, on the other hand, they will be blinded to the hypothesis and research questions of the study.|This is a parallel, randomized controlled trial (RCT) comparing two arms: intervention and wait-list control.||||
34070481|NCT00966407|||COHORT||CROSS_SECTIONAL|||||||
34070482|NCT04423562|||COHORT||RETROSPECTIVE|||||||
33882263|NCT05077488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882264|NCT03130790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882265|NCT05455957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882266|NCT01943565|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34070483|NCT04582383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||200 participants will be randomized to treatment with spironolactone 100mg/day and 200 participants will be randomized to treatment with doxycycline hyclate 100mg/day.|t|t|t|t
34070484|NCT00038805|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759534|NCT02073461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882267|NCT02841059|||CASE_CONTROL||PROSPECTIVE|||||||
33882268|NCT00584961|||COHORT||PROSPECTIVE|||||||
33882269|NCT00494143|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33882270|NCT03104725|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882271|NCT03692858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882272|NCT03889561|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882273|NCT04435223|||COHORT||PROSPECTIVE|||||||
33882274|NCT00460343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882275|NCT04702009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882276|NCT01390259|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33882277|NCT03972722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882278|NCT04822987|||CASE_ONLY||PROSPECTIVE|||||||
33882279|NCT05559723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882280|NCT04991298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882281|NCT00715988|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882282|NCT04271098|||COHORT||PROSPECTIVE|||||||
33882283|NCT02721355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882284|NCT05264259|||COHORT||RETROSPECTIVE|||||||
33882285|NCT04393532|NA|SINGLE_GROUP||TREATMENT||NONE|single arm study|All recruited patients will undergo a laparoscopic hernia repair procedure using the Su2ura Approximation Device.||||
33882286|NCT01271673|||COHORT||PROSPECTIVE|||||||
33882287|NCT06257030|||COHORT||PROSPECTIVE|||||||
33759535|NCT04293263|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759536|NCT04059757|NA|SINGLE_GROUP||TREATMENT||NONE||The study follows R. Simon's minimax two-stage phase II design with type I error of 0.05 and power of 80%. Ten participants will be enrolled on stage one. If there are 2 or less responses, the trial will be stopped and the treatment will be considered less than 60% effective for this patient population. If there are 3 or more responses, 7 additional patients will be enrolled.||||
33759537|NCT02644590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759538|NCT03381261|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33759539|NCT02503267|||CASE_ONLY||CROSS_SECTIONAL|||||||
33882288|NCT06399874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind|Phase IIa, two-arm, block randomized controlled pilot trial|f|f|f|t
33882289|NCT02745561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882290|NCT04957134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882291|NCT00022087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882292|NCT01034046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882293|NCT00775580|RANDOMIZED|CROSSOVER||||NONE||||||
33882294|NCT02373280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients selected study||||
33882295|NCT01236430|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33882296|NCT05168215|||OTHER||PROSPECTIVE|||||||
33882297|NCT03396380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33882298|NCT04586985|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Randomized double-blind, placebo-controlled|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption and CYP3A induction|t|t|t|t
33882299|NCT06501625|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33882300|NCT05948280|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor who is independent of the research will be trained before formally conducting data collecting.|Participants are assigned to three groups in parallel for the duration of the study. Participants in Group A receive Virtual reality-based mindfulness. Participants in Group B receive general mindfulness exercises. Participants in Group C receive no intervention as control.|f|f|f|t
33882301|NCT03257787|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882302|NCT03044860|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882303|NCT02882295|||OTHER||CROSS_SECTIONAL|||||||
33882304|NCT00956878|||CASE_ONLY||PROSPECTIVE|||||||
33882305|NCT03995290|||COHORT||PROSPECTIVE|||||||
33882306|NCT02761954|||OTHER||PROSPECTIVE|||||||
33882307|NCT01920360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971439|NCT04437693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The process of keeping the study group assignment hidden after allocation will be used where the investigator and participants will be unaware of the drug.A double blind randomized clinical trial has been proposed having 250 subjects in each arm. 500 subjects will be selected using randomly permuted blocks of 2,4, and 8 for the random process to allocate subjects into the two groups equally by using computer software.|An interventional, double-blind, placebo-controlled randomized trial|t|f|f|f
33759540|NCT04849130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study assessments blinded by separating the clinicians performing the surgery and independent blind observers assessing the study data. Patients will be blinded to the surgery procedure.|Multicentre prospective longitudinal randomized clinical trial|t|f|f|t
33759541|NCT02827448|||COHORT||PROSPECTIVE|||||||
33759542|NCT06023875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759543|NCT05224375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759544|NCT01487980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33759545|NCT04150991|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will receive 3-week fiber/placebo treatment and 3-week alternate fiber/placebo treatment with a 4-week washout period in between.|t|f|f|f
33759546|NCT05032365|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33759547|NCT01062503|||CASE_ONLY||PROSPECTIVE|||||||
33759548|NCT00109044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759549|NCT04322604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759550|NCT00426608|RANDOMIZED|CROSSOVER||DIAGNOSTIC||||||||
33759551|NCT01456299|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33882308|NCT04459455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This randomization of the order will occur using the randomizer within Qualtrics Survey Software, making the randomization process double-blind. To triple-blind our analysis process, the data will be downloaded from Qualtrics and the variable indicating what order the SSIs were presented in will be recoded before the primary analyses are conducted. Therefore, the primary analyses will be conducted without the knowledge of which condition is which.|We will use a between-subjects design; participants will be randomized to receive either the active Contain COVID Anxiety SSI or the placebo Remain COVID Free SSI|t|f|t|t
33759552|NCT04177225|||CASE_ONLY||PROSPECTIVE|||||||
33759553|NCT03945864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental group will be compared with parental antibiotics group||||
33759554|NCT01360541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882309|NCT05402644|||COHORT||RETROSPECTIVE|||||||
33882310|NCT00772629|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882311|NCT00477165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882312|NCT05008094|||COHORT||PROSPECTIVE|||||||
33882313|NCT06001944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treating therapists and patient will be aware of treatment. Grip strength objective measure will be performed by a clinician blinded to the participant's treatment group. All other outcome measures are patient-reported on outcome forms.|Randomized controlled trial|t|f|f|f
33882314|NCT01013987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882315|NCT04264247|||COHORT||PROSPECTIVE|||||||
33882316|NCT05403983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882317|NCT04729777|||OTHER||PROSPECTIVE|||||||
33882318|NCT05272865|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882319|NCT04476602|||COHORT||RETROSPECTIVE|||||||
33882320|NCT02486757|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882321|NCT05273580|||COHORT||PROSPECTIVE|||||||
33882322|NCT06334094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882323|NCT03675880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882324|NCT03190408|||COHORT||PROSPECTIVE|||||||
33882325|NCT02757274|||COHORT||PROSPECTIVE|||||||
33882326|NCT00559507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882327|NCT02810964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759555|NCT06524063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882328|NCT05297968|RANDOMIZED|CROSSOVER||TREATMENT||NONE|open|randomized,two-treatment,two-period,two-sequence||||
33882329|NCT01243320|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33882330|NCT01474655|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882331|NCT03174145|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882332|NCT03548441|||COHORT||PROSPECTIVE|||||||
33882333|NCT05115097|||COHORT||PROSPECTIVE|||||||
33882334|NCT00466310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882335|NCT05441774|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|"Study design and aims will be concealed from participants. They will not be made aware of the presence of active versus sham conditions (all participants are given the expectation of active stimulation and imagery).~Participants are informed of their imagery condition before consent is obtained on the first lab session.~Study aims will be disclosed at debriefing, after all experimental procedures have been completed."|Factorial 2 (sham stimulation v active stimulation) x 2 (sham v self-compassion imagery)|t|f|f|f
33882336|NCT04126746|||COHORT||PROSPECTIVE|||||||
33882337|NCT06086847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971440|NCT02325700|||CASE_CONTROL||PROSPECTIVE|||||||
33971441|NCT03393442|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Female subjects exposed to Gd-based contrast media and female subjects not exposed to Gd-based contrast media will be examined by a diagnostic test (brain MRI scan) to determine the presence or absence of Gd-deposit related signal alterations in the brain.||||
33971442|NCT00359437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070485|NCT00415896|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34070486|NCT03508180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070487|NCT05784376|||COHORT||PROSPECTIVE|||||||
34070488|NCT03513471|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The randomization will be done by the department biostatistician and communicated with Investigational Drug Services so the experiment will remain blinded.|Study subjects will be randomized to one of two arms, either receiving Anakinra or placebo, then having a washout period and receiving the opposite treatment.|t|f|t|f
34070489|NCT05742074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized.|t|f|t|t
34070490|NCT00639106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070491|NCT03136926|||COHORT||PROSPECTIVE|||||||
34070492|NCT03941028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070493|NCT03295032|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1: Randomised Controlled Trial with an intervention (ACT group) and Waiting List Control arm.~Part 2: Interviews"||||
33882338|NCT00401063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882339|NCT03909958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882340|NCT02163434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882341|NCT05072847|||COHORT||PROSPECTIVE|||||||
33882342|NCT02574637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882343|NCT04127448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882344|NCT05185375|||CASE_ONLY||RETROSPECTIVE|||||||
33882345|NCT05412914|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33882346|NCT00104897||||TREATMENT||NONE||||||
33882347|NCT00863577||PARALLEL||||NONE||||||
33882348|NCT02653222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882349|NCT04154501|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33882350|NCT04213859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882351|NCT06240910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882352|NCT04363372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882353|NCT01555255|||CASE_ONLY||PROSPECTIVE|||||||
33882354|NCT02810028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971443|NCT00050661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971444|NCT02497391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33971445|NCT04938778|NA|SINGLE_GROUP||OTHER||NONE||||||
34070494|NCT01695382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34070495|NCT03181945|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Whether 4 weeks anti-epileptic drug is as efficacious as 12 weeks anti-epileptic drug therapy for Acute Encephalitis syndrome||||
34070496|NCT02624882|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34070497|NCT04780633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070498|NCT02378974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34070499|NCT03278366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070500|NCT06169826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070501|NCT00159107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070502|NCT06355726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070503|NCT03840941|||CASE_CONTROL||PROSPECTIVE|||||||
34070504|NCT04578522|||COHORT||RETROSPECTIVE|||||||
34070505|NCT00057525|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34070506|NCT05984108|||COHORT||RETROSPECTIVE|||||||
34070507|NCT00212264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070508|NCT01772459|||COHORT||PROSPECTIVE|||||||
34070509|NCT05727748|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||There are three different groups: a) a control group; b) a multimodal training group that combined physical training with cognitive training; c) a multimodal training group with augmented reality.||||
34070510|NCT05030571|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34070511|NCT05323175|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant will not know which type of block they receive|Standard of care group + sham normal saline ESP block vs Standard of care + Ropivacaine ESP nerve Block group|t|f|f|f
34070512|NCT06385327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34070513|NCT00313833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070514|NCT03416478|||CASE_ONLY||PROSPECTIVE|||||||
34070515|NCT02683408|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34070516|NCT01155349|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33882355|NCT04749069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In our study, random allocation sequence was performed using a computer programme for each patient to prevent bias. For concealed allocation, patients were randomly allocated into one group using a numbered, opaque and sealed envelope. A randomized block design is as follows: code A was given to the first group, and code B was given to the second group. The participant, data collector and data analyzer were blinded. This study was a single-blinded controlled study because the sedation and analgesia were administered by anesthesiology residents who were unaware of the technique and the study protocol however, the protocol was known by the experienced anesthesiologist who was attending the case and collecting the data during the procedure. The preparation of remifentanil solutions and installation of the infusion devices were done by an anesthesiologist who was blinded for the study groups.|This is a prospective, single-blinded randomized clinical study. The patients were divided into two groups with the method of one to one allocation and with the use of sealed envelope randomization.The first group was continuous infusion group (Group CI) and intravenous continuous remifentanil was infused after starting at a dosage of 0.1 µg/kg/min and the dose was raised incrementally up to 1µg/kg/min if required. The second group was intravenous bolus patient-controlled sedation analgesia (PCSA) and remifentanil infusion at a dose of 0.05 µg/kg, bolus of 0.1 μg/kg with lock-out time of three minutes was used. In both groups, a bolus dose of 0.1 µg/kg remifentanil was administered. The data evaluated include; level of pain and sedation, total amount of remifentanil consumption, bolus doses of remifentanil, use of a rescue medication, patient and surgeon satisfaction, hemodynamic data and adverse events.|t|f|f|t
33882356|NCT00374309|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33882357|NCT01980472|NA|SINGLE_GROUP||OTHER||NONE||Chemotherapy Regimen Plus Bevacizumab||||
33882358|NCT01131195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882359|NCT00394849|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|did not tell participant which side was sutured.|sutured one tonsillar fossa. pain was compared side to side. which side was sutured was randomized|t|f|f|f
33882360|NCT01472887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882361|NCT01116544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882362|NCT02475655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882363|NCT04545255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Shockwave probes were either active or sham (by blocking energy transfer from probe)|A double-blinded, randomized, sham-controlled, prospective study|t|f|t|f
33882364|NCT02790242|||COHORT||OTHER|||||||
33882365|NCT00982904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882366|NCT01369966|||||OTHER|||||||
33882367|NCT02219139|NA|SINGLE_GROUP||||NONE||||||
33882368|NCT03958578|||COHORT||PROSPECTIVE|||||||
33882369|NCT05412771|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882370|NCT00648167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070517|NCT02485756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070518|NCT02532283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882371|NCT04812626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This study will be double blinded with both the participants (keloid/hypertrophic scar patient fulfilling all the criteria)) and trial investigator (treatment provider) being blinded. The participants will be unaware of the treatment group that they will be allocated. And even the investigator performing the procedure and assessing the scar in each visit will be unaware of the drugs that will be given.~The independent dermatologist, which will have the sealed envelope will open the envelope and instruct the trained nurse to prepare the mixture of drugs as the group written in the envelope and provide it to the blinded investigator after removing the label on the mixture of drug."|Randomized, Parallel Group, Double Blinded, Clinical Trial Group A: Will receive Intralesional Triamcinolone acetonide only Group B: Will receive Intralesional Triamcinolone acetonide + 5 fluorouracil combination|t|t|f|f
33882372|NCT04926779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882373|NCT02600507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882374|NCT03159312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882375|NCT04813029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882376|NCT04428177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882377|NCT00063401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882378|NCT04852445|||CASE_CONTROL||PROSPECTIVE|||||||
33882379|NCT03631823|||CASE_CONTROL||PROSPECTIVE|||||||
33882380|NCT02723825|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882381|NCT03260569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both nitric oxide and placebo nitrogen will be made available in unmarked cylinders.|Following initial non-invasive measurements, patients will be randomized to either an active treatment (inhaled nitric oxide at 30 parts per million) or placebo (nitrogen only). After two hours, measurements will be reassessed. If the patient remains on the mechanical ventilator at 72 hours post-admission, a third set of non-invasive measurements will be taken.|t|t|t|f
33882382|NCT00055666|NON_RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33882383|NCT05872087|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33882384|NCT03349814|||COHORT||PROSPECTIVE|||||||
33882385|NCT04010669|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33882386|NCT03915873|||CASE_CONTROL||PROSPECTIVE|||||||
33882387|NCT03823612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882388|NCT05442619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Control Group Portable Therapeutic Baby Nest Using Group|t|f|t|f
33882389|NCT03790280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A double-blinded randomized control trial including children with refractory focal epilepsy who undergo surgery with intra- or extra-operative electrocorticography. Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1), or tailored by standard ECoG alone (arm 2).~Informed consent will be obtained 1 to 7 days to up to 3 months prior to the day of surgery. Prior to surgery, the subject will be randomized into the cohort arms in a 1:1 ratio.~Blinding of the clinical neurophysiologists and neurosurgeons for treatment allocation is not feasible because of the character of the intervention. Therefore, this is a double-blinded trial as subjects will be blinded to the cohort arm to minimize bias of the follow-up results. The treating neurologist will also be blinded."|Randomization into standard arm and the treatment arm in a 1:1 ratio.|t|t|f|f
33882390|NCT01989000|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33882391|NCT00658242|||||PROSPECTIVE|||||||
33882392|NCT01487915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882393|NCT05699174|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm, randomized controlled multicenter Phase III trial||||
33882394|NCT05627076|||COHORT||PROSPECTIVE|||||||
33882395|NCT00035594|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33882396|NCT01676285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882397|NCT05625776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Application of pain or attentional control or no stimulus cannot be masked from participants, nor from outcomes assessors.|||||
33882398|NCT06549959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882399|NCT05422872|||COHORT||CROSS_SECTIONAL|||||||
33882400|NCT05250700|||COHORT||PROSPECTIVE|||||||
33882401|NCT00284037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759556|NCT05168579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation to treatment v. control group will be masked to the person doing the analysis until the data is locked.|two arm randomized trial|f|f|f|t
33759557|NCT04956328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759558|NCT00872040|||COHORT||PROSPECTIVE|||||||
33759559|NCT03773185|||COHORT||CROSS_SECTIONAL|||||||
33759560|NCT02865070|||COHORT||PROSPECTIVE|||||||
33759561|NCT00005855|NON_RANDOMIZED|||TREATMENT||NONE||||||
33759562|NCT02491775|||COHORT||OTHER|||||||
33759563|NCT05384028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759564|NCT03078816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759565|NCT04333420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase II: Open label study (30 patients), Phase III: Double- blind (360 patients)|Two phases with 2 parallel arms each|t|f|t|f
33759566|NCT03668587|||CASE_CONTROL||PROSPECTIVE|||||||
33759567|NCT00190502|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33759568|NCT00794638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882402|NCT04816812|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will apply a superior trial design in this randomized clinical trial with two arms, intervention, and comparison.||||
33882403|NCT00540579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882404|NCT02337088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882405|NCT04525105|||CASE_CONTROL||PROSPECTIVE|||||||
33882406|NCT04279015|RANDOMIZED|PARALLEL||TREATMENT||NONE||pretest-posttest control groups in randomized parallel groups||||
33882407|NCT06175897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33882408|NCT04873479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882409|NCT03077568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882410|NCT04730154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33759569|NCT01222195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759570|NCT02930473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882411|NCT00969215|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33882412|NCT02639780|||CASE_CONTROL||PROSPECTIVE|||||||
33882413|NCT04479800|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33882414|NCT05175807|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882415|NCT02238457|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33882416|NCT03238105|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|There will be 2 blinded evaluators who will not know which side of the periorbital hyperchromia (right or left) received which treatment (IPL or peeling of 10% thioglycolic acid). They will do the evaluation through photographs, comparing the photos before the treatments with the photos after 1, 2 and 3 sessions after the treatments, without knowing what therapeutic modality was adopted in each periorbital region.|The selected patients will have each region of periorbital hyperchromia (right and left) randomized to one of the treatments (split face study).|f|f|f|t
33759571|NCT03841045|||COHORT||PROSPECTIVE|||||||
33759572|NCT04068350|||COHORT||PROSPECTIVE|||||||
33759573|NCT00213655|||CASE_CONTROL||PROSPECTIVE|||||||
33759574|NCT03839654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||A total of 300 patients with rheumatic valvular heart disease waiting for cardiac valve replacement were screened for obstructive sleep apnea (OSA). Of them, 40 OSA patients were enrolled and randomly received CPAP treatment and non-CPAP treatment (20:20 patients). The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline medicine treatment.|t|t|f|t
33759575|NCT01843998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759576|NCT03404492|NA|SINGLE_GROUP||OTHER||NONE||||||
33759577|NCT04236258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759578|NCT01747590|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33759579|NCT06349148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33759580|NCT05795530|||COHORT||PROSPECTIVE|||||||
33759581|NCT03075059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33759582|NCT00844857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882417|NCT01480297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882418|NCT01583894|||CASE_ONLY||CROSS_SECTIONAL|||||||
33882419|NCT03221218|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients will be blinded to their group assignment. Family physicians will not be aware that they are involved in a research study until the completion of the study.||t|t|f|f
33882420|NCT00700180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882421|NCT00521521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882422|NCT03883880|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33882423|NCT00044512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882424|NCT02814149|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882425|NCT04347083|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882426|NCT00142129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759583|NCT03991117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The study investigators that performed the histochemical analysis were masked to which participant and which condition they were assessing at the time of analysis.|Each individual performed four bouts of resistance exercise that varied in load and speed of contraction on two separate days (one condition each leg per visit).|f|f|f|t
33759584|NCT05383664|NA|SEQUENTIAL||SCREENING||NONE|Baseline measurements serve as control; experimental design is sequential, no placebo or masking is necessary for the experimental design.|Sampling of blood biomarkers subsequent to successive bouts of UV-light exposure.||||
33759585|NCT01320332|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33759586|NCT00875381|||CASE_ONLY||PROSPECTIVE|||||||
33759587|NCT00107055|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33759588|NCT05826925|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882427|NCT05213364|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33882428|NCT01761266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070519|NCT04893681|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Masking will be managed by the a Data Management System which will execute three tasks:~1. Study participants' treatment group allocation will be stored in a dataset accessible only to the masked data manager~2. A separate dataset will record unique identification codes that will be affixed as labels to 5-gallon bottles of water; the same dataset will also record the public water supply used to fill the bottle (New Bern or North Lenoir). After the barcode label is affixed, the processing slip indicating the bottle's source of water (New Bern or North Lenoir), will be removed, thereby masking the contents.~3. When new water bottles are to be delivered to a study participant's dwelling, the Data Management System will execute a bottle allocation routine that will retrieve the study participant's study group assignment and select from the supply of masked bottles the necessary number of masked bottles that conform with the study participant's treatment group assignment."|Block randomized, double-masked, placebo controlled, parallel group study.|t|t|t|t
33882429|NCT05906277|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||The recruiting of two simultaneous cohorts is scheduled. a) patients of illness onset (Cohort 1); b) patients with locoregional disease and/or metastatic designed for systemic therapies (cohort 2).||||
33882430|NCT02752100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882431|NCT00171860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882432|NCT00000873||PARALLEL||TREATMENT||||||||
33882433|NCT01805947|||COHORT||PROSPECTIVE|||||||
33882434|NCT01164722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882435|NCT03995264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882436|NCT03863626|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial 2 equal groups for IV shots and continuous infusion of frusemide in cases of diuretic resistance, metolazone will be added for sequential blockade in the IV shots arm qualifying diuretic resistance, there will be second levle of randomization into time adjusted versus random time metolazone administration||||
33882437|NCT03798886|||OTHER||PROSPECTIVE|||||||
33882438|NCT01661036|||OTHER||CROSS_SECTIONAL|||||||
33882439|NCT04867915|||CASE_ONLY||PROSPECTIVE|||||||
33882440|NCT01403337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882441|NCT05692388|||OTHER||CROSS_SECTIONAL|||||||
33882442|NCT03664375|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 46 patients were recruited in the study using non-probability purposive sampling and were divided randomly into two equal groups; control and experimental group, by sealed envelope method. The experimental group received botulinum toxin A followed by task specific training, while the control group received only task-specific training for 12 weeks. Data was collected at baseline, after 4 weeks, 8 weeks and 12 weeks by using upper extremity items of Motor Assessment Scale and Fugl Meyer Assessment scale of upper limb, Stroke specific quality of Life, Arm dystonia Disability scale and WOLF Motor function test.||||
33882443|NCT01625273|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33882444|NCT06314555|||CASE_ONLY||PROSPECTIVE|||||||
33882445|NCT05314244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882446|NCT01851408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882447|NCT03056118|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33882448|NCT05131061|||COHORT||PROSPECTIVE|||||||
33882449|NCT05006014|||CASE_ONLY||PROSPECTIVE|||||||
33882450|NCT03423498|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882451|NCT03847285|||CASE_ONLY||PROSPECTIVE|||||||
33882452|NCT01006070|||CASE_ONLY||PROSPECTIVE|||||||
33882453|NCT03940911|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33971446|NCT05085613|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Model Description: Participants will be randomized to view one of four messages. The control message explains why people are hesitant to accept the FDA authorized COVID vaccines are safe and effective and how they are evaluated. Arm 2 additionally includes consequent framing regarding economic recovery (e.g. If everyone gets vaccinated, we can keep schools, stores, and other businesses open so more Americans can keep working and supporting their families. With a picture of an open for business sign), arm 3 includes consequent framing regarding freedom to behave as one chooses (e.g. Everyone getting vaccinated is the key to freedom! A vaccine can give us the freedom to hang out with friends, shop, and worship together again safely. With a picture of an American flag), and arm 4 includes humor (e.g. Unfortunately, everyone getting vaccinated means leaving the house again.)."|t|f|f|f
33971447|NCT00152321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33971448|NCT00077779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971449|NCT03995069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759589|NCT00790452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882454|NCT04592783|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center Prospective Randomized Controlled Trial||||
33882455|NCT00106652|||||OTHER|||||||
33882456|NCT01559155|||COHORT||CROSS_SECTIONAL|||||||
33882457|NCT02443064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882458|NCT00416338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882459|NCT06427460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882460|NCT02599961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882461|NCT06517134|||COHORT||CROSS_SECTIONAL|||||||
33882462|NCT02950519|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971450|NCT05103956|||CASE_CONTROL||PROSPECTIVE|||||||
33971451|NCT01405820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882463|NCT05108987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882464|NCT01557166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882465|NCT04821804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971452|NCT00406185|||COHORT||PROSPECTIVE|||||||
33882466|NCT05788679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882467|NCT06303609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882468|NCT05280977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single blinded as the assessor will be unaware of the treatment that will be given to both groups.||f|f|f|t
33882469|NCT00280410|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33882470|NCT05291858|||COHORT||CROSS_SECTIONAL|||||||
33882471|NCT04906135|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882472|NCT04405401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized screening phase II trial|f|f|f|t
33882473|NCT00005012||||TREATMENT||||||||
33882474|NCT05984563|||COHORT||PROSPECTIVE|||||||
33882475|NCT06191250|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-centre, phase 2, WOO trial in patients with T2b-3N0-1M0 NSCLC evaluating the biologic efficacy of NORT-durvalumab administered prior to surgery. The trial will assess the feasibility of the study design using neoadjuvant NORT-durvalumab.||||
33882476|NCT05079997|||COHORT||PROSPECTIVE|||||||
33882477|NCT01872728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759590|NCT04462666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759591|NCT02015494|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759592|NCT06526364|||COHORT||PROSPECTIVE|||||||
33759593|NCT03790995|||CASE_CONTROL||PROSPECTIVE|||||||
33759594|NCT01443221|RANDOMIZED|CROSSOVER||||NONE||||||
33882478|NCT04911582|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33882479|NCT01150266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882480|NCT03356184|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||The RHEA device and Patient Monitor are used to monitor the heart rate (HR) and respiratory rate (RR) of participants at the same time in Test 1. The reference device and patient monitor are used to monitor the heart rate and respiratory rate of the same participant at the same time in Test 2. The two tests results will be compared and evaluated the accuracy of the two devices. And the RHEA device is used alone to evaluate the accuracy of motion and no motion.||||
33882481|NCT04711200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759595|NCT05855369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A separate outcomes assessor, blind to treatment intervention for all participants, will perform all clinician-administered primary outcomes (i.e. olfactory function determined by Sniffin' Sticks, ratings for odor intensity/hedonics, clinician-administered assessment of cognitive function, and the clinical global impressions for smell dysfunction). This outcomes assessor will not be involved with any other aspects of the trial.~Additionally, the participant will be blind to ST versus PBO group assignment, but not TNS+ST assignment."||t|f|f|t
33759596|NCT04414579|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label crossover trial. Subjects will be randomized to treatment sequence (Fiasp then NovoLog or NovoLog then Fiasp), each for a 12-week treatment period, by CSII. Randomization sequence will be determined by computerized randomization program. All patients will receive both treatments unless they drop out. Dropouts are unlikely since the participants are all regular continuing patients of the site's clinical practice.|This is a 25-week open-label prospective single center 2 arm crossover trial consisting of a CSII settings (basal, bolus, and correction factors) will be optimized for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.||||
33759597|NCT02537639|||COHORT||PROSPECTIVE|||||||
33882482|NCT00684515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882483|NCT01827384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882484|NCT06548763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882485|NCT03188445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882486|NCT01575210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882487|NCT01080885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882488|NCT02061254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882489|NCT03873155|NA|SINGLE_GROUP||TREATMENT||NONE|No party will be masked in this study. There is only one arm and participants will act as their own controls|A single-group case-series design will be adopted, whereby one group of participants will complete daily and weekly measures over the course of 1) a 4-week randomised multi-baseline period; 2) a 9-week intervention period (one introductory week added on to usual structure); 3) a 4-week follow up-period. Variables collected during the intervention and follow-up period will be compared with those from the baseline period.||||
33882490|NCT01184937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882491|NCT02504229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882492|NCT05881187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971453|NCT00252187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882493|NCT01584037|||||PROSPECTIVE|||||||
33882494|NCT05792878|||COHORT||PROSPECTIVE|||||||
33882495|NCT00751673|||COHORT||PROSPECTIVE|||||||
33882496|NCT03472560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882497|NCT00985400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882498|NCT00197197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882499|NCT00845988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882500|NCT00301171|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33882501|NCT01407926|||COHORT||PROSPECTIVE|||||||
33882502|NCT02306460|||CASE_CONTROL||PROSPECTIVE|||||||
33882503|NCT01014585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882504|NCT01363986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882505|NCT01882283|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33882506|NCT03607331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882507|NCT06237894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882508|NCT01365663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882509|NCT01042080|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33971454|NCT06316583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This experiment is a single-blind study where randomization occurs centrally through an online data management system after collecting baseline data from participants. A designated research coordinator manages the randomization process and facilitates communication among research personnel. Due to the nature of the intervention, operators are aware of the group assignments, but evaluators, unaware of these assignments, assess and collect baseline, post-treatment, and follow-up data. Since none of the participants have received any prior acupuncture or trigger point dry needling treatments, using a scalable sham needle on the same trigger points ensures blinding by simulating the effects of actual treatment.|Using a single-center randomized controlled patient-blind study design, 150 eligible participants are randomly assigned to three groups: a placebo group (sham trigger point needling), a dry-needling trigger points treatment (TrP-DN)group, and a traditional acupuncture group. Compared to the placebo group, this study assesses the effects of TrP-DN and traditional acupuncture on pain and quality of life for primary dysmenorrhea patients, as well as their long-term outcomes. Additionally, the study observes their impact on inflammatory factors and local uterine blood flow, aiming to explore the mechanisms underlying TrP-DN and traditional acupuncture treatments for PD.|t|f|f|t
33971455|NCT00306969|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971456|NCT00543361|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33971457|NCT02959775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33971458|NCT04031027|||OTHER||RETROSPECTIVE|||||||
33971459|NCT00112489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971460|NCT04009330|||COHORT||PROSPECTIVE|||||||
33971461|NCT03662386|||COHORT||PROSPECTIVE|||||||
33971462|NCT04083014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971463|NCT02753400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971464|NCT05484375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971465|NCT02786498|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33971466|NCT04577274|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33971467|NCT00627718|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33971468|NCT04014998|RANDOMIZED|PARALLEL||TREATMENT||NONE||Virtual Reality||||
33882510|NCT03891511|||CASE_ONLY||PROSPECTIVE|||||||
33882511|NCT02415205|||COHORT||PROSPECTIVE|||||||
33882512|NCT06501274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882513|NCT03805893||PARALLEL||BASIC_SCIENCE||NONE||Two groups: patients with peripheral neuropathy and normal controls||||
33882514|NCT00838019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882515|NCT04973943|||COHORT||PROSPECTIVE|||||||
33882516|NCT00406770|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33882517|NCT03607279|||CASE_CONTROL||PROSPECTIVE|||||||
33971469|NCT05057156|RANDOMIZED|PARALLEL||PREVENTION||NONE||multicentric, transversal and randomized trial.||||
33971470|NCT00001228||||TREATMENT||||||||
33971471|NCT02786199|||CASE_ONLY||PROSPECTIVE|||||||
33971472|NCT01694615|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971473|NCT03819933|NON_RANDOMIZED|FACTORIAL||OTHER||NONE|There will be no masking in this behavioral intervention trial.|This pre/post, mixed method behavioral intervention study will enroll \~130 families (pregnant women and their partners) at extreme prematurity and their counseling providers from Maternal Fetal Medicine (MFM) and Neonatology (total possible participants \~460) to determine whether developed educational interventions for providers (workshop, online module or both) improve counseling practices and outcomes using comparative statistical analyses.||||
34070520|NCT04360473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The person responsible for generating the sequence will use the result of the lottery to number the opaque envelopes and place the intervention corresponding to the group to which that lottery number belongs. This professional will not administer anesthesia to the patients in the study and will not participate in the collection or evaluation of the studied variables.~The envelopes will be opened by professionals who will prepare the corresponding solution, keeping this information covered for the other members of the team and for the patients.~The groups will be covered up for patients and for professionals who carry out the assessments."|This is a prospective, controlled, covered and randomly distributed trial|t|t|t|t
34070521|NCT02801461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33882518|NCT02371265|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33882519|NCT01744288|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33882520|NCT03836300|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention, called Parent-infant Interaction Intervention (PIXI) is a comprehensive intervention provided across the first year of life for parents/caregivers of infants identified with a rare neurogenetic disorder. It includes psychoeducation around the disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.||||
33882521|NCT04911946|||OTHER||CROSS_SECTIONAL|||||||
33882522|NCT01820325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882523|NCT00002147||||TREATMENT||NONE||||||
34070522|NCT03134911|||OTHER||CROSS_SECTIONAL|||||||
34070523|NCT02903420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070524|NCT03833232|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070525|NCT05791526|||COHORT||PROSPECTIVE|||||||
34070526|NCT00528359|||||PROSPECTIVE|||||||
34070527|NCT00547157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070528|NCT00070564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070529|NCT05006274|||CASE_CONTROL||PROSPECTIVE|||||||
33882524|NCT04090541|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||This study was conceived as a randomized placebo controlled prospective trial. With the aim of blocking effects of morphological specifities of participants, this study was designed on a four stage application on the same participants. This stages were (1) control testing with No Tape(NT) (2) placebo testing with Sham Tape(ST) application (3) Kinesology Tape(KT) application (4) Biomechanical Tape (BT) application. With the aim of blocking bias effects, randomization was designed with the computerized system using four way algorithm which led to NT, ST, KT and BT applications for each participant in mixed order but all applications have equal time in order.|t|f|f|f
33882525|NCT03686566|||CASE_ONLY||PROSPECTIVE|||||||
33882526|NCT04613726|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The anesthesiologist in charge, and the patient and investigators were blinded to the group allocation.|Comparator / control treatment Control group consisted of patients receiving IV 10 ml normal saline. A comparator group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline, Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline.|t|f|t|t
33882527|NCT04448990|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Real tVNS will be applied using pre-defined characteristics of tVNS device to cymba conchae of the auricle, sham procedure will be the same, however applied to tubule of the auricle|Two periods (real and sham tVNS) randomized crossover investigation in healthy volunteers|t|f|f|t
33882528|NCT02356562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882529|NCT02049047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971474|NCT04984850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Following baseline, participants randomized immediately to receive either the intervention plus usual care (experimental group, n = 26) or usual care only (control group, n = 26).||t|f|f|f
33882530|NCT01113970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882531|NCT03353727|NA|SINGLE_GROUP||OTHER||NONE||||||
33882532|NCT06025266|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The same 19 people were seen 3 times to evaluate.||||
33882533|NCT04121442|NA|SEQUENTIAL||TREATMENT||NONE||||||
33882534|NCT00355394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882535|NCT01626105|||COHORT||PROSPECTIVE|||||||
33882536|NCT04465682|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882537|NCT01526083|RANDOMIZED|CROSSOVER||||NONE||||||
33882538|NCT01241214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882539|NCT03498274|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a controlled, randomized, cross-over, open label, comparative clinical investigation. A randomized cross-over design is used with half of the test subjects wearing the device fit with the traditional fitting method first and the other half using the self-directed method and then switching after approximately 10 +/-5 days.||||
33882540|NCT02710357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882541|NCT02623335|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33882542|NCT03796767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882543|NCT05847088|||CASE_ONLY||RETROSPECTIVE|||||||
33882544|NCT01135589|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882545|NCT00486278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882546|NCT02833246|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882547|NCT02361164|||COHORT||PROSPECTIVE|||||||
33882548|NCT00197054|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33882549|NCT00343512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882550|NCT02602223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882551|NCT00500682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971475|NCT05014386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a single-center, randomized, controlled couple armed study.|t|t|f|t
33971476|NCT01876862|NA|SINGLE_GROUP||||NONE||||||
33971477|NCT05112445|||COHORT||CROSS_SECTIONAL|||||||
33971478|NCT03810833|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33971479|NCT06344442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All the clinical teams involved intraoperatively (anaesthetists, nurse anaesthetists and surgeons) and postoperatively (doctors and nurses who will take care of the patient postoperatively) and the families will ignore the allocation of treatments for the duration of the trial,except the nurse in charge of preparing the infusions ,She will ensure respect for the blind|Prospective, national multicentre, double-blinded, randomized ,controlled superiority trial with two parallel arms|t|t|t|t
33971480|NCT01759381|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971481|NCT05480397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33971482|NCT06527911|||COHORT||PROSPECTIVE|||||||
34070530|NCT04565405|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Eligible patients will be randomized in 1:1 fashion using permuted blocks with different block sizes. The subjects and lab operators will be blinded to the block size and randomization. In the event unmasking need to be performed, a staff who is not involved in this study from Clinical Trial Unit will perform the unmasking.|"This is a single centre, single blinded, randomized cross over study comparing two decontamination procedures Detergent (A) and Sterile water (B) on inner cannulas.~To avoid the influence of confounding covariates, we propose to have a cross over study. The cross over patient will act as his own control. The selected patients will be randomly allocated to sequence AB or BA in 1:1 fashion using permuted blocks with different block sizes.~The change of sequence A \> B and B \> A will take place only after minimum of 24 hours after the first part of sequence has been completed."|t|f|f|t
33971483|NCT04110795|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34070531|NCT00532727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971484|NCT01508585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971485|NCT02733237|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33971486|NCT00685919|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33882552|NCT03880201|||COHORT||PROSPECTIVE|||||||
33882553|NCT03875950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882554|NCT01817816|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33882555|NCT06057779|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcome assessor was blinded to the specific intervention (protocol type); due to the nature of the interventions, participants were aware of the exercise intervention they were performing each week. However, participants will not be informed of the hypothesis of the study nor will this be disclosed at any time in written materials or verbal interactions.|Repeated measure design|f|f|f|t
33882556|NCT06439368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882557|NCT01625520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882558|NCT00035204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33882559|NCT02569060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882560|NCT04312698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971487|NCT03346395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971488|NCT02362906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971489|NCT01720186|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971490|NCT00000295||CROSSOVER||TREATMENT||DOUBLE||||||
33971491|NCT04670757|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Only Phase IB is to be double-blind||t|f|t|f
34070532|NCT04013880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070533|NCT06608407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070534|NCT00170352|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34070535|NCT00003032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070536|NCT01563198|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34070537|NCT02486172|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34070538|NCT04388176|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The study will be conducted in double-blind fashion and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.|This is a randomised, double-blind, placebo-controlled cold challenge study. A cross-over design is applied to control for inter-individual variability in response to cold challenge.|t|t|t|f
34070539|NCT02849704|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34070540|NCT05857410|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34070541|NCT04308252|||COHORT||PROSPECTIVE|||||||
34070542|NCT04595929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070543|NCT00614978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759598|NCT04807465|RANDOMIZED|PARALLEL||TREATMENT||NONE||47 participants having at least three non-carious cervical lesions were included in the study. Participants were divided into two groups as smokers and non-smokers. Before treatment, the dimensions and depth of the lesions were measured with periodontal probe and the sensitivity of each tooth was determined using VAS scale. All of the non-carious cervical lesions were restored with a resin composite, Essentia,GC using one of three different application modes of universal adhesive, G-Premio Bond (etch\&rinse, selective-etch, self-etch). The restorations were placed by a single operator. Two calibrated examiners who were fully blind to restorative procedure evaluated the restorations in terms of retention, marginal discoloration, marginal adaptation, color match, postoperative sensitivity and secondary caries using modified USPHS criteria. The plaque and gingival index were also asessed at baseline and every 6 months of clinical service for 18 months.||||
33759599|NCT00779389|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882561|NCT04313829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Cluster randomization by institution was used in this study. The four Puskesmas were randomized by asking the person in charge of the Prolanis at these centers to choose a closed envelope containing an identifier indicating the control group or the intervention group. Two Puskesmas were used as the control group and the remaining two were used as the intervention group.|All patients provided written informed consent before participating in the study. The participants were administered the EQ-5D-5L questionnaire in the first month of the study, as a pre-test procedure. The patients in the control group participated in the standard Prolanis T2DM program for 6 months and were asked to fill out the questionnaire again at the 6-month time point, as a post-test procedure. The patients in the intervention group participated in the standard Prolanis T2DM program and received a 15 min face-to-face counseling session from a pharmacist once a month for 6 months. At the 6-month time point, subjects in the intervention group were asked to fill out the EQ-5D-5L questionnaire again, as a post-test procedure. Patients in the control group also received a 15 min face-to-face counseling session from a pharmacist once a month for 6 months after the intervention study was completed.|f|t|f|f
34070544|NCT04386005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will have the continuous glucose monitoring device placed.||||
34070545|NCT06007560|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34070546|NCT02855567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070547|NCT04746950|||CASE_CONTROL||PROSPECTIVE|||||||
34070548|NCT02500719|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070549|NCT04350879|||CASE_ONLY||CROSS_SECTIONAL|||||||
33882562|NCT01043757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33882563|NCT04003688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The anesthesiologist in charge of randomization will number 75 opaque envelopes and insert a card in each with the corresponding information of the group (according to the lottery) and the medication to be administered. Another anesthesiologist in charge of preparing the blind solution alone will open the envelope. Both of these investigators, as well as the anesthesiologist providing anesthesia and the anesthesiologist in charge of data evaluation will not participate in any of the other steps of the trial. The patients will be blinded to their own treatment group.|Prospective, double-blind, randomized clinical trial.|t|t|t|t
33882564|NCT02910245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882565|NCT06071858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882566|NCT02449642|||COHORT||PROSPECTIVE|||||||
33882567|NCT01180933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882568|NCT04031079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers performing the analyses will be blinded|A parallel group design with two groups|f|f|t|f
33882569|NCT02456350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882570|NCT01720758|||OTHER||PROSPECTIVE|||||||
33882571|NCT04688294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882572|NCT04233749|NA|SINGLE_GROUP||TREATMENT||NONE||This a proof-of-concept study. Five subjects will be enrolled and all five will receive tranexamic acid.||||
33882573|NCT00482014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882574|NCT02587338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070550|NCT00281723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070551|NCT04615221|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070552|NCT00962078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070553|NCT03092648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||open, non-random, concurrent control||||
34070554|NCT02335385|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34070555|NCT01288365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070556|NCT01902511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070557|NCT05614635|||OTHER||PROSPECTIVE|||||||
33759600|NCT02513069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759601|NCT00559208|||CASE_CONTROL||PROSPECTIVE|||||||
33759602|NCT03281122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33759603|NCT00676286|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33759604|NCT01152502|||||CROSS_SECTIONAL|||||||
33759605|NCT04340310|||COHORT||PROSPECTIVE|||||||
33759606|NCT02560870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759607|NCT05065515|||COHORT||PROSPECTIVE|||||||
33759608|NCT03414801|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33759609|NCT03372330|||COHORT||PROSPECTIVE|||||||
33759610|NCT05861362|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33759611|NCT00947661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759612|NCT03818529|||COHORT||OTHER|||||||
33759613|NCT03504098|||CASE_ONLY||PROSPECTIVE|||||||
33759614|NCT03848702|RANDOMIZED|PARALLEL||OTHER||DOUBLE|For part 1, a randomization list will be generated using an online program. For the 10 participants, five braces will be developed for the dominant side and five for the nondominant side. The physician and participant will be concealed for allocated side until the scan will be made.|Two consecutive prospective case series to investigate brace feasibility.|t|t|f|f
33759615|NCT02007642|||CASE_ONLY||PROSPECTIVE|||||||
33759616|NCT01855854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759617|NCT00209807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759618|NCT05582304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759619|NCT04379843|||COHORT||OTHER|||||||
33759620|NCT02605226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759621|NCT02158884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759622|NCT03793725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759623|NCT01398670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759624|NCT02486601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759625|NCT05667467|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33759626|NCT00001981|||COHORT||PROSPECTIVE|||||||
33759627|NCT02780232|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33882575|NCT00214123|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33882576|NCT01076257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882577|NCT00137917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882578|NCT06050538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each patient was randomly allocated to the TAPP group or the TEP group by sequentially numbered, opaque , sealed envelope (SNOSE) technique on the day of surgery. An independent statistician , who was not involved in patient care, generated the randomization sequence via a computer generated random number. The randomization code was contained in opaque sealed envelopes. A junior resident , who opened the envelope , was not actively involved in outcome measurements .Before randomization and during the consent, all patients received an explanation of the objectives of the study, techniques and complications associated with both procedures.|patients diagnosed with recurrent inguinal hernia. The study population were randomly distributed into 2 groups by computer generating program; group (1) included patients who had Transabdominal preperitoneal (TAPP) approach while group (2) included patients who had Total extraperitoneal (TEP) approach.|t|t|f|f
33882579|NCT05466461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During treatment, the type of material will be concealed from the patient, and the patient will have no information which material will be used. The type of restoration will not mentioned in the patient's file. Instead, it will be replaced by a combination which the evaluators will be not familiar with. The operator will be blinded for the type of restoration during tooth preparation and was informed only at the time of restoration placement. The purpose of this discretion is to ensure double blinding both at the patient, as well as the evaluators level.|Compare between S-PRG-containing injectable flowable resin composite (Beautifil Flow Plus X) and smart bioactive flowable resin composite (Activa bioactive restorative) over one year through evaluation of the modified USPHS clinical performance in patients with carious class V moderately deep cavities.|t|f|f|t
33882580|NCT01175941|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33882581|NCT00341250||||TREATMENT||||||||
33882582|NCT03793387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882583|NCT04378803|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The wait-list control group will receive the training program at a later point.||||
33882584|NCT03553186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Simple blinded randomization will occur by the pharmacy prior to distribution of the intervention drug.||t|t|t|t
33882585|NCT03940066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882586|NCT05524545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882587|NCT05156931|||COHORT||CROSS_SECTIONAL|||||||
33882588|NCT01793415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971492|NCT05146466|RANDOMIZED|PARALLEL||OTHER||NONE|Given the differences between the two arms, participants will be aware of the arm they have been randomised into. Outcome assessments will be self-reported and returned to research staff with no information on allocation. Blinding will be maintained throughout data analysis. Unblinding will be facilitated by the independent statistician following completion of the protocol-specified data analysis.|Data will be collected in up to 12 Gaelic Athletic Association (GAA) sports clubs. For each of the participating GAA clubs, individual participants will be randomised with the same probability to one of the two arms (E-MATVR \[intervention\]/E-MATE \[control\]). Allocation concealment will be maintained using a computerised system. Once participants have consented and their baseline assessment has been entered into the computer database, their allocation will be given by automated email. Randomisation and allocation concealment will be conducted according to the standard operating procedures (SOPs) of the Statistics and Data Analysis Unit of the HRB Clinical Research Facility-Cork (HRB CRF-C).||||
33971493|NCT05303142|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33971494|NCT04057781|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental There will be three groups in this study; control, DN alone and DN/IES. Each group will have approximately 20 subjects, resulting in approximately 60 subjects total. Subjects will be randomized into one of the three groups via block randomization method based on order of entry into the study.||||
33971495|NCT00002571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070558|NCT06248593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Before starting the study, a simple randomization sequence for at least 140 codes divided into two equal-sized groups will be generated. One code for each patient will be placed into a sealed, opaque, sequentially numbered envelope by a research assistant, who is not involved in patient management or data collection.~A Medical staff member who is not involved in subsequent patient care or assessement either, will open the envelope for each patient shortly before commencement of the cesarean delivery and prepared two identical 50-mL syringes according to the code contained in the envelops, patients will be randomly allocated to receive Phenylephrine or Norepinephrine infusion. All the syringes will be labelled as study drug, therefore it will be impossible for the anesthesiologists involved in patient care to identify whether it contained norepinephrine or phenylephrine."|It's a randomized, double-blind, two-arm, parallel, non-inferiority, controlled trial, which tha aim is to test the hypothesis that neonatal outcome, as assessed by umbilical artery pH, is at least as good (non-inferior) when prophylactic continuous manually controlled infusion of norepinephrine is used to maintain blood pressure during spinal anaesthesia for elective cesarean delivery compared with the same infusion modalities of phenylephrine with more stable blood pressure and less bradycardia.|t|t|t|t
34070559|NCT00405340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070560|NCT01800799|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|||||
34070561|NCT05702099|||CASE_CONTROL||PROSPECTIVE|||||||
34070562|NCT01586377|||CASE_CONTROL||PROSPECTIVE|||||||
34070563|NCT01502956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070564|NCT02334345|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070565|NCT01642706|||CASE_CONTROL||PROSPECTIVE|||||||
34070566|NCT04153565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759628|NCT05657626|||COHORT||CROSS_SECTIONAL|||||||
33759629|NCT03951038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882589|NCT06205186|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882590|NCT03282760|NA|SEQUENTIAL||TREATMENT||NONE||"Fifteen to 24 patients affected by SPMS will be enrolled, according to a standard phase I design over 18 months. All patients will enter a 3 months run in phase. Thereafter they will receive one of four different doses of allogenic hNSCs (dose A=5 millions hNSCs; dose B=10 millionshNSCs; dose C=16 millions hNSCs; dose D=24 millions hNSCs)."||||
33882591|NCT03529292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882592|NCT03254966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882593|NCT06084130|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Placebo is corn-starch contained in identical white-color opaque medicine capsule to zolpidem|The eligible participants will be informed and consented. After then, the participants in group 1 will receive 10 milligrams zolpidem contained in white-color opaque medicine capsule prepared by the pharmacist, meanwhile the participants in group 2 will receive placebo which is corn-starch contained in identical white-color opaque medicine capsule. The participants will be advised to take the medication 30 minutes prior to the bedtime until the 1-week follow up visit. On the second week, the participants in group 1 will alternatively receive placebo, meanwhile the participants in group 2 will receive 10 milligrams zolpidem in identical capsules. The wash-out period is 24 hours as the fact that the half-life of zolpidem is 2 hours and total zolpidem elimination time is 10 to 12 hours.|t|t|t|t
33882594|NCT00217087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882595|NCT02412293|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33882596|NCT03913156|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33882597|NCT03869580|||COHORT||PROSPECTIVE|||||||
33882598|NCT05506397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|A double-blind design was applied, including participants, interviewers and outcomes assessors.|randomized, placebo-controlled, pretest-posttest control group study.|t|t|f|t
33882599|NCT02784938|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882600|NCT01988090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882601|NCT05983289|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34070567|NCT06399354|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A parallel, cross-over study in participants with heart failure and in a healthy age- and BMI-matched participants with normal heart function as control group.||||
34070568|NCT01493115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34070569|NCT01936207|||COHORT||PROSPECTIVE|||||||
33759630|NCT04092725|RANDOMIZED|CROSSOVER||OTHER||NONE||"Subjects will be randomized to a treatment sequence (AB or BA) in a crossover fashion with a minimum 10-day washout period between treatments.~Treatment A = Single oral 150-mg dose of DAB on Day 1 AM. Treatment B = Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078."||||
33759631|NCT05752799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Infusions will be prepared by independent staff not involved in the study. All preparations will be alike in the volume and appearance.||t|t|t|f
33759632|NCT06259422|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759633|NCT04961008|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33759634|NCT02543255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882602|NCT03817372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882603|NCT00625092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882604|NCT02458508|||CASE_ONLY||RETROSPECTIVE|||||||
33882605|NCT00286676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882606|NCT01629641|||COHORT||PROSPECTIVE|||||||
33882607|NCT00626093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882608|NCT05613530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33882609|NCT06102733|||COHORT||PROSPECTIVE|||||||
33882610|NCT01055002|RANDOMIZED|PARALLEL||||NONE||||||
33882611|NCT01595815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882612|NCT05358847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882613|NCT03489798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882614|NCT02368327|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33882615|NCT06471764|||OTHER||PROSPECTIVE|||||||
33882616|NCT05949229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participating patients will be randomly allocated using computer generated randomizer program (http://www.randomizer.org) into 2 study groups .|The participating patients will be randomly allocated using computer generated randomizer program (http://www.randomizer.org) into 2 study groups . Duloxetine group (Group D): patients received oral duloxetine 60 mg 2 hours just before operation. Control group (Group C): patients received an identical placebo pill 2 hours just before operation|t|t|t|t
33882617|NCT04543214|||OTHER||PROSPECTIVE|||||||
33882618|NCT03438045|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Feasibility and acceptability study.||||
34070570|NCT06246097|||OTHER||PROSPECTIVE|||||||
34070571|NCT06443515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070572|NCT00306410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33882619|NCT04753411|||OTHER||PROSPECTIVE|||||||
33882620|NCT03388463|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34070573|NCT01639703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070574|NCT00613379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070575|NCT06076122|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The BIO-DIS company in Seville prepared the extract/placebo bottles for each study arm by assigning them a unique coding for each participant that does not distinguish between extract and placebo. This coding is then the participant's study code. Treatment bottles were prepared and coded according to the ratio of dietary supplement/placebo (1:1 for Branch B, C and D and 2:1 for Branch A) and the number of participants in each branch.~The list indicating which treatment (supplement/placebo) each coding corresponds to will be kept at the Hospital Universtario Virgen Macarena (HUVM) Pharmacy Service for the duration of the study. The blind will only be disclosed in the event of an adverse event (AE) that requires it and/or after completion of the analysis of the main end-points of each arm in a blinded manner."|Multicentre, randomised, triple-blind, parallel-group, placebo-controlled pilot trial.|t|t|t|t
34070576|NCT03646071|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33882621|NCT03833830|||OTHER||PROSPECTIVE|||||||
34070577|NCT02468999|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34070578|NCT04760535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070579|NCT01616160|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34070580|NCT03791801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||RCT|t|f|f|t
34070581|NCT05853029|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Randomization using envelop|||||
34070582|NCT06610097|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34070583|NCT04122209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34070584|NCT00573872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070585|NCT01515566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33971496|NCT03507439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882622|NCT00883532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33971497|NCT01493297|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33971498|NCT02758002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971499|NCT03475732|NA|SINGLE_GROUP||TREATMENT||NONE||100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days||||
33971500|NCT05612386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
33971501|NCT04468256|||CASE_CONTROL||PROSPECTIVE|||||||
33971502|NCT04125004|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34070586|NCT01592604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070587|NCT05463588|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34070588|NCT04684108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070589|NCT05455333|||COHORT||PROSPECTIVE|||||||
34070590|NCT05822505|||COHORT||PROSPECTIVE|||||||
33882623|NCT00820755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070591|NCT00985686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070592|NCT02434900|||COHORT||PROSPECTIVE|||||||
34070593|NCT05449444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible patients will be randomized by means of a computerized central randomization system called IWRS (interactive web response system).|Randomized, double-blind, placebo-controlled, parallel-group, multicenter comparative study with ascending dose titrations of masitinib and matching placebo|t|f|t|f
34070594|NCT04027179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34070595|NCT02042261|||COHORT||PROSPECTIVE|||||||
33882624|NCT05213988|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882625|NCT05276661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33882626|NCT00930215|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33882627|NCT00532480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882628|NCT02800655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882629|NCT00317460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882630|NCT04771533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882631|NCT00168831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33882632|NCT04257760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The patients, the palliative care physicians and the research team will know if a palliative care consultation has been done or not.|It is a pilot trial to assess the feasibility of palliative care for ALS patients. Patients will be in the palliative care or non-palliative care arm of the trial based on their decision to have a palliative care consultation or not. If they do not initially chose a palliative care consult they can change their mind during the course of the trial.||||
33882633|NCT05254028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be 4 outcome assessors who do not know the intervention status of study subjects||f|f|f|t
33882634|NCT02340663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34070596|NCT04724785|||COHORT||PROSPECTIVE|||||||
34070597|NCT06583798|||COHORT||RETROSPECTIVE|||||||
34070598|NCT03955809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34070599|NCT00186485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070600|NCT06253247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors (patients and statistician) will not know which group the participants are related to|Parallel randomized clinical trial|t|f|f|t
34070601|NCT03334188|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34070602|NCT04299867|||COHORT||PROSPECTIVE|||||||
34070603|NCT03603288|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Extension Study||||
33759635|NCT02037438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759636|NCT01851174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759637|NCT01301391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759638|NCT05606016|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882635|NCT01349166|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971503|NCT03867383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Randomization has been performed and study ID designation to drug or placebo arm allocated to opaque envelopes prior to subject enrollment. An anesthesiologist not involved in clinical care of the patient or data entry or analysis opens the envelope at the time of subject enrollment and prepares the study drug versus placebo in a 60mL syringe, labeled only with subject ID#. Drug and placebo appear identical as clear solutions and are administered by the same protocol.~The key designating whether each study ID patient received calcium or placebo has been uploaded to the redCAP data entry database and cannot be retrieved without entering a passcode."|Patients are randomized via stratified, permuted block randomization to receive a single dose of either calcium chloride 1 gram administered intravenously or placebo at the time of fetal delivery.|t|t|t|t
33882636|NCT03683394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized after baseline assessments to the SMARRT intervention arm or Health Education (HE) control arm. Randomization will be stratified by clinic, race/ethnicity (non-Hispanic white vs. non-white or Hispanic) and age (70-79, 80-89).|f|f|f|t
33971504|NCT00308022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971505|NCT03831633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971506|NCT04716114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971507|NCT06178146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070604|NCT01156493|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Standard Formula|Protein Hydrolized Formula|t|t|t|t
33882637|NCT01507376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882638|NCT02304198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882639|NCT00535925|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882640|NCT02635620|||CASE_CONTROL||PROSPECTIVE|||||||
33882641|NCT01492998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882642|NCT04226404|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882643|NCT01516515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882644|NCT00720148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882645|NCT00874211|||COHORT||PROSPECTIVE|||||||
33882646|NCT04160390|||COHORT||PROSPECTIVE|||||||
33882647|NCT00573001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882648|NCT02082886|||CASE_ONLY||PROSPECTIVE|||||||
33882649|NCT00852293|||COHORT||PROSPECTIVE|||||||
33882650|NCT02441790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33882651|NCT04358783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|RCT double blind comparative study|t|t|t|t
33882652|NCT04492436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33882653|NCT04410419|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33882654|NCT05467722|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882655|NCT00358787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882656|NCT00485888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882657|NCT00841763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33971508|NCT03141177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070605|NCT03526991|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE||A total of 10 patients with a diagnosis of Parkinson's disease and treatment refractory freezing of gait will be recruited in this study.|t|f|f|f
34070606|NCT00501137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34070607|NCT02699827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33882658|NCT05223361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33882659|NCT01968460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882660|NCT01656434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882661|NCT00173849|||NATURAL_HISTORY||OTHER|||||||
33971509|NCT03649737|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34070608|NCT03817099|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned to two groups in parallel for the duration of the study based on their choice||||
34070609|NCT00612651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070610|NCT01504191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070611|NCT03989596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070612|NCT05942391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a parallel-group randomised controlled intervention study|f|f|f|t
33882662|NCT02240043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971510|NCT00200928|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33971511|NCT03731182|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33971512|NCT06402747|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882663|NCT02126085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971513|NCT06201624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971514|NCT03922477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971515|NCT03341286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized, placebo-controlled|t|t|t|f
33971516|NCT05619146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The participants will complete 60min of active cycling training paradigm, 5 times a week, for 12 weeks. The cycling ergometer will be used to provide motorized assistance during simultaneous arms and legs cycling to the participant while they are seated.||||
33971517|NCT03441542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971518|NCT00925379|||COHORT|||||||||
33971519|NCT03117673|||CASE_ONLY||PROSPECTIVE|||||||
33882664|NCT01733030|||OTHER||CROSS_SECTIONAL|||||||
33882665|NCT04497025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882666|NCT02513329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33882667|NCT02580331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882668|NCT05352581|||COHORT||PROSPECTIVE|||||||
33882669|NCT00744900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070613|NCT01393522|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34070614|NCT03335683|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Triple blind|Split mouth design|t|t|t|t
34070615|NCT02290119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34070616|NCT04404049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070617|NCT02548663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070618|NCT04644159|||COHORT||PROSPECTIVE|||||||
34070619|NCT00305409|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33882670|NCT01739751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882671|NCT04086251|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882672|NCT03020862|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33971520|NCT05088512|||OTHER||PROSPECTIVE|||||||
33971521|NCT05723497|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34070620|NCT02966717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070621|NCT01277120|||COHORT||PROSPECTIVE|||||||
34070622|NCT05171205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070623|NCT06258707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070624|NCT04130152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070625|NCT05141929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized control study||||
34070626|NCT04288427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070627|NCT05723952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070628|NCT02766036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34070629|NCT02193555|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34070630|NCT03960333|||OTHER||CROSS_SECTIONAL|||||||
34070631|NCT05312970|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial 1:1 assignment||||
34070632|NCT00814723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070633|NCT04219761|||COHORT||PROSPECTIVE|||||||
34070634|NCT03552601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070635|NCT03381859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070636|NCT02888990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070637|NCT01308892|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34070638|NCT06082310|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Data collected on the volunteers will be made anonymous.||t|f|f|f
34070639|NCT04003623|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be assigned to 1 of 2 cohorts (Cohort A: FGFR1-3 in-frame fusions or FGFR2 intron 17 rearrangements; Cohort B: Known/predicted activating point mutations in FGFR1-3 \[excluding kinase domain\]) but there is no difference in the treatment regimen between the cohorts.||||
33971522|NCT04690413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971523|NCT02089828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971524|NCT04777032|||COHORT||PROSPECTIVE|||||||
33971525|NCT00321711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33971526|NCT01567306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971527|NCT02035137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971528|NCT00751374|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971529|NCT02761369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070640|NCT02926261|||COHORT||CROSS_SECTIONAL|||||||
34070641|NCT05815277|||OTHER||CROSS_SECTIONAL|||||||
33971530|NCT03520283|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33971531|NCT00293956|||COHORT||PROSPECTIVE|||||||
34070642|NCT04221568|RANDOMIZED|PARALLEL||OTHER||SINGLE||multiparous parturients at term pregnancy (American society of anathesiologist physical status grade II)|f|f|t|f
34070643|NCT02090387|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34070644|NCT04563637|||COHORT||PROSPECTIVE|||||||
33971532|NCT02460328|||CASE_ONLY|||||||||
33971533|NCT00745251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971534|NCT02038478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971535|NCT01070641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971536|NCT05986877|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33971537|NCT00367315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971538|NCT04035590|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study design is a randomized controlled trial. All patients are \> 18 years and will be enrolled after obtaining informed consent in the surgical out patient clinics of Zuyderland Medical Center Sittard. All patients have an indication to undergo mastectomy due to invasive breast cancer or DCIS.~Follow up will be performed until 6 months after surgery. Patients will be evaluated in the out patient clinic 1 week, 6 weeks, 3 months and 6 months."||||
33971539|NCT02711956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971540|NCT00087191|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971541|NCT03592381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double Blinded, Parallel group, Randomized controlled trial.|t|f|f|t
33971542|NCT00850278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971543|NCT03231618|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33971544|NCT03980379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971545|NCT02730390|||COHORT||PROSPECTIVE|||||||
33971546|NCT05427838|||COHORT||CROSS_SECTIONAL|||||||
33971547|NCT01828255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971548|NCT03020472|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971549|NCT01488578|||CASE_ONLY||PROSPECTIVE|||||||
33971550|NCT03790787||SEQUENTIAL||TREATMENT||NONE||||||
33971551|NCT04484597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33971552|NCT04111237|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|measuremenst of CO are masked from participants||t|f|f|f
33971553|NCT01414946|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971554|NCT05455242|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33971555|NCT02203136|||COHORT||PROSPECTIVE|||||||
33971556|NCT03979209|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The sample size is 45 patients. Patients will sign the consent form and get a baseline morning cortisol blood draw to confirm eligibility. Once enrolled, they will be instructed on how to perform the nasal irrigation twice a day with a 240 milliliter saline filled Neilmed bottle. Patients will receive either the 1 milligram mometasone dose, 2 milligram mometasone dose, or 4 milligram of mometasone dose. The dose assignment will be determined by the treating physician. After 12 weeks of continuous use of the mometasone irrigation, there will be a repeat morning blood draw to compare cortisol levels to the baseline blood draw.||||
33971557|NCT01093079|||COHORT||PROSPECTIVE|||||||
34070645|NCT05989919|||OTHER||OTHER|||||||
34070646|NCT06493318|||COHORT||PROSPECTIVE|||||||
34070647|NCT00683488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070648|NCT04769102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070649|NCT03282422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|f|f|t|t
34070650|NCT02904083|NON_RANDOMIZED|PARALLEL||||NONE||||||
34070651|NCT01825746|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070652|NCT04762394|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34070653|NCT02995629|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33882673|NCT05325775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, the Investigator, and other members of the staff involved with the study will remain blinded to study treatment.|"Subjects will be randomized in a 1:1:1:1 ratio to ACER-801 per one of the following dosing schedules prior to dosing:~* 50 mg BID,~* 100 mg BID,~* 200 mg BID, or~* Placebo BID~Each arm is administered orally for 14 consecutive days (28 doses)."|t|t|t|t
33882674|NCT05598255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|patient and parents, recovery nurses and study nurse will be blinded.||t|t|f|t
33882675|NCT01171235|||COHORT||PROSPECTIVE|||||||
33882676|NCT02279030|||CASE_CONTROL||RETROSPECTIVE|||||||
33882677|NCT05162066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three parallel treatment cohorts based on diagnosis of C3G, IgAN, or PMN. All eligible participants will receive open-label BCX9930.||||
33882678|NCT01711827|NA|SINGLE_GROUP||||NONE||||||
33882679|NCT01231997|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882680|NCT03213366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both Peer Leaders and participants will be masked to the group randomized to. The statistician, who will be analyzing the data, will also be masked to group assignment.|There will be two groups of Peer Leaders recruited. One group of Peer Leaders will be randomized to deliver the E-PrEP intervention and the second group of peer leaders will be randomized to deliver a general health campaign (control).|t|f|f|t
33882681|NCT00963898|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33759639|NCT04949958|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple Blinded|"Experimental: Exercise Based Manual (Supervised) Supervised exercise based Manual (exercise \& Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of combination of different exercises including warm up and rest interval~Experimental: Exercise Based Manual (Home Based) Home Based- Exercise Manual (Exercise \& Educational Component) for 16 weeks. Subject will be asked to maintain a regular exercise and dietary education to ensure adherence to the program~Placebo Comparator: Control Age matched Control Group followed for 16 weeks with General Advise to be active."|t|f|t|t
33882682|NCT05296577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882683|NCT01064167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882684|NCT03319862|||COHORT||RETROSPECTIVE|||||||
33882685|NCT02693314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33882686|NCT04280354|||CASE_CONTROL||PROSPECTIVE|||||||
33882687|NCT01499017|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33882688|NCT04747015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33882689|NCT01009957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882690|NCT01155115|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882691|NCT05197231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882692|NCT02266680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882693|NCT03437551|||CASE_CROSSOVER||PROSPECTIVE|||||||
33882694|NCT03036527|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882695|NCT04357106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882696|NCT03851783|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stepped-wedge cluster randomized controlled trial.||||
33882697|NCT02568358|||COHORT||PROSPECTIVE|||||||
33882698|NCT01484301|||COHORT||PROSPECTIVE|||||||
33882699|NCT00502333|||COHORT||PROSPECTIVE|||||||
33882700|NCT05481372|NA|SINGLE_GROUP||OTHER||NONE||Single centre feasibility study||||
33882701|NCT03094195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882702|NCT01436344|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33882703|NCT05883189|||COHORT||PROSPECTIVE|||||||
33882704|NCT05031026|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971558|NCT04184310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971559|NCT02356965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971560|NCT06087809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971561|NCT00395083|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971562|NCT04899856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is an open label, randomized, cross-over study in adult open cardiac surgery patients. All subjects will receive TransLoc electrodes at the time of open sternotomy cardiac procedure. Half of subjects will have TransAeris turned on upon entry to ICU, the other half will receive standard of care with TransAeris turned on if still intubated on mechanical ventilation after 120 hours.||||
33971563|NCT02087046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971564|NCT06456047|||COHORT||PROSPECTIVE|||||||
33971565|NCT03191747|||CASE_ONLY||CROSS_SECTIONAL|||||||
33971566|NCT00935987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971567|NCT02770183|||COHORT||PROSPECTIVE|||||||
33971568|NCT03112356|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971569|NCT03954561|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33971570|NCT05966857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"During the 30-day telemonitoring period in the TLM (Telemonitoring) group, the ECG report evaluator was blinded to the patient's clinical condition and the presence of underlying atrial fibrillation (AF).~This masking approach was adopted to ensure that the evaluator was not influenced by prior clinical information or knowledge of the presence of AF before analyzing the ECG results provided by the smartwatch. The objective is to ensure impartiality and objectivity in the evaluation of the data obtained during the telemonitoring period.~By keeping this information hidden from the evaluator, a more unbiased and accurate analysis of the results can be achieved, without the influence of prior knowledge about the patient's clinical condition or the presence of AF. This contributes to ensuring the validity and reliability of the results obtained through smartwatch telemonitoring in the TLM group."|This interventional study utilized a parallel assignment model to develop and validate an assisted digital telemonitoring platform for patients with POAF. The telemonitored group received interventions and telemonitoring through the platform, while the control group followed the standard institutional patient journey without any intervention or telemonitoring.|f|f|f|t
33971571|NCT06544798|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to the follow-up group or active treatment group based on the group to which they were randomized in Study MGT-AQP1-201.||||
33971572|NCT02287454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971573|NCT00790374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971574|NCT01396642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971575|NCT05729100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33971576|NCT04085081|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33971577|NCT05007691|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||patients are included in a single study group. In a study group, each patient is assessed for both of the same primary treatment. The final results for each of the treatments for each patient are used for further analysis by the finite element method.||||
34070654|NCT04387409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The reconstitution and administration of trial intervention will be done by unblinded site personnel who will not be involved in the collection or evaluation of outcome data.|Subjects who fulfil the inclusion/exclusion criteria will be centrally randomized in a 1:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or Placebo.|t|f|t|t
33882705|NCT05241327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Randomized placebo-controlled trial (RCT)|t|t|t|t
33882706|NCT03644433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33882707|NCT03056573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Portico TF and ALT Delivery System||||
33882708|NCT05997355|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Treatment with gabapentin vs no treatment||||
33882709|NCT04787965|||COHORT||PROSPECTIVE|||||||
33882710|NCT05730595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882711|NCT02218918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Treadmill training vs ground walk training|f|f|f|t
34070655|NCT06236048|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33882712|NCT00654498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882713|NCT03220672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882714|NCT04622176|||COHORT||PROSPECTIVE|||||||
33882715|NCT05595278|||CASE_ONLY||PROSPECTIVE|||||||
33882716|NCT05054725|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33882717|NCT03581851|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath trough a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia|t|f|f|f
33882718|NCT04525716|||COHORT||PROSPECTIVE|||||||
33882719|NCT01238692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882720|NCT00369187|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33882721|NCT05156294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical examiners evaluating and recording the outcome measurements will be masked to the treatment allocation and the patients will be asked not to reveal their treatment assignment to the examiners.|doubled-blind, parallel groups, randomized clinical trial|f|f|t|t
33882722|NCT03664245|||COHORT||PROSPECTIVE|||||||
33882723|NCT05644574|||CASE_ONLY||PROSPECTIVE|||||||
33882724|NCT01207271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882725|NCT04058327|||COHORT||PROSPECTIVE|||||||
33882726|NCT04820400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882727|NCT02396732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882728|NCT05535881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The current study is a two-wave randomized controlled trial that employs a 2 (group - between participants) by 2 (time - within participants) mixed measures design to assess a brief online strength-based parenting program.||||
33882729|NCT04126382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882730|NCT02711280|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33882731|NCT06542315|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Statisticians|Multi-arm parallel group pilot trial|t|f|t|t
33882732|NCT03669809|||COHORT||OTHER|||||||
33882733|NCT03429946|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Investigator performing the clamp studies is only aware of the type of clamp - euglycemic versus hypoglycemic - but not aware of placebo versus spironolactone.|Participants complete all 3 arms of the study in random order.|t|f|t|t
33882734|NCT02301923|||COHORT||RETROSPECTIVE|||||||
33882735|NCT04143269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882736|NCT02748460|||CASE_ONLY||PROSPECTIVE|||||||
33882737|NCT05547646|||COHORT||CROSS_SECTIONAL|||||||
33882738|NCT01110395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882739|NCT02595190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882740|NCT02971878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882741|NCT02067754|||OTHER||OTHER|||||||
33882742|NCT01769092|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33882743|NCT04429126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882744|NCT03739073|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882745|NCT05408520|RANDOMIZED|PARALLEL||TREATMENT||NONE||A traditional amputation follows the normal standard of care, with transection of peripheral nerves. The TMR procedure will transfer the transected nerves to adjacent muscle nerves.||||
33882746|NCT03657901|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized control trial with a cross-over design.||||
33882747|NCT00170430|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33882748|NCT05271513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|masking enclosed envelop||t|t|t|t
33882749|NCT05031741|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will assign participants a Telemedicine or In-person Mobile unit card as they enroll in the study at events. Teens with a telemedicine card will get education exposure to telemedicine with a video and an ipad that demonstrates a pretend telehealth visit. Teens with an In-person mobile unit card will have the opportunity to learn how a health visit can be done on the unit with a health care provider.||||
33882750|NCT04566575|||COHORT||RETROSPECTIVE|||||||
33882751|NCT01412970|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882752|NCT01491256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759640|NCT04859725|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"During the first 9 months, the initially collected spectrally corrected datacubes will be analyzed using machine learning. After 9 months, an interim analysis will be made on the datacubes from this primary set with an estimated 10 participants.~If a reliable and robust discriminative signal can be detected in low grade glioma tissue, segregating these signals from those in normal tissue, the trial will go on collecting samples for the following 26 months with an inclusion of 10 to 15 participant per year. Within the expanded dataset, the different spectral data patterns will be translated into user's friendly pattern codes for rapid real-time, on-site detection and interpretation through development of dedicated software.~If no reliable signal can be retrieved from low grade glioma tissue in vivo during the surgery, further recruitment of patients will be stopped. At that time, a decision will be taken on whether or not relevant amendments to the study will be proposed."||||
34070656|NCT06272149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759641|NCT03582774|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759642|NCT02513108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|original sample size calculation is amended from 151 patients to 82 patients after recalculation|||||
33759643|NCT05765279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33759644|NCT01806584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759645|NCT06469749|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention will be a pilot trial, conducted through a Randomized controlled trial design.||||
33759646|NCT03065296|NA|SINGLE_GROUP||OTHER||NONE||||||
33759647|NCT03041779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759648|NCT00639730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759649|NCT00420199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759650|NCT06128733|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Modified double-blind: in order to maintain the blind, a placebo injection will be given and blood sample will be collected from all participants at each visit||t|f|t|t
33759651|NCT02524041|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882753|NCT02995304|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33882754|NCT03992625|||OTHER||RETROSPECTIVE|||||||
33882755|NCT03664414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Plaebo controlled|blinded,multicenter, randomized, pentoxifylline vs placebo controlled clinical trial. Time: two years after the enrollment of the last patient.|t|f|t|f
33882756|NCT00880256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882757|NCT02935400|||OTHER||PROSPECTIVE|||||||
33882758|NCT05164445|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33882759|NCT00248703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882760|NCT04765280|||OTHER||CROSS_SECTIONAL|||||||
33882761|NCT05368610|||CASE_CONTROL||PROSPECTIVE|||||||
33882762|NCT01657578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33882763|NCT02544412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33882764|NCT02294513|||CASE_CONTROL||PROSPECTIVE|||||||
33882765|NCT02582957|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882766|NCT02801214|||COHORT||CROSS_SECTIONAL|||||||
33882767|NCT04189679|||COHORT||PROSPECTIVE|||||||
33882768|NCT00897078|||CASE_ONLY||PROSPECTIVE|||||||
33882769|NCT01078766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882770|NCT06300853|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882771|NCT00262431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882772|NCT02549482|NA|SINGLE_GROUP||||NONE||||||
33882773|NCT06548204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882774|NCT04857099|||CASE_ONLY||RETROSPECTIVE|||||||
33882775|NCT01627860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882776|NCT02103868|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882777|NCT03842930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882778|NCT01975532|||CASE_ONLY||PROSPECTIVE|||||||
33882779|NCT06550037|||CASE_ONLY||PROSPECTIVE|||||||
33882780|NCT03516344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882781|NCT05184647|||OTHER||RETROSPECTIVE|||||||
33882782|NCT01481675|||CASE_ONLY||PROSPECTIVE|||||||
33882783|NCT03768947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882784|NCT05630287|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882785|NCT04418765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070657|NCT01744483|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34070658|NCT04110171|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070659|NCT03603561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34070660|NCT04767971|||OTHER||RETROSPECTIVE|||||||
34070661|NCT02296762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070662|NCT03056014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blind||t|f|f|f
34070663|NCT03887208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients receive injections of autologous SVF or ADSC cells isolated in the laboratory from adipose tissue.|t|f|t|f
34070664|NCT04798326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070665|NCT04662723|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the enrolment the eligible biopsy-proven IgAN patients will be randomized, separately, in each trial in a 1 to 1 ratio via a web-based program generating random numbers. The allocation will be not blinded to the group of assignment.||||
34070666|NCT00642603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070667|NCT01113307|||COHORT||PROSPECTIVE|||||||
34070668|NCT00274378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33882786|NCT04102969|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinding will be used in this study, by not telling the participants, interventionist, and research assistants what the researcher is looking for to study, what the research outcomes are, and by making them not aware who is receiving the intervention or in which group they are in control or intervention group. So, the participants, interventionist, and research assistants who are in the study will be less likely to inadvertently bias the result.|"A cluster randomized controlled trial design (RCT) with two conditions (experimental versus control group) and four repeated measures time points for this study; at baseline test (before intervention), a post-test (immediately after the intervention), and follow up at one month post-intervention, and follow up at two months' post-intervention.~Two hospitals will be divided in to Experimental and control hospital. participants in the experimental hospital will receive the intervention of Benson Relaxation technique (Intervention group).~participants in the control hospital will receive the nutrition package session (control group)."|t|f|t|t
33882787|NCT06502093|||COHORT||CROSS_SECTIONAL|||||||
33882788|NCT00006023||||TREATMENT||||||||
33882789|NCT05928975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked assessor will conduct the measurements|Sixty participants with non-specific chronic low back pain will be randomly assigned to three groups of 20 each. The allocation of the sample to the groups will be performed using a randomization program (https://www.randomizer.org/) by an independent researcher. The first group will receive MT and PNE with MI, the second group will receive MT alone, while participants in the control group (third group) will follow a home-based exercise program. Participants of the two intervention groups will follow a total of 10 treatment sessions over a period of 4 weeks.|f|f|f|t
33882790|NCT02836015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882791|NCT05649995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882792|NCT01450423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882793|NCT01051141|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882794|NCT01207973|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33882795|NCT05220605|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070669|NCT00199849|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070670|NCT02799888|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34070671|NCT02508103|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34070672|NCT02477371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070673|NCT02237989|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34070674|NCT00680615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070675|NCT01411514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070676|NCT02550236|||COHORT||PROSPECTIVE|||||||
34070677|NCT02254356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070678|NCT00768885|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34070679|NCT06013514|||COHORT||PROSPECTIVE|||||||
33882796|NCT03099707|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882797|NCT02586792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882798|NCT05230888|||COHORT||PROSPECTIVE|||||||
33882799|NCT04979754|||OTHER||RETROSPECTIVE|||||||
33882800|NCT03370159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070680|NCT00071838||||TREATMENT||||||||
34070681|NCT04645329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes assessor will be blinded to the allocation of the patients|Randomized prospective study. (computer-generated randomization list and saved in opaque envelopes)|f|f|f|t
34070682|NCT06045494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070683|NCT01219192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882801|NCT01791907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882802|NCT02769728|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|The endobarrier device was implanted and explanted under general anaesthesia by trained gastroenterologists.||||
33882803|NCT01871584|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33882804|NCT02112500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882805|NCT06492044|NA|SINGLE_GROUP||OTHER||NONE||||||
33882806|NCT00682266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882807|NCT03276611|||COHORT||PROSPECTIVE|||||||
33882808|NCT02013843|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33882809|NCT03167073|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The coding team has labeled BFF and the dummy app as BFF-1 and BFF-2. The research team is blinded to which app is BFF-1 and which is BFF-2. Sprint Telecommunications will receive the .apks files for both apps and load one app to each research phone according to the randomization algorithm that researchers at Washington University will provide to them. This algorithm has been created to randomize participants in blocks of four. Sprint will then send the phones to the research team with labels on the box that state the research phone number and app number (ie, phone 18, BFF-2). Participants will be given the phones in a sequential manner. After the study is completed, the researchers will contact the coding team, and the study will be un-blinded."|All participants will receive a complementary android phone with 3 months of complementary internet service upon enrollment at approximately 36 weeks gestation. Women will be randomized to receiving Breastfeeding Friend (BFF; the intervention) or a dummy app (control), which looks identical to BFF but contains limited breastfeeding content available during routine prenatal care.|t|t|t|t
33882810|NCT04405375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882811|NCT00610142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33882812|NCT03439709|RANDOMIZED|PARALLEL||TREATMENT||NONE|Technically, the procedure of gamma knife radiosurgery includes fixating stereotactic frame on the head of patients. Therefore, It is not possible to keep masking for participants and other investigators.|The patients with acromegaly due to growth hormone secreting pituitary adenoma who receive primary surgical resection and fail to achieve endocrinologic remission at 3 months after surgical resection are enrolled. They are devided into two groups; One consists of patients underwent upfront stereotactic radiosurgery combinated with standard drug therapy, and another group consists of patients receiving only standard drug therapy.||||
33882813|NCT01910675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882814|NCT03588377|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33882815|NCT04072757|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882816|NCT02337790|||COHORT||RETROSPECTIVE|||||||
33882817|NCT05664165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882818|NCT05139225|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A standard 3+3 dose escalation design.||||
33882819|NCT06399497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to the intervention assigned to each participant.||f|f|f|t
33882820|NCT01663948|||COHORT||PROSPECTIVE|||||||
33882821|NCT02419885|||CASE_ONLY||RETROSPECTIVE|||||||
33882822|NCT05788731|||CASE_ONLY||PROSPECTIVE|||||||
33882823|NCT01647607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33882824|NCT04938505|||COHORT||PROSPECTIVE|||||||
33882825|NCT05443204|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned in a 1:1 ratio||||
33882826|NCT01227447|||||PROSPECTIVE|||||||
33882827|NCT00291551|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971578|NCT03458507|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The patients will be randomized for two periods of one week to use NIV either with nasal or oronasal mask. The randomization will be stratified according to the type of interface previously used at home by the patient (nasal and oronasal). Such stratification will allow a balance between the number of patients that will begin with their usual interface versus with an alternative interface. In these patients, NIV withdrawal is not acceptable in terms of patient's security and ethics. Therefore, it is not possible to include a wash out period between both arms. The potential carry-over effect will be taken into account in the statistical analysis.||||
33971579|NCT05563597|||CASE_CONTROL||PROSPECTIVE|||||||
33971580|NCT02197728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759652|NCT04189354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882828|NCT02584192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070684|NCT03075332||SEQUENTIAL||PREVENTION||NONE||This is a longitudinal study of the non-randomized experimental type, presenting a non-probabilistic sample for convenience and independent groups. The sample consisted of 21 individuals divided into 2 groups: Experimental Group (EG) and Control Group (CG). The EG was composed of 11 people living with HIV/AIDS and CG composed of 10 people with no infection||||
33882829|NCT03036293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882830|NCT06207266|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants with opioid use disorder were divided into two groups: group with emotion intelligence program (n=20) and group without intelligence program (n=20). A healthy group (n=20) served as a control group.|t|f|f|f
33882831|NCT02604940|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33882832|NCT04044833|||OTHER||PROSPECTIVE|||||||
33882833|NCT02903537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882834|NCT04580290|||CASE_ONLY||RETROSPECTIVE|||||||
33882835|NCT04498845|RANDOMIZED|PARALLEL||PREVENTION||NONE||After a cross sectional preliminary trial of the in-home family educational session in a one time home visit, there will be 3 types of interventions (basic, intermediate, and advanced) conducted in \~20 homes with \~50 participants for each intervention type.||||
34070685|NCT03067922|||COHORT||PROSPECTIVE|||||||
33882836|NCT05644366|NA|SINGLE_GROUP||SCREENING||NONE||The balance assessment procedure included the following; each subject was instructed to stand on both feet for 15 seconds on the pressure MatScan under eight different conditions.||||
33882837|NCT01548001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882838|NCT03993366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This study is a randomized, 2-way, crossover trial assessing:~i. Fiasp-alone closed-loop system with full carbohydrate counting ii. Fiasp-plus-Pramlintide closed-loop system with simple meal announcement in regulating glucose levels in patients with type 1 diabetes, over a period of 24h in an inpatient setting."||||
33882839|NCT00000559|RANDOMIZED|||PREVENTION||DOUBLE||||||
33882840|NCT05599997|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882841|NCT03382574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882842|NCT04541004|NA|SINGLE_GROUP||TREATMENT||NONE|Non applicable|single-armed||||
33882843|NCT06000358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882844|NCT01061450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882845|NCT04475692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be an assessor-blinded protocol, due to the nature of the intervention, participants cannot be blinded.|A multicentre pilot RCT, parallel design, comparing intervention group (self-selected dose of self-directed technology-based UL exercise as an adjunct to conventional care) with a control group receiving conventional care only.|f|f|f|t
33882846|NCT05922865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882847|NCT05616702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070686|NCT05659303|||COHORT||RETROSPECTIVE|||||||
34070687|NCT04040647|||COHORT||PROSPECTIVE|||||||
34070688|NCT03373253|||COHORT||PROSPECTIVE|||||||
34070689|NCT04464408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070690|NCT04140812|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34070691|NCT02813473|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070692|NCT02442648|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070693|NCT06253910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double (Participant, Investigator)||t|f|t|f
34070694|NCT00299403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070695|NCT03000322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070696|NCT00274547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070697|NCT02308228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34070698|NCT03570203|||COHORT||OTHER|||||||
33971581|NCT05228119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882848|NCT02181166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882849|NCT03879941|||COHORT||RETROSPECTIVE|||||||
33882850|NCT03665051|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882851|NCT00331409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882852|NCT02153567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882853|NCT05239520|||COHORT||PROSPECTIVE|||||||
33882854|NCT01833884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882855|NCT05854901|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||This is a prospective randomized clinical multi-center study to evaluate procalcitonin-guided treatment regarding antibiotic use in patients who are admitted because of an acute COPD exacerbation. Patients who are admitted are randomly assigned to either procalcitonin-guided treatment (in which antibiotics are started when the procalcitonin concentration is above 0.25 ng/mL) or usual care in which the treating physician decides whether or not to start with antibiotic treatment. Patients will be stratified for study center.|f|f|f|t
33882856|NCT03963609|||COHORT||CROSS_SECTIONAL|||||||
33882857|NCT00374738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882858|NCT01636466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882859|NCT03280160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882860|NCT04429815|||COHORT||PROSPECTIVE|||||||
33882861|NCT01370395|||COHORT||PROSPECTIVE|||||||
33882862|NCT06481761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, neither participants nor investigators can be blinded.|study is a randomized clinical trial, single-center, parallel group, two-arms with 1:1 allocation ratio|f|f|f|t
33882863|NCT01899170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882864|NCT05299385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882865|NCT02944448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882866|NCT02381431|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882867|NCT01014845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33882868|NCT03024775|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33882869|NCT02734251|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33882870|NCT06348342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Before starting the research, four groups of mothers will be randomly formed. As a randomization method, mothers who meet the sampling inclusion criteria determined in the research will be identified and listed. Individuals to be taken into two groups will be determined by randomization method from the random numbers table. (http://www.stattrek.com/statistics/randomnumbergenerator.aspx).|t|f|f|t
33882871|NCT01092845|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33882872|NCT01238939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882873|NCT04880187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882874|NCT00837785|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882875|NCT03308864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882876|NCT05666531|||OTHER||PROSPECTIVE|||||||
33882877|NCT04142983|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882878|NCT01801098|||COHORT|||||||||
33882879|NCT06214260|||CASE_CONTROL||PROSPECTIVE|||||||
33882880|NCT02007603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882881|NCT01465308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33882882|NCT03344666|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33882883|NCT01554930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882884|NCT02900703|||COHORT||PROSPECTIVE|||||||
33882885|NCT00330187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882886|NCT06348381|||COHORT||PROSPECTIVE|||||||
33882887|NCT01925209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882888|NCT03885271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33882889|NCT01660217|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33882890|NCT02887131|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33882891|NCT02491294|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33882892|NCT00272987|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33882893|NCT06419114|||OTHER||PROSPECTIVE|||||||
33971582|NCT02386592|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971583|NCT06002295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971584|NCT04544891|||COHORT||PROSPECTIVE|||||||
33971585|NCT04180345|||CASE_ONLY||RETROSPECTIVE|||||||
33882894|NCT01450982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882895|NCT04437212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882896|NCT00376467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882897|NCT04660643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882898|NCT06128655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882899|NCT00016666||||TREATMENT||||||||
33882900|NCT02280213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33882901|NCT01717131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882902|NCT06488261|||COHORT||PROSPECTIVE|||||||
33882903|NCT04840472|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33882904|NCT05455047|||COHORT||RETROSPECTIVE|||||||
33882905|NCT01924208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882906|NCT04702932|||COHORT||PROSPECTIVE|||||||
33882907|NCT00207415|RANDOMIZED|PARALLEL||ECT||NONE||||||
33882908|NCT01964235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882909|NCT06451432|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention (different type of scars), masking is not possible.|Randomized controlled trial comparing two study groups||||
33882910|NCT01882907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882911|NCT02613728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33882912|NCT04041895|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33882913|NCT00801866||||TREATMENT||||||||
33882914|NCT03341169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A Randomized, Double-Blinded, Placebo-Controlled Trial|t|t|t|t
33882915|NCT03373565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882916|NCT06358222|||COHORT||PROSPECTIVE|||||||
33882917|NCT00703664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882918|NCT01323205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882919|NCT04291755|||CASE_ONLY||PROSPECTIVE|||||||
33882920|NCT05152082|||CASE_CONTROL||RETROSPECTIVE|||||||
33882921|NCT01511653|||CASE_CONTROL||PROSPECTIVE|||||||
33882922|NCT05364411|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two parallel, non-comparative phase-I trials of HYDRA-protons run at HollandPTC (group 1, n=25) and HYDRA-photons (group 3, n=25) run at the Erasmus MC. Toxicity will be monitored until 1 year after the last patient has completed HYDRA. This will result in a median follow-up of approximately 2 years. Patients will subsequently receive follow-up according to standard of care up to 5 years after treatment for the evaluation of very late-onset toxicity.~For translational immune profiling, HYDRA-protons and HYDRA-photons will be randomized by minimization (1:1 ratio) against SOC: conventional fractionated proton therapy in HPTC (group 2, n=25) and conventional fractionated photon therapy in the Erasmus MC (group 4, n=25), respectively."||||
33882923|NCT00524537|||COHORT||PROSPECTIVE|||||||
33882924|NCT01775631|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971586|NCT02631109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971587|NCT01373606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971588|NCT02448459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971589|NCT05141266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971590|NCT01575392|||||CROSS_SECTIONAL|||||||
33971591|NCT02429869|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971592|NCT02115191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33971593|NCT05064813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33971594|NCT04280172|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33971595|NCT03008460|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33759653|NCT00533104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759654|NCT02979639|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33759655|NCT03221725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759656|NCT01624948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882925|NCT01747421|||COHORT||PROSPECTIVE|||||||
33882926|NCT02160405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882927|NCT04672161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882928|NCT04755946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33882929|NCT01963481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882930|NCT02499029|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33882931|NCT00292500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33882932|NCT02738658|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33882933|NCT02816957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882934|NCT01121380|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33882935|NCT01997463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882936|NCT02082678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882937|NCT06253039|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33882938|NCT06425809|||COHORT||CROSS_SECTIONAL|||||||
33882939|NCT03050580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882940|NCT05719480|||COHORT||OTHER|||||||
33882941|NCT00763321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882942|NCT04264871|||COHORT||RETROSPECTIVE|||||||
33882943|NCT06500832|||OTHER||CROSS_SECTIONAL|||||||
33882944|NCT00000645||||TREATMENT||NONE||||||
33882945|NCT00328146|||OTHER||RETROSPECTIVE|||||||
33882946|NCT03247894|||COHORT||OTHER|||||||
33882947|NCT00624520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882948|NCT03285230|||COHORT||PROSPECTIVE|||||||
33882949|NCT04991701|||COHORT||RETROSPECTIVE|||||||
33882950|NCT06528470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33882951|NCT04307238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double blinded study design (participants, evaluator)||t|f|t|f
33882952|NCT04774965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33882953|NCT02397850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759657|NCT03921125|||CASE_CONTROL||PROSPECTIVE|||||||
33759658|NCT03261284|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||D-dimer is mornitored. If D-dimer levels continue to rise (\>1.5 times previous result ), increase the dose of heparin to reach the upper limit of the treatment target; If the D-dimer levels is stable (\<1.5 times previous result ) or is decreasing, the anticoagulation dose is maintained at current level (no active bleeding) or decreased (active bleeding).||||
33759659|NCT01737346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759660|NCT00002180||||TREATMENT||DOUBLE||||||
33759661|NCT00290602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759662|NCT04093674|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Split mouth|t|f|t|t
33759663|NCT04111757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759664|NCT00264420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759665|NCT06286085|||COHORT||PROSPECTIVE|||||||
33759666|NCT04295954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assignment to groups will be blind. A random number computer application will be awarded each participant to a group.|Two groups will be formed with women who meet the inclusion criteria. Each participant will be randomly assigned to each group, receiving different treatment depending on the group in which it has been assigned: the intervention group will receive yoga intervention and the control group will continue with its conventional treatment for the dysmenorrhea.|f|f|f|t
33759667|NCT04602884|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759668|NCT00056225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33759669|NCT01600664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33759670|NCT01820949|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33759671|NCT02127086|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759672|NCT01873170|||COHORT||PROSPECTIVE|||||||
33759673|NCT04939545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators, care providers, data analyst and trial participants are blinded|Prospective, placebo-controlled, randomised, double-blind, superiority|t|t|t|t
33759674|NCT06525818|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33759675|NCT06448338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33759676|NCT05484388|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||"This is a prospective, randomized pre-market feasibility clinical investigation designed to evaluate the clinical performance and safety of the investigational product in its intended target population.~The clinical investigation is designed according to the ISO 14155:2020 as follows:~Prospective.~Randomized cross-over.~Interventional but non-invasive.~Decentralized in a home-care environment.~A pairwise comparative study."|f|f|t|f
33759677|NCT05771701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The raters will be unaware of each other's test results. Furthermore, the participants will not be informed of their results. Assessor and investigator will be blinded from the providers and participants.|Before starting the investigation, the raters will practice the procedure together in a 30-min training session on a person with lateral epicondylitis. The rater will stabilize the participant's elbow with one hand. The most tender spot in the joint line of each elbow identified by palpation will be assessed with PPT algometry three times with ≥20-second intervals by each rater in a single session. The rubber tip will be placed perpendicular to the skin. The participants will be instructed to give a verbal signal as soon as the sensation of pressure turns into pain, at which time the rater will immediately remove the algometer and record the score. The display of the algometer will face the floor during the testing to blind the raters and participants for the levels of force. There will only be one rater and participant present during the testing at a time. The pause between each rater will be approximately one minute, and the rater order will change randomly during the study period.||||
33882954|NCT03174210|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||patients will be randomized into two different Groups (prospective cross-over design)|t|f|f|t
33882955|NCT00006295|||FAMILY_BASED||PROSPECTIVE|||||||
33882956|NCT04733547|||COHORT||PROSPECTIVE|||||||
33882957|NCT05573971|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33882958|NCT06229951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882959|NCT06520189|||COHORT||PROSPECTIVE|||||||
33882960|NCT04438031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33882961|NCT05953792|||COHORT||PROSPECTIVE|||||||
33882962|NCT02171975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33882963|NCT01382459|||CASE_CONTROL||PROSPECTIVE|||||||
33882964|NCT03686501|NA|SINGLE_GROUP||OTHER||NONE||||||
33882965|NCT05350059|NA|SINGLE_GROUP||TREATMENT||NONE||High Intensity Focused Ultrasound (HIFU) treatment to breast cancer||||
33882966|NCT02416557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33882967|NCT01791855|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33882968|NCT05999825|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33882969|NCT02795078|||COHORT||PROSPECTIVE|||||||
33882970|NCT04527198|NA|SINGLE_GROUP||OTHER||NONE||||||
33882971|NCT05730400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33882972|NCT02049398|||COHORT||PROSPECTIVE|||||||
33882973|NCT05227339|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882974|NCT03440827|NA|SINGLE_GROUP||OTHER||NONE||||||
33882975|NCT00679952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33882976|NCT00067704|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33882977|NCT05116800|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882978|NCT01929304|||COHORT||PROSPECTIVE|||||||
33882979|NCT06483880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33882980|NCT00065338|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33882981|NCT02605642|||COHORT||PROSPECTIVE|||||||
33882982|NCT05982262|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33882983|NCT01700192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33882984|NCT02913157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882985|NCT01331304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882986|NCT01310335|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33882987|NCT00053248||||TREATMENT||NONE||||||
33882988|NCT02401737|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33882989|NCT05680987|NA|SINGLE_GROUP||OTHER||NONE||||||
33882990|NCT02532855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33882991|NCT01192347|||CASE_ONLY||PROSPECTIVE|||||||
33882992|NCT03027583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33882993|NCT02916654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33882994|NCT02453074|||||PROSPECTIVE|||||||
33882995|NCT00769119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33882996|NCT03514927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33882997|NCT01820442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33882998|NCT00450931|RANDOMIZED|||||||||||
33882999|NCT03345472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883000|NCT05211557|NA|SEQUENTIAL||TREATMENT||NONE||||||
33883001|NCT06176937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070699|NCT04926025|||CASE_CONTROL||PROSPECTIVE|||||||
34070700|NCT05329350|||CASE_ONLY||PROSPECTIVE|||||||
34070701|NCT00528918|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33883002|NCT02787850|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883003|NCT04663945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883004|NCT05797428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33883005|NCT00526344|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883006|NCT00517972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883007|NCT03598855|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33883008|NCT03908619|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Diagnosed H. pylori positive patients (n=252) will be randomized into four study groups:~* Group A: Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days (n=42)~* Group B: Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days (n=42)~* Group C: Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days(n=42)~* Group D: Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days (n=42)"||||
33883009|NCT03473132|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study of consecutive patients.||||
33883010|NCT04538391|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Each woman received a disposable syringe containing a medication corresponding to her order of participation in the trial. Packing. Sealing and numbering were performed by health care provider who did not actively share in the process of the study.|"Group A (bupivacaine group): included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with 20 ml of 0.25% bupivacaine hydrochloride. (Marcaine, 25% vial, Astra Zeneca) diluted in 20 ml of 0.9% saline.~Group B (meloxicam group): included 35 patients in which and subcutaneous tissue (upper and lower flaps) were infiltrated with meloxicam 15mg (Anticox 2 ampoule 15mg/3ml, ADWIA Pharmaceuticals). diluted in 20 ml of 0.9% saline.~Group C (placebo group): included 35 patients in which skin and subcutaneous tissue was infiltrated with 20 ml 0.9% saline."|t|t|t|f
33883011|NCT00222859|||||PROSPECTIVE|||||||
33883012|NCT02580500|RANDOMIZED|PARALLEL||||NONE||||||
33883013|NCT01461174|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33883014|NCT04232735|NA|SINGLE_GROUP||OTHER||NONE||Pragmatic Stepped Wedge Design||||
33883015|NCT03380910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883016|NCT04458844|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Cluster randomised control trial.||||
33883017|NCT02262494|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883018|NCT00720460|||CASE_ONLY||PROSPECTIVE|||||||
34070702|NCT02066597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070703|NCT05756751|NA|SINGLE_GROUP||TREATMENT||NONE||Impella 5.5® with SmartAssist® (Impella 5.5®)||||
34070704|NCT02379455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34070705|NCT05391880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070706|NCT02100735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34070707|NCT00151086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070708|NCT05649696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34070709|NCT03180957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During Dose Response part of the trial the Investigator will be blinded. During the Early Disease part of the trial the Investigator will not be blinded but will not carry out any outcome assessments.||t|t|t|t
34070710|NCT06199427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759678|NCT00114608|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33759679|NCT03965156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759680|NCT03200106|||CASE_CONTROL||RETROSPECTIVE|||||||
33759681|NCT05127525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34070711|NCT02816320|||COHORT||RETROSPECTIVE|||||||
34070712|NCT04520906|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, multi-center, single-group target value||||
34070713|NCT03664921|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34070714|NCT01227525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070715|NCT03049423|||OTHER||PROSPECTIVE|||||||
34070716|NCT00264251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070717|NCT00823030|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34070718|NCT01998347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070719|NCT00250809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070720|NCT05365919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A cluster-randomized trial will be conducted at 12 homecare services (6 services=intervention, 6 services=control).||||
33759682|NCT04955834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759683|NCT04885933|||COHORT||PROSPECTIVE|||||||
33759684|NCT03379194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|For final data analysis the biostatistician will be blinded for treatment allocation of physicians.||t|f|t|t
33759685|NCT04537468|NA|SEQUENTIAL||OTHER||NONE||"The study consisted of 3 sequential groups:~1. Collection of skin squames by scraping.~2. Collection of tape strip samples.~3. Collection of tape strip samples and skin biopsies."||||
33759686|NCT00656279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33759687|NCT02706314|||CASE_CONTROL||PROSPECTIVE|||||||
33759688|NCT01406522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759689|NCT03292848|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33759690|NCT02839343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759691|NCT02187913|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33759692|NCT04440839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients identified as having a lower extremity wound with peripheral artery disease or diabetes mellitus are offered a telemedicine consult. Patients are then followed for time to consultation, time to revascularization if needed, and time to wound healing.||||
33759693|NCT04876040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759694|NCT04504331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759695|NCT01968525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759696|NCT04424784|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33759697|NCT03727243|||COHORT||PROSPECTIVE|||||||
33759698|NCT00824980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759699|NCT01542957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33759700|NCT00003578|RANDOMIZED|||TREATMENT||||||||
33883019|NCT00926692|||CASE_ONLY||PROSPECTIVE|||||||
33971596|NCT02735083|NA|SINGLE_GROUP||OTHER||NONE||||||
33971597|NCT00021502|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971598|NCT00820235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971599|NCT00004812||||TREATMENT||||||||
33759701|NCT03831243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All subjects will be randomly assigned in a 1:1 ratio to receive either a single fraction of 8.0 Gy to the painful bone metastasis through 3D-CRT (control arm) or a single fraction of 20.0 Gy to the painful bone metastasis through SBRT (experimental arm).|t|f|f|f
33759702|NCT04709172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759703|NCT02573922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759704|NCT03265106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759705|NCT02158117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759706|NCT01331057|||OTHER||PROSPECTIVE|||||||
33759707|NCT01119898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759708|NCT02888470|||COHORT||PROSPECTIVE|||||||
33759709|NCT05788302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971600|NCT02643901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971601|NCT05727267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971602|NCT05417399|||COHORT||CROSS_SECTIONAL|||||||
33971603|NCT04499183|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33971604|NCT01636297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971605|NCT00100490|||||PROSPECTIVE|||||||
33971606|NCT03297359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971607|NCT01066494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971608|NCT03205384|||COHORT||PROSPECTIVE|||||||
33971609|NCT05928000|||COHORT||PROSPECTIVE|||||||
33971610|NCT03832933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971611|NCT00386672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971612|NCT01703741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971613|NCT00102869|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33971614|NCT03654898|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigators, Data analysis||f|f|f|t
33971615|NCT01928784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971616|NCT04521400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971617|NCT00310856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971618|NCT05113225|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|the oocytes of each patient will be randomly divided before denudation and will be distributed in the ICSI dishes of different previously described PVP pattern and sperm processing|Single group of patients will be recruited in the study and each patient's oocytes will be divided into two groups and each group of patients will be injected with sperm processed by normal DG or H pattern micro- swim up technique. The PVP was used to produce the H pattern (length of about 2 cm from one side of the plate to the middle of the disk, total volume 10 μL). A small amount of semen (3 μL) was placed on one side of the H, and some time was allowed for it to migrate to the other side where the sperm was then collected. The dishes were incubated for three minutes allowing sperm migration along the outer perimeter of the H. After the completion of sperm migration, the plate was turned before the upload to avoid the contamination of the injection pipette by the sample.The injection pipette was introduced into the H-ICSI™ and used to immobilize a single sperm by crushing the membrane of its tail.|t|t|f|f
33971619|NCT05785520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971620|NCT02748109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971621|NCT02278679|||COHORT||PROSPECTIVE|||||||
33971622|NCT04625582|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Ante-post evaluation study of the effectiveness of an educational intervention to improve empathy, with three arms: face-to-face, online and control group, lasting 2 years. The intervention is organized during the training of residents of Family Medicine and Community Nursing in three teaching units in different Spanish Health Authorities.|f|f|f|t
33971623|NCT02259842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971624|NCT03339882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759710|NCT04453423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759711|NCT06256289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759712|NCT01355601|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33759713|NCT00567021|||||PROSPECTIVE|||||||
33759714|NCT02710292|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33759715|NCT00736489|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33759716|NCT05781425|||OTHER||PROSPECTIVE|||||||
33759717|NCT05601401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759718|NCT05100225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blinded trial, in which neither participant nor investigator will know the content of the investigational product. Additionally, the study staff preparing the syringe. The unblinded personnel must not be involved in any other operational aspects of the trial.|A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study|t|f|t|f
33883020|NCT05167019|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Patients will be blinded to the 4 months intervention period in junior and senior doctors.|Sample size for this stepped wedge randomised controlled trial is listed for patients potentially receiving excessive treatment (n=1700) together with one of their relatives who will be identified by junior doctors (n=75) , senior doctors (n=75) and nurses (n= 600) working in 10 departments of the Ghent university hospital during a 12 months period. Junior and senior doctors working in each department will be coached in self-reflective and empowering leadership, and in managing group dynamics with regard to patients potentially receiving excessive treatment for whom they are in charge of during a 4 month period. The impact of the intervention on the quality of ethical decision-making will be assessed at the patient (n=1700), relatives (n=1700) and team level (n=750).|t|f|f|f
33883021|NCT06308770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician who analyses the results will be blind to the intervention to which the participant was randomised.|"The pilot study for the FLIP trial is a single centre three arm, randomised controlled trial (RCT) comparing the effectiveness of a virtual group fatigue management intervention with standard care in SLE participants. Participants will self-enrol via a secure database and then be randomised electronically to one of the three interventions;~1. Standard care (SC) - Lupus UK and Versus Arthritis Booklets~2. SC and 4 week Fatigue management Programme (FMP)~3. SC and 7 week FMP Results will be measured by comparing Patient Reported Outcome measures (PROMs) submitted before and after the intervention and, at 6 and 12 months."|f|f|f|t
33883022|NCT02161562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971625|NCT05423756|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomized controlled trial||||
33971626|NCT04237571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971627|NCT00987987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971628|NCT05628623|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to 1 of 4 arms in a 1:1:1:1 ratio.||||
33971629|NCT00352079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971630|NCT05024461|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971631|NCT02473328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971632|NCT03074526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Approximately 180 subjects will be enrolled in one of three dose arms ( 4ml, Saline Placebo and 4ml 2x).|t|f|t|f
33971633|NCT01749176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971634|NCT00496184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971635|NCT01056757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971636|NCT04606563|RANDOMIZED|PARALLEL||TREATMENT||NONE|Our RCT uses blinded randomization and a usual care control.|||||
33971637|NCT05751681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971638|NCT05012306|||COHORT||PROSPECTIVE|||||||
34070721|NCT04351880|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a randomized trial to compare two approaches to meal delivery. Group 1 will receive meal delivery for 2 weeks (1 meal per day for a total of 14 days) and Group 2 will receive meal delivery for 4 weeks (1 meal per day for a total of 28 days). A concurrent propensity matched control group which will not receive an intervention will also be used.|f|f|t|f
34070722|NCT03300362|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators recording clinical outcomes will also be blinded||t|f|f|f
34070723|NCT06414772|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883023|NCT04508660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759719|NCT00003979||||TREATMENT||||||||
33759720|NCT02026856|||OTHER||PROSPECTIVE|||||||
33759721|NCT03034343|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33883024|NCT01277094|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33883025|NCT00356031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971639|NCT00956228|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971640|NCT02999464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971641|NCT03150121|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33971642|NCT04712435|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Matching placebo|This is a single-center, randomized, placebo-controlled study to evaluate the efficacy and safety of N-acetylcysteine|t|f|t|f
33971643|NCT03449082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971644|NCT00708929|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33971645|NCT04612920|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971646|NCT03273387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971647|NCT02095847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971648|NCT04972214|||COHORT||PROSPECTIVE|||||||
33971649|NCT00322907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971650|NCT02737306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects were randomized to the blinded part of the study using an IRT system. Unblinded pharmacists at clinical sites were notified of the arm to which the subjects were enrolled in order to prepare the appropriate treatment.||t|t|t|t
33971651|NCT00785525|NA|SINGLE_GROUP||OTHER||NONE||||||
33971652|NCT03943342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971653|NCT03267030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971654|NCT03147651|||COHORT||OTHER|||||||
34070724|NCT03070756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070725|NCT04396379|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||prospective, single arm, un-blinded, multi-center early feasibility study||||
34070726|NCT05460858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34070727|NCT02232711|||CASE_ONLY||PROSPECTIVE|||||||
34070728|NCT04757805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070729|NCT03474445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070730|NCT00885378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070731|NCT01672905|||COHORT||RETROSPECTIVE|||||||
33759722|NCT03654781|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants with positive for both for H. pylori in gastric biopsy specimens and dental plaque samples by histologic examination with immunostaining and the rapid urease test (RUT), on gastric biopsy specimens obtained during gastrointestinal endoscopy were divided into 2 groups. Patients were allocated to one of the eradication regimens: triple therapy only or triple therapy combined with periodontal treatment. Each participant in both group received of a 10-day course of a proton pump inhibitor (Lansoprazole ) combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily). Meanwhile, combined treatment group further received periodontal treatment consisted of scaling or combined with root planing and oral hygiene instructions.|f|f|f|t
33759723|NCT02487498|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33759724|NCT03895164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Control Group will receive standard nutrition education package from primary health care.~Intervention Group will receive standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation."|f|f|t|f
33759725|NCT02448758|||COHORT|||||||||
33759726|NCT06277479|||COHORT||CROSS_SECTIONAL|||||||
33883026|NCT06221020|||CASE_CONTROL||PROSPECTIVE|||||||
33883027|NCT01625780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33883028|NCT02397928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883029|NCT05151107|||COHORT||RETROSPECTIVE|||||||
33883030|NCT03461133|||COHORT||RETROSPECTIVE|||||||
33883031|NCT01469000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883032|NCT05261204|||COHORT||RETROSPECTIVE|||||||
33883033|NCT06350383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will not be told which arm they have been randomized to. Additionally, to reduce contamination, community health volunteers (CHVs) will either carry out assessment or intervention, not both. Assessors will not be told to which arm participants they are assessing have been assigned.|Two-arm, parallel-group design|t|f|f|t
33883034|NCT05834010|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||1 single FMT event either oral route or rectal. Sampling fecal matter and blood at baseline and 1 week after FMT.||||
33883035|NCT02668367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883036|NCT04235686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study subjects will be randomized to receive MYDAYIS® or placebo on a 1:1 ratio according to computer-generated coding. Each site will have its own randomization list. Allocation concealment will be achieved by having the research pharmacy perform the randomization, package the study medication, and maintain the integrity of the blinded information throughout the study.||t|t|t|f
33883037|NCT03031600|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This study will use a prospective validation design. In this design, each subject will experience both estimation methods/arms (radiodilution and hematocrit dilution) in a fixed sequence. The fixed order is necessary, as hematocrit dilution would bias the results of radiodilution by iatrogenically increasing plasma volume as part of the estimation process.||||
33883038|NCT00000321||||TREATMENT||||||||
33883039|NCT03723681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33883040|NCT01649947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883041|NCT01535365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883042|NCT05323435|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33883043|NCT02065739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883044|NCT02264587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883045|NCT06117527|||OTHER||OTHER|||||||
33883046|NCT02436603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883047|NCT00141765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883048|NCT01004302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883049|NCT03572036|||COHORT||RETROSPECTIVE|||||||
33883050|NCT06220656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883051|NCT01652287|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33883052|NCT02399033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883053|NCT01002092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883054|NCT03174483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883055|NCT00915200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883056|NCT02864472|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33883057|NCT03737773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883058|NCT02417389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883059|NCT05604599|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33883060|NCT03268330|||COHORT||PROSPECTIVE|||||||
33883061|NCT04314960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883062|NCT02721537|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33883063|NCT04001855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control split body study||||
33883064|NCT04835285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883065|NCT02734069|||COHORT||PROSPECTIVE|||||||
33883066|NCT04752995|NA|SINGLE_GROUP||TREATMENT||NONE||prospective randomized study||||
33883067|NCT05381129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759727|NCT03507621|||CASE_CONTROL||PROSPECTIVE|||||||
33883068|NCT04075929|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33883069|NCT05673941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be pseudonymized by using a study code. The researchers will be blind to group allocation when analyzing data.||f|f|t|t
33883070|NCT04123158|||COHORT||PROSPECTIVE|||||||
33883071|NCT00511680|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33883072|NCT04337411|||COHORT||PROSPECTIVE|||||||
33883073|NCT01893398|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33883074|NCT01469910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971655|NCT03419663|||OTHER||RETROSPECTIVE|||||||
33883075|NCT04677439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883076|NCT05004545|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883077|NCT05462509|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33883078|NCT03126760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While Care Provider and Outcomes Assessor were also blinded, it was considered a double-blind study.||t|f|t|f
33971656|NCT01841606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971657|NCT00712010|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33971658|NCT00991198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33971659|NCT01035528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33971660|NCT02930083|||CASE_ONLY||RETROSPECTIVE|||||||
33971661|NCT02110420|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33971662|NCT04968210|||CASE_ONLY||PROSPECTIVE|||||||
33759728|NCT06484569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759729|NCT01493687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759730|NCT02877030|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33759731|NCT05488275|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33759732|NCT01674309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883079|NCT05201755|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Interventional cross-over study.||||
33883080|NCT05634759|RANDOMIZED|PARALLEL||TREATMENT||NONE||Thirty villages will be randomized to one of two intervention arms (15 villages per study arm). To conduct the cost comparison, comparator data for the standard-of-care annual MDA will be obtained from the MDA conducted in 2022 in a random selection of 15 non-study villages.||||
33883081|NCT04468217|||CASE_CONTROL||PROSPECTIVE|||||||
33883082|NCT06067880|||CASE_CONTROL||RETROSPECTIVE|||||||
33883083|NCT05376085|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover Assignment single-dose, 2-sequence, 2-period Bioequivalence Study||||
33883084|NCT01780610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883085|NCT04825327|||COHORT||PROSPECTIVE|||||||
33883086|NCT01736046|||COHORT||PROSPECTIVE|||||||
33971663|NCT01851213|||COHORT||PROSPECTIVE|||||||
33883087|NCT00112905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883088|NCT05120739|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883089|NCT01052649|||COHORT||PROSPECTIVE|||||||
33883090|NCT05982340|||CASE_CONTROL||PROSPECTIVE|||||||
33883091|NCT01614561|||CASE_ONLY||CROSS_SECTIONAL|||||||
33883092|NCT06438081|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators did a pilot study to compare 5 patients using Cook double-catheter balloon priming and 5 patients using Propess. The investigators found the mean priming to delivery interval was 1971.6 minutes in Propess group and 1212.0 minutes in Cook double-catheter balloon group. The investigators assumed ratio of sample size in Propess and Cook double-catheter balloon was 1:1. In order to achieve 35% reduction of priming to delivery interval, a sample size of 28 is required for Type I error of 0.05, and Type II error of 0.2.||||
33759733|NCT03738839|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|It was not possible for the clinicians and their interventions to be blocked. The patients and the specialists were blinded to the treatment groups when their treatment groups were aware.|Random sequence generation was performed with a computerized random 1:1 allocation using block sizes of 4.|t|f|f|t
33759734|NCT01059643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883093|NCT01423539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883094|NCT00090545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883095|NCT01654679|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33883096|NCT04568668|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study participants, outcomes assessors, and study investigators will be blinded to treatment allocation. Community pharmacists cannot be blinded to the intervention, as we are studying the change in pharmacists' dispensing behavior due to the provision of new adverse drug event information. The information will only appear for patients in the experimental arm.|We will conduct a triple-blind randomized controlled trials. We will enroll consecutive eligible patients presenting to the Emergency Department with an adverse drug event to prescribed outpatient medication. Randomization is implemented in the ActionADE application. Randomization will be equal (1:1) and stratified by site and age (\< 80, ≥ 80). A statistician otherwise uninvolved in the study will generate a list of treatment assignments using permuted blocks of varying sizes for each stratum. ActionADE will store the randomization list for each stratum. Once eligibility has been determined, the application will allocate the patient to the next available assignment within the stratum.|t|f|t|t
33883097|NCT02049944|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883098|NCT03757832|||COHORT||PROSPECTIVE|||||||
33883099|NCT03897543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883100|NCT03018574|||CASE_CONTROL||RETROSPECTIVE|||||||
33883101|NCT04432363|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Three groups cross over study with two intervention groups and one sham group.|t|t|t|t
33883102|NCT02773342|||COHORT||RETROSPECTIVE|||||||
33883103|NCT00662844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33883104|NCT06436456|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Online psychological intervention~2. Individual psychological intervention"||||
33883105|NCT01639833|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33883106|NCT01813890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883107|NCT01148212|||CASE_ONLY|||||||||
33883108|NCT01964066|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33883109|NCT01688050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759735|NCT04034108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759736|NCT06303076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759737|NCT01758835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759738|NCT04452292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759739|NCT03865966|||CASE_ONLY||PROSPECTIVE|||||||
33883110|NCT00433407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883111|NCT03781648|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33883112|NCT04901039|||COHORT||PROSPECTIVE|||||||
33883113|NCT01239160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883114|NCT05434039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|diclofenac phonophoresis and high power pain threshold|t|f|f|t
33883115|NCT01505998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883116|NCT02201160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883117|NCT04628923|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33883118|NCT03015467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883119|NCT02274610|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883120|NCT01638780|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33883121|NCT00804388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883122|NCT00902603|||COHORT||PROSPECTIVE|||||||
33883123|NCT01001039|||COHORT||PROSPECTIVE|||||||
33971664|NCT03775356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single masked. The entropy and EEG module will be masked for the responsible anesthetist as well as the study team during the entire investigation.||f|t|t|f
33883124|NCT02823158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883125|NCT04704479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883126|NCT00311857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883127|NCT05536323|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33883128|NCT05581732|||CASE_CONTROL||PROSPECTIVE|||||||
33883129|NCT05588635|||COHORT||RETROSPECTIVE|||||||
33883130|NCT03416361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070732|NCT04499833|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective evaluation of patients with hepatocellular carcinoma in cirrhotic liver, outside the Milan Criteria for liver transplant, that comply with the morphologic criteria stablished for the proposed HepatoPredict Tool: (1) Total tumour volume below 500 cm3; (2) Total number of tumour lesions below 10; and (3) maximum individual tumour diameter below 10 cm. Those patients are proposed to be submitted to molecular study of the hepatocellular carcinoma and, if comply with the HepatoPredict genomic signature, liver transplantation will be proposed. Patients will be followed up for up to 5 years after transplantation for survival and survival-free-of-disease."||||
34070733|NCT04446429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.|t|t|t|t
34070734|NCT02584374|||CASE_CONTROL||PROSPECTIVE|||||||
34070735|NCT04023214|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34070736|NCT00076310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070737|NCT06285370|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking|This is an open-label, multicenter, single arm study.||||
33883131|NCT04987138|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The patient and site personnel administering follow-up assessments to 3 months will be blinded to the study assignment. Unblinding will occur at 3 months post procedure after follow-up assessments are completed.~All patients will be asked post-treatment if they believe they are in the Treatment Arm, Control Arm, or do not know. The blinding questionnaire will be administered at discharge and at the 1-month and 3-month follow-up assessments.~Control Arm patients can receive treatment with the Zenflow Spring System within 30 days after their 3-month follow-up assessments are completed, and their symptoms warrant treatment and enrollment criteria are met."|Prospective, multi-center, multinational, 2:1 randomized, single-blinded, controlled clinical trial of the Zenflow Spring System. Following unblinding, control patients may elect to receive treatment with the Zenflow Spring System or exit the study.|t|t|f|t
33883132|NCT00006388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883133|NCT02035826|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883134|NCT02302560|||COHORT||PROSPECTIVE|||||||
33883135|NCT01977235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883136|NCT01291901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883137|NCT01046500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883138|NCT01654900|||COHORT||RETROSPECTIVE|||||||
33883139|NCT01978379|||COHORT||PROSPECTIVE|||||||
33883140|NCT04385563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883141|NCT00878839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883142|NCT03214484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"In total, 80 patients (40 for the Electronc Tablet group, 40 for the computeur group) will be included in the study.~Using the pre-established randomization list, in order of inclusion in the study, each patient will be assigned to one of the 2"|t|f|f|f
33883143|NCT00911690|||CASE_CONTROL||PROSPECTIVE|||||||
33883144|NCT01197365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33883145|NCT02456246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883146|NCT03187600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be told what procedure they have received until after completion int he study. Speech language pathologists performing assessments will not be made aware of what procedure the patients have received. Nasovideo endoscopy will be reviewed in a blinded fashion without knowledge of what procedure the patient received.|1 group will receive a pharyngeal flap procedure comprised of pharyngeal muscle while the other group will receive of a procedure with only mucosa/submucosa.|t|f|f|t
33883147|NCT02137408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883148|NCT02630238|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33883149|NCT01267708|||COHORT||PROSPECTIVE|||||||
33883150|NCT04958538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070738|NCT05682599|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070739|NCT00389467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070740|NCT04321083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||INVOS Medtronic device will be applied simultaneously with sleep lab monitoring||||
33883151|NCT00004260||||TREATMENT||||||||
34070741|NCT03124498||SEQUENTIAL||TREATMENT||NONE||||||
34070742|NCT04473534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070743|NCT06612125|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34070744|NCT01624285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070745|NCT04730401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Some of the investigators are masked and some are not|Double blind, randomized, placebo controlled trial|t|t|t|f
34070746|NCT00027287||||TREATMENT||||||||
34070747|NCT05016375|||OTHER||OTHER|||||||
34070748|NCT05621707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883152|NCT03882307|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||assess serum level of interleukin-6 and transforming growth factor beta before intervention and after intervention with sofosbuvir and daclatasvir.|t|f|t|f
34070749|NCT01514877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070750|NCT05355077|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential||||
34070751|NCT06482840|||COHORT||PROSPECTIVE|||||||
34070752|NCT01671137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070753|NCT05725824|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070754|NCT01962948|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I Treatment: Paclitaxel IV given over 1 hour at 80 mg/m2 days 1, 8 and 15 of a 28-day cycle. PLUS ganetespib IV at a starting dose of 100 mg/m2 on days 1, 8 and 15 of a 28-day cycle. Ganetespib escalation will follow a modified 3+3 design and escalate from 100mg/m2 to 125mg/m2 to 150mg/m2. Phase II Treatment: Paclitaxel IV given over 1 hour at 80 mg/m2 days 1, 8 and 15 of a 28-day cycle. PLUS ganetespib IV at MTD/MED from Phase I on days 1, 8 and 15 of a 28-day cycle.||||
33883153|NCT01827891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33883154|NCT02652884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883155|NCT01431404|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33883156|NCT01314950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883157|NCT03914976|||OTHER||PROSPECTIVE|||||||
33883158|NCT03750851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883159|NCT02272686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883160|NCT03426020|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Effect of pharmacologic or nonpharmacologic premedication on emergency agitation|t|f|f|f
33883161|NCT01531842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883162|NCT02828410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883163|NCT01641939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883164|NCT03969888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883165|NCT00360659|NON_RANDOMIZED|PARALLEL||||NONE||||||
33883166|NCT05934266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883167|NCT03204123|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33883168|NCT01195337|||COHORT||PROSPECTIVE|||||||
33883169|NCT03433222|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single-blind, dose escalation, randomized controlled Phase 1 study|t|f|f|f
33883170|NCT05489601|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883171|NCT02480933|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33883172|NCT01235962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883173|NCT04173819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study is a randomized, double-blind, placebo-controlled Phase 1/2 study intended to evaluate the safety and pharmacokinetics of 10-1074-LS-J and 3BNC117-LS-J, alone or in combination, in healthy HIV-uninfected individuals.|t|f|t|f
33883174|NCT04395261|||COHORT||PROSPECTIVE|||||||
33883175|NCT05637554|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be divided randomly into two groups, in the first group the investigators will use clipping in securing the base of the appendix but in other groups investigators will use extracorporeal ligation.||||
33883176|NCT02890680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883177|NCT02319044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070755|NCT04425811|RANDOMIZED|PARALLEL||OTHER||SINGLE|Original kinesiological tape was applied to the participants. Then sham banding application was done with sticking plaster tape.|Sham Controlled Study|t|f|f|f
34070756|NCT00005802||||TREATMENT||||||||
34070757|NCT05221320|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070758|NCT06188325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34070759|NCT03459508|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070760|NCT05291923|||CASE_ONLY||PROSPECTIVE|||||||
34070761|NCT02450838|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070762|NCT01861353|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070763|NCT04226014|||COHORT||PROSPECTIVE|||||||
34070764|NCT04872387|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34070765|NCT04361760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34070766|NCT04433923||||TREATMENT||||||||
34070767|NCT00240968|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070768|NCT01909960|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34070769|NCT06155474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During trial conduct, the following groups will all be blinded to participants' allocation Healthy/Control, Malnutrition (RUTF) and Malnutrition (RTUF + prebiotics)|Prebiotic|t|f|t|f
34070770|NCT04693299|||COHORT||PROSPECTIVE|||||||
34070771|NCT02617498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070772|NCT06524167|||COHORT||PROSPECTIVE|||||||
33883178|NCT02996747|||CASE_ONLY||RETROSPECTIVE|||||||
33883179|NCT01346878|||COHORT||RETROSPECTIVE|||||||
33883180|NCT02963376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883181|NCT02161159|||COHORT||PROSPECTIVE|||||||
33883182|NCT02215603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070773|NCT00481364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070774|NCT00748163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070775|NCT01706432|||CASE_ONLY||PROSPECTIVE|||||||
34070776|NCT02924233|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883183|NCT04315896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Clinical practitioners and data analysts will remain blinded all through the study. Blinding will end in case the attending physician considers the patient should abandon the study or some of the exclusion/elimination criteria apply.|Double blinded, randomized controlled trial|t|t|t|t
33883184|NCT02244710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070777|NCT03403881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883185|NCT02817412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883186|NCT06228456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070778|NCT01983163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070779|NCT03368118|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, follow-up study||||
34070780|NCT00315718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070781|NCT03292614|||COHORT||PROSPECTIVE|||||||
34070782|NCT05234268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070783|NCT03465709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070784|NCT06304480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Randomised, open label, controlled, parallel study in healthy males and females.|Randomised, open label, controlled, parallel study in healthy males and females.||||
33971665|NCT03136991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be a randomized, single-blind (site personnel to remain blinded until SRC meeting), placebo-controlled, MAD, sequential group design study in healthy male subjects, performed at a single study center.|"This study will be a randomized, single-blind (site personnel to remain blinded until SRC meeting), placebo-controlled, MAD, sequential group design study in healthy male subjects, performed at a single study center. Up to 60 healthy male subjects aged 18 to 50 years (inclusive) are planned to be investigated in 4 cohorts, but up to 6 cohorts may be included if the SRC considers it necessary to repeat a dose level or if additional dose levels are required.~Up to 10 subjects will participate in each cohort. Within each cohort 8 subjects will be randomly assigned to receive AZD4831 and 2 subjects to receive placebo. AZD4831 or placebo will be administered once daily for a period of 10 days. It is anticipated this will be sufficient to achieve and maintain steady state PK profiles for several days, permitting evaluation of the safety and tolerability of multiple dose administrations at steady state. The subjects will stay at the study center during the whole dosing period and until 48h"|t|f|f|f
33971666|NCT05097885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070785|NCT04923880|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We have created a framework for a nationally generalizable model to improve best practices in generalist-level palliative care in CF. This framework links the screening approach of the CF Foundation Models of Palliative Care Guidelines to new sets of provider-level clinical best practice guides and practice-level processes of care, supported by targeted education and quality management. This protocol describes an implementation trial of this model that will rigorously evaluate its feasibility, uptake, and preliminary outcomes.||||
33883187|NCT04587388|||COHORT||PROSPECTIVE|||||||
33883188|NCT04957290|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070786|NCT01564316|||COHORT||RETROSPECTIVE|||||||
34070787|NCT01191099|||COHORT||PROSPECTIVE|||||||
33883189|NCT04133961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34070788|NCT06492668|||COHORT||PROSPECTIVE|||||||
34070789|NCT03748368|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34070790|NCT01124799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34070791|NCT04084587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A: 15 patients rehabilitated with Retimax Vision Trainer, 10 consecutive sessions of 8 minutes each, performed twice a week in the best eye.~Group B: 9 patients control group without rehabilitation.~Given the need for constancy and collaboration on the part of the patient, these are allocated to the group of treaties or to the controls based on the fact that they declare themselves more or less available: patients who have transport problems, who live farther away or who in any case they cannot guarantee their presence twice a week, they are allocated to the control group."||||
33883190|NCT03112239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070792|NCT05223803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070793|NCT02740790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34070794|NCT06411522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070795|NCT04990609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070796|NCT03086005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070797|NCT05481827|NA|SINGLE_GROUP||OTHER||NONE||||||
34070798|NCT03644420|||CASE_ONLY||PROSPECTIVE|||||||
34070799|NCT02542592|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34070800|NCT00344838|||CASE_ONLY||PROSPECTIVE|||||||
34070801|NCT00460863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883191|NCT05273684|NA|SINGLE_GROUP||OTHER||NONE||||||
33883192|NCT00428649|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883193|NCT00476580|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33883194|NCT04710329|||COHORT||RETROSPECTIVE|||||||
34070802|NCT04033406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070803|NCT00001070||||TREATMENT||||||||
34070804|NCT03338504|||COHORT||PROSPECTIVE|||||||
34070805|NCT06376409|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment 6-month, single-center, prospective interventional study||||
33883195|NCT00294541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883196|NCT05935254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33883197|NCT02421237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883198|NCT00448708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971667|NCT00962299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971668|NCT02572583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883199|NCT06152588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971669|NCT02724137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883200|NCT06507163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883201|NCT02658422|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33883202|NCT00711633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33971670|NCT05876702|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883203|NCT03190057|||COHORT||PROSPECTIVE|||||||
33883204|NCT02170441|||COHORT||PROSPECTIVE|||||||
33883205|NCT03262363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patient Blinding: Patients with EDN will be blinded to the intervention they will receive Evaluator Blinding: The principal investigator will be blinded to the intervention that patients will receive (curcumin or placebo), but will know the genotype distribution in both Experimental and Placebo groups. The external investigator will be blinded to the knowledge of the patients genotype, but will know the intervention group to which each patient was assigned according to a registry (but will not know the identity of the patients). The Doctorate Program Student will be blinded to the distribution of patients genotype and the type of intervention patients will receive.~Statistical Blinding: An associated researcher will be blinded to the distribution of patients genotype and the type of intervention patients will receive, but not to the knowledge of the database."|"The study starts from the classification of patients according to the genotype for the rs35652124 polymorphism (-653G\>A) of the NFE2L2 gene. Two Experimental groups and two Control groups will be formed according to the following:~Experimental group 1: Diabetic patients with early CKD homozygous for the -653G (G/G) allele of the NFE2L2 gene that will receive curcumin.~Experimental group 2: Diabetic patients with early CKD carrying the allele -653A (G/A or A/A) of the NFE2L2 gene that will receive curcumin.~Control group 1: Diabetic patients with early CKD homozygous for the -653G (G/G) allele of the NFE2L2 gene receiving placebo.~Control group 2: Diabetic patients with early CKD carrying the allele -653A (G/A or A/A) of the NFE2L2 gene who will receive placebo."|t|t|t|f
33883206|NCT03616431|||COHORT||PROSPECTIVE|||||||
33883207|NCT06272344|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective, single-center, single-arm, pairwise comparison trial||||
33883208|NCT00276575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883209|NCT06501417|||COHORT||PROSPECTIVE|||||||
33883210|NCT04381208|||COHORT||PROSPECTIVE|||||||
33883211|NCT03491332|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33883212|NCT02344966|||COHORT||OTHER|||||||
33883213|NCT04599062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883214|NCT01835119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971671|NCT05945394|||COHORT||CROSS_SECTIONAL|||||||
33971672|NCT03687125|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Does escalation followed by Phase 2 Expansion at MTD||||
33883215|NCT00433329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883216|NCT03447158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883217|NCT02952183|NA|SINGLE_GROUP||||NONE||||||
33883218|NCT04481997|||COHORT||PROSPECTIVE|||||||
33883219|NCT00001357||||TREATMENT||||||||
33971673|NCT06278285|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33971674|NCT01851161|||CASE_CONTROL||PROSPECTIVE|||||||
33971675|NCT01314755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||either Impact or an iso-nitrogenous, iso-caloric control feed for five days pre and seven days post-surgery|t|f|t|f
33971676|NCT02489890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971677|NCT05852548|NA|SINGLE_GROUP||TREATMENT||NONE||One group, pre, post-test||||
33971678|NCT02184949|||COHORT||RETROSPECTIVE|||||||
33971679|NCT01693484|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883220|NCT06149234|RANDOMIZED|PARALLEL||OTHER||DOUBLE|An oral and maxillofacial radiologist assessed the radiographs in single-blinded random selection to identify and record the errors.||f|f|t|t
33971680|NCT02140957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33883221|NCT05192811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883222|NCT04388306|||OTHER||CROSS_SECTIONAL|||||||
33883223|NCT02383342|||CASE_CONTROL||PROSPECTIVE|||||||
33971681|NCT02693496|||COHORT||PROSPECTIVE|||||||
33971682|NCT02598648|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33971683|NCT02542124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070806|NCT03446118|NA|SINGLE_GROUP||OTHER||NONE||Twenty patients with eosinophilic esophagitis will be studied. Ten of these patients will have mild to moderate stricture formation (narrowed segment \<8 cm in length and lumen diameter \> 12mm) and 10 will have small caliber esophagus (a narrowed segment \>8 cm in length with minimum diameter \< 10mm). These groups will be delineated by routine barium esophagography performed in all Mayo patients with eosinophilic esophagitis during their initial clinical evaluation. Patients will then undergo an 8 week treatment with 3 mg budesonide twice daily as per routine clinical treatment with clinically indicated follow up endoscopy with esophageal biopsies to assess mucosal response. All patients will complete the EESAI dysphagia score per routine practice at Mayo. MRI of the esophagus will be performed in these patients initially and upon completion of the 8 week course of steroid therapy.||||
33883224|NCT02402855|RANDOMIZED|PARALLEL||||NONE||||||
33971684|NCT05683795|||OTHER||PROSPECTIVE|||||||
33971685|NCT00062140||||TREATMENT||NONE||||||
33971686|NCT05313828|||CASE_CONTROL||PROSPECTIVE|||||||
33971687|NCT02925767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070807|NCT00401518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070808|NCT02535650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070809|NCT04605653|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after study design||||
34070810|NCT02841384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070811|NCT01808222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070812|NCT05625152|||CASE_ONLY||RETROSPECTIVE|||||||
34070813|NCT04875780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All outcome assessors will be blinded to group allocation|"It is a 12-month 3-arm randomised controlled trial, RCT (the digital diabetes prevention app group, the digital weight loss tracking app group, and the wait-list usual care group). The digital diabetes prevention app group will receive these intervention components: web-based diabetes prevention curriculum, virtual social group support, goal setting and self-monitoring via the smartphone app. The digital weight loss tracking group will receive digital tracking of weight loss, diet and physical activity and virtual social support group function (mimicking the publically available weight loss apps), but without the web-based diabetes prevention curriculum.~The wait-list usual care group will receive usual care in the form of an annual review and blood test, together with general lifestyle advice at our NGO collaborator's (UCN) community clinics."|f|f|f|t
33883225|NCT03909360|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33883226|NCT03961360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971688|NCT06483581|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33971689|NCT00121654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971690|NCT02295774|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971691|NCT01018888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971692|NCT06121869|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All supplements will be provided in blinded, labeled containers prior to them arriving to the site. Each supplement will be of similar volume, texture, and labeled in indistinguishable bottles to ensure blinding of both participant and invesitigator|Randomized, Double-Blind, Placebo-Controlled|t|f|t|f
33971693|NCT01092520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971694|NCT03396718|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33971695|NCT00590356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971696|NCT01885637|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33971697|NCT03801733|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||This is a three-part sequential design study. Part 2 will be initiated based upon the outcome of Part 1 and Part 3 will be initiated after completion of Part 2.||||
33971698|NCT05840120|||CASE_CROSSOVER||PROSPECTIVE|||||||
33971699|NCT00631670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971700|NCT04163692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A computer generated list of random sequence numbers was created with 1:1 allocation ratio to randomise participants into study or control groups. Randomisation sequence was concealed until assignment of interventions. The group allocation was made by study researcher who implemented the PRE.|f|f|f|t
33971701|NCT05216978|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive the PATH intervention.||||
33971702|NCT04944602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971703|NCT04871217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971704|NCT01037166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971705|NCT01620983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34070814|NCT01703169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070815|NCT00523692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070816|NCT05861895|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070817|NCT01563913|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34070818|NCT06373055|||COHORT||PROSPECTIVE|||||||
34070819|NCT00664118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070820|NCT00039299||||TREATMENT||||||||
34070821|NCT03246061|RANDOMIZED|CROSSOVER||TREATMENT||NONE||BVN Ablation vs Standard Care Control||||
34070822|NCT01289301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070823|NCT04239352|||CASE_CONTROL||PROSPECTIVE|||||||
33971706|NCT03888833|||COHORT||RETROSPECTIVE|||||||
33971707|NCT04300179|||COHORT||RETROSPECTIVE|||||||
33971708|NCT00359970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971709|NCT02739815|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33971710|NCT02802514|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33971711|NCT05325892|||COHORT||PROSPECTIVE|||||||
33971712|NCT04192825|||COHORT||PROSPECTIVE|||||||
33883227|NCT05825677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"The subject will be blind of the treatment he receives (active or placebo). The experimenter, caregiver and investigator will also be blinded from stimulation (active or placebo).~Each subject will be assigned a randomization code, corresponding to the code to enter the tDCS device. This system allows the person who administers tDCS and the subject receiving the stimulation to be blind."|In a randomized controlled double-blind study, 30 healthy subjects, will be randomly assigned to 2 groups. A group of 15 participants will receive 30 minutes of active tDCS (1mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC); a group of 15 participants will receive 30 minutes of placebo stimulation. All participant will be in a PET-MRI scanner for 110min, during which they will undergo the stimulation (either active or sham). During this stimulation session, all participants will undergo a standardized stress test combining psychosocial stress and physical stress.|t|t|t|t
33883228|NCT00949156|||COHORT||CROSS_SECTIONAL|||||||
33883229|NCT03729947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883230|NCT04778280|||CASE_CONTROL||PROSPECTIVE|||||||
33883231|NCT02372487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883232|NCT02011191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33883233|NCT06449768|||CASE_ONLY||PROSPECTIVE|||||||
33883234|NCT02997592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883235|NCT00003665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971713|NCT04023565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971714|NCT04896385|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind|Randomized, double-blind, vehicle-controlled, with an open-label treatment extension.|t|f|t|t
33971715|NCT03187652|||COHORT||PROSPECTIVE|||||||
33971716|NCT05124691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971717|NCT02012647|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33971718|NCT06218420|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971719|NCT04517656|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33971720|NCT04039581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971721|NCT04778527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971722|NCT01725113|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33971723|NCT00190853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971724|NCT06359678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971725|NCT01117883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971726|NCT05899465|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, care providers, investigators/outcome assessors are all blinded to the intervention. Selected trained personnel who does not treat or assess the participants will be unblinded to prepare the intervention for administration and deliver the intervention to blinded personnel for administration.|Parallel, two-arm, randomized, blinded Danish multi-center trial|t|t|t|t
33971727|NCT03551730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This study has four modules with a total of 21 cohorts, each module was reported and submitted separately.~Module 1, NCT01758432 (54 subjects with 7 cohorts including placebo); Module 2, NCT03578146 (48 subjects with 6 cohorts including placebo); Module 3, NCT03551730 (27 subjects with 4 cohorts including placebo); Module 4, NCT03551743 (28 subjects with 4 cohorts including placebo)"|t|t|t|t
33971728|NCT05824182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971729|NCT01270022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33971730|NCT03931096|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33971731|NCT04059666|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33971732|NCT00974493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971733|NCT01788722|||COHORT||PROSPECTIVE|||||||
33971734|NCT03391297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prolonged exposure therapy (PE), a specific exposure therapy for PTSD, has been proved an effective treatment for PTSD. PE usually consists of 10-15 individual sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).||||
33971735|NCT03436628|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33971736|NCT04878406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33764936|NCT03288896|RANDOMIZED|PARALLEL||PREVENTION||NONE||A Cluster Randomized Controlled Trial is conducted to test the effectiveness of Alerta Alcohol in students aged 16 to 18 years. The study is performed in 16 high schools from Andalusia (southern Spain), which are randomized either to the experimental or the control condition (EC and CC). The EC receives the Alerta Alcohol intervention, which consists of four sessions at school. The adolescents are provided highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence, and self-efficacy. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. The CC just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition).||||
33764937|NCT05884229|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33971737|NCT00278512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971738|NCT00092859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971739|NCT01424956|||CASE_CONTROL||RETROSPECTIVE|||||||
33971740|NCT05864625|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33971741|NCT01953783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971742|NCT04340232|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open label, single site study. Data from participants in this study with data from other COVID-19 patients not receiving baricitinib.||||
33971743|NCT02492958|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33971744|NCT06524791|||COHORT||PROSPECTIVE|||||||
33971745|NCT02875171|||COHORT||PROSPECTIVE|||||||
34070824|NCT00771940|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34070825|NCT01240499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070826|NCT04161521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070827|NCT01463943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070828|NCT04981197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34070829|NCT05401461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All outcomes will be collected by an independent researcher blinded to group allocation|Mixed methods, randomised controlled feasibility study|f|f|t|t
34070830|NCT06480136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070831|NCT04692116|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site open clinical investigation||||
33883236|NCT03705182|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The 250 participants will be allocated to an intervention- or a control group, around 125 in each. The intervention group will be shown the fluorescent areas on their skin, while the control group will not have this opportunity. Work teams of approximately 40 workers with comparable work procedures, are allocated together.||||
34070832|NCT00824655|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34070833|NCT01462305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883237|NCT02908880|NA|SINGLE_GROUP||OTHER||NONE||||||
33883238|NCT03705793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070834|NCT04099238|||COHORT||RETROSPECTIVE|||||||
34070835|NCT02788188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070836|NCT03877588||SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34070837|NCT01980628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070838|NCT06229964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All patients will receive 2 concomitant injections: 1 IACI and 1 SSNB. Control group : sham SSNB is performed with a short-acting local anesthetic (Linisol 2%).~Intervention group : SSNB is performed with a long-acting anesthestic (Ropivacaine 2%) + 40-mg methylprednisolone acetate.~Same injected volume (5ml) in sham and intervention group. The advantage of using a short-acting anesthetic as a sham injection instead of a saline, is that at the time of injection the patient may perceive the anticipated short effect of the anesthetic similar to the intervention SSNB.~The care provider will be unaware of the type of SSNB of the allocation group. The outcomes assessor will be unaware of the type of SSNB of the allocation group.~The investigator who administers the injections, will be unaware of the allocation.~The investigational products will be prepared by the pharmacist according to a pre-defined co-variate constrained randomization key."|Prospective single-center Randomized Parallel-group|t|t|t|t
34070839|NCT01653340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070840|NCT05771454|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070841|NCT05560022|||COHORT||PROSPECTIVE|||||||
34070842|NCT04801043|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34070843|NCT05085470|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34070844|NCT06480760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double-blinded longitudinal study in approximately 120 PAD patients|t|f|t|f
33764938|NCT06133842|||CASE_ONLY||PROSPECTIVE|||||||
33764939|NCT01372605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764940|NCT02087501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764941|NCT00084643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764942|NCT05982704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764943|NCT03202095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764944|NCT01361373|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33883239|NCT04756375|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33883240|NCT00619437|||FAMILY_BASED||PROSPECTIVE|||||||
33883241|NCT03402997|||CASE_ONLY||PROSPECTIVE|||||||
33883242|NCT00704262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883243|NCT04473963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883244|NCT02007226|||CASE_ONLY||PROSPECTIVE|||||||
33883245|NCT03073135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34070845|NCT01270360|||COHORT||PROSPECTIVE|||||||
34070846|NCT02800369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070847|NCT01679730|||CASE_CONTROL||PROSPECTIVE|||||||
33883246|NCT01485692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070848|NCT06144450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34070849|NCT01005017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070850|NCT01857804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070851|NCT01512433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883247|NCT03301181|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883248|NCT05620355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883249|NCT02631538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883250|NCT00494091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070852|NCT04819100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070853|NCT01238419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070854|NCT02681458|||CASE_CONTROL||PROSPECTIVE|||||||
34070855|NCT00864305|RANDOMIZED|CROSSOVER||||NONE||||||
33883251|NCT00002623|RANDOMIZED|||TREATMENT||||||||
33883252|NCT01450176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971746|NCT06546878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971747|NCT04178915|||COHORT||PROSPECTIVE|||||||
33971748|NCT02363010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883253|NCT02852382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883254|NCT03006939|||COHORT||PROSPECTIVE|||||||
33883255|NCT00498745|RANDOMIZED|CROSSOVER||||NONE||||||
33883256|NCT04009993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33883257|NCT03145298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Notification of subject randomization will be received by an independent storage/distribution center; the storage/distribution center will have password protected access to the randomization in order to retrieve the treatment assignment. The storage/distribution center will randomly assign an appropriate donor (or placebo) once they receive the designation of active treatment vs. placebo from the interactive system. All Sponsor staff will remain blinded to treatment (CAP-1002 or placebo) assignments. The only time other Sponsor staff will become aware of individual treatments is in the case of an emergency blind break resulting from an SAE.|The study is divided into two portions. The first (Phase 1a) evaluates safety and efficacy of 2 different doses of cells (50 and 100 million cells). The second phase (Phase 1b) takes place after an independent data safety monitoring board has reviewed all the data from Phase 1a and deems it safe and appropriate to proceed to Phase 1b. The latter is a randomized double-blind study in which subjects receive either CAP-1002 or placebo in a 1:1 ratio.|t|t|t|f
33883258|NCT05116124|||COHORT||RETROSPECTIVE|||||||
33883259|NCT03450083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883260|NCT03892447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883261|NCT03123497|||OTHER||PROSPECTIVE|||||||
33883262|NCT00343031|||COHORT||PROSPECTIVE|||||||
33971749|NCT04799210|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33971750|NCT04038970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971751|NCT01125995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971752|NCT05107284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention is an online program, not an individual administering it, so masking is not necessary. Similarly, the same online survey is deployed in all follow-up assessments regardless of condition, and data are not collected by individuals, so masking of investigators is not necessary.||t|f|f|f
33764945|NCT04313569|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arthroscopic meniscectomy||||
33764946|NCT05787158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883263|NCT03884400|||OTHER||CROSS_SECTIONAL|||||||
33883264|NCT06186687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883265|NCT04364919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"One hundred and forty women who met the inclusion criteria and returned their consent documents were systematically assigned, from a random starting point to experimental (n = 70) or a control (n = 70) group. Women usually talk to each other during the prenatal check and this could cause study data contamination, so we used a month as the unit of allocation to avoid between-group data contamination. The first month collecting data was control group decided by drawing lots (two lots which were marked E for experimental group and marked C for control group in a sack). Research assistant drew the lot from the sack. Then, the following month, group allotment was systematically assigned in sequence to either the experimental group or the control group."|In addition to routine care, the experimental group was given a DVD and instructed to engage in the aerobic exercise program shown on the DVD. The DVD with low-impact aerobic exercises developed by the researchers in collaboration with a qualified prenatal yoga teacher. The program incorporated modified yoga movements suitable for pregnant women. Women in experimental group were instructed to use the DVD 3 times a week for 3 months. The control group received routine prenatal care only.|t|f|f|f
33883266|NCT05606133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883267|NCT01637142|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33883268|NCT05417958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883269|NCT01624181|||CASE_ONLY||PROSPECTIVE|||||||
33883270|NCT02242500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883271|NCT04736654|||OTHER||PROSPECTIVE|||||||
33883272|NCT00999908|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33971753|NCT00222677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971754|NCT01957683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971755|NCT03027336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The study included two arms: a treatment arm with dietary supplement (Coleosoma) and a placebo arm.~Coleosoma is the name of a new patented dietary supplement composed by Berberin 200 mg, Fermented Red Rice from Monascus purpureus 100 mg (correspondiing at 3 mg of monacolin K), Chitosan 100 mg e Q10 Coenzyme10 mg"|t|t|t|t
33971756|NCT01717456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33971757|NCT03905291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971758|NCT05170828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070856|NCT00565201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33883273|NCT01443780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883274|NCT03779022|||COHORT||PROSPECTIVE|||||||
33883275|NCT02424838|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33883276|NCT01363687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33883277|NCT03587532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883278|NCT01095146|||CASE_ONLY||RETROSPECTIVE|||||||
33883279|NCT00624390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33883280|NCT01635790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883281|NCT06269250|||COHORT||PROSPECTIVE|||||||
33883282|NCT01409109|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883283|NCT03128229|||COHORT||PROSPECTIVE|||||||
33883284|NCT04226391|||COHORT||CROSS_SECTIONAL|||||||
33883285|NCT02549339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883286|NCT01951001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883287|NCT05203731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34070857|NCT02369263|||COHORT||PROSPECTIVE|||||||
33883288|NCT03468309|||CASE_ONLY||PROSPECTIVE|||||||
33759740|NCT04916600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Sham controls for placebo effects, and is designed to minimize sham recognition by participants, research, and treatment personnel. Active and sham arms will receive identical device care and use instructions, equipment, and attachment locations. Visual cues from the device heartbeat indicator (light-emitting diode) indicate the device is working. Sham and active both use the NET device without alteration. Sham uses a lead wire rendered non-conductive beforehand, preventing electrical stimulation. The biostatistician will randomly and uniquely assign a pre-printed Study Device Number (SDN) to each lead wire by overlaying a heat shrink tube, pre-printed with a unique SDN, recording the active and sham assignments. Lead wires are inserted into the device. The biostatistician will keep the data in a secure database and will not be involved in recruitment or study procedures. Unblinding will only occur when necessary for treating an adverse event."|This study is prospective, randomized, double-blind, parallel-group, sham-controlled and superiority in design. Study enrollees will be assigned in equal proportions (1:1) to one of two groups: active or sham treatment. Group assignment will be stratified by sex. The biostatistician will perform stratified randomization to maintain balance between active and sham groups. The biostatistician will maintain the blinding so that the study sponsor, PI, study monitor, research assistants, treatment staff, and the participants remain blinded. No interim analysis is planned.|t|t|t|t
33759741|NCT02032160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33759742|NCT04329780|||OTHER||RETROSPECTIVE|||||||
33759743|NCT00785317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759744|NCT02262546|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33759745|NCT03002064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759746|NCT04469881|NA|SINGLE_GROUP||OTHER||NONE||||||
33759747|NCT05082389|||COHORT||PROSPECTIVE|||||||
33759748|NCT00207038|||COHORT||CROSS_SECTIONAL|||||||
33759749|NCT06341621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1# endocrine drug plus 3-year abemaciclib without chemotherapy Arm 2# treatment of physician's choice||||
33759750|NCT03532308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759751|NCT04521543|||COHORT||RETROSPECTIVE|||||||
33759752|NCT02395133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759753|NCT02238925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759754|NCT01299519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883289|NCT00491647|||CASE_CONTROL|||||||||
33759755|NCT02296190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|If, during the double-blind study, PSVT could not be induced, the mechanism of PSVT was neither atrioventricular (AV) reentrant tachycardia (AVRT) nor AV nodal reentrant tachycardia (AVNRT), or it was not possible to sustain an episode of PSVT for 5 minutes in a subject who previously provided written informed consent for substudy participation, the subject was eligible to participate in the optional open-label substudy.||t|f|t|f
33759756|NCT01472874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759757|NCT03019354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759758|NCT03241979|||COHORT||PROSPECTIVE|||||||
33759759|NCT03848598|||COHORT||PROSPECTIVE|||||||
33759760|NCT03262740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764947|NCT04140500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764948|NCT05528718|||COHORT||PROSPECTIVE|||||||
33764949|NCT01486056|||CASE_ONLY||PROSPECTIVE|||||||
33764950|NCT00094211|||COHORT||CROSS_SECTIONAL|||||||
33764951|NCT03968315|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33883290|NCT05345925|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883291|NCT03598387|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects eligible for this study will be randomized into APD group and IHD group. In APD group, subjects will receive PD catheter placement and subsequent APD treatment. In IHD group, subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis.||||
33883292|NCT02624037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883293|NCT03007173|||CASE_ONLY||PROSPECTIVE|||||||
33883294|NCT01515033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883295|NCT05491785|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-dummy|Randomized, double blind, four- period, six-treatment, double-dummy, placebo controlled, partial-crossover study|t|t|t|t
33883296|NCT01724528|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070858|NCT05477875|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883297|NCT02310620|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883298|NCT00868101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33883299|NCT04340622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sham is created by putting a piece of aluminum foil over the light-emitting diode. It will be placed there or not placed there by a 3rd party so that neither the participant nor the outcomes assessor will know the condition of the study.|20 participants will receive twice a week active treatment for 4-weeks of a 4-minute near-infrared light treatment through the forehead to a brain hemisphere and 20 will receive a sham treatment.|t|f|f|t
33883300|NCT04502303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with intestinal stricture will undergo 18F-FDG and 68Ga-FAPI PET/CT on two consecutive days.||||
33883301|NCT06066892|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33883302|NCT01316393|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33883303|NCT01935843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883304|NCT06046703|||COHORT||PROSPECTIVE|||||||
33883305|NCT02512185|||COHORT||PROSPECTIVE|||||||
33883306|NCT02109341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883307|NCT05352542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883308|NCT00358605|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33883309|NCT01825096|||CASE_ONLY|||||||||
33883310|NCT04132986|||CASE_ONLY||RETROSPECTIVE|||||||
33883311|NCT02419508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971759|NCT04512768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971760|NCT06223581|||COHORT||CROSS_SECTIONAL|||||||
33971761|NCT03128593|NA|SEQUENTIAL||TREATMENT||NONE||||||
33971762|NCT02114931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971763|NCT04104646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind, double-dummy||t|f|t|t
33971764|NCT04919928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971765|NCT00190866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971766|NCT02844374|NA|SINGLE_GROUP||||NONE||||||
33971767|NCT01873859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971768|NCT06437132|||COHORT||PROSPECTIVE|||||||
33971769|NCT03760393|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study will employ a prospective, 2-group, repeated measure (2x5), randomized controlled trial (RCT) design. All participants will be randomized into either a 6-week HAPA-treatment (SB-related planning + text messages intervention) or waitlisted control (no treatment) condition.~All primary outcomes will be assessed at four time points (baseline, 2, 4, and 6 weeks), and again at a two-week follow-up (8 weeks). Action and coping planning and action control towards reducing occupational (student) sitting time will be assessed at the same time points. Secondary outcome assessments (i.e., work- and health-related outcomes) will occur pre-(baseline) and post-intervention (6 weeks)."||||
33971770|NCT04017182|||COHORT||PROSPECTIVE|||||||
33971771|NCT01934374|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33971772|NCT00671879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971773|NCT04665323|||OTHER||CROSS_SECTIONAL|||||||
33971774|NCT02251587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971775|NCT00001728||||TREATMENT||||||||
33971776|NCT05045729|||COHORT||RETROSPECTIVE|||||||
33971777|NCT03069079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971778|NCT03027570|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33971779|NCT05092061|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will consist of both a crossover study model (acute phase) and parallel model (chronic phase).||||
33971780|NCT04161794|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Non-randomised|This is a single arm intervention study, comparing the results to that of a historical control Group.||||
33971781|NCT04622384|||COHORT||PROSPECTIVE|||||||
33971782|NCT03336983|RANDOMIZED|PARALLEL||TREATMENT||NONE||prostate cancer patients with hormone sensitive metastatic bone disease||||
33971783|NCT03974594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883312|NCT04428606|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This is a double blinded, pilot placebo-controlled trial of two interventions compared to placebo to determine the effects individually of Metabolic Rheostat™ and Butyrate Ultra daily consumption for 8 weeks on glucose homeostasis in subjects with prediabetes. The study will include 20 subjects with prediabetes treated with Metabolic Rheostat™; 20 subjects with prediabetes treated with Butyrate Ultra and 20 subjects with prediabetes treated with placebo. Participants will take 6 capsules daily, two capsules three times per day 30 minutes prior to each meal for 56 days.|t|t|t|f
33883313|NCT05836376|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883314|NCT00817011|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883315|NCT03760484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070859|NCT04571216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070860|NCT06272825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcomes Assessor will be different persons.|Randomised controlled|f|f|t|t
34070861|NCT05418959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Non-invasive adhesive biopsies of suspicious skin lesions.||||
34070862|NCT04889053|||COHORT||PROSPECTIVE|||||||
34070863|NCT06608095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070864|NCT05844839|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34070865|NCT01398657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883316|NCT04557852|||COHORT||RETROSPECTIVE|||||||
33883317|NCT04780542|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participant recruiters will be blinded to the participant's intended treatment arm.|||||
33883318|NCT00661271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33883319|NCT00955994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33883320|NCT02648126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883321|NCT02736032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883322|NCT05501119|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33883323|NCT01960322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883324|NCT03932071|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33883325|NCT01430650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883326|NCT03266887|||COHORT||PROSPECTIVE|||||||
33883327|NCT06286865|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33883328|NCT05771727|||FAMILY_BASED||PROSPECTIVE|||||||
33883329|NCT02673645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883330|NCT04295694|||COHORT||PROSPECTIVE|||||||
33883331|NCT02944019|||COHORT||PROSPECTIVE|||||||
33883332|NCT05081284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33883333|NCT05135832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883334|NCT03474679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883335|NCT02769624|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33883336|NCT04228185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883337|NCT01469559|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883338|NCT06388486|||COHORT||PROSPECTIVE|||||||
33883339|NCT02026063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883340|NCT01613326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070866|NCT05226117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070867|NCT02482753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070868|NCT01569282|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070869|NCT04442477|||COHORT||PROSPECTIVE|||||||
34070870|NCT02330185|NA|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33883341|NCT03493360|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34070871|NCT03900572|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070872|NCT01215149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34070873|NCT01533402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070874|NCT01127594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070875|NCT05890014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The investigators who process, score and analyse data will be masked||f|f|f|t
34070876|NCT02555917|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34070877|NCT04127396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883342|NCT06107010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind|f|f|f|t
33883343|NCT03850197|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883344|NCT04276584|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients are given a serial number. The randomization orders are blinded to the outcome assessor.|Positive expiratory pressure is given to patients after abdominal surgery in order to improve postoperative oxygen saturation and lung function. We aim to test whether speaking loudly from a given text improve postoperative oxygen saturation and ventilation. 50 patients will be investigated in a randomized controlled trial with cross-over design starting either with positive expiratory pressure therapy (10 times 3 inspiration and expiration to positive expiratory pressure) or with speaking loudly from a given text.|f|f|f|t
33883345|NCT01258959|||COHORT||PROSPECTIVE|||||||
33883346|NCT05048160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883347|NCT00459069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883348|NCT01718184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883349|NCT01209026|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33883350|NCT06519591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883351|NCT04002544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33883352|NCT00488787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883353|NCT03948230|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Salt / placebo will be consumed by capsule under a double-blind procedure|The study has six arms. Salt alone; salt plus water; salt plus colored water; placebo alone; placebo plus water; placebo plus colored water|t|f|t|f
33883354|NCT00918814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883355|NCT00129155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883356|NCT00584870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883357|NCT04647292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883358|NCT05742555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33883359|NCT01484067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070878|NCT04999085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm pilot study of supportive care interventions||||
34070879|NCT03161067|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34070880|NCT03589157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33883360|NCT04992975|||CASE_CONTROL||PROSPECTIVE|||||||
33883361|NCT05628194|||COHORT||OTHER|||||||
33883362|NCT02495727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883363|NCT06548711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the specific nature of acupuncture clinical research, it is difficult to accomplish double blinding of subjects and operators, so this trial was blinded to subjects and statisticians only. The statistical analyst was a non-subject and was not aware of the patient treatment or the trial protocol. For all patients who participated in acupuncture, blinded evaluation questions were asked at the 1 week after acupuncture.||t|f|t|f
33759761|NCT04839263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"FAST TRACK protocol Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op 2) Conventional setting protocol~Preoperative strategy:~* Hospitalization on surgery day~* Fasting as of midnight prior to the day of surgery~Perioperative strategy:~- Balanced anaesthesia via halogens gases~Postoperative strategy:~* Same day refeeding and mobilization minimum 6 hours post operation~* Bladder catheter and Venflon removal on day 1"||||
33883364|NCT03007212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883365|NCT05752214|||COHORT||PROSPECTIVE|||||||
33883366|NCT03491410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759762|NCT02053441|||CASE_CONTROL||PROSPECTIVE|||||||
33883367|NCT01178645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759763|NCT02733809|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883368|NCT00754897|||CASE_ONLY||RETROSPECTIVE|||||||
33883369|NCT05811403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator will not be blinded because of the nature of the intervention and comparator (the flushing agent and pulp capping material)||t|f|f|t
33759764|NCT01079559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759765|NCT03105284|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will act as their own control. Each participant will receive both excision and liposuction of fat.||||
33759766|NCT05174481|||COHORT||PROSPECTIVE|||||||
33759767|NCT01597830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759768|NCT01693692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883370|NCT02322710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883371|NCT01648257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883372|NCT02601924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33883373|NCT00891579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883374|NCT00621504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883375|NCT01950832|||CASE_CONTROL||PROSPECTIVE|||||||
33883376|NCT00760357|||||RETROSPECTIVE|||||||
33883377|NCT06113874|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33883378|NCT01710488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33883379|NCT04438447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be randomly allocated to ERAS or ERAS plus PN at 8:00 PM of the first postoperative days. Randomisation will be performed by a computed-generated permuted-block sequence. A specific code will be generated for each centre to achieve equivalent grouping. The allocation ratio will be 1:1 with a block size of 4. Randomization will be competitive among centers.~Surgeons will not be blinded to treatment arm. Masking to allocation will be impossible to achieve for the nature of the study. Patients will be evaluated for outcomes by assessors not directly involved in patient care and masked to patient allocation"|RASTA will be a randomised controlled multicentre single-blind, parallel arm, superiority, phase-3 trial|f|f|f|t
33883380|NCT03396016|||COHORT||PROSPECTIVE|||||||
34070881|NCT06372314|NA|SINGLE_GROUP||OTHER||NONE||||||
34070882|NCT06109350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blinded with the outcome assessor blinded to the group allocation and the parent of preterm infants will be blinded since they will be scheduled for appointment on the different day. The outcome assessor will not be disclosed with the infants information, such as age , any medical diagnosis and group identification.||f|t|f|t
34070883|NCT01319942|||COHORT||PROSPECTIVE|||||||
33759769|NCT04536311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759770|NCT02878928|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33759771|NCT05145725|||COHORT||PROSPECTIVE|||||||
33759772|NCT01257880|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33759773|NCT01893385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33764952|NCT05897801|||COHORT||PROSPECTIVE|||||||
33883381|NCT00598299|||CASE_CONTROL||PROSPECTIVE|||||||
33883382|NCT06446557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971784|NCT00384033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971785|NCT02669264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971786|NCT00991770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34070884|NCT02279615|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34070885|NCT02660684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070886|NCT00437060|||COHORT||PROSPECTIVE|||||||
34070887|NCT03271632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070888|NCT05341973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34070889|NCT04754542|||CASE_CONTROL||PROSPECTIVE|||||||
34070890|NCT00507520|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34070891|NCT05500014|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33759774|NCT01727063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intramyocardial injection of bone marrow-derived cells OR placebo (saline) during CABG|t|f|t|f
33759775|NCT01834508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759776|NCT01686880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759777|NCT02223039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759778|NCT05081492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883383|NCT06550154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883384|NCT01639872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883385|NCT02483741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883386|NCT02639663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883387|NCT05914701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883388|NCT03654846|RANDOMIZED|PARALLEL||OTHER||SINGLE||Test of EmergencyEye functionality in real environment, comparison with conventional emergency call.|f|t|f|f
33883389|NCT02631200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33883390|NCT06541405|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33883391|NCT01243905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883392|NCT00864266|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883393|NCT06182735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883394|NCT03246815|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883395|NCT03460431|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883396|NCT06037668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883397|NCT02714114|||CASE_CONTROL||PROSPECTIVE|||||||
33883398|NCT02328898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971787|NCT02456233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971788|NCT00368537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971789|NCT00843453|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34070892|NCT05285059|||COHORT||PROSPECTIVE|||||||
34070893|NCT00537355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070894|NCT06120478|||OTHER||RETROSPECTIVE|||||||
34070895|NCT03923777|NA|SINGLE_GROUP||TREATMENT||NONE||"Investigators propose a study involving active surveillance for NSCLC where patients would have consideration of SABR if either the tumor exceeded 3 cm in size or the volume doubling time (VDT) decreased to \<400 days. Following enrollment, chest CT with contrast (with slice thickness ≤3 mm) to be performed 3 months (+/- 30 days) after the initial CT\]. Patients with VDTs \<400 days must be considered for SABR. SABR is not mandatory \[patient choice\] and active surveillance may be continued. Patients with VDTs ≥400 days continue active surveillance via serial CTs with intervals of every 3 months (+/- 30 days) up to 2 years total.~Following informed consent, blood samples will be acquired following the protocol schedule based on enrollment group. Quality of life questionnaires will also be completed following the protocol schedule for the main cohort only."||||
34070896|NCT00216528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883399|NCT02662647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883400|NCT06547970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33883401|NCT06201507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883402|NCT00876993|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33883403|NCT01500356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33971790|NCT00701428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971791|NCT03801837|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33971792|NCT01532245|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33971793|NCT02796196|||COHORT||PROSPECTIVE|||||||
33971794|NCT03929211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971795|NCT00371800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971796|NCT02668783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971797|NCT01604083|||COHORT||PROSPECTIVE|||||||
33971798|NCT01857193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971799|NCT04248855|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33971800|NCT02352506|||COHORT||PROSPECTIVE|||||||
33971801|NCT01576757|||OTHER||PROSPECTIVE|||||||
33883404|NCT03558347|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study consists of 20 patients (15 female, 5 male, mean age 59) who, after implant placement and second stage surgery, are randomly divided into two groups: group A was treated with two splinted crowns, group B with non-splinted single crowns. Four patients with bilateral free-end situation received both splinted and non-splinted restorations.||||
33883405|NCT05558150|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomization, Open-label, Repeated administration, Crossover||||
33883406|NCT03537391|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Imaging modalities will be read blindly without the knowledge of results of the other imaging modalities. Readers will only know that a patient has prostate cancer with high risk for metastases. All imaging data will be analyzed visually with classifying lesions as normal, equivocal or metastatic.|This is a prospective single-institutional study comparing the diagnostic accuracy of novel imaging modalities to traditional imaging modalities among high risk prostate cancer patients at initial diagnosis||||
33883407|NCT03479632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971802|NCT03244956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation||||
33971803|NCT01241409|RANDOMIZED|CROSSOVER||||NONE||||||
33971804|NCT03192059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971805|NCT03249090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33971806|NCT04739449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will have a cluster-randomized design in which two of the four nursing homes will be randomized to the intervention arm or the control arm.||||
33971807|NCT01266174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070897|NCT00457288|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34070898|NCT01958203|||||RETROSPECTIVE|||||||
34070899|NCT00786253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070900|NCT06198998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070901|NCT00501709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070902|NCT03301077|||OTHER||CROSS_SECTIONAL|||||||
34070903|NCT01526278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070904|NCT03460626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Group-I and Group-II will be blinded to the intervention while Group-III would not be administered an intervention.|The students will be divided into three groups randomly as Group-I (Control group: treated with a placebo that is an odorless oil without any therapeutic effect), Group-II (Treated group: administered with lavender oil) and Group-III (Untreated group)|t|f|f|f
34070905|NCT03373760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070906|NCT04237545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization will be done using assignment from a computerized algorithm program. This will be done using a fixed block randomization scheme to ensure 1:1 ratio between test and control groups. Sealed envelopes containing randomization cards (code) will be used.|The patient will be randomized to receive either the T3 short (test device) or the T3 standard length, ≥10mm, (control device) implant.|f|f|t|f
33971808|NCT00192296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971809|NCT00424658|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33971810|NCT04306822|||COHORT||PROSPECTIVE|||||||
33971811|NCT00557882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33971812|NCT03758833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971813|NCT06355739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070907|NCT03213392|||COHORT||PROSPECTIVE|||||||
34070908|NCT02372994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34070909|NCT02421783|||CASE_CONTROL||PROSPECTIVE|||||||
34070910|NCT05462236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070911|NCT00571103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070912|NCT04255537|||COHORT||PROSPECTIVE|||||||
34070913|NCT01212159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070914|NCT02097511|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34070915|NCT03188783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759779|NCT00586599|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33759780|NCT00432874|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33759781|NCT04111068|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant and the researcher will be blind to the order of the sessions for each participant.|1 session of active brain stimulation and 1 session of placebo sham stimulation. Each participant will perform both sessions in a randomly-assigned order.|t|f|t|f
33759782|NCT06363825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070916|NCT03750877|RANDOMIZED|PARALLEL||OTHER||SINGLE|"the number of files from the volunteer participants were grouped into one group and the ones with double file numbers were included in the other group.~participants do not know which group of patients to be in. Only practitioners know about the procedure."|The aim of this study was to evaluate the success rate of median and paramedian approach in spinal anesthesia in geriatric patients, number of trials, number of attempts at another interval due to failure, duration of procedure, patient comfort, change to other method in case of failure and success rate. In the study, two groups were formed: the median approach and the paramedian approach.|t|f|f|f
34070917|NCT06149104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070918|NCT06404255|||COHORT||PROSPECTIVE|||||||
33759783|NCT04447430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070919|NCT00777335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759784|NCT01916005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070920|NCT02497937|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34070921|NCT00643981|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759785|NCT03610763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759786|NCT00034957||||TREATMENT||||||||
33759787|NCT02236065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759788|NCT01690130|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33883408|NCT02636777|||OTHER||PROSPECTIVE|||||||
33883409|NCT00634569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883410|NCT02305693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759789|NCT05448898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070922|NCT04697030|||OTHER||CROSS_SECTIONAL|||||||
34070923|NCT02044003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070924|NCT05187091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759790|NCT02569710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759791|NCT04391946|||COHORT||PROSPECTIVE|||||||
33759792|NCT01768832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759793|NCT03403426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883411|NCT00370201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33883412|NCT04421690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to cognitive training or trivia training and will complete measures of anxiety, sleep, cognition (objective, self-efficacy), and self-reported arousal at baseline, and post-intervention|f|f|f|t
34070925|NCT01084902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070926|NCT02388087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070927|NCT04499196|||CASE_ONLY||PROSPECTIVE|||||||
34070928|NCT05400044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34070929|NCT00921258|||COHORT||PROSPECTIVE|||||||
34070930|NCT00926341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070931|NCT04047732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070932|NCT02889770|||COHORT||PROSPECTIVE|||||||
34070933|NCT01679808|||CASE_ONLY||CROSS_SECTIONAL|||||||
34070934|NCT04870632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070935|NCT00405015|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33759794|NCT05213195|NA|SEQUENTIAL||TREATMENT||NONE||||||
33759795|NCT02607982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883413|NCT03757104|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33883414|NCT02800187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883415|NCT01745640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759796|NCT06327464|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33759797|NCT06143696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883416|NCT00004914||||SUPPORTIVE_CARE||||||||
33883417|NCT01044966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883418|NCT01226238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883419|NCT05012072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The PI will not be allowed to review any data that is not deidentified. The statistician will also not know which participant is in which group by participant names, only by deidentified data.~The clinical outcomes assessor will not know the group the participant has been in or their study number, but will know the participant names to be able to put the clinical outcomes in the database."|Usual care group: routine prenatal care by private practice provider Experimental group: Six week group session of the MLI|f|f|t|t
33883420|NCT04128540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883421|NCT05481866|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33883422|NCT01425112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883423|NCT01124487|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33883424|NCT04482946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883425|NCT00005956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883426|NCT04394442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883427|NCT02326519|NA|SINGLE_GROUP||OTHER||NONE||||||
33759798|NCT01678131|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33759799|NCT06254898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33759800|NCT04078737|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33759801|NCT00194688|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33759802|NCT03489590|NA|SINGLE_GROUP||OTHER||NONE||This study enrolls both healthy volunteers and volunteers with cystic fibrosis. Both healthy and CF participants will receive the same treatment throughout the entirety of the study.||||
33764953|NCT02646215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33764954|NCT04461795|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33971814|NCT04711525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The single-blind RCT will be applied in the present study, in which the researcher but not the study participants know which intervention has been allocated at the preschool level. In the experimental group, the preschool children will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program. Whereas in the control group, the preschool children will be received a standard preschool health education curriculum, and their parents will have access to the general Web-based health newsletters.||t|f|f|f
33764955|NCT03285841|||OTHER||OTHER|||||||
33971815|NCT00366756|||||PROSPECTIVE|||||||
33971816|NCT05252416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33971817|NCT04388059|||CASE_CONTROL||RETROSPECTIVE|||||||
33971818|NCT02397681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971819|NCT02153047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971820|NCT05719571|||OTHER||PROSPECTIVE|||||||
33764956|NCT02676908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764957|NCT03963947|||COHORT||PROSPECTIVE|||||||
33764958|NCT04084977|||CASE_CONTROL||RETROSPECTIVE|||||||
33764959|NCT02911350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883428|NCT00136591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883429|NCT05722379|||COHORT||RETROSPECTIVE|||||||
33883430|NCT05982587|||COHORT||PROSPECTIVE|||||||
33883431|NCT02100605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33883432|NCT03395379|||COHORT||RETROSPECTIVE|||||||
33883433|NCT04297215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883434|NCT00689572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883435|NCT00266253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883436|NCT06500806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked assessor will conduct the measurements|This randomized clinical trial will be under the supervision of the Department of Physiotherapy at the School of Health Sciences, International Hellenic University. Participants will be adolescents aged 10 to 17 years with mild to moderate scoliosis (Cobb angle from 10° to 45°) who will be prescribed a brace. The participants will be randomly assigned to two groups. The intervention group will follow a supervised Schroth exercise program alongside brace use for 12 months, with sessions three times a week. The control group will receive only brace treatment and recommendations for physical activity. The intervention will last one year, with a follow-up six months after the end of the intervention (18th month)|f|f|f|t
33883437|NCT03054610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33883438|NCT06420310|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883439|NCT02975687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883440|NCT04882176|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm1: LM-061 2.5mg P.O QD Arm2: LM-061 5mg, P.O QD Arm3: LM-061 10mg, P.O QD Arm4: LM-061 20mg, P.O QD Arm5: LM-061 30mg, P.O QD Arm6: LM-061 40mg, P.O QD Arm7: LM-061 60mg, P.O QD||||
33883441|NCT04628195|||COHORT||PROSPECTIVE|||||||
33883442|NCT06541223|||CASE_CONTROL||PROSPECTIVE|||||||
33971821|NCT03389984|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971822|NCT06064253|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33971823|NCT01514266|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33971824|NCT05765955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764960|NCT05096468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883443|NCT03315832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients with the diagnosis of severe AS and indication for valve intervention (i.e. SAVR or TAVR) fulfilling all inclusion/exclusion criteria will be randomized using 1:1 ratio.|t|t|t|t
33883444|NCT06500416|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective, non-comparative, interventional study will include 15 cataract patients (30 eyes) who will undergo femtosecond laser-assisted cataract surgery with implantation of the Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL in both eyes.||||
33883445|NCT01699256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33883446|NCT01311700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883447|NCT02772861|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33883448|NCT03653598|||COHORT||PROSPECTIVE|||||||
33883449|NCT05659446|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective randomized controlled clinical trial included all patients who developed the manifestations of low output recurrent colonic fistula or leak after colonic anterior resection for rectal cancer at Zagazig University hospital between (December 2020 to August 2022). the calculated sample size equal 78 patients divided into two equal groups.endoscopicgroup included 39 patients and surgical group included 39 patients.||||
33883450|NCT04758494|||CASE_CONTROL||OTHER|||||||
33883451|NCT02479802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883452|NCT02990260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33883453|NCT00955435|||COHORT||PROSPECTIVE|||||||
33883454|NCT00845442|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||DOUBLE|||f|t|t|f
33883455|NCT03887130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971825|NCT00021658||||PREVENTION||||||||
33971826|NCT00406978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971827|NCT00020891||||DIAGNOSTIC||||||||
33971828|NCT01519128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971829|NCT04615442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971830|NCT01615081|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33971831|NCT06141915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971832|NCT03776409|||COHORT||RETROSPECTIVE|||||||
33971833|NCT02611284|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33883456|NCT04428801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and evaluators|The Phase 2 study is a randomized, double-blind, placebo-control study conducted in multiple clinic facilities.|t|f|f|t
33883457|NCT03488160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883458|NCT05083455|||COHORT||RETROSPECTIVE|||||||
33883459|NCT05098041|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33883460|NCT05025826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The placebo will match as much as possible all the characteristics of the Phycocare®|Arm A: Phycocare Arm B: Placebo|t|t|f|f
33883461|NCT04355598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883462|NCT00890838|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33883463|NCT06412874|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883464|NCT06530784|NA|SINGLE_GROUP||TREATMENT||NONE||Cryoablation combined with PD-1 antibody and bevacizumab||||
33883465|NCT06040983|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33883466|NCT01613755|RANDOMIZED|CROSSOVER||||NONE||||||
33883467|NCT00134628|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33883468|NCT04244929|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The Co-Investigator who assesses the outcomes will be blind to the treatment group's allocation|Prospective, two arms, multicenter study that aims to involve up to 10 hospitals in Italy|f|f|f|t
33883469|NCT02211391|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33883470|NCT06421220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883471|NCT03439033|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Subjects may be assigned to one of three groups, each with a different intervention in terms of either mode or frequency||||
33883472|NCT04511728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883473|NCT06548698|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33883474|NCT01076465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883475|NCT00220246|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33883476|NCT06351930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomised, assessor-blind, parallel group controlled trial|f|f|f|t
33883477|NCT05329935|||COHORT||OTHER|||||||
33883478|NCT00087646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883479|NCT00909311|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883480|NCT01874171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883481|NCT00809380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883482|NCT04137783|||COHORT||RETROSPECTIVE|||||||
33759803|NCT03996057|RANDOMIZED|PARALLEL||PREVENTION||NONE|Attempt will be made to mask the current arm during assessment of outcomes (symptomatic UTI) when the participant calls in with symptoms, as the participant will be asked not to reveal their current prophylaxis regimen unless deemed medically or clinically necessary at the time.|Randomized control pilot trial||||
33759804|NCT00985725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759805|NCT01530672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759806|NCT02020122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33759807|NCT02310555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759808|NCT05485792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects with various types of cancer undergo contemporaneous 18F-FAPI and 18F-FDG PET/CT either for an initial assessment or for recurrence detection.||||
33759809|NCT04842578|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33759810|NCT00084370|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759811|NCT02706860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759812|NCT03455322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33759813|NCT04814680|||CASE_ONLY||PROSPECTIVE|||||||
33759814|NCT01241149|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759815|NCT02914925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759816|NCT01928966|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33883483|NCT02656602|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33883484|NCT03116945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883485|NCT05565963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971834|NCT02701075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33759817|NCT06575569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759818|NCT06069583|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||mixed-method multi-site, 2 arms, non-randomized, type 1 hybrid effectiveness-implementation trial||||
33759819|NCT06429605|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33759820|NCT00453011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33759821|NCT00286793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759822|NCT03356730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking for placebo or vitamin D use|This is a clinical research study, characterized by a randomized, double-blind, placebo-controlled trial.|t|f|t|f
33759823|NCT00387894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764961|NCT06324721|NA|SINGLE_GROUP||SCREENING||NONE||Prospective cohort study||||
33764962|NCT05040022|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will be randomized according to the sequence of random numbers generated by a computer using a specific program (www.random.org). For each patient, an opaque envelope containing the group to which the patient will be allocated will be prepared, sealed, and numbered sequentially.|Prospective, randomized and double-blinded|t|t|t|t
33764963|NCT03311932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764964|NCT01686581|||CASE_ONLY||PROSPECTIVE|||||||
33883486|NCT01497977|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33883487|NCT02260518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33883488|NCT02641509|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33971835|NCT01738581|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33883489|NCT00003100||||PREVENTION||||||||
33883490|NCT05401266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883491|NCT02482155|NA|SINGLE_GROUP||||NONE||||||
33883492|NCT02714166|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33883493|NCT03459027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33883494|NCT02576314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883495|NCT01966549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883496|NCT04400474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971836|NCT04989062|||CASE_ONLY||PROSPECTIVE|||||||
33971837|NCT05379543|||COHORT||PROSPECTIVE|||||||
33971838|NCT04658056|||COHORT||PROSPECTIVE|||||||
33883497|NCT05265403|||CASE_ONLY||CROSS_SECTIONAL|||||||
33883498|NCT01325012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883499|NCT04809610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883500|NCT03442673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883501|NCT00006093||||TREATMENT||||||||
33883502|NCT03351777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883503|NCT02814565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883504|NCT02571010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883505|NCT01707615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883506|NCT03595540|NA|SINGLE_GROUP||OTHER||NONE||This is a pilot, single arm prospective trial assessing feasibility and safety of a 5-day fasting-mimicking diet in patients with different cancer types and concomitant anticancer treatments.||||
33883507|NCT01316250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883508|NCT03734757|NA|SINGLE_GROUP||OTHER||NONE||||||
33883509|NCT06289231|||COHORT||PROSPECTIVE|||||||
33883510|NCT01518595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883511|NCT00647556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883512|NCT04397705|NA|SINGLE_GROUP||OTHER||NONE||Single arm open label study.||||
33971839|NCT03903484|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a single group study using a pre-, post-analysis. We will examine medication use, medication appropriateness, quality of life, and satisfaction with the intervention for participants before and after our deprescribing intervention.||||
33971840|NCT03836781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||split mouth|t|t|t|f
33971841|NCT05361148|||COHORT||CROSS_SECTIONAL|||||||
33971842|NCT01995617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971843|NCT03086720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|f|t
33971844|NCT05332210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883513|NCT02979210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883514|NCT03608917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883515|NCT05840939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study was conducted as a single-blind randomized controlled study with pretest-posttest.|t|f|f|f
33883516|NCT05301387|||OTHER||RETROSPECTIVE|||||||
33883517|NCT05654844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883518|NCT00516555|||COHORT||PROSPECTIVE|||||||
33883519|NCT05601557|||COHORT||PROSPECTIVE|||||||
33883520|NCT01086995|||COHORT||PROSPECTIVE|||||||
33883521|NCT00574574|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33883522|NCT01602341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883523|NCT05431257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883524|NCT01707849|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883525|NCT03390413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883526|NCT03244007|||CASE_CONTROL||RETROSPECTIVE|||||||
33883527|NCT03378063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883528|NCT00785057|||COHORT||RETROSPECTIVE|||||||
33883529|NCT02486315|||COHORT||PROSPECTIVE|||||||
33883530|NCT00707798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33883531|NCT03354182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients didn't know whether they were the control or test group|Randomized clinical study with 1 control group and 1 test group|t|f|f|f
33883532|NCT02617810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883533|NCT03208231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883534|NCT05169528|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||before-after trial||||
33883535|NCT05508087|||COHORT||PROSPECTIVE|||||||
33883536|NCT05449704|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883537|NCT02543138|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33883538|NCT03219866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883539|NCT02282969|||COHORT||CROSS_SECTIONAL|||||||
33883540|NCT01060657|||CASE_CONTROL||PROSPECTIVE|||||||
33883541|NCT03295864|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33883542|NCT03648632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883543|NCT04519723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883544|NCT05083637|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33883545|NCT00003267|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33883546|NCT00083577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883547|NCT03162679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883548|NCT05790265|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883549|NCT04855773|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883550|NCT00564811|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883551|NCT01175785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883552|NCT02602730|RANDOMIZED|PARALLEL||||NONE||||||
33883553|NCT03459573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883554|NCT02271165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883555|NCT05055180|||CASE_CONTROL||PROSPECTIVE|||||||
33883556|NCT02212132|||||PROSPECTIVE|||||||
33883557|NCT00344097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33883558|NCT06182592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883559|NCT02093247|||COHORT||PROSPECTIVE|||||||
33883560|NCT05623293|||COHORT||PROSPECTIVE|||||||
33883561|NCT06170996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883562|NCT01078805|||COHORT||PROSPECTIVE|||||||
33883563|NCT04166279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883564|NCT00639938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33883565|NCT04436146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883566|NCT05837741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883567|NCT03265912|||COHORT||PROSPECTIVE|||||||
33883568|NCT04627909|||OTHER||PROSPECTIVE|||||||
33883569|NCT03814200|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33883570|NCT01424696|||COHORT||PROSPECTIVE|||||||
33883571|NCT00653237|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33883572|NCT04834869|||OTHER||PROSPECTIVE|||||||
33883573|NCT00278603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883574|NCT06109480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971845|NCT03713710|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33764965|NCT04301440|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study concerns adult patients hospitalized for the management of a chronic pathology and / or its complications||||
33883575|NCT05425563|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-participant design with behavioral manipulations||||
33883576|NCT05735548|||COHORT||PROSPECTIVE|||||||
33883577|NCT02305784|||COHORT||PROSPECTIVE|||||||
33883578|NCT02802605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883579|NCT02886416|||COHORT||OTHER|||||||
33883580|NCT03573713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||IPT-G Promoters will screen all women for depression who are pregnant or will have a child who will be 18m old or younger by 2 May 2018 in each of the 34 Care Group Service Areas chosen for the study. If informed consent is obtained and the women's scores on the PHQ-9 indicate mild to severe depression, they will be put into groups of approx. 8 women for IPT-G. The 34 Care Group Service Areas (CGSAs) will then be randomized into 2 arms (IPT-G and control). Women in the CGSAs in the IPT-G arm who screen positive for depression will receive IPT-G for 12 weeks. Following IPT-G treatment, all women who are pregnant or that have a child born on or after 3 August 2016 in the project area will be provided with psychoeducation through the Care Group structure. For the assessments conducted after the baseline, trained external (non-staff) enumerators will be used to assess for depression and other things, and they will be blind to which group the mothers are in (treatment or control).|f|f|f|t
33894559|NCT06377189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"In order to answer the research question of the PLIMeC-P (pilot study), aiming to determine the feasibility and practicability of the main PLIMeC study, in the initial phase, the statistical procedures will be limited to questions of practicability and quality.~For the main PLIMeC study we will use a mixed method approach, combining various data collection and analysis methods (qualitative and quantitative). Quantitative methods will be used to obtain a breadth of understanding of the phenomenon of interest, and qualitative methods will be used to explore and obtain depth of this understanding. More specifically, the combination of methods will be used for complementarity, using qualitative data to examine how the participants, patients and healthcare providers, experience this specific CL-psychiatric intervention and quantitative methods to examine the impact of such an intervention on patients. In data analysis, the priority among the two methods will be equal."||||
33894560|NCT04305392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971846|NCT00614055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971847|NCT02853929|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33971848|NCT05593406|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Randomly divided through folders|The children who participated in the study were randomly divided through folders into an intervention group and a control group. The control group continued the physical therapy program they were already following, while the intervention group, in addition to the conventional physical therapy they received, did also receive mechanical vibration.|t|f|f|f
33971849|NCT01523795|RANDOMIZED|PARALLEL||||NONE||||||
33971850|NCT03348709|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Randomisation by Third party; Unblinded study nurse to mix and deliver study product; masking of product to ensure comparable palatability and appearance; blinding to analyses|Double-blinded, active comparator, cross-over intervention study|t|t|t|t
33971851|NCT02531542|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33971852|NCT01684566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971853|NCT01808209|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33764966|NCT02018445|NA|SINGLE_GROUP||OTHER||NONE||||||
33764967|NCT03202472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971854|NCT01178983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971855|NCT03811041|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33971856|NCT02062606|||COHORT||PROSPECTIVE|||||||
33971857|NCT05579041|||COHORT||PROSPECTIVE|||||||
33971858|NCT05273385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study personnel who will evaluate the IOP and economic endpoints will be blinded to patients' assigned dispenser types for the duration of the study.||f|f|f|t
33971859|NCT04783363|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33971860|NCT01816698|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971861|NCT01063478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759824|NCT05035368|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The identity of the treatment will remain unknown to the patient, Investigator, site staff, CRO and Dompé's Development personnel until the study is unmasked.|"This study is a randomized, placebo-controlled, double-blinded, 2-arm, 2-period crossover phase II trial using the CXCR1/CXCR2 chemokine receptor antagonist ladarixin versus placebo as adjunctive therapy to insulin to improve insulin sensitivity as well as glucometabolic outcomes in adult, insulin-requiring, overweight, IR T1D patients.~This trial will randomize 38 male and female patients 21-65 years of age, inclusive, with established insulin requiring T1D and IR. After a 2:1 randomization into a treatment sequence (either ladarixin followed by placebo, or placebo followed by ladarixin, respectively), patients will be followed up for a maximum of 53 weeks."|t|t|t|t
33883581|NCT04126655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Randomisation will be performed by a sealed envelope system. The randomisation envelopes are kept in a locked cabinet together with the randomisation list Two sets of code envelopes are prepared. The study personnel that will be responsible for study drug administration will have one set for the randomisation of patients and one set will be held by the investigator for emergency code breaking.~The code envelopes are prepared for each patient and contain information about what treatment the patient should receive. The randomisation will be made by the study personnel responsible for the administration of the study drugs at the day of the surgery. The patients will be randomised in consecutive order. The date and time of randomisation should be recorded on the document followed by a signature of the person opening the envelope."|"A total of 30 patients will be included in the study and will be equally randomised in three steps.~In the first phase, six patients will receive a reduced dose 5-FU; 250 mg / m², of which three patients will be randomized to additional Calciumfolinate and three patients will be randomized to additional Arfolitixorin. P When all six patients have been followed up in the context of visits consultation, a clinical safety evaluation (SE) of all AE, and SAE will be performed by two independent physicians If the responsible physicians finds that it is safe that the study will continue, we intend to increase the dose of 5-FU 500 mg / m, after which additional 12 patients will be included.~After inclusion of 6 patients receiving 5-FU 500 mg /m² in combination with Arfolitixorin in the dose of 30mg/m2 a dose adjustment will take place and the last 12 patients will be randomised to either Calciumfolinate 60 mg/m2 or Arfolitixorin 120 /m2."|t|t|t|f
33883582|NCT02055612|||COHORT||CROSS_SECTIONAL|||||||
33883583|NCT03171883|||CASE_ONLY||CROSS_SECTIONAL|||||||
33883584|NCT01409720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971862|NCT04877184|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33883585|NCT01534650|||CASE_ONLY||PROSPECTIVE|||||||
33883586|NCT02771522|NA|SINGLE_GROUP||OTHER||NONE||||||
33883587|NCT01009710|||CASE_ONLY||PROSPECTIVE|||||||
33971863|NCT05139693|||COHORT||RETROSPECTIVE|||||||
33759825|NCT01555788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759826|NCT00341302|||COHORT||PROSPECTIVE|||||||
33759827|NCT02368106|||COHORT||PROSPECTIVE|||||||
33759828|NCT02824302|||COHORT||PROSPECTIVE|||||||
33883588|NCT05054452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883589|NCT03895125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33883590|NCT04789356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental study||||
33883591|NCT00054977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883592|NCT01897246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883593|NCT06444646|||COHORT||CROSS_SECTIONAL|||||||
33883594|NCT00259480|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33883595|NCT00041678||||TREATMENT||||||||
33883596|NCT05032820|NA|SINGLE_GROUP||TREATMENT||NONE||Assess anti-B Cell Maturation Antigen(BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).||||
33883597|NCT02286531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883598|NCT03516266|||COHORT||CROSS_SECTIONAL|||||||
33883599|NCT05919602|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33883600|NCT06454370|||OTHER||PROSPECTIVE|||||||
33883601|NCT02101970|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883602|NCT00492973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33759829|NCT05794802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33883603|NCT06213922|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33883604|NCT01308866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883605|NCT01265771|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33883606|NCT05519735|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883607|NCT03042000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759830|NCT06203886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759831|NCT03054038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759832|NCT05939921|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883608|NCT05464433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883609|NCT06548737|||COHORT||OTHER|||||||
33883610|NCT03071783|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33883611|NCT02277717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883612|NCT00800397|||CASE_ONLY||PROSPECTIVE|||||||
33883613|NCT00133380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33883614|NCT03663088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883615|NCT04172051|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial||||
33883616|NCT02713568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33883617|NCT06114173|NA|SEQUENTIAL||TREATMENT||NONE||||||
33883618|NCT01012492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883619|NCT01014403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971864|NCT06169774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971865|NCT00002315||||TREATMENT||DOUBLE||||||
33971866|NCT01902602|||COHORT||PROSPECTIVE|||||||
33971867|NCT03164954|||COHORT||PROSPECTIVE|||||||
33971868|NCT02646345|||CASE_CONTROL||RETROSPECTIVE|||||||
33883620|NCT00632801|NA|SINGLE_GROUP||||NONE||||||
33883621|NCT02710409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883622|NCT03979326|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33971869|NCT06014450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971870|NCT06173245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759833|NCT01166516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759834|NCT05399225|||COHORT||PROSPECTIVE|||||||
33759835|NCT02447289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759836|NCT06196216|||CASE_CONTROL||RETROSPECTIVE|||||||
33759837|NCT00615264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759838|NCT03221855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759839|NCT04626739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759840|NCT05398302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759841|NCT03466424|||COHORT||PROSPECTIVE|||||||
33759842|NCT01376323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759843|NCT01915576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883623|NCT02409238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883624|NCT02821858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883625|NCT03317951|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, controlled, open-label, randomized, bicenter study parallel-group design||||
33883626|NCT03429127|||CASE_CONTROL||PROSPECTIVE|||||||
33883627|NCT00288574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883628|NCT04289896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33971871|NCT01080027|||COHORT||PROSPECTIVE|||||||
33759844|NCT01659814|||CASE_CONTROL|||||||||
33759845|NCT00356330|||DEFINED_POPULATION||PROSPECTIVE|||||||
33759846|NCT00971750|||CASE_ONLY||PROSPECTIVE|||||||
33759847|NCT02043028|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33759848|NCT03060655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759849|NCT00212498|||||PROSPECTIVE|||||||
33759850|NCT03038906|||COHORT||PROSPECTIVE|||||||
33759851|NCT01956422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759852|NCT03321825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33759853|NCT02202746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759854|NCT06624748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33883629|NCT06419764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971872|NCT02115256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971873|NCT01441271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971874|NCT04508712|||CASE_ONLY||PROSPECTIVE|||||||
33759855|NCT00674570|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33759856|NCT02782390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759857|NCT03015506|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33759858|NCT03375281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759859|NCT00161590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759860|NCT01906684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759861|NCT00817557|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33759862|NCT04748081|||COHORT||RETROSPECTIVE|||||||
33759863|NCT04247282|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33883630|NCT03436615|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33883631|NCT05950685|||COHORT||PROSPECTIVE|||||||
33883632|NCT05116241|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883633|NCT00875069|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33894561|NCT04824989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are blind to participant assignment. Participant and Care Provider cannot be blind as the assignment determines the focus of the intervention received (sleep, behavior, choice, or safety/hygiene).|Families are randomly assigned to one of four groups for an 8-week parent coaching intervention program: focus on (1) child sleep, (2) child behavior, (3) parent choice of child sleep or child behavior, (4) active control - safety \& hygiene|f|f|f|t
33894562|NCT00643149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894563|NCT01877655|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759864|NCT03607357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759865|NCT05026125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|with randomization envelopes opened by the care provider|Prospective, randomized, controlled, double blinded and monocentric Pilot Study|t|f|t|t
33759866|NCT02101086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759867|NCT03260582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759868|NCT02308579|||CASE_CONTROL||RETROSPECTIVE|||||||
33759869|NCT01342458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33759870|NCT05261893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759871|NCT00085202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759872|NCT00855010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894564|NCT03919240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070936|NCT05388656|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|There will be one unblinded Research Assistant administering interventions to preserve masking of research personnel and participants involved. Care provider may be unmasked for specific participants if there are adverse events requiring referral.||t|t|t|t
34070937|NCT01407146|||CASE_ONLY||RETROSPECTIVE|||||||
34070938|NCT01135043|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34070939|NCT02927574|||OTHER||OTHER|||||||
34070940|NCT02693457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070941|NCT04037514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070942|NCT02469168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34070943|NCT00420953|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34070944|NCT04056312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070945|NCT03904810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||5 groups ×3 times factorial design|t|f|f|f
34070946|NCT01983826|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33894565|NCT03890055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070947|NCT01698268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070948|NCT02878096|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34070949|NCT03175315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070950|NCT00374023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34070951|NCT02889614|||COHORT||RETROSPECTIVE|||||||
34070952|NCT00672607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759873|NCT03039439|||CASE_ONLY||RETROSPECTIVE|||||||
33759874|NCT03948984|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33759875|NCT01368848|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764968|NCT02642081|||CASE_ONLY||RETROSPECTIVE|||||||
33764969|NCT02653573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764970|NCT01351025|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33764971|NCT02300012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764972|NCT01776814|||||PROSPECTIVE|||||||
33764973|NCT04318093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764974|NCT06210503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894566|NCT03754049|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894567|NCT06066879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894568|NCT05505058|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cross-sectional study with parallel randomized design (allocation 1:1)||||
33894569|NCT03153852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070953|NCT05456724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070954|NCT01645956|||COHORT||PROSPECTIVE|||||||
34070955|NCT00376532|||CASE_CONTROL||PROSPECTIVE|||||||
34070956|NCT05752747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"In order to prevent selection bias, the assignment of infants to groups will be made using stratification and randomization methods with blocks. Parents will not be informed which group their baby is in (ShotBlocker©, cold massage, control). In the study, the pain level of the infants will be evaluated by the family health worker, the researcher and their parents who administered the vaccine. At the end of the study, inter-observer agreement will be evaluated. Parents and family health workers will be informed by the researcher about the pain scale to be used in the research. In addition, the database of the research will be created by a university graduate statistician working in a statistical center independent of the research, apart from the researcher."|This study was planned as randomized controlled experimental.|t|f|f|t
34070957|NCT04648449|||CASE_ONLY||PROSPECTIVE|||||||
34070958|NCT05971264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34070959|NCT02096276|||COHORT||PROSPECTIVE|||||||
33883634|NCT06549400|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label extension study intended to evaluate the continuous long-term (18 months) safety and efficacy of once daily mexiletine-prolonged release (mexiletine PR) for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302. The MEX-DM-302 is a multicenter, randomized, double-blind, parallel-group, placebocontrolled study intended to evaluate the safety and efficacy of mexiletine PR in patients with DM1 and DM2) for 6 months. At the completion of the final visit in Study MEX-DM-302 patients who continue to meet the eligibility criteria will be invited to rollover into this open-label study for an additional 18 months. All patients who elect to continue into this open-label study will receive active mexiletine PR (no placebo).||||
33883635|NCT00479154|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33883636|NCT04780269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883637|NCT05488847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33883638|NCT00859703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883639|NCT05079360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only independent central reader will be blinded|Multicenter, randomized, open-label, two treatment arm study|f|f|f|t
33883640|NCT03522441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883641|NCT04506697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883642|NCT04785365|NA|SINGLE_GROUP||OTHER||NONE||||||
33883643|NCT06471582|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883644|NCT02354703|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|treatment assignment and genotype classification known only to research pharmacist and study biostatistician who performed randomization.|2 x 2 factorial design: treatment intervention (active, placebo) x genotype (responsive, non-responsive)|t|t|t|t
33883645|NCT05543668|||COHORT||PROSPECTIVE|||||||
33971875|NCT04473079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, placebo-controlled, double-blind trial|t|t|t|t
33971876|NCT01640028|||CASE_ONLY||PROSPECTIVE|||||||
33971877|NCT01793610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34070960|NCT06479408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070961|NCT05395156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34070962|NCT02588586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070963|NCT04129294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070964|NCT02797977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34070965|NCT02320448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070966|NCT05259319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070967|NCT00308516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070968|NCT02076347|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34070969|NCT04067596|NA|SINGLE_GROUP||OTHER||NONE||||||
34070970|NCT04141397|||COHORT||RETROSPECTIVE|||||||
34070971|NCT02792439|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33883646|NCT00616109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883647|NCT02713308|||COHORT||PROSPECTIVE|||||||
33883648|NCT04941144|||COHORT||PROSPECTIVE|||||||
34070972|NCT05753735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study will be a randomized, controlled, unblinded, double-arm study with 2:1 randomization to the intervention group.||||
34070973|NCT02957617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070974|NCT03909737|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||This study will enroll three study cohorts: (1) a rural cohort of pregnant mother-infant pairs based in the southern region of Sikasso where infant mortality rates are higher than the national average (2) a rural cohort of only infants enrolled from the same communities as the mother-infant pairs, and (3) an urban cohort of pregnant mother-infant pairs based in Bamako. Cohort 1 will use a 2x2 factorial design. The pregnant women will be randomized to receive either oral azithromycin or placebo, and their infants, once born, will be separately randomized to receive either oral azithromycin or placebo. Cohorts 2 and 3 will use a parallel design. In Cohort 2, infants will be randomized to either azithromycin or placebo. In Cohort 3, mother-infant pairs will be randomized in tandem to either azithromycin or placebo.|t|t|t|t
34070975|NCT03963921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34070976|NCT02447913|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883649|NCT00743808|||COHORT||PROSPECTIVE|||||||
33883650|NCT01815931|||COHORT||PROSPECTIVE|||||||
33883651|NCT03624946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894570|NCT00886938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070977|NCT02105285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070978|NCT04501055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, the investigator and the outcomes assessor were all masked. Only the care provider who performed the anaesthesia were not blinded but they were not involved in the subsequent prostate biopsy, pain assessment, data collection and data analysis.||t|f|t|t
34070979|NCT06303206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971878|NCT02226796|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33971879|NCT02017028|||COHORT||PROSPECTIVE|||||||
33971880|NCT02958657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971881|NCT01618266|||COHORT||PROSPECTIVE|||||||
33971882|NCT01243996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33971883|NCT02540148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971884|NCT02971956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971885|NCT03991832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971886|NCT03317236|RANDOMIZED|CROSSOVER||OTHER||NONE||Single-dose, two-way crossover.||||
33971887|NCT01215123|||COHORT||RETROSPECTIVE|||||||
33971888|NCT00004342|||OTHER||CROSS_SECTIONAL|||||||
33971889|NCT03853577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33971890|NCT00820456|||CASE_ONLY||PROSPECTIVE|||||||
33971891|NCT03735784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33971892|NCT05448716|||COHORT||PROSPECTIVE|||||||
33759876|NCT06254534|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The anesthesiology technician selected an envelope in order of numbers written on it and prepared unlabeled saline infusions according to the predetermined protocols of each group. Each group received one of the protocols as lidocaine (1.5 mg/kg), dexmedetomidine (1 mcg/kg), esmolol (1 mcq/kg), and magnesium (20 mg/kg) prepared in 50 ml of unlabeled physiological saline, after standard monitoring on the operating room table. In the control group, only saline was administered intravenously for 10 minutes; then general anesthesia was applied. Along with the study participants, the primary investigator was kept blind to the study groups as the sole applier of the ONSD measurement and the only observer of the hemodynamic changes.|Standardized, controlled, randomized, double blind|t|f|t|f
33759877|NCT04983108|||CASE_ONLY||CROSS_SECTIONAL|||||||
33759878|NCT01194895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759879|NCT05956704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759880|NCT01874457|||||PROSPECTIVE|||||||
33759881|NCT04075825|NA|SINGLE_GROUP||OTHER||NONE||||||
33759882|NCT05252819|||OTHER||CROSS_SECTIONAL|||||||
33759883|NCT05850039|||CASE_CONTROL||PROSPECTIVE|||||||
33759884|NCT01946022|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33759885|NCT01422525|||COHORT||PROSPECTIVE|||||||
33759886|NCT01546259|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33759887|NCT01756664|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33759888|NCT02849275|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will pass through 2 arms, control and probiotic, in a randomized, counter-balanced order.|t|f|t|f
33759889|NCT01208948|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33759890|NCT01953614|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33759891|NCT04894526|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33759892|NCT03464279|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33759893|NCT02385994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759894|NCT05728255|||COHORT||PROSPECTIVE|||||||
33759895|NCT06221423|||COHORT||PROSPECTIVE|||||||
33759896|NCT04786379|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who are diagnosed with septic arthritis of the native knee will be randomized to either arthroscopic or open treatment.||||
33759897|NCT03705195|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Proof-of-Concept Physiological Study||||
33759898|NCT03540511|||COHORT||RETROSPECTIVE|||||||
33883652|NCT06489717|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Each highlander with HAPH will be assessed for SDB at 3200 m and at 760 m according to a prospective study design||||
33883653|NCT01337973|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33883654|NCT03436355|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883655|NCT05844215|||COHORT||PROSPECTIVE|||||||
33759899|NCT01860469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33759900|NCT00462280|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33759901|NCT01303081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33759902|NCT04378192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33759903|NCT03293225|||CASE_CONTROL||PROSPECTIVE|||||||
33759904|NCT05722470|||COHORT||PROSPECTIVE|||||||
34070980|NCT04585243|NA|SINGLE_GROUP||SCREENING||NONE||Participants who enroll in the study will be asked to complete an HPV self-sampling kit in addition to completing their colposcopy exam. Participants will collect the sample at home before or after their exam and mail it back to the Penn State Health laboratory for analysis. The results will be compared to those of the clinician-collected (standard of care) colposcopy exam, Pap, and HPV test. Participants will also complete a follow up survey over the phone after their sample is collected.||||
33759905|NCT01192425|||||PROSPECTIVE|||||||
33759906|NCT03348072|||CASE_CONTROL||PROSPECTIVE|||||||
33759907|NCT02276170|||COHORT||PROSPECTIVE|||||||
34070981|NCT02595112|NA|SINGLE_GROUP||SCREENING||NONE||||||
33759908|NCT01382329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33759909|NCT00006825||||TREATMENT||||||||
34070982|NCT00940576|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33759910|NCT03013088|NA|SINGLE_GROUP||OTHER||NONE||||||
33759911|NCT06187740|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Initial dose of 30 Gy in 10 fractions (3 patients, Arm 1). Dose escalation will start after acceptable safety was observed, 35 Gy/10Fx (3 patients, Arm 2), 40 Gy/10Fx (22 patients, Arm 3).||||
33759912|NCT06373484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759913|NCT02847299|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33883656|NCT04269395|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33883657|NCT06115109|||COHORT||PROSPECTIVE|||||||
33883658|NCT04218097|||COHORT||RETROSPECTIVE|||||||
34070983|NCT06553079|||OTHER||CROSS_SECTIONAL|||||||
34070984|NCT02149264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34070985|NCT04227405|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34070986|NCT03017196|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34070987|NCT06076187|||COHORT||CROSS_SECTIONAL|||||||
34070988|NCT00992017|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34070989|NCT05991960|||COHORT||RETROSPECTIVE|||||||
34070990|NCT01610856|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
34070991|NCT00701792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34070992|NCT02811991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34070993|NCT06490783|||COHORT||PROSPECTIVE|||||||
34070994|NCT05045846|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34070995|NCT04911595|||CASE_ONLY||RETROSPECTIVE|||||||
34070996|NCT04322669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34070997|NCT04391179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34070998|NCT01306279|||COHORT||PROSPECTIVE|||||||
34070999|NCT05013502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071000|NCT00789685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071001|NCT06099925|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071002|NCT01110577|||COHORT||CROSS_SECTIONAL|||||||
34071003|NCT01869218|||CASE_ONLY||CROSS_SECTIONAL|||||||
34071004|NCT05965765|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34071005|NCT03243123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071006|NCT06017895|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34071007|NCT00002692|RANDOMIZED|||TREATMENT||||||||
34071008|NCT06433843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071009|NCT01117077|||CASE_CONTROL||PROSPECTIVE|||||||
34071010|NCT06047223|||COHORT||CROSS_SECTIONAL|||||||
34071011|NCT03445806|||COHORT||PROSPECTIVE|||||||
34071012|NCT02870556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34071013|NCT03129815|||COHORT||PROSPECTIVE|||||||
34071014|NCT00700128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071015|NCT02456025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071016|NCT04116008|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Controlled randomized study|t|f|f|f
34071017|NCT02677597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071018|NCT06612736|||COHORT||RETROSPECTIVE|||||||
34071019|NCT04108741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34071020|NCT05088681|||CASE_CONTROL||PROSPECTIVE|||||||
34071021|NCT00171158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071022|NCT00531947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071023|NCT04316260|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071024|NCT05013632|||COHORT||PROSPECTIVE|||||||
34071025|NCT03821246|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34071026|NCT03914274|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33759914|NCT00895622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759915|NCT01424930|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759916|NCT03675932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759917|NCT03600584|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33759918|NCT01837004|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33759919|NCT02573025|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33759920|NCT04060602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759921|NCT06443619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759922|NCT04344639|||CASE_ONLY||PROSPECTIVE|||||||
33759923|NCT00508261|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759924|NCT05807581|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33759925|NCT00732186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071027|NCT02764476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blinded randomized control trial for 8 weeks, then control group will be offered active treatment if desired.|t|f|f|f
34071028|NCT05415436|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071029|NCT02938156|||COHORT||PROSPECTIVE|||||||
33883659|NCT03632980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883660|NCT04039997|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33971893|NCT01095757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759926|NCT02411838|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33759927|NCT06121622|||OTHER||PROSPECTIVE|||||||
33759928|NCT00325325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883661|NCT02859909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883662|NCT00731874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883663|NCT03590509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|While the families and HRCC staff cannot be blinded, the healthcare economist and the statistician will remain blinded to treatment group when performing the analyses.|Randomized Quality-Improvement Trial|f|f|t|f
33883664|NCT01734655|||COHORT||CROSS_SECTIONAL|||||||
33883665|NCT06158165|||COHORT||PROSPECTIVE|||||||
33883666|NCT02803073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971894|NCT01161654|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971895|NCT00050895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971896|NCT02001779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971897|NCT03065127|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33971898|NCT01831063|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33971899|NCT00988169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759929|NCT00249743|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33883667|NCT00368576|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33883668|NCT02288273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33883669|NCT04349046|||COHORT||OTHER|||||||
33883670|NCT02488304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883671|NCT01658657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883672|NCT02271412|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33883673|NCT04654858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding to the child participants and legal guardian of each participating child, operator, outcome assessor and statistician.||t|t|t|t
33883674|NCT02194439|||COHORT||PROSPECTIVE|||||||
33971900|NCT06325085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971901|NCT03381547|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33971902|NCT00317954|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33971903|NCT03827213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759930|NCT04104451|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33759931|NCT00641823|||COHORT||CROSS_SECTIONAL|||||||
33759932|NCT05863130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759933|NCT01781676|||COHORT||PROSPECTIVE|||||||
33759934|NCT01601288|||CASE_ONLY||PROSPECTIVE|||||||
33759935|NCT01933022|NA|SINGLE_GROUP||OTHER||NONE||||||
33759936|NCT05363969|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759937|NCT03877458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759938|NCT04765735|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33759939|NCT01741376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883675|NCT02471716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883676|NCT01909284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883677|NCT01389557|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33883678|NCT02715687|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883679|NCT02809066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883680|NCT03512548|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33883681|NCT02796573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33883682|NCT05392452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883683|NCT03047785|||COHORT||PROSPECTIVE|||||||
33883684|NCT04669990|||CASE_ONLY||PROSPECTIVE|||||||
33883685|NCT02017574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33883686|NCT05129397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There are two arms: an experimental group receiving the Mom Power group intervention over 10 weeks, and a control group that will receive informational virtual mailings over 10 weeks. Treatment delivery will be consistent with the Mom Power manual and informational mailings will contain content from the Mom Power Curriculum.|f|f|f|t
33971904|NCT00753714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883687|NCT03222466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33883688|NCT05218616|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34071030|NCT00825838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071031|NCT01014052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071032|NCT02787122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded rating of diagnostic interviews|The CBT-E group receives 15-25 sessions of cognitive behavior therapy with a special focus on emotion regulation (CBT-E), the wait list group receives CBT-E after six month waiting time|t|f|f|f
34071033|NCT03223012|||COHORT||PROSPECTIVE|||||||
34071034|NCT05183347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071035|NCT04912479|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883689|NCT00305578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33883690|NCT02629159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883691|NCT03898063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883692|NCT04613115|||CASE_ONLY||PROSPECTIVE|||||||
33883693|NCT01505907|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33883694|NCT03544073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and provider will both be blinded to the medication that the patient receives.||t|t|f|f
33883695|NCT03058913|||COHORT||PROSPECTIVE|||||||
33883696|NCT00031161|RANDOMIZED|||PREVENTION||DOUBLE||||||
33883697|NCT05642858|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883698|NCT02614079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883699|NCT04723576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Masking of research staff will be performed to the extent possible in this study. The survey data can be analyzed in a blinded fashion. However, due to the nature of qualitative research (described below), masking will not be possible for this data collection effort. Given that no qualitative research can be performed in a blinded way, we do not anticipate the lack of masking to affect our qualitative results adversely.||f|f|f|t
33883700|NCT04587674|NA|SINGLE_GROUP||SCREENING||NONE||||||
33883701|NCT02676687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883702|NCT03457675|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."|At the end of month 8 after DBS implant, all subjects will enter a one-month delayed onset withdrawal period in which the subject and Independent Evaluators are blinded to timing of discontinuation. See description below.|t|f|f|t
33883703|NCT00928421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883704|NCT05675137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33883705|NCT02516670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883706|NCT05674474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883707|NCT05542238|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33883708|NCT04082260|||COHORT||PROSPECTIVE|||||||
33883709|NCT00332540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33883710|NCT02608918|NA|SINGLE_GROUP||OTHER||NONE||||||
33883711|NCT01558063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883712|NCT00522795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883713|NCT03842293|||COHORT||PROSPECTIVE|||||||
33883714|NCT02362841|||COHORT||PROSPECTIVE|||||||
33883715|NCT04788940|||COHORT||PROSPECTIVE|||||||
33883716|NCT01233479||||BASIC_SCIENCE||NONE||||||
33883717|NCT04617366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883718|NCT05253417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind: Study staff (including the study investigators, the clinical trials coordinator and the study medical officer) and the participants will be blinded. Blinding will be maintained by the use of identical containers and labels except for the patient identification code and unique batch number.|Randomised, placebo-controlled, double-blind, parallel trial|t|f|t|f
33883719|NCT05450588|||OTHER||CROSS_SECTIONAL|||||||
33883720|NCT01163058|||COHORT||RETROSPECTIVE|||||||
33883721|NCT03693248|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of clinical outcomes between two and three cycles of neoadjuvant chemotherapy followed by interval debulking surgery.||||
33883722|NCT05334446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The Effect ''of Follow-up With the Mobile Application'' on Treatment Compliance with the intervention group.|t|f|f|t
33883723|NCT06201832|||COHORT||PROSPECTIVE|||||||
33883724|NCT06349057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883725|NCT03158766|||COHORT||PROSPECTIVE|||||||
33883726|NCT00133523|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33883727|NCT05816863|||COHORT||PROSPECTIVE|||||||
33883728|NCT04396899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071036|NCT02963636|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33759940|NCT05884463|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759941|NCT04069598|||CASE_ONLY||PROSPECTIVE|||||||
33759942|NCT05403190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759943|NCT00775814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759944|NCT06569875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759945|NCT00962247||SEQUENTIAL||OTHER||NONE||||||
33759946|NCT05801575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this stepped wedge design trial, the participants will be aware of the transition from no intervention period to intervention period, therefore it is unlikely to blind participants. Outcome assessors will be blinded to reduce the introduction of bias into the assessments.|This is a stepped wedge cluster randomized controlled trial design.|f|f|f|t
33759947|NCT05850468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33759948|NCT00465933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759949|NCT00167830|NA|SINGLE_GROUP||||NONE||||||
33759950|NCT05476835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"50 patients were enrolled in the study post hospitalization due to severe COVID 19 infection. Dyspnea score, Spirometry and 6minute walk test were performed upon discharge. Pulmonary rehabilitation program was performed. Follow up assessment of the same parameters was done 6 weeks after the program.~These results were compared with another 50 patients who were admitted in hospital due to severe COVID 19 infection but no pulmonary rehabilitation program was performed to them after hospitalization."||||
33759951|NCT06277362|||COHORT||PROSPECTIVE|||||||
34071037|NCT05703334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"seventy male athletic subjects with exercise induced asthma, their age ranged from 18-30 years old in this study , with group (A) mean age (21.03+3.6 years), and mean BMI values (27.6+.9 kg/m2) ,and group (B) mean age (21.9+3.8 years),and mean BMI values (27.8+1.3 kg/m2), and group (C) mean age(22+3.1 years), and mean BMI values (27.8+1.3 kg/m2).~Subjects were assigned randomly into tow study groups and one control group:Group(A) 30 subjects were treated by kinesio tap therapy 2sessions per week,Ground(B) 30 subjects were treated by myofascial release therapy 3 sessions per week ,Group (C) 10 subjects were not recieved treatment."|t|f|f|f
34071038|NCT00314808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071039|NCT00158262|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34071040|NCT02834858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071041|NCT00951158|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071042|NCT06060028|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33759952|NCT06446505|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33759953|NCT06212648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|This clinical trial is a randomized, double-blind, parallel design, placebo and active drug comparison, and multicenter clinical trial to evaluate the safety and efficacy of investigational drugs after 8 weeks of administration.|t|f|t|f
33759954|NCT01580839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33759955|NCT04059692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects do not know the group to which they belong. The evaluator does not know the treatment applied.|The study design is experimental|t|f|f|t
33759956|NCT03073564|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The first arm of the study consists of the identification of patients who present dynamic hyperinflation (HD) through the incremental cardiopulmonary test for upper limbs. Following the HDP patients will perform a resistance test for the upper limbs with an application of EPAP. A final stage of the study will be a test for the upper limbs with an EPAP application.||||
33759957|NCT05836870|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33759958|NCT03562065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071043|NCT03670511|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34071044|NCT05503017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33759959|NCT02203708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33759960|NCT03888339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33759961|NCT03123848|NA|SINGLE_GROUP||OTHER||NONE||||||
33759962|NCT00429663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759963|NCT00021814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759964|NCT04149925|||CASE_ONLY||PROSPECTIVE|||||||
33759965|NCT01133158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33759966|NCT00263328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759967|NCT00256958|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33759968|NCT02768610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33759969|NCT02561286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33759970|NCT00019058||||TREATMENT||||||||
33759971|NCT00005296|||COHORT||PROSPECTIVE|||||||
33759972|NCT00392301|||OTHER||PROSPECTIVE|||||||
33759973|NCT02994914|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071045|NCT04762563|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33759974|NCT00823784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759975|NCT01242748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759976|NCT04946175|||OTHER||PROSPECTIVE|||||||
33759977|NCT02920697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759978|NCT01590290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071046|NCT04050085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071047|NCT04204083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071048|NCT02258594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071049|NCT02425735|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33759979|NCT00304512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759980|NCT02756754|NA|SINGLE_GROUP||OTHER||NONE||||||
33759981|NCT05042089|||OTHER||RETROSPECTIVE|||||||
33759982|NCT06151535|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33759983|NCT02933801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33759984|NCT03952702|||COHORT||PROSPECTIVE|||||||
33759985|NCT04665648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071050|NCT00583011|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34071051|NCT02168023|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34071052|NCT00703677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071053|NCT04954417|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34071054|NCT00556257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759986|NCT00958763|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33759987|NCT02010632|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34071055|NCT02662335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33759988|NCT01865916|RANDOMIZED|PARALLEL||||NONE||||||
33759989|NCT00685945|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33759990|NCT02329574|||COHORT||PROSPECTIVE|||||||
33759991|NCT03048344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Part 1 of the study is parallel. Part 2 will be an expansion phase.||||
33759992|NCT05782543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759993|NCT04963205|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33759994|NCT00431925|||DEFINED_POPULATION||PROSPECTIVE|||||||
33759995|NCT01742156|||COHORT||PROSPECTIVE|||||||
34071056|NCT05376761|NA|SINGLE_GROUP||OTHER||NONE||||||
34071057|NCT00435461|RANDOMIZED|PARALLEL||TREATMENT||||||||
34071058|NCT03367234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071059|NCT02555085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071060|NCT03442231|||COHORT||OTHER|||||||
34071061|NCT02295332|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34071062|NCT00921713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34071063|NCT05352880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071064|NCT02029482|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34071065|NCT02099253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071066|NCT02725437|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34071067|NCT03140540|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The intensivist taking care of the patient postoperatively not aware of the intervention|TEE as guide for tailoring perioperative fluid therapy to achieve individualized hemodynamic endpoint , target hemodynamic goals of stroke volume index (SVI) greater than 35 mL/m2 and cardiac index greater than 2.5 L/min/m2 and tissue oxygen delivery. Lactate levels as a surrogate indicator of organ perfusion as measured by arterial blood gas analysis intraoperatively , after 12 hours and 48 hrs postoperatively.|f|t|f|f
33759996|NCT02887430|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33759997|NCT05526586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33759998|NCT04886479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33759999|NCT00687570|RANDOMIZED|CROSSOVER||||NONE||||||
33760000|NCT06580093|||COHORT||PROSPECTIVE|||||||
33760001|NCT02163590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33760002|NCT01381419|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33760003|NCT03285048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760004|NCT02789475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760005|NCT01746043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764975|NCT06071832|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"In Aim 1, we will focus on the effects of structured video chat on child engagement and initiations of joint attention during video chat with grandparents.~In Aim 2, we will determine whether structured video chat increases grandparents' enjoyment of the video chats and leads to greater feelings of closeness to their grandchild."||||
33764976|NCT05389891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764977|NCT00133536|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33764978|NCT00004401||||TREATMENT||NONE||||||
33764979|NCT04758767|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single arm dose escalation, followed by dose expansion arm (2 cohorts)||||
33764980|NCT02438839|||CASE_ONLY||PROSPECTIVE|||||||
33764981|NCT03170245|||CASE_CONTROL||PROSPECTIVE|||||||
33764982|NCT05125523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883729|NCT04044755|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessors involved in data management and analysis will be blinded to the group assignment. The study participants, the investigators responsible for randomization will not be masked.||f|f|f|t
33883730|NCT06020235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883731|NCT03416283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Investigator)||f|f|t|f
33883732|NCT01356550|NON_RANDOMIZED|PARALLEL||||NONE||||||
33883733|NCT00469612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883734|NCT05788185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883735|NCT04106531|||COHORT||PROSPECTIVE|||||||
33883736|NCT00523588|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34071068|NCT01251159|||OTHER||RETROSPECTIVE|||||||
34071069|NCT00790556|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34071070|NCT00484926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071071|NCT02007213|||COHORT||PROSPECTIVE|||||||
34071072|NCT01853748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071073|NCT03162068|||CASE_CONTROL||PROSPECTIVE|||||||
34071074|NCT04687826|||COHORT||RETROSPECTIVE|||||||
34071075|NCT00667303|||||PROSPECTIVE|||||||
34071076|NCT00164632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071077|NCT01509612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34071078|NCT04773938|||CASE_ONLY||RETROSPECTIVE|||||||
33883737|NCT02468336|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33883738|NCT06473909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883739|NCT00273819|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33883740|NCT03325946|||COHORT||PROSPECTIVE|||||||
33883741|NCT02705898|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33883742|NCT03129074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883743|NCT02722681|||COHORT||PROSPECTIVE|||||||
33883744|NCT06193941|||COHORT||RETROSPECTIVE|||||||
33883745|NCT04516473|||CASE_CONTROL||PROSPECTIVE|||||||
33883746|NCT01047878|||CASE_ONLY||PROSPECTIVE|||||||
34071079|NCT02916134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071080|NCT05162430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34071081|NCT02335346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071082|NCT06265909|||COHORT||PROSPECTIVE|||||||
34071083|NCT00581932|||COHORT||PROSPECTIVE|||||||
34071084|NCT04481594|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|double-blind (participant, investigator)|Parallel Assignment|t|f|t|f
34071085|NCT06291129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071086|NCT02705378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071087|NCT01450618|||COHORT||RETROSPECTIVE|||||||
34071088|NCT04558671|||COHORT||RETROSPECTIVE|||||||
34071089|NCT00851188|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071090|NCT01013831|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071091|NCT03488797|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34071092|NCT04260295|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34071093|NCT00402623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071094|NCT00715468|||CASE_CROSSOVER||PROSPECTIVE|||||||
34071095|NCT01420341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071096|NCT06321120|NA|SINGLE_GROUP||TREATMENT||NONE||An open-labeled, prospective, single-center proof-of-concept clinical trial lasting 14 weeks was conducted to investigate the impact of an algorithm-based regimen on enhancing lenvatinib effectiveness.||||
34071097|NCT03791112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071098|NCT01401946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071099|NCT01337817|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34071100|NCT00002773||||TREATMENT||||||||
34071101|NCT00821405|||COHORT||CROSS_SECTIONAL|||||||
34071102|NCT00461929|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071103|NCT05258682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071104|NCT02382809|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34071105|NCT04472494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071106|NCT05964153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071107|NCT02359279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071108|NCT01580566|||COHORT||PROSPECTIVE|||||||
34071109|NCT02447471|||COHORT||PROSPECTIVE|||||||
34071110|NCT05485870|||COHORT||PROSPECTIVE|||||||
34071111|NCT00032500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34071112|NCT00629759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071113|NCT02799914|||COHORT||PROSPECTIVE|||||||
34071114|NCT01842425|||CASE_ONLY||PROSPECTIVE|||||||
34071115|NCT03835507|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34071116|NCT01388712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071117|NCT02347735|||COHORT||PROSPECTIVE|||||||
34071118|NCT02162095|||CASE_CONTROL||RETROSPECTIVE|||||||
34071119|NCT01017081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34071120|NCT01758614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883747|NCT02456688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071121|NCT01497067|NA|SINGLE_GROUP||OTHER||NONE||||||
34071122|NCT05230797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071123|NCT04469634|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071124|NCT05413057|||COHORT||PROSPECTIVE|||||||
34071125|NCT02073539|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34071126|NCT03171597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071127|NCT04753502|||COHORT||RETROSPECTIVE|||||||
34071128|NCT02839031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34071129|NCT03056612|||CASE_CONTROL||PROSPECTIVE|||||||
34071130|NCT00738855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071131|NCT03076515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071132|NCT05631145|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial testing MT combined with XKSA versus MT alone.||||
34071133|NCT03852186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071134|NCT03088228|||CASE_CONTROL||OTHER|||||||
33760006|NCT05067569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will not be blinded as they will know what treatment they receive. This is typical of behavioural interventions.~Note: the study project coordinator will not be blinded as they will be managing the study such as sending sleep-tracking wearable devices to the intervention arm and communicating with participants. All investigators and data analysts will be blinded."|Participants will be provided with a digital brief behavioural therapy (SleepFix app) which provides personalised sleep retraining therapy. Participants will also be provided a sleep-tracking wearable device (Fitbit) that synchronises the going to bed and getting out of bed times with the SleepFix app. Participants will complete a daily sleep diary and can modify the sleep-tracking wearable device sleep data. The program will provide an individualised sleep window of when to go and when to get out of bed. There are five stages focusing on bed timings, sleep efficiency and a maintenance phase for consolidating the new sleep pattern. The program provides information related to sleep hygiene and stimulus control. This will be available for participants for 6 weeks. An active wait-listed control of sleep health education will consist of 3 modules delivered biweekly of generalised sleep health information that could be found on the internet.|f|f|t|f
33760007|NCT06185010|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33760008|NCT02160314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760009|NCT02164994|||COHORT||PROSPECTIVE|||||||
33760010|NCT02417584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760011|NCT02036645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33760012|NCT00777907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760013|NCT00420992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760014|NCT03571958|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760015|NCT06214286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 100 females patients ( two groups each group 50 females) who were diagnosed as having mild or moderate carpal tunnel syndrome were included in the study. One group received shock wave therapy with the conventional physical therapy program including kinesio taping, the second group received the conventional physical therapy program including kinesio taping without shock wave therapy. The patients were evaluated using a Visual Analog Scale-pain, a Visual Analog Scale-numbness, the Boston Symptom Severity Scale, the Boston Functional Status Scale, and handgrip strength tests and Nerve conduction study before treatment 1 and 12 wks after the treatment.|f|f|f|t
33764983|NCT02257905|||COHORT||PROSPECTIVE|||||||
33764984|NCT00361101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764985|NCT00544960|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34071135|NCT05730855|||OTHER||PROSPECTIVE|||||||
33760016|NCT05312567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Matching placebo tablets. Double-blind treatment packaging and dispensation.|Randomized, double-blind, parallel-group, placebo-controlled study to compare patient-reported changes in VMS for the IMP vs. placebo. The study will be run as a fully decentralized clinical trial.|t|f|t|f
33760017|NCT03591367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760018|NCT05244603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760019|NCT02465671|||CASE_ONLY||PROSPECTIVE|||||||
34071136|NCT00005822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071137|NCT05455619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071138|NCT03939533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071139|NCT01935986|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34071140|NCT05514613|||OTHER||RETROSPECTIVE|||||||
34071141|NCT01941199|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071142|NCT03678415|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071143|NCT06365190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071144|NCT02932800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34071145|NCT02344511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071146|NCT04482088|NA|SINGLE_GROUP||TREATMENT||NONE|The occupational therapist that rates goal attainment will be blinded to treatment condition.|All participants will receive 10 weeks of occupational therapy in a clinic, followed by occupational therapy in an equine environment||||
34071147|NCT05055154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071148|NCT00520039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34071149|NCT03195322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760020|NCT01160874|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760021|NCT04436263|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34071150|NCT03357848|||COHORT||PROSPECTIVE|||||||
34071151|NCT04481763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071152|NCT03518086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071153|NCT04328428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants only know that they accept acupuncture ,but do not know which acupoint needling they receive.|three groups randomly:experiment group and two control groups. Patients in experiment group receive modified BL40 acupuncture. Control group one receives EM32 acupuncture and control group two receives BL40 acupuncture|t|f|f|f
34071154|NCT04168255|NA|SINGLE_GROUP||TREATMENT||NONE||Retinal detachment with proliferative vitreoretinopathy and inferior breaks||||
34071155|NCT06612294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research Coordinators conducting interviews and all investigators will be blinded to treatment allocation. Project staff will be assigned as Care Coaches for the intervention and the control treatments.||t|f|t|f
34071156|NCT02349139||SEQUENTIAL||TREATMENT||NONE||||||
34071157|NCT02204345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071158|NCT03703674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071159|NCT01051440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071160|NCT00394888|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34071161|NCT04162405|||CASE_CONTROL||PROSPECTIVE|||||||
34071162|NCT05524454|NA|SINGLE_GROUP||OTHER||NONE||This is a single-site study designed to generate data describing the quality and applicability of a novel on-couch CBCT imaging system for anatomy visualization and radiation treatment dosimetry planning.||||
34071163|NCT06296277|||COHORT||PROSPECTIVE|||||||
34071164|NCT05446051|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single-blind(Participant)|Experimental Group：New patients and take the TRAEs Questionnaire on week. Control Group：Old patients and usual care.|t|f|f|f
34071165|NCT06199544|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
34071166|NCT04484194|NA|SINGLE_GROUP||SCREENING||NONE||Single center pilot feasibility study.||||
34071167|NCT05348954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled experimental study|t|f|f|f
33760022|NCT04506255|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|Staff surgeons who are responsible for assessing outcomes will be masked to which side is receiving the silicone tape. At the initial two-week post-op visit, patients will meet with the research coordinator for randomization assignments of their incisions. Surgeons will be masked to assignments. Patients will remove their dressings one day prior to their appointment with their surgeon. This will ensure no local reaction (i.e. redness after tape removal) that would compromise the masking of staff surgeons.|This is a prospective, single center, masked, randomized self-controlled clinical human trial to evaluate the appearance of abdominal scars after autologous free-flap breast reconstruction following post-operative application of silicone tape to improve scar quality.|f|t|f|t
33760023|NCT01957917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760024|NCT06096480|||COHORT||RETROSPECTIVE|||||||
33760025|NCT02584725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760026|NCT03484455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760027|NCT02719379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760028|NCT02804087|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33971905|NCT04990622|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The investigators who process, score and analyse data will be masked.||f|f|f|t
33971906|NCT04773093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971907|NCT04537676|||COHORT||CROSS_SECTIONAL|||||||
33971908|NCT04141410|||CASE_CONTROL||PROSPECTIVE|||||||
33971909|NCT01405950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760029|NCT01802684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760030|NCT02115867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760031|NCT04936854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment will be allocated by the investigator trough the procedure with sealed envelopes, thereafter the investigator will enroll patients and assign patients to treatment. The treatment options will be conceal to prevent participants knowing until final trial analysis.||t|f|f|f
33760032|NCT04384016|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33760033|NCT05767151|||COHORT||PROSPECTIVE|||||||
33760034|NCT03360630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760035|NCT05753865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760036|NCT05840874|||CASE_ONLY||RETROSPECTIVE|||||||
33760037|NCT01237795|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33760038|NCT00887276|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33760039|NCT03401892|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760040|NCT01970787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760041|NCT02799615|||COHORT||PROSPECTIVE|||||||
33760042|NCT04678921|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33760043|NCT04954313|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and all sub-investigators will make every effort to remain blinded as to the subject regimen. Periodontal treatment throughout the Study will be provided only by experienced general dentists, periodontists or dental hygienists who are licensed, trained and calibrated prior to the start of the study. In order to maintain examiner blinding throughout the study, the treatment provider will be a person other than the dental examiner and will exclusively provide treatment and not participate in patient assessments.||f|f|t|t
33760044|NCT05356598|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760045|NCT01974700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760046|NCT01038388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760047|NCT06273943|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned in a 1:1 ratio to remain on their current oral PrEP regimen with daily and/or on-demand TDF/FTC (Control arm) or to switch to a CAB-LA based PrEP (Intervention arm).||||
33760048|NCT02491190|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33760049|NCT03881098|NA|SINGLE_GROUP||SCREENING||NONE||||||
33760050|NCT00180479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971910|NCT05692882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971911|NCT03548688|||COHORT||PROSPECTIVE|||||||
33971912|NCT03104556|||COHORT||PROSPECTIVE|||||||
33971913|NCT02585674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071168|NCT04307524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|computer-generated sequence|randomized controlled trial|t|f|f|f
34071169|NCT04932135|||COHORT||PROSPECTIVE|||||||
34071170|NCT00223002|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34071171|NCT04198909|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071172|NCT01249859|||CASE_CONTROL||RETROSPECTIVE|||||||
34071173|NCT01462656|||COHORT||PROSPECTIVE|||||||
34071174|NCT01775787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34071175|NCT04337021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Caregiver SOS is delivered by phone and offers evidence-based, work and CG role performance-focused self-management counseling to employed CGs. The program includes 6, 1-hour telephonic sessions with a care manager.|f|f|f|t
34071176|NCT06613282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883748|NCT03222349|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This was a multicenter study comprised of 2 treatment periods with a minimum 14 days between the 2 treatment periods.||||
33760051|NCT05130125|||COHORT||RETROSPECTIVE|||||||
33760052|NCT01924611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760053|NCT05593302|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline single case experimental design wherein all patients are first assigned to the control condition (or control period) and are then assigned to the intervention condition (or intervention period) and finally the follow-up period (control period). Patients are randomized for the time (t) at which they start with the intervention. CONSORT recognizes this design as an N=1 Trial, please refer to https://www.consort-statement.org/extensions/overview/n-of-1||||
33764986|NCT03354728|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33764987|NCT02176044|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33764988|NCT04978545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764989|NCT05252429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883749|NCT02981069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883750|NCT01242644|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33883751|NCT00836355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883752|NCT05772845|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All participants will complete two visits, one following 24-hour abstinence, the other while smoking/vaping as usual.||||
33883753|NCT05060757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883754|NCT06178549|NA|SINGLE_GROUP||SCREENING||NONE||||||
33883755|NCT02989935|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Study of RELVAR drug effect on respiratory physiology variables including breathing pattern, and EMG.||||
33883756|NCT06454526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All of the participants were blinded to the randomization procedure.|Randomized controlled trial|t|f|f|f
33883757|NCT02159300|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883758|NCT01445769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883759|NCT00632853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883760|NCT02542488|||COHORT||PROSPECTIVE|||||||
33883761|NCT04444232|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33883762|NCT03932994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883763|NCT00670410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883764|NCT01380808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883765|NCT04484532|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33883766|NCT04193930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883767|NCT01324167|||CASE_ONLY||PROSPECTIVE|||||||
33883768|NCT02651428|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883769|NCT02743247|NA|SINGLE_GROUP||||NONE||||||
33883770|NCT03343015|||COHORT||RETROSPECTIVE|||||||
33971914|NCT05788042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Trial participants, their treating psychiatrist, ward staff, and a study staff member (who will conduct blinded assessments of mood secondary outcome measures) will be blinded after assignment to intervention until the database is locked and the primary analysis completed. The following measures will be taken to ensure preservation of blinding to treatment allocation:~* Unblinded personnel (i.e., Neurostimulation Nurse(s) and/or tDCS research assistant), will be present during rTMS treatment delivery. tDCS will be self administered in the presence of ward staff. Team members involved in conducting blinded assessments for mood (i.e., MADRS) must not be present in the room during research treatment delivery.~* Knowledge of the code (i.e., which of 'A', 'B', 'C' or 'D' refers to which randomised treatment) will only be known to study staff responsible for treatment delivery, the study CI and study statistician involved in the study."|Double-blind, randomised, sham-controlled trial, parallel group design. Participants will be randomised to one of four groups (2:1:2:1 ratio): Active or sham tDCS, or Active or sham rTMS. The brain stimulation protocols involve 84 sessions of tDCS (active or sham) or 56 sessions of rTMS (active or sham) over the 8 week acute treatment period.|t|t|t|t
33971915|NCT00186914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971916|NCT00887627|NON_RANDOMIZED|PARALLEL||||NONE||||||
33971917|NCT02535819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883771|NCT01631305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971918|NCT03331965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33883772|NCT04106622|||CASE_ONLY||CROSS_SECTIONAL|||||||
33883773|NCT00003209||||TREATMENT||||||||
33883774|NCT00273000|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33971919|NCT01497483|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33971920|NCT03057587|||CASE_ONLY||PROSPECTIVE|||||||
33883775|NCT02893449|RANDOMIZED|PARALLEL||||NONE||||||
33883776|NCT06197061|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34071177|NCT02905045|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33971921|NCT04709900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971922|NCT00003557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971923|NCT00445289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071178|NCT04457401|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The participants, investigators, and anyone else directly involved with the study will remain blinded for its entirety.|A randomized, double-blind, placebo-controlled parallel study in which participants receive one of the study supplements (probiotic or placebo) for an 8-week intervention.|t|f|t|t
34071179|NCT01939223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071180|NCT00003007||||TREATMENT||||||||
34071181|NCT03484624|NA|SINGLE_GROUP||OTHER||NONE||||||
34071182|NCT00000411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071183|NCT02278029|||CASE_CONTROL||RETROSPECTIVE|||||||
34071184|NCT06039137|||COHORT||OTHER|||||||
34071185|NCT01505231|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34071186|NCT02847910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071187|NCT05978219|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental pre-post intervention trial||||
34071188|NCT03247322|RANDOMIZED|PARALLEL||OTHER||SINGLE|In order to minimize bias, data for outcomes will be collected by a blinded study coordinator.||f|f|f|t
34071189|NCT04350047|||CASE_ONLY||RETROSPECTIVE|||||||
33883777|NCT02239822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33883778|NCT01640457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883779|NCT04557280|RANDOMIZED|CROSSOVER||OTHER||NONE||Single-center, randomized, 3-period crossover.||||
33883780|NCT05347641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883781|NCT03455699|||COHORT||PROSPECTIVE|||||||
33883782|NCT03720132|NA|SINGLE_GROUP||OTHER||NONE||||||
33883783|NCT06277752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883784|NCT04000802|||CASE_CONTROL||PROSPECTIVE|||||||
33883785|NCT00742469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33883786|NCT02012530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883787|NCT03118297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971924|NCT00310427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971925|NCT03362151|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects will not be told which meal they are eating.|"Subjects will consume pre-determined meals on 6 difference occasions. There will be three categories of study meals consisting of:~1. Regular pasta (42 grams carbohydrate per meal)~2. High protein pasta (38 grams carbohydrate per meal)~3. White rice (43 grams carbohydrate per meal)~Each subject will consume each meal on two separate occasions in random order."|t|f|t|f
33764990|NCT03472703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||We will use a counter-balanced, crossover, within-subject design||||
33883788|NCT03860922|||CASE_ONLY||PROSPECTIVE|||||||
33883789|NCT00215384|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33883790|NCT04755959|||CASE_CONTROL||RETROSPECTIVE|||||||
33883791|NCT05219955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33883792|NCT01867229|||OTHER||PROSPECTIVE|||||||
33883793|NCT00847587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971926|NCT02087059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971927|NCT02689895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971928|NCT00508378|||CASE_ONLY||PROSPECTIVE|||||||
33971929|NCT03103581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071190|NCT02391792|||COHORT||PROSPECTIVE|||||||
34071191|NCT01856998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071192|NCT04851366|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|A three-armed simple-blind RCT will be conducted.|Two interventions are evaluated in parallel against a active control group|t|f|f|t
34071193|NCT01007370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071194|NCT04187274|||COHORT||PROSPECTIVE|||||||
34071195|NCT05256966|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071196|NCT02255071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34071197|NCT03454477|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071198|NCT03612479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34071199|NCT02080364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071200|NCT00931112|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34071201|NCT02957487|||COHORT||PROSPECTIVE|||||||
33883794|NCT03311048|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants, divided in four groups based on workplace: Hospital, University, Housekeeper and Control.|: This study included 167 participants, divided in four groups based on workplace: Hospital, University, Housekeeper and Control. Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.|t|f|f|f
33971930|NCT03496792|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Outcomes assessor will not know trial intervention prior to data analysis.|"The investigators will examine if individuals with elevated standing blood pressure have a heightened VDR. Two groups of subjects, BP elevated with standing group and BP maintained with standing group will be examined for this experiment. The tilt + external pressure and tilt + no external pressure, or the limb occlusion + negative pressure and limb occlusion + no negative pressure trials will be performed in random order using a Latin Square design. Because the nature of the interventions, neither the subjects nor the investigators can be blinded to the interventions"|f|f|f|t
34071202|NCT04648657|||COHORT||PROSPECTIVE|||||||
34071203|NCT04285216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessor will be binded||f|f|f|t
34071204|NCT04142398|||COHORT||PROSPECTIVE|||||||
34071205|NCT00104377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33883795|NCT06342674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (participant) blinding was used in the study. For this purpose, it was not stated which group the participating mothers were in the research, but they were informed about the procedure to be performed. Therefore, a separate informed consent form was prepared for each group. Statistician blinding will also be applied. While coding the research data, the research group will be coded as A and B, and the statistician will be prevented from knowing which letter represents which group.|Randomized Controlled Trial|f|f|f|t
33883796|NCT01328795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883797|NCT02505399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33883798|NCT03887299|RANDOMIZED|PARALLEL||TREATMENT||NONE|Data analysis will be blinded to assignment including the principal investigator.|Open label randomized control trial||||
33971931|NCT01433536|||COHORT||CROSS_SECTIONAL|||||||
33971932|NCT01938976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33971933|NCT00063128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33971934|NCT01234779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33971935|NCT02003495|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33971936|NCT03183466||||TREATMENT||||||||
33971937|NCT02224209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971938|NCT04579874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971939|NCT05117008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971940|NCT04624191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34071206|NCT01156805|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071207|NCT05825963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Triple blind study design||t|t|t|t
34071208|NCT02714010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071209|NCT06326086|||COHORT||PROSPECTIVE|||||||
34071210|NCT03026283|||COHORT||PROSPECTIVE|||||||
34071211|NCT00568893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883799|NCT01897467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883800|NCT05457192|||CASE_ONLY||PROSPECTIVE|||||||
34071212|NCT05289388|||COHORT||PROSPECTIVE|||||||
34071213|NCT02745483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071214|NCT00287456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071215|NCT00137787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071216|NCT01972464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071217|NCT06163027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34071218|NCT04245618|||COHORT||PROSPECTIVE|||||||
34071219|NCT00604747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071220|NCT00144560|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071221|NCT02506062|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33883801|NCT01181414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883802|NCT04285385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883803|NCT05618873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883804|NCT01327651|RANDOMIZED|PARALLEL||PREVENTION||NONE||One arm is daily TDF/FTC. One arm is twice weekly TDF/FTC with a post-exposure dose. One arm is as needed TDF/FTC with a post-exposure dose.||||
33883805|NCT00008112||||TREATMENT||||||||
33883806|NCT00967720|||OTHER||RETROSPECTIVE|||||||
33883807|NCT02287987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883808|NCT01289015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883809|NCT06235476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study consists of 4 arms of which 3 arms that receive a supplement and 1 arm that will use an e-health application to enhance protein intake. The 3 supplement arms are double-blind. The e-health arm is not; since it is not possible to blind either the participants in this group neither the investigators.|4-arm intervention study|t|f|t|f
33883810|NCT00868686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071222|NCT03972501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34071223|NCT04192890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071224|NCT06235320|||COHORT||PROSPECTIVE|||||||
34071225|NCT00020202||||TREATMENT||||||||
34071226|NCT03845621|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34071227|NCT01450514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071228|NCT02311608|||COHORT||PROSPECTIVE|||||||
34071229|NCT00048633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071230|NCT05006456|||COHORT||PROSPECTIVE|||||||
34071231|NCT01472133|||COHORT||PROSPECTIVE|||||||
34071232|NCT05772117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071233|NCT05019573|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||A randomised, double-blind (subject/investigator), placebo controlled, parallel study.|t|f|t|t
34071234|NCT04536116|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883811|NCT03879564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|ketamine and normal saline will be filled in 50-ml syringe and will be administered in the same condition||t|t|t|f
33883812|NCT02055404|RANDOMIZED|PARALLEL||||NONE||||||
33883813|NCT03261531|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883814|NCT05797272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883815|NCT04823351|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The objective is to perform a cluster-randomized, parallel, controlled, non-inferiority study among Swiss nursing and retirement homes to evaluate the efficacy of surgical masks vs. FFP2 masks during patient care and prospectively observe possible infections amongst both vaccinated and unvaccinated staff.||||
33883816|NCT03436186|||COHORT||PROSPECTIVE|||||||
33883817|NCT00145847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883818|NCT01015833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33883819|NCT05798845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883820|NCT00440505|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33883821|NCT02002260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883822|NCT00844467|||CASE_ONLY||PROSPECTIVE|||||||
33883823|NCT01311947|||COHORT||RETROSPECTIVE|||||||
33883824|NCT03419715|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883825|NCT04241614|||COHORT||PROSPECTIVE|||||||
33883826|NCT00234312|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33883827|NCT05922748|NON_RANDOMIZED|PARALLEL||OTHER||NONE||We will study patients (n= 300) suffering from focal brain lesions and healthy control subjects (n= 600 for imaging, n= 600 for purely behavioural studies)||||
33883828|NCT01276236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883829|NCT06357650|||OTHER||CROSS_SECTIONAL|||||||
33883830|NCT00744445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883831|NCT02986087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883832|NCT05434832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of three groups as 2 intervention (virtual reality, local cold-vibration) and control group (routine application)||||
33883833|NCT02965079|||COHORT||PROSPECTIVE|||||||
33883834|NCT01381159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33883835|NCT00180960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883836|NCT05104047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33883837|NCT01898182|NA|SINGLE_GROUP||||NONE||||||
33883838|NCT02350803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883839|NCT04630379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760054|NCT05878119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study is double-blind in that the study participants and the study staff involved in outcomes assessments will be unaware of the intervention assignment. The randomization schedule will be masked from all study personnel except those specifically designated below.~The unblinded study biostatistician The staff of the Investigational Drug Pharmacy Services. The DSMB, if requested"|This will be two center, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βNMN, after its daily oral administration, is associated with a greater reduction in the UACR compared to placebo|t|t|t|t
33760055|NCT04193501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participant and Investigator Blinded|Randomized, Parallel Group, Placebo Controlled Trial|t|f|t|f
33760056|NCT03019146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760057|NCT01718002|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760058|NCT00498563|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||||||
33760059|NCT00110890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760060|NCT02547870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760061|NCT01037842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760062|NCT01468298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760063|NCT03486028|||CASE_CONTROL||OTHER|||||||
33971941|NCT04261257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"As part of the usual care of patients hospitalized for stroke, the following examinations are carried out: a serum pregnancy test for women of childbearing age, a trans-thoracic cardiac ultrasound, a transesophageal cardiac ultrasound according to the needs of your care, an echo-doppler of the supraaortic trunks, a CT angiography of the supraaortic trunks (CT scan of the cerebral arteries), a transcranial Doppler, a biological assessment, a 24-hour holter or long-term holter.~Within 24 hours after admission: The cerebral artery scan, (usual care), is carried out and is supplemented by the additional examination of this research corresponding to a cardiac scanner (not requiring additional injection of contrast medium).~The following examinations of usual care are carried out within 3 days of inclusion: a trans-thoracic cardiac ultrasound, and a transesophageal cardiac ultrasound according to the needs of patient's care."||||
33971942|NCT06463964|||COHORT||PROSPECTIVE|||||||
33971943|NCT01273103|NA|SINGLE_GROUP||||NONE||||||
33971944|NCT03349333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971945|NCT05186610|||COHORT||PROSPECTIVE|||||||
33971946|NCT03309800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760064|NCT01618474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883840|NCT00984750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883841|NCT05683483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|As interventions will be implemented on the level of the department (for 6 departments), it will not be possible to blind health care providers, researchers or patients for the intervention that the patient is receiving.|We will perform a cluster randomized controlled trial. Randomization will be stratified, to ensure that departments are comparable at baseline in terms of types of patients, and that not all intervention departments are in one of our two locations and all control departments in the other location..||||
33883842|NCT00699348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883843|NCT03575715|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883844|NCT03259945|||CASE_ONLY||RETROSPECTIVE|||||||
33883845|NCT02670265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883846|NCT03742349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883847|NCT02132104|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33883848|NCT05933538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883849|NCT01132209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883850|NCT05313867|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33971947|NCT04288596|||COHORT||PROSPECTIVE|||||||
33971948|NCT03028272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be blinded to the type of barrier received.||t|f|f|f
33971949|NCT04158856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971950|NCT02419313|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33971951|NCT04275687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971952|NCT02214927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971953|NCT01393990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971954|NCT04669821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971955|NCT03500770|NA|SINGLE_GROUP||OTHER||NONE||||||
33971956|NCT01623661|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33971957|NCT04297683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||As new investigational products become available, additional regimens will be added to the HEALEY ALS Platform Trial.|t|t|t|t
33971958|NCT06544343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971959|NCT04978454|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|f|t
33971960|NCT03072459|||COHORT||OTHER|||||||
33971961|NCT00861237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971962|NCT00906347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760065|NCT03448445|||CASE_CONTROL||PROSPECTIVE|||||||
33760066|NCT01073904|RANDOMIZED|CROSSOVER||||NONE||||||
33760067|NCT01302470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760068|NCT00000431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971963|NCT01834521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760069|NCT00003132||||TREATMENT||||||||
33760070|NCT00022230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760071|NCT02238002|||COHORT||PROSPECTIVE|||||||
33760072|NCT04425902|NA|SINGLE_GROUP||TREATMENT||NONE|This is a single-group, single-arm study that has no masking.|This is a single-sequence, one-way drug interaction study.||||
33971964|NCT00003361||||TREATMENT||||||||
33971965|NCT03555370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33971966|NCT01775761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33971967|NCT02209779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33971968|NCT00923650|||||PROSPECTIVE|||||||
33971969|NCT02593981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33971970|NCT04435613|NA|SINGLE_GROUP||OTHER||NONE||A quasi-experimental, non-randomized study||||
33971971|NCT04648410|||OTHER||PROSPECTIVE|||||||
33971972|NCT03191721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33971973|NCT00417599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971974|NCT03978871|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33971975|NCT06547528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971976|NCT00682721|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33971977|NCT04556669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971978|NCT05089994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971979|NCT02623790|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33971980|NCT01117961|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33971981|NCT04317196|||COHORT||PROSPECTIVE|||||||
33971982|NCT04084756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33971983|NCT03419195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760073|NCT02141763|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33760074|NCT01037439|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33760075|NCT02342522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760076|NCT01117103|||COHORT||PROSPECTIVE|||||||
33760077|NCT06222216|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33760078|NCT00065585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760079|NCT05493072|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33760080|NCT04345159|||COHORT||RETROSPECTIVE|||||||
33760081|NCT05962710|||COHORT||PROSPECTIVE|||||||
33760082|NCT02464800|||CASE_CONTROL||RETROSPECTIVE|||||||
33760083|NCT02901626|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is an unblinded randomized controlled trial. Participants will receive usual care (vaginal progesterone if they meet criteria per local standard of care) or an Arabin cervical pessary (plus progesterone if the local usual care is to receive vaginal progesterone for a short cervix).||||
33760084|NCT04434911|||COHORT||PROSPECTIVE|||||||
33760085|NCT04906525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33760086|NCT02149784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760087|NCT01104194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760088|NCT02000414|NA|SINGLE_GROUP||TREATMENT||NONE||dose-finding study||||
33971984|NCT05358210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Individual, parallel-design, randomized trial|f|f|f|t
33971985|NCT04559620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33971986|NCT02212405|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34071235|NCT05895643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071236|NCT03633253|||COHORT||RETROSPECTIVE|||||||
34071237|NCT05435352|||COHORT||PROSPECTIVE|||||||
34071238|NCT05102435|||OTHER||CROSS_SECTIONAL|||||||
33760089|NCT00163995|||DEFINED_POPULATION||OTHER|||||||
33760090|NCT00459238|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33760091|NCT00496405|NA|PARALLEL||OTHER||NONE||||||
33760092|NCT05462535|||OTHER||PROSPECTIVE|||||||
33760093|NCT03522805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760094|NCT00894673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33760095|NCT00959543|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33760096|NCT02807428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071239|NCT00700024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071240|NCT00524771|||COHORT||PROSPECTIVE|||||||
34071241|NCT03222453|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760097|NCT04524598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760098|NCT02430467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760099|NCT00856674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760100|NCT04574830|||COHORT||PROSPECTIVE|||||||
33760101|NCT01291147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760102|NCT03588793|||COHORT||PROSPECTIVE|||||||
33760103|NCT01368146|RANDOMIZED|PARALLEL||||NONE||||||
33760104|NCT02237508|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760105|NCT00893399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760106|NCT00726362|||COHORT||PROSPECTIVE|||||||
33760107|NCT04040257|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33760108|NCT04719039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883851|NCT03228160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33883852|NCT03504592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883853|NCT01228903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883854|NCT00264004|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33883855|NCT04396509|||CASE_CONTROL||PROSPECTIVE|||||||
33883856|NCT01916629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883857|NCT04205890|NA|SINGLE_GROUP||TREATMENT||NONE||The purpose of this study is to investigate the neuroanatomical effects of ketamine treatment on patients with treatment-resistant depression. We will compare the neuroimaging of patients several days before and after injection in order to assess the more durable changes induced by ketamine. We will analyze changes in perfusion, neurovascular coupling, and functional connectivity that are correlated with psychiatric measures.||||
33883858|NCT02924662|||CASE_CROSSOVER||PROSPECTIVE|||||||
33760109|NCT03830190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the type of intervention (Parkinson's disease nurse specialist care), the participant and care provider cannot be masked. The investigator and outcome assessor (conducting the questionnaires) will be blinded.|Randomized controlled trial with 2 study arms: the intervention group and the control group. Participants are allocated to each arm in a 1:1 ratio.|f|f|t|t
33971987|NCT05314569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|patients will be allocated to the study using a computer-generated random list and the group assignments will be sealed in opaque envelopes that will be opened after induction. The drugs will be prepared by an anesthetist who is blind to the study groups.|patients will be allocated to three groups|t|t|t|f
33971988|NCT00979160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33971989|NCT00674219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33971990|NCT06546579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study design is cross-sectional in terms of the diagnostic process, which aims to determine the presence of scabies in an individual at a specific point in time. All participants will undergo the same diagnostic procedures.||||
34071242|NCT02477436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071243|NCT04288882|||COHORT||PROSPECTIVE|||||||
34071244|NCT02498977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34071245|NCT01070433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760110|NCT05068869|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33760111|NCT03089125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research staff collecting patient-reported measures will be blind to study assignment group|Nurse administered dyspnea intervention|f|f|f|t
33760112|NCT02462902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760113|NCT05356754|NA|SINGLE_GROUP||OTHER||NONE||||||
33760114|NCT04892784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760115|NCT06113510|||CASE_CONTROL||PROSPECTIVE|||||||
33760116|NCT01696331|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760117|NCT05582005|||CASE_CONTROL||PROSPECTIVE|||||||
33760118|NCT04601558|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33760119|NCT01755143|RANDOMIZED|PARALLEL||||NONE||||||
33760120|NCT03090867|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33760121|NCT03362463|||COHORT||PROSPECTIVE|||||||
33760122|NCT03262857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760123|NCT05174793|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||urine color was measured during dehydration and rehydration||||
33760124|NCT00227526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33760125|NCT00273702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760126|NCT00503022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760127|NCT02484001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760128|NCT00582257|||COHORT||PROSPECTIVE|||||||
33760129|NCT01931735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33760130|NCT06067633|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Masking securities: Editors will be restricted from accessing the editorial manager for the duration of the project. Additionally, since articles won't be assigned to editors, they won't be able to see anything from their immediate accounts. This should block them from the masked information and preserve the integrity of the project. Editors will be able to search for reviewers with specific expertise from an external, cleaned nominative version of the editorial manager database. They won't however know who, from the reviewers selected, accepted the invitation and wrote the review. In this sense, reviews' authorship will be masked to the editor.|Two group, parallel, superiority trial with 1:1 allocation|t|t|t|f
34071246|NCT00790504|||COHORT||PROSPECTIVE|||||||
34071247|NCT01551017|||CASE_CONTROL||PROSPECTIVE|||||||
34071248|NCT02666833|||CASE_ONLY|||||||||
34071249|NCT04324528|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||randomized controlled trial examining COVID-patients requiring vv-ECMO therapy (+/- cytokine adsorption)||||
34071250|NCT06500429|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33760131|NCT05197361|||COHORT||PROSPECTIVE|||||||
33760132|NCT03764449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760133|NCT03047928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760134|NCT05461261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760135|NCT02393872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760136|NCT04061343|||COHORT||PROSPECTIVE|||||||
33760137|NCT03718689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33760138|NCT00004670|RANDOMIZED|||TREATMENT||||||||
33760139|NCT06081595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760140|NCT00292175|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760141|NCT01341002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760142|NCT05435755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study plans to recruit 12 patients who meet the criteria. 50 millions hAESCs will be transplanted to participants with PD.|t|f|t|f
33760143|NCT00583622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760144|NCT03607188|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33760145|NCT03285425|||COHORT||RETROSPECTIVE|||||||
33760146|NCT03681418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760147|NCT01170416|||COHORT||PROSPECTIVE|||||||
33760148|NCT04194203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760149|NCT02571374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33883859|NCT05348798|||COHORT||CROSS_SECTIONAL|||||||
33883860|NCT05618743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arm clinical trial||||
33883861|NCT05083819|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33883862|NCT04882397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33883863|NCT03783260|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883864|NCT03135847|NA|SINGLE_GROUP||OTHER||NONE||||||
33883865|NCT02176707|||COHORT||PROSPECTIVE|||||||
33883866|NCT02667080|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883867|NCT05560932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883868|NCT05849870|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|There will be different people assigned to the delivery and the intervention. The effectiveness of this will be established as part of the feasibility evaluation.|A feasibility trial employing a cluster randomized control trial design.|t|f|t|t
33883869|NCT02307682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883870|NCT01332682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33883871|NCT04880928|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33883872|NCT04803760|||CASE_CONTROL||PROSPECTIVE|||||||
33883873|NCT00911131|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33883874|NCT04929912|||COHORT||OTHER|||||||
33883875|NCT01937273|||COHORT||PROSPECTIVE|||||||
33971991|NCT06398470|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|After LaserSAFE, images are acquired, they will be annotated with the study identifier only. Images will be stored and kept until the end of recruitment. Once all specimens have been evaluated using paraffin analysis, a dedicated meeting with the evaluating pathologist will be carried out. A set of images without any patient identifier will be shown in random order. A purposely built document will allow the pathologist to report the images. This meeting will be repeated with every evaluating pathologist until all images have been analysed.|The investigators aim to recruit a group of 20 patients who will undergo radical prostatectomy as a treatment for prostate cancer. The prostate specimen will be analysed using both techniques, but decisions on how much tissue to resect during surgery will depend on the results of NeuroSAFE.||||
33971992|NCT04371614|RANDOMIZED|PARALLEL||PREVENTION||NONE||The women are randomly assigned to receive the PTSC intervention or usual care from the FQHC. The intervention last for 3 months. The women are followed for 1 year after receiving the intervention||||
33971993|NCT02831062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33971994|NCT02655354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883876|NCT02678715|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33883877|NCT03132584|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I study in the standard 3+3 dose escalation design||||
33883878|NCT00114062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33883879|NCT00375102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883880|NCT04491656|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883881|NCT03072693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Remote monitoring device given to subjects for daily monitoring to vital signs, activities and discomfort. Medication to be adjusted by investigators according to the recorded parameters and patients' condition.|t|f|f|f
33883882|NCT00004575||||TREATMENT||||||||
33883883|NCT04177719|NON_RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33883884|NCT02765451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33883885|NCT05726721|||COHORT||PROSPECTIVE|||||||
33883886|NCT01136499|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883887|NCT02735629|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33883888|NCT04135898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883889|NCT00046787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760150|NCT00828308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760151|NCT04958330|||COHORT||RETROSPECTIVE|||||||
33760152|NCT01325025|NON_RANDOMIZED|PARALLEL||||NONE||||||
33760153|NCT06182566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760154|NCT04029701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This Trials is a randomly controlled, double-blinded and placebo-controlled trial.And the methodology team of Guangdong Provincial Hospital of Chinese Medicine is responsible for the editing of blindness.||t|t|t|t
33760155|NCT00110370|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760156|NCT03261128|||COHORT||PROSPECTIVE|||||||
33760157|NCT00687999|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760158|NCT03536910|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33760159|NCT03637452|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33760160|NCT06408584|||COHORT||PROSPECTIVE|||||||
33760161|NCT01548430|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33760162|NCT01795365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760163|NCT00813852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760164|NCT06619691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760165|NCT04433884|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Computer generated randomization using envelopes||t|f|f|f
33760166|NCT05672212|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33883890|NCT00289107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33971995|NCT04139174|||OTHER||RETROSPECTIVE|||||||
33971996|NCT05044442|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33971997|NCT04058483|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants not told their hypnotizability score from the first exam prior to completing the second exam.~Study personnel performing the second hypnotizability test are masked to the first hypnotizability score. Two separate investigators will test each participant."|Participants are randomized to first undergo phone-administered testing vs. in-person testing.|t|f|t|f
33971998|NCT01720628|||CASE_CONTROL||PROSPECTIVE|||||||
33883891|NCT04202731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883892|NCT00690885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33883893|NCT00807755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883894|NCT04424069|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33883895|NCT04756713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment assignments are made by a remote investigator not involved in the clinical care of the patient using a coded key with random block sizes.|Randomized|f|f|t|t
33883896|NCT01230957|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883897|NCT04658394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883898|NCT05029063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind Randomized Control Trial||t|t|t|t
33971999|NCT03642574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760167|NCT02617875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33760168|NCT00508404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760169|NCT05520463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33760170|NCT00437645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760171|NCT04366063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760172|NCT05576532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760173|NCT03800732|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760174|NCT01286441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760175|NCT02500459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760176|NCT01853514|||OTHER||CROSS_SECTIONAL|||||||
33760177|NCT03034616|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760178|NCT03516643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760179|NCT04377230|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The radiologist evaluating bone mineral density will be blinded to the biliopancreatic limb length||f|f|f|t
33760180|NCT01057784|||COHORT||PROSPECTIVE|||||||
33760181|NCT03322098|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33760182|NCT00112580||||TREATMENT||NONE||||||
33760183|NCT05321355|||CASE_CONTROL||PROSPECTIVE|||||||
33760184|NCT04164654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760185|NCT00922025|||||PROSPECTIVE|||||||
33760186|NCT02312856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760187|NCT06162143|||CASE_ONLY||PROSPECTIVE|||||||
33760188|NCT02799784|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760189|NCT04437420|||COHORT||PROSPECTIVE|||||||
33760190|NCT05181514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33760191|NCT04108130|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33883899|NCT06108362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33883900|NCT04208854|||COHORT||PROSPECTIVE|||||||
33883901|NCT04154059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33883902|NCT00721084|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883903|NCT01906125|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33883904|NCT00062387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883905|NCT00454805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071251|NCT00778791|RANDOMIZED|CROSSOVER||||NONE||||||
34071252|NCT00622492|||COHORT||PROSPECTIVE|||||||
33883906|NCT00916240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883907|NCT00382993|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33883908|NCT04503876|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Statistical analysis will be conducted by an independant statistician not involved in data collection|Interventional trial comparing two strategies of PEEP optimization during mechanical ventilation in two groups of ICU patients: with healthy lungs or with ARDS. The study consists of comparing pulmonary pathophysiological parameters for different PEEP levels. The first strategy implies the use of an ARM followed by a stepwise decremental PEEP titration whereas the second considers a stepwise incremental PEEP titration without any previous ARM, during controlled invasive mechanical ventilation. Each patient will receive both strategies in a random consecutive order|t|f|f|f
33883909|NCT00894179|||CASE_ONLY||PROSPECTIVE|||||||
33883910|NCT05780671|||COHORT||CROSS_SECTIONAL|||||||
33883911|NCT05399316|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|All participants and study staff are blinded||t|t|t|t
33883912|NCT01270399|||CASE_CONTROL||PROSPECTIVE|||||||
33883913|NCT04193371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a cross-sectional case-control part and an open-labelled RCT with a comparative effectiveness design. The inter-ventions to be tested are (1) acupuncture during 4 months+lifestylemanagement; (3) sham acupuncture+lifestyle management|f|f|t|t
33883914|NCT00783588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883915|NCT01540799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33883916|NCT04911010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, controlled, parallel-group, two-armed, multicentre, open trial|f|f|f|t
33883917|NCT03078465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33883918|NCT03326141|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The specific content of the intervention condition/arm that is assigned to each participant will be masked from data collectors/outcome assessors.|Our research team will conduct a 2 x 2 factorial experiment testing the individual and combined effects of two empirically and theoretically relevant sets of behavior change strategies on community-dwelling older adults' physical activity.|f|f|f|t
33883919|NCT06237231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883920|NCT04272567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33760192|NCT04781361|||CASE_CONTROL||PROSPECTIVE|||||||
33760193|NCT00321048|RANDOMIZED|PARALLEL||TREATMENT||NONE||Left breast/chest wall irradiation with or without ABC (active breathing coordinator)||||
33883921|NCT04576598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized clinical trial|f|f|t|t
33883922|NCT05150548|||COHORT||RETROSPECTIVE|||||||
33883923|NCT05666778|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33883924|NCT00727363|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883925|NCT01612715|||CASE_ONLY||PROSPECTIVE|||||||
33883926|NCT03369145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study design is a randomised, controlled, crossover design in which participants undertake two 7-day dietary conditions in a randomised order with a three week washout period in between.||||
34071253|NCT03529214|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34071254|NCT04435899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34071255|NCT03775967|||COHORT||PROSPECTIVE|||||||
34071256|NCT06087497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071257|NCT03327857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760194|NCT06626373|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Double (ParticipantOutcomes Assessor)||t|f|f|f
33760195|NCT05083195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760196|NCT01337557|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33760197|NCT04904822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Closed envelopes containing allocations|2 groups parallel allocation|t|f|f|f
33760198|NCT05810493|||COHORT||RETROSPECTIVE|||||||
33760199|NCT03268239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760200|NCT04913064|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760201|NCT06409221|||COHORT||RETROSPECTIVE|||||||
33760202|NCT02390726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883927|NCT05873985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||double-blind randomized controlled trial|t|f|t|f
33883928|NCT05438381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33883929|NCT00004979||||TREATMENT||||||||
33883930|NCT02425098|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883931|NCT02121366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071258|NCT06228235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071259|NCT04333212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33883932|NCT03113305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33883933|NCT00865215|RANDOMIZED|CROSSOVER||||NONE||||||
33883934|NCT01052025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33883935|NCT01155700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883936|NCT06471881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883937|NCT00006552|||||RETROSPECTIVE|||||||
33883938|NCT02091609|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33883939|NCT04316169|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33883940|NCT01501058|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883941|NCT04714515|||COHORT||RETROSPECTIVE|||||||
33883942|NCT00999895|||CASE_ONLY||PROSPECTIVE|||||||
33883943|NCT02755194|||OTHER||CROSS_SECTIONAL|||||||
33883944|NCT00746967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883945|NCT02076542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883946|NCT03682315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33883947|NCT00501267|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33883948|NCT01946815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883949|NCT03657173|||COHORT||PROSPECTIVE|||||||
33883950|NCT04355780|||COHORT||PROSPECTIVE|||||||
33883951|NCT02846103|NA|SINGLE_GROUP||OTHER||NONE||||||
33883952|NCT06133660|||COHORT||RETROSPECTIVE|||||||
33972000|NCT02322879|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||"Eligible subjects will then be randomized at a 1:1 ratio to receive either acetaminophen (APAP) or APAP + propylene glycol for 2 weeks (Treatment Period 1). At the end of the Treatment Period 1 subjects will enter the Wash-Out period for 2 weeks. Study subjects will then receive the alternative treatment for 2 weeks (Treatment Period 2). Overall, the maximum duration of treatment is approximately 6 weeks.~RESPONDERS: Subjects whose transaminase levels rise to 3 times normal or greater during either of the Treatment Periods will be deemed responders and the intervention will cease.~* If subjects are in the Treatment Period 1, they will enter the washout period and continue to return daily to ensure that liver function tests decline. After the 2 week washout-period, responders will cross over to Treatment Period 2.~* If subjects are in the Treatment Period 2 phase, they will continue to return to the CRC and have their transaminases checked until they return to normal."|f|f|t|t
33972001|NCT05359432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972002|NCT05055271|||OTHER||PROSPECTIVE|||||||
34071260|NCT04702451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|t|f|f|t
33883953|NCT01900093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883954|NCT03942432|NA|SINGLE_GROUP||OTHER||NONE||||||
33883955|NCT03128957|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33883956|NCT02615743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33883957|NCT06309056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients being followed at the Lethbridge-Layton-Mackay Rehabilitation Centre Salivation Management Clinic and the Dysphagia and Feeding Disturbance Clinic who meet inclusion criteria will be recruited. If caregivers/participants consent to the study, they will be enrolled in the intervention arm. Any potentially eligible participant who declines to participate in the study will be recruited as a control group. These participants will complete the questionnaires at the same timepoints as the interventional group and data from the medical charts will be included in the study.||||
33883958|NCT01361997|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33883959|NCT00604968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33883960|NCT01367730|||COHORT||PROSPECTIVE|||||||
33894571|NCT03643887|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Double-blind, randomized, placebo controlled trial|t|t|t|f
33894572|NCT02031679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760203|NCT02153138|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760204|NCT06625034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760205|NCT04135963|||COHORT||RETROSPECTIVE|||||||
33760206|NCT01445808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760207|NCT02239016|||COHORT||PROSPECTIVE|||||||
33760208|NCT04242693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants were randomized to either an experimental or a control group after they completed a preliminary questionnaire.|t|f|f|f
33883961|NCT05902000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|1. Randomization results are known only to the patients themselves and the treating physicians. Baseline and in-hospital visits related to the study endpoint should be evaluated by a third party who is unknown to the patients' grouping and actual treatment status.2. Visits to the primary endpoint were conducted by trained third-party personnel. Standardized visits were conducted under the premise of unknown patient randomization and actual treatment status, and follow-up reports were prepared.3. All research-related image data will be collected for centralized interpretation. The images at each site were interpreted independently, and the readers were not aware of the patient's baseline condition, treatment received (except the images during baseline surgical treatment), and prognosis.|Carotid artery stenting after intracranial or middle cerebral artery embolization and balloon dilation of the extracranial segment of the ipsilateral internal carotid artery|f|f|f|t
33883962|NCT03799900|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33883963|NCT04632355|||COHORT||PROSPECTIVE|||||||
33883964|NCT05894954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked psychometrician will conduct the Montreal Cognitive Assessments (MoCA) and Alzheimers Questionnaires.|Participants will be randomized to one of two treatment groups. Group A is Precision Medicine Approach and Group B is the Standard-of-Care (Control) Group. Both groups will be on study for 9 months. Biomarker tests and cognition tests will be conducted in both groups at baseline, defined visits during the study and again at end of the 9-month period.|f|f|f|t
33883965|NCT01818297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33883966|NCT04553211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972003|NCT00242762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972004|NCT01811446|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760209|NCT06460558|||COHORT||PROSPECTIVE|||||||
33760210|NCT02765919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760211|NCT01126827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760212|NCT02295514|NA|SINGLE_GROUP||||NONE||||||
33883967|NCT04375774|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Enrolment will be a onetime selection of 10 healthy volunteers||||
33972005|NCT02780778|NA|SINGLE_GROUP||SCREENING||NONE||||||
33760213|NCT03181802|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This study was a randomized, double-blinded, placebo-controlled phase 3 trial comparing Intramuscular injections of botulinum toxin A to a placebo in patients with chronic low-back pain (LBP)|t|f|t|f
33972006|NCT04264728|||CASE_ONLY||RETROSPECTIVE|||||||
33972007|NCT03409185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972008|NCT01108900|||CASE_ONLY||PROSPECTIVE|||||||
33972009|NCT05326022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972010|NCT06395649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||When 50% of inclusion is completed, a preplanned interim futility analysis is scheduled to examine safety and the main outcome.|t|f|t|f
33760214|NCT02260076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760215|NCT03483974|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33972011|NCT03824522|||COHORT||PROSPECTIVE|||||||
33972012|NCT00793845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972013|NCT05645458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33972014|NCT01252433|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33972015|NCT00064181|RANDOMIZED|||TREATMENT||DOUBLE||||||
33972016|NCT01760122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972017|NCT04588428|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33972018|NCT01987284|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34071261|NCT04039659|RANDOMIZED|PARALLEL||PREVENTION||NONE||After signing the informed consent of those patients who meet the inclusion criteria, they will be randomized into two groups to install the PICOⓇ device or conventional dressings over the wound. After 7 days, the PICOⓇ device will be removed and both preoperative and postoperative variables will be studied.||||
34071262|NCT04272047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Physiotherapists who assess injuries are blinded to group belonging. Statistician performing outcome analyses are blinded to group belonging.|This is a three-armed intervention study that evaluates the injury preventive effects of three different training interventions in youth and adult football players. Two intervention arms are randomized and one arm acts as a non-randomized comparison group.|f|f|f|t
34071263|NCT04877899|||COHORT||RETROSPECTIVE|||||||
33883968|NCT00820573|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33883969|NCT04514679|||COHORT||PROSPECTIVE|||||||
33883970|NCT01479140|||COHORT||PROSPECTIVE|||||||
33883971|NCT01370460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33894573|NCT06230796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Sham stimulation|In a monocentric, single-blind, randomized, controlled trial, hemiparetic post stroke patients will be randomized to receive FES-induced cycling training or placebo FES cycling.|t|f|f|t
33894574|NCT00155402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894575|NCT06647823|||COHORT||CROSS_SECTIONAL|||||||
33894576|NCT01504503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071264|NCT02834078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071265|NCT05076877|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071266|NCT04241822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"After 1 year participants who still have dizziness complaints will be offered one of two interventions:~1. Group-based vestibular rehabilitation combining cognitive intervention, vestiular exercises and body awareness therapy~2. Exergaming intervention with virtual reality exercises using data games and videos, and other balance exercises."||||
34071267|NCT01963507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071268|NCT05301582|||COHORT||PROSPECTIVE|||||||
34071269|NCT02876861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071270|NCT02716584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071271|NCT04531332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894577|NCT00499707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894578|NCT01568216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894579|NCT02670304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33894580|NCT02678806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894581|NCT06133673|||OTHER||CROSS_SECTIONAL|||||||
33972019|NCT03781856|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972020|NCT03949556|RANDOMIZED|PARALLEL||PREVENTION||NONE||An open three-arm randomized controlled trial will be conducted to assess the effectiveness of two programmes of suicide prevention in fourth-year medical students and first-year interns; one based on stress management using cognitive and behavioural principles and the other on health promotion. Their respective effectiveness will be compared with a control condition. Participants will be assessed using validated questionnaires online at inclusion (before intervention) and at 6 (end of the intervention), 12, and 18 months.||||
33972021|NCT03286413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972022|NCT01011569|||COHORT||PROSPECTIVE|||||||
33894582|NCT02939521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894583|NCT02053688|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33894584|NCT04847986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894585|NCT02719054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894586|NCT05035498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894587|NCT04391764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894588|NCT03007277|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894589|NCT01154413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883972|NCT05764148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||schizophrenia group and treatment as usual||||
33883973|NCT01311466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883974|NCT05576402|||CASE_ONLY||CROSS_SECTIONAL|||||||
33883975|NCT04779151|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883976|NCT00939692|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33883977|NCT02847598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883978|NCT05891054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883979|NCT02521701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883980|NCT03676127|||OTHER||CROSS_SECTIONAL|||||||
33883981|NCT01705847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883982|NCT02205684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33883983|NCT01166451|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33883984|NCT04835012|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972023|NCT00289627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972024|NCT02140684|||COHORT||RETROSPECTIVE|||||||
33972025|NCT02676219|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34071272|NCT00587938|||COHORT||PROSPECTIVE|||||||
33883985|NCT04902365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|"In a double-blind, randomized and placebo-controlled longitudinal experiment, the investigators will use real-time functional magnetic resonance imaging (rtfMRI) neurofeedback to teach patients to downregulate activity in different regions of the visual cortex.~50 patients (25 in each arm)"|t|f|t|f
33883986|NCT06335056|RANDOMIZED|PARALLEL||PREVENTION||NONE||In this 12-week long intervention project, 480 adolescent participants are randomized, at the school level, to 2 arms - ProudMe or waitlist control conditions.||||
33883987|NCT01756729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883988|NCT01463813|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33883989|NCT03687502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The CEUS image will be read at a future time by a Children's Mercy Hospital radiologist blinded to the results of the gray scale ultrasound and computed tomography (CT) scan if one was obtained; these will be used for comparison.|||||
33883990|NCT01274884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33883991|NCT05305807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764991|NCT02707523|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Participant, clinical providers and study staff are masked to the intervention. The random assignment of treatment was determined by random permutation. A statistician generated the randomization schedule and provided the randomization schedule (with randomization IDs) in an excel file to the study pharmacist in charge of dispensing the appropriate treatment.||t|t|t|t
33764992|NCT02067234|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33883992|NCT03617211|||OTHER||CROSS_SECTIONAL|||||||
33883993|NCT03513653|||COHORT||RETROSPECTIVE|||||||
33883994|NCT03568019|||CASE_ONLY||RETROSPECTIVE|||||||
33883995|NCT01602588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33883996|NCT06131619|||CASE_CONTROL||PROSPECTIVE|||||||
33883997|NCT05181995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33883998|NCT00626743|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33883999|NCT01757717|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33972026|NCT03114956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who is analyzing the data will be blinded to the assigned groups to prevent bias.||f|f|f|t
33972027|NCT00398021|||COHORT|||||||||
33884000|NCT03569852|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33884001|NCT00413959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884002|NCT03213301|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective 2-stage single-arm open-label multicenter phase II trial.||||
33972028|NCT03849365|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple center, single-arm, open-label, 12-month follow-up phase IV pragmatic clinical trial.||||
33972029|NCT04433481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972030|NCT01777685|NA|SINGLE_GROUP||||NONE||||||
33972031|NCT04712006|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972032|NCT02135874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972033|NCT02473510|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33972034|NCT02588183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972035|NCT02286518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972036|NCT03888001|||COHORT||PROSPECTIVE|||||||
33972037|NCT06547853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972038|NCT00708331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972039|NCT03693690|||COHORT||PROSPECTIVE|||||||
33972040|NCT03807323|NA|SINGLE_GROUP||PREVENTION||NONE||Feasibility study||||
33972041|NCT01729416|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33972042|NCT06543836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972043|NCT02863250|||COHORT||PROSPECTIVE|||||||
33972044|NCT04887883|||COHORT||RETROSPECTIVE|||||||
33972045|NCT00606684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760216|NCT04814654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Data Manager (who has no contact with study participants) will assign participants to a study group and cross-reference encrypted files with our technology consultant. Participants will be unaware of arm assignment and will receive automated messages to complete online surveys. Study staff collecting HIV testing and linkage-to-care outcomes will also be blinded to the participants' study arm. Finally, the team of Virtual Peers will not be informed of study hypothesis.|Subjects meeting all eligibility criteria will be randomized to one of three study arms. Participants will be assigned either to CHALO! 2.0 (intervention), to an Attention-Matched Control, or to a Digital Coupon for free HIV testing only arm. After baseline survey completion, the research team will use random blocked design, with a fixed block size, to stratify randomization by prior HIV testing history (never tested vs. not tested in \>6 months).|t|f|t|f
33760217|NCT02633930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760218|NCT01621880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884003|NCT00067652|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33884004|NCT04775511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884005|NCT03631498|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884006|NCT02776163|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760219|NCT00431184|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33760220|NCT02093182|||CASE_ONLY||RETROSPECTIVE|||||||
33760221|NCT00652938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760222|NCT02487472|||COHORT||PROSPECTIVE|||||||
33760223|NCT00933101|||CASE_ONLY||PROSPECTIVE|||||||
33760224|NCT06344598|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33760225|NCT01599390|||||RETROSPECTIVE|||||||
33760226|NCT02323087|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760227|NCT05271058|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Purpose: Investigating the effect of intracameral steroids at the end of phacoemulsification on corneal edema and endothelial count.~Methods: Prospective, interventional case control study. Sixty-nine eyes were randomized into 3 groups, 23 eyes each : 2groups received intracameral dexamethasone and triamcinolone (TA) respectively, while controls didn't receive any intraoperative steroids."||||
33760228|NCT03928028|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Any study team member who is assessing for outcomes will not which participant/family is in which group.|Random assignment to one of three groups.|f|f|f|t
33760229|NCT03278535|||COHORT||PROSPECTIVE|||||||
33760230|NCT03556475|||COHORT||PROSPECTIVE|||||||
33760231|NCT04000867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|20 patients given the choice of 1 out of 20 envelopes they pick, 10 will be randomized to either the real TCMS treatment arm or 10 to the sham treatment arm|Multi-site double blinded randomized control clinical trial|t|t|f|t
33760232|NCT01224925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient -blinded|Multicenter study a randomized, controlled, parallel, patient-blinded, two-arm superiority trial with a 1:1 allocation ratio|t|f|f|f
33760233|NCT05598242|RANDOMIZED|PARALLEL||TREATMENT||NONE||active-controlled, parallel-group trial||||
33760234|NCT02404389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760235|NCT04378322|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33760236|NCT01330316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760237|NCT05578950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760238|NCT03662074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760239|NCT00204984|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760240|NCT01055730|||COHORT||PROSPECTIVE|||||||
33760241|NCT00449280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760242|NCT03088709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760243|NCT00246987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760244|NCT04010630|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33760245|NCT05769738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both medications will be prepared by the pharmacists, the only unblinded personnel in the study, as transparent solutions in similar syringes.||t|t|t|t
33760246|NCT03550833|||CASE_ONLY||PROSPECTIVE|||||||
33760247|NCT02516722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760248|NCT02127372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760249|NCT01435655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760250|NCT05904470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760251|NCT05078060|||OTHER||PROSPECTIVE|||||||
33760252|NCT06320301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760253|NCT01969019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760254|NCT03532438|||CASE_ONLY||CROSS_SECTIONAL|||||||
33760255|NCT00806234|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33884007|NCT02154425|NA|SINGLE_GROUP||OTHER||NONE||||||
33884008|NCT01633463|||CASE_ONLY||PROSPECTIVE|||||||
33884009|NCT00052195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884010|NCT06473038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants who eat often foods sold on campus will be selected from the online validated questionnaire (part 1) in a randomized manner and they form the intervention group who will be eating the foods sold on campus that have reduced salt and sugar. Participants who do not eat often the food sold on campus will be the control group.||||
33884011|NCT05536661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33884012|NCT05236803|NA|SINGLE_GROUP||OTHER||NONE||||||
33884013|NCT02504554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884014|NCT05495204|||OTHER||OTHER|||||||
33884015|NCT04451707|||COHORT||RETROSPECTIVE|||||||
33884016|NCT01894204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884017|NCT05135715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884018|NCT04772027|||COHORT||PROSPECTIVE|||||||
33884019|NCT05673343|||COHORT||PROSPECTIVE|||||||
33884020|NCT05284409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"The assigned medication will be prepared in a color coded 250 ml polypropylene bottle of normal saline. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over a duration of 15 to 20 minutes, the study drugs will be prepared by the hospital pharmacy and follow-up of the patients will be conducted by the anesthesia residents not involved in any other part of the study.~Group A: (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.~Group B: 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.~Group C: 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia."|t|t|f|f
33884021|NCT04178772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972046|NCT01680185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972047|NCT01626378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972048|NCT03487796|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33972049|NCT04675177|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, unicentric study (Centro Hospitalar Universitário do Porto (CHUP)) which is aimed to compare the efficacy and safety of the treatment techniques in patients with hemorrhoidal disease grade II and III.~Patients referred to consultation were randomly allocated to one of the two treatments (polidocanol foam sclerotherapy and hemorrhoid artery ligation +- rectoanal repair)."||||
33972050|NCT00530400|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33972051|NCT05689398|||COHORT||PROSPECTIVE|||||||
33972052|NCT05266781|||COHORT||RETROSPECTIVE|||||||
33884022|NCT05447182|||COHORT||PROSPECTIVE|||||||
33884023|NCT02647073|NA|SINGLE_GROUP||OTHER||NONE||||||
33972053|NCT02757586|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33972054|NCT02563483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972055|NCT01513668|RANDOMIZED|CROSSOVER||||NONE||||||
33972056|NCT06098170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be enrolled and randomized 1:1:1 to receive unguided use of the My SCI Toolkit program (number (n)=20), coached My SCI Toolkit (n=20) or wait-list control (n=20; treatment as usual) for an 8-week treatment period.||||
33972057|NCT03958279|||COHORT||PROSPECTIVE|||||||
33972058|NCT06114056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972059|NCT03075033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This prospective, randomized study was approved by the local ethical committee of Alexandria main university hospital. Written informed consent was obtained from all the participants. Sixty patients aged 18-65 year with American Society of Anaesthesiologists physical status I-III with a neurosurgical diagnosis of cervical instability or at risk of secondary cervical injury, who were scheduled for awake intubation and self-positioning prone for elective neurological intervention, were enrolled in this study.|f|f|t|f
33972060|NCT04654403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972061|NCT02414880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972062|NCT05702281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972063|NCT05071547|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon acceptance and after informed consent has been obtained, participants are consecutively randomized to one of two study groups.||||
33972064|NCT06432621|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33972065|NCT04919083|||COHORT||OTHER|||||||
33972066|NCT05924711|||CASE_CONTROL||RETROSPECTIVE|||||||
33972067|NCT06163833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972068|NCT04841278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single prospective arm with historical controls as comparator||||
33972069|NCT02008721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972070|NCT06544876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760256|NCT01886001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760257|NCT00936832|NON_RANDOMIZED|||TREATMENT||NONE||||||
33760258|NCT01916655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760259|NCT03375476|||COHORT||PROSPECTIVE|||||||
33760260|NCT01368900|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33884024|NCT06548191|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinding disease condition and arm|TREAD will enroll 40 older adults (65+ years) with cognitive impairment and clinically diagnosed with Mild Cognitive Impairment (MCI) or early to moderate AD; and 20 cognitively normal age-matched subjects. The investigators will recruit individual participants with a diagnosis of MCI/AD (n=20 subjects) and 20 dyads of participants (n=40 subjects) composed of an MCI/AD patient and a cognitively normal living partner. This design is necessary to evaluate how feasible and burdensome is to follow a time-restricted eating pattern for individuals with cognitive impairment. Individual and dyad participants will be randomized in equal ratios to the complete prolonged nightly fasting intervention (14 h fast with no energy intake after 8 pm for 12 months) or to a delayed-start prolonged nightly fasting intervention (6 initial months of unrestricted eating patterns followed by 6 months of 14 h fast with no energy intake after 8 pm) using a random permuted-block design.|f|f|t|t
33884025|NCT01263041|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33884026|NCT05070884|||COHORT||RETROSPECTIVE|||||||
33884027|NCT05501600|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884028|NCT00087373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884029|NCT02528240|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33884030|NCT02831465|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884031|NCT02167945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884032|NCT04801628|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33884033|NCT03685461|RANDOMIZED|PARALLEL||OTHER||DOUBLE|participant blinded to condition surgeon aware by necessity data reviewers blinded|Sample of cochlear implant recipients. Half randomized for observation with ECOchG on, half randomized to ECochG off|t|f|f|t
33884034|NCT03429478|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The Participants will be randomized to be part of the study groups. The Care providers will not be aware of the grouping of the participants as the intervention is done in the pre-operative holding area. All patients will undergo Laparoscopic Cholecystectomy under standard operative and anesthesia protocol. The Investigator (Nurse and the doctor staff) will also be unaware of the grouping of the patients. The recorded data will be analyzed by an individual outcome asser unaware of the grouping or identity of the patient.|50 patients meeting the inclusion criteria will be included in the study after written and informed consent. They will be randomized and divided into 2 groups. Group 1 will be labelled as intervention group (recieving pre-operative music intervention), The group 2 will be labelled as controlled group (Not receiving pre-operative music intervention). Clinico-biochemical, Bio-cellular \& Neurohumoral data evaluation will be done in both the groups.The results will be analyzed using standard SPSS software.|f|t|t|t
33884035|NCT01865058|||COHORT||PROSPECTIVE|||||||
33884036|NCT03168984|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33884037|NCT01422993|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884038|NCT04524611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884039|NCT04164303|||OTHER||RETROSPECTIVE|||||||
33884040|NCT00128466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884041|NCT03504202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884042|NCT02167178|||||PROSPECTIVE|||||||
33884043|NCT05234580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884044|NCT00310830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884045|NCT04738357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972071|NCT03673878|||COHORT||PROSPECTIVE|||||||
33972072|NCT05118321|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33972073|NCT06229600|||COHORT||PROSPECTIVE|||||||
33972074|NCT00472550|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33760261|NCT06068231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study takes a single-blind method. During research process, the researchers and paticipant cannot avoid knowing the time of loading during the clinical examination and operation, so the outcomes assessor can only be single-blinded.The clinical examination data were measured and averaged by two independent clinicians. The data was analysed by a third person.||f|f|f|t
33760262|NCT01521962|RANDOMIZED|PARALLEL||||||||||
33760263|NCT02081950|NA|SINGLE_GROUP||OTHER||NONE||||||
33760264|NCT04828564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760265|NCT06389201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760266|NCT04376398|||CASE_ONLY||PROSPECTIVE|||||||
33760267|NCT00622011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760268|NCT00915135|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33760269|NCT03915210|||CASE_CONTROL||RETROSPECTIVE|||||||
33760270|NCT03621202|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760271|NCT00016692||||TREATMENT||DOUBLE||||||
33760272|NCT00584935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760273|NCT05672602|||COHORT||PROSPECTIVE|||||||
33760274|NCT05147610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||all participants receive the same intervention||||
33884046|NCT04130802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"For masking purposes, each dosing box and the pouches within it will be labeled either AM or PM. Dosing boxes and pouches will be labeled this way regardless of whether the product within the 2 boxes is the same (i.e. OCS-01 BID and placebo treatment arms) or different (i.e. OCS-01 QD)."|Randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle|t|f|f|t
33884047|NCT04759300|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The patients will be randomly assigned into two equal groups using computer-generated randomization technique. Group C-MAC VS (VS group) included patients undergoing tracheal intubation using the C-MAC VS. Group C-MAC VL D -blade (D group) included patients undergoing intubation using the C-MAC VL D-blade.|t|f|t|f
33884048|NCT01769755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884049|NCT02545725|||COHORT||RETROSPECTIVE|||||||
33884050|NCT04922411|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Only the PI and the technician/nurse know the order of DBS On/Off conditions|Subjects with DBS have stimulators turned on and off while undergoing imaging and doing behavioral tests||||
33884051|NCT04886934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884052|NCT01923688|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33972075|NCT05466890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All trial participants, investigator sites, and Sponsor are blinded.|A non-stratified permuted block randomization scheme will be used to randomize the patients in a 3:1 ratio (PL8177: placebo).|t|t|t|f
33972076|NCT05420428|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|We masked the participants, care provider and outcomes assessor.|controll group: tracheal intubation; intervention group: supraglottic airway device|t|t|f|t
33972077|NCT02960074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884053|NCT00070941|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33972078|NCT04666766|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|No results of the biomarker assays or microwave scans will be visible to the care givers or the participants.||t|t|f|f
33972079|NCT05718388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33884054|NCT00001387||||TREATMENT||||||||
33884055|NCT00599807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884056|NCT01113203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884057|NCT01871090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884058|NCT03575104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884059|NCT04575701|||OTHER||RETROSPECTIVE|||||||
33884060|NCT04199325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972080|NCT01297257|||CASE_ONLY||PROSPECTIVE|||||||
33972081|NCT03974633|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Outcomes were studied by an investigator that did not participate in the practical part of the trial.|All subjects received four injections of 0,1mL of physiologic saline (0,9%NaCl) in the forehead, 2cm above the eyebrows, with a 29G needle, after applying each one of the 4 non-invasive anesthetic methods studied in the trial, except for the control zone. The anesthetic method utilized in each part of the forehead of each patient was randomized through simple randomization.|f|f|f|t
33972082|NCT00004457|||DEFINED_POPULATION||PROSPECTIVE|||||||
33972083|NCT04467008|||COHORT||RETROSPECTIVE|||||||
34071273|NCT01027468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071274|NCT01999764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071275|NCT05250986|||OTHER||PROSPECTIVE|||||||
33760275|NCT04735744|||COHORT||PROSPECTIVE|||||||
33972084|NCT06017414|RANDOMIZED|PARALLEL||OTHER||NONE||"Our study is comprised of two main components:~An exploratory randomized, natural setting, pre-post-follow-up study design based on systemic principles and techniques assessing changes over time, and comparing:~1. the OSI/growth path training condition with a waitlist comparator condition,~2. paraprofessional provider/listener training condition with a waitlist comparator condition."||||
33972085|NCT00219856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972086|NCT02355548|||COHORT||PROSPECTIVE|||||||
33972087|NCT05728177|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33972088|NCT03130205|||COHORT||PROSPECTIVE|||||||
33972089|NCT03749655|RANDOMIZED|PARALLEL||OTHER||NONE|Principle investigator will be blinded from the randomisation as this member will conduct CBT with all patients.|Single centre feasibility, single blind, parallel, randomised controlled study.||||
33972090|NCT01548781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33972091|NCT05946083|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Binge Drinkers will be randomly distributed for one of two groups: 23 subjects with inulin intervention and 23 subjects with maltodextrin intervention (\~50 % male and \~50 % female in each group).~There will also be a non-interventional control group consisting of 36 non/low-drinkers."|t|t|f|t
33972092|NCT03118739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Verinurad capsules/matching placebo capsules and febuxostat/matching placebo capsules with randomization code printed on each label|Randomized, double-blind, double-dummy, placebo-controlled, parallel, independent groups, repeated measures, multi-center study|t|t|t|t
33972093|NCT01415921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972094|NCT00322556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972095|NCT03253978|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Not applicable - no masking|A randomised feasibility study||||
33972096|NCT01886300|||COHORT||PROSPECTIVE|||||||
33972097|NCT02202018|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33972098|NCT06406647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33972099|NCT02924857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972100|NCT04468386|||CASE_ONLY||PROSPECTIVE|||||||
33972101|NCT04124861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972102|NCT04089683|||COHORT||PROSPECTIVE|||||||
33972103|NCT01853306|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071276|NCT03116295|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071277|NCT06314360|||COHORT||CROSS_SECTIONAL|||||||
33972104|NCT01547039|||COHORT||PROSPECTIVE|||||||
33972105|NCT01830920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071278|NCT05205980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessor will be blinded to the group assignment of each participant.||f|f|f|t
34071279|NCT01625442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884061|NCT03498157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884062|NCT02149030|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34071280|NCT05103969|||COHORT||PROSPECTIVE|||||||
33884063|NCT00732095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884064|NCT01551784|||||RETROSPECTIVE|||||||
33884065|NCT06315075|NA|SINGLE_GROUP||TREATMENT||NONE|An independent evaluator will assess participants at post treatment and one year follow-up. Due to the single group design, the assessor will be aware that participants have received the intervention, but will not be involved in recruitment and treatment.|Single group, uncontrolled, pre-post-one year follow-up study||||
33884066|NCT05301075|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33884067|NCT06437938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33884068|NCT00764556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972106|NCT02233790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972107|NCT04289727|||COHORT||PROSPECTIVE|||||||
33972108|NCT06417996|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33972109|NCT03440203|||OTHER||CROSS_SECTIONAL|||||||
33972110|NCT06170814|||COHORT||CROSS_SECTIONAL|||||||
33972111|NCT05861609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the outcome assessors as well as the investigator (statistician) will be blinded.||f|f|t|t
33972112|NCT06107296|||CASE_ONLY||RETROSPECTIVE|||||||
33972113|NCT03910816|||COHORT||RETROSPECTIVE|||||||
33972114|NCT05585463|||OTHER||RETROSPECTIVE|||||||
34071281|NCT06454123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071282|NCT05926141|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||All participants enter a control phase for 12 weeks where they receive no intervention. After 12 weeks, the same group of participants receive the ACE intervention.||||
34071283|NCT02667314|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34071284|NCT00001646||||TREATMENT||||||||
34071285|NCT03475758|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071286|NCT02862938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071287|NCT05341778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the type of treatment provided to the patients.||f|f|f|t
34071288|NCT01034228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071289|NCT04504578|NA|SINGLE_GROUP||TREATMENT||NONE||patients with progressive keratoconus with thin corneas less than 400 micron||||
34071290|NCT04919603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071291|NCT03566381|||OTHER||PROSPECTIVE|||||||
34071292|NCT04039204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071293|NCT05405777|||OTHER||RETROSPECTIVE|||||||
34071294|NCT03290118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071295|NCT03351634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071296|NCT03043963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34071297|NCT01451099|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34071298|NCT06524154|RANDOMIZED|PARALLEL||OTHER||NONE||"The study sample will comprise three groups, 14 children each randomly chosen. Group I: positive reinforcement, with praising the child with encouraging words and pleasing smiles.~Group II: contingent escape, by giving some rest of the procedure while the child on the chair.~Group III: rewarding the child with simple gifts like stickers at the end of the procedure."||||
34071299|NCT01748019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972115|NCT04843085|||COHORT||RETROSPECTIVE|||||||
33972116|NCT04738877|||OTHER||OTHER|||||||
33972117|NCT06379074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each participant will be assigned an identification code (ID-code) randomly generated by a computer. The codes associated to participants in Group B will be randomly assigned to intervention (Group B2) or placebo (Group B1). E-mail addresses will be created for each participant using the ID-code to access the private area of the study website. The code will be associated with responses to online questionnaires, actigraphy recording, saliva samples and sleep diaries.|"Participants will receive a personal e-mail address to access their reserved area of the study's website. Each e-mail address is created using the pre-defined pseudonymized code, which will be assigned to each participant after screening (participants with sleep difficulties will be randomly assigned a code for condition B1 or B2).~This procedure is designed to increase privacy protection, allow for matching of responses throughout study's phases, and blind outcome assessors to participants allocation.~The personal website areas include contents based on their group allocation:~* A: online questionnaire and sleep diaries;~* B1: online questionnaire and sleep diaries; placebo intervention's contents (videos and pdf);~* B2: online questionnaire and sleep diaries; intervention's contents (videos and pdf); weekly optional private chat with a clinician (a psychotherapist expert in CBT-I and insomnia during pregnancy)."|f|f|f|t
33972118|NCT02837510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972119|NCT00670475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972120|NCT00290745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972121|NCT04368585|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34071300|NCT02211664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071301|NCT02281955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071302|NCT00177866|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34071303|NCT03921632|NA|SINGLE_GROUP||OTHER||||||||
34071304|NCT02511132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part 1: Participants will be randomized 1:1 to receive Vigil immunotherapy alone or gemcitabine / docetaxel. Part 2 participants will be a single group of subjects to receive Vigil immunotherapy in combination with irinotecan and temozolomide.||||
34071305|NCT01442649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071306|NCT04326387|||COHORT||PROSPECTIVE|||||||
34071307|NCT02806271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972122|NCT00798889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972123|NCT01492582|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972124|NCT04738747|RANDOMIZED|PARALLEL||PREVENTION||NONE||Study the impact of the WHOOP fitness tracker||||
34071308|NCT06613178|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple. blinded medication with codes kept by pharmacy director|randomized double blind double dummy two arm study|t|t|t|t
34071309|NCT01913574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071310|NCT04553081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071311|NCT02688803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071312|NCT04854057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33972125|NCT04875156|NA|SINGLE_GROUP||TREATMENT||NONE||measurement of the joint mobility and the force of the thumb||||
34071313|NCT06462742|||COHORT||PROSPECTIVE|||||||
34071314|NCT00143169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34071315|NCT05998694|||CASE_CONTROL||PROSPECTIVE|||||||
34071316|NCT00669188|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34071317|NCT04095325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33972126|NCT00275535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071318|NCT03944278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071319|NCT01471444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071320|NCT05103800|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33972127|NCT02585882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972128|NCT03198299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33972129|NCT00546182|||CASE_CONTROL||PROSPECTIVE|||||||
33972130|NCT00202137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972131|NCT02764489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972132|NCT00892697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972133|NCT06320379|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Participants will be randomized to take either a placebo or Zypan dietary supplement three times per day for four weeks.|t|t|t|t
34071321|NCT01353391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071322|NCT00313352|||COHORT||RETROSPECTIVE|||||||
34071323|NCT00132288|RANDOMIZED|CROSSOVER||||NONE||||||
34071324|NCT05573438|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||This will be a three-arm crossover, randomized, double-blind clinical trial.|t|f|t|t
34071325|NCT05103306|||CASE_CONTROL||PROSPECTIVE|||||||
34071326|NCT00851656|||CASE_ONLY||PROSPECTIVE|||||||
34071327|NCT04895852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071328|NCT00078910|NON_RANDOMIZED|||TREATMENT||||||||
34071329|NCT05109026|||COHORT||CROSS_SECTIONAL|||||||
34071330|NCT02072941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34071331|NCT03894475|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071332|NCT06402461|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Outcome measures will be collected online using Qualtrics without involvement of a researcher.|3x2x3: 'group' (preference vs. randomly allocation) by 'practice type' (mindfulness of the breath vs. mindfulness of sounds) by 'time' (baseline vs. post-allocation vs. post-intervention).|f|f|f|t
33972134|NCT05079685|||CASE_CONTROL||PROSPECTIVE|||||||
33972135|NCT03639272|||CASE_ONLY||RETROSPECTIVE|||||||
33972136|NCT01082952|||CASE_CONTROL|||||||||
34071333|NCT02338401|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34071334|NCT04310293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071335|NCT06238219|||COHORT||RETROSPECTIVE|||||||
34071336|NCT05805852|||CASE_ONLY||PROSPECTIVE|||||||
34071337|NCT02819440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071338|NCT03886584|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2 arms||||
34071339|NCT04501952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071340|NCT00019357||||TREATMENT||||||||
33972137|NCT03404661|||CASE_CONTROL||PROSPECTIVE|||||||
33972138|NCT04328948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972139|NCT01195922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972140|NCT05507554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972141|NCT04894422|||CASE_ONLY||PROSPECTIVE|||||||
33972142|NCT03611114|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33972143|NCT00417313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33972144|NCT05979181|||COHORT||RETROSPECTIVE|||||||
33972145|NCT04402515|||COHORT||PROSPECTIVE|||||||
33972146|NCT02687256|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33972147|NCT00818714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972148|NCT03275701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972149|NCT01691755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972150|NCT06207825|||COHORT||PROSPECTIVE|||||||
33972151|NCT05186961|||FAMILY_BASED||PROSPECTIVE|||||||
33972152|NCT01077206|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34071341|NCT03504189|NA|SINGLE_GROUP||OTHER||NONE||Open Label||||
33760276|NCT00551070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760277|NCT00846638|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33760278|NCT04769323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760279|NCT01376648|||||PROSPECTIVE|||||||
33760280|NCT04504201|||COHORT||PROSPECTIVE|||||||
33884069|NCT05998837|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Once eligibility is verified, the Investigator will randomize the subject contacting by e-mail the Secretarial Office of the Nephrologic Clinic of the Ospedale Policlinico San Martino The assigned randomization number will communicated via e-mail and recorded by the Investigator in the CRF. Therefore both investigators and participants will be blind|"Allocation to treatment group will be done by stratified randomization for diabetics and non-diabetics.~The randomization list will be generated with a designed computer program."|t|f|t|f
33884070|NCT05624463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The questionnaire collectors and outcomes assessor will not be informed of the group of patients|Randomized controlled trial：Participants who enroll in randomized controlled trials differ from one another in known and unknown ways that can influence study outcomes, and yet cannot be directly controlled. By randomly allocating participants among compared treatments, an randomized controlled trial enables statistical control over these influences. Provided it is designed well, conducted properly, and enrolls enough participants, an randomized controlled trial may achieve sufficient control over these confounding factors to deliver a useful comparison of the treatments studied.|f|f|t|t
33884071|NCT05682872|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33884072|NCT01703858|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884073|NCT02983487|||COHORT||PROSPECTIVE|||||||
33884074|NCT02679469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884075|NCT04710095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884076|NCT02183090|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884077|NCT04244565|||CASE_CONTROL||PROSPECTIVE|||||||
33884078|NCT00372437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884079|NCT01762566|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33884080|NCT02594436|||COHORT||PROSPECTIVE|||||||
33884081|NCT05797077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884082|NCT04087226|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33884083|NCT05998915|||COHORT||CROSS_SECTIONAL|||||||
33884084|NCT04191915|||CASE_CONTROL||PROSPECTIVE|||||||
33884085|NCT01371669|||COHORT||PROSPECTIVE|||||||
33884086|NCT06538285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884087|NCT03980938|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33884088|NCT03052803|||COHORT||PROSPECTIVE|||||||
33884089|NCT02296242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884090|NCT05748379|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Each patient has their individual ID number||t|f|f|f
33884091|NCT02829021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884092|NCT06047509|NA|SINGLE_GROUP||TREATMENT||NONE||the investigators intend to use Focal Laser Ablation guided by the UnfoldAI software to identify cancer margins and create ablation treatment plans and use the FocalPoint System to deploy and monitor thermal energy in cancerous regions of the prostate.||||
33884093|NCT01358032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884094|NCT00605085|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33884095|NCT04416880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884096|NCT05523882|||COHORT||PROSPECTIVE|||||||
33884097|NCT03644368|||OTHER||RETROSPECTIVE|||||||
33884098|NCT01608035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884099|NCT05042739|||FAMILY_BASED||PROSPECTIVE|||||||
33884100|NCT06540404|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33884101|NCT00821678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884102|NCT04863274|||COHORT||PROSPECTIVE|||||||
33884103|NCT04475614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884104|NCT05286060|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884105|NCT05329675|RANDOMIZED|PARALLEL||PREVENTION||NONE||Study Type : Interventional (Clinical Trial) Actual Enrollment : 108 participants Allocation: Randomized Intervention Model: Parallel Assignment, matching sex, age, and performance status Primary Purpose: Number of NK cells。||||
33884106|NCT00033865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884107|NCT02374866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34071342|NCT02417857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760281|NCT01718743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760282|NCT00005954||||TREATMENT||||||||
33760283|NCT01919359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33760284|NCT00082732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760285|NCT02864225|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|f|t
33760286|NCT00302783|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33760287|NCT01538472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760288|NCT05602545|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||parallel controlled trial||||
33884108|NCT05313997|||CASE_CONTROL||RETROSPECTIVE|||||||
33884109|NCT00110019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884110|NCT00216970|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884111|NCT03629548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884112|NCT01428466|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33884113|NCT05740956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884114|NCT02153762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884115|NCT00054587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884116|NCT02445833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884117|NCT05776069|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33972153|NCT06481800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial. To assign patients to different treatment groups, a table of random numbers generated by a computer will be used. Patients will be allocated randomly into three groups using this method|t|f|t|f
33972154|NCT01100684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972155|NCT01629875|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33972156|NCT06541470|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective randomized, parallel controlled||||
33972157|NCT05936528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884118|NCT01004757|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33884119|NCT01893567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884120|NCT01260454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884121|NCT00649103|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33884122|NCT03196128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884123|NCT05058183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study is looking into the ctDNA diagnostic test, this is given after breast cancer surgery to see whether patient is clear from cancer||||
33972158|NCT02549742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972159|NCT02791776|NA|SINGLE_GROUP||OTHER||NONE||||||
33972160|NCT00000614|RANDOMIZED|||PREVENTION||DOUBLE||||||
33972161|NCT03508895|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33884124|NCT05886933|||OTHER||PROSPECTIVE|||||||
33884125|NCT01984021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884126|NCT01406067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884127|NCT04144439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884128|NCT05926310|NA|SINGLE_GROUP||OTHER||NONE||||||
33884129|NCT03581331|NA|SINGLE_GROUP||OTHER||NONE||||||
33884130|NCT05996796|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884131|NCT04888663|NA|SEQUENTIAL||TREATMENT||NONE||||||
33884132|NCT05965674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884133|NCT01554579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884134|NCT05194254|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884135|NCT06547476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884136|NCT03536351|NA|SINGLE_GROUP||TREATMENT||NONE||One group design||||
33884137|NCT00183742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884138|NCT03827759|||COHORT||PROSPECTIVE|||||||
33884139|NCT06467812|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33884140|NCT05603429|||COHORT||PROSPECTIVE|||||||
33884141|NCT05479292|||COHORT||RETROSPECTIVE|||||||
33884142|NCT04336904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This is a multi-center, randomized, double-blind, placebo-controlled (1:1) clinical study to explore the efficacy and safety of Favipiravir in the treatment of adult subjects with COVID-19-moderate type.~Subjects within 10 days of COVID-19 onset will be screened, and be randomized as early as possible within 24 hours following screen success.~It is planned to randomize 100 subjects in an 1:1 ratio. Subjects in the test group will receive supportive care recommended in the current guidelines+Favipiravir, and subjects in the control group will receive supportive care recommended in the current guidelines+placebo control; the efficacy and safety of Favipiravir versus the placebo in the treatment of COVID-19-moderate type will be compared."|t|t|f|f
33884143|NCT02546986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884144|NCT05351580|||COHORT||PROSPECTIVE|||||||
33884145|NCT00945360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884146|NCT05103865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884147|NCT05066672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|matched placebo|randomized, double-blind, placebo-controlled|t|f|t|t
33972162|NCT02168647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972163|NCT05784571|||COHORT||CROSS_SECTIONAL|||||||
33972164|NCT03465410|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, prospective, multicenter study||||
33884148|NCT06501053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884149|NCT00769288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884150|NCT00235131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884151|NCT05149833|||COHORT||PROSPECTIVE|||||||
33884152|NCT05835947|||COHORT||RETROSPECTIVE|||||||
33972165|NCT00936377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972166|NCT02038634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760289|NCT06063798|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33884153|NCT05445245|||COHORT||PROSPECTIVE|||||||
33884154|NCT05576571|||CASE_ONLY||PROSPECTIVE|||||||
33972167|NCT02082613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071343|NCT02728817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760290|NCT01718028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33760291|NCT05440461|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33760292|NCT02249455|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071344|NCT01845571|||CASE_ONLY||OTHER|||||||
34071345|NCT00401492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071346|NCT06045000|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071347|NCT06462729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the treatment assigned and received.|"This is a prospective, randomized, controlled, single-blind, dose-finding, multi-center study which intends to demonstrate the safety of both LDGraft groups versus allograft during a single level ALIF procedure.~The study will enrol patients with lumbar degenerative disc disease (DDD) requiring single level ALIF. After a screening period, qualified participants will be enrolled and randomized using a 3:3:2 ratio to receive the LDGraft or the control treatment-allograft bone via spinal surgery and will then complete the safety follow-up period."|t|f|f|f
34071348|NCT06407492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071349|NCT03061188|NA|SEQUENTIAL||TREATMENT||NONE||||||
34071350|NCT06014879|RANDOMIZED|PARALLEL||OTHER||NONE|"For the teen videos, all video participants will be in a single group, so there will be no masking.~For the randomized control trial, because of the nature of the behavioral intervention, participants and investigators will be aware of their assignment to the intervention condition or the enhanced usual care condition."|"For the first phase of this project, all teen participants (up to 40 total) will create videos about living well with type 1 diabetes. The videos will be used in the upcoming randomized clinical trial of the new intervention.~For the randomized control trial, a parallel two group design will be used to evaluate the intervention among n=250 parents and youth dyads assigned to the Type 1 Doing Well intervention condition or the enhanced usual care condition (1:1). All parent and youth dyads are randomized to either the Type 1 Doing Well intervention condition or the enhanced usual care condition. Parents and youth dyads will be in the the study for approximately 12 months.~Providers (up to 20 per site, 40 total) will also be enrolled as participants to deliver the provider conversation intervention to parent and youth dyads randomized to the intervention condition, and to provide data about their experiences."||||
34071351|NCT04116775|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label phase II study of fecal microbiota transplant for metastatic castration-resistant prostate cancer that has not responded to treatment with pembrolizumab and enzalutamide.||||
34071352|NCT00869128|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34071353|NCT05924841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071354|NCT02371876|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071355|NCT03967041|||CASE_CONTROL||RETROSPECTIVE|||||||
34071356|NCT05834218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071357|NCT01839071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071358|NCT00866112|RANDOMIZED|PARALLEL||||NONE||||||
34071359|NCT01190904|||COHORT||PROSPECTIVE|||||||
34071360|NCT00565604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071361|NCT01266005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071362|NCT01556555|||CASE_ONLY||PROSPECTIVE|||||||
34071363|NCT03939650|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"For each of the six resident physicians of the outpatients clinic, the 6 first eligible patients will be attributed to the control group (with access to Diaana), then the 12 next eligible patients will be attributed to the interventional group (with access to Diaana). There will therefore be 36 patients in the control group and 72 in the interventional group."||||
34071364|NCT05802303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All cases undergoing frozen embryo transfer with own or donor gametes.||t|f|f|f
34071365|NCT04522570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884155|NCT04213755|||CASE_ONLY||PROSPECTIVE|||||||
33884156|NCT01200745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884157|NCT00223899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884158|NCT01627587|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884159|NCT01522846|||CASE_ONLY||PROSPECTIVE|||||||
33884160|NCT00083187||||TREATMENT||NONE||||||
33884161|NCT05821140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884162|NCT01318122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884163|NCT05197803|NA|SINGLE_GROUP||TREATMENT||NONE||1 group with three randomized conditions (unaided, aided with RIC, aided with BTE).||||
33884164|NCT04336020|||COHORT||CROSS_SECTIONAL|||||||
33884165|NCT02788500|||COHORT||PROSPECTIVE|||||||
33884166|NCT04024800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972168|NCT03926078|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|All measurements will be performed by three blinded observers that are not responsible to perform a comprehensive interpretation of the study.||f|f|f|t
33972169|NCT04351295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972170|NCT01380028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972171|NCT04626427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972172|NCT04931420|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972173|NCT02861183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972174|NCT05731154|||CASE_ONLY||CROSS_SECTIONAL|||||||
33972175|NCT03828461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972176|NCT06528249|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an investigator-initiated, open-label, multicenter, multidose, dose escalation and expansion study to evaluate the safety, tolerability, and efficacy of Erythrocyte-αPD-1 conjugates in patients with advanced malignancies||||
34071366|NCT02213770|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34071367|NCT00311753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071368|NCT02922465|NA|SINGLE_GROUP||||NONE||||||
34071369|NCT01843803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34071370|NCT01874626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071371|NCT05122780|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized 1:1 (using an online software available 24h/24h) to precision medicine approach vs standard approach."||||
33884167|NCT03892161|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Eligible volunteers will be switched from their standard of care PI to DRV/r 800/100 mg daily, and intensive sampling for measurement of drug concentrations will be performed at steady state. Rifampicin (600-750 mg daily depending on body weight) will then be started and subsequently the protease inhibitor doses escalated to DRV/r 1600/200 mg daily (participants randomized to arm A), OR 800/100 mg 12-hourly (arm B) for 7 days, after which patients will be switched from the daily to the 12-hourly dosing schedule (arm A) or vice versa (arm B) for a further 7 days. Rifampicin will then be stopped but the increased doses of DRV/r will be continued for a further week, before participants are switched back to their standard-of-care ART regimen. Dolutegravir (DTG) 50 mg twice daily (the dose which overcomes any interaction with rifampicin (Dooley 2013) will be added to minimize the risk of viral rebound due to possible suboptimal protease inhibitor exposures during the study.|A phase I, open-label, cross-over, single center, PK drug-drug interaction study will be conducted in 24 medically stable HIV-1 infected adults with viral suppression (viral load \<50 copies/mL).|t|t|t|f
33884168|NCT05212740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884169|NCT02619500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33884170|NCT03595280|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized trial with 3 groups: 1) Control group that receives no study messages; 2) Untailored message group that receives general messages about the risks of hookah tobacco; 3) Tailored message group that receives messages about the risks of hookah tobacco that are personalized to their hookah tobacco use behavior and beliefs.||||
33884171|NCT03256045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884172|NCT00681239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884173|NCT04870073|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||single-centre, single blinded, 2x2 factorial, cluster randomized trial|t|f|f|f
33884174|NCT03014960|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884175|NCT04407858|||COHORT||PROSPECTIVE|||||||
33884176|NCT03686969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884177|NCT02656927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884178|NCT06333873|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Prospective, longitudinal, interventional, exploratory, non-randomised, single-centre study including healthy volunteers and patients with AMD||||
33972177|NCT06022133|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Binding not possible as patients needs to carry out dietary sodium restriction themselves.|Not blinded cross over trial. First arm is usual diet for two weeks, second arm is sodium dietary restriction.||||
33972178|NCT01431755|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34071372|NCT00460239|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33760293|NCT02461810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760294|NCT00423384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760295|NCT00871637|||CASE_CONTROL||PROSPECTIVE|||||||
33760296|NCT06116565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760297|NCT03914599|||COHORT||PROSPECTIVE|||||||
33884179|NCT04991337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label study and participants are not blinded to group allocation. Researchers and staff are unblinded during all procedures. AF burden will be adjudicated by a blinded endpoint committee and researchers will be blinded to group allocation when performing statistical analyses.|Two-arm international multicenter open-label randomized (1:1) controlled trial with blinded end-point evaluation.|f|f|f|t
33884180|NCT01292655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071373|NCT04953143|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33760298|NCT03114280|NA|SINGLE_GROUP||TREATMENT||NONE||Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin in untreated unresectable locally-advanced Head and Neck Squamous Cell Carcinoma (HNSCC).||||
33760299|NCT03821090|||CASE_CONTROL||OTHER|||||||
33884181|NCT05723432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884182|NCT01039532|||CASE_CONTROL||PROSPECTIVE|||||||
33760300|NCT01170338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884183|NCT03399266|RANDOMIZED|PARALLEL||TREATMENT||NONE||"200 pregnant women with one previous cesarean section and PROM along with an unfavourable cervix (Bishop Score ≤ 6) are expected to be entered into the study.~All eligible women will be presented with the study protocol by a study coordinator.The following screening medical procedures will be completed:~Medical and gynecological history, physical and vaginal speculum examination, Ultrasonography and a non-stress test (NST).~For eligible patients, and following an informed consent, group randomization will take place:~GROUP 1: Expectant management (standard protocol). GROUP 2: Insertion of a balloon cervical catheter (study group).~The randomization process will be as follows:~A. The eligible patient will sign the informed consent prior to randomization. B. The patient will receive a subject number for the study (from 1 to 200) The study coordinator will open a sealed envelope with the patient's study number to reveal the patient's assigned study group."||||
33884184|NCT05340985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"All participants at the MS clinic will be blinded to trial intervention allocation. The main outcomes will be evaluated by neurologists.~Investigator is also blind; two type of vitamin D; 25(OH)D3 and cholecalciferol capsules with similar shape and color."|This is a randomized clinical trial with a parallel group and allocation 1:1.|f|f|f|t
33884185|NCT02258880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884186|NCT03321448|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884187|NCT05302687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomization will be performed by the study statistician, who had no contact with the participants. The allocation sequence will not available to any member of the research team until databases had been completed and locked. Since this is a double-blinded study, both the research team and subject will not know in which group the subject is assigned to.|A double-blind randomized placebo-controlled trial design has been chosen. Randomization for the parallel prevention phase will be carried out after checking the inclusion and exclusion criteria.|t|t|t|f
33884188|NCT03932799|||COHORT||PROSPECTIVE|||||||
33884189|NCT04545905|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33884190|NCT05936320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884191|NCT06153212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884192|NCT01699139|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33884193|NCT00944034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884194|NCT01721499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884195|NCT05416008|||COHORT||PROSPECTIVE|||||||
33884196|NCT03122431|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study includes 3 subprojects that will assess serum drug levels for efficacy and toxicity. In the first two subprojects, hydroxychloroquine will be studied in SLE population. In the third subproject, thalidomide and SLE and cutaneous lupus will be studied.||||
33884197|NCT04210466|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884198|NCT03529877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884199|NCT01579695|||COHORT||PROSPECTIVE|||||||
33884200|NCT00402441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33884201|NCT01214785|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760301|NCT03287739|||COHORT||PROSPECTIVE|||||||
33972179|NCT06547723|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In this study, simple individual randomization method is used. None of the participants and researchers will be informed about the placement of the participants in the groups until the start of the project, and for this purpose, spss software will be used.|This is a feasibility study with a control group along with randomized double-blind parallel groups on 40 elderly patients with chronic pain.|t|f|f|t
33972180|NCT03644095|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33760302|NCT00066430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760303|NCT01473498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760304|NCT04520802|||OTHER||PROSPECTIVE|||||||
33760305|NCT00330915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760306|NCT01694784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33760307|NCT02427711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33972181|NCT00859469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972182|NCT01842958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972183|NCT06026982|NA|SINGLE_GROUP||TREATMENT||NONE||Consent and a pre survey on cravings will be collected. Then participants will take a probiotic/prebiotic and a pickle for 30 days. After 30 days the same survey will be taken by the participants and a paired t test will be used to analyze if there is a statistical change in cravings.||||
33972184|NCT00575133|||COHORT||PROSPECTIVE|||||||
33972185|NCT05175079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972186|NCT01753037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33972187|NCT03426930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760308|NCT01105026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760309|NCT04696913|||CASE_CONTROL||RETROSPECTIVE|||||||
33760310|NCT03978325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double||f|f|t|t
33760311|NCT01512771|||CASE_CROSSOVER||PROSPECTIVE|||||||
33760312|NCT00315419|||COHORT||PROSPECTIVE|||||||
33764993|NCT04481828|||COHORT||RETROSPECTIVE|||||||
33764994|NCT02884414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764995|NCT01704911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764996|NCT05295914|||COHORT||RETROSPECTIVE|||||||
33764997|NCT00608725|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33764998|NCT01052909|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972188|NCT01159327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972189|NCT00324415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972190|NCT01274728|||COHORT||PROSPECTIVE|||||||
33972191|NCT04984109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* Sham ESP block will be administrated in the control group~* Measurements will be obtained by anesthetists not participating in the study and blinded to its group"|Prospective study|t|f|t|t
33972192|NCT01093456|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972193|NCT01501695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760313|NCT05971914|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|Eight patients aged 8-12 years exhibiting uni- or bilateral alveolar cleft defects and oronasal fistulas underwent supra-, subgingival scaling and received individual oral hygiene instructions prior to surgery at the Department of Periodontology, Semmelweis University, Budapest, Hungary. Surgeries will be performed at the I. Department of Paediatrics, Semmelweis University, Budapest, Hungary between January 2021 and November 2021. The study was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (Approval Number SE TUKEB x/2020). Patients is treated in accordance with the World Medical Association Declaration of Helsinki (version 2008). Surgical interventions are undertaken with the understanding and written consent of each subject's caregiver||||
33760314|NCT06474897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764999|NCT03301090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884202|NCT02024971|||COHORT||PROSPECTIVE|||||||
33884203|NCT02668146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884204|NCT00364299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884205|NCT02576405|||COHORT||PROSPECTIVE|||||||
33884206|NCT00282841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884207|NCT02530931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884208|NCT03786432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972194|NCT00071916|||CASE_CONTROL||PROSPECTIVE|||||||
33884209|NCT04420364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind trial, in that only the assessor will be blinded to the treatment assignment.|Single-blind, parallel-group, randomized, active-controlled trial|f|f|f|t
33884210|NCT00421330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884211|NCT03976622|||COHORT||PROSPECTIVE|||||||
33884212|NCT02946801|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33884213|NCT04992143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884214|NCT02849639|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33884215|NCT04433507|RANDOMIZED|PARALLEL||PREVENTION||NONE||50 patients in the SG group and 50 in the SG + primary hiatal hernia repair group following randomization||||
33884216|NCT00568555|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33884217|NCT05535179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884218|NCT00449514|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884219|NCT06097520|RANDOMIZED|PARALLEL||OTHER||NONE||investigator-initiated, single-center, randomized controlled study||||
33884220|NCT00808041|||CASE_ONLY||PROSPECTIVE|||||||
33884221|NCT03715426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884222|NCT06522776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884223|NCT05463809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33884224|NCT05544890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The groups will be arranged randomly and the masking technique to be used will be the doble blind procedure. The subjects will be randomly selected through the EPIDAT 4.2 program. The random allocation to each group will be made just by one external researcher, this way, neither the main researcher, nor the participants, will know their allocation. Furthermore, the inspector who will collect the evaluation data won´t know the allocation of each subject.||t|t|f|f
33884225|NCT05590598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884226|NCT02194153|||COHORT||PROSPECTIVE|||||||
33884227|NCT03237468|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33884228|NCT04181879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Members of the research team who are pharmacists will undertake an assessment of medication appropriateness following medication review by GPs and will be blind to the allocation of patients to either arm.~Due to the nature of the intervention package (i.e. access to the video and patient recall), we will be unable to blind the GPs or patients."|A pilot cluster randomised controlled trial (cRCT). Eligible GP practices will be allocated to intervention or control (usual care) arm by a Northern Ireland Clinical Trials Unit (NICTU) statistician using an automated randomisation system. Practices will be randomised on a 1:1 allocation ratio stratified by country (i.e. Northern Ireland or the Republic of Ireland).|f|f|f|t
33884229|NCT01183624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972195|NCT06544187|||COHORT||PROSPECTIVE|||||||
33884230|NCT04532710|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, placebo controlled, double-blind, single site trial in a validated allergen exposure chamber setting using grass pollen induced rhinoconjunctivitis.|t|t|t|t
33884231|NCT05689931|||COHORT||CROSS_SECTIONAL|||||||
33884232|NCT06297928|||COHORT||PROSPECTIVE|||||||
33884233|NCT03640832|RANDOMIZED|PARALLEL||OTHER||SINGLE|Evaluator blinded (dermatologist and ophthalmologist).||f|f|f|t
33884234|NCT03303911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884235|NCT01448395|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884236|NCT03335085|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33884237|NCT02061852|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884238|NCT05670080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"A physiotherapist with a master's degree who is unaware of the study's content will apply the physical therapy program and assessments.~Participants will take physical therapy program and MI training without being told which group they were in."|The study will be divided into two parallel groups: the MI group and the Control group. Both groups will participate in a routine physical therapy program after 4 weeks of immobilization, with the MI group receiving additional motor imagery training during the preoperative period. MI training will be provided to Group 1 participants who are planning for rotator cuff repair in the pre-surgical period by the corresponding researcher. The physical therapy program will be applied by a physiotherapist with a master's degree and 8 years of professional experience in the field of orthopedic rehabilitation, who is different from the corresponding researcher of the study.|t|t|f|f
33884239|NCT00602355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884240|NCT01846286|||CASE_ONLY||PROSPECTIVE|||||||
33884241|NCT02366000|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33884242|NCT01441063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884243|NCT01230879|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884244|NCT00996203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884245|NCT05753826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884246|NCT04408807|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33884247|NCT00384241|||COHORT||RETROSPECTIVE|||||||
33884248|NCT00723788|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33972196|NCT00328874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972197|NCT02742090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071374|NCT06172738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded.|Randomized control trial.|t|f|f|t
34071375|NCT06549738|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, controlled study planned for 50 women with lipedema with half (25) women in the Treatment group and half (25) women in the Control group. Both legs of all enrolled women will be studied for a total of 100 legs evaluated. All participants in the Treatment group will be supplied the Lympha Press Optimal Plus IPCD and the Lympha Pants™ garment to treat the lower body including the abdomen, pelvis, and buttocks (trunk) and the lower extremities. All participants in the study (Treatment and Controls) will receive compression leggings, and will be instructed to wear them daily.||||
33884249|NCT03404466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884250|NCT03891550|NA|SINGLE_GROUP||TREATMENT||NONE||active, open labeled, single arm study||||
33972198|NCT04935827|||COHORT||RETROSPECTIVE|||||||
33972199|NCT01340352|||COHORT||PROSPECTIVE|||||||
34071376|NCT03558685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071377|NCT01765569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071378|NCT04378595|||COHORT||PROSPECTIVE|||||||
34071379|NCT05778292|||COHORT||PROSPECTIVE|||||||
34071380|NCT04982744|||CASE_ONLY||OTHER|||||||
33884251|NCT00600015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884252|NCT00051155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884253|NCT01017510||PARALLEL||||NONE||||||
33884254|NCT04428411|||COHORT||RETROSPECTIVE|||||||
33884255|NCT06136936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972200|NCT04066881|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The vaccine component of PrEPVacc is placebo-controlled. Study staff, participants, laboratory staff and clinical staff assessing safety outcomes will not know who has been allocated vaccine or placebo, but pharmacy staff will know. The committee assessing the efficacy endpoints will not see the allocation in the first instance. The IDMC and statistical staff preparing the closed reports for the IDMC will also know the allocation.~Clinic staff will see the difference in volume between CN54gp140 in MPLA-L/matched placebo (0.4ml) and DNA-HIV-PT123/matched placebo (1ml) due to the position of the plunger, but they will not be able to differentiate between active and placebo.~The randomisation to control PrEP: experimental PrEP is 1:1 and all study staff and participants will know the allocation after randomisation as this is open-label."|"Group A: DNA-HIV-PT123/AIDSVAX B/E®/TDF/FTC (Truvada) once daily (wks 0-26) Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (wks 0,4), then MVA-CMDR and CN54gp140+MPLA-L/ TDF/FTC(Truvada) once daily (wks 0-26) Group C: Saline placebo (wks 0,4,24,48)/ TDF/FTC (Truvada) once daily (wks 0-26) Group D: DNA-HIV-PT123/AIDSVAX B/E®/ TAF/FTC (Descovy) once daily (wks 0-26) Group E: DNA-HIV-PT123 and CN54gp140+MPLA-L (wks 0,4), then MVA-CMDR and CN54gp140+MPLA-L/ TAF/FTC (Descovy) once daily (wks 0-26) Group F: Saline placebo (wks 0,4,24,48)/ TAF/FTC (Descovy) once daily (wks 0-26)~Group G: Saline placebo (wks 0,4,24,48)/ TAF/FTC (Descovy) once daily (wks 0-26)"|f|t|t|t
33972201|NCT06301555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884256|NCT02574533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884257|NCT05563896|||COHORT||CROSS_SECTIONAL|||||||
33884258|NCT01565980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33884259|NCT04995874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884260|NCT03831568|||OTHER||PROSPECTIVE|||||||
33884261|NCT05320575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884262|NCT03789591|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study is designed with a double-blind design. The clinical provider and participant/family will be aware of the absolute (mg) starting dose and could theoretically calculate the mg/kg starting dose, but the treatment assignment will not explicitly be provided to the provider or the family, and the same procedures will be used for dose escalation or reduction. Although most doses in the Alternative Arm will be different than 20 mg/kg, there are some patients on the standard arm who may have a PK-guided dose that is close to or at 20 mg/kg. Thus, although it may be possible to deduce the study arm, the study is designed technically in a double-blind fashion.||t|t|t|f
34071381|NCT00645372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071382|NCT02629185|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34071383|NCT00202020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33884263|NCT01746771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884264|NCT02509091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071384|NCT04245176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071385|NCT01269619|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071386|NCT02664064|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34071387|NCT05466292|||COHORT||RETROSPECTIVE|||||||
34071388|NCT05951452|||CASE_CONTROL||PROSPECTIVE|||||||
34071389|NCT04817176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33765000|NCT05957302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33884265|NCT04615143|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33884266|NCT01926184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884267|NCT05630157|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||non randomized cluster controlled trial||||
33884268|NCT01653041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884269|NCT03633357|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Crossover, Mechanistic Pharmacological Neuroimaging Study|t|f|t|f
33884270|NCT00003031|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33884271|NCT04270760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884272|NCT02380755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|randomized, double blinded, placebo-controlled, parallel group, single-center study|78 patients were randomized (1:1) to receive Clomiphene Citrate (CC) 50 mg during 12 weeks or placebo (PLB). MAIN OUTCOME MEASURES: flow-mediated dilatation of the brachial artery (FMDAB), circulating levels of sICAM-1, sVCAM-1, E-selectin and progenitor endothelial cells. Secondary endpoints: Body mass index (BMI), abdominal circumference (AC), glycaemia, total cholesterol, fractions and triglycerides, HOMA-IR index, bioelectrical impedance parameters, Adam questionnaire and hormonal parameters (total testosterone levels, SHBG, LH, FSH and Estradiol).|t|t|t|f
33884273|NCT06011720|||CASE_ONLY||RETROSPECTIVE|||||||
33884274|NCT04735003|||COHORT||PROSPECTIVE|||||||
33884275|NCT00002944|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884276|NCT00417001|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33884277|NCT01715584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33884278|NCT04550130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884279|NCT01884831|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33884280|NCT04290702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||3 groups with different regional analgesic technique|t|t|t|t
33884281|NCT05278182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884282|NCT01592760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884283|NCT06158646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884284|NCT01246544|||COHORT||PROSPECTIVE|||||||
33884285|NCT02733874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33884286|NCT06540469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972202|NCT01761526|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33972203|NCT04633837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a double-blinded study, thus, neither the surgeon nor the patient will know if the extracellular matrix injection was given. A total of 70 envelopes will be made with 35 containing a card designating treatment and 35 designating control. Envelopes will be randomly opened at completion of the surgery and if the treatment group is selected the patient will be administered the injectable extracellular matrix graft. Dr. Badman will place a 22 gauge needle transtendon into the glenohumeral joint space and will then exit the room prior to the envelope being opened. If the treatment group is selected, his physician assistant will administer the injection. If the control group is selected, the needle will be removed and no injection will be given."|The extracellular matrix implant injection is the intervention in this study. One group of patients undergoing arthroscopic shoulder surgery will receive 2cc of the injectable implant placed into the glenohumeral joint space at completion of the rotator cuff repair and the other group will not.|t|t|t|f
33972204|NCT00004686|RANDOMIZED|||TREATMENT||DOUBLE||||||
33972205|NCT02244437|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972206|NCT02545413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972207|NCT01288859|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33972208|NCT00654485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33972209|NCT03881332|||COHORT||PROSPECTIVE|||||||
33972210|NCT06165120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972211|NCT02724007|||COHORT||RETROSPECTIVE|||||||
33972212|NCT01855126|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Enrolled participants will be randomized to receive either the active intervention or placebo intervention and then crossed over to receive the opposite intervention. The study consisted of two intervention periods of 8 weeks separated by a two week washout period.|t|t|f|t
33972213|NCT01802346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972214|NCT03857113|||CASE_ONLY||PROSPECTIVE|||||||
33972215|NCT04531033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||3 treatments: low dose probiotic, high dose probiotic, placebo|t|f|t|f
33972216|NCT00564161|||||PROSPECTIVE|||||||
33972217|NCT03013933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972218|NCT01616303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972219|NCT00281619|||COHORT||PROSPECTIVE|||||||
33972220|NCT05768828|||CASE_CONTROL||PROSPECTIVE|||||||
33972221|NCT01768962|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33972222|NCT00711503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33972223|NCT05720533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972224|NCT05517850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will know about the randomization to one of two types of cognitive behavioral therapy. Participants will have no way to know their assignment beforehand, or the defining characteristics of either condition.||t|f|f|f
33972225|NCT01562795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972226|NCT01195571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972227|NCT05452577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071390|NCT04516239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be informed of the randomization group, 6 months after surgery.|This study is a prospective randomized clinical trial with two parallel treatment groups. At the preoperative teaching session, the study objectives and the risks and benefits of surgery will be explained to the patient by the research assistant or the surgeon in order to obtain consent. A randomization table will be generated by the SPSS 10 software and sealed numerated envelopes will be assigned to each patient entering the study. A research assistant will coordinate the study and data collection.|t|f|f|f
33972228|NCT03432000|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"This study consists in:~* evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls~* investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia~The measures that will be realized are:~* Performances of patients and controls on temporal task~* Subjective alterations of time perception in patients with an adapted scale (EAWE)~* Global symptomatology with PANSS (positive and negative symptom scale)"||||
33972229|NCT00208390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071391|NCT01030913|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34071392|NCT03092947|||COHORT||PROSPECTIVE|||||||
34071393|NCT06612372|NA|SINGLE_GROUP||OTHER||NONE||||||
33884287|NCT03043833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884288|NCT01817738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884289|NCT06548867|||COHORT||RETROSPECTIVE|||||||
33884290|NCT04418856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884291|NCT04687644|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Online Education Program|t|f|f|f
33884292|NCT00273143|||||PROSPECTIVE|||||||
33884293|NCT01459536|||CASE_CONTROL||PROSPECTIVE|||||||
33884294|NCT01428401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884295|NCT06218472|||COHORT||PROSPECTIVE|||||||
33884296|NCT01974609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33884297|NCT04623645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884298|NCT00728221|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33884299|NCT03246633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884300|NCT00883675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884301|NCT05082701|||COHORT||PROSPECTIVE|||||||
33884302|NCT02065453|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884303|NCT00364689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884304|NCT03611426|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The first part is ascending dose study: 3 subjects take rhThromb and 1 subjects take the same volume of saline; The second part is dose extension study:2 cohorts and 1 blank control group( the same volume of saline) used with absorbable collagen sponge;every group need 12 subject; The second part is dose extension study: 2 cohorts and 1 blank control group( the same volume of saline);every group need 12 subject;|t|f|f|f
33884305|NCT02342132|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33884306|NCT02404103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884307|NCT06092294|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study has masking at 2 levels. the first one is in the outcome assessors and the second level of masking is in the analysis of the data.||f|f|f|t
33884308|NCT05397132|||CASE_ONLY||CROSS_SECTIONAL|||||||
33884309|NCT02221544|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33884310|NCT02373761|||CASE_ONLY||PROSPECTIVE|||||||
33884311|NCT03312517|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Study is double blinded. Investigator, participant, or care provider will be blinded to watch drug the subject receives during each treatment week.|double-blind, randomized 3-way crossover design|t|t|t|f
33884312|NCT00858429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071394|NCT01110967|||COHORT||RETROSPECTIVE|||||||
34071395|NCT02279290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071396|NCT03943797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071397|NCT03300414|||COHORT||PROSPECTIVE|||||||
34071398|NCT01995344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071399|NCT06611527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071400|NCT03699371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||prospective, randomised, multi-centre assessor-blinded study|f|f|f|t
34071401|NCT02179346|||CASE_ONLY||PROSPECTIVE|||||||
34071402|NCT01773629|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071403|NCT06376617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||BAL will stained by fungal staining with lactophenol stain as well as culture on Sabouraud dextrose agar.||||
34071404|NCT05497297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071405|NCT02263378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071406|NCT03876483|RANDOMIZED|PARALLEL||TREATMENT||NONE||Facilities randomized to receive the behavioral intervention or standard of care||||
34071407|NCT06593834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884313|NCT02689323|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33884314|NCT01472120|||CASE_CONTROL||PROSPECTIVE|||||||
33884315|NCT00305942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884316|NCT03342950|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33884317|NCT02087787|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884318|NCT03426098|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded-investigator assessments will be performed at Baseline and Days 28, 56, 146, and 180 to evaluate treatment efficacy for facial wrinkling. Of note, the blinded-investigators will be blinded to treatment settings and technique, and number of treatments.|All subjects will receive up to three treatments at four week intervals to their full faces with the Secret RF device.||||
33884319|NCT06109194|NA|SINGLE_GROUP||TREATMENT||NONE|No masking to occur|pre-test, intervention, post-test||||
33884320|NCT02388373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884321|NCT03996915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind|Bio-equivalence Study Enrollment:40|f|f|t|f
33884322|NCT02198248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884323|NCT02338102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884324|NCT01272466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884325|NCT02838173|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884326|NCT01457183|NA|SINGLE_GROUP||OTHER||NONE||||||
34071408|NCT03183843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071409|NCT02157571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071410|NCT01674465|||OTHER||PROSPECTIVE|||||||
34071411|NCT06164899|||COHORT||PROSPECTIVE|||||||
33884327|NCT03390179|||CASE_CONTROL||PROSPECTIVE|||||||
33884328|NCT03775876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|surgeons, patients as well as the outcome assessor were blinded in regards of the drug used for sedation during surgery (Propofol vs dexmedetomidine)|randomised controlled double blind trial|t|t|f|t
33884329|NCT00784797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884330|NCT00003490||||TREATMENT||||||||
33884331|NCT04970004|||CASE_ONLY||RETROSPECTIVE|||||||
33760315|NCT03168295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Post renal transplant type 2 diabetes mellitus patients and non-diabetic mellitus patients after renal transplant with a control group of type 2 diabetes mellitus who have not undergone renal transplant||||
33884332|NCT01864408|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884333|NCT01409460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884334|NCT06545162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884335|NCT01072292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884336|NCT01099228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884337|NCT04070482|||COHORT||PROSPECTIVE|||||||
33884338|NCT02529579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884339|NCT02051010|||CASE_ONLY||PROSPECTIVE|||||||
33884340|NCT03623867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subject will be randomised into secukinumab or placebo group in 1:1 ratio|t|t|t|t
33884341|NCT05510505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884342|NCT00556426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884343|NCT00453401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884344|NCT06232200|RANDOMIZED|PARALLEL||TREATMENT||NONE||The conventional treatment group will be determined as the control group and the patients in the treatment group will receive acupuncture treatment twice a week, a total of 8 sessions.||||
33884345|NCT04146142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized study 1:1||||
33884346|NCT00109473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884347|NCT00135603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884348|NCT02135380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884349|NCT04563065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33884350|NCT00004941|RANDOMIZED|||TREATMENT||DOUBLE||||||
33884351|NCT02945956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884352|NCT00374803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884353|NCT03803332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884354|NCT00865384|RANDOMIZED|CROSSOVER||||NONE||||||
33884355|NCT04226794|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Only the tDCS intervention was masked||t|f|f|t
33884356|NCT05252793|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33884357|NCT01144598|||||CROSS_SECTIONAL|||||||
33884358|NCT02058602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884359|NCT06399926|||COHORT||PROSPECTIVE|||||||
33884360|NCT01622569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884361|NCT04536064|||OTHER||OTHER|||||||
33884362|NCT00503204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972230|NCT05522010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A calculated minimum sample of 50 patients with single or multiple symptomatic cervical DDD with radiculopathy and\\or myelopathy not responding to non-surgical management will be needed. The sample will be randomly assigned for one of two equal groups (Group I (n=25); will undergo ACDF and Group II (n=25) will undergo DCI to detect an effect size of 0.42 in the rate of adjacent segment degeneration (main clinical and radiological outcomes), with an error probability of 0.05 and 80%|t|f|t|f
33972231|NCT01162590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33972232|NCT00614159|||COHORT||PROSPECTIVE|||||||
33972233|NCT00001074||||TREATMENT||||||||
33972234|NCT01399177|||COHORT||PROSPECTIVE|||||||
33972235|NCT06527716|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be aware that the teaching pertains to the prevention of pressure injuries, but they will not be informed about the specifics of the research methodology or the group assignments within the study. They will only know that this teaching is part of the in-service education program planned by the research site for that year.|Control Group and Experimental Group|t|f|f|f
33972236|NCT03243279|||COHORT||PROSPECTIVE|||||||
33972237|NCT01653197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33972238|NCT06224582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972239|NCT03875183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972240|NCT06287697|||OTHER||OTHER|||||||
33972241|NCT05713877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study personnel, care provider, patients and their families will remain blinded. Randomization will be performed by members of the Pharmacy Research Department.||t|t|t|t
33972242|NCT04740684|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will consume the exact same diet for one week. Samples will be collected before, during and after the intervention.||||
33884363|NCT00146263|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760316|NCT01006200|||COHORT||RETROSPECTIVE|||||||
33760317|NCT01199926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33760318|NCT02837354|||COHORT||PROSPECTIVE|||||||
34071412|NCT00929487|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34071413|NCT02841475|||COHORT||RETROSPECTIVE|||||||
34071414|NCT02934555|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33760319|NCT00965926|RANDOMIZED|CROSSOVER||||NONE||||||
33760320|NCT00570674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760321|NCT05506735|||COHORT||RETROSPECTIVE|||||||
33760322|NCT06156722|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33760323|NCT00946296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33760324|NCT05660590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|radiologist who assessed soft tissue thickness assessment is masked and the patients did't know which group they belong to.|Randomised comparison trial|t|f|f|t
33760325|NCT04131270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomly assigned to an active control group (education on sedentary behavior and physical activity) or to a planning intervention (education on sedentary behavior and physical activity + education on how to form behavior change plans + forming a plan to change sedentary behavior using a planning sheet)|t|f|f|f
33760326|NCT05604716|||COHORT||CROSS_SECTIONAL|||||||
33760327|NCT00187330|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34071415|NCT05686460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The researcher gave each students a number in random. Then, they were divided into three groups by random sampling method using the Excel program. The students who were randomly assigned to the 1st group with the Excel program were determined as intervention group 1 (ice massage), the 2nd group students were intervention group 2 (music medicine), the 3rd group students were group 3 control.||t|f|t|f
34071416|NCT02211703|||COHORT||PROSPECTIVE|||||||
33760328|NCT01584180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760329|NCT03590340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33760330|NCT02634788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760331|NCT02859610|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760332|NCT02228395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33760333|NCT06020625|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760334|NCT00463827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760335|NCT03502486|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760336|NCT02103621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760337|NCT03546348|||CASE_ONLY||CROSS_SECTIONAL|||||||
33760338|NCT00674089|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33760339|NCT05440513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760340|NCT01337674|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33760341|NCT05272891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After determining the patients who meet the inclusion criteria, a randomization program will be used to ensure homogeneous distribution among the groups (Random Allocation Software). A list will be created according to the randomization program and 60 patients included in the study will be assigned to the experimental (30 patients) and control groups (30 patients).||||
33760342|NCT02708784|||||CROSS_SECTIONAL|||||||
33760343|NCT04617184|||COHORT||PROSPECTIVE|||||||
33760344|NCT02978443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760345|NCT02249819|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sequence of stimulation conditions was randomized across subjects.|All participants received both stimulation conditions (active tDCS + computerized naming therapy and sham tDCS + computerized naming therapy), separated by a 1-week washout period.|t|t|t|t
33760346|NCT02405260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760347|NCT05573503|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33884364|NCT04864873|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patient sample will be divided between standard diagnostic pathways and the mNGS pathway, so each patient will have testing provided by both techniques for direct comparison.||||
33884365|NCT03900390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884366|NCT03440593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884367|NCT00317148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884368|NCT01992809|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|f|t
33884369|NCT05065398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884370|NCT06342869|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33884371|NCT05633810|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33884372|NCT03269344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33884373|NCT01160939|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
33884374|NCT01504555|||CASE_ONLY||PROSPECTIVE|||||||
33884375|NCT01600872|||COHORT||PROSPECTIVE|||||||
33884376|NCT01097304|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33884377|NCT01572090|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884378|NCT03551587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884379|NCT02344225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884380|NCT05192369|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33884381|NCT04830267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884382|NCT04456452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884383|NCT02303717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071417|NCT03304106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972243|NCT04801979|||COHORT||CROSS_SECTIONAL|||||||
33972244|NCT03820154|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Comparison of conventional Skin Prick Test vs. Tape SPT||||
33972245|NCT02161952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972246|NCT05653791|||COHORT||PROSPECTIVE|||||||
33972247|NCT06230471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972248|NCT03776032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972249|NCT06545422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective pretest-posttest controlled study||||
33972250|NCT03333525|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972251|NCT02367053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972252|NCT00783757|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33972253|NCT05220670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assignment to the groups will be of simple random type and hidden. Those responsible for admitting patients to the intervention phase will not know what group has been assigned each. This assignment will be made in advance by a researcher who will not intervene in the later stages of evaluation, intervention, data recording and elaboration of database. The assignment will be communicated through sealed and totally opaque envelopes.|Randomized controlled trial|f|t|t|t
33972254|NCT01823445|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972255|NCT01104857|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972256|NCT00171509|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33972257|NCT02429154|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33972258|NCT00373659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972259|NCT04611269|||COHORT||PROSPECTIVE|||||||
33972260|NCT05373875|||OTHER||PROSPECTIVE|||||||
33972261|NCT03446560|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, multicenter, parallell group design||||
33972262|NCT04396470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33972263|NCT02022501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972264|NCT00902135|||COHORT||PROSPECTIVE|||||||
33972265|NCT01033383|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33972266|NCT05736081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972267|NCT00891293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972268|NCT01573520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972269|NCT05079737|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34071418|NCT04075136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071419|NCT01942876|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34071420|NCT01463800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972270|NCT00793052|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33972271|NCT04314882|||OTHER||CROSS_SECTIONAL|||||||
33972272|NCT03561259|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Two-arm, non-randomized, open-label study.||||
33972273|NCT00545558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972274|NCT01214603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972275|NCT02056275|RANDOMIZED|PARALLEL||||NONE||||||
33972276|NCT05544266|||COHORT||PROSPECTIVE|||||||
33972277|NCT01692171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972278|NCT02405611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33972279|NCT06364020|||COHORT||PROSPECTIVE|||||||
33972280|NCT04585555|||CASE_ONLY||PROSPECTIVE|||||||
34071421|NCT00657657|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34071422|NCT02827175|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972281|NCT04476082|||OTHER||PROSPECTIVE|||||||
33972282|NCT06245616|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33972283|NCT00447603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972284|NCT03237559|||FAMILY_BASED||OTHER|||||||
33972285|NCT01141283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972286|NCT00209209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972287|NCT04875234|||COHORT||RETROSPECTIVE|||||||
33972288|NCT06240962|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33972289|NCT04990297|||CASE_CONTROL||PROSPECTIVE|||||||
34071423|NCT03965520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071424|NCT02800005|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34071425|NCT00970671|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34071426|NCT05358990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34071427|NCT04717089|||CASE_CONTROL||RETROSPECTIVE|||||||
34071428|NCT05165719|||COHORT||PROSPECTIVE|||||||
34071429|NCT01443234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071430|NCT00352625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34071431|NCT03159299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34071432|NCT00391872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071433|NCT02807831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972290|NCT06546111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071434|NCT01888952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972291|NCT05416658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33972292|NCT05729633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"To prevent subversion of the allocation sequence, study team members who enrol patients to the trial will be distinct and kept separate from the study team member that open the sealed envelopes and perform group assignment We will establish procedures to maintain separation between study team members that assess the outcomes, and those that perform group assignment. At the start of every assessment, patients will be reminded to not reveal their treatment assignment by referring to elements of the treatment that are unique to their treatment group.~Functional outcome scales are performed by blinded therapists who work in the unit."|Randomized controlled study|f|t|f|t
33972293|NCT03788681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972294|NCT01464827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972295|NCT01504113|||COHORT||PROSPECTIVE|||||||
33972296|NCT04050397|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participant will be randomized 1:1 to either supervised exercise for 12 weeks or to follow given exercise program on their own.||||
34071435|NCT05314777|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34071436|NCT01443741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972297|NCT01516359|||||PROSPECTIVE|||||||
33972298|NCT00131989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972299|NCT04548895|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34071437|NCT05693753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33972300|NCT03273985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972301|NCT04968171|||CASE_ONLY||PROSPECTIVE|||||||
33972302|NCT02200133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972303|NCT05057195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972304|NCT04604639|||COHORT||RETROSPECTIVE|||||||
33972305|NCT00819728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071438|NCT03774888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071439|NCT02494856|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34071440|NCT00005587|RANDOMIZED|||TREATMENT||||||||
34071441|NCT05764954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071442|NCT05916807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071443|NCT01712971|||CASE_CONTROL||PROSPECTIVE|||||||
34071444|NCT03163537|||OTHER||PROSPECTIVE|||||||
34071445|NCT01730716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071446|NCT05003869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071447|NCT05498597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071448|NCT00519467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071449|NCT05398796|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34071450|NCT03731390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071451|NCT01060917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071452|NCT00884078|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760348|NCT02725125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760349|NCT00002832|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760350|NCT06274684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760351|NCT04045444|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760352|NCT00499863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760353|NCT02081625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760354|NCT01370512|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Placebo-controlled, double-blind, randomized four-way crossover|t|t|t|t
33884384|NCT02093702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884385|NCT00606242|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33884386|NCT05293457|||COHORT||PROSPECTIVE|||||||
33884387|NCT01952587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884388|NCT00004029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884389|NCT04804592|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884390|NCT06241586|||CASE_CONTROL||RETROSPECTIVE|||||||
33760355|NCT02243241|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33760356|NCT06359457|||CASE_ONLY||CROSS_SECTIONAL|||||||
33760357|NCT01575353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972306|NCT03753997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760358|NCT02514421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760359|NCT02472652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760360|NCT03687801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33760361|NCT02073097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765001|NCT05917223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is double-blind, placebo-controlled, randomized parallel control trial|This study is double-blind, placebo-controlled, randomized parallel control trial|t|f|t|f
33765002|NCT00737412|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33884391|NCT02901431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884392|NCT00002520|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33972307|NCT06527352|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33765003|NCT05891730|||CASE_CROSSOVER||PROSPECTIVE|||||||
33765004|NCT00365378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972308|NCT03316859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972309|NCT05642026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972310|NCT00214630|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972311|NCT01856985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972312|NCT04741360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972313|NCT04354194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972314|NCT04634409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Includes open label arms||t|f|t|f
33972315|NCT04775784|||COHORT||PROSPECTIVE|||||||
33972316|NCT06545240|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33972317|NCT02136732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33972318|NCT00169936|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33972319|NCT02231710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972320|NCT00405977|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33972321|NCT04098081|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel arm phase II study of galeterone alone or galeterone with gemcitabine in advanced pancreatic cancer||||
33972322|NCT01806974|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972323|NCT04025385|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972324|NCT03741491|||OTHER||CROSS_SECTIONAL|||||||
33972325|NCT01319097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972326|NCT04049552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Study participants will serve as their own control, using intervention on one keloid and placebo on the other|t|f|f|f
33972327|NCT06091800|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972328|NCT05943925|||CASE_CONTROL||OTHER|||||||
33972329|NCT05892757|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972330|NCT01533857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972331|NCT00672828|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972332|NCT00522288|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33972333|NCT00223327|||COHORT||PROSPECTIVE|||||||
33972334|NCT01371513|||OTHER||RETROSPECTIVE|||||||
33972335|NCT00031421|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972336|NCT05725590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972337|NCT01377363|||OTHER||PROSPECTIVE|||||||
33972338|NCT02478060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33972339|NCT01472588|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972340|NCT02140164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071453|NCT02913781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071454|NCT06260345|||CASE_ONLY||PROSPECTIVE|||||||
34071455|NCT06033261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071456|NCT00647595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34071457|NCT00729092|||COHORT||PROSPECTIVE|||||||
34071458|NCT04035499|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Evaluating the feasibility of a mobile health exercise intervention in older adults with myeloid neoplasms||||
34071459|NCT04693078|NA|SINGLE_GROUP||SCREENING||NONE||||||
34071460|NCT00810498|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34071461|NCT01018914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071462|NCT00494429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071463|NCT05534828|||COHORT||PROSPECTIVE|||||||
34071464|NCT05372185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071465|NCT02634619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071466|NCT05621850|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34071467|NCT05593653|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34071468|NCT02697916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972341|NCT01602614|||OTHER||PROSPECTIVE|||||||
33972342|NCT05336279|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study is a single-center, single-dose, randomized, open-label, two-cycle, crossover study.||||
33972343|NCT00288171|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33972344|NCT01451905|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33972345|NCT01729702|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972346|NCT01839084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972347|NCT04767269|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"1. Group phase A~2. Group phase B~3. Group phase C"|t|t|t|t
33972348|NCT01887509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972349|NCT01409356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972350|NCT05684926|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled||||
33972351|NCT04290078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972352|NCT01193621|RANDOMIZED|PARALLEL||||NONE||||||
33972353|NCT02078063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972354|NCT01117155|||||PROSPECTIVE|||||||
33972355|NCT01449058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972356|NCT02598102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972357|NCT05904015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972358|NCT00996866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071469|NCT05298683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071470|NCT04589884|||COHORT||PROSPECTIVE|||||||
34071471|NCT02927054|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071472|NCT00806858|||||PROSPECTIVE|||||||
34071473|NCT03541148|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34071474|NCT05613959|||COHORT||PROSPECTIVE|||||||
34071475|NCT00458861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071476|NCT03608813|||CASE_CONTROL||PROSPECTIVE|||||||
34071477|NCT04833062|||CASE_CONTROL||PROSPECTIVE|||||||
34071478|NCT01166711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071479|NCT05542251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071480|NCT00730574|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34071481|NCT02122315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34071482|NCT05230355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071483|NCT06609408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Single blind randomised controlled trial|t|f|f|t
34071484|NCT01302795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071485|NCT03182881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34071486|NCT03107208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071487|NCT00498953|RANDOMIZED|||TREATMENT||NONE||||||
34071488|NCT04969783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blind|Phase III randomized, single blind, multi-center study assessing the impact of filter ventilation|t|f|f|f
34071489|NCT05710016|||COHORT||PROSPECTIVE|||||||
34071490|NCT02214303|||||PROSPECTIVE|||||||
33760362|NCT03652974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Drug: amisulpride, sodium valproate , placebo and Clozapine amisulpride, sodium valproate and placebo may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia Other Name: Valproate Device: modified electroconvulsive therapy(MECT) with Clozapine modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia Device: Modified electroconvulsive therapy(MECT) with Clozapine|t|t|t|t
33760363|NCT01778556|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760364|NCT00596323|||COHORT||CROSS_SECTIONAL|||||||
33972359|NCT00217854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972360|NCT00901368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972361|NCT02248532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33760365|NCT00370721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760366|NCT03534310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||lifestyle modification alone, lifestyle modification and Liraglutide 3 mg daily, sleeve gastrectomy||||
33760367|NCT03725150|||COHORT||PROSPECTIVE|||||||
33760368|NCT05608304|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33760369|NCT03122561|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Healthy Volunteers||||
33760370|NCT03217448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760371|NCT00628901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760372|NCT05873725|||COHORT||RETROSPECTIVE|||||||
33760373|NCT00548730|||COHORT||PROSPECTIVE|||||||
33760374|NCT00926601|||COHORT||PROSPECTIVE|||||||
33760375|NCT01804101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760376|NCT02402088|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33760377|NCT01668082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760378|NCT00406224|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760379|NCT06406920|||CASE_CONTROL||PROSPECTIVE|||||||
33760380|NCT03402256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All clinical members of the liver transplantation service will be blind to the results of self-report data collected during the study and to urine toxicology results. The PI and Co-I, who also serves as the Project Manager, will not be blind to participant condition. The Research Assistant will not be blind to the participant condition after delivery of the study-provided cell phone to participants randomized to the Text Message condition.|Participants will be randomized to either the Text Message intervention or to Standard Care based on a preset randomization schedule generated via computer by a statistician.|f|t|f|f
33760381|NCT06491199|||COHORT||PROSPECTIVE|||||||
33760382|NCT01544998|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33760383|NCT04807985|||COHORT||PROSPECTIVE|||||||
33760384|NCT04874402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33760385|NCT01499225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33760386|NCT01695824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760387|NCT03389568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760388|NCT01793025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760389|NCT06198023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760390|NCT04056884|RANDOMIZED|CROSSOVER||PREVENTION||NONE|N/A, not possible|Participants are randomized to intervention or 12-week waitlist. All participants who are randomized to waitlist will receive the intervention after waitlist.||||
33760391|NCT03296202|||COHORT||PROSPECTIVE|||||||
33760392|NCT00603577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760393|NCT00520390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760394|NCT01082562|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33760395|NCT00897130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760396|NCT04957017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33972362|NCT06286553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||In this interventional study, three distinct groups are included. The Trunk Exercise Group (TEG) will partake in a comprehensive 12-week therapeutic exercise program that involves progressive strengthening exercises specifically targeting the trunk and pelvic floor muscles, alongside functional retraining exercises. The Trunk Exercise and Inspiratory Muscle Training Group (IMT+TEG) will adhere to the same 12-week therapeutic exercise program as TEG, with additional exercises focusing on strengthening the inspiratory muscles using inspiratory resistance (IMT). The control group (CG) will not participate in the 12-week exercise program but will receive a single exercise session and general management information (oral and written) for DRA.|t|f|t|t
33972363|NCT00648453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972364|NCT03361514|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is designed as a cluster-randomized controlled trial conducted in primary care, randomizing General Practitioners over a.) Supported Protocolized Discontinuation (SPD) alone or b.) SPD with additional Mindfulness-Based Cognitive Therapy (MBCT). Both the patient, GP and the research team will be aware of the allocated condition.||||
33972365|NCT04779619|||COHORT||CROSS_SECTIONAL|||||||
33972366|NCT04120168|||OTHER||PROSPECTIVE|||||||
33884393|NCT03075085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Investigators will use a Type 3 Hybrid Design to test the effectiveness of the enhanced implementation strategy (i.e., facilitation) on uptake while also assessing impacts of the intervention on child outcomes. Investigators expect that the effectiveness of WISE on child outcomes will vary by the level of implementation fidelity, and a Hybrid 3 design allows for us to explore this hypothesis. RE-AIM provides an evaluation framework to assess key aspects of intervention programs implemented in real-word settings. Investigators will modify and use The Organizational Readiness to Change Assessment (ORCA) as developed for use with the i-PARiHS framework to assesses change commitment (e.g., We value this change) and change efficacy (e.g., We can keep the momentum going) both prior to and during implementation.|t|f|f|f
34071491|NCT05660668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071492|NCT02959333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071493|NCT00116714|||COHORT||PROSPECTIVE|||||||
33884394|NCT05764486|NA|SINGLE_GROUP||OTHER||NONE||||||
33884395|NCT00403221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884396|NCT01002079|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884397|NCT00459992|RANDOMIZED|PARALLEL||TREATMENT||||||||
33884398|NCT05237895|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884399|NCT00113594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884400|NCT03183128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972367|NCT02180061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972368|NCT05781659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33972369|NCT04448171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, the physician administering the Botox, and the study coordinator (outcomes assessor) assigned to the study will be blinded to the randomization. Both groups of participants will receive the TENS unit electrode placement by the assigned clinical nurse who is not blinded.||t|f|t|t
33972370|NCT05642156|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972371|NCT04939974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972372|NCT03385746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071494|NCT06015230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071495|NCT02047435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071496|NCT06404879|||COHORT||PROSPECTIVE|||||||
34071497|NCT01410994|||COHORT||PROSPECTIVE|||||||
34071498|NCT01010802|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071499|NCT04140721|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Vanderbilt's Investigational Pharmacy will randomly assign participants to the moxonidine/placebo or placebo/moxonidine arm of the study. They will also provide the active drug and matching placebo. The medication distribution list will be kept by a dedicated person not involved in the study.|randomized, double blind, crossover design|t|f|t|f
34071500|NCT01494012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071501|NCT06606366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071502|NCT00056303|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34071503|NCT01542086|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071504|NCT05850000|||CASE_CROSSOVER||PROSPECTIVE|||||||
34071505|NCT00469248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071506|NCT00913211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071507|NCT04663165|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||a clinical prospective interventional study with longterm follow-up||||
34071508|NCT02499263|||CASE_ONLY||PROSPECTIVE|||||||
34071509|NCT01259934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071510|NCT04732767|||COHORT||PROSPECTIVE|||||||
34071511|NCT03085719|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972373|NCT00016055||||TREATMENT||||||||
33972374|NCT05615623|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33972375|NCT02716883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33972376|NCT01815021|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972377|NCT00565981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972378|NCT06036758|||COHORT||RETROSPECTIVE|||||||
33972379|NCT02539030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972380|NCT00093639||||TREATMENT||NONE||||||
33972381|NCT01396044|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33972382|NCT03587181|||COHORT||PROSPECTIVE|||||||
33972383|NCT01021995|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33972384|NCT05425186|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33972385|NCT00425685|||DEFINED_POPULATION||OTHER|||||||
33972386|NCT00004576||||TREATMENT||||||||
33972387|NCT05017233|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972388|NCT05635825|||COHORT||CROSS_SECTIONAL|||||||
34071512|NCT00447551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071513|NCT03665077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071514|NCT03208894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071515|NCT05876884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071516|NCT01472822|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34071517|NCT03023267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34071518|NCT05555277|||COHORT||RETROSPECTIVE|||||||
34071519|NCT00005067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071520|NCT03922282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071521|NCT04077749|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34071522|NCT01424917|||COHORT||CROSS_SECTIONAL|||||||
34071523|NCT01383408|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33972389|NCT05877820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972390|NCT00106028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972391|NCT05477979|||COHORT||PROSPECTIVE|||||||
33884401|NCT03856151|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||"30 eligible participants diagnosed with IDH will be enrolled and divided randomly and equally into Group 1 and Group 2 . Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks. For Group 1, each subject will receive Treatment 1# first, for Group 2, Treatment 2# will be received first. Then, a 2-week washout period with regular dialysis 3 times per week will be carried out. Group 1 will then receive Treatment 2# and Group 2 will then receive Treatment 1#. Subjective questionnaires will be done before and after each Treatment period."|t|f|f|f
33884402|NCT05870904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884403|NCT04464213|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884404|NCT00434135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884405|NCT06056258|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double blind|randomized, double-blind, placebo-controlled trial.|t|t|t|f
33884406|NCT01934140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884407|NCT02770937|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33884408|NCT03671928|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884409|NCT01154933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884410|NCT02934009|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760397|NCT02624739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760398|NCT01992679|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760399|NCT01945749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760400|NCT01204268|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33760401|NCT02417064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760402|NCT05550415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760403|NCT00284063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884411|NCT01074138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884412|NCT03546855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884413|NCT00159432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884414|NCT03639948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884415|NCT04148261|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33884416|NCT01439945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33884417|NCT01399060|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34071524|NCT05274529|NA|SINGLE_GROUP||PREVENTION||NONE||This is a pre-post type intervention study where baseline measurements are made at 0 months from the study start and follow up measurements are made at 4, 8 ,12, 24 and 36 months.||||
34071525|NCT06222762|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trial of superiority in parallel arms. Randomised parallel group trial divided into groups according to a ratio (1:1) comparing the follow-up and personalised support after a cardiac rehabilitation programme (experimental group) versus a control group receiving only the usual care, i.e. without follow-up by a sports-health professional (control group), in patients with heart failure.||||
33884418|NCT01958957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884419|NCT05617287|NA|SINGLE_GROUP||OTHER||NONE||||||
33884420|NCT05646108|||CASE_ONLY||OTHER|||||||
33884421|NCT03102229|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884422|NCT06326242|||OTHER||PROSPECTIVE|||||||
33884423|NCT04531475|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|This trial uses a double-blind double-dummy design, where both the investigator and the subject are blinded to the drug given to the subject. X842 capsules (test group), lansoprazole enteric-coated capsules (control group), and placebo are provided by the sponsor. The physical appearance, shape, specification and dosage of the test drug and comparator as well as the placebo are generally similar.|After completing the relevant laboratory tests and endoscopic examinations at screening, subjects who meet the inclusion criteria and do not meet the exclusion criteria are randomly assigned to X842 capsule low-dose group, X842 capsule high-dose group, and lansoprazole enteric-coated capsule group for 4-week treatment and then receive endoscopy. In the study, the duration of subjects receiving treatment with the test drug or comparator is 4 weeks. If a subject has the reflux esophagitis (RE) uncured under endoscopy at week 4 of treatment, the sponsor will give the subject lansoprazole enteric-coated capsules for free for another 4 weeks' treatment.|t|t|t|t
33884424|NCT00481065|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884425|NCT06469060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884426|NCT00598975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884427|NCT01903499|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33884428|NCT02455635|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884429|NCT05461079|||CASE_CONTROL||PROSPECTIVE|||||||
33884430|NCT02598765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34071526|NCT01594918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760404|NCT03017430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760405|NCT00428558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760406|NCT02834702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760407|NCT01760889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760408|NCT01126138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760409|NCT01480947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760410|NCT04751201|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33760411|NCT04128241|||OTHER||CROSS_SECTIONAL|||||||
33760412|NCT00859287|||COHORT||PROSPECTIVE|||||||
33760413|NCT02967614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760414|NCT01452997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760415|NCT05596890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760416|NCT03390699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Microbial profile among patients before partial maxillectomy||||
34071527|NCT04333849|||COHORT||PROSPECTIVE|||||||
33760417|NCT04552743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071528|NCT04652726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked (Year 1) to No Masking (Year 2)|Parallel (Year 1) to single-group (Year 2)|t|f|t|f
34071529|NCT04520048|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071530|NCT03128853|NA|SINGLE_GROUP||OTHER||NONE||||||
34071531|NCT04567004|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071532|NCT05206110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients participating in the study, the surgeons, the researchers assessing the different outcome parameters and the data managers will all be blinded for group allocation.||t|f|t|t
34071533|NCT03896997|||OTHER||CROSS_SECTIONAL|||||||
34071534|NCT00528749|NA|SINGLE_GROUP||||NONE||||||
34071535|NCT05121805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071536|NCT01039779|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34071537|NCT01997801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34071538|NCT05612217|||OTHER||CROSS_SECTIONAL|||||||
34071539|NCT01084148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071540|NCT06612580|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071541|NCT00558805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34071542|NCT05464420|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34071543|NCT02801799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34071544|NCT02256735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34071545|NCT02447328|NA|SINGLE_GROUP||OTHER||NONE||||||
33760418|NCT01292070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760419|NCT03184584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760420|NCT05038280|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760421|NCT03036384|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33760422|NCT02613104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760423|NCT03566303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)|f|f|t|f
33760424|NCT03907163|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33884431|NCT03121391|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|All study sites begin in usual care and each site is randomly assigned to crossover to the intervention arm until all sites conclude in the intervention arm.|Stepped wedge cluster randomized trial||||
33884432|NCT03175341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Participant)|Randomized Parallel Assignment|t|f|f|f
33972392|NCT06399770|||CASE_CONTROL||PROSPECTIVE|||||||
33972393|NCT04829695|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible children for whom parent/guardian informed consent are obtained will be randomized to receive either artesunate-amodiaquine (group A) or artemether-lumefantrine (group B) in the ratio 1:1.||||
33972394|NCT04431986|||COHORT||PROSPECTIVE|||||||
34071546|NCT02411734|||COHORT||PROSPECTIVE|||||||
34071547|NCT01384747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071548|NCT03492879|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071549|NCT02435888|||CASE_ONLY||CROSS_SECTIONAL|||||||
34071550|NCT03963219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomised controlled non-inferiority crossover study||||
34071551|NCT02357745|||||CROSS_SECTIONAL|||||||
34071552|NCT04575090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760425|NCT05674630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760426|NCT03627364|||OTHER||CROSS_SECTIONAL|||||||
33760427|NCT05797922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33760428|NCT01641263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33972395|NCT00969332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972396|NCT05763433|||COHORT||PROSPECTIVE|||||||
33972397|NCT03058510|||CASE_ONLY||PROSPECTIVE|||||||
33972398|NCT03588390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972399|NCT02566135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760429|NCT05089032|||COHORT||CROSS_SECTIONAL|||||||
33760430|NCT03174314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760431|NCT01683760|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884433|NCT02817087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, only the care provider is aware of active treatment assignment.|Active repetitive transcranial magnetic stimulation administered through cap worn by patient under healthcare provider.|t|f|t|t
33884434|NCT01265680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884435|NCT02638636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884436|NCT05274230|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single group study. All participants will receive identical instructions regarding the device and will complete the same survey measures.||||
33884437|NCT00003793|||COHORT||PROSPECTIVE|||||||
33884438|NCT06429930|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|This is a double-blinded, single ascending dose escalation design. After confirmation of eligibility, subjects will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for rest of the cohorts to receive the assigned dose of L608 or placebo.|Randomized, Placebo-controlled, double-blinded, single ascending dose escalation|t|f|t|f
33884439|NCT06101576|||CASE_ONLY||RETROSPECTIVE|||||||
33884440|NCT05499962|NA|SINGLE_GROUP||PREVENTION||NONE||Recruit 30 PrEP-using Black SMM, including those who use substances, as Recruiters to identify and refer Network Associates to PrEP services. The pilot will occur in six blocks of up to 5 Recruiters to further develop all intervention procedures and enhance the SNS intervention's feasibility and acceptability.||||
33884441|NCT04821583|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Both the participant and the investigator are masked. The investigator is also the care provider and outcomes assessor. The statistician and clinical pharmacist are unblinded.|An N-of-1 study is considered as a reliable and suitable design to assess the efficacy of a treatment at an individual level. The study will consist of two cycles with each two periods of active treatment or placebo, a run-in period, tapering period and a wash-out period. Within each cycle, the sequence of the hydrocortisone and placebo period is randomized.|t|t|t|t
33884442|NCT06388473|NA|SINGLE_GROUP||SCREENING||NONE||||||
33884443|NCT03090685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sample randomization procedure will be performed by means of a computer program, which will generate a random sequence to be placed in an opaque envelope by an assistant not involved in the evaluation and treatment.|Prospective, double-blind randomized controlled trial (RCT).|t|f|f|t
33884444|NCT01099787|||CASE_ONLY||PROSPECTIVE|||||||
33884445|NCT03242330|RANDOMIZED|PARALLEL||TREATMENT||NONE|After assignment to interventions, blinding of trial participants, care providers and outcome assessors is not applicable. Data analysts will be blinded.|||||
34071553|NCT03848793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071554|NCT04995809|||OTHER||PROSPECTIVE|||||||
34071555|NCT00063336|RANDOMIZED|PARALLEL||TREATMENT||||||||
34071556|NCT03334422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071557|NCT04644120|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34071558|NCT03812445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071559|NCT02095197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071560|NCT02852057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071561|NCT03049020|||COHORT||PROSPECTIVE|||||||
34071562|NCT01358942|||COHORT||PROSPECTIVE|||||||
34071563|NCT05936814|||COHORT||PROSPECTIVE|||||||
34071564|NCT06413160|||COHORT||PROSPECTIVE|||||||
34071565|NCT02849886|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34071566|NCT00000200|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34071567|NCT02527317|||COHORT||PROSPECTIVE|||||||
34071568|NCT01189461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071569|NCT01078142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071570|NCT00778349|RANDOMIZED|CROSSOVER||||NONE||||||
34071571|NCT06613230|||CASE_CONTROL||RETROSPECTIVE|||||||
34071572|NCT00626652|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34071573|NCT06369831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Interventional, Phase IIb, prospective, single arm radio-diagnostic study.~Driven by number of biopsied lesions (and not by number of patients)"||||
34071574|NCT01561157|||COHORT||OTHER|||||||
34071575|NCT00420719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760432|NCT06492798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760433|NCT00048672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760434|NCT00377286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760435|NCT05977426|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|This study was designed as a randomized controlled trial|This study was designed as a randomized controlled trial|t|f|f|f
33760436|NCT04947163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760437|NCT05403099|RANDOMIZED|PARALLEL||OTHER||SINGLE||Twenty implants were inserted in patients seeking for replacement of missed single or multiple posterior maxillary teeth. Patients were divided randomly into two groups. In the control group, ten implants were placed and immediately loaded. While in the study group, ten implants were coated with hyaluronic acid (HA) immediately before placement and immediately loaded. All patients were clinically evaluated at implant placement time, one, three and six months after loading regarding implant stability. Peri-implant pocket depth and modified sulcus bleeding index were evaluated clinically at six months in all patients. Bone density was evaluated radiographically after three months. All clinical and radiographic data were subjected to statistical analysis.|f|f|f|t
33760438|NCT04990869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled|t|t|t|t
33884446|NCT05730894|||COHORT||RETROSPECTIVE|||||||
33884447|NCT02170116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884448|NCT03668509|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33760439|NCT05088369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be conducted as a double-blind study. All subjects and clinical personnel will involved in the collection, monitoring, revision, safety and adverse events will be blinded in regards to the subject's treatment assigned of HM201 or the HM201 placebo. All personnel affecting the outcome of the study's treatment assignment will be blinded.|SAD \& MAD study|t|t|t|t
33760440|NCT03646032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A total of 200 AAA males and females will be recruited from Washington, DC (n=100) and Birmingham, Alabama (n=100). At both data collection sites, participants will be randomly assigned to one of two groups i.e., intervention and control during the pilot.||t|f|f|f
33760441|NCT01638247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760442|NCT03859414|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||4-way Crossover Assignment|t|t|t|t
33760443|NCT00408148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760444|NCT00662857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760445|NCT02905383|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33760446|NCT01498432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33884449|NCT04790032|||CASE_ONLY||PROSPECTIVE|||||||
33760447|NCT02767063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760448|NCT06053034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071576|NCT00717652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760449|NCT05659225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884450|NCT01976780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884451|NCT04853628|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is performed in 24 high schools from Andalusia (southern Spain), which are randomized either to the experimental (EC-1, EC-2) or the control conditions (CC). The EC-1 receives Alerta Alcohol, with personalized health advice, using textual feedback and several gamification techniques; and consists of nine sessions (performing seven of them at the high school): session 1 or baseline, sessions 2 and 3 where adolescents are provided with answers related to their views to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence and self-efficacy; sessions 4, 5, 7 and 8 are reinforcement sessions (booster sessions) and sessions 6 and 9 are follow-up questionnaires at six and twelve months. The EC-2 receives Alerta Alcohol 2.0, using animated videos and new gamification strategies. The CC just completes the baseline and the evaluation questionnaires.||||
33884452|NCT02161887|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33884453|NCT00860158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884454|NCT02470455|||COHORT||PROSPECTIVE|||||||
33884455|NCT00391404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884456|NCT05836792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33884457|NCT05548088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884458|NCT04156555|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884459|NCT00372879|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33884460|NCT00826319|||COHORT||PROSPECTIVE|||||||
33760450|NCT01568099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760451|NCT02669147|||COHORT||PROSPECTIVE|||||||
33760452|NCT04062448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760453|NCT01656330|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33760454|NCT03203109|||COHORT||RETROSPECTIVE|||||||
33884461|NCT03784183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind: Neuropsychologists and Neurophysiologists are prevented from having knowledge of the intervention assigned to the participants.|A Randomized, Single-Blind, Placebo-Controlled, Parallel-Group|f|f|f|t
33884462|NCT03790592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884463|NCT00898222|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884464|NCT05452967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group C (conventional analgesia group) Group CD (conventional analgesia plus distraction technique)||||
33884465|NCT05365763|||COHORT||CROSS_SECTIONAL|||||||
33884466|NCT03119142|||COHORT||PROSPECTIVE|||||||
33884467|NCT04697329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884468|NCT04728490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884469|NCT00485641|||DEFINED_POPULATION||OTHER|||||||
33884470|NCT04981275|||CASE_CONTROL||PROSPECTIVE|||||||
33884471|NCT00616135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884472|NCT00002162||||TREATMENT||||||||
33884473|NCT01178138|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33884474|NCT01194440|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884475|NCT00694291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884476|NCT02429531|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884477|NCT03915145|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33760455|NCT06047002|||COHORT||PROSPECTIVE|||||||
33884478|NCT05149170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884479|NCT00319969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884480|NCT01460823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884481|NCT01885780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884482|NCT00845195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884483|NCT05708391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884484|NCT03033771|NA|SINGLE_GROUP||TREATMENT||NONE||Dragon Study Europe is an international, multicenter, prospective, non-randomized study. It is designed to evaluate safety and performance of the MFM for the treatment of chronic type B aortic dissection. About 35 patients in up to 11 countries will be enrolled and screened per the protocol-required inclusion, exclusion criteria, in order to obtain 30 completed patients. The main interim analysis, aiming at the early demonstration of safety and performance, will be performed after all patients included will complete their 6-month follow-up. A preliminary interim analysis will be performed on the first patients enrolled (15 completed patients) and with their 6-months follow-up available.||||
33884485|NCT00592475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884486|NCT03088865|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884487|NCT05286606|||COHORT||PROSPECTIVE|||||||
33884488|NCT05406856|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is designed as a prospective, multicenter, nonrandomized phase-II-trial. During the first phase of the trial, 15 patients will be enrolled in the IMRT/VMAT treatment group. In the second phase of the trial, 15 patients will be enrolled in the IMPT group.||||
33884489|NCT04469192|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study participants will then be randomized to cryotherapy + education vs. education alone. The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture.~Those randomized to the intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) at this initial visit where they will be monitored for any adverse response as well as for any immediate change to the NPRS and PGQ. The participant will place the icepack over the low back region and the sacrum if the pain is bilateral. If the pain is unilateral will place the icepack over just that side."||||
33884490|NCT01416363|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884491|NCT01542645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884492|NCT02452671|||CASE_CONTROL||PROSPECTIVE|||||||
33884493|NCT06549140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884494|NCT06098859|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants did not know which method was applied to them. Those who evaluated the research results did not know the groups|The effects of thoracic epidural analgesia and erector spinae plane block on postoperative pain were compared with the control group.|t|f|f|t
33884495|NCT06054295|||FAMILY_BASED||PROSPECTIVE|||||||
33884496|NCT03880500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of Investigator to type of Intervention Blinding of Outcome assesors during follow-up.|20 Controls, 50 Patients|f|f|t|t
33884497|NCT02947867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884498|NCT04846244|||COHORT||PROSPECTIVE|||||||
33884499|NCT02095821|||COHORT||PROSPECTIVE|||||||
33884500|NCT04473417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884501|NCT03324204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33884502|NCT05642442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884503|NCT05131607|NA|SINGLE_GROUP||OTHER||NONE||||||
34071577|NCT06056453|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34071578|NCT03317717|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34071579|NCT06350201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33884504|NCT02315924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071580|NCT03361358|||CASE_ONLY||RETROSPECTIVE|||||||
34071581|NCT02706769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34071582|NCT03739424|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34071583|NCT03540797|||COHORT||PROSPECTIVE|||||||
34071584|NCT00398047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071585|NCT00519584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34071586|NCT02951026|||COHORT||PROSPECTIVE|||||||
34071587|NCT02559570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071588|NCT03091738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071589|NCT02085746|||OTHER||PROSPECTIVE|||||||
34071590|NCT04235166|||COHORT||PROSPECTIVE|||||||
34071591|NCT06229041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071592|NCT06225661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study investigators and outcome assessors are blinded to allocation assignment.||f|f|f|t
34071593|NCT01614444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071594|NCT02726594|||CASE_CONTROL||PROSPECTIVE|||||||
34071595|NCT03971916|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34071596|NCT06105814|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||COPEXNOR is a prospective, randomized controlled trial with two arms: (1) Standard microbiological diagnostics, with nasopharyngeal swab and induced sputum or endotracheal aspirate for real-time polymerase chain reaction (PCR) and culture, blood cultures and urinary antigen tests, and (2) in addition to (i), induced sputum or endotracheal aspirate analyzed with multiplex PCR (FilmArray).|t|t|f|f
33760456|NCT05056870|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33972400|NCT01896297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972401|NCT01666886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972402|NCT00385151|||||PROSPECTIVE|||||||
33972403|NCT06321081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972404|NCT02517190|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972405|NCT00918970|||CASE_ONLY||PROSPECTIVE|||||||
33972406|NCT05653713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33972407|NCT01686178|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972408|NCT03338465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants will be blinded to the type of ESWT treatment and the assessor, data managers, statistician and study monitors will be blinded to the allocation. All participants who receive ESWT treatment will be treated using the same device (Duolith SD1, STORZ Medical, Switzerland) regardless of what group they are included in. The participants will not be able to predict the allocated group based on the appearance of the ESWT treatment. The blinding will be maintained until the data are locked. For blinding evaluation, allocation guessing will be assessed immediately after the final treatment. Practitioners and assessors will be instructed to treat the participants according to predefined standard operating procedures during the trial to maintain blinding.||t|f|t|t
33972409|NCT01861327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972410|NCT00132509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972411|NCT06304870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760457|NCT02124343|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33760458|NCT03675152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||patients are in two groups treated with soft spinal brace or with thoracolumbar orthosis.||||
33760459|NCT02317393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760460|NCT06391021|||COHORT||PROSPECTIVE|||||||
33760461|NCT04317508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Administration of local anesthetic will be video recorded.~* An independent investigator who is blinded to the type of topical applied will evaluate the outcome from the video recordings."|Split mouth randomized clinical trial.|t|f|f|t
33760462|NCT01612325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760463|NCT04636658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760464|NCT05351996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972412|NCT03271528|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This study is double-blind. Medications are over-encapsulated.|This is a double-blind, randomized, placebo-controlled, crossover design trial to test the effect of lacosamide on alcohol self-administration and craving following a priming dose of alcohol.This study is a within subjects design in which each subject receives both study drug (lacosamide) and placebo during participation.|t|t|t|t
33972413|NCT01188733|RANDOMIZED|||PREVENTION||QUADRUPLE|||t|t|t|t
34071597|NCT05265832|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071598|NCT00608218|||CASE_ONLY||PROSPECTIVE|||||||
34071599|NCT01681953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071600|NCT04060797|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly divided into two groups: the endovascular revascularization (ER) group and the ER + endovascular denervation (EDN) group treating with EDN at the site of the distal iliac artery or the proximal superficial femoral artery before ER||||
34071601|NCT01357005|||FAMILY_BASED|||||||||
34071602|NCT01314079|||||PROSPECTIVE|||||||
33760465|NCT04737564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The standard Attachment and Biobehavioral Catch-up intervention (ABC10) is a 10-session home-visiting intervention. The ABC parenting targets include: nurturing children when they are distressed (Sessions 1 and 2), following the child's lead in play (Sessions 3 and 4), and avoiding harsh or frightening behavior (Sessions 5 and 6). Sessions 7 and 8 help parents consider how their own experiences of being parented affect their sensitivity, and Sessions 9 and 10 consolidate gains with additional practice. Session content focusing on parenting targets is guided by a manual. Additionally, parent coaches make frequent in-the-moment comments (at least once per minute) about parent-child interactions as they occur in session, and use video feedback."|f|f|f|t
33760466|NCT02708875|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33760467|NCT01346319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760468|NCT01487278|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760469|NCT04073264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760470|NCT04434157|||COHORT||CROSS_SECTIONAL|||||||
33760471|NCT04175795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|For this study, it will not be possible to blind the participants as the intervention is their personalized health profile. To avoid bias in measure, those collecting and analyzing the data will be kept blind to group assignment.|A blinded, stratified, randomized, controlled trial design will be used to assess the impact of the personalized health profile on number and specificity of person-defined self-management goals. All participants in the BHN2 cohort will be randomized into one of two groups, the intervention and control group. Participants will be stratified based on gender and number of visits (i.e., whether 1 visit or 2 visits) they had or will attend. Randomization will be done through the computer by the study statistician using randomization.com. All participants enrolled in the parent trial (BHN1) have a numerical ID. The new participants who will be recruited for the BHN2 will be enumerated and then the numbers will be randomized.|f|f|t|t
33760472|NCT04539821|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This single-arm feasibility study will be conducted in two VA sites.||||
33760473|NCT00111748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760474|NCT06526403|NA|SINGLE_GROUP||TREATMENT||NONE||Zero-fluoroscopy oval-shaped secundum ASD closure||||
33760475|NCT00003835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760476|NCT00834808|RANDOMIZED|CROSSOVER||||NONE||||||
33760477|NCT00265135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760478|NCT02877602|||OTHER||OTHER|||||||
33760479|NCT00677625|||COHORT||PROSPECTIVE|||||||
33760480|NCT03002610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33760481|NCT01489189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760482|NCT04367558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760483|NCT04987125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760484|NCT01089322|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study. All subjects received the same treatment|Retrospective analysis after treatment outcome (controlled vs. non controlled) based on the primary outcome; and post hoc analysis after oral steroid treatment based on pulmonary function reversibility||||
33760485|NCT02235246|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33760486|NCT04191629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760487|NCT03627039|||COHORT||RETROSPECTIVE|||||||
33760488|NCT02200263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760489|NCT01040702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33760490|NCT02331797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760491|NCT04551092|NA|SINGLE_GROUP||OTHER||NONE||||||
33760492|NCT03406819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33760493|NCT00886639|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33760494|NCT03147235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760495|NCT02098187|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760496|NCT05120115|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884505|NCT00142896|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33884506|NCT03140904|RANDOMIZED|PARALLEL||OTHER||NONE||"1. Standard weekly visits at the outpatient therapeutic feeding center until discharge~2. Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge."||||
33884507|NCT06545487|||OTHER||RETROSPECTIVE|||||||
33884508|NCT04722211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||120 Participants are assigned to the PS128 and a placebo group, under the double-blind trial.|t|f|t|f
33884509|NCT01590147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884510|NCT01551979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33884511|NCT01356004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884512|NCT01681420|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33884513|NCT02685709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972414|NCT05785455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33972415|NCT02617108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33972416|NCT02302573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972417|NCT05923164|||CASE_ONLY||CROSS_SECTIONAL|||||||
33972418|NCT06154382|||CASE_CONTROL||RETROSPECTIVE|||||||
33972419|NCT05781698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
33972420|NCT05921903|RANDOMIZED|PARALLEL||PREVENTION||NONE|This study is an open label study. Potential bias will be reduced by central randomization.|||||
33972421|NCT04473976|||OTHER||CROSS_SECTIONAL|||||||
33972422|NCT04820842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972423|NCT01890707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972424|NCT05363124|NA|SINGLE_GROUP||OTHER||NONE||||||
33972425|NCT03317197|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33972426|NCT02506790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972427|NCT06194097|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33972428|NCT00389506|NON_RANDOMIZED|||TREATMENT||||||||
33972429|NCT01169090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972430|NCT05964647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Crossover Assignment|t|t|t|t
33972431|NCT00729235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972432|NCT04023331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972433|NCT00036413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33972434|NCT04744844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A single IVF centre double-blind randomised controlled trial.|t|t|f|f
33972435|NCT03246542|||COHORT||PROSPECTIVE|||||||
34071603|NCT04319926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972436|NCT03957733|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II/III randomized controlled parallel group study. Patients are randomized between Chemoradiotherapy followed by surgery or chemoradiotherapy followed by folfox/xelox chemotherapy then surgery||||
33972437|NCT03475797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972438|NCT06152913|NA|SEQUENTIAL||TREATMENT||NONE|Note that research assistants will be blinded for the baseline length of participants during the interview assessments|Multiple baseline single-case experimental design||||
33972439|NCT01645020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972440|NCT02541110|||CASE_CONTROL||PROSPECTIVE|||||||
33972441|NCT00268320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972442|NCT01014390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972443|NCT05555459|NA|SINGLE_GROUP||TREATMENT||NONE||A single group study including 125 adult patient participants. All patients undergo a bone fixation surgical operation in foot/ankle area. Indications are specified in the study description. All operations are performed in the one study center using Inion CompressOn screws.||||
33972444|NCT05287659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972445|NCT02402868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972446|NCT01508273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972447|NCT04558216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972448|NCT00636831|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33972449|NCT04951128|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Participants in this study will undergo bilateral upper/lower eyelid surgery. The treatment side with tranexamic acid will be randomized for each patient using a random coin flip generator (head for the right side and tail for left side). The surgeons, participants, and photo reviewers will be blinded to the treatment side.|Randomized control trial|t|t|f|t
33972450|NCT00734864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972451|NCT01965561|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33972452|NCT05503849|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33972453|NCT05635045|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33972454|NCT05436821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33972455|NCT01748890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972456|NCT03887689|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972457|NCT02729155|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33972458|NCT00244920|RANDOMIZED|||TREATMENT||NONE||||||
33972459|NCT01743365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972460|NCT03908255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This study design will be a double-blinded, randomized clinical control trial in which treatment-naïve patients diagnosed with HCC will be screened at baseline before being randomized to either a treatment group, which will receive standard of care and BCAA supplement, or to a control group which will receive standard of care and a maltodextrin placebo. Both groups will receive liver directed therapy including transarterial chemoembolization (TACE) at baseline. In the intervention group, patients will receive current standard of care and consume BCAA supplements beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months. The control group will receive current standard of care, consume a maltodextrin placebo beginning two weeks prior to liver directed therapy and continue supplementation for the following 12 months.|t|t|t|f
33972461|NCT01566799|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33972462|NCT00434070|||||PROSPECTIVE|||||||
33972463|NCT03265899|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33972464|NCT04658875|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants' group allocations will be performed by an independent researcher, who has not any other participation during the study.|"evaluate the synergy presented by a supplement such as S. maxima in a systematic physical exercise program on the body composition, physical function and blood lipid profile of sedentary older adults with excess weight in a randomized, double-blind, crossover, placebo controlled trial.~This experimental design was chosen to eliminate inter-individual differences related to Spirulina maxima/placebo"|t|f|t|f
33972465|NCT00613574|||COHORT||PROSPECTIVE|||||||
33972466|NCT00279942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972467|NCT06354985|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|All members of the research team and the participants will be blinded to medication group allocation, but cannot be blinded to exercise group allocation. Evaluators and the study statistician will be blinded to the exercise group allocation. The study statistician and the rest of the Data Safety Monitoring Board will have access to the medication assignment if needed (e.g. adverse drug reaction).||t|t|t|t
33972468|NCT02010723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972469|NCT03517852|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is an open-label, non-randomized, single center, study of IVM observation in conjunction with fluorescein and ICG in subjects with peritoneal carcinomatosis undergoing CRS-HIPEC.|||||
33972470|NCT01289509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071604|NCT04557436|NA|SINGLE_GROUP||OTHER||NONE||"This is an open label, single-centre, phase I, cohort study using genome edited T cells to bring patients with relapsed or refractory B-cell acute lymphoblastic leukaemia (B-ALL) into remission in anticipation of a haematopoietic stem cell transplant (HSCT) that will hopefully prevent the leukaemia from returning. It involves a single infusion of allogenic T cells transduced with a self-inactivating (SIN) lentiviral vector in up to 10 subjects aged from 6 months to 18 years. The primary objective in this study is to test the safety and secondary objective will test the efficacy of this gene therapy procedure in this population.~Patients will be enrolled following diagnosis and referral to GOSH, and will receive TT52CAR19 cells at GOSH after lymphodepleting conditioning. They will be followed on this protocol for 12 months post IMP infusion."||||
34071605|NCT04034511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor and data-analyst will be masked to treatment assignment||f|f|f|t
33972471|NCT00859625|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071606|NCT03141515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071607|NCT04959864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization scheme is 1 : 1 (treated with food supplement vs placebo). The different treatments (2) have been anonymized, a randomization list is used to assign an anonymous box number (5 random numbers) according to the patient's order of inclusion. Only the promoter is aware of the assignment of the randomization number with which treatment it corresponds.|The randomization scheme is 1 : 1 (treated with food supplement vs placebo). The different treatments (2) have been anonymized, a randomization list is used to assign an anonymous box number (5 random numbers) according to the patient's order of inclusion. Only the promoter is aware of the assignment of the randomization number with which treatment it corresponds.|t|t|f|f
33972472|NCT00938652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972473|NCT02472678|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972474|NCT00006291||||TREATMENT||DOUBLE||||||
34071608|NCT02164071|||COHORT||PROSPECTIVE|||||||
33760497|NCT04049747|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two linked Randomised Controlled Trials with CHRONOS-A and CHRONOS-B discussed with patients and choice of A or B dependent on physician and patient equipoise.~* CHRONOS-A Two arm RCT~* CHRONOS-B Multi-Arm Multi-Stage (MAMS) Randomised Control Trial"||||
33760498|NCT00992953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760499|NCT03152955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760500|NCT06624319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will receive pre-emptive ultrasound-guided tap block with two different doses of dexmedetomidine in 20 ml volume added to 20 mL of 0.25% bupivacaine (40 ml in total) 20 ml will be applied on each side of the abdominal wall after induction of GA.||||
33760501|NCT06457425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760502|NCT04969237|||COHORT||RETROSPECTIVE|||||||
33760503|NCT01330810|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33760504|NCT05203120|NA|SINGLE_GROUP||TREATMENT||NONE||National phase II non-randomized single-arm study of proton therapy in patients with hepatocellular carcinoma.||||
33760505|NCT02207725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760506|NCT04531566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760507|NCT05477732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760508|NCT02766621|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33760509|NCT03605433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760510|NCT06340074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33760511|NCT04903171|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigators and outcomes assessor do not know which groups the participants belongs to|Cluster controlled trial|f|f|t|t
33760512|NCT02755064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33765005|NCT06096155|||COHORT||PROSPECTIVE|||||||
33972475|NCT02714686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972476|NCT03724110|||COHORT||PROSPECTIVE|||||||
33972477|NCT04096391|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomized in a 1:1 ratio to one of two groups||||
33972478|NCT00004584||||TREATMENT||||||||
33972479|NCT06376032|RANDOMIZED|CROSSOVER||OTHER||NONE||"Eligible students will be randomized\* to two cohorts: the first will receive immediate access to AKL-T01, and the second will complete weekly online surveys and receive access to AKL-T01 after the first group has completed the recommended 6 weeks of use. Regardless of group assignment, all participants will receive full 12-weeks of access to AKL-T01 during the course of the study.~\*Depending on enrollment numbers for a given semester (e.g., if \<100 students are enrolled and the study is underpowered to conduct between-group comparisons), all participants may be assigned to receive treatment immediately (i.e., single-arm design) and primary study hypotheses may be evaluated according to within-person changes in outcomes."||||
33972480|NCT02004847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972481|NCT05291845|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33972482|NCT00855452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760513|NCT03594539|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|The pharmacy dispensing the drug will be responsible for generating placebo and distributing drug. The investigators, care providers and patient will not have access to this data. Study outcomes will be comparing arms but not with knowledge of which arm occurred when.|Participants will be randomized to either lanthanum carbonate or placebo for 2 weeks. They will then be assigned to the other arm of the study. They will be in the alternate arm for 2 weeks and then complete the study,|t|t|t|t
33760514|NCT04185714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760515|NCT02153801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760516|NCT00004408|RANDOMIZED|||TREATMENT||DOUBLE||||||
33760517|NCT05086016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760518|NCT02494622|||||RETROSPECTIVE|||||||
33760519|NCT03716921|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33760520|NCT05924178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760521|NCT03818789|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33760522|NCT02579564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760523|NCT01553318|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33760524|NCT02019628|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760525|NCT01457781|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33760526|NCT02561169|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33760527|NCT01321541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760528|NCT02699879|||COHORT||PROSPECTIVE|||||||
33760529|NCT00627900|NON_RANDOMIZED|||||||||||
33760530|NCT04072614|||COHORT||PROSPECTIVE|||||||
33760531|NCT00942617|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760532|NCT01719107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760533|NCT01137188|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33760534|NCT02403882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760535|NCT00873938|||COHORT||PROSPECTIVE|||||||
33760536|NCT04416893|||COHORT||PROSPECTIVE|||||||
33760537|NCT00186316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760538|NCT01980238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760539|NCT03331484|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760540|NCT03520400|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33760541|NCT02480595|||COHORT||PROSPECTIVE|||||||
33760542|NCT06208085|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized to avocado or no avocado groups. The avocado group will be asked to consume an avocado a day for 12 weeks.||||
33760543|NCT02098213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Taking into account the hypothesis of a proportion of patients with a DLQI≤10 (absence of repercussion or low impact of psoriasis on quality of life) of 25% at 4 months 1/2 in the arm immediate spa treatment versus 10% in the usual care group (late spa treatment), 113 patients per group is required, with an alpha 5% risk and a power of 80 %. Given the risk of potential patients lost to follow-up estimates of 15%, we plan to include 130 patients per randomisation group, so 260 patients in total.~According to the protocol submitted to authorities, given the uncertainties of necessary hypothesis, a re-evaluation of the number of subjects required after the first 100 inclusions is planned. This reassessment will be carried out without intermediate analysis but in view of the results observed for the primary endpoint in mean and standard deviation (event driven)."||||
33760544|NCT03586583|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33760545|NCT02857530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760546|NCT03006484|||COHORT||PROSPECTIVE|||||||
33760547|NCT04457830|NA|SINGLE_GROUP||TREATMENT||NONE||F520||||
33760548|NCT02594748|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33760549|NCT02568631|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33760550|NCT02716948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760551|NCT06162832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is a triple-blind study, where the operator, the investigator and the statistician have no knowledge of the material placed in the procedure.|The study was conducted in two groups with control and experimental groups which were evaluated during a period of six months with monthly evaluation until the results were obtained.|t|t|f|t
33760552|NCT04782557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760553|NCT05823246|NA|SEQUENTIAL||TREATMENT||NONE||||||
33760554|NCT04426864|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to three groups in parallel for the duration of the study.||||
33760555|NCT03269240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The assessors will blinded with respect to which study arm the participants (health care workers) were assigned to.|Cluster randomized control trial|f|f|f|t
33760556|NCT04607655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a double-blind study. The blinding will be maintained throughout the study.|"All subjects eligible for the study will be randomised into one of the three treatment arms:~A. GB1211 100 mg twice a day B. GB1211 10 mg twice a day C. Placebo twice a day"|t|t|t|t
33760557|NCT01771393|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33760558|NCT05379257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760559|NCT00426725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760560|NCT01009879|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760561|NCT02198495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760562|NCT06255392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760563|NCT03348579|||CASE_ONLY||PROSPECTIVE|||||||
33760564|NCT03435575|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization into intervention or control group. Children in the intervention group will receive Boosth at the start of the study. Children in the control group will receive Boosth after the study is finished|Intervention and control group parallel||||
33760565|NCT04572178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760566|NCT02463734|||||CROSS_SECTIONAL|||||||
33760567|NCT04890535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760568|NCT00664898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760569|NCT01392300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760570|NCT01662063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760571|NCT00051168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760572|NCT06368986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760573|NCT05809661|||COHORT||CROSS_SECTIONAL|||||||
33760574|NCT04202081|||OTHER||CROSS_SECTIONAL|||||||
33760575|NCT03163914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Partipicants and care providers will not known which medication will apply.||t|t|f|f
33760576|NCT03655925|||COHORT||PROSPECTIVE|||||||
33760577|NCT00129922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765006|NCT03180671|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33765007|NCT05487430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Blinding the intervention group from the clinical staff and from the researchers was not possible due to the fact that the patients were listening to the affirmation recordings.|Randomised assignation of participants into two study groups: Intervention and Control.||||
33765008|NCT03648125|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||"Prospective, monocentric, randomized, open-label, cross-over study. Randomization applies on the order of the training sessions with or without occlusal disturbance."||||
33765009|NCT02230436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071609|NCT06352866|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This study is an open label single cohort feasibility and efficacy study of siltuximab prophylaxis prior to infusion of teclistamab for treatment of RRMM. There is no planned dose escalation and no separate cohorts.~Participants will receive a single dose of prophylactic siltuximab, 11 mg/kg, 2 hours prior to the administration of the first dose of teclistamab on day 1. There is no planned dose escalation of siltuximab, and teclistamab dosing will be done following the standard planned ramp-up. Participants will be hospitalized for 9 days according to teclistamab package insert and Cleveland Clinic institutional practice. Participants will be followed for the incidence of CRS and ICANS for the first two 22-day cycles of treatment."||||
33884514|NCT03603769|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|A placebo capsule (glycerine only, with no SPL)|"Each subject will participate in five daily trials on 5 separate days, at least 2 weeks apart.~Within each appointment each participant will come (after fasting overnight, 10-12 h), to our metabolic unit early in the morning (07:30 - 08.30 am) and will initially give a fasting baseline blood sample. Afterwards, in specific time he/she will be provided to consume a standardized breakfast and then he/she will be administered randomly either placebo or several versions of the food supplement containing Salmon Polar Lipids (Low Dose stomach release or High Dose stomach release or Low Dose intestine release or High Dose Intestine Release). Thus, the sequence of the trials will be randomly selected for each subject."|t|f|t|f
33884515|NCT05030688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient, and the outcomes assessor who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is fascia iliaca compartment block (FICB). The second one is PENG block group.|t|f|f|t
33884516|NCT03275545|||CASE_CONTROL||PROSPECTIVE|||||||
33884517|NCT02591433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33884518|NCT00181233|||OTHER||PROSPECTIVE|||||||
33884519|NCT02876692|||COHORT||PROSPECTIVE|||||||
33884520|NCT03840330|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||HIT; MIT; GC||||
34071610|NCT05320419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071611|NCT06132984|||COHORT||PROSPECTIVE|||||||
34071612|NCT04146389|||CASE_ONLY||PROSPECTIVE|||||||
34071613|NCT00005083||||DIAGNOSTIC||||||||
34071614|NCT01602705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34071615|NCT03009227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071616|NCT06185439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The data will be collected by the assistant researcher and entered into the SPSS program as A and B groups. Analyzes will be performed by the principal investigator who is blind to the groups.|Following recruitment, the pregnant women were divided into a study and a control group by randomization (1:1 randomization)|f|f|t|t
34071617|NCT05940961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071618|NCT04531111|||CASE_ONLY||CROSS_SECTIONAL|||||||
34071619|NCT03578445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071620|NCT01850394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071621|NCT05003284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34071622|NCT05519956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884521|NCT01307930|NA|SINGLE_GROUP||OTHER||NONE||||||
33884522|NCT05150366|NA|SINGLE_GROUP||OTHER||NONE||||||
33884523|NCT01039857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071623|NCT02171117|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071624|NCT04786405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The experimenter will remain blind to participant condition.|Single-blind, two-arm, parallel-group randomized design.|f|f|f|t
34071625|NCT05678712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071626|NCT05627947|RANDOMIZED|PARALLEL||TREATMENT||NONE||compare the recurrence rates and complications associated with instillation of topical mitomycin C and cyclosporine after primary pterygium surgery||||
34071627|NCT04827758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071628|NCT04053907|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071629|NCT03823820|||CASE_CONTROL||PROSPECTIVE|||||||
34071630|NCT04285905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071631|NCT05530655|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34071632|NCT06019026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
33760578|NCT05739669|NA|SEQUENTIAL||DIAGNOSTIC||NONE|The quality of all the EEG recordings will be assessed by two highly qualified clinicians blinded to the recording condition and device. The diagnostic value of the home EEG monitoring will be evaluated by clinicians blinded to the patient's diagnosis.|"The EEG recordings will be gathered from each patient (single group) with two devices, in two different conditions and their quality assessed according to international standards by the IFCN.~1. one EEG recording gathered with a CE-certified wet electrode device (Micromed Brain Quick; comparator device) by specialized staff in a clinician's office~2. one EEG recording gathered with the investigational device Atlas with dry electrodes by specialized staff, in a clinician's office, immediately after (1)~3. multiple EEG recordings gathered at home by non-specialized staff, for 14 days, using the investigational device Atlas with dry electrodes The study is exploratory.~To further explore the diagnostic yield of recordings with the investigational device Atlas with dry electrodes, the concordance of recorded dry electrode EEG data, semiautomatic analysis in encevis and data from the empatica EmbracePlus wrist device with established diagnoses will be investigated."||||
33760579|NCT05950425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33760580|NCT00278070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760581|NCT01033214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760582|NCT04840277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760583|NCT05777967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760584|NCT00001599||||TREATMENT||||||||
34071633|NCT06409728|||COHORT||OTHER|||||||
34071634|NCT01473017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071635|NCT00263419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071636|NCT01551446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071637|NCT05565170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be actively told to what group they have been assigned (intervention or control). Outcome assessors will be blinded to the group allocation.|"Participants are randomised 1:1 to two parallel arms:~* structured ICT-assisted multimodal lifestyle intervention (intervention group)~* self-guided multimodal lifestyle intervention (control group)"|t|f|f|t
34071638|NCT00230724|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34071639|NCT02860962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071640|NCT02375425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34071641|NCT01482988|||||PROSPECTIVE|||||||
34071642|NCT06364371|||OTHER||PROSPECTIVE|||||||
34071643|NCT00990509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071644|NCT02491970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071645|NCT00064415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071646|NCT04331509|||COHORT||PROSPECTIVE|||||||
33884524|NCT06061198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||2 arms are involved in the study . first arm will receive local anesthesia with virtual reality during the surgery to reduce patient's anxiety . second arm will receive standards care under regional anesthesia|f|f|f|t
33884525|NCT02944916|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884526|NCT02015169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884527|NCT01570647|||COHORT||CROSS_SECTIONAL|||||||
33884528|NCT03087006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33884529|NCT03754907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884530|NCT03671057|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Two sets of cartboard boxes will be prepared. The boxes are prepared and numbered by the study investigator (F.V.) (the unique randomized test number) and distributed amongst the consultation offices of the surgeons by the researchers. To blind both the researchers and the surgeons, the 2 sets of boxes will have the same weight. The weight of the ipad is simulated in the boxes of the control group by the use of a coloring book. This will prevent patient selection bias.~After the consultation and when the parent and the child has agreed to participate, the surgeon hands over a box to the parent. The surgeon writes the box number, name of the child, date of birth and the phone number of the child in an excel sheet. This document will be used during data procession.~The patients participating in the trial, the treating physicians, the surgeons dispensing the study boxes, the researchers assessing outcomes and the data-managers will be blinded for group allocation."|The design of the study will be a single blinded randomized clinical trial. Children will be divided in 2 research groups: an intervention group (children who will play the game HospiAvontuur as a non-pharmacological at home preparation prior to the hospital admission. These children will not receive any pharmacological preparation - Midazolam - at the hospital) and a control group (children who do not play the game at home and do receive a pharmacological preparation - Midazolam - at the hospital). Participants will be randomly assigned to the intervention group or the control group using a computer-generated random allocation sequence, created by the study investigator (F.V.). Each patient will receive a unique randomized test number.|f|t|t|t
34071647|NCT03655600|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized two arm (intervention and usual care) clinical trial|f|f|t|t
34071648|NCT03694223|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071649|NCT04824742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071650|NCT01176526|||||RETROSPECTIVE|||||||
34071651|NCT04369963|||COHORT||PROSPECTIVE|||||||
34071652|NCT04404504|||OTHER||PROSPECTIVE|||||||
34071653|NCT05177068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071654|NCT01008774|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071655|NCT02686814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071656|NCT04810910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071657|NCT02601222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071658|NCT05392530|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34071659|NCT06025149|||COHORT||PROSPECTIVE|||||||
34071660|NCT05061147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071661|NCT01067417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071662|NCT03800680|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071663|NCT05603572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Oral administration (KAT-101)~2. IT administration (KAT-201)~3. Oral administration (KAT-101) + IT administration (KAT-201)"||||
34071664|NCT00635934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071665|NCT04653259|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071666|NCT03438942|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34071667|NCT00893074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Dronbinol doses were double blind and placebo controlled|Within-subjects cross-over evaluation of 0, 30, 60, and 120mg dronabinol per day on withdrawal, cognitive performance, and response to acute cannabis exposure|t|f|f|t
34071668|NCT02106741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34071669|NCT02935257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071670|NCT03836534|||CASE_ONLY||PROSPECTIVE|||||||
34071671|NCT03565705|||CASE_CONTROL||RETROSPECTIVE|||||||
34071672|NCT04656301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760585|NCT02615236|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33972483|NCT03801629|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects are informed that they will receive a single morphine injection. Subjects are blinded to the morphine dose condition. Investigators and assessors are not blinded to morphine dose condition.|Subjects will receive a single intramuscular morphine dose: 'High' (0.07mg/kg i.m.) vs. 'Low' (0.04mg/kg i.m.)|t|f|f|f
33972484|NCT00860314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972485|NCT04895618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071673|NCT04727736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071674|NCT03562858|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33760586|NCT03552302|||CASE_ONLY||PROSPECTIVE|||||||
33760587|NCT01910623|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972486|NCT05885230|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33972487|NCT02840656|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33972488|NCT06486363|RANDOMIZED|PARALLEL||TREATMENT||NONE||To compare the antiplatelet efficacy of aspirin combined with clopidogrel and aspirin combined with half-dose ticagrelor in in patients with unruptured intracranial aneurysms with normal CYP2C19 metabolizer phenotype||||
33760588|NCT02609646|||CASE_ONLY||PROSPECTIVE|||||||
33760589|NCT01744886|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760590|NCT04970199|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33760591|NCT04127487|||OTHER||OTHER|||||||
33760592|NCT06165406|||COHORT||PROSPECTIVE|||||||
33760593|NCT05225688|||COHORT||PROSPECTIVE|||||||
33760594|NCT00365586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760595|NCT01937039|||OTHER||PROSPECTIVE|||||||
33760596|NCT02427659|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33760597|NCT02432469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33760598|NCT03202043|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33760599|NCT00760539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760600|NCT00058422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760601|NCT02673970|||COHORT||PROSPECTIVE|||||||
33760602|NCT02693821|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Cuando el paciente dé su consentimiento, será reclutado y randomizado a un grupo control (recibirá placebo) o a un grupo tratamiento (recibirá gabapentin) Los pacientes recibirán una técnica anestésica habitual, basadas en drogas endovenosas mediante el método TCI (target controlled infusión). Con este método se unifica el uso de las drogas anestésicas, que son utilizadas de acuerdo a sexo, edad, género, peso y altura en cada uno de los pacientes.~La analgesia será la convencional para cada cirugía y se continuará con el uso de catéteres epidurales, para analgesia en aquellas intervenciones donde su aplicación sea habitual."|Estudio Controlado, randomizado, prospectivo y ciego.|t|f|t|f
33760603|NCT03366922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Two research assistants will be recruited and trained as observers and data collectors to increase accuracy and consistency in documenting the needed data. They will be assisted by the HIV clinic staff and these research assistants will be blinded to the hypotheses of this study to minimize observer bias and facilitate participant randomization. Senior clinician at the HIV clinic will supervise the trial and administration of treatments for HAART patients attending at the MRRH clinic.~* To endure blinding, a study nurse will randomize and interview the participants and or draw blood whenever necessary. Study phlebotomist will draw blood and deliver it to the respective laboratory with codes masking the arm in which that patient is randomized. Independent laboratory technicians will run the tests at Epicenter and MUST research Labs."|Participants will be stratified according to baseline CD4 levels: 350 - 250, 249 - 150, below 149. Computer generated numbers will be used to assign selected participants into study groups using simple randomization method to either control group with HAART only, or HAART with Artemisia annua group or HAART with Artemisia annua and Moringa oleifera group of 1:1:1.|t|t|f|f
33760604|NCT04438863|||COHORT||PROSPECTIVE|||||||
33760605|NCT02603822|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open Label|||||
33972489|NCT00781755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972490|NCT06544525|NA|SINGLE_GROUP||TREATMENT||NONE||This study will be a quasi-experimental, one-group repeated measures design.||||
33760606|NCT03167684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760607|NCT04365517|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled open label intervention study is proposed. Patients hospitalized for COVID-19 and suffering from type 2 diabetes will be included in the study and divided into two groups by randomization: sitagliptin add-on therapy with nutritional therapy with or without insulin (study group) vs nutritional therapy with or without insulin (group of control, standard therapy)||||
34071675|NCT00552214|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760608|NCT05444062|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33760609|NCT00867022|||CASE_CONTROL||PROSPECTIVE|||||||
33884531|NCT02665429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884532|NCT00575562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884533|NCT00441545|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884534|NCT04844255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Time series design||||
33884535|NCT02904980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884536|NCT01645267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884537|NCT01822808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884538|NCT05874531|||COHORT||PROSPECTIVE|||||||
33884539|NCT05770986|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomly allocated to an experimental and a control group as follow: Group A (n= 26) will receive the eight phases of the Powers program plus a conventional treatment of flexibility exercises, hot pack, transcutaneous electrical stimulation (TENS), prone resisted hip extension for 12 sessions (3 sessions per week for 4 weeks). Group B (n= 26) will receive the same conventional treatment only.||||
33884540|NCT06454084|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884541|NCT01106040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972491|NCT02447536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972492|NCT00927121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972493|NCT00545233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972494|NCT02588573|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33972495|NCT02616692|||OTHER||PROSPECTIVE|||||||
33972496|NCT04485988|||COHORT||RETROSPECTIVE|||||||
33884542|NCT01075880|||COHORT||PROSPECTIVE|||||||
33884543|NCT00749008|||COHORT||PROSPECTIVE|||||||
33884544|NCT04111614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884545|NCT05613413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884546|NCT02421341|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33884547|NCT01461044|||COHORT|||||||||
33972497|NCT05764889|RANDOMIZED|PARALLEL||OTHER||NONE||Patients in the experimental group were wrapped with this device postoperatively Patients in the control group were wrapped with traditional gauze postoperatively.||||
33972498|NCT02539563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33972499|NCT03085446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071676|NCT02233621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071677|NCT03872843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded||t|f|t|f
34071678|NCT04158505|||COHORT||PROSPECTIVE|||||||
34071679|NCT01135524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972500|NCT04297852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33972501|NCT04383704|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33972502|NCT04973956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participant does not know what the other participants are doing, the researcher knows which study and group the subject is in, but only sets up the computerized presentations for each group and assigns folders within the computer that collects the data, thus avoiding a possible information bias, and finally, another researcher blind to the intervention will analyse the data to obtain the results.|As participants complete the State-Trait Anxiety Inventory, and are found to be anxiety, they will be randomised in parallel to one of the two intervention groups.|t|f|f|t
33972503|NCT01928446|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33972504|NCT01225328|NA|SINGLE_GROUP||||NONE||||||
34071680|NCT01579669|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760610|NCT05817266|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760611|NCT05597722|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized 1:1 block design trial evaluating the effect of a digital cognitive behavioral app versus a drug therapy (amphetamine-dextroamphetamine \[Adderall\]) on cognitive impairment and other secondary outcomes in subjects with post-COVID symptoms (Long-COVID). The participants will be stratified by depression severity.||||
33760612|NCT02398968|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33760613|NCT01423682|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760614|NCT04148014|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study without randomization or controlled design||||
33760615|NCT01786330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760616|NCT05199623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760617|NCT04012515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972505|NCT05954715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Both Sham and IPC consist of 5 min bouts of cuff inflation, using an identical cuff. While the applied pressure will differ between conditions, this will not be communicated with the study participants prior to the experiment.|Acute single blind randomised controlled trial|t|f|f|f
33972506|NCT02801058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972507|NCT05349903|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33972508|NCT03465891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-arm, parallel, open-label, phase II clinical trial.||||
33972509|NCT05429203|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33760618|NCT03527355|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer Blinded|Participants age 6-23 months|t|t|t|t
33765010|NCT04731415|NA|SINGLE_GROUP||OTHER||NONE||||||
33765011|NCT03746184|||COHORT||PROSPECTIVE|||||||
33765012|NCT03690219|||COHORT||RETROSPECTIVE|||||||
33765013|NCT05441618|||CASE_ONLY||RETROSPECTIVE|||||||
33765014|NCT03446300|||COHORT||PROSPECTIVE|||||||
33765015|NCT03274154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765016|NCT04082520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765017|NCT05885282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765018|NCT04588233|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33765019|NCT02995902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33765020|NCT04990141|||CASE_CONTROL||PROSPECTIVE|||||||
33765021|NCT06625450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765022|NCT04954937|||OTHER||PROSPECTIVE|||||||
33765023|NCT02344537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972510|NCT02347930|||OTHER||PROSPECTIVE|||||||
33972511|NCT02463617|NA|SINGLE_GROUP||OTHER||NONE||||||
34071681|NCT04306393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is blinded to the treatment.||t|f|f|f
34071682|NCT03731949|||OTHER||PROSPECTIVE|||||||
33884548|NCT06549244|||COHORT||PROSPECTIVE|||||||
33884549|NCT03893149|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33884550|NCT05199324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884551|NCT00031031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884552|NCT01175746|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33884553|NCT03341676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, Investigator supervising the visit and the Outcome Assessor will be blinded to the treatment allocation|Double-blind, randomised controlled trial|t|f|t|t
33884554|NCT02793362|||COHORT||PROSPECTIVE|||||||
34071683|NCT04020978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972512|NCT04466150|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This is a nested case-controlled study.~By nesting this ocrelizumab interventional treatment arm within an observational study, the investigators will be able to compare treatment with ocrelizumab to usual care for patients who are matched for the same disease duration. Because the same clinical and biomarker assessments will be acquired for both the ocrelizumab interventional arm and the usual care observational cohort, this study will allow direct comparison of ocrelizumab with a usual care control group."||||
33972513|NCT04580056|||COHORT||PROSPECTIVE|||||||
33972514|NCT04137263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972515|NCT03276975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33972516|NCT02919475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071684|NCT00204061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884555|NCT00122135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884556|NCT03845387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884557|NCT03996330|||COHORT||PROSPECTIVE|||||||
33884558|NCT06214767|||COHORT||PROSPECTIVE|||||||
33884559|NCT04737473|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33884560|NCT01196559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884561|NCT06375304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884562|NCT01957137|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33884563|NCT02659592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884564|NCT05182346|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33884565|NCT01694004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884566|NCT01001702||PARALLEL||TREATMENT||NONE||||||
33884567|NCT03336502|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33884568|NCT02389270|||CASE_ONLY||CROSS_SECTIONAL|||||||
33884569|NCT04297462|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients randomly allocated into 3 or 7-days postexposure chemoprophylaxis group||||
33884570|NCT06075225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884571|NCT01046695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884572|NCT06270979|||COHORT||CROSS_SECTIONAL|||||||
33884573|NCT02654002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884574|NCT01984255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884575|NCT01722513|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33884576|NCT03194984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the patient did not know in which region each gel was applied the investigator did not know in which region each gel was applied the outcomes assessor did not know in which region each gel was applied|range of patients aged 18 to 25 years receiving two types of geis and range of patients aged 40-65 years receiving two types of geis|t|f|t|t
33884577|NCT05971966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884578|NCT03509220|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33884579|NCT03248726|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33884580|NCT05325320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884581|NCT00434044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884582|NCT05730179|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33884583|NCT03280979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884584|NCT00855660|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33884585|NCT01289496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884586|NCT00424970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884587|NCT01833130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884588|NCT04817501|||CASE_CONTROL||PROSPECTIVE|||||||
33972517|NCT05043532|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The patient undergoing the procedure, research coordinator calling patients for follow-up and the pathologist performing molecular profiling will be blinded to the randomization group.||t|t|f|t
33972518|NCT02289209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972519|NCT01712412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972520|NCT00579319|||CASE_ONLY||RETROSPECTIVE|||||||
33972521|NCT06081725|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|One designated experiment assigned each participant randomly to one of the interactions (playful or control), to keep the other experiments blind to the activity.|"Participants will be randomly assigned to four arms. At first they will randomly assign to one of two conditions (online or face to face).~On the second and third session the participants will be randomly assigned to a playful or control interaction.~The interactions will be separated in a week. A random half of the participants will be assigned to practice the playful interaction at the first week and control interaction in the second week, whereas for the other half this order will be reversed."|f|f|f|t
33972522|NCT00514293||||TREATMENT||NONE||||||
33884589|NCT05224544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884590|NCT04271332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo-controlled||t|t|t|t
34071685|NCT06294119|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884591|NCT00639080|||CASE_CONTROL|||||||||
33972523|NCT05431153|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open-label Study|Randomized, open-label, 4-period, 5-treatment, 6-sequence, crossover study.||||
33972524|NCT00604656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972525|NCT05586971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972526|NCT01625377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972527|NCT01790620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33972528|NCT04925206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972529|NCT02509000|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33884592|NCT06087757|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This study is an open-label study with a blinded randomized withdrawal||t|f|t|f
33884593|NCT02998723|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33884594|NCT05753956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This study will include separate single and multiple-dose parts.~Single-dose Part:~A double-blind, placebo-controlled, randomized, dose escalation design with single doses of GH002 delivered by i.v. bolus injection in 7 consecutive cohorts with 8 subjects per cohort (randomized as 6 active and 2 placebo):~Cohort A: Dose A~Cohort B: Dose B~Cohort C: Dose C~Cohort D: Dose D~Cohort E: Dose E~Cohort F: Dose F~Cohort G: Dose G~Up to 2 additional cohorts may be added before the IDR part is initiated. These will be named cohorts H and I, if needed.~Multiple-Dose Part:~An open-label, non-randomized design with up to 3 doses of GH002 administered to subjects by i.v. bolus injection(s) on a single day in one cohort of 8 subjects:~Cohort J: Individualized Dosing Regimen with GH002.~The exact doses of study drug to be administered will be determined after an unblinded review of the safety, PK and PD data from all of the cohorts in the single dose part of the trial"|t|f|t|t
33884595|NCT04150380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||longitudinal, double blind, randomized placebo-controlled design|t|f|t|t
33884596|NCT02452372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884597|NCT05699720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884598|NCT03931278|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884599|NCT02346474|||COHORT||CROSS_SECTIONAL|||||||
33884600|NCT00560755|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33884601|NCT06312891|||COHORT||PROSPECTIVE|||||||
33884602|NCT02199899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884603|NCT05729893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients were randomly divided into two groups according to material used for obturation . each patients name will be replaced with a case number within the group to protect the privacy of medical information and data of the patients care provider and the investigator will not know the name of the patient and the assessor doesn't know the group he is assessing|randomized clinical trial|t|t|t|t
33972530|NCT03443869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972531|NCT00317161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33972532|NCT04034030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972533|NCT06404697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972534|NCT04109027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Outcomes assessors and investigators will be blinded to study arm. Participants will have equal expectations of learning and benefit from the two active comparisons, though they cannot be blinded to the content of the training interventions. Trainers will have to be aware of the training content.|Randomized trial with two active comparison interventions|t|f|t|t
33972535|NCT03811197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972536|NCT04113395|||CASE_ONLY||PROSPECTIVE|||||||
34071686|NCT01535469|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34071687|NCT02287688|||COHORT||PROSPECTIVE|||||||
34071688|NCT03144791|||CASE_ONLY||PROSPECTIVE|||||||
33884604|NCT01361347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884605|NCT05394038|||COHORT||RETROSPECTIVE|||||||
33884606|NCT01201473|||COHORT||CROSS_SECTIONAL|||||||
34071689|NCT00084227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760619|NCT04137354|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|"Iron supplements and their placebo: Both iron and placebo supplements will be produced by Metagenics (Belgium) for the context of this study. Placebo tablets will have the same taste, and shape of the iron tablets, the colour is slightly different because of the characteristics of the products but the blinding is ensured. The blister/ the tablets will be packed and only coded.~Vitamin A and its placebo: Vitamin A capsule is oral liquid, red, oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E. The placebo supplement will have the same oil composition except that it will not contain vitamin A equivalent. Placebo oil and vitamin A preparation will be transferred to two colored (red and orange) Eppendorf® Safe-Lock microcentrifuge tubes volume 0.6 mL by a researcher who is not involved in the study."|"In randomized placebo-control trial eligible primary school children in the Arba Minch HDSS will be randomly assigned to four groups of treatment in a factorial 2x2 design:~1. A control placebo receiving placebo vitamin A at baseline and after 5 months, and placebo iron supplement weekly;~2. A high dose vitamin A at baseline and after 5 months and weekly placebo iron supplement;~3. Weekly iron supplementation for 10 months and placebo vitamin A at baseline and after 5 months;~4. Combined weekly iron supplementation and high dose vitamin A at baseline and after 5 months.~At the end of the study, and if the results are positive, children who receive the placebo iron supplement will receive weekly iron supplementation (42mg of elemental iron once a week) for 10 months. Children in all the treatment groups remain eligible to benefit from the standard health care and nutrition programs provided at school, such as deworming at the beginning of the school year"|t|t|t|t
33760620|NCT04770363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double (Participant, Outcomes Assessor) To make sure that no bias should enter the assessment of the results, neither the patient nor the external assessor will be aware whether active tDCS will be applicated to a particular case. The patients don't know if which group they are participated in, bihemispheric, unihemispheric, of sham group, external assessor was recruited to assess patients after the intervention ended.|Participants will participate into the study, each patient will undergo a detailed neurological examination through filling out a medical sheet questionnaire and checking the most common risk factors of stroke and other parameters. ActivaDose tDCS (USA), the only FDA cleared device available for tDCS will be used in the clinical study. Thirty patients will be allocated randomly into three group.|t|t|f|t
33760621|NCT01546961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760622|NCT03099330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760623|NCT02582138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33760624|NCT04570917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33760625|NCT01570530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760626|NCT06176001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760627|NCT05794048|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760628|NCT06378853|||COHORT||RETROSPECTIVE|||||||
33760629|NCT04080752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760630|NCT02144922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760631|NCT03261102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Some of the participants, care providers and investigators will eventually, in the course of the study, have knowledge of the arm they were assigned.||t|t|t|f
33760632|NCT03895411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760633|NCT05976204|||COHORT||RETROSPECTIVE|||||||
33760634|NCT04710927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant were not informed regarding intervention given||t|f|f|f
33884607|NCT01799057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884608|NCT03410511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33972537|NCT05055791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972538|NCT02984839|||OTHER||CROSS_SECTIONAL|||||||
33972539|NCT02272348|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33972540|NCT02139683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884609|NCT01779674|||COHORT||PROSPECTIVE|||||||
33972541|NCT05079854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972542|NCT03509298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
33972543|NCT02100865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972544|NCT06015373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972545|NCT05432271|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to 1 of 5 front-of-package labeling arms with equal probability: Participants will complete two vending machine choice tasks with their assigned labels shown (one for beverages, one for snack foods, in random order). For each choice task, participants will be asked to select 1 item they most wish to purchase. We will incentivize truthful responding by instructing participants that they could be randomly selected to have their choice delivered to them. We will record participants' selections and match these to nutrition information.||||
33972546|NCT02668302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients were wearing eye masked and noise-cancelling headsets during placement and follow-up endoscopies.~The primary outcome was assessed by an independent sinus surgeon based on a centralized, blinded video-endoscopy review."|Patients assigned to the treatment group underwent a bilateral in-office placement of a steroid-eluting sinus implant 7 days following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids. Patients randomized to the control group received same standard of care alone.|t|f|f|t
33972547|NCT05333250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33972548|NCT02678910|NA|SINGLE_GROUP||OTHER||NONE||||||
33972549|NCT03955692|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33972550|NCT00260780|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33972551|NCT02410148|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33972552|NCT04707274|||OTHER||PROSPECTIVE|||||||
33972553|NCT03246698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All of participants must have subacromial impingement syndrome with glenohumeral internal rotation deficit.|There are 3 groups. First group will receive isolytic stretching in modified cross body stretching position and standard physiotherapy program. Second group will receive static stretching in modified cross body stretching position and standard physiotherapy program. Control group will receive only standard physiotherapy program. In standard physiotherapy program, there are TENS, hotpack, posture and strengthening training program. Treatment program will last four weeks.|t|f|f|f
33972554|NCT04812509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972555|NCT00654706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972556|NCT03741608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups will both participate in the 7-part educational series to reduce high blood pressure. One of the two groups will also be given a blood pressure cuff and will be trained to check their own blood pressure. We will track blood pressure and stress level of both groups for 6 months||||
33972557|NCT00467584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972558|NCT01960816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972559|NCT03538756|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants were randomized only during the baseline visit.||||
33972560|NCT05112328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33972561|NCT02874495|||CASE_ONLY||PROSPECTIVE|||||||
33972562|NCT06529263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental study|f|f|t|f
33972563|NCT02265848|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33972564|NCT06243354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972565|NCT01801696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972566|NCT02779816|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33972567|NCT06252779|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33972568|NCT01309919|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972569|NCT02505100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972570|NCT03931083|||OTHER||PROSPECTIVE|||||||
33972571|NCT03454633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomised controlled study|t|f|f|f
33972572|NCT00875719|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972573|NCT04110028|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||QUADRUPLE|The safety committee will have access to unblinded results during the study.|"Participants will be randomized to placebo or nicotinamide riboside (NR) in increasing doses. The safety of each dose will be evaluated before commencing the next phase. In each phase nicotinamide or placebo will be administered.~The patients will use NR for 90 days. When all patients have completed their NR treatment the study will be unblinded and the follow-up visits at one year later and further on will be unblinded."|t|t|t|t
33972574|NCT05963061|||COHORT||OTHER|||||||
33972575|NCT00188370|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972576|NCT03449628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972577|NCT02153736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972578|NCT03072836|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972579|NCT03742674|||COHORT||PROSPECTIVE|||||||
33972580|NCT04232397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972581|NCT01280981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760635|NCT05644223|||COHORT||PROSPECTIVE|||||||
33760636|NCT03384810|||COHORT||PROSPECTIVE|||||||
33760637|NCT01928134|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972582|NCT01082107|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972583|NCT03490682|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760638|NCT05541302|||OTHER||RETROSPECTIVE|||||||
33760639|NCT04115007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760640|NCT03576768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760641|NCT03765333|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33760642|NCT00895882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972584|NCT02904421|||COHORT||OTHER|||||||
33760643|NCT04615130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As the control group will undergo rehabilitation after the study period as well, it is possible to blind patients and outcome assessors to the treatment group.||t|f|f|t
33972585|NCT03090984|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33972586|NCT05608564|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the non-surgical periodontal treatment, the test group will be treated with local antibiotics, while the control group will be treated with systemic antibiotics. Randomization will be performed using randomization envelopes.||||
33760644|NCT02507908|||OTHER||PROSPECTIVE|||||||
33760645|NCT00489385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972587|NCT06358352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760646|NCT03408275|||COHORT||PROSPECTIVE|||||||
33760647|NCT00378001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760648|NCT00521144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760649|NCT03464487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760650|NCT03886259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded towards group allocation.||f|f|f|t
33972588|NCT02809092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071690|NCT04900649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972589|NCT02117193|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33760651|NCT01712100|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760652|NCT02293772|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33760653|NCT05648825|NA|SINGLE_GROUP||TREATMENT||NONE||Beating-Heart Myectomy Device||||
33760654|NCT00071721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760655|NCT01407211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760656|NCT03966443|||COHORT||PROSPECTIVE|||||||
33760657|NCT06170775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760658|NCT03608280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760659|NCT00944047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760660|NCT03110341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760661|NCT00081302||||TREATMENT||NONE||||||
33760662|NCT00105235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760663|NCT02656576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972590|NCT06364800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972591|NCT00838877|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972592|NCT01346410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972593|NCT02320357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972594|NCT05786807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972595|NCT05488184|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33972596|NCT05112809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972597|NCT03577184|||OTHER||PROSPECTIVE|||||||
33972598|NCT06545968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The proposed project is a mixed-methods prospective cohort study of adolescents and young adults with HIV, clinic counsellors. The study will design and test a social media mHealth intervention to improve retention in care for adolescents and young adults with HIV.||||
33760664|NCT05850780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760665|NCT03117348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760666|NCT05378984|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The chocolate given to the participant was of a different concentration of cocoa, distributed in a randomized and double-blinded order. The participants where given the chocolate with their eyes closed. A non-blinded examiner fed the chocolate to the participant at each clinical trial, while a blinded examiner did the assessments. The different types of chocolates were given at three different visits to all participants with at least one week of washout in between. To randomize the order in which the chocolates were given to each participant, an internet-based site was used (www.randomization.com; Seed 19525). The randomization was done in five blocks of six participants each, by a researcher who did not participate in the data collection||t|f|t|t
33760667|NCT01770210|||||PROSPECTIVE|||||||
33760668|NCT01619514|||COHORT||RETROSPECTIVE|||||||
33760669|NCT03753295|||CASE_CONTROL||RETROSPECTIVE|||||||
33760670|NCT02518854|||COHORT||CROSS_SECTIONAL|||||||
33760671|NCT05411432|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760672|NCT01224158|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33884610|NCT02183519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|1) baseline respiratory maneuvers for calibration of the Respitrace system with spirometry 2) sequential voluntary cough (no cueing), 3) reflex cough sensitivity testing to establish the lowest concentration of capsaicin that elicits a two cough response (C2) (no cueing), 4) randomized production of sequential voluntary cough (3x) or reflex cough induced with C2 (3x) with cueing to 'cough long and hard' and 5) flexible laryngoscopy to assess age-related changes to the larynx that may impact cough function.|Participants with Parkinson's Disease are evaluated in parallel against a control group of health older adults||||
33884611|NCT01072409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884612|NCT04255667|||COHORT||PROSPECTIVE|||||||
33884613|NCT00805740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884614|NCT00440726|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33884615|NCT03711604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884616|NCT02376465|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884617|NCT02019654|||COHORT||PROSPECTIVE|||||||
33884618|NCT03591081|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972599|NCT02479828|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33972600|NCT00327951|||||RETROSPECTIVE|||||||
33760673|NCT02173054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972601|NCT01713712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972602|NCT02542020|||COHORT||PROSPECTIVE|||||||
33972603|NCT00969839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760674|NCT06361901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760675|NCT02500329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760676|NCT00740961|||CASE_CONTROL||PROSPECTIVE|||||||
33760677|NCT00800202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760678|NCT06524999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized-controlled clinical trial||||
33884619|NCT02159144|NA|SINGLE_GROUP||||NONE||||||
33884620|NCT06439030|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33884621|NCT02268435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972604|NCT04405362|||COHORT||PROSPECTIVE|||||||
33972605|NCT00976547|||||PROSPECTIVE|||||||
33972606|NCT03731481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Comparative effectiveness research of two interventions across four cohorts||||
33972607|NCT03329118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972608|NCT00677911|NON_RANDOMIZED|SINGLE_GROUP||OTHER||||||||
33972609|NCT05238493|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33972610|NCT00784212|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972611|NCT01960751|NA|SINGLE_GROUP||SCREENING||NONE||||||
33972612|NCT03427957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the type of grasper used to perform hysteroscopic endometrial biopsy.|Randomized controlled trial|t|f|f|f
33972613|NCT05368142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972614|NCT01697007|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33972615|NCT02688608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972616|NCT06041581|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33884622|NCT06462014|||COHORT||RETROSPECTIVE|||||||
33884623|NCT04176185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomised|Parallel assignment|t|f|t|f
33884624|NCT01779284|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33884625|NCT05708001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884626|NCT01160601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884627|NCT05329077|NA|SINGLE_GROUP||OTHER||NONE||||||
33884628|NCT01137240|||COHORT||PROSPECTIVE|||||||
33884629|NCT00080782|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884630|NCT00697671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972617|NCT02806349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972618|NCT00617435|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972619|NCT04559685|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972620|NCT03833388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972621|NCT00577759|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33972622|NCT00963183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33972623|NCT05295771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||30 patients with bilaterally thin gingival phenotype and minimal keratinized tissues will be treated randomly (left or right maxillary site to be randomized) with either Geistlich Fibro- Gide ® (Test arm) on one side and Autogenous Connective Tissue Graft (Control arm) on the contralateral side of the mouth.|f|f|t|t
33972624|NCT01477437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33972625|NCT01033344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972626|NCT06482593|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972627|NCT05240339|||COHORT||PROSPECTIVE|||||||
33972628|NCT04727697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972629|NCT01805427|||COHORT||PROSPECTIVE|||||||
33760679|NCT04460144|||COHORT||PROSPECTIVE|||||||
33760680|NCT01055925||||TREATMENT||||||||
33760681|NCT04543006|NA|SEQUENTIAL||PREVENTION||NONE||sample of patients 6 and 12 months after the acute disease||||
33760682|NCT02310022|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760683|NCT02273284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760684|NCT06325748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760685|NCT00704301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760686|NCT05367063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||On the basis of a stable dose of metformin, the test group was treated with Canagliflozin tablets (SGLT2 inhibitor), and the control group was treated with Sitagliptin tablets (DPP-4 inhibitor).||||
33760687|NCT04932499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single blinded, block randomized controlled trial|f|f|t|t
33760688|NCT01875354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760689|NCT00264979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760690|NCT04810221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760691|NCT02336399|||COHORT||PROSPECTIVE|||||||
33760692|NCT00809692|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884631|NCT01859247|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33884632|NCT06127641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial|t|f|f|f
33884633|NCT00892554|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884634|NCT03163654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single Blind|Parallel Assignment|t|f|t|f
33884635|NCT03329456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884636|NCT00859482|||COHORT||PROSPECTIVE|||||||
33884637|NCT02642978|RANDOMIZED|PARALLEL||TREATMENT||NONE||micro-invasive surgery||||
33884638|NCT04640766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884639|NCT01301430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884640|NCT05961033|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884641|NCT02225548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884642|NCT04389242|RANDOMIZED|PARALLEL||TREATMENT||NONE||Online Cognitive Behavioral Therapy||||
33884643|NCT04629677|||COHORT||OTHER|||||||
33884644|NCT02548026|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33760693|NCT05706090|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33760694|NCT04532723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760695|NCT01936701|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33884645|NCT02080793||||OTHER||||||||
33884646|NCT03592160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33760696|NCT02489110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760697|NCT01249469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884647|NCT01471080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884648|NCT02320487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760698|NCT01905644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760699|NCT05930197|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884649|NCT00802685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884650|NCT03555266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The only person unblinded to treatment allocation will be the individual applying the device to the patient.||t|t|f|t
33884651|NCT03718845|||COHORT||PROSPECTIVE|||||||
33884652|NCT01976559|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33972630|NCT01806233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972631|NCT00803842|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33972632|NCT00294424|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33972633|NCT00638859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972634|NCT04255459|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33972635|NCT00174499|NON_RANDOMIZED|PARALLEL||||NONE||||||
33972636|NCT05200702|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Comparison of the results obtained during different standardized physical evaluations by patients and healthy subjects, with or without a movement assistance device.||||
33972637|NCT05434208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760700|NCT03434470|||COHORT||PROSPECTIVE|||||||
33760701|NCT05490121|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Research Assistant will be blinded to group allocation. The RA will be responsible for following-up with participants to make sure they've completed quantitative assessments (online survey) or, if participants choose to complete the surveys over the phone, the RA will complete them over the phone with the participant.|To determine the feasibility of evaluating the effectiveness of both of VEGA's educational approaches, as well as to generate preliminary estimates of effect for sampling and effect size calculations, a two-arm pilot randomized controlled trial (RCT) will be used (Eldridge et al., 2016). Eligible participants will be randomly assigned to receive either self-directed (i.e., experimental) or facilitator-led (i.e., active control (AC)) VEGA.|f|f|f|t
33760702|NCT05842655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760703|NCT05535543|||COHORT||PROSPECTIVE|||||||
33760704|NCT05278559|||COHORT||PROSPECTIVE|||||||
33760705|NCT06624514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972638|NCT05715255|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33972639|NCT01206361|||COHORT||RETROSPECTIVE|||||||
33972640|NCT02488928|||COHORT||PROSPECTIVE|||||||
33972641|NCT02277457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071691|NCT06612047|||OTHER||PROSPECTIVE|||||||
34071692|NCT04736719|||COHORT||RETROSPECTIVE|||||||
34071693|NCT02893046|||COHORT||PROSPECTIVE|||||||
34071694|NCT05978700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071695|NCT05288322|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071696|NCT02771860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071697|NCT04030234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071698|NCT02633280|||CASE_CONTROL||PROSPECTIVE|||||||
34071699|NCT03499106|NA|SINGLE_GROUP||OTHER||NONE||||||
34071700|NCT00028626||||TREATMENT||||||||
34071701|NCT05551650|||COHORT||PROSPECTIVE|||||||
34071702|NCT02734862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071703|NCT03839615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|each patient will be given a code by researcher and observer will be blind to which group this case belong||f|f|t|f
33884653|NCT06391398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||parallel-group, randomized controlled trial will be conducted to assess the effect of the Stoma Care Training Belt on patients' stoma care skills, adaptation, anxiety, and satisfaction. A total of 170 patients, with 85 in the intervention group and 85 in the control group, will be included. All patients in the study will receive routine stoma care education as part of their standard treatment and care. In addition to routine treatment and care, patients in the intervention group will receive education with the Stoma Care Training Belt during the preoperative period.||||
33884654|NCT01717469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884655|NCT01260103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972642|NCT03291977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972643|NCT02934295|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972644|NCT02956642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760706|NCT00682643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760707|NCT01705262|||CASE_ONLY||PROSPECTIVE|||||||
33760708|NCT00466102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760709|NCT00004884|RANDOMIZED|||TREATMENT||||||||
33760710|NCT00859651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884656|NCT01798576|||COHORT||PROSPECTIVE|||||||
33760711|NCT04899245|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a single site study taking place over 24 months and involving (65) caregivers and their children, and (50) school staff.||||
33760712|NCT00524199|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33760713|NCT00605514|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760714|NCT06432933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760715|NCT02789683|RANDOMIZED|CROSSOVER||||NONE||||||
33765024|NCT01215214|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071704|NCT05718440|||COHORT||PROSPECTIVE|||||||
34071705|NCT06299267|NA|SINGLE_GROUP||SCREENING||NONE||||||
34071706|NCT01158937|RANDOMIZED|CROSSOVER||||NONE||||||
33884657|NCT02999490|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884658|NCT01150084|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33884659|NCT02113670|NA|SINGLE_GROUP||OTHER||NONE||||||
33884660|NCT00002120||||TREATMENT||DOUBLE||||||
33884661|NCT05317494|||COHORT||PROSPECTIVE|||||||
33884662|NCT02965235|||CASE_CONTROL||PROSPECTIVE|||||||
34071707|NCT04843540|NA|SEQUENTIAL||OTHER||NONE||||||
34071708|NCT02297425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071709|NCT04604977|NA|SINGLE_GROUP||OTHER||NONE||||||
34071710|NCT02702362|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34071711|NCT02585713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884663|NCT01515228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884664|NCT02328066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884665|NCT00653861|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33884666|NCT01044186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884667|NCT04033419|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33884668|NCT02977104|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||40 subjects with Atrial Fibrillation 10 subjects with Atrial Flutter 20 subjects with Sinus Rhythm||||
33884669|NCT05941819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884670|NCT06233695|||COHORT||PROSPECTIVE|||||||
33884671|NCT01697930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071712|NCT03581370|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patient will be randomized either in the 4-hours or in the 1-hour infusion group||||
34071713|NCT01349530|RANDOMIZED|CROSSOVER||||NONE||||||
34071714|NCT03569826|||COHORT||OTHER|||||||
34071715|NCT00098670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071716|NCT04685642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071717|NCT00540644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071718|NCT06314126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and investigators will be masked to the treatment allocation. Treatment pills and placebo pills will be the same in shape, taste, color, and size.|Randomized placebo-controlled trial|t|t|t|f
34071719|NCT05145257|NA|SINGLE_GROUP||OTHER||NONE|Open-label observational single-group|||||
34071720|NCT05927103|||OTHER||CROSS_SECTIONAL|||||||
34071721|NCT03782987|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34071722|NCT00232518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34071723|NCT02185456|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34071724|NCT00001031||||PREVENTION||DOUBLE||||||
34071725|NCT05645861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, investigators and outcome assessors are blinded to randomization allocation using opaque envelopes.||t|f|t|t
34071726|NCT00791037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071727|NCT04094116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non randomised control trials||||
34071728|NCT02306850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071729|NCT04407143|||COHORT||PROSPECTIVE|||||||
34071730|NCT00831402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071731|NCT00609544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071732|NCT02754518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071733|NCT06432101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071734|NCT01093586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071735|NCT06195176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34071736|NCT05592002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071737|NCT04678609|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34071738|NCT00412789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071739|NCT06549153|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34071740|NCT06095479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071741|NCT02017756|||CASE_ONLY||CROSS_SECTIONAL|||||||
34071742|NCT02579382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071743|NCT04078724|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34071744|NCT01505556|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34071745|NCT02479113|||COHORT||PROSPECTIVE|||||||
34071746|NCT03240276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071747|NCT05516771|||COHORT||PROSPECTIVE|||||||
33884672|NCT05644171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972645|NCT05333419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972646|NCT02780700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972647|NCT04995978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972648|NCT03107013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884673|NCT03163381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884674|NCT04507087|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884675|NCT02155933|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884676|NCT04628546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are randomly assigned to intervention or control and not informed which condition to which they were assigned.|Twenty parents that will be randomly assigned to the intervention group (random assignment determined through a random number generator). Twenty parents will be assigned to a control condition.|t|f|f|f
33884677|NCT01584245|NA|SINGLE_GROUP||||||||||
33972649|NCT03273244|||OTHER||PROSPECTIVE|||||||
33972650|NCT00631865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972651|NCT02587702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|t|t|f
33972652|NCT01981486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33972653|NCT01595009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972654|NCT00418483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972655|NCT05489185|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33972656|NCT02459704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972657|NCT01617733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972658|NCT00977002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972659|NCT00003235|RANDOMIZED|||TREATMENT||||||||
33972660|NCT04371250|||COHORT||PROSPECTIVE|||||||
33972661|NCT04144296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972662|NCT02687009|NA|SINGLE_GROUP||OTHER||NONE||||||
33972663|NCT05638152|||COHORT||PROSPECTIVE|||||||
33972664|NCT04947579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972665|NCT04254523|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (participant)||t|f|f|f
33972666|NCT03947606|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Data collectors and principal investigator will be blind to participant condition; participants will be instructed NOT to discuss their assignment with data collectors. Trials participants will know their intervention condition as will the nurse coach involved in delivering the intervention.|2x2x2 full factorial pilot randomized trial|f|f|t|t
33972667|NCT02495610|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972668|NCT02342444|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972669|NCT06012058|RANDOMIZED|PARALLEL||SCREENING||NONE||This is a randomized clinical trial with the primary objective to compare the diagnostic performance of two screening strategies - Retinal nerve fiber layer Optical Texture Analysis (ROTA) assessment by Artificial Intelligence (AI) versus (vs.) optic disc photography assessment by AI or trained graders - for detection of glaucoma in a population-based sample.||||
33972670|NCT01115218|||CASE_ONLY||PROSPECTIVE|||||||
33972671|NCT03907826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972672|NCT01338844|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33972673|NCT04279639|||COHORT||PROSPECTIVE|||||||
33972674|NCT03982849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972675|NCT04209920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972676|NCT00467818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972677|NCT03120156|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Sensomotoric insoles and normal insoles or no insoles are not maskable.Patients and all involved persons will be able to easily see which type of insoles are used.~No blinding possible."|Prospective randomized controlled trial||||
33972678|NCT00330421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972679|NCT04984291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972680|NCT02408666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071748|NCT03260790|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071749|NCT00572871|||CASE_ONLY||CROSS_SECTIONAL|||||||
34071750|NCT02087670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071751|NCT04465526|||COHORT||PROSPECTIVE|||||||
34071752|NCT05660785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071753|NCT00257738|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071754|NCT03300050|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An unblinded pharmacist will prepare Dose 1 and Dose 2. Participants and study staff will remain blinded to their exact treatment group but will be unblinded to their overall group allocation (inpatient or outpatient).|Eligible enrolled subjects will be randomized to any of the treatment arms (LAIV-IIV, Groups 1, 2, and 3; or IIV-IIV, Groups 4 and 5) under one allocation sequence, stratified by site, to allow comparability between study groups, such as LAIV-IIV vs IIV-IIV regimens (Groups 1 vs 4). Groups 1-3 will be inpatient and receive either LAIV or placebo as nasal drops at Dose 1. Groups 4-5 ill be outpatient and receive either IIV or placebo as an injection at Dose 1.|t|t|t|f
34071755|NCT04324762|||COHORT||PROSPECTIVE|||||||
34071756|NCT05436639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071757|NCT00002261||||PREVENTION||||||||
34071758|NCT02666820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071759|NCT01827592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071760|NCT05906394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071761|NCT01344473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071762|NCT03001908|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34071763|NCT05118217|||COHORT||CROSS_SECTIONAL|||||||
34071764|NCT03440138|||CASE_ONLY||RETROSPECTIVE|||||||
33972681|NCT05551377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the investigator and the participants are blinded to treatment allocation.|Participants are divided into two groups, the intervention and control (delayed intervention) group.|t|f|t|f
33972682|NCT04100499|||CASE_ONLY||OTHER|||||||
33972683|NCT05736965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972684|NCT06383559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972685|NCT01838902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972686|NCT00928252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972687|NCT04292106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33972688|NCT03454971|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33972689|NCT03158142|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972690|NCT02043366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33972691|NCT03727178|||COHORT||PROSPECTIVE|||||||
33972692|NCT01323881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972693|NCT06171698|NA|SINGLE_GROUP||OTHER||NONE||||||
33972694|NCT02833415|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972695|NCT06038357|RANDOMIZED|PARALLEL||TREATMENT||NONE||CBITS intervention vs. Treatment as Usual (TAU+)||||
33972696|NCT00720122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972697|NCT05322564|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33972698|NCT05639842|||OTHER||OTHER|||||||
33972699|NCT02461368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972700|NCT05618119|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups of healthy volunteers (5 male, 5 female)||||
33972701|NCT00054483|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972702|NCT00135395|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972703|NCT01073306|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34071765|NCT04304508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071766|NCT05667506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071767|NCT01563315|||COHORT||PROSPECTIVE|||||||
34071768|NCT04164797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071769|NCT02608814|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
34071770|NCT01966744|||OTHER||PROSPECTIVE|||||||
34071771|NCT00280514|NON_RANDOMIZED|||||||||||
33972704|NCT00387998|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33972705|NCT02330120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972706|NCT05493696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972707|NCT00569426|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972708|NCT03247283|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33972709|NCT04248374|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|three random number and covered sample cup\[|Fatty Acid taste with and without sour adaptation|t|f|f|f
33972710|NCT01041781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071772|NCT06612112|||CASE_ONLY||CROSS_SECTIONAL|||||||
34071773|NCT00192777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071774|NCT04275453|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34071775|NCT02484092||SEQUENTIAL||TREATMENT||NONE||||||
34071776|NCT06612528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants were randomly assigned to one of three groups (M1, Cerebellum, or sham) using a computer-generated randomization list. All participants will receive 10 consecutive sessions of anodal tDCS combined with vocal exercises, except on weekends. Stimulation parameters and electrode placement varied by group: M1 - C5 (anode) and contralateral supraorbital (cathode); Cerebellum - cerebellar cortex (anode) and right deltoid (cathode); sham - identical electrode placement to the Cerebellum group, but with stimulation ceasing 30 seconds after onset. Vocal exercises consisted of four 3-minute bouts with a 2-minute rest between bouts. To maintain blinding, a towel was placed over the participant\&amp;amp;amp;amp;#39;s head during the procedure.|t|t|t|t
34071777|NCT05891769|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center, single-arm study enrolling 100 adult participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT.||||
34071778|NCT03184571|NA|SINGLE_GROUP||TREATMENT||NONE||Extension to Simon's 2-stage design allowing termination at the end of Stage 1 for either futility or efficacy.||||
34071779|NCT01681342|||CASE_ONLY||PROSPECTIVE|||||||
33972711|NCT03214718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760716|NCT05668169|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To prevent contact between participants in the intervention and control groups, we allocated participants from the G ward to the intervention group and those from the H ward to the control group. Participants were not given information about the group allocations.|"The family-centered support program included four components:~(A) Stroke and rehabilitation education. (B) Problem-solving skills training. (C) Long-term care information support. (D) Instant messaging application-based 24-h peers-support group for caregivers."|t|f|f|f
33760717|NCT02316769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071780|NCT00911417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071781|NCT01673087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071782|NCT01855087|||CASE_ONLY||RETROSPECTIVE|||||||
34071783|NCT06165198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071784|NCT00428012|RANDOMIZED|PARALLEL||||NONE||||||
34071785|NCT03283046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071786|NCT02695862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071787|NCT05310435|||OTHER||PROSPECTIVE|||||||
34071788|NCT04472598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071789|NCT01818089|||COHORT||PROSPECTIVE|||||||
34071790|NCT00361608|||CASE_CONTROL||PROSPECTIVE|||||||
33760718|NCT04668716|||COHORT||CROSS_SECTIONAL|||||||
33760719|NCT03988634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760720|NCT05401643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is designed as a prospective, longitudinal, randomized 1:1 trial, with two arms: a control group and an intervention group. The intervention will be 12 months long for each participant. There will be a total of 150 participants. Half (75) will comprise the control group and half (75 more) the intervention group. Only the intervention group will have access to the Xemio mobile app.||||
33760721|NCT04887792|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participant, care providers, Investigators and assessors will all be blinded. Study staff responsible for randomization will be unblinded.|This study will be a randomized placebo-controlled sequential parallel comparison design (SPCD).|t|t|t|t
33760722|NCT02260401|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760723|NCT00473070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760724|NCT00449241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760725|NCT00202774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760726|NCT03540355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760727|NCT04085302|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33760728|NCT06391684|||CASE_CONTROL||PROSPECTIVE|||||||
33760729|NCT03771430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760730|NCT06624527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, the sample group was determined in the masking process. The sample group was divided into a control group and an intervention group using a random sampling method. It was not disclosed which group the participants were in.|This study was planned as a pre-test/post-test, single blind randomized controlled experimental design|t|f|f|f
33760731|NCT05647525|||COHORT||PROSPECTIVE|||||||
33760732|NCT00853502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760733|NCT03291886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blinded, randomized trial|t|t|t|t
33760734|NCT02424084|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33760735|NCT04953364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial (RCT)|f|f|f|t
33760736|NCT01898702|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760737|NCT04867356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760738|NCT04676425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760739|NCT04968691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33760740|NCT02835339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760741|NCT06343311|NA|SEQUENTIAL||TREATMENT||NONE||||||
33760742|NCT03716817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760743|NCT02661100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760744|NCT05178121|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760745|NCT01208298|NA|SINGLE_GROUP||||NONE||||||
33760746|NCT03472456|||CASE_CONTROL||PROSPECTIVE|||||||
33760747|NCT06154343|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33760748|NCT06501157|||COHORT||PROSPECTIVE|||||||
33760749|NCT06037590|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, randomized, crossover, comparative bioavailability study in healthy volunteers||||
33760750|NCT01109823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760751|NCT01987817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760752|NCT00817999|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33760753|NCT06286124|||COHORT||PROSPECTIVE|||||||
33760754|NCT00779974|||CASE_ONLY||PROSPECTIVE|||||||
33760755|NCT00403897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760756|NCT05392023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760757|NCT04411602|NA|SINGLE_GROUP||TREATMENT||NONE||Severely ill patients with COVID-19 severe respiratory distress||||
33760758|NCT01105923|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760759|NCT02228954|||COHORT||PROSPECTIVE|||||||
33760760|NCT01114204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760761|NCT05416255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Consecutive patients treated for knee osteoathritis with dextrose injection, hemaopoietic stem cell injection, PRP injection, or no injection.||||
33760762|NCT00962351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760763|NCT02569437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760764|NCT01616394|||COHORT||PROSPECTIVE|||||||
33760765|NCT04406480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760766|NCT01933451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33884678|NCT05242783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded randomized|Subjects who meet diagnostic requirements as listed in the inclusion and exclusion criteria will be included in the study. Women will be randomized to one of the three arms using a computer-generated randomization table with a 1:1:1 group allocation.|t|f|t|t
33884679|NCT02244242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972712|NCT04835103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation; psychotherapy for patients with somatoform disorders (combined cognitive-behavioral treatment and biofeedback therapy)||||
33972713|NCT01413399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972714|NCT04935775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884680|NCT01726088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884681|NCT00570102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884682|NCT05538611|||CASE_CONTROL||RETROSPECTIVE|||||||
33884683|NCT00501982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884684|NCT01679041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884685|NCT03198130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884686|NCT01793402|||COHORT||PROSPECTIVE|||||||
33884687|NCT04881123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884688|NCT06447428|||COHORT||PROSPECTIVE|||||||
33884689|NCT00165958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884690|NCT01682850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884691|NCT05768490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884692|NCT01734317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884693|NCT00814814|||COHORT||OTHER|||||||
33884694|NCT01273545|||COHORT||RETROSPECTIVE|||||||
33884695|NCT00666926|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972715|NCT04347447|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||three intervention groups|t|f|f|f
33972716|NCT00968383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972717|NCT05909267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33972718|NCT01584609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972719|NCT01182818|||COHORT||PROSPECTIVE|||||||
33972720|NCT03060720|||OTHER||PROSPECTIVE|||||||
33972721|NCT04473508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972722|NCT00383604|||COHORT||PROSPECTIVE|||||||
33884696|NCT04849572|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a permuted block randomization study to assess the efficacy of the new intervention and the primary outcome variable is the sleep time. A total of 100 subjects (50 per group) will be randomized to each treatment group, stratified by gender. The first group will receive the intervention and be enrolled into the trial after the run-in period and the baseline data collection, and the second group will receive the intervention at 6 weeks after trial start.||||
33884697|NCT00097357|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33884698|NCT03961711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884699|NCT01902732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884700|NCT02883244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33884701|NCT04304131|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33884702|NCT00123565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884703|NCT04635306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884704|NCT05693415|||CASE_CONTROL||RETROSPECTIVE|||||||
33884705|NCT04082663|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive a custom-fitted dental mouthpiece and asked to wear the mouthpiece for one month.||||
33884706|NCT01386333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884707|NCT02366507|||CASE_CONTROL||PROSPECTIVE|||||||
33884708|NCT04357457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972723|NCT02029209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33972724|NCT05477329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a controlled, randomized, double-masked trial. The Test group will wear the myopia control spectacle lens and the Control group will wear the single vision spectacle lens.|This will be a controlled, randomized, double-masked trial. The Test group will wear the myopia control spectacle lens and the Control group will wear the single vision spectacle lens.|t|t|t|f
33972725|NCT01394458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972726|NCT02028000|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33972727|NCT00280436|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33972728|NCT03306576|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant will receive 2 matched restorations, one of each material.||||
33972729|NCT03213756|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-label, prospective, controlled, randomized, multicenter study in parallel groups, where in the preoperative AVF period, one group of patients will perform an isometric exercise protocol for 8 weeks and will be compared with a control group of patients that will not perform this preoperative exercise||||
33972730|NCT06042283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972731|NCT04464694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972732|NCT02629874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33972733|NCT04774575|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a 12-month follow-up multicenter, randomized, biomarker strategy design trial, whereby kidney transplant patients will be randomized 1:1 at the time of transplantation in 2 study groups:~* Group I (routine group): Patients will follow a standard clinical follow-up based on kidney allograft function (serum creatinine, estimated glomerular filtration rate (eGFR), proteinuria) and a surveillance allograft biopsies performed at 3 and 12 months after transplantation (M3 and M12).~* Group II (biomarker guided follow-up): Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed.~In both groups, a biopsy can be performed up on clinical decision if needed."||||
33972734|NCT04634110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972735|NCT06057285|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33972736|NCT02637076|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be recruited to fill 2 separate study groups: 1) participants with a diagnosis of narcolepsy with cataplexy; 2) healthy controls.||||
33972737|NCT06035783|||COHORT||PROSPECTIVE|||||||
33972738|NCT06296420|||COHORT||PROSPECTIVE|||||||
33972739|NCT05489484|NA|SINGLE_GROUP||TREATMENT||NONE||one sample study||||
33972740|NCT01236170|||COHORT||CROSS_SECTIONAL|||||||
33972741|NCT02680795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972742|NCT03804320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972743|NCT00993616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972744|NCT00672620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972745|NCT03880279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972746|NCT04811261|NA|SINGLE_GROUP||OTHER||NONE||Subjects will be entered into a 3+3 dose escalation study, a standard design for initial trials to evaluate tolerability of a therapeutic agent and identify a maximal tolerated dose if indeed toxicities are identified in the pre-specified dosing range.||||
33972747|NCT02151097|||||PROSPECTIVE|||||||
33972748|NCT04106375|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One group of 25 currently remitted recurrent major depression patients undergoing mindfulness based cognitive therapy for 8 weeks and one group of 25 matched healthy controls to control for time-repetition effects on brain activity and task performance||||
34071791|NCT04332003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The subject and principle investigator will remain blinded throughout the trial. Every site will have a designated unblinded study coordinator. The unblinded coordinator will choose the appropriately labeled device for the subject during the weekly SOC visits. The patient will place the cuff and operate the device under the direction of the unblinded coordinator. The principle investigator is prohibited from entering the room during the treatment. The unblinded coordinator will place a sign on the outside of the study room door stating, Do not enter. Study in Progress."|LifeCuff device includes a controller attached to a standard inflatable cuff used for blood pressure measurements.The controller includes a controller electronics board connected to a pneumatic assembly designed to automatically inflate and deflate the cuff to desired air pressures while monitoring and analyzing the oscillometric pulsations modulating the cuff pressure as captured by the system's pressure transducer. LifeCuff can be battery-powered or connected by an adaptor to a house electrical outlet.|t|f|t|f
34071792|NCT03932916|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34071793|NCT05964920|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34071794|NCT04873635|||CASE_ONLY||PROSPECTIVE|||||||
34071795|NCT03289013|NA|SINGLE_GROUP||OTHER||NONE||||||
34071796|NCT03114085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071797|NCT04098796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071798|NCT00516685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071799|NCT02426034|NA|SINGLE_GROUP||TREATMENT||NONE||A large-scale single-arm phase IV study||||
34071800|NCT03206827|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760767|NCT03270514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation in double-blind fashion||t|t|t|t
33760768|NCT04729894|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760769|NCT04773158|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Will perform cluster randomization by clinic. The unit of randomization will be the clinic site, but the unit of analysis will be the individual patient.||||
33760770|NCT00740558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33760771|NCT04660422|||COHORT||OTHER|||||||
33760772|NCT02761109|||COHORT||PROSPECTIVE|||||||
33760773|NCT00893243|||COHORT||PROSPECTIVE|||||||
33760774|NCT01074606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760775|NCT04978974|NA|SINGLE_GROUP||TREATMENT||NONE||The patients with chronic conditions which included type 2 diabetes and hypertension were selected through purposive sampling technique||||
33760776|NCT06342180|||CASE_CONTROL||PROSPECTIVE|||||||
33760777|NCT01279343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760778|NCT05943769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760779|NCT04999644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33760780|NCT04106232|||COHORT||PROSPECTIVE|||||||
34071801|NCT01423929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760781|NCT06056609|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33760782|NCT03642938|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pseudo-randomized controlled trial||||
34071802|NCT05102071|||COHORT||RETROSPECTIVE|||||||
34071803|NCT06067581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071804|NCT06357520|NA|SINGLE_GROUP||OTHER||NONE||||||
33884709|NCT01912209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884710|NCT02514967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884711|NCT06350214|||COHORT||RETROSPECTIVE|||||||
33884712|NCT00331500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884713|NCT00132730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884714|NCT06496672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884715|NCT00781157|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33884716|NCT01975922|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884717|NCT02917967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884718|NCT02776241|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884719|NCT03064672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884720|NCT01533675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33884721|NCT03064490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884722|NCT06375343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase I, controlled, comparative, single-blind, single-center, comparative clinical trial.|t|t|t|t
33884723|NCT02986594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071805|NCT04691804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P|t|t|t|f
34071806|NCT06003075|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Chemo, biopsy, surgery with option for post op chemo or no surgery with concurrent chemo||||
34071807|NCT02714556|||COHORT||PROSPECTIVE|||||||
34071808|NCT06037018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071809|NCT03595059|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34071810|NCT00065702|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34071811|NCT01066312|||OTHER||OTHER|||||||
34071812|NCT03629808|||COHORT||PROSPECTIVE|||||||
34071813|NCT01322087|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34071814|NCT03046771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071815|NCT03029455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071816|NCT02981914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071817|NCT02482545|RANDOMIZED|PARALLEL||||NONE||||||
34071818|NCT04633772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071819|NCT01442350|||COHORT||PROSPECTIVE|||||||
34071820|NCT03770026|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34071821|NCT02429102|RANDOMIZED|PARALLEL||||DOUBLE||||||
34071822|NCT01859949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071823|NCT02117219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071824|NCT01012583|||CASE_CONTROL||PROSPECTIVE|||||||
33884724|NCT02313129|||CASE_CONTROL||PROSPECTIVE|||||||
33884725|NCT03834532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants enrolled in the study will complete a baseline survey. Participants will then be randomized to receive a breast reconstruction decision aid or an educational website on healthy living with breast cancer. Participants will complete a second survey after viewing the assigned material. Participants may be invited to complete a third survey six months after surgery.|Participants enrolled in the study will complete a baseline survey. Participants will then be randomized to receive a breast reconstruction decision aid or an educational website on healthy living with breast cancer. Participants will complete a second survey after viewing the assigned material. Participants may be invited to complete a third survey six months after surgery.|t|f|f|f
33884726|NCT03118596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884727|NCT02132351|||COHORT||PROSPECTIVE|||||||
33884728|NCT01940666|||CASE_CONTROL||RETROSPECTIVE|||||||
33884729|NCT01790048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884730|NCT02847754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884731|NCT03454854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884732|NCT05533892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884733|NCT04342728|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single-center, prospective, open label four arm study (1. Zinc only 2. Zinc and ascorbic acid 3. Ascorbic acid only 4. Standard of care.||||
33884734|NCT04846361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the trial hygiene wash and placebo wash are labelled A or B in identical packaging by manufacturer's company and blinded from both participants and investigators and only revealed at the end of data completion|hygiene wash plus antibiotic, placebo wash plus antibiotic|t|f|t|f
33884735|NCT00962026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884736|NCT01743638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884737|NCT05490797|RANDOMIZED|PARALLEL||TREATMENT||NONE||total 22 participants will be enrolled. In experimental group app based training will be performed along with conventional hand fine motor skills and dexterity therapy. Conventional hand therapy will be given to the second group.||||
33884738|NCT01348373|||COHORT||PROSPECTIVE|||||||
33884739|NCT01027533|||||PROSPECTIVE|||||||
33884740|NCT04018079|||COHORT||OTHER|||||||
33884741|NCT05361629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071825|NCT05166226|||CASE_ONLY||PROSPECTIVE|||||||
34071826|NCT05568797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071827|NCT06542900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071828|NCT04087902|||COHORT||PROSPECTIVE|||||||
34071829|NCT03243253|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34071830|NCT04993872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071831|NCT03787602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071832|NCT03451955|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071833|NCT03457818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Clinical Research Coordinators|The study is a 12 month randomized (2:1 assignment) double-blind placebo-controlled trial of T2D postmenopausal women assigned to either Denosumab 60 mg subcutaneously (SC) at baseline and 6 months (n=44) or placebo (n=22); total study n=66.|t|f|t|f
34071834|NCT04569929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071835|NCT00760487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071836|NCT03327038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34071837|NCT00362661|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34071838|NCT04854759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071839|NCT02768792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760783|NCT00485225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760784|NCT01623258|||COHORT||PROSPECTIVE|||||||
33760785|NCT04539314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760786|NCT02231866|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760787|NCT04098406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The drug formulations were identical in appearance (size, shape, volume, color) and smell. The packaging and labeling were designed to maintain blinding to the Investigator's team and to patients. There are no visible differences between the active drug, and placebo dosing units|randomized, double-blind, parallel group, placebo-controlled study|t|t|t|t
33884742|NCT06176157|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33760788|NCT03337932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760789|NCT03587142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants, all clinic staff and the investigators will be masked as to whether the participant is receiving buspirone or the placebo.~The study drug will be over encapsulated in a size 0 gelatin capsule with partial filler to be identical to the placebo capsule, which contains only filler.~The random treatment assignment will consist of a numbered study drug bottle; each bottle number will be unique and each participant will be assigned a specific bottle number, which is labelled: Buspirone or placebo 10 mg. with directions.~The randomization scheme will assign participants in randomly permuted blocks of assignments stratified by clinical center. The randomization plan will be prepared and administered centrally via a secure web application by the Scientific Data Research Center."|BESST is a multi-center, randomized, placebo-controlled, double-masked, parallel treatment groups phase 2 trial with half the participants receiving the study drug, buspirone, and half receiving the placebo.|t|t|t|f
33760790|NCT01892345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760791|NCT02953743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760792|NCT00108238|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33760793|NCT04392063|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, cohort study||||
33760794|NCT03306901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors and data analysists will be blinded||f|f|f|t
33760795|NCT03884114||SEQUENTIAL||OTHER||NONE||All medical students are evaluated using a high-fidelity simulation environment, then using a serious game, then using multiple choice questionnaire, all on the same topic.||||
33760796|NCT03753451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760797|NCT05516225|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33760798|NCT02800967|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33884743|NCT01931059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33884744|NCT06089447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The children and young people will not know which group they have been assigned to.||t|f|f|f
33884745|NCT02312947|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33760799|NCT06441747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760800|NCT04192084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760801|NCT00659490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760802|NCT06246448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33765025|NCT03237520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be masked to the group allocation and the intervention|An open labeled, randomized controlled, parallel design, superiority trial|f|f|f|t
33765026|NCT01535742|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33884746|NCT05529563|||OTHER||RETROSPECTIVE|||||||
33884747|NCT01305863|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33884748|NCT00449709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884749|NCT04462198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The dose preparer and treatment administrator will be unmasked.||t|f|f|t
33884750|NCT01869647|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33884751|NCT03336255|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33760803|NCT04194567|RANDOMIZED|CROSSOVER||OTHER||NONE||The study will have a randomized, cross-over design and will be conducted at the Human Nutrition Laboratory, ETH Zurich (scientific responsibility). From an initial screening of 150 women, 25 non-pregnant non-lactating women with a marginal iron status (PF \<25 ng/ml) will be recruited. In total, participants will consume the 2 intervention products in a random, balanced order. Participants will consume the first intervention product as a breakfast meal for 5 days in a week, and the second intervention product as a breakfast meal as well for 5 days the following week. A blood sample will be collected 14 days after the last meal administration day which will be used to measure the shift in the isotopic ratio||||
33760804|NCT06057207|||CASE_CONTROL||PROSPECTIVE|||||||
33765027|NCT03135561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33765028|NCT02799225|||COHORT||PROSPECTIVE|||||||
33765029|NCT06257355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765030|NCT00242801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33765031|NCT00642798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765032|NCT04035200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33765033|NCT02893306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765034|NCT02565121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765035|NCT01934998|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884752|NCT02624492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884753|NCT03905863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884754|NCT03396094|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study consists of 2 arms (intervention and control) of parallel design. The intervention arm will receive high flow nasal cannula (HFNC) oxygenation at 60L/min for pre- and apnoeic oxygenation while the control arm will receive pre-oxygenation via non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min.||||
33884755|NCT03797105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884756|NCT04515966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884757|NCT02690623|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884758|NCT00510185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884759|NCT05091320|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||case control|t|f|f|f
33972749|NCT00385541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972750|NCT03248856|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972751|NCT01765985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972752|NCT00326079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972753|NCT03522948|NA|SINGLE_GROUP||PREVENTION||NONE||Open pilot study to test feasibility of intervention||||
33972754|NCT06484556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972755|NCT01410318|||COHORT||PROSPECTIVE|||||||
33972756|NCT02516566|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33972757|NCT05312645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972758|NCT04916925|NA|SINGLE_GROUP||TREATMENT||NONE||a single arm clinical trail||||
33972759|NCT01730677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972760|NCT04368442|||COHORT||PROSPECTIVE|||||||
33972761|NCT00838474|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33972762|NCT05279014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33972763|NCT04402554|||COHORT||OTHER|||||||
33972764|NCT00282555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33972765|NCT01557595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972766|NCT04243174|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Group where they start receiving SMS messages about the importance of physical activity and its benefits on T2DM.||||
33972767|NCT00533403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33972768|NCT01958281|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972769|NCT01352754|||COHORT||PROSPECTIVE|||||||
33972770|NCT00736320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972771|NCT05152342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972772|NCT00582751|||COHORT||PROSPECTIVE|||||||
33972773|NCT02519283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33840765|NCT06341686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"1. Patients randomized to the prophylaxis group: Letermovir 480mg, 1x/day, from D14 to D98. Letermovir prophylaxis will start on day 14 after the kidney transplant.~2. Patients randomized to the preemptive treatment group: Preemptive treatment (PET) will begin on day 21, evaluating CMV DNAnemia weekly until D98.CMV DNAnemia weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98). The threshold for starting treatment with Ganciclovir is a CMV DNAemiaDNAemia \> 5,000 IU in a single measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (CMV syndrome or disease).~3. In both groups, CMV DNAemia will be monitored weekly until day 98 (21, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91 and 98), and after any acute rejection treatment occurring between 3 months and 6 months after kidney transplantation."|t|f|f|f
33972774|NCT05043233|||COHORT||PROSPECTIVE|||||||
33972775|NCT03291457|||COHORT||PROSPECTIVE|||||||
33972776|NCT01862809|||CASE_CONTROL||OTHER|||||||
33972777|NCT00580853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972778|NCT01144884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972779|NCT01555502|||COHORT||PROSPECTIVE|||||||
33972780|NCT01865513|||COHORT||PROSPECTIVE|||||||
33972781|NCT05544747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33972782|NCT01704664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972783|NCT01292200|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33972784|NCT06398782|||COHORT||PROSPECTIVE|||||||
33972785|NCT04212702|||CASE_ONLY||PROSPECTIVE|||||||
33972786|NCT00981253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972787|NCT04087668|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33972788|NCT03862599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking of probe applicator at device manufacturer before ESWT use|Randomised controlled trial|t|t|t|t
33972789|NCT02661126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972790|NCT00794261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972791|NCT04902274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33972792|NCT05074186|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33972793|NCT03404076|||CASE_ONLY||PROSPECTIVE|||||||
33972794|NCT03563950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972795|NCT04179591|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33972796|NCT00264810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33972797|NCT03553784|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A pragmatic non-randomized controlled design.||||
33972798|NCT01501799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972799|NCT06544993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972800|NCT01632787|||COHORT||PROSPECTIVE|||||||
33972801|NCT05911230|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||one-arm, monocentric pilot trial||||
33972802|NCT00673985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972803|NCT03064542|||COHORT||OTHER|||||||
33972804|NCT05022836|||COHORT||PROSPECTIVE|||||||
33972805|NCT02405910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972806|NCT06158061|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33972807|NCT03463356|NA|SINGLE_GROUP||TREATMENT||NONE||non-concurrent multiple baseline design||||
33972808|NCT04336956|||COHORT||OTHER|||||||
34071840|NCT02096562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071841|NCT00114829|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33884760|NCT03980366|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects and their legally-appointed guardians will participate in a total of 18 visits over the course of 1 year. Visits 1 and 2 will occur during weeks 1 and 2. These visits will be for psychiatric and medical evaluations and will take about 1 hour each. Visits 3-14 will take place three times a week for four weeks. These visits will be for the ECT treatments and will take about 2-3 hours each. Visit 15 will take place 1 week post-treatment and visit 16 will take place 4 weeks post-treatment. Guardians will keep a daily diary card between visits 1 and 16, spanning a time of 10 weeks. Visits 17 and 18 will take place at 6 months and 12 months, respectively, and take about 1 hour each.||||
33884761|NCT00782548|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33884762|NCT01172015|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884763|NCT04151979|||COHORT||CROSS_SECTIONAL|||||||
33884764|NCT02794220|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33972809|NCT05159310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study methodology will be a non-inferiority randomized controlled trial (RCT). A non-inferiority design was selected because it is unlikely that splints are superior to casts with regards to the primary outcome - final functional outcome at 12 months. Both intention-to-treat and per-protocol analyses will be performed.|f|f|f|t
33972810|NCT01165996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972811|NCT01658475|||COHORT||PROSPECTIVE|||||||
33972812|NCT04556110|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33972813|NCT02931812|||COHORT||PROSPECTIVE|||||||
33972814|NCT06482463|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33972815|NCT01903486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972816|NCT04884958|||COHORT||PROSPECTIVE|||||||
33760805|NCT03367507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be blinded to group assignment, as it would be impossible to make them unaware of how intense their exercise prescription should be but they will be blinded to the other treatment assignment and masked to the study hypothesis. The treating sport medicine physician will be blinded to group assignment. There will be an exercise physiologist who will be responsible for conducting the treadmill tests and, prescribing aerobic exercise programs. The study exercise physiologist will not be blinded and will not relay any information pertaining to group assignment to other members involved in the study other than the participants themselves and their parents. Those assessing adverse events will not be masked and if needed to facilitate clinical care the managing physician will be made aware of the treatment group. Compliance will be tracked through the use of Actigraph accelerometers, heart rate monitors and daily activity logs.|Research statement:This study is a multi-centre RCT. The purpose of the RCT is to evaluate the efficacy of a moderate intensity (80% symptom threshold HR, Borg RPE 12-16) sub-symptom aerobic exercise prescription compared to a lower level aerobic exercise group (60% HR, Borg RPE 7-11) on time to medical clearance to receive medical clearance to return to play in adolescents (aged 13-19) with suggested physiological Post-Concussion Disorder (P-PCD).|f|f|t|t
33760806|NCT03909178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760807|NCT04294992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760808|NCT01718093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760809|NCT05731089|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective||||
33760810|NCT06038955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study has a double-blinded design. Neither the participant nor the outcome-assessors will know whether the participant is receiving VR-based cognitive remediation or VR control treatment|Randomized, controlled, double-blinded, parallel-group design|t|f|f|t
33760811|NCT00746096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760812|NCT04654039|||COHORT||PROSPECTIVE|||||||
33884765|NCT02000141|||COHORT||PROSPECTIVE|||||||
33760813|NCT00131339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33760814|NCT00847405|RANDOMIZED|CROSSOVER||||NONE||||||
33760815|NCT04484025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760816|NCT02986607|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760817|NCT01715974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760818|NCT01875939|RANDOMIZED|CROSSOVER||||NONE||||||
33760819|NCT00335257|||COHORT||PROSPECTIVE|||||||
33760820|NCT05631184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers who perform the assessment and analysis will be blinded to group allocation.|"Two-arm parallel assignment involves two groups of participants. In this study, one group will receive self-administered acupressure, and the other group will receive the mental health education. So during the trial, participants in one group receive self-administered acupressure in parallel to participants in the other group, who receive the mental health education."|f|f|f|t
33760821|NCT06580015|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33760822|NCT03135665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760823|NCT05593757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760824|NCT03295903|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33760825|NCT03112941|RANDOMIZED|PARALLEL||TREATMENT||NONE||164 patients with traumatic incomplete spinal cord injury (SCI) were recruited in the plateau from June 2012 to February 2016.||||
33760826|NCT03852238|||CASE_CONTROL||PROSPECTIVE|||||||
33760827|NCT02329184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760828|NCT00153855|||DEFINED_POPULATION||PROSPECTIVE|||||||
33760829|NCT05292534|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33884766|NCT04687501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884767|NCT05596019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind masking with blinded assessor.|Longitudinal prospective, controlled, single-blind study|t|f|f|t
33884768|NCT02337803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884769|NCT03015805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884770|NCT01815541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884771|NCT05635890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|t|f|t|f
33884772|NCT04523532|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884773|NCT05927883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884774|NCT01420484|||COHORT||PROSPECTIVE|||||||
33760830|NCT02106585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760831|NCT03156322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760832|NCT04413591|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760833|NCT05556174|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33760834|NCT01446484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760835|NCT00390104|||FAMILY_BASED||PROSPECTIVE|||||||
33760836|NCT06484270|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participant: patients undergoing surgery in post-op 0 and 1 Care provider: surgical nurses|An experimental and follow-up study a pre-test, post-test with control group.|t|t|f|f
33760837|NCT01533701|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972817|NCT01809054|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972818|NCT06531174|||COHORT||PROSPECTIVE|||||||
33972819|NCT00588393|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760838|NCT04392778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760839|NCT03108157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760840|NCT00181571|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33760841|NCT01450748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760842|NCT04426396|||COHORT||PROSPECTIVE|||||||
33760843|NCT00258999|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760844|NCT02955030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33760845|NCT01848379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33760846|NCT04462315|||COHORT||PROSPECTIVE|||||||
33760847|NCT06001502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33760848|NCT03319784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes.||t|f|f|f
33760849|NCT00118781|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33760850|NCT06260930|||CASE_ONLY||CROSS_SECTIONAL|||||||
33760851|NCT02301351|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33760852|NCT00061763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760853|NCT01750879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33760854|NCT06229834|RANDOMIZED|PARALLEL||OTHER||DOUBLE|While participants, treating chiropractors, study coordinators, and research assistants will be unblinded to treatment assignment, study investigators who are not involved in providing chiropractic care treatments or monitoring adverse events will be blinded. The blinding of these investigators and the programmer will only be broken after approval of the final statistical analysis plan and locking of the trial data.|A two-arm pilot randomized attention-controlled trial at two sites which are representative of sites to be included in the future large-scale trial (Osher Clinic, BWH, and VA Medical Center, West Haven, CT). We will recruit and randomize 60 individuals (30 per site). Individuals will be randomized (1:1) to: 1) 14 sessions of CC (6 sessions of chiropractic care over 3 weeks followed by 8 sessions of chiropractic care (CC) over 12 weeks); or 2) 14 sessions of headache health education (15-minute 1:1 virtual sessions focused on pre-defined migraine-specific topics) - both added to usual medical care. Individuals will be followed for 4 weeks after the end of their intervention period.|f|f|t|t
33760855|NCT04149990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760856|NCT05217095|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33760857|NCT05634239|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760858|NCT02044627|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760859|NCT05873543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760860|NCT00946335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760861|NCT00286117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760862|NCT05809713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized trial||||
33760863|NCT03091686|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33972820|NCT02915679|NA|SINGLE_GROUP||OTHER||NONE||||||
33972821|NCT04593290|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33884775|NCT03545256|NA|SINGLE_GROUP||TREATMENT||NONE||"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloide labeled with technetium99, around the primary tumor.~- Surgery on D0: The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG."||||
33884776|NCT01360645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884777|NCT02460211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884778|NCT02000804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884779|NCT01493180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33884780|NCT01983787|||CASE_ONLY||PROSPECTIVE|||||||
33884781|NCT02641535|NA|SINGLE_GROUP||||NONE||||||
33884782|NCT02452762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884783|NCT01822002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884784|NCT06348563|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33884785|NCT01512940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884786|NCT02052557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33884787|NCT01208090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884788|NCT00224536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884789|NCT05859477|NA|SINGLE_GROUP||TREATMENT||NONE||Nivolumab in combination with chemotherapy||||
33884790|NCT02174718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884791|NCT04283903|||COHORT||PROSPECTIVE|||||||
33760864|NCT00446069|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33884792|NCT04110041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884793|NCT04634266|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Prospective, controlled, multicenter, randomized, open label trial|f|f|t|f
33884794|NCT03728205|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884795|NCT06239129|||COHORT||PROSPECTIVE|||||||
33760865|NCT01908465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760866|NCT00666432|||FAMILY_BASED||OTHER|||||||
33760867|NCT01615679|||COHORT||PROSPECTIVE|||||||
33760868|NCT03224221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760869|NCT05514080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760870|NCT01106053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760871|NCT03899168|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33760872|NCT02946840|||COHORT||PROSPECTIVE|||||||
33760873|NCT05322525|NA|SINGLE_GROUP||OTHER||NONE||The study consists of 3 periods, a Screening/Run-in period, a treatment period, and a follow-up period.||||
33760874|NCT00724464|||CASE_ONLY||RETROSPECTIVE|||||||
33760875|NCT04751422|||CASE_ONLY||RETROSPECTIVE|||||||
33760876|NCT03299686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760877|NCT06468033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33760878|NCT06510725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760879|NCT01780935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760880|NCT01572064|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33760881|NCT00595504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884796|NCT00453466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33884797|NCT06542146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884798|NCT04036669|||COHORT||RETROSPECTIVE|||||||
33884799|NCT03597165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884800|NCT04696640|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33972822|NCT06008405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972823|NCT01460927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972824|NCT03650400|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be 2 treatment dose cohorts studied (fevipiprant dose A once daily and one higher dose selected based on PK obtained at dose A mg/day, fevipiprant dose B once daily). Within each dose cohort, subjects will be stratified approximately 1:1 ratio into 2 age groups: ages 6 to \< 9 years and ages 9 to \< 12 years.||||
33760882|NCT03243162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760883|NCT00170833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33760884|NCT02076984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760885|NCT01691521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760886|NCT00626366|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33760887|NCT00582946|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33884801|NCT01560273|||COHORT||PROSPECTIVE|||||||
33884802|NCT00000704||||TREATMENT||NONE||||||
33884803|NCT05655377|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33972825|NCT06239922|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33972826|NCT03189797|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A total number of 144 high caries risk dental students are selected based on the applied caries risk assessment method (CAMBRA). In the study group they are given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) in addition to fluoride mouth rinse. For the clinical approach motivational engagement isdone by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year.application of fluoride varnish every 6 months and dietary intake interventions.~In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study."||||
33972827|NCT02477761|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972828|NCT03951428|||CASE_CONTROL||RETROSPECTIVE|||||||
33972829|NCT04224090|||CASE_ONLY||PROSPECTIVE|||||||
33972830|NCT01454700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972831|NCT04817592|||COHORT||PROSPECTIVE|||||||
33972832|NCT03971942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972833|NCT05719714|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 subjects will be randomized to intervention. 30 subjects will be randomized to standard of care.||||
33972834|NCT02266836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972835|NCT03690479|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34071842|NCT05607888|||COHORT||PROSPECTIVE|||||||
34071843|NCT03130374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071844|NCT04321486|||COHORT||PROSPECTIVE|||||||
34071845|NCT06478329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34071846|NCT04909515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071847|NCT05314829|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34071848|NCT01486823|NON_RANDOMIZED|PARALLEL||||NONE||||||
34071849|NCT02164318|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071850|NCT00565552|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884804|NCT04167475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884805|NCT01668654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884806|NCT00243997|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33884807|NCT05589285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884808|NCT02256930|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33884809|NCT02250209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884810|NCT02816879|NA|SINGLE_GROUP||SCREENING||NONE||||||
33884811|NCT00772447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33884812|NCT01481896|||COHORT||RETROSPECTIVE|||||||
34071851|NCT00170274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071852|NCT00767598|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34152247|NCT03514433|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"A randomized cluster stepped wedge design will be conducted. This pragmatic design involves a sequential, randomized roll-out of the intervention across 5 participating clinical sites or clusters over 3 month intervals or steps. Consistent with a stepped wedge design with one cluster per step, prior to the collection of data in the pre-intervention period, the investigators will generate a set of uniform random numbers for each of the five clusters to assign a starting period for the study intervention. There will be no crossover of patients from usual care to the intervention. That is, patients at each site during the pre-intervention period will experience only usual care and will act as historical controls and those enrolled after the initiation of intervention will experience the intervention."|f|f|f|t
33760888|NCT01988272|||CASE_ONLY||PROSPECTIVE|||||||
33760889|NCT04151784|||COHORT||CROSS_SECTIONAL|||||||
33760890|NCT01873261|||COHORT||PROSPECTIVE|||||||
33760891|NCT04465279|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, non-comparative, non-randomized study including 36 eyes had implantation of trifocal diffractive IOL||||
33760892|NCT03802643|||COHORT||PROSPECTIVE|||||||
33840766|NCT05400577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840767|NCT06419153|||COHORT||PROSPECTIVE|||||||
34071853|NCT03343366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A parallel group, single blind three-arm design randomized controlled trial (RCT) will be conducted. The examiners, both for periodontal examination and laboratory investigations will be blinded.|This multi-centric randomized controlled trial (RCT) will be conducted on the baseline sample derived from periodontal clinics of dental institutes of Dow University of Health Sciences. More than 1000 patients will be screened to recruit 150 calculated sample participants (with 50 in each group) with reference to 0.7%, 0.6% reduction and no reduction (0.06%) in the baseline mean HbA1c over a period of 3 months among SRP+AAT, SRP Only and no treatment groups respectively(48) the calculated sample size is 35 in each group (1:1:1) with 99% power of test and 99% confidence interval. Adding 40% dropout rate expected over 6-months follow-up, 49 participants in each group will be required that will be rounded off to 50 in each group (with a ratio of 1:1:1).|f|f|t|f
34071854|NCT02568462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071855|NCT05110365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071856|NCT01792102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071857|NCT01409915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071858|NCT01639248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071859|NCT06260917|||OTHER||PROSPECTIVE|||||||
34071860|NCT01199887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071861|NCT03597191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The primary investigator (PI) of this study, the outcomes assessor, will be blinded to participants' group assignment and will perform the eligibility screening and standard physical therapy examination for all participants. In addition, the PI will perform the pre- and post-intervention measurements of dynamic balance using the Y- balance test, functional performance using Functional Movement Screen, pain scores using the Numeric Pain Rating Scale, and disability levels using the Modified Oswestry Low Back Pain Disability Questionnaire.~Investigator #2, the care provider, will be blinded to the outcomes measurements and will be responsible for group allocation and administering the intervention, either a spinal stabilization exercises program or a general exercises program, to participants in both groups.~Participants will be randomly assigned to one of the two study groups and will be blinded to the other group exercise program."|"This study will be a randomized clinical trial (RCT) using a prospective two-way (2 × 4) mixed-design to examine the effectiveness of spinal stabilization exercises (SSEs) on dynamic balance, functional performance, pain intensity, and disability level in adults with sub-acute and chronic low back pain (LBP).~The two independent variables are group, which is a between-subject factor, and time which is a within-subject factor. The independent variable of group has two levels: (1) the treatment group which will receive SSEs, and (2) the placebo group which will receive general range of motion and flexibility exercises.~The independent variable of time has four levels: pre-intervention at baseline, and two weeks, four weeks, and eight weeks after intervention.~The four dependent variables are (1) dynamic balance, (2) functional performance, (3) pain intensity, and (4) disability level."|t|t|f|t
34071862|NCT00397189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071863|NCT02104245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071864|NCT01504373|||COHORT||PROSPECTIVE|||||||
34071865|NCT04462822|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
34071866|NCT01212146|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34071867|NCT03790865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071868|NCT05098366|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Randomized controlled trial|t|f|f|f
34071869|NCT06549192|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071870|NCT06269146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacy will blind drug and placebo through identical encapsulation. Placebo will match the study drug in mode of administration, color, size, and taste.||t|t|t|t
34071871|NCT02358265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071872|NCT02329236|||COHORT||PROSPECTIVE|||||||
34071873|NCT05305456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071874|NCT01721447|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071875|NCT04547686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152248|NCT00366327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152249|NCT06190080|NA|SINGLE_GROUP||OTHER||NONE||||||
34152250|NCT00771056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152251|NCT02379468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152252|NCT01042652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152253|NCT04904848|||CASE_ONLY||OTHER|||||||
34152254|NCT06137599|||COHORT||PROSPECTIVE|||||||
34152255|NCT02989285|||COHORT||PROSPECTIVE|||||||
34152256|NCT05240521|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34152257|NCT03090672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152258|NCT06203587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152259|NCT01781780|RANDOMIZED|PARALLEL||||NONE||||||
34152260|NCT05753163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152261|NCT04005079|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The Treatment Group will use 2% pilocarpine in the postoperative period in addition to standard post-operative drops (Prednisolone acetate and Ofloxacin). The Control Group will use only Prednisolone acetate and Ofloxacin, without pilocarpine."||||
34152262|NCT06329024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152263|NCT00302913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152264|NCT01919736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34152265|NCT03344627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972836|NCT04249089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972837|NCT00774358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972838|NCT05566665|||CASE_ONLY||PROSPECTIVE|||||||
33972839|NCT04457869|NA|SINGLE_GROUP||TREATMENT||NONE||F520||||
33972840|NCT00446498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972841|NCT03350048|||COHORT||PROSPECTIVE|||||||
33972842|NCT05268978|||COHORT||PROSPECTIVE|||||||
33972843|NCT01894984|||COHORT||PROSPECTIVE|||||||
33972844|NCT03788265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972845|NCT01939600|NA|SINGLE_GROUP||||NONE||||||
33972846|NCT05287139|||OTHER||CROSS_SECTIONAL|||||||
33972847|NCT00213902|||||PROSPECTIVE|||||||
33972848|NCT01153061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972849|NCT04467697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972850|NCT04906603|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label pilot study||||
33972851|NCT04463433|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33972852|NCT01609660|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972853|NCT03522922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972854|NCT00186927|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972855|NCT05029583|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The care provider is masked to the primary outcome of the study, but not masked to the intervention.||f|t|f|f
33972856|NCT04676594|||OTHER||RETROSPECTIVE|||||||
33972857|NCT03133442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Blinding of the participants is impossible, as the stimulation is easy to perceive and cannot be confused with a baseline night. Therefore, participants are informed about the character of the night (max. 5 minutes) before the moment of lights off. For safety reasons the experimenter that is present is also aware of the condition.~However, data is stored in a coded way, so that during data analysis the experimenter is not aware of the condition."|The study has a two-by-two cross-over design. Participants spend two consecutive baseline nights (without stimulation) and two consecutive movement nights (with stimulation) in the laboratory. The order of baseline and movement nights is randomized.|f|f|t|t
33972858|NCT05716139|RANDOMIZED|PARALLEL||TREATMENT||NONE|Parallel group open labelled masking|Open labelled parallel group randomized Controlled Trial||||
34071876|NCT06194162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded to treatment allocation where possible. Researchers will be blinded through data management and analysis. By introducing a sham blanket, participants and parents will not be made aware of their assigned intervention during the trial.|"This study is designed as a randomised controlled trial with two parallel groups.~Participants will be randomly assigned 1:1 into two groups using computer-generated random numbers. The allocation sequence will be stratified by age (5-8 years vs 9-12 years), ADHD medication (yes vs no) and use of melatonin/sleep medication (yes vs no)."|t|f|f|t
34071877|NCT04062721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840768|NCT03452215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840769|NCT04016155|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33840770|NCT01933243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840771|NCT01827046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840772|NCT03332043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840773|NCT04640831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A: Dose ranging in four dose groups Part B: One group with individualized dosing||||
34071878|NCT00551395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071879|NCT04577794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760893|NCT04368650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomization involved the computerized generation of the allocation sequence in random permuted blocks (block randomization) and blinding was ensured by assigning the block of sites to study groups according to the specified sequence by a second operator who coded the two treatment sites selected from every patient by the first operator into the following groups|t|f|t|t
33760894|NCT04246983|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760895|NCT00194051|||||PROSPECTIVE|||||||
33760896|NCT01729884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760897|NCT06066281|||COHORT||PROSPECTIVE|||||||
33760898|NCT05718843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomised, single dose, open-label, individual-matched design.||||
33760899|NCT04444635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blindness will be achieved by patient codes which will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A physician not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anaesthesiologist who is expert in doing the serratus anterior plane block in patients included within the block group. This expert anaesthesiologist will not be involved in collecting data but another anaesthesia doctor will be responsible for patient management and collecting the intraoperative and postoperative data.||t|t|t|t
33760900|NCT00616356|||CASE_ONLY||CROSS_SECTIONAL|||||||
33884813|NCT06548659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A blind technique was used for the expert who would perform the statistical analysis of the study. The data were tabulated as groups A and B, without using the terms intervention and control group. Statistical analysis of the data was carried out by a statistician other than the person who performed the randomization. The hypotheses of the study were kept confidential in order to prevent the detection bias and risk of bias of the statistician. Thus, internal validity was ensured by randomization and blinding techniques.|Randomization took place among 198 people. While the intervention group was given training on pediatric medication practices with a screen-based simulation, the control group was not given simulation training at this stage of the study, and ended with training on pediatric medication practices, with the training that both groups received in the 2nd step.|f|f|f|t
33884814|NCT03466892|||COHORT||PROSPECTIVE|||||||
33884815|NCT00308607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071880|NCT03486405|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This study will be a randomized control trial crossover design.|t|f|f|f
34071881|NCT01808937|||COHORT||PROSPECTIVE|||||||
34071882|NCT00090870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071883|NCT04682379|||COHORT||PROSPECTIVE|||||||
34071884|NCT06231134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071885|NCT00321906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071886|NCT01017562|||CASE_CONTROL||PROSPECTIVE|||||||
34071887|NCT04301726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Placebo-controlled pilot study|t|f|t|t
34071888|NCT02049983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071889|NCT04633993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071890|NCT05132647|||COHORT||PROSPECTIVE|||||||
34071891|NCT01075919|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33884816|NCT03883737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884817|NCT00620243|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33884818|NCT05660733|||COHORT||CROSS_SECTIONAL|||||||
33884819|NCT04105777|||COHORT||PROSPECTIVE|||||||
33884820|NCT02892266|||COHORT||OTHER|||||||
33884821|NCT00200850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884822|NCT02796105|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884823|NCT02567929|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33884824|NCT03542058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884825|NCT06107556|||COHORT||RETROSPECTIVE|||||||
33884826|NCT05883280|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884827|NCT03442634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884828|NCT01187537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884829|NCT02583334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884830|NCT05233657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884831|NCT01494363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884832|NCT01239355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884833|NCT01484782|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884834|NCT02581254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884835|NCT04275115||SEQUENTIAL||TREATMENT||NONE||||||
34071892|NCT05858866|||OTHER||CROSS_SECTIONAL|||||||
34071893|NCT03026829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071894|NCT01877668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071895|NCT00587795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884836|NCT02298933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884837|NCT01056445||PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33884838|NCT01567098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884839|NCT02173119|||COHORT||PROSPECTIVE|||||||
33884840|NCT01836679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884841|NCT03728946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33884842|NCT03452566|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the toxicity profile and the maximum tolerated dose (MTD) of ingenol mebutate for treatment of actinic cheilitis and to determine the therapeutic response with a dose below the maximum tolerated dose (MTD). The MTD will be tested in the phase 2 stage of this study.||||
33884843|NCT05435898|||COHORT||PROSPECTIVE|||||||
33884844|NCT00652353|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34071896|NCT03339713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33884845|NCT01744132|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33884846|NCT02762513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884847|NCT03604185|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixty hearing aided older adults will be randomly assigned to one of three conditions: a choir singing class (n=20), a music appreciation class (n=20), and a do-nothing control group (n=20). Choir participants will take part in a singing class for 14 weeks, during which they will take part in group singing (2 hours/week) supported by individual online musical training (1 hour/week). Participants will undergo pre- and post-training assessments, conducted during the first week of the choir class and again after the last week. The music appreciation group will consist of hearing aided older adults attending 14 weeks of music listening classes, and the do-nothing control group will not be engaged in an active intervention. All participants will undergo the same battery of assessments, measured before and after the 14-week time frame.||||
33884848|NCT05977647|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomized into two groups.~1. A permuted block randomization technique will be used~2. A block represents a separate center/site of enrollment.~3. There will be 19 recruitment centers~4. Each center will enroll total 20-25 subjects"||||
33884849|NCT02596659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884850|NCT02128126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884851|NCT03169426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33884852|NCT00481845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884853|NCT00888238|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33884854|NCT00757731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884855|NCT03324360|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884856|NCT01821300|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884857|NCT04663178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|t|f|f|f
33884858|NCT04173741|||OTHER||PROSPECTIVE|||||||
33884859|NCT03903380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884860|NCT02072473|||COHORT||PROSPECTIVE|||||||
33884861|NCT02935309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884862|NCT06028633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884863|NCT01893333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884864|NCT00013286|||||PROSPECTIVE|||||||
33884865|NCT03932552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884866|NCT00019760||||TREATMENT||||||||
33884867|NCT03897738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33884868|NCT05130307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Although no deception is involved, participants who receive VR will remain unaware of the immersiveness of the VR systems they are receiving.|"A Mixed Model repeated measures ANOVA or non-parametric tests if appropriate will be conducted on worst pain ratings. Within subjects crossover design, VR treatment order randomized (some participants receive order 1 Low Tech VR + High Tech VR = Arm 1, some participants receive order 2 High Tech VR + Low Tech VR) = Arm 2.~. Treatment order 1: Low Tech/less interactive Virtual Reality for 1st brief pain stimulus+ washout period + High Tech for 2nd brief pain stimulus.~Treatment order 2: High Tech/more interactive VR for 1st brief pain stimulus + washout period + Low Tech for 2nd brief pain stimulus (Arm 2).."|t|f|f|f
33884869|NCT02940067|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884870|NCT02056158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884871|NCT06215833|||OTHER||PROSPECTIVE|||||||
33884872|NCT01775917|||||PROSPECTIVE|||||||
33884873|NCT04360356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study will be a double blind randomized controlled parallel study|t|f|t|f
33884874|NCT02912273|||COHORT||PROSPECTIVE|||||||
33760901|NCT06225856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760902|NCT00591201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760903|NCT01934803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33760904|NCT01536041|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33760905|NCT01847170|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760906|NCT02565719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760907|NCT02174887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760908|NCT01564368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33760909|NCT05924399|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33760910|NCT02985762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760911|NCT00525525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33760912|NCT02609321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760913|NCT03719794|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33760914|NCT00155584|||NATURAL_HISTORY||PROSPECTIVE|||||||
33760915|NCT05968014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||randomised-controlled trial with two parallel study groups. Participants will be randomised 1:1 to the PENG group or FICB group. The PENG group was treated with PENG block following randomisation, whereas the FICB group received a fascia iliaca compartment block.|f|f|f|t
33760916|NCT01036308|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33760917|NCT03975764|||OTHER||PROSPECTIVE|||||||
33760918|NCT01379976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760919|NCT03298282|||COHORT||PROSPECTIVE|||||||
33884875|NCT01284114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071897|NCT00346762|||COHORT||PROSPECTIVE|||||||
34071898|NCT00886366|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34071899|NCT04110886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071900|NCT03130959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071901|NCT00705341|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33760920|NCT03778034|||OTHER||CROSS_SECTIONAL|||||||
33760921|NCT04000620|||COHORT||PROSPECTIVE|||||||
33760922|NCT01323179|||COHORT||PROSPECTIVE|||||||
33760923|NCT04433962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760924|NCT02201056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071902|NCT03821077|||COHORT||PROSPECTIVE|||||||
33760925|NCT02484170|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||1 week observation, one week cream A assigned, 3 day crossover, one week of cream B assigned. After the crossover study, 3 months of mannitol cream assigned.|t|t|t|t
33760926|NCT01191840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760927|NCT01210521|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33760928|NCT00758459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760929|NCT01226511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760930|NCT02380222|||CASE_ONLY||CROSS_SECTIONAL|||||||
33760931|NCT02434289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33760932|NCT02346396|NA|SINGLE_GROUP||TREATMENT||SINGLE|"Efficacy will be assessed in a single-blind trial, with each patient receiving a series of placebo stimulations to check the clinical reality of the effects on pain."||t|f|f|f
33760933|NCT01091402|||CASE_CONTROL||PROSPECTIVE|||||||
33760934|NCT06487598|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple||t|t|t|t
33760935|NCT02268695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760936|NCT01986881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760937|NCT06520943|||COHORT||PROSPECTIVE|||||||
33760938|NCT01040143|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33760939|NCT03354364|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33760940|NCT04896333|||OTHER||PROSPECTIVE|||||||
33760941|NCT03559088|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760942|NCT02416492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33760943|NCT06451822|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33760944|NCT05343416|||COHORT||PROSPECTIVE|||||||
33760945|NCT04074200|||CASE_ONLY||PROSPECTIVE|||||||
33760946|NCT00743561|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33760947|NCT05756231|NA|SINGLE_GROUP||SCREENING||NONE||||||
33760948|NCT03338621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2c multi-center, open-label, partially randomized clinical trial in DS-TB and DR-TB participants||||
33760949|NCT04772222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants randomized to receive open-label dexmedetomidine (DMT) or morphine for pain and sedation.||||
33760950|NCT01834105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884876|NCT02346188|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33884877|NCT03728387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884878|NCT06527365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884879|NCT00814957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071903|NCT05240807|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760951|NCT04766086|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but all other study personnel, including the principal investigator, and the subject, will be blinded.||t|f|t|f
33760952|NCT03371641|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33760953|NCT02382718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33760954|NCT05274932|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33972859|NCT04748211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be a two-arm parallel assignment. One group will receive infraclavicular block and the other will receive interscalen block|t|f|f|f
33972860|NCT04509973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972861|NCT04003870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972862|NCT03867851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972863|NCT04195997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972864|NCT06543264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).||t|f|t|f
33972865|NCT05564949|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will adhere to a classic ketogenic diet for a period of 3 months with a possible extension depending on their compliance on the diet.||||
33972866|NCT04081337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33972867|NCT06530745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was designed as a two-arm equal-allocation clinical trial with a non-concurrent active treatment control.||||
34071904|NCT04013503|||COHORT||CROSS_SECTIONAL|||||||
34071905|NCT01357395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972868|NCT00004843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972869|NCT04836156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34071906|NCT01960465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34071907|NCT04676152|NA|SINGLE_GROUP||OTHER||NONE||||||
33972870|NCT00948402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972871|NCT03342703|||CASE_ONLY||PROSPECTIVE|||||||
33972872|NCT01890083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33972873|NCT03654209|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to Argon Plasma Coagulation vs Snare Tip Soft Coagulation vs no treatment||||
33972874|NCT03215173|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Controlled study|f|f|t|t
33972875|NCT05347992|||COHORT||PROSPECTIVE|||||||
33972876|NCT04064229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972877|NCT05900661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972878|NCT05717881|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||The present trial was a randomized, double-bind, controlled, crossover, dietary intervention study. During this trial, two types of supplementations were randomly administered during two treatment periods (propolis and placebo), using a random number table. The placebo served as the reference group for comparison. Participants and caregivers were blinded to the type of treatment consumed.|t|t|t|f
33972879|NCT04488640|||COHORT||RETROSPECTIVE|||||||
34071908|NCT02798107|||OTHER||RETROSPECTIVE|||||||
33972880|NCT05203887|||COHORT||PROSPECTIVE|||||||
34071909|NCT03378245|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
34071910|NCT06610643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071911|NCT00593918|||CASE_CONTROL||PROSPECTIVE|||||||
34071912|NCT03305692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individual analyzing echocardiograms (primary outcome) will not know randomization of the subject.|1:1 randomization|f|f|f|t
34071913|NCT00159770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071914|NCT04540328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071915|NCT04663243|NA|SINGLE_GROUP||PREVENTION||NONE||Quasi experimental study||||
34071916|NCT01223937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071917|NCT06285266|||OTHER||CROSS_SECTIONAL|||||||
34071918|NCT02360423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071919|NCT00473447|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34071920|NCT04824937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972881|NCT02203747|||CASE_CONTROL||PROSPECTIVE|||||||
33972882|NCT03491358|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33972883|NCT06160999|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped wedge design with a cross-sectional sampling structure.||||
33972884|NCT05293028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972885|NCT01439100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33972886|NCT05303922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patient will be scanned with both DECT and MRI.||||
33972887|NCT04551885|NA|SEQUENTIAL||TREATMENT||NONE||||||
33972888|NCT04735419|||CASE_CONTROL||PROSPECTIVE|||||||
34071921|NCT00811980|||||PROSPECTIVE|||||||
34071922|NCT01666912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071923|NCT01620541|||COHORT||PROSPECTIVE|||||||
34071924|NCT00624689|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34071925|NCT05251116|NA|SINGLE_GROUP||OTHER||NONE||||||
34071926|NCT03326297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071927|NCT00185042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972889|NCT04527471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972890|NCT06313320|||COHORT||PROSPECTIVE|||||||
33972891|NCT00471406|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972892|NCT04679870|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects eligible for the study will receive GB2064 1000mg, twice a day||||
33972893|NCT00717756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972894|NCT04701697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33972895|NCT01123486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972896|NCT00532597|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33972897|NCT01638702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33884880|NCT02276586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884881|NCT02029287|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884882|NCT06405672|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33884883|NCT04799561|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This QI study will include one group of 100 patients who will receive distance-delivered support for all components of the home-based prehabilitation regimen in addition to 2 months of follow-up post-surgery. The program will include: exercise, nutrition, mental well-being and, if needed, smoking cessation. The technologies (a tablet and an active lifestyle watch) will be used to provide counselling, educate patients on lifestyle modifications and assess adherence remotely. Telephone calls will also be made on a weekly basis, if participants were unable to attend their video-conferencing counselling sessions.||||
33884884|NCT00553046|||COHORT||RETROSPECTIVE|||||||
33884885|NCT01970163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884886|NCT04942392|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33884887|NCT00140894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33884888|NCT06459947|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33884889|NCT05340920|||COHORT||RETROSPECTIVE|||||||
33972898|NCT03692676|||COHORT||CROSS_SECTIONAL|||||||
33972899|NCT05207215|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Sequential multiple assignment randomized trial.|f|f|t|t
33972900|NCT01259427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972901|NCT01314742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972902|NCT04999332|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Single intervention arm with trial treatment||||
33972903|NCT02663089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972904|NCT01713309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972905|NCT03013179|||COHORT||PROSPECTIVE|||||||
33972906|NCT02165579|||CASE_ONLY||PROSPECTIVE|||||||
33972907|NCT01411267|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33972908|NCT01797471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972909|NCT01664689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972910|NCT03414866|||COHORT||PROSPECTIVE|||||||
33884890|NCT01130987|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33884891|NCT02971124|||CASE_CONTROL||PROSPECTIVE|||||||
33884892|NCT05156541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884893|NCT00510809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884894|NCT02100904|||COHORT||PROSPECTIVE|||||||
33884895|NCT02093442|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33884896|NCT02592889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||mitraclip versus control|f|f|f|t
33884897|NCT03568877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33884898|NCT03934788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33972911|NCT03854084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972912|NCT03577236|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, prospective, single-arm.||||
33972913|NCT06318650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Randomized Controlled Clinical Trial|t|f|t|t
33972914|NCT04299854|||COHORT||OTHER|||||||
33972915|NCT06546644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only the Outcomes Assessor will be blinded regarding group allocation|The participants after baseline measures, will be randomly assigned into two groups intervention and control in a parallel way.|f|f|f|t
33972916|NCT06467422|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33972917|NCT03129386|||COHORT||PROSPECTIVE|||||||
33972918|NCT06315270|||CASE_CONTROL||PROSPECTIVE|||||||
33972919|NCT00108420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33972920|NCT03082391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972921|NCT02691897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972922|NCT02755480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972923|NCT03378622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972924|NCT02784925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33972925|NCT01147120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33972926|NCT06484049|||OTHER||PROSPECTIVE|||||||
33972927|NCT04487210|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33972928|NCT02729688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760955|NCT03956290|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33760956|NCT03538483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972929|NCT04777630|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972930|NCT00331630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972931|NCT00471835||||TREATMENT||NONE||||||
33972932|NCT00007878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972933|NCT04259021|||COHORT||PROSPECTIVE|||||||
33972934|NCT00050921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972935|NCT06052371|||CASE_ONLY||PROSPECTIVE|||||||
33972936|NCT02133339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972937|NCT00608205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972938|NCT02721797|||CASE_CONTROL||PROSPECTIVE|||||||
33972939|NCT00371605|||||PROSPECTIVE|||||||
33972940|NCT02232074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34071928|NCT00549549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34071929|NCT03999359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34071930|NCT03989336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34071931|NCT01871077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071932|NCT06224218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071933|NCT00546169|||CASE_CONTROL||PROSPECTIVE|||||||
33972941|NCT00376571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071934|NCT02641275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34071935|NCT01932749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071936|NCT00826098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33972942|NCT02337933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972943|NCT04177069|||COHORT||PROSPECTIVE|||||||
33972944|NCT03077997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972945|NCT06451809|||CASE_ONLY||PROSPECTIVE|||||||
33972946|NCT04740021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071937|NCT04408664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized double-blinded clinical trial|t|t|f|f
34071938|NCT00594230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760957|NCT01677702|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33972947|NCT05583383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972948|NCT05571709|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Aged individuals who perform exercise training are compared to aged individuals who remain sedentary.|f|f|f|t
33972949|NCT02419482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760958|NCT02168764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760959|NCT04665154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760960|NCT03339284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients are randomized and allocated in blocks of nine to either placebo or QLB with dexamethasone or QLB without dexamethasone group||t|t|t|t
33760961|NCT01938014|||COHORT||PROSPECTIVE|||||||
33884899|NCT01397578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884900|NCT00400400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884901|NCT03404999|NA|SINGLE_GROUP||SCREENING||NONE||Four-month time series trial||||
33884902|NCT03806127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884903|NCT04593732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884904|NCT05773404|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33884905|NCT05504161|||CASE_CONTROL||PROSPECTIVE|||||||
33884906|NCT05606926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884907|NCT06076629|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33884908|NCT06416163|||COHORT||PROSPECTIVE|||||||
33884909|NCT03137615|||CASE_ONLY||PROSPECTIVE|||||||
33884910|NCT06194357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884911|NCT05809531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972950|NCT04104958|||CASE_CONTROL||PROSPECTIVE|||||||
33972951|NCT04570566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The present randomized clinical study was conducted to assess histological, histomorphometric, radiographic and the clinical response of bone after 4 months of augmentation and to compare the amount of horizontal bone gained between both groups and compare the quality of gained bone using a native pericardium physical resorbable barrier made of bovine pericardium with 1:1 mixture of bone graft in test group versus using titanium mesh with 1:1 mixture of bone graft in control group to augment localized horizontal alveolar ridge defects for the subsequent placement of dental implants.|f|f|t|t
33972952|NCT01123785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972953|NCT00532519|NA|SINGLE_GROUP||||NONE||||||
33972954|NCT04602104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972955|NCT04381585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972956|NCT04675983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972957|NCT04844697|||COHORT||PROSPECTIVE|||||||
33972958|NCT05521763|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33972959|NCT02682290|NA|SINGLE_GROUP||OTHER||NONE||||||
33972960|NCT01987622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33972961|NCT02353065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972962|NCT03615794|||CASE_CONTROL||PROSPECTIVE|||||||
33972963|NCT01674478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972964|NCT05720871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded. Blinding will be applicable for clinical and instrumental assessments for investigators, and for intervention condition for patients.|Single-center, double-blinded, two-arm, double-randomization RCT to assess the effect of paired sensory (capsaicin vs placebo) and motor stimulation (rTMS vs tDCS) for post-stroke patients with oropharyngeal dysphagia.|t|t|f|t
33884912|NCT05112887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Individual testing smell function was masked to whether participant was in treatment group or placebo|Participants will have to email a positive COVID-19 test result \>14 days prior to MS861918@ohio.edu. There will be a correspondence with the participant to ask them if they feel their sense is still decreased or absent and then candidacy for study will be determined. 20 participants will be divided randomly into sham OMT treatment groups and real OMT treatments. 10 in each group. Participants will rate on a scale of 0-10 (0 being no smell, and 10 being pre-COVID19 exposure smell) the ability to smell 4 items blindfolded pre-treatment as well as attempt to identify the substance|t|f|f|t
33884913|NCT00816374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33884914|NCT04624425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884915|NCT00733590|||COHORT||PROSPECTIVE|||||||
33884916|NCT03014856|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33884917|NCT03508492|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33884918|NCT05370573|||COHORT||RETROSPECTIVE|||||||
33884919|NCT01389115|||CASE_CONTROL||PROSPECTIVE|||||||
33884920|NCT01412957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884921|NCT04067830|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33884922|NCT02388568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884923|NCT06501703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participants ,outcome assessors)|Parallel double blinded|t|f|f|t
33884924|NCT01539980|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33884925|NCT01158339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884926|NCT06373861|||OTHER||PROSPECTIVE|||||||
33884927|NCT00434200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33884928|NCT01099202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884929|NCT04055103|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Each arm will receive the intervention for 6 months.|f|t|f|f
33884930|NCT03922854|||COHORT||PROSPECTIVE|||||||
33884931|NCT06466330|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Only the interventional radiologist cannot be blinded, given the procedure (embolization with microparticles) . This means that the patient and the principal investigator at each center involved in the clinical evaluation of the patient will be blinded.||t|t|t|t
33884932|NCT01764633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884933|NCT05057455|||COHORT||PROSPECTIVE|||||||
33884934|NCT01889849|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33884935|NCT04676048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884936|NCT04655066|||CASE_ONLY||PROSPECTIVE|||||||
33884937|NCT02630953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884938|NCT04227756|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions|t|t|t|t
33884939|NCT02420769|||OTHER||PROSPECTIVE|||||||
33972965|NCT05912686|RANDOMIZED|PARALLEL||TREATMENT||NONE|Single (Outcomes Assessor)|||||
33972966|NCT01833949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071939|NCT05136079|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participant: Participants will not be informed of their study arm allocation until they complete the study. Regardless of study arm, participants will be injected with the requisite blue dye to perform the LVA procedures, thereby providing no visible clue as to whether they are control or intervention participants. The exception will be in the case where a participant is diagnosed with lymphedema post-operatively but prior to their study participation completion and their healthcare management requires knowledge of surgical history.~Radiologist: At 24 months each participant will undergo a radionuclide lymphoscintigraphy to assess the functioning of the lymphatic system. The radiologist reading the results will be blinded as to the participants' study allocation."|A total of 40 study participants will be block (axilla, groin) randomized using 2 equal groups (control/intervention) of 20 participants each.|t|f|f|t
34071940|NCT05441553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071941|NCT05448742|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Six cadaveric lower limbs will have biplanar PSI slope-reducing MOWHTO performed on and accuracy of biplanar correction will be assessed.||||
34071942|NCT04577417|||COHORT||CROSS_SECTIONAL|||||||
34071943|NCT03441659|||COHORT||PROSPECTIVE|||||||
34071944|NCT06302049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34071945|NCT04750434|||CASE_CROSSOVER||PROSPECTIVE|||||||
34071946|NCT00289224|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34071947|NCT02256917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34071948|NCT02285075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071949|NCT01533961|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34071950|NCT01726465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33884940|NCT01165957|||CASE_CONTROL||RETROSPECTIVE|||||||
34071951|NCT06014996|RANDOMIZED|PARALLEL||TREATMENT||NONE||symptomatic paroxysmal AF||||
34071952|NCT01763827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071953|NCT03489980|||COHORT||PROSPECTIVE|||||||
33884941|NCT05423405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Patients population with depression (mild, moderate, or severe)|t|t|f|f
33972967|NCT06210412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The introductory information form and MÖYKÖ tests will be applied. Women with high MÖYKÖ scores will be divided into experimental and control groups using purposeful sampling, according to the lottery method, and those in the experimental group will be contacted by phone and asked to come to the Famagusta Development Academy (MGA) on the day and time determined. Sessions will begin after 12 weeks of health training and Hatha yoga practice are planned. At the end of 12 weeks, final tests will be administered to women who have participated for at least 10 weeks. Those in the control group will be called by phone and invited to MGA Maraş for their first test, and an appointment will be made 12 weeks later for their final test.||||
34071954|NCT01904032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are randomized to either 50,000 international units of weekly vitamin D3 or to 5,000 international units of weekly vitamin D3 using a 1:1 allocation|t|t|t|t
33972968|NCT02337179|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33972969|NCT03291509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972970|NCT03540810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972971|NCT03709082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972972|NCT01766778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972973|NCT06303583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972974|NCT01136226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972975|NCT04857307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34071955|NCT03139136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34071956|NCT03763201|||COHORT||PROSPECTIVE|||||||
34071957|NCT00534638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34071958|NCT01580826|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34071959|NCT00561938|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071960|NCT02533583|||CASE_CROSSOVER||PROSPECTIVE|||||||
34071961|NCT05403840|||COHORT||PROSPECTIVE|||||||
34071962|NCT04076852|||COHORT||OTHER|||||||
33884942|NCT02504281|||CASE_CONTROL||PROSPECTIVE|||||||
33884943|NCT01864616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33884944|NCT01681329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884945|NCT04147468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One group will receive virtual reality; the other group will receive functional strength training|f|f|f|t
33884946|NCT04578002|||COHORT||PROSPECTIVE|||||||
33884947|NCT04113915|||COHORT||RETROSPECTIVE|||||||
33884948|NCT03778086|||COHORT||PROSPECTIVE|||||||
33884949|NCT05959473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Specimens from NSCLC patient with FFPE FNA samples, will be extracted and tested with the Idylla EGFR_IUO/3.20.|||||
33884950|NCT02870231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884951|NCT06244797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33884952|NCT03661320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884953|NCT03365778|RANDOMIZED|PARALLEL||OTHER||NONE||"Selective Laser Trabeculoplasty (SLT) Educational Intervention group (n=20) or Usual Care group (n=20). Knowledge, beliefs, barriers, and attitudes about SLT vs. medication as first line treatment of glaucoma will be assessed in both groups.~To evaluate barriers for widespread adoption of this procedure, we assessed beliefs and attitudes of ophthalmologists regarding SLT. We developed an educational slide presentation targeted at physicians to increase consideration of SLT earlier in glaucoma treatment paradigm."||||
33884954|NCT05079490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884955|NCT03206723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884956|NCT00545701|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33972976|NCT02487784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34071963|NCT00184002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071964|NCT02382315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33884957|NCT04822545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884958|NCT00141973|||||PROSPECTIVE|||||||
33884959|NCT01662440|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33884960|NCT01885000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884961|NCT04241965|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33884962|NCT01936389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33884963|NCT01308411|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33884964|NCT05825066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884965|NCT04573387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The design is open labeled with only the investigators for postoperative follow-up evaluation, the outcome assessors, and data analysts being blinded in all 19 centers. Before outcome assessment begins at every follow-up evaluation, the patients will be reminded not to reveal any information about their group allocation. If details of group allocation can be detected by the investigator during follow-ups, another blinded researcher will replace to evaluate outcome.||f|f|f|t
34071965|NCT04726111|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34071966|NCT02790918|||CASE_CONTROL||PROSPECTIVE|||||||
34071967|NCT03643302|||COHORT||PROSPECTIVE|||||||
33972977|NCT01812421||||PREVENTION||NONE||||||
33884966|NCT03942315|||COHORT||RETROSPECTIVE|||||||
33884967|NCT03290339|||COHORT||PROSPECTIVE|||||||
33972978|NCT04459663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884968|NCT02213874|NA|SINGLE_GROUP||OTHER||NONE||||||
33972979|NCT02866175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972980|NCT01866956|||COHORT||CROSS_SECTIONAL|||||||
33972981|NCT02116283|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33972982|NCT05218863|||COHORT||PROSPECTIVE|||||||
33884969|NCT04931953|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants will not be told whether they have been allocated to an active iTBS or sham iTBS administration until the end of their study participation, where they will be informed whether they received active or sham iTBS administration. The two technicians (including the research fellow) administering the iTBS will not be blind to group allocation.~The RA conducting the cognitive assessments and analysing these (and the questionnaires) will be blinded to group allocation. We aim to stagger the commencement of the iTBS intervention schedule per group (with those in Group C \[4-week intervention schedule\] to begin first), to avoid participants returning for their EOI assessments 1, 2, or 4 weeks later depending upon group allocation. We hope that this will minimise the chance of unblinding the RA to group allocation."||t|f|f|t
33884970|NCT01557829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884971|NCT06314464|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33884972|NCT03931356|||COHORT||PROSPECTIVE|||||||
33884973|NCT01966770|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33884974|NCT05513014|||COHORT||RETROSPECTIVE|||||||
33884975|NCT06124131|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Primary care outreach staff will recruit and randomize participants and deliver the intervention. Group assignment will be documented in a separate study database not accessible by the primary care provider. Outcomes will be assessed in electronic health records data, which will be queried by primary care staff who do not have access to group assignment.|Participants will be randomly assigned to a study arm for the duration of their two months in the study|f|t|f|t
33884976|NCT03603002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel T-cell receptor (TCR) sequencing assay.||||
33884977|NCT01901094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884978|NCT01291017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884979|NCT05000346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884980|NCT04982640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Codes identifying randomization assignment are withheld from the research staff conducting study outcome assessments.||f|f|f|t
33884981|NCT01482078|||COHORT||PROSPECTIVE|||||||
33884982|NCT02146287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33884983|NCT05501093|||COHORT||PROSPECTIVE|||||||
33884984|NCT00464204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33884985|NCT06237517|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33884986|NCT02481505|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33884987|NCT03430986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884988|NCT01877564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972983|NCT02557256|||COHORT||RETROSPECTIVE|||||||
33972984|NCT00097071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972985|NCT03908021|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33972986|NCT05613699|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33972987|NCT00000992||||TREATMENT||NONE||||||
33972988|NCT00174642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33972989|NCT00240006|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33972990|NCT03302052|||COHORT||PROSPECTIVE|||||||
33972991|NCT06544434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33972992|NCT05026983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33972993|NCT05026515|||COHORT||PROSPECTIVE|||||||
33760962|NCT04728308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Caesarean section will be done under spinal anesthesia by a well-trained consultant obstetrician. The surgeon will be provided with a 20 ml syringe filled either with 20 ml of 0.5% Bupivacaine or 20 ml of placebo (distill water). The syringe will be prepared by our researcher obstetrician. The contents of the syringe will be determined by numbers generated from the computer and the operating surgeon will be unaware of these contents. Before closing the skin incision, the operating surgeon will infiltrate the solution in subcutaneous tissue around the incision. Severity of pain , need for amount of opioids and duration of hospital stay will be assesed by doctor incharge in postoperative ward.|Informed written consent will be taken. Patients will be divided into two groups randomly, by a computer-generated method. Caesarean section will be done under spinal anesthesia by a well-trained consultant obstetrician. The surgeon will be provided with a 20 ml syringe filled either with 20 ml of 0.5% Bupivacaine or 20 ml of placebo (distill water). The syringe will be prepared by our researcher obstetrician. The contents of the syringe will be determined by numbers generated from the computer and the operating surgeon will be unaware of these contents. Before closing the skin incision, the operating surgeon will infiltrate the solution in subcutaneous tissue around the incision.|t|t|f|t
33760963|NCT03361995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760964|NCT04157101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator, assessor, biostatistician|Clinical Trial|f|f|t|t
33760965|NCT04984057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760966|NCT04318158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33760967|NCT04531163|RANDOMIZED|PARALLEL||TREATMENT||NONE|All participants,investigators, care providers, and outcome assessor have knowledge of the interventions assigned to individual participants.|Two arms are being used parallel to each other at the same time. Participants are assigned to two groups in parallel for the duration of the study. One arm is interventional assigned to drug administration and the other is a control arm.||||
33760968|NCT02886806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760969|NCT04382924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760970|NCT03361748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760971|NCT01241383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760972|NCT02609880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33884989|NCT04172883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is unaware of which type of programming changes have been made ( whether it is the reduced sequence programming or the standard Minerva setting )||t|f|f|f
33884990|NCT03682120|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33884991|NCT00741156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884992|NCT00073320|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33884993|NCT00624455|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33884994|NCT03221894|||COHORT||RETROSPECTIVE|||||||
33884995|NCT06095388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33884996|NCT03129308|||COHORT||CROSS_SECTIONAL|||||||
33884997|NCT00760981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33884998|NCT02557178|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33884999|NCT00417872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885000|NCT00984672|||CASE_CONTROL||PROSPECTIVE|||||||
33885001|NCT00518479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885002|NCT02147873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885003|NCT00212173|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33885004|NCT02436460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885005|NCT05306132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885006|NCT05545956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subjects will be blinded to the intervention.||t|f|f|f
33885007|NCT02435602|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33885008|NCT03633084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open label, non-controlled, sequential, dose-escalating study||||
33885009|NCT02440087|||COHORT||PROSPECTIVE|||||||
33885010|NCT01178866|||COHORT||PROSPECTIVE|||||||
33885011|NCT01758510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885012|NCT01145937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885013|NCT03176316|NA|SINGLE_GROUP||PREVENTION||NONE||All participants who agree to participate in the study and meet the inclusion and exclusion criteria may receive the planned study intervention.||||
33885014|NCT00167245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33972994|NCT05067049|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33972995|NCT05341128|||COHORT||RETROSPECTIVE|||||||
33972996|NCT00325403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33972997|NCT00005782||||TREATMENT||||||||
33972998|NCT01685970|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33972999|NCT05248932|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33973000|NCT04170699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be a two-arm parallel assignment. One group will receive PECS 1 block and the other will receive infiltrative anesthesia.|t|f|f|f
33885015|NCT03705585|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Volunteers who choose to take part in this study will receive the licensed FDA approved Oral Typhoid Vaccine (Vivotif) and/or the licensed FDA approved Oral Cholera Vaccine (Vaxchora). Volunteers also have the possibility of being a control participant who will not be vaccinated.||||
33885016|NCT00565331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885017|NCT03501966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Partially-masked technicians for perimetry, fundus photos, OCT, and refraction/ visual acuity|Subjects will be randomly assigned with equal allocation to one of the three treatment groups. Using a permuted block design, randomization will be stratified by PMD (average of 2 size V stimulus tests) in the eligible eye(s) (-6 dB to \>-12 dB; -12 dB to \>-20 dB; -20 dB to -27 dB). If a subject has two eligible eyes, the average PMD of the two eyes will be used for stratification.|f|f|f|t
33885018|NCT01610635|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885019|NCT01758757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885020|NCT04635865|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients fulfilling the eligibility criteria and willing to participate will be randomised after baseline assessment (1:1 allocation ratio). A priori, an independent statistician will prepare a computer-generated randomisation schedule in a random-sized permuted blocks of four or six patients stratified by location of reconstruction (maxilla/mandible) and gender (F/M) to ensure that the numbers of participants receiving the two interventions are closely balanced within each stratum. The allocation numbers will be concealed in opaque sealed envelopes prepared by a central study coordinator, only opening them after informed consent and baseline measures have been obtained.||||
33885021|NCT03629483|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885022|NCT05866107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885023|NCT03665363|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33885024|NCT00132041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885025|NCT04401592|||CASE_CONTROL||PROSPECTIVE|||||||
33885026|NCT03891147|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two arm pragmatic randomized controlled trial design will be conducted at the Prince of Wales Hospitals. 132 patients diagnosed of symptomatic gallstone diseases are on waiting list for cholecystectomy or being recommended to have cholecystectomy by surgeons will be allocated in either EA group (n = 66); or control group (n=66). Treatment group will be offered 20 sessions of EA in 10 weeks, while the control group will remain in the usual care for solely assessment. Primary outcome is the proportion of patients with total clearance of gallstones after treatment with confirmation by ultrasonography. The secondary outcome is the monitoring the incidence of common bile duct stone by liver function test (LFT) and MRCP.||||
33973001|NCT03105609|||COHORT||PROSPECTIVE|||||||
33973002|NCT05399810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973003|NCT00440596|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33973004|NCT04899739|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973005|NCT05652621|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33973006|NCT01957657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973007|NCT02235233|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973008|NCT04122274|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33973009|NCT03558100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973010|NCT01081184|||CASE_CONTROL||PROSPECTIVE|||||||
33973011|NCT00929357|||COHORT||RETROSPECTIVE|||||||
33973012|NCT00645619|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973013|NCT02512913|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33973014|NCT02576990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973015|NCT05291143|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||educational video||||
34071968|NCT05757752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071969|NCT03785314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34071970|NCT01925976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071971|NCT05534503|||CASE_ONLY||RETROSPECTIVE|||||||
34071972|NCT00722683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34071973|NCT04129112|||CASE_CONTROL||PROSPECTIVE|||||||
34071974|NCT03919747|||OTHER||CROSS_SECTIONAL|||||||
34071975|NCT03605381|||COHORT||PROSPECTIVE|||||||
34071976|NCT01826097|NA|SINGLE_GROUP||SCREENING||SINGLE||||||
34071977|NCT06257953|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34071978|NCT06236854|||COHORT||PROSPECTIVE|||||||
34071979|NCT01300247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071980|NCT01562652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071981|NCT06316596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The research is a prospective, randomized, single-blind, parallel group study. In the study, the Quincke needle will be used for spinal anesthesia and the Tuoghy needle will be used for epidural anesthesia. Oxygenation will be evaluated with the help of NIRS probe in the post-cesarean newborns of pregnant women who will undergo elective cesarean section.~Vitals will be monitored throughout the case with electrocardiography (ECG), non-invasive blood pressure monitoring and spO2. The amount of vasopressor agent and hydration required by the mother throughout the case will be recorded. While one anesthesiologist will monitor the anesthesia method and maternal vitals, the other anesthetist will monitor the NIRS monitoring attached to the newborn."|The research is a prospective controlled,randomized,double-blind study|t|f|f|f
34071982|NCT02976246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34071983|NCT03327285|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34071984|NCT06611566|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking was possible|The studydesign was crossover and sequential. All participants tried VR- and TV- guided aerobic exercise and VR-and TV-guided mindfulness exercises, but in counterbalanced order||||
34071985|NCT06014164|||CASE_ONLY||PROSPECTIVE|||||||
34071986|NCT01553344|||CASE_ONLY||PROSPECTIVE|||||||
34071987|NCT03701438|||CASE_ONLY||PROSPECTIVE|||||||
34071988|NCT01345214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071989|NCT04135313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34071990|NCT00560040|||||PROSPECTIVE|||||||
34071991|NCT03610880|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||randomized, open-label, two-arm, parallel design||||
34071992|NCT01957579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34071993|NCT04633499|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"Participants will receive either an active or a sham tDCS stimulation. Sham stimulation will use a ramp-up, so that participants are not able to tell whether they are stimulated or not, if they are tDCS naive.~Sham or active tDCS is applied via codes. Principal Investigators are blinded for these codes."|It is a randomized, balanced cross-over design with within- as well as between group comparisons. Two groups will be investigate: young participants (n = 30) and older participants (n = 60). The group of young participants will serve as a control group and will only get a neuropsychological assessment of their cognitive abilities at the beginning of the study, an MRI assessment and one session of the investigated paradigms (without tDCS). The group of older participants will conduct a session of MRI assessment and neuropsychological assessment, as well as two tDCS sessions (anodal/sham). The stimulation will either be over the rTPJ or the dmPFC. This set-up is identical to the study of Martin et al., (2020).|t|f|t|t
34071994|NCT01770821|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34071995|NCT03024281|||CASE_ONLY||RETROSPECTIVE|||||||
34071996|NCT01494272|||COHORT||PROSPECTIVE|||||||
34071997|NCT03602703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34071998|NCT00250757|||CASE_CONTROL||PROSPECTIVE|||||||
34071999|NCT02293239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072000|NCT01315288|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072001|NCT03079167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072002|NCT01944644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072003|NCT03097432|||COHORT||PROSPECTIVE|||||||
34072004|NCT03055910|||COHORT||PROSPECTIVE|||||||
34072005|NCT02088892|NON_RANDOMIZED|PARALLEL||||NONE||||||
34072006|NCT00889915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885027|NCT04954807|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"One investigator who do not involve in recruitment and outcome measures will generate randomization list by computer application and set up the list into Redcap randomization set up. No one except him will know the sequence of randomization. Research assistant will randomize subjects into one of four group according to Redcap assignment. The manufacturer prepare the study product into four groups: A,B,C,D and kept the code until the statistical analysis completed. All investigators, care providers and study subjects aware of the active or placebo group. Research assistants who recruit the study subject are not allowed to open the tin. One research assistant who does no meet study subject will measure the weight of tin before and after the supplementation.~Subject only meet with researchers individually and will not meet other subjects so they will not know the content of the other tin."|"Subjects in the intervention group will be given the new human milk fortifier which contains protein, lipid, carbohydrate and micronutrients while the control group will receive placebo (polysaccharides 0.9 g/1 g placebo and maltose 0.1 g/1 g placebo and minerals). Assuming the average weight is 2 Kg, 6 scoops (@1.0 g) will provide 1.95 g protein and 25.5 Kcal in the intervention group while 6 scoops of 1.1 g in the control group will provide 26.4 Kcal with no protein. Three times a day, supplementation with 2.0 gram (intervention group) or 2.2 gram (control group) of study product will be provided, regardless of the actual weight of the subject.~Both groups will receive iron supplementation 2 drops daily (5 mg elemental iron in forms of Fe III hydroxide polymaltose complex) since 2 month old as a routine supplementation recommended by Indonesian Pediatrics Society."|t|t|t|t
33885028|NCT02024516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973016|NCT05112900|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||"A Sequential Multiple Assignment Randomized Trial (SMART) design will be employed using short time frames (\<1 month) and iterative evaluation cycles. The proposed trial will compare the efficacy of text messaging (TM) versus usual care in a first randomization of the study. Non-compliant participants (if no COVID-19 test is completed or no response received) will then receive their Phase 2 condition of continued TM or TM + Health Navigator (HN) to test whether stepping up to HN improves outcomes for those not responding to the first-line intervention of TM. All randomizations will take place on the individual level at the beginning of the study; participants will be randomized to the initial intervention (TM vs. usual care; Phase 1 Randomization), and TM participants will also be randomized to the Phase 2 condition (TM or TM+HN) which they would receive during cycles during which they are non-compliant."||||
33973017|NCT01811277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973018|NCT01309009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973019|NCT05830448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The nurses to be included in the study will be assigned to the intervention and control groups by simple randomization using the computer-assisted randomization application (www.randomizer.org). Determination of the intervention and control group will be drawn between set1 and set2. The ranking to be given to the participants (eg 1,2,3,....32) will be created by recording the number of participants when they approve to participate in the research (eg, the 10th person who accepts to participate will automatically be the 10th participant). No new applications will be accepted when the number of people to be included in the sample is reached. Participants in the study will not know which group they belong to. The researcher will contact the individual assigned to the control and intervention group according to the number given without knowing who the participant is. Blinding will be provided by Outcomes Assessor during data entry and statistics stages.|Experimental study with randomized pretest-posttest control group|t|f|f|t
33973020|NCT03689296|||COHORT||PROSPECTIVE|||||||
33973021|NCT00497133|||CASE_CONTROL||PROSPECTIVE|||||||
33973022|NCT03907280|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973023|NCT02752256|||COHORT||PROSPECTIVE|||||||
33973024|NCT06527963|||COHORT||PROSPECTIVE|||||||
33973025|NCT02260375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973026|NCT00947063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973027|NCT00721058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973028|NCT02660190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072007|NCT03426943|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072008|NCT01517308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072009|NCT02085928|||CASE_ONLY||PROSPECTIVE|||||||
34072010|NCT00001338||||TREATMENT||||||||
34072011|NCT06585085|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072012|NCT03628833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072013|NCT05018676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072014|NCT00996034|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34072015|NCT01076608|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34072016|NCT05586542|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|At each site, at least 1 staff member will be identified as the Unblinded Investigational Product Administrator. This site staff member will be responsible for all IP application and wound dressing and undressing at each study visit||t|t|t|t
33885029|NCT05095142|||OTHER||PROSPECTIVE|||||||
33885030|NCT02809833|||COHORT||PROSPECTIVE|||||||
33885031|NCT02591719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885032|NCT04385173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885033|NCT04557384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885034|NCT02111564|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33885035|NCT04430179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Active drug vs placebo|t|t|t|t
33885036|NCT00828282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885037|NCT05882786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded.|Randomized controlled trial|f|f|f|t
33885038|NCT00741819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885039|NCT01488253|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885040|NCT00356642|RANDOMIZED|PARALLEL||TREATMENT||||||||
33885041|NCT00145405|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885042|NCT02981836|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33760973|NCT06019689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researcher conducting assessments will be masked to participant group allocation. This will be achieved by briefing participants and research staff in advance around maintaining masking.|multicenter exploratory RCT|f|f|f|t
33760974|NCT06345976|||COHORT||PROSPECTIVE|||||||
33760975|NCT05794633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All patients will be evaluated by the same physiatrist who are blinded to the randomization process and treatment protocols|Randomized placebo-controlled trial|t|f|f|t
33885043|NCT02480452|||COHORT||OTHER|||||||
33885044|NCT05815355|||CASE_ONLY||RETROSPECTIVE|||||||
33885045|NCT04982081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33885046|NCT01334398|||CASE_CONTROL||PROSPECTIVE|||||||
33885047|NCT05660304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the nature of the study, study personnel administering brain stimulation cannot be masked regarding whether the participant receives ccPAS or sham ccPAS. To minimize bias, neither the participant nor the speech-language pathologist will have knowledge of which group the participant is assigned to. However, the researcher administering ccPAS or sham ccPAS will know which intervention is applied.|A parallel randomized study will be performed. Three patients will be randomly assigned to receive ccPAS followed by speech-language therapy or sham ccPAS followed by speech-language therapy. Whether the participant receives ccPAS or sham ccPAS alongside speech-language therapy will be determined, at random, using a randomized number generator and enrollment order.|t|f|f|f
33885048|NCT02688647|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In Part 1: Subjects are randomized to treatment with either Belumosudil 400 mg PO QD (Belumosudil-R) or to BSC (BSC-R).~In Part 2: Subjects who are randomized and receive Belumosudil 400 mg PO QD during Part 1 have the option to continue treatment with Belumosudil 400 mg PO QD and subjects randomized to BSC have the option to cross over to treatment with Belumosudil 400 mg PO QD.~No subject is permitted \> 96 weeks of treatment with belumosudil"||||
33885049|NCT03691415|||COHORT||PROSPECTIVE|||||||
33885050|NCT02492633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885051|NCT02363478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885052|NCT05398198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and site staff will be blinded to the study intervention.|"Part A: In therapeutic treatment cohorts (cohort 1 and 2) repeat doses of GSK3923868 are administered after experimental viral infection with increasing time windows between viral inoculation and the initiation of study drug. The treatment is initiated 2, 3 and 4 days post-viral inoculation for cohort 1 and 2.~Part B: In prophylactic treatment cohort (cohort 3), treatment is initiated before inoculation with virus.~Of 3 cohorts planned, two cohorts will be performed (Cohort 1 and either Cohort 2 or 3). Cohort 1 data will be used to determine which cohort to progress to along with any study design changes."|t|f|t|f
33885053|NCT01826708|NA|SINGLE_GROUP||||NONE||||||
33885054|NCT05572463|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||An open-label platform study that will allow evaluation of multiple novel IPs. The study will include multiple treatment arms that can be added sequentially or in parallel. There will be a master protocol describing study design elements common to all treatment arms with treatment arms described in the appendices, added through amendments.||||
33885055|NCT04610658|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33885056|NCT02906072|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885057|NCT00759070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885058|NCT04856657|||CASE_CONTROL||PROSPECTIVE|||||||
33885059|NCT05539781|||CASE_CONTROL||PROSPECTIVE|||||||
33885060|NCT04251364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885061|NCT01914952|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33885062|NCT03789383|||OTHER||OTHER|||||||
33885063|NCT01601899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885064|NCT00217165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885065|NCT04415866|NA|SINGLE_GROUP||OTHER||NONE||Participants sensitivity to pressure, heat, and light will be modulated by an attention task.||||
33885066|NCT01621685|NA|SINGLE_GROUP||||NONE||||||
33885067|NCT05698173|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33885068|NCT03287180|RANDOMIZED|PARALLEL||TREATMENT||NONE||This 12-week randomized controlled pilot trial will begin by an induction on sublingual buprenorphine/naloxone for all participants who would usually receive buprenorphine based treatment in the clinic. After the two-week induction phase, participants will be randomized into two groups. While continuing buprenorphine/naloxone the experimental group will receive a 12-week course of A-CRA, while the control group will be provided medical management by the prescriber. Medical management is the standard treatment approach for prescribing buprenorphine and covers medication adherence, side effects of the medication, assessment of withdrawal/cravings and dose adjustment as indicated. After completion of the 12-week A-CRA intervention, all individuals will receive weekly medical management sessions until week 24 (6 month follow up).||||
33885069|NCT03850184|||CASE_ONLY||PROSPECTIVE|||||||
33885070|NCT01810679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885071|NCT00859365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33885072|NCT03432728|||CASE_CONTROL||PROSPECTIVE|||||||
33885073|NCT02642926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885074|NCT05597293|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973029|NCT06059170|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||cross sectional study||||
33973030|NCT06157307|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33973031|NCT01139255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973032|NCT05170256|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a two-staged single arm national phase II trial~* Stage 1: 17 patients~* Stage 2: 7 patients"||||
33760976|NCT04606095|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The statistician and the study principal investigator will remain blinded as to which data arise from HD-tDCS and Sham, until the study database is locked. The only study personnel that will not be blinded are the staff performing treatment and the project manager, in order to facilitate safety and treatment delivery.|This study can run Aims 1 and 3 and the same time. Females that have FM can participate in Aim 3.|t|f|t|t
33760977|NCT05287555|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, double-arm, controlled-randomized clinical trial||||
33885075|NCT00709956|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33885076|NCT05734729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885077|NCT03668574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885078|NCT05374707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|He groups of smoking teachers were known by the researcher. In order to provide one sided blindness in the study, the smoking teachers were not informed about the groups to which their schools were assigned and therefore the groups they were in.|"The sample of the study included the teachers working in six state secondary schools, which had the highest number of teachers among all secondary schools in Yunusemre and Şehzadeler districts and provided permission (n:446). Individuals who volunteered to participate in the study, did not have a malignant disease or a psychiatric problem, were non-smokers, and taught at schools included in the study were enrolled.~The sample of the study consists of teachers working in six state secondary schools, which have the highest number of teachers among all secondary schools in the two central districts of a city and are allowed (n:446). Since schools were preferred as the randomization unit, three schools from six state secondary schools were determined as the experimental group and three schools as the control group by means of the random number generation software Research Randomizer."|t|f|f|f
33973033|NCT00956033|||CASE_ONLY||PROSPECTIVE|||||||
33973034|NCT01982487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973035|NCT01784133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973036|NCT01835145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973037|NCT03882827|||COHORT||PROSPECTIVE|||||||
33885079|NCT00660894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885080|NCT00010231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973038|NCT03387033|NA|SINGLE_GROUP||OTHER||NONE||||||
33973039|NCT02887209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973040|NCT03384745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973041|NCT02470039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072017|NCT02799277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33973042|NCT02581800|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973043|NCT02123927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973044|NCT02890823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33973045|NCT00232115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973046|NCT00221390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973047|NCT02732561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973048|NCT02167464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The PI was blinded to clinic and group assignment when he conducted the final statistical analysis.||f|f|f|t
33973049|NCT05494684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The children blood sampling will be videotaped. The principal investigator videos the blood sampling, and then external observer assesses the child's anxiety (mYPAS=Modifield Yale preoperative anxiety scale) on video.The environment is masked and sounds are silenced on video (nature intervention includes nature sounds) so that the assessor does not know whether the child is in the intervention or control group, in order to reduce measurement bias. The video camera is pre-installed in the blood sampling room and positioned so that it does not attract attention.|Randomization of the children participating in the study will be carried out using the Stratified Block Randomization-on method, which allows randomization in two groups, according to age, as follows: group 1 (5-6 years old) and group 2 (7-9 years old). This is to ensure that the intervention and control groups have the same number of children of the same age and do not differ in their starting level. The randomization lists are made by a statistician.|f|f|f|t
33973050|NCT04655287|||COHORT||PROSPECTIVE|||||||
33973051|NCT01829477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973052|NCT04253548|NA|SINGLE_GROUP||OTHER||NONE||||||
33973053|NCT02857881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072018|NCT01563731|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34072019|NCT01283087|||CASE_ONLY||PROSPECTIVE|||||||
34072020|NCT00227019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072021|NCT05576792|||COHORT||PROSPECTIVE|||||||
33973054|NCT05100758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator will be blinded from the allocation (not allowed to observe the allocation and intervention) and the outcome assessor will not be informed the code of allocation|One group will be given Active Hexose Correlated Compound as adjuvant and the comparison group will only receive the tuberculosis treatment|f|f|t|t
33973055|NCT02688400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33973056|NCT06302231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973057|NCT06301802|||CASE_ONLY||PROSPECTIVE|||||||
33973058|NCT03765268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33760978|NCT02434458|||COHORT||CROSS_SECTIONAL|||||||
33760979|NCT02397239|||COHORT||PROSPECTIVE|||||||
33760980|NCT04975022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33885081|NCT05554627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be open-label where both the treating staff and the participant are unblinded to their treatment assignment, but the primary outcome will be assessed via telehealth by blinded remote raters without knowledge of treatment assignment.||f|f|f|t
33885082|NCT02292771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885083|NCT02988102|||COHORT||PROSPECTIVE|||||||
33885084|NCT05631912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885085|NCT06159075|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33885086|NCT00991679|||CASE_CONTROL||PROSPECTIVE|||||||
33885087|NCT03871855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885088|NCT01256216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885089|NCT02628860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760981|NCT01291537||||TREATMENT||||||||
33760982|NCT05842512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized, double-blind trial.|To evaluate efficacy and safety of ADI-PEG 20 or Placebo in patients with NASH|t|t|t|f
33973059|NCT01487733|||OTHER||RETROSPECTIVE|||||||
33973060|NCT00143754|RANDOMIZED|PARALLEL||||SINGLE||||||
33973061|NCT05917444|||OTHER||CROSS_SECTIONAL|||||||
33760983|NCT06300255|||COHORT||PROSPECTIVE|||||||
33760984|NCT06384612|NON_RANDOMIZED|PARALLEL||OTHER||NONE||experimental||||
33760985|NCT01457378|||CASE_CONTROL||RETROSPECTIVE|||||||
33760986|NCT02094014|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33760987|NCT01185093|||COHORT||PROSPECTIVE|||||||
33760988|NCT03520595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33760989|NCT04416698|||OTHER||CROSS_SECTIONAL|||||||
33760990|NCT00238030|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33760991|NCT00045435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760992|NCT05325255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33760993|NCT02252432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33760994|NCT02028559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Outcome Assessors a) evaluating imaging for stone growth, b) evaluating relatedness of safety events to the device/procedure or underlying stone condition, and c) evaluating relapse events are blind to the exposure condition.||f|f|f|t
33760995|NCT01912924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760996|NCT00820274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33760997|NCT01261585|||||PROSPECTIVE|||||||
33760998|NCT05316779|||COHORT||RETROSPECTIVE|||||||
33760999|NCT04410068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33761000|NCT06182657|||COHORT||PROSPECTIVE|||||||
33761001|NCT02897479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885090|NCT03799510|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|||||
33885091|NCT05049603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be double-blinded. Investigational Pharmacy will prepare identical bottles containing the medications. Each bottle will be marked with a code, to be assigned to a patient. Once a patient is screened and eligible, upon request from Centers, Investigational Pharmacy will send sets of 2 bottles per patient (one containing atorvastatin and one containing placebo). Following randomization, the Investigational Pharmacy will communicate to the Center the code of the bottle to be used. On-site principal investigators will be entitled to identify a patient's intervention only in the case of an emergency. Data from patients collected in an online, password-protected, central database, will be handled by the statistician, who will perform the final analyses. The statistician will be informed the Investigational Pharmacy to which randomization group patients were assigned to, in order to perform the analysis|Standard therapy (intravenous glucocorticoids) plus atorvastatin vs standard therapy plus placebo|t|t|t|t
33885092|NCT04956900|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort study design with each cohort having an ascending dose of Aurase wound gel. At the time of initiation, 5 sequential cohorts are planned.||||
33885093|NCT04109404|||COHORT||RETROSPECTIVE|||||||
33885094|NCT03792074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885095|NCT00576173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885096|NCT03881969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885097|NCT04988100|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973062|NCT03661437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973063|NCT05738109|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33973064|NCT05858385|||COHORT||RETROSPECTIVE|||||||
33973065|NCT06014684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973066|NCT02454270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885098|NCT03609619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973067|NCT02051881|NA|SINGLE_GROUP||||NONE||||||
33973068|NCT05468164|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33973069|NCT04928651|||CASE_ONLY||PROSPECTIVE|||||||
33885099|NCT05445973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885100|NCT00701714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885101|NCT02758457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885102|NCT01742260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885103|NCT02597855|||COHORT||PROSPECTIVE|||||||
33973070|NCT06430879|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized, double-blind, placebo controlled, crossover trial with functional measurements|t|t|f|t
33885104|NCT04415073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33885105|NCT00257010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885106|NCT02127255|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33885107|NCT05873348|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885108|NCT05738577|||CASE_CONTROL||OTHER|||||||
33973071|NCT00453570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973072|NCT01022788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973073|NCT06214897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention and control sachets of RUSF will be packaged such that investigators, outcomes assessors, and participants/caregivers will not know their identity.||f|f|t|t
33973074|NCT04020107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973075|NCT02862639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973076|NCT01787474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885109|NCT05521737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patient masking: During the application of the intervention, a bandage is placed over the patients eyes so that the participants cannot see the type of therapy applied (electroacupuncture or sham acupuncture).~Statistical masking: The researcher in charge of the statistical analysis is unaware of the type of intervention received by the patients and delivers the results to the responsible researcher."|The protocol consists of two study groups, including a control group of sham acupuncture, and an interventional group of Electroacupuncture. Both interventions will be applied in a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. ,Acupuncture points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).|t|f|t|t
33885110|NCT06538766|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33885111|NCT00841737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885112|NCT03899701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973077|NCT02795104|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33973078|NCT02916979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973079|NCT01506323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973080|NCT01628120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973081|NCT00176904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072022|NCT05164198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 4, randomized, parallel, non-inferiority, open-label, multi-center clinical trial||||
33973082|NCT05403411|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072023|NCT04303416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973083|NCT05582733|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Free envelop method|Control was treated with Manual Pressure release followed by stretching while in experimental received cervical spine manipulation (chin hold) kaltenborn followed by stretching.|t|f|f|f
33973084|NCT02812953|||COHORT||PROSPECTIVE|||||||
33973085|NCT05598437|||CASE_CONTROL||RETROSPECTIVE|||||||
33973086|NCT00536965|||COHORT||PROSPECTIVE|||||||
33973087|NCT06271811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33973088|NCT00712595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973089|NCT03858881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be partly blind to condition =. A computer-based survey will randomize participants into one of three conditions: an online mindset program, an online control program, or a virtual reality program. If a participant is randomized into one of the first 2 programs, the participant will know that s/he is not assigned to the VR program, but neither the experimenter nor the participant will be aware of which of the two computer-based programs s/he is completing. However, both participants and the experimenter leading the study visit will be aware of whether he participant was allocated to the VR condition (specific equipment set-up is required). The experimenters leading the study visits will be trained RAs not involved in data analysis. The study PI will remain blind to participants' condition assignments.||t|f|t|t
33973090|NCT00589095|||CASE_ONLY||PROSPECTIVE|||||||
33973091|NCT03724006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Parents will be divided in 2 study groups: INTERVENTION group (I) and CONTROL group (C).~Group I will receive a psychoeducational intervention in addition to the usual routines of the Service. Group C will receive the usual routines of the Service. The intervention will be performed as soon as possible after inclusion in the study.~Participants will be evaluated in 3 moments: M1 beginning of the study; M2 4 weeks after the intervention (I) or after enrollment (C) and M3 16 weeks after intervention/enrollment. The primary outcome will be parental QoL, which will be evaluated through the WHOQOL-Bref. The family impact and the perception of positive contributions will be secondary outcomes. These outcome variables will be assessed by the Impact on Family Scale and the Positive Contributions Scale - Kansas Inventory of Parental Perceptions, respectively. A semi-structured interview will be performed after all quantitative data have been collected."||||
33973092|NCT04461509|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients are identified by investigator and enrolled in Arm 1 (HIFU) or Arm 2 (RP)||||
34072024|NCT03413163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34072025|NCT03602196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072026|NCT03405168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072027|NCT05720429|NA|SINGLE_GROUP||PREVENTION||NONE||Quasi-experimental pragmatic study in a real clinical practice environment with a design before after with mixed quantitative-qualitative methodology. The intervention will be carried out in a decentralized way through the primary care centres of the Catalan Health Institute (over 250). All of the groups are supposed to receive the same intervention, although the diverse range of experiences will be described and measured as part of the program's implementation feasibility evaluation.||||
33761002|NCT06320626|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"* PK-guided dosing - Intervention group (12M): Subjects with emicizumab concentration of ≥ 40 μg/mL will receive individualized PK-guided dose reduction of emicizumab targeted at a Ctrough of 30μg/mL. The validated population PK model is based on published population PK and PK/PD modelling studies. (9,10,15)~* PK-Guided dosing - Non-intervention group (12M): Subjects with emicizumab concentration of 25-39 μg/mL will continue on their current dose regimen and will be followed according to the same assessment schedule as the Intervention Group. Only subjects with emicizumab plasma concentration \< 25 μg/mL will be adjusted in dosing regimen according to local protocol. These subjects will be followed for selective safety data only."||||
33761003|NCT04860518|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The study will be performed in a double-blind and randomized manner.||t|t|t|t
33885113|NCT03194815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885114|NCT03538743|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33885115|NCT03791333|||CASE_ONLY||PROSPECTIVE|||||||
33885116|NCT06401304|||COHORT||OTHER|||||||
33885117|NCT03838224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885118|NCT06002503|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33885119|NCT05466214|RANDOMIZED|PARALLEL||TREATMENT||NONE||Conjoint Behavioral Consultation (CBC) is an indirect consultation process focused on ameliorating problematic behaviors associated with severe emotional disturbance through structured, data-based problem solving and collaborative, consistent implementation of evidence-based interventions across home and school settings, while simultaneously enhancing family-school partnerships.. In CBC, problems are identified, defined, analyzed, and treated through strengths-based, mutual, collaborative interactions between parents and teachers with the support of a consultant. Through CBC, parents and teachers are taught evidence-based procedures to address behavior problems in their respective settings. Parents and teachers assume complementary roles and shared responsibility for identifying student goals and addressing challenging behaviors.||||
33885120|NCT04319900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33885121|NCT06536452|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33885122|NCT00233467|||OTHER||RETROSPECTIVE|||||||
33885123|NCT03446885|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||All participants received placebo and 40 mg Vyvanse in a cross-over design. Order of administration was randomly assigned and counter-balanced across participants|t|f|t|t
33885124|NCT01301989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885125|NCT05729009|||COHORT||CROSS_SECTIONAL|||||||
33973093|NCT00525109|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33973094|NCT02796027|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Design||||
33761004|NCT01436201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761005|NCT04948450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33761006|NCT02392325|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885126|NCT02894840|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33885127|NCT00190593|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33885128|NCT03804385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885129|NCT05825872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33973095|NCT04256902|||COHORT||PROSPECTIVE|||||||
33973096|NCT04381286|||COHORT||PROSPECTIVE|||||||
33973097|NCT02444559|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33973098|NCT04847297|||COHORT||PROSPECTIVE|||||||
33885130|NCT04684420|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33885131|NCT05585034|NA|SEQUENTIAL||TREATMENT||NONE||||||
33885132|NCT03986255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885133|NCT06387680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33885134|NCT01274247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885135|NCT05205408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885136|NCT05819255|||COHORT||PROSPECTIVE|||||||
33885137|NCT03440359|RANDOMIZED|PARALLEL||OTHER||SINGLE|Data analysis was completed by blinded observer who had access only to participant ID number, cycle number and treatment, and pregnancy outcome|Participants who met criteria were randomized to either Crinone vaginal therapy versus no therapy in the luteal phase of an ovulation induction cycle. Participants who did not achieve a pregnancy were able to participate in up to 3 cycles, and were re-randomized with each cycle.|f|f|f|t
33885138|NCT03502720|||CASE_CONTROL||PROSPECTIVE|||||||
33885139|NCT01641120|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33885140|NCT01415635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33885141|NCT03176082|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33885142|NCT04478825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885143|NCT03337256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Early endoscopy in emergency department + other clinical parameters||||
33885144|NCT01324557|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072028|NCT03536663|NA|SEQUENTIAL||TREATMENT||NONE||12 HD treatments (4 weeks) with Optiflux dialyzer followed by 38 HD treatments (13 weeks) with Endexo dialyzer||||
34072029|NCT01014078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072030|NCT06251921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885145|NCT02141893|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885146|NCT04047901|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled clinical trial||||
33885147|NCT06273254|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33885148|NCT03725410|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33885149|NCT05990855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All researchers involved in clinical assessments or data processing will be blinded to the assignment of these different conditions. Participants will be asked not to discuss the modality of sleep measurements (Sleep diary or EEG headband) with the research staff or their care provider.||f|t|f|t
33885150|NCT02657135|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33885151|NCT00769145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885152|NCT02899858|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072031|NCT03259256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072032|NCT04788849|||CASE_ONLY||PROSPECTIVE|||||||
33885153|NCT02343484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885154|NCT03657719|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Part 1 : Open label, Part 2 : Double blind|Part 1 : Single group, Part2 : Parallel group|t|f|t|f
33885155|NCT03093155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885156|NCT03634800|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached. Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.||||
33885157|NCT04707755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885158|NCT05539846|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33885159|NCT04689776|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885160|NCT02629562|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33885161|NCT03539445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885162|NCT02314507|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33885163|NCT02058147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885164|NCT05728879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885165|NCT02338687|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster randomized||||
33885166|NCT00643994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885167|NCT01171651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885168|NCT01740180|||COHORT||PROSPECTIVE|||||||
33885169|NCT05673538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885170|NCT00179387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885171|NCT04741269|||OTHER||RETROSPECTIVE|||||||
34072033|NCT00217581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885172|NCT04183985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33885173|NCT02266030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885174|NCT05486403|RANDOMIZED|PARALLEL||PREVENTION||NONE||The effectiveness measures are assessed using a parallel cluster-controlled design. The preschool center is considered a cluster for randomisation to either an Intervention Group or Waitlist Control Group. All preschool centers will deliver the Appetite Toolbox programme by the end of the research and contribute to the implementation outcomes.||||
33885175|NCT02135731|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33885176|NCT03658369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34072034|NCT00916981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072035|NCT05964985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34072036|NCT05976178|||COHORT||PROSPECTIVE|||||||
34072037|NCT02542137|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072038|NCT02723448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072039|NCT00552708|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34072040|NCT06274619|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072041|NCT03475290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072042|NCT04932343|||COHORT||PROSPECTIVE|||||||
34072043|NCT04329845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885177|NCT02640963|RANDOMIZED|PARALLEL||||NONE||||||
33885178|NCT04986787|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34072044|NCT05261243|||COHORT||OTHER|||||||
34072045|NCT01940640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33885179|NCT05892887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34072046|NCT02821416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072047|NCT01841047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072048|NCT02575378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072049|NCT04568798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel 2-arm study in which patients will be randomly assigned to either active treatment or Sham control arms.|t|t|t|f
34072050|NCT00809536|RANDOMIZED|CROSSOVER||||NONE||||||
34072051|NCT06371274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072052|NCT01112592|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072053|NCT04536805|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34072054|NCT02573623|||||PROSPECTIVE|||||||
33885180|NCT03543410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind||t|t|t|t
33885181|NCT06157385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885182|NCT06205056|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33885183|NCT01725750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885184|NCT02697942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885185|NCT00003788|RANDOMIZED|||TREATMENT||||||||
34072055|NCT05421780|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34072056|NCT04076436|||CASE_CONTROL||PROSPECTIVE|||||||
34072057|NCT01731327|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34072058|NCT03160495|||OTHER||PROSPECTIVE|||||||
33885186|NCT00684190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33885187|NCT02977455|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33885188|NCT06485128|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885189|NCT01345500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885190|NCT03651947|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33885191|NCT02796755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885192|NCT01671345|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33973099|NCT02368847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973100|NCT02371798|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33973101|NCT00909727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973102|NCT00215982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973103|NCT00455663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973104|NCT01200056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973105|NCT05998213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33973106|NCT06119607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973107|NCT05200221|||OTHER||PROSPECTIVE|||||||
33973108|NCT05605964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973109|NCT01090765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973110|NCT00006156|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973111|NCT05128188|||CASE_ONLY||PROSPECTIVE|||||||
33973112|NCT01439503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33973113|NCT00793728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973114|NCT03643419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072059|NCT06091098|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a mechanistic physiology study, employing unblinded within-night sham-controlled dynamic interventions to examine OSA pathophysiology Two groups of patients with classic OSA (n=18) and with drive-dependent (n=18)|t|t|f|t
34072060|NCT05937620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072061|NCT04531735|||CASE_CONTROL||PROSPECTIVE|||||||
34072062|NCT03226808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072063|NCT06268795|||COHORT||PROSPECTIVE|||||||
34072064|NCT04063501|||COHORT||PROSPECTIVE|||||||
34072065|NCT03705286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34072066|NCT02385565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072067|NCT01858415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072068|NCT06223607|||OTHER||RETROSPECTIVE|||||||
34072069|NCT06351241|||OTHER||PROSPECTIVE|||||||
34072070|NCT01852513|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072071|NCT05582876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072072|NCT04260074|||CASE_CONTROL||PROSPECTIVE|||||||
34072073|NCT06224998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072074|NCT04171193|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will have two groups, one arm with oral antidepressants and other arm without oral antidepressants, no placebo, no control. Everyone receives the intervention. Those who respond to treatment, will be followed for 24 weeks, those who do not respond, if not in the oral antidepressant group, will star oral antidepressants and be followed for 24 weeks||||
34072075|NCT00068029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072076|NCT04241913|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|There are two arms: an experimental group receiving the Mom Power group intervention over 10 weeks, and a wait list control group. Treatment delivery will be consistent with the Mom Power manual. The waitlist control group will be offered to participate in the intervention following the trial period.||||
33973115|NCT02851290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33885193|NCT03729778|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Participants with be given a screening number and a participant number as a unique identifier that does not involve their name.|Healthy control and HIV-1-infected adults aged 21-45 and 55-75 years old. For HIV-1+ undetectable plasma HIV-1 RNA and documented PPSV23. Two-time blood draw, nasopharyngeal fluid collection, physical function test, fecal collection and questionnaire. Participants will be given PCV13.|t|f|f|f
33885194|NCT05063812|||OTHER||RETROSPECTIVE|||||||
33885195|NCT01651780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973116|NCT04361019|||COHORT||PROSPECTIVE|||||||
33973117|NCT02725944|||COHORT||PROSPECTIVE|||||||
34072077|NCT02997813|||COHORT||RETROSPECTIVE|||||||
34072078|NCT03185520|||COHORT||PROSPECTIVE|||||||
34072079|NCT01912859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072080|NCT02225808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072081|NCT02635256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072082|NCT04283253|NA|SINGLE_GROUP||TREATMENT||NONE||One-arm, multiple baseline sequential, cohort study||||
34072083|NCT02930681|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34072084|NCT02213588|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885196|NCT06496373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885197|NCT00809328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761007|NCT05771337|||CASE_CONTROL||RETROSPECTIVE|||||||
33761008|NCT01713543|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33761009|NCT03472222|NA|SINGLE_GROUP||PREVENTION||NONE||Quasi experimental design||||
33761010|NCT03517592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761011|NCT03670225|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomized||||
33761012|NCT00000280||||TREATMENT||||||||
33885198|NCT02246257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761013|NCT01106443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761014|NCT06108401|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885199|NCT03550560|||CASE_ONLY||PROSPECTIVE|||||||
33885200|NCT02505282|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33885201|NCT04869800|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885202|NCT05745935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973118|NCT03818958|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973119|NCT06230120|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33973120|NCT03672500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|a randomized, single-masked, controlled trial|a randomized, single-masked, controlled trial|t|f|f|t
33973121|NCT01077713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973122|NCT01001169|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973123|NCT05269654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject and Outcome Assessor will be unaware of which side of the subject is treated with the study device and which is treated with saline.|This is a prospective, single-site, double-blinded, split-body, randomized controlled trial.|t|f|f|t
33973124|NCT00788203|||CASE_CONTROL||PROSPECTIVE|||||||
33973125|NCT06546371|NA|SINGLE_GROUP||TREATMENT||NONE||Mono-center explorative pilot study in 12 patients||||
33973126|NCT02445170|||||CROSS_SECTIONAL|||||||
33885203|NCT05827757|NA|SINGLE_GROUP||PREVENTION||NONE||Evaluating the Safety and Efficacy of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Transplantation on Proinflammatory Cytokines and Anti-inflammatory Cytokines on Ageing-related Low-grade Inflammation Patients.||||
33885204|NCT03006809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885205|NCT05818865|NA|SINGLE_GROUP||TREATMENT||NONE||"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."||||
33885206|NCT06340009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885207|NCT01692678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885208|NCT00525577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885209|NCT03902080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885210|NCT04951076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885211|NCT00569894|||COHORT||PROSPECTIVE|||||||
33885212|NCT04182867|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33885213|NCT05587283|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Eight participants will be randomized to be allocated into either a treatment group or a placebo control group (3:1 ratio) for each cohort. There will be three ascending dose cohorts. For the first two doses, the next dose cohorts will begin enrollment only after the safety data review meets a satisfactory evaluation by the safety review committee.|t|t|t|t
33885214|NCT03683784|||COHORT||PROSPECTIVE|||||||
33885215|NCT03074929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885216|NCT01267448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885217|NCT01019785|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885218|NCT05422066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885219|NCT04679831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Dietary Supplement: Ujiplus Ujiplus flour, a nutritional supplement. The flour will be used to prepare porridge and each child is given a serving of 300 ml every school day for 90 days.|f|f|t|f
33885220|NCT04167345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885221|NCT05489445|||COHORT||PROSPECTIVE|||||||
33885222|NCT02413437|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885223|NCT00874302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885224|NCT01618292|||COHORT||RETROSPECTIVE|||||||
33885225|NCT04873466|NA|SINGLE_GROUP||TREATMENT||NONE|Open label, single arm|Prospective Cohort||||
33885226|NCT00630331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885227|NCT04456829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885228|NCT00130715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33885229|NCT04653493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885230|NCT04228848|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||4 subgroups performing jump test||||
33885231|NCT01309087|||COHORT||PROSPECTIVE|||||||
33885232|NCT00263263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885233|NCT04381442|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Buccal \&palatal LLLT Group, Buccal \&palatal LLLT Group||||
33885234|NCT04222751|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33973127|NCT04780503|||COHORT||PROSPECTIVE|||||||
33973128|NCT01161641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973129|NCT06545071|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33885235|NCT05792514|||CASE_CROSSOVER||PROSPECTIVE|||||||
33973130|NCT02310477|||COHORT|||||||||
33973131|NCT05267808|||COHORT||PROSPECTIVE|||||||
33973132|NCT02015793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973133|NCT04960696|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33973134|NCT04643678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973135|NCT00414947|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973136|NCT03928782|||CASE_ONLY||PROSPECTIVE|||||||
33973137|NCT01663909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973138|NCT01342679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973139|NCT00738556|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33973140|NCT04296864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-masked study in which both participants and investigators will be masked to study treatment.||t|f|t|f
33973141|NCT00893542|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973142|NCT03629574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973143|NCT02697500|||COHORT||CROSS_SECTIONAL|||||||
33973144|NCT04455568|||OTHER||PROSPECTIVE|||||||
33973145|NCT00322309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885236|NCT03170752|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33885237|NCT03828487|NA|SINGLE_GROUP||OTHER||NONE||||||
33885238|NCT03904797|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33973146|NCT02099500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973147|NCT00519012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973148|NCT00711906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973149|NCT04706975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973150|NCT04648059|||COHORT||PROSPECTIVE|||||||
33973151|NCT03868449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973152|NCT01590498|||COHORT||PROSPECTIVE|||||||
33973153|NCT05131854|||COHORT||PROSPECTIVE|||||||
33973154|NCT01220349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973155|NCT00743691|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973156|NCT03342898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33973157|NCT01950988|RANDOMIZED|PARALLEL||||SINGLE||||||
33973158|NCT04756609|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33973159|NCT03776903|||COHORT||OTHER|||||||
33885239|NCT04405960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This study used Contract Research Organization (CRO) Equilab to ensure the quality. In this study, researchers, respondents, interviewers, supplement providers, radiology and laboratory staffs were blinded. The interviewers used a questionnaire that had been prepared previously and was used equally for the intervention and control groups.~Knee x-ray examination was performed to determine knee OA severity based on Kellgren-Lawrence grading system. It was carried out using the same method and technique between the intervention and control groups. X-ray examination was carried out at the same hospital's radiology unit and was interpreted blindingly by the same radiologist. Blood examination to measure 25(OH)D and COMP was carried out using the same methods and techniques between the intervention and control groups by staffs from the same certified laboratory."|This is a randomized, double-blind, and placebo-controlled trials. Elderly subjects with symptomatic knee OA visited our clinic in Jakarta were recruited. Medical history taking, physical examinations, knee radiology, blood test for Vitamin D (25(OH)D), calcium, and COMP serum were performed. Subjects were then randomly allocated to either intervention group to be given 1 µg Alphacalcidol or control group to be given placebo in 12 weeks.|t|t|t|f
33885240|NCT00808743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33885241|NCT02554929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885242|NCT00967278|||COHORT||CROSS_SECTIONAL|||||||
33885243|NCT00422760|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33885244|NCT00805896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33885245|NCT01301846|||COHORT||PROSPECTIVE|||||||
33885246|NCT05220267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973160|NCT06415253|||CASE_CONTROL||PROSPECTIVE|||||||
33973161|NCT05367856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973162|NCT03636321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973163|NCT03993171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Research participants and site personnel are not masked to study drug, but will be blinded to study dose for each cohort (single-blinded).|Open Label, Investigator Blinded, Sequential Cohort (max of 2 cohorts amongst the possible 4 interventions)||||
33973164|NCT01915056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973165|NCT06452810|NA|SINGLE_GROUP||OTHER||NONE|"Masking:~None (Open Label)"|"Study Type:~Interventional (Clinical Trial)~Estimated Enrollment:~35 participants~Allocation:~Non-randomized~Intervention Model:~Single Group Assignment~Masking:~None (Open Label)~Primary Purpose:~Treatment"||||
33885247|NCT05086601|||COHORT||PROSPECTIVE|||||||
33885248|NCT01186393|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33885249|NCT01940614|||COHORT||PROSPECTIVE|||||||
33885250|NCT02700178|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885251|NCT01750814|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885252|NCT04293016|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33885253|NCT05769660|NA|SEQUENTIAL||TREATMENT||NONE|open label|||||
33885254|NCT03313050|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Observer-blinded||t|t|t|f
33885255|NCT02690194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973166|NCT05304299|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups of subjects are subject to pre-test and post-test intraocular pressure measurements.||||
33973167|NCT05936879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"A randomized control trial in which two groups one is intervention and the other is controlled group .Patient in the Intervention group will be treated with routine pysical therapy, Inspiratory muscle training and early ambulation after surgery, whereas patients in the control group will be not be treated with these interventions and will rather undergo routine physical therapy (ankle pumps, hand pumps isometrics of upper and lower limbs).~Patients in the intervention group will receive treatment until discharge from hospital."|"A randomized control trial in which two groups one is intervention and the other is controlled group .Patient in the Intervention group will be treated with routine pysical therapy, Inspiratory muscle training and early ambulation after surgery, whereas patients in the control group will be not be treated with these interventions and will rather undergo routine physical therapy (ankle pumps, hand pumps isometrics of upper and lower limbs).~Patients in the intervention group will receive treatment until discharge from hospital."|t|f|f|f
33973168|NCT06543147|RANDOMIZED|PARALLEL||SCREENING||NONE||Administering a pre-test to the participants in the experimental and control groups. After the pre-test, the participants in the experimental group were given breast cancer and breast self-examination training, brochure distribution, and reminders of breast self-examination by phone for six months. They administered a post-test to the participants in the experimental and control groups six months later.||||
33973169|NCT06375590|||COHORT||PROSPECTIVE|||||||
33973170|NCT03602014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973171|NCT03554421|NA|SINGLE_GROUP||TREATMENT||NONE|Treatment known to both investigator and patient|Only patients with chronic anal fissures treated||||
33973172|NCT04845061|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33973173|NCT02637557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973174|NCT00442845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885256|NCT00176293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885257|NCT04528121|RANDOMIZED|PARALLEL||TREATMENT||NONE||control group which received conventional selected exercise program in form of static and dynamic balance training exercises and study group received the same exercise training program in addition to CoDuSe balance training and step square exercises, three times per week for four weeks.||||
33885258|NCT00898365|||CASE_ONLY||PROSPECTIVE|||||||
33885259|NCT04299100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885260|NCT04276207|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33885261|NCT06540950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885262|NCT03696680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885263|NCT02672085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885264|NCT02538484|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33885265|NCT04805086|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective trial||||
33761015|NCT05547425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Of the 3 obfuscation settings (blur, mask, cartoon), participants are randomly assigned to 1, which they test for the first or second 7-day test period. During the remaining test period, participants use WildCam with the raw images setting. There is a washout period between each test period. The order of the test sequence is counterbalanced across participants to reduce carryover effects.||||
33761016|NCT04070625|||COHORT||PROSPECTIVE|||||||
33885266|NCT00374244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072085|NCT03337620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subject, investigator, study coordinator, and additional study staff will remain blinded. One member of the staff will assign subjects to a treatment group based on a computerized randomization number produced by a computer software system. The number will correspond to a kit number, of which the staff member will then use to prepare the Tx360® device for each of the subject's treatments during the 4-week treatment phase. If the clinical site has a pharmacy, it is preferred that the pharmacy receive the study medication and Tx360® devices, maintain custody of the study medication and Tx360® devices during the study, and prepared the medication in Tx360® devices for each subject's treatment, according to the computer-generated randomization. In order to maintain subject-blinding during the active phase of the study, subjects will be given a piece of lemon candy prior to each procedure as a taste distractor|multi-center, double blind, parallel, prospective, randomized; 28 days of screening; 4 weeks active treatment; 3 months of follow-up post-treatment|t|t|t|t
34072086|NCT02903810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761017|NCT03324893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761018|NCT01737099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761019|NCT06626113|||COHORT||PROSPECTIVE|||||||
33761020|NCT02130284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761021|NCT00876213|||CASE_CONTROL|||||||||
33761022|NCT02348684|||CASE_ONLY||PROSPECTIVE|||||||
33761023|NCT00384059|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761024|NCT06248398|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33761025|NCT03175627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind (Subject, Investigator, Outcomes Assessor)|In a split-mouth design, each participant will receive 2 matched restorations, one of each material.|t|f|t|t
33761026|NCT05281835|||COHORT||PROSPECTIVE|||||||
33761027|NCT05782725|||COHORT||PROSPECTIVE|||||||
33761028|NCT05035914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761029|NCT00622843|RANDOMIZED|PARALLEL||||NONE||||||
33761030|NCT00681616|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072087|NCT06241885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34072088|NCT05420142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34072089|NCT03495297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885267|NCT03077932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072090|NCT05033925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|double blind; Randomized Controlled Trial||t|t|t|t
34072091|NCT01961570|||COHORT||PROSPECTIVE|||||||
34072092|NCT01670045|||COHORT||PROSPECTIVE|||||||
34072093|NCT03094884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072094|NCT01749046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072095|NCT02721498|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34072096|NCT02487537|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33761031|NCT01019538|||CASE_ONLY||PROSPECTIVE|||||||
33761032|NCT06043986|||OTHER||OTHER|||||||
33885268|NCT02274337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885269|NCT01979497|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33885270|NCT00617877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885271|NCT03005626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072097|NCT00002255||||TREATMENT||NONE||||||
34072098|NCT04542876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072099|NCT01787006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072100|NCT01923324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072101|NCT01990573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885272|NCT00706030|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33885273|NCT00211107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072102|NCT00441870|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072103|NCT00061178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072104|NCT03387969|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072105|NCT03147950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072106|NCT04235322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072107|NCT04655729|||COHORT||PROSPECTIVE|||||||
34072108|NCT06476704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072109|NCT03959527|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single dose of Zoliflodacin or comparators combination in single dose: ceftriaxone and azithromycin||||
34072110|NCT06178484|||COHORT||CROSS_SECTIONAL|||||||
34072111|NCT05122455|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||This is a prospective, non-randomized, interventional study of SCAD patients||||
34072112|NCT02991963|||CASE_CONTROL||PROSPECTIVE|||||||
34072113|NCT02090283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072114|NCT01098162|||COHORT||PROSPECTIVE|||||||
34072115|NCT00762190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072116|NCT00971490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34072117|NCT06468124|||COHORT||PROSPECTIVE|||||||
34072118|NCT04618991|NA|SINGLE_GROUP||OTHER||NONE||||||
33761033|NCT04281186|||CASE_CONTROL||PROSPECTIVE|||||||
33761034|NCT02900625|||COHORT||OTHER|||||||
33761035|NCT00538928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761036|NCT03874065|||OTHER||PROSPECTIVE|||||||
33885274|NCT04924855|||COHORT||CROSS_SECTIONAL|||||||
33885275|NCT01275222|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33885276|NCT00934076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885277|NCT04201080|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Patients will be randomised to receive TRV250 20 mg or placebo in Part A and 1 of 3 doses of TRV250 or placebo in Part B. The study will be conducted in a double-blinded fashion (Investigator- and patient -blinded). Only unblinded personnel will have access to the randomisation list before official unblinding of treatment assignment. Interim analyses will be conducted at the end of Part A of the study prior to proceeding to Part B and the preliminary efficacy pharmacokinetic, safety and tolerability data will be evaluated unblinded at the end of Part A and shared with the Investigators in an unblinded manner, prior to starting Part B.|The study consists of 2 parts: Part A is a proof of concept study; and Part B will be a dose ranging study|t|f|t|f
33885278|NCT05019105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885279|NCT00578643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885280|NCT06385704|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885281|NCT01946516|||COHORT||PROSPECTIVE|||||||
33885282|NCT03246828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885283|NCT03603652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072119|NCT06598124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Single coding|Double-blind, randomized, 2x2 cross-over study|t|f|t|t
34072120|NCT06285071|||CASE_ONLY||PROSPECTIVE|||||||
34072121|NCT03941145|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34072122|NCT06483126|||CASE_ONLY||CROSS_SECTIONAL|||||||
34072123|NCT01148264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34072124|NCT05851638|||COHORT||PROSPECTIVE|||||||
34072125|NCT03698539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072126|NCT05004792|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participating Pathologists are either given access to a learning intervention called DermLoop Learn for a short period or not given access to any learning intervention. During the trial, both groups interpret histopathological skin lesions with access to clinical information, an overview picture, and a dermoscopic picture of the lesion.|Randomized clinical trial. Pathologists are randomized to either the control group or the intervention group, allocation ratio of 1:1.|f|f|t|t
34072127|NCT00095342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33761037|NCT00534222|||COHORT||PROSPECTIVE|||||||
33761038|NCT00087958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761039|NCT00524225|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761040|NCT06262061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized in a 1:1 allocation to either the propranolol or control group. Our hospital pharmacy will control the randomization procedure. The propranolol group will receive over-encapsulated whole marketed tablets comprised of 20mg oral propranolol \[USP grade\] filled with lactose monohydrate powder \[NF grade\] encapsulated with opaque gelatin capsules twice daily for 14 days (or until hospital discharge or death). The control group will receive an oral placebo comprised of lactose monohydrate powder \[NF grade\] encapsulated with indistinguishable opaque gelatin capsules. The pharmacy will have access to the randomization key. Nursing staff will remove the gelatin capsule casing and dissolve the trial drug \& placebo in sterile water prior to administering it enterally via a feeding tube to the participants. Aside from the nursing staff, the participants, research team, and remainder of the clinical care teams will all remain blinded to treatment allocation.|Prospective, single- center double- blinded randomized control trial comparing placebo to propranolol for the treatment of moderate- severe traumatic brain injury.|t|t|t|t
33761041|NCT03253484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor will not know which side is the treated side of scar|split scar study|f|f|f|t
33761042|NCT02317939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761043|NCT02843256|||COHORT||PROSPECTIVE|||||||
33761044|NCT06100510|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33761045|NCT01147484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761046|NCT02277743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761047|NCT04904770|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to nature of therapy, it is impossible to mask participants, care provider, investigators or outcomes assessors. Statistician will however be blinded to allocation.|Randomized Controlled Trial||||
33885284|NCT02058901|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33885285|NCT01267630|||COHORT||PROSPECTIVE|||||||
33885286|NCT02921451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885287|NCT01625325|||COHORT||PROSPECTIVE|||||||
33885288|NCT05405647|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fifty menopausal women with mild to moderate CTS will be selected randomly from outpatient clinic of the physical therapy department of El khazendara general hospital, Shobra to participate in this study,Group A: Represented the study group, it consisted of 25 patients who received a program of 6 session of Shock wave Therapy on the affected wrist,5 minute per session. Group B: Represented the control group, it consisted of 25 patients who received a program of kinesio tape application on the affected wrist for 3 days .||||
33885289|NCT02120755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885290|NCT04378283|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885291|NCT05124223|||OTHER||RETROSPECTIVE|||||||
33885292|NCT00814242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885293|NCT01120665|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33885294|NCT04488510|||OTHER||PROSPECTIVE|||||||
33885295|NCT00331006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885296|NCT00899093|||COHORT||PROSPECTIVE|||||||
33885297|NCT02012556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885298|NCT02146339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33885299|NCT03644628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33885300|NCT01087541|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33885301|NCT05023031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885302|NCT05762328|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33885303|NCT00035451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885304|NCT04202640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885305|NCT04959331|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 short-course antibiotic regimens and one-dose of fosfomycin||||
33885306|NCT01564836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885307|NCT01638728|||CASE_CROSSOVER||PROSPECTIVE|||||||
33885308|NCT02911766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885309|NCT05783700|||OTHER||CROSS_SECTIONAL|||||||
33885310|NCT04162210|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized and multi-center study||||
33885311|NCT05590520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072128|NCT02164643|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34072129|NCT05767697|||COHORT||PROSPECTIVE|||||||
34072130|NCT04030676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072131|NCT05743777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072132|NCT04640155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34072133|NCT02132728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34072134|NCT05569369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072135|NCT01897883|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34072136|NCT06613009|NA|SEQUENTIAL||TREATMENT||NONE||||||
34072137|NCT01237288|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072138|NCT03295136|NA|SINGLE_GROUP||PREVENTION||NONE||This study includes a pre/post study.||||
34072139|NCT00765817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072140|NCT04120181|||CASE_CONTROL||RETROSPECTIVE|||||||
34072141|NCT03453814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34072142|NCT02250963|||CASE_ONLY||PROSPECTIVE|||||||
34072143|NCT01167348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072144|NCT04301739|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34072145|NCT05859308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072146|NCT03746405|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34072147|NCT00243971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072148|NCT01738776|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072149|NCT04118647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072150|NCT04680247|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
34072151|NCT06215482|||COHORT||PROSPECTIVE|||||||
34072152|NCT00972283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072153|NCT04849624|||COHORT||PROSPECTIVE|||||||
34072154|NCT02371863|||||CROSS_SECTIONAL|||||||
34072155|NCT03429621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34072156|NCT04485663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072157|NCT01535443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072158|NCT04716374|||COHORT||RETROSPECTIVE|||||||
34072159|NCT02748057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072160|NCT03360214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072161|NCT06156605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072162|NCT04724551|||COHORT||RETROSPECTIVE|||||||
33761048|NCT06178861|RANDOMIZED|PARALLEL||TREATMENT||NONE|Test group: Group wearing a radiotherapy bra / Control group: Group not wearing a radiotherapy bra -Allocation: Random -Blinding: None -Time: Prospective|Test group: Group wearing a radiotherapy bra / Control group: Group not wearing a radiotherapy bra -Allocation: Random -Blinding: None -Time: Prospective||||
33761049|NCT03220399|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761050|NCT03381404|NA|SINGLE_GROUP||OTHER||NONE||Open Label||||
33761051|NCT00871689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761052|NCT01203670|NA|SINGLE_GROUP||||NONE||||||
33761053|NCT01963338|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33885312|NCT02369081|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33885313|NCT00946309|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33885314|NCT05772637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885315|NCT01234155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885316|NCT02361645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33885317|NCT02797119|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33885318|NCT05591495|||COHORT||PROSPECTIVE|||||||
33885319|NCT04148274|||CASE_ONLY||PROSPECTIVE|||||||
33885320|NCT05902104|||COHORT||PROSPECTIVE|||||||
33885321|NCT01642745|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33885322|NCT05141305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885323|NCT01556984|||CASE_CONTROL||PROSPECTIVE|||||||
33885324|NCT06547983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885325|NCT03162705|||COHORT||PROSPECTIVE|||||||
33885326|NCT01691469|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885327|NCT02018497|||COHORT||PROSPECTIVE|||||||
33761054|NCT03786952|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33761055|NCT00117156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761056|NCT04242433|||COHORT||PROSPECTIVE|||||||
33761057|NCT00003163||||TREATMENT||||||||
33761058|NCT03420924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885328|NCT00135304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885329|NCT00760409|||OTHER||PROSPECTIVE|||||||
33885330|NCT00245947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885331|NCT00003721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885332|NCT02720757|||COHORT||PROSPECTIVE|||||||
33885333|NCT00267553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885334|NCT02497807|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33885335|NCT00080197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072163|NCT03138577|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician reviewing the ultrasound images and determining the presence/absence of diaphragm paralysis is masked to treatment assignment.|"A modified 3+3 dose escalation design, modeled after Phase I dose-finding trials, was used to define the dose response curve for local anesthetic volume in the supraclavicular block and resulting hemidiaphragmatic paresis in patients undergoing right upper extremity surgery with supraclavicular block as the primary anesthetic. Possible dosing levels of 5, 10, 15, 20, 25, 30, 35 and 40 mL of local anesthetic were pre-specified with a cohort of three subjects per dose. Diaphragm function was determined by a blinded assessor with M-mode tracings of the right diaphragm before and after supraclavicular block. Secondary objectives included the assessment of respiratory function via negative inspiratory force, oxygen saturation and subjective dyspnea, as well as the extent of sensory and motor blockade."|f|f|f|t
34072164|NCT03621436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072165|NCT02820571|||COHORT||PROSPECTIVE|||||||
34072166|NCT06011993|||OTHER||RETROSPECTIVE|||||||
34072167|NCT01190189|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34072168|NCT02833064|||COHORT||PROSPECTIVE|||||||
34072169|NCT05681832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885336|NCT00505453|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973175|NCT03422146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Information concerning the group the patient was randomized into will not be available to the physicians that will see the participants at future appointments and grade their outcomes (masked assessor).~* All microbiology readers will be masked to treatment group allocation."|"This study is a single-centre, randomized, outcomes-assessor masked trial with two groups. Patients with chronic blepharitis will be randomized into either the Cliradex® eyelid hygiene or I-Lid 'n Lash® Hygiene group.~There will be 20 participants enrolled in each group. Although both eyes will receive treatment, only the worse eye will be enrolled in the study. In addition to randomizing the participants into treatment group they will also be placed by chance into either the 3 visit or 4 visit group (n=10 per group)."|f|f|t|t
33973176|NCT03857022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973177|NCT01268176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33973178|NCT06332547|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33973179|NCT04169282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072170|NCT04514250|||COHORT||PROSPECTIVE|||||||
34072171|NCT01343537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072172|NCT01229319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34072173|NCT02861963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072174|NCT04438616|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33885337|NCT05610371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|RCT double blind|RCT double blind|t|t|t|f
33885338|NCT05764967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885339|NCT02758535|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33885340|NCT03881007|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33885341|NCT01953718|||CASE_ONLY||RETROSPECTIVE|||||||
33885342|NCT01931761|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885343|NCT01214044|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885344|NCT00809731|||CASE_ONLY||PROSPECTIVE|||||||
33885345|NCT00713219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973180|NCT04559256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973181|NCT05869097|||COHORT||RETROSPECTIVE|||||||
33973182|NCT06280469|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33973183|NCT04312984|||CASE_ONLY||RETROSPECTIVE|||||||
33973184|NCT05269628|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33973185|NCT01272557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973186|NCT00898482|||CASE_ONLY|||||||||
33973187|NCT06482970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973188|NCT00783666|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33973189|NCT00448955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973190|NCT03878316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973191|NCT06166472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072175|NCT05871528|||COHORT||PROSPECTIVE|||||||
34072176|NCT02362737|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072177|NCT01533948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885346|NCT02549716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33885347|NCT02932787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885348|NCT02185937|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33885349|NCT02118376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885350|NCT05772897|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All participants will ultimately receive the parenting group intervention. A waitlist control design will be implemented to compare outcomes between those not having received the intervention yet and those having completed it. Data collection will occur pre-intervention, immediately post-intervention, at 6 months post-intervention, at 12 months post-intervention, and at approximately 5 years post-intervention (when child is school-aged).||||
33885351|NCT01656772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885352|NCT01417845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885353|NCT06217120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This will be a pilot mechanistic study. Patients will be randomly assigned in a 1:1 ratio to receive colchicine 0.5 mg daily or a matched placebo. Follow-up will occur at 6 months after randomization.|t|t|t|t
33885354|NCT00705263|||COHORT||PROSPECTIVE|||||||
33885355|NCT02656628|||COHORT||PROSPECTIVE|||||||
33885356|NCT04259853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33973192|NCT03416595|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The model is a randomized, double-blinded, parallel, placebo-controlled intervention study to assess effect of N1115 Probiotic Supplement (containing Junlebao Lp. N1115) on gut development in young children. Up to 60 healthy children, between the ages of 6 months and 3 years who were born by caesarean section will be recruited into this study. Participants will be randomly assigned to one of two treatment groups, one group is N1115 Probiotic Supplement intervention which contains Lp. N1115 and maltodextrin, the other group is placebo intervention which contains maltodextrin only.|t|t|t|t
33973193|NCT00138359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973194|NCT05446727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||f|f|t|f
33973195|NCT00535509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973196|NCT00380003|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33885357|NCT04786067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973197|NCT02935959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761059|NCT05354843|NA|SEQUENTIAL||TREATMENT||NONE||"Anticipated ET0038 Dose Escalation Schedule Cohort ET0038 dose at each treatment administration point~1. SDL = 10 mg QD 2 .SDL × 2 = 20 mg QD 3. SDL × 4 = 40 mg QD 4 .SDL × 6 = 60 mg QD 5 .SDL × 8 = 80 mg QD Maximum Dose Level Abbreviations: QD=once a day; SDL=Starting Dose Level"||||
33761060|NCT06065878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761061|NCT02755597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761062|NCT04302376|||COHORT||PROSPECTIVE|||||||
33761063|NCT01970852|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33761064|NCT00048230|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761065|NCT06014138|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|None, open label, physiological study|Prospective, cross-over trial design comparing intravenous versus inhaled volatile sedation||||
33761066|NCT00047775|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33761067|NCT04012060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients randomized to either the limited access or conventional aortic valve replacement will be blinded for the treatment until day four postoperatively. The patients participating in the prospective registry will not be blinded for their treatment.~All nurses on the postoperative ward are blinded for the treatment the patients received."|Patients will be randomized 1:1 to both arms with 80 patients per arm. Patients who are unwilling or unable to participate in the randomized study will be treated via conventional median sternotomy with a sutured aortic valve prosthesis and participate in a prospective registry.|t|t|f|f
33761068|NCT00983632|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761069|NCT06624579|NA|SINGLE_GROUP||OTHER||NONE||26 adult subjects with moderate-to-severe active (defined as having patient-reported outcomes, PRO \&gt; 2), left-sided or extensive UC, requiring small molecules therapy according to the standards of care (ECCO guidelines) and performing routine investigations with Colonoscopy before starting appropriate therapy, according to the current standard of care indications and ECCO guidelines.||||
33761070|NCT02730182|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761071|NCT04341961|NA|SINGLE_GROUP||OTHER||NONE||||||
33761072|NCT01437163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761073|NCT03625986|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33761074|NCT04980664|NA|SINGLE_GROUP||OTHER||NONE||||||
33761075|NCT01618734|||COHORT||RETROSPECTIVE|||||||
33761076|NCT05680337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||1:1 randomization of active stimulation vs. sham stimulation|f|f|t|f
33761077|NCT05064787|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single cohort of 50 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of which will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled from a single site, The University of Texas MD Anderson Cancer Center.||||
33761078|NCT01410370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761079|NCT05416905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761080|NCT04461327|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Painful stimulations (see detailed description)||||
33761081|NCT01557322|||COHORT||RETROSPECTIVE|||||||
33761082|NCT00462137|||CASE_CONTROL||PROSPECTIVE|||||||
33761083|NCT02740075|||COHORT||PROSPECTIVE|||||||
33761084|NCT02980926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885358|NCT00457340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885359|NCT02920788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885360|NCT01415024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885361|NCT00332709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885362|NCT00997009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885363|NCT02382133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885364|NCT04074772|||OTHER||OTHER|||||||
33885365|NCT00565994|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33885366|NCT04399083|NA|SINGLE_GROUP||OTHER||NONE||||||
33885367|NCT02468648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885368|NCT03830216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants in the control arm will use a blinded device. All participants will be blinded to baseline time-in-range and HbA1c measures. Investigators will be blinded to professional CGM baseline time-in-range.|Prospective, randomized, controlled treatment|t|f|t|f
33885369|NCT04957381|||COHORT||OTHER|||||||
33885370|NCT00783393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885371|NCT05100641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, 2:1 randomization|t|t|t|t
33885372|NCT00000984||||TREATMENT||NONE||||||
33973198|NCT00727454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33973199|NCT06057883|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A Single Arm, Open-Label, and Proof-of-Concept Study||||
33973200|NCT02267057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973201|NCT03777137|||OTHER||PROSPECTIVE|||||||
33973202|NCT06245174|||COHORT||CROSS_SECTIONAL|||||||
33973203|NCT06393101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973204|NCT02752776|NA|SINGLE_GROUP||OTHER||NONE||||||
33973205|NCT00329602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973206|NCT01499121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973207|NCT02022813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33973208|NCT06541366|||CASE_CONTROL||OTHER|||||||
33973209|NCT03777475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973210|NCT03942510|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33973211|NCT00409994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973212|NCT03662919|||COHORT||PROSPECTIVE|||||||
33973213|NCT00003706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973214|NCT02363582|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33973215|NCT03270345|||COHORT||CROSS_SECTIONAL|||||||
33973216|NCT01901055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel was a one-way cross over after 12 weeks with persons originally in the sham group being titrated onto active CPAP.|t|f|t|t
33973217|NCT03622502|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33973218|NCT04217226|||COHORT||PROSPECTIVE|||||||
33973219|NCT03238950|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33973220|NCT02353000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973221|NCT05015556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of results by computer of the outcome results. Blinding of the patients or the care provider is not possible due to the obvious differences.||f|f|f|t
33973222|NCT03604887|||OTHER||CROSS_SECTIONAL|||||||
33973223|NCT03277781|||OTHER||CROSS_SECTIONAL|||||||
33973224|NCT01665053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885373|NCT04947527|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All study personnel except for designated personnel in the data center will be blinded to the participant treatment assignment. In order to maintain blinding and eliminate examiner bias, the staff member applying these varnishes will not perform the caries scoring exams.|This is a single center randomized, double-blind, placebo-controlled, parallel-group trial.|t|t|t|t
33973225|NCT03377556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973226|NCT02938494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973227|NCT01538342|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973228|NCT02465411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885374|NCT01037673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885375|NCT01543347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885376|NCT01535079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885377|NCT06341673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and those who undertake data input and data analysis will be blind to group allocation to reduce the risk of performance bias. A principal investigator and co-investigator will insert data into SPSS so that the researchers can analyse data without having access to the allocation.|Randomized, sham-controlled, double blind study with 1:1 allocation ratio.|t|f|f|t
33885378|NCT02078531|||CASE_ONLY||PROSPECTIVE|||||||
33885379|NCT01961479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885380|NCT04373460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A total of approximately 1344 eligible subjects stratified with a target goal (but not binding) of 50:50 in the \<65 vs ≥ 65 age range will be randomized in a 1:1 ratio to receive either HCIP or control plasma.|t|t|t|f
33885381|NCT00226551|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33885382|NCT04999579|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33885383|NCT02808390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885384|NCT05042427|||FAMILY_BASED||PROSPECTIVE|||||||
33885385|NCT05281263|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33885386|NCT05300945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885387|NCT00483860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973229|NCT04240483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973230|NCT01191021|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33973231|NCT05566093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761085|NCT01971164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885388|NCT05281874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and principal investigator will be masked to intervention conditions.||t|f|t|f
33761086|NCT05144932|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The patients are in this clinical trial instructed to use the device continuously for 1 month. There will be no masking.|"The patients are in this clinical trial instructed to use the device continuously for 1 month.~No comparator will be used in this clinical trial. The main reason is that there are no similar systems available. Feasibility is the main research question."||||
33761087|NCT03430141|NA|SINGLE_GROUP||PREVENTION||NONE||Hybrid effectiveness-implementation||||
33761088|NCT05234359|||COHORT||CROSS_SECTIONAL|||||||
33761089|NCT03880630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761090|NCT03148769|||COHORT||PROSPECTIVE|||||||
33761091|NCT01567358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761092|NCT01455207|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33761093|NCT06171230|NA|SINGLE_GROUP||TREATMENT||NONE|In psychological research, it is not feasible to employ a 'blind' approach for both participants and EMDR therapists regarding the intervention. An independent research assistant, not otherwise involved in the study, oversees the completion of daily measurements and questionnaires. This ensures that EMDR therapists remain blind to the obtained data. An exception to this is the utilization of the results from the LEC and PCL-5, which are employed for case conceptualization. There will be no randomization of baseline length or initiation of the intervention, as seen in multiple baseline designs.|A single-case experimental design, replicated nine times (N-of-1 study).||||
33885389|NCT04861220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher by statistical analysis will be blind, as he will not be participating in the data collection.|This is a randomized clinical trial in women diagnosed with breast cancer who will undergo cancer treatment with a curative therapeutic proposal. Women who attend the Hospital do Câncer III / INCA for clinical screening consultation, before starting cancer treatment, will be evaluated by physiotherapy and nutrition and recruited as to the eligibility criteria for the study. Women who agree to participate will sign the Informed Consent Form and will be submitted to an initial inclusion assessment. After recruitment and definition of their initial treatment - neoadjuvant treatment or immediate surgical treatment, women will be randomly allocated to the Intervention Group (Group A - Prehabilitation Program + neoadjuvant treatment or Group B - Prehabilitation Program + immediate surgical treatment) and Control Group (Group C - Usual activities + neoadjuvant treatment or Group D - Usual activities + immediate surgical treatment).|f|f|f|t
33885390|NCT03981432|RANDOMIZED|PARALLEL||TREATMENT||NONE||all participants receive the same intervention||||
33885391|NCT00110942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885392|NCT01497262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885393|NCT01140009|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33885394|NCT02373111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885395|NCT02583685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885396|NCT05366283|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33885397|NCT04409184|||COHORT||RETROSPECTIVE|||||||
33885398|NCT05147480|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention group (yoga) and control group (standardized protocol)||||
33761094|NCT00638235|||COHORT||PROSPECTIVE|||||||
33885399|NCT05268406|NA|SINGLE_GROUP||SCREENING||NONE||||||
33885400|NCT02262169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885401|NCT03050983|||COHORT||PROSPECTIVE|||||||
33885402|NCT02115230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885403|NCT04172558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885404|NCT03274921|||COHORT||PROSPECTIVE|||||||
33885405|NCT06491134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885406|NCT00109148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885407|NCT01171820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885408|NCT01784835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33885409|NCT01692808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885410|NCT06156865|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the scorers of the outcomes are not informed of participants' group status|toddlers who are late talking receive either intervention or are waitlist controls. There is also a group of typically developing children|f|f|f|t
33885411|NCT02714478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885412|NCT00140764|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33885413|NCT06064344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885414|NCT03669315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Outcome assessor, investigators and participants will be blinded to the type of treatment (active TMS or Placebo)|After selection and enrollment, participants will be screened at baseline with MRI and a complete diagnostic and clinical assessment, described in the following corresponding sections. Using a placebo-controlled double-blind design patients will be randomized to receive active or placebo cTBS.|t|f|t|t
33885415|NCT06406348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072178|NCT02384538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072179|NCT02264210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072180|NCT00101699|||DEFINED_POPULATION||PROSPECTIVE|||||||
34072181|NCT05922514|||CASE_ONLY||PROSPECTIVE|||||||
34072182|NCT02235129|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
34072183|NCT04335058|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34072184|NCT00613392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761095|NCT05775679|||COHORT||PROSPECTIVE|||||||
33885416|NCT05653778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be masked on whether they will receive scrambler therapy or TENS treatment for neuropathic pain.|Randomly assigned scrambler therapy or TENS treatment to patients.|t|f|f|f
33885417|NCT02840851|||CASE_CONTROL||PROSPECTIVE|||||||
34072185|NCT01275794|||CASE_ONLY||RETROSPECTIVE|||||||
33761096|NCT03280771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761097|NCT04849221|||CASE_CONTROL||PROSPECTIVE|||||||
33761098|NCT04624503|||COHORT||PROSPECTIVE|||||||
33761099|NCT00963911|NA|SINGLE_GROUP||SCREENING||NONE||||||
33761100|NCT04417387|||COHORT||PROSPECTIVE|||||||
33761101|NCT02468635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761102|NCT06483425|||COHORT||PROSPECTIVE|||||||
33761103|NCT03526601|||COHORT||CROSS_SECTIONAL|||||||
34072186|NCT06180434|||COHORT||RETROSPECTIVE|||||||
34072187|NCT04636502|||OTHER||RETROSPECTIVE|||||||
34072188|NCT04823390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33761104|NCT01704625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33761105|NCT01520402|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761106|NCT06232720|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be an open label study, non-controlled and non-randomized.||||
33761107|NCT01827826|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33761108|NCT03897062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be treated from pre-packaged blinded treatment schedules.|A placebo-controlled, double-blind randomised trial|f|f|f|t
33885418|NCT01602055|RANDOMIZED|CROSSOVER||||NONE||||||
33885419|NCT02324166|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33885420|NCT05438667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885421|NCT03757988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885422|NCT00796588|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33885423|NCT02538172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072189|NCT01038102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072190|NCT03287115|NA|SINGLE_GROUP||OTHER||NONE||||||
34072191|NCT01738529|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34072192|NCT05007626|||CASE_CONTROL||RETROSPECTIVE|||||||
34072193|NCT05881031|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a 12-week, open-label feasibility study of a pragmatic, two-arm parallel-group, randomized controlled trial with 1:1 allocation of children newly initiating NiPPV that compares home NiPPV initiation to usual care of initiating NiPPV in a one-night in-hospital polysomnogram.||||
34072194|NCT03734523|||COHORT||PROSPECTIVE|||||||
34072195|NCT05926843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072196|NCT06510907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34072197|NCT02665741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34072198|NCT04021498|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34072199|NCT04877990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072200|NCT01965314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072201|NCT05275582|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will not know which version of CARE that the patient receives.|The CARE intervention will be piloted in two formats: 1) that includes a conjoint meeting between a PACT medical provider and a behavioral health provider; and 2) does not include the conjoint meeting with the medical provider. All other elements of the treatment are identical.|f|f|f|t
34072202|NCT05225389|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open-label, single-dose study||||
34072203|NCT01139346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072204|NCT03444259|||COHORT||PROSPECTIVE|||||||
34072205|NCT06414603|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34072206|NCT04569604|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761109|NCT05601934|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33761110|NCT01042028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761111|NCT03841656|||COHORT||RETROSPECTIVE|||||||
33761112|NCT02476955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761113|NCT02617992|||COHORT||PROSPECTIVE|||||||
33761114|NCT01618084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885424|NCT01390909|||COHORT||RETROSPECTIVE|||||||
33885425|NCT04361201|||CASE_CONTROL||PROSPECTIVE|||||||
33885426|NCT01823068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885427|NCT05309759|||COHORT||PROSPECTIVE|||||||
33973232|NCT06187922|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients will be randomly assigned into two equal groups; Group P: Pregablain group and Group C: control group. Group P will receive oral capsule pregabalin 75mg one hour preoperatively and will continue as B.D for 72 hrs, Group C will not receive any premedication preoperatively.~Intraoperatively both groups will receive inj. Midazolam 2 mg before subarachnoid block with hyperbaric Bupivacaine 0.5% 2.5-3ml and fentanyl 15mcg in the operation theatre (OT). Both groups will also receive parecoxib 40mg IV and paracetamol 1G Intravenous (IV) as part of multimodal analgesia. Both groups will receive dexamethasone 8mg IV prophylactically. Postoperatively both groups will receive adductor canal block with bupivacaine and dexmedetomidine."||||
33973233|NCT00889278|||COHORT||PROSPECTIVE|||||||
33973234|NCT00639171|||CASE_ONLY||PROSPECTIVE|||||||
33973235|NCT01842451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973236|NCT05186519|||COHORT||RETROSPECTIVE|||||||
33885428|NCT04856241|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"It will not be possible to blind all involved research fellows, or the Prep-to-Play Physiotherapists involved in the project. The statistician will be unblinded to information required to complete the analyses (i.e. timing of transition) but blinded to team information (e.g. location, name). Teams will be given a unique code.~To optimise allocation concealment: i) each cluster will be a league or leagues in a unique geographical area; ii) data collection at all sites will commence in the control period, iii) team designate and/or sports trainers will remain blinded to allocation sequence; iv) Prep-to-Play observers validating the primary outcome (Prep-to-Play implementation) will be independent to the club and blinded to allocation; v) research fellows collecting injury data will be independent of the club and blinded to allocation."|Stepped-wedge randomised controlled trial. Prior to study initiation, the leagues will be randomly allocated to one of the five wedges for time of crossover from the control to the intervention phase using a computer-generated list of random numbers provided by a statistician. The randomisation sequence will be concealed to the coaches until shortly before the switch (\~four weeks to allow time to organise their workshop).|f|f|f|t
33885429|NCT04955275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885430|NCT04282031|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33885431|NCT06270680|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33885432|NCT01175005|||COHORT||PROSPECTIVE|||||||
33885433|NCT06451965|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885434|NCT05855512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intervention and control group|t|t|f|f
33885435|NCT00818376|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33885436|NCT05431296|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomised control trial||||
33885437|NCT02182349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885438|NCT02676830|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885439|NCT05640401|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Non (open label)|A non-blinded, multicenter, non-randomized prospective trial.||||
33885440|NCT03952260|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded against those who are doing ultrasound assessment of gastric residual volume prior to anaesthesia||f|f|f|t
33885441|NCT04388501|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33885442|NCT04773405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885443|NCT01119235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885444|NCT05429567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885445|NCT01051492|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33885446|NCT00122330|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33885447|NCT01385735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885448|NCT06332898|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, Double-Blind, Placebo Controlled Design|t|f|t|t
33885449|NCT01726179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885450|NCT05836233|||COHORT||PROSPECTIVE|||||||
33973237|NCT00492089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33885451|NCT01410279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885452|NCT02848833|||COHORT||PROSPECTIVE|||||||
33885453|NCT02313831|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33885454|NCT02039739|||COHORT||PROSPECTIVE|||||||
33885455|NCT01486030|||COHORT||PROSPECTIVE|||||||
33885456|NCT01824979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885457|NCT00497211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885458|NCT03360760|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885459|NCT05152940|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33973238|NCT04922502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor is blinded|Randomized assignment to one of two conditions|f|f|f|t
33973239|NCT01396941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973240|NCT02205957|||COHORT||CROSS_SECTIONAL|||||||
33973241|NCT04211467|||CASE_ONLY||PROSPECTIVE|||||||
33973242|NCT05065463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973243|NCT03199599|||COHORT||PROSPECTIVE|||||||
33973244|NCT01460251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885460|NCT04928261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885461|NCT03632395|||COHORT||PROSPECTIVE|||||||
33885462|NCT00155480|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973245|NCT04184037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The outcomes assessor and all individuals involved in analyzing data will be blind to the participant's study arm. Only the research assistant who will be introducing participants to their meditation app will be aware of their study arm assignment. Participants will be told that they are randomized into one of two types of meditation programs, but will not be told about the difference in the two programs and will not be told if they are in the main intervention group or the control group. That said, given the nature of auditory neurofeedback, participants in the NFB group will be aware that they are receiving neurofeedback. Participants in the no-NFB group will not be experiencing any neurofeedback and, a priori, they should not be aware that neurofeedback is missing.|This is a pilot randomised, controlled trial conducted in two study populations: older adults diagnosed with mild cognitive impairment (MCI) and family caregivers of individuals diagnosed with any neurodegenerative disease or MCI. Dyads of participants (older adult with MCI and their caregiver) may also be enrolled. Participants are randomly allocated to a mindfulness meditation with neurofeedback (NFB) or mindfulness meditation without neurofeedback (no-NFB).|t|f|t|t
33973246|NCT03238768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Parents, participant and Outcomes assessor will be blinded to the nutritional intervention group.|Infants will be randomized to receive either standard parenteral nutrition via the NICU protocol or enhanced parenteral nutrition via the Study protocol during their first week of life through higher initial macronutrient provision and faster advancement of macronutrient provision.|t|f|f|t
33973247|NCT01603290|||COHORT||PROSPECTIVE|||||||
33973248|NCT05371301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973249|NCT01569828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973250|NCT02002780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973251|NCT00918671|||COHORT||PROSPECTIVE|||||||
33973252|NCT01382433|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973253|NCT04535609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973254|NCT04318470|||OTHER||PROSPECTIVE|||||||
33885463|NCT03352531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885464|NCT02078219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885465|NCT04009941|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885466|NCT05014477|||COHORT||RETROSPECTIVE|||||||
33973255|NCT03125083|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973256|NCT03385096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973257|NCT04018144|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072207|NCT03800407|||COHORT||PROSPECTIVE|||||||
34072208|NCT03021629|||CASE_CONTROL||PROSPECTIVE|||||||
33885467|NCT02926326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885468|NCT01570244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885469|NCT05800587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885470|NCT06017154|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885471|NCT00000690||||TREATMENT||NONE||||||
33885472|NCT04888897|||COHORT||CROSS_SECTIONAL|||||||
33885473|NCT00504764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885474|NCT03889041|||COHORT||PROSPECTIVE|||||||
33885475|NCT06184347|||COHORT||PROSPECTIVE|||||||
33885476|NCT03670355|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885477|NCT02063035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33885478|NCT06449586|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885479|NCT04866290|||COHORT||PROSPECTIVE|||||||
33885480|NCT02562326|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33885481|NCT01019018|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33885482|NCT00799305|||CASE_ONLY||PROSPECTIVE|||||||
33885483|NCT01439763|||COHORT||CROSS_SECTIONAL|||||||
33885484|NCT02633371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885485|NCT01811147|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885486|NCT01886521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885487|NCT03484715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|As the primary aim of this study is to establish feasibility of the intervention and study processes, there will be no outcome assessor or participant blinding.|Randomised controlled pilot feasibility study||||
33885488|NCT01780155|||COHORT||PROSPECTIVE|||||||
33885489|NCT02027740|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885490|NCT05458336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885491|NCT02363075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885492|NCT05700474|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33885493|NCT01790503|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33885494|NCT04799041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a double-blind, placebo-controlled, randomized study in patients with acute back pain. This was a proof of concept study to determine efficacy and safety in two groups: active and placebo. Each patient participated in only one group. This was a single-center clinical trial.|t|f|t|f
33885495|NCT04871503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects will be enrolled and assigned into two study groups; HIFEM+RF (HR) and HIFEM (H) group. Subjects of both groups will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.||||
33885496|NCT01809548|RANDOMIZED|PARALLEL||TREATMENT||NONE|"After interim analysis switch from prospective randomised to baseline adaptive randomised controlled - stratified according birthweight below /equal 800g and equal/more than 801 grams.~After an interim analysis 1/2019: During the whole study period we had a very low drop out rate of 11% so far. Therefore we adapt the sample size calculation from the anticipated 30% drop out rate to an one-to-one replacement for dropouts + a surplus of 5 patients"|||||
33885497|NCT02594488|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885498|NCT03820557|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33885499|NCT05185154|||COHORT||PROSPECTIVE|||||||
33761115|NCT05166525|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study is a virtual, remote, decentralized pragmatic clinical trial comparing the efficacy of medically tailored meals alone or medically tailored meals with remote nutritional counseling compared with usual standard of care in adults with a targeted, nutrition-sensitive chronic medical condition (heart failure, diabetes mellitus, chronic kidney disease)|f|f|f|t
33761116|NCT01706302|||||RETROSPECTIVE|||||||
33761117|NCT03080116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761118|NCT00612534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761119|NCT00797979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973258|NCT03392597|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Waitlist control design in which matched sites are randomly assigned to an intervention or waitlist control group to implement and evaluate the Brothers as Allies program. Intervention groups will participate in the Brothers as Allies program from the Council for Boys and Young Men. Waitlist control groups will participate in programming-as-usual until implementation with the intervention groups is complete, at which point they will receive the intervention. All participants will complete surveys at baseline, immediate post-intervention, and at 3 and 6 months post-intervention.||||
33973259|NCT02292238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973260|NCT00977925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973261|NCT00261729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761120|NCT01842113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761121|NCT02541825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761122|NCT00943306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761123|NCT04606537|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33761124|NCT03760770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761125|NCT01830088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors (HAM-D) are masked and do not know the treatment arm of the participant|The two treatment arms are i) Attachment Based Family Therapy and ii) Treatment as usual|f|f|f|t
33973262|NCT03572933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The double-blind phase will randomize subjects to adjunctive ganaxolone or placebo at a 1:1 ratio to standard of care|t|t|t|t
34072209|NCT04995263|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Two investigators will work on-site collecting data for each of the variables, uploading them to a secure database (REDCap) as anonymous data. Afterwards, data and outcomes will be analyzed by a blinded investigator.|Before-after design for the implementation of unit-wide intervention, with a later randomization for individualized interventions.|f|f|f|t
34072210|NCT03828227|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072211|NCT01292707|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34072212|NCT03869762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072213|NCT02778035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072214|NCT01304134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885500|NCT03633500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Block size and number of blocks: the sample size estimated for the study was 48 the size of the blocks is fixed in nature. Hence there are 6 blocks with a block size of 8 preterm babies each in every block.~Allocation ratio: one to one allocation ratio will be used for the study. Since the block size is 8 and one to one allocation was used, each block consist of 4 babies in each group (experimental:4, control =4) Sequence generation: 6 sets of random sequence will be generated with the help of research randomizer, an online random number generator. The sequence will be generated by an external member, who was not directly involved in the study.~Allocation concealment: Concealed allocation was achieved using sequentially Numbered, Opaque, Sealed Envelopes (SNOSESs). SNOSESs were prepared by an external member, who was not a part of study and kept in an opaque envelope.~Blinding: is done by covering the syringe with adhesive silk tape."|the intervention is carried out among preterm babies below 33 weeks of gestation or weight less than 1500gm|f|t|t|f
33885501|NCT03966326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973263|NCT03152461|||COHORT||PROSPECTIVE|||||||
33973264|NCT04804449|||CASE_ONLY||PROSPECTIVE|||||||
33973265|NCT00762957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973266|NCT01717014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973267|NCT00770003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973268|NCT00754806|||||PROSPECTIVE|||||||
33973269|NCT00258973|||||PROSPECTIVE|||||||
33973270|NCT01499875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973271|NCT02125188|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33973272|NCT06394323|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072215|NCT05680948|||COHORT||PROSPECTIVE|||||||
34072216|NCT04967157|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The placebo will match the TP in physical and visual appearance and packaging and each participant's study product assignments will be associated with a unique code to prevent premature unblinding. Planned unblinding will occur following database lock, definition of study populations, and a blinded statistical analysis Delegated unblinded site personnel will be responsible for study product accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records) throughout the course of the study. The investigator will have oversight in a blinded manner.|There are 2 study groups, including one test product (TP) group and one placebo (PL) group. . Healthy adult males and females who are 18 to 35 years of age (inclusive) at screening will be enrolled.|t|f|t|t
33761126|NCT02222480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072217|NCT02638974|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072218|NCT01853683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072219|NCT04346407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo, randomization and blinding will be maintained by the Hospital Pharmacy|Double-blind Placebo controlled|t|t|t|t
34072220|NCT04727528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||NEUTRALIZE is a prospective, randomized, double-blind, placebo-controlled, parallel, multicenter, Phase IIIb study|t|f|t|f
33761127|NCT01551602|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33761128|NCT06496191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761129|NCT04623073|||COHORT||RETROSPECTIVE|||||||
33761130|NCT06403579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33973273|NCT02776761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Subjects will be blinded to the vaccine(s) they are receiving. All subjects will receive active product; there is no placebo control group.|Study will enroll 3 randomized groups of 9 subjects for a total of 27 subjects. Every subject will receive a total of 3 vaccinations. Subjects will be blinded to the group they are randomized to. Each vaccination consists of 2 administrations of 1 mg (left/right deltoid) for a total of 2 mg/vaccination. Group 1 will be vaccinated with the HTNV vaccine, pWRG/HTN-M (co). Group 2 will be vaccinated with the PUUV vaccine, pWRG/PUU-M (s2). Group 3 will be vaccinated with a combined HTNV/PUUV vaccines. Each group will be vaccinated on Days 0, 28, and 56. An optional 4th vaccination on Day 168 with follow-up on Day 196. All doses will be administered with PharmaJet Stratis device. All subjects to be followed until at least 3 months post last vaccination with Day 252 the final study visit (a 12-month, optional follow-up visit may be requested approximately on Day 365). Subjects will complete postinjection memory aids for 7 days after each vaccination.|t|f|f|f
33973274|NCT00716183|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072221|NCT04445090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||SRD-Part: parallel-group design BA/FE-Part: three-way crossover design|t|f|f|f
34072222|NCT06077162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||3 arm RCT (nutrition education classes only, nutrition education classes + healthy food resource, healthy food resource only) - randomized at pt level, no stratification||||
34072223|NCT03089645|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34072224|NCT02522416|||COHORT||CROSS_SECTIONAL|||||||
34072225|NCT04442087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072226|NCT05782972|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, prospective study||||
34072227|NCT02712918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072228|NCT04731831|||COHORT||PROSPECTIVE|||||||
34072229|NCT02118779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072230|NCT04273997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded|Randomised, double-blind, placebo-controlled trial evaluating the effects of metronidazole ointment in facilitating resolution of non-healing pilonidal sinus wounds|t|t|t|f
34072231|NCT06104566|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 ratio to investigational arm (lisaftoclax in combination with BTKi ) or the control arm (BTKi).||||
34072232|NCT02830399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072233|NCT04058028|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a Bayesian adaptive phase 2b, multi-center, double-blind, randomized, placebo-controlled, 52-week, dose-ranging study in subjects with active SLE and inadequate response to SOC therapies including OCS, immunosuppressants, and immunomodulators. Subjects will be randomized to receive placebo or 1 of 3 doses of Rozibafusp Alfa with the last dose at week 50. Treatment will be administered every 2 weeks (Q2W). All subjects will be required to complete a 16-week follow-up period after the 52-week treatment period.~The first interim analysis (IA) will be executed after the first 40 enrolled subjects have had the opportunity to complete the week 24 assessment. Additional IAs may be executed after approximately every 32 newly enrolled subjects have had the opportunity to complete the week 24 assessment. The last IA will occur when all subjects have had the opportunity to complete the week 24 assessment."||||
34072234|NCT05615142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072235|NCT00940888|||CASE_ONLY||PROSPECTIVE|||||||
33761131|NCT01265901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885502|NCT05247788|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33761132|NCT01974037|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33761133|NCT01732081|||COHORT||PROSPECTIVE|||||||
33761134|NCT01439061|||COHORT||OTHER|||||||
33761135|NCT01521884|||||PROSPECTIVE|||||||
33885503|NCT00250692|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33973275|NCT06441981|NA|SINGLE_GROUP||OTHER||NONE||The questionnaire in whatsapp chatbot format will be given to 100 and up to 200 persons from each targeted population. There Four targeted population namely, The public overall (comprised mostly of 18-29 years old adults whom have the most cases), Vulnerable groups (including the elderly between 50-80 years old, parents of children 0-12 years, and pregnant women), Doctors and other frontline health workers, and Program implementers and policy makers.||||
33973276|NCT02840383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973277|NCT03372980|||COHORT||OTHER|||||||
33973278|NCT03497533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973279|NCT04730557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973280|NCT05611307|||COHORT||PROSPECTIVE|||||||
33973281|NCT03376958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973282|NCT00593879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973283|NCT03850509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Two or more parties are unaware of the intervention assignment.|Participants are assigned to one of two or more groups in parallel for the duration of the study|t|t|t|t
33973284|NCT04659681|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participant was masked about Group it belonged||t|f|f|f
33973285|NCT00545012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973286|NCT05887765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33973287|NCT04366700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33973288|NCT04665674|||COHORT||PROSPECTIVE|||||||
33973289|NCT02586831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33973290|NCT03357783|||COHORT||PROSPECTIVE|||||||
33761136|NCT03299764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761137|NCT05870202|||COHORT||PROSPECTIVE|||||||
33761138|NCT04131790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33761139|NCT02323646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761140|NCT04288635|||COHORT||PROSPECTIVE|||||||
33761141|NCT04363099|||COHORT||OTHER|||||||
33761142|NCT05319106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761143|NCT03021668|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761144|NCT05742243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33885504|NCT01709188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761145|NCT04591990|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33761146|NCT01124721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761147|NCT03823222|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761148|NCT01370681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33761149|NCT02020239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761150|NCT02806037|||COHORT||PROSPECTIVE|||||||
33761151|NCT02699502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885505|NCT01467492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885506|NCT03396770|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||open labeled randomized clinical trial||||
33885507|NCT02266433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33885508|NCT03325179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885509|NCT05410548|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patient participant satisfaction surveys, which are a primary outcome, will be collected in sealed envelopes and data will be entered by a research team member who is not a practitioner conducting the intervention. Satisfaction data will be stored in a separate database that is concealed from practitioners until the last participant completes their 3-month follow-up. Three-month follow-ups will occur remotely and without practitioner input. Patient care minutes will be extracted from the electronic medical record generated during actual patient visits.||f|f|f|t
33885510|NCT06198725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973291|NCT06543654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This clinical trial was double-blind since the evaluators who were not included in the restorative procedures and the participants were blinded to tested groups, but the operator wasn't blinded to these groups|randomized controlled clinical study|t|f|f|t
33973292|NCT01300845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973293|NCT00133718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were randomized to intensive care of standard care, outcomes were assessed by experts who where unaware of group allocation||f|f|f|t
33973294|NCT01992107|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33973295|NCT01375881|||COHORT|||||||||
33973296|NCT02072356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973297|NCT01165684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973298|NCT01132118|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34072236|NCT00421083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885511|NCT05285501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072237|NCT05524766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072238|NCT06052995|||COHORT||PROSPECTIVE|||||||
33885512|NCT05000515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34072239|NCT01792440|||COHORT||CROSS_SECTIONAL|||||||
33885513|NCT03603041|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33973299|NCT00058279||||TREATMENT||NONE||||||
34072240|NCT04541329|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072241|NCT05458947|RANDOMIZED|PARALLEL||TREATMENT||NONE||To examine the effects of PT wound care modalities (PWI + ES, PWI only, and ES only) on wound healing in patients with SCI||||
33885514|NCT01592201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072242|NCT06467747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072243|NCT01213446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885515|NCT02300766|||COHORT||PROSPECTIVE|||||||
34072244|NCT02135016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072245|NCT01085422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072246|NCT06130085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072247|NCT06079996|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34072248|NCT04910581|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patients are centrally randomized to receive first either the active stimulation (80% of the resting motor threshold) or the sham stimulation (using a visually identical coil to reproduce the click sound and the scalp sensation of the active coil). The operator is unblided. The evaluator is blinded.|After randomization, patients are to receive blindly the first rTMS session according to the arm (placebo or active). A second stimulation session is to be performed 3 days apart to apply the reverse arm.|t|f|f|t
34072249|NCT00999310|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072250|NCT04617795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072251|NCT06157983|||COHORT||PROSPECTIVE|||||||
33885516|NCT02803164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072252|NCT01176786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34072253|NCT04806321|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants (anticipated N = 1,000), ages 10-14 years old, will be randomized to complete one of two 30-minute, digital programs: (1) Project SOLVE: a program designed to teach adolescents how to solve, rather than be overwhelmed by, everyday problems; or (2) Project SUCCESS: a control program designed to teach adolescents helpful study skills.|t|f|t|t
34072254|NCT03919123|||COHORT||RETROSPECTIVE|||||||
34072255|NCT05906654|NA|SINGLE_GROUP||PREVENTION||||21 individuals without cognitive impairment engage in the study intervention over 24 weeks||||
34072256|NCT06175039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TRGr) and Control Group (KGr).|t|f|f|f
34072257|NCT06611969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluators are unaware of the assignment at all times. Outcomes assessor will discover group assigment after data analysis.||f|f|t|t
33885517|NCT06140979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients in the test group will be given a visual focus game to play and the patients in the control group will be given an animated video of the game that had no therapeutic effect.|t|f|f|t
33885518|NCT06348082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Hybrid Type 1 effectiveness/implementation study using a pragmatic randomized controlled trial (RCT) with MBTI and a waitlist control. Participants will be randomly assigned by a computer-generated sequence to either the MBTI or waitlist control in a 1:1 ratio using permuted blocks stratified by age (2 strata: ≤50 or postmenopausal age \>51) with random block sizes of 2 or 4 to reduce predictability.|t|t|t|t
33885519|NCT04416802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885520|NCT05784207|||COHORT||RETROSPECTIVE|||||||
33885521|NCT01069445|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885522|NCT03675867|||CASE_ONLY||RETROSPECTIVE|||||||
33885523|NCT04095169|||COHORT||PROSPECTIVE|||||||
33885524|NCT02567526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885525|NCT04172285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885526|NCT00962845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973300|NCT05753657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973301|NCT01924871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973302|NCT02398461|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33973303|NCT00295854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973304|NCT01766674|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34072258|NCT03285035|||COHORT||PROSPECTIVE|||||||
34072259|NCT01183403|||COHORT||PROSPECTIVE|||||||
34072260|NCT00638469|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072261|NCT03015298|||COHORT||PROSPECTIVE|||||||
34072262|NCT02964338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072263|NCT05768997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072264|NCT01844817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072265|NCT00010751|RANDOMIZED|||TREATMENT||SINGLE||||||
34072266|NCT05122377|||COHORT||PROSPECTIVE|||||||
34072267|NCT01504139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072268|NCT04241016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072269|NCT04127877|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled study||||
34072270|NCT04430088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973305|NCT03635853|NA|SINGLE_GROUP||TREATMENT||NONE||a single group of patients with palmar arsenical keratosis are given the drug, under study||||
33973306|NCT05492071|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973307|NCT00297271|||COHORT||PROSPECTIVE|||||||
33973308|NCT02491788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973309|NCT03982433|NA|SINGLE_GROUP||TREATMENT||NONE||Participants all undergo assessment and intervention||||
33973310|NCT01541878|||COHORT||PROSPECTIVE|||||||
33885527|NCT04870671|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|When measuring TFV levels in the biological fluids, the outcomes assessor in the laboratory will not know whether the samples are from the high or low adherence group|Women will be randomized into one of two groups: high adherence (7 pills/week) and how adherence (3 pills/week)|f|f|f|t
33885528|NCT04285333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|all blocks were performed in a special area outside operating room by docters only implicated in performance assessement of block and not in patient care. Patients where after moved to operating room, care provider wil assess pain before spinal anesthesia|Prospective randomised single blinded study|t|t|f|f
33885529|NCT05163288|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Randomized, placebo-controlled, double-blind, crossover, multi-center, study with 1:1 randomization of IB1001 plus SOC for 12-weeks versus placebo plus SOC for 12-weeks, followed by open-label extension study.|t|t|t|t
33885530|NCT02431416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33885531|NCT01200784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885532|NCT01262976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33885533|NCT02534636|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33885534|NCT02828072|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33973311|NCT03290534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973312|NCT06031584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973313|NCT03179618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973314|NCT02346201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973315|NCT02097121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33885535|NCT06503445|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33885536|NCT04620486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be masked to which group they are assigned. Care Providers will not be masked as they will be shown a Best Practice Alert (BPA) only for patients in the treatment arm. The investigators will not be masked.|Patients whose medical record numbers (MRN) are odd will be assigned to the treatment group, while those whose MRNs are even will be assigned to the control group. The intervention, which is the Best Practice Alert in Epic, will only be displayed to the patient's care providers for the treatment group.|t|f|f|f
33885537|NCT01193400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885538|NCT00199732|||||PROSPECTIVE|||||||
33885539|NCT00360581|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885540|NCT00536172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885541|NCT02613455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973316|NCT05033301|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33973317|NCT03437759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973318|NCT01733719|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973319|NCT00000464|RANDOMIZED|PARALLEL||PREVENTION||||||||
33973320|NCT05694325|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973321|NCT04715607|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||All participants will have Saliva collected and recieve nasopharyngeal swabs and oropharyngeal swabs for SARS-COV2. To avoid systematic bias we plan to randomize the sequence of testing.|f|f|t|t
33973322|NCT02304120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973323|NCT06503237|NA|SEQUENTIAL||TREATMENT||NONE||||||
33973324|NCT02114307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973325|NCT04254952|||CASE_ONLY||PROSPECTIVE|||||||
33973326|NCT01319682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072271|NCT04254081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A clinician who will not be administering the paracervical block will open the designated sealed sequentially numbered opaque randomization envelope containing computer generated randomization code and prepare the designated paracervical block into two 10 mL syringes. The syringes used to prepare the medication will be identical between study groups and the solutions will appear visually identical. A different clinician blinded to the treatment group will perform the standardized procedure for osmotic dilator insertion.|This is a randomized, placebo controlled trial with stratified block randomization based on vaginal parity (vaginally nulliparous versus vaginally multiparous). Vaginal parity may influence pain during osmotic dilator insertion and thus the participants will be evenly distributed between strata.|t|t|t|t
33973327|NCT05106933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Carbohydrate loading vs Clear water|t|t|t|t
33973328|NCT06262698|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participants were assigned to groups using the simple randomization method. Participants were not informed of which group they were in. Automated computer-based randomization resulted in the implementation of the experiment with the scheduling scenario and confidential allocation of participants to one of the four intervention branches. The researcher was blind to all conditions until the participants started the computer program and the intervention began. Participants were also unaware of whether the group they were assigned to was an experimental or a control condition. In addition, researchers coding and analyzing data will be blind to randomization and interventions."|The experimental group will receive six weeks of HBM-based training.|t|f|t|t
33973329|NCT00816088|||COHORT||PROSPECTIVE|||||||
33973330|NCT03495869|||COHORT||PROSPECTIVE|||||||
34072272|NCT01467271|||COHORT||PROSPECTIVE|||||||
34072273|NCT03145103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072274|NCT01941784|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34072275|NCT04521478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072276|NCT01553448|||CASE_CONTROL||PROSPECTIVE|||||||
34072277|NCT06289777|||COHORT||PROSPECTIVE|||||||
34072278|NCT03517241|||CASE_CONTROL||PROSPECTIVE|||||||
34072279|NCT05935592|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34072280|NCT05002504|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will not know whether they will be treated or given a placebo.|25 patients in the placebo group (group 1), 30 patients in the craniosacral therapy group (group 2) and 31 patients in the balance and coordination therapy group (group 3)|t|t|t|t
34072281|NCT02169843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34072282|NCT05382429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Whereas patients and surgeons were aware of the group assignments, the outcome assessors and data analysts were remained blinded during the study period.|Before initiating the trial, an investigator who was not involved in the study generated a computer-generated randomization list (block length 10, ratio 1:1). Allocation concealment was achieved by using opaque, sealed, sequentially numbered envelopes containing details of group assignment. Assignment occurred after baseline information was recorded. According to preoperative allocation, the patients were given open wedge high tibial osteotomy or closingwedge high tibial osteotomy.For the open wedge high tibial osteotomy group, Those who were randomly assigned to the OWHTO group, OWHTO Surgical procedure will be performed.For the closing wedge high tibial osteotomy group, hose who were randomly assigned to the CWHTO group, CWHTO Surgical procedure will be performed.|f|f|f|t
34072283|NCT02413671|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34072284|NCT05781087|||COHORT||PROSPECTIVE|||||||
34072285|NCT04559009|||CASE_CONTROL||PROSPECTIVE|||||||
34072286|NCT02435563|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33885542|NCT05848661|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The training will be performed at home. The investigators/evaluators will send a download link of the therapy to the patients without knowing which therapy it corresponds to.|In this study, 240 patients will be randomized in four groups. The first group will be trained with AUDISSEE-verbal, AUDISSE-non-verbal then with the placebo therapy. The second group will be trained with AUDISSEE-non-verbal, AUDISSEE-verbal, then with the placebo therapy. The third group will be trained with the placebo therapy then AUDISSEE-verbal, and AUDISSE-non-verbal. The fourth group will be trained with the placebo therapy then AUDISSEE-non-verbal, and AUDISSE-verbal.|f|f|t|t
33885543|NCT01598376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33885544|NCT01361763|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33885545|NCT04945798|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33885546|NCT03924401|NA|SINGLE_GROUP||PREVENTION||NONE||The trial will include two strata: one for patients with a 7/8 matched donor and one for those with a matched 8/8 donor.||||
33885547|NCT01902979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885548|NCT00434525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885549|NCT06545357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A double-blind, randomized controlled trial|t|f|f|t
33885550|NCT01041248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885551|NCT05911100|||COHORT||PROSPECTIVE|||||||
33761152|NCT05719948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|None of the investigator or outcomees assessor know the intervention used|One model recieved continous RF while the other recieved combined pulsed and continous RF.|f|f|t|t
33885552|NCT00576979|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33885553|NCT04763330|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The participant's assignment to treatment will not be shared with the outcomes assessor. A randomizer will provide treatment assignment to the participant after the assessment."|The study design is random assignment to the treatment, PST plus EUC, or the control condition, EUC only. Both the treatment and the control are evidence-based interventions delivered in six sessions. The study will occur at VA Palo Alto (primary site) and VA Syracuse/VA Canandaigua (secondary site).|f|f|f|t
33885554|NCT01656902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885555|NCT03346408|||COHORT||PROSPECTIVE|||||||
33885556|NCT01926925|||||CROSS_SECTIONAL|||||||
33885557|NCT01163786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885558|NCT06113107|||CASE_ONLY||RETROSPECTIVE|||||||
33885559|NCT00214461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885560|NCT03765645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885561|NCT03075163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885562|NCT04107727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized into 1 of the 2 treatment groups (quizartinib or placebo) in a 2:1 ratio. The randomization will be stratified by age (\<60 vs. ≥60 years old) at the time of diagnosis of AML. Neither the subjects nor any of the Investigators, Sponsor, or contract research organizations (CROs) will be aware of the treatments received. An independent biostatistician, not otherwise part of the study team, will generate the randomization schedule.|"Safety run-in phase: multicenter, prospective, open-label.~Phase II: multicenter, prospective, randomized, placebo-controlled, double-blinded"|t|t|t|t
33761153|NCT06445790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885563|NCT06327646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33761154|NCT05395988|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33761155|NCT00714376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761156|NCT01007864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973331|NCT00913757|||CASE_CONTROL||PROSPECTIVE|||||||
33973332|NCT00735241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973333|NCT06144814|RANDOMIZED|PARALLEL||TREATMENT||NONE||The objective of this randomized controlled trial was to compare the effect of Hyaluronic acid and Estradiol and to determine the effect on VHI. Secondary objective was to investigate the effect of VVA/GSM on symptoms.||||
33973334|NCT01350063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973335|NCT01135771||||DIAGNOSTIC||NONE||||||
33973336|NCT00929708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761157|NCT02736825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761158|NCT02462954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33761159|NCT00402480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761160|NCT05654792|||COHORT||RETROSPECTIVE|||||||
33973337|NCT06099314|||COHORT||RETROSPECTIVE|||||||
33973338|NCT04316858|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33973339|NCT02030574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973340|NCT05544513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973341|NCT03333967|||COHORT||PROSPECTIVE|||||||
33973342|NCT02498522|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973343|NCT01533168|||CASE_CONTROL||RETROSPECTIVE|||||||
33973344|NCT04430270|||CASE_CONTROL||RETROSPECTIVE|||||||
33973345|NCT03876574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973346|NCT03463525|NA|SINGLE_GROUP||OTHER||NONE||||||
33973347|NCT03799601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973348|NCT05120011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33973349|NCT05151835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973350|NCT01937364|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33973351|NCT00526695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973352|NCT00524459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33973353|NCT04572568|||COHORT||PROSPECTIVE|||||||
33973354|NCT02717221|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33973355|NCT04524039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072287|NCT05897372|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open-label, parallel-group, clinical trial.||||
34072288|NCT01689441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072289|NCT02363712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072290|NCT01340729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072291|NCT00186407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072292|NCT03540069|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||a cluster-randomized stepped wedge study across three representative clusters (each containing a district center and two rural sites) in the Kedougou region. For each aim we will collect data at baseline and at 6-month intervals in each cluster (data collection intervals coincide with the initiation of the intervention in a new cluster).||||
34072293|NCT01569945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761161|NCT05357014|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761162|NCT02498353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761163|NCT00153959|RANDOMIZED|CROSSOVER||||NONE||||||
33973356|NCT03075137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33973357|NCT04219059|||CASE_CONTROL||RETROSPECTIVE|||||||
33973358|NCT00672971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973359|NCT02494128|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973360|NCT04253561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973361|NCT04834245|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33973362|NCT03605706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973363|NCT06170580|||COHORT||CROSS_SECTIONAL|||||||
33973364|NCT05403021|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single-arm mixed method pilot trial||||
33973365|NCT04447976|||CASE_ONLY||PROSPECTIVE|||||||
33973366|NCT05799872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072294|NCT00912132|||COHORT||PROSPECTIVE|||||||
34072295|NCT03480594|||CASE_CONTROL||PROSPECTIVE|||||||
34072296|NCT01727856|||COHORT||PROSPECTIVE|||||||
34072297|NCT02741648|||CASE_CONTROL||PROSPECTIVE|||||||
34072298|NCT05600153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072299|NCT01690195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072300|NCT06121440|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34072301|NCT03109626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double-blind randomised placebo-controlled phase, followed by an open-label phase|t|f|t|t
34072302|NCT01481883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072303|NCT01113918|||COHORT||RETROSPECTIVE|||||||
34072304|NCT00988676|||COHORT||PROSPECTIVE|||||||
34072305|NCT02586311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072306|NCT01423201|||COHORT||PROSPECTIVE|||||||
34072307|NCT02717364|||COHORT||PROSPECTIVE|||||||
34072308|NCT01307878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072309|NCT02608996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072310|NCT00753298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072311|NCT02499120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072312|NCT03328598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072313|NCT05965427|||COHORT||RETROSPECTIVE|||||||
34072314|NCT02017093|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34072315|NCT06612684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072316|NCT00629538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072317|NCT06425211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072318|NCT05171270|||CASE_ONLY||CROSS_SECTIONAL|||||||
33973367|NCT00314171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973368|NCT02600013|||COHORT||OTHER|||||||
33973369|NCT05747638|||OTHER||CROSS_SECTIONAL|||||||
33973370|NCT04317625|NA|SINGLE_GROUP||SCREENING||NONE||||||
33973371|NCT06215781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Three-arms groups||||
33973372|NCT01505465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33973373|NCT03547947|||COHORT||PROSPECTIVE|||||||
33973374|NCT03872037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For the radiographic evaluation, the evaluators had no information about the group to which the parent was randomized. Only the periapical tissues were evaluated, and the coronary portion of the restored tooth was concealed with adhesive tape.|A total of 150 children were allocated to two parallel groups: group 1 (G1, n = 70, control, Ketac Molar Easymix®, 3M/ESPE, Seefeld, GE) and group 2 (G2, n = 80, test, Maxxion®, FGM, Joinville, BR). The study was double-blinded, and an operator specialized in paediatric dentistry performed the selective removal of soft dentine and the restoration of the cavity with GIC. During the follow-up periods, the teeth were evaluated via periapical radiography by two trained examiners specialized in radiology. Statistical analysis was performed using Stata 11.2 software (StataCorp, Texas, USA) and a survival curve (Kaplan-Meier).|t|f|t|f
33973375|NCT00651456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973376|NCT01250158|NA|SINGLE_GROUP||||NONE||||||
33973377|NCT04523805|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Baseline data are collected at T1-Baseline, at the start of the programme and eight weeks later, scores are recorded for T2-Control, which represents a control period. During the control period, part of which includes the winter break from classes, the students not participate in any extracurricular physical activities, as their organised physical exercise is limited to their regular physical education classes at school. Between this second measurement and T3-Judo. T4-Follow up The judo sessions are performing in a large and well-ventilated space suitable for athletic activities in general and for judo in particular, such that the safety of the participants was maintained. Each participant is outfitted with a judogi (a traditional uniform consisting of a cotton jacket and trousers and a belt). The choice was made to include the control period at the start of the process because we did not have a control group willing to submit to all the measurements over the course of the project.||||
33973378|NCT03721848|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"* Condition 1: an existing NCD preventive intervention consisting of 24 sessions, which are 45 minutes covering diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies and smoking;~* Condition 2: The existing NCD preventive intervention with 4 added mental health awareness sessions covering traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma;~* Condition 3: Treatment as usual"||||
34072319|NCT01376973|||CASE_CONTROL||PROSPECTIVE|||||||
34072320|NCT03420339|NA|SINGLE_GROUP||TREATMENT||NONE||In this study all participants will participate in behavioral assessments (i.e., preference assessments, functional analysis, choice assessments) while taking a stimulant medication and without taking a stimulant medication. All participants will experience the same protocol.||||
34072321|NCT00007319|||||PROSPECTIVE|||||||
34072322|NCT06501807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072323|NCT01285778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885564|NCT04555941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant and principal investigator do not know what treatment is applied. The outcomes assessor will also be blinded. Only the co-PI who perform the TMS will know the stimulation condition.||t|f|t|t
34072324|NCT03214679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761164|NCT03074214|||COHORT||PROSPECTIVE|||||||
34072325|NCT03706664|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|Neither the Radiologists nor the Computer scientists/outcomes assessors will be masked to the image labels or if a given MR Enterography has been used in the training or validation dataset.|"Radiologists will label 226 MR Enterography images as normal or abnormal. The labelled images will be randomised between training and validation sets.~The training dataset will be used to develop machine learning algorithm to localise the terminal ileum \& classify the terminal ileum as normal or abnormal.~The validation dataset will test the accuracy of the algorithm against the Radiologists labels."||||
34072326|NCT00905632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072327|NCT03731195|||COHORT||PROSPECTIVE|||||||
33761165|NCT05662384|||COHORT||PROSPECTIVE|||||||
33761166|NCT06509451|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized clinical trial|t|f|f|t
33885565|NCT02276859|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33885566|NCT05097586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885567|NCT01455103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33885568|NCT00309322|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33885569|NCT01916980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885570|NCT01008345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072328|NCT01539746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761167|NCT02136433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761168|NCT04182854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761169|NCT06135311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761170|NCT00215540|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761171|NCT01817374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761172|NCT03745222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761173|NCT03883516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33761174|NCT05301504|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33761175|NCT05011643|||COHORT||CROSS_SECTIONAL|||||||
33761176|NCT03737786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761177|NCT04931641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
33761178|NCT01768208|NA|SINGLE_GROUP||||NONE||||||
33761179|NCT01250535|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33761180|NCT00312702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761181|NCT02959086|||COHORT||PROSPECTIVE|||||||
33761182|NCT02361125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761183|NCT01424475|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33761184|NCT06084559|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Sham SOT (placebo, ambient hypoxic air at 2840m) versus high-flow oxygen 10l/min both via a facial mask with reservoir will be applied|Each participant works as its own perfect control|t|f|f|f
33761185|NCT03364855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761186|NCT01586559|||COHORT||PROSPECTIVE|||||||
33761187|NCT05517200|||OTHER||PROSPECTIVE|||||||
33761188|NCT00409695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761189|NCT00881881|||COHORT||RETROSPECTIVE|||||||
33761190|NCT05824689|||OTHER||PROSPECTIVE|||||||
33761191|NCT05673408|||COHORT||PROSPECTIVE|||||||
33761192|NCT04332510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|\*\*Note: Human breast milk samples were not blinded for the care provider as they were supplied in different containers to the other milks.||t|t|t|t
33761193|NCT00252434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761194|NCT05490264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761195|NCT03143114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973379|NCT03330756|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center, open randomized controlled clinical trial||||
33973380|NCT04326842|||COHORT||RETROSPECTIVE|||||||
33973381|NCT05737056|||COHORT||RETROSPECTIVE|||||||
33761196|NCT06458920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||During one MRI scan, participants will spend part of the time regulating emotion on their own and part of the time regulating emotion with the help of a friend||||
33761197|NCT01673763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33761198|NCT01518946|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33761199|NCT05518383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761200|NCT06437197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761201|NCT01269905|||CASE_CONTROL||RETROSPECTIVE|||||||
33761202|NCT03269994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761203|NCT05300971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators collecting and analyzing data will be blinded to subject treatment arms. Treatment arm will not be revealed to subjects but they may realize if they are in the experimental vs. sham group.|Randomized, sham controlled (parallel design), single-blind|f|f|t|f
33761204|NCT05703984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||an open-label, randomized, fasting, single-dose, 2-group, 2-period, crossover design||||
33761205|NCT00176163|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33761206|NCT04829825|||COHORT||PROSPECTIVE|||||||
33761207|NCT05937425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blind (Outcomes Assessor)|This is a randomized controlled trial consisting of two groups: experimental and control.|f|f|f|t
33761208|NCT02904616|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33761209|NCT02573480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761210|NCT06186206|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33761211|NCT03573661|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34072329|NCT03568383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761212|NCT01569659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761213|NCT02305641|||COHORT||PROSPECTIVE|||||||
33761214|NCT03264703|||COHORT||PROSPECTIVE|||||||
33761215|NCT02318043|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33761216|NCT05107960|||COHORT||PROSPECTIVE|||||||
33761217|NCT02535364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761218|NCT04258228|||COHORT||PROSPECTIVE|||||||
33761219|NCT01861457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33761220|NCT03904030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Anti-gravity treadmill rehabilitation and traditional rehabilitation|f|f|t|f
33761221|NCT05446610|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761222|NCT03732118|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761223|NCT02335008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761224|NCT04007458|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Outcomes assessor will be blind to which intervention the subjects have received.|"Eligible patients will be randomly assigned to one of the following two groups:~1. Control Group:~o Annual reminder letter only~1. Intervention Group:~2. Annual reminder letter and Community Health Worker proactive outreach"|f|f|f|t
33761225|NCT03833635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33761226|NCT05127148|||COHORT||PROSPECTIVE|||||||
33761227|NCT02150720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761228|NCT01337986|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33761229|NCT05358678|||COHORT||PROSPECTIVE|||||||
33761230|NCT01633125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761231|NCT01058317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761232|NCT02008591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Anesthesiologist performing technique and bedside nurse instructed not to reveal randomization arm to the patient or study co-investigator who was waiting outside the room, and notified only after completion of the neuraxial placement protocol.|Randomized controlled trial with computer generated (Microsoft Excel 2015) assignment placed in sealed envelopes.|t|f|t|t
33761233|NCT03943589|NA|SINGLE_GROUP||TREATMENT||NONE||Data from each patient enrolled in this study will be compared with a control group consisting of up to 4 subjects treated with IVIg only from the International Guillain-Barré Syndrome Outcome Study (IGOS) database (ClinicalTrials.gov identifier: NCT01582763) fulfilling a subset of the eligibility criteria in the current imlifidase GBS study protocol. Matching will be done on geographical locations, age, presence of diarrhoea, and severity of condition.||||
33761234|NCT02106130|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761235|NCT02613221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761236|NCT00637130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761237|NCT02473484|||COHORT||PROSPECTIVE|||||||
33761238|NCT05445154|NA|SEQUENTIAL||TREATMENT||NONE||||||
33761239|NCT05505474|||COHORT||PROSPECTIVE|||||||
33761240|NCT06003465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33761241|NCT03633929|||COHORT||PROSPECTIVE|||||||
33885571|NCT02590484||||TREATMENT||||||||
33885572|NCT03136107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trained grader responsible for assessing Minimal Erythemal Dose of unprotected skin (MEDu) and Minimal Erythemal Dose of product treated (MEDp) at Visit 5 will be blinded to the product allocation of subjects. The trained grader responsible for assessing the provisional MEDu at Visit 3 will, necessarily, not be blinded since only one test site will be exposed to Ultraviolet (UV) radiation.||f|f|f|t
33885573|NCT05600595|||COHORT||PROSPECTIVE|||||||
33885574|NCT03287128|||COHORT||RETROSPECTIVE|||||||
33885575|NCT01619215|||COHORT||PROSPECTIVE|||||||
33885576|NCT03120832|NA|SEQUENTIAL||TREATMENT||NONE||||||
33885577|NCT01437241|||COHORT||PROSPECTIVE|||||||
33885578|NCT03950973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33885579|NCT02098954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885580|NCT01642641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885581|NCT04674566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885582|NCT04615637|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885583|NCT04596345|||COHORT||PROSPECTIVE|||||||
33885584|NCT04417829|||COHORT||PROSPECTIVE|||||||
33885585|NCT01933841|||CASE_CONTROL||PROSPECTIVE|||||||
33885586|NCT03033745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885587|NCT05701865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33973382|NCT04850638|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973383|NCT04738279|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33973384|NCT04120194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33973385|NCT04848610|||OTHER||CROSS_SECTIONAL|||||||
33973386|NCT00164320|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33885588|NCT04207047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973387|NCT00294723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973388|NCT03845179|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blinded study. Both participants and investigators are blinded to interventions.|Randomized, placebo-controlled, cross-over.|t|f|t|f
33973389|NCT05711030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blocks will be performed by a different anesthesiologist||f|t|t|t
33973390|NCT00527189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973391|NCT04527497|||COHORT||PROSPECTIVE|||||||
33973392|NCT02550756|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072330|NCT03748901|||COHORT||RETROSPECTIVE|||||||
33761242|NCT03782090|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients, investigators who evaluate complication of intubation are blinded to the study group.|Patients were randomly allocated into either control group (n = 95) or experimental group (n = 95) by a computerized randomization table. In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA). In experimental group, patients are intubated with novel double-lumen endotracheal tube (Ankor®,Insung Medical, Wonjou, S. Korea).|t|f|f|f
34072331|NCT04291118|NON_RANDOMIZED|PARALLEL||OTHER||NONE||New patients diagnosed with CRS (with or without polyps) who will receive medical or/and surgical management will be recruited for the study. They will be separated into one of 3 study arms based on the clinical care they require.||||
33885589|NCT01888614|||CASE_ONLY||PROSPECTIVE|||||||
33885590|NCT00360399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885591|NCT02307916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885592|NCT05061303|||COHORT||PROSPECTIVE|||||||
33885593|NCT02327091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885594|NCT04681404|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34072332|NCT03281850|||COHORT||PROSPECTIVE|||||||
34072333|NCT03516162|||COHORT||PROSPECTIVE|||||||
33885595|NCT00685594|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33885596|NCT01808612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973393|NCT01530685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973394|NCT01919294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973395|NCT03818503|||COHORT||PROSPECTIVE|||||||
33973396|NCT01333033|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973397|NCT01895920|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973398|NCT00854009|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33973399|NCT06545292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single center prospective clinical validation study.||||
34072334|NCT05073445|||OTHER||PROSPECTIVE|||||||
33761243|NCT02496338|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33761244|NCT05276167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be randomly (1:1) divided into the experimental and control groups.|The participants will be divided into two groups (the experimental group and control group). Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy. Participants in the control group will receive radical cystectomy alone.|t|f|f|f
33761245|NCT00708435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761246|NCT04547088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761247|NCT01991821|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761248|NCT05903222|||COHORT||PROSPECTIVE|||||||
33761249|NCT00402571|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33761250|NCT01075360|||COHORT||RETROSPECTIVE|||||||
33885597|NCT01528787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885598|NCT04965740|||COHORT||CROSS_SECTIONAL|||||||
33885599|NCT02542072|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33885600|NCT01273064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885601|NCT02969902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885602|NCT01495494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885603|NCT02493569|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34072335|NCT05504889|||COHORT||PROSPECTIVE|||||||
33885604|NCT00145990|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33885605|NCT03017573|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885606|NCT00217347|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885607|NCT02556567|NA|SINGLE_GROUP||OTHER||NONE||||||
33885608|NCT02984592|||COHORT||CROSS_SECTIONAL|||||||
33885609|NCT02055755|||COHORT||PROSPECTIVE|||||||
33885610|NCT03739528|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized, parallel-group study|f|f|f|t
33885611|NCT00317213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885612|NCT00786877|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33885613|NCT01852084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness|t|f|t|f
33885614|NCT01944709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885615|NCT03609372|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33885616|NCT03562663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Staff delivering the transcranial direct current stimulation and performing evaluations are blinded to active vs. sham stimulation.|We conducted a double-blind, sham-controlled, repeated-measures study design evaluating the effects of 12 weeks of robot-assisted upper-limb training (3x/week, 36 sessions) with tDCS (Robot-tDCS) or sham tDCS (Robot-Sham ) delivered at rest before each robot-assisted training session.|f|t|f|t
33885617|NCT05102526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885618|NCT06334588|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885619|NCT05497726|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-centre, open-label, non-randomized cohort safety and feasibility study.||||
33885620|NCT03022942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33885621|NCT01609595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885622|NCT01525186|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33885623|NCT02111902|||COHORT||PROSPECTIVE|||||||
33885624|NCT02451787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33885625|NCT06438679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885626|NCT02492438|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885627|NCT00482118|||CASE_CONTROL||RETROSPECTIVE|||||||
33885628|NCT06549010|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||30 healthy subjects 30 glaucoma subjects||||
33885629|NCT04015830|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885630|NCT04887402|||COHORT||PROSPECTIVE|||||||
33885631|NCT06147557|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885632|NCT01354028|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33885633|NCT04959357|||CASE_CONTROL||RETROSPECTIVE|||||||
33973400|NCT02883790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33973401|NCT03895099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973402|NCT06369415|||COHORT||PROSPECTIVE|||||||
33973403|NCT02410252|NA|SINGLE_GROUP||OTHER||NONE||||||
34072336|NCT03017391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973404|NCT02466100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072337|NCT05405764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical non-transparent sachets with circle or square|parallel two-arm randomized blinded controlled trial|t|t|t|t
34072338|NCT05359952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072339|NCT04200183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072340|NCT02840474|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072341|NCT06122285|||COHORT||PROSPECTIVE|||||||
34072342|NCT00836446|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072343|NCT00766623|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34072344|NCT01646840|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34072345|NCT05912257|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34072346|NCT01712048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072347|NCT00815997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072348|NCT02091401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072349|NCT05149261|||COHORT||PROSPECTIVE|||||||
34072350|NCT00610779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072351|NCT05880667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072352|NCT01909973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072353|NCT04497532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34072354|NCT01213927|||COHORT||PROSPECTIVE|||||||
34072355|NCT01155622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072356|NCT04794517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34072357|NCT05524649|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Every product will be provided in identical packaging|Double-blind, randomized, placebo-controlled trial in 120 healthy infants between 60 and 90 days of age, who will be allocated to receive either one of the probiotic strains or placebo for 3 months|t|t|t|t
34072358|NCT00418028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072359|NCT05399147|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33761251|NCT01755702|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33761252|NCT03009682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761253|NCT06325423|||COHORT||OTHER|||||||
33761254|NCT02148939|||CASE_CONTROL||PROSPECTIVE|||||||
33761255|NCT03707639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072360|NCT02217852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072361|NCT04566718|||COHORT||PROSPECTIVE|||||||
33761256|NCT04393116|||COHORT||RETROSPECTIVE|||||||
33761257|NCT02914808|||OTHER||PROSPECTIVE|||||||
33761258|NCT04209413|||OTHER||OTHER|||||||
33761259|NCT04446897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761260|NCT00493077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072362|NCT00478075||||TREATMENT||NONE||||||
34072363|NCT01963559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34072364|NCT01788319|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34072365|NCT04153955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors blind to the subject's treatment/arm will do the evaluations at 90 days||f|f|f|t
34072366|NCT00273598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34072367|NCT00161668|||DEFINED_POPULATION||PROSPECTIVE|||||||
34072368|NCT03323827|||COHORT||PROSPECTIVE|||||||
34072369|NCT03543176|||COHORT||CROSS_SECTIONAL|||||||
34072370|NCT05518955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34072371|NCT02591641|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33761261|NCT05365243|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761262|NCT01127880|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761263|NCT01478009|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33761264|NCT02259504|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33761265|NCT01105702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761266|NCT02601534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761267|NCT04128293|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|Eligible participants will be randomly assigned to 1 of 4 treatment sequences (ABCD, BADC, CDAB, or DCBA) in each treatment period.||||
33761268|NCT02307201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761269|NCT00530803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33761270|NCT03962244|||COHORT||PROSPECTIVE|||||||
33885634|NCT02312570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885635|NCT05770128|||COHORT||PROSPECTIVE|||||||
34072372|NCT03104608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34072373|NCT04468724|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In order to measure the impact of the intervention, we propose a two-arm essay: an intervention arm and a control arm. However, for ethical reasons, it was impossible not to offer help to all the screened persons who were in need of help for social or health reasons. That is why we will compare an arm where the intervention is immediate with an arm where the intervention is differed by three months (control arm). The comparison about what happens in the three first months will allow us to measure the impact of the intervention at three months. All participants will have a follow up of six months after the intervention.~The participants will be randomly allocated to the immediate arm or the differed arm (please see below)."||||
34072374|NCT02232061|NA|SINGLE_GROUP||OTHER||NONE||||||
34072375|NCT05035875|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072376|NCT06092034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072377|NCT02483988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072378|NCT02787681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072379|NCT01057290|||CASE_CONTROL||RETROSPECTIVE|||||||
34072380|NCT05834127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072381|NCT03097926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34072382|NCT03052920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072383|NCT03077607|NON_RANDOMIZED|||TREATMENT||NONE||||||
34072384|NCT05515510|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two arm, care-based, controlled, randomized clinical trial (RCT) using questionnaires and intraoral assessment.|t|t|f|f
34072385|NCT03456687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072386|NCT02709837|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34072387|NCT04620070|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Stepped-wedge design||||
34072388|NCT06478082|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33761271|NCT04612946|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Primary analyst and statistician will be blinded to the randomization assignment. The investigators and research coordinators will be unblinded to facilitate coordination with telehealth referral. The analyst will create the randomization assignments on a master list (using Stata) and enter into REDCap using the randomization module (stratified by batch). Assignments will be maintained by the research coordinator on a password protected computer. The blind may be broken in the case of an emergency.|Participants will be randomized (1:1) intervention or usual care|f|f|f|t
33761272|NCT01570855|||COHORT||PROSPECTIVE|||||||
33761273|NCT04190628|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Study consists of Three Parts:~Part A: ABM-1310 Dose Escalation and MTD/RP2D Dose Confirmation~Part B: Combination agent (ABM-1310 and cobimetinib (Cotellic®)) Dose Escalation and MTD/RP2D Dose Confirmation~Part C: Dose Expansion (ABM-1310 Monotherapy/Combination Therapy)"||||
33761274|NCT02020525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33885636|NCT04868552|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|investigators analyzing data will not know whether participants are in the intervention or no-intervention group|prospective randomized|f|f|f|t
33885637|NCT01526421|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33885638|NCT05357131|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Methodology of virtual reality hypnosis prevents masking the participants and the experimenter.|Cross-over and within-participant control design.||||
33885639|NCT01888692|||||PROSPECTIVE|||||||
33885640|NCT02999087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885641|NCT04713761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885642|NCT02070107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33885643|NCT04161287|||CASE_CONTROL||PROSPECTIVE|||||||
33885644|NCT01283932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885645|NCT01988389|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33885646|NCT02276092|||COHORT||PROSPECTIVE|||||||
33885647|NCT00734669|||COHORT||PROSPECTIVE|||||||
33885648|NCT00510276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973405|NCT01643148|||CASE_CONTROL||PROSPECTIVE|||||||
33973406|NCT05197712|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33973407|NCT06301997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761275|NCT02124889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The Pi does not know which participants are randomized to get the weekly survey.|Participants are assigned to either receive the weekly survey or not.|f|f|t|f
33761276|NCT00000844||||TREATMENT||DOUBLE||||||
33761277|NCT01432496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885649|NCT02786823|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|f|t
33885650|NCT03018886|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885651|NCT00098917||||TREATMENT||||||||
33885652|NCT05185349|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33885653|NCT04360967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33885654|NCT04219228|||COHORT||PROSPECTIVE|||||||
33885655|NCT01902615|||COHORT||RETROSPECTIVE|||||||
33885656|NCT05546619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885657|NCT02303431|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885658|NCT02435914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885659|NCT02953145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885660|NCT06419283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885661|NCT01288560|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885662|NCT01260155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885663|NCT05850845|||OTHER||OTHER|||||||
33885664|NCT03357393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The bronchoscopist is blinded regarding given premedication for patients given PCS (two sedation arms).||f|t|f|f
33885665|NCT04878367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||COPD without intervention group , with intervention group|f|f|t|t
33885666|NCT00364182|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33885667|NCT04095767|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, multi-center, study||||
33885668|NCT02211261|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33885669|NCT01091571|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33885670|NCT04642742|||OTHER||RETROSPECTIVE|||||||
33885671|NCT01323478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885672|NCT02686229|||COHORT||PROSPECTIVE|||||||
33885673|NCT02498873|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885674|NCT05574257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885675|NCT01340521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885676|NCT03143803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885677|NCT03152240|||COHORT||PROSPECTIVE|||||||
33973408|NCT02213796|NA|SINGLE_GROUP||||NONE||||||
33973409|NCT06032351|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885678|NCT05436548|RANDOMIZED|PARALLEL||PREVENTION||NONE||Primary care clinics randomly assigned to the intervention will conduct frequent supervisor-employee check-ins. Supervisors at those clinics will receive training to conduct such check-ins. Control clinics will continue as usual practice.||||
33885679|NCT06271525|NA|SINGLE_GROUP||TREATMENT||NONE||cupping therapy||||
33885680|NCT00235079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973410|NCT05140642|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Measurements shown in Picture Archiving and Communication System (PACS) without direct communication between sonographer and cardiologist. Annotations are shown without identifiers on how the annotations were done. Cardiologists are blinded to source of preliminary interpretation.|Studies will be randomized 1:1 to either sonographer preliminary report finding or AI preliminary report finding with final adjudication by the cardiologist. With AI preliminary report, the preliminary interpretations will be generated by AI (artificial intelligence) technology \[a semantic segmentation model\] and the PACS system's native EF calculation workflow will be used to calculate LVEF. The study team will assess how much cardiologists edit and change this preliminary interpretation is from the final interpretation.|t|f|f|f
33973411|NCT01094444|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33973412|NCT01897974|||COHORT||PROSPECTIVE|||||||
33973413|NCT05763966|||COHORT||PROSPECTIVE|||||||
33973414|NCT00759148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973415|NCT03229252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33973416|NCT06222710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973417|NCT02557945|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33973418|NCT06313047|||COHORT||PROSPECTIVE|||||||
33885681|NCT00408967|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885682|NCT00983411|||OTHER||PROSPECTIVE|||||||
33885683|NCT01677247|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33885684|NCT06549179|||COHORT||PROSPECTIVE|||||||
33885685|NCT03929887|||COHORT||PROSPECTIVE|||||||
33885686|NCT03926676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885687|NCT02137967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885688|NCT01208129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885689|NCT01796951|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885690|NCT00002310||||TREATMENT||NONE||||||
33885691|NCT02765282|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33885692|NCT01483430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33885693|NCT00715975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885694|NCT00732745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885695|NCT03446456|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Randomization will be performed/maintained by the University of Maryland Medical Center Pharmacy. Blind will only be broken in case of a potential medical emergency during the experiment.|This experiment has a between-subjects design. Participants will be randomized into two groups: AVP and control. Both the experimenter and participant will be blinded to the group allocation. Participants have 50%/50% chance of being placed in either group. Participants in the AVP group will receive intranasal AVP and the participants in the control group will receive intranasal saline before the fMRI experiment. The experiment in the fMRI scanner is divided into two phases: an observational phase in which participants will observe a video of a demonstrator experiencing analgesia and a testing phase in which study participants will receive heat pain to investigate how their pain perception. During both phases there will be a placebo condition (pain with the expectation of having received a treatment) and a control condition (pain without the expectation of having received a treatment). All participants will complete both phases, including the observational and testing phase.|t|f|t|f
33885696|NCT01812967|RANDOMIZED|CROSSOVER||PREVENTION||||||||
33885697|NCT01872338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885698|NCT01130571|||COHORT||PROSPECTIVE|||||||
33885699|NCT03312569|||CASE_ONLY||PROSPECTIVE|||||||
33885700|NCT01096147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885701|NCT04258579|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will be comparing data collected from this project to previously collected data from the first phase of this project, in which PROTECT was delivered only in-person.||||
33885702|NCT01819519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33885703|NCT05713864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885704|NCT00006519||||TREATMENT||||||||
33885705|NCT00167635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885706|NCT02463955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885707|NCT03437239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885708|NCT05296590|||COHORT||RETROSPECTIVE|||||||
33885709|NCT04869267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcomes assessors who are independent with the research will be trained before formally conducting data collecting.|Participants are assigned to two groups in parallel for the duration of the study. Participants in Group A receive Acceptance and Commitment Therapy based on usual care. Participants in Group B receive usual care.|f|f|f|t
33885710|NCT06014944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885711|NCT01724437|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33885712|NCT00933036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885713|NCT00631137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33761278|NCT03326960|||COHORT||PROSPECTIVE|||||||
33761279|NCT01925625|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33761280|NCT04581421|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized diet intervention study in a cross over design||||
33761281|NCT05993702|||COHORT||PROSPECTIVE|||||||
33761282|NCT04449848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761283|NCT00524030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761284|NCT01965379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761285|NCT05041153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761286|NCT04186845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Positron Emission Tomography (PET) Imaging study||||
33761287|NCT03749122|||COHORT||RETROSPECTIVE|||||||
33761288|NCT01677364|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761289|NCT00829335|||COHORT||PROSPECTIVE|||||||
33761290|NCT06413316|||CASE_CONTROL||PROSPECTIVE|||||||
33761291|NCT03958916|||COHORT||PROSPECTIVE|||||||
33761292|NCT03761537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761293|NCT02769234|||COHORT||PROSPECTIVE|||||||
33761294|NCT05558865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761295|NCT05509725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33761296|NCT03171480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A double blinded, placebo controlled, randomized clinical trial of patients undergoing induction of labor for preeclampsia. Study drug or identical appearing placebo will be delivered to labor floor by pharmacist, after randomization.||t|t|t|t
33761297|NCT04963374|||CASE_CONTROL||RETROSPECTIVE|||||||
33761298|NCT06191809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761299|NCT02595216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761300|NCT05218993|||COHORT||PROSPECTIVE|||||||
33761301|NCT01712009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761302|NCT02991482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761303|NCT01645748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761304|NCT03665844|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||1 week baseline, 3 weeks active condition||||
33761305|NCT02380443|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885714|NCT01795547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885715|NCT01977885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885716|NCT05520528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885717|NCT02006992|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33885718|NCT03983551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761306|NCT01900262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761307|NCT02515565|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33761308|NCT03519750|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each volunteer will have melatonin administered through all five routes of administration, and will have a wash-out of a minimum of 7 days between each administration.||||
33761309|NCT01787097|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33761310|NCT05276232|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33761311|NCT05279456|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be stratified for analysis by age, sex and seropositivity at time of study entry||||
33761312|NCT03651102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761313|NCT00642837|||||PROSPECTIVE|||||||
33761314|NCT01969422|||CASE_ONLY||RETROSPECTIVE|||||||
33761315|NCT03122119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761316|NCT00177203|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761317|NCT05751174|||CASE_ONLY||PROSPECTIVE|||||||
33761318|NCT05542810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33761319|NCT04955847|||CASE_ONLY||RETROSPECTIVE|||||||
33761320|NCT01117389|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761321|NCT03515382|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33761322|NCT00998907|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761323|NCT05780814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33761324|NCT00998400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761325|NCT05476055|||COHORT||PROSPECTIVE|||||||
33761326|NCT01063322|||||PROSPECTIVE|||||||
33761327|NCT06072222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||200 patients included in our study from those who showed no improvement and still had respiratory failure and completed ventilation for 4 days and fulfilled \> 2 parameters on SOFA score \[9-10\] and \> 6 on CPIS score and randomly allocated in two groups 100 patients in each.|f|f|t|f
33761328|NCT04077957|RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled participants will be randomly divided into 2 groups evenly. Participants in Group 1 will be treated with etanercept and conventional synthetic DMARDs based on treat-to-target strategy, while the others in Group 2 will be treated with conventional therapy scheme using etanercept only.||||
33885719|NCT00264914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885720|NCT04792710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The out comes assessor will not have access to the arm the patient was randomised to.|Randomised placebo controlled trial|f|f|f|t
33885721|NCT01896960|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885722|NCT06501456|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33885723|NCT01271621|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33885724|NCT02684721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885725|NCT02950792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973419|NCT03262974|||OTHER||RETROSPECTIVE|||||||
33973420|NCT03438448|||COHORT||PROSPECTIVE|||||||
33885726|NCT03285256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the participant and the research assistant conducting the assessments will be blinded to group assignment.|Participants will be randomly assigned to one of three treatment conditions: an experimental memory training program or one of two comparator memory training programs.|t|f|t|f
33885727|NCT01505829|||COHORT||PROSPECTIVE|||||||
33885728|NCT04457960|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33885729|NCT01002508|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33885730|NCT05836454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations will be made by another physical therapist who is blinded to the groups.|Single Blind Randomized Controlled Study|f|f|f|t
33761329|NCT00003884|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33885731|NCT02817672|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33885732|NCT02881034|||COHORT||RETROSPECTIVE|||||||
33885733|NCT00697957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33885734|NCT06192173|||COHORT||RETROSPECTIVE|||||||
33885735|NCT02056509|||COHORT||PROSPECTIVE|||||||
33885736|NCT04345445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885737|NCT04295070|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33885738|NCT05223595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885739|NCT00983190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885740|NCT06496412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885741|NCT01501903|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885742|NCT03760497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885743|NCT03056105|||CASE_CONTROL||PROSPECTIVE|||||||
33973421|NCT03379077|RANDOMIZED|PARALLEL||OTHER||SINGLE|researchers doing outcome assessment will be kept blind on both implementation groups||f|f|f|t
33973422|NCT01026961|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33973423|NCT01527448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973424|NCT01482156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973425|NCT01236833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973426|NCT04416984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973427|NCT04795661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973428|NCT03929939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885744|NCT00389025|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33885745|NCT00188630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885746|NCT06177366|||COHORT||PROSPECTIVE|||||||
33885747|NCT04041856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885748|NCT03951636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885749|NCT04870437|NA|SINGLE_GROUP||OTHER||NONE||||||
33885750|NCT01951677|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33885751|NCT03607773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The PI will not know which group each participant has been randomized to, nor will the study coordinator.~One study team member, who is leading the Mindfulness sessions, will be unblinded."||f|f|t|t
33885752|NCT06364995|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group used the intervention of specialised physical education teaching of volleyball. However, the control group only conducted traditional physical education teaching content|t|f|t|t
33885753|NCT01471665|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33885754|NCT00113243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885755|NCT00519740|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885756|NCT05176912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33885757|NCT04019366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were masked from the treatment procedure by Sealed envelope methods. Patients were randomly distributed into two groups.|Parallel Assignment of patients into two groups|t|f|f|f
33885758|NCT02844998|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33973429|NCT05705297|||COHORT||PROSPECTIVE|||||||
33761330|NCT03447080|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover study||||
33761331|NCT00159705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33761332|NCT02614443|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761333|NCT05497713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33761334|NCT01322555|||||PROSPECTIVE|||||||
33761335|NCT05356325|||CASE_CROSSOVER||PROSPECTIVE|||||||
33761336|NCT02786914|||COHORT||PROSPECTIVE|||||||
33761337|NCT05375123|||COHORT||PROSPECTIVE|||||||
33761338|NCT02493400|||COHORT||PROSPECTIVE|||||||
33761339|NCT01978639|||COHORT||PROSPECTIVE|||||||
33761340|NCT00242528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761341|NCT05388058|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33885759|NCT00002969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885760|NCT00397722|RANDOMIZED|PARALLEL||TREATMENT||||||||
33885761|NCT06339398|||COHORT||PROSPECTIVE|||||||
33973430|NCT02335970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973431|NCT05181982|||COHORT||PROSPECTIVE|||||||
33973432|NCT04806984|||OTHER||OTHER|||||||
33973433|NCT00696709|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33973434|NCT01273610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973435|NCT05939661|NA|SEQUENTIAL||TREATMENT||NONE||RT→Chemo→Surgery||||
33973436|NCT06404593|||COHORT||PROSPECTIVE|||||||
33973437|NCT03830983|||CASE_CONTROL||PROSPECTIVE|||||||
33973438|NCT05169164|||COHORT||PROSPECTIVE|||||||
33973439|NCT01199406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973440|NCT06256250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33973441|NCT04639427|||CASE_ONLY||PROSPECTIVE|||||||
33973442|NCT03726190|||COHORT||RETROSPECTIVE|||||||
33761342|NCT03760601|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Single case experimental AB design with optional replication (ABAB)||||
33761343|NCT03343158|||OTHER||CROSS_SECTIONAL|||||||
33761344|NCT06379191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33761345|NCT02907814|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761346|NCT03060798|||COHORT||PROSPECTIVE|||||||
33761347|NCT01696448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761348|NCT00006002|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761349|NCT05227755|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|A third party vendor will provide the coded samples. The vendor will only reveal the actual products once the study has ended and analysis has occurred.|This is a 12-week interventional, double-blind randomized controlled crossover clinical trial designed to evaluate the impact of whey (control) and soy (intervention) protein isolate oral supplements on protein status and inflammation markers.|t|f|t|f
33761350|NCT00483834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761351|NCT06447350|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. control condition with motivational interview~2. IH condition with motivational interview avec IH program~3. SIM condition with motivational interview avec SIM program~4. MM condition with motivational interview avec MM program"||||
33761352|NCT03727009|||COHORT||CROSS_SECTIONAL|||||||
33761353|NCT02863211|||COHORT||PROSPECTIVE|||||||
33761354|NCT00695786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761355|NCT04458623|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33761356|NCT04496999|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized prospective open-label single-arm clinical phase I trial investigating dose finding, feasibility and safety of the combined treatment of HDM201 and midostaurin||||
33761357|NCT04274270|NA|SINGLE_GROUP||TREATMENT||NONE||Radiotherapy was performed with a cyberknife or accelerator stereotactic radiotherapy, which lasted 3-10 days.After the end of radiotherapy,S1 60mg, BID, day 1-28, as taken orally, and repeated every 6 weeks, with concurrent Endostar therapy: 210mg was used by intravenous infusion for 7 consecutive days during each cycle of chemotherapy, and 30mg was used every 24 hours.||||
33761358|NCT03631225|||COHORT||PROSPECTIVE|||||||
33761359|NCT02178059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33761360|NCT00420758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761361|NCT05073042|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33761362|NCT04760522|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761363|NCT01013610|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33761364|NCT04732052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761365|NCT03215901|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33761366|NCT01064908|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761367|NCT00375362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33761368|NCT01522534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761369|NCT01373632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761370|NCT01976065|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33761371|NCT03895463|||COHORT||PROSPECTIVE|||||||
33761372|NCT01238640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761373|NCT01724645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761374|NCT02465502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761375|NCT03234153|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm open-Label prospective Phase II||||
33761376|NCT03996408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761377|NCT00317889|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885762|NCT01385020|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885763|NCT02400255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885764|NCT03094000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Following an evaluation and screening process, those who fit the criteria will be allocated randomly to one of the two research groups: experiment or control.|f|f|f|t
33885765|NCT06056752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885766|NCT03696992|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective randomized design|t|f|f|f
33885767|NCT04451330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973443|NCT05065879|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Serum testing technicians will be masked.||f|f|f|t
33973444|NCT03604120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761378|NCT05154123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761379|NCT02707458|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761380|NCT03391765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761381|NCT04770064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761382|NCT06184243|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be a single subject design which will be replicated across multiple participants. The participants are pairs of one parent and one child for each session. The participants will be observed during the initial baseline phase before the intervention. The baseline phase will be used to compare the initial abilities before the intervention of the participants to their abilities after the intervention. After the baseline, the parent will participate in a parent training on how to use video modeling intervention with their child. Then the intervention phase begins. The parent and child will watch the video created to show new play skills for the child together and then have a play session. The parent will receive coaching before and after sessions.||||
33885768|NCT02238535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885769|NCT06265844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33885770|NCT03132402|||COHORT||PROSPECTIVE|||||||
33885771|NCT01438008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885772|NCT03169608|||COHORT||PROSPECTIVE|||||||
33885773|NCT02117726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885774|NCT03867045|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33885775|NCT00219115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33885776|NCT00584233|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885777|NCT01119547|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885778|NCT00827697|||COHORT||CROSS_SECTIONAL|||||||
33973445|NCT01776593|||COHORT||RETROSPECTIVE|||||||
33973446|NCT01235156|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761383|NCT01299155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885779|NCT04698967|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in Phase 3 will be randomly assigned to either a treatment as usual condition or to receive the additional intervention of Purposeful Pathways.||||
33973447|NCT05600374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is a multicenter randomized controlled double-blind three-arm parallel-group exploratory clinical trial. The subjects as well as the as the rater in the post- and the follow-up assessment will be blinded to the intervention condition the patient receives.|Multicenter randomized controlled double-blind three-arm parallel-group exploratory clinical trial Medical Device Regulation (MDR) clinical trail|t|f|f|t
33761384|NCT05386667|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761385|NCT04461743|||COHORT||PROSPECTIVE|||||||
33761386|NCT05982665|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Hydrogen and placebo generators indistinguishable to the human senses||t|f|t|f
33761387|NCT02415699|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761388|NCT02240108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973448|NCT04495491|||OTHER||PROSPECTIVE|||||||
33973449|NCT03091166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33973450|NCT02471300|||CASE_ONLY||PROSPECTIVE|||||||
33973451|NCT00106262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973452|NCT05948345|||CASE_CROSSOVER||PROSPECTIVE|||||||
33973453|NCT00093964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973454|NCT01103557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973455|NCT03294512|NA|SINGLE_GROUP||OTHER||NONE||||||
33761389|NCT05404425|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761390|NCT02668016|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33761391|NCT02206490|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33761392|NCT02857426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761393|NCT03916744|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33761394|NCT01646190|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761395|NCT04055922|||COHORT||RETROSPECTIVE|||||||
33885780|NCT03092050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blinded to study hypotheses. Under UCSF IRB #16-20163, on 07.21.2016 (prior to participant enrollment), IRB approval was received for a single-blind study (participant blinding only) due to funding constraints.|2 arm randomized controlled trial. During the conduct of the trial, the investigators noted that due to staffing constraints, participant availability, and funding limitations, it would not be feasible to complete a crossover study. This was due to the fact that the investigators were unable to offer crossover group therapy visits at the same time as the initial group sessions. Rather, groups with new participants had to be prioritized and scheduled during the most accessible time slots. Times that the investigators could offer for crossover groups were often inaccessible to participants. Thus, the investigators determined that in the context of this pilot trial, it was not feasible to conduct a full crossover trial due to accessibility. The trial design was therefore updated to parallel (in accordance with the initial funding application).|t|f|f|f
33885781|NCT03685773|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The subject will be blinded to which study drug is received first (Drug or Placebo).||t|f|f|f
33885782|NCT00947401|||COHORT||PROSPECTIVE|||||||
33885783|NCT01840046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885784|NCT02118792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885785|NCT02023658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885786|NCT04553107|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33885787|NCT06310746|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33885788|NCT03177733|||COHORT||PROSPECTIVE|||||||
33885789|NCT03871478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885790|NCT02500004|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885791|NCT01110252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885792|NCT01154647|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33885793|NCT00254410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885794|NCT00173862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885795|NCT01502904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885796|NCT05206448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885797|NCT04534777|||COHORT||OTHER|||||||
33885798|NCT06335615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885799|NCT04764552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||double-blinded crossover|t|f|t|f
33885800|NCT05187832|NA|SEQUENTIAL||TREATMENT||NONE||||||
33885801|NCT00756938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885802|NCT01351441|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33885803|NCT05622539|||CASE_ONLY||PROSPECTIVE|||||||
33761396|NCT04491812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind masking|Group A: physical therapy program Group B: physical therapy program inaddition to kinesiotaping|t|f|f|f
33885804|NCT01114633|||CASE_ONLY||PROSPECTIVE|||||||
33885805|NCT04439955|NA|SINGLE_GROUP||TREATMENT||NONE||Each patient will commence the study with a one month run-in period in which he/she will be administered individual with placebo (olive oil). At the end of the one month run-in period, all trial subjects will receive CBD||||
33885806|NCT06237114|||COHORT||PROSPECTIVE|||||||
33973456|NCT04385446|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The patients did not know what kind of material was used in their surgery. The assessor who performed tear film analysis did not know what material was used in the patient.|Two groups of patients in whom Conventional Pterygium surgery was performed Each patient was randomly assigned for either received amniotic membrane transplantation or conjunctival autograft as a recovering method in the pterygium removed area after surgery. Tear film Mucins were measured in both groups|t|f|f|t
33973457|NCT00861783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973458|NCT00585351|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
33973459|NCT05828550|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973460|NCT04522414|||COHORT||PROSPECTIVE|||||||
33973461|NCT01968109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973462|NCT03267264|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33973463|NCT03368989|||COHORT||PROSPECTIVE|||||||
33973464|NCT02546713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973465|NCT01886456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973466|NCT01798745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761397|NCT03985332|||COHORT||RETROSPECTIVE|||||||
33761398|NCT05810207|||COHORT||PROSPECTIVE|||||||
33973467|NCT01610258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973468|NCT02404597|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973469|NCT01641744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973470|NCT04573842|||COHORT||PROSPECTIVE|||||||
33973471|NCT00278200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973472|NCT00457522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973473|NCT05522608|||COHORT||PROSPECTIVE|||||||
33973474|NCT01127009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885807|NCT00047346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973475|NCT03805191|||OTHER||PROSPECTIVE|||||||
33885808|NCT00775489|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33885809|NCT06548802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33885810|NCT04480281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33885811|NCT03543085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885812|NCT04133584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885813|NCT03868943|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33885814|NCT00693199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885815|NCT03653520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon was not aware which medication the patient received||f|t|f|f
33885816|NCT02168595|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33885817|NCT00212147|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33885818|NCT01827631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973476|NCT00048360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33973477|NCT03761836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973478|NCT06422117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885819|NCT02238847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885820|NCT06031155|||COHORT||PROSPECTIVE|||||||
33761399|NCT04119453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885821|NCT06300515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The staff in charge of outcome assessment will be blinded to the group assigned to each participant.||f|f|f|t
33885822|NCT03004807|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33761400|NCT01271569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885823|NCT02702648|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33885824|NCT05137561|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Simple randomization using RRApp||||
33885825|NCT03644563|||COHORT||PROSPECTIVE|||||||
33885826|NCT06199245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher knows the distribution of the groups, but the participants do not know whether they are in the experimental or control group.|An experimental group in which EFT was applied and a control group in which the routine procedure was applied.|t|f|f|f
33885827|NCT04915040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885828|NCT06452264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885829|NCT00582647|||COHORT||PROSPECTIVE|||||||
33761401|NCT02596126|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885830|NCT05420389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The volunteer who is in the latent phase of labor will not know which group she will be in before joining the study. After accepting to participate in the study, the volunteer will be informed about which group she will be in.|There will be 4 groups.three interventional and one control group.|t|f|f|f
33885831|NCT04097327|||OTHER||PROSPECTIVE|||||||
33885832|NCT05916404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple-blind study; the patients will not be informed about their groups (training group or the control group) and they will be evaluated and trained at different places and times.~Evaluations and interventions will be performed different physiotherapist. In addition, before statistical analysis patients' groups will be coded."||t|f|t|t
33885833|NCT03983395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885834|NCT03746561|||CASE_ONLY||RETROSPECTIVE|||||||
33885835|NCT02004002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885836|NCT04525963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind|A quasi-experimental pre-test post-test control group design in non-randomized groups study,to determine the effect of the preoperative visit by the operating room nurse on the postoperative anxiety level and pain severity of patients undergoing open heart surgery|f|f|f|t
33885837|NCT00832897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885838|NCT01868360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885839|NCT04620330|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885840|NCT00848120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885841|NCT03464617|||COHORT||PROSPECTIVE|||||||
33885842|NCT06356233|||COHORT||PROSPECTIVE|||||||
33885843|NCT01569984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885844|NCT05568589|||COHORT||PROSPECTIVE|||||||
33885845|NCT01774422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885846|NCT06361641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885847|NCT00664248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885848|NCT06100575|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885849|NCT00508573|||CASE_ONLY||PROSPECTIVE|||||||
33885850|NCT01865331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885851|NCT03382509|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885852|NCT02290314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885853|NCT05313542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885854|NCT05689333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973479|NCT00482313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973480|NCT03613350|||CASE_ONLY||RETROSPECTIVE|||||||
33973481|NCT02444312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33973482|NCT02281409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33973483|NCT02384681|||CASE_CONTROL||PROSPECTIVE|||||||
33973484|NCT01573091|||COHORT||PROSPECTIVE|||||||
33973485|NCT00425815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973486|NCT00679783|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"4 parallel arms for the 2 tumour types and the BRCA mutation groups:~1. Triple negative breast Cancer with unknown BRCA mutation status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~2. Known BRCA mutation positive breast cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) to be administered orally~3. High grade serous/undifferentiated tubo-ovarian carcinoma with unknown BRCA status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~4. Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally."||||
33973487|NCT03591549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973488|NCT00836927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973489|NCT01892774|||CASE_ONLY||PROSPECTIVE|||||||
33973490|NCT03596996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973491|NCT04489550|||COHORT||RETROSPECTIVE|||||||
33885855|NCT00457496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885856|NCT00478491|||CASE_CONTROL||PROSPECTIVE|||||||
33885857|NCT05888688|||COHORT||CROSS_SECTIONAL|||||||
33885858|NCT01067131|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33973492|NCT03425864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double blinded Blinding will be done to the clinical, radiographic assessors, without involving them in sequence generation or allocation concealment or surgery performing.~Blinding of the biostatistian."|Eligible patients will be randomized using sequence generation program (Random.org in equal proportions between control group (immediate implant alone) and study group (immediate implant covered with sub-epithelial connective tissue graft with full coverage technique).|t|f|f|t
33973493|NCT03304509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients will be included and assigned randomly, using an informatic program, to one of the study arms before hospital discharge.||||
33973494|NCT00598559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973495|NCT05671289|||COHORT||CROSS_SECTIONAL|||||||
33973496|NCT01502618|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885859|NCT00481416|||||PROSPECTIVE|||||||
33885860|NCT02709278|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33885861|NCT06068387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885862|NCT04040361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885863|NCT05429879|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized control study that is designed to study outcomes between subjects. Participants will be randomly assigned to one of three groups and will be stratified according to sex. Stratified randomization will be done by selection of sequential pre-filled envelopes containing the group for a particular patient at the time of cystoscopy - This is a 1:1:1 randomization with equal group membership performed for both male and female sexes - The envelopes will be randomized by pre-assigning an order of participants to each of the three groups within each sex using a Random sequence generator.||||
33885864|NCT03704129|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33885865|NCT02476318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885866|NCT06369493|||OTHER||CROSS_SECTIONAL|||||||
33885867|NCT01112709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885868|NCT02663739|||CASE_ONLY||PROSPECTIVE|||||||
33885869|NCT01745757|||COHORT||PROSPECTIVE|||||||
33885870|NCT03902678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Use of histopathology obtained from endoscopic ultrasound -fine needle aspiration of portal vein thrombus for identification of malignant thrombus which did not fulfill criteria of malignancy by abdominal ultrasound and triphasic abdominal CT||||
33885871|NCT02805205|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33885872|NCT01629615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885873|NCT04946266|||COHORT||PROSPECTIVE|||||||
33885874|NCT02071433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33885875|NCT01324284|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33885876|NCT00000815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885877|NCT05310214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomised clinical trial|t|f|t|t
33885878|NCT06112769|||CASE_ONLY||PROSPECTIVE|||||||
33761402|NCT00622180|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33761403|NCT01939886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33761404|NCT02034825|||COHORT||RETROSPECTIVE|||||||
33761405|NCT03674554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation sequence generation will be performed by the Senior supervisor. Enrolment of participants will be performed by the principle investigator where the patients will be assessed for eligibility.||t|f|f|t
33761406|NCT03161457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761407|NCT02450630|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33761408|NCT05305014|||COHORT||RETROSPECTIVE|||||||
33761409|NCT01937923|||COHORT||PROSPECTIVE|||||||
33885879|NCT00903279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885880|NCT03737162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885881|NCT01180387|||||PROSPECTIVE|||||||
33885882|NCT04217564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"All attending patients will be checked for the inclusion and exclusion criteria. Eligible patients will be randomly allocated to either the intervention or control group by randomized block design.~Patients in the 2 groups will be initially assessed. Those in the intervention group will receive a counselling session then instructed on the subsequent follow up dates. Those in the control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study. Apart from counselling, patients will receive the same care from the clinic medical staff. After the final assessment the control group will be invited to receive the nutritional counselling material to gain its suspected benefits."||||
33885883|NCT02324270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973497|NCT03788577|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33761410|NCT04336748|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33761411|NCT05210829|||COHORT||PROSPECTIVE|||||||
33761412|NCT00714922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761413|NCT00593125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761414|NCT04829721|NA|SINGLE_GROUP||OTHER||NONE||||||
33761415|NCT01605760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33761416|NCT00168545|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761417|NCT01919970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761418|NCT03454165|NA|SEQUENTIAL||TREATMENT||NONE||Open label dose escalation study, with a Storer D ; 3-3 cohort design||||
33885884|NCT06504277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Study participants will be randomized on the day of surgery, and the research nurse will set the insufflation pressure to the pre-randomized pressure identified in the envelope. The surgeon, research team, participants and data analysts will be blinded to treatment group.~Study participants will be randomized on the day of surgery. After Veress-needle insufflation and laparoscopic port insertion at a pneumoperitoneum of 20mmHg (standard entry pressure), the patient will be placed in Trendelenberg position. At this time, the research nurse will set the insufflation pressure to the pre-set randomized number. This insufflation pressure will be blinded on the machine from the surgeon. If the surgeon is not satisfied with the visibility, they may ask to set the pressure to 15mmHg, however, they will remain blinded. The surgeon, research team, participants and data analysts will be blinded to treatment group."|"This proposed study is a single-center parallel group RCT comparing the use of low (10 mm Hg) versus standard pressure (15 mm Hg) pneumoperitoneum at the time of benign gynecologic laparoscopic surgery. Participants will be selected using a convenience sample from Women's College Hospital operating room list. All potentially eligible patients will be invited to participate in this study by the MIS fellow on the day of surgery up to 2 hours before the scheduled surgery.~We will create a randomization list in equal ratio with study numbers 1 to 128. A member of the research team who will have no interaction with patients in this study will prepare the low and standard pressure envelopes and label them according to the randomization list."|t|t|t|t
33885885|NCT02504788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885886|NCT01303055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885887|NCT05916586|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel-group, comparative, open-label, randomised, controlled trial.||||
33885888|NCT01823419|||CASE_ONLY||CROSS_SECTIONAL|||||||
33885889|NCT01653119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885890|NCT05508555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885891|NCT04436276|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33885892|NCT04989608|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33885893|NCT00003454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885894|NCT00622895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885895|NCT05731804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885896|NCT00792298|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33973498|NCT02607800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973499|NCT01840956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973500|NCT06545513|||COHORT||RETROSPECTIVE|||||||
33973501|NCT04244747|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973502|NCT03247296|||COHORT||PROSPECTIVE|||||||
33973503|NCT04521959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|40 COPD patients will be randomised divided into two equal groups according to age, gender and disease severity.|Two randomized controlled intervention groups will be formed.|t|t|f|t
33973504|NCT03339037|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|randomization by computer, sham/ treatment will be known to chamber technicians and nurses but not to investigators|randomized controlled trial using a SHAM treatment compared to treatment|t|t|t|t
33973505|NCT01871779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973506|NCT04895410|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33973507|NCT03843957|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33973508|NCT01006707|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33973509|NCT02916173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973510|NCT04652570|NA|SEQUENTIAL||TREATMENT||NONE||||||
33973511|NCT03954028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The biopsy sites will be coded alphanumerically. The investigator performing the gingival grafts will be different from the examiner performing the gingival biopsies. The examiner performing the gingival biopsies will be blinded to the grafting type source of the biopsy sites.The results from coded samples will be reported to the PI, who will summarize the data.|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half.|f|f|t|f
33973512|NCT03602690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973513|NCT00004659|RANDOMIZED|||TREATMENT||||||||
33973514|NCT04562649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33973515|NCT01767597|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33761419|NCT01468441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761420|NCT00575445|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761421|NCT02597465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33885897|NCT05095025|NA|SEQUENTIAL||TREATMENT||NONE|The assessor and the patient will be unaware of the dose of bupivacaine administered. The bupivacaine solution will be prepared by an investigator other than those involved in the performance of the PENG block or the assessment of block outcome.|Using a sequential step-up, step-down dosing model the dose of bupivacaine administered will be determined by the response of the preceding patient. Each participant will receive a total injectate volume of 20ml. Based upon the published efficacy literature, the starting dose of bupivacaine will be 50mg. The dose of bupivacaine will be adjusted by 5mg up or down based on the outcome (analgesic success or failure) of each subsequent participant.||||
33885898|NCT03057366||SEQUENTIAL||OTHER||NONE||||||
33885899|NCT00882141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885900|NCT02190019|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33885901|NCT05774340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885902|NCT02385279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885903|NCT05512871|RANDOMIZED|PARALLEL||OTHER||NONE|60-80 female subjects will be randomized to either Group 1 (Intervention group) or Group 2 (Control group) based on 1:1 allocation. HealthifySG App will only be installed on the phones of subjects for Group 1(Intervention group).|"The study is a parallel 2-arm, single-centre randomized controlled trial based on 1:1 allocation ratio:~Group1 (Intervention group) - Oura ring with Oura App + HealthifySG App (receive lifestyle interventions via HealthifySG App) Group 2 (Control group) - Oura ring with Oura App alone (without lifestyle interventions)"||||
33885904|NCT05039060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Approximately 40 participants will be randomly assigned to following group (group 1 or group 2). The subjects will be consumed the modified MAC or conventional diet for first 3-weeks period then cross-over to second 3-weeks period.||||
33885905|NCT05315609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885906|NCT03818698|||COHORT||PROSPECTIVE|||||||
33885907|NCT06498934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, therapists, care providers, investigators, and outcomes assessors do not know which group (real DN-DBS or control) the patients are randomized. Only the programmer who programs the device settings knows which group the subject is randomized into.|Double blind, randomized, parallel study with partial crossover (control subjects crossover to treatment after randomized portion)|t|t|t|t
33885908|NCT03436173|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33885909|NCT04724473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33885910|NCT03618745|||COHORT||PROSPECTIVE|||||||
33885911|NCT03977246|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885912|NCT04345666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the primary investigator will be blinded to the treatment allocation. The study coordinator will be unblinded.|Randomized, double-blinded, placebo controlled model|t|f|t|f
33885913|NCT06469463|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33885914|NCT00242008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33885915|NCT00412776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885916|NCT02770521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33885917|NCT01126255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885918|NCT02537990|||COHORT||PROSPECTIVE|||||||
33885919|NCT06024525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The use of a third-party independent CEC and an independent coronary angiography core laboratory to adjudicate each primary and other endpoints helps reduce measurement bias from outcome measures.||f|f|f|t
33885920|NCT00766805|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33885921|NCT04657432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study 1: All participants will be randomized to 10 different active doses of accelerated, intermittent theta burst rTMS.|"Study 1: Participants will be randomized to 10 different doses of accelerated intermittent theta burst rTMS for remediation of depression symptoms. The goal is to determine the optimal dose in terms of efficacy while minimizing burden and side effects.~Study 2: Participants will be assigned to 10 active sessions (per treatment day) of accelerated rTMS for 5 treatment days. All doses are active and within established therapeutic levels of rTMS. The goal is to determine the role of individual variations of their functional networks compared to the site of stimulation."|t|f|f|f
33973516|NCT00582309|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33973517|NCT04657484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973518|NCT05325242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973519|NCT01118728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973520|NCT02219191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973521|NCT02946957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973522|NCT05808556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973523|NCT01533428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973524|NCT02561819|||COHORT||PROSPECTIVE|||||||
33973525|NCT04990830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment Group - Control Group||||
33973526|NCT02521675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33973527|NCT06321146|||COHORT||PROSPECTIVE|||||||
33973528|NCT04902807|||COHORT||PROSPECTIVE|||||||
34072389|NCT03671512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessments of efficacy measurements of pocket depth and attachment gain CAL will be performed by a dental professional staff member at the investigator site who is blinded to which procedure was performed in each quadrant. Whenever possible, the same staff member will make these assessments throughout the study. The pocket depth assessments will be performed by a dental professional who has been trained on the actual method. Personnel will be trained to use the University of North Carolina (UNC) probe by the central trainer provided by the sponsor or CRO.|For each subject, one quadrant will be randomized to PSR and the other quadrant will be randomized to conventional scaling and root planing.|f|f|f|t
33973529|NCT01137305|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||f|t|t|t
33885922|NCT04749381|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Patients enrolled are randomized into acupoint application group and placebo acupoint application group|t|t|t|t
33885923|NCT00166855|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973530|NCT02717975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885924|NCT03641131|||CASE_ONLY||RETROSPECTIVE|||||||
33885925|NCT02476669|||COHORT||PROSPECTIVE|||||||
33973531|NCT00870909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973532|NCT03999437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33973533|NCT03712657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973534|NCT03557138|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973535|NCT01048333|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33973536|NCT05240651|||COHORT||PROSPECTIVE|||||||
33973537|NCT03890874|||OTHER||PROSPECTIVE|||||||
33885926|NCT02249702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973538|NCT04037566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973539|NCT02398318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973540|NCT01787825|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33973541|NCT01127490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973542|NCT05760079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973543|NCT01480531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072390|NCT03827694|||COHORT||PROSPECTIVE|||||||
34072391|NCT06481943|||COHORT||PROSPECTIVE|||||||
34072392|NCT04437836|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Enroll children participant and giving them treatment care as well as safety monitoring|Safety and tolerability study|t|t|t|f
34072393|NCT06508060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072394|NCT05013580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885927|NCT02149810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973544|NCT02318927|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33973545|NCT04082975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973546|NCT05502315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072395|NCT01133704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885928|NCT01587742|||||RETROSPECTIVE|||||||
33885929|NCT02648386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33885930|NCT00591695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885931|NCT04753892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885932|NCT04513483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885933|NCT05587751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33885934|NCT06526936|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885935|NCT06236347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33885936|NCT00157547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33885937|NCT04690114|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33885938|NCT00576238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973547|NCT03849781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973548|NCT00880282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973549|NCT02051127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33973550|NCT02210884|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33973551|NCT04638686|||COHORT||PROSPECTIVE|||||||
33885939|NCT02061735|||CASE_CONTROL||PROSPECTIVE|||||||
33885940|NCT02644226|||COHORT||RETROSPECTIVE|||||||
33885941|NCT03135912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885942|NCT00074958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885943|NCT02652039|||||PROSPECTIVE|||||||
33973552|NCT00952484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973553|NCT03184636|||COHORT||PROSPECTIVE|||||||
33973554|NCT01919268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973555|NCT05396456|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with refractory Fecal Incontinence (FI) will be identified from the Atrium Wake Forest Baptist Health outpatient Gastroenterology, Urogynecology and Colorectal Surgery clinics.||||
33973556|NCT05914519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973557|NCT04615156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973558|NCT05233683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"All patients will receive general anesthesia. Patients will be randomly allocated to one of 4 arms of the study:~* Group 1 will receive are caudal block (CB) and circumcision with Plastibell,~* Group 2 will receive CB and circumcision with conventional dissection method (CDM),~* Group 3 will receive dorsal penile block (DPNB) and ring block (RB) and circumcision with Plastibell, and~* Group 4 will receive DPNB+ RB and circumcision with CDM."|t|f|f|t
33973559|NCT00003520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761422|NCT03737084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Intervention group: The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver.~Control Group: Patients and caregivers in the control group will receive standard hospital care. Patients and caregivers of the control group will receive the same compassion intervention at the end of the study."|t|t|f|f
33885944|NCT02909894|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33885945|NCT04935983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33885946|NCT03163420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885947|NCT02675075|||COHORT||PROSPECTIVE|||||||
33885948|NCT04121845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Punction of the right internal jugular vein and CSR implantation procedure simulation.||t|t|f|f
33885949|NCT03706703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885950|NCT00483886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885951|NCT00159094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973560|NCT01614509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973561|NCT02957279|||COHORT||PROSPECTIVE|||||||
33973562|NCT06337006|||OTHER||PROSPECTIVE|||||||
33973563|NCT05417048|||COHORT||PROSPECTIVE|||||||
33973564|NCT00175578|||COHORT||PROSPECTIVE|||||||
33973565|NCT03482479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33973566|NCT00927810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973567|NCT02450565|||CASE_CONTROL||PROSPECTIVE|||||||
33885952|NCT02836119|||COHORT||PROSPECTIVE|||||||
33885953|NCT04571255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33885954|NCT05398614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885955|NCT03869255|||CASE_CONTROL||PROSPECTIVE|||||||
33885956|NCT00508391|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33885957|NCT06018857|||COHORT||RETROSPECTIVE|||||||
33885958|NCT02000947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885959|NCT02753010|||COHORT||PROSPECTIVE|||||||
33885960|NCT05030727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885961|NCT03247621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33885962|NCT00975247|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33885963|NCT06111989|||CASE_ONLY||PROSPECTIVE|||||||
33885964|NCT00888511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885965|NCT01292278|||COHORT||PROSPECTIVE|||||||
33885966|NCT00382031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973568|NCT03177356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973569|NCT01549288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973570|NCT04133181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973571|NCT01441557|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33973572|NCT05287880|||CASE_CONTROL||PROSPECTIVE|||||||
33973573|NCT05092347|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33973574|NCT02437214|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33973575|NCT05265026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973576|NCT00295126|RANDOMIZED|||TREATMENT||NONE||||||
33885967|NCT06261671|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomization list (indicating Gx Media Vitrolife or GT Coopersurgical) will be used to verify to which group the first half of oocytes will be allocated to. In case an odd number of oocytes is present, one extra oocyte is allocated to the group as indicated by the randomization list.||||
33885968|NCT01837693|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33885969|NCT04901156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885970|NCT04988698|||COHORT||PROSPECTIVE|||||||
33885971|NCT03529747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33885972|NCT05073848|||COHORT||PROSPECTIVE|||||||
33885973|NCT06062446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885974|NCT00590421|||COHORT||RETROSPECTIVE|||||||
33885975|NCT05523700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective multicenter, randomized control trial to assess the efficacy of an AI-based recommendation program to improve healthcare outcomes in women with ovarian, fallopian tube, or primary peritoneal cancer occurring in the outpatient setting.||||
33885976|NCT03749395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The practitioner and the patient are not blinded.The outcomes assessor will not know which group each patient is in.|Two parallel arms. One group will receive erector spinae plane block, and the other will receive nothing.|f|f|f|t
33885977|NCT02266108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33885978|NCT05285137|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33885979|NCT05643079|||CASE_CONTROL||PROSPECTIVE|||||||
33885980|NCT00849667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885981|NCT02229734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885982|NCT03412409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885983|NCT00787787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885984|NCT05136963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33885985|NCT04999189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking will not be possible as participants will know to which group they are assigned. The medical staff will also know this as they will teach them how to use the mobile app.|||||
33885986|NCT02469571|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33885987|NCT00851604|||COHORT||PROSPECTIVE|||||||
33885988|NCT02393391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33885989|NCT05191160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding of the participants and investigators will not be possible due to packaging, taste and look of the interventions. However, outcome assessors (laboratory, microbiome analysis) and the statistician will be blinded to the identity of the treatments.|2-phase, 3-arm, non-inferiority, open-label, parallel group, randomized controlled trial|f|f|t|t
33885990|NCT00205218|||||PROSPECTIVE|||||||
33885991|NCT06388902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33885992|NCT05236998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33885993|NCT06158503|||OTHER||PROSPECTIVE|||||||
33885994|NCT03052452|||COHORT||PROSPECTIVE|||||||
33885995|NCT06307704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33885996|NCT03118440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33885997|NCT06415721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33885998|NCT01075386|||CASE_CONTROL||PROSPECTIVE|||||||
33885999|NCT00763009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886000|NCT03618056|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33886001|NCT02777528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886002|NCT05611957|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33886003|NCT02955745|||OTHER||PROSPECTIVE|||||||
33886004|NCT02793180|||CASE_ONLY||CROSS_SECTIONAL|||||||
33886005|NCT06546982|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||Spectroscopic assessment of serum samples from healthy and typhoid fever patients to identify characteristics for diagnosis and staging.|t|f|f|f
33886006|NCT02070861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886007|NCT06119919|||OTHER||CROSS_SECTIONAL|||||||
33886008|NCT04024501|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886009|NCT00004493||||TREATMENT||||||||
33886010|NCT01506882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886011|NCT01275209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886012|NCT02862314|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33886013|NCT02321293|NA|SINGLE_GROUP||||NONE||||||
33886014|NCT02417727|||COHORT||PROSPECTIVE|||||||
33886015|NCT03219073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and assessing investigator will be blinded to group allocation while the treating investigator, who has to set the tDCS or sham-stimulation protocol on the stimulator, will be the only person aware of the stimulation condition. To minimize communication between blinded and non-blinded participants, the treating investigator will be instructed not to talk to patients and the assessing investigator about the study protocol.|Two age and sex matched groups, each n =8, will be randomized to receive either tDCS or SHAM stimulation.|t|t|f|f
33886016|NCT01672931|||CASE_CONTROL||PROSPECTIVE|||||||
33886017|NCT05866198|NA|SINGLE_GROUP||OTHER||NONE||Prospective, observational, single arm||||
33886018|NCT05679362|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled trial||||
33886019|NCT03327233|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Matched intervention - control group study||||
34072396|NCT01429558|||COHORT||PROSPECTIVE|||||||
33886020|NCT02557061|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072397|NCT05227118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886021|NCT04455711|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33973577|NCT05611268|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The professional responsible for obtainment of laboratory data including outcome measures will not have access to any clinical data or patient allocation to the study groups.||f|f|f|t
34072398|NCT04668209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072399|NCT03903250|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Two groups: placebo and active|t|f|t|f
34072400|NCT03372382|RANDOMIZED|PARALLEL||TREATMENT||NONE||two parallel groups included, randomized to control analgesic regimen versus alternative analgesic regimen and followed prospectively.||||
34072401|NCT00950729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33886022|NCT03285932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072402|NCT02716779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072403|NCT02710019|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072404|NCT04582201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072405|NCT00478712|||FAMILY_BASED||PROSPECTIVE|||||||
34072406|NCT06009679|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms: the intervention groups will include patients with suspected postpartum RPOC that will receive treatment with Misoprostol, and the control group will undergo conservative follow-up with ultrasound. The primary endpoint will be the number of patients with histopathology-proven retained products of conception at 8-16 weeks postpartum in each group. secondary endpoints will be the number of hysteroscopies in each group, side effects of treatment, late postpartum hemorrhage, blood transfusion, endomyometritis / PID and re-admissions to the hospital in each group.||||
34072407|NCT02360488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072408|NCT01205880|RANDOMIZED|||TREATMENT||SINGLE|||f|f|t|f
33886023|NCT01567644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886024|NCT02630160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886025|NCT04909905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33886026|NCT00700804|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33886027|NCT01256177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886028|NCT02419976|NA|SINGLE_GROUP||SCREENING||NONE||||||
33886029|NCT06225284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072409|NCT04637594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072410|NCT00869908|||COHORT||PROSPECTIVE|||||||
34072411|NCT06544746|||CASE_CONTROL||RETROSPECTIVE|||||||
34072412|NCT03581916|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072413|NCT04091737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886030|NCT05323422|||OTHER||PROSPECTIVE|||||||
33886031|NCT02701673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973578|NCT02933593|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973579|NCT00521170|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33973580|NCT00940199|||COHORT||PROSPECTIVE|||||||
33973581|NCT00303745|RANDOMIZED|||TREATMENT||NONE||||||
33973582|NCT00601484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973583|NCT04279184|||COHORT||CROSS_SECTIONAL|||||||
33973584|NCT04834557|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized controlled prospective study||||
34072414|NCT05777837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973585|NCT06543693|||COHORT||PROSPECTIVE|||||||
33973586|NCT03674008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072415|NCT03315455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072416|NCT03560778|||COHORT||RETROSPECTIVE|||||||
34072417|NCT04966650|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The data collector is blinded. Those who analyses the data, using the electronic form, do not know the group belongs to.|Randomized Control Trial|f|f|f|t
34072418|NCT04420169|||OTHER||PROSPECTIVE|||||||
34072419|NCT06103071|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|lottery method for selection|randomization intervention RCT|t|f|f|f
34072420|NCT04441788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072421|NCT04555707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072422|NCT04694976|||OTHER||PROSPECTIVE|||||||
33761423|NCT05885659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers who will develop the pre-treatment evaluation and the intervention program will not participate in the randomization process. The patients will be masked with respect to the study group to which they will belong. On the other hand, psychologists who develop the intervention must necessarily know the type of treatment they are applying (in trials where interventions of a psychological nature are assessed, it is usually not possible to mask the professionals implementing the intervention). However, such psychologists will not participate in the randomization process of the participants or in the analysis of the data, therefore the possible biases of the evaluator regarding such tasks will be deleted. Moreover, the following strategies will be carried out: 1) specialized training on the treatments to be applied, emphasizing the need to maintain masking of the participants; 2) professionals will rotate through all treatment modalities.|Participants will be assigned to one of three groups (Control Group, Experimental Group 1, Experimental Group 2). A member of the research team who will not be directly involved in the trial (i.e., development of the assessments and treatment sessions) will create a simple computer-generated randomization sequence using Research Randomizer software (version 4.0, Urbaniak GC and Plous S, Middletown, CT, USA; http://www.randomizer.org).|t|f|f|t
33761424|NCT00133757|RANDOMIZED|PARALLEL||||DOUBLE||||||
33761425|NCT03364348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761426|NCT04032535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SAD and MAD in healthy volunteers plus 2way crossover in COPD patients|t|t|t|t
33761427|NCT05966402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33761428|NCT02723058|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761429|NCT03119727|NA|SINGLE_GROUP||OTHER||NONE||||||
33761430|NCT05865613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761431|NCT00836602|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33886032|NCT04127201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886033|NCT06550167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The randomized drawing was carried out through the Randomization.com program, which is an online platform that provides randomization services for clinical studies.~In addition, the treatments received were previously labeled and randomized by the sponsor."||t|t|t|f
33886034|NCT05464745|RANDOMIZED|CROSSOVER||OTHER||NONE||Two-period, two-sequence, cross-over single dose study||||
33886035|NCT01959165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886036|NCT03643172|||COHORT||PROSPECTIVE|||||||
33886037|NCT02257580|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33886038|NCT02723201|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886039|NCT04719351|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The factorial experimental trial will randomize participants to one of 32 experimental conditions which consist of any combination of the five components: 1) questions about positive emotions (yes/no), 2) questions about work environment (yes/no), 3) questions about controllability (yes/no), 4) questions with open answers (yes/no), and 5) behavioral prompts (yes/no). The purpose of this factorial experiment is to estimate the main effects of the five intervention components and interactions between the components.||||
33886040|NCT04750460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886041|NCT00689533|||COHORT||PROSPECTIVE|||||||
33886042|NCT03372239|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33973587|NCT06380465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research was conducted using a single-blind approach, where the participants were unaware of the intervention being implemented|The participant who meet the inclusion criteria and have signed the consent will be subjected to a baseline assessment followed by randomization into 2 groups/arms consisting of 2 treatments (1 group getting the water extract pf purple sweet potato) and 1 control group that got placebo.|t|f|f|t
33973588|NCT02896465|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33973589|NCT05751629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072423|NCT06552403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761432|NCT01888211|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33761433|NCT00838799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761434|NCT00642902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761435|NCT01807650|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33761436|NCT06071065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients were not informed of which groups they belonged to and what type of intervention is provided.||t|f|f|f
33761437|NCT04473690|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761438|NCT00571766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761439|NCT03170167|||OTHER||PROSPECTIVE|||||||
33761440|NCT01253863|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33761441|NCT04362163|||CASE_CROSSOVER||PROSPECTIVE|||||||
33761442|NCT02452086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761443|NCT01331460|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33761444|NCT01856712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761445|NCT00677443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761446|NCT04361344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, descriptive, monocentric, non-controlled study||||
33761447|NCT04069130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761448|NCT03156933|||OTHER||RETROSPECTIVE|||||||
33761449|NCT00385411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072424|NCT02946892|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33761450|NCT01840553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886043|NCT02235506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33761451|NCT00097643|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33886044|NCT03209284|||COHORT||PROSPECTIVE|||||||
33886045|NCT05442710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized, controlled parallel-group study||||
33886046|NCT01423045|||COHORT||PROSPECTIVE|||||||
33886047|NCT02551120|||COHORT||PROSPECTIVE|||||||
33886048|NCT00373984|||||PROSPECTIVE|||||||
33761452|NCT01086202|||CASE_ONLY||PROSPECTIVE|||||||
33761453|NCT02691182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761454|NCT00070135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761455|NCT00237939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761456|NCT03988296|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761457|NCT05343338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761458|NCT02426723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761459|NCT02826967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761460|NCT05116423|||COHORT||PROSPECTIVE|||||||
33761461|NCT06337383|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761462|NCT00916461|RANDOMIZED|||TREATMENT||DOUBLE||||||
33886049|NCT06500754|||COHORT||CROSS_SECTIONAL|||||||
33886050|NCT02130713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886051|NCT05758883|||COHORT||PROSPECTIVE|||||||
33973590|NCT01977430|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973591|NCT00850902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761463|NCT04894734|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33761464|NCT02621346|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33761465|NCT05096208|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a double-blinded, placebo controlled study||t|f|t|f
33761466|NCT00546962|||||PROSPECTIVE|||||||
33761467|NCT05064826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761468|NCT01184599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761469|NCT01253525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761470|NCT01209637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761471|NCT01440686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886052|NCT01291602|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33886053|NCT05074108|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33886054|NCT05384041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Remote, randomized, decentralized, controlled, triple-blind (subject, Principal Investigator, Sponsor) pivotal investigation.|Pivotal Study|t|f|t|t
33886055|NCT05222074|||COHORT||RETROSPECTIVE|||||||
33886056|NCT06487546|NA|SINGLE_GROUP||OTHER||NONE||||||
33886057|NCT01811511|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33886058|NCT04878133|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients with STEMI who underwent successful culprit-lesion PCI will be enrolled after the index PCI. Eligible patients will be required to have residual multivessel disease, defined as at least one stenosis \>~50 %. Patients will be randomized in a 1:1 fashion to OCT guided PCI of non-culprit lesions (Group A) vs complete PCI. (Group B)"||||
33886059|NCT03012373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886060|NCT00721487|||CASE_ONLY||RETROSPECTIVE|||||||
33886061|NCT01953744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886062|NCT01671280|||CASE_ONLY||PROSPECTIVE|||||||
33886063|NCT05222633|||COHORT||PROSPECTIVE|||||||
33886064|NCT01848145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886065|NCT04485585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886066|NCT04735276|||COHORT||PROSPECTIVE|||||||
33886067|NCT03492684|||CASE_ONLY||PROSPECTIVE|||||||
33886068|NCT03635931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The test and control group was formed of patients with adjacent papillary defects In test group, elective minimally invasive surgery for papillary regeneration with CGF was performed. A control group was formed of patients with adjacent papillary defects who were not included to have surgical treatment.|f|f|f|t
33886069|NCT05215366|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886070|NCT06549088|||COHORT||PROSPECTIVE|||||||
34072425|NCT05951361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patients were randomly assigned to avoid bios.||t|f|t|f
34072426|NCT01951573|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34072427|NCT03864523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072428|NCT01369745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072429|NCT02253888|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072430|NCT01297543|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33886071|NCT00463476|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34072431|NCT00530608|||COHORT||PROSPECTIVE|||||||
34072432|NCT05024656|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, multicenter, randomized, parallel-group Trial comparing the outcomes associated with the use of AmnioExcel® Plus Placental Allograft Membrane (AmnioExcel® Plus) used in conjunction with Standard of Care (SOC) compared to SOC alone in the management of diabetic foot ulcers (DFUs).||||
34072433|NCT02422004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072434|NCT01156909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072435|NCT05348044|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The proposed feasibility study is a rolling enrollment mixed-methods, one-group quasi-experimental design.||||
34072436|NCT01344759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072437|NCT06111898|||COHORT||PROSPECTIVE|||||||
34072438|NCT04121676|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
34072439|NCT01779063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072440|NCT05456243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072441|NCT02595385|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34072442|NCT05656326|||COHORT||PROSPECTIVE|||||||
34072443|NCT01280071||||BASIC_SCIENCE||||||||
34072444|NCT00704977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072445|NCT01377636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072446|NCT00838617|||CASE_ONLY||PROSPECTIVE|||||||
34072447|NCT06173518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072448|NCT00844662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072449|NCT03072420|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34072450|NCT06118463|||COHORT||PROSPECTIVE|||||||
34072451|NCT06277570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The sample of the study will consist of participants who applied to Etlik City Physical Therapy and Rehabilitation Hospital, were diagnosed with knee osteoarthritis by the physician, and will receive routine treatment in the electrotherapy unit. Patients will be randomly assigned to groups.|t|f|f|t
34072452|NCT00271219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072453|NCT02785562|NA|SINGLE_GROUP||OTHER||NONE||||||
34072454|NCT02290847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072455|NCT05490914|||COHORT||PROSPECTIVE|||||||
34072456|NCT06494592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072457|NCT05947162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072458|NCT05165641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072459|NCT01643317|||COHORT||PROSPECTIVE|||||||
34072460|NCT04350645|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34072461|NCT03481231|||COHORT||PROSPECTIVE|||||||
34072462|NCT00540670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072463|NCT01014195|||CASE_ONLY||PROSPECTIVE|||||||
34072464|NCT03806517|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34072465|NCT00144950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072466|NCT04418271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with frailty syndrome (≥1 of the standardized parameters (Pre-Frail = 1-2; Frail≥3) according to Fried et al.(2001) are offered randomised participation in the new form of care.||||
33886072|NCT00378326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886073|NCT05086042|||CASE_CONTROL||PROSPECTIVE|||||||
33886074|NCT00215007|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34072467|NCT01048840|||CASE_CONTROL||RETROSPECTIVE|||||||
34072468|NCT00928850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072469|NCT01528280|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072470|NCT04225013|||CASE_CONTROL||RETROSPECTIVE|||||||
33886075|NCT01132105|||||PROSPECTIVE|||||||
33886076|NCT03567148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886077|NCT01424735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886078|NCT06098638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participant, outcomes Assessor)|parallel assignment|t|f|f|t
33886079|NCT01554501|||CASE_CONTROL||PROSPECTIVE|||||||
34072471|NCT01054495|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34072472|NCT00873067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072473|NCT01784276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072474|NCT06612333|||OTHER||CROSS_SECTIONAL|||||||
34072475|NCT01627743|||COHORT||PROSPECTIVE|||||||
34072476|NCT03397303|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34072477|NCT00758381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072478|NCT04121455|RANDOMIZED|PARALLEL||TREATMENT||NONE||3+3 dose escalation (sequential) followed by a multiple-arm expansion group (parallel)||||
34072479|NCT01996150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072480|NCT02026596|||COHORT||PROSPECTIVE|||||||
34072481|NCT01141920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072482|NCT05051891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072483|NCT03629145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072484|NCT02112409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072485|NCT00203697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072486|NCT00650338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072487|NCT00328588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072488|NCT05030532|RANDOMIZED|FACTORIAL||PREVENTION||NONE||After signing up for a specific time slot, participants were randomized in blocks of 20 to the EVERYbody Project or video comparison condition (two blocks of 10 participant slots were available in each time slot)||||
34072489|NCT03944603|||COHORT||PROSPECTIVE|||||||
34072490|NCT04387461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072491|NCT00060606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072492|NCT01537835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072493|NCT05088096|||OTHER||CROSS_SECTIONAL|||||||
34072494|NCT04428840|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients are randomised in blocks per day regarding use of the kiosk||||
34072495|NCT03701802|||COHORT||PROSPECTIVE|||||||
34072496|NCT06071546|NA|SINGLE_GROUP||OTHER||NONE||||||
34072497|NCT00219219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072498|NCT05984433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient will be under sedation during procedure, so will not be aware of whether or not they received acupuncture treatment.~Anesthesia team in the operating room will be aware of treatment. PACU team and outcomes assessor will not be aware of group assignment"|Randomized controlled trial. Group 1 - acupuncture Group 2 - no acupuncture 70 patients per group|t|f|f|t
34072499|NCT05263518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072500|NCT06262646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eligible parents consenting to participate will be randomly assigned to either the FACT or Control Group in a 1:1 ratio, using the permuted block size of 6 through sequentially numbered, opaque and sealed envelopes with number cards (1=intervention, 2=control). A separate set of random numbers, concealed from the research team and RAs, will be generated by a statistician. Clerical staff uninvolved in the project will administer the randomisation. The research assistant (RA-1), blinded to subject selection, will open the envelopes only after informed consent and baseline assessments are completed. The research assistant (RA-2) is also blinded to group assignments and will conduct assessments/evaluations.|Two-arm Randomised Controlled Trial (RCT) with a repeated-measures parallel-group design|f|t|t|t
34072501|NCT01044160|||CASE_CONTROL||PROSPECTIVE|||||||
34072502|NCT02271217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886080|NCT06112041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886081|NCT01470235|||CASE_CONTROL||RETROSPECTIVE|||||||
33886082|NCT00486447|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886083|NCT00004183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886084|NCT02129673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33761472|NCT06127576|||CASE_ONLY||RETROSPECTIVE|||||||
33761473|NCT03746054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761474|NCT06521164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761475|NCT01936896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761476|NCT02030730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761477|NCT04305288|||COHORT||RETROSPECTIVE|||||||
33761478|NCT01041014|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33886085|NCT01777763|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33886086|NCT01647230|||COHORT||PROSPECTIVE|||||||
33886087|NCT00843908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886088|NCT03436784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants who were recruited at the same time and location were assigned to the same treatment group to prevent knowledge of different treatment groups in the study.|Parallel-arm intervention with inactive control group and intervention group|t|f|f|f
33886089|NCT00594217|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, placebo-controlled, crossover study|t|t|t|f
33886090|NCT01748604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33886091|NCT05220839|||CASE_ONLY||PROSPECTIVE|||||||
33886092|NCT00060255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886093|NCT00249574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973592|NCT03820193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33973593|NCT05770258|NA|SINGLE_GROUP||TREATMENT||NONE|An open label, single arm and before and after treatment comparison study|||||
33973594|NCT01876186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973595|NCT05277727|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Both subjects and study research team will not be aware of their assigned conditions.|This is a prospective, double-blinded, placebo-controlled, cross-over design study. Participants will be randomized to one of the two SP sequences \[either FMAS (2 weeks) → washout (1 week) → IPC (2 weeks): sequence A, or IPC (2 weeks) → washout (1 week) → FMAS (2 weeks): sequence B\]. Each participant will act as their own control due to the cross-over design of the study.|t|f|t|t
33973596|NCT00599183|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973597|NCT03822052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761479|NCT03954743|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data were collected in an observer-blind manner. By observer-blind, it is meant that during the study period, the vaccine(s) recipient and those responsible for the evaluation of any study endpoint (e.g. safety and reactogenicity) were all unaware of which vaccine was administered.||t|t|t|t
33761480|NCT05908214|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stroke patients in the training group will be compared to stroke patients in the control group.~Participants prone to cramps will be compared to healthy participants. Patients with restless legs syndrome will be compared to healthy participants."||||
33761481|NCT04444648|||COHORT||RETROSPECTIVE|||||||
33761482|NCT00691808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761483|NCT04043962|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive internet-delivered CBT for pain self-management (Web-MAP).||||
33973598|NCT05882474|||CASE_CONTROL||PROSPECTIVE|||||||
33973599|NCT01016652|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33761484|NCT05306093|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761485|NCT05312580|||COHORT||RETROSPECTIVE|||||||
33761486|NCT03437395|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be offered either balloon brachytherapy or 3D conformal radiation therapy to treat the tumor bed alone. Data will be collected so that our results can be compared to the results of the randomized trial. Specifically, we will be comparing our local control rates and cosmetic results to those of favorable risk patients from the NSABP B-39 trial.||||
33761487|NCT02084537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761488|NCT04580563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761489|NCT04603976|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761490|NCT00604838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761491|NCT03921190|RANDOMIZED|PARALLEL||OTHER||NONE||Providing dental local anesthesia (maxillary buccal infiltration) using two techniques; open-mouth and closed-mouth||||
33761492|NCT04210414|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33761493|NCT00027924||||TREATMENT||||||||
33761494|NCT00514943|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886094|NCT03502850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886095|NCT02365623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886096|NCT03372941|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be single center, randomized, non-blinded study comparing two active treatment arms to treat uncomplicated ABSSSI suspected to be due to Gram-positive bacteria:~* Alternative treatment strategy comprised of a single dose of dalbavancin administered in the BJH ED or ED observation unit followed by discharge w/ close Infectious Disease outpatient clinic follow-up vs.~* Usual care (i.e., hospital admission for intravenous antibiotics - typically, vancomycin) - antibiotic and doses to be determined at the discretion of the treating clinician (both in the BJH ED and on the BJH inpatient ward)"||||
33886097|NCT05862792|||COHORT||PROSPECTIVE|||||||
33886098|NCT03498820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34072503|NCT03094793|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886099|NCT00419471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886100|NCT04909684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886101|NCT05994937|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34072504|NCT03875196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The sample of the research is comprised of patients diagnosed with stress urinary incontinence and volunteered for participating in the study with the following specifications: with pelvic floor power 2 and over, sexually active and no restrictions for the magnetic chair treatment. Patients with the following conditions were excluded: prosthesis, other implanted metallic devices, cardiac pacemaker, arrhythmia, pelvic malignancies, under radiotherapy, pelvic floor defect, previous surgery for urinary incontinence, neurological diseases and pregnancy.||t|f|f|f
34072505|NCT06346782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pilot feasibility trial. We are using a 2:1 (intervention: waitlist control) randomized controlled design.||||
34072506|NCT03448523|RANDOMIZED|PARALLEL||PREVENTION||NONE||open label, randomised, efficacy study||||
34072507|NCT04581408|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, before vs after treatment||||
33761495|NCT03725839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761496|NCT04709601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761497|NCT02643576|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33761498|NCT02767583|NA|SINGLE_GROUP||SCREENING||NONE||||||
33761499|NCT02401464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761500|NCT06624696|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761501|NCT06248138|||CASE_CONTROL||RETROSPECTIVE|||||||
33761502|NCT04396002|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761503|NCT00294099|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33761504|NCT04235790|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33761505|NCT00187915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761506|NCT04876794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761507|NCT00582621|||FAMILY_BASED||PROSPECTIVE|||||||
33761508|NCT02243644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761509|NCT04073810|||COHORT||PROSPECTIVE|||||||
33761510|NCT00106132||||TREATMENT||||||||
33761511|NCT01438125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761512|NCT01322789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761513|NCT05600049|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33761514|NCT05254639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761515|NCT00861601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886102|NCT01011348|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33886103|NCT04069663|||COHORT||RETROSPECTIVE|||||||
33886104|NCT00427856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886105|NCT02899156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886106|NCT01018355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886107|NCT05606237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This trial is a single-center, multi-ethnic, single-blind, parallel-group randomized controlled trial designed to evaluate the efficacy and safety of low level red light treatment on myopia among multi-ethnic schoolchildren.|f|t|f|f
33886108|NCT04761796|||COHORT||PROSPECTIVE|||||||
33886109|NCT05891665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886110|NCT03038347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33886111|NCT02911688|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33761516|NCT01839422|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761517|NCT03057743|||COHORT||PROSPECTIVE|||||||
33761518|NCT04197648|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Just before the intervention and baseline evaluation, each subject will be randomized either in the exercise or the control group.~Experimental group (exercise): 24 week supervised exercise program. Control group: Daily life activities"|f|t|t|t
33761519|NCT02716337|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761520|NCT05259787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886112|NCT03244657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886113|NCT03779438|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A Double-Blind Randomized Clinical Trial|A Double-Blind Randomized Clinical Trial|t|t|t|t
33886114|NCT04869241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886115|NCT00150098|RANDOMIZED|PARALLEL||||NONE||||||
33886116|NCT03012074|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33886117|NCT04940234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33886118|NCT02681666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886119|NCT01390792|||OTHER||PROSPECTIVE|||||||
33886120|NCT00559273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973600|NCT06504472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)||t|f|t|t
33973601|NCT05149742|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973602|NCT03184454|NA|SINGLE_GROUP||TREATMENT||NONE||Cortical and subcortical electrodes||||
34072508|NCT02590991|||CASE_CONTROL||PROSPECTIVE|||||||
33761521|NCT00291759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761522|NCT05976425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761523|NCT02041689|||CASE_ONLY||PROSPECTIVE|||||||
33761524|NCT05965063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761525|NCT05655026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33761526|NCT03266614|RANDOMIZED|PARALLEL||OTHER||NONE||||||
9970463|NCT05845606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33761527|NCT05114330|||COHORT||PROSPECTIVE|||||||
33761528|NCT06255015|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A regression discontinuity design.||||
33886121|NCT05619458|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33886122|NCT04774939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886123|NCT05749757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886124|NCT01777672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886125|NCT05402826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33886126|NCT02439684|||COHORT||CROSS_SECTIONAL|||||||
33886127|NCT05679206|||COHORT||PROSPECTIVE|||||||
33973603|NCT01879839|RANDOMIZED|PARALLEL||PREVENTION||NONE||One arm with controlled diet, second arm as control group with no diet.||||
33973604|NCT04845074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33973605|NCT03204591|||COHORT||PROSPECTIVE|||||||
33973606|NCT02660411|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33973607|NCT01305083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973608|NCT02307136|||COHORT||RETROSPECTIVE|||||||
33973609|NCT00210626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973610|NCT04732299|||COHORT||PROSPECTIVE|||||||
33973611|NCT03872284|||COHORT||PROSPECTIVE|||||||
33973612|NCT02710461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973613|NCT01102205|||COHORT||PROSPECTIVE|||||||
33973614|NCT00886483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973615|NCT00778557|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33973616|NCT04839588|||OTHER||OTHER|||||||
33973617|NCT02336997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973618|NCT02577354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072509|NCT05812053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761529|NCT00768430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761530|NCT04243070|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33761531|NCT01609816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761532|NCT01533363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886128|NCT05050760|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Patients fulfilling Eligibility Criteria will be included in our study.After three cycles of resectable esophageal cancer treated with DCF combined with camrelizumab neoadjuvant therapy, the researchers determined whether the patient should undergo surgical treatment according to clinical diagnosis and patient willingness.If the patient underwent surgery, surgery was performed 6-8 weeks after discontinuation;If the patient did not receive surgical treatment, the patient was continued to receive 3 cycles of adjuvant therapy with camrelizumab combined with DCF regimen||||
33886129|NCT01772667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33886130|NCT01698957|||CASE_ONLY||PROSPECTIVE|||||||
33886131|NCT05546892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886132|NCT00983567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33886133|NCT04007315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A pragmatic, multicentre, parallel-group, randomised controlled trial|f|f|f|t
33761533|NCT01720732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761534|NCT01909414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33761535|NCT05927025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking was applied only to the patients and their parents included in the study.||t|f|f|f
33761536|NCT02768454|||CASE_ONLY||RETROSPECTIVE|||||||
33761537|NCT05297890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761538|NCT03249506|||COHORT||RETROSPECTIVE|||||||
33761539|NCT03021577|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761540|NCT02372721|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886134|NCT01449708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33886135|NCT03752645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33886136|NCT05480319|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33886137|NCT05730387|||COHORT||PROSPECTIVE|||||||
33761541|NCT05917301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886138|NCT02561936|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761542|NCT01396317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761543|NCT02092558|||CASE_CONTROL||RETROSPECTIVE|||||||
33761544|NCT04567511|NA|SINGLE_GROUP||TREATMENT||NONE||single arm prospective open-label single-center study||||
33761545|NCT04576364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886139|NCT04391725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886140|NCT02856984|||COHORT||PROSPECTIVE|||||||
33886141|NCT02337673|||OTHER||PROSPECTIVE|||||||
33886142|NCT02117687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886143|NCT02688348|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33886144|NCT03226626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Persons making decision to categorize the outcome as either Infection Occurred or No Infection Occurred will be masked with respect to whether or not the subject received Standard pre-operative IV antibiotics alone or received both IV antibiotics and tumescent anesthesia \& antibiotic delivery (TAAD)."|Prospective Meta-Analysis Multicenter Randomized Clinical Trial|f|f|f|t
33886145|NCT02667145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886146|NCT00524056|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33886147|NCT00283556|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886148|NCT03653390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33886149|NCT04025645|||CASE_CONTROL||PROSPECTIVE|||||||
33886150|NCT02538302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886151|NCT01466244|||OTHER||RETROSPECTIVE|||||||
33886152|NCT06068972|||COHORT||RETROSPECTIVE|||||||
33886153|NCT00004899||||TREATMENT||||||||
33886154|NCT03417271|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Neither participants nor outcomes assessors will be aware whether the patient is receiving stimulation at 30us or 60us pulse widths.||t|f|f|t
33973619|NCT04941222|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33973620|NCT00006129|RANDOMIZED|||TREATMENT||||||||
33973621|NCT03393858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973622|NCT03322462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973623|NCT04093661|||COHORT||RETROSPECTIVE|||||||
33973624|NCT02811809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973625|NCT06103409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761546|NCT01665339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33761547|NCT05458375|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study design will be a randomized controlled trial involving patients seen in the Urogynecology clinic with pelvic organ prolapse or incontinence who were recently fit with a pessary.||||
33761548|NCT06374940|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33761549|NCT02871960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761550|NCT03265054|||COHORT||RETROSPECTIVE|||||||
33761551|NCT01704469|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761552|NCT00782496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761553|NCT01864928|||COHORT||PROSPECTIVE|||||||
33886155|NCT00236080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886156|NCT04138160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33886157|NCT01773421|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886158|NCT03045003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33886159|NCT02939157|||CASE_ONLY||CROSS_SECTIONAL|||||||
33886160|NCT03817203|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33886161|NCT06549751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33886162|NCT05351307|||CASE_CONTROL||PROSPECTIVE|||||||
33886163|NCT00230347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886164|NCT01211808|RANDOMIZED|CROSSOVER||||NONE||||||
33886165|NCT02617238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973626|NCT03542136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973627|NCT02979379|||CASE_CONTROL||PROSPECTIVE|||||||
33973628|NCT00914433|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33973629|NCT05503303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072510|NCT05820243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Antihistamine and placebo treatments will be provided in opaque gel capsules by a member of the research team not involved in data collection or analysis.||t|f|t|f
33886166|NCT04082208|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Unicentre controlled clinical trial, unmasked, performed in the Digestive Endoscopy Unit of the Hospital Clínic. 172 patients submitted to Endoscopic Retrograde Cholangiography who agree to participate in the study will be included consecutively and randomly.~Patients will be randomized into two groups: Control group: low flow device (nasal glasses) and High Flow device group (LAF)."||||
33886167|NCT02971202|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33886168|NCT05055232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886169|NCT00334503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886170|NCT00002800||||TREATMENT||||||||
33886171|NCT04703569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886172|NCT02077933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886173|NCT00638937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886174|NCT03162640|||COHORT||PROSPECTIVE|||||||
33886175|NCT04462900|||OTHER||PROSPECTIVE|||||||
33886176|NCT05007353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33886177|NCT00505947|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33886178|NCT05182047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33886179|NCT01799876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886180|NCT05835414|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a staged, open-label, Phase II/III safety, feasibility, and efficacy investigational device trial. A staged approach will be utilized to assess safety, feasibility, and preliminary efficacy with 30 participants with an interim analysis after data collection at 6 weeks. If safety benchmarks are passed, the study will proceed with Stage 2, in which an additional 270 participants will be enrolled using randomization to multiple baselines for efficacy analyses.||||
33886181|NCT01084551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886182|NCT00183690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886183|NCT02336477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33761554|NCT03417947|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The Applied Clinical Research Unit of Sainte-Justine UHC will generate the randomisation scheme. Group allocation codes will be held in a secure location with a restricted access by the Central pharmacy (Sainte-Justine UHC). All participants and research personnel, including the nurse, research trainee and research team will be blinded to group assignment.~The supplier Euro-Pharm will provide the placebo and vitamin D3 preparations in coded bottles. Pharmacy will prepare the 6-mL bolus in coded syringes following the randomisation scheme."|This is a randomised, quadruble-blind, placebo-controlled, parallel-group trial of vitamin D3 bolus supplementation.|t|t|t|t
33761555|NCT03552133|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One control study night vs. two intervention study nights (subject serves as own control).||||
33973630|NCT05271539|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first group received 3 monthly intravitreal injections of 0.5 mg in 0.05 mL ranibizumab alone (Lucentis, by Novartis), aspirated from vial through 5-micron sterile filter needle (19-gauge × 1-1/2 inch), with a 1-mL syringe and injected through a 30-gauge × ½ inch sterile injection needle. While the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN).||||
34072511|NCT04716621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072512|NCT04241510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Evaluation of patients after taping application will be done by another physiotherapist who does not know the taping techniques and also cannot see the taped area by clothes of patients.|Prospective, Double-Blinded, Randomized Crossover Study|t|f|f|t
34072513|NCT02549664|||COHORT||PROSPECTIVE|||||||
34072514|NCT06263283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Control Group: Standard care according to the modalities of each center (concomitant treatment prescription, psychological support, physiotherapy or dietetic are supports that can be proposed if needed) Experimental Group: Standard support with Daily realization of a session of Kine-Yoga supervised by a physiotherapist at J2, J3 and J4 of uterovaginal brachytherapy.||||
34072515|NCT01768559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072516|NCT01590901|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34072517|NCT03207490|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention is provided by a robotic device for hand motion, controlled by closed loop surface electromyography (sEMG)||||
34072518|NCT04308876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072519|NCT05208827|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized controlled study design|t|t|t|f
34072520|NCT00343577|||||PROSPECTIVE|||||||
34072521|NCT03470454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072522|NCT04934163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072523|NCT03809234|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34072524|NCT02780271|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34072525|NCT02029274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072526|NCT03915626|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The same healthy subjects are assigned to all four treatments.||||
34072527|NCT00494546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761556|NCT06260735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072528|NCT02103699|||COHORT||PROSPECTIVE|||||||
34072529|NCT03563898|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.||||
34072530|NCT00210886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072531|NCT03758599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial with three arms for the comparison of the efficacy of a climbing exercise program, an aerobic exercise program and a social contact control group on symptoms of AD/PTSD, worry symptoms, quality of life, physical activity, health-related resources and affective responses in patients with AD or PTSD.|t|f|f|f
34072532|NCT06483906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761557|NCT02936050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761558|NCT00962143|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33761559|NCT06259643|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761560|NCT03634748|||CASE_CONTROL||RETROSPECTIVE|||||||
33761561|NCT03517423|||CASE_ONLY||PROSPECTIVE|||||||
33761562|NCT02056860|||CASE_ONLY||PROSPECTIVE|||||||
33761563|NCT04182763|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|Masking was used for the initial double-blind phase.|An initial 6-month, dose-ranging, parallel-group, randomized, double-blind, placebo-controlled phase is followed by an 18-month, single-dose, open-label phase--these arms met enrollment goals. A direct-to-open-label arm of the study was opened to allow for additional enrollment.|t|t|t|t
33761564|NCT02827591|||COHORT||PROSPECTIVE|||||||
33761565|NCT05916976|NA|SEQUENTIAL||DIAGNOSTIC||NONE|MRI data are made available for clinical decision. Score will not be made available to treatment decision team. Nor is the study team involved in the clinical decision process until completion of follow-up data acquisition|all patients scheduled for MRI for follow-up of repaired Tetralogy of Fallot.||||
33761566|NCT01191203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761567|NCT02676596|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33761568|NCT02947438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761569|NCT01194284|||CASE_ONLY||PROSPECTIVE|||||||
33761570|NCT02104492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33761571|NCT01217424|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33761572|NCT04138836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761573|NCT01563848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761574|NCT00889057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761575|NCT02470858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761576|NCT01546467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761577|NCT02444221|||COHORT||PROSPECTIVE|||||||
33886184|NCT06543433|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention will be given to all participants and the investigators will test how many hours of SSC per day the parents can achieve.||||
33886185|NCT05537545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As this RCT concerns a surgical intervention, patients and treating clinicians can not be masked.|Randomized controlled trial|f|f|t|t
33886186|NCT01111266|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761578|NCT03988582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886187|NCT01904981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072533|NCT06028854|||COHORT||PROSPECTIVE|||||||
34072534|NCT03999957|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33886188|NCT05360667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Because of the design of the study and the nature of the interventions, blinding the staff and participants of the LTCFs is impossible. The assessors, measuring the outcomes, and the interpreter, analyzing the data, will be blinded in this study.|"@Intervention group: The program consists of PRT and functional movement of the four extremities but mainly the upper limbs. We used RFA to deliver the program. The exergame-based exercise were performed two times per week, at least 48 h apart from each training session, 50 min per session (10 min each for a warm-up and cool-down and 30 min for the main program), for 12 weeks, and will be supervised by a therapist.~@Control group: Participants in the control group received standard care that applied as usual in the LTCFs, in the way of group activities, including calisthenics (that could be performed in the sitting position), horticultural therapy, and group static activities (e.g., tabletop games). The programs were performed two times per week for approximately 30-60 min, depending on the activity, and will be led by a therapist."|f|f|f|t
33886189|NCT02244151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886190|NCT01438697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886191|NCT04861337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886192|NCT00389584||||TREATMENT||||||||
34072535|NCT00549796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072536|NCT02583022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072537|NCT06613165|||CASE_CONTROL||PROSPECTIVE|||||||
34072538|NCT03351088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072539|NCT01984957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072540|NCT05934123|||COHORT||OTHER|||||||
34072541|NCT00278031|||COHORT||RETROSPECTIVE|||||||
34072542|NCT04007510|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072543|NCT03476902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072544|NCT01601496|NA|SINGLE_GROUP||TREATMENT||NONE||Patients treated with the FUSION Vascular Graft||||
34072545|NCT03388398|||OTHER||CROSS_SECTIONAL|||||||
34072546|NCT00092963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072547|NCT05450172|||COHORT||PROSPECTIVE|||||||
34072548|NCT02837393|||COHORT||PROSPECTIVE|||||||
34072549|NCT03826537|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34072550|NCT00921583|||COHORT||RETROSPECTIVE|||||||
34072551|NCT00638092|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072552|NCT02482883|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072553|NCT02865694|||COHORT||PROSPECTIVE|||||||
34072554|NCT04697290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072555|NCT04322084|||COHORT||PROSPECTIVE|||||||
34072556|NCT04262193|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Suvorexant (20mg) and placebo research tablets will appear identical.|Participants will be randomly assigned to one of the 2 parallel groups for the duration of the study.|t|t|t|t
34072557|NCT06612905|||OTHER||PROSPECTIVE|||||||
34072558|NCT03665662|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34072559|NCT03090061|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The assessors will not be blind about the type of intervention/control assessment methods. However it will not be allowed amongst the examiners to exchange any information throughout the entire study period||f|f|f|t
34072560|NCT05534568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072561|NCT06612450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|only one surgeon did the surgeries, other two assessors didnt know which intervention was done, the patient didn\&#39;t know which group did they belong to||t|f|t|t
34072562|NCT03042351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072563|NCT01449734|||COHORT||PROSPECTIVE|||||||
34072564|NCT02423811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072565|NCT06477705|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34072566|NCT01865656|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33886193|NCT03780504|||COHORT||PROSPECTIVE|||||||
33886194|NCT02495948|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33886195|NCT05773677|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Case group: prospective Control group: retrospective||||
33886196|NCT02575209|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886197|NCT00618748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072567|NCT02714036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants were assigned to one of 2 groups at the discretion of the Principal Investigator.|||||
33886198|NCT06332508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886199|NCT05589792|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33886200|NCT00361738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886201|NCT02347904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886202|NCT04285775|||COHORT||PROSPECTIVE|||||||
33886203|NCT02762487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886204|NCT01295060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886205|NCT04865965|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886206|NCT02485080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886207|NCT05303129|NA|SINGLE_GROUP||OTHER||NONE||||||
33886208|NCT01817790|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33886209|NCT05779709|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Children between ages 5-18, who were diagnosed with bladder and bowel dysfunction without any neurological abnormalities were invited. Children with neuropathic or anatomical abnormalities in the urinary tract or gastrointestinal tract, inflammatory bowel disease or any other disorder affecting bladder or bowel function and who requested withdrawal from the study at any stage were excluded.~The children who met the inclusion criteria were invited for pre-intervention meeting and assessments. The aim of study and reformer pilates exercise intervention explained parents and children during the meeting. The children and their parents who want to join exercise sessions during the study were assigned in the reformer pilates group and who did not accept to perform reformer pilates exercises were assigned in the urotherapy group"|f|f|f|t
33886210|NCT01089660|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072568|NCT01904968|||COHORT||RETROSPECTIVE|||||||
33886211|NCT00242294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886212|NCT02043925|||COHORT||PROSPECTIVE|||||||
33886213|NCT06068114|||CASE_CONTROL||PROSPECTIVE|||||||
33886214|NCT03955094|NA|SINGLE_GROUP||OTHER||NONE||Prospective observational study All eligible patients will be approached and recruited All patients will be assigned to a single group - the use of AMBU® AURAGAIN™ as a conduit for flexible scope intubation No comparison groups||||
33886215|NCT03787589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886216|NCT04990921|NA|SINGLE_GROUP||TREATMENT||NONE||The primary objective is to evaluate the efficacy of SBRT in combination with pembrolizumab as assessed by Overall Response Rate in subjects with stage IV breast cancer.||||
33886217|NCT03450928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886218|NCT00094757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072569|NCT03625700|||COHORT||RETROSPECTIVE|||||||
34072570|NCT00411723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072571|NCT02937740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072572|NCT04215796|NA|SINGLE_GROUP||TREATMENT||NONE||Open study for subjects receiving home-based medication: CFTR modulators (Kalydeco, Orkambi, Simdeko) treatment. Subjects receive these medication by ReX-C device. Medication adherence, treatment instructions and side effects are recorded and monitored online in real time during the Study, by the ReX-C system.||||
34072573|NCT05116254|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||I: AZD1390 and RT II: AZD1390, durvalumab and RT||||
34072574|NCT02155309|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34072575|NCT06612788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072576|NCT02406456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072577|NCT05936021|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||All patients placed on dialysis receive standard of care for a minimum of 150 days; after qualifying for the study, they enter the experimental intervention arm.||||
34072578|NCT04626258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072579|NCT05996822|||COHORT||RETROSPECTIVE|||||||
34072580|NCT02216279|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886219|NCT04025593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886220|NCT01894126|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072581|NCT03921476|||CASE_ONLY||PROSPECTIVE|||||||
34072582|NCT04036591|||OTHER||CROSS_SECTIONAL|||||||
34072583|NCT05156996|||COHORT||PROSPECTIVE|||||||
33886221|NCT01526525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886222|NCT01189383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886223|NCT03342755|||CASE_CONTROL||OTHER|||||||
33886224|NCT04208425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants in the study will be masked by using Qualtrics built in randomization function.|This study will be a two-arm randomized controlled trial, including one active intervention conditions and one active control condition. Adolescents (and one caregiver per adolescent participant) will visit the Social Competence and Treatment Lab in the Department of Psychology at Stony Brook University. This lab visit will last approximately 2.5 hours. Adolescents and parents will complete baseline questionnaires (see sections below for details). Participants will then be randomized to one of two intervention conditions, using Qualtrics built in functionality: the single session growth mindset intervention (SSI GMI), or an active control program, designed to replicate supportive therapy (ST) and tested in previous work. Immediately after intervention completion, adolescents will complete a brief post-intervention questionnaire battery. Adolescents and parents will then be asked to complete online follow-up questionnaire batteries 3-months post-intervention.|t|f|t|f
33886225|NCT02020044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886226|NCT00445302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886227|NCT01926626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886228|NCT00544869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886229|NCT02411747|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33886230|NCT01261559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33886231|NCT04736667|||COHORT||PROSPECTIVE|||||||
33886232|NCT01934569|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886233|NCT02550028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886234|NCT04688203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33886235|NCT00716469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886236|NCT04642846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886237|NCT02896530|||CASE_ONLY||RETROSPECTIVE|||||||
33886238|NCT01707030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886239|NCT01007214|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886240|NCT00222027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886241|NCT03655834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886242|NCT05479903|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886243|NCT05140148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886244|NCT00603135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886245|NCT00605267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886246|NCT03007862|||CASE_ONLY||PROSPECTIVE|||||||
33973631|NCT04571242|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two study treatment groups:~* Test treatment group with DTM-SCS programming approach~* Control treatment group with Conventional SCS programming approach~Data at follow-up visits will be compared between the two treatment groups, and in reference to baseline assessments collected at the beginning of the study."||||
33973632|NCT03939169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973633|NCT02045628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973634|NCT02067780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33973635|NCT04665076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973636|NCT04041765|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33973637|NCT05742581|||COHORT||RETROSPECTIVE|||||||
33973638|NCT01107535|||COHORT||PROSPECTIVE|||||||
33973639|NCT06479304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973640|NCT01608009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973641|NCT04550195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973642|NCT06277258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the end of the study, the outcome will be assessed by blinded.||f|f|f|t
33973643|NCT03031522|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33973644|NCT05652920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973645|NCT03051685|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33973646|NCT05304637|NA|SINGLE_GROUP||TREATMENT||NONE||Open labe therapeutic study||||
33973647|NCT00638170|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33973648|NCT06483373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973649|NCT04884659|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Investigator and participants will be blinded to randomization prior to initiation of study arm. The randomization will be determined by the research pharmacist. Since the arms require different timing of meals it will be obvious as to the arm, once it is started. However, neither the investigator nor the participant can choose the order of the arms.|10 obese, pre-diabetic participants will be randomly assigned to usual eating pattern vs timed restricted eating over 5 days as inpatient in a metabolic unit. They will undergo baseline and post-intervention measurements of glucose tolerance, body compostion by Bod Pod, continuous glucose monitoring by Free-Syle Libre monitor and donate blood for markers of inflammation. They will consume their usual pre-study diet. After completing Arm I, they will cross-over to Arm 2.|t|f|t|f
33973650|NCT00767117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973651|NCT02545998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33973652|NCT01236820|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973653|NCT05040685|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective not randomized pilot study to validate the axillary mapping reverse technique by using indocyanine green.||||
33973654|NCT01164423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886247|NCT00892580|||COHORT||PROSPECTIVE|||||||
33886248|NCT04447885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33973655|NCT03503357|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33973656|NCT05575960|NA|SEQUENTIAL||TREATMENT||NONE|Not possible to mask psychotherapy for patient or therapist.|Multiple Baseline Design||||
33973657|NCT04459546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled pre-post test design||||
33973658|NCT00904020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973659|NCT01170364|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33761579|NCT06296823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33973660|NCT05815043|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33973661|NCT00319956|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33973662|NCT06152627|||CASE_ONLY||PROSPECTIVE|||||||
33973663|NCT04703946|||OTHER||RETROSPECTIVE|||||||
33973664|NCT02129374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973665|NCT02184000|||CASE_ONLY||PROSPECTIVE|||||||
33973666|NCT01580761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33973667|NCT01368276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973668|NCT00730522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886249|NCT01262625|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This randomized, controlled, diagnostic, multicenter trial will follow participants at 6-month intervals for up to 24 months to determine the incidence of MACE, defined as myocardial infarction (MI) or cardiac-related death, and cross-over to revascularization.||||
33973669|NCT01910766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33973670|NCT03358459|||CASE_ONLY||CROSS_SECTIONAL|||||||
34072584|NCT00666159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34072585|NCT02843815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761580|NCT02996357|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761581|NCT05760807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886250|NCT03711903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||The treatment arm will be given CN 105 The placebo arm will be give 0/9% NaCl|t|t|t|t
33886251|NCT04569838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886252|NCT05944536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients who the inclusion criteria and agreed to participate were randomly allocates to Group 1 \[Balance Exercises(BE)\] and Group 2 \[BE+Dual Tasks(DT)\]|t|f|f|f
33886253|NCT04120155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886254|NCT00804687|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33886255|NCT04748055|||COHORT||PROSPECTIVE|||||||
33886256|NCT05034900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886257|NCT04664348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886258|NCT02804763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886259|NCT03215563|||COHORT||PROSPECTIVE|||||||
33886260|NCT05408260|NA|SINGLE_GROUP||SCREENING||NONE||||||
33886261|NCT05073055|RANDOMIZED|PARALLEL||TREATMENT||NONE||Spinal anesthesia was determined as the standard method. Erectile spina block was determined as a research group. There were equal numbers of patients in both groups. The patients to be assigned to the groups were determined by the closed envelope drawing method.||||
33886262|NCT01357811|NON_RANDOMIZED|PARALLEL||||NONE||||||
33886263|NCT00862095|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33886264|NCT00435734|||COHORT||PROSPECTIVE|||||||
33886265|NCT00958672|||COHORT||PROSPECTIVE|||||||
33886266|NCT03014609|||COHORT||PROSPECTIVE|||||||
33886267|NCT01384682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886268|NCT02002702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886269|NCT04678648|NA|SEQUENTIAL||TREATMENT||NONE||||||
33886270|NCT06166628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886271|NCT04880005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886272|NCT03630055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Eligible patients will undergo a 1:1 randomization using a computer-generated randomization sequence to either receive a direct oral anticoagulant (i.e. rivaroxaban 15mg oral daily) for 7 days or to the standard of care arm (i.e. no rivaroxaban)|f|f|f|t
33886273|NCT00905957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886274|NCT05319236|NA|SINGLE_GROUP||OTHER||NONE||||||
33886275|NCT05368545|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886276|NCT00332956|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33886277|NCT03543514|||CASE_ONLY||PROSPECTIVE|||||||
34072586|NCT05953155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072587|NCT05900908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886278|NCT04175145|||COHORT||RETROSPECTIVE|||||||
33886279|NCT00423059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886280|NCT02062567|||COHORT||PROSPECTIVE|||||||
33886281|NCT02022449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973671|NCT05974748|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be aware of their interventional group. A proforma and pain intensity scale will be provided to the patient by an intern not involved in the study, to be completed at 24, 48, and 72 hours following the procedure to assess post-operative pain. this proforma will be collected and assessed by the intern.|2 interventional groups assigned. 1 will be receiving routine intervention and other is the experimental group.|t|f|f|t
33973672|NCT05102279|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Participants were randomly divided into two groups.A group of participants first received a normal phosphorus diet for 2 days, followed by a low-phosphorus diet for 3 days, then a normal phosphorus diet for 2 days, and a high-phosphorus diet for 3 days.The other group of participants first received a normal phosphorus diet for 2 days, followed by a high phosphorus diet for 3 days, then a normal phosphorus diet for 2 days, and a low phosphorus diet for 3 days.|t|f|f|f
33973673|NCT05678348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973674|NCT00425529|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33973675|NCT02215694|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33973676|NCT01488032|||CASE_CONTROL||PROSPECTIVE|||||||
33973677|NCT01574989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33973678|NCT02523911|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33973679|NCT02511236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973680|NCT03699709|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization to one of two arms: intervention or control group||||
33973681|NCT04576767|||CASE_CONTROL||PROSPECTIVE|||||||
33973682|NCT00752791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973683|NCT02352337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973684|NCT06041464|||OTHER||OTHER|||||||
33973685|NCT02102165|NA|SINGLE_GROUP||SCREENING||NONE||||||
33973686|NCT03502642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|healthy, term women scheduled for cesarean delievry|randomized controlled trial|t|t|f|t
33761582|NCT02643862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In a 3:1 ratio, 36\* participants will receive Xolair for 16 weeks while 12\* will receive corresponding placebo instead of Xolair. 12 controls will be enrolled who will receive no OIT and no Xolair. These 12 controls are not part of the randomization. The total number of participants randomized to the two arms is 48\*.|t|f|t|f
33761583|NCT04038528|||CASE_CONTROL||PROSPECTIVE|||||||
33761584|NCT00634816|||CASE_ONLY||CROSS_SECTIONAL|||||||
33886282|NCT04278807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886283|NCT03540186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886284|NCT02427048|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33886285|NCT01722838|RANDOMIZED|PARALLEL||PREVENTION||NONE||Assignment to behavioral intervention or comparison group||||
33886286|NCT01658267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886287|NCT02553135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886288|NCT05158855|NA|SINGLE_GROUP||PREVENTION||NONE||Volunteers who vaccinated with COVID-19 vaccines for over 6 months will be recruited and will receive 1 capsule of neutralizing antibody booster. Their weight, blood pressure, and the concentration of neutralizing IgG antibody against receptor binding domain of spike protein in SARS-CoV2 will be measured before the oral administration and 14, 28 days after the administration. Number of adverse event from the beginning of the administration to 30 days after the administration will also be recorded.||||
33886289|NCT03780829|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|participants and some research personnel will be blinded|repetitive intermittent hypoxia treatment combined with exercise and/or NMDA agonist|t|f|t|f
33761585|NCT04441281|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blinded - Participants will be blinded towards the intervention used. Additionally, the type of device used will only be revealed to the practitioner after randomization, immediately prior IUD insertion.||t|f|f|f
33761586|NCT00448890|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33761587|NCT03404102|||COHORT||PROSPECTIVE|||||||
33761588|NCT05285462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761589|NCT04004390|||OTHER||RETROSPECTIVE|||||||
33761590|NCT05133050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761591|NCT05912140|||COHORT||CROSS_SECTIONAL|||||||
33761592|NCT02943941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761593|NCT01772784|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33761594|NCT02739048|||COHORT||PROSPECTIVE|||||||
33761595|NCT01438788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761596|NCT06383780|RANDOMIZED|PARALLEL||TREATMENT||NONE||Active Comparator:Drug:GP（Gemcitabine combined with cisplatin）regimen combined with Tislelizumab Experimental:Drug：TPC（cisplatin, nab-paclitaxel and capecitabine）regimen combined with Tislelizumab||||
33761597|NCT00756522|||OTHER||CROSS_SECTIONAL|||||||
33761598|NCT06212908|NA|SEQUENTIAL||PREVENTION||NONE||||||
33761599|NCT00968435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761600|NCT03661502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761601|NCT03895489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761602|NCT01494870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761603|NCT04732208|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761604|NCT04987632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761605|NCT02931201|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761606|NCT03150498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33761607|NCT00061516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33761608|NCT02564302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761609|NCT04923555|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Product kit (yogurt) will be labelled and packaged according to the pre-established randomization plane by the pharmacy department of University Hospital of Clermont-Ferrand, France. Kits will be distributed in a blind fashion for each cross over period on the basis of the randomization schedule.||t|t|t|t
33761610|NCT00849914|||CASE_CONTROL||PROSPECTIVE|||||||
33886290|NCT05752929|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded, randomized, controlled clinical trial in patients with hyperglycemia and type 2 diabetes mellitus hospitalized||||
33886291|NCT03856931|||COHORT||PROSPECTIVE|||||||
33886292|NCT00483327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761611|NCT02799472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761612|NCT04238312|RANDOMIZED|PARALLEL||TREATMENT||NONE|The operator will not be blinded to the treatment as the RESPeRATE™ will be used for the study group while the device will not be applied to the control group.|The study will be a randomized controlled clinical trial, with 1:1 allocation ratio.||||
33761613|NCT04409067|||CASE_CONTROL||RETROSPECTIVE|||||||
33761614|NCT03384264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33761615|NCT05538195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761616|NCT02960399|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761617|NCT03074812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761618|NCT06424730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study has two main objectives. First, to evaluate multi-level barriers and facilitators for recruitment and participation of Black patients in a TET-HTN clinical trial (Aim 1). Second objective is to evaluate the feasibility of TET-HTN intervention in a randomized comparison with usual clinic-based hypertension care approach (Aim 2).||||
33886293|NCT00496392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886294|NCT04158063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|knows what kind of training, but not whether the trainings-group is the control group||t|f|f|t
33886295|NCT03155646|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886296|NCT03082001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||There were two study groups A and B. The enrolled infants were administered either sterile solution of 0.2 ml of 24% sucrose or 0.2 ml of 12% sucrose 2 min prior to the procedure. The procedure involved putting first cannula in the dorm of the right hand. A 24 G needle was inserted into the vein after asepsis 2 min after the neonate had been given the allocated solution. The process was divided into three phases, the pre procedure, intraprocedure and post procedure lasting for 4 minutes. Video recording on the face of the neonate was done using a fixed video camera. The NFCS was used to evaluate and score neonatal pain.It was scored at pre, intra and post procedure 30 sec, 1 min and 2 min of the procedure.|t|t|t|f
33886297|NCT03158220|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886298|NCT05874388|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is an open-label, comparative study. The study will involve two groups: a group of adolescents and adults symptomatic of FA with a confirmed molecular diagnosis, followed in the diagnosis, followed in the genetics department of the Necker Hospital, and a control group subjects without any motor or cognitive impairment, recruited among healthy relatives of patients (siblings, cousins, etc.).||||
33886299|NCT06173557|||CASE_ONLY||OTHER|||||||
33886300|NCT04582838|||COHORT||PROSPECTIVE|||||||
33886301|NCT03266835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886302|NCT02813122|||COHORT||RETROSPECTIVE|||||||
33886303|NCT04376437|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Syqe Medical Cannabis inhaler is approval medical device in Israel , this is only Basic science study with main purpose to learn more about the kinetics of endocannabinoids .||||
33886304|NCT00006247||||TREATMENT||||||||
33886305|NCT01547767|||CASE_ONLY||OTHER|||||||
33886306|NCT00313573|RANDOMIZED|||||||||||
33886307|NCT05886062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886308|NCT06499818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886309|NCT03611439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomized, double blind|randomized, placebo-controlled, double blind study|t|t|t|t
33886310|NCT01405092|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33886311|NCT06103747|RANDOMIZED|CROSSOVER||OTHER||NONE||open label, randomized, fed, single oral dose, two-treatment, two-sequence, and two-period crossover study with a washout interval of at least one week between dosing||||
33886312|NCT00189644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886313|NCT01561651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886314|NCT05255380|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants are assigned to either a Mindful Activity group or a Mindful Awareness group. Randomization will occur by chance (50%) at the end of the baseline visit.|f|f|t|f
33886315|NCT01618760|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886316|NCT03529409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973687|NCT03246932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the group assignments.||f|f|f|t
33973688|NCT00291395|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33973689|NCT01650324|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33886317|NCT04043000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The subjects took the test article, Super 13 Pro \& Prebiotics or the control article, The placebo without Super 13 Pro \& Prebiotics during the 4-week drug-intake period."|"This study aim to investigate the roles of the test article in improving gastrointestinal functions and gut microbiota of humans. A total 40 healthy adults were recruited and randomly divided into experimental and control groups, with 20 subjects each, for a 4-week trial. The subjects took the test article, Super 13 Pro \& Prebiotics or the control article, The placebo without Super 13 Pro \& Prebiotics during the 4-week drug-intake period. Fecal specimens were collected at the 0th, 2nd, and 4th weeks of the trial for analyzing the bacterial counts of Bifidobacterium spp., Clostridium perfringens, Lactobacillus spp., and Coliform."|t|t|t|t
33886318|NCT05918380|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33886319|NCT05242692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The labeled Study medication syringes (50ml) in identical appearance, and the infusion regimen formulated by the pharmacist based on the randomization, will be distributed to the attending anesthesiologists responsible for anesthetic management as soon as the research team informs the central pharmacy about the patient heading for surgery. To avoid anesthesiologists' speculation about the randomized assignment, the study drugs will be infused at a similar rate. The anesthesiologists, the patients, the investigators responsible for follow-up, and the statisticians are all masked to randomized allocations until the final statistical analyses are completed. The blindness will be unmasked by the primary investigator in a medical emergency including deterioration of patient's condition intraoperatively or adverse events postoperatively."||t|t|t|t
33886320|NCT01551693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886321|NCT00818259|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886322|NCT00927641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072588|NCT05072210|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be issued a specific ID number to be used within the mobile app to ensure that any identifiable information within this app will remain anonymous. A master linking log will serve as the only link between participants and the study data collected in the mobile app.|Upon logging into the study platform, half of the participants will be automatically randomized to receive (for 4 weeks) daily-personalized automated alerts (The mobile intervention). This feature will be made available to all participants after 4 weeks. Hence, for the first 4 weeks, this study can be described as having a parallel group study model. After 4 weeks, the study switches to a single group study model, and can therefore be described as having a single group interventional model after 4 weeks from the start date until the rest of the duration of the study.|t|f|t|f
33886323|NCT03720457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886324|NCT05585749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program|t|f|f|f
33886325|NCT04206826|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each patient will apply the two films (PreDelfi and control according to randomization) at the level of the gingival mucosa next to the maxillary vestibule for 30 days|t|f|t|f
33886326|NCT04915287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072589|NCT03688347|||OTHER||PROSPECTIVE|||||||
33886327|NCT02059876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886328|NCT02269722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886329|NCT03851497|||COHORT||PROSPECTIVE|||||||
33886330|NCT02953717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886331|NCT03692416|RANDOMIZED|PARALLEL||TREATMENT||NONE|No other parties are masked in this clinical trial.|The aim of this work is to assess the effect of various forms of treatment of vasculitis on C3, C4, C5a \& ANCA levels in blood, in infants \& children.||||
33886332|NCT01290887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886333|NCT04275713|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomized to intervention Group (metformin in combination with radiotherapy) or standard of care.||||
33886334|NCT04673097|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34072590|NCT00508677|||COHORT||PROSPECTIVE|||||||
33886335|NCT04230447|||COHORT||PROSPECTIVE|||||||
34072591|NCT02263053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886336|NCT02704598|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33886337|NCT00578357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072592|NCT04758247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072593|NCT01543802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072594|NCT04457362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Cohort Study, Diagnostic||||
34072595|NCT00200577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072596|NCT05274867|||OTHER||OTHER|||||||
34072597|NCT02027077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072598|NCT00165217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886338|NCT03329378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886339|NCT00004160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886340|NCT05636631|||COHORT||PROSPECTIVE|||||||
33886341|NCT06091839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886342|NCT03142698|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072599|NCT05027815|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34072600|NCT02103660|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072601|NCT00015652||||TREATMENT||||||||
34072602|NCT06202014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072603|NCT02997423|||COHORT||PROSPECTIVE|||||||
34072604|NCT02541955|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34072605|NCT02797145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886343|NCT00784667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761619|NCT03092375|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Main Study Up to 225 subjects will be enrolled into 4 study arms A, B, C and D with Glecaprevir/Pibrentasvir (G/P) with or without Ribavirin (RBV).~About 75-90 non-cirrhotic subjects will be randomized in a 2:1 ratio to Arms A and B, and about 110-135 compensated cirrhotic subjects will be randomized in a 1:1 ratio to Arms C and D.~Non-cirrhotic subjects will be randomized 2:1 to:~1. Arm A: G/P 300 mg/120 mg Once a day for 12 weeks~2. Arm B: G/P 300 mg/120mg Once a day for 16 weeks~   Subjects with compensated cirrhosis will be randomized 1:1 to:~3. Arm C: G/P 300 mg/120 mg QD + weight-based RBV (Ribavirin) Twice a day (1000 mg or 1200 mg total daily dose) for 12 weeks~4. Arm D: G/P 300 mg/120 mg QD for 16 weeks Retreatment sub-study Up to 11 subjects who still have hepatitis C virus after being treated in the Main study will have the option to enter the Retreatment sub-study and receive G/P plus Sofosbuvir and with or without RBV."||||
33886344|NCT04535219|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33886345|NCT06230354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886346|NCT06040294|RANDOMIZED|PARALLEL||OTHER||SINGLE||two-group randomised controlled trial|f|f|f|t
33886347|NCT05973136|NA|SINGLE_GROUP||TREATMENT||NONE||The study design is a pre-post without a control group||||
33886348|NCT00455117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886349|NCT02926703|||COHORT||PROSPECTIVE|||||||
33886350|NCT03201055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886351|NCT04934930|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective multicenter, single arm, phase II study||||
33886352|NCT02111733|NA|SINGLE_GROUP||||NONE||||||
33886353|NCT06439420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886354|NCT06395493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886355|NCT05666557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886356|NCT00045032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886357|NCT00635973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886358|NCT02666326|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33886359|NCT00167258|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33886360|NCT04434352|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patients will be randomized to either the treatment group or sham group.||t|f|f|t
33886361|NCT00927563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886362|NCT03499730|||COHORT||PROSPECTIVE|||||||
33886363|NCT02159027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886364|NCT01172756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886365|NCT02975830|||CASE_ONLY||RETROSPECTIVE|||||||
33973690|NCT02696811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33886366|NCT05658224|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will be randomized into 1 of 2 groups. Outcome assessor will not be informed of participant grouping.||t|f|f|t
33886367|NCT00949741|||COHORT||RETROSPECTIVE|||||||
33886368|NCT00002309||||TREATMENT||DOUBLE||||||
33886369|NCT04960085|||CASE_CONTROL||PROSPECTIVE|||||||
33761620|NCT02848482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33761621|NCT01460498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886370|NCT02009878|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33886371|NCT04273048|RANDOMIZED|PARALLEL||OTHER||NONE||This research will last up to 12 weeks. The participant will attend two research study visits and will be asked to donate oocytes and follicular fluid to the study team during their oocyte retrieval procedures. They will be randomized (like flipping a coin) to either a standard of care group or an intervention group. If they are in the intervention group, they will also be asked to follow a Mediterranean diet (all meals will be shipped to their home weekly) and exercise at least 3 times a week at a gym or at their house. If they are in the control group, they will follow the normal fertility clinic procedures.||||
33886372|NCT00085280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886373|NCT01703000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886374|NCT05157126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data collectors (research coordinators) and data analysts will also be masked|Single-center individually-randomized placebo-controlled superiority trial|t|t|t|t
33886375|NCT03168815|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized to either HFNC delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure; or to conventional supplemental LFNC delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.||||
33886376|NCT00121628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886377|NCT00947284|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33886378|NCT00047658|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33886379|NCT02766660|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33886380|NCT04120558|||COHORT||PROSPECTIVE|||||||
33886381|NCT04938440|||COHORT||CROSS_SECTIONAL|||||||
33886382|NCT04274296|||COHORT||PROSPECTIVE|||||||
33886383|NCT03294551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33761622|NCT01995539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886384|NCT02274285|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33886385|NCT03135405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33886386|NCT02293122|||COHORT||PROSPECTIVE|||||||
33886387|NCT06173999|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||SHR2554 with CHOP/CHOEP.||||
33973691|NCT03467334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The control group is the usual treatment that is administered differently (oral drops, 4 times a day) to the 2 research treatments (powder, 1 time a day).||f|f|t|t
33973692|NCT00356720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33973693|NCT03517137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973694|NCT00060957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886388|NCT04146922|RANDOMIZED|PARALLEL||TREATMENT||NONE||Computer generated block randomization into permuted blocks of 4, 6 and 8||||
33886389|NCT03286673|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33886390|NCT06500377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33886391|NCT00046228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886392|NCT01647737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886393|NCT05322213|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Single-Center, double-blind, placebo-controlled, crossover study.|t|f|t|f
33886394|NCT05533749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to the intervention group or to care as usual. In the intervention group patients will receive the GILL eHealth intervention focusing on systematic somatic screening and lifestyle behaviours.|f|f|f|t
33886395|NCT02084446|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973695|NCT01709383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973696|NCT02130466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973697|NCT00101543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33973698|NCT02003040|||COHORT||PROSPECTIVE|||||||
33973699|NCT00582036|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973700|NCT03408366|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty consecutive patients will be enrolled: the first 10 will have skin closure with staples, and the second 10 will have skin closure with a running subcuticular suture.||||
33973701|NCT02489838|||COHORT||PROSPECTIVE|||||||
33973702|NCT00915057|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072606|NCT04444765|||CASE_ONLY||PROSPECTIVE|||||||
34072607|NCT01400724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34072608|NCT00371475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072609|NCT05950880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072610|NCT00023738||||TREATMENT||||||||
33886396|NCT04588103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33973703|NCT03104790|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups based on prior vaccination history||||
33973704|NCT00408733|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34072611|NCT02421419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072612|NCT03828214|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-subject design||||
34072613|NCT00291564|||||PROSPECTIVE|||||||
34072614|NCT06501599|||COHORT||RETROSPECTIVE|||||||
33886397|NCT05901467|NA|SINGLE_GROUP||OTHER||NONE||||||
33886398|NCT00870337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886399|NCT04351139|||CASE_CONTROL||OTHER|||||||
33886400|NCT02009241|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973705|NCT01773512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973706|NCT00794183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973707|NCT06484972|||OTHER||PROSPECTIVE|||||||
33973708|NCT01292109|||COHORT||PROSPECTIVE|||||||
33973709|NCT01448135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33973710|NCT03211156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886401|NCT02519881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886402|NCT00771784|||CASE_CONTROL||PROSPECTIVE|||||||
33886403|NCT06206096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886404|NCT03110588|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The first cohort will administer the following to three patients: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks. If there are no dose limiting toxicities, the cabazitaxel will be escalated to 20 mg/m2 in a second cohort. The other three drugs will remain at the same dose.||||
34072615|NCT03309228|||OTHER||CROSS_SECTIONAL|||||||
34072616|NCT06503978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Investigators and outcome assessors were all blinded. Only the Pharmacist distributing the medication knew the randomization code.|"Part 1: Randomized, Double-Blinded, Placebo-Controlled with 2 Treatment groups and 2 Placebo Groups (15 weeks)~Part 2: Open-Label Observation and Cross-over or Treatment Part 3: Follow Up (Group B Only)"|t|t|t|t
34072617|NCT01211145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072618|NCT06609291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34072619|NCT02729480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761623|NCT06625671|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33761624|NCT02016404|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33761625|NCT01058837|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886405|NCT05888350|RANDOMIZED|PARALLEL||OTHER||DOUBLE||a multi-center, randomized, double-blind, placebo-controlled trial|t|f|t|f
33886406|NCT02917460|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33886407|NCT03147469|RANDOMIZED|CROSSOVER||OTHER||SINGLE||"AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order.~Fiberoptic bronchoscopic view will be also assessed for each head and neck positions."|t|f|f|f
33973711|NCT06298435|||COHORT||RETROSPECTIVE|||||||
33886408|NCT06384092|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Proof of science/concept||||
33973712|NCT02322528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886409|NCT04947644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886410|NCT01431092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886411|NCT04577963|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33886412|NCT01054079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886413|NCT02439580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33886414|NCT03416231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886415|NCT01149070|||COHORT|||||||||
33973713|NCT02099279|||COHORT||PROSPECTIVE|||||||
33973714|NCT05779150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||self-controlled clinical trial|t|t|t|t
34072620|NCT02040974|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072621|NCT04491981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072622|NCT02666001|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34072623|NCT04059289|||COHORT||PROSPECTIVE|||||||
34072624|NCT05515484|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886416|NCT01176916||||||NONE||||||
33886417|NCT01191112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886418|NCT06548139|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||There were 120 healthy people aged 10-50 years, divided into 3 groups: test group 1 rabies mAb CBB1 50.0 µ g / kg + vaccine; test group 2 rabies mAb CBB1 100.0 µ g / kg + vaccine; and control group HRIG 20IU / kg + vaccine|t|f|t|t
33886419|NCT04159883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886420|NCT00861159|||CASE_ONLY||PROSPECTIVE|||||||
34072625|NCT04177992|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The study is randomised but not blinded. Infants will be randomised to commence on either automated (servo) control or manual mode, and then cross-over to the alternative range after 6 hours of monitoring (total study time of 12 hours). SpO2 (range 90-95%) will be continuously monitored as per normal standard of care.|This is a randomised cross-over study of servo-controlled oxygen targeting in premature infants, with infants acting as their own controls.||||
33761626|NCT04074967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase lb: subjects with advanced solid tumors will receive ARRY-614 in combination with nivolumab or ARRY-614 in combination with nivolumab + ipilimumab immunotherapy.~Phase ll: Subjects with NSCLC or HNSCC will receive ARRY-614 combined with nivolumab. Subjects with melanoma will receive ARRY-614 combined with nivolumab + ipilimumab. Subjects with RCC will receive ARRY-614 combined with nivolumab + ipilimumab."||||
33973715|NCT03673059|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Subjects were randomly assigned to two groups. One group was supplied with a test product containing an OTC drug monographed ingredient for treatment of eczema and the other group was supplied with a cosmetic test product which is a standard dry skin daily moisturizer. Both groups were also provided with a cosmetic test cleanser to use in place of their normal cleanser. There was a 7-day regression period following the 14 days of product use.|t|f|t|t
33761627|NCT02026648|||CASE_ONLY||RETROSPECTIVE|||||||
33761628|NCT03131960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, therapists (care providers), investigators, and outcomes assessors do not know which group (VNS or control VNS) the patients are randomized. Only one person at the site - the programmer who programs the device settings - knows which group the subject is randomized into.|Double blind, randomized, parallel study with partial crossover (control subjects crossover to treatment after randomized portion)|t|t|t|t
33761629|NCT02413060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761630|NCT00137943|RANDOMIZED|PARALLEL||||NONE||||||
33761631|NCT00402194||PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886421|NCT06228612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient's randomization was performed by two assistants who did not participate in the trial. One assistant had prepared sequentially numbered sealed envelopes with random assignment. The assignment of the treatment was then completed by another assistant from outside the trial.|Patient's randomization was performed by two assistants who did not participate in the trial. One assistant had prepared sequentially numbered sealed envelopes with random assignment. The assignment of the treatment was then completed by another assistant from outside the trial. Patients whose treatment plans included vacuum therapy (VT) were designated group (I) and included 14 patients, and those with stabilization splint therapy (SST) were designated (group (II) and included 14 patients. Patients whose treatment plans included both vacuum therapy and splint therapy (VT + SST) were designated as group (III) and included 14 patients.|t|f|f|t
33973716|NCT01544166|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973717|NCT05105165|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973718|NCT00779077|||COHORT|||||||||
33973719|NCT04683822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33973720|NCT02484820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973721|NCT03244020|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three separate patient categories are being investigated in this trial. All patients are undergoing pelvic and/or lower extremity surgery for one of three possible conditions: 1) soft tissue sarcoma; 2) primary bone sarcoma; 3) metastatic bone disease. Within each of these groups, patients will be randomized to either aspirin or low molecular weight heparin (enoxaparin) for venous thromboembolism prophylaxis post operatively.||||
33973722|NCT03198013|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33886422|NCT03750188|||CASE_ONLY||RETROSPECTIVE|||||||
33886423|NCT05158322|||OTHER||PROSPECTIVE|||||||
33886424|NCT01307033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973723|NCT04579926|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Randomized step wedge design with multiple baselines. Parents and adolescents were enrolled as dyads. Only adolescents received the intervention and will be reported.||||
33973724|NCT00198497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973725|NCT02079792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973726|NCT03402893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973727|NCT03651115|||OTHER||PROSPECTIVE|||||||
33973728|NCT02559050|||CASE_ONLY||RETROSPECTIVE|||||||
33973729|NCT05945199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973730|NCT01461200|||CASE_CONTROL||PROSPECTIVE|||||||
33973731|NCT04081480|NA|SINGLE_GROUP||OTHER||NONE||Intervention is pharmacokinetic (PK) curve collection in children, two age groups||||
33973732|NCT00630565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886425|NCT04041336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Assess the feasibility of measuring the thickness of retinal layers using a handheld optical coherence tomography device in older patients after hips fracture surgery. Consecutively recruited consenting patients will be included.||||
33886426|NCT02437136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886427|NCT02685917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886428|NCT00491179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886429|NCT01590173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886430|NCT03706053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized to intervention or placebo by the investigational pharmacy. Care providers, investigators and participants will be blinded to study arm.||t|t|t|f
33973733|NCT05561309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||HR18034 compared with active comparator|t|t|t|t
33973734|NCT04293666|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33973735|NCT05695248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33973736|NCT01939119|||CASE_ONLY||PROSPECTIVE|||||||
33973737|NCT02641613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33973738|NCT04867525|||COHORT||PROSPECTIVE|||||||
33973739|NCT06483295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973740|NCT05247710|||CASE_ONLY||PROSPECTIVE|||||||
33973741|NCT00208650|||||PROSPECTIVE|||||||
33973742|NCT02833402|||COHORT||PROSPECTIVE|||||||
33886431|NCT00003378||||TREATMENT||||||||
33973743|NCT04553575|||COHORT||PROSPECTIVE|||||||
33973744|NCT01011647|||COHORT||PROSPECTIVE|||||||
33973745|NCT02044172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973746|NCT05913336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886432|NCT01983644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886433|NCT02761967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973747|NCT06038513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973748|NCT01577511|||COHORT||PROSPECTIVE|||||||
33973749|NCT03781297|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33973750|NCT00427622||||DIAGNOSTIC||NONE||||||
33973751|NCT05059535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33886434|NCT05903287|||CASE_CONTROL||RETROSPECTIVE|||||||
33886435|NCT05695326|NA|SINGLE_GROUP||OTHER||NONE||||||
33886436|NCT02662790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886437|NCT01072344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886438|NCT05088408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33973752|NCT05083650|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|We never let the patient know the performed surgery|Large MHs (diameter \> 550 μm)|t|t|f|f
33973753|NCT03467477|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973754|NCT00686036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973755|NCT02710071|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33973756|NCT05730140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973757|NCT06126809|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"This study is double-blinded at the level of runs within a single session. Participants and the researchers at the time of stimulation are unaware of which type of stimulation the participant will receive for each block. This is accomplished using randomization codes maintained within the computer. Furthermore, this study utilizes an active sham stimulation. This means that the active sham condition includes some stimulation, mimicking the skin sensations associated with tRAS. Participants receive all three types of stimulation in a single session over twelve five-minute blocks with an intermixed, balanced, and randomized order."|All participants receive all three types of transcranial random aperiodic stimulation (tRAS): steep-tRAS, flat-tRAS, and sham-tRAS. The type of stimulation received is randomized and intermixed for each task block lasting approximately 5 minutes. The participant receives 12 task blocks, each with one of the stimulation types that are randomized, intermixed, and balanced for order.|t|f|t|f
33973758|NCT00600197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973759|NCT02497677|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33973760|NCT01230151|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33973761|NCT01000740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973762|NCT02133456|||ECOLOGIC_OR_COMMUNITY|||||||||
33973763|NCT03967249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973764|NCT00766207|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33973765|NCT05033613|||CASE_ONLY||PROSPECTIVE|||||||
33973766|NCT00458302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973767|NCT03381248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973768|NCT01270750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973769|NCT01201746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886439|NCT06420232|NA|SINGLE_GROUP||OTHER||NONE||usual care waitlist control period followed by one month intervention||||
33886440|NCT02381379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886441|NCT03987204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973770|NCT00195299|||||PROSPECTIVE|||||||
33973771|NCT04203407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33973772|NCT05647083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973773|NCT05728632|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients, treating physicians, investigators, and outcome assessors are masked to the allocated treatment.|Participants are randomized 1:1 to two groups in parallel for the duration of the study|t|t|t|t
33973774|NCT01883089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886442|NCT01338467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886443|NCT04281199|NA|SINGLE_GROUP||TREATMENT||NONE||Radiation||||
33886444|NCT05721066|||COHORT||PROSPECTIVE|||||||
33886445|NCT04530162|||COHORT||PROSPECTIVE|||||||
33973775|NCT05305209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973776|NCT00551564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973777|NCT04984018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886446|NCT04577040|||CASE_CONTROL||PROSPECTIVE|||||||
33886447|NCT05697133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33886448|NCT04685187|||OTHER||PROSPECTIVE|||||||
33886449|NCT01728779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886450|NCT02384811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886451|NCT00004433|RANDOMIZED|||TREATMENT||||||||
33886452|NCT05571683|||COHORT||PROSPECTIVE|||||||
33886453|NCT00410176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886454|NCT01597102|||OTHER||PROSPECTIVE|||||||
33886455|NCT00930059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886456|NCT04334382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886457|NCT02492945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886458|NCT05033392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886459|NCT02909621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33886460|NCT01233206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886461|NCT03480802|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33886462|NCT01052857|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886463|NCT01571063|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33886464|NCT05134467|||OTHER||PROSPECTIVE|||||||
33886465|NCT02972320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886466|NCT04278885|NA|SINGLE_GROUP||TREATMENT||NONE||exploratory, proof-of-concept, single-center, open-label pilot study||||
33886467|NCT03568890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886468|NCT00348621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33973778|NCT00174733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973779|NCT04472975|||COHORT||OTHER|||||||
33973780|NCT05476874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973781|NCT05461820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973782|NCT02110771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973783|NCT03828123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973784|NCT03757455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33973785|NCT04072718|NA|SINGLE_GROUP||TREATMENT||NONE||To be treated with hypofractionated radiotherapy of 34Gy in 10 fractions to whole breast and 40Gy in 10fractions to the tumor bed||||
33973786|NCT01740700|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33973787|NCT04741035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973788|NCT05942612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973789|NCT00804609|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33886469|NCT02848079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886470|NCT02522767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973790|NCT00193778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973791|NCT05329909|||COHORT||RETROSPECTIVE|||||||
33973792|NCT03154788|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33973793|NCT04025034|NA|SINGLE_GROUP||TREATMENT||NONE||Retrsopective, non-comparative case series||||
33973794|NCT01679132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886471|NCT03773302|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Open Label, 2:1 Randomized, Controlled Phase 3||||
33886472|NCT03625440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886473|NCT01578031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886474|NCT01374061|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886475|NCT01361581|||COHORT||PROSPECTIVE|||||||
33886476|NCT00289263|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886477|NCT03419078|||COHORT||RETROSPECTIVE|||||||
33886478|NCT00141947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886479|NCT02808104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886480|NCT01484964|RANDOMIZED|CROSSOVER||||NONE||||||
33886481|NCT03229720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The statistician is blinded by naming the groupes into group A and group B~."||f|f|f|t
33886482|NCT02542267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973795|NCT02229006|||CASE_CONTROL||PROSPECTIVE|||||||
33973796|NCT02437799|||COHORT||PROSPECTIVE|||||||
33973797|NCT05834790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Three activity centers from the list will be randomly chosen and assigned to MAR, lecture, and no intervention groups.||||
33761632|NCT02119143|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33973798|NCT03140592|||COHORT||PROSPECTIVE|||||||
33761633|NCT02802501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973799|NCT04840407|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33973800|NCT04661137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973801|NCT02127047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072626|NCT05010317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|This will be an open label randomized study because the staff will be involved in the care of the participants, assessment of the outcome and the nature of the psychosocial interventions to be administered.|One group of adolescents (treatment group), will be exposed to a mindfulness and acceptance based psychotherapy on top of usual clinic care services, while the other group will keep receiving usual clinic care. Then comparison will be made at post intervention on experiences of depression, stigma, anxiety, psychological flexibility and then self-reported medical adherence at post intervention between the two groups, adjusting for baseline measures.||||
34072627|NCT02103023|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34072628|NCT02136901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072629|NCT02675270|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33761634|NCT04369001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761635|NCT03917940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blind|The patients will be divided into two groups: group 1 treated with (Omega - 3 and glimepiride, n=35). group 2 treated with glimepiride alone, n=35).|t|f|f|f
33761636|NCT00106184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761637|NCT01490125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33761638|NCT04009590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761639|NCT04846023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center prospective interventional study of children admitted to a PICU||||
33761640|NCT04837859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761641|NCT01661556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761642|NCT05249062|NA|SINGLE_GROUP||OTHER||NONE||||||
33886483|NCT01111305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Drug assignment (reslizumab vs. placebo) and eosinophil count||t|t|t|f
33886484|NCT05574179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33886485|NCT04884789|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33886486|NCT00220376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886487|NCT02887443|NA|SINGLE_GROUP||OTHER||NONE||||||
33886488|NCT01759082|||CASE_ONLY||PROSPECTIVE|||||||
33886489|NCT00138697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886490|NCT04760145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886491|NCT04009928|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|An independent researcher will perform the randomization and institute the sham/active stimulation, allowing for continued blinding of participants/care providers/investigators/outcomes assessors.|After 6 months of open-label stimulation, patients will enter a blinded, randomized, crossover phase. After a 1 week washout phase with stimulation turned OFF, patients will randomly be assigned to receive 2 weeks of sham stimulation followed by 2 weeks of active stimulation (at their optimized settings), or vice versa.|t|t|t|t
33886492|NCT01583179|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33886493|NCT02921386|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Open-label, randomized, 5-period crossover food effect study||||
33886494|NCT04112680|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participant will not know the group they are assigned to, as all groups (also the control group) will receive audio messages.~The investigator and outcomes assessors will only be handed an anonymised data set."|Interventional study, with 3 arms (2 intervention groups, 1 control group) to test communication elements of audio dramas aiming to counter prevalent belief in misinformation about an infectious disease in Freetown, Sierra Leone|t|f|t|t
33886495|NCT02005120|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886496|NCT03718936|||COHORT||CROSS_SECTIONAL|||||||
33886497|NCT00000655||PARALLEL||TREATMENT||||||||
33973802|NCT05747079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973803|NCT00313885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973804|NCT06303635|||OTHER||PROSPECTIVE|||||||
33973805|NCT01751412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072630|NCT05135936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Parallel Assignment, Sham- and treatmentgroup|t|f|f|f
34072631|NCT04866082|||COHORT||PROSPECTIVE|||||||
34072632|NCT05212584|NA|SEQUENTIAL||TREATMENT||NONE||CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.||||
34072633|NCT01136564|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34072634|NCT04996836|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34072635|NCT01768065|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33761643|NCT00298922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761644|NCT00978484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761645|NCT00459342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886498|NCT04722185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||each patient will have 2 scans - one on a conventional system and one on the newer technology||||
33886499|NCT06448065|||COHORT||RETROSPECTIVE|||||||
33886500|NCT00363792|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
33886501|NCT05074758|||COHORT||PROSPECTIVE|||||||
33886502|NCT06312787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072636|NCT05118035|RANDOMIZED|PARALLEL||SCREENING||SINGLE||intervention group:8001 control group:7964|t|f|f|f
34072637|NCT02146209|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072638|NCT05095194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886503|NCT05950763|||OTHER||RETROSPECTIVE|||||||
33886504|NCT01370967|||COHORT||PROSPECTIVE|||||||
33973806|NCT05498285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33973807|NCT02294656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973808|NCT02387320|RANDOMIZED|PARALLEL||||NONE||||||
33973809|NCT02347878|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33973810|NCT03880526|||COHORT||PROSPECTIVE|||||||
33973811|NCT04584125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a multicenter, double-masked, parallel, and randomized study with a subsequent follow-up period of 30 months. 216 subjects (of any race or gender) who have keratoconus (between the ages of 18 and 50) will sign the consent for their first PK or DALK surgery in the study eye. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be given the opportunity to participate in the study. Subjects will either randomized to the treatment group (crosslinked corneal tissue) or control group (non-crosslinked corneal tissue that has been exposed to riboflavin, but no ultraviolet light).|t|f|t|f
33973812|NCT03589183|||COHORT||PROSPECTIVE|||||||
33973813|NCT03616613|||COHORT||PROSPECTIVE|||||||
33973814|NCT03283709|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|A prospective, randomized controlled trial comparing treatment outcomes for partial edentulism using two restorative materials. A convenience sample of study participants will be randomly assigned to either a treatment group or a control group.||||
33973815|NCT04809870|||CASE_CONTROL||RETROSPECTIVE|||||||
33973816|NCT01783106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973817|NCT00399113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973818|NCT05157321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33973819|NCT03845920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33973820|NCT03571308|NA|SEQUENTIAL||TREATMENT||NONE|"A multicentre open-label non-randomised phase Ib/II two stage trial. Stage 1 - dose escalation will proceed until a maximum tolerated dose (MTD) is defined or the maximal administered dose (MAD) is determined in order to define the recommended Phase II dose (RP2D). 6 - 24 patients. Stage 2 - expansion to gain additional information on safety and efficacy at the RP2D from a total of 15 patients recruited.~Patients will receive conventionally dosed R-CHOP chemotherapy for 6 cycles with acalabrutinib introduced on cycle 2 onwards, at a dosage according to cohort number. This will allow for both clarity in the toxicity profile of the combination and also assess the impact of acalabrutinib on ADCC.~patients who do not complete six cycles of treatment for reasons other than toxicity will be replaced."|||||
33973821|NCT05738356|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The investigator was capturing the images (that were analyzed to measure the outcomes), while a research assistant was saving the images of the patients with coding system|Three parallel groups|t|f|t|t
34072639|NCT06226337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33761646|NCT05108649|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Participants are unblinded to the nicotine content of their cigarette, either normal nicotine content (NNC) cigarettes or reduced nicotine content (RNC) cigarettes. However, participants will not be aware of the messaging condition assignment, either Nicotine Corrective Messaging (NCM) or the Delayed Control Messaging.|This project will recruit current, daily, non-menthol cigarette smokers to a 35-day, randomized, factorial design protocol. After a 7-day period of smoking own preferred brand cigarettes, participants will be randomized to a 28-day experimental period and will be randomized to one of four conditions: 1) Nicotine Corrective Messaging (NCM) + Reduced nicotine content (RNC) cigarettes, 2) NCM + normal nicotine content (NNC) cigarettes, 3) Delayed Control Messaging + RNC cigarettes, or 4) Delayed Control Messaging + NNC cigarettes.|t|f|f|f
33761647|NCT02277990|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33886505|NCT05853471|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||\[18F\]MC225 is administrated to patients in three groups to evaluate the P-glycoprotein function in these groups and compare the results with the P-gp function of healthy volunteers obtained in a previous study||||
33886506|NCT02487992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886507|NCT01864785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886508|NCT00061256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886509|NCT00786045|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33886510|NCT01929057|||COHORT||CROSS_SECTIONAL|||||||
33886511|NCT00988247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886512|NCT00299988|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33886513|NCT03782454|||COHORT||PROSPECTIVE|||||||
33886514|NCT04793399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886515|NCT00793351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886516|NCT04008732|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33886517|NCT06050135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33886518|NCT00552110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33886519|NCT02704247|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886520|NCT05179616|||COHORT||PROSPECTIVE|||||||
33886521|NCT04022382|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33886522|NCT05863117|NA|SINGLE_GROUP||SCREENING||NONE||||||
33886523|NCT05249946|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster-randomized Trial||||
33886524|NCT03917199|||COHORT||PROSPECTIVE|||||||
33886525|NCT06526780|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886526|NCT04313972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886527|NCT03016780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886528|NCT01973309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886529|NCT02407093|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33886530|NCT05607628|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886531|NCT00477789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886532|NCT03705416|||COHORT||PROSPECTIVE|||||||
34072640|NCT00004057||||TREATMENT||||||||
34072641|NCT01305772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761648|NCT00516464|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33886533|NCT05064657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment First sub purpose was designed as parallel group, two intervention groups in pre-test and post-test order, and a randomized controlled control group.||||
33886534|NCT04633590|NA|SINGLE_GROUP||OTHER||NONE||A single-centre, single-armed, open label pilot study||||
33886535|NCT03006614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886536|NCT05782829|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||prospective, monocentric, double-blind randomized study|t|f|t|f
33886537|NCT05760326|||CASE_ONLY||PROSPECTIVE|||||||
33886538|NCT03695913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886539|NCT06126991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886540|NCT04524845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, cross-over, open labelled, monocentric, controlled trial||||
33886541|NCT03120169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886542|NCT05166707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886543|NCT05025566|||COHORT||PROSPECTIVE|||||||
33886544|NCT06070948|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886545|NCT04586829|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33886546|NCT02682680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886547|NCT02269358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886548|NCT00936988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886549|NCT02317757|||COHORT||PROSPECTIVE|||||||
33886550|NCT05025215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886551|NCT03709927|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Single dose study treatments will be administered in blinded, randomized sequence in separate periods with each subject in the study exposed to each of the four treatments.|4-way cross over (two doses of ZTI-01, placebo and oral moxifloxacin)|t|f|t|t
33886552|NCT04639323|||COHORT||PROSPECTIVE|||||||
33886553|NCT01029730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886554|NCT01573910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886555|NCT00501475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33886556|NCT03655444|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33886557|NCT00789633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886558|NCT04977206|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886559|NCT05708742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Apart from the anesthesiologists who performed the blocks, all patients, surgeons, and postoperative nurses remained blinded to randomization throughout the study period.||t|t|f|t
33886560|NCT03556215|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was used in the study|Interventional parallel randomized controlled prospective trial||||
33886561|NCT03599700|||COHORT||PROSPECTIVE|||||||
33886562|NCT00130286|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33886563|NCT00650858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886564|NCT04505683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886565|NCT03690310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973822|NCT04999514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants do not have prior knowledge of the interventions that they will be assigned to.~The research assistants who support data collection do not know the interventions assigned to individual participants."|A randomized controlled design will be adopted. There will be two intervention groups, namely Mindful Parenting group and Tuning in to Kids group, and also one waitlist control group.|t|f|f|t
33973823|NCT00581620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973824|NCT03634826|||CASE_ONLY||PROSPECTIVE|||||||
33973825|NCT01417897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973826|NCT03510299|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33973827|NCT03149913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|drug coated balloon versus uncoated balloon|The vessel patency (measured by angiography at 6 months) will be compared after patients have been treated either with paclitaxel coated or uncoated balloons (control) in BTK arteries|t|f|f|f
33973828|NCT05170555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973829|NCT04215055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072642|NCT00812942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072643|NCT00195195|||CASE_ONLY||PROSPECTIVE|||||||
34072644|NCT03639129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072645|NCT00533221|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34072646|NCT01461733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072647|NCT01727817|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072648|NCT00591929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072649|NCT03352492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subject is masked to which eye has the iridotomy at which location|Paired eye|t|f|f|f
33886566|NCT00495157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886567|NCT05628922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886568|NCT03449264|NA|SINGLE_GROUP||OTHER||NONE||||||
34072650|NCT05285787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886569|NCT04157387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973830|NCT00647582||||TREATMENT||NONE||||||
33973831|NCT05753774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Children with functional gastrointestinal disease were divided into two groups, one group was given FMT combined with conventional drug intervention, and the other group was given conventional drug intervention, including: probiotics and/or omeprazole, and/or cyproheptadine, and/or amitriptyline, and/or moxapride||||
33973832|NCT04102774|RANDOMIZED|PARALLEL||TREATMENT||NONE||All the patients meeting inclusion/esclusion criteria will be enrolled and randomized into one of the two arms. The control arm will receive standard therapy. The treatment arm will receive standard therapy + long-term humidification therapy with myAIRVO2 at home overnight.||||
33973833|NCT00492206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973834|NCT05063955|||COHORT||PROSPECTIVE|||||||
33886570|NCT04770519|||FAMILY_BASED||RETROSPECTIVE|||||||
33886571|NCT00927368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33886572|NCT03048955|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multi-center, randomized, controlled||||
33886573|NCT00389155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886574|NCT00874198|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33973835|NCT05646121|||COHORT||PROSPECTIVE|||||||
33973836|NCT04693065|||COHORT||PROSPECTIVE|||||||
33973837|NCT03259581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973838|NCT01645800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973839|NCT00374413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973840|NCT02435979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072651|NCT00593424|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34072652|NCT03472612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072653|NCT01427270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886575|NCT00217919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973841|NCT01285531|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33973842|NCT02346968|||COHORT||PROSPECTIVE|||||||
33973843|NCT03718455|NA|SINGLE_GROUP||OTHER||NONE||Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization. The Magseed is a FDA approved device for pre-surgical localization and has been recently approved for use in the axilla and for placement longer than 30 days.||||
33973844|NCT01656889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973845|NCT00601354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973846|NCT00531375|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33973847|NCT04750811|||COHORT||PROSPECTIVE|||||||
33973848|NCT03734965|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33973849|NCT03323554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a prospective, randomised, multicentre, comparative, open label, non-inferiority study in parallel groups of patients presenting stress urinary incontinence following prostate ablation for cancer.|f|f|f|t
33973850|NCT06380946|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33973851|NCT01032395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973852|NCT04455659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973853|NCT06200896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973854|NCT02944643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973855|NCT04574583|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33973856|NCT00003942||||TREATMENT||||||||
33973857|NCT00030108||||TREATMENT||||||||
33973858|NCT03299153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33973859|NCT04222205|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Cluster-Randomized Crossover Trial||||
33973860|NCT01455714|||CASE_CONTROL||PROSPECTIVE|||||||
33973861|NCT02849925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973862|NCT04529148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973863|NCT01172600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33973864|NCT00567281|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|t|f|t
33973865|NCT05621642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973866|NCT04480723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973867|NCT06113796|||COHORT||PROSPECTIVE|||||||
33973868|NCT02410525|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33973869|NCT00219258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33973870|NCT02832609|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33973871|NCT04110522|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33973872|NCT02253277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973873|NCT04040010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled trial|t|t|f|f
33973874|NCT00027469||||TREATMENT||||||||
34072654|NCT05176717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subject, site staff (study coordinator, imaging technician, etc) and Investigator will be completely masked. Physician performing IVT and post-IVT monitoring will know if subject is receiving sham or treatment, but will be masked to the dose level. Pharmacist is the only site staff that will be completely unmasked.|"After primary endpoint is assessed at 12 months, subjects continue the same randomized treatment in the fellow eye. Subjects enrolled to sham treatment will be randomized to receive one of the two ultevursen doses in a parallel design fashion.~Double-masked, randomized, controlled, multiple-dose study. Subjects will be randomized to one of three treatment groups:~1. Group 1: QR-421a 180/60 µg (180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter)~2. Group 2: QR-421a 60/60 µg (60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter; n = 27)~3. Group 3: Sham-procedure (administered on Day 1, Month 3 and every 6 months thereafter; n = 27)"|t|t|t|t
33973875|NCT00669422|||CASE_ONLY||PROSPECTIVE|||||||
33973876|NCT05849610|NA|SEQUENTIAL||TREATMENT||NONE||||||
33973877|NCT04310410|NA|SEQUENTIAL||OTHER||NONE||Prospective case series (n = 6 - 10), stage I and IIA study according to the Innovation, Development, Evaluation, Assessment and Long term evaluation (IDEAL) recommendations. The study will be performed in male and female adult (≥ 18 years) cancer patients capable of giving informed consent and referred for EBRT of painful bone metastases (Numerical Rating Scale (NRS) ≥ 4).||||
33973878|NCT05117892|RANDOMIZED|PARALLEL||OTHER||NONE|Due to the nature of the intervention, it will not be possible to mask allocation to the researchers and the participants. Masking will only be done at analysis stage, meaning that analysis will be done without revealing group allocation (A/B) and by someone who is not knowledgeable about the allocation of clusters to treatment or control. Masking will only be broken after the primary analyses have been completed|"A two-arm cluster-randomized, non-masked, community-based trial will be used to estimate the effectiveness of the MoreMilk intervention. A baseline and an endline survey will be done for each arm with 12 months in between; the same vendors and households will be surveyed at baseline and endline.~The unit of randomization is a cluster of 1 to 5 vendors and the households consuming milk from those vendors. Study clusters will be randomly assigned to one of two arms: (1) Treatment arm: Training, certification, and marketing scheme for milk vendors; (2) Control arm: Delayed intervention (implemented after endline survey)."||||
33973879|NCT04568447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973880|NCT05038813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973881|NCT05933096|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Subjects will ingest three different standardized meals called breakfast 1, breakfast 2, and breakfast 3. They will ingest one meal per day, there is a minimum of 48 hours between measurement days. Every subject will ingest every meal.||||
33973882|NCT06192082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|On the premise of ensuring clinical work and safety, in order to objectively evaluate the research results, the single blind method is reasonably used in this project. Patients are unaware of the anesthesia plan, and preoperative data collection and implementation of the anesthesia plan are carried out by experienced anesthesiologists who have undergone detailed training. Postoperative PACU clinical data and postoperative follow-up were followed up by another anesthesiologist who was unaware of the trial group over the phone.|Using a stratified randomization method, the candidate subjects were divided into two groups: the conscious sedation group (Group A); Intravenous general anesthesia group (Group B); There are 54cases in each group, with a total of 108 cases in both groups. The computer generated random group numbers will be printed and placed in a separate sealed envelope. When accepting subjects who meet the inclusion criteria, the anesthesiologist will assign the newly recruited subjects to the corresponding groups based on the number in the envelope, and the anesthesiologist will be responsible for recording the physiological characteristics of the patients. Another anesthesiologist followed up the patient after the surgery. Both the follow-up doctor and the patient are unaware of the treatment plan. In emergency situations, anesthesiologists can change the anesthesia method to ensure clinical safety and truthfully record it.|f|f|t|t
33973883|NCT01508026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973884|NCT00939445|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33973885|NCT05634187|||COHORT||PROSPECTIVE|||||||
33973886|NCT05433428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973887|NCT01046253|RANDOMIZED|CROSSOVER||||NONE||||||
33973888|NCT02174939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973889|NCT02185781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973890|NCT02062047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973891|NCT05164549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072655|NCT01395810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072656|NCT00905567|RANDOMIZED|CROSSOVER||||NONE||||||
34072657|NCT02317484|||COHORT||PROSPECTIVE|||||||
34072658|NCT04621058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple-blind study, neither the patients, nor the researchers, nor those responsible for the statistical analysis will know the treatment that the patient is undergoing.|Randomized controlled clinical trial.|t|t|t|t
34072659|NCT02028780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072660|NCT00707980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072661|NCT03324477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34072662|NCT00406081|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072663|NCT05605522|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33973892|NCT03486613|RANDOMIZED|CROSSOVER||OTHER||NONE||A randomised, within-participants, open, cross-over design trial||||
33973893|NCT02034799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973894|NCT00192699|||COHORT||RETROSPECTIVE|||||||
33973895|NCT05378906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33973896|NCT01053273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33973897|NCT05987046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973898|NCT02583542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973899|NCT00274209|||COHORT||PROSPECTIVE|||||||
34072664|NCT03549598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072665|NCT04031326|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a single-blind randomized trial with 2 groups.|t|f|f|f
34072666|NCT02182986|||CASE_CONTROL||PROSPECTIVE|||||||
34072667|NCT01153009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072668|NCT00063804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072669|NCT06548646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All clinical staff, including surgeons, and anesthetists except the one giving the block, nurses, investigators, and patients will be blinded to the treatment group assignment||t|f|t|t
34072670|NCT01067898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072671|NCT06088745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072672|NCT02377583|||FAMILY_BASED||PROSPECTIVE|||||||
34072673|NCT05811559|||COHORT||RETROSPECTIVE|||||||
34072674|NCT04026750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34072675|NCT06048393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34072676|NCT03435627|||COHORT||PROSPECTIVE|||||||
34072677|NCT02608242|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072678|NCT03784313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072679|NCT01416077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072680|NCT03709147|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single Institution, open-labeled, triple arm, non-comparative phase II trial||||
34072681|NCT00920504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34072682|NCT01920724|||OTHER||CROSS_SECTIONAL|||||||
34072683|NCT03344146|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34072684|NCT01033630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072685|NCT00736294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072686|NCT01883739|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34072687|NCT03972384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data collectors are blind to condition.|Two groups randomized to treatment (Post-ICU problem solving program) or usual care (no Post-ICU problem solving program).|f|f|f|t
34072688|NCT05201677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072689|NCT05476354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072690|NCT04339205|||COHORT||RETROSPECTIVE|||||||
34072691|NCT02665598|||COHORT||RETROSPECTIVE|||||||
34072692|NCT01348685|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34072693|NCT00588705|||FAMILY_BASED||PROSPECTIVE|||||||
34072694|NCT06165237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34072695|NCT01005784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072696|NCT01481402|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34072697|NCT01236625|||COHORT||PROSPECTIVE|||||||
33973900|NCT00000819||||TREATMENT||||||||
33973901|NCT03486977|||COHORT||PROSPECTIVE|||||||
34072698|NCT00944632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973902|NCT02477566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973903|NCT02386410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33973904|NCT04806009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973905|NCT01126515|||COHORT||PROSPECTIVE|||||||
33973906|NCT00228202|||NATURAL_HISTORY||OTHER|||||||
33973907|NCT05155800|||COHORT||PROSPECTIVE|||||||
33973908|NCT03065361|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973909|NCT00949130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33973910|NCT04833712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973911|NCT02964728|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34072699|NCT03338283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34072700|NCT03948971|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Adult patients aged 18-60 years determined to be candidates for elective cerebral arteriography will be screened for inclusion in this study.||||
34072701|NCT00205998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072702|NCT05977855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072703|NCT05333796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072704|NCT01745614|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34072705|NCT03155347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072706|NCT00041197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072707|NCT04028791|NA|SINGLE_GROUP||SCREENING||NONE||"All participants in each group (AA, AS) will carry out the following 3 sessions:~1. Exercise performed in hot environment (33 °C) with recovery in the same environment~2. Exercise and recovery performed in a control (thermoneutral) environment (22 °C),~3. Exercise performed in a hot environment (33 °C) with recovery in a thermoneutral, environment (22 °C)."||||
34072708|NCT06144203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34072709|NCT03308604|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 1 clinical trial evaluating the safety, tolerability of escalating doses of AGuIX-NP in combination with radiation and cisplatin in patients with locally advanced cervical cancer. Dose escalation will be conducted using the modified toxicity probability interval (mTPI) method. Three dose levels of intravenous AGuIX nanoparticles will be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2).||||
34072710|NCT04883151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34072711|NCT00671801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072712|NCT02778022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study team member who will administer the follow-up study interviews will remain blinded to the group status throughout the duration of the study.||f|f|f|t
34072713|NCT04063735|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized double-blinded placebo study|t|f|t|t
34072714|NCT02831296|||CASE_CONTROL||PROSPECTIVE|||||||
34072715|NCT00817908|||COHORT||PROSPECTIVE|||||||
34072716|NCT01054222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072717|NCT02820870|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072718|NCT01635374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072719|NCT05227443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The current study has 2 groups of patients subjected to 2 different modalities of aerobic exercise training and a control group.||||
34072720|NCT03701412|||COHORT||CROSS_SECTIONAL|||||||
34072721|NCT00617747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072722|NCT03199950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072723|NCT01909843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072724|NCT03327818|||CASE_ONLY||RETROSPECTIVE|||||||
34072725|NCT02968459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072726|NCT03454087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Infusion solutions will be prepared by pharmacy services at the local institution but participants, investigators, care providers, and outcomes assessors will be blinded to group allocation until the end of the study.|Participants will be randomized in a blinded 1:1 fashion to receive either a low level enteral infusion of dextrose solution (intervention group) or an enteral infusion of free water (placebo group)|t|t|t|t
34072727|NCT05521074|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34072728|NCT00472745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072729|NCT00576524|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34072730|NCT05415462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072731|NCT06612190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072732|NCT03444805|||COHORT||PROSPECTIVE|||||||
34072733|NCT01901042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33761649|NCT01439607|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33761650|NCT01465607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33761651|NCT01815528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973912|NCT01150448|NON_RANDOMIZED|||TREATMENT||NONE||||||
33973913|NCT04523558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973914|NCT01241942|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33973915|NCT05710185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973916|NCT02405507|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33973917|NCT03029533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973918|NCT05391399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973919|NCT05465213|||COHORT||PROSPECTIVE|||||||
33973920|NCT05180578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973921|NCT04538040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973922|NCT00642538|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33973923|NCT02767388|||COHORT||PROSPECTIVE|||||||
34072734|NCT03207997|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34072735|NCT00339833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072736|NCT04398602|||COHORT||PROSPECTIVE|||||||
34072737|NCT03255928|||COHORT||PROSPECTIVE|||||||
34072738|NCT00770913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886576|NCT01958645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33886577|NCT00424060|NON_RANDOMIZED|||TREATMENT||NONE||||||
33886578|NCT05926427|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33886579|NCT03776656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886580|NCT03470181|||COHORT||PROSPECTIVE|||||||
33886581|NCT01575795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886582|NCT06151561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886583|NCT06048185|||COHORT||PROSPECTIVE|||||||
33886584|NCT00917956|||COHORT||PROSPECTIVE|||||||
33886585|NCT03209219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886586|NCT02342834|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33886587|NCT05891067|RANDOMIZED|PARALLEL||PREVENTION||NONE||The design of the current study is a cluster Randomized Controlled Trial (RCT) with two conditions: the intervention condition and a waitlist control condition (TAU: treatment-as-usual). Schools are randomized into the intervention or control condition.||||
33886588|NCT03387631|||CASE_ONLY||PROSPECTIVE|||||||
33886589|NCT05612919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a pilot, open, non-randomized, single-center clinical study, whose main objective is to evaluate the safety, feasibility and efficacy of red blood cell from umbilical cord blood (UCB-RBC) transfusion in extremely preterm infants (EPI).~When infants fit criteria for red blood cells transfusion the blood bank of reference will be contacted and availability of compatible UCB-RBC bags within those 6 hours will be checked. When it is possible (available compatible UCB-RBC bag within 6 hours), UCB-RBC will be transfused, otherwise patient will receive RBC from adult donor. Patients who initially received RBC from adult donor will remain in this group if repeated transfusions are needed. In patients who initially received UCB-RBC transfusion, availability of compatible UCB-RBC bags will have to be reviewed again. Only when it is not possible to transfuse UCB-RBC at this repeated occasion, the patient will receive RBC from adult blood donor."||||
33886590|NCT05662267|||COHORT||PROSPECTIVE|||||||
33886591|NCT06074952|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33886592|NCT03530384|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33886593|NCT05641532|NA|SINGLE_GROUP||OTHER||NONE||All participants will undergo one intervention condition remotely delivered using electronic newsletters and one-on-one video coaching. Outcome measures will be assessed at two time points: baseline and post-intervention.||||
33886594|NCT02021409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886595|NCT02611401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33886596|NCT02784093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886597|NCT05231083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Monocebtric randomized unblinded pilote study|f|f|t|f
33886598|NCT04280432|||COHORT||PROSPECTIVE|||||||
33886599|NCT00392184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886600|NCT00611494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886601|NCT01446939|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886602|NCT04067765|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will undergo a validated cue exposure protocol involving exposure to neutral beverage cues followed by exposure to alcohol beverage cues||||
33886603|NCT00055952||||TREATMENT||NONE||||||
33886604|NCT05686109|||OTHER||PROSPECTIVE|||||||
33886605|NCT00325078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886606|NCT03281785|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33886607|NCT03871114|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886608|NCT01268254|||CASE_CONTROL||PROSPECTIVE|||||||
33886609|NCT06461910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886610|NCT03977636|||OTHER||PROSPECTIVE|||||||
33886611|NCT00470080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886612|NCT03980314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886613|NCT02508805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886614|NCT02497001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886615|NCT05307458|||COHORT||PROSPECTIVE|||||||
33886616|NCT02387684|||COHORT||PROSPECTIVE|||||||
33886617|NCT01831128|||COHORT||PROSPECTIVE|||||||
33886618|NCT04093596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886619|NCT02153502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886620|NCT01052441|||||PROSPECTIVE|||||||
33886621|NCT05559567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886622|NCT04038944|||COHORT||PROSPECTIVE|||||||
33886623|NCT01468311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886624|NCT05812677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886625|NCT01232478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33886626|NCT01403909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33886627|NCT05202626|||COHORT||PROSPECTIVE|||||||
33886628|NCT03633188|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886629|NCT00542997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973924|NCT01204320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33973925|NCT00317499|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33973926|NCT06105281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Monocentric Randomised controlled trail in the Vitaz Hospital of Sint-Niklaas. It will take place at the pain clinic where patient with chronic pain come for a treatment or infiltration against chronic pain. There will be two groups of patients, an intervention and an control arm with an equal allocation (1:1). The intervention and control arm will complete the study simultaneous. In each group will count 86 participance at the begin of the trail. This give us the possibility of 35% loss of follow up in each group, so that we can end the study with 64 participants in each group.||||
33973927|NCT04295395|||COHORT||PROSPECTIVE|||||||
33973928|NCT05252806|||CASE_ONLY||PROSPECTIVE|||||||
33973929|NCT04881955|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33973930|NCT01918878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973931|NCT04758650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The trial consists of 7 different patient cohorts that are each investigated using a new diagnostic imaging radiopharmaceutical||||
33973932|NCT06037200|||COHORT||PROSPECTIVE|||||||
33973933|NCT03004521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973934|NCT02391428|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33973935|NCT05460442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973936|NCT02699580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33973937|NCT00995137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973938|NCT04266691|||COHORT||RETROSPECTIVE|||||||
33973939|NCT04170179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973940|NCT05694091|||CASE_CONTROL||PROSPECTIVE|||||||
33973941|NCT03896217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973942|NCT01320618|||COHORT||RETROSPECTIVE|||||||
33973943|NCT05262621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research assistants who assess outcome data, data entry and analysis will be blinded to avoid the risk of assessor bias. The assistants will not participate in any other stage of implementing the program.|Parallel Assignment|f|f|f|t
33973944|NCT04516525|||COHORT||CROSS_SECTIONAL|||||||
33973945|NCT05426720|||CASE_ONLY||PROSPECTIVE|||||||
33973946|NCT00491504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973947|NCT00043836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973948|NCT02206204|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33973949|NCT05116020|||COHORT||PROSPECTIVE|||||||
33973950|NCT04209972|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients does not know if he is on the standard CT scanner, or on the UHR CT scanner|2 groups, 40 patients on one CT scanner, 40 different patients on the other CT scanner.|t|f|f|f
33973951|NCT01346423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973952|NCT05894863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973953|NCT01579474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33973954|NCT00992264|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33973955|NCT02809183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33973956|NCT03847558|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33973957|NCT05819567|NA|SINGLE_GROUP||OTHER||NONE||||||
33973958|NCT00134836|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
33973959|NCT00343980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973960|NCT06013709|||COHORT||RETROSPECTIVE|||||||
33973961|NCT05065970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33973962|NCT00421096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973963|NCT01492270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973964|NCT04482114|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective transversal monocentric study||||
33973965|NCT02165670|||COHORT||PROSPECTIVE|||||||
33973966|NCT06104696|||COHORT||PROSPECTIVE|||||||
33973967|NCT02459054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973968|NCT04138459|||OTHER||OTHER|||||||
33973969|NCT00617110|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33973970|NCT04345978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33973971|NCT03150979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, single-blinded, randomized, clinical trial.|f|f|t|t
33973972|NCT00688285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33973973|NCT00003148||||TREATMENT||||||||
33973974|NCT04586647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973975|NCT01572649|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33973976|NCT03805828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33973977|NCT06366256|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33973978|NCT02261428|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33973979|NCT05816330|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|t|t|f
33973980|NCT01998321|NON_RANDOMIZED|PARALLEL||||NONE||||||
33973981|NCT03345316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33973982|NCT00663559|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33973983|NCT05688930|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||G1: Neuromuscular training program of prevention of functional ankle instability PEMNT; G2: FIFA 11+ Program Group (control).|f|f|t|f
33973984|NCT02408783|||CASE_ONLY||CROSS_SECTIONAL|||||||
33973985|NCT03972982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33973986|NCT03270176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973987|NCT05834712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33973988|NCT00254111|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34072739|NCT06548633|NA|SINGLE_GROUP||TREATMENT||NONE|The participants were blinded to the intervention they were receiving.|The design of the study was a randomised, single-blind, repeated measures, cross-over design, performed in a single-centre environment.||||
33973989|NCT03567720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2, Multi-Cohort, Open-Label, Multi-Center Study||||
33973990|NCT03933657|NA|SINGLE_GROUP||TREATMENT||NONE||The population includes subjects with documented symptomatic peripheral CTOs.||||
33973991|NCT03256799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973992|NCT03318770|||CASE_CONTROL||PROSPECTIVE|||||||
33973993|NCT06547229|||COHORT||OTHER|||||||
33973994|NCT04675710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973995|NCT00780520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33973996|NCT00870922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33973997|NCT02160197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33973998|NCT04876196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded about the two conditions of the study and told that the assigned waiting time for the web-based intervention varies randomly. Therefore, participants in the control group do not know that the other group starts the intervention immediately. However, complete masking of participants is precluded as all subjects are aware of when they get access to the intervention.|Randomized controlled trial with an intervention group and a waiting list control group|f|t|t|t
33973999|NCT03304080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974000|NCT00043706||||TREATMENT||||||||
33974001|NCT04252469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974002|NCT04774081|||COHORT||CROSS_SECTIONAL|||||||
34072740|NCT00222638|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33974003|NCT02553239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974004|NCT03701828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974005|NCT02419677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974006|NCT06172842|||CASE_CONTROL||PROSPECTIVE|||||||
33974007|NCT04208139|||OTHER||OTHER|||||||
33974008|NCT00003938|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33974009|NCT05224921|||COHORT||PROSPECTIVE|||||||
33974010|NCT05621486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974011|NCT05158114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974012|NCT04203680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33974013|NCT01824251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072741|NCT02998151|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||This study was designed as a 4-intervention crossover, with all study participants receiving all possible interventions. These were originally placebo, acamprosate, minocycline, and lovastatin. Midway through the study (n=16) it was determined that acamprosate was undetectable in serum and this intervention was replaced by baclofen. Remaining participants (n=13) received baclofen and 5 participants were re-enrolled to receive baclofen or a second round of placebo, so investigators and participants would remain blinded to drug status during the baclofen visit. The second round of placebo was not analyzed.|t|t|t|t
34072742|NCT02131233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072743|NCT04783233|||CASE_CONTROL||PROSPECTIVE|||||||
34072744|NCT00806208|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886630|NCT05885581|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Randomization will occur once base-line data is collected. Comparisons will be made between the intervention and control groups during the first 6 months of the intervention. The focus is on Latinx Spanish-speaking families; however, all our material is in English and Spanish to accommodate language preferences. Additionally, if a mother or caregiver prefers Purépecha, a language commonly spoken in the region, a Purépecha-speaking team member can translate orally from Spanish to Purépecha as this is an oral and not written language.|"The goal of the research is to provide nutrition education on healthy infant feeding to reduce risk for early childhood obesity. The prevalence of obesity in early life remains unacceptably high, especially among low-income children, most are ethnic minorities. Marked ethnic disparities are evident by two years of age, which suggests that existing interventions are not adequate. Early prevention is critical, especially for low-income children.~This project, which focuses on an-at-risk child population, has great potential to address our nation's growing crisis of childhood obesity, which can dramatically improve the health of millions of low-income children, their families, and their future children."|f|t|f|f
33886631|NCT03131102|||COHORT||PROSPECTIVE|||||||
33886632|NCT06542562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886633|NCT03406871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886634|NCT04297358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886635|NCT02736903|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33886636|NCT00773279|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974014|NCT05493111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the randomized treatment period, the investigator and site staff performing eligibility / efficacy and safety assessments and the subjects will be masked.|Qualified subjects will be enrolled in the study and randomized in a 2:1 ratio within each site to receive 0.003% AR-15512 or AR-15512 vehicle to be administered twice daily (BID) as 1 drop in each eye for 365 days.|t|t|t|t
33974015|NCT00635154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974016|NCT02381821|||COHORT||PROSPECTIVE|||||||
33974017|NCT04862390|||COHORT||PROSPECTIVE|||||||
34072745|NCT03992378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Randomized controlled trial|t|f|f|t
33761652|NCT02850822|||CASE_CONTROL||PROSPECTIVE|||||||
33761653|NCT01960647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761654|NCT03260530|||COHORT||PROSPECTIVE|||||||
33761655|NCT01448694|||CASE_ONLY||PROSPECTIVE|||||||
34072746|NCT01440634|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886637|NCT05617521|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Randomization will be performed using a web-based computer system (Research Randomizer, Geoffrey C. Urbaniak and Scott Plous) by an independent statistician who had no other intervention in the study. An independent operator will print the randomization number and group for each participant (either the AB or SB group) in individual cards, which will be hidden in a locked black box by the same independent operator. Only the nurse, who will fit the abdominal binder to all the patients in a private space, will have access to the cards. Randomized data and cards will be concealed to study coordinators, endoscopists, clinical staff, and participants.~For the participants in the SB group the same binder will be fitted, but once the patient is sedated, it will be loosened by the same nurse. The participants will wear a non-transparent gown over the binder so that it will not be visible to the endoscopists."|Once enrolled, patients will be randomized to either the abdominal binder (AB) group or the sham binder (SB) group in a 1:1 ratio.|t|f|t|f
33886638|NCT01664793|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33886639|NCT03396991|||OTHER||CROSS_SECTIONAL|||||||
33886640|NCT00663741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886641|NCT02978482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886642|NCT04326634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072747|NCT01204086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886643|NCT05032950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a Phase I, crossover, 3-treatment, 6-sequence study to evaluate the effect of PF-07321332/ritonavir and ritonavir on the PK of midazolam in healthy participants. Midazolam is a substrate for CYP3A4. A total of approximately 12 healthy male and/or female participants will be enrolled into the study.||||
33886644|NCT00196417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886645|NCT04590001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886646|NCT06120257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886647|NCT05777733|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||N-acetylcystein in dose 10mg /kg single oral dose will be given for 6 months||||
33886648|NCT00388050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886649|NCT05340205|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886650|NCT05671380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33886651|NCT00177515|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
33886652|NCT00441792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886653|NCT04401033|||COHORT||PROSPECTIVE|||||||
33886654|NCT06011135|||OTHER||OTHER|||||||
33886655|NCT01705704|||COHORT||RETROSPECTIVE|||||||
33886656|NCT01325103|NA|SINGLE_GROUP||TREATMENT||NONE||Mesenchymal stem cell transplantation.||||
33886657|NCT06249750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886658|NCT02731742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886659|NCT02834949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886660|NCT01501591|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33886661|NCT02409511|||CASE_ONLY||PROSPECTIVE|||||||
33886662|NCT02949830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761656|NCT04202926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886663|NCT02085291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886664|NCT02356809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886665|NCT01944085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33974018|NCT03083483|RANDOMIZED|PARALLEL||OTHER||DOUBLE|For the tDCS portion of the protocol, the subject and investigator will be blinded to active vs sham. The configuration and order of FLS tasks will be known to both.|Subjects are randomized into SMA or bilateral M1 tDCS configurations. They are further randomized into active or sham tDCS.|t|f|t|f
33974019|NCT02097446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34072748|NCT00178217|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33886666|NCT00887861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886667|NCT00706017|||COHORT||PROSPECTIVE|||||||
33886668|NCT03931304|||CASE_CONTROL||RETROSPECTIVE|||||||
33886669|NCT03417856|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886670|NCT00546975|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33886671|NCT00006227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886672|NCT02603744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886673|NCT05207228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886674|NCT02844387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33886675|NCT02088385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974020|NCT01387282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974021|NCT04190654|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974022|NCT05053698|||COHORT||RETROSPECTIVE|||||||
33974023|NCT02460848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974024|NCT02304874|NA|SINGLE_GROUP||OTHER||NONE||||||
33974025|NCT06109558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072749|NCT02693262|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34072750|NCT04979416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants do not know if they are in control or treatment or the type of treatment.||t|f|f|f
34072751|NCT06612502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072752|NCT01343979|||CASE_CONTROL||RETROSPECTIVE|||||||
33886676|NCT04926935|||COHORT||PROSPECTIVE|||||||
33886677|NCT05193565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886678|NCT06007989|||OTHER||CROSS_SECTIONAL|||||||
33886679|NCT01635725|||CASE_ONLY||PROSPECTIVE|||||||
33886680|NCT04282005|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study's population includes patients with severe obesity and non-alcoholic fatty liver disease who are eligible for bariatric surgery and are on the waiting list for either Roux en Y gastric bypass or sleeve gastrectomy at King's College Hospital.~Main outcome measures will include several markers of inflammation and liver fibrosis assessed in plasma samples and Fine Needle Aspiration of the liver. Secondary outcome measures will include novel markers of cardiovascular risk, bile acids as well as standard markers of metabolic disease."||||
33886681|NCT05756725|NA|SINGLE_GROUP||SCREENING||NONE||||||
33886682|NCT01859377|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886683|NCT01286857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886684|NCT05488860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparison is designed in each participant. For each individual, two similar hypertrophic scar/keloid or a single hypertrophic scar/keloid is randomly assigned into traditional injection group or piezoelectric divied microneedling group.|f|f|f|t
33886685|NCT03992144|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33886686|NCT00397332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886687|NCT01568203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33886688|NCT05202145|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This will be a 3-part study with each part being an open-label, fixed-sequence study in healthy adult participants. The 3 parts of the study may be conducted concurrently.||||
33886689|NCT02367521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886690|NCT00935389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886691|NCT05949307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886692|NCT03239431|||COHORT||PROSPECTIVE|||||||
33761657|NCT02093455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886693|NCT05708807|||CASE_ONLY||PROSPECTIVE|||||||
33886694|NCT01445535|NA|SEQUENTIAL||TREATMENT||NONE||||||
33886695|NCT04905745|||CASE_ONLY||PROSPECTIVE|||||||
33886696|NCT00002948||||TREATMENT||||||||
33886697|NCT03623919|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761658|NCT03185559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886698|NCT02292212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886699|NCT06484894|||COHORT||PROSPECTIVE|||||||
33761659|NCT01264380|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761660|NCT05285384|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761661|NCT02209012|||CASE_CONTROL||PROSPECTIVE|||||||
33761662|NCT00327184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761663|NCT01928316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761664|NCT02678325|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33761665|NCT00461292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761666|NCT04798443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886700|NCT04941196|RANDOMIZED|CROSSOVER||OTHER||NONE||single centre, cross over, single dose, two period, randomized, open label Bioequivalence Study||||
33886701|NCT00005979|RANDOMIZED|||TREATMENT||||||||
33886702|NCT05925205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Firstly, the research assistant, another qualified physical therapist, performing the assessment process, pre and post-treatment, will be blinded regarding the patients allocation into the three treatment groups. Secondly, the patients themselves will be blinded regarding which treatment group they will be allocated into. So the research assistant won't know the randomization results, and the main investigator won't know the assessment results which will make it a double-blinded study.|Randomized controlled trial|t|f|t|f
33886703|NCT00599417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886704|NCT00924157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33886705|NCT06250140|||COHORT||RETROSPECTIVE|||||||
33886706|NCT04725279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886707|NCT04390867|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participant and Outcomes Assessor blinded to DBS pattern in use|Random order of presentation of all three TOPS and Standard DBS in each participant|t|f|f|t
33886708|NCT02152345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886709|NCT01206855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33886710|NCT05116774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886711|NCT03665038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886712|NCT01217541|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33886713|NCT04214847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Coin test to choice the participants for both groups and reduce bias. Single surgeon ,highly expert in glaucoma to minimize unnecessary postoperative result changes.|comparing clinical outcome variables (IOP, number of glaucoma medications, visual acuity, and complications) after using S2 and FP7 models of Ahmed Glaucoma Valves.|t|f|t|f
33886714|NCT01361516|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33886715|NCT04758962|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33886716|NCT01032148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886717|NCT01231555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886718|NCT03543280|||COHORT||RETROSPECTIVE|||||||
33974026|NCT04866589|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The analyst will receive a dataset in a format which makes it impossible for him/her to know which of the two arms in the dataset represents intervention or control.|"The team members from the Stovner district-administration will send a numbered list to Norwegian Institute of Public Health-team, with the names of the stores. The ordering of the stores will define the numbers used to represent each store in the randomisation process. Using Stata software, we will carry out 13 separate and independent randomisations, each assigning the intervention to half the included stores. An additional randomisation to the treatment or control group will be carried out for a marginal store each day in the event of an odd number of stores.~Unless it proves too logistically cumbersome, we will also randomise the corona hosts, i.e. the store they are allocated to will be decided through randomisation."||||
33974027|NCT02020603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886719|NCT00428740|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33886720|NCT00844233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886721|NCT00384020|||CASE_ONLY|||||||||
33886722|NCT04233515|||COHORT||RETROSPECTIVE|||||||
33886723|NCT05429086|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33886724|NCT00354601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886725|NCT02908100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886726|NCT03144648|||CASE_CONTROL||OTHER|||||||
33886727|NCT00427362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886728|NCT00168610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33886729|NCT03118947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886730|NCT01277640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33886731|NCT00529737|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33886732|NCT05845359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33886733|NCT00956943|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33886734|NCT02222714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886735|NCT05357378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886736|NCT00963950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886737|NCT02787772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33886738|NCT00001398||||TREATMENT||||||||
33886739|NCT03118193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072753|NCT04407702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All volunteers and the evaluator of the degree of sensitivity will be blinded to the allocation. The researcher in charge of applying the products will not be blinded due to the different forms of clinical manipulation of the products.||t|f|f|t
34072754|NCT02455453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34072755|NCT02010905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072756|NCT04152083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886740|NCT00000573|RANDOMIZED|||||||||||
33886741|NCT05959889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|prospective, double blind randomized (1:1) controlled trial|a prospective, randomized (1:1) controlled trial that will be carried out on 50 patients who are candidate to evaluate the effect of montelukast on doxorubicin induced cardiotoxicity after 4 cycles of AC. Patients will be randomly allocated into two equal groups (25 patients each); group (A) for controlled (placebo), and group (B) for montelukast|t|f|t|f
33886742|NCT05299073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886743|NCT03642145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886744|NCT02104414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33886745|NCT01285427|||CASE_ONLY|||||||||
33886746|NCT06151652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33886747|NCT01629797|NA|SINGLE_GROUP||||NONE||||||
33886748|NCT01868984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886749|NCT05107167|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33886750|NCT02849756|||COHORT||PROSPECTIVE|||||||
33886751|NCT03644160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-centre randomised pilot study|f|f|t|t
33886752|NCT05504200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886753|NCT04915196|||COHORT||PROSPECTIVE|||||||
33886754|NCT06287879|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886755|NCT04134494|NA|SINGLE_GROUP||TREATMENT||NONE|No masking will be used as all patients will receive the treatment.|The objective was to enroll a single group of 30 patients with biopsy-proven Lichen sclerosus will be treated on a monthly basis for 3 months. Biopsy to be repeated at month #6. The biopsy from before treatment will be compared with biopsies after treatment. Enrollment ended early.||||
33886756|NCT05684380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886757|NCT01265836|||COHORT||PROSPECTIVE|||||||
33886758|NCT01299766|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33886759|NCT03308188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886760|NCT04152382|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33886761|NCT00854347|||COHORT||PROSPECTIVE|||||||
34072757|NCT05547880|||COHORT||PROSPECTIVE|||||||
34072758|NCT04235504|RANDOMIZED|PARALLEL||TREATMENT||NONE||"There will be 2 Cohort for this study:~1. Cohort A: Subjects on MDI + FGM will be randomized into: Treatment Arm (AHCL) and Control Arm (MDI+ FGM)~2. Cohort B: Subjects on MDI + Real-Time CGM will be randomized into: Treatment Arm (AHCL) and Control Arm (MDI+ CGM) (exploratory analysis)"||||
34072759|NCT01540981|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34072760|NCT00030628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072761|NCT05555576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Double-blind randomized placebo-controlled trial|t|t|t|f
34072762|NCT01960166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886762|NCT04031456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886763|NCT04058522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Off site randomisation|Single blind randomised trial|f|f|t|t
33886764|NCT02680782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886765|NCT02421887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886766|NCT01151722|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33886767|NCT04591054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||single-center, double-arm, patient and assessor blinded|t|f|f|t
33886768|NCT03029013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886769|NCT04573101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participants is exposed to 24 different audio recordings and asked to select emotion that best describes feeling after each auditory stimulus. The 24 audio stimuli are distributed in a random manner by computer. In addition, emotional assessment is performed before and after the session. This is a total of 26 arms.||||
33886770|NCT03860948|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886771|NCT04023656|||COHORT||PROSPECTIVE|||||||
33886772|NCT02736747|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33886773|NCT01349647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886774|NCT03656302|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886775|NCT01451619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886776|NCT05792436|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33886777|NCT02859155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886778|NCT02669979|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33886779|NCT04831060|||COHORT||PROSPECTIVE|||||||
33886780|NCT06381661|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will concern 3 specific domains (immunomodulation, coagulation, and corticosteroids); in each domain, patients will be randomly allocated between control (standard of care) and 1-4 experimental treatments using parallell arms||||
33886781|NCT04075331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886782|NCT02813772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33886783|NCT05257512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886784|NCT05198713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886785|NCT00199979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886786|NCT02172157|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886787|NCT00971126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886788|NCT00002550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886789|NCT03463070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33886790|NCT02500693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886791|NCT02502760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33886792|NCT06381830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886793|NCT04152876|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33886794|NCT03089307|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients (n=44) will be randomised into 2 groups to receive low intensity extracorporeal shock wave treatment for a 6 weeks period utilising the Dornier Aries ED device.Group A (n=21) will receive 6 sessions (one session per week) and group B (n=21) will receive 12 sessions (2 sessions per week).||||
33886795|NCT03426176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33974028|NCT04411459|||COHORT||PROSPECTIVE|||||||
33974029|NCT04769466|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974030|NCT01206842|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33974031|NCT00004143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974032|NCT05311852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind randomized placebo-controlled study|Participants are randomized and assigned to one of two or more groups in parallel for the duration of the study|t|f|t|f
33974033|NCT03027661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974034|NCT00246974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974035|NCT05055921|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Multi-Pulse Therapy as delivered from the Cardialen External Stimulation System (CESS)||||
33974036|NCT06546787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34072763|NCT00000332||||TREATMENT||||||||
33886796|NCT05238038|||COHORT||PROSPECTIVE|||||||
33886797|NCT03263559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072764|NCT03413475|||OTHER||PROSPECTIVE|||||||
34072765|NCT04826471|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open label, uncontrolled, single arm, post-market clinical folow-up study||||
34072766|NCT03767426|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Independent group comparison||||
33886798|NCT00181077|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886799|NCT05085509|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886800|NCT05698667|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974037|NCT03985592|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||The multi-component intervention aims to evaluate the feasibility as well as success of imparting educational knowledge and applied techniques to ICU clinicians (i.e., physicians, RNs, social workers) on how to support bereaved FMs. The overall purpose of the intervention is to optimize preemptive strategies in reducing SGRs in FMs. To determine the effectiveness of this intervention a series of standardized and validated measures of wellbeing will be given to FMs after the typical bereavement period ends. The intervention is designed to be implementable in any ICU setting across Canada and potentially abroad.||||
33886801|NCT05560737|||COHORT||PROSPECTIVE|||||||
33886802|NCT03110055|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center, open label, prospective pilot study. The study will enroll 20 HCV genotype 1 cirrhotic patients with advanced and un-resectable HCC who are eligible for TACE. The patients will receive Grazoprevir/Elbasvir anti-viral treatment in accordance with established guidelines together with regular TACE treatments. Follow up will be for up to 24 months from TACE initiation.||||
33886803|NCT01404663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886804|NCT01196702|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886805|NCT03566329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33886806|NCT04925310|||COHORT||PROSPECTIVE|||||||
33886807|NCT03998657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974038|NCT01773564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974039|NCT05234437|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label multicentre study||||
33974040|NCT05267756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974041|NCT00342576|||COHORT||PROSPECTIVE|||||||
33974042|NCT04828161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Double Blind: two or more parties are unaware of the intervention assignment~* Masked roles are: Subject, Caregiver, Investigator or Outcomes Assessor."|"* Parallel: participants are assigned to one of two or more groups in parallel for the duration of the study.~* 4 Arms under Phase 2 and 2 Arms under Phase 3"|t|t|t|t
33974043|NCT01132456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974044|NCT03640156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33974045|NCT04592354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded active and placebo groups|Double Blinded placebo controlled comparison study|t|t|t|t
33974046|NCT04816097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34072767|NCT04958408|||COHORT||RETROSPECTIVE|||||||
34072768|NCT00585338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072769|NCT03258645|||CASE_ONLY||RETROSPECTIVE|||||||
33886808|NCT00936624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886809|NCT02440581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886810|NCT03402776|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized, open-label, prospective, multicenter study||||
33974047|NCT06348472|||CASE_ONLY||PROSPECTIVE|||||||
33974048|NCT00191009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33974049|NCT06362993|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33974050|NCT03565211|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label trial|||||
33974051|NCT02234297|NA|SINGLE_GROUP||||NONE||||||
33974052|NCT01758302|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974053|NCT01011322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974054|NCT01880333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974055|NCT00434161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33974056|NCT04782830|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and outcome assessor will be blinded to the study medications|placebo-controlled, double-blind, randomized crossover|t|f|f|t
34072770|NCT01185002|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34072771|NCT01912794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072772|NCT02302040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886811|NCT01911026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33974057|NCT01385410|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33974058|NCT03495648|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072773|NCT02329782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072774|NCT03814902|NA|SINGLE_GROUP||OTHER||NONE||||||
34072775|NCT05276206|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33974059|NCT03231839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974060|NCT01512381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974061|NCT01442909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974062|NCT00720850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974063|NCT01683617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974064|NCT03731351|||CASE_ONLY||PROSPECTIVE|||||||
34072776|NCT06218771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072777|NCT04665973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33886812|NCT05062057|||COHORT||PROSPECTIVE|||||||
33886813|NCT03222427|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Open label|||||
33886814|NCT03334084|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33886815|NCT01976806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886816|NCT00102180|||CASE_CONTROL||RETROSPECTIVE|||||||
33886817|NCT02005185|||OTHER||PROSPECTIVE|||||||
33886818|NCT01391247|||||PROSPECTIVE|||||||
33974065|NCT02736227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974066|NCT01101009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886819|NCT03585855|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||comparison with historic control||||
33886820|NCT01670266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886821|NCT05774327|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial: Two parallel treatment groups; participants were randomly allocated to Group 1 \[Foam Roller+Foot Core Exercises\] and Group 2 \[Foot Core Exercises\]||||
33886822|NCT00895830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886823|NCT04317651|||COHORT||RETROSPECTIVE|||||||
33886824|NCT01439438|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33886825|NCT01936220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974067|NCT02627027|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974068|NCT00992069|NA|CROSSOVER||TREATMENT||NONE||||||
33974069|NCT00484523|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974070|NCT04147754|||COHORT||PROSPECTIVE|||||||
33974071|NCT01889511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33974072|NCT03471962|||CASE_ONLY||PROSPECTIVE|||||||
33974073|NCT02307383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974074|NCT00221897|||COHORT||PROSPECTIVE|||||||
33974075|NCT00822198|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974076|NCT00429923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974077|NCT02123992|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974078|NCT03294356|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072778|NCT03467542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072779|NCT01610869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072780|NCT05822193|||COHORT||RETROSPECTIVE|||||||
34072781|NCT04142905|||OTHER||RETROSPECTIVE|||||||
33886826|NCT04325477||SEQUENTIAL||TREATMENT||NONE||A prospective one-arm study with subjects serving as their own control.||||
33886827|NCT05456425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, Double-Masked, Randomized, Vehicle-Controlled Parallel Comparison with dosing twice-daily in eye(s) with pterygium|t|t|t|t
33886828|NCT01977963|||COHORT||PROSPECTIVE|||||||
33974079|NCT02006485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974080|NCT06177678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974081|NCT05813782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974082|NCT02784106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974083|NCT04352413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974084|NCT03167099|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both investigators and participants are aware of the assignment. There is no masking; only randomization.|||||
33974085|NCT02277652|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33974086|NCT01813461|NA|SINGLE_GROUP||||NONE||||||
33974087|NCT04497480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974088|NCT05374863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study, where evaluators and participants will not be aware of the details of the research. All outcomes will be measured by blinded raters as they will not be involved in the randomization process and will not receive details about interventions. All participants will be blinded as to whether or not the NMES will be performed, as both the intervention group and the control group will have the electrodes positioned and will remain there for the same time.|This is a controlled, randomized, double-blind clinical trial with an intention-to-treat analysis.|t|f|f|t
34072782|NCT06007495|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Randomized Cross-Over study|f|f|f|t
34072783|NCT05174156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072784|NCT00167518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34072785|NCT01240902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072786|NCT00256932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886829|NCT01756274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886830|NCT06547957|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33886831|NCT05831982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the vulnerable group masking was not possible for care provider or baseline tester, but randomization will take place after baseline tests have been performed. Tester at 15 and 26 weeks will be masked.|Randomized controlled trial|f|f|f|t
33886832|NCT03681444|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33974089|NCT02636127|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974090|NCT00508586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974091|NCT01966042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974092|NCT04228510|||COHORT||PROSPECTIVE|||||||
33886833|NCT05190952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patient and the attending anesthesiologist will be blinded to the drugs injected (a randomized, controlled, double blind study)|a randomized, controlled, double blind study|t|f|t|f
33974093|NCT05713474|||OTHER||OTHER|||||||
33974094|NCT04272021|NA|SINGLE_GROUP||OTHER||NONE||||||
33974095|NCT06053099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886834|NCT04698629|||CASE_ONLY||PROSPECTIVE|||||||
33886835|NCT06377904|||COHORT||OTHER|||||||
33974096|NCT06084507|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974097|NCT06483152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974098|NCT06464809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants who met the inclusion criteria were randomized into one of two treatment groups: KT group and TENS group. Participants were blinded to the treatments used in the other group.|This was a prospective, randomized-controlled trial.|t|f|f|f
33974099|NCT00553540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974100|NCT05150509|||CASE_CONTROL||RETROSPECTIVE|||||||
33974101|NCT01868152|||COHORT|||||||||
33974102|NCT03044158|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974103|NCT05147454|||CASE_CROSSOVER||PROSPECTIVE|||||||
33974104|NCT05266456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Triple (Participant, Investigator, Outcomes Assessor)||t|t|t|t
33974105|NCT05822518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974106|NCT00427986|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974107|NCT01215942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072787|NCT03153241|||COHORT||PROSPECTIVE|||||||
34072788|NCT00652145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072789|NCT04847583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072790|NCT04529239|||COHORT||PROSPECTIVE|||||||
34072791|NCT02928523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072792|NCT01952899|||COHORT||PROSPECTIVE|||||||
33886836|NCT01348802|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33886837|NCT02083458|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33886838|NCT04905667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind (Participant, Investigator)||t|f|t|f
33886839|NCT03280251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33886840|NCT01222650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886841|NCT04674462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886842|NCT06370416|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33886843|NCT02664116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974108|NCT03051256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974109|NCT02334059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974110|NCT03029520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974111|NCT01304446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974112|NCT03872648|||COHORT||PROSPECTIVE|||||||
33974113|NCT04753736|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974114|NCT05559411|||COHORT||PROSPECTIVE|||||||
33974115|NCT02752945|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33974116|NCT00916890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974117|NCT01226277|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886844|NCT03417050|||COHORT||RETROSPECTIVE|||||||
33886845|NCT03315351|NA|SINGLE_GROUP||OTHER||NONE||||||
33886846|NCT01076348|||COHORT||OTHER|||||||
33886847|NCT00836550|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33886848|NCT06298071|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||According to the sequence from low-dose group to high-dose group, there are 12 participants in each group, totaling 36 participants.||||
33974118|NCT05263583|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose range findings study||||
33974119|NCT05747378|||CASE_CROSSOVER||PROSPECTIVE|||||||
33974120|NCT01255371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974121|NCT04272359|||COHORT||PROSPECTIVE|||||||
33974122|NCT01144910|||COHORT||PROSPECTIVE|||||||
33974123|NCT00041574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974124|NCT06126796|||COHORT||PROSPECTIVE|||||||
33974125|NCT05178355|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33974126|NCT04459195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34072793|NCT04849117|||COHORT||RETROSPECTIVE|||||||
34072794|NCT03464084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34072795|NCT04747249|NA|SINGLE_GROUP||TREATMENT||NONE||Psychological support||||
34072796|NCT00753129|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34072797|NCT02105194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072798|NCT04880668|RANDOMIZED|PARALLEL||OTHER||NONE|Unable to blind due to the nature of the intervention|Randomized controlled trial, two study arms||||
34072799|NCT01380652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072800|NCT06192238|||COHORT||OTHER|||||||
34072801|NCT06361186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072802|NCT01275989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33974127|NCT01701128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33974128|NCT03175120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974129|NCT05205850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974130|NCT06486597|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974131|NCT06543524|||COHORT||PROSPECTIVE|||||||
33974132|NCT00296114|||CASE_CONTROL||PROSPECTIVE|||||||
33974133|NCT05728047|||COHORT||CROSS_SECTIONAL|||||||
33974134|NCT00444795|||CASE_ONLY||PROSPECTIVE|||||||
33974135|NCT00760383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974136|NCT02059993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33974137|NCT03309397|||COHORT||PROSPECTIVE|||||||
33974138|NCT04223505|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974139|NCT01968733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974140|NCT02495961|||COHORT||PROSPECTIVE|||||||
33974141|NCT04247490|||COHORT||RETROSPECTIVE|||||||
33974142|NCT06094868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974143|NCT04342923|||COHORT||PROSPECTIVE|||||||
33974144|NCT01832805|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33974145|NCT03641898|||CASE_ONLY||PROSPECTIVE|||||||
33974146|NCT01059071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974147|NCT02004379|||COHORT|||||||||
33974148|NCT03940430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072803|NCT01816932|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072804|NCT02589509|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34072805|NCT04221360|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072806|NCT06517745|||CASE_CONTROL||RETROSPECTIVE|||||||
34072807|NCT05490251|||COHORT||PROSPECTIVE|||||||
34072808|NCT02412176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|RV lead in the septum|RV lead in the apex|t|f|f|f
34072809|NCT05497765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|t|f
34072810|NCT06612489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The intervention product consists of a serious game designed to facilitate digitalized distraction therapy, integrated with a wearable device that monitors the user's real-time immersion level. The serious game is presented as a mobile game where users must consistently identify target elements following a specific rhythm to achieve a distraction effect. The game theme, centered around fishing and music, was chosen to align with the hobbies of the target population. Design elements were carefully selected based on age-friendly design criteria from previous research.The wearable device features the TGAM chip as its central component, which captures electroencephalogram (EEG) signals from the patients and processes them to derive an immersion level score.|f|f|t|f
34072811|NCT01977768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34072812|NCT05297461|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072813|NCT01121939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761667|NCT04604301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The final thickness of the restoration was not identified until before treatment started The final cement was not identified in the treatment process until the crown was milled.||f|t|f|f
33761668|NCT00008021||||TREATMENT||NONE||||||
33761669|NCT01092481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072814|NCT05161026|NA|SINGLE_GROUP||OTHER||NONE||||||
33761670|NCT04305002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761671|NCT00161070|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761672|NCT04680325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761673|NCT03952221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33761674|NCT05946980|RANDOMIZED|PARALLEL||PREVENTION||NONE|Lab technicians will be masked for hand-rinse sample processing and analysis.|Cluster randomized multi-center controlled trial In each country there is an intervention and control group. The control group will not receive anything until the end of data collection. Afterwards they will receive the intervention as well, improved if needed.||||
33761675|NCT04834700|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33761676|NCT06245122|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33761677|NCT01262326|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33761678|NCT00235599|||DEFINED_POPULATION||OTHER|||||||
34072815|NCT05053971|NA|SEQUENTIAL||TREATMENT||NONE||Patients are assigned to ZEN003694 or entinostat in the Phase II Run-In period based on the order to which they are enrolled to the study||||
34072816|NCT02357056|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34072817|NCT02190214|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33761679|NCT05373797|||OTHER||OTHER|||||||
33761680|NCT06266039|||CASE_ONLY||PROSPECTIVE|||||||
33761681|NCT02575898|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761682|NCT00336141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886849|NCT04957186|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"There will be two groups in this study : one Focus group consisting of 10 patients who have undergone breast cancer surgery (tumorectomy, mastectomy, lymph node dissection), and one group of 10 caregivers consisting of 3 surgeons, 3 algologists, 3 oncologists and one study coordinator."||||
33886850|NCT04479904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886851|NCT00397683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33886852|NCT04574596|||CASE_CONTROL||PROSPECTIVE|||||||
33886853|NCT02820467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886854|NCT03079479|||OTHER||CROSS_SECTIONAL|||||||
33761683|NCT03207139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761684|NCT04808375|||OTHER||RETROSPECTIVE|||||||
33761685|NCT05581680|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886855|NCT05680233|NA|SEQUENTIAL||TREATMENT||NONE|All subjects will be blinded to IP dose/level.|Single ascending dose (SAD) sequential group study of a sc dose of OA-235i in five (5) planned dose cohorts with 3 subjects/cohort administering a bolus injection at escalating dose levels from 4 to 40 mg. One (1) planned multiple dose (MD) expansion dose cohort with 8 NAFLD/NASH subjects will be enrolled for a 7-day dosing regimen at a dose level to be determined from the SAD portion of the study.||||
33886856|NCT02022605|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33886857|NCT01086436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886858|NCT05667324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886859|NCT01225562|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886860|NCT00964431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974149|NCT03141099|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Target blood pressure will be blinded by offsetting the blood pressure measurering module.~The oxygenation- and fever control interventions will be open label. Further life-sustaining treatment will be delivered according to standard procedures and withdrawal of active intensive care will be at the discretion of the treating physicians, but must be delayed for at least 108 hours post ROSC. The steering group and the management group will be blinded to the type of intervention during the entire trial period, when handling the trial database.~Follow-up at 30 days (phone call) and 90 days (meeting) will be performed by personnel unaware of the allocation group, treatment complications at the ICU, if they occurred or specialized neurological rehabilitation."|"Multicenter, randomized trial in 2\*2 factorial design allocating comatose OHCA patients to one of two target blood pressures (double blind) and restrictive vs. liberal oxygenation (open label) during ICU stay with blinded outcome evaluation.~Sample size: 800 patients. Patient will be allocated 1:1; for all interventions, no interaction with regards to outcome is expected."|t|t|t|t
33974150|NCT03616834|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert, and then initiate Tomivosertib (eFT-508) at 200 mg twice daily (bid) 7 days prior to their next scheduled anti-PD-1/anti-PD-L1 therapy.||||
33974151|NCT05174143|||COHORT||PROSPECTIVE|||||||
33974152|NCT00346086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33974153|NCT04648475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974154|NCT00000563|RANDOMIZED|||PREVENTION||DOUBLE||||||
33974155|NCT06244303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33974156|NCT01727479|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33974157|NCT01851070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974158|NCT00227825|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974159|NCT04674098|||COHORT||PROSPECTIVE|||||||
33886861|NCT04428047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886862|NCT02410694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886863|NCT02870725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886864|NCT01047202|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33886865|NCT00364715|||CASE_CONTROL||OTHER|||||||
33886866|NCT03684135|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33886867|NCT04435457|||COHORT||CROSS_SECTIONAL|||||||
33886868|NCT03544112|||COHORT||PROSPECTIVE|||||||
33886869|NCT01709331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886870|NCT03885778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974160|NCT03155958|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33974161|NCT00450996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974162|NCT02006706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974163|NCT02634060|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974164|NCT02708277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974165|NCT00888810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974166|NCT03586336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974167|NCT03819686|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33974168|NCT04426409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33974169|NCT03265496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886871|NCT02574104|||COHORT||PROSPECTIVE|||||||
33974170|NCT00118300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974171|NCT00962000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974172|NCT00141752|||COHORT||PROSPECTIVE|||||||
33974173|NCT06143735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974174|NCT01598285|||CASE_ONLY||RETROSPECTIVE|||||||
33974175|NCT00359853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33974176|NCT00788619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974177|NCT02249884|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33974178|NCT05879328|||COHORT||PROSPECTIVE|||||||
33974179|NCT06100237|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33974180|NCT06203899|RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-blinded cluster-randomized controlled trial with two parallel conditions (experimental and control)||||
33974181|NCT01390883|||||PROSPECTIVE|||||||
33974182|NCT01058161|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974183|NCT04964999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized controlled study - Participants will be randomly allocated to the exercise or control group.||||
33974184|NCT03314766|||COHORT||PROSPECTIVE|||||||
33886872|NCT02241837|||CASE_ONLY||PROSPECTIVE|||||||
33886873|NCT02863341|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33886874|NCT03684109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886875|NCT02631707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886876|NCT03199859|||COHORT||PROSPECTIVE|||||||
33886877|NCT04948008|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||The first phase of this research is the randomized design of open labels. The second stage is an open, single-arm design.|t|t|t|f
33886878|NCT03623724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The RCT is composed by an experimental condition and a control condition. In the experimental condition, patients will receive a treatment that integrates face-to-face cognitive-behavioral sessions with online sessions delivered through Moodbuster system (bCBT). In the control condition, patients will receive TAU that consists in routine care that they usually receive in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked, as well as medicine intake. One-hundred patients will be recruited and randomized in two conditions: 50 for bCBT condition and 50 for TAU condition. New cases of Major Depression signaled by GPs or other healthprofessionals will be invited to participate in the RCT. Once obtained the signed informed consent, the patients will be randomized at an individual level. The allocation will be performed by an independent researcher not involved in data collection using an automated computer-based random intergenerator.|f|f|f|t
33886879|NCT01292967|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33886880|NCT02109159|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33886881|NCT01634932|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33886882|NCT02427113|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33886883|NCT02107755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886884|NCT02066714|||CASE_CONTROL||PROSPECTIVE|||||||
33886885|NCT01109940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886886|NCT00234039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886887|NCT05492955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974185|NCT00673491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33974186|NCT01033162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974187|NCT04383990|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label Randomized||||
33974188|NCT00149292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and patients were blinded to each patient's treatment. Only a pharmacist or designated person at the study site were unblinded to each patient's treatment.||t|t|t|f
33974189|NCT03777410|||COHORT||PROSPECTIVE|||||||
33974190|NCT00208156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974191|NCT06223997|||OTHER||PROSPECTIVE|||||||
33974192|NCT04174924|||CASE_CONTROL||PROSPECTIVE|||||||
34072818|NCT05598749|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34072819|NCT00027547||||TREATMENT||NONE||||||
34072820|NCT01462864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072821|NCT03126461||SEQUENTIAL||TREATMENT||NONE||||||
34072822|NCT00297661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34072823|NCT00404209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072824|NCT01684852|||CASE_CONTROL||PROSPECTIVE|||||||
34072825|NCT02959203|||COHORT||PROSPECTIVE|||||||
34072826|NCT00691288|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34072827|NCT04262063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients, their parents and the statistician will be blinded ,|parallel group two arms superiority trial with 1:1 allocation ratio|t|f|f|f
34072828|NCT00656175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072829|NCT05739071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomly assigned into the two groups with equal number. The JING SI HERBAL TEA and placebo have the same outer packaging. One dedicated researcher will be responsible for random allocation and administration, neither the patients nor the attending physicians (responsible for recording symptoms) knows the correct grouping.|Double Blind (patients and attending physicians), parallel design Experimental group: JING SI HERBAL TEA, twice a day, every time 1 sachet for 3 days after each intravesical installation Control group: Placebo, twice a day, every time 1 sachet for 3 days after each intravesical installation|t|t|f|f
34072830|NCT02943798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072831|NCT03984214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072832|NCT05482503|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34072833|NCT00964379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072834|NCT00420628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761686|NCT01568346|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761687|NCT04508452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072835|NCT01863615|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34072836|NCT04690634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34072837|NCT05767593|||CASE_CONTROL||PROSPECTIVE|||||||
34072838|NCT03430908|||COHORT||PROSPECTIVE|||||||
33761688|NCT01175889|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33761689|NCT02768662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886888|NCT04665557|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking not possible for participants within design, but outcome assessors will not know what condition participants are assigned to.|Two-arm parallel clustered randomised controlled trial|f|f|f|t
33886889|NCT03072160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886890|NCT01901835|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33886891|NCT00050102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886892|NCT06549621|||COHORT||RETROSPECTIVE|||||||
33886893|NCT02288884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886894|NCT03002974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761690|NCT05434845|RANDOMIZED|PARALLEL||SCREENING||NONE||"Divide urine into 4 different specimen cups with 20 mLs of urine each to measure urinalysis (UA) and PC ratio:~1. UA and PC ratio on original sample~2. UA and PC ratio with 1 mL of whole blood added~3. UA and PC ratio with 2 mL of whole blood added~4. UA and PC ratio with 5 mL of whole blood added"||||
33761691|NCT05492825|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1||||
33761692|NCT01555190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761693|NCT00745706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886895|NCT00824915|||COHORT||PROSPECTIVE|||||||
33886896|NCT01814787|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33886897|NCT03160014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072839|NCT02335879|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34072840|NCT04964336|||CASE_ONLY||OTHER|||||||
34072841|NCT05118997|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34072842|NCT05207202|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
34072843|NCT02090777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34072844|NCT03970759|||OTHER||RETROSPECTIVE|||||||
34072845|NCT01351090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072846|NCT02259205|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34072847|NCT06404359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34072848|NCT06265337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||In a randomized, double-blinded, placebo-controlled crossover trial, we will investigate the effect of addition of 25 g lactate vs. placebo to an OGTT on two trial days separated by a minimum of fourteen days and a maximum of one month. We will include 12 individuals with pre-diabetes \[9\], having HbA1c 39-47 mmol/L and being above 40 years of age.|t|f|t|t
34072849|NCT03837457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072850|NCT00187785|RANDOMIZED|PARALLEL||ECT||NONE||||||
34072851|NCT05853718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072852|NCT01830933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34072853|NCT05038449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072854|NCT06361888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974193|NCT02985151|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This is a crossover study where subjects are randomized into two arms. Subjects in the sham arm are allowed to crossover at the end of their initial intervention period.|t|f|t|t
33974194|NCT01336894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974195|NCT06008600|||OTHER||CROSS_SECTIONAL|||||||
33974196|NCT04259606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel, randomized, double blind, with control group. The study consists in two groups assigned to take either cassia cinnamon or placebo. Both groups will be taken Metformin as first line therapy for type 2 diabetes mellitus|t|f|t|f
33974197|NCT02587442|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974198|NCT03265470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33974199|NCT05236075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974200|NCT01146132|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33974201|NCT02320474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974202|NCT06545123|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants that meet the inclusion/exclusion criteria will be randomly assigned to: i) moderate aerobic exercise (AER); ii) resistance exercise (RES); or iii) concurrent exercise training (RES+AER).|f|f|f|t
33974203|NCT01033474|||CASE_ONLY||PROSPECTIVE|||||||
33974204|NCT00656500|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33974205|NCT04909632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974206|NCT03756753|RANDOMIZED|PARALLEL||OTHER||NONE|Patients will be enrolled in the study, and will not initially know their study arm. After enrollment, the professional research assistant (PRA) will find out the study arm. Providers will be notified of the results for the intervention group. Providers are able to let patients know of their results.|Participants will be allocated 1:1 by computer-generated randomization to either the intervention group - test result available to providers, or the control group- test result not available (routine clinical care).||||
33974207|NCT01133821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974208|NCT04782102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974209|NCT03603756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974210|NCT00386113|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974211|NCT05963256|||COHORT||PROSPECTIVE|||||||
33974212|NCT00124020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974213|NCT01836835|||CASE_CONTROL||PROSPECTIVE|||||||
33974214|NCT00783406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33974215|NCT05067257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974216|NCT05073575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patients will be unaware of the type of treatment performed, with prior written informed consent. So, they will be divided in the two groups of study after a process of randomization|The study will be designed as a double-arm randomized controlled clinical trial. The suprabony defects of subjects allocated in HA group will be treated with open flap debridement and application of hyaluronic acid, while the suprabony defects of No-HA Group will be treated with open flap debridement alone. The null hypothesis of no statistically significant differences between the two modalities for the treatment of suprabony defects will be tested.|t|f|f|f
33974217|NCT01696591|||CASE_CONTROL||PROSPECTIVE|||||||
33974218|NCT03885102|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment in 1:1 ratio into either intervention group (12 months intradialytic exercise intervention; 50% aerobic exercise, 50% resistance training; thrice a week for 60 min per dialysis session) and health literacy counselling (HLC) or control group/usual care (Usual care without any exercise intervention or HLC)||||
33974219|NCT01795781|||COHORT||PROSPECTIVE|||||||
33974220|NCT01448083|||CASE_ONLY||PROSPECTIVE|||||||
33974221|NCT01919632|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34072855|NCT05341791|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34072856|NCT00073762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33974222|NCT02311023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974223|NCT02236130|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33974224|NCT05543200|||COHORT||PROSPECTIVE|||||||
33974225|NCT00910182|||COHORT||RETROSPECTIVE|||||||
33974226|NCT01319656|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33974227|NCT05895253|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33974228|NCT02725970|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33974229|NCT05336084|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974230|NCT02233179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974231|NCT03445975|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study had a cluster-crossover design, where each of the two involved ICUs was the cluster. The genaral aim was to test the effectiveness of a 3-in-1 perineal care washcloth versus standard of care (e.g., water and pH neutral soap) to prevent and treat pressure ulcers in ICUs. The study has been articulated in two phases, lasted three months each. In the first phase, from the 1st of February to the 2nd of May, the 3-in-1 perineal care washcloth procedure has been adopted by the ICU of San Donato Hospital (Milan, Italy), while the Cardiovascular Intensive Care Unit (CVICU) continued to adopt the standard procedure (water and pH neutral soap). In the second phase, from the 2nd of May to 31st of July, the two procedures have been switched between the two wards.||||
34072857|NCT04232345|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This study is single-blind with regards to treatment (AZD4831 or placebo) at each dose level. AZD4831 and placebo will be matched for appearance and amount. Subjects randomized to placebo will receive the same volume of oral suspension as subjects on active drug.|"This study will be a randomized, single-blind, placebo-controlled, MAD sequential-group study in healthy Japanese (Part 1, Cohorts 1, 2, and 3) and Chinese (Part 2, Cohort 4) male subjects, conducted at a single study center. Up to 40 healthy male subjects aged 18 to 50 years (inclusive) are planned to be investigated in 4 cohorts, but up to 5 cohorts may be included if the SRC considers it necessary to repeat a dose level or if additional dose levels are required.~Up to 8 subjects will participate in each cohort. Within each cohort 6 subjects will be randomly assigned to receive AZD4831 and 2 subjects to receive placebo. AZD4831 or placebo will be administered once daily for a period of 10 days. It is anticipated this will be sufficient to achieve and maintain steady state pharmacokinetic (PK) profiles for several days, permitting evaluation of the safety and tolerability of multiple dose. The subjects will stay at the study center during the whole dosing period and until 48 hours."|t|f|f|f
33974232|NCT04187651|NA|SINGLE_GROUP||TREATMENT||NONE||PRP gel will be applicated to all cases||||
33974233|NCT00379457|RANDOMIZED|||TREATMENT||||||||
33974234|NCT00099528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33974235|NCT01638936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974236|NCT05236946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974237|NCT06124430|||COHORT||PROSPECTIVE|||||||
33974238|NCT00913965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974239|NCT02518685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33974240|NCT01375933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974241|NCT01047345|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33974242|NCT00274326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33974243|NCT02688894|||OTHER||PROSPECTIVE|||||||
33974244|NCT03714100|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974245|NCT04529642|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33974246|NCT03252795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974247|NCT03083210|NA|SINGLE_GROUP||TREATMENT||NONE||Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.||||
34072858|NCT04215601|||COHORT||PROSPECTIVE|||||||
34072859|NCT00004067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072860|NCT03943355|||CASE_CONTROL||RETROSPECTIVE|||||||
34072861|NCT03911076|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Safety run-in is open label (no control), followed by randomized double-blind, placebo-controlled study|Safety run-in followed by randomized double-blind, placebo-controlled study|t|t|t|t
34072862|NCT05718674|||CASE_ONLY||PROSPECTIVE|||||||
33974248|NCT00795561|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072863|NCT00578279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072864|NCT04626609|||COHORT||PROSPECTIVE|||||||
34072865|NCT06010602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072866|NCT01360008|||COHORT||PROSPECTIVE|||||||
33974249|NCT00401219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974250|NCT06188390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Hyaluronic acid and dextrose are both transparent, which is prepare by technician who is not participate in intervention and assessment||t|t|f|t
34072867|NCT05582629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel|t|t|t|t
34072868|NCT06020170|||CASE_CROSSOVER||PROSPECTIVE|||||||
34072869|NCT01789424|||CASE_ONLY||PROSPECTIVE|||||||
34072870|NCT01973426|||CASE_ONLY||PROSPECTIVE|||||||
34072871|NCT03864991|RANDOMIZED|FACTORIAL||OTHER||NONE||A factorial design approach will be taken to study the lifestyle change for self-management of T1D. A randomized controlled method will enroll patients in four groups. All groups will be working with a standard log book for documenting blood sugar and routine care as advise by doctors, nurses, and nutritionists. First group will be entirely of routine care follow up, second group will receive additional e-device for step count (fitbit), third group will receive routine care and e-messages as reminders to maintain a daily log book, and fourth group will be receiving e-device for step count (fitbit) and e-messages for maintain blood glucose and step count log book in addition to routine care. All four groups will be followed up for a period of six months. Log book data will be obtained at a monthly interval and HbA1c as a main outcome will be measured three times, at baseline, at three and six months.||||
33886898|NCT05808036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will start with the DOMINO diet. Depending on the symptom improvement they will continue the DOMINO diet or switch to the strict low FODMAP diet.||||
33974251|NCT03658135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind - only investigational pharmacist is unblinded|"This is a phase 1b, randomized, double-blind, placebo-controlled, parallel cohort study of the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of BIIB092 in patients with 4 different primary tauopathy syndromes: CBS, nfvPPA, sMAPT, and TES.~A basket trial design will be used for a parallel evaluation of BIIB092 in four heterogeneous clinicopathological syndromes that share a common molecular target (tau). There will be four cohorts of approximately 8 participants each, one for each specific primary tauopathy syndrome listed above (for a total of approximately 32 participants). For each diagnostic cohort, eligible participants will be randomized 3:1 to active or placebo (i.e., 6 participants receiving BIIB092 and 2 participants receiving placebo). All eligible participants will be administered study drug (BIIB092 or placebo) as an 1-hour intravenous (IV) infusion q4w for 20 weeks (for a total of 6 infusions)."|t|t|t|t
33974252|NCT00003213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33974253|NCT06384144|||COHORT||RETROSPECTIVE|||||||
33974254|NCT00162604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34072872|NCT03234803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072873|NCT02446548|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34072874|NCT03883763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072875|NCT04719598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|all participants will randomly assign to either an internet-based group and control group through a generated computer selection|one intervention group ( internet-based cognitive behavioral therapy) and one control group|t|f|f|f
34072876|NCT00417157|||COHORT||PROSPECTIVE|||||||
34072877|NCT03060369|||COHORT||PROSPECTIVE|||||||
34072878|NCT01049191|||||CROSS_SECTIONAL|||||||
34072879|NCT04391842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072880|NCT06267820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34072881|NCT04961697|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Since the intervention is the use of hospital diaries there will be masking in the outpatient follow-up data collection and posterior data analysis.|This is a multicentric two-arm two-period crossover study: in the first phase each PICU will be randomized between intervention (PICU with diaries) and control (PICU without diaries), crossing over in the second phase after a washout period.|f|f|f|t
34072882|NCT02731274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072883|NCT06054763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072884|NCT05926622|||COHORT||PROSPECTIVE|||||||
34072885|NCT05883163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A independent, blinded Core Lab will analyze the primary endpoint data.|The study is a prospective, multi-center, randomized, controlled study using adaptive design to assess the evidence of safety and performance of the STIMIT Activator 1 System|f|f|f|t
34072886|NCT02778152|NA|SINGLE_GROUP||TREATMENT||NONE||Laser hair removal||||
34072887|NCT01923675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34072888|NCT05708040|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072889|NCT04245917|||COHORT||PROSPECTIVE|||||||
34072890|NCT00527137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974255|NCT04641429|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinding the participants to the allocation is impossible due to the nature of intervention. But prior to the first training session, participants have no knowledge on which type of training they are going to receive.|In this intervention study, each participant is allocated to either the Qigong or stretching exercise training group in a pseudo-randomized order based on the recruitment orders and their availability.||||
34072891|NCT03193229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072892|NCT01792765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072893|NCT05084105|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33886899|NCT01912625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886900|NCT02069002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886901|NCT04764435|||COHORT||RETROSPECTIVE|||||||
33886902|NCT00802360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974256|NCT03674164|NA|SINGLE_GROUP||OTHER||NONE||||||
33974257|NCT01568489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974258|NCT00604409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974259|NCT02907112|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974260|NCT02720952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974261|NCT02903056|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34072894|NCT04219592|||CASE_CONTROL||RETROSPECTIVE|||||||
33886903|NCT05222321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be aware of group assignment, but will be notified of their group assignment at the end of the three intervention sessions upon request. The percentage of on and off-task behaviors will be calculated by two coders, blinded to the group assignment will code session. Prior to the study, both coders will achieve a reliability of at least 95% accuracy in training sessions.|To address the aims of this study, the investigators will recruit 20 participants and utilize a randomized, experimental study with a two-group longitudinal, pre-posttest, linear association study design to measure attention levels and off-task behaviors. This is the first step in determining the effects of the SenPlay intervention on focused attention. The intervention will occur over three time points in a clinic therapy room and occupational therapy gym in an outpatient pediatric clinic.|t|f|f|t
33886904|NCT01437787|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33974262|NCT02322047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No study staff, including the participants, will know which condition the participants are in. Only the Research Pharmacist will know the participants' conditions.|Eligible participants will be randomized into one of four study conditions: Naltrexone/Prazosin (Nal/Praz), Naltrexone/Placebo (Nal/Pl), Prazosin/Placebo (Praz/Pl), and Placebo/Placebo (Pl/Pl). Randomization will be blocked by gender, PTSD status, and alcohol consumption goal (abstention vs. reduction) and will be conducted by a VA Puget Sound Research Pharmacist using randomization tables supplied by the study Principal Investigator (PI). The Research Pharmacist will have no additional contacts with the participants.|t|f|t|t
33974263|NCT05921058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Mesenchymal stem cell placebo and secretome using injections that are similar in shape and color|This study was divided into two groups, namely, control and treatment. Both received intervention in the form of a 1.5 cc injection on the scheduled day|t|t|t|t
34072895|NCT01559610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33886905|NCT00955773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886906|NCT00891995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974264|NCT03289975|||OTHER||PROSPECTIVE|||||||
33886907|NCT01442181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886908|NCT02429856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33886909|NCT05623891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974265|NCT04963348|||CASE_ONLY||RETROSPECTIVE|||||||
33886910|NCT05077696|||COHORT||PROSPECTIVE|||||||
34072896|NCT00426764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974266|NCT05896670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974267|NCT00249548|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974268|NCT03544320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The participants will be aware of the two different study arms and the wearable devices used in both. The study investigator will not have not have knowledge of the participants assigned to each arm.|Participants are randomized to one of two wearable devices and will wear that device for the duration of the study.|f|f|t|t
33974269|NCT04436692|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34072897|NCT05139420|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33886911|NCT03125278|||OTHER||PROSPECTIVE|||||||
33886912|NCT04351802|||COHORT||PROSPECTIVE|||||||
34072898|NCT06587633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072899|NCT01670383|||COHORT||PROSPECTIVE|||||||
33886913|NCT05859035|NA|SINGLE_GROUP||OTHER||NONE||||||
33886914|NCT03433781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||3 dose-escalation cohorts in a 3+3 design. One subject at a time will be enrolled into the first cohort until the first dose level cohort is completed and all patients treated successfully for one cycle.||||
33886915|NCT00655928|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33886916|NCT06501859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974270|NCT00783796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072900|NCT03509181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072901|NCT03987113|||OTHER||PROSPECTIVE|||||||
33886917|NCT01425385|||COHORT||PROSPECTIVE|||||||
34072902|NCT04482907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups were created. Patients with thyroid nodules were divided into two groups given dill and placebo. The study was planned for 90 days. 900 mg of powder dill was given daily to the dill group. Placebo was given to the control group. Serum thyroid stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (Anti-Tg) and C-reactive protein (CRP) levels of both groups were examined at the beginning and at the end of the study. Thyroid nodule dimensions were measured at the beginning and at the end of the study by ultrasonography. The results were evaluated statistically.||||
34072903|NCT00448240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34072904|NCT00878800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072905|NCT05640063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We are considering Union Council as a cluster. Clusters will be identified and matched on population size, socio-economic status (including structure, electricity, drinking water assets with HH density), birth/death rates, and number of functional LHWs and CMWs. Paired randomization will be done to allocate one group (intervention/control) to each cluster and all the LHWs in one union council will be assigned to one group to avoid any sort of contamination.||||
33886918|NCT00135460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886919|NCT03346174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be analyzed by an experienced paediatric gastro-enterologist, blinded to the different treatment modalities||f|f|f|t
33886920|NCT04473547|||OTHER||PROSPECTIVE|||||||
33886921|NCT03892837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886922|NCT05374473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Two forms of the course were developed:~1. an intervention course based delivering evidence based information regarding modifiable lifestyle related risk factors implicated in disease progression; and~2. a standard-care course, similar in format and presentation, but containing general information sourced from standard MS websites."|t|f|f|f
33886923|NCT06548321|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33886924|NCT01983995|||COHORT||PROSPECTIVE|||||||
33886925|NCT05980884|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886926|NCT03524573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the intervention.|Randomized Controlled Trial|f|f|f|t
34072906|NCT02034318|||CASE_ONLY||PROSPECTIVE|||||||
34072907|NCT06101147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072908|NCT02991248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761694|NCT02039986|||COHORT||PROSPECTIVE|||||||
33761695|NCT04382703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All postal questionnaires will be placed in opaque envelope and each envelope will be given a unique number, these unique numbers will be fed into a computerized list generator (www.random.org). The generated list will be used to put the questionnaires in batches for the audiologist to give to thier participants. The online version will automatically randomly assign participants to either the intervention or control.|Participants are randomly assigned to an intervention which is a questionnaire based with a self-affirmation embedded at the end of the questionnaire or they are assigned to a control group who undertake the same questionnaire minus the self-affirmation exercise.|t|f|t|f
33761696|NCT00361959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33761697|NCT04768842|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761698|NCT04665024|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761699|NCT06038435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33761700|NCT01089257|||CASE_CONTROL||PROSPECTIVE|||||||
34072909|NCT02732288|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072910|NCT01383018|||COHORT||PROSPECTIVE|||||||
34072911|NCT04611022|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34072912|NCT01535313|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34072913|NCT01229215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072914|NCT05695729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072915|NCT01488552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072916|NCT00002168||PARALLEL||TREATMENT||||||||
34072917|NCT04686708|||COHORT||RETROSPECTIVE|||||||
33761701|NCT00001579||||TREATMENT||||||||
33761702|NCT01657266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761703|NCT00137384|||||PROSPECTIVE|||||||
33761704|NCT00482820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33761705|NCT02345525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072918|NCT02954549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34072919|NCT00679822|||CASE_ONLY|||||||||
33761706|NCT05540314|||COHORT||RETROSPECTIVE|||||||
33761707|NCT05555992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761708|NCT03233867|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761709|NCT00771225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33886927|NCT02703857|NA|SINGLE_GROUP||OTHER||NONE||||||
33761710|NCT04679337|||COHORT||PROSPECTIVE|||||||
33761711|NCT00425425||||TREATMENT||NONE||||||
33761712|NCT00079911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761713|NCT01319799|||CASE_ONLY||PROSPECTIVE|||||||
33761714|NCT02079064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34072920|NCT04162795|NA|SINGLE_GROUP||OTHER||NONE|Participants were blinded to product brand|||||
34072921|NCT02403583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34072922|NCT04079686|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34072923|NCT02377609|||CASE_ONLY|||||||||
34072924|NCT03697941|||COHORT||PROSPECTIVE|||||||
34072925|NCT03559751|RANDOMIZED|CROSSOVER||OTHER||NONE||In part A each subject will have the opportunity to use either their own brand cigarette, nicotine gum or VLN cigarettes ad libitum for 4 hours after which they will answer a questionnaire on using the product again. In Part B the subjects will have a controlled use session with each product followed by and uncontrolled session.||||
33886928|NCT03889587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886929|NCT01917786|||CASE_CONTROL||PROSPECTIVE|||||||
33886930|NCT02977923|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072926|NCT00767221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886931|NCT03084965|||OTHER||RETROSPECTIVE|||||||
33886932|NCT00684177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886933|NCT01921998|||CASE_ONLY||PROSPECTIVE|||||||
33886934|NCT02700984|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886935|NCT06549361|||COHORT||RETROSPECTIVE|||||||
34072927|NCT02710487|NON_RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The sleep technician in charge to apply the study intervention was the only person to be aware of the sleep phase the patient was awaken from.|Awakening from NREM vs. REM sleep.|t|f|t|t
34072928|NCT04526600|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33886936|NCT04754789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"To assess the impact of treatment preloading with high dose statins (atorvastatin 80mg) pre-primary PCI on:~The inflammatory markers (TLC, NLR, CRP), TIMI flow (corrected TIMI frame count), Myocardial blush ST resolution at 90 min after PCI, Major adverse cardiovascular events (MACE) (in-hospital, 30 days, 3months), (Cardiac mortality, MI, HF, stroke, revascularization, stent thrombosis)."|f|f|t|f
33886937|NCT05464537|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33886938|NCT05115084|||CASE_ONLY||PROSPECTIVE|||||||
33886939|NCT00968422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886940|NCT05857176|||OTHER||CROSS_SECTIONAL|||||||
33886941|NCT04041115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761715|NCT03077984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761716|NCT03016910|||COHORT||PROSPECTIVE|||||||
33761717|NCT06100315|||COHORT||PROSPECTIVE|||||||
33761718|NCT01725269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761719|NCT03340584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761720|NCT05161325|||COHORT||RETROSPECTIVE|||||||
33761721|NCT00212381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|central pharmacy dispenses based on sealed randomization table|randomized double blind intervention trial|t|t|t|t
33761722|NCT02014818|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients' information will be blinded to OCT image analyzers.|This study will comprise of 1 month follow-up and 3-month follow up arm, which enroll patients in a parallel manner.|f|f|f|t
33761723|NCT01500330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761724|NCT03666884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants chose their treatment regime randomly|The comparison of 50 % concentration autologous serum eye drops versus preservative free artificial eye drop plus 0.05 % cyclosporin ophthalmic emulsion in the treatment of severe dry eye syndrom|t|f|f|t
33761725|NCT03425448|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multi-center, double-blind, randomized controlled trial||||
33761726|NCT02247336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761727|NCT06624540|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Study 2: A pre- and post- quasi-experimental study to evaluate the knowledge and skill of nurses.~Study 3: A pre- and post- quasi-experimental study to evaluate the outcomes of the patients in the ICU, using study 1 historical data as a control."||||
33886942|NCT04305015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesia clinicians cannot be blinded since they will need to titrate opioid administration to NOL. However, all postoperative care and evaluations will be fully blinded to randomization, thus preventing measurement bias|NOL-Guided analgesia vs. Routine Management|t|f|f|t
33886943|NCT03270215|||COHORT||RETROSPECTIVE|||||||
33886944|NCT00524160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33886945|NCT01468987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886946|NCT01322022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886947|NCT06265142|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The statistician who will analyze the data will be blinded.|Patient will be assessed in triage and cases to be included in the study as per the inclusion criteria, after that patients will be randomized using computerized block randomization technique into two groups. Then, patients will be assigned to a bed, pulse oximetry to be applied, data collection sheet to be filled, confirm that infant had good feeding/ didn't pass urine over last 20 minutes and proper cleaning to be done. The next step will be, collecting urine sample according to randomization group. Group A patients (control group), urine to be collected by standardized catheterization technique while group B by standard CCU technique. Meanwhile, time of each procedure to be documented. Regarding group B , after collecting urine by CCU , we recommend to collect another sample by catheterization to guide the management and antibiotic choice.|f|f|f|t
33886948|NCT01501279|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33886949|NCT00891826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886950|NCT00788645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33886951|NCT05328570|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886952|NCT01451645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886953|NCT01656720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33886954|NCT00067756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886955|NCT04355988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886956|NCT02481635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886957|NCT06321692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33886958|NCT03394560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33886959|NCT05145621|RANDOMIZED|CROSSOVER||OTHER||NONE||two way crossover||||
33886960|NCT02008825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886961|NCT06386848|||COHORT||RETROSPECTIVE|||||||
33886962|NCT05850208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886963|NCT01992822|NA|SINGLE_GROUP||OTHER||NONE||||||
33886964|NCT05710263|NA|SINGLE_GROUP||OTHER||NONE||||||
33886965|NCT04978558|||COHORT||PROSPECTIVE|||||||
33886966|NCT03359135|||CASE_CONTROL||PROSPECTIVE|||||||
33974271|NCT05031728|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be interviewed by a clinician and asked to complete the Clinician-Administered PTSD Scale (CAPS-5), Beck Depression Inventory (BDI-II), Beck Anxiety Inventory (BAI). Assessments will be conducted at baseline, 3-, and 12-months post treatment.||||
33974272|NCT05197907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974273|NCT01498484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974274|NCT01947777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974275|NCT02064426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974276|NCT06375928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761728|NCT03994458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded evaluators and participants are not aware which version of the program they got.|Randomized controlled trial, double blinded|t|f|f|t
33761729|NCT05788835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886967|NCT01508741|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33886968|NCT02257424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886969|NCT01255774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886970|NCT02399306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886971|NCT00768898|||COHORT||PROSPECTIVE|||||||
33886972|NCT03777449|||COHORT||PROSPECTIVE|||||||
33886973|NCT04021134|||CASE_ONLY||PROSPECTIVE|||||||
33886974|NCT04828044|||CASE_ONLY||PROSPECTIVE|||||||
33886975|NCT00369031|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974277|NCT01875575|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33974278|NCT01468051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974279|NCT02184273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33974280|NCT05096325|||COHORT||PROSPECTIVE|||||||
33974281|NCT03280784|||CASE_ONLY||PROSPECTIVE|||||||
33761730|NCT03503825|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a Phase 1, non-randomized, open-label, single-centre clinical trial. A total of 12 to 24 subjects will be enrolled:~* 6 Healthy volunteers (HV) (3 males and 3 females)~* 6 - 18 subjects with osteoarthritis of the knee (KOA) Once 6 HVs and 6 KOA subjects (to be enrolled concurrently) have completed the study, image data will be assessed to determine whether any more KOA subjects should be imaged."||||
33761731|NCT06525402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The study will be conducted as a randomized controlled trial.|t|t|t|t
33761732|NCT01887470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761733|NCT01390714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761734|NCT04189263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761735|NCT01146301||||TREATMENT||||||||
33761736|NCT02291523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761737|NCT02552290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761738|NCT05586464|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33761739|NCT03573908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761740|NCT00651196|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761741|NCT04649346|||CASE_ONLY||PROSPECTIVE|||||||
33761742|NCT02731625|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33761743|NCT04247997|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34072929|NCT02197585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761744|NCT03842410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886976|NCT05087615|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|After taking informed consent, patients enrolled in the groups. Each group had 26 members, and the subjects were unaware of which group they had been assigned. Also, the investigators weren't aware of the treatment assignment until the end of the trial.|"the patients were divided into five parallel groups including control and study groups.~Group 1: Patients who did not receive any antiemetic during hospitalization (NA).~Group 2: Patients receiving metoclopramide alone (MA). Group 3: Patients who received ondansetron only. (OA) Group 4: Patients receiving a combination of metoclopramide and ondansetron (MO).~Group 5: Patients who received granisetron alone (GA)."|t|t|t|f
33886977|NCT05422131|||COHORT||PROSPECTIVE|||||||
33886978|NCT01183273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886979|NCT04810702|||CASE_CONTROL||RETROSPECTIVE|||||||
33886980|NCT04217265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886981|NCT00567619|||||PROSPECTIVE|||||||
33886982|NCT01187992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33886983|NCT03482869|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort||||
33886984|NCT04140214|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A superiority, 2x2 factorial randomised open label trial with a 52-week follow-up period.||||
33886985|NCT01736904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974282|NCT03535909|||COHORT||CROSS_SECTIONAL|||||||
33974283|NCT01276782|NA|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33974284|NCT05825300|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The patients in the study will not know that other messages are being sent to other patients, although they will see the text of their own message. Providers will be blind to patient conditions.||f|t|f|f
33886986|NCT03497845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761745|NCT03896009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761746|NCT04307433|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data collector who assesses the follow-up assessments will be blind to treatment condition|"The proposed study has two phases:~Phase 1. Development of Narrative Video: The investigators will first develop culturally-grounded and human-centered storytelling narrative intervention videos in Chichewa, the local language to address sociocultural and individual factors which influence cervical cancer prevention behaviors. The video will be filmed in person in community organizations in Malawi.~Phase 2: A Pilot Randomized Controlled Trial (RCT) of a Story Telling Narrative Intervention: The investigators will conduct a three-arm pilot RCT using the storytelling-based intervention delivered by mHealth (tablets) with 180 women residing in a rural community in Malawi. The intervention groups (Arm 1: storytelling narrative video on tablets \[n=60\] \& Arm 2: a video with a voice over presenting didactic materials on tablets \[n=60\]) will watch approximately 30 minutes of video intervention and the comparison group (Arm 3 \[n=60\]) will be read non-narrative educational materials"|f|f|f|t
33761747|NCT00586170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761748|NCT00671905|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33886987|NCT05459532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|Molnupiravir is a broad-spectrum antiviral that is an orally bioavailable prodrug of the nucleoside analogue NHC. NHC distributes into cells where it is phosphorylated to form the pharmacologically active NHC-TP. NHC-TP acts by a mechanism known as viral error catastrophe. NHC-TP incorporation into viral RNA by the viral RNA polymerase, results in an accumulation of errors in the viral genome leading to inhibition of replication.|t|t|t|f
33886988|NCT00877292|||COHORT||CROSS_SECTIONAL|||||||
33974285|NCT00501761|||CASE_CONTROL||PROSPECTIVE|||||||
33974286|NCT04181450|||COHORT||PROSPECTIVE|||||||
33974287|NCT05832255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974288|NCT04118231|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33974289|NCT05866146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, research staff collecting outcome data from patients will be blinded to the group allocation. However, the treating health professionals and patients will not be blinded to group allocation due to the nature of the intervention.|A two-arm parallel single-blinded pilot randomized control trial (RCT) will be employed to evaluate the feasibility and preliminary effectiveness of an interprofessional rehabilitation program compared to the usual care in patients with CLBP. Each eligible patient will have an equal chance to be allocated to the intervention or control group. Those who provide informed consent will complete a baseline assessment before being randomly assigned to the intervention or the control group without knowing the allocation of the group. Each group will be allocated/randomized 1:1 to the intervention and control groups. Except for the intervention being evaluated, all groups will be treated identically in every way.|f|f|f|t
34072930|NCT00637026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072931|NCT01455584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761749|NCT02080104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072932|NCT03885323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not know if the toothbrush is a treatment or control brush. Outcome assessor will be blinded as well and will not know which product was dispensed to which participant.|Single blind prospective study|t|f|f|t
33761750|NCT00336843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761751|NCT02819102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761752|NCT03274739|||COHORT||PROSPECTIVE|||||||
33761753|NCT05297474|||COHORT||PROSPECTIVE|||||||
33761754|NCT03803891|||COHORT||PROSPECTIVE|||||||
33761755|NCT04609202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761756|NCT06244810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33761757|NCT05400512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33761758|NCT05175144|||COHORT||PROSPECTIVE|||||||
33761759|NCT03361891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:~1. Standard of care; or~2. WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the Research Coordinator to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team."|f|f|f|t
33761760|NCT03582605|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The Amoxicillin and the placebo (glucose) will be prepared in capsule form by a pharmacist and made to look identical.|The study will be a double-blind randomized control trial in which half the participants will be given two grams of amoxicillin in capsule form, prepared by a pharmacist, and the other half will be given a placebo in capsule form, prepared by a pharmacist, 1 hour prior to MSI placement. Sealed envelopes containing either antibiotics or placebo capsules will be given to patients, with only the research committee chair knowing which patients are in the control group (placebo) and which are in the experimental group (antibiotics). Test subjects will be followed for 1 month (T1), 3 months (T2), 6 months (T3) following placement of MSIs.|t|t|t|f
33761761|NCT05252845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761762|NCT03875625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Four groups of interventional groups will be applied. Group 1 for subjects with morbid obesity who have consented to bariatric surgery, Group 2 for subjects with morbid obesity and have opted for dietitian led lifestyle modification intervention, Group 3 and 4 for subjects with mild to moderate obesity randomly (RCT) assigned to either dietitian led life style modification intervention group or conventional care (control group).|t|t|t|t
33761763|NCT00122564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761764|NCT06303154|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, exploratory, monocentric, uncontrolled clinical study.||||
34072933|NCT03782181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this clinical trial design strategy, the participants and the investigator do not know which participants have been assigned which interventions so there is a double-blind masking.|In this clinical,two groups of participants receive different interventions. One group receives a training with a whole body vibration plattform and the other is the control group.|t|f|t|f
33761765|NCT02540694|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33761766|NCT04173767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886989|NCT04625777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The analysis statistician will remain blinded to intervention allocation and waitlist randomized assignment until the analysis plan has been finalized and initial blind reviews have been performed.|The investigators will employ a waitlist preference trial study design. Participants will rank the three interventions and be assigned to their highest-ranking intervention. Participants who rank three interventions equally will be randomly assigned to one of the interventions or the waitlist group. Participants who rank two interventions equally will be randomly assigned to one of their preferred interventions and then randomly assigned to immediate intervention vs waitlist. For the waitlist, participants will be randomly assigned to an intervention with an immediate start of prior to Nov 2020, or to the waitlist control group with a delayed start of Nov 2020 or later. If assigned to the delayed start (a.k.a. waitlist) group, they will be asked for data while waiting (i.e. control group data). The investigators may continue to enroll additional participants following the initial enrollment period and receive their preferred intervention without randomization.|f|f|t|f
33886990|NCT05503355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886991|NCT02680353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33886992|NCT01960855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33886993|NCT05183919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886994|NCT04252599|||OTHER||OTHER|||||||
33886995|NCT04274348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33886996|NCT01081756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33886997|NCT04619394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34072934|NCT00735943|||CASE_ONLY||PROSPECTIVE|||||||
34072935|NCT04332926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to their condition (nicotine level) used in each session, except during their 'own brand' session.||t|f|f|f
34072936|NCT03241329|||CASE_CONTROL||PROSPECTIVE|||||||
33886998|NCT00620061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33886999|NCT03403192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The surgeon will be blinded to technique and queried as to the quality of isolation upon entry into the chest and this will be recorded.|The objective of this study is to evaluate the positional stability and quality of lung isolation provided by the EZ-blocker compared to a DLT for both right and left sided thoracic surgery|f|t|f|f
33887000|NCT02987894|||COHORT||PROSPECTIVE|||||||
33887001|NCT01633957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33887002|NCT05600075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34072937|NCT05816668|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Just ICESP's Clinical Research Pharmacy team will be not blinded. The surgical and anesthetic teams will be blinded in relation to the placebo or tranexamic acid intervention during the preoperative period and during the postoperative follow-up and, if any case loses the blinding, it will be excluded from the analysis. The preparation of packaging, dilution and dispensing or the material containing tranexamic acid or placebo will be carried out by the ICESP's Clinical Research Pharmacy division.||t|t|t|f
34072938|NCT03583879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072939|NCT04819789|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34072940|NCT04294199|RANDOMIZED|PARALLEL||TREATMENT||NONE||Dual-arm randomized intervention comparison study evaluation two rehabilitation protocols for individuals following a first time lateral patella instability episode.||||
34072941|NCT05621447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072942|NCT03246022|||COHORT||PROSPECTIVE|||||||
33887003|NCT03822481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group given the MCD (experimental) other group not given the MCD (control).||||
34072943|NCT03103256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072944|NCT00005033||||TREATMENT||||||||
33887004|NCT05799014|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33887005|NCT04313556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887006|NCT02803333|||COHORT||PROSPECTIVE|||||||
33887007|NCT03939182|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I with dose expansion, open label single institution trial. The first stage is a standard 3+3 dose escalation trial. In the second stage, the dose expansion cohort will accrue patients at the MTD abexinostat and ibrutinib previously determined.||||
33887008|NCT03857789|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33887009|NCT06395844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887010|NCT05140057|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33887011|NCT05706935|||COHORT||PROSPECTIVE|||||||
33887012|NCT00546923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33887013|NCT02268461|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33887014|NCT01929135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887015|NCT00065143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887016|NCT06018779|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34072945|NCT05292274|||COHORT||RETROSPECTIVE|||||||
34072946|NCT01954238|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34072947|NCT01188668|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34072948|NCT06153615|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34072949|NCT02183012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34072950|NCT05339815|||CASE_CONTROL||RETROSPECTIVE|||||||
34072951|NCT04090346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072952|NCT03126786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072953|NCT05495386|NA|SINGLE_GROUP||OTHER||NONE||||||
34072954|NCT00537290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072955|NCT00547248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34072956|NCT03205475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a play based targeted social communication intervention. Sessions will be delivered one on one by an interventionist in training with a child age 2.0-8.11 years who has autism.|t|f|f|f
34072957|NCT02421302|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072958|NCT03442244|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34072959|NCT04845880|NA|SINGLE_GROUP||SCREENING||NONE||||||
34072960|NCT04615078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34072961|NCT05457179|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm multi-site randomized clinical trial. The intervention arm will consist of peer counselor-led park-based physical activity sessions 3 days per week for 12 weeks incorporated into weekly peer counseling sessions. The active control arm will consist of physical activity and park information. Both arms will include standard of care peer-group counseling services.||||
34072962|NCT01545141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072963|NCT02809950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34072964|NCT04399889|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34072965|NCT01668056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072966|NCT03868839|NA|SINGLE_GROUP||OTHER||NONE||||||
34072967|NCT00832988|||CASE_CROSSOVER||PROSPECTIVE|||||||
34072968|NCT02768402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072969|NCT01363284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072970|NCT06355440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34072971|NCT04008888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072972|NCT06226519|||COHORT||PROSPECTIVE|||||||
34072973|NCT01964989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33887017|NCT03038308|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label studies|1) Forced titration dose response PKPD study and 2) A prospective open-label outpatient dose escalation trial of ropinirole for treatment of prolactinomas and hyperprolactinemia.||||
33887018|NCT02243228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072974|NCT04265261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072975|NCT05114187|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This study is a two-arm pilot randomized controlled trial.|t|f|t|t
34072976|NCT04004260|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group will initially undergo the ICBT intervention while the control group are monitored weekly. Once the experimental group has completed the intervention, the control group will undertake the ICBT intervention.||||
34072977|NCT00674206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34072978|NCT03620526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34072979|NCT02732392|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34072980|NCT01373814|||CASE_ONLY||PROSPECTIVE|||||||
33887019|NCT00110994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887020|NCT02789813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887021|NCT01098890|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33887022|NCT02090855|||COHORT||RETROSPECTIVE|||||||
33887023|NCT01182038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887024|NCT02769598|||COHORT||PROSPECTIVE|||||||
33887025|NCT03948932|||COHORT||PROSPECTIVE|||||||
33887026|NCT03365193|||COHORT||PROSPECTIVE|||||||
34072981|NCT02403804|NA|SINGLE_GROUP||OTHER||NONE||||||
34072982|NCT06491680|RANDOMIZED|PARALLEL||PREVENTION||NONE||"it is a randomized controlled trial for at least 40 breast cancer patients who receive 4 cycles of anthracyclines.~These patients are divided into 2 groups . Group 1 take anthracyclines with dapagliflozin 10 mg and group 2 take anthracyclines only."||||
34072983|NCT01082679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072984|NCT01396889|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34152266|NCT05351775|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The part I trial is open, prospective interventional trial. These recordings are used merely to technical testing, validity evaluation and algorithm development purposes and the data is not used in any clinical evaluation whatsoever.~The part II is a prospective, randomized, open-label, interventional study. Upon receipt of the signed written informed consent and satisfactory documentation that the patient met all inclusion and had no exclusion criteria, the study subjects will be randomized to either intervention or control arm. The randomization allocation will take into account the procedure subgroup of the patient (open-heart surgery, aortic valve replacement and transcatheter aortic valve implantation (TAVI) or coronary bypass and percutaneous coronary intervention (PCI)). In both subgroups the randomization will be done 1:1. Patients will be randomized before hospital discharge."||||
34152267|NCT06156501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887027|NCT03544580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887028|NCT01667263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887029|NCT04765605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887030|NCT06020794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RANDOMIZED CONTROLLED|f|f|t|f
33887031|NCT03064763|NA|SINGLE_GROUP||OTHER||NONE||||||
33887032|NCT01199666|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33887033|NCT03084185|||COHORT||PROSPECTIVE|||||||
33887034|NCT01016379|||CASE_ONLY||RETROSPECTIVE|||||||
33887035|NCT05888974|||COHORT||PROSPECTIVE|||||||
33887036|NCT00891202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34072985|NCT03952962|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE|"The investigators propose a clinical trial involving 12-months open-label bilateral DBS that targets SCC (using TOT) in subjects with TRD. The open label period is intended to ensure that maximal benefit can be achieved with the current proposed protocol.~Following open label optimization, to control for possible placebo, each subject will enter a double blinded randomized discontinuation, intended to confirm clinical benefit of DBS among responders (6 months)."|There will be an initial 12-month open label period for all participants involved. In the second period of the study, patients will be divided into groups: responders (defined as a 40% reduction or more in MADRS) versus non-responders. Responders will continue to the 6-month double-blinded discontinuation phase (see below for additional details of study procedures during this phase). The non-responders, after the open label period (12 months) will have monthly follow-up visits for 12 mo. During the discontinuation period, patients will be randomized to either the ON or OFF stimulation phase for 3 mo each. If randomized to ON, there will be no change for 3 mo, then a biweekly 25% reduction in stimulation amplitude for the next 3 mo until stimulation is off. If randomization to OFF phase, there will be an initial biweekly 25% reduction in stimulation amplitude for 3 mo until the device is off then the stimulation settings will be turned back to the optimized settings for three months.||||
34072986|NCT03373747|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34072987|NCT00382785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34072988|NCT03711305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072989|NCT02532062|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34072990|NCT02501941|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34072991|NCT06173388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34072992|NCT02260219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34072993|NCT03166839|||COHORT||PROSPECTIVE|||||||
34072994|NCT03958110|||COHORT||PROSPECTIVE|||||||
34072995|NCT04793477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34072996|NCT01700257|NA|SINGLE_GROUP||SCREENING||NONE||||||
33887037|NCT01800942|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33887038|NCT01440335|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33887039|NCT06325501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33887040|NCT02048345|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33887041|NCT03479047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887042|NCT01350089|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33887043|NCT06056947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887044|NCT01650987|||COHORT||PROSPECTIVE|||||||
33887045|NCT05119803|||CASE_CONTROL||PROSPECTIVE|||||||
33887046|NCT01737931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887047|NCT03835741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887048|NCT05146557|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887049|NCT02606578|||COHORT||PROSPECTIVE|||||||
33887050|NCT05651971|||OTHER||PROSPECTIVE|||||||
33887051|NCT01474694|||CASE_ONLY||PROSPECTIVE|||||||
33887052|NCT02597062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887053|NCT03644290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887054|NCT06381193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887055|NCT06157671|||COHORT||PROSPECTIVE|||||||
33887056|NCT00555087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887057|NCT02527707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887058|NCT06318845|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33887059|NCT03957967|||COHORT||PROSPECTIVE|||||||
33887060|NCT01400256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33974290|NCT05850351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the study, outcomes assessor will not know which group the children belong to.||f|f|f|t
33974291|NCT00640978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974292|NCT04771000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974293|NCT04759495|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974294|NCT04552704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974295|NCT01348295|||CASE_ONLY||PROSPECTIVE|||||||
33761767|NCT06096545|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients were randomized into two groups based on the initial biopsy method. In Group A, patients with axillary metastasis identified by FNAB were subjected to repeat ultrasound-guided FNAB after completion of neoadjuvant treatment, while in Group B, patients with axillary metastasis identified by CNB underwent repeat biopsy using the same method after completing neoadjuvant treatment. The obtained biopsies were sent for histopathological evaluation without revealing patient names to avoid influencing the research results, and the surgical team was not informed of the biopsy results. During surgery, both dyed lymph nodes and clipped lymph nodes were excised for SLNB and assessed by frozen section evaluation. Thus, the predictability of axillary metastasis by preoperative FNAB/CNB was tested.||||
34072997|NCT06180161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34072998|NCT02377492|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34072999|NCT01826981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761768|NCT01084512|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073000|NCT04600791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073001|NCT04855214|||COHORT||RETROSPECTIVE|||||||
33761769|NCT04916964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761770|NCT02727686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887061|NCT00777179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887062|NCT04825054|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||"1. pressure control ventilation~2. pressure support ventilation~3. neurally adjusted ventilatory assist"|t|f|f|f
33887063|NCT06217315|||COHORT||RETROSPECTIVE|||||||
33887064|NCT01097772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887065|NCT00216723|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33887066|NCT00308763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887067|NCT04298762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33887068|NCT05903521|||CASE_CONTROL||PROSPECTIVE|||||||
33887069|NCT01987908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887070|NCT00454779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887071|NCT00198692|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33887072|NCT04523974|||COHORT||PROSPECTIVE|||||||
33887073|NCT03689192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887074|NCT04206878|||COHORT||PROSPECTIVE|||||||
33887075|NCT02139956|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887076|NCT03091504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887077|NCT00126165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887078|NCT03434184|||CASE_ONLY||PROSPECTIVE|||||||
33887079|NCT01857921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887080|NCT04234737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33887081|NCT04481022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887082|NCT00880360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887083|NCT01818726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887084|NCT00003632||||TREATMENT||||||||
33887085|NCT01136343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33887086|NCT00152867|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33887087|NCT02186184|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33887088|NCT02494596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073002|NCT00829699|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34073003|NCT05644288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data will be collected by three team members who will make a telephone call to the study participants and record the study variables on four occasions throughout the study. They will be blinded, i.e., they will have no information about the major. Also, the data analyst will not know to which group each subject belongs.|Two-arm parallel stratified randomized clinical trial with 12 months duration performing measurements at time 0, 3, 6, 9 and 12 months.|f|f|t|t
34073004|NCT03626701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"1. Blinded Evaluator/Observer - local burn specialist~2. Independent Reviewer"||f|f|f|t
34073005|NCT05679453|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34073006|NCT04567017|||COHORT||PROSPECTIVE|||||||
34073007|NCT00469716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33761771|NCT03460457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887089|NCT04513470|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33887090|NCT04005794|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants with schizophrenia and Outcome assessors will be blind to the training condition.|"Two conditions are compared in individuals with schizophrenia: VR social training and active control condition of computerized cognitive training.~Healthy controls are run on the baseline tasks to provide the comparison data for the patient groups but the controls do not undergo VR training."|t|f|f|t
33887091|NCT02062957|||CASE_CONTROL||PROSPECTIVE|||||||
33887092|NCT00778973|RANDOMIZED|CROSSOVER||||NONE||||||
33887093|NCT00182104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887094|NCT02629731|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33761772|NCT03076944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887095|NCT01845714|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33887096|NCT06170970|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33887097|NCT06303661|NA|SINGLE_GROUP||TREATMENT||NONE||Combination of two therapies with conservative devices is proposed.||||
33887098|NCT00652184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887099|NCT03871686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Investigators and participants will know which arm of the study participants are randomly assigned to.|The experimental group will take a 4-session Internet-based behavioral activation intervention and the control group will receive no treatment and may continue services as usual as provided by the Children's Brain Tumor Foundation.||||
33887100|NCT03030963|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33887101|NCT00770055||||HEALTH_SERVICES_RESEARCH||||||||
33887102|NCT02208245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887103|NCT01679002|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887104|NCT04239326|||COHORT||CROSS_SECTIONAL|||||||
34073008|NCT05149547|||COHORT||PROSPECTIVE|||||||
34073009|NCT00410072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073010|NCT04444518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34073011|NCT00105989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073012|NCT01523834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974296|NCT04017013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The masking process will be done as follows:~Masking of the data collection and analysis staff: The investigative staff who performs the data collection and who evaluates the outcomes after the anesthetic act, will not have information about the intervention received by the patient. Those who participate in the data analysis phase will also be blind to the intervention.~For practical and ethical point of view, it is not possible to mask the doctors who perform the intervention and neither the patients. A SHAM or simulated intervention is not possible given that this would require an unnecessary invasive procedure that would not be used, which would make it ethically questionable."|All patients who accept participation in the study and meet all inclusion criteria will be randomly assigned at the time of anesthetic induction. The assignment to the group of epidural analgesia vs IV lidocaine will be 1: 1 randomly using permuted blocks generated by a computer operated by an external assistant to the investigation. The size of the blocks will be variable between 4, 6, and 8, and will be kept confidential to guarantee the concealment of the groups.|t|f|t|t
33974297|NCT05855915|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33974298|NCT00745095|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33974299|NCT02462538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974300|NCT04228341|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover design||||
33974301|NCT04164888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974302|NCT01813656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974303|NCT04043520|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33974304|NCT01341639|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34073013|NCT01473940||SEQUENTIAL||TREATMENT||NONE||||||
34073014|NCT03241576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34073015|NCT05394701|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34073016|NCT05258253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073017|NCT06415435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34073018|NCT01254656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073019|NCT01678664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073020|NCT05419167|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761773|NCT02536638|||CASE_CONTROL||PROSPECTIVE|||||||
33761774|NCT05716230|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33761775|NCT02301156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761776|NCT02333760|NA|SINGLE_GROUP||OTHER||NONE||||||
33761777|NCT04131530|||COHORT||PROSPECTIVE|||||||
33761778|NCT01626222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761779|NCT04212364|RANDOMIZED|PARALLEL||PREVENTION||NONE||Index participants will be randomized into 1 of two study arms.||||
33761780|NCT03017326|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33761781|NCT04836221|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34073021|NCT01858207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073022|NCT04156243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073023|NCT02809352|||COHORT||PROSPECTIVE|||||||
34073024|NCT00330694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34073025|NCT02899975|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073026|NCT02487797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073027|NCT00176657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073028|NCT06391359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073029|NCT01836146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073030|NCT06412523|||COHORT||PROSPECTIVE|||||||
34073031|NCT00979095|||CASE_CONTROL||PROSPECTIVE|||||||
34073032|NCT01635621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073033|NCT02858271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073034|NCT04351451|||COHORT||PROSPECTIVE|||||||
33761782|NCT00259922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152268|NCT00094848|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152269|NCT05283590|||CASE_CONTROL||PROSPECTIVE|||||||
34152270|NCT03624127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152271|NCT00261703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152272|NCT04759469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34152273|NCT01426776|NA|SINGLE_GROUP||SCREENING||NONE||||||
34152274|NCT01935414|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152275|NCT02564484|||CASE_CONTROL||PROSPECTIVE|||||||
34152276|NCT04547582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152277|NCT01789216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152278|NCT04405245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152279|NCT00120328|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34152280|NCT05818722|||OTHER||RETROSPECTIVE|||||||
34152281|NCT04046731|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152282|NCT04371692|||COHORT||PROSPECTIVE|||||||
34152283|NCT02056613|||COHORT||PROSPECTIVE|||||||
34152284|NCT05470634|||COHORT||PROSPECTIVE|||||||
34152285|NCT00902174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152286|NCT03461081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073035|NCT03122392|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Volume and Pressure Profiles in the AMS 800 cuff. The cuff is filled with deionized water and the amount of fluid in it decides the pressure it will apply while wrapped around the urethra. The pressure-volume profiles will be taken from 6 patients consented by the PI and these will be used for the secondary end point.||||
34073036|NCT06135571|||COHORT||RETROSPECTIVE|||||||
34073037|NCT01749410|||CASE_ONLY||RETROSPECTIVE|||||||
34073038|NCT03791762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial|f|f|t|f
33887105|NCT02903004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887106|NCT05855304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33887107|NCT02686294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887108|NCT01446809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073039|NCT05935696|||COHORT||PROSPECTIVE|||||||
33887109|NCT06031233|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073040|NCT05101759|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887110|NCT04067518|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention study model is sequential in results section of record.||||
34073041|NCT04117542|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073042|NCT02163681|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073043|NCT03243305|NA|SINGLE_GROUP||PREVENTION||NONE||Single Arm, unblinded||||
34073044|NCT05873270|||COHORT||CROSS_SECTIONAL|||||||
34073045|NCT05258734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34073046|NCT02862392|||COHORT||PROSPECTIVE|||||||
34073047|NCT03210051|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33887111|NCT04427254|NA|SINGLE_GROUP||OTHER||NONE||||||
33887112|NCT05883098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887113|NCT03897751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33887114|NCT00553462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887115|NCT02507804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887116|NCT00823641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887117|NCT00145444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33887118|NCT03728881|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887119|NCT04850560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887120|NCT06213662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887121|NCT02487186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887122|NCT03604731|||COHORT||PROSPECTIVE|||||||
33887123|NCT05284201|NA|SEQUENTIAL||TREATMENT||NONE||||||
33887124|NCT05299801|||COHORT||RETROSPECTIVE|||||||
33887125|NCT01247857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887126|NCT00947531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887127|NCT00437216|||CASE_ONLY||OTHER|||||||
33887128|NCT01857609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887129|NCT00294944|RANDOMIZED|PARALLEL||||DOUBLE||||||
33887130|NCT03806426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887131|NCT03710447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors involved in data analysis will not be aware of the arm to which the participants were allocated (single-blinded masking).|Parallel Assignment parallel-group, randomized-controlled study|f|f|f|t
33887132|NCT01597063|||CASE_ONLY||PROSPECTIVE|||||||
34073048|NCT05123352|||COHORT||PROSPECTIVE|||||||
34073049|NCT04348942|||COHORT||PROSPECTIVE|||||||
34073050|NCT04418050|||COHORT||RETROSPECTIVE|||||||
34073051|NCT00208260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073052|NCT01046331|||COHORT|||||||||
34073053|NCT04744506|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: CG-TAD Group (Control) US-guided clip insertion into suspicious ALNs pre-NAC Post-NAC, TAD removing SLNs and clipped LNs Group 2: CN-LNM Group US-guided CNSI injection to tattoo suspicious ALNs pre-NAC Post-NAC, TAD removing SLNs and carbon-marked LNs Group 3: PCN-MAP Group US-guided CNSI injection around primary tumor pre-NAC, additional US-guided clip placement for metastatic LN Post-NAC, TAD removing SLNs, carbon-marked LNs, and clipped LNs||||
34073054|NCT04602156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073055|NCT00496158|RANDOMIZED|||TREATMENT||DOUBLE||||||
34073056|NCT01711255|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073057|NCT03822156|||COHORT||PROSPECTIVE|||||||
34073058|NCT05799430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A cluster-randomized control trial|f|f|f|t
34073059|NCT06611956|||COHORT||CROSS_SECTIONAL|||||||
34073060|NCT02158377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073061|NCT03082469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Inflammatory cytokine removal by Cyto Sorb treatment||||
34073062|NCT04684134|||CASE_CONTROL||PROSPECTIVE|||||||
33887133|NCT00006981||||TREATMENT||NONE||||||
33887134|NCT01474590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33887135|NCT01203657|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33887136|NCT01786317|||CASE_CONTROL||PROSPECTIVE|||||||
33887137|NCT02198833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33887138|NCT01693172|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974305|NCT05380856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After a month of optimization where the IPG is turned on at subsensory stimulation the participants will be randomly assigned to either intervention or placebo group with a 1:1 allocation as per a computer generated randomization schedule by a clinician who is not involved in the assessment of the clinical outcome.|"After the implantation of the IPG the patients will be grouped into three strata:~1. Patients with urgency frequency syndrome and/or urgency incontinence: at least 50% decrease in number of voids and/or number of leakages and/or increased voided volume and/or more than 50% reduction in pad weight~2. Patients with chronic urinary retention: at least 50% decrease in post void residual and/or reduction in number of CISC~3. Patients with a combination of urgency frequency syndrome and/or urgency incontinence and chronic urinary retention: at least 50% decrease in number of voids and/or number of leakages and/or more than 50% reduction in pad weight, and/or at least 50% decrease in post void residual and/or a reduction in number of CISC~After four months all IPG´s are turned on."|t|f|t|t
33887139|NCT04266535|||CASE_CONTROL||OTHER|||||||
33887140|NCT01261819|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33887141|NCT05790993|||CASE_ONLY||RETROSPECTIVE|||||||
34073063|NCT01720524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887142|NCT05112510|||CASE_CONTROL||RETROSPECTIVE|||||||
34073064|NCT05556460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887143|NCT04489979|||COHORT||RETROSPECTIVE|||||||
34073065|NCT03300440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33887144|NCT04993625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073066|NCT00677313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887145|NCT06411093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887146|NCT05460585|||COHORT||PROSPECTIVE|||||||
33887147|NCT03290950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase II study and treated with 4-drug combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone.||||
33887148|NCT03656965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887149|NCT03038646|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33887150|NCT05105386|||COHORT||PROSPECTIVE|||||||
33887151|NCT01244256|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33887152|NCT05449457|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Two blinded observers will record their scores independently using the POSAS instrument.||f|f|f|t
33887153|NCT04953871|NA|SINGLE_GROUP||SCREENING||NONE|All patients were evaluated by the researcher who had a 10-year experience of musculoskeletal ultrasonography and is blind to clinical evaluation.|||||
33974306|NCT00343850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33974307|NCT06077565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34073067|NCT02093416|||COHORT||PROSPECTIVE|||||||
34073068|NCT01643447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073069|NCT04616677|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34073070|NCT03866356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34073071|NCT05917327|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multinational, multicentric, single-arm, open label, pivotal/registration clinical trial.||||
34073072|NCT03314883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152287|NCT03368235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double dummy technique|Randomized, double blind, parallell arm study with two weeks treatment of AZD9567 or prednisolone|t|t|t|f
34152288|NCT01309269|||COHORT||PROSPECTIVE|||||||
34152289|NCT00480870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34152290|NCT01026220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152291|NCT02858557|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34152292|NCT02157077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152293|NCT03617055|||COHORT||PROSPECTIVE|||||||
34152294|NCT03842072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152295|NCT00424697|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34152296|NCT03665584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152297|NCT02940483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152298|NCT02744651|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34152299|NCT06526000|||COHORT||RETROSPECTIVE|||||||
34152300|NCT02450916|||CASE_ONLY||CROSS_SECTIONAL|||||||
34152301|NCT05338879|||COHORT||RETROSPECTIVE|||||||
34152302|NCT05188703|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single arm study. All participants will receive the intervention.||||
34152303|NCT05856565|||COHORT||OTHER|||||||
34152304|NCT00915551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152305|NCT01983774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152306|NCT04181177|||OTHER||OTHER|||||||
34152307|NCT02953886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887154|NCT04942886|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887155|NCT00059202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887156|NCT04790227|||COHORT||PROSPECTIVE|||||||
33974308|NCT03785977|||CASE_ONLY||PROSPECTIVE|||||||
33974309|NCT05283239|||COHORT||PROSPECTIVE|||||||
33974310|NCT05101928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974311|NCT00650156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974312|NCT02352883|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33974313|NCT01640496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073073|NCT05661695|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignment RTs will be observed during patient care without the use of the RT Assistant during the non-interventional phase and with the use of the RT Assistant during the interventional phase. RTs will be observed by highly trained RTs during both phases. RTs will answer a likert scale questionnaire about the use of the RT Assistant used to make clinical decisions.||||
34073074|NCT05273723|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|None (Open Label)|The study utilizes a modified Time-to-Event Continual Reassessment Method Dose-Finding Design||||
34073075|NCT02829658|||COHORT||PROSPECTIVE|||||||
33887157|NCT02125214|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33887158|NCT06229392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887159|NCT04052581|||CASE_ONLY||PROSPECTIVE|||||||
33887160|NCT00932633|||COHORT||PROSPECTIVE|||||||
33887161|NCT05210504|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33887162|NCT00008190||||TREATMENT||||||||
33887163|NCT02667184|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33887164|NCT05244239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887165|NCT01246206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887166|NCT02282787|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33887167|NCT03712826|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887168|NCT00699179|||COHORT||PROSPECTIVE|||||||
33887169|NCT00727207|NON_RANDOMIZED|||TREATMENT||||||||
33887170|NCT04972994|RANDOMIZED|PARALLEL||TREATMENT||NONE||right and left hemicolectomies in colonic cancers||||
33887171|NCT02835430|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33887172|NCT03030287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887173|NCT02168686|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, multicenter, dose-escalation clinical study to assess the safety and treatment effect of ADVM-043 in subjects with Alpha-1 Antitrypsin Deficiency.||||
33887174|NCT02835885|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34073076|NCT00995722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34073077|NCT06333886|||COHORT||PROSPECTIVE|||||||
33887175|NCT00000584|RANDOMIZED|||PREVENTION||DOUBLE||||||
33887176|NCT06190457|||CASE_ONLY||RETROSPECTIVE|||||||
33887177|NCT05213247|||CASE_ONLY||CROSS_SECTIONAL|||||||
33887178|NCT04598490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After recruiting patients who met the inclusion criteria, the intervention was randomly allocated to either the right or left side using the permuted random block size of 2 with 1:1 allocation ratio. The random sequences for each intervention to either right or left sides was concealed in opaque envelopes and shuffled before the intervention to increase the unpredictability of the random allocation sequence. Each patient was asked to pick a sealed envelope to assign the intervention to either the right or left side. Allocation concealment was aimed to prevent selection bias and to protect the assignment sequence until allocation.|Space closure into old extraction space|t|f|f|t
33974314|NCT03537781|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomly allocated to a food labelling or no food labelling condition. Participants in each condition will be tested when hungry and when satiated|t|f|f|f
33974315|NCT05200858|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Devices may be high-dose (delivering 100% of the dose) or low-dose (delivering 10% of the dose) TENS|"Participants, who satisfy the inclusion and exclusion criteria and sign the informed consent form will be randomly assigned with ratio of 1:1 into two groups. One group will utilize TENS high-dose devices (Intervention group, IG); the other group will utilize TENS low-dose devices (Placebo group, PG).~Both groups will receive their respective devices at the initial visit (BL) and will be asked to return in 4 weeks for follow-up assessment (4W visit). At this 4 week visit, study participants will be unblinded and the IG will keep their high-dose device, while the PG will switch from low-dose to high-dose TENS device. Study participants will return for a final in-person visit at the 8th week (8W), which will include the assessments described above. Throughout this 8-week period the participants may receive follow-up phone calls assessing their compliance. All subjects will keep the commercial (high-dose TENS) device after completion of the 8-week study."|t|t|f|f
33887179|NCT02914509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887180|NCT01062360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887181|NCT05796986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887182|NCT01956851|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887183|NCT04390087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized controlled trial||||
33761783|NCT00369538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33761784|NCT05786729|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention will consist of aerobic exercise sessions at predetermined heart rate range.||||
33761785|NCT05358925|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"While the investigators will not explicitly inform participants of their condition, it will be apparent based on the content of the videos they receive and whether or not they receive feedback.~The investigators and study staff will be aware of condition assignments in order to facilitate the delivery of the appropriate videos and the neuropsychological feedback."|This study includes two randomization branching points: (1) BPD-related videos vs. non-BPD-related videos, and (2) receive neuropsychological feedback vs. not. At branching point (1), 2/3 of participants will be directed to the BPD-video condition, and 1/3 to the non-BPD-video condition. Only the participants in the BPD-video condition will be randomized to receive feedback or not (1/2 each condition). No non-BPD-video participants will receive feedback.||||
33761786|NCT05083143|||CASE_CONTROL||RETROSPECTIVE|||||||
33761787|NCT00903786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761788|NCT02504125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34073078|NCT00205660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761789|NCT06449092|||OTHER||CROSS_SECTIONAL|||||||
33761790|NCT04199260|||CASE_ONLY||PROSPECTIVE|||||||
33761791|NCT02421562|NA|SINGLE_GROUP||||NONE||||||
33761792|NCT04437095|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomized 1:1 to intervention vs standard care. Using data from our prior observational study, mean (SD) HADS-Anxiety subscale was 7.3 (4.1) among these subjects (coefficient of variation = 4.1/7.3 = 0.56). A total 300 subjects will be enrolled and randomized until 100 subjects per arm recruitment target is reached to allow for mortality and dropout.~The analysis will compare 6 month HADS-A by treatment arms using ANCOVA. The analysis will be conducted under a modified intention to treat principle, with subjects analyzed according to randomized arm, but excluding patients who die before follow up. Additional outcomes including HADS-D, MoCA-blind, and EQ-5D will be analyzed similarly using ANCOVA, and IES-R subscore\>1.6 will be analyzed by Chi-square test."||||
33761793|NCT02712125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761794|NCT04918225|||CASE_CONTROL||PROSPECTIVE|||||||
33761795|NCT02809898|||CASE_CONTROL||PROSPECTIVE|||||||
33761796|NCT04196998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761797|NCT00079508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887184|NCT01806467|||COHORT||PROSPECTIVE|||||||
33887185|NCT00893516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887186|NCT01344967|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33887187|NCT03718364|||COHORT||PROSPECTIVE|||||||
33887188|NCT05203250|||COHORT||OTHER|||||||
33887189|NCT02719340|||CASE_ONLY||RETROSPECTIVE|||||||
33887190|NCT01714986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073079|NCT00324974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073080|NCT05868681|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073081|NCT05264909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073082|NCT05798143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761798|NCT00002763|RANDOMIZED|||TREATMENT||||||||
33761799|NCT04074590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject and investigator blinded via randomization|"This is a randomized, placebo-controlled, subject and investigator blinded, multicenter, non-confirmatory, parallel group, proof of concept study in patients with mild to moderate ulcerative colitis. This study consists of a screening period of up to 4 weeks, and a 8 week treatment period followed by a 30 day post treatment period safety follow up. The maximum study duration for each such including the 4 week screening period is 16 weeks.~At the beginning of the treatment period, subjects will be randomized to one of the two following treatment groups in 2:1 ratio:~* LYS006~* matching placebo"|t|f|t|f
33761800|NCT02810093|||COHORT||RETROSPECTIVE|||||||
33761801|NCT05319249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761802|NCT03393832|||COHORT||PROSPECTIVE|||||||
33887191|NCT04406870|NA|SINGLE_GROUP||TREATMENT||NONE||Recruiting patients with IHHE who have no response to propranolol after 3 months. Then propranolol combined with sirolimus will be given.||||
33887192|NCT02487108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887193|NCT00831454|||COHORT||RETROSPECTIVE|||||||
33974316|NCT04914715|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be done via random allocation software 1.0.0. This software produces as its output a sequence of allocation based on selected type. Considering 2 groups with equal sample size, a simple random allocation list will be generated using block randomization. The list will be used to create Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) to assure allocation concealment. The process of randomization will be conducted by Indus Hospital Research Centre (IHRC) independently.||||
33974317|NCT05393947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34073083|NCT05205512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073084|NCT00868647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073085|NCT00610272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073086|NCT03307941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073087|NCT03252145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887194|NCT05812664|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Limitation of the study; since the patients were intubated and under sedation, they did not know the diet applied to them, but the physician/nurse who examined the residue and PGD knew the diet. Unfortunately, the person who evaluated these two parameters could not be blinded, as it would not be possible to give without showing the feeding methods. However, groups 1-2-3 were reported to the statistician who analyzed the data. The feeding methods of the groups was not reported.|If the patients were diagnosed with sepsis in ICU, they were not fed after 24:00, and if the gastric residual measured at 05:00 in the morning was negative, they were included in the study. The patients were examined in 3 groups. The number of samples required to be taken in the power analysis performed (G\*power 3.1) was found to be 93 (31 patients in each group) (power value 0.80, alpha error probability=0.05). Patients for the groups were randomly selected by the closed envelope method. A total of 93 envelopes, 31 for each group, were prepared. When the patient was diagnosed with sepsis, if he/she met the inclusion criteria, a random envelope was selected to determine the patient's group. After inclusion in the study, a closed envelope was added again for the patients who should be excluded from the study.|t|f|f|t
33974318|NCT03482713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Japanese adult participants with refractory or unexplained chronic cough will be randomized to 1 of 2 treatment groups: gefapixant 45 mg twice daily (BID), or placebo BID.|t|f|t|f
33887195|NCT00341614|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33887196|NCT03575026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887197|NCT04424563|||COHORT||PROSPECTIVE|||||||
33887198|NCT02393911|RANDOMIZED|PARALLEL||||NONE||||||
33887199|NCT02553694|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33887200|NCT04519996|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33887201|NCT05527457|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants and outcomes assessor (sleep scorer) blinded to all 3 study arms. Investigator blinded to 2/3 arms.||t|f|t|t
33887202|NCT01967290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887203|NCT01869348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33887204|NCT05275569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887205|NCT06485193|||CASE_ONLY||CROSS_SECTIONAL|||||||
33887206|NCT00997516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887207|NCT05242770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887208|NCT03882424|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double-blind||t|f|t|f
33887209|NCT00004054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887210|NCT05861505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974319|NCT00710203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33974320|NCT04032873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974321|NCT00219661|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974322|NCT02133755|NA|SINGLE_GROUP||||NONE||||||
33974323|NCT02177955|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33974324|NCT04153253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974325|NCT02746263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974326|NCT01557647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974327|NCT04145908|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|patient don't know the procedure|two groups one group for onlay mesh position the other for preperitoneal position|t|f|f|f
33974328|NCT00000275||||TREATMENT||||||||
33974329|NCT04639934|||COHORT||PROSPECTIVE|||||||
33887211|NCT05518604|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Active Duty women will be enrolled during pregnancy and randomized postpartum to one of three groups for the first year postpartum.~Group 1- dietary counseling with close monitoring utilizing a biometric fitness device Group 2- Close monitoring with biometric fitness device Group 3 Routine postpartum care"||||
33887212|NCT03547557|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33974330|NCT00958581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887213|NCT03062657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887214|NCT00687791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887215|NCT01911858|NA|SINGLE_GROUP||||NONE||||||
33887216|NCT02886299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887217|NCT00773409|||CASE_CONTROL||PROSPECTIVE|||||||
33974331|NCT04664842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974332|NCT06339593|||COHORT||PROSPECTIVE|||||||
33974333|NCT00976235|NA|SINGLE_GROUP||OTHER||NONE||||||
33974334|NCT00315549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974335|NCT01388023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974336|NCT04109911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974337|NCT02046291|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33974338|NCT02442479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974339|NCT01983020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974340|NCT04884581|NA|SINGLE_GROUP||OTHER||NONE||||||
33974341|NCT02025114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974342|NCT00171496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974343|NCT05657093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blinded (Participant, Investigator and Outcomes Assessor) The participant was blinded not knowing the treatment to which he was submitted, investigator and outcome assessor responsible for collecting the results, without commenting on the group from which the subject came.|Parallel allocation was carried out in the two groups|t|f|t|t
34073088|NCT02477358|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participant and Operating Surgeon were masked to tooth designation. Principal investigator/outcomes assessor aware of designation.|Multiple teeth (2-6 teeth per participant) will be removed with the root attached and then half of the total teeth(per participant) will be placed back in the socket with Platelet Rich Fibrin (PRF) and the other half will be placed in the socket without PRF.|t|t|f|f
34073089|NCT05678439|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34073090|NCT06404749|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|data analysts||t|f|t|f
34073091|NCT03370965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073092|NCT01147718|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073093|NCT06158035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34073094|NCT03783377|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34073095|NCT02058589|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34073096|NCT06212986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887218|NCT01694043|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34073097|NCT04090385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974344|NCT04915807|||CASE_ONLY||PROSPECTIVE|||||||
33974345|NCT06460974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073098|NCT06506058|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The study will use a cross-sectional design to examine the effects of group (PD with FOG vs. PD without FOG vs. matched controls; older adults vs. younger adults)|f|f|f|t
34073099|NCT01857180|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34073100|NCT06355375|RANDOMIZED|PARALLEL||PREVENTION||NONE||Exercise during pregnancy||||
34073101|NCT03489252|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34073102|NCT04820296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single|Posttest and control grouped randomized controlled clinical trial|f|f|f|t
33887219|NCT05068609|||COHORT||PROSPECTIVE|||||||
33974346|NCT05895370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974347|NCT03172637|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073103|NCT00220181|||CASE_CONTROL||OTHER|||||||
34073104|NCT05995587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in the intervention group will either receive mindfulness training from a certified mindfulness teacher or from social workers (supervised by a certified mindfulness teacher). The care as usual group will receive usual service provided in District Elderly Community Centres (DECC) and Integrated Community Centre for Mental Wellness (ICCMW).||||
33974348|NCT03833596|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment options are randomized and masked for participants and study staff until Visit 2, where participants and investigators are made aware of treatment arm.|Randomized control trial with three arms of treatment: EEN plus standard or short course of CS versus CS alone.||||
33974349|NCT04784117|||COHORT||RETROSPECTIVE|||||||
33974350|NCT01136707|||COHORT||RETROSPECTIVE|||||||
33974351|NCT03083249|||COHORT||PROSPECTIVE|||||||
33974352|NCT06102629|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Case control study with two parallel groups||||
33974353|NCT05091606|||COHORT||PROSPECTIVE|||||||
33974354|NCT02534948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887220|NCT04214652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887221|NCT03531996|||COHORT||PROSPECTIVE|||||||
33887222|NCT03649152|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double-blind, Randomised, Placebo-Controlled, Crossover Study|t|t|t|t
33974355|NCT04409366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974356|NCT03035279|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33974357|NCT01741857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974358|NCT00387712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073105|NCT05906342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators will not know the fat quantity of the meal that is being consumed or the order in which the meals are provided to the participant. A non-investigator member of the research team will be responsible for creating the meals and keeping track of which meals are being consumed.|Each participant will be required to consume four breakfast meals (containing 20, 40, 60, or 80% energy from fat) in a randomized order with a washout period between meals|t|f|t|f
34073106|NCT04136483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887223|NCT02519660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887224|NCT00030069|NON_RANDOMIZED|||TREATMENT||NONE||||||
33887225|NCT01652924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33887226|NCT04819906|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33887227|NCT02505529|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33887228|NCT02181933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887229|NCT03705481||SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Prospective, single-arm, single center, non-randomized feasibility study||||
33887230|NCT00199004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887231|NCT01716481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887232|NCT04119570|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||During the first half of the study, participants will be surveyed and observed without the intervention. During the second half, participants will be surveyed and observed with the intervention (CKD Report Card)||||
33887233|NCT01880411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887234|NCT03743831|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33887235|NCT01825902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974359|NCT05924256|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974360|NCT06484309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887236|NCT05957887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887237|NCT02970929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887238|NCT00320970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887239|NCT00403260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887240|NCT02953808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887241|NCT03623789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887242|NCT01237860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33887243|NCT01834404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887244|NCT03805126|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33887245|NCT05768373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only subject will be blinded.||t|f|f|f
33887246|NCT02034045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887247|NCT05048563|||COHORT||PROSPECTIVE|||||||
33761803|NCT06363422|||CASE_ONLY||RETROSPECTIVE|||||||
33761804|NCT04802343|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33761805|NCT02184702|||CASE_ONLY||PROSPECTIVE|||||||
33761806|NCT01463280|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33761807|NCT03245385|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single treatment arm study||||
33761808|NCT06197906|NA|SINGLE_GROUP||SCREENING||NONE||||||
33761809|NCT02600884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761810|NCT03617848|||COHORT||PROSPECTIVE|||||||
33761811|NCT05199363|RANDOMIZED|PARALLEL||OTHER||NONE||"Study participants will be randomly assigned into one of 4 groups:~* Group A, 25% of the sample - patients subject to intervention No 1: Information leaflet~* Group B, 25% of the sample - patients subject to intervention No. 2: Educational movie~* Group C, 25% of the sample - patients subject to intervention No. 3 Demonstration~* Group D, 25% of the sample - control group, with no intervention."||||
33887248|NCT02780076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073107|NCT06072118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887249|NCT05446493|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33887250|NCT01743833|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34073108|NCT01327248|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887251|NCT04802473|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective case series with a 6-month follow-up.||||
34073109|NCT02741375|||CASE_CONTROL||PROSPECTIVE|||||||
33887252|NCT03204630|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33887253|NCT06018701|RANDOMIZED|PARALLEL||TREATMENT||NONE||Total forty eight (48) dental devices made of zirconia will be cemented. 12 dental device in each allocated quadrant, i.e., maxillary anterior, maxillary posterior, mandibular anterior and mandibular posterior. And the results will be compared.||||
33887254|NCT01730248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887255|NCT00237679|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887256|NCT01891071|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33887257|NCT03527576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887258|NCT05232058|||COHORT||PROSPECTIVE|||||||
33887259|NCT03168516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887260|NCT06443658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887261|NCT01061931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33887262|NCT00700856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073110|NCT03084302|||COHORT||PROSPECTIVE|||||||
34073111|NCT03944863|||CASE_CONTROL||RETROSPECTIVE|||||||
34073112|NCT05887700|||COHORT||RETROSPECTIVE|||||||
34073113|NCT02033044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34073114|NCT06572163|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33761812|NCT05239325|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761813|NCT06016010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761814|NCT00005993||||TREATMENT||||||||
33761815|NCT02916602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761816|NCT04618601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887263|NCT03499431|||COHORT||PROSPECTIVE|||||||
33887264|NCT01044563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887265|NCT00923429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887266|NCT06190821|||CASE_ONLY||RETROSPECTIVE|||||||
33887267|NCT01231165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887268|NCT03015103|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33887269|NCT02550158|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33887270|NCT02619851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887271|NCT02932267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887272|NCT05061407|||COHORT||PROSPECTIVE|||||||
33887273|NCT01276184|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33887274|NCT01552681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887275|NCT02690909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887276|NCT03288246|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887277|NCT04500704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887278|NCT05641701|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will act as their own control. Each individual's stutter will be assessed with DBS system OFF (control) and DBS ON (treatment).||||
33887279|NCT06126640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887280|NCT05912933|||COHORT||OTHER|||||||
33887281|NCT04426695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 1/Phase 2/Phase 3|t|t|t|t
33887282|NCT04093648||SEQUENTIAL||TREATMENT||NONE||||||
33887283|NCT01196442|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887284|NCT03475212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887285|NCT04495699|||COHORT||PROSPECTIVE|||||||
33761817|NCT03919812|NA|SINGLE_GROUP||TREATMENT||NONE||This study was designed as a non-randomized, open label, intervention study and performed at the thalassemia clinic of the Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.||||
33761818|NCT00228696|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33761819|NCT02985983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761820|NCT04797091|||CASE_CONTROL||RETROSPECTIVE|||||||
33761821|NCT05322070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761822|NCT00711815|||COHORT||PROSPECTIVE|||||||
33887286|NCT05152381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887287|NCT04452890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center, prospective feasibility trial||||
33761823|NCT04816019|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33761824|NCT04178057|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761825|NCT05278689|||COHORT||RETROSPECTIVE|||||||
33887288|NCT03148730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|single blinded ( outcome assessor)|2 groups one = manually conducted anesthesia second = fully automated anesthesia, analgesia, ventilation and fluid management|t|f|f|t
33887289|NCT00002085||||TREATMENT||||||||
33887290|NCT04244370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887291|NCT00887458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887292|NCT04311658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33887293|NCT04248205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887294|NCT04859413|||COHORT||CROSS_SECTIONAL|||||||
33887295|NCT02273245|||COHORT||RETROSPECTIVE|||||||
33887296|NCT05011487|NA|SINGLE_GROUP||TREATMENT||NONE||osimertinib plus chemotherapy||||
33887297|NCT03624257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking for the assessors of microbial, immunological and radiographic analyses.||f|f|f|t
33887298|NCT00623571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33887299|NCT01590342|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33887300|NCT05974982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887301|NCT01275014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887302|NCT05389449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887303|NCT01107444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887304|NCT05977907|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive same dose of drug. One Cohort||||
33887305|NCT01524991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887306|NCT01957956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887307|NCT01854060|||COHORT||RETROSPECTIVE|||||||
33887308|NCT03608748|||COHORT||PROSPECTIVE|||||||
33887309|NCT05910229|RANDOMIZED|PARALLEL||OTHER||DOUBLE||comparative monocentric study with randomisation between two parallel arms|f|t|t|f
33887310|NCT00931164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887311|NCT02096094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33887312|NCT05136833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887313|NCT02908516|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33887314|NCT00733525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887315|NCT05554120|||COHORT||PROSPECTIVE|||||||
33887316|NCT02770157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887317|NCT02775032||||HEALTH_SERVICES_RESEARCH||||||||
33887318|NCT03969875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887319|NCT04691102|||CASE_CONTROL||PROSPECTIVE|||||||
33887320|NCT01050114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887321|NCT06091644|NA|SINGLE_GROUP||OTHER||NONE||||||
33887322|NCT02195492|||COHORT||RETROSPECTIVE|||||||
33887323|NCT00748748|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33974361|NCT06546241|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The project coordinator and PI oversee the randomization and participant tracking. However, participants do not know their assigned condition, and facilitators that run the workshops are blind to participant condition, and undergraduate research assistants that oversee the distribution of surveys are blind to participant condition.|Participants are randomized to the intervention or wait-list control group. The intervention group will complete a baseline survey, receive the 60 minute workshop, and completes a post-intervention survey. The control group receives a survey, waits, completes a baseline survey, then receives the 60 minute workshop, and completes a post-intervention survey.|t|t|f|t
33974362|NCT02598271|||OTHER||PROSPECTIVE|||||||
33974363|NCT03890250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assessor will be blind to the randomization and the investigator will be blind to the results of assessments.|Thirty IPF patients aged 40-80 years who are followed up at Istanbul University, Istanbul Medical Faculty Chest Disease Department will include in the study. Participants will be divided into two groups as the NMES group and the Sham Training Group, using a computer-assisted randomization table.|t|f|t|t
33974364|NCT02153307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887324|NCT00252330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887325|NCT01206881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887326|NCT06202573|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||prospective randomised self-controlled clinical study|t|f|t|t
33887327|NCT03646448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887328|NCT05869006|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||In a single-blind randomized controlled study, 3X4 split-plot design was used. A stratified randomization was carried out according to gender with 30 students who met the criteria for inclusion in the sample from the determined target group. The research was conducted with a total of 30 students, 10 of whom were in the intervention group, 10 in the placebo control group, and 10 in the control group. In order to evaluate the data, Psychological Well-Being Scale (PWS) and Creativity Scale (CS) were applied at time series points (pretest, posttest, 1st month follow-up and 3rd month follow-up).|t|f|f|f
33887329|NCT04629560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients will be randomly assigned either to the miracle fruit intervention or to supportive measures at first and later participants will cross over to the other intervention.||||
33887330|NCT01417754|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887331|NCT01576640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887332|NCT00363831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887333|NCT03227367|RANDOMIZED|PARALLEL||OTHER||NONE||"Control group: (Healthy individuals) comprised of 25 participants with clinically healthy periodontium.~Test group: (Chronic periodontitis patients) comprised of 25 participants with signs of clinical inflammation and bone loss."||||
33887334|NCT04929990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887335|NCT01873755|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33887336|NCT03640884|||COHORT||PROSPECTIVE|||||||
33887337|NCT03047525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887338|NCT04566367|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The participants don't know which arm they were allocated to.|This study is a prospective randomised mono centric study with a one to one allocation in two different treatment arms.|t|f|f|f
33887339|NCT05740774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887340|NCT05755815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation, perform the block, and administer bupivacaine solution.|Prospective, randomized, double blind study|t|f|f|t
33887341|NCT04548557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||one group in conventional with routine therapy and interventional group will receive intravenous immunoglobulin therapy|f|f|t|t
33974365|NCT00311779|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33974366|NCT01762358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33974367|NCT02776007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974368|NCT03845946|||COHORT||PROSPECTIVE|||||||
33974369|NCT04105790|NA|SINGLE_GROUP||TREATMENT||NONE||The overarching design of the proposed study is a formative program evaluation using a case series methodology.||||
33974370|NCT04951050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974371|NCT03212196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33974372|NCT04764500|||COHORT||PROSPECTIVE|||||||
33974373|NCT03101943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887342|NCT03996772|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An Event Adjudication Committee (EAC) will be established. The EAC will consist of experts in relevant fields of the Study such as neurology, cardiology, and haematology. An event adjudication charter with clear definitions of pre-specified outcome events will be developed by the steering committee and agreed by the EAC. After formal training, the EAC will be provided with pseudonymised data for adjudication of pre-specified outcome events and serious adverse events using an online platform provided by the data management centre, Clinical Trials Center Wuerzburg at the University of Wuerzburg.|"PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation is a phase 3b investigator-led, multicentre, parallel group, prospective randomised, open, blinded end-point assessment (PROBE) clinical trial comparing direct oral anticoagulants against no anticoagulation in patients with a recent intracerebral haemorrhage (ICH) and comorbid atrial fibrillation (AF).~Randomisation will occur in a 1:1 ratio. Participants will be stratified according to two factors: lobar and non-lobar location of ICH and gender. Choice and dose of direct oral anticoagulant treatment and use of concomitant medication during the study treatment will be at the Principal Investigator´s discretion within the licensed doses for stroke prevention in AF patients in Europe. The control group will receive no anticoagulant but the use of an antiplatelet is at the Principal Investigator´s discretion who will use their clinical judgment to initiate an antiplatelet drug of their choice."|f|f|f|t
33887343|NCT01713192|||COHORT||PROSPECTIVE|||||||
33887344|NCT04420130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887345|NCT04460755|RANDOMIZED|PARALLEL||SCREENING||NONE||The study is randomized, prospective clinical trial.||||
33887346|NCT03103893|NA|SINGLE_GROUP||TREATMENT||NONE|Clinical assessors are blinded to recruitment and treatment assignment.|Patients will apply lotions containing either rapamycin or vehicle to 2 distinct areas of sun exposed skin.||||
33887347|NCT03677414|||COHORT||CROSS_SECTIONAL|||||||
33887348|NCT04320524|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33974374|NCT03902275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974375|NCT04955379|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887349|NCT05953636|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This research is a randomized multi-center clinical trial in which 120 hemodialysis patients will be randomly assigned to one of the study groups.~* Group A: 40 patients will receive oral protein nutritional supplement (ONS) (Fresubin protein powder 25mg/5scoops per hemodialysis session) for 8 weeks 1 hour before the start of the session (pre-dialytic).~* Group B: 40 patients will receive oral protein nutritional supplement (ONS) for 8 weeks 2 hours after the start of the session (intra-dialytic).~* Group C: 40 patients will receive oral protein nutritional supplement (ONS) for 8 weeks in non-dialysis days (inter-dialytic)."||||
33887350|NCT00424398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887351|NCT02825121|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887352|NCT05358132|||COHORT||PROSPECTIVE|||||||
33887353|NCT04061135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073115|NCT04303195|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Parallel Assignment|t|t|t|t
33887354|NCT04610476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887355|NCT05027386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887356|NCT01708057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33887357|NCT04660188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974376|NCT02490423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974377|NCT02089490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887358|NCT04371367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
33974378|NCT05645679|||COHORT||PROSPECTIVE|||||||
34073116|NCT02587195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974379|NCT04272775|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33974380|NCT05865509|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974381|NCT00841256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974382|NCT04689477|||COHORT||PROSPECTIVE|||||||
33974383|NCT04453566|||OTHER||RETROSPECTIVE|||||||
33974384|NCT05566886|||COHORT||PROSPECTIVE|||||||
33974385|NCT00471861|||CASE_CROSSOVER||PROSPECTIVE|||||||
34073117|NCT04041596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073118|NCT03749057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974386|NCT05469282|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974387|NCT04530786|||COHORT||PROSPECTIVE|||||||
34073119|NCT02195973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073120|NCT02537600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073121|NCT04721197|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The principal investigator and statistician will be blinded to the treatment group.||f|f|t|f
34073122|NCT02091414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073123|NCT05830890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073124|NCT00960804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073125|NCT03198429|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Randomly assigned groups are: 1) treatment as usual; 2) embedded father intervention; 3) embedded mother-child intervention; 4) embedded father and mother-child intervention|f|f|f|t
34073126|NCT01005901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073127|NCT05077553|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34073128|NCT04282629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Group milrinone versus group placebo|t|t|t|t
34073129|NCT05219604|NA|SINGLE_GROUP||OTHER||NONE||||||
34073130|NCT00006146||||PREVENTION||||||||
33761826|NCT04327141|RANDOMIZED|PARALLEL||TREATMENT||NONE||40 overweight/obese adult men (n=20) and women (n=20) will be quasi-randomized to one of the two groups matched by sex (men/women) and body weight. Participants will be enrolled in the study as a single cohort and participate in a 8-week weight loss (WL) trial consisting of a single dietary intervention phase. A single male participant from the original P-IF group will continue following the identical P-IF from the original 4-8 week phase and 12 month follow up period (5-6 days of P; 1-2 day of IF) for an additional 12 month period (beyond the initial 12 monthfollow up case study period). The participant will consume the identical P-IF meal plan as the original 8 week study and 24 month follow up.||||
33761827|NCT00222001|||COHORT||PROSPECTIVE|||||||
33761828|NCT03124199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761829|NCT01446367|||CASE_CONTROL||PROSPECTIVE|||||||
33761830|NCT03960632|||COHORT||CROSS_SECTIONAL|||||||
33761831|NCT03852849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33761832|NCT04289922|||COHORT||PROSPECTIVE|||||||
33761833|NCT00262717|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761834|NCT06339060|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomize patients who meet the inclusion criteria Grouping, randomly assigned to the experimental group in a 1:1 ratio (organ preservation strategy after neoadjuvant chemotherapy combined with immunotherapy) And the control group (limited time for esophageal cancer radical surgery after neoadjuvant radiotherapy and chemotherapy)|||||
33761835|NCT06203184|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761836|NCT05587244|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, Prospective, Non-controlled, Non-randomized, Consecutive series of patients, two cohort study||||
33761837|NCT02228967|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33761838|NCT06140901|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This is a single-center prospective longitudinal study (AP-HM), in children aged 1 month to 6 years, comparing children hospitalized for lower respiratory infection by ADV or RV progressing or not to PIBO.~After inclusion of the patients, a second nasal swab will be taken as part of the research for the PCR study of the subtypes of the virus responsible for the viral infection. Following the diagnosis of PIBO, bronchial endoscopy for microbiology and bronchial biopsies will be performed as part of routine care to rule out differential diagnoses. During this endoscopy, 2 additional bronchial biopsies and nasal brushing for research will be performed to recover epithelial cells."||||
33761839|NCT06273111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761840|NCT02417532|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761841|NCT05290844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33887359|NCT02749214|||CASE_CONTROL||PROSPECTIVE|||||||
33887360|NCT03455673|||COHORT||CROSS_SECTIONAL|||||||
33887361|NCT00976144|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33887362|NCT02968017|||COHORT||PROSPECTIVE|||||||
33887363|NCT01766947|NA|SINGLE_GROUP||||NONE||||||
33887364|NCT02266173|||COHORT||PROSPECTIVE|||||||
33887365|NCT04822532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887366|NCT01137357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887367|NCT00240760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33887368|NCT00732173|RANDOMIZED|PARALLEL||||NONE||||||
33887369|NCT01487369|||COHORT||PROSPECTIVE|||||||
33887370|NCT04226313|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33887371|NCT06224114|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Technicians responsible for study measurements, Chief Investigator (CI), Principal Investigator (PI) and collaborators will be masked to the treatment allocation. It is not possible for participants to be fully masked as they will know which wavelength (colour) of light they have been provided, but they will not be told which wavelength of light is the active intervention. Participants will be advised not to discuss the colour of light used with the masked technicians and study team members.||f|t|t|t
33887372|NCT04086732|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33887373|NCT02700451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887374|NCT04997239|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887375|NCT06353776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887376|NCT01366248|||CASE_CONTROL||PROSPECTIVE|||||||
33887377|NCT00245271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887378|NCT03592979|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath trough a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia|t|f|f|f
33761842|NCT01807156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073131|NCT01351454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887379|NCT03541421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34073132|NCT05676788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073133|NCT03059537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887380|NCT04711096|||COHORT||PROSPECTIVE|||||||
33887381|NCT04103866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887382|NCT01589484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887383|NCT01247311|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34073134|NCT05201326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887384|NCT06206889|||COHORT||PROSPECTIVE|||||||
33887385|NCT02058732|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33887386|NCT02116621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887387|NCT02772757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887388|NCT05812391|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33887389|NCT01884792|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33887390|NCT03688217|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Since data will be entered directly into a tablet device by the participant, the outcomes assessor (ie: the tablet) will have no knowledge of the interventions assigned to individual participants. Additionally, the phone survey company performing the follow-up surveys will be blinded to the interventions assigned to individual participants.|This is a cluster-randomized controlled trial with baseline covariate adjustment and stratification.The randomization unit is the mentor-mother. The clusters are pregnant participants enrolled by each mentor-mother over the course of the trial. The randomization will be stratified by neighborhood type, to ensure balance of intervention versus control assignment by this covariate. The following baseline characteristics will be measured and adjusted for in the main analysis of the primary and secondary outcomes to increase statistical efficiency: 1. participant's number of previous children, 2. participant's age, 3. running water in the home, 4. electricity in the home, 5. participant's employment status, 6. participant's education level|f|f|f|t
33887391|NCT03553394|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either receive a fluid bolus immediately when urinary output is decreased for two consecutive hours or to await fluid bolus therapy for two more hours.||||
33887392|NCT01575613|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887393|NCT06261411|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Inter-rater variability will be masked.|Case-Control|f|f|f|t
33887394|NCT02599974|||COHORT||PROSPECTIVE|||||||
33887395|NCT00649454|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33761843|NCT00245102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887396|NCT04996355|||CASE_ONLY||PROSPECTIVE|||||||
33887397|NCT01841892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887398|NCT02455401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33887399|NCT00445887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33887400|NCT05451719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887401|NCT00055380||||TREATMENT||||||||
33887402|NCT01894672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887403|NCT01505894|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34073135|NCT00401193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073136|NCT00417625|||||PROSPECTIVE|||||||
34073137|NCT00002034||||TREATMENT||||||||
34073138|NCT03153800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073139|NCT02643433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073140|NCT06611579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073141|NCT06611787|||CASE_ONLY||CROSS_SECTIONAL|||||||
34073142|NCT01916460|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073143|NCT05693129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073144|NCT04947410|RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 interventional groups (15 OSAS patients into CPAP group versus 15 OSAS patients into nasal dilators group) are evaluated in parallel against a control group (15 Non-OSAS Patients)"||||
33974388|NCT02807142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974389|NCT04168476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind clinical trial|Randomized prospective controlled trial|t|f|f|f
33887404|NCT00727402|||COHORT||PROSPECTIVE|||||||
33887405|NCT00501228|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887406|NCT02511496|||||PROSPECTIVE|||||||
33887407|NCT04792502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887408|NCT02368548|RANDOMIZED|PARALLEL||||NONE||||||
33887409|NCT02674945|||COHORT||PROSPECTIVE|||||||
33887410|NCT03325322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887411|NCT00838591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887412|NCT04523740|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33887413|NCT00967447|||COHORT||PROSPECTIVE|||||||
33887414|NCT04188730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33887415|NCT05175261|||COHORT||PROSPECTIVE|||||||
33887416|NCT05611073|||CASE_CONTROL||PROSPECTIVE|||||||
33887417|NCT02131857|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887418|NCT00582556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887419|NCT05807009|NA|SINGLE_GROUP||TREATMENT||NONE||core exerscie||||
33887420|NCT04453735|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Prospective, open, intervention study||||
33887421|NCT01820715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887422|NCT04957459|||OTHER||PROSPECTIVE|||||||
33887423|NCT03695029|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887424|NCT06220006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887425|NCT04003129|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33887426|NCT03883269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator-blinded|A randomized, open-label, placebo-controlled, evaluator-blinded study.|f|f|f|t
33887427|NCT00454207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887428|NCT00093613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887429|NCT03251885|||COHORT||PROSPECTIVE|||||||
33887430|NCT06160401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887431|NCT00308165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887432|NCT06154902|||COHORT||OTHER|||||||
33887433|NCT01976949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887434|NCT05501626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974390|NCT03363581|||CASE_CONTROL||PROSPECTIVE|||||||
34073145|NCT06328257|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33887435|NCT01362582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887436|NCT04582760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33887437|NCT00275561|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33887438|NCT00533962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887439|NCT02989337|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887440|NCT03104842|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887441|NCT02616913|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33887442|NCT06549803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887443|NCT04760002|||COHORT||CROSS_SECTIONAL|||||||
33887444|NCT03108716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators collected data of 28 hamate hook fractures patients, who were treated in the Siping Central People's Hospital and had complete follow-up records.||||
33887445|NCT01384292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887446|NCT05472389|NA|SINGLE_GROUP||OTHER||NONE||||||
33887447|NCT00712374|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33887448|NCT03419858|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Only the study physician, research coordinator, and research pharmacist were aware of drug assignments. Research staff (nurses; research technicians) and the PI were not blinded to drug assignment.|The study employed a double blind 3x2x2 crossover factorial design. Baseline pain intensity and pain unpleasantness ratings were assessed using visual analog scales (11 point) obtained before and after four, 5-minute noxious heat stimulation series (49°C). Study volunteers (20/group; 60 total) were randomized and subsequently participated in a four session (20min/session) mindfulness meditation, placebo-meditation, or slow-breathing training regimen. After training completion, subjects reported to the Wake Forest Clinical Research Unit to test the study hypotheses across two separate experimental sessions. Half of the study volunteers (n=10) from each group were administered naloxone (opioid antagonist; 0.15 mg/kg bolus+ 0.1mg/kg/hour infusion) and in the subsequent session were administered IV placebo-saline and vice versa.|t|f|t|t
33974391|NCT01953497|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33974392|NCT04967313|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The order of administration for the 4 Behavioral Change Techniques (BCTs) will be randomized by the study statistician.||||
33887449|NCT00578123|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887450|NCT02856750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887451|NCT02930174|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33887452|NCT02452502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887453|NCT06322719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33887454|NCT06348121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887455|NCT05986942|||CASE_CONTROL||PROSPECTIVE|||||||
33887456|NCT05359107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887457|NCT02670603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study is open-labeled study. But outcome would be assessed the statistician who did not involve this study with blind data.||f|f|f|t
33887458|NCT04303000|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33887459|NCT00167674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887460|NCT04539093|||CASE_ONLY||PROSPECTIVE|||||||
33887461|NCT00667576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887462|NCT03856944|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, single center, open clinical trial to collect normative performance data.||||
33887463|NCT03135145|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||This is a single group repeated measures cross-over design. The study will include 4 sessions for each participant, with 2 sessions conducted using the Lite Run and 2 sessions conducted using the method of choice of the therapist (Usual Treatment).||||
33887464|NCT02789657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887465|NCT04726332|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single-agent and combination therapy dose-escalation followed by cohort-expansion||||
33887466|NCT01727258|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33887467|NCT00503256|||CASE_CONTROL||PROSPECTIVE|||||||
33887468|NCT04101175|||COHORT||PROSPECTIVE|||||||
33887469|NCT06435702|||COHORT||PROSPECTIVE|||||||
33887470|NCT01279057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887471|NCT00938730|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33887472|NCT06044896|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33887473|NCT03043144|||COHORT||PROSPECTIVE|||||||
34073146|NCT04002791|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized comparison of patent hemostasis achievement with single bladder radial artery compression device with a dual-bladder ulnar compression capable radial artery compression device.||||
34073147|NCT02500823|||CASE_CONTROL||RETROSPECTIVE|||||||
34073148|NCT01360788|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073149|NCT02590237|RANDOMIZED|PARALLEL||||NONE||||||
34073150|NCT03233815|||COHORT||CROSS_SECTIONAL|||||||
33974393|NCT05180006|RANDOMIZED|PARALLEL||TREATMENT||NONE||The design of this study follows an adaptive, open, prospective randomized model : Cohort 1 TNBC patients: they will be randomized 1:1 to either atezolizumab alone administered as one single IV infusion on day -15 +/- 48h prior to the date of surgery or the start of the standard of care neoadjuvant systemic treatment, or atezolizumab and bevacizumab as one single IV infusion on day -15 +/- 48h prior to the date of surgery or the start of neoadjuvant treatment Cohort 2 in HER2-positive patients: they will be randomized 1:1 to either trastuzumab and pertuzumab for one IV infusion on day -15 +/- 48h prior to the surgery or the start of neoadjuvant treatment, or atezolizumab as one single IV infusion in combination with trastuzumab and pertuzumab for one IV infusion on day -15 +/- 48h prior to the surgery or the start of neoadjuvant treatment||||
33974394|NCT05981885|||COHORT||PROSPECTIVE|||||||
33974395|NCT02789007|NA|SINGLE_GROUP||OTHER||NONE||||||
33974396|NCT04366479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This type of quasi-experimental research (quasy experiment) with pre-test and post-test research design with only control design.||||
33974397|NCT05214742|||CASE_ONLY||PROSPECTIVE|||||||
33974398|NCT02655627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974399|NCT02518230|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073151|NCT02666989|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974400|NCT05622955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974401|NCT03386097|||CASE_CONTROL||OTHER|||||||
33974402|NCT00391690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974403|NCT01051609|||||PROSPECTIVE|||||||
33974404|NCT01689480|||COHORT||PROSPECTIVE|||||||
33974405|NCT01399723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073152|NCT02762071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761844|NCT01544959|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761845|NCT03725540|||COHORT||PROSPECTIVE|||||||
33974406|NCT00271804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974407|NCT05933304|||COHORT||RETROSPECTIVE|||||||
34073153|NCT02121548|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34073154|NCT06376708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||use of platelet rich fibrin after maxillary sinus elevation using PEEK|t|f|f|f
34073155|NCT06164483|||CASE_CONTROL||PROSPECTIVE|||||||
34073156|NCT05013242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34073157|NCT02191345|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974408|NCT03752671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded to the randomisation arm. As the procedure is conducted under general anaesthesia, the patient will not be informed whether the procedure which was performed on him/her did or did not result in the implantation of the IntraSPINE® device (which is not visible on radiographs)||t|f|f|f
33974409|NCT00993057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974410|NCT06030921|||OTHER||CROSS_SECTIONAL|||||||
33974411|NCT05074082|||COHORT||RETROSPECTIVE|||||||
33974412|NCT02289768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974413|NCT00002407||||TREATMENT||||||||
33974414|NCT04757415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
33974415|NCT01110681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073158|NCT00229827|||||RETROSPECTIVE|||||||
34073159|NCT05290948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34073160|NCT01564992|||COHORT||PROSPECTIVE|||||||
34073161|NCT03166488|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34073162|NCT03948152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073163|NCT05328453|||COHORT||PROSPECTIVE|||||||
34073164|NCT01184170|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34073165|NCT06437340|||OTHER||CROSS_SECTIONAL|||||||
34073166|NCT03929263|NA|SINGLE_GROUP||OTHER||NONE||||||
33974416|NCT00982410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974417|NCT01304173|||CASE_ONLY||RETROSPECTIVE|||||||
33974418|NCT03842371|||CASE_CONTROL||PROSPECTIVE|||||||
33974419|NCT01680679|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33974420|NCT01485913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The methodologist who performed the randomisation was not directly involved in the recruitment of patients. Recruiting physicians were blinded to the allocation sequence.||f|t|f|f
33974421|NCT02848430|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073167|NCT03291951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized controlled trial of resistance training intervention in colon cancer patients receiving chemotherapy consists of two arms: an in-person and telephone-based intervention to promote home-based resistance training, and a wait-list, control group.||||
34073168|NCT06132282|NA|SINGLE_GROUP||TREATMENT||NONE||A technology-based application (administered via tablet) that addresses the interrelated topics of substance use and risky sex practices, within the context of personal relationships.||||
34073169|NCT04240223|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34073170|NCT00672633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073171|NCT05265039|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34073172|NCT02521597|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34073173|NCT06110598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized 2:1 to the treatment arm. There will be no blinding of participants and the trial will not be placebo-controlled||||
34073174|NCT00735514|||CASE_CONTROL||PROSPECTIVE|||||||
33761846|NCT02554591|||COHORT||RETROSPECTIVE|||||||
33974422|NCT03149588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33974423|NCT03176225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974424|NCT02246842||||TREATMENT||||||||
34073175|NCT00758498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073176|NCT04616612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two-group, randomized, controlled trial|f|t|f|f
34073177|NCT01816178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073178|NCT02527174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761847|NCT05699421|||COHORT||PROSPECTIVE|||||||
33887474|NCT03233932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887475|NCT01630525|||CASE_CONTROL||PROSPECTIVE|||||||
33887476|NCT04622345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33887477|NCT01961544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887478|NCT00914381|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33887479|NCT05009901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887480|NCT05904444|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887481|NCT05313438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887482|NCT04724148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887483|NCT03462095|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33887484|NCT06164769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887485|NCT00579813|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33887486|NCT00000981||||TREATMENT||||||||
33887487|NCT04918563|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33887488|NCT01984515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887489|NCT03235687|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||This is a prospective, randomized blinded, shared decision-impact and health-economic assessment study. 1000 appropriately screened consecutive patients seen during planning for a prostate biopsy will be enrolled. 500 patients will be randomized (blinded) to have the ExoDx Prostate (IntelliScore) test (Cohort A) and 500 (Cohort B) will proceed with conventional standard of care. At time of enrollment, neither the patient nor the urologist will be made aware of whether the patient will have an ExoDx Prostate (IntelliScore) test as part of their work-up. Cohort A EPI test results will be sent to the urologist for assessment and ultimately shared with the patient.|t|t|t|f
33887490|NCT03190187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomly allocated to spinal manipulation group or sham group.|Single blind parallel clinical trial|t|t|f|t
33887491|NCT02334150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887492|NCT02417545|||CASE_CONTROL||PROSPECTIVE|||||||
33887493|NCT03538769|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887494|NCT03393026|NA|SINGLE_GROUP||TREATMENT||NONE||Lurasidone 40-160 mg/day||||
33887495|NCT02867631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33887496|NCT03414957|||COHORT||PROSPECTIVE|||||||
33887497|NCT03594968|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887498|NCT05290363|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two groups are included Group 1: 60 patients with axial SpA Group 2 : 30 patients with SpA and peripheral joint involvement, with a medical decision to treat peripheral joint inflammation by arthrocentesis||||
33974425|NCT03141489|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|Patients and care provider(nurse) will be masked(not informed), Patients will be screened (height and weight) and handgrip strength will be performed by the investigator. Patients will sign a written consent, and then randomized to either the control or an intervention group. Patients will be tested on day 4, 7 and at 3 months by a research assistant/outcome assessor and is blinded treatment allocations. Blood tests are drawn daily. A nurse will administered the tubefeeding according to written orders in the medical journal; nurses are not informed about treatment allocation or the outcome measures. Physicians are informed about the study, but will not know what treatment patients will receive.|Refeeding protocol: Standardised refeeding protocols will be used for each of the patient groups; the control group will start tube feeding at 5 or 10 kcal/kg/day depending on their BMI and increase until needs are met within 7 days. The intervention group will start tube feeding at 20 kcal/kg/day and increase until needs are met within 3 days, but continue feeding minimum of 7days. Electrolytes will be monitored daily The patients will receive100 mg thiamine, and 1 multivitamin/mineral daily, all recorded in the medical journal. The intervention group will receive approximately 40% higher amount of protein and calories compared to the control group in the end of day 7.|t|t|f|t
33974426|NCT01188707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974427|NCT00035009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073179|NCT00525473|||||RETROSPECTIVE|||||||
34073180|NCT05849363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073181|NCT06613191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34073182|NCT04392219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073183|NCT03761485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Randomized double blind clinical trial|t|t|t|t
34073184|NCT02804971|||OTHER||PROSPECTIVE|||||||
34073185|NCT02377232|RANDOMIZED|SINGLE_GROUP||SCREENING||TRIPLE|||t|t|t|f
34073186|NCT04570709|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||This is a feasibility study. This study is conducted on one unit and to reduce bias and contamination, the control patients will be recruited and consented first. After recruitment of the 20 control patients, we will then recruit 20 intervention patients.||||
34073187|NCT05138055|||CASE_CONTROL||PROSPECTIVE|||||||
33887499|NCT03452267|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33887500|NCT05430269|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single center, parallel group randomised controlled trial.||||
33887501|NCT02586714|||COHORT||PROSPECTIVE|||||||
33887502|NCT00935935|||COHORT||CROSS_SECTIONAL|||||||
33887503|NCT03557567|||COHORT||OTHER|||||||
33887504|NCT04122287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33887505|NCT01902940|||COHORT||RETROSPECTIVE|||||||
33887506|NCT00546364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887507|NCT03757884|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-posttest study design||||
33887508|NCT00536328|||||PROSPECTIVE|||||||
33887509|NCT02268162|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974428|NCT06528717|||COHORT||RETROSPECTIVE|||||||
33974429|NCT03803709|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33974430|NCT00555009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974431|NCT04528095|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33974432|NCT03150251|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33974433|NCT05984537|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|single-blind|single-center|t|f|f|f
33974434|NCT03341273|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33974435|NCT04690270|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33974436|NCT01877707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974437|NCT04409665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||60 infants randomized 1:1 to receive ketamine or glucose||||
33974438|NCT01963364|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974439|NCT06264947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887510|NCT05801237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887511|NCT02744976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887512|NCT04568850|||CASE_ONLY||PROSPECTIVE|||||||
33887513|NCT00355316|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33887514|NCT00205933|||COHORT||CROSS_SECTIONAL|||||||
33887515|NCT02525289|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33887516|NCT01213030|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33887517|NCT00715130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887518|NCT00774657|||COHORT||PROSPECTIVE|||||||
33887519|NCT05359393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887520|NCT05762926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Care Provider, Outcomes Assessor)|Parallel Assignment|f|t|f|t
33887521|NCT02840331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887522|NCT03257189|NA|SINGLE_GROUP||OTHER||NONE||||||
33887523|NCT04523051|||COHORT||PROSPECTIVE|||||||
33887524|NCT01854346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887525|NCT02984800|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33887526|NCT01783067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33974440|NCT00026104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974441|NCT01584661|||COHORT||PROSPECTIVE|||||||
33974442|NCT06371599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The children and their parents will be blinded to the groups. The principal researchers (R1, R2) will be blinded to the research hypotheses. The opaque envelopes are stored in a locked cabinet by the researcher who performed the randomization. Data entries will be performed using the codes A and B. Codes will be shared with the researchers after statistical analyses are conducted and the research report is written.||t|f|f|t
34073188|NCT02213380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors or outcome assessors, e.g. the medical staff who provide post-operative care in the ward and visit patients for preoperational assessment, hospital visits and subsequent follow-ups, will be blinded from group allocation throughout the study.||f|f|f|t
34073189|NCT03132090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33887527|NCT02199132|||CASE_ONLY||RETROSPECTIVE|||||||
34073190|NCT04047823|||COHORT||PROSPECTIVE|||||||
34073191|NCT02822521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33887528|NCT00825604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887529|NCT04051957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded||t|t|t|f
33887530|NCT03908944|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study participant will be blinded||t|f|f|f
33887531|NCT06154967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887532|NCT02382094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887533|NCT02664155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887534|NCT00313066|||DEFINED_POPULATION||OTHER|||||||
33887535|NCT04061083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974443|NCT03395821|RANDOMIZED|PARALLEL||OTHER||NONE||Two groups will be compared according to their surgical skills.||||
33974444|NCT00208949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974445|NCT03996603|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33974446|NCT00679523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974447|NCT01213654|||COHORT||PROSPECTIVE|||||||
33974448|NCT00182091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073192|NCT02943187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073193|NCT04808934|||OTHER||RETROSPECTIVE|||||||
34073194|NCT04609020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073195|NCT00762034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073196|NCT04839198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073197|NCT04284826|NA|SINGLE_GROUP||TREATMENT||NONE||Endoscopic intralesional Mitomycin-C injection in patients with refractory benign esophageal stricture||||
34073198|NCT05802940|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|We will randomize at level of the patient as to whether or not a BPA will fire when the patient is seen in clinic. Any obstetric care provider who sees a patient that has been randomized to BPA group will receive the alert if indicated. If the alert doesn't fire, the care provider will not be aware as to whether the patient is randomized to the BPA group or whether the alert was not indicated. Clinical investigators and outcomes assessors are blinded.||t|f|t|t
33761848|NCT06382714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33887536|NCT00675597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887537|NCT02257047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33887538|NCT01382160|NA|SINGLE_GROUP||||NONE||||||
33887539|NCT05093101|||COHORT||RETROSPECTIVE|||||||
33887540|NCT04744974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to either Mediterranean or Dietary Approaches to Stop Hypertension (DASH) diet|t|f|f|f
33887541|NCT06259799|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33887542|NCT02495922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974449|NCT01661413|||COHORT||PROSPECTIVE|||||||
33974450|NCT02247700|||COHORT||PROSPECTIVE|||||||
33974451|NCT05955352|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||there are two groups randomly selected. intervention and control group, One group will be used perineal heat application and the control group will be received standardized care.||||
33974452|NCT00739856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974453|NCT01990547|||COHORT||PROSPECTIVE|||||||
34073199|NCT04750369|||CASE_CONTROL||PROSPECTIVE|||||||
34073200|NCT04993079|NA|SINGLE_GROUP||OTHER||NONE||||||
34073201|NCT03128619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073202|NCT03223155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761849|NCT01491139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761850|NCT03183102|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Biological samples will be masked for endpoint analysis||f|f|f|t
33761851|NCT00953537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761852|NCT01426243|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761853|NCT06103214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33761854|NCT04563650|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33761855|NCT05185778|||COHORT||CROSS_SECTIONAL|||||||
33761856|NCT06194084|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761857|NCT01315730|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33761858|NCT03615781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761859|NCT04577807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761860|NCT04387864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761861|NCT00880308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761862|NCT05594030|||COHORT||PROSPECTIVE|||||||
33761863|NCT06395155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, Open-label, Multiple-dose, Six-sequence, Three-period, Three-treatment, Crossover||||
33761864|NCT06452953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761865|NCT01310309|||COHORT||PROSPECTIVE|||||||
33761866|NCT00326586|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33761867|NCT02950857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761868|NCT00693576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761869|NCT03912493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761870|NCT03571737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761871|NCT03333915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761872|NCT06625619|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33761873|NCT01808625|NA|SINGLE_GROUP||OTHER||NONE||||||
33761874|NCT02977702|||CASE_ONLY||RETROSPECTIVE|||||||
33761875|NCT06282315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open study. Participants and the study investigators assessing drug safety will not be blinded to treatment arms. Only the laboratory-based effectiveness measurement will be performed by blinded operators.|Open-label, randomized at the school level, and each eligible participant within a school will receive only one of the study treatments (ALB or IVM).|f|f|f|t
33761876|NCT01423786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761877|NCT01859793|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761878|NCT04274959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participant, outcomes assessor) double blind||t|f|f|t
33761879|NCT00433862|||||PROSPECTIVE|||||||
33761880|NCT04782934|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33761881|NCT05750186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887543|NCT02149680|||CASE_CONTROL||RETROSPECTIVE|||||||
33887544|NCT02572284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887545|NCT00995254|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33887546|NCT01701622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887547|NCT03543683|||COHORT||PROSPECTIVE|||||||
33887548|NCT00669617|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33887549|NCT02868476|||COHORT||PROSPECTIVE|||||||
33887550|NCT05662514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33887551|NCT00151892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887552|NCT00570648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887553|NCT01454076|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33761882|NCT01416233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761883|NCT00838682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761884|NCT01021592|||CASE_ONLY||PROSPECTIVE|||||||
33761885|NCT01498822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761886|NCT02823821|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33761887|NCT02143037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761888|NCT02171858|||COHORT||PROSPECTIVE|||||||
33761889|NCT05048849|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33761890|NCT06247202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Lab technician who will handle the saliva analysis and the person who will be doing the statistical analysis will be blinded of any data related to the grouping of the participants.|"Participants will be randomly divided into intervention group and control group.~intervention group will receive smart phone delivered nutrition education while control group will receive paper delivered nutrition education."|f|f|f|t
33761891|NCT00509236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761892|NCT02524301|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761893|NCT01300325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761894|NCT04671901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761895|NCT05538962|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All subjects will receive the sensor but they are 3 different populations, which is why there are 3 different arms||||
33761896|NCT02579798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33761897|NCT05981664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|All participants are provided the intervention, and act as their own control when they are evaluated with and without the intervention.|||||
33761898|NCT04947254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761899|NCT05886725|||COHORT||PROSPECTIVE|||||||
33761900|NCT02073916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761901|NCT05878392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761902|NCT00658437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761903|NCT05363319|||COHORT||PROSPECTIVE|||||||
33761904|NCT06473844|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33761905|NCT01889186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761906|NCT03390777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761907|NCT00000192||||TREATMENT||DOUBLE||||||
33761908|NCT00314561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887554|NCT02626676|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33887555|NCT04590456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887556|NCT05809141|||OTHER||CROSS_SECTIONAL|||||||
33887557|NCT01907620|NON_RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33887558|NCT02599584|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33974454|NCT02215174|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33974455|NCT04810819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974456|NCT05734378|||COHORT||PROSPECTIVE|||||||
33974457|NCT03968471|||CASE_ONLY||RETROSPECTIVE|||||||
33974458|NCT00226720|RANDOMIZED|PARALLEL||||NONE||||||
33974459|NCT02841306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974460|NCT00367588|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974461|NCT00999609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974462|NCT02591784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974463|NCT02929693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974464|NCT06546410|||COHORT||RETROSPECTIVE|||||||
33974465|NCT03057262|||COHORT||PROSPECTIVE|||||||
33974466|NCT02942303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33974467|NCT00798551|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974468|NCT05930574|||CASE_ONLY||CROSS_SECTIONAL|||||||
33974469|NCT05812105|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants received an intervention (i.e., Healthy Buddy Program providing a list of transportation/aging/health-related services available in their community) and complete pre- and post-surveys \& interviews.||||
33974470|NCT00625690|||COHORT||PROSPECTIVE|||||||
33974471|NCT06484712|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Cross sectional study of responses to visual perturbations in one group, people with chronic ankle instability. Each participant will undergo two stimulation conditions, stochastic resonance (SR) stimulation and a control / no stochastic resonance (no-SR) condition while walking with and without visual perturbations.|t|f|f|f
33974472|NCT02638831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974473|NCT01140074|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33974474|NCT05133128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974475|NCT02267096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974476|NCT04428671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974477|NCT02675543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974478|NCT04843163|RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals are assigned to immediate NAMI Basics or waitlist control. Those in the waitlist control may take the NAMI Basics class after the 8 week waiting period.||||
33974479|NCT06484101|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974480|NCT04686136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974481|NCT02948322|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33974482|NCT01621490|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974483|NCT05666843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of the intervention does not allow for blinding of the participants or researchers. After data collection, the database will be coded by an independent researcher to ensure that data analysis is conducted in a blinded way.||f|f|f|t
33974484|NCT00907842|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974485|NCT01466803|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974486|NCT05267509|||COHORT||PROSPECTIVE|||||||
33974487|NCT04571723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blind to the condition they are in.|One group will receive the original diabetes prevention program curriculum, and other group will receive modified health mindset curriculum.|t|f|f|t
33974488|NCT05209646|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups; interventional and control groups||||
34073203|NCT04582279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This study is not blinded|There is only 1 group of participants being monitored. Every patient will follow the same study procedures||||
34073204|NCT04738578|||OTHER||OTHER|||||||
34073205|NCT05195216|||COHORT||RETROSPECTIVE|||||||
34073206|NCT01360801|||CASE_ONLY||PROSPECTIVE|||||||
34073207|NCT00858806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073208|NCT00820287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073209|NCT02537665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34073210|NCT03744403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073211|NCT00563914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073212|NCT00069849|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34073213|NCT02143024|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34073214|NCT04808258|||COHORT||PROSPECTIVE|||||||
34073215|NCT04932096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33761909|NCT00738101|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|"Initiation of Study is defined as the day the Fish Oil Emulsion was initiated.~End of Study (EOS) is defined as discontinuation of fish oil emulsion, death, transplant, or discharge from the hospital.~In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study. Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion."||||
33761910|NCT02645084|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33761911|NCT05530590|RANDOMIZED|PARALLEL||OTHER||NONE||The study involves conducting a 3-arm, stratified (management/staff), group (agency) randomized controlled trial (RCT) of the in-person vs. online intervention vs. waitlist control on organizational factors (i.e., environment and policy) and on staff knowledge, attitudes, and skills.||||
33761912|NCT02093858|||CASE_ONLY||PROSPECTIVE|||||||
34073216|NCT02562599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073217|NCT04984122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073218|NCT05006599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither participants or site personnel will know which drug intervention (insulin or placebo) is being administered. Exceptions will be the Study Nurse who is directly involved in preparing the insulin or placebo.||t|t|t|t
34073219|NCT02914535|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only 3 arms are blinded in this study.||t|f|t|f
34073220|NCT02366299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073221|NCT06458907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761913|NCT02835872|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33761914|NCT03490214|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33761915|NCT05877443|||COHORT||RETROSPECTIVE|||||||
33761916|NCT05712902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761917|NCT02872948|||COHORT||PROSPECTIVE|||||||
33761918|NCT00001785||||TREATMENT||||||||
33887559|NCT04541914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887560|NCT00004987||||TREATMENT||NONE||||||
33887561|NCT01425099|NA|SINGLE_GROUP||||NONE||||||
33887562|NCT06330779|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33887563|NCT04350333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33887564|NCT02002143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887565|NCT04317755|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Masking not possible for participants within design, but investigators and outcome assessors will not know what condition participants are assigned to.|Parallel 2-arm cluster randomised controlled trial|f|f|t|t
33974489|NCT06465823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The responsible for the collection of the assessments or evaluator will remain blind to treatment allocation during the trial and primary analyses. The diuretic actions of Bumetanide may impact the blinding procedure. To reduce this impact, the psychologist evaluator will be separated from the pediatrician who will treat the children, thus ensuring the blindness to the treatment. A supervisor during each assessment session will control for any possible interference with the evaluator's blindness. The randomization schedule will be kept inaccessible to the personnel involved in the study. In cases of serious adverse effects, the envelope will only be opened by the Principal Investigator who will be the only one to know the treatment assignment. The Principal Investigator will ensure that the contents of the envelope are kept in a place inaccessible to others.|This is a double-blind placebo-controlled study. The enrolment will include 64 patients. Children and adolescents with DS (aged 10-17) will be assigned to one of the two conditions by an automated process: Bumetanide treatment or control group, by a stratified random sampling based on the mental age (≥ 4.5 age \<5.5 yrs vs ≥5.5 age \< 8.5yrs). Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. Patients in the control group will be administered a placebo. The randomization will be conducted during the first appointment after the informed consent has been signed, and the inclusion and exclusion criteria have been verified.|t|f|t|t
33974490|NCT00035633||||TREATMENT||||||||
33974491|NCT01127542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974492|NCT00356746|||COHORT||PROSPECTIVE|||||||
33974493|NCT00597285|||||PROSPECTIVE|||||||
33974494|NCT02750761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974495|NCT01409850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33974496|NCT06211426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33761919|NCT04659395|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A methodology study||||
33761920|NCT01453348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887566|NCT00460980|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
33887567|NCT01770327|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33887568|NCT01722461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887569|NCT04992702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887570|NCT04856137|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase Ib Dose Escalation~All patients received:~Rituximab 375mg/m2 on D1 of each cycle, and Paclitaxel 200mg/m2 on D1 of each cycle, plus, G-CSF 1PC sc qd, starting D7 until ANC recovery Ruxolitinib continuously given (D1-21) in the following dose schema~Phase II Efficacy Study~All patients received:~Rituximab 375mg/m2 on D1 of each cycle, and Paclitaxel 200mg/m2 on D1 of each cycle, plus Ruxolitinib using RP2D daily on D1-21 G-CSF 1PC sc qd, starting D7 until ANC recovery~Repeat every 21 days"||||
33887571|NCT06541431|||COHORT||PROSPECTIVE|||||||
33887572|NCT01755663|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33887573|NCT05995392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974497|NCT04954131|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33887574|NCT06267963|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33887575|NCT02668614|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887576|NCT04184817|||COHORT||RETROSPECTIVE|||||||
33887577|NCT03609788|||OTHER||PROSPECTIVE|||||||
33887578|NCT05407987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761921|NCT02620943|||COHORT||PROSPECTIVE|||||||
33761922|NCT06437093|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-group pre-test post-test experimental study.||||
33887579|NCT03494647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33974498|NCT03960320|||COHORT||RETROSPECTIVE|||||||
33974499|NCT00284297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974500|NCT02033265|||COHORT||PROSPECTIVE|||||||
33974501|NCT01443806|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974502|NCT04370184|||CASE_ONLY||RETROSPECTIVE|||||||
33974503|NCT04261608|||CASE_ONLY||RETROSPECTIVE|||||||
33974504|NCT06209788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974505|NCT01338428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974506|NCT06379009|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both participants and investigators will know which arm the participants are randomized to. Training is not easy to mask|2 arms randomized control study. The intervention arm is exposed of a 12 week home-based training program. The control arm follow standard of care.||||
33974507|NCT03407859|NA|SEQUENTIAL||TREATMENT||NONE||||||
33974508|NCT02855190|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761923|NCT06437535|||CASE_CONTROL||RETROSPECTIVE|||||||
33761924|NCT02816190|||COHORT||PROSPECTIVE|||||||
33761925|NCT05134402|||COHORT||PROSPECTIVE|||||||
33761926|NCT00904332|||||PROSPECTIVE|||||||
33761927|NCT05485363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761928|NCT00480792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761929|NCT04418934|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33761930|NCT03350100|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33761931|NCT01465828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974509|NCT04700995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|f|t
33761932|NCT01960595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761933|NCT05124093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761934|NCT02564679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761935|NCT03994042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761936|NCT05002205|||COHORT||PROSPECTIVE|||||||
33761937|NCT06610981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33761938|NCT03042962|||COHORT||CROSS_SECTIONAL|||||||
33761939|NCT05977894|||COHORT||PROSPECTIVE|||||||
33761940|NCT05470478|NA|SINGLE_GROUP||OTHER||NONE||Each participant enrolled in this early feasibility study is essentially an independent data point. The primary outcome of the IDE to which this VA study is attached is safety; feasibility is a secondary outcome. The outcome of this specific VA study, which engages participants in the BrainGate IDE, is usability of the mobile iBCI decoding system as measured through quantitative performance measures.||||
33761941|NCT02223884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761942|NCT00676130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33761943|NCT03156634|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The statistician will be masked to the group assignment.|Participants will be randomized to view materials via one of to systems (Patient Activated Learning System or WebMD)|f|f|f|t
33761944|NCT01825564|||COHORT||PROSPECTIVE|||||||
33761945|NCT03737201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, three-arm parallel, two-blinded clinical trial|t|f|f|t
33761946|NCT01308606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974510|NCT01909466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974511|NCT01049958|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33974512|NCT04107493|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"This is a prospective, randomized, cross-over study design with participants serving as their own controls. A within- participants, repeated-measures design is used during 6MWT. Eligible participants will complete two 6MWTs: one with their usual portable oxygen cylinder, and one with Mobi™. All participants entered into the study will be randomized in a 1:1 ratio to the following order of device use:~* Control device (portable oxygen cylinder) first; or~* Study device (Mobi™, POC) first."||||
34073222|NCT03638141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974513|NCT01395953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761947|NCT01789697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33761948|NCT04885270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761949|NCT05921305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761950|NCT02486679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33761951|NCT05265455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover Assignment|t|f|t|f
33761952|NCT00116272|||COHORT||OTHER|||||||
33761953|NCT05819996|NA|SINGLE_GROUP||OTHER||NONE||An educational campaign targeting the community||||
33761954|NCT03135535|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33761955|NCT01373450|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33761956|NCT00765284|||COHORT||PROSPECTIVE|||||||
33761957|NCT05994391|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All supplements will be in sealed, blinded packaging with identical information on each package. Supplements will be blinded by a third party who is not a member of the research team.|Randomized, double-blind, placebo-controlled, parallel design|t|f|t|f
33761958|NCT00926510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33761959|NCT01741454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974514|NCT03937466|NA|SINGLE_GROUP||TREATMENT||NONE||24 peri or postmenopausal women aged 45-60 experiencing at least 4 hot flashes/night sweats/day will use a cooling mattress pad nightly for approximately 8 weeks||||
33974515|NCT00000898||||TREATMENT||||||||
33974516|NCT01589536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974517|NCT02076477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974518|NCT04760067|||OTHER||PROSPECTIVE|||||||
33974519|NCT02971046|NA|SINGLE_GROUP||OTHER||NONE||||||
33974520|NCT02231190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974521|NCT02823704|||COHORT||PROSPECTIVE|||||||
34073223|NCT05254340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073224|NCT00096538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073225|NCT03603119|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|concealed envelopes||f|t|f|f
34073226|NCT02063594|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33761960|NCT02074046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33761961|NCT00954616|||CASE_ONLY||PROSPECTIVE|||||||
33761962|NCT01288339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761963|NCT00114361|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
33761964|NCT02627508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761965|NCT00832195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761966|NCT05791448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761967|NCT01575743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33761968|NCT02145325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761969|NCT02202278|||CASE_CONTROL||PROSPECTIVE|||||||
33761970|NCT06578715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
33761971|NCT01022086|||OTHER||PROSPECTIVE|||||||
33761972|NCT00357721|RANDOMIZED|CROSSOVER||||NONE||||||
33761973|NCT00372801|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33761974|NCT01296022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761975|NCT01488708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761976|NCT03237273|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33761977|NCT01481155|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33761978|NCT04256356|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33761979|NCT00865943|RANDOMIZED|CROSSOVER||||NONE||||||
33761980|NCT02294136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33761981|NCT05756608|||COHORT||PROSPECTIVE|||||||
33761982|NCT06352359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33761983|NCT02217280|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34073227|NCT01403571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33761984|NCT04555096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33761985|NCT02102880|NA|SINGLE_GROUP||OTHER||NONE||||||
33761986|NCT00705302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761987|NCT00876915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33761988|NCT00643123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33761989|NCT03013946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33761990|NCT04495439|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33761991|NCT05696535|||CASE_ONLY||CROSS_SECTIONAL|||||||
33761992|NCT00377780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974522|NCT05698836|||CASE_CONTROL||PROSPECTIVE|||||||
33974523|NCT03841097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974524|NCT02259712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974525|NCT05050786|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33974526|NCT06338709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974527|NCT05134064|||CASE_ONLY||PROSPECTIVE|||||||
33974528|NCT04371978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974529|NCT00908752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073228|NCT04213092|||CASE_CONTROL||PROSPECTIVE|||||||
34073229|NCT02052297|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073230|NCT01634503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073231|NCT02335255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974530|NCT03686709|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a feasibility study assessing radiation exposure and distribution of Y90 therapy agents. Two groups of 10 patients will be recruited with equal numbers in each group for each of the two types of Y90 radioembolization products commercially available in the United States.Both groups undergo the same monitoring procedures throughout the study and then will be compared. Stratification of patients into therapy groups is solely based on clinical standard of care decision making.||||
34073232|NCT00684164|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33974531|NCT06543641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The study's cardiac radiologist was blinded for symptomatic data, stent type and stent quantity. The target vessel of implanted coronary artery stents was provided.|||||
34073233|NCT06371690|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33974532|NCT02452645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33761993|NCT01368445|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33761994|NCT01044849|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33974533|NCT02375126|||COHORT||PROSPECTIVE|||||||
33761995|NCT03034499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33761996|NCT00959101|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33761997|NCT05716984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33761998|NCT02212444|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33761999|NCT01201811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762000|NCT03728608|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33762001|NCT05629663|NA|SINGLE_GROUP||OTHER||NONE||||||
33974534|NCT04583579|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Subjects will be assigned to try all five scleral lens application methods in a random order.||||
33974535|NCT00886665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974536|NCT02677909|||COHORT||PROSPECTIVE|||||||
34073234|NCT06159543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974537|NCT00466297|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33974538|NCT01820871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974539|NCT06067711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Resistance training will be performed during 12-weeks for 3 sessions/week on non-consecutive days. The program will consist of six exercises: triceps press, biceps curl, lat pull down, leg press, leg extension and sit-ups using resistance band. Each session will last approximately 45 minutes and consist of a 5-minute warm-up with stretching following by resistance training that will be done as a cir¬cuit, ending with 5-minute cool down. The 1 repetition maximum (1RM) is measured at baseline and follow¬ing the intervention.|t|f|t|f
33974540|NCT02510716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073235|NCT02454010|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073236|NCT03719495|||COHORT||PROSPECTIVE|||||||
34073237|NCT00324662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073238|NCT03064048|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Randomization for treatment assignment is by the providing Institution's Investigational Pharmacy Services.|"Active Comparator: Nitric oxide supplement Active Comparator will l not contain nitric oxide supplement.~Placebo Comparator: Placebo Placebo will not contain nitric oxide supplement."|t|t|t|f
34073239|NCT05532384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The anesthesiologists will obtain the group of patients through computer randomization before the patients leave the Post-Anesthesia Care Unit, and guide the patients to drink water. The questionnaire collectors and outcomes assessor will not be informed of the group of patients.|Randomized controlled trial：Participants who enroll in RCTs differ from one another in known and unknown ways that can influence study outcomes, and yet cannot be directly controlled. By randomly allocating participants among compared treatments, an RCT enables statistical control over these influences. Provided it is designed well, conducted properly, and enrolls enough participants, an RCT may achieve sufficient control over these confounding factors to deliver a useful comparison of the treatments studied.|f|f|t|t
34073240|NCT00503347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073241|NCT00616876|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34073242|NCT02855801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34073243|NCT05705921|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III multi-centre randomized trial||||
34073244|NCT00005959||||TREATMENT||||||||
34073245|NCT04912180|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34073246|NCT01979523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762002|NCT01013792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762003|NCT05917977|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study adopted a two-armed RCT to examine the efficacy of CMI in improving IGD among adolescents with IGD. The research participants will be randomly assigned to either the intervention group (four-session CMI intervention plus IGD educational materials) or the control group (IGD education materials alone). Block randomization will be executed, of which the block size is 4. Computer-generated randomization allocation codes will be produced and sealed in opaque envelopes by a research associate with no involvement in recruitment. One envelope will be drawn and opened by the project officer.||||
33762004|NCT03076541|||COHORT||RETROSPECTIVE|||||||
33762005|NCT04141735|||COHORT||RETROSPECTIVE|||||||
33762006|NCT04269239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be assigned to either the a healthy habits group or a sleep habits group.|t|f|f|t
33887580|NCT03135366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"We will employ a randomized controlled trial (RCT) with 600 patients included in the treatment group and 600 patients included in the control group. We have selected this methodology for the following reasons:~1. RCTs are the gold-standard for providing evidence-based evaluation of medical interventions, and recommended when feasible.~2. Keheala is a new program, and cannot be studied using existing data.~3. We are working with researchers from Harvard's Program for Evolutionary Dynamics and Yale's Human Cooperation Lab, who have an established record of designing large-scale RCTs in real-world settings such as ours.~This sample size was chosen to achieve 80% power in detecting improvements of 7.5% or more in the relevant health outcomes. To do this calculation, we employed Monte Carlo simulations of patient outcomes, based on the Kenyan Ministry of Health's 2013 TB Case Findings Report.~Note: The sample size and outcomes were registered in December 2015 with the IRB."|f|t|f|t
33887581|NCT01286493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887582|NCT06366243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887583|NCT01260558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887584|NCT02992002|||COHORT||PROSPECTIVE|||||||
33887585|NCT00191672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887586|NCT01270334|||CASE_CONTROL||PROSPECTIVE|||||||
33887587|NCT01796002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887588|NCT01254669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887589|NCT00951821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887590|NCT02521155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887591|NCT03567421|||CASE_ONLY||PROSPECTIVE|||||||
33887592|NCT05388747|||COHORT||PROSPECTIVE|||||||
33887593|NCT00853437|||CASE_ONLY||PROSPECTIVE|||||||
33887594|NCT02050412|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33887595|NCT04544722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887596|NCT00826735||||PREVENTION||||||||
33887597|NCT00859755|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33887598|NCT01075347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887599|NCT05312008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The pharmacy will prepare the intranasal spray (both oxytocin and placebo) and deliver it in coded syringes to the lab. Investigators, laboratory staff and subjects will be unaware of the identity of the spray on session days. The pharmacy will provide the unmasking information after all sessions are completed..|2 Arms; both 2 session parallel design|t|f|t|f
33887600|NCT03387787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887601|NCT05261854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study Would be double blind as the identity of patients group will not be revealed to the assessor and the patient will also be unaware of group to which they will be allocated.||t|f|f|t
33887602|NCT03198689|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33887603|NCT05503290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a randomized-controlled pilot study where enrolled subjects (primiparous individuals with epilepsy) will be randomized 1:1 to the control or intervention group (participation in the Lullaby Project). Outcomes of interest will be measured in each participant at day of consent, 3 weeks after, 7 weeks after, and 10 weeks after. A follow-up via email will be conducted for intervention participants 6 months after their last workshop.||||
33887604|NCT03454373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887605|NCT01016873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887606|NCT02707185|RANDOMIZED|PARALLEL||||NONE||||||
33887607|NCT01444300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887608|NCT02204631|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887609|NCT05473065|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded to the commercial prosthetic foot type and to the emulated foot condition||t|f|f|f
33887610|NCT06424496|NA|SINGLE_GROUP||OTHER||NONE||Quazi-Experimental study (pre/post design).||||
33887611|NCT04225325|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible patients will be randomised in a ratio 10:10:8 to be treated with one of the three antiretroviral regimens:~* TDF/FTC 245 mg/200 mg single tablet QD + DRV /cobicistat 800 mg /150 mg single tablet QD (Arm A, standard regimen),~* TDF/FTC 245 mg/200 mg single tablet QD + DTG 50 mg QD (Arm B, standard regimen).~* TDF/FTC 245 mg/200 mg single tablet QD + DRV 800 mg /cobicistat single tablet QD + DTG 50 mg QD (Arm C, experimental regimen)."||||
33887612|NCT00289913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887613|NCT00000733||||TREATMENT||NONE||||||
33887614|NCT02229422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762007|NCT05114525|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33762008|NCT06153043|||COHORT||RETROSPECTIVE|||||||
33762009|NCT02653638|NA|SINGLE_GROUP||OTHER||NONE||||||
33762010|NCT06307184|||COHORT||OTHER|||||||
33887615|NCT03783949|RANDOMIZED|PARALLEL||TREATMENT||NONE||Standard arm (arm A): Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w) First experimental arm (arm B): Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w) Second experimental arm (arm C): Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)||||
33887616|NCT05804799|||COHORT||PROSPECTIVE|||||||
33887617|NCT01545960|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887618|NCT06257914|||COHORT||PROSPECTIVE|||||||
33887619|NCT01460784|||COHORT||CROSS_SECTIONAL|||||||
33887620|NCT06054217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33887621|NCT05136625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33887622|NCT00381407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887623|NCT02298114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33887624|NCT03160560|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33887625|NCT02898714|||COHORT||PROSPECTIVE|||||||
33887626|NCT02108925|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33887627|NCT03585140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Diet intervention was made by the nutrition specialist. Neither the principal investigator nor the outcome assessor were aware about the group of diet intervention.|Randomized clinical trial, two-arm|f|f|t|t
33762011|NCT06472336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762012|NCT05868915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762013|NCT05362552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762014|NCT02546414|||CASE_CONTROL||RETROSPECTIVE|||||||
33762015|NCT04104750|||COHORT||PROSPECTIVE|||||||
33762016|NCT02525003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33762017|NCT01121302|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33762018|NCT03730285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887628|NCT02091180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887629|NCT02245048|||COHORT||PROSPECTIVE|||||||
33887630|NCT03089957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33887631|NCT05948215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887632|NCT04858893|||COHORT||PROSPECTIVE|||||||
33887633|NCT03472508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multicenter, randomized, double-blind, controlled clinical trial|t|f|t|f
33887634|NCT04287621|||COHORT||PROSPECTIVE|||||||
33887635|NCT00254566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887636|NCT05430620|RANDOMIZED|PARALLEL||TREATMENT||NONE||Kidneys originating from deceased donors after circulatory death (DCD), category 3 and 5 (controlled) will be preserved from procurement until transplantation on hypothermic machine perfusion conditions and prospectively randomized into 2 study groups: 1) intermittent surface oxygenation during HMP (surface oxygenation interrupted during organ transport (2-4h)(I-HMPO2 group), and 2) continuous surface oxygenation during HMP (surface oxygenation during the whole machine preservation period included organ transport)(C-HMPO2 group)||||
33887637|NCT06174350|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|There is a control and experimental group. Analysis was masked.|two groups: therapy group and control group.|t|f|f|t
33887638|NCT02835170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887639|NCT02149225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887640|NCT00542620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887641|NCT01900002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974541|NCT03263481|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974542|NCT03752541|NA|SEQUENTIAL||TREATMENT||NONE||0.5-1\*10\~6/KgBW, 1-2\*10\~6/KgBW,2-3\*10\~6/KgBW||||
33974543|NCT00034125|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33974544|NCT03513497|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33974545|NCT06544005|||CASE_CONTROL||RETROSPECTIVE|||||||
33974546|NCT05822596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessors of the outcomes will not be involved in the recruitment and intervention delivery and will be blinded to group allocation (single blindness).|The participants will be randomly allocated into either intervention group and control group in a 1:1 allocation ratio. The target participants are residents in elderly residential settings, members in day care units for the elderly, and persons with intellectual disabilities in day activity centre cum hostel. Participants in the experimental group will participate in a 12-week cognitive training program that includes facilitated sessions and non-facilitated sessions.|f|f|f|t
33974547|NCT04263870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974548|NCT01099384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974549|NCT06318858|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Letter codes were assigned to the iron syrup and the placebo by researchers who have not involved in the study. The codes have been kept until data analysis and report writing are complete.|group 1: daily iron syrup supplementation group 2: weekly iron syrup supplementation|t|t|t|f
33974550|NCT06350721|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33762019|NCT02981901|||COHORT||RETROSPECTIVE|||||||
33762020|NCT05275439|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33762021|NCT03542526|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887642|NCT00511043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887643|NCT05112796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33887644|NCT04075435|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label trial; all participants will receive active drug.||||
33887645|NCT02424279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887646|NCT05038527|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled clinical trial||||
33887647|NCT05378009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887648|NCT02898480|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33887649|NCT01970176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33887650|NCT02054182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974551|NCT03465371|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 3-arm randomized controlled trial||||
33974552|NCT03108365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974553|NCT03109366|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33974554|NCT02422290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974555|NCT05286528|||OTHER||RETROSPECTIVE|||||||
33887651|NCT00142948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887652|NCT03409874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887653|NCT01541293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887654|NCT02471157|||CASE_CONTROL||PROSPECTIVE|||||||
33887655|NCT02615457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887656|NCT02210663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974556|NCT03182608|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|An investigator evaluate the interspinous level using anatomic landmarks, then other independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one using ultrasonography. Participants are blinded to the assessment results.|Crossover|t|f|f|t
33974557|NCT02958215|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33974558|NCT01414465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974559|NCT06347497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either zonisamide and acetaminophen or topiramate and acetaminophen from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included zonisamide and acetaminophen, and Drug B included topiramate and acetaminophen. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B|We will assess The number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.|f|f|t|t
33974560|NCT00917033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974561|NCT00959959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073247|NCT06319729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All the study drugs and placebo should be in the same package with the same drug appearance and blinded according to the randomized numbers of the subgroups. The specific blinding method is set as follows: the study drugs and placebo are uniformly packaged and numbered according to the corresponding randomized group results. One copy of the blinding letter in duplicate is sent with the test drug to the project leader of the test center for storage, and the other copy is kept by the pharmacy until the end of the trial.|A double-blind, placebo-controlled randomized clinical trial|t|t|t|t
34073248|NCT02493452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073249|NCT02696486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073250|NCT00292253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073251|NCT00752336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073252|NCT04461548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
33887657|NCT02393209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887658|NCT03204149|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33887659|NCT05881382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887660|NCT03804671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887661|NCT06226363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887662|NCT03475979|||COHORT||PROSPECTIVE|||||||
33887663|NCT04566484|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Observer-blind in Phase 2 (parts A and B) and phase 3 in the immuno subcohort of Part C. It will be Open label in the safety cohort||t|f|t|f
33887664|NCT01253239|||COHORT||RETROSPECTIVE|||||||
33887665|NCT00680836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887666|NCT02077790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887667|NCT01030692|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33887668|NCT04796519|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887669|NCT03765593|||COHORT||PROSPECTIVE|||||||
33887670|NCT02065544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887671|NCT04726358|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33887672|NCT00723684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887673|NCT00750984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887674|NCT06318208|||COHORT||PROSPECTIVE|||||||
33887675|NCT04880122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887676|NCT05750472|||COHORT||PROSPECTIVE|||||||
33887677|NCT05650021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974562|NCT06087913|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind|Randomized, Placebo-Controlled, Double-Blind|t|t|t|t
33887678|NCT00646659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974563|NCT05312125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 groups of children with Cerebral palsy are going to be involved at the same time. One of the groups will be enrolled in the routine physiotherapy intervention. The other group will be enrolled to the routine physiotherapy intervention + backward downhill walking.|t|t|f|t
33887679|NCT00883883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974564|NCT01167621|||COHORT||PROSPECTIVE|||||||
33974565|NCT04392089|||COHORT||PROSPECTIVE|||||||
33887680|NCT05495347|||COHORT||OTHER|||||||
33887681|NCT00563147|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974566|NCT05658367|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Although there is information in the literature that it is not possible to blind the participants due to the characteristic smell of aromatherapy oils, patients are shown blind in aromatherapy massage because the oils are formulated and the oil content is not known by the patients (Nasiri and Farsi, 2017; Rasooli et al., 2016). Due to the feasibility and nature of the study, the principal investigator cannot be blinded during grouping, while blinding will be provided for the patients and the analyst.|The research was carried out to determine the effect of aromatherapy arm massage with sesame oil, sesame-lavender oil mixture, and paraffin oil on acute pain severity and anxiety level in women who underwent Interventional Simple Mastectomy (BM)/Modified Radical Mastectomy (MRM). The study design arm is three groups and a randomized controlled, double-blind, drug-free clinical trial.|t|f|f|t
33974567|NCT02354378|||COHORT||PROSPECTIVE|||||||
33974568|NCT06154863|||COHORT||RETROSPECTIVE|||||||
33974569|NCT01669109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974570|NCT04170166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974571|NCT02892877|||COHORT||PROSPECTIVE|||||||
34073253|NCT04983290|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Randomized nutraceutical clinical trial controlled with cross-over design on two groups|f|f|f|t
34073254|NCT06222970|||COHORT||PROSPECTIVE|||||||
34073255|NCT01647295|||CASE_CONTROL||PROSPECTIVE|||||||
34073256|NCT05929989|||COHORT||PROSPECTIVE|||||||
34073257|NCT05323877|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-centred, non-randomized study to investigate the safety and performance of the PerQseal®||||
34073258|NCT00682604|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34073259|NCT04506723|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34073260|NCT01514110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073261|NCT03295240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073262|NCT04186624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||This randomized controlled study is designed to have two groups with a single arm.|f|f|t|f
34073263|NCT05365815|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The research team working on the effectiveness evaluation of group care is blinded to study condition and is charged with collecting the Aim 1 effectiveness data from the individuals.||f|f|t|t
34073264|NCT05150457|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|None (open label)|Sequential Assignment||||
34073265|NCT00171626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34073266|NCT01083992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887682|NCT01245088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887683|NCT04211129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887684|NCT01105637|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33887685|NCT02184637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073267|NCT04026230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073268|NCT00791427|||CASE_ONLY||PROSPECTIVE|||||||
34073269|NCT02074293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34073270|NCT04384419|||CASE_ONLY||RETROSPECTIVE|||||||
34073271|NCT01065558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073272|NCT05651386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073273|NCT04230343|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34073274|NCT00910845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073275|NCT05618288|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to mobile health or in-person breastfeeding counseling||||
34073276|NCT00433433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887686|NCT04187235|||CASE_CONTROL||PROSPECTIVE|||||||
33887687|NCT01813994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887688|NCT03423745|||COHORT||PROSPECTIVE|||||||
33887689|NCT04742335|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33887690|NCT01027117|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33887691|NCT04512833|||COHORT||PROSPECTIVE|||||||
33887692|NCT00657384|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33887693|NCT00392028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887694|NCT01670994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887695|NCT02567448|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974572|NCT02626793|||COHORT||PROSPECTIVE|||||||
33974573|NCT02497781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974574|NCT01584336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073277|NCT02680171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34073278|NCT01655095|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34073279|NCT02953496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073280|NCT02603211|||CASE_ONLY||RETROSPECTIVE|||||||
34073281|NCT02895191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073282|NCT02589847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073283|NCT06480019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34073284|NCT04283435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One hundred envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside.||t|t|t|t
33974575|NCT00815490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974576|NCT03992287|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33974577|NCT05117099|RANDOMIZED|PARALLEL||PREVENTION||NONE||Families will be assigned to treatment vs. waitlist control. The investigators will assess families at baseline and at 2-, 4-, and 6-month follow-ups. Families in the treatment condition will receive the intervention between baseline and the 2-month follow-up.The control group will receive the intervention following the 4-month assessment.||||
33974578|NCT04016649|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33974579|NCT04616417|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Investigational Oocyte Cryopreservation||||
33974580|NCT01494688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974581|NCT03533946|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open label, phase II trial to assess efficacy of rucaparib||||
33974582|NCT03654378|||COHORT||PROSPECTIVE|||||||
33974583|NCT04810923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974584|NCT00468741|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974585|NCT03982966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||enrolled patients will be divided into 2 groups, Group 1 will be 40 patients that will take omega 3fatty acids and Group 2 will be 20 patients served as control will not take omega 3 fatty acids.||||
33974586|NCT05411042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group and control group were randomly allocated (1:1) with no stratification. The intervention group received the dance somatosensory videogame (DSG) training program at the community health center, which consisted of two 30-minute sessions per week for 6 months. The control group were provided with health education for healthy aging and were followed by telephone survey for their daily activities every month during the study period.||||
33974587|NCT02359604|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Longitudinal study||||
33974588|NCT01599208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974589|NCT04142346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33974590|NCT00520507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974591|NCT01679821|||COHORT||CROSS_SECTIONAL|||||||
33974592|NCT03267342|NA|SINGLE_GROUP||TREATMENT||NONE||Investigators will be testing four main interventions for clients of a Community Mental Health Center (CMHC) with serious mental illnesses who currently have control of their finances, based on our study of the literature on financial health and our preliminary research at CMHC. Participating clients will be free to choose which of the services to access and will be free to withdraw at any time.||||
33974593|NCT01604681|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33974594|NCT04380220|||CASE_CONTROL||PROSPECTIVE|||||||
33974595|NCT03516383|||CASE_CONTROL||PROSPECTIVE|||||||
33974596|NCT04018261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974597|NCT02789033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974598|NCT00523393|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33974599|NCT00290121|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33974600|NCT03348215|NA|SEQUENTIAL||TREATMENT||NONE|The primary gait measure (number of daily steps in teh community) will be collected by an independent assessor.|This is a singles subject design with participants acting as their own control. Control data being recorded during the week before the intervention begins||||
33974601|NCT04222036|||OTHER||PROSPECTIVE|||||||
33974602|NCT03431584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33974603|NCT04200508|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Nursing home units with a mix of long- and short-stay residents will be the unit of analysis. All nursing homes participating will go through a 8-12 week baseline. Two nursing homes will be randomized to perform the intervention, while the other two continue with an extended baseline. After 8-12 weeks, there will be a washout period of 4 weeks and then the nursing homes will crossover; nursing homes that were in the intervention arm will go back to baseline and those in the extended baseline will perform the intervention. Throughout each study period, we will be assessing Staphylococcus aureus and carbapenem resistant gram-negative bacteria acquisition among residents on each of the nursing homes units being studied||||
33974604|NCT05977621|||CASE_ONLY||PROSPECTIVE|||||||
33974605|NCT01290393|||COHORT||PROSPECTIVE|||||||
33974606|NCT03970772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a Randomize Crossover study with a pre-crossover phase and a crossover trial phase, which will include a minimum of 20 participants and consist of two (2-weeks) periods.||||
33974607|NCT00650299|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33974608|NCT05064696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974609|NCT02962011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|unblinded|Knotless barbed suture vs conventional suture of uterine incision|t|f|f|f
33974610|NCT00575757|||COHORT||PROSPECTIVE|||||||
33974611|NCT03229655|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective study||||
33887696|NCT05709808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|all components of the study will be concealed to the allocation process. while the participants, investigator (who collect data), and statistician will be blinded till the end of the study|randomized controlled trials contain 2 groups|t|f|t|t
33974612|NCT03356613|||OTHER||PROSPECTIVE|||||||
33974613|NCT02084381|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974614|NCT04787406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974615|NCT04897698|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33887697|NCT05434884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial (RCT)|t|t|f|f
33974616|NCT04302779|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All samples provided to the participant are labelled with 3 digit random codes|This study involves both a crossover design where each participant tastes both the control product (not fortified) and the protein fortified product with an appropriate break between the two sessions. It is also both a within and between groups design as the responses from the older participants will be compared to the younger participants. The study will be conducted single blind as it not feasible to blind the researcher. Each participant will attend 2 study visits and all foods will be presented with random blinding codes.|t|f|f|f
33974617|NCT01081561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974618|NCT06134674|||COHORT||RETROSPECTIVE|||||||
33887698|NCT06180850|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887699|NCT03261115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887700|NCT01571479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887701|NCT03761329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887702|NCT01124565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887703|NCT01184690|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33887704|NCT04485455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887705|NCT02660125|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33887706|NCT00643630|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33887707|NCT03628027|RANDOMIZED|PARALLEL||OTHER||DOUBLE|GPs will need to be made aware of their treatment arm in order to implement the correct treatment. However, this should not be disclosed to patients, either by the GP or Trial Co-ordinator who will also be blinded.|Cluster-randomised controlled clinical trial. GPs are randomised in blocks of N = 2 to a treatment arm. All patients under the care of a GP receive the treatment to which the GP was randomised.|t|f|f|t
33887708|NCT01327755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887709|NCT01422954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34073285|NCT04642417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Using a randomization design, investigators randomly placed the number into the envelope. This procedure was concealed from the provider or patients.|Patients were randomly assigned (1:1) to routine or EL group. EL group received simulated dietary-fiber experiential learning and one dietary application consultation session one month post-surgery, in addition to routine care before discharge.|f|t|f|t
33762022|NCT00006048||||TREATMENT||||||||
33887710|NCT02733029|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33887711|NCT04828863|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887712|NCT04901572|NA|SINGLE_GROUP||OTHER||NONE||Up to 75 sperm samples will be evaluated using the Q300 system and a standard staining method for device feasibility testing. No other groups will be present in this study.||||
34073286|NCT02006199|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33887713|NCT00797420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887714|NCT03242954|RANDOMIZED|PARALLEL||OTHER||NONE||"Consent 2.0 has a parallel group-like design for adolescents. Adolescents will be randomized into 1 of 3 consent conditions using a randomized block design that is stratified by study site and the adolescent's natal sex. The order in which the hypothetical trials are presented to adolescents will be randomized using a block design. A subset of 6-8 adolescents per site will be selected for a debriefing interview.~Consent 2.0 has a crossover-like design for parents. Parents will provide feedback on all three consent conditions and for both hypothetical trials. The order in which the hypothetical trials are presented to parents will be determined using a randomized block design that is stratified by study site and the parent's adolescent's natal sex. The presentation order for the 3 consent condition vignettes for each hypothetical trial will be determined using a randomized block design. A subset of 6-8 parents by site will be selected for debriefing interview."||||
33887715|NCT04741373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887716|NCT06546748|||COHORT||RETROSPECTIVE|||||||
33887717|NCT03012555|||COHORT||PROSPECTIVE|||||||
33887718|NCT00342368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887719|NCT04704622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887720|NCT02790866|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33887721|NCT03569202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Part 1. Piiloset Trehalose Emulsion Eye Drop is administered on the worst eye four times during office hours of one day at the study centre.~Part 2. Piiloset Trehalose Emulsion Eye Drop is self-administered on a randomized eye and the control eye drops on the contralateral eye three times a day for 10 days in a double-blinded fashion.~Part 3. Either Piiloset Trehalose Emulsion Eye Drop or the control eye drops are self-administered on both eyes three times a day for 30 days in a randomized and double-blinded fashion."|t|t|t|t
33887722|NCT00896532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762023|NCT05348525|||OTHER||PROSPECTIVE|||||||
33762024|NCT02391636|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33887723|NCT05038137|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887724|NCT02532348|||COHORT||PROSPECTIVE|||||||
33887725|NCT06296121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887726|NCT01948830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33887727|NCT01220414|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33887728|NCT01302873|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33887729|NCT02491385|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887730|NCT00454493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, placebo-controlled, randomized, double-blind trial||||
33887731|NCT03844009|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessor (questionnaire) was blinded of the allocation group of the participant.|randomized controlled study comparing two groups, one intervention group (debriefing) and one control group (no debriefing)|f|f|f|t
33887732|NCT05123560|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33887733|NCT02317107|||COHORT||PROSPECTIVE|||||||
33887734|NCT02475889|||CASE_CONTROL||RETROSPECTIVE|||||||
33887735|NCT04413955|||COHORT||PROSPECTIVE|||||||
33887736|NCT04384237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single (outcomes Assessor) An external clinic is going to do the measures||f|f|f|t
33887737|NCT02718859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887738|NCT05798052|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Assessors, who are blinded to the study hypotheses and manipulations, will score video-recordings of the teams, in terms of their performance and their coordination patterns.|Teams will be assigned to manage simulated clinical scenarios in two order: low stress then high stress, high stress then low stress.|f|f|f|t
33887739|NCT00001676||||TREATMENT||||||||
33887740|NCT03346330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887741|NCT05274646|||CASE_ONLY||OTHER|||||||
33762025|NCT03756584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||single-blind parallel-group crossover design|t|f|f|t
33762026|NCT02878174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34073287|NCT02635321|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762027|NCT02630095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762028|NCT05685992|||COHORT||PROSPECTIVE|||||||
33762029|NCT01988948|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762030|NCT04095260|||COHORT||PROSPECTIVE|||||||
33762031|NCT06539351|NA|SINGLE_GROUP||OTHER||NONE||Pilot study to optimize sample processing||||
33887742|NCT04409704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887743|NCT00456690|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887744|NCT00738816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33887745|NCT04029857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887746|NCT02799862|||COHORT||PROSPECTIVE|||||||
33887747|NCT01552902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073288|NCT06274944|||COHORT||PROSPECTIVE|||||||
33762032|NCT00892125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762033|NCT01793376|||OTHER||RETROSPECTIVE|||||||
33762034|NCT03237858|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33762035|NCT06328582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33762036|NCT00674466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762037|NCT00961025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762038|NCT04286126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762039|NCT01555164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762040|NCT04524078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events|f|f|t|f
33762041|NCT00509548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762042|NCT00632957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887748|NCT05876403|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33887749|NCT03189979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887750|NCT00434967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887751|NCT03839108|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|randomised single blind study||f|f|t|f
33887752|NCT06031077|||OTHER||RETROSPECTIVE|||||||
33887753|NCT05396209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887754|NCT00788905|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887755|NCT02327260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762043|NCT05698134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants will be randomized into two parallel groups:~First group will receive standard of care based on institutional protocol for blood product transfusion Second group will receive ROTEM guided protocol for blood product transfusion"|t|t|f|f
33887756|NCT06417554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887757|NCT02254915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887758|NCT05050045|||COHORT||PROSPECTIVE|||||||
33887759|NCT05758090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887760|NCT01631669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887761|NCT04336163|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the control group, the laser surgeon would be unaware of OCT measurements of patients in the control group and would need to rely on his/her experience and intuition to determine the laser settings to treat the patient. For the experimental group, the laser surgeon will be exposed to the OCT measurements.|A prospective study on the impact of Optical Coherence Tomography in laser treatment of vascular skin conditions.|f|t|f|f
33887762|NCT03295214|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33887763|NCT05586126|||COHORT||PROSPECTIVE|||||||
33887764|NCT05316714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887765|NCT03345056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887766|NCT05670626|NA|SINGLE_GROUP||OTHER||NONE||||||
33887767|NCT06548841|||COHORT||OTHER|||||||
33887768|NCT06018649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The subject will be randomly assigned to the study group (I-VI) by a computer program after the initial examination (T0) at the study centers. Grouping will be done by a statistician. Coding/blinding will be done so that researchers, statisticians, etc. will not know which group the subject belongs to. After the initial screening, the completed questionnaires will be modally coded by a statistician. The researchers conducting the clinical trial will not know which group the subject belongs to.|In a parallel study 6 groups of participants will receive different interventions modalities (duration, procedures complex, inpatient/outpatient, control). Participants will be assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial. Assignment to a group will be randomized. There will be possibility to compare few treatments modalities results.|f|f|t|t
33887769|NCT02958943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33887770|NCT06299189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887771|NCT03269981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887772|NCT00000479|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33887773|NCT05594784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887774|NCT01320605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887775|NCT04909528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33887776|NCT05797714|RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects were randomly divided into two groups. One group received TMF treatment for 48 weeks. Aonther group received no antiviral therapy and served as a blank control.||||
33887777|NCT01858233|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34073289|NCT03571776|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, National, assignment 1: 1, stratified by age, previous oophorectomy and uni- or bilateral ovarian involvement.||||
33887778|NCT06426940|||CASE_ONLY||PROSPECTIVE|||||||
33887779|NCT00621413|||COHORT||PROSPECTIVE|||||||
33762044|NCT06013943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762045|NCT00464451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762046|NCT01394874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33762047|NCT03580590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33762048|NCT00927056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762049|NCT03266822|||CASE_CONTROL||PROSPECTIVE|||||||
33762050|NCT00699088|||COHORT||PROSPECTIVE|||||||
33762051|NCT04671238|||CASE_ONLY||RETROSPECTIVE|||||||
33762052|NCT06262165|||CASE_ONLY||PROSPECTIVE|||||||
33762053|NCT01154478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762054|NCT06228521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762055|NCT03749577|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762056|NCT03198286|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33762057|NCT02998814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762058|NCT05384925|||COHORT||PROSPECTIVE|||||||
33762059|NCT02437825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887780|NCT04415398|NA|SINGLE_GROUP||OTHER||NONE||Totally n=3 AED-drones are deployed as a complement to standard care (EMS) in all cases of suspected OHCA occurring within service areas||||
33887781|NCT04920773|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887782|NCT00934102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887783|NCT01294384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887784|NCT00797693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887785|NCT05448014|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study design: A two-arm (treatment group vs. control group) pilot randomized controlled trial will be carried out with 40 adolescents.||||
33887786|NCT03141944|||COHORT||OTHER|||||||
33887787|NCT05003557|||COHORT||RETROSPECTIVE|||||||
33887788|NCT00181792|||FAMILY_BASED|||||||||
33887789|NCT04937010|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33887790|NCT03341260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"The patients will be randomly divided into 2 groups:~Experimental group:~50 mg Diclofenac Potassium to be administered one hour before treatment.~Control group:~Placebo to be administered one hour before treatment."|t|t|t|t
33887791|NCT02913313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887792|NCT03863314|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33887793|NCT04630275|||COHORT||CROSS_SECTIONAL|||||||
33887794|NCT02809664|||OTHER||RETROSPECTIVE|||||||
33887795|NCT04348448|||COHORT||PROSPECTIVE|||||||
33887796|NCT05266404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33887797|NCT05510960|||COHORT||PROSPECTIVE|||||||
33887798|NCT05744427|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33887799|NCT01361841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887800|NCT00854646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887801|NCT06078657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887802|NCT01851538|||COHORT||PROSPECTIVE|||||||
33887803|NCT06369714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762060|NCT04731155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762061|NCT03816995|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33762062|NCT05226858|||CASE_ONLY||PROSPECTIVE|||||||
33762063|NCT02422719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762064|NCT01301274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762065|NCT02013336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762066|NCT01939340|||COHORT||PROSPECTIVE|||||||
33762067|NCT03300570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33762068|NCT04211415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant, care provider, investigator, and outcomes assessor will be blinded in Part 1 and Part 3 of the study. Part 2 of the study will be unblinded.||t|t|t|t
33762069|NCT00158340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887804|NCT04769791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33887805|NCT05904392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33887806|NCT02932956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887807|NCT04886271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887808|NCT04873492|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|NA/NO|"The study model consists of two cohorts, the first one or learning cohort includes a group of health volunteers and 2 groups of MS patients from who clinical outcome (aggressive vs non-aggressive) is already known based on clinical follow up since first event. Clinical data and blood sample have been already collected and are available from OFSEP (Observatoire français de la Sclérose en plaques). Blood will be analyzed to characterize transcriptomic, epigenomic, genomic immune cells features to discover predictive markers of clinical outcome. The second cohort or validation cohort consists of MS patients enrolled after their first event and followed for maximum 2-years until the determination of their clinical outcome. Blood will be collected after their first event and used in FACS to classified the patients based on molecule of interest discover thanks to learning cohort and predict clinical outcome."||||
33887809|NCT00094614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887810|NCT00690157|||COHORT||PROSPECTIVE|||||||
33887811|NCT02312973|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33887812|NCT03496753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistic analysis|Randomized clinical trial|f|f|f|t
33887813|NCT02423096|||CASE_CONTROL||PROSPECTIVE|||||||
33887814|NCT01978002|||CASE_CONTROL||PROSPECTIVE|||||||
33887815|NCT00220220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33887816|NCT03270956|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33887817|NCT02144779|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887818|NCT05035680|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33887819|NCT00771472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887820|NCT05682014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Random sampling method will be used in the research. Randomization Pregnant women will be evaluated in terms of their eligibility for the study, a list of pregnant women included in the study will be created and divided into two groups. The assignment of pregnant women to the intervention and control groups in the study will be realized by assigning a number to each of the participants, forming a number group for the intervention group, and planning the numbers outside of this group as the control group.|f|f|f|t
33887821|NCT05175170|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887822|NCT03972072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887823|NCT05211778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33887824|NCT02148367|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33887825|NCT00974220|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33887826|NCT01552057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887827|NCT00531960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887828|NCT03883074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33887829|NCT04362709|||COHORT||PROSPECTIVE|||||||
33887830|NCT05265767|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Severe haemophilia A||||
33762070|NCT01758484|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887831|NCT02591264|||CASE_CONTROL||PROSPECTIVE|||||||
33887832|NCT05173584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887833|NCT04210271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887834|NCT03032783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887835|NCT04684654|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33887836|NCT05313880|||COHORT||CROSS_SECTIONAL|||||||
33887837|NCT06148961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887838|NCT04724161|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33974619|NCT05412758|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||There are two arms to this study; AROMA 1 and BIORESOURCE. It is the AROMA 1 arm of the study that involves an intervention. A total of 648 patients will be recruited for development of an augmented breath test to detect oesophageal and gastric cancer at early stages of disease. Three groups, each containing 216 patients, will be recruited: (i) oesophageal cancer (ii) gastric cancer and (iii) control/normal patients with upper gastrointestinal symptoms. After two baseline breath samples at 0 minutes and 10 minutes are collected, subjects will then be asked to consume a standard nutrient drink. Further breath samples will be collected at 15, 60 and 90 minutes after consumption of the drink.||||
33974620|NCT03795103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators won't know which arm is allocated to arteriopathic patients. Program will be send to patients by a outcome research engineer||f|f|t|f
33974621|NCT06545383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participant will not know which exercise group she/he is in|Comparing two exercise groups|t|f|f|f
33974622|NCT03424291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974623|NCT00240682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974624|NCT01298856|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073290|NCT03591224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are not told of their group assignment until the end of the study, at which point they would receive a copy of their pharmacogenetic report. The consulting pharmacist also does not have knowledge of the patient's group assignment in the first encounter for baseline data collection. Group assignment is only revealed to the pharmacist after two weeks when the pharmacogenetic report is available on the Pillcheck online portal. Patients assigned to the control group will have their report appear blank to the pharmacist, whereas the intervention patient group will have their full pharmacogenetic report accessible by the consulting pharmacist. Prescribers are also informed via fax briefly of the study protocol and asked to maintain blinding of their patient's group assignment.|Enrolled subjects will be randomly assigned to either the control arm (pharmacist standard of care) or intervention arm (pharmacogenetic guided decision making by the pharmacist) in optimizing antidepressant drug therapy. Randomization is done by the primary investigator who isn't directly involved with patient consultations.|t|t|f|f
34073291|NCT03063619|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33887839|NCT05012878|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized control trial comparing two cardiac rehabilitation exercise groups: 1) high intensity interval training; and 2) moderate intensity continuous training. There will also be an observational control group who decline participation in cardiac rehabilitation, and an observational cardiac rehabilitation group who participate in cardiac rehabilitation but decline randomization. There is also a healthy control group without cardiovascular disease for baseline comparison only (no intervention).|f|f|f|t
33887840|NCT04972877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33887841|NCT00138021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887842|NCT03624738|RANDOMIZED|PARALLEL||TREATMENT||NONE||Femorofemoral bypass in redo cardiac surgery||||
33887843|NCT00191841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887844|NCT00211614|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33887845|NCT00482716|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33887846|NCT04356456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomization at 1:1 ratio for active or placebo|t|t|t|t
33887847|NCT00106951|||||RETROSPECTIVE|||||||
33887848|NCT02337387|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33887849|NCT00267527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33887850|NCT04106154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research assistant or graduate student blind to participants' intervention status will complete all measures.||f|f|f|t
33887851|NCT00641121|||CASE_ONLY||PROSPECTIVE|||||||
33887852|NCT01540643|||COHORT||PROSPECTIVE|||||||
33974625|NCT03947580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974626|NCT02145975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974627|NCT03144856|NA|SINGLE_GROUP||TREATMENT||NONE||Apatinib single agent||||
33762071|NCT04282421|||COHORT||RETROSPECTIVE|||||||
33887853|NCT00224562|||CASE_CONTROL||PROSPECTIVE|||||||
33887854|NCT02224898|||CASE_CONTROL||PROSPECTIVE|||||||
33887855|NCT04402801|||COHORT||PROSPECTIVE|||||||
33887856|NCT01587066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887857|NCT05830383|NA|SINGLE_GROUP||OTHER||NONE||||||
33887858|NCT02866864|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33887859|NCT04788420|||COHORT||RETROSPECTIVE|||||||
33887860|NCT01555229|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33887861|NCT00170300|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33887862|NCT03679325|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33887863|NCT03073746|RANDOMIZED|PARALLEL||OTHER||SINGLE|Healthcare providers will not have knowledge of the interventions assigned to individual participants.|Participants presenting with new symptoms to either an urgent care center or emergency department will be randomized in a 1:1:1 ratio to one of three groups. 1. Access to Health Search (i.e. Google's new health search platform for mobile devices; Health Knowledge Panels and Symptom Search Tool); 2. Access to Standard Search (i.e. prior version of Google search); 3. Usual Care. Groups 1 and 2 will use a tablet or mobile phone to search while group 3 will not.|f|t|f|f
33887864|NCT00629395|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33887865|NCT03303001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887866|NCT03464669|||COHORT||PROSPECTIVE|||||||
33887867|NCT06454708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887868|NCT05293730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887869|NCT02404987|||COHORT||PROSPECTIVE|||||||
33887870|NCT03339492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887871|NCT03049449|NA|SEQUENTIAL||TREATMENT||NONE||||||
33887872|NCT05274126|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective longitudinal uncontrolled multicenter study, with cohort follow-up, focusing on patients, professionals, relatives and structures.||||
33887873|NCT01801033|||||PROSPECTIVE|||||||
33887874|NCT05322408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887875|NCT04168294|||COHORT||PROSPECTIVE|||||||
33887876|NCT01091636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded to the participants|HIPEC vs. no HIPEC after primary cytoreductive surgery or interval cytoreductive surgery|t|f|f|f
33887877|NCT00003414|RANDOMIZED|||TREATMENT||||||||
33887878|NCT04922866|||COHORT||RETROSPECTIVE|||||||
33887879|NCT02673255|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33887880|NCT02637817|||COHORT||PROSPECTIVE|||||||
33887881|NCT06290440|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33887882|NCT00899652|||COHORT||PROSPECTIVE|||||||
33887883|NCT05123235|RANDOMIZED|PARALLEL||TREATMENT||NONE||Physical activity group and a control group||||
33887884|NCT01356381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887885|NCT01747460|||||PROSPECTIVE|||||||
33887886|NCT04515030|||CASE_CONTROL||PROSPECTIVE|||||||
33974628|NCT05733195|||COHORT||PROSPECTIVE|||||||
33974629|NCT01614327|||CASE_ONLY||PROSPECTIVE|||||||
33974630|NCT04431271|||COHORT||RETROSPECTIVE|||||||
33974631|NCT00615784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887887|NCT01073579|||||PROSPECTIVE|||||||
33762072|NCT01840384|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33762073|NCT00691925|||COHORT||PROSPECTIVE|||||||
33762074|NCT03499522|||COHORT||PROSPECTIVE|||||||
33887888|NCT03262376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is double-blinded. The supplement manufacturer will independently create codes for the 4 treatment conditions. The study statistician will use the treatment codes generated to allocate participants to treatments. Researchers and participants will be blind treatment allocation.|The study conforms to a double blind, quasi-randomised (randomisation will be balanced across condition based on age and sex), placebo controlled, parallel group design comprising 4 treatment conditions|t|t|t|f
33887889|NCT02529033|||OTHER||PROSPECTIVE|||||||
33887890|NCT03896295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887891|NCT04555109|||COHORT||PROSPECTIVE|||||||
33887892|NCT04687319|||CASE_ONLY||PROSPECTIVE|||||||
33887893|NCT02147444|||COHORT||PROSPECTIVE|||||||
33887894|NCT06089044|||CASE_ONLY||RETROSPECTIVE|||||||
33887895|NCT05295537|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized, parallel assignment.||||
33887896|NCT03486392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887897|NCT00770848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762075|NCT04307459|||COHORT||PROSPECTIVE|||||||
33762076|NCT03790670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762077|NCT05670925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762078|NCT05683717|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33762079|NCT04345458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762080|NCT04803578|||CASE_CONTROL||PROSPECTIVE|||||||
33762081|NCT03287414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762082|NCT01329354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762083|NCT02085681|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762084|NCT00161239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762085|NCT04394247|||COHORT||RETROSPECTIVE|||||||
33762086|NCT02628132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762087|NCT02677025|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762088|NCT05163613|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762089|NCT00570024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762090|NCT05199610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762091|NCT06249763|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Participants are randomised by an external source. Participants, care provider, investigator and outcomes assessor will be blinded to the randomisation. In case of adverse events, the randomization will be revealed to the investigator.||t|t|t|t
33762092|NCT03122054|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients suffering acute pain because of acute cholecystitis||||
33762093|NCT04230057|||COHORT||PROSPECTIVE|||||||
33762094|NCT00496002|RANDOMIZED|||TREATMENT||DOUBLE||||||
33887898|NCT01023984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887899|NCT04601480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||43 Primary Care Clinics will be randomized to be in one of 4 arms: 1) Care as usual, 2) Choice architecture nudge, 3) Prescription Drug Monitoring Program (PMP) Integration \& nudge, 4) Choice architecture nudge + PMP Integration \& nudge|f|f|t|f
33887900|NCT02208960|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33887901|NCT03536442|||CASE_ONLY||RETROSPECTIVE|||||||
33887902|NCT02525549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887903|NCT02239172|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33887904|NCT06549075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33887905|NCT02151344|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33887906|NCT03700099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887907|NCT01273441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887908|NCT05084352|||COHORT||PROSPECTIVE|||||||
33887909|NCT05785195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887910|NCT00388947|||COHORT||PROSPECTIVE|||||||
33887911|NCT02140255|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33887912|NCT00473876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887913|NCT04324645|||CASE_CONTROL||PROSPECTIVE|||||||
33887914|NCT02197377|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33887915|NCT01955707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887916|NCT00135980|NON_RANDOMIZED|PARALLEL||ECT||NONE||||||
33887917|NCT01832740|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33887918|NCT06075381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Due to the nature of the intervention, it is not feasible to mask the treatment in the control group and intervention group, although both groups will receive a standard treatment. One group will receive treatment through the use of the PED, while the other group will receive treatment through intermittent positive pressure in cases of lung atelectasis or mild persistent hypoxemia.~After obtaining informed consent from eligible participants, the assignment to the therapeutic group will be carried out using a code that does not openly indicate the assigned group. Individuals aware of the assignment will be the physiotherapists administering the interventions and collecting data in the electronic format, which will be isolated from the data analysis. Generating these codes for each patient aims to blind the interventions during the statistical analysis process. All information will be recorded in electronic format."|Controlled, randomized, blinded, parallel-group, Phase II clinical study of applying conventional management plus the use of a lung reexpansion device versus conventional management alone as a lung reexpansion strategy in tracheostomized patients.|f|f|f|t
33887919|NCT04695873|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open label, randomized parallel group, no treatment control investigation.||||
33887920|NCT02949128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887921|NCT02698098|||COHORT||PROSPECTIVE|||||||
33887922|NCT02510352|||COHORT||PROSPECTIVE|||||||
33887923|NCT00268645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073292|NCT02273362|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33887924|NCT04698525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinician will make an evaluation and if the patient has the criteria for inclusion will be by randomization in one group or another. Neither the clinician and the patient will not know the administrated treatment.|A double-blind study with two groups. One using VPA and the other one using memantine in subjects with a diagnosis of episodic migraine.|f|f|t|f
33887925|NCT01577238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887926|NCT02850419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887927|NCT04947813|||COHORT||PROSPECTIVE|||||||
33974632|NCT04152928|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974633|NCT02701478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974634|NCT00003145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974635|NCT01474278|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33974636|NCT05060627|NA|SEQUENTIAL||TREATMENT||NONE||A phase I classic 3+3 design, to establish the maximum tolerated dose (MTD) of the combination. Once the MTD will be defined, a dose expansion phase II will be open to recruit up to 60 patients.||||
33974637|NCT05241236|||COHORT||PROSPECTIVE|||||||
33974638|NCT01729936|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33974639|NCT02893748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33974640|NCT04262583|||COHORT||PROSPECTIVE|||||||
33974641|NCT02952248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974642|NCT02424981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974643|NCT06191367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974644|NCT00957983|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33974645|NCT02989766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974646|NCT03287596|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974647|NCT00838318|||CASE_ONLY||PROSPECTIVE|||||||
33974648|NCT00584363|||OTHER||CROSS_SECTIONAL|||||||
33974649|NCT01185288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974650|NCT02327000|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33974651|NCT04053842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974652|NCT00026936||||TREATMENT||||||||
33974653|NCT01193608|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33974654|NCT04291079|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33974655|NCT04630197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974656|NCT05107440|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33974657|NCT04001608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974658|NCT02455700|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33974659|NCT05791760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974660|NCT02264951|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33974661|NCT03164148|NA|SINGLE_GROUP||OTHER||NONE||||||
33974662|NCT00619632|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33974663|NCT01548872|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33974664|NCT05505123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33974665|NCT01400113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974666|NCT01927757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974667|NCT04567095|||OTHER||OTHER|||||||
33974668|NCT01315145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974669|NCT01568008|||COHORT||PROSPECTIVE|||||||
33974670|NCT03294538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974671|NCT02271555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33974672|NCT05131126|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33974673|NCT04755881|||CASE_ONLY||PROSPECTIVE|||||||
34073293|NCT06171529|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||"For patients who randomize to CTM: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the CTM Flow material. A 23, or 20 gauge needle will be used to inject the CTM after arthroplasty and prior to closure of the capsule. To draw up the injection: allow the particulate to settle to the bottom and withdrawal fluid into the 3 or 5 cc syringe. It is ok if some particulate is drawn up into the syringe. 2cc of CTM will be injected into each patient.~For patients who randomize to Saline: An unblinded IHTSC Fellow, nurse/PA, or OR staff will use a 3 or 5 cc syringe to draw up the saline. A 23 gauge needle will be used to inject the saline after arthroplasty and prior to closure of the capsule. 2cc of saline will be injected into each patient."|t|f|t|f
33887928|NCT05936762|NA|SINGLE_GROUP||TREATMENT||NONE||"Of the 36 screened patients, 15 had to be included and treated patients (15 as planned per-protocol). Of these, 14 patients completed the study and attended the visit at Month 6 . Since all patients were treated , the Full Analysis Set (FAS, all randomized and treated patients) was identical to the Safety Set (all treated patients).~The mean age at enrollment was 71±7 years (range 54-80;median 73), and 12 of patients were women (85.7%) and 2 male (14.3%) . The mean BMI were26.6±3.4 (range 21-30;median 28.5) . Overall patients had knee OA with a Kellgren-Lawrence grade II and III (50/50)."||||
33887929|NCT01940484|||COHORT||PROSPECTIVE|||||||
33887930|NCT00834015|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33887931|NCT03283085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887932|NCT03153839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887933|NCT02377895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974674|NCT04561128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974675|NCT02027779|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974676|NCT02505854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974677|NCT04414215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A double blind design will be used, where participants will be randomly assigned to placebo or emotional working memory training|f|f|t|f
33974678|NCT05053893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974679|NCT03081715|NA|SINGLE_GROUP||TREATMENT||NONE|open-label|||||
33974680|NCT01919879|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974681|NCT03646981|||COHORT||PROSPECTIVE|||||||
33974682|NCT04893148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974683|NCT00772564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974684|NCT00003961||||TREATMENT||NONE||||||
33974685|NCT02236533|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974686|NCT04511559|||COHORT||PROSPECTIVE|||||||
33974687|NCT03486652|||COHORT||PROSPECTIVE|||||||
33974688|NCT04126057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974689|NCT04125628|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33974690|NCT04497428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33974691|NCT06241898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073294|NCT00685867|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34073295|NCT05090943|||COHORT||PROSPECTIVE|||||||
34073296|NCT04817267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073297|NCT02094326|||CASE_ONLY||CROSS_SECTIONAL|||||||
34073298|NCT02627573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073299|NCT04736069|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1 received 21 sessions of inpatient physical therapy program including electrotherapy, superficial- deep heat applications and basic knee exercise program. Group 2 received the same physical therapy program at outpatient clinic.||||
34073300|NCT02646319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073301|NCT02149563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073302|NCT04359498|||CASE_ONLY||RETROSPECTIVE|||||||
33887934|NCT01756456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887935|NCT00850746|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33887936|NCT05593848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887937|NCT02024984|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33887938|NCT03844867|NA|SINGLE_GROUP||SCREENING||NONE||||||
33974692|NCT01573065|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974693|NCT05881148|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Each participant is self-blinded, but also blinded to other participants ' alternative order|Multiple N-of-1 Trial: within-subjects repetitive blinded randomized crossovers|t|f|f|t
33974694|NCT01433835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073303|NCT06517095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The intervening measure is utilize the OVDs to partially fill the peripheral capsule, causing the central posterior capsule to bulge, and then employ the double-ended Whitman Shepherd capsular polisher to meticulously polish both the anterior and equator of the capsule. By rotating the polisher 180°along one side, followed by switching ends to cover the remaining 180° range, even the main incision site can be effectively addressed due to its curved tip design.|t|t|f|t
34073304|NCT01151969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34073305|NCT05681364|||COHORT||PROSPECTIVE|||||||
34073306|NCT04201236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887939|NCT00944827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33887940|NCT03168867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33887941|NCT01144585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33887942|NCT01364805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887943|NCT01629745|||CASE_ONLY||RETROSPECTIVE|||||||
33887944|NCT03370770|||COHORT||RETROSPECTIVE|||||||
33887945|NCT02472847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33887946|NCT01586988|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33887947|NCT01290627|||CASE_ONLY||RETROSPECTIVE|||||||
33887948|NCT00006131|RANDOMIZED|||TREATMENT||DOUBLE||||||
33887949|NCT03135249|NA|SINGLE_GROUP||TREATMENT||NONE||To determine if treatment with alemtuzumab after natalizumab maintains or reduces the ARR in patients with RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in patients who received the natalizumab-alemtuzumab sequential therapy.||||
33887950|NCT03097380|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33887951|NCT01436721|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33887952|NCT05821270|RANDOMIZED|PARALLEL||OTHER||NONE||"1 group randomly divided in: yoga intervention plus regular military training; and waiting list with only military training"||||
33887953|NCT02153099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887954|NCT05367102|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigator will run workshops virtually, through Zoom, and in person. Participants will be randomized either to the virtual condition, or to the in person condition.||||
33887955|NCT03489733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33887956|NCT04289688|||COHORT||OTHER|||||||
33974695|NCT05016349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974696|NCT03337178|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33974697|NCT05681624|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33974698|NCT06130956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073307|NCT05437445|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762095|NCT02891343|NA|SINGLE_GROUP||OTHER||NONE||||||
33887957|NCT04707638|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887958|NCT01749384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887959|NCT05172544|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33887960|NCT00679458|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33887961|NCT00885079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887962|NCT03696472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887963|NCT00024427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887964|NCT01840202|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33887965|NCT02532478|||COHORT||RETROSPECTIVE|||||||
33974699|NCT02605109|||CASE_CONTROL||RETROSPECTIVE|||||||
33974700|NCT06544551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974701|NCT05503004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33974702|NCT05654779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974703|NCT06484036|RANDOMIZED|PARALLEL||OTHER||NONE||This is a multicenter, open-label, randomized controlled superiority trial in 2 parallel groups with adjudication of the primary endpoint blinded to the randomization group and centrally (PET reading).||||
33974704|NCT01933295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974705|NCT03267056|||COHORT||PROSPECTIVE|||||||
33974706|NCT00743067|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33974707|NCT02507375|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887966|NCT05459376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All assessments will be carried out by researcher A who will not be involved with the interventions and will remain blind to the identification of groups.~Each participant will remain identified by numbers and not names. Participants will be informed about the aim of the study to assess the additional effect of two different cupping techniques, the classic and the sham, in association with active exercise. In order not to compromise the blinding of the study, all participants will undergo the same assessment before the interventions. Intervention times will be differentiated so that there is no contact between the groups and possible exchanges of information. Data collected during participant assessments will not be revealed to the researchers responsible for the interventions."|Intervention Group and Sham Group|f|f|t|t
33887967|NCT02251808|||COHORT||PROSPECTIVE|||||||
33974708|NCT04820608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974709|NCT01701284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974710|NCT05263232|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33974711|NCT02663596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974712|NCT03199248|||CASE_ONLY||RETROSPECTIVE|||||||
33974713|NCT01055249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33887968|NCT00977470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887969|NCT02139150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33887970|NCT00506857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887971|NCT01005160|RANDOMIZED|CROSSOVER||||NONE||||||
33887972|NCT06088927|||COHORT||PROSPECTIVE|||||||
33887973|NCT01097629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887974|NCT00156598|||COHORT||PROSPECTIVE|||||||
33887975|NCT01486576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33887976|NCT01639326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887977|NCT00426348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887978|NCT03862027|NA|SINGLE_GROUP||OTHER||NONE||||||
33887979|NCT05531747|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Biological assays will be performed by technician blinded from patients clinical status|||||
33887980|NCT05277974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887981|NCT04937504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887982|NCT02673229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887983|NCT00694057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887984|NCT00318292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887985|NCT01100489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887986|NCT04613986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33887987|NCT03504826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33887988|NCT00281814|||COHORT||PROSPECTIVE|||||||
33887989|NCT00368706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974714|NCT03757962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073308|NCT00384202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073309|NCT05082337|NA|SINGLE_GROUP||OTHER||NONE||Patient with severe symptomatic aortic stenosis with a clinical indication for TAVR according to the Heart Team criteria will be treated with an approved aortic valve (balloon-expandable or self-expandable aortic valve) and the SAVVY guidewire will be used for the rapid pacing runs and ventricular pressure measurements.||||
34073310|NCT05214209|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Cluster randomisation with blinding of statisticians||t|f|f|t
34073311|NCT03825081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073312|NCT02875795|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073313|NCT01922258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073314|NCT04530929|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||70 people meeting the inclusion criteria were included in the intervention and observational study. The study was randomized using a double-blind trial. 35 persons selected in the draw were G1 group and the remaining G2 group (n=35). The tests were completely anonymous, the competitors gave their informed written consent to carry them out. Interventional study was conducted using a probiotic or placebo. The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies) or placebo (created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.). Competitors used probiotic/ placebo for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).|t|f|t|f
34073315|NCT01218971|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33887990|NCT06130332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33887991|NCT00000855||||TREATMENT||NONE||||||
33887992|NCT03573167|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33887993|NCT02542176|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33974715|NCT05893550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is double-blind. Neither the participant nor the caregiver not the outcomes Assessor will know which group the participant is assigned to. The local PI in Mauritius (Tashneem Mahoomed, National Director) will also be blind to treatment condition. Only the PI in Philadelphia will have knowledge of treatment assignment, and he has no contact with participants in Mauritius.|2 x 2 randomized, double-blind, stratified, placebo-controlled trial|t|t|t|t
33974716|NCT01197963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974717|NCT00765700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974718|NCT01633827|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974719|NCT02518646|||COHORT||PROSPECTIVE|||||||
33974720|NCT04879420|||COHORT||RETROSPECTIVE|||||||
33974721|NCT00901628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974722|NCT06227975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974723|NCT01807871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073316|NCT05205382|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34073317|NCT06038500|NA|SINGLE_GROUP||PREVENTION||NONE||quasi-experimental Pre-test/Post-test design - pilot||||
34073318|NCT00596050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073319|NCT04754516|||COHORT||RETROSPECTIVE|||||||
34073320|NCT01127048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073321|NCT03297164|||COHORT||PROSPECTIVE|||||||
34073322|NCT02609386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073323|NCT05982106|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34073324|NCT03020550|||COHORT||PROSPECTIVE|||||||
34073325|NCT00435110|||COHORT||PROSPECTIVE|||||||
33887994|NCT01227967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33887995|NCT00102310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33887996|NCT03855501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33887997|NCT04561232|NA|SEQUENTIAL||TREATMENT||NONE||||||
33887998|NCT04052841|RANDOMIZED|PARALLEL||TREATMENT||NONE||The recruitment of subjects must meet the diagnosis criteria of MGD the international workshop on meibomian gland dysfunction.||||
33887999|NCT06278688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888000|NCT02689492|||COHORT||PROSPECTIVE|||||||
33888001|NCT01042808|||||PROSPECTIVE|||||||
33888002|NCT01099969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888003|NCT04415424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, their study clinicians and study researchers assessing the outcomes will be blinded to the treatment arm (4CMenB vaccine or placebo).|Randomised 1:1 to receive 4CMenB vaccine or a matching placebo|t|t|t|t
33888004|NCT02856165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888005|NCT04863963|||CASE_CONTROL||OTHER|||||||
33974724|NCT00042497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974725|NCT04381884|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive Ivermectin 600 µg / kg / once daily plus standard care or standard care upon diagnosis of COVID-19.||||
33974726|NCT05313204|||COHORT||CROSS_SECTIONAL|||||||
33974727|NCT00135707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33974728|NCT01727245|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33974729|NCT04447274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974730|NCT03654456|||CASE_CONTROL||RETROSPECTIVE|||||||
33974731|NCT03538236|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34073326|NCT04199377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073327|NCT00482170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073328|NCT03777280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073329|NCT00089518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34073330|NCT02629744|NA|SINGLE_GROUP||||NONE||||||
34073331|NCT05722743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34073332|NCT03565003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888006|NCT04257331|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of parent training and the use of a waitlist control group, it will not be possible to blind participants or facilitators. However, research staff who collect the data will be blinded for the baseline and post-intervention assessment. Data collectors will not be involved in the delivery process and will be trained on the topic of risk of bias. Parents will also be asked not to reveal their allocation condition to outcome data collectors. Process evaluation data will be collected by a separate group of research staff. Given that all families will ultimately receive the training, blinding will not be possible at the follow-up time-points. Blinding will be protected and monitored, while the violation of blinding will be detected and incorporated into the interpretation of results.|A pragmatic quasi-experimental study will be conducted to examine the effectiveness of the SREIA programme. The study will be conducted within the context of routine services and will involve two consecutive deliveries of the SREIA programme. One hundred families of children with ASD age three to six will be recruited and allocated to the two waves of delivery based on their availability and preference, with 50 families in each wave. Each wave will comprise two versions of the programme that are delivered concurrently, with 30 families in version A and 20 in version B. Participants will be self-selected into either version. The 50 families who choose to participate in the first wave will be the treatment group, and the 50 families in the second wave will service as the waitlist control group.|f|f|f|t
33888007|NCT04755829|||OTHER||CROSS_SECTIONAL|||||||
33888008|NCT02620904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888009|NCT03954626|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study|Single arm, multicenter||||
33888010|NCT01431183|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33888011|NCT01286584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888012|NCT06359184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33974732|NCT03742531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974733|NCT02524379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974734|NCT00265759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974735|NCT04459481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888013|NCT03841552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators who collected the outcome data, as well as the statistician were blinded to group allocation.|Randomized controlled pilot trial|f|f|t|t
33888014|NCT02278913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888015|NCT01353989|||COHORT||PROSPECTIVE|||||||
33888016|NCT01451801|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33888017|NCT06351033|||CASE_CONTROL||PROSPECTIVE|||||||
33888018|NCT03195517|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This was an interventional, single group assignment study in which the subjects were first assigned to the control group and, after 1-month interval with no physical training, were shifted into the 3-months exercise intervention group. Thus, the subjects acted as their own control at the end of the study.||||
33888019|NCT06490861|NA|SINGLE_GROUP||OTHER||NONE||||||
33888020|NCT01750255|RANDOMIZED|PARALLEL||||NONE||||||
33888021|NCT00689247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888022|NCT03079440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888023|NCT05943730|NA|SINGLE_GROUP||OTHER||NONE||||||
33888024|NCT06185855|||COHORT||RETROSPECTIVE|||||||
33888025|NCT06313437|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33888026|NCT00650611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888027|NCT04939688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All patients will have the benefit of two CT scans : one normal dose and one ultra low-dose. However, the results of scans will be interpreted by two independent radiologists (senior and junior) who do not know whether the scan has been done with the normal, classic dose or with the ultra low-dose protocol.|All patients requiring investigation of traumatic injuries after moderate or severe head trauma as identified at the emergency department. All patients will receive a standard dose CT scan of the skull according to the usual management, as well as a ULD scan of the same area, performed specifically for the needs of the study, following a pre-established standardized protocol. The center's radiologist will interpret the conventional CT scan in real time for patient diagnosis and management, but this interpretation will not be used in the study. The patient will then be redirected to the emergency department for his or her usual management.||||
33888028|NCT02113787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888029|NCT06083584|||COHORT||PROSPECTIVE|||||||
33888030|NCT02837679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888031|NCT03707457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888032|NCT00814385|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||f|f|t|t
33888033|NCT02750202|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974736|NCT01994603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974737|NCT02326428|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974738|NCT01761357|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33974739|NCT04130256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized 1:1 trial||||
33974740|NCT05463861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33974741|NCT01630200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762096|NCT01015976|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762097|NCT06625073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects will be randomized to either empagliflozin 10 mg daily for 12 months or matching placebo. The subjects and the investigators will not know whether subjects are randomized to active arm (empagliflozin) or to control arm (placebo).|Empagliflozin 10 ng daily for 12 months|t|t|t|t
34073333|NCT04411758|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE||In this clinical trial, participants with CKD undergoing hemodialysis or peritoneal dialysis will be instructed to use 4 capsules of 500mg/day containing concentrated and standardized dry green propolis extract (EPP-AF®) for 2 months or placebo (4 capsules of 500mg/day of magnesium stearate, silicon dioxide and microcrystalline cellulose) for two months, and then the groups will be crossed and will receive the same amount of propolis as the first group.|t|f|t|t
33888034|NCT03115931|||COHORT||PROSPECTIVE|||||||
33888035|NCT02612376|||CASE_CONTROL||PROSPECTIVE|||||||
33888036|NCT02299960|||CASE_CONTROL||PROSPECTIVE|||||||
33888037|NCT02157454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888038|NCT02651090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888039|NCT02867397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888040|NCT04573673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073334|NCT01475344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073335|NCT05621395|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Sequentially numbered, sealed, opaque envelopes|Randomized, Parallel Group, Placebo Controlled Trial|t|t|f|f
34073336|NCT03235323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.|f|f|f|t
34073337|NCT05161845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33888041|NCT04491227|||COHORT||RETROSPECTIVE|||||||
33888042|NCT05743933|||CASE_CONTROL||PROSPECTIVE|||||||
33888043|NCT01236456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888044|NCT03636906|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind||t|t|t|t
33888045|NCT05200260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888046|NCT01851837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888047|NCT01402245|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073338|NCT04811807|||COHORT||PROSPECTIVE|||||||
33888048|NCT05450614|RANDOMIZED|PARALLEL||TREATMENT||NONE||Initially, patients who accept the invitation will be randomized between groups Thrive vs CBCT. In the Thrive group, access to the application and information regarding its use will be made available to participants. Reassessments and data collection will be performed at 5 points: baseline, 4, 8, 12 weeks and 6 months. These five evaluations will be carried out through questionnaires sent to the participants. Participants selected for the TCCG group will undergo a new randomization, which will select 50% of patients for immediate start of online sessions and the remainder for inclusion in a waiting list. Participants selected for immediate start will start the CBCT sessions at the time of the initial assessment and will be reassessed at the same points as the Thrive group, also through self-administered online questionnaires. A 12-week assessment list through online auto scales will take place at the end of the period. Patients at PHQ≥ 9 will initiate CBCT protocol sessions online.||||
33888049|NCT04236544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|We will explain in our information and consent form that we intend to assess whether patients with mutiple sclerosis find different health information websites helpful on a range of self-reported outcomes. Researchers involved in study recruitment, administration of interventions and data analysis will be blind to the allocation of intervention and control group.|After informed consent, baseline data will be obtained by the staff member responsible for enrolment and people with multiple sclerosis will be randomly allocated in blocks with variable block length at a 1:1 ratio to the intervention or the control group. The allocation sequence will be computer-generated by a statistician not involved in the conduction of the trial.|t|t|t|t
33888050|NCT00962273|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33888051|NCT01348737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33888052|NCT01743573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974742|NCT04468919|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|In single case research design, each participant is their own control. The proposed intervention is behavioral and study personnel are aware of each data collection condition.|"Single case research design with:~Alternating treatments without baseline for experiments 1.3a, 2.2; Alternating treatments without baseline for experiments 1.3b and 3.4"||||
33974743|NCT00719784|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974744|NCT03019393|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974745|NCT05973227|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33974746|NCT04002921|||OTHER||PROSPECTIVE|||||||
33974747|NCT02577159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974748|NCT03664856|NA|SINGLE_GROUP||OTHER||NONE||||||
33888053|NCT02908399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888054|NCT04011202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Control group and experimental group|f|f|f|t
33888055|NCT04141657|||OTHER||PROSPECTIVE|||||||
33888056|NCT02436941|||OTHER||PROSPECTIVE|||||||
33888057|NCT01693445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888058|NCT01742429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888059|NCT01989221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888060|NCT03082560|||CASE_ONLY||PROSPECTIVE|||||||
33888061|NCT00783016|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33888062|NCT01071187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974749|NCT01698996|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974750|NCT04921033|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open-label, randomized, multicenter, interventional, parallel-group study, designed to evaluate the efficacy and tolerability of EEN in inducing clinical remission at 12 weeks in subjects with ileocaecal CD.~Patients will receive EEN for 8 weeks, initially building up to the full required volume of formula over the first 3 to 4 days, depending on tolerance and side effects After the completion of the period of EEN, foods will be reintroduced slowly and supplementary enteral nutrition will be continued for another 4 weeks.~A total of 256 patients with ileocaecal CD will be randomized in a 1:1 ratio to receive steroids and EEN. Each of the treatment arms will comprise 128 subjects. In order to make the groups comparable, randomization will be stratified according to the severity of the disease according to Crohn's Disease Activity Index (CDAI):~1. CDAI between 150-220 --\> Mild~2. CDAI between 220-450 --\> Moderate~3. CDAI\>450 --\> Severe"||||
33974751|NCT06349720|||COHORT||PROSPECTIVE|||||||
33974752|NCT01604421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073339|NCT04369846|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34073340|NCT02119078|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34073341|NCT05828368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073342|NCT05207527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be randomized; however, since it is an exercise intervention, the participants cannot be masked. When the interpretation of the data is performed, the researcher will not know what type of treatment the person being evaluated is receiving, and the researcher's advisor will make the comparison without knowing what intervention the participant was subjected to.|There will be 4 parallel groups, 3 intervention and 1 control group.|f|f|t|t
34073343|NCT01556997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073344|NCT00716807|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34073345|NCT05138978|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each subject will be randomized.|t|f|t|t
34073346|NCT00891969|||COHORT||PROSPECTIVE|||||||
34073347|NCT06307730|||COHORT||RETROSPECTIVE|||||||
34073348|NCT00184535|||CASE_ONLY||CROSS_SECTIONAL|||||||
33888063|NCT01487603|||OTHER||PROSPECTIVE|||||||
33888064|NCT03775707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888065|NCT00168350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33888066|NCT01907386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888067|NCT04417244|||CASE_CONTROL||RETROSPECTIVE|||||||
33888068|NCT00291720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888069|NCT01785355|||COHORT||PROSPECTIVE|||||||
33888070|NCT00974415|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33888071|NCT02145494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888072|NCT01905475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888073|NCT02221492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888074|NCT05220592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinded|This study was a two-armed controlled trial in which an internet-based recovery training program (iRTP) was compared with a wait-list control group (WLC). The study followed Consolidated Standards of Reporting Trials (CONSORT) guidelines (Schulz et al., 2010) and was conducted between February 2018 and May 2019. Since this was a pilot trial, no power calculation and estimates of sample size were conducted.|t|f|f|f
33888075|NCT01371461|||OTHER||PROSPECTIVE|||||||
33888076|NCT02520986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888077|NCT00003141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888078|NCT05827796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888079|NCT06253416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants: Patients with fibromyalgia Care provider: Physiotherapist who showed and followed the patients exercise programme Researchers were blinded to the patients groups|prospective, randomized, single-blind, clinical study patients were randomized into two groups by a physiotherapist with sealed envelopes|t|t|t|f
33888080|NCT00984204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888081|NCT03183544|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||5 patients with limited recurrent prostate cancer and 3 healthy volunteers will be enrolled in this clinical trial||||
33888082|NCT05210595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974753|NCT05697809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A is open-label, no masking. Part B is masked for the subject and the outcomes assessing site team and central reading center.|"The trial will include previously IVT anti-VEGF treated (in Part A and B) and treatment-naive (in Part B only) DME subjects.~In Part A, approximately 18 subjects will be randomly assigned (ratio 1:1) to receive either a mid-dose or high-dose of suprachoroidal OXU-001.~In Part B, approximately 110 subjects will be randomly assigned (ratio 2:2:1) to receive a single treatment of either suprachoroidal OXU-001 Dose 1, or Dose 2 or intravitreal Ozurdex®"|t|f|t|t
33974754|NCT06528106|||COHORT||OTHER|||||||
33974755|NCT00796510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974756|NCT04469608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974757|NCT02901899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974758|NCT00719381|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974759|NCT02180308|||CASE_ONLY||CROSS_SECTIONAL|||||||
33974760|NCT01809613|||COHORT||PROSPECTIVE|||||||
33974761|NCT02139514|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974762|NCT00362674|||COHORT||PROSPECTIVE|||||||
34073349|NCT02019550|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974763|NCT02922218|||COHORT||PROSPECTIVE|||||||
33974764|NCT00747552|||COHORT||PROSPECTIVE|||||||
33974765|NCT05158777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33974766|NCT01797120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073350|NCT02239445|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
34073351|NCT06067997|||COHORT||PROSPECTIVE|||||||
34073352|NCT04293484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34073353|NCT02210507|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34073354|NCT05065294|NA|SINGLE_GROUP||OTHER||NONE||Open-label, single-arm, pilot study||||
34073355|NCT04955613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A non-blinded controlled study of adults. Each patient admitted to the study will be randomly allocated to either the treatment or control group (provided standard care) in consecutive order.||||
34073356|NCT05119075|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34073357|NCT01116622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073358|NCT04054817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073359|NCT03479008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073360|NCT06248684|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073361|NCT05454020|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34073362|NCT01465230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073363|NCT04346160|||CASE_CONTROL||PROSPECTIVE|||||||
34073364|NCT01290952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073365|NCT03730376|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The care provider and patient will not be informed as to which group the participant is in|"Participants will be randomized into 1 of 2 study arms arm 1: control arm 2: intervention.~We will use a random block generator to assign participants to their study arm."|t|t|f|f
34073366|NCT03518424|||COHORT||PROSPECTIVE|||||||
34073367|NCT06431529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073368|NCT01080092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073369|NCT05459337|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel block randomized control trial|f|f|t|f
34073370|NCT02565602|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073371|NCT01298167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888083|NCT03658226|NA|SINGLE_GROUP||TREATMENT||NONE|The PI/therapist will be blind to the outcome measures. All measures will be marked with a participant ID by an alternative researcher so that the therapist/PI will be unaware of individual participants' scores when analysing the data.|"A series of experimental single case studies comparing individual CLBP participants' clinical outcomes during a baseline phase (receive no treatment) with those during a treatment phase (receive 8 sessions of PIT). Clinical outcomes will be the impact of treatment on pain distress/intensity, self-efficacy, mood and interpersonal functioning. There will be repeated measurement (daily/weekly) of the outcomes during baseline and intervention phases, to assess real-time change in these variables on a case-by-case basis. We will vary the length of the baseline phase randomly across participants, who will commence treatment following 3, 4, 5 or 6 weeks. This multiple baselines design will allow us to establish whether any improvement in clinical outcomes is caused by the intervention rather than natural change over time. We will assess feasibility/acceptability of the intervention by recording adverse reactions, side effects, adherence and participants' views about the intervention."||||
33888084|NCT04551014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33888085|NCT03919643|||CASE_CONTROL||OTHER|||||||
33888086|NCT03803878|||CASE_ONLY||PROSPECTIVE|||||||
33888087|NCT05585255|||COHORT||PROSPECTIVE|||||||
33888088|NCT01232699|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888089|NCT06433076|||COHORT||PROSPECTIVE|||||||
33888090|NCT00261235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888091|NCT03311256|||COHORT||PROSPECTIVE|||||||
33888092|NCT05075668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888093|NCT06337435|||OTHER||PROSPECTIVE|||||||
33888094|NCT00103012|RANDOMIZED|CROSSOVER||||NONE||||||
34073372|NCT04868578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073373|NCT02637310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073374|NCT01947842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073375|NCT06613152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073376|NCT04940663|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073377|NCT04970121|NA|SINGLE_GROUP||TREATMENT||NONE||Duloxetine treatment||||
34073378|NCT00977613|NA|SINGLE_GROUP||||||||||
34073379|NCT02496364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073380|NCT04561661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial|f|f|f|t
34073381|NCT03571685|NA|SINGLE_GROUP||OTHER||NONE||This is an open label, quasi-experimental study of adult patients with Schizophrenia or Schizoaffective Disorder within five years of diagnosis who are receiving SEEC intervention in phases. Approximately 50 patients will be enrolled in the study. Caregivers who would like to participate will also be included. Patients will be followed prospectively over the study period up to 36 months.||||
34073382|NCT02258217|NA|SINGLE_GROUP||OTHER||NONE||||||
34073383|NCT01570257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073384|NCT05281757|||COHORT||PROSPECTIVE|||||||
34073385|NCT00848757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073386|NCT05534243|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Multicenter, stepped wedge, cluster randomized trial|t|f|f|t
34073387|NCT01710397|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34073388|NCT03074604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The CANON trial is designed as a randomised, controlled, investigator and patient blinded single center superiority trial with three parallel arms and a primary endpoint being the appearance of new lesions on control brain magnetic resonance imaging 3 days after surgery.|t|f|t|t
34073389|NCT00136214|||CASE_CONTROL||PROSPECTIVE|||||||
34073390|NCT00935077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34073391|NCT01073163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073392|NCT06553404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and site staff will be masked to the assigned arm|RCT|t|t|t|f
34073393|NCT05204290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073394|NCT03293394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073395|NCT03147118|||CASE_ONLY||PROSPECTIVE|||||||
34073396|NCT04094779|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34073397|NCT00848029|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34073398|NCT01737411|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073399|NCT00696007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073400|NCT00036088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33888095|NCT05490706|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33888096|NCT06076668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33888097|NCT05643664|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. In both groups, aneurysmectomy with prosthetics of the abdominal aorta is performed using the standard technology.~2. In the first group, the aortic and main artery clamping zone is determined by the surgeon intraoperatively.~In the second group, before surgery, multispiral computed tomography data is evaluated using artificial intelligence and the definition of safe areas of aortic and main artery clamping is performed. Intraoperatively, clamping is performed in the settlement zones."||||
33888098|NCT02040025|||CASE_ONLY||PROSPECTIVE|||||||
33888099|NCT03390140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888100|NCT00656890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888101|NCT05356767|||CASE_CONTROL||PROSPECTIVE|||||||
33888102|NCT03733912|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888103|NCT00893308|||COHORT||PROSPECTIVE|||||||
33888104|NCT03663166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33888105|NCT05100537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888106|NCT02649257|NA|SINGLE_GROUP||||NONE||||||
33888107|NCT05840614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888108|NCT02078349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888109|NCT00989989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888110|NCT00130338|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888111|NCT03311971|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of intervention with conventional therapy. The intervention group includes use of virtual reality spectacles. The control group includes routine postoperative care||||
33888112|NCT04931836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33888113|NCT03211390|||COHORT||CROSS_SECTIONAL|||||||
33888114|NCT03377920|NA|SINGLE_GROUP||OTHER||NONE||||||
33888115|NCT01880307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888116|NCT02313740|||COHORT||PROSPECTIVE|||||||
33888117|NCT02050867|||||PROSPECTIVE|||||||
33888118|NCT04872491|||COHORT||PROSPECTIVE|||||||
33888119|NCT04244344||SEQUENTIAL||PREVENTION||NONE||"The subjects who meet the criteria of high fall risk using STRATIFY' tool will receive several fall preventions in order to prevent their fall incidence, survey will be conducted to gether their opinion about the interventions"||||
33888120|NCT03835091|||COHORT||PROSPECTIVE|||||||
33888121|NCT05976256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|t|f|f|f
33888122|NCT04923594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888123|NCT03983499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888124|NCT01185847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888125|NCT03371563|||CASE_CONTROL||PROSPECTIVE|||||||
33888126|NCT00208637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888127|NCT02893345|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33888128|NCT00018954||||TREATMENT||||||||
33888129|NCT01993472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073401|NCT00223665|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects underwent androgen suppression with a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate. If PSA reached the appropriate nadir at by month 9, the androgen suppression was interrupted. Once the PSA reached the appropriate threshold, the subjects resumed treatment for another 9 months. These cycle continued until the patient withdrew from the study, was taken off the study due to toxicities or the decision of the investigator, or until the treatment with IAS was no longer effective in controlling the prostate cancer.||||
34073402|NCT01583790|||CASE_ONLY||RETROSPECTIVE|||||||
34073403|NCT01263067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073404|NCT03238794|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34073405|NCT00320788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073406|NCT04591756|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34073407|NCT04949282|||CASE_ONLY||RETROSPECTIVE|||||||
34073408|NCT02208921|||||CROSS_SECTIONAL|||||||
33888130|NCT01557790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888131|NCT00292084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888132|NCT01705015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888133|NCT00372892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888134|NCT01354132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888135|NCT05331911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33888136|NCT05725304|||COHORT||PROSPECTIVE|||||||
33888137|NCT00747487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888138|NCT01499173|NA|SINGLE_GROUP||OTHER||NONE||||||
33888139|NCT02060422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888140|NCT03381456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||10 patient with dystonia and 10 healthy subject paired by sex and age.||||
33888141|NCT01105390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888142|NCT01763164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888143|NCT06017531|||COHORT||PROSPECTIVE|||||||
33888144|NCT05309824|||COHORT||PROSPECTIVE|||||||
33888145|NCT03842566|||OTHER||CROSS_SECTIONAL|||||||
33888146|NCT02319876|||CASE_CONTROL||PROSPECTIVE|||||||
33888147|NCT03367871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888148|NCT01838044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888149|NCT05717348|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33888150|NCT01077765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888151|NCT06520566|||CASE_CONTROL||PROSPECTIVE|||||||
33888152|NCT00682656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888153|NCT06503315|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888154|NCT01007526|NA|SINGLE_GROUP||TREATMENT||NONE|Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy|VIDL (Etoposide, ifosfamide, dexamethasone and L-asparaginase)||||
33888155|NCT00446914|RANDOMIZED|PARALLEL||||NONE||||||
33888156|NCT01256541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888157|NCT06058065|||COHORT||PROSPECTIVE|||||||
33888158|NCT05774821|||COHORT||CROSS_SECTIONAL|||||||
33888159|NCT01745289|||OTHER||PROSPECTIVE|||||||
33888160|NCT02185378|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33888161|NCT05253456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888162|NCT01511757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888163|NCT02029742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888164|NCT00092508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33888165|NCT01113320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33888166|NCT04171739|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33888167|NCT05786157|NA|SINGLE_GROUP||OTHER||NONE||Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)||||
33888168|NCT00708370|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33888169|NCT03305640|||COHORT||RETROSPECTIVE|||||||
33888170|NCT01133964|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33974767|NCT02473978|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33974768|NCT05177757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888171|NCT01051089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974769|NCT03243539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974770|NCT04043845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974771|NCT05721144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974772|NCT05659550|RANDOMIZED|CROSSOVER||TREATMENT||NONE|It is impossible to mask the participants or the investigator since they will be aware if the fan is pointed to the face, to the leg, or there is no fan. However, participants will not be informed of which interventional arm is suspected to be beneficial.|Each participant will complete the same constant work rate exercise test under three random-order experiemental conditions.||||
33974773|NCT05699356|||CASE_ONLY||RETROSPECTIVE|||||||
33974774|NCT03301675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073409|NCT01419535|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34073410|NCT04183725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073411|NCT04811859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34073412|NCT03076996|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group pre/post design||||
34073413|NCT04478162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The randomization will be done through the program with the Uniform Resource Locator (URL) address httpp://www.randomizer.org and it is planned to work with 1 month intervention and 1 month control group to prevent the groups from being affected by each other.|Randomized Controlled Trial|f|f|f|t
33888172|NCT01941589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34073414|NCT05867134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073415|NCT05892250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33888173|NCT00927420|||||CROSS_SECTIONAL|||||||
33888174|NCT03625531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888175|NCT04153084|||CASE_ONLY||PROSPECTIVE|||||||
33888176|NCT03785054|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|• Placebo capsules will be identical in appearance to the HTL0014242 capsules|Single ascending dose|t|f|t|f
33888177|NCT00191373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888178|NCT05311384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888179|NCT06055166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||4 arms include rectal cancer, non-small cell lung cancer, oesophageal squamous cancer, and cervical cancer, accept sequential fluzoparib after chemoradiotherapy||||
33888180|NCT05976607|||COHORT||PROSPECTIVE|||||||
33974775|NCT00194103|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33974776|NCT05215899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Comparison group~Intervention group:"||||
33974777|NCT05137080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974778|NCT05306379|NA|SINGLE_GROUP||OTHER||NONE||||||
33974779|NCT01817556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974780|NCT05084742|||OTHER||OTHER|||||||
33974781|NCT03761433|||CASE_ONLY||PROSPECTIVE|||||||
33974782|NCT04122105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33974783|NCT06357026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974784|NCT03034083|||COHORT||PROSPECTIVE|||||||
34073416|NCT03285945|||COHORT||PROSPECTIVE|||||||
34073417|NCT04068831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, open-label, single-institution trial.This is a phase II, open-label, single institution clinical trial of combination talazoparib and avelumab in patients with metastatic RCC. This clinical trial will enroll two separate cohorts in parallel.||||
34073418|NCT04293497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The conventional staining method and new staining method will be performed in cytology specimens obtained from same patient.||||
34073419|NCT00226798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073420|NCT03135509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073421|NCT00293852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073422|NCT02758288|||OTHER||PROSPECTIVE|||||||
34073423|NCT05785039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073424|NCT04498702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073425|NCT03604848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073426|NCT06039072|||COHORT||PROSPECTIVE|||||||
34073427|NCT06234592|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34073428|NCT04919408|NA|SINGLE_GROUP||OTHER||NONE||||||
34073429|NCT05242536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34073430|NCT04145206|||COHORT||PROSPECTIVE|||||||
34073431|NCT01272908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073432|NCT06431984|NA|SINGLE_GROUP||OTHER||NONE||||||
34073433|NCT06099093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073434|NCT06142344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073435|NCT00716768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073436|NCT02321423|||CASE_ONLY||CROSS_SECTIONAL|||||||
34073437|NCT03677115|NA|SINGLE_GROUP||TREATMENT||NONE||a single-dose thoracic paravertebral analgesia for postoperative pain control after thoracoscopic lobectomy||||
34073438|NCT03112486|||COHORT||PROSPECTIVE|||||||
34073439|NCT05750563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP OF THE FOOD SUPPLEMENT MICROSMIN® PLUS (DIOSMIN AND MICRONIZED FLAVONOIDS)|t|f|t|f
34073440|NCT05075863|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34073441|NCT00952315|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34073442|NCT02980406|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34073443|NCT03111277|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34073444|NCT01973517|||CASE_ONLY||CROSS_SECTIONAL|||||||
34073445|NCT06032585|||CASE_ONLY||RETROSPECTIVE|||||||
34073446|NCT04832451|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||randomized controlled, pre-test-post-test control group design and follow-up test patterns|t|f|f|f
34073447|NCT02626663|||COHORT||PROSPECTIVE|||||||
34073448|NCT01955746|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34073449|NCT04516967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073450|NCT03363867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888181|NCT05868421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessors are blinded to intervention group assignment.|pragmatic randomized controlled trial that will randomize Smoker-Support Person dyads with 1:1 allocation|f|f|f|t
34073451|NCT00387283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888182|NCT00842933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888183|NCT04815837|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33888184|NCT02325544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888185|NCT03089788|NA|SINGLE_GROUP||OTHER||NONE||||||
34073452|NCT06517121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888186|NCT05900804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33888187|NCT02548065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888188|NCT00588367|||COHORT||PROSPECTIVE|||||||
33888189|NCT05096299|||CASE_ONLY||PROSPECTIVE|||||||
33888190|NCT04023188|||COHORT||PROSPECTIVE|||||||
33888191|NCT02906254|||COHORT||PROSPECTIVE|||||||
33888192|NCT03467178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888193|NCT03502512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888194|NCT02397473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888195|NCT03567902|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33888196|NCT02413203|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33888197|NCT04354428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073453|NCT02229799|||COHORT||PROSPECTIVE|||||||
34073454|NCT01142947|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Discovery set for ICS treatment response biomarker analysis||||
33888198|NCT04123821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33888199|NCT02536287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888200|NCT02713451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888201|NCT02794337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888202|NCT04310644|||CASE_CONTROL||PROSPECTIVE|||||||
33888203|NCT02138734|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Single arm phase Ib.~Two-arm phase IIb, two-cohort: each randomized 1:1 via randomization scheme stratified by disease and ECOG status.~Cohort A: patients with CIS disease (with or without Ta/T1); planned enrollment = 366 Cohort B: patients with high-grade papillary disease (Ta/T1 only); planned enrollment = 230"||||
33888204|NCT02312804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888205|NCT00848744|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33888206|NCT00211406|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888207|NCT00474240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888208|NCT03180892|||COHORT||OTHER|||||||
33888209|NCT02344576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33888210|NCT05294029|||COHORT||OTHER|||||||
33888211|NCT01466842|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073455|NCT04403113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34073456|NCT00192972|RANDOMIZED|PARALLEL||ECT||NONE||||||
34073457|NCT00882271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073458|NCT00789607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073459|NCT01075997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073460|NCT03704831|||OTHER||RETROSPECTIVE|||||||
34073461|NCT02497508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073462|NCT00215644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073463|NCT04408651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34073464|NCT05200377|||COHORT||PROSPECTIVE|||||||
34073465|NCT04389515|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34073466|NCT01051557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073467|NCT04425681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073468|NCT05641844|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34073469|NCT05646732|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|order of presentation is randomized|A mechanistic study using TMS-functional MRI||||
34073470|NCT02104882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073471|NCT04455217|||COHORT||RETROSPECTIVE|||||||
34073472|NCT04544059|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33888212|NCT00815958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33888213|NCT00395967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888214|NCT00324103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888215|NCT03981159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Non-pharmacological interventional study|t|t|t|t
33888216|NCT01928628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888217|NCT04749394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888218|NCT02051907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888219|NCT01299727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888220|NCT05448625|||COHORT||PROSPECTIVE|||||||
33888221|NCT01424592|||CASE_ONLY||PROSPECTIVE|||||||
33888222|NCT02047669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888223|NCT02905734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888224|NCT00367211|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33888225|NCT03729882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888226|NCT00256295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888227|NCT01583478|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888228|NCT03320655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888229|NCT04536220|||CASE_CONTROL||PROSPECTIVE|||||||
33888230|NCT03964584|||COHORT||PROSPECTIVE|||||||
33888231|NCT01226290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073473|NCT03871985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34073474|NCT04560556|||COHORT||PROSPECTIVE|||||||
34073475|NCT04319653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073476|NCT05789212|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Mixed between and within (Crossover) participant assignment. The study uses a between participant randomization; each of the two arms have a multiple crossover design (with different intervention orders to the crossover).||||
34073477|NCT05283265|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073478|NCT01296139|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073479|NCT06512922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073480|NCT01460602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073481|NCT00123994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34073482|NCT03905304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073483|NCT04928456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Care providers will not be involved with any of the data acquisition or analysis. Investigators will be blinded to which participants are in each group and will collect data using only subject numbers provided on labels.|The design of this study is a randomized, no-treatment control group, OMT intervention group with a parallel group design.|f|t|t|f
34073484|NCT04421352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073485|NCT00249418|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073486|NCT00699023|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34073487|NCT00109746|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34073488|NCT02198508|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073489|NCT04468893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are not aware that there is an intervention group and a comparison group, the participants are not related and do not know each other. The conditions of the study are only known by the researcher, the therapists, and the Ethics Committee of ELPAC-UU Universidad de Ciencias del Comportamiento|The study has two arms, one is the intervention group that receives the treatment in addition to a chat service and the other is the comparison group that will receive treatment without the chat service. The patients in both groups will be evaluated pre and post/treatment. The participants are assigned randomly to the intervention or comparison group.|t|f|f|f
34073490|NCT05279495|NA|SINGLE_GROUP||OTHER||NONE|Subjects will receive sufficient CANNAXR cream (CANNAXR pods filled with CBD) and VEHICLE cream (cream with empty CANNAXR pods without CBD) in pump containers, marked right or left. Contents of pump containers unknown to subjects and investigators. All 20 subjects are treated with CANNAXR and Vehicle and the exposed to 3X their individual MED-UVA. The masking relates to which hip (right or left) of each individual receives which treatment, CANNAXR or Vehicle. Therefore there is masking of the treatments of all 20 subjects receiving both treatments, considered by clinicaltrial.gov a single arm study.|Study Design: Prospective, double-blind, vehicle-controlled pilot study||||
34073491|NCT03508349|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Health facilities in high malaria transmission zones were pair matched and then randomized to be an intervention or a control facility.|t|f|f|f
34073492|NCT01930916|NA|SINGLE_GROUP||||NONE||||||
34073493|NCT03974802|NA|SINGLE_GROUP||TREATMENT||NONE|Study lenses will be transferred, by an assistant, out of their packaging to unmarked new contact lens cases filled with unpreserved sterile saline just prior to dispensing to maintain subject masking of the study lenses.|First pair of study lenses (habitual lenses) will be dispensed and worn for 4 weeks for daily wear, then second pair of lenses (test lenses) will be dispensed and worn for 4 weeks for daily wear.||||
34073494|NCT00823602|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073495|NCT03162042|||CASE_CONTROL||PROSPECTIVE|||||||
34073496|NCT05929742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants were divided into two groups: the experimental group, which received early rehabilitation combined with VR training, and the comparison group, which received only early rehabilitation.|f|f|t|t
34073497|NCT04349813|||OTHER||RETROSPECTIVE|||||||
34073498|NCT01599169|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34073499|NCT05820490|||OTHER||CROSS_SECTIONAL|||||||
34073500|NCT00512499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34073501|NCT05797441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Conducting a planning RCT in preparation for a fully powered trial using a parallel two-group pragmatic RCT design in which providers (n = 36) will be randomized at a 2:1 ratio to deliver either EMPOWER (n = 60) or TAU (n = 30) to veterans who have completed prolonged exposure or cognitive processing therapy.|f|f|f|t
33888232|NCT02548702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888233|NCT05728788|||COHORT||PROSPECTIVE|||||||
33888234|NCT00699192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974785|NCT01752348|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33974786|NCT02390622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888235|NCT02678429|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33888236|NCT02577263|||COHORT||PROSPECTIVE|||||||
33888237|NCT02086331|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888238|NCT04232176|||COHORT||PROSPECTIVE|||||||
33888239|NCT05119829|||COHORT||RETROSPECTIVE|||||||
33888240|NCT01496157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888241|NCT01151683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33888242|NCT01711242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888243|NCT03812406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33888244|NCT00312455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33888245|NCT03379519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33888246|NCT00138086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888247|NCT02562547|||CASE_CONTROL||RETROSPECTIVE|||||||
33888248|NCT01819181|||COHORT||PROSPECTIVE|||||||
33888249|NCT02440334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888250|NCT02297789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888251|NCT04671836|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33888252|NCT01219842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974787|NCT03028662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974788|NCT04210895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974789|NCT04684329|||CASE_ONLY||PROSPECTIVE|||||||
33974790|NCT00522457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073502|NCT04825951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and statistician will be blinded (double blind) to the intervention group. After data collection is completed, the randomization code will be broken to reveal the allocation group. The operator will be blinded during recording of the measurements.|randomized controlled clinical trial, parallel design.|t|f|t|t
34073503|NCT03320174|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Identically matched placebo control.||t|t|t|t
34073504|NCT00640419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073505|NCT02420262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073506|NCT00905424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888253|NCT05572476|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized phase II study in which eligible patients will be randomized (2:1) according to two therapeutic strategies||||
33888254|NCT00005724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888255|NCT05438173|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33888256|NCT03033329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888257|NCT01628926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888258|NCT04600167|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888259|NCT01997151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33888260|NCT03717376|||COHORT||PROSPECTIVE|||||||
33888261|NCT03526289|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33888262|NCT02948361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888263|NCT03667001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Measures taken to minimize or avoid bias include randomization and blinding of participants after they have given their informed consent. Blinding of medical practitioner and medical personnel will be conducted by provision of equal looking and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy.|"The investigators plan to evaluate the analgesic effect of systemic Lidocaine in Addition to general anesthesia during bariatric surgery.~* Lidocaine group: perioperative application of systemic Lidocaine up to four hours from end of surgical procedures.~* Control group: perioperative application of Placebo (NaCl 0.9%) up to four hours from end of surgical procedures."|t|t|t|t
33888264|NCT01649336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888265|NCT02349126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888266|NCT02310048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888267|NCT02857218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888268|NCT00102089||||TREATMENT||||||||
33888269|NCT01587989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888270|NCT00826813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888271|NCT00542711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888272|NCT02484027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888273|NCT00152633|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33888274|NCT01413386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33762098|NCT06347484|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"Participants enrolling in CONNECT will receive tailored educational text messages and opportunities to join cardiovascular research studies. Recruitment will occur via electronic health record (EHR)-informed and community-engaged methods. Enrollment yield will be evaluated for all outreach modalities, both overall and by priority populations (women and Black and Latino adults). The study will also assess participant trust in biomedical research, awareness of clinical trials, and willingness to participate at baseline, 6 months, and 12 months.~Sub-study 1: This sub-study will evaluate the effectiveness of three EHR-informed outreach methods: patient portal message, email, and postal mail. Potentially eligible individuals will be identified through EHR query and randomly assigned to one of these methods. Enrollment yield will be assessed by outreach method and priority population."||||
33762099|NCT01802437|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33762100|NCT01949103|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33762101|NCT06484829|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762102|NCT05944055|||COHORT||RETROSPECTIVE|||||||
33762103|NCT05652348|||COHORT||PROSPECTIVE|||||||
33762104|NCT04693676|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
33888275|NCT02933918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888276|NCT04894955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888277|NCT01486420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762105|NCT01542060|||COHORT||PROSPECTIVE|||||||
33762106|NCT06231823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762107|NCT00901888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33762108|NCT04754672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Treatment allocation is concealed. Baseline assessments prior to group allocation.|Randomised controlled trial||||
33762109|NCT04137614|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33762110|NCT02093663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762111|NCT06427122|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open randomised controlled trial, with two arms: 1) EMD-U, 2) CAU (control).||||
33762112|NCT01125722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762113|NCT02313909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762114|NCT04575363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762115|NCT04839029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762116|NCT03590600|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Subjects, investigators and investigators' staff, persons performing the assessments or being responsible for determining dosing regimen/adjustments, and staff of the sponsor or data analysts, will remain blinded from the time of randomization until database lock, using the following methods: randomization data, including any documentation identifying the treatment allocation, are kept strictly confidential until the time of unblinding with the following exceptions: staff responsible for study drug management (i.e. the staff in the CRO CTS department preparing the IMP).||t|t|t|t
33762117|NCT02296632|||CASE_ONLY||PROSPECTIVE|||||||
33762118|NCT05164302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||2-arm crossover design, a pilot study||||
33762119|NCT03482505|NA|SINGLE_GROUP||OTHER||NONE||||||
33762120|NCT01905930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762121|NCT02809144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762122|NCT04976803|||COHORT||PROSPECTIVE|||||||
33762123|NCT02740322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762124|NCT01592162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762125|NCT05917704|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762126|NCT03626090|NA|SINGLE_GROUP||TREATMENT||NONE||As the primary objective of the study is to assess safety of MSC infusion, a single arm non-blinded study design has been adopted.||||
33762127|NCT03324438|RANDOMIZED|FACTORIAL||TREATMENT||NONE||MOST methodology uses factorial designs and the hypotheses in Aim 1 will be tested through a 2x2 factorial experiment, a highly efficient experimental design despite several common misconceptions about sample size requirements and power. A 2x2 factorial experiment is NOT a 4-arm trial in which each condition is compared in turn to a control condition. In fact, factorial designs do not require a larger number of participants than other designs (e.g., RCT) and when used to address suitable research questions, they require fewer participants than other designs. Adding factors does not require a dramatic increase in sample size to maintain power. The number of arms is listed below as 4 as # of arms is required by the clinicaltrails.gov site; please refer above for a more accurate description of the study design.||||
33762128|NCT03113123|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33762129|NCT05115344|NON_RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33762130|NCT05094167|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The random assignment of patients was performed by Nanchang Medical University with a computer-generated random number code. Patients were randomly distributed in a 1:1 ratio to receive probiotics or a placebo (the block size was known only to the statistician). The drug was distributed and packaged in accordance with random numbers, and the documents stating the parameters, such as the blinding codes for the seeds of the random numbers, the block length, and the random numbers, were sealed in envelopes||t|t|t|t
33762131|NCT04219852|||CASE_ONLY||PROSPECTIVE|||||||
33762132|NCT05539703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|We will, to the extent feasible, mask the data analysts to group allocation.|The trial is designed as a register-based randomized trial. The investigators will draw a random sample from the whole population aged 45-64 years, which will constitute the intervention group and will receive a personal offer to receive a 2nd booster dose of a COVID-19 vaccine in their municipality. The rest of the population aged 45-64 will receive no such offer or information and will serve as control group. The random sample will be defined by drawing a set of birth dates. This allows the investigators to identify persons in the intervention group directly in the Norwegian Preparedness Register for COVID-19 without identifying them individually, since personal identification numbers are encrypted in this database. The random sample will receive the offer of vaccination either (i) via Helsenorge (National online health services in Norway) , or (ii) directly from their municipality.|f|f|f|t
33762133|NCT01445405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762134|NCT04036071|||COHORT||PROSPECTIVE|||||||
33888278|NCT04668898|||CASE_CONTROL||OTHER|||||||
33888279|NCT02472457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888280|NCT02737865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888281|NCT02848937|||CASE_CROSSOVER||PROSPECTIVE|||||||
33888282|NCT03409822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888283|NCT01130129|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33888284|NCT02764541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888285|NCT00856310|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33888286|NCT03700957|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888287|NCT02901470|||COHORT||PROSPECTIVE|||||||
33888288|NCT06657196|||CASE_ONLY||RETROSPECTIVE|||||||
34073507|NCT03218371|||COHORT||RETROSPECTIVE|||||||
33974791|NCT05636878|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||For the primary objective, i.e., analysis of the effect of the intervention at age 2 (and the first SO, i.e., analysis of the effect of the intervention at age 4), a difference-in-differences analysis will be performed. That is, the difference in the prevalence of abnormal psychomotor development at age 2 (and at age 4) before and after the implementation of the EMPPer in the target territory will be compared to the difference in the prevalence of abnormal psychomotor development at age 2 (and at age 4) between the periods corresponding to the implementation of the EMPPer in the territories that did not benefit from it, using a mixed linear regression model with psychomotor developmental abnormalities as the variable to be explained, year (pre vs. post intervention) and region (with vs. without intervention) as explanatory variables, and which will include the year\*region interaction. The assumption of equivalence of temporal developmental trends here and elsewhere will be tested||||
34073508|NCT04727593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|At baseline, everyone (participants, study coordinator, mindfulness instructor(s), research assistant, and statistician) will be blinded to conditions as it is expected to occur before randomization. Once participants are randomized, the study coordinator will inform them of the group assignments, and all of them will become unblinded to the conditions. Due to the specificities of this type of study and intervention, it is not possible to guarantee the blinding of personnel and participants.|||||
34073509|NCT02638987|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34073510|NCT00925808|||CASE_ONLY||PROSPECTIVE|||||||
34073511|NCT02155452|||CASE_CONTROL||OTHER|||||||
34073512|NCT01052532|||CASE_ONLY||PROSPECTIVE|||||||
34073513|NCT02232477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073514|NCT00005916||||TREATMENT||||||||
34073515|NCT03887585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888289|NCT03936387|NA|SINGLE_GROUP||TREATMENT||NONE||Single intervention group, bilateral erector spinae blocks with 0.2% ropivacaine, to assess the feasibility of this technique for postoperative pain control following surgeries involving sternotomies in children.||||
34073516|NCT02120209|||COHORT||PROSPECTIVE|||||||
34073517|NCT00260260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888290|NCT05383924|RANDOMIZED|PARALLEL||PREVENTION||NONE|masking is not applicable|This study aims to compare immediate postplacental IUD insertion versus delayed insertion as regards patient's compliance in women undergoing planned cesarean section. One group will have the IUD inserted during cesarean section. Another group will undergo IUD insertion after 6 weeks of delivery by CS.||||
33888291|NCT02484469|RANDOMIZED|PARALLEL||||NONE||||||
33888292|NCT03975192|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study subject will be randomized to receive study treatment (PENFS device treatment) or the Standard of Care treatment (Methadone wean) for prevention of opiate withdrawal symptoms||||
33888293|NCT03085784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888294|NCT02037789|||CASE_CONTROL||RETROSPECTIVE|||||||
33888295|NCT00067210||||TREATMENT||||||||
33888296|NCT01748799|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33888297|NCT02308644|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33888298|NCT00119340||||TREATMENT||||||||
33888299|NCT02502864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888300|NCT05595538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888301|NCT03244358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888302|NCT01956214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888303|NCT03713190|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33974792|NCT01479452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974793|NCT00004376||||TREATMENT||||||||
33974794|NCT01647906|||COHORT||PROSPECTIVE|||||||
33974795|NCT04605510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study includes two groups. Intervention group including women with non-specific neck pain will applied cervical passive joint mobilization and assessment protocol. Control group including healthy women without pain will applied only assessment protocol.||||
34073518|NCT04711694|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants cannot be blinded to MBI time (early vs late). Outcome assessors are blind to intervention group. One of the two mindfulness instructors is not blind, as she works as clinical research coordinator. However, MBI are always held by both instructors together and the groups are mixed between early and late intervention allocated participants, diminishing the impact of the lack of blinding of one instructor.||f|f|t|t
34073519|NCT01951118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073520|NCT03382418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073521|NCT04816760|||COHORT||PROSPECTIVE|||||||
34073522|NCT04687111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind, double-dummy.|Randomised, prospective, active comparator, double blind, double dummy, controlled trial.|t|t|t|t
34073523|NCT05094414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The IC/BPS patients would be investigated for baseline clinical symptoms questionnaire including VAS, QoL, ICPI, ICSI, and OSS. All of our patients would receive open-label oral valacyclovir 500 mg twice per day for 4 weeks. We estimate to enroll 30 IC/BPS patients. The overall improvement of current therapy would be assessed with Global Response Assessment (GRA).The GRA, VAS, and any adverse effect would be investigated in the telephone interview. After the full 4 weeks treatment, the patients would be asked to back to our clinic. All symptoms questionnaire (GRA, VAS, QoL, ICPI, ICSI, and OSS) and adverse effect would be evaluated again. The patients would be asked to provide urine sample again. The primary endpoint of this study is the GRA at 4 weeks. The secondary endpoints include the changes of VAS, VAS, QoL, ICPI, ICSI, and OSS between baseline and end of the study.||||
34073524|NCT06515964|||COHORT||RETROSPECTIVE|||||||
34073525|NCT04224532|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34073526|NCT05789056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|Open Label||||
34073527|NCT00373126|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33888304|NCT02159807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888305|NCT04213404|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, phase I study with dose titration plan.||||
33888306|NCT05818670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|t|t|f
33888307|NCT04689230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888308|NCT06013774|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33888309|NCT00330707|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33888310|NCT03008187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888311|NCT03049709|||COHORT||CROSS_SECTIONAL|||||||
33888312|NCT02920060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888313|NCT03474055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888314|NCT02154399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888315|NCT00412256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33888316|NCT04756414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888317|NCT01646359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888318|NCT03216382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Baseline outcome measures will be completed at the first visit to the lab. Participants will then engage in a week of reporting on their worry and attention on their own, before coming back to the lab to recomplete the outcome measures. They will then be randomly assigned to the intervention or control condition and will engage in a week of daily listening to the corresponding recording for their condition on their own, while reporting on their worry and attention again during that week. Outcome measures will be completed again at the lab immediately following the intervention.|t|f|f|f
33888319|NCT00940004|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888320|NCT05941104|||COHORT||PROSPECTIVE|||||||
33888321|NCT02073487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888322|NCT01536301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888323|NCT01268293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888324|NCT00758784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888325|NCT02066792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888326|NCT06021249|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33888327|NCT05659888|||COHORT||OTHER|||||||
33888328|NCT03457961|||COHORT||PROSPECTIVE|||||||
33888329|NCT00005433|||COHORT||PROSPECTIVE|||||||
33888330|NCT05619965|RANDOMIZED|PARALLEL||OTHER||NONE||The investigators will compare awake endotracheal intubation with glidescope video assisted laryngoscope vs fiberoptic bronchoscope in patients with traumatic cervical injury||||
33888331|NCT03787914|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The investigators conducted a two-arm, parallel design\[1:1\], single blind randomized control trial in 200 newly diagnosed TB patients|f|f|f|t
33974796|NCT06386497|NA|SINGLE_GROUP||OTHER||NONE||||||
33974797|NCT00003536||||TREATMENT||||||||
33974798|NCT05210023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial, parallel, with 2 study groups|t|f|f|f
33974799|NCT03279679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||costoclavicular group and paracoracoid group|t|f|f|t
33974800|NCT00829413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974801|NCT04936971|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, open label, randomized, two arms, paralel, compared to Standard of Care treatment||||
33974802|NCT06169098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33974803|NCT02103088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974804|NCT00805909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974805|NCT05650788|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974806|NCT01474226|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33974807|NCT01844583|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974808|NCT01578174|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33974809|NCT04165720|||CASE_ONLY||CROSS_SECTIONAL|||||||
33974810|NCT03185897|||COHORT||PROSPECTIVE|||||||
33974811|NCT04060823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974812|NCT03347695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974813|NCT03249181|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, multi-centre randomised controlled trial||||
33974814|NCT02497833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974815|NCT01572766|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974816|NCT05789277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974817|NCT02010411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974818|NCT04388891|NA|SINGLE_GROUP||OTHER||NONE||||||
33974819|NCT04969614|||COHORT||PROSPECTIVE|||||||
33974820|NCT00810732|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762135|NCT03976466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|No participant will know during the study in which group will be assigned.|Randomised controlled trial. Study participants are randomly assigned to one of two groups: the experimental group receiving the Calcium sulfate beds with antibiotics and a comparison group (control) which receives a conventional prophylactic therapy.|t|f|f|f
33762136|NCT06223503|RANDOMIZED|PARALLEL||PREVENTION||NONE||Veterans will be randomized to either be enrolled into the Salt Lake City VAMC transitional pain service or to receive only the usual care through the community care surgeon.||||
33762137|NCT06054230|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762138|NCT01680393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33762139|NCT05248321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33762140|NCT00855595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33762141|NCT00379119|||COHORT||PROSPECTIVE|||||||
33762142|NCT02816086|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762143|NCT04131595|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762144|NCT00615381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888332|NCT03884465|NA|SEQUENTIAL||TREATMENT||NONE||"Subjects will be enrolled in 4 sequential cohorts, each with an increasing initial dose of inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, and 100μg capsule strengths (8 subjects at each dose level). Subjects will undergo right heart catheterization (RHC) at Day 1 to assess hemodynamic response.~Subjects enrolled in Germany will continue in a follow-up hemodynamic and long-term safety study beginning immediately after the conclusion of the post-RHC assessments on Day 1 of Part A. Subjects will continue on therapy at four times daily (QID) on Day 1 and until Week 16 and may be titrated up or down by no more than one 25 μg increment per week, based upon symptomatic relief or side effects experienced by the subject. Investigators may also initiate Part B dosing at 25 μg before following this titration schedule."||||
33888333|NCT02803957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888334|NCT03666351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, multicentre, randomized, open label, evaluator-blind study|f|f|f|t
33888335|NCT02959814|||COHORT||PROSPECTIVE|||||||
33888336|NCT06427551|||COHORT||RETROSPECTIVE|||||||
34073528|NCT00490919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888337|NCT00918944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33888338|NCT05015309|NA|SEQUENTIAL||TREATMENT||NONE||||||
33888339|NCT05282732|||OTHER||RETROSPECTIVE|||||||
33888340|NCT06277973|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be informed that the intervention will occur between 2 days and 14 days and that they will fill 3-4 surveys. They will not be aware that there are two groups.|"Participants will be randomly allocated to one of the following groups: the experiment group and the waiting list group. Each group will receive the intervention but in the waiting list group this will occur a week later:~Experiment group:~Day 1 - questionnaires (T1) Day 4 - intervention Day 7 - questionnaires (T2) Day 97 - follow up questionnaires (T3)~Waiting list group:~Day 1 - questionnaires (T0) Day 7 - questionnaires (T1) Day 11- intervention Day 14- questionnaires (T2) Day 104- follow up questionnaires (T3) The parallel element of this model lies in the first week of the study: the experiment group goes through 2 measurements with the intervention in the middle of the week, whereas the waiting list group goes through 2 measurements without the intervention."|t|f|f|f
33888341|NCT00285532|||||PROSPECTIVE|||||||
33888342|NCT05332119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Each patient will be randomized in a 1:1 ratio between the two arms of the study||||
33888343|NCT06280547|||OTHER||OTHER|||||||
33888344|NCT00189462|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33888345|NCT00686556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888346|NCT00000191||||TREATMENT||||||||
33888347|NCT03088969|||OTHER||OTHER|||||||
33888348|NCT03291561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888349|NCT01267539|||CASE_ONLY||PROSPECTIVE|||||||
33888350|NCT01919892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888351|NCT05690659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33888352|NCT00005630||||TREATMENT||||||||
33888353|NCT03972631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888354|NCT05850936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and physicians are not masked as to the treatment assignment. The study outcomes will be obtained by masked ophthalmic technicians according to standard protocols and read by masked graders at the End Point Adjudication Committee. The masking status of the technicians collecting data will be recorded at each study visit. The study data will be analyzed by masked researchers.|Open-label, single-center, randomized controlled trial|f|f|f|t
33974821|NCT01455753|||OTHER||RETROSPECTIVE|||||||
33974822|NCT04656977|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33974823|NCT05783583|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33974824|NCT02453425|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33974825|NCT05017181|||CASE_ONLY||PROSPECTIVE|||||||
33974826|NCT06341088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974827|NCT05593198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34073529|NCT01738919|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34073530|NCT04559646|||COHORT||PROSPECTIVE|||||||
34073531|NCT02983760|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073532|NCT03365934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073533|NCT06296472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34073534|NCT04396600|||COHORT||PROSPECTIVE|||||||
34073535|NCT00289588|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34073536|NCT04086121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073537|NCT02028507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073538|NCT05300334|||OTHER||PROSPECTIVE|||||||
34073539|NCT05921656|||COHORT||PROSPECTIVE|||||||
34073540|NCT05448378|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Human healthy women||||
34073541|NCT00412932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073542|NCT05115539|||OTHER||CROSS_SECTIONAL|||||||
34073543|NCT01498471|||COHORT||PROSPECTIVE|||||||
34073544|NCT06613113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073545|NCT03545932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073546|NCT03984955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient will be blinded/masked to their group allocation: For Groups (B) and (C), the withdrawn blood will be discarded into a suitable clinical waste container out of sight of the participant in an adjoining room. The centrifuge, also in the adjoining room, will be set to run at 32000rpm for 15 minutes in order to aid in participant blinding.~The class-based physiotherapy sessions will be taught be a physiotherapist who is blind to the treatment allocation of the study participants attending the class.~The outcome assessments will be recorded by a member of the research team blind to the participant's treatment allocation."|Prospective, Controlled, Randomised, Double Blind, Single Centre Trial|t|f|f|t
34073547|NCT03620149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073548|NCT02440048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073549|NCT06056635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073550|NCT04948827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073551|NCT04062734|||CASE_CONTROL||RETROSPECTIVE|||||||
34073552|NCT02953015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073553|NCT01681238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34073554|NCT02512172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073555|NCT00168428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073556|NCT00169104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073557|NCT03293017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33762145|NCT00953134|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33888355|NCT06368726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments regarding clinical recovery will be conducted by an assessor blind to treatment allocation.|Two groups of childs: 90 childs receive tDCS treatment and 90 traditional treatments with Risperidone educational training, speech therapy and visual training.|f|f|t|f
33888356|NCT05019937|RANDOMIZED|PARALLEL||OTHER||NONE||Two-armed cluster-randomized controlled trail||||
33888357|NCT05489393|||COHORT||PROSPECTIVE|||||||
33888358|NCT00052390||||TREATMENT||NONE||||||
34073558|NCT02859350|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073559|NCT06612892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073560|NCT06190600|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized into two groups. Patients which are set to receive neoadjuvant chemotherapy will be selected. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).~The group in which additional intervention IPA will be ordered, in means of supervised high intensity interval training twice a week. During the course of chemotherapy, the intensity of physical activity will be increasing. Moreover, throughout the entire therapy time, there will be introduced a 45-minute aerobic training session (e.g.: walk, jogging, roller skates, swimming) ones a week. In the control group patients will be asked to independently continue their regular physical activity same as prior to the oncologic treatment."||||
34073561|NCT02805946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073562|NCT00618826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073563|NCT02407873|||COHORT||PROSPECTIVE|||||||
34073564|NCT03306095|||CASE_CONTROL||PROSPECTIVE|||||||
34073565|NCT02153125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073566|NCT04305028|||CASE_CONTROL||PROSPECTIVE|||||||
34073567|NCT00983463|||CASE_CONTROL||PROSPECTIVE|||||||
33888359|NCT02251912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888360|NCT04363333|||COHORT||PROSPECTIVE|||||||
33888361|NCT04716361|||COHORT||PROSPECTIVE|||||||
33888362|NCT04781075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888363|NCT01420510|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888364|NCT00929955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33888365|NCT00420511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888366|NCT03184207|||COHORT||PROSPECTIVE|||||||
33888367|NCT00241332|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33888368|NCT03281642|||OTHER||OTHER|||||||
33888369|NCT03162848|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33888370|NCT04905420|||COHORT||RETROSPECTIVE|||||||
33888371|NCT05401747|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33888372|NCT00705978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888373|NCT03778437|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33888374|NCT00877630|||COHORT||PROSPECTIVE|||||||
33888375|NCT03598907|||OTHER||PROSPECTIVE|||||||
33888376|NCT03611699|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind masking. Participant and Investigators will not know if the participants has received a long-acting bronchodilator or a placebo inhaler.||t|f|t|f
33974828|NCT04309409|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients with a risk score of \> 0.0 (HR 1.48, 1.11-1.98) corresponding to high risk of relapse will be randomized at a ratio of 2:1 to receive either nivolumab as adjuvant treatment (arm A) or observation only (arm B).~All screened patients with a risk score of ≤ 0.0 who are not eligible for randomization will be followed for RFS, DMFS and OS for at least 5 years according to German Follow-up guidelines (Arm C)."||||
33974829|NCT05420506|NA|SEQUENTIAL||TREATMENT||NONE||||||
33974830|NCT02946164|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888377|NCT05904626|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33974831|NCT01323348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888378|NCT01323907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888379|NCT05112731|||COHORT||PROSPECTIVE|||||||
33888380|NCT04418921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888381|NCT03012581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974832|NCT01539109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33974833|NCT02123056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974834|NCT02486796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974835|NCT00040872||||TREATMENT||NONE||||||
33888382|NCT01419132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888383|NCT05345470|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33888384|NCT04589598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888385|NCT01402219|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33974836|NCT06283862|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to immediately receive 4 sessions of tailored guidance or to receive it after 12 weeks, as a waitlist control condition.||||
33974837|NCT01908114|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33888386|NCT00393718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974838|NCT02318498|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33974839|NCT02958956|||COHORT||PROSPECTIVE|||||||
33974840|NCT02984436|||COHORT||PROSPECTIVE|||||||
33888387|NCT03501927|RANDOMIZED|PARALLEL||PREVENTION||NONE||Preoperative point-of-care focused cardiopulmonary ultrasound (FOCUS) Patients are to be randomised in a 1:1 ratio to either 1) FOCUS prior to anaesthesia or 2) no FOCUS performed (standard treatment).||||
33888388|NCT00877344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessment of outcomes (pregnancy conceived within one year) will be assessed through documentation of pregnancy in health administrative data.|"This study uses a drug (levonorgestrel-releasing intrauterine contraception (Mirena (R)), but as the study is conducted in Canada the FDA approval is not required. We have approval (a Letter of No Objection) from the Canadian Equivalent Institution: Health Canada"|f|f|f|t
33888389|NCT01684228|||CASE_CONTROL||PROSPECTIVE|||||||
33888390|NCT05533060|||CASE_CONTROL||PROSPECTIVE|||||||
33888391|NCT04141176|NA|SINGLE_GROUP||TREATMENT||NONE||It's a prospective, open, monocentric study.||||
33888392|NCT02970695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888393|NCT00755079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974841|NCT00719342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33762146|NCT01852058|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762147|NCT04508179|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This study consists of three parts, Part A, Part B and Part C, which will be undertaken sequentially. Part A is a SAD study to determine the safety, tolerability and PK of 7HP349 in healthy male subjects, and to define the OPD. Part B is a MAD study to determine the safety, tolerability and PK of 7HP349 following up to 5 once daily oral doses in healthy male subjects. Part C is a crossover study to evaluate the effect of the fed or fasting prandial state on the single dose PK of 7HP349.|t|t|t|t
33762148|NCT05374044|||COHORT||PROSPECTIVE|||||||
33762149|NCT04495790|||COHORT||PROSPECTIVE|||||||
33762150|NCT05886322|||COHORT||PROSPECTIVE|||||||
33888394|NCT05391243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeons will not be provided information about the menstrual cycle|Prospective randomized trial with 2 groups (follicular phase, luteal phase)|f|t|f|f
33888395|NCT04864457|||COHORT||PROSPECTIVE|||||||
33888396|NCT04644848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888397|NCT05726357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888398|NCT02774993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888399|NCT00124345|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888400|NCT03223571|||COHORT||RETROSPECTIVE|||||||
33888401|NCT01989130|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888402|NCT04120688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888403|NCT00240435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33762151|NCT05838001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762152|NCT01461382|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33762153|NCT03502616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762154|NCT04498325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinicians, participants, and clinical research coordinators will be blinded|The study will open as a phase I study to test three different dose levels of NT-I7. Once a safe tolerated dose is established, the pilot portion of the study will be activated wherein participants will be randomized on a 1:1 basis to receive a single injection of NT-I7 (at the safe tolerated dose) or placebo.|t|t|t|f
33888404|NCT03973476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33888405|NCT02965378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888406|NCT02653950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888407|NCT03352401|||OTHER||PROSPECTIVE|||||||
33888408|NCT01422005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888409|NCT05030714|NA|SINGLE_GROUP||OTHER||NONE||||||
33888410|NCT01111604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888411|NCT04902235|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|participants will be blinded to the intervention assignment|Single-blind, randomized, placebo-controlled proof-of-concept studies with a crossover assignment|t|f|f|f
33974842|NCT01501656|||COHORT||PROSPECTIVE|||||||
33888412|NCT03084133|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention group means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Control group: provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the case-index according to its usual practice and adapted to the level of understanding of Case-index."||||
33888413|NCT04024592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888414|NCT02647151|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33888415|NCT00537433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888416|NCT04196257|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33888417|NCT01214486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888418|NCT01169779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888419|NCT02227576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888420|NCT06042673|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33888421|NCT05110079|||CASE_ONLY||PROSPECTIVE|||||||
33888422|NCT01243268|||OTHER||PROSPECTIVE|||||||
33888423|NCT02412280|||||RETROSPECTIVE|||||||
33888424|NCT01339442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888425|NCT05641883|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, open label, single arm study||||
33888426|NCT03990870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888427|NCT02222402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888428|NCT00315861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888429|NCT00000927||||PREVENTION||||||||
33888430|NCT04217395|||OTHER||PROSPECTIVE|||||||
33888431|NCT03105739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33888432|NCT06260514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888433|NCT00585234|||COHORT||PROSPECTIVE|||||||
33888434|NCT00834054|||COHORT||PROSPECTIVE|||||||
33888435|NCT00468390|||CASE_CONTROL||PROSPECTIVE|||||||
33888436|NCT02031094|||CASE_CONTROL||PROSPECTIVE|||||||
33888437|NCT02109081|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888438|NCT00661583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888439|NCT04207476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888440|NCT04843514|||COHORT||RETROSPECTIVE|||||||
33888441|NCT02730156|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33888442|NCT00548548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888443|NCT01653730|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33888444|NCT00180973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888445|NCT01990157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888446|NCT02773797|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33888447|NCT00049387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888448|NCT01096914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888449|NCT05679414|||CASE_CONTROL||PROSPECTIVE|||||||
33888450|NCT02218229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888451|NCT02537041|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888452|NCT00540891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888453|NCT03437421|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-masked study. Clinicians and researchers in charge of main outcomes (eg cardiac remodelling and global function, regional myocardial function) measurements will not be aware of group allocation (eg vitamin D deficient and non-deficient sub-groups) and time study (eg baseline or post vitamin D supplementation).|Type I and II diabetic patients will be investigated. Within each diabetic population, vitamin D deficient and non-deficient individuals will be compared at baseline. Then, within each diabetic population, those with vitamin D deficiency at baseline will be compared before and after a 3 month vitamin D supplementation.|f|f|f|t
33974843|NCT00281294|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974844|NCT01626859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974845|NCT03923595|||COHORT||PROSPECTIVE|||||||
33974846|NCT03513354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded assessment|3 groups (swimming pool, soil, control group)|f|f|t|f
33974847|NCT05259033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974848|NCT05253560|||COHORT||CROSS_SECTIONAL|||||||
33974849|NCT04156269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974850|NCT03305055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Pharmacy receives order from provider and then prepares the study drug in an unmarked, nondescript delivery system (bag) and the study drug information is entered from the bag into the pump so that delivery that is timed and volume controlled per study protocol. This is hung next to patient, connected and started. Masked personnel include provider (order study drug protocol), nurse (wound care), data assessor (Research Assistant), and consenting participant (patient with acute burn)."|Randomized, placebo-controlled, repeated exposure (twice daily, 7 days), safety and efficacy trial of Usual Care (fentanyl PLUS saline / placebo) versus Usual Care plus Study Drug Augmentation (fentanyl PLUS ketamine) in reducing acute pain severity assessed before, during and after wound care for acute burn injury in the Burn Center of an Academic Medical Center.|t|t|t|t
33888454|NCT00682058|||COHORT||PROSPECTIVE|||||||
33888455|NCT00457574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888456|NCT01224548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888457|NCT01278576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888458|NCT03425708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888459|NCT06005454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|f|f|t|f
33888460|NCT00591279|||COHORT||PROSPECTIVE|||||||
33888461|NCT00235105|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33888462|NCT02221128|||CASE_ONLY||PROSPECTIVE|||||||
33888463|NCT01429571|||CASE_CONTROL||PROSPECTIVE|||||||
33888464|NCT03595202|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33888465|NCT05618392|||COHORT||PROSPECTIVE|||||||
33888466|NCT02862769|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33888467|NCT01223092|||COHORT||PROSPECTIVE|||||||
33888468|NCT04459845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assessor are masked to the treatment group||f|f|t|t
33888469|NCT03618641|NA|SEQUENTIAL||TREATMENT||NONE||||||
33888470|NCT04484350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762155|NCT04176341|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Intervention group : chronic pain patient consulting in Grenoble Alps University Hospital and Grenoble Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.~Control group : chronic pain patient consulting in Lyon University Hospital who will receive usual care."||||
33762156|NCT04513522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888471|NCT00135629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 arm, randomized, double-blind trial|t|f|f|f
33762157|NCT04379193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888472|NCT01357213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762158|NCT00017940||||TREATMENT||NONE||||||
33762159|NCT05565807|NA|SEQUENTIAL||TREATMENT||NONE||To determine DLT and RP2D, the design uses a accelerated titration design and a 3+3 design for the dose-escalation stage.||||
33762160|NCT03115333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762161|NCT04773210|||COHORT||PROSPECTIVE|||||||
33888473|NCT02730260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888474|NCT06418178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888475|NCT05601245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Closed envelop method|"Sixty patients (male and female) with chronic wounds (pressure ulcers) does not heal within six weeks were involved in the study.~The diagnosis will be made clinically by the physician. The patients will be randomly assigned into two equal groups in number, two study groups (one for high-voltage pulsed galvanic current and the other for microcurrent therapy). Both groups will receive the same traditional physical therapy routine and conservative treatment for the wound for six weeks."|f|f|f|t
33888476|NCT05389488|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888477|NCT01629407|||COHORT||PROSPECTIVE|||||||
33888478|NCT03119012|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open label, two-arm, randomized controlled trial||||
33762162|NCT01397721|||OTHER||PROSPECTIVE|||||||
33762163|NCT03810534|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||The Connect-Home study employs a stepped wedge cluster-randomized trial design, which is a crossover design at the cluster level where clusters of individuals (i.e., residents in a nursing home) crossover from control to intervention condition at randomly assigned timepoints or steps.|f|f|f|t
33762164|NCT04794426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762165|NCT06426017|NA|SINGLE_GROUP||TREATMENT||NONE||"It will be a quasi-experimental study, where 110 individuals with obesity will be allocated into three allele groups i.e. TT, AT and AA based on minor allele frequency. Each participant in the study will go through intervention of high protein, low calorie diet for four weeks.~BMI, waist to hip ratio, body composition, lipid profile, fasting glucose level, insulin resistance, advanced glycation end-products will measure at the start and end of the study while hunger hormone will be measured at the start, mid and end of the study."||||
33762166|NCT02790008|||COHORT||PROSPECTIVE|||||||
33762167|NCT03052114|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762168|NCT02622204|||COHORT||PROSPECTIVE|||||||
33762169|NCT03873818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762170|NCT06194409|||OTHER||CROSS_SECTIONAL|||||||
33762171|NCT01460082|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762172|NCT03389152|||COHORT||RETROSPECTIVE|||||||
33974851|NCT01618799|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974852|NCT02729896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762173|NCT01529008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762174|NCT04271943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762175|NCT05742425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762176|NCT01769170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762177|NCT06342986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A minimum of 28 days must separate each Dose Cohort. A minimum of 30 days must separate the 1st and 2nd patient. All patients are assessed for Dose Limiting Toxicity (DLT)||||
33888479|NCT02594644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888480|NCT03709602|||COHORT||OTHER|||||||
33888481|NCT03109431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974853|NCT01892579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33974854|NCT03873701|||CASE_ONLY||PROSPECTIVE|||||||
33974855|NCT01911585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33974856|NCT01924390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888482|NCT05205590|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888483|NCT05790486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33974857|NCT03156166|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33888484|NCT03205202|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33888485|NCT02586805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888486|NCT00808444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33888487|NCT03266679|NA|SINGLE_GROUP||TREATMENT||NONE||Case-Series Design||||
33888488|NCT03554044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073568|NCT04957212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients were randomly assigned to treatment by a central randomization procedure via telephone call for each consecutive eligible patient. Randomization codes were allocated after all eligibility criteria were approved, stratification factors were identified and the informed consent form was signed.~After randomization procedure, a code was allocated to each patient that was used as patient identifier throughout the study. The assigned code was denoted by 4 initials (corresponding to the 2 first letter of the first name, the 2 first letter of the first surname) and 3 numbers (center code)."||t|t|t|t
33888489|NCT01666223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33888490|NCT00078130||||TREATMENT||||||||
33888491|NCT05689619|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized (1:1) phase 2 trial|t|t|t|f
33888492|NCT05808257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974858|NCT06045481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888493|NCT01470677|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33974859|NCT04251611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974860|NCT03081767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974861|NCT00449072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974862|NCT01704391|||COHORT||PROSPECTIVE|||||||
33974863|NCT01687309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974864|NCT01781065|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974865|NCT00349505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974866|NCT04330248|NA|SINGLE_GROUP||OTHER||NONE||||||
33974867|NCT02281942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33974868|NCT06542159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974869|NCT06205719|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33974870|NCT03882164|||CASE_CONTROL||PROSPECTIVE|||||||
33974871|NCT04954456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974872|NCT04807114|||COHORT||PROSPECTIVE|||||||
34073569|NCT06092463|||COHORT||PROSPECTIVE|||||||
33888494|NCT00284830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34073570|NCT01147562|NA|SINGLE_GROUP||OTHER||NONE||||||
34073571|NCT01438242|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33888495|NCT00382967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974873|NCT01776346|||CASE_CONTROL||PROSPECTIVE|||||||
33974874|NCT03651674|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33974875|NCT01899963|||COHORT||PROSPECTIVE|||||||
33974876|NCT01842048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974877|NCT05561114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974878|NCT01411995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33974879|NCT04510701|||OTHER||PROSPECTIVE|||||||
34073572|NCT06382129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073573|NCT01818193|||CASE_ONLY||PROSPECTIVE|||||||
34073574|NCT01296854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073575|NCT01734057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073576|NCT05028829|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34073577|NCT03112226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34073578|NCT02757352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888496|NCT01734876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33888497|NCT04850729|||COHORT||PROSPECTIVE|||||||
33888498|NCT03424161|NA|SINGLE_GROUP||OTHER||NONE||||||
33888499|NCT05121415|||OTHER||PROSPECTIVE|||||||
33888500|NCT01690845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888501|NCT04301427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974880|NCT03811379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974881|NCT05780437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974882|NCT00622908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974883|NCT03841383|||CASE_CONTROL||PROSPECTIVE|||||||
33974884|NCT03064412|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974885|NCT05316675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974886|NCT03158298|||CASE_ONLY||PROSPECTIVE|||||||
33974887|NCT05392621|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This is a 2x2x2 randomized factorial pilot trial. Participants will be randomized to receive one of 8 possible combinations of yoga (yes/no), progressive muscle relaxation (yes/no), or deep breathing (yes/no).||||
34073579|NCT05385341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34073580|NCT05349019|||COHORT||PROSPECTIVE|||||||
34073581|NCT00179803|NA|SINGLE_GROUP||TREATMENT||NONE||high dose chemotherapy with stem cell rescue thiotepa, carboplatin \& etoposide||||
34073582|NCT02654158|||CASE_ONLY||PROSPECTIVE|||||||
33762178|NCT04905277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Atenolol vs. Placebo|t|t|t|t
33762179|NCT02323984|||COHORT||PROSPECTIVE|||||||
33762180|NCT02628392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974888|NCT03076177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33974889|NCT05188521|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33762181|NCT03263832|||CASE_CONTROL||PROSPECTIVE|||||||
33762182|NCT06624891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective comparative randomized clinical trial|t|f|f|f
33762183|NCT02512679|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762184|NCT01163643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762185|NCT02309112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33762186|NCT01190046|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762187|NCT00954954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762188|NCT03809364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762189|NCT05964855|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33762190|NCT04360850|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33974890|NCT06090656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974891|NCT06244979|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888502|NCT06412692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomized|In our study; The motivational interview technique will be applied to the intervention group individually by the researcher at 2-week intervals, including a preliminary interview and 6 motivational interview sessions.|f|f|f|t
33888503|NCT02103140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33888504|NCT04968444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinding of investigator through masking of participant identified to each group|Randomised controlled trial|f|f|t|t
33974892|NCT00794079|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33974893|NCT01400321|||COHORT||PROSPECTIVE|||||||
33974894|NCT04623736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974895|NCT01107236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974896|NCT03763110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33974897|NCT02254148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974898|NCT01339910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974899|NCT04972656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974900|NCT05869942|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Under complete sterile precautions, Skin biopsy will be taken from healthy volunteers of the control group via 3 mm disposable punches and two biopsies will be taken from patients with vitiligo, one from vitiligenous lesion and another from normal skin then will be rinsed in physiological saline and fixed in formalin for 24 hours. The preserved tissues will be trimmed for processing, then undergo dehydration with ethyl alcohol, clearing with xylene, infiltration and embedding with paraffin wax. Paraffin wax blocks will be sectioned at 5μ then mounted on glass slides. Sectioned slides will be stained with hematoxylin and eosin and other histological stains and mounted with (DPX). And examined by light microscope.~The pathological changes in vitiligenous skin will be detected. Monoclonal HMGB1 and active caspase 3 antibodies assessment."||||
33974901|NCT01555619|||CASE_ONLY||PROSPECTIVE|||||||
33974902|NCT03043378|||COHORT||PROSPECTIVE|||||||
33762191|NCT05316584|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|It will not be possible to blind participants to their respective group assignment. However, to minimize bias, we will collect all outcome data electronically by study staff at the Data Management Center at the University of North Carolina masked to the group assignment.|Multicenter, randomized, controlled trial|f|f|f|t
33762192|NCT01480596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762193|NCT00148226|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33762194|NCT00035035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762195|NCT06624761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||There will be 2 groups (ShotBlocker and control )|f|f|t|f
33762196|NCT02788838|||COHORT||OTHER|||||||
33762197|NCT01814059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762198|NCT00134602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762199|NCT04792125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33974903|NCT03852199|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762200|NCT05893680|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE||"This study was designed as a randomized controlled experiment to compare the effects of cold application, online gaming, and placebo on postoperative pain in children. Participants who met the selection criteria were randomly assigned to the online gaming, cold application, placebo, and online gaming and cold application groups through a pre-determined lottery. Subsequently, the pain-reducing intervention specific to the assigned group was applied to the child who was randomized to that group."|t|t|f|f
33762201|NCT01152775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33762202|NCT03258424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073583|NCT02996890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073584|NCT02506699|||COHORT||PROSPECTIVE|||||||
33762203|NCT04309825|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||To examine the efficacy of transgastrostomal endoscopies among a single group of patients with a gastrostomy feeding tube||||
33762204|NCT06624774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be partially blinded. The participants in both groups will be blinded from the goal of the measurements taking place. For example, the participants will not be informed specific goal of change of appendicular skeletal muscle mass. The reason for this is, if the participant knows the exact aims of the study, there would be an increased risk of the participants implementing unnatural daily habits, potentially skewing the results. The study cannot be fully blinded due to the exercise and education intervention taking place|Pilot randomised clinical trial with two groups|t|f|f|t
33762205|NCT05616741|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is an open-label, randomized, wait-list controlled multicenter trial with a run-in phase.||||
33762206|NCT00844909|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33888505|NCT03185689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||DSME is model assumed to empower diabetes patients in the area of self-care practice. To bring this behavioral change it has been hypothesized that an intensified DSME which is given in organized, interlinked and supported by take home activities is effective in glycemic control. As a teaching material, illustrative booklet was prepared in two local languages. Similarly, fliers have been given following each DSME session. Specifically for educational sessions, copy of the booklet was prepared in larger posters. The education is not only one way type of education, rather there have been a vast experience sharing among the patient, whether they have been doing in the recommended way or not. Then the facilitator educate them what is right and recommended. Local culture, values and beliefs were taken into account on each of the sessions.||||
33888506|NCT04002167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34073585|NCT06460454|||COHORT||RETROSPECTIVE|||||||
33888507|NCT06311032|||COHORT||PROSPECTIVE|||||||
33888508|NCT04892563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888509|NCT05447702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888510|NCT02605525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888511|NCT04345419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888512|NCT00627237|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888513|NCT00736554|||COHORT||PROSPECTIVE|||||||
33888514|NCT01765894|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888515|NCT00734084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888516|NCT04752761|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33888517|NCT01433211|||COHORT||CROSS_SECTIONAL|||||||
33888518|NCT01296048|||COHORT||RETROSPECTIVE|||||||
33888519|NCT01261403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888520|NCT04194060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patient will be allocated into two arms, ERAS(Enhanced recovery after surgery) group and Conventional group. 30 patients will be recruited in each arm.||||
33974904|NCT02829671|NA|SINGLE_GROUP||OTHER||NONE||||||
33888521|NCT06213428|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|all investigators and participants will be masked to which condition they receive||t|f|t|t
33888522|NCT04850183|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||intervention group and control group|t|f|f|f
33888523|NCT00192374|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33888524|NCT03921996|RANDOMIZED|PARALLEL||TREATMENT||NONE||SAKK 09/18 is an international, multicenter, randomized, phase III surgical intervention trial||||
33888525|NCT04156321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888526|NCT04480619|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Ga-68 PEG-Αvβ3-IAC PET/CT||||
33888527|NCT06415370|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888528|NCT03820245|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double blind||t|f|t|f
33888529|NCT05477186|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33888530|NCT06075823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888531|NCT01727960|||COHORT||PROSPECTIVE|||||||
33888532|NCT01860560|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33888533|NCT00970606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33974905|NCT03327896|||CASE_ONLY||RETROSPECTIVE|||||||
33974906|NCT03743428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|No masking|Head-to-head comparison of apatinib versus bevacizumab plus second-line chemotherapy regimen FOLFIRI for treatment of metastatic colorectal cancer||||
34073586|NCT01229969|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073587|NCT05279131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073588|NCT02742363|||CASE_ONLY||PROSPECTIVE|||||||
33888534|NCT00697996|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888535|NCT03690154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888536|NCT03228563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888537|NCT02232256|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33888538|NCT04184687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888539|NCT04788082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888540|NCT00313924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888541|NCT04201743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Data will be prospectively collected on all injectable acellular amniotic membrane derived allograft knee performed at our institute.~Inclusion criteria will be all patients age between 21 and 80 years with a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren Lawrence grading scale.~Methods for collecting data will be through validated patient-reported outcome tools that the patient will complete pre-injection and at specified time intervals after injection: 90 days, 180 days and 365 days."|t|t|t|f
33888542|NCT06037356|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a prospective, non-inferiority randomized controlled trial with the aim of detecting a non-inferiority margin of 5%. Subjects will be randomized in a 1:1 ratio.||||
34073589|NCT06484283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34073590|NCT05017805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073591|NCT02334826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073592|NCT01435889|||COHORT||PROSPECTIVE|||||||
34073593|NCT06611826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888543|NCT01889602|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33974907|NCT03430375|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Participants, care providers if present, and investigators who are the outcomes assessors will all be aware of which cushion that the participant is sitting on, the participants' diagnoses or if healthy, the static and active conditions described above, and outcome measures results; therefore, no masking is taking place.|Each of 3 populations or groups (healthy adults, participants post-stroke, participants with spinal cord injury) will sit on two wheelchair cushions (alternating air cushion, static air cushion) under two conditions including static sitting (#1 static condition) and while performing upper extremity reaching (#2 active condition) while monitoring interface pressure between the cushion and buttock/posterior thighs.||||
33888544|NCT03595696|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888545|NCT05769231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888546|NCT02280850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888547|NCT04389177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888548|NCT00073840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888549|NCT00166387|||FAMILY_BASED|||||||||
33888550|NCT02712541|||COHORT||PROSPECTIVE|||||||
33888551|NCT02867007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888552|NCT05028803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888553|NCT03023904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888554|NCT00030784||||TREATMENT||||||||
33888555|NCT04206150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator and outcomes assessor are blinded to group assignment.|Ninety six patients scheduled for total knee arthroplasty will be randomly divided into the three groups. In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal). In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1. In group 3, the adductor canal catheter is inserted femur length/15\*2 cm below the location where the nerve block performed in group 1.|t|t|t|t
33888556|NCT00670787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888557|NCT00000943||||TREATMENT||||||||
33974908|NCT04708795|NA|SINGLE_GROUP||OTHER||NONE||||||
33974909|NCT06009523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974910|NCT02973009|||COHORT||PROSPECTIVE|||||||
33974911|NCT04284371|||COHORT||PROSPECTIVE|||||||
33974912|NCT05432843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the parallel period, the trial is double blinded. After this blinded treatment period, the code will be broken so that patients which received placebo are able to receive the treatment for another 8 weeks.|Parallel design with open label period|t|f|t|t
33974913|NCT02158936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974914|NCT02417090|||CASE_CONTROL||RETROSPECTIVE|||||||
33974915|NCT05976971|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33974916|NCT06544083|||COHORT||PROSPECTIVE|||||||
33974917|NCT06358378|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974918|NCT02519790|||COHORT||PROSPECTIVE|||||||
33974919|NCT00697775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33974920|NCT05602090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974921|NCT00132002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974922|NCT02899130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974923|NCT02863302|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33974924|NCT03303638|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33974925|NCT01974895|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33974926|NCT00866242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33974927|NCT02255513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974928|NCT00315263|||CASE_CONTROL||PROSPECTIVE|||||||
33974929|NCT02202174|||COHORT||PROSPECTIVE|||||||
33974930|NCT00661505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974931|NCT04758936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974932|NCT00365261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974933|NCT06421844|||COHORT||PROSPECTIVE|||||||
33974934|NCT06485895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974935|NCT01841320|RANDOMIZED|PARALLEL||||NONE||||||
33974936|NCT03818620|||OTHER||PROSPECTIVE|||||||
33974937|NCT04277611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33974938|NCT03529955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974939|NCT03925220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974940|NCT04043013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974941|NCT04350567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974942|NCT03866226|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33974943|NCT04389879|RANDOMIZED|PARALLEL||OTHER||NONE|The outcome assessor will be blinded only to the patient satisfaction and cost-effectiveness outcomes.|"Two-center randomized controlled clinical trial. Consecutive patients who are about to finish their fixed appliance orthodontic treatment at the two orthodontic departments will be screened for eligibility criteria. Eligible subjects will be randomized to have one of either two different fixed retainers to be bonded (to the upper and lower anterior teeth) by one operator in each center.~Subjects will be allocated 1:1 into one of the two groups."||||
33974944|NCT02565420|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Alternating intervention||||
33974945|NCT00475020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974946|NCT03881813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33974947|NCT06327295|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33974948|NCT04076358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study uses an experimental pre- and post-test repeated measures design. Those satisfying the inclusion and exclusion criteria are randomly assigned to the intervention (Tab-CBI, n=12) or comparison group (n=12).||||
33974949|NCT00000654||||TREATMENT||||||||
33974950|NCT02442856|NA|SINGLE_GROUP||OTHER||NONE||||||
33974951|NCT02563522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Active: Engensis (VM202) + standard of care - 200 subjects Control: Placebo (VM202 vehicle) + standard of care - 100 subjects|t|t|t|f
34073594|NCT03025269|||CASE_ONLY||PROSPECTIVE|||||||
34073595|NCT01435759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073596|NCT01822210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073597|NCT02594059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073598|NCT00458757|||CASE_CONTROL||PROSPECTIVE|||||||
34073599|NCT01176123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765036|NCT04402658|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Both participants and key study personnel will be blinded for the intervention as an external person will provide the participant with sequentially numbered drug containers of identical appearance, for salbutamol and placebo, respectively.|The present study has a double-blinded and randomized cross-over design with participants visiting the laboratory on three separate occasions. The purpose of the first visit is to familiarize the participant with the equipment and the exercise performance protocol as well as to assess physiologic exercise data that will be used to determine the power output of the endurance exercise protocol on visits two and three. For a given participant, trials on day two and three will be conducted in randomized order, on the same time of day, and separated by more than 72 hours to ensure complete wash-out of salbutamol, and less than three weeks. The randomization will be performed using a computer random number generator.||||
34073600|NCT03902470|RANDOMIZED|PARALLEL||TREATMENT||NONE||In determining a significant difference (20%) in the occurrence of postoperative pain score by using the power of 80% and a significance level of 5% and this will result in 30 patients in each group.||||
33765037|NCT05745428|||CASE_CONTROL||PROSPECTIVE|||||||
33765038|NCT00002537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765039|NCT06389097|||COHORT||CROSS_SECTIONAL|||||||
33888558|NCT05035121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The participants were divided into three groups, such as control, milk supplement and soy milk supplement. The milk and soy milk groups provided 200 mL milk or soy milk two times per day. Moreover, all participants joined the resistance exercise training program, three times per week (30min/time).|t|t|f|f
33888559|NCT04268719|||COHORT||PROSPECTIVE|||||||
33888560|NCT01045954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888561|NCT00321165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888562|NCT02557087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888563|NCT02608632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888564|NCT00709202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888565|NCT03227809|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two experimental groups (one group receives a handbook, one group receives a handbook plus text messages) and one control group (no intervention)||||
33888566|NCT00888667|||OTHER||PROSPECTIVE|||||||
33888567|NCT00607048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888568|NCT05029050|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A parallel-group treatment, five-centre, participant and investigator masked, three-arm study to assess the safety and effectiveness of dexmedetomidine or clonidine infusion compared to placebo for the prevention of delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery.|t|t|t|t
33888569|NCT01336790|||CASE_ONLY||OTHER|||||||
33888570|NCT03311087|||COHORT||OTHER|||||||
33888571|NCT00480857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888572|NCT00600171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888573|NCT04171609|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33888574|NCT01444755|||CASE_CONTROL||PROSPECTIVE|||||||
33888575|NCT04142645|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A pragmatic cluster-randomized trial with the inclusion of two NHs where the feasibility and acceptability of the OptiMEDs intervention will be tested and one NH where the standard of care will be registered.||||
33888576|NCT06140771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888577|NCT00889044|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33888578|NCT01130922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974952|NCT06131021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PBRN practitioner- and patient participant-level masking. Statistician assessor will also remain blinded; a separate biostatistician will remain unblinded in order to implement randomization.|The sample size will be a target of approximately 544 patient participants enrolled from approximately 34 National Dental PBRN practices. All patient participants are indicated to receive SRP and have been diagnosed with periodontitis stages II-III, grades A-C. A double-blinded patient participant-randomized design is used to assign patient participants to SRP plus AMXM versus SRP plus placebo prior to treatment.|t|t|f|f
33974953|NCT02354300|||CASE_ONLY||PROSPECTIVE|||||||
33974954|NCT00197275|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33974955|NCT01223807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34073601|NCT00064103|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073602|NCT00304460||||TREATMENT||||||||
34073603|NCT04928144|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single-center, Open-label, first-in-human dose-escalation.||||
34073604|NCT00279344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073605|NCT05831124|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888579|NCT01207830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073606|NCT06611384|||COHORT||PROSPECTIVE|||||||
33888580|NCT05114083|||OTHER||PROSPECTIVE|||||||
33888581|NCT03619629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33888582|NCT00961961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888583|NCT03431233|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33888584|NCT03411395|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33888585|NCT02868203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888586|NCT02055625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974956|NCT06201273|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|"The concealment of allocation will be conducted by a researcher not involved in the clinical procedures of the intervention using the method of opaque, sealed, and consecutively numbered envelopes. The random sequence and allocation concealment allow for the control of selection bias.~For enhanced bias control, the data analysis will be performed by a researcher blinded to the intervention groups."||f|t|t|t
33974957|NCT01649141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974958|NCT00071552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974959|NCT03765073|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but all other study personnel, including the principal investigator, and the participant, will be blinded.||t|f|t|f
33974960|NCT06374030|||COHORT||RETROSPECTIVE|||||||
34073607|NCT00597389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888587|NCT05887999|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33974961|NCT04905342|RANDOMIZED|CROSSOVER||TREATMENT||NONE||single-dose, crossover study||||
33974962|NCT02407379|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33974963|NCT02894775|||CASE_CONTROL||RETROSPECTIVE|||||||
33974964|NCT02775890|||CASE_CROSSOVER||PROSPECTIVE|||||||
33974965|NCT05618171|||COHORT||PROSPECTIVE|||||||
33974966|NCT05571527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33974967|NCT00830674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33974968|NCT05679765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073608|NCT03915483|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073609|NCT02950116|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073610|NCT01515098|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34073611|NCT06515626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073612|NCT04437914|||COHORT||CROSS_SECTIONAL|||||||
34073613|NCT05906147|||COHORT||PROSPECTIVE|||||||
34073614|NCT06611501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073615|NCT04972799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34073616|NCT04058457|||CASE_CONTROL||PROSPECTIVE|||||||
33888588|NCT04864587|||COHORT||RETROSPECTIVE|||||||
33888589|NCT05821361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888590|NCT00456313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888591|NCT01365156|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888592|NCT05118126|||COHORT||PROSPECTIVE|||||||
33888593|NCT04421326|||COHORT||PROSPECTIVE|||||||
33888594|NCT00282126|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33974969|NCT01127581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33974970|NCT00349063|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33974971|NCT05343156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888595|NCT02104284|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33888596|NCT01661790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888597|NCT01695421|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33888598|NCT02582996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888599|NCT05858190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888600|NCT02746510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888601|NCT05302635|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33888602|NCT00322790|||COHORT||RETROSPECTIVE|||||||
33888603|NCT04066387|||COHORT||RETROSPECTIVE|||||||
33888604|NCT02379325|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33888605|NCT05302323|RANDOMIZED|PARALLEL||PREVENTION||NONE||major abdominal surgery||||
33888606|NCT01856114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888607|NCT00358813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888608|NCT05539014|||COHORT||PROSPECTIVE|||||||
33888609|NCT04208295|||COHORT||CROSS_SECTIONAL|||||||
33888610|NCT03151486|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33888611|NCT05405517|||OTHER||CROSS_SECTIONAL|||||||
33888612|NCT01646099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33888613|NCT05435820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974972|NCT00279448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974973|NCT05811156|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33888614|NCT06151392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974974|NCT01176448|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33888615|NCT02254343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888616|NCT00478829|||||PROSPECTIVE|||||||
33888617|NCT00611247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888618|NCT00544921|RANDOMIZED|PARALLEL||||NONE||||||
33974975|NCT03438110|||COHORT||PROSPECTIVE|||||||
33974976|NCT01105650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974977|NCT01490281|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33974978|NCT01524042|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33974979|NCT02456909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33974980|NCT00347503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33974981|NCT03420066|||CASE_ONLY||RETROSPECTIVE|||||||
33888619|NCT00961987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888620|NCT02952976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888621|NCT04897867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888622|NCT01554787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888623|NCT01083667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888624|NCT05375279|||COHORT||PROSPECTIVE|||||||
33888625|NCT05559307|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33888626|NCT05535647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888627|NCT00308451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33888628|NCT01201213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888629|NCT04217369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be assigned randomly at the time of recruitment into two groups: a treatment group and a control group. Both groups will be given the app, but the control group will not have predictions enabled.||||
33888630|NCT00909155|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33888631|NCT00490542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888632|NCT05700266|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Endpoint assessments, including neurological function evaluation, primary and secondary ending points, will be performed blindly by an assessment group who are blind to this study.|This study is an investigator initiated, randomized, blinded endpoint assessment, clinical trial and conducted at 10 sites in the China. Patients meeting the enrollment criteria will be randomly assigned to one of the two treatment groups (1:1) and will be followed up for 1 year.|f|f|f|t
33888633|NCT02965157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888634|NCT06127329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888635|NCT05357456|||COHORT||PROSPECTIVE|||||||
33974982|NCT01997554|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33974983|NCT04736264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33888636|NCT05848934|||COHORT||PROSPECTIVE|||||||
33888637|NCT03566940|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33974984|NCT03498443|||CASE_CONTROL||PROSPECTIVE|||||||
33974985|NCT01326026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33974986|NCT02362919|||COHORT||PROSPECTIVE|||||||
34073617|NCT01833585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073618|NCT00412126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073619|NCT03576443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073620|NCT02212925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33762207|NCT04402437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All subjects will be positioned, prepped and sedated for the randomized regional anesthesia procedure in the preoperative holding area. The subject will be positioned in the lateral decubitus position with the operative side up and pulse oximetry and blood pressure cuff placed for monitoring. As part of routine care, the subject will receive sedation for their comfort. All subjects would receive 20 ml of 0.5% ropivacaine in their nerve block regardless of randomization. The relevant anatomy will then be identified using either surface landmarks (lumbar plexus block) or an ultrasound (quadratus lumborum block). Surface anatomy will be marked with a marking pen for both groups to keep the intraoperative and surgical team blinded. The skin will be cleaned with chlorhexidine. Subject, surgeon, intraoperative anesthesia team and data collectors would all be blinded to the allocated group.|The subject will be positioned in the lateral decubitus position with the operative side up and pulse oximetry and blood pressure cuff placed for monitoring. As part of routine care, the subject will receive sedation for their comfort. All subjects would receive 20 ml of 0.5% ropivacaine in their nerve block regardless of randomization. The relevant anatomy will then be identified using either surface landmarks (lumbar plexus block) or an ultrasound (quadratus lumborum block). Surface anatomy will be marked with a marking pen for both groups to keep the intraoperative and surgical team blinded. The skin will be cleaned with chlorhexidine.|t|f|f|f
33762208|NCT03439189|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The collaborator is responsible for the masking process.|The population performing the MBT at weeks 24 and 48 will have approximately an equal number of subjects from each of the 4 parallel treatment arms (5 mg, 25 mg, 50 mg or placebo).|t|t|t|f
33762209|NCT05915962|NA|SINGLE_GROUP||SCREENING||NONE||||||
33762210|NCT05108168|||COHORT||RETROSPECTIVE|||||||
33762211|NCT00944723|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762212|NCT02729181|||COHORT||RETROSPECTIVE|||||||
33765040|NCT04586413|||COHORT||PROSPECTIVE|||||||
33765041|NCT00284141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33765042|NCT01356953|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888638|NCT02007551||PARALLEL||||SINGLE|||f|f|f|t
33888639|NCT04042194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888640|NCT03599180|||CASE_CONTROL||PROSPECTIVE|||||||
33888641|NCT00888563|||COHORT||PROSPECTIVE|||||||
33888642|NCT03588741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888643|NCT01393977|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33888644|NCT02894229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888645|NCT00688909|NA|SINGLE_GROUP||OTHER||NONE||||||
33888646|NCT00562809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073621|NCT05886088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888647|NCT03124069|NA|SINGLE_GROUP||TREATMENT||NONE||After a period of baseline, all enrolled participants will be put on the same trial mask.||||
33888648|NCT00754156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073622|NCT06609681|||COHORT||PROSPECTIVE|||||||
34073623|NCT00021931|||||RETROSPECTIVE|||||||
34073624|NCT00263380|||CASE_CONTROL||PROSPECTIVE|||||||
34073625|NCT05276583|||CASE_CONTROL||PROSPECTIVE|||||||
34073626|NCT02141906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762213|NCT06089122|NA|SINGLE_GROUP||TREATMENT||NONE|The trial will be open-label and single-arm. Therefore, there will be no randomization or blinding.|Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology in a run-in period of 2 to 6 administrations. In the one-year test period, the patients will receive the test IVIG at 21- or 28-day intervals and be followed. IgG trough levels will be collected at all visits. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.||||
33762214|NCT03205540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762215|NCT02714855|||COHORT||CROSS_SECTIONAL|||||||
34073627|NCT04051697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-armed (intervention vs usual care) non-blinded pilot randomised control trial||||
33762216|NCT00615186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762217|NCT03340948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot and feasibility study of one cohort.||||
33762218|NCT03509532|||COHORT||PROSPECTIVE|||||||
33762219|NCT03312153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* The study will be double-blinded which are the patients and the assessor.~* The participants will drag the envelop and will not know which irrigant they will be treated with to not affect their behavior and their responses to the subjective outcome measures. also, not provide biased assessment of the effectiveness of the intervention .~* The study will be double-blinded which are the patients and the assessor.~* The participants will drag the envelop and will not know which irrigant they will be treated with .~* Assessors in the microbiology laboratory in Microbiology department, Faculty of Medicine, Cairo University also will be blinded during assessment of data of endotoxins will not know the treatment group of the patients."||t|f|f|t
33762220|NCT04092465|||COHORT||PROSPECTIVE|||||||
33762221|NCT03688152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762222|NCT02731664|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33762223|NCT02012062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762224|NCT03158363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Healthy young adults will be randomized to either intervention Endotoxemia, 36 hour immobilization and fasting or overnight fast being the control day."||||
33888649|NCT00369057|||COHORT||PROSPECTIVE|||||||
33888650|NCT03404778|||COHORT||PROSPECTIVE|||||||
33888651|NCT00952757|||CASE_ONLY||PROSPECTIVE|||||||
33888652|NCT01487421|||COHORT||PROSPECTIVE|||||||
33888653|NCT01774214|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33888654|NCT01262183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888655|NCT01961115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888656|NCT04273074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888657|NCT00254306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888658|NCT01269164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888659|NCT03283202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888660|NCT04706884|||CASE_CONTROL||PROSPECTIVE|||||||
33888661|NCT01231412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888662|NCT04387097|||COHORT||RETROSPECTIVE|||||||
34073628|NCT02658669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073629|NCT01965002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073630|NCT04878939|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinding of the main investigator to the interventions was difficult, yet the outcome assessor was masked to the intervention and assessed unidentified CBCTs||f|f|f|t
33762225|NCT03993509|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Both the subject and the TMS operator will be blinded as to the study condition (active vs. sham)|Aims 1 and 2 will be tested using a between-subjects design where 1 group of healthy volunteers will receive 4-day courses of active and sham 1 Hz stimulation to the right dlPFC, while the other group will receive 4-day courses of active and sham 10 Hz stimulation to the right dlPFC. Aim 1, will test the effects of this stimulation on anxiety during the NPU threat task. Aim 2, will test the effects of this stimulation on anxiety-related working memory (WM) deficits using the Sternberg WM paradigm. Aim 3 will be tested using a within-subjects design where this same group of subjects will receive single-pulse active and sham stimulation to the right dlPFC during the Neutral, Predictable, and Unpredictable (NPU) threat task while in the MRI scanner. BOLD activity to the TMS pulses will be the primary outcome measure.|t|f|t|t
33762226|NCT00871650|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33762227|NCT04585659|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33762228|NCT00145457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762229|NCT05265663|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective multicenter randomized controlled trial according to the 'cohort multiple randomized controlled trial (cmRCT)'-design.||||
33762230|NCT02636257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762231|NCT01599923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762232|NCT01295658|||CASE_ONLY||CROSS_SECTIONAL|||||||
33888663|NCT05466643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888664|NCT03670030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888665|NCT02479789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33888666|NCT05136274|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial comparing ipsilateral tubal patency with the use of two therapeutic methods, groups A; with intramuscular methotrexate administration and B conservative surgery (linear salpingostomy)||||
33888667|NCT03157531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888668|NCT04887571|||COHORT||PROSPECTIVE|||||||
33888669|NCT05238376|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33888670|NCT01369121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888671|NCT02455674|||COHORT||CROSS_SECTIONAL|||||||
33762233|NCT04269915|NA|SINGLE_GROUP||OTHER||NONE||||||
33762234|NCT00231907|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33762235|NCT01578863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762236|NCT03213990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762237|NCT02107794|RANDOMIZED|PARALLEL||||NONE||||||
33762238|NCT03929562|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33762239|NCT01099514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762240|NCT03663764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888672|NCT05409287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888673|NCT00950170|NA|SINGLE_GROUP||OTHER||NONE||||||
33888674|NCT01707992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888675|NCT01998542|NA|SINGLE_GROUP||TREATMENT||NONE||12 subjects with externally measurable disease||||
33888676|NCT00127751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888677|NCT01285349|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888678|NCT00972699|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33888679|NCT01592994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888680|NCT03633279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888681|NCT05249049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888682|NCT00412477|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33888683|NCT05650034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888684|NCT00206921|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33974987|NCT04317573|RANDOMIZED|PARALLEL||OTHER||NONE||A total of 59 patients were recruited for the study. Subjects were randomised into three groups: control (n=19), card only (n=20), card and tele-reminder (n=20) with an allocation ratio of 1:1:1. (Figure 1). Sample size was calculated based on similar drug adherence studies powered to detect a true difference in adherence rates with power at 80% and alpha at 5% - 20 patients per group were required.12,13||||
33974988|NCT03316937|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.|t|f|f|f
33974989|NCT05116228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888685|NCT03275909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888686|NCT03068715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888687|NCT00404092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888688|NCT06077084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|t|f|f|t
33888689|NCT03388593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888690|NCT04312087|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33888691|NCT02247024|||COHORT||PROSPECTIVE|||||||
33888692|NCT03942393|||COHORT||PROSPECTIVE|||||||
33888693|NCT06069661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888694|NCT04847388|||CASE_ONLY||PROSPECTIVE|||||||
33888695|NCT04897490|||COHORT||PROSPECTIVE|||||||
33888696|NCT02928952|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33888697|NCT01946178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073631|NCT03108066|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label Phase 2 study that will be conducted with a 2-stage design.||||
34073632|NCT03887182|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073633|NCT00834847|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33974990|NCT05709509|RANDOMIZED|PARALLEL||TREATMENT||NONE||All subjects were allocated to 4 different groups: Late PCI + Colchicine, Late PCI + Optimal Medical Treatment, Optimal Medical Treatment + Colchicine, and Optimal Medical Treatment Only||||
33974991|NCT05163509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888698|NCT05427578|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888699|NCT03494556|||COHORT||PROSPECTIVE|||||||
33888700|NCT05568771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888701|NCT05340504|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind||t|t|t|f
33888702|NCT03624816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888703|NCT06499922|||COHORT||PROSPECTIVE|||||||
33888704|NCT05963763|RANDOMIZED|PARALLEL||PREVENTION||NONE||Step wedge design: participants randomized in two groups, Group 1, and Group 2 - intervention on different timeframe, analysis of the difference and similarities between groups pre- and post-survey.||||
33888705|NCT02509559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33888706|NCT06005584|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33888707|NCT05406908|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33888708|NCT03542539|||COHORT||PROSPECTIVE|||||||
33888709|NCT03514082|||CASE_CONTROL||PROSPECTIVE|||||||
33888710|NCT00470821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33888711|NCT06154070|||CASE_ONLY||PROSPECTIVE|||||||
33888712|NCT05494307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888713|NCT00955058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888714|NCT03906253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888715|NCT02773966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888716|NCT00723957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888717|NCT03838484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33888718|NCT05655403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33888719|NCT00883493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888720|NCT02524431|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33888721|NCT06255873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888722|NCT03563300|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||Parallel Assignment|t|t|t|t
33888723|NCT01499290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888724|NCT03670459|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33888725|NCT04488458|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888726|NCT02506738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888727|NCT05596266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888728|NCT03160729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888729|NCT03325582|||COHORT||PROSPECTIVE|||||||
33888730|NCT05229939|||COHORT||PROSPECTIVE|||||||
33974992|NCT00161278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33974993|NCT02354586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33974994|NCT06412393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33974995|NCT05775757|||COHORT||PROSPECTIVE|||||||
33974996|NCT05520281|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-Post Design||||
33974997|NCT05140161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33974998|NCT00597233|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33974999|NCT04429451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975000|NCT01673009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975001|NCT01095003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888731|NCT03228121|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Only the on-site PI and research nurse administering the treatment or placebo will know which group the participant belongs to. Patients are blinded. All follow-up contact and measurement of outcomes will be done by off-site research nurses who are blinded.|"0 participants will be recruited for each arm of the study.~Cohort A will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.~Cohort B will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure."|t|f|f|t
33888732|NCT00692367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975002|NCT03504852|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33975003|NCT05977257|||COHORT||PROSPECTIVE|||||||
33975004|NCT06096623|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33975005|NCT06427993|||COHORT||PROSPECTIVE|||||||
33975006|NCT05749783|||CASE_ONLY||PROSPECTIVE|||||||
33975007|NCT04052867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33888733|NCT01904799|NA|SINGLE_GROUP||OTHER||NONE||||||
33975008|NCT03519256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975009|NCT03246230|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Newborn infants will have delayed immunization, with catch-up immunization at day of life 7 (DOL7), or immunization at birth with hepatitis B vaccine (HBV), Bacille Calmette-Guérin (BCG) or (HBV +BCG). All participants will have peripheral blood collected at birth (DOL0) and each group will be divided into sub-groups with follow-up peripheral blood collection at DOL1, DOL3, or DOL7.||||
33975010|NCT01821625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975011|NCT04082962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Twenty patients will be enrolled in this randomized pilot study. Patients will be randomized (1:1) to receive the dexamethasone implant or no treatment. A stratified randomization scheme will be performed, with strata defined by tumor height (\< 5mm and 5mm - \< 10 mm). Patients with newly diagnosed choroidal melanoma meeting specified eligibility criteria will be randomly assigned to receive Ozurdex™ (0.7 mg dexamethasone) or no treatment at the time of their tumor localization (tantalum ring placement) surgery for patients receiving PBI or at the time of plaque removal for those patients receiving plaque radiotherapy.|t|f|f|f
33888734|NCT02858427|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33975012|NCT04543136|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33975013|NCT04787757|||COHORT||PROSPECTIVE|||||||
33975014|NCT03966170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975015|NCT02494726|||CASE_CONTROL||PROSPECTIVE|||||||
33888735|NCT00888355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888736|NCT02076165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888737|NCT00630045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888738|NCT00191854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888739|NCT01920802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888740|NCT05184907|RANDOMIZED|PARALLEL||TREATMENT||NONE||RME (1-3 sessions) versus information alone||||
33888741|NCT01284504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888742|NCT02844465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975016|NCT00017563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975017|NCT03580343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975018|NCT02485496|||COHORT||PROSPECTIVE|||||||
33975019|NCT00698685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073634|NCT02861664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073635|NCT02170857|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34073636|NCT00872612|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073637|NCT03556514|||CASE_ONLY||RETROSPECTIVE|||||||
33888743|NCT05489081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participating teachers, and the students nested within their classroom, are randomized to one of two conditions: implementation strategy resource package or support as usual.||||
33888744|NCT06418620|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888745|NCT00670007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888746|NCT03995719|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33888747|NCT06366529|||COHORT||PROSPECTIVE|||||||
33888748|NCT06134297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33888749|NCT02511977|||CASE_ONLY||RETROSPECTIVE|||||||
33888750|NCT00120614|RANDOMIZED|PARALLEL||||SINGLE||||||
33888751|NCT00323284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|IOP measurement||f|f|f|t
33888752|NCT00237133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888753|NCT04315467|NA|SINGLE_GROUP||OTHER||NONE||||||
33888754|NCT04348851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary investigator and staff collecting outcome data will be blinded.|Four-arm randomized controlled trial|f|f|t|t
33888755|NCT03898635|||COHORT||RETROSPECTIVE|||||||
33888756|NCT02357511|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33888757|NCT04000477|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33975020|NCT04936997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975021|NCT03784261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975022|NCT01657539|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33975023|NCT02015091|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975024|NCT01800565|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33975025|NCT00922779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073638|NCT05205304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be divided into two groups. The first group is treated with CO2 transdermal administration and the second group is the control group.|t|f|f|t
34073639|NCT05516238|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073640|NCT02084017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34073641|NCT06612593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective Randomized Single-blinded Controlled trial|t|f|f|f
34073642|NCT05803694|||OTHER||OTHER|||||||
34073643|NCT05313399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073644|NCT05514457|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34073645|NCT02313623|||COHORT||PROSPECTIVE|||||||
34073646|NCT06611293|||COHORT||PROSPECTIVE|||||||
33762241|NCT06111339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will then be randomized in a double-blind fashion to receive either ketamine (0.8 mg/kg) or a matched volume saline placebo in the ED. Randomization will use a permuted block method58. The randomization ratio will be 1:1. A biostatistician will generate the randomization codes and provide the randomization list to the hospital's Investigational Drug Services (IDS). The study RA will contact IDS once the participant has signed informed consent and IDS staff will randomize participants. Both RA, study team and the clinical team will be blinded to the allocation.||t|f|t|f
33762242|NCT04571099|||COHORT||PROSPECTIVE|||||||
33975026|NCT01164943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33975027|NCT00885690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975028|NCT01774955|||COHORT||PROSPECTIVE|||||||
33975029|NCT00228904|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33975030|NCT00409890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34073647|NCT05932771|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Before commencing each experimental trial, a laboratory technician (independent to the study) made up the three doses of hydrolyzed collagen (HC) and randomly assigned the order of HC dose (Excel 2016, Microsoft, Washington, USA) for each participant. Also, for each trial, the technician recorded the date, randomly allocated trial number (1, 2 or 3) and corresponding HC dose to blind the investigator.|A double-blind, randomised cross-over design|t|f|t|t
33762243|NCT01822938|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33888758|NCT00619957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888759|NCT04798287|||COHORT||RETROSPECTIVE|||||||
33888760|NCT04529655|||COHORT||PROSPECTIVE|||||||
33975031|NCT05166993|||COHORT||PROSPECTIVE|||||||
33975032|NCT02367495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975033|NCT06192251|||COHORT||PROSPECTIVE|||||||
33975034|NCT01174056|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33975035|NCT02856256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975036|NCT00624156|||COHORT||PROSPECTIVE|||||||
33975037|NCT00364403|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073648|NCT03683563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073649|NCT04608916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33762244|NCT05202795|||COHORT||CROSS_SECTIONAL|||||||
33762245|NCT01960725|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Label|||||
33762246|NCT01975155|||CASE_CONTROL||PROSPECTIVE|||||||
33888761|NCT03170830|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Sample inspector||t|f|f|f
33888762|NCT05693402|||OTHER||CROSS_SECTIONAL|||||||
33888763|NCT06302257|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33888764|NCT02055001|||COHORT||PROSPECTIVE|||||||
33888765|NCT00200265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888766|NCT04049019|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||10 boys with nocturnal enuresis and 10 healthy boys will be included for urine collection.||||
33888767|NCT02863198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888768|NCT02080052|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34073650|NCT00826566|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34073651|NCT03099603|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34073652|NCT00361803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073653|NCT05292885|||CASE_ONLY||PROSPECTIVE|||||||
34073654|NCT00159952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073655|NCT01150253||CROSSOVER||||||||||
33762247|NCT03319511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|a dorsal thoracic gauze cover.||t|f|f|t
33888769|NCT04187092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded and will be responsible for executing the baseline and follow-up outcome measures. Assessors have the adequate training and experience for recording the patient reported outcome measures along with conducting the thigh muscle strength and balance testing.|"Participants with knee osteoarthritis will be randomly assigned to Group 1 or 2. During each exercise session all the participants will perform stretching exercises, strengthening exercises and balance exercises. Dosage of exercises will be based on the rehabilitation principles and will be guided and progressed the way the participants feel about their knee health throughout the rehabilitation program.~Participants in Group1 (KneeBright group), will perform some of the exercises with the KneeBright Device and while playing a video game, while Group 2 will undergo standard knee rehabilitation exercises without the KneeBright device.~Both groups will undergo a 12 week program including 3 exercise sessions per week that include a combination of in-person and at home sessions. Participants in both groups will undergo 36 exercise sessions in total, each lasting for 1 hour. Among these 36 sessions 20 will be performed in clinic under supervision and 16 will be performed at home."|f|f|f|t
33888770|NCT02781792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888771|NCT00518817|||DEFINED_POPULATION||PROSPECTIVE|||||||
33975038|NCT05435222|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||"six-arm randomized controlled superiority trial 2x3 factorial study design Additionally, a healthy control group will be examined, which will undergo only baseline assessments.~The study is a six-arm randomized controlled superiority trial. Participants will be stratified by testosterone status (eugonadal / hypogonadal) and then randomized into one of the three groups (MSPP, CBT or Waitlist). The study presents a 2x3 factorial study design. In addition, a separate healthy control group will be examined, which will undergo only baseline assessments."|t|f|f|t
33888772|NCT04175470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33888773|NCT02749149|||COHORT||PROSPECTIVE|||||||
33888774|NCT04472728|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33888775|NCT03072602|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each participant will be enrolled into one of the two groups by race.||||
33888776|NCT02530645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888777|NCT01015508|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33888778|NCT01731002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975039|NCT04956549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33975040|NCT01134653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975041|NCT00953979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975042|NCT00517101|||DEFINED_POPULATION||PROSPECTIVE|||||||
33762248|NCT05347901|||COHORT||RETROSPECTIVE|||||||
33762249|NCT01036022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762250|NCT00234650|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
33762251|NCT02949921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762252|NCT03536364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762253|NCT05149092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33762254|NCT02125448|||COHORT||PROSPECTIVE|||||||
33762255|NCT00221143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762256|NCT04334239|||COHORT||RETROSPECTIVE|||||||
33762257|NCT00160420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762258|NCT00175344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762259|NCT06625424|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will be a randomized controlled trial (single blinded), consisting of 2 groups: intervention group A (active recovery) and intervention group B (passive recovery).||||
33762260|NCT03075592|||COHORT||PROSPECTIVE|||||||
33762261|NCT02162680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975043|NCT02192905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975044|NCT02739542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975045|NCT06469879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975046|NCT02467699|||OTHER||RETROSPECTIVE|||||||
33975047|NCT01503723|||COHORT||PROSPECTIVE|||||||
33975048|NCT00727285|||COHORT||PROSPECTIVE|||||||
33762262|NCT04557839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||parallel assignment|f|f|f|t
33762263|NCT01257464|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762264|NCT02799186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762265|NCT05282290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762266|NCT02172989|||CASE_ONLY||PROSPECTIVE|||||||
33762267|NCT02564783|||COHORT||PROSPECTIVE|||||||
33762268|NCT01336985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762269|NCT00697190|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33762270|NCT00005625||||TREATMENT||||||||
33762271|NCT01471132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762272|NCT03304002|||COHORT||PROSPECTIVE|||||||
33762273|NCT01933035|||COHORT||PROSPECTIVE|||||||
33762274|NCT05747339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888779|NCT04608214|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomised, open-label, proof of-concept, Phase 2 study to evaluate the efficacy, safety and tolerability of alisporivir plus SOC as compared to SOC for the treatment of hospitalised patients with infections due to SARS-CoV-2||||
33888780|NCT00977509|||CASE_ONLY||PROSPECTIVE|||||||
33888781|NCT04291144|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888782|NCT05685940|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open label, non-randomized study||||
33888783|NCT04819321|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The sample will comprise 12 adult women (aged 18 to 40 years) and overweight (BMI\> 24.9 kg / m² and \<30.0 kg / m²).||||
33888784|NCT01349309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33888785|NCT01219556|||COHORT||PROSPECTIVE|||||||
33888786|NCT06192979|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888787|NCT02773329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33888788|NCT05888896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double( Participants, outcomes Assessor)|anti-hypertensive drugs and foot reflexology|t|f|f|t
33888789|NCT01418495|||CASE_ONLY||CROSS_SECTIONAL|||||||
33888790|NCT00806104|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33975049|NCT00929409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975050|NCT06398769|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|"Patients will be unaware that they will undergo an abdominal hysterectomy using VCare or SecuFix for their surgical procedure.~Data entry will utilize a coded system within a pre-designed SPSS spreadsheet. A research assistant, who will be independent of the intervention administration, will enter data for each patient using a designated code (1 or 2) that corresponded to the group assignment. All data will send to an independent statistician for blinded analysis."|prospective randomized trial|t|f|f|t
34073656|NCT00497146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888791|NCT03870802|||COHORT||PROSPECTIVE|||||||
33888792|NCT03825913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888793|NCT02305563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888794|NCT04617808|||COHORT||PROSPECTIVE|||||||
34073657|NCT01734460|||COHORT||PROSPECTIVE|||||||
33888795|NCT03648918|||FAMILY_BASED||PROSPECTIVE|||||||
33888796|NCT05487794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33888797|NCT00929240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888798|NCT04668508|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib combined with radiation||||
34073658|NCT00627562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888799|NCT03227874|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33888800|NCT02557425|||COHORT||PROSPECTIVE|||||||
33888801|NCT02798926|||CASE_CONTROL||PROSPECTIVE|||||||
33888802|NCT05825690|||COHORT||RETROSPECTIVE|||||||
33888803|NCT01124825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33888804|NCT00675025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888805|NCT06358014|RANDOMIZED|PARALLEL||TREATMENT||NONE||The combination group will receive estrogen combined with Selective serotonin reuptake inhibitors (SSRIs) , while the control group will only receive Selective serotonin reuptake inhibitors (SSRIs) intervention.SSRIs include Citalopram (Celexa) , Escitalopram (Lexapro) ,Fluoxetine (Prozac) ,Paroxetine (Paxil, Pexeva) and Sertraline (Zoloft)||||
33888806|NCT01769937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888807|NCT02463461|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888808|NCT02075801|||CASE_CONTROL||PROSPECTIVE|||||||
33975051|NCT03432377|||COHORT||PROSPECTIVE|||||||
34073659|NCT01034033|||COHORT||PROSPECTIVE|||||||
34073660|NCT01966887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073661|NCT02812082|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073662|NCT02853526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073663|NCT04646187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073664|NCT01091870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073665|NCT00621257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073666|NCT02664012|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34073667|NCT04917354|||CASE_ONLY||PROSPECTIVE|||||||
34073668|NCT04797429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|blinding is not possible because of obvious differences between the interventions: the intervention group participates in the IMS-intervention and the control group does not|||||
34073669|NCT02750696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073670|NCT05621772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Single-center, Rater-blinded, Parallel Randomized Controlled Trial|f|f|t|t
34073671|NCT05447845|||COHORT||CROSS_SECTIONAL|||||||
34073672|NCT05525000|NA|SINGLE_GROUP||OTHER||NONE||||||
33888809|NCT02145962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888810|NCT05042726|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33888811|NCT03471325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The examiner, who chart the plaque score is blinded to the treatment assignment.|In each subject, his/her right and left dentition will be randomized into Plaque Disclosed (PD) and Non Plaque Disclosed (NPD) groups. Subsequently, the upper and lower jaws will be randomized into Air Flow (AF) and Rubber Cup (RC).|t|f|f|t
33888812|NCT03737656|RANDOMIZED|PARALLEL||OTHER||NONE||Single site, open-label, randomized, single-dose, with three groups.||||
33888813|NCT03521947|||CASE_ONLY||CROSS_SECTIONAL|||||||
33888814|NCT04626414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will be randomized 1:1:1:1 to one of the treatment sequences. ie. single dose of 30 mg ferric maltol capsule in a fed condition single dose of 30 mg (5 ml) ferric maltol suspension in a fed condition single dose of 30 mg ferric maltol capsule in a fasted condition single dose of 30 mg (5 ml) ferric maltol suspension in a fasted condition||||
33888815|NCT01082484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888816|NCT01658514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33888817|NCT00615537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888818|NCT04405219|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33888819|NCT02804360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888820|NCT00516919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888821|NCT01562028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888822|NCT01752023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888823|NCT01225666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888824|NCT01509625|||COHORT||RETROSPECTIVE|||||||
33888825|NCT06528600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multi-center, randomized (1:1 allocation Hymovis ONE®: Monovisc™), double-blind, active comparator-controlled, non-inferiority study|t|f|f|t
33888826|NCT01780792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33888827|NCT02853760|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33888828|NCT03198143|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33888829|NCT01903265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975052|NCT03711955|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Investigator will not engage in the 8 week training program occurring, a leading supervisor will lead every training session so that the primary investigator (myself) will be blinded to the participants and their performance throughout the 8 week training interventions.~Participants from the opposite training groups will have separate training session times. In this way, no participant from the opposite training group will have contact with each other (ex. aerobic training group's session is at 12pm; instability resistance training group's session is at 4pm)."|Participants will be randomly assigned to either the aerobic training group/intervention or the instability resistance training group/intervention|t|f|t|f
33975053|NCT01384695|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33975054|NCT01693783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975055|NCT02224456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975056|NCT02925273|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33975057|NCT00800059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975058|NCT03756909|||COHORT||CROSS_SECTIONAL|||||||
33975059|NCT02775968|||COHORT||PROSPECTIVE|||||||
33975060|NCT03405285|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975061|NCT05166330|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975062|NCT00165399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975063|NCT01691859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975064|NCT01989507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975065|NCT01364870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33975066|NCT03987152|NA|SEQUENTIAL||TREATMENT||NONE||Challenge-Dechallenge-Rechallenge design All patients receive Sirolimus during challenge phase (6 months), stop Sirolimus during dechallenge phase (12 months), and if pain/symptoms returns Sirolimus intake is restarted during the rechallenge phase.||||
33975067|NCT02051803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975068|NCT01508936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975069|NCT03295643|NA|SINGLE_GROUP||OTHER||NONE||All subjects experience same program||||
33975070|NCT02989142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975071|NCT00506753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33975072|NCT03581474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975073|NCT00290056|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33975074|NCT02240758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975075|NCT02596607|||COHORT||PROSPECTIVE|||||||
33975076|NCT00002174||||TREATMENT||DOUBLE||||||
33975077|NCT00766584|||COHORT||PROSPECTIVE|||||||
33975078|NCT05152641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975079|NCT05775913|NA|SINGLE_GROUP||SCREENING||NONE||||||
33975080|NCT02625948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975081|NCT04223050|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be performed as block randomization with a 1:1 allocation using an electronic randomization system accessible via the internet (REDCap via OPEN at the University of Southern Denmark). The participants will be randomized electronically bedside by the study representatives.||||
33975082|NCT03496870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073673|NCT03247088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975083|NCT04604665|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Telephone randomization Random numbers centers Blinded for analyst and researchers|Clinical trial, randomized, pragmatic, of parallel groups (1: 1), by clusters, blinded for the collection of information, sending, and in the evaluation of outcomes.|f|f|t|t
33975084|NCT05830006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975085|NCT03583333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975086|NCT05731713|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||A randomized waitlist stepped wedge design with study participants recruited in staggered cohorts, with those in each annual recruitment wave receiving individual-level random assignment to either immediate intervention or waitlist control.|f|t|t|t
33888830|NCT00355121|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888831|NCT01523873|||COHORT||PROSPECTIVE|||||||
34073674|NCT01431313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073675|NCT04639362|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||After 15 to 16 cycles of treatment the PI will assign patients to either observation (no further treatment) or intensification (treatment with ibrutinib and obinutuzumab), based on MRD results.||||
34073676|NCT06523049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073677|NCT05283577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This is a randomized sham-controlled, patient and assessor-blinded pilot trial.|t|f|t|t
33888832|NCT06260592|||OTHER||CROSS_SECTIONAL|||||||
33888833|NCT00623519|||||PROSPECTIVE|||||||
33888834|NCT02318784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888835|NCT01845545|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33888836|NCT00348140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975087|NCT02314377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975088|NCT01555320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975089|NCT06544668|||COHORT||RETROSPECTIVE|||||||
33975090|NCT04023279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The hidden assignment of the participants was carried out using the method of opaque envelopes sealed and numbered consecutively.~The assessor in charge of evaluating the participants was blind to the treatment assignment, where he proceeded to take the measurements with a prior instruction of the procedures."|Quantitative, experimental prospective, explanatory type, randomized controlled parallel with simple blind.|t|t|f|t
33975091|NCT03807687|||COHORT||OTHER|||||||
33975092|NCT05191446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants completing follow up interviews with participants will be blinded to study condition.|Randomized trial with patients assigned to an experimental condition or to usual care.|f|f|f|t
33975093|NCT01946347|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33975094|NCT02676154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975095|NCT06297889|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||In this experiment, the experimental group engaged in the core strength training segment of the intervention specifically devised for this study, whereas the control group underwent conventional strength training activities.|t|f|t|f
33975096|NCT01326403|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33975097|NCT02568384|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975098|NCT00722254|||COHORT||PROSPECTIVE|||||||
33975099|NCT05628675|NA|SINGLE_GROUP||PREVENTION||NONE||Single-arm repeated measures||||
33975100|NCT05435001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073678|NCT04742504|||CASE_CONTROL||PROSPECTIVE|||||||
34073679|NCT01865721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073680|NCT04400149|||COHORT||PROSPECTIVE|||||||
34073681|NCT05413226|NA|SEQUENTIAL||BASIC_SCIENCE||NONE|The participants will be masked to the dose|Healthy males from 18 to 40 years old||||
34073682|NCT05819879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073683|NCT00553527|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34073684|NCT03105557|||COHORT||PROSPECTIVE|||||||
34073685|NCT01956188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33888837|NCT05059990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888838|NCT01106547|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33888839|NCT01482533|||COHORT||PROSPECTIVE|||||||
33888840|NCT04376450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|a randomized, triple-blinded, parallel study|GROUP A: NONINCISED PAPILLAE SURGICAL APPROACH (NIPSA) GROUP B: ENTIRE PAPILLA PRESERVATION TECHNIQUE (EPP)|t|f|t|t
33888841|NCT00889798|||COHORT||PROSPECTIVE|||||||
33888842|NCT00739284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888843|NCT03794401|||COHORT||PROSPECTIVE|||||||
33888844|NCT03137979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975101|NCT02385526|||COHORT||PROSPECTIVE|||||||
33975102|NCT05368896|||OTHER||PROSPECTIVE|||||||
34073686|NCT01648062|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33975103|NCT01025856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975104|NCT01791283|||COHORT||PROSPECTIVE|||||||
34073687|NCT04352777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073688|NCT05982197|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups A) curcuma longa oral gel group B) standard treatment group||||
34073689|NCT04032197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33975105|NCT06203275|RANDOMIZED|PARALLEL||TREATMENT||NONE||This proof of concept pilot study is designed as a randomized placebo controlled parallel trial. Forty four patients of both gender with confirmed diagnosis of T2DM will be randomized using sealed envelope method into two groups||||
34073690|NCT05781022|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigators included all patients who were presented to General Surgery Department with Iatrogenic Esophageal Perforation after Laparoscopic Upper Gastrointestinal Surgery at Zagazig University hospital between (December 2020 to August 2023).Patients will be divided into 2 groups in accordance type of preoperative~Therapy :~Group 1: Endoscopic Group, EG included 42 patients. Group 2: Surgical Group , SG included 42 patients."||||
34073691|NCT02541409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975106|NCT03617484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975107|NCT04155164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants and researchers are double-blind. After signing informed consent, subjects who meet the inclusion criteria will be randomly divided into the oral Metformin experimental group or the oral placebo control group at a ratio of 1:1. Random lists will be generated by independent statisticians. Randomized group will be sealed in a separate opaque envelope, showing only the research identification number. Participants and researchers (medical evaluators, outcome evaluators and data analysts) will be unaware of the grouping.~During the period of treatment, if patient suffers from lactic acidosis, excessive ventilation, myalgia, the masking should be unveiled and his/her systematic and eye conditions should be assessed to choose the best treatment. The choice of remedial treatment plan is based on the consensus of doctors and patients. The changes of treatment methods and curative effect should be recorded in detail for future analysis"||t|t|t|t
34073692|NCT04165356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"All mouth-rinse bottles will have the same external appearance, being plastic bottles with integrated spray atomizer and protective plastic cap. Each bottle will have a unique folio for identification printed on the identification label.~The clinical staff working in the Hospital and having contact with the study subjects will be blinded at all times to the care group assigned to the patient.~Academic staff working outside the Hospital and will not have direct contact with the study subjects, will not be blinded to the assigned group, in order to administer a second bottle of treatment if necessary."|"Randomly asignated to one of two parallel groups of mouth-rinse treatments:~1. Mouth-rinse with 0.12% clorhexidine + tooth brushing twice daily~2. Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate + tooth brushing twice daily"|t|t|f|f
34073693|NCT04000126|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34073694|NCT01853787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34073695|NCT02035553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073696|NCT00807885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073697|NCT01679392|NA|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34073698|NCT05341050|||COHORT||PROSPECTIVE|||||||
34073699|NCT01242540|||CASE_ONLY||CROSS_SECTIONAL|||||||
34073700|NCT04457700|||COHORT||PROSPECTIVE|||||||
34073701|NCT03311841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073702|NCT00100347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073703|NCT00883415|||CASE_CROSSOVER||PROSPECTIVE|||||||
34073704|NCT02251821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073705|NCT04280159|||COHORT||PROSPECTIVE|||||||
34073706|NCT00193583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073707|NCT03681899|||COHORT||PROSPECTIVE|||||||
34073708|NCT03635827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073709|NCT03132415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34073710|NCT06128720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888845|NCT05987748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888846|NCT01527526|||CASE_CONTROL||PROSPECTIVE|||||||
33888847|NCT03591900|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33888848|NCT04727541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888849|NCT05513443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888850|NCT03446495|||OTHER||PROSPECTIVE|||||||
33888851|NCT02235649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888852|NCT00863551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888853|NCT01724957|||COHORT||PROSPECTIVE|||||||
33888854|NCT04232657|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and study investigators / team members will be blinded to the treatment group assignment. The designated study drug administrator will be the only individual unblinded. This individual will administer the drug/placebo saline injections behind a sheet.|Randomized, double-blind, placebo-controlled, parallel group clinical trial|t|f|t|t
33888855|NCT02598830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888856|NCT02582658|||COHORT||PROSPECTIVE|||||||
33888857|NCT03638492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975108|NCT06483659|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization of the study medication will be performed by the investigational drug pharmacy and the unblinded key will be stored in a secure location in the pharmacy.|152 study subjects who are having minimally invasive abdominal hysterectomy will be randomized into one of two treatment groups, the first group will receive Oxytocin I.V. infusion and the second group will receive Saline infusion, and both groups will be followed up with surveys for up to 3 months after surgery.|t|t|t|t
33975109|NCT02974972|||COHORT||PROSPECTIVE|||||||
34073711|NCT05028816|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Randomization will be unknown to PI and additional care providers until an envelope is opened by research staff at the time of final layer closure in the OR.|Randomization will occur after all the portions of the surgical procedure are completed except for final skin layer closure.|t|t|t|t
34073712|NCT05485480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the investigator carrying out the nociception level measurement and the postoperative assessments will be blinded to the type of anaesthesia protocol that the patient is allocated to.|Double blind, randomised controlled non-inferiority trial|t|f|t|f
33888858|NCT04975802|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33888859|NCT01511445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888860|NCT06501846|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomised Controlled Trial||||
33888861|NCT02937805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888862|NCT05426200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33888863|NCT03335540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888864|NCT04461821|||COHORT||PROSPECTIVE|||||||
33888865|NCT06461598|||COHORT||PROSPECTIVE|||||||
33888866|NCT05868785|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover pilot study||||
33975110|NCT04132661|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The study is a double blind study with a randomization ratio 1:1. The subjects, the investigator and the Sanofi team will be blinded to the treatment sequences allocation until the database lock. The medicinal product and placebo are indistinguishable using exactly the same packing and form.|Phase IV, single center, double blind, randomized (1:1 ratio), two arms (bisacodyl and placebo), single-dose, and crossover clinical trial.|t|f|t|t
34073713|NCT00812032|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33888867|NCT02649101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888868|NCT01241500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975111|NCT03650582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-blinded study with participant blinded to treatment|Participants receive either glucagon or placebo as intranasal spray, in random order on 2 separate study visits, with indirect calorimetry, appetite and food intake assessment|t|f|f|f
33975112|NCT01543100|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975113|NCT02934750|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33975114|NCT02984306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33975115|NCT03389386|||CASE_CONTROL||PROSPECTIVE|||||||
33975116|NCT01197313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975117|NCT00322400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975118|NCT04805684|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The investigator was unaware of patient information such as medical history, PCR (polymerase chain reaction) test result, laboratory measurements, and CT scan results||f|f|t|f
33975119|NCT00948311|||COHORT||PROSPECTIVE|||||||
33975120|NCT00231868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975121|NCT03997747|||COHORT||PROSPECTIVE|||||||
33975122|NCT01055964|RANDOMIZED|CROSSOVER||||NONE||||||
33975123|NCT05787756|||CASE_CONTROL||PROSPECTIVE|||||||
33975124|NCT05299268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Assessor and participants will be blinded to the order of injections.|This study is a 2-arm randomized controlled cross-over trial with 1-7 days between arms|t|f|t|f
33975125|NCT02022007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33975126|NCT06227065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase II, all 28 patients will follow the same treatment. Only, selection of the use drug is performed using drug screens in patient derived organoids and is specific for each patient||||
33975127|NCT01104519|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34073714|NCT01827735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975128|NCT06543706|||COHORT||RETROSPECTIVE|||||||
33975129|NCT02033525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975130|NCT04931329|||COHORT||PROSPECTIVE|||||||
33975131|NCT03632174|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Comparison of two cosmetic products|t|f|t|f
33888869|NCT01881646|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888870|NCT00854269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33888871|NCT00589641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888872|NCT02285179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded study||t|t|t|f
33888873|NCT06325514|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33888874|NCT04268030|||CASE_ONLY||CROSS_SECTIONAL|||||||
33888875|NCT04265664|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group, pre-post study design||||
33888876|NCT03018132|NA|SINGLE_GROUP||SCREENING||NONE||||||
33888877|NCT03619213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||International, Double-blind, Randomised, Placebo-Controlled|t|t|t|t
33888878|NCT04553237|||COHORT||RETROSPECTIVE|||||||
33975132|NCT03631524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Block Randomisation, Initial and final outcome assessors blinded to treatment arm|Two arm single blinded RCT|f|f|f|t
33975133|NCT04044430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888879|NCT04925960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients and all study personnel will remain blinded to the original treatment assignment until study close.|Subjects will be randomized to treatment or placebo. Patients and study staff will be blinded to the study arm.|t|t|t|t
33888880|NCT02836561|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975134|NCT04670913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888881|NCT01316042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888882|NCT05789992|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888883|NCT04824378|||COHORT||RETROSPECTIVE|||||||
33975135|NCT00999869|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33975136|NCT04049331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975137|NCT00203879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975138|NCT00645489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33975139|NCT04871737|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Patients will be assigned in the order they enter the study into nine treatment groups according to dose and route of administration.||||
33975140|NCT01604213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975141|NCT04546607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and Investigator Blinded|Randomized, Parallel Group, Placebo Controlled Trial. the study was intervention type, in which different cancer patients were administered with relevant chemotherapeutic drugs + Nuvastatic. The drug-type of Nuvastatic is a botanical drug which was used as chemo-adjuvant.|t|f|t|f
33975142|NCT01684410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975143|NCT05496075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975144|NCT04236765|NA|SINGLE_GROUP||SCREENING||NONE||||||
33975145|NCT03791450|||COHORT||RETROSPECTIVE|||||||
33975146|NCT00788190|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33975147|NCT02867904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975148|NCT00163384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33975149|NCT05783479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of endpoints in three study arms: i) estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure, ii) hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure, iii) no treatment (control).||||
33975150|NCT05751070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975151|NCT03093454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized study with control group and test group. Using a 1:1 treatment allocation ratio, the total of 60 patients (30 per arm) will be randomly assigned to control or treatment arm. The Statistical Investigator will generate the randomization scheme and monitor the randomization process over the course of the trial. The study will use randomization with random permuted blocks. The test group will receive 50% lavender oil diluted in fractionated coconut oil and the control group will have the current standard of care with no essential oil intervention. Fractionated coconut oil is being used because it is colorless, odorless, does not stain clothing, and has a long shelf life. It also serves as a carrier oil for the essential oil to absorb into the skin instead of evaporating off the skin due to essential oils volatile nature.||||
33888884|NCT00105872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33888885|NCT06356792|||COHORT||OTHER|||||||
33888886|NCT02224235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888887|NCT02274688|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Patient-centered care transition intervention|f|f|f|t
34152308|NCT05233345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Investigator)|This prospective studies that measure the effectiveness of occupational therapy intervention. Randomized controlled trials (RCT) are prospective studies that measure the effectiveness of a new intervention or treatment. Participants are recruited and randomly assigned to either the intervention or the comparator group. It is important to ensure that at the time of recruitment there is no knowledge of which group the participant will be allocated to; this is known as concealment. It is examined whether there is any difference in the results of the study intervention and also the intervention and control group are compared.|f|f|t|f
33888888|NCT06481137|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33888889|NCT04030078|||OTHER||CROSS_SECTIONAL|||||||
33888890|NCT04004949|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33888891|NCT01592487|||COHORT||PROSPECTIVE|||||||
33888892|NCT02203149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888893|NCT04019262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888894|NCT01830426|||CASE_CONTROL||PROSPECTIVE|||||||
33888895|NCT01736956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888896|NCT04222283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888897|NCT03437447|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33888898|NCT01245647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975152|NCT03734237|RANDOMIZED|PARALLEL||PREVENTION||NONE||A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019,2019-2020, 2020-2021, and 2021-2022).||||
33975153|NCT01398579|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33975154|NCT00257296|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33975155|NCT01948505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888899|NCT01793103|||COHORT||PROSPECTIVE|||||||
33888900|NCT02910427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33888901|NCT01070329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888902|NCT02351232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975156|NCT01455558||CROSSOVER||TREATMENT||NONE||||||
33975157|NCT03316313|||COHORT||RETROSPECTIVE|||||||
33888903|NCT05947721|||COHORT||CROSS_SECTIONAL|||||||
33888904|NCT02303925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888905|NCT06314724|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975158|NCT05549284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975159|NCT05265195|||OTHER||OTHER|||||||
33975160|NCT05289622|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective, Single Arm Safety and Efficacy Study to evaluate the expandable polyurethane valve in the pulmonary position, in 5 patients over 18 years of age, with pulmonary valve dysfunction and moderate to severe impairment of cardiac ventricular function.||||
33975161|NCT05558774|||COHORT||CROSS_SECTIONAL|||||||
33975162|NCT01009398|||CASE_ONLY||PROSPECTIVE|||||||
33975163|NCT01079611|||COHORT||PROSPECTIVE|||||||
33975164|NCT04954950|||OTHER||CROSS_SECTIONAL|||||||
33888906|NCT02459379|||CASE_ONLY||PROSPECTIVE|||||||
33888907|NCT00838357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888908|NCT01705626|||COHORT||PROSPECTIVE|||||||
33888909|NCT04091893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Due to covid the in-person RCT was suspended and transitioned to virtual museum programming. Twenty-seven individuals were randomized into the in-person study and 122 individuals were randomized into the virtual study for a total of 149 enrolled individuals.|f|f|t|f
33975165|NCT05575375|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34152309|NCT00417430|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33888910|NCT01762514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33888911|NCT06032221|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The purpose of the study is to determine if the Thermidas camera with telemedicine app is a feasible device in the 2 patient cohorts (15 patients who have had previous diabetes foot ulceration and 15 patients who are deemed to be high risk of foot ulceration)||||
33888912|NCT00898092|||CASE_ONLY||RETROSPECTIVE|||||||
33888913|NCT00612599|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33888914|NCT05133830|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms will be evaluated in parallel in Part A. After Part A, if Part B is conducted, one of the two remaining arms will be evaluated.||||
33888915|NCT05947240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group A will be training group and group B will be control group. Deep breathing exercises will be done as baseline treatment in both groups. Both groups will be assessed with Modified Borg scale, 6-PBRT and Fatigue severity scale at the baseline. The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute.~Intervention will be for 3 times a week or 6 weeks"|t|f|f|f
33975166|NCT02363309|||CASE_CONTROL||PROSPECTIVE|||||||
33975167|NCT04812106|||COHORT||PROSPECTIVE|||||||
33975168|NCT04776460|||OTHER||CROSS_SECTIONAL|||||||
33975169|NCT00006166|RANDOMIZED|||TREATMENT||NONE||||||
33975170|NCT04621409|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Day A and B will be conducted in a randomised, double-blinded order (blinded for the participant and the investigator) and noted by a third person not participating in the collection or analyses of data. The infusion order will be opened after the primary data analyses.|The study is designed as a clinical, placebo-controlled, double-blinded cross-over study involving two experimental study days.|t|f|t|f
33975171|NCT01968798|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975172|NCT01189825|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975173|NCT03376594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Grouping uses Randomize controlled trial (RCT) and groups by using Random allocation by means of Simple Randomization as well as using the code with BJK followed by 3 digits (BJK001, BJK002, ...) and treating in double blinding form.|RCT|t|f|t|f
33888916|NCT03835650|||COHORT||PROSPECTIVE|||||||
33975174|NCT06424847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975175|NCT03400306|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975176|NCT01482624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888917|NCT05877131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975177|NCT00265304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33975178|NCT00729859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33975179|NCT00657956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975180|NCT05006937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975181|NCT04262596|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33975182|NCT06483607|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34073715|NCT05335655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Each patient is assigned to one of the two treatment groups (A of B) according to a computer-generated chart of random numbers. Under standard preanesthetic procedures (non-invasive monitoring, premedication), we blindly administer an IV bolus of dexmedetomidine tittered to 0.5mcg per kilogram (real weight), diluted in 10 ml of 0.9% saline solution during 15 minutes before the spinal block. Once the anesthetic effect is confirmed, we begin a maintenance IV infusion for group A, based on dexmedetomidine 100 mcg diluted in 100 ml of 0.9% saline solution tittered at 0.5 mcg per kilogram per hour (real weight). On the other hand, for group B, we administer the same volume (10 ml) of IV 0.9% saline solution for the initial bolus, and for the maintenance infusion we keep equivalent organoleptic characteristics of simple intravenous 0.9% saline solution as well.||t|t|f|t
34073716|NCT06612957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073717|NCT06055218|||OTHER||PROSPECTIVE|||||||
34073718|NCT03298997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding will exist at the level of the patient and the investigator who will record the data postoperatively, regarding the surgical technique applied. There will be no blinding at the level of the surgeon and the anesthesiologist.||t|f|t|t
34073719|NCT00108290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888918|NCT03286972|||CASE_ONLY||PROSPECTIVE|||||||
33888919|NCT02321592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888920|NCT03931018|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Simple Blind|Two groups (one receiving 70 g and other receiving 100 g)|t|f|f|f
33888921|NCT00542191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888922|NCT00937222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975183|NCT01927536|||COHORT||PROSPECTIVE|||||||
33975184|NCT02275923|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888923|NCT01371630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888924|NCT02343692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888925|NCT03706586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|outcome assessed will be unaware of group allocation||f|f|f|t
33888926|NCT00331435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975185|NCT05309096|||OTHER||OTHER|||||||
33975186|NCT05625256|||COHORT||PROSPECTIVE|||||||
33975187|NCT01843283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33975188|NCT01054599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975189|NCT04185558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975190|NCT03845556|||CASE_ONLY||PROSPECTIVE|||||||
33888927|NCT02633540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888928|NCT01332448|||OTHER||RETROSPECTIVE|||||||
33888929|NCT03462251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975191|NCT04954014|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II, multi-centered, randomized, open label, two-armed clinical trial to study the safety and efficacy of bevacizumab in COVID-19 positive patients who consequently developed ARDS (acute respiratory distress syndrome) and who have previously received anti-viral and anti-inflammatory treatment.||||
33975192|NCT02197533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975193|NCT00521456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975194|NCT04395365|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33888930|NCT05522426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888931|NCT02954380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33888932|NCT04416022|||COHORT||PROSPECTIVE|||||||
33888933|NCT03561402|||CASE_CONTROL||PROSPECTIVE|||||||
33888934|NCT06251011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33888935|NCT04876547|||COHORT||RETROSPECTIVE|||||||
34073720|NCT03938363|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762275|NCT06625970|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Patients will be randomized (1:1:1:1) to receive either:~* Arm A (Standard arm): ADT + conventional fractionated or moderately hypo-fractionated prostate radiotherapy including pelvic nodal radiotherapy~* Arm B (Experimental arm): ADT + conventional fractionated or moderately hypo-fractionated prostate radiotherapy including pelvic nodal radiotherapy + darolutamide~* Arm C (Experimental arm): ADT + conventional fractionated or moderately hypo-fractionated pelvic nodal radiotherapy + Prostate SBRT~* Arm D (Experimental arm): ADT + conventional fractionated or moderately hypo-fractionated pelvic nodal radiotherapy + Prostate SBRT + darolutamide~Patients will be stratified according to the number of risk factors (2 vs. 3) and the presence of a dominant intraprostatic lesion prostate imaging-reporting and data system (PI-RADS) 5 (yes vs no) and investigational site."||||
33762276|NCT00378443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762277|NCT06029894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Citicoline and placebo treatment will be blinded. The study treatment will be labeled using a unique Kit ID number that is linked to a randomization scheme. The active and placebo tablets will be identical and presented in the same packaging to ensure the blinding of the study medication.||t|f|t|f
33762278|NCT04034394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to the group allocation.||f|f|f|t
33762279|NCT05613114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33762280|NCT00800280|RANDOMIZED|CROSSOVER||||NONE||||||
33762281|NCT05430971|||CASE_ONLY||OTHER|||||||
33762282|NCT02357004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762283|NCT03113084|RANDOMIZED|CROSSOVER||OTHER||NONE||Hospitalizations for administration of study medications will occur in two periods (visits 1 and 2) for administration of the drugs, and participants who receive the test medication at visit 1 will receive the comparator medication at Visit 2 and vice versa.||||
33762284|NCT04410289|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33762285|NCT03893201|||COHORT||PROSPECTIVE|||||||
33762286|NCT03983122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762287|NCT03629652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762288|NCT05673876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762289|NCT04597710|||COHORT||PROSPECTIVE|||||||
33762290|NCT03874845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician will not know the group assignment until blind is broken. Statistician randomizes the groups. Principal investigator will not know group assignment until blind is broken.|treatment groups will consist of a minimum of 4 participants (preferably 5-8). The statistician will randomize the groups once a sufficient number of participants have enrolled to ensure desired group size.|f|f|t|t
33762291|NCT05599802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762292|NCT04587128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is an open label phase 2 clinical trial with 3 independent study arms conducted through the University of Wisconsin Carbone Cancer Center||||
33762293|NCT03083535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762294|NCT00046501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762295|NCT00195026|||CASE_ONLY||PROSPECTIVE|||||||
33762296|NCT00738686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762297|NCT02246335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762298|NCT01622244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33762299|NCT05239988|||COHORT||RETROSPECTIVE|||||||
33762300|NCT05313386|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Randomized, double-blind, placebo-controlled|Cohorts will be enrolled sequentially in this dose escalating design.|t|t|t|t
33762301|NCT03033459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762302|NCT05856214|NA|SINGLE_GROUP||PREVENTION||NONE||Single group assignment: intervention group vs Control group||||
33762303|NCT06434792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762304|NCT00710632||||SUPPORTIVE_CARE||||||||
33762305|NCT00735501|||COHORT||PROSPECTIVE|||||||
33762306|NCT00840801|RANDOMIZED|||PREVENTION||SINGLE|||t|f|f|f
33762307|NCT00000379|RANDOMIZED|||TREATMENT||||||||
33888936|NCT02237690|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888937|NCT01097928|||OTHER||PROSPECTIVE|||||||
33975195|NCT00046709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975196|NCT05073653|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975197|NCT04538963|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Outcomes assessor (individual assessing radiographs for evidence of carious lesion progression or stabilization) will be masked. Due to the nature of the intervention (orthodontic band placement), the participant and care providers will not be able to be masked.|Split-mouth design- individual patient has a pair of carious lesions; one will receive the intervention, the other will be monitored per standard of care.|f|f|f|t
33975198|NCT00815451|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33975199|NCT01325675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33975200|NCT04258670|||COHORT||PROSPECTIVE|||||||
33975201|NCT03996486||SEQUENTIAL||OTHER||NONE||||||
33975202|NCT00544765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975203|NCT01689259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975204|NCT01717378|||COHORT||PROSPECTIVE|||||||
33762308|NCT03540875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762309|NCT05762848|||COHORT||PROSPECTIVE|||||||
33762310|NCT03262558|||COHORT||PROSPECTIVE|||||||
33762311|NCT01487876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762312|NCT04822844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33762313|NCT02666287|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762314|NCT01879592|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33762315|NCT02087436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762316|NCT06009601|||OTHER||PROSPECTIVE|||||||
33762317|NCT02042079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762318|NCT04975633|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33762319|NCT03140501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Since it is not possible to blind the participants or the interventionists, a single blind study design will be employed in which data collectors are blinded to participants' group allocation.|Mixed-methods, rater-blinded, randomized controlled trial with a stepped wedge design (i.e., delayed intervention control group). The qualitative portion will consist of semi-structured interviews with a sub-sample of the participants.|f|f|f|t
33762320|NCT03547492|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Random assignment to language (intervention) or motor (control) focused curriculums||||
33762321|NCT02340923|||COHORT||CROSS_SECTIONAL|||||||
33762322|NCT02503683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762323|NCT03692338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be assigned to one of three cohorts: Supervised exercise, semi-supervised exercise or usual care.||||
33762324|NCT05968768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762325|NCT06267456|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||handball, volleyball and basketball players 18-30 years Someone who has been participating in sports for at least three years and trains at least three times a week||||
33762326|NCT01885728|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762327|NCT03761082|||COHORT||PROSPECTIVE|||||||
33762328|NCT03315130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762329|NCT06161311|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33762330|NCT00671957|||CASE_ONLY||PROSPECTIVE|||||||
33762331|NCT03842839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762332|NCT06407076|||COHORT||CROSS_SECTIONAL|||||||
33762333|NCT06624553|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Open and exploratory parallel randomized single-center clinical trial in a 1:1 ratio of three months duration. A computerized randomization by blocks of 10 without blinding will be performed.||||
33762334|NCT04709432|||OTHER||CROSS_SECTIONAL|||||||
33888938|NCT05105763|RANDOMIZED|SEQUENTIAL||OTHER||NONE||A counterbalanced repeated measures design will be used in this study to examine the adaptation of children and young adults with brain injury who have SKG to two types of feedback training: feedback training on the knee alone (Condition B) and sequential switched feedback training on the knee and the hip (Condition A). The participants will participate in treadmill training twice with a 2-weeks washout period between the two visits and will receive the two training conditions in different orders. Ten participants will be alternately allocated to two subgroups according to the sequence they are recruited to the study. In the end, the investigators will have five participants in Subgroup 1 and the other five participants in Subgroup 2. Participants in Subgroup 1 will first undergo Condition B in the first visit and then Condition A in the second visit, while participants in Subgroup 2 will start with Condition A in the first visit and then undergo Condition B in the second visit.||||
33888939|NCT03580330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study reports on a community trial in which PHC centers, along their respective catchment areas, were randomly allocated into control and intervention sites with the aim of assessing the change in selected NCD care quality indicators (QIs) among community individuals and patients. Patients in the intervention sites received a 1-year mHealth intervention, and their pre- and postintervention outcomes were assessed through measurement of QIs. Patients in the control sites received no intervention.||||
33888940|NCT06503770|||OTHER||RETROSPECTIVE|||||||
33888941|NCT02236169|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33888942|NCT03878485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888943|NCT05647330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888944|NCT01580930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888945|NCT03389945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34073721|NCT02413632|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34073722|NCT02187237|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34073723|NCT01216501|||COHORT||PROSPECTIVE|||||||
34073724|NCT04069728|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective randomised pilot study||||
34073725|NCT01955239|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34073726|NCT05609214|||COHORT||PROSPECTIVE|||||||
33762335|NCT04945421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762336|NCT03244150|||COHORT||PROSPECTIVE|||||||
33888946|NCT00408863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33888947|NCT00799526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33888948|NCT04426305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33888949|NCT01126580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33888950|NCT04349137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34073727|NCT00443157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33888951|NCT06322082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33888952|NCT01453881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33888953|NCT00003400||||TREATMENT||||||||
33888954|NCT04474327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888955|NCT04022564|||COHORT||RETROSPECTIVE|||||||
33888956|NCT05896007|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33975205|NCT00049036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975206|NCT03680170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|At the pre and first post test the person performing the testing is blinded to which group the participant is allocated to. The participant is blinded to which intervention he/she is participating in. At the second post-test the research assistant know which training the participant has been allocated to. Person performing the statistical analysis will be blinded to study group allocation.|Two parallel assigned intervention groups with randomized allocation.The intervention of focus is a web-based working memory updating training. The placebo condition consists of a web-based low dose short term memory training. Both groups received pretesting (pre-test) before 30 sessions (6-8 weeks) of training followed by immediate post-testing (post-test 1) and a long term follow up four months after training (post-test 2)|t|f|t|t
33975207|NCT00152165|||||PROSPECTIVE|||||||
34073728|NCT03143777|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073729|NCT01719991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073730|NCT05765669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073731|NCT01137097|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073732|NCT03758768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A third-party investigator is recruited to be present during the intervention. This third-party investigator has no knowledge of the hypotheses of the study.~Although the participants can see the type of light they receive, they have no knowledge of the study hypotheses."|Randomized, controlled, single-blinded trial.|t|f|t|f
34073733|NCT03101384|||COHORT||PROSPECTIVE|||||||
34073734|NCT02426008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34073735|NCT01347593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073736|NCT00006929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073737|NCT04504565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073738|NCT05946915|||COHORT||PROSPECTIVE|||||||
34073739|NCT00680849|||COHORT||PROSPECTIVE|||||||
34073740|NCT03610334|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Capsules used for verum or placebo (Size 5 white opaque HPMC capsule) are identical and equally-weighted|double-blind, randomized, placebo-controlled, combined single and multiple ascending dose of IFB-088 by successive cohorts study|t|t|t|t
34073741|NCT04547140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073742|NCT03576638|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34073743|NCT01149031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073744|NCT00110357|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073745|NCT05386290|||COHORT||PROSPECTIVE|||||||
34073746|NCT00065273|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34073747|NCT04370067|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34073748|NCT00233584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073749|NCT02252107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073750|NCT00985972|||||RETROSPECTIVE|||||||
34073751|NCT00254423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073752|NCT06183437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762337|NCT04556994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762338|NCT00767923|||COHORT||PROSPECTIVE|||||||
33762339|NCT03566459|||CASE_ONLY||PROSPECTIVE|||||||
33762340|NCT05302505|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975208|NCT04523649|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Independent research officers and data staff responsible for data entry will be blinded from randomization assignment.|Prospective, multi-centered, randomized controlled, parallel-group study|f|f|f|t
33975209|NCT05918523|||COHORT||PROSPECTIVE|||||||
33975210|NCT01768728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975211|NCT03777670|||CASE_CONTROL||PROSPECTIVE|||||||
33975212|NCT01027442|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33975213|NCT06544837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33975214|NCT03217279|||COHORT||PROSPECTIVE|||||||
33975215|NCT02201498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975216|NCT04891588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975217|NCT00017784||||TREATMENT||||||||
33975218|NCT00897897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975219|NCT03248479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975220|NCT04713696|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33975221|NCT05819008|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33975222|NCT05749718|||CASE_ONLY||PROSPECTIVE|||||||
33975223|NCT04852536|||COHORT||RETROSPECTIVE|||||||
33975224|NCT05342350|||COHORT||PROSPECTIVE|||||||
33975225|NCT05698381|RANDOMIZED|PARALLEL||OTHER||SINGLE|liquid vinegar (contains active dose of acetic acid) vinegar pill (contains only a trace of acetic acid)|Randomized controlled trial|t|f|f|f
34073753|NCT03075189|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Two of the study officials will be masked and therefore responsible for testing the participants at baseline, at discharge and follow-up - and in charge of data processing.~Contrary to the masked officials two non-masked officials are responsible for randomization, serving of meals, diet registration and dietary counseling."|Inclusion and testing of intervention and control group is carried out at the same time|f|f|t|t
34073754|NCT00419042|||CASE_ONLY||PROSPECTIVE|||||||
34073755|NCT05841797|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and care providers will not be blinded to study arm, however investigators and analyst will be.|The investigators will conduct a pilot hybrid type 2 effectiveness-implementation trial in which pregnant women at higher risk for missed visits and treatment failure are randomized to one of three study arms 1:1:1 standard of care, mHealth PM+, or in-person PM+ and followed through 6 months postpartum. Feasibility, acceptability, intervention satisfaction, and preliminary efficacy on mental health and HIV outcomes (combined outcome of continuous viral suppression and engagement in care) will be assessed.|f|f|t|t
33762341|NCT01475695|NA|SINGLE_GROUP||OTHER||NONE||||||
33762342|NCT02098018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762343|NCT04598035|||COHORT||PROSPECTIVE|||||||
33762344|NCT02939300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762345|NCT04323982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762346|NCT02788630|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33762347|NCT01539876|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762348|NCT04490564|||OTHER||PROSPECTIVE|||||||
33762349|NCT05889884|NA|SINGLE_GROUP||OTHER||NONE||single arm prospect cohort study||||
33762350|NCT05341986|RANDOMIZED|PARALLEL||OTHER||NONE||Using a convergent parallel quantitative-qualitative design (mixed-methods), we propose a stepped-wedge cluster randomized trial design with the implementation of an electronic health record (EHR) clinical decision support (CDS) tool in adults with new-onset AF that are OAC-naïve and at significant risk for stroke, in three ED settings with different practice patterns and culture, patient populations, and organizational readiness. In parallel, we will use qualitative approaches to evaluate clinician facilitators and barriers to tool utilization as well as patient satisfaction and engagement with the tool.||||
33975226|NCT01519609|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33975227|NCT02564913|||CASE_CONTROL||PROSPECTIVE|||||||
33975228|NCT06075654|||OTHER||CROSS_SECTIONAL|||||||
33975229|NCT04055363|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975230|NCT01820377|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33888957|NCT06064760|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Quantitative, observational and longitudinal study with three measurements (pre-intervention, post-intervention and monitoring).~The measurements will be taken before the intervention, at the end of the intervention and at three months."||||
33888958|NCT02347631|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33888959|NCT02038348|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33888960|NCT02755402|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33888961|NCT02200484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33888962|NCT01054066|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33888963|NCT03377647|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33888964|NCT04703023|||COHORT||PROSPECTIVE|||||||
33888965|NCT02281890|||COHORT||PROSPECTIVE|||||||
33888966|NCT04508907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073756|NCT00059410|||||PROSPECTIVE|||||||
33888967|NCT05527990|||OTHER||PROSPECTIVE|||||||
33888968|NCT01135732|||CASE_CONTROL||PROSPECTIVE|||||||
33888969|NCT01321489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888970|NCT04323930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888971|NCT04497519|NA|SINGLE_GROUP||TREATMENT||NONE||Healthy volunteers||||
33888972|NCT06355882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33888973|NCT03791632|RANDOMIZED|PARALLEL||OTHER||SINGLE||"1. Test group~2. Classes with a classical lecture style presentation~3. classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)~4. classes with digital media intervention"|t|f|f|f
33888974|NCT03052647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|computer randomized list of closure type opened from a sealed envelope on the day of surgery|"A control group of subcuticular closure and the experimental group is skin closure withthe adhesive latch device (dermaclip)"|t|f|t|f
33888975|NCT03821584|||OTHER||PROSPECTIVE|||||||
33888976|NCT00260585|||OTHER||PROSPECTIVE|||||||
33888977|NCT03211182|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33888978|NCT02939131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888979|NCT00006449|RANDOMIZED|||TREATMENT||DOUBLE||||||
33888980|NCT01488006|||COHORT||PROSPECTIVE|||||||
33888981|NCT05786963|||COHORT||CROSS_SECTIONAL|||||||
33888982|NCT00054132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888983|NCT03521791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The double-blind study is a procedure in which the subject and the principal investigator do not know which of the intervention groups was assigned to the subject of the study. To achieve the blinding of the drug, both the investigational drug and the placebo, will be packed in the same bottle, containing the same legends on the label. The blinding codes are protected by a person outside the study designated by the sponsor. The codes are also available in the research center (fully sealed), so that they can be consulted by the Investigator in the event that the subject presents a serious adverse event, prior authorization of the study sponsor, as well as strict continuous blindness during the analysis of data.|A controlled, randomized, double-blind, masked clinical trial comparing the safety and efficacy of PRO-155 in the treatment of conjunctival hyperemia in pterygium I to III compared to placebo.|t|f|t|t
33888984|NCT05114772|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33888985|NCT03489330|||COHORT||RETROSPECTIVE|||||||
33888986|NCT01369940|||COHORT||PROSPECTIVE|||||||
33888987|NCT00360347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888988|NCT01543620|||CASE_CONTROL||PROSPECTIVE|||||||
33888989|NCT00862251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33888990|NCT02155400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34073757|NCT05355909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, randomised, single blinded (patient-blinded) with two study groups|t|f|f|f
33888991|NCT02295722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33888992|NCT02953041|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33888993|NCT02684305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888994|NCT04550182|RANDOMIZED|PARALLEL||PREVENTION||NONE||To assess efficacy of a positioning schedule whose frequency of positioning is adapted every day to pressure ulcer risk assessed by Braden scale on the occurrence of pressure ulcer in adult ICUs, in comparison with the routine patients' management (without positioning schedule adapted on PU risk) at the 28th day, or when leaving ICU, or at death if it occurs before.||||
33888995|NCT01848275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888996|NCT01483677|RANDOMIZED|PARALLEL||||NONE||||||
33888997|NCT05651945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33888998|NCT05312957|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group ESP;The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process T5 transverse process is detected. When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed. Then, 20 ml of 0.25% bupivacaine was administered to this area, and an ESP block was applied Group Control : no intervention||||
33888999|NCT00923637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889000|NCT01883505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889001|NCT00241748|||CASE_CONTROL||RETROSPECTIVE|||||||
33889002|NCT05415748|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33889003|NCT01993888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889004|NCT06057311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33889005|NCT05192343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized controlled study was conducted at Ondokuz Mayis University Training and Research Hospital, Obstetrics and Gynecology polyclinic between February 2022 and August 2022. The CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting randomised controlled trials (RCTs) has been used to describe the methods.||||
33889006|NCT04574726|RANDOMIZED|CROSSOVER||SCREENING||NONE||Prospective, multicenter, controlled, randomized, intervention study with minimal risks and constraints (RIPH2) on healthy volunteers.||||
33889007|NCT02512458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889008|NCT01535235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889009|NCT06002464|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single center, open label, prospective randomized controlled trial||||
33889010|NCT01523483|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889011|NCT04023084|NA|SINGLE_GROUP||OTHER||NONE||children diagnosed with AD and aged 4 months-17 years old will receive intervention||||
33889012|NCT02613208|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889013|NCT05158894|||COHORT||PROSPECTIVE|||||||
33889014|NCT04899635|||COHORT||PROSPECTIVE|||||||
33975231|NCT05655936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and Investigators will be blinded until randomization assignment is executed.|The investigators will conduct a prospective single site, single-blinded, parallel randomized control trial in which women diagnosed with HDP will be randomized into either the control or intervention group. The investigators will randomize 454 women into usual care, or an 8-12-week heart health intervention program provided by a postpartum Doula. Randomization will be stratified by race to achieve over enrollment of Black and African American participants.|t|f|f|f
33975232|NCT04481971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33975233|NCT05518942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975234|NCT04790305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975235|NCT02229890|||COHORT||PROSPECTIVE|||||||
33975236|NCT01489722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975237|NCT01566409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975238|NCT04489407|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Subjects enrolled in the study will be undergoing vital sign monitoring with the rPPG vital sign monitoring app and the conventional vital sign monitor. Readings with each vital sign monitoring technology will be taken simultaneously on all enrolled subjects.||||
33975239|NCT04840979|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33975240|NCT01781039|||COHORT||CROSS_SECTIONAL|||||||
33975241|NCT05572411|||CASE_CONTROL||PROSPECTIVE|||||||
33975242|NCT03845933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The second endoscopist will perform tandem right colon examination and is blinded to the insertion method used by the first endoscopist.||f|f|f|t
33975243|NCT00138385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975244|NCT00362986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33975245|NCT05067348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975246|NCT00894907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975247|NCT04511390|NA|SINGLE_GROUP||OTHER||NONE||||||
33889015|NCT02996877|||COHORT||PROSPECTIVE|||||||
33889016|NCT00820326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889017|NCT00166348|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889018|NCT01955616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889019|NCT00643240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889020|NCT00404521|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889021|NCT03047499|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889022|NCT05675449|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33889023|NCT06248957|||COHORT||PROSPECTIVE|||||||
33889024|NCT02563301|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33889025|NCT02407626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889026|NCT00945919|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975248|NCT03864588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975249|NCT01058421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975250|NCT04025619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 groups of participant, one of the group took the questionnaire then received the intervention for seven days, then took the same questionnaire again.~The other group took the physical examination and received the intervention immediately, then took the physical examination again when the intervention is on the treating area."||||
33975251|NCT04560764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975252|NCT02872649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975253|NCT03321058|||CASE_ONLY||CROSS_SECTIONAL|||||||
33889027|NCT03674021|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient, attending physicians, and study team will not be blinded. Outcomes will be assessed through tracing electronic records as well as telephone calls for those whose electronic records are unobtainable. The outcome assessors will be blinded and will follow a telephone script for follow-up.|This is a randomized controlled trial where subjects are stratified by gender and then randomized 1:1 to the intervention (CPC) or control arm (usual care).|f|f|f|t
33889028|NCT06110650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889029|NCT05833802|||COHORT||PROSPECTIVE|||||||
33889030|NCT02555163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889031|NCT02421250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889032|NCT02441361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889033|NCT04371796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889034|NCT05530057|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm A (Eribulin + SB3) Arm B (Eribulin monotherapy)||||
33889035|NCT00999830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889036|NCT06200350|RANDOMIZED|PARALLEL||OTHER||SINGLE|As this study needs a intervention different from the conventional, the blinding of the participants is imposible.|Control group will continue with the conventional training. Experimental group will carry out a tailored training based on the profile of each participant.|f|f|f|t
33889037|NCT06214988|RANDOMIZED|PARALLEL||TREATMENT||NONE||Observational trial with nested randomized trial||||
33889038|NCT01727089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889039|NCT02071238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33975254|NCT01936779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34073758|NCT03003702|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34152310|NCT01078168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152311|NCT01341028|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34152312|NCT05281055|||COHORT||PROSPECTIVE|||||||
34152313|NCT00695552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152314|NCT06206655|||COHORT||PROSPECTIVE|||||||
34152315|NCT01116973|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34152316|NCT01142427|||CASE_ONLY||PROSPECTIVE|||||||
34152317|NCT00911339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152318|NCT03543943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The posterior site of the achilles tendon region is covered by dark tape during the functional assesments.||f|f|f|t
34152319|NCT00653081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152320|NCT00651365|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152321|NCT05718960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152322|NCT04708860|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34152323|NCT03293758|||COHORT||PROSPECTIVE|||||||
34152324|NCT03180307|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34152325|NCT01702506|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34152326|NCT00169507|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152327|NCT03330470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34152328|NCT05817032|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152329|NCT01399710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152330|NCT00483795|RANDOMIZED|PARALLEL||||SINGLE||||||
34152331|NCT04472312|||COHORT||PROSPECTIVE|||||||
34152332|NCT01431963|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152333|NCT01108198|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34152334|NCT01735370|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152335|NCT04631965|||COHORT||PROSPECTIVE|||||||
34152336|NCT00988364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, placebo-controlled clinical trial with 4 arms|t|t|f|f
33889040|NCT05408611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Adolescents who agreed to participate in the study by signing the voluntary consent form after being informed about the study will be assigned to the study or placebo groups by matching the numbers on the envelope according to their school numbers. In the study, a researcher will determine the acupressure and placebo points to be applied in adolescents and this researcher will make the first cycle application. Therefore, the researcher cannot be blinded. However, the participants will practice and be blinded without knowing whether the points to be treated are the acupressure point or the placebo point. Thus, the research will be carried out as a single-blind randomized controlled trial. When the research is completed, the data of the control and study groups (coded as A or B) will be transferred to the computer environment by a researcher independent of the research, and the data will be analyzed by a statistician and the findings will be reported.|Prospective, parallel, two arm, randomized controlled clinical trial|t|f|f|f
33889041|NCT00120003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889042|NCT03018548|NA|SINGLE_GROUP||OTHER||NONE||||||
33889043|NCT05046756|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889044|NCT05360589|||CASE_CONTROL||PROSPECTIVE|||||||
33889045|NCT06316284|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33889046|NCT04492566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889047|NCT02480530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33889048|NCT06124989|||COHORT||PROSPECTIVE|||||||
33889049|NCT00430755|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33889050|NCT01639430|||COHORT||RETROSPECTIVE|||||||
33889051|NCT05491759|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33889052|NCT05961748|||COHORT||PROSPECTIVE|||||||
33889053|NCT05444712|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889054|NCT01009528|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889055|NCT00083161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889056|NCT00631631|||COHORT||PROSPECTIVE|||||||
33889057|NCT06329479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889058|NCT02913248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889059|NCT04675047|||COHORT||PROSPECTIVE|||||||
33889060|NCT04477226|||CASE_ONLY||PROSPECTIVE|||||||
33889061|NCT00670826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889062|NCT05332860|||COHORT||PROSPECTIVE|||||||
33889063|NCT02246972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975255|NCT03154658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized interventional prospective model to investigate effect of block placement in two treatment arms. Opioid consumption in the first 24 hours after the operation will be main outcome variable.|t|f|f|f
33975256|NCT02295709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975257|NCT05906082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889064|NCT03913663|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889065|NCT02747485|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889066|NCT05855733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889067|NCT06091722|||CASE_ONLY||CROSS_SECTIONAL|||||||
33889068|NCT03386292|||COHORT||CROSS_SECTIONAL|||||||
33975258|NCT04837053|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pragmatic Multicenter Cluster Randomized Controlled Trial with stepped wedged design||||
33975259|NCT04524299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975260|NCT00002175||||TREATMENT||||||||
34073759|NCT06266130|RANDOMIZED|PARALLEL||OTHER||NONE|Due to the nature of the devices, Investigator blinding is not feasible for the study.|There are two groups, treatment group (digital bonding) and control group (direct bonding). Subjects will be enrolled and randomized into treatment or control group at each orthodontic practice.||||
34073760|NCT06299449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34073761|NCT04712864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073762|NCT03099577|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34073763|NCT02749227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073764|NCT03176641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073765|NCT06473116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073766|NCT06611449|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
34073767|NCT01743846|||CASE_ONLY||PROSPECTIVE|||||||
33889069|NCT03289130|||CASE_ONLY||CROSS_SECTIONAL|||||||
33889070|NCT03509324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889071|NCT01495455|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889072|NCT05852639|||OTHER||CROSS_SECTIONAL|||||||
33889073|NCT01929083|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33889074|NCT00582894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889075|NCT02633449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889076|NCT01511484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889077|NCT00065026|NON_RANDOMIZED|||PREVENTION||NONE||||||
33975261|NCT04879810|RANDOMIZED|PARALLEL||TREATMENT||NONE||three Arms: 1. Ginger exosomes;2. Curcumin; 3. Ginger exosomes plus curcumin, Each PO daily times 28 days. All subjects will receive active treatment.||||
33975262|NCT02471066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975263|NCT06546189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073768|NCT03295734|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073769|NCT01572714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073770|NCT06611995|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073771|NCT04506931|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomized to one of three mobile phone survey modalities: 1) SMS; 2) IVR; 3) CATI.|f|f|f|t
34073772|NCT04553614|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073773|NCT03557918|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34073774|NCT01526564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073775|NCT02030964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073776|NCT03677739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34073777|NCT02763319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor: blinding on treatment group||f|f|f|t
33889078|NCT04531267|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33889079|NCT00358657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889080|NCT01486862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889081|NCT00157833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889082|NCT05726214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Due to the difficulties observed during the recruitment, an allocation based on participants' will was conducted to ensure attendance. Thus, participants were allocated by convenience into two groups|f|t|t|t
33889083|NCT01965249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889084|NCT00800215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889085|NCT00217633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889086|NCT04702958|||COHORT||PROSPECTIVE|||||||
33889087|NCT01042444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889088|NCT02763956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33889089|NCT06203301|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33889090|NCT02844127|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889091|NCT04186611|NA|SINGLE_GROUP||OTHER||NONE||||||
33889092|NCT06108102|||CASE_CONTROL||PROSPECTIVE|||||||
33889093|NCT00948740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889094|NCT02418130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889095|NCT00340301|||CASE_CONTROL||RETROSPECTIVE|||||||
33889096|NCT06543628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Separate the person responsible for randomization and assignment from the outcome assessor, ensure that the evaluator does not have access to information for the participant group, and assign a unique code to the participant, and the evaluator is only exposed to the code without knowing the specific intervention behind it.||f|f|f|t
33889097|NCT02663895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975264|NCT04127409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomisation and masking The randomisation schedule was computer generated. Separate sealed opaque envelopes were prepared for male and female participants. All investigators involved in participant recruitment, data collection and entry, sample collection, processing and analysis, will be masked to the randomisation groups until data entry is completed and the database is locked.|"This will be a controlled, double-blind randomized study. Using a 2X2 factorial design, 160 participants will be randomized to eat at least three portions/week of omega-3-PUFA enriched (or control) chicken-meat, and to eat at least three omega-3-PUFA enriched (or control) eggs/week, for 6 months.~Numbers in each treatment group are indicated below; Control chicken-meat \& Control Eggs (n=40) Control chicken-meat \& Omega-3 PUFA enriched Eggs (n=40) Omega-3 PUFA enriched chicken-meat \& Control Eggs (n=40) Omega-3 PUFA enriched chicken-meat \& Omega-3 PUFA enriched Eggs (n=40)"|t|f|t|t
33975265|NCT06413537|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
33889098|NCT02514759|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33889099|NCT01554657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889100|NCT03065179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889101|NCT01284790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889102|NCT04314050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33889103|NCT06183008|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||N-of-one trial, individual randomized, double-blind, and multiple crossover comparisons of an interventional treatment and placebo|t|t|t|t
33889104|NCT00619502|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889105|NCT00003200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889106|NCT01461681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33889107|NCT02224131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889108|NCT00442403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889109|NCT05765903|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a two-arm interventional study where participants will be randomized to receive either the Standard of Care or Enhanced Care treatment. Participants in the Standard of Care arm will receive the Transitional Care protocol most commonly used for patients at the University of Maryland Charles Regional Medical Center (UM CRMC). Participants in the Enhanced Care arm will receive the interventions in the Standard of Care arm plus the additional protocols unique to Enhanced Care arm (Social Determinants of Health Wheel assessment in the University of Maryland Medical System electronic medical record, coordination of home health services, and additional diagnosis education). These arms are designed to ensure that participants receive the same high quality of care that they would have received before the study while also focusing on some added interventions from the enhanced care arm to help determine if these additional interventions help improve patient outcomes.||||
33889110|NCT04113967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889111|NCT00340470||||TREATMENT||||||||
33975266|NCT06163703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33975267|NCT02328781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975268|NCT00004776|RANDOMIZED|||TREATMENT||DOUBLE||||||
33975269|NCT06412497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975270|NCT03493100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975271|NCT03752593|||COHORT||PROSPECTIVE|||||||
33975272|NCT04095299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975273|NCT04501471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and providers were not aware that the Fuel condition was considered an attention control||t|t|f|f
33975274|NCT03145532|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|tDCS will be blinded in that even children in the sham group will receive a low level of stimulation for a brief period.|Children will be randomized to receive either real or sham tDCS plus robotic training. Children in the sham group will be given the opportunity to repeat the protocol and receive real stimulation after they complete the sham protocol.|t|t|f|t
33975275|NCT01253720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975276|NCT00883025|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33975277|NCT02272868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975278|NCT02052609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975279|NCT00424489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975280|NCT01000896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975281|NCT00090038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975282|NCT02215642|||COHORT||PROSPECTIVE|||||||
33975283|NCT01073995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975284|NCT02584140|NA|SINGLE_GROUP||PREVENTION||NONE||All enrolled participants will receive daily oral emtricitabine/tenofovir disoproxil fumarate, adherence counseling, and daily text message reminders.||||
33762351|NCT04504695|||COHORT||PROSPECTIVE|||||||
33889112|NCT00728065|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33889113|NCT03009604|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975285|NCT00156949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975286|NCT04469738|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33975287|NCT02127996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889114|NCT03631927|||OTHER||CROSS_SECTIONAL|||||||
33889115|NCT01142414|RANDOMIZED|||TREATMENT||NONE||||||
33889116|NCT02646293|||COHORT||PROSPECTIVE|||||||
33889117|NCT05360550|NA|SINGLE_GROUP||PREVENTION||NONE||The study will consist of two subject cohorts; Cohort #1 will consist of a total of 16 healthy women aged 18-35 years with a BMI of ≥ 18 kg/m2 to ≤ 30 kg/m2, Cohort #2 will consist of up to 10 healthy women aged 18-35 years with a BMI of \> 30 kg/m2 to ≤ 35 kg/m2. The study will consist of 3 treatment cycles each consisting of a 26 day ring-insertion period followed by a 2-day ring-free period.||||
33889118|NCT02732067|||||PROSPECTIVE|||||||
33889119|NCT05373550|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|As blinding is a necessary condition in this type of study, the knowledge of the surveyors in the collection of the data, about the experimental group and comparison group will be safeguarded, for which the list of the participating women will be delivered in sealed envelopes and they will only know as group A and group B, both at the beginning and at the end of the study in the pre-test and post-test, with the aim of preventing certain biases in some of the stages of the study, reducing the possibility that the variables of results and their measurement are influenced by lack of blinding.|The design will be a sequential exploratory mixed design, which consists of an initial phase of qualitative data collection and analysis and a final phase where quantitative data are collected and analyzed. This mixed mixture allows for clear stages to be determined, with the data from one stage needing to be thoroughly analyzed before the other stage provides details about the intervention study model.||||
33889120|NCT01717534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33889121|NCT00714779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889122|NCT01572155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889123|NCT01352481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889124|NCT00712348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889125|NCT01656525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889126|NCT01157117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889127|NCT03316352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889128|NCT03288948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975288|NCT01369277|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33975289|NCT04665505|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single group data from the 6-month interventional period will be compared to data from the 3-month pre and post interventional periods.||||
33975290|NCT03775681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975291|NCT00234429|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33975292|NCT00519337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975293|NCT00003399||||TREATMENT||||||||
33975294|NCT01005836|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33975295|NCT04689074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33975296|NCT01495377|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34073778|NCT06185738|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"All participants will have a data collection session by phone lasting about 60 minutes, and to complete a demographic and health questionnaire, that includes questions such as sex, age, race, ethnicity, marital status, cancer type, time since diagnosis, date of diagnosis, stage of illness, type of primary treatment, type of disability, current activity level, health conditions, annual income, educational history.~WeCanManage (WCM) app orientation by Zoom lasting about 60 minutes. Participants will complete WCM app program, about 10 minutes per day for 30 days and up to 45 days. Data collection by phone lasting about 60 minutes after completion of WCM app program and 4 weeks after completion of WCM app program All participants will have an intervention of 4 modules (WeCanRelate, WeCanAdapt, WeCanBe, and WeCanSpeakUp) that are presented as series of micro-learning sessions"||||
34073779|NCT02420119|||COHORT||PROSPECTIVE|||||||
34073780|NCT01341899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073781|NCT06392152|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34073782|NCT00586248|||||PROSPECTIVE|||||||
33889129|NCT06544980|||CASE_ONLY||PROSPECTIVE|||||||
33889130|NCT01392183|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889131|NCT01583426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889132|NCT02407535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889133|NCT01893749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33889134|NCT00348166|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33889135|NCT06096792|||OTHER||PROSPECTIVE|||||||
33889136|NCT04801290|||COHORT||CROSS_SECTIONAL|||||||
33975297|NCT00767507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975298|NCT01904578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975299|NCT04000321|RANDOMIZED|PARALLEL||TREATMENT||NONE|The primary objective of the study is to compare the success rate of removing the placenta in retained placenta pregnencies between the Windmill technique and the control group. Based on this objective, we expected the difference of success rate between groups of 30% (from the previous study, the success rate of the Windmill technique was 86% . The sample size of 35 participants per group will be required to provide 90% power at a 0.05 two-sided significance level.|The primary objective of the study is to compare the success rate of removing the placenta in retained placenta pregnencies between the Windmill technique and the control group. Based on this objective, we expected the difference of success rate between groups of 30% (from the previous study, the success rate of the Windmill technique was 86%. The sample size of 35 participants per group will be required to provide 90% power at a 0.05 two-sided significance level.||||
33975300|NCT01523899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889137|NCT02286388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889138|NCT02321969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889139|NCT00211003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889140|NCT05602584|||COHORT||PROSPECTIVE|||||||
33889141|NCT04447053|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33889142|NCT01596257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889143|NCT00355264|NA|SINGLE_GROUP||TREATMENT||NONE||Outcomes were to be evaluated for all subjects with primary BH4 disease. Outcomes were also evaluated based on the type of BH4 deficiency either due to defects in the genes encoding the enzymes involved in BH4 biosynthesis, GTPcyclohydrolase I (GCH1), 6-pyruvoyl-tetrahydropterin synthase (PTPS), and sepiapterin reductase (SR); or defects in the genes encoding the enzymes involved in BH4 recycling, pterin-4a-carbinolamine dehydratase (PCD) and dihydropteridine reductase (DHPR)||||
33889144|NCT04006184|||OTHER||RETROSPECTIVE|||||||
33889145|NCT04480151|||COHORT||RETROSPECTIVE|||||||
33889146|NCT01249235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889147|NCT03625388|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized to receive either dasatinib 50 mg or dasatinib 100 mg orally once daily for the duration of the study which is 18 months.||||
33889148|NCT02408692|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889149|NCT00202592|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33889150|NCT05451420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889151|NCT01075178|||COHORT||RETROSPECTIVE|||||||
33889152|NCT06023667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study PI, statistician, co-investigators, and all personnel who are involved in endpoint assessments will be blinded. Only study coordinators will have access to the assignment of each participant.||f|f|t|t
33889153|NCT00265655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889154|NCT03320499|||CASE_CONTROL||PROSPECTIVE|||||||
33889155|NCT00907244|||CASE_ONLY||PROSPECTIVE|||||||
33889156|NCT00608855||||TREATMENT||NONE||||||
33889157|NCT03309371|||COHORT||RETROSPECTIVE|||||||
33889158|NCT01872455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889159|NCT04680117|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975301|NCT03104322|NA|SINGLE_GROUP||OTHER||NONE||Fixed-order, two-period crossover (2 x 8 weeks), no washout, usual care controlled||||
33975302|NCT00708422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975303|NCT04363125|||CASE_ONLY||OTHER|||||||
33975304|NCT01928277|||||PROSPECTIVE|||||||
33975305|NCT02507206|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33975306|NCT05008289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975307|NCT03830645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975308|NCT01691248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34073783|NCT00872521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762352|NCT06101251|RANDOMIZED|PARALLEL||TREATMENT||NONE||"At the end of the 6-week baseline period, participants who have the app installed and collecting data, and who meet a minimum number of driver trips with trips scores, will be randomized into one of 4 arms via Way to Health:~Arm 1, Control: Way to Drive app only monitors trips in the background~Arm 2, Standard feedback + UBI-like Financial Incentive: Receive weekly feedback on all four behaviors and overall driver safety; safety tips on all four behaviors; up to $100 based on their overall driver safety at end of intervention.~Arm 3, Assigned Goal + UBI-like Financial Incentive: Receive weekly feedback on behavior that presents greatest opportunity for improvement; safety tips on this behavior; up to $100 based on their overall driver safety at end of intervention.~Arm 4, Self-Chosen Goal + UBI-like Financial Incentive: Receive weekly feedback on behavior of their own choosing; safety tips on this behavior; up to $100 based on their overall driver safety at end of intervention."||||
34073784|NCT02260206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||None (Open label)|t|f|t|f
34073785|NCT03726801|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a non-blinded, randomized, controlled clinical trial consisting of 64 participants, which aims to assess the effectiveness of a nursing intervention for family members and patients prior to surgery to prevent body image disorder in breast cancer operated subjects. or colon (32 participants), compared to the intervention limited only to patients (32 participants).|This is a non-blinded, randomized, controlled clinical trial consisting of 64 participants, which aims to assess the effectiveness of a nursing intervention for family members and patients prior to surgery to prevent body image disorder in breast cancer operated subjects. or colon (32 participants), compared to the intervention limited only to patients (32 participants).|f|f|t|f
34073786|NCT06312397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients in the acupressure and sham acupressure groups were blinded as to which groups they were in.|Three groups ( acupressure group, sham acupressure group and control group)|t|f|f|f
34073787|NCT02184039|||COHORT||PROSPECTIVE|||||||
34073788|NCT04298580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor will be blinded to study group||f|f|f|t
34073789|NCT01387698|||COHORT||PROSPECTIVE|||||||
34073790|NCT01890759|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073791|NCT01462110|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34073792|NCT02804048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073793|NCT00436826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34073794|NCT00428480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762353|NCT05962983|NA|SINGLE_GROUP||PREVENTION||NONE||This study is a treatment-only repeated measures design.||||
33762354|NCT01632943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889160|NCT04343950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Invited individuals to the cancer screening programs will not be aware of the different arms of the study.|"Intervention 1: SMS reminders for colorectal cancer screening compared to reminder letters.~Intervention 2: SMS reminders to return the fecal occult blood test at the pharmacy compared to no intervention.~Intervention 3: Invitation by SMS for women with a prior participation in the breast cancer screening program compared to invitation letter."||||
33889161|NCT01016626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889162|NCT02992574|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm Experimental Post Mastectomy Radiotherapy Arm No Intervention: No Post Mastectomy Radiotherapy||||
33762355|NCT01702441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762356|NCT01786486|||CASE_ONLY||PROSPECTIVE|||||||
33762357|NCT00382824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, Double-blind, Randomized, Placebo-Controlled Clinical Trial to examine tolerability, safety, and efficacy of CoenzymeQ10|t|t|t|t
33975309|NCT04813250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|De-identify the data before analyse the data by outcome saaessor|Ventilation strategies with 4 different ventilation mode since weaning cardiopulmonary bypass (CPB), Four group were control EtCO2 between 35～45mmHg by adjusting respiratory rate, EIT Measurements were performed under supine position|f|f|f|t
33762358|NCT02993887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33975310|NCT02031848|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975311|NCT01508416|||CASE_ONLY||PROSPECTIVE|||||||
33975312|NCT03715621|||COHORT||PROSPECTIVE|||||||
33975313|NCT00209118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33975314|NCT04750005|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33975315|NCT01021436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975316|NCT04308681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975317|NCT01266538|||||PROSPECTIVE|||||||
33975318|NCT01937390|||COHORT||PROSPECTIVE|||||||
33975319|NCT00731159|||||PROSPECTIVE|||||||
33975320|NCT03665181|||CASE_CONTROL||PROSPECTIVE|||||||
34073795|NCT01115777|||COHORT||PROSPECTIVE|||||||
34073796|NCT01775423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762359|NCT00881491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762360|NCT00185640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762361|NCT03911427|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33762362|NCT00328614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975321|NCT00855283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975322|NCT02208141|||COHORT||CROSS_SECTIONAL|||||||
33975323|NCT01110265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975324|NCT01412138|||||PROSPECTIVE|||||||
33762363|NCT00816933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33975325|NCT03820102|||COHORT||CROSS_SECTIONAL|||||||
33975326|NCT03476720|||COHORT||PROSPECTIVE|||||||
33975327|NCT04641936|||COHORT||PROSPECTIVE|||||||
33975328|NCT05033223|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33975329|NCT03383393|||COHORT||PROSPECTIVE|||||||
33975330|NCT04174508|||COHORT||PROSPECTIVE|||||||
33975331|NCT01606306|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762364|NCT06475001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible patients are randomized to one of four different dose groups (cohorts) in a 1:1:1:1 ratio and either active drug (VER-01) or placebo.|t|t|t|t
33975332|NCT01623622|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33762365|NCT04469647|||COHORT||CROSS_SECTIONAL|||||||
33762366|NCT01092403|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762367|NCT01830595|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762368|NCT01418014|||COHORT||PROSPECTIVE|||||||
33762369|NCT05837208|||COHORT||PROSPECTIVE|||||||
33762370|NCT02332343|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33762371|NCT04588935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762372|NCT03585296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762373|NCT00774384|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762374|NCT00004410|RANDOMIZED|||TREATMENT||||||||
33762375|NCT00246337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762376|NCT03324880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762377|NCT04045093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762378|NCT02890537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762379|NCT03518125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Subjects will be randomized to receive either BioThrax or AV7909. Randomization will be stratified by sex and age (18-50, 66-74, and ≥75 years). Subjects ≥66 years of age will be randomized 1:1:1:1 within stratum across 4 treatment arms (approximately 50 subjects per group), and subjects 18 through 50 years of age will be randomized 1:1 within stratum across 2 treatment arms (approximately 50 subjects per group). Once randomized, subjects will receive 3 vaccinations, each separated by approximately 14 days, on Day 1, Day 15, and Day 29, based on their assigned treatment arm.|t|f|t|t
33762380|NCT02320643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762381|NCT05862467|NA|SINGLE_GROUP||TREATMENT||NONE|No masking -- as single group design, all participants receive the program.|This is a single group study, where all participants receive telehealth-based Written Exposure therapy (WET). Feasibility and initial efficacy is assessed via pre-post assessments, conducted pre-WET, at the end of WET, and 1 and 6 months post program completion.||||
33762382|NCT02848261|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33762383|NCT00172354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762384|NCT05338255|||COHORT||RETROSPECTIVE|||||||
33762385|NCT00487058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762386|NCT00203060|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33762387|NCT03577158|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Longitudinal, prospective, interventional study.|t|f|f|f
33762388|NCT03035890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762389|NCT00180128|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33975333|NCT06015633|||COHORT||OTHER|||||||
33975334|NCT05670054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762390|NCT00087360||||SCREENING||||||||
33762391|NCT00339690|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33762392|NCT01208740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889163|NCT05383235|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Apart from investigators in charge of inclusions, outcome assessors will not know to which group the subjects belong.|"PATIENTS:~1. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting~2. RUN-IN PERIOD:~   * Eligibility criteria will be assessed during the multidisciplinary meeting~  * Delivery of the information note~3. STUDY:~   * Collection of consent form~  * Facial emotion stimuli presentation task with EEG recording and facial emotion recognition task~  * Neuropsychological evaluation~  * Scales + questionnaires~  * Debriefing~CONTROLS:~1. RUN-IN PERIOD phone call:~   * Study presentation~  * Retrieval of sociodemographic characteristics including age and educational level for matching with patients~  * Assessment of eligibility criteria~  * Psychiatric assessment with MINI 5.0 evaluation~2. STUDY:~   * Delivery of the information note~  * Collection of consent form~  * Facial emotion stimuli presentation task with EEG recording and facial emotion recognition task~  * Neuropsychological evaluation~  * Scales + questionnaires~  * Debriefing"|f|f|f|t
33889164|NCT04068857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889165|NCT04139083|||COHORT||RETROSPECTIVE|||||||
33889166|NCT03561233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889167|NCT00864240|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33889168|NCT01712347|||COHORT||PROSPECTIVE|||||||
33762393|NCT05244005|||COHORT||PROSPECTIVE|||||||
33762394|NCT02309437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33762395|NCT04141631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762396|NCT05087914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762397|NCT03474549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762398|NCT00981851|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33762399|NCT02483286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33762400|NCT03395808|NA|SINGLE_GROUP||OTHER||NONE||||||
33762401|NCT02028832|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762402|NCT01395823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762403|NCT00990340|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762404|NCT06205732|||COHORT||RETROSPECTIVE|||||||
33762405|NCT03177122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762406|NCT03551314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762407|NCT01247428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762408|NCT00118092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762409|NCT06058390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762410|NCT05553639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762411|NCT00993239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762412|NCT01056588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762413|NCT02178644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889169|NCT00840827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889170|NCT01396369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889171|NCT05014854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975335|NCT03341507|NA|SINGLE_GROUP||TREATMENT||NONE||A group of patients with difficult airway criteria will be intubated using the rigid tube for laryngoscopy. A classical laryngoscopy with a McIntosh laryngoscope will be performed prior intubation and the Cormack-Lehane grade of glottis visualisation will be noted. If the Cormack -Lehane grade of glotic visualisation 2b, 3 or 4, the intubation maneuvre is carried further with the rigid tube. If the Cormack-Lehane glottic visualisation grade is less than 2b (1 or 2a) the intubation is accomplished with the MacIntosh laryngoscope (conventional laryngoscope) and the patient is excluded from the study from that point further.||||
33975336|NCT03829098|||COHORT||RETROSPECTIVE|||||||
33889172|NCT03452839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889173|NCT00096161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889174|NCT03606382|||CASE_ONLY||PROSPECTIVE|||||||
33889175|NCT02146586|||COHORT||PROSPECTIVE|||||||
33889176|NCT04772573|||CASE_ONLY||PROSPECTIVE|||||||
33889177|NCT01495143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889178|NCT00522067|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33889179|NCT05233358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889180|NCT00849017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889181|NCT05787847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889182|NCT00004396||||TREATMENT||||||||
33889183|NCT00594477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889184|NCT01684462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889185|NCT05241249|NA|SINGLE_GROUP||OTHER||NONE||This is a Phase IIA study evaluating short term parasympathetic activation with fixed dose bethanechol in subjects with pancreatic cancer who should proceed to surgery after 4 -6 months of chemotherapy.||||
33889186|NCT04155502|||COHORT||PROSPECTIVE|||||||
33889187|NCT02771834|||CASE_CONTROL||PROSPECTIVE|||||||
33889188|NCT03242655|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random Controlled Trials (RCT)||||
33889189|NCT06438328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889190|NCT02567136|||CASE_CONTROL||PROSPECTIVE|||||||
33889191|NCT02747524|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889192|NCT05851469|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33889193|NCT04928183|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will not be aware of which rebreathe treatment (CO or Room Air) they are receiving.|Participants will partake in both room air and CO exposure on 2 separate visits.|t|f|f|f
33889194|NCT04364204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889195|NCT04034017|||OTHER||CROSS_SECTIONAL|||||||
33889196|NCT04005274|||CASE_ONLY||RETROSPECTIVE|||||||
33889197|NCT01504932|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975337|NCT03089528|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prosspective randomised||||
33975338|NCT03049683|||CASE_CONTROL||PROSPECTIVE|||||||
33889198|NCT05588427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||1 session with ketone ester supplementation and 1 session with taste and viscosity matched placebo|t|f|t|f
33889199|NCT03913754|||COHORT||PROSPECTIVE|||||||
33889200|NCT03607721|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were divided in two groups: Parkinson's Disease patients that underwent deep brain stimulation and a control group with healthy subjects matched by age and gender.||||
33889201|NCT00535340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889202|NCT03576144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889203|NCT02639351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33889204|NCT03809897|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive varenicline or nicotine patch during 12 weeks.||||
33889205|NCT00766792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889206|NCT01070914|||CASE_ONLY||CROSS_SECTIONAL|||||||
33889207|NCT04092842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group whith silicone prothesis Group whith standard surgical procedure|f|f|f|t
33889208|NCT06284044|||COHORT||OTHER|||||||
33889209|NCT03663257|||COHORT||PROSPECTIVE|||||||
33889210|NCT01990261|||COHORT||PROSPECTIVE|||||||
33889211|NCT03050164|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33889212|NCT00275431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889213|NCT03219164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889214|NCT05317767|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33889215|NCT00906438|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33889216|NCT04898166|||OTHER||OTHER|||||||
33889217|NCT05638100|||COHORT||PROSPECTIVE|||||||
33889218|NCT03894345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889219|NCT03849326|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33975339|NCT05226910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is a blind triple randomized clinical trial where patients, families and assessors are blinded and they do not know if the child is with placebo or current while is performing intensive therapies.|Two groups: tDCS and Intensive therapies (experimental group), placebo and intensive therapies (control group)|t|t|f|t
33975340|NCT05070156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975341|NCT00996190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975342|NCT00757913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975343|NCT01579409|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33975344|NCT02320942|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975345|NCT02741492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33975346|NCT02970643|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33975347|NCT06143059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Only the nurse administering the IV alcohol or saline will know which one has been administered|Women will complete one alcohol-placebo session pair during the mid-follicular phase of the menstrual cycle and one pair during the late luteal phase. Men will complete two session pairs at matched intervals.|t|f|t|t
33975348|NCT02942966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975349|NCT04152629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975350|NCT02511509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975351|NCT02229240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975352|NCT00981305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975353|NCT05847582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889220|NCT00468897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889221|NCT02891421|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889222|NCT00215930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889223|NCT00872222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889224|NCT01267955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889225|NCT04947475|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33889226|NCT00032084|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889227|NCT01533727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889228|NCT01272583|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33889229|NCT01341457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889230|NCT04489992|||CASE_CROSSOVER||PROSPECTIVE|||||||
33889231|NCT01700829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889232|NCT03514914|RANDOMIZED|PARALLEL||OTHER||NONE||To evaluate the impact of CHARM2 on reversible contraceptive use (including LARC), unintended pregnancy, and MSV via a two armed cluster RCT with N=1000-1200 married couples from 20 geographic clusters (n=50-60 couples per cluster) in rural India. The control arm will receive standard of care in the form of community health workers offering pills/condoms and linking women to public health clinics.||||
34073797|NCT05358548|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be three groups to this study. Each group will include up to 50 patients, which means about 150 participants in total. Treatments will be given in cycles. Each induction phase cycle is made up of two parts (A \& B), and each part lasts 21 days (three weeks). If a participant has lung cancer, the goal is four cycles of induction treatment. If a participant has head \& neck cancer, the goal is six cycles. After completion of the induction phase cycles, the participant will receive additional standard maintenance phase cycles of therapy every three weeks to help control the cancer. Once the participant has stopped receiving treatment on study, they will continue to be followed up for two years. The participant will be given study treatment for as long as the tumor is responding and the participant is not experiencing severe side effects.||||
33889233|NCT04623957|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Patients will be randomized into two groups whereas both groups will experience the therapy during the course of the clinical investigation.~Group 1 receives the intervention for a duration of three months. This Phase I is followed by a Washout period of one month and by a non-interventional phase (Phase II).~Group 2 receives no initial treatment for a duration of three months (Phase I). This Phase I is followed by a Washout period of one month and by an interventional phase (Phase II). Phase III is introduced for both groups for ethical and motivational purposes and to observe potential long-term effects within Group 2."||||
33889234|NCT00806221|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889235|NCT00832819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073798|NCT06101186|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34073799|NCT03591601|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
34073800|NCT00963976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073801|NCT04423133|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889236|NCT01964404|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33889237|NCT02034487|||CASE_ONLY||RETROSPECTIVE|||||||
33889238|NCT06218927|||CASE_CONTROL||PROSPECTIVE|||||||
34073802|NCT06489314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Hybrid type-1 waitlist control pilot trial. Fathers at risk for depression will be randomized randomized 2:1 to the intervention or waitlist. All participants will receive referrals to treatment at usual at baseline. Waitlist participants will be offered the intervention at the completion of their assessments.|f|f|f|t
34073803|NCT01818973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073804|NCT01712139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975354|NCT05898178|RANDOMIZED|PARALLEL||OTHER||SINGLE|The cohort of oocyte-cumulus complexes will be divided into either the study or control group by simple randomization. All embryologists involved in the study will be blinded during embryo assessment, measurement, and selection for embryo transfer or vitrification. A code system will be used on the Petri dishes to ensure the embryologists are blinded.|"496 sibling oocytes will be randomly allocated for culture either at low oxygen tension (5% O2) (n = 248 oocytes) or a more physiological oxygen gradient (8-5-2% O2) (n = 248 oocytes) for the next 5 days. Immediately after allocation, the oocytes will be inseminated through Intracytoplasmic Sperm Injection (ICSI). The sibling oocytes will always be injected by the same embryologist.~Under standard (5%) oxygen concentration, which is currently being used in the cultivating incubators, approximately 15% of all embryos manage to reach a morphological optimal blastocyst, in a patient group younger than 35 years (see Inclusion Criteria). According to the hypothesis that cultivating embryos under a more physiological atmosphere (gradient from 8% to 2%) improves the blastulation rate of embryos to 25%, a sample size of 496 Injected oocytes (248 in each arm), will be needed. Whereby a statistical strength of 80% and α = 0.05 is considered (calculated using power analysis)."|f|f|t|f
33889239|NCT06055257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|One unblinded clinician will be required for management of side effects and dose adjustments of pentoxifylline and clodronate as required in the event of side effects or intolerance. However, all other participants including, patients, assessors, research team and data analysts will be blinded to group allocation. At standard follow-up examination, imaging and photographs will be taken and de-identified and then presented to a blinded oral and maxillofacial surgeon for EBA calculation and to a blinded radiologist for allocation of Notani classification grade.|Prospective, pilot, double blind, randomized (stratified to ORN stage), controlled trial|t|f|t|t
33889240|NCT05350787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889241|NCT05637255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889242|NCT05636280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889243|NCT06001567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889244|NCT02871479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889245|NCT05704114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889246|NCT01029314|||COHORT||PROSPECTIVE|||||||
33889247|NCT04752202|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889248|NCT04274439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a controlled clinical trial, with the Intervention group performing the 8-week follow-up and access to 8 pain education videos and 8 exercise videos prescribed for patients with chronic pain, and the control group receiving information on chronic pain for one booklet. Randomized through site programming, so that the subject enters his / her login and password and is directed to one of the study groups, with blind evaluator without access to randomization information throughout the course of the study and follow-up of the outcome measures for 3 , 6 and 12 months after randomization.|f|f|t|t
33889249|NCT03396289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889250|NCT00998439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975355|NCT04971057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33975356|NCT02520115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975357|NCT02761096|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975358|NCT05294575|||COHORT||RETROSPECTIVE|||||||
33975359|NCT05285280|||COHORT||PROSPECTIVE|||||||
33975360|NCT03997266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975361|NCT01576588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073805|NCT01222312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073806|NCT00855946|||COHORT||PROSPECTIVE|||||||
34073807|NCT01308034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073808|NCT03269903|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter non-randomized prospective clinical study in 30 patients with malignant dysphagia||||
34073809|NCT02793219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073810|NCT04921800|NA|SINGLE_GROUP||OTHER||NONE||Patients enrolled in the study \& scheduled for surgical intervention with anterior cervical discectomy and fusion will have the superficial sensor applied to the suprasternal notch following closure of the surgical incision. The data collected by the sensor will be recorded via a remote application and the sensor will then be removed 24 hours following placement. All patients enrolled in the study will be affixed with an identical sensor in accordance with the procedure outlined in the study protocol.||||
34073811|NCT05503459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The staff responsible for the cognitive assessments and data analyses were not aware of the participants' group assignments.||f|f|f|t
33975362|NCT04352374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pregnant women were randomized using an opaque sealed envelope that was sequentially numbered and statistically generated by a computer program. The envelope contained information about the random allocation group: group (A), engaged in aerobic exercise twice a week under the supervision of a physical therapist, and group (B), engaged in device guided breathing exercises. Both groups received antihypertensive medications. Random allocation of the subjects was performed by another investigator, who did not participate directly in the research study.|A total of 75 participants were initially screened. After the screening process, 60 participants were found to be eligible to participate in the study. In total, 50 (100%) participants completed the treatment program|t|t|t|t
33975363|NCT02529059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975364|NCT00153283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33975365|NCT06307028|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33975366|NCT05707299|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34073812|NCT06047756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized||t|f|t|f
34073813|NCT03713671|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Parallel Assignment|f|f|f|t
34073814|NCT00173732|||CASE_CONTROL||PROSPECTIVE|||||||
34073815|NCT02541864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073816|NCT00114673|||DEFINED_POPULATION||OTHER|||||||
34073817|NCT05953402|||COHORT||PROSPECTIVE|||||||
34073818|NCT05837091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073819|NCT02094638|||COHORT|||||||||
34073820|NCT02824835|||CASE_ONLY||PROSPECTIVE|||||||
34073821|NCT02374424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073822|NCT06548854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study used 0.9% sodium chloride injection without any active drug as a placebo control, which was comparable to the characteristics and appearance of the experimental drug Imitation. The investigational drug and placebo are packaged and coded by a third party independent of the investigator and cannot be directly distinguished. by IWRS assigns study medication to subjects. Before database locking, subjects, researchers, in addition to DSMB and independent statistical teams and sponsors (including subjects and families, study physicians, study nurses, clinical coordinators, monitors, data managers, and statisticians) all were blind to the allocation of investigational drugs.|Three parallel groups were set up in this trial, including two different doses of STC314 injection treatment group (group 1 and group 2) and one placebo Dose control group (group 3).|t|t|t|t
34073823|NCT02346877|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34073824|NCT00536770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073825|NCT03512353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073826|NCT00822146|NA|SINGLE_GROUP||OTHER||NONE||||||
34073827|NCT02858635|NA|SINGLE_GROUP||||NONE||||||
34073828|NCT03560869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Normal Hydration and Dehydration|f|f|t|f
34073829|NCT06344559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants numbers will be assigned three blinded codes which are linked with either sham, active continuous, or active intermittent theta burst stimulation in the stimulator protocol. The investigator will enter the code to initiate the corresponding stimulator protocol, but will not know which protocol is active.~Half of participants will be assigned a sham code corresponding to sham continuous theta burst stimulation and half will be assigned a sham code corresponding to sham intermittent theta burst stimulation. So, for any given session, either continuous or intermittent theta burst stimulation will be used, but it will be unclear whether the stimulation is active or sham."|The study will involve three sessions of within-subject, crossover, double-blind transcranial magnetic stimulation with either 1) active intermittent theta burst stimulation, 2) active continuous theta burst stimulation or 3) sham intermittent or continuous theta burst stimulation.|t|f|t|f
34073830|NCT03726073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|transcutaneous electrical acupoint stimulation and auricular acupressure is given by an investigator who is not involved in anesthesia and outcome assessment||f|t|f|t
34073831|NCT01449292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073832|NCT05311020|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34073833|NCT02204644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073834|NCT05141318|||CASE_ONLY||PROSPECTIVE|||||||
34073835|NCT00005032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073836|NCT03390595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073837|NCT03630705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073838|NCT06608017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blinded, placebo controlled trial|t|t|t|t
34073839|NCT05035745|NA|SEQUENTIAL||TREATMENT||NONE||"Phase I Patients will be treated with Talazoparib daily and Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days) in a modified 3+3 dose escalation/ de-escalation design~Phase II Patients with advanced/ metastatic triple negative breast cancer, unselected for known platinum sensitivity or resistance, will be enrolled. A pilot of 10 patients will be enrolled. If 0-1 patients achieve an objective response, the combination is deemed to be of no interest for further development. If 2 or more of 10 patients achieve an objective response, another 20 patients will be enrolled to confirm the objective response rate. In the final objective response analysis, TNBC patients will be stratified into platinum-naïve/platinum sensitive versus platinum-resistant to determine if prior platinum sensitivity impacts objective response rates to the combination of Talazoparib and Selinexor."||||
34073840|NCT06249607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34073841|NCT04938544|||OTHER||CROSS_SECTIONAL|||||||
34073842|NCT04142671|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group trial pre- post-intervention||||
34073843|NCT00006390||||TREATMENT||NONE||||||
34073844|NCT03230435|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073845|NCT03803163|NA|SINGLE_GROUP||OTHER||NONE||||||
34073846|NCT06611930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel group clinical trial.|t|t|t|t
34073847|NCT02248168|||COHORT||PROSPECTIVE|||||||
34073848|NCT06574568|NA|SEQUENTIAL||TREATMENT||NONE||||||
34073849|NCT01408212|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34073850|NCT06490081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889251|NCT06166550|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The arms will be labelled as group A and group B. The statisticians will be blind about the labelling. Thus, the masking will be ensured.|The intervention is based on Emotional Intelligence. A training session will be given in-person; a diary and a mobile app will be given to practice emotional intelligence at home.|f|f|f|t
34073851|NCT03955159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975367|NCT05400265|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33975368|NCT00002719|RANDOMIZED|||TREATMENT||||||||
33889252|NCT04650633|NA|SINGLE_GROUP||TREATMENT||NONE||2 cohorts||||
33975369|NCT01297010|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33889253|NCT01780233|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889254|NCT04970667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975370|NCT04450303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975371|NCT01576978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975372|NCT00873951|RANDOMIZED|PARALLEL||||||||||
33975373|NCT02213978|||COHORT||PROSPECTIVE|||||||
33975374|NCT05057559|||COHORT||PROSPECTIVE|||||||
33975375|NCT04373577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33975376|NCT06547138|||COHORT||PROSPECTIVE|||||||
33975377|NCT00140257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33975378|NCT03739190|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Each condom will be contained within an individual foil packet on which all branding will been masked. All the condom types will be masked in the same manner and identical boxes will be used for the test and comparator condoms A and B.|The condom types will be tested in a three-way cross-over design where couples will be randomised to use each of the three condom types in a defined order, according to the randomisation schedule.|t|f|t|t
33975379|NCT01234636|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33975380|NCT01891513|||CASE_CONTROL||PROSPECTIVE|||||||
33975381|NCT01075763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975382|NCT03341065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33975383|NCT05037149|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||One subject will be enrolled at dose level 1. After the first subject has passed the DLT period, defined as 28 days, the second and third subject will be enrolled at least 24 hours apart. If more than 3 subjects have been identified for a given dose level, additional subjects may be enrolled in a lower dose level that has passed the DLT period up to a maximum of 12 subjects per dose level for dose levels 3 and 4 and up to a maximum of 9 subjects for dose levels A and 5. Subjects enrolled to backfill cohorts may be enrolled simultaneously, without a waiting period between subjects.||||
33975384|NCT00462982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975385|NCT00046423|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975386|NCT02200900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34073852|NCT06245421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073853|NCT01221805|||COHORT||PROSPECTIVE|||||||
34073854|NCT05716685|||OTHER||PROSPECTIVE|||||||
34073855|NCT04549636|||COHORT||PROSPECTIVE|||||||
33889255|NCT03437603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889256|NCT00318435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889257|NCT02581995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889258|NCT03371355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889259|NCT04082104|||CASE_ONLY||CROSS_SECTIONAL|||||||
33889260|NCT05981066|NA|SEQUENTIAL||TREATMENT||NONE||||||
33889261|NCT02921425|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33889262|NCT04106388|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Locations offering the program are randomized|t|f|f|f
33889263|NCT00432809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889264|NCT00786708|||COHORT||PROSPECTIVE|||||||
33975387|NCT01100970|||COHORT||PROSPECTIVE|||||||
33975388|NCT04601584|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential dose-escalation cohorts in B-ALL patients||||
33975389|NCT04102020|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33975390|NCT01485536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975391|NCT04921280|||COHORT||PROSPECTIVE|||||||
33975392|NCT05285020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975393|NCT00743197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975394|NCT00160771|||OTHER||PROSPECTIVE|||||||
33975395|NCT01400282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975396|NCT04143113|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Step-wedge design||||
33975397|NCT03462940|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975398|NCT00860028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073856|NCT01406314|NA|SINGLE_GROUP||OTHER||NONE||||||
33975399|NCT00185419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975400|NCT00452309|||DEFINED_POPULATION||OTHER|||||||
33975401|NCT05408286|||COHORT||PROSPECTIVE|||||||
33975402|NCT02294071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975403|NCT00494104|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33975404|NCT05056181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975405|NCT05079009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975406|NCT01104662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073857|NCT06612996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889265|NCT05020561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33889266|NCT05759884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889267|NCT02168582|||CASE_ONLY||PROSPECTIVE|||||||
33889268|NCT04899583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889269|NCT00362973|||CASE_ONLY||PROSPECTIVE|||||||
33889270|NCT00631878|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33889271|NCT01119027|||COHORT||PROSPECTIVE|||||||
33889272|NCT03971721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889273|NCT06304324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889274|NCT00932516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889275|NCT04217343|||CASE_CONTROL||PROSPECTIVE|||||||
33889276|NCT03993015|||COHORT||RETROSPECTIVE|||||||
33889277|NCT02718378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33889278|NCT04737044|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Study 1:~The study will be using a two-arm single-blinded RCT with 40 subjects in each of the intervention and control groups.~Study 2:~The study will be using a three-arm RCT with 23 subjects in each groups (two interventions and one control groups)."|t|f|f|f
33889279|NCT00158366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889280|NCT06656403|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33889281|NCT00917436||||TREATMENT||||||||
33889282|NCT00002884|RANDOMIZED|||TREATMENT||||||||
33889283|NCT04977648|||COHORT||PROSPECTIVE|||||||
33889284|NCT00943995|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889285|NCT00095563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889286|NCT00295269|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33889287|NCT01844921|||CASE_ONLY||PROSPECTIVE|||||||
33889288|NCT03746691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33889289|NCT04872920|||COHORT||PROSPECTIVE|||||||
33889290|NCT00079378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889291|NCT02005822|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889292|NCT04779502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889293|NCT06376721|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with linperlisib in combination with camrelizumab and pegaspargase for advanced or relapsed/refractory ENKTCL patients||||
33889294|NCT03499509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975407|NCT04892459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Unblinded staff will responsible for the vaccine administration and management, and other investigators will be kept blinded.|Subjects who have been primed with one dose or two doses of inactive SARS-CoV-2 vaccine will be recruited and randomized at a 1:1 ratio to receive a booster dose of inactive SARS-CoV-2 vaccine or recombinant SARS-CoV-2 Ad5 vectored vaccine|t|f|t|t
33975408|NCT01362634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975409|NCT04314739|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33975410|NCT01635985|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33975411|NCT00102362|RANDOMIZED|||||||||||
33975412|NCT00306748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33975413|NCT00722397|||CASE_ONLY||CROSS_SECTIONAL|||||||
33975414|NCT04886375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33975415|NCT00704418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975416|NCT00680875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975417|NCT02727036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975418|NCT00996736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975419|NCT04525807|||COHORT||PROSPECTIVE|||||||
33975420|NCT01437956|||CASE_CONTROL||PROSPECTIVE|||||||
33975421|NCT01336829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975422|NCT00319111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975423|NCT00863525|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33975424|NCT02362477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975425|NCT06161402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33975426|NCT01334788|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975427|NCT00672854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975428|NCT03085875|||COHORT||CROSS_SECTIONAL|||||||
33975429|NCT02010047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975430|NCT06179966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled trial|t|f|f|t
33975431|NCT04544371|||CASE_CONTROL||PROSPECTIVE|||||||
33975432|NCT01322568|||||PROSPECTIVE|||||||
33975433|NCT04360421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33975434|NCT04414501|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975435|NCT01142037|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33975436|NCT01596647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073858|NCT04584840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Unicentric quasi-experimental clinical trial||||
33889295|NCT04108429|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Mobile self-help intervention||||
33975437|NCT05329636|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Capsules will be either with FMT or placebo. Same appearance. Patients will be randomized to either arm.|FMT through capsules FMT through enema- open label in 3-4 patients to examine feasibility Control group without FMT|t|f|t|f
33975438|NCT01455454|||COHORT||PROSPECTIVE|||||||
33975439|NCT00023283|RANDOMIZED|PARALLEL||TREATMENT||||||||
33975440|NCT02507856|||COHORT||PROSPECTIVE|||||||
34073859|NCT00918593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073860|NCT04042987|||COHORT||OTHER|||||||
34073861|NCT00402727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073862|NCT00929344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073863|NCT05543928|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34073864|NCT00726180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073865|NCT05905029|||COHORT||PROSPECTIVE|||||||
34073866|NCT04324567|||COHORT||PROSPECTIVE|||||||
33889296|NCT02210338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889297|NCT03037281|||CASE_CONTROL||PROSPECTIVE|||||||
33889298|NCT05951283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889299|NCT04599361|||COHORT||PROSPECTIVE|||||||
33889300|NCT05354960|||COHORT||PROSPECTIVE|||||||
33889301|NCT00749333|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33889302|NCT00805415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889303|NCT02840136|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33889304|NCT01510327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975441|NCT02780557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33975442|NCT04552613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975443|NCT01475474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975444|NCT01682174|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33975445|NCT01634828|||COHORT||PROSPECTIVE|||||||
33975446|NCT02941809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34073867|NCT00219427|||CASE_ONLY||PROSPECTIVE|||||||
34073868|NCT04344652|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single visit cross sectional prospective study||||
34073869|NCT01361828|||COHORT||PROSPECTIVE|||||||
33975447|NCT00407849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975448|NCT04371484|||COHORT||RETROSPECTIVE|||||||
33975449|NCT02823899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975450|NCT00000695||||TREATMENT||NONE||||||
33975451|NCT05742633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975452|NCT01829464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975453|NCT05809674|||COHORT||CROSS_SECTIONAL|||||||
33975454|NCT02467751|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33975455|NCT05254366|||COHORT||PROSPECTIVE|||||||
34073870|NCT02895295|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34073871|NCT00008125||||TREATMENT||||||||
34073872|NCT03417752|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34073873|NCT02992860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073874|NCT06612723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073875|NCT01290510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073876|NCT03744936|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33975456|NCT00792649|||CASE_CONTROL||PROSPECTIVE|||||||
33975457|NCT04065893|||COHORT||RETROSPECTIVE|||||||
33975458|NCT06101836|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889305|NCT05675007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Stratified 1 to 1 randomization will be automatically performed in Castor. Participant, Investigator and Outcome Assessor will not be aware of the treatment group. An independent researcher will have access to randomization details, and make sure the participant will receive the correct supplement type.|This randomized controlled trial has two parallel intervention arms. One group will daily consume a colon-delivered multivitamin supplement for 6 weeks. The other group will daily consume a placebo tablet for 6 weeks. Participants will we randomly assigned to one of the two groups.|t|f|t|t
34073877|NCT00442234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073878|NCT00511173|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34073879|NCT02793947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34073880|NCT03093441|RANDOMIZED|PARALLEL||PREVENTION||NONE||A parallel-group randomized controlled trial with 9-month follow-up will be conducted. Once initial screening is completed, participants will be randomized into one of three arms: 1) MM-HIIT, 2) R-HIIT, and 3) control.||||
33889306|NCT04957563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||control group and experimental group|f|f|f|t
34073881|NCT00536510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073882|NCT01152996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889307|NCT06331624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34073883|NCT04423640|||COHORT||PROSPECTIVE|||||||
34073884|NCT06050070|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Subjects will be randomized to sham or active feedback conditions, using block randomization stratified by gender, in a 50:50 allocation.|t|t|f|f
33889308|NCT00531193|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34073885|NCT05023538|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Researchers performing the outcome assessments and analyses will be blinded to treatment.|Single-blind randomized controlled trial and a cohort study.|f|f|t|t
34073886|NCT06548503|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|same taste, same case, just a letter on the external case.|Two groups, one with placebo, one with the Si.Pi.Mi product|t|t|t|f
34073887|NCT02511041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34073888|NCT01672268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073889|NCT03486379|||COHORT||PROSPECTIVE|||||||
34073890|NCT04519983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073891|NCT03522818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073892|NCT01534416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34073893|NCT00856999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073894|NCT02951624|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34073895|NCT01091246|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889309|NCT02768376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889310|NCT00061711|RANDOMIZED|||TREATMENT||DOUBLE||||||
33889311|NCT01553149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889312|NCT03011125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889313|NCT01133340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889314|NCT04321811|||COHORT||PROSPECTIVE|||||||
33889315|NCT05642377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889316|NCT01804231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889317|NCT01480739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33889318|NCT05863611|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889319|NCT05215184|||COHORT||PROSPECTIVE|||||||
33889320|NCT01530139|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889321|NCT01815957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889322|NCT01622426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889323|NCT04980131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889324|NCT06042374|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind study; the athletes were not informed about whether they were in the study group or control group.||t|f|f|f
33889325|NCT04224935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889326|NCT00587535|||COHORT||PROSPECTIVE|||||||
33889327|NCT05046028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889328|NCT05252910|||COHORT||PROSPECTIVE|||||||
33889329|NCT00702143|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33889330|NCT01906749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889331|NCT05657184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889332|NCT05329116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889333|NCT01459978|||OTHER||PROSPECTIVE|||||||
33889334|NCT03624647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33889335|NCT03762304|||OTHER||PROSPECTIVE|||||||
33889336|NCT06199167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know the other intervention and were not exposed to each other||t|f|f|f
33889337|NCT00928330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889338|NCT05935384|||COHORT||PROSPECTIVE|||||||
33889339|NCT00559689|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33889340|NCT04917926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33889341|NCT06329934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33889342|NCT03056443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889343|NCT03512236|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33889344|NCT00930202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889345|NCT05750992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889346|NCT00510042|||COHORT||CROSS_SECTIONAL|||||||
33975459|NCT02941458|||OTHER||PROSPECTIVE|||||||
33975460|NCT01435681|||CASE_CONTROL||PROSPECTIVE|||||||
33975461|NCT05434403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975462|NCT02980848|||COHORT||PROSPECTIVE|||||||
33975463|NCT02007148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975464|NCT03097042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Controlled Trial|t|t|t|t
33975465|NCT02005133|||OTHER||PROSPECTIVE|||||||
33975466|NCT02837978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975467|NCT04767074|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Pre/Post interventional study||||
33975468|NCT06203314|||||PROSPECTIVE|||||||
33975469|NCT06138535|NA|SINGLE_GROUP||TREATMENT||NONE||single arm group study||||
33762414|NCT04338854|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33762415|NCT05930301|||CASE_ONLY||RETROSPECTIVE|||||||
33889347|NCT01734148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889348|NCT03967821|||CASE_ONLY||PROSPECTIVE|||||||
33889349|NCT01853943|||CASE_CONTROL||PROSPECTIVE|||||||
33889350|NCT02991599|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889351|NCT05239845|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33889352|NCT01676831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889353|NCT02737163|||COHORT||PROSPECTIVE|||||||
33889354|NCT05564338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889355|NCT04107038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889356|NCT02316834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889357|NCT01773655|||COHORT||PROSPECTIVE|||||||
33889358|NCT01068444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889359|NCT01849757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889360|NCT02432547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33889361|NCT01868321|||COHORT||PROSPECTIVE|||||||
33975470|NCT04976959|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33975471|NCT00006259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975472|NCT03892759|NA|SINGLE_GROUP||TREATMENT||NONE||Pre/post prospective one group pilot study||||
33975473|NCT05892211|||COHORT||CROSS_SECTIONAL|||||||
33975474|NCT03439163|||COHORT||CROSS_SECTIONAL|||||||
33975475|NCT02669680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975476|NCT05662553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975477|NCT02923466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975478|NCT00390312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975479|NCT02730715|||COHORT||PROSPECTIVE|||||||
33889362|NCT00595634|||COHORT||PROSPECTIVE|||||||
33889363|NCT03341884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889364|NCT04917783|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|This study will use a single-blinded (qualitative coder), randomized controlled trial to evaluate the efficacy of the passport card in improving caregiver understanding and follow through with testing recommendations.||f|f|t|f
33889365|NCT01665937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889366|NCT02304926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889367|NCT01062477|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889368|NCT05054855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A minimum total of 90 students will be recruited for the study. Study personnel will recruit 30 students in each of years 2, 3, and 4. Of the 30 students per year, 15 will be randomly assigned to the full treatment intervention and 15 students will be randomly assigned to the control group. Participants will range in age from approximately 18 years to 25 years, but all ages are welcome to participate.|t|f|f|f
33889369|NCT01767402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33889370|NCT02750683|||COHORT||PROSPECTIVE|||||||
33975480|NCT01003886|||COHORT||PROSPECTIVE|||||||
33975481|NCT01803152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975482|NCT06482307|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||patients with HNSCC||||
33975483|NCT03592875|||CASE_ONLY||CROSS_SECTIONAL|||||||
33975484|NCT00135213|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34073896|NCT03810456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Persons completing follow-up assessments will be masked to the conditions to which patients were randomized.|The proposed study is a randomized controlled trial with 3 treatment arms. A transdiagnostic group CBT protocol will be compared in a compressed weekend format (iCBT) with a standard group delivery format involving 3 months of weekly sessions (sCBT). A treatment as usual (TAU) condition will be included to compare outcomes. Veterans with one or more anxiety-based disorder(s) (with or without co-occurring depression) will be randomized to one of the three treatment arms. Veterans will be asked to attend a total of four assessments during the study including a baseline evaluation, 1-month, 3-month, and 6-month follow-ups.|f|f|f|t
34073897|NCT04453020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889371|NCT04343651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889372|NCT03024216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889373|NCT03054363|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889374|NCT03996447|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33889375|NCT01147614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889376|NCT06487013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889377|NCT05499520|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33889378|NCT04201379|||OTHER||PROSPECTIVE|||||||
33889379|NCT03430310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889380|NCT00331760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889381|NCT06296563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889382|NCT03648164|||OTHER||PROSPECTIVE|||||||
33889383|NCT00299793|||DEFINED_POPULATION||PROSPECTIVE|||||||
33889384|NCT06178068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889385|NCT06164405|||COHORT||PROSPECTIVE|||||||
33889386|NCT00415220|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33889387|NCT00957541|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33889388|NCT01908595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889389|NCT03202693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889390|NCT03864796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889391|NCT05289960|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889392|NCT05846321|||COHORT||PROSPECTIVE|||||||
33889393|NCT01048346|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33889394|NCT05071131|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33889395|NCT06642545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889396|NCT01755832|||COHORT||PROSPECTIVE|||||||
33889397|NCT02043886|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33889398|NCT00643383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889399|NCT01337349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889400|NCT05468970|||COHORT||PROSPECTIVE|||||||
33889401|NCT03824301|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33889402|NCT04597476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Patients will be centrally randomized in a 1:1 ratio to receive either Fucoidan or placebo (potato starch) Eligible subjects will receive fucoidan twice daily (BID) in combination with chemotherapy and radiation therapy over a 24-week treatment period.|Fucoidan Group: Fucoidan 4.4 g, PO, bid for 24 weeks Placebo Group: Potato starch 4.4 g, PO, bid for 24 weeks|t|t|t|t
33889403|NCT03778489|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized double blinded case-control interventional study|t|t|t|f
33889404|NCT05362266|||COHORT||RETROSPECTIVE|||||||
33889405|NCT05543590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889406|NCT00426673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889407|NCT03471026|||CASE_CONTROL||PROSPECTIVE|||||||
33889408|NCT01973855|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33889409|NCT00420030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889410|NCT05680558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889411|NCT05655117|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33889412|NCT00286052|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33975485|NCT02940743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975486|NCT01182233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975487|NCT05561413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33975488|NCT04620174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"Three groups will be included;~1. Custom-made Zirconia Crowns Group (10 molars)~2. Prefabricated Zirconia Crowns Group (10 molars)"|t|f|f|f
33975489|NCT05892978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The intervention and measurements will carried out by the researcher (for hand manipulation standard) and the patients will discovered their own groups when intervention will applied to them. Because of the nature of the intervention, blinding will not be performed.|This is a prospective, randomized controlled experimental study.||||
33975490|NCT03656796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975491|NCT02194309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975492|NCT04498923|||COHORT||PROSPECTIVE|||||||
33975493|NCT03932266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975494|NCT06265935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The sample size was calculated as 60 pregnant women by performing GPower analysis, taking into account the tests to be used to calculate the minimum sample size to be included in the study. The sampling will include a total of 60 primiparous pregnant women, including 30 pregnant women diagnosed with gestational diabetes who meet the inclusion criteria for the study, who agree to participate in the study, and 30 pregnant women diagnosed with gestational diabetes who are applied diaphragmatic breathing exercise and who are not applied diaphragmatic breathing exercise.|Randomize|t|f|f|f
33975495|NCT05881694|||COHORT||PROSPECTIVE|||||||
33762416|NCT00691132|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33762417|NCT01023802|||CASE_ONLY||PROSPECTIVE|||||||
33762418|NCT01403025|||COHORT||PROSPECTIVE|||||||
33975496|NCT01143025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975497|NCT06138379|NA|PARALLEL||SCREENING||SINGLE|It will be collected using the Patient Introduction Form, Chronic Disease Adaptation Scale, Immunosuppressive Drug Use Compliance Scale and Rational Drug Use Scale.|The research will be conducted as a randomized controlled experimental study. The population of the research will consist of adult patients who received liver transplantation at İnönü University Turgut Özal Medical Center. The sample will consist of 90 patients determined by power analysis.|f|f|f|t
33975498|NCT02042391|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975499|NCT00252551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975500|NCT03036579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Final surface fabrication was not identified in the treatment process until the crown was milled.||f|t|f|f
33975501|NCT00332293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975502|NCT00684333|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33975503|NCT04886336|||CASE_ONLY||CROSS_SECTIONAL|||||||
33975504|NCT04066153|||COHORT||CROSS_SECTIONAL|||||||
33975505|NCT04509609|||COHORT||RETROSPECTIVE|||||||
33975506|NCT03246295|||COHORT||PROSPECTIVE|||||||
33975507|NCT01418326|||COHORT||RETROSPECTIVE|||||||
33975508|NCT01270048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975509|NCT06057519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975510|NCT04359095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975511|NCT03834675||CROSSOVER||OTHER||SINGLE|||f|f|f|t
33975512|NCT04595136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The mapping sequence will be hidden from the researcher by enrolling and evaluating participants in sequentially numbered, sealed, and stapled envelopes. To avoid the subversion of the allocation sequence, the name and date of birth of the participant will be written in the envelope, a second researcher verifies the process. The corresponding envelopes will be opened only after the enrolled participants complete all the reference assessments and assignment of the intervention by the protocol|Interventional study, randomized controlled, double-blind (i.e., active and passive control), 1 intervention group with investigative medicine, and a control group that will receive placebo intervention.|t|t|t|f
33975513|NCT03092908|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975514|NCT03877770|||COHORT||PROSPECTIVE|||||||
33975515|NCT02686840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073898|NCT03176121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073899|NCT01499693|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33762419|NCT01494155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762420|NCT02583438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762421|NCT05222464|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33762422|NCT04067401|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study design will involve randomizing approximately 1440 Airman-in-Training (AiT) within 160 Technical Training classes to one of two conditions: Wingman-Connect or a brief Stress Management training. Randomization will occur at the class level, since Wingman-Connect is designed to train AiTs within a class together as a group (those who voluntarily enroll).||||
33762423|NCT02560662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762424|NCT01667913|NA|SINGLE_GROUP||SCREENING||NONE||||||
33762425|NCT00122590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762426|NCT02259517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762427|NCT02544464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073900|NCT06043648|||CASE_CONTROL||PROSPECTIVE|||||||
34073901|NCT03446976|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762428|NCT02293395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762429|NCT04445857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33889413|NCT01136239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889414|NCT05678803|||CASE_ONLY||RETROSPECTIVE|||||||
33889415|NCT01032629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889416|NCT04232826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889417|NCT01485614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889418|NCT06055634|||CASE_CONTROL||PROSPECTIVE|||||||
33889419|NCT03326934|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|None of the subjects will be aware of the intent of the study to the type of chocolate consumed prior to each of two testing sessions|Randomized, single-masked crossover study to assess potential effects of dark chocolate vs. milk chocolate on multiple aspects of visual function and performance.|t|f|f|f
33889420|NCT01284803|NA|SINGLE_GROUP||||NONE||||||
33889421|NCT03631576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889422|NCT04439890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889423|NCT05299658|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label extension||||
33889424|NCT03345186|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Interventional group: structured nurse led patient management programm \& sc Control group standard of care (sc) alone|f|f|t|t
33975516|NCT00268346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975517|NCT03468036|||CASE_CONTROL||PROSPECTIVE|||||||
33975518|NCT00002637||||TREATMENT||||||||
33975519|NCT05095064|||CASE_ONLY||RETROSPECTIVE|||||||
33975520|NCT03987438|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975521|NCT04485052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975522|NCT03422926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33889425|NCT03406533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889426|NCT05238584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889427|NCT06222944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889428|NCT01166048|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33889429|NCT03804541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889430|NCT05766722|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33889431|NCT01714466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889432|NCT00645086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889433|NCT03886844|||COHORT||RETROSPECTIVE|||||||
33975523|NCT02879721|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33975524|NCT01537484|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33975525|NCT06125613|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|A randomized number is allocated for all participants.|Pre-post||||
33975526|NCT02508961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975527|NCT03262298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889434|NCT00924703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889435|NCT05897814|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33889436|NCT01805180|RANDOMIZED|CROSSOVER||||NONE||||||
33889437|NCT03248921|||COHORT||PROSPECTIVE|||||||
33889438|NCT00670709|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889439|NCT02341612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889440|NCT02296060|NA|SINGLE_GROUP||||NONE||||||
33889441|NCT03017209|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889442|NCT02971592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889443|NCT02519114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975528|NCT03871283|||COHORT||PROSPECTIVE|||||||
33975529|NCT00546390|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33975530|NCT03666637|||COHORT||RETROSPECTIVE|||||||
33975531|NCT01142843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975532|NCT04299997|||COHORT||RETROSPECTIVE|||||||
33975533|NCT02767193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975534|NCT05370521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind randomization performed by IRT||t|t|t|f
33975535|NCT03089398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The DCC Research Coordinator will be blinded to treatment assignment during follow-up telephone calls and will be blinded to aggregate outcomes data.|This trial is a prospective, multi-center randomized comparative effectiveness trial of HCR compared to multi-vessel PCI with metallic DES in patients with multi-vessel CAD involving the LAD or LM territories.|f|f|f|t
33975536|NCT01497236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33975537|NCT05317156|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who were hospitalized for surgical intervention in the supine and prone position and met the sample selection criteria will be included in the experimental and control groups by block randomization method using the random numbers table on the computer.||||
33975538|NCT03162666|||COHORT||PROSPECTIVE|||||||
33975539|NCT01999309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975540|NCT05072301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762430|NCT03748511|||COHORT||PROSPECTIVE|||||||
33762431|NCT05647863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessors in the RCT will be blind to group allocation|Randomized controlled trial with an experimental group and a control group|f|f|f|t
33762432|NCT00722501|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33762433|NCT05614414|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33762434|NCT03762343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An online randomization program (http://www.randomizer.org) will be used to generate random list and to allocate patients into two study groups. Random allocation numbers will be concealed in opaque closed envelops. The patient and investigator performing the block and assessing study outcomes will all be blinded to the study group allocation. The intraoperative study outcomes will be assessed by an anesthetist who is not involved in the block performance and postoperative data will be collected by PICU trained nurses who are blinded to the study groups.||t|f|t|t
33762435|NCT02355613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762436|NCT01782872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33975541|NCT03181438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975542|NCT00919581|||COHORT||PROSPECTIVE|||||||
33975543|NCT05592756|||COHORT||RETROSPECTIVE|||||||
33975544|NCT03767777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975545|NCT04959695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analyst will be blind to the coding of assigned treatment intervention in the data set until analyses are complete.||f|f|f|t
33975546|NCT01333241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975547|NCT00658320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975548|NCT06014632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975549|NCT03013374|||COHORT||PROSPECTIVE|||||||
33975550|NCT01352650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762437|NCT00511979|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762438|NCT01965782|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975551|NCT05810766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975552|NCT00232336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762439|NCT04728178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762440|NCT02126683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762441|NCT03458767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A trained research assistant, blinded to the participant's group assignment, will collect the NIH Toolbox measures using an iPad at baseline and 8-weeks (post-intervention).|"This pilot feasibility study employs a mixed methods design conducted in a community setting. Phase 1 uses a single-group qualitative design involving a convenience sample of 5 adults with MS; Phase 2 uses a randomized controlled trial (RCT) design conducted with a sample of 20 adults with MS (10 intervention/10 control). Phase 2 data will be collected at baseline (before the intervention) and at 8-weeks (post-intervention). Data includes self-report measures, an objective measure of physical activity, and neurocognitive tests. An enhanced usual care control group is selected as most appropriate for this pilot feasibility study of a non-pharmacologic, behavioral intervention."|f|f|f|t
33762442|NCT03062202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762443|NCT04763811|||CASE_ONLY||PROSPECTIVE|||||||
33762444|NCT01511796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975553|NCT03405207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||we have 2 groups entitled active drug receiver and placebo receiver and patients will randomly allocated between these two groups at first and continue until finishing the study.|t|t|t|f
33975554|NCT00380471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34073902|NCT04978337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073903|NCT03523195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33762445|NCT04897425|NA|SINGLE_GROUP||TREATMENT||NONE|However, the person treating the subject is different than the person evaluating the outcomes. This is done to reduce the influence that the care provider might have on the patient reporting positive outcomes.|Single arm clinical trial||||
33762446|NCT00270361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762447|NCT04934722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889444|NCT05421000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|10 block randomization was done by an external observer. Accordingly, the surgeon, the anesthesic or the patient didn't know about intervention until it was time to be exposed to the treatment|"Patients who had a surgical distal radius fracture, met all the inclusion criteria and signed the informed consent were randomized either to Group A in which WALANT technique was performed or Group B in which locoregional anesthesia(LRA) and upper limb tourniquet was used. This process was done by the external observer with 10 block randomization. Blinding was not possible as the differences between the anesthetic techniques are evident. However, none of the patients nor the surgeon or the anesthesiologist knew the group of intervention until the patient arrived at the operating anteroom the same day of surgery.~Since the investigators considered this was a complex intervention, all patients were offered to receive sedation from the anesthesiologist if they presented any level of anxiety."|t|t|f|f
33889445|NCT04828824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889446|NCT06138145|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33889447|NCT00619008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33889448|NCT02747914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889449|NCT04711837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889450|NCT04453774|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33889451|NCT01176045|||COHORT||PROSPECTIVE|||||||
33889452|NCT01832961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889453|NCT01451593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889454|NCT02610309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889455|NCT00969657|||CASE_ONLY||PROSPECTIVE|||||||
33889456|NCT03443167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only the phase of data analysis will be masked|multicentric clinical trial based on an ad hoc questionnaire|f|f|f|t
33889457|NCT02006771|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33889458|NCT05567523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33889459|NCT00430144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889460|NCT00036335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889461|NCT03758586|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33975555|NCT00564525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975556|NCT05187026|||COHORT||PROSPECTIVE|||||||
33975557|NCT00365612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975558|NCT01290939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975559|NCT00487760|||||PROSPECTIVE|||||||
34073904|NCT06178042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding was not feasible during the intervention, but the data evaluation and outcome assessment were blinded.|Thirty-nine patients were randomized in a 1:1:1 ratio to either MI Paste Plus or Remin Pro or control group.|f|f|f|t
34073905|NCT05645302|||CASE_ONLY||RETROSPECTIVE|||||||
33975560|NCT02331537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975561|NCT06078254|||COHORT||PROSPECTIVE|||||||
33975562|NCT03356587|NA|SINGLE_GROUP||PREVENTION||NONE||"During or after palliative 1st line platinum based chemotherapy, we will perform prescreening NGS based molecular characterization.~Molecular tumor board to determine characterization will be held for every patients. Once each patients have relevant genetic pathway, the patients will be allocated each treatment arm"||||
33975563|NCT05487833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975564|NCT06408909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized controlled trial.|t|f|f|f
33975565|NCT02347579|||CASE_CONTROL||PROSPECTIVE|||||||
33975566|NCT01325207||SEQUENTIAL||TREATMENT||NONE||||||
33975567|NCT02918162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975568|NCT05700591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073906|NCT06611865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A split-mouth group was included with 70 teeth extracted from 35 patients. In such cases, involving bilaterally indicated teeth, ILA and IANB were used on opposite sides, but the second tooth was anesthetized only after the first extraction had completed and had been recorded. The second group had 500 patients with unilateral extractions. ILA was compared with IANB in each group separately, and the results in group I were then compared descriptively with those in group II.||||
33975569|NCT02914795|||CASE_CONTROL||PROSPECTIVE|||||||
34073907|NCT02388828|||COHORT||PROSPECTIVE|||||||
34073908|NCT05959967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomly assigned to one of two groups: the VRE group or the GFT group.|f|f|f|t
34073909|NCT02364583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975570|NCT06486324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Split-mouth model. The crossbite side of the patients was assigned as the treatment group, while the normal bite or non-crossbite side of the same patients was assigned as the positive control group.|f|f|f|t
33975571|NCT02765321|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073910|NCT04346576|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|A controlled field trial was implemented with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed 65 mL/day of fermented milk containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group did not. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline and 4, 8, and 12-week of intervention and after the 4-week follow up period.|A controlled field trial was implemented with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed 65 mL/day of fermented milk containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group did not. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline and 4, 8, and 12-week of intervention and after the 4-week follow up period.||||
34073911|NCT04976439|||OTHER||RETROSPECTIVE|||||||
34073912|NCT06102720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073913|NCT05707390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073914|NCT06431945|||COHORT||PROSPECTIVE|||||||
34073915|NCT02383901|||COHORT||RETROSPECTIVE|||||||
34073916|NCT04335084|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||This study will focus on medical workers who at elevated risk of COVID-19 due to exposure to positive patients in the Emergency Department or Intensive Care Unit|t|f|t|f
34073917|NCT06612216|||OTHER||PROSPECTIVE|||||||
34073918|NCT05038683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the interventions, it will not be possible to blind the healthcare providers administering the interventions. We will attempt to blind the participants by not informing them about which intervention group we consider experimental and which group we consider control. However, the participants included in HOT will be governed by a digital solution where Dr. Holm will be identifiable and thus revealing the HOT. In all other aspects of the trial, we will employ blinding, incl. outcome assessment. Statisticians, and investigators drawing conclusions will be fully blinded. We will conduct the statistical analyses with the intervention groups coded as eg. 'A' and 'B'. The steering committee will write two abstracts while the blinding is intact; one assuming the experimental intervention group is 'A' and the control intervention group is 'B', and one assuming the opposite. After these two abstracts have both obtained consensus, the code will be broken.||f|f|t|t
34073919|NCT04286620|||COHORT||PROSPECTIVE|||||||
34073920|NCT05736692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a straightforward two-arm parallel randomized clinical trial with follow-up 1 week and 1 month post-randomization. Eligible adolescents will participate for up to 5 weeks. Week 1 will involve pre-randomization sleep monitoring, and will conclude with a study visit during which staff will review sleep data and give measures of PPCS severity and other outcomes. At that visit, youth who have both PPCS and poor sleep quantity or quality will be evenly randomized to receive the intervention or continue care-as-usual (control). Short-term and extended follow-up assessment will occur in Weeks 2 and 5.|f|f|f|t
34073921|NCT04687904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975572|NCT02046421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975573|NCT03688230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889462|NCT05405556|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A pre-defined algorithm for suggested management of acute changes in eGFR will be provided to all treating physicians. To test the proportion of patients successfully completing the protocol according to two different eGFR reporting strategies, randomization at the patient level will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR values will be provided to patients and providers"||||
33889463|NCT05939297|||COHORT||RETROSPECTIVE|||||||
33889464|NCT00386841|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33889465|NCT05387356|||COHORT||RETROSPECTIVE|||||||
33889466|NCT01586845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33889467|NCT03313960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889468|NCT03478618|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33889469|NCT03793400|||CASE_ONLY||RETROSPECTIVE|||||||
33889470|NCT02599506|||COHORT||PROSPECTIVE|||||||
33889471|NCT02158559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889472|NCT01935895|||CASE_CONTROL||PROSPECTIVE|||||||
33889473|NCT01636492|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33889474|NCT04378426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding Protections: First, the investigators will separate personnel and location of the team providing study drug from the team performing psychiatric evaluations. Independent evaluators (IEs) blind to treatment assignment will assess participants . Second, records for drug administration will be kept separate from psychiatric assessment case report forms until completion of the study. Third, all participants will be blinded as to the nature of the inhaled gas and IV drug at each session; all participants will be informed that they will receive either nitrous oxide and IV saline or an air mixture with a high nitrogen component and IV midazolam. Integrity of the blinding will be assessed by recording each patient's guess as to which drug was received.|Randomized placebo-controlled clinical trial including two groups: Experimental (admixture of up to 50% nitrous oxide and 50% oxygen plus IV saline) and Active Comparator (admixture of up to 50% nitrogen and 50% oxygen plus 0.045mg/kg midazolam).|t|f|t|t
33889475|NCT05836298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sealed envelopes|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST treatment|t|t|t|f
33889476|NCT02160860|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33889477|NCT05763602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889478|NCT02493348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889479|NCT00793767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33889480|NCT01846455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889481|NCT01067820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889482|NCT05478694|||CASE_ONLY||PROSPECTIVE|||||||
33889483|NCT04967131|||CASE_ONLY||PROSPECTIVE|||||||
33889484|NCT04547322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researchers involved in the data analysis and statistics stages were blinded to the group assignment, too. However, those involved in the running of the study were not blinded. Also, the person who performed the measurements was not blinded due to the nature of VR application.|prospective, parallel, two arm, randomized controlled clinical trial|t|f|f|f
33889485|NCT05759299|||COHORT||PROSPECTIVE|||||||
33889486|NCT02221609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889487|NCT02229773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889488|NCT04550026|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33889489|NCT02467998|||CASE_CONTROL||PROSPECTIVE|||||||
33889490|NCT05258461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33889491|NCT06416501|||COHORT||RETROSPECTIVE|||||||
33889492|NCT01982591|||COHORT||PROSPECTIVE|||||||
33889493|NCT01271140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889494|NCT04653519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975574|NCT04262830|||COHORT||PROSPECTIVE|||||||
33975575|NCT02725307|||CASE_ONLY||PROSPECTIVE|||||||
33975576|NCT00035087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975577|NCT05898451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975578|NCT02339909|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33975579|NCT04337996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975580|NCT03916653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33975581|NCT04258241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33975582|NCT00249275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33975583|NCT00194740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889495|NCT00433238|RANDOMIZED|PARALLEL||SCREENING||SINGLE||||||
33889496|NCT00375544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889497|NCT05850078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Subjects, clinical investigators as well as outcome assessors (laboratories) will be blinded to treatment.|Randomised, double-blind, parallel, 3-arm, placebo-controlled study.|t|f|t|t
33889498|NCT01147926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975584|NCT06101654|||CASE_ONLY||PROSPECTIVE|||||||
33975585|NCT04121806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975586|NCT00513968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975587|NCT02324465|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33975588|NCT05637281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975589|NCT02687204|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34073922|NCT06607796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073923|NCT01735149|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34073924|NCT01647568|||CASE_CONTROL||PROSPECTIVE|||||||
34073925|NCT04832256|||COHORT||PROSPECTIVE|||||||
33889499|NCT03156803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889500|NCT00267735|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34073926|NCT04124770|||COHORT||PROSPECTIVE|||||||
34073927|NCT02155985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34073928|NCT04450693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the test article, the trial is open label, with no blinding of the site staff. The determination of wound closure will be made by the Investigator based on visual and tactile assessment of the wound. To reduce bias in the ascertainment of closure, one independent blinded reviewer will review the image obtained from a wound measurement device in each case where the Investigator makes a determination of closure. Discordant opinions will be adjudicated by a second independent blinded reviewer who will examine multiple additional images taken at various angles to the wound surface.||f|f|f|t
34073929|NCT00441519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073930|NCT01352273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073931|NCT01649115|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34073932|NCT06508827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073933|NCT05062746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762448|NCT01222143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762449|NCT01038115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762450|NCT00805090||CROSSOVER||||NONE||||||
33889501|NCT03268356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889502|NCT00895063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889503|NCT04852640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762451|NCT03188120|||COHORT||PROSPECTIVE|||||||
33762452|NCT02796430|||COHORT||PROSPECTIVE|||||||
33762453|NCT02913066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762454|NCT02923739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762455|NCT00735111|NA|SINGLE_GROUP||||NONE||||||
33762456|NCT04774523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two arms with the same study flow chart along the study.||||
33762457|NCT02243202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889504|NCT04812561|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33889505|NCT03982550|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||There are two phases in this single-group study: an initial control period and an intervention period. All control periods will take place before the RT intervention to ensure that results are not confounded by detraining effects or long-term cognitive benefits of RT.||||
33889506|NCT03807531|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, non-randomized, single-arm study||||
33889507|NCT04323371|||COHORT||PROSPECTIVE|||||||
33889508|NCT04126824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889509|NCT00476099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889510|NCT01662648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889511|NCT02327299|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33889512|NCT01300104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889513|NCT01790490|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33889514|NCT01328457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889515|NCT06314087|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Randomized|||||
33975590|NCT01886274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975591|NCT02785913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975592|NCT01917409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975593|NCT06202157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975594|NCT03105999|||COHORT||PROSPECTIVE|||||||
33975595|NCT06145178|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33975596|NCT02987309|||COHORT||PROSPECTIVE|||||||
33975597|NCT02573909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|similar syringes equal amount of drug||t|f|t|f
33975598|NCT01386346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073934|NCT05454995|NA|SINGLE_GROUP||TREATMENT||NONE||NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease||||
34073935|NCT05660382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking for participants, care providers, Investigators, outcome assessors|Participants are assigned to one of two groups in parallel for the duration of the study|t|t|t|t
34073936|NCT02446444|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stratification Factors:~* Gleason score (\<=7 versus 8-10),~* Regional lymph nodes involvement (N0 versus N1)~* Clinical T-stage (T2 and below versus T3 and above),~* PSA (\<20ng/mL versus ≥ 20ng/mL)~* Study Site~* Brachytherapy (yes versus no)~* Pelvic Field (yes versus no)"||||
34073937|NCT06612307|||COHORT||PROSPECTIVE|||||||
34073938|NCT03367975|||COHORT||PROSPECTIVE|||||||
34073939|NCT04135755|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34073940|NCT01420250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975599|NCT01430741|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975600|NCT03401905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized list that was only known by the therapist. Subjects do not know about the treatment they were receiving.|Double blind randomized control trial.|t|f|f|t
34073941|NCT00901615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073942|NCT01096381|||COHORT||PROSPECTIVE|||||||
34073943|NCT03893760|||COHORT||RETROSPECTIVE|||||||
33762458|NCT03732625|NA|SINGLE_GROUP||OTHER||NONE||Multicenter, open, non-randomized pilot trial.||||
33762459|NCT02669095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762460|NCT05412888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33889516|NCT02935972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889517|NCT02800460|NA|SINGLE_GROUP||OTHER||NONE||||||
33889518|NCT03968419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889519|NCT03906682|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33889520|NCT02627040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889521|NCT00247104|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33889522|NCT04607395|||COHORT||PROSPECTIVE|||||||
33889523|NCT05051956|||COHORT||PROSPECTIVE|||||||
33889524|NCT06146894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33889525|NCT04839861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889526|NCT01952717|||CASE_CONTROL||RETROSPECTIVE|||||||
33889527|NCT02419027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889528|NCT03614572|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor will be blinded to the condition of the subjects||f|f|f|t
33889529|NCT04736823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889530|NCT03354689|||COHORT||PROSPECTIVE|||||||
33889531|NCT00544934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889532|NCT04149314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the interventional study group HPI monitoring is used for hemodynamic optimization while in the control group HPI monitoring is blinded.|The study is designed as a single center randomized prospective blinded interventional trial comparing goal directed hemodynamic management using HPI compared to standard care.|f|f|t|f
33975601|NCT05412732|||OTHER||PROSPECTIVE|||||||
33889533|NCT04737148|||COHORT||RETROSPECTIVE|||||||
33889534|NCT04285320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889535|NCT04827641|||COHORT||PROSPECTIVE|||||||
33889536|NCT04261530|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Each patients will have a medical consultation and will have to fill-in questionnaires (T0). After, the care staff will have a multidisciplinary discussion and will randomize the participants to different treatment groups : self-hypnosis/self-care, music/self-care, self-care and psycho-education. Another group will be included but will not be randomized because it includes patients who demand to learn self-hypnosis/self-care (group named self-hypnosis/self-care motivation). After, participants will receive a 7 months (2 hours session a month) learning program of self-hypnosis/self-care animated by a therapist specialized in hypnosis or music/self-care (identical procedure but the hypnosis is replaced by music) or self-care or psycho-education at the end if which they will complete the same questionnaire (T2). A follow-up at 6 (T3) and 12 (T4) months will also be conducted to account for any long term effect."||||
33975602|NCT02806232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975603|NCT02895529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975604|NCT00406757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975605|NCT00258622|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33975606|NCT02190461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975607|NCT05437107|||COHORT||PROSPECTIVE|||||||
33762461|NCT05664932|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33889537|NCT00582517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889538|NCT02130414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889539|NCT05555004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind|comparator-controlled|t|f|t|f
33975608|NCT06547710|||COHORT||PROSPECTIVE|||||||
33889540|NCT03735719|||COHORT||PROSPECTIVE|||||||
33889541|NCT01800188|||CASE_ONLY||PROSPECTIVE|||||||
33975609|NCT05361278|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33975610|NCT04843670|||COHORT||RETROSPECTIVE|||||||
33975611|NCT01479881|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975612|NCT01884025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073944|NCT04929977|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Wearable device combined with a smart mobile phone and back-end analytics system that acts as a temperature and touch sensor and actuator will be evaluated.||||
33889542|NCT01775748|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33889543|NCT06418646|||COHORT||PROSPECTIVE|||||||
34073945|NCT02411279|||COHORT||PROSPECTIVE|||||||
33889544|NCT03508986|||COHORT||PROSPECTIVE|||||||
33889545|NCT04361864|||COHORT||RETROSPECTIVE|||||||
33975613|NCT00352495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975614|NCT00922532|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34073946|NCT02384213|||COHORT||RETROSPECTIVE|||||||
34073947|NCT02207400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33889546|NCT00379951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889547|NCT01808560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889548|NCT04920240|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||Multi-center unification, before-after study,||||
33889549|NCT02371850|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)||||
33975615|NCT05796609|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants of the treatment group are aware of the possible induction of alcohol (purpose of the study), but blinded to the actual amount and target blood alcohol concentration. The participants of the reference group are fully informed that they do not get alcohol (open-label). The participants of the placebo group are not informed that they do not get alcohol but a placebo (blinded).|Treatment group (32 participants); Reference group (12 participants); Placebo group (12 participants)|t|f|f|f
33975616|NCT04207281|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33975617|NCT04645095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33975618|NCT02748226|||COHORT||OTHER|||||||
33975619|NCT01911975|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33975620|NCT02137083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975621|NCT03958890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975622|NCT03915938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975623|NCT00249821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975624|NCT03308448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are unaware of the dose of EPO. Outcome assessors are masked to the dose of EPO|3 treatment groups of patients with TON will receive different total dose of EPO.|t|f|f|t
33975625|NCT02396381|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975626|NCT00902083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975627|NCT04620109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975628|NCT01235052|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34073948|NCT04225455|||COHORT||CROSS_SECTIONAL|||||||
34073949|NCT06248814|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34073950|NCT03738163|NA|SINGLE_GROUP||TREATMENT||NONE||infants (0-36 months old), children (3-18 years old) and adults (\>18 years old)||||
34073951|NCT06437509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975629|NCT04867395|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33975630|NCT05289765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33975631|NCT02860481|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975632|NCT00358384|RANDOMIZED|PARALLEL||TREATMENT||||||||
34073952|NCT03660891|||CASE_ONLY||PROSPECTIVE|||||||
33889550|NCT00100048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889551|NCT04804891|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889552|NCT02310373|NA|SINGLE_GROUP||OTHER||NONE||||||
33889553|NCT04522869|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889554|NCT03347149|||COHORT||PROSPECTIVE|||||||
33889555|NCT04223609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33889556|NCT03026738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889557|NCT06340217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889558|NCT06273969|NA|SINGLE_GROUP||TREATMENT||NONE||"Twelve consented male and/or female volunteers between the ages of 18 and 65 with intermittent tingling and/or numbness in one or both hands that has occurred with two weeks of the start date of the study will be evaluated using pulsed-wave doppler ultrasonography (US) and then treated with osteopathic manipulative treatment (OMT).~US examination of the thoracic outlet will be performed using a Mindray-6 ultrasound machine and will include 4 views/positions with the subject in a seated position.~The following intervention will consist of four osteopathic manipulation techniques (OMT) being performed that target the somatic dysfunctions associated with TOS. These techniques include: 1) Direct Thoracic Inlet Myofascial Release (TIMFR); 2) Direct Muscle Energy for the Scalene Muscles; 3) Direct Muscle Energy for the Pectoralis Muscles; and 4) Supraclavicular Fascial Release."||||
33889559|NCT00428402|||||PROSPECTIVE|||||||
33889560|NCT04122599|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889561|NCT01784796|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33889562|NCT05330026|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33762462|NCT04655885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762463|NCT06446076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33975633|NCT01412541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All Duplex Ultrasound operators, core lab evaluators, and members of the Clinical Events Committee (CEC) will be blinded to the subject's treatment assignment. Both the subject as well as the Investigator conducting the follow-up visit will be blinded to treatment until the completion of the 12 month visit.||t|t|t|t
33762464|NCT04358172|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The clinician who check the oral index is masked with the group of subjects|Participants are randomly allocated into the intervention group (educated using mobile application) and control group (educated using verbal instructions accompanied by demonstrations on dental models)|f|f|f|t
33975634|NCT04480203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Only the staff that have contact with the participants will know who receives which intervention. The statistician and investigators will be masked.|An intervention study of breast cancer patients with two digital intervention arms and one control group.|f|f|t|t
33975635|NCT00586521|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975636|NCT04281511|||COHORT||PROSPECTIVE|||||||
33975637|NCT04812587|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762465|NCT04958356|||CASE_ONLY||PROSPECTIVE|||||||
33762466|NCT05966038|||OTHER||PROSPECTIVE|||||||
33889563|NCT06015490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33889564|NCT03440944|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the devices are different we will not be able to mask.|randomized to one of two therapies, peripheral ultrasound IV or midline||||
33889565|NCT00859859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889566|NCT06052956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject and study doctor will not be masked to group assignment, as it would be difficult or impossible to do so and unethical to subject patients to sham procedures if they are not assigned to a PDT group. However, all follow-up and subsequent data collection will be performed by a member of the study team that is masked to group assignment. Group assignment will only be unmasked to the study biostatistician at the time of statistical analysis. The remainder of the study team will only be unmasked after final results are published. This will reduce the potential for bias in collection of follow-up data, and protect the integrity of the study.|The study includes three arms: (1) MB-PDT at a fixed drug/light dose plus standard of care abscess drainage, (2) MB-PDT at a patient-specific dose determined by pre-treatment optical measurements plus standard of care abscess drainage, and (3) standard of care abscess drainage.|f|f|t|t
33975638|NCT03887195|||COHORT||PROSPECTIVE|||||||
33975639|NCT00347542|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33889567|NCT00124280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889568|NCT01413958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889569|NCT01114789|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33765043|NCT03276637|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.||||
33975640|NCT00721409|RANDOMIZED|||TREATMENT||NONE||||||
33975641|NCT02047266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33975642|NCT04226911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975643|NCT00000882||||TREATMENT||||||||
33975644|NCT06441552|||COHORT||PROSPECTIVE|||||||
33975645|NCT00125359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975646|NCT05004428|||COHORT||RETROSPECTIVE|||||||
33975647|NCT05899790|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"2 Group~1. İntervention~2. Control"|t|t|t|t
33975648|NCT05042635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889570|NCT05671276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889571|NCT03359902|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The sham stimulation experience is very similar to the tVNS stimulation experience. The electrodes are placed in a proximal location. Thus, without knowledge of the anatomy, the participants will be unable to determine which stimulation session is the tVNS one.|All participants will be assigned to either transcutaneous vagal nerve stimulation or sham for the first session, then switch to the other condition for their second session after a 1 week washout period.|t|f|t|f
33889572|NCT04338490|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889573|NCT04742673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889574|NCT05943080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was designed as blinded, randomized and controlled.the person who evaluates the patients before and after the treatment is blind.In other words,the person evaluating the patients and the person giving the treatment are different.|randomized controlled study|t|f|f|t
33889575|NCT01381094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889576|NCT03177161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Participants will not be made aware of the other modes of delivery available and will be assigned a single method of delivery prior to consent.|||||
33889577|NCT02265484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889578|NCT05337618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to one of two study groups based on a block design with randomized block sizes of 2, 4 or 6 determined individually for each study site.|f|f|f|t
33889579|NCT06484335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, clinical staff, laboratory staff, Principal Investigator (PI) and the Sponsor will be blinded to vaccine/placebo allocation. The pharmacist with primary responsibility for vaccine dispensing will not be blinded to the treatment and maintains the randomization code and completes assignments of participants according to the randomization allocation.||t|t|t|f
33889580|NCT00603239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889581|NCT03837184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889582|NCT00295945|||CASE_CONTROL||PROSPECTIVE|||||||
33889583|NCT03314506|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33889584|NCT04879797|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Hybrid type 1 implementation||||
33889585|NCT01200433|RANDOMIZED|PARALLEL||||NONE||||||
33889586|NCT00004826|RANDOMIZED|||TREATMENT||DOUBLE||||||
33889587|NCT05349955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessment Committee members will be blinded to outcome assignment.|Guideline based comprehensive management on the diabetic patients. In brief, SGLT2i or GLP-1RA will be used in priority in elderly diabetic patients with very high/high CV risk, and blood pressure controlled under 130/80mmHg， LDL-c\<1.8mmol/L in the very high-risk patients or \<2.6mmol/L in the high risk patients according to ESC/EASD guidelines.|f|f|f|t
33975649|NCT06382116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975650|NCT03177603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975651|NCT03758365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Visual assessments of potential skin blanching will be made independently by 2 trained observers, according to a grading scale (0 to 4)|Single application, intra individual comparison on mini-test sites (n=7)|f|f|f|t
33975652|NCT01547195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975653|NCT02703610|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33975654|NCT01523964|NON_RANDOMIZED|PARALLEL||||NONE||||||
33975655|NCT03567109|||CASE_CONTROL||PROSPECTIVE|||||||
33975656|NCT05402449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized Controlled Trail|t|f|t|f
33975657|NCT04861883|||COHORT||PROSPECTIVE|||||||
33975658|NCT04744740|||CASE_CONTROL||PROSPECTIVE|||||||
33975659|NCT05127993|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33975660|NCT05049044|||COHORT||PROSPECTIVE|||||||
33975661|NCT04216212|||OTHER||OTHER|||||||
33975662|NCT00119613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975663|NCT03361423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"For sham control, electrical pulses of similar width and intensity, but much lower frequency compared to the active device will be administered. This sham program produces pulses that are perceivable by the user, thus maintaining the blinding, but on the other hand do not have therapeutic qualities.~The devices will be delivered with an identifying number, without exposing to the investigator or participant if it is an active or a pacebo/sham device"|A prospective, randomized, double blinded, sham controlled study|t|f|t|f
33975664|NCT03543956|||CASE_ONLY||PROSPECTIVE|||||||
33975665|NCT00675649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975666|NCT02081521|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34073953|NCT04373317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In order to facilitate titrations, study drug will be provided in blister cards with a sufficient number of over-encapsulated drug to bridge participants to their next titration step. Each blister card will contain a one-week supply of study drug. Because dosing will be nightly, and the study will use a combination of quetiapine strengths for all protocol-specified quetiapine doses, participants in both treatment groups will take two identical capsules both of which containing the protocol-specified nightly dose. For example, if a participant is randomized to quetiapine and is up-titrated from 50 to 100 mg ER, this participant will take 2 identical capsules, each containing 50 mg of ER quetiapine. Similarly, participants randomized to pimavanserin will take two capsules every night, one containing a placebo capsule, and the other containing 34 mg of pimavanserin.|Two active treatments will be administered in this RCT, with 1:1 treatment assignment to either quetiapine or pimavanserin. Both active treatments are FDA-approved antipsychotics.|t|t|t|f
34073954|NCT04034212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking of participants not possible due to the nature of the intervention.||f|f|t|t
34073955|NCT04014218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque envelopes||f|f|t|f
34073956|NCT02300870|||CASE_CONTROL||PROSPECTIVE|||||||
34073957|NCT01268657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073958|NCT00115206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073959|NCT04575441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073960|NCT04233242|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multi-centre, open-label, parallel-group (1:1 allocation), superiority randomised clinical trial||||
33762467|NCT04129814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistical software (STATA 13.1, Stata Corp, Texas, USA) was used for random and equal stratification of the participants according to their mean values of IIEF, and this identify to which group the patients were enrolled, using 1:1 allocation ratio.|After periodontal and medical screening, all eligible patients will informed of potential risks, study objective, and benefits of their participation in this study. Non-surgical periodontal treatment consisted of oral hygiene instructions (OHI), single session full-mouth scaling and root planing (SRP) that will be performed by the same periodontist using Gracey curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic apparatus (Cavitron Select SPC, Dentsply professional, New York, USA) for all participants within a test group at baseline and after three months for patients in a control group because of ethical reasons. Therefore, no periodontal treatment will be performed during the follow-up period in control group.|t|f|f|f
33762468|NCT01945905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33762469|NCT00751764|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33762470|NCT01550484|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33762471|NCT04203043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762472|NCT03628586|||COHORT||PROSPECTIVE|||||||
33762473|NCT00624611|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762474|NCT02675478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762475|NCT04842214|||COHORT||PROSPECTIVE|||||||
33762476|NCT01715610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33762477|NCT06311084|NA|SINGLE_GROUP||TREATMENT||NONE||Open ended feasibility and acceptability of novel blended digital psychological intervention||||
33762478|NCT01105286|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33762479|NCT03010839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33762480|NCT06626152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762481|NCT04741516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762482|NCT00224770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762483|NCT02572947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762484|NCT05591248|NA|SINGLE_GROUP||SCREENING||NONE||||||
33762485|NCT00347516|RANDOMIZED|PARALLEL||||SINGLE||||||
33762486|NCT00717314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889588|NCT05490992|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a quasi-experimental within-subjects group design. It consists of two experiments that included an equal number of participants.||||
33889589|NCT05698290|||COHORT||PROSPECTIVE|||||||
33889590|NCT03798288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The analysis of the data will be performed blindly.|The study design is a multi-center randomised controlled trial with 2 parallel arms|f|f|t|f
33889591|NCT00562380|RANDOMIZED|||TREATMENT||NONE||||||
33975667|NCT05559268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975668|NCT00198029|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975669|NCT02315898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975670|NCT05531266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975671|NCT02992171|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975672|NCT02864758|||COHORT||RETROSPECTIVE|||||||
34073961|NCT05957861|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|PI will be blinding.|we will design a randomized controlled trial comprising two arms of a 16-week exercise web-based aerobic exercise (AE) training and another control group without any exercise intervention.|f|f|f|t
34073962|NCT03046953|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm trial with bayesian design||||
33889592|NCT02247089|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33889593|NCT01294228|||COHORT||PROSPECTIVE|||||||
33889594|NCT00967265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889595|NCT04308486|||COHORT||PROSPECTIVE|||||||
33889596|NCT03258892|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33889597|NCT03011645|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33889598|NCT02063555|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889599|NCT00989599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889600|NCT01879410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889601|NCT04525729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975673|NCT03953170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The drug will be delivered to the patient according to the randomization scheme and neither the patient nor the investigators will know which patient is randomized into which group until the study is completed. Only the pharmacist at the AHN pharmacy will know the patient assigned to each group.|Study subjects will be randomized to Teduglutide or placebo arm in a 1:1 allocation.|t|t|t|f
33975674|NCT04480463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the unmasked investigator involved in performing the IVT injections will be unmasked to study treatment. These individuals are not allowed to discuss treatment and/or subject outcome with masked study staff, including the evaluating investigator.||t|t|t|t
33975675|NCT02579096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975676|NCT03471598|||COHORT||PROSPECTIVE|||||||
33975677|NCT03147196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975678|NCT02651636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073963|NCT01429298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34073964|NCT05434663|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34073965|NCT02130388|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762487|NCT01682993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762488|NCT03010462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889602|NCT04686422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889603|NCT00484315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889604|NCT00787436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889605|NCT04120922|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|This is a time series open label trial so there is no randomisation or blinding to treatment. All analyses will be performed in a blinded manner and the treating clinicians will be blinded to the results of the calcium isotope ratios until after participants have completed their trial related administration of P-binder.|A open label, time series trial||||
33889606|NCT05047523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is rater-blinded for the Unified Wilson Disease Rating Scale (UWDRS) assessment only.||f|f|f|t
33889607|NCT06129890|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33975679|NCT06000423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|Participants assigned to either the TXA treatment group or the placebo group.|t|f|t|f
33975680|NCT01491620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975681|NCT04306900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975682|NCT06081751|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33975683|NCT04326777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975684|NCT06433453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975685|NCT03869749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The majority of study personnel, including the PI and study statistician, will be blinded until database lock. All individuals who will be involved with endpoint assessment will be blinded until database lock. Intervention facilitators will not be blinded, but will not be involved in endpoint assessment.|Participants will be assigned to one of two study interventions in an open randomized trial.|f|f|t|t
33975686|NCT00778947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33975687|NCT03139968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, operator and investigator are blinded to dummy drape vs RADPAD.||t|t|t|f
33975688|NCT02772536|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975689|NCT01484821|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33975690|NCT02563509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975691|NCT01427374|||COHORT||PROSPECTIVE|||||||
34073966|NCT04323384|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This project will use a crossover, repeated measures design to test the previously stated hypotheses. The benefits of using this design include improved control of between-subject variability and improved statistical power.||||
33975692|NCT03845309|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34073967|NCT05926648|NA|SINGLE_GROUP||OTHER||NONE||||||
34073968|NCT05755646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34073969|NCT03237650|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34073970|NCT02179047|||CASE_CONTROL||PROSPECTIVE|||||||
34073971|NCT00193414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073972|NCT02788721|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34073973|NCT05902871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762489|NCT04359771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765044|NCT05674890|RANDOMIZED|CROSSOVER||OTHER||NONE||The described study was a validation study comparing a novel testing device to the current clinical standard. The order of testing was randomized, so the design is that of a crossover study.||||
33765045|NCT00737880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33765046|NCT03809884|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33889608|NCT06391645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889609|NCT04488237|||CASE_CONTROL||PROSPECTIVE|||||||
33889610|NCT00745108|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33889611|NCT05599958|||OTHER||CROSS_SECTIONAL|||||||
33889612|NCT06195202|||COHORT||PROSPECTIVE|||||||
33889613|NCT04058587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889614|NCT03892421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889615|NCT04614818|||COHORT||RETROSPECTIVE|||||||
33889616|NCT01527721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889617|NCT02658448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889618|NCT02051114|||COHORT||PROSPECTIVE|||||||
33889619|NCT04434976|||CASE_CONTROL||RETROSPECTIVE|||||||
33889620|NCT02750059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889621|NCT00008385|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33889622|NCT03502330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889623|NCT01710930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889624|NCT00462787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889625|NCT02493647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33889626|NCT00448292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889627|NCT06091345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889628|NCT06545227|||COHORT||PROSPECTIVE|||||||
33889629|NCT01860937|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889630|NCT00271388|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33889631|NCT03216460|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This study is a single-arm, multi-center, observational clinical study.||||
33889632|NCT01349140|NA|SINGLE_GROUP||TREATMENT||DOUBLE|"Investigational Drug Service prepared all study medication, with each dose provided to the caregivers in a 30-mL syringe with IV line extension tubing, both wrapped in opaque tape to retain masking since the relative study drug concentration could be inferred by the opacity of the injectate. One syringe was labeled Dominant and the other labeled Other. In this manner, all investigators, nursing staff, and subjects remained masked to the specific concentration/dose during all outcome measurements."|Each subject is assigned two possible doses between 0-80 mg by the investigators based on previous participants' responses to various doses; and, the dominant side is then randomized to either the higher or lower dose. The response for each dose is the primary interest, and not a comparison of the left vs. the right or different dose combinations within each subject. In other words, of interest are the different doses effects on muscle strength and skin sensitivity across participants (eg., Dose A vs Dose B vs Dose C, etc).||||
33889633|NCT04673383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|RCT||t|t|t|t
33889634|NCT04890873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975693|NCT06545877|||COHORT||PROSPECTIVE|||||||
33975694|NCT00536926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975695|NCT04050488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization is carried out by research assistants, then making sequential numbers with closed envelopes that have been prepared. The results of the randomization are only known by research assistants. At the age of 3 days or priming\> 20cc / kg body weight/day, the research assistant will give a bottle of medicine containing zinc/placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse. The researcher monitors all patients who are sampled without knowing which group is the test and which group is the control.|Double-blind randomized controlled clinical trial in preterm infants (28 - 32 weeks) who are newborn or less than 3 days old who are admitted to the perinatology room. There were two research groups, namely the treatment group (the group that received zinc supplementation) and the control group (the group that received the placebo). In both groups the differences in growth indicators (body weight, body length, and head circumference) will be evaluated, the incidence of morbidity (sepsis, necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage and bronchopulmonary dysplasia).|t|f|t|t
33975696|NCT03112057|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33975697|NCT02210351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975698|NCT01621464|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33975699|NCT05840809|||COHORT||PROSPECTIVE|||||||
33975700|NCT00748293|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33975701|NCT00098709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975702|NCT02939274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975703|NCT02142764|NON_RANDOMIZED|PARALLEL||||NONE||||||
33889635|NCT01361256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889636|NCT00054847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889637|NCT02922387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889638|NCT03357094|||CASE_ONLY||PROSPECTIVE|||||||
33889639|NCT00866099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889640|NCT06211855|||CASE_ONLY||PROSPECTIVE|||||||
33889641|NCT04581720|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33889642|NCT01973257||PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33889643|NCT04748263|||COHORT||PROSPECTIVE|||||||
33975704|NCT06094556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975705|NCT03951948|||COHORT||RETROSPECTIVE|||||||
33889644|NCT05159414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889645|NCT00558935|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33889646|NCT05651347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple-blinded, parallel group, placebo controlled trial|PROTECT Me aims to be a multicentre, triple-blinded, randomized, parallel group, placebo controlled trial|t|t|t|t
34073974|NCT05204914|NA|SINGLE_GROUP||SCREENING||NONE||||||
34073975|NCT05850702|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34073976|NCT02811315|||OTHER||PROSPECTIVE|||||||
34073977|NCT05660252|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|All participants are necessarily unblinded|Open-label multicenter randomized controlled trial||||
33889647|NCT04917770|NA|SINGLE_GROUP||TREATMENT||NONE||Sintilimab in combination with Multimodality Radiotherapy group||||
33889648|NCT03048630|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889649|NCT05288582|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will be given the eye drop and will have their tear lipid examined before and after use of the drop.||||
34073978|NCT00738426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889650|NCT05079789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073979|NCT04057378|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. ECT 1.0 ms pulse width~2. ECT 0.5 ms pulse width"||||
34073980|NCT01258478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889651|NCT03403400|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental Design. To answer the study objective, a pragmatic, randomized, prospective, clinical study on 54 older adults with dizziness will be utilized. This will be conducted at Florida Hospital Sports Medicine and Rehabilitation locations that offer vestibular therapy. These are in East Orlando and Winter Park.||||
33889652|NCT01023789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889653|NCT03241446|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34073981|NCT04939649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889654|NCT04804618|||COHORT||PROSPECTIVE|||||||
34073982|NCT00670722|||COHORT||PROSPECTIVE|||||||
34073983|NCT01516489|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34073984|NCT00000311|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34073985|NCT04973657|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33889655|NCT00006187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889656|NCT04760184|||COHORT||RETROSPECTIVE|||||||
33889657|NCT03742778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889658|NCT02093611|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33889659|NCT02926807|||COHORT||PROSPECTIVE|||||||
33889660|NCT00188578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889661|NCT01032226|||COHORT||PROSPECTIVE|||||||
33889662|NCT01125332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34073986|NCT06203158|||COHORT||RETROSPECTIVE|||||||
34073987|NCT05833919|RANDOMIZED|PARALLEL||TREATMENT||NONE||"HER 2 negative MBC patients, who have progressed to a first line chemotherapy for metastatic disease and meet all the inclusion criteria, will be considered eligible for study enrollment. Patients will be randomly allocated using a 1:1 allocation centralized method into the two study arms: ARM A or ARM B.~Randomization will be performed with a minimization procedure that will account for the following parameters as strata:~* center;~* ECOG Performance Status (0-1 vs 2);~* previous use of CDK inhibitor (yes vs no);~* previous use of bevacizumab (yes vs no);~* triple negative breast cancer (yes vs no)."||||
34073988|NCT03112070|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34073989|NCT05438342|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34073990|NCT05430802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073991|NCT05324449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073992|NCT04354818|||COHORT||PROSPECTIVE|||||||
34073993|NCT05182801|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34073994|NCT02494895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073995|NCT02799017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34073996|NCT06605846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
34073997|NCT03273920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34073998|NCT02989402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34073999|NCT03944213|||CASE_CONTROL||PROSPECTIVE|||||||
34074000|NCT04543175|||CASE_ONLY||PROSPECTIVE|||||||
34074001|NCT01451918|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34074002|NCT05060991|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized open-labeled||||
34074003|NCT00178516|||CASE_CONTROL||PROSPECTIVE|||||||
34074004|NCT04410471|||CASE_CONTROL||PROSPECTIVE|||||||
34074005|NCT00956332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074006|NCT03958188|||COHORT||RETROSPECTIVE|||||||
34074007|NCT06007846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074008|NCT02908984|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34074009|NCT03905941|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This is a randomized, controlled, double blinded, controlled, crossover study.|t|t|t|t
33762490|NCT06365307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"During the preliminary screening and indication for surgical treatment, patients are divided into 2 groups depending on the location of the pathological process: 1 - cervical spine, 2 - lumbar spine. During independent sequential randomization in a 1:1 ratio, patients in each of these groups are divided into clinical (A) and control (B) groups.~Distribution of treatment methods by groups:~1A - use of Histograft for spinal fusion of the cervical spine, 50 patients~1. B - use of synthetic osteoplastic material based on β-TCP for spinal fusion of the cervical spine, 50 patients~2. A - use of Histograft for spinal fusion of the lumbar spine, 100 patients~2B - use of bone autograft for spinal fusion of the lumbar spine, 100 patients"||||
33762491|NCT03635346|||COHORT||PROSPECTIVE|||||||
33762492|NCT00327002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33762493|NCT02974881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762494|NCT00949715|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33762495|NCT05709990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|outcome evaluators, and statisticians were blinded.|The 3 groups will be treated at the same time|f|f|t|t
33762496|NCT00979823|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762497|NCT05474521|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This study was performed according to the predictive correlational research design, which is one of the quantitative research methods. Participants included in the study were determined according to the simple random sampling method. Athletes who studied at the faculty of sports sciences participated in this research and the research was carried out with a single group.||||
33762498|NCT04308902|||COHORT||PROSPECTIVE|||||||
33762499|NCT03494569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762500|NCT04961866|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33762501|NCT03145766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074010|NCT04649086|RANDOMIZED|PARALLEL||TREATMENT||NONE|Evaluations will be carried out with blinding by investigators different from those involved in the exercise training sessions. Patients will be blinded to the training mode hypothesis.|"All included participants will be randomly assigned (1:1) using the REDCap software, , at the experimental group or the control group.~Participants will perform 24 exercise sessions on cycloergometer (3 sessions/week, 8 weeks).~The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation.~The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test."||||
34074011|NCT02482142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33889663|NCT03649919|||CASE_ONLY||PROSPECTIVE|||||||
33889664|NCT06068582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be done by investigators who are not involved in data collection and analyses. Intervention will be carried out by people not involved in data collection and analyses||f|f|t|t
33889665|NCT00452725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074012|NCT05973461|RANDOMIZED|PARALLEL||SCREENING||NONE||males and females, with and without symptoms of depression||||
34074013|NCT06215066|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients were randomly assigned to one of both groups (PMR group and VR group, 75 patients for each) by computer-generated sequences and a sequential number will be assigned to the patient.||||
34074014|NCT01854697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889666|NCT04088448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889667|NCT01324830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889668|NCT04333082|||COHORT||RETROSPECTIVE|||||||
33889669|NCT00716976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889670|NCT06488300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889671|NCT00947648|RANDOMIZED|PARALLEL||||NONE||||||
33762502|NCT02929355|||COHORT||PROSPECTIVE|||||||
33889672|NCT05309447|||COHORT||PROSPECTIVE|||||||
33889673|NCT05749835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889674|NCT06310148|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889675|NCT06295445|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33889676|NCT03796403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized into two groups by simple random. In bupivacaine and diclofenac group (n=70), Twenty ml of bupivacaine was infiltrated into surgical-site peritoneum and diclofenac 75 mg was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing. In the bupivacaine alone group (n=70), 20 ml of bupivacaine was infiltrated into surgical-site peritoneum before closure and a 3 ml of sterile water was intramuscularly injected immediately after complete the procedure. Intravenous morphine injection was given if the pain score was more than 6 in the first 24 hours. Post-operation; time to first request of pain medication, doses, side effects, and vital signs were recorded. VAS was recorded at 2, 6, 12 and 24 hours post-operation and patients' satisfied score was recorded after 24 hours post-operation.|t|t|f|t
33889677|NCT05877144|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Data Available|No Data Available||||
33889678|NCT00876369|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33889679|NCT00868790|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33889680|NCT02285400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889681|NCT03935516|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a prospective, randomized controlled trial comparing extended elbow and flexed elbow casting.||||
33889682|NCT06544109|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889683|NCT02156856|||||PROSPECTIVE|||||||
33889684|NCT03680937|||CASE_CONTROL||PROSPECTIVE|||||||
33889685|NCT05507957|||COHORT||PROSPECTIVE|||||||
33889686|NCT06160050|RANDOMIZED|PARALLEL||PREVENTION||NONE||The Preserve and Connect Project will be a two arm (BPC+ TAU vs TAU) parallel randomized clinical trial to determine the efficacy of the BPC and establish the evidence base to allow the BPC to be listed on the Title IV-E Clearing House. Participants will be recruited from individuals seeking treatment from our community partners.||||
34074015|NCT05138601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33889687|NCT01871792|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889688|NCT04820751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889689|NCT03152942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889690|NCT03420534|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33889691|NCT04304456|||COHORT||PROSPECTIVE|||||||
33889692|NCT04147793|||CASE_CONTROL||PROSPECTIVE|||||||
33889693|NCT02527356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889694|NCT04939857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889695|NCT02415790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889696|NCT02604264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889697|NCT04782167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889698|NCT00392132|||||OTHER|||||||
33889699|NCT00552357|||CASE_ONLY||PROSPECTIVE|||||||
34074016|NCT05772676|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple-blinded, 1:1ratio to Aprepitant or placebo|A randomized controlled clinical trial conducted in obese patients undergoing laparoscopic gastric sleeve surgery to assess the efficacy of Aprepitant (80 or 125 mg) in combination with a standard antiemetic regimen (Ondansetron + Metoclopramide + Dexamethasone) is presented vs placebo + the same standard regimen, evaluating postoperative nausea and vomiting by means of a specific scale (Rhodes index) for the assessment of nausea and vomiting|t|t|t|f
34074017|NCT05513846|||COHORT||CROSS_SECTIONAL|||||||
33889700|NCT02964598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889701|NCT05431244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889702|NCT01526356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889703|NCT06450665|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will go through three 30-minute VR sessions over a period of 3 weeks. The wait-list control group will complete the questionnaires in the same interval as the intervention group, with promise of receiving VR intervention after 1-month follow-up is over.||||
34074018|NCT01013714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074019|NCT03416192|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074020|NCT02581488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074021|NCT03019991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074022|NCT04611568|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074023|NCT06079749|||COHORT||RETROSPECTIVE|||||||
34074024|NCT04198220|||OTHER||PROSPECTIVE|||||||
34074025|NCT03571607|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074026|NCT03215875|RANDOMIZED|CROSSOVER||TREATMENT||NONE||60mg ER Torsemide study in fed and fasting conditions||||
34074027|NCT05450913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074028|NCT01228656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074029|NCT00907023|||COHORT||PROSPECTIVE|||||||
33889704|NCT00807950||||TREATMENT||||||||
33889705|NCT01061281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889706|NCT03374280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889707|NCT04313725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Test and placebo treatment kits will be randomized by the sponsor prior to sending to clinical site.||t|t|t|t
33889708|NCT05533567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33889709|NCT04909606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34074030|NCT06312800|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34074031|NCT04443647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34074032|NCT04195178|||COHORT||OTHER|||||||
34074033|NCT02894814|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074034|NCT01273636|||CASE_ONLY||RETROSPECTIVE|||||||
34074035|NCT04878055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||subjects will be randomized with a 2:1 randomization ratio|t|t|t|t
33762503|NCT04946929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762504|NCT01802255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33762505|NCT00052676|RANDOMIZED|||DIAGNOSTIC||||||||
33762506|NCT00148382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33762507|NCT03129048|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33889710|NCT04818515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889711|NCT05394415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889712|NCT04568837|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized into one of two groups: treatment group vs control (no treatment) group||||
33889713|NCT01614964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889714|NCT03453892|||CASE_ONLY||PROSPECTIVE|||||||
33889715|NCT03303989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Phase II, double blind, placebo controlled multisite proof-of-concept trial in subjects initiating pegloticase for treatment of chronic gout|t|f|t|f
34074036|NCT06612619|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34074037|NCT01773603|RANDOMIZED|PARALLEL||||NONE||||||
34074038|NCT05947669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074039|NCT06311461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34074040|NCT01004978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762508|NCT05211271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762509|NCT05865704|||COHORT||PROSPECTIVE|||||||
33762510|NCT00985985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762511|NCT00953303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762512|NCT05186337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34074041|NCT02710084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074042|NCT01968811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074043|NCT02912312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074044|NCT04179279|||OTHER||PROSPECTIVE|||||||
34074045|NCT06452602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074046|NCT03832829|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective clinical trial||||
34074047|NCT02108977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074048|NCT03651817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34074049|NCT00173680|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34074050|NCT02298426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34074051|NCT03510975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All participants were divided into three groups. Twenty-five children and their parents were instructed only a verbal behavioral therapy, 25 were instructed a behavioral therapy with a written check-list form and 25 children received desmopressin treatment plus verbal behavioral therapy were randomly included in the study.|t|f|f|f
33889716|NCT05333094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single (Outcomes Assessor) Only the outcome assessors will be blind. The patients name will be sealed from pre and post radiographs and study models. Then two assessors will carry out, blindly and independently, the measurements and analysis of the study||t|f|f|t
33889717|NCT03013465|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33889718|NCT06100783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889719|NCT04223245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded to subject group assignment|Single blind randomized trial with 2 groups|f|f|f|t
33889720|NCT01551745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889721|NCT03775837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889722|NCT01455974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889723|NCT05972512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study is double blind wherein neither the subjects nor the Investigator shall be aware of the test treatment allocation|A Randomized, Double-Blind, Placebo-Controlled, Safety, and Efficacy Study|t|f|t|f
33889724|NCT05243849|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889725|NCT01110187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33889726|NCT05722964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Comparison of SHR-1906 injection and placebo|t|t|t|t
34074052|NCT02045186|NA|SINGLE_GROUP||OTHER||NONE||||||
34074053|NCT01128400|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074054|NCT01325545|||CASE_CONTROL||PROSPECTIVE|||||||
33762513|NCT04105335|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The principal objective of the first part of the study (Phase 1a) is to establish if a combination of an experimental drug (MTL-CEBPA) with pembrolizumab (PD-1 inhibitor) is safe and well-tolerated in patients with advanced solid tumours.~Phase 1b will aim to confirm the doses of the drugs obtained in Phase 1a in a larger population and if it has potential to reduce the size of the tumour and/or extend the life of participants."||||
33762514|NCT04900350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762515|NCT01683162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33762516|NCT02965222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33762517|NCT06274814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33762518|NCT03846778|||COHORT||RETROSPECTIVE|||||||
33762519|NCT06142825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Type III hybrid effectiveness-implementation trial||||
33762520|NCT01673893|||COHORT||PROSPECTIVE|||||||
33762521|NCT06623396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762522|NCT04766632|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33762523|NCT00425958|||||OTHER|||||||
33762524|NCT03862287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889727|NCT02847884|||COHORT||PROSPECTIVE|||||||
33889728|NCT04356014|||CASE_ONLY||RETROSPECTIVE|||||||
33889729|NCT03093402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889730|NCT04209231|||OTHER||CROSS_SECTIONAL|||||||
33889731|NCT03780998|||COHORT||PROSPECTIVE|||||||
33889732|NCT03850821|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized study design will be implemented in which 6 ASPs are randomly assigned to either the Connect Social Mechanisms intervention condition or the active-wait list control condition (8-week intervention, with a 2 week post-intervention data collection).||||
33889733|NCT03772327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889734|NCT03465033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All patients will be told that two interventions are compared but they will not know which one is the usual care or the early physiotherapy. Professionals that will evaluate the measurements and the investigators that will make the statistical analysis, all will be blinded to treatment allocation.|Patients undergoing OS will be studied. All patients will be told that two interventions are compared but they will not know which one is the usual care or the early physiotherapy. All of them will receive instructions of basic care after surgery: use of intermaxillary elastics, soft diet during the first month and semi-soft during the second month. Patients will be asked to remove the intermaxillary elastics 30min before the measurements.|t|f|t|t
34074055|NCT00320268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889735|NCT00224666|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33889736|NCT04514263|||COHORT||PROSPECTIVE|||||||
33889737|NCT04513691|||COHORT||CROSS_SECTIONAL|||||||
33889738|NCT03893045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889739|NCT04529291|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889740|NCT03990129|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Two phase study, before-after comparison||||
33889741|NCT02834910|||CASE_CONTROL||PROSPECTIVE|||||||
34074056|NCT06612671|||CASE_CONTROL||RETROSPECTIVE|||||||
34074057|NCT06453733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074058|NCT02915172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074059|NCT00370773|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34074060|NCT01344239|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33975706|NCT03196024|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, community health workers, and assessors are blinded to which arm is the active intervention and which arm is the active comparator. Participants, community health workers, and assessors will be blinded to hypotheses regarding group differences and will be informed that both groups are intervention groups and that we are examining how well both intervention types perform.|We will conduct a randomized controlled trial with Hispanic family dyads using a 2-group design (Corazón de la Familia active intervention versus control condition) to test effects of a type 2 diabetes and CVD risk reduction intervention at 3 (short-term) and 12 (long-term) months. For dyads randomized to the active intervention, the participant with 2 or more CVD or type 2 diabetes risk factors (index participant) and their co-participating family member will attend 8 sessions that provide type 2 diabetes and CVD risk reduction and lifestyle modification education. For dyads randomized to the control condition, only the index participant will attend 8 educational lifestyle modification sessions. Participants in both groups will receive monthly follow up phone calls up through 12 months post-baseline. The sessions for both the intervention and the control group and the monthly post-intervention phone calls will be provided by community health workers.|t|t|f|t
33975707|NCT05056142|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34074061|NCT02517736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074062|NCT05381454|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975708|NCT06314321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975709|NCT04253431|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33975710|NCT03936400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975711|NCT02819674|||COHORT||PROSPECTIVE|||||||
33762525|NCT05674591|NA|SINGLE_GROUP||TREATMENT||NONE||The current study is a clinical trial, including the repeated assessments of a single sample of Syrian women. Pre-treatment, posttreatment and 12-month posttreatment assessments were conducted on participants. PTSD severity, depression, anxiety and difficulties in emotion regulation will be assessed as outcomes.||||
33975712|NCT05492591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multicenter, randomized, active drug-controlled, dose-finding phase II clinical study.|t|t|t|t
33975713|NCT05441202|||COHORT||PROSPECTIVE|||||||
33975714|NCT05448677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975715|NCT03354247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074063|NCT06491355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074064|NCT06346041|NA|SEQUENTIAL||TREATMENT||NONE||||||
34074065|NCT02849080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074066|NCT00206427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074067|NCT06487715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074068|NCT03510819|||OTHER||CROSS_SECTIONAL|||||||
33762526|NCT03757143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762527|NCT03830203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889742|NCT06331091|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled study||||
33889743|NCT02618369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889744|NCT01085188|RANDOMIZED|FACTORIAL||TREATMENT||||||||
33889745|NCT00260208|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889746|NCT05163704|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889747|NCT03182738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33889748|NCT05146141|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34074069|NCT03000985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33762528|NCT05608096|||CASE_ONLY||PROSPECTIVE|||||||
33889749|NCT04646148|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||f|f|t|t
33889750|NCT06546033|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first group will be fed with Mediterranean diet The second group will be fed with intermittent diet||||
33889751|NCT03651843|||OTHER||PROSPECTIVE|||||||
33889752|NCT04329026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889753|NCT01145560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889754|NCT06190496|||COHORT||PROSPECTIVE|||||||
33889755|NCT01206907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074070|NCT01466413|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34074071|NCT02812641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074072|NCT05293860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074073|NCT02085265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889756|NCT03254173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* Treatment allocation will be concealed from patients, investigators, and study coordinators enrolling the participants.~* The pills used in the study ( either remeron or placebo ) will be kept into opaque containers , in order to be concealed from patients , investigators and study coordinators."|double-blinded randomized controlled trial.|t|t|t|f
33889757|NCT00431392|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33762529|NCT03839732|||CASE_ONLY||RETROSPECTIVE|||||||
33889758|NCT02601573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889759|NCT03566212|RANDOMIZED|PARALLEL||TREATMENT||NONE||local anesthesia is administered by using either camouflaged syringe or conventional syringe and was compared for reduction in anxiety levels in both groups||||
33889760|NCT05530096|||COHORT||PROSPECTIVE|||||||
33889761|NCT04856592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889762|NCT04235387|||CASE_CONTROL||PROSPECTIVE|||||||
33889763|NCT04572009|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889764|NCT05390216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889765|NCT01431287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889766|NCT00793793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889767|NCT01148173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889768|NCT06330909|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, randomized two arm phase III multicentre trial comparing image-guided focal dose escalation using SBRT in patients with primary PCa treated with primary external beam hypofractionated radiation therapy.~Patients will be randomized to either arm A (experimental intervention) or arm B (control intervention)."||||
33889769|NCT01948492|NA|SINGLE_GROUP||OTHER||NONE||||||
33889770|NCT04178148|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889771|NCT05825807|||OTHER||CROSS_SECTIONAL|||||||
33889772|NCT00663000|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762530|NCT00732602|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33762531|NCT04908059|||CASE_ONLY||OTHER|||||||
33762532|NCT05999084|||CASE_ONLY||PROSPECTIVE|||||||
33762533|NCT01546792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889773|NCT01091961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33889774|NCT02734173|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889775|NCT01910792|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33889776|NCT02033356|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889777|NCT02684071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975716|NCT05371522|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All individuals included will undergo a \[18F\]DPA-714 positron emission tomography (PET) scan||||
33975717|NCT01946165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975718|NCT01922349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33975719|NCT04407819|||CASE_CONTROL||RETROSPECTIVE|||||||
33975720|NCT00002387||PARALLEL||TREATMENT||||||||
33889778|NCT02087332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889779|NCT05173129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||cross-sectional study for two groups||||
33889780|NCT00055640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889781|NCT02487875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889782|NCT00000148|RANDOMIZED|||TREATMENT||||||||
33889783|NCT00981526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074074|NCT01351207|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34074075|NCT04680533|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm||||
34074076|NCT06279195|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants in two groups with different conditions will be give REL-CT.||||
34074077|NCT00385918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074078|NCT02423083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074079|NCT04244903|||OTHER||CROSS_SECTIONAL|||||||
34074080|NCT05132660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be assigned a number and treatment group will be assigned according to randomization strategy by pharmacy personnel|Sinemet CR 25 mg carbidopa/100 mg levodopa or placebo will be given twice daily for 6 months or 24 months.|t|f|t|f
33762534|NCT05318469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889784|NCT01136551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889785|NCT05379751|NA|SINGLE_GROUP||TREATMENT||NONE||A cohort of 54 patients diagnosed with Spigelian hernia who underwent open surgical repair with the tentacle shaped implant (Freedom Octomesh VHR XS produced by Insightra Medical Inc. - USA) forms the body of this study||||
33889786|NCT02416869|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33889787|NCT05946967|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33889788|NCT02735213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889789|NCT01193686|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889790|NCT05863715|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive each level of visual cue type.||||
33889791|NCT00127127|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33889792|NCT02162862|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33889793|NCT01898156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074081|NCT00018564|RANDOMIZED|||TREATMENT||DOUBLE||||||
34074082|NCT06612983|NA|SINGLE_GROUP||OTHER||NONE||All participants will experience the IASTM treatment first and the first session and the walking - sham treatment at the second session.||||
33762535|NCT02282397|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33762536|NCT01957501|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33762537|NCT01959347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33762538|NCT02269514|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33762539|NCT03767270|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33889794|NCT02173340|||||PROSPECTIVE|||||||
33889795|NCT04294485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (participant)||t|f|f|f
33889796|NCT05255003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975721|NCT00002965|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975722|NCT05743218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|On account of the particularity of acupuncture research, it is impossible to blind acupuncture operators. Blinded evaluation will be adopted in the trial, and the third party who does not know the grouping will evaluate the efficacy. Blind statistical analysis was used in the data summary stage, and the researchers, operators and statisticians were separated.|The subjects were randomly assigned to the liver meridian group, the stomach meridian group and the non-acupoint acupuncture groups group at a ratio of 1:1:1.|t|f|t|t
34074083|NCT06384027|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This is a crossover, randomized study, blinded|t|f|t|f
34074084|NCT06319092|||OTHER||CROSS_SECTIONAL|||||||
34074085|NCT03964077|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074086|NCT01869088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889797|NCT01746251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762540|NCT05671640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074087|NCT04714190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762541|NCT00229957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762542|NCT02552238|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889798|NCT03751267|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889799|NCT00574028|||CASE_CONTROL||PROSPECTIVE|||||||
34074088|NCT03556969|||COHORT||CROSS_SECTIONAL|||||||
34074089|NCT05530486|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074090|NCT03284853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074091|NCT01492192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074092|NCT00455676|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074093|NCT06248307|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||2 parallel groups, double-blind, randomized intervention|t|f|t|t
34074094|NCT00079053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762543|NCT01227603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762544|NCT00830622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762545|NCT01257711|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33762546|NCT03161366|NA|SINGLE_GROUP||PREVENTION||NONE||Interventional, single arm, open-label, non-randomized||||
33762547|NCT01120158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762548|NCT05124106|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|Patient tumor stage is unknown for the examiner.|Tumor identified during endoscopy of the bladder is examined with Raman spectrometry. Tumor is resected. Histopathological diagnosis is compared with results of Raman spectrometry.||||
33889800|NCT05699148|||COHORT||PROSPECTIVE|||||||
33889801|NCT06160102|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participatory action research||||
33889802|NCT02945657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889803|NCT04768582|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33889804|NCT00255073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975723|NCT04646174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975724|NCT05164809|||COHORT||RETROSPECTIVE|||||||
33975725|NCT01945632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975726|NCT02492490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975727|NCT00368966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33975728|NCT00334490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762549|NCT00849004|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33762550|NCT05418855|||COHORT||PROSPECTIVE|||||||
33762551|NCT03034018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762552|NCT02530814|||CASE_CONTROL||PROSPECTIVE|||||||
33975729|NCT06344000|||COHORT||PROSPECTIVE|||||||
33762553|NCT01874314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762554|NCT00027001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762555|NCT03877965|||COHORT||PROSPECTIVE|||||||
33762556|NCT01618890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762557|NCT00231673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33762558|NCT02891538|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762559|NCT05250622|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762560|NCT00235092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889805|NCT03244059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded placebo controlled randomized clinical trial|Patients will be randomly assigned to receive active:placebo in a ratio of 2:1.|t|t|t|t
33889806|NCT01150487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889807|NCT03683602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889808|NCT04196114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889809|NCT04531202|||COHORT||PROSPECTIVE|||||||
33889810|NCT00472693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889811|NCT02392598|||COHORT||PROSPECTIVE|||||||
33889812|NCT02533089|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
33889813|NCT01592539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33889814|NCT03677193|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be conducted a single-case experimental design (SCED). Participants will be randomly assigned to begin the intervention at staggered starting-points.||||
33889815|NCT03792048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889816|NCT05202457|||CASE_ONLY||RETROSPECTIVE|||||||
33889817|NCT04790591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Open clinical trial with a subgroup analysis~(One can argue whether this study should be defined as a cohort study or as an open clinical trial. The idea of the study originated from the need to observe/confirm the feasibility and safety aspects of a routine which as of today has become common practice, namely same-day surgery, but as such it may also be categorized as a treatment... Either way, based on the preselection of age and comorbidity often reported in the literature, a two-arm subgroup analysis of the nonselective study participants will be conducted.)"||||
33889818|NCT03530514|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33975730|NCT01790022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975731|NCT01447264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975732|NCT01353300|||CASE_ONLY||RETROSPECTIVE|||||||
33975733|NCT01083875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33975734|NCT00646945|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33975735|NCT02992405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33975736|NCT01520090|||||CROSS_SECTIONAL|||||||
33975737|NCT01440530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33975738|NCT05190263|||OTHER||RETROSPECTIVE|||||||
33975739|NCT01622582|||||RETROSPECTIVE|||||||
33975740|NCT02623829|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975741|NCT02470195|NON_RANDOMIZED|PARALLEL||||NONE||||||
33975742|NCT02301247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975743|NCT06543576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975744|NCT00455052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975745|NCT05632965|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33975746|NCT04452578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762561|NCT00661661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762562|NCT01076283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762563|NCT00846443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762564|NCT03585101|NA|SINGLE_GROUP||OTHER||NONE||||||
33762565|NCT00650195|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33975747|NCT05462288|||CASE_ONLY||CROSS_SECTIONAL|||||||
34074095|NCT01676012|||CASE_ONLY||CROSS_SECTIONAL|||||||
33975748|NCT05690568|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||single group pilot study to determine feasibility and potential effect size||||
33975749|NCT03392974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975750|NCT03320408|||COHORT||PROSPECTIVE|||||||
33975751|NCT03718338|||CASE_CONTROL||PROSPECTIVE|||||||
33975752|NCT03872999|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975753|NCT03317613|NA|SINGLE_GROUP||TREATMENT||NONE||Cancer patients treated with qutenza (capsaicin patch)||||
33975754|NCT06231758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33975755|NCT00314691|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975756|NCT00310258|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33975757|NCT00215462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975758|NCT02228174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975759|NCT02378103|||CASE_CONTROL||RETROSPECTIVE|||||||
33975760|NCT05485909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975761|NCT03110666|NA|SINGLE_GROUP||TREATMENT||NONE||autologous concentrated bone marrow aspirate||||
33975762|NCT06291883|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33975763|NCT04910490|||CASE_CONTROL||RETROSPECTIVE|||||||
33975764|NCT01438723|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975765|NCT01654380|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33975766|NCT03676777|||COHORT||PROSPECTIVE|||||||
33975767|NCT01941095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975768|NCT03262181|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are masked to their group assignment until the end of the study. Investigator is masked to intervention condition.||t|f|t|f
33975769|NCT00006443||||TREATMENT||||||||
33762566|NCT04667975|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Part 1(Dose Escalation)~  1. Level 1(10mg/kg)~ 2. Level 2(15mg/kg)~ 3. Level 3(20mg/kg)~ 4. Level 4(25mg/kg)~* Part 2(Dose Expansion)~  1. EGFR TKI resistance~ 2. EGFR Wild Type"||||
33762567|NCT01889173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762568|NCT03473223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762569|NCT00816179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762570|NCT01581723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762571|NCT01664520|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762572|NCT06300138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762573|NCT03226964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762574|NCT06075797|RANDOMIZED|PARALLEL||OTHER||NONE||2:1 parallel RCT||||
33762575|NCT04665011|||COHORT||PROSPECTIVE|||||||
33762576|NCT03489096|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, open-label pilot study||||
33889819|NCT04297943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33889820|NCT03589001|||COHORT||PROSPECTIVE|||||||
33889821|NCT03173703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889822|NCT02104063|||COHORT||PROSPECTIVE|||||||
33889823|NCT04095455|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33889824|NCT00213239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889825|NCT06435390|||COHORT||RETROSPECTIVE|||||||
33889826|NCT01136395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889827|NCT02326948|||CASE_CONTROL||RETROSPECTIVE|||||||
33889828|NCT02358811|||COHORT||PROSPECTIVE|||||||
33889829|NCT06213220|||OTHER||OTHER|||||||
33889830|NCT01624194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889831|NCT02000609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33889832|NCT03975998|||COHORT||PROSPECTIVE|||||||
33975770|NCT00203307|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33975771|NCT05063461|NA|SINGLE_GROUP||OTHER||NONE||||||
33975772|NCT04685421|NA|SINGLE_GROUP||TREATMENT||NONE||Study population of 30 pediatric cardiac surgery patients (ages 2 to 17_cohort I) undergoing elective operations between the ages of two through seventeen years. Cohort II (Ages 2 \< 6)||||
33975773|NCT03673826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975774|NCT00775697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889833|NCT04409678|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975775|NCT01243554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33975776|NCT04534283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975777|NCT00279721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975778|NCT00619385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975779|NCT05690685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975780|NCT03749265|||COHORT||PROSPECTIVE|||||||
33762577|NCT03389139|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33762578|NCT05426564|||COHORT||PROSPECTIVE|||||||
33762579|NCT05628805|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33762580|NCT01722162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762581|NCT03394443|||CASE_ONLY||PROSPECTIVE|||||||
33762582|NCT05588609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33762583|NCT04391465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762584|NCT00232960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762585|NCT01495884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889834|NCT01855256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889835|NCT01897909|||CASE_CONTROL||PROSPECTIVE|||||||
33889836|NCT00078364||||TREATMENT||||||||
33889837|NCT01180803|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889838|NCT02119520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975781|NCT03879213|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single (Participant) Single blinded|Multi center, randomized, single-blind, 2-arm, placebo-controlled, within subject cross-over trial, featuring a repeated postprandial sampling paradigm|t|f|f|f
33975782|NCT04302948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study staff who abstract outcomes from medical record will not be aware of patients' study arm allocation.|Randomized controlled trial.|f|f|f|t
33975783|NCT04642456|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||control group with healthy subjects and patient group with spinal deformity (ASD)||||
33975784|NCT04576546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975785|NCT01775215|||COHORT||PROSPECTIVE|||||||
33975786|NCT03713138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded trial, Intervention and placebo given|Randomized controlled placebo trial|t|f|f|f
33975787|NCT02397070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975788|NCT01636856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975789|NCT02426619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33975790|NCT05337956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975791|NCT02709356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975792|NCT02463513|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33975793|NCT03352427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975794|NCT02106065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33975795|NCT06458790|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33975796|NCT04933513|||COHORT||RETROSPECTIVE|||||||
34074096|NCT06462898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded. The research team will pre-mix the drinks and have them labeled for participants daily. Both drinks look and taste the same.|A blinded randomized-placebo control trial will be conducted in collaboration with the Army Holistic Health and Fitness (H2F) Program. Participants will be randomly selected from two H2F training sites: Ft. Campbell and Ft. Drum. In total, 100 participants will be randomly selected. Each site will have participants assigned to the placebo group and omega-3 enhanced smoothie group. Participants will be excluded if they have a fish allergy or if they are unable to complete an Army Combat Fitness Test (ACFT) for any reason. Participants taking omega-3 supplements will not be excluded, but will be instructed to be consistent for the duration of the study.|t|f|f|f
34074097|NCT03997396|||COHORT||PROSPECTIVE|||||||
34074098|NCT03894839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074099|NCT05725915|||CASE_ONLY||PROSPECTIVE|||||||
34074100|NCT06474572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074101|NCT05575739|||COHORT||PROSPECTIVE|||||||
33889839|NCT01335971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889840|NCT00143325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33889841|NCT01236391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889842|NCT00869297|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33889843|NCT02351102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889844|NCT03352245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889845|NCT05547945|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study used a randomized control trial design to perform simple sampling with using computer random sampling. Due to research recruitment, treatment intervention, and follow-up data tracking are different researchers, a single blind could reduce interference. The randomization procedure of this study was handled by the trained researcher. The researchers were responsible for different research interventions and data collection. The randomization of the password was not released during the study intervention to ensure the purpose of the randomization.|Sixty caregivers were randomized to the health promotion group intervention (n=30) and the control groups (n=30). The control group received usual care.|f|t|t|t
33889846|NCT00755820|||||PROSPECTIVE|||||||
33889847|NCT03311672|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33889848|NCT05352685|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889849|NCT05946590|NA|SINGLE_GROUP||TREATMENT||NONE||An exploratory prospective cohort study.||||
33889850|NCT06334367|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889851|NCT01871883|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34074102|NCT06447701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subject numbers and corresponding medication numbers are permanently identified and unique for each successfully randomized patient. If any patients who have been successfully randomized do not receive the trial medication or cannot be reassigned to others, their medication and medication numbers will be invalidated by the medication administrator. To ensure blinding during the trial execution, unblinded personnel responsible for administering and configuring the trial drug must sign a confidentiality agreement.|The subject numbers and corresponding medication numbers are permanently identified and unique for each successfully randomized patient. If any patients who have been successfully randomized do not receive the trial medication or cannot be reassigned to others, their medication and medication numbers will be invalidated by the medication administrator. To ensure blinding during the trial execution, unblinded personnel responsible for administering and configuring the trial drug must sign a confidentiality agreement. Investigators, other blinded investigators, subjects, and sponsors will not have access to any information regarding group assignment or related documents pertaining to the trial drug.|t|t|t|t
34074103|NCT06612749|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074104|NCT02082171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34074105|NCT06613373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074106|NCT05316181|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled, open-label, multicenter phase III trial||||
34074107|NCT05042752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074108|NCT03162406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel assignment|t|t|t|t
34074109|NCT02820519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074110|NCT04871152|||COHORT||PROSPECTIVE|||||||
34074111|NCT03140163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074112|NCT04124380|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34074113|NCT04084002|||COHORT||PROSPECTIVE|||||||
34074114|NCT02869477|||COHORT||PROSPECTIVE|||||||
34074115|NCT00844402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074116|NCT02010112|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34074117|NCT01321632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074118|NCT02968108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074119|NCT02640313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074120|NCT00054223||||||NONE||||||
34074121|NCT03635762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074122|NCT05418907|||COHORT||PROSPECTIVE|||||||
34074123|NCT05477004|||CASE_ONLY||PROSPECTIVE|||||||
34074124|NCT05927077|||OTHER||RETROSPECTIVE|||||||
34074125|NCT03646747|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single site, non-randomised basic science study||||
34074126|NCT03239067|||COHORT||PROSPECTIVE|||||||
34074127|NCT03812939|||COHORT||PROSPECTIVE|||||||
34074128|NCT01148394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074129|NCT01659840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074130|NCT03908554|RANDOMIZED|PARALLEL||TREATMENT||NONE||The WHPP was applied to the intervention group in the workplace for two times a week for five weeks. During the first 5 minutes of the session, breathing exercises, 20 minutes, PMR and 10 minutes, posture exercises were performed. PMR has progressed gradually to every session. The program is under control with a follow-up chart of what the participants do every day, and the participants were supported with various reminders (i.e., graphical leaflets on PMR techniques which also can be used as a guide while practicing at home). Participants of the control group rested in a room for 40 minutes and were told that they could read every session.||||
33889852|NCT06072014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33889853|NCT03192904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889854|NCT02683369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889855|NCT05405829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889856|NCT05548036|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomised at recruitment then due to the nature of the intervention masking is not viable|Randomised Control Trial||||
33889857|NCT02529527|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33889858|NCT01239407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889859|NCT01541566|||CASE_CONTROL||PROSPECTIVE|||||||
33889860|NCT04070794|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33889861|NCT01216774|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33889862|NCT05932719|||COHORT||RETROSPECTIVE|||||||
33889863|NCT01907165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889864|NCT02504255|||COHORT||PROSPECTIVE|||||||
33889865|NCT03766347|||COHORT||PROSPECTIVE|||||||
33889866|NCT04335487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Preference trial||||
33889867|NCT01938157|NA|SINGLE_GROUP||SCREENING||NONE||||||
33889868|NCT05859087|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1 randomized controlled trial||||
33889869|NCT00891735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762586|NCT04713267|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Randomised crossover interventional trial allocating patients with POSA to ISABel Bed 1 or ISABel Bed 2 in random order to study the effect on POSA. Patients with POSA (untreated, or if treated, following a short-term therapy withdrawal) will undergo an in-laboratory polysomnography in ISABel Bed 1 and Bed 2.||||
33762587|NCT01165879|||CASE_CONTROL||RETROSPECTIVE|||||||
33762588|NCT01027975||||TREATMENT||||||||
33762589|NCT02227316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33762590|NCT03575338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will not know the technique|Randomized controlled trial|f|f|f|t
33762591|NCT00070811|||COHORT||PROSPECTIVE|||||||
33762592|NCT03790332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762593|NCT00003084|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762594|NCT00069784|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33762595|NCT00621608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762596|NCT01164462|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762597|NCT02467517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762598|NCT03677011|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33762599|NCT04836858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762600|NCT04483154|||CASE_ONLY||PROSPECTIVE|||||||
33762601|NCT00103961|||COHORT||PROSPECTIVE|||||||
33762602|NCT05596084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The maxillary sinus augmentation procedure has been a common treatment method since the 1980s. In patients who have insufficient bone height in the maxillary posterior edentulous region and who want implant placement, materials that provide bone formation are placed in the sinus cavity. When the bone height is 4 mm or less, it is necessary to provide bone formation with maxillary sinus augmentation surgery 6 months before implant placement. The aim of this study is to determine the primary stability of the implant by placing a titanium-rich fibrin on one side and a bovine bone graft on the other side with a sinus lift applied 6 months before the implant in bilateral maxillary posterior region with insufficient bone height with tooth deficiency. is the evaluation of the effect on the obtained bone histology, volume, height and density.|t|f|t|t
33762603|NCT04143386|||CASE_ONLY||PROSPECTIVE|||||||
33889870|NCT04580147|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33889871|NCT02100384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889872|NCT06541444|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33889873|NCT03846245|||OTHER||CROSS_SECTIONAL|||||||
33889874|NCT00347815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889875|NCT05739773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762604|NCT03642860|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The study will be conducted as a randomized, placebo-controlled, double blind, crossover study consisting of two 14 days treatment periods set apart by minimum a 7-days wash-out period where no treatment is taken. In one treatment period, the subjects receive UX007 treatment and placebo treatment in the other. The study will consist of three separate groups; one group consisting of GSD III, one group of GSD VII, and one group of GSD XV subjects. Each of these groups will be blinded and randomized separately|t|t|t|t
33762605|NCT06499623|||COHORT||PROSPECTIVE|||||||
33762606|NCT03711630|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a non-randomized interventional study in which subjects with bothersome tinnitus will meditate to investigate how meditation effects the level of bother of their tinnitus.||||
33762607|NCT04740619|||OTHER||RETROSPECTIVE|||||||
34074131|NCT04900454|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an, open-label, non-randomized Phase 1 dose-finding study of DVX201 in patients hospitalized with COVID-19. Subjects will enroll and the MTD and/or the RP2D of DVX201 will be determined utilizing a modified 3+3 enrollment schema."||||
34074132|NCT06349239|||COHORT||RETROSPECTIVE|||||||
34074133|NCT01206426|||CASE_ONLY||PROSPECTIVE|||||||
33762608|NCT01450722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762609|NCT05467579|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33762610|NCT02542644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762611|NCT04215016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762612|NCT04858802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intrapatient control in which eligible subjects will receive the PROPEL Contour Sinus Implant (Treatment) on one side, and no implant (Control) on the contralateral side.|f|f|f|t
33762613|NCT04146246|||CASE_CONTROL||PROSPECTIVE|||||||
34074134|NCT04405323|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34074135|NCT03560453|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-pharmacologic randomized clinical trial and followed the Non-pharmacological Consolidated Standards of Reporting Trials Statement recommendations to conduct the research (CONSORT; Boutron, Altman, Moher, Schulz, \& Ravaud, 2017)||||
34074136|NCT05291130|||COHORT||RETROSPECTIVE|||||||
34074137|NCT01007604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074138|NCT01388933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074139|NCT01938846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889876|NCT05264220|NA|SINGLE_GROUP||TREATMENT||NONE||Single group study - multiple baseline case series||||
33889877|NCT03700047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889878|NCT04969055|||OTHER||PROSPECTIVE|||||||
33889879|NCT01290926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889880|NCT05590572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33889881|NCT06047704|||COHORT||CROSS_SECTIONAL|||||||
33889882|NCT02486861|||COHORT|||||||||
33889883|NCT01447394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889884|NCT03543813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889885|NCT00270608|||COHORT||PROSPECTIVE|||||||
33889886|NCT00716716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889887|NCT03851510|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Participants are first getting screened with Resmon Pro they then will be screened with the Vector ventilator for EFL. Those that screen positive with EFL with the Vector ventilator will be treated with the vector device with a 20 minute titration protocol.||||
33889888|NCT04847700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33889889|NCT04653948|||COHORT||PROSPECTIVE|||||||
33889890|NCT06071325|||COHORT||PROSPECTIVE|||||||
33889891|NCT02590029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889892|NCT02823457|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33889893|NCT05931783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889894|NCT05527002|||COHORT||RETROSPECTIVE|||||||
33889895|NCT01097044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889896|NCT01930786|||CASE_ONLY||PROSPECTIVE|||||||
33889897|NCT04525833|||COHORT||RETROSPECTIVE|||||||
33889898|NCT02812199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889899|NCT03831087|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33889900|NCT01975103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One arm receives laser treatment and second arm received powerless laser treatment as a Sham group.||t|f|t|f
33889901|NCT01903941|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889902|NCT06028620|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33889903|NCT05995444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Screening of subjects will occur within 28 days prior to the first dosing. Subjects will be housed on Day -1, at the time indicated by the CRU, until completion of study procedures on Day 2 of each period. On Day 1 of each period, subjects will receive 1 of 4 treatments: a single therapeutic dose of epetraborole (Treatment A), a single supratherapeutic dose of epetraborole (Treatment B), a single dose of epetraborole matching-placebo (Treatment C), or a single dose of moxifloxacin (Treatment D). Cardiodynamic ECGs and PK blood samples for epetraborole, metabolite M3, and moxifloxacin (as applicable) will be collected predose and for 24 hours postdose in each period. There will be a washout of at least 10 days between doses. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations, including a follow-up visit approximately 14 days after the last dose.|t|t|t|t
33889904|NCT01895530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889905|NCT00006417||||TREATMENT||||||||
33889906|NCT04801407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective case -series hospital based study||||
33889907|NCT00691665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889908|NCT01517880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975797|NCT05344183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33975798|NCT06444074|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study design is a pragmatic cluster randomised controlled trial. Each cluster consists of a Teamlet in a National Health Group Polyclinic (NHGP), consisting of a regular group of Family Physicians, a Care Manager, and a Care Coordinator, that provide chronic care for a regular group of about 5000 patients.~Teamlets in each polyclinic will be randomised to either the PACT Program condition or Usual Care condition. Patients who belong to Teamlets that are randomised to the PACT Program condition will be recruited for participation in the PACT Program, and patients who belong to Teamlets that are randomised to the Usual Care condition will be recruited and provided with routine care."||||
33975799|NCT05859165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975800|NCT02506647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33975801|NCT02112240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975802|NCT04930081|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants do not have knowledge of the interventions assigned to individual participants.~The research assistant who supports in data collection do not know the interventions assigned to individual participants."|A randomized-controlled design will be adopted. There will be two intervention groups, i.e. PMT and the MP programme, and one waitlist-control group.|t|f|f|t
33975803|NCT04702620|||COHORT||PROSPECTIVE|||||||
33975804|NCT05854654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975805|NCT01773148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975806|NCT05782790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33975807|NCT03168074|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase II window-of-opportunity study of single agent lenvatinib in estrogen receptor positive early stage breast cancer||||
33975808|NCT00013351|||||PROSPECTIVE|||||||
33975809|NCT00993187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975810|NCT05677607|||COHORT||PROSPECTIVE|||||||
33975811|NCT05673668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975812|NCT02441426|||COHORT||PROSPECTIVE|||||||
33975813|NCT00493571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975814|NCT02789306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33975815|NCT03339349|NA|SINGLE_GROUP||OTHER||NONE||||||
33975816|NCT04190290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized group|Quasi experimental prospective study|t|f|f|t
33975817|NCT05663281|||COHORT||PROSPECTIVE|||||||
33975818|NCT00006381||||TREATMENT||||||||
33975819|NCT06364605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975820|NCT02199509|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33975821|NCT05825053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975822|NCT05154721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In order to maintain the blinding of the patient and his/her family, the study will be presented to them as evaluating the effect of serious games on a child's learning without explaining that the study is specifically interested in the Mila-Learn game, music and rhythm.~Evaluations will be carried out in a double-blind manner. The evaluators will not know to which group the children belong."|"The experimental arm (EXPE Group) will receive the Mila-Learn game and the control arm (CONT Group) will receive the Mila-Placebo game.~In each group, the children will follow the same training protocol consisting of five training sessions per week on the game corresponding to their group. Each game comprises 8 tasks to be completed on a touchscreen tablet. Each session lasts 25 minutes (±20%)."|t|f|t|f
33975823|NCT00980603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975824|NCT04947956|||OTHER||PROSPECTIVE|||||||
33975825|NCT01282996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975826|NCT06232083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975827|NCT04054024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo is saline||t|f|t|f
33975828|NCT01519583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975829|NCT05478993|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients diagnosed with multiple myeloma with CNS involvement to receive Selinexor (60 mg QW), pomalidomide (4 mg/day, on Days 1-21), and dexamethasone (40 mg/day, on Days 1, 8, 15, 22), with all agents dosed 28 days per cycle.~If patients reach maximum efficacy and have received SPD treatment for 8-12 cycles, maintenance treatment of Selinexor (20-60mg QW, optimal dose determined by the investigator) will be started and continued until disease progression or intolerable adverse events."||||
33975830|NCT02026414|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33975831|NCT04943809|||CASE_CONTROL||PROSPECTIVE|||||||
33975832|NCT01103037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975833|NCT00311818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975834|NCT02093689|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975835|NCT04956419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Fluconazole Controlled, Multicenter Phase III Clinical Study|t|t|t|t
33975836|NCT02673164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975837|NCT02849821|NA|SINGLE_GROUP||||NONE||||||
33975838|NCT01874951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975839|NCT04662892|||COHORT||PROSPECTIVE|||||||
33975840|NCT01492062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975841|NCT04642352|||COHORT||PROSPECTIVE|||||||
33975842|NCT01725984|||COHORT|||||||||
33975843|NCT02520557|||CASE_CONTROL||RETROSPECTIVE|||||||
33975844|NCT03919201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||exercise intervention group, control group||||
33975845|NCT03672110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074140|NCT03360019|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Counterbalanced within-subject design. Specifically, each target patient will randomly be assigned to either have the technology or not have the technology applied for a period of three months, followed by three months of the opposite condition. Caregivers will provide caregiver ratings twice monthly during these two epochs.||||
34074141|NCT06451666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"For arm 1, patients received pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.~For arm 2, patients received vehicle, one drop in each eye, once daily, for up to 30 days."|t|f|t|t
34074142|NCT00959283|||CASE_CONTROL||PROSPECTIVE|||||||
34074143|NCT02332941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074144|NCT02372383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074145|NCT03758157|||COHORT||OTHER|||||||
34074146|NCT01873118|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074147|NCT06005753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074148|NCT02235025|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34074149|NCT05050305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074150|NCT06144112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074151|NCT05632263|||COHORT||PROSPECTIVE|||||||
34074152|NCT03727841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074153|NCT03529760|||CASE_ONLY||PROSPECTIVE|||||||
34074154|NCT03356600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074155|NCT02606240|||COHORT||PROSPECTIVE|||||||
34074156|NCT00807365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074157|NCT00866957|||COHORT||PROSPECTIVE|||||||
33889909|NCT03757039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This was a double-masked trial for the contact lens wearers. The PAL wearers were not masked.||t|f|t|f
33889910|NCT00693706|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33889911|NCT02335684|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33889912|NCT03010540|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33889913|NCT04007159|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The human repeated insult patch test (HRIPT) is a long standing, standard method to determine whether exposure to a topical product will elicit a cutaneous (dermal) irritant or allergic response (sensitization) under exaggerated (occluded) conditions.|f|f|f|t
33889914|NCT00024232||||TREATMENT||||||||
33889915|NCT00444301|||COHORT||PROSPECTIVE|||||||
33889916|NCT04523662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889917|NCT05462379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889918|NCT05383690|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, with independent variable being percent device use.||||
33889919|NCT02960282|||CASE_ONLY||PROSPECTIVE|||||||
33889920|NCT05684640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|There are 2 parts to the study. Part one is an open label parallel study and Part 2 is a randomized double-blind placebo controlled study|Single and multiple dose|t|f|t|f
33889921|NCT00179959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889922|NCT02643095|NA|SINGLE_GROUP||OTHER||NONE||||||
33889923|NCT05963503|||CASE_CONTROL||PROSPECTIVE|||||||
33889924|NCT00527449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889925|NCT00790517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889926|NCT04561349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33889927|NCT00595231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33889928|NCT02844790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889929|NCT03870841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074158|NCT01523145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074159|NCT04887350|RANDOMIZED|PARALLEL||TREATMENT||NONE|All study participants will be blinded to the study hypotheses to prevent expectation bias.|Participants will be randomized in a 1:1:1 ratio to one of the three study groups.||||
34074160|NCT04399369|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||5% NaF and 38% SDF|t|t|f|t
33889930|NCT03215784|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33889931|NCT03288298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889932|NCT00000257|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33889933|NCT05862389|||CASE_CONTROL||PROSPECTIVE|||||||
33889934|NCT04991831|||COHORT||PROSPECTIVE|||||||
33889935|NCT05305482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889936|NCT00116025|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33889937|NCT05003115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33889938|NCT03646084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33889939|NCT02147314|||CASE_ONLY||PROSPECTIVE|||||||
33889940|NCT00460382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889941|NCT03044392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33889942|NCT00507325|||CASE_ONLY||PROSPECTIVE|||||||
33762614|NCT04806646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762615|NCT04981691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762616|NCT00891865|||CASE_ONLY||PROSPECTIVE|||||||
33762617|NCT01058538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975846|NCT00372788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975847|NCT03211559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975848|NCT04588259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33975849|NCT05252481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762618|NCT02506361|||CASE_CONTROL||PROSPECTIVE|||||||
33762619|NCT02292264|||COHORT||RETROSPECTIVE|||||||
33762620|NCT01800201|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33762621|NCT04069780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762622|NCT04002804|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, 2-stage Simon design (Simon et al., 1997), single-centre, un-controlled, open label, non randomized study.||||
33762623|NCT01819025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975850|NCT05510011|||COHORT||RETROSPECTIVE|||||||
33975851|NCT00217256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33975852|NCT02058056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975853|NCT00216398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975854|NCT05414474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975855|NCT05731427|||CASE_CONTROL||PROSPECTIVE|||||||
34074161|NCT04194983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After subjects have successfully completed the screening, they will be randomly allocated in a 1:1 ratio, using a 4-code system, to one of the two interventions (intervention or control). The intervention and control will each be individually coded with a randomly generated 3 letter coding system with 2 codes allocated to intervention product and the other 2 codes allocated to the control product. sachets will be generated by the product manufacturer and the corresponding blinding label will be added to the sachets, prior to shipment to the study sites. The un-blinding-key will be sent to the project leaders in sealed envelopes. In this way, both the participants and principle investigator will be blinded throughout the study.|A multicenter, double-blind, randomised, controlled, parallel trial, where fish oils combined with dairy or plant based fat supplements are consumed for 12-weeks.|t|f|t|f
34074162|NCT04397874|||COHORT||PROSPECTIVE|||||||
34074163|NCT04799262|NA|SINGLE_GROUP||TREATMENT||NONE|Assessor and data analyst blindness. To avoid bias, physicians who assess disease activity will be blinded. Participants are required not to discuss their treatment regimen with physicians at each visit. The success of the blind method will be judged by requiring the assessors to determine the therapy of participants after each visit. When the database is locked, the statistician will carry on the data analysis in the hidden of therapy.|||||
34074164|NCT03183115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074165|NCT02910921|||COHORT||PROSPECTIVE|||||||
34074166|NCT03418285|||CASE_ONLY||PROSPECTIVE|||||||
34074167|NCT02824224|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34074168|NCT02899247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074169|NCT04367662|NA|SINGLE_GROUP||OTHER||NONE||||||
34074170|NCT03287557|||CASE_ONLY||PROSPECTIVE|||||||
34074171|NCT04819139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34074172|NCT04000971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Primary outcomes will be assessed by telephone at 3, 6, and 12 months by the University of Alabama at Birmingham (UAB)'s Survey Research Unit (SRU). Research staff at the SRU will be masked to treatment arm.|Pragmatic randomized trial of approximately 22 clinical sites in the United States; randomization is by clinical site.|f|f|f|t
34074173|NCT03679143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking for Participant, Investigator and Clinical Research Associate||t|t|t|t
34074174|NCT04156893|NA|SINGLE_GROUP||TREATMENT||NONE||"Subjects will receive RH genotype matched red cell units for transfusion. For subjects with a history of stroke/recurrent transient ischemic attack or other indication who require tight control of Hb S, and RH genotyped blood is not available, standard of care serologic matched blood would be administered rather than delaying transfusion and risking higher Hb S level.~For all subjects, standard of care serologic matched blood would be administered rather than delaying transfusion beyond 7 days"||||
34074175|NCT01707628|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34074176|NCT02821039|||COHORT||PROSPECTIVE|||||||
34074177|NCT03559283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074178|NCT03666247|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074179|NCT01718392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762624|NCT05566808|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074180|NCT06202703|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762625|NCT03319082|||COHORT||PROSPECTIVE|||||||
33889943|NCT01206569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889944|NCT01737814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889945|NCT00382148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889946|NCT03823391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889947|NCT02620020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975856|NCT03963570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All outcomes are self-reports and self-assessments by the participants and reported in digital surveys. Outcomes will not be influenced by any other outcome assessors. Data set will be blinded regarding group allocation (and the code for the groups will be held by a researcher not involved in the study) when performing analyses for main outcomes.|This is a randomized controlled trial (RCT) comparing a digital exercise program with a control group. The intervention will last for 12 months with follow-up assessments at 3, 6, 9 and 12 months.|f|f|t|t
33889948|NCT04964011|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34074181|NCT04356287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study participants, physicians (including the outcome assessors) and research nurses will be blinded to treatment arm. Only the study statistician and the personnel at the manufacturing laboratory at the Medical University of South Carolina will be aware of the subject's treatment allocation. The Medical University of South Carolina will send blinded infusion bag(s) to the Clinical Research Unit of the Jewish General Hospital.||t|t|t|t
33975857|NCT04752436|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33975858|NCT04861545|||OTHER||OTHER|||||||
33975859|NCT00535106|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33975860|NCT04168541|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Study staff will not be blinded to product assignment. Study participants will be blinded to product assignment. Product will be provided in unlabeled plastic cups.|This will be a randomized crossover design. The subjects will be randomized to one of six interventions on six separate study days, one week apart.|t|f|f|f
33975861|NCT02483637|NA|SINGLE_GROUP||TREATMENT||NONE||RejuvenAir||||
33975862|NCT04514393|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33975863|NCT04383756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||20 recipients receive donor whole blood 20 historic match controls are compared to the 20 study participants||||
33975864|NCT02976298|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33975865|NCT02220907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975866|NCT01183000|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074182|NCT01996111|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33889949|NCT00003417||||TREATMENT||||||||
33889950|NCT03322358|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33975867|NCT05409911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975868|NCT02506166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975869|NCT03466957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975870|NCT02707536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975871|NCT06546293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074183|NCT05748574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975872|NCT06450002|||OTHER||PROSPECTIVE|||||||
33975873|NCT01903577|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33975874|NCT00809042|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33975875|NCT03866850|||COHORT||PROSPECTIVE|||||||
33975876|NCT03686358|||CASE_ONLY||RETROSPECTIVE|||||||
33975877|NCT03473782|||COHORT||PROSPECTIVE|||||||
34074184|NCT04986774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074185|NCT06612411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34074186|NCT03166501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074187|NCT05935865|||CASE_CONTROL||PROSPECTIVE|||||||
34074188|NCT02651844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074189|NCT05827692|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||This is a single-center randomized controlled trial with an intrasubject pre-post design. The intervention is developed by means of two crossed treatment arms: Arm A (intervention + control); Arm B (control + intervention).|t|t|t|t
34074190|NCT06358118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762626|NCT05176977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762627|NCT03138733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762628|NCT04879199|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cross sectional, age-matched-controlled and monocentric study with an exploratory approach.||||
33762629|NCT06621966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762630|NCT00947726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762631|NCT01231139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762632|NCT05672238|||COHORT||RETROSPECTIVE|||||||
33762633|NCT05770830|||CASE_CONTROL||RETROSPECTIVE|||||||
33762634|NCT01003665|||CASE_CONTROL||PROSPECTIVE|||||||
33762635|NCT03837808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762636|NCT06215001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762637|NCT06492161|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33762638|NCT00146601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762639|NCT05375955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762640|NCT05254444|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33762641|NCT06210906|||CASE_CONTROL||PROSPECTIVE|||||||
33762642|NCT04366726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762643|NCT06448325|||COHORT||RETROSPECTIVE|||||||
33762644|NCT05842785|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Firstly conduct the phase I and find the RP2D. Once we have the RP2D, we will conduct the phase II study.||||
33762645|NCT05787613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762646|NCT05958498|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762647|NCT06439056|NA|SINGLE_GROUP||TREATMENT||NONE||Single ascending dose study including 3 cohorts (3 patients/cohort). The subjects will be enrolled in the respective cohorts, starting with cohort 1. NEX-22A will be administered in a sentinel fashion within the cohorts. A single participant will be dosed first in every cohort. If there are no safety concerns as judged by the investigator, the remaining subjects will be dosed at least 10 days after the sentinel.||||
33762648|NCT04422613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762649|NCT03819582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889951|NCT03078062|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Patients in both groups will receive the study drug (dexamethasone or placebo) in the same volume of normal saline. The study drug will be prepared by an independent assistant.|Prospective, randomized, double-blind, placebo-controlled study|t|t|t|t
33889952|NCT05206461|||OTHER||CROSS_SECTIONAL|||||||
33889953|NCT00500266|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33889954|NCT04647110|||COHORT||RETROSPECTIVE|||||||
33889955|NCT04764942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889956|NCT05841940|NA|SINGLE_GROUP||OTHER||NONE||||||
33889957|NCT02906800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889958|NCT01147497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33889959|NCT02947919|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33889960|NCT01250821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889961|NCT02040688|||CASE_CONTROL||PROSPECTIVE|||||||
33889962|NCT02446587|||COHORT||PROSPECTIVE|||||||
33889963|NCT02976155|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Before-after study model||||
33975878|NCT00752323|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Neurosurgeons and investigators responsible for determining pathologic characteristics, for quantifying fluorescence images, for extracting chemical PpIX, for co-localizing fluorescence images with MR images will be blinded to the ALA dose and administration time. In case of emergency, such as toxicity or allergic reaction attributable to the drug, the research pharmacist on call will break the blind and inform the physician responsible for clinical management.||f|f|f|t
33975879|NCT02028936|RANDOMIZED|PARALLEL||||DOUBLE||||||
33975880|NCT01989065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975881|NCT05197946|||CASE_CONTROL||PROSPECTIVE|||||||
33975882|NCT00555256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975883|NCT02720003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975884|NCT00200798|||OTHER||PROSPECTIVE|||||||
33975885|NCT00108732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975886|NCT00865709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975887|NCT01627873|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33975888|NCT03513393|RANDOMIZED|CROSSOVER||OTHER||NONE||An open-label, 3-period, single-centre, phase-I, multi PPI dose, single velpatasvir dose trial in 12 healthy volunteers.||||
33975889|NCT01332409|||||PROSPECTIVE|||||||
33975890|NCT06338397|NA|SINGLE_GROUP||OTHER||NONE||||||
33762650|NCT06336408|||COHORT||PROSPECTIVE|||||||
33762651|NCT02295566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762652|NCT01005303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33975891|NCT05569148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975892|NCT05816876|||OTHER||RETROSPECTIVE|||||||
33975893|NCT01769209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975894|NCT04493450|||CASE_ONLY||PROSPECTIVE|||||||
33889964|NCT06353672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889965|NCT03312192|RANDOMIZED|PARALLEL||TREATMENT||NONE||1. Stand-alone ACDF, which means the placement of an interbody device (cage) without anterior fixation or plating; 2. ACDF with and interbody cage and anterior plating for fixation.||||
33889966|NCT05011084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889967|NCT02047084|||COHORT||PROSPECTIVE|||||||
33889968|NCT03099733|NA|SINGLE_GROUP||OTHER||NONE||||||
33889969|NCT04141371|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|paticipant and radiologists are masked||t|f|f|t
33889970|NCT03146286|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33889971|NCT03561727|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Neither the patients included in the study nor the investigators assessing the presence of incisional hernia during follow-up visits will be aware of the type of surgical technique used for abdominal closure (double-blinded study). Only the professionals present in the operating room during surgical procedure, including operator, assistants, anesthesiologist, and nurses, will be aware of the type of assigned intervention.|"The technique comprising continuous suture and mass closure will be compared to the technique 2 separate layers of continuous sutures.~Patients will be randomly assigned to one of the two techniques of abdominal closure during the operative procedure and after its main part has been completed, just before the beginning of closure of the abdominal cavity. Randomization will be performed in a 1:1 ratio and in blocks of 20 patients."|t|f|t|t
33889972|NCT01417130|||COHORT||PROSPECTIVE|||||||
33889973|NCT04974788|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three groups with a conventional therapy||||
33889974|NCT06096025|||OTHER||RETROSPECTIVE|||||||
33889975|NCT02185391|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33889976|NCT00763802|||COHORT||PROSPECTIVE|||||||
33889977|NCT06246773|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33889978|NCT02021994|||||PROSPECTIVE|||||||
33889979|NCT02515513|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33889980|NCT04730518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded psychologist who works independently of the (co-) psychologist conducts the rater-questionnaires. Due to the psychotherapeutic nature of the study, information about the treatment allocation has to be shared with the co-psychologist and the participants. Randomization is conducted by the Random Group Generator (pubmed, 2018).|A rater-blinded randomized controlled trial with a parallel group design is used. The participants in the conditional group receive the usual treatment (TAU), while the experimental group receives yoga-based group therapy (YBGT) in addition to TAU.|f|f|f|t
33975895|NCT03349671|||OTHER||CROSS_SECTIONAL|||||||
33975896|NCT03403764|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|The investigator and participants involved in this clinical trial are prevented from having knowledge which intervention is assigned to individual participants. A second control group has no knowledge of the parallel conducted Consciousness Field Project.|Participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study and are evaluated in parallel against a control group|t|f|t|t
33975897|NCT04653220|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participant is blinded.|Randomized crossover study|t|f|f|f
33975898|NCT05814081|||CASE_CONTROL||PROSPECTIVE|||||||
33975899|NCT02134522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975900|NCT01943071|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33975901|NCT05646680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975902|NCT04582266|||COHORT||PROSPECTIVE|||||||
33975903|NCT00103675|NON_RANDOMIZED|PARALLEL||ECT||NONE||||||
33975904|NCT04566159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975905|NCT05002907|||COHORT||PROSPECTIVE|||||||
33975906|NCT03363295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both the patients and the investigator will be masked. The cataract surgeon won't be.||t|f|t|f
33975907|NCT04811768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Histology analysis was performed blinded, randomization sequence was revealed after histomorphometry|40 patients underwent sinus floor augmentation - 20 patients treated by bony wall repositioning, 20 patients treated by collagen membrane coverage|f|f|f|t
33975908|NCT00528281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975909|NCT06546813|||CASE_ONLY||PROSPECTIVE|||||||
33975910|NCT01432171|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33975911|NCT01428505|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33975912|NCT00952783|||CASE_ONLY||PROSPECTIVE|||||||
33975913|NCT05050409|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Our design is a sequential multiple randomization (SMART) study design with 2 treatment phases with a possibility of 2 randomizations per participant.|f|t|t|t
33975914|NCT06206395|||COHORT||PROSPECTIVE|||||||
33975915|NCT03992196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762653|NCT04465825|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Part 2 is a randomized crossover design.||||
33762654|NCT00993824|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762655|NCT05941325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762656|NCT04112225|RANDOMIZED|PARALLEL||OTHER||NONE||Users are randomly assigned between arms after completing baseline assessment and stay in that arm for the duration of the study.||||
33762657|NCT03070717|||COHORT||PROSPECTIVE|||||||
33762658|NCT03557086|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762659|NCT06624787|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Operators performing the RT-PCR will be unaware to the RDT results. This removes bias of the RT-PCR and RDT results. The results of the RDTs will not be shared with the participants and the healthcare staff will be trained to not use the results, as the RDT is not an approved device for CCHF diagnosis. Participants will follow the local standard of care of CCHF diagnosis and management which dependent on the MoH RT-PCR result.|A diagnostic evaluation study where each participant undergoes both reference testing and the diagnostic testing||||
33762660|NCT04850404|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33762661|NCT04384822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors are unaware of the group allocation.||f|f|f|t
33889981|NCT01427309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074191|NCT00254215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975916|NCT06046027|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33975917|NCT05159635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975918|NCT05602922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975919|NCT03551249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975920|NCT02462824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975921|NCT05409677|||COHORT||RETROSPECTIVE|||||||
33975922|NCT00306345|||DEFINED_POPULATION||PROSPECTIVE|||||||
33975923|NCT01977092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975924|NCT01171066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074192|NCT00253292|||COHORT||PROSPECTIVE|||||||
34074193|NCT06488898|NA|SINGLE_GROUP||OTHER||NONE||Phase IIa, single-center clinical trial compared with historical cohorts to evaluate the preliminary safety and efficacy of an allogeneic adipose tissue-derived mesenchymal stem cells infusion in an aneurysmal sac for the treatment of AAA.||||
34074194|NCT02801825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33975925|NCT01096927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074195|NCT00357877|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074196|NCT02309970|||COHORT||PROSPECTIVE|||||||
33975926|NCT03967002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975927|NCT05092490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are not informed about which block they are receiving~1 study personnel assess the pain scores and patient satisfaction postoperative"||t|f|f|t
33975928|NCT00984685|||COHORT||RETROSPECTIVE|||||||
33975929|NCT05059756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Treatment group: PTNS and PFR treatment; Control group: ( Sham stimulation and PFR training)|t|f|t|t
33975930|NCT00116935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975931|NCT01136538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975932|NCT06126081|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized to two groups||||
33762662|NCT03570502|||COHORT||PROSPECTIVE|||||||
33762663|NCT01689584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975933|NCT03475927|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34074197|NCT06005701|||COHORT||PROSPECTIVE|||||||
34074198|NCT03085693|||CASE_ONLY||PROSPECTIVE|||||||
34074199|NCT06611462|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statistical analyses will be conducted blinded.|Randomised parallel design using block randomisation. Stratification for centre and number of SNAP factors (one, two, or ≥ 3).||||
34074200|NCT00570336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074201|NCT02646683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762664|NCT06437652|||COHORT||CROSS_SECTIONAL|||||||
33762665|NCT01834443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762666|NCT02302131|||CASE_ONLY||OTHER|||||||
33762667|NCT06339580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762668|NCT03501329|||COHORT||PROSPECTIVE|||||||
33762669|NCT02234063|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33762670|NCT00959062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762671|NCT01406704|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33762672|NCT02055560|||COHORT||RETROSPECTIVE|||||||
33762673|NCT01785563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762674|NCT05705999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762675|NCT01927679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33762676|NCT04191109|||COHORT||PROSPECTIVE|||||||
33762677|NCT05548439|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33762678|NCT02458001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762679|NCT01648621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762680|NCT04280523|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762681|NCT05240430|||CASE_ONLY||OTHER|||||||
33762682|NCT05914402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762683|NCT05083325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33762684|NCT02456701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762685|NCT05061537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762686|NCT02681575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33889982|NCT04187027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).|Patients were divided randomly into two groups. Group (A) which is the control group received medical care and standard urotherapy only. And Group (B) which is the study group received medical care and standard urotherapy in addition to pulsed electromagnetic field therapy for three successful months. All children were assisted using urodynamic studies before and after three months of intervention.|f|f|f|t
34074202|NCT04173416|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase 1 of the study (years 1-2) will include a single group, open-label, intervention only arm. After iterative cycles of testing and refinement, we will proceed with a parallel group RCT in Phase 2 of the study (years 3-5).||||
34074203|NCT06133998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074204|NCT00264485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074205|NCT04784078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074206|NCT04954495|||COHORT||CROSS_SECTIONAL|||||||
33762687|NCT02536014|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762688|NCT06510530|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762689|NCT03042598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single arm interventional feasibility trial to determine if the use of a Biphasic Cuirass Ventilator during the apneic period of intubation will decrease the prevalence of oxygen desaturation in patients undergoing RSI as compared to historical proportions of 20%.||||
33762690|NCT02049125|||||PROSPECTIVE|||||||
33762691|NCT02481375|RANDOMIZED|FACTORIAL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33762692|NCT05067439|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33762693|NCT03056625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33762694|NCT05140291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be asked to keep their eyes closed during the treatment. Clinicians will be blinded to group and outcomes|Double blinded, sham controlled, randomized trial.|t|t|f|t
33762695|NCT00250913|RANDOMIZED|PARALLEL||||NONE||||||
33889983|NCT06351202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33889984|NCT02144272|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33889985|NCT02595242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889986|NCT01878630|RANDOMIZED|PARALLEL||TREATMENT||NONE||Remote patient management with telemedical devices (ECG, scale, blood-pressure device)||||
33975934|NCT01046123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975935|NCT00454974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975936|NCT02203565|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33975937|NCT05428852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33975938|NCT00422656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074207|NCT05837286|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|The primary objective of this study is to analyze the effectiveness of a nighttime PIP joint extension orthosis to improve pain and restore functional outcomes in TF and comparing two groups of participants with TF, one group receiving a cortisone injection only and the experimental group receiving the nighttime orthosis after cortisone injection using the QuickDASH.||||
33762696|NCT06253949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762697|NCT05796180|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33762698|NCT04228640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomized, Double-Blind|A Multicenter, Randomized, Double-Blind, Placebo-Controlled|t|f|t|f
33762699|NCT04269018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To maintain blinding, randomization will occur after the baseline assessment and both groups will receive welcome message for participating in the study. Then motivational and general healthy related texts will be delivered to controls one times per week.|Participants will be randomly assigned to intervention and control group, the intervention group will be received daily text message while the controls will receive general health messages once a week.|t|f|f|f
33762700|NCT01908322|||COHORT||PROSPECTIVE|||||||
33762701|NCT01483937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33975939|NCT01363037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33975940|NCT02745977|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975941|NCT06027840|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33975942|NCT00001090||||PREVENTION||DOUBLE||||||
34074208|NCT03793023|||CASE_CROSSOVER||PROSPECTIVE|||||||
33975943|NCT01274416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33975944|NCT03269110|||COHORT||PROSPECTIVE|||||||
33975945|NCT04059601|||COHORT||PROSPECTIVE|||||||
33975946|NCT04725084|||COHORT||RETROSPECTIVE|||||||
33975947|NCT05150236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975948|NCT01631864|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33975949|NCT00635778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074209|NCT06609200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After a participant's eligibility is confirmed, a randomization number that corresponds to the group allocation will be provided to the acupuncturist. The clinical assessor and participants will be blinded to the allocation.|Each patient will be scheduled for 16 treatment sessions, each lasting 30 minutes, twice a week over 8 weeks.|t|f|f|t
34074210|NCT00155948|||DEFINED_POPULATION||OTHER|||||||
33975950|NCT00282256|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33975951|NCT01063530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975952|NCT03713268|||COHORT||PROSPECTIVE|||||||
33975953|NCT00309075|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33975954|NCT05777538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975955|NCT03828045|||COHORT||PROSPECTIVE|||||||
33975956|NCT01560078|||COHORT||PROSPECTIVE|||||||
33975957|NCT05133895|||COHORT||PROSPECTIVE|||||||
33975958|NCT05750628|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is open-label|||||
33975959|NCT03849599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with moderately to severely active UC. Randomization will be stratified by Mayo score.|t|t|t|t
33975960|NCT00001052||||PREVENTION||DOUBLE||||||
33762702|NCT00909428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762703|NCT06138249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762704|NCT05617001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762705|NCT04011579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762706|NCT01023243|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33762707|NCT06063122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|nurses/physicians treating the patient and the personnel collecting the outcomes data are masked|Randomized Controlled Trial with double blind|f|t|f|t
33762708|NCT02661802|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33762709|NCT02258048|||CASE_ONLY||PROSPECTIVE|||||||
33762710|NCT05222048|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33762711|NCT00978965|||COHORT||PROSPECTIVE|||||||
33762712|NCT02425748|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33762713|NCT02320747|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33762714|NCT03221088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762715|NCT03322371|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33762716|NCT06386003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762717|NCT05931627|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Treating physicians and subjects will be blinded to treatment group.|Double-blinded randomized controlled clinical trial|t|f|t|f
33762718|NCT05545891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762719|NCT03271476|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All the women will receive the same intervention.||||
33762720|NCT02995850|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33762721|NCT00925535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33762722|NCT00618696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762723|NCT04503096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762724|NCT01984801|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33762725|NCT05564741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762726|NCT01228422|||||PROSPECTIVE|||||||
33762727|NCT05313750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762728|NCT01897831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762729|NCT04302831|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33762730|NCT03960229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762731|NCT03020563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762732|NCT01639313|||COHORT||PROSPECTIVE|||||||
33762733|NCT00518635|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762734|NCT00641719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762735|NCT00578721|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33762736|NCT04425018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762737|NCT03427554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33762738|NCT01108393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762739|NCT01960075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||ESETT had 478 enrollments. They were 16 re-enrollers. This was an EFIC trial so all consents happened after treatment and all enrollments went through the same process of consent even if they were re-enrolled. Some information presented here only includes the first 400 patients since there was a prespecified stopping rule and the trial stopped early for futility.|t|f|t|t
33762740|NCT00004062||||TREATMENT||||||||
33762741|NCT01829984|||COHORT||PROSPECTIVE|||||||
33762742|NCT04990284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762743|NCT01605214|||COHORT||PROSPECTIVE|||||||
33762744|NCT04863989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762745|NCT04444284|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|The study is single-mask in 2 of the 3 dosage groups: study participants and their parent(s)/guardian(s) will not know their child's study assignment, whereas investigators, site staff, and site pharmacists will remain unmasked.|The first 15 enrolled participants will be assigned to Dosage Group 1 and be randomly allocated to receive either investigational vaccine at Dosage 1 or placebo. The Safety Monitoring Committee will subsequently review Dosage Group 1 safety data through Day 14, to allow dosage escalation. The next 15 enrolled participants will be assigned to Dosage Group 2 and be randomly allocated to receive investigational vaccine at Dosage 2 or placebo. The Safety Monitoring Committee will subsequently review Dosage Group 2 safety data through Day 14, to allow dosage escalation. The final group (Dosage Group 3) will consist of up to 12 enrolled participants who will be allocated to receive investigational vaccine at Dosage 3.|t|f|f|f
33762746|NCT00201500|||CASE_CONTROL|||||||||
33762747|NCT04499716|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33762748|NCT04581148|||COHORT||PROSPECTIVE|||||||
33762749|NCT04658823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded||t|t|t|t
33762750|NCT05050578|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762751|NCT06626022|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33762752|NCT01743794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762753|NCT00156806|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33762754|NCT04148339|||CASE_ONLY||PROSPECTIVE|||||||
33762755|NCT04687735|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, prospective cohort study||||
33762756|NCT00978354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762757|NCT00577018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762758|NCT00768508|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34074211|NCT04837287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants of the study will be included in the stretching exercise program, but the participants will not have information about which group the participants belong to.||t|f|f|f
33762759|NCT04555902|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|Participants and providers are not aware of the different mailer versions.|1 x 3 design|t|t|f|f
33762760|NCT01691183|||COHORT||PROSPECTIVE|||||||
33762761|NCT03186482|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33762762|NCT00581373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762763|NCT00295763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762764|NCT05391932|NA|SINGLE_GROUP||TREATMENT||NONE||Single-cohort double-baseline design||||
33762765|NCT03561337|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blinded|block randomized controlled intervention|t|f|f|f
33762766|NCT05233202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, multicenter, randomized (two arms, parallel groups); double-blind, placebo-controlled study|t|t|t|f
33762767|NCT00017056||||TREATMENT||||||||
33762768|NCT04075617|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinding isn't feasible except for the statistician.|||||
33762769|NCT01053260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762770|NCT02189902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762771|NCT03697525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|prospective randomized double-blind sham-controlled study|t|t|f|t
33762772|NCT01489644|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33762773|NCT04013412|RANDOMIZED|PARALLEL||PREVENTION||NONE||3:2 randomization to short-term protein calorie restriction diet versus regular meals prior to elective major vascular surgery||||
33762774|NCT05381805|||COHORT||PROSPECTIVE|||||||
33762775|NCT06425848|||OTHER||OTHER|||||||
33762776|NCT02544828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33762777|NCT00784433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762778|NCT04573725|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33762779|NCT03217435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762780|NCT03519243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762781|NCT05739383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762782|NCT06525363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762783|NCT01674348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762784|NCT00755222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33889987|NCT02611713|||COHORT||PROSPECTIVE|||||||
33889988|NCT01995929|||CASE_CONTROL||PROSPECTIVE|||||||
33889989|NCT04784962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham and active devices are identical and will be randomly allocated||t|f|f|f
33889990|NCT03867630|||COHORT||RETROSPECTIVE|||||||
33889991|NCT05407792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33889992|NCT02882256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889993|NCT04755374|||OTHER||RETROSPECTIVE|||||||
34074212|NCT00182741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074213|NCT03977987|||COHORT||PROSPECTIVE|||||||
34074214|NCT04874818|||COHORT||PROSPECTIVE|||||||
33762785|NCT03114371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The packaging, presentation and labelling of the bottles used during the blind phase will guarantee the blindness to the healthcare team and the patient.~The allocation of the treatment arms to each treatment number will be carried out according to the randomization table established beforehand.~Until the end of the study, neither the investigating physician nor the patient will know the group to which the patient has been randomly assigned."|Children will receive after randomization either placebo or oxytocin administration (daily intranasal) for a total duration of 12 consecutive weeks.|t|f|t|f
33762786|NCT00925405|||CASE_ONLY||PROSPECTIVE|||||||
33762787|NCT03754205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762788|NCT02290002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33762789|NCT00547287||CROSSOVER||TREATMENT||NONE||||||
33762790|NCT02874651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762791|NCT02492555|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762792|NCT06623968|||COHORT||OTHER|||||||
33762793|NCT02932592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|CGMS|CGMS||||
33762794|NCT04489693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This Compares the CCP ,C4P and Traditional Care Coordination Models||||
33762795|NCT05046496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762796|NCT05839223|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33762797|NCT01846000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762798|NCT03710525|RANDOMIZED|FACTORIAL||OTHER||NONE||This study will utilize a three factor design, with one between-subject factor and two within-subject factors. The between-subject factor is participation in a federal food assistance program. The within-subject factors are price change condition and price change scenario.||||
33762799|NCT01567332|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33762800|NCT05525936|||COHORT||PROSPECTIVE|||||||
33762801|NCT01756521|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33889994|NCT05174091|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33762802|NCT01238224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762803|NCT00575497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762804|NCT02850432|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762805|NCT01515462|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single-arm study. All subjects will receive OTL-103 gene therapy and will be followed up for 15 years post gene therapy||||
33762806|NCT05389111|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33762807|NCT02623114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762808|NCT00819364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762809|NCT02317055|NON_RANDOMIZED|PARALLEL||||NONE||||||
33762810|NCT04141449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Paired, community-randomized trial||||
33762811|NCT02789384|NA|SINGLE_GROUP||OTHER||NONE||||||
33762812|NCT00939601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33762813|NCT00239564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762814|NCT01452646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762815|NCT02563002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762816|NCT01677221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762817|NCT06284863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33762818|NCT04761276|||COHORT||PROSPECTIVE|||||||
33762819|NCT05537480|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|All are blinded to the CGM results.||t|t|t|t
33762820|NCT03911453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762821|NCT03850080|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort prospective interventional study||||
33762822|NCT05432908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762823|NCT06214858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762824|NCT02393521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33889995|NCT02314793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33889996|NCT04037189|||COHORT||RETROSPECTIVE|||||||
33889997|NCT05340972|||COHORT||PROSPECTIVE|||||||
33762825|NCT06315296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33762826|NCT04325113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33762827|NCT04492319|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762828|NCT04167995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using a computer-based randomization program. The allocation was concealed in sealed envelopes. Only the researchers collecting and analyzing the data were blinded to the study groups (assessor-blinded).||f|f|t|t
33762829|NCT01105013|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762830|NCT06622785|||OTHER||PROSPECTIVE|||||||
33762831|NCT05279222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762832|NCT02531763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33762833|NCT01287884|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33889998|NCT01517035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33889999|NCT00709826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890000|NCT05305326|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33890001|NCT05707572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890002|NCT03793439|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, interventional, proof of concept, hypothesis-generating study||||
33890003|NCT05984446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33890004|NCT00006430||||TREATMENT||||||||
33890005|NCT02800174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890006|NCT03181113|||COHORT||PROSPECTIVE|||||||
33890007|NCT02357420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890008|NCT00746174|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762834|NCT03327584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33890009|NCT06030934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890010|NCT02507479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890011|NCT06373874|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Assignment experimental study with experimental and control group||||
33890012|NCT05564767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890013|NCT05376917|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33890014|NCT04507009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33890015|NCT05381350|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33975961|NCT04094870|RANDOMIZED|PARALLEL||TREATMENT||NONE||Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline initial dose of 25 mg tablet versus IPT in a 1:1 ratio commenced between six and 8 weeks postpartum and continued through 30 weeks postpartum.||||
33762835|NCT03030937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762836|NCT04601441|NA|SINGLE_GROUP||SCREENING||NONE||||||
33762837|NCT03733561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762838|NCT03249610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890016|NCT04375306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients in both arms. In the control arm (angiography guided CABG) the RFR values will be blinded to the cardiothoracic surgeon.|International prospective randomized multicenter superiority trial|t|t|t|f
33890017|NCT00891514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890018|NCT04636905|||COHORT||RETROSPECTIVE|||||||
33890019|NCT05228366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Double-blind|3-armed randomized controlled trial|t|f|f|f
33890020|NCT06258642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890021|NCT01133145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890022|NCT00351364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33890023|NCT04396704|||COHORT||RETROSPECTIVE|||||||
33890024|NCT03691714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890025|NCT04874857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33890026|NCT01969266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890027|NCT04324853|||COHORT||PROSPECTIVE|||||||
33890028|NCT04766606|||COHORT||PROSPECTIVE|||||||
33890029|NCT03851692|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Prospective randomized single blinded parallel group controlled study|t|f|t|t
33890030|NCT02111005|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33762839|NCT01606696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33762840|NCT06537011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762841|NCT04144803|||COHORT||PROSPECTIVE|||||||
33762842|NCT04774133|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33762843|NCT03116464|NA|SINGLE_GROUP||TREATMENT||NONE||"Family based telemental health intervention that incorporates: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs."||||
33762844|NCT06019195|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33762845|NCT06626256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762846|NCT05773014|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33762847|NCT05686772|||COHORT||PROSPECTIVE|||||||
33762848|NCT00548132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762849|NCT00970216|||||PROSPECTIVE|||||||
33762850|NCT01756261|||COHORT||PROSPECTIVE|||||||
33762851|NCT04095143|||COHORT||PROSPECTIVE|||||||
33762852|NCT02319070|||COHORT||PROSPECTIVE|||||||
33762853|NCT04538365|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The samples will be sent to the laboratory with numbers|Crossover design is used|f|f|f|t
33762854|NCT00541203|||COHORT||PROSPECTIVE|||||||
33762855|NCT00278538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762856|NCT01710163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762857|NCT00651235|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33762858|NCT05582694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762859|NCT03254160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762860|NCT03354650|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762861|NCT01042509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762862|NCT04620629|||COHORT||PROSPECTIVE|||||||
33762863|NCT00601003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762864|NCT06095557|NA|SINGLE_GROUP||OTHER||NONE||||||
33762865|NCT03966053|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33762866|NCT04763603|||CASE_CONTROL||PROSPECTIVE|||||||
33762867|NCT02283489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762868|NCT00265330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762869|NCT01073670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33762870|NCT01237184|||COHORT||PROSPECTIVE|||||||
33890031|NCT05996484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890032|NCT00746499|NA|SINGLE_GROUP||||NONE||||||
33890033|NCT02150031|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33890034|NCT02246452|||||RETROSPECTIVE|||||||
33890035|NCT06252116|||COHORT||PROSPECTIVE|||||||
33890036|NCT04533802|||COHORT||PROSPECTIVE|||||||
33890037|NCT01523080|RANDOMIZED|CROSSOVER||||NONE||||||
33890038|NCT00972465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890039|NCT04032340|||OTHER||CROSS_SECTIONAL|||||||
33890040|NCT03029832|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study design has been amended in that the study blinding will not be maintained.|||||
33890041|NCT01449890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890042|NCT00206726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890043|NCT00313274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890044|NCT05573802|NA|SEQUENTIAL||TREATMENT||NONE||||||
33890045|NCT04026984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890046|NCT02690701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975962|NCT00814099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975963|NCT04025788|||COHORT||PROSPECTIVE|||||||
33762871|NCT04952584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762872|NCT03608709|||COHORT||PROSPECTIVE|||||||
33762873|NCT04164602|||COHORT||PROSPECTIVE|||||||
33762874|NCT01106430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762875|NCT05287308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762876|NCT02242448|||COHORT||PROSPECTIVE|||||||
33762877|NCT04711356|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive a single dose of Ad26.ZEBOV at a dose of 5x10\^10 viral particles (vp) administered intramuscularly.||||
33762878|NCT05964088|||COHORT||RETROSPECTIVE|||||||
33762879|NCT04266639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot, Single-center, Randomized, Patient-assessor blinded, Sham-controlled Trial|t|f|f|t
33762880|NCT04860817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762881|NCT01583101|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33762882|NCT02628002|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33762883|NCT05929443|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762884|NCT00249067|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33762885|NCT03694314|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33975964|NCT01575678|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33890047|NCT06351293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to the treatment assignment, in which randomization and treatment side will be concealed in order to avoid bias in subjective assessment. The clinic staff will mask the product identity by covering the packaging and product name (e.g., using tape, marker, wipe-out, etc.) so that it is not visible to the subjects. The Investigator will not be blinded.||t|f|f|f
33890048|NCT01508455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890049|NCT03445702|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|Investigators, participants, research coordinator will be blinded to intervention provided to subject|Randomized, double blinded, placebo controlled crossover trial|t|t|t|t
33890050|NCT03192748|||COHORT||PROSPECTIVE|||||||
33890051|NCT00900003|||CASE_ONLY||PROSPECTIVE|||||||
33890052|NCT02964156|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33890053|NCT02457234|NON_RANDOMIZED|PARALLEL||||NONE||||||
33890054|NCT05869994|||COHORT||PROSPECTIVE|||||||
33890055|NCT01380054|||CASE_ONLY||PROSPECTIVE|||||||
33890056|NCT05519631|||OTHER||CROSS_SECTIONAL|||||||
33890057|NCT02612909|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33890058|NCT00058461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890059|NCT02466620|||||CROSS_SECTIONAL|||||||
33890060|NCT03719235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890061|NCT03195894|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||A randomized, controlled, open study to compare conventional treatment with and without addition of TripleA||||
33890062|NCT00570245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890063|NCT01305499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890064|NCT03716479|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|fiber will be mixed into orange juice|subjects will consume 0, and 2 doses of acacia gum|t|f|t|f
33890065|NCT01472484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33890066|NCT00522392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890067|NCT02204904|||COHORT||OTHER|||||||
33890068|NCT03172689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||children with an clinical indication for cardiac output monitoring in ICU or OR||||
33890069|NCT03185546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33890070|NCT04326530|||COHORT||PROSPECTIVE|||||||
33890071|NCT01994083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890072|NCT04658602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Quadruple ( Participant, Care Provider, Investigator, Outcomes Assessor ) Blinding to the child participants and legal guardian of each participating child, operator, outcome assessor and statistician.|Parallel groups|f|f|t|t
33890073|NCT00140855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762886|NCT05982301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762887|NCT00146614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762888|NCT03682705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762889|NCT05412810|||COHORT||PROSPECTIVE|||||||
33762890|NCT02352441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762891|NCT02081235|||COHORT||RETROSPECTIVE|||||||
33762892|NCT03685396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33762893|NCT01100255|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33762894|NCT00886067|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890074|NCT01053429|||CASE_ONLY||PROSPECTIVE|||||||
33762895|NCT00076791|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890075|NCT00022074|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33890076|NCT04908995|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33890077|NCT00705237|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890078|NCT05462184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890079|NCT04720703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890080|NCT03890809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890081|NCT00575861|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33975965|NCT03312062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All of participants must be healthy.|There are 2 groups. Study group will receive foam rolling exercise. Control group will receive no foam rolling exercise. They will be handed a brochure about the proprioception and its role in injury prevention and foam rolling . Study group will be evaluated before foam rolling exercise . Afterwards, second evaluation will be performed after 4 weeks and follow up after 4 more weeks. Control group will be evaluated for the first time. Afterwards, second evaluation will be performed after 4 weeks and follow up after 4 more weeks.|t|f|f|f
33975966|NCT03821220|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33975967|NCT04519307|||CASE_CONTROL||PROSPECTIVE|||||||
33975968|NCT05388682|||COHORT||PROSPECTIVE|||||||
33975969|NCT05219227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33975970|NCT04121390|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33975971|NCT00003696|RANDOMIZED|||TREATMENT||||||||
33975972|NCT01929109|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762896|NCT00803621|||COHORT||PROSPECTIVE|||||||
33762897|NCT05217186|||COHORT||PROSPECTIVE|||||||
33762898|NCT02701335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33762899|NCT04871035|||COHORT||PROSPECTIVE|||||||
33975973|NCT04017936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762900|NCT04889235|||COHORT||PROSPECTIVE|||||||
33762901|NCT02635074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762902|NCT05300802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762903|NCT06431438|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33762904|NCT06214078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762905|NCT01450202|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33890082|NCT04052737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour (total dose/day: 0.9 µg/kg body weight). The same dosing regimen will be repeated every month for 6 months post randomization.~In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1 post randomization. The same dosing regimen will be repeated every month for 6 months post randomization.~In both treatment groups, subjects will be provided the best available standard of care."|t|t|t|t
33890083|NCT02494570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890084|NCT04668560|RANDOMIZED|PARALLEL||PREVENTION||NONE|Behavioural intervention, masking N/A|Randomised controlled trial||||
33890085|NCT05148871|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomised into 4 groups, where the only difference will be the time between vaccine doses (3, 4, 5 or 6 weeks)||||
33890086|NCT06166836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890087|NCT01191814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890088|NCT00864760|RANDOMIZED|CROSSOVER||||NONE||||||
33890089|NCT01849926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890090|NCT02323022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890091|NCT05177055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All eligible participants will be informed that there may be a waitlist (length not specified) and receive a start-date without being informed that thay are in a waitlist group or not a waitlist group.||t|f|f|f
33975974|NCT02933866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33975975|NCT03560609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975976|NCT03387098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975977|NCT04181242|||COHORT||PROSPECTIVE|||||||
33762906|NCT02634840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762907|NCT01379027|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33762908|NCT02376621|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33762909|NCT06624982|||COHORT||PROSPECTIVE|||||||
33762910|NCT00723099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762911|NCT00884754|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33762912|NCT05464381|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762913|NCT02782884|||COHORT||PROSPECTIVE|||||||
33762914|NCT00762632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762915|NCT04130139|||COHORT||PROSPECTIVE|||||||
33762916|NCT04376801|||COHORT||RETROSPECTIVE|||||||
33762917|NCT01896284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762918|NCT03493763|||CASE_ONLY||RETROSPECTIVE|||||||
33762919|NCT00421213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762920|NCT05827458|||COHORT||PROSPECTIVE|||||||
33762921|NCT00977756|||COHORT||PROSPECTIVE|||||||
33762922|NCT01960530|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33762923|NCT02507778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762924|NCT01357330|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33762925|NCT06550349|||CASE_ONLY||PROSPECTIVE|||||||
33762926|NCT00650143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762927|NCT01583686|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33762928|NCT03928145|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The study medication will have the same color, taste, consistency, odor and appearance. In this way, patients, care providers, outcome assessors and the entire research team will be blinded regarding the allocation to the treatment groups throughout the study.|The trial has a factorial design, where participants will receive two simultaneous interventions: a thiazide diuretic (chlorthalidone 25 mg or hydrochlorothiazide 50 mg) and a potassium-sparing diuretic (amiloride 10 mg or amiloride 20 mg). Randomization will be done in 1:1:1:1 ratio, and participants will be randomly assigned to four groups: a) chlorthalidone 25 mg + amiloride 10 mg; b) chlorthalidone 25 mg + amiloride 20 mg; c) hydrochlorothiazide 50 mg + amiloride 10 mg; and d) hydrochlorothiazide 50 mg + amiloride 20 mg.|t|t|t|t
33762929|NCT04846764|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33762930|NCT04143984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762931|NCT04567264|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional, single center||||
33762932|NCT02857439|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33762933|NCT01446796|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33762934|NCT01492686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890092|NCT05028621|NA|SINGLE_GROUP||SCREENING||NONE||||||
33890093|NCT02452333|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890094|NCT02544555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890095|NCT04256967|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33890096|NCT04178655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890097|NCT00925600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33890098|NCT02571348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890099|NCT01886118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33975978|NCT00751946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975979|NCT04022499|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33975980|NCT00113490|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33975981|NCT01626820|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33762935|NCT02974816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762936|NCT00286208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762937|NCT01667367|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33762938|NCT00266994|||COHORT||PROSPECTIVE|||||||
33762939|NCT02975635|||COHORT||PROSPECTIVE|||||||
33762940|NCT03804775|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33762941|NCT05153460|||COHORT||PROSPECTIVE|||||||
33762942|NCT00519701|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33890100|NCT04139122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890101|NCT03046420|||OTHER||RETROSPECTIVE|||||||
33890102|NCT02006784|||OTHER||PROSPECTIVE|||||||
33890103|NCT01442298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33890104|NCT01503216|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33890105|NCT02507349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890106|NCT05401890|||CASE_CONTROL||PROSPECTIVE|||||||
33890107|NCT04013126|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2 groups (treatment, control) each group is evaluated pre and post-surgery||||
33890108|NCT02786901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890109|NCT04537611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33762943|NCT04570241|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A 2-arm, open-label, randomized controlled clinical trial will be adopted with the Mbandjock health district as the test district and Sa'a Health District a Control Health District.~The Lot Quality Assurance Sampling (LQAS) method was used. Since this method requires that the intervention zones be divided into supervision areas, the health areas of each district were considered as supervision areas. The health area was selected in the ratio 2:1. In the test district 11 health areas were used and 6 health district in the control district. 19 households were selected for each health area as required by the LQAS method.~A total of 209 pupils and 209 adults shall be enrolled from households in Mbandjock. Similarly, 114 pupils and 114 adults will be recruited in Sa'a. In addition, 57 teachers shall be enrolled in the District of Mbandjock only. A total of 703 participants shall be enrolled during the study."||||
33762944|NCT05806944|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||double-blinded, pseudorandomized crossover|t|f|t|f
33762945|NCT03379623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomization will be performed by an independent person from Kulliyyah of Nursing research unit. The researcher will not be involved in allocation to intervention or control group. The participants will be advised not to talk about the study during assessments to prevent unblinding.||t|f|t|f
33762946|NCT03842592|NA|SINGLE_GROUP||SCREENING||NONE||||||
33890110|NCT04035876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762947|NCT05680454|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Sponsor, investigators and biostatisticians will remain blinded to subject allocation.|"The trial will be conducted in two stages:~Stage 1: An open-label trial will be carried out in 40 healthy women ages 27-45 in the enrolment order of mid-dosage group followed by high-dosage group. Each group of 20 subjects will be administered the mid-, and high-dosage form respectively.~Stage 2: A randomized and blinded (as to intra-dosage group) trial, with Gardasil9 as the positive control will be carried out in 120 healthy women ages 18-26 in the enrolment order of low-, mid-, and high-dosage groups. Each group of 40 subjects will be enrolled and randomized at a 3: 1 ratio to receive the investigational vaccine or positive control, respectively."|t|f|t|f
33762948|NCT02832622|||COHORT||PROSPECTIVE|||||||
33762949|NCT05760976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762950|NCT00302432|NON_RANDOMIZED|PARALLEL||||NONE||||||
33762951|NCT01852331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762952|NCT05175599|RANDOMIZED|PARALLEL||OTHER||NONE||Women are randomized 1:2 land birth to waterbirth.||||
33762953|NCT02592330|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the study intervention, a stem cell graft cultivated from their own cells.||||
33762954|NCT01437150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762955|NCT00385892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762956|NCT03040921|NA|SINGLE_GROUP||OTHER||NONE||Recruitment completed. Final data collection in April/2020.||||
33762957|NCT01437124|||COHORT||PROSPECTIVE|||||||
33762958|NCT04142502|RANDOMIZED|PARALLEL||OTHER||NONE||Propofol group: propofol infusion as sedation drug Dexmedetomidine group: dexmedetomidine infusion as sedation drug||||
33890111|NCT01284881|||COHORT||PROSPECTIVE|||||||
34074215|NCT04693780|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Once randomized, each participant will be allocated to their respective group by the website programmers who will allocate based on identification number and will not be privy to personal information regarding the participants.|Both the intervention and control groups will continue for three months. After three months, the control group will be sent a message highlighting some additions to the content provided to them. From his point forward when they login to the system they will be presented with the same content that was previously only available to the intervention group. Providing those in the control group access to the same material as the intervention group for a period of the study will allow for direct within- group comparison as well as a direct comparison between groups. Both groups will continue in this manner for an additional three months.|t|f|t|t
34074216|NCT05505383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074217|NCT01630018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074218|NCT04126044|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34074219|NCT04085718|||COHORT||PROSPECTIVE|||||||
34074220|NCT01898052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074221|NCT03003169|||COHORT||PROSPECTIVE|||||||
34074222|NCT00027885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890112|NCT01833871|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33890113|NCT00801814|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33890114|NCT00828464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890115|NCT05395676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomised controlled trial||||
33890116|NCT00971308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890117|NCT02850848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890118|NCT02421861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890119|NCT00882414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890120|NCT05792826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890121|NCT02322359|||CASE_CROSSOVER||PROSPECTIVE|||||||
33890122|NCT00508729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890123|NCT00459030|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890124|NCT05562817|||CASE_ONLY||CROSS_SECTIONAL|||||||
33890125|NCT04268134|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890126|NCT02820961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890127|NCT02016014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33890128|NCT00706628||PARALLEL||TREATMENT||||||||
33890129|NCT05284695|||CASE_ONLY||RETROSPECTIVE|||||||
33890130|NCT01172067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890131|NCT05811065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a multi-centric randomized clinical trial study with two arms (one arm for OPTIVF and one arm for the conventional approach) . In our study, the tool will be using the patient's age and day three serum AMH and FSH levels to decide the starting dose for the patient's cycle. Tool will use the first two days of data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient with the help of the decision support tool (OPTIVF )for this intervention in the clinical trial.|t|f|t|t
33890132|NCT01511731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890133|NCT02375867|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33890134|NCT03490487|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33890135|NCT06299943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Clinicians involved in the measurements and researchers that worked with data results did not know which group each patient was in.|Parallel-group, single-blinded controlled clinical trial.|t|t|t|t
33890136|NCT04219436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study consisted of two groups the number of patient was determined by sample size calculation through G power analysis (15 patients). Patients were randomly selected using computer generated randomization (www.randomizer.org).|2 arms undergoing the same surgical procedure but with different suturing techniques for flap closure|t|f|f|t
33890137|NCT06051630|RANDOMIZED|PARALLEL||OTHER||SINGLE||This will be a randomized, double-blind clinical trial conducted at University hospital Charles De Gaulle of Ouagadougou, comparing the results of intravenous administration of lidocaine perioperatively versus administration of saline|t|f|f|f
33890138|NCT05485207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762959|NCT04021186|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Prevention of hyperglycemia. The study will involve an intervention and a control group - only the intervention group will receive different treatment and the other standard care.||||
33762960|NCT06155305|||COHORT||PROSPECTIVE|||||||
33762961|NCT05762835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33762962|NCT00649363|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33762963|NCT00405457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33762964|NCT02587026|||COHORT||OTHER|||||||
33762965|NCT01933880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762966|NCT03569696|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment All the participating patients will receive 240mg nivolumab every 2 weeks for 8 doses for 4 months, and later 480 mg every 4 weeks for 2 years (cycle 9-30) for a maximum of 30 doses, starting 10±2 weeks after the last cycle of immunochemotherapy.||||
33762967|NCT02981381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762968|NCT03712735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33762969|NCT04450186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762970|NCT04871984|||COHORT||PROSPECTIVE|||||||
33762971|NCT05807659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762972|NCT02929225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33762973|NCT02785874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33762974|NCT03008525|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33762975|NCT05360030|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33762976|NCT03068325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762977|NCT00353613|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33762978|NCT01980615|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33762979|NCT00780650|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33762980|NCT05296395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33762981|NCT00668135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33762982|NCT02565901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762983|NCT00002760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762984|NCT02366897|NA|SINGLE_GROUP||OTHER||NONE||||||
33762985|NCT06524141|||OTHER||PROSPECTIVE|||||||
33762986|NCT02181686|||CASE_ONLY||PROSPECTIVE|||||||
33762987|NCT04140253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33762988|NCT01776021|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33762989|NCT04086784|||COHORT||PROSPECTIVE|||||||
33762990|NCT04532658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33762991|NCT00883038|RANDOMIZED|PARALLEL||TREATMENT||||||||
33762992|NCT02100150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33762993|NCT03021486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33762994|NCT05356390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33762995|NCT05839353|||OTHER||PROSPECTIVE|||||||
33762996|NCT02304965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33762997|NCT00750464|||CASE_ONLY||CROSS_SECTIONAL|||||||
33762998|NCT02421666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33762999|NCT01711957|||COHORT||PROSPECTIVE|||||||
33763000|NCT03798600|||COHORT||PROSPECTIVE|||||||
33763001|NCT04096612|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33763002|NCT05030896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763003|NCT00236171|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33763004|NCT02401074|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763005|NCT05728203|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33763006|NCT00717821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763007|NCT01669590|||COHORT||PROSPECTIVE|||||||
33763008|NCT05811039|NA|SINGLE_GROUP||TREATMENT||NONE||Open, single-arm, non-randomized study||||
33763009|NCT02378740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763010|NCT00703040|||OTHER||PROSPECTIVE|||||||
33763011|NCT03072238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763012|NCT00904891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33763013|NCT02307591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763014|NCT02869919|||CASE_CONTROL||PROSPECTIVE|||||||
33763015|NCT05428514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Clients will be consented on a baseline application. After the application, clients will be on a waitlist. When a bed is available, the agency will bring the top two moms on the waitlist in for an in person interview to confirm they are good fits for the home. The agency will then use a computer to randomly assign one mom to treatment (receiving the bed in the home) and one mom to control (referrals to other services).||||
33763016|NCT01163890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763017|NCT06419244|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33890139|NCT04096534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890140|NCT00707356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763018|NCT01598298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763019|NCT00014963|||||CROSS_SECTIONAL|||||||
33763020|NCT01398423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763021|NCT04504643|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33763022|NCT01003522|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33763023|NCT01896635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763024|NCT01925027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763025|NCT04983758|||COHORT||PROSPECTIVE|||||||
33763026|NCT02541032|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33763027|NCT02532179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763028|NCT05667766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763029|NCT01112228|||COHORT||PROSPECTIVE|||||||
33763030|NCT00909480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763031|NCT02098408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763032|NCT04566302|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33763033|NCT04959630|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33763034|NCT05550363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)|Prospective, Randomized, Double-masked, Placebo-controlled,Parallel-design, Multicenter Study|t|f|t|t
33763035|NCT06359236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763036|NCT05502614|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33763037|NCT00267410|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33763038|NCT03659604|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Clustered randomized controlled trial/parallel assignment~Different school classes will be allocated to one of the three groups: 1) intervention group with a game based on tailored feedback, 2) active control group with a game not using tailored feedback, 3) passive control group (waiting list group)."||||
33763039|NCT01913106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763040|NCT01087996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763041|NCT06251986|||OTHER||CROSS_SECTIONAL|||||||
33763042|NCT04045730|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label single arm|This is an open-label single arm||||
33763043|NCT06065384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33763044|NCT01949233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763045|NCT00954226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763046|NCT05741099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763047|NCT03841955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763048|NCT03997513|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.||||
33763049|NCT02017080|||CASE_CONTROL||PROSPECTIVE|||||||
33763050|NCT03857568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763051|NCT00886028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763052|NCT02331719|||CASE_CONTROL||OTHER|||||||
33763053|NCT02491021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763054|NCT01551004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763055|NCT05999786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data manager knows whether the patients are in the intervention or control group. However, the patients, caregiver, investigator, and outcome assessors do not know whether the patients are in the intervention or control group.|Patients receive early recovery of swallowing rehabiliation before surgery and continued to after surgery|t|t|t|t
33763056|NCT06197555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33890141|NCT03478384|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment of patients to two groups (group A: patients receive self-efficacy coaching, group B: patients do not receive additional coaching)||||
33890142|NCT04271761|||CASE_ONLY||PROSPECTIVE|||||||
33890143|NCT06456177|||CASE_ONLY||PROSPECTIVE|||||||
33890144|NCT03758560|||COHORT||PROSPECTIVE|||||||
33763057|NCT06426784|||OTHER||CROSS_SECTIONAL|||||||
33763058|NCT06619782|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The intervention involves training and implementation of the NIMH suicide prevention pathway in pediatric primary care and family medicine practices|t|f|f|t
33763059|NCT05995301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients were randomly assigned to two groups having 50patients in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesia assistant who was not involved in the study.|Patients were randomly assigned to two groups having 50patients in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesia assistant who was not involved in the study.|t|t|f|f
33763060|NCT03379701|||COHORT||PROSPECTIVE|||||||
33763061|NCT03857230|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33763062|NCT05882175|||COHORT||PROSPECTIVE|||||||
33763063|NCT01397994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763064|NCT05448547|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, parallel, open-label||||
33763065|NCT01303120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763066|NCT05438186|||COHORT||RETROSPECTIVE|||||||
33763067|NCT03962296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763068|NCT00368420|||COHORT||PROSPECTIVE|||||||
33763069|NCT03680664|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33763070|NCT03915184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763071|NCT00749125|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763072|NCT02655601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763073|NCT00595270|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763074|NCT01203930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763075|NCT02710305|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33763076|NCT03831984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33763077|NCT01040390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890145|NCT02122627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763078|NCT01824615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763079|NCT05971901|||COHORT||PROSPECTIVE|||||||
33763080|NCT02378558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763081|NCT06212466|||COHORT||OTHER|||||||
33763082|NCT03264885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33763083|NCT03326310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763084|NCT03114917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All Research Assistants will be blinded to treatment allocation. The Research Assistants will be carrying out outcomes assessments at baseline, 6 month and 12 month.|Randomised-controlled trial with a qualitative component.|f|f|f|t
33763085|NCT05156502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763086|NCT04598854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The treatment group will receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 \~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.|t|f|t|f
33763087|NCT04358276|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763088|NCT01821417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33763089|NCT00910403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763090|NCT04465461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890146|NCT00781365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890147|NCT02392260|NA|SINGLE_GROUP||||NONE||||||
33890148|NCT05728814|||CASE_ONLY||RETROSPECTIVE|||||||
33890149|NCT04959123|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890150|NCT02986178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890151|NCT02924701|||COHORT||PROSPECTIVE|||||||
33890152|NCT00450944|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890153|NCT01983891|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33890154|NCT05207475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763091|NCT03118102|||CASE_CONTROL||PROSPECTIVE|||||||
33763092|NCT00594191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763093|NCT00407199|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33763094|NCT00288301|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33763095|NCT03998683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763096|NCT05205317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763097|NCT05889806|||COHORT||PROSPECTIVE|||||||
33763098|NCT03390530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded and randomized|Double-blinded, placebo-controlled, and randomized controlled trial to compare outcomes between thyroxine and placebo treatment|t|t|t|t
33763099|NCT01417052|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33763100|NCT02311816|||CASE_CONTROL||RETROSPECTIVE|||||||
33763101|NCT05981222|||COHORT||PROSPECTIVE|||||||
33763102|NCT02612480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33763103|NCT03485677|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33763104|NCT01496586|||COHORT||CROSS_SECTIONAL|||||||
33763105|NCT02110745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33763106|NCT01630720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763107|NCT00242281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763108|NCT01547988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763109|NCT04959487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor) The analyst(s) and investigator(s) conducting and reviewing the analyses of the data will be masked to whether participants were in the intervention or control arm.|Participants (n=440) will be randomized to the intervention (n=220) or control (n=220) arms, stratified by county (San Francisco vs. Alameda County) and poor diabetes control (A1c \< 9%, vs. ≥ 9%). The intervention consists of providing diabetes-tailored food support and nutritional education (two sessions of individual counseling and four session of in-group diabetes-tailored nutrition education sessions) over six months to patients with type 2 diabetes.|f|f|t|t
33763110|NCT00344604|||||PROSPECTIVE|||||||
33763111|NCT00658502|||COHORT||PROSPECTIVE|||||||
33763112|NCT00602914|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33890155|NCT01245673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074223|NCT05701280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Care Providers (Therapists), Investigators, and Outcome Assessors do not know to which group the participants are randomized.|Double-blinded, randomized, parallel study with partial crossover.|t|t|t|t
34074224|NCT06360965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34074225|NCT03570047|||COHORT||RETROSPECTIVE|||||||
34074226|NCT05203601|NA|SINGLE_GROUP||TREATMENT||NONE||This is a dose escalation and extension study which designed as an open and multi-dose escalation study with single and multiple dosing.||||
34074227|NCT04130074|||CASE_ONLY||CROSS_SECTIONAL|||||||
34074228|NCT01957423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074229|NCT02252302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34074230|NCT02022046|||COHORT||PROSPECTIVE|||||||
34074231|NCT01707888|||CASE_ONLY||PROSPECTIVE|||||||
34074232|NCT06611774|||OTHER||CROSS_SECTIONAL|||||||
34074233|NCT00002479||||TREATMENT||||||||
33890156|NCT02673333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890157|NCT03973450|||COHORT||RETROSPECTIVE|||||||
33890158|NCT01776125|||COHORT||RETROSPECTIVE|||||||
33890159|NCT01691638|||CASE_CONTROL||RETROSPECTIVE|||||||
33890160|NCT03146364|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33890161|NCT03884686|RANDOMIZED|PARALLEL||OTHER||NONE||One group will receive intervention and other group will receive usual care.||||
33890162|NCT00108329|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890163|NCT06202248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890164|NCT03475511|||CASE_CONTROL||PROSPECTIVE|||||||
34074234|NCT06442722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074235|NCT04646018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074236|NCT05510414|RANDOMIZED|PARALLEL||OTHER||NONE||The intervention program was taught by experts with at least the title of deputy chief nurse who had been engaged in clinical psychological nursing for a long time. These teachers helped nurses with burnout to develop their own positive psychology, learn optimism, embrace hope, find available support systems and resources, plan their careers. Training took the form mainly of Balint groups, lectures, group discussions, video watching and outdoor development. Personalized counseling was provided to address specific psychological problems in individuals, in a way that ensured personal privacy. The intervention occurred as 12 sessions of 60 min each, twice a month, lasting altogether six months.||||
34074237|NCT03014271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890165|NCT00047567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074238|NCT00190788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074239|NCT04203212|||CASE_CONTROL||PROSPECTIVE|||||||
34074240|NCT00239473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074241|NCT05394285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074242|NCT00042055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074243|NCT00467155|||CASE_ONLY||PROSPECTIVE|||||||
34074244|NCT02532257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074245|NCT01345656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074246|NCT05680077|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074247|NCT01326247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074248|NCT02235181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074249|NCT02879955|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34074250|NCT03821766|||COHORT||PROSPECTIVE|||||||
34074251|NCT00334087|||DEFINED_POPULATION||OTHER|||||||
34074252|NCT03131726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34074253|NCT00734708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890166|NCT00021983||||TREATMENT||||||||
33890167|NCT00376961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890168|NCT04738955|NA|SINGLE_GROUP||TREATMENT||NONE||The patients will be randomized either low dose group or high dose group||||
33890169|NCT01065584|||COHORT||PROSPECTIVE|||||||
33890170|NCT02876978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890171|NCT00145223|||||PROSPECTIVE|||||||
33890172|NCT06657703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890173|NCT01573312|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34074254|NCT03212859|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||stepped wedge cluster randomised trial and mixed methods process analysis|t|f|f|f
34074255|NCT02299388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074256|NCT00595543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074257|NCT00002295||||TREATMENT||DOUBLE||||||
33975982|NCT04175496|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33975983|NCT05411809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975984|NCT00404274|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33975985|NCT04287881|NA|SINGLE_GROUP||SCREENING||NONE||||||
33975986|NCT05259111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975987|NCT03978884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975988|NCT01799590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975989|NCT05563909|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The researcher evaluating the participants will be blind to the group distributions.|54 patients with CTS who met the inclusion criteria will be included in this prospectively planned study. At the beginning of the study, 54 patients with a diagnosis of CTS who met the inclusion criteria will be randomized into three groups according to the random order created by a computer program after being numbered according to the general polyclinic application order of Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation.|f|f|f|t
33975990|NCT02873390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33975991|NCT04241159|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All eligible study participants will undergo once weekly PF24 infusion for 8 weeks in the WFBH Clinical Research Unit (CRU), and return for cognitive, physical, and biomarker testing 1 week and 5 weeks after receiving the last dose of PF24.||||
33975992|NCT01536223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074258|NCT05704270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074259|NCT03225677|||CASE_CONTROL||OTHER|||||||
34074260|NCT04530669|RANDOMIZED|PARALLEL||TREATMENT||NONE||"active arm and placebo arm; in the active arm patients will receive high tone power therapy in addition to the physical therapy conventional selected exercise program, and the placebo arm will receive the same physical exercise program with sham high tone power therapy."||||
34074261|NCT03580161|||COHORT||PROSPECTIVE|||||||
34074262|NCT00532532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074263|NCT05646030|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||A prospective three-armed cohort study.||||
33763113|NCT04062123|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|single-blind|Placebo-controlled, within-subject|t|f|f|f
33763114|NCT06129240|||COHORT||PROSPECTIVE|||||||
33975993|NCT01626547|||COHORT||PROSPECTIVE|||||||
33975994|NCT06542965|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33975995|NCT00433381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074264|NCT01588158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33975996|NCT06016465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|study drug pills (dexamethasone or placebo) will be placed in identical colored capsules and then into numbered packets. Only pharmacist will be unblinded.|Randomized 1:1 for study drug vs placebo|t|t|t|t
33975997|NCT02586766|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33975998|NCT03432195|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33975999|NCT00513851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976000|NCT00550069|||CASE_CONTROL||PROSPECTIVE|||||||
34074265|NCT02454348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074266|NCT03503110|NA|SINGLE_GROUP||OTHER||NONE||||||
34074267|NCT05587894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763115|NCT05555160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763116|NCT04340128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33890174|NCT05025943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074268|NCT03576274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33890175|NCT02601144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33890176|NCT04796402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763117|NCT03211299|||OTHER||CROSS_SECTIONAL|||||||
33890177|NCT04558697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890178|NCT02151825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33763118|NCT05159323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763119|NCT00082394|RANDOMIZED|PARALLEL||TREATMENT||||||||
33763120|NCT06614049|RANDOMIZED|PARALLEL||OTHER||NONE||Intervention group receives coaching from trained coaches and health-related information through an app, curated by coaches. Control group follows the standard of care of hyperlipidaemia patients.||||
33763121|NCT00641914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763122|NCT03771014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessment at ICU discharge, hospital discharge and 3 month follow-up will be undertaken by an assessor, blinded to study group allocation.|Feasibility study of two-arm pilot RCT, randomised 1:1 with blinded outcome assessments|f|f|f|t
33763123|NCT04299516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890179|NCT01390545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890180|NCT00879450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33890181|NCT00855439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890182|NCT04406571|||COHORT||PROSPECTIVE|||||||
33890183|NCT03733652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890184|NCT04879615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33890185|NCT02606552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890186|NCT03679403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976001|NCT04582721|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976002|NCT05899166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976003|NCT05263219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976004|NCT05487456|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976005|NCT03182257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976006|NCT04714619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976007|NCT05795491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976008|NCT05865054|||COHORT||PROSPECTIVE|||||||
33976009|NCT05258656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33976010|NCT04373759|||COHORT||PROSPECTIVE|||||||
33976011|NCT03243370|||COHORT||PROSPECTIVE|||||||
33763124|NCT05166538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Postoperative cardiac surgery, patients were randomized to receive ticagrelor or clopidogrel (n=102), respectively. The selected agent was applied in the operating room.|t|f|f|f
33976012|NCT04544176|||COHORT||RETROSPECTIVE|||||||
33976013|NCT01185990|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976014|NCT03800069|||COHORT||CROSS_SECTIONAL|||||||
33763125|NCT02856425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763126|NCT04370054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763127|NCT02104362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763128|NCT02276924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763129|NCT00617695|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33763130|NCT05006677|||OTHER||RETROSPECTIVE|||||||
33763131|NCT03263221|||COHORT||PROSPECTIVE|||||||
33763132|NCT03484676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763133|NCT05640414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763134|NCT01874145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763135|NCT00432250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
33763136|NCT03160287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763137|NCT01728792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763138|NCT01519388|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33763139|NCT03207906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization will be done centrally by a randomization programmer/statistician who will be the only un-blinded participant. That person will not have any part in the decisions regarding patient populations and/or protocol violations.|Once subjects have been determined to be eligible for participation in the study, they will be randomized to one of the three treatment arms. The randomization number will be generated according to the randomization schedule prepared prior to the start of the study. Participants will be assigned to receive assign treatment solution VBP-926 (either lower or higher concentration) or vehicle in 1:1:1 ratio using the IWRS system.|t|t|t|t
33763140|NCT01101360|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33763141|NCT02944656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763142|NCT00253201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763143|NCT02347514|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33763144|NCT00221286|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33763145|NCT02440984|NA|SINGLE_GROUP||OTHER||NONE||||||
33763146|NCT01623648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763147|NCT02226081|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763148|NCT00003137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763149|NCT01364597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763150|NCT04191447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind and double-dummy||t|f|t|f
33763151|NCT00402701|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763152|NCT06626438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763153|NCT00864708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763154|NCT00154206|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33763155|NCT06181032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976015|NCT04059796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be masked to which eye receives the study device||t|f|f|f
33976016|NCT02565095|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33976017|NCT00368277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976018|NCT05427097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be done by lottery. In a container, papers will be placed in the same number of study subjects and, then, the arm in which the subject will be allocated will be drawn. The team physiotherapist is blinded to the individual's allocation group.|Two groups, one placebo and one intervention|t|t|f|t
33976019|NCT04872907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33976020|NCT00275002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976021|NCT04319484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients enrolled in the study were randomly allocated in the lenvatinib group (54 patients) and the control group (54 patients) after stable condition.|t|t|t|t
33763156|NCT02607371|||OTHER||PROSPECTIVE|||||||
33763157|NCT02466646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763158|NCT04018248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33763159|NCT04077255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763160|NCT04061226|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763161|NCT01339286|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763162|NCT00170222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763163|NCT02753348|||COHORT||PROSPECTIVE|||||||
33763164|NCT00113932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763165|NCT05907486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763166|NCT01576367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33763167|NCT05933265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763168|NCT01581385|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976022|NCT00662129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976023|NCT04471935|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33976024|NCT01056874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976025|NCT03803566|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33763169|NCT06281353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890187|NCT00666562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33890188|NCT06281392|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33976026|NCT02018146|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33976027|NCT02546908|||COHORT||PROSPECTIVE|||||||
33976028|NCT01229085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763170|NCT06319703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33763171|NCT00727324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763172|NCT04083716|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763173|NCT03120689|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33763174|NCT03007654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33763175|NCT05922839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763176|NCT00765310|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33763177|NCT01768546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763178|NCT05340751|||COHORT||PROSPECTIVE|||||||
33763179|NCT04835714|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"Description to randomisation:~In Part A and Part B no randomisation will be performed. In Part C and Part D randomisation will be performed."|||||
33763180|NCT01438463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763181|NCT03391960|NA|SINGLE_GROUP||OTHER||NONE||||||
33976029|NCT04842110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763182|NCT05232032|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33763183|NCT05882201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"* The study will be a prospective randomized controlled study. Patients will be randomized by a computer-generated program into 3 equal parallel groups that will be randomly assigned to either:~* Control group;(30 patient).~* Group FICB; (30 patients) Fascia Iliaca compartment block group.~* Group FNB; (30 patients) Femoral nerve block group."|t|t|t|t
33763184|NCT05590988|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Results are evaluated by an independent scientists and group assignment is pseudonymised.||f|f|f|t
33763185|NCT02475135|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763186|NCT04500496|RANDOMIZED|PARALLEL||PREVENTION||NONE|open label randomized controlled study|open label randomized controlled study||||
33763187|NCT01731743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890189|NCT04879329|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohorts A, B, C, and D will enroll simultaneously. Cohort E will begin enrollment after Cohort D participants have completed the DLT evaluation period.||||
33890190|NCT01954823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890191|NCT05658757|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants are aware of study arm, but measured primary preliminary outcome is from a blinded CGM. Additionally, participants are not provided any of measured data during participation.||t|f|f|f
33890192|NCT05369819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients will be unaware of the group assignments and monitored in the reception area by a blinded anesthesiologist who will be in charge of the intervention and the evaluation of anxiety and sedation levels.||t|f|t|t
33976030|NCT02189083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976031|NCT00698906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763188|NCT00286000|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763189|NCT00156858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763190|NCT00517309|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33763191|NCT05155995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763192|NCT01457235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33763193|NCT04943263|NA|SINGLE_GROUP||OTHER||NONE||||||
33976032|NCT01834053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074269|NCT00256009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763194|NCT05256095|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All participants will receive the Thinking in Speech Therapy||||
33763195|NCT00954733|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763196|NCT01117701|RANDOMIZED|PARALLEL||||NONE||||||
33763197|NCT05782010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763198|NCT01141023|NA|SINGLE_GROUP||OTHER||NONE||||||
33763199|NCT00061113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763200|NCT00957606|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763201|NCT00255346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763202|NCT02459158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763203|NCT05958160|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Open-label study||||
33763204|NCT04568954|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"The objective of the trial is to assess Truenat platform/TB assays in clinical care. The use of Truenat platform/TB assays does not allow blinding of clinicians and participants in this trial. The trial-related procedures will be embedded into the routine practice at the primary-level facility. Data analysts will be blinded to intervention allocation.~Randomisation takes place on a cluster level rather than for the individual patients to avoid contamination between the arms within a health facility. Since clinics will be relatively far apart, contamination is unlikely."||f|f|f|t
33763205|NCT01637701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890193|NCT03358914|||COHORT||PROSPECTIVE|||||||
33890194|NCT05850741|NA|SINGLE_GROUP||OTHER||NONE||||||
33890195|NCT05020379|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Intervention Model: Parallel Assignment||||
33890196|NCT03409549|||COHORT||PROSPECTIVE|||||||
33890197|NCT02005055|||||PROSPECTIVE|||||||
33890198|NCT03770403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890199|NCT00461175|||COHORT||PROSPECTIVE|||||||
33763206|NCT00457639|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33763207|NCT00283920||||TREATMENT||||||||
33763208|NCT03204058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763209|NCT04146896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization algorithm, randomization allocation, allocation to study drug or placebo.|Subjects will be randomized to receive either placebo or NYX-2925.|t|f|t|t
33763210|NCT05923229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33763211|NCT06623071|||COHORT||PROSPECTIVE|||||||
33763212|NCT03489057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The investigator and data collectors will be masked to intervention.||f|t|t|t
33763213|NCT02239497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763214|NCT06465277|||COHORT||PROSPECTIVE|||||||
33763215|NCT04529265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33890200|NCT00277758|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890201|NCT06402409|||COHORT||PROSPECTIVE|||||||
34074270|NCT00540397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074271|NCT01265394|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074272|NCT01680809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074273|NCT03156257|||CASE_ONLY||PROSPECTIVE|||||||
34074274|NCT04265222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized||t|f|f|t
34074275|NCT01104883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074276|NCT03425318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890202|NCT03463772|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients that have provided informed consent will be randomized to either IVM or standard IVF. Randomization and allocation of patients to study groups will be performed on the day 2 or 3 of the menstrual cycle. Randomization will be centrally controlled by administrative staff in the trial center, who are not involved in the treatment procedure. When there is an eligible participant to be enrolled into the study, nurses from the specific site will log in the trial center to get allocation of patients according to a computer-generated randomization list in a 1:1 ratio, with a variable block size of 2, 4 or 8 and stratified by center.||||
33890203|NCT05320939|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot open-label single arm study.||||
33890204|NCT00880750|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33890205|NCT03578835|||COHORT||PROSPECTIVE|||||||
33890206|NCT00737529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890207|NCT04233125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890208|NCT04300868|||OTHER||OTHER|||||||
33890209|NCT01118910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890210|NCT06519656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890211|NCT02300649|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33890212|NCT05674448|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890213|NCT00642330|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33890214|NCT06217393|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a Phase 3, randomized, open-label, multicenter, parallel-group, active-controlled study to evaluate the non-inferiority efficacy of Itopride Hydrochloride 150mg extended release tablet ( administered once daily) compared to Itopride Hydrochloride 50 mg film coated tablets (administered TID) in subjects with gastrointestinal symptoms caused by gastric dysmotility and delayed gastric emptying, like sensation of bloating, early satiety, postprandial fullness, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting; functional (non-ulcer) dyspepsia or chronic gastritis. This study will enroll 564 subjects and the duration of subject participation will be approximately 11 weeks.~Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"||||
33890215|NCT01931046|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33890216|NCT03614936|||COHORT||PROSPECTIVE|||||||
33890217|NCT02901171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890218|NCT02126059|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33890219|NCT00628186|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890220|NCT00162903|||DEFINED_POPULATION||OTHER|||||||
33890221|NCT05764369|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know which group they are assigned to, however, study staff will know.||t|f|f|f
33890222|NCT05162079|||COHORT||PROSPECTIVE|||||||
33890223|NCT05616143|||COHORT||RETROSPECTIVE|||||||
33890224|NCT02041962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33890225|NCT01278290|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33890226|NCT01253603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074277|NCT02665819|||CASE_ONLY||PROSPECTIVE|||||||
34074278|NCT05423457|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34074279|NCT05111535|||COHORT||PROSPECTIVE|||||||
34074280|NCT02370511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074281|NCT02404402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074282|NCT02576977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074283|NCT04298827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074284|NCT04870021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074285|NCT00228839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074286|NCT04655326|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant receives a customized probiotic based on the results of the measurement of their gut microbiota||||
34074287|NCT03179657|||COHORT||PROSPECTIVE|||||||
34074288|NCT05851573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074289|NCT02633943|||CASE_ONLY||PROSPECTIVE|||||||
34074290|NCT00787163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074291|NCT05661019|||CASE_CONTROL||PROSPECTIVE|||||||
34074292|NCT04398940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890227|NCT00928070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890228|NCT01841632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890229|NCT02190734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074293|NCT05205499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074294|NCT02196298|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34074295|NCT01218815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074296|NCT03602716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074297|NCT02503241|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Physiologic crossover study. There is no randomization. All participants will receive the same interventions in the same order.||||
34074298|NCT02933398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074299|NCT03320265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074300|NCT01653457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074301|NCT01778491|||||PROSPECTIVE|||||||
33763216|NCT01167686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890230|NCT00242918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890231|NCT03871894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890232|NCT05589818|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, Interventional, Single-Center, Open-Label, Non-Comparative, Single Cohort, Single-Arm, Trial||||
33890233|NCT04928014|||COHORT||PROSPECTIVE|||||||
33890234|NCT03654157|||OTHER||PROSPECTIVE|||||||
33890235|NCT06500663|||OTHER||CROSS_SECTIONAL|||||||
33890236|NCT05257122|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open Label, non-randomized, single-arm and multi-centered phase II clinical trial.||||
33890237|NCT03965143|||COHORT||PROSPECTIVE|||||||
33890238|NCT04584177|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33890239|NCT05346107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890240|NCT05970692|||OTHER||CROSS_SECTIONAL|||||||
33890241|NCT00470496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074302|NCT04211012|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
34074303|NCT01477528|||COHORT||PROSPECTIVE|||||||
34074304|NCT05807035|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects ewill receive active intervention in an n=1 study design||||
34074305|NCT05572021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Comparison of prospective group to retrospective group||||
34074306|NCT00622102|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34074307|NCT00673257|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074308|NCT00301457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074309|NCT02141191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074310|NCT04256291|||COHORT||PROSPECTIVE|||||||
34074311|NCT03030677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074312|NCT04959409|||COHORT||RETROSPECTIVE|||||||
34074313|NCT01945983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976033|NCT05720572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"After eligible patients provide informed consent, they are assigned a specific identifier. Neither the patient nor the researcher knows which group the subject will be assigned to. Patients are randomized according to the implemented random allocation sequence using numbered sealed envelopes, which are opened after inclusion of the patient for the study in a 1:1 ratio to treatment with antazoline or propafenone.~After inclusion of the patient the study the nurse will open the numbered envelope and prepare three 10 cm3 syringes with study drugs according to randomization and pass them to the enrolling physician and nurse who will administer the drug.~The patient, enrolling physician, nurse who administering the drug, and clinician reviewing the clinical outcomes will all be blinded to the treatment. The statistician, study nurse who prepares the syringes and clinician involved in safety control will be unblinded to the patient's assignment."|"Study design This randomized, double-blind, placebo-controlled, non-inferiority clinical study is actually carried out at the Department of Heart Disease, Centre of Postgraduate Medical Education, Warsaw, Poland. The study will include 390 participants presenting with an episode of AF lasting less than 48 h. All participants must sign an informed consent form.~The study protocol was approved by the local ethics committee and is in full compliance with the Declaration of Helsinki."|t|f|t|t
33976034|NCT01988454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074314|NCT04407039|||COHORT||PROSPECTIVE|||||||
34074315|NCT00873717|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33976035|NCT04897828|||COHORT||RETROSPECTIVE|||||||
34074316|NCT02437994|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074317|NCT03560011|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|"2 Arms :~* Rituximab (375 mg/m2)~* Rituximab (375 mg/m2) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dise 100g)"||||
34074318|NCT01673178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976036|NCT00299156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976037|NCT00140517|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34074319|NCT03289988|||COHORT||CROSS_SECTIONAL|||||||
34074320|NCT00968955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34074321|NCT06149572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The data collector and primary investigators will be blinded for the position of parturient|the sitting and lateral groups followed and assessed parallelly|f|f|t|t
33976038|NCT06288282|||COHORT||CROSS_SECTIONAL|||||||
34074322|NCT01084057|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074323|NCT06092528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.~Evaluations and interventions will be performed different physiotherapist. In addition, before statistical analysis patients' groups will be coded."|Parallel Assignment|t|f|t|t
34074324|NCT00003197||||TREATMENT||||||||
34074325|NCT00837967|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33976039|NCT02852564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976040|NCT06348836|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either a closed-chain (weightbearing) exercise group or an open-chain (non-weightbearing) exercise group||||
33976041|NCT04559607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976042|NCT04842487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976043|NCT02750306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976044|NCT01362933|||COHORT||PROSPECTIVE|||||||
33976045|NCT04165681|NA|SINGLE_GROUP||OTHER||NONE||||||
33976046|NCT03567213|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34074326|NCT01019629|||COHORT||OTHER|||||||
34074327|NCT04110314|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34074328|NCT05844332|||OTHER||OTHER|||||||
34074329|NCT04959799|||COHORT||RETROSPECTIVE|||||||
34074330|NCT06528613|||OTHER||PROSPECTIVE|||||||
34074331|NCT02872233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074332|NCT01771757|||COHORT||PROSPECTIVE|||||||
34074333|NCT00463918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074334|NCT02477878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976047|NCT02763722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976048|NCT02320279|||COHORT||PROSPECTIVE|||||||
33976049|NCT00200122|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33976050|NCT04569500|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976051|NCT04191564|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|normal perfusion|low perfusion||||
33976052|NCT01717898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074335|NCT00292708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074336|NCT04666545|RANDOMIZED|PARALLEL||OTHER||SINGLE||Pilot parallel block randomized controlled trial|f|f|t|f
34074337|NCT02546128|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34074338|NCT05116371|||COHORT||PROSPECTIVE|||||||
34074339|NCT01566422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074340|NCT03507985|||COHORT||PROSPECTIVE|||||||
34074341|NCT02227784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074342|NCT05018416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074343|NCT01137487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074344|NCT01330550|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
33890242|NCT05541783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890243|NCT03184844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890244|NCT04351412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, clinical trial|t|t|t|t
33890245|NCT05480969|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33890246|NCT00419796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890247|NCT00976014|||CASE_CONTROL||PROSPECTIVE|||||||
33890248|NCT02537678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890249|NCT04410874|NA|SEQUENTIAL||TREATMENT||NONE||||||
33976053|NCT01977261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976054|NCT00928837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976055|NCT04177264|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|There is no masking. The nature of the intervention makes it impossible to prevent the participants from knowing what intervention will be performed on them. The investigators will be performing the interventions and, thus, cannot be masked.|Three groups of research participants will undergo four study sessions each, during which different combinations of osteopathic manipulative treatment or sham procedures (OMT, Group 1), transcutaneous auricular vagus nerve stimulation combines with OMT or sham procedures (taVNS, Group 2), or no intervention (Group 3, time control) will be performed.||||
33976056|NCT00801190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33976057|NCT03097822|||COHORT||PROSPECTIVE|||||||
33976058|NCT04709159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial with two arms. Interventional Arm will receive the intervention (daily pill reminders, health messages, clinic appointment reminders, remote symptom reporting service, toll-free number to call in to receive services, plus the option to co-register a caregiver who will receive the same services as the patient) as well as standard of care. The Control arm will have patients who will receive only standard of care available at the TB clinics as per the Uganda National Tuberculosis Treatment guidelines.||||
33976059|NCT05958290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976060|NCT01189864|||COHORT||PROSPECTIVE|||||||
33976061|NCT01065103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976062|NCT02678195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976063|NCT00882622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976064|NCT06545084|||COHORT||PROSPECTIVE|||||||
33976065|NCT00245713|RANDOMIZED|PARALLEL||||DOUBLE||||||
33976066|NCT04161144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976067|NCT02224391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074345|NCT04473872|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Our study will include individuals aged 40-75 years, diagnosed with ischemic or hemorrhagic stroke, who applied to the Kırıkkale University Faculty of Medicine physical therapy and rehabilitation clinic. After the patients are separated according to the specified exclusion and inclusion criteria, they will be divided into 3 groups using the Online Random Allocation Software program.~In addition to normal neurodevelopmental therapy (NGT) 5 days a week, respiratory physiotherapy will be applied. The total duration of treatment will take 6 weeks.~1. Neurodevelopmental treatment program (BOBATH treatment approach) will be applied to the group.~2. The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises.~3. The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and respiratory muscle training with the THRESHOLD IMT device."||||
33890250|NCT06657521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890251|NCT05710432|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The two training techniques will be randomized using sealed opaque envelopes.|As soon as patients can be disconnected from the ventilator and able to perform IMT, the order of the two training techniques (Quasi-isometric neck flexion exercise and inspiratory muscle training) will be randomized (using sealed opaque envelopes).|f|f|t|f
33890252|NCT02899169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890253|NCT04532788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890254|NCT04795479|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33976068|NCT01158456|||COHORT||PROSPECTIVE|||||||
33976069|NCT06167538|||COHORT||RETROSPECTIVE|||||||
33976070|NCT02848599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976071|NCT00780026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976072|NCT02848703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976073|NCT00678067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763217|NCT02596763|NA|SINGLE_GROUP||OTHER||NONE||||||
33763218|NCT03978910|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074346|NCT06325891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33890255|NCT04397484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"1. Patients will be blinded to the treatment arm in which he/she is allocated to.~2. Anesthesiologist performing the block will receive identical syringes with equal volume of local anaesthetics, prepared by a nurse/ pharmacist who is not involved in the study.~3. Anaesthesiologist performing the block will be blinded.~4. Outcome assessor assessing the outcomes will be blinded."|The randomization sequence will be generated using online randomization software. The randomization sequence will be assigned as Group 1 =0.5% Chirocaine (levobupivacaine) and Group 2 =1.5% Xylocaine with adrenaline 1:200,000, and the group allocation will be sealed within an opague envelop by a research assistant, who is not involved in this study. After recruitment, patients will be randomly allocated to receive ultrasound guided subparaneural popliteal sciatic nerve block below bifurcation using either 0.5% Chirocaine (levobupivacaine) (Group 1) or 1.5% Xylocaine with adrenaline 1: 200,000 (Group 2).|t|t|t|t
33890256|NCT04899479|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study, therefore, no masking will be performed.|Randomization will be performed 1:1 between SGLT-2 inhibitor and control. Stratification will be done by DM and clinical presentation (STEMI vs. NSTEMI).||||
33890257|NCT03156036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890258|NCT01569633|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
33890259|NCT04911621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Both newly diagnosed patients and patients who previously underwent anti-glioma treatment are eligible for the study, provided they comply with all in- and exclusion criteria. The study hence consists of two strata, newly diagnosed patients are included in stratum A, while pre-treated patients are included in stratum B.||||
33763219|NCT03041844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890260|NCT05957705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researchers responsible for the tomographic and histometric analysis will not be aware of the type of group in which the sample is located.||t|t|t|f
33890261|NCT04931602|||COHORT||PROSPECTIVE|||||||
33890262|NCT01559103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33890263|NCT04545957|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890264|NCT02285829|||COHORT||PROSPECTIVE|||||||
33890265|NCT03388814|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33890266|NCT01145235|||COHORT||PROSPECTIVE|||||||
33890267|NCT03180814|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33890268|NCT03106532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890269|NCT01991561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33890270|NCT05456750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890271|NCT01113151|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33890272|NCT03496701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890273|NCT05104944|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|It is not possible to blind this study due to the nature of reporting the MRIs, whereby comparison is made with the previous images, which indicates the trial arm the participant has been randomised to.|Intervention: Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinue immobilisation in addition to standard care||||
33890274|NCT02241473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890275|NCT03448640|||CASE_CONTROL||PROSPECTIVE|||||||
33976074|NCT02611024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with selected advanced solid tumors will be divided into 3 groups: the Lurbinectedin Escalation Group, the Irinotecan Escalation Group and the Intermediate Escalation group. Each group will have a different dose escalation scheme.||||
33976075|NCT04039542|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed methods - qualitative and quantitative||||
33976076|NCT02920164|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33976077|NCT04712656|||COHORT||PROSPECTIVE|||||||
33976078|NCT04331756|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976079|NCT03763500|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized and open study||||
33976080|NCT01703507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976081|NCT03435198|||OTHER||PROSPECTIVE|||||||
33976082|NCT03528408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976083|NCT00681720|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33976084|NCT05260645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33976085|NCT04172389|||CASE_ONLY||RETROSPECTIVE|||||||
33976086|NCT02012309|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976087|NCT04126356|||COHORT||PROSPECTIVE|||||||
33976088|NCT02162758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976089|NCT00977834|||COHORT||CROSS_SECTIONAL|||||||
33976090|NCT05588284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976091|NCT02371525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976092|NCT04291066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976093|NCT00720798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074347|NCT03762577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074348|NCT05359211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074349|NCT04232644|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33890276|NCT03478241|RANDOMIZED|PARALLEL||SCREENING||SINGLE|the patient did not know which shaping system was used on them|after each group has been treated with their respective Ni-Ti root canal shaping system, post operative pain was assessed at 6, 12, 18, 24, 48, and 72 h; 7 days; and 1 month.|t|f|f|f
33890277|NCT00222105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976094|NCT03912207|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Volunteers in groups 1-5 will be blinded to eliminate subject bias (either conscious or subconscious) using a 10:3 randomised control design (BCG:placebo) whereby volunteers randomised to the BCG arms (Arm A) will inhale aerosolised BCG mixed with normal saline and those randomised to the placebo arms (Arm B) will inhale aerosolised normal saline.~The volunteers will be unblinded just prior to the 3 month visit when those in Arm A may have sputum collected and those in Arm B will not. Volunteers in group 6 and 8 will not be blinded.~For groups 1 -5, the bronchoscopist performing the procedure will also be blinded to eliminate any bias in the reporting of the appearance of the lung mucosa and extent of airway inflammation.~All samples will be anonymised and the subject number will be allocated sequentially and therefore not identifiable with the allocated Arm. The senior immunologist will be blinded to reduce any bias that could be introduced at the sample processing stage."||t|t|f|t
33976095|NCT02243956|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33976096|NCT00284102|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976097|NCT04644133|||CASE_CONTROL||PROSPECTIVE|||||||
33976098|NCT04998409|||CASE_ONLY||OTHER|||||||
33976099|NCT04873583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multi-center, randomized, controlled, non-blinded trial|f|f|f|t
33976100|NCT01609764|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33976101|NCT01499914|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33976102|NCT00724555|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33976103|NCT00663221|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33976104|NCT01699581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074350|NCT04664101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074351|NCT02565316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074352|NCT01354197|||COHORT||PROSPECTIVE|||||||
34074353|NCT02047370|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34074354|NCT00719160|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34074355|NCT05122624|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study includes an intervention arm (four clinics) and a control arm (four clinics).||||
33763220|NCT06611683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074356|NCT04224025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074357|NCT03592836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34074358|NCT00810069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074359|NCT04881214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074360|NCT01562717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074361|NCT03519126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a randomized, controlled, simple blind trial with comparative analysis between study groups and a control, performed in three moments: pre and post clinical intervention and one month after the end of treatment (follow up).|f|f|f|t
34074362|NCT01457417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074363|NCT01560026|||COHORT||RETROSPECTIVE|||||||
34074364|NCT01409187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074365|NCT05242302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074366|NCT04069676|||COHORT||PROSPECTIVE|||||||
34074367|NCT03350490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074368|NCT05194345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors/outcomes assessors will be masked on whether the participants are in the intervention or the control (enhanced usual care) group.|randomized controlled trial|f|f|f|t
34074369|NCT03842904|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a phase IV, open-label, randomised, single centre, 2-way crossover study.||||
34074370|NCT03560063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants: participants in both arms will undergo total hip replacement while under general anaesthetic. Participants will not be aware of the templating method used during the total hip replacement due to the general anaesthetic, therefore will remain blinded. Wounds and dressings will be the same for both study arms. Participants in the two study arms will undergo the same pre- and post-operative imaging to prevent unmasking.~Outcomes assessors examine patients from 3 months post-operatively. There is no risk they will know which arm the patient is in, as they will not have access to the study database."|"Participants will be recruited and randomised into the two parallel study arms. Interventional arm: total hip replacement with use of the Corin Optimised Positioning System to guide templating.~Comparator arm: total hip replacement, guided by standard templating techniques"|t|f|f|t
33763221|NCT02442843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074371|NCT03701542|||CASE_ONLY||PROSPECTIVE|||||||
34074372|NCT00329693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33763222|NCT01069835|||COHORT||PROSPECTIVE|||||||
33890278|NCT05011591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890279|NCT06656143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890280|NCT01237951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890281|NCT02505256|||CASE_ONLY||PROSPECTIVE|||||||
33890282|NCT01856101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890283|NCT06444438|||COHORT||PROSPECTIVE|||||||
33976105|NCT05100745|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Clinicians and subjects in both the active and sham group will be blinded to the randomized treatment assignments until 2-month follow-up visit. The sham and active devices will appear the same and appear to be utilized in the same manner. Only the Vibrato Medical person controlling the treatment device will be aware of the respective randomization for each subject. The second phase of this study, crossing over from sham to active treatment will not be concealed.|Prospective, double-blinded, randomized controlled trial to evaluate the feasibility of TUS in the treatment of PAD.|t|t|t|f
33976106|NCT04536259|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Consenting participants be randomly assigned to one of three groups in a 1:1:1 fashion. Each group will be asked to imagine receiving an invitation to attend a hospital outpatient appointment by video or in-person. In the first group, the proposed attendance mode will be by video. In the second group, the proposed attendance mode will be in-person. In the third group, participants will simply be asked to select which mode of attendance they prefer: video or in-person.|t|f|t|f
33976107|NCT03208426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The technicians who performed the UBT test are blind to the treatment allocation||f|f|f|t
33890284|NCT05195788|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The CongeNIRS study uses the prospective, randomised, open-label, blinded end-point (PROBE) design.~The participation in this study is expected to be three months and two weeks, comprising three months of physical training and 2 weeks of testing (baseline and three months, one week each)."||||
33976108|NCT01545635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976109|NCT03491436|NA|SINGLE_GROUP||PREVENTION||NONE||Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips.||||
33976110|NCT04403048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976111|NCT00600795|||CASE_ONLY||PROSPECTIVE|||||||
33976112|NCT01434342|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976113|NCT00625807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976114|NCT04000009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976115|NCT00358826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976116|NCT02419352|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33976117|NCT06528665|||COHORT||PROSPECTIVE|||||||
33976118|NCT03147170|||CASE_CROSSOVER||PROSPECTIVE|||||||
33976119|NCT02768298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976120|NCT06004609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33976121|NCT00720486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976122|NCT05760664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976123|NCT06437080|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After randomization, 100 patients will be allocated to each of the three study groups, (total participants selected 300) i.e., group A, B and C.~The participants of Group A will get oral Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg (Fersip) daily for three months, participants of group B will get IV Ferric Carboxymaltose (Ferinject) for 03 months (3 doses) and Group C will remain on their normal diet~All 03 groups will be called and their blood samples will be taken to evaluate the effect of iron supplementation on serum ferritin levels and severity of symptoms to assess the effectiveness of the intervention."||||
33976124|NCT05725746|||COHORT||CROSS_SECTIONAL|||||||
33976125|NCT02547857|||COHORT||PROSPECTIVE|||||||
33890285|NCT03041311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890286|NCT03670576|||COHORT||PROSPECTIVE|||||||
33890287|NCT05634902|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33890288|NCT03709992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33890289|NCT00340431||||TREATMENT||||||||
33976126|NCT05591196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective, randomized, two-arm cross-over study: All participants will receive one of the two treatment arms one after the other. The order of the treatments will be randomized.||||
33976127|NCT00040378|||COHORT||PROSPECTIVE|||||||
33976128|NCT01073436|||CASE_ONLY||PROSPECTIVE|||||||
33976129|NCT00275483|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33976130|NCT03401710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976131|NCT01020682|||COHORT||PROSPECTIVE|||||||
34074373|NCT00130689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074374|NCT02128659|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074375|NCT05186584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074376|NCT05013957|||COHORT||RETROSPECTIVE|||||||
33890290|NCT01942252|||CASE_CONTROL||PROSPECTIVE|||||||
33890291|NCT05148884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo-controlled Phase 2a study|t|t|t|t
33890292|NCT03135392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Participants who are having implant reconstruction will act as controls for all other breast reconstructions. If the participant is having autologous tissue reconstruction, she will be randomly put into one of the study groups. Neither the study doctor nor the participant can choose the treatment. Assignment is done randomly, like the flip of a coin. If the participant is having only one breast reconstructed, she will be randomly assigned to either receive the nerve reconstruction or not.~If the participant is having both of her breasts reconstructed, one side will receive the nerve reconstruction and one will not. The participant will not know which group you have been assigned to until the completion of the study or if voluntarily withdraw from the study"|This is a prospective cohort study|t|f|f|f
33890293|NCT05408689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890294|NCT06158243|||COHORT||PROSPECTIVE|||||||
33890295|NCT00792779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890296|NCT05212025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890297|NCT05664620|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Diagnostic Test: Risk Stratification Tool Patients will be allocated to three groups (Low, medium and high risk) by using the Risk Stratification Tool, and High-risk patients will receive multidisciplinary treatment assigned to them by a physician.||||
33890298|NCT02440750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890299|NCT01812902|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890300|NCT06400992|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890301|NCT04417257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomly assigned to take either the active drug (LAU-7b capsule) or a matching inactive placebo (inactive capsule)|Double-blind, randomized, parallel groups and placebo-controlled trial|t|t|t|t
33890302|NCT00564993|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33890303|NCT03339895|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33890304|NCT00341328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890305|NCT01572935|||||CROSS_SECTIONAL|||||||
33890306|NCT04826900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be a research code representing patients' identity, this code will not show patients' name, social security number, and home address. For the results of patients' visit and the diagnosis, the study moderator will maintain a confidential attitude and be careful to maintain patients' privacy.||t|f|f|f
33890307|NCT00981994|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890308|NCT01238120|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33890309|NCT02351362|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890310|NCT03124459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890311|NCT05756192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Care providers will be masked as we do not want bias to impact provider counseling at time of visit.||f|t|f|f
33890312|NCT06033729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The bronchoscopist, the patient and the research assistant administrating the questionnaires were blinded to the assigned group. It was not possible to blind anesthesiologists involved in the patient's care.|"Informed consent was obtained from each patient or legally authorized representative prior to enrollment in this study.~After obtaining a signed informed consent the patient was randomly allocated 1:1 to the group REMIFENTANIL TCI or STANDARD. A research randomizer software was used for randomization (iRANDOMIZER-SHMOOPI LLC-version 2.5)."|t|f|f|t
33890313|NCT05623566|NA|SINGLE_GROUP||SCREENING||NONE||||||
33890314|NCT03987750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890315|NCT05335889|||CASE_ONLY||PROSPECTIVE|||||||
33890316|NCT06124079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890317|NCT01479608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890318|NCT00302393|RANDOMIZED|CROSSOVER||||NONE||||||
33890319|NCT03132077|||COHORT||RETROSPECTIVE|||||||
33890320|NCT02770807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Sponsor, Investigator, site staff, and patients were not aware of the treatment assignments.||t|t|t|f
33890321|NCT01305447|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33890322|NCT06085183|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33890323|NCT04651634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This study design will minimize bias and provide reference data (i.e., data from placebo treated subjects) which will aid in the interpretation of results. To limit the occurrence of conscious and unconscious bias in the conduct and interpretation of safety and efficacy results, the study is double blind where the subject, the Investigators/site staff, and the Sponsor staff remain unaware of the treatment assignment. The planned safety assessments that will be performed during the study are considered acceptable measures for ensuring the safety of subjects during a clinical study.|The three active treatment groups will receive either 20, 40, and 60 mg/day of MIT-001 IV infusion for 30 minutes, two times per week for 5 to 7 continuous weeks until a cumulative radiation dose of between 60 and 72 Gy, with CCRT. Placebo group will receive placebo, manufactured with the same properties and appearance as MIT 001, at same treatment frequency as MIT-001 with CCRT.|t|t|t|t
33890324|NCT00316264|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33976132|NCT04932356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Patients will be randomly assigned to each group at the beginning of recruitment. Patients who are in the intervention group will be aware of the group in which they are because it requires biweekly telephone visits.|Fortnightly reinforcement of diabetes education, diet review, exercise, emotional support, doubts with insulin or oral medication and the registration of blood glucose controls, through telephone calls scheduled at a specific time during a semester.||||
33976133|NCT02512354|||COHORT||PROSPECTIVE|||||||
33976134|NCT00028353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33890325|NCT03843047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete different purchasing scenarios in the Experimental Tobacco Marketplace in which different e-liquid nicotine concentrations are available (3, 6, 12, and 24 mg/mL nicotine). In all scenarios, a range of other tobacco products will also be available.||||
33890326|NCT00061386|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33976135|NCT04581005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33763223|NCT04535622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the interventions participants and researchers cannot be blinded to group allocation. The treating healthcare professionals (i.e. the Research Nurse and Clinical Research Fellow) will also not be masked due to nature of the service. The surgeon will be masked to allocation. The data manager and trial statistician will be masked to allocation throughout the study.||f|f|f|t
33890327|NCT05071898|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study will employ a paired design with each participant being studied both before and after receiving semaglutide treatment for six weeks.||||
33976136|NCT04965571|||COHORT||RETROSPECTIVE|||||||
33976137|NCT06328283|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976138|NCT01082783|||CASE_CONTROL||PROSPECTIVE|||||||
33976139|NCT03615937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976140|NCT00535522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976141|NCT01296932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976142|NCT00288613|||CASE_ONLY||PROSPECTIVE|||||||
33976143|NCT02159105|||COHORT||PROSPECTIVE|||||||
33976144|NCT03218592|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Prospective. Single-center, open-label, 3-arm, triple stage study||||
33976145|NCT02943525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976146|NCT01775033|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33976147|NCT02472392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976148|NCT02117583|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33976149|NCT03170648|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33976150|NCT03708913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976151|NCT00907309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976152|NCT01429311|||OTHER||PROSPECTIVE|||||||
33976153|NCT02241603|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|participants are expressly assigned to intervention groups through a non-random method based on metabolic testing|Participants are assigned to two groups in parallel for the duration of the study. There is a dietary weight loss intervention aiming for \~5-10% weight loss|t|f|f|f
34074377|NCT01952418|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|15 endoscopists and 1805 patients on which procedures were performed were randomly assigned to each room.||t|f|f|f
34074378|NCT04041921|||COHORT||PROSPECTIVE|||||||
33976154|NCT01478620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976155|NCT02201251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976156|NCT03561506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976157|NCT02537756|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|t|f|f
33976158|NCT01961908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976159|NCT05411770|||COHORT||CROSS_SECTIONAL|||||||
33976160|NCT00000909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976161|NCT02762097|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33976162|NCT00966225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976163|NCT05538884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The ITPB block at T5-6 level will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine.||||
33763224|NCT00002635|NA|SINGLE_GROUP||TREATMENT||||||||
33763225|NCT06470074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomly assigned to the active stimulation group and sham stimulation group, Patients，Care Provider and Outcomes Assessor did not know the patient grouping.|Patients were randomly assigned to the active stimulation group and sham stimulation group.|t|t|f|t
33763226|NCT05578625|||CASE_ONLY||PROSPECTIVE|||||||
33890328|NCT04057209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The secondary phoniatric assessments will be carried out centrally by blinded phoniatricians.||f|f|f|t
33890329|NCT05300087|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33890330|NCT06216093|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33763227|NCT00804492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890331|NCT05865184|||COHORT||PROSPECTIVE|||||||
33890332|NCT04059744|NA|SINGLE_GROUP||OTHER||NONE||"Convenience sampling will be used. Participants will be recruited through email.~Participants will be number-coded.Participants will be guided to put on the Fun-Knee sleeve. They will perform 3 repetitions of maximal knee flexion and maximal knee extension. A delegated study team member will teach the participant to use the mobile game application that is preloaded on a provided smartphone. Thereafter, they will be given time to complete two games at their own pace, inside a quiet, conducive room. After their trial use of the Fun-Knee prototype, participants will be asked to complete a survey on their experience and impression of Fun-Knee. Following that, a few open-ended questions will be asked."||||
33890333|NCT00997971|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33890334|NCT02583984|||COHORT||PROSPECTIVE|||||||
33890335|NCT00730340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890336|NCT03669978|||COHORT||PROSPECTIVE|||||||
33890337|NCT02193789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890338|NCT04399382|||COHORT||PROSPECTIVE|||||||
33976164|NCT04122222|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|"* A prospective cohort study in chronic dialysis patients during the 2016 and 2017 influenza seasons~* All participants received a single standard dose of trivalent influenza vaccine~* The elicited humoral immune response by hemagglutination inhibition test, and cell-mediated immune response by enumeration of lymphocyte cellular markers and proliferation assays are studied."||||
33976165|NCT01645306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976166|NCT00696449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976167|NCT05528757|||COHORT||PROSPECTIVE|||||||
33976168|NCT00738673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976169|NCT01024933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074379|NCT06161714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This is a double blinded randomized clinical trial, which neither the injector (investigator) nor the participant will know what anesthesia type was used in each session.|"One 1.8 ml cartridge of 4% articaine with 1:100,000 epinephrine will be utilized in the articaine group and one 1.8 ml cartridge of 2% lidocaine with 1:100,000 epinephrine will be utilized in the lidocaine group. The cartridges will be of similar size and shape, to be allotted a special code, enclosed in thin, adhesive tape by the distributor, and kept into one box for articaine and another box for lidocaine.~A 27-gauge needle will be used for buccal infiltration in each case. Any sensation of pain after administering the local anesthesia will be considered as a failure and an inferior alveolar nerve block will be given. Otherwise, the tooth will be extracted with no additional anesthesia."|t|f|t|f
34074380|NCT00305669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074381|NCT02794688|||COHORT||PROSPECTIVE|||||||
33763228|NCT05995080|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The control and study groups were determined by applying randomization at a ratio of 1:1 to the patients which participated to the study.|The control and study groups were determined by applying randomization at a ratio of 1:1 to the patients which participated to the study.|f|f|t|f
33890339|NCT02006576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890340|NCT03859284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890341|NCT03501979|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive combination treatment with tucatinib + trastuzumab + capecitabine every 21 days, which is one cycle. Evaluation will be done every two cycles with an MRI of the brain and spine. Cycles 3 and beyond will be at the discretion of the physician. A scan will be done every four cycles.||||
33976170|NCT01338636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976171|NCT04204148|||COHORT||PROSPECTIVE|||||||
33976172|NCT03106090|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention (group receiving eSCPs) will be compared to 2 control groups: group receiving prior standard of care and standard of care SCP||||
33976173|NCT03801161|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976174|NCT02040766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976175|NCT04484337|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind (sponsor-unblind) study.|Participants will receive repeat doses of long-acting CAB 400 mg/mL or CAB 200 mg/mL at four-weekly (Q4W) interval in Part 1 and at 12-weekly (Q12W) interval in Part 2.|t|f|t|f
33976176|NCT01665170|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34074382|NCT04252885|RANDOMIZED|PARALLEL||TREATMENT||NONE||125 patients are randomized in 3 groups (2:2:1). In group A(Standard treatment+lopinavir/ritonavir) , 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days). In group B (Standard treatment+arbidol), 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days). In group C (Standard treatment）, 25 cases are only given ordinary treatment.||||
33890342|NCT06070428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators will use mixed block sizes (2, 4, 6) for randomizing participants. Control versus PAC interventional units will be prepared by study staff who will not directly enroll patients. The crosswalk for patient study ID and randomization status will be kept in a secure separate location so that PI and staff in charge of data analysis will not be aware of randomization status.|ACHIEVE-P4: PATHFINDER is a randomized, blinded clinical trial of portable air cleaners (PAC) provided at the time of hospital discharge to Heart Failure (HF) patients. It will be carried out at Henry Ford Hospitals.|t|t|t|t
33890343|NCT00333216|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33890344|NCT03506503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890345|NCT03537040|NA|SINGLE_GROUP||OTHER||NONE||||||
33890346|NCT00129025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976177|NCT04502342|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible consenting symptomatic patients with COVID-19 confirmed by a positive Polymerase Chain Reaction test were subjected to the 10 days of treatment allocated to each of the 3 arms of the trial. Virological clearance is assessed on days 3, 6 and 14. Side effects and the onset of COVID symptoms are evaluated throughout the trial period. Clinical, paraclinical and laboratory examinations are occasionally provided. The data are statiscally processed.||||
33976178|NCT05938790|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976179|NCT00878995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33976180|NCT00526578|||CASE_CONTROL||PROSPECTIVE|||||||
34074383|NCT02187003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890347|NCT06546865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976181|NCT02736500|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976182|NCT01341795|||||RETROSPECTIVE|||||||
33890348|NCT01083914|||CASE_CONTROL||PROSPECTIVE|||||||
33976183|NCT04963426|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33976184|NCT04699422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This trial is designed as a mono-center, double-blinded, prospective, randomized controlled superiority trial comparing 2 groups of patients|t|t|t|t
34074384|NCT02962232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890349|NCT02359786|||||RETROSPECTIVE|||||||
33976185|NCT00266409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976186|NCT01368003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763229|NCT04645784|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33976187|NCT03232203|||COHORT||CROSS_SECTIONAL|||||||
33976188|NCT02098993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976189|NCT01351584|||COHORT||PROSPECTIVE|||||||
34074385|NCT00720070|RANDOMIZED|||DIAGNOSTIC||||||||
34074386|NCT06597292|NA|SINGLE_GROUP||TREATMENT||NONE|Patient IDs will be assigned and used.|||||
34074387|NCT00667485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763230|NCT03123289|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Same patients are scanned with two radiotracers within 24-48 hours. Results of the two scans are compared against each other.||||
33763231|NCT04959474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763232|NCT01602081|||COHORT||PROSPECTIVE|||||||
34074388|NCT02990130|||COHORT||PROSPECTIVE|||||||
34074389|NCT04351165|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34074390|NCT04366154|||COHORT||PROSPECTIVE|||||||
34074391|NCT01407263|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33763233|NCT03018002|RANDOMIZED|PARALLEL||||NONE||||||
33763234|NCT03775226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763235|NCT03909425|||COHORT||PROSPECTIVE|||||||
33890350|NCT01057277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890351|NCT03069651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890352|NCT02968355|||CASE_ONLY||PROSPECTIVE|||||||
33890353|NCT04680650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890354|NCT03461055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890355|NCT02429999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890356|NCT05410990|||OTHER||OTHER|||||||
33890357|NCT00175305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890358|NCT03205579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33890359|NCT04003714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890360|NCT01126346|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890361|NCT01724892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890362|NCT03978273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890363|NCT03773614|||CASE_ONLY||PROSPECTIVE|||||||
33890364|NCT04495660|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890365|NCT04210726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which Group (Active/Control) they are assigned to, only the Investigator will know. The amount of Salt added to each bath (and hence the concentration of each bath) will not be known by Participants. Assignment will be random using a simple computer program.|A pilot randomized blinded controlled study, whereas a number of patients with clinically-diagnosed Cancer (any type, any location and any stage), and who were poorly responsive to at least one cycle of conventional and standard therapy (Chemotherapy or Radiation therapy), are equally divided into 2 groups, Active and Control groups. The Active group patients will separately have an immersion bath in 25% Sea Salt in Water solution at a temperature comfortable to every patient, whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers. The Control group's patients will separately have a bath in 0.9% Sea Salt in Water at a comfortable temperature whereas the bath solution is in direct contact with the skin, for 30 minutes once daily for 7 consecutive days, in addition to their standard treatments they receive from their health care providers.|t|f|f|f
33890366|NCT01708031|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33890367|NCT01883037|||COHORT||PROSPECTIVE|||||||
33976190|NCT05911607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Histological examination|Comparing between 2 laser' effect on extraction socket healing|t|f|f|f
33890368|NCT02983604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890369|NCT00618722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976191|NCT04148222|||CASE_ONLY||PROSPECTIVE|||||||
33976192|NCT01893138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890370|NCT00652678|||CASE_ONLY||CROSS_SECTIONAL|||||||
33890371|NCT03872492|NA|SINGLE_GROUP||OTHER||NONE||||||
33976193|NCT02660242|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33976194|NCT00314938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976195|NCT05805475|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33976196|NCT01351142|NA|SINGLE_GROUP||||||||||
33976197|NCT06543966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parrallel Assignment|t|t|t|t
33976198|NCT00981786|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33976199|NCT01973114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976200|NCT01904500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976201|NCT03086356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976202|NCT01721525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976203|NCT06094374|||COHORT||OTHER|||||||
33976204|NCT06436196|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are not aware of the method which will be used to secure their airway.|Comparitive study between 2 groups.|t|f|f|f
33976205|NCT00521248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890372|NCT05699655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890373|NCT01055509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890374|NCT06494579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890375|NCT03421015|||COHORT||RETROSPECTIVE|||||||
33890376|NCT06172556|||CASE_CONTROL||RETROSPECTIVE|||||||
33890377|NCT02335502|||COHORT||PROSPECTIVE|||||||
33890378|NCT02428504|||||PROSPECTIVE|||||||
33890379|NCT01642212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890380|NCT05448118|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A virtual point-of-care toxicology testing process will be evaluated in a single arm pilot trial among providers and patients at VACT and VACWM. Acceptability will be evaluated through patient and provider semi-structured interviews. Overall feasibility will be determined by evaluating virtual toxicology testing utilization, as well as the frequency of toxicology testing and of addiction treatment contacts.||||
33890381|NCT04531384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33890382|NCT00333996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890383|NCT02612870|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33890384|NCT04952623|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33890385|NCT02550899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890386|NCT06175416|||CASE_ONLY||RETROSPECTIVE|||||||
33890387|NCT04749212|||COHORT||PROSPECTIVE|||||||
33890388|NCT03813030|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Pilot Study with 6 participants and pivotal study with 20 participants||||
33890389|NCT02427282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890390|NCT00135057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890391|NCT06199466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890392|NCT03781492|||COHORT||PROSPECTIVE|||||||
33890393|NCT05504109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890394|NCT04866927|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976206|NCT04026672|||COHORT||CROSS_SECTIONAL|||||||
33976207|NCT00816959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976208|NCT03621709|||COHORT||PROSPECTIVE|||||||
33976209|NCT01503775|||COHORT||PROSPECTIVE|||||||
33976210|NCT04844177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976211|NCT00045448||||TREATMENT||||||||
33763236|NCT00660335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763237|NCT02374411|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763238|NCT04452448|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective clinical study including 20 eyes of 10 cases undergoing LASIK with wave front optimized ablation profile||||
33763239|NCT00501878|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33763240|NCT01659892|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763241|NCT00433615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763242|NCT06056921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763243|NCT00927355|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33763244|NCT00145301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763245|NCT06494969|||OTHER||PROSPECTIVE|||||||
33763246|NCT04735016|||COHORT||PROSPECTIVE|||||||
33890395|NCT02920125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For subjects/patients -Control and Trial medication are packaged in same looking blister / alu alu strips.~For Investigator and Outcome Assessor: no information on patient allocation (trial or Control group)"|Double Blind, Placebo controlled, two arm, on patients of vascular disease / atherosclerosis. Intervention is given in addition to ongoing conventional therapy.|t|f|t|t
33890396|NCT06574633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890397|NCT02300493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890398|NCT01596101|||CASE_CONTROL||PROSPECTIVE|||||||
33890399|NCT00844493|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33890400|NCT06428903|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33890401|NCT04320836|||COHORT||PROSPECTIVE|||||||
33890402|NCT02536248|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33890403|NCT01661322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890404|NCT06294600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This is a prospective, 1:1 randomized, double-blind, placebo-controlled trial|t|t|t|t
33890405|NCT04402047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Efficacy evaluators and data analysts will be blinded to the group assignments.||f|f|f|t
33890406|NCT02822456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890407|NCT05946343|||OTHER||CROSS_SECTIONAL|||||||
33890408|NCT04237493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890409|NCT01382615|||COHORT||PROSPECTIVE|||||||
33890410|NCT03803527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890411|NCT00002285||||TREATMENT||||||||
33890412|NCT03622281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33763247|NCT05845775|||COHORT||PROSPECTIVE|||||||
33763248|NCT00228293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763249|NCT03448159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Arm 1: Intervention group (will receive the trial drug, fluoxetine, as well as an exercise intervention) Arm 2: Placebo group (will receive a placebo as well as an exercise intervention|t|t|t|t
33763250|NCT06488820|||COHORT||PROSPECTIVE|||||||
33763251|NCT02696564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763252|NCT04748042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763253|NCT01985620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890413|NCT03481270|RANDOMIZED|PARALLEL||OTHER||DOUBLE||RCT|t|t|f|f
33890414|NCT06292078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33890415|NCT00914875|||CASE_ONLY||PROSPECTIVE|||||||
33890416|NCT01608334|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33890417|NCT04026568|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33763254|NCT00058201|RANDOMIZED|||TREATMENT||||||||
33763255|NCT04557826|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label||||
33763256|NCT04436458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763257|NCT00171639|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33890418|NCT06363162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Blind assessment: Researchers using Raman analyzer during surgery are not aware of the subjects' preoperative diagnostic results, while researchers conducting immunohistochemistry or genetic test after surgery are not aware of the subjects' preoperative diagnostic results and the diagnostic results of Raman analyzer.|The same sample was diagnosed using Raman spectroscopy and immunohistochemistry or genetic test, respectively. Calculate the AUC, the accuracy, the sensitivity and specificity of a Raman analyzer using immunohistochemistry or genetic test results as the gold standard.||||
33890419|NCT00803114|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33890420|NCT00749190||PARALLEL||TREATMENT||||||||
33890421|NCT02345798|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890422|NCT03396328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890423|NCT01393093|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33890424|NCT01682005|||COHORT||RETROSPECTIVE|||||||
33890425|NCT00004479|RANDOMIZED|||TREATMENT||DOUBLE||||||
33890426|NCT05696938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33890427|NCT04994925|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33890428|NCT04552470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33890429|NCT00717730|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33890430|NCT02995434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33890431|NCT05005884|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33890432|NCT03545139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890433|NCT01498133|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33890434|NCT05432531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|patient and outcome assessor||t|t|t|t
33890435|NCT05338008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890436|NCT01504802|||COHORT||PROSPECTIVE|||||||
33890437|NCT06393283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890438|NCT01743430|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33890439|NCT01053910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890440|NCT00239850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890441|NCT04747405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890442|NCT06008548|||OTHER||RETROSPECTIVE|||||||
33890443|NCT06220695|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33890444|NCT04574843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890445|NCT01705691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763258|NCT02705781|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763259|NCT05346848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890446|NCT06322758|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparing ΔP-guided VT to traditional PBW-guided VT during mechanical ventilation of patients with ARDS.||||
33890447|NCT02278783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890448|NCT04807959|||COHORT||RETROSPECTIVE|||||||
33890449|NCT05083520|||OTHER||CROSS_SECTIONAL|||||||
33890450|NCT03881709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33890451|NCT04222829|||CASE_CONTROL||PROSPECTIVE|||||||
33890452|NCT00759603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890453|NCT00001303||||TREATMENT||||||||
33890454|NCT01154608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
33890455|NCT03999814|||OTHER||RETROSPECTIVE|||||||
33890456|NCT03933943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33890457|NCT02252367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890458|NCT02886702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890459|NCT02976415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890460|NCT02241486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890461|NCT00003688||||TREATMENT||||||||
33890462|NCT01908348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890463|NCT01591070|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33890464|NCT04030000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||During Week 1-18, subjects will be placed on open-label IP Carboplatin/IV Paclitaxel on Day 1, then administered IP Paclitaxel on Day 8. This will be repeated every 3 weeks for 6 cycles. A CT imaging scan will be performed after six cycles of chemotherapy, prior to radiation. Also, in Week 19-23, subjects will receive Pelvic radiation therapy (IMRT) if deemed necessary. Additionally, from Week 24-26, High Dose Radiation or IMRT will be used where appropriate.||||
33763260|NCT01672853|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33763261|NCT04912674|||COHORT||PROSPECTIVE|||||||
33763262|NCT01705535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33763263|NCT06263088|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm study to address the existing disparities faced by Black participants with gastrointestinal (GI) cancer in accessing crucial biomarker testing, receiving evidence-based care, and participating in clinical trials.||||
33763264|NCT06000319|||COHORT||PROSPECTIVE|||||||
33763265|NCT02739347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763266|NCT03666936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763267|NCT03634618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Study||||
33763268|NCT04805749|NA|SINGLE_GROUP||TREATMENT||NONE|The gut inflammation and gut permeability laboratory analysis will be performed by a independent laboratory testing services (FLUIDS iQ® Inc.,Ontario, Canada)|||||
33890465|NCT04621903|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890466|NCT02471690|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33890467|NCT05191043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||f|f|f|t
33890468|NCT00756548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890469|NCT05654402|||COHORT||PROSPECTIVE|||||||
33890470|NCT02862691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890471|NCT04992416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890472|NCT00623831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890473|NCT03495492|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm||||
33890474|NCT03718416|||COHORT||OTHER|||||||
33890475|NCT05381506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890476|NCT01841619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890477|NCT04302506|||COHORT||RETROSPECTIVE|||||||
33890478|NCT02489214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763269|NCT00210327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763270|NCT06153602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890479|NCT00257634|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763271|NCT01633801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763272|NCT01750762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763273|NCT05542290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763274|NCT04121884|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A prospective, longitudinal, descriptive study design.||||
33890480|NCT01443013|||COHORT||PROSPECTIVE|||||||
33890481|NCT06184438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"We designed a randomized controlled trial including 150 eligible patients who underwent fistulotomy or fistulectomy. To evaluate the benefit of using MPFF after fistula surgery, patients were classified into 2 groups:~1. Received MPFF(Daflon 1000mg BID) after surgery.~2. Received placebo after surgery."|t|t|f|f
33890482|NCT01977287|||CASE_CONTROL||PROSPECTIVE|||||||
33890483|NCT03934645|||OTHER||PROSPECTIVE|||||||
33890484|NCT03251326|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||All patients will contribute to each of 4 drug conditions (placebo, nabilone, smoked cannabis, and propranolol).|t|f|t|f
33890485|NCT05994170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33890486|NCT01454804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890487|NCT04576312|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33890488|NCT00737139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890489|NCT02000687|||OTHER||PROSPECTIVE|||||||
33890490|NCT01475734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890491|NCT06379334|||CASE_CONTROL||PROSPECTIVE|||||||
33976212|NCT03366909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976213|NCT01439893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976214|NCT04857619|||OTHER||RETROSPECTIVE|||||||
33890492|NCT04272593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is a randomized crossover home trial consisting of two 8-week periods with an intermittent 1-week washout period (17 weeks total). Participants will use either simultaneous control or convention seamless, sequential control in the first 8-week period followed by using the opposite control style in the second 8-week period.||||
33890493|NCT02318758|RANDOMIZED|CROSSOVER||||NONE||||||
33890494|NCT00357773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33890495|NCT05246540|||COHORT||RETROSPECTIVE|||||||
33890496|NCT03502187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890497|NCT00624221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890498|NCT01412853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890499|NCT01625806|NON_RANDOMIZED|PARALLEL||||NONE||||||
33890500|NCT03333473|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890501|NCT02395991|||OTHER||PROSPECTIVE|||||||
33890502|NCT02272790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890503|NCT03519048|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890504|NCT04203901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890505|NCT05527951|RANDOMIZED|PARALLEL||OTHER||NONE||The study protocol involves a 2-arm cluster RCT of enhanced versus standard measurement-based care implementation for depression.||||
33890506|NCT00797433|||CASE_ONLY||PROSPECTIVE|||||||
33890507|NCT03823664|||OTHER||CROSS_SECTIONAL|||||||
33890508|NCT05925608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase I requires no masking as all participants will receive one of the three cell doses. Phase II requires masking in order to evaluate treatment effect. Patients will randomized 2:1 to either the treatment or control groups.|Phase I: Dose escalation, safety study consisting of 3 cell doses of 20million, 100 million and 200 million allogeneic hMSC. Each dose cohort will consist of 3 patients. Phase II: Randomized, controlled trial to evaluate the treatment.|t|f|f|t
33890509|NCT02036229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890510|NCT04900402|||CASE_CROSSOVER||PROSPECTIVE|||||||
33890511|NCT05422092|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33890512|NCT03058744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890513|NCT04992988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890514|NCT01485978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890515|NCT02197325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890516|NCT00003060||||TREATMENT||||||||
33890517|NCT06657040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890518|NCT01152606|||COHORT||PROSPECTIVE|||||||
33890519|NCT03148210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763275|NCT04737109|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33890520|NCT02539706|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33976215|NCT04458077|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33890521|NCT00511420|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33890522|NCT00486486|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33890523|NCT01906437|||CASE_ONLY||PROSPECTIVE|||||||
33890524|NCT00206167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890525|NCT06273995|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open-label behavioral activation||||
33890526|NCT01689038|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890527|NCT01781949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976216|NCT00858000|||CASE_ONLY||RETROSPECTIVE|||||||
33890528|NCT01913782|||CASE_CONTROL||PROSPECTIVE|||||||
33890529|NCT05068856|NA|SINGLE_GROUP||TREATMENT||NONE||HRS2543 monotherapy||||
33890530|NCT00539019|||||PROSPECTIVE|||||||
33890531|NCT01211912|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890532|NCT01036399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890533|NCT05740150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33890534|NCT03945279|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33890535|NCT03772912|||COHORT||PROSPECTIVE|||||||
33890536|NCT00014092||||TREATMENT||||||||
33890537|NCT04284293|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33976217|NCT00005842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890538|NCT06642974|RANDOMIZED|PARALLEL||SCREENING||NONE||experimental and control group, experimental group will receive formal education control group will receive informative pamphlets||||
33890539|NCT04807894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890540|NCT01815645|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both participants and researchers know the treatment alocations|||||
33890541|NCT00450580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890542|NCT00289640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890543|NCT05502497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33890544|NCT03182764|||COHORT||CROSS_SECTIONAL|||||||
33890545|NCT01400932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890546|NCT03939013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Access to point-of-care hepatitis C testing in community setting to facilitate hepatitis C treatment.||||
33890547|NCT04116099|||COHORT||PROSPECTIVE|||||||
33890548|NCT02633176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890549|NCT02547727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890550|NCT04698928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890551|NCT01962779|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890552|NCT03067090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890553|NCT00308724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890554|NCT00902837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890555|NCT01947829|||CASE_ONLY||PROSPECTIVE|||||||
33890556|NCT04672083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890557|NCT04133077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The intervention consists in the realization of additional blood samples to carry out serologies and genetic analyses||||
33890558|NCT02818699|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33890559|NCT00131807|||||PROSPECTIVE|||||||
33890560|NCT03979976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33890561|NCT00499109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890562|NCT00024687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890563|NCT02198950|||COHORT||PROSPECTIVE|||||||
33890564|NCT00365755|RANDOMIZED|||TREATMENT||||||||
33890565|NCT04971525|||COHORT||RETROSPECTIVE|||||||
33890566|NCT01085682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890567|NCT02119715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890568|NCT01869335|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33890569|NCT05524883|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33890570|NCT03744455|||COHORT||PROSPECTIVE|||||||
33890571|NCT01490593|||OTHER||PROSPECTIVE|||||||
33890572|NCT01950819|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label study||||
33890573|NCT00332202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33890574|NCT05646810|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33890575|NCT03217851|||OTHER||CROSS_SECTIONAL|||||||
33890576|NCT03378570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890577|NCT03492593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33890578|NCT00452803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890579|NCT04794335|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976218|NCT00782509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976219|NCT05443243|||CASE_CONTROL||RETROSPECTIVE|||||||
33976220|NCT05683509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor will be blinded about the grouping and which patient got which treatment|The application of deep collagen layer, xenograft and collagen membrane seal versus the use of xenograft and collagen membrane seal alone in alveolar ridge preservation procedures.|f|f|f|t
33976221|NCT01106183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33976222|NCT03301909|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074392|NCT04888494|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||All participants will receive the 2 modalities of stimulation (hippocampal and sham-TMS). Each stimulation round is composed by 5 daily sessions of stimulation, participants will not know which round is active and which is sham. The order of the stimulation modalities will be different across subjects. Subjects will be randomly assigned to one of two possible modality order according to the entrance in the study.|t|t|f|t
34074393|NCT03002636|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34074394|NCT02921945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890580|NCT03584763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding of the patients or staff in this study is not generally feasible. However, the measured outcomes in this study are objective and are unlikely to be biased by lack of blinding.|Our randomized controlled study was conducted on patients with high risk pregnancies at their third trimester who attended Ain Shams University Maternity Hospital. A total of 292 high risk pregnant women fulfilling the inclusion criteria were selected by random sampling and divided between two groups with 146 patients in each group. Group I underwent Doppler every other week and Group II underwent Doppler once weekly|t|f|f|t
34074395|NCT06473831|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label multicenter study enrolling up to 30 participants at up to 3 sites in Australia.||||
34074396|NCT01695005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074397|NCT01409980|||COHORT|||||||||
33890581|NCT04331041|RANDOMIZED|PARALLEL||TREATMENT||NONE||The enrolled patients are 6:1 randomized to either Experimental Arm or Adaptive Comparator Arm.||||
33890582|NCT03926143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976223|NCT02178709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976224|NCT03696381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976225|NCT01620177|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33976226|NCT03305029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976227|NCT03824626|||COHORT||PROSPECTIVE|||||||
33976228|NCT03530956|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33976229|NCT04120428|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental group: 24-week aquatic exercise training program Control group: maintain life style routine as usual||||
33976230|NCT01310049|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33976231|NCT01922700|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33976232|NCT04547946|||COHORT||PROSPECTIVE|||||||
34074398|NCT04133597|NA|SINGLE_GROUP||SCREENING||NONE||||||
34074399|NCT03511950|||COHORT||PROSPECTIVE|||||||
34074400|NCT03364036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074401|NCT03100656|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34074402|NCT01635517|||COHORT||PROSPECTIVE|||||||
33976233|NCT04578470|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient will also undertake a vitamin D and corrected calcium test. Based on the blood test results, the randomisation process and administration of Vitamin D treatment or placebo will be administered by unblinded team while the clinicians and the patients will remain blinded and will not be informed of their allocation within the study.||t|f|t|f
33976234|NCT04146974|||OTHER||OTHER|||||||
34074403|NCT05468983|RANDOMIZED|PARALLEL||OTHER||SINGLE|"All the Selected patients were rehabilitated with the upper and the lower complete denture then was divided by computer randomization using random allocation software: into two equal groups"|to compare BioHPP used as a skeletal substructure for hybrid (implant fixed, detachable) prostheses versus BioHPP bar supporting and retaining by using radiographic tracing to the marginal bone height changes around the implants, patient satisfaction can be improved.|f|f|t|f
34074404|NCT01909141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074405|NCT01100723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074406|NCT00289094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074407|NCT02719002|NA|SINGLE_GROUP||SCREENING||NONE||||||
34074408|NCT01320241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074409|NCT05490355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976235|NCT04663126|NA|SINGLE_GROUP||OTHER||NONE||||||
33976236|NCT02986009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976237|NCT02079948|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33976238|NCT05567380|||COHORT||PROSPECTIVE|||||||
33976239|NCT01076803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074410|NCT03520712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976240|NCT01540175|||CASE_ONLY||PROSPECTIVE|||||||
33976241|NCT01521559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976242|NCT03029663|||COHORT||PROSPECTIVE|||||||
33976243|NCT03231254|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976244|NCT03774667|||CASE_CONTROL||PROSPECTIVE|||||||
34074411|NCT04684563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial will evaluate up to 7 dose levels using the Bayesian Optimal Interval (BOIN) design with accelerated titration to determine the maximum tolerated dose (MTD) of huCART19-IL18 cells. Subjects will be assigned to a dose level prior to study treatment based on available safety experience at the current and prior dose levels.||||
34074412|NCT05027438|NA|SINGLE_GROUP||TREATMENT||NONE||pre-post design||||
34074413|NCT03189212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074414|NCT03072290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074415|NCT03540732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor (in our study, person measuring participants' quadriceps muscle thickness) is blinded.|Randomized Controlled Trial|f|f|f|t
34074416|NCT01221558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34074417|NCT01745562|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34074418|NCT04330417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34074419|NCT04967105|||COHORT||PROSPECTIVE|||||||
34074420|NCT03096561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074421|NCT00003471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074422|NCT05505292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074423|NCT01360346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074424|NCT06612164|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890583|NCT06544278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double(Participant,Investigator)||t|f|t|f
33890584|NCT03236714|||OTHER||PROSPECTIVE|||||||
33890585|NCT06147024|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890586|NCT06295055|NA|SINGLE_GROUP||TREATMENT||NONE||Before- after augmentation in patients with alveolar bone defects||||
33890587|NCT00550160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33890588|NCT02151513|||CASE_ONLY||PROSPECTIVE|||||||
33890589|NCT04145466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to diet assignment and genotype pattern. Interventionists will be blind to genotype pattern, but not diet type. To enhance external validity, participants will be told if they are carbohydrate or fat responders.|"Randomized controlled parallel arm trial with 4 groups over 12 weeks~1. Fat responders receiving a high-fat diet (n=52)~2. Fat responders receiving a high-carbohydrate diet (n=52)~3. Carbohydrate responders receiving a high-fat diet (n=25)~4. Carbohydrate responders receiving a high-carbohydrate diet (n=25)~The total number per group is an estimate. We will not close cells to enroll this exact number per group, and the total number of people enrolled will not exceed 154."|f|f|f|t
33890590|NCT00004165||||TREATMENT||||||||
33890591|NCT03190525|||CASE_ONLY||PROSPECTIVE|||||||
33890592|NCT01953952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890593|NCT02503605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890594|NCT00976430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890595|NCT02614209|||COHORT||PROSPECTIVE|||||||
33890596|NCT02644408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients and the medical professionals who cared for them were unaware of the assigned study regimen.|1:1|t|t|t|t
33890597|NCT06544239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Experimental Group (virtual reality training) \& Control Group (traditional training)|t|f|f|f
33890598|NCT00433888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890599|NCT00948961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890600|NCT03369795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890601|NCT06093347|||OTHER||OTHER|||||||
33890602|NCT04381234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||open-label sequential cross-over study||||
33890603|NCT06129630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Control Group (CG), which received their usual sessions of conventional occupational therapy, and an Experimental Group (EG), which received therapy with Nintendo Switch, plus their conventional occupational therapy sessions.|f|f|f|t
33890604|NCT00622193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890605|NCT02377102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763276|NCT03779178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763277|NCT03351738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763278|NCT01481545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890606|NCT06413004|NA|SINGLE_GROUP||TREATMENT||NONE||Unblinded elimination and re-introduction of a positive tested food item, identified during CLE or COLAP||||
33890607|NCT00393419|RANDOMIZED|PARALLEL||ECT||NONE||||||
33890608|NCT00341263|||CASE_CONTROL||PROSPECTIVE|||||||
33890609|NCT01228747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074425|NCT03407001|NA|SINGLE_GROUP||SCREENING||NONE||||||
33890610|NCT04249882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study team, medical personnel, and participants will be blind to drug condition.|Randomized, double-blind, placebo-controlled, 3-arm, parallel-group study of naltrexone (50 mg QD) and varenicline (1 mg BID).|t|t|t|f
33890611|NCT03609255|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890612|NCT01096394|||COHORT||PROSPECTIVE|||||||
33890613|NCT00648401|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33890614|NCT01688869|||COHORT||PROSPECTIVE|||||||
33890615|NCT03314805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890616|NCT02059824|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890617|NCT03006653|||COHORT||PROSPECTIVE|||||||
33890618|NCT04213651|||CASE_ONLY||PROSPECTIVE|||||||
33890619|NCT01129193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890620|NCT05121402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890621|NCT00569257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890622|NCT01372319|||CASE_CONTROL||PROSPECTIVE|||||||
33890623|NCT01678274|||COHORT||PROSPECTIVE|||||||
33890624|NCT04924426|||CASE_CONTROL||PROSPECTIVE|||||||
33890625|NCT06162884|||COHORT||PROSPECTIVE|||||||
33890626|NCT01746433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890627|NCT05314673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890628|NCT00733902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890629|NCT06428890|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34074426|NCT03792334|||CASE_ONLY||PROSPECTIVE|||||||
34074427|NCT04769232|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34074428|NCT05895357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074429|NCT00874315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074430|NCT00563615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074431|NCT02318888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074432|NCT04097769|NA|SINGLE_GROUP||TREATMENT||NONE||HX009||||
34074433|NCT02902549|||COHORT||PROSPECTIVE|||||||
33763279|NCT03549884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The health care giver who will perform hematocrit measurement (primary outcome) and the statistician who will perform data analysis will be blind for treatment allocation.||t|t|f|t
33763280|NCT03767725|NA|SINGLE_GROUP||TREATMENT||NONE||Anti-BCMA or/and Anti-CD19 CAR Autologous T Cells||||
34074434|NCT02983890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074435|NCT05143632|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34074436|NCT03018275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763281|NCT05256030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763282|NCT03853460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|both patients and data collector will be unaware of the group nature||t|f|f|t
33763283|NCT02124148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763284|NCT03761498|||COHORT||PROSPECTIVE|||||||
33763285|NCT05965843|||COHORT||CROSS_SECTIONAL|||||||
33763286|NCT02541214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763287|NCT05537558|||COHORT||PROSPECTIVE|||||||
33763288|NCT03386032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|As above|Subjects will be randomized and balanced into one of the 3 treatment groups by their baseline SCORAD grade (moderate = 25-40 and severe = 41+) and ethnicity (black or non-black).|t|f|t|t
33763289|NCT00544063|NON_RANDOMIZED|||TREATMENT||||||||
33763290|NCT02484079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763291|NCT02239575|||CASE_ONLY||PROSPECTIVE|||||||
33890630|NCT01348230|||COHORT||PROSPECTIVE|||||||
33890631|NCT06190587|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890632|NCT04963829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Twenty-five people, regardless of gender, participated in this study. The patients were divided into 3 groups (Control 1, Control 2 and, Study Group). The Control Group 1 (CG1) consisted of seven participants who were subjected to a standardized treatment (collagenase ointment was selected for this treatment), the Control Group 2 (CG2) accounted for seven participants who used a gel made of 10% peel powder of unripe banana (M. sapientum), and the Study Group (SG) involved eleven participants who used the abovementioned gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration.|f|f|f|t
33890633|NCT04934826|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33890634|NCT06432738|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33890635|NCT03358472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890636|NCT00006120|RANDOMIZED|||TREATMENT||||||||
33890637|NCT03306654|RANDOMIZED|PARALLEL||OTHER||NONE||Users are randomly assigned between arms after completing baseline assessment and stay in that arm for the duration of the study.||||
34074437|NCT00873080|||||CROSS_SECTIONAL|||||||
34074438|NCT01146535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074439|NCT02163889|||CASE_ONLY||PROSPECTIVE|||||||
33890638|NCT00203684|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33890639|NCT02824484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34074440|NCT03973541|RANDOMIZED|PARALLEL||TREATMENT||NONE|Assignment will be kept blind for participants and clinicians until the first exposure session.|An equal number of participants will be assigned to each group, but at the end of treatment participants in the third group will be randomly re-allocated to one of the two former groups||||
34074441|NCT02196857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074442|NCT03002545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890640|NCT03467906|||COHORT||CROSS_SECTIONAL|||||||
33890641|NCT01222793|||||PROSPECTIVE|||||||
33890642|NCT01574534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890643|NCT02943395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890644|NCT01318629|||COHORT||PROSPECTIVE|||||||
33890645|NCT03906825|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double Blind Placebo Controlled|t|t|t|t
33890646|NCT06316479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890647|NCT00914693|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33890648|NCT06142084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33890649|NCT01313130|||CASE_CONTROL||PROSPECTIVE|||||||
33890650|NCT01330901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890651|NCT02887911|||CASE_CONTROL||PROSPECTIVE|||||||
33890652|NCT01422330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890653|NCT01167296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890654|NCT05011396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890655|NCT03200951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigator are blinded to group assignment.|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidudral block. In contrast, patients in the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.|t|f|t|f
33890656|NCT03793543|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890657|NCT00827190|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33890658|NCT05629039|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33890659|NCT02688517|||COHORT||PROSPECTIVE|||||||
33890660|NCT02792244|||COHORT||PROSPECTIVE|||||||
33890661|NCT03291314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open label, single-center, stratified phase II clinical trial.~Patients will be stratified according to their baseline use of corticosteroids: \<Stratum A\> = no need for corticosteroids and \<Stratum B\> = baseline need for steroid treatment"||||
33890662|NCT00323661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890663|NCT02874911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890664|NCT06016478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind (subject, investigator), randomized, cross-over, placebo-controlled|Double-blind (subject, investigator), randomized, cross-over, placebo-controlled|t|f|t|f
33890665|NCT06119880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33890666|NCT01409928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890667|NCT00704470|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33890668|NCT00962715|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890669|NCT01442467|||CASE_CONTROL||PROSPECTIVE|||||||
33890670|NCT01287754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890671|NCT03971188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890672|NCT00018902|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33890673|NCT03864692|||COHORT||PROSPECTIVE|||||||
33890674|NCT02631720|||COHORT||PROSPECTIVE|||||||
33890675|NCT06110052|||COHORT||PROSPECTIVE|||||||
33890676|NCT00260221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33890677|NCT02013544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890678|NCT05525663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890679|NCT02103686|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890680|NCT01912755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890681|NCT01644903|||COHORT||PROSPECTIVE|||||||
33890682|NCT06247969|||CASE_ONLY||PROSPECTIVE|||||||
33890683|NCT00080847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890684|NCT06030180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890685|NCT06053021|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33890686|NCT05563493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33890687|NCT00686816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890688|NCT00136864|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976245|NCT06409962|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The randomisation will be conducted based on an artificial model, utilising a coding system that assigns numerical identifiers to names, postal codes, and grade levels. This approach ensures a systematic and unbiased selection process, allowing for a fair representation of participants across various demographic factors.~The sampling has been estimaited by Epidat program. The experimental group, receiving nutritional intervention, will consist of approximately 50% of the total sample, equivalent to 215 participants. Meanwhile, the control group, not receiving the intervention, will comprise the remaining 50% of the sample, also around 215 participants. This distribution will enable an effective comparison of results between the two groups and assess the effectiveness of the nutritional intervention."|"Our proposed intervention, which integrates nutritional intervention with the use of innovative technologies, holds significant potential for yielding tangible outcomes in the prevention and management of this condition within the region. By doing so, it mitigates the risk of overweight and obesity-related pathologies in adulthood.~The inclusion of both experimental and control groups in the sample distribution will facilitate an effective evaluation of the nutritional intervention, offering concrete data on the efficacy of the implemented strategies. Furthermore, the comprehensive assessment encompassing anthropometric measurements, biometric data, and physical activity records will provide a detailed understanding of the intervention's effects on the school population."|f|f|t|f
33976246|NCT03562806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890689|NCT02319902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074443|NCT02038179|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34074444|NCT03106883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074445|NCT06477081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation sequence concealment will be done with sealed opaque envelopes. The envelope will be open prior to the intervention only to surgical team. The technique will not be known by the patient or the staff responsible of the follow-up.||t|t|f|t
34074446|NCT00558012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890690|NCT01238003|||COHORT||RETROSPECTIVE|||||||
33890691|NCT03900195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33890692|NCT05601700|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33890693|NCT01644877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890694|NCT02902094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890695|NCT02912364|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34074447|NCT05677425|NA|SINGLE_GROUP||TREATMENT||NONE||Patients ≥ 18 years with a ureteral stone (with or without a concomitant renal stone) and an indwelling nephrostomy tube scheduled for URS lithotripsy at the Day Surgery unit at Haukeland University Hospital, can be enrolled in the study.||||
33890696|NCT06441708|||OTHER||OTHER|||||||
33890697|NCT03879291|||COHORT||PROSPECTIVE|||||||
33890698|NCT01383031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33890699|NCT02209766|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33890700|NCT00935883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890701|NCT00190060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074448|NCT04307862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890702|NCT03560973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890703|NCT00518349|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34074449|NCT04403555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074450|NCT03953521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074451|NCT04037371|||CASE_ONLY||CROSS_SECTIONAL|||||||
34074452|NCT04659863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked (Year 1) to No Masking (Year 2)|Parallel (Year 1) to single-group (Year 2)|t|f|t|f
34074453|NCT04830618|||COHORT||PROSPECTIVE|||||||
34074454|NCT01007162|||COHORT||CROSS_SECTIONAL|||||||
34074455|NCT05128266|||COHORT||RETROSPECTIVE|||||||
34074456|NCT01967004|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074457|NCT05737901|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was carried out quasi-experimentally.||||
34074458|NCT04761757|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074459|NCT06412848|||COHORT||RETROSPECTIVE|||||||
34074460|NCT02342392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074461|NCT00640939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074462|NCT01675492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074463|NCT05714540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34074464|NCT05171114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, descriptive and comparative, monocentric pilot study||||
34074465|NCT01878318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074466|NCT05177146|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot study||||
34074467|NCT01316159|||CASE_ONLY||PROSPECTIVE|||||||
34074468|NCT05602506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890704|NCT05653375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074469|NCT01299818|||COHORT||PROSPECTIVE|||||||
34074470|NCT04052321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074471|NCT05645042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34074472|NCT03231189|||COHORT||PROSPECTIVE|||||||
34074473|NCT05828953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074474|NCT01585246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34074475|NCT06017622|||COHORT||PROSPECTIVE|||||||
34074476|NCT02360280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976247|NCT01254409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976248|NCT05520424|NA|SINGLE_GROUP||OTHER||NONE||||||
33976249|NCT03194035|||COHORT||PROSPECTIVE|||||||
33890705|NCT03501862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assignment to the study groups will be made independently of staff involved in the recruitment and management of participants in the study.|"Participants referred to the study will be assessed at a screening examination to ensure eligibility and obtain written consent by a research assistant. Eligible participants will undertake a further interview on outcome measures prior to randomization within 3 weeks the commencement of intervention.~Eligible participants will be randomly assigned to receive Mindfulness-based Cognitive Therapy for Psychosis (MBCTp) plus TAU or TAU plus Psychoeducation for Psychosis (PEp).~Simple randomization will be used to ensure that participants will have equal opportunity to be included into the study (Altaman and Bland, 1999)."|f|f|f|t
33890706|NCT05983640|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, three arm, parallel, open-label trial||||
33890707|NCT04278794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Study patients will be blinded to their group allocation. Those aware that they are receiving or not receiving the intervention are more likely to provide biased assessments of the effectiveness of the intervention than blinded participants. Participants who are aware that they are not receiving the intervention may be less likely to comply with the trial protocol, and more likely to drop out of the trial. To minimize assessment bias, Research Assistants will be blinded to group allocation. The statistical analyst will be blinded to the group allocation of the participants when analyzing the data.|Effectiveness-implementation hybrid type I design.|t|f|f|t
33890708|NCT02022826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890709|NCT03283631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890710|NCT05731921|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized controlled trial with pretest-posttest control group||||
33890711|NCT03140319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33890712|NCT06657014|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The Mind-Mindedness Training group will participate in three structured online sessions aimed at enhancing caregivers' ability to recognize and respond to their child's thoughts and feelings. This training seeks to improve caregivers' mentalization, which may help reduce social anxiety symptoms in children. Meanwhile, the Peer Support group will have access to a private online platform where caregivers can share experiences and coping strategies, creating a supportive environment without the structured intervention.~Data will be collected at baseline, immediately after the intervention, and during a three-month follow-up to assess changes in mind-mindedness, child social anxiety, attachment styles, and theory of mind. This parallel assignment model enables an effective evaluation of the intervention's impact on the target population while controlling for external variables through random assignment."||||
34074477|NCT03718390|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|Sealed opaque envelopes containing simple randomization via computerized sequence generation|A total of 40 eligible subjects participate in the Dosing and Observation period. The enrollment occurs in five Dosing Groups. Within each Dosing Group, subjects are randomized to receive either one of four LYN-PLT extended release capsules or a placebo capsule (8 per formulation).|t|t|t|t
34074478|NCT04658979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976250|NCT06048900|NA|SINGLE_GROUP||SCREENING||NONE||In patients in head-down position who will undergo laparoscopic hysterectomy, it is planned to measure the optic nerve sheath diameter with ultrasound at the beginning and at certain periods of the surgery.||||
33976251|NCT05753384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976252|NCT05355597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This a double blinded study in which the investigator nor subjects will know which drug he or she receives.|Total of 140 subjects are recruited. Group A Receives one drug (70) and Group B receives the other drug (70)|t|t|f|f
33976253|NCT03534986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074479|NCT01686685|||COHORT||PROSPECTIVE|||||||
33976254|NCT01441661|||COHORT||RETROSPECTIVE|||||||
34074480|NCT02412202|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074481|NCT05217602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34074482|NCT02726789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074483|NCT03839329|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized (stratified by sex) to either the ACT workshop group or to the assessment-only control group. Participants in the ACT group will complete two 90-minute group workshops (scheduled approximately one week apart) and will complete a baseline, 1-month, 3-month, and 6-month follow-up assessment. Participants in the time-matched assessment only-group will complete assessments at baseline, 1-month, 3-month, and 6-month follow-up.||||
34074484|NCT01416545|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34074485|NCT03263715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074486|NCT06049446|||COHORT||PROSPECTIVE|||||||
34074487|NCT06469450|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074488|NCT01030016|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34074489|NCT03442647|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34074490|NCT03939923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The nurses in the cardiac intensive care unit will be blinded to treatment allocation (Group 1 or 2).|"Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015 mg/kg up to 1mg maximal dosage).~Group 2 (treatment) will receive reversal with sugammadex 2 mg/kg."|f|t|f|f
34074491|NCT02472886|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074492|NCT05010746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074493|NCT00242697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074494|NCT02739854|||COHORT||PROSPECTIVE|||||||
34074495|NCT05745545|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34074496|NCT04255758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective interventional study model, all subjects undergo the same exercise intervention and results are compared to baseline values||||
34074497|NCT04655508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074498|NCT05819372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074499|NCT04852731|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34074500|NCT01939730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074501|NCT04001803|NA|SINGLE_GROUP||OTHER||NONE||||||
34074502|NCT06521190|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, double-blind, and placebo-controlled multicenter split body trial|t|t|t|t
34074503|NCT00540839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074504|NCT04272463|||COHORT||RETROSPECTIVE|||||||
34074505|NCT04780672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074506|NCT05851248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074507|NCT02412397|||COHORT||CROSS_SECTIONAL|||||||
34074508|NCT04240951|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subject subject serves as their own control at each testing session. The prototype patch and reference method are both worn during each session.||||
34074509|NCT00848900|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33976255|NCT00883610|||COHORT||PROSPECTIVE|||||||
33976256|NCT00153088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976257|NCT00505609|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33976258|NCT04632823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, single-center|f|f|f|t
33976259|NCT06047145|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34074510|NCT06613295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074511|NCT05672316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763292|NCT05207930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors at both pre- and post-observations will be blinded to the group label.|A total of 40 eligible subjects will be randomly assigned into 2 groups, with block sizes of 8 people in a ratio of 1:1. The intervention group will undertake a 4-week centre-based training followed by an 8-week home-based gamified cognitive-nutrition training (i.e., GAHOCON). Meanwhile, the control group will also receive the same 4-week centre-based training. Afterwards, the control group will be introduced to some open-source cognitive game and will be encouraged to participate in these games in the elderly centre. In other words, the control will not receive the GAHOCON treatment at all.|f|f|f|t
33890713|NCT02500537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890714|NCT00516594|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33890715|NCT00465257|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33890716|NCT06383494|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33890717|NCT05310409|||COHORT||PROSPECTIVE|||||||
33890718|NCT05043584|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cohort study||||
33890719|NCT04587115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects will be administered one of two fixed dose drug combinations. The control will be oxycodone plus placebo, whereas the treatment groups will receive oxycodone plus one of the two atypical antipsychotics (Risperidone, Ziprasidone) under study. Study drug will be compounded by outside research pharmacy.||t|f|f|t
33890720|NCT04045067|||OTHER||PROSPECTIVE|||||||
33890721|NCT01755169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074512|NCT05525546|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074513|NCT01243515|||COHORT||PROSPECTIVE|||||||
34074514|NCT05654064|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participant and surgeon will be blinded to which combination of medications are used during the procedure.||t|t|f|f
33890722|NCT04851184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976260|NCT02619123|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33976261|NCT00721877|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33976262|NCT02072564|||CASE_ONLY||PROSPECTIVE|||||||
33976263|NCT00298870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074515|NCT02749162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074516|NCT02030119|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33976264|NCT02496026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976265|NCT01823003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976266|NCT04790851|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|serum testing technicians were masked.||f|f|f|t
33976267|NCT05474625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976268|NCT02574052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890723|NCT01917123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890724|NCT04082221|||COHORT||PROSPECTIVE|||||||
33890725|NCT06427512|||CASE_CONTROL||PROSPECTIVE|||||||
33890726|NCT04372095|||CASE_CONTROL||PROSPECTIVE|||||||
33890727|NCT01082276|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33890728|NCT01193335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890729|NCT00864734|RANDOMIZED|CROSSOVER||||NONE||||||
33890730|NCT04489654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890731|NCT05798988|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33890732|NCT04921215|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33890733|NCT01021566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890734|NCT06193473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33890735|NCT04130815|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants will not know which droplet size they will be receiving on any one test day|Furosemide will be inhaled on 4 separate days each with a different pattern of breathing/droplet size combination. The four combinations will be: (i) slow/deep breathing with small droplet size, (ii) slow/deep breathing with large droplet size, (iii) fast/shallow breathing with large droplet size and (iv) fast/shallow breathing with small droplet size.|t|f|f|f
33890736|NCT01321047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976269|NCT00099736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976270|NCT04474938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976271|NCT02318121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976272|NCT01776281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33976273|NCT04535908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976274|NCT03629158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976275|NCT06193278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976276|NCT02204371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074517|NCT04360369|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||All study-related tests will be conducted in a single stage, with one clinical visit, to a single clinical center.||||
34074518|NCT02465164|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34074519|NCT03209193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890737|NCT04114721|||COHORT||PROSPECTIVE|||||||
33890738|NCT00686543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890739|NCT02956811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890740|NCT03721068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890741|NCT03793257|||COHORT||PROSPECTIVE|||||||
33890742|NCT04766866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Upon agreement to participate in this study, patients will be randomized to one of the following groups:~• Intervention group or reveal group (sFlt-1/PlGF result known to clinicians). A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery"|Prospective, open-label randomized study with parallel groups.|t|t|f|f
33890743|NCT04022486|||COHORT||RETROSPECTIVE|||||||
33890744|NCT00928811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890745|NCT00002283|RANDOMIZED|||TREATMENT||||||||
33890746|NCT03399383|NA|SINGLE_GROUP||OTHER||NONE||Within the longitudinal part of the trial, patients with chronic adrenal insufficiency will be assessed by questionnaire before and after participation in the standardized education program (=intervention).||||
33890747|NCT00331305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890748|NCT03240900|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Only the surgeon will be aware of the laterality of the intervention. The patient will not be performed. All outcomes will be assessed by the investigators, who will be masked to the laterality until the completion of the study when the surgeon will unmask.|Patients will receive the intervention to one breast and not the other, therefore acting as their own internal control. The laterality of the intervention will be randomized by a coin flip.|t|t|t|t
33890749|NCT02314806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33890750|NCT02978937|||COHORT||RETROSPECTIVE|||||||
33890751|NCT04360265|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890752|NCT01938287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890753|NCT05073185|||CASE_CROSSOVER||PROSPECTIVE|||||||
33890754|NCT00521781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890755|NCT01495988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890756|NCT04782791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976277|NCT05128409|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||TRIPLE||5 dose cohorts: 0.5, 1.67, 3.34, 5.0 and 10.0 mg/kg. Three subjects will be enrolled in 0.5 mg/kg cohort (Cohort 1). All subjects in Cohort 1 will receive open-label XKH001. Eight subjects will be enrolled in the remaining dose cohorts (Cohort 2-5) and randomized to XKH001or placebo after baseline evaluations are completed. Subjects will be admitted to the clinical research center the day before the administration of study drug (Day -1) For the study treatment of Cohort 2-5, the Investigator and other clinical center staff will be blinded. Any off-site staff who are unblinded will have no contact with the study participants. Two sentinel participants (randomized in a 1:1 ratio) will be dosed 48 hours prior to dosing the remainders of Cohort 2-5 (n=6, randomized in a 5:1 ratio).|f|t|t|t
33976278|NCT01891292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976279|NCT01199757|||COHORT||CROSS_SECTIONAL|||||||
33890757|NCT02069691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890758|NCT03709563|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33890759|NCT06079216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890760|NCT00609622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976280|NCT05537844|||CASE_ONLY||PROSPECTIVE|||||||
33890761|NCT01516827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890762|NCT03063749|||COHORT||PROSPECTIVE|||||||
33890763|NCT00359892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890764|NCT00001757||||TREATMENT||||||||
33890765|NCT03752125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Flavonoid and placebo capsules|Randomized, crossover|t|f|t|f
33976281|NCT00584766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976282|NCT05346549|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Two similar tasting drinks will be used in random order, one low and one high energy after a standardized meal. The weight of food consumed will be measured by an observer blind to which supplement has been used.|cross-over energy compensation study, participants acting as their own controls|t|f|t|f
33976283|NCT01747850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976284|NCT03233620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976285|NCT02275364|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33976286|NCT02359890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976287|NCT03222141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976288|NCT02503579|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33976289|NCT04516148|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33976290|NCT04196465|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, IMC-001 single arm, open label, single center, phase II study.||||
33976291|NCT05525195|||COHORT||RETROSPECTIVE|||||||
33976292|NCT05067088|||COHORT||PROSPECTIVE|||||||
33976293|NCT05657548|||COHORT||PROSPECTIVE|||||||
33976294|NCT05665582|||COHORT||PROSPECTIVE|||||||
33976295|NCT02578732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976296|NCT04313621|||COHORT||CROSS_SECTIONAL|||||||
33976297|NCT02637193|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33763293|NCT05164874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This intervention will be conducted as a prospective randomized controlled cluster trial.The cluster of the study is an aggregation of géographical areas. It was done according to the travel time to the radiology centres, the most distant areas has been selected and then merged with neighbouring areas, still by distance run, until reaching areas of the expected population size. This except size is around 100 women. Expecting a 40% participation to the mobile unit, we will achieve 32 to 48 mammograms daily. A randomization in parallel group have been perform to constitute the intervention arm and the control arm.|t|f|f|f
33763294|NCT04854005|||COHORT||PROSPECTIVE|||||||
33763295|NCT03456037|||OTHER||RETROSPECTIVE|||||||
33763296|NCT00718822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33763297|NCT03857503|||COHORT||PROSPECTIVE|||||||
33763298|NCT01255592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763299|NCT02420743|||CASE_ONLY||PROSPECTIVE|||||||
33763300|NCT02743923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763301|NCT05003050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomised controlled trial|3 groups each group 10 participants 10 Standard of Care Group 10 Meditation Based Practice 10 Energy Therapy (Pranic Healing)|t|f|t|f
33763302|NCT01423214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763303|NCT01053377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33763304|NCT00502034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763305|NCT03763916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763306|NCT02000830|||COHORT||PROSPECTIVE|||||||
33763307|NCT01271998|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763308|NCT01407588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763309|NCT05791890|||CASE_CONTROL||OTHER|||||||
33763310|NCT01993459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763311|NCT00257959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890766|NCT04493047|NA|SINGLE_GROUP||PREVENTION||NONE||"The design of model will be based on the Replicating Effective Program (REP) framework of implementation. The first phase of REP is comprised of a systematic review (SR) on best mobile health based approaches for LHWs on management of childhood illness followed by formative research (FR). The study consists of the following three stages:~* Pre-intervention phase~* Intervention phase~* Post-intervention phase"||||
33890767|NCT01577862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976298|NCT04356521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976299|NCT00926744|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33976300|NCT06325878|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33976301|NCT04212039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976302|NCT04603963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Stratified randomization was performed in which the impaired chest tomography (absent, less than 50% or greater than 50%)|Only patients with respiratory muscle weakness that were considered as the maximum inspiratory pressure value (less than or equal to 60% of the predicted value) entered for randomization. Stratified randomization was performed in which the impaired chest tomography (absent, less than 50% or greater than 50%) was taken into account to be randomly allocated to the groups.|f|f|t|f
33763312|NCT06625008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking was not performed as it was not feasible|||||
33763313|NCT04821128|||OTHER||RETROSPECTIVE|||||||
33763314|NCT05019833|NA|SINGLE_GROUP||OTHER||NONE||||||
33763315|NCT03766841|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33763316|NCT02334514|||COHORT||PROSPECTIVE|||||||
33763317|NCT04598906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763318|NCT05848921|||COHORT||PROSPECTIVE|||||||
33763319|NCT02205216|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33763320|NCT06450717|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study is a two-year multicenter prospective clinical-experimental study. The project involves the initial small-scale application of a telerehabilitation study protocol to test whether the methodology is appropriate, establish its feasibility, and derive useful information for sample size calculation for subsequent randomized trials. For prospective data collection, patients will be consecutively enrolled at participating centers. At least 10 patients (age 4-18) per pole are expected to be enrolled in this pilot phase.||||
33763321|NCT03819725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763322|NCT04843722|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Open label 2 Cohort Phase 1 Study leading to Randomized Phase 2 Study|t|t|t|f
33763323|NCT05301270|||CASE_CONTROL||PROSPECTIVE|||||||
33763324|NCT00785707|||COHORT||PROSPECTIVE|||||||
33763325|NCT01119430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763326|NCT03950180|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33763327|NCT06437236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763328|NCT04414280|||COHORT||OTHER|||||||
33763329|NCT00206557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890768|NCT01035190|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33890769|NCT03112811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890770|NCT06226402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890771|NCT02717156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890772|NCT02518555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890773|NCT01019564|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33890774|NCT02132442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890775|NCT05148026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890776|NCT03724448|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33763330|NCT01770301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890777|NCT05925426|||COHORT||PROSPECTIVE|||||||
33976303|NCT00944970|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33976304|NCT05498246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were divided into two groups by close envelope method in this prospective study. group (A) included 30 cases in which we used bipolar coagulation for hemostasis ,group (B) included 30 cases in which we used suture renorrhaphy.|Patients were divided into two groups by close envelope method in this prospective study. group (A) included 30 cases in which we used bipolar coagulation for hemostasis ,group (B) included 30 cases in which we used suture renorrhaphy.|t|f|f|f
33976305|NCT01001065|||COHORT||PROSPECTIVE|||||||
33976306|NCT00221507|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976307|NCT01711021|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33976308|NCT05174611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is double blinded, subject will receive either the supplement or the placebo with same appearance and package. The lot number of the bottle will be used for randomization. And the investigators will ask the manufactory about it at the end of the study.|Participants will be assigned into either treatment or placebo groups|t|t|f|f
33976309|NCT02744183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33976310|NCT06117488|||OTHER||CROSS_SECTIONAL|||||||
33976311|NCT00002583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976312|NCT01016509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976313|NCT02113306|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33976314|NCT02207309|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33976315|NCT01093937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890778|NCT03151889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890779|NCT01560351|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33890780|NCT00990171|||COHORT||PROSPECTIVE|||||||
33890781|NCT03429868|NA|SINGLE_GROUP||OTHER||NONE||||||
33890782|NCT06121128|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial (RCT): with a Female Control Group (FCON), a Male Control Group (MCON), a Female Training Group (FTRAIN), a Male Training Group (MTRAIN)||||
33890783|NCT01530243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890784|NCT02670876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890785|NCT03661684|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Two groups. Condition group and Control group, both receiving the investigated medication using the same protocol||||
33763331|NCT06065813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890786|NCT04143633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient doesn´t know the type of diet (standard or low FODMAP)||t|f|f|f
33890787|NCT02547623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890788|NCT00541983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890789|NCT00667706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890790|NCT05057364|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study, single group, no control. pre-post data collection||||
33890791|NCT05548478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890792|NCT00216567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890793|NCT06054529|||OTHER||PROSPECTIVE|||||||
33890794|NCT02698189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890795|NCT01306760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890796|NCT00469079|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890797|NCT00902629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890798|NCT05292755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890799|NCT04216173|NA|SINGLE_GROUP||OTHER||NONE||||||
33890800|NCT00502840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890801|NCT06300736|||COHORT||RETROSPECTIVE|||||||
33890802|NCT02266550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890803|NCT05072444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind, Single-Dose|Double-Blind, Single-Dose, Drug-Drug Interaction Study|t|t|t|f
33890804|NCT04328506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890805|NCT00624234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890806|NCT02021721|||FAMILY_BASED||PROSPECTIVE|||||||
33890807|NCT02309047|||COHORT||CROSS_SECTIONAL|||||||
33890808|NCT01596179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890809|NCT00130871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890810|NCT01026584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976316|NCT03965312|NA|SINGLE_GROUP||TREATMENT||NONE||"In the first phase of the study, a novel neonatal temperature monitor and a commercially available patient monitor (Philips Intellivue MP30) will be applied to the same infant; results between them will be compared.~In the second phase of the study, infants at risk for hypothermia will be placed in an infant incubator; the accuracy of the temperature sensor, time required for infant to become normothermic, and the proportion of time that the infant remains normothermic will be measured."||||
33976317|NCT00487344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
33976318|NCT04905264|||COHORT||PROSPECTIVE|||||||
33976319|NCT06456307|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 1:1 cluster-randomized trial will be conducted in 20 facilities in Western Kenya among pregnant women (3rd trimester) with perinatal mood and anxiety (PMAD) symptoms (Patient Health Questionnaire-2 \[PHQ-2\]≥3 or Generalized Anxiety Disorder-7 \[GAD-7\]≥3). Control facilities will provide enhanced standard of care (PMAD screening followed by standard of care). Intervention facilities will provide IPMH. Effectiveness outcomes will be compared between study arms.||||
33976320|NCT00662766||CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33976321|NCT01872143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976322|NCT05528458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976323|NCT03820713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Prospective, randomized, double blinded, parallel, controlled, two-arm, two-center|t|t|t|f
33890811|NCT00940277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890812|NCT02661594|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33976324|NCT02238223|||COHORT||PROSPECTIVE|||||||
33890813|NCT02508155|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33890814|NCT04278911|||COHORT||PROSPECTIVE|||||||
33890815|NCT04514614|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976325|NCT03812081|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"72 Patients are randomly divided by computer designed lists and then concealed in closed envelopes into 2 equal groups: Group A (n= 37), in which Baska Mask Airway _ (size 3,4,5) will used for ventilation according of patient body weight.~Group B (n= 37), in which Laryngeal Mask Airway- Proseal LMA_ (size 3,4,5) was used for ventilation according of patient body weight"|"Following approval from EL Kasr Al-Ainy teaching hospital ethical committee and an informed patient consent, the investigators enrolled 74adult patients ASA I and II, non-obese (BMI\<30) ranging from18-45 yrs. of age, Patients underwent a variety of elective surgical procedures in the supine position with SAD placement for ≤ 2 hours duration. Patients randomly divided by computer designed lists and then concealed in closed envelopes into 2 equal groups:~Group A (n= 37), in which Baska Mask Airway _ (size 3,4,5) will used for ventilation according of patient body weight.~Group B (n= 37), in which Laryngeal Mask Airway- Proseal LMA_ (size 3,4,5) was used for ventilation according of patient body weight."|t|t|f|f
33976326|NCT02324998|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976327|NCT02631928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33976328|NCT02270879|||COHORT||RETROSPECTIVE|||||||
33976329|NCT03702088|||COHORT||PROSPECTIVE|||||||
33976330|NCT06015048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976331|NCT05803915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976332|NCT01290263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976333|NCT01595503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976334|NCT00992407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976335|NCT05612438|||COHORT||RETROSPECTIVE|||||||
33976336|NCT01066052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976337|NCT03199157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33976338|NCT01530815|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33976339|NCT00368732|||CASE_CONTROL||RETROSPECTIVE|||||||
33976340|NCT02370407|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33976341|NCT01373775|||COHORT||RETROSPECTIVE|||||||
33976342|NCT06412133|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976343|NCT00482547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976344|NCT05295758|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33976345|NCT05966064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976346|NCT00719290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976347|NCT03643666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890816|NCT02276261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890817|NCT00200837|||NATURAL_HISTORY||PROSPECTIVE|||||||
33890818|NCT02760290|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33890819|NCT02850302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890820|NCT05995535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind placebo-controlled randomized trial|Active pregabalin plus lofexidine versus placebo pregabalin plus lofexidine|t|f|t|f
33890821|NCT05245123|||COHORT||CROSS_SECTIONAL|||||||
33890822|NCT04004052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33890823|NCT02434302|||COHORT||CROSS_SECTIONAL|||||||
33890824|NCT03941002|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33890825|NCT04502615|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomised, repeated measures crossover design.||||
33976348|NCT02326077|||COHORT||PROSPECTIVE|||||||
33976349|NCT01760603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976350|NCT00395798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976351|NCT00843609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976352|NCT05485675|RANDOMIZED|PARALLEL||PREVENTION||NONE||SMW and SMW+ will be running simultaneously.||||
33976353|NCT03879356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976354|NCT06074471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Drugs used (bupivacaine-lidocaine-Dexamethazone) Rescue analgesic is morphine|t|f|f|t
33976355|NCT05640310|||OTHER||PROSPECTIVE|||||||
33976356|NCT05387265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976357|NCT01569152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976358|NCT00855556|||COHORT||PROSPECTIVE|||||||
34074520|NCT03419117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Recruited patients will be allocated to an experimental or placebo-control arm. Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection, while patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.||t|t|f|f
33976359|NCT05013671|NON_RANDOMIZED|PARALLEL||OTHER||NONE||First, the nursing home resident will be assessed for the presence of BPPV. Based on the presence of BPPV, two groups will be formed: BPPV-group and control group. The residents suffering from BPPV will undergo balance tests and will be treated for their BPPV (BPPV-group). The nursing home residents with BPPV will be matched to residents without the disease (case control design) and will also undergo balance tests. At 1,3,6 and 12 months the presence of balance problems will be followed up in both groups.||||
33976360|NCT01316653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976361|NCT04016636|||COHORT||PROSPECTIVE|||||||
33976362|NCT02703077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976363|NCT03224676|||OTHER||PROSPECTIVE|||||||
33976364|NCT02277769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976365|NCT00506909|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33976366|NCT05345132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976367|NCT05961800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Quantitative Sensory Testing||||
33976368|NCT00648323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976369|NCT04113343|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34074521|NCT01581515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976370|NCT05156242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participant will be blinded using active vs sham intervention. Care provider is not involving in data collection and blinded to type of stimulation.~Outcomes assessor will be blinded to the group assignment."|4-arm randomized controlled trial (active-tDCS priming MCE, sham-tDCS priming MCE, NMES priming MCE, and conventional physical therapy)|t|t|f|t
33976371|NCT06130358|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33976372|NCT00676000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976373|NCT05137756|||COHORT||RETROSPECTIVE|||||||
33976374|NCT01059500|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33976375|NCT06054932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976376|NCT00431262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074522|NCT06170944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074523|NCT02192112|||COHORT||PROSPECTIVE|||||||
34074524|NCT03202446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074525|NCT03283930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The active and control treatment arms differ in the spatial arrangements of figures on a computer screen. Because these figures are presented for very brief periods of time, subjects cannot easily decipher differences in the arrangements across the active and control treatments. All study team members who work with patients remain blind to the treatment conditions as well.|Patients with anxiety disorders are assessed on a number of mental health and biological variables. Patients who can agree to attend regular psychotherapy sessions are randomized to receive cognitive behavioral therapy with computer-based augmentation. In one study arm, these patients receive cognitive behavioral therapy with an active form of a computer game. In the other treatment arm, subjects receive cognitive behavioral therapy with a control treatment.|t|f|t|f
34074526|NCT01381926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34074527|NCT00570960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074528|NCT03723863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074529|NCT06494501|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074530|NCT02380404|||COHORT||PROSPECTIVE|||||||
34074531|NCT04546633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment and food condition during the Run-in cohort will be open to patients/patients' parents/legal guardian, investigators staff and study monitors, as well as to the Clinical Trial Team (CTT) to allow continuous review of safety, drug exposure and efficacy data in pediatric population. For Cohorts 1 and 2, treatment/food condition will be open to patients/patients' parents/legal guardian, investigators staff and study monitors but will be blinded to the Clinical Trial Team (CTT).|"This is a multicenter, open-label, randomized study in adolescents and children with confirmed uncomplicated P. falciparum malaria.~This study will first explore the effect of food on lumefantrine and KAF156 PK in a Run-in Cohort of patients 12 to \< 18 years old with malaria caused by P. falciparum, before younger patients are assessed. Then, efficacy, safety and tolerability of the combination of KAF156 and LUM-SDF will be evaluated in younger patients, first in Cohort 1 of patients 2 to \< 12 years old and then in Cohort 2 of patients 6 months to \< 2 years old.~Randomization is stratified by country for patients in the Run-in cohort, by age group (6 years to \<12 and 2 to \<6 years) and country in Cohort 1 and by country in Cohort 2."|f|f|f|t
34074532|NCT05118347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study participants will be randomized into two groups, Buteyko breathing technique group and incentive spirometry group|t|t|f|t
34074533|NCT06075771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2:1 randomization to L-DOPA versus placebo|t|f|t|f
34074534|NCT00102115|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074535|NCT02768688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074536|NCT00934245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074537|NCT05285410|||COHORT||PROSPECTIVE|||||||
34074538|NCT05502952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890826|NCT06423248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both patient and investigators were blind to treatment allocation, with an independent researcher providing the allocated treatments to the participants.||t|f|t|t
33890827|NCT01696357|||CASE_CONTROL||PROSPECTIVE|||||||
33890828|NCT02201758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Flaxseed Lignan-Enriched Complex (FLC) vs. placebo|t|t|f|f
33890829|NCT02095301|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33890830|NCT03386084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890831|NCT00337233|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890832|NCT03760588|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, placebo controlled, double blind design|t|t|t|t
33890833|NCT02479347|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33890834|NCT06343090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||a prospective cohort study||||
33890835|NCT03115996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double-blinded||t|t|t|t
33890836|NCT03809624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33890837|NCT03448679|||COHORT||RETROSPECTIVE|||||||
33890838|NCT05740241|||COHORT||PROSPECTIVE|||||||
33890839|NCT01823809|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890840|NCT03651076|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33890841|NCT05304364|NA|SEQUENTIAL||TREATMENT||NONE||||||
33890842|NCT04947202|||COHORT||RETROSPECTIVE|||||||
33890843|NCT00421876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890844|NCT01412229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890845|NCT06329050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33890846|NCT02964637|||COHORT||CROSS_SECTIONAL|||||||
33890847|NCT01892722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There are 2 arms in the core phase. In the extension phase all participants are receiving open-label.study drug. A third arm has been added to enroll up to 25 new younger patients per HA post approval commitment.|t|f|t|f
33890848|NCT00881660|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33890849|NCT01137214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074539|NCT04826484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074540|NCT02633969|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890850|NCT03689218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890851|NCT05439616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890852|NCT01851967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890853|NCT03996967|||CASE_CONTROL||PROSPECTIVE|||||||
33890854|NCT02207114|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33890855|NCT01805648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890856|NCT04117321|||COHORT||PROSPECTIVE|||||||
33890857|NCT06318936|||COHORT||PROSPECTIVE|||||||
33890858|NCT03072537|||OTHER||PROSPECTIVE|||||||
33890859|NCT03696329|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890860|NCT00640094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890861|NCT04022746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890862|NCT03420976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890863|NCT03911622|||COHORT||PROSPECTIVE|||||||
33890864|NCT04114981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890865|NCT04378166|RANDOMIZED|PARALLEL||OTHER||SINGLE||Compares central venous catheterization using smart-glasses and conventional method|t|f|f|f
33890866|NCT04840121|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be randomized in either the study group - AdhesioRT or in the control group - standard of care. All participants recruited, including the control group, will have the AdhesioRT biopsies performed.||||
33890867|NCT01892488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890868|NCT01604746|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33890869|NCT00642642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890870|NCT06654557|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33890871|NCT00284570|||CASE_ONLY||PROSPECTIVE|||||||
33890872|NCT02662478|||COHORT||PROSPECTIVE|||||||
33890873|NCT00294151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890874|NCT01678976|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890875|NCT02628587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33890876|NCT01339455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890877|NCT03720314|||OTHER||PROSPECTIVE|||||||
33890878|NCT01202461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890879|NCT03781557|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33890880|NCT05199584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890881|NCT00317044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890882|NCT01012908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33890883|NCT03569267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074541|NCT00826410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074542|NCT00001296||||TREATMENT||||||||
34074543|NCT02407847|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074544|NCT03069534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074545|NCT01263717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074546|NCT03397121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34074547|NCT04551664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34074548|NCT01986738|||COHORT||PROSPECTIVE|||||||
33890884|NCT02832089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890885|NCT05501925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||GlideSheath Slender® group Conventional Sheath group (TERUMO, Introducer II )|f|f|f|t
33890886|NCT00298714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890887|NCT04125537|||COHORT||OTHER|||||||
33890888|NCT01672957|||COHORT||PROSPECTIVE|||||||
33890889|NCT06656884|||COHORT||PROSPECTIVE|||||||
34074549|NCT04306497|||COHORT||OTHER|||||||
34074550|NCT03197467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763332|NCT05286944|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|The participant will be assigned a study number based on the recruitment timeline and assigned into the pre-randomized groups. Throughout the study, the primary investigator will not know which group is assigned for the mobile phone daily alarm. A second investigator will select the group for mobile phone daily alarm and set the alarm.|Single blinded randomized controlled trial|f|t|t|t
33763333|NCT02543190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Care provider did not know study assignment. Reviewer for primary outcomes did not know study assignment||f|t|f|t
33763334|NCT01792141|||COHORT||PROSPECTIVE|||||||
34074551|NCT02008136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763335|NCT01899456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763336|NCT04822350|||COHORT||PROSPECTIVE|||||||
33890890|NCT03704337|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, cross-over administration of supplements with approximately 7-10 days between testing sessions.||||
33890891|NCT04301414|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33890892|NCT01417676|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are allocated for lymph node irradiation, either up front combined with prostate irradiation or lymph node irradiation after primary lymph adenectomy after combined with prostate irradiation.||||
33890893|NCT02370121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33890894|NCT03534037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890895|NCT01778244|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34074552|NCT02510612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976377|NCT04251065|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective, multicenter, single arm, single-stage phase II trial in patients with refractory/relapsed CD38 positive PTCL-NOS, AITL and TFH with centrally assessed CD38 expression ≥ 5%.~It is expected for the current trial that D-GDP will improve the CR rate to 40% with an absolute improvement of 20%, while the toxicity rate is maintained at 30%.~Sample size: A'Hern's Single-Stage Phase II design will be used. The sample size was calculated according to the primary efficacy endpoint. Based on literature, the null hypothesis that the true proportion of CR after four courses of D-GDP is 0.20 will be tested against an alternative CR proportion of 0.40 with an absolute improvement of 0.20, considered clinically promising with the experimental treatment. Assuming a type I error rate of 5% and a power of 80% when the CR proportion is 40% overall 35 patients will be accrued. The null hypothesis will be rejected if 12 or more CR out of 35 patients are observed after four courses of D-GDP."||||
33976378|NCT00001765||||TREATMENT||||||||
33976379|NCT00612326|||COHORT||PROSPECTIVE|||||||
33976380|NCT04669665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 is open-label. Part 2 is a double-blind placebo-controlled study.|Part 1 is a single group. Part 2 is a parallel group 1:1 randomization of SLS-002 to placebo, plus standard of care.|t|t|t|t
33976381|NCT01908127|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33976382|NCT03788499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976383|NCT00629616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976384|NCT01662466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976385|NCT00858195|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976386|NCT05767723|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33976387|NCT00055783||||TREATMENT||NONE||||||
34074553|NCT05133284|||COHORT||RETROSPECTIVE|||||||
34074554|NCT05933330|||COHORT||PROSPECTIVE|||||||
34074555|NCT02816073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074556|NCT00431327|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33763337|NCT06149546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763338|NCT04772846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33763339|NCT01139463|||COHORT||PROSPECTIVE|||||||
33763340|NCT02671201|||OTHER||PROSPECTIVE|||||||
33763341|NCT03715400|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33763342|NCT02478346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763343|NCT03723343|||CASE_CONTROL||PROSPECTIVE|||||||
33890896|NCT02001545|||COHORT||PROSPECTIVE|||||||
33976388|NCT01096290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976389|NCT00487838|||||PROSPECTIVE|||||||
33976390|NCT05339009|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976391|NCT02343120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074557|NCT02575196|||COHORT||PROSPECTIVE|||||||
33763344|NCT01388348|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33763345|NCT00825097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763346|NCT02994602|NA|SINGLE_GROUP||OTHER||NONE||||||
33763347|NCT02433002|||COHORT||PROSPECTIVE|||||||
33890897|NCT06227130|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Intervention group (IG) and waiting group (WG). IG will start with intervention program. After 6 weeks WG does the intervention program. PSS-questionnaire will be performed at baseline and after 6 weeks for both groups, and after 12 weeks for WG.||||
33890898|NCT04772248|||COHORT||RETROSPECTIVE|||||||
33976392|NCT03891056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be blinded for patients, who will not know the surgery technique they will go on. Dieticians and Endocrinologists who will follow the patients up after the surgery neither will not know it, so differences in dietary recommendations will not appear with this masking.|Randomization will be a simple one with Epidat 4.1. A number sequence will be carried out and it will be kept in opaque closed envelopes. The envelope will be opened the operation day and the surgery technique will be decided randomly, according to the randomization sequence.|t|t|f|f
33976393|NCT02796235|NA|SINGLE_GROUP||OTHER||NONE||||||
33976394|NCT05664256|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34074558|NCT04784507|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34074559|NCT06259149|||COHORT||PROSPECTIVE|||||||
34074560|NCT02050139|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34074561|NCT01655719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074562|NCT06611917|||COHORT||PROSPECTIVE|||||||
34074563|NCT02258659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074564|NCT03638960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and data collectors are unaware of which group the patient belongs to. The anesthesiologist performing the nerve block will not be blinded.|The investigators plan to perform a double blinded randomized control study. Patients will be randomly assigned to either group A or group B. Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine. Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.|t|f|f|t
34074565|NCT00868478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074566|NCT02356952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074567|NCT00264784|||||PROSPECTIVE|||||||
34074568|NCT03752879|||CASE_CONTROL||PROSPECTIVE|||||||
34074569|NCT05018702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074570|NCT03746639|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34074571|NCT03168451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The intervention group will receive data collection messages and culturally tailored messages encouraging them to quit smoking. The control group will only receive data collection messages.|t|f|f|f
34074572|NCT03521869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Only bilateral knee replacements will be utilized so each patient can serve as their internal control||||
34074573|NCT05934916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.|f|f|f|t
34074574|NCT05642104|||COHORT||PROSPECTIVE|||||||
34074575|NCT01537848|||CASE_ONLY||RETROSPECTIVE|||||||
34074576|NCT04865029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded clinical trial|Randomized, placebo-controlled|t|t|t|t
33763348|NCT06298565|||COHORT||PROSPECTIVE|||||||
33763349|NCT06178302|||COHORT||PROSPECTIVE|||||||
33763350|NCT03833128|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33763351|NCT05076149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890899|NCT00559091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890900|NCT06156527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890901|NCT02740309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33890902|NCT04172090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33890903|NCT01524380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074577|NCT03824717|NA|SINGLE_GROUP||TREATMENT||NONE|There is no masking|Biased coin design and up and down method to determine the minimum effective volume of Ropivacaine in ultrasound guided infraclavicular brachial plexus blocks.||||
34074578|NCT02078271|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34074579|NCT02781987|||CASE_CONTROL|||||||||
33890904|NCT05195528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890905|NCT01309737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890906|NCT05093127|||CASE_ONLY||PROSPECTIVE|||||||
33890907|NCT00866437|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|t|f|f
33890908|NCT02029976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890909|NCT06237881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890910|NCT01130506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890911|NCT06162455|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33976395|NCT03138070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976396|NCT06041256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976397|NCT01531205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976398|NCT04191239|||CASE_CROSSOVER||PROSPECTIVE|||||||
33976399|NCT05029323|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33763352|NCT03575533|||COHORT||PROSPECTIVE|||||||
33763353|NCT00632281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763354|NCT04479033|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33763355|NCT04795921|||COHORT||PROSPECTIVE|||||||
33763356|NCT05466539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763357|NCT06139068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|An intervention was applied to both groups and blinding of the participants was ensured. It is planned to analyze the data by a statistician independent of the research. In the study, blinding was not possible since it was the researcher who implemented the intervention.|The research was used parallel group, randomized, controlled experimental design.|t|f|f|t
33763358|NCT01971294|||COHORT||PROSPECTIVE|||||||
33763359|NCT06134921|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33763360|NCT02202434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976400|NCT05366764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976401|NCT03275233|||CASE_ONLY||PROSPECTIVE|||||||
33976402|NCT02928848|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33976403|NCT04883736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976404|NCT00913107|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33976405|NCT00109109|NON_RANDOMIZED|||TREATMENT||NONE||||||
33976406|NCT02155907|||CASE_ONLY||PROSPECTIVE|||||||
34074580|NCT05404711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects will wear a continuous glucose monitor (CGM) to determine the feasibility and acceptability of the device to evaluate risk of youth developing Type 2 Diabetes (T2D).||||
33976407|NCT05557565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976408|NCT04366609|||COHORT||PROSPECTIVE|||||||
33976409|NCT03504111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976410|NCT04356859|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization will be based on intent to treat. Consecutively admitted and eligible burn patients will be assigned to one of two treatment groups (Colloid or Crystalloid) within 12 hours of burn injury."||||
33976411|NCT00879242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976412|NCT05273619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976413|NCT03979248|NA|SEQUENTIAL||TREATMENT||NONE||||||
33976414|NCT05361122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Psychologists and dentists will be blinded to the treatment status (xylitol or no xylitol use during pregnancy) of the mothers of the pediatric subjects.|We will enroll 1000 children aged 4-8 years of age. n=500 will be former term children and additional n=500 will be former preterm children. Half in each group (n=250) will be gestationally xylitol-exposed, and the other half (n=250) will not be xylitol-exposed.|f|t|f|f
33976415|NCT00479622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976416|NCT01979848|||CASE_ONLY||PROSPECTIVE|||||||
33976417|NCT04238520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind- Study participants will be aware of the treatment assigned. The oral examiners and data collectors will not know the group allocation. To check the success or failure of the blinding, the oral examiners and data collectors will be asked after each assessment whether they have been told or know for sure to which group each dyad has been assigned.|control vs. intervention|f|f|t|f
33976418|NCT04384172|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976419|NCT00436358|||||PROSPECTIVE|||||||
33976420|NCT03967236|||COHORT||PROSPECTIVE|||||||
33976421|NCT04627376|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33976422|NCT00942461|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33976423|NCT01409044|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33976424|NCT01878370|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976425|NCT00764309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074581|NCT05888480|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||The IG will receive the end-of-life CST between the two measurement points, and the CG will be a waitlist group and receive the training after the end of data collection.|t|f|f|t
34074582|NCT02938338|||CASE_ONLY||PROSPECTIVE|||||||
34074583|NCT01639144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33890912|NCT00908284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763361|NCT00525135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33890913|NCT02395549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890914|NCT00342355|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33890915|NCT04409847|||COHORT||PROSPECTIVE|||||||
33890916|NCT04753125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890917|NCT02575430|||||RETROSPECTIVE|||||||
33890918|NCT05855161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups as rebound group and control group|t|f|f|t
33763362|NCT04092179|NA|SEQUENTIAL||TREATMENT||NONE||||||
33890919|NCT02469129|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890920|NCT05564559|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||It is a 2-arm, non-randomized clinical study consisting of an intervention and a control group (waiting list) aiming to provide 8 weeks of multi-family psychoeducation to the families of people living with a diagnosis of substance abuse disorder.||||
33890921|NCT03115190|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890922|NCT01668368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890923|NCT01468649|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33890924|NCT00246168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33890925|NCT00956930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890926|NCT00439855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890927|NCT02601456|||CASE_ONLY||CROSS_SECTIONAL|||||||
33890928|NCT01349348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890929|NCT04144621|||COHORT||RETROSPECTIVE|||||||
33890930|NCT05872048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890931|NCT05796479|RANDOMIZED|PARALLEL||OTHER||NONE||2-part, open-label study with 1 arm in Part 1 and a randomized, 2 arms parallel design in Part 2||||
33890932|NCT01322906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890933|NCT06606028|||COHORT||PROSPECTIVE|||||||
33890934|NCT02706938|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Because HBE is not susceptible to double-blinding, patients allocated to the intervention group will always be aware of the group they belong to. However, the researcher in charge of statistical analysis of data and writing the results report will work with random-generated alphabetical group codes for masking the intervention in each one of the periods of the trial.|Randomized single-blind single-centre controlled clinical trial with a 2x2 cross-over design.|f|f|f|t
33890935|NCT05424393|||COHORT||PROSPECTIVE|||||||
33890936|NCT03381443|||COHORT||PROSPECTIVE|||||||
33890937|NCT04080011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890938|NCT02226341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890939|NCT04159090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890940|NCT05397236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33976426|NCT05638503|||COHORT||PROSPECTIVE|||||||
33976427|NCT01349439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976428|NCT05682495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be two independent cohorts of subjects who will each receive two treatments (high dose strength and low dose strength), and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability. In each cohort approximately 42 healthy subjects will be randomized to receive treatment with IP to complete at least 36 evaluable subjects.||||
33976429|NCT00379548|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976430|NCT02623959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976431|NCT04697966|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33976432|NCT01298570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976433|NCT05608356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data assessment will be blinded as an assessor not participating in the study will be responsible for measuring the rate of en masse retraction, as the patient name could be hidden during data analysis. The models will be coded with numbers assigned to the participants, and will be sent to an assessor not participating in the research.|interventional group will receive injectable platelet rich fibrin intraligamentally distal to the right and left canines, and palatal to the upper 4 incisors, in three time points with 21 days interval, control group will receive sham injection instead.|t|f|f|t
33976434|NCT01138683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976435|NCT00383890|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33976436|NCT05468229|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double blind placebo controlled||t|t|t|f
33976437|NCT03587207|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976438|NCT02949323|||CASE_CONTROL||PROSPECTIVE|||||||
33976439|NCT03770923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976440|NCT01392898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976441|NCT00002252||||TREATMENT||||||||
33976442|NCT02801877|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33976443|NCT03832465|RANDOMIZED|PARALLEL||TREATMENT||NONE||"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution. Patients failed to achieve intraluminal eradication of H. pylori will be randomly assigned to 7-day or 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, and esomeprazole 40 mg twice daily)."||||
33976444|NCT03202758|NA|SINGLE_GROUP||TREATMENT||NONE||"Step 1: Phase Ib with the aim to confirmed the safety of the association of Durvalumab (q2w 750mg) + Tremelimumab (q4w 75mg) + FOLFOX~Step 2: Phase II with the aim to assess efficacy of the association of Durvalumab (q2w 750mg) + Tremelimumab (q4w 75mg) + FOLFOX"||||
34074584|NCT04563754|NA|SINGLE_GROUP||SCREENING||NONE|No masking will be used in this study.|This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging.||||
34074585|NCT05005936|||COHORT||PROSPECTIVE|||||||
34074586|NCT03095352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074587|NCT02998996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074588|NCT05122689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33763363|NCT01953003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074589|NCT00122525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074590|NCT04382716|||COHORT||PROSPECTIVE|||||||
34074591|NCT01307059|||COHORT||OTHER|||||||
34074592|NCT03189355|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074593|NCT02597179|||COHORT||PROSPECTIVE|||||||
34074594|NCT04835064|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074595|NCT01673984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074596|NCT05254899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074597|NCT03072095|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34074598|NCT01901016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074599|NCT06004271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization will be made and divided into 3 groups with equal number of participants. The groups will be called control, experiment, and placebo. Only physiotherapy will be applied to the control group, kinesio taping and physiotherapy to the experimental group, and damask taping and physiotherapy to the placebo group.|f|f|f|t
34074600|NCT01267929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074601|NCT00661635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763364|NCT06625814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33763365|NCT00992537|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763366|NCT00297193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763367|NCT01516775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33763368|NCT01798524|||COHORT||RETROSPECTIVE|||||||
33890941|NCT04268888|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients shall be randomised on a 1:1 basis throughout the study and allocated using pre-generated lists produced by the study statistician. List shall be produced using permuted blocks algorithm with random block sizes of 2 and 4. Stratification factors used in the study are randomising centre, baseline HAP score (A vs. B vs. C) and vascular invasion (No vs. Yes).||||
33890942|NCT01835184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890943|NCT03339804|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33890944|NCT05548686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33890945|NCT04995094|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Randomized||||
33763369|NCT01737684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890946|NCT04057001|||CASE_CONTROL||RETROSPECTIVE|||||||
33890947|NCT03404648|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763370|NCT01335516|||||PROSPECTIVE|||||||
33763371|NCT01282801|RANDOMIZED|CROSSOVER||||NONE||||||
33763372|NCT01920048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763373|NCT03468933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763374|NCT01755624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890948|NCT01578902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890949|NCT01070420|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33890950|NCT01769105|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33890951|NCT00221364|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33890952|NCT02617355|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33890953|NCT03224286|||OTHER||PROSPECTIVE|||||||
33890954|NCT02162888|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33976445|NCT01953666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074602|NCT03280056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study where the investigators, participants and all sponsor and CRO personnel involved in the conduct, data management or analysis of the study will remain blinded to the treatment assignments|Randomized, Double-Blind, Placebo-Controlled Multicenter Study|t|t|t|t
34074603|NCT00894088|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074604|NCT03446378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled double-blind clinical trial|t|f|f|t
34074605|NCT03642535|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
34074606|NCT04147247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34074607|NCT04821843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074608|NCT05897515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants are not provided investigational results and will only be provided with routine standard of care diagnostics results.|||||
33763375|NCT02070705|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33763376|NCT05348967|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33890955|NCT00398112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890956|NCT04137471|||COHORT||PROSPECTIVE|||||||
33890957|NCT04366999|||COHORT||PROSPECTIVE|||||||
33890958|NCT01963494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890959|NCT00486603|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34074609|NCT03764514|||COHORT||PROSPECTIVE|||||||
33976446|NCT04582396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In addition to the unblinded coordinator, and due to the nature of the study treatment, the person performing the procedure cannot be blinded (i.e. the person performing the procedure needs to assess the effectiveness of the block objective physical signs and symptoms), but is encouraged not to disclose the allocation to the patient or outcome assessors either before or after the procedure.|This is a pilot RCT to gain preliminary evidence regarding the acceptability, tolerability, safety, and efficacy of a combined intervention of Stellate Ganglion Blockade and psychoeducation vs sham-procedure and psychoeducation on trauma symptoms and health behaviors in patients exhibiting early PTSD symptoms after cardiac arrest.|t|t|t|t
34074610|NCT00624000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074611|NCT01908712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976447|NCT03258359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976448|NCT00100165|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33976449|NCT04401566|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The gynecologist was blind about treatment and the investigator was blind about assesment.||f|t|t|t
33976450|NCT03335371|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34074612|NCT05063578|NA|SEQUENTIAL||TREATMENT||NONE||||||
33976451|NCT03707873|RANDOMIZED|PARALLEL||TREATMENT||NONE||AF patients will be divided in three groups: one group will have in-person education, the second group will have online education and the third group will receive standard AF care. Cardiovascular outcomes will be compared between these groups.||||
33976452|NCT00602030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976453|NCT02454673|||COHORT||RETROSPECTIVE|||||||
33976454|NCT03943251|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33976455|NCT05915052|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||To minimize bias in baseline characteristics between the B-suture stoma group and the conventional method stoma group, we performed propensity score matching (pSM) with a matching tolerance (M) set at 0.02 and nearest neighbor matching without put-back at a ratio of 1:1. Baseline information for matching was: gender, age, BMI, hemoglobin, albumin, diabetes, hypertension, previous abdominal surgery history, distance of the lower margin of the tumor from the anal margin, tumor diameter, American Society of Anesthesiology (ASA) physical classification, and tumor stage. 62 patients in the B-suture stoma group were successfully matched 1:1 with 123 patients in the conventional stoma group to 59 patients in the B-suture stoma group and 59 patients in the conventional stoma group. 59 patients in the B-stitch stoma group and 59 patients in the conventional stoma group.||||
33890960|NCT05591781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890961|NCT05621356|||COHORT||PROSPECTIVE|||||||
33890962|NCT00365989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890963|NCT05534373|||CASE_ONLY||RETROSPECTIVE|||||||
33890964|NCT05827159|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants will be identified through targeted screening for DSM-5 criteria for moderate to severe AUD and the study inclusion/exclusion criteria. Therefore, the Screening component of the SBIRT intervention in the proposed RCT will be conducted before eligible ED patients who are interested in study participation are consented and randomized.||||
33890965|NCT05426421|||COHORT||PROSPECTIVE|||||||
33890966|NCT06428214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890967|NCT04321161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074613|NCT00190359|||CASE_CONTROL||OTHER|||||||
34074614|NCT02810275|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34074615|NCT01614002|||||PROSPECTIVE|||||||
34074616|NCT06069739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible participants were randomly assigned in a 1:1 ratio to a 12-week program of either; (a) guided-exercise of moderate intensity and frecuency, and incentive of autonomous physical activity proposals by the specialist; guided physical activity group (GPAG), or (b) 12 weeks of an exercise program standard physical activity without guided and incentives; standard physical activity group (SPAG). Both groups followed the same randomized recruitment procedure, data collection and follow-up. All treatment sessions were conducted from March to June 2016. To maintain the rigor of the research, possible risks that could question the internal and external validity of the study results were identified and strategies were proposed to eliminate them.|t|f|f|f
34074617|NCT03004768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074618|NCT02324361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Participants were given a choice to select one of the two interventions, which were made clear to them. There was no masking of the study.|2-arm interventional study||||
34074619|NCT05002166|||OTHER||PROSPECTIVE|||||||
34074620|NCT02959918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074621|NCT04512144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33890968|NCT05381909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890969|NCT01116050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890970|NCT05873712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890971|NCT06543771|NA|SINGLE_GROUP||OTHER||NONE||In situ used for near patient In vitro Medical device.||||
33890972|NCT05029557|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33890973|NCT05569135|||COHORT||RETROSPECTIVE|||||||
33890974|NCT03912584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33890975|NCT02848755|||COHORT||PROSPECTIVE|||||||
33890976|NCT02495337|||COHORT||PROSPECTIVE|||||||
33890977|NCT04116021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers and outcome assessors will be blinded.|Parallel assignment|t|t|f|t
33890978|NCT05922202|||COHORT||PROSPECTIVE|||||||
33890979|NCT00887952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33890980|NCT04151108|||COHORT||PROSPECTIVE|||||||
33890981|NCT03533166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33890982|NCT04816240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33890983|NCT00274391|RANDOMIZED|PARALLEL||||DOUBLE||||||
33890984|NCT06340919|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33890985|NCT03782337|||COHORT||PROSPECTIVE|||||||
33890986|NCT02829879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33890987|NCT05464017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Investigators will implement improvements to the mHealth triage tool using a machine learning approach, optimizing both the efficiency of the call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the CTR, as well as post-discharge phone contact attempts and survey information. The backbone of investigators' estimators is the ensemble machine learning algorithm the Superlearner|t|f|f|f
33890988|NCT05888025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890989|NCT00595907|||||PROSPECTIVE|||||||
33890990|NCT00899340|||CASE_ONLY||RETROSPECTIVE|||||||
33890991|NCT05495048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33890992|NCT02006134|||COHORT||PROSPECTIVE|||||||
33890993|NCT04439786|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Participants are randomly assigned to controll group or lidocaine group. Participants of control group are given placebo while participants of lidocaine group are given lidocaine.|t|t|f|t
33890994|NCT01128387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose escalation study||||
33890995|NCT05097625|||COHORT||PROSPECTIVE|||||||
33890996|NCT06044324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33890997|NCT03751332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33890998|NCT02532049|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33890999|NCT04790942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763377|NCT01784692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33763378|NCT03604822|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single-subject design (Repeated measures)||||
33891000|NCT05920213|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|participants' attendants will also be masked and will give consent for the study in case the participant is admitted to the Intensive care unit and is not mentally stable to give consent.||t|f|f|f
33891001|NCT04695509|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33891002|NCT02226666|||COHORT||PROSPECTIVE|||||||
33891003|NCT06657690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891004|NCT04526184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|25 COPD patients were referred to the study from the pulmonology clinic of the hospital where the study was conducted by a medical secretary who was blinded to the intervention. In addition, 21 healthy individuals volunteered to participate in the study from the same hospital where the study was previously announced.|Two groups will be formed as healthy and patient groups and the same treatment initiative will be applied.|t|f|f|t
33891005|NCT03063593|||OTHER||PROSPECTIVE|||||||
33891006|NCT00456703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891007|NCT01106924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891008|NCT04848493|||COHORT||PROSPECTIVE|||||||
33891009|NCT05960565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||One day with glucagon and one day without glucagon||||
33891010|NCT02216136|||COHORT||PROSPECTIVE|||||||
33891011|NCT04265066|||CASE_ONLY||PROSPECTIVE|||||||
33891012|NCT02292823|||CASE_ONLY||PROSPECTIVE|||||||
33976456|NCT05755425|||COHORT||PROSPECTIVE|||||||
33976457|NCT04164953|NA|SINGLE_GROUP||TREATMENT||NONE||Surgical intervention as second-line surgery for the treatment of Dupuytren's disease.||||
33891013|NCT01865734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891014|NCT02918084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891015|NCT05427474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33891016|NCT01305512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976458|NCT06358183|||OTHER||CROSS_SECTIONAL|||||||
33976459|NCT04554654|||COHORT||PROSPECTIVE|||||||
33976460|NCT01941420|||COHORT||PROSPECTIVE|||||||
33976461|NCT04464044|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33976462|NCT00531206|||||PROSPECTIVE|||||||
33976463|NCT01346852|||COHORT||RETROSPECTIVE|||||||
33976464|NCT06233253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976465|NCT06312683|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33976466|NCT01241981|||COHORT||PROSPECTIVE|||||||
33976467|NCT01816477|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976468|NCT06388980|||CASE_CONTROL||PROSPECTIVE|||||||
33976469|NCT02347670|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33976470|NCT00655642|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33891017|NCT02531815|RANDOMIZED|||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33891018|NCT02598414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891019|NCT02866344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891020|NCT02581709|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33891021|NCT06228157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33891022|NCT00003729||||TREATMENT||||||||
33891023|NCT00850252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891024|NCT00352703|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33891025|NCT03590678|||COHORT||PROSPECTIVE|||||||
33891026|NCT00665275|||COHORT||CROSS_SECTIONAL|||||||
33891027|NCT04681261|||COHORT||CROSS_SECTIONAL|||||||
33891028|NCT02842931|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33891029|NCT04233489|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891030|NCT03920969|||COHORT||PROSPECTIVE|||||||
33891031|NCT00632580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891032|NCT01996787|RANDOMIZED|PARALLEL||||NONE||||||
33891033|NCT04920409|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33891034|NCT04525703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891035|NCT01361711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891036|NCT02426307|||COHORT||RETROSPECTIVE|||||||
33891037|NCT05971849|NA|SINGLE_GROUP||OTHER||NONE||||||
33891038|NCT01578915|||CASE_CONTROL||PROSPECTIVE|||||||
33976471|NCT02309749|||COHORT||PROSPECTIVE|||||||
33976472|NCT02799602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976473|NCT00670956|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33976474|NCT04108182|||COHORT||PROSPECTIVE|||||||
33763379|NCT04637464|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Patients receiving empirical antibiotic treatment due to high risk neutropenic fever will be randomly assigned 1:1 to one of two groups regimens. Randomization can occur from 36 hours after initiation of antibiotics until 48 hours of apyrexia and clinical stability. The allocated treatment regimen is followed from randomization until neutrophil recovery, also in case of relapsing fever after termination of antibiotic treatment.~A participant can be randomized more than once, but only one time during each episode of neutropenia, i.e. bone marrow recovery and subsequent chemotherapy treatment must have taken place before a new randomization can occur."||||
34074622|NCT05686863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Since propofol is white uniform emulsion, and ramazolam is colorless, clear and transparent liquid, anesthesiologists and surgeons may see the color of the study drug during operation, so this study is a single blind clinical study|Prospective, randomized controlled study|t|t|f|t
33763380|NCT01986101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763381|NCT02713711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763382|NCT04262765|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects are to be admitted the night before dose no. 1 administration, confining at clinical site until the 24 hours post dose no. 5 administration. 4-days off interval between last dose of treatment A and first dose of treatment B allowed. Subjects to be admitted the night before dose no. 6 administration, confining at clinical site until the 24 hours post dose no. 10 administration. 4-days off interval between last dose of treatment B and first dose of treatment C allowed. Subjects to be admitted the night before dose no. 11 administration, confining at clinical site until the 24 hours post dose no. 26 administration.||||
33763383|NCT03387202|||CASE_ONLY||PROSPECTIVE|||||||
34074623|NCT06027762|||COHORT||PROSPECTIVE|||||||
33763384|NCT05802186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763385|NCT03578614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind|Single-blind, randomized controlled trial, with a six-month intervention treatment and an additional follow-up of six months. After a four-week run-in period, the participants are randomized into two parallel groups (control group and intervention group).|f|f|t|f
34074624|NCT01383434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763386|NCT00280657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763387|NCT03708640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33763388|NCT05158101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763389|NCT05568524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891039|NCT03906266|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|tests are made by different persons|tests for understanding nutritional deficiency will be compared in a single patient group|f|f|t|f
33891040|NCT00723593|||||PROSPECTIVE|||||||
33891041|NCT02205450|||COHORT||PROSPECTIVE|||||||
33891042|NCT03766243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33891043|NCT03417440|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Study measures (apart from accelerometry, Health-ITUES, and usage data-see below) will be administered by a condition-blind tester at a study site at baseline and post-intervention.|Multiphase Optimization Strategy (MOST) is a recent methodology for optimizing multi-component interventions prior to performing more comprehensive testing in large RCTs. The Most Framework includes 5 steps: (1) Establish theoretical model; (2) Identify individual intervention components; (3) Conduct experiment to examine individual components; (4) Assemble beta intervention package; and (5) Confirm efficacy of optimized intervention. To our knowledge, only two prior studies have used MOST to refine a complex app with physical activity elements and disentangle the relative efficacy of specific features within a larger suite.|f|f|t|t
33891044|NCT01129947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891045|NCT00289822|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074625|NCT00630799|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074626|NCT04592549|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34074627|NCT03677869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074628|NCT00701688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074629|NCT04394156|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline case-series design (AB), with a randomised duration of baseline length.||||
34074630|NCT04964661|||COHORT||RETROSPECTIVE|||||||
34074631|NCT00013871||||PREVENTION||||||||
34074632|NCT00022750|RANDOMIZED|||PREVENTION||||||||
34074633|NCT04877808|||COHORT||RETROSPECTIVE|||||||
34074634|NCT01088490|||COHORT||PROSPECTIVE|||||||
34074635|NCT03934008|||OTHER||OTHER|||||||
34074636|NCT00953888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34074637|NCT05637307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074638|NCT00201344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074639|NCT01881607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074640|NCT00331838|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34074641|NCT01427010|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
34074642|NCT00534248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34074643|NCT04017715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34074644|NCT03925129|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34074645|NCT00635544|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34074646|NCT05391997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074647|NCT00603603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074648|NCT02983045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074649|NCT00812175|||COHORT||PROSPECTIVE|||||||
34074650|NCT00766597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763390|NCT05016726|||COHORT||PROSPECTIVE|||||||
33763391|NCT05043701|NA|SINGLE_GROUP||TREATMENT||NONE||Open labelled intervention study||||
33763392|NCT00903734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763393|NCT02978001|||CASE_CONTROL||PROSPECTIVE|||||||
33763394|NCT05781139|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763395|NCT06215690|||CASE_CONTROL||PROSPECTIVE|||||||
33891046|NCT06144008|||COHORT||PROSPECTIVE|||||||
34074651|NCT06254989|NA|SINGLE_GROUP||OTHER||NONE||||||
34074652|NCT04710004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891047|NCT03880877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891048|NCT03871491|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Both the azithromycin and placebo will be procured from the same manufacturer. The packaging will be standardized across sites and will be labeled as: Azithromycin 2 g or Placebo, with the expiration data and a unique identifier.~Clinical and research staff as well as the women will be masked to treatment status unless there is a serious adverse event potentially related to the treatment modality that requires unmasking for safety reasons. There will be one pharmacist at each site who will monitor randomization, drug supply, and safety. If concerns about randomization or participant safety are identified, the data coordinating center will authorize and instruct the study pharmacist to apply un-masking procedures."|Randomized, placebo-controlled, parallel multicenter clinical trial. Women in labor will be randomized with one-to-one ratio to intervention/placebo.|t|t|t|f
33891049|NCT03059290|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33891050|NCT05267626|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891051|NCT00843570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891052|NCT04365244|||COHORT||RETROSPECTIVE|||||||
33891053|NCT05237557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single center, Open-label, Randomized controlled trial||||
33891054|NCT03898648|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33891055|NCT02521129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891056|NCT03152292|||COHORT||PROSPECTIVE|||||||
33891057|NCT04047888|||COHORT||PROSPECTIVE|||||||
33891058|NCT03158753|||COHORT||PROSPECTIVE|||||||
33891059|NCT01164878|||COHORT||RETROSPECTIVE|||||||
33891060|NCT05103150|||COHORT||CROSS_SECTIONAL|||||||
33891061|NCT04028037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Custom made computer-generated table provides the randomly allocation of experimental unit in the two groups.||t|f|t|t
33891062|NCT06075303|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The participating children will not be aware of the targets identified as easier or harder"|Children will engage in 4 weeks of treatment on easier targets and 4 weeks of treatment on harder targets. The order (easier first or harder first) will be counterbalanced across participants.|t|f|f|f
33891063|NCT02987855|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976475|NCT00536575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976476|NCT04488575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Fully blinded to the participants, investigator, and sponsor|Patients will be randomized to either the active (EDP1815) or placebo group (1:1 randomization), in addition to standard of care. Dosing will be initiated on a twice daily regime for the first 3 days (6 doses) and then once daily for the remaining 11 days (14 days total treatment course).|t|f|t|t
33976477|NCT02382666|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33976478|NCT00198081|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33976479|NCT02666274|||CASE_CONTROL||PROSPECTIVE|||||||
33976480|NCT02105376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976481|NCT05132413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1701/ Placebo Plus Chemotherapy With or Without Bevacizumab|t|t|t|t
33763396|NCT03263689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subjects were randomly assigned to a study group (intrathecal morphine - ITM group - or TAP - TAP group) by a computer random number generator. Patients were blinded to their study allocation. Those in the ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia. The TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.|The patients in the intrathecal morphine (ITM group) were given a sham block, while the patients in the TAP group were given a TAP block. Sham blocks consisted of a non-invasive ultrasound scan. A blunt needle was gently pressed on either side of the abdomen. Bilateral TAP blocks were placed after ultrasound location of the transversus abdominis and internal oblique muscles, with the injection sites in the Triangle of Petit located at the lateral edge of the mid-abdomen. Following negative aspiration for blood, the local anaesthetic (0.25% bupivacaine with 1:200000 epinephrine) was injected in the transversus abdominis plane under ultrasound visualization in 5 cc aliquots for a total volume of 15cc per side.|t|f|f|f
33763397|NCT02457416|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763398|NCT02224963|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33763399|NCT03780114|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763400|NCT05098106|||OTHER||PROSPECTIVE|||||||
33763401|NCT05291182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763402|NCT03120754|RANDOMIZED|PARALLEL||TREATMENT||NONE||SPSS statistical analysis system by the deputy director of our department physician, accepted treatment of 80 subjects (test group and control group) randomly arranged, which lists the serial number from 1 to 80 corresponding to the treatment assignment. In the experiment, 1 patients were divided into the exper||||
33763403|NCT02000739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763404|NCT00001060||||PREVENTION||DOUBLE||||||
33763405|NCT03323580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33763406|NCT05159401|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33763407|NCT00002802|NON_RANDOMIZED|||TREATMENT||||||||
33763408|NCT06439940|||COHORT||PROSPECTIVE|||||||
33763409|NCT02629835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33763410|NCT02150200|RANDOMIZED|PARALLEL||||NONE||||||
33763411|NCT00005837||||TREATMENT||||||||
33763412|NCT02729935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33763413|NCT00906048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763414|NCT03389360|||COHORT||RETROSPECTIVE|||||||
33763415|NCT03771196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763416|NCT03866668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763417|NCT03916601|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33763418|NCT02138643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763419|NCT02244164|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763420|NCT00594295|||COHORT||PROSPECTIVE|||||||
33763421|NCT05044325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891064|NCT03065829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Our model posits that effective caregiver self-management depends on analytic and emotional processing. The investigators hypothesize the ASSIST intervention will improve analytic processing by improving self-monitoring. ASSIST will expose subjects to mindfulness meditation training and promote self-awareness, which will aid the regulation of their emotional processing and improve proximal outcomes. The investigators expect proximal self-management outcomes to influence the distal outcomes of caregiver health. Our model will also test the mediating effects of decentering, processing, the hypothalamic-pituitary axis (HPA), inflammatory stress response, and cognitive mediators. The influence of potential moderators will be assessed for their effect on the relationship between the self-management intervention and the proximal and distal outcomes.|t|f|t|f
33891065|NCT03593915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763422|NCT00529321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763423|NCT00709059|||CASE_ONLY||PROSPECTIVE|||||||
33763424|NCT05152134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891066|NCT01816503|||COHORT||PROSPECTIVE|||||||
33891067|NCT00839631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891068|NCT00926926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33891069|NCT05033002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763425|NCT00147901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763426|NCT05900622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763427|NCT04642963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763428|NCT00722384|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763429|NCT00873236|RANDOMIZED|||DIAGNOSTIC||NONE||||||
33763430|NCT05936606|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to receive either standard clopidogrel monotherapy or tailored antiplatelet therapy at 12 months after DES implantation.||||
33763431|NCT01986361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074653|NCT03263026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Denovo Biopharma, the study Sponsor, will also be blinded.|"Subjects will be randomly assigned to receive one of the following: R-CHOP plus enzastaurin or R-CHOP plus placebo, during two treatment periods: induction and maintenance. Induction phase: all subjects will receive R-CHOP for up to six, 21-day cycles. Subjects in the enzastaurin arm will receive a 1125 mg loading dose on Day 2 followed by 500 mg daily. Subjects in the placebo arm will take an identical number of tablets.~After 4-\<6 cycles of induction therapy treatment assignment will be unblinded. Subjects in the enzastaurin arm who have achieved a response will have the opportunity to continue in the single-agent, maintenance phase of the study, and will receive single-agent enzastaurin at 500 mg/day for up to 2 years. Eligible subjects must begin the maintenance phase of the study within 6 weeks of completing induction therapy."|t|t|t|f
33763432|NCT03917992|||COHORT||PROSPECTIVE|||||||
34074654|NCT00527826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074655|NCT03619655|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34074656|NCT00303238|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34074657|NCT01421641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34074658|NCT03321201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgeons will not be blinded. All the other investigators, as well as study participants, outcome assessors and author that will analyze the data will be blinded.||t|f|t|t
34074659|NCT04554602|||CASE_CONTROL||PROSPECTIVE|||||||
34074660|NCT02600611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074661|NCT00152113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074662|NCT04710680|||CASE_ONLY||PROSPECTIVE|||||||
34074663|NCT03162185|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind||t|f|t|f
34074664|NCT05204147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074665|NCT03897569|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074666|NCT05383417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient will not be aware of their treatment arm. Investigator and Care Provider will be aware of treatment are but data analysis (outcomes assessor) will be blinded to treatment groups.|2 arm parallel trial where one group will receive the endotracheal tube clip during general endotracheal anesthesia and the other group will not.|t|f|f|t
34074667|NCT04210128|||COHORT||PROSPECTIVE|||||||
34074668|NCT05148637|RANDOMIZED|PARALLEL||OTHER||SINGLE|The methods of anesthesia were described to the enrolled patients preoperatively, but the patients were unaware about their group.|Montreal Cognitive Assessment (MoCA) were used to assess cognitive function the day before surgery and seventh postoperative day.|t|f|f|f
34074669|NCT05603585|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants and their legally acceptable representative will not be made known of the experimental arms that the participant is allocated to.|Eligible patients will be randomly assigned to receive either standard feeding or optimised protein feeding based on random permuted blocks with age (≥65 years or \< 65 years) and ICU site of recruitment as the stratification factors. The primary endpoint is difference in FSS between the two groups at Day 7.|t|f|f|f
34074670|NCT06611891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||25 patients: 25 patients with breast cancer labeled on the primary lesion ER+HER2-||||
34074671|NCT01911754|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074672|NCT02776072|||CASE_CONTROL||RETROSPECTIVE|||||||
34074673|NCT06285799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074674|NCT00642213|||COHORT||PROSPECTIVE|||||||
34074675|NCT00141414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074676|NCT04703010|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Longitudinal study with measures at birth and at age 2.||||
34074677|NCT01433419||PARALLEL||||||||||
34074678|NCT00361452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074679|NCT00107562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074680|NCT03666416|NA|SINGLE_GROUP||TREATMENT||NONE||This is a within-subjects design where participants complete outcome measures with and without exercise intervention.||||
34074681|NCT03735407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, Multi-center, Single-arm, safety study||||
34074682|NCT05179746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074683|NCT04330144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34074684|NCT04701450|||COHORT||PROSPECTIVE|||||||
34074685|NCT03703752|||CASE_ONLY||RETROSPECTIVE|||||||
34074686|NCT00914134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074687|NCT00738491|||CASE_CROSSOVER||PROSPECTIVE|||||||
34074688|NCT01967771|NA|SINGLE_GROUP||||NONE||||||
34074689|NCT02166359|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763433|NCT00890175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763434|NCT06175793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763435|NCT03076372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891070|NCT02236689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891071|NCT02811835|||COHORT||PROSPECTIVE|||||||
33891072|NCT03370679|||COHORT||PROSPECTIVE|||||||
33891073|NCT00825370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976482|NCT00836836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976483|NCT02975089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33976484|NCT03870997|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33891074|NCT06059586|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33976485|NCT01141725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891075|NCT05086679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891076|NCT01411787|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891077|NCT03392766|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33891078|NCT02060734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33891079|NCT04035044|||OTHER||PROSPECTIVE|||||||
33891080|NCT00510705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976486|NCT04792528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study personnel except for the PI, coaches and Study secretary will be blinded for group allocation regarding types of memory training.|Randomization in blocks of six to eight will be performed by the regional research support statistics service to either two training periods, one training period or generalized brain training/active control.|f|f|t|f
33976487|NCT02672553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976488|NCT04217278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976489|NCT00046813||||TREATMENT||DOUBLE||||||
33976490|NCT06210347|||COHORT||RETROSPECTIVE|||||||
33976491|NCT00940056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976492|NCT01349556|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33976493|NCT05611749|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will be randomized on the day of surgery in the preoperative area by the investigational pharmacist, who will be the only staff unblinded. The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment via 'Meds to Beds.'|Patients will be randomized to either a control group receiving a placebo (n=65) or a treatment group receiving 60 mg Duloxetine (a selective serotonin and norepinephrine reuptake inhibitor) (n=65). Surgeons, patients, research staff, PACU staff, and floor staff will be blinded to group allocation.|t|t|t|t
33976494|NCT05654909|||COHORT||RETROSPECTIVE|||||||
33976495|NCT06322927|||OTHER||CROSS_SECTIONAL|||||||
33976496|NCT02665897|||CASE_CONTROL||PROSPECTIVE|||||||
33976497|NCT01817881|||COHORT||PROSPECTIVE|||||||
34074690|NCT03455712|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Subjects to be enrolled into the intervention and standard-of-care groups depending on their gestational age at the time of consent during the expected 2 month period of enrollment. Any subject who is between 6 weeks 0 days and 14 weeks 6 days of pregnancy at the time of consent and who has had no prior prenatal visits will be enrolled in the intervention group. Any subject who is between 15 weeks 0 days to 22 weeks 6 days of pregnancy at the time of consent and who has had at least one prior prenatal visit will be enrolled in the control group.||||
34074691|NCT01488760|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33891081|NCT05792202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891082|NCT00238264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891083|NCT03903757|||CASE_CONTROL||PROSPECTIVE|||||||
34074692|NCT04167189|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|"The scoring of the lidocaine test is masked, using the coded identity of the tastes. The tastes will be assessed in random order. The subjects and other study personnel will be told not to discuss what the subject could or couldn't taste. Scoring will not be shared with the testing site until all testing is complete.~This is one of the last studies with an IRB for each arm and site. Hence it appears to be a single arm, but the other arms are separately registered with ClinicalTrials.gov"|Using a taste-based test before and after the application of lidocaine gel to the tongue, we will assess the degree to which lidocaine is effective at blocking taste in those with hard-to-treat ADHD||||
34074693|NCT03533231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074694|NCT06025604|||COHORT||RETROSPECTIVE|||||||
34074695|NCT03974282|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34074696|NCT00196105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074697|NCT00697593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891084|NCT05208229|||COHORT||PROSPECTIVE|||||||
33891085|NCT02291211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891086|NCT03120143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891087|NCT05264350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomised in proportions 2:1, Viiral® Nasal Spray group: Isotonic Saline Nasal Spray group. Block randomisation will be performed with varying block sizes. Numbered randomisation envelopes containing cards with code numbers will be prepared.|t|f|t|f
33891088|NCT04919915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891089|NCT03035760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891090|NCT05825248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be administered and scored by a masked examiner who is licensed to practice occupational therapy.|participants will be assigned to one of two groups. Each group will recieve the same minutes of treatment however one group will include reflex integration and one will include fine and gross motor intervention (standard OT treatment) only.|f|f|f|t
33891091|NCT04012749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistician blinded to study arm|Cluster randomized trial at the primary care clinic level|f|f|f|t
33891092|NCT02461017|||COHORT||PROSPECTIVE|||||||
33891093|NCT05934214|||CASE_ONLY||RETROSPECTIVE|||||||
33891094|NCT05448079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The sample was divided into intervention and control groups sexual counseling based on the PLISSIT model||||
33891095|NCT02856334|||COHORT||CROSS_SECTIONAL|||||||
33891096|NCT03309852|||COHORT||PROSPECTIVE|||||||
33891097|NCT00158184|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34074698|NCT00765739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074699|NCT06134661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074700|NCT00685360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074701|NCT00538226|NA|SINGLE_GROUP||||NONE||||||
34074702|NCT02824146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074703|NCT05989204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will take place in two parts: a Dose-Finding Phase to determine the maximum tolerate dose (MTD), followed by a Dose Expansion Phase. In the Dose-Finding Phase,up to 4 total dose levels will be evaluated using a 3+3 dose escalation design in order to determine the maximum tolerated dose. Both safety and manufacturing feasibility will then be used to identify the dose level that can be progressed into the Dose Expansion Phase.~This study will be initiated with a single disease-specific cohort (Cohort A: Non-Hodgkin Lymphoma). However, the study design allows for additional disease populations to be incorporated into the protocol as new cohorts in the future. Each disease-specific cohort will be evaluated independently for safety and dose-limiting toxicities (DLTs)."||||
34074704|NCT05816382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074705|NCT06612814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891098|NCT02243384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and researchers do not understand the test grouping, but the research designer arranges and controls all trials.||f|f|t|t
33891099|NCT01159262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891100|NCT03360773|||COHORT||OTHER|||||||
33891101|NCT04833439|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891102|NCT06112587|NA|SINGLE_GROUP||TREATMENT||NONE||A Single-Arm Open-Label Trial||||
33891103|NCT05838326|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33891104|NCT00001310|||COHORT||PROSPECTIVE|||||||
33891105|NCT02604004|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33891106|NCT01311778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33891107|NCT03304522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891108|NCT00110305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891109|NCT00002586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33891110|NCT03652922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891111|NCT01797718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891112|NCT05129449|||OTHER||PROSPECTIVE|||||||
33891113|NCT01629849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891114|NCT04003610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891115|NCT00851903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891116|NCT03083717|||CASE_CONTROL||PROSPECTIVE|||||||
33891117|NCT03282032|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33891118|NCT00037648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891119|NCT00205036|||||PROSPECTIVE|||||||
33891120|NCT05668221|||COHORT||PROSPECTIVE|||||||
33891121|NCT04134650|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Medications in both groups will be supplied in identical envelopes and by a person not involved in the study. Persons involved in the follow-up and outcomes measurements will be masked to the patient´s treatment allocation.|1:1 ratio allocation|t|t|t|t
33891122|NCT01891643|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33976498|NCT02337465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074706|NCT05434572|||OTHER||CROSS_SECTIONAL|||||||
34074707|NCT03959046|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patient participants will be seeing the same physician they usually see, and they won't know if their physician was assigned to GIST or not.||t|f|f|f
34074708|NCT06611592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33976499|NCT02946099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976500|NCT03565549|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double||t|f|f|t
33976501|NCT04068142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976502|NCT01493765|||OTHER||PROSPECTIVE|||||||
34074709|NCT02340143|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34074710|NCT01252407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074711|NCT02554045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891123|NCT04610255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891124|NCT01883141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891125|NCT02034123|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891126|NCT06179901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891127|NCT05022238|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34074712|NCT01941394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891128|NCT05338229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891129|NCT04222517|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33891130|NCT05024006|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adaptive design||||
33891131|NCT04603144|||COHORT||OTHER|||||||
33891132|NCT06196411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33891133|NCT04474730|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||In this study, we conduct a small randomized controlled trial to study the feasibility of an Apple Watch app developed to monitor bone marrow transplant patients' physical activities at their initial hospitalization.|f|f|f|t
33891134|NCT00567723|||COHORT||PROSPECTIVE|||||||
33891135|NCT04396587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33891136|NCT06503198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The VICTORY Trial is a multicenter, innovative clinical trial using an individual patient, parallel-arm randomized controlled trial design of 1,000 older patients living with frailty being discharged from hospital after elective surgery.|Individual patient, parallel-arm randomized controlled trial|f|f|f|t
33976503|NCT00133770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891137|NCT04857021|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33976504|NCT01161251|||COHORT||PROSPECTIVE|||||||
33976505|NCT03532009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976506|NCT04924309|||COHORT||PROSPECTIVE|||||||
33976507|NCT01173809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976508|NCT03065309||SEQUENTIAL||SUPPORTIVE_CARE||NONE|Participant will receive propofol before induction|Adaptative clinical trial, Dixon's Up-And-Down Method||||
33976509|NCT01000753|||CASE_ONLY||PROSPECTIVE|||||||
33976510|NCT02405195|||COHORT||PROSPECTIVE|||||||
33976511|NCT05431868|||COHORT||PROSPECTIVE|||||||
33976512|NCT00450307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976513|NCT00376220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891138|NCT02498210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891139|NCT04048512|||CASE_CONTROL||PROSPECTIVE|||||||
33891140|NCT05814445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891141|NCT05904587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33891142|NCT00030082||||TREATMENT||||||||
33891143|NCT03860506|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33891144|NCT02094599|NA|SINGLE_GROUP||||TRIPLE|||t|f|t|t
33891145|NCT05802030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891146|NCT06655987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891147|NCT05940675|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1||||
33891148|NCT00927485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891149|NCT05402384|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33891150|NCT01597947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891151|NCT01627418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33891152|NCT04239209|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants are randomized in a 1:1:1:1 ratio to view a video depicting one of four different ways intensivists answered a patient surrogate's prognostic question What do you think is most likely to happen? during a simulated ICU family meeting."||||
33891153|NCT03394638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891154|NCT00354302|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33891155|NCT05971797|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Randomized clinical trial in patients with depression or anxiety identified at prior psychological counseling prior to joint replacement surgery with or without comorbidities||||
33891156|NCT00484224|||DEFINED_POPULATION||OTHER|||||||
33891157|NCT02505984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891158|NCT06399783|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be divided randomly into three groups:~Group A: Patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months.~Group B: Patients will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.~Group C: Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of topical steroid."||||
33891159|NCT02113293|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891160|NCT01482702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33891161|NCT04355715|||COHORT||PROSPECTIVE|||||||
33891162|NCT05034640|||CASE_CONTROL||RETROSPECTIVE|||||||
33891163|NCT00870688|||||PROSPECTIVE|||||||
33891164|NCT01276288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891165|NCT03541473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33891166|NCT02566720|NA|SINGLE_GROUP||||NONE||||||
33891167|NCT03900780|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot RCT||||
33891168|NCT03662295|||CASE_ONLY||PROSPECTIVE|||||||
33891169|NCT01961531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891170|NCT04239846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891171|NCT00956826|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33891172|NCT02752828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891173|NCT05617170|||CASE_CONTROL||PROSPECTIVE|||||||
33891174|NCT03476044|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33891175|NCT03399461|||COHORT||CROSS_SECTIONAL|||||||
33891176|NCT01717638|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891177|NCT00507247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891178|NCT04724525|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33891179|NCT01724281|||COHORT||PROSPECTIVE|||||||
33891180|NCT04522492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two assessors will evaluate patients before and after the intervention, thru an online consultation and application of instruments to assess symptoms. The assessors will be blinded about the intervention received by the patient.|randomized clinical trial with the intervention consisting of cognitive behavioral therapy in an online setting, and the control consisting of an active control group (guidelines about strategies to improve quality of life).|f|f|f|t
33891181|NCT01888094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891182|NCT03424226|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Visually identical pills|Double blind randomized controlled trial|t|t|t|t
33891183|NCT01126905|||COHORT||PROSPECTIVE|||||||
33891184|NCT03688386|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization of mother infant pairs to a language curriculum with reading (intervention) or an infant bonding curriculum (control)||||
33891185|NCT00298103|||||RETROSPECTIVE|||||||
33976514|NCT06460714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separated treatment protocols and possible efforts will be put to mask the both groups about the treatment.|Randomized Control trial in which non-probability convenient sampling will be used. Both group of spastic CP of age 6 to 12 will be randomly divided. Group A will receive shockwave, stretching and orthosis. Group B will receive stretching and orthosis.|t|f|f|f
33891186|NCT03041727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a statistic techinician, with any knowledge about the group composition and the rehabilitative intervention.|Participants are assigned to one of two or more groups in parallel for the duration of the study are evaluated in parallel against a control group.|f|f|f|t
33891187|NCT06551623|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33891188|NCT05523934|||COHORT||RETROSPECTIVE|||||||
33891189|NCT00634231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891190|NCT01829126|||COHORT||PROSPECTIVE|||||||
33891191|NCT04561505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891192|NCT03596346|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double-blind|parallel-group|t|t|t|t
33976515|NCT03879200|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Recruitment of controls conducted meanwhile developing the intervention in collaborations with Somali born women, partners, midwives and project steering group.||||
33976516|NCT04375254|||COHORT||PROSPECTIVE|||||||
33976517|NCT00274703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976518|NCT04447638|||CASE_ONLY||RETROSPECTIVE|||||||
33976519|NCT03203148|||CASE_ONLY||PROSPECTIVE|||||||
33976520|NCT01652365|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976521|NCT04238767|||COHORT||PROSPECTIVE|||||||
33976522|NCT03457909|NA|SINGLE_GROUP||OTHER||NONE||||||
33976523|NCT04809181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33976524|NCT04419337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976525|NCT04442906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|anesthetist not sharing in the study will assess patient|analgesia for postoperative pain after knee arthroscopy: dexmedetomidine+bupivacaine, fentanyl+bupivacaine , bupivacaine|t|f|f|t
33976526|NCT03231670|||CASE_ONLY||PROSPECTIVE|||||||
33976527|NCT00963157|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33976528|NCT04655599|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33976529|NCT00989261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976530|NCT04303338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976531|NCT03272256|NA|SEQUENTIAL||TREATMENT||NONE||||||
33976532|NCT02222766|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33976533|NCT00522613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976534|NCT00006075||||PREVENTION||||||||
33891193|NCT03184948|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Hospitals (i.e., participants) receive the intervention (i.e., Brilliance phototherapy device) at different times in the study. In the first phase, a set of hospital facilities receive the device. After three months of using the device, another set of hospital facilities receive the device. And after an additional three months (approximately 6 months after the first set of hospitals implemented their device), all hospitals will have been provided with the intervention.||||
33891194|NCT03677674|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33891195|NCT04949893|||COHORT||RETROSPECTIVE|||||||
33891196|NCT05078489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891197|NCT01936740|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33891198|NCT00206973|||||OTHER|||||||
33891199|NCT04701125|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"Twenty-eight teams from the elite ice hockey leagues for males in Sweden were invited to participate in the study. Participating teams were given the option to be in the study group (receiving selective head-neck cooling after SRC) or the control group (standard SRC management). Any player with a suspected or diagnosed concussion was immediately removed from practice or game participation for further evaluation. Concussion diagnosis was established using the concussion in the sports consensus statement. At the time of SRC, any presence of red flags mandated the player to be taken to the hospital. As soon as the diagnosis of SRC was established the player was included in the study and players in the intervention teams were treated by selective head-neck cooling system for a minimum of 30 minutes. The primary endpoint of the study was the time (in days) from concussion until returning to full practice or game."||||
33976535|NCT03478059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976536|NCT05745298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976537|NCT01251926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976538|NCT02140450|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33891200|NCT00474916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891201|NCT04792229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891202|NCT03216993|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33891203|NCT00907075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891204|NCT00430118|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33891205|NCT00889096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33891206|NCT02016248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891207|NCT03812809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891208|NCT00057707|RANDOMIZED|CROSSOVER||OTHER||||||||
33976539|NCT00902551|||CASE_CONTROL||PROSPECTIVE|||||||
33976540|NCT00878254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976541|NCT01904786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976542|NCT01496040|NA|SINGLE_GROUP||||NONE||||||
33976543|NCT03338361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33976544|NCT04963465|||COHORT||PROSPECTIVE|||||||
33976545|NCT03960697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33976546|NCT04983121|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group: single arm study||||
33976547|NCT02380846|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33976548|NCT04566835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Assignment to the experimental and control groups was made by a person independent of the researcher. Two balls in different colours, red and white, were placed in a black bag. Assignment to the experimental and control groups was performed by randomly selecting the balls. The following steps:~Step 0: the first child selected the white ball and was included in the experimental group.~Step 1: a ball was selected randomly. Step 2: The child was assigned to the experimental group (E) if the ball was white, and to the control group (C) if the ball was red.~Step 3: A ball in the opposite colour of the selected ball was thrown into the bag (For instance; if the selected ball was red, a white ball was thrown into the bag).~Step 4: The process was repeated starting from Step 1. The researcher and the subjects did not know which subjects would fall into which group until the intervention was administered. In this way, the possible bias was prevented."||t|t|t|f
33976549|NCT03697421|||COHORT||PROSPECTIVE|||||||
33976550|NCT01421888|||||PROSPECTIVE|||||||
33976551|NCT02101632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33891209|NCT05147675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891210|NCT02476487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891211|NCT02722044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891212|NCT06354933|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33891213|NCT00000769||||TREATMENT||NONE||||||
33891214|NCT00457535|||DEFINED_POPULATION||PROSPECTIVE|||||||
33891215|NCT05091138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33891216|NCT00195650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891217|NCT04285060|NA|SINGLE_GROUP||OTHER||NONE||||||
33891218|NCT00486902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891219|NCT03759158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891220|NCT01587950|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891221|NCT00787293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891222|NCT01006343|RANDOMIZED|PARALLEL||PREVENTION||||||||
33891223|NCT02514044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33891224|NCT00572884|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891225|NCT00591734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891226|NCT05379387|||COHORT||RETROSPECTIVE|||||||
33891227|NCT04097548|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891228|NCT01106755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891229|NCT04444245|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976552|NCT03197402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|parallel group design (with repeated measurements within each group)|t|f|t|f
33976553|NCT02368613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976554|NCT04357275|||COHORT||PROSPECTIVE|||||||
33976555|NCT03464136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976556|NCT02627911|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976557|NCT03182179|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33976558|NCT02531932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976559|NCT03674710|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33976560|NCT05320263|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is planned to include a total of 480 patients (240 per am) to show with a 80% power an 12% increase in FPE rate at end of MT with contact aspiration technique, assuming 23 % of FPE in control arm, 5% of spontaneous recanalization and considering one interim futility analysis||||
33976561|NCT06484946|NA|SINGLE_GROUP||TREATMENT||NONE|Every participant participated in the aquatic group so the participant, care provider, and investigator were all aware of the intervention provided--therapy in the water.|Every participant receives the intervention. Each child participates in the 8-week aquatic group.||||
33891230|NCT05134909|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891231|NCT00346827||SEQUENTIAL||TREATMENT||DOUBLE||3-week, double-blind, placebo-controlled, 3 × crossover efficacy phase followed by 12 week open label phase, followed by 36 week open continuation phase|t|f|t|f
33891232|NCT03751293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891233|NCT06274593|||COHORT||PROSPECTIVE|||||||
33891234|NCT05152186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33891235|NCT04770766|||COHORT||OTHER|||||||
33891236|NCT04392193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891237|NCT01914679||SEQUENTIAL||TREATMENT||SINGLE|Participants did not know when the stimulation was occurring or not.|All participants went through a 4 week sham period, followed by a 12 week intervention with the device.|t|f|f|f
33891238|NCT01549301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891239|NCT03973814|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"The investigators will assess body temperature before-, during- and after Thermax blood warming treatment. Patients are essentially their own controls.~Moreover, we will use historic data on the previous blood warmer for the Prismaflex device to assess temperature changes."||||
33891240|NCT01138644|||CASE_ONLY||PROSPECTIVE|||||||
33891241|NCT03512535|||OTHER||PROSPECTIVE|||||||
33891242|NCT00820430|||CASE_CONTROL||PROSPECTIVE|||||||
33891243|NCT05415410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891244|NCT05522959|||COHORT||PROSPECTIVE|||||||
33891245|NCT02851264|||COHORT||PROSPECTIVE|||||||
33891246|NCT02619422|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891247|NCT06117189|||OTHER||CROSS_SECTIONAL|||||||
33891248|NCT00216034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891249|NCT03252782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm parallel-group||||
33891250|NCT03812510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891251|NCT02899663|||CASE_ONLY||RETROSPECTIVE|||||||
33891252|NCT03819075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical measurements will be performed by an evaluator unaware of group assignment.|Two groups; laser and control|f|f|f|t
33891253|NCT02595034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891254|NCT05657769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is conducted with the primary hypothesis that the diabetes treatment with Medwell intervention can significantly reduce the HbA1c level better than without Medwell intervention.||||
33891255|NCT00125047|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891256|NCT02600299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33891257|NCT01992029|||COHORT||PROSPECTIVE|||||||
33891258|NCT01875497|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33891259|NCT03415165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891260|NCT00904787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891261|NCT00064922||||TREATMENT||||||||
33891262|NCT01368796|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891263|NCT02479243|||CASE_CONTROL||PROSPECTIVE|||||||
33891264|NCT04666207|||COHORT||PROSPECTIVE|||||||
33891265|NCT05374486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891266|NCT02446392|||COHORT||PROSPECTIVE|||||||
33891267|NCT06124703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891268|NCT02743091|||CASE_ONLY||RETROSPECTIVE|||||||
33891269|NCT04223466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33891270|NCT01811914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891271|NCT01302704|||FAMILY_BASED||PROSPECTIVE|||||||
33891272|NCT05021809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blind allocation will be followed in the study .~* Group A: will not receive any intracanal medication.(control group)~* Group B :will recieve calcium hydroxide intracanal medication without iodoform (Metapaste)~* Group c: will receive calcium hydroxide intracanal medication with iodoform (Metapex)."||t|f|f|f
33891273|NCT04250584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891274|NCT02354833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891275|NCT02890719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891276|NCT00371267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891277|NCT06644989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single blinded study||t|f|f|t
33891278|NCT02229201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891279|NCT01865292|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891280|NCT05529654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891281|NCT05328947|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891282|NCT04387292|NA|SINGLE_GROUP||OTHER||NONE||||||
33891283|NCT01446211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891284|NCT00773487|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891285|NCT04739839|||COHORT||PROSPECTIVE|||||||
33891286|NCT03422822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891287|NCT05652426|||CASE_ONLY||RETROSPECTIVE|||||||
33891288|NCT05213871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33891289|NCT01859403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891290|NCT00422279|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33891291|NCT03036878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891292|NCT06386328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891293|NCT05124626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891294|NCT04076826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891295|NCT01725880|||COHORT||PROSPECTIVE|||||||
33891296|NCT04899908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891297|NCT05669690|||COHORT||PROSPECTIVE|||||||
33891298|NCT04836949|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33891299|NCT02312024|||CASE_ONLY||PROSPECTIVE|||||||
33891300|NCT03663452|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This project will use a cluster-randomized stepped wedge design in eight MHS behavioral health outpatient clinics. All sites first receive PE training, and are randomly allocated to receive the TACTICS intervention either 5, 10, or 15 months later.||||
33891301|NCT00260130|RANDOMIZED|CROSSOVER||||NONE||||||
33891302|NCT06195228|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891303|NCT05258227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double blinded as the assessors and the subjects of the study are kept blind towards the treatment group to which patients are allocated.||t|f|f|t
33891304|NCT03639376|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33891305|NCT00976755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891306|NCT04725682|RANDOMIZED|CROSSOVER||OTHER||NONE||a single-dose, randomized, open-label, four-period, two-sequence, two- treatment, single-center, crossover, bioequivalence study||||
33891307|NCT00646295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891308|NCT02628925|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33891309|NCT01246492|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33891310|NCT02292849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891311|NCT06559436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891312|NCT03766425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891313|NCT05738915|||CASE_CONTROL||RETROSPECTIVE|||||||
33891314|NCT02086019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891315|NCT06318884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891316|NCT01323296|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33891317|NCT02318056|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33891318|NCT05742867|||COHORT||PROSPECTIVE|||||||
33891319|NCT05411302|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Administrative data outcome assessors will be blinded to treatment group allocation by not involving them in discussions about study participants and not granting them access to the randomization code database.||f|f|f|t
33891320|NCT03542838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Except for the sentinel subject, the treatment assigned to each subject in the dose-escalation cohorts is blinded to the subject, investigators, and sponsor study team. The sentinel subject, the first subject in each dose-escalation cohort, is dosed with resiniferatoxin in an open-label fashion. Subjects in the dose-escalation cohorts who received placebo may receive resiniferatoxin in an open-label fashion after unblinding. All subjects in the dose-expansion cohorts are dosed with resiniferatoxin in an open-label fashion.||t|f|t|f
33891321|NCT04927273|||OTHER||CROSS_SECTIONAL|||||||
33891322|NCT02909153|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891323|NCT04275427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891324|NCT01676038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891325|NCT01978704|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891326|NCT05807308|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33891327|NCT01956006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891328|NCT02284165|||COHORT||RETROSPECTIVE|||||||
33891329|NCT06366776|||COHORT||RETROSPECTIVE|||||||
33891330|NCT05122325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind and concealed randomisation will be performed in assessment and data analysis. The assignment to groups will only be known by the main researcher who will be in charge of indicating in a sealed envelope to care providers and each participant the group to which participants have been assigned.|"Participants will randomize to three groups: an intervention group 1 contracted transcutaneous electrostimulation through the tibial nerve (n = 18), an intervention group 2 that occurred with genital vibration (n = 18) and a control group (n = 18)"|f|f|f|t
33891331|NCT06301360|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT with two treatment arms||||
33891332|NCT03669523|NA|SINGLE_GROUP||TREATMENT||NONE||National (French), multicenter, prospective, open, single-arm phase II study||||
33891333|NCT04604925|||COHORT||PROSPECTIVE|||||||
33891334|NCT02293109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891335|NCT01800721|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33891336|NCT05589142|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891337|NCT03542994|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The study is a double-blind dose escalation cohort study in healthy volunteers and participants with either mild to moderate psoriasis or mild to moderate atopic dermatitis. The study consists of 9 cohorts and will test doses of EDP1066 versus placebo. The safety and tolerability of EDP1066 will be tested in participants with psoriasis and atopic dermatitis alongside pharmacodynamic effects on the systemic immune system and observation of any clinical effects.|t|f|t|f
33891338|NCT05224778|||COHORT||PROSPECTIVE|||||||
33891339|NCT01264939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891340|NCT06261814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||No Data Available||||
33891341|NCT04179903|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33891342|NCT01151137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891343|NCT01147809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33891344|NCT00953394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891345|NCT01271686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891346|NCT03866200|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33891347|NCT00753389|||||PROSPECTIVE|||||||
33976562|NCT05705713|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976563|NCT01911494|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976564|NCT03336541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33976565|NCT02879279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976566|NCT05936749|||COHORT||RETROSPECTIVE|||||||
33976567|NCT03916952|||CASE_ONLY||PROSPECTIVE|||||||
33976568|NCT02889185|NA|SINGLE_GROUP||OTHER||NONE||||||
33976569|NCT00158119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33976570|NCT04042532|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33976571|NCT04695405|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33976572|NCT00215319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976573|NCT00277745|||COHORT||PROSPECTIVE|||||||
33976574|NCT03492359|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33891348|NCT05241158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The randomisation process was performed by a house officer who was not involved in performing any of the endoscopy procedures and was responsible to break the code in case of adverse event. The allocation sequence to the study conditions was kept concealed from psychologists measuring outcome variables, using sequentially numbered, opaque and sealed envelopes. Patients were told not to inform anyone about their allocation.|The patients were then randomly allocated between two groups (group 1 watched animated video of endoscopy procedure, however, group 2 didn't watch any video) on a 1:1 ratio using permuted block randomization with a fixed block sizes of four, by a house officer who wasn't involved in providing intervention to any group or in assisting any of the endoscopy procedures. The allocation sequence to the study conditions was kept concealed from psychologists measuring outcome variables, using sequentially numbered, opaque and sealed envelopes.|f|f|f|t
33891349|NCT03325764|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal study comparing data before bariatric surgery and one year after bariatric surgery||||
33891350|NCT01217502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33891351|NCT01413893|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763436|NCT04976114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As it is not possible for the participants to be blinded, they were asked not to mention to the assessment researchers (or other parents they could meet) what was the information they received, ensuring the researchers to remain blinded.|A randomised and blind clinical trial. The parents could be randomly assigned to the control group, and received the standard procedure, or to the experimental groups. Three experimental groups were possible regarding the various types of interventions: story book (IG1), video (IG2), or both instruments (IG3)|f|f|t|f
33763437|NCT03763955|||COHORT||OTHER|||||||
33763438|NCT01179360|||COHORT||PROSPECTIVE|||||||
33763439|NCT03620838|||COHORT||PROSPECTIVE|||||||
33763440|NCT04585438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation sequence generation: The co-supervisor who will assign the participants to either groups and will be the only one to know whether A or B represents the intervention or the control group. The principal investigator will enroll according to the previously mentioned eligibility criteria. The participant will drag an envelope and will be given a number. The patient will be allocated to either intervention or control group after contacting the co-supervisor to reveal the assigned group of the current patient according to the generated random sequence. The patient and the operator will not know the intervention done. The treatment groups will remain anonymous at the end of the study during assessment by the statistician.|Trial Design: Randomized Clinical Trial (Parallel Group) Two Arms Allocation Ratio: 1:1 Framework: Superiority|t|t|f|t
33763441|NCT03303469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763442|NCT02875405|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33763443|NCT02387892|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33763444|NCT05841238|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Part A open label. Part B double blinded.|||||
33763445|NCT05798039|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33891352|NCT04429022|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective cohort with retrospective controls||||
33891353|NCT00925847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891354|NCT04947293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891355|NCT00457405|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891356|NCT06657495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three arms: basic dose, 1.5 basic dose and placebo|t|f|t|f
33891357|NCT02867306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891358|NCT01761734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33891359|NCT01847287|||CASE_ONLY||PROSPECTIVE|||||||
33891360|NCT03602092|||COHORT||PROSPECTIVE|||||||
33891361|NCT00268814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891362|NCT01843010|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33891363|NCT02658461|||COHORT||PROSPECTIVE|||||||
33891364|NCT04598542|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33891365|NCT01463254|||||PROSPECTIVE|||||||
33891366|NCT03069911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891367|NCT04975958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891368|NCT02443402|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33891369|NCT03827161|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33763446|NCT00737386|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33891370|NCT06321575|NA|SINGLE_GROUP||TREATMENT||NONE||The investigation is a prospective, multicenter, non-randomized, single-arm, open-label pivotal clinical study.||||
33891371|NCT01453504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891372|NCT06564454|||OTHER||CROSS_SECTIONAL|||||||
33891373|NCT01116193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891374|NCT04766853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33891375|NCT03330327|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891376|NCT04970329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participant and investigator will be masked about the treatment options.|96 eyes will be divided into 3 groups (32 eyes each) and will be provided intervention which is Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. , Dextran 0.1%Hypromellose 0.3%, and placebo(normal saline)|t|f|t|f
33891377|NCT01221857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891378|NCT02882607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891379|NCT00004373||||TREATMENT||||||||
33891380|NCT00002025||||TREATMENT||NONE||||||
33891381|NCT05328050|||COHORT||OTHER|||||||
33891382|NCT04684199|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891383|NCT01564784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891384|NCT01725139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891385|NCT04911387|||COHORT||PROSPECTIVE|||||||
33891386|NCT04996056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891387|NCT06153147|||COHORT||PROSPECTIVE|||||||
33891388|NCT00628355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33891389|NCT01943656|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33976575|NCT02247479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976576|NCT03562442|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups are recruited in parallel (A) Smokers who quit smoking (Visit 1 before cessation, Visit 2 six weeks after cessation) (B) Never-smokers (Visit 1 only)||||
33976577|NCT03082274|||CASE_ONLY||PROSPECTIVE|||||||
33976578|NCT05256628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Neither the patient nor their surgeon will be blinded. However, outcome assessors will be blinded throughout the duration of the study. Assessors will screen for complications at follow-up visits.||f|f|f|t
33976579|NCT00446732|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33976580|NCT00439075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976581|NCT00964626||||TREATMENT||NONE||||||
33976582|NCT06546215|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33976583|NCT02052245|||COHORT||PROSPECTIVE|||||||
33976584|NCT00139321|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976585|NCT06046664|NA|SINGLE_GROUP||OTHER||NONE||||||
33976586|NCT04166708|||CASE_ONLY||OTHER|||||||
33976587|NCT01978678|||COHORT||PROSPECTIVE|||||||
33976588|NCT04807842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blinded, randomized placebo controlled.|t|t|t|t
33976589|NCT01699607|NA|SINGLE_GROUP||OTHER||NONE||||||
33976590|NCT05925790|||COHORT||PROSPECTIVE|||||||
33976591|NCT06044181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976592|NCT05130892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976593|NCT02287168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891390|NCT01212445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891391|NCT00680030|||CASE_ONLY||PROSPECTIVE|||||||
33976594|NCT02141100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891392|NCT03590860|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Part C will be open label||t|f|t|f
33891393|NCT00000402|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33891394|NCT05574140|||CASE_CONTROL||PROSPECTIVE|||||||
33891395|NCT06590116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976595|NCT05749627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976596|NCT03972566|||CASE_CONTROL||RETROSPECTIVE|||||||
33976597|NCT06496919|||COHORT||RETROSPECTIVE|||||||
33976598|NCT04721756|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976599|NCT01564433|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33976600|NCT05803018|NA|SEQUENTIAL||TREATMENT||NONE||||||
33976601|NCT05292742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976602|NCT02014974|||COHORT||PROSPECTIVE|||||||
33891396|NCT05900115|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be informed which condition they are assigned (intervention or active control). All measures are assessed using a web-based data collection system rather than a human outcomes assessor.||t|f|f|t
33891397|NCT02626728|||COHORT||PROSPECTIVE|||||||
33891398|NCT04492904|||CASE_CONTROL||OTHER|||||||
33891399|NCT03806244|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891400|NCT06601712|RANDOMIZED|PARALLEL||PREVENTION||NONE||A multi-centre cluster randomized implementation trial with three arms at health facilities and their catchment communities (clusters) to enhance end-user adherence to post-discharge malaria chemoprevention (PDMC) compared to a control arm of PDMC without specific adherence support strategies.||||
33891401|NCT06484166|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891402|NCT05676710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891403|NCT03856957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891404|NCT02828176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891405|NCT04080206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891406|NCT02570451|||COHORT||PROSPECTIVE|||||||
33891407|NCT00853983|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891408|NCT04654312|RANDOMIZED|PARALLEL||OTHER||DOUBLE||National, prospective, single-center, double-blind, parallel group, randomized, controlled, interventional Trial.|t|f|t|f
33891409|NCT04407377|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891410|NCT02331576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891411|NCT06568094|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||HRS-5041 tablets combined with antitumor therapy||||
33891412|NCT01412879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976603|NCT02773836|||COHORT||PROSPECTIVE|||||||
33976604|NCT00930865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976605|NCT02755779|||COHORT||PROSPECTIVE|||||||
33976606|NCT05718609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976607|NCT03202225|||COHORT||RETROSPECTIVE|||||||
33976608|NCT03706638|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment groups are blinded and becomes unmasked when assigning the patient to a treatment group. At this time, the patient and the investigator becomes aware of the treatment assigned.|Randomized Noninferiority Trial||||
33891413|NCT04567563|RANDOMIZED|PARALLEL||TREATMENT||NONE||Will have intervention group and standard of care group||||
33891414|NCT02610985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891415|NCT02811744|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976609|NCT05042856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976610|NCT03630666|RANDOMIZED|PARALLEL||TREATMENT||NONE||phase 3 study, randomised, open||||
33976611|NCT01361126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976612|NCT03286582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976613|NCT03890185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763447|NCT03397680|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants with positive rapid urease test or pathologic findings were divided into 2 groups and enrolled into randomization with 1:1 block of four methods. Each participant in group1 received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.~Meanwhile, each participant in group2 received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal."||||
33891416|NCT04177303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All pills will be provided as effervescent, pre-scored 1000mg tablets, so that they may easily be dichotomized.Boxes with active drug or placebo will be covered to conceal the identity of the test article. Sponsor will provide covering materials.The unblinded designee will provide the covered boxes to the blinded nurse or blinded investigator who will dispense the pills.Participants will be given study drug diaries, which they will complete during study drug intake.|Pilot, mechanistic, phase 3, randomized, placebo-controlled, parallel designed, double-blinded clinical trial|t|f|t|f
33891417|NCT02892136|||COHORT||PROSPECTIVE|||||||
33891418|NCT03664726|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Participants will be assigned to complete an episodic future or recent thinking task and asked to describe positive events for different time periods.||||
33976614|NCT03340168|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33976615|NCT06141096|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33976616|NCT05103722|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33976617|NCT02536378|||CASE_ONLY||PROSPECTIVE|||||||
33976618|NCT05533346|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976619|NCT06441435|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976620|NCT03917771|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|randomization according to system of envelopes with code|Recruitment Process: patients will be selected consecutively and offered to participate in the study|f|f|f|t
33976621|NCT06088771|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1b of the study will consist of a safety run-in phase following a modified 3+3 design without dose escalation using the treatment administration plan in protocol patients will be enrolled and monitored for dose-limiting toxicities (DLTs), from the start of treatment up to 30 days following the administration of dupilumab. Patients will be entered in escalating cohorts of 3 patients.||||
33976622|NCT06284525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976623|NCT00218179|||CASE_CONTROL||RETROSPECTIVE|||||||
33976624|NCT00514137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976625|NCT06322407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|f|f|f|t
33976626|NCT03627936|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33976627|NCT03942523|NA|SINGLE_GROUP||PREVENTION||NONE||Behavior change communication sessions will be administered to school children belonging to 1-5 grades in schools||||
33976628|NCT06526962|||CASE_CONTROL||PROSPECTIVE|||||||
33976629|NCT03862248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891419|NCT01390389|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33891420|NCT00384579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891421|NCT02785809|||COHORT||PROSPECTIVE|||||||
33891422|NCT00448461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891423|NCT03094130|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis|Two arms, parallel group, randomized controlled trial|t|f|f|f
33763448|NCT04256109|||OTHER||CROSS_SECTIONAL|||||||
33763449|NCT04402463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"the evaluator (investigator who will carry out the measurements) and the results analysis consultant will be masked.~After second pre-intervention assessment, the physiotherapist who will apply the interventions will carry out the allocation. Randomization will be done using a computerized randomization system (randomized.com), and concealment of allocation will be ensured by sequentially numbered, opaque, sealed envelopes."||f|f|t|t
33763450|NCT02820363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763451|NCT02385734|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33763452|NCT00497640|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33763453|NCT01529281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763454|NCT05094401|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Pragmatic||||
33763455|NCT04534634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763456|NCT01423422|||CASE_CONTROL||PROSPECTIVE|||||||
33891424|NCT01966731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||After enrollment, a two-month screening phase was used to perform baseline evaluations including nutritional and infectious assessments, along with supplements and treatments as deemed necessary by local guidelines (e.g., penicillin, pneumococcal immunization, Vitamin A and albendazole/mebendazole treatment per WHO recommendations, malaria prophylaxis, and iron/folate supplementation)||||
33891425|NCT02421393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891426|NCT03777514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The IV bags will be opaque and patients will be asked to wear a eye mask during the infusion of iron vs. saline.~The oral tables will be identical in color and shape (iron in the form of ferrous sulphate and vitamin C)"|"The study is a randomized, comparative double blind, double dummy study to evaluate efficacy and time course of treatment response of bariatric surgical patients found to have IDA, three months or greater following bariatric surgery (Roux-en Y gastric bypass and vertical sleeve gastrectomy) over 6 weeks with a 46-week follow-up extension. Two medications and placebos will be used with equal random assignment to both groups~* Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.~* Ferrous sulfate 325 mg (oral) tabs morning and evening.~* Placebo: oral vitamin C 500 mg tabs, saline infusion"|t|t|t|t
33891427|NCT04144972|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|There will be assigned active intervention and non-active intervention periods for each patient throughout Phase 2 and 3 of the study. The participant will not know if he/she is in the active or non-active period of the phase.|All participants will participate in the Stage 0, in-clinic evaluation period to assess potential effectiveness of trial. A subset of those enrolled will proceed into the rest of the Stages (1-3).|t|f|f|f
33891428|NCT01225341|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33891429|NCT01972321|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33891430|NCT06372717|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891431|NCT02270567|||COHORT||PROSPECTIVE|||||||
33976630|NCT02583620|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33976631|NCT03060005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976632|NCT06132646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be anonymized with a number and randomized with a web program (random.org)||t|f|f|f
33976633|NCT00447135|||||RETROSPECTIVE|||||||
33976634|NCT05640453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976635|NCT06381063|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33976636|NCT06403865|||OTHER||PROSPECTIVE|||||||
33891432|NCT04871815|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will be monitored for 1 week without intervention to obtain a baseline for signs and symptoms associated with COVID19 Long Haulers. All subjects will then be monitored for an additional week for signs and symptoms of COVID19 Long Haulers while using the N115 sodium pyruvate nasal spray 3x daily for that week.||||
33976637|NCT05802966|||COHORT||PROSPECTIVE|||||||
33976638|NCT01195259|||COHORT||RETROSPECTIVE|||||||
33976639|NCT00812253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976640|NCT05017584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33976641|NCT04078451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976642|NCT02679482|||CASE_CONTROL||PROSPECTIVE|||||||
33976643|NCT04800653|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33976644|NCT02285127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891433|NCT01046812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891434|NCT01442025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891435|NCT03434821|||OTHER||PROSPECTIVE|||||||
33976645|NCT04901000|||COHORT||RETROSPECTIVE|||||||
33976646|NCT04029675|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Double blinded ,Prospective, Randomized clinical trial|t|t|t|t
33976647|NCT01584908|||COHORT||PROSPECTIVE|||||||
33976648|NCT04281680|||CASE_CONTROL||RETROSPECTIVE|||||||
33976649|NCT01686841|NA|SINGLE_GROUP||OTHER||NONE||||||
33976650|NCT05147051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074713|NCT04275258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The team member that coordinates subject's follow-up survey completion after hospital discharge will be masked.~Team members involved with outcome analysis will be masked.~."|The investigators will use a randomized controlled trial design. Patients taking opioids prior to trauma are at an increased risk for adverse opioid outcomes, therefore we will stratify randomization so that the intervention and control groups are half opioid exposed and half opioid naïve at the time of trauma, Patients with any prescription opioid use in the 30 days prior to trauma will be considered opioid-exposed, while those with no prescription opioid use in the prior 30 days will be considered opioid naïve.|f|f|f|t
34074714|NCT04227418|||COHORT||PROSPECTIVE|||||||
34074715|NCT05395871|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The screening services will not have access to the allocation of participants and will be masked. They will not be able to determine which messages are being sent to different women being invited to screen, as allocation will be undertaken by the third party messaging company following provision of a screening invitation list by the service.|3 arm randomised controlled trial|f|t|f|f
34074716|NCT05117112|NA|SINGLE_GROUP||SCREENING||NONE||Three groups of subjects will be studied: young/health, older/healthy, and older/sarcopenic.||||
34074717|NCT03743766|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the 4-week lead-in phase, subjects will be randomized to one of three arms for 1 cycle (4 weeks) of lead-in treatment with nivolumab, relatlimab, or the combination of nivolumab and relatlimab. Following 1 cycle of lead-in treatment, all subjects will be treated with the combination of relatlimab and nivolumab every 4 weeks.||||
34074718|NCT02975817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34074719|NCT05728333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34074720|NCT01481415|||||RETROSPECTIVE|||||||
34074721|NCT06024811|||CASE_CONTROL||PROSPECTIVE|||||||
34074722|NCT06164938|||COHORT||PROSPECTIVE|||||||
34074723|NCT03143101|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
33891436|NCT06231017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891437|NCT00610636|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33976651|NCT03012477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074724|NCT01766531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074725|NCT04587141|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three iron supplementation regimens will be compared in terms of effectiveness and safety in the treatment of IBD-associated IDA. Primary outcome is the relative effectiveness of an oral iron supplementation regimen compared with two iv iron regimens.||||
34074726|NCT02223351|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33763457|NCT03859401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976652|NCT05867355|||COHORT||PROSPECTIVE|||||||
33976653|NCT00423956|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33976654|NCT04390828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33976655|NCT03783208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976656|NCT00914888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976657|NCT00177593|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976658|NCT04597086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763458|NCT03704584|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, unblinded controlled clinical trial||||
33763459|NCT05813067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, double-blinded, placebo-controlled, parallel|t|t|t|t
33763460|NCT05582551|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33763461|NCT04045821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763462|NCT01352585|||CASE_ONLY||PROSPECTIVE|||||||
33763463|NCT05996328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Due to the nature of the intervention, participants, dietitians, and site coordinators can't be blinded. However, the investigators and outcome assessors will be blinded|Two-arm study: active intervention vs study-defined standard of care|f|f|t|t
33763464|NCT03145571|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Specific output monitored in villages where the program had been implemented, and where it was not implemented||||
33763465|NCT04264793|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster Randomized Trial||||
33763466|NCT01954368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763467|NCT05751031|||COHORT||PROSPECTIVE|||||||
33763468|NCT03653507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763469|NCT00285493|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763470|NCT05493423|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763471|NCT00087542|RANDOMIZED|||TREATMENT||DOUBLE||||||
33763472|NCT03881280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33763473|NCT01478074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763474|NCT05075187|||CASE_ONLY||PROSPECTIVE|||||||
33763475|NCT01020500|||COHORT||PROSPECTIVE|||||||
33763476|NCT04859660|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33891438|NCT01766648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891439|NCT05532397|NA|SINGLE_GROUP||TREATMENT||NONE||This is an interventional, non-randomized, open-label study. Enrolled subjects will receive QPOP-guided chemotherapy at the time of first high grade astrocytic glioma recurrence.||||
33891440|NCT02758964|||COHORT||PROSPECTIVE|||||||
33891441|NCT01364987|NA|SINGLE_GROUP||||NONE||||||
33891442|NCT00379327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891443|NCT00123084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976659|NCT03997448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976660|NCT05722600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33763477|NCT03611504|||COHORT||RETROSPECTIVE|||||||
33763478|NCT04214119|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763479|NCT05673590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763480|NCT05135546|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Patients and study investigators will be blinded to subject treatment|"At clinical centers, patients will be randomly distributed by the envelope method into two groups to receive Fortelyzin® or placebo.~The drugs will be administered after the signed informed consent. Fortelyzin® will be administered by inhalation of a dose of 15 mg."|t|t|t|f
33763481|NCT05455437|||OTHER||PROSPECTIVE|||||||
33763482|NCT04804995|||COHORT||PROSPECTIVE|||||||
33763483|NCT02002884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891444|NCT05090956|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891445|NCT01740336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891446|NCT02522637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976661|NCT03593382|||COHORT||CROSS_SECTIONAL|||||||
33976662|NCT00011297|RANDOMIZED|||TREATMENT||DOUBLE||||||
33976663|NCT05730686|||CASE_ONLY||OTHER|||||||
33976664|NCT02592148|||COHORT||CROSS_SECTIONAL|||||||
33891447|NCT01293617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891448|NCT06227832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891449|NCT05300048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891450|NCT01276886|||COHORT||PROSPECTIVE|||||||
33891451|NCT03270748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891452|NCT03471455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33976665|NCT05045209|||CASE_ONLY||PROSPECTIVE|||||||
33976666|NCT01415466|RANDOMIZED|CROSSOVER||||NONE||||||
33976667|NCT00280267|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33891453|NCT01920906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763484|NCT04935814|NA|SEQUENTIAL||BASIC_SCIENCE||NONE|"Patients are under general anesthesia and outcomes assessor (statistician) will be blinded of patients positions orders.~Sequential positions of patients will be randomized."|CORVaso is a pharmacological trial which aims to determine the variations of cardiac output during vasopressin infusion in major abdominal surgery patients.||||
33763485|NCT00048880||||TREATMENT||||||||
33763486|NCT02497898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763487|NCT03690830|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two case groups (Recurrent Implantation Failure and idiopathic recurrent pregnancy loss ) One control group (patients undergoing Assisted ReproductiveTechnologies (ART) for male factor infertility)||||
33763488|NCT04749082|||OTHER||RETROSPECTIVE|||||||
33763489|NCT00412048|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763490|NCT00934869|||COHORT||PROSPECTIVE|||||||
33763491|NCT01581840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763492|NCT02801669|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33763493|NCT03933111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard to divide the patients into pancreatic cancer and pancreatic cancer group.||||
33763494|NCT02932059|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763495|NCT03784690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33763496|NCT03036059|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33763497|NCT04748016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are randomly assigned to either one of the interventional arm and will not be informed of the randomisation result.~A blinded reviewer will assess the postoperative radiographs and surgical quality."|Double-blind randomised control trial with 40 patients in two interventional arm|t|f|f|t
33891454|NCT05021926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blinded (blinded evaluator and subject) study and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.|Pivotal, prospective, active-controlled, randomized, double blinded (blinded evaluator and subject), intra-individual split-face comparison, non-inferiority study|t|f|f|t
33891455|NCT03584009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891456|NCT00849589|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33891457|NCT01207466|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33891458|NCT06246383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33891459|NCT06585306|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33891460|NCT01381081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891461|NCT00227058|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33891462|NCT05247411|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33891463|NCT00432237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891464|NCT02041559|||COHORT||RETROSPECTIVE|||||||
34074727|NCT03092570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891465|NCT01552876|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33976668|NCT04371809|||CASE_CONTROL||PROSPECTIVE|||||||
33976669|NCT00769106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976670|NCT01617577|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33976671|NCT03882320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976672|NCT06263322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Participants are masked to whether their PGHD are being sent to their care provider. Care providers are masked to who receives standard of care. Investigators (except for one who will be the point person for randomization) will be masked to intervention assignments. Staff assessors will be masked to whether PGHD are being sent to their care provider.|Parallel Randomized Clinical trial. Comparison study to test the feasibility of patient generated health data compared to standard of care post-surgical observation.|t|t|t|t
33976673|NCT03769480|||COHORT||PROSPECTIVE|||||||
33976674|NCT00340548|||COHORT||PROSPECTIVE|||||||
34074728|NCT04814589|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33976675|NCT04790084|||OTHER||PROSPECTIVE|||||||
34074729|NCT02759094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891466|NCT03360812|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33891467|NCT06090071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phyto A+ Brightening Treatment and placebo moisturizer will be labeled as Study Product A or Study Product B. Subjects, delegated site staff, or investigators will not know which product is applied to either side of the face.|Split-Face study design. Phyto A+ Brightening Treatment and placebo moisturizer will be randomized regardless of Fitzpatrick Skin Type (FST). Subjects will be assigned to a laser treatment based on their Fitzpatrick Skin Type, as determined by the Investigator. Subjects with FST I-III will receive the Sciton laser procedure. Subjects with FST IV-VI will receive LaseMD laser procedure. Half of the face will be treated with Phyto A+ Brightening Treatment and assigned laser treatment. The other half of the face will be treated with placebo moisturizer and assigned laser treatment.|t|f|t|f
33891468|NCT04247048|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Kinetic study of lipoprotein metabolism with stable isotope tracers.||||
33891469|NCT03228368|||CASE_ONLY||PROSPECTIVE|||||||
33891470|NCT02661984|||COHORT||PROSPECTIVE|||||||
33891471|NCT00662961|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33891472|NCT02296411|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891473|NCT00519870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891474|NCT06487156|||COHORT||PROSPECTIVE|||||||
33891475|NCT03784196|||CASE_CONTROL||PROSPECTIVE|||||||
33891476|NCT00401440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891477|NCT01608425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763498|NCT03440502|||CASE_CONTROL||PROSPECTIVE|||||||
33763499|NCT04302623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33891478|NCT05439031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891479|NCT02340650|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976676|NCT00617461|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33976677|NCT05131906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976678|NCT05934201|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976679|NCT04296357|||COHORT||PROSPECTIVE|||||||
33976680|NCT02234609|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33763500|NCT02269371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976681|NCT03629925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976682|NCT00810368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976683|NCT04456361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976684|NCT01002690|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33763501|NCT05034848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||observational, interventional, non comparative, prospective, monocentric open study||||
33763502|NCT04551599|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This will be 2-part study. Part 1 will be a randomized, 2-sequence, 2-period crossover study, and Part 2 will be a 1-period study.||||
33763503|NCT01721265|||COHORT||PROSPECTIVE|||||||
33976685|NCT03321565|||COHORT||CROSS_SECTIONAL|||||||
33976686|NCT04130789|||CASE_CONTROL||PROSPECTIVE|||||||
33763504|NCT01320943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763505|NCT05529160|||CASE_ONLY||PROSPECTIVE|||||||
33763506|NCT05799326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763507|NCT03192644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976687|NCT00145938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763508|NCT00374660|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763509|NCT05732792|||COHORT||PROSPECTIVE|||||||
33763510|NCT04962399|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763511|NCT02717169|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763512|NCT03572660|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm intervention study||||
33891480|NCT04453111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: HA + stem cells therapy Experimental Group 1: three intra-articular injection of allogeneic P-MMSCs with up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients Experimental Group 2: three intra-articular injection of autologous BM-MMSCs up to 2•107cells (target dose up to 6•107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients Control Group: three intra-articular injection of 20 mg Hyaluronic Acid, no cell therapy - 15 patients||||
33891481|NCT00550498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891482|NCT00452712|||DEFINED_POPULATION||PROSPECTIVE|||||||
33891483|NCT02183714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891484|NCT05973370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized, prospective, placebo-controlled study that will be conducted on 60 patients who fulfill the selection criteria and will be classified randomly into two groups.|t|f|t|f
33891485|NCT02436109|||COHORT||PROSPECTIVE|||||||
33891486|NCT06656104|||OTHER||PROSPECTIVE|||||||
33891487|NCT06335121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33891488|NCT04873687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessor and study statistician will not be aware of intervention assignment|The intervention will be administered to eligible stable angina pectoris patients Dr. Hasan Sadikin General Hospital in a randomized manner neither of experiment or control group.|f|f|f|t
33891489|NCT06657586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33891490|NCT06488404|||CASE_ONLY||CROSS_SECTIONAL|||||||
33891491|NCT05805514|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a community based randomized cobtrolled trial. Participants, care provider and investigator will know the intervention. Outcomes assessor (e.g. Anthrpometric measurer and psychosocial stimulation evaluator) will not know about the participant allocation and major outcome of the intervention.|We will perform a post hoc test, which will enable us to examine the difference between various group means while simultaneously controlling for the family-wise error rate, to determine precisely which groups are distinct from one another. We will use linear mixed models for continuous outcomes (e.g. Bayley scores) and generalized linear mixed models for non-continuous outcomes (e.g. logistic mixed models for binary outcomes). Models will include a fixed effect, children as a random effect to account for the repeated measurements, and community-cluster as a random effect to account for the cluster effect. The models will be able to evaluate the impact of the interventions over time by testing for an interaction between time and intervention group. Analyses will be conducted to identify the baseline characteristics of mother-infant dyads who may benefit most from the intervention. Model assumptions will be checked and appropriate adjustments to the analysis will be made where necessary.|f|f|f|t
33976688|NCT00006052||||TREATMENT||||||||
33976689|NCT03842943|NA|SINGLE_GROUP||OTHER||NONE||||||
33976690|NCT05960864|||COHORT||PROSPECTIVE|||||||
33976691|NCT04604184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976692|NCT06157086|||COHORT||PROSPECTIVE|||||||
33976693|NCT05159661|||OTHER||PROSPECTIVE|||||||
33976694|NCT02991547|||COHORT||PROSPECTIVE|||||||
33763513|NCT06129253|||OTHER||OTHER|||||||
33763514|NCT04837872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763515|NCT02335151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763516|NCT01177514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33763517|NCT00182962|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33763518|NCT01187914|||COHORT||RETROSPECTIVE|||||||
33763519|NCT05537402|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomly assigned to one of two study arms:~Arm A: Atezolizumab and bevacizumab or Arm B: Locoregional therapy with TACE or TARE as determined by local site. Randomization will occur on 1:1 ratio through permuted-block randomization method and will be stratified."||||
33763520|NCT05235620|||COHORT||PROSPECTIVE|||||||
33763521|NCT03146039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763522|NCT01273428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33763523|NCT03082716|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Blinding :~Surgeons will know the type of cardioplegia in the OR while other assessor will be blinded ."|"Randomisation :~Computer generated randomisation into two groups based on cardioplegia solution .~if randomised to blood patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.~if randomised to custodial patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested."|t|f|t|t
33763524|NCT06539975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Allocation concealment is the use of sequentially numbered,opaque,sealed envelopes.|The study will be a douple-centered, serially-numbered closed opaque envelope, randomised clinical trial.|f|f|t|f
33763525|NCT06183814|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
33763526|NCT04667364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891492|NCT02183454|||COHORT||PROSPECTIVE|||||||
33891493|NCT00046722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891494|NCT04626063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891495|NCT03114449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891496|NCT06657053|||COHORT||PROSPECTIVE|||||||
33891497|NCT04657848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891498|NCT04673058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|2 staff members who will administer the treatment to active intervention and sham therapy groups will not be able to be blinded due the inherent of manual therapy. Staff members who are responsible for statistical analysis, participants and outcome assessors will be blinded.|Prospective, triple-blinding, randomized controlled and 3-arm parallel group design clinical study. 3 arms of the study were planned to consist of active intervention group, sham treatment group and no intervention group.|t|f|t|t
33891499|NCT01649700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891500|NCT04404335|||COHORT||PROSPECTIVE|||||||
33891501|NCT00289705|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976695|NCT06378619|||CASE_CROSSOVER||PROSPECTIVE|||||||
33976696|NCT01030965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976697|NCT03576391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The researcher that will perform the EMG-analysis, i.e. onset determination of the various muscles that were measured, will be blinded for participant, condition and muscle during that process.|Each participant will perform all 3 experimental conditions spread out over 2 test days. At test day 1 the control condition is performed. Test day 2 follows at least 5 days after the 1st one in order to make sure participants are physically and mentally recovered as the protocol at test day 1 might induce some physical or mental fatigue. On test day 2 the other 2 conditions are tested in a randomised order: either first the physical fatigue condition, followed by the cognitive fatigue condition or vice versa.|f|f|f|t
33976698|NCT05283681|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33976699|NCT05813587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976700|NCT03281499|NA|SINGLE_GROUP||TREATMENT||NONE|No masking will be used in this study for both participants and the study team|There will only be a single group of participants in this study||||
33891502|NCT06083909|||OTHER||PROSPECTIVE|||||||
33976701|NCT00806156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976702|NCT04491409|||COHORT||PROSPECTIVE|||||||
33976703|NCT04626999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976704|NCT03192774|||COHORT||PROSPECTIVE|||||||
33976705|NCT06021977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976706|NCT02419690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976707|NCT04041609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976708|NCT05305274|||COHORT||RETROSPECTIVE|||||||
33763527|NCT02261584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763528|NCT05765760|||COHORT||PROSPECTIVE|||||||
33763529|NCT00910455|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33891503|NCT05085899|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33891504|NCT04271462|||CASE_CROSSOVER||PROSPECTIVE|||||||
33891505|NCT01986530|||COHORT||PROSPECTIVE|||||||
33891506|NCT03295825|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891507|NCT03226990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The measurements are done on the day of denture insertion with no follow up timing intervals|t|f|f|t
33891508|NCT00785577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891509|NCT00319514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891510|NCT02815215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891511|NCT04774003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a participant, investigator and sponsor blinded, randomized study|This is a placebo-controlled study of inclisiran sodium given as a single subcutaneous injection of either 100 mg and 300 mg.|t|t|t|t
33891512|NCT04203914|NA|SINGLE_GROUP||TREATMENT||NONE||Open label trial with before and after design||||
33891513|NCT01934504|||COHORT||PROSPECTIVE|||||||
33891514|NCT00943683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891515|NCT02415309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33976709|NCT03778866|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33976710|NCT01060592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976711|NCT02259751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976712|NCT05348109|||COHORT||OTHER|||||||
33976713|NCT05647421|RANDOMIZED|PARALLEL||TREATMENT||NONE||AcrySof™ IQ Vivity™ and TECNIS Synergy™ Intraocular Lens (Model ZFR00V )||||
34074730|NCT01095627|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074731|NCT00792909|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074732|NCT00961779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074733|NCT03020628|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074734|NCT03494608|||COHORT||PROSPECTIVE|||||||
34074735|NCT00254059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074736|NCT00938665|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074737|NCT02186977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074738|NCT01801488|||CASE_CONTROL||PROSPECTIVE|||||||
34074739|NCT01688323|||OTHER||PROSPECTIVE|||||||
34074740|NCT02217111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074741|NCT05262335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074742|NCT01431339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074743|NCT05302375|NA|SINGLE_GROUP||OTHER||NONE||||||
34074744|NCT00002917||||TREATMENT||||||||
34074745|NCT06484296|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34074746|NCT03975504|NA|SINGLE_GROUP||SCREENING||NONE||||||
34074747|NCT04500301|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074748|NCT03339414|||COHORT||PROSPECTIVE|||||||
34074749|NCT02988739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074750|NCT04988334|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||wait list control to intervention||||
34074751|NCT03976661|||CASE_CONTROL||OTHER|||||||
33763530|NCT04378023|||COHORT||PROSPECTIVE|||||||
33891516|NCT04081805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"the outcomes assessor will not have access to the treatment that was used in each patient.~the investigator will not have acess to the treatment that was used in each group"|The patient will be randomized in block to receive one of the three intravaginal therapies: LASER, Radiofrequency and promestriene|f|f|t|t
33891517|NCT03104582|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891518|NCT03756792|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33891519|NCT00873002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891520|NCT05606939|||COHORT||PROSPECTIVE|||||||
33891521|NCT04626622|||COHORT||PROSPECTIVE|||||||
33891522|NCT05409105|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized treatment, crossover||||
33891523|NCT01922921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891524|NCT02893267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33891525|NCT01722383|||COHORT||PROSPECTIVE|||||||
33891526|NCT00250393|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33891527|NCT03632642|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a pilot open-label multicentre randomised trial that is investigator-initiated comparing two drug regimens: benzylpenicillin vs. flucloxacillin for penicillin susceptible S. aureus bloodstream infections. We will aim to enrol 60 patients (30 in each arm) over a 12-month period. The participation duration for each enrolled patient is 90 days. Data will be collected for the participants from the date of when the first positive blood culture was obtained, which will be within 72 hours of enrollment. Consented patients will be randomised on day 1 (the day of randomisation) to either benzylpenicillin or flucloxacillin.||||
33891528|NCT04640727|||COHORT||OTHER|||||||
33891529|NCT04267640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891530|NCT02673281|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33976714|NCT05451459|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976715|NCT04759508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976716|NCT02090608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976717|NCT06011577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976718|NCT05202704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976719|NCT02815878|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976720|NCT00001337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976721|NCT01368523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976722|NCT03086772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074752|NCT00768690|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34074753|NCT03068689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074754|NCT06612138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque sealed envelope|pilates, yoga, tai chi and traditional therapy|f|f|f|t
34074755|NCT02526160|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34074756|NCT05371561|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants, legal guardians, and the dentist who carried out the examination were not blinded as it was inapplicable. The accessor and statistician were blinded||f|f|f|t
34074757|NCT02465437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074758|NCT05182411|||OTHER||PROSPECTIVE|||||||
34074759|NCT01972412|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074760|NCT01318759|||COHORT||PROSPECTIVE|||||||
34074761|NCT00646373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34074762|NCT00002071||||TREATMENT||DOUBLE||||||
34074763|NCT01290302|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34074764|NCT00094679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074765|NCT03783286|||COHORT||PROSPECTIVE|||||||
34074766|NCT01124669|||OTHER||RETROSPECTIVE|||||||
33891531|NCT04591093|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: the patient and the investigator don't know the strategy|"Crossover Assignment two arms A and B: Arm A: patient's fitting with strategy FS4 and 10 more apical electrodes activated--\> 1 month use --\> tests and patient's fitting with strategy FS4 and 10 more basal electrodes --\> 1 month use --\> tests~Arm B: patient's fitting with strategy FS4 and 10 more basal electrodes activated --\> 1 month use --\> tests and patient's fitting with strategy FS4 and 10 more apical electrodes --\> 1 month use --\> tests"|t|f|t|f
33891532|NCT04519944|||COHORT||PROSPECTIVE|||||||
33891533|NCT04490889|||OTHER||PROSPECTIVE|||||||
33891534|NCT00220363|RANDOMIZED|PARALLEL||||DOUBLE||||||
33891535|NCT03582111|||COHORT||RETROSPECTIVE|||||||
33891536|NCT04487665|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33891537|NCT06181955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two group experimental-control design|t|f|f|t
33891538|NCT02562625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891539|NCT03448744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33891540|NCT00635622|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33891541|NCT06656611|NA|SINGLE_GROUP||SCREENING||NONE||||||
33891542|NCT04987281|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33891543|NCT03656913|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891544|NCT01542307|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891545|NCT04708912|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33891546|NCT02599402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891547|NCT04833803|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33891548|NCT06327230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976723|NCT01286038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976724|NCT01836848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976725|NCT04659915|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Placebo-controlled|Double-blind, randomized, placebo-controlled cross-over study|t|f|t|f
33891549|NCT02304003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891550|NCT05225155|||CASE_CONTROL||RETROSPECTIVE|||||||
33891551|NCT03173469|||OTHER||PROSPECTIVE|||||||
33891552|NCT00817271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891553|NCT01621932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891554|NCT04769557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33891555|NCT00267241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33891556|NCT01974817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891557|NCT04278443|||COHORT||PROSPECTIVE|||||||
33976726|NCT03875157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976727|NCT03554096|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The dietary supplement will be delivered to the Clinical Research Center by the Investigational Pharmacy at Vanderbilt University Medical Center.|||||
33763531|NCT05381298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763532|NCT04329286|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763533|NCT05688735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, randomized||t|t|t|f
33763534|NCT06289699|||CASE_ONLY||PROSPECTIVE|||||||
33763535|NCT05481216|||CASE_CONTROL||RETROSPECTIVE|||||||
33763536|NCT04902222|||COHORT||PROSPECTIVE|||||||
33763537|NCT04187391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763538|NCT01165073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763539|NCT06624709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33763540|NCT00305383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763541|NCT03844022|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763542|NCT03264963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763543|NCT01146366|||COHORT||PROSPECTIVE|||||||
33763544|NCT04285632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33763545|NCT01949688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763546|NCT06510452|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33763547|NCT02013388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763548|NCT03587298|||CASE_CONTROL||PROSPECTIVE|||||||
33763549|NCT05137379|||COHORT||PROSPECTIVE|||||||
33763550|NCT02889666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763551|NCT06040034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Comparison|t|t|f|f
33763552|NCT06318442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33763553|NCT04966143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763554|NCT02464683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763555|NCT03021135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763556|NCT05514262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The intervention and measurements were carried out by the researcher.||f|f|t|f
33763557|NCT01644201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763558|NCT01231035|||COHORT||PROSPECTIVE|||||||
33763559|NCT00390195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763560|NCT03794375|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763561|NCT04845464|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763562|NCT03583645|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation was concealed to the participants, researchers -who were in class the assessment days- and teachers.|Participants were randomized in a 1:1 ratio blocked by gender to one of two groups: experimental condition (ITP intervention) versus control condition (educational intervention) in parallel for the duration of the study.|t|f|f|t
33763563|NCT02282410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763564|NCT00892489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763565|NCT06449716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763566|NCT05058209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigator and participant were blinded to study arm until the end of thier final visit/phone call. Medical assistant prepping injections and CCRC were not blinded.|Randomized and Controlled Blinded Clinical Trial|t|t|t|f
33763567|NCT06324019|NA|SINGLE_GROUP||OTHER||NONE||"The study was carried out as a post-test control group design from randomised controlled studies. The intervention group of the study was dressed in gynaecological examination clothes, while the control group used the drape given to the patient during the examination, which is a routine practice in the health institution where the study was conducted.~Hypotheses of the Study~1. Ho: There is no difference between the perception of privacy in the experimental and control group women.~   H1: There is a difference between the perception of privacy in the experimental group and control group women.~2. Ho: There is no difference between the perception of satisfaction in the experimental group and control group women.~H1: There is a difference between the satisfaction perception of women in the experimental group and the control group."||||
33763568|NCT05779306|||COHORT||OTHER|||||||
33763569|NCT00002396||||TREATMENT||DOUBLE||||||
33891558|NCT06649994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The psychologists that conduct the assessments (screening, assessment sessions and follow-ups) will be blinded to the group allocation during the whole project. Further, all participants will be blind to their condition. Also, the people who perform the statistical analyses will be blind to the condition of the groups, through the coding of the interventions. Only the therapist performing the interventions will not be blind to the allocation of the participants.|Parallel group randomized controlled trial|t|f|f|t
33891559|NCT00001087||||TREATMENT||DOUBLE||||||
33891560|NCT03698201|||COHORT||PROSPECTIVE|||||||
33891561|NCT02682836|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33891562|NCT04449692|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Partially single-blinded (oral carbohydrate administration will not be blinded)|Single-blinded, randomized (using blocks of 3/6 and stratification by treatment modality), three-arm crossover study|t|f|f|f
33891563|NCT05516329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891564|NCT03213665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763570|NCT02364180|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All subjects taking Pyridostigmine for at least 6mo, except for myasthenia gravis patients, will be considered for the study.Those that participate will answer a few questions pertaining to their medical history and will then undergo electromyography (CMAP) measurement with repetitive stimulation at 2 sites (ulnar nerve at the wrist and the accessory nerve in the neck). The first and fifth stimuli are delivered 2 seconds apart. Eight percent or greater decrement in the CMAP response on repetitive stimulation will be considered positive.||||
33763571|NCT01996358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33763572|NCT04006925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled trial|t|t|t|t
33763573|NCT02206217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763574|NCT03371264|||COHORT||RETROSPECTIVE|||||||
33763575|NCT01923805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763576|NCT05480020|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A staff member not part of the study group will be assigned to distribute blinded samples. The participant or the investigators will not be aware of the dose groups.|Participants will be randomly assigned to one of the 3 groups for brushing teeth with a probiotic toothpaste containing different doses of Streptococcus salivarius M18 Study Group A: BLIS M18 Toothpaste (1 Million Cfu/dose) (n = 10) Study Group B: BLIS M18 Toothpaste (10 Million Cfu/dose) (n = 10) Study Group C: BLIS M18 Toothpaste (100 Million Cfu/dose) (n = 10)|t|f|f|f
33763577|NCT01032980|||COHORT||PROSPECTIVE|||||||
33763578|NCT02556151|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33763579|NCT04131478|||CASE_CONTROL||PROSPECTIVE|||||||
33763580|NCT02935049|||COHORT||PROSPECTIVE|||||||
33763581|NCT01918696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33763582|NCT02173730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891565|NCT04968418|||CASE_ONLY||CROSS_SECTIONAL|||||||
33891566|NCT05796947|||COHORT||CROSS_SECTIONAL|||||||
33976728|NCT01345032|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33976729|NCT03363074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976730|NCT05719870|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be randomized to the intervention vs. control group. The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments. Control group will follow usual care.~After 7 days medication adherence will be assessed for both study groups through structured phone interviews.~Over 30 and 90 days from discharge, data on falls, rehospitalizations and vital status will be collected through hospital records."||||
33976731|NCT01912105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976732|NCT00702065|||||PROSPECTIVE|||||||
33976733|NCT02476526|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976734|NCT05925153|||OTHER||CROSS_SECTIONAL|||||||
33976735|NCT00027807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976736|NCT00428415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976737|NCT02590861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976738|NCT01202006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976739|NCT05694468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976740|NCT03144687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976741|NCT02167295|||||CROSS_SECTIONAL|||||||
33976742|NCT00195221|||||RETROSPECTIVE|||||||
33976743|NCT03123822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976744|NCT05391009|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976745|NCT00991848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976746|NCT01477359|||COHORT||PROSPECTIVE|||||||
33976747|NCT01930461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976748|NCT02457858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976749|NCT03873480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33976750|NCT05875688|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33976751|NCT02177084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976752|NCT04509479|||COHORT||PROSPECTIVE|||||||
33976753|NCT00195598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976754|NCT05764122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976755|NCT01966081|NON_RANDOMIZED|PARALLEL||||NONE||||||
33976756|NCT03574155|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"|f|f|t|f
33976757|NCT05113056|NA|SINGLE_GROUP||TREATMENT||NONE||The patient population will consist of men and women between the ages of 18 - 80 years, presenting for a de novo ablation for atrial fibrillation.||||
33976758|NCT05330507|||CASE_CONTROL||OTHER|||||||
33976759|NCT03602768|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The study personnel who conduct screening and send pre/post-test surveys to participants are all blinded.~Randomizer is blinded to all participant pre-test outcomes. Care providers know what their participants are doing, but not aware of the full study design, including details of the other conditions or outcome test characteristics."|Participants are screened, undergo a battery of cognitive testing for the pre-test, and then are randomly assigned to one of four intervention groups: MAP, GMT, Cambridge Brain Sciences brain training (active control), or waitlist. After intervention, the participants take the same test battery and complete it once more at 6 week followup.|t|f|t|t
33976760|NCT03680963|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976761|NCT05702177|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33976762|NCT04682002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976763|NCT06298656|||COHORT||PROSPECTIVE|||||||
33976764|NCT01347788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976765|NCT05105698|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976766|NCT06243211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blinded (with outcome assessors blinded to treatment allocation)|"This is a single-blinded (with outcome assessors blinded to treatment allocation), 12-month pilot study to evaluate of the safety, feasibility, and preliminary efficacy of dorsal myelotomy and expansive duraplasty performed either without or with autologous nerve graft implantation after acute traumatic spinal cord injury.~Ten participants will be allocated to receive either DMED (n=5) or DMED + ANGI (n=5) based on a block design. Participants and assessors will be blinded to group allocation. Excess sural nerve samples will be collected for banking/analysis (may include proteomic, culturing, genomic, cellular analysis)."|t|f|t|t
33976767|NCT05241821|||COHORT||RETROSPECTIVE|||||||
33976768|NCT01600209|||CASE_ONLY|||||||||
33976769|NCT05259306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976770|NCT02470507|||CASE_CONTROL||PROSPECTIVE|||||||
33976771|NCT04872322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074767|NCT02690272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074768|NCT01963884|||COHORT||PROSPECTIVE|||||||
34074769|NCT06347367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator and Outcomes Assessor)|Participants will be assigned to Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles) and Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles).|t|f|t|t
34074770|NCT01735188|||OTHER||OTHER|||||||
34074771|NCT03923881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||20 patients that have been included in the ICON-study (NCT03134846) and therefore will be administered with cetuximab-800CW||||
34074772|NCT00172445|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34074773|NCT01517633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074774|NCT02853045|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34074775|NCT02434185|||OTHER||CROSS_SECTIONAL|||||||
34074776|NCT01559038|||COHORT||PROSPECTIVE|||||||
34074777|NCT05074524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891567|NCT03176849|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled in the study will be randomized to either a control or intervention arm prior to the start of transplant using block randomization of blocks of 6. Those randomized to the intervention arm will receive the intervention (Stoss Therapy dosing of vitamin D) at the start of transplant followed by maintenance supplementation of vitamin D according to standard of care. Those randomized into the control arm will receive only maintenance supplementation of vitamin D according to standard of care throughout transplant.||||
33891568|NCT04924127|||CASE_ONLY||RETROSPECTIVE|||||||
33891569|NCT01644227|||COHORT||RETROSPECTIVE|||||||
33976772|NCT01769378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33976773|NCT05969470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976774|NCT01630980|||||PROSPECTIVE|||||||
34074778|NCT06221371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded-endpoint|A multi-center, prospective, open-label, blinded endpoint (PROBE), randomized, controlled clinical trial|f|f|f|t
34074779|NCT00338403|RANDOMIZED|CROSSOVER||||NONE||||||
34074780|NCT02602314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074781|NCT04220801|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34074782|NCT04826159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074783|NCT02137148|||CASE_ONLY||PROSPECTIVE|||||||
34074784|NCT00874159|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34074785|NCT05639218|||COHORT||PROSPECTIVE|||||||
34074786|NCT02105233|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763583|NCT02415348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763584|NCT02110732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33763585|NCT00235924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074787|NCT03113968|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the study treatments it is not possible to blind patients or investigators.|unblinded prospective randomized open-label||||
34074788|NCT03940196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074789|NCT00943397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074790|NCT05185466|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34074791|NCT03438201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074792|NCT02030262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074793|NCT00438204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763586|NCT03600675|||OTHER||CROSS_SECTIONAL|||||||
33891570|NCT01175369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33891571|NCT05192603|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open study for dietary intervention||||
33891572|NCT00496366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891573|NCT05791058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976775|NCT05382923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are informed that we are exploring different types of stimuli (including exercise, melatonin, and light) to help adjust to simulated jet lag.|Random assignment to one of three conditions|t|f|f|f
33976776|NCT04574882|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976777|NCT01672190|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976778|NCT02994056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976779|NCT05981625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33976780|NCT06342921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976781|NCT00819247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976782|NCT01673958|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976783|NCT06428708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976784|NCT00160212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976785|NCT03244774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976786|NCT02427607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976787|NCT03977584|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33976788|NCT05095909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976789|NCT00803959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976790|NCT00509964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976791|NCT03698526|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33976792|NCT00970281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976793|NCT01473966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976794|NCT00805298|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33976795|NCT02779309|||COHORT||RETROSPECTIVE|||||||
33976796|NCT01786447|||CASE_CONTROL||PROSPECTIVE|||||||
33976797|NCT06249399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups: aerobic exercise group and control group.||||
33976798|NCT00889590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976799|NCT03122002|||COHORT||PROSPECTIVE|||||||
33976800|NCT00570271|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33976801|NCT02122081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976802|NCT02072759|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33976803|NCT06261970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976804|NCT01964690|||COHORT||PROSPECTIVE|||||||
33976805|NCT06483945|||COHORT||PROSPECTIVE|||||||
33976806|NCT03830528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976807|NCT03169959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33976808|NCT04529070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976809|NCT04525001|||CASE_ONLY||PROSPECTIVE|||||||
33976810|NCT01269970|||COHORT||PROSPECTIVE|||||||
33976811|NCT05329805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|open-label|open-label, two-arm Randomized Control Trail (RCT)||||
33976812|NCT02928913|||COHORT||CROSS_SECTIONAL|||||||
33976813|NCT05140096|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33976814|NCT03042676|||COHORT||PROSPECTIVE|||||||
33976815|NCT04471207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976816|NCT02921477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074794|NCT01793038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074795|NCT03159832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074796|NCT00712894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074797|NCT00073450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074798|NCT04974892|||COHORT||PROSPECTIVE|||||||
33976817|NCT03489603|||OTHER||PROSPECTIVE|||||||
33976818|NCT02842697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976819|NCT03653195|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
33976820|NCT05629949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976821|NCT04716738|||CASE_CONTROL||PROSPECTIVE|||||||
33976822|NCT00503620|||||PROSPECTIVE|||||||
33976823|NCT03714295|||OTHER||PROSPECTIVE|||||||
33976824|NCT04048109|||COHORT||PROSPECTIVE|||||||
33976825|NCT06485414|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976826|NCT05713591|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|"Eligible patients who signed the written informed consent will be blindly randomized (allocation 1:1) in each involved CHD center at the baseline phase. However, considering the type of interventions is not possible to guarantee the patients' blindness during the study, as well as for the care provider.~The eligible patients will be randomized by using a pre-determined randomization sheet that considers patients' entry ID (the chronological number of enrollment) to perform randomization (each CHD center that participates in the research project will have a specific pre-determined randomization sheet). Patients will be randomized on a 1:1 basis to receive the TC model or usual care during the transition from childhood to adulthood.~Only the outcome assessor and the principal investigator will be blind to the patient allocation."|"The model of Transition Care (TC) is a complex educational intervention that encompasses three main steps (first step: understanding of their clinical condition; second step: education and support; third step: involvement and collaboration). Each step was developed to include, simplify and standardize the implementation of targeted and personalized interventions.~After the eligibility criteria check, patients will be randomized in experimental or control arms. Patients in the experimental arm were involved in the model TC, while patients in the control group received the standard of care. Data collection for each group was performed at baseline and at three, six, nine, and twelve months."|f|f|t|t
33976827|NCT00559156|NON_RANDOMIZED|||TREATMENT||||||||
33976828|NCT02771665|||CASE_CONTROL||RETROSPECTIVE|||||||
33976829|NCT02745951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976830|NCT03720964|||CASE_CONTROL||PROSPECTIVE|||||||
33976831|NCT05641597|NA|SINGLE_GROUP||OTHER||NONE||||||
33976832|NCT02380183|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976833|NCT05047406|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized, controlled, open-label, parallel, single-center study||||
33976834|NCT04911959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763587|NCT06618105|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor|Prospective, Randomized, Single-dose, Double-blind, Double-dummy, Four-period, Four-treatment Crossover|t|t|t|t
33763588|NCT02121678|RANDOMIZED|PARALLEL||||NONE||||||
33891574|NCT06621407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the inherent nature of the intervention blinding of the treating personnel is not possible. However, patients, the study statisticians, the 90-day outcome assessors, and the study steering group will be blinded to the allocation. Furthermore, statistical analyses and initial interpretation of the results will be performed using data with blinded treatment allocation|Randomized multicenter clinical non-inferiority trial encompassing all neurosurgical units in Denmark. All adult patients with symptomatic unilateral CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be considered for inclusion. Before surgical hematoma evacuation patients will be randomized to 24 hours passive subdural drainage or 24 hours active subperiostal drainage, and the drain placed accordingly at the end of the hematoma evacuation procedure. The primary end point is a composite outcome of 90-day mortality, and recurrent CSDH on the same side as the primary operation requiring reoperation within the 90-day follow-up period.|t|f|f|t
33891575|NCT01266564|||COHORT||PROSPECTIVE|||||||
33891576|NCT00701493|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891577|NCT02368470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891578|NCT01274221|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891579|NCT02318095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891580|NCT06651957|||COHORT||CROSS_SECTIONAL|||||||
33891581|NCT03055026|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33891582|NCT02832050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33891583|NCT01812642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976835|NCT02006680|||COHORT||PROSPECTIVE|||||||
33976836|NCT06001632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33976837|NCT00583960|||CASE_ONLY||RETROSPECTIVE|||||||
33976838|NCT04589052|||CASE_ONLY||PROSPECTIVE|||||||
33976839|NCT04400526|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33976840|NCT01759290|||COHORT||PROSPECTIVE|||||||
33976841|NCT01190969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33976842|NCT03781700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
33976843|NCT04784195|||COHORT||CROSS_SECTIONAL|||||||
33976844|NCT01171495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976845|NCT02381977|||||CROSS_SECTIONAL|||||||
33976846|NCT04849845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976847|NCT05042141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33976848|NCT02506374|||COHORT|||||||||
33976849|NCT00454636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976850|NCT00922974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976851|NCT06303999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33976852|NCT04800588|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976853|NCT01091025|NA|SINGLE_GROUP||SCREENING||NONE||||||
33976854|NCT00365352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976855|NCT02233348|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074799|NCT01918657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074800|NCT01945047|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34074801|NCT03452956|||COHORT||RETROSPECTIVE|||||||
34074802|NCT02608385|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34074803|NCT04522557|NA|SEQUENTIAL||TREATMENT||NONE||||||
34074804|NCT03574974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be blind to group assignment (experimental feedback intervention or control feedback intervention). The outcome assessor will be blind to group assignment.|Participants will receive either an experimental feedback intervention or a control feedback intervention. Participants who receive the control feedback intervention will be offered to return to receive the experimental feedback intervention upon completion of the study.|t|t|t|t
34074805|NCT05359614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074806|NCT02949882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763589|NCT05089435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients should wear simultaneously the trial device EZYPRO and a 24-hr Holter monitor.||||
33891584|NCT03917121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The duplicate outcome assessor (study director) and the assigned data analyst/ statistician will be blinded.|Parallel group trial with a 1:1 allocation ratio|f|f|f|t
33891585|NCT04255511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891586|NCT04792866|||COHORT||RETROSPECTIVE|||||||
33976856|NCT03741413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976857|NCT00846625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976858|NCT02070744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33891587|NCT04240652|||COHORT||PROSPECTIVE|||||||
33891588|NCT01122927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891589|NCT05704985|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891590|NCT04727671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976859|NCT02978326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074807|NCT04552561|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34074808|NCT05278741|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-centre, non-randomized interventional study in a single arm||||
34074809|NCT02052427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074810|NCT05433545|||COHORT||CROSS_SECTIONAL|||||||
34074811|NCT06508203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|triple masking|two arm randomized clinical trial with study group and positive control|t|t|t|t
34074812|NCT00202501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074813|NCT02966847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074814|NCT01265160|||CASE_CONTROL||PROSPECTIVE|||||||
34074815|NCT03586050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074816|NCT05056402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074817|NCT05098327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891591|NCT00138216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891592|NCT04965519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891593|NCT02013219|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891594|NCT00833092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33891595|NCT00002113|RANDOMIZED|||TREATMENT||||||||
33891596|NCT04586491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, randomised, parallel trial design|t|f|f|f
33891597|NCT05511103|||COHORT||RETROSPECTIVE|||||||
33891598|NCT00287742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891599|NCT00809133|NON_RANDOMIZED|||TREATMENT||NONE||||||
33891600|NCT04626830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33891601|NCT04743050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976860|NCT03481309|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|This is a double-blind and cross-over study.|Each participant will be assigned to 2 active and sham conditions on a different day.|t|t|t|t
33976861|NCT02494713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976862|NCT01648010|NON_RANDOMIZED|PARALLEL||||NONE||||||
33976863|NCT05793736|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||This is a controlled clinical feasibility trial with three evaluation times (T0 pre-treatment; T1 post treatment five weeks after T0; T2 nine weeks after T1) aimed at verifying the feasibility and tolerability of an intervention performed with biofeedback training (already extensively tested on other clinical populations and free of side effects) and aimed to obtain a preliminary measure of its effectiveness on patients with Long Covid syndrome|f|f|t|f
33976864|NCT01506830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891602|NCT02036320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763590|NCT04194372|||COHORT||PROSPECTIVE|||||||
33763591|NCT04787510|||COHORT||PROSPECTIVE|||||||
33763592|NCT03012061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763593|NCT03828396|||COHORT||PROSPECTIVE|||||||
33763594|NCT06147518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763595|NCT06023602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763596|NCT02949401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763597|NCT01871558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763598|NCT00401635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763599|NCT03496974|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33763600|NCT01799460|||COHORT||RETROSPECTIVE|||||||
33763601|NCT05224635|||CASE_ONLY||RETROSPECTIVE|||||||
33763602|NCT00818363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763603|NCT06152068|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33763604|NCT01845974|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33763605|NCT03873220|||CASE_ONLY||PROSPECTIVE|||||||
33763606|NCT00637819|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763607|NCT04639193|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, cross-over trial.|t|t|t|t
33763608|NCT01359267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763609|NCT00341848|||CASE_ONLY||PROSPECTIVE|||||||
33763610|NCT05398380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763611|NCT00385554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33763612|NCT03292601|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||(No Feedback Group was removed in 2019)||||
33763613|NCT01942902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763614|NCT01995448|||COHORT||PROSPECTIVE|||||||
33763615|NCT01454635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763616|NCT01407354|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33763617|NCT02780830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763618|NCT05643599|||OTHER||PROSPECTIVE|||||||
33763619|NCT02645786|||CASE_CONTROL||PROSPECTIVE|||||||
33763620|NCT03768102|||COHORT||PROSPECTIVE|||||||
33763621|NCT05767528|||CASE_ONLY||PROSPECTIVE|||||||
33763622|NCT04227080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763623|NCT05103163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Which of the patients included in the study would be in the experimental group and which would be in the control group was determined according to the randomization table determined by the web-based random assignment software (RAY). There are two columns in the table as group 1 and group 2. Which column would be in the experimental group and which would be in the control group was determined by drawing lots. As a result of the draw, it was determined that group 1 would be in the control group and group 2 would be in the experimental group. Then, group assignments were made in accordance with the randomization order determined by RAY.||t|f|f|f
33763624|NCT02815995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763625|NCT06192147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763626|NCT04963894|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Subjects will participate in a baseline assessment session (T0) before rehabilitative treatment, followed by random allocation to the Experimental group (8 weeks of functional balance physiotherapy) or the Home control group (daily functional activity). After these 8 weeks, all the participants will develop a second assessment session (T1) and rested for the next 8 weeks to develop after that the follow-up assessment session (T2). At this time, patients from the Home control group will be switch to the Experimental group, and participants from the Experimental group will follow a 4-month of inactivity wash-out period. After this, they will carry out the T0, T1, and T2 evaluations following the Home control group protocol.~Additionally, a third group of participants with Parkinson's disease who habitually developed conventional physiotherapy in a rehabilitation gym and in groups of 6 people, were evaluated (Conventional control group) at T0, T1 and T2."|f|f|f|t
33763627|NCT04389502|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33891603|NCT00828451|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891604|NCT00371319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891605|NCT01850615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976865|NCT00487864|||NATURAL_HISTORY||OTHER|||||||
33976866|NCT00381537|RANDOMIZED|PARALLEL||||NONE||||||
33763628|NCT06030401|||COHORT||PROSPECTIVE|||||||
33763629|NCT04048863|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The study will be divided into 4 Stages: 3 Clinical Stages and 1 Educational Stage.||||
33763630|NCT00673062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763631|NCT04614883|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763632|NCT03918070|||COHORT||PROSPECTIVE|||||||
33763633|NCT00725465|||COHORT||PROSPECTIVE|||||||
33763634|NCT03233061|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Women OBESE group VS Women NON-OBESE group||||
33763635|NCT06524076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763636|NCT00508352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763637|NCT03109821|||COHORT||PROSPECTIVE|||||||
34074818|NCT00331539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074819|NCT02608567|||OTHER||RETROSPECTIVE|||||||
34074820|NCT04080830|||COHORT||PROSPECTIVE|||||||
33763638|NCT03036501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763639|NCT00744094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763640|NCT06089252|NA|SINGLE_GROUP||TREATMENT||NONE||Lazolex gel||||
33763641|NCT04121481|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Double-Blind Placebo-Controlled Study|The aim of this pilot study is to evaluate the effect of oral supplementation of Prodovite® VMP35 on exercise endurance, muscle strength, anabolic parameters and lean body mass in healthy human subjects. We hypothesize that Prodovite® VMP35 supplementation will enhance and increase exercise performance, tolerance, lean-body muscle mass, improve anabolic parameters and blood chemistry parameters in healthy human subjects. Accordingly, 150 healthy male and female subjects will be randomly assigned to receive either Prodovite® VMP35 or placebo in the form of single dose sealed containers for 90 consecutive days and muscle strength, endurance, speed, anabolic/catabolic parameters and muscle mass will be evaluated by dual energy X-ray absorptiometry (DEXA), hand-grip strength test, cycle ergometer test, spirometer assessment and assay of Blood chemistry and serum biomarkers will be evaluated before and after intervention.|t|f|f|f
33763642|NCT03592225|RANDOMIZED|PARALLEL||OTHER||DOUBLE||2 groups of General practitioners are randomized to be allocated either in the intervention group or the control group|t|t|f|f
33763643|NCT05095363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Palliative Care planner (PCplanner) is a mobile app platform that aims to facilitate communication on unmet needs and advance care planning between patients with idiopathic pulmonary fibrosis and their pulmonary clinicians. Participants will be randomized to intervention arm in a 2:1 intervention:control ratio.||||
33763644|NCT05956548|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763645|NCT01653080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763646|NCT00258180|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33763647|NCT05298098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The present study is a single-center, randomized, double-blind, placebo-controlled trial performed in a tertiary hospital. It designed to evaluate the effects of the administration of hypertonic saline solution (NaCl 10%) + furosemide to patients with decompensated heart failure.~Population:~This study will include adult patients admitted in the emergency department for ADHF"|t|f|f|f
33763648|NCT01619358|||COHORT||PROSPECTIVE|||||||
33763649|NCT03166475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763650|NCT02245347|||CASE_ONLY||PROSPECTIVE|||||||
33763651|NCT01571934|||COHORT||PROSPECTIVE|||||||
33763652|NCT02991144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763653|NCT05684913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator assessing the clinical outcomes is blinded to the study groups||f|f|f|t
33763654|NCT04879459|||OTHER||PROSPECTIVE|||||||
33763655|NCT06540001|NA|SINGLE_GROUP||SCREENING||NONE||||||
33763656|NCT05694403|||OTHER||CROSS_SECTIONAL|||||||
33763657|NCT01781390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763658|NCT01320930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763659|NCT02529475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763660|NCT00494325|||COHORT||PROSPECTIVE|||||||
33763661|NCT05338918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763662|NCT01978366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763663|NCT04723316|||OTHER||PROSPECTIVE|||||||
33763664|NCT01759654|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763665|NCT06625294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074821|NCT05927558|||CASE_ONLY||RETROSPECTIVE|||||||
33763666|NCT01491074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074822|NCT05717712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763667|NCT02684201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763668|NCT01671839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763669|NCT04498195|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763670|NCT00079638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763671|NCT05296291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763672|NCT05084222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763673|NCT01074892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763674|NCT00219440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763675|NCT05536778|||COHORT||OTHER|||||||
33763676|NCT03044522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33763677|NCT06386263|||COHORT||OTHER|||||||
33763678|NCT03117725|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33763679|NCT06321458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Due to the nature of the interventions, it will not be possible to blind the participants or the healthcare providers administering the interventions. In all other aspects of the trial, blinding will be employed. Outcome assessors will be blinded to group allocation. Participants will also be requested not to disclose their allocation when outcomes are assessed.~Statisticians and investigators drawing conclusions will be fully blinded. The statistical analyses will be conducted with the intervention groups coded as e.g., 'A' and 'B'. The Steering Committee will write two abstracts while the blinding is intact; one assuming the experimental intervention group is 'A' and the control intervention group is 'B', and one assuming the opposite. After these two abstracts have both obtained consensus, the code will be broken by the data manager."|f|f|t|t
33763680|NCT01649518|||||RETROSPECTIVE|||||||
33763681|NCT01295723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763682|NCT06480214|||COHORT||PROSPECTIVE|||||||
33763683|NCT00434889|||COHORT||PROSPECTIVE|||||||
34074823|NCT05586997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients will be masked by receiving sham LASER therapy in the control group. While, the outcome assessors will evaluate unidentified radiographic images and will have no knowledge of the intervention allocated.||t|f|f|t
34074824|NCT02600923|NA|||TREATMENT||NONE||||||
34074825|NCT03335813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34074826|NCT03505580|||COHORT||PROSPECTIVE|||||||
33763684|NCT03396484|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33763685|NCT02034253|||CASE_CONTROL||PROSPECTIVE|||||||
33763686|NCT00817375|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33763687|NCT05157074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned based on diagnosis, into two intervention groups 1) patients diagnosed with Parkinson's disease and their study partners, 2) patients diagnosed with Huntington's disease.||||
33763688|NCT01614639|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33763689|NCT03736343|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33763690|NCT01694602|||CASE_ONLY||PROSPECTIVE|||||||
33763691|NCT06116201|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33763692|NCT05425251|||COHORT||PROSPECTIVE|||||||
33763693|NCT03482856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The trial will randomize 120 patients with CSP and comorbid insomnia, aged between 18 and 65 years, to the experimental intervention (i.e. 18 sessions of the modern neuroscience approach combined with CBT-I, including 3 sessions of therapeutic pain neuroscience education, 6 sessions of CBT-I and 9 sessions of cognition-targeted exercise therapy, n=60) or the control intervention (i.e. 18 sessions of the modern neuroscience approach alone, including 3 sessions of therapeutic pain neuroscience education, and 15 sessions of cognition-targeted exercise therapy, n=60).|t|f|t|t
33891606|NCT03376633|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment individuals will be provided information about the trial and consented into the study as part of WOW program materials (note: program participation is not conditional on participation in the research). Control individuals will not be provided information about the study, but may be provided information if they inquire about programming. Due to the intervention type, it is not possible to mask the identity of treatment participants from the provider or from participants. However, the provider will not be informed of the identity of the control group.|||||
34074827|NCT00642005|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33891607|NCT01262898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074828|NCT00550797|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891608|NCT04610814|||COHORT||PROSPECTIVE|||||||
33891609|NCT00326092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976867|NCT06095258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome data collectors are blinded throughout the study. Patients will be specifically instructed not to disclose specific treatment received to outcome data collectors.|Totally 162 patients with long COVID recruited into the study will be randomly assigned to the traditional Chinese medicine treatment group or the Western medicine control group. Patients in the treatment group will receive individualized TCM syndrome differentiation treatment, and patients in the control group will receive conventional Western medicine symptomatic treatment from general Western medicine practitioners.|f|f|f|t
33763694|NCT01615354|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33763695|NCT02585596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33891610|NCT02498821|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33891611|NCT06583083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891612|NCT05372809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the test article, a placebo harvest procedure or placebo treatment is not possible. Patients will be treated by an unblinded investigator. Wounds will be assessed at each visit by a blinded assessor. Wound closure determined by the blinded assessor will be confirmed by a blinded adjudicator.|mult-center, randomized controlled trial|f|f|f|t
33891613|NCT05426356|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are randomized to sacral fracture fixation and SI joint fusion using iFuse-TORQ vs. non-surgical management (NSM). There is a crossover component for subjects who fail NSM.||||
33891614|NCT02016287|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891615|NCT04378777|||COHORT||PROSPECTIVE|||||||
33891616|NCT03705390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891617|NCT06656520|||CASE_ONLY||PROSPECTIVE|||||||
33891618|NCT03601871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891619|NCT03551548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891620|NCT03528525|||CASE_ONLY||PROSPECTIVE|||||||
33891621|NCT03258814|||COHORT||PROSPECTIVE|||||||
33891622|NCT01129752|||CASE_CONTROL||PROSPECTIVE|||||||
33891623|NCT00112476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891624|NCT00212043|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891625|NCT01445171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891626|NCT05052489|||COHORT||PROSPECTIVE|||||||
33976868|NCT01964664|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976869|NCT00502775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074829|NCT00998712|||CASE_CONTROL||PROSPECTIVE|||||||
34074830|NCT06128421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074831|NCT06014177|RANDOMIZED|PARALLEL||OTHER||NONE||Individuals will be randomized into the control arm (standard of care) or STIckER arm to receive the intervention.||||
34074832|NCT03146338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074833|NCT02267070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074834|NCT00610181|||CASE_ONLY||PROSPECTIVE|||||||
34074835|NCT01341093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074836|NCT04002726|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34074837|NCT05701540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074838|NCT00672568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074839|NCT00657800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33976870|NCT04125654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763696|NCT06287996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763697|NCT02555462|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33763698|NCT02635165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763699|NCT02293746|NA|SINGLE_GROUP||TREATMENT||NONE||Inspire Upper Airway Stimulation System||||
33763700|NCT04630990|||COHORT||PROSPECTIVE|||||||
33763701|NCT00600379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976871|NCT05250414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976872|NCT04516850|||OTHER||RETROSPECTIVE|||||||
33976873|NCT02220322|||COHORT||PROSPECTIVE|||||||
33976874|NCT05606393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763702|NCT03713021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763703|NCT05023135|||CASE_CONTROL||PROSPECTIVE|||||||
33763704|NCT00487734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763705|NCT05582096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33763706|NCT04079530|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33763707|NCT04222062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be randomized to either 1) the GLIADEL Arm or 2) the Standard of Care Arm (SRS post-op).|t|t|f|t
33763708|NCT01201603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33763709|NCT01031901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763710|NCT01021774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33763711|NCT02675790|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33763712|NCT05116449|||CASE_CONTROL||PROSPECTIVE|||||||
33763713|NCT05634967|||COHORT||PROSPECTIVE|||||||
33763714|NCT06456099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763715|NCT01480427|||CASE_ONLY||PROSPECTIVE|||||||
33763716|NCT04795310|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763717|NCT05649345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763718|NCT03281824|NA|SINGLE_GROUP||OTHER||NONE||||||
33763719|NCT02833441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33763720|NCT06564636|||COHORT||PROSPECTIVE|||||||
33763721|NCT02813746|||COHORT||PROSPECTIVE|||||||
33763722|NCT05093387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763723|NCT00011440|||NATURAL_HISTORY||PROSPECTIVE|||||||
33763724|NCT03245255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976875|NCT04586621|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33976876|NCT00389142|||FAMILY_BASED||PROSPECTIVE|||||||
33976877|NCT00933751|||CASE_ONLY||PROSPECTIVE|||||||
33976878|NCT01934296|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33976879|NCT03085173|NA|SINGLE_GROUP||TREATMENT||NONE||"A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL Armored Chimeric Antigen Receptor (CAR) Modified T Cells in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)"||||
33763725|NCT04699916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763726|NCT00576732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763727|NCT03999268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763728|NCT02452684|||COHORT||PROSPECTIVE|||||||
33763729|NCT02696902|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33763730|NCT01235572|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33976880|NCT05997056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976881|NCT02490488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976882|NCT04801966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763731|NCT02080182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763732|NCT05022095|||COHORT||PROSPECTIVE|||||||
33763733|NCT04942314|||COHORT||RETROSPECTIVE|||||||
33763734|NCT01460160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763735|NCT06625827|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33763736|NCT05978505|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Identical capsule for placebo and study drug prepared by study pharmacist|Double-blind, randomized, placebo-controlled, cross-over study|t|t|t|t
33763737|NCT05011123|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Investigators, Sponsor, and Study staff who conduct the safety assessment and the participant will not know which vaccine is administered. Only the study staff who prepare and administer the vaccine and are not involved with the safety evaluation (vaccinator) will know which vaccine is administered."||t|t|t|t
33763738|NCT05299021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763739|NCT03790943|||COHORT||PROSPECTIVE|||||||
33763740|NCT04006561|||COHORT||PROSPECTIVE|||||||
33763741|NCT03637855|||COHORT||PROSPECTIVE|||||||
33763742|NCT04860960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Randomized, placebo-controlled, multi-center, double-blind and parallel group study with 2:1 randomization of Trappsol Cyclo plus SOC versus placebo plus SOC over 96 weeks, followed by open-label extension study of 96 weeks|t|t|t|t
33763743|NCT06230068|NA|SINGLE_GROUP||OTHER||NONE||||||
33891627|NCT04026542|||COHORT||CROSS_SECTIONAL|||||||
34074840|NCT02371902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074841|NCT05920499|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the study it is not possible to blind at the practice level. Physicians will always be aware to which group they belong. At Healthdata (data collection) practices included in the intervention group will be identified so the extended feedback report can be made available only to them.|||||
34074842|NCT04659148|||CASE_ONLY||RETROSPECTIVE|||||||
34074843|NCT00028262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074844|NCT01001520|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33976883|NCT03473314|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
34074845|NCT04020419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|investigational pharmacy will have access to randomization schemes and will package study drug from bulk supplies. All other study team members and participants are blinded.|pilot study to determine effect size for possible FDA phase I/II trial|t|t|t|t
34074846|NCT01405495|||COHORT||PROSPECTIVE|||||||
33976884|NCT04323670|NA|SINGLE_GROUP||OTHER||NONE||Guiding catheter Selectra 3D||||
34074847|NCT03145753|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"DRIVE study (Diagnóstico Rápido de la Infección por VIH/HCV en España, in English Rapid HIV/HCV testing in Spain) was designed to investigate the different aspects of HIV testing. DRIVE 01 and 02 had been already completed and communicated.~This new study has been designed as a prospective randomized clustered crossover study in one Health Care Area of Madrid Spain, to compare two implementation HIV/HCV testing programs: only EDSUP vs. EDSUP plus a resourced HIV/HCV testing program which provide rapid HIV/HCV tests, and testing staff to conduct all procedures.~Four PCC´c belonging to the influenced area of Ramón y Cajal Area will be randomized 1:1 to receive sequentially any of the two HIV/HCV testing programs."||||
33976885|NCT03415906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double|Prospective, monocentric, active-controlled, double-blind, cross-over with randomized sequence of treatments|t|f|t|f
33976886|NCT01788956|||COHORT||PROSPECTIVE|||||||
33976887|NCT05528016|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All evaluations and data collection were performed by a blinded investigator.||f|f|t|f
33976888|NCT00669864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976889|NCT03876613|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33976890|NCT01623128|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34074848|NCT01307891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074849|NCT00526448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074850|NCT01897051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074851|NCT03566277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074852|NCT03197662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976891|NCT03236857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976892|NCT01766921|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33976893|NCT04560881|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Clinical trial conducted in randomized, double-blinded, placebo-controlled design.|t|t|t|f
34074853|NCT03671655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient and study coordinator performing patient follow-up will be blinded to the allocated treatment strategy. Angiographic and US analyses will also be done blinded to study-arm allocation. Breaking the blind will be possible for any patient who develops a complication or whose clinical care requires knowledge of the study group allocation.|This is a phase 3, multi-center, randomized controlled, parallel-group study in patients with long Superficial Femoral Artery (SFA) lesions and SFA Chronic Total Occlusion (CTO), undergoing clinically indicated stent-based percutaneous revascularization .Patients will be randomized into Drug eluting stent (DES) arm (intervention) vs. Bare Metal Stent (BMS) arm (control).|t|f|f|f
33891628|NCT04910984|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891629|NCT03234335|||COHORT||PROSPECTIVE|||||||
33891630|NCT02543242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891631|NCT01237912|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976894|NCT01659567|||COHORT||PROSPECTIVE|||||||
33976895|NCT00408902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976896|NCT00442806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976897|NCT02740608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976898|NCT03146091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976899|NCT04646057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976900|NCT00352157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33976901|NCT00212095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891632|NCT05092607|NA|SINGLE_GROUP||OTHER||NONE|267 Symptomatic hospitalized patients 400 Symptomatic or symptomatic patients not hospitalized 800 asymptomatic patients|Cross-sectional study||||
33891633|NCT04317690|||OTHER||RETROSPECTIVE|||||||
33891634|NCT03294993|NA|SINGLE_GROUP||SCREENING||NONE||Doppler Ultrasonography Assessed Vascular Changes Before and After Radial Artery Puncture||||
33891635|NCT01918254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891636|NCT02315521|||COHORT||PROSPECTIVE|||||||
33891637|NCT03955367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891638|NCT03537664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891639|NCT01061008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33891640|NCT03276741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Personal identification removed (use of personal identification code)|quantitative, randomized experimental design study|f|f|f|t
33891641|NCT00719199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891642|NCT00477087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891643|NCT05983848|||COHORT||CROSS_SECTIONAL|||||||
33891644|NCT02154594|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33891645|NCT00751452|||||PROSPECTIVE|||||||
33891646|NCT03773952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double blind, placebo controlled, multicenter clinical trial|t|t|t|t
33891647|NCT02319369|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Parts 1 and 1A are sequential, then Part 2 is parallel||||
33891648|NCT00165009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976902|NCT03166982|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open|Participants receive an intervention throughout the protocol||||
33976903|NCT01153984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976904|NCT00233857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33976905|NCT05993338|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||assess pulmonary hemodynamics in COVID-19 survivors||||
33976906|NCT04439656|||OTHER||OTHER|||||||
33976907|NCT05153122|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33976908|NCT01314521|||CASE_ONLY||CROSS_SECTIONAL|||||||
33976909|NCT02523456|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976910|NCT02873988|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976911|NCT05123937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976912|NCT06132035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976913|NCT05530356|||COHORT||PROSPECTIVE|||||||
33976914|NCT02686216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976915|NCT06220799|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976916|NCT02962128|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33976917|NCT00892398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976918|NCT02845258|||COHORT||PROSPECTIVE|||||||
33976919|NCT00399581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976920|NCT06036511|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI."||||
33976921|NCT03047226|||CASE_ONLY||RETROSPECTIVE|||||||
33891649|NCT05871203|||COHORT||PROSPECTIVE|||||||
33891650|NCT00978302|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891651|NCT01253733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33891652|NCT02852525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891653|NCT02066064|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33891654|NCT01128985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33891655|NCT06657625|||OTHER||RETROSPECTIVE|||||||
33891656|NCT06035822|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The students did not know whether they were a control group or an intervention group|The assignment of the 30 groups to the intervention or control group was randomized. Fifteen were assigned to the intervention group (IG) and were given the High-Fidelity Simulation (HFS) intervention with a debriefing script, and 15 were assigned to the control group (CG) and were given the HFS intervention without a debriefing script.|t|f|f|t
33891657|NCT06261879|NA|SINGLE_GROUP||SCREENING||NONE||||||
33891658|NCT05303740|||COHORT||RETROSPECTIVE|||||||
33891659|NCT04290637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891660|NCT03182530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891661|NCT01781455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891662|NCT00837187|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33891663|NCT00629083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891664|NCT03869814|||CASE_CONTROL||PROSPECTIVE|||||||
33891665|NCT00703313|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33891666|NCT05015101|||OTHER||RETROSPECTIVE|||||||
33976922|NCT06121453|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33976923|NCT04072588|||COHORT||PROSPECTIVE|||||||
33976924|NCT02142244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976925|NCT01170442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976926|NCT01921426|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33976927|NCT03472729|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33891667|NCT00316875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976928|NCT03020121|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33976929|NCT03054103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgical conditions and patient response not aware of medication given.|Randomized, controlled, double-masked, three-armed clinical comparison|t|t|f|t
33976930|NCT04502875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind clinical trial to evaluate efficacy, feasibility and safety with two groups in a 1:1 ratio; where the control group corresponds to patients who will receive PPP and an experimental group where patients will receive PRP, both collected by apheresis.|t|f|t|t
34074854|NCT02111174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33976931|NCT06120127|RANDOMIZED|PARALLEL||TREATMENT||NONE||adjuvant radiotherapy: SBRT; immunotherapy: sintilimab chemotherapy: XELOX||||
33976932|NCT06146257|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33976933|NCT02268669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976934|NCT01024738|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33976935|NCT03050593|||COHORT||PROSPECTIVE|||||||
33976936|NCT01925755|||COHORT||PROSPECTIVE|||||||
33976937|NCT03806036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891668|NCT04844138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research team (principal investigator, co-investigators, research coordinator, and research assistants) will be blinded during the randomization process. To protect participants' identifying information throughout the study, a non-team member will generate a randomized list of unique participant IDs prior to starting recruitment. The non-team member will then randomly assign these IDs to the online self-directed program or waitlist conditions, and will black out this information to conceal it from the research team. The research coordinator will assign participants to a participant ID when they are enrolled in our study. After participants complete their second screening interview (clinical symptom interview), the research coordinator will access the blacked-out information and reveal the participant's condition. Once revealed, this information may be viewed by all members of the research team.|Participants will be randomly assigned to either the online self-directed program condition or the waitlist condition. Throughout the study, participant outcomes for both conditions will be measured to evaluate the effects of our online program compared to treatment as usual.|f|f|t|t
33891669|NCT02693223|||COHORT||OTHER|||||||
33891670|NCT02221089|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33891671|NCT05384301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891672|NCT00553995|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33891673|NCT04020744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For blinding of the participants, they will be told that they will be asked to regulate one of two brain regions, without mentioning the specific area.||t|f|f|f
33891674|NCT00898547|||CASE_ONLY||PROSPECTIVE|||||||
33891675|NCT04118803|||COHORT||PROSPECTIVE|||||||
33891676|NCT03939234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891677|NCT05760716|||CASE_CONTROL||PROSPECTIVE|||||||
33891678|NCT03757598|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are two study groups, each with 6 health facilities. All providers offering maternity care were trained in labor management practices and use of the partograph approved for national use in Kenya. In the intervention group only, providers were offered training and Android tablets to use the electronic partogram with clients. The 6-month intervention phase was simultaneous in both groups.||||
33891679|NCT05422729|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891680|NCT02510807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976938|NCT00944866|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33976939|NCT00785564|||COHORT||PROSPECTIVE|||||||
33976940|NCT04723602|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||2 cohorts of 16 participants each.||||
33976941|NCT01909622|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33976942|NCT04956666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976943|NCT00261157|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33976944|NCT02593851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976945|NCT04823195|||COHORT||PROSPECTIVE|||||||
33976946|NCT01725945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33976947|NCT01827722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33976948|NCT00359086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976949|NCT00704795|||CASE_CONTROL|||||||||
33976950|NCT03466190|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because the two interventions used in this trial are clearly different and easily recognized by the participants and investigators, neither the investigator nor participants can be blinded|"* A Randomized clinical trial.~* A trial will be carried out in hospital of Oral and Maxillofacial surgery department- Faculty of Oral and Dental Medicine Cairo University~* Equal randomization: participants with equal probabilities for intervention.~* Positive controlled: Both groups receiving treatment.~* Parallel group study: Each group of patients receives a single treatment simultaneously."||||
34074855|NCT00777868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074856|NCT04283812|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No other parties will be masked|||||
34074857|NCT03866421|||COHORT||PROSPECTIVE|||||||
34074858|NCT00652704|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34074859|NCT03654703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763744|NCT04919902|||COHORT||PROSPECTIVE|||||||
33976951|NCT04154748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were blinded to the power settings used for APC, but they knew the PPI dose they received. The endoscopist performing APC ablation was blinded to participant allocation and APC power setting (the power was set up by an assistant who knew the group allocation and the power display remained covered during the entire procedure). The endoscopist and pathologist involved in efficacy assessment were blinded to participant allocation.|Investigator initiated, single-center, parallel-group RCT conducted in a tertiary referral center in Poland.|t|f|f|t
33976952|NCT01226056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976953|NCT02297009|||COHORT||PROSPECTIVE|||||||
33976954|NCT01989520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33976955|NCT01055223|||CASE_CONTROL||RETROSPECTIVE|||||||
33976956|NCT03560375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation concealment and blinding of primary outcome assessors will be implemented|This is a single center, open-label (primary outcome assessors blinded), parallel group, clinical trial of circuit resistance training for 10 weeks; V-Med diet for 10 weeks and then circuit resistance training on top of diet for 10 weeks; empagliflozin 10mg/day for 10 weeks and then circuit resistance training on top of drug therapy for 10 weeks in subjects with type 2 diabetes mellitus|f|f|f|t
33976957|NCT04322175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976958|NCT05115032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled interventional trial; single crossover; single-centre, open label||||
34074860|NCT03822260|||COHORT||PROSPECTIVE|||||||
34074861|NCT05288946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|segmental stabilization exercises|f|f|t|t
34074862|NCT02794636|||COHORT||RETROSPECTIVE|||||||
33763745|NCT04472377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|the specimen was marked by code which was intended to mask the sample pairing|Two samples were collected, one by the study investigator using a cervical swab and another one by the patient using the study device immediately after viewing the instruction video and illustration. The association of the self-collected sample and the physician-collected sample was blinded to the laboratory personnel.||||
33763746|NCT03051022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33763747|NCT04636346|||COHORT||RETROSPECTIVE|||||||
33763748|NCT04116749|||CASE_CONTROL||PROSPECTIVE|||||||
33763749|NCT00186498|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33763750|NCT01364922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763751|NCT05999708|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33763752|NCT05929235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation design with 1 expansion arm at RP2D||||
33763753|NCT06283446|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups.||t|f|f|f
33763754|NCT00766454|||OTHER||PROSPECTIVE|||||||
33763755|NCT04508556|||COHORT||CROSS_SECTIONAL|||||||
33763756|NCT01081041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763757|NCT04501289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be informed of the drug to be administered and the duration but were unaware of the dosage of the drug to be administered to them. However, the investigator knew the dosage each study cohort received|The participants in the study will be randomized into two study groups in ratio 1:1. Participants in group 1 will receive 4g of 20% intravenous (I.V.) MgSO4, followed by 3g of 50% intramuscular (I.M.) MgSO4 in each buttock statim. Then, maintenance doses will be given as 2.5g of 50% MgSO4 I.M. 4 hourly for 24 hours, for patients with severe preeclampsia and for 24 hours post-delivery or post last seizure episode, for patients with eclampsia; while those in group 2 will receive loading dose as 4g of 20% MgSO4 I.V., followed by 5g of 50% MgSO4 I.M. in each buttock. Maintenance doses will be given as 5g of 50% MgSO4 I.M. 4 hourly in alternate buttock until 24 hours for participants with eclampsia and for 24 hours after delivery or after last fit, whichever occurs later, for those with eclampsia|t|f|f|f
33763758|NCT04338425|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763759|NCT06315140|NA|SINGLE_GROUP||SCREENING||NONE||||||
33763760|NCT00000157|RANDOMIZED|||PREVENTION||||||||
33763761|NCT06061432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763762|NCT01386996|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33763763|NCT03863522|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763764|NCT00844116|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33763765|NCT04703296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763766|NCT03450655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Data Analyst will also be masked.||f|f|f|t
33763767|NCT00405639|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33763768|NCT04623320|||COHORT||PROSPECTIVE|||||||
33763769|NCT00067990|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33763770|NCT06291155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open-label, non-randomized mechanistic trial of an FDA-approved drug||||
33763771|NCT03443713|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects randomly assigned to one of three types of exercise.||||
33763772|NCT06624423|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33891681|NCT03886168|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|A randomization schedule will be generated by study statistician and provided to PIs prior to study commencement. To ensure equal numbers of participants in each arm, a computer-generated, permuted blocking algorithm (blocks of 4 participants) will be used to develop the schedule. The schedule will be password protected and saved on an encrypted server housed at the Vanderbilt Bill Wilkerson Center. The investigators will be using identical procedures for all participants regardless of arm to which the participants randomize. Both the experimenters and the participants will be blinded. The experimenters will be notified of the randomization for a given participant on the day of the baseline visit. Only the PIs and study statistician will know whether the participant is in the intervention or deferred waitlist group until the end of the study. Neither PI nor study statistician will be personally administering assessments nor scoring tests for the participants.|The total sample (n = 72) will be randomly assigned to either immediate IGCIP intervention (n = 36) or a deferred waitlist condition (n = 36). Both groups will be monitored for 24 months, with testing at time 1 (baseline), time 2 (2 months), time 3 (6 months), and time 4 (12 months). After 12 months, the deferred treatment group will receive the IGCIP intervention. Testing will then continue at time 5 (14 months), time 6 (18 months), and time 7 (24 months). At the conclusion of the project, the investigators will have 12 months of data on untreated growth, 12 months data of treated growth in the deferred treatment group, and 24 months of growth in the immediate IGCIP treatment group.|t|t|f|t
33891682|NCT01106001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891683|NCT04401657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891684|NCT01518530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891685|NCT03741361|||COHORT||PROSPECTIVE|||||||
33891686|NCT03717740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|both participants and researchers will be blinded to the intervention given.|The population of interest involves women attending the study hospital for antenatal care and delivery. The intervention involves randomization to oral esomeprazole tablets40 mg or identical placebo tablet from recruitment until delivery. Randomization is achieved using computational random allocation, and both participants and researchers will be blinded to the intervention given.|t|t|t|t
34074863|NCT06014086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763773|NCT04425343|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|. A total of 80 plaque samples were collected with the clinical characteristics of the patient comprising of age between 25-39 years, 36 females and 44 males|". Patients recruited for the study were diagnosed as Stage II Generalized periodontitis according to the classification from the 2017 world workshop on the classification of periodontal and peri-implant disease and conditions. Periodontal status indicating the severity of interdental clinical attachment loss of 3-4mm, radiographic bone loss between 15%-33% and with no tooth loss were included. The complexity of periodontitis with a maximum probing depth of ≤ 5mm with horizontal bone loss and having an extent and distribution with \>30% teeth involved were included in the study."|f|f|t|f
33763774|NCT04547439|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants and investigators are blinded.|Double blinded randomized controlled study|t|f|t|t
33763775|NCT02648984|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33763776|NCT02412501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763777|NCT01233583|||CASE_CONTROL||PROSPECTIVE|||||||
33763778|NCT01885260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763779|NCT02671383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763780|NCT00325221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763781|NCT00550550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763782|NCT04152343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763783|NCT06261684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763784|NCT01382602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33891687|NCT01479348|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33891688|NCT05555550|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891689|NCT02279511|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33891690|NCT00699790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891691|NCT05989503|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Pragmatic study to be conducted in real-life routine practice conditions with a two-arm open randomization, to evaluate the efficacy (on surrogate markers) and safety of ARNi and SGLT2i combination in patients with HFrEF/HFmrEF and the doses of ARNi.~1. initiation of ARNi and SGLT2i simultaneously (same day or within ± 5 days);~2. initial SGLT2i initiation followed by ARNi between week 4 and 12 after randomization."||||
33891692|NCT02049502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891693|NCT06071611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891694|NCT05888831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33891695|NCT06486831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33891696|NCT03240926|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33891697|NCT04511702|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three different infusion durations may be used. 60-minute infusion, 45-minute infusion and 30-minute.||||
33891698|NCT00441688||||OTHER||NONE||||||
33891699|NCT04964869|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33891700|NCT03505437|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33891701|NCT03275155|||COHORT||PROSPECTIVE|||||||
33891702|NCT05150132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The examiner who performed clinical periodontal parameters was blinded to group assignment.||f|f|t|t
33976959|NCT05251493|RANDOMIZED|PARALLEL||TREATMENT||NONE||IDA is associated with poor neonatal outcomes and maternal morbidity. This clinical trial will compare IV iron isomaltoside to IV iron sucrose for correction of IDA, along with the potential impacts to the patient: physical, emotional and convenience of attending, receiving and follow up appointments associated with iron infusion. The study will also take into consideration the financial and resource impacts to the healthcare system, and to the patient, and determine the validity of using iron isomaltoside and iron sucrose in second and third trimester pregnancy.||||
33976960|NCT00004109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976961|NCT02034331|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33763785|NCT05578586|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized pilotstudy 1:1.||||
33763786|NCT05829980|||COHORT||PROSPECTIVE|||||||
33763787|NCT00555022|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33763788|NCT00980005|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33763789|NCT06625658|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891703|NCT05230147|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Stimulation patches will be applied in all patients and simulating of stimulation will be provided by an audible order by an investigator. Since high-frequency stimulation is almost non-sensible, masking is possible.|"Patients will undergo spinal cord stimulation or a sham procedure during tilt testing following randomization. Then a second test will be performed the same day after crossover.~A repeated test will be performed after 7 days in reverse order (sham or stimulation)."|f|f|t|f
33891704|NCT05669521|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study will be partially blinded. The patient and investigator as well as site personnel will be blinded as to whether TK-90 or TK-90 placebo is administered. The CRO, sponsor, and site pharmacist will know whether the patient was administered active drug or TK-90 placebo.|A total of 24 patients will be enrolled into one of 2 different: TK112690 treated or placebo treated|t|t|t|f
33891705|NCT01778725|||COHORT||PROSPECTIVE|||||||
33891706|NCT03885297|||COHORT||PROSPECTIVE|||||||
33891707|NCT03284190|||COHORT||RETROSPECTIVE|||||||
33891708|NCT06217250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891709|NCT05395221|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33891710|NCT00049348|RANDOMIZED|||TREATMENT||||||||
33763790|NCT03645135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The care provider will not be informed as to which group their patient is in.|"Patients will be randomized into 1 of 2 study arms arm 1: control arm 2: intervention.~We will use a random block generator to assign participants to their study arm."|f|t|f|f
33891711|NCT02757547|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891712|NCT02478476|||COHORT||PROSPECTIVE|||||||
33891713|NCT00620984|||COHORT||PROSPECTIVE|||||||
33891714|NCT03011229|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33891715|NCT02988856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891716|NCT03993717|||COHORT||PROSPECTIVE|||||||
33891717|NCT02456584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891718|NCT03106233|||COHORT||PROSPECTIVE|||||||
33891719|NCT06002152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33891720|NCT00184457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891721|NCT00886990|||COHORT||RETROSPECTIVE|||||||
33891722|NCT05759052|||COHORT||CROSS_SECTIONAL|||||||
33891723|NCT04025632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891724|NCT01994187|||CASE_ONLY||PROSPECTIVE|||||||
33891725|NCT05806242|||CASE_ONLY||CROSS_SECTIONAL|||||||
33891726|NCT01491178|||CASE_ONLY||PROSPECTIVE|||||||
33891727|NCT05303454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33891728|NCT00087438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891729|NCT03755622|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Patients who received the Transpalatal Arch (TPA) are not aware whether the appliance is fabricated conventionally or made from 3D reconstructed study model.|"Group C : Patients who receive Transpalatal Arch (TPA) that is conventionally constructed on stone models.~Group 3D : Patients who receive Transpalatal Arch (TPA) fabricated from three dimensionally (3D) reconstructed study model."|t|f|f|f
33891730|NCT03547141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33891731|NCT04241029|NA|SEQUENTIAL||TREATMENT||NONE||||||
33891732|NCT01602731|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33891733|NCT00673595|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33891734|NCT02115308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891735|NCT03839602|NA|SINGLE_GROUP||TREATMENT||NONE||The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC.||||
33891736|NCT01021943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891737|NCT06656325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891738|NCT04733820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891739|NCT02412865|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891740|NCT05816603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891741|NCT05896345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891742|NCT02739087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891743|NCT03192579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Consecutive patients with stent implantation who were performed coronary angiography and OCT follow-up of the coronary arteries were screened. The patients with neoatherosclerosis were randomly assigned to either 2.5-5mg/day of rosuvastatin therapy or 10mg/day(up to 20mg) of rosuvastatin and 1800mg/day of eicosapentaenoic acid therapy at a 1:1 ratio for 12 months.|f|f|t|t
33976962|NCT00634907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976963|NCT02718495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976964|NCT02948270|||CASE_CONTROL||PROSPECTIVE|||||||
33976965|NCT05424926|||COHORT||PROSPECTIVE|||||||
33763791|NCT04617548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891744|NCT06151925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891745|NCT05102565|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33891746|NCT00336102|||CASE_CONTROL||PROSPECTIVE|||||||
33891747|NCT04469569|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Cluster-randomized stepped-wedge design with 6 clusters||||
33891748|NCT00743704|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33891749|NCT06399315|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-Blind, Placebo-Controlled||t|f|t|f
33891750|NCT06214312|||CASE_CONTROL||PROSPECTIVE|||||||
33891751|NCT01536444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891752|NCT05600127|NA|SINGLE_GROUP||TREATMENT||NONE|single arm study, therefore no masking possible|||||
33976966|NCT02149303|||COHORT||RETROSPECTIVE|||||||
33976967|NCT02433665|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33976968|NCT06079580|||COHORT||CROSS_SECTIONAL|||||||
33976969|NCT05276284|NA|SINGLE_GROUP||TREATMENT||NONE||The TEMPLE study is a single-center prospective phase Ib and II trial to determine the safety, tolerability and efficacy of Atezolizumab given in combination with thiopurine therapy in patients with advanced and/or metastatic solid tumors with an intermediate tumor mutational burden.||||
33976970|NCT03923036|||COHORT||RETROSPECTIVE|||||||
33976971|NCT02520271|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33976972|NCT05790174|||FAMILY_BASED||RETROSPECTIVE|||||||
33891753|NCT04814264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blood bank staff will be blinded to the treatment allocation schedule and the use of random block sizes in the allocation schedule will ensure that they are not aware of which treatment will be assigned next. The clinical staff will be blinded to the intervention. The study biostatistician will be blinded to treatment allocation for any analyses performed.|Multicentre, pilot randomized controlled trial.|t|t|t|t
33891754|NCT05242887|||COHORT||CROSS_SECTIONAL|||||||
33976973|NCT03382366|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33976974|NCT03937063|||COHORT||PROSPECTIVE|||||||
33976975|NCT02841774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976976|NCT01153048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33976977|NCT03494595|||COHORT||PROSPECTIVE|||||||
33976978|NCT06461208|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"All participants, Chief Investigator, Site Principal Investigators and outcome assessors will be fully blinded throughout the trial. The site pharmacy trials team and the nurse administering the treatment will be unblinded to a patients treatment allocation.~The senior statistician will also be fully blinded, but the junior statistician will be unblinded from the 1st DMC meeting with data onwards."|Patients will be randomised 1:1 to FMT or placebo.|t|t|t|t
33976979|NCT04319666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33976980|NCT01984242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976981|NCT00551005||||TREATMENT||||||||
33976982|NCT03559387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33976983|NCT03820583|NA|SINGLE_GROUP||TREATMENT||NONE||Patients undergoing Whipple procedure due to pancreatic tumor were included in the study||||
33976984|NCT04483700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763792|NCT00462670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763793|NCT01268202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891755|NCT01239927|RANDOMIZED|PARALLEL||TREATMENT||||||||
33891756|NCT04894799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891757|NCT04132050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891758|NCT06003062|||CASE_ONLY||PROSPECTIVE|||||||
33891759|NCT02505048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891760|NCT02912663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891761|NCT02150811|||COHORT||PROSPECTIVE|||||||
33891762|NCT02792868|||CASE_ONLY||PROSPECTIVE|||||||
33891763|NCT00749203|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891764|NCT02113202|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33891765|NCT02185521|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891766|NCT01322815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891767|NCT00757315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976985|NCT04832113|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33976986|NCT00016926||||TREATMENT||||||||
33976987|NCT00343759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33976988|NCT02975271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976989|NCT05102175|||COHORT||CROSS_SECTIONAL|||||||
33976990|NCT00202449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074864|NCT04056949|NA|SINGLE_GROUP||TREATMENT||NONE||SCLC patients who have failed platinum-etoposide chemotherapy||||
34074865|NCT03975257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074866|NCT04152291|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Baseline measurements are compared to different time points during the study.||||
34074867|NCT06367946|||OTHER||PROSPECTIVE|||||||
34074868|NCT05272553|NA|SEQUENTIAL||TREATMENT||NONE||Naturalistic, mixed-method, explanatory sequential measurement single case series design||||
34074869|NCT03751475|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel arms stratified on site and degree of acute malnutrition. 890 participants for the principal objective 480 participants with severe acute malnutrition for the secondary main objective||||
34074870|NCT01869777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34074871|NCT00921661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074872|NCT06071117|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34074873|NCT01678248|||COHORT||RETROSPECTIVE|||||||
34074874|NCT03936153|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm treatment group||||
33891768|NCT05533801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33891769|NCT00104871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891770|NCT05916352|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The research is a double-blind randomized controlled comparative cross-sectional study.|t|f|t|f
33891771|NCT00212329|||||PROSPECTIVE|||||||
33891772|NCT05916872|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients will be allocated to two groups by randomization. Patients in Group A will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique \& EMS patients in Group B will receive conventional therapy.||||
33891773|NCT02625402|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33891774|NCT03124043|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33891775|NCT03467620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891776|NCT00728429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33891777|NCT03040154|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33891778|NCT00316823||||DIAGNOSTIC||NONE||||||
33891779|NCT00682630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891780|NCT05040529|||COHORT||RETROSPECTIVE|||||||
33891781|NCT02781974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891782|NCT00807664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891783|NCT04337957|||CASE_ONLY||RETROSPECTIVE|||||||
33891784|NCT01149200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891785|NCT04658069|||COHORT||PROSPECTIVE|||||||
33891786|NCT05207761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074875|NCT01302418|||CASE_ONLY||PROSPECTIVE|||||||
34074876|NCT01733121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074877|NCT04720989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33891787|NCT02569034|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33891788|NCT02133417|||CASE_CROSSOVER||PROSPECTIVE|||||||
33891789|NCT02917590|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33891790|NCT05669742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891791|NCT04089956|||COHORT||RETROSPECTIVE|||||||
33891792|NCT00609921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891793|NCT05786482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891794|NCT02692625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891795|NCT05532956|||OTHER||PROSPECTIVE|||||||
33891796|NCT01360255|||COHORT||PROSPECTIVE|||||||
33891797|NCT04077333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized, clinical, parallel-group study|f|f|f|t
33891798|NCT04125680|NA|SINGLE_GROUP||PREVENTION||NONE|Investigator|A pilot trial will be used: study participants will be registered and placed into the program on a first-come, first-served basis. This will result in a study assessing correlation rather than causation.||||
34074878|NCT05684289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074879|NCT00003205||||TREATMENT||||||||
34074880|NCT02203344|||||PROSPECTIVE|||||||
34074881|NCT02378948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074882|NCT06309823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074883|NCT00696735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074884|NCT03341845|NA|SINGLE_GROUP||TREATMENT||NONE||simon's two stage design||||
33976991|NCT06454006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (placebo or active) and will be instructed not to inform the patients, therapists or other researchers as to the type of treatment (placebo or active). Therefore, the patients, therapists, and the outcome assessors will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or active).||t|t|t|t
33976992|NCT06098846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33976993|NCT01054508|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33976994|NCT04962685|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33976995|NCT00417690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33976996|NCT05412498|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34074885|NCT05323747|||OTHER||PROSPECTIVE|||||||
34074886|NCT06344975|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34074887|NCT04612283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|double blind, randomized, parallel group study against placebo|t|t|t|f
34074888|NCT02256813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074889|NCT01664702|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33891799|NCT04963478|||COHORT||RETROSPECTIVE|||||||
33891800|NCT04265404|||OTHER||PROSPECTIVE|||||||
33763794|NCT05650723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33763795|NCT04459286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763796|NCT00001015||||TREATMENT||NONE||||||
33891801|NCT02828267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and outcome assessors are not privy as to which arm patients were randomized to. Participants obviously are aware if they participate in a discussion and receive texts.|This is an feasiblity trial of a three stage adaptive clinical trial. Stage one has three arms (UC, BNI, BNI+ Standard booster). Stage two drops usual care arm. Stage three continues the strongest arm for phase two (which was choosen as BNI + Standard Booster for this feasiblity trial not powered to determine efficacy) and a new arm BNI + Personalized Booster.|f|f|t|t
33891802|NCT03282747|||COHORT||CROSS_SECTIONAL|||||||
33891803|NCT03669705|||COHORT||PROSPECTIVE|||||||
33976997|NCT01819636|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074890|NCT00279383|||CASE_CONTROL||RETROSPECTIVE|||||||
34074891|NCT01388855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34074892|NCT04009187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074893|NCT04474561|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34074894|NCT05118620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple (Participant, Care Provider, Investigators/Outcomes Assessors) Study solution containing either local anesthetic (bupivacaine) or normal saline will be prepared by the University of California San Diego Investigational Drug Study Service. Both bupivacaine and normal saline are clear and indistinguishable visually.|Parallel Assignment|t|t|t|t
34074895|NCT01153607|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34074896|NCT02077686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763797|NCT03154281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The statistical analysis will be mainly descriptive. Continuous variables will be summarized using descriptive statistics: N, mean, standard deviation, median, minimum and maximum. Categorical variables will be presented using frequencies and percentages. Time-to-event will be described by N, median, range, number censored, and Kaplan-Meier plots. A traditional dose escalation design will be used, beginning with the lowest dose level and escalating to the maximum allowable dose level as specified in the protocol. Three patients will be treated one at a time at a given dose level. A maximum of 4 dosing levels results in a maximum sample size of n=24 subjects.||||
33976998|NCT00315874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763798|NCT05434117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome variables will be assessed by study personnel who are blinded to patient allocation.|Parallel-group pilot RCT|f|f|f|t
33763799|NCT04175301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subjects will be randomly assigned in a 2:1 ratio to receive hydrogen or placebo, additionally to all standard-of-care treatments by the SB Research Pharmacy. Masking of active and placebo treatments will be preserved by creating study medication containers that appear identical.||t|t|t|t
33763800|NCT02962856|NA|SINGLE_GROUP||OTHER||NONE||||||
33763801|NCT06120517|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763802|NCT05177406|||COHORT||RETROSPECTIVE|||||||
33763803|NCT00012038||||TREATMENT||||||||
33763804|NCT06436001|||OTHER||RETROSPECTIVE|||||||
33976999|NCT02551289|||COHORT||PROSPECTIVE|||||||
33977000|NCT01152203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977001|NCT06496737|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 171 people tested were randomly divided into 3 groups of 57 each during the intervention phase, with two groups carrying out a intervention||||
33977002|NCT05249907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33977003|NCT00698100|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977004|NCT05855538|||COHORT||PROSPECTIVE|||||||
33977005|NCT04255719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Throughout the study, all participants, independent raters/evaluators and statisticians will be blind to the treatment conditions and parameter configurations. Independent raters who are blind to the conditions will be responsible for the conduct of all the assessments. Participants are blind to the treatment conditions. Movement disorders clinician responsible for programming are blind to the study protocol. They are simply told to adjust parameter to optimize therapeutic effects.||t|f|f|t
33977006|NCT02032368|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33977007|NCT01157390|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977008|NCT02259556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977009|NCT01095510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977010|NCT03767192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977011|NCT05152719|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study will include participants aged 18-39, 3 conditions analyzed for cognitive function and body composition. It will involve 120 participants randomly assigned to one of three groups with either sprint interval training, time restricted eating, or both. The study will be 6 weeks in duration.||||
33977012|NCT02920411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977013|NCT02353130|||COHORT||PROSPECTIVE|||||||
33977014|NCT00927147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074897|NCT03460873|||COHORT||PROSPECTIVE|||||||
34074898|NCT06612060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33763805|NCT03894150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763806|NCT06382038|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33763807|NCT00477061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33763808|NCT02320032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763809|NCT06625164|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33763810|NCT01749072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763811|NCT05118230|||COHORT||PROSPECTIVE|||||||
33763812|NCT03118284|||CASE_CONTROL||PROSPECTIVE|||||||
33763813|NCT05335109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763814|NCT05091853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33763815|NCT00214825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33977015|NCT02401542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977016|NCT02029937|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33977017|NCT01683175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977018|NCT02120053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763816|NCT03610737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763817|NCT04942301|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763818|NCT01319292|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33763819|NCT02493491|||COHORT||PROSPECTIVE|||||||
33763820|NCT03628963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two Family Medicine Groups (FMG) from the same health region but covering distinct areas have been selected as the clusters. The FMGs will be randomily selected for the experimental (CONCERTO+) or control (usual care) group.|f|f|f|t
33763821|NCT04398446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763822|NCT01218945|||||PROSPECTIVE|||||||
33977019|NCT02161965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977020|NCT00003908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977021|NCT04308577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763823|NCT02623816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891804|NCT05073692|||COHORT||RETROSPECTIVE|||||||
33891805|NCT01287104||SEQUENTIAL||TREATMENT||NONE||||||
33891806|NCT05777928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891807|NCT06320444|||COHORT||PROSPECTIVE|||||||
33891808|NCT04506112|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomized trial with participants assigned to one of two groups in parallel for the duration of the study.||||
33891809|NCT05843214|||CASE_ONLY||PROSPECTIVE|||||||
33891810|NCT06004544|||COHORT||PROSPECTIVE|||||||
33891811|NCT04394988|||COHORT||RETROSPECTIVE|||||||
33891812|NCT05646056|||COHORT||PROSPECTIVE|||||||
33891813|NCT04899648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891814|NCT02339467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891815|NCT00666744|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33891816|NCT06337396|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891817|NCT03398343|||COHORT||PROSPECTIVE|||||||
33891818|NCT01203488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33891819|NCT00960271|||CASE_ONLY||PROSPECTIVE|||||||
33891820|NCT05232734|NA|SINGLE_GROUP||OTHER||NONE|The study drug is oral caffeine solution which will be prepared by pharmacy laboratory using caffeine powder into 20mg/mL caffeine solution. The solution will be packed in amber glass bottle ready for administration by nurses at bedside without further dilution.|Multi-center pilot observational single-arm clinical feasibility trial||||
33891821|NCT05168930|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891822|NCT00471770|||||PROSPECTIVE|||||||
33891823|NCT00185861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33891824|NCT05675709|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33891825|NCT05057390|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891826|NCT05803941|NA|SINGLE_GROUP||OTHER||NONE||||||
33891827|NCT00777543|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33891828|NCT03648801|||OTHER||PROSPECTIVE|||||||
33977022|NCT00750659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977023|NCT05984056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977024|NCT03990675|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33977025|NCT01085344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977026|NCT06262711|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double blind masking|Crossover Assignment|t|f|t|t
33977027|NCT03235778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33891829|NCT02609581|||OTHER||PROSPECTIVE|||||||
33891830|NCT03088501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|After meeting inclusion criteria, consenting to participate and completing a baseline questionnaire, participants will be immediately assigned to the randomized study arm by the RA who will open one of the sequentially numbered envelopes to determine allocation. Before opening the envelope, the Respondent ID number will be written on the envelope. The assignment schedule will be kept in a locked filing cabinet in the study coordinator's office at the Indian Institute of Public Health. Research staff and pregnant women cannot be blinded because the intervention requires their participation; however, the data analyst will be blinded to the study arm assignment.|Participants will be randomized into each arm on a 1:1:1, using a computer-generated randomization list. Written allocation of assignments will be sealed in individual, sequentially numbered, non-resealable, opaque envelopes that will be used to allocate to the targeted number of participants.Once the participant is assigned to the arm, their unique respondent Identification Number ID(RID) and the arm to which they are allocated are recorded by the research assistants|f|f|f|t
33891831|NCT03483571|||COHORT||PROSPECTIVE|||||||
33891832|NCT03411343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33891833|NCT03429218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977028|NCT05870553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977029|NCT05111821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977030|NCT01191320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074899|NCT03937544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763824|NCT04999358|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single centre, parallel-group, two arm, randomised controlled trial.||||
33891834|NCT04475328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33891835|NCT05318521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded.|Approximately 500 evaluable patients will be enrolled. The randomized, IP-treated subject with baseline value for primary analysis will be considered evaluable. Considering an estimated randomization failure rate of 10%, approximately 556 eligible patients will be recruited. Eligible patients will be randomly assigned to receive IBUMR or placebo at a fixed ratio of 1:1. The treatment regimen will be dosing twice a day (BID) for a total of 12 weeks.|t|t|t|t
33977031|NCT05635149|||COHORT||PROSPECTIVE|||||||
33891836|NCT05929534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977032|NCT05596708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977033|NCT02639949|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34074900|NCT03241394|||OTHER||CROSS_SECTIONAL|||||||
34074901|NCT06611904|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34074902|NCT05426187|||COHORT||PROSPECTIVE|||||||
34074903|NCT02762435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074904|NCT04649879|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised 2:1 to treatment with convalescent plasma and standard of care only. Randomisation is by random permutated blocks using Redcap or equivalent.||||
34074905|NCT00478270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074906|NCT03409536|||COHORT||PROSPECTIVE|||||||
33891837|NCT05690321|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891838|NCT05192187|NA|SINGLE_GROUP||OTHER||NONE||||||
34074907|NCT00333710|RANDOMIZED|PARALLEL||||NONE||||||
33891839|NCT01573442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33891840|NCT04653584|||OTHER||CROSS_SECTIONAL|||||||
34074908|NCT00848406|||COHORT||PROSPECTIVE|||||||
34074909|NCT01247350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074910|NCT02653911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34074911|NCT06338943|||COHORT||CROSS_SECTIONAL|||||||
34074912|NCT02014519|NA|SINGLE_GROUP||OTHER||NONE||||||
34074913|NCT05704205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized controlled trial|f|f|f|t
34074914|NCT04254276|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34074915|NCT05136235|NA|SINGLE_GROUP||SCREENING||NONE||||||
34074916|NCT02597738|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33763825|NCT01121198|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34074917|NCT03045653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763826|NCT02390856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33763827|NCT05732532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763828|NCT05116176|||COHORT||PROSPECTIVE|||||||
33763829|NCT01337414|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patient education and self-monitoring vs. customary care||||
33763830|NCT01140334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33763831|NCT01377480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763832|NCT02765022|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33763833|NCT04489420|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||2 modalities Systemic vs Intratumoral. For systemic experimental: Cyclophosphamide at Day -3 followed by CYNK-001. On Days 0, 7, and 14. Experimental IntraTumoral, Ommaya placement surgery 7 days prior to CYNK-001 administrations at Days 0, 7 and 14||||
33763834|NCT06100302|||COHORT||PROSPECTIVE|||||||
33763835|NCT00345319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33763836|NCT02889601|||CASE_CONTROL||PROSPECTIVE|||||||
33763837|NCT05649826|||OTHER||PROSPECTIVE|||||||
33977034|NCT01159795|||COHORT||PROSPECTIVE|||||||
33977035|NCT01829009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977036|NCT05914103|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33977037|NCT01550588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33977038|NCT04117165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patient will not know if his bDMARD treatment was prescribed with or without the help of SinnoTest® software|Prospective clinical trial, phase III, randomized in 2 parallel groups, multicentric, controlled (prescription with SinnoTest® software versus prescription without SinnoTest® software), single-blind|t|f|f|f
33977039|NCT02492399|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33977040|NCT05867160|||OTHER||PROSPECTIVE|||||||
34074918|NCT03728439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a randomized crossover (crossover) trial. Participants will be randomized to not receive LED (CO) or have the application of LED therapy at three different times: before (Lpré), in the interval (Lin) and after (Lpós) of the Bangsbo and YoyoIR1 performance tests. At 7, 14 and 21 days after the initial tests, the same test and evaluation protocol will be performed. In addition, 48 hours after each test protocol, functional tests, recovery questionnaire and blood collection will be applied for analysis of creatine kinase.|f|f|t|t
34074919|NCT06424561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34074920|NCT06363019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-group parallel-armed randomized controlled trial with a pretest and repeated post-test experimental design||||
34074921|NCT00477802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34074922|NCT00826059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34074923|NCT00731796|||COHORT||PROSPECTIVE|||||||
34074924|NCT06050096|||COHORT||PROSPECTIVE|||||||
33977041|NCT05091788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977042|NCT02585466|||CASE_CONTROL||PROSPECTIVE|||||||
33977043|NCT00858910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977044|NCT03799263|||COHORT||PROSPECTIVE|||||||
33977045|NCT04740385|||OTHER||CROSS_SECTIONAL|||||||
33977046|NCT01255475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977047|NCT03896100|||COHORT||PROSPECTIVE|||||||
33977048|NCT00950157|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33977049|NCT04232462|||OTHER||PROSPECTIVE|||||||
33977050|NCT00821210|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977051|NCT02877056|||COHORT||PROSPECTIVE|||||||
33977052|NCT02774798|||COHORT||PROSPECTIVE|||||||
33977053|NCT01180595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891841|NCT06491043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Eligible subjects will be randomized to one of the three groups: placebo control, low-dose allogeneic umbilical cord-derived mesenchymal stem cells UMC119-06-05 treatment, or high-dose UMC119-06-05 treatment.|t|t|t|t
33891842|NCT01882361|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33891843|NCT02071940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891844|NCT06408844|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are two groups in this study: the experimental group and the control group.||||
33891845|NCT00787111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891846|NCT04271267|||CASE_CONTROL||RETROSPECTIVE|||||||
33891847|NCT05595876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The angiographic outcomes will be assessed by a centralized Core Laboratory, not involved in patient management.||f|f|f|t
33891848|NCT00116454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891849|NCT02272192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891850|NCT02804100|||CASE_ONLY||PROSPECTIVE|||||||
33891851|NCT01419509|||CASE_ONLY||RETROSPECTIVE|||||||
33891852|NCT01543321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977054|NCT03863678|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
33977055|NCT05722067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763838|NCT02576756|||CASE_CONTROL||RETROSPECTIVE|||||||
33763839|NCT00656318|||COHORT||PROSPECTIVE|||||||
33763840|NCT04754139|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33763841|NCT00885963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891853|NCT03314285|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33891854|NCT05617560|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||investigator-initiated, prospective, single-center clinical intervention study||||
33891855|NCT00831376|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891856|NCT01449838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977056|NCT01687686|||COHORT||RETROSPECTIVE|||||||
33977057|NCT00988923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977058|NCT02521207|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33977059|NCT03594123|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33977060|NCT05034731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977061|NCT06217172|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Number of participants was considered after sample size estimation for non-inferiority margins to the outcome expected.|f|t|t|t
33977062|NCT03679377|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After clinical testing during the surgery the plates are removed and the osteotomy is fixated with bicortical screws.||||
33977063|NCT06427317|||OTHER||PROSPECTIVE|||||||
33977064|NCT01034319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977065|NCT04898062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977066|NCT01029353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977067|NCT05852847|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus danazol or danazol alone. Each group requires 108 patients (considering 20% drop-off) to achieve the superiority comparison.||||
33977068|NCT04114695|||COHORT||CROSS_SECTIONAL|||||||
33977069|NCT00678392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977070|NCT03284775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977071|NCT01932034|||CASE_ONLY||PROSPECTIVE|||||||
33977072|NCT05959785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|plain blind|Clinical trial with control group and random assignment intervention|t|f|f|f
33977073|NCT05969197|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33977074|NCT05069636|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33977075|NCT01136642|RANDOMIZED|SINGLE_GROUP||OTHER||||||||
33977076|NCT02551445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977077|NCT02068482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33891857|NCT00235521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891858|NCT00083538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891859|NCT01935219|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33891860|NCT04313946|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33891861|NCT02131844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33891862|NCT00702676|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891863|NCT04643184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Co-management program (cardiological-geriatric) to carry out during hospitalization a comprehensive evaluation that allows to know the medical and socio-environmental needs of the patients to plan the required care at home and achieve an effective transition.|f|f|f|t
33891864|NCT04698876|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33891865|NCT03728088|||CASE_ONLY||CROSS_SECTIONAL|||||||
33977078|NCT02336737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977079|NCT06272409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977080|NCT02237183|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33977081|NCT04726202|||CASE_CONTROL||PROSPECTIVE|||||||
33977082|NCT04344418|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||2-cluster stepped wedge clinical feasibility trial||||
33891866|NCT04574999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study drug, 0.005% Estriol vaginal gel, and its vehicle in gel (placebo) will have identical appearance, same aroma and the same texture in order to maintain the double blind.||t|t|t|f
33891867|NCT06109545|||COHORT||CROSS_SECTIONAL|||||||
33891868|NCT02249741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891869|NCT05592340|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to see a restaurant menu with one of two labeling schemes: 1) Control: calorie labels only; 2) Carbon footprint labels in addition to calorie labels. Participants will be instructed to select an entree to hypothetically order from the online restaurant menu. We will record participants' selections and match these to nutrition and carbon footprint information.||||
33891870|NCT02603575|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33891871|NCT05828914|||COHORT||RETROSPECTIVE|||||||
33891872|NCT03639740||SEQUENTIAL||TREATMENT||NONE||Dose will be increased or maintained after predetermined intervals depending on remission||||
33891873|NCT02779205|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33891874|NCT05503953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891875|NCT03133767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Fluid being administered to participants will be covered by an opaque bag. The investigator calling the participant for follow-up does not know how the participant was allocated.||t|f|f|t
34074925|NCT00534872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977083|NCT01303562|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33977084|NCT02283775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977085|NCT03445195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of IV ETX2514SUL in patients with cUTIs.|t|t|t|t
33977086|NCT02974114|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33977087|NCT00128557|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33977088|NCT04126681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763842|NCT04005027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The investigators will use a replicated randomised repeated measures crossover design in which the participants will be randomised to different sequences of four experimental conditions||||
33763843|NCT00591864|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33763844|NCT05492526|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, randomised, open -label study||||
33977089|NCT05147077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977090|NCT00674180|||OTHER||OTHER|||||||
33977091|NCT01399164|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33977092|NCT01038570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977093|NCT01583777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977094|NCT04502069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977095|NCT05415566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The population of the randomized controlled experimental study was composed of children aged 3-8 years who applied to the pediatric emergency department due to respiratory system disease.||||
33977096|NCT03186066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074926|NCT01867320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891876|NCT01594112|||COHORT||PROSPECTIVE|||||||
33763845|NCT05826080|||COHORT||PROSPECTIVE|||||||
33763846|NCT06232668|||CASE_CONTROL||PROSPECTIVE|||||||
33763847|NCT01645826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763848|NCT03844243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded||t|f|t|f
33763849|NCT03982043|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Ultimately, this study design was an open trial after unsuccessful attempts to maintain initial recruitment sites in the study.~This study initially attempted to use a stepped wedge design, which involves the sequential random rollout of an intervention over 2 time periods. Following a baseline period in which no clusters (= practices) are exposed to the intervention, the crossover is typically in one direction, from control to intervention and continues until both of the clusters have crossed-over to receive the intervention, with observations taken from each cluster and at each time period."||||
33763850|NCT03718962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763851|NCT00247858|||CASE_ONLY||PROSPECTIVE|||||||
33763852|NCT03312608|||CASE_CONTROL||PROSPECTIVE|||||||
33763853|NCT04328402|||CASE_ONLY||CROSS_SECTIONAL|||||||
33763854|NCT02733783|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891877|NCT05397314|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33891878|NCT06468358|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase Ib/II, open, dose-escalation and expansion study of LB1410 in combination with LB4330 in patients with advanced or metastatic solid tumors. The study includes 2 parts, Part 1 Dose Escalation and Part 2 Dose Expansion. Initially, participants with pancreatic ductal adenocarcinoma, cholangiocarcinoma, colorectal cancer, ovarian, fallopian tube, or primary peritoneal cancer, non-small cell lung cancer, gastric and gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, renal cell carcinoma, cervical squamous cell carcinoma, and endometrial carcinoma will be enrolled in the study; additional tumor types may be explored and added in a future amendment to the CSP.||||
33763855|NCT00099099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33891879|NCT02747784|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891880|NCT03617731|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 x 2 arms, 1. randomization before induction therapy (arm IA and IB), 2. randomization before maintenance therapy (arm IIA and IIB)||||
33891881|NCT02134600|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33891882|NCT01696812|NA|SINGLE_GROUP||SCREENING||NONE||||||
33891883|NCT04917874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891884|NCT06656845|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33891885|NCT02149641|||COHORT||PROSPECTIVE|||||||
33891886|NCT00345605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891887|NCT05596214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"2 Stage study: Stage 1 will comprise an open label single arm exploratory study of 10 patients suffering from post AD SUDD investigating oral Cur-Berberine (Coptis) therapy for induction of clinical response.~Stage 2: If clinical response is achieved in ≥ 3 patients and no significant safety signals will emerge, we will proceed to a prospective pilot randomized placebo-controlled study."|t|t|t|f
33891888|NCT06638112|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, open-label randomized trial||||
33977097|NCT03070249|||CASE_ONLY||PROSPECTIVE|||||||
33763856|NCT01043016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763857|NCT00058019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763858|NCT02061696|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33763859|NCT03913208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763860|NCT02454829|||COHORT||PROSPECTIVE|||||||
33891889|NCT06016816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763861|NCT05556317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random generator|Resistive exercise on insomnia|t|f|f|t
33891890|NCT04319848|NA|SINGLE_GROUP||TREATMENT||NONE||interventional||||
33763862|NCT05764343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763863|NCT05414318|||CASE_ONLY||PROSPECTIVE|||||||
33763864|NCT04815317|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33763865|NCT05171413|||COHORT||OTHER|||||||
33891891|NCT02078479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891892|NCT05218811|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are scheduled for a surgical procedure: robotic partial nephrectomy, and the investigators will use a cryoablation probe(s) for selective ischemia rather than full blood flow interruption with a vascular clamp||||
33891893|NCT00349128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891894|NCT01771029|||COHORT||PROSPECTIVE|||||||
33891895|NCT02154646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891896|NCT05146908|||COHORT||PROSPECTIVE|||||||
33891897|NCT06656156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891898|NCT02399761|||COHORT||PROSPECTIVE|||||||
33891899|NCT04613206|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33891900|NCT05484193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891901|NCT05987761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891902|NCT03060421|||COHORT||RETROSPECTIVE|||||||
33891903|NCT03572088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891904|NCT03415555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
33891905|NCT04460430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891906|NCT00778830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891907|NCT06483919|||CASE_CONTROL||RETROSPECTIVE|||||||
33891908|NCT02210780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891909|NCT03189108|||COHORT||PROSPECTIVE|||||||
33891910|NCT06338644|||COHORT||PROSPECTIVE|||||||
33891911|NCT02333227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891912|NCT00979394|||COHORT||PROSPECTIVE|||||||
33891913|NCT01120639|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation with 2-level stratification||||
33891914|NCT01346956|||CASE_ONLY||PROSPECTIVE|||||||
33891915|NCT00188188|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33977098|NCT03520673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic Accuracy Study||||
33977099|NCT03947515|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33977100|NCT02844153|||COHORT|||||||||
33977101|NCT02096419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977102|NCT05868109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The nitric oxide delivery device is covered with a secure shroud and Respiratory Therapists (RTs) are able to safely administer the nitric oxide or sham and document nitric oxide dose and their delivery device checks and monitor for adverse effects according to there clinical standard of care throughout the study intervention. The RTs also document whether there has been a unmasking of the intervention every 12 hours.|Randomized controlled trial|t|t|t|t
33891916|NCT06222892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study.|||||
33977103|NCT04080583|||COHORT||PROSPECTIVE|||||||
33891917|NCT03007264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977104|NCT01628081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977105|NCT03665909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074927|NCT01355562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074928|NCT05352932|||CASE_ONLY||CROSS_SECTIONAL|||||||
33891918|NCT03932526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074929|NCT01028404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074930|NCT03893955|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34074931|NCT04770454|||COHORT||PROSPECTIVE|||||||
33891919|NCT02367950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074932|NCT04927897|||COHORT||PROSPECTIVE|||||||
33891920|NCT01968941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891921|NCT06325449|NA|SINGLE_GROUP||TREATMENT||NONE||Clinic patients with PCOS will be recruited to participate in a 24-week weight loss program. They will all receive the program. There is no control group.||||
33891922|NCT02091440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891923|NCT02790229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891924|NCT06334939|||CASE_CROSSOVER||PROSPECTIVE|||||||
33891925|NCT02052102|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891926|NCT05422976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891927|NCT06381583|||CASE_CONTROL||RETROSPECTIVE|||||||
34074933|NCT01968187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074934|NCT03363932|||COHORT||PROSPECTIVE|||||||
34074935|NCT00753675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074936|NCT04912492|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34074937|NCT01575756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34074938|NCT05488951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators conducting the testing will be masked to group assignment.|For this pilot study, participants will be randomly assigned (1:1) to the exercise (n=21) or control group (n=21). The statisticians (Dr Jennifer Waller and Dr. Brittany Ange) will generate the randomization sequence and provide it to the study coordinator after the baseline assessment; they will also conceal the treatment allocation from the assessors. Randomization will be stratified by biological sex (female/male) and study site. Blocked randomization will be performed using random block sizes of 2 and 4. Permutations of exercise or control will be performed in each block.|f|f|f|t
34074939|NCT03034837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34074940|NCT03877146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both conditions receive audio-recordings, and the radiologist care providers are blinded to the audio recordings participants receive.||f|t|f|f
34074941|NCT01136252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074942|NCT00134966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074943|NCT02145208|NA|SINGLE_GROUP||TREATMENT||NONE||iTind||||
34074944|NCT03011177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074945|NCT06180122|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34074946|NCT00888888|||COHORT||RETROSPECTIVE|||||||
34074947|NCT05413915|RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 study phases:~* Consolidation phase: 52 weeks of consolidation treatment on study with asciminib 60 mg PO QD in addition to current dose mg imatinib (300 or 400 mg PO QD) vs. current dose imatinib alone.~* TFR follow up phase: all participants attempting TFR to be followed for CML remission status."||||
34074948|NCT01900041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074949|NCT02472158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34074950|NCT06609278|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34074951|NCT02870192|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33891928|NCT04222465|||OTHER||CROSS_SECTIONAL|||||||
34074952|NCT06515418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34074953|NCT01497548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074954|NCT04785898|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a diagnostic cohort study.||||
34074955|NCT02966132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074956|NCT04016142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074957|NCT06378307|||CASE_ONLY||PROSPECTIVE|||||||
34074958|NCT00943592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074959|NCT05588752|RANDOMIZED|PARALLEL||OTHER||SINGLE||Patients admitted for caesarean under spinal anesthesia were randomized according to the sealed envelope method into two groups. Group 1 received 100 µg of morphine intrathecally at induction and group 2 a bilateral TAP block at the end of cesarean section with 20 ml of bupivacaine 0.25% and dexamethasone 4 mg in the same syringe on each side.|t|f|f|f
33891929|NCT00104130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34074960|NCT04601168|||COHORT||PROSPECTIVE|||||||
34074961|NCT03790852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074962|NCT02945735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074963|NCT02007720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34074964|NCT05339919|||CASE_CONTROL||PROSPECTIVE|||||||
34074965|NCT04406714|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"Trial (Age Group 50-75) Using a randomized controlled trial study design, subjects are assigned to one of two arms: Arm 1: Trial Mailed FIT Intervention; or Arm 2: Trial Usual Care. Arm 1 (intervention) receives a mailed FIT plus up to two reminder letters. Subjects are randomized 1:1 at baseline and remain in their assigned arm for the duration of the study (i.e., two annual rounds of mailed FIT).~Sub-study (Age Group 45-49) Subjects, ages 45-49, are randomly assigned to one of two arms: Arm 3: Sub-Study Mailed FIT Intervention - Enhanced Envelope; or Arm 4: Sub-study Mailed FIT Active Comparator Plain Envelope. Subjects in both Arm 3 and Arm 4 receive mailed FIT plus up to two reminder letters. Subjects are randomized 1:1 at baseline and remain in their assigned arm for the duration of the sub-study (i.e., one annual round of mailed FIT)."|f|f|f|t
34074966|NCT02003755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074967|NCT05452915|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33891930|NCT03763786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891931|NCT02916277|||COHORT||PROSPECTIVE|||||||
33891932|NCT03747445|||CASE_CONTROL||PROSPECTIVE|||||||
33891933|NCT01121289|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33891934|NCT02295202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34074968|NCT03170817|||COHORT||PROSPECTIVE|||||||
33891935|NCT04295590|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33891936|NCT02507830|||COHORT||PROSPECTIVE|||||||
33891937|NCT02586480|||COHORT||PROSPECTIVE|||||||
33891938|NCT02553837|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33891939|NCT01624584|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33891940|NCT02970773|NA|SINGLE_GROUP||OTHER||NONE||||||
34074969|NCT05452148|||CASE_CONTROL||RETROSPECTIVE|||||||
34074970|NCT01794962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074971|NCT03459716|||COHORT||PROSPECTIVE|||||||
34074972|NCT03625882|||COHORT||PROSPECTIVE|||||||
34074973|NCT06612801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891941|NCT00212407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891942|NCT05736263|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33891943|NCT01046526|||||OTHER|||||||
33891944|NCT05626088|||COHORT||OTHER|||||||
33891945|NCT02180009|||COHORT||PROSPECTIVE|||||||
33891946|NCT02485717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891947|NCT01296906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33891948|NCT05844917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891949|NCT03980587|||CASE_ONLY||RETROSPECTIVE|||||||
33891950|NCT05119387|||CASE_ONLY||CROSS_SECTIONAL|||||||
33891951|NCT02065089|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33891952|NCT00167479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891953|NCT00878124|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33891954|NCT03125603|||COHORT||OTHER|||||||
33891955|NCT03277196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891956|NCT02623179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891957|NCT00089557||||TREATMENT||NONE||||||
33891958|NCT03232541|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|All other care providers beside the acupuncture/sham providing therapists are blinded to randomization group. For example, care providers providing the standard antiemetic treatment and the chemotherapy per se are blinded regarding randomization group.||t|f|t|t
33891959|NCT03088514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33891960|NCT03545464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891961|NCT03485989|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33891962|NCT00710645|||COHORT||PROSPECTIVE|||||||
33891963|NCT04762030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891964|NCT03136939|||CASE_CONTROL||PROSPECTIVE|||||||
33891965|NCT04528485|NA|SINGLE_GROUP||OTHER||NONE||||||
33891966|NCT03732547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891967|NCT04713943|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33891968|NCT02018692|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33891969|NCT03522129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind for study site and participants|Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.|t|t|t|t
33891970|NCT00138762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33891971|NCT06352177|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomization||||
33891972|NCT02406846|||COHORT||PROSPECTIVE|||||||
33891973|NCT05865483|||COHORT||CROSS_SECTIONAL|||||||
33891974|NCT05551130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33891975|NCT00576771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891976|NCT00626873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33891977|NCT06656624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891978|NCT02406755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891979|NCT01392833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891980|NCT06296394|||COHORT||PROSPECTIVE|||||||
34074974|NCT03055247|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34074975|NCT00500578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33891981|NCT01146470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891982|NCT01235676|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33891983|NCT05435521|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Masking will not be performed due to the necessity of active supervision and follow up of the activity program|Multicentric prospective longitudinal clinical study with intervention with a control group (Non HIV patients) and a group wih HIV||||
33977106|NCT05105373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The allocation status of other participating families will be concealed from participants, thus reducing the potential for contamination. Research assistants conducting data assessments and statisticians conducting analysis will be blind to allocation in order to minimise assessment bias. Different groups of research assistants will be employed for outcome assessments and monitoring of implementation fidelity and adherence. Any instances of compromised blinding will be immediately reported. In the case of instances of harm or severe abuse being reported by a participant at any stage of the study, the allocation status of the participant will be un-blinded. All cases of un-blinding will be reported. Because of facilitators' involvement in the programme implementation, blinding will not be possible for service providers. Similarly, of course, participants cannot be blind to their own treatment condition.|Cluster Randomized Controlled Trial Hybrid Type 2 Evaluation|t|f|f|t
33977107|NCT02518113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977108|NCT04782726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977109|NCT02200965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977110|NCT03777033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized control trial - control group ( supplements of calcium and vit D on demand) vs study group ( systematic administration of oral calcium and vit D )|f|f|f|t
33977111|NCT05510648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977112|NCT02035709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33891984|NCT00619229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33891985|NCT05760495|||CASE_CROSSOVER||PROSPECTIVE|||||||
33891986|NCT03845530|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33891987|NCT01126229|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33891988|NCT00190775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33891989|NCT04774250|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The study will be masked or blinded in the sense that all the study participants and the study team members will be blinded to the assignment in the study groups. Only the pharmacist who will prepare the drug packets and will seal the envelopes, and the programmer not involved with the study who will produce the random treatment assignments and print the labels will know the order of treatments for any subject. An independent medical professional who is not part of the study team will complete the de-identification of the study drug, and a procedure and documentation log will be in place for quality assurance purposes. The ZNS and placebo capsules will look, taste, and smell the same."|Randomized, double-blind, and placebo-controlled|t|f|t|t
33891990|NCT05486078|NA|SINGLE_GROUP||TREATMENT||NONE||One sample study||||
33891991|NCT02861170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33977113|NCT03601663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33891992|NCT01497171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33891993|NCT01258920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891994|NCT05992467|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33891995|NCT06500741|||OTHER||PROSPECTIVE|||||||
33891996|NCT05278390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977114|NCT05838066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977115|NCT02957656|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977116|NCT05713409|||COHORT||PROSPECTIVE|||||||
33977117|NCT01198236|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977118|NCT03526965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977119|NCT00944697|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33977120|NCT03263299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977121|NCT01840189|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977122|NCT02999035|||OTHER||OTHER|||||||
33977123|NCT02313103|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33977124|NCT06071013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977125|NCT00386464|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33891997|NCT00278876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33891998|NCT03817671|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33891999|NCT06234267|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892000|NCT04576442|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977126|NCT03130764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977127|NCT06194474|||OTHER||RETROSPECTIVE|||||||
33977128|NCT03791749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074976|NCT02362893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977129|NCT05395000|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Half of the participants will perform the simulation study with the intranasal device first and the other half with the injectable glucagon to minimize the bias related to the lower stress of the second simulation.||||
33977130|NCT00263107|||DEFINED_POPULATION||OTHER|||||||
33977131|NCT04552574|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34074977|NCT03564769|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34074978|NCT02360787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34074979|NCT00889655|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34074980|NCT00423280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34074981|NCT01885832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34074982|NCT00197431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892001|NCT06399757|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892002|NCT03618030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33892003|NCT01739426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892004|NCT00782249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892005|NCT01083108|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33892006|NCT04610099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892007|NCT04117750|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33977132|NCT00289601|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34074983|NCT00300222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34074984|NCT01280526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892008|NCT01533311|||COHORT||PROSPECTIVE|||||||
33892009|NCT00183846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892010|NCT01276821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892011|NCT04274322|||COHORT||PROSPECTIVE|||||||
33892012|NCT01416129|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892013|NCT05645094|||CASE_ONLY||PROSPECTIVE|||||||
33892014|NCT01817140|||OTHER||PROSPECTIVE|||||||
34074985|NCT01276912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074986|NCT05453110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Mixed Design with Time Repeated and Group Between-Factor, Randomized Controlled Trial|t|f|f|t
34074987|NCT03335319|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients will be randomized and stratified (by gender and age) into either one of the two groups exercise training groups: 1) periodization or 2) non periodization. The randomization code will be developed with a computer random-number generator to select random permuted blocks.|t|t|f|t
34074988|NCT02690012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34074989|NCT06117722|||OTHER||PROSPECTIVE|||||||
34074990|NCT04270617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074991|NCT04530838|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34074992|NCT00666211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34074993|NCT06612359|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
34074994|NCT00075452|RANDOMIZED|||TREATMENT||||||||
34074995|NCT01293747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34074996|NCT05113680|RANDOMIZED|PARALLEL||TREATMENT||NONE||compassion focused group, emotional competencies group, control group||||
34074997|NCT03628378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34074998|NCT06119165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34074999|NCT02128139|||CASE_ONLY||PROSPECTIVE|||||||
33977133|NCT02509013|||COHORT||PROSPECTIVE|||||||
34075000|NCT05556980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the Outcomes Assessor would not know which approach the patient received.||f|f|f|t
34075001|NCT04324632|||CASE_ONLY||CROSS_SECTIONAL|||||||
34075002|NCT05633641|||COHORT||PROSPECTIVE|||||||
34075003|NCT04658433|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34075004|NCT01698970|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34075005|NCT02632006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977134|NCT02324972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977135|NCT06396520|||COHORT||PROSPECTIVE|||||||
33977136|NCT05927285|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Allocation was performed by the cardiology staff on a concealed opaque envelope until the beginning of the study. A double-blind, double dummy design was used.|"The control group is considered the conventional approach, where the treatment was guided by improvement in clinical data, imaging, or laboratory studies during the daily evaluation until categorized as decongested.~The VExUS group was considered the intervention group, where in addition to all the above, the decision for decongestant treatment was guided by the VExUS score until reaching a score that VExUS considered noncongestive, which was grade 0."|t|f|f|f
33977137|NCT00012714|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977138|NCT05198804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977139|NCT02448771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977140|NCT01627275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977141|NCT05405998|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977142|NCT02276313|||OTHER||PROSPECTIVE|||||||
33977143|NCT01431924|||COHORT||RETROSPECTIVE|||||||
33977144|NCT02560350|||COHORT||PROSPECTIVE|||||||
33977145|NCT01224132|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34075006|NCT02948647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977146|NCT00154414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977147|NCT04393506|NA|SEQUENTIAL||TREATMENT||NONE||||||
33977148|NCT02437149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977149|NCT02663648|||CASE_CONTROL||PROSPECTIVE|||||||
34075007|NCT05221697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075008|NCT01369459|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075009|NCT02533934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075010|NCT00616252|||COHORT||PROSPECTIVE|||||||
34075011|NCT00608751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075012|NCT01608464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075013|NCT05361967|||COHORT||PROSPECTIVE|||||||
34075014|NCT04781296|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The single group model will enroll subjects from 5 anatomical areas (lungs, brain/carotid vessels, heart/chest, MSK and abdomen) where CT imaging is applicable and where data on the photon-counting CT is needed to assess feasibility and guide further development of the technology.||||
34075015|NCT02536105|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34075016|NCT00527280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075017|NCT03861091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075018|NCT05163262|NA|SINGLE_GROUP||OTHER||NONE||||||
34075019|NCT00760721|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34075020|NCT01944748|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075021|NCT04033146|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants will perform the same trials/sessions to complete the entire protocol. After each participant has performed all trials for this study, the investigators will analyze the data of this repeated-measures design.||||
34075022|NCT02571062|RANDOMIZED|CROSSOVER||||NONE||||||
34075023|NCT01772927|||COHORT||PROSPECTIVE|||||||
34075024|NCT04643327|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double-blind randomised-controlled within-subject crossover trial|t|t|t|t
34075025|NCT03795337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075026|NCT01619878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075027|NCT03113110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075028|NCT01074177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075029|NCT02954328|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33892015|NCT02355301|||CASE_CONTROL||PROSPECTIVE|||||||
33892016|NCT05129150|||CASE_ONLY||PROSPECTIVE|||||||
33892017|NCT05852483|||COHORT||RETROSPECTIVE|||||||
33892018|NCT00743795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075030|NCT04657263|||COHORT||PROSPECTIVE|||||||
33892019|NCT02249052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892020|NCT06656754|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33892021|NCT05019456|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants who elect to receive the COVID-19 vaccine will be asked to completed an acute bout of exercise 2 weeks after their final dose.||||
33892022|NCT06131710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892023|NCT03671122|||COHORT||PROSPECTIVE|||||||
33892024|NCT00416533||||TREATMENT||NONE||||||
33892025|NCT02208648|||COHORT||RETROSPECTIVE|||||||
33892026|NCT02219230|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34075031|NCT01275443|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33892027|NCT03550690|||COHORT||PROSPECTIVE|||||||
33892028|NCT01474577|||COHORT||RETROSPECTIVE|||||||
33892029|NCT01409317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892030|NCT01870544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892031|NCT05177484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075032|NCT05364476|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm, non-randomized clinical trial, which will collect participant's baseline data, apply relevant assessment scales, collect data using a comprehensive digital intervention in 16 weeks to evaluate the improvement of relevant markers post intervention.||||
34075033|NCT05622461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075034|NCT04485078|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892032|NCT05296967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892033|NCT03373019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892034|NCT02948166|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33892035|NCT03848819|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a randomised crossover trial. Patients will perform two identical exercise tests and the intervention (VitaBreath) will be compared to control condition (pursed-lip breathing) in the same patients.The order of testing will be determined by simple randomisation (sealedenvelope.com).||||
33892036|NCT02087566|RANDOMIZED|PARALLEL||||NONE||||||
33892037|NCT06404190|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|GROUP A: 10 SRP ALONE GROUP B: 10 SRP+3%HYDROGEN PEROXIDE+DIODE LASER|GROUP A: ultrasonic GROUP B: laser and hydrogen peroxide||||
33892038|NCT05662592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892039|NCT00638664|||OTHER||PROSPECTIVE|||||||
33892040|NCT01360996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892041|NCT02931448|||CASE_ONLY||PROSPECTIVE|||||||
33892042|NCT04716322|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective monocentric cohort with consecutive inclusions of participants with chronic disease, and followed for 5 years after an initial 16-week physical activity program intervention||||
33892043|NCT00146042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892044|NCT03268629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892045|NCT01205009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892046|NCT03232307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892047|NCT05312502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The sample size was 106 pregnant women, 53 in each group, with a known score using the G\*Power 3.1.7 program (intervention group=29.19±5.86-control group=26.51±5.13) with 85% power, 0.48 effect size and 0.15 error. was calculated as. Considering data loss, it is planned to reach 10% more pregnant women. Intervention group=57, control group=54 pregnants, and the study was terminated. The women were divided into two groups using the random numbers table in the simple random sampling method. Single blinding was performed on the women participating in the study. However, in order to prevent bias, the researcher who collected the data gave codes to the questionnaire forms of the pregnant women.|t|f|t|f
34075035|NCT06473207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075036|NCT02931786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34075037|NCT02542397|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Enrolled subjects all receive pharmacogenomic testing with the intention of guiding pain management. This single-arm trial is testing against a published historical control.||||
34075038|NCT00762762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075039|NCT02997605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33763866|NCT03919786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Intervention is not blinded to anesthesiologists and nurses participating intraoperative management.These anesthesiologists and nurses will not participate the follow-up study of this patient.Surgeons performing surgery are blinded.||t|t|t|t
33763867|NCT04369638|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33763868|NCT06202027|||COHORT||PROSPECTIVE|||||||
33763869|NCT02920775|||CASE_CONTROL||RETROSPECTIVE|||||||
33763870|NCT03541772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33892048|NCT06656013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892049|NCT00779129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892050|NCT06030011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33892051|NCT06654648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892052|NCT06228755|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34075040|NCT04010292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075041|NCT04635930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075042|NCT04058197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892053|NCT02765659|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892054|NCT04836039|||COHORT||RETROSPECTIVE|||||||
33892055|NCT04704934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892056|NCT05559814|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33892057|NCT05962008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075043|NCT01405898|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34075044|NCT00214617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075045|NCT00653367|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34075046|NCT03793647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, randomized controlled study|f|f|t|f
34075047|NCT03212014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075048|NCT00397605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33892058|NCT04996693|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|no masking required|Randomization of patients referred for a CT scan of the thorax on one of three CT scanners routinely used for this purpose in our department||||
33892059|NCT02317510|RANDOMIZED|PARALLEL||||NONE||||||
33892060|NCT03904680|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients will be randomly divided into 2 groups:~Group A: 15 patients will take methotrexate weekly for 3 months for the treatment of psoriasis.~Group B: will take methotrexate weekly in addition to Vitamin D injections monthly for 3 months for treatment of psoriasis"||||
33892061|NCT04746586|||CASE_CONTROL||OTHER|||||||
33892062|NCT05937477|||CASE_ONLY||PROSPECTIVE|||||||
33892063|NCT01591005|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892064|NCT02859038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892065|NCT06617481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892066|NCT00867750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892067|NCT03783195|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are assigned to high genetic risk score group in parallel to low genetic risk score group||||
33892068|NCT03478826|||OTHER||RETROSPECTIVE|||||||
33892069|NCT03931174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster Randomized Trial|f|f|f|t
33892070|NCT05452603|||OTHER||CROSS_SECTIONAL|||||||
33892071|NCT05733455|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33892072|NCT02155426|||CASE_ONLY||PROSPECTIVE|||||||
33892073|NCT04810273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892074|NCT06464107|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33892075|NCT05507424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892076|NCT00212914|RANDOMIZED|FACTORIAL||||NONE||||||
33892077|NCT06657456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892078|NCT02810990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892079|NCT04814979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892080|NCT04436302|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33892081|NCT01099111|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892082|NCT00009672||||TREATMENT||||||||
33892083|NCT03505268|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33892084|NCT03343964|||COHORT||PROSPECTIVE|||||||
33892085|NCT01400737|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33892086|NCT02783560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892087|NCT03023748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892088|NCT03617705|NA|SINGLE_GROUP||OTHER||NONE||||||
33892089|NCT05641350|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33892090|NCT04423848|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33892091|NCT01128205|||COHORT||CROSS_SECTIONAL|||||||
33892092|NCT02276651|||CASE_CONTROL||PROSPECTIVE|||||||
33892093|NCT02513446|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892094|NCT02160067|RANDOMIZED|CROSSOVER||||NONE||||||
33892095|NCT06574035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33892096|NCT04757129|||CASE_CONTROL||PROSPECTIVE|||||||
33892097|NCT06657430|||CASE_ONLY||CROSS_SECTIONAL|||||||
33892098|NCT00797121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892099|NCT00764725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892100|NCT04697914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33892101|NCT05369806|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants are enrolled into the MWACh SMS system||||
33892102|NCT00627666||||TREATMENT||NONE||||||
33892103|NCT03095092|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892104|NCT06041243|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33892105|NCT06487351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open label|Pharmacy intern participants will be randomized 1:1 using permuted block and stratified by gender and race/ethnicity to the adapted intervention or control group. Participants will be notified after consent.||||
33977150|NCT05823090|NA|SINGLE_GROUP||TREATMENT||NONE|"Participants were blinded as to the type of light they received from the BLT device.~Participants were assessed by both a blinded and non-blinded investigator. The blinded investigator assigned the Clinical Global Impressions Severity and Improvement Scales. The non-blinded investigator made clinical decisions regarding the BLT dose."|placebo lead-in open trial||||
33977151|NCT04297280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977152|NCT04872049|||COHORT||CROSS_SECTIONAL|||||||
33977153|NCT03870620|||OTHER||OTHER|||||||
33977154|NCT01890915|||CASE_CONTROL||PROSPECTIVE|||||||
33977155|NCT03785236|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33977156|NCT05053165|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33977157|NCT03526939|||COHORT||PROSPECTIVE|||||||
33977158|NCT01820039|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33977159|NCT02986763|||COHORT||CROSS_SECTIONAL|||||||
33977160|NCT02540356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977161|NCT05376046|||COHORT||PROSPECTIVE|||||||
33977162|NCT00873054|||CASE_ONLY||PROSPECTIVE|||||||
33977163|NCT00587574|||COHORT||PROSPECTIVE|||||||
33977164|NCT01393236|||||PROSPECTIVE|||||||
33977165|NCT03625609|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33977166|NCT04906577|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33977167|NCT04500522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized controlled trial|double blind randomized controlled trial|t|t|t|t
33977168|NCT00532337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763871|NCT00730379|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763872|NCT01285284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33892106|NCT06656442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be a prospective, randomized controlled, open-label clinical trial conducted on 60 acute ischemic stroke patients|t|f|f|f
33892107|NCT06286423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study team is planning to use controls in the present study. Controls will be patients from the target population, i.e. acutely decompensated heart failure with reduced ejection fraction.|t|t|t|f
33892108|NCT02772783|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33892109|NCT00282243|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33977169|NCT01690442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977170|NCT01209052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977171|NCT06496087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977172|NCT04078048|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33977173|NCT04111770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977174|NCT02619799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33977175|NCT06308874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977176|NCT05876195|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel group randomised experimental medicine study|t|f|f|f
33977177|NCT03048162|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977178|NCT04908566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977179|NCT05132309|||COHORT||PROSPECTIVE|||||||
33977180|NCT00392639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33977181|NCT03774238|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|COPD patient group (n=50) and Healthy control Group (n=24)|||||
33892110|NCT02471287|||COHORT||PROSPECTIVE|||||||
33892111|NCT06349629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892112|NCT00511303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892113|NCT02706639|||COHORT||PROSPECTIVE|||||||
33892114|NCT03471403|||COHORT||PROSPECTIVE|||||||
33892115|NCT02047006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977182|NCT03868137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization sequence will be generated and given to the research pharmacist who will dispense the appropriate medications to the participants in each arm. Only the pharmacist will know which patient is in which trial arm until the study has ended and data has been analyzed.|Triple blind randomized control trial involving placebo arm and intervention arm (Ibuprofen)|t|t|t|t
33977183|NCT01456182|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33977184|NCT06257108|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Split-mouth design|t|f|f|t
33977185|NCT06387875|||COHORT||PROSPECTIVE|||||||
33977186|NCT02248077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977187|NCT01521442|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33977188|NCT00966953|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977189|NCT02369809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977190|NCT01963039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892116|NCT01049776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977191|NCT02114697|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The protocol originally specified randomizing participants to a study arm, but the protocol was amended to clarify that a participant's cardiologist could change the treatment regimens that participants were assigned to so that no participant was restricted from statin therapy.|f|f|t|f
33977192|NCT05445128|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33977193|NCT01160783|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33977194|NCT04634448|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective clinical cohort study||||
33977195|NCT01945138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977196|NCT01580878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977197|NCT00747188||||HEALTH_SERVICES_RESEARCH||||||||
33977198|NCT04438057|RANDOMIZED|PARALLEL||TREATMENT||NONE||Outpatient open label randomized study||||
33977199|NCT01144663|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977200|NCT01004172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763873|NCT02558270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33763874|NCT01175148|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33763875|NCT03352843|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763876|NCT03962725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763877|NCT05566639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33892117|NCT01042262|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33892118|NCT06529796|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33892119|NCT05605756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892120|NCT03180736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking: Open Label|Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment|t|f|f|f
33892121|NCT03488199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892122|NCT03650062|||COHORT||PROSPECTIVE|||||||
33892123|NCT06105138|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33892124|NCT01438645|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33892125|NCT06427109|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892126|NCT04673981|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892127|NCT00780403|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33892128|NCT02909868|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33977201|NCT03841032|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977202|NCT01996033|||COHORT||PROSPECTIVE|||||||
33977203|NCT06547580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763878|NCT00510458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892129|NCT02214849|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33892130|NCT00222911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892131|NCT04073667|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33892132|NCT00412529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892133|NCT02844855|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892134|NCT04433117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial. Entails 2 groups of subjects which will be randomly assigned. Group 1 will be the control group, and group 2 is test group.|t|f|t|t
33892135|NCT02303054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892136|NCT06217679|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33763879|NCT01212536|RANDOMIZED|PARALLEL||||NONE||||||
33892137|NCT03754985|||COHORT||PROSPECTIVE|||||||
33892138|NCT00144170||PARALLEL||TREATMENT||||||||
33892139|NCT02338843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892140|NCT02386774|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892141|NCT03634982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892142|NCT05655585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892143|NCT01143480|||COHORT||CROSS_SECTIONAL|||||||
33892144|NCT00019955||||TREATMENT||NONE||||||
33892145|NCT04379752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892146|NCT05987644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892147|NCT04807361|||CASE_CONTROL||OTHER|||||||
33892148|NCT01982825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892149|NCT06192121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Simple Randomization and single blinding will be done.|Randomised Control Trial|t|f|f|f
33892150|NCT00791726|||COHORT||CROSS_SECTIONAL|||||||
33892151|NCT03959189|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33892152|NCT03567655|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single arm, prospective multi-institutional study.||||
33892153|NCT04837417|||COHORT||PROSPECTIVE|||||||
33892154|NCT00807469|||CASE_CONTROL||PROSPECTIVE|||||||
33892155|NCT05742321|||COHORT||PROSPECTIVE|||||||
33892156|NCT01477450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892157|NCT01283256|||COHORT||PROSPECTIVE|||||||
33892158|NCT04647214|||COHORT||PROSPECTIVE|||||||
33892159|NCT00000979||||TREATMENT||||||||
33892160|NCT01254344|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33892161|NCT02427165|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33892162|NCT04938856|RANDOMIZED|CROSSOVER||OTHER||NONE||open label, randomized, single-dose, 2 way cross-over study||||
33763880|NCT05102422|||COHORT||PROSPECTIVE|||||||
33892163|NCT00023322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892164|NCT04751721|NA|SINGLE_GROUP||SCREENING||NONE||||||
33892165|NCT00013078|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33892166|NCT06401980|RANDOMIZED|PARALLEL||TREATMENT||NONE||International, randomized, open label, phase II study.||||
33892167|NCT02898012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892168|NCT00712101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892169|NCT04466124|||COHORT||PROSPECTIVE|||||||
33892170|NCT01340183|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33892171|NCT01086787|||COHORT||PROSPECTIVE|||||||
33892172|NCT01947023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892173|NCT05864378|||COHORT||RETROSPECTIVE|||||||
33892174|NCT03332069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinicians conducting follow up evaluations, radiographers and nuclear medicine physicians reporting on the PET/CT investigations are unaware of the group that the participants have been assigned to.||f|t|f|t
33892175|NCT02163070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892176|NCT03744650|NA|SINGLE_GROUP||PREVENTION||NONE||A two-phase study design will be adopted. Phase 1 is a pilot, two-arm randomized controlled trial (RCT) study and phase 2 is a single group pretest and repeated posttest longitudinal study.||||
33892177|NCT04792294|||OTHER||RETROSPECTIVE|||||||
33892178|NCT00329290|||CASE_ONLY||RETROSPECTIVE|||||||
33892179|NCT06179472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of outcomes between patients who elect to receive the intervention versus those that do not in the specified time-frame||||
33892180|NCT06041555|||COHORT||PROSPECTIVE|||||||
33892181|NCT03290014|||COHORT||PROSPECTIVE|||||||
33892182|NCT04036825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33892183|NCT01213056|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892184|NCT02176486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892185|NCT00963807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892186|NCT02867696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892187|NCT04746326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Conservative treatment, Operative treatment||||
33892188|NCT06256848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33977204|NCT01789320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763881|NCT05351476|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33892189|NCT05576220|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33892190|NCT00789347|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892191|NCT03343821|||CASE_ONLY||PROSPECTIVE|||||||
33892192|NCT00004486|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33892193|NCT01999738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892194|NCT01902108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33892195|NCT02885129|||COHORT||PROSPECTIVE|||||||
33892196|NCT02806401|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33977205|NCT04173936|||COHORT||RETROSPECTIVE|||||||
33977206|NCT03617692|||COHORT||PROSPECTIVE|||||||
33763882|NCT03620721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33763883|NCT05012475|NA|SINGLE_GROUP||TREATMENT||NONE|No masks needed as no direct contact will take place. This study is designed to be entirely virtual.|Investigators accept individuals with Rett syndrome who meet the inclusion criteria that requires functional arm range of motion, understanding of cause and effect and a diagnosis of Rett syndrome.||||
33765047|NCT04099602|RANDOMIZED|PARALLEL||PREVENTION||NONE||In the study, the investigators were decided that at least 30 premature infants were included in each group considering that losses might occur during data collection. Block randomization method was used to control the selection bias that might arise during the determination of the study groups. In this method, the number and probability of groups are equal in each block. Infants in both groups were randomized to block stratified by sex and gestational week. In the block randomization, blocks are selected randomly and this process is continued until all the subjects to be included in the study are assigned to the groups and the number of subjects in the groups is equalized at the end of this procedure||||
33765048|NCT00410787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892197|NCT05405426|RANDOMIZED|PARALLEL||OTHER||SINGLE|Adjudicators for the primary endpoint (organ failure assessment score) will be blinded to treatment assignment. Specialists for neurodevelopmental assessment of participants will be blinded to treatment assignment.|Two independent study arms will be used: indication-based red blood cell transfusion strategy vs. a center-specific standard of care hemoglobin/hematocrit threshold-based red blood cell transfusion strategy|f|f|f|t
33892198|NCT04687124|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization by sealed envelopes. Stratified for location of cancer||||
33892199|NCT06657781|||COHORT||CROSS_SECTIONAL|||||||
33892200|NCT00977652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977207|NCT04437342|||OTHER||PROSPECTIVE|||||||
33977208|NCT02697409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977209|NCT05951569|||COHORT||PROSPECTIVE|||||||
33977210|NCT03528668|||OTHER||PROSPECTIVE|||||||
33977211|NCT04568681|||CASE_ONLY||RETROSPECTIVE|||||||
33977212|NCT01107002|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33977213|NCT05265182|RANDOMIZED|SEQUENTIAL||OTHER||NONE||HMD and Semi-Cave||||
33892201|NCT03420560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will not knowing the exact temperature of the room,thought they will have their own feeling about it. Data was collecting with a anesthesia nurse who do not know what will do with these data. data were assessed to an anesthesiologist who did not know the Group allocation.|patients for observation will sent to a warmer operating room,while Patients in controled Group will send to normal setting operating room at about 23 centigrade.|t|f|f|t
33977214|NCT02954679|||OTHER||PROSPECTIVE|||||||
33977215|NCT02015975|||CASE_ONLY||PROSPECTIVE|||||||
34075049|NCT03779347|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|Study assessor /investigator will be blinded from the treatment allocation. Treatment for study participants will be given under the supervision of the trained nurses at the ANC, while the study assessor will assess participants for clinical events at the research center||f|f|t|t
34075050|NCT02455505|||COHORT||PROSPECTIVE|||||||
34075051|NCT01951417|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075052|NCT00991289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075053|NCT05602740|||COHORT||PROSPECTIVE|||||||
34075054|NCT02907463|||OTHER||OTHER|||||||
34075055|NCT00120705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075056|NCT00254553|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34075057|NCT02440061|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34075058|NCT02051790|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34075059|NCT03438084|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34075060|NCT00002182||||TREATMENT||DOUBLE||||||
34075061|NCT06171854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075062|NCT00118989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34075063|NCT01711983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075064|NCT01289548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34075065|NCT03414333|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075066|NCT03559543|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075067|NCT01867515|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34075068|NCT05714696|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34075069|NCT06300099|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34075070|NCT04181671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|Both experimental and control groups will be treated at the same time following their respective protocols|t|f|f|f
33892202|NCT00716443|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33892203|NCT00021294||||TREATMENT||||||||
33892204|NCT00503191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892205|NCT04918121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892206|NCT01128712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977216|NCT00757601|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977217|NCT02388178|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33977218|NCT00349947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977219|NCT05822401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977220|NCT01328275|||COHORT||PROSPECTIVE|||||||
33977221|NCT01775020|NA|SINGLE_GROUP||||NONE||||||
33977222|NCT04242771|NA|SINGLE_GROUP||OTHER||NONE||||||
34075071|NCT02408042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075072|NCT02541422|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34075073|NCT03574077|RANDOMIZED|PARALLEL||OTHER||SINGLE|All outcome assessors will be blinded to the group allocation, this RCT will be single-blinded.|"This pilot randomized controlled trial (RCT) has 2 arms: intervention group A (Group A), and control group (Group B). The participants will be randomly assigned to one of the 2 groups. The investigators will randomly select 12 smoking hotspots (SH) from different locations in Hong Kong Island, Kowloon and New Territories for recruitment (4 in each region). A total of 24 sessions of recruitment activities will be organized to recruit 282 participants. The onsite recruitment and counselling will be conducted by trained SC ambassadors. SC ambassadors will approach smokers using a foot-in- the-door technique. Smoking status will be validated using exhaled carbon monoxide (CO) and eligibility will be checked by a short questionnaire."|f|f|f|t
34075074|NCT00181883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075075|NCT05084183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is intended that blinded assessment of wounds will be performed at 14 days after treatment.|Prospective, randomized, single-blinded, adaptive, controlled clinical trial.|f|f|f|t
33892207|NCT05313048|||COHORT||PROSPECTIVE|||||||
33765049|NCT04170686|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765050|NCT05365711|||COHORT||PROSPECTIVE|||||||
33765051|NCT04954586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33765052|NCT02094521|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892208|NCT05250856|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The study was designed with multiple ascending doses of CNP-201 in a Dose Escalation Phase, with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects in a Dose Expansion Phase. However, the study was terminated for administrative reasons and lagging enrollment within the Dose Escalation Phase.|t|t|t|t
33765053|NCT04438902|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open, single-arm, exploratory phase 2 trial.||||
33765054|NCT01545180|||COHORT||PROSPECTIVE|||||||
33892209|NCT04418817|||COHORT||RETROSPECTIVE|||||||
33892210|NCT00032929|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33892211|NCT04825548|||CASE_ONLY||CROSS_SECTIONAL|||||||
33892212|NCT05373238|||CASE_CONTROL||PROSPECTIVE|||||||
33892213|NCT05013840|||CASE_ONLY||CROSS_SECTIONAL|||||||
33892214|NCT00875758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892215|NCT04471896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892216|NCT01767584|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33892217|NCT00872313|||CASE_ONLY||PROSPECTIVE|||||||
33892218|NCT02082197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892219|NCT02137044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892220|NCT02792140|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33892221|NCT00001515||||TREATMENT||||||||
33892222|NCT01283737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892223|NCT00683540|||OTHER||PROSPECTIVE|||||||
33892224|NCT04209270|||COHORT||PROSPECTIVE|||||||
33892225|NCT06062719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Enrolled patients were assigned to one of two groups. After the initial endoscopy, both groups received either an 80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours or the octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours.|t|f|f|t
33892226|NCT05723887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892227|NCT06368947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33892228|NCT05321186|NA|SINGLE_GROUP||TREATMENT||NONE||the study will be a prospective interventional case series.||||
33892229|NCT00966927|||COHORT||CROSS_SECTIONAL|||||||
33892230|NCT00794586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892231|NCT00444015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977223|NCT04809246|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This study will be conducted as a prospective historically controlled study with a primary objective of assessing the effect of an intervention integrating point-of-care HCV RNA testing, non-invasive liver fibrosis assessment, fast-tracked DAA therapy, and linkage to hepatitis care (a 'one-stop-shop' intervention) on the proportion of participants initiating DAA therapy among people who are recently incarcerated within reception correctional centre(s) in Australia.~All people who are newly incarcerated (in the previous six weeks) will be offered participation. The first 240 individuals will be enrolled into a control period to receive HCV testing and treatment via the standard of care with the current health service model. After the control period, the next 300 individuals will be enrolled in the intervention period to receive HCV testing and treatment via the 'one-stop-shop' intervention."||||
33977224|NCT01608581|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977225|NCT01827007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977226|NCT01779622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33977227|NCT01124851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977228|NCT00605449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33765055|NCT02468102|||COHORT||PROSPECTIVE|||||||
33765056|NCT04257708|||OTHER||PROSPECTIVE|||||||
33765057|NCT00815035|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33765058|NCT03454464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892232|NCT03551522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind Placebo Controlled|Randomization: 1:2:2:2 (placebo: seladelpar 10 mg: 20 mg: 50 mg)|t|t|t|t
33892233|NCT03339141|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|||||
33892234|NCT01407120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892235|NCT00420108|||COHORT||PROSPECTIVE|||||||
33892236|NCT01201499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075076|NCT04487808|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34075077|NCT00507260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892237|NCT01065935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892238|NCT05793619|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33892239|NCT01039207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892240|NCT01477021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892241|NCT03637049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892242|NCT01548261|||CASE_ONLY|||||||||
33892243|NCT00389207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892244|NCT00003803|RANDOMIZED|||TREATMENT||||||||
33892245|NCT01814657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892246|NCT03931655|||CASE_ONLY||PROSPECTIVE|||||||
33892247|NCT03603743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|heart rate variability analyses and echocardiography were performed by investigators blind to randomization|"subjects were randomly assigned to one of the two groups:~1. high intensity interval training~2. moderate intensity and continuous training Block size = 4, allocation ratio 1:1"|f|f|t|t
33892248|NCT02071693|||CASE_ONLY||RETROSPECTIVE|||||||
33892249|NCT05037929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892250|NCT03718247|||COHORT||PROSPECTIVE|||||||
33892251|NCT03963973|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33892252|NCT05911022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher will use sealed envelopes containing code for intervention or control.|Three-arm randomized controlled interventional study|t|f|f|f
33892253|NCT06656533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892254|NCT03592459|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33892255|NCT06278623|||COHORT||PROSPECTIVE|||||||
33892256|NCT02226965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892257|NCT03380858|||COHORT||PROSPECTIVE|||||||
33892258|NCT02882477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892259|NCT03280212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892260|NCT01626157|||COHORT||PROSPECTIVE|||||||
33892261|NCT03981601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892262|NCT03377634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892263|NCT00002462|RANDOMIZED|||TREATMENT||||||||
33892264|NCT01523821|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will have three escalating alpha 1 anti-trypsin (AAT) dose cohorts with six patients in each cohort (Phase I). Based on response and toxicity, an additional six patients will be enrolled in the optimal dose (Phase II).||||
33892265|NCT04723095|||COHORT||OTHER|||||||
33892266|NCT00740805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892267|NCT05237245|||COHORT||PROSPECTIVE|||||||
33892268|NCT00722293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892269|NCT04114305|||COHORT||PROSPECTIVE|||||||
34075078|NCT04338477|NA|SINGLE_GROUP||OTHER||NONE||||||
33892270|NCT05932732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Not applicable, no masking.|Approximately 5 subjects of each Fitzpatrick skin types I-VI will be included, with a total of 30 subjects participating, assessing efficacy and subject satisfaction, before and after three (3) hydrafacial treatments each performed 28 days apart.||||
34075079|NCT00933504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075080|NCT05533489|||COHORT||RETROSPECTIVE|||||||
34075081|NCT06612242|||OTHER||OTHER|||||||
34075082|NCT02706080|||OTHER||PROSPECTIVE|||||||
33892271|NCT00294125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892272|NCT01171612|||COHORT||PROSPECTIVE|||||||
33892273|NCT04954482|||CASE_CONTROL||PROSPECTIVE|||||||
33892274|NCT00885365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892275|NCT04732663|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892276|NCT05319860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892277|NCT02160457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892278|NCT05865327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the anesthesiologist responsible for performing cryoneurolysis will be aware of group allocation. All others, including participants, other clinical team, data collectors and analysts will be blinded. Participants in the control group will receive sham cryoneurolysis to maintain blinding.|Single-centre, prospective, parallel, randomized, blinded (participant, data collectors/analysts) pilot feasibility trial|t|f|t|t
33892279|NCT04060615|NA|SINGLE_GROUP||TREATMENT||NONE||All patients with chronic total occlusion will undergo the PCI procedure of the occlusion.||||
33892280|NCT00215254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33892281|NCT01629303|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33977229|NCT02756312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The anesthesiologist know the grouping .The subjects and the outcome assesor trained for telephone visit were blinded to the grouping|This is a single centre, randomized, parallel group controlled clinical trial in patients with primary HGG. All eligible patients will be 1:1 randomized to the TIVA or INHA group. The object of the trail is to evaluate the effect of propofol or sevoflurane on the prognosis of supratentorial HGG patients after craniotomy.|t|f|t|t
33892282|NCT05535361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892283|NCT02388295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892284|NCT01755988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977230|NCT05749133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977231|NCT00510510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977232|NCT03129919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977233|NCT02282436|||COHORT||PROSPECTIVE|||||||
33977234|NCT04865107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized (2:1) placebo-controlled trial|t|t|t|t
33977235|NCT00760058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977236|NCT00499798|||COHORT||PROSPECTIVE|||||||
33977237|NCT03540056|||COHORT||CROSS_SECTIONAL|||||||
33977238|NCT05431881|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A prospective randomized study|f|f|t|t
33977239|NCT00561730|||CASE_ONLY||PROSPECTIVE|||||||
33977240|NCT06355245|||COHORT||PROSPECTIVE|||||||
34075083|NCT04691219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075084|NCT02454751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075085|NCT05748964|||COHORT||PROSPECTIVE|||||||
34075086|NCT03485794|||CASE_ONLY||PROSPECTIVE|||||||
34075087|NCT04956783|||COHORT||RETROSPECTIVE|||||||
34075088|NCT05940415|||COHORT||PROSPECTIVE|||||||
34075089|NCT05364788|||OTHER||RETROSPECTIVE|||||||
34075090|NCT05492149|||COHORT||PROSPECTIVE|||||||
33892285|NCT00843180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892286|NCT03977233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892287|NCT00006383||||TREATMENT||||||||
34075091|NCT03315845|||COHORT||PROSPECTIVE|||||||
34075092|NCT01124318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763884|NCT03873194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding will be used in the following manner: after informed consent, an auxiliary researcher will randomly allocate participants to 2 research groups (Group A or Group B). After this step, the auxiliary researcher will collect data for the study and will refer the patient for the usual treatment or for the usual treatment and also meditation.~The lead researcher will not have access to the data that was collected at the beginning of the study by the auxiliary researcher before the end of the intervention step. He will analyse the results without knowing which patients were in which group (A or B). Only after statistical analysis the groups composition will be revealed."|"The objective of this study is assess the effect of meditation as a complementary therapy in hypertensive pregnant women.~The method used will be a randomized, controlled and blinded clinical trial, where meditation is going to be offered between March 2019 and July 2020 at the Obstetrics Clinic of Hospital of Clinics, Faculty of Medicine, University of São Paulo. Patients are going to be randomly assigned to two groups: Group I, patients who are going to practice meditation and Group II, patients that will receive only the usual outpatient care.~The allocation will be performed according to CONSORT criteria and sequential within two classifications of diastolic blood pressure values.~Differences between the means of the variables (blood pressure levels and questionnaires about life quality, anxiety, resilience and mindfulness) will be compared between the groups. Values of p\<0,05 will be considered significant."|f|f|t|t
33763885|NCT02640443|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33763886|NCT05518292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33765059|NCT04235582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33892288|NCT02585557|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33892289|NCT02566538|||COHORT||PROSPECTIVE|||||||
33892290|NCT02102750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892291|NCT03617926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33892292|NCT01307423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892293|NCT06103110|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
33892294|NCT06208488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open-label study. To avoid potential bias and maintain the data integrity, the analysis and reporting performed before database lock for Primary Analysis, ie, dry run/blinded data review for Primary Analysis, will be based on blinded data in which the treatment information is based on a dummy randomization schedule.|Separate randomization lists will be produced for each weight stratum (ie, 50 to \< 70 kg, 70 to \< 90 kg, and 90 to \< 110 kg) and within each of the three weight strata, participants will be randomized 1:1:1:1:1:1 to one of the six combinations of device (PFS-SD or AI) and injection site (abdomen, thigh, or upper arm).|f|f|f|t
33892295|NCT00435422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892296|NCT04376619|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Two part study: all patients will be triaged by alert system whether they are high risk for acute kidney injury and those patients that are identified as high risk for AKI have standard of care implemented by following kidney disease improving global outcomes guidelines in preventing AKI and part 2 will perform procedure called remote ischemic preconditioning in addition to standard of care in part1 in those patients that are identified as high risk for acute kidney injury.||||
33892297|NCT06275126|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The study is a pragmatic, Type II hybrid effectiveness-implementation, stepped-wedge design that will incorporate a mixed-methods approach to test the efficacy and evaluate the implementation of the CONSYDER intervention||||
33892298|NCT03714126|||CASE_ONLY||OTHER|||||||
33892299|NCT01309347|||||CROSS_SECTIONAL|||||||
33892300|NCT04470895|||CASE_CONTROL||PROSPECTIVE|||||||
33892301|NCT05995704|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The pharmacist and designated staff will be unblinded.||t|t|t|t
33892302|NCT01564706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892303|NCT04996719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892304|NCT04640714|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33892305|NCT00251602|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33892306|NCT00363961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33763887|NCT05923580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|All the participants are being treated in a healthcare unit that uses digital care pathways for coronary patients. Patients can choose the usual care or group-based cardiac telerehabilitation as follow-up care. All the patients are invited to the study after the chosen follow-up care (telerehabilitation or usual care)|Participants' quality of life (measured with the 15D quality of life instrument), lifestyle changes, and adherence to treatment will be measured using quantitative methods with a quasi-experimental research design and interrupted time- series design. The power analysis for the study will be conducted using Finnish population norms for the 15D instrument. The sample size will be 198 cardiac rehabilitation participants (N=198), with 99 participants in the intervention group (N=99) and 99 participants in the control group (N=99). With this sample size, a power of over 80% (p=0.05) will be achieved to detect a difference of 0.12 (0.95 vs. 0.83, SD=0.3) in quality of life between the groups.||||
33763888|NCT05174923|||CASE_ONLY||PROSPECTIVE|||||||
33763889|NCT05889923|NA|SINGLE_GROUP||OTHER||NONE||||||
33763890|NCT06444022|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study plans to recruit 18 participants who meet the criteria and is divided into two groups with 9 subjects individually. Infusion of hAESCs/placebo at the day before HSCT and 7th days after HSCT.||||
33763891|NCT02948881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33892307|NCT03127449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892308|NCT01713634|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33892309|NCT05985681|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|The study staff (excluding the pharmacist) and participants will be blinded to the vaccination arm.||t|f|t|f
33892310|NCT03372525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||When the neonate had fulfilled the included criteria, selective HFOV or CMV were started immediately on the basis of the group assignment.|t|f|t|t
33892311|NCT00001050|||NATURAL_HISTORY|||||||||
33892312|NCT02484872|||COHORT||PROSPECTIVE|||||||
33892313|NCT02367846|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892314|NCT02582671|||CASE_ONLY||PROSPECTIVE|||||||
33892315|NCT01559909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892316|NCT05773391|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892317|NCT03389243|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33892318|NCT00686127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33892319|NCT01322763|||||PROSPECTIVE|||||||
33892320|NCT02246361|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33892321|NCT03530423|||CASE_ONLY||PROSPECTIVE|||||||
33892322|NCT01140087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892323|NCT00680225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892324|NCT04205435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892325|NCT00270894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892326|NCT03985176|||COHORT||PROSPECTIVE|||||||
33892327|NCT05975229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trained independent evaluator conducting the performance evaluations and calculating the scores of the self-reported questionnaires was blinded.|Single-blind, two-arm pilot RCT with a parallel group design|f|f|f|t
33892328|NCT02298101|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33892329|NCT05200793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977241|NCT03558308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients know that one of the conditions is a control-condition not expected to have significant clinical effects (required by the danish scientific committee), but they don't know which treatment condition they are randomised to. The outcome assessor is blind to the group allocation of patients.||t|f|f|t
33977242|NCT01637038|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33977243|NCT04040920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Splith mouth design|f|f|f|t
33977244|NCT03413631|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants were randomized into the intervention and control groups using a computer-generated block-randomization with block size of four. A separate randomisation assignment was used for women medication-assisted treatment for opioid addiction.||||
33977245|NCT02444403|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977246|NCT03726463|||COHORT||PROSPECTIVE|||||||
33977247|NCT02841709|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33977248|NCT05474196|||COHORT||PROSPECTIVE|||||||
33977249|NCT04819971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977250|NCT03556371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients admitted will be randomly assigned to one of the two treatment groups, according to the table previously generated by the pharmaceutical chemist (PhCh) of the research team, according to a block randomization system, every 10 patients. This will be done with an Excel spreadsheet of Random Assignment by Blocks delivered by the statistical engineer of the research team to the PhCh to generate a table with patients belonging to both groups and number the bottles with the different treatments to administer according to this. Later, the PhCh will deliver them already numbered to the clinical team, being this clinical team blind to the treatment that each patient will receive (they will only handle the bottles with the number of each patient, without knowing which group each of them will belong to). In addition, both the NAC and the placebo bottles will have the same pharmaceutical presentation, so, the patients will also be blind to the pharmacotherapy they will receive.|Randomized, double-blind, controlled, phase II-b clinical trial, with a parallel group design with CBP dependent patients in different outpatient care units in the province of Concepción, Chile. Patients who meet the cocaine (CBP) consumption disorder criteria, who have used CBP within the last month and who have started use one year at least prior to admission to the study, will be selected from among the consulting population. Patients who agree to participate in the study must sign an informed consent form before being clinically evaluated. During the evaluations, semi-structured interviews and standardized questionnaires will be used to investigate both consumption habits and symptoms of withdrawal and intensity of CBP craving, among others. All patients in the study will be attended twice weekly to treatment centers for four weeks, reporting craving, possible use of for CBP (as well as urine tests), adverse reactions to the indicated medication, among others.|t|t|t|f
33977251|NCT02001558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977252|NCT06404411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977253|NCT05559203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977254|NCT06484959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33892330|NCT00096733|||COHORT||OTHER|||||||
33892331|NCT05219695|NA|SINGLE_GROUP||OTHER||NONE||||||
33977255|NCT03151239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34075093|NCT03153046|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blinding of compounds will be provided by Clasado Ltd., the company supplying the prebiotics and maltodextrin.|24 week cross-over at 12 week involving preiotics and maltodextrin|t|f|t|f
34075094|NCT05407688|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075095|NCT00884403|||COHORT||RETROSPECTIVE|||||||
34075096|NCT04767113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Infant participants were blinded naturally, while ultrasonographers for central venous catheter (CVC)-related thrombosis were blinded, especially after interventions were stopped.||t|f|f|t
34075097|NCT03741322|||OTHER||PROSPECTIVE|||||||
34075098|NCT02195635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075099|NCT00156026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075100|NCT00248157|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075101|NCT00447525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075102|NCT00718094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075103|NCT04742192|||COHORT||PROSPECTIVE|||||||
33892332|NCT04256928|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be randomized to either the intervention group (preoperative electrical clipping) clipping or the control group (leaving the body hair intact) using a 1:1 randomization ratio. The randomization is performed electronically by a medical student or the operating surgeon and the pre-assessment consultation.~Hair removal is performed with an electric clipper. Clipping is performed by hospital staff on the day of surgery. The degree of body hair on both knees is photo-documented for all participants, for the intervention group after the clipping of body hair on the relevant knee has been performed.~4 microbiological samples will be taken during surgery from each participant using Copan ESwabs."||||
33892333|NCT05191628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763892|NCT01526590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763893|NCT04157998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33765060|NCT00793221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33892334|NCT03427437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double Participant, Outcomes Assessor||t|f|f|f
33892335|NCT01097902|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33892336|NCT03642561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group 1 RFA alone group 2 TACE alone|f|f|f|t
33892337|NCT02834130|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33892338|NCT00223340|RANDOMIZED|FACTORIAL||||SINGLE||||||
33892339|NCT05189899|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover clinica trial||||
33892340|NCT02299193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892341|NCT02725502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892342|NCT06327152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Families, nurses, therapists, and doctors will be blinded. Only pharmacy will be unblinded and know which subjects are in each treatment arm.|This is a randomized, double-blinded, placebo-controlled trial of 40 preterm infants born at less than or equal to 32 weeks and 0 days gestation. Infants will be randomized to receive either caffeine or placebo for up to maximum of additional four (4) weeks after meeting clinical criteria to come off caffeine.|t|f|t|f
33892343|NCT05782530|||COHORT||PROSPECTIVE|||||||
33892344|NCT00868049|||||CROSS_SECTIONAL|||||||
33892345|NCT01475890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892346|NCT02938182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892347|NCT03124225|||COHORT||PROSPECTIVE|||||||
33892348|NCT01974791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892349|NCT05243888|RANDOMIZED|PARALLEL||SCREENING||NONE||The study is a randomised controlled trial with three arms: a control arm (conventional invitation letter) and two experimental arms (mailing of a urine or vaginal self-sampling kit).||||
33892350|NCT06387056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892351|NCT06656962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892352|NCT06412341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33892353|NCT06356506|||COHORT||PROSPECTIVE|||||||
33892354|NCT05384730|NA|SINGLE_GROUP||OTHER||NONE||||||
33892355|NCT01415388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33765061|NCT03861806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||We plan a randomized crossover study of sham and true PAS.|t|f|t|t
33892356|NCT04095520|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33892357|NCT03529656|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892358|NCT02760251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892359|NCT00003558|RANDOMIZED|||TREATMENT||||||||
33892360|NCT00000851||||TREATMENT||DOUBLE||||||
33892361|NCT06618157|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The order in which all four scenarios are tested will be randomized. The MDS-UPDRS III scale will be scored blindly by a second rater based on the de-identified video recorded exam. Participants will be blinded to which stimulation is being used during the recording of their exam.|"Two alternative deep brain stimulation (DBS) stimulation plans will be created by maximizing the stimulation to the cerebellothalamic tract (1) and to the pallidothalamic tract (2) based on the patient-specific connectomic DBS model previously created with recruitment curves. Participants will be asked to attend one single research encounter for DBS programming, MDS-UPDRS scoring and wearable data collection. During their research visit, MDS-UPDRS III (clinical scale) and wearable data will be collected in different scenarios (each setting will be recorded for 20 minutes):~* OFF oral dopaminergic medication: during no DBS stimulation, usual care stimulation, cerebellothalamic optimized, and pallidothalamic optimized. This will be collected during the morning.~* ON oral dopaminergic medication: during no DBS stimulation, usual care stimulation, cerebellothalamic optimized, and pallidothalamic optimized"|t|f|f|t
33892362|NCT04946318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892363|NCT01350661|||COHORT||PROSPECTIVE|||||||
33892364|NCT00686348|||OTHER||PROSPECTIVE|||||||
33892365|NCT03987945|||COHORT||RETROSPECTIVE|||||||
33892366|NCT06046482|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892367|NCT02048904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892368|NCT02369783|NA|SINGLE_GROUP||SCREENING||NONE||||||
33892369|NCT01624142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892370|NCT06603883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892371|NCT00430807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977256|NCT02366221|||COHORT||PROSPECTIVE|||||||
33977257|NCT02153398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977258|NCT05362448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33977259|NCT04975399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977260|NCT06105983|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33977261|NCT02192099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977262|NCT02156648|NA|SINGLE_GROUP||OTHER||NONE||||||
33977263|NCT03805230|||COHORT||PROSPECTIVE|||||||
33977264|NCT04170881|||COHORT||PROSPECTIVE|||||||
33977265|NCT02586103|||COHORT||PROSPECTIVE|||||||
33977266|NCT05327166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the intervention, this is an open label study since participants will know whether they are receiving ED-LINC resources or usual care.|Participants will be randomized to either usual care (n=250) or ED-LINC intervention (n=250). Patients assigned to the ED-LINC intervention will receive 1) overdose education, 2) brief bedside intervention targeting motivation to engage in outpatient care, 3) a patient-centered approach to MOUD using a treatment decision support tool, 4) longitudinal and proactive care management which will proceed for 3 months, and 5) weekly caseload supervision allowing for stepped-up care targeting opioid use and comorbidity.||||
33977267|NCT02374918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977268|NCT01056549|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33892372|NCT06346665|||COHORT||PROSPECTIVE|||||||
33892373|NCT06062784|||OTHER||OTHER|||||||
33892374|NCT00551837|||COHORT||PROSPECTIVE|||||||
33892375|NCT05012748|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study will be performed as a randomized, placebo-controlled crossover study in 12 healthy obese patients (BMI: 28-40 kg/m2) in the age group 50-70 years. Each participant will undergo two periods of three weeks, during which they must follow a ketogenic diet or a standard diet in random order with one week of wash out between periods. At the end of each period, a study day with Metabolic and PET examinations will be performed.||||
33892376|NCT03538028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892377|NCT02774590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892378|NCT00239031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892379|NCT03367156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33892380|NCT01288768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33892381|NCT00638872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892382|NCT04730895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892383|NCT01568723|||COHORT||PROSPECTIVE|||||||
33892384|NCT00175981|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33892385|NCT01331161|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33892386|NCT01526148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977269|NCT00508170|||COHORT||PROSPECTIVE|||||||
33763894|NCT06576687|NA|SINGLE_GROUP||TREATMENT||NONE||14 mechanical ankle instability, 14 functional ankle instability and 14 Coper (as the comparison group, total n=42) participants will complete a 4-week balance training protocol. Prior to and following the training protocol, each of the outcomes previously described including patient-reported outcome measures, neurocognitive hop-testing, force-control, and fNIRS tasks will be completed.||||
33892387|NCT05269576|NA|SINGLE_GROUP||OTHER||NONE|The investigator and the outcomes assessor didn't know the moment of the interventions in each participant of the group.|||||
33892388|NCT05381402|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33977270|NCT01729130|||COHORT||PROSPECTIVE|||||||
33977271|NCT06237075|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with neuropathic pain versus healthy controls||||
33977272|NCT06424899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977273|NCT00084084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977274|NCT00000619|RANDOMIZED|||TREATMENT||||||||
33977275|NCT02743702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892389|NCT01147679|||CASE_CONTROL||PROSPECTIVE|||||||
33892390|NCT00525291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977276|NCT02281578|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33977277|NCT02553369|||COHORT||PROSPECTIVE|||||||
33977278|NCT00216437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977279|NCT04365751|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33977280|NCT02030184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977281|NCT04464135|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33892391|NCT04407715|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A total of 80 patients who underwent laparotomic gynecological surgery were divided into two groups prospectively: high flow of 2 L/min and minimal flow of 0.5 L/min. Anesthesia was maintained with 50% oxygen-50% air at 2 L/min and desflurane at 1.1 MAC in Group 1 (n=40) and with 50% oxygen-50% air at 2 L/min and desflurane at 1.1 MAC in Group 2 (n=40). After 10-15 minutes, group 2 was administered minimal flow with 50-60% oxygen-40-50% air at 0.5 L/min and desflurane, and 10 minutes before the end of the surgery, the patients were switched to high flow with 50% oxygen-50% air at 2 L/min.||||
33977282|NCT05658887|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977283|NCT04322071|||CASE_ONLY||CROSS_SECTIONAL|||||||
33977284|NCT01454466|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33977285|NCT04496635|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The study compare two phases: baseline (BP), from 2008 to 2015, and implementation (IP), from 2016 to 2018.||||
33977286|NCT01471483|||COHORT||PROSPECTIVE|||||||
33977287|NCT03190746|||COHORT||CROSS_SECTIONAL|||||||
33977288|NCT04164771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33977289|NCT01396681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977290|NCT01644890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977291|NCT02831569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977292|NCT05123625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977293|NCT06158321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Group assignment will be concealed through opaque and sealed envelopes, which will be administered by a research assistant who is not involved in the study. The envelopes will be opened after the participant consented to participate in the trial. Assessors, participants, and therapists will be blind to the allocation of rTMS.|Three-arm pilot randomized controlled trial (RCT)|t|t|t|t
33977294|NCT04677062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977295|NCT04277533|||CASE_CONTROL||PROSPECTIVE|||||||
33977296|NCT00058292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977297|NCT01915732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977298|NCT03874130|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33977299|NCT02596334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977300|NCT04987164|||CASE_CONTROL||PROSPECTIVE|||||||
33977301|NCT04289428|||COHORT||PROSPECTIVE|||||||
33977302|NCT05592509|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Twenty subjects will be divided into two groups of 10 subjects following randomization. The first group will take the dietary supplement (three capsules per day) for 60 days, while the second group will take a placebo (three capsules per day) for 60 days.~During the treatment period (60 days), the two groups will undergo follow-ups at days 0, 15, 30 and 60 within which clinical and hematochemical examinations will be conducted as per Table 2. At the end of the 60 days, after the wash-out period (two weeks), as per the cross-over design the group previously taking the dietary supplement will be on placebo (three capsules per day) for 60 days, while the group previously taking placebo will take the dietary supplement (three capsules per day) for 60 days. Again, follow-ups will be at 0, 15, 30 and 60 days."||||
33977303|NCT00178581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977304|NCT05884853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||40 autistic adolescents are recruited with their care givers. Also, 40 healthy controls.||||
33977305|NCT04282538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34075104|NCT05347810|NA|SINGLE_GROUP||OTHER||NONE||The study is a cross-sectional intervention study with one measurement session, where participants will provide a continuous comfort rating during exposure to repetitive normal and shear forces.||||
34075105|NCT06420817|NA|SINGLE_GROUP||PREVENTION||NONE||"The study would be done in 2 phases. In the first phase the pretest questionnaire would be administered throughGoogle forms and health education on various Lifestyle Medicine interventions would be given. In the second phase Intervention would be carried out and monitoring would be done online daily / weekly by the investigative team.~The following five strategies of lifestyle medicine will be tried to lower the lipid levels in the study group:~1. Nutrition - modified/Indianized Portfolio diet - (Primary Intervention)~2. adequate exercise - 180 minutes of moderate intensity exercises every week~3. intermittent fasting of 12 hours every day~4. sleep monitoring and~5. monitoring stress levels"||||
34075106|NCT01067534|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33977306|NCT01215448|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977307|NCT01242280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075107|NCT01062893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075108|NCT01437683|||COHORT||RETROSPECTIVE|||||||
33763895|NCT00347997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763896|NCT02749851|||COHORT||PROSPECTIVE|||||||
33763897|NCT03760263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33763898|NCT06539507|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Parts 1 and 2 will be blinded; Part 3 will be open label|In Parts 1 and 2, participants will be randomized to BCX17725 or placebo under double-blind conditions. In Part 3, participants will receive open-label BCX17725.|t|f|t|f
33763899|NCT05477277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763900|NCT02322541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763901|NCT04699357|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33763902|NCT00161395|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33763903|NCT05299918|||COHORT||PROSPECTIVE|||||||
33763904|NCT01488565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763905|NCT01860443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763906|NCT00213564|||||PROSPECTIVE|||||||
33763907|NCT00566176|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763908|NCT00405405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763909|NCT06625385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763910|NCT03322826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763911|NCT05737433|NA|SINGLE_GROUP||TREATMENT||NONE||open label, non-randomized, single period, and single dose||||
33763912|NCT02816034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33763913|NCT02010801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763914|NCT01641926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763915|NCT06623214|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical design adopted the single-group target value method||||
33892392|NCT03731663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||After receiving an explanation about the study and providing informed consent online, participants will complete questionnaires assessing demographic variables, SNS food preoccupation and disturbed eating online via Qualtrics link. Participants will then be randomly assigned to view a video clip showing pictures of either appetizing pictures of food (experimental group) or sightseeing pictures in a tourist destination (control group). After viewing the video, participants will respond to online questionnaire measuring external eating and food cravings, and will also be asked to order food they would like to eat immediately from a hypothetical menu.|t|f|f|f
33892393|NCT00629421|||CASE_ONLY||PROSPECTIVE|||||||
33892394|NCT06036875|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33763916|NCT01931969|||CASE_ONLY||PROSPECTIVE|||||||
33763917|NCT04244851|||COHORT||PROSPECTIVE|||||||
33763918|NCT06444295|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33763919|NCT05666986|||COHORT||PROSPECTIVE|||||||
34075109|NCT05607316|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label (unmasked)|Open-label (unmasked) study||||
34075110|NCT02992028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34075111|NCT04875910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763920|NCT05967780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763921|NCT04570813|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33763922|NCT06625983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Practices will be randomized to receive the decision tool or not receive the decision tool.||||
33763923|NCT04172805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763924|NCT00813137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763925|NCT03279055|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33763926|NCT05413525|||OTHER||RETROSPECTIVE|||||||
33763927|NCT02688465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763928|NCT05720013|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized repeated-measure crossover study|t|t|f|t
33763929|NCT03613623|||COHORT||CROSS_SECTIONAL|||||||
33763930|NCT01181505|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33763931|NCT01548937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763932|NCT04139980|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33763933|NCT03520465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind, for the patient and the radiologist who analyses the results of the imaging tests.||t|f|f|t
33763934|NCT03098940|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763935|NCT01861886|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33763936|NCT00100932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892395|NCT05238051|RANDOMIZED|PARALLEL||PREVENTION||NONE||Gastric residual volume (GRV) was measured in one group and not in the other. Nutrition was started at an infusion rate of 20 ml/hour in the GRV group. The GRV was measured every four hours. When it was less than 200 ml, the infusion rate was increased by 20 ml/hour. The infusion rate, which was increased every four hours according to the GRV, was continued constantly when the target calorie was reached. It was kept constant when the GRV was above 200 ml, and then the feeding rate was reduced to half when the GRV volume was above 400 ml. In four patients, enteral nutrition was discontinued due to melena and excluded from the study. In six patients with persistently high GRV values, enteral nutrition was discontinued and parenteral nutrition initiated. The study was completed with 62 patients. GRV (n=31) and Non-GRV (n=31).||||
33892396|NCT00128687|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33892397|NCT01472523|||OTHER||OTHER|||||||
33977308|NCT06214377|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Triple-blind criteria will be achieved by identic collocation of the electrodes in both conditions and by activating the double-blind option in the Starstim tDCS® Software (Neuroelectrics Inc, Barcelona, Spain) that allows concealing the protocol by writing a neutral number. The evaluator, not allowed to stay in the same room while the interventions, will conceal the protocols with the neutral number and the therapist will read it in the envelope, ignoring which number coincides with each intervention. At the end of the second session, patients will be asked whether they received the order 1.active-2.sham or 1.sham-2.active, to assess the blinding success. The statistician will also be blinded through the mentioned neutral numbers. Unblinding will be permissible when any event could suppose a risk to the patient's health."|"This study will be a triple-blinded experimental randomized controlled trial with a crossover design. The randomization will be conducted through the GraphPad software by an independent investigator. All the participants who fulfill the inclusion criteria and have none of the exclusion ones will be randomly allocated into two groups (depending on the order of the intervention allocation): 1.active-tDCS-2.shamtDCS or 1.sham-tDCS-2.active-tDCS. Allocation concealment will be ensured by the inclusion of the assigned group in closed opaque envelopes that will be opened at the time of the first intervention."|t|t|t|t
33977309|NCT06455826|NA|SEQUENTIAL||TREATMENT||NONE||Participants will be assigned sequentially to the VP-001 escalation dose (30 μg and 75 μg) groups. Participants will receive three repeat IVT injections of VP-001, 8 weeks apart, in the study eye.||||
33977310|NCT06364722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects, efficacy assessors and statisticians were blinded.||t|f|f|t
33977311|NCT05221580|||COHORT||PROSPECTIVE|||||||
33977312|NCT06266377|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-randomized multi-center intervention with a single arm. Study participants will receive new adapted canteen menus according to the nutritional and sensory needs of the target population.||||
33892398|NCT05637268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892399|NCT03182439|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33892400|NCT01836861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892401|NCT06249529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977313|NCT01608295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977314|NCT00287118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977315|NCT06190925|||COHORT||PROSPECTIVE|||||||
33892402|NCT01543750|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33892403|NCT02814721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892404|NCT04690699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892405|NCT03431220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892406|NCT00425490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33892407|NCT05823142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Both conditions will receive time-balanced sessions with the study team. Participants will not be told whether in the experimental condition or the condition delivering usual care until after the completion of the study.|Behavioral: Sleep Self-Management|t|f|f|f
33892408|NCT01193764|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33892409|NCT04052139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892410|NCT03515187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892411|NCT01636557|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892412|NCT02128438|||||RETROSPECTIVE|||||||
33892413|NCT04337437|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind (participant, investigator), excluding one non-blind investigator doctor.||t|f|t|f
33892414|NCT04240587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892415|NCT05694598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892416|NCT02714179|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
33892417|NCT04360304|NA|SINGLE_GROUP||OTHER||NONE||"This study aims at assessing the interest of automated LVOT VTI measurement compared to the manual standard one when performing a cardiac echography for hemodynamic assessment of patients hospitalised in ICU. Otherwise, a measure of the  Best-VTI  will be done at the same time in accordance with the current practice, in order to assess this approach.~Finally, when a fluid resuscitation will be indicated, a second exam will be done, and agreement of VTI variation between automated and manual method studied."||||
33892418|NCT01798303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892419|NCT01901887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892420|NCT00876642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892421|NCT02243501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892422|NCT04533711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892423|NCT03960528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892424|NCT02311348|||CASE_CONTROL||PROSPECTIVE|||||||
33977316|NCT04112485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977317|NCT00758849|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33977318|NCT00341354||||TREATMENT||||||||
33977319|NCT00029679|RANDOMIZED|||TREATMENT||||||||
33763937|NCT03541044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33763938|NCT00297115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33763939|NCT02813356|||COHORT||RETROSPECTIVE|||||||
33763940|NCT00243828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763941|NCT00722579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763942|NCT02875275|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33892425|NCT02954315|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33892426|NCT00815646|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33892427|NCT01715844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892428|NCT04372238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The biostatistician will be blinded to the intervention/control group assignment throughout the course of the study and the assignments.|Participants randomized to receive the RAPIDS intervention will receive fentanyl test strips and additional fentanyl-specific education. Both arms will receive standardized overdose prevention education and naloxone.|f|f|f|t
33892429|NCT05792384|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33892430|NCT04958785|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892431|NCT02109237|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33892432|NCT01822561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892433|NCT02570373|NA|SINGLE_GROUP||OTHER||NONE||||||
33892434|NCT05412706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892435|NCT06190483|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33892436|NCT00380562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33892437|NCT00775164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892438|NCT02033226|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33977320|NCT05815381|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763943|NCT04433442|||COHORT||PROSPECTIVE|||||||
33763944|NCT03968003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||165 participants Children, age 7 to 15 years with Body mass index (BMI) ≥ median + 2 Standard deviation(SD) will be randomized into one of the three arms of 55 participants per group.Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.|t|t|t|t
33763945|NCT06439641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33763946|NCT03305874|||CASE_CONTROL||OTHER|||||||
33763947|NCT02024672|||COHORT||PROSPECTIVE|||||||
33763948|NCT00166725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763949|NCT04827433|||CASE_CONTROL||PROSPECTIVE|||||||
33763950|NCT02184780|||COHORT||RETROSPECTIVE|||||||
33763951|NCT00344812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763952|NCT06319846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33763953|NCT02465996|RANDOMIZED|PARALLEL||||NONE||||||
33892439|NCT00004255|RANDOMIZED|||TREATMENT||NONE||||||
33763954|NCT06625229|||CASE_ONLY||PROSPECTIVE|||||||
33977321|NCT02252679|||CASE_CONTROL||PROSPECTIVE|||||||
33977322|NCT01805609|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977323|NCT04941664|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will be blinded to the amount of local anesthetic agent used. Outcome assessor assessing the outcomes will be blinded of the amount of local anaesthetic used.|||||
33977324|NCT01619748|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33763955|NCT04354766|||COHORT||PROSPECTIVE|||||||
33763956|NCT00542048|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763957|NCT01650519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892440|NCT06390670|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33892441|NCT00710190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977325|NCT03797755|||COHORT||PROSPECTIVE|||||||
33977326|NCT00981604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977327|NCT03820921|||COHORT||PROSPECTIVE|||||||
33977328|NCT05856175|||COHORT||PROSPECTIVE|||||||
33977329|NCT04868526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977330|NCT04448665|||COHORT||PROSPECTIVE|||||||
33977331|NCT02933775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977332|NCT01150747|||CASE_ONLY||PROSPECTIVE|||||||
33977333|NCT06299137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research Assistants who collect the data will be blinded to which arm of the study the participants are in.||f|f|f|t
33977334|NCT00706745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977335|NCT06456372|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33977336|NCT04749602|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort 1 (renal cell carcinoma / lung cancer) Cohort 2 (lung cancer)||||
33977337|NCT01376128|||OTHER||RETROSPECTIVE|||||||
33977338|NCT01690936|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977339|NCT04709848|||OTHER||CROSS_SECTIONAL|||||||
33977340|NCT02090439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977341|NCT04826588|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Overarching trial design with treatment arms that are both available at the hospital and not believed by the enrolling doctor to be contraindicated (e.g. by particular co-morbid conditions or concomitant medications). Treatment arms to be added or removed according to the emerging evidence.~Main randomisation part A: Methylprednisolone 2 mg/kg for three days intravenous or orally vs corticosteroids methylprednisolone 10mg/kg intravenous for three days vs intravenous immunoglobulin."||||
33763958|NCT03421496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763959|NCT02160171|||COHORT||PROSPECTIVE|||||||
33763960|NCT06616844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763961|NCT02063100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33763962|NCT03347175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33763963|NCT06028035|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763964|NCT06433310|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33763965|NCT04707404|||COHORT||RETROSPECTIVE|||||||
33892442|NCT04033289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892443|NCT06179992|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||All participants were requested to complete web-based assessment, with questionnaires relating to maladaptive beliefs associated with ED, eating and emotional symptomatology, body satisfaction and self-esteem at baseline (T1). The experimental group started using the app for 15 days, and later completed the following assessment (T2). The control group also completed the T2 in the same date but started to use the app after this second assessment.15 days and one month later, both groups completed T3 and T4.|t|f|f|f
33892444|NCT06657248|||CASE_CONTROL||PROSPECTIVE|||||||
33892445|NCT06063473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33892446|NCT00586365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892447|NCT06067854|||COHORT||RETROSPECTIVE|||||||
33977342|NCT00295958||||TREATMENT||NONE||||||
33977343|NCT05118295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977344|NCT03499938|||COHORT||PROSPECTIVE|||||||
33977345|NCT05582499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977346|NCT00005381|||COHORT||PROSPECTIVE|||||||
33977347|NCT02649283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977348|NCT06395857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parallel randomised controlled trial|f|f|f|t
33977349|NCT04704609|||CASE_CONTROL||PROSPECTIVE|||||||
33977350|NCT01072942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892448|NCT02872103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892449|NCT05714904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892450|NCT03501056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
33892451|NCT01838057|||COHORT||PROSPECTIVE|||||||
33892452|NCT02883699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892453|NCT03422484|||OTHER||PROSPECTIVE|||||||
33892454|NCT06326944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33892455|NCT00269009|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
33892456|NCT04093830|NA|SINGLE_GROUP||OTHER||NONE||||||
33892457|NCT03494283|||COHORT||PROSPECTIVE|||||||
33892458|NCT04776850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977351|NCT00336310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33977352|NCT02001454|||CASE_ONLY||PROSPECTIVE|||||||
33977353|NCT02824900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977354|NCT02585284|||CASE_CONTROL||PROSPECTIVE|||||||
33977355|NCT01825109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977356|NCT04139096|||CASE_CONTROL||RETROSPECTIVE|||||||
33977357|NCT02407444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977358|NCT00427492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33977359|NCT04963088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977360|NCT02236338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977361|NCT02514174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977362|NCT03858257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33977363|NCT03849313|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double Blind|3 arm trial|t|t|t|t
33977364|NCT02073630|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977365|NCT03516747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||open label, non- randomised, prospective||||
33977366|NCT02295397|NA|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33977367|NCT06004466|||CASE_ONLY||PROSPECTIVE|||||||
33977368|NCT06455020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977369|NCT00948675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977370|NCT00508560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977371|NCT02556242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977372|NCT02898649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977373|NCT01241461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977374|NCT04085835|||COHORT||OTHER|||||||
33977375|NCT06110039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977376|NCT00006864||||TREATMENT||||||||
33977377|NCT00154024|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33977378|NCT01520051|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33977379|NCT03752788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892459|NCT00592683|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33977380|NCT06373575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33977381|NCT02983448|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33977382|NCT03287050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977383|NCT05338060|||CASE_ONLY||PROSPECTIVE|||||||
33977384|NCT05802680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977385|NCT05722509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre-measurements will be performed by 2 previously calibrated examiners (R.R.P and J.R.M). The calibration will consist of evaluating the periodontal probing of 10 patients in the mesial, distal, vestibular, and palatal/lingual areas and comparing the results of both examiners until an excellent degree of agreement is achieved. The surgical procedure will be performed by the principal investigator (RRM). Measurements of the results in the different study periods will be performed by a third independent evaluator (JFF) who will be blinded.||f|f|f|t
33977386|NCT00802802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977387|NCT00244322|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33892460|NCT00249379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892461|NCT01299025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892462|NCT05991024|||COHORT||RETROSPECTIVE|||||||
33892463|NCT01002781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892464|NCT02896478|||COHORT||RETROSPECTIVE|||||||
33892465|NCT06656260|||COHORT||PROSPECTIVE|||||||
33892466|NCT02210156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33892467|NCT05327062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigation will include 9 European and 4 US investigational sites. The goal is to enroll a total number of 150 patients. It is expected about 1.5 patients per site per month over a period of maximum 8 months after site opening. The study duration is set at 12-month, 6 months for patient enrollment and 6 months of follow-up.||||
33892468|NCT05116657|||COHORT||PROSPECTIVE|||||||
33977388|NCT02185612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33977389|NCT04639596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977390|NCT02046928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977391|NCT02207231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977392|NCT01116375|||COHORT||PROSPECTIVE|||||||
33977393|NCT06274606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Randomization will be completely random and will only be known by biostatistician and study coordinator in department but not on study to retain true randomization unaffected by study team.|In accordance with a parallel study design, 30 pre-bariatric-surgery patients will be randomized in a 1:1 ratio to either undergo 8-weeks of pre-operative standard of care or 8-weeks of pre-operative standard of care plus moderate exercise prior to undergoing bariatric-surgery. Randomization scheme: The randomization will be generated utilizing a permuted block randomization scheme in which 5 blocks of 6 treatment assignments (3 per treatment) will be generated via a computer algorithm. The 6 treatment assignments of each block will be listed in random sequential order and the treatment assignments will be assigned according to the random sequential order. The randomization will be generated by our biostatistician.||||
33977394|NCT02154529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase 1b ascending dose-finding study for establishing the maximum tolerated dose (MTD) of tesevatinib (with trastuzumab).||||
33977395|NCT03287700|||OTHER||CROSS_SECTIONAL|||||||
33977396|NCT03069274|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33977397|NCT00925249|||||PROSPECTIVE|||||||
33977398|NCT01669395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977399|NCT04232150|RANDOMIZED|PARALLEL||PREVENTION||NONE||Overall, 116 patients were enrolled, out of which 20 were excluded before start of study for the following reasons: contraindication for spinal anesthesia (n=10), preoperative administration of sedative agent (n=3), refusal to be enrolled in study (n=4), a patient with neurological disorder (Schizophrenia), a blind patient, and a deaf patient. Of the 96 patients included, 33 were enrolled in group C, 32 in group S; however, 2 patients requested a deeper level of sedation so an added dose of midazolam and fentanyl were given thus excluding them from study, and 31 patients in group R.||||
33977400|NCT04835948|||CASE_CONTROL||RETROSPECTIVE|||||||
33977401|NCT02280629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977402|NCT01784042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977403|NCT04195165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977404|NCT02764008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977405|NCT04154709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075112|NCT03576339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075113|NCT00242515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977406|NCT05172375|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is designed as a non-randomized intervention study with pre- and post design and with a control group.||||
33977407|NCT06386783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|concealed based on study drugs assigned to each group \& to conduct this double -blinded clinical trials, our study drugs will be prepared by the senior anesthesiologist who won't be involved in further observations of the patients and neither patients nor outcome assessor will be aware of which drugs they will receive.|This randomized double blinded study will be conducted at Aswan university hospitals at patients scheduled for emergency appendectomy|t|t|f|t
33977408|NCT02473809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977409|NCT04414956|NA|SINGLE_GROUP||SCREENING||NONE||Patients with cirrhosis will receive the surveillance test using three biomarker tests and sonography every six months and contrast-enhanced CT annually||||
33977410|NCT03385473|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33977411|NCT00628823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977412|NCT03452098|||CASE_ONLY||RETROSPECTIVE|||||||
34075114|NCT04884646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as accessor of the study would be kept blind of the treatment group to which patient would be allocated.After the complete initial screening process, every recruited patient will be accessed by an independent assessor, expert will use outcome measuring tools. his will be recorded as baseline measurement assessment||f|f|f|t
34075115|NCT02089802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075116|NCT06039319|||COHORT||CROSS_SECTIONAL|||||||
34075117|NCT05886114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34075118|NCT04244617|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a mixed methods design consisting of an un-controlled pragmatic effectiveness study combined with semi-structured interviews||||
34075119|NCT05641441|||COHORT||OTHER|||||||
34075120|NCT02775097|||COHORT||PROSPECTIVE|||||||
34075121|NCT01945879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075122|NCT01373034|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34075123|NCT06010212|NA|SINGLE_GROUP||TREATMENT||NONE||Fruquintinib,Camrelizumab, Paclitaxel liposome combined with nedaplatin||||
34075124|NCT01693744|||CASE_CONTROL||PROSPECTIVE|||||||
34075125|NCT03191565|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075126|NCT00727935|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34075127|NCT00301912||||TREATMENT||NONE||||||
34075128|NCT02090686|RANDOMIZED|||TREATMENT||SINGLE|||t|f|f|f
34075129|NCT04789447|||COHORT||RETROSPECTIVE|||||||
34075130|NCT01697800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34075131|NCT03988140|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||This study was designed as a prospective, split-mouth, randomized controlled trial|t|f|f|f
34075132|NCT00291200|||CASE_CONTROL||PROSPECTIVE|||||||
34075133|NCT00643019|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075134|NCT02752360|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34075135|NCT01032447|||CASE_ONLY||PROSPECTIVE|||||||
34075136|NCT00664352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075137|NCT00679848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075138|NCT03452462|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33892469|NCT05657262|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|"Participants were divided into groups using the simple randomization method. Participants were not informed about which group they belonged to. Automated computer-based randomization resulted in the execution of the experiment with the timing scenario and the confidential assignment of participants to one of the 2 intervention arms. The researcher was blind to all conditions until the participants started the computer program and the intervention began. Participants were also unaware of whether the group they were assigned to was an experimental or control condition. Additionally, researchers who code and analyze data will be blind to randomization and interference."|experimental group: application of immunotherapy via Z technique control group: immunotherapy administration with standard procedure|t|f|t|t
33892470|NCT00193830|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33892471|NCT02786069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892472|NCT06458764|||COHORT||CROSS_SECTIONAL|||||||
33892473|NCT04592003|||COHORT||OTHER|||||||
33892474|NCT04493164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892475|NCT00751894|NON_RANDOMIZED|||TREATMENT||NONE||||||
33892476|NCT02040142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892477|NCT04820270|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm feasibility and safety study||||
33892478|NCT04702737|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892479|NCT00321516|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33892480|NCT04079023|||COHORT||PROSPECTIVE|||||||
33892481|NCT06657157|||COHORT||PROSPECTIVE|||||||
33892482|NCT01172379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33892483|NCT02497703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892484|NCT00370214|||COHORT||PROSPECTIVE|||||||
33892485|NCT05693584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Pain assessments were made by the service nurses, and virtual reality glasses were applied by the researcher. The data were collected by one researcher and the analysis and evaluations were made by the other researcher.||f|t|f|t
33892486|NCT01830530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892487|NCT02064764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892488|NCT04845217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The peppermint-oil and placebo treatments will be kept in a locked and secured area of the office, in a room not used for patient care. The bottles will be de-identified, with labels detailing the specific instructions for how to take the soft gels and the number in each bottle. Each group will be instructed to take one soft gel three times daily.~The peppermint oil and placebo medications will be distributed by the research team. The manufacturer label will be covered up/removed and a study label stating the use of a study medication will be used to maintain patient blinding."|Participants will be randomized in a 1:1 ratio to the intervention or placebo arm. Allocation concealment will be in place to ensure the individual enrolling the subject into the study has no a priori knowledge of group assignment. Block randomization will occur with randomly mixed block sizes of 4, 6, and 8 using the randomization list generator at www.sealedenvelope.com. Randomization information will be kept confidential and only available to study personnel.|t|f|f|f
33892489|NCT02160418|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
33892490|NCT04161040|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will not be told which group they have been assigned to.|Block randomization will be used to assign participants to one of three groups (one experimental and two control groups). All groups will experience three phases of the study. Opportunities for sedentary leisure and physical activities will be continuously available throughout all phases.|t|f|f|f
33892491|NCT03046251|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33892492|NCT02405533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo control phase II study that patients receive either AHCC or placebo.|t|t|t|t
33892493|NCT01746407|||CASE_ONLY||PROSPECTIVE|||||||
33892494|NCT00917384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892495|NCT05159180|||CASE_ONLY||PROSPECTIVE|||||||
33892496|NCT06657716|||COHORT||PROSPECTIVE|||||||
33892497|NCT02974244|||COHORT||RETROSPECTIVE|||||||
33892498|NCT01397851|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33892499|NCT02743858|||COHORT||PROSPECTIVE|||||||
33892500|NCT00312130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33892501|NCT02639377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892502|NCT04341779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892503|NCT02536586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075139|NCT00112918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075140|NCT01329770|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33763966|NCT05086250|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|"Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, research staff, or subjects. The following study procedures will be in place to ensure double-blind administration of study treatments.~* Access to the randomization code will be strictly controlled~* Packaging and labeling of test and control treatments will be identical to maintain the blind The research pharmacist will manage the investigational agent. The blind will be maintained through the effort of the research pharmacist and the pharmacy. Unblinding will only occur when it is deemed medically necessary. The date and reason for breaking the blind will be documented."||t|f|t|f
33763967|NCT02053077|||CASE_ONLY||PROSPECTIVE|||||||
33892504|NCT04976452|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33892505|NCT03557021|RANDOMIZED|PARALLEL||TREATMENT||NONE||Case control study||||
33892506|NCT05747989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892507|NCT01073150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892508|NCT03263091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892509|NCT00234949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33892510|NCT03959436|||COHORT||PROSPECTIVE|||||||
33892511|NCT04432038|||COHORT||PROSPECTIVE|||||||
33892512|NCT03882918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892513|NCT02747082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075141|NCT01690455|||COHORT||PROSPECTIVE|||||||
34075142|NCT05005624|||COHORT||PROSPECTIVE|||||||
34075143|NCT00871624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075144|NCT00457041|||||PROSPECTIVE|||||||
34075145|NCT00537186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075146|NCT01299883|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33892514|NCT00327938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33892515|NCT03206593|||COHORT||PROSPECTIVE|||||||
33977413|NCT03810430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|After baseline survey was carried out, two sub-districts (10 clusters each) were allocated into intervention and control clusters in a 1:1 ratio (10 intervention and 10 control clusters). This allocation of intervention and control clusters was randomly carried out and each sub district had an equal chance of being in either group. For randomization, the two sub districts were listed (1 to 2) and drew randomly by health manager there. Intervention group was informed that participants had been received the intervention, hence it was impossible to fully mask (blind) the study participants. The primary outcomes of interest were measured by observers who were not connected with the intervention implementation, in order to reduce the observer bias|The frame work used in this study depends on the Evo-Eco theory of behavior change.This approach consists of five steps; assess, build, create, develop and evaluate (A, B, C, D and E). In the assessment steps, the researcher made a review about the role of water, hygiene and infant feeding promotion in reducing child morbidity and changing mothers' behavior. Based on this review and experience, the researcher developed a baseline questionnaire that was used two months ago before starting the intervention. Based on the results of baseline survey and literature, the researcher with expert team developed the health promotion messages. After developing the messages, interventions took six months. Furthermore, the implementation of the health promotion intervention was at household and community level. Two months later of performing the intervention, the post intervention survey was carried out to measure the primary and secondary outcome of the interventions.|t|f|f|f
33977414|NCT06288061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33977415|NCT01003132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977416|NCT02966379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977417|NCT04808089|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective randomized control trial||||
33977418|NCT00861445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977419|NCT05638425|||COHORT||PROSPECTIVE|||||||
33977420|NCT05213936|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Hair counts using trichoscopy and photographs will be taken at baseline and at the beginning of each chemotherapy cycle, which will be graded by two independent clinicians blinded to the patient group.||f|f|t|f
33977421|NCT01645384|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977422|NCT06545747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763968|NCT00787319|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33977423|NCT01987193|||COHORT||PROSPECTIVE|||||||
33977424|NCT00538343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977425|NCT02215577|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977426|NCT00680121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977427|NCT05072340|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The allocation was done based on the participants' sequence of enrolment, and another research assistant opened the opaque envelopes and allocated participants to either the blended or self-guided RISE group.||t|f|f|t
33763969|NCT02584348|NA|SINGLE_GROUP||||NONE||||||
33763970|NCT02263001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892516|NCT03293654|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33977428|NCT05382221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977429|NCT02456532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977430|NCT00004381||||TREATMENT||||||||
33977431|NCT04076501|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33977432|NCT06189378|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33763971|NCT01433523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892517|NCT02488447|||CASE_CROSSOVER||PROSPECTIVE|||||||
33892518|NCT02688413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892519|NCT00947349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33763972|NCT05636462|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33763973|NCT05019274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This pragmatic effectiveness trial randomizes patients 1:1 to a series of 6 virtual Culinary Medicine classes or 6 standard of care nutrition visits .||||
33892520|NCT01607892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892521|NCT05335538|||COHORT||PROSPECTIVE|||||||
33892522|NCT06488677|||COHORT||CROSS_SECTIONAL|||||||
33892523|NCT00681551|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33892524|NCT01447238|||CASE_ONLY||PROSPECTIVE|||||||
33892525|NCT01802281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33892526|NCT06100432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892527|NCT06095830|||COHORT||PROSPECTIVE|||||||
33892528|NCT06657755|||CASE_ONLY||RETROSPECTIVE|||||||
33892529|NCT03539432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892530|NCT04279197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892531|NCT01561664|NON_RANDOMIZED|PARALLEL||||NONE||||||
33892532|NCT06656429|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental study||||
33892533|NCT04358458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892534|NCT03458169|NA|SINGLE_GROUP||OTHER||NONE||||||
33892535|NCT01075087|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33892536|NCT00748657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892537|NCT01846780|||CASE_CONTROL||PROSPECTIVE|||||||
33892538|NCT02290210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892539|NCT05198648|||COHORT||PROSPECTIVE|||||||
33892540|NCT06479603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892541|NCT01289613|||CASE_ONLY||PROSPECTIVE|||||||
33892542|NCT01923025|NA|SINGLE_GROUP||||NONE||||||
33892543|NCT00352248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33892544|NCT00836940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892545|NCT03582358|||COHORT||PROSPECTIVE|||||||
33892546|NCT04881838|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients stratified into high risk group are assigned to one treatment regimen||||
33892547|NCT03934762|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33892548|NCT06253923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892549|NCT06645340|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||In this prospective cohort study, women at high risk of developing preeclampsia were recruited.||||
33892550|NCT05111314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892551|NCT05461443|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The sachets containing the different LGG strains were labelled as A, B, and C. The codes for each strain were kept by the industrial partner that provided the probiotic strains. Only at the end of the data analyses were the codes disclosed|The individuals did receive the three treatment combinations in a randomised order.|t|t|t|f
33892552|NCT06656208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977433|NCT06546267|||COHORT||RETROSPECTIVE|||||||
33977434|NCT01611025|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33977435|NCT05342857|||COHORT||PROSPECTIVE|||||||
33977436|NCT05071807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33977437|NCT01752257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977438|NCT01619826|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33977439|NCT02933281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977440|NCT05052138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33977441|NCT01600495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33892553|NCT05109312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In each cohort, subjects will be randomized in a 2:1 ratio to HTX-011 or bupivacaine HCl, respectively. All subjects will receive a scheduled postoperative non opioid multimodal analgesic (MMA) regimen.|t|f|f|t
33892554|NCT01350869|||COHORT||PROSPECTIVE|||||||
33892555|NCT06036966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892556|NCT02154750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892557|NCT01867489|||COHORT||PROSPECTIVE|||||||
33977442|NCT03188081|||COHORT||PROSPECTIVE|||||||
33977443|NCT05271474|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977444|NCT01697020|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977445|NCT05698368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Blind investigator and outcomes assessor: does not know group label|Participants are randomly assigned to one of three groups in parallel for the duration of the study.|f|f|t|t
33977446|NCT05894161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To prevent human bias regarding to participants and outcomes assessor||t|f|f|t
33892558|NCT04253132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|This is a randomized, double-blind, placebo-controlled parallel group study.|t|t|t|t
33892559|NCT04579549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892560|NCT00751413|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892561|NCT00332787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33892562|NCT00058864|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33892563|NCT05602428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892564|NCT06656806|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blinded Parallel Study|t|t|t|f
33977447|NCT01817348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977448|NCT03918798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34075147|NCT05545137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075148|NCT00581412|||CASE_ONLY||RETROSPECTIVE|||||||
34075149|NCT04092530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Effectiveness-Implementation Hybrid Design||||
33977449|NCT05759975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will not know the laser protocol of each patient (single blind) .|Patients will be randomized to one of two groups for the duration of the study. Group I (PBMI, n=21) photobiomodulation intraoral with a low potency laser, and Group II: photobiomodulation with high power extraoral unfocused laser with 1 W power (PBME, n=21).|f|f|f|t
33977450|NCT01502566|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33977451|NCT05493007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977452|NCT00978900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33977453|NCT04114669|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977454|NCT05863546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977455|NCT00237549|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33977456|NCT00741793|||COHORT||PROSPECTIVE|||||||
33977457|NCT01860248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33977458|NCT04208659|NA|SINGLE_GROUP||OTHER||NONE||This is a pilot project to assess safety of self-administration of auricular acupuncture over a six-month period and how well a custom prosthesis facilitates needle placement.||||
33977459|NCT04812756|NA|SINGLE_GROUP||OTHER||NONE||Single group prospective pre-post study||||
34075150|NCT00889447|||CASE_ONLY||CROSS_SECTIONAL|||||||
34075151|NCT04348097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075152|NCT06028126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, intervention appliers (i.e. the operating room staff), medical practitioners, and outcome assessors will all be blinded to the randomized treatment arm until the database is locked. Unblinding procedures will be made available for breaking codes if necessary for clinical treatment.||t|t|t|t
34075153|NCT01541995|||COHORT||PROSPECTIVE|||||||
34075154|NCT05438238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a comparison between the current standard practice of performing an egg retrieval with paracervical block (PCB) and virtual reality that is added to the above mentioned standard practice of TVOR + PCB. The aim of the study is to find out whether this newer technology has an advantage for the patient, in terms of anxiety and pain reduction, by aid of questionnaires||||
34075155|NCT04001556|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The examiner performin the evaluation of ultrasound features of the main salivary glands will not have acess at the first part of patient evaluation.|cross-sectionnal pilot study|f|f|f|t
34075156|NCT06135441|||OTHER||PROSPECTIVE|||||||
34075157|NCT04269720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075158|NCT02247739|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34075159|NCT02453880|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34075160|NCT03687866|||COHORT||PROSPECTIVE|||||||
34075161|NCT06432647|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34075162|NCT05495308|||COHORT||PROSPECTIVE|||||||
34075163|NCT04724603|||COHORT||RETROSPECTIVE|||||||
34075164|NCT03235466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial of 3 groups: 1) standard voice therapy 2) voice therapy and heart rate variability biofeedback and 3) heart rate variability biofeedback|t|f|f|f
34075165|NCT00244153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34075166|NCT02490826|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34075167|NCT02677415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34075168|NCT04474886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977460|NCT03730103|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective cohort study with historical controls||||
33977461|NCT02128048|||||PROSPECTIVE|||||||
33977462|NCT04053790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind||t|t|t|f
33977463|NCT05381623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation to the test or control group will be revealed to the surgeon only after completing the harvest of the free gingival graft.||f|t|f|f
33977464|NCT03408626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075169|NCT03301987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075170|NCT03468725|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34075171|NCT04247165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075172|NCT01386931|||CASE_CONTROL||PROSPECTIVE|||||||
34075173|NCT06169306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075174|NCT06251271|||COHORT||PROSPECTIVE|||||||
33892565|NCT01552434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892566|NCT00743886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892567|NCT04430907|||COHORT||PROSPECTIVE|||||||
33892568|NCT04515355|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33892569|NCT05779085|||COHORT||PROSPECTIVE|||||||
33892570|NCT01569581|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33892571|NCT04740229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|f|f|t|t
33892572|NCT02972827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892573|NCT06234904|NA|SEQUENTIAL||TREATMENT||NONE||||||
33892574|NCT00816803||PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892575|NCT05180812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892576|NCT04318392|||CASE_CONTROL||PROSPECTIVE|||||||
33892577|NCT02748343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892578|NCT03384329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892579|NCT05628844|||COHORT||PROSPECTIVE|||||||
33892580|NCT05965037|||OTHER||PROSPECTIVE|||||||
33892581|NCT05046288|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33892582|NCT06262828|||COHORT||PROSPECTIVE|||||||
33892583|NCT03737825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking: Triple (Participant, Investigator, Outcomes Assessor) Study assessment administrator is blinded to what digital tool the subject has been assigned.||t|f|f|t
33892584|NCT06052748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892585|NCT04800380|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|In the study, randomization and evaluation of results will be carried out by an independent statistician. Researchers will not know to which group the students are included. In conducting the research, an independent researcher will know in which group the students are. Students will also be given information about the study, but not in which group they are included. Thus, triple blinding will be created by providing both participant, entrepreneur and statistician blinding.|Randomized controlled trial in parallel groups|t|f|t|f
33892586|NCT02101437|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33892587|NCT04702711|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33892588|NCT02656472|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33892589|NCT06657144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892590|NCT02344810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33892591|NCT05987215|||CASE_CONTROL||RETROSPECTIVE|||||||
33892592|NCT05334979|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33892593|NCT05735899|||COHORT||PROSPECTIVE|||||||
33892594|NCT01995890|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33763974|NCT02481492|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33763975|NCT00351637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892595|NCT01824784|||COHORT||PROSPECTIVE|||||||
33892596|NCT01478958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33892597|NCT01485874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892598|NCT01403298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892599|NCT05555810|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will secure Cystic duct and artery with traditional sutures(ligation) in a group. In the another group the cystic duct and artery will be put a clips .||||
33892600|NCT01162850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33892601|NCT05614050|||COHORT||PROSPECTIVE|||||||
33892602|NCT00957853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892603|NCT03935971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892604|NCT00098787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892605|NCT06159478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892606|NCT06001606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892607|NCT01591330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892608|NCT01929070|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892609|NCT06656819|||COHORT||CROSS_SECTIONAL|||||||
33892610|NCT05106530|||CASE_CONTROL||OTHER|||||||
33892611|NCT01748071|||CASE_CONTROL||PROSPECTIVE|||||||
33892612|NCT06006975|||COHORT||RETROSPECTIVE|||||||
33892613|NCT03204344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor who perform postoperative follow-up is masked to group assignment.|This is a outcomes assessor-blinded, randomized controlled trial with two parallel arms.|f|f|f|t
33892614|NCT01058603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892615|NCT01525758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892616|NCT04919655|||CASE_ONLY||RETROSPECTIVE|||||||
33892617|NCT01938859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892618|NCT01476462|||CASE_ONLY||RETROSPECTIVE|||||||
33892619|NCT05217914|||COHORT||RETROSPECTIVE|||||||
33892620|NCT04681092|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Single-center, open-label, combinatorial safety, tolerability and exploratory efficacy||||
33892621|NCT03122626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be unaware of group assignment|A 2-group randomized controlled trial in which participants are assigned to immediate or delayed participation in a community exercise program|f|f|f|t
33892622|NCT01687790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892623|NCT01716819|NA|SINGLE_GROUP||||NONE||||||
33977465|NCT03167671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is the only one masked in the study. They are independent of the randomization, trial coordination, and care providers.|Single blinded (evaluator), single-center, randomized controlled trial. Interventional and Control group with option for Control group to Cross over.|f|f|f|t
33977466|NCT04465942|||COHORT||PROSPECTIVE|||||||
33977467|NCT03840733|||COHORT||PROSPECTIVE|||||||
33977468|NCT01835678|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977469|NCT02004704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977470|NCT01195714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892624|NCT04325503|NA|SINGLE_GROUP||OTHER||NONE||||||
33892625|NCT00011115||FACTORIAL||TREATMENT||||||||
33892626|NCT04659993|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33892627|NCT04811092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33892628|NCT01023282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892629|NCT02511522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892630|NCT01122355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892631|NCT04637867|NA|SINGLE_GROUP||OTHER||NONE||||||
33892632|NCT05653895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple (Participant ,Care provider ,Outcomes Assessor)|Treatment of PCOS with Metformin vs Combination therapy|t|t|f|t
33892633|NCT03064464|||CASE_ONLY||PROSPECTIVE|||||||
33892634|NCT01933087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892635|NCT04210479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892636|NCT02669693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892637|NCT00534534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892638|NCT05095935|||COHORT||PROSPECTIVE|||||||
33892639|NCT04073745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892640|NCT05437887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892641|NCT01027689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892642|NCT05521165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892643|NCT03660878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892644|NCT00499785|||COHORT||PROSPECTIVE|||||||
33892645|NCT03684655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Adults with HIV Infection taking or not taking antiretroviral therapy||||
33892646|NCT05075915|||CASE_ONLY||RETROSPECTIVE|||||||
33892647|NCT05408858|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open trial||||
33892648|NCT05929599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo Navax and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax suspension are unrecognizable to investigators, nurses, patient's parents, and patients except for the PI, principal nurses, and analyzer, due to opaque plastic containers.|Blind, randomized, and controlled clinical trial|t|t|t|f
33892649|NCT05035420|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33892650|NCT05428709|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892651|NCT03026582|||COHORT||PROSPECTIVE|||||||
33892652|NCT01337401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892653|NCT03614247|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who had a lower calyceal stone between 1cm and 2cm in size||||
33892654|NCT03193268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33892655|NCT05003362|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|randomized control|After screening, patients will be randomized and one group will receive the intervention. The investigators will do sequential interventions of the ACT|f|f|f|t
33892656|NCT03862456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The subjects were randomly assigned to the treatment groups in ascending order according to a balanced distribution system through a computer generated random number design table (random block design). Randomization was balanced according to the smoking habit at the initial visit to ensure homogeneity in the treatment groups.~The method of allocation concealment selected were opaque envelopes. The research coordinator was responsible for the randomization and allocation of patients.~The 50 opaque envelopes (25 / group) were prepared."||t|f|t|t
33977471|NCT00665041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977472|NCT03239132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892657|NCT02054702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977473|NCT03197064|NA|SINGLE_GROUP||TREATMENT||NONE||A single group of up to 50 patients will be administered a standard dose of fosaprepitant 150 mg IV after induction of anesthesia. A standard neuromonitoring setup utilizing motor evoked potentials, and somatosensory evoked potentials will be used as indicated for the type of surgery. After baseline neuromonitoring measurements have been made, but prior to surgery starting, we will administer the fosaprepitant to determine if there are any effects on the motor evoked potentials or somatosensory evoked potentials measurements.||||
33892658|NCT04728204|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either control or intervention group. Participants in the control group will receive the same treatment after the intervention group is finished with the treatment.||||
33763976|NCT02281396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892659|NCT04474912|||CASE_CONTROL||RETROSPECTIVE|||||||
33892660|NCT05779891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892661|NCT00278525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892662|NCT02491541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33892663|NCT02852226|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33892664|NCT06559839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892665|NCT02970617|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892666|NCT03294876|||COHORT||PROSPECTIVE|||||||
33892667|NCT01512589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892668|NCT04740411|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892669|NCT00752986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892670|NCT05970887|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||prospective, non-randomized clinical cohort study||||
33892671|NCT00596544|||COHORT||PROSPECTIVE|||||||
33892672|NCT04154098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All patients perform the experiment in all conditions. The without orthosis, with orthosis and manual assistance conditions will be presented in randomized order, followed by the functional task.||||
33892673|NCT00566787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892674|NCT04868123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|co-investigators involved with measurement for the interventional phase will not know which of the 3 groups a participant was randomized to|randomized controlled interventional pilot with 3 groups (2 treatment groups and 1 control group)|f|f|f|t
33892675|NCT00264407|||CASE_CONTROL||OTHER|||||||
33892676|NCT04355286|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Part 1 is an open label, 1-arm pilot study to evaluate the effects of multiple applications of a topical sunscreen formulation in healthy adult subjects.||||
33892677|NCT05413330|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participants)|Prospective randomized single-blinded clinical trial|t|f|f|f
33977474|NCT05564832|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977475|NCT01265784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977476|NCT04799158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the Run-In Period, participants will receive open-label vonoprazan.||t|f|t|f
33977477|NCT05549856|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33977478|NCT00168883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977479|NCT00565305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33977480|NCT01644500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977481|NCT01749683|||OTHER||PROSPECTIVE|||||||
33977482|NCT02009800|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33977483|NCT02788461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977484|NCT03652701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977485|NCT00332761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33977486|NCT05231642|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double blind|A single centre, randomised and counter-balanced, two-arm cross-over study.|t|f|t|f
33977487|NCT05169762|||COHORT||PROSPECTIVE|||||||
33977488|NCT05896631|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33977489|NCT05936099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977490|NCT01938118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33977491|NCT01106963|||COHORT||PROSPECTIVE|||||||
33977492|NCT00208624|||||RETROSPECTIVE|||||||
33977493|NCT04825938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977494|NCT04353908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977495|NCT00821392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977496|NCT01206309|||COHORT||PROSPECTIVE|||||||
33977497|NCT05413603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977498|NCT04676438|||COHORT||PROSPECTIVE|||||||
33977499|NCT02717247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977500|NCT01900236|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33977501|NCT05585996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977502|NCT06485024|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33977503|NCT01742975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33977504|NCT00618163|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977505|NCT00006250|RANDOMIZED|||TREATMENT||||||||
33977506|NCT03744260|||COHORT||PROSPECTIVE|||||||
33977507|NCT05448144|||COHORT||PROSPECTIVE|||||||
33977508|NCT06412562|||COHORT||CROSS_SECTIONAL|||||||
33977509|NCT00991588|||COHORT||PROSPECTIVE|||||||
33977510|NCT02572310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977511|NCT02127606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977512|NCT00426062|||DEFINED_POPULATION||PROSPECTIVE|||||||
33977513|NCT03411005|NA|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 3 levels of lysine provided as free amino acids, sorghum, or sorghum combined with lentils for a total of 8 studies x 3 days per study.||||
33977514|NCT06370897|||COHORT||OTHER|||||||
33977515|NCT05473676|NA|SINGLE_GROUP||TREATMENT||NONE|Because there is only 1 arm in the study, and each participant proceeds through the same study timeline, participants, care providers, investigators, and outcome assessors will know the intervention received.|All participants will proceed through the same study timeline from the time of enrollment.||||
33977516|NCT01621425|||CASE_ONLY||PROSPECTIVE|||||||
33977517|NCT04991558|||OTHER||PROSPECTIVE|||||||
34075175|NCT05199922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant will be blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic inguinal hernia repair surgery will be included in the study. Patients will be randomly divided into two groups (Group M = M-TAPA group, Group C = Control group) including 30 patients each, before entering the operating room.|t|f|f|t
34075176|NCT03565874|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34075177|NCT04398810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075178|NCT00006114||||TREATMENT||||||||
34075179|NCT02982889|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34075180|NCT02061813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075181|NCT02459197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34075182|NCT00010504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33977518|NCT04076176|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977519|NCT05909475|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33977520|NCT03383744|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||n subjects received the treatment and then randomly divided in two groups for outcome evaluation after one and three months respectively||||
33977521|NCT01625156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977522|NCT03718949|||COHORT||PROSPECTIVE|||||||
33977523|NCT03104738|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-label randomized controlled trial||||
33977524|NCT03558477|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each arm is assignted 10 persons\[the percent of each arm is (treatmnet: comparator=4:1)\]||||
33977525|NCT05180864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977526|NCT04654104|||COHORT||PROSPECTIVE|||||||
33977527|NCT00065858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33977528|NCT00469625|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33977529|NCT05495542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants in the study and the researcher who evaluated the pain were blinded.||t|f|t|f
33977530|NCT03186911|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33977531|NCT03459937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors will be masked to intervention condition. Selected investigators who are overseeing the intervention will also be masked to study outcomes.|Participants will be randomly assigned to one of two intervention conditions, with assessments occurring at pre-intervention and post-intervention.|f|f|t|t
33977532|NCT00967642|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763977|NCT01153269|||CASE_ONLY||PROSPECTIVE|||||||
33977533|NCT04750187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977534|NCT06456203|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33977535|NCT02576509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977536|NCT05307861|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled trial|t|t|f|f
34075183|NCT06612385|||COHORT||PROSPECTIVE|||||||
34075184|NCT02309957|||CASE_ONLY||PROSPECTIVE|||||||
34075185|NCT03828955|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34075186|NCT03609814|||OTHER||PROSPECTIVE|||||||
34075187|NCT03060057|||COHORT||PROSPECTIVE|||||||
34075188|NCT03871530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double-blind randomized trial|t|f|t|t
34075189|NCT05619315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33763978|NCT04788953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892678|NCT04709549|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the nature of lifestyle behavioral intervention, the study design prevents participants and study staff blinding to allocation. However, to minimize bias, outcomes will be assessed by independent study staff blinded to allocation status.|The parallel, interventional SCULPT-Job Study model randomizes persons to either the Diabetes Prevention Program (DPP) only OR the DPP plus job readiness/legal services.|f|f|t|t
33763979|NCT02821819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892679|NCT00759629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892680|NCT06653777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892681|NCT04412304|||COHORT||RETROSPECTIVE|||||||
33892682|NCT00146692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892683|NCT06657027|||COHORT||PROSPECTIVE|||||||
33892684|NCT00296322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892685|NCT04568330|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33763980|NCT00101127||||TREATMENT||NONE||||||
33763981|NCT06070584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33763982|NCT03432884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Part A: zanubrutinib and placebo will be double-blind Part B: zanubrutinib and placebo will be double-blind; Moxifloxacin will be open-label|Part A: Single Group Part B: Crossover|t|f|t|f
33763983|NCT01289418|||COHORT||PROSPECTIVE|||||||
33763984|NCT02167217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33763985|NCT01595412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763986|NCT05492773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33763987|NCT05720585|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33763988|NCT03946800|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763989|NCT00449098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763990|NCT03584503|RANDOMIZED|PARALLEL||OTHER||SINGLE||A randomized prospective controlled study|t|f|f|f
33763991|NCT00535743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763992|NCT04230655|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is an open labelled, randomized, controlled clinical trial, with a ratio 1:1.||||
33763993|NCT02935348|||CASE_ONLY||PROSPECTIVE|||||||
33763994|NCT02221102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33763995|NCT02801188|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33892686|NCT05275114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33892687|NCT05098184|NA|SINGLE_GROUP||TREATMENT||NONE||1x10\^9-5x10\^10 in vitro expanded autologous TILs will be infused i.v. to patients with advanced melanoma after NMA lymphodepletion treatment with fludarabine and cyclophosphamide.||||
33892688|NCT01610921|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33892689|NCT00541307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892690|NCT06560359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Two groups (Trial group and Control group) start with 2 weeks of no F\&V, following 12 weeks of intervention, and then 4 weeks of washout (both groups with no intervention), this full study takes 18 weeks.|t|t|t|t
33892691|NCT01661257|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892692|NCT06543992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892693|NCT05445193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is single-blinded, with balance randomization (1:1) and parallel-group design. Dyads will be recruited from chosen nurseries and kindergartens. Following that, the dyads will be randomly assigned to either an intervention group or a controlled group by using Microsoft Excel Random Number Generator. Dyads will then fill out the sociodemographic information form, the Child Healthy Eating Knowledge Questionnaire, and the food intake form. The research team will also measure the children's weight and height using standard methods. Next, the nutritional status of each child is assessed by using WHO Anthro Software version 3.2.2.|t|f|f|f
33892694|NCT00403104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892695|NCT00684814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892696|NCT06657287|||CASE_ONLY||PROSPECTIVE|||||||
33892697|NCT03817918|NA|SINGLE_GROUP||OTHER||NONE||Prospective, interventional, cohort study||||
33892698|NCT00367757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892699|NCT03475225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|Double blind|t|t|t|f
33892700|NCT00768560|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33892701|NCT01747902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892702|NCT06247826|NA|SINGLE_GROUP||OTHER||NONE||||||
33977537|NCT02608853|||COHORT||RETROSPECTIVE|||||||
33977538|NCT00096395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892703|NCT04629729|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892704|NCT06656416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892705|NCT03135886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a cluster randomized controlled trial (RCT) where approximately 51 sites will be randomly inducted into the study. Site randomization to condition will occur on a rolling basis in intervals of approximately 14-18 days. Selected sites will be invited to participate in the study and randomly assigned to one of the three conditions (described below).||||
33892706|NCT01967043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892707|NCT03652909|||COHORT||PROSPECTIVE|||||||
33892708|NCT03487445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892709|NCT04490629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892710|NCT02235818|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33892711|NCT01916395|||CASE_CROSSOVER||PROSPECTIVE|||||||
33892712|NCT00002850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33892713|NCT00170521|||||PROSPECTIVE|||||||
33892714|NCT02509325|||COHORT||PROSPECTIVE|||||||
33977539|NCT05589675|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a three-arm study with a parallel study design||||
33977540|NCT00777829|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33977541|NCT01570465|||CASE_ONLY||PROSPECTIVE|||||||
33977542|NCT01017783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977543|NCT02995070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977544|NCT00472290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075190|NCT05455151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The patients were divided into 4 groups depending on the substances introduced into the basal layer of the endometrium. Group 1 underwent conservative therapy. Group 2 received intraendometrial injections of autologous PRP instead of the conservative therapy. Group 3 received identical injections after conservative therapy. Group 4 received injections of the minimally manipulated autologous endometrial cells suspended in autologous PRP.|t|f|f|f
34075191|NCT02691390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892715|NCT03560661|||OTHER||PROSPECTIVE|||||||
33892716|NCT00269763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892717|NCT02226354|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33892718|NCT06084806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892719|NCT06136858|||OTHER||PROSPECTIVE|||||||
33892720|NCT05700461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892721|NCT04176861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075192|NCT01787669|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075193|NCT00201019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33763996|NCT03701295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075194|NCT05258487|||COHORT||PROSPECTIVE|||||||
34075195|NCT04608331|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33763997|NCT01336634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33763998|NCT02736968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33763999|NCT05195619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"A total of 16 evaluable patients will be recruited, eight in each cohort.~Cohort 1: metastatic non-small cell lung cancer of any histology without any actionable oncogenic driver treated by SOC. Maintenance treatment with pemetrexed and/or maintenance/continuation of pembrolizumab, nivolumab or atezolizumab is allowed.~Cohort 2: metastatic NSCLC with actionable oncogenic driver such as EGFR mutation, ROS-1 or ALK rearrangement, currently receiving osimertinib, alectinib, lorlatinib or crizotinib as per SOC in each disease entity."||||
33764000|NCT03755635|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Controlled before and after interventional trial||||
33764001|NCT05445544|||COHORT||PROSPECTIVE|||||||
33764002|NCT05904223|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33764003|NCT06453122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764004|NCT03288090|||COHORT||PROSPECTIVE|||||||
33764005|NCT03148236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764006|NCT01695733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764007|NCT05806502|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764008|NCT02375282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075196|NCT02440893|||COHORT||PROSPECTIVE|||||||
34075197|NCT04175275|||OTHER||RETROSPECTIVE|||||||
33764009|NCT00584402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764010|NCT03465020|||COHORT||PROSPECTIVE|||||||
33764011|NCT05465512|||COHORT||PROSPECTIVE|||||||
33764012|NCT01145807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764013|NCT01837329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764014|NCT06625866|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two hospitals (clusters) will be assigned to intervention and standard of care.||||
33764015|NCT00291902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764016|NCT06001983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764017|NCT02531178|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33764018|NCT00113282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764019|NCT04484714|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group before and after||||
33764020|NCT03559218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764021|NCT02477280|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33764022|NCT01835262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764023|NCT03626532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind. Any investigators administering assessments will be blind to participants' group allocation.||f|f|f|t
33764024|NCT02446795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764025|NCT00793156|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33764026|NCT02326350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33764027|NCT06293300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892722|NCT03578679|NA|SINGLE_GROUP||TREATMENT||NONE|Evaluation of therapeutic efficacy of a combination of two usual drugs.|Interventional prospective study with only one arm||||
33892723|NCT06447506|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blinded study until the qualifying parent study has reported out.||t|f|t|f
33892724|NCT03502122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075198|NCT04978272|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Administration of all study drugs will be double blinded. All doses of study drugs will be prepackaged by a study pharmacist and administered by a study nurse blinded to the study participant's treatment regimen. All 3 daily doses will be directly observed in the clinic. If a study participant vomits the study drug within 30 minutes of administration, the drug will be re-administered. All doses of study drugs will be given between 8 and 104 weeks (2 years) of age.|Double blinded randomized controlled trial|t|t|t|f
33892725|NCT04788264|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33892726|NCT02954471|||COHORT||RETROSPECTIVE|||||||
33892727|NCT05211167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892728|NCT04865848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33892729|NCT06656858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892730|NCT06657313|||CASE_CONTROL||PROSPECTIVE|||||||
33892731|NCT03021902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892732|NCT05017545|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892733|NCT00468234|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33892734|NCT05511038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892735|NCT03310125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33892736|NCT03026387|NA|SINGLE_GROUP||OTHER||NONE||||||
33892737|NCT01608152|||COHORT||PROSPECTIVE|||||||
33892738|NCT00503399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892739|NCT03924843|||OTHER||PROSPECTIVE|||||||
33892740|NCT04239417|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: groups (A) \& (B) \& (C) ( three study groups ) and group (D) ( control group )|Sixty patients with ventral hernia, preoperatively, were randomly distributed into four equal groups: groups (A) \& (B) \& (C) ( three study groups ) and group (D) ( control group ).|f|f|f|t
33892741|NCT02585427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892742|NCT05152212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892743|NCT00552266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892744|NCT04472689|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33892745|NCT03325309|||COHORT||RETROSPECTIVE|||||||
33892746|NCT00683943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892747|NCT00932997|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33892748|NCT06367322|||COHORT||PROSPECTIVE|||||||
33892749|NCT01986335|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33892750|NCT00558090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892751|NCT03231514|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are blinded to the pre-workout drink content.|Semi-randomized, parallel-group, single-blind diet and exercise intervention|t|f|f|f
33892752|NCT05334329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892753|NCT04042480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892754|NCT00125034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892755|NCT03107195|||OTHER||OTHER|||||||
33892756|NCT04948996|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892757|NCT00482963|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075199|NCT00387972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34075200|NCT02908152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075201|NCT00657696|||OTHER||CROSS_SECTIONAL|||||||
34075202|NCT01429844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764028|NCT03944044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a comparative, randomized, open, crossover, bicenter clinical trial with SC and IV paracetamol injections successively given to each patient.||||
33764029|NCT00001125||||PREVENTION||NONE||||||
33764030|NCT02649062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764031|NCT00000664||PARALLEL||TREATMENT||||||||
33892758|NCT03171922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892759|NCT02780791|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892760|NCT00613626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33892761|NCT05731960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|f|t
33892762|NCT03884075|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33892763|NCT02689128|||COHORT||PROSPECTIVE|||||||
33764032|NCT04539457|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33764033|NCT02352363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764034|NCT05493384|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764035|NCT03987425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33764036|NCT01542021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764037|NCT01226563|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|randomized 2:1 active vs placebo|Multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effects of IK-5001. 306 trials randomized 2:1 active vs placebo|t|t|t|f
33764038|NCT02534584|||COHORT||PROSPECTIVE|||||||
33764039|NCT03372824|||COHORT||PROSPECTIVE|||||||
33764040|NCT04040881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764041|NCT04985006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The outcome measurement (microRNA measurement using qPCR and PGC 1 alpha measurement using ELISA) will be done by professional laboratory assistant who is blind about the intervention given to the participant.|All the participant will be asked to run in moderate and high intensity in random order. The interval between the first exercise and the next is 48 hours to 14 days.|f|f|f|t
33764042|NCT03861858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764043|NCT03990584|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33764044|NCT00939731|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892764|NCT05634499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892765|NCT02945982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892766|NCT04628507|||COHORT||PROSPECTIVE|||||||
33892767|NCT04386889|NA|SINGLE_GROUP||SCREENING||NONE||||||
34075203|NCT00816777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075204|NCT01005576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764045|NCT05968040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33764046|NCT02162303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33764047|NCT05497427|||OTHER||PROSPECTIVE|||||||
33764048|NCT03513601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764049|NCT00955786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764050|NCT00094328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764051|NCT04028310|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33764052|NCT04524143|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled||||
33764053|NCT05290246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764054|NCT06248840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33764055|NCT06082921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33764056|NCT05842213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764057|NCT03381001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective, randomized, triple-blinded study|t|f|t|t
33764058|NCT04573543|||CASE_CONTROL||PROSPECTIVE|||||||
33892768|NCT01948752|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33892769|NCT05239104|||COHORT||PROSPECTIVE|||||||
33892770|NCT03871907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators who will perform follow-up will be masked||f|f|t|f
33892771|NCT03943329|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33892772|NCT04398732|||COHORT||RETROSPECTIVE|||||||
34075205|NCT04087837|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||bougie or nasogastric tube|t|f|f|f
34075206|NCT02489448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075207|NCT00055445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075208|NCT06084702|RANDOMIZED|CROSSOVER||OTHER||SINGLE|non-identifiable bottles|Randomized Crossover|t|f|f|f
33764059|NCT06344234|||COHORT||PROSPECTIVE|||||||
33764060|NCT05190302|||OTHER||PROSPECTIVE|||||||
33764061|NCT05915390|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and outcome assessor will not be aware which participant is in what arm. The participant and the care provider will know about the treatment allocation|This will be a parallel, free-living, randomized controlled trial with 54 men and post-menopausal women|f|f|t|t
33764062|NCT00861614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892773|NCT04398901|||COHORT||PROSPECTIVE|||||||
33892774|NCT05749731|||COHORT||PROSPECTIVE|||||||
33892775|NCT02978222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892776|NCT04288024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892777|NCT00538642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892778|NCT04007484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892779|NCT00187590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892780|NCT02811705|||COHORT||PROSPECTIVE|||||||
33764063|NCT00415584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764064|NCT03350126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764065|NCT06103084|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075209|NCT03287076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764066|NCT02286167|NA|SINGLE_GROUP||OTHER||NONE||||||
33764067|NCT01838408|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33764068|NCT03486262|||COHORT||RETROSPECTIVE|||||||
33764069|NCT01958840|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33764070|NCT03183388|NA|SINGLE_GROUP||TREATMENT||NONE||It is planned that 72 of the 86 participants who meet criteria for bipolar disorder (BDI, BDII, BD-OS) will complete this combined psychotherapy (BE-SMART) and imaging study. There will be variation of therapies, but no comparison between groups. Actigraphy and ecological momentary assessments on 20 participants will be integrated as part of the supplement to parent grant.||||
33764071|NCT04804098|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33764072|NCT04775121|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Deuterium glucose ingestion on a 3-hour period to label rapidly proliferating cells, followed by sequential collection of sorted classical monocytes on a 30-day period||||
33764073|NCT05494827|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The intervention (drinking water) was masked for participants through the same indistinguishable bottle design, whereas the taste of the water was different. The research team was unmasked as visits for participants from comparable groups assigned for separate days in order to prevent the possible discussion of water taste between groups.||t|f|f|f
33764074|NCT05420922|||COHORT||RETROSPECTIVE|||||||
33764075|NCT05214313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33764076|NCT03078153|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33764077|NCT05287425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33764078|NCT06310902|||COHORT||PROSPECTIVE|||||||
33764079|NCT02448667|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33764080|NCT00426426|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33764081|NCT03151915|||COHORT||RETROSPECTIVE|||||||
33764082|NCT03510624|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764083|NCT06013501|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomised|f|f|f|t
34075210|NCT02488018|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075211|NCT04579432|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will not know which group they are in. they won't interact with each other.|There is a control group and an experimental group in this research. Pre-test and post-test will be carried out with a pattern. A pre-test will be made to the control and experimental groups simultaneously. Then, the experimental group will be trained and the final test will be conducted simultaneously with the non-intervened control group.|t|f|f|f
34075212|NCT03996668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients are not made aware of their study group or the presence of intraoperative cerebral desaturation events||t|f|f|f
34075213|NCT00614172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075214|NCT04214366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764084|NCT03626441|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Sequentially numbered, sealed, opaque envelopes prepared and opened the evening before the surgery. Tablets containing either placebo or ginger allocated by a person not involved in any other aspect of the study and administered on the morning of surgery.|Quadruple, blind randomized, controlled trial|t|t|t|t
33764085|NCT01350505||CROSSOVER||BASIC_SCIENCE||DOUBLE||The order of the interventions were randomized to the four visits.|t|f|t|f
33764086|NCT00628914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764087|NCT04372225|||COHORT||PROSPECTIVE|||||||
33764088|NCT02338479|||COHORT||PROSPECTIVE|||||||
33764089|NCT05012371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764090|NCT05345379|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|This trial will be triple-blinded in which neither the participants nor the trial team will know which one of the primers a patient has received, as well as the outcome assessor will be blinded. This can be achieved by placing the two primers in two similar masked bottles and giving them numerical coding i.e. number one and number two coding for either type of primer.|The primers will be randomly allocated using a split-mouth, cross-quadrant design. In each patient, two diagonal quadrants (i.e. upper right and lower left, or vice versa) will be randomly assigned to each primer group.|t|t|t|t
33764091|NCT03324464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764092|NCT03938597|||OTHER||RETROSPECTIVE|||||||
34075215|NCT04256564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant will not be aware of the catheterization technique used.|There will be two parallel groups in each a different central catheterization method will be performed.|t|f|f|f
34075216|NCT02364297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075217|NCT06609122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are unaware of which treatment they are receiving, but the researchers know.||t|f|f|f
34075218|NCT02584270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892781|NCT01088425|||CASE_CONTROL||RETROSPECTIVE|||||||
33892782|NCT01838135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892783|NCT05426148|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33892784|NCT02635204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892785|NCT01696461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892786|NCT05381831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892787|NCT01087554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892788|NCT05556785|||COHORT||PROSPECTIVE|||||||
33892789|NCT05974306|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33892790|NCT02134886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892791|NCT05705726|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33892792|NCT04377945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33892793|NCT04885283|||COHORT||RETROSPECTIVE|||||||
33892794|NCT04128111|||OTHER||CROSS_SECTIONAL|||||||
33892795|NCT01059448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892796|NCT00876031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892797|NCT01769911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892798|NCT01282125|||COHORT||CROSS_SECTIONAL|||||||
33892799|NCT03715465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33892800|NCT00543179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892801|NCT02934607|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33892802|NCT01939379|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34075219|NCT02368132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34075220|NCT03038529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075221|NCT00107757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34075222|NCT02770235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075223|NCT00092976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075224|NCT03687723|||COHORT||PROSPECTIVE|||||||
33892803|NCT05809973|||COHORT||PROSPECTIVE|||||||
33892804|NCT04300348|RANDOMIZED|PARALLEL||OTHER||SINGLE|An evaluator who does not know to which group the participant was assigned will conduct the evaluations. The outcomes are tests of performance.|Standard two-group, sequential design, with 2:1 randomization (intervention:control) and only a within-group analysis.|f|f|f|t
33892805|NCT03874234|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study. Subjects and Investigator will be blinded to the study treatment.|Subjects will receive escalating doses of GSK3186899 and placebo in Part A of the study. Subjects will receive repeat doses either of GSK3186899 or placebo in Part B of the study.|t|f|t|f
34075225|NCT06263647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be partially blinded in that they will know some information about the intervention but will not be exposed to the details of the intervention or the intervention manual.||t|f|f|t
34075226|NCT04793646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding of identical bottles of N-acetylcysteine and placebo syrup|Randomized, double-blind controlled study of N-acetylcysteine for treatment of dryness symptoms due to primary Sjogren's syndrome|t|t|t|t
34075227|NCT02380937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075228|NCT00198263|NA|SINGLE_GROUP||TREATMENT||NONE||Medpulser electroporation with Bleomycin||||
34075229|NCT05046015|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single Blind (Investigator) Non-Randomized 60 \[Anticipated\]|f|f|t|f
34075230|NCT00784719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764093|NCT01642602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764094|NCT01043237|||CASE_ONLY||PROSPECTIVE|||||||
33764095|NCT02463201|||COHORT||PROSPECTIVE|||||||
34075231|NCT00447902||PARALLEL||TREATMENT||||||||
34075232|NCT00160056|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34075233|NCT01706835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075234|NCT04189432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Multicenter, Randomized, Parallel Group, Double-blind|t|t|t|f
34075235|NCT04788095|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34075236|NCT00370591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075237|NCT03292185|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|Three-period complete cross-over, six treatment sequences|t|t|t|t
34075238|NCT00455000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892806|NCT06642480|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes. Tramadol had an onset time of 15-60 minutes, with peak effectiveness at 2-6 hours postoperatively. Pain level was categorized into 0 (no pain), 1-3 (signifying mild), 4-6 (middle), and 7-10 ( heavy pain).||||
33892807|NCT06351072|||COHORT||PROSPECTIVE|||||||
33892808|NCT03226093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892809|NCT00016458||||TREATMENT||||||||
33892810|NCT06154629|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33892811|NCT05040191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892812|NCT00443508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892813|NCT05152355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single blind||t|f|t|t
34075239|NCT00707057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075240|NCT02702843|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34075241|NCT02193750|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
34075242|NCT04715282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075243|NCT01472445|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34075244|NCT03012841|NA|SINGLE_GROUP||TREATMENT||NONE||Arctic Front Advance Cardiac CryoAblation Catheter and Freezor MAX Cardiac CryoAblation Catheter||||
34075245|NCT00086450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075246|NCT04860479|||COHORT||PROSPECTIVE|||||||
34075247|NCT02949154|||COHORT||RETROSPECTIVE|||||||
33892814|NCT01941225|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33892815|NCT05747690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075248|NCT01857505|||CASE_ONLY||RETROSPECTIVE|||||||
34075249|NCT05897866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075250|NCT05783947|||COHORT||RETROSPECTIVE|||||||
34075251|NCT00280592|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34075252|NCT03318003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075253|NCT06337357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075254|NCT02895685|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34075255|NCT03202290|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075256|NCT03340038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075257|NCT01757860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075258|NCT00606749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075259|NCT04868773|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label, single arm clinical trial.||||
34075260|NCT06069024|||OTHER||OTHER|||||||
34075261|NCT02898233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075262|NCT02026752|||COHORT||CROSS_SECTIONAL|||||||
34075263|NCT04006470|||OTHER||RETROSPECTIVE|||||||
34075264|NCT06612632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An Umbrella Study||||
34075265|NCT00780780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075266|NCT03682068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892816|NCT02812511|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892817|NCT05170360|||CASE_CONTROL||PROSPECTIVE|||||||
33892818|NCT01332708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892819|NCT00584974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892820|NCT02707770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892821|NCT01939795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892822|NCT02179840|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33892823|NCT03051633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892824|NCT04419103|||OTHER||CROSS_SECTIONAL|||||||
33892825|NCT03251547|||COHORT||RETROSPECTIVE|||||||
33892826|NCT05407623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892827|NCT02946112|||CASE_CONTROL|||||||||
33892828|NCT03433625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892829|NCT03469076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892830|NCT02000843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892831|NCT02554305|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33892832|NCT01926587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892833|NCT05030805|||COHORT||PROSPECTIVE|||||||
33892834|NCT00679887|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33892835|NCT01477905|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33892836|NCT00813995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892837|NCT03142100|||COHORT||PROSPECTIVE|||||||
33892838|NCT05269355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892839|NCT04880811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075267|NCT03954002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075268|NCT02674724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075269|NCT00604994|||CASE_CONTROL||PROSPECTIVE|||||||
34075270|NCT06152380|||OTHER||PROSPECTIVE|||||||
34075271|NCT01918917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075272|NCT02356757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34075273|NCT04803214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075274|NCT06318403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075275|NCT04147143|||COHORT||RETROSPECTIVE|||||||
34075276|NCT06422871|||COHORT||PROSPECTIVE|||||||
34075277|NCT00230789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075278|NCT04718480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind, placebo-controlled,|Randomized, double-blind, placebo-controlled, adaptive design add-on treatment study.|t|t|t|t
34075279|NCT00970645|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075280|NCT04734808|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34075281|NCT02669316|||COHORT||CROSS_SECTIONAL|||||||
34075282|NCT05664308|||OTHER||PROSPECTIVE|||||||
34075283|NCT02598739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34075284|NCT05170646|||COHORT||PROSPECTIVE|||||||
34075285|NCT01799252|||COHORT||PROSPECTIVE|||||||
34075286|NCT01214668||SEQUENTIAL||TREATMENT||NONE||||||
34075287|NCT03513263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants will not know the arm of the study they are in.|scaling and polishing plus oral hygiene instructions will be provided for the intervention arm while only oral hygiene instruction will be provided for the control arm. At the end of the six month follow up the control arm will also be provided with scaling and polishing.|t|f|f|f
34075288|NCT03450577|||COHORT||PROSPECTIVE|||||||
34075289|NCT04491461|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study uses a randomized double-blinded controlled cross-over study design.||||
34075290|NCT06420245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34075291|NCT04368507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075292|NCT02571764|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075293|NCT02740959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075294|NCT03441685|NA|SINGLE_GROUP||TREATMENT||NONE|Participants' completion of study tasks requires knowledge of intervention condition. Participants are blinded to study hypotheses.|All participants complete the three intervention conditions within a single session. Order of conditions is counterbalanced across participants.||||
33764096|NCT01950065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892840|NCT01964248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892841|NCT02406157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892842|NCT06557512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892843|NCT06642753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34075295|NCT06336057|||CASE_CONTROL||PROSPECTIVE|||||||
34075296|NCT00074815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075297|NCT04177134|||COHORT||OTHER|||||||
33764097|NCT02298816|||COHORT||PROSPECTIVE|||||||
33764098|NCT01028261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892844|NCT01993979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892845|NCT03246074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892846|NCT02337842|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33892847|NCT06296264|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33892848|NCT02906553|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33892849|NCT05817045|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Volunteers meeting all inclusion criteria and none of the exclusion criteria will be randomized to the RD-X19 treatment arm or the sham treatment arm within each cohort in a 1:1 ratio according to a fixed schedule via a permuted block design.|t|t|t|t
33892850|NCT00481858|||COHORT|||||||||
33892851|NCT06023108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33892852|NCT04294888|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All participants will undergo SHAM stimulation as a control condition. They will be blinded as to whether they are receiving active or SHAM stimulation.|Participants will each undergo, in a crossover, within-subject design, two blocks of rTMS: active and SHAM.The order of active and SHAM blocks will be counterbalanced across subjects.|t|f|f|f
33892853|NCT04567784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a randomized clinical trial in which subjects will receive either placebo or 800mg cannabidiol (CBD).|t|t|f|t
33892854|NCT04234217|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33892855|NCT00635102|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33764099|NCT04585893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764100|NCT02914314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764101|NCT03117283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892856|NCT05631132|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34075298|NCT02303639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075299|NCT04878120|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34075300|NCT06612658|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, double-blind, placebo-controlled, cross-over study|t|f|t|t
33892857|NCT00432692|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33892858|NCT02042066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892859|NCT06145230|||COHORT||CROSS_SECTIONAL|||||||
33892860|NCT00644267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892861|NCT06456710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33892862|NCT01886664|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33977545|NCT05240209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Randomization:In order not to affect the groups from the applications Schools were randomized.Schools hold closed-envelope lots,it is selected by the method.It is divided into intervention and control Group.YalçınEskiyapanSecondarySchool(Group I)Education Group was assigned as the HacıMustafaTarmanSecondarySchool(Group II)Control Group.Intervention and control groups in order to reduce selection bias and control the variables that may have an effect on the outcome variables;Randomized assignment was made by a statistician who did not know the student names and characteristics.In determining the students to be included in the research;student lists and Excel2016program were used,Simple RandomSampling was done.The student lists assigned to the groups by the expert were sent to the researcher before the initiatives started.It was planned to include one parent of each student in the study by selecting students.The researcher who evaluated the outcomes was blinded to determine the groups.|randomized controlled experimental research|t|f|f|f
33977546|NCT04536402|||OTHER||PROSPECTIVE|||||||
33977547|NCT04112251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For the implementation of the intervention, they are masked by means of the following measures:~1. The organoleptic characteristics of the interventions will be the same in color, smell, taste, texture, consistency, weight and size.~2. The primary container will be the same size, and will contain 65 capsules, which will be identified by means of a code.~3. The delivery of the treatment will be carried out by a collaborator who is not directly related to the research project, which will be assigned by the Hospital's clinical epidemiology area, according to the randomization list sent by the Integral Cardiometabolic Research Laboratory of the Polytechnic Institute National, in a sealed security envelope.~4. No direct participant should adjust the dose of the treatment, during the follow-up they will only verify the attachment of the intervention based on the capsule count, collection of anecdotes and direct interview."|A randomized, double-blind, placebo-controlled clinical trial will be conducted, which will be conducted at the Federico Gómez Children's Hospital in Mexico, during the period from October 2019 to October 2020; with patients with exogenous obesity from 10 to 16 years.|t|t|t|f
33977548|NCT03365323|||CASE_CONTROL||RETROSPECTIVE|||||||
33977549|NCT00990613|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34075301|NCT05377112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind (sponsor-open),|Placebo control (3:2 \[active: placebo\]) is included for a better understanding of the safety and tolerability of SYNB8802v1.|t|f|t|f
33892863|NCT05640648|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|Blinding of the assigned intervention is not feasible with the stepped-wedge cluster randomized implementation trial design, because interventions are implemented at the health-facility level and all health facilities receive the standard strategy followed by the enhanced, user-centered strategy. Community Health Workers will collect all data, and adjudicate all outcomes, except TB diagnoses and treatments initiated which will be collected from on-site National TB and Leprosy Programme registers. Where possible, the investigators and study staff, except for the statistician and data manager, will be blinded to any aggregated analyses of TB outcomes by study period.|The investigators will conduct a stepped-wedge, cluster-randomized implementation trial with nested mixed-methods evaluations of fidelity and context and health economic analyses. The stepped-wedge trial will include six transition steps in a complete (also known as closed) design, providing a 1:1 ratio of time periods allocated to the pre-implementation standard strategy and the post-implementation user-centered strategy.|f|f|t|t
33977550|NCT05351164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892864|NCT04791384|NA|SEQUENTIAL||TREATMENT||NONE||||||
33977551|NCT04531228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892865|NCT01702116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977552|NCT02192736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977553|NCT03828942|||CASE_ONLY||CROSS_SECTIONAL|||||||
33977554|NCT00004096||||TREATMENT||||||||
33977555|NCT00337571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977556|NCT00946257|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33977557|NCT06401083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977558|NCT00958243|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977559|NCT04305964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977560|NCT00857636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34075302|NCT06373341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34075303|NCT02546869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075304|NCT02638402|||CASE_CONTROL||RETROSPECTIVE|||||||
34075305|NCT01948921|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34075306|NCT01061541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34075307|NCT01750060|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34075308|NCT06083363|||COHORT||PROSPECTIVE|||||||
34075309|NCT02553824|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33977561|NCT01714570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977562|NCT01906541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075310|NCT04378686|||COHORT||PROSPECTIVE|||||||
34075311|NCT01803087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34075312|NCT04998890|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34075313|NCT04143191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34075314|NCT01751750|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34075315|NCT01388153|RANDOMIZED|CROSSOVER||||NONE||||||
34075316|NCT04653831|RANDOMIZED|PARALLEL||TREATMENT||NONE||Following initial diagnosis of COVID-19, severe ARDS patient will be admitted to a dedicated intensive care unit (ICU) at Soroka University Medical Center (Day 0). Upon admission, patients will be randomized according to 1:1 ratio to one of the trial arms and receive either Pirfenidone 2,403mg administered through nasogastric tube as 801mg TID (intervention arm) plus SoC or SoC alone (control arm).||||
34075317|NCT02896569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075318|NCT05463497|RANDOMIZED|SEQUENTIAL||OTHER||NONE||A randomized, open-label, multiple-dose, 2x3 crossover clinical trial||||
34075319|NCT03021447|||COHORT||PROSPECTIVE|||||||
34075320|NCT04998214|||CASE_CONTROL||PROSPECTIVE|||||||
34075321|NCT03593954|NA|SINGLE_GROUP||OTHER||NONE||||||
34075322|NCT03679416|||COHORT||RETROSPECTIVE|||||||
34075323|NCT01649362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075324|NCT06084910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34075325|NCT06520527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075326|NCT05259163|RANDOMIZED|CROSSOVER||SCREENING||NONE||The investigational product was compared to the traditional phoropter. Subjects were randomized to the order of testing.||||
34075327|NCT05130996|||COHORT||PROSPECTIVE|||||||
34075328|NCT02475772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075329|NCT00977912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34075330|NCT03649893|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Randomised Controlled Trial||||
34075331|NCT06175208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This is a multi-site, randomized, three arm trial that will evaluate the efficacy of two distinct types of group interventions to target fear of cancer recurrence (FCR) in cancer survivors.~The first intervention entails emotional freedom techniques (EFT). The other intervention is mindfulness meditation. The third group is the wait-list control group."||||
34075332|NCT00101868|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34075333|NCT01273909|||COHORT||PROSPECTIVE|||||||
33977563|NCT01870661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977564|NCT03428594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, multi-center, phase 3 clinical trial|t|t|t|t
33977565|NCT06073249|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33977566|NCT04073147|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three sequential dosing groups. Starting with dosing group 1 (5 patients), followed by dosing group 2 (5 patients) if no dose limiting toxicities occur during dosing group 1, and finally followed by dosing group 3 (5 patients) if no dose limiting toxicities occur in dosing group 2||||
33977567|NCT00093990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977568|NCT05435508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Parallel Assignment|t|t|t|t
33977569|NCT00216502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33977570|NCT01238848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075334|NCT00539071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075335|NCT04655781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075336|NCT00649077|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34075337|NCT04609423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Participants, investigators, care providers, data collectors, outcomes assessors, and data analysts will be masked to the group assignment of each participant.~Unmasking will be done after analysis of all primary endpoints and, preferably, also all secondary endpoints are completed.~After unmasking the unmasked list will only be made available to study personnel needing this for conducting their tasks."|A parallel-group treatment, two-arm study where participants are randomly assigned to cod liver oil or placebo (corn oil) in a 1:1 ratio|t|t|t|t
34075338|NCT02144038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075339|NCT03200210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075340|NCT02630810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34075341|NCT01209169|||COHORT||PROSPECTIVE|||||||
34075342|NCT02241525|||CASE_CONTROL||PROSPECTIVE|||||||
33892866|NCT03888625|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Group A, patients will undergo peeling with complete removal of the internal limiting membrane (ILM) and in the group B, the inverted ILM peeling technique will be performed.||||
33892867|NCT00353977|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33892868|NCT06487052|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients will be randomized into 2 parallel groups||||
34075343|NCT02521792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892869|NCT02380131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892870|NCT05423379|||COHORT||PROSPECTIVE|||||||
34075344|NCT00970021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075345|NCT02246283|||COHORT||RETROSPECTIVE|||||||
34075346|NCT03624491|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a prospective, open label, randomized study|Randomization to two different groups.||||
34075347|NCT03860298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075348|NCT00354965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075349|NCT06434675|||CASE_ONLY||CROSS_SECTIONAL|||||||
34075350|NCT05387993|||CASE_ONLY||CROSS_SECTIONAL|||||||
34075351|NCT02132143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33892871|NCT06139289|||COHORT||RETROSPECTIVE|||||||
33892872|NCT00442598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892873|NCT05001178|||OTHER||RETROSPECTIVE|||||||
34075352|NCT03249168|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blind||t|t|f|t
34075353|NCT03410992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075354|NCT00006029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075355|NCT05105672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075356|NCT00379899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075357|NCT02100280|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34075358|NCT03783117|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects in second stage of hypertension: the systolic blood pressure in a range of 140-180 mmHg or diastolic blood pressure in a range 90-120 mmHg. For safety, subjects, who have a pacemaker or other metallic devices implanted, will not be admitted.||||
34075359|NCT05691413|NA|SINGLE_GROUP||OTHER||NONE||||||
34075360|NCT02040753|||COHORT||RETROSPECTIVE|||||||
34075361|NCT01236040|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34075362|NCT05216107|||COHORT||PROSPECTIVE|||||||
34075363|NCT06106880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075364|NCT04019145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34075365|NCT04241770|||COHORT||PROSPECTIVE|||||||
34075366|NCT05888298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075367|NCT03343743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075368|NCT01491867|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075369|NCT04279080|||COHORT||RETROSPECTIVE|||||||
34075370|NCT05930314|NA|SINGLE_GROUP||TREATMENT||NONE||refractory systemic lupus erythematosus(SLE) presented with active lupus nephritis or active immune thrombocytopenia.||||
33892874|NCT01642355|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892875|NCT03685448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892876|NCT03511365|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group interventional pilot study with each subject serving as his or her own control||||
33892877|NCT04512261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892878|NCT03804151|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33892879|NCT04558502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892880|NCT06603636|||OTHER||CROSS_SECTIONAL|||||||
33892881|NCT04029376|||COHORT||PROSPECTIVE|||||||
33892882|NCT04932889|||CASE_CONTROL||RETROSPECTIVE|||||||
33892883|NCT03596164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892884|NCT02520479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892885|NCT05426811|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33892886|NCT02318602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892887|NCT06656169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind, randomized, masked, placebo-controlled, randomized clinical trial will be conducted|t|t|t|t
33892888|NCT00559338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892889|NCT04636112|||CASE_CONTROL||RETROSPECTIVE|||||||
33764102|NCT03166371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764103|NCT01741116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764104|NCT00015821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892890|NCT02024776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33892891|NCT00814931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892892|NCT01627145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892893|NCT06372977|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892894|NCT02158078|||CASE_ONLY||PROSPECTIVE|||||||
33892895|NCT00813748|||OTHER||OTHER|||||||
33892896|NCT03467230|||CASE_ONLY||PROSPECTIVE|||||||
33892897|NCT04708067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892898|NCT03009357|||COHORT||PROSPECTIVE|||||||
33892899|NCT01479972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892900|NCT03425903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All participants received WBC sessions and after that become controls||||
33892901|NCT02267486|||||PROSPECTIVE|||||||
34075371|NCT02247882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075372|NCT01085708|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34075373|NCT02458560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075374|NCT02794298|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34075375|NCT00650819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075376|NCT00500734|||CASE_ONLY||PROSPECTIVE|||||||
34075377|NCT04754646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded-Live Evaluator||f|f|f|t
34075378|NCT01023347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764105|NCT03668262|||COHORT||PROSPECTIVE|||||||
33764106|NCT00003511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892902|NCT06023212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892903|NCT01360125|||||RETROSPECTIVE|||||||
33892904|NCT00817414|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34075379|NCT02033707|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34075380|NCT00788489|||COHORT||PROSPECTIVE|||||||
34075381|NCT00613366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34075382|NCT00535431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075383|NCT05083910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34075384|NCT02594917|||COHORT||PROSPECTIVE|||||||
33764107|NCT05355480|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33764108|NCT02206295|RANDOMIZED|CROSSOVER||||NONE||||||
33764109|NCT02303158|||COHORT||PROSPECTIVE|||||||
33764110|NCT04601363|||COHORT||OTHER|||||||
33764111|NCT04100122|||COHORT||PROSPECTIVE|||||||
33764112|NCT00525772|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33764113|NCT01119768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764114|NCT04263103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33764115|NCT00171873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764116|NCT06010901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764117|NCT00358137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33764118|NCT06261190|||COHORT||PROSPECTIVE|||||||
33764119|NCT01528449|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764120|NCT04754256|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764121|NCT05923086|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|This is a multi-center, randomized, double blind, placebo-controlled, phase 2 pilot efficacy study.|t|t|t|t
33977571|NCT04613830|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33764122|NCT04866121|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33764123|NCT00086541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764124|NCT03767283|||OTHER||PROSPECTIVE|||||||
33764125|NCT04407013|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33892905|NCT06602141|RANDOMIZED|PARALLEL||OTHER||NONE|Participants will be randomized into either the control (CTRL) group or the endurance exercise (EX) group.|||||
33892906|NCT05549388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistical analyst will be masked to the study arms during the analysis phase.||f|f|f|t
33892907|NCT02643550|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33892908|NCT01819935|||COHORT||RETROSPECTIVE|||||||
33892909|NCT03550248|NA|SINGLE_GROUP||PREVENTION||NONE||Participating organizations will deliver the Healthy Together (HT) program to children/youth and their parents/caregivers. Participants in the program will be invited to complete questionnaires to evaluate the program at mid point (after 15 sessions) and post program (after 30 sessions).||||
33892910|NCT04548076|||CASE_CONTROL||PROSPECTIVE|||||||
33977572|NCT00429806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977573|NCT02253979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977574|NCT01818856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977575|NCT05182632|NA|SINGLE_GROUP||TREATMENT||NONE|N/A (single-arm study)|Feasibility pilot study||||
33977576|NCT00212537|||CASE_CONTROL||OTHER|||||||
33892911|NCT05836090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977577|NCT01032369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33977578|NCT04438005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977579|NCT01415778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977580|NCT00625911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764126|NCT02698540|||COHORT||PROSPECTIVE|||||||
33764127|NCT06626035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial|t|f|f|f
33764128|NCT03365986|||COHORT||PROSPECTIVE|||||||
33764129|NCT01316770|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33764130|NCT00880425|||CASE_ONLY||RETROSPECTIVE|||||||
33764131|NCT02871830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33764132|NCT06622304|||COHORT||RETROSPECTIVE|||||||
33764133|NCT03059407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects will be assigned into one of three groups: 1) Canine assisted therapy only; 2) Canine assisted therapy plus standard distraction techniques; and 3) Standard distraction techniques only.||||
33764134|NCT05778721|||CASE_ONLY||RETROSPECTIVE|||||||
33892912|NCT04657822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892913|NCT04513158|NA|SINGLE_GROUP||TREATMENT||NONE||All hospitalized patients meeting study inclusion/exclusion criteria and providing informed consent for participation in the study will receive one unit (approximately 200 mL) of convalescent plasma over one hour to with data collection of routine physical exams/clinical assessments (daily) and routine lab results (every 3 days).||||
33892914|NCT01746134|||COHORT||PROSPECTIVE|||||||
33892915|NCT05125653|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||2 arms, randomized, double blinded|t|f|t|f
33892916|NCT05752448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Will mask all study personnel except care provider who will not be engaged with data interpretation|Randomized controlled trial double blinded|t|f|t|t
33892917|NCT06656130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892918|NCT01397019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892919|NCT06618651|NA|SINGLE_GROUP||TREATMENT||NONE||To evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.||||
33977581|NCT03196999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blind to which condition they will be in.|Participants will be assigned to either a threat attention bias modification training or a neutral bias modification training.|t|f|f|f
33977582|NCT01855724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977583|NCT02857842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075385|NCT05275933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|A randomised, double-blind, placebo-controlled study|t|f|t|t
33764135|NCT04079868|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Outcome assessors will be masked to the group assignment|Stratified, block randomization will be used. A statistician unaware of team identity will randomize PACTs in blocks of 2 within strata to ensure similar distributions. If insufficient numbers of PACTs are recruited within small CBOCs, they will be combined with other similar CBOCs (rural vs. urban) for randomization.|f|f|f|t
33764136|NCT02450721|||COHORT||CROSS_SECTIONAL|||||||
34075386|NCT02077309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764137|NCT02922894|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33764138|NCT01073800|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33764139|NCT02630524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764140|NCT06151990|||CASE_CONTROL||RETROSPECTIVE|||||||
33892920|NCT04425655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892921|NCT05252689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|f|t
33892922|NCT01389245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892923|NCT01599559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892924|NCT03254056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33892925|NCT03483532|||COHORT||PROSPECTIVE|||||||
33892926|NCT02913989|||||CROSS_SECTIONAL|||||||
33892927|NCT04102150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892928|NCT03040024|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
33892929|NCT05302752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33892930|NCT04468477|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764141|NCT02093039|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764142|NCT01304121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33892931|NCT02346344|||CASE_CROSSOVER||PROSPECTIVE|||||||
33892932|NCT06190314|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33892933|NCT03375385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892934|NCT02712775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977584|NCT00193609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977585|NCT02684552|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34075387|NCT05765357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764143|NCT02496767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764144|NCT03155932|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33764145|NCT02112760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977586|NCT00664781||||TREATMENT||NONE||||||
33977587|NCT04059211|||OTHER||PROSPECTIVE|||||||
33977588|NCT04549064|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075388|NCT00946660|||CASE_ONLY||PROSPECTIVE|||||||
34075389|NCT03014206|||CASE_ONLY||PROSPECTIVE|||||||
34075390|NCT00270296|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34075391|NCT04849663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded||f|f|t|f
34075392|NCT03297866|||COHORT||CROSS_SECTIONAL|||||||
34075393|NCT03102957|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2 arms : epileptic patient and healthy volonteers||||
34075394|NCT01243060|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34075395|NCT02981199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075396|NCT03695263||SEQUENTIAL||TREATMENT||NONE|The analysis will proceed automatically without knowledge of which 3-day treatment periods were associated with one of the five interventions and which were associated with the subject's usual activities.|"Each participant will enroll in a personalized (N-of-1) crossover trial."||||
33977589|NCT04021537|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The investigators are using a blinding box with a code entry system that determines which stimulation location is used. The study coordinator/care providers will know the code, but not the stimulation location. Participants will know the stimulation location (they can feel it) but not which location is the investigators' hypothesized actor (i.e., they don't which is sham and which is target). The investigators will not know which is which until the data are in analyzable form.|The study is a cross-over design comparing two stimulation locations. The order of stimulation is randomly assigned.|t|t|t|f
33977590|NCT02959905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977591|NCT01723995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977592|NCT03818048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33977593|NCT05159609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|auditory stimulus was played at 0 or 50 decibels during sleep|Within subject comparison of stimulus and sham sessions|t|f|f|f
33977594|NCT05653596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33977595|NCT05023213|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The datasets given to the statistician will be blinded to the condition.||f|f|f|t
33977596|NCT02815852|||OTHER||RETROSPECTIVE|||||||
33977597|NCT00859209|||COHORT||PROSPECTIVE|||||||
33977598|NCT05854758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977599|NCT05129579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977600|NCT02877251|||COHORT||OTHER|||||||
33977601|NCT05601570|||COHORT||RETROSPECTIVE|||||||
33977602|NCT05263648|NA|SINGLE_GROUP||OTHER||NONE||||||
33977603|NCT04776551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075397|NCT04858308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind.|A multicenter, Double-blind, Randomized, Active-controlled, Double dummy, Parelle-group comparative.|t|t|t|t
34075398|NCT01602796|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34075399|NCT05220514|||CASE_CONTROL||PROSPECTIVE|||||||
34075400|NCT04986241|||COHORT||RETROSPECTIVE|||||||
34075401|NCT03297229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075402|NCT01971567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075403|NCT05409950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075404|NCT06503068|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34075405|NCT04452851|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Subjects will be asked to participate in four (4) visits. During the first visit, baseline measurements will be made. In the subsequent three (3) sessions, subjects will be asked to perform two (2) tests from a group of six (6) options. This list of tests is comprised of three BiPAP Equivalency tests and three Activity of Daily Living Simulations. Participants will be randomized to study groups using a table of random numbers generated at the outset of the study to determine the test order.||||
34075406|NCT03245320|||CASE_CONTROL||OTHER|||||||
34075407|NCT00751140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075408|NCT06455852|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34075409|NCT00763997|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34075410|NCT04485728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075411|NCT00508911|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075412|NCT02041806|||COHORT||PROSPECTIVE|||||||
34075413|NCT00401128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075414|NCT06604832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34075415|NCT03675360|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34075416|NCT05449171|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764146|NCT06624605|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized study assessing the efficacy of Large Language Model-generated Plain Language Summaries of Ophthalmology notes in increasing non-ophthalmologist note understanding. Notes were randomized to intervention (Summary + Original Note) or control (Original note only) arms. Non-ophthalmology providers were sent surveys assessing note comprehension for both control and treatment arm notes, and Ophthalmologists were sent surveys for intervention arm notes regarding Summary accuracy and other attributes. Conducted as a Quality Improvement initiative.||||
33977604|NCT02260557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977605|NCT06542081|||OTHER||CROSS_SECTIONAL|||||||
33977606|NCT00930488|||COHORT||PROSPECTIVE|||||||
33977607|NCT04931667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977608|NCT06121206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Substudy 1: The study has a double-blinded design. Neither the participant nor the outcome assessors will know whether the participant is receiving (1) altitude-like hypoxia (12%) combined with cognitive training, (2) hypoxia with no training, (3) cognitive training under normoxia (20%), or (4) normoxia with no training.~Substudy 2: The study has an assessor-blinded design. The outcome assessor will not know whether the participant is receiving (1) altitude-like hypoxia (12%) combined with cognitive training or (2) treatment as usual (TAU)."||t|f|f|t
34075417|NCT06612398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research Assistant who evaluated patient's anxiety levels did not know who watched the intervention and who did not.|Randomized controlled trial|f|f|f|t
34075418|NCT01863290|||COHORT||PROSPECTIVE|||||||
34075419|NCT02688933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075420|NCT01342575|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34075421|NCT00327717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977609|NCT01530100|||||PROSPECTIVE|||||||
33977610|NCT04359238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977611|NCT04552509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977612|NCT01079637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977613|NCT00000359|RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
33977614|NCT03295721|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33977615|NCT03598439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33977616|NCT02296580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977617|NCT05128357|||CASE_ONLY||CROSS_SECTIONAL|||||||
33977618|NCT05667870|||OTHER||CROSS_SECTIONAL|||||||
33977619|NCT04428567|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The subjects will be randomly assigned to 2 groups: 1) treadmill training group with a cognitive task (Intervention group) 2) Control group. The entire intervention period is 6 weeks in both groups, with interventional training occurring 3 days per week for approximately 45 minutes per session. Evaluations will take place at baseline, 3 weeks, at the end of 6 weeks, and 1 month and 6 months after the intervention.|f|f|f|t
33977620|NCT03942965|||COHORT||PROSPECTIVE|||||||
33977621|NCT04826796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33977622|NCT00322478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977623|NCT04026126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075422|NCT06129383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Within the scope of this study, two different research groups were identified for which clinical research was planned. The significance level of the power analysis was determined as 0.05 and the power level was determined as 0.80. However, for this study, it was decided to consider the effect size value as 0.4, based on similar studies in the literature. It was deemed sufficient to include n = 26 cases in each group, and it was deemed appropriate to include n = 30 cases in each group, considering a 20% wastage margin. The cases will be divided into 2 groups of 30 people using the sealed envelope method. Group I will include patients who underwent SAP block under general anesthesia (Control group), and Group II will include patients who underwent SAP and PIFB block under general anesthesia (Experimental group).|f|t|f|f
34075423|NCT06612697|||CASE_CONTROL||RETROSPECTIVE|||||||
34075424|NCT05923047|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This trial includes three treatment arms.~1. Combined group (In-office nasal polypectomy group with mepolizumab): This group will undergone in-office nasal polypectomy and will receive Mepolizumab.~2. Medical group (mepolizumab): This group will receive Mepolizumab.~3. Surgical group (In-office nasal polypectomy): This group will undergone in-office nasal polypectomy."||||
34075425|NCT06246188|||OTHER||PROSPECTIVE|||||||
34075426|NCT02447445|||CASE_ONLY||OTHER|||||||
34075427|NCT02620787|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075428|NCT05127564|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075429|NCT02558764|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34075430|NCT02193204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34075431|NCT06065644|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||15 patients with long fixation and 15 with fixation of L4/5.||||
34075432|NCT05199792|||COHORT||PROSPECTIVE|||||||
34075433|NCT06232967|||COHORT||RETROSPECTIVE|||||||
34075434|NCT03746834|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are treated with injection of NASHA/Dx and act as their own Controls over time.||||
34075435|NCT03870334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study. The purpose of this study is to evaluate the efficacy and safety of oral BT-11 induction compared to placebo in subjects with moderate to severe CD. Approximately 100 sites will participate from Europe and the USA. A total of 150 subjects with moderate to severe CD (CDAI Score 220-450 and a Simplified Endoscopic Index of Severity of Crohn's Disease (SES-CD) SCORED ≥ 6 (≥ 4 for isolated ileitis) will be randomized in a 1:1 ratio to receive BT-11 1,000 mg or placebo. Each of the treatment arms will comprise 75 subjects. The randomization will be stratified by prior exposure to biologic therapy for CD (yes/no) and corticosteroid use at baseline (yes/no). The study consists of a 28-day screening period, a 12-week induction phase, and a 2-week post-treatment safety follow-up period.|t|f|t|t
33977624|NCT03041766|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977625|NCT01894711|||COHORT||RETROSPECTIVE|||||||
33977626|NCT06121466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977627|NCT02304432|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33977628|NCT01456611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977629|NCT01714648|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977630|NCT05151406|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|coding of data|An intervention Quasi Experimental study design (pre/post-test)|t|f|f|f
33977631|NCT05010603|||FAMILY_BASED||PROSPECTIVE|||||||
33977632|NCT06151977|||OTHER||CROSS_SECTIONAL|||||||
33977633|NCT05265325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33977634|NCT02927847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33977635|NCT00138905|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33977636|NCT01578707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977637|NCT03682042|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Neurodevelopmental providers will be blinded to the randomization of the toddler during the examination.|Neurodevelopmental assessments will be done at 2 years of age (22-26 months) for subjects who were randomized to receive either early cord clamping or umbilical cord milking as part of the CORDMILK trial.|f|f|f|t
33977638|NCT00958256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977639|NCT03309449|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33977640|NCT01867242|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33977641|NCT01483508|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33977642|NCT01601509|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33977643|NCT04433390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the nurse giving the treatment is not the outcomes assessor.||t|t|t|t
33977644|NCT02270788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977645|NCT03038113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34075436|NCT05140889|||CASE_CONTROL||PROSPECTIVE|||||||
33892935|NCT04508387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists.|The patients were divided into two groups according to a randomization scheme created by a computer: Group CD (cold-dry) patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH (heated-humidified) patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia (PCA) device and the visual analog scale (VAS) the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form.|f|f|t|f
33892936|NCT04266574|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33892937|NCT01046188|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
33892938|NCT00123929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892939|NCT04721353|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study of prazosin for treatment of cannabis use disorder||||
33892940|NCT05117970|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33892941|NCT05824910|NA|SINGLE_GROUP||TREATMENT||NONE||one group pre/post assessment (feasability study)||||
33892942|NCT04420793|||CASE_ONLY||PROSPECTIVE|||||||
33892943|NCT00502450|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892944|NCT05918887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892945|NCT03246438|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33892946|NCT06260787|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33892947|NCT02028949|NON_RANDOMIZED|||||NONE||||||
33892948|NCT05984745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977646|NCT05362435|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"This will be a self-control, non-randomised intervention. Participant data collection will occur at the following times:~Cohort A \& B T1 = 3 months pre-program T2 = Week 1 = immediately pre-program T3 = Week 12 = post live program (12 weeks) T4 = Week 24 = post full program T5 = 1 year after T4~Cohort C, D, E 3-month control removed after consultation. T1 = Week 1 = immediately pre-program T2 = Week 12 = post live program (12 weeks) T3 = Week 18 or 24 = post full program T4 = 1 year after T4~Data input will occur in March and July annually, there will be 5 cohorts over the three years (Jan 2022 \[COHORT A\], Sept 2022 \[COHORT B\], Jan 2023 \[COHORT C\], Sept 2023 \[COHORT D\], Jan 2024 \[COHORT E\]). Cohorts A, B, C will have all data points collected, cohorts D and E will not have data collected 1-year post completion (unless the researchers are able to extend funding to include the one-year follow-up for these cohorts). Each cohort will be exposed to the same intervention."||||
34075437|NCT02027233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34075438|NCT05551390|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Late preterm pregnant women (34-36+6 week's gestation) that exclude placenta accrete/percreta, placenta previa, placental abruption, congenital anomaly and hydrops fetalis, were randomized in a 1:1 ratio to either one-time or three-times UCM.||||
34075439|NCT03260608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The individual who evaluates the outcome(s) of interest in this case the applicators of scales and questionnaires|"We will select 148 caregivers. Patients will be divided into two groups, both groups will receive printed materials about problematics behaviors in dementia.~Participants in the intervention group will receive weekly telephone contacts over a period of eight weeks, previously scheduled with psychoeducational and support in the management of their relatives with dementia. Caregivers in the intervention group will have access to a number of phones to spontaneously contact specific guidelines during the eight weeks of intervention.~Patients from both groups will be interviewed in the baseline, at 8 weeks and 16 weeks."|f|f|f|t
34075440|NCT03747705|||CASE_ONLY||PROSPECTIVE|||||||
34075441|NCT00353223|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34075442|NCT01158261|||COHORT||PROSPECTIVE|||||||
34075443|NCT01144455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075444|NCT05073419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical information regarding ICM implantation will be withheld from outcome assessors|Pilot randomized controlled trial|f|f|f|t
34075445|NCT00803712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075446|NCT04716972|||COHORT||PROSPECTIVE|||||||
34075447|NCT00954122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075448|NCT03169907|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This will be a prospective study. Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion.Selected patients will be monitored weekly from 15 weeks gestational age till 28 weeks of gestational age.||||
34075449|NCT02843126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075450|NCT05746169|||COHORT||PROSPECTIVE|||||||
34075451|NCT00945412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34075452|NCT02282865|||CASE_CONTROL||PROSPECTIVE|||||||
34075453|NCT01129245|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34075454|NCT00705757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075455|NCT00824213|||CASE_ONLY||PROSPECTIVE|||||||
34075456|NCT00816127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764147|NCT05364684|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study with historical controls.||||
33764148|NCT04775238|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33892949|NCT06042686|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Repeated measures study design where each participant gets both devices on different nights in random order||||
33892950|NCT01315574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892951|NCT01106378|||||PROSPECTIVE|||||||
33892952|NCT05855356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||unblinded randomized controlled trial||||
33892953|NCT06386458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892954|NCT00885443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33892955|NCT03118622|||CASE_CONTROL||PROSPECTIVE|||||||
33892956|NCT02296034|||COHORT||PROSPECTIVE|||||||
33892957|NCT04561180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892958|NCT05356793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33892959|NCT04702230|||CASE_ONLY||PROSPECTIVE|||||||
33892960|NCT00370344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892961|NCT00097539|||COHORT||PROSPECTIVE|||||||
33892962|NCT00056199||||TREATMENT||||||||
33892963|NCT00462423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33892964|NCT02846519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892965|NCT00492219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892966|NCT06656091|RANDOMIZED|PARALLEL||TREATMENT||NONE||"simmitinib 6mg,QD ,3 weeks on 1 week off Control Group：investigator's choice of chemotherapy,include docetaxel or irinotecan.~docetaxel injection 75mg/m\^2,d1,every 3 weeks； ilinotecan injection 180mg/m\^2,d1,every 2 weeks"||||
33892967|NCT01903876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892968|NCT01810809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892969|NCT01667848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33892970|NCT01851096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892971|NCT06129084|||CASE_ONLY||CROSS_SECTIONAL|||||||
33892972|NCT05157633|||CASE_CONTROL||OTHER|||||||
33892973|NCT00960076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892974|NCT02515240|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892975|NCT06292897|||CASE_CONTROL||RETROSPECTIVE|||||||
33977647|NCT01138072|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33977648|NCT04682041|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open-label clinical study evaluating the effectiveness of EnteraGam 10.0 g BID added to standard of care, as compared to standard of care alone, in subjects with COVID-19. Eligible subjects will be randomized in a 2:1 ratio.||||
33977649|NCT06130020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977650|NCT00718159||SEQUENTIAL||TREATMENT||NONE||||||
33977651|NCT04788680|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||All participants receive all interventional diets|t|f|f|f
33977652|NCT01173770|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977653|NCT00738166|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33977654|NCT00617526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977655|NCT02931474|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33977656|NCT05496140|RANDOMIZED|PARALLEL||TREATMENT||NONE||8-school clustered randomized controlled trial (RCT).||||
33977657|NCT02837965|||COHORT||PROSPECTIVE|||||||
33977658|NCT02369237|||||CROSS_SECTIONAL|||||||
33977659|NCT05720663|||COHORT||PROSPECTIVE|||||||
33977660|NCT03871608|||OTHER||PROSPECTIVE|||||||
33977661|NCT04591626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977662|NCT00417274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977663|NCT00922597|||COHORT||PROSPECTIVE|||||||
33977664|NCT03747822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a third party oral surgery specialist will be asked to assess the study participate according to a standardized assessment tool||f|f|f|t
33977665|NCT05447338|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The selection of the intervention group will be made by lottery. The participant will not know to which intervention group they will belong, that is, they will be blinded.|The sample will be divided into three intervention groups. Two experimental groups and a control group. Experimental group A: Will receive as treatment the specific joint mobilization technique post muscle inhibition (MAEPI). Experimental group B: Will receive the MAEPI technique as treatment and myofascial induction techniques will be added. The control group: will receive two techniques whose effectiveness is scientifically proven. Which are: Maitland central posterior-anterior passive joint mobilization in C2 + Sustained natural apophyseal sliding (SNAG) in rotation on C1.|t|f|f|f
33977666|NCT04700449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977667|NCT05760703|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33977668|NCT02806921|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33977669|NCT02274298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977670|NCT06236737|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two intervention group||||
33977671|NCT01151813|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33977672|NCT05905848|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|open label, blinded endpoint|RASI group and CCB group|f|f|f|t
33977673|NCT01420783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977674|NCT01938950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977675|NCT01688661|||CASE_CROSSOVER||PROSPECTIVE|||||||
33977676|NCT00418470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977677|NCT04384549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33977678|NCT01031537|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977679|NCT01968382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977680|NCT04617665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977681|NCT06087874|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|It is a double-blind study||t|t|t|t
33977682|NCT03392571|NA|SINGLE_GROUP||TREATMENT||NONE||Patients receive 3 cycles of preoperative chemotherapy. The regimen consists of gemcitabine 800 mg/m2, nab-paclitaxel 100 mg/m2 and cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).||||
33977683|NCT01263158|RANDOMIZED|||TREATMENT||NONE||||||
33892976|NCT04299529|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Caregivers will know the group to which their patients were randomly assigned. In the two groups, both patients and caregivers will have full access to the HTM data. In both treatment groups, caregivers will be informed about the UPP risk profile. However, in the experimental group, patients will be informed about their UPP risk profile shortly after randomisation and in the control group, only when they leave randomised follow-up or at the completion of the trial. The central study coordinating team will remain blinded to the primary endpoint and all of its components until completion of the trial and until all datasets have been cleaned and frozen for the final analysis.|Parallel group design|f|f|f|t
33892977|NCT01818544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33892978|NCT04224363|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33892979|NCT06417632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33892980|NCT00337389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33892981|NCT05195606|RANDOMIZED|PARALLEL||OTHER||SINGLE|In the application process, single blinding will be provided as the patients do not know which group they are included in.||t|f|f|f
33892982|NCT06101901|||CASE_CROSSOVER||PROSPECTIVE|||||||
33892983|NCT04988373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33892984|NCT06125860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892985|NCT06116305|||COHORT||PROSPECTIVE|||||||
33892986|NCT04242537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892987|NCT05418764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will perform five hysterectomies on the Miya Model with a trainer who is a sub-PI at each institution, with each of these training sessions filmed and then scored by blinded experts - o Residents in the simulation arm will train until they reach a score of 27 on the modified Vagina Surgical Skills Index (VSSI)|Study participants will be residents at participating institutions who agree to participate in the study.|f|f|f|t
33892988|NCT02320578|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|t|f
33892989|NCT00599768|||CASE_ONLY||PROSPECTIVE|||||||
33892990|NCT04837014|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Although the patient and operative team will not be blinded to the allocation, the research team member completing the post-operative questionnaires as well as the statistician responsible for data analysis will remain blinded to the allocation.|In this randomized controlled trial, consented patient will be randomly allocated to either intervention or control groups in a 1:1 fashion. Allocation will be determined by a computerized randomization generator with block randomization in groups of four. Allocations will be placed in sequentially numbered, sealed, opaque envelopes to be opened only upon completion of surgery of consenting patients.|f|f|t|t
33892991|NCT00172991|||CASE_CONTROL||OTHER|||||||
33977684|NCT01252069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977685|NCT02258256|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Pregnant women will have their blood pressure measured by both the experimental device (Sphygmo ) and the gold-standard, commercial device (GE Dinamap Procare).||||
33977686|NCT01450709|||COHORT||PROSPECTIVE|||||||
33977687|NCT02309099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977688|NCT06244654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33977689|NCT03510364|NA|SINGLE_GROUP||OTHER||SINGLE|Participants were blinded to the actual study aim. They were told that the aim of the study is to study the relationship between consumption of dietary macronutrient ratios and metabolic rate.|A prospective feeding study with convenience sampling|t|f|f|f
33977690|NCT00617448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977691|NCT06325579|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33977692|NCT06220292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33977693|NCT02470559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977694|NCT04622709|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center (multi-clinic), open-label, non-randomized pilot study to test whether oral furosemide is safe and effective at increasing urine volume in HD patients. The study will consist of 2 periods: a 6-week dose escalation period (period 1) and a subsequent 12-week follow-up period (period 2). During period 1, all participants will receive escalating doses of furosemide as tolerated, and the short-term safety, tolerability, and efficacy of furosemide will be examined. During period 2, all participants will continue the maximally tolerated period 1 furosemide dose, and the acceptability of and adherence to furosemide and the longer-term safety and efficacy of furosemide will be examined.||||
33977695|NCT02632877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977696|NCT05310565|NA|SINGLE_GROUP||OTHER||NONE||Single-Arm pilot||||
33977697|NCT02132247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977698|NCT03665649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977699|NCT03423888|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977700|NCT01267266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977701|NCT06266988|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33977702|NCT00486083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33977703|NCT03923764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized||||
33977704|NCT03066453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977705|NCT06114407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977706|NCT02449707|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33977707|NCT01365650|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977708|NCT01346085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977709|NCT00776503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977710|NCT02907996|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33977711|NCT01575054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977712|NCT01282359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977713|NCT04659538|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977714|NCT02585700|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977715|NCT02714309|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977716|NCT04480398|||COHORT||RETROSPECTIVE|||||||
33892992|NCT03463330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Qigong exercise in intervention arm and mild body exercise in control arm|t|f|f|t
33892993|NCT03855072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* A Randomized Controlled Trial~* A Trial will be carried out in Hospital of Oral and Maxillofacial surgery departement- faculty of Dentistry , Cairo University~* Equal randomization : participant with equal probabilities for intervention~* Parallel group study : Each group of patients recieves a single treatment simultaneously"|t|f|f|f
34075457|NCT02493517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075458|NCT03221998|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is designed as a population-based prospective randomized cohort study. A prospective cohort of patients admitted to laparoscopic sleeve gastrectomy due to morbid obesity||||
34075459|NCT06553690|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34075460|NCT01253096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075461|NCT05488769|||COHORT||PROSPECTIVE|||||||
33892994|NCT04855695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33892995|NCT04986501|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is a randomized, open-labelled crossover trial.||||
33892996|NCT05265650|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ib/II study with one single treatment arm (BO-112 in combination with SABR and nivolumab)||||
33892997|NCT04207398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33892998|NCT02421198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075462|NCT04762199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075463|NCT01366313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33892999|NCT02886429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893000|NCT05984927|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation Study with 3 dose cohorts||||
33893001|NCT02589977|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33893002|NCT05527925|||COHORT||PROSPECTIVE|||||||
33893003|NCT00987844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893004|NCT00527202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893005|NCT03394339|||OTHER||PROSPECTIVE|||||||
33893006|NCT05553860|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33893007|NCT04627740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893008|NCT06656065|||COHORT||PROSPECTIVE|||||||
33893009|NCT03740334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893010|NCT03977779|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33893011|NCT01571492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893012|NCT03441126|||COHORT||PROSPECTIVE|||||||
33893013|NCT01178021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893014|NCT04426630|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center prospective cohort study. The researchers will use consecutive sampling to identify potential patient participants.||||
34075464|NCT01629095|||COHORT||RETROSPECTIVE|||||||
33893015|NCT02560454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977717|NCT04071600|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893016|NCT00466505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893017|NCT05745129|||OTHER||PROSPECTIVE|||||||
33893018|NCT03021837|||OTHER||RETROSPECTIVE|||||||
33893019|NCT03820492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893020|NCT01360203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33893021|NCT06655961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel group (experimental-control) randomised controlled experimental design|f|f|f|t
33893022|NCT03101072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, their care providers, and study investigators having contact with participants \& their providers will be blinded until the antibiotic therapy is discontinued. Outcomes assessors and data analysts will be fully blinded.|"With day 1 defined as the first day of appropriate (microbiologically efficacious) antibacterial therapy, patients will be randomized 1:1:1 on day 5 (±1) to one of the following three arms:~* Fixed long antibiotic course of 14 days (control arm)~* Fixed short antibiotic course of 7 days (first intervention arm)~* Individualized antibiotic course (second intervention arm): • Starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75% In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care."|t|t|t|t
33893023|NCT01839474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893024|NCT05879133|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977718|NCT05889338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977719|NCT05848986|||COHORT||OTHER|||||||
33977720|NCT05186571|||COHORT||PROSPECTIVE|||||||
33977721|NCT05656742|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive the same intervention: 8 weeks of daily oral vitamin D3 supplements, each containing 5,000 IU||||
33977722|NCT05991739|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will randomize 35 parent-youth dyads to the treatment arm or waitlist-control arm using block randomization. Each group will have 7-9 dyads, with two groups running simultaneously (treatment arm) and the remaining two groups running in three months (waitlist-control arm). After all participants are enrolled, families will be randomly selected to participate in either the treatment arm (immediate start) or waitlist-control arm (delayed start after 3 months).||||
33977723|NCT03484871|||COHORT||PROSPECTIVE|||||||
34075465|NCT04613739|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Outcomes will be assess through an online survey of participants with additional recoding done by an analyst blinded to study group|||||
34075466|NCT01060423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075467|NCT04538469|||COHORT||RETROSPECTIVE|||||||
34075468|NCT04546750|||COHORT||PROSPECTIVE|||||||
34075469|NCT04827979|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34075470|NCT04806269|||CASE_CONTROL||PROSPECTIVE|||||||
33893025|NCT03732924|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33977724|NCT01774266|||COHORT||PROSPECTIVE|||||||
33977725|NCT02375009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977726|NCT01098721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977727|NCT03728842|||COHORT||PROSPECTIVE|||||||
33977728|NCT01624220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977729|NCT04245826|||COHORT||PROSPECTIVE|||||||
33977730|NCT06126393|||COHORT||OTHER|||||||
33977731|NCT06411366|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33977732|NCT01232270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33977733|NCT02612636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977734|NCT03732846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977735|NCT01681030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977736|NCT05357157|||COHORT||PROSPECTIVE|||||||
34075471|NCT00434772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075472|NCT01438619|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34075473|NCT02259400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075474|NCT02716792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075475|NCT00452660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075476|NCT00738634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075477|NCT04168645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned (using a computer-generated randomization schedule) to either BCBT or TAU using stratified block randomization on Substance Use Disorder (SUD). We expect, based on pilot data analyses, that approximately two-thirds of patients in each group will be diagnosed with SUD.|f|f|f|t
34075478|NCT04917614|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33764149|NCT04698317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"40 Patients will be randomly assigned to either test or control group. 20 patients will be treated by surgery plus biodegradable gelatin/beta-tricalcium phosphate sponges alone.~(control group), the other 20 patients will be treated with the same surgical technique plus biodegradable gelatin sponge loaded with Beta-tricalcium phosphate socked in concentrated growth factors (test group)."|t|f|t|t
33764150|NCT02357290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764151|NCT00873665|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764152|NCT04387981|NA|SINGLE_GROUP||OTHER||NONE||Open label, single dose||||
33764153|NCT02648971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764154|NCT02757482|RANDOMIZED|PARALLEL||||NONE||||||
33764155|NCT06120673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764156|NCT05585138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764157|NCT00621712|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33764158|NCT04644393|||OTHER||RETROSPECTIVE|||||||
33764159|NCT04331535|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants are randomized to have them and their primary care providers receive their PRS results at baseline (PRS) or after 24 months (usual care, UC). Randomization is stratified by PRS results: A high-risk stratum consists of all participants with at least one PRS indicating high risk, while the remaining participants comprise the average-risk stratum. Participants who do not receive their results at baseline are blinded to whether they have all average-risk PRS results or any high-risk PRS results. Outcomes assessors and data analysts will be blinded to randomization and PRS results status.|Randomized clinical trial comparing polygenic risk score (PRS) testing and reporting to delayed reporting|f|f|f|t
33764160|NCT04916119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764161|NCT01681108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764162|NCT01147692|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764163|NCT00004011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764164|NCT02920203|||FAMILY_BASED||PROSPECTIVE|||||||
33764165|NCT01994356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764166|NCT01774071|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33764167|NCT03007784|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33764168|NCT02166450|||CASE_CONTROL||PROSPECTIVE|||||||
33764169|NCT06188520|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33764170|NCT06232291|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33764171|NCT06190262|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||One arm pre-test/post-test design.||||
33764172|NCT04183634|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33764173|NCT02722343|RANDOMIZED|PARALLEL||||NONE||||||
33764174|NCT04400448|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33764175|NCT00206193|||||PROSPECTIVE|||||||
33764176|NCT02837562|||CASE_CONTROL||PROSPECTIVE|||||||
33764177|NCT03644901|||COHORT||PROSPECTIVE|||||||
33764178|NCT00560664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764179|NCT02244801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764180|NCT00002443||||TREATMENT||DOUBLE||||||
33764181|NCT02574000|||COHORT||PROSPECTIVE|||||||
33893026|NCT03567187|NA|SEQUENTIAL||TREATMENT||NONE||||||
33893027|NCT02639676|||COHORT||PROSPECTIVE|||||||
33893028|NCT05153343|NON_RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33893029|NCT01588821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893030|NCT03742427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893031|NCT04874272|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"Phased single group study. Phase (arm) 1: Participants complete a survey Phase (arm) 2- Pilot (single hospital unit): Participants attend a chaplain led post-code debrief, complete a survey Phase (arm) 3 (multiple hospital units): Participants attend a chaplain led post-code debrief, complete a survey.~During all phases participants may be approached to complete an additional interview with the research team."||||
33893032|NCT02979756|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33893033|NCT04970706|||COHORT||PROSPECTIVE|||||||
33893034|NCT05575310|||CASE_CONTROL||PROSPECTIVE|||||||
33893035|NCT05716919|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33977737|NCT05777213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977738|NCT04111744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients enrolled to the study were randomised in a Treatment and a control Group|t|f|t|f
33977739|NCT00683020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977740|NCT02443870|||OTHER||RETROSPECTIVE|||||||
33977741|NCT02309827|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33977742|NCT06108765|||OTHER||PROSPECTIVE|||||||
33977743|NCT01802879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977744|NCT00000775||||PREVENTION||DOUBLE||||||
33977745|NCT04394754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33977746|NCT05557786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977747|NCT04596956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977748|NCT01210729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893036|NCT04929639|||CASE_ONLY||PROSPECTIVE|||||||
33977749|NCT03759821|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Eighty villages in the Mara region of Tanzania will be randomly selected and randomly allocated with equal probability and in equal numbers to one of the five EFFECTS study arms. In each participating village, one sub village will be randomly selected with equal probability, and a sampling frame of all households in that sub village will be created with the help of local leaders. Households will be selected from this sampling frame using simple random sampling. The selected households will be listed in random order and visited by study staff, who will assess whether a household meets all inclusion criteria and provides informed consent. Households will be visited until 12 households are enrolled in each village. If not enough eligible households are found, additional households will be selected using the same procedure from the nearest sub village in the same village.|f|f|f|t
33977750|NCT04614961|||COHORT||PROSPECTIVE|||||||
33977751|NCT00638365|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33977752|NCT00261196|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33977753|NCT01226797|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33977754|NCT03703063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Resectable patients And Borderline resectable patients||||
33893037|NCT03190343|||COHORT||PROSPECTIVE|||||||
33893038|NCT00312013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893039|NCT03031561|NA|SINGLE_GROUP||SCREENING||NONE||||||
33977755|NCT01684969|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33977756|NCT05764044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, randomized, multicenter, national, superiority, parallel, clinical trial, design to evaluate the use of adjuvant chemotherapy in patients with locally advanced cervical cancer, selected by cfDNA-HPV biomarker. Intervention arm will count on application of two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days. Randomization will be allocated 1:1. Participants will be followed at every 4 months, in person or by phone. Primary endpoint is progression-free survival time.|f|f|f|t
33977757|NCT04167566|NA|SINGLE_GROUP||SCREENING||NONE||The interventions are designed to compare the baseline to evaluation findings. There are two components to this implementation study a) The longitudinal (cohort) study: This is basically the prevalence surveys to be conducted with the selected cohort of children 6 months to 15 years - at baseline and before each of the subsequent MTTT rounds. b) The Survey involves using structured questionnaire to interview caretakers of children under five to solicit their views on the implementation process perceived benefits and challenges etc. Though the target group is children from 6 months to 15 years of age, all parasitised adults will be cleared of the parasite during the interventions as well to reduce the parasite reservoirs. Prevalence of malaria trends in cohort group over the study period will reveal the effect of MTTT scale-up on the children 6 month to 15 years. Between interventions, the teams will conduct homes-based management of malaria for confirmed febrile cases.||||
33977758|NCT02947009|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33893040|NCT01686568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893041|NCT06107829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977759|NCT03561948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977760|NCT00464750|||||PROSPECTIVE|||||||
33977761|NCT04765709|NA|SINGLE_GROUP||TREATMENT||NONE||multicentric, open label, single arm, minimax Simon 2 stages, phase 2 trial||||
33977762|NCT01684358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977763|NCT00918437|||COHORT||PROSPECTIVE|||||||
33977764|NCT04730505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977765|NCT01424722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893042|NCT03545282|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators and outcomes assessor will not have knowledge of the interventions assigned to individual participants.||f|f|t|t
33893043|NCT06657443|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The two researchers involved in the study will contact the mentee students who have enrolled at the beginning of the autumn term of the 2024-2025 academic year and make the assignments of the peer mentors. These processes will be carried out by an independent researcher. Peer mentor and mentee assignments will remain confidential from the researchers until the pre-test is conducted by the research team.|||||
33893044|NCT05502289|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33893045|NCT01989663|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33893046|NCT02338986|||COHORT||PROSPECTIVE|||||||
33764182|NCT06388811|||COHORT||CROSS_SECTIONAL|||||||
33893047|NCT05720312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893048|NCT03822910|||CASE_CONTROL||PROSPECTIVE|||||||
33893049|NCT00157300|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893050|NCT05516914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893051|NCT04109599|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33893052|NCT05491122|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be screened to identify habitually low, i.e., total fluid intake: men ≤ 1.6 L/day, women ≤ 1.5 L/day and high i.e., total fluid intake: men ≥ 2.9 L/day, women ≥ 2.5 L/day drinkers. Each subject will undergo two different and consecutive experimental periods: 8 days on habitual fluid intake and a 1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI.||||
33893053|NCT01979107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893054|NCT02739464|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33764183|NCT01544400|||||PROSPECTIVE|||||||
33893055|NCT06656481|||COHORT||CROSS_SECTIONAL|||||||
33893056|NCT04177836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participant and the people interacting with participants will be blind to condition.|There are 2 arms to this intervention - mindfulness and active control.|t|f|f|f
33893057|NCT02955329|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33893058|NCT02649634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977766|NCT01725425|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33977767|NCT02583204|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977768|NCT05964634|||COHORT||CROSS_SECTIONAL|||||||
33977769|NCT06181825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977770|NCT06336863|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33977771|NCT00655577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33977772|NCT02467621|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977773|NCT02178826|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Rapid Maxillary Expansion|t|f|f|t
33977774|NCT03106584|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The supplements provided by Marigot Ltd. will be marked either A or B. No member of the research team will be aware of the ingredients in either of the supplements, the only distinguishing feature will be the labels - A and B. It is for this reason that we can say that the study will be double blind as neither investigators nor participants will have any knowledge of the supplement that they will be consuming.|"The project is a double blind randomized controlled clinical trial (pilot), with a cross-over design. Participants, will be randomized to begin taking either Aquamin-plus or Glucosamine sulphate following medical diagnosis and baseline assessment.~Following 12 weeks of supplementation of Glucosamine sulphate or Aquamin-plus there will be a 4-week washout period before participants consume the other supplement."|t|t|t|t
33977775|NCT05861726|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977776|NCT05873894|||COHORT||PROSPECTIVE|||||||
33977777|NCT06324136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977778|NCT00868309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977779|NCT01208064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977780|NCT03406481|||CASE_ONLY||PROSPECTIVE|||||||
34075479|NCT00522548|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking description is not applicable since no masking was used in this study.|This study consisted of 2 parallel active comparator arms.||||
34075480|NCT00335517|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075481|NCT05801861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single (Participant) Participants will be blinded to the TMS condition (active or sham)||t|f|f|f
34075482|NCT01242241|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075483|NCT05389007|||COHORT||PROSPECTIVE|||||||
33893059|NCT03759275|||CASE_ONLY||PROSPECTIVE|||||||
33977781|NCT04363983|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33977782|NCT04725149|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Taste-matched placebo|Repeated measures, double-blind, counter-balanced|t|t|t|t
33977783|NCT02334371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977784|NCT02161874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977785|NCT01591707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977786|NCT05762783|||COHORT||CROSS_SECTIONAL|||||||
34075484|NCT03854721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075485|NCT04032795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075486|NCT05435469|||OTHER||CROSS_SECTIONAL|||||||
34075487|NCT02868021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34075488|NCT01733745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075489|NCT01992250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075490|NCT01051817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764184|NCT02826122|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764185|NCT03570983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33764186|NCT01338012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075491|NCT01015716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34075492|NCT04818073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized single-blinded||f|f|f|t
33764187|NCT03244462|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34075493|NCT04917848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075494|NCT00260546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075495|NCT01720316|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34075496|NCT03735082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075497|NCT03464032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075498|NCT01754324|||COHORT||PROSPECTIVE|||||||
34075499|NCT00125060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34075500|NCT04380870|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34075501|NCT04956510|||OTHER||CROSS_SECTIONAL|||||||
34075502|NCT05497453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1 OTX-2002 monotherapy dose escalation and expansion in participants with hepatocellular carcinoma (HCC) and other solid tumors~During the monotherapy dose escalation phase, participants will be enrolled in sequential cohorts of increasing doses of OTX-2002.~Part 2 of the study is a safety run-in and expansion study of OTX-2002 participants with HCC will be administered OTX-2002 in combination with tyrosine kinase inhibitor One (Part 2A), Tyrosine Kinase Inhibitor Two (Part 2B), or Checkpoint Inhibitor (Part 2C)."||||
34075503|NCT00237692|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34075504|NCT02906124|||OTHER||PROSPECTIVE|||||||
34075505|NCT05004337|||COHORT||PROSPECTIVE|||||||
34075506|NCT00850369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075507|NCT02307149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075508|NCT06357624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075509|NCT01822834|||COHORT||PROSPECTIVE|||||||
34075510|NCT03832270|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and assessors will be blind to treatment allocation.|Parallel pilot RCT (MRC feasibility phase)|t|f|f|t
34075511|NCT02012725|||CASE_CONTROL||PROSPECTIVE|||||||
34075512|NCT05074641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075513|NCT02288702|||OTHER||PROSPECTIVE|||||||
33893060|NCT05106361|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will enroll pregnant women who report experience of IPV in the past 6 months, and who screen positive for elevated depressive and/or PTSD symptoms. The intervention lasts 9 months after enrollment. Those in the intervention arm will receive MOSAIC Plus (an enhanced MOSAIC intervention that includes IPT) while those in the active control would receive MOSAIC intervention.||||
34075514|NCT04793984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|randomized placebo-controlled double blinded trial|t|f|t|f
34075515|NCT00725907|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34075516|NCT05225545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33764188|NCT04933201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075517|NCT00447096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33764189|NCT05643820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764190|NCT04845724|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Catering staff, who were blinded to the identity of the participants, provided meals in random order. Participants were blinded to the initial meal selection until the day of the study.|||||
33764191|NCT06516627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764192|NCT04786314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764193|NCT01862796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893061|NCT00140803|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33893062|NCT03415230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|therapeutic massage vs sham massage||t|t|f|f
33893063|NCT04947137|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, open-label, multicenter, single-dose study designed to develop a normative database of TUVjoint in HCs and to assess the feasibility of qualitative and quantitative SPECT/CT assessments in HCs and subjects with active RA. Subjects will be enrolled in 1 of 2 study arms with distinct study procedures in accordance with Arm-specific eligibility requirements.||||
33893064|NCT05747924|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33893065|NCT00030576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893066|NCT01355289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893067|NCT05127486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893068|NCT03456011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893069|NCT03635944|||COHORT||RETROSPECTIVE|||||||
33893070|NCT03435978|||COHORT||PROSPECTIVE|||||||
33893071|NCT04333966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893072|NCT04178590|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||split mouth design|f|f|t|f
33893073|NCT05367661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34075518|NCT01825304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075519|NCT02340377|||CASE_ONLY||PROSPECTIVE|||||||
34075520|NCT06380205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075521|NCT04249362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075522|NCT02264808|||COHORT||RETROSPECTIVE|||||||
34075523|NCT03151447|NA|SINGLE_GROUP||TREATMENT||NONE||Stereotactic Body Radiation Therapy With Concurrent Anti-PD1antibody (JS001) injected intravenously 120mg or 240mg or 360mg until disease progresses or unacceptable tolerability occurs||||
34075524|NCT05828459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Monotherapy dose escalation followed by dose confirmation of combination regimens.~Further expansion of each groups."||||
34075525|NCT02136459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893074|NCT02588378|||COHORT||PROSPECTIVE|||||||
33893075|NCT04101890|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33893076|NCT00577811|||CASE_CONTROL||PROSPECTIVE|||||||
33764194|NCT02853461|||COHORT||PROSPECTIVE|||||||
33764195|NCT05677932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subjects will be explained that the study aims to test the efficacy of two different modalities of light treatments for fatigue including white light and red light, without mentioning which one is the placebo.|Randomized placebo-controlled trial|t|f|f|f
34075526|NCT02721056|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation (volume) of NBTXR3 (SBRT 45 Gy \[15 Gy x 3 fractions over 5 - 7 days\] or 50 Gy \[10 Gy x 5 fractions over 5 - 15 days\]), to define the early dose limiting toxicities (DLTs) and the recommended dose (volume) for further development.||||
34075527|NCT02479659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34075528|NCT01025284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34075529|NCT06240611|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075530|NCT00870467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075531|NCT02250300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764196|NCT03885466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research assistants and technicians collecting data will be blinded as to whether participants are in the exercise or control group. Participants will not be blinded for Nordic walking. All methods and reporting of the trial will follow Consolidated Standards of Reporting Trials (CONSORT) guidelines.|A parallel group randomized control trial will be used to test our hypotheses. Participants randomized to the waiting-list control group will serve as controls for the baseline and 3-month measurements. The control group will receive the same 3-month Nordic walking intervention after their control follow-up measurements are completed.|f|f|t|t
33764197|NCT00039325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764198|NCT04599101|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||single site, prospective||||
33764199|NCT03424590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33893077|NCT00446303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893078|NCT01093495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893079|NCT03408132|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893080|NCT00397150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893081|NCT04611607|||COHORT||RETROSPECTIVE|||||||
33893082|NCT01009294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893083|NCT06250387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893084|NCT00277537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893085|NCT02979314|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33893086|NCT04979624|||CASE_ONLY||CROSS_SECTIONAL|||||||
33893087|NCT03036930|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33893088|NCT03140826|||COHORT||PROSPECTIVE|||||||
33893089|NCT06656676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893090|NCT04358757|||COHORT||PROSPECTIVE|||||||
33893091|NCT04402502|NA|SINGLE_GROUP||OTHER||NONE||Healthy Population||||
33893092|NCT06559709|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893093|NCT04339868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Performed a randomization table before enrollment. Prepare the study drug receiving or placebo receiving according to sequential number derived from the randomization table and keep it in a conceal envelop. Prepare study drug and placebo by a pharmacist or an investigation nurse, according to the randomization table number, and keep both study drug and placebo in the identical containment which labeled by a sequential number. Once a patient was enrolled and informed was signed, then study drug or placebo was start according to sequential number.|Intervention arm: Terlipressin plus Norepinephrine and/or Epinephrine Controlled arm: Placebo plus Norepinephrine and/or Epinephrine for Treatment Refractory Septic Shock|t|t|t|t
33893094|NCT04352920|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assesor|Medical Doctor diagnosed muscle fibrosis||||
33893095|NCT06448988|||CASE_CROSSOVER||PROSPECTIVE|||||||
33893096|NCT00279747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33893097|NCT03102684|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33893098|NCT02897609|||COHORT||PROSPECTIVE|||||||
33893099|NCT01717248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893100|NCT00942006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893101|NCT01639183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33893102|NCT00900796|||COHORT||PROSPECTIVE|||||||
33893103|NCT04085432|||OTHER||OTHER|||||||
34075532|NCT06612073|||COHORT||PROSPECTIVE|||||||
34075533|NCT00294814|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075534|NCT01503983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075535|NCT04380376|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent central blinded assessor will be blinded to study treatment and will review the clinical response assessments. In case of a discrepancy with the Investigator's assignment of clinical response, the adjudication committee's assessment will prevail.|Prospective, Single-center, Open-Label, Central Assessor Blinded, Comparative Study|f|f|f|t
34075536|NCT06331663|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34075537|NCT04569175|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075538|NCT02283658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075539|NCT01420120|||CASE_ONLY||PROSPECTIVE|||||||
34075540|NCT04493372|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34075541|NCT02284633|||COHORT||PROSPECTIVE|||||||
34075542|NCT01184521|||CASE_CONTROL||PROSPECTIVE|||||||
33893104|NCT02594501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893105|NCT01617538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893106|NCT03643692|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33893107|NCT02941367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893108|NCT04205552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893109|NCT04331301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|interventions are blinded to both patients and doctors who 1ry assess and follow-up patients.||t|f|f|t
33893110|NCT06065046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893111|NCT02687269|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33893112|NCT04000646|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled trial||||
33893113|NCT05436249|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33893114|NCT06122584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893115|NCT00281450|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33893116|NCT02795988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Partially blinded - blinded central review of progression.||f|f|f|t
33893117|NCT06504381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893118|NCT02248376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893119|NCT04209738|||COHORT||PROSPECTIVE|||||||
33893120|NCT04475341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893121|NCT03050684|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE||Randomized Controlled Study|t|t|t|t
33893122|NCT04827238|||COHORT||OTHER|||||||
33893123|NCT04764188|||COHORT||PROSPECTIVE|||||||
33893124|NCT05666089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893125|NCT05787704|||COHORT||CROSS_SECTIONAL|||||||
33893126|NCT02913144|||COHORT||PROSPECTIVE|||||||
33893127|NCT04407767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be blind to treatment condition.|This randomized controlled clinical trial seeks to examine the relative efficacy of a case formulation approach integrated into cognitive processing therapy as compared to standard cognitive processing therapy. Randomization to study condition will occur at the provider level (50 providers will be randomized to either CPT or CF-CPT. Each provider will treat the next 4 eligible veterans (total sample = 200 Veterans) seeking care for PTSD who agree to participate in the study.|f|f|f|t
33893128|NCT03756090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893129|NCT05347615|||OTHER||PROSPECTIVE|||||||
33893130|NCT00988390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893131|NCT04848805|||COHORT||RETROSPECTIVE|||||||
33893132|NCT04469491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893133|NCT03293680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893134|NCT05273151|NA|SINGLE_GROUP||PREVENTION||NONE||Open label Investigation||||
33893135|NCT05634577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893136|NCT05591833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33893137|NCT02360098|||COHORT||PROSPECTIVE|||||||
33893138|NCT03723213|||CASE_CONTROL||PROSPECTIVE|||||||
33893139|NCT06454864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is not possible to blind participants to their assigned intervention. Care providers are not involved. The outcome assessors for any assessments involving potential for subjectivity in data collection or analysis will be blinded to group assignment.|3-arm parallel-group randomized controlled trial|f|f|f|t
33893140|NCT00826748|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33977787|NCT00278694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977788|NCT04716660|||COHORT||PROSPECTIVE|||||||
33977789|NCT05744609|||COHORT||RETROSPECTIVE|||||||
33977790|NCT04007133|||CASE_ONLY||PROSPECTIVE|||||||
33977791|NCT02398877|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977792|NCT02226328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977793|NCT05418348|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977794|NCT01232673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977795|NCT03825458|||COHORT||PROSPECTIVE|||||||
33977796|NCT01258491|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
33977797|NCT05565820|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group design with participants randomised 1:1 to Vamousse Spray 'n' Go or 1% Permethrin control.||||
33977798|NCT03344367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977799|NCT03935269|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33977800|NCT01957488|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33977801|NCT00967538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977802|NCT05664464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764200|NCT03480217|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be blinded to group assignment when coding medical records to determine whether providers ordered out-of-office BP testing for eligible patients.||f|f|f|t
33764201|NCT03942302|||OTHER||OTHER|||||||
33764202|NCT04399356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|As all members of the Study Team will be blinded, Tufts Investigational Drug Services (IDS) will be unblinded and will dispense both the Niclosamide and placebo. The study intervention (Niclosamide) and placebo will be packaged and as indistinguishable as possible.|Double-blinded randomized controlled trial.|t|t|t|f
33764203|NCT03400501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764204|NCT06624631|RANDOMIZED|PARALLEL||PREVENTION||NONE||A multi-centre, 2-arm, cluster-randomised trial evaluating two health system delivery strategies and a 3-arm nested individually randomised trial evaluating two new intervention strategies to enhance end-user adherence to post-discharge malaria chemoprevention (PDMC) with dihydroartemisinin-piperaquine compared to the standard of care without adherence strategies||||
33764205|NCT01331668|||COHORT||PROSPECTIVE|||||||
33764206|NCT02390739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764207|NCT00695747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764208|NCT01611584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893141|NCT03370757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Infants will be randomly assigned and stratified by birth weight (≤ 800 grams, \>800 grams to 1150 grams, \> 1150 grams) to either 3- or 6- hour bundled diaper care.||||
33893142|NCT02456220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893143|NCT04770103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33893144|NCT05841472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893145|NCT05988814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893146|NCT00283010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893147|NCT05620342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893148|NCT03719599|||COHORT||CROSS_SECTIONAL|||||||
33893149|NCT06651567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893150|NCT02544776|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33893151|NCT04396977|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-blind, single-group study||||
33893152|NCT02886104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893153|NCT03001544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893154|NCT00849550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893155|NCT00749606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893156|NCT03084523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893157|NCT05766579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893158|NCT01916772|||COHORT||PROSPECTIVE|||||||
33893159|NCT04821284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893160|NCT05537038|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Double-blinded trial||t|t|t|t
33893161|NCT01620125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893162|NCT04459962|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants who are Covid-19 negative, Covid-19 positive or suspected with Covid-19 infection will be recruited||||
33893163|NCT04246554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893164|NCT02582515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893165|NCT05794139|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||2-way crossover|t|f|t|t
33893166|NCT01536821|||||PROSPECTIVE|||||||
33893167|NCT00200057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893168|NCT02789696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893169|NCT03588689|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective randomized controlled non-blinded pilot study.||||
33893170|NCT05613270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893171|NCT05902585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients are randomized in a 1:1 ratio to the intervention group (use of virtual reality during blood collection) and the control group (usual care). The randomization sequence is different for each participating center.||||
33893172|NCT04940923|||COHORT||PROSPECTIVE|||||||
33893173|NCT06637176|||CASE_ONLY||PROSPECTIVE|||||||
33893174|NCT01962220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893175|NCT06448793|||COHORT||OTHER|||||||
33893176|NCT02915458|||CASE_CONTROL||PROSPECTIVE|||||||
33893177|NCT01871506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893178|NCT03619915|||OTHER||RETROSPECTIVE|||||||
33893179|NCT04827355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomized to one of two arms: control or experimental. Randomization will be 1:1 to control (sham, known not to provide intervention) and experimental (fit to manufacturer guidelines).|t|t|t|t
33893180|NCT03696784|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893181|NCT04820179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893182|NCT02148029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893183|NCT05332444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893184|NCT06601192|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33893185|NCT04126837|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33893186|NCT06656728|||COHORT||PROSPECTIVE|||||||
33893187|NCT00049127|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893188|NCT02691000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893189|NCT04985565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893190|NCT03245879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33893191|NCT00073190|RANDOMIZED|FACTORIAL||||SINGLE||||||
33893192|NCT00868387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893193|NCT05325918|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33893194|NCT05564858|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33893195|NCT05237388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893196|NCT03057444|NA|SINGLE_GROUP||TREATMENT||NONE||open intervention study||||
33893197|NCT01719757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893198|NCT05086315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893199|NCT01021007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893200|NCT05887635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893201|NCT04259502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The two interventions will be performed at the same thoracic region using the same technique as so; there participant will be blinded to the study. The investigator who performs the intervention will be unblinded. The investigator who will follow up the patients and collect the postoperative pain data will be blinded.|The patients included in the study will be assigned to one group of two in which two different regional block technique will be performed alone.|t|t|f|f
34075543|NCT05562297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075544|NCT00873730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33764209|NCT04550663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764210|NCT05720234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893202|NCT01783665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893203|NCT03145701|||COHORT||PROSPECTIVE|||||||
33893204|NCT01497392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893205|NCT02714530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893206|NCT01752283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893207|NCT03202654|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34075545|NCT02761018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34075546|NCT06517498|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34075547|NCT04943939|||COHORT||PROSPECTIVE|||||||
33893208|NCT01770340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893209|NCT02081963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893210|NCT02712502|||CASE_CONTROL||PROSPECTIVE|||||||
33893211|NCT05446948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893212|NCT04609748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075548|NCT03493438|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controled clinical trial||||
34075549|NCT05180162|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34075550|NCT02131064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075551|NCT04712136|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34075552|NCT01492504|||COHORT||PROSPECTIVE|||||||
34075553|NCT02842372|||CASE_ONLY||PROSPECTIVE|||||||
34075554|NCT02791529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075555|NCT04474808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34075556|NCT02480881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075557|NCT01001312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764211|NCT01273870|||CASE_CROSSOVER||PROSPECTIVE|||||||
33764212|NCT02118662|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33893213|NCT00691171|||CASE_CONTROL||PROSPECTIVE|||||||
33893214|NCT00188084|||DEFINED_POPULATION||PROSPECTIVE|||||||
33893215|NCT00668005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893216|NCT03058484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893217|NCT06460350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a double-blinded randomized (1:1) placebo-controlled clinical trial to determine the feasibility and effectiveness of a 2-week application of the NEUROCUPLE device for pain relief and reduction of opioid refills after TKA. We have a placebo device (sham device without the captor array layer) that looks exactly like the active device, allowing us to conduct a true placebo-controlled randomized study. The trial will include 140 participants over a 1-year period.|t|t|f|f
33893218|NCT01583348|||CASE_ONLY||PROSPECTIVE|||||||
33893219|NCT02144649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893220|NCT06004804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will rely on a blinded outcomes assessor who will be blind to condition assignment. Investigators will be blind to outcomes until the conclusion of the trial.|Three-Group Parallel Comparison Trial|f|f|t|t
33893221|NCT00706732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33893222|NCT05048290|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33893223|NCT06346522|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A prospective, randomized, comparative, clinical trial study|t|f|t|t
33893224|NCT03006783|||CASE_ONLY||CROSS_SECTIONAL|||||||
33893225|NCT03234114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075558|NCT04617119|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|COVID-19 patient will be blinded from the study aim. The outcomes assessor will be blinded from the study aim and patient allocation.|A pilot study following a randomized controlled trial design.|t|f|f|t
34075559|NCT03997097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075560|NCT05627050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075561|NCT05098782|||COHORT||PROSPECTIVE|||||||
34075562|NCT01893697|||CASE_CROSSOVER||PROSPECTIVE|||||||
34075563|NCT01628848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075564|NCT02777905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075565|NCT01345812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075566|NCT04663685|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"This is an 8-week feasibility study with a 4-week follow-up. Time series design.~Note: 6-month follow-up was optional and exploratory in nature."||||
34075567|NCT03707743|||COHORT||OTHER|||||||
34075568|NCT03182790|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34075569|NCT05504837|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34075570|NCT05470244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be unaware of the treatment group||f|f|f|t
34075571|NCT05030233|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|The statistician performing the data analysis will be blinded to group.|randomized cross-over design||||
34075572|NCT01951599|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075573|NCT03237897|||CASE_CONTROL||PROSPECTIVE|||||||
33977803|NCT04318561|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The details of patient groups will be sealed in sequentially numbered, opaque, sealed envelopes generated by Xuezhu Wang from the nuclear medicine department, Peking Union Medical College Hospital, who will not participate in other parts of the study.||t|f|f|t
33977804|NCT04027764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977805|NCT01264952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977806|NCT04862078|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33977807|NCT06159062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893226|NCT04486560|NA|SINGLE_GROUP||OTHER||NONE||This is a multi-center, non-randomized, single-arm, prospective trial. Therefore, all participants will have their transbronchial biopsy with the 1.1mm sheath cryoprobe rather than forceps or another currently available larger cryoprobe.||||
33893227|NCT03865472|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33893228|NCT00304473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893229|NCT03075839|NA|SINGLE_GROUP||OTHER||NONE||Within-subject design comparing smoking behavior when using menthol vs. non-menthol cigarettes||||
33893230|NCT02555800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33893231|NCT00378118|||COHORT||PROSPECTIVE|||||||
33893232|NCT01133743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893233|NCT04078750|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893234|NCT01051739|||CASE_CONTROL||PROSPECTIVE|||||||
33893235|NCT03097887|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33893236|NCT04634578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893237|NCT02247869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893238|NCT00407355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893239|NCT02443610|||COHORT||PROSPECTIVE|||||||
33893240|NCT04693871|||CASE_CONTROL||PROSPECTIVE|||||||
33893241|NCT03510793|||CASE_CONTROL||PROSPECTIVE|||||||
33893242|NCT03210844|||COHORT||RETROSPECTIVE|||||||
33893243|NCT05154474|||COHORT||PROSPECTIVE|||||||
33893244|NCT01420133|RANDOMIZED|PARALLEL||||NONE||||||
33893245|NCT05316896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893246|NCT06275217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33977808|NCT01443065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977809|NCT06547190|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized Cross-over Trial||||
33977810|NCT03164044|||COHORT||PROSPECTIVE|||||||
33977811|NCT03996512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977812|NCT02629549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977813|NCT03997370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977814|NCT02896088|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|test and control tooth groups. Each patient is therefore his own witness|test and control tooth groups. Each patient is therefore his own witness|t|f|f|f
33977815|NCT03993925|||COHORT||PROSPECTIVE|||||||
33977816|NCT03736109|||CASE_CONTROL||PROSPECTIVE|||||||
33977817|NCT01805713|||COHORT||PROSPECTIVE|||||||
33977818|NCT01211548|||COHORT||PROSPECTIVE|||||||
33977819|NCT02932254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977820|NCT06345248|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33977821|NCT02625831|||CASE_CONTROL||RETROSPECTIVE|||||||
33977822|NCT01379781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977823|NCT00661999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33977824|NCT02493244|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33977825|NCT05560464|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33977826|NCT04886115|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33977827|NCT00018447|RANDOMIZED|||TREATMENT||NONE||||||
33977828|NCT06496269|||COHORT||PROSPECTIVE|||||||
33977829|NCT00890019|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977830|NCT00682084|||COHORT||PROSPECTIVE|||||||
33977831|NCT00356798|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33977832|NCT00954967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977833|NCT05458609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomized to two different arms: lemborexant plus naltrexone versus placebo plus naltrexone using a computer-generated randomization scheme.|t|f|t|f
33977834|NCT05583812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977835|NCT00806832|||CASE_CONTROL||PROSPECTIVE|||||||
33977836|NCT05476575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective case control study||||
33977837|NCT02319928|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33977838|NCT02805803|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33977839|NCT01697722|||COHORT||RETROSPECTIVE|||||||
33977840|NCT03195985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33893247|NCT05595525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"the blinded investigator will complete the Scientific Assessment Scale of Skin Quality (SASSQ). , the blinded investigator will complete the Physician Global Aesthetic Improvement Scale (PGAIS) and percent improvement evaluation. Percent Improvement Evaluation by Blinded investigator .~Subjects are blinded to which side receives which laser"|subjects will be randomized to have either their right facial half or left facial half treated with the 1064nm picosecond laser with diffractive lens array. The contralateral facial half not randomized will be treated with the 755nm picosecond laser with diffractive lens array.|t|f|t|f
33893248|NCT01748227|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33893249|NCT01966510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893250|NCT03176290|||CASE_ONLY||PROSPECTIVE|||||||
33977841|NCT05282654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|During main trial (post-implementation period), study investigators, outcomes assessor will be masked to randomization status of all participants|Baseline, pre-implementation period (usual care arm 1) and main trial (RCT) period (usual care arm 2 and intervention/experimental arm 3)|f|f|t|t
34075574|NCT03227731|RANDOMIZED|PARALLEL||OTHER||NONE||Pregnant women considered at high risk for HIV infection will be randomized to commencing PrEP in pregnancy with continued use throughout breastfeeding or deferred PrEP until breastfeeding cessation. Women in either group will receive the standard of care for prevention of HIV and other sexually transmitted infections.||||
34075575|NCT02188069|||COHORT||PROSPECTIVE|||||||
34075576|NCT00915941|||CASE_ONLY||PROSPECTIVE|||||||
34075577|NCT05876429|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34075578|NCT04712409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075579|NCT01042821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075580|NCT04178408|||OTHER||PROSPECTIVE|||||||
34075581|NCT00713271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764213|NCT02178410|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33764214|NCT04138342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764215|NCT01872910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764216|NCT05461690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764217|NCT00150774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33893251|NCT04585685|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33893252|NCT06600906|||CASE_ONLY||PROSPECTIVE|||||||
33893253|NCT00701987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893254|NCT05750940|||COHORT||PROSPECTIVE|||||||
33893255|NCT03607344|||COHORT||PROSPECTIVE|||||||
33893256|NCT06258525|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33893257|NCT05493514|||COHORT||PROSPECTIVE|||||||
33893258|NCT04705467|NA|SINGLE_GROUP||OTHER||NONE||Patients who are assigned to gynecological brachytherapy||||
33893259|NCT06657729|||COHORT||PROSPECTIVE|||||||
33977842|NCT02602184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977843|NCT05936944|||CASE_CONTROL||PROSPECTIVE|||||||
33977844|NCT06206356|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33977845|NCT05372081|||OTHER||PROSPECTIVE|||||||
33977846|NCT02478307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977847|NCT00718679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33977848|NCT01289652|||COHORT||PROSPECTIVE|||||||
33977849|NCT06217809|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977850|NCT04868448|||COHORT||PROSPECTIVE|||||||
34075582|NCT00959348|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075583|NCT04078971|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Treatment and control were masked with A and B|It is single blind, parallel arms study|f|f|t|t
34075584|NCT02689804|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34075585|NCT05304988|||COHORT||CROSS_SECTIONAL|||||||
33893260|NCT02830802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893261|NCT02053805|NA|SINGLE_GROUP||SCREENING||NONE||||||
34075586|NCT04940247|||COHORT||PROSPECTIVE|||||||
34075587|NCT06271863|||CASE_ONLY||PROSPECTIVE|||||||
34075588|NCT01971814|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34075589|NCT05924659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double bling computizded neurofeed back training|Randomized assigment, neurofeedback training versus control|t|t|t|f
34075590|NCT03331263|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|laboratory-blinded, 3-period, 3-sequence, crossover study||f|f|f|t
34075591|NCT00920777|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34075592|NCT03248648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)||t|t|t|t
33764218|NCT03324984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977851|NCT01220206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764219|NCT04307654|||COHORT||RETROSPECTIVE|||||||
33764220|NCT03548805|RANDOMIZED|PARALLEL||TREATMENT||NONE||ologen® Collagen Matrix, Model 830601, shape Round cylindrical, Size 6mm (diameter) x 2mm (thickness),Manufacturer Aeon Astron Europe B. V.||||
33764221|NCT01213108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764222|NCT01342822|||CASE_ONLY||PROSPECTIVE|||||||
33764223|NCT00710801|||COHORT||PROSPECTIVE|||||||
33977852|NCT03031054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33977853|NCT04219202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977854|NCT00846378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33977855|NCT05898568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33977856|NCT00235456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977857|NCT05364827|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective randomised feasibility study||||
34075593|NCT00398216|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34075594|NCT02169505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075595|NCT02326272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075596|NCT04009304|RANDOMIZED|PARALLEL||PREVENTION||NONE||Assigned afterschool sites (not individual participants) to group with block randomization approach, delayed intervention design offered effective intervention to control group in year 2||||
34075597|NCT04217460|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All details pseudo-anonymized before analysis.|Children screened for word-finding difficulty. Children at risk are matched with controls who do not have word-finding difficulty. Blind intervention.|t|t|t|f
34075598|NCT04835727|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective interventional cohort study in patients with clinically quiescent IBD. At enrollment, clinical information, dietary intake, inflammatory markers, and fecal microbiota were recorded. Dietary intake was assessed by an experienced nutritionist using pictures of food, a dietary questionnaire, and patient interviewing. The nutritionist advised the participants to intake a semi-vegetarian diet and increase dietary fiber consumption. The changes in clinical symptoms, dietary intake, inflammatory markers, and fecal microbiota were recorded in each visit for 1 year.||||
33764224|NCT00142922|RANDOMIZED|PARALLEL||||NONE||||||
33977858|NCT05480722|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double blinded|double blinded randomized crossover design|t|f|t|f
34075599|NCT03939442|||COHORT||RETROSPECTIVE|||||||
34075600|NCT04288583|||COHORT||PROSPECTIVE|||||||
33764225|NCT02105805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977859|NCT01048320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977860|NCT05893056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075601|NCT00288418|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34075602|NCT06117020|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double blind - placebo-controlled.|This randomized, placebo-controlled, first-in-human (FIH) study of MTR-601 in normal healthy volunteers will consist of 3 single ascending dose (SAD) level cohorts, 1 SAD Level 2, Two-Dose cohort, 3 multiple ascending dose (MAD) level cohorts, and 1 optional MAD level cohort, each comprised of 8 subjects (6 MTR-601; 2 placebo).|t|t|t|t
34075603|NCT05919082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34075604|NCT05276102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"One forearm will be treated with the commercially available emollient while the other will be left untreated. Therefore the participants will not be blinded but the outcomes assessor and the principal investigator will be blinded to the treatment.~Disinterested third party will perform the randomization and treatment allocation, as well as keep the code breaks in case of medical emergency or adverse events of the interventions."|"Each volar forearm of the participants will be divided in three sites, with each site randomly assigned to repeated exposure to antiseptic, repeated exposure to deionized water (sham irritation) or will be left intact.~One forearm will be treated with the commercially available emollient three times a day while the other will be left untreated. Treated forearm (left or right) will be chosen according to randomization protocol (double randomization)."|f|f|t|t
34075605|NCT03141190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants do not know we are testing mindfulness only that they will be learning stress-reduction skills for surgeons|Randomized, partially-blinded|t|f|f|t
34075606|NCT06525051|||CASE_CONTROL||PROSPECTIVE|||||||
34075607|NCT04853823|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977861|NCT02582970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977862|NCT02658084|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977863|NCT01271439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075608|NCT00828425|||||RETROSPECTIVE|||||||
34075609|NCT02308449|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34075610|NCT00198991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075611|NCT01702909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075612|NCT03157674|||COHORT||RETROSPECTIVE|||||||
33764226|NCT02078505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764227|NCT01541163|||COHORT||PROSPECTIVE|||||||
33764228|NCT04838418|||COHORT||PROSPECTIVE|||||||
33764229|NCT03066843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764230|NCT02753205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33764231|NCT05280769|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm study||||
33764232|NCT05297643|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trials||||
33764233|NCT00920023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764234|NCT04875832|NA|SINGLE_GROUP||TREATMENT||NONE||Pre versus post EMDR treatment feasibility study||||
33764235|NCT05851599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764236|NCT01538108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764237|NCT05932056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33977864|NCT03891719|NA|SINGLE_GROUP||TREATMENT||NONE||we conduct a prospective analysis of 35 cases to assess difference between preoperative and postoperative nostril symmetry by using autologous cartilage graft and sliding chondrocutaneous flap||||
33977865|NCT02974153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33977866|NCT04172298|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33977867|NCT01607775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33977868|NCT05631626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33977869|NCT04024956|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm, multicenter study||||
33977870|NCT05354414|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33977871|NCT03416764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant is aware of treatment group (NF or TAU) Participant is unaware of allocation to treatment estrogen phases (high or low) Investigator and outcome assessor are unaware of group allocation||t|f|t|t
33977872|NCT02715947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33977873|NCT06261853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Outcomes Assessor) A single-blinded methodology will be employed due to the nature of the image-based investigation where the surgeon is required to utilise one imaging modality during the surgery. In order to eliminate any influence or bias on the outcomes and data obtained for the primary objective, both the subject (patient) and the study member who will do the follow-up call will be blinded to the imaging techniques used on the day of surgery.|Pragmatic, two-arm, single-blinded, randomised controlled trial designed to investigate the differences between 3D cone-beam computerised tomography (CBCT) and 2D orthopantomography (OPG) in reducing inferior alveolar nerve injuries during wisdom tooth surgery.|t|f|f|t
33977874|NCT02724683|||COHORT||PROSPECTIVE|||||||
33977875|NCT05744973|||COHORT||PROSPECTIVE|||||||
33977876|NCT03066999|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33977877|NCT04713059|||CASE_CONTROL||RETROSPECTIVE|||||||
34075613|NCT04726826|||COHORT||PROSPECTIVE|||||||
33977878|NCT06019273|||OTHER||PROSPECTIVE|||||||
33977879|NCT04449653|||CASE_CONTROL||PROSPECTIVE|||||||
33977880|NCT01703403|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33977881|NCT05585957|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977882|NCT06290180|NA|SINGLE_GROUP||PREVENTION||NONE||Pre/post/3-month follow-up model||||
33977883|NCT01025531|||COHORT||PROSPECTIVE|||||||
34075614|NCT03625739|||COHORT||PROSPECTIVE|||||||
34075615|NCT04750018|||COHORT||RETROSPECTIVE|||||||
34075616|NCT01793753|||CASE_ONLY||PROSPECTIVE|||||||
34075617|NCT03816553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075618|NCT06039644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Parallel Assignment, Randomized Controlled Trial|t|f|t|f
34075619|NCT03782714|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a split-mouth randomized controlled clinical trial||||
34075620|NCT05141435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764238|NCT05694897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764239|NCT01054573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764240|NCT01576835|||CASE_ONLY||PROSPECTIVE|||||||
33977884|NCT01158365|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33977885|NCT05456607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33977886|NCT06286969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075621|NCT04664257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomly assigned to intervention or control||||
34075622|NCT00369343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075623|NCT00048035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075624|NCT06324643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34075625|NCT05923710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764241|NCT05563363|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study, randomized, open, non-blinded||||
34075626|NCT05624411|||COHORT||CROSS_SECTIONAL|||||||
34075627|NCT05342753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764242|NCT06050902|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient will be blinded to his or her assignment group. The primary endpoint and secondary endpoints A, D, G, H, will be collected by an assessor independent from the operator, during the central venous catheterization procedure. This assessor will not be blinded to the technique used.|A randomized, patient- and evaluator-blinded, controlled superiority trial comparing standard ultrasound guidance and a new needle-steering device.|t|f|f|f
33764243|NCT00002901||||TREATMENT||||||||
33764244|NCT06568341|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764245|NCT05483933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764246|NCT02720822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764247|NCT01326273|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764248|NCT02237235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764249|NCT01712555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764250|NCT05740410|||COHORT||RETROSPECTIVE|||||||
33764251|NCT02567825|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects in the randomization phase of the study will be randomized to either medical management or tube surgery. No masking will occur.|||||
33764252|NCT04280822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764253|NCT03434002|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"1. building the technical components for interaction within the virtual reality environment (phase 1);~2. application of this virtual reality in medical training (phase 2) and~3. measurement of training effectiveness with this Virtual Reality simulator against mannequin based training (phase 3)."||||
33764254|NCT01536184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764255|NCT05529745|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33764256|NCT01452282|||COHORT||PROSPECTIVE|||||||
33764257|NCT03032354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764258|NCT02437474|||COHORT||PROSPECTIVE|||||||
33764259|NCT00210262|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33764260|NCT03880084|||COHORT||PROSPECTIVE|||||||
33764261|NCT03393702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33764262|NCT00226512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893262|NCT04108507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893263|NCT02432807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893264|NCT02634866|||COHORT||PROSPECTIVE|||||||
33893265|NCT00679861|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33893266|NCT00283387|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33893267|NCT02593929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893268|NCT06338787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893269|NCT03469011|NA|SEQUENTIAL||TREATMENT||NONE||||||
33893270|NCT06656039|||COHORT||RETROSPECTIVE|||||||
33893271|NCT02499952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893272|NCT01563601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893273|NCT02730559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34075628|NCT04612985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764263|NCT06483997|||COHORT||PROSPECTIVE|||||||
33764264|NCT02444663|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Participants will have the interventions in each of the ten arms of the study.|f|f|f|t
33764265|NCT03176238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075629|NCT03675568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075630|NCT04449289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764266|NCT05409963|||COHORT||CROSS_SECTIONAL|||||||
33764267|NCT06362902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764268|NCT03944967|||COHORT||PROSPECTIVE|||||||
33764269|NCT04616014|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|This is an open, multi-center study||||
33764270|NCT00006008||||TREATMENT||||||||
33764271|NCT05857111|||CASE_ONLY||CROSS_SECTIONAL|||||||
33764272|NCT04477421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893274|NCT00812669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075631|NCT02691546|||COHORT||PROSPECTIVE|||||||
33764273|NCT05782387|||COHORT||RETROSPECTIVE|||||||
33764274|NCT03673462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A modified double blind design was used. With the exception of the personnel administering the vaccine, everyone involved in study (participants, care provider, investigator, safety outcomes assessor, Sponsor) was blinded.||t|t|t|t
33764275|NCT05151497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33764276|NCT00671008|||COHORT||PROSPECTIVE|||||||
33893275|NCT05729841|||COHORT||PROSPECTIVE|||||||
33893276|NCT02204865|||COHORT||PROSPECTIVE|||||||
33893277|NCT06657573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33893278|NCT03198221|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be receive either Golytely or Clenpiq bowel prep solutions. Both agents will either be administered as full dose the evening before or as split-dose on the evening before and on the day of the colonoscopy procedure.||||
34075632|NCT02917317|||COHORT||PROSPECTIVE|||||||
34075633|NCT02093936|||||CROSS_SECTIONAL|||||||
34075634|NCT02902042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075635|NCT01138020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34075636|NCT00463801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893279|NCT05928806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893280|NCT05355961|||COHORT||PROSPECTIVE|||||||
33893281|NCT01716065|||COHORT||PROSPECTIVE|||||||
33893282|NCT05222139|||COHORT||PROSPECTIVE|||||||
33893283|NCT00373074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893284|NCT04368754|||OTHER||PROSPECTIVE|||||||
33893285|NCT04604327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893286|NCT06113081|||COHORT||RETROSPECTIVE|||||||
34075637|NCT01285869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33893287|NCT05805501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075638|NCT03620188|||COHORT||PROSPECTIVE|||||||
34075639|NCT04394702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33893288|NCT05144425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893289|NCT06382090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups: comparative experiment and control||||
34075640|NCT05401721|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075641|NCT06008054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075642|NCT00715234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34075643|NCT05076604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34075644|NCT01411319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764277|NCT02938923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators, and study staff conducting the interventions will be aware of the exercise group assignment. A Blinded Outcomes Assessor will be masked to study group assignment. Only the study pharmacist, an unblinded study physician, and Data Coordinating Center staff will be unblinded to gel treatment assignment.||t|t|t|t
33764278|NCT05007145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764279|NCT04667013|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33764280|NCT03412968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The perfusionist's role is essential during the procedure involving Cardiopulmonary Bypass (CPB). This study purpose to know the impact of using polysulfone membranes on continuous ultrafiltration with volume replacement in patients undergoing cardiac surgery. In this type of surgery, techniques such as conventional ultrafiltration (CUF) and modified ultrafiltration (MUF) are known for controlling the patient's fluid balance and blood lactate levels during the procedure.|t|f|f|f
33764281|NCT00964457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764282|NCT05555888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764283|NCT01600222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764284|NCT02759185|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33764285|NCT01059032|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33764286|NCT02480816|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33764287|NCT00238732|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33764288|NCT05302557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764289|NCT00949884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764290|NCT03221101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075645|NCT04624048|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34075646|NCT05547256|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34075647|NCT01688622|NA|SINGLE_GROUP||||NONE||||||
33764291|NCT03992534|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764292|NCT04670237|||COHORT||PROSPECTIVE|||||||
33764293|NCT04705064|||COHORT||PROSPECTIVE|||||||
33764294|NCT03780374|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant's will not know which intervention will be applied.|Each participant will be treated with sound principle 1, 2 and 3 in a crossover design.|t|f|f|f
33764295|NCT03970993|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764296|NCT04052191|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participant blind with dose.|Dose escalation.|t|f|f|f
33764297|NCT04802096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33893290|NCT01170689|||COHORT||CROSS_SECTIONAL|||||||
33893291|NCT01028352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893292|NCT05308212|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33893293|NCT02300129|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33893294|NCT02281812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893295|NCT05280561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||288 subjects were recruited for the study. The sample size was based on a prior power analyses using G-Power 3, for a Mixed Model Repeated Measures Analysis of Variance (MMRMA) design, assuming a statistical power of 0.8, moderate effects of the DHM effects on sleep outcomes, and hypothesis tests conducted at a probability value of .05.|t|f|f|f
33893296|NCT00728546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893297|NCT02966314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34075648|NCT03160040|||CASE_ONLY||RETROSPECTIVE|||||||
34075649|NCT06001970|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34075650|NCT03815773|||COHORT||PROSPECTIVE|||||||
34075651|NCT05710328|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34075652|NCT05679115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075653|NCT00761072|||COHORT||RETROSPECTIVE|||||||
34075654|NCT03608384|||COHORT||RETROSPECTIVE|||||||
33764298|NCT04236921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"* Part I: bioequivalence, food-effect, randomized, open-label, single-dose, 3-period, 6-sequence, crossover design.~* Part II: multiple-dose (every 4 hours), open-label, 1-period design.~* Part III: multiple-dose (every 2 hours), open-label, 1-period design. Subjects enrolled in Part II and Part III will be a subset of those who completed Part I."||||
33764299|NCT04219098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the surgeon and PA will be aware of the randomization assignment|This study is designed to be prospective randomized (1:1) controlled independent trial.|f|t|t|f
33764300|NCT04797182|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33764301|NCT06362525|||COHORT||PROSPECTIVE|||||||
33764302|NCT02013596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764303|NCT03821337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, Randomized, Placebo-Controlled Trial|t|f|t|f
33764304|NCT04496869|||COHORT||RETROSPECTIVE|||||||
33764305|NCT00113360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764306|NCT00925821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33764307|NCT02428244|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33764308|NCT05005364|||COHORT||PROSPECTIVE|||||||
33764309|NCT06264544|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33764310|NCT01726855|||CASE_CONTROL||RETROSPECTIVE|||||||
33764311|NCT03812861|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study introduction and familiarisation of the simulation lab and cognitive aid bundle will be done blindly for both participant and study staff. Randomisation will be done after study introduction and familiarisation of the simulation lab and cognitive aid bundle by means of opening a opaque sealed envelope. The randomisation is done by a computer generated code for use of the CAMDS (intervention) or not (control) and 3 patient scenario's|50 surgical teams (1 doctor, 2 nurses) will be randomly allocated to intervention or control group||||
33764312|NCT00893347|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33764313|NCT01555801|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33764314|NCT03227016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764315|NCT06309238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Due to the nature of the interventions, it will not be possible to blind the participants or the healthcare providers administering the interventions.~Blinded outcome assessment will be employed for the primary outcome and anywhere else possible. When assessing clinical outcomes, the participants will be asked not to disclose their assigned intervention group to the outcome assessor. Further, they will be provided with a plain white t-shirt, or similar, to wear during clinical assessments to cover the presence of surgical scars.~Statisticians and investigators drawing conclusions will be fully blinded. We will conduct the statistical analyses with the intervention groups coded as e.g., 'A' and 'B'. We will write two abstracts while the blinding is intact; one assuming the experimental intervention group is 'A' and the control intervention group is 'B', and one assuming the opposite. After these two abstracts have both obtained consensus, the code will be broken by the data manager."||f|f|t|t
33764316|NCT00621816|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33764317|NCT05925634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment of the 6- minute walk test, handgrip strength, and Short Physical Performance Battery \[SPPB\]) will be performed by a blinded research team member. The blinding will occur at baseline, end of cardiac rehabilitation, and at 6 months after cardiac rehabilitation.|A practical two-arm, parallel-group, open-label, efficacy randomized trial.|f|f|f|t
33764318|NCT03009721|||CASE_ONLY||RETROSPECTIVE|||||||
33764319|NCT01862952|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764320|NCT01857622|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764321|NCT04785664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is a pragmatic trial according which, according to the ecological model, provides for a Community-based Pro-Active Monitoring intervention, on people aged\>80, compared with a standard of care in two Italian Regions. The study is articulated in two phases: the baseline assessment provides a multidimensional assessment of the Functional Geriatric Evaluation questionnaire to the Long Live the Elderly (LLE) and Standard of Care (SoC) cohort. The follow up provides to collect information as Hospital Admission, Emergency Room accesses, Mortality rate, Admission to LCT facilities and use of home care services, with the collaboration of GPs and the regional database. The follow up will be gathered every six months over three years.||||
33764322|NCT00153621|||||PROSPECTIVE|||||||
33764323|NCT03017157|||COHORT||PROSPECTIVE|||||||
33764324|NCT00189592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33764325|NCT04618263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple, Participant, Investigator, Outcomes Assessor|Parallel Assignment|t|f|t|t
33764326|NCT00328640|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33764327|NCT01272960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764328|NCT02306122|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33764329|NCT04895189|||COHORT||PROSPECTIVE|||||||
33764330|NCT00003086||||TREATMENT||||||||
33764331|NCT03565068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33764332|NCT06155383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764333|NCT00644462|||CASE_CONTROL||RETROSPECTIVE|||||||
33764334|NCT02956434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764335|NCT04615182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764336|NCT06626100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764337|NCT05266963|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Participants will receive CREON and placebo in a random, blinded order.|t|t|t|t
33764338|NCT04704154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764339|NCT04207840|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33893298|NCT03698734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33893299|NCT03406026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764340|NCT04244019|||COHORT||PROSPECTIVE|||||||
33764341|NCT00699140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764342|NCT01378910|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764343|NCT04706533|||COHORT||PROSPECTIVE|||||||
33764344|NCT02654210|||COHORT||PROSPECTIVE|||||||
33764345|NCT05696314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The intervention (transoral and transcervical ultrasound) is performed on all included patients. All patients will also receive a standard MRI of the oropharynx. All tumors will be biopsy verified.||||
33764346|NCT02118480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764347|NCT06546319|RANDOMIZED|PARALLEL||OTHER||NONE||This study will utilize a mixed-methods intervention design in which qualitative data are embedded in the framework of a randomized controlled trial. Participants receiving music therapy will be compared to participants in a waitlist control group.||||
33893300|NCT02984462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33893301|NCT00189761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33893302|NCT01802359|||COHORT||PROSPECTIVE|||||||
33893303|NCT06392815|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893304|NCT00674011|||CASE_ONLY||PROSPECTIVE|||||||
33893305|NCT06556108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893306|NCT03840876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33893307|NCT06656832|RANDOMIZED|PARALLEL||TREATMENT||NONE|The primary endpoint (NT-proBNP) will be measured by lab personnel blinded to patients´ group assignment|||||
33893308|NCT01217775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893309|NCT04340050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893310|NCT05089708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33893311|NCT03771625|||COHORT||PROSPECTIVE|||||||
33893312|NCT04261543|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33893313|NCT05122130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be double-blinded where the patients and the statistician will be unaware of the treatment assignment till the end of the trial.||t|f|f|t
33893314|NCT01491087|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33977887|NCT03882047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participant and investigator were blinded to treatment identity. Because the mometasone furoate and fluticasone propionate bottles were not identical in appearance, a double-dummy study design was used and each bottle had a matching placebo. Thus, although participants received bottles of different appearance, they did not know whether bottles contained active substance or placebo.||t|f|t|f
33977888|NCT00997581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33977889|NCT00046865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33977890|NCT05116995|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Study personnel performing bleeding time and laboratory staff will be blinded to treatment allocation.|Treatment #1 for one week then on Day 21 they enter Treatment #2 for 1 week.|f|t|f|f
33977891|NCT01437865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33977892|NCT03775395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34075655|NCT04753957|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33764348|NCT03266848|||COHORT||PROSPECTIVE|||||||
33764349|NCT02993939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33764350|NCT04146649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893315|NCT04785612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double blinded, placebo-controlled study||t|t|t|t
33977893|NCT04971096|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This is a double blind randomized control study|Participates in three groups, 60 patients in each group. One group of patients will be given PS23, one will be given heat-treated PS23 and the other one will be given placebo.|t|f|t|t
33977894|NCT00088062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33977895|NCT04478019|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Two-period cross-over trial with a wash-out period between two study intervention periods. Participants will be randomized in a 1:1 ratio to two intervention sequences: active intervention followed by a no intervention control; or no intervention control followed by active intervention||||
33764351|NCT06434714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized to either active Bridge device, sham (non-functional) device, or standard of care post-operative pain regimen. Participants, care providers, and investigators will be blinded to those in active or sham device groups.|Double-blinded, placebo-controlled, 3 arm randomized controlled trial|t|t|t|t
33764352|NCT04310917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764353|NCT05130814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764354|NCT05088889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764355|NCT02836158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764356|NCT06624384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33764357|NCT00227864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764358|NCT02843802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764359|NCT00153387|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34075656|NCT00174824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34075657|NCT01060189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34075658|NCT05867667|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33764360|NCT05437354|||OTHER||CROSS_SECTIONAL|||||||
33764361|NCT05892666|||COHORT||PROSPECTIVE|||||||
33764362|NCT02955472|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33764363|NCT01373216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33764364|NCT01547026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33764365|NCT02893059|||COHORT||PROSPECTIVE|||||||
33764366|NCT04853732|||CASE_CONTROL||PROSPECTIVE|||||||
33764367|NCT02778126|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764368|NCT02291484|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33764369|NCT04078360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and outcomes assessor will be masked. The screeners will recruit participants into the study, who will then be randomised to one of the three arms of the study. The data team will then assign a masked outcome assessor to collect outcome data.|This will be a parallel three-arm single blind individually randomised controlled trial, with a nested qualitative study.|f|f|t|t
33764370|NCT02343003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764371|NCT03040882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764372|NCT03299790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33764373|NCT03355430|||CASE_ONLY||RETROSPECTIVE|||||||
33764374|NCT01525134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764375|NCT03463915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33764376|NCT02210793|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33764377|NCT02986490|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33764378|NCT03609346|||COHORT||PROSPECTIVE|||||||
33764379|NCT00118261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764380|NCT06189404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33764381|NCT01369134|||OTHER||PROSPECTIVE|||||||
33764382|NCT05425511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"We will recruit workers from hospitals who will be randomized in two groups:~* the intervention group will have a longitudinal follow-up of seven months in total (a control period of 1 month, then 6 to 8 sophrology sessions during two months, then a 4-month follow-up)~* the control group will have a differed intervention (longitudinal follow-up of seven months in total beginning by a control period without intervention of 3 months, then 6 to 8 sophrology sessions during two months, then a 2-month follow-up)."||||
33764383|NCT00840255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764384|NCT00030420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075659|NCT03583008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764385|NCT05970302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764386|NCT02294630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33764387|NCT04895514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764388|NCT05763784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33764389|NCT06326255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33764390|NCT01421095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33764391|NCT04033263|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Mouth rinses will be placed in coded bottles, and the investigator and patients will not know to which group they belong.|Cross-over study, where all participants will use all treatments. The treatment order will be set at random.|t|t|f|f
34075660|NCT02587767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34075661|NCT06074783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34075662|NCT05859607|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33893316|NCT06376149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be blinded to their group assignment: all participants will be told that they will receive the intervention. Program facilitators will be blinded to participant group assignment order, since sessions for both study arms would run on a rolling basis. The statistician will also be blinded to the group assignment and order.|"The primary objective is to conduct a pilot RCT to evaluate the effectiveness of a live-online mindfulness-based family intervention program, Making Mindfulness Matter (M3©) for children with JIA and their caregiver(s).~Measures will be obtained via questionnaires at 3 time points for the intervention group: baseline, 9 weeks and 2 months post-intervention. For the control group questionnaires will be obtained 4 time points: baseline, 9 weeks, 18 weeks and 2 months post intervention.~Additionally, at the start of each session, parents will complete a one-page semi-structured questionnaire evaluating treatment fidelity and at home utilization of M3© skills. At the end of each session, parent participants will complete a one-page structured questionnaire providing feedback on the session, and facilitators will complete the M3© Adherence Checklist, evaluating whether planned activities were completed, and any modifications made."|t|t|f|f
33893317|NCT01295125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893318|NCT04800315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33893319|NCT02426814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33893320|NCT03628157|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33893321|NCT04091217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893322|NCT05878028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893323|NCT06294028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33893324|NCT03216629|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33893325|NCT04767425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893326|NCT00297414|||CASE_ONLY||RETROSPECTIVE|||||||
33893327|NCT03678974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893328|NCT01665638|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33893329|NCT00162773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33893330|NCT03668756|||COHORT||PROSPECTIVE|||||||
33893331|NCT05819229|||COHORT||PROSPECTIVE|||||||
33893332|NCT03677570|||CASE_CONTROL||PROSPECTIVE|||||||
33893333|NCT04697225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33893334|NCT03947229|RANDOMIZED|PARALLEL||TREATMENT||NONE|Antiplatelet drugs will be open-label and prescribed by attending physician.|Patients will be assigned to continue DAPT (aspirin plus clopidogrel) or to change to single antiplatelet therapy with clopidogrel (clopidogrel-alone) for further 24 months.||||
33765995|NCT04723849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Using a computer-generated randomization schedule, study supplement and placebo were randomized (1:1) into 70 batches (each consisting of 6 packs containing 30 tablets a pack) and each was given a unique identification number. The coordinator of the study maintained the randomization list. Study physicians, other study personnel, and parents or legal guardians were blinded to of the batches of medication and to the identification. Subjects who satisfied the inclusion for the study were assigned an identification number (linked to a batch) in sequential order.|Using a computer-generated randomization schedule, study supplement and placebo were randomized (1:1) into 70 batches (each consisting of 6 packs containing 30 tablets a pack) and each was given a unique identification number. The coordinator of the study maintained the randomization list. Study physicians, other study personnel, and parents or legal guardians were blinded to of the batches of medication and to the identification. Subjects who satisfied the inclusion for the study were assigned an identification number (linked to a batch) in sequential order. Subjects took one tablet per day orally starting day one after the visit and continuing for the 6-month duration of the study. A number of tablets not taken equal to of greater of 2 tablets/month was considered not adherence to the study (drop out).|t|t|t|t
33765996|NCT06626477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Manufacturer, Monitor|During the first half (6 weeks) the subjects receive either active or sham treatment (randomized). During the final half (6 weeks) all subjects receive active treatment.|t|t|t|t
33765997|NCT06625580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33765998|NCT01080651|NON_RANDOMIZED|PARALLEL||||NONE||||||
33765999|NCT02007408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766000|NCT01365533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33766001|NCT05474729|NA|SINGLE_GROUP||TREATMENT||NONE||minocycline capsule||||
33766002|NCT01978080|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33766003|NCT06304662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33766004|NCT00282724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766005|NCT04513678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33766006|NCT02243774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766007|NCT05145842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766008|NCT04598893|||COHORT||PROSPECTIVE|||||||
33766009|NCT02332018|||COHORT||OTHER|||||||
33766010|NCT04989075|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This trial is designed as an two-arm parallel cluster randomized controlled trial with antenatal obstetric clinic as the unit of randomisation and an allocation ratio of 1:1|t|t|t|t
33766011|NCT05667701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither participants nor the clinical center investigators will be informed of the treatment group assignment to maintain the mask. The randomization sequence will be generated by the study statistician and uploaded to the REDCap database, and randomization will be implemented through REDCap. Only the treatment distribution center (study pharmacist) and the independent unblinded study statistician will have access to the actual treatment assignments.|genotype stratified, quadruple blinded randomized clinical trial|t|t|t|t
33766012|NCT02127619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766013|NCT02306265|NA|SINGLE_GROUP||SCREENING||NONE||||||
33766014|NCT04527848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The individuals were randomized in a 1: 1: 1: 1 ratio. Block sizes of 4 individuals stratified according to gas type were used (SF6 or C3F8). In each block, two individuals were allocated to each group (0.9-1.0 mL of 100% gas or 15-20 mL of 20% gas).||t|f|f|t
33766015|NCT01756820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978085|NCT03333226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomized before the SLNB procedure. Due to the type of intervention, the blinding of the treating surgeon will not be possible, thus the surgeon will be aware of both the intraoperative crossover between ARM lymph node and SLN (secondary outcome) and the allocation to ARM lymph node preservation or removal. Data about BCRL (primary outcome) will be collected by the physiatrist and the physiotherapist that will be blinded about the allocation (ARM lymph node preservation/removal) and the crossover between SLN of the breast and the arm's lymph node. The assessment of lymphoscintigraphic subclinical modification in the arm lymphatic drainage after SLNB and ALND (secondary outcomes) will be performed by a blinded nuclear medicine physician that will not be aware of the allocation (ARM lymph node preservation/removal) and the crossover between ARM lymph node and breast's SLN.|"Eligible patients for radioguided sentinel lymph node biopsy (rSLNB) will be randomly divided in two groups:~1. experimental group in which all patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.~2. control group in which all patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed."|t|f|f|t
33978086|NCT03919942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978087|NCT05241535|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Partially blinded. Placebo tablets to match active MT-7117 tablets|This is a Phase 1, randomized, partial double-blind, placebo and positive-controlled, three-way crossover study to evaluate the effect of a single oral dose of MT-7117, placebo, and positive control, moxifloxacin, on the QT/QTc interval in healthy subjects. The study consists of 3 treatments administered in a specific sequence as per the randomization list. Each subject will receive all 3 treatments over a specific sequence.|t|t|t|t
33978088|NCT04897802|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33978089|NCT03129477|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computorizada randomizados selection||f|t|f|f
33766016|NCT00096928|||COHORT||PROSPECTIVE|||||||
33766017|NCT06624436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||DEDICATE-LPS is a randomized double-blind placebo-controlled (double-dummy) study. A total of 48 healthy male volunteers will undergo experimental human endotoxemia twice separated by one week. Volunteers will be randomized to an allocated study treatment (dexamethasone 6 mg i.v. (n = 12), tocilizumab 600 mg i.v. (n = 12), anakinra 200 mg i.v. (n = 12) or placebo (NaCl 0.9% i.v., n = 12)). Furthermore, 4 healthy male volunteers will be enrolled as a control group (receiving no study treatment or LPS).|t|t|t|t
33766018|NCT03107377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind placebo-controlled efficacy trial of EVO100|Phase 2B double-blind placebo-controlled efficacy trial of EVO100 for the prevention of acquisition of urogenital Chlamydia trachomatis infection|t|t|t|t
33766019|NCT05710705|NA|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34076813|NCT04790578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be unaware of the intervention the participants received. Due to the nature of the intervention (a eHealth application) participants can't be blinded to the intervention. Furthermore, due to the intention to integrate the application as part of extended support provided in the EXCEL program, exercise class instructors (care providers) will be made aware of participant group assignment. The research coordinator will also be aware of the intervention of each participant to aid in troubleshooting with the ZoeInsights application.|Participants of the EXCEL study will be randomly allocated to either receiving the ZoeInsigths application during their 12 week baseline class + 12 week follow-up (intervention) or only receiving the 12 week baseline class (waitlist control). Those in the waitlist control group will be offered the ZoeInsights application at the end of the 24-week study period after completing their 24-week measures. Block randomization will be used so that all EXCEL participants in a single group-based class will be assigned to either the intervention or waitlist control group.|f|f|f|t
33766020|NCT06178783|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34076814|NCT06436989|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33766021|NCT06624956|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Potentially eligible patients will be approached on the day of surgery in a private room. Following formal, in person screening and informed consent by study team member who can thoroughly explain the study and answer patient questions, patients will be randomized to the study drug or to standard of care treatment (i.e. crystalloid infusion). All subjects will receive the same size bag of fluid and will have an infusion running during surgery. The administration of crystalloid is standard for surgeries performed at UW. Subjects in the standard/placebo arm will receive only regular crystalloid. Subjects in the GIK arm will receive regular crystalloid with GIK added. The contents of the bag will be blinded. The two fluids look the same to maintain blinding.|t|f|t|f
33766022|NCT05942755|||COHORT||PROSPECTIVE|||||||
33766023|NCT00025584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766024|NCT03872388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766025|NCT01725386|||COHORT||PROSPECTIVE|||||||
33766026|NCT02378519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766027|NCT02730221|||COHORT||PROSPECTIVE|||||||
33766028|NCT03115554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766029|NCT02888717|NA|SINGLE_GROUP||OTHER||NONE||||||
33766030|NCT04145037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766031|NCT01170195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766032|NCT00568191|||CASE_ONLY||PROSPECTIVE|||||||
33766033|NCT06616311|NA|SINGLE_GROUP||TREATMENT||NONE||Radiofrequency microneedling (RFMN) as a treatment for melasma||||
33766034|NCT04678622|||OTHER||PROSPECTIVE|||||||
33766035|NCT04929093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766036|NCT06394765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized (1:1) using a computer-generated randomization sequence created by the PI prior to the study start date.|This project is a single-site, two-arm, pilot study assessing the feasibility and preliminary efficacy of a 5-minute Mindful Mapping intervention for adults with chronic musculoskeletal pain relative to a time- and attention-matched control condition.|t|f|f|f
33766037|NCT02402296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076815|NCT03764280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This is an open-label, randomized, two-way, parallel study to compare the glucose control between physician adjusted basal-bolus parameters and our computer basal-bolus optimizing algorithm. Children and adolescent type 1 diabetes patients at Camp Carowanis, a camp for diabetes, will be enrolled in the study, where they will randomly undergo one of two interventions:~1. MDI with Physician Adjusted Basal-Bolus Parameters~2. MDI with Basal-Bolus Optimization Algorithm Adjusted Basal-Bolus Parameters (OA)"|t|f|f|f
34076816|NCT04067869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766038|NCT01048645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766039|NCT02999425|NA|SINGLE_GROUP||OTHER||NONE||||||
33766040|NCT00281034|||COHORT||PROSPECTIVE|||||||
33766041|NCT00433953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766042|NCT00301080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33766043|NCT05486910|||COHORT||PROSPECTIVE|||||||
33766044|NCT03485274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|treatment in each intervention arms is masked to the outcome assessor|prospective randomised single-blinded|f|f|f|t
33766045|NCT05324345|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33766046|NCT05696561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766047|NCT03980184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind|randomized double blind, placebo controlled|t|t|t|t
33766048|NCT02924389|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33766049|NCT04444661|||COHORT||RETROSPECTIVE|||||||
33766050|NCT02092246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766051|NCT06051487|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33766052|NCT04242420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluation of clinical parameters by genotype||||
33766053|NCT00812084|||||PROSPECTIVE|||||||
34076817|NCT00055120|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33766054|NCT02164968|||COHORT||PROSPECTIVE|||||||
33766055|NCT01350141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766056|NCT06413784|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were blind|This study is a single-blind (participants), parallel trial|t|f|f|f
33766057|NCT00003315|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33766058|NCT02710695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33766059|NCT01713699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766060|NCT01057615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766061|NCT04141020|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33766062|NCT04853147|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766063|NCT02475317|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33766064|NCT03004313|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33766065|NCT02814474|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33766066|NCT05260372|||COHORT||PROSPECTIVE|||||||
33766067|NCT00653549|RANDOMIZED|CROSSOVER||||NONE||||||
33766068|NCT00525265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766069|NCT05177731|RANDOMIZED|PARALLEL||TREATMENT||NONE||De novo adult AML patients randomly assigned to two induction treatment groups: venetoclax+decitabine group and conventional idarubicin(12mg/m2)+cytarabine group.||||
33766070|NCT06459830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized||f|f|t|f
33766071|NCT04406350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A pilot study to determine the feasibility of tight control of end-tidal respiratory gases during the conduct of anesthesia in major surgery.||||
33766072|NCT02379065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766073|NCT00193713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766074|NCT03369184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients are randomized in a double blinded fashion by a designated study nurse (simple envelope randomization) to either supplemental oxygen 6l/min delivered by an open face mask (Oxymask®) or ambient air (sham placement of Oxymask®). Neither the patient, nor the performing physician will be aware of the randomization status. Peripheral oxygen saturation will be disclosed only to the nurse responsible for randomization.||t|t|f|t
33766075|NCT00847795|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33766076|NCT06006702|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33766077|NCT04935138|||CASE_ONLY||PROSPECTIVE|||||||
33766078|NCT01373996|||CASE_ONLY||PROSPECTIVE|||||||
33766079|NCT06284967|||CASE_CONTROL||PROSPECTIVE|||||||
33766080|NCT02811757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766081|NCT02696044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978090|NCT02968888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33978091|NCT01968252|||COHORT||CROSS_SECTIONAL|||||||
33978092|NCT00148564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978093|NCT05209945|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single Group Assignment||||
33978094|NCT01924130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076818|NCT05102669|||COHORT||PROSPECTIVE|||||||
34076819|NCT06041906|||COHORT||OTHER|||||||
34076820|NCT02329327|NA|SINGLE_GROUP||OTHER||NONE||||||
34076821|NCT04194489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076822|NCT02392026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076823|NCT04302402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076824|NCT00467428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34076825|NCT05053269|||COHORT||PROSPECTIVE|||||||
34076826|NCT00678847|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076827|NCT04052880|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive initial therapy with 12 cycles of daratumumab in combination with dose-attenuated bortezomib, lenalidomide and dexamethasone (VRd). Maintenance treatment cycles are 28 days in duration with daratumumab and either lenalidomide or ixazomib. The choice of maintenance therapy will be based on cytogenetic risk status at diagnosis. For patients with high-risk MM defined by FISH with t(4;14) only; maintenance therapy will consist of daratumumab with ixazomib. For all other patients, maintenance therapy will consist of daratumumab with lenalidomide. All subjects will continue maintenance treatment until disease progression, except maintenance daratumumab will be discontinued after 2 years if subjects remain on maintenance treatment at that time.||||
34076828|NCT03907696|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076829|NCT03967860|||COHORT||RETROSPECTIVE|||||||
34076830|NCT00943657|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34076831|NCT04204161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076832|NCT03094585|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076833|NCT04214496|||COHORT||PROSPECTIVE|||||||
34076834|NCT02097823|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34076835|NCT00333489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076836|NCT01246895|||CASE_CONTROL||PROSPECTIVE|||||||
34076837|NCT02039778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076838|NCT05882500|||COHORT||PROSPECTIVE|||||||
34076839|NCT05719194|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Double blind is not possible as this study evaluate a care strategy. However, in order to limit evaluation bias, the methodologist will be blinded to the group.|Pragmatic, controlled, multicenter, stepped wedge cluster randomized trial, considering centers as clusters.|f|f|f|t
34076840|NCT00000863||||TREATMENT||||||||
34076841|NCT00078286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076842|NCT04175132|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34076843|NCT04424225|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34076844|NCT06145126|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Placebo-controlled, randomized, crossover|t|t|t|t
34076845|NCT01006005|||COHORT||PROSPECTIVE|||||||
34076846|NCT06328517|||COHORT||PROSPECTIVE|||||||
34076847|NCT05192317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076848|NCT00936455|||COHORT||RETROSPECTIVE|||||||
34076849|NCT03082027|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076850|NCT05867056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants will receive a single dose of IMC-I109V-101 in Part 1 (SAD) and 24 weekly doses in Part 2 (MAD). Participants in Part 3 will receive weekly doses of IMC-I109V until disease progression, unacceptable toxicity, or other reason for treatment discontinuation occurs.||||
34076851|NCT06344169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, non-inferiority trial||||
34076852|NCT00431093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076853|NCT05308290|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34076854|NCT04839172|||CASE_ONLY||RETROSPECTIVE|||||||
34076855|NCT04823312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076856|NCT03920475|||COHORT||PROSPECTIVE|||||||
34076857|NCT00680329|||COHORT||PROSPECTIVE|||||||
34076858|NCT02007317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076859|NCT05699512|||COHORT||PROSPECTIVE|||||||
34076860|NCT05767853|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34076861|NCT01014598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076862|NCT05100602|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076863|NCT01886508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34076864|NCT02760719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076865|NCT06073457|NA|SINGLE_GROUP||TREATMENT||NONE||"A 2-stage, open-label, multicenter study enrolling up to 35 subjects at 6 study centers, as follows:~* Stage 1: First-in-human (FIH) and proof-of-concept with up to 5 subjects; and~* Stage 2: Feasibility with up to 30 subjects There will be a pause after completing enrollment in Stage 1 to allow completion of Day 30 and evaluation of safety by the independent Data Safety Monitoring Committee (DSMB). The DSMB will confirm whether the study can advance to Stage 2. All subjects in Stage 1 and 2 will be followed for 12 months."||||
34076866|NCT05419713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34076867|NCT00105612|RANDOMIZED|||||||||||
33978095|NCT02206659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766082|NCT03785457|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The primary investigator will be blinded to the measurements of spinal height using stadiometry, and to the group assignment of each participant (sustained versus repetitive extension postures)||f|t|t|t
33766083|NCT02419430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33766084|NCT01108757|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33766085|NCT05983744|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33766086|NCT03564782|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects will receive intratumoral injection of the study drug PVSRIPO at a dose of 1x10\^8 TCID50 (tissue culture infectious dose). On Day 14 after injection, subjects will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.||||
33766087|NCT02823964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766088|NCT01737996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766089|NCT06038890|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A single cohort of consecutively performed cases in participating centers done by new learners using the assigned technique||||
33766090|NCT05809349|NA|SINGLE_GROUP||OTHER||NONE||||||
33766091|NCT06028074|NA|SINGLE_GROUP||TREATMENT||NONE||Part A: Single Ascending Dose (SAD), Multiple Ascending Dose (MAD), Part B: Dose Expansion||||
33766092|NCT00119990|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33766093|NCT03264768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766094|NCT00563225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766095|NCT02372760|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33766096|NCT03600896|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766097|NCT06082414|||COHORT||RETROSPECTIVE|||||||
33766098|NCT00192023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766099|NCT06158425|||COHORT||RETROSPECTIVE|||||||
33766100|NCT05420441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766101|NCT01503840|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33766102|NCT04218773|NA|SEQUENTIAL||TREATMENT||NONE||||||
33766103|NCT01909570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766104|NCT00006432|RANDOMIZED|||TREATMENT||SINGLE||||||
33766105|NCT05520840|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766106|NCT02105441|||COHORT||PROSPECTIVE|||||||
33766107|NCT00913185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766108|NCT05275491|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33766109|NCT06289634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766110|NCT02312401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766111|NCT00369681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766112|NCT02500563|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33766113|NCT05375435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766114|NCT00765297|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33766115|NCT00713102|||CASE_ONLY||RETROSPECTIVE|||||||
33766116|NCT05971342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766117|NCT03408743|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33766118|NCT06133114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766119|NCT02948959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766120|NCT00621907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766121|NCT02810314|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33766122|NCT02672501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766123|NCT00875732|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33766124|NCT02139475|||COHORT||PROSPECTIVE|||||||
33766125|NCT02643719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766126|NCT05043402|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33978096|NCT05963100|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose climbing test||||
33978097|NCT00425737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33978098|NCT05583071|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, prospective, multicenter, single-stage phase-II trial||||
33978099|NCT00988624|RANDOMIZED|CROSSOVER||||NONE||||||
33766127|NCT04947046|||COHORT||PROSPECTIVE|||||||
33766128|NCT02183116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766129|NCT05287516|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33766130|NCT04278677|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This is a provider-crossover study design: subjects will receive treatment according to their provider's standard of care|This is a provider-crossover study design.|t|f|f|f
33766131|NCT01291238|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33766132|NCT00840008|RANDOMIZED|PARALLEL||||NONE||||||
33766133|NCT05844891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research assistants conducting telephone follow-up assessments 3, 6, 9, and 12 months after enrollment will be blinded to group allocation.||f|f|f|t
33766134|NCT01030978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766135|NCT04902417|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Two-phase, randomized, controlled, crossover trial design.|f|f|f|t
33766136|NCT03222258|||COHORT||PROSPECTIVE|||||||
33766137|NCT02066896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766138|NCT04068363|||OTHER||RETROSPECTIVE|||||||
33766139|NCT00482638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766140|NCT05182073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766141|NCT03612427|||CASE_CONTROL||PROSPECTIVE|||||||
33766142|NCT03062774||SEQUENTIAL||TREATMENT||NONE||||||
33766143|NCT01022801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978100|NCT05911373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978101|NCT05562310|NA|SINGLE_GROUP||OTHER||NONE||||||
33978102|NCT00409019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978103|NCT00705809|||||PROSPECTIVE|||||||
33978104|NCT00676871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978105|NCT00071136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978106|NCT05713500|||OTHER||PROSPECTIVE|||||||
33978107|NCT00465686|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34076868|NCT03944772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2 platform study in patients with advanced Non-Small Lung Cancer harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation with evidence of radiological progression following first-Line osimertinib therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. The study will be conducted in three groups (Groups A, B and C). Patient allocation to a study treatment within each group will be based on tumour molecular profile. Biomarker positive patients or patients with histologically identifiable neuroendocrine transformation to small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (NEC) will be allocated to a biomarker-matched study treatment in Group A, patients without a biomarker will be allocated to a study treatment in Group B and patients with a biomarker amenable to therapies not currently available in ORCHARD will be allocated to Group C.||||
34076869|NCT03054181|||COHORT||PROSPECTIVE|||||||
34076870|NCT06117696|||CASE_CONTROL||PROSPECTIVE|||||||
34076871|NCT03894709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All participants will be informed that there two groups of the study. They will be randomized and allocated to one group and the research assistant explains the study to you does not know which group you will be, nor does the outcome assessor.|To develop a family-centered care model which providing health teaching to family caregivers of hip-fractured older persons with cognitive impairment how to care including rehabilitation exercises, diet, and management of behavioral problems.|t|f|f|t
34076872|NCT06394947|||COHORT||PROSPECTIVE|||||||
34076873|NCT04061278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076874|NCT01051479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076875|NCT06611735|||CASE_ONLY||CROSS_SECTIONAL|||||||
34076876|NCT02993796|||COHORT||PROSPECTIVE|||||||
34076877|NCT03301662|||COHORT||PROSPECTIVE|||||||
34076878|NCT04518618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"* The patients will be blinded to their groups.~* An anesthesia resident who will not participate in the study and have no subsequent rule in it will help in the preparation of local anesthetic mixtures under strict aseptic precautions.~* The anesthetist who will perform the spinal anesthesia will be blinded to the local anesthetic mixtures he will inject intrathecally.~* An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in collection of the data of measurments."||t|t|t|t
34076879|NCT05506969|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
34076880|NCT00610168|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076881|NCT01839916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076882|NCT02078193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076883|NCT01116752|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34076884|NCT02843009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076885|NCT03784391|||COHORT||RETROSPECTIVE|||||||
34076886|NCT03113565|||COHORT||PROSPECTIVE|||||||
34076887|NCT00825357|||CASE_CONTROL||PROSPECTIVE|||||||
34076888|NCT05869071|||OTHER||CROSS_SECTIONAL|||||||
34076889|NCT01406119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076890|NCT02149407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103506|NCT05151419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A total number of 30 participants were enrolled in our study. These individuals had a diagnostic bronchoscopy because they had a suspicion of lung cancer and needed tissue samples to confirm the diagnosis. All of the procedures were carried out with 2% lidocaine instillation and midazolam IV sedation||||
33766144|NCT05699122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Through the results of the verbal and numerical scale or PANAID obtained on the first and last day of follow-up, it will be verified whether or not there was an improvement in pain during intimate hygiene in the area affected by IAD.~With the results of the specialists' evaluations of the first and last day of follow-up, it will be verified whether or not there was an improvement in the characteristics of the IAD, verifying the effectiveness of the proposed treatment."||t|f|f|t
33766145|NCT00632008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766146|NCT04865211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766147|NCT03973866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766148|NCT02436083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33766149|NCT01771822|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894590|NCT05085210|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|"Group 1b is guaranteed actual stimulation.~Randomization for sham vs actual stimulation will be conducted by a predetermined member of the research team, ensuring that participants, care providers, investigators and outcome assessors all remain blinded to the intervention at the time of each assessment.~Given this is a pilot study and that both groups receive randomization over the type of stimulation we do not anticipate that randomization for enrolling subjects into group 1 or 2 is necessary."|"This is a pilot interventional study in patients with visual field deficit (VFD). Participants will undergo a screening evaluation that includes a neuro-ophthalmologic, cognitive and medical assessment, a confirmation of ischemic or hemorrhagic stroke diagnosis with subsequent VFD including verification of prior clinical imaging. Baseline assessments will consist of visual field perimetry, quality of life assessments and EEG/MRI for Groups 1a and 2.~Group 1a aims to examine the effects of two weeks (10 days) of visual training with tRNS vs visual training with sham tRNS.~Group 1b aims to examine the effects of two weeks (10 days) of visual training in a virtual reality environment with tRNS.~Group 2 aims to examine the effects of two weeks (10 days) of tRNS vs 2 weeks of sham tRNS (no visual training in this group)."|t|f|t|f
33894591|NCT01794780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894592|NCT02426866|||COHORT||RETROSPECTIVE|||||||
33894593|NCT00000889||||TREATMENT||||||||
33978108|NCT00514254|||CASE_CONTROL||PROSPECTIVE|||||||
33978109|NCT02188797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076891|NCT04277780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistical analysis to be performed on the primary and secondary outcome measure data will be provided to the assessor without information indicating whether or not a subject received the CGM sensor.|70 patients assigned to intervention group (to receive CGM sensor + conventional diabetes management); 70 patients assigned to control group (to receive only conventional diabetes management)|f|f|f|t
33978110|NCT02276677|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33978111|NCT04971551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978112|NCT00926406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076892|NCT02092454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076893|NCT04331834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766150|NCT04065217|NA|SINGLE_GROUP||TREATMENT||NONE||uni-center, government clinic, randomized within patient trial||||
33766151|NCT03613701|||CASE_CONTROL||PROSPECTIVE|||||||
33766152|NCT00720525|||CASE_CONTROL||PROSPECTIVE|||||||
33766153|NCT05222035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766154|NCT04243460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766155|NCT01369238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766156|NCT06355635|||COHORT||PROSPECTIVE|||||||
33766157|NCT03163576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766158|NCT01993017|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33766159|NCT03277378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33766160|NCT05763758|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33766161|NCT01445223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766162|NCT01729117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766163|NCT01401413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766164|NCT04986735|||COHORT||PROSPECTIVE|||||||
33766165|NCT01737281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766166|NCT03835169|||COHORT||RETROSPECTIVE|||||||
33894594|NCT00792766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894595|NCT04177030|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33894596|NCT04915001|||OTHER||OTHER|||||||
33894597|NCT03240081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
33978113|NCT03202836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978114|NCT06056388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978115|NCT00653536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978116|NCT01469546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978117|NCT02148302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978118|NCT03150836|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33978119|NCT05272358|||COHORT||RETROSPECTIVE|||||||
33978120|NCT02129023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33978121|NCT00394056|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33978122|NCT02497456|RANDOMIZED|PARALLEL||||NONE||||||
33978123|NCT06170268|||CASE_ONLY||OTHER|||||||
33978124|NCT05278806|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33978125|NCT00648518|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34076894|NCT00082212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076895|NCT05286853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34076896|NCT01720641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076897|NCT00598065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34076898|NCT04780815|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076899|NCT00492726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076900|NCT05028764|||CASE_ONLY||PROSPECTIVE|||||||
34076901|NCT05648552|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34076902|NCT01170325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34076903|NCT04868110|RANDOMIZED|PARALLEL||PREVENTION||NONE||Women in the control group will participate in weekly lessons for 18 weeks on eating a high fiber diet and will received daily snacks.||||
33894598|NCT00661375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894599|NCT06487403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894600|NCT01363050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894601|NCT01586091|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33894602|NCT01047410|RANDOMIZED|PARALLEL||TREATMENT||NONE|Outcomes assessors are blinded if possible.|3-arm randomized controlled trial||||
33894603|NCT04756544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894604|NCT04751500|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study involves two phases: 1) All recruited women will be scanned for RPOC at 8 weeks post-miscarriage diagnosis. 2) Women that have RPOC on this scan will then be randomised in a 1:1 manner to either outpatient hysteroscopy or standard treatment.||||
33894605|NCT05917886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants were unaware which auditory beat stimulation condition they received in which order.|Patients participated in both the control and active auditory beat conditions, each lasting 1 week. Conditions were randomised across participants.|t|t|f|f
33894606|NCT01662999|RANDOMIZED|CROSSOVER||||NONE||||||
33894607|NCT00003789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978126|NCT01513551|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33978127|NCT04278469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978128|NCT03318692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient is masked to the surgery procedure|prospective, randomized, partially blinded|t|f|f|f
33978129|NCT02832856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978130|NCT02744352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978131|NCT03735446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978132|NCT04051970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978133|NCT00082563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978134|NCT04826510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomly assigned to the lithium carbonate group, piperopirone hydrochloride group or the lithium carbonate + Piperopirone hydrochloride group after obtaining the corresponding random number according to the order of inclusion. According to the random centers, the lithium carbonate group: piperopirone hydrochloride group: lithium carbonate + Piperopirone hydrochloride group was 1:1:1|The study is expected in the nine and clinical study of cooperative unit to carry out clinical research network, each is expected to include subjects about 21 cases (7 cases of lithium carbonate group, pp horse of the 7 cases, hydrochloric acid hydrochloric acid lithium carbonate + pp ROM horse lung group of 7 cases), with 189 recruit subjects (lithium carbonate group 63 examples, hydrochloric acid pp ROM horse lung group 63 examples, lithium carbonate + pp hydrochloride horse lung group 63 examples. The study is expected to be completed within two years.|t|f|f|t
33978135|NCT05375149|||CASE_CONTROL||PROSPECTIVE|||||||
33978136|NCT01868841|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33978137|NCT00689013|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33978138|NCT04450745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978139|NCT05647486|||COHORT||RETROSPECTIVE|||||||
33978140|NCT05241769|||OTHER||RETROSPECTIVE|||||||
33978141|NCT01849042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978142|NCT02745002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978143|NCT01141465|||COHORT||RETROSPECTIVE|||||||
33978144|NCT03294863|RANDOMIZED|FACTORIAL||OTHER||SINGLE||Each subject receives both types of interventions upon the same scar in order for comparison.|f|f|f|t
33978145|NCT00181922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978146|NCT05817916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Group 1: The patients in the first group (ESP Group) will be applied ultrasound guided ESP block at the lateral position at the end of the surgery. ESP will be performed with a posterior approach, under ultrasound guidance, by imaging the muscles and the needle.~Group 2: At the end of the surgery, patients in the second group (LP Group) will have an appropriate level of LP block with ultrasound guidance and, if necessary, using a neurostimulator."|t|t|f|t
33978147|NCT02688556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978148|NCT05437965|||CASE_CONTROL||PROSPECTIVE|||||||
33978149|NCT00207337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978150|NCT04351009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The pathologist involved in routine histological assessment of the resected lymph nodes including lymph nodes in the gross specimen and sentinel lymph nodes will be blinded to the identity of the sentinel lymph nodes.|Sentinel lymph node mapping: 25 mg of Indocyanine green dye diluted in 1 ml of 20% Albumin solution and 9 ml of 0.9% Normal saline solution will be used. Injections (0.5-1 ml) will be given in the submucosa or subserosa at 2-4 points around the tumor proximally and distally. Lymphatic flow will be followed after injection in real time with Near-infrared fluorescence imaging scope until sentinel lymph nodes will be identified.||||
33978151|NCT00919308|||CASE_CONTROL||PROSPECTIVE|||||||
33978152|NCT00005939||||TREATMENT||||||||
33978153|NCT00725439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978154|NCT01205607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33978155|NCT03702621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patients and the research staff doing assessments will be blinded to the randomization.|"1. LB group (Liposomal Bupivacaine)~2. SB group (Standard Bupivacaine)"|t|f|t|f
33978156|NCT01035697|||COHORT||PROSPECTIVE|||||||
33978157|NCT05529511|||OTHER||OTHER|||||||
33978158|NCT01695109|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33978159|NCT06496763|||COHORT||PROSPECTIVE|||||||
34024496|NCT01211938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024497|NCT00792935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024498|NCT05736653|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||We will employ a single group pre-post design.|t|f|f|f
34024499|NCT01746459|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024500|NCT05881746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024501|NCT00599963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34024502|NCT02188186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34025582|NCT06634056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025583|NCT01464931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076904|NCT00152607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766167|NCT00756808|||||PROSPECTIVE|||||||
34076905|NCT04533113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34076906|NCT02676557|||COHORT||PROSPECTIVE|||||||
34076907|NCT00137345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076908|NCT05086588|||COHORT||PROSPECTIVE|||||||
34076909|NCT05748132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076910|NCT04383197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076911|NCT06441318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076912|NCT02296658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076913|NCT02292459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076914|NCT01687218|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34076915|NCT02038556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34076916|NCT05465369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076917|NCT02835859|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34076918|NCT01353131|||COHORT||PROSPECTIVE|||||||
33766168|NCT01861574|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33766169|NCT00553098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766170|NCT05458167|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33766171|NCT01552122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766172|NCT01295567|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766173|NCT02420756|||COHORT||PROSPECTIVE|||||||
33766174|NCT03346213|||COHORT||PROSPECTIVE|||||||
33766175|NCT05622448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766176|NCT00737581|||OTHER||PROSPECTIVE|||||||
33766177|NCT00146250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766178|NCT00708526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33766179|NCT03942679|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766180|NCT03050645|||COHORT||PROSPECTIVE|||||||
33766181|NCT02351323|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766182|NCT04627519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomised to be in Arm 1 or Arm 2 using pre-defined randomisation list; 1:1 for each arm.~Arm 1 receives Standard of Care (day 1 to 10) Arm 2 receives Standard of Care + Rhea Health Tone (day 1 to 10)"||||
33766183|NCT00852826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33766184|NCT05538260|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33766185|NCT03773718|||COHORT||PROSPECTIVE|||||||
33978160|NCT05832463|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"Cohort 1 is single-blind. Participants will not know their treatment allocation in either arm of the study. Furthermore, in cohort 1, the participants may receive a 250 mg or 500 mg CBS dose, but will not be informed which they receive. In order to preserve blinding to dosage allocation, participants will be instructed to consume two capsules prior to each meal.~* Participants receiving the 500 mg CBS dose will take 2 CBS capsules~* Participants receiving the 250 mg CBS dose will take 1 CBS capsule and 1 placebo capsule~* Participants in the placebo arm will take 2 placebo capsules~Cohort 2 is double blind - participants will know that they will receive either the treatment or placebo first, but will be blinded to which they receive. All members of research staff will be blinded with the exception of a designated member"||t|f|t|f
34076919|NCT05780138|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-post-test intervention study||||
34076920|NCT05994547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076921|NCT05841433|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34076922|NCT05930717|||COHORT||PROSPECTIVE|||||||
34076923|NCT02543047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076924|NCT06219863|NA|SINGLE_GROUP||OTHER||NONE||||||
34076925|NCT03867175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076926|NCT06203470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076927|NCT04951089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076928|NCT05710146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076929|NCT00417144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34076930|NCT04123457|||CASE_ONLY||PROSPECTIVE|||||||
33766186|NCT05188755|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||group 1: healthy controls group 2 : young adults recovered from lymphoma or Hodgkin's disease||||
33766187|NCT02795208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766188|NCT06015555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766189|NCT05606263|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33978161|NCT05228314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978162|NCT03961464|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34076931|NCT01173315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34076932|NCT05275465|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34076933|NCT03289767|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34076934|NCT02467361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076935|NCT02701725|||CASE_CONTROL||PROSPECTIVE|||||||
33766190|NCT00509002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766191|NCT03881930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations are carried out outside the rehabilitation programme, by blind evaluators.|Observe in patients with chronic acquired demyelinating neuropathy, the effects on balance of a rehabilitation with modified visual input (deceived visual input, or visual deprivation); compared to an identical rehabilitation of balance performed with the non-modified visual input.|f|f|f|t
33766192|NCT02321280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894608|NCT05004675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|efficacy parameters (lipids) blinded after randomization|randomized, comparative trial|t|t|t|t
33894609|NCT01815385|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33894610|NCT00874380|||COHORT||PROSPECTIVE|||||||
33894611|NCT06657482|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894612|NCT06657209|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Control group will undergo baseline testing to provide information about people without diabetes, but will not proceed with treatment.||||
33894613|NCT04998006|||COHORT||PROSPECTIVE|||||||
33894614|NCT02239406|||COHORT||PROSPECTIVE|||||||
33894615|NCT02934854|||COHORT||PROSPECTIVE|||||||
33894616|NCT00784758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766193|NCT02687490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766194|NCT03216902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978163|NCT01179919|NA|SINGLE_GROUP||||NONE||||||
33978164|NCT04465188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978165|NCT00794742|||CASE_CONTROL||PROSPECTIVE|||||||
33978166|NCT05754047|||CASE_ONLY||CROSS_SECTIONAL|||||||
33978167|NCT02447900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978168|NCT00039611||||TREATMENT||NONE||||||
33978169|NCT04958980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The formation of randomized groups will occur by random drawing, obeying the proportion of 1: 1 in both groups, that is, 12 participants in each group (control and intervention) that will be selected after the screening carried out by the research nurse (to verify some possible exclusion criteria for research participants), reducing the occurrence of methodological bias in the sampling phase and ensuring the possibility that all participants can be included in the intervention group.|randomized clinical study conducted in an educational group at the Basic Health Unit of Nova Bonsucesso with six monthly meetings scheduled with 24 patients with type II diabetes mellitus users of oral hypoglycemic agents divided into two subgroups: 12 users of the control group and 12 users of the study group (who will receive the researchers' interventions) and will be accompanied by laboratory tests and individual evaluations to verify the effectiveness of multiprofessional action in the control of diabetes mellitus.|t|f|f|f
33978170|NCT04349605|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to one of the three treatment arms of the study - Kundalini Yoga, Meditation, or Treatment as usual.||||
33978171|NCT00322933|||DEFINED_POPULATION||PROSPECTIVE|||||||
33978172|NCT03319420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigator staff involved in the dispensation of study treatments and treatment compliance checks will not be involved in data collection - doublemasked treatment design.|A randomized, double-Masked, comparative study|t|f|t|t
33978173|NCT02991625|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33978174|NCT03082781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978175|NCT05512000|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adapted alternating treatments research design with 3 conditions per participant. Four participants are randomly assigned to each contrast (arm).||||
34076936|NCT03773289|||COHORT||RETROSPECTIVE|||||||
34076937|NCT04687410|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33766195|NCT01562535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766196|NCT02291432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766197|NCT03646630|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33766198|NCT03720418|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Study Part A open-label and Study Part B randomized, double-blind||t|t|t|t
33766199|NCT00868699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766200|NCT05102123|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||2x2 factorial|t|t|t|t
33766201|NCT03624374|||COHORT||PROSPECTIVE|||||||
33766202|NCT03748836|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blinded, placebo-controlled|Randomized, placebo-controlled, double-blinded, dose escalation to evaluate the safety, PK, and PD of single and multiple doses of ALPN-101|t|f|t|f
33766203|NCT00803166|||COHORT||PROSPECTIVE|||||||
33766204|NCT00462254|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33766205|NCT04380298|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33766206|NCT02252614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33766207|NCT04959760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Operator of the device will be blinded to the outcome|||||
33766208|NCT00303160|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766209|NCT03357120|NA|SINGLE_GROUP||OTHER||NONE||||||
33766210|NCT04066140|||COHORT||PROSPECTIVE|||||||
33766211|NCT03966690|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33766212|NCT00696306|||CASE_ONLY||PROSPECTIVE|||||||
33766213|NCT02571790|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766214|NCT03090581|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|A prospective, randomized, comparative study in all patients.|||||
33766215|NCT06622278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766216|NCT06319235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766217|NCT01062763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766218|NCT03874182|||OTHER||CROSS_SECTIONAL|||||||
33766219|NCT03535402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766220|NCT05384665|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Double-blind randomized controlled study|t|f|t|f
33766221|NCT00816387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766222|NCT01131117|||COHORT||PROSPECTIVE|||||||
33766223|NCT01834222|||COHORT||PROSPECTIVE|||||||
33766224|NCT02020980|||COHORT||PROSPECTIVE|||||||
33766225|NCT05645783|||OTHER||PROSPECTIVE|||||||
33766226|NCT03093740|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Based on the genotype and viral resistance testing of the donor, that will be determined within the first week, we will initiate a genotype specific regimen for HCV treatment as available by prescription||||
33766227|NCT04929808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766228|NCT06294912|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766229|NCT03068013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766230|NCT06528548|||COHORT||PROSPECTIVE|||||||
33766231|NCT06024772|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766232|NCT00879996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766233|NCT03361826|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Using a case-control design, the investigators will compare individuals receiving MST and DBT with matched patient control group receiving DBT alone.||||
33766234|NCT02139423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766235|NCT04100109|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33766236|NCT01858480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766237|NCT03719053|NA|SINGLE_GROUP||OTHER||NONE||||||
33766238|NCT04157465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-center, prospective randomized, open-labeled with blinded end-point (PROBE) assessment||f|f|f|t
33766239|NCT01742637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894617|NCT01848314|NA|SINGLE_GROUP||||NONE||||||
33894618|NCT01574573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894619|NCT01677845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894620|NCT00537719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33978176|NCT04351178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants will be randomly assigned to participate in F@ce 2.0 (IG) or a control group (CG) receiving usual rehabilitation at two different sites; both an urban (IG+CG) and rural site (CG+IG) in Sweden|f|f|f|t
33978177|NCT01045590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978178|NCT05368623|||CASE_ONLY||CROSS_SECTIONAL|||||||
33978179|NCT04324008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978180|NCT04390854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The radiographic specialist and the statistician will be blinded to treatment group||f|f|f|t
33978181|NCT02393781|||CASE_ONLY||PROSPECTIVE|||||||
33978182|NCT03868709|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978183|NCT06124196|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978184|NCT05346055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978185|NCT02788422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978186|NCT06340464|||COHORT||PROSPECTIVE|||||||
33978187|NCT02535507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978188|NCT00838552|||CASE_CONTROL||PROSPECTIVE|||||||
33978189|NCT02066675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978190|NCT03645577|||CASE_ONLY||RETROSPECTIVE|||||||
33978191|NCT04195295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978192|NCT06428448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978193|NCT00431548|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978194|NCT04978025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978195|NCT03455166|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978196|NCT02850068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978197|NCT00818623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978198|NCT01082653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978199|NCT00311961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978200|NCT00761592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978201|NCT05101174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33978202|NCT01734772|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978203|NCT01275326|||CASE_ONLY|||||||||
33978204|NCT02309125|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34076938|NCT01116947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076939|NCT00671346|||COHORT||PROSPECTIVE|||||||
34076940|NCT02021214|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE||Double-blind, cross-over design with two drug conditions. Drug conditions are placebo and methylphenidate 40 mg. Order will be balanced and pseudo-random.||||
34076941|NCT05826210|||COHORT||RETROSPECTIVE|||||||
34076942|NCT04717258|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study consists of a two-arm main trial, with two embedded two-arm SWATs.||||
34076943|NCT01693679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076944|NCT02176369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076945|NCT01340755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076946|NCT02667301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102948|NCT06444633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The enumerator and the outcomes assessor will be masked to the assignment of intervention.|The study is a parallel, cluster randomized controlled trial, randomizing administrative wards in Bauchi, Nigeria to treatment (receiving pre-emptive, free ORS+Zinc co-packs (2 nos) per child under 5 to households, along with information about proper use of ORS and Zinc for treating child diarrhea) or delayed-start control (receiving intervention after the end of the study period).|f|f|f|t
34102949|NCT03607669|||COHORT||PROSPECTIVE|||||||
33978205|NCT05135442|NA|SINGLE_GROUP||TREATMENT||NONE||Clinically diagnosed as TTP (thrombocytopenia + MAHA± clinical evidence of related organ damage), confirmed by ADAMTS13 activity level decreased significantly and/or positive antibody screening||||
33978206|NCT02498548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978207|NCT03353909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33978208|NCT02439008|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978209|NCT01029938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978210|NCT04117607|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33978211|NCT04896983|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33978212|NCT01986036|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33978213|NCT03137563|||COHORT||PROSPECTIVE|||||||
33978214|NCT04960488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978215|NCT04041947|||COHORT||PROSPECTIVE|||||||
33978216|NCT05420051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978217|NCT02791100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978218|NCT02220465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978219|NCT01624766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978220|NCT05544448|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study is a multicenter, open-label, non-controlled, non-randomized in vitro study.||||
33978221|NCT01403766|||COHORT||PROSPECTIVE|||||||
33978222|NCT02594462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978223|NCT04025879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978224|NCT06135532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978225|NCT03236766|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33978226|NCT05631366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|t|f
33978227|NCT00653783|||CASE_CONTROL||PROSPECTIVE|||||||
33978228|NCT03555409|||CASE_ONLY||RETROSPECTIVE|||||||
33978229|NCT00136201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978230|NCT05608161|||COHORT||PROSPECTIVE|||||||
33978231|NCT04876378|||COHORT||PROSPECTIVE|||||||
33978232|NCT05411536|||COHORT||CROSS_SECTIONAL|||||||
33978233|NCT01758848|||COHORT||PROSPECTIVE|||||||
33978234|NCT01261884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978235|NCT02545946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978236|NCT03619031|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33978237|NCT02474264|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33978238|NCT04172870|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978239|NCT04556214|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33978240|NCT01556009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103507|NCT03599297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076947|NCT03459625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will participate in laboratory assessments at baseline and immediately post-treatment, as well as at 6 months and 12 months post-treatment. Measures include standardized and validated parent and teacher questionnaires, gold-standard psychological assessments, and observational and interview ratings. All assessors for laboratory assessments will remain blind to treatment group assignment for the duration of the project. Teachers will also be blind to treatment group assignment. Research assistants involved in observational coding will be blind to both treatment condition and visit time point.|The proposed study is a randomized controlled trial of 138 families that will be conducted in three cohorts. Each cohort will involve a recruitment phase of 46 participants. Within each cohort parents will be randomly assigned to the MBSR (N=23) or PE group (N=23), and the groups will run concurrently.|f|f|f|t
34076948|NCT04990115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sequentially generated numbers were placed in opaque envelopes until the intervention was conducted and each participant was asked to select an envelope that determine which group of intervention was assumed|The trial design is a prospective, parallel, randomized with an allocation ratio (1:1), double-blinded, single-center clinical trial|t|f|f|t
34076949|NCT00277966|||||RETROSPECTIVE|||||||
33719850|NCT03527966|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The surgical team, including the surgeons, will be blinded to the treatment options until decompression/instrumentation have been completed. The patients and all staff, including hospital nursing staff, case management, and physical therapists, will be blinded as to which bone graft treatment the patient received.||t|t|f|f
34076950|NCT04292210|NA|SINGLE_GROUP||OTHER||NONE|"The training consisted of two cycles in which the moderator guided the subject and three cycles in which the subject guided the moderator through the complete handling of the device.~For each subject, one moderator and one observer were involved in the study. The moderator was the interface between the subject and the device both in training and in testing. This person was employed by an external agency to avoid any influence on the subject.~The observer saw the handling with the help of a live feed from a separate room. He evaluated the handling steps in the categories of safe use and use error according to IEC 62366-1 (2015). For each use error, the observer described the observed situation from his point of view."|"The growth in the RRT population is primary in the elderly age group, a population with a high frailty and comorbidity burden. Facilitating PD in this group of patients requires improved PD technology with greater accessibility tailored to patient needs. It is proposed that by making PD treatment simpler, more standardized and better protected from infections, patient access to PD could be increased significantly. Following evaluation of specific barriers to the use of PD including feedback from established PD patients, a novel connection-assist device has been developed.~As part of the CE marking authorization, the connection device has been evaluated for safety and ease of use in a study at University Hospitals Birmingham NHS Foundation Trust involving 24 patients and carers."||||
34076951|NCT05193513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076952|NCT01919034|||CASE_CONTROL||PROSPECTIVE|||||||
34076953|NCT03899857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076954|NCT03210493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076955|NCT01835912|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34076956|NCT03471832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each subject will be masked as to which lens is worn on each eye.|This will be a non-dispensing, randomized, contralateral study comparing a test lens against the appropriate control lens.|t|f|f|f
33978241|NCT03951337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multicentric, open prospective study||||
33978242|NCT04796909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978243|NCT01552096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978244|NCT00073294|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33978245|NCT03030196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719851|NCT03746769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719852|NCT00411645|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33719853|NCT05186597|||COHORT||PROSPECTIVE|||||||
33978246|NCT02898623|||CASE_CONTROL||PROSPECTIVE|||||||
33978247|NCT00000804|RANDOMIZED|||TREATMENT||||||||
33978248|NCT05380635|NA|SINGLE_GROUP||OTHER||NONE||||||
33978249|NCT03654196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025584|NCT06148415|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Single|Randomized controlled trial conducted with experimental and control groups.|t|f|f|f
34025585|NCT02647385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076957|NCT01766908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34076958|NCT03719430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978250|NCT05375175|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|To ensure double-blindness, the wrapper of the snacks will be the same and nursing will only be able to distinguish the product by the assigned code, as will the statistician|"A randomized, crossover and controlled clinical trial will be developed with 23 individuals to evaluate the post-prandial effect of consuming snacks rich in vegetable and animal protein compared to a high-quality pork sausage. Each participant will consume the 2 types of snacks (20 grams) following a random assignment order.~It is a randomized, crossover, double-blind, and controlled trial. The intervention will consist of the administration of 20 g of one or another snack (Fertinagro Company) that will be eaten at fasting in the morning. Participants will be fasting for 12 hours for solid or liquid food and more than 1 hour after ingestion of water. Blood samples will be obtained after venepuncture at 7:45 a.m. before eating snacks and 15, 30, 60, 90 and 120 minutes after it.~Within a period of 20 days +_5 days, the intervention will be carried out with the second type of snack according to randomization. The total duration of the study is expected to be 2.5 to 3 months."|t|t|t|f
33978251|NCT01279525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978252|NCT03816657|||COHORT||RETROSPECTIVE|||||||
33978253|NCT01217242|||COHORT||CROSS_SECTIONAL|||||||
33978254|NCT01373970|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33766240|NCT06414512|NA|PARALLEL||TREATMENT||NONE||Prospective, open-label trial to compare the efficacy and safety of lower doses of 5FC during induction therapy to historical controls with standard 5FC dosing. Historical controls drawn from the AMBITION trial will be used as a comparison group, selected weighted by inclusion/exclusion criteria, baseline characteristics and therapies received.||||
33766241|NCT05368181|NA|SINGLE_GROUP||PREVENTION||NONE||methylprednisolone||||
33766242|NCT00347243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766243|NCT02268617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766244|NCT04533451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766245|NCT03579914|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33766246|NCT02826590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978255|NCT00929539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978256|NCT01383525|NA|SINGLE_GROUP||TREATMENT||NONE|No masking for treatment. The follow-up and primary endpoint assessment, intra-ocular pressure (IOP) measurement, is performed by masked ophthalmologist.|||||
33978257|NCT02679677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978258|NCT03683407|||COHORT||PROSPECTIVE|||||||
33978259|NCT00436007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978260|NCT04330937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978261|NCT02438878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978262|NCT06485401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978263|NCT04201171|||COHORT||OTHER|||||||
33978264|NCT00046267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978265|NCT01375322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978266|NCT01722981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33978267|NCT03259100|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33978268|NCT02674334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978269|NCT02483975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978270|NCT02329652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719854|NCT03201289|||COHORT||OTHER|||||||
33978271|NCT05530109|||CASE_CONTROL||PROSPECTIVE|||||||
33978272|NCT03260764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978273|NCT00263809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766247|NCT05784805|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients with ongoing non-convulsive or focal motor SE despite treatment with standard of care antiseizure medications.||||
33766248|NCT01020890|||||CROSS_SECTIONAL|||||||
33766249|NCT06624813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766250|NCT06626308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766251|NCT05453916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766252|NCT02527408|||||PROSPECTIVE|||||||
33766253|NCT00274690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33766254|NCT01589952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766255|NCT05238064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766256|NCT01616771|NA|SINGLE_GROUP||||NONE||||||
34076959|NCT05199467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33766257|NCT06625749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766258|NCT02746913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766259|NCT00073827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766260|NCT00326638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766261|NCT06624826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766262|NCT05969821|||COHORT||OTHER|||||||
33766263|NCT01473472|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766264|NCT02265016|||COHORT||OTHER|||||||
33766265|NCT05680974|||CASE_ONLY||PROSPECTIVE|||||||
33766266|NCT00458614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766267|NCT00647634|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33766268|NCT00827593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766269|NCT05692713|||COHORT||PROSPECTIVE|||||||
34076960|NCT01525966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34076961|NCT01190813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34076962|NCT01861769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076963|NCT04748289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open labelled, single centre clinical investigation, with the new ICU Cockpit Software Platform (medical device).||||
34076964|NCT03118518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076965|NCT03188055|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34076966|NCT05078203|RANDOMIZED|CROSSOVER||PREVENTION||NONE||18 adults with healthy weight (BMI 18.5-25.0kg/m2) and 18 adults with obesity (BMI 30.0kg/m2) will be asked to complete a counter-balanced crossover trial. After initial baseline testing, participants will be asked to complete either an acute exercise bout or sedentary control session in a counter-balanced order.||||
34076967|NCT05761418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34076968|NCT04101383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|This study was blinded for Sponsor, investigators and analytical laboratory|two-way crossover|t|t|t|t
33766270|NCT05942352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766271|NCT05817578|||COHORT||CROSS_SECTIONAL|||||||
33766272|NCT05014321|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"Each spot will be treated by a defined prototype / device (always the same prototype / device on the same spot all along the study - one unique prototype/device per spot). The application order of the different device prototypes (810A-v1), (810B-v1), (810C-v1) will be defined by randomization except for CNV Body that will always be applied last.~Each prototype will be identified by a 3 characters internal code (00-x) corresponding to the treated spot with 00 corresponding to the subject number from 01 to 12 and x corresponding to the selected spot from A to D."||t|t|t|f
33766273|NCT03059875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766274|NCT05199805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data collectors will be blinded. Blinding of study participants is not possible due to the study design.|"40 patients with chronic (specific and non-specific) musculoskeletal pain will be randomized into two study conditions. The intervention group will receive MBPM sessions of 150 minutes each once a week for 8 weeks, while the control group will receive standard therapy (waiting list).~The control group does not receive any active intervention in addition to treatment as usual during the intervention period. After completion of data collection, the control group will be offered an identical program, 6 months after randomization."|f|f|t|t
33766275|NCT01103960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978274|NCT04882293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978275|NCT00821834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978276|NCT02333370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978277|NCT05190510|||COHORT||PROSPECTIVE|||||||
33978278|NCT01567956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978279|NCT06497387|NA|SEQUENTIAL||TREATMENT||NONE||||||
33978280|NCT01018706|||COHORT||PROSPECTIVE|||||||
33978281|NCT03565809|||CASE_CONTROL||RETROSPECTIVE|||||||
33978282|NCT04555928|||COHORT||PROSPECTIVE|||||||
33978283|NCT02602379|||COHORT||PROSPECTIVE|||||||
33978284|NCT04627506|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Subjects will be randomly allocated to either interventional or control group according to a computer generated randomization code in predetermined size blocks.~Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS screen will be concealed in the control group to ensure blinding."|This is a prospective, randomized, controlled clinical trial.|t|f|f|t
33978285|NCT00684671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978286|NCT04260503|||CASE_CONTROL||PROSPECTIVE|||||||
33978287|NCT04118478|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The investigator performing the randomization will be blinded and will not participate in the recruitment process. Participants and group assignment will be blinded to investigators and technicians performing statistical analysis. Participants will be explicitly informed of their assigned group, without the possibility of modification throughout the program. The evaluation team will be made up of five researchers and technicians, two will apply the different phases of the program, one will randomly assign the participants and two others will oversee the statistical analysis. All the analysis of the results will be gathered by the same researcher. The researcher will neither know which group the participant belongs to, nor the main design of the study or the foreseen changes.|A study protocol of a randomized controlled clinical trial with blinded examiners is presented.|t|t|f|t
33978288|NCT01968265|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33978289|NCT04820868|||CASE_CONTROL||PROSPECTIVE|||||||
33978290|NCT01856088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978291|NCT00356200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978292|NCT02008903|||OTHER||PROSPECTIVE|||||||
33978293|NCT01187862|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33978294|NCT02879019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978295|NCT03838653|||COHORT||PROSPECTIVE|||||||
33978296|NCT04091126|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will evaluate different doses/dose schedules of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone, (VRd) in up to 8 cohorts and will determine the Recommended Phase 3 dose (RP3D).||||
33978297|NCT06291636|||COHORT||RETROSPECTIVE|||||||
33978298|NCT04333706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978299|NCT00323947|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978300|NCT03737955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978301|NCT00530010|||COHORT||PROSPECTIVE|||||||
33978302|NCT05779449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33978303|NCT05624164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978304|NCT01599338|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33978305|NCT03316729|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Ascending doses in sequential cohorts (1-3) will be evaluated against placebo|t|f|t|f
33719855|NCT01477840||PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33719856|NCT05306054|||COHORT||CROSS_SECTIONAL|||||||
33719857|NCT03182829|||OTHER||PROSPECTIVE|||||||
33978306|NCT00925314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978307|NCT02739932|||COHORT||PROSPECTIVE|||||||
33978308|NCT01166568|RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-randomized arm was run in parallel with a randomized sub-study consisting of 2 arms; Immediate Treatment and Deferred Treatment. Upon completion of the 6 month observation period, the Deferred Treatment group then crosses over upon implantation to become part of the overall study group.||||
33978309|NCT00789425|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978310|NCT04051242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978311|NCT06145815|||COHORT||RETROSPECTIVE|||||||
33978312|NCT02495558|NA|SINGLE_GROUP||||NONE||||||
33894621|NCT03950986|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention is designed to target patients of primary care providers (physicians, physician assistants and nurse practitioners) in the Atlanta VA Medical System. Primary care providers will be assigned to a provider-side treatment (modified vaccine reminders in the electronic health record (EHR) system) or to control (existing vaccine reminders). Outcomes will be tracked for patients who have appointments with these providers.||||
33894622|NCT03880812|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomized in an intervention group that reviewed societal costs associated with carpal tunnel release and a control group that did not.||||
33894623|NCT00364793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978313|NCT01737671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894624|NCT06653166|||COHORT||RETROSPECTIVE|||||||
33894625|NCT01395238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894626|NCT06153862|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894627|NCT03185130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|By necessity the subject will be blinded but the RN administering the IV fluids will need to know the rate of infusion.|This will be a single center, prospective, single blinded randomized controlled trial on a convenience sample of patients presenting to the adult or pediatric ED with a chief complaint of headache.|t|f|f|f
33894628|NCT00428363|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33894629|NCT04438538|||COHORT||RETROSPECTIVE|||||||
33894630|NCT05113940|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33894631|NCT02622932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894632|NCT03263806|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894633|NCT04820192|||COHORT||RETROSPECTIVE|||||||
33894634|NCT05738863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Effects of Repetative Transcranial Magnetic Stimulation Therapy on Lower Urinary System Dysfunctions in Stroke Patients; A Randomized Study of Double Blind With Sham Control|t|f|f|t
33894635|NCT03982667|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33894636|NCT04924322|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The CRETE Studies are open-label with blinded endpoint. Systematic ultrasonographic assessment will be performed with the images blindly and centrally adjudicated.|Older children 1-17 years old and infants \<1 year old will be randomized separately. Older children will be randomized 2:1 to prophylactic dose of enoxaparin or control stratified by age. Infants will be randomized 1:1:1 to therapeutic dose of enoxaparin with high or low anti-Xa target or control stratified by age.|f|f|f|t
33978314|NCT06316609|||COHORT||PROSPECTIVE|||||||
33978315|NCT02000856|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978316|NCT00891475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978317|NCT00219297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978318|NCT03560557|||COHORT||PROSPECTIVE|||||||
33978319|NCT01616810|||OTHER||OTHER|||||||
33978320|NCT05060900|NA|SINGLE_GROUP||TREATMENT||NONE||All patients enrolled in the study will undergoing their ligament reconstruction procedure with allograft ligament.||||
33978321|NCT02217865|||COHORT||PROSPECTIVE|||||||
33978322|NCT03715270|||CASE_ONLY||PROSPECTIVE|||||||
33978323|NCT02467036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978324|NCT05240677|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33978325|NCT02053532|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978326|NCT03437083|||COHORT||RETROSPECTIVE|||||||
33978327|NCT03129269|NA|SINGLE_GROUP||OTHER||NONE||||||
33978328|NCT04885699|||COHORT||PROSPECTIVE|||||||
33978329|NCT01137695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978330|NCT01767064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33978331|NCT04894513|RANDOMIZED|PARALLEL||TREATMENT||NONE||control group which received conventional selected program, and study group received the same exercise training program in addition to Kabat motor control re-education therapy||||
33978332|NCT04690777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This pilot study is a controlled and randomized clinical trial (simple ER) with two groups in parallel, comparing the combination of a multi-component therapeutic exercise protocol (MS) versus vestibular exercises (EVs) in over 70 years. participants were randomly assigned to the therapeutic exercise group or the vestibular exercise group|f|t|t|f
33978333|NCT04312906|||COHORT||PROSPECTIVE|||||||
33978334|NCT01774474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33978335|NCT05743920|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33978336|NCT03738332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-and post design||||
33978337|NCT01550211|||CASE_CONTROL||PROSPECTIVE|||||||
33978338|NCT01093209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978339|NCT00188734|||COHORT||PROSPECTIVE|||||||
33978340|NCT00120900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978341|NCT00295178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33978342|NCT03508713|||COHORT||PROSPECTIVE|||||||
33978343|NCT02728037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978344|NCT02546973|||COHORT||CROSS_SECTIONAL|||||||
33978345|NCT00159965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978346|NCT01061164|||COHORT||PROSPECTIVE|||||||
33978347|NCT01611090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978348|NCT03978403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects are randomized to receive one of four treatment sequences of four open-label treatments 48 hours apart.||||
33978349|NCT06062771|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each eye will be randomly assigned to Test or Reference such as the subject has one eye treated with FIDIAL PLUS solution and the other with IAL-F solution. For all subjects the worst eye will be operated on first.|t|f|f|f
33978350|NCT00663871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33978351|NCT02580630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978352|NCT00002899|RANDOMIZED|||TREATMENT||||||||
33978353|NCT03717064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978354|NCT01493479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978355|NCT03199729|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled design to understand the mechanisms of adaptive interference and generalization, their interaction with retention, and how these can be applied to maximize training effects for minimizing falls-risk among older adults.||||
33978356|NCT03213210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766276|NCT04998305|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33894637|NCT05745727|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33894638|NCT03121690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894639|NCT02689700|||COHORT||PROSPECTIVE|||||||
33894640|NCT05742945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33894641|NCT05957874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is an experimental study with pretest and posttest control measurement and control group.|t|f|f|f
33894642|NCT05191212|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894643|NCT04945382|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A split mouth study design will be adopted , which consists of a simple division of the mouth into two parts (right and left) for the first four permanent molars of each patient, where the placement of the materials will be on the right / left side of the mouth and contralateral. They will then be randomly assigned following block randomization procedures with a 1: 1 allocation using the random block sizes of 4 and 8. A computerized random number generator and combinations will be used to select the tooth and material to be sealed first.|t|t|t|t
33894644|NCT04452643|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind placebo control|Double blind placebo control|t|t|t|f
33894645|NCT06010667|||COHORT||PROSPECTIVE|||||||
33894646|NCT00847613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894647|NCT02305433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894648|NCT05589493|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33894649|NCT01796457|||OTHER||PROSPECTIVE|||||||
33894650|NCT05366829|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm open-label phase II clinical trial to evaluate safety of the sequence of definitive therapy followed by Tislelizumab in participants with locally advanced unresectable hepatocellular carcinoma.||||
33894651|NCT03883061|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33894652|NCT02112448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894653|NCT03114761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894654|NCT03660501|||COHORT||PROSPECTIVE|||||||
33894655|NCT06189820|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33894656|NCT04203303|||COHORT||PROSPECTIVE|||||||
33894657|NCT04976465|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33894658|NCT06001580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894659|NCT03572374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894660|NCT05218213|||COHORT||CROSS_SECTIONAL|||||||
33894661|NCT01982630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894662|NCT00491530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894663|NCT05235646|||CASE_ONLY||PROSPECTIVE|||||||
33894664|NCT06540235|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The device setting order is randomized to the participant.||t|f|f|f
33766277|NCT02904902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766278|NCT03325140|||COHORT||PROSPECTIVE|||||||
33766279|NCT02117934|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766280|NCT05141903|||COHORT||PROSPECTIVE|||||||
33766281|NCT00019032||||TREATMENT||||||||
33766282|NCT05977920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||There is only one group.||||
33766283|NCT06428461|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||"Four different volumes will be administered for the supraclavicular block:~1. For the control group, we plan to use a mixture of 7.5 mL of 0.5% bupivacaine (BUVICAINE-POLIFARMA-TEKIRDAG) and 7.5 mL of 2% prilocaine (PRILOC-VEM İlaç San. ve Tic. A.Ş. Kapaklı/TEKIRDAĞ) for a total of 15 mL.~2. For the research group, we plan to use a mixture of 10 mL of 0.5% bupivacaine and 10 mL of 2% prilocaine for a total of 20 mL.~3. For the research group, we plan to use a mixture of 12.5 mL of 0.5% bupivacaine and 12.5 mL of 2% prilocaine for a total of 25 mL.~4. For the research group, we plan to use a mixture of 15 mL of 0.5% bupivacaine and 15 mL of 2% prilocaine for a total of 30 mL.~Glob axis and optic nerve sheath diameter measurements for both eyes will be re-measured and recorded using B-mode ultrasound at 20 and 60 minutes after the supraclavicular block."|t|t|f|t
33766284|NCT04435171|||COHORT||PROSPECTIVE|||||||
33766285|NCT00184483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766286|NCT01014975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766287|NCT00683280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894665|NCT04764812|||COHORT||PROSPECTIVE|||||||
33894666|NCT03892655|||CASE_ONLY||PROSPECTIVE|||||||
33894667|NCT05651646|NA|SINGLE_GROUP||OTHER||NONE||Stimfix Trail lead Anchor System for Dorsal Column Stimulator Trail Leads: A single-arm, Open-label, Multicenter (SECURE Study)||||
33894668|NCT04392414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978357|NCT02187042|||COHORT||PROSPECTIVE|||||||
33978358|NCT03094910|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978359|NCT05803746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978360|NCT06394102|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33766288|NCT02507882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766289|NCT00002502||||TREATMENT||||||||
33766290|NCT01118455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766291|NCT02650232|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33766292|NCT06624397|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||CAREFREE is a 12-session Carer's Programme for carers of adults with moderate to severe Anorexia Nervosa. This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE is based on a Schema Therapy - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.||||
33766293|NCT02190825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766294|NCT03191929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766295|NCT00994786|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33766296|NCT04293588|||COHORT||PROSPECTIVE|||||||
33766297|NCT05424224|||COHORT||PROSPECTIVE|||||||
33766298|NCT03455296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33766299|NCT02467322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766300|NCT01802814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766301|NCT02420145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33766302|NCT03542097|||COHORT||PROSPECTIVE|||||||
33766303|NCT01780129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766304|NCT05761574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Postoperative dental pain following third molar extraction.|t|f|t|f
33766305|NCT05646394|||COHORT||PROSPECTIVE|||||||
33766306|NCT03434457|||COHORT||PROSPECTIVE|||||||
33766307|NCT02238717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33766308|NCT04710043|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766309|NCT02035332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766310|NCT01533571|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766311|NCT06623058|||COHORT||PROSPECTIVE|||||||
33766312|NCT02424409|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766313|NCT02479516|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33766314|NCT04496141|||COHORT||RETROSPECTIVE|||||||
33766315|NCT06203652|||COHORT||OTHER|||||||
33766316|NCT04576819|||COHORT||PROSPECTIVE|||||||
33766317|NCT02990416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766318|NCT00412633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766319|NCT01872130|||COHORT||PROSPECTIVE|||||||
33766320|NCT03758014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33766321|NCT06425926|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766322|NCT03736564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766323|NCT01965158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766324|NCT01764763|||COHORT||RETROSPECTIVE|||||||
33766325|NCT04811963|||OTHER||PROSPECTIVE|||||||
33766326|NCT06615505|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"The following individuals should be blinded in the ASCEND Clinical Trial:~Participants: when randomized into the trial, the patient will consent to be blinded to the type of treatment they will receive~Outcome assessors:~* Clinicians (sub-Is) completing the physical or neurological examination~* Study coordinator administering patient-reported outcomes and collecting other participant data"|"At the 12-week follow-up, all participants will remain blinded and will be given the option to be considered for crossover. Only participants allocated to the needle sham control group will be given the option to crossover into the VIA Disc NP group at the 12-week visit if they meet the following requirement:~The participant has not experienced at least a 30% reduction in pain severity as determined by their 12-week VAS score~Sham participants who crossover into the VIA Disc NP group will receive an injection of VIA Disc NP and continue in the study."|t|f|f|t
33766327|NCT00615134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766328|NCT05516368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766329|NCT02704897|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33978361|NCT05108623|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766330|NCT05981963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766331|NCT01126554|||COHORT||PROSPECTIVE|||||||
33766332|NCT01981421|||CASE_ONLY||PROSPECTIVE|||||||
33978362|NCT01612390|||CASE_CONTROL||PROSPECTIVE|||||||
33978363|NCT04360811|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33766333|NCT03788005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766334|NCT04506749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766335|NCT02863718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766336|NCT05598177|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33766337|NCT00000561|RANDOMIZED|||TREATMENT||||||||
33766338|NCT03811106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will not know the applications|Randomized Controlled|t|f|f|f
33766339|NCT04203537|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part A: dose ascending, placebo-controlled Part B: randomized, double-blind, placebo-controlled, parallel design|t|t|t|t
33766340|NCT04530357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33766341|NCT02599103|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33766342|NCT01108835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766343|NCT02057744|||CASE_CONTROL||PROSPECTIVE|||||||
33766344|NCT02348398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766345|NCT04741802|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33766346|NCT01861821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766347|NCT01007890|||COHORT||PROSPECTIVE|||||||
33766348|NCT05713604|||COHORT||PROSPECTIVE|||||||
33766349|NCT03697980|||COHORT||PROSPECTIVE|||||||
33766350|NCT03739294|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33766351|NCT05754684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766352|NCT03469349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766353|NCT03486587|NA|SINGLE_GROUP||PREVENTION||NONE||a single-arm, single-institutional, phase II study||||
33766354|NCT01777321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766355|NCT01008475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766356|NCT03808337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766357|NCT02283359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766358|NCT05838924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766359|NCT05385302|||COHORT||PROSPECTIVE|||||||
33978364|NCT06464328|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978365|NCT03856970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978366|NCT02060006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978367|NCT00148915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978368|NCT03493126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978369|NCT02363907|||COHORT||PROSPECTIVE|||||||
33978370|NCT05456074|||COHORT||RETROSPECTIVE|||||||
33978371|NCT00614549|||COHORT||PROSPECTIVE|||||||
33978372|NCT03093909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978373|NCT02427685|||||PROSPECTIVE|||||||
33978374|NCT01204580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978375|NCT04015232|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study staff taking care of subject's safety and the laboratory personnel doing the sample analysis of PK, PD, and immunogenicity data were blinded||f|f|f|t
33978376|NCT03883607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978377|NCT05991661|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33978378|NCT03034226|RANDOMIZED|CROSSOVER||PREVENTION||NONE||9 diabetic subjects and 9 healthy control subjects will be randomized to undergo either first day 1 + day 2 (two consecutive episode of hypoglycemia) or first day 3 + day 4 (one episode of hypoglycemia).||||
33766360|NCT00399763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766361|NCT06213194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To reduce biases, a single-blind procedure will be applied. It will be provided basic information about topics including social-cognitive skills and mental health but no detailed description of training will be given.|All participants would be assigned randomly to the experimental group and control group (wait-list condition) to see whether the combined training program is effective for the general population.|t|f|f|f
33766362|NCT05250401|||CASE_CONTROL||PROSPECTIVE|||||||
33766363|NCT06382909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Double blind, randomized, with placebo control||||
33766364|NCT06243107|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Quasi-experimental research|f|f|f|t
33766365|NCT00274001|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33766366|NCT01441817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894669|NCT06332443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The group assignment will be given to the intraoperative anesthesia team by writing, by a research team member who will not participate in postoperative assessments. The intraoperative anesthesia team will not be blinded to the group assignment, but surgeons, patients, and assessors will be blinded. For the SA group, a sham epidural catheter will be placed on the patient's back by the anesthesia team in order to keep the surgeons, patients and assessors blind to the randomization group.|This study is a RCT with two parallel treatment groups: THA/TKA with single-shot SA group and THA/TKA with SED-EA group|t|f|t|t
33894670|NCT05443022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The placebo group will have a simulation of application of the laser, with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off. In the group that receives the photobiomodulation the device will have its timer turned off, to avoid the perception of sound difference.||t|f|f|f
33894671|NCT02331264|||CASE_CONTROL||PROSPECTIVE|||||||
33894672|NCT06143384|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33978379|NCT06014411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33978380|NCT01100749|||CASE_ONLY||PROSPECTIVE|||||||
33978381|NCT02837822|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33978382|NCT01493908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978383|NCT03712722|||COHORT||PROSPECTIVE|||||||
33978384|NCT04047095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33978385|NCT02815969|||COHORT||PROSPECTIVE|||||||
33978386|NCT05984771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator and examiner did not know the type of drug provided|pilot study|t|t|t|t
33978387|NCT00091598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025586|NCT04731246|NA|SINGLE_GROUP||OTHER||NONE||"Prospective, descriptive, interventional, monocentric study. Participants perform an annual evaluation, which combine neurological and neuropsychological evaluations and a video-oculography examination.~Follow-up is carried out over 7 years."||||
34076969|NCT00775762|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34076970|NCT01548352|||COHORT||PROSPECTIVE|||||||
33766367|NCT03383159|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33766368|NCT06619730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33766369|NCT04515121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766370|NCT04122235|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A multicenter controlled clinical trial of individualized nurse/physician-led follow-up (treatment group) versus standard care (control group) in approximately 754 women treated for gynecological cancer||||
33766371|NCT06625801|||COHORT||PROSPECTIVE|||||||
33766372|NCT01973036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766373|NCT00152009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076971|NCT00541567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076972|NCT01398852|NA|SINGLE_GROUP||OTHER||NONE||||||
33766374|NCT04877093|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The pharmacist will determine the groups for each patient and will not reveal groups to anyone on the study team or the participant until they have finished the trial.|Randomized, placebo-controlled, blinded crossover|t|t|t|t
33766375|NCT01654991|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33766376|NCT02581332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766377|NCT04000594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766378|NCT04181840|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766379|NCT03075241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766380|NCT01129505|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33766381|NCT06416813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766382|NCT03634501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766383|NCT04275843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|As this is feeding study with two very much different diets, participants and investigators were not blinded. The Core facilities that are analyzing de-identified coded samples and remain blinded to treatments.||f|f|f|t
33766384|NCT05016544|NA|SEQUENTIAL||TREATMENT||NONE||Sequential assignment by traditional 3+3 dose escalation||||
33766385|NCT03711474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded (participant and investigator)|Randomized; double blinded (participant and investigator)|t|f|t|f
33766386|NCT04278378|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33766387|NCT00102479|RANDOMIZED|||TREATMENT||NONE||||||
33766388|NCT03806504|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||prospective, randomized|t|f|t|f
33766389|NCT00621296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766390|NCT04404088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766391|NCT02192775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766392|NCT04437225|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Subject will undergo the gold-standard technique of steady-state intravenous infusion of 13-glycolate administration. Selected subjects will also undergo other modified modalities of 13-glycolate administration.||||
33766393|NCT03560245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible subjects will be stratified based on Mini Mental State Exam (MMSE-2) scores 4-9 vs. 10-15 and will be randomized 1:1 to one of two treatment arms: 20µg bryostatin or placebo for twelve weeks (7 doses).|t|t|t|t
33766394|NCT06361667|RANDOMIZED|PARALLEL||TREATMENT||NONE||"We will follow standard practice for RCTs and apply an ANCOVA model to estimate the effects of treatment. The formalism is:~y \~ b0 + b1xtreatment_group + b2xtime + b3xtreatment_groupxtime + covariates (1)~Where, y is each outcome, b1-b3 are the regression coefficients and covariates denotes covariates at randomisation (DETERMINE)~The inference of interest for the model concerns b3, the interaction term, as we posit that there will be a difference in slopes between the treatment groups.~The inference is going to happen via an estimation of the t-statistic, defined as follows~t = b3/SE (2)~Where SE is the standard error for coefficient b3~t \> 1.96 (3)~And 1.96 is the critical value for statistical significance at alpha = 0.05."||||
33766395|NCT00960752|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33766396|NCT03659253|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33766397|NCT02487550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766398|NCT05201222|||COHORT||RETROSPECTIVE|||||||
33766399|NCT02536001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766400|NCT00157807|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33766401|NCT04804774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894673|NCT04513145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the investigator and participant will be blinded to the injection administered perioperatively||t|f|t|f
33894674|NCT02211339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An experimental parallel group design|f|f|f|t
33894675|NCT03457298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894676|NCT00257127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894677|NCT06337201|||OTHER||OTHER|||||||
33894678|NCT04714112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894679|NCT01172080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894680|NCT02858479|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894681|NCT01972646|||COHORT||PROSPECTIVE|||||||
33894682|NCT01697332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894683|NCT01495871|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33894684|NCT02845869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33894685|NCT04783207|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33894686|NCT03429075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894687|NCT06656741|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894688|NCT04242030|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33766402|NCT05633407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766403|NCT05304715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a prospective, 1:1 randomized, double-blind, placebo-controlled trial|t|t|t|t
33766404|NCT03355755|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm safety and feasibility study.||||
33766405|NCT02076074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766406|NCT02372864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766407|NCT02873026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766408|NCT06329674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766409|NCT02206022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33766410|NCT06220383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was performed by a computer-generated random sorting sequence|Randomized controlled, double-blind clinical trial|t|f|f|t
33766411|NCT04139148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766412|NCT01059513|||OTHER||OTHER|||||||
33766413|NCT04762225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894689|NCT03783156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34076973|NCT04710238|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34076974|NCT04907292|||COHORT||PROSPECTIVE|||||||
34076975|NCT03163719|||OTHER||PROSPECTIVE|||||||
34076976|NCT05173077|||COHORT||PROSPECTIVE|||||||
34103508|NCT06687577|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to DBT or to treatment as usual (TAU)||||
34076977|NCT05545423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|instrument-assisted soft tissue mobilization and traditional therapy|f|f|t|t
33766414|NCT04095221|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single institution study to determine the recommended phase 2 dose of prexasertib when given in combination with irinotecan and temozolomide. Patients with relapsed or refractory desmoplastic small round cell tumor or rhabdomyosarcoma of any subtype will receive prexasertib using the 3+3 dose-escalation schema.||||
33766415|NCT06150846|||CASE_ONLY||CROSS_SECTIONAL|||||||
33766416|NCT02820805|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34076978|NCT05985057|||COHORT||RETROSPECTIVE|||||||
34076979|NCT02492893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34076980|NCT02104076|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34076981|NCT03534167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076982|NCT02348697|||CASE_ONLY||PROSPECTIVE|||||||
33766417|NCT03862196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|After consenting, participants will be randomly assigned to the intervention or control with a 1:1 ratio and random block sizes of 2 and 4 using computer generated random numbers. Block sizes will not be disclosed. Allocations will be sealed in individual, sequentially numbered opaque envelopes. The RECRUITER, who will be masked to the group assignment, will give instructions to all participants on how they should interact if they start receiving SMS. After completing the baseline survey, one of the principal investigators will assign the participant to a group by opening the corresponding envelope. The PI will report to one of trained providers in charge of delivering the intervention (different from recruiters) when a new participant of the intervention arm is enrolled. Because of the nature of the participation, providers and participants will not be masked to group assignment.|Randomized controlled pilot study with a parallel 2-arm design.The intervention arm will receive 2 tailored text messages weekly from a trained counselor during 3 months. The control arm will receive the standard of care, which consists of pre and post counseling after the HIV diagnosis and referral to a health facility to start antiretroviral treatment.|f|t|f|f
33766418|NCT03061448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894690|NCT04616586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"At all times, randomized study treatment assignment information will be kept confidential and will not be released to the patient, investigator, the study staff (except the pharmacist), or the Sponsor's Study Team until following the conclusion of the study, except as described below.~At the initiation of the study, the study site will be instructed on procedures for breaking the blind. Blinding codes should be broken only in emergency situations for reasons of patient safety. If a patient has an AE that may be considered treatment-related, treatment for the AE should be administered as if the patient is receiving siltuximab. Whenever possible, the investigator should contact the Sponsor's Medical Monitor before breaking the blind. When the blind for a patient has been broken, the reason must be fully documented. The patient for whom the blind has been broken will not receive further doses of study treatment."|This is a prospective, multicenter, randomized (2:1), double-blind, parallel-arm, placebo-controlled, Phase 3 clinical trial of 1-3 doses of siltuximab 11 mg/kg IV over 1 hour plus SOC vs. matched-volume normal saline (NS) IV over 1 hour plus SOC in 555 patients with SARS-CoV-2 previously treated with corticosteroids or another respiratory virus infection with elevated CRP levels who have developed serious respiratory complications|t|t|t|t
33894691|NCT06656897|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894692|NCT01896232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894693|NCT06322381|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894694|NCT05786170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766419|NCT05431634|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33766420|NCT05318534|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33766421|NCT01992705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766422|NCT06172608|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33766423|NCT06625359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766424|NCT03692221|RANDOMIZED|PARALLEL||TREATMENT||NONE||24 participants will be equally randomized into two groups; 12 Healthy controls subjects \& 12 treatment subjects. The treatment group will then be sub-divided and randomized into 6 subjects receiving a low dosage treatment and 6 subjects receiving a high dosage treatment||||
33766425|NCT03062059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766426|NCT03651063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3 groups, two groups each have a different intervention program, one control group with no intervention, only standard care.|t|f|f|t
33766427|NCT00977496|||COHORT||PROSPECTIVE|||||||
33766428|NCT02128256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766429|NCT02419729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766430|NCT03581123|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||2x2 factorial design|f|f|t|t
33766431|NCT05039879|||COHORT||PROSPECTIVE|||||||
33766432|NCT05036928|||COHORT||PROSPECTIVE|||||||
33766433|NCT02568579|||COHORT||PROSPECTIVE|||||||
33766434|NCT01032044|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33766435|NCT02091739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766436|NCT00003344||||TREATMENT||||||||
33766437|NCT03820479|||COHORT||PROSPECTIVE|||||||
33894695|NCT05793567|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33894696|NCT04945655|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Multicentre cluster randomized controlled trial using an incomplete factorial design||||
33894697|NCT05437796|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The purpose of this study is to evaluate the effectiveness of hypnotic virtual reality support on the patient's state of anxiety before and after prosthetic knee surgeries under spinal anesthesia.||||
33894698|NCT01420575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894699|NCT04536194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33894700|NCT04887298|NA|SEQUENTIAL||TREATMENT||NONE||||||
33894701|NCT06655948|||COHORT||PROSPECTIVE|||||||
33894702|NCT01179529|NA|SINGLE_GROUP||TREATMENT||||||||
33894703|NCT02986373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894704|NCT05178537|||COHORT||PROSPECTIVE|||||||
33894705|NCT00533000|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33894706|NCT00094120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766438|NCT04772053|NA|SINGLE_GROUP||OTHER||NONE||||||
33766439|NCT06432660|||COHORT||PROSPECTIVE|||||||
33766440|NCT04813601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766441|NCT01691196|||COHORT||CROSS_SECTIONAL|||||||
33766442|NCT01468779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766443|NCT04454086|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33766444|NCT05716620|||CASE_ONLY||PROSPECTIVE|||||||
33766445|NCT05434221|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33894707|NCT04723030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894708|NCT00000312||||TREATMENT||||||||
33894709|NCT03265691|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33894710|NCT05952414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33894711|NCT01844076|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33894712|NCT03062501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894713|NCT04930939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and assessors recoding the outcome measurements were blinded to the group allocations|Parallel assignment, two groups randomly assigned|t|f|f|t
33894714|NCT02721862|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894715|NCT05794529|||COHORT||OTHER|||||||
33894716|NCT03344835|||COHORT||OTHER|||||||
33894717|NCT00468715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894718|NCT04012255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894719|NCT01590329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894720|NCT00586690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894721|NCT04684030|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized controlled, single-center clinical study. Patients will randomized 1:1 to either CGMS or conventional self-monitoring of blood glucose (SMBG) group.||||
33894722|NCT02032524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894723|NCT01998607|||OTHER||CROSS_SECTIONAL|||||||
33894724|NCT00109421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894725|NCT03918512|||CASE_CONTROL||PROSPECTIVE|||||||
33894726|NCT04831450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894727|NCT01797523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894728|NCT01173653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894729|NCT00222508|||||PROSPECTIVE|||||||
33894730|NCT05268848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33894731|NCT01793987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894732|NCT01167127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894733|NCT00509106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894734|NCT02966457|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33894735|NCT00659438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894736|NCT02279316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33894737|NCT02111538|||CASE_ONLY||PROSPECTIVE|||||||
33894738|NCT02179554|||COHORT||PROSPECTIVE|||||||
33894739|NCT00631462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894740|NCT02032953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894741|NCT05077761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894742|NCT06037655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894743|NCT03864276|RANDOMIZED|PARALLEL||OTHER||TRIPLE|patients will be randomly allocated to 2 groups using computer-generated randomization method. Care provider will not be blinded to the group allocation, because anesthesiologists should be aware of the method of anesthesia.|Arm 1: inhalation anesthesia (desflurane) group Arm 2: total intravenous anesthesia (propofol) group|t|f|t|t
33894744|NCT02799199|||COHORT||RETROSPECTIVE|||||||
33894745|NCT00318955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894746|NCT01061489|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894747|NCT01179295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894748|NCT00003956||||TREATMENT||||||||
33894749|NCT03280329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894750|NCT01309516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34076983|NCT02738359|||COHORT||PROSPECTIVE|||||||
33894751|NCT00919659|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33894752|NCT02113657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894753|NCT01183494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894754|NCT01814423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894755|NCT05290220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894756|NCT03389672|||CASE_ONLY||PROSPECTIVE|||||||
33894757|NCT06197126|||COHORT||PROSPECTIVE|||||||
33894758|NCT02464631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894759|NCT03237676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants are randomised on treatment arm. Co-investigators are blinded from knowing which participant receives which treatment arm.~Cognitive outcome assessor is blinded from knowing which participant receives which treatment arm."|intervention group receives structured cognitive rehabilitation therapy, control group receives conventional/pre-existing cognitive rehabilitation therapy.|t|f|t|t
33894760|NCT06655883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894761|NCT06278636|||OTHER||PROSPECTIVE|||||||
33894762|NCT04030130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894763|NCT03803215|||CASE_CONTROL||PROSPECTIVE|||||||
33894764|NCT01710761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33894765|NCT05698186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894766|NCT05178901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind for placebo-controlled portion; open label for Booster advance subset; single blind for remaining Booster||t|t|t|t
33894767|NCT05931770|||COHORT||PROSPECTIVE|||||||
33894768|NCT03333577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894769|NCT05076422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33894770|NCT06488118|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33894771|NCT04815096|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single center exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants 18 years of age and older with recent SARS-CoV-2 diagnosis and COVID-19 at least 14 days following onset of symptoms.||||
33894772|NCT00783640|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33894773|NCT00497224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894774|NCT05809687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33894775|NCT00302692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894776|NCT05352191|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|placebo||t|t|t|t
33894777|NCT00374556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33894778|NCT02509962|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894779|NCT03898934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and gynecologists were binded|The 2 groups will be treated at the same time|t|t|f|f
33894780|NCT06346795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894781|NCT02646475|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33894782|NCT01907685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894783|NCT06533592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894784|NCT03243903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894785|NCT01153490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894786|NCT01978561|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33894787|NCT00378846||||DIAGNOSTIC||||||||
33894788|NCT01089855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894789|NCT00608088|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33894790|NCT03734510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894791|NCT01489150|||CASE_ONLY||PROSPECTIVE|||||||
33894792|NCT04100525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were informed that they would receive feedback but were not told whether it would be in person or by phone until after randomization. Participants were not informed that only one group received case management calls.||t|f|f|f
33894793|NCT04001686|||OTHER||OTHER|||||||
33894794|NCT03216616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894795|NCT00147927|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894796|NCT05695547|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894797|NCT02675777|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33894798|NCT00221091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894799|NCT06407856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894800|NCT05749588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894801|NCT02500550|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33978388|NCT03378700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The principal investigator and the nurse providing the intervention are aware of the patient group assignment. Assessment of the baseline and endpoints of the patient outcomes will be performed by an independent research assistant blinded to group allocation, who was not involved in the intervention.|This study is a single-blinded randomised controlled trial. On completion of the baseline assessment and the screening procedure, eligible participants will be randomly assigned in equal number into either a brief hope intervention (BHI) or the control group using sets of computer-generated random numbers.|f|f|f|t
33978389|NCT03209570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978390|NCT00824265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978391|NCT02363790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978392|NCT06056479|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978393|NCT03676803|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33978394|NCT01802502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978395|NCT05192005|||COHORT||RETROSPECTIVE|||||||
33978396|NCT03991156|||COHORT||PROSPECTIVE|||||||
33978397|NCT00079170||||TREATMENT||NONE||||||
33894802|NCT03981029|||COHORT||CROSS_SECTIONAL|||||||
33894803|NCT06082336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894804|NCT01103739|RANDOMIZED|PARALLEL||||NONE||||||
33894805|NCT05011461|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894806|NCT03968965|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single center, prospective, randomized cohort study.||||
33894807|NCT01605474|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894808|NCT03836144|||CASE_CONTROL||PROSPECTIVE|||||||
33894809|NCT01284192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894810|NCT03842137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33894811|NCT00460928|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33894812|NCT04297007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anesthesiologist who performs postoperative pain evaluation will not know the group.|There are three models for this study. Patients will be randomly divided into three groups (Group P = PECS group, Group R = RIB group, Group C = Control group), before entering the operating room.|f|f|f|t
33894813|NCT04635176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"The study personnel, including research team, anesthesiologists, surgeons, physiotherapists, recovery room and ward nurses, as well as patients will be blinded to the group allocation. Anesthesia assistants not involved in study data collection or patient care will prepare the sham or real local anesthetic injectate solution for iPACK block. Syringes will be prepared immediately after randomization and before block placement and provided to the blinded anesthesiologist.~The statistician who run randomization would only know study IDs and stay blinded to patients' treatment arms."|Group A will receive perioperative ACB, LIA, and sham IPACK block. Group B will receive perioperative ACB, LIA, and real IPACK block.|t|t|t|t
33894814|NCT01585389|||CASE_ONLY||RETROSPECTIVE|||||||
33894815|NCT05452382|||COHORT||RETROSPECTIVE|||||||
33894816|NCT05343390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants and investigators will not be masked. For fidelity assessments, those coding audio recordings will be masked with respect to study arm.|This is a cluster randomized control trial with 2:1 randomization (standard: enhanced).|f|f|f|t
33894817|NCT02397655|||CASE_ONLY||CROSS_SECTIONAL|||||||
33894818|NCT03068559|||CASE_ONLY||PROSPECTIVE|||||||
33894819|NCT04375878|RANDOMIZED|CROSSOVER||TREATMENT||NONE||2, 2x2 Crossover||||
33894820|NCT03139370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894821|NCT04856761|||COHORT||PROSPECTIVE|||||||
33894822|NCT01147783|||COHORT||PROSPECTIVE|||||||
33894823|NCT05999305|RANDOMIZED|PARALLEL||OTHER||NONE||Two teaching methods in the Critical Care Nursing course will be implemented including the conventional teaching combining an escape room game and the conventional class with case-based teaching.||||
33894824|NCT05671003|||COHORT||CROSS_SECTIONAL|||||||
33894825|NCT06143631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894826|NCT05875168|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33894827|NCT00825071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33894828|NCT03431389|RANDOMIZED|PARALLEL||TREATMENT||NONE||Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre. The patients were followed up daily until discharge from ICU. The following items were recorded: Duration of application of tracheostomy tube before decannulation (cannulation time), complications of tracheostomy, mortality due to tracheostomy.||||
33894829|NCT05110066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894830|NCT04439734|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Outcomes assessor were unaware of participants status (i.e. WB-EMS or control) and were not allowed to ask correspondingly|Randomized controlled trial with two study groups in parallel: (1) Whole body electromyostimulation (WB-EMS) or 16 weeks (b) non WB-EMS control|f|f|t|t
33894831|NCT00708396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894832|NCT02466256|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33894833|NCT06229509|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33894834|NCT05553132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894835|NCT04177498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894836|NCT06656936|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|This is a pragmatic trial, so study participants and the investigator team will be unblinded to study procedures, however, the outcomes assessors (biostatistical team) will be blinded to arm assignments.|Participants are assigned to one of two or more groups in parallel for the duration of the study|f|f|f|t
33894837|NCT04108767|||COHORT||CROSS_SECTIONAL|||||||
33894838|NCT03163342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open label||||
33894839|NCT00313430|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33894840|NCT04462237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894841|NCT05772364|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33894842|NCT04661813|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single arm hybrid type 3 implementation study||||
33978398|NCT01798069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33894843|NCT04630054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The intervention involves wearing a face mask so participants will know if they are in the intervention group. The investigators will be blinded as to intervention assignment.||f|f|t|f
33894844|NCT00606515|RANDOMIZED|PARALLEL||||NONE||||||
33894845|NCT05213169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind trial|Apomorphine treatment or placebo|t|f|t|t
33894846|NCT04722718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894847|NCT05928143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894848|NCT01288183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894849|NCT06489418|NA|SINGLE_GROUP||OTHER||SINGLE||A prospective, control-arm, site randomized, evaluator-blinded, single-centre, safety, and efficacy study.|f|f|f|t
33894850|NCT01029561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894851|NCT00454233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894852|NCT02256358|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33894853|NCT04987203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894854|NCT02957773|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33894855|NCT00099671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33894856|NCT05927454|||COHORT||PROSPECTIVE|||||||
33894857|NCT05712824|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894858|NCT04036617|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33894859|NCT03004560|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33894860|NCT01408238|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894861|NCT01242111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978399|NCT04194866|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33978400|NCT04714658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33894862|NCT03010189|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33894863|NCT06143410|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|computered randomisation, sealed enveloppes linisol versus placebo prepared by anesthesist not involved in the study or in patient care||t|t|t|t
33894864|NCT01616914|||COHORT||PROSPECTIVE|||||||
33894865|NCT04113629|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Sequential Assignment||||
33978401|NCT00265733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894866|NCT02085655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894867|NCT03941444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||36 participants: 3 PK open-label followed by 33 double-blind, randomized, placebo-controlled|t|t|t|t
33894868|NCT01275638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894869|NCT00195351|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894870|NCT06178640|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33894871|NCT04287153|NA|SINGLE_GROUP||TREATMENT||NONE||Assessment of the effectiveness and tolerance of cryotherapy in the thinning of the abdomen and saddelbags||||
33894872|NCT03545243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective interventional study with study procedures at inclusion, after a baseline period of 4 weeks and Pantoprazole therapy for 4 weeks||||
33894873|NCT03729180|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33894874|NCT06246682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978402|NCT03803865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcomes assessor will remain masked to which program the participant will use. However the experimenter will be helping set up the participants with the app content and thus will not be masked to condition.||f|f|f|t
33978403|NCT04407221|||COHORT||PROSPECTIVE|||||||
34076984|NCT03995888|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Positron Emission Tomography (PET) Imaging study||||
34076985|NCT01519011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076986|NCT06406335|NA|SINGLE_GROUP||PREVENTION||NONE||To measure the impact of a multidimensional health education program on patients' adherence to the healthy life style and behavioral therapy , and to correlate it with severity of ADHD symptoms.||||
34076987|NCT04632277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33719858|NCT01132404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719859|NCT03564847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers doing outcome assessment will be kept blind to the group allocations||f|f|f|t
33894875|NCT02849769|||COHORT||PROSPECTIVE|||||||
33894876|NCT04881539|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A person who does not interact with the study participants will be completing the masking.|Study participants will be randomly assigned to either a CBD group or a placebo group and followed throughout the 8 week intervention period.|t|f|t|f
33894877|NCT04034615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33894878|NCT03999970|RANDOMIZED|PARALLEL||OTHER||NONE||Clinical study||||
33894879|NCT03368859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894880|NCT04143503|||COHORT||PROSPECTIVE|||||||
33894881|NCT01123889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894882|NCT01397344|||CASE_ONLY||CROSS_SECTIONAL|||||||
33894883|NCT04515836|NA|SEQUENTIAL||TREATMENT||NONE||||||
33894884|NCT02333708|||CASE_CONTROL||PROSPECTIVE|||||||
33894885|NCT03853694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894886|NCT06236217|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894887|NCT04557904|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894888|NCT05480514|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Brand masking: subjects, investigators, and clinical site personnel will be unaware of the identity (brand) of both study lenses.|||||
33894889|NCT00903084|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33894890|NCT05955742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and statistician were blind to the groups but the operator who performed all treatment procedures could not be blinded to the study group owing to the study design.|Group 1: control Group 2: ProGlider Group 3: WaveOne Gold Glider|t|f|f|t
33894891|NCT03840629|||COHORT||RETROSPECTIVE|||||||
33894892|NCT00444184|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33894893|NCT04490057|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential multiple assignment randomized trial||||
33894894|NCT03067220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33894895|NCT06656247|||COHORT||PROSPECTIVE|||||||
33894896|NCT02152969|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33894897|NCT02980614|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894898|NCT02112110|NA|SINGLE_GROUP||||NONE||||||
33894899|NCT01468519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894900|NCT00843401|||COHORT||PROSPECTIVE|||||||
34076988|NCT01190085|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34076989|NCT05418803|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34076990|NCT04531748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Medical Safety Officer will not be blinded.||t|t|t|t
34103509|NCT04019704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103510|NCT03737890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766446|NCT03325205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766447|NCT01905254|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33766448|NCT04169919|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1 modified method Group 2 ordinary method||||
33766449|NCT02974530|||COHORT||PROSPECTIVE|||||||
34076991|NCT04036721|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization is 1:1 to Arms A and B, it will be conducted using adaptive minimization method. the randomization will be stratified upon three criteria:~1. severity of suspected pneumonitis at baseline (G2 vs. G3-4)~2. response for oncological treatment (PR and CR vs. SD and PD) 3) chronic respiratory system disorders The first patient will be randomized to Arm A or B with simple randomization method using computer program, this part will be oversight by medical monitor. The randomization will be performed for each patient by Primary Investigator."||||
34076992|NCT04356469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766450|NCT02875834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766451|NCT01556698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766452|NCT03313102|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33766453|NCT01377558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33766454|NCT01779479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766455|NCT01119014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766456|NCT00981396|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766457|NCT02111226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766458|NCT03056664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766459|NCT06625190|NA|SEQUENTIAL||TREATMENT||NONE||||||
33766460|NCT02122653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766461|NCT00206154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766462|NCT03086018|NA|SINGLE_GROUP||TREATMENT||NONE|The hardware will be obviously different from the control devices and impossible to blind.|A single group, controlled test design will be used. There are various aspects of testing including lab and field tests.||||
33766463|NCT02260505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766464|NCT03607825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766465|NCT03846414|||COHORT||PROSPECTIVE|||||||
33766466|NCT00621972|||COHORT||PROSPECTIVE|||||||
33894901|NCT01870492|||COHORT||RETROSPECTIVE|||||||
33894902|NCT02835495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33894903|NCT03709615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766467|NCT03987126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No other parties will be masked for the study. A part of the study will be open label.|One placebo arm and one active treatment arm, participants will be assigned to each arm equally based on their Neurogenic Bowel Dysfunction score.|t|t|t|f
33766468|NCT01720784|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33766469|NCT01751230|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33766470|NCT00077311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766471|NCT03429790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978404|NCT06149936|||CASE_CONTROL||PROSPECTIVE|||||||
33978405|NCT02554864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33766472|NCT03555630|||OTHER||CROSS_SECTIONAL|||||||
33766473|NCT04117269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766474|NCT03556358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766475|NCT02961881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766476|NCT06525558|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978406|NCT04043065|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Day A and B will be conducted in a randomised, double-blinded order (blinded for the participant and the investigator) and noted by a third person not participating in the collection or analyses of data. The infusion order will be opened after the primary data analyses.|The study is designed as a clinical, placebo-controlled, double-blinded cross-over study involving two experimental study days.|t|f|t|f
33766477|NCT00005028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894904|NCT03319550|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"The three different protein supplements will be fabricated with the same taste, colour and weight. They will be named A, B and C and the investigator will not know which protein is which until all data has been collected and analysed."|"Interventions\*:~I. LPS (1 ng/kg as bolus) + 36 h fasting + 36 h bedrest + Casein~II. LPS (1 ng/kg as bolus) + 36 h fasting + 36 h bedrest + Whey~III. LPS (1 ng/kg as bolus) + 36 h fasting + 36 h bedrest + Leucine-enriched whey~\* LPS will be administered on study day 1 and measurements of metabolism will be performed on study day 2 where we see the secondary effects of acute inflammation. The patient will stay at the hospital over night to ensure continues fast and bedrest.~The beverages will be isocaloric and with the same total protein content. The basal period will be 2,5 hour with infusion of tracer. Hereafter a total amount of 0,6 g protein/kg bodyweight will be orally administered, 1/3 as a bolus and 2/3 as sipping over 3,5 hours. Muscle biopsies and blodsampels will be collected during both the basal and the sipping period."|t|f|t|f
33894905|NCT04032366|||COHORT||PROSPECTIVE|||||||
33894906|NCT05797129|||COHORT||PROSPECTIVE|||||||
33978407|NCT01955590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978408|NCT02697903|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33978409|NCT00459888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978410|NCT00444145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978411|NCT02184130|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978412|NCT03956264|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34076993|NCT05653947|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34076994|NCT04884347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076995|NCT05119595|||COHORT||PROSPECTIVE|||||||
33894907|NCT01334073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894908|NCT03397836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894909|NCT05268380|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33894910|NCT02240134|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33894911|NCT04726306|||OTHER||PROSPECTIVE|||||||
33894912|NCT01457248|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33894913|NCT01881555|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33894914|NCT00528229|||||OTHER|||||||
33894915|NCT05647993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894916|NCT03638011|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, randomized study evaluating the effectiveness of abdominal analgesia when using 266 mg EXPAREL delivered into the bilateral TAP blocks. TAP blocks are an excellent method for providing adequate analgesia following lower abdominal surgery.~Those patients who wish to participate will be asked to sign a study consent form. Patients that decide to participate in this study will be randomized to either group 1 or group 2 (like the flip of a coin). Both groups will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control."||||
33894917|NCT04432428|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentric interventional prospective cohort study||||
33894918|NCT04222985|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33894919|NCT01965925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766478|NCT04812613|||OTHER||PROSPECTIVE|||||||
33766479|NCT02490358|||||CROSS_SECTIONAL|||||||
33766480|NCT06625879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766481|NCT04114747|RANDOMIZED|PARALLEL||PREVENTION||NONE||To describe renal physiology parameters when starting CRRT and compare renal physiology parameters when using high blood pressure target (MAP 80-90 mmHg) and low blood pressure target (MAP 60-70 mmHg).||||
33766482|NCT03657459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Documentation of enrollment will not include group assignment Investigator will be blinded from group assignment via a separate excel file with that detail|Randomized, controlled prospective trial|f|t|t|f
33766483|NCT06369246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766484|NCT01333878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766485|NCT04492150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33766486|NCT01126060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766487|NCT00750282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766488|NCT02980003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33894920|NCT02242279|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33894921|NCT03146312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33894922|NCT04025840|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|For dexamethasone administration, all the participants, care providers, investigators, and outcomes assessors are masked. For epidural block, outcome assessors are masked.|2×2 factorial trial|f|f|f|t
33894923|NCT04038333|||CASE_ONLY||CROSS_SECTIONAL|||||||
33894924|NCT05283733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978413|NCT05293990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||For a single malignant mass in the brain, conventional T1 highlighted contrast enhancement findings and histological results (glioblastoma/metastatic brain cancer) were compared and analyzed, followed by diagnosing a single brain mass (Df/Dt1, Dt2/Dt1, Dt2/Df ratio) and histological results.||||
33978414|NCT06364670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978415|NCT00512603|||COHORT||PROSPECTIVE|||||||
33978416|NCT00604071|||COHORT||PROSPECTIVE|||||||
33978417|NCT00495326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978418|NCT04581538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Three parallel arms investigate 1) the control group, where home care is being continued as before, 2) combined effects of the e-learning platform and the networking platform, and 3) effects of the entire intervention (e-learning platform, networking platform, digital care documentation). The interventions last 12 months, with effects being investigated in two follow-ups after three and 12 months. The main one-sided alternative hypothesis, assumes a positive trend from 1 ) towards 3) in the outcomes studied. Planned contrasts are:~1. control vs. experimental arm 3 (indicating effects of the entire experimental intervention)~2. arm 2 vs. arm 3 (indicating whether arm 3 has additional effects as compared to arm 2)~Planned contrasts are ignored, if the overall null hypothesis is not rejected in the ANOVA."||||
33978419|NCT06193395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978420|NCT01143857|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33978421|NCT00692653|RANDOMIZED|PARALLEL||||NONE||||||
33978422|NCT02756325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978423|NCT06367309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial participants and the assessors (trained investigators not involved in the operative procedures) of the primary outcome are blinded regarding the performed procedure during the first seven days after the procedure to reduce bias. The blinding is guaranteed by not sharing the detailed operation report with anyone involved in the aftercare of the patient or in the assessment of study outcomes.||t|f|f|t
33978424|NCT04919421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978425|NCT04162626|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978426|NCT00719966|||COHORT||PROSPECTIVE|||||||
33978427|NCT05507619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978428|NCT06365723|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||The study is a randomized crossover trial with a 4-week washout period.|f|f|f|t
33978429|NCT02678832|||OTHER||CROSS_SECTIONAL|||||||
34076996|NCT02727738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719860|NCT01607086|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33719861|NCT05919381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719862|NCT05212012|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I: 3+3 dose escalation study (non-randomized) - max. 18 participant~after Phase I start with a Amendment Phase II: Open-label, 2:1 randomized, controlled trial - 64 participant Patients in the mFOLFOX6 alone arm are allowed to cross over and receive methadone hydrochloride in combination with mFOLFOX6 upon disease progress"||||
33719863|NCT00702819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719864|NCT01973907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719865|NCT01076881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33719866|NCT03348020|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33766489|NCT03479190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The trial will be a two arm single centre double blind randomised control trial. The study will include a two-way comparison between PRP and placebo normal saline injections for treating GTPS. Participants will be reviewed at baseline, 3, 6 and 12 with patient reported outcome measures (PROM) completed at each of these reviews.|t|t|t|t
33766490|NCT06312982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766491|NCT06153823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766492|NCT01155037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766493|NCT05772312|||COHORT||PROSPECTIVE|||||||
33766494|NCT01254864|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33766495|NCT02142582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33766496|NCT00572338|||CASE_ONLY||PROSPECTIVE|||||||
33766497|NCT00476619|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33766498|NCT06435780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766499|NCT01548859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766500|NCT01233609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766501|NCT02768558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766502|NCT06376981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766503|NCT04183907|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Interested employees working at Fraser Health can sign up to our study. They will fill in a prediabetes check list. By filling out this check list (online survey) participants' the Blue Mesa Health portal assigns a participant number to each participant. The names of participants are stored on the portal.~Participants scoring as 'risk for prediabetes' are invited to participate in the study. Of the interested participants 100 will be randomly assigned to the Transform group or the Control group (n = 50 in each group). Participants will know whether they participate in the lifestyle intervention (Transform program) or not. The researchers do not know (it is an online program) although they could in theory look up in the data which person is in the control vs treatment group."|There will be one group that participates in the intervention, and one control group that does not.||||
33766504|NCT03798704|||COHORT||PROSPECTIVE|||||||
33766505|NCT02667886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766506|NCT04325087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants receive either three sessions of iTBS over the dorsolateral prefrontal cortex or three sessions of a placebo stimulation.|t|f|f|f
33766507|NCT00557609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766508|NCT02481843|||CASE_CONTROL||PROSPECTIVE|||||||
33766509|NCT04619953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766510|NCT05032118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33766511|NCT05899660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double-blind||t|t|t|f
33766512|NCT01653808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766513|NCT04426084|||CASE_CONTROL||OTHER|||||||
33766514|NCT03329430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766515|NCT04107896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34076997|NCT05865587|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33766516|NCT06617234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766517|NCT03424486|||OTHER||CROSS_SECTIONAL|||||||
33766518|NCT04818697|||CASE_CONTROL||PROSPECTIVE|||||||
33766519|NCT04168372|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33766520|NCT01099930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766521|NCT03604757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766522|NCT02819856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766523|NCT02011425|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33766524|NCT05709158|||CASE_CONTROL||OTHER|||||||
33766525|NCT02689934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind (subjects, investigators)||t|t|t|t
33766526|NCT00248300|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33766527|NCT00284908|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33894925|NCT03257046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multiple rising dose in sequential cohorts of 8 patients randomized in a 6:2 ratio to receive ITI-214 or placebo|t|t|t|t
33894926|NCT06334679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|When cold application studies in the literature are examined, cold gel packs are placed in a sheath and contacted with the skin of the patients. Therefore, due to the nature of the application method to be used, patients and the researcher will not be considered blind. The evaluator will be considered blind in the analysis of the study.|It is a prospective interventional type two-group randomized controlled clinical study. Distribution according to the groups and layers to be assigned for each intervention; Group-1 (Experiment) was designed as clinical routine (liquid petroleum jelly) and cold gel pack, and Group-2 (Control) was designed as clinical routine (liquid petroleum jelly).|f|f|f|t
33894927|NCT02730806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894928|NCT01471327|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33894929|NCT01739595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33894930|NCT06283706|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894931|NCT06070363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigator blind the participant allocation||f|f|f|t
33894932|NCT00274430|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33894933|NCT03273621|||CASE_ONLY||PROSPECTIVE|||||||
33894934|NCT02592564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894935|NCT04754087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894936|NCT04054310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894937|NCT01020318|||||PROSPECTIVE|||||||
33894938|NCT01071070|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33894939|NCT06258278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894940|NCT01812161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33894941|NCT01305915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33766528|NCT06432413|||CASE_CONTROL||RETROSPECTIVE|||||||
33766529|NCT05013866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766530|NCT00979602|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33766531|NCT00400543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33766532|NCT06091657|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766533|NCT04399733|||COHORT||PROSPECTIVE|||||||
33766534|NCT02220504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894942|NCT03117803|||COHORT||PROSPECTIVE|||||||
33894943|NCT05519696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All measurement staff will be blind to treatment condition||f|f|f|t
33894944|NCT06172543|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33894945|NCT02569515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33894946|NCT00161317|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33894947|NCT04774601|||OTHER||CROSS_SECTIONAL|||||||
33766535|NCT01211236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766536|NCT03313258|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33766537|NCT05907460|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label study|||||
33766538|NCT01412814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766539|NCT03560258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766540|NCT00714532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766541|NCT06625346|||COHORT||PROSPECTIVE|||||||
33766542|NCT01006317|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766543|NCT05423327|NA|SINGLE_GROUP||SCREENING||NONE||N/A: No study drug administered||||
33766544|NCT04924686|||OTHER||CROSS_SECTIONAL|||||||
33766545|NCT06280495|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, multicenter clinical trial. Stratified randomization based on liver metastasis characteristics, including timing, number, and size, will be conducted in eligible patients.||||
33766546|NCT05815901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766547|NCT03211715|||COHORT||PROSPECTIVE|||||||
33766548|NCT02900612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766549|NCT00000508|RANDOMIZED|||PREVENTION||||||||
33766550|NCT04922190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766551|NCT00674323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33766552|NCT04733911|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33766553|NCT00179712|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33766554|NCT01621204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766555|NCT00233441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766556|NCT00010439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766557|NCT01091896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33766558|NCT04570995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The capsules are of nearly identical color rendering them indistinguishable in appearance|randomized, double-blind, placebo-controlled, two-arm intervention study|t|f|t|f
33766559|NCT00888758|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33766560|NCT02772575|||COHORT||PROSPECTIVE|||||||
33766561|NCT00004202||||TREATMENT||||||||
33766562|NCT00174603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766563|NCT05620901|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study aims to enroll 30 pediatric patients undergoing routine retinal surgery or laser treatment under anesthesia. Patients in each treatment group (surgery or laser) will be randomized 2:1 at the time of surgery/ laser to receive either the Dextenza insert or the Control (Prednisolone Acetate 1%) steroid drops tapered for 28 days post-operatively.||||
33766564|NCT05016414|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33766565|NCT05303597|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766566|NCT00136032|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33766567|NCT01959191|||CASE_CONTROL||PROSPECTIVE|||||||
33766568|NCT01414426|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766569|NCT01488591|||||PROSPECTIVE|||||||
33766570|NCT02477397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766571|NCT05520502|||COHORT||OTHER|||||||
33766572|NCT03772951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33766573|NCT01678443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894948|NCT01363726|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33894949|NCT04155879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and participants will be blinded regarding levels of anti-inflammatory markers||t|f|t|f
33894950|NCT03887767|||COHORT||RETROSPECTIVE|||||||
33894951|NCT06488196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators used a randomized controlled trial (RCT) design and randomized consenting mothers (1:1) in blocks of 10 to the MI-arm or a treatment-as-usual (TAU) control-arm.||||
33894952|NCT00413751|||||PROSPECTIVE|||||||
33894953|NCT05847881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766574|NCT02446925|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33766575|NCT01988441|||COHORT||PROSPECTIVE|||||||
33766576|NCT03394456|RANDOMIZED|PARALLEL||TREATMENT||NONE|In the last secondary study, there is single blinding (data collectors)|||||
33766577|NCT02746042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766578|NCT06383325|||COHORT||PROSPECTIVE|||||||
33766579|NCT00885352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34076998|NCT02717000|||COHORT||PROSPECTIVE|||||||
34076999|NCT01789788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077000|NCT02376504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077001|NCT06195618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077002|NCT02462512|||COHORT||PROSPECTIVE|||||||
34077003|NCT04856111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33894954|NCT06315010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894955|NCT05041335|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"These needle preparations will be wrapped in non-transparent 2-inch tape to hide the appearance of the injectate agent. The needle is prepared by removing the stylet and flushing with the selected substance. The PI/Co-I will then flush the needle with the selected substance until drops of the liquid are seen exiting the needle tip. Those randomized to have the needle flushed with heparin will be termed dry heparin and will be flushed with 500 U heparin USP per 10 mL. Those who randomize not to receive heparin, the needle will be flushed with saline. The device shall then be placed into the linear echoendoscope and the FNB will be performed. The PI is blinded to heparin vs. no heparin only. Randomization to the microsieve vs. not is apparent to the PI."|The control group will have 21 patients and the group receiving heparin will have 21 patients; the randomization is 1:1:1:1; heparin and microsieve, heparin and no microsieve, no heparin and microsieve and no heparin and no microsieve. Forty two subjects will be enrolled at UH for a total of 42 subjects.|t|t|t|f
33894956|NCT04285528|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894957|NCT01471561|||COHORT||RETROSPECTIVE|||||||
33894958|NCT04278742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Suitable participants recruited and randomised into Study Intervention Group or Control Group.|t|f|f|f
33894959|NCT00705900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33894960|NCT04849481|||CASE_ONLY||RETROSPECTIVE|||||||
33894961|NCT00231140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894962|NCT00391976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894963|NCT04568499|||COHORT||PROSPECTIVE|||||||
33894964|NCT06657300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|10 ml of blood required for PRP preparation was taken from all patients to make the patients blind to which treatment they received. The injectors were taped closed. Outcomes were measured at 1, 3 and 6 months after injection by the physician who performed the initial assessment and was blinded to the type of injection.||t|f|f|t
33894965|NCT01928979|||||RETROSPECTIVE|||||||
33894966|NCT02224664|NON_RANDOMIZED|||BASIC_SCIENCE||NONE||||||
33894967|NCT02384720|||CASE_ONLY|||||||||
33894968|NCT02389881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894969|NCT04910217|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-centre randomized parallel group neurorehabilitation trial||||
33894970|NCT02172118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894971|NCT03245814|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Clinician Administered PTSD Scale for DSM-V (CAPS-5) assessments will be completed via telephone by a trained CAPS-5 rater who will be masked to the intervention and treatment arm of each participant.||f|f|f|t
33894972|NCT04893668|||COHORT||PROSPECTIVE|||||||
33894973|NCT05621863|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Aim 1: crossover, Aim 2: parallel, Aim 3: observational||||
33894974|NCT03783910|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This dose-titration study was conducted with randomized, multi-center, double-blind, placebo-controlled, crossover design and multiple administrations in 2 treatment sequences in treatment periods 1 and 2: Sequence GRT9906-Placebo and sequence Placebo-GRT9906.|t|t|t|t
33894975|NCT01191593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894976|NCT00987415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894977|NCT00524303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894978|NCT05361512|||COHORT||PROSPECTIVE|||||||
33894979|NCT05159193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894980|NCT05623644|||CASE_ONLY||PROSPECTIVE|||||||
33894981|NCT00594399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33894982|NCT01901744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33894983|NCT05635565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not have access to the group allocation of the participants.|Randomized clinical trial with 2 groups|f|f|f|t
33894984|NCT01552174|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33894985|NCT05813470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33894986|NCT00156481|||||CROSS_SECTIONAL|||||||
33894987|NCT01593982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33894988|NCT05241587|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This was a prospective, non-randomized experimental study involving a control group.|t|f|f|f
33894989|NCT05157425|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Both placebo and active product will be provided in identical packaging.|Double blind, randomized controlled trial in 140 subjects 50-80 years old receiving influenza vaccination, who will be allocated to receive either an experimental product containing multi-strain probiotic formula or placebo for 28 days|t|t|t|t
33894990|NCT04248166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33894991|NCT04978623|||CASE_CONTROL||RETROSPECTIVE|||||||
33894992|NCT01955486|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33894993|NCT05911997|RANDOMIZED|PARALLEL||PREVENTION||NONE|All open label|Four different interventions||||
33894994|NCT02786641|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33894995|NCT05833880|||CASE_ONLY||PROSPECTIVE|||||||
33894996|NCT04833036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894997|NCT02587494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33894998|NCT03338946|||COHORT||PROSPECTIVE|||||||
33894999|NCT02725788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766580|NCT03781089|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study is open-label and therefore the subjects, coordinators and investigators are not blinded to the intervention. Titration of the patiromer will require viewing of the serum potassium values. During the data analysis, however, personnel involved will remain blinded.|This is a prospective, randomized, open-label trial. Eligible ESRD patients who are on thrice weekly HD schedule will be screened from retrospective review of clinical and laboratory parameters from our clinical practice group. A total of 40 patients (randomized 1:1 study drug: usual care) will be enrolled. Duration of study medication exposure will be 4 weeks. The total duration of study, from enrollment until the end of the washout period will be 7 weeks.|f|f|f|t
33766581|NCT00805493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895000|NCT02516930|RANDOMIZED|PARALLEL||||NONE||||||
33895001|NCT01059812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895002|NCT00049764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895003|NCT00786773|||||PROSPECTIVE|||||||
33895004|NCT01358110|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33895005|NCT05274438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895006|NCT00542984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895007|NCT01328873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895008|NCT06056284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The experimental group will be subjected to progressive relaxation exercise and the outcome assesment will be performend by an outcomes assessor blinded to group allocation|two groups with experimental and control group|t|f|f|t
33895009|NCT03820115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895010|NCT04935944|||OTHER||OTHER|||||||
33895011|NCT01817010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895012|NCT00602407|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895013|NCT02811926|||OTHER||RETROSPECTIVE|||||||
33895014|NCT01135238|||COHORT||RETROSPECTIVE|||||||
33895015|NCT00954785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895016|NCT05897424|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, single arm, open-label extension study||||
33895017|NCT05609526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895018|NCT03762980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33895019|NCT05180786|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33895020|NCT00001446||||TREATMENT||||||||
33895021|NCT01364415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895022|NCT04609384|||COHORT||PROSPECTIVE|||||||
33895023|NCT01220219|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33895024|NCT00035893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895025|NCT00201799|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33978430|NCT06233266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The randomization schedule will be blinded to the analysts until the end of the study.|||||
33978431|NCT05318651|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978432|NCT02044783|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766582|NCT00453479|RANDOMIZED|PARALLEL||DIAGNOSTIC||||||||
33978433|NCT01871467|NA|SINGLE_GROUP||OTHER||NONE||||||
33978434|NCT04595981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978435|NCT05376566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be blinded using masked vial containing either hydrochloric acid or normal saline and coloured syringes. All masked vials have a unique three-figure randomization code.||t|t|t|t
33978436|NCT05065645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978437|NCT02769208|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33978438|NCT02141256|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33978439|NCT04109170|||CASE_CONTROL||PROSPECTIVE|||||||
33978440|NCT04786652|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978441|NCT00337077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978442|NCT00744809|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33978443|NCT06158269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978444|NCT06482489|||COHORT||PROSPECTIVE|||||||
33978445|NCT06003920|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Interventionist was blinded to which group participants were also research participants.||f|t|f|f
33978446|NCT01456481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978447|NCT05936710|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978448|NCT06224400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978449|NCT02642666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978450|NCT03314025|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Everyone is blinded except the pharmacy department where the randomization list is kept. This department is the one able to unblind a patient, if needed.|Randomized, double-blind, placebo-controlled clinical trial|t|t|t|t
33978451|NCT00417209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978452|NCT05094453|||CASE_ONLY||PROSPECTIVE|||||||
33978453|NCT00963209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978454|NCT01728012|||CASE_ONLY||CROSS_SECTIONAL|||||||
33978455|NCT00000391|NON_RANDOMIZED|||TREATMENT||NONE||||||
33978456|NCT02659722|||CASE_ONLY||PROSPECTIVE|||||||
33978457|NCT03409601|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33978458|NCT01992055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978459|NCT04806308|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33978460|NCT01986582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978461|NCT04168346|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978462|NCT05231109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978463|NCT06159270|||COHORT||PROSPECTIVE|||||||
33978464|NCT04853459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978465|NCT04228952|||COHORT||PROSPECTIVE|||||||
33978466|NCT02776709|||COHORT||PROSPECTIVE|||||||
33978467|NCT06330870|NA|SINGLE_GROUP||SCREENING||NONE||||||
33978468|NCT06176287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled study|t|f|f|f
33978469|NCT06495658|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator and outcomes assessor will not be aware of participants' assignments.||f|f|t|t
33978470|NCT02698800|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33978471|NCT00050856||||TREATMENT||||||||
33978472|NCT03080649|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcome assessor have not met the patient before assessing the outcome. No information about which excavation method used is available.|prospective, single-blind, randomized and controlled investigation|f|f|f|t
33978473|NCT06029036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978474|NCT02218164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978475|NCT05522270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participant,outcomes Assessor)|parallel assignment|t|f|f|t
33978476|NCT05898204|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are sequentially allocated to one of the 2 arms of intervention: the ketogenic diet arm or the balanced diet arm.||||
34077004|NCT03424798|||CASE_ONLY||PROSPECTIVE|||||||
34077005|NCT04230369|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All assessments will be conducted by participants over the internet, why there can be no influence from study staff during data collection.|The participants will be randomised to immediate internet-CBT or 4 months of treatment as usual before cross-over to internet-CBT.|f|f|f|t
34077006|NCT05862493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Blinded data analysis|This is a randomized, open label, superiority trial with a 1:1 allocation ratio||||
34077007|NCT04030598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part A was randomized, double-blind; Part B was open-label.||t|f|t|t
34077008|NCT00115778|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34077009|NCT02274597|||COHORT||PROSPECTIVE|||||||
34077010|NCT00572260|NA|SINGLE_GROUP||||NONE||||||
34077011|NCT00612911|||CASE_ONLY||PROSPECTIVE|||||||
34077012|NCT00959465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077013|NCT03948880|||COHORT||PROSPECTIVE|||||||
33766583|NCT02086162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978477|NCT06426056|NA|SINGLE_GROUP||TREATMENT||NONE||Radiation Therapy Concurrently With Nab-Paclitaxel Plus Cisplatin||||
34077014|NCT00090727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077015|NCT03805737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077016|NCT02348229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077017|NCT05308966|||COHORT||RETROSPECTIVE|||||||
34077018|NCT02361034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33978478|NCT05530681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978479|NCT00163449|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33978480|NCT05123456|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33978481|NCT01907009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978482|NCT05946148|||COHORT||PROSPECTIVE|||||||
33978483|NCT00944879|||COHORT||PROSPECTIVE|||||||
33978484|NCT04815642|||COHORT||RETROSPECTIVE|||||||
33978485|NCT02627742|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33978486|NCT01880073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978487|NCT02401282|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33978488|NCT04229849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978489|NCT00102908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33978490|NCT00000880||||TREATMENT||||||||
33978491|NCT05836077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Pecha kucha method and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33978492|NCT02297451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33978493|NCT02463149|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766584|NCT01778946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978494|NCT03256968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978495|NCT04462263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766585|NCT01761539|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33766586|NCT02827318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766587|NCT02571946|NA|SINGLE_GROUP||TREATMENT||NONE||Proton beam radiotherapy||||
33766588|NCT02762838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766589|NCT06351644|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm optimal biologic dose finding phase I/II clinical trial.||||
33766590|NCT06014736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766591|NCT00273559|||CASE_CONTROL||PROSPECTIVE|||||||
33766592|NCT05434299|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766593|NCT00892190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766594|NCT02429687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766595|NCT01566305|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766596|NCT00544544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766597|NCT06561217|||OTHER||RETROSPECTIVE|||||||
33766598|NCT03708588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895026|NCT03445286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and outcome Assessor will be blinded The participants will be blinded about which interventions they will receive and the Outcomes Assessor who will evaluate the gingival condition will be blinded about the interventions, and also the care provider who will apply the intervention will be blinded|The participants with gingivitis are randomly allocated to two groups: group 1(case group) who will receive SDF application once every week within three weeks period and group 2 (control group) who will receive normal saline application once a week within three-week period|t|f|f|t
33895027|NCT03022422|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895028|NCT03679221|||COHORT||CROSS_SECTIONAL|||||||
33895029|NCT06016712|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
33895030|NCT05539430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895031|NCT04621747|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895032|NCT04516252|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33978496|NCT01617954|||CASE_ONLY||PROSPECTIVE|||||||
33766599|NCT02978053|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33978497|NCT02449876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978498|NCT03194581|||CASE_ONLY||PROSPECTIVE|||||||
33978499|NCT03660839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978500|NCT02159716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077019|NCT01096160|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33766600|NCT02207439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766601|NCT02379559|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33766602|NCT03248609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33766603|NCT00308737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766604|NCT05755464|||COHORT||PROSPECTIVE|||||||
33766605|NCT04692844|||COHORT||PROSPECTIVE|||||||
33766606|NCT03491098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978501|NCT04216043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The RUSF food products are very similar in appearance and texture; thus, subjects and caretakers will be blinded. The investigators making the clinical assessments will not have information as to specialized food product assignment of the subject, and will remain blinded.||t|t|t|t
33978502|NCT04533607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Schools will be randomized to either MAAPS or waitlist control with equal probability. Randomization at the school level will minimize the risk of spillover between MAAPS and the waitlist control group. Randomization will be conducted for each site to guarantee equal representation of treatment and control schools at each site. The project statistician will generate a randomization sequence that is concealed from the study team.|f|f|f|t
33978503|NCT00185523|||COHORT||PROSPECTIVE|||||||
33978504|NCT00650936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978505|NCT02103738|||OTHER||PROSPECTIVE|||||||
33978506|NCT01505257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33978507|NCT01131858|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33978508|NCT05844969|||CASE_ONLY||OTHER|||||||
33978509|NCT05770752|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978510|NCT05875818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33978511|NCT04782609|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined. Part 2 will be a dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D). The RP2D is defined as the dose level recommended for further clinical study, or the highest dose tested. The RP2D may be the same as the MTD or modified from the MTD based on assessment of overall exposure, safety experience in Cycle 2 and beyond, and clinical benefit data in the study. The RP2D will be determined in the dose expansion phase of the study.||||
33978512|NCT02517801|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33978513|NCT04790448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978514|NCT00576901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978515|NCT05003648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978516|NCT03254251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33978517|NCT01989728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978518|NCT03057249|||OTHER||PROSPECTIVE|||||||
33978519|NCT00950872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978520|NCT00000941||||TREATMENT||NONE||||||
33978521|NCT03788525|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978522|NCT04814745|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077020|NCT03607877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization was conducted using opaque envelops and a randomly generated number sequence by an independent research assistant who had no prior knowledge of the recruited elders. Researchers allocated participants to their treatment condition based on the randomization code in the sealed envelope (opened in order of sequence). Investigator was blind to participants, but researchers were not blind to the patients' treatment allocation.|Three arms of experimental design were used: Pedometer walking training (PWT), positive education and pedometer walking training (PEPWT), and pedometer walking (PW). Trained walking exercise was provided by a physical education expert three times per week, 45 minutes per session. Positive education was designed and led by a licensed psychologist. Six sessions of activities targeted participants' self-strength, competence and self-efficacy in walking exercise; positive relations with others; and positive emotions about life and healthy lifestyle. Of 150 participants, 60, 60 and 30 were randomly assigned to PWT, PEPWT, and PW, respectively. Demographic information, Chinese Happiness Inventory (CHI), regular walking exercise and six-minute walking distance were assessed before and after the intervention.|f|f|t|f
33978523|NCT02531984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978524|NCT01627366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33978525|NCT04818242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978526|NCT02403752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978527|NCT03309956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients will receive the same intervention, namely both devices at the same time for 48 hours.||||
33978528|NCT03050632|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077021|NCT05682417|NA|SINGLE_GROUP||OTHER||NONE||||||
34077022|NCT03768778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077023|NCT03752476|||CASE_CONTROL||RETROSPECTIVE|||||||
34077024|NCT02107846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978529|NCT03325530|||CASE_ONLY||RETROSPECTIVE|||||||
33978530|NCT01135641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077025|NCT03941340|NA|SINGLE_GROUP||OTHER||NONE||||||
34077026|NCT04533789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group 1 (control group) and Group 2 (virtual reality group), group 3 (task oriented training)|"G 1 (control) received traditional physical therapy program for 60 min. G 2 (study) received traditional physical therapy program for 30 min. and virtual reality for 30 min.~G 3 (study) received traditional physical therapy program for 30 min. and task oriented training for 30 min.~all groups treated for four successive months."|t|f|t|f
34077027|NCT00209001|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077028|NCT01701804|||COHORT||PROSPECTIVE|||||||
34077029|NCT03701880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077030|NCT05854420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077031|NCT02219685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077032|NCT04214522|||OTHER||PROSPECTIVE|||||||
34077033|NCT02582333|||COHORT||PROSPECTIVE|||||||
34077034|NCT04284683|NA|SINGLE_GROUP||OTHER||NONE||||||
34077035|NCT05070078|||OTHER||PROSPECTIVE|||||||
34077036|NCT00049725||||TREATMENT||||||||
33978531|NCT06200701|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33978532|NCT03823300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978533|NCT05369871|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 13-week interventional, randomized, controlled, crossover, open-label, multicenter main study, followed by an optional, open-label, additional 4-week study.||||
33978534|NCT05232162|||COHORT||CROSS_SECTIONAL|||||||
33978535|NCT05111470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978536|NCT00977106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978537|NCT03421860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895033|NCT04397679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895034|NCT02209883|||COHORT||PROSPECTIVE|||||||
33895035|NCT06123156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895036|NCT01584024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895037|NCT05498298|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895038|NCT06509698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomized clinical trial||f|f|f|t
33895039|NCT03217162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895040|NCT00631319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895041|NCT04553783|||COHORT||PROSPECTIVE|||||||
33895042|NCT03829761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895043|NCT03018015|RANDOMIZED|CROSSOVER||||NONE||||||
33895044|NCT01358383|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895045|NCT00002523|RANDOMIZED|||TREATMENT||||||||
33895046|NCT01157169|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33895047|NCT03253640|||COHORT||PROSPECTIVE|||||||
33895048|NCT05393154|||OTHER||PROSPECTIVE|||||||
33895049|NCT03061708|NA|SINGLE_GROUP||TREATMENT||NONE||AZD2014 50mg BD continuous schedule of a 28 day cycle||||
33895050|NCT05957081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895051|NCT01052064|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895052|NCT06231043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895053|NCT02001740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895054|NCT00998738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33895055|NCT02173600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33895056|NCT04346342|||COHORT||RETROSPECTIVE|||||||
33895057|NCT05077514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895058|NCT05382481|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895059|NCT06079502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978538|NCT02761980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978539|NCT05897580|RANDOMIZED|PARALLEL||TREATMENT||NONE||Heart rate variability-biofeedback (HRV-BF) has been shown to decrease symptoms of stress, anxiety, depression, and PTSD, however HRV-BF has not been tested with the most vulnerable of populations, homeless adults||||
33978540|NCT05918003|||COHORT||PROSPECTIVE|||||||
33978541|NCT06291688|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33978542|NCT06367569|||COHORT||PROSPECTIVE|||||||
33978543|NCT02922868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33895060|NCT02332252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895061|NCT06657560|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895062|NCT05071339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895063|NCT02561182|||COHORT||PROSPECTIVE|||||||
33895064|NCT02843243|||COHORT||PROSPECTIVE|||||||
33895065|NCT05137938|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot study||||
33978544|NCT00321542|||COHORT||PROSPECTIVE|||||||
33978545|NCT06451484|||CASE_ONLY||RETROSPECTIVE|||||||
33895066|NCT00658229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895067|NCT01962142|||OTHER||PROSPECTIVE|||||||
33895068|NCT04387279|||COHORT||CROSS_SECTIONAL|||||||
33895069|NCT03738956|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will be given tofacitinib 5 mg BD ,at the end of 1st and 3rd months they will be assessed for safety and efficacy.At 3rd months if any patient wll not responds then they will be given tofacitinib 10 mg BD,at the end of 6th month they will be assessed for safety and efficacy.If any adverse events occur they will be treated accordingly.||||
33895070|NCT05394844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Real Time Continuous Glucose Monitoring using Dexcom G6 and Diabetes education|f|f|t|t
33895071|NCT06001450|||CASE_CONTROL||PROSPECTIVE|||||||
33895072|NCT05951582|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33895073|NCT05086237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The second phase of the study will be an randomized controlled trial to randomly assign parents/guardians of children who missed a WCV to an intervention condition or no intervention, and assess reasons for missed visits and experiences at last visit. Each reminder message will at minimum direct parents/guardians to reschedule by phone or by the patient portal.||||
33895074|NCT03984409|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Group 1 kcit x 7 days ↓ Litholink on day 7~↓ off therapy x 7 days~↓ OJ 500 ML + 1.5L water /day x 7 days~↓ Litholink on day 7~↓ OJ 1000 ML + 1L water /day x 7 days~↓ Litholink on day 7 Return to kcit therapy~Group 2 OJ 500 ML + 1.5L water /day x 7 days ↓ Litholink on day 7~↓ OJ 1000 ML + 1L water /day x 7 days~↓ Litholink on day 7~↓ off therapy x 7 days~↓ kcit x 7 days~↓ Litholink on day 7 Continue on kcit therapy"||||
33895075|NCT03080987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895076|NCT03456492|||CASE_CONTROL||PROSPECTIVE|||||||
33895077|NCT03940885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||single-blind study|f|f|f|t
33895078|NCT05057988|NA|SINGLE_GROUP||TREATMENT||NONE||Single intervention||||
33895079|NCT00230763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895080|NCT05740787|||CASE_ONLY||PROSPECTIVE|||||||
33895081|NCT01261676|||CASE_CONTROL||RETROSPECTIVE|||||||
33895082|NCT06031753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||group 1: time restricted eating with NO hormonal treatment group 2: time restricted eating with hormonal treatment group 3: hormonal treatment with NO time restricted eating||||
33895083|NCT04191668|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Sleep technician which analyses the PSG data will be blinded from any prior PSG analysis and the NightOwl analysis|Single Group will undergo both gold standard polysomnography (PSG) and NightOwl Sleep Apnea Test||||
33895084|NCT05947019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895085|NCT04203173|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33895086|NCT01818349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895087|NCT04696549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895088|NCT04903860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895089|NCT05150860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895090|NCT04915521|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33895091|NCT05432544|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||SHR-1918 injection compared with placebo|t|t|t|t
33895092|NCT05279378|||COHORT||PROSPECTIVE|||||||
33895093|NCT02191748|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895094|NCT03785080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895095|NCT01053676|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895096|NCT03421548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895097|NCT00365781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895098|NCT00226642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895099|NCT01796132|NON_RANDOMIZED|PARALLEL||||NONE||||||
33895100|NCT01671410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895101|NCT03390829|||OTHER||OTHER|||||||
33895102|NCT01444716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895103|NCT03284450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895104|NCT05601206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
33895105|NCT00025038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978546|NCT04101149|||COHORT||PROSPECTIVE|||||||
33978547|NCT03441581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978548|NCT01328730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978549|NCT03342495|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two groups of participants will be randomized by primary clinical area||||
34077037|NCT00302536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077038|NCT01481558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34077039|NCT06540560|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34077040|NCT01841970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077041|NCT03281746|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077042|NCT01705938|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33895106|NCT05233046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The participants will know only that they have been selected for a study but not what group they are in or what the study is investigating.~The administrators of the study will know what clients have been assigned the study and what participants are in the control group."|"Couseling sessions provided by RDs and licensed board certified mental health professionals are trained with standard protocol and evaluated individually. Training protocol includes handbook and virtual instruction with motivational interviewing techniques like using open-ended questions.~Both study and control group a counseled with standard protocol that includes weekly nutrition services and biweekly mental health services. Study group receives counseling sessions combined with Nourish Carolina program. Control group won't be taught mindfulness-based concepts.~Standardized focus includes all participants are presented essential nutrition concepts. Also, nutrition and mental health mindfulness sessions will be coordinated and will compliment each other. Each week designed so that the mindful based mini-exercises outlined in Nourish Carolina will have the same theme for both nutrition and mental health sessions."|t|f|f|f
33895107|NCT03815292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895108|NCT04744558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895109|NCT05412433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33895110|NCT04674943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895111|NCT00109811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895112|NCT04068883|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||two groups||||
33895113|NCT06477042|||CASE_ONLY||PROSPECTIVE|||||||
33895114|NCT05064241|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not be told which discussion board they are randomized to. However, they may possibly discover that one board has a genetic counselor, and the other does not.|One group has access to a genetic counselor answering their questions, another group has peer-to-peer conversation. However, at the end of the study, the genetic counselor will answer the questions asked in the peer-to-peer discussion board.|t|f|f|f
33895115|NCT05015712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895116|NCT05465135|NA|SINGLE_GROUP||TREATMENT||NONE||20 participants with PCOS receive dihydroartemisinin for 3 months||||
33895117|NCT03425383|||OTHER||CROSS_SECTIONAL|||||||
33895118|NCT03099759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895119|NCT02277171|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895120|NCT01187225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895121|NCT05293418|||COHORT||RETROSPECTIVE|||||||
33895122|NCT05621668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895123|NCT04802837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895124|NCT05747404|||COHORT||PROSPECTIVE|||||||
33895125|NCT03384043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33895126|NCT03946176|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33895127|NCT02843711|||COHORT||RETROSPECTIVE|||||||
33895128|NCT06137352|||COHORT||PROSPECTIVE|||||||
33895129|NCT02596776|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895130|NCT03195140|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Multi-center, randomized, crossover design, consisting of two 3-week periods, with the PLGS System used during one period and SAP therapy used during the other period. The crossover trial will be preceded by a run-in phase in which participants may receive training using the study devices.~For 10 adult participants, a PLGS Pilot Period will proceed to the crossover trial to ensure safety and usability objectives are met prior to the start of the crossover trial."||||
33895131|NCT00133926|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33895132|NCT06519929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants, care providers, and investigators will not be blinded but outcome assessors will be unaware of group assignment when doing baseline assessments and when performing some post-randomization assessments, such as those at 30 and 90 days by phone call.|3-arm, parallel-group, randomized controlled trial|f|f|f|t
33895133|NCT01257971|||COHORT||CROSS_SECTIONAL|||||||
33895134|NCT03359603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895135|NCT02286960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895136|NCT00562419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895137|NCT01660815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895138|NCT01503021|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33895139|NCT00467649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895140|NCT01717885|||COHORT||PROSPECTIVE|||||||
33895141|NCT03270722|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895142|NCT02125994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33895143|NCT00936949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895144|NCT00942409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895145|NCT00998530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34077043|NCT02318030|||CASE_ONLY||PROSPECTIVE|||||||
34077044|NCT02910830|||COHORT||PROSPECTIVE|||||||
33895146|NCT04146688|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103511|NCT06684821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766607|NCT05531019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The vials of the nutraceutical are identical to each other as well as the labels. It is impossible to distinguish one from the other.|Ramdomized Control|t|t|t|t
33766608|NCT04595539|RANDOMIZED|PARALLEL||TREATMENT||NONE|A blinding procedure was used for the pre-post evaluations: interviews were recorded and each video or sound recording was evaluated at the end of the study by one (or two) independent evaluator who was unaware of the recordings' assessment time.|||||
33766609|NCT01306201|||CASE_ONLY||PROSPECTIVE|||||||
33766610|NCT02069574|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33766611|NCT03267823|||COHORT||PROSPECTIVE|||||||
33766612|NCT00512369|||||PROSPECTIVE|||||||
33766613|NCT00994773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766614|NCT01570595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766615|NCT01821898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766616|NCT02862041|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33766617|NCT00672958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766618|NCT03324503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766619|NCT05749601|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33766620|NCT03850041|||COHORT||PROSPECTIVE|||||||
33766621|NCT00460317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766622|NCT02966535|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33766623|NCT02671318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766624|NCT00984360|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766625|NCT03800979|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Cohort study which all recruited volunteers will receive Tofacitinib for total of 24 weeks. The 19 volunteers are mixed male and female Thais who suffer from severe AA over 50% of the entire scalp.||||
33766626|NCT03120208|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|open|||||
33766627|NCT05962320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33978550|NCT06162923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a randomised, single-blind clinical trial. Because the allocation sequence and types of interventions delivered to the participants will be performed by an independent clinician, the main investigator can be blinded to the types of interventions that the participants will receive. The main clinician will be in charge of data collection. The data will be passed to the independent clinician once the main clinician has completed data collection. The data will be entered into the Data Collection Sheet by the independent clinician, who will also generate coding for the participants' names and types of interventions. The data is then passed to the main clinician for analysis. As a result, the main clinician is also blinded during the data analysis stage|Participants will be randomly allocated to three groups (control group, onsite video group and remote video group) at a 1:1:1 ratio in this three-arm parallel.|f|f|t|t
33766628|NCT00315588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766629|NCT06143657|||CASE_ONLY||PROSPECTIVE|||||||
33766630|NCT00381355|RANDOMIZED|PARALLEL||||SINGLE||||||
33766631|NCT06419218|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigator and data analyst will not be aware of participants' assignments.||f|f|t|f
33766632|NCT02386917|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33766633|NCT05367609|NA|SINGLE_GROUP||TREATMENT||NONE||PK sampling and genetic testing will determine the type of analgesia medication treatment the patient receives||||
33766634|NCT05677802|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33766635|NCT05229458|||OTHER||PROSPECTIVE|||||||
33766636|NCT00715572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33766637|NCT04588818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766638|NCT05650944|||CASE_CONTROL||RETROSPECTIVE|||||||
33978551|NCT01434966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978552|NCT00497796|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33978553|NCT01705873|||COHORT||RETROSPECTIVE|||||||
33766639|NCT01302938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766640|NCT05817435|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33766641|NCT06124742|||COHORT||PROSPECTIVE|||||||
33766642|NCT01916941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766643|NCT00548067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840420|NCT04542967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research was blinded as possible for the result's evaluators and those responsible for the statistical analysis. All patients admitted to the investigation were placed with a marker indicating that they were a patient of the plasma protocol, but not mention the study group. The data collectors and the outcome adjudicators were unaware of the treatment assignments.|The PC-COVID-HCM clinical trial is a randomized, controlled, single-blind study .|t|t|t|t
33840421|NCT00855647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766644|NCT03791203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blinded after assignment to interventions or control group.|Participants who fulfilled the selection criteria were randomly assigned to the modified alternate-day calorie restriction (MACR) group or the control group after a 2 week run-in period. During the 2 weeks, participants were required to keep their body weight stable by maintaining their usual eating habits and their daily activities. Randomization was performed using a random number generator with recruitment aimed for three MACR participants for every control participant by principal investigator.|t|f|f|f
33766645|NCT02621736|||COHORT||PROSPECTIVE|||||||
33766646|NCT01392716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766647|NCT03659643|||CASE_CONTROL||PROSPECTIVE|||||||
33766648|NCT05427513|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766649|NCT01207323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895147|NCT01214525|||CASE_CONTROL||PROSPECTIVE|||||||
33895148|NCT01656239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895149|NCT04573959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895150|NCT05812716|RANDOMIZED|PARALLEL||TREATMENT||NONE||Waitlist control design||||
33895151|NCT02801175|||COHORT||PROSPECTIVE|||||||
33895152|NCT02513615|||COHORT||PROSPECTIVE|||||||
33895153|NCT02111811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895154|NCT04243759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Staff working with participants will not know app assignment.|Heavy drinking young adults will be randomized to 1 of the 3 apps. After initial use of their randomized app, they will then be dosed to .06% blood alcohol content (BAC) in a naturalistic lab, followed by app use. For 4 weeks post-session, all participants will use the experimental app for 2 weeks in real drinking occasions and not use it the other 2 weeks.|t|t|f|f
33895155|NCT03026803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895156|NCT01960686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895157|NCT02047240|||COHORT||CROSS_SECTIONAL|||||||
33895158|NCT00003029|RANDOMIZED|||TREATMENT||||||||
33895159|NCT03590457|NA|SINGLE_GROUP||OTHER||NONE||||||
33895160|NCT04644900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33895161|NCT03473262|||CASE_CONTROL||PROSPECTIVE|||||||
33895162|NCT03304457|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open label, active controlled study||||
33895163|NCT04599309|||COHORT||PROSPECTIVE|||||||
33978554|NCT00427128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978555|NCT04940455|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33978556|NCT01725451|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33978557|NCT01569451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895164|NCT04352829|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE||"STUDY TYPE and STUDY AIM The study was experimentally undertaken in pre-test post-test control group design in order to assess the effect of video-training-session method upon adequacy of metered dose inhaler (MDI) among individuals with COPD.~STUDY POPULATION and SAMPLING In case of drop outs (wish to withdraw from the study, early hospital discharge, loss of life, etc), 20 patients were assigned to each group. The first 20 COPD patients who met the inclusion criteria were assigned to the control group whereas the second 20 COPD patients were assigned to the experimental group."|f|t|t|t
33766650|NCT05690061|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will not know which type of burger they consume.|Randomized cross-over design with 250 g of cooked meat (grain-fed hamburger, grass-fed hamburger, Impossible Burger) ingested and blood draws, urine, and questionnaires collected on separate visits.|t|f|f|t
33766651|NCT03027687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766652|NCT05538182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"For the following objectives, all tests will be conducted by trained researchers who will be masked to the hyperopia status of the children:~1. Prevalence of moderate to high hyperopia (\>+2.00D in the more hyperopic meridian, in the more hyperopic eye, using cycloplegic autorefraction).~2. The diagnostic accuracy of four screening tools for detecting hyperopia compared to the gold standard of cycloplegic refraction.~3. The cross-sectional association between uncorrected moderate to high hyperopia and baseline reading levels (using the Happy Readers V4 tool). We will compare the results to age-, gender-and school-matched emmetropic children."|Children in Grade 2 and 4 at 16 randomly-selected primary schools in Mashonaland Central province of Zimbabwe will receive free glasses as described in the protocol.|f|f|f|t
33766653|NCT02287116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33895165|NCT05910827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895166|NCT00339573|||OTHER||CROSS_SECTIONAL|||||||
33895167|NCT03114969|||COHORT||PROSPECTIVE|||||||
33895168|NCT03426046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895169|NCT05978453|||OTHER||PROSPECTIVE|||||||
33895170|NCT02215681|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978558|NCT05694065|||CASE_ONLY||PROSPECTIVE|||||||
33978559|NCT03699267|||COHORT||PROSPECTIVE|||||||
33978560|NCT00855842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978561|NCT04079907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be aware if the supplement they receive is the experimental supplement or the placebo control|Participants will be randomized into 1 of 2 groups, experimental or placebo control, and will remain in that group for the duration of the study.|t|f|f|f
33978562|NCT02847806|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33978563|NCT04670432|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|While patients are aware of their treatment allocation, the physicians (incl. radiologist) and researchers are not, as to provide unbiased outcome assessment.||f|t|t|t
33978564|NCT01385033|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33978565|NCT01977469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978566|NCT05704556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766654|NCT03295266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978567|NCT03650777|NA|SINGLE_GROUP||OTHER||NONE||Educational Intervention||||
33978568|NCT04985422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978569|NCT00437242|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33978570|NCT00418184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978571|NCT02969837|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"All participants will receive E-KRd regimen (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) for up to 12 Cycles.~After Cycle 12, participants that are MRD negative will move to E-Rd (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) maintenance regimen and continue until disease progression. Participants that are MRD positive will continue to receive E-KRd regimen for an additional 6 cycles followed by E-Rd maintenance regimen and continue until disease progression"||||
33978572|NCT05309421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766655|NCT03696719|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33766656|NCT06111144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766657|NCT02437695|||||RETROSPECTIVE|||||||
33766658|NCT00013065|||||PROSPECTIVE|||||||
33766659|NCT02899364|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33766660|NCT02687412|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients were randomly divided into two groups（ FTS group/traditional group）, after that doctors and patients were aware of the grouping situation.|prospective randomised controlled trial||||
33766661|NCT05059912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766662|NCT02221245|||COHORT||PROSPECTIVE|||||||
33766663|NCT01619657|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766664|NCT02128165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766665|NCT00878332|||COHORT||PROSPECTIVE|||||||
33766666|NCT05942079|||CASE_CONTROL||PROSPECTIVE|||||||
33766667|NCT02712398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766668|NCT01617317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766669|NCT05164497|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The blinding of raters will be ensured for the primary performance-based outcome (i.e., Facilitative Interpersonal Skills) by assigning the video-recorded responses randomly to the raters and concealing the group allocation (experimental vs. control) and time of measurement (week 0, 5, or 10). Furthermore, analyses of outcomes and the conclusion regarding hypotheses 1 and 2 will be performed blinded to allocation (i.e., results in favor of condition X or Y).|Students will be individually randomized within each study site using a random number generator with a 1:1 allocation ratio, determining the order in which the experimental and control condition will be delivered. Half of the students will first receive the experimental condition, followed by the control condition, while the other half will receive the conditions in the reverse order. By the end of the course, all students will have received the same teaching and training, in reverse order. Main outcome analyses will be performed before the crossover (reflecting true randomization).|f|f|f|t
33766670|NCT06546553|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766671|NCT03311022|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33766672|NCT03752710|||CASE_CONTROL||RETROSPECTIVE|||||||
33766673|NCT05114694|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33766674|NCT02341287|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33766675|NCT04004286|||OTHER||PROSPECTIVE|||||||
33766676|NCT03088358|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33766677|NCT06062901|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33766678|NCT06561230|||OTHER||PROSPECTIVE|||||||
33766679|NCT00829205|NON_RANDOMIZED|||TREATMENT||NONE||||||
33766680|NCT00762840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766681|NCT01408758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766682|NCT03150927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Product will be given to subjects in a capsule form. Participant and participants legal guardians, and care providers will not know if the capsule is a placebo or the Probiotic Microbial Composite™|"The Randomized Clinical Trial (RCT) will typically involve 250 subjects randomized into two arms based on age and sex.~Following a positive outcome in the RCT (following 6 months), we envisage converting the study to an observational based study (case-study) based on ethical principles where the placebo arm of the study would be administered the test product. Each subject will be assessed for a total of two years."|t|t|f|f
33978573|NCT02907203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978574|NCT00699504|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33766683|NCT02503917|||COHORT||PROSPECTIVE|||||||
33766684|NCT04671043|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|In each of the conditions, participants will receive a taste-matched drink containing either • caffeine and 10 g rapid-acting carbohydrate (CAF+lowCHO); 20 g rapid acting carbohydrate (20g CHO); or placebo. The drink will be made by an independent member of the research team to ensure that neither the investigators or participants know the order of the drinks (double-blind)|Single-centre, randomised, double-blind crossover design|t|f|t|f
33766685|NCT02882711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766686|NCT01850368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766687|NCT04192474|NA|SINGLE_GROUP||OTHER||NONE||"A prospective, multicenter, single- arm open-label clinical study on the performance and safety~* 50% of the patients undergo flexible diagnostic cystoscopy~* 50% of the patients undergo flexible cystoscopy intervention with endoscopic accessories"||||
33766688|NCT04297787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895171|NCT05483127|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33895172|NCT02167061|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895173|NCT00761540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895174|NCT05502588|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|At the study site participants will be randomized in 1:1 ratio to guided forest bathing walk or self-guided forest bathing walk.|Participants are invited four times over one year to a forest bathing session that takes place on a barrier-free Vancouver, B.C. park trail. Each session is 2-hours including time for pre-test and post-test health measurements. At the study site participants will be randomized in 1:1 ratio to guided forest bathing walk or self-guided forest bathing walk. Subsequent sessions will be counterbalanced.|t|f|f|f
33895175|NCT03215277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is an investigator-blind and subject-blind study.||t|t|t|t
33895176|NCT03898570|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895177|NCT00800072|NA|SINGLE_GROUP||||NONE||||||
33978575|NCT04432948|||OTHER||PROSPECTIVE|||||||
33978576|NCT01361477|||COHORT||PROSPECTIVE|||||||
33978577|NCT02534493|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33978578|NCT03510559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research assistants who will be performing the follow-up assessments of the patient will be blinded as to block group allocation. No other members of the team will be blinded for this study due to methodological constraints as the end result of these blocks is very different due to upper arm weakness expected with brachial plexus blocks, but not with forearm blocks.|"Patients scheduled for ambulatory hand surgery will be assessed in the pre-operative assessment clinic at the time of surgical booking for recruitment into the study by their surgeon. A research assistant will then speak with the patient regarding the study in order to obtain informed consent for their participation.~If the patient consents to participate in the study, they will be randomized into either the brachial plexus or forearm nerve block groups. The research assistants will be blinded as to the patient's allocation and during block performance to minimize bias."|f|f|f|t
33895178|NCT06198257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get seperate treatment protocols and possible efforts will be put to mask the both groups about their treatment.|It will be Randomized Controlled trial in which non probability convenience sampling technique will be used. Two groups of 8 to 12 age will be formed in which participants will be randomly divided by lottery method. Group A will be given modified Thera suits and the other group B will receive spider cage therapy on trunk stability and pelvic control.|t|f|f|f
33978579|NCT02997319|||COHORT||CROSS_SECTIONAL|||||||
33978580|NCT02428699|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33978581|NCT03206710|||CASE_CONTROL||PROSPECTIVE|||||||
33978582|NCT00197951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978583|NCT01025037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895179|NCT01655511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33895180|NCT03629509|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Trial||||
33895181|NCT03529487|NA|SEQUENTIAL||TREATMENT||NONE||||||
33895182|NCT00046566|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The randomization assignment list was generated by a computer program that could only be accessed by the study data coordinator. Apart from the data coordinator, all research personnel, including study coordinators and BP technicians, and the study participants were unaware of treatment assignment.|The trial participants were assigned to take 40 g/d soy protein, milk protein, or carbohydrate supplementation each for 8 weeks in a random order. A 3-week washout period was implemented between the interventions.|t|f|t|t
33895183|NCT03395522|NA|SINGLE_GROUP||TREATMENT||NONE||device group only||||
33895184|NCT03644576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33895185|NCT00833859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895186|NCT04297644|||OTHER||PROSPECTIVE|||||||
33978584|NCT02090829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895187|NCT04642235|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33766689|NCT05415033|NA|SINGLE_GROUP||SCREENING||NONE||||||
33766690|NCT01744925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766691|NCT01878760|||COHORT||PROSPECTIVE|||||||
33766692|NCT01767935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766693|NCT02421900|||CASE_ONLY||PROSPECTIVE|||||||
33766694|NCT00201864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766695|NCT00663377|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33766696|NCT05533359|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients will not know what intervention arm they are in.|Patient-level, four-arm randomized design for Population Health Management interventions: (1) TM + No PN, (2) TM + Request PN, (3) CA + No PN, or (4) CA + Request PN|t|f|f|f
33766697|NCT05107479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since data will be entered directly by health workers via IVR, the outcomes assessor (ie: IVR platform) will have no knowledge of the interventions assigned to individual participants. Additionally, the control group health workers will not be informed they are part of a control arm, but rather that they will receive the training after a delay.|This is a randomized trial with baseline covariate adjustment and stratification. The randomization unit is the health worker. The randomization will be stratified by province, health worker role, and whether the health worker holds a supervisory role to ensure balance of intervention versus control across characteristics. The following baseline characteristics will be measured and adjusted for in the main analysis of primary outcomes to increase statistical efficiency: 1) age, 2) gender, 3) years of work experience in healthcare, 4) prior vaccination experience, 5) facility type, 6) COVID-19 vaccination status, 7) COVID-19 vaccine knowledge, and 8) COVID-19 vaccine beliefs.|t|f|f|t
33766698|NCT04311541|||COHORT||PROSPECTIVE|||||||
33766699|NCT00010686|RANDOMIZED|||TREATMENT||||||||
33766700|NCT01003600|||COHORT||PROSPECTIVE|||||||
33840422|NCT03080168|||COHORT||PROSPECTIVE|||||||
33840423|NCT01718808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895188|NCT04143022|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||40 eligible participants diagnosed as mild to moderate OSA will be enrolled and randomly allocated to group A and group B. Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course. The primary outcomes include the apnea-hypopnea index (AHI), snore time, snore index assessed by polysomnography, snore sound assessed by SnoreLab (snore recording and analysis application), and secondary outcome includes snore outcome survey questionnaire (SOS).|t|f|f|f
33719867|NCT03437525|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study uses a cluster randomized controlled trial design with one experimental condition and one control condition. Ten community health centers (CHC) will be randomized to either the experimental or control condition. The five CHCs in the experimental group will deliver the peer support intervention for 12 months and the five CHCs in the control group will deliver usual care.||||
33721115|NCT04070391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The student investigator (only investigator interacting with participants) and all participants were blinded to the active supplement.|At the start of the trial, participants are instructed to take the provided pills once daily for four weeks. For weeks 5-8, participants will not take any pills (the washout period). Daily pill consumption will resume during weeks 9-12 (the crossover treatment). Participants are their own control in this crossover trial.|t|t|f|t
33721116|NCT02878655|||COHORT||PROSPECTIVE|||||||
33721117|NCT02905682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978585|NCT05036603|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups; different chest physitherapy approach and 1 grup(control): routine medical care for newborns and neonatal intensive care unit's routin daily care||||
33978586|NCT04566809|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33978587|NCT04107870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978588|NCT03825809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33978589|NCT06165900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978590|NCT01134081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978591|NCT04948970|||COHORT||PROSPECTIVE|||||||
33978592|NCT04988386|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study extension study from the AG10-301 double-blind study.||||
33978593|NCT00172757|||CASE_CONTROL||PROSPECTIVE|||||||
33978594|NCT02613923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978595|NCT01968863|||CASE_ONLY||PROSPECTIVE|||||||
33978596|NCT00636896|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33978597|NCT03491449|RANDOMIZED|PARALLEL||TREATMENT||NONE||National, multicenter, open, two-parallel groups, randomized 1: 1||||
33978598|NCT03106870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sixty-two opaque envelopes were numbered serially and in each envelope the corresponding letter which detect allocated group were put according to randomization then all envelops were closed and put in one box .When the first patient arrives , the first envelope were opened and the patient were allocated according to the letter inside .|"Group I: pregnant women who received oral metformin in addition to insulin therapy.~Group II: pregnant women who received insulin therapy only."|t|f|f|f
33978599|NCT05928780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978600|NCT00430079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978601|NCT00899964|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33978602|NCT00348010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978603|NCT00516776|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978604|NCT04659109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study. The study evaluates the efficacy and safety of glenzocimab.|t|t|t|f
33978605|NCT00543478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978606|NCT04608643|||COHORT||PROSPECTIVE|||||||
33978607|NCT00309972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978608|NCT05997407|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978609|NCT01586741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978610|NCT04913896|||COHORT||PROSPECTIVE|||||||
33978611|NCT05282888|||CASE_ONLY||PROSPECTIVE|||||||
33978612|NCT04014322|NA|SINGLE_GROUP||OTHER||NONE||||||
33978613|NCT05903326|||COHORT||PROSPECTIVE|||||||
33978614|NCT03427970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978615|NCT05945641|RANDOMIZED|PARALLEL||PREVENTION||NONE|Since the interventions are exercise interventions it is not possible to blind either the participants or Investigator to which condition each participants leg receives. However, the legs will be randomly assigned to their conditions (neither the participant nor the Investigator will determine this.)|Within subject Design: Each participant will have one leg randomly assigned to each training condition. Training for each leg will occur over the same 12 week training period.||||
33978616|NCT04159909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, single-blinded Treatment vs sham|t|f|f|t
33978617|NCT04770623|NA|SINGLE_GROUP||TREATMENT||NONE||Patients from multiple oncology centers across Egypt are recruited for this study. Second line treatment of advanced gastric cancer will be tested with irinotecan and docetaxel combination||||
33978618|NCT01305070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978619|NCT01104207|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33978620|NCT03409757|||CASE_CONTROL||PROSPECTIVE|||||||
33978621|NCT06198790|||COHORT||PROSPECTIVE|||||||
33978622|NCT04088838|||COHORT||PROSPECTIVE|||||||
33978623|NCT06229925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978624|NCT04188821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978625|NCT05241184|||COHORT||PROSPECTIVE|||||||
33978626|NCT02888171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978627|NCT03101657|||CASE_ONLY||RETROSPECTIVE|||||||
33978628|NCT05531409|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot randomized waitlist-controlled trial.||||
33978629|NCT01161667|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978630|NCT03767088|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled parallel group design||||
33978631|NCT03811080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978632|NCT02083315|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978633|NCT00449150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978634|NCT05153265|||COHORT||PROSPECTIVE|||||||
33978635|NCT03501680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978636|NCT05195372|||COHORT||RETROSPECTIVE|||||||
33721118|NCT00256945|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33978637|NCT01806090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978638|NCT06441396|RANDOMIZED|PARALLEL||OTHER||NONE||Telerehabilitation is a group Video-based rehabilitation is the other group||||
33978639|NCT02490709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978640|NCT01759199|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33978641|NCT02885337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33978642|NCT02327195|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33978643|NCT05216536|||COHORT||PROSPECTIVE|||||||
33978644|NCT05586061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978645|NCT00868400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978646|NCT03215108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Flower-CSEMS vs. Conventional-CSEMS|t|f|t|f
33978647|NCT05086523|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||each patient serves as his/her own control, in the PHC ON (baseline) to OFF transition (early time point), then a week later again, the OFF value (late time point) will be compared to baseline.||||
33978648|NCT01432977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978649|NCT01649622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978650|NCT00214279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978651|NCT03125200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978652|NCT06242756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978653|NCT02534779|NA|SINGLE_GROUP||||NONE||||||
33978654|NCT04126850|||COHORT||PROSPECTIVE|||||||
33766701|NCT05401032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Complete (double) blinding is not possible to achieve, nonetheless, in order to lessen assessment bias, efficacy and safety assessment procedures will be performed by the assigned blinded research staff. In order to assure blinding across the study, randomization data will be kept confidential and will not be accessible to anyone, except to unblinded research staff, pharmacy staff. Both groups will be monitored for the same study duration||f|f|t|t
33766702|NCT03329521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766703|NCT03690934|RANDOMIZED|PARALLEL||TREATMENT||NONE||Assignment||||
33766704|NCT00762021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766705|NCT04778514|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A randomized, open-label, parallel group, 2-way crossover study A total of 24 weeks (6 28-day menstrual cycles); 3 cycles of DPP capsule (12 weeks); 3 cycles of 2 separate tablets (PrEP and COC tablets; 12 weeks)||||
33766706|NCT03164941|||COHORT||PROSPECTIVE|||||||
33766707|NCT03243643|NA|SINGLE_GROUP||OTHER||NONE||||||
33766708|NCT00002928||||TREATMENT||||||||
33766709|NCT02040272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766710|NCT06442540|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33766711|NCT03038984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||120 IBD patients has been randomized to screen for disease activity and FC either OD or every 3 months. 60 patients in each group||||
33766712|NCT00873249|||||PROSPECTIVE|||||||
33766713|NCT03967990|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33766714|NCT01191060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766715|NCT00298142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766716|NCT03116490|||COHORT||PROSPECTIVE|||||||
33766717|NCT04725968|||COHORT||RETROSPECTIVE|||||||
33766718|NCT04071977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Drug|Clinical trial phase IIa|t|f|t|f
33766719|NCT05258123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766720|NCT04851496|||CASE_CONTROL||RETROSPECTIVE|||||||
33766721|NCT04135118|||COHORT||PROSPECTIVE|||||||
33766722|NCT05890625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33766723|NCT03762629|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766724|NCT01434992|||COHORT||PROSPECTIVE|||||||
33766725|NCT02606955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766726|NCT05196048|||CASE_ONLY||PROSPECTIVE|||||||
33766727|NCT05220007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized, prospective comparative study||||
33766728|NCT04342624|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33766729|NCT02702700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766730|NCT04810039|||OTHER||PROSPECTIVE|||||||
33766731|NCT02800603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33766732|NCT03366220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33766733|NCT05309460|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm, block randomized Arm A: Nifedipine Arm B: Labetalol||||
33766734|NCT02603315|||COHORT||RETROSPECTIVE|||||||
33766735|NCT04407351|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33766736|NCT03326947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895189|NCT03551509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895190|NCT04810052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895191|NCT03401749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33895192|NCT01273818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33895193|NCT03847311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research pharmacist will randomize and prepare the drugs so that the drugs look similar, the pharmacist will dispense the drugs into vials, and label the drug so is not identified.|Double blind study|t|f|t|t
33895194|NCT03853421|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|The clinical study will be performed in a double-blind manner. Only the site pharmacy personnel, who are responsible for preparing the study drug, will have knowledge of the treatment assigned|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.|t|t|t|t
33895195|NCT05006612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients will be randomly assigned into two equal comparable groups using computer- generated random numbers in opaque closed envelopes, each of which will include 30 patients. Randomization will be done by statistician and each group of the patient will revealed only when the included patient is transferred to preanesthetic room.|"To determine the analgesic effect of ultrasound guided Serratus anterior block combined with modified pectoral nerve block compared to ultrasound guided Serratus Anterior block in patients undergoing modified radical mastectomy regarding the following :~1-Post-operative opioid (morphine) consumption in the 1st 24 hours 2- Post-operative Numeric Pain Rating Scale.~3. Effect on hemodynamics:~Mean arterial blood pressure and Heart rate.~4. Intraoperative fentanyl consumption.~5. Duration of analgesic effect"|t|f|t|f
33895196|NCT01917331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978655|NCT02854280|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33978656|NCT02567968|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33978657|NCT06004102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978658|NCT03164603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978659|NCT04860492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization sequence will be computer-generated by the study coordinating team||t|f|t|f
33978660|NCT05293353|||COHORT||PROSPECTIVE|||||||
33978661|NCT01624519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978662|NCT02946385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978663|NCT00658398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895197|NCT03433066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This clinical study will be conducted on twenty-two (22) interproximal intrabony defects in patients with moderate to severe chronic periodontitis.These patients will be divided randomly into two groups:~* Group I: (test) will include eleven interproximal intrabony defects that will be treated with (Advanced platelet rich fibrin \& biphasic alloplast)~* Group II: (control) will include eleven interproximal intrabony defects that will be treated with (biphasic alloplast mixed with saline.)"|t|f|t|t
33895198|NCT01419990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895199|NCT00919412|||COHORT||PROSPECTIVE|||||||
33895200|NCT06269523|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895201|NCT00489762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33895202|NCT01733563|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33895203|NCT01237470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895204|NCT03752905|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Single-blind|Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center|t|t|t|t
33895205|NCT00242879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895206|NCT00834548|||COHORT||PROSPECTIVE|||||||
33895207|NCT04937023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33895208|NCT03926403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895209|NCT00396578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895210|NCT06380140|||COHORT||PROSPECTIVE|||||||
33895211|NCT03681717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895212|NCT05446844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33895213|NCT04207710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The microbiology lab staff culturing and analyzing the samples for microbial growth will not know what type of treatment each sample received. Each sample will only be labelled with a numerical string. The research staff will have a spreadsheet to determine which numerical string corresponds with which treatment.|72 participants will have an area of skin on the wrist and lower back swabbed three times each. First, the untreated patch of skin will be swabbed, then it will be treated with ChloraPep and swabbed, then Pain Ease spray will be applied and the area will be swabbed again. The same process will be performed using Ethyl Chloride spray instead of Pain Ease on the opposite wrist and adjacent area on the lower back. The bacterial growth will be compared amongst the different treatments, based on the number of colony forming units that are present.|f|f|f|t
33895214|NCT05954039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895215|NCT06257212|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Single-blinded 1:1:1 block randomized controlled trial (with varying block sizes of 3-6), stratified by sex.|t|f|f|f
33895216|NCT00588679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895217|NCT00991900|||OTHER||PROSPECTIVE|||||||
33895218|NCT04840667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895219|NCT01420185|||CASE_CONTROL||RETROSPECTIVE|||||||
33895220|NCT03444337|||CASE_ONLY||PROSPECTIVE|||||||
33895221|NCT02282761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895222|NCT01266096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895223|NCT06146114|||OTHER||RETROSPECTIVE|||||||
33895224|NCT00082082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895225|NCT05432570|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Before the operation, the appropriate anesthesia approach will be selected for the randomized patient group and anesthesia management will be performed according to the selected group. The surgeon who will perform the operation will perform the operation without knowing which method is chosen.||t|f|f|f
33895226|NCT04802746|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Part A of the Study will be 3-Way Crossover Design and Part B will be a Parallel Design.|t|t|t|t
33895227|NCT03015532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895228|NCT04234438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective open-label clinical trial, included 32 eyes of 29 patients who had cystoid macular edema secondary to retinitis pigmentosa. Patients were treated by subliminal micropulse yellow laser for one session. Central macular thickness and best corrected visual acuity changes were investigated just before the treatment and 1 year later after the one session of the treatment.||||
33895229|NCT02910778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895230|NCT04264104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895231|NCT04837560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895232|NCT02334709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895233|NCT00012610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895234|NCT05434546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, open-label, multicenter, randomized, parallel group study||||
33895235|NCT05564130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895236|NCT00691548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895237|NCT02724033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33895238|NCT03032744|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group will receive the morning dose of their daily preventive asthma medication at school. The student \& family will be responsible to administer the evening dose \& both doses on non-school days.||||
33895239|NCT00454597|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33978664|NCT00777426|||COHORT||PROSPECTIVE|||||||
33978665|NCT02899390|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33978666|NCT00582400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978667|NCT01098123|||CASE_CONTROL||RETROSPECTIVE|||||||
33978668|NCT03288766|||CASE_ONLY||PROSPECTIVE|||||||
33978669|NCT02837757|NA|SINGLE_GROUP||OTHER||NONE||||||
33978670|NCT06344338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients who meet the eligibility requirements will be randomized in a 1:1 ratio to undergo targeting tDCS stimulation (up to 10 times) or sham stimulation|t|t|f|f
33978671|NCT04415125|NA|SINGLE_GROUP||SCREENING||NONE||||||
33978672|NCT00028665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978673|NCT05895552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895240|NCT05888116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To maintain the double-blind, both the investigational and comparator products will be dispensed in white boxes, labeled with the study code and the patient code. Each patient code will be assigned to one treatment or the other according to a predetermined randomization list.|"This is a multicenter, randomized, controlled, double-blind study with two parallel group of subjects. The clinical investigation will be performed in 9 clinical sites.~The follow-up will be 4 weeks, with 3 face-to-face controls (baseline, 7 days and 30 days) and 2 telephone controls (3 days and 21 days).~At all on-site visits (baseline, Day 7, Day 30), the investigator will record the severity of patient-reported symptoms (via VAS of 0 to 100 mm) and perform a gynecological examination to evaluate signs of vaginal atrophy. Potential adverse events and potential device deficiencies will be recorded at each visit.~The patients will have a patient notebook where they will record the intensity of the symptoms on the third day and weekly, as well as the possible appearance of adverse events or product deficiencies."|t|f|t|f
33895241|NCT00345072|RANDOMIZED|PARALLEL||ECT||NONE||||||
33895242|NCT01702142|||CASE_ONLY||PROSPECTIVE|||||||
33895243|NCT06483776|||CASE_CONTROL||PROSPECTIVE|||||||
33895244|NCT05052203|||COHORT||PROSPECTIVE|||||||
33895245|NCT05992077|NA|SINGLE_GROUP||TREATMENT||NONE||Non-comparative multicenter pilot therapeutic prospective study. First, all children aged ≥ 6 years old and adolescents (expected 21000 participants) will be screened for HCV infection using HCV rapid test. HCV RNA will be performed in case of HCV rapid test positivity. Then, children and adolescents confirmed with active HCV infection (positive HCV RNA) during the screening phase will be referred to a specific consultation for treatment after evaluation of liver disease. We expect to enroll 60 participants in the therapeutic phase.||||
33895246|NCT06054360|||CASE_ONLY||PROSPECTIVE|||||||
33895247|NCT05998343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Primary outcomes will be assessed after 12 weeks by a research assistant who is blinded to the intervention group and who has had no prior contact with the participants. Participants will also be instructed not to reveal the intervention they have received to any research staff.|This study is a three-arm outcome assessor blinded randomized controlled trial will follow SPIRIT reporting guidelines and is part of a program of research that adheres to the ORBIT model for developing complex behavioural interventions.|f|f|f|t
33895248|NCT05309083|NA|SINGLE_GROUP||TREATMENT||NONE||In Aim 2, participants will receive the mindfulness intervention as part of the open pilot.||||
33895249|NCT02058121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895250|NCT00704106|||COHORT||OTHER|||||||
33895251|NCT06028815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895252|NCT03648450|||CASE_ONLY||PROSPECTIVE|||||||
33766737|NCT04654247|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33766738|NCT06619457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33895253|NCT06127212|RANDOMIZED|CROSSOVER||OTHER||NONE||This was a bioequivalence study.||||
33895254|NCT03473873|||COHORT||PROSPECTIVE|||||||
33895255|NCT00002700|RANDOMIZED|||TREATMENT||||||||
33895256|NCT00418743|||CASE_ONLY||PROSPECTIVE|||||||
33895257|NCT03503123|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978674|NCT00006470||||TREATMENT||||||||
34077045|NCT03625596|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Crossover assignment|t|f|t|t
34077046|NCT01309295|||COHORT||PROSPECTIVE|||||||
33766739|NCT06207643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766740|NCT01947595|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766741|NCT05236621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766742|NCT02172300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766743|NCT05310201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33766744|NCT06440018|||CASE_CONTROL||PROSPECTIVE|||||||
33766745|NCT01354275|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33766746|NCT00221949|||||PROSPECTIVE|||||||
33766747|NCT01112696|NA|SINGLE_GROUP||OTHER||NONE||||||
33766748|NCT03584776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766749|NCT03596437|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33766750|NCT05985603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766751|NCT05761145|||COHORT||PROSPECTIVE|||||||
33766752|NCT05258747|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33766753|NCT01027364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766754|NCT06162338|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective, Single-center, Open-label, Single-arm study||||
33766755|NCT06620159|||COHORT||RETROSPECTIVE|||||||
33766756|NCT03101124|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||12 participants will be included in each of 3 groups: wound moistening group (skin reduction surgery), wound bolus group (after skin reduction surgery), and (for comparison) a group getting usual intravenous tranexamic acid before orthopedic surgery. It is not possible to conduct a formal power calculation, as it is completely unknown which concentrations could be expected after topical use; however, these concentrations are expected to be considerably lower than after intravenous use. Consequently, it is expected that the AUC values in all subjects in the topical (skin reducing surgery) group are far lower than in all subjects in the intravenous (orthopaedic surgery) group. 12 subjects is therefor considered an appropriate number.||||
33766757|NCT01375205|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33766758|NCT00421525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766759|NCT05436379|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed study will use theta burst stimulation (TBS) in an open-label, non-randomized open study for young adults with depression. The study will include measurement of brain function before and after TBS to investigate treatment mechanisms. A subset of participants will also complete a training to enhance positive emotions.||||
33721119|NCT00353912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721120|NCT02824250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33721121|NCT00992082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33766760|NCT04598932|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33766761|NCT05625581|||CASE_CONTROL||PROSPECTIVE|||||||
33766762|NCT02220296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766763|NCT03861520|||CASE_ONLY||PROSPECTIVE|||||||
33766764|NCT01913639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766765|NCT01719237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766766|NCT01862991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766767|NCT03450681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766768|NCT06417541|||COHORT||PROSPECTIVE|||||||
33766769|NCT02548858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077047|NCT05384002|||COHORT||OTHER|||||||
33721122|NCT01715311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840424|NCT00640770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840425|NCT05125926|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33840426|NCT03691077|NA|SINGLE_GROUP||TREATMENT||NONE||The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.||||
33895258|NCT03149835|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895259|NCT02863263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33978675|NCT04297228|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Program to Implement a Family Centered Pediatric Obesity Treatment Program in a Safety Net Clinic using Goal Setting Principles and Behavior Change Theory||||
33978676|NCT04909437|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomised, double blind, placebo controlled, parallel arm, cross-over|t|t|t|t
33978677|NCT03679741|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33978678|NCT00826774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978679|NCT04442776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial (Parallel Assignment)|t|f|t|t
34077048|NCT04078711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077049|NCT03748134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077050|NCT03334357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077051|NCT02915224|||CASE_ONLY||PROSPECTIVE|||||||
34077052|NCT00875563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077053|NCT00514618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077054|NCT05704400|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II Proof of concept, the Dual 1 is a before-after clinical trial testing the superiority of rituximab plus daratumumab in maintaining drug free disease remission in patients with multi-drug dependent nephrotic syndrome||||
34077055|NCT04743934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077056|NCT05682547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Masked examiner for all clinical assessments will not involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the two groups.|Prospective, randomised control trial.|f|t|t|t
34077057|NCT04528134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not know which interventions they receive. The investigator, who will be providing the treatment, will be aware of which treatments they are receiving (the investigator is impossible to mask due to the different applications of the treatment interventions). Outcomes assessors will be masked and score outcomes based on photos and microbiological data that is de-identified.|Subjects will be randomized into one of 3 groups, each of which will receive two of the following three interventions: extended contact varnish, traditional fluoride varnish, placebo varnish. Subjects will receive the interventions in a split-mouth design, with one treatment on half of their teeth and another treatment on the other half of their teeth.|t|f|f|t
34077058|NCT01124747|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34077059|NCT03834025|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE|Participants are unaware of other study arms.|||||
33895260|NCT00451087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895261|NCT02549950|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895262|NCT05586334|NA|SINGLE_GROUP||PREVENTION||DOUBLE|lack of result reporting||t|f|t|f
33895263|NCT05953064|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33895264|NCT06498037|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||a single-arm PK-study design||||
33895265|NCT03306147|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33895266|NCT03944837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895267|NCT06499636|||COHORT||OTHER|||||||
33895268|NCT02912871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895269|NCT00404729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895270|NCT01440101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895271|NCT05732129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895272|NCT06513676|||COHORT||PROSPECTIVE|||||||
33895273|NCT05936086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895274|NCT00345111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895275|NCT00142506|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33978680|NCT05608512|||OTHER||CROSS_SECTIONAL|||||||
33978681|NCT04000503|RANDOMIZED|PARALLEL||SCREENING||NONE||Pragmatic cluster randomized control trial||||
33978682|NCT02134756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33978683|NCT00958178|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33978684|NCT00439790|||COHORT||PROSPECTIVE|||||||
33978685|NCT03256110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster-randomized design with providers randomized to intervention or control and patients nested within provider.||||
33978686|NCT05889871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978687|NCT03296475|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A single arm prospective cohort study||||
33978688|NCT01055626|||COHORT||CROSS_SECTIONAL|||||||
33978689|NCT00308529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978690|NCT00543309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077060|NCT05722262|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, open-label, six-sequence, three-period, crossover study|t|t|t|t
34077061|NCT00585884|||OTHER||PROSPECTIVE|||||||
34077062|NCT03307928|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The investigator did not have access to the exams that the volunteers realized, either they have access to what they were doing or the order of the exams.|The participants were divided into two groups: (1) hypertension without OSA (NO-OSA group; AHI \< 5 events/h; n = 15) and (2) hypertension with OSA (OSA group: AHI ≥ 15 events/h; n = 13).|t|f|t|f
34102950|NCT05212337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|groups designated with X and Y|Interim analysis will be forward to study committee to evaluate data and decide whether study should proceed to be stopped|t|t|t|t
34102951|NCT00859274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34102952|NCT06487286|||COHORT||PROSPECTIVE|||||||
34102953|NCT02271919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077063|NCT03796312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Physiological data was collected by nurses trained by the lead researcher. Data on neonatal comfort behavior was collected by a second researcher and by research nurses who had been trained by the lead researcher. Those responsible for data collection were blinded as to the allocation of infants they were assessing.|A randomized controlled two-group pre-test and repeated post-test study design were adopted. Preterm infants were randomly allocated before bathing by the researcher using a random computer-generated table to one of two groups: sponge bathing (routine care) or tub bathing. The bathing procedures were performed by the researcher. Nurses and a second researcher were blinded to the study hypotheses.|f|f|f|t
34077064|NCT02318849|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Students did not know the schedule for rolling out the intervention by university.|Online educational intervention of choice to be an organ donor was provided to undergraduate students at three universities. The intervention launch at the universities were sequentially initiated, in random order. The design included cross-sectional assessments (unique respondents at each site over time ) as well as longitudinal assessments (same students repeatedly assessed over time).|t|f|f|f
34077065|NCT01575171|||CASE_CONTROL||PROSPECTIVE|||||||
34077066|NCT02513004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077067|NCT05983796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840427|NCT00144495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840428|NCT00604708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33840429|NCT02701881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840430|NCT00777738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840431|NCT03655782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Staff will not be told whether the subject was in the treatment or control group. The statistician will not know which group was the treatment group and which was the control group.|The investigators will show that working memory, processing speed, reading speed, and attention improve more in mTBI patients after neurotraining that improves sensory and processing speed functions, improving the motion working range (PATH), more than after Sham training that activates a different visual pathway, or N-Back WM training that activates dlPFC to show the feasibility of PATH training to improve cognitive skills the most. MEG brain imaging will be used to show that PATH neurotraining improves the function of the dorsal, attention, and working memory networks (e.g., PPC, DLPFC and ACC/PCC areas), reducing over recruitment, more than found after N-Back WM training.|t|t|f|t
33840432|NCT02536820|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840433|NCT05410639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33895276|NCT04763525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895277|NCT03364218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895278|NCT01697345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895279|NCT04192604|||COHORT||PROSPECTIVE|||||||
33895280|NCT04874740|||COHORT||OTHER|||||||
33895281|NCT02650011|||COHORT||PROSPECTIVE|||||||
33721123|NCT02024620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33721124|NCT01883414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721125|NCT06120036|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33721126|NCT03674918|||COHORT||RETROSPECTIVE|||||||
33721127|NCT00048295|RANDOMIZED|||TREATMENT||DOUBLE||||||
33840434|NCT04557358|||COHORT||PROSPECTIVE|||||||
33840435|NCT02793739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840436|NCT01277887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840437|NCT03113318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840438|NCT02876289|||COHORT||RETROSPECTIVE|||||||
33840439|NCT05338125|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot proof-of-concept study||||
33840440|NCT00612872|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33978691|NCT04637997|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind study. Neither investigator nor patient knows the compression class (class I versus class II) of the compression stockings used in the different investigation periods in this patient.|This is a single group study with crossover components. Participants receive randomly and double-blinded either class I compression stockings or class II compression stockings. After four weeks, an exchange of compression classes takes place, so that all participants wear both classes of compression stockings within eight weeks.|t|f|t|f
33978692|NCT03561883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978693|NCT00401778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978694|NCT05607914|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978695|NCT05733247|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33978696|NCT03832179|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel groups, one group receiving anti-vascular endothelial growth factor and the other group receiving Ozurdex.||||
33978697|NCT05584475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978698|NCT03937453|||COHORT||PROSPECTIVE|||||||
33978699|NCT05608421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to one of the two groups for the duration of the study.|t|f|f|f
33978700|NCT03577509||SEQUENTIAL||TREATMENT||NONE||||||
33978701|NCT04108325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978702|NCT02036372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978703|NCT04541719|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33978704|NCT01208480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978705|NCT04299178|||COHORT||PROSPECTIVE|||||||
33978706|NCT03307239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the researcher assigned participants to one of the two groups: cold application (experimental group) or tap water packs application (sham group) according the random allocation sequence.|subjects in the experimental group received cold application of 600 g ice packs 15 min before CTR, whereas subjects in the sham group|t|f|f|f
33978707|NCT02551497|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33978708|NCT03164395|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in block fashion to either internal or external cardioversion||||
33978709|NCT05075564|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33978710|NCT06357338|||CASE_ONLY||RETROSPECTIVE|||||||
33978711|NCT00605748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978712|NCT02286128|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978713|NCT00842842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978714|NCT00695266|||COHORT||PROSPECTIVE|||||||
33978715|NCT00487227|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
33978716|NCT02295956|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33978717|NCT02234466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978718|NCT04598243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978719|NCT03151018|||CASE_ONLY||PROSPECTIVE|||||||
33978720|NCT04057703|||COHORT||PROSPECTIVE|||||||
33978721|NCT04483583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978722|NCT06304389|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Patients with refractory epilepsy (divided in non responders \& responders), and healthy subjects|t|f|f|f
33978723|NCT03270007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978724|NCT02026453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33721128|NCT03826979|NA|SINGLE_GROUP||TREATMENT||NONE||The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months||||
33978725|NCT05404035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Randomized Control Trial, Efficacy Study|t|f|t|f
33978726|NCT05201690|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33978727|NCT06348693|||OTHER||PROSPECTIVE|||||||
33978728|NCT02747745|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33978729|NCT05366959|||OTHER||CROSS_SECTIONAL|||||||
33978730|NCT01526538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978731|NCT00796900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978732|NCT02287532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895282|NCT02371629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895283|NCT04847271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895284|NCT05223101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895285|NCT01386671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895286|NCT04934735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The intervention group received a complex case-management rehabilitation program (described below) and the control group received the standard care.|"This prospective randomized controlled trial was conducted among patients who underwent an uncomplicated acute MI. Two weeks after hospitalization patients were referred to an examination by a cardiologist (to obtain a standardized clinical examination for all participants). Following this examination, the patients were assigned to an intervention group and a control group using simple randomization based on a computer-generated random sequence of numbers.~The main outcomes are the rate of return to work in each phase of the study (meaning after 6,12,18, and 24 months)"|t|f|f|f
33895287|NCT02875288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895288|NCT01897194|||CASE_CONTROL||PROSPECTIVE|||||||
33895289|NCT00499915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33895290|NCT00860470|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33895291|NCT05531240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895292|NCT03543371|||COHORT||PROSPECTIVE|||||||
33895293|NCT05326919|||COHORT||PROSPECTIVE|||||||
33895294|NCT00290472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978733|NCT04418141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978734|NCT02465658|||CASE_ONLY||RETROSPECTIVE|||||||
33978735|NCT03102580|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Surgeon offices will be randomized to Usual Care or Intervention sites. During Aim 2, after completing the surveys in the clinic, usual care patients and surgeons will have the ability to see PRO scores, but will NOT receive feedback (no OA Care Plan). This is the current standard of care in orthopedic clinics. For intervention sites, the patient and surgeon will receive the OA Care Plan.~During Aim 3, Usual Care sites will receive the OA Care Plan, and Intervention sites will receive the Enhanced OA Care Plan, including access to Patient Peer Support website and PCP reports (currently under development). All surgeons that used the OA Care plan in Aim 2 will be invited to participate in the Enhanced OA Care plan in Aim 3."||||
33978736|NCT05367908|||COHORT||PROSPECTIVE|||||||
33978737|NCT00238069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978738|NCT01925313|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978739|NCT01051193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978740|NCT01783171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978741|NCT02070237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978742|NCT06495983|||COHORT||PROSPECTIVE|||||||
33978743|NCT03228095|||COHORT||PROSPECTIVE|||||||
33978744|NCT01418157|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33978745|NCT04276038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978746|NCT02658604|||COHORT||CROSS_SECTIONAL|||||||
33978747|NCT00949299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33978748|NCT05515952|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33978749|NCT03230851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978750|NCT02270736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978751|NCT00894296|||CASE_CONTROL||PROSPECTIVE|||||||
33978752|NCT01291303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978753|NCT02348268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978754|NCT05801263|||COHORT||PROSPECTIVE|||||||
33978755|NCT02647983|NA|SINGLE_GROUP||OTHER||NONE||||||
33978756|NCT04901325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978757|NCT00989352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766770|NCT05660954|NA|SINGLE_GROUP||TREATMENT||NONE||"Experimental arm Patients with advanced radioactive-iodine refractory DTC who progressed to previous TKIs (including but not limited to lenvatinib or sunitinib). Patients will have not received previously cabozantinib, selective small-molecule BRAF kinase inhibitors, immune checkpoint inhibitor therapy, or systemic chemotherapy regimens~All patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation."||||
33766771|NCT00702416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766772|NCT00957931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766773|NCT03155230|||COHORT||PROSPECTIVE|||||||
33766774|NCT05303064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766775|NCT05065190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766776|NCT02344394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766777|NCT03283696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766778|NCT00791323|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33766779|NCT02958462|NA|SINGLE_GROUP||SCREENING||NONE||||||
33766780|NCT00001866||||TREATMENT||||||||
33766781|NCT06205797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766782|NCT03567486|||COHORT||PROSPECTIVE|||||||
33766783|NCT03841123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766784|NCT01098149|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33766785|NCT01394484|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33766786|NCT06158763|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This will be a randomized controlled trial to evaluate the feasibility and acceptability of delivering a new intervention. Participants who meet the inclusion criteria will be randomly allocated to intervention or control groups in a 1:1 ratio.||||
33895295|NCT01006330|||COHORT||PROSPECTIVE|||||||
33895296|NCT04109040|||COHORT||PROSPECTIVE|||||||
33895297|NCT01947270|||OTHER||PROSPECTIVE|||||||
33895298|NCT01667887|||COHORT||PROSPECTIVE|||||||
33895299|NCT04885543|||COHORT||PROSPECTIVE|||||||
33895300|NCT04813744|NA|SINGLE_GROUP||TREATMENT||NONE||The clinical studies were carried out in the occlusal dentin caries of 25 permanent molar teeth in participants with high caries risk and between 19-35 years of age. The caries tissue were removed with hand instruments in accordance procedure of atraumatic restorative treatment. Then the total counts of bacteria, facultative anaerobe bacteria, Mutans Streptococci, and Lactobacilli supp. counts in the affected dentin were evaluated quantitatively. The weights of samples were measured with an electronic balance (Shimadzu, Type AX200, Japan). The cavities were restored with a glass ionomer cement (KetacTM Molar Easymix, ESPE Dental AG, Seefeld, Germany). Twenty replicas of randomly selected ART restorations were prepared and marginal adaptation was evaluated by scanning electron microscopy. After 6 months, the same protocols were repeated. Data were analyzed with Paired Sample and Wilcoxon Paired t-tests, Pearson, Spearman correlation, and Chi-Square tests (p\< 0.05).||||
33895301|NCT03340350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766787|NCT04394507|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33766788|NCT04250337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, parallel group, placebo controlled|t|t|t|t
33766789|NCT00409786|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33766790|NCT01876563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766791|NCT04464616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33766792|NCT02635724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766793|NCT01320735|||||PROSPECTIVE|||||||
33978758|NCT00577460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978759|NCT01755858|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33978760|NCT04002388|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33978761|NCT04787302|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978762|NCT04832230|||CASE_CONTROL||PROSPECTIVE|||||||
33978763|NCT05624931|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Aims 1 and 2 will assess a single group of pregnant women. In Aim 3, a randomized control trial will include an intervention group and control group that are running in parallel.|f|f|t|t
33978764|NCT04085770|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized ,controlled, open-label, parallel clinical trial||||
33978765|NCT06484218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978766|NCT06382519|||COHORT||PROSPECTIVE|||||||
33978767|NCT01574248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978768|NCT02655237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978769|NCT01581957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33978770|NCT01102465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978771|NCT02608502|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33895302|NCT02649036|||COHORT||RETROSPECTIVE|||||||
33895303|NCT04847128|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors and statisticians were blinded to group allocations.||f|f|f|t
33895304|NCT00193505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895305|NCT02743468|||COHORT||CROSS_SECTIONAL|||||||
33895306|NCT06117514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895307|NCT00160927|||CASE_CONTROL||OTHER|||||||
33895308|NCT04919564|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Allocation group was blinded for participants, care provider, and investigators||t|t|t|f
33895309|NCT05816681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895310|NCT00786240|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895311|NCT00565630|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33895312|NCT02820259|||COHORT||PROSPECTIVE|||||||
33895313|NCT02085811|||COHORT||RETROSPECTIVE|||||||
33895314|NCT00548912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978772|NCT00414401|RANDOMIZED|PARALLEL||||NONE||||||
33895315|NCT05495607|||COHORT||RETROSPECTIVE|||||||
33895316|NCT06392490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33895317|NCT01199094|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33895318|NCT02261740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895319|NCT02605577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33895320|NCT02950506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33895321|NCT05063370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895322|NCT00075517||||TREATMENT||NONE||||||
33978773|NCT00421005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978774|NCT04854148|||CASE_ONLY||CROSS_SECTIONAL|||||||
33978775|NCT04550949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978776|NCT04289545|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33978777|NCT03076021|NA|SINGLE_GROUP||OTHER||NONE||Prospective, pre-post drug interaction study evaluating an approved drug (Phase 4) with a Phase 1 study design.||||
33978778|NCT04238156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978779|NCT00965653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895323|NCT00845429|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33895324|NCT03233399|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895325|NCT04519554|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33895326|NCT02327650|||COHORT||RETROSPECTIVE|||||||
33895327|NCT05614011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective clinical study enrolling adult patients with signs and symptoms that are consistent with SARS-CoV-2. Positive and negative specimens will be run on the Q-POC SARS-CoV-2 Assay in comparison with an FDA-approved reference standard to calculate both the positive percent agreement (PPA, or sensitivity) and the negative percent agreement (NPA, or specificity)||||
33895328|NCT01663649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766794|NCT05121623|||OTHER||PROSPECTIVE|||||||
33766795|NCT03176446|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||The total sample is divided into two subgroups, with 105 children aged 5 to 8 years and 105 children aged 9 to 12 years. The analysis is more sensitive and specific to each subgroup. The results of each subgroup will be analyzed in isolation and give rise to two different papers.|f|f|t|f
33766796|NCT06199661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766797|NCT04049903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766798|NCT01382966|||||CROSS_SECTIONAL|||||||
33766799|NCT00227500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766800|NCT04925674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766801|NCT06201221|||COHORT||RETROSPECTIVE|||||||
33766802|NCT06295614|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site, single-arm, non-blinded, non-randomized, interventional||||
33766803|NCT02492113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766804|NCT05080881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33766805|NCT05960760|||COHORT||CROSS_SECTIONAL|||||||
33766806|NCT02144948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766807|NCT00941564|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33766808|NCT05232513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Hand massage|f|f|f|t
33766809|NCT04182880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766810|NCT05730790|RANDOMIZED|PARALLEL||PREVENTION||NONE||Block randomization||||
33766811|NCT01760018|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33766812|NCT00003216|RANDOMIZED|||TREATMENT||||||||
33766813|NCT02590692|NA|SINGLE_GROUP||OTHER||NONE||||||
33766814|NCT06089174|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study is a descriptive cohort study comparing the occurrence of infection between exposed (runners of an ultra-trail) and unexposed subjects (their companions).||||
33766815|NCT01293019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766816|NCT03350243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33766817|NCT00332605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766818|NCT03825432|||OTHER||CROSS_SECTIONAL|||||||
33766819|NCT02673905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766820|NCT04408547|||COHORT||PROSPECTIVE|||||||
33766821|NCT05091944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33766822|NCT04323228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The intervention-supplement and isocaloric-placebo will be served in the same shape, size and color. the care providers (nurses, dietitians) will not know members of each groups or the nature or composition of the ONS.|Participants will be randomly allocated into two study groups; intervention group (IG, n=20) and placebo group (PG, n=20). Computer-generated random numbers will be used to randomize the participants into one of two intervention groups.|t|t|f|f
33766823|NCT03917641|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant is his own control||||
33895329|NCT04544566|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33766824|NCT02678767|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33766825|NCT05269784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766826|NCT00068380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766827|NCT05403060|RANDOMIZED|PARALLEL||PREVENTION||NONE||An intervention group and a control group (no intervention, with usual education)||||
33766828|NCT00348660|||COHORT||PROSPECTIVE|||||||
33895330|NCT02054858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33895331|NCT03360929|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open-label, dose escalation and phase II study, consisting of dose escalation study in Part A and phase II study in Part B.||||
33895332|NCT01756157|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33895333|NCT01817257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895334|NCT03304808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895335|NCT03469427|||CASE_ONLY||PROSPECTIVE|||||||
33895336|NCT04026789|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial (plus prospective cohort for those interested in participation but unwilling to be randomized)||||
33978780|NCT04132856|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33978781|NCT02863575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978782|NCT05561400|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Sham controlled blinded crossover design|t|f|t|f
33766829|NCT05914025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766830|NCT03321006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766831|NCT01679301|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33766832|NCT03274219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766833|NCT02676193|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33766834|NCT02679521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978783|NCT05478226|||COHORT||RETROSPECTIVE|||||||
33978784|NCT02015000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978785|NCT04590443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978786|NCT01830569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978787|NCT01861366|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33978788|NCT04842058|||COHORT||PROSPECTIVE|||||||
33978789|NCT00143156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33978790|NCT05439824|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33978791|NCT00344552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978792|NCT03342144|||COHORT||PROSPECTIVE|||||||
33978793|NCT00950807|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978794|NCT05084781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind - patient and outcome assessor.|Paralle study arms for 1)coblation debridement, 2) mechanical debridement|t|f|f|t
33978795|NCT00756288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33978796|NCT01111110|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34077068|NCT04001010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077069|NCT05459909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978797|NCT03836209|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Randomized trial of Daunorubicin/Cytarabine and High Dose Cytarabine + Gilteritinib vs Midostaurin for Induction and Consolidation. FLT3 mutated patients will be stratified based on TKD vs ITD. Patients who are FLT3 ITD will be further stratified by Signal Ratio (high vs. low of FLT3 Wild Type) and Nucleophosmin 1-Mutated (NPM1) \[positive vs negative\].||||
33978798|NCT01042366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978799|NCT00724568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978800|NCT01451853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978801|NCT00526968|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33978802|NCT03703713|||COHORT||PROSPECTIVE|||||||
33978803|NCT04360031|||COHORT||PROSPECTIVE|||||||
33978804|NCT06486246|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||UNIcenter Non-randomized trial|t|t|f|t
33978805|NCT00067236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978806|NCT04668339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind|sequential assignment|t|t|t|t
33978807|NCT04858100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978808|NCT04189848|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978809|NCT04276870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978810|NCT02519413|||COHORT||RETROSPECTIVE|||||||
33978811|NCT00098488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978812|NCT03659409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants are randomized to receive either the intervention or treatment as usual. The intervention is for 4 weeks, and 3 months from the start of the intervention, participants who were assigned to the treatment as usual group will receive the same intervention.||||
33978813|NCT02240407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33978814|NCT05701683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077070|NCT05225025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34077071|NCT00922116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077072|NCT04630223|||CASE_CONTROL||PROSPECTIVE|||||||
34077073|NCT00437996|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34077074|NCT00616746|NA|SINGLE_GROUP||||TRIPLE|||t|f|t|t
34077075|NCT05724342|||COHORT||PROSPECTIVE|||||||
34077076|NCT05411393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the group allocation of the patients.|Experimental arm versus the control arm|f|f|f|t
34077077|NCT03019900|||||CROSS_SECTIONAL|||||||
34077078|NCT01625871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077079|NCT02415192|||COHORT||PROSPECTIVE|||||||
34077080|NCT06136468|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34077081|NCT06239610|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||longitudinal, repeated measures design replication study||||
34103512|NCT05213429|||COHORT||PROSPECTIVE|||||||
34103513|NCT06689033|||CASE_CONTROL||PROSPECTIVE|||||||
34103514|NCT00870324|||COHORT||PROSPECTIVE|||||||
34103515|NCT06687811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766835|NCT03240536|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Study||||
33766836|NCT01346514|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766837|NCT02200939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766838|NCT00884858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103516|NCT05465408|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33766839|NCT05157841|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Individuals preparing and administering study drug, or transporting unblinded drug will not be allowed to perform any of the study assessments after randomization (with the possible logistical exception of drawing blood in the operating room (OR) to be processed by blinded staff for the PK assessments) or reveal the assigned study treatment to any other members of the study team at any time. Additionally, efforts will be made to prevent the subject from observing the study drug syringe. Staff members conducting study-specific, postsurgical assessments and the subjects will remain blinded to the assigned treatment throughout the study in part by not being present during the administration of the nerve block. The site PI must be blinded to the study drug and will not be involved in and/or present during study drug administration. No crossover will be permitted between the blinded and unblinded study personnel throughout the study.||t|f|t|t
33766840|NCT06626217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional prospective single-arm study||||
33766841|NCT04488367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33766842|NCT02039661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766843|NCT02679534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895337|NCT05015387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients were allocated by the Examiner 1. The same examiner performed the coding and randomization of the participants in the treatment groups with a computer-generated randomization table. Both groups received full-mouth minimally invasive non-surgical therapy procedure by single periodontist (Examiner 2), and patients in MINST+PACNs group received collagen hydrogel chips with proanthocyanidins, placed subgingivally in periodontal pockets with PPD≥4mm. After minimally invasive non-surgical therapy patients returned for the next appointment (8 weeks after baseline). Periodontal reevaluation of encoded patients was performed by a single periodontist (Examiner 2).|All patients were allocated by the same examiner to two groups: the first group received minimally invasive non-surgical therapy only (MINST group), the second group- minimally invasive non-surgical therapy and subgingival application of collagen hydrogels with PACNs (MINST+PACNs group). The same examiner performed the coding and randomization of the participants in the treatment groups with a computer-generated randomization table.|t|t|t|t
33895338|NCT04307667|||CASE_ONLY||PROSPECTIVE|||||||
33895339|NCT00036114||||TREATMENT||||||||
33895340|NCT04900701|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895341|NCT05689060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895342|NCT00170976|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895343|NCT01874483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895344|NCT02593370|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33895345|NCT03436264|||COHORT||CROSS_SECTIONAL|||||||
33895346|NCT00232037|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895347|NCT02502214|||OTHER||PROSPECTIVE|||||||
33895348|NCT00015548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895349|NCT04954677|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Both participates and outcomes Assesors will be masked||t|f|f|t
33895350|NCT01723306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895351|NCT00755001|||COHORT||PROSPECTIVE|||||||
33895352|NCT02807077|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895353|NCT01045070|||||PROSPECTIVE|||||||
33895354|NCT06176703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33895355|NCT00861185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895356|NCT02985346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895357|NCT01937312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895358|NCT04391140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895359|NCT02511210|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895360|NCT00579943|||COHORT||PROSPECTIVE|||||||
33895361|NCT04721873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978815|NCT04558554|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||During Studies 1a, 1b, and 2, all individuals meeting study and PrEP eligibility criteria will have the option Study 2, study pharmacies will also offer post-exposure prophylaxis (PEP) for HIV prevention to individuals meeting study and PEP eligibility criteria. Also during Study 2, a subset of four study pharmacies (2 per region) will offer STI testing and treatment to individuals meeting study eligibility criteria.||||
33978816|NCT02319109|||||PROSPECTIVE|||||||
33978817|NCT03734185|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE|"Included municipalities are expected to receive 2,310 patients with IHD per year (figures from 2017) to attend a CR program. Statistical power; These figures were used to address the difference in patient outcome in intervention CR and usual CR. Using the minimally important difference available for HeartQoL (mean difference of 2.0, standard deviation 2.0)(1) and the HADS (mean difference of 2.0 and standard deviation of 3.8)(2) and within site clustering ( intra-cluster correlation of 0.01 and an average cluster size of 185 patients - design effect of 2.84) we would need to recruit at least 312 patients per group at 90% power and 5%.~References~1. Smid DE, et al. Responsiveness and MCID Estimates for CAT... J Am Med Dir Assoc 2017 Jan;18(1):53-58.~2. Oldridge N, et al. The HeartQoL: Part II. Validation of a new core health-related quality of life questionnaire... Eur J Prev Cardiolog 2014 01/01; 2017/09;21(1):98-106."|||||
33978818|NCT01567930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978819|NCT02109822|||COHORT||PROSPECTIVE|||||||
33978820|NCT01517256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33978821|NCT00717457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978822|NCT00476606|||COHORT||PROSPECTIVE|||||||
33978823|NCT00763022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978824|NCT01997541|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978825|NCT03552757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978826|NCT03500484|RANDOMIZED|PARALLEL||OTHER||SINGLE||15 control and 30 obese subjects|t|f|f|f
33978827|NCT02317237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978828|NCT01282151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978829|NCT05765565|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33978830|NCT04057053|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a pilot study to determine whether there is any benefit to using Netarsudil after DWEK surgery. The study plans to enroll 10 patients (20 eyes) with Fuchs endothelial dystrophy and cataract to under combined cataract surgery with DWEK sequentially in both eyes. The first eye will be treated with Netarsudil after surgery and time to clearance will be noted. The second eye will not be treated with Netarsudil and if time to clearance is longer than the first eye, Netarsudil will be added to test if it can be used as a rescue drop."||||
34103517|NCT01423084|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33721129|NCT00574509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721130|NCT05855031|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Randomized concealed allocation to intervention or control|f|t|f|t
33721131|NCT02507674|||COHORT||PROSPECTIVE|||||||
33721132|NCT00455429|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33721133|NCT02592174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978831|NCT03913000||SEQUENTIAL||OTHER||NONE||Single-center, open-label, single-dose study is conducted in male and female subjects with renal function impairment and in healthy subjects. Groups A (mild), B (moderate), C (severe) and D (healthy subjects) will be studied in a staggered way, starting with the group with mild renal function impairment||||
33766844|NCT05191641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician will be blind in evaluating the results. The intervention and control group will be defined as group 1 and group 2 for statistical analysis. Scales will be evaluated by the researcher who cannot be blinded due to the nature of the study.|Single-blind randomized controlled study|f|f|f|t
33766845|NCT05482737|||COHORT||RETROSPECTIVE|||||||
33978832|NCT06115005|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33978833|NCT04449484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects are randomised to one of two groups within a cohort of 12 subjects (N=9 MEDI1341; N=3 Placebo)|t|t|t|t
33766846|NCT00088179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766847|NCT02566070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766848|NCT04191681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766849|NCT06342895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Usual use of standard clinical and biological information related to nutritional support as available through the ICU electronic health record (i.e. without any calculated information on recommended, prescribed, or received calories and protein, only information on prescribed products and volumes as collected by and presented in the ICU EHR) In this arm, participants, investigators, and healthcare professionals will be blinded to real-time enteral feed volumes that will be collected by the Feedim medical device and transmitted to the electronic study case report form.||||
33766850|NCT05494229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978834|NCT01634906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33978835|NCT05588856|||OTHER||PROSPECTIVE|||||||
33978836|NCT05328713|||CASE_CONTROL||OTHER|||||||
33978837|NCT00442910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33978838|NCT05883410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants does not know which type of treatment is received themselves.|Randomized Controlled Clinical Trial|t|f|f|f
33978839|NCT03694990|||COHORT||PROSPECTIVE|||||||
33766851|NCT00119925|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33766852|NCT04372160|||CASE_ONLY||CROSS_SECTIONAL|||||||
33766853|NCT06625736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33766854|NCT02273297|||COHORT||PROSPECTIVE|||||||
33766855|NCT01743300|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33766856|NCT02590328|||COHORT||PROSPECTIVE|||||||
33766857|NCT05321706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One year's blinded treatment + two years' open-label extension. The primary endpoint of the blinded phase of the trial is the difference in the slope from 2 weeks to 12 months in the eGFR. The major endpoint of the open-label phase is the baseline-adjusted eGFR measured 1 months after the end of treatment.|The DAPARHT trial is a randomised, controlled, double blind, parallel group trial with an open-label extension phase. The primary endpoint is the slope of the eGFR measured from 2 weeks after randomisation and start of treatment to 12 months after start of treatment. The trial subjects immediately continue into the open-label phase. In this phase, patients assigned to dapagliflozin continue treatment for another 24 months. The primary endpoint of the open-label extension is the baseline-adjusted eGFR measured one month after the end of treatment, 37 months after randomisation.|t|t|f|f
33766858|NCT02443506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766859|NCT03386955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766860|NCT00610974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33766861|NCT03555357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject will not be aware of which side is treated with PRP vs. PRF. The blind observer will also not be informed which side was treated with PRP vs. PRF.|Subjects will receive both PRP and PRF injections to the scar. One side will be assigned to PRP and the other PRF (randomly assigned by Clinical Research Coordinator).|t|f|f|t
33766862|NCT02887469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766863|NCT04935723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients who will form the experimental group will not be told which method (reiki, sham reiki) will be applied.|The study was planned as a three-group interventional randomized controlled study to examine the effect of Reiki touch therapy, which is a complementary method in relieving surgical fear, pain and anxiety in patients who will undergo open abdominal surgery.|t|f|f|f
33766864|NCT01190215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102954|NCT04732221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A total of approximately 450 participants will be randomized in this operationally seamless adaptive Phase 2/3 study. Phase 2 of the study will randomize approximately 164 participants into 4 arms, and Phase 3 of the study will randomize approximately 286 participants into 2 arms.|t|f|t|t
33766865|NCT00882921|||COHORT||PROSPECTIVE|||||||
33766866|NCT02342665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766867|NCT01508013|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34102955|NCT06688292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102956|NCT06413758|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34102957|NCT03006315|||COHORT||PROSPECTIVE|||||||
34102958|NCT05090397|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34102959|NCT06431386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical outcome assessments will be performed by raters blind to treatment allocation and not the treating therapist or physician. Ratings will be acquired prior to treatment administration.|This pilot study is a single-site, parallel-arm, randomized clinical trial.|f|f|f|t
34103518|NCT05970497|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33766868|NCT02223754|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895362|NCT04180592|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Randomized cross-over designed trial||||
33766869|NCT01097486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766870|NCT04548271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766871|NCT04315103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study blinding was accomplished by having an investigator (blinded to the randomization and treatment) perform all the assessments|Patients with symptomatic knee OA were randomized to receive a single intraarticular injection of HYAJOINT Plus (3 ml) followed by 3 ml PRP (the combined-injection group) or a single injection of 3 ml PRP (the one-injection group).|f|f|f|t
33766872|NCT02544802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766873|NCT04485715|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33766874|NCT06474858|||CASE_CONTROL||PROSPECTIVE|||||||
33766875|NCT03091101|NA|SINGLE_GROUP||OTHER||NONE||||||
33766876|NCT01450605|||CASE_ONLY||PROSPECTIVE|||||||
33766877|NCT04996290|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled trial||||
33766878|NCT04898712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33766879|NCT00988546|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766880|NCT03418870|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Phase 1 is usual care and Phase 2 is the intervention phase."||||
33840441|NCT00594880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840442|NCT04942366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While the exercise protocol will be explained to the participant and care giver however the they will be blinded regarding which is intervention group or control group and which exercise is the main interventional exercise will not be disclosed.|Two groups in which participants are randomly allocated while both groups will perform warm up and cool down session, Group A will perform High intensity interval training and Group B will perform strength training exercises.|t|t|f|f
33840443|NCT03758989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840444|NCT04367064|||COHORT||PROSPECTIVE|||||||
33840445|NCT05765305|||CASE_CONTROL||RETROSPECTIVE|||||||
33895363|NCT05802329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 design with parallel and sequential dosing.||||
33895364|NCT01774942|NA|SINGLE_GROUP||TREATMENT||NONE||"Because it is unethical to withhold treatment that is known to be efficacious for severe periodontal infections, there is no control group that would not be treated or that would receive delayed treatment. Enrollment criteria included end-stage (terminal) periodontal infection of all teeth, which is a condition that must be treated immediately due to its severity and potential for very severe consequences."||||
33895365|NCT00896519|NON_RANDOMIZED|||TREATMENT||NONE||||||
33895366|NCT02884635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895367|NCT05422079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, randomised clinical trial|t|f|f|f
33895368|NCT02975128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895369|NCT05048472|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Intervention arm will use point of care viral load monitoring (Abbott PoC devices) while the control arm will use the standard of care (centralized viral load monitoring).||||
33895370|NCT01733329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33895371|NCT00795730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978840|NCT02746952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978841|NCT01575509|NA|SINGLE_GROUP||||NONE||||||
33978842|NCT01856153|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33978843|NCT00421174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978844|NCT01089699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33978845|NCT05115305|||CASE_ONLY||PROSPECTIVE|||||||
33978846|NCT06085677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33978847|NCT06434285|||OTHER||CROSS_SECTIONAL|||||||
33978848|NCT03914313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33978849|NCT04289636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978850|NCT00175019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978851|NCT00499642|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33978852|NCT05081440|||COHORT||PROSPECTIVE|||||||
33978853|NCT02557607|NA|SINGLE_GROUP||||NONE||||||
33978854|NCT03655106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control parallel assignment||||
33978855|NCT02384616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33978856|NCT05524688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978857|NCT06078163|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33978858|NCT00577668|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33978859|NCT00576381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978860|NCT05145283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients will be randomized in two parallel groups to receive either conestat alfa or placebo.|t|f|t|f
33978861|NCT02635100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978862|NCT02596503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978863|NCT04641559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33978864|NCT04574193|RANDOMIZED|PARALLEL||TREATMENT||NONE||The evaluation will involve a two-group RCT in which 100 men and women on probation or parole, who are currently receiving outpatient substance use treatment at THC, will be randomly assigned to one of two conditions: (1) Continuing Care app (CC app; n=50): Participants will receive the CC app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy), or (2) Treatment As Usual (TAU; n=50): Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.||||
33978865|NCT04207879|||COHORT||PROSPECTIVE|||||||
33978866|NCT00937066|||COHORT|||||||||
33978867|NCT03709862|||CASE_ONLY||RETROSPECTIVE|||||||
33978868|NCT04021069|||COHORT||RETROSPECTIVE|||||||
33978869|NCT03958032|||COHORT||PROSPECTIVE|||||||
33978870|NCT01315249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978871|NCT04751110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33978872|NCT06485219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077082|NCT03905837|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The randomization will be carried out through the EPIDAT 3.1 program. Randomization codes will be obtained prior to the recruitment of the first patient and will be kept in a sealed envelope with numbering on the outside of the envelope. The operating room anesthesiologist will receive the assigned medication from the corresponding group with the only identification of intravenous perfusion and paravertebral perfusion, without having knowledge of the group to which the patient belongs.~Bias control: The anesthesiologist responsible for the intraoperative management of the patient, the physician responsible for postoperative control in the postoperative care unit and the guard physician who will perform the cognitive dysfunction test preoperative and postoperative and the follow up until the month of surgery will be blind to the technique used, as well as those responsible for the analysis of the biological samples."|"Unicentric, randomized, blind and controlled phase IV Clinical trial of three parallel groups.~Randomization: Patients will be randomized into three groups (ratio 1: 1: 1): intravenous lidocaine and paravertebral saline (group 1), intravenous and paravertebral saline solution with lidocaine (group 2) and intravenous remifentanil and paravertebral saline solution (group 3) ). The randomization will be carried out through the EPIDAT 3.1 program prior to the recruitment of the first patient and the randomization codes will be kept in a sealed envelope with the number on the outside of the envelope. Patients will be followed from the day of hospital admission until hospital discharge and after 30 days of surgery."|t|t|t|t
34077083|NCT00033319||||PREVENTION||||||||
33978873|NCT02361047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33978874|NCT01089647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978875|NCT00600925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33978876|NCT05903365|||COHORT||PROSPECTIVE|||||||
33978877|NCT00592098|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978878|NCT01584921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33978879|NCT01163760|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33978880|NCT03744416|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomised trial.||||
33978881|NCT06009913|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|triple blinded|two group survey 40 students had online teaching 40 students had real time teaching|t|t|t|t
33978882|NCT03487055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978883|NCT01716845|||COHORT||PROSPECTIVE|||||||
34077084|NCT02479074|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33766881|NCT03817021|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Parents, educators and children will not be informed of their treatment factor status, but it will not be hidden from them either.|Using Multiphase Optimization (MOST) Strategy, we will examine 3 treatment factors and their interactions to determine a 'best' or optimum approach to education of the Early Childhood Environment (ECE), child and family.||||
33895372|NCT02502929|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895373|NCT01275404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895374|NCT01676961|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33895375|NCT00513344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33895376|NCT03736044|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* Group A: patients on treatment with TNF-blockers plus DMARDs~* Group B: patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.~In addition a cohort of healthy subjects matched for sex and age used as a control."||||
33895377|NCT01020669|||||OTHER|||||||
33895378|NCT06024252|||COHORT||RETROSPECTIVE|||||||
33978884|NCT03614377|||COHORT||PROSPECTIVE|||||||
33895379|NCT04331899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind study in which only patients are blinded.|An open-label, single-blind randomized controlled trial. Study participants will be randomly assigned 1:1 to a single subcutaneous dose of Peginterferon Lambda-1a or placebo along with the standard of care.|t|f|f|f
33978885|NCT05707000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978886|NCT04982146|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm experimental analytical study||||
33978887|NCT03118466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978888|NCT02606500|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978889|NCT03075774|||CASE_ONLY||PROSPECTIVE|||||||
33721134|NCT04091373|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33721135|NCT00324324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33721136|NCT05014750|||COHORT||PROSPECTIVE|||||||
33766882|NCT05902221|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized two-arm (parallel) comparative open-label cohort clinical trial.||||
33766883|NCT01720134|||COHORT||RETROSPECTIVE|||||||
33766884|NCT04719403|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766885|NCT03422263|||CASE_CONTROL||PROSPECTIVE|||||||
33766886|NCT01836627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33895380|NCT05637450|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants are assigned to intervention groups by chance|Double-blind randomised control trial|t|t|t|t
33895381|NCT06085157|||COHORT||PROSPECTIVE|||||||
33895382|NCT02420457|||COHORT||PROSPECTIVE|||||||
33895383|NCT04712175|||CASE_CONTROL||PROSPECTIVE|||||||
33895384|NCT05021224|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895385|NCT02509546|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33895386|NCT00358163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895387|NCT05254119|||OTHER||PROSPECTIVE|||||||
33895388|NCT02594592|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33895389|NCT04460703|RANDOMIZED|PARALLEL||OTHER||NONE||In this study, 2/15 of participants will be assigned to a control message (bird feeding passage), 3/15 of sample to a baseline vaccine message, and 1/15 to each of the 10 other treatment arms.||||
33895390|NCT04642144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Not Masking|A group with yerba mate infusion and carbohydrate meal, a group with only yerba mate infusion, and a group with water and carbohydrate. The washout period between treatments will be seven days||||
33895391|NCT06380998|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895392|NCT04518371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895393|NCT05890703|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33895394|NCT02833311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33895395|NCT03003819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895396|NCT04101812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978890|NCT01208519|||COHORT||PROSPECTIVE|||||||
33978891|NCT03328793|RANDOMIZED|PARALLEL||OTHER||SINGLE|The research assistant who will be doing the Visual Analog Mood Scale (VAMS) with the patients pre and post intervention will be blinded in regards to the group attribution of the patient.||f|f|f|t
33978892|NCT01604044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978893|NCT03682952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077085|NCT03296969|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34077086|NCT02267915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978894|NCT06440655|NA|SINGLE_GROUP||TREATMENT||NONE||All subject were injected with PRP and PRF at baseline, 4 weeks and 8 weeks with split-head of sides of injection.||||
33978895|NCT02800798|||||CROSS_SECTIONAL|||||||
34077087|NCT00248651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33978896|NCT02603952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978897|NCT04809675|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34077088|NCT02435303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801202|NCT05279157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients who agree to participate in the study and sign the informed consent will be randomized to enter one of the three groups in a 1: 1: 1 ratio. For this, a randomization scheme will be used that will be unknown to the patient, the center staff, and the promoter staff who intervene directly in the study.|In this study, 15 evaluable patients affected by corneal stromal dystrophies of any type (particularly keratoconus) will be included in 3 different groups. Ten patients will be included in the two experimental groups and five in the control group with cell-free treatment (5 patients per group and a total of 3 groups)|t|t|t|f
33978898|NCT04375293|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33978899|NCT05237596|||CASE_CONTROL||RETROSPECTIVE|||||||
33978900|NCT00628160|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978901|NCT00840905|||COHORT||RETROSPECTIVE|||||||
33978902|NCT01506947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978903|NCT04578964|||OTHER||CROSS_SECTIONAL|||||||
33978904|NCT03033420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978905|NCT02439398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978906|NCT03331042|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33978907|NCT05143671|||COHORT||PROSPECTIVE|||||||
33978908|NCT04085666|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33978909|NCT03323125|||OTHER||CROSS_SECTIONAL|||||||
33978910|NCT05792059|||OTHER||PROSPECTIVE|||||||
34077089|NCT01151345|RANDOMIZED|CROSSOVER||||NONE||||||
34077090|NCT02718911|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34077091|NCT01450813|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34077092|NCT03043742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077093|NCT03639857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077094|NCT00437476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077095|NCT03747848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077096|NCT03736135|||COHORT||PROSPECTIVE|||||||
34077097|NCT02511925|||CASE_CROSSOVER||PROSPECTIVE|||||||
34077098|NCT00095979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077099|NCT04331691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077100|NCT06008119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077101|NCT04718870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077102|NCT02548624|||CASE_ONLY||PROSPECTIVE|||||||
34077103|NCT04801251|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||The relation between the presence of abnormal clinical cardiac findings and the abnormal echocardiographic findings||||
34077104|NCT00516100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077105|NCT04614298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077106|NCT05235360|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33766887|NCT05632536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study was planned to be performed as a double blind. User sacral ESP and caudal block will be administered by an anesthesiologist not responsible for the perioperative and postoperative management of the patients. A second anesthesiologist, who will be in charge of patient monitoring and data recording, will be unaware of the patients' group assignments. Additionally, parents, surgeons, and other personnel involved in the data collection process will be unaware of the group to which the child is assigned. Surgeons will not be present in the operating room while the anesthesiologist administers the block (sacral ESP block or caudal block). All patients will undergo aseptic skin preparation using Betadine. Since bandages will be applied to two points, the actual injection site will not be known.|Our research will be conducted in a single center as a prospective randomized controlled study. It was planned to include 60 patients from the ASA I-II pediatric patient group aged between 6 months and 7 years, who will undergo hypospadias surgery in our hospital between December 2022 and December 2023, and randomization will be done by closed envelope method. Two groups with sacral ESP and caudal block will be formed, each with 30 patients.|t|t|f|f
33766888|NCT03236922|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33766889|NCT05730530|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group-randomized trial with individual-level outcomes||||
34077107|NCT03878823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077108|NCT00984932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077109|NCT02899065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077110|NCT02381613|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34077111|NCT03060304|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Parallel Assignment||||
34077112|NCT00005743|RANDOMIZED|||||||||||
33721137|NCT00425230|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33721138|NCT05347550|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721139|NCT00914862|RANDOMIZED|PARALLEL||||NONE||||||
33721140|NCT00437099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721141|NCT04611750|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33721142|NCT01438918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721143|NCT02741882|||CASE_CONTROL||RETROSPECTIVE|||||||
33721144|NCT03403816|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766890|NCT04962438|||COHORT||PROSPECTIVE|||||||
33895397|NCT00763893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895398|NCT02291159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895399|NCT00016315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895400|NCT00605826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895401|NCT01857895|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895402|NCT03469310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||option 1: Tylenol (also known as acetaminophen) with tramadol if needed, or option 2: Tylenol #3 as needed||||
33895403|NCT03492164|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895404|NCT01627704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895405|NCT00228371|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33895406|NCT05446597|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a single-blind randomized controlled superiority trial with three treatment groups. Trial participants will be screened for headache and neck pain/dizziness based on symptom ratings on the Sport Concussion Assessment Tool 5 (SCAT5) Post-Concussion Symptom Scale (PCSS) (rating 0-2 mild, 3-4 moderate, 5-6 severe /6). Patients will be allocated to one of three treatments based on symptom severity:~1. Headache treatment~2. Neck pain / Dizziness treatment~3. Multimodal treatment All participants will receive standard of care education and exercise recommendations based on BCTT and sub-symptom threshold tolerance at baseline"||||
33978911|NCT04091347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician will be responsible for randomization and the investigator and study team will not have knowledge if participants are assigned to intervention group or wait list control group.|The investigator will conduct subsequent single blind wait list control design to test the preliminary effects of DAPPER and the feasibility of older African American women integrating strategies to address pain, depression, and frailty that are tailored to the individual into the individual's daily routines.|f|f|t|t
33978912|NCT04281992|NA|SEQUENTIAL||TREATMENT||NONE||Analyses for phase 1 part will be done by cohort and analyses for phase 2A part will be done by treatment arms.||||
33978913|NCT03582332|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33978914|NCT00597194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978915|NCT03665103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33978916|NCT01582607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33978917|NCT03392298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978918|NCT06196684|||COHORT||PROSPECTIVE|||||||
33978919|NCT00802451|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978920|NCT05449977|||CASE_ONLY||CROSS_SECTIONAL|||||||
33978921|NCT05140447|RANDOMIZED|PARALLEL||OTHER||NONE||"Forty posterior teeth were randomly divided into two groups of 20 teeth. According to types of restorative materials used (A), the first group was restored by Bis-GMA free resin composite (A1) and the second group was restored by Bis-GMA containing resin composite (A2).~Each group was subdivided into 2 subgroups of 10 teeth each according to preheating temperatures used (T), the first subgroup (T1) was preheated at 50◦ C and the second subgroup (T2) was preheated at 70◦ C."||||
33721145|NCT03559153|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33978922|NCT05769530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33978923|NCT00002047||||TREATMENT||||||||
33978924|NCT01230580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978925|NCT02213471|||COHORT||PROSPECTIVE|||||||
33978926|NCT01933607|NA|SINGLE_GROUP||||NONE||||||
33978927|NCT01352325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978928|NCT06012903|||COHORT||CROSS_SECTIONAL|||||||
33978929|NCT00663546|||||PROSPECTIVE|||||||
33978930|NCT00218309|||||PROSPECTIVE|||||||
33978931|NCT05543148|||CASE_ONLY||CROSS_SECTIONAL|||||||
33978932|NCT01147952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33978933|NCT01400425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978934|NCT03814343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind controlled trial between participants, drug preparing team, doctors, investigators, and outcome assessors.|Randomized double blind controlled trial pilot study|t|t|t|t
33978935|NCT03490721|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33978936|NCT01911195|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33978937|NCT04578743|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a Phase 2, open-label study of a therapeutic intervention (graded exercise) compared to a reference therapy (passive stretching) in patients who have sustained mTBI. Subjects will be randomly assigned with a ratio of 1:1 to complete either graded exercise or passive stretching using a parallel-group design.||||
33978938|NCT02305758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978939|NCT05460065|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33978940|NCT01531465|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33978941|NCT02425579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33978942|NCT05428722|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized conrolled trial in the parallel group||||
33978943|NCT00593281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33978944|NCT05011500|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33978945|NCT04126811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978946|NCT02171533|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33978947|NCT04648358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978948|NCT04696419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Randomised within-subject design. Each subject is exposed to three different levels of contact with a dog and a control situation in randomised order.||||
33978949|NCT04123210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants blinded (Indonesian), double blinded (USA)|Parallel assignment to 0 or 525 micrograms supplemental vitamin A/day (Indonesia) or 0, 175 or 525 micrograms supplemental vitamin A/day (USA).|t|t|t|f
33978950|NCT01479439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978951|NCT00765609|||CASE_ONLY||PROSPECTIVE|||||||
33978952|NCT00013546||||TREATMENT||||||||
33978953|NCT03311646|NA|SINGLE_GROUP||OTHER||NONE||All participants experienced an NNC phase (baseline) and a VLNC phase.||||
33978954|NCT05627427|NA|SINGLE_GROUP||TREATMENT||NONE||Three cohorts.||||
33978955|NCT05814458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978956|NCT00389636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978957|NCT03803410|||COHORT||PROSPECTIVE|||||||
33978958|NCT03488342|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Double (Participant, Investigator)|randomized,controlled and double-blind study|t|f|t|f
33978959|NCT00580138|||CASE_ONLY||PROSPECTIVE|||||||
33978960|NCT01179048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33978961|NCT01658943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978962|NCT01292161|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33978963|NCT00723554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978964|NCT00802100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33978965|NCT03931863|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All solutions will be prepared by an independent researcher who will not be further involved in the study eg data collecting or analyzing them. All solutions will look identical to the anesthetist who will administer them to the patients.Apart from the anesthetist, the surgery staff and the researchers recording the measurements will not know the therapeutic intervention team in which each patient has been randomized.||t|t|t|t
33978966|NCT01837862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978967|NCT03172780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978968|NCT01110447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766891|NCT01203839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978969|NCT05805553|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Three groups are made. one will receive steroid (control group). other will receive propranolol and third will receive both propranolol and steroid. their results will be compared|t|f|f|f
33978970|NCT03886090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978971|NCT04666909|||OTHER||PROSPECTIVE|||||||
33978972|NCT05921890|NA|SINGLE_GROUP||OTHER||NONE||||||
33978973|NCT04360993|||COHORT||RETROSPECTIVE|||||||
33978974|NCT02315690|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978975|NCT02846948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33978976|NCT05043636|||COHORT||CROSS_SECTIONAL|||||||
33721146|NCT04220008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721147|NCT03566368|||COHORT||PROSPECTIVE|||||||
33721148|NCT04760912|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33721149|NCT02663609|||CASE_ONLY||RETROSPECTIVE|||||||
33721150|NCT00874523|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801203|NCT04422418|||COHORT||PROSPECTIVE|||||||
33801204|NCT02584829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801205|NCT01186159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801206|NCT00543894|||||PROSPECTIVE|||||||
33895407|NCT00075881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895408|NCT01855438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33895409|NCT04223089|||COHORT||PROSPECTIVE|||||||
33895410|NCT05142709|||COHORT||RETROSPECTIVE|||||||
33895411|NCT01615510|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33895412|NCT02406664|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33895413|NCT04400500|||COHORT||PROSPECTIVE|||||||
33895414|NCT02680067|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy individuals and subjects that have rheumatoid arthritis may participate in the developmental arm. Healthy individuals may participate in the clearance arm. There will be no randomization.||||
33895415|NCT02108457|||CASE_ONLY||PROSPECTIVE|||||||
33895416|NCT02366819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895417|NCT03497299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators will have a sham rTMS coil to provide full blinding for the active rTMS condition.|The study is a randomized controlled trial of active versus sham high frequency rTMS to the dorsolateral prefrontal cortex (DLPFC) in patients with schizophrenia who have co-occurring tobacco use disorder. The duration of treatment is 4 weeks and all subjects would receive open label Varenicline 2mg/day. The primary outcome measure is time to lapse to smoking.|t|t|t|t
33895418|NCT00356915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33895419|NCT05060861|||OTHER||OTHER|||||||
33895420|NCT01091129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895421|NCT04492410|NA|SINGLE_GROUP||SCREENING||NONE||||||
33895422|NCT00664170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895423|NCT04075643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895424|NCT00843986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895425|NCT04747145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895426|NCT02237027|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895427|NCT00424307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895428|NCT03305744|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33895429|NCT03314168|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895430|NCT02799381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895431|NCT03864965|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895432|NCT04938648|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patient and care partner dyads are randomly assigned to receive the pharmacist-led intervention immediately after an educational mailing or to a delayed intervention control group that will receive the pharmacist-led component 3 months after the mailing.||||
33895433|NCT02682810|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33895434|NCT03361501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895435|NCT03542214|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33895436|NCT05144165|||OTHER||PROSPECTIVE|||||||
33895437|NCT00224016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895438|NCT02362607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895439|NCT05041101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895440|NCT04194177|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33895441|NCT01586728|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895442|NCT05163054|||COHORT||PROSPECTIVE|||||||
33895443|NCT01985321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895444|NCT04582240|||OTHER||RETROSPECTIVE|||||||
33895445|NCT00472303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895446|NCT02363205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895447|NCT06075056|||OTHER||PROSPECTIVE|||||||
33895448|NCT01706913|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895449|NCT05055908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895450|NCT01073943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895451|NCT04988230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895452|NCT02267928|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
33895453|NCT05282940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33801207|NCT00031785||||SUPPORTIVE_CARE||||||||
33801208|NCT00105807||||TREATMENT||||||||
33801209|NCT05193786|RANDOMIZED|PARALLEL||TREATMENT||NONE||Low versus high PEEP||||
33801210|NCT01692483|||COHORT||PROSPECTIVE|||||||
33801211|NCT00548418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801212|NCT04436900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801213|NCT02941575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33978977|NCT04175951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33978978|NCT02426957|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33978979|NCT02236507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33978980|NCT00951288|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33978981|NCT06001125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978982|NCT03061409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33978983|NCT01510886|||||RETROSPECTIVE|||||||
33978984|NCT02983708|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978985|NCT05059769|||COHORT||PROSPECTIVE|||||||
33978986|NCT02192346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801214|NCT00770523|||CASE_ONLY||PROSPECTIVE|||||||
33801215|NCT04248998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801216|NCT00289835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801217|NCT06465446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801218|NCT04484753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801219|NCT01864512|||COHORT||PROSPECTIVE|||||||
33801220|NCT06514482|||CASE_CONTROL||PROSPECTIVE|||||||
33801221|NCT01439048|||CASE_CONTROL||PROSPECTIVE|||||||
33801222|NCT03632616|||COHORT||PROSPECTIVE|||||||
33801223|NCT01003834|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33801224|NCT05326607|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33801225|NCT04042207|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||N-of-1 trials consists in a prospectively planned, multiple crossover study in a single individual.||||
33801226|NCT06427863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801227|NCT03882385|||COHORT||PROSPECTIVE|||||||
33801228|NCT02555215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801229|NCT02160951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801230|NCT01510977|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33801231|NCT01759264|||CASE_ONLY||PROSPECTIVE|||||||
33801232|NCT03640949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801233|NCT02294617|RANDOMIZED|CROSSOVER||||NONE||||||
33801234|NCT06445257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801235|NCT04252586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801236|NCT00631436|||CASE_CONTROL||PROSPECTIVE|||||||
33801237|NCT06010862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801238|NCT01373385|||COHORT||PROSPECTIVE|||||||
33801239|NCT01828554|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801240|NCT00915564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801241|NCT03991286|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33801242|NCT03197116|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33801243|NCT00767559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801244|NCT04038814|||COHORT||OTHER|||||||
33801245|NCT01842945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801246|NCT04424940|||COHORT||PROSPECTIVE|||||||
33801247|NCT06233435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective study||||
33801248|NCT04770831|||COHORT||PROSPECTIVE|||||||
33801249|NCT03432858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Principal investigator, co-investigators, and participants are blinded to study intervention||t|f|t|f
33801250|NCT05188300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801251|NCT00890305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801252|NCT06083155|||OTHER||PROSPECTIVE|||||||
33801253|NCT00370383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801254|NCT03338816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801255|NCT03990649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801256|NCT02850744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801257|NCT04676321|||COHORT||RETROSPECTIVE|||||||
33801258|NCT00001017||PARALLEL||TREATMENT||||||||
33801259|NCT03492424|||OTHER||PROSPECTIVE|||||||
33801260|NCT00997490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801261|NCT00586222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33801262|NCT02208596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801263|NCT06099249|||COHORT||PROSPECTIVE|||||||
33801264|NCT01077986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801265|NCT01266122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33801266|NCT00014040||||TREATMENT||||||||
33801267|NCT02344641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077113|NCT04464291|NA|SINGLE_GROUP||SCREENING||NONE||Prospective Multicentre Microbiological study||||
33766892|NCT04707690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Eligible patients will receive written and oral information about the study. After informed consent patients will be randomized into the intraurethral laser treatment group or sham laser group using the internet based program randomizer, at a 1.1 ratio without stratification. Patients and the person performing the laser treatment will not aware of the treatment given. The laser devices can be used as a placebo laser blocking the laser beam with a plug."|Prospective randomized sham - controlled trial|t|t|f|f
33766893|NCT00095914||||TREATMENT||||||||
33766894|NCT02617264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33766895|NCT03380793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766896|NCT04060225|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33766897|NCT03959670|||COHORT||RETROSPECTIVE|||||||
33766898|NCT05334927|||COHORT||PROSPECTIVE|||||||
33766899|NCT00006232|RANDOMIZED|||TREATMENT||||||||
33766900|NCT04072848|||COHORT||PROSPECTIVE|||||||
33766901|NCT04703634|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||It is a single centre, randomized, prospective method comparison study.|t|f|t|f
33766902|NCT05332977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"As the placement of implants and the type of implant is clearly distinguishable and require different handling, blinding of the prosthodontist is not feasible.~Patients are blinded to the type of implant received and to the type of procedure followed for the fabrication of the provisional prosthesis."|"The edentulous patients recruited in the study will be randomized into the following two groups:~* Placement of tilted implants in the distal most position (group-Til) with straight implants in the anterior region~* Placement of axial implants in the distal most position (group-Axl) with straight implants in the anterior region~Subjects from the above groups will be further divided into following two sub-groups:~* Immediate loading using denture conversion prosthesis (group DC)~* Immediate loading using milled PMMA prosthesis (group CAD-CAM)"|t|f|f|f
33766903|NCT00003415||||TREATMENT||||||||
33766904|NCT01744860|||COHORT||PROSPECTIVE|||||||
33766905|NCT04590859|||COHORT||PROSPECTIVE|||||||
33766906|NCT02281760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766907|NCT05425030|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|intervention), participants cannot be blinded. Investigators not involved in the allocation and direct data collection efforts, however, including the analysts, will be blinded to which household received which intervention. Of note, the community health workers responsible for provisioning the intervention and conducting the baseline survey will be a separate team of field workers from those collecting the endline outcomes assessment.|The primary analysis is a cluster randomized controlled trial involving 309 households in rural Bangladesh previously identified and characterized by the BRAC James P Grant School of Public Health, BRAC University. These households will be randomly divided into three arms: (1) Control, i.e., no intervention; (2) Information only, i.e., community health workers will provide basic information on the health consequences of high blood pressure, excessive salt consumption, and feedback to the participant on the likely quantity of salt s/he consumes (estimated using a questionnaire); (3) Free LSSS Arm: The same information as in Arm 2 will be provided, but participants will receive 6 months of free low-sodium salt by delivery from the community health worker.|f|f|t|t
33766908|NCT03697382|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Subjects will complete three experimental conditions which include 2 days of reduced step count (2,500, 5,000, and 7,500 steps/day) with 1-hour of exercise at 65% VO2max.||||
33766909|NCT01966796|||COHORT||RETROSPECTIVE|||||||
33766910|NCT02082626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766911|NCT05021003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766912|NCT04464837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Proof-Of-Concept||||
33766913|NCT05660915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The way of surgery|The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.In the intermediate approach group, the area between superior mesenteric artery and superior mesenteric vein was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas. Subsequently, data related to intraoperative conditions (such as operation time, amount of blood loss, etc.) and postoperative complications were collected and statistically analyzed to verify the safety of the intermediate approach, and short-term prognostic data was collected to verify its effectiveness.|f|f|f|t
33766914|NCT06547372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33766915|NCT02357810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895454|NCT00996840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895455|NCT06657222|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33895456|NCT04507815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895457|NCT01416090|||CASE_CONTROL||PROSPECTIVE|||||||
33895458|NCT02886715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895459|NCT03203629|||COHORT||PROSPECTIVE|||||||
33895460|NCT03946540|||COHORT||OTHER|||||||
33895461|NCT02288637|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33895462|NCT05692349|||OTHER||PROSPECTIVE|||||||
33895463|NCT03513640|||COHORT||PROSPECTIVE|||||||
33895464|NCT04549012|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|women will be given serial number ,randomization will be done through a computer generated system|Group (A) will receive oxytocin only Group (B)will receive oxytocin plus tranexamic acid|t|t|t|f
33895465|NCT02039947|NON_RANDOMIZED|||TREATMENT||NONE||||||
33895466|NCT02756871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895467|NCT02503891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721151|NCT03877289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33895468|NCT01919307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895469|NCT06656455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721152|NCT03159481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895470|NCT00337051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895471|NCT06098014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895472|NCT02957708|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895473|NCT00203567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895474|NCT01671670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895475|NCT05796661|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a randomized, crossover, single-center study, with inclusion of patients over a period of 11 months, between January 9, 2023 and November 30, 2023. We aim to include 27 patients. Randomized by raffle, which will be carried out manually in blocks divided into 3 envelopes numbered from 01 to 03, and within them will contain 9 papers, also numbered from 1 to 27 with the definition of control group and experimental group. Following the order from 01 to 03, the envelopes will have: envelope 1: 9 samples (5 for control group and 4 for experimental group); envelope 2: 9 samples (4 for control group and 5 for experimental group); envelope 3: 9 samples (5 for control group and 4 for experimental group). Groups: Qb150 (control group) (blood flow 150 mL/min), Qb250 (experimental group) (blood flow 250 mL/min). Time for each treatment: 72 hours. Crossover: after 72 hours. Treatment pause (wash-out): 4 (minimum) to 6 (maximum) hours.||||
33895476|NCT01719575|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33895477|NCT00838734|||COHORT||PROSPECTIVE|||||||
33895478|NCT06356740|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized, controlled study with 2 parallel arms (Add-on treatment versus standard of care treatment)||||
33895479|NCT00609609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895480|NCT02413658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895481|NCT02111369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895482|NCT01123590|||CASE_CONTROL||RETROSPECTIVE|||||||
33895483|NCT04884828|||COHORT||PROSPECTIVE|||||||
33895484|NCT00388089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895485|NCT00377650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895486|NCT05994625|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895487|NCT04754711|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization of patients included in 2 groups~* Group 1: receiving an oral nutritional supplement to increase calorie intake by around 20%~* Group 2: controls receiving normal calorie intake without oral nutritional supplement Randomization will take into account age, gender and severity of disease in order to create two homogenous groups~Monitoring by biphotonic absorptiometry, dietetic, clinical and biological~Creation of a sero-type blood bank for the 2 groups"||||
33895488|NCT02591992|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895489|NCT03290404|||COHORT||PROSPECTIVE|||||||
33895490|NCT02220881|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895491|NCT01787071|||COHORT||PROSPECTIVE|||||||
33895492|NCT04937387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895493|NCT01687673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895494|NCT03068962|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33895495|NCT00904254|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895496|NCT02364817|||COHORT||PROSPECTIVE|||||||
33895497|NCT00440323|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33895498|NCT02638181|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895499|NCT02224222|||COHORT||PROSPECTIVE|||||||
33978987|NCT02972398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978988|NCT01969357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978989|NCT00938210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33978990|NCT04316312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33978991|NCT00043381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33978992|NCT05989516|||OTHER||RETROSPECTIVE|||||||
33978993|NCT01718938|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33978994|NCT00331890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33978995|NCT06130735|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm.||||
33978996|NCT05121233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33978997|NCT04022148|||COHORT||PROSPECTIVE|||||||
33978998|NCT02256085|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33978999|NCT02457013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979000|NCT04895111|||COHORT||PROSPECTIVE|||||||
33979001|NCT04491149|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33979002|NCT05310370|||COHORT||PROSPECTIVE|||||||
33979003|NCT04316273|||CASE_ONLY||CROSS_SECTIONAL|||||||
33979004|NCT04035642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979005|NCT01491009|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979006|NCT04110158|||OTHER||CROSS_SECTIONAL|||||||
33979007|NCT03451669|||COHORT||PROSPECTIVE|||||||
33979008|NCT02116049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979009|NCT01625026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33979010|NCT02230397|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33979011|NCT00002027||||TREATMENT||||||||
33979012|NCT04714268|||COHORT||RETROSPECTIVE|||||||
33895500|NCT05990439|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|randomization, assignment of arms, assessments|Randomized Clinical Trial|t|f|t|f
33895501|NCT04358393|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34077114|NCT00061841|RANDOMIZED|PARALLEL||PREVENTION||||||||
34077115|NCT01877200|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34077116|NCT03450759|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895502|NCT00488527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895503|NCT03486730|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33895504|NCT02574221|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33895505|NCT05057728|NA|SINGLE_GROUP||PREVENTION||NONE||Participants in the current study will be assigned to either: 1) the intervention condition, which will receive the SEP+; or 2) the wait-list control group. A partially-randomized controlled trial (RCT) will be employed, in which schools will be randomly assigned to either the intervention or control group, so that all classrooms within a school will either receive the SEP+ or not. This was done in order to prevent contamination effects, which are more likely to occur when classrooms from the same school participate in the intervention and others do not.||||
33895506|NCT01491945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895507|NCT00551707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895508|NCT01613105|||COHORT||PROSPECTIVE|||||||
33895509|NCT05375292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Monocentric, interventional, randomized, controlled, open study.||||
33895510|NCT01249170|NON_RANDOMIZED|PARALLEL||||NONE||||||
33895511|NCT04614792|NA|SINGLE_GROUP||TREATMENT||NONE||open lable treatment||||
33895512|NCT02355340|||COHORT||PROSPECTIVE|||||||
33895513|NCT06388057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with Crohn's disease with an indication for surgery||||
33895514|NCT03306303|||COHORT||OTHER|||||||
33895515|NCT02580422|||COHORT||PROSPECTIVE|||||||
33766916|NCT05521451|||COHORT||PROSPECTIVE|||||||
33766917|NCT03178513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979013|NCT00520741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979014|NCT06076681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979015|NCT02910609|||COHORT||PROSPECTIVE|||||||
33979016|NCT05906810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sealed envelopes|The main objective of this study is to evaluate the efficacy of periodontal treatment on the improvement in cardiovascular parameters.|t|t|t|f
33979017|NCT00971893|||COHORT||PROSPECTIVE|||||||
33766918|NCT01469455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766919|NCT01777958|||COHORT||PROSPECTIVE|||||||
33766920|NCT01863927|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33766921|NCT04279327|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33766922|NCT00714623|||||PROSPECTIVE|||||||
33766923|NCT00573521|||OTHER||RETROSPECTIVE|||||||
33766924|NCT03904511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33766925|NCT00575211|||COHORT||PROSPECTIVE|||||||
33801268|NCT04978051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801269|NCT02201134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979018|NCT05197166|||COHORT||PROSPECTIVE|||||||
33979019|NCT01434836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979020|NCT01245166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979021|NCT05389410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979022|NCT06495762|||CASE_ONLY||PROSPECTIVE|||||||
33979023|NCT05739578|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33895516|NCT04814537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The biased-coin allocation after each successful response will be implemented by flipping a virtual biased coin (10% vs. 90% probability of randomizing the next patient to the lower vs. same dose than received by the last patient with the same epidural technique) using R statistical software (R Foundation for Statistical Computing, Vienna, Austria). Care Provider (Clinical Anesthesiologist) will administer the identified dose, then summon blinded observer.|Randomized Controlled Trial Using Biased Coin Design to Determine Effective Dose for 90% (ED90) of Subjects|t|f|t|t
33895517|NCT00315302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895518|NCT04335825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895519|NCT05700214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||f|f|t|f
33895520|NCT04652934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|f|t|t
33895521|NCT03460418|||COHORT||PROSPECTIVE|||||||
33979024|NCT05394168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979025|NCT00861965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979026|NCT02563756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979027|NCT04991779|||COHORT||PROSPECTIVE|||||||
33979028|NCT05438797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979029|NCT05990478|||COHORT||PROSPECTIVE|||||||
33979030|NCT00464165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979031|NCT00747175|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33979032|NCT05975970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979033|NCT04327258|||COHORT||CROSS_SECTIONAL|||||||
33979034|NCT03312257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979035|NCT05300984|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Split face/arm design|t|t|t|t
33979036|NCT01638286|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33979037|NCT04099888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895522|NCT05972187|NA|SINGLE_GROUP||OTHER||NONE||||||
33895523|NCT01416311|||OTHER||PROSPECTIVE|||||||
33979038|NCT00032162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979039|NCT05518435|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33979040|NCT00920140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979041|NCT04986228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking is only possible for data analysis, but not for participants, therapists, and study staff, because treatment is different in the two groups.|Participants will be assigned to one of two groups. One group will be offered regular follow-up consultations in the clinic (Control group). The other group will receive a digital aftercare service, consisting of video calls and an app, for a period of up to eight weeks after discharge (Intervention group). These enable an uncomplicated and yet intensive exchange with the clinic from the comfort of the participants' own homes. To enable to optimally plan the treatment and assess its success, all participants complete questionnaires on multiple time points about different topics.|f|f|f|t
33979042|NCT00117949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979043|NCT03929367|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single intravenous administration of oxytocin (Pitocin®), 10 IU||||
33979044|NCT05360316|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled, double blind||||
33979045|NCT01562496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766926|NCT04478513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is two-period, fixed sequence study in healthy volunteers who are either smokers or non-smokers. Twenty-eight subjects are planned to be enrolled; 14 subjects who are smokers and 14 subjects who are non-smokers. Enrolling 28 subjects will ensure that at least 12 subjects each from the smoking and the non-smoking populations are evaluated in this study.||||
33766927|NCT03456167|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33766928|NCT06047236|||CASE_CONTROL||PROSPECTIVE|||||||
33766929|NCT05246215|||CASE_CONTROL||PROSPECTIVE|||||||
33766930|NCT06281223|||COHORT||PROSPECTIVE|||||||
33766931|NCT01884714|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33766932|NCT01974505|NA|SINGLE_GROUP||||NONE||||||
33766933|NCT06371365|||COHORT||RETROSPECTIVE|||||||
33766934|NCT00825032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766935|NCT00847990|||CASE_ONLY||CROSS_SECTIONAL|||||||
33766936|NCT04412590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766937|NCT02019784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33766938|NCT00242749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766939|NCT05801458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766940|NCT00001064||||TREATMENT||||||||
33766941|NCT01427192|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33766942|NCT05939258|||OTHER||PROSPECTIVE|||||||
33766943|NCT05936229|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33766944|NCT01517243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766945|NCT03048084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766946|NCT05315661|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33766947|NCT01878123|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33766948|NCT00981474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33766949|NCT04446780|||COHORT||PROSPECTIVE|||||||
33766950|NCT01199458|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33766951|NCT02139358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766952|NCT05108064|||COHORT||OTHER|||||||
33766953|NCT04296890|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive single-agent MIRV at 6 mg/kg adjusted ideal body weight (AIBW) administered on Day 1 of every 3-week cycle (Q3W)||||
33766954|NCT00203151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766955|NCT02001974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766956|NCT03847467|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33766957|NCT01562912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766958|NCT05434143|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a waitlist controlled design to a behavioral intervention. Assignment will not be masked.|||||
33766959|NCT02540785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766960|NCT01729234|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33895524|NCT03754153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At each site, a masked orthoptist will carry out the study assessments.|Two-group parallel randomized controlled trial|f|f|f|t
33766961|NCT03341663|||CASE_ONLY||CROSS_SECTIONAL|||||||
33766962|NCT03846505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Oxytocin and Therapy Placebo and Therapy|t|t|t|t
33766963|NCT04575727|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33766964|NCT05402540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895525|NCT06618313|NA|SEQUENTIAL||TREATMENT||NONE||||||
33895526|NCT01657123|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33895527|NCT02592005|||COHORT||PROSPECTIVE|||||||
33895528|NCT01587963|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33895529|NCT05367531|NA|SINGLE_GROUP||OTHER||NONE|The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience).|"For each scenario participants will be asked to administer/inject the medication (likely saline or air) using various methods: 1) standard protocol , 2) Autoinjector 3) Pre-filled syringes. For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding)."||||
33895530|NCT00087295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895531|NCT06656351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895532|NCT03353090|||COHORT||RETROSPECTIVE|||||||
33895533|NCT04339504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895534|NCT00215618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895535|NCT00475163|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895536|NCT01078753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895537|NCT00714142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895538|NCT05026775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant: The randomization is conducted at the primary care centre level. Patients from intervention areas will receive enhanced care but will not be aware of the group assigned.~Investigator: Data analysists will not have information on which group is the intervention group when conducting the analysis."||t|f|t|f
33979046|NCT03712553|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33979047|NCT01532622|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33979048|NCT04330807|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33979049|NCT04058223|||COHORT||RETROSPECTIVE|||||||
33979050|NCT04219501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33979051|NCT00622609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979052|NCT01462565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979053|NCT03670238|RANDOMIZED|PARALLEL||TREATMENT||NONE||A cross-over randomized trial||||
33979054|NCT00361322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979055|NCT03784456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The program is designed as a double blind test, randomized intervention. Which meant that neither the subjects nor the PI and co-PI would not know which kind of diet they're going to obtain. Only investigators and test provider would know the meals corresponding to respective groups of subjects.|This program is designed as a double blind parallel randomized intervention. The primary purpose of this program is Prevention.|t|f|f|f
33979056|NCT05108038|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979057|NCT00243932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979058|NCT01249664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979059|NCT03778905|||OTHER||RETROSPECTIVE|||||||
33979060|NCT04469153|||COHORT||RETROSPECTIVE|||||||
33979061|NCT02402166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979062|NCT01309945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979063|NCT01179490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979064|NCT02086058|||||PROSPECTIVE|||||||
33979065|NCT04611698|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979066|NCT01335477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979067|NCT02876913|||COHORT||PROSPECTIVE|||||||
33979068|NCT02197468|||COHORT||PROSPECTIVE|||||||
33979069|NCT06346548|||COHORT||OTHER|||||||
33979070|NCT02386033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979071|NCT04686253|||COHORT||PROSPECTIVE|||||||
33979072|NCT02541526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979073|NCT02896361|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33979074|NCT02472288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33721153|NCT04396990|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33721154|NCT02268812|||OTHER||OTHER|||||||
33766965|NCT03966079|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Single Group Assignment||||
33766966|NCT04540484|||COHORT||PROSPECTIVE|||||||
33766967|NCT00211978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33766968|NCT02328092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33766969|NCT00389181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895539|NCT03542188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded||f|f|t|f
33895540|NCT01753492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895541|NCT01020331|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895542|NCT03165396|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33895543|NCT03774550|||COHORT||RETROSPECTIVE|||||||
33895544|NCT03808311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895545|NCT06657079|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33895546|NCT03095703|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective phase II pilot study with 5 patients with a follow-up of 6 months.||||
33895547|NCT01240070|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895548|NCT00104507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895549|NCT04410302|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895550|NCT05288465|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Longitudinal study of hair repigmentation in patients receiving cererbolisin treatment for neurological diseases||||
33895551|NCT05664633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895552|NCT06022770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33979075|NCT02681965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979076|NCT03148574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979077|NCT01765530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33979078|NCT01079442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979079|NCT03541564|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33979080|NCT03505853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979081|NCT03544138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895553|NCT04665102|||COHORT||RETROSPECTIVE|||||||
33895554|NCT05051618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895555|NCT02375022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895556|NCT00753636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895557|NCT03514147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33895558|NCT00337948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895559|NCT00368173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895560|NCT03427073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766970|NCT03301727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979082|NCT02878109|||CASE_ONLY||PROSPECTIVE|||||||
33979083|NCT04518176|RANDOMIZED|PARALLEL||PREVENTION||NONE|open label randomized controlled study|randomized controlled study||||
33766971|NCT02092064|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33766972|NCT06392672|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial.||||
33766973|NCT05142982|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766974|NCT02554630|||CASE_CONTROL||PROSPECTIVE|||||||
33766975|NCT04453215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33766976|NCT00597714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766977|NCT05727943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766978|NCT02917577|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33766979|NCT01512745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979084|NCT02822781|||COHORT||PROSPECTIVE|||||||
33979085|NCT04132479|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised control trial||||
33979086|NCT00782132|||COHORT||CROSS_SECTIONAL|||||||
33979087|NCT03619252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33979088|NCT05948748|||OTHER||OTHER|||||||
33979089|NCT03805464|NA|SINGLE_GROUP||OTHER||NONE||||||
33979090|NCT06143865|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979091|NCT03287609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979092|NCT01060670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979093|NCT01881321|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33766980|NCT00305500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33766981|NCT03545373|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|All laboratory forms for mycobacteriology and nasopharyngeal pneumococcal work will have no reference to participant treatment allocation. On Day-8, assessment of improvement from baseline symptoms will utilize audio computer-assisted self-interview (ACASI) to minimise potential for social-mediated reporting and ascertainment biases. On Day-29, clinical outcome assessment forms will bear no reference to treatment arm. Participants, research coordinators, and routine care staff will not be masked to ensure safety of the participants and allow appropriate patient management decision-making which may be related to the trial interventions.|Three treatment arms allocated using computer generated block randomization in a 1:1:1 ratio.|f|f|f|t
33766982|NCT03788902|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33766983|NCT02724813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33766984|NCT01231503|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33766985|NCT02321046|||CASE_ONLY||PROSPECTIVE|||||||
33766986|NCT04931394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766987|NCT05640622|||COHORT||PROSPECTIVE|||||||
33766988|NCT00004650|RANDOMIZED|||TREATMENT||DOUBLE||||||
33895561|NCT05346302|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Double-blind randomized placebo-controlled vaccine administration (pneumococcal (PPSV23), typhoid (inactivated), or saline)|t|f|t|f
33895562|NCT04680884|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33895563|NCT00584350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33895564|NCT04966221|||COHORT||OTHER|||||||
33895565|NCT02888626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895566|NCT00607750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895567|NCT04876339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895568|NCT05568576|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895569|NCT06644612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded trials will be conducted where participants will be unaware of the intervention they will receive.|Participants will be randomly allocated into two groups: one group will undergo hernia repair using light-weighted polypropylene mesh, and the other group will receive heavy-weighted polypropylene mesh. The incidence of SSIs post-operatively will be compared between the two groups.|t|f|f|f
33895570|NCT02286102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895571|NCT01243840|||COHORT||PROSPECTIVE|||||||
33895572|NCT06389370|||OTHER||CROSS_SECTIONAL|||||||
33895573|NCT02513381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33895574|NCT02473406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33895575|NCT05779852|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33895576|NCT03083912|||OTHER||PROSPECTIVE|||||||
33895577|NCT01812525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979094|NCT05712330|NA|SINGLE_GROUP||SCREENING||NONE||||||
33979095|NCT01345019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33979096|NCT04495049|||CASE_ONLY||PROSPECTIVE|||||||
33895578|NCT05259475|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both study team and the subjects receiving diet intervention will be blinded on the allocation to food product with or without odd-chain fatty acids (OCFA).||t|f|t|f
33895579|NCT02122289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979097|NCT04823299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant only blinded to the treatment arm.|Single-blind, prospective, randomized|t|f|f|f
33979098|NCT01535326|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33979099|NCT04453748|||COHORT||PROSPECTIVE|||||||
33979100|NCT02351726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979101|NCT05048303|NA|SINGLE_GROUP||TREATMENT||NONE||A multi-center, prospective, single-arm clinical intervention cohort study.||||
33979102|NCT01411332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979103|NCT05003011|||COHORT||PROSPECTIVE|||||||
33979104|NCT00004193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979105|NCT00232947|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33979106|NCT02706236|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33979107|NCT04366336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979108|NCT02891941|||CASE_CONTROL||PROSPECTIVE|||||||
33979109|NCT04878146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||f|f|t|f
33979110|NCT01706926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979111|NCT01371409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979112|NCT06343168|||OTHER||CROSS_SECTIONAL|||||||
33979113|NCT03565432|||COHORT||PROSPECTIVE|||||||
33979114|NCT02014181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979115|NCT04637438|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33979116|NCT02179983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979117|NCT03458871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979118|NCT05749172|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33979119|NCT05162404|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979120|NCT00968370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979121|NCT00639990|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979122|NCT00442936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979123|NCT02193438|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33979124|NCT01189123|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33979125|NCT00048568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979126|NCT05434481|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Aneurysm and Dissection of Ascending Thoracic Aorta||||
33979127|NCT04087395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-face design|t|t|t|f
33979128|NCT02295878|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33979129|NCT02223000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895580|NCT00040534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895581|NCT02167269|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33895582|NCT01880450|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33895583|NCT00688038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895584|NCT01152099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895585|NCT00001923||||TREATMENT||||||||
33895586|NCT00002208||||TREATMENT||||||||
33895587|NCT00883753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895588|NCT04943588|||OTHER||OTHER|||||||
33895589|NCT05011552|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33979130|NCT04741100|||OTHER||CROSS_SECTIONAL|||||||
33979131|NCT03958825|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33979132|NCT00854321|||CASE_ONLY||RETROSPECTIVE|||||||
33979133|NCT04440254|NA|SINGLE_GROUP||SCREENING||NONE||||||
33979134|NCT02705053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979135|NCT04705142|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded Study|Case control study||||
33979136|NCT04955262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979137|NCT02822248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979138|NCT00534703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979139|NCT01022619|||CASE_CONTROL||PROSPECTIVE|||||||
33979140|NCT06376786|||COHORT||PROSPECTIVE|||||||
33979141|NCT01056796|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979142|NCT02524223|NA|SINGLE_GROUP||SCREENING||NONE||||||
33979143|NCT02524990|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33979144|NCT05387902|||COHORT||OTHER|||||||
33979145|NCT03577964|||CASE_CONTROL||PROSPECTIVE|||||||
33979146|NCT02143102|||COHORT||PROSPECTIVE|||||||
33979147|NCT02518581|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34077117|NCT01997034|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34077118|NCT06291766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33766989|NCT06189118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Investigator and outcome assessors will not be aware of allocation. Randomization and allocation will be conducted by an independent statistician.|A Randomized Controlled Clinical Trial (n=100-120) older adults aged 60 and over who experience symptoms of depression (MADRS score 10 and more) and provide written consent will go through 1:1 stratified randomization (stratified cognition by Telephone-Montreal Cognitive Assessment, T-MoCA 19-25 and 26+points). The intervention will consist of 8 online sessions (90-min each) of Mindfulness based Cognitive Therapy. The active control will consist of 8 online sessions (90-min each) of Health Education Program. Participants in both study arms will continue with their usual antidepressant therapy and/or psychosocial care. Primary outcome: depressive symptoms; Secondary outcome: quality of life and cognition; Exploratory outcomes: anxiety and mindfulness presence. Baseline (weeks -2 to 0) and post-intervention (weeks 8-10) assessments will be conducted.|f|f|t|t
33766990|NCT01335503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34077119|NCT03414944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33766991|NCT01290822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33766992|NCT06327763|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895590|NCT00604578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895591|NCT06279923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895592|NCT01163344|||COHORT||PROSPECTIVE|||||||
33979148|NCT06396468|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"In group Sevoflurane, anesthesia was maintained with sevoflurane (1-1.2 MAC) with oxygen /air 1:1.~In group propofol , anesthesia was maintained continuous infusion of 100-400 mcg/kg /min of propofol and fentanyl 0.1 ug / kg/ min with oxygen /air 1:1."|t|f|f|t
33979149|NCT00981357|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33979150|NCT00004099|RANDOMIZED|||TREATMENT||NONE||||||
33979151|NCT03372538|||CASE_CONTROL||PROSPECTIVE|||||||
33979152|NCT01811043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33979153|NCT05886426|||COHORT||PROSPECTIVE|||||||
34077120|NCT04916717|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||This is a quantitative study and has a quasi-experimental design with a control group.||||
34077121|NCT03175614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34077122|NCT02930057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077123|NCT00205101|||COHORT||PROSPECTIVE|||||||
34077124|NCT03383991|RANDOMIZED|PARALLEL||TREATMENT||||||||
33979154|NCT01151748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
19198045|NCT05549440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077125|NCT04552132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077126|NCT00327223|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077127|NCT01407991|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34077128|NCT00004102||||TREATMENT||||||||
34077129|NCT05360407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34077130|NCT04190862|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33979155|NCT00698399|||CASE_CONTROL||PROSPECTIVE|||||||
33979156|NCT01433666|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33979157|NCT05368636|||COHORT||PROSPECTIVE|||||||
34077131|NCT02762448|||COHORT||PROSPECTIVE|||||||
34077132|NCT02361112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077133|NCT00729716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077134|NCT06346847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double-blind, Placebo-controlled|t|t|t|f
34077135|NCT00632918|||CASE_ONLY||RETROSPECTIVE|||||||
34077136|NCT04250116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077137|NCT03930095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After all the participants signed a consent form, each subject was randomized to a single treatment by using the method of randomly permuted blocks (Matts \& Lachin, 1988) on http://www.randomization.com. Randomization was stratified in two blocs by use of psychotropic medication in order to have medication use equally distributed between groups. To that end, patients on psychotropic medication were randomized first.|This was a controlled randomized clinical trial involving 10 sessions of ABBT or 10 sessions of NDST (both in groups) completed within 14 weeks.|t|f|f|f
34077138|NCT02403050|||CASE_CONTROL|||||||||
34077139|NCT01858038|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34077140|NCT00334789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077141|NCT05986981|NA|SINGLE_GROUP||TREATMENT||NONE||The study flow included a screening period (week -4 to day -1), a treatment period (day 1 to week 8 or 16, including a DLT observation period on days 1-28), an end-of-treatment visit, and a survival follow-up. The treatment period included the initial treatment period (day 1 to week 8) and the augmentation period (week 12 to week 16). Subjects after signing and providing formal informed consent entered the screening period, during which eight separate administrations of the vaccine were administered, of which the investigator determined whether to continue treatment from week 8 to week 12 based on a combination of efficacy, safety, and adherence.||||
33979158|NCT06545201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979159|NCT01447563|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33979160|NCT05150964|NA|SINGLE_GROUP||OTHER||NONE||||||
33979161|NCT01241968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33979162|NCT00788125|NA|SEQUENTIAL||TREATMENT||NONE||Level -1: 25 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 1: 35 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 2: 50 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 3: 65 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 4: 85 mg/m\^2/dose BID PO Dasatinib x 17 days. Period 5 (Dasatinib alone phase only): 110 mg/m\^2/dose BID PO. Sponsor withdrew support before a second level could be attempted.||||
33766993|NCT03405272|NA|SINGLE_GROUP||TREATMENT||NONE|Single Arm, Open-label|Treated with recombinant anti-EGFR Monoclonal antibody（SCT200）until disease progression||||
33766994|NCT05799664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895593|NCT01264003|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33895594|NCT02504541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895595|NCT03818815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895596|NCT02963857|||COHORT||PROSPECTIVE|||||||
33895597|NCT03394950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33895598|NCT03265587|||COHORT||PROSPECTIVE|||||||
33766995|NCT01286220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33766996|NCT04458116|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Is a longitudinal randomized clinical study where participants will be randomized into two groups: Turmeric Group, in which participants will receive 1.5 grams of turmeric 95% curcumin (ACTIVE PHARMACEUTICA LTDA) for 1 month (3 capsules / day containing 500mg each for 4 weeks), and placebo group, where participants will receive capsules containing corn starch. Randomization will be done in blocks.|t|f|t|t
33766997|NCT02482272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979163|NCT03732170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be done to the assessors to reduce bias to healing assessment. As well, participants won't know which treatment they are undergoing.|Study subject (tooth) will be randomized in a 1:1 allocation ratio between the two treatment groups.|t|f|f|t
33766998|NCT04727476|||COHORT||RETROSPECTIVE|||||||
33766999|NCT05429658|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33895599|NCT04039139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be partially blinded. Participants in the usual care arm will be blinded to the specifics of the interventions. Intervention participants will be blinded to the specifics of the intervention until after they have been randomized into that arm. Data analysis will be conducted by persons who are completely blinded.|Usual Care, Intervention|t|f|f|t
33895600|NCT05176210|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33895601|NCT03391869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077142|NCT01265186|||||PROSPECTIVE|||||||
33895602|NCT00192790|||DEFINED_POPULATION||PROSPECTIVE|||||||
33895603|NCT05446675|||COHORT||OTHER|||||||
33895604|NCT01740895|||CASE_ONLY||PROSPECTIVE|||||||
33895605|NCT00628810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895606|NCT00994188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895607|NCT03652454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single outcome assessor|parallel assignment|f|f|f|t
33895608|NCT02498652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895609|NCT05253521|||COHORT||CROSS_SECTIONAL|||||||
33895610|NCT03119649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895611|NCT04421651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895612|NCT04728945|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33895613|NCT04954846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33895614|NCT01554202|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895615|NCT05290870|||COHORT||RETROSPECTIVE|||||||
33895616|NCT00930410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979164|NCT06195943|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979165|NCT02426970|||COHORT||PROSPECTIVE|||||||
33979166|NCT05258864|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33979167|NCT04529109|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33979168|NCT00094302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979169|NCT03141203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077143|NCT05159557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are randomly assigned to treatment arms by People Power. Identical systems are self-installed by caregivers in all homes regardless of treatment arm. Initiating the features of the system appropriate to the assigned treatment arm is done remotely by a member of the People Power staff following the installation. All participants complete the same questionnaires at the same intervals.||f|f|t|f
33895617|NCT05243771|||COHORT||PROSPECTIVE|||||||
33895618|NCT01158183|||COHORT||PROSPECTIVE|||||||
33895619|NCT03489213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895620|NCT04942639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data analysis performed on anonymous database.|Two parallel groups: Standard Asthma Maintenance Treatment (SAMT) vs SAMT + Joe robot (a new DTX)|f|f|f|t
33895621|NCT00921921|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33895622|NCT04278573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895623|NCT01272531|||OTHER||PROSPECTIVE|||||||
33895624|NCT03166800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077144|NCT00238407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077145|NCT01676051|||COHORT||PROSPECTIVE|||||||
34077146|NCT05160844|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34077147|NCT01804088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077148|NCT03961763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34077149|NCT06203509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077150|NCT06262971|||COHORT||PROSPECTIVE|||||||
34077151|NCT03372798|||CASE_ONLY||PROSPECTIVE|||||||
34077152|NCT01057355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077153|NCT04074434|||COHORT||PROSPECTIVE|||||||
34077154|NCT00132080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077155|NCT00081887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077156|NCT01598610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077157|NCT04753294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Four different patient groups treated with the Avance Solo NPWT System or Avance Solo Adapt NPWT System.||||
34077158|NCT01703390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077159|NCT04904471|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34077160|NCT05332314|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will be a prospective interventional study with two randomized parallel groups.~Randomization will take place immediately following the identification of a potential participant. The control group will receive the standard of care for diaphyseal tibia fractures. The standard of care consists of intramedullary nailing and post-operative opioids for pain control. The interventional group will have the same surgical indication and intervention but will differ in the primary method of pain control. The study group will receive NSAIDs and a reduced dosage of opioids for pain control. Primary outcome measures will be time to union, non-union, and pain over the post-operative period measured by a VAS pain scale. Once the data collection of both groups is complete, the statistical analysis will begin to determine if there is a statistical difference between the control and study groups in the primary outcome measurements"||||
34077161|NCT02475434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077162|NCT06017401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34077163|NCT00528307|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077164|NCT02985112|||COHORT||PROSPECTIVE|||||||
34077165|NCT03050827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomizing and blinding an investigational drug will be done by assigning each patient/subject a study number in the order they are recruited. The patients are randomized using a randomizing web site at (www.randomizer.org). The randomized patient numbers are recorded. This code is then placed in an envelope and sealed. This envelope will remain sealed until the study is concluded. A blinding/randomization patient form will be completed for each patient and sealed in the individual envelopes. The outside of the envelopes will contain patient numbers for identification purposes. This will allow the research coordinator to break the individual blind in emergency situations without compromising the rest of the blinding data. All instances where the blind is broken will be documented appropriately.|The investigators propose a placebo controlled, double blinded study to examine efficacy of topical Gelnique 3%TM (3% oxybutynin) daily for 20 weeks) in improving IENF density in type 2 diabetic subjects with established peripheral neuropathy. Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into placebo (N=30) or active drug (N=30) arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site, as per the manufacturers instructions (http://www.gelnique.com/gel3/). Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance. After 20 weeks, subjects will return for a second study visit and will undergo a series of measurements and 3 mm skin biopsy from the treated region of skin.|t|t|t|f
34077166|NCT00091468|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34077167|NCT01348724||CROSSOVER||BASIC_SCIENCE||NONE||||||
34077168|NCT00570375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767000|NCT01879423|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895625|NCT04087499|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33895626|NCT01570010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Parallel randomized clinical trial|f|f|t|t
33895627|NCT05939284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895628|NCT05917743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895629|NCT03250741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895630|NCT05596981|||COHORT||PROSPECTIVE|||||||
33895631|NCT02869191|||OTHER||PROSPECTIVE|||||||
33895632|NCT03884634|||OTHER||PROSPECTIVE|||||||
33895633|NCT03645291|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|None of the patients and participants know the type of insect allergen extracts used in skin prick and intradermal test|Comparison of skin prick testing and Intradermal skin test result of local and imported insect allergen extracts in patients with severe insect sting allergy|t|t|t|t
33895634|NCT01486264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895635|NCT05080829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895636|NCT02657239|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895637|NCT00077454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895638|NCT06657066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|Randomize Clinical Trial|t|f|t|f
33895639|NCT03036670|||COHORT||RETROSPECTIVE|||||||
33895640|NCT03370146|||COHORT||PROSPECTIVE|||||||
33895641|NCT05888259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895642|NCT05460208|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33895643|NCT05654480|||COHORT||CROSS_SECTIONAL|||||||
33895644|NCT03552783|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The program coordinator is intimately involved with program participants as his role includes completing the intakes with each participant, implementing the program, and for the purpose of the study, the screening process. To eliminate the bias, the program coordinator will continue to collect intake data and screen the participants. However, we will include a Licensed Mental Health Professional (LIMHP) who will utilize the screening information to complete the comprehensive assessment, randomize, and enroll the participants in the study. In addition, the LIMHP will also complete the follow-up data collection. This will prevent researcher bias during program delivery.|The intervention will be a quasi-experimental study. The participants will be randomized into one of two study arms: Father For a Lifetime (FFL) + Cognitive Behavioral Therapy (CBT) (intervention arm) or FFL only (comparison arm).|t|f|f|f
33895645|NCT03288805|||COHORT||PROSPECTIVE|||||||
33895646|NCT02291341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895647|NCT04537442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895648|NCT01855230|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33895649|NCT00980083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33979170|NCT03247556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895650|NCT06254274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895651|NCT04813510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895652|NCT05784090|||CASE_CONTROL||PROSPECTIVE|||||||
33895653|NCT03030040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random allocation of participants to arms will be conducted by a statistician independent of the study.||f|f|t|f
33895654|NCT05881993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895655|NCT00686751|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895656|NCT04096456|||CASE_CONTROL||RETROSPECTIVE|||||||
33895657|NCT01462513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979171|NCT05813028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979172|NCT00796822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077169|NCT05738746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sequentially numbered drug containers of identical appearance|parallel-groups, randomized, placebo-controlled clinical study|t|t|t|f
33979173|NCT02397733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34077170|NCT02562586|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34077171|NCT02377869|||COHORT||PROSPECTIVE|||||||
34077172|NCT00777166|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34077173|NCT00808067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077174|NCT03621033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077175|NCT01372631|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34077176|NCT00183118|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34077177|NCT02340000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077178|NCT05564481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a research assistant blind to condition of participant will complete outcome assessments.|wait-list control; all participants receive intervention- randomized to start immediately or 6 months after CGM start|f|f|f|t
34077179|NCT01649882|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979174|NCT04260204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blind masking|Patients were included in the study if they had left to right shunt due to volume or pressure overload|t|f|t|f
33979175|NCT05670652|||OTHER||CROSS_SECTIONAL|||||||
33979176|NCT00599209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767001|NCT03661034|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, four-arm prospective dose-adjusting study (2 cohorts sequentially enrolled, each with 2 randomly assigned dose levels)||||
33979177|NCT00622232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077180|NCT00247520|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33767002|NCT04221282|||COHORT||PROSPECTIVE|||||||
33895658|NCT01699217|||COHORT||PROSPECTIVE|||||||
33979178|NCT00584181|||COHORT||PROSPECTIVE|||||||
33979179|NCT04607720|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33895659|NCT00575679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33895660|NCT05158348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979180|NCT04296903|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Registry, multi center, single arm, non-randomized, new enrollment cohort study||||
33979181|NCT03515395|||COHORT||PROSPECTIVE|||||||
33979182|NCT02422823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33979183|NCT04611256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979184|NCT01951846|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33979185|NCT05400876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979186|NCT02162069|NA|SINGLE_GROUP||TREATMENT||NONE||TAVR||||
33979187|NCT04817007|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33979188|NCT01890239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33979189|NCT06258694|||COHORT||RETROSPECTIVE|||||||
33979190|NCT01659307|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077181|NCT03656627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077182|NCT04413344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||\[Double-blind phase\] Multicenter, randomized, placebo-controlled, double-blind, parallel-group comparison clinical trial \[Extension phase\] Multicenter, open-label, extension trial|t|t|t|t
34077183|NCT05736328|||COHORT||PROSPECTIVE|||||||
34077184|NCT00288652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077185|NCT04176211|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33767003|NCT04116528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767004|NCT02415374|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33767005|NCT04924972|||COHORT||PROSPECTIVE|||||||
33767006|NCT01774318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33767007|NCT04856943|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767008|NCT04937426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767009|NCT05017324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized Controled Phase 4 pragmatic single blinded medical device trial.|t|f|f|f
33767010|NCT06299514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33767011|NCT05613283|||COHORT||PROSPECTIVE|||||||
33767012|NCT00812188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33767013|NCT03748238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767014|NCT06249490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33767015|NCT03084497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33767016|NCT03942380|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33767017|NCT00774449|||COHORT||PROSPECTIVE|||||||
33767018|NCT02970032|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33767019|NCT05307328|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Staggered parallel crossover|t|t|t|t
33767020|NCT02989272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33767021|NCT06076356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Concurrent Parallel Randomized Clinical Trial|t|f|f|f
33767022|NCT00610701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767023|NCT00613288|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33767024|NCT04482829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767025|NCT06167551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The baby's crying time will be monitored and recorded. KTA and SpO2 will be recorded by the researcher during blood collection. Pain assessment of the babies will be made by two independent neonatal nurses other than the researcher. Both observers must have worked in the clinic for at least 5 years.~Analysis of the data will be done by an independent analyst, not by researchers."|Comparison of 3 different auditory applications with the control group during heel prick collection in newborns.|t|f|f|t
33767026|NCT02168543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767027|NCT02400437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895661|NCT03328819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|According to the computer-generated permuted block randomization, 75 sealed envelopes containing notes with 1\~75 numbers assigned to the depression-pain group or pain-depression group. Before each new treatment course began, the acupuncturists opened one of the 75 envelopes in numerical order and treated the newly included participants with pain-specific or depression-specific acupoints, according to the notes. The intervention and research teams were physically segregated during the trial. The patients, the assessor, and the biostatistician were blinded to the allocation process until the data were analyzed. After the interventions were completed, the patients were asked to indicate the interventions they perceived to have received during the first and second six-week periods. Research nurses recorded the results.||t|f|f|t
33895662|NCT02760628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895663|NCT01771549|||CASE_ONLY||PROSPECTIVE|||||||
33895664|NCT02045199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33895665|NCT03795350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895666|NCT06656234|||COHORT||PROSPECTIVE|||||||
33895667|NCT04359966|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised procpective multicenter trial||||
33895668|NCT04967690|NA|SEQUENTIAL||TREATMENT||NONE||Up to 27 subjects will be included in the trial (estimated; 21 subjects in total for dose escalation following a 3+3 rule based design for six doses in total, including three more subjects at RP2D, and an additional six subjects for dose expansion at RP2D).||||
33895669|NCT01195025|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895670|NCT06264453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895671|NCT04112914|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Consecutive cohort design with randomization||||
33895672|NCT05498272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895673|NCT05750914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895674|NCT03661385|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Perfusionist (operating bypass) is unblinded to randomisation. They will randomize patient in a computer base (REDcap).Randomization is blinded to all other staff and the nitric oxide container is draped. Nitric oxide container will be attached in all cases.|Double blinded, randomised controlled, parallel study comparing an intervention with a control.|t|t|t|t
33895675|NCT04646395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895676|NCT06388408|||COHORT||PROSPECTIVE|||||||
33895677|NCT06336525|||COHORT||CROSS_SECTIONAL|||||||
33895678|NCT04248777|NA|SINGLE_GROUP||OTHER||NONE||Patients with left main artery planned PCI for stable or unstable coronary artery disease.||||
33895679|NCT05932433|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895680|NCT02484261|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895681|NCT03465956|NA|SINGLE_GROUP||TREATMENT||NONE||All patients,males and females with age (20-50 years old) with morbid obesity (BMI ≥ 40 kg/m2 or \> 35 kg/m2 associated with co-morbidity).||||
33895682|NCT05164523|||CASE_CONTROL||PROSPECTIVE|||||||
33767028|NCT03266185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767029|NCT05958329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767030|NCT03857412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33767031|NCT02326896|||COHORT||RETROSPECTIVE|||||||
33767032|NCT00818103|RANDOMIZED|CROSSOVER||||NONE||||||
33767033|NCT02641249|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open Label|"In the same subject there were 2 periods:~Arm 1. 'No intervention' period (no vibrations) - two 6 hour epochs - total of 12 hours of 'No intervention' Arm 2. Experimental period (with vibrations) - two 6 hour epochs - total of 12 hours of 'vibration intervention'~In the same subjects cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the experimental period (vibration) and druing the no intervention period (no vibration)."||||
33767034|NCT03615521|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33767035|NCT02120664|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33767036|NCT06128174|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Multicenter Single-Arm Investigator-Initiated IDE study||||
33767037|NCT04746651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767038|NCT02778399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767039|NCT02185885|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33767040|NCT06250647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767041|NCT04337086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was a double-blind study, as the participant and the outcome assessors were blinded to the type of treatment.||t|f|f|t
33767042|NCT03244293|||CASE_ONLY||PROSPECTIVE|||||||
33767043|NCT01161303|||COHORT||CROSS_SECTIONAL|||||||
33767044|NCT01381874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767045|NCT02826525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767046|NCT02756832|||COHORT||PROSPECTIVE|||||||
33767047|NCT04172493|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33767048|NCT05477706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized clinical trial|f|f|f|t
33767049|NCT02348853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767050|NCT02401308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767051|NCT04651114|NA|SINGLE_GROUP||OTHER||NONE||A pre-post design was selected for feasibility and preliminary efficacy.||||
33767052|NCT01024790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767053|NCT02340702|||COHORT||PROSPECTIVE|||||||
33767054|NCT02478021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33767055|NCT01255553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767056|NCT00245856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767057|NCT04613882|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33767058|NCT00965003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767059|NCT04930770|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33767060|NCT01535274|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767061|NCT03312686|||COHORT||PROSPECTIVE|||||||
33767062|NCT00811421|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33767063|NCT03946514|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomly divided into two groups, taking losartan 100 mg/hydrochlorothiazide 25 mg fixed combination once a day or amlodipine besylate tablets (5 mg/tablet) + hydrochlorothiazide tablets (25 mg/tablet) once a day.||||
33767064|NCT03492892|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767065|NCT00406549|||||PROSPECTIVE|||||||
33767066|NCT04783298|||OTHER||PROSPECTIVE|||||||
33767067|NCT06041958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767068|NCT01370603|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33767069|NCT06159374|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33767070|NCT03082833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767071|NCT02080195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767072|NCT04851860|NA|SINGLE_GROUP||TREATMENT||NONE||allergic rhintis children from 6 to12 years||||
33767073|NCT01603563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767074|NCT03020329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767075|NCT02560935|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
33767076|NCT03835936|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-blind controlled clinical trial||||
33767077|NCT02766179|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767078|NCT04805463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Split mouth design was used in the study. The chin was divided into lower, upper and right, and left anterior regions. The distribution of the platelet concentrate and control group to be used after gingivectomy and gingivoplasty was randomly decided.||||
33767079|NCT02922790|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767080|NCT06160622|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767081|NCT06626386|||CASE_ONLY||OTHER|||||||
33767082|NCT02225977|||COHORT||PROSPECTIVE|||||||
33767083|NCT06215651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767084|NCT01339598|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33767085|NCT04561882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767086|NCT03416881|||CASE_ONLY||CROSS_SECTIONAL|||||||
33767087|NCT02703207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767088|NCT05635136|||COHORT||PROSPECTIVE|||||||
33767089|NCT04707911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895683|NCT04655625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33895684|NCT04397120|||CASE_ONLY||RETROSPECTIVE|||||||
33895685|NCT00815308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767090|NCT03781765|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a pilot study with no control group. All youth will be treated with MPH or ATX and receive pre and post fMRI.||||
33767091|NCT06625840|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33767092|NCT05675865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767093|NCT05124041|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||140 patients having ACLF with bleeding will be randomized into two groups. One will be treated conventionally, i.e. using clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm|t|f|f|t
33767094|NCT00006115||||TREATMENT||||||||
33895686|NCT02195830|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895687|NCT00957372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895688|NCT01936337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895689|NCT05347823|||COHORT||PROSPECTIVE|||||||
33895690|NCT03102411|||OTHER||CROSS_SECTIONAL|||||||
33895691|NCT04673838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33895692|NCT04252378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895693|NCT06477718|||CASE_CONTROL||RETROSPECTIVE|||||||
33979191|NCT03384719|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The study is a randomized, controlled, double-blind, parallel food intervention study with 3 study arms|t|t|t|t
33895694|NCT00117767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33895695|NCT00644579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895696|NCT06166771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895697|NCT05671900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895698|NCT03975543|||COHORT||RETROSPECTIVE|||||||
33895699|NCT02362373|NA|SINGLE_GROUP||||NONE||||||
33895700|NCT04291157|RANDOMIZED|PARALLEL||PREVENTION||NONE||Large simple randomized trial||||
33895701|NCT00327392|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895702|NCT04819828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33895703|NCT05427630|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Each participant will have an identification number and randomization of drug sequence allocation will be performed a priori using a random number generator by the study pharmacist. The 4 treatments will be identically encapsulated by the study pharmacist. The study pharmacist will place the capsules in identical sealed plastic bags labeled Migraine 1 through Migraine 4."|Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial|t|t|t|t
33895704|NCT05289661|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33895705|NCT05839132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33895706|NCT05260411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895707|NCT04626713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895708|NCT01106638|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895709|NCT05958420|||COHORT||PROSPECTIVE|||||||
33895710|NCT06657261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The anesthesia and surgical method will be the same for both patient groups. One group of patients will receive deep and superficial serratus anterior plane block. The other group will receive a combination of deep serratus anterior plane block and transverse thoracic muscle plane block. Postoperative visual pain scores will be observed for both groups. At the end of the study, the analgesic efficacy of the two groups will be compared."|t|f|f|f
33895711|NCT02631161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895712|NCT06221930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895713|NCT02495363|||CASE_ONLY||PROSPECTIVE|||||||
33895714|NCT03180996|||COHORT||PROSPECTIVE|||||||
33895715|NCT01316484|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895716|NCT01412242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895717|NCT01329757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895718|NCT03240640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895719|NCT01158898|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33895720|NCT04824261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895721|NCT02070432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895722|NCT03016234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33895723|NCT04112758|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33895724|NCT03992300|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|The frameworks are marked with a triangle or a circle in the distal aspect of the distal right molar. The outcomes assessor does not now to which group corresponds each framework|Two frameworks with the same design obtained from two different models (intraoral scanning and conventional impression) are processed and tested in every patient|f|f|f|t
33895725|NCT04024696|NA|SEQUENTIAL||TREATMENT||NONE||Cohort 1: 40 mg BID Cohort 2: 60 mg BID Cohort 3: 80 mg BID||||
33895726|NCT04373525|||COHORT||PROSPECTIVE|||||||
33895727|NCT04062812|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Quasi-experimental design|f|f|t|f
33895728|NCT05232955|||CASE_CONTROL||PROSPECTIVE|||||||
33895729|NCT00336362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895730|NCT01826214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979192|NCT03400384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33979193|NCT03348943|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33979194|NCT03003338|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33979195|NCT01972022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979196|NCT02385097|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33979197|NCT01824758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34077186|NCT04135482|||COHORT||PROSPECTIVE|||||||
34077187|NCT04409106|||CASE_ONLY||CROSS_SECTIONAL|||||||
34077188|NCT01715233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077189|NCT06607900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077190|NCT05137717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077191|NCT03211520|||CASE_ONLY||PROSPECTIVE|||||||
34077192|NCT02121860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077193|NCT02443831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077194|NCT04609683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077195|NCT03685097|||COHORT||PROSPECTIVE|||||||
34077196|NCT04092738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial.|t|f|f|f
34077197|NCT03323112|||COHORT||PROSPECTIVE|||||||
33979198|NCT03250533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Volunteers will also be randomized between groups:~* LED treatment group 620 nm (G-LED 620; n = 13)~* Treatment group with LED 940 nm (G-LED 940; n = 13)~* Treatment group with fixed diphasic current (G-DF; n = 13)~* Control group (G-C; n = 13)"|f|f|t|t
33979199|NCT01836419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979200|NCT00472888|||DEFINED_POPULATION||OTHER|||||||
33979201|NCT04216069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will not know to which group the participant belongs.||f|f|f|t
33979202|NCT04953247|||COHORT||RETROSPECTIVE|||||||
33979203|NCT00438828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979204|NCT06093425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|TST001, Placebo|Randomized, Double-Blind, Placebo-Controlled|t|f|f|f
33979205|NCT04325074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979206|NCT03238066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979207|NCT05249413|||CASE_ONLY||RETROSPECTIVE|||||||
33979208|NCT03159156|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE|Behavioral procedures that cannot be masked to participant or others.|The primary goal is to examine the role of hyperventilation in blood donation-related vasovagal reactions and whether breathing is influenced by two treatments (alone and in combination) for reactions. The study will examine the clinical impact of these treatments but this is not the primary goal of the project.||||
33979209|NCT00184808|||DEFINED_POPULATION||OTHER|||||||
33979210|NCT06179238|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33979211|NCT03969953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple-blind, Placebo-controlled|The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector, outcomes assessor), placebo-controlled trial. The trial will test for the superiority of the trial intervention using a 1:1 allocation to parallel trial groups, on the basis of a pre-specified number of primary outcomes events.|t|t|t|t
33979212|NCT04989036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blinded (patient, radiographic assessors of results and statistician)|Randomized controlled trial (RCT), parallel group with 1:1 allocation ratio and equivalence framework. Triple blinded (patient, radiographic assessors of results and statistician) Ethics approval by the Human Research Ethics committee at Faculty of Dentistry- Cairo University was taken.|t|t|f|t
33979213|NCT02834000|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979214|NCT02210403|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33979215|NCT01484405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979216|NCT01225146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979217|NCT02393040|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33979218|NCT00870870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979219|NCT05856045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979220|NCT01323764|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33979221|NCT00000566||||DIAGNOSTIC||||||||
33979222|NCT02684682|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33979223|NCT00483496|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33979224|NCT01915251|||||PROSPECTIVE|||||||
33979225|NCT01223300|||CASE_ONLY||PROSPECTIVE|||||||
33979226|NCT00257153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979227|NCT01932840|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33979228|NCT02154308|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979229|NCT00784849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979230|NCT05184049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979231|NCT04140175|||COHORT||PROSPECTIVE|||||||
33979232|NCT02833038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33979233|NCT03852706|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33979234|NCT06033482|||COHORT||PROSPECTIVE|||||||
34077198|NCT02550743|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a phase I dose escalation study adding BYL719 to standard capecitabine and radiation.||||
33979235|NCT00727571|||||PROSPECTIVE|||||||
33979236|NCT05742529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979237|NCT06298019|NA|SEQUENTIAL||TREATMENT||NONE||Patients will be enrolled in a sequential manner with respect to the aggressiveness of the conditioning regimen used prior to receiving the CAR T infusion therapy. The first 3 patients will undergo standard conditioning--daily cyclophosphamide (IV, 300 mg/m2) and fludarabine (30 mg/m2) x 3 days. If this regimen is found to allow sufficient engraftment of the CAR T cells, participants will be enrolled in sequential groups (of 3-5) representing milder doses or alternative medications that overall represent gentler cytoreduction, which advancement to each sequential group contingent upon satisfactory number and function of infused CAR T cells.||||
33979238|NCT06121037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979239|NCT00688064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979240|NCT06196242|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33979241|NCT01632709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979242|NCT04204577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979243|NCT01715038|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33979244|NCT00405678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979245|NCT00048048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077199|NCT03116217|||CASE_ONLY||PROSPECTIVE|||||||
34077200|NCT01493895|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34077201|NCT01985503|||COHORT||PROSPECTIVE|||||||
34077202|NCT06344715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077203|NCT01699724|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33767095|NCT01454674|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33767096|NCT00295438|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33767097|NCT05711888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Semantic recognition task outcomes are observed in people diagnosed with Alzheimer's disease with Non-Alzheimer population.||||
33767098|NCT04581200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Outcomes assessor will be blinded to group assignment, as will the investigators|Randomized clinical trial|f|f|t|t
33767099|NCT05085821|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33767100|NCT00989586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767101|NCT00975988|||||PROSPECTIVE|||||||
33767102|NCT06434597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767103|NCT05015764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767104|NCT03028090|||CASE_ONLY||PROSPECTIVE|||||||
33767105|NCT05414097|||OTHER||PROSPECTIVE|||||||
33767106|NCT00706225|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33767107|NCT00218803|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33767108|NCT03387241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A double blind, double dummy, randomised, multicentre, two arm parallel design||t|t|t|t
33767109|NCT02387216|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized, open-label, international, multi-center, Phase 2 study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)||||
33767110|NCT00879580|||COHORT||PROSPECTIVE|||||||
33767111|NCT02712632|||COHORT||PROSPECTIVE|||||||
33767112|NCT00231660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33767113|NCT02281526||PARALLEL||TREATMENT||NONE||||||
33767114|NCT01842737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33979246|NCT04669236|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pre, post and follow-up testing with 3 intervention and 6 control schools||||
33767115|NCT06624462|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, open label, non-blinded randomized controlled trial||||
33767116|NCT01357590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767117|NCT03195465|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33767118|NCT03047772|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33767119|NCT05581615|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767120|NCT00420134|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33767121|NCT04187820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767122|NCT06568744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767123|NCT02790073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767124|NCT03383796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767125|NCT04538989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33767126|NCT00857805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801270|NCT02503397|||COHORT||PROSPECTIVE|||||||
33801271|NCT02267824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801272|NCT00047931||||TREATMENT||||||||
33801273|NCT00277355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801274|NCT00897169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801275|NCT02830464|||COHORT||PROSPECTIVE|||||||
33979247|NCT00795665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979248|NCT05223556|||COHORT||PROSPECTIVE|||||||
33979249|NCT00928083|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33979250|NCT03482882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979251|NCT04640103|||COHORT||PROSPECTIVE|||||||
33979252|NCT00726960|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33979253|NCT02805322|NON_RANDOMIZED|PARALLEL||||NONE||||||
33979254|NCT00789984|||||PROSPECTIVE|||||||
33979255|NCT01739283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33979256|NCT02802371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33979257|NCT02538445|RANDOMIZED|PARALLEL||||NONE||||||
33979258|NCT03056248|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients and investigators will be blinded to the study|Patients will be randomized to lithium versus placebo and rates of acute kidney injury will be measured|t|t|t|f
33979259|NCT06145139|||COHORT||PROSPECTIVE|||||||
33979260|NCT00252356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979261|NCT03176550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979262|NCT05274711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Opaque sealed envelope|This trail has 2 groups one control and one experimental|f|f|t|t
33979263|NCT03274310|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33979264|NCT02175797|NA|SINGLE_GROUP||OTHER||NONE||||||
33979265|NCT01695070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979266|NCT02308774|||COHORT||PROSPECTIVE|||||||
33979267|NCT00345410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979268|NCT01179880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979269|NCT02886078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979270|NCT03266237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979271|NCT03145714|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33979272|NCT04183231|NA|SINGLE_GROUP||TREATMENT||NONE||Open label exposure--response study||||
33979273|NCT05478148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979274|NCT00631033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979275|NCT01860976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077204|NCT02631317|||COHORT||PROSPECTIVE|||||||
34077205|NCT02884739|||COHORT||PROSPECTIVE|||||||
34077206|NCT04213391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979276|NCT05965609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors. Participants are asked not to share details of their treatment with other individuals at their workplace.||f|f|t|t
33979277|NCT00930423|||CASE_CONTROL||PROSPECTIVE|||||||
34077207|NCT06151353|||COHORT||PROSPECTIVE|||||||
34077208|NCT06434194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34077209|NCT00302978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077210|NCT00014872|||COHORT||PROSPECTIVE|||||||
34077211|NCT00427141|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34077212|NCT00700375|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34077213|NCT03141112|||OTHER||RETROSPECTIVE|||||||
34077214|NCT05243914|||COHORT||PROSPECTIVE|||||||
34077215|NCT01961414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077216|NCT05893862|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34077217|NCT01380418|||OTHER||CROSS_SECTIONAL|||||||
34077218|NCT00419757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077219|NCT01439243|RANDOMIZED|CROSSOVER||||NONE||||||
34077220|NCT06258434|||COHORT||PROSPECTIVE|||||||
34077221|NCT01801709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077222|NCT04953195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077223|NCT04195425|||COHORT||PROSPECTIVE|||||||
34077224|NCT00227539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077225|NCT05943470|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979278|NCT01118936|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33979279|NCT05587088|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"At the screening visit, all subjects will be randomly assigned a unique subject number (e.g., 001,002,003, etc.). Enrolled subjects will retain the subject number assigned at Screening Visit throughout the study. In phase Ib, no randomization will be performed. All subjects will receive the therapy chosen by the treating physician.~Patients enrolled in phase II will be randomized through the application built in the eCRF in RedCap® for this purpose. Participant, care provider and Investigator will be blind."|This is a phase Ib/II clinical study that has two phases. In phase Ib, the safety evaluation of the extract of Petiveria alliacea (Esperanza) will be carried out in patients with metastatic gastrointestinal tumors (colon, pancreas, stomach and biliary tract) and patients with newly diagnosed and relapsed acute leukemia. In phase IIb, the safety will continue to be evaluated and the efficacy of the Esperanza extract will be explored in combination with chemotherapy in patients with metastatic gastrointestinal tumors (colon, pancreas, stomach and biliary tract) and patients with newly diagnosed acute leukemias and relapses|t|t|t|f
33979280|NCT05223582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979281|NCT01202981|||CASE_ONLY||PROSPECTIVE|||||||
33979282|NCT05680350|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33979283|NCT00059371|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33979284|NCT05116930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077226|NCT01944436|||COHORT||PROSPECTIVE|||||||
34077227|NCT01519817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077228|NCT05681013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34077229|NCT00429832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077230|NCT03172728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077231|NCT03912740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077232|NCT03565757|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077233|NCT02752815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077234|NCT03575247|||COHORT||RETROSPECTIVE|||||||
34077235|NCT02926105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34077236|NCT05874102|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077237|NCT03113669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077238|NCT01168921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077239|NCT03175081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will involve two groups with equal allocation of patients in the test group (local anaesthesia) and control group (normal saline) by randomization. All patients who agree to participate in this study will be randomized into one of the study groups.|t|f|t|f
34077240|NCT00035178|RANDOMIZED|||TREATMENT||NONE||||||
34077241|NCT02168491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077242|NCT02076620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979285|NCT03976713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979286|NCT01941030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979287|NCT06306742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979288|NCT03237143|||COHORT||RETROSPECTIVE|||||||
34077243|NCT03983408|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Allocation concealment for first 12 weeks is maintained; all participants are provided with KRG during during another 12 weeks for the open-label extension.||t|t|t|f
34077244|NCT04295798|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|Study personnel administering tDCS and the participants will not be aware of tDCS intervention arm assignment. The investigators will ensure such double-blinding by programming the tDCS software with intervention-specific stimulation codes, as supplied by personnel uninvolved in data collection, prior to study initiation.|"The investigators will conduct a within-subject, double-blinded, randomized controlled study comparing the after-effects of single sessions of traditional tDCS, personalized tDCS, and two different sham conditions on dual task performance in men and women aged 65-85 years with poor baseline dual task performance. Participants will complete a structural brain MRI. They will then complete four visits during which they will receive one of the four interventions in random order."|t|t|t|t
34077245|NCT04651998|||COHORT||PROSPECTIVE|||||||
34102960|NCT06222736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The numbers determined using the Research Randomiser program will be placed in an opaque envelope, and participants will be asked to choose an envelope. Participants will be included in groups according to the number they choose.|Our study will be conducted at the Istanbul University-Çapa Faculty of Dentistry Total and Partial Prosthesis clinic with volunteers who have been diagnosed with Temporomandibular disfunction.|t|f|f|f
34102961|NCT06688370|||CASE_ONLY||PROSPECTIVE|||||||
34102962|NCT06258785|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102963|NCT06668467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33767127|NCT06493123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"* Group I/Control: Conventional cardiopulmonary rehabilitation will be applied in the postoperative period.~* Group II/ Bottle P.E.P.: Conventional cardiopulmonary rehabilitation and bottle-PEP therapy will be applied in the postoperative period.~* Group III/Early Mobilization: An early mobilization program will be started in conventional cardiopulmonary rehabilitation in the postoperative period."|t|f|t|f
33767128|NCT05357937|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33767129|NCT02733172|||COHORT||PROSPECTIVE|||||||
33767130|NCT03885804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|a physician assessing outcomes blinded to the nature of the study as first and second rescue analgesics respectively.Drug packs will be prepared before commencement of the study by a pharmacist unaware of the nature of the study|randomisation by concealed envelope method|t|f|f|t
33979289|NCT02659852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979290|NCT04141033|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33979291|NCT04506242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979292|NCT04416477|||COHORT||OTHER|||||||
33979293|NCT00525590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979294|NCT03843203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The researcher will receive equipment already programmed by a research assistant, so the researcher who will deliver the tDCS to perform stimulation will not know the programed stimulation. Patients will be instructed to discuss aspects of treatment with the respective investigator. Two independent evaluators who will not participate in the consultations where guidance on the use of tDCS will be provided will be trained to make outcome assessments in follow-up. Patients will not be aware of the type of intervention received, since the sham condition produces a stimulus, but no expected effects. In order to study the level of the blinding, at each moment of evaluation, the patient will be asked about the type of intervention that he / she believes to have received (active or simulated), and about the degree of safety in the response, using a standardized questionnaire. The blinding will be evaluated at the end of each treatment week by means of a standardized instrument.|Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial|t|t|t|t
34077246|NCT04192721|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study used a randomized control clinical trial design. In the BDI pre-test, 80 of the students with mild or moderate depressive symptoms met the other inclusion criteria of the study and volunteered to participate in the study. Out of 80 participants, 40 were randomly assigned to the intervention group and 40 to the control group using computer-generated random number sequences. The study was completed with a total of 63 participants (n=31 for the intervention group; n=32 for the control group). While CBT-based group counseling was given to the intervention group, no counseling was given to the control group during the study.~The participants were evaluated at three time points: at screening (pre-test), six weeks after screening (post-intervention/post-test), and two months after the post-test. The measurements were taken simultaneously in the intervention and control groups."||||
34077247|NCT01278602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077248|NCT01657162|NA|SINGLE_GROUP||TREATMENT||NONE|Even though this is an open-label study, participants and Investigators who will be participating in this study (BA058-05-005) will remain blinded to the prior treatment assignment in Study BA058-05-003 (NCT02653417) until all participants completed the first 6 months of BA058-05-005 for prespecified data analysis. Complete data analysis for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417.|||||
34077249|NCT00689689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077250|NCT05483868|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077251|NCT02316639|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102964|NCT03740165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102965|NCT05467098|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pre-test post-test Design.||||
33767131|NCT05282849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767132|NCT01476488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767133|NCT01706419|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33767134|NCT01381627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33767135|NCT02873130|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767136|NCT04919174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979295|NCT02853500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979296|NCT02924480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33979297|NCT01924858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979298|NCT04104568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants are not unaware of the intervention received as they are active parts of the intervention. The data analyst will be blinded to the intervention assigned to the participants. Data collection at baseline and outcomes assessment are carried out in a computerized manner via study online platform and resorting to self-report/self-administered instruments, thus the researcher has no control or influence over the measurements.|Experimental parallel between-group design with two arms.|f|f|t|t
33979299|NCT02559583|||CASE_CONTROL||RETROSPECTIVE|||||||
33979300|NCT04270305|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33979301|NCT01310296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33979302|NCT03220919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomised controlled trial|t|f|f|f
33979303|NCT00623779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979304|NCT03392909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979305|NCT03614520|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|The subjects, because of the wine taste that cannot be hidden, will know what they drink, except from the three beers (the three types will not be distinguishable).|A 40 people group of healthy men and women. Two Cohorts group of 20 healthy volunteers of both genders.||||
33979306|NCT03556566|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|Single arm, open label Phase II study in volunteers with ovarian cancer receiving daily dose of one pill of vaccine V3-OVA||||
33979307|NCT01568164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979308|NCT02906709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979309|NCT02820142|||CASE_ONLY||PROSPECTIVE|||||||
33979310|NCT01819623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979311|NCT03658837|||COHORT||PROSPECTIVE|||||||
33979312|NCT00424203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979313|NCT04041570|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Sequential Assignment Dose Escalation||||
33767137|NCT06136715|||COHORT||RETROSPECTIVE|||||||
33979314|NCT04913909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse, who was also responsible for keeping the codes and information confidential until after the statistical calculations. Statistical analysis were performed by a blind assessor.|"The trial was a prospective randomized, double-blind, placebo-controlled intervention study.~All patients took an oral hygiene education and were invited to give paraffin-stimulated saliva, and blood samples in the Diabetic Center. All patients were examined clinically and the results of the intraoral examination were recorded. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for at least one minute before going to bed and after tooth brushing. Dentoblis™, contains 4x 109 CFU/g S. salivarius M18 strain probiotic isolated from a healthy oral microbiota.~Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse, who was also responsible for keeping the codes and information confidential until after the statistical calculations. At baseline and at the end of the 30 day- intervention period, all measurements were retested."|t|f|t|t
33979315|NCT02164786|||COHORT||PROSPECTIVE|||||||
33979316|NCT00003313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979317|NCT01668888|||COHORT||CROSS_SECTIONAL|||||||
33979318|NCT06266962|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077252|NCT05236907|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|It has been done on all the study's contributors and workers.|Patients were divided into three groups at random, with 12 patients in each group, using a double-blinded method.|t|t|t|t
34077253|NCT02073526|||COHORT||PROSPECTIVE|||||||
34077254|NCT01171157|||CASE_CONTROL||PROSPECTIVE|||||||
33767138|NCT05041816|NA|SINGLE_GROUP||TREATMENT||NONE||A 6-week, single group, repeated measures with double baselines research design to characterize the changes in sensory and motor nerve performance in DPN, and examine the relations between these changes and changes in pain and mobility||||
33767139|NCT00288028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767140|NCT02690077|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767141|NCT04430413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767142|NCT04904081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind (participants only)||t|f|f|f
33767143|NCT01770535|||CASE_ONLY||PROSPECTIVE|||||||
33767144|NCT05232474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767145|NCT01486134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767146|NCT04547270|||COHORT||PROSPECTIVE|||||||
33767147|NCT02751918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767148|NCT01090908|||CASE_ONLY||PROSPECTIVE|||||||
33767149|NCT02732093|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33767150|NCT00405353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767151|NCT03949088|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33767152|NCT00244374|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33767153|NCT03096171|RANDOMIZED|CROSSOVER||OTHER||NONE||"Behavioral: Flourishing App Program This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.~No Intervention: Control App This group will observe their psychological and physical condition (levels of stress and well-being) during their daily activities and social interactions for 8 weeks. After the evaluations, this group will receive the intervention (Flourishing App Program) for more 8 weeks."||||
33767154|NCT06422403|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective, open label, multi-centre phase 2 trial||||
33979319|NCT03304600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979320|NCT03493737|||CASE_CONTROL||PROSPECTIVE|||||||
33979321|NCT06413225|||COHORT||PROSPECTIVE|||||||
34077255|NCT01781104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767155|NCT00477477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840446|NCT05260177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|A parallel-group randomized (1:1), double-blinded, placebo-controlled, clinical trial|t|f|t|t
33840447|NCT00788242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840448|NCT04025489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979322|NCT05822232|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979323|NCT05886543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979324|NCT03634709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to allocated condition|Single blind, randomized controlled trial comparing active intervention to waitlist control|f|f|f|t
33979325|NCT03475784|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33979326|NCT00212849|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33979327|NCT00248638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33767156|NCT03360877|NA|SINGLE_GROUP||PREVENTION||NONE||The initial 8-month baseline period will be used to collect data on the evaluation criteria of interest prior to the administration of any intervention of the study and will develop appropriate pedagogical tools to support the uptake of each cleaning strategy during subsequent intervention periods. After the reference period, a one-month introductory period will allow the organization of the first intervention at each site (ie - a soap and water cleansing administered by the carers in a structure or - a cleaning HCG administered by caregivers in the other facility) followed by eight months of active follow-up of the study with the first intervention. Following the eight months of active follow-up with the first intervention, there will be a crossover with an introductory period of one month and eight months of active follow-up with the other intervention. A final period of interruption will occur during the last eight months of the study.||||
33979328|NCT01074710|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33979329|NCT03679000|||COHORT||PROSPECTIVE|||||||
33979330|NCT01280253|||CASE_ONLY||PROSPECTIVE|||||||
34077256|NCT02182401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077257|NCT00631059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077258|NCT03174015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study will be partially single blinded. Participants and investigators cannot be masked to the intervention but outcome assessors will not know where the intervention has taken place and will be given only minimal information to enable assessment of intervention exposure at the end of the survey.|A random sample of plots will be selected in Bauleni Compound and invited to participate. Intervention allocation will also be randomized, with approximately equal numbers of plots allocated to the intervention and control arms. Within the chosen plots, resident landlord households will receive the intervention and resident landlord households and one randomly selected tenant household will be chosen for data collection for both intervention and control plots.|f|f|f|t
34077259|NCT00407225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077260|NCT06203821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077261|NCT06202144|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767157|NCT04023097|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|Before they start their part in the study, participants won't be aware if they can use the brush or not.|5 participants are suppose to exclude themselves from the use of the device, while the 5 others should claim they can use it.|t|f|f|f
33767158|NCT00542841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767159|NCT06017674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Procedures and evaluations were performed by different practitioners|Single-center, single-blinded, randomized prospective trial|f|f|t|f
33767160|NCT00434928|||DEFINED_POPULATION||PROSPECTIVE|||||||
33767161|NCT00002658|RANDOMIZED|||TREATMENT||||||||
33767162|NCT04696718|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|single blind|Crossover Assignment patient may receive 3 products in 3 interventions sequentially during the protocol|t|f|f|f
33767163|NCT00708721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767164|NCT04341155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33767165|NCT00023140|||||PROSPECTIVE|||||||
33767166|NCT00936481|||CASE_CONTROL||PROSPECTIVE|||||||
33767167|NCT00864526|RANDOMIZED|CROSSOVER||||NONE||||||
33767168|NCT06172491|||COHORT||PROSPECTIVE|||||||
33767169|NCT02047565|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33767170|NCT00260819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33767171|NCT03361696|||COHORT||PROSPECTIVE|||||||
33767172|NCT02163655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767173|NCT01923896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767174|NCT03939247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients receiving the Placebo Tecare will be blinded by using an identical device as in the active group but which cannot provide any current"|Randomized controlled Trial|t|f|f|t
33767175|NCT02576782|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33767176|NCT01468532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767177|NCT01362556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767178|NCT02111837|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33767179|NCT00332332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767180|NCT00251927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767181|NCT02829333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33767182|NCT05666687|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||There will be 5 Cohorts||||
33767183|NCT05919147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33979331|NCT03019965|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33979332|NCT01653665|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33979333|NCT02116803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979334|NCT05141864|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33979335|NCT04137211|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33979336|NCT00003584||||TREATMENT||||||||
33979337|NCT05425667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979338|NCT02199392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979339|NCT05717777|||COHORT||PROSPECTIVE|||||||
33979340|NCT02973893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979341|NCT05685381|||CASE_CONTROL||PROSPECTIVE|||||||
33979342|NCT00098371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979343|NCT03714165|||OTHER||PROSPECTIVE|||||||
33979344|NCT05019066|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33979345|NCT04056143|||COHORT||PROSPECTIVE|||||||
33979346|NCT02126865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077262|NCT03030625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979347|NCT03057899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979348|NCT05628636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33979349|NCT04281706|||COHORT||RETROSPECTIVE|||||||
33979350|NCT06487676|||COHORT||RETROSPECTIVE|||||||
33979351|NCT02636816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33979352|NCT03196947|NA|SINGLE_GROUP||TREATMENT||NONE||Dose Escalation followed by an extension phase using the recommended dosage||||
33979353|NCT06082258|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33979354|NCT05912322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979355|NCT06246032|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33979356|NCT04736992|||COHORT||PROSPECTIVE|||||||
33979357|NCT04870190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979358|NCT02862184|||COHORT||PROSPECTIVE|||||||
33979359|NCT02323490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979360|NCT04346706|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The radiographic measurements were done by a different clinician than the surgeon||f|f|f|t
33979361|NCT01353495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077263|NCT03534947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot study which will evaluate the efficacy and safety of short term neoadjuvant sonidegib followed by surgery or imiquimod in the management of basal cell carcinomas in cosmetically challenging locations, assessed by optical coherence tomography and histopathology. The data from this pilot study may lead to the design of larger scale trials of neoadjuvant targeted therapy with the aim to decrease the morbidity of surgical treatment and increase the probability of a curative resection in larger patient populations.||||
34077264|NCT01575418|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34077265|NCT01121510|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077266|NCT06265090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the participants were selected randomly without their knowledge about in experimental or control group the assessor was for assessment only and the therapist was for treatment only|"This randomized controlled experimental trial was carried out at the outpatient clinic of faculty of physical therapy, Delta University for science and technology from April 2023 to October 2023. The aims of the study and the study protocol were explained for each patient before participation in the study. All patients signed an approved informed consent form for participation in this study. Before starting the treatment program, a complete history and physical examination will be taken for all patients.~Subjects:~Seventy male and female physiotherapy students have chronic non-specific low back pain will be chosen from faculty of physical therapy, delta university for science and technology.~The local ethics committee approved this study (Delta University for science and technology, faculty of Physical Therapy, Ethics committee F.P.T 2307017)."|t|t|t|f
34077267|NCT05083663|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34077268|NCT03639246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077269|NCT04307134|||CASE_ONLY||PROSPECTIVE|||||||
33979362|NCT03189706|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study of HITS in patients with resistant NB.||||
33979363|NCT04558307|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33979364|NCT03572309|||COHORT||PROSPECTIVE|||||||
33979365|NCT01092351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979366|NCT05251103|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33979367|NCT01406678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33979368|NCT06069297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The trial is designed as a randomized, controlled, assessor-blind trial|Enrolled patients will be randomized (ratio 1:1) and allocated either to the intervention group (Multimodal Prehabilitation) or to the usual care group|f|f|f|t
33979369|NCT00818337|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979370|NCT01471366|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33979371|NCT00280371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979372|NCT03109938|||COHORT||PROSPECTIVE|||||||
33979373|NCT02268500|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33979374|NCT01939197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979375|NCT00395226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979376|NCT03110315|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|investigator is blinded to randomization and results until study completion|randomized cross-over trial of suvorexant and placebo for people with multiple sclerosis (MS), insomnia and fatigue|t|f|t|f
33979377|NCT00186108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979378|NCT00413556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979379|NCT03207581|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33979380|NCT00928954|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33979381|NCT01303978|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979382|NCT02403700|||COHORT||PROSPECTIVE|||||||
33979383|NCT01625637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33979384|NCT02969499|||CASE_ONLY||PROSPECTIVE|||||||
33979385|NCT04784000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979386|NCT02456948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979387|NCT03039309|||COHORT||PROSPECTIVE|||||||
34077270|NCT05544591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077271|NCT03819413|||CASE_ONLY||PROSPECTIVE|||||||
34077272|NCT02656238|||COHORT||PROSPECTIVE|||||||
34077273|NCT03445000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077274|NCT05429541|||CASE_ONLY||PROSPECTIVE|||||||
34077275|NCT05306717|||CASE_ONLY||RETROSPECTIVE|||||||
34077276|NCT04633746|||CASE_CONTROL||PROSPECTIVE|||||||
34077277|NCT05701982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and study staff who conduct follow-up visits for outcome assessments will be blinded to each participant's randomization group.|The intervention is ESC-TC which is delivered remotely. It a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The investigators will randomize participants 1:1 to ESC-TC or usual care for 6 months.|f|f|t|t
34077278|NCT05649670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessment of 3-month mRS (via telephone interview)|Randomized controlled trial, PROBE design|f|f|f|t
34077279|NCT04086888|||CASE_ONLY||PROSPECTIVE|||||||
33767184|NCT00332683|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767185|NCT02442635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767186|NCT02176681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767187|NCT01806740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767188|NCT05241561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767189|NCT06624046|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, pretest, post-test design using a sleep stability intervention||||
33767190|NCT01679236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767191|NCT02826980|||COHORT||PROSPECTIVE|||||||
33767192|NCT02841293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979388|NCT04896164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The test drug and the placebo are available in USP grade plastic bottles. The bottles are identical in all respect. Each bottle have a unique identifier number provided by the manufacturer. The transplant physician, patients and the blinded statistician will remain blinded to the treatment.|Patients receiving high dose chemotherapy with any of the conditioning regimens specified in the inclusion criteria will be randomized in two arms. Central telephonic randomization will be carried out with the help of a computer generated random sequence using permuted blocks.|t|t|t|t
33979389|NCT00269048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33979390|NCT02373332|||CASE_CONTROL||PROSPECTIVE|||||||
33979391|NCT05080751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will not know whether they will be in the control or intervention group.|two groups: intervention and control|t|f|f|f
33979392|NCT00192608|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979393|NCT03044548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979394|NCT01505530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077280|NCT01906242|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34077281|NCT00994110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077282|NCT03112694|||COHORT||RETROSPECTIVE|||||||
34077283|NCT02130947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34077284|NCT06116578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077285|NCT03225170|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34077286|NCT00362947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077287|NCT01076543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077288|NCT06175286|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34077289|NCT02616783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767193|NCT04904068|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767194|NCT04022837|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33767195|NCT03363659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767196|NCT01758874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767197|NCT05204641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33767198|NCT00612157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33767199|NCT03655990|||OTHER||PROSPECTIVE|||||||
33767200|NCT04446715|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33767201|NCT03924713|||CASE_CONTROL||PROSPECTIVE|||||||
33767202|NCT01770522|||COHORT||OTHER|||||||
33767203|NCT02751463|NA|SINGLE_GROUP||OTHER||NONE||||||
34077290|NCT06390657|||OTHER||OTHER|||||||
34077291|NCT01562977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077292|NCT01635829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077293|NCT05739487|||CASE_ONLY||RETROSPECTIVE|||||||
34077294|NCT00970905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077295|NCT00055341|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077296|NCT06063928|||COHORT||PROSPECTIVE|||||||
34077297|NCT06139250|||COHORT||PROSPECTIVE|||||||
34077298|NCT05863650|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Stepped wedge design|f|f|f|t
33721155|NCT06530342|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721156|NCT00090311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33767204|NCT00819403|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33767205|NCT00009581||||TREATMENT||||||||
33767206|NCT00154310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767207|NCT02835846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767208|NCT04082091|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33767209|NCT00234156|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767210|NCT00877903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979395|NCT04332978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In the present double-blind study, the original bottles of the two drugs under study (Plurair® and Flixonase®) had their labels sealed and were packed in identical secondary packaging (with specific label for clinical research), associated with a unique identification code.~Page 75 of 207 Clinical Report LB1108 Version 1.0 of February 8, 2018 CONFIDENTIAL Libbs Farmacêutica Ltda. Each cartridge of the study drug had a unique identification code related to one of the treatment arms through an electronically generated list, stratified by center. Participants were allocated to one of two treatment groups at a 1: 1 ratio. This list was not accessible to the study doctor, study participant and team, in order to guarantee the study blinding"|"Phase III, prospective, comparative, double-blind, parallel, multicenter, randomized, non-inferiority clinical study between two brands of nasal topical fluticasone propionate:~* Plurair® - Experimental medicine.~* Flixonase® - Comparator. Study treatment was allocated by centralized randomization, and each participant remained on the same treatment (dose, dosing regimen and brand) allocated throughout the study period."|t|f|t|f
33979396|NCT00002005||||TREATMENT||||||||
33979397|NCT06257290|||COHORT||PROSPECTIVE|||||||
33979398|NCT03548168|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33979399|NCT04005664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre prospective alternating intervention study||||
33979400|NCT05068622|||CASE_ONLY||RETROSPECTIVE|||||||
33979401|NCT03022071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be provided by raters blinded to the randomization|In this study we want to examine moderators and mediators in two equally effective, well known psychotherapeutic treatments (Psychodynamic and cognitive behavior therapy)|f|f|f|t
33979402|NCT00626548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077299|NCT02067520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
34077300|NCT03489343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077301|NCT02874313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077302|NCT02810418|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34077303|NCT05874362|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Subjects will be separated into two groups at the end of the study to conduct analyses, depending on the development of a psychiatric complication or not.||||
34077304|NCT00001322|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
34077305|NCT04478565|||OTHER||CROSS_SECTIONAL|||||||
34077306|NCT03435588|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||"Procedures are performed with a linear echoendoscope under conscious sedation. EUS-FNB is performed with a 22G or 25G needles Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist. EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle.~This is a multi-center, randomized, single blinded, non-inferiority, trial comparing EUS-FNB alone to EUS-FNA with ROSE in the diagnosis of solid pancreatic masses. Following consent, patients are randomized, at the time of the procedure, to undergo either EUS-FNB alone or EUS-FNA with ROSE. The randomization sequence will be generated by a computerized randomization scheme using a block size of 10 stratified according to the endoscopist."|t|f|f|f
34077307|NCT01546051|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34077308|NCT00844090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077309|NCT00533819|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077310|NCT00990002|||COHORT||PROSPECTIVE|||||||
34077311|NCT03204617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double Blind: two or more parties are unaware of the intervention assignment||t|t|t|t
33767211|NCT02302066|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767212|NCT03562455|RANDOMIZED|PARALLEL||OTHER||SINGLE|The individual assessing performance outcomes will not be aware of which intervention the participants received.|The study will contain two arms. One group will receive virtual reality power wheelchair training, and the other will receive in-person wheelchair training by a therapist.|f|f|f|t
33767213|NCT04031430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767214|NCT00684762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33767215|NCT00781066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979403|NCT04799600|||COHORT||CROSS_SECTIONAL|||||||
34077312|NCT00120237|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34077313|NCT01316575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767216|NCT04235101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895731|NCT06214728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects having more than one intrabony defect that meets the inclusion criteria, only one intraosseous defect per patient was included based on a preliminary randomisation by a coin toss (UGE). Patients were then block randomised and the allocation sequence was computer-generated using www.randomizer.org. The patient groups were recorded by another investigator who did not perform the treatment application and clinical measurements (SG).|t|f|f|t
33767217|NCT03734991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, placebo-controlled, double-blind study|t|t|t|f
33767218|NCT05282498|||COHORT||RETROSPECTIVE|||||||
33895732|NCT02302911|||OTHER||PROSPECTIVE|||||||
33895733|NCT03397186|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895734|NCT00430534|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33895735|NCT04752787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Since the education about twin babies breastfeeding will be given by the researchers, single-blind randomization will be provided.~The statistician will also be made blind for the data analysis purpose"|Randomized Controlled Trial|f|f|f|t
33767219|NCT06381011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluator and the researcher administering the local vibration application will be different. Patients will be blinded to their group assignment.||t|f|t|f
33767220|NCT05558553|||OTHER||RETROSPECTIVE|||||||
33767221|NCT03572855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767222|NCT02254421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767223|NCT04997044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33767224|NCT01918319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33767225|NCT06446219|||COHORT||RETROSPECTIVE|||||||
33767226|NCT00526383|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767227|NCT04515667|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33767228|NCT01740102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767229|NCT01976364|NA|SINGLE_GROUP||TREATMENT||NONE|The sub-study will be participant, care provider, investigator and outcomes assessor masked.|||||
33767230|NCT01904214|NA|PARALLEL||OTHER||NONE||||||
33767231|NCT01852656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767232|NCT01610232|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33767233|NCT02777996|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33895736|NCT02734563|||CASE_CONTROL||PROSPECTIVE|||||||
33895737|NCT04676243|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, randomized phase in patients with FLT3-ITD positive AML comparing quizartinib in combination with SOC chemotherapy versus treatment according to physician's choice (PhC).||||
33979404|NCT02161913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767234|NCT04000932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will not be informed about which group will be taken. Randomization will be performed by a simple randomization method by a researcher who is blind to the clinical and electrophysiological findings. The injection will be performed by a second researcher who is blind to the contents of the injection. The evaluations of the patients will be performed by a researcher who is blinded to the treatment applied and the initial assessment.|prospective, randomized, controlled, double blind.|t|f|t|t
33767235|NCT00877578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767236|NCT02762734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33767237|NCT00545363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767238|NCT05568641|||OTHER||RETROSPECTIVE|||||||
33767239|NCT00847821|||COHORT||RETROSPECTIVE|||||||
33767240|NCT04607824|||CASE_CONTROL||PROSPECTIVE|||||||
33979405|NCT04903262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767241|NCT00278590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767242|NCT02568332|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33767243|NCT01084967|||COHORT||CROSS_SECTIONAL|||||||
33767244|NCT03354130|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Data analyst will know the foods consumed before samples were taken|Volunteers consume five different diets in a randomized cross-over dietary intervention.||||
33767245|NCT00001266||||TREATMENT||||||||
33767246|NCT04178538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767247|NCT00103337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767248|NCT01332396|||OTHER||OTHER|||||||
33767249|NCT00469469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767250|NCT05417984|||COHORT||PROSPECTIVE|||||||
33767251|NCT00001010||||TREATMENT||NONE||||||
33767252|NCT04559282|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33767253|NCT05067946|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33767254|NCT03784235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767255|NCT01433393||PARALLEL||||||||||
33767256|NCT04015700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767257|NCT04707339|||COHORT||RETROSPECTIVE|||||||
33895738|NCT03364998|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each subject will receive the two treatments. Pharmacokinetic samples will be collected from pre-dose until 120 hours after the end of the injection of the single dose in each treatment arm.||||
33895739|NCT04741464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895740|NCT01733355|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33895741|NCT02610283|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077314|NCT01235065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077315|NCT02200679|||OTHER||CROSS_SECTIONAL|||||||
34077316|NCT05662748|||CASE_ONLY||PROSPECTIVE|||||||
34077317|NCT02922153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767258|NCT01364974|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33767259|NCT03614338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767260|NCT01651273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767261|NCT01946581|||||RETROSPECTIVE|||||||
33767262|NCT05425849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33767263|NCT00764374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767264|NCT04581473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767265|NCT04745494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double-blind, placebo-controlled, case-controlled, randomised controlled-trial, within-subjects, cross-over design.|t|f|t|f
33767266|NCT05231265|||CASE_ONLY||PROSPECTIVE|||||||
33767267|NCT06273982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767268|NCT01269008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767269|NCT00905502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33767270|NCT01583023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767271|NCT01346618|||OTHER||CROSS_SECTIONAL|||||||
33767272|NCT03184090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767273|NCT03184922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. The patients will be informed they will not be told which arm of the study they are allocated to.~2. The outcomes assessor for the KT1000 will be a physiotherapist not a surgeon and will not be told which type of surgery the patient has undergone"|This is a blinded randomised controlled trial with 1 arm of the study having femoral side cortical fixation using a fixed length suspensory loop and the other an adjustable loop|t|f|f|t
34077318|NCT00092924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767274|NCT02354924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33767275|NCT02042638|||CASE_ONLY||PROSPECTIVE|||||||
33895742|NCT01612910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767276|NCT03679767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767277|NCT01625923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767278|NCT04683809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33767279|NCT01240954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767280|NCT05790213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767281|NCT02918734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767282|NCT01893827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767283|NCT05023967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767284|NCT06463223|||OTHER||PROSPECTIVE|||||||
33767285|NCT02527837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33767286|NCT01299064|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33767287|NCT03705455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767288|NCT02556437|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33767289|NCT04684082|||OTHER||PROSPECTIVE|||||||
33895743|NCT00827489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895744|NCT06006078|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group of patients will be randomly assigned to receive an endoscopic facemask and one group of patients will undergo endoscopy without a facemask.||||
33895745|NCT04439578|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895746|NCT02635230|||COHORT||PROSPECTIVE|||||||
33767290|NCT06291662|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Oncologic patients||||
33767291|NCT01784432|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33767292|NCT02409550|||CASE_ONLY||PROSPECTIVE|||||||
33767293|NCT02790723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767294|NCT05281432|||OTHER||PROSPECTIVE|||||||
33767295|NCT01280734|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33767296|NCT00460044|||DEFINED_POPULATION||OTHER|||||||
33767297|NCT04500860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767298|NCT04169711|NA|SEQUENTIAL||TREATMENT||NONE||||||
33767299|NCT02050737|||COHORT||PROSPECTIVE|||||||
33767300|NCT00749216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767301|NCT01208155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33767302|NCT01222468|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33767303|NCT05883761|||OTHER||CROSS_SECTIONAL|||||||
33767304|NCT00003759|RANDOMIZED|||TREATMENT||NONE||||||
33767305|NCT01900574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767306|NCT02294474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767307|NCT05905419|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33767308|NCT00204126|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33767309|NCT00747123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767310|NCT06625996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767311|NCT01083147|||COHORT||PROSPECTIVE|||||||
33895747|NCT04556864|||COHORT||PROSPECTIVE|||||||
33895748|NCT03905772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895749|NCT02203682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077319|NCT03186144||||DIAGNOSTIC||NONE||||||
34077320|NCT06342713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The cohorts in Part A, B, and C will be double-blinded, while the food effect study in Part D will be open-label||t|t|f|f
34077321|NCT01893112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34077322|NCT00268983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077323|NCT03588858|||CASE_ONLY||OTHER|||||||
34077324|NCT03166787|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077325|NCT03328247|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34077326|NCT01018758|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34077327|NCT02288104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077328|NCT04198831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077329|NCT03065686|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34077330|NCT06323785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767312|NCT01596218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767313|NCT00335686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767314|NCT03430063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979406|NCT01874158|||COHORT||PROSPECTIVE|||||||
33979407|NCT06116409|||CASE_CONTROL||PROSPECTIVE|||||||
33979408|NCT00000132|RANDOMIZED|||TREATMENT||||||||
33979409|NCT00582088|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979410|NCT05417425|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm to evaluate efficacy of 11 weekly treatments with OCM® in patients with chronic, non-healing Diabetic Foot Ulcers. Percent area reduction (PAR) measurements to be taken at week 5 treatment visit and at week 12 end of study (EOS) visit.||||
33979411|NCT01075581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979412|NCT00003064||||TREATMENT||||||||
33979413|NCT00150007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979414|NCT05423808|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||stepped wedge randomized controlled trial (cross-over type)||||
33979415|NCT00637299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979416|NCT05706077|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Participants will be randomized into four intervention groups: transcranial Direct Current Stimulation + Physical Therapy Group (tDCS active + PT active), tDCS group (tDCS active + PT placebo), PT group (tDCS sham + PT active), control group (tDCS sham + PT placebo ).|t|f|f|t
33979417|NCT02330068|||CASE_CONTROL||PROSPECTIVE|||||||
33979418|NCT01048437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979419|NCT02753842|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|In this closed label trial, study condoms were manufactured in plain foil packaging with identifying 2-digit random codes printed on each foil. Blinding of study staff was role-based; the study statistician and the principal investigator were blinded. To allow for blinded participants to identify preferred condoms, we provided condom sets in color-coded bags. We selected colors that could accommodate common forms of color vision deficiency.|We recruited 504 participants into the crossover trial. Participants were randomized into one of six sequences, each representing the order in which a participant would receive batches of five study condoms of a particular type.|t|f|t|t
33979420|NCT00307190|||CASE_CONTROL||PROSPECTIVE|||||||
33979421|NCT01802697|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33979422|NCT02227251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077331|NCT00823264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077332|NCT05391100|||OTHER||PROSPECTIVE|||||||
33721157|NCT03863223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979423|NCT04480788|NA|SINGLE_GROUP||TREATMENT||NONE||CD7-CART||||
33979424|NCT00208286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979425|NCT04098536|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double blind|Cross over double blind|t|f|t|f
34077333|NCT01222208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34077334|NCT00179595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
34077335|NCT03983200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077336|NCT03052881|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34077337|NCT00000237||||TREATMENT||||||||
34077338|NCT05686655|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34077339|NCT05619471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077340|NCT03426410|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34077341|NCT04904627|||COHORT||RETROSPECTIVE|||||||
34102966|NCT05835973|NA|SINGLE_GROUP||OTHER||NONE||||||
34102967|NCT03813290|NA|SINGLE_GROUP||OTHER||NONE||||||
34102968|NCT06288659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895750|NCT04987593|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895751|NCT06301854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895752|NCT04698187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895753|NCT04884243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895754|NCT06468579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895755|NCT01810887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895756|NCT02626338|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895757|NCT03319628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, dose escalation to reach MTD. The MTD will be confirmed in parallel cohorts: patients with platinum-resistant ovarian cancer; patients with non-squamous NSCLC, adenocarcinoma subtype||||
33895758|NCT02659189|||COHORT||PROSPECTIVE|||||||
33895759|NCT01759303|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33895760|NCT06631287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Investigators will use adequate allocation concealment using a computer-generated, permuted-block randomization with varying block size. Randomization (1:1) will be stratified by site, SARS CoV-2 confirmatory test (cohort 1), and opting into the LP sub-study. The block size and treatment allocation will only be known to a biostatistician creating the randomization list and the study pharmacist and will not be shared with trial investigators or any other study personnel.|t|t|t|t
33895761|NCT01310738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895762|NCT03206658|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33895763|NCT01617486|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895764|NCT02234037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895765|NCT02051101|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895766|NCT00264277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895767|NCT02014948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895768|NCT03386240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A confidential computer-generated simple randomization scheme will be prepared and provided on an ongoing basis. A randomization log will be used to track the randomization process. Patients will be masked to the suture material. Both suture types look similar. Patient, surgeons, and staff ascertaining the outcomes will be masked for the suture type.|Double-blinded controlled clinical trial|t|t|t|f
33895769|NCT04046302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895770|NCT06657742|||COHORT||CROSS_SECTIONAL|||||||
33895771|NCT03968146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33895772|NCT00159484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895773|NCT06454968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895774|NCT04348903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33895775|NCT04720144|||CASE_CONTROL||PROSPECTIVE|||||||
33895776|NCT05417321|NA|SEQUENTIAL||TREATMENT||NONE||A single-subject cohort will be enrolled at the protocol starting dose of HB0036 every 3 weeks (Q3W). Dose escalation will proceed to the next main dose level according to the 3+3 dose-escalation procedure until the MTD/OBD is reached. Phase II of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose-escalation phase.||||
33895777|NCT01712360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895778|NCT02450357|||COHORT||PROSPECTIVE|||||||
33895779|NCT03707717|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895780|NCT06365359|||COHORT||PROSPECTIVE|||||||
33895781|NCT01282931|||COHORT||CROSS_SECTIONAL|||||||
33895782|NCT06210126|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33979426|NCT06139003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33979427|NCT00948519|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895783|NCT06411444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895784|NCT04497467|||COHORT||RETROSPECTIVE|||||||
33895785|NCT02589431|||CASE_CONTROL||PROSPECTIVE|||||||
33895786|NCT03846947|NA|SINGLE_GROUP||OTHER||NONE||||||
33895787|NCT00736229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895788|NCT04756297|||COHORT||PROSPECTIVE|||||||
33895789|NCT02258412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33895790|NCT03445676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895791|NCT02049567|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33895792|NCT02354001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895793|NCT05453799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895794|NCT05428371|||CASE_CONTROL||PROSPECTIVE|||||||
33979428|NCT05829148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979429|NCT01799681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33979430|NCT05751382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The aesthetic integration of the restoration will be evaluated by two experienced and blinded operators following the aesthetic criteria of the FDI.|Split-mouth design, i.e. each subject have both treatment arms.|f|f|f|t
33979431|NCT00186290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979432|NCT01453075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979433|NCT05055349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34102969|NCT06268678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomised cross-over design.||||
33895795|NCT04837612|||COHORT||PROSPECTIVE|||||||
33895796|NCT01661647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895797|NCT00319163|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33895798|NCT02940964|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33979434|NCT06300957|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In Phase one investigators will recruit 10 participants to test out the study protocols. All 10 participants will go through the same study procedures.~In Phase two, investigators will recruit 300 participants to take part in the RCT, 200 in the HW group and 100 in the WL group. After consenting to participate and completing the first online survey, participants will be randomized to either an intervention condition (N =200) or wait-list control condition (N =100) using a 2:1 allocation. The intervention group will gain access to Help Wanted for 1 month after which the participants will complete a post-intervention survey and then a three-month follow up survey. Participants in the control group will receive alternative resources for one month, then complete a one-month post-waitlist survey before being granted access to Help Wanted for a one-month period. The control group participants will then complete a one-month post-intervention survey and three-month follow-up survey."||||
33979435|NCT02242201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979436|NCT00494169|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33979437|NCT04813809|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979438|NCT03920007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979439|NCT04996238|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979440|NCT03319056|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33979441|NCT03532321|||COHORT||PROSPECTIVE|||||||
33979442|NCT04791553|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33979443|NCT02067364|NA|SINGLE_GROUP||||NONE||||||
33979444|NCT00919464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979445|NCT00210548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979446|NCT01879280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979447|NCT01520857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979448|NCT00556049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979449|NCT00650000|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33979450|NCT00728026|||CASE_ONLY||RETROSPECTIVE|||||||
33979451|NCT00559481|RANDOMIZED|||TREATMENT||NONE||||||
33979452|NCT05286411|||COHORT||RETROSPECTIVE|||||||
33979453|NCT03238677|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Individuals who conduct the phonetic transcriptions that will be used for the primary outcome data will be blinded as to whether the recordings were collected before or after treatment, and also blinded as to the group assignment of the participant.|2 x 2 design Scheduling: Mass--\>Distributed vs. Distributed only Visual feedback: Sequenced Ultrasound Biofeedback vs. No biofeedback|f|f|f|t
33979454|NCT06096103|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator) The study is double blind wherein neither the subjects nor the Investigator shall be aware of the test treatment allocation|Randomized, Double-Blind, Parallel, Three-Arms, Placebo-Controlled|t|f|t|f
33979455|NCT06196060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979456|NCT00861809|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33979457|NCT00925769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979458|NCT03858712|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Hybrid type 3 implementation study||||
33979459|NCT00649870|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33979460|NCT06371248|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979461|NCT03089112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979462|NCT00000866||||PREVENTION||DOUBLE||||||
33979463|NCT04060368|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: Endoscopic Sleeve Gastroplasty with OverStitch® system + Lifestyle modifications Comparator: Laparoscopic Sleeve Gastrectomy + Lifestyle modifications||||
33979464|NCT01264224|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33979465|NCT03972852|||CASE_ONLY||PROSPECTIVE|||||||
33979466|NCT01521195|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979467|NCT03621748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979468|NCT04090892|||COHORT||PROSPECTIVE|||||||
33979469|NCT00957047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979470|NCT06291948|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Study subjects, investigators, Sponsor, monitor, analytical center, and data analyst will be unaware of assigned treatments.~Each product in its original primary packaging will be blinded and labeled with a fantasy name Product A or Product B.~The link between Product A or B with the Test Product or Reference Product will be kept in two separate copies in a sealed envelope. One copy will remain with the Sponsor and the other will be provided to the Principal Investigator. The envelope may only be opened in the event of a medical emergency. The investigator must follow the trial's randomization procedures, and must ensure that the code is broken only in accordance with the protocol. The investigator must promptly document and explain to the Sponsor should the identity of the investigational product be revealed (whether accidentally or due to a serious adverse event)."|A Randomized, Double Blind, Parallel groups, Phase 1 Clinical Study comparing the Pharmacokinetic, Safety and Immunogenicity of Adalimumab in Healthy Subjects.|t|t|t|t
33979471|NCT05944354|||CASE_CONTROL||PROSPECTIVE|||||||
34077342|NCT03310216|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Patients are assigned to two groups: participants in group I are provided AI visual inspection system first and EDTRS later, while in Group II, the participants are provided EDTRS first and AI visual inspection system later.|f|f|f|t
34077343|NCT01571960|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34077344|NCT01552226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767315|NCT01338558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767316|NCT04717973|||OTHER||PROSPECTIVE|||||||
34077345|NCT06166017|||COHORT||CROSS_SECTIONAL|||||||
33721158|NCT04097704|||CASE_ONLY||PROSPECTIVE|||||||
33840449|NCT00529880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721159|NCT03984604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767317|NCT04824248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial, including two comparative, balanced online treatment arms.|t|f|t|t
33767318|NCT02732613|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33767319|NCT03997058|RANDOMIZED|PARALLEL||TREATMENT||NONE||Negative control group, auricular acupoint pressing group, estazolam group， combined treatment group||||
33767320|NCT06399367|||CASE_CONTROL||PROSPECTIVE|||||||
33767321|NCT01720823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767322|NCT00747526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077346|NCT04527029|||COHORT||PROSPECTIVE|||||||
33767323|NCT00282997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767324|NCT00497965|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33895799|NCT04543448|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants are grouped randomly. First group and second group are applied different rehabilitation programs. Both of group is rest four weeks. Than second group is applied first group's rehabilitation program and first group is applied second group's rehabilitation program.|f|f|f|t
33895800|NCT03578705|||CASE_ONLY||PROSPECTIVE|||||||
33895801|NCT04438421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The products will be packaged in such a way that they are not recognizable neither by the operator, nor by the patient. Each package will be assigned a number that in turn will refer to the type of the product. The association between the number and type of the product will be collected by another operator according to the association carried out by a dedicated software. The operator who will deliver the product will be informed about the type only at the end of the treatment.|50 subjects affected with gingivitis, caused by accumulation of plaque and/or tartar, will be selected and enrolled in this study. Subsequently, subjects will be equally divided and randomly allocated to either the test group or the control group.|t|f|t|f
33895802|NCT00815789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33895803|NCT01927458|NA|SINGLE_GROUP||OTHER||NONE||||||
33895804|NCT00138840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33895805|NCT04935736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participant will be blind from the treatment|Study subject (tooth) will be randomized in a 1:1 allocation ratio between the 2 treatment groups.|t|f|f|f
33895806|NCT04248010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Active vs. sham will be masked; type of tDCS (standard or HD) will not be.|Participants will receive one of the following: standard tDCS, HD-tDCS - anterior target, HD-tDCS - posterior target, or sham.|t|f|t|t
33895807|NCT04632849|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the GEM intervention.||||
33895808|NCT06109909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham treatment, single-blind design. During the sham treatment, we will prep and place electrodes in the same manner as participants receiving the LIP-tES treatment. However, no LIP-tES pulses will be sent from the system during the sham treatment. The operator will know which group the participant is assigned to but all aspects of study design and data collection will be the same from the perspective of the participant.|After consent, participants will be randomly assigned to either the LIP-tES intervention or sham control group. Participants will complete 12 sessions over 6 weeks during which photosensitivity symptoms will be tracked using the Utah Photophobia Symptom Impact Scale (UPSIS). A subset of participants will also complete a resting-state MRI scan session during the initial visit and again during the 12th visit. A follow-up phone call will be placed after a 6 week wash-out period. Group assignment will be disclosed at this time and participants in the sham condition who would like to receive the LIP-tES intervention will be able to return for an additional 12 sessions over 6 weeks during which they will receive LIP-tES and photosensitivity symptoms will be tracked using the UPSIS questionnaire.|t|f|f|f
33895809|NCT01773473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895810|NCT02638246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895811|NCT00775567|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33895812|NCT02183389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895813|NCT00104104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979472|NCT02827409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979473|NCT05396430|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not applicable, duration of urinary catheter treatment is decided at the time of surgery.|The parturients are randomized into 3 different treatment arms with different duration of planned urinary catheter treatment||||
33979474|NCT02003183|||COHORT||CROSS_SECTIONAL|||||||
33979475|NCT06278142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33979476|NCT03955770|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34077347|NCT02993861|||COHORT||PROSPECTIVE|||||||
34077348|NCT02485327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077349|NCT03714464|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Principal investigators and co-investigators were blinded when measuring gastric volumes, small bowel water content and colonic volumes.|"The intervention to be tested in this study is dietary intake of apples which are naturally high in fermentable carbohydrate. The investigators purchased the apples from a mainstream high street supermarket.~The test meals consisted of whole apples (Meal A), apple puree (Meal B) and apple juice (Meal C)"||||
34077350|NCT01309412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895814|NCT03142607|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Subjects will be assigned to one of the three study groups using a computer generated randomization list. The recruitment of the patients will be performed by one investigator. All the measurements at the baseline and follow ups will be performed by the second investigator. Patient, the care provider, the investigator who is taking the measurement and the statistician will be blinded about the intervention groups. This will be ensured by giving codes to the intervention groups only known to the principal investigator who is not involved in the measurement and interaction with the patient.|Group A has Metronidazole gel Group B has Chlorhexidene gel Group C has combination of metronidazole and chlorhexidene gel|t|t|t|t
33895815|NCT03747952|||COHORT||PROSPECTIVE|||||||
34077351|NCT04166604|NA|SINGLE_GROUP||TREATMENT||NONE||It was planned to include 250 patients in a prospective cohort, to obtained 89 patients in the phase II (experience a grade 3-4 neutropenia)||||
34077352|NCT05761353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077353|NCT02298972|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33721160|NCT05602987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33721161|NCT03895996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721162|NCT00048607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895816|NCT06453694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895817|NCT06273904|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895818|NCT02975323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895819|NCT00002103||||TREATMENT||NONE||||||
33895820|NCT01301326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895821|NCT02860793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33895822|NCT06319911|||COHORT||PROSPECTIVE|||||||
33895823|NCT05085002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895824|NCT00608140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895825|NCT02677584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33895826|NCT04427085|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33895827|NCT01773824|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33895828|NCT04878783|||CASE_ONLY||RETROSPECTIVE|||||||
33895829|NCT00938548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895830|NCT02748369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33895831|NCT03405103|RANDOMIZED|PARALLEL||PREVENTION||NONE||Repeated measures randomized clinical trial||||
33895832|NCT02053974|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33895833|NCT02421874|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33895834|NCT03157544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895835|NCT04979637|||COHORT||PROSPECTIVE|||||||
33895836|NCT05008887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895837|NCT05466435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895838|NCT05835401|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33895839|NCT03037216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single Group Assignment||||
33895840|NCT06513702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a single center,prospective, a randomized controlled trial (RCT) study in cardiac surgery patient.|t|f|f|t
33895841|NCT01498991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895842|NCT02075164|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33895843|NCT02452359|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study where all subjects assigned to receive 5 treatments every 2 weeks. Subjects acted as their own control.||||
33895844|NCT02904226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895845|NCT05981950|||COHORT||PROSPECTIVE|||||||
33895846|NCT03222271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"All patients will be subjected to history and clinical examination,severity assessment(mMRC dyspnea scale,APACHE II Score and CAT score).~A) Extubation to NIV: SBT will be attempted once the patients achieve stability regarding clinical, neurological and biochemical parameters.Failure of SBT is considered if:pH \< 7.35,PaCO2 \> 15-20% increase above baseline,PaO2 \< 50 mmHg.Heart rate \> 100 bpm or respiratory rate \> 35 cycle/min.~* RSBI and P 0.1. will be recorded while on SBT~B) The patients will be randomized to receive NIV using either ST or iVAPS mode.~C) The patients will be categorized in analysis into 3 groups,Group I: Simple weaning ,Group II: Difficult weaning and Group III: Prolonged weaning.~-The following parameters will be recorded for the patients at the beginning of the study and at 1, 2, 12, 24 and 48 hours after initiation of NIV therapy:GCS,Vital signs (HR, SBP\& DBP,RR), ABG analysis and Patient's comfort."|t|f|f|f
33895847|NCT05422300|RANDOMIZED|CROSSOVER||OTHER||NONE||This study uses a 2-way counterbalanced crossover design. A total 10 young women (Ages: 18-35 years old) will be recruited and randomized into either the mid- follicular (7-10 days after the onset of menses) or mid-luteal phase (5-7 days after ovulation) (n=5, respectively). Participants will take part in two metabolic trials: Fed trial at rest (FED) and fed trial with resistance exercise (EX-FED). Following a minimum 3-day washout period, participants will complete the other trial, where both trials will be completed within the same phase of the menstrual cycle, depending on which group they were randomized into. Participants will be asked to self-report their menstrual cycle status, albeit ovulation test kits will be used to verify the cycle phase prior to each metabolic trial.||||
33895848|NCT01866631|||COHORT||RETROSPECTIVE|||||||
33895849|NCT06282380|NA|SINGLE_GROUP||OTHER||NONE||||||
33895850|NCT04554368|||CASE_ONLY||PROSPECTIVE|||||||
33895851|NCT05969210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895852|NCT05861583|||OTHER||PROSPECTIVE|||||||
33895853|NCT00004046||||TREATMENT||||||||
33895854|NCT04538404|||CASE_ONLY||RETROSPECTIVE|||||||
33895855|NCT03816605|||CASE_CONTROL||RETROSPECTIVE|||||||
33895856|NCT05060042|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34077354|NCT02939209|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767325|NCT05943275|NA|SINGLE_GROUP||OTHER||NONE||comparison between two measurement methods, one of which serves as a reference in a single group of patients patients, without randomization, prospective and monocentric. This is a proof-of-concept pilot study. concept.||||
33767326|NCT04748419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767327|NCT01416701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979477|NCT01825993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767328|NCT03100994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3 group: Group A: without intervention; Group B: Ultrasound-guided transmuscular quadratus lumborum block; Group C: Ultrasound-guided quadratus lumborum type II block||||
33767329|NCT02478125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979478|NCT04303988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979479|NCT02974075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979480|NCT02325271|||CASE_CONTROL||PROSPECTIVE|||||||
33979481|NCT04457843|||COHORT||PROSPECTIVE|||||||
33979482|NCT01432795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979483|NCT00584311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979484|NCT00881621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979485|NCT02063295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979486|NCT00596388|||COHORT||PROSPECTIVE|||||||
33979487|NCT05062850|||CASE_ONLY||CROSS_SECTIONAL|||||||
33979488|NCT03111043|||CASE_ONLY||PROSPECTIVE|||||||
33979489|NCT03878095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979490|NCT00357448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979491|NCT05090657|NA|SINGLE_GROUP||PREVENTION||NONE|As an infection prevention study the intervention of nasal photodisinfection will be applied to all willing participants within the time frame. Pre and post intervention nasal cultures will be performed. Clinicians will not be aware of these results during the patients hospital course.|The sample size will be one month of all surgical cases and is estimated at 500-600 cases. Both genders and a wide range of ages and medical conditions will be represented from all ethnic/demographic groups and of varying health status.||||
33979492|NCT04891081|||COHORT||PROSPECTIVE|||||||
33979493|NCT04366232|RANDOMIZED|PARALLEL||TREATMENT||NONE||Assignment to one of two or more groups in parallel during the study No crossover||||
33979494|NCT03536338|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Purposefully sampled trial||||
33979495|NCT02735746|||COHORT||PROSPECTIVE|||||||
33979496|NCT00302952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33979497|NCT00820625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979498|NCT01936948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979499|NCT03735602|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979500|NCT04298164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will generate a Unique Identifier Code which will be used to identify their data across each time point, but will mask their allocation until all of the data is entered and analysed.||f|f|f|t
33979501|NCT05941221|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979502|NCT03432013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979503|NCT04844840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. All subjects, investigator, and site staff (except unblinded pharmacist or designated site staff) in the study will be blinded to the treatment assignment.|"10 subjects each will be randomly allocated to either the assigned STP705 treatment group, placebo or SOC alone in a 1:1:1:1:1:1 ratio.~An individual, independent of the clinical trial team, will develop the randomization schedules. The actual randomization assignment will be prepared through a web-based system. STP705 or placebo will be injected intradermally at the keloid excision site."|t|f|t|f
33979504|NCT05425147|||COHORT||PROSPECTIVE|||||||
33979505|NCT02968485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979506|NCT00270959|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33979507|NCT01900509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979508|NCT01184209|||COHORT||PROSPECTIVE|||||||
33979509|NCT04090086|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33979510|NCT01954680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither participant nor independent evaluator knows group assignment in R33 phase randomized controlled trial.|"R21 phase was an open phase 1a trial for feasibility and acceptability with enrollment goal including intervention development of 20.~R33 phase enrollment goal of 40 including double-blind placebo-controlled randomized trial of 2 versions of video game potential intervention."|t|t|f|t
33979511|NCT03561142|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients will undergo different treatments based on response achieved after radiochemotherapy.~1. Clinical Complete Response: Omission of surgery and follow-up~2. Near clinical complete response: Reevaluation in three months~3. Poor / no response: Surgery"||||
33979512|NCT02041871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979513|NCT01164813|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077355|NCT03040401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767330|NCT02140710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077356|NCT06613204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Care Partners will be randomized to either the test or control group using an electronic randomization process and will be blinded to their group designation. Interventionists will not be blinded, but will only teach their designated group (test or control).|STELLA-FTD is a 36-week randomized controlled, repeated measures study.|t|f|f|f
34077357|NCT04235400|||CASE_CONTROL||PROSPECTIVE|||||||
34077358|NCT03107910|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants and investigator are masked to study intervention assignment. Participants are informed that they are randomly assigned to conditions.|This project is 2 x 2 factorial approach designed to test an intervention that is aimed at increasing HIV/STI testing uptake among BMSM; this approach includes testing HIV/STI stigma focused counseling, and online HIV/STI test counseling with at-home, self-administered HIV and STI test kits.|t|f|t|f
33767331|NCT01411501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767332|NCT01932294|||COHORT||PROSPECTIVE|||||||
33767333|NCT05636150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767334|NCT04245085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767335|NCT02403843|||COHORT||PROSPECTIVE|||||||
33767336|NCT02043639|||CASE_ONLY||PROSPECTIVE|||||||
33767337|NCT01582789|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34077359|NCT04088669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077360|NCT00372632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077361|NCT02521363|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34077362|NCT03082729|NA|SINGLE_GROUP||TREATMENT||NONE|Imaging data files will be sent to the central core of the National Institutes of Health (NIH) Imaging Lab for measuring the standardized uptake values (SUVs). The NIH central PET/CT readers will be blinded to time point of scan via Digital Imaging and Communication in Medicine (DICOM) file editing applied by the University of Pennsylvania.|||||
34077363|NCT06044818|||COHORT||PROSPECTIVE|||||||
34077364|NCT02936375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077365|NCT03073486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077366|NCT01023204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077367|NCT04578171|||COHORT||PROSPECTIVE|||||||
34077368|NCT00752089|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34077369|NCT04122118|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34077370|NCT00269945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077371|NCT05946200|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only the care provider will know what's going on in the management of the patient. Cause that they should manage the case properly.||t|f|t|t
34077372|NCT01615705|||COHORT||PROSPECTIVE|||||||
34077373|NCT06612021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34077374|NCT05538013|||COHORT||CROSS_SECTIONAL|||||||
34077375|NCT00147706|RANDOMIZED|PARALLEL||||SINGLE||||||
34077376|NCT00954265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33721163|NCT02338960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721164|NCT05476341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721165|NCT00640445|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33895857|NCT01538615|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is a behavioral intervention. Masking is not feasible.|||||
33895858|NCT03770143|||CASE_CONTROL||PROSPECTIVE|||||||
33895859|NCT01106781|||CASE_ONLY||PROSPECTIVE|||||||
33895860|NCT00662155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895861|NCT02139189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895862|NCT01189773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895863|NCT06448156|||COHORT||RETROSPECTIVE|||||||
33895864|NCT06114043|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trial investigating patients with painful mild to moderate hallux valgus deformity||||
33895865|NCT05218629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895866|NCT06375850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895867|NCT03576027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895868|NCT00101361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895869|NCT03972371|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomised, single centre, safety and feasibility study||||
33895870|NCT01981187|NA|SINGLE_GROUP||TREATMENT||||||||
33895871|NCT04627545|RANDOMIZED|PARALLEL||TREATMENT||NONE||Oocytes of one patient will be evenly and randomly distributed between two timings of exposure to sperm: 2h exposure versus overnight exposure (16-20h)||||
33895872|NCT02048514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895873|NCT01270425|||COHORT||PROSPECTIVE|||||||
33895874|NCT01068470|||COHORT||PROSPECTIVE|||||||
33895875|NCT03283215|||COHORT||PROSPECTIVE|||||||
33895876|NCT00404443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895877|NCT04184648|||CASE_CONTROL||RETROSPECTIVE|||||||
33895878|NCT01132014||||TREATMENT||||||||
33895879|NCT02381158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895880|NCT03572634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL (Group 1-TP 0903 monotherapy); or have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient (Group 2-TP-0903 and ibrutinib combination therapy)"||||
33895881|NCT01575912|||COHORT||PROSPECTIVE|||||||
33895882|NCT06035718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33895883|NCT03669393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767338|NCT00363337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767339|NCT02024035|||COHORT||PROSPECTIVE|||||||
33767340|NCT00152971|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33767341|NCT01167283|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33767342|NCT02012192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767343|NCT00371852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767344|NCT00675415|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33767345|NCT02732626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767346|NCT04599738|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33895884|NCT03554239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895885|NCT05598086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33895886|NCT04544267|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"A total of 100 participants will be in an uncontrolled, open-label sentinel cohort, while all other participants will be in an randomized, modified double-blind design. The following measures will ensure the integrity of the blinded data for the participants in the randomized, modified double-blind cohort:~* The unblinded qualified study staff member, independent of the safety evaluation and other study evaluations, will administer the vaccine~* The Investigators (or delegates) in charge of safety assessment, the study staff who collect the safety data, and the laboratory personnel who analyze the blood samples will not know which product was administered~* The participant / parent / guardian will not know which product was administered. To maintain the blinding of the participant / parent / guardian, the vaccine syringe label will be covered with appropriate materials prior to administration."|"A sentinel safety cohort is selected for collection safety events where QIV-HD will be administered open-label in 100 participants. These subjects will not provide blood samples and will not be followed for influenza-like illness (ILI) surveillance.~A re-vaccination cohort will be composed of a subset of approximately 120 participants from Season 1 (2021-2022 Northern Hemisphere) will be re-enrolled and re-randomized in Season 3.The re-vaccination cohort will be included re-randomized to receive either QIV-HD or QIV-SD, will provide blood samples in Season 1 and Season 3, and will not be followed for ILI surveillance during their participation in Season 3."|t|t|t|t
33767347|NCT01849432|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33895887|NCT03348514|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase I, first-in-human, multicenter, open label, dose escalating study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically- or cytologically-confirmed solid tumor type.||||
33895888|NCT00006072||||TREATMENT||NONE||||||
33895889|NCT01086111|||CASE_CONTROL||PROSPECTIVE|||||||
33895890|NCT06511752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Behavioral intervention- support group||||
33895891|NCT00388466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895892|NCT04885738|||COHORT||PROSPECTIVE|||||||
33895893|NCT03636815|||COHORT||RETROSPECTIVE|||||||
33895894|NCT06251687|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33895895|NCT05203627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33895896|NCT05290467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|ANC allocation will be concealed from investigators who will enroll and assign the participants. Participants and care providers will not be masked to the allocation because of the nature of the ANC, while the outcome assessors and data statistical analysts will be blinded.|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Message, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.|f|f|t|t
33895897|NCT03244098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767348|NCT03413254|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|In order to prevent caretakers from being influenced by the assigned follow-up strategy, the randomization outcome will remain unknown to everyone involved in the patient's care until the 18 months CT-scan is reported by the radiologist.|||||
33767349|NCT06340165|||CASE_ONLY||RETROSPECTIVE|||||||
33767350|NCT00037557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767351|NCT00659594|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33767352|NCT04990206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767353|NCT05989373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767354|NCT05767996|||COHORT||PROSPECTIVE|||||||
33767355|NCT02529878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767356|NCT05185141|||COHORT||PROSPECTIVE|||||||
33767357|NCT02527070|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33767358|NCT02681705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767359|NCT06625944|||COHORT||PROSPECTIVE|||||||
33895898|NCT00080327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33895899|NCT04914338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33895900|NCT03062189|||COHORT||PROSPECTIVE|||||||
33895901|NCT05858008|NA|SINGLE_GROUP||OTHER||NONE||||||
33895902|NCT00452621|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33895903|NCT03261869|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33895904|NCT01811030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895905|NCT04689308|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33895906|NCT03920605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895907|NCT04894383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895908|NCT04859946|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33895909|NCT01475201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895910|NCT00567931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767360|NCT04180735|||CASE_CONTROL||RETROSPECTIVE|||||||
33767361|NCT04199533|||COHORT||RETROSPECTIVE|||||||
33767362|NCT01998490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767363|NCT01962701|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767364|NCT00911313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767365|NCT02611830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767366|NCT03590665|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||The acute response to exercise in blood flow is non-invasively assessed in group of individuals with Down syndrome and a control group of age- and sex-matched individuals without Down syndrome.||||
33767367|NCT03447730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 was open-label; Part 2 was double-blinded||t|t|t|t
33767368|NCT04299334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767369|NCT03491423|NA|SINGLE_GROUP||OTHER||NONE||||||
33895911|NCT05600010|||COHORT||RETROSPECTIVE|||||||
33895912|NCT02730702|||COHORT||PROSPECTIVE|||||||
33895913|NCT04560413|||OTHER||CROSS_SECTIONAL|||||||
33895914|NCT04006769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895915|NCT02803502|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895916|NCT00060892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895917|NCT03731715|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open-label||||
33895918|NCT01645163|NA|SINGLE_GROUP||||||||||
33895919|NCT05856864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895920|NCT02366962|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33895921|NCT06286215|||COHORT||PROSPECTIVE|||||||
33895922|NCT00467883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895923|NCT01390168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895924|NCT04402489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33895925|NCT00036790||||TREATMENT||||||||
33895926|NCT02259231|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33895927|NCT06495710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895928|NCT03560440|||OTHER||RETROSPECTIVE|||||||
33895929|NCT02250287|||CASE_CONTROL||RETROSPECTIVE|||||||
33895930|NCT01895686|||COHORT||PROSPECTIVE|||||||
33895931|NCT02303587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895932|NCT03501576|||COHORT||PROSPECTIVE|||||||
33895933|NCT00484354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895934|NCT00984451|||COHORT||PROSPECTIVE|||||||
33895935|NCT03864354|||CASE_ONLY||PROSPECTIVE|||||||
33895936|NCT04101110|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33895937|NCT02463942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767370|NCT01947660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767371|NCT04549311|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pragmatic, multicenter, open-label, three-arm parallel-group Vanguard feasibility randomized controlled trial||||
33767372|NCT06279572|||COHORT||PROSPECTIVE|||||||
33767373|NCT00879320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767374|NCT06251739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767375|NCT01469780|||COHORT||RETROSPECTIVE|||||||
33767376|NCT04956978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767377|NCT01067027|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33767378|NCT02778620|||COHORT||PROSPECTIVE|||||||
33767379|NCT00830141|||CASE_CONTROL||PROSPECTIVE|||||||
33767380|NCT06314490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767381|NCT06202183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|blinded to block size||f|f|t|f
33767382|NCT03648255|||COHORT||PROSPECTIVE|||||||
33767383|NCT05930418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767384|NCT02198053|||CASE_CONTROL||PROSPECTIVE|||||||
33767385|NCT05800808|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33767386|NCT02019134|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840450|NCT05646576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840451|NCT05254080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33895938|NCT00440401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895939|NCT01166009|||COHORT||RETROSPECTIVE|||||||
33840452|NCT02537210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840453|NCT00505154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840454|NCT02666664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840455|NCT00003391||||TREATMENT||||||||
33840456|NCT05009784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840457|NCT04001647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A study monitor not involved in data collection or analysis will perform masking of both the participant and investigator for the interventions for the older obese participants. These participants will be randomized into placebo or TUDCA treatment groups.|Participants from each group (young healthy weight, young obese, older healthy weight, older obese) will be studied before and after 8 weeks of tauroursodeoxycholic acid (TUDCA) treatment. Additional older obese participants will be studied before and after 8 weeks of a placebo treatment.|t|f|t|f
33840458|NCT05959759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients with intracranial aneurysms will be numbered and randomly divided into two groups, 30 patients in each group, and seal them. Through blind method, one group will be given dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months). The other group took placebo with the same appearance (color, taste, size, shape) as the test drug.|A total of 60 patients will be enrolled in this study. Randomly divide the patients into experimental group and placebo group according to 1:1 ratio.|t|t|t|t
33840459|NCT03191513|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33840460|NCT04693039|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33840461|NCT00288639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840462|NCT01344772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840463|NCT02872805|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33840464|NCT04309591|||COHORT||RETROSPECTIVE|||||||
33840465|NCT03473353|NA|SINGLE_GROUP||OTHER||NONE||||||
33840466|NCT04934956|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767387|NCT05027399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After filtering this patient database, following the inclusion and exclusion criteria, will be performed randomization in two groups of 30 participants, randomization will be stratified by two variables, Age and Ejection Fraction, using the Jamovi statistical software. Group A will be composed of the participants who will have intervention, that is, the patients will receive fortnightly follow-up in nursing telephone consultation concurrently with follow-up usual outpatient clinic and group B (control) will be composed of the participants who will have no intervention and will continue to monitor according to the institution's routine.||||
33767388|NCT01155661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767389|NCT04968262|||COHORT||PROSPECTIVE|||||||
33767390|NCT00591123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767391|NCT01420263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767392|NCT02367716|||CASE_ONLY||CROSS_SECTIONAL|||||||
33767393|NCT01930630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33895940|NCT02542995|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33895941|NCT04269408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical trial is defined as a single-blind study. For ethical reasons, no placebo implants will be used and therefore the surgeon cannot be blinded. All investigators/surgeons who have not been involved in the operation of a patient will remain blinded for this particular patient.||t|t|f|t
33895942|NCT06433115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind|Parallel Assignment|t|f|f|f
33895943|NCT00474331|||CASE_ONLY||RETROSPECTIVE|||||||
33895944|NCT03646019|||CASE_CONTROL||PROSPECTIVE|||||||
33895945|NCT01925521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33895946|NCT01860170|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895947|NCT00885469|||COHORT||PROSPECTIVE|||||||
33895948|NCT02140463|||OTHER||PROSPECTIVE|||||||
33895949|NCT03554512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33895950|NCT00815971|||CASE_ONLY||PROSPECTIVE|||||||
33895951|NCT01090557|||CASE_CONTROL||PROSPECTIVE|||||||
33895952|NCT01099345|||CASE_CONTROL||PROSPECTIVE|||||||
33895953|NCT00837538|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895954|NCT02711371|||COHORT||CROSS_SECTIONAL|||||||
33895955|NCT04914897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895956|NCT06340711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895957|NCT01673061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895958|NCT03135093|||OTHER||CROSS_SECTIONAL|||||||
33895959|NCT04936932|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895960|NCT03958201|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33895961|NCT02621333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895962|NCT05928741|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Triple-blind (participant, investigator, outcomes assessor)||t|f|t|t
33895963|NCT04632979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895964|NCT04976712|||CASE_ONLY||PROSPECTIVE|||||||
33895965|NCT06444893|||COHORT||PROSPECTIVE|||||||
33895966|NCT00006122||||TREATMENT||||||||
33895967|NCT00929292|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33895968|NCT02913807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33895969|NCT01193647|||CASE_ONLY||CROSS_SECTIONAL|||||||
33895970|NCT03014648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895971|NCT00117312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895972|NCT04518384|||COHORT||RETROSPECTIVE|||||||
33895973|NCT02629705|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33895974|NCT02832271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895975|NCT05959499|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33895976|NCT04696094|||CASE_CONTROL||PROSPECTIVE|||||||
33895977|NCT00003323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33895978|NCT03845283|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33895979|NCT02632825|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33895980|NCT01548638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895981|NCT00811226|||COHORT||PROSPECTIVE|||||||
33895982|NCT04807491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33895983|NCT04673994|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33895984|NCT00702624|||OTHER||PROSPECTIVE|||||||
33895985|NCT04837391|||COHORT||PROSPECTIVE|||||||
33895986|NCT02493907|||COHORT||PROSPECTIVE|||||||
33895987|NCT00520026|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33895988|NCT06430541|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33895989|NCT05068804|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33895990|NCT01025336|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33895991|NCT06312306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33895992|NCT03597906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective, randomized and comparative interventional study|t|f|t|f
33979514|NCT00947258|RANDOMIZED|||PREVENTION||SINGLE|||f|f|f|t
33979515|NCT04113239|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33895993|NCT04477122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will take and opaque enveloped who revealed the allocation group (named as RED or BLUE for blindness conditions). Investigators will not be aware of the which device is sham or real treatment due to codification. The outcomes assessor will be a different person from the investigator and the care providers, unaware of group allocation and treatment.|Two groups: experimental one and placebo group, receiving the intervention at the same time|t|f|t|t
33979516|NCT05067361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33979517|NCT01621022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33979518|NCT05341232|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33979519|NCT01652079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979520|NCT00583258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979521|NCT02367638|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33979522|NCT06139237|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33979523|NCT06248450|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Preference-based allociation to group yoga in a physical or in a digital setting||||
33979524|NCT03881826|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33979525|NCT04603092|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|"The control and experiment group will both be provided a hard-copy of a health literacy booklet and electronically administered the: (a) base-line survey, and (b) the pre-test survey and the post-test survey.~The experiment group will receive a digital health literacy intervention in two target areas: (i) hygiene and sanitation, and (ii) coronavirus awareness and prevention."||||
33979526|NCT01642511|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33979527|NCT05649475|||COHORT||PROSPECTIVE|||||||
33895994|NCT00693186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33895995|NCT00288340|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33895996|NCT03133715|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive either laparoscopic or robot-assisted repair of ventral hernia.||||
33895997|NCT04287530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33895998|NCT01609283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33895999|NCT04304677|||CASE_CONTROL||PROSPECTIVE|||||||
33896000|NCT01480986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896001|NCT03659513|||CASE_ONLY||PROSPECTIVE|||||||
33896002|NCT02826057|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33896003|NCT06041347|||COHORT||PROSPECTIVE|||||||
33896004|NCT05434910|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||In the study, the infusion rate of noradrenaline will be temporarily adjusted to the following three levels MAP: 65, 80, and 95 mmHg and measurements will be conducted at each level of MAP. See detailed description elsewhere.||||
33979528|NCT06486116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979529|NCT05902143|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33979530|NCT01072110|||OTHER||PROSPECTIVE|||||||
33979531|NCT03392610|||CASE_CONTROL||PROSPECTIVE|||||||
33979532|NCT02187978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979533|NCT00188656|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979534|NCT01601197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077377|NCT00317915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077378|NCT06548282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34077379|NCT03943498|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077380|NCT06034093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The developed AI assistant, named RAIMUS, was deployed in real-time using the PRETUS tool. The ultrasound machine HDMI output was connected to the laptop via a USB framegrabber. This allowed the user to use an external screen with an AI overlay instead of the screen of the ultrasound machine.~The interface to RAIMUS is as follows. On the right of the screen, there is a widget containing information from the automatic muscle segmentation, including the muscle delineation continuously overlaid onto the ultrasound image and the corresponding cross-sectional area in cm2. The segmentation overlay and related information can be enabled or disabled by the user."||||
33979535|NCT01297049|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979536|NCT04078477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research Randomizer|Intervention: parallel assignment. Blind for statisticians: statisticians from a different institution will only know type A or B randomization.|f|t|f|f
33979537|NCT04149964|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, randomized into one of two arms study. Study arm 1: Standard of care arm of Acetaminophen (Tylenol) 325 mg every 6 hours as needed plus acetaminophen/hydrocodone 7.5 mg/325mg every 4 hours for breakthrough pain. Study arm 2: Acetaminophen 650 mg. every 6 hours round the clock plus 5 mg oxycodone every 4 hours as needed for breakthrough pain.||||
33979538|NCT02366780|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33979539|NCT06223451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients participating in the study are unaware of their group assignment, and the evaluator assessing the results is also blinded to the patients' group allocation; therefore, a double-blind study has been designed.||t|f|f|t
34077381|NCT03756415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077382|NCT01028729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077383|NCT02670746|||COHORT||PROSPECTIVE|||||||
34077384|NCT04486508|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"For the first hypothesis, allocation sequence concealment and blinded endpoint adjudication.~For the second hypothesis, allocation sequence concealment, double-blind medication administration, and blinded endpoint adjudication."|1:1 multicenter open-label 2x2 factorial design randomized controlled trial with allocation sequence concealment and blinded endpoint adjudication.|f|f|f|t
34077385|NCT04743089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077386|NCT03798418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34077387|NCT03569098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077388|NCT03871153|NA|SEQUENTIAL||TREATMENT||NONE||||||
34077389|NCT03861780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Samples are blinded to the participant and technical team||t|f|f|f
33979540|NCT00554151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896005|NCT00900432|||CASE_ONLY||PROSPECTIVE|||||||
34077390|NCT01819727|RANDOMIZED|PARALLEL||TREATMENT||NONE|"All subjects receive Study Drug. Subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day.Eligible subjects will be randomized 1:1 using an IWRS to titrate to one of two dose regimens:~20 mg/day or 40 mg/day. The randomization will be stratified by blood Phe levels of 600 to 900 µmol/L and \>900 µmol/ using the last available blood Phe concentration prior to Day 1 of the study."|||||
33979541|NCT01008657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979542|NCT03237819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"For each day of treatment, 4 ampoules of 10 ml will be distributed to the patient's nurse (4 ampoules of 1.5g of magnesium sulphate or 3 ampoules of 5% glucose as placebo).~The bulbs will be labeled identically so that the blind can be maintained Moreover, in order to preserve the blind, the dosage of magnesemia should not be performed outside of a necessity judged by the clinician in charge of the patient"|multicentre double-blind randomized clinical trial|t|t|t|t
33979543|NCT03677232|||CASE_ONLY||CROSS_SECTIONAL|||||||
33979544|NCT03641742|||COHORT||PROSPECTIVE|||||||
33979545|NCT02210715|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33979546|NCT00662025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979547|NCT02310165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979548|NCT02115906|||CASE_CONTROL||PROSPECTIVE|||||||
33979549|NCT01544790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979550|NCT00489203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33979551|NCT02754401|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33979552|NCT04338867|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Patients were randomized 1:1 to received TN plus WBR or only WBR. ICPFS was evaluated by two blinded and independent radio-oncologist with MRI.|We perform an open phase II clinical trial among ninety-six histologically confirmed NSCLC patients with BM.||||
33979553|NCT02752126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979554|NCT02242552|||CASE_ONLY||PROSPECTIVE|||||||
33979555|NCT02925442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Genicular radiofrequency ablation performed prior to total knee arthroplasty for pain management|t|t|t|f
33979556|NCT02759289|||CASE_CROSSOVER||PROSPECTIVE|||||||
33896006|NCT04328662|||COHORT||PROSPECTIVE|||||||
33896007|NCT03291327|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The study randomisation schedule will be provided by an independent statistician in a sealed envelope and will be kept in a Study Master File (Test Products). The study blind will only be broken in an emergency where it was essential to know which formulation a participant had received in order to give the appropriate medical care. In the event of the requirement to break the code, the investigator (or designee) will, where possible, contact the Sponsor prior to breaking the blind. The investigator will then sign and date the broken code envelope and document the reason for breaking the code.~All study products will be provided by the Sponsor, in blister packs pre-labelled with randomisation numbers according the Sponsor's randomisation schedule. Toothpaste with Fluoride (Colgate/Crest) together will also be provided."|Single Centre parallel arm (3) double blind placebo controlled study|t|t|t|t
33896008|NCT04598438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896009|NCT00215150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896010|NCT00659672|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33896011|NCT02750410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896012|NCT00581607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896013|NCT02278978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896014|NCT00243737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896015|NCT01771302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896016|NCT02446782|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896017|NCT05478915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896018|NCT00003176||||TREATMENT||||||||
33896019|NCT02271490|RANDOMIZED|PARALLEL||||NONE||||||
33896020|NCT05681728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896021|NCT03103399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896022|NCT05000320|||COHORT||PROSPECTIVE|||||||
33896023|NCT02054546|||COHORT||PROSPECTIVE|||||||
33979557|NCT04888910|||OTHER||PROSPECTIVE|||||||
33979558|NCT01333527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979559|NCT05395858|||COHORT||RETROSPECTIVE|||||||
34077391|NCT01823471|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34077392|NCT01557673|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34077393|NCT06011694|||COHORT||PROSPECTIVE|||||||
34077394|NCT04771013|NA|SINGLE_GROUP||TREATMENT||NONE||A participant-level comparison based on registry data from the Hospital de Santa Bárbara Integrado will be performed after propensity score matching.||||
34077395|NCT06398236|NA|SINGLE_GROUP||OTHER||NONE||Multicentre, exploratory, prospective, open-labelled study to evaluate the efficacy of SE5-OH tablets on menopausal symptoms in healthy women experiencing menopausal symptoms after 12 weeks of administration.||||
34077396|NCT04899115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study staff will remain blinded to subject randomization until the study period is over.|"Subjects will be randomized 2:1 to VE303 vs placebo. There will be no stratification.~After the trial enrolls the first 9 patients, an interim analysis to evaluate safety of VE303 in this population will take place. If there is no concern for a higher rate of Serious adverse events (SAEs) in the VE303 group, enrollment will continue to reach a total of 18 patients."|t|f|t|f
33767394|NCT06379256|||COHORT||PROSPECTIVE|||||||
33767395|NCT00034645|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33767396|NCT05184153|||COHORT||RETROSPECTIVE|||||||
33767397|NCT01083420|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33767398|NCT02085538|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767399|NCT02608905|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33767400|NCT04821271|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33767401|NCT02005315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767402|NCT04610216|||COHORT||PROSPECTIVE|||||||
33767403|NCT01935921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767404|NCT00980122|||COHORT||CROSS_SECTIONAL|||||||
33767405|NCT03720782|||COHORT||OTHER|||||||
33767406|NCT01312987|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767407|NCT04112940|||COHORT||CROSS_SECTIONAL|||||||
33767408|NCT04154215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767409|NCT03679195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767410|NCT01678820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767411|NCT03620643|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||This multi-centre study design will aim to complete recruitment over 18 months from six high volume centres including the Royal Marsden. Parallel recruitment to breast and basket cancer cohorts will take place for this study.|t|f|f|f
33767412|NCT04780724|RANDOMIZED|CROSSOVER||OTHER||SINGLE||All participants go through all study arms, in random order. Two measuring devices are active simultaneously during measurement on each participant and their functioning is compared.|t|f|f|f
33767413|NCT01265589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767414|NCT06325137|||OTHER||CROSS_SECTIONAL|||||||
33767415|NCT02958618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767416|NCT01305278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767417|NCT03594903|RANDOMIZED|PARALLEL||OTHER||DOUBLE||participants are assigned to one of two groups in parallel for the duration of the study|t|f|t|f
33767418|NCT03305224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767419|NCT03239873|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33767420|NCT01382485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767421|NCT06125743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767422|NCT01949597|||COHORT||PROSPECTIVE|||||||
33767423|NCT03764423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767424|NCT01754454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767425|NCT00376051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767426|NCT02396537|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33767427|NCT02835456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767428|NCT02340286|||COHORT||PROSPECTIVE|||||||
33767429|NCT05217836|||COHORT||PROSPECTIVE|||||||
33767430|NCT05349721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767431|NCT03337191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767432|NCT00211341|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767433|NCT05033080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767434|NCT05777954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33979560|NCT05602519|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34077397|NCT00222703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077398|NCT00053885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077399|NCT02732808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077400|NCT00295165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077401|NCT04951908|||COHORT||RETROSPECTIVE|||||||
34077402|NCT00124891|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34077403|NCT05563545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077404|NCT00514878|||COHORT||PROSPECTIVE|||||||
34077405|NCT04553172|||FAMILY_BASED||OTHER|||||||
34077406|NCT04740463|||COHORT||PROSPECTIVE|||||||
34077407|NCT03346824|||OTHER||RETROSPECTIVE|||||||
34077408|NCT01735318|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077409|NCT05209230|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077410|NCT03247777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077411|NCT02162160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077412|NCT00157768|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767435|NCT04303312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment will be placed in identical spray containers|Randomized Controlled Trial|t|t|f|f
33979561|NCT00440557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979562|NCT05287594|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two group design where 40 firefighters are cluster randomized (3:2 ratio) into a TRAINER or waitlist control group. There will be 6 trainers who will lead the TRAINER condition. All participants in the TRAINER group and following the intervention in the waitlist control group will receive the same integrated exercise program, led by a peer-trainer, including a neuromuscular warm-up and high intensity interval training at their respective fire stations 2 times per week for 6 weeks.||||
33979563|NCT00804661|||COHORT||CROSS_SECTIONAL|||||||
33979564|NCT00883090|NA|SINGLE_GROUP||||NONE||||||
34077413|NCT00814138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077414|NCT03874013|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34077415|NCT02228005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077416|NCT01296412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077417|NCT00924846|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34077418|NCT05042817|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Patient assessments and bladder urodynamic data collection were performed by two blinded anesthesiologists.~Randomization was performed using the sealed envelopes method. Therefore, one of the anesthesiologists of the research team, who was unblinded, opened the envelopes and prepared the injection mixtures.~Another two blinded anesthesiologists administered perioperative anesthesia and monitored the patient during the perioperative period, and evaluated sensitive and motor block."||t|t|f|t
34077419|NCT04211350|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077420|NCT03771963|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34077421|NCT00405418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077422|NCT01602991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077423|NCT00180908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077424|NCT03200353|NA|SINGLE_GROUP||OTHER||NONE||||||
34077425|NCT03498729|||CASE_CONTROL||PROSPECTIVE|||||||
34077426|NCT02622152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34077427|NCT00299819|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34077428|NCT00657423|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34077429|NCT03383224|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized to genotype-guided therapy or standard of care||||
34077430|NCT00445471|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767436|NCT04485130|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind|This is a dose escalation double blind randomized (2:1) placebo-controlled trial of disulfiram given as 1000 mg/day x 5 consecutive days (Cohort 1: N=20 drug/N=10 placebo) or 2000 mg/day x 5 consecutive days (Cohort 2: N=20 drug/N=10 placebo) among 60 acute symptomatic lab-confirmed (\<7 days) COVID+ individuals .|t|t|t|t
33767437|NCT02281175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767438|NCT06480682|||COHORT||PROSPECTIVE|||||||
34077431|NCT00988104|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34077432|NCT02227277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102970|NCT02844816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767439|NCT00125580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33767440|NCT03774602|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33767441|NCT00735644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33767442|NCT02618720|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33767443|NCT03331185|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective,randomized clinical trial will be conducted. The trial aims at obtaining information to determine which material would provide a superior clinical result, as well as reporting on patient related outcomes. 42 participants will be randomly assigned to two groups and a direct comparison will be made between the results obtained from the two groups.||||
33767444|NCT01115543|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33767445|NCT04262492|||COHORT||PROSPECTIVE|||||||
33767446|NCT03967080|||COHORT||PROSPECTIVE|||||||
33767447|NCT05097768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To blind the experiment, each of the 50 patients in each group will be randomly allocated a code consists of 2 letters and one number. Only the random numbers identify the medications; thus, the patient and doctor are uninformed of which medication will be given to them.|The trial will include five study groups, each consists of 50 patients who exhibits symptomatic irreversible pulpitis of a mandibular first or second molar. The patients will receive identically appearing capsules containing either dexamethasone 0.5 mg, ketorolac 10 mg, meloxicam 7.5 mg, ibuprofen 600 mg, or placebo by mouth 60 minutes before the administration of an IANB. Endodontic access will begin 15 minutes after completion of the IANB. The IANB success is defined as no or mild pain (Heft Parker visual analog scale recordings) on pulpal access or instrumentation.|t|f|t|f
33767448|NCT00341380|||CASE_ONLY||PROSPECTIVE|||||||
33767449|NCT04512222|||COHORT||PROSPECTIVE|||||||
33767450|NCT05765084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767451|NCT06177236|NA|SINGLE_GROUP||SCREENING||NONE||randomized controlled trial||||
33767452|NCT01515904|||CASE_CONTROL||PROSPECTIVE|||||||
33767453|NCT04706741|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|"The primary purpose of the study is treatment of active Noninfectious Intermediate, Posterior or Pan-uveitis~The study includes one treatment arm, into which 10 patients are planned to be enrolled"||||
33767454|NCT04229030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767455|NCT00583232|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767456|NCT05824390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
33767457|NCT03180879|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33767458|NCT05981313|||CASE_CONTROL||PROSPECTIVE|||||||
33767459|NCT01519024|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767460|NCT03290560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767461|NCT00299195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767462|NCT03303586|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomly assigned to wearing compression stockings for next two weeks or not wearing compression stockings for next two weeks, and crossed over.||||
33767463|NCT06332950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801276|NCT05646329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the study, it was not possible to blind the researcher and the participant who applied the intervention, but the statistics and report writing process were blinded.The students in the experimental and control groups related to the research were informed about the purpose of the study.The person conducting the research knows which is the experimental group and which is the control group. For this reason, single and double blinding was not done in the study. The data regarding the measurements were written as 'A' and 'B' without specifying the experimental and control groups, and the groups were coded.The analysis of the data coded in terms of groups will be done by the statistics expert. After the statistical analyzes are made and the research report is written, the coding for the experimental and control groups will be explained.|In the study, 66 students were taken as sampling, 33 of which were experimental and 33 were control.|f|f|f|t
33801277|NCT01933802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801278|NCT04739527|NA|SINGLE_GROUP||TREATMENT||NONE||Open label phase I study||||
34102971|NCT06051968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767464|NCT04437147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The phisician (care provider), the research subjects (participants) and outcome assessor (had access to the results) will be blinded. All groups received sachets with the same characteristics (taste and packaging) different only in the numbering of the manufacturing batches. The phisician separated each volunteer in according to lot number corresponding to the randomisation.|Interventions: in particular, subjects were divided into 3 groups: i) 50 subjects in the group A will receive placebo, ii) 50 subjetcs in the group B will receive mixed L. acidophilus LA 02 ID 1688, B. bifidum BB 01 ID 1722 and L. rhamnosus LR 04 ID 1132 (1 x 10⁹ colony-forming units/d of each strain) and 50 subjects em the group C will receive L. acidophilus LA 02 ID 1688, B. bifidum BB 01 ID 1722, L. rhamnosus LR 04 ID 1132, L. paracasei LPC 00 ID 1076, B. longum BL 03 ID 1152, B. lactis BS 01 ID 1195, L. casei LC 03 ID 1872, B. animalis LMG 10508 (1 x 10⁹ colony-forming units/d of each strain) for 30 days. At the beginning of the interventional study, the healthy status of volunteers will be evaluated by a complete, laboratory and by the clinical evaluation by the doctor using as reference ROMA IV for intestinal constipation. Exclusion criteria will be items of gastrointestinal diseases, pregnant and antibiotic intake.|t|t|f|t
33979565|NCT05127577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"According to the randomization table, the information showing the patients included in the research sample is assigned to the A and B groups will be put in an opaque envelope. This envelope will be kept by the coordinator researcher (GAU) and when the researcher (CK) goes to the patient for application, after filling out the Informed Voluntary Consent Form, he will open the envelope and learn which group is in which group. Due to the nature of the study, patients and the researcher (CK) will not be blinded, since abdominal massage will be applied only to the patients included in the study. When the research is completed, the data will be transferred to the computer environment by a statistician who does not know the A and B groups, and the data will be analyzed by a statistician independent of the research and the findings will be reported. Thus, the data analysis and statistics phase will be blind to group assignment."|Prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
33979566|NCT01806922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979567|NCT01242865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767465|NCT04686565|||CASE_ONLY||CROSS_SECTIONAL|||||||
33979568|NCT04646109|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group||||
34077433|NCT05597995|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled subjects will undergo aspiration of cyst contents through an 18g needle immediately followed by injection of 1.5% STS foam (until the cyst is full and foam is flowing out of the injection site) followed by surgical excision 60 days later. The foam will be created by diluting 3% STS with an equal volume of normal saline then mixing with air in a 1:4 ratio using a female-to-female coupler.||||
34077434|NCT04574453|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open label, multicentre study with two parallel groups of patients and a non-inferiority hypothesis.||||
34077435|NCT02876796|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34077436|NCT00545623|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34077437|NCT03007355|||OTHER||PROSPECTIVE|||||||
33767466|NCT06259734|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Data collection on the appropriateness of blood transfusion orders will be collected for educational course participants and compared with orders of physicians who did not receive the intervention.||||
33767467|NCT01568632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767468|NCT04773639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The PI will be blinded to condition assignment. Outcomes will be assessed in REDCap.|In a randomized controlled trial, this project evaluates the M-ACT intervention for community patients with metastatic cancer relative to the usual care control condition, reflecting Stage IIb/III of the NIH stage model for evaluating behavioral interventions. We will randomize 240 patients to M-ACT or usual care for five weeks (n per condition = 120) and assess them at Baseline (Pre), Mid-Intervention (Mid), Post-Intervention (Post), and 2-month Follow-Up (FU).|f|f|t|t
33979569|NCT05780541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979570|NCT05368337|||COHORT||CROSS_SECTIONAL|||||||
33979571|NCT01189669|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34077438|NCT01167569|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077439|NCT05252741|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34077440|NCT00588146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077441|NCT00249873|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34077442|NCT00145769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077443|NCT05370898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077444|NCT03847740|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077445|NCT04288934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with complete transection of the spinal cord. Each group will then be subdivided into 2 subgroups with of 5 patients each; the 1st subgroup will be the patients with chronic SCI and the 2nd subgroup will be for the patients with subacute SCI.||||
34077446|NCT05375500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979572|NCT03602326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients admitted to Gazi University Hospital with stroke findings diagnosed with ischemic stroke by a Neurologist will be included in the study. Patients older than 18 years of age with a systolic blood pressure between 120 and 220 mmHg, whose oxygen saturation is \>92% (with or without O2 support), with a heart rate of 40 to 100 beats/min, a body temperature of \<38.5°C, a disability level of ≤4 according to the Modified Rankin Scale and those who could respond to verbal commands will be included in the study. Patients with; a history of previous stroke or any other disorder that would prevent mobilization will not be included in the study. The patients will be randomly divided into two groups: NDT-B Group and the Standard Rehabilitation Group.|t|t|t|f
33896024|NCT06421324|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||In practice, for rare diseases we chose a sample size that will allow estimation of sensitivity of the risk score to a pre-specified precision. We have chosen the sample size assuming that the resulting precancer detection model will have a sensitivity of at least 85%, and so that the lower 95% confidence interval will exceed 76%, with 80% power. The R package MKmisc estimates sample size for a proportion based on the Binomial distribution rather than a Normal approximation. In this case, we have estimated a sample size of 141 GIM + cancer and 141 GIM controls (282 in total). With 5% of samples assumed to be failing to be analysed due to a variety of technical reasons, we would need \~300 samples in total. In addition, to train the system 150 gastric cancer cases will be recruited which will provide pathology samples images and endoscopy images that will be taken as part of the clinical practice.||||
33979573|NCT03030066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979574|NCT05960526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33979575|NCT00137397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979576|NCT03460197|||COHORT||PROSPECTIVE|||||||
33979577|NCT01822600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979578|NCT05165862|||COHORT||PROSPECTIVE|||||||
33979579|NCT01739790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077447|NCT02123719|||COHORT||RETROSPECTIVE|||||||
33979580|NCT03815838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979581|NCT02485808|||COHORT||PROSPECTIVE|||||||
34077448|NCT01644097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34077449|NCT00827710|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077450|NCT03957486|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077451|NCT02601079|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34077452|NCT04710485|||OTHER||PROSPECTIVE|||||||
34077453|NCT05052853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077454|NCT01156688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077455|NCT05469529|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34077456|NCT04279340|||OTHER||OTHER|||||||
34077457|NCT06377293|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Laboratory technicians who assess the study outcomes will be masked|A randomized, active-controlled trial with cross-over design|f|f|f|t
34077458|NCT02224612|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34077459|NCT01496313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077460|NCT01542138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896025|NCT03528681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896026|NCT04093219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The research pharmacists at each institution will prepare the placebo and will dispense the study drug according to treatment allocation. Treatment allocation will otherwise remain concealed from all others involved in the conduct and analysis of the trial, including those performing statistical analysis. Study participants will remain blinded throughout.||t|t|t|t
33896027|NCT02631187|NA|SINGLE_GROUP||OTHER||NONE||||||
33896028|NCT01351662|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33979582|NCT02920996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896029|NCT02418494|||CASE_ONLY||PROSPECTIVE|||||||
33896030|NCT06512402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896031|NCT04666883|||COHORT||RETROSPECTIVE|||||||
33979583|NCT00339768|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33979584|NCT03272139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979585|NCT05984420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979586|NCT02471469|||COHORT||PROSPECTIVE|||||||
34077461|NCT00325819|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34077462|NCT05908396|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33979587|NCT03203915|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33979588|NCT05679648|||CASE_CONTROL||PROSPECTIVE|||||||
33979589|NCT04296149|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979590|NCT04314349|||COHORT||PROSPECTIVE|||||||
33979591|NCT04097600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077463|NCT02581683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077464|NCT00113295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077465|NCT06203535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077466|NCT01712828|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34077467|NCT03643510|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single arm study of combination CDK4 and CDK6 dual inhibitor Abemaciclib and selective estrogen receptor degrader Fulvestrant in hormone receptor positive recurrent endometrial carcinomas.||||
34077468|NCT00281697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979592|NCT06056869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979593|NCT01064128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077469|NCT03644771|||CASE_CONTROL||PROSPECTIVE|||||||
34077470|NCT02951832|||COHORT||PROSPECTIVE|||||||
34077471|NCT00727129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979594|NCT04982848|||CASE_ONLY||PROSPECTIVE|||||||
34077472|NCT03278496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896032|NCT05977543|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Only investigators knew the group in which each participant were enrolled.|On enrolment, all subjects were randomly assigned to the C: F1:F2 group (Control: Functional 1: Functional 2), to the F1: C: F2 group (Functional 1: Control: Functional 2) or to the F2: F1: C group (Functional 2: Functional 1: Control). Subjects in the C: F1:F2 group received the Control meal on the first visit, the Functional meal 1 on the second visit and the Functional meal 2 on the third visit; those in the F1:C:F2 group received the Functional meal 1 on the first visit, the Control meal on the second visit and the Functional meal 2 on the third visit while those in the F2:F1:C group received the Functional meal 2 on the first visit, the meal Functional meal 1 on the second visit and the Control meal on the third visit.|t|f|f|f
33979595|NCT02511405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896033|NCT00577590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896034|NCT05248997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979596|NCT01356849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979597|NCT01272752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896035|NCT06075940|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects enrolled will be treated with the MAGNITUDE BRS||||
33896036|NCT00385021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979598|NCT03682900|RANDOMIZED|PARALLEL||PREVENTION||NONE||Schools were stratified by state, size of school (small, medium, large) and desired start date and randomized to intervention or control. Intervention and control schools were yoked for the timing of assessments (baseline and follow-up assessments).||||
33979599|NCT02042846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896037|NCT00296439|RANDOMIZED|FACTORIAL||ECT||NONE||||||
33896038|NCT02107664|||COHORT||PROSPECTIVE|||||||
33979600|NCT00720096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896039|NCT03222661|||OTHER||PROSPECTIVE|||||||
33896040|NCT03851601|||COHORT||PROSPECTIVE|||||||
34077473|NCT03280485|||COHORT||PROSPECTIVE|||||||
34077474|NCT06436079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34077475|NCT00698815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077476|NCT00583908|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34077477|NCT01559805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077478|NCT06148103|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34077479|NCT05210439|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Randomized 1:1 to experimental group (short-treatment arm):control group (long-treatment arm)||||
34077480|NCT02764437|||OTHER||PROSPECTIVE|||||||
34077481|NCT01810562|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33896041|NCT03668132|||CASE_CONTROL||PROSPECTIVE|||||||
33896042|NCT05731739|||COHORT||RETROSPECTIVE|||||||
33896043|NCT04321863|||COHORT||PROSPECTIVE|||||||
33979601|NCT05806710|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979602|NCT02227121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979603|NCT04785456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979604|NCT00411866|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33979605|NCT03201497|||COHORT||PROSPECTIVE|||||||
33979606|NCT02840409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cross over to bevacizumab-vinblastine allowed in case of progression on vinblastine only||||
33979607|NCT05836805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979608|NCT02094820|||COHORT||CROSS_SECTIONAL|||||||
34077482|NCT00631982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077483|NCT03967067|||COHORT||RETROSPECTIVE|||||||
34077484|NCT04158219|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty subjects will be given the intervention according to the treatment manual.||||
34077485|NCT02956538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077486|NCT02068976|||COHORT||PROSPECTIVE|||||||
34102972|NCT05209737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102973|NCT06606600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34102974|NCT05132582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102975|NCT06685939|||COHORT||RETROSPECTIVE|||||||
33767469|NCT03146832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were not aware which experimental condition they were allocated to.|participants are assigned to one of three experimental groups in parallel for the duration of the study|t|f|f|f
33767470|NCT03173781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767471|NCT01929174|||CASE_CONTROL||PROSPECTIVE|||||||
33767472|NCT05236413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessor will be blinded to group allocations. Subjects will know which group they have been randomized to.|Randomized, blinded, 3-arm parallel-group design|f|f|f|t
33767473|NCT01045122|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33896044|NCT06208176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and experimenters (including tDCS operator) will not be informed about the nature (active or sham) of the stimulation they will receive.|The study is a multicentre, prospective, randomised, double-blind, parallel group, sham-controlled, two-arm clinical trial. Arm one is repeated active HD-tDCS guided by the fMRI-capture of hallucinations. Arm two is the blinded repeated sham HD-tDCS guided by the fMRI-capture of hallucinations|t|f|t|t
33896045|NCT05611138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Healthy male and female adult subjects (n=87) will be recruited to take part in a double-blinded, randomized, 3-arms parallel trial. Subjects that are eligible to take part in the study will be blinded and randomly allocated to consume an isolated plant protein (arm 1) or isolated animal protein (arm 2) or plant-based source of protein (arm 3). The subjects eligible to take part in this study will consume the proteins for 4 weeks, before the intervention they will have a baseline of two weeks, and after the intervention, they will have more two visits. Faecal and blood samples will be used to answer the main outcome of gut-related metabolites and microbiota profile. Blood and urine samples will be used to measure health status and compliance (protein intake markers). Questionnaires will be used to access gastrointestinal symptoms and bowel movement, physical activity level and dietary intake.|t|f|t|t
33896046|NCT04884087|RANDOMIZED|FACTORIAL||OTHER||NONE||2x2 factorial design (fixed incentive model vs. prize-based model; random assessment 3x vs. 6x per day)||||
33896047|NCT05069779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33896048|NCT05182164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 independent sigle-arm, multicenter, phase II trials, based on 2-stage Simon's optimal design||||
33896049|NCT04918693|||COHORT||PROSPECTIVE|||||||
33896050|NCT02472483|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896051|NCT01715025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896052|NCT00156078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33896053|NCT03009747|||COHORT||PROSPECTIVE|||||||
33896054|NCT00302640|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33896055|NCT02404506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896056|NCT04366765|||CASE_CONTROL||PROSPECTIVE|||||||
33896057|NCT03308630|NA|SINGLE_GROUP||OTHER||NONE||||||
33979609|NCT06369948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be divided into two groups randomized by computer generated random numbers that will be placed in separate opaque envelopes that will be opened by study investigators just before the block.|"We will include 60 patients who will undergoe elective hip hemiarthroplasty. Patients will be divided into two groups randomized by computer generated random numbers that will be placed in separate opaque envelopes that will be opened by study investigators just before the block.~Pericapsular Nerve Group (PENG) Block (P group) includes 30 patients who will receive a PENG block.~Control group (C group) includes 30 patients who will not receive a PENG block."|t|t|t|t
33979610|NCT03622658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979611|NCT02464566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979612|NCT04192500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized assignment to experimental vaccine (2 dosage levels or active control (commercial influenza vaccine) in a 1:1:1 ratio.|t|f|t|f
33979613|NCT03827109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102976|NCT05009069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102977|NCT06526520|||CASE_CROSSOVER||PROSPECTIVE|||||||
34102978|NCT01261351|||CASE_CONTROL||PROSPECTIVE|||||||
34102979|NCT04889950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Evaluator|A Randomized, Masked (Evaluator), Controlled, Prospective Pilot Study|f|f|f|t
34102980|NCT06424860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102981|NCT05604157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34102982|NCT06580899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102983|NCT04235062|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979614|NCT04522609|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Investigator will collect baseline data before the participant is randomized. The intervention will be set-up by the Investigator.|This is a single-blinded, randomized longitudinal study design to determine if NMES will increase muscle mass and strength and improve exercise capacity and right-ventricle diastolic function in patients with advanced HF. Patients will be randomized to either intervention that includes NMES or to a control group. In order to ensure that the two groups are comparable between treatment and control, the participants will be randomized according to gender. Randomization via minimization will be used in order to avoid an unbalanced number of women in the two comparison groups due to chance. A file of the computer-generated random assignments will be kept.|f|f|f|t
33979615|NCT01282606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979616|NCT06545253|||CASE_CONTROL||PROSPECTIVE|||||||
33979617|NCT03417544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979618|NCT01574170|NA|SINGLE_GROUP||OTHER||NONE||||||
33979619|NCT01964742|NA|SINGLE_GROUP||||NONE||||||
33979620|NCT05090332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979621|NCT04172363|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is monocentric, prospective, controlled, open, randomized, 2-armed interventional pilot trial.||||
33979622|NCT04103177|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot study will incorporate instructor led guidance of a range of chair-based exercises that focus on balance, strength, fitness, endurance and flexibility with some exercises having a cardiovascular component. These chair based exercises are drawn from programmes recommended for similar long term clinical conditions (e.g cardiovascular disease, sarcopenia, frail and elderly and renal disease) and can be performed in the clinical environment or at home.The intervention is multifaceted comprising of the following; an education booklet about PA and the chair based exercise programme, face to face instructor led support detailing the chair based exercises and instructor/nurse led motivational interviewing.||||
33979623|NCT05314400|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33801279|NCT03844152|NA|SINGLE_GROUP||OTHER||NONE|The intervention will be provided in non-descript bottles. Fermented whey is mixed with sugar-free flavoured water to mask its taste from participants.|Stratified single arm study||||
33979624|NCT02126306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979625|NCT01950208|||COHORT||PROSPECTIVE|||||||
33979626|NCT06458439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979627|NCT04505033|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33979628|NCT00532636|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33979629|NCT00385684|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33979630|NCT00369590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979631|NCT01256684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979632|NCT02152878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979633|NCT03765632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979634|NCT04598984|||COHORT||PROSPECTIVE|||||||
33979635|NCT03093506|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33979636|NCT02128152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979637|NCT00914667|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979638|NCT00005948||||TREATMENT||||||||
33979639|NCT03839706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979640|NCT01365429|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979641|NCT01234103|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979642|NCT01563757|||CASE_CONTROL||PROSPECTIVE|||||||
33979643|NCT02101346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33979644|NCT01617668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979645|NCT04457999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979646|NCT01309607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979647|NCT05897398|||COHORT||OTHER|||||||
33979648|NCT04217408|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|An independent member of the study team will perform the randomization and programming, allow for care givers, participants, investigator, and outcomes assessors to be blinded.|1 year of open-label treatment, followed by 5 week double blinded crossover phase consisting of 2 weeks of ON stimulation and 2 weeks of OFF stimulation separated by a 1 week washout period with OFF stimulation.|t|t|t|t
33979649|NCT01840371|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33979650|NCT05344872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979651|NCT00539877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979652|NCT05866497|||OTHER||CROSS_SECTIONAL|||||||
33979653|NCT03091946|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33979654|NCT00637390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979655|NCT01184560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979656|NCT06324149|||COHORT||PROSPECTIVE|||||||
33979657|NCT05904808|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-site, single-arm, open-label, cross-over controlled study Randomization will determine the sequence of the three (3) regimens||||
33979658|NCT01738386|||||RETROSPECTIVE|||||||
33979659|NCT05874466|||COHORT||PROSPECTIVE|||||||
33979660|NCT05432011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979661|NCT05881096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979662|NCT03236181|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33767474|NCT05527730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participant were be blind folded for the type of fitting for the study.|This multi-center, prospective, randomized cross-over clinical trial compares two methods of fitting individuals with hearing loss with a therapeutic amplification device (i.e., hearing aids). Subjects will wear the Whisper Hearing System for the PRO-FIT and SELF-FIT for two weeks each, totalling to approximately 1 month of wear throughout the trial.|t|f|f|f
33767475|NCT05351645|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Participants were not explicitly told which group (Treatment or Control) they were assigned to, but the Treatment group received an article by email each day, in addition to questionnaires, and the Control group received only questionnaires. Thus, Group assignment was likely detectable by participants|Participants were randomized to one of two groups (Treatment and Control) after providing informed consent. Participants in the Treatment group received the digital bibliotherapy intervention, and participants in the Control group were assigned to a waitlist.||||
34077487|NCT04435938|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible and consenting patients will be treated with the dose prescribed in the study of 45Gy in 5 fractions, delivered once every 3-4 days, such that treatment is completed within 15 days (Exceptions: treatment duration of up to 18 days will be allowed to account for cancer centre closures and unforeseen patient issues). Using the Simon optimal two-stage design, 11 patients will be recruited in the first stage. If 6 or less patients have a response, the study will be stopped at the end of stage I, however, if 7 or more patients have a response the study will continue to stage II, in which an additional 27 patients (for a total of 38) will be recruited. At the end of stage II, if 26 or less patients have a response, then H0 will be accepted and the treatment regimen deemed not worthy of further study, however, if 27 or more patients have a response, the treatment regimen will be recommended for further study in phase III.||||
33767476|NCT00284869|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33767477|NCT05818878|||COHORT||PROSPECTIVE|||||||
33767478|NCT00668824||||DIAGNOSTIC||||||||
33767479|NCT01435434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077488|NCT01038687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077489|NCT02154438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077490|NCT04221269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077491|NCT00538941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077492|NCT04819165|||COHORT||RETROSPECTIVE|||||||
34077493|NCT03841214|||COHORT||PROSPECTIVE|||||||
34077494|NCT00596102|||COHORT|||||||||
34077495|NCT01540513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077496|NCT06431334|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767480|NCT03759899|||CASE_ONLY||PROSPECTIVE|||||||
33767481|NCT04774822|||CASE_ONLY||CROSS_SECTIONAL|||||||
33767482|NCT00702182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767483|NCT05790564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767484|NCT05039762|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective, single center, non-randomized, non-blinded||||
33767485|NCT00482274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767486|NCT02799303|RANDOMIZED|PARALLEL||SCREENING||NONE||Intervention not a drug/biologic.||||
33767487|NCT03128437|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767488|NCT01070823|||||PROSPECTIVE|||||||
33767489|NCT03465449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767490|NCT05596422|||COHORT||RETROSPECTIVE|||||||
33767491|NCT04186403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767492|NCT02146222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767493|NCT03580213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33767494|NCT02496403|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767495|NCT06081374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33767496|NCT05242016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Questionnaires are administered to three groups: structured individual reminiscence, unstructured social interview, and control, before the application (day 1) and after the application (day 15).||||
33767497|NCT04246515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767498|NCT06474689|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33767499|NCT04646200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767500|NCT04041440|NA|SINGLE_GROUP||TREATMENT||NONE||Within subjects A1 - A2 - B1 - B2 design||||
33767501|NCT02040987|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33767502|NCT01376960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077497|NCT01438112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767503|NCT03719365|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Randomized, interventional, prospective study||||
33767504|NCT00790153|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767505|NCT03278886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767506|NCT01086605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767507|NCT03218332|||CASE_CONTROL||PROSPECTIVE|||||||
33767508|NCT01569035|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33767509|NCT05417334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767510|NCT03813342|RANDOMIZED|CROSSOVER||TREATMENT||NONE||treadmill with multi-dimensional and one-dimensional feedback||||
33767511|NCT03077620|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33801280|NCT01557335|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801281|NCT02543125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801282|NCT03825978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33801283|NCT01104441|||CASE_ONLY||PROSPECTIVE|||||||
33801284|NCT02352675|||CASE_CONTROL||PROSPECTIVE|||||||
34077498|NCT03175887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077499|NCT02438189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896058|NCT05012696|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Analysis of work of breathing and of data derived from Electric impedance tomography will be performed blind to arm assignment||f|f|f|t
33896059|NCT04154618|||COHORT||PROSPECTIVE|||||||
33979663|NCT01462214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979664|NCT02954757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979665|NCT03735758|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicentric, controlled, randomized, open Label, parallel-group, prospective||||
34077500|NCT05947604|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||"On Period 1, participants will receive: A single oral dose of Dextromethorphan on Day and of midazolam on Day 8.~On Period 2, participants will receive: A single oral dose of acoziborole on Day 12, of dextromethorphan on Day 14, and of midazolam on Day 21.~The study duration will be approximately 8 weeks:~Screening period before the first study drug administration, Period 1 with a hospitalisation period from the day before the first dose of dextromethorphan until 24 h after the first dose of midazolam, Wash-out period: 3 days, Period 2 with a hospitalisation period from the day before the single administration of acoziborole until 24 h after the last dose of midazolam .~End of study (EoS) visit between 7-10 days after last dose of midazolam on Period 2"||||
34077501|NCT02025283|||CASE_CONTROL||RETROSPECTIVE|||||||
33979666|NCT01667783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077502|NCT05105191|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077503|NCT06240117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979667|NCT05586009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33979668|NCT04277910|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, sequential parallel group|t|t|t|t
33979669|NCT03270293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979670|NCT04525248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896060|NCT05042245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979671|NCT02512666|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33979672|NCT01114464|||CASE_ONLY||PROSPECTIVE|||||||
33896061|NCT03730389|RANDOMIZED|PARALLEL||TREATMENT||NONE||External Physical Vibration Lithecbole(EPVL) for ureteral stone||||
33979673|NCT04588753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979674|NCT02475915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979675|NCT01099865|||COHORT||CROSS_SECTIONAL|||||||
33896062|NCT04596371|||COHORT||PROSPECTIVE|||||||
33896063|NCT01864044|||COHORT||PROSPECTIVE|||||||
33896064|NCT02651610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896065|NCT04740242|||COHORT||PROSPECTIVE|||||||
33896066|NCT06278259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979676|NCT00118053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979677|NCT04347291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigators use mail-in A1c kits for the primary outcome - hemoglobin A1c - and the lab analyzing these samples is masked to study description or participants' assigned condition.||f|f|f|t
33979678|NCT00188864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979679|NCT04849884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979680|NCT04761731|NA|SINGLE_GROUP||SCREENING||NONE||||||
33979681|NCT01282047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979682|NCT05268432|||COHORT||OTHER|||||||
33979683|NCT00379600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979684|NCT03209882|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33979685|NCT01217086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979686|NCT00001025||||TREATMENT||||||||
33979687|NCT00208988|RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
33979688|NCT05289713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979689|NCT03500692|||COHORT||PROSPECTIVE|||||||
33979690|NCT06144671|NA|SEQUENTIAL||TREATMENT||NONE||||||
33979691|NCT00751465|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33979692|NCT05718778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979693|NCT00678665|||CASE_CONTROL||PROSPECTIVE|||||||
33979694|NCT05978427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979695|NCT02912897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077504|NCT04346199|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study will consist of two arms Arm 1 is acalabrutinib + best supportive care or Arm 2 is best supportive care alone||||
34077505|NCT01114009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979696|NCT00160407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077506|NCT02511327|||CASE_CONTROL||PROSPECTIVE|||||||
34077507|NCT03069235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077508|NCT05722730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Initial assessments and assessments relating to clinical evolution will be conducted by an assessor blinded to treatment allocation. The evaluator will undergo an in-depth evaluation training program. An employee outside the research team will feed the computer database into secretly coded spreadsheets so that the independent statistician and researchers can analyze the data without having access to allocation information.|Randomized Clinical Trial involving participants, who have developed the severe form of COVID-19 and required at least 7 days of invasive mechanical ventilation. They will be previously randomized in a 1:1 ratio by electronic system and blindly allocated to the intervention group that will perform an exercise protocol based on the Pilates method, 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min. All patients will be evaluated before and after for six minutes walk distance test, peripheral and respiratory muscle strength and endurance, post-COVID-19 functional status, dyspnea, fatigue and quality of life. The analysis of the data obtained during the research was carried out by an independent statistician who had access to the coded data and were based on intention-to-treat principles.|t|t|t|t
34077509|NCT03614403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077510|NCT00976326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077511|NCT05995938|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Experimental|t|t|t|t
34077512|NCT06608121|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34077513|NCT01241708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077514|NCT04313517|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102984|NCT05519475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767512|NCT05406960|NA|SINGLE_GROUP||TREATMENT||NONE||"The gynecologist who decided if the participant met the selection criteria or not Participants meeting the selection criteria will be included in the study.~* Before starting all the included participants underwent a complete physical examination. Written informed consent will be obtained.~* The herbal tea infusion will be self-administrated by participants at home.~* Participants will receive training on how to make herbal tea infusions at home.~* Participants will be interviewed by the investigator of the study:~* To complete a quality-of-life questionnaire to determine the impact of the illness on their daily life.~* Pictorial Bleeding Assessment Chart (PBAC): The history of the last menstruation period~Participants will be asked to perform before starting the treatment :~* Complete blood count (CBC)~* Prothrombin Time (PT)~* Prothrombin ratio (INR)~* Fibrinogen (FIB) to detect bleeding disorders~* serum Creatinine to detect urinary toxicity"||||
33767513|NCT05817305|||COHORT||PROSPECTIVE|||||||
33767514|NCT01676532|||COHORT||PROSPECTIVE|||||||
33767515|NCT05393271|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind (sponsor unblinded) study.|This is a randomized and placebo-controlled study.|t|f|t|f
33767516|NCT00376441|||CASE_CONTROL||PROSPECTIVE|||||||
33767517|NCT04642586|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33767518|NCT00976469|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767519|NCT02069769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33767520|NCT04567693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767521|NCT00005881|||||CROSS_SECTIONAL|||||||
33767522|NCT01464021|||COHORT||PROSPECTIVE|||||||
33767523|NCT02308332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767524|NCT06017388|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767525|NCT06625697|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767526|NCT04498247|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
33767527|NCT01541618|||COHORT||PROSPECTIVE|||||||
33767528|NCT06523738|||COHORT||PROSPECTIVE|||||||
33767529|NCT05967676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Adaptation, validity and reliability||||
33767530|NCT02081456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767531|NCT03375580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767532|NCT06229704|||COHORT||PROSPECTIVE|||||||
33767533|NCT05545241|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767534|NCT02279147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767535|NCT02323347|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33767536|NCT02903277|||COHORT||PROSPECTIVE|||||||
33767537|NCT01028079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767538|NCT06087562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be randomized to one of two groups with a computer-generated arm assignment. The sealed envelopes will be opened immediately before the nerve block. One group will receive an iPACK block, and the other will receive a placebo block. The provider performing the league will not be blinded. However, all other care team members, the patient, and the investigator collecting data will be blinded to randomization.|Randomized, triple-blind, placebo-controlled|t|t|t|f
33767539|NCT05126459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767540|NCT03327402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767541|NCT01409681|||CASE_ONLY||PROSPECTIVE|||||||
33767542|NCT02703545|||CASE_CONTROL||PROSPECTIVE|||||||
33767543|NCT04942860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767544|NCT00742820|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767545|NCT04953013|||COHORT||RETROSPECTIVE|||||||
33767546|NCT02841267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767547|NCT05724264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767548|NCT04879758|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Group allocation will be concealed from study staff until the 7-day pre-intervention period begins (for preparation of corresponding e-leaflets, genetic risk estimates and/or baseline Fitbit step goal calculations), and from participants until the interventions are delivered. Given the nature of the interventions delivered, it will be impossible for participants to be blinded to the specific intervention they receive once the initial interventions are provided; however, study staff analyzing participants' de-identified data will remain blinded to participant randomization assignment.|parallel-group, open randomized controlled trial|f|f|t|t
33767549|NCT05722847|||COHORT||PROSPECTIVE|||||||
33767550|NCT00004438||||TREATMENT||||||||
33767551|NCT00715663|||COHORT||PROSPECTIVE|||||||
33767552|NCT02454036|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33767553|NCT04346056|||COHORT||RETROSPECTIVE|||||||
33767554|NCT04432532|||CASE_CONTROL||PROSPECTIVE|||||||
33767555|NCT02179372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767556|NCT00518128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767557|NCT03792321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||55 patients were divided in two groups. P group patients were receiving placebo throughout the first year of this study and T group patients were receiving testosterone. Both groups were receiving TRT throughout the second year.|t|f|t|f
33767558|NCT02851966|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767559|NCT00127972|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33767560|NCT01914809|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801285|NCT02622568|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801286|NCT01873326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801287|NCT03628235|||OTHER||PROSPECTIVE|||||||
33801288|NCT00573482|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33896067|NCT00840463|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33896068|NCT04527757|||COHORT||PROSPECTIVE|||||||
33767561|NCT05619510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The data collectors, interventionists, and investigator will be masked to which group participants belong to.|A wait list control group will be used for this study. Participants will be randomized to either the intervention group or the wait list control group. Participants in the intervention group will start the intervention immediately. Participants in the wait list control will start after 2-3 months.|f|f|t|t
33767562|NCT00005788||||TREATMENT||||||||
33767563|NCT00545350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33801289|NCT00006786||||TREATMENT||||||||
33896069|NCT04153630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896070|NCT01878565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896071|NCT01013727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33896072|NCT03332888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896073|NCT02158533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896074|NCT05511922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896075|NCT02388776|NA|SINGLE_GROUP||OTHER||NONE||||||
33896076|NCT03896425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896077|NCT04734873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896078|NCT01850810|RANDOMIZED|CROSSOVER||||NONE||||||
33896079|NCT04506424|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants will undergo a Flat Panel (high resolution) CT scan of the temporal bones, including the inner ear structures. The research team will make measurements of the cochleas from the CT scans, including cochlear duct length and depth of CI electrodes. The research team will generate custom frequency allocation tables to be used in the experimental programs for the CI.~Participants may have the experimental programs uploaded to their CI and use these programs to listen to speech and music stimuli and provide feedback. The participants may be asked to listen to these programs for acute and/or chronic periods of time. Participants may also have their performance on speech and music assessments measured using a clinical default program."||||
33896080|NCT05449353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801290|NCT06145984|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33801291|NCT03285386|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Participants will serve as their own controls. Participants will alternate between primed (experimental condition) and non-primed (control condition) in their visits."||||
33896081|NCT00459927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33896082|NCT04479761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We will have 3 groups: people with unilateral vestibular loss, people with single-sided hearing loss and controls. All groups will go through the same procedure.||||
33896083|NCT00206141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33896084|NCT04872725|||COHORT||PROSPECTIVE|||||||
33896085|NCT01491958|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33896086|NCT00986336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896087|NCT05782296|||COHORT||PROSPECTIVE|||||||
33896088|NCT02001012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896089|NCT05476796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896090|NCT00522860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077515|NCT04406922|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study design encompasses a single-arm randomized intervention study using cold exposure.||||
34077516|NCT02126215|||CASE_ONLY||PROSPECTIVE|||||||
34077517|NCT01808001|||||PROSPECTIVE|||||||
34077518|NCT05914818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077519|NCT04572776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Follow-up visit examinations will be performed by a blinded outcomes assessor.||f|f|f|t
34077520|NCT04639557|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit a group of mother-child dyads in which the mother meets the current criteria for major depressive disorder. Mothers will be randomly assigned to one of two intervention arms, which will occur concurrently over 16-weeks. Both arms incorporate intervention materials from Dialectical Behavior Therapy (DBT) and parent skills training.||||
34077521|NCT02958371|NA|SINGLE_GROUP||||NONE||||||
34077522|NCT02187549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077523|NCT01533116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077524|NCT02288819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077525|NCT03718429|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed investigation will be a prospective PD (pharmacodynamic) study conducted in cohorts of patients with CAD, PAD, or atrial fibrillation||||
34077526|NCT05515133|||COHORT||PROSPECTIVE|||||||
34077527|NCT01063855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077528|NCT00076037|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34077529|NCT00004002||||TREATMENT||||||||
34077530|NCT04611841|||COHORT||CROSS_SECTIONAL|||||||
34077531|NCT04578704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient will be decided for the type of retention treatment by picking an opaque and sealed envelope.~The participants study models will be examined and assigned with a blinding code by first researcher , who will be blinded to the subjects' retainer allocation. Patients name on the printed radiograph will also be removed. Therefore,the first researcher will be blinded to those she will be measuring. The blinding code will be prepared by second researcher before first researcher measure the casts and radiographs."|"This study will be encompassed 3 groups of patients that will be assigned for 3 types of retention methods;~1. VFR (upper and lower arches)~2. Fixed bonded retainers (upper and lower arches)~3. Double regime (bonded retainers \& VFR for upper and lower arches). (Abd Rahman 2016)"|t|f|f|t
34077532|NCT03207789|||COHORT||CROSS_SECTIONAL|||||||
34077533|NCT01062308|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34077534|NCT01328470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077535|NCT03380871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077536|NCT03573596|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2, multicenter study, prospective, open label, uncontrolled.||||
34077537|NCT04030169|NA|SINGLE_GROUP||TREATMENT||NONE|This study will be open label|Examining safety and effects of two sessions of MDMA-assisted psychotherapy, with Clinician-Administered PTSD Scale for DSM 5 (CAPS-5) severity after treatment compared with baseline||||
34077538|NCT03892226|||COHORT||PROSPECTIVE|||||||
34077539|NCT01449669|||COHORT|||||||||
34077540|NCT03414853|||COHORT||PROSPECTIVE|||||||
34077541|NCT00908271|NA|SINGLE_GROUP||||NONE||||||
34077542|NCT06325436|||COHORT||PROSPECTIVE|||||||
34077543|NCT00689338|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102985|NCT06688188|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801292|NCT05984212|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Investigator prepared the drug and participant and outcomes assessor were blind to the group allocation|Double blind randomized controlled trial|t|t|t|t
33801293|NCT00856739|||ECOLOGIC_OR_COMMUNITY|||||||||
33801294|NCT03068624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801295|NCT00760136|||CASE_ONLY||RETROSPECTIVE|||||||
33801296|NCT01872078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33801297|NCT01449617|||CASE_ONLY||PROSPECTIVE|||||||
33801298|NCT00006198||||TREATMENT||NONE||||||
33801299|NCT00205179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801300|NCT03052335|NA|SINGLE_GROUP||SCREENING||NONE||||||
33801301|NCT03692780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801302|NCT04045782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801303|NCT02711865|||CASE_CONTROL||PROSPECTIVE|||||||
33801304|NCT06516809|||COHORT||RETROSPECTIVE|||||||
33801305|NCT01125124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801306|NCT05079126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801307|NCT05877807|||CASE_CONTROL||PROSPECTIVE|||||||
33801308|NCT03918967|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33801309|NCT05443685|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33801310|NCT05894252|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There are 2 groups (i) walking intervention (ii) control group.||||
33801311|NCT00632749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801312|NCT02769819|NA|SINGLE_GROUP||OTHER||NONE||||||
33801313|NCT06267690|||COHORT||RETROSPECTIVE|||||||
33801314|NCT01955226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33801315|NCT01596933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33801316|NCT05235178|||COHORT||PROSPECTIVE|||||||
33801317|NCT02318901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801318|NCT05209477|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896091|NCT03767569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
33896092|NCT01828827|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767564|NCT04116944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator was blinded to participant allocation, and the analyses were performed blinded to group. Participants' individual identification numbers assigned at baseline were used during the course of the trial. Following full data extraction from SurveyMonkey.com, identifying information were removed, such that no participant could be identified in the working dataset through one, or a combination of different variables.|Two parallel, randomized controlled trials of an eight-week resistance exercise training intervention compared to a wait-list control condition among young adults with and without analogue-Generalized Anxiety Disorder|f|f|t|t
33767565|NCT01598402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767566|NCT03270813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33767567|NCT03607513|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33767568|NCT05124834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896093|NCT02782715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896094|NCT03088579|||COHORT||PROSPECTIVE|||||||
33896095|NCT02141061|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33896096|NCT02900092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896097|NCT00920543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896098|NCT03658889|||CASE_ONLY||CROSS_SECTIONAL|||||||
33896099|NCT02850796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33896100|NCT03540823|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896101|NCT00000899||||TREATMENT||||||||
33896102|NCT01259466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896103|NCT02795234|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33896104|NCT04902885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767569|NCT05970380|||CASE_CROSSOVER||PROSPECTIVE|||||||
33767570|NCT06445387|RANDOMIZED|PARALLEL||OTHER||SINGLE|It is a randomized controlled, single-blind, experimental study.|It is a randomized controlled, single-blind, experimental study. Participants were assigned to three groups: intervention (virtual reality group and ice group) and control group.|f|f|f|t
33767571|NCT04032379|||COHORT||PROSPECTIVE|||||||
33767572|NCT02779023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767573|NCT03813628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767574|NCT03340558|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33767575|NCT00790920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767576|NCT06026319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767577|NCT06205641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767578|NCT00366301|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33767579|NCT01024959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767580|NCT05883917|NA|SINGLE_GROUP||TREATMENT||NONE||Gait training using SUBAR® (Cretem, Korea) proceeded by adjusting parameters (gait speed, step length, and degree of knee flexion) according to the patient's leg length and gait function. The parameters were set to the maximum levels tolerated by the patient. The patients underwent 30 min of robot-assisted training using SUBAR® with 30 min of conventional physiotherapy, 5 days a week for 12 weeks.||||
33767581|NCT06320873|NA|SINGLE_GROUP||OTHER||NONE||||||
33767582|NCT04699227|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33767583|NCT03875079|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767584|NCT05782205|||COHORT||RETROSPECTIVE|||||||
33767585|NCT04939636|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Computed randomization will be used to divide conscripts into two groups; the intervention group, who received vitamin D3 capsules (4000 IU/100µg) or the intervention group, who received vitamin D3 capsules (600 IU/15µg)~."|Triple blinded randomized placebo-controlled study|t|t|t|f
33767586|NCT02757222|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a radiation dose escalation study.||||
33767587|NCT03145467|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33767588|NCT05266105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33767589|NCT01526811|||COHORT||PROSPECTIVE|||||||
33767590|NCT04855292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767591|NCT02490618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767592|NCT05603988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767593|NCT03183583|||COHORT||RETROSPECTIVE|||||||
33767594|NCT02387437|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767595|NCT03975426|||COHORT||RETROSPECTIVE|||||||
33767596|NCT06251037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767597|NCT04109638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767598|NCT02875301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Study participants will be randomly assigned to one of three exercise intervention arms.|f|f|t|t
33767599|NCT02626221|||COHORT||PROSPECTIVE|||||||
33767600|NCT02056821|||COHORT||PROSPECTIVE|||||||
33767601|NCT03075956|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767602|NCT01274065|||COHORT||PROSPECTIVE|||||||
33767603|NCT00004585||||TREATMENT||||||||
33767604|NCT02031120|||COHORT||PROSPECTIVE|||||||
33767605|NCT04002219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A triple-blind, randomized-controlled trial|t|t|t|t
33767606|NCT02926235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767607|NCT00584701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767608|NCT00068874|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33896105|NCT04292600|||COHORT||PROSPECTIVE|||||||
33896106|NCT03420677|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33896107|NCT03289715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33896108|NCT00583739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896109|NCT05176678|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33896110|NCT00679107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896111|NCT01186653|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896112|NCT01357239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979697|NCT03450564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The study was masked to the participants in which they don't disclose the type of intervention.|The cluster randomized controlled trail will be designed to enhance family planning (FP) utilization in pastoralist community. An integrated behavioral model was used to guide the intervention. It has three arm and these are two community-based intervention and one control group and it was carried out for 9 months. Baseline and end line data was collected. The package of health education message was given to the married women of both arm (women and male involvement) arm and men in the male arm. Different modality was used in the men and women arm. These are involving faema leader, use of audiovisual materials of role model person in the community and providing training for health extension workers (HEW) and health care provider to assist for the faema leader.|t|f|f|f
34102986|NCT06171737|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|There is limited blinding in the trial due to the pragmatic focus and batched stepped wedge design. Patients will be told that the study is testing different types of decision support and while they will not be blinded to the materials they receive, they will not know what materials other patients receive. Clinicians and staff will be involved in delivery of the decision aids and will not be blinded to the study arm. Research staff entering survey data and conducting chart review will not be given any explicit information about study assignment; however, it is likely that they will have a sense for the arm due to the timing. The statistician conducting analyses will be blinded to group assignment at each step. For the clinician survey, we will use computer generated random assignment to select one specialist (either interventional cardiologist or cardiac surgeon) to receive the post-visit survey for each patient participant.||t|f|f|t
33767609|NCT05774899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767610|NCT01263106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767611|NCT05245604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767612|NCT02309177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767613|NCT05183217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767614|NCT03361787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767615|NCT01230606|||CASE_CONTROL||PROSPECTIVE|||||||
33767616|NCT00294216|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33767617|NCT04944394|||COHORT||PROSPECTIVE|||||||
33767618|NCT02538770|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767619|NCT02276391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767620|NCT02771730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33767621|NCT04885387|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767622|NCT04190147|||COHORT||PROSPECTIVE|||||||
33767623|NCT03707444|||COHORT||PROSPECTIVE|||||||
33767624|NCT05712161|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A prospective, non-randomized, single-arm, multi-center study||||
33767625|NCT05962593|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33767626|NCT06167629|||COHORT||PROSPECTIVE|||||||
33767627|NCT05971160|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33767628|NCT02881008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767629|NCT05342103|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomly allocated into two groups; patients will receive high-flow nasal oxygenation via nasal cannula (HFNC) or continuous positive airway pressure (CPAP)||||
33767630|NCT02149602|||COHORT||PROSPECTIVE|||||||
33767631|NCT02451501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767632|NCT03221504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33767633|NCT03837392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767634|NCT02695602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767635|NCT01454453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767636|NCT04500639|||CASE_CONTROL||PROSPECTIVE|||||||
33767637|NCT02267720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767638|NCT05362682|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34102987|NCT06690112|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label Randomized controlled study||||
33767639|NCT02676752|||CASE_ONLY||CROSS_SECTIONAL|||||||
33767640|NCT05158478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767641|NCT05226260|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33767642|NCT04227496|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33767643|NCT01597505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767644|NCT01455792|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767645|NCT04219618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767646|NCT02145416|||COHORT||PROSPECTIVE|||||||
33767647|NCT00119262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767648|NCT02411305|||COHORT||PROSPECTIVE|||||||
33767649|NCT02215733|||COHORT||RETROSPECTIVE|||||||
33767650|NCT01411722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767651|NCT05929508|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33767652|NCT04702880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767653|NCT00278382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767654|NCT03344822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Even if the study has only one arm, the results of both PET imageries will be blind assessed.|Each patient will realize a 18F-Choline PET/CT then a 68Ga-PSMA-11 PET/CT||||
33767655|NCT04676126|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A remotely located Guardion Health Sciences designee will utilize a computer-generated random number table to assign patients to placebo or experimental group. Subjects will have the supplement/placebo delivered to their homes in identical (except lot number) packaging.|This is a prospective double-masked, randomized controlled study which compares pre- supplementation macular pigment optical density, contrast sensitivity, dermal carotenoid levels, and visual field status to post-supplement measurements of the same.|t|t|t|f
33767656|NCT00642629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767657|NCT03562546|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767658|NCT05112211|NA|SINGLE_GROUP||SCREENING||NONE|Assessors who calculate the changes of the images are masked of the diagnosis and treatment.|Patients diagnosed by Thyroid-Associated Ophthalmopahty||||
33767659|NCT06319768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767660|NCT03839186|||CASE_ONLY||PROSPECTIVE|||||||
33767661|NCT03330951|||COHORT||PROSPECTIVE|||||||
33767662|NCT06286540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33767663|NCT00745628|||COHORT||PROSPECTIVE|||||||
33896113|NCT03980093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33896114|NCT04632199|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33896115|NCT06009614|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
33896116|NCT05651087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896117|NCT01882725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896118|NCT04090164|||CASE_CONTROL||RETROSPECTIVE|||||||
33896119|NCT00364260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896120|NCT03501212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721166|NCT04234282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will be randomly assigned using a random number generator to either the control or treatment group. The investigator and outcome assessor will not be present when the patient is receiving the control or treatment interventions. Pt will be instructed not to reveal which group they were assigned to when tested by the blinded assessor.|Randomized Controlled Trial|f|f|t|t
33721167|NCT05478447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721168|NCT03284164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Tenofovir exalidex (TXL)||||
33767664|NCT06488183|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33767665|NCT05426382|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center single-arm open label intervention study||||
33896121|NCT03744689|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33896122|NCT04246047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896123|NCT01111071|||||PROSPECTIVE|||||||
33896124|NCT01362322|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33896125|NCT03512847|||COHORT||PROSPECTIVE|||||||
33896126|NCT05355012|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"In order to evaluate the effectiveness of 5A-QUIT-N, we will conduct a trial in New Aquitaine using a mixed quantitative and qualitative method.~The quantitative study is a stepped-wedge cluster randomized trial (SWCRT) with a transition phase (deployment). The duration of each period is set at 3 months."||||
33896127|NCT02261623|||COHORT||PROSPECTIVE|||||||
33896128|NCT03883893|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Clinical research coordinator, parent and participant will be masked until participant is discharged from hospital. OR staff will not be masked.||t|f|t|f
33979698|NCT06254248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979699|NCT00128453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979700|NCT01991470||SEQUENTIAL||TREATMENT||NONE||||||
33979701|NCT03255109|||COHORT||PROSPECTIVE|||||||
33979702|NCT03489759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|"The randomization list will be kept in a special lockable closet, not accessible to the other investigators involved in the study. The one who will create the list will not be involved in any other role in the present study.~The filter label, and hence the name, will be covered by a white covering label. Each kit of filters needed to perform a single treatment will be prepared in a closed box and the patient number will be written on it, so that the user who performs the treatment will not be able to understand which filter it is.~All the other investigators involved in the present study (nurses in the Nephrology department who will follow the treatment, the researchers who will collect the clinical data, the biologists who will analyze the samples and the statisticians who will analyze the data) will not know which filter has been applied in each treatment."||t|t|t|t
33979703|NCT04883801|||CASE_CONTROL||RETROSPECTIVE|||||||
33979704|NCT03677648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979705|NCT04355455|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33979706|NCT05163951|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, parallel, open, non-inferior randomized controlled trial||||
33979707|NCT00063206||||TREATMENT||||||||
33979708|NCT00093925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979709|NCT04433910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979710|NCT00166842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896129|NCT04612088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be blindly randomized to one of the two groups and the Cognitive Dissonance doses will be given by two Psychology undergraduate students that are not part of the research team.|randomized controlled trial|t|f|t|t
33896130|NCT00650585|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33896131|NCT05375981|||COHORT||PROSPECTIVE|||||||
33979711|NCT00638599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979712|NCT06217653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the study, the researcher and statistician who collected the data were blinded due to the nature of the study. In the data, groups were coded as groups A and B, and only the non-blind researcher who collected the data knew which group was the intervention or control.|The study is of the randomized controlled type.|f|f|t|f
33979713|NCT04265365|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33979714|NCT00257712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979715|NCT04551638|||COHORT||CROSS_SECTIONAL|||||||
33979716|NCT05258942|||COHORT||PROSPECTIVE|||||||
33979717|NCT05364957|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomly assigned either to the group treated with IGB combined with diet and exercise or the group treated with diet and exercise alone.||||
33979718|NCT05473052|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979719|NCT04981899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979720|NCT01127022|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33979721|NCT02451605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979722|NCT04942756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979723|NCT01314690|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
34102988|NCT04279769|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34102989|NCT05901597|||COHORT||PROSPECTIVE|||||||
33721169|NCT02632552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33721170|NCT04565301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33721171|NCT05873647|||COHORT||PROSPECTIVE|||||||
33721172|NCT00129493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721173|NCT01014429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721174|NCT03014323|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34102990|NCT04486677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The current study is a single-site, 2-year pilot trial that employs an open-trial, pre/post research design. This study's primary aim is to establish the feasibility and acceptability of Caring Cards for Veterans, a peer-centered intervention that facilitates suicide prevention and social connectedness.||||
33767666|NCT04380337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767667|NCT00423293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102991|NCT00978185|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33767668|NCT01998594|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767669|NCT02145078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767670|NCT00049998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767671|NCT01662531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767672|NCT06416683|||COHORT||RETROSPECTIVE|||||||
33767673|NCT00960674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767674|NCT02929550|||COHORT||PROSPECTIVE|||||||
33767675|NCT01051063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767676|NCT05833243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinded, only the investigator was blinded, using a randomization center for concealment.|Intervention Group (modified diaphragmatic training) and control group (standard diaphragmatic training)|f|f|t|f
33767677|NCT04248842|||COHORT||PROSPECTIVE|||||||
33767678|NCT00004924||||TREATMENT||||||||
33767679|NCT00764192|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767680|NCT00562978|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33767681|NCT05082142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767682|NCT04944030|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767683|NCT04378660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767684|NCT00885989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767685|NCT05278052|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, Open-label, Randomized controlled trial,||||
33767686|NCT05146960|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33767687|NCT04147182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767688|NCT02184546|||COHORT||PROSPECTIVE|||||||
33767689|NCT04479605|||COHORT||PROSPECTIVE|||||||
33767690|NCT03108729|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33767691|NCT06023004|||CASE_CONTROL||PROSPECTIVE|||||||
33979724|NCT05875337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|In the study, a researcher (F.E.Ö.) will determine the acupressure and placebo points to be applied to the patients. However, the certified researcher (T.Ç.Y.) who will perform the acupressure and placebo application will perform the application without knowing whether these points are acupressure or placebo points and will be blinded. The participants will not know whether they are in the acupressure or placebo acupressure group. Thus, the research will be carried out as a double-blind randomized controlled trial. When the research is completed, the data of the acupressure and placebo acupressure groups (coded as A or B) will be transferred to the computer environment by a researcher independent of the research, and the data will be analyzed and reported by a statistician using blinded technique.|Double-blind randomized controlled experimental trial|t|t|f|t
33979725|NCT00154180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33979726|NCT03221374|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33979727|NCT01440283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767692|NCT02721641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767693|NCT03918954|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767694|NCT03484806|||COHORT||PROSPECTIVE|||||||
33767695|NCT04257305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767696|NCT00101335|RANDOMIZED|||PREVENTION||DOUBLE||||||
33767697|NCT04855110|RANDOMIZED|PARALLEL||TREATMENT||NONE||114 pregnant women with mechanical prosthetic mitral and/or aortic valves, will be divided equally into 2 groups.Using a table of random numbers, participants will be divided into 2 equal groups. Group A (57 patients) in which warfarin will be started day 2 after caesarean delivery (i.e. 24 hours postoperative), and group B (57 patients) in which warfarin will be started day 5 after caesarean delivery.||||
33767698|NCT03962569|||CASE_ONLY||PROSPECTIVE|||||||
33767699|NCT05437822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be allocated into two groups based on randomized 20-block method by an independent assistant using computer generated randomization|"All patients will be treated surgically with an internal fixation or arthroplasty. The two patient groups will include: 1) Study group treated with topic tranexamic acid infused in shoulder joint; 2) Control group with no drug treatment.~Blood transfusion criteria will remain consistent with hospital standards. Deep vein thrombosis (DVT) prophylaxis will remain consistent with hospital standards (subcutaneous heparin from admission until 12 hours prior to surgery and beginning 6 hours after surgery).~Patients will be followed 30 days"|t|f|f|t
33767700|NCT00318149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767701|NCT02340754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33767702|NCT04249219|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33767703|NCT01356667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767704|NCT06438419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767705|NCT00402545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767706|NCT04932005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33767707|NCT02827942|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of the dual VPZ/AMPC therapy and triple VPZ/AMPC/CAM therapy||||
33767708|NCT01829074|||COHORT||PROSPECTIVE|||||||
33767709|NCT05594849|||COHORT||PROSPECTIVE|||||||
33767710|NCT03141710|NA|SINGLE_GROUP||OTHER||NONE||20ml of prebiotic per day for 12 weeks||||
33767711|NCT03609554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767712|NCT00098163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767713|NCT01486602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767714|NCT01798186|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants are blind to the THC concentrations of cannabis being administered|Between subjects Phase I study|t|f|f|f
33767715|NCT02461927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801319|NCT01159275|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33801320|NCT04261231|||COHORT||PROSPECTIVE|||||||
33801321|NCT02901197|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33801322|NCT04452513|||COHORT||PROSPECTIVE|||||||
33896132|NCT05713955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible patients will be randomized in a 1:1 allocation to either the autologous BioMatrix OBSiDiAN group (study group) or the standard of care group (control group). Subjects will be randomized at the ending of the abdominal phase of the surgery. In the event, that a potential subject fails the intra-operative criteria, an intention-to-treat protocol is followed. Given the nature of the study, blinding the surgeon to the treatment is not possible. The patient will be blinded for the study.|"Design :~An international, multicentre randomized controlled trial evaluating the effectiveness and safety of autologous BioMatrix OBSiDiAN in reducing the incidence of anastomotic leaks following Ivor Lewis esophagectomy for oesophageal carcinoma.~Randomization :~Eligible patients will randomized in a 1:1 allocation to either the autologous BioMatrix OBSiDiAN group (study group) or the standard of care group (control group).~Procedure:~For both the control group and intervention group: A standard laparoscopic, robotic or open Ivor Lewis esophagectomy with an intrathoracic end-to-side stapled esophagogastric anastomosis.~For the intervention group: After the abdominal fase and randomisation, a 120 ml blood sample will be drawn from the patient and put in the Vivostat® processor unit to make Obsidian. At the time of the anastomosis Obsidian will be applied between and around the esophagogastric anastomosis"|t|f|f|f
33896133|NCT00148239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33896134|NCT00653315|RANDOMIZED|CROSSOVER||||NONE||||||
33979728|NCT03156764|||OTHER||PROSPECTIVE|||||||
33979729|NCT01775319|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33979730|NCT01734291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979731|NCT04266210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721175|NCT02268786|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33721176|NCT02484742|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33721177|NCT04341142|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896135|NCT01035151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896136|NCT02132221|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896137|NCT01565525|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33896138|NCT04219371|||COHORT||PROSPECTIVE|||||||
33896139|NCT01305369|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896140|NCT06118879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33896141|NCT04718090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33896142|NCT01466751|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33896143|NCT01217749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896144|NCT01006356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896145|NCT03455946|NA|SINGLE_GROUP||OTHER||NONE||||||
33896146|NCT01314365|||COHORT||PROSPECTIVE|||||||
33896147|NCT00011895||||TREATMENT||||||||
33896148|NCT06052462|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33896149|NCT05797766|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33896150|NCT06046560|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||One group of patients, upon randomization, will immediately begin participation in a remote, pharmacist-driven clinic that will initiate and titrate medications according to a standardized medical algorithm. The comparator group will first receive curated patient education, an alert to providers, and provider education, and then after 2 months begin participation in the remote clinic.||||
33896151|NCT03592862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Placebo controlled|t|f|t|f
33896152|NCT04579861|||COHORT||PROSPECTIVE|||||||
33896153|NCT04066621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896154|NCT00467844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33896155|NCT00691574|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33896156|NCT02128568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896157|NCT01442584|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33896158|NCT00883324|||CASE_CONTROL||PROSPECTIVE|||||||
33896159|NCT03361670|||CASE_ONLY||PROSPECTIVE|||||||
33896160|NCT03426969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896161|NCT01945892|||CASE_CONTROL||PROSPECTIVE|||||||
33896162|NCT00674531|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33896163|NCT00800761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896164|NCT04176510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33896165|NCT02438930|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33896166|NCT05946252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a prospective randomized controlled study.|t|f|f|t
33896167|NCT01634243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979732|NCT05291871|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33979733|NCT03418441|||COHORT||PROSPECTIVE|||||||
33979734|NCT00262600|RANDOMIZED|PARALLEL||PREVENTION||||||||
33979735|NCT00236457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896168|NCT05619926|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896169|NCT02339714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896170|NCT02571413|RANDOMIZED|PARALLEL||||NONE||||||
33896171|NCT03086850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896172|NCT05817201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721178|NCT00560950|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896173|NCT05252312|||OTHER||PROSPECTIVE|||||||
33896174|NCT06217406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896175|NCT01923610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896176|NCT02171715|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896177|NCT00968734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896178|NCT05174715|||COHORT||RETROSPECTIVE|||||||
33896179|NCT04453644|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33721179|NCT01395160|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721180|NCT05581537|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33721181|NCT01163487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721182|NCT00456131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721183|NCT02386904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721184|NCT00775970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33721185|NCT05383300|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Double-blinded- participant and investigator.|Double-binded placebo-controlled crossover trial|t|t|t|f
33721186|NCT04405648|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721187|NCT00565968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896180|NCT00480428|||||RETROSPECTIVE|||||||
33896181|NCT02062086|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896182|NCT01789879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896183|NCT03908632|||CASE_CONTROL||PROSPECTIVE|||||||
33896184|NCT05647213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896185|NCT02417623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896186|NCT02615301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896187|NCT00564928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979736|NCT02498964|||OTHER||PROSPECTIVE|||||||
33979737|NCT05666583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33979738|NCT01616732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979739|NCT05071937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979740|NCT01471405|||COHORT||RETROSPECTIVE|||||||
33979741|NCT04604704|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive LDN and NAD+ treatment for 12 weeks. The researchers will assess fatigue and quality of life using validated surveys. Surveys will be conducted at baseline (at time of enrollments, before treatment), and at 2, 4, 8, and 12 weeks. Improvement of scores from baseline levels will be determined.||||
33979742|NCT03237364|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979743|NCT02429271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979744|NCT03344081|||COHORT||CROSS_SECTIONAL|||||||
33979745|NCT05188937|NA|SINGLE_GROUP||PREVENTION||NONE||Cross-Sectional||||
33979746|NCT04066361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979747|NCT03799666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979748|NCT01654107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979749|NCT04875065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979750|NCT00714103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979751|NCT04458649|||COHORT||PROSPECTIVE|||||||
33979752|NCT05473169|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33979753|NCT01720082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979754|NCT02166697|||COHORT||PROSPECTIVE|||||||
33979755|NCT04908748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Packages of Investigative Medicinal product will be non-distinguishable to patients, study site staff and monitors.~Randomization data are kept strictly confidential, accessible only to authorized persons, until the time of unblinding the identity of the treatments will be concealed by the use of study drugs that are all identical in packaging, labeling, schedule of administration, appearance and odor.~Unblinding will only occur in the case of patient emergencies and at the conclusion of the study."|Randomized, controlled, double-blind, multi-center|t|t|t|t
33979756|NCT03194464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, repeated measures||||
33979757|NCT03165565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979758|NCT01365962|||CASE_ONLY||RETROSPECTIVE|||||||
33979759|NCT02946762|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33979760|NCT03501875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979761|NCT02576249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979762|NCT05048992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979763|NCT00001221||||TREATMENT||||||||
33979764|NCT01103505|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33979765|NCT05962554|RANDOMIZED|PARALLEL||OTHER||NONE||The two independent groups (intervention vs. waiting list control group) will be crossed with three measurement times (i.e., baseline, post-intervention, and 1-month follow-up). Hence, the design will be a 2 (intervention vs. control) X 3 (baseline, post-intervention, and 1-month follow-up) factorial design.||||
33979766|NCT02651441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979767|NCT05641909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979768|NCT03909516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979769|NCT02745899|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33979770|NCT03059862|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||All subjects will be following a standardized low-tryptophan diet and randomized to L-tryptophan supplements or placebo, for three weeks. After a 2 weeks washout period, subjects will crossover to the other arm.|t|t|t|t
34077544|NCT05119127|NA|SINGLE_GROUP||TREATMENT||NONE||Study will include adults (45 years and older) who plan to have cataract extraction and subsequent implantation of AcrySof® IQ Vivity™Extended Vision Toric IOL in at least one eye. Approximately 40 eye will be screened to identify 35 qualified eyes. Within 40 days of screening, qualified subjects will receive cataract surgery followed by implantation of the AcrySof® IQ Vivity™Extended Vision Toric IOL at the surgery visit. If the second eye will participate in the study, subjects will receive the second eye cataract surgery within 60 days of the Screening visit 0. Four postoperative follow up visits are planned to occur at 1-2 days, 7-14 days, and 28-35 days for each enrolled eye. Subject participation in this study is expected to last up to 2 months, including a total of 5 study visits for subjects implanted in one eye and up to 9 visits for subjects implanted in both eyes. Upon completion of the 35 day follow up visit subjects will be exited from the study.||||
33979771|NCT02494765|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33979772|NCT02548507|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33979773|NCT02923947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979774|NCT03564548|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33979775|NCT02696681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979776|NCT01074554|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33979777|NCT03377400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979778|NCT02208726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979779|NCT00285636|||CASE_ONLY||PROSPECTIVE|||||||
33979780|NCT04284488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979781|NCT04607239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The interventional group (Telemonitoring) in addition to the usual care group (conventional) will benefit from:~* a weekly telephone call for collection of home Blood Pressure measurements , therapeutic education \& treatment compliance check~* a monthly call for treatment titration and side effects check"|f|f|f|t
33979782|NCT02799797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34025587|NCT04249869|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Placebo is manufactured to have the same appearance as VGH-AD1. Both VGH-AD1 and placebo will be coded as packages A and B by the manufacturer and the codes will only be revealed after the study ends. Therefore, patients and investigators will both be blinded.|28 participants will be recruited from the Division of Psychiatry and Neurology in a Medical Center. They will be randomized allocated into treatment and control groups, each including 14 participants. After eight weeks of taking, there is two-weeks of wash-out period. And then two groups will be switched for another eight weeks. Post-study follow up will be 4 weeks later once the intervention end. The study duration is totally 22 weeks.|t|t|t|f
34025588|NCT04701164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077545|NCT00861666|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34077546|NCT05184348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077547|NCT03161730|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34077548|NCT02315144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077549|NCT00874185|||COHORT||PROSPECTIVE|||||||
34077550|NCT03327324|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34077551|NCT00448214|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077552|NCT04654715|||CASE_ONLY||RETROSPECTIVE|||||||
34077553|NCT04033978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants don't know the select group.|Parallel Assignment|t|f|f|f
34077554|NCT00765856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077555|NCT00205114|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34077556|NCT01999985|NA|SEQUENTIAL||TREATMENT||NONE||||||
34077557|NCT00228228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077558|NCT01089283|||COHORT||PROSPECTIVE|||||||
34077559|NCT00002293||||TREATMENT||||||||
34077560|NCT04967807|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|None (Open Label)|The study population will include 2 cohorts of patients post COVID-19 vaccination. Cohort A) symptomatic patients with clinical signs or symptoms suggestive of myocardial injury and Cohort B) asymptomatic patients without symptoms suggestive of myocardial injury who have had prior cardiac MRI.||||
34077561|NCT02830412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34077562|NCT03669549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077563|NCT03924388|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Project 1 and 2: This multi-site open-label exploratory clinical trial (phase IIb) on examination of the effects of non-invasive transcutaneous spinal cord stimulation will take place at University of Calgary and the University of British Clombia, Canada. In a pseudo-randomized controlled 2×2 between-subject factorial design.~Project 3: This is a multi-site open-label case study exploring the effects of invasive epidural spinal cord stimulation on small number of individuals with SCI who underwent epidural implantation in Canada or abroad."||||
34077564|NCT03832647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|100 subjects per arm|t|f|t|f
34077565|NCT00449631|||||OTHER|||||||
34077566|NCT05704855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will only be aware that the researchers are comparing two exercise conditions and therefore will be blinded to the study hypotheses.|Participants will be randomized to one of two conditions: combined exercise (aerobic + resistance training) or stretching/toning (active control). They will receive a home-based program lasting 1 hour on 3 days per week for 12 weeks. Randomization will be performed using a computer-generated program in blocks of four for even distribution between study conditions. BCS will be assigned in a 1:1 ratio to one of two study conditions, stratified by treatment type (anthracycline vs. non-anthracycline chemotherapy; hormonal vs. no hormonal therapy).|t|f|f|f
34077567|NCT03217552|||COHORT||PROSPECTIVE|||||||
34077568|NCT02727049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077569|NCT05237115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077570|NCT03502538|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||This is a study designed where all the participants will have to try the two devices that were being tested.|t|f|t|f
34077571|NCT01142934|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077572|NCT05636709|||OTHER||PROSPECTIVE|||||||
34077573|NCT03898193|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participants and the investigator will not be blinded towards the identity of the study products. However, bioanalytical laboratory will be blinded towards identity of the study products administered.||f|f|f|t
34077574|NCT02089048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077575|NCT03590171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077576|NCT00938353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077577|NCT05794815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077578|NCT00606307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077579|NCT00308789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077580|NCT06467604|||COHORT||PROSPECTIVE|||||||
34077581|NCT04144959|||COHORT||PROSPECTIVE|||||||
34077582|NCT05553873|||COHORT||OTHER|||||||
34077583|NCT05429671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077584|NCT06090968|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34077585|NCT01591798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077586|NCT04483466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"* In the treatment group, participants will receive methotrexate 15mg by mouth/week with optional for increase up to 20mg/week in non-responders and folic acid 1mg by mouth daily for six months in Phase I.~* In the control group, participants will receive placebo methotrexate tablets by mouth/week with faux increase optional in non-responders and folic acid 1mg by mouth daily for six months in Phase I.~* In Phase II, any patient may elect to stop taking the study drug or transition to open label active treatment group for the following six months if non-responder."|t|f|t|f
34077587|NCT00877318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077588|NCT04987463|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Triple||t|f|t|f
34077589|NCT02752672|||OTHER||PROSPECTIVE|||||||
34077590|NCT03800316|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34077591|NCT00632567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077592|NCT05923918|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34077593|NCT02221648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077594|NCT01252771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077595|NCT06122389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR2554 control Chidamide was randomly assigned to either the test group or the control group in a 1:1 ratio|t|t|t|t
34077596|NCT00006329|RANDOMIZED|||TREATMENT||||||||
34077597|NCT05861414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077598|NCT02365935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077599|NCT01804517|||CASE_CONTROL||PROSPECTIVE|||||||
34077600|NCT02717728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34077601|NCT01223404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Only the statistician performing the randomization and the pharmacist dispensing the drugs were aware which drug was given on which day.||t|f|t|t
34077602|NCT03198845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34077603|NCT00510341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077604|NCT00914225|||COHORT||PROSPECTIVE|||||||
34077605|NCT04009603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077606|NCT01056393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077607|NCT01701544|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34077608|NCT00393666|||CASE_CONTROL||PROSPECTIVE|||||||
34077609|NCT04754893|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077610|NCT00947310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077611|NCT04777058|||COHORT||PROSPECTIVE|||||||
34077612|NCT04113941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077613|NCT04520217|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34077614|NCT02571556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077615|NCT00358696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077616|NCT01214993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077617|NCT06378424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34077618|NCT04608071|||CASE_CONTROL||PROSPECTIVE|||||||
34077619|NCT05897671|||COHORT||RETROSPECTIVE|||||||
34077620|NCT02972983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077621|NCT02317991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077622|NCT03006237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077623|NCT01878903|||CASE_ONLY||PROSPECTIVE|||||||
34077624|NCT06332196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients diagnosed with non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL) aged and patients with previous lymphoma and signs of immunodeficiency||||
34077625|NCT03041662|||COHORT||PROSPECTIVE|||||||
34077626|NCT04776928|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34077627|NCT03108612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The care providers that administer the index test and the EPT assessment are not masked. However, the outcomes assesors of the EPT (gold standard) are masked to the results of the WAI (index test). The adminstrators of the WAI are unaware of the EPT result, as this evaluation is conducted after the application of the index test.|Participants are enrolled consecutively in the occupational health care clinic. After signing the informed consent form, the evaluators administer the index diagnostic test (WAI). Subsequently, the study participants are referred to the gold standard (EPT). Study participants, WAI evaluators and EPT evaluators are blinded to the results of the other test.||||
33721188|NCT02085187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721189|NCT05744947|||COHORT||RETROSPECTIVE|||||||
33721190|NCT03208842|||COHORT||PROSPECTIVE|||||||
34077628|NCT03228641|NA|SINGLE_GROUP||TREATMENT||NONE|subject is blinded to the needle gauge and density of treatment|||||
34077629|NCT00582348|||CASE_ONLY||RETROSPECTIVE|||||||
34102992|NCT06067334|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33721191|NCT03667365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721192|NCT00855998|||FAMILY_BASED||PROSPECTIVE|||||||
33801323|NCT03578198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801324|NCT01510067|||COHORT||PROSPECTIVE|||||||
33721193|NCT02428946|RANDOMIZED|CROSSOVER||||NONE||||||
33721194|NCT00534274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721195|NCT05566990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801325|NCT04761536|||CASE_CONTROL||RETROSPECTIVE|||||||
33801326|NCT00086775|RANDOMIZED|||TREATMENT||NONE||||||
33801327|NCT00445315|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33801328|NCT01579968|||COHORT||PROSPECTIVE|||||||
33801329|NCT02700516|||CASE_CONTROL||RETROSPECTIVE|||||||
33801330|NCT02538458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801331|NCT05439317|||OTHER||PROSPECTIVE|||||||
33801332|NCT01879189|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33801333|NCT01306500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801334|NCT01837940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801335|NCT04698655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33801336|NCT03220100|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33767716|NCT04078035|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Samples of plasma and serum will be identified by participant identification number only. Technicians assessing levels of biological measures in these samples will be blind to condition.|The investigators propose a crossover experimental trial examining physiological responses to a socio-evaluative speech task under laboratory conditions. Participants will be tested on two occasions separated by at least 1 month. On one occasion, participants will be exposed to the speech task. On the other occasion, participants will rest quietly for the same period of time with identical assessment in the absence of the stressor. Conditions will be counterbalanced in randomized starting order across subjects.|f|f|f|t
34025589|NCT06029179|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This research is a prospective randomized multicentric clinical trial in which 60 hemodialysis patients will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1.~* Group A: 40 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.~* Group B: 40 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks."||||
34025590|NCT04258033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025591|NCT01957735|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34025592|NCT00464438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025593|NCT04731792|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34025594|NCT01819610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025595|NCT03076580|||COHORT||PROSPECTIVE|||||||
33979783|NCT04602507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Once the participant consents, staff will collect relevant demographic and clinical data from the clinical chart and a consecutive code from 001 to 100 will be assigned to each in order of arrival. 100 vials of ivermectin or placebo will be stored in the pharmaceutical service with a randomly assigned number from 001 to 100. After placement of medical order, the qualified nursing staff will dispense ivermectin or placebo. Blinded study physicians will carry on daily medical evaluation. Neither the researchers collecting data nor the analyzers will be aware of the patients' treatment arm.~To achieve blinding, a certified pharmaceutical laboratory produced a placebo identical in color, physical form, sensory perception (appearance, smell, and taste), packaging, and labeling to ivermectin."|"Arm #1: 50 patients with routine care offered in the hospital plus ivermectin 400 µg/kg orally in a single dose.~Arm #2: 50 patients with routine care offered in the hospital plus placebo in a single dose."|t|t|t|t
33979784|NCT05757011|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33979785|NCT02276196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979786|NCT05627609|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33979787|NCT02003053|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33979788|NCT05146596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||1.Registered nurses who consciously have insomnia and ISI\>=9. 2. People who have clear consciousness, can understand and agree to participate in this research. 3. Registered nurses who have been on shifts in the past six months. 4. Have the same type of shift within the four weeks.||||
33979789|NCT02125266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979790|NCT00416481|||CASE_ONLY||PROSPECTIVE|||||||
33979791|NCT00623207|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979792|NCT01117610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979793|NCT01650922|||COHORT||RETROSPECTIVE|||||||
33979794|NCT04217447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||It's a prospective, randomized, double-blind, placebo controlled, parallel-group, multi-center study.|t|t|t|t
33979795|NCT04820803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomized double-blind pilot clinical trial (evaluator and patients) in patients with a diagnosis of COVID-19 and symptoms of the disease.|Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a bilateral contrast, 40 subjects in the first group and 40 in the second were required to detect a difference equal to or greater than 5 units. The common standard deviation is assumed to be 10 (12). A loss to follow-up rate of 20% has been estimated.|t|f|t|f
33979796|NCT03155984|||COHORT||PROSPECTIVE|||||||
33979797|NCT02931318|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33979798|NCT05399264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077630|NCT04064203|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||12 totally pancreatectomized patients and 12 healthy control subjects||||
33767717|NCT03965819|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|All products look identical in identical opaque capsules|Randomized, double-blind, placebo-controlled, cross-over|t|t|t|t
33979799|NCT03682562|||CASE_CONTROL||PROSPECTIVE|||||||
33979800|NCT05834283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979801|NCT00220337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025596|NCT02340052|||COHORT||PROSPECTIVE|||||||
34025597|NCT00530218|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34025598|NCT05754710|||COHORT||PROSPECTIVE|||||||
34025599|NCT01970800|NA|SINGLE_GROUP||OTHER||NONE||This study was changed to a retrospective chart review. There was no prospective component.||||
34025600|NCT01888770|||CASE_CONTROL||PROSPECTIVE|||||||
34025601|NCT04842786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Subjects will be randomly assigned to receive coconut oil or no treatment using a random number scheme after stratification for gestational age group|Randomized, single-blind, parallel group, controlled trial|f|f|f|t
34025602|NCT01596309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077631|NCT03487770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979802|NCT04700826|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individual patient, open-label, event driven RCT with 1:1 allocation to DOAC or no additional therapy (usual care). Choice of DOAC (apixaban, dabigatran, edoxaban or rivaroxaban) according to local practice||||
33979803|NCT04105881|||CASE_CONTROL||PROSPECTIVE|||||||
33979804|NCT01587222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979805|NCT03772483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Intervention Model: Split-mouth assignment||||
33979806|NCT03711409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are divided into soft tissue biased manual therapy group and conventional physical therapy group by two different hospitals||||
33979807|NCT01485965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979808|NCT01610466|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33979809|NCT04362397|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The investigator responsible for the statistical analysis will be blind to the groups.|Group A will receive training in the FoCo program and group B will be a waiting list group. After a period of one month, group B will receive training in FoCo and group A will be instructed to continue on their own to apply FoCo in their daily lives.|f|f|t|t
33979810|NCT02305966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33979811|NCT03083548|||COHORT||PROSPECTIVE|||||||
33979812|NCT04010799|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"Part I:~Randomised, double-blind, placebo-controlled, single-dose escalation, cross-over design in one cohort of CF patients and in one cohort of NCFB patients.~Part II:~Randomised, double-blind, placebo-controlled, repeated-dose, parallel-group design in one cohort of CF patients and in one cohort of NCFB patients."|t|t|t|t
33979813|NCT05617703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double blinded study. The participants will not be informed to which group they will be assigned. The operator will be blinded because the restorative procedures for both groups are the same, the outcome assessors will not be informed about the type of restoration they evaluate.|Participants will be randomly divided into two groups with a 1:1 allocation using computer generated randomization list (www.random.org).|t|t|t|t
33979814|NCT02195778|||||CROSS_SECTIONAL|||||||
33979815|NCT01636570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979816|NCT04071444|RANDOMIZED|PARALLEL||OTHER||SINGLE|The data of Intestinal Peristalsis in four quadrants were collected by a research assistant.|The participants were divided into experimental and control groups through block randomization.|t|f|f|f
33979817|NCT01492361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33979818|NCT01491581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33979819|NCT04590378|||COHORT||RETROSPECTIVE|||||||
33979820|NCT03273322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979821|NCT00918567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979822|NCT02407730|||COHORT||PROSPECTIVE|||||||
33979823|NCT02917902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979824|NCT01591174|||COHORT||PROSPECTIVE|||||||
33979825|NCT04034576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979826|NCT03062566|||COHORT||PROSPECTIVE|||||||
33979827|NCT05976399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individuals to be included in the study were listed on the computer according to their application order, and then a randomization process was employed to divide them into two groups: the manual lymph drainage group and the connective tissue massage group. Individuals with odd-numbered positions were assigned to the manual lymph drainage group, while individuals with even-numbered positions were assigned to the connective tissue massage group.|The study included forty individuals with migraine. Participants' neck pain was evaluated with the Neck Pain and Disability Scale, pressure perceptions and pain sensitivity with an algometer, quality of life with the Short Form-3, and headaches with a pain diary kept for 15 days before and after treatment. Then, the individuals were randomly divided into two as the manual lymph drainage group and the connective tissue massage group. Both groups were treated for 45 minutes twice a week for 6 weeks. The groups were assessed before the treatment and at the end of 6 weeks.|t|f|f|f
33979828|NCT06148090|NA|SINGLE_GROUP||PREVENTION||NONE||"At two occasions during the clobetasol decreasing, cortisol and ionogram measurement at 8 AM and clinical assessment by a physician:~* Visit 1: 20-40 g clobetasol twice a week for at least 1 month~* Visit 2: 20-40 g clobetasol once a week for at least 1 month A third visit (visit 3) is necessary if blood cortisol is between 138 and 500 nmol/L, to make a Synacthen® test (new cortisol dosage at 8 AM, then IM or IV injection of a 250 microgram ampoule of Synacthen® completed by a 2nd cortisol dosage one hour later)"||||
33979829|NCT02946125|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34077632|NCT00173355|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34077633|NCT03328234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077634|NCT05277857|||COHORT||PROSPECTIVE|||||||
34077635|NCT00035269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077636|NCT04838561|||CASE_CONTROL||PROSPECTIVE|||||||
34077637|NCT03281941|NA|SINGLE_GROUP||OTHER||NONE||||||
34077638|NCT05833126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077639|NCT05569798|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A parallel single centre feasibility randomised controlled trial||||
34077640|NCT01316224|||CASE_ONLY||PROSPECTIVE|||||||
34077641|NCT02199769|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077642|NCT04812184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077643|NCT01368510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34077644|NCT03368313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077645|NCT04017767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077646|NCT02974933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896188|NCT04002687|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|This study will be conducted in a double-blind fashion whereby subjects and clinical study site staff are blinded. Because the placebo tablets are not an exact match for the active treatment, tablets will be administered by an un-blinded member of clinical study staff, who will protect the blinding from both subjects and all other site staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. The pharmacy staff preparing the investigational products will not be blinded to study drug assignment. During the study, the individual randomisation codes will be kept in the site's clinical trials pharmacy, accessible to the pharmacy personnel only. Upon completion of the study, after the database lock and after the blind is revealed, the randomisation list will be filed in the Trial Master File. Sponsor staff involved in clinical decision-making (such as those involved in SRC decisions) will be blinded to study drug assignment.|"Fifty-two subjects will be enrolled and randomized to one of the four treatment (Cohorts 1 to 4) in a ratio of 4:3:3:3 as described below:~* Treatment 1 (n=16) - ATV-PG 1000-400 mg + AQ 612 mg;~* Treatment 2 (n=12) - ATV-PG 1000-400 mg + AQ unmatched placebo;~* Treatment 3 (n=12) - ATV-PG unmatched placebo + AQ 612 mg;~* Treatment 4 (n=12) - ATV-PG unmatched placebo + AQ unmatched placebo."|t|t|t|t
33896189|NCT06150209|NA|SINGLE_GROUP||TREATMENT||NONE||Time points to wound closure compared to retrospective standard of care closure times. If closure is not achieved the reduction in wound volume will be evaluated||||
33896190|NCT00824421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896191|NCT02007837|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896192|NCT01217281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979830|NCT03652077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979831|NCT06317246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979832|NCT00191932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979833|NCT04287426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979834|NCT00006174||||TREATMENT||||||||
33979835|NCT01475838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979836|NCT01502943|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33979837|NCT04909164|||CASE_CONTROL||PROSPECTIVE|||||||
33979838|NCT01718639|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33979839|NCT04797403|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomized trial with randomization at the clinic level||||
34077647|NCT00887614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077648|NCT05299684|||OTHER||CROSS_SECTIONAL|||||||
34077649|NCT00160108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077650|NCT00231790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077651|NCT00356447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077652|NCT05959213|||COHORT||RETROSPECTIVE|||||||
33979840|NCT02079532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979841|NCT05842538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979842|NCT06170866|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective feasibility trial, single group pre-posttest design and it aims to enroll 20 participants. For this feasibility study, the sample size is comparable to other feasibility trials in populations of individuals with Parkinson disease (Lima \& Rodrigues-de-Paula, 2013; Ellis et al., 2013, Colón-Semenza et al., 2018)17,19,20. This sample size will allow for a comparison in feasibility, acceptability, and appropriateness within and across groups. This sample will allow for identifying trends and preliminary efficacy for this intervention. This study will help to inform an appropriate sample size to adequately power larger samples in future studies||||
33979843|NCT00970697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979844|NCT01975805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979845|NCT03757364|||CASE_CONTROL||RETROSPECTIVE|||||||
33979846|NCT03055949|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979847|NCT00095381|NON_RANDOMIZED|||TREATMENT||NONE||||||
33979848|NCT02924948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33979849|NCT05010226|||CASE_ONLY||PROSPECTIVE|||||||
33979850|NCT02829268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979851|NCT03239522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979852|NCT03165448|||COHORT||PROSPECTIVE|||||||
33979853|NCT01921920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33979854|NCT02820090|||CASE_CONTROL||PROSPECTIVE|||||||
33979855|NCT02016170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979856|NCT04230226|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33979857|NCT03980483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Participants will be randomized to one of six intervention arms in ratio of 6:6:3:1:1:1.|t|f|t|f
33979858|NCT01023074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979859|NCT02722590|||OTHER||PROSPECTIVE|||||||
33979860|NCT02997800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979861|NCT04323202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979862|NCT05845996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979863|NCT04941248|||COHORT||PROSPECTIVE|||||||
33979864|NCT01643707|||OTHER||PROSPECTIVE|||||||
33979865|NCT04630938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33979866|NCT01470066|||COHORT||PROSPECTIVE|||||||
33979867|NCT06256536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979868|NCT03308019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979869|NCT01545076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979870|NCT06093997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979871|NCT03436680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979872|NCT00097695|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33896193|NCT03826914|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The selected participants will be randomly assigned in equal numbers to the experimental or control group. Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day. Participants in the control group will be given a flavored 10g placebo that looks and tastes exactly like Cardioflex. Participants will be instructed to consume the beverage in 500mL of water upon waking each morning, prior to eating or drinking anything else.~The clinical trial is double blinded so neither the participants or investigators will know which experimental group they are in until the data collection period is over."|A 90-day double blinded controlled clinical trial|t|t|t|f
33896194|NCT03665597|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896195|NCT03560076|||COHORT||OTHER|||||||
33896196|NCT03792958|NA|SEQUENTIAL||TREATMENT||NONE||The initial dose is set at 200 mg, followed by 400 mg, 600 mg and 800 mg for dose increment.||||
33896197|NCT05631028|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This study is a clinical trial of dynamic design dose exploration evaluating the effect of dexmedetomidine pretreatment on the effective dose of remimazolam tosilate inhibiting cardiovascular response to intubation of double-lumen endobronchial tubes. Following the design principle, conduct dynamic exploration by sequential method, using the near ED95 drug dose for subjects according to the pretest.To determine whether the next subject increases or decreases the pre-set fixed drug dose according to the previous subject. The trial was stopped when seven exchange points occurred, at which point the total sample size was obtained.||||
33896198|NCT03671044|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental: T1, Nanosomal Docetaxel Lipid Suspension (75 mg/m2) Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity.~Experimental: T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2) Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity.~Active Comparator: R, Taxotere® (100 mg/m2) Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity."||||
33896199|NCT06076044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896200|NCT04151602|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33896201|NCT00533572|||COHORT||CROSS_SECTIONAL|||||||
33896202|NCT04562363|||COHORT||PROSPECTIVE|||||||
33896203|NCT02573116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896204|NCT04146558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33896205|NCT01104831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896206|NCT02830425|||COHORT||PROSPECTIVE|||||||
33896207|NCT04615871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized open-label blinded evaluation trial. There will be an independent events adjudication committee|Patients will be randomized to receive active treatment - s.c. semaglutide for 4 weekly doses in addition to standard of care or control - standard of care only|f|f|f|t
33896208|NCT01106261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896209|NCT02215629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896210|NCT00189826|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896211|NCT06604325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33896212|NCT04691661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896213|NCT03788473|||CASE_CONTROL||PROSPECTIVE|||||||
33896214|NCT02998502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896215|NCT01772134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896216|NCT02343328|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896217|NCT03379350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896218|NCT03880396|||COHORT||PROSPECTIVE|||||||
33896219|NCT03394495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent assessor who is blinded to the group allocations will assess the participants' outcomes.|"A three-arm parallel (single-blinded) cluster randomized controlled trial involves three groups of participants (the COMB, the EXER and the control group). Twelve community health centres that provide similar types of community care and social support services for community-dwelling older people, have been invited by a convenience method to work as collaborators in this study. Using computer-generated random numbers, a biostatistician not affiliated with this study will randomize the centres into either: control, EXER, or COMB group. So during the trial, participants in one group receive combination intervention in parallel to participants in the other two groups (the control group and the exercise group)."|f|f|f|t
33896220|NCT02924844|||CASE_CONTROL||PROSPECTIVE|||||||
33896221|NCT03405844|||COHORT||PROSPECTIVE|||||||
33896222|NCT05766735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to individualized routine care (RC) or to individualized RC in addition to post-nutrient glucose excursion minimization (RC+GEM). A Randomized Controlled Trial (RCT) design will be used to assign participants to treatment groups.||||
33896223|NCT04408456|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896224|NCT00652587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896225|NCT03037905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896226|NCT00618956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896227|NCT06439043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be a single-blinded study in which only the participants will be unaware of certain aspects of the research design. Typically, this means that the participants will not know which treatment they are receiving or the mode of treatment (online or face-to-face), while the researchers administering the treatment and collecting data will be aware.|The adapted EMDR treatment protocol will be administered both online and face-to-face. Patients will be randomly allocated to either the face-to-face mode or the online mode of EMDR at the same time.|t|f|f|f
33896228|NCT05435430|||OTHER||PROSPECTIVE|||||||
33979873|NCT04833998|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The allocation ratio is 2:1, favouring the active treatment. In this study we are using unequal allocation ratios for a variety of reasons, including allowance for learning curves, and ethical considerations when the balance of existing evidence appears to be in favour of one intervention over the placebo.|t|f|t|t
33767718|NCT00965835|||CASE_CONTROL||PROSPECTIVE|||||||
33767719|NCT02349464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767720|NCT03709290|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767721|NCT01732146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767722|NCT01246180|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33767723|NCT04733196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and providers did not have information about the ingredients in the mouthwashes.|180 participants are assigned to 6 groups. Each group of 30 participants with gingivitis rinse with one of the mouthwashes: based on prebiotic, hydrogen peroxide, essential oils, essential oils in combination with 0,12% chlorhexidine, 0,20% chlorhexidine for 3 weeks after mechanical plaque control.|t|t|f|f
33979874|NCT01439165|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33979875|NCT04217720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979876|NCT06367829|||OTHER||OTHER|||||||
33979877|NCT02146430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979878|NCT05508100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979879|NCT01880034|||OTHER||OTHER|||||||
33979880|NCT03131180|RANDOMIZED|PARALLEL||OTHER||NONE||This trial is a single center randomized controlled trial to investigate the ability of the RLHS to improve patient-centered outcomes in pediatric patients with complex colorectal diseases. Patients and caregivers are randomized to either receive access to a website that displays the colorectal RLHS dashboard prior to standard consultation or to standard consultation alone.||||
33979881|NCT05543356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and those evaluating reactogenicity will be blinded to the vaccine allocation for the first 7 days following vaccination. After that, both clinical investigators and participants will be aware of their investigational product. Laboratory staff will remain blinded to the investigational product.|Study participants who have received two doses of either Pfizer or Astrazena vaccine as their primary vaccine and a standard dose of Pfizer for their booster will be randomised into one of four groups. The four groups consist of a standard dose of either the monovalent or bivalent Pfizer or Moderna vaccine.|t|f|t|f
33979882|NCT00852436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979883|NCT01949428|||COHORT|||||||||
33979884|NCT02037997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979885|NCT00843271|||COHORT||PROSPECTIVE|||||||
33979886|NCT05522907|||COHORT||PROSPECTIVE|||||||
33979887|NCT02395003|||COHORT||CROSS_SECTIONAL|||||||
33979888|NCT03724149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979889|NCT04315857|||COHORT||PROSPECTIVE|||||||
33979890|NCT03249064|||CASE_CONTROL||PROSPECTIVE|||||||
33979891|NCT05703308|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979892|NCT00515203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979893|NCT05189184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979894|NCT04894747|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33979895|NCT01159548|RANDOMIZED|||PREVENTION||QUADRUPLE|||t|t|t|t
33979896|NCT01056770|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33979897|NCT00733616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077653|NCT03647566|||COHORT||PROSPECTIVE|||||||
33767724|NCT03605160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33767725|NCT02743715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|all study staff were blind to the participant's condition; only the neuromodulation staff, external to the study team, were aware of the participant's treatment group|randomized, sham-controlled trial|t|t|t|t
33767726|NCT00027638||||TREATMENT||||||||
33767727|NCT06152523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767728|NCT06400680|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767729|NCT03792217|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33767730|NCT03501693|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33767731|NCT02737020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767732|NCT04876651|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Approximately 387 eligible patients will be randomized to one of two groups in a 2:1 ratio to receive one of the following treatments:~* Group A: Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC~* Group B: Best SoC.~Additionally, up to 10 patients, in New Zealand only, will be recruited for evaluation of biodistribution and dosimetry of 177Lu- DOTA-TLX591(m17 allotype) in combination with the SoC. These patients will receive two single intravenous (IV) injections of 76 mCi (±10%) each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591 (m17), given 14 days apart, plus best SoC (abiraterone/prednisolone or enzalutamide or docetaxel). After the first dose, the patients will undergo single-photon emission computerized tomography/computerized tomography (SPECT/CT)."||||
33767733|NCT00509158|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767734|NCT00617721|||FAMILY_BASED||PROSPECTIVE|||||||
33767735|NCT03428126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767736|NCT01927601|||COHORT||PROSPECTIVE|||||||
33767737|NCT03954457|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077654|NCT01935089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077655|NCT00469222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077656|NCT00394186|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34077657|NCT02912221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34077658|NCT06477744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34077659|NCT00732069|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34077660|NCT00802646|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34077661|NCT01789047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077662|NCT00484471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077663|NCT00913081|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34077664|NCT05657366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077665|NCT05628246|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34077666|NCT00185315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077667|NCT03045939|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077668|NCT00712257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077669|NCT03139734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077670|NCT00910598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077671|NCT04863612|||COHORT||PROSPECTIVE|||||||
34077672|NCT00398944|RANDOMIZED|PARALLEL||||NONE||||||
34077673|NCT02762084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077674|NCT05318989|||COHORT||CROSS_SECTIONAL|||||||
34077675|NCT01714544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077676|NCT00744718||FACTORIAL||TREATMENT||NONE||||||
34077677|NCT03615261|NA|SINGLE_GROUP||OTHER||NONE||All participants engaged in the Mothers \& Babies Intervention while wearing a biosensor.||||
34077678|NCT05191719|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All study participants are evaluated with and without the effect Botox treatment before surgery. Botox is the gold standard treatment and used as a comparator. As all study patients have failed current evidence based treatment options, a comparative group not receiving treatment would imply a strong information bias.|f|f|f|t
34077679|NCT04037124|||COHORT||RETROSPECTIVE|||||||
34077680|NCT03827421|||OTHER||PROSPECTIVE|||||||
34077681|NCT05582278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077682|NCT01348139|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34077683|NCT02849743|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34077684|NCT00006320||||TREATMENT||||||||
34077685|NCT02492165|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077686|NCT01914237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077687|NCT02157519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34077688|NCT02699996|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077689|NCT01475903|||||PROSPECTIVE|||||||
34077690|NCT05863819|||COHORT||PROSPECTIVE|||||||
34077691|NCT02463669|||COHORT||PROSPECTIVE|||||||
34077692|NCT00525837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077693|NCT03018314|||COHORT||PROSPECTIVE|||||||
34077694|NCT00738647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077695|NCT06331507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077696|NCT02068911|||||PROSPECTIVE|||||||
34077697|NCT04632459|NA|SINGLE_GROUP||TREATMENT||NONE||Pembrolizumab Plus Ramucirumab||||
34077698|NCT00750802|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34077699|NCT00263198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077700|NCT03031717|||COHORT||RETROSPECTIVE|||||||
34077701|NCT00167349|||COHORT||PROSPECTIVE|||||||
34077702|NCT03695718|||COHORT||PROSPECTIVE|||||||
34077703|NCT00524251|||||PROSPECTIVE|||||||
34077704|NCT01181739|||CASE_ONLY||CROSS_SECTIONAL|||||||
34077705|NCT04329429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077706|NCT01773083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077707|NCT02864069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077708|NCT01023594|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077709|NCT05931536|||OTHER||CROSS_SECTIONAL|||||||
34077710|NCT06492447|||COHORT||PROSPECTIVE|||||||
34077711|NCT05687097|||OTHER||CROSS_SECTIONAL|||||||
34077712|NCT01289327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077713|NCT00456872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077714|NCT01441128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077715|NCT00692380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077716|NCT04426097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33896229|NCT03318367|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33896230|NCT04177329|||OTHER||PROSPECTIVE|||||||
33896231|NCT01228773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767738|NCT04665310|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Group - Dose Escalation with 2 groups stratified by pPRA \<75% and \>75% and then randomized into 3 Intensity Arms (Low, Moderate and High) based on dosing of Envarsus XR.||||
33767739|NCT01291225|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767740|NCT01930435|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||humidification feasibility and efficacy||||
33767741|NCT02751736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896232|NCT03486236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896233|NCT03490344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077717|NCT04566640|||COHORT||PROSPECTIVE|||||||
33767742|NCT01100060|RANDOMIZED|PARALLEL||||NONE||||||
33767743|NCT01082146|NA|SINGLE_GROUP||||NONE||||||
33767744|NCT04652141|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The randomization procedure will be masked to investigator by study nurse.|Randomization (1:1) to trial treatment with either AsthmaTuner or traditional during 3 months.|f|f|t|f
33767745|NCT03214510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767746|NCT05416996|||COHORT||PROSPECTIVE|||||||
33767747|NCT06080932|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767748|NCT01305928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767749|NCT01107743|||CASE_ONLY||PROSPECTIVE|||||||
33767750|NCT00753883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767751|NCT02443922|NON_RANDOMIZED|PARALLEL||||NONE||||||
33767752|NCT04577313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767753|NCT05966961|||CASE_CONTROL||PROSPECTIVE|||||||
33767754|NCT03746743|||COHORT||PROSPECTIVE|||||||
33896234|NCT01813344|||||RETROSPECTIVE|||||||
33896235|NCT03662321|||CASE_CONTROL||OTHER|||||||
33896236|NCT02585544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767755|NCT00210522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767756|NCT01516203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767757|NCT02896816|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33767758|NCT06321432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Due to the nature of the interventions, it will not be possible to blind the participants or the healthcare providers administering the interventions. In all other aspects of the trial, blinding will be employed. Outcome assessors will be blinded to group allocation. Participants will also be requested not to disclose their allocation when outcomes are assessed.~Statisticians and investigators drawing conclusions will be fully blinded. The statistical analyses will be conducted with the intervention groups coded as e.g., 'A' and 'B'. The Steering Committee ill write two abstracts while the blinding is intact; one assuming the experimental intervention group is 'A' and the control intervention group is 'B', and one assuming the opposite. After these two abstracts have both obtained consensus, the code will be broken by the data manager."||f|f|t|t
33767759|NCT02305381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767760|NCT05240378|||COHORT||RETROSPECTIVE|||||||
33767761|NCT04795817|||COHORT||PROSPECTIVE|||||||
33767762|NCT06150989|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33767763|NCT03508999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767764|NCT01306175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767765|NCT02781896|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33767766|NCT01960790|||COHORT||PROSPECTIVE|||||||
33767767|NCT05510726|||COHORT||PROSPECTIVE|||||||
33767768|NCT01356641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767769|NCT03222544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33767770|NCT02131038|||CASE_ONLY||PROSPECTIVE|||||||
33767771|NCT02943889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077718|NCT02383069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077719|NCT01991353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077720|NCT04994561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077721|NCT00944710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077722|NCT02852460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767772|NCT02682212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767773|NCT01278875|||CASE_CONTROL||PROSPECTIVE|||||||
33767774|NCT00563589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077723|NCT03482271|||OTHER||RETROSPECTIVE|||||||
34077724|NCT00168948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33767775|NCT04102436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767776|NCT02486549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34077725|NCT00666107|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34077726|NCT01749956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077727|NCT03289247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator evaluating primary outcome is blinded to intervention||f|f|t|f
34077728|NCT03099460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077729|NCT06366646|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A quasi-experimental design utilized one group for pre-, post, and follow-up intervention.|A quasi-experimental design|t|f|f|f
34077730|NCT02109952|||CASE_ONLY||PROSPECTIVE|||||||
34077731|NCT03206879|||COHORT||PROSPECTIVE|||||||
34077732|NCT01589367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077733|NCT04778852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34077734|NCT00689962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077735|NCT03547024|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077736|NCT00713843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077737|NCT02298348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077738|NCT05991011|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33721196|NCT03071627|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
33721197|NCT02429895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721198|NCT03384550|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33721199|NCT00254540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721200|NCT04712773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721201|NCT05156879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721202|NCT02093481|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33721203|NCT02848157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33721204|NCT01395433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721205|NCT00569296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721206|NCT04699708|||COHORT||PROSPECTIVE|||||||
33721207|NCT06019637|||COHORT||OTHER|||||||
33721208|NCT04136925|||OTHER||CROSS_SECTIONAL|||||||
33721209|NCT05830487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721210|NCT06000254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721211|NCT03438812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721212|NCT02204787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767777|NCT02674932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721213|NCT00385879|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33721214|NCT00002733||||TREATMENT||||||||
33721215|NCT01239706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721216|NCT01846611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721217|NCT03106155|NA|SINGLE_GROUP||TREATMENT||NONE||Vistusertib monotherapy (50 mg BID per os every 12 hours)||||
33721218|NCT04136054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33721219|NCT02976623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33721220|NCT00002490|RANDOMIZED|||TREATMENT||||||||
33721221|NCT06537154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721222|NCT03774953|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized to intervention or control arm||||
33721223|NCT00257842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721224|NCT00002433||||TREATMENT||||||||
33721225|NCT05662085|||COHORT||PROSPECTIVE|||||||
33721226|NCT06478160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and statistician who analyze the results||f|f|t|t
33721227|NCT00944450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721228|NCT05092685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721229|NCT04886050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767778|NCT05373134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767779|NCT02891239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767780|NCT00190905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767781|NCT06112639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767782|NCT04230460|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|University of Iowa: Triple (Participant, Investigator, Outcomes Assessor) blind|The University of Iowa study is a counter-balanced dose-response protocol where all participants will receive all three doses of marijuana (plus alcohol if they qualify).|t|f|t|t
33767783|NCT02471885|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33767784|NCT00054964|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767785|NCT00914290|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33767786|NCT02508922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33767787|NCT03864601|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33767788|NCT00216450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767789|NCT02134210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767790|NCT01163110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767791|NCT00641758|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33767792|NCT00655330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767793|NCT00871403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767794|NCT02021539|||COHORT||PROSPECTIVE|||||||
34077739|NCT01178905|NA|SINGLE_GROUP||PREVENTION||||||||
34077740|NCT05417412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077741|NCT04054544|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Experimental study to determine blood and duodenal T cell changes following administration of an 8 g gluten challenge daily for 13 days in participants with celiac disease||||
34077742|NCT04961437|||COHORT||PROSPECTIVE|||||||
34077743|NCT05545176|||OTHER||OTHER|||||||
34077744|NCT06519838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33979898|NCT04339465|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Assessors are blind regarding the randomization (group affiliation) of the families.|The study is a prospective, randomized controlled multicenter study (RCT) with a factorial design with four groups: CAREFAM (face to face), WEP-CARE (online), both interventions, control group (TAU = treatment as usual).|f|f|t|f
34077745|NCT04693429|NA|SINGLE_GROUP||OTHER||NONE||Controlled, single center, non comparative||||
34077746|NCT01781208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077747|NCT02320708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077748|NCT02104024|||COHORT||PROSPECTIVE|||||||
33979899|NCT02365207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979900|NCT02069626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979901|NCT01659203|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979902|NCT03746353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979903|NCT04652453|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Pre-/Post-Intervention Design||||
34025603|NCT04005014|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Examinations of visual acuity, eye refraction and biometrics will be performed in each participating clinic by trained investigators. The investigators, outcomes assessors involved in data management and analysis will be blinded to the group assignment. The study participants, the coordinator, senior consultants, and study personnel responsible for randomisation will not be masked.||f|f|t|t
33896237|NCT00663130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896238|NCT03715543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896239|NCT01999829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896240|NCT00608465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33896241|NCT02039154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896242|NCT01946009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896243|NCT05255757|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||There are two interventions randomly assigned to participants in a factorial experimental design. The first intervention is the search intervention. In addition to the candidate survey, transplant candidates assigned to this intervention will be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation. The second intervention is the script intervention, where in addition to the survey, transplant candidates will review a set of suggested talking points and an example script to guide discussion of potential living donation with members of their network. 25% of participants will be assigned to each of the following factorial experimental groups: no intervention, search intervention only, script intervention only, or both search and script intervention.||||
33896244|NCT05813821|NA|SINGLE_GROUP||PREVENTION||NONE||Multicenter, prospective, interventional, cohort study analysing the effect of an antimicrobial stewardship intervention in surgery.||||
33896245|NCT03175523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896246|NCT01480180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896247|NCT04599426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896248|NCT05308147|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33896249|NCT01421446|||CASE_ONLY||CROSS_SECTIONAL|||||||
33896250|NCT01983865|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33896251|NCT03215914|NA|SINGLE_GROUP||TREATMENT||NONE|No masking.|Open label, single-arm trial of the effect of hybrid closed-loop insulin delivery on glucose counterregulatory mechanisms assessed by the stepped- hyperinsulinemic hypoglycemic clamp in patients with long standing type 1 diabetes complicated by hypoglycemia unawareness.||||
34025604|NCT05498779|||COHORT||RETROSPECTIVE|||||||
34025605|NCT02777398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025606|NCT01216787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025607|NCT05604989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34025608|NCT04837131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025609|NCT04223557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blinded, sham-controlled study.The ratio of the treatment group versus sham-control group was 2:1.|t|t|t|t
34025610|NCT02882308|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34025611|NCT02602444|||COHORT||PROSPECTIVE|||||||
34077749|NCT00503893|||FAMILY_BASED||PROSPECTIVE|||||||
34077750|NCT00334412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077751|NCT05978518|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||There is a study group that uses the device \& the data is monitored and sent to the physician. The second group is a control group that uses the device, but the data is not monitored or sent to the physician.|t|f|f|t
34077752|NCT01429662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077753|NCT02694133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077754|NCT02353026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077755|NCT02993848|||COHORT||PROSPECTIVE|||||||
34077756|NCT01656395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077757|NCT05798715|RANDOMIZED|CROSSOVER||OTHER||NONE||Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study||||
34077758|NCT00333567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34077759|NCT04571047|||COHORT||PROSPECTIVE|||||||
34077760|NCT01421498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34077761|NCT00533715|||||OTHER|||||||
34077762|NCT01298700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077763|NCT01831219|||CASE_CONTROL||PROSPECTIVE|||||||
34077764|NCT01224483|||||RETROSPECTIVE|||||||
34077765|NCT05555238|||OTHER||PROSPECTIVE|||||||
34077766|NCT01214889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077767|NCT06018155|||COHORT||RETROSPECTIVE|||||||
34077768|NCT01535677|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34077769|NCT01301261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077770|NCT04458675|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34077771|NCT03717103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077772|NCT04184557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Principal investigator randomize the participants. Two psychologists who do not know the allocation perform the assessments, mostly through self-reported instruments. Another investigator analyze the outcomes.|Participants are randomly allocated to the intervention arm (app) or to the control arm (treatment as usual \[TAU\])|f|f|t|t
34077773|NCT00443222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077774|NCT00580411|||COHORT||RETROSPECTIVE|||||||
34077775|NCT05441228|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participant are divided into two groups. The group a received virtual reality and group b received mirror therapy.||||
34077776|NCT00846053|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||In this pilot study, we examined the value of FDG-PET scans as a noninvasive measure of neutrophilic inflammation in adolescents and young adults with cystic fibrosis. All subjects underwent scans.||||
34077777|NCT03351543|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33896252|NCT00308815|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33896253|NCT04909567|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled study||||
33896254|NCT05954754|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|This study was designed as a randomized controlled trial|This study was designed as a randomized controlled trial|t|f|f|f
33896255|NCT01953315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767795|NCT03936140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767796|NCT00345813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767797|NCT03219268|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896256|NCT06584279|||COHORT||PROSPECTIVE|||||||
33896257|NCT01870635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896258|NCT06379347|||CASE_ONLY||PROSPECTIVE|||||||
33896259|NCT05034679|||CASE_CONTROL||PROSPECTIVE|||||||
33896260|NCT00677950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896261|NCT02981290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896262|NCT06411626|||COHORT||PROSPECTIVE|||||||
33896263|NCT02493751|NA|||TREATMENT||NONE||||||
33896264|NCT00167622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896265|NCT02988648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896266|NCT04240743|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33896267|NCT01887912|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This study was observer-blind. The vaccine preparer and administrator may have been unblinded to treatment assignment due to the steps necessary for vaccine preparation. However, the participant, the Investigator, and study staff members who collected the safety data and laboratory personnel who analyzed the blood and stool samples were all blinded to the group assignment.|t|f|t|t
33896268|NCT01538771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896269|NCT03446924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|An individual with no direct study involvement will administer treatments in a double-blind manner. Investigators will be un-blinded to treatment arms upon completion of data analysis.|Parallel-designed study in which participants will be randomized to receive phosphatidic acid or placebo treatment. A parallel design was chosen due to the number of invasive muscle biopsies performed during each experimental trial.|t|f|t|f
33896270|NCT04049825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896271|NCT02515669|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33896272|NCT01069848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896273|NCT05780866|NA|SINGLE_GROUP||OTHER||NONE||||||
33896274|NCT01649492|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33896275|NCT01923064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896276|NCT00986960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33896277|NCT02522377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896278|NCT01609933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896279|NCT01447693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896280|NCT03645187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896281|NCT02296346|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896282|NCT04220905|||COHORT||PROSPECTIVE|||||||
33721230|NCT01589445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33721231|NCT03475381|||COHORT||RETROSPECTIVE|||||||
33721232|NCT00038207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721233|NCT01272609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721234|NCT01656590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721235|NCT02145728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721236|NCT00654160|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33721237|NCT02390401|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33721238|NCT02436356|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721239|NCT00469092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896283|NCT00041899||||TREATMENT||||||||
33767798|NCT03097003|||COHORT||PROSPECTIVE|||||||
33767799|NCT02292810|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
33767800|NCT04096521|||COHORT||PROSPECTIVE|||||||
33767801|NCT05358587|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33767802|NCT04653636|||COHORT||RETROSPECTIVE|||||||
33767803|NCT01330693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767804|NCT02920151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767805|NCT06436963|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767806|NCT03691948|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33767807|NCT06186557|||OTHER||PROSPECTIVE|||||||
33767808|NCT02433548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33767809|NCT04418713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767810|NCT02441946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767811|NCT00847301|||COHORT||PROSPECTIVE|||||||
33896284|NCT00327444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896285|NCT02783781|||OTHER||PROSPECTIVE|||||||
33896286|NCT04377529|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33896287|NCT03545516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896288|NCT02865369|||COHORT||PROSPECTIVE|||||||
33896289|NCT03079661|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33896290|NCT05741021|NA|SINGLE_GROUP||TREATMENT||NONE||Rulonilimab+Chemotherapy||||
33896291|NCT06443086|||COHORT||RETROSPECTIVE|||||||
33896292|NCT02109029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33721240|NCT04343599|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|An independent assessor blinded to the data collection was responsible for the allocation process. A list of the computer-generated number was employed to assign participants to experimental or control group|This study was a single-blinded randomized controlled trial|f|t|t|t
33721241|NCT06124612|||COHORT||PROSPECTIVE|||||||
33721242|NCT06384716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomised clinical trial. The research will be conducted in accordance with the framework of application of the Helsinki declaration (21) and the law on Personal Data Protection and guarantee of digital rights (Organic Law 3/2018) . The design of this project will follow the definition of the standard elements of a clinical trial protocol: SPIRIT declaration|f|f|t|f
33721243|NCT02337907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721244|NCT05718895|NA|SEQUENTIAL||TREATMENT||NONE||A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg Q3W with 1 subject||||
33721245|NCT02947529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the participants and the operating surgeons, who are members of the investigative team, will be blinded to which study group the participant is in throughout the study period.|Subjects undergoing surgery for acute hip fractures with a long trochanteric femoral nail (TFN) or hemiarthroplasty will randomized 50:50 to receive 1 dose of either tranexamic acid (TXA) or saline placebo solution prior to surgery and 1 dose during wound closure.|t|f|t|f
33721246|NCT00567892|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33721247|NCT01519453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721248|NCT03514784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The head statistician and study pharmacist will be aware of randomization scheme. The investigators will use an adaptive minimization program for randomization that balances the 3 study arms with respect to distributions of sex and age (4-10 vs. 11-16 y.o.). Patients will be randomized to placebo, 1 billion CFU, and 10 billion CFU study arms at a ratio of 1:2:2. (Currently marketed over-the-counter probiotics typically contain 0.1-50 billion CFUs per dose.) The performance of our covariate adaptive randomization algorithm will be verified through simulation studies before implementation.|After psychological screening, the subjects will be randomize children to one of 3 groups. The total number of subject to be enrolled will be 70 healthy children with confirmed ASD status, randomizing each child to placebo (maltodextrin), low daily dose (1 billion cfu's), and higher daily dose (10 billion cfu's) of BB-12+LGG once daily at 1:2:2 ratio. Data will be combined with 30 patients obtained from two funding sources: Texas (THECB) and U.T. pilot project. The data will be combined and an identical design of the placebo and 1 billion cfu dose arms.|t|t|t|f
33721249|NCT00695396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896293|NCT02624648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896294|NCT05467085|NA|SINGLE_GROUP||TREATMENT||NONE||This open-label early feasibility study will be conducted in 20 subjects with OCD across two centers, Baylor College of Medicine (BCM)and Massachusetts General Hospital (MGH).||||
33896295|NCT05036785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single centre prospective randomized assessor blinded parallel group feasibility study|f|f|t|f
33896296|NCT01043640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896297|NCT01748760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896298|NCT05282212|||COHORT||CROSS_SECTIONAL|||||||
33896299|NCT04680923|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All patients, care providers in PACU \& ward (nurses), and outcome assessors (assistant anesthesiologist) will be blinded to the group allocation. Only the assigned anesthesiologist responsible for perioperative care and the surgeon performing preperitoneal local anesthetic infiltration will be aware of the group allocation to treat any unwanted side effects during and after the operation.|117 adult patients scheduled for Laparoscopic Sleeve Gastrectomy (LSG) will be recruited in this prospective clinical study. The patients will be divided into two groups; group-1 (CPPLAI) (n= 59) will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline and group 2 (placebo) (n= 58) periportal and preperitoneal 40 ml of sterile water will be injected.|t|t|f|t
33896300|NCT05330520|NA|SINGLE_GROUP||OTHER||NONE||||||
33896301|NCT04063943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979904|NCT05865600|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be blinded to the specific result of the initial \[15O\]H2O cardiac PET/CT. The result will be reported as normal, abnormal, or suspicion of unprotected left main coronary stenosis (exclusion criteria) until the termination of the study. Investigators and invasive coronary angiography operators are not blinded to the specific result of the initial \[15O\]H2O cardiac PET/CT in order to evaluate clinical indication for invasive coronary angiography. The coronary CT angiography will only be evaluated for unprotected left main coronary artery stenosis - the rest of the coronary CT angiography as well as the two additional \[15O\]H2O cardiac PET/CT scans at 3 and 6 months assessment will only be analyzed after the termination of the study. Investigators will be blinded to the results of baseline, 3, and 6 month questionnaires and walking distances until the termination of the study.|"All eligible patients are included in a prospective cohort with repeated questionnaires.~Patients with abnormal perfusion and clinical indication for invasive coronary angiography are randomized 1:1 in permuted blocks with random varying sizes of 4,6 and 8 to either immediate invasive coronary angiography or delayed invasive coronary angiography via a standard computerized random-number generator stratified for age ≥70 years and sex (REDcap). Proper concealment of randomization is obtained by the use of an external randomization service (Clinical Trial Unit, Dept. of Clinical Medicine, Aarhus University, Denmark)."||||
33979905|NCT00125424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979906|NCT04780009|||CASE_ONLY||PROSPECTIVE|||||||
33979907|NCT05896956|||COHORT||PROSPECTIVE|||||||
33979908|NCT05228522|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979909|NCT04165538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979910|NCT00313703|||COHORT||PROSPECTIVE|||||||
33979911|NCT01764438|||COHORT||PROSPECTIVE|||||||
33979912|NCT05825495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33979913|NCT05133609|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33979914|NCT01832701|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33979915|NCT03328780|||COHORT||PROSPECTIVE|||||||
33979916|NCT00098878|RANDOMIZED|||TREATMENT||||||||
33979917|NCT04835922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded study : participants and investigator will be blinded using sealed enveloped method.|the study will be prospective double blind randomized trial using 0.25% bupivacaine in patients undergoing PCNL under one of the two arms: Intercostal Nerve block or Peritract Infiltration.|t|f|t|f
33979918|NCT06131281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to which procedure they received. The physician performing the procedure cannot be blinded to the procedure type.|Prospective, single-blinded, randomized controlled trial|t|f|f|f
33979919|NCT03805438|NA|SEQUENTIAL||DIAGNOSTIC||NONE|The solutions and their administration procedures are identical to those used outside this research and are almost exclusively used for patients requiring spinal anesthesia for cervical cerclage. The only deviation involves diluting the chloroprocaine with saline so that study solutions are of equal volume to maintain blinding.|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."||||
33979920|NCT04927533|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979921|NCT01464866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979922|NCT01976130|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33979923|NCT01442402|||COHORT||OTHER|||||||
33979924|NCT02980978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979925|NCT01887626|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33979926|NCT04946877|||CASE_CONTROL||RETROSPECTIVE|||||||
33979927|NCT02607319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979928|NCT05616247|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979929|NCT00002064||||TREATMENT||||||||
33979930|NCT03080090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896302|NCT06656468|||COHORT||PROSPECTIVE|||||||
33979931|NCT04856449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025612|NCT05478577|||COHORT||RETROSPECTIVE|||||||
34077778|NCT05658471|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be randomized to the starting condition using a Latin square design||||
34077779|NCT05002595|||COHORT||PROSPECTIVE|||||||
34077780|NCT03268343|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767812|NCT03693274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33767813|NCT01393041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767814|NCT00547690|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767815|NCT05562063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896303|NCT00117962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896304|NCT03233048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896305|NCT01508676|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33896306|NCT03903328|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33896307|NCT00429910|||COHORT||PROSPECTIVE|||||||
33896308|NCT00754390|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33896309|NCT00761111|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33896310|NCT00978276|||CASE_CONTROL||RETROSPECTIVE|||||||
33896311|NCT06085066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33896312|NCT06447792|||COHORT||RETROSPECTIVE|||||||
33896313|NCT06656026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33896314|NCT01813487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896315|NCT02065778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896316|NCT01585649|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33896317|NCT00677261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33896318|NCT03426059|||COHORT||PROSPECTIVE|||||||
33896319|NCT00553787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896320|NCT05394298|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, multicentre, phase IV open trial of real clinical practice||||
33896321|NCT01658800|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33896322|NCT05117801|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33896323|NCT01381107|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33896324|NCT02579603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896325|NCT01175512|NON_RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33896326|NCT01571271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896327|NCT02334267|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33896328|NCT00189358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896329|NCT05088317|||OTHER||OTHER|||||||
33896330|NCT01368068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896331|NCT03368898|||OTHER||CROSS_SECTIONAL|||||||
33896332|NCT04731064|||OTHER||OTHER|||||||
33896333|NCT01333189|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33896334|NCT04782739|||OTHER||OTHER|||||||
34025613|NCT02565212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025614|NCT03590769|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Patient undergoing percutaneous angioplasty of SFA or popliteal artery, or stenting of the iliac artery or SFA, will have 18F-FDG-PET scan at the region of interest before intervention, then post-operatively 1 day and 1 week from treatment.||||
34025615|NCT04727047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025616|NCT06211491|||CASE_ONLY||PROSPECTIVE|||||||
33896335|NCT03792711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896336|NCT00196885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33896337|NCT02454114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896338|NCT03392233|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.||||
33896339|NCT02764879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896340|NCT00291343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896341|NCT03876587|NA|SINGLE_GROUP||TREATMENT||NONE||Pyrotinib Maleate combine with Docetaxel||||
33896342|NCT00073944||||TREATMENT||NONE||||||
33896343|NCT01794390|||CASE_ONLY||CROSS_SECTIONAL|||||||
33896344|NCT06016543|||COHORT||PROSPECTIVE|||||||
33896345|NCT00907738|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896346|NCT04610307|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896347|NCT01233726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025617|NCT02656888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind study||t|f|t|f
34025618|NCT00010114|||COHORT||PROSPECTIVE|||||||
34025619|NCT01866046|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025620|NCT03399825|||CASE_ONLY||PROSPECTIVE|||||||
34025621|NCT01403857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025622|NCT06470178|||COHORT||RETROSPECTIVE|||||||
33896348|NCT00262405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896349|NCT04015765|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33896350|NCT05325112|||CASE_CONTROL||PROSPECTIVE|||||||
33896351|NCT02894073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896352|NCT03013595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33896353|NCT05357183|||COHORT||PROSPECTIVE|||||||
33896354|NCT05734287|||COHORT||OTHER|||||||
34077781|NCT00015002|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34077782|NCT04081675|||COHORT||PROSPECTIVE|||||||
34077783|NCT04715464|||COHORT||RETROSPECTIVE|||||||
34077784|NCT06213753|||COHORT||RETROSPECTIVE|||||||
34077785|NCT03724357|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Volunteers who choose to take part in this study will receive the licensed FDA-approved Oral Cholera Vaccine (Vaxchora).||||
34077786|NCT03432481|NA|SINGLE_GROUP||TREATMENT||NONE||Single group||||
34077787|NCT00054496||||TREATMENT||NONE||||||
34077788|NCT03569397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077789|NCT06320418|||CASE_CONTROL||RETROSPECTIVE|||||||
34077790|NCT00958854||||TREATMENT||NONE||||||
34077791|NCT03124160|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34077792|NCT03255694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896355|NCT06495151|||CASE_CONTROL||PROSPECTIVE|||||||
34077793|NCT04492423|||COHORT||PROSPECTIVE|||||||
34077794|NCT01542450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077795|NCT02359110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077796|NCT02948712|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077797|NCT06010797|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|It was a double blinded randomized controlled trial. Patients and the investigator recording indices were blinded.||t|f|t|f
34077798|NCT06135467|||OTHER||CROSS_SECTIONAL|||||||
34077799|NCT05849038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896356|NCT00442312|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34077800|NCT04135794|||COHORT||PROSPECTIVE|||||||
34077801|NCT06334263|||OTHER||OTHER|||||||
34077802|NCT01429467|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077803|NCT00849563|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34077804|NCT04856332|||COHORT||PROSPECTIVE|||||||
34077805|NCT00078013|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34077806|NCT06064058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Three Groups:~* Case~* Palcebo~* No placebo, no intervention group"|t|t|t|t
34077807|NCT04350268|||COHORT||PROSPECTIVE|||||||
34077808|NCT05252715|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896357|NCT04746521|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33896358|NCT03477240|||CASE_ONLY||CROSS_SECTIONAL|||||||
33896359|NCT04541069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|When the early childhood development assessment will be done by data collectors through ASQ insruments, they will not be aware of the respondent's status of whether they received the intervention or not.|Pragmatic Cluster Randomized Trial|f|f|f|t
33896360|NCT06656286|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33896361|NCT02991612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896362|NCT05996744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896363|NCT02997514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896364|NCT06346275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896365|NCT06106698|||COHORT||PROSPECTIVE|||||||
33896366|NCT02427581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896367|NCT01939262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896368|NCT04109079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896369|NCT00527852|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33896370|NCT05170191|||COHORT||PROSPECTIVE|||||||
33896371|NCT00666315|||CASE_CONTROL||PROSPECTIVE|||||||
33896372|NCT06644183|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1: single arm, Phase 2: two arm, randomized trial||||
33896373|NCT02852629|||CASE_ONLY||PROSPECTIVE|||||||
33896374|NCT00251797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896375|NCT02712450|||OTHER||PROSPECTIVE|||||||
33896376|NCT02696083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077809|NCT04078009|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|An open labelled randomised to either start with Aquagen or Grazax NAC|This is a single group study assessing symptoms scores 4 weeks between the two assessments (Grazax NAC and Aquagen NAC) performed to avoid any carry-over effects of this cross-over design.||||
34077810|NCT06209073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|virtual reality and conventional treatment|f|f|t|t
34077811|NCT00846586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896377|NCT05461729|||COHORT||PROSPECTIVE|||||||
33896378|NCT06657534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33896379|NCT03271489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896380|NCT00197860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896381|NCT00110643|NA|SINGLE_GROUP||TREATMENT||SINGLE||||||
33896382|NCT05594524|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33896383|NCT05286671|||COHORT||RETROSPECTIVE|||||||
34077812|NCT02029222|||COHORT||RETROSPECTIVE|||||||
34077813|NCT02532335|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34077814|NCT00251134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077815|NCT03502499|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34077816|NCT00633607|||FAMILY_BASED||OTHER|||||||
34077817|NCT05702437|||COHORT||PROSPECTIVE|||||||
34077818|NCT05916989|||OTHER||RETROSPECTIVE|||||||
34077819|NCT04797507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896384|NCT00147771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077820|NCT03627793|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34077821|NCT04420728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077822|NCT06499194|RANDOMIZED|PARALLEL||TREATMENT||NONE||an Open-label parallel design prospective controlled clinical trial||||
33896385|NCT02179398|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33896386|NCT05596825|||COHORT||PROSPECTIVE|||||||
33896387|NCT00942682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896388|NCT03619785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896389|NCT02730247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896390|NCT04757337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896391|NCT03584321|||COHORT||RETROSPECTIVE|||||||
33896392|NCT04382508|||COHORT||PROSPECTIVE|||||||
33896393|NCT00473694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896394|NCT06656559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896395|NCT01561131|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33896396|NCT00951795|||COHORT||PROSPECTIVE|||||||
33896397|NCT05509244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33896398|NCT02765893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896399|NCT05811195|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assesor will not know the laser protocol of each patient (single blind)|Participants will be allocated and randomized into 2 groups: Group I: PBMI (n=17) photobiomodulation intra oral low potency laser and Group II: PBME (n=17) photobiomodulation with high potency extraoral unfocoused laser with 1W.|f|f|f|t
33896400|NCT05098288|NA|SINGLE_GROUP||TREATMENT||NONE||Single Case Design (n=1) (multiple baselines)||||
33896401|NCT03842709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33896402|NCT04135781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896403|NCT00749086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896404|NCT01561638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33896405|NCT03918993|||CASE_CONTROL||RETROSPECTIVE|||||||
33896406|NCT03823729|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients assigned to the Elosan group (group A) will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions. Patients assigned to the control group (group B) will have no treatment except for the continuation of their prescribed pain medication and pain therapy.||||
33979932|NCT05702567|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|"The INDIBA radiofrequency device is randomized in a total of 99 programs, and in order of arrival, a number is assigned to each patient in which the intervention of the number is unknown. Patients will always be treated with the same program number, throughout all sessions.~The evaluations of the study will be carried out by the physiotherapist 1 (Yasmin Er Rabiai Boudallaa) who is blinded during the clinical trial.~And by the physiotherapist 2 (Marta Martínez Colmenar), is the responsible for the treatment of patients."|"The present study is a double-blind randomized clinical trial. Two groups are located, case group and placebo group.~The total number of sessions will be 18 sessions per patient, divided into three sessions per week for a total of six weeks. These sessions last one hour, with a net treatment time of 40 minutes in the supine position.~The vaginal probe is inserted into the cavity using a lubricant suitable for intracavitary use and RF, the device is turned on, while the RF is applied, pelvic floor contractions are performed guided by the physiotherapist 2 (Marta Martínez Colmenar) .~The evaluations before and after the study will be carried out by the physiotherapist 1 (Yasmin Er Rabiai Boudallaa) who is blinded to group allocation. All participants will be assessed before, after six weeks and 6 months after the start of the study."|t|f|t|t
33979933|NCT04211818|NA|SINGLE_GROUP||OTHER||NONE||||||
33979934|NCT06113653|||OTHER||PROSPECTIVE|||||||
33979935|NCT05167357|NON_RANDOMIZED|PARALLEL||SCREENING||NONE|All subjects, whether partaking in the COVID+ group or control group, got the same intervention. As such, the 'intervention' rather is the having undergone COVID19 or not. Involving sanitary reasons surrounding the COVID pandemic, a lack of communication concerning the COVID diagnosis between and to any party would have led to unnecessary health endangerment of concerned parties.|From the patients who came for consultation between 2015 and 2020, subjects have been recruited by mail for the Coronaltitude study from the 1st of March (2021) on. Subjects have been asked if they have suffered COVID19 in the 12 months before inclusion, during whichever wave, attested by a positive PCR, positive serology test or positive chest CT scan. Both patients answering positively and those answering negatively on the latter question have been included in the study. All included subjects, divided into those having suffered COVID19 (COVID+ group) and those having stayed free of COVID19 (control group), will retake an altitude mountain consultation.||||
33979936|NCT02502253|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33979937|NCT02519322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979938|NCT01166542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979939|NCT05539820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The students and investigators knew which group they were assigned to. Only the outcome assessor did not know which student was assigned to which group.||f|f|f|t
33979940|NCT01185496|||COHORT||PROSPECTIVE|||||||
33979941|NCT00146523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979942|NCT02408900|||COHORT||CROSS_SECTIONAL|||||||
33979943|NCT03527745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33979944|NCT05739045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979945|NCT03193008|||CASE_ONLY||RETROSPECTIVE|||||||
33979946|NCT06257745|||COHORT||PROSPECTIVE|||||||
33896407|NCT01432639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896408|NCT02936440|||COHORT||PROSPECTIVE|||||||
33896409|NCT05381961|||COHORT||PROSPECTIVE|||||||
33896410|NCT03702933|||CASE_CONTROL||PROSPECTIVE|||||||
33896411|NCT05230043|||CASE_CONTROL||PROSPECTIVE|||||||
33896412|NCT04073615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896413|NCT03435900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-randomised controlled trial||||
33896414|NCT01930071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896415|NCT02449330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896416|NCT03414359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34077823|NCT03566095|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were not aware of their status as a treatment or comparison community.|All data were collected from both treatment an comparison communities at the same time points.|t|f|f|f
33896417|NCT06293092|RANDOMIZED|PARALLEL||TREATMENT||NONE||control group receive medical treatment only ,first study group receive medical treatment and intradialytic aerobic exercise , second study group receive medical treatment and intradialytic resistive exercise||||
33896418|NCT00738738|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896419|NCT05091346|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896420|NCT00760175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33896421|NCT05179395|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All Participants unilateral upper limb amputation participants will wear the Brasthesis harness with their prosthetic arm for 4 weeks. Each subject served as their own control with baseline data collected at visit 1 and interventional data collected after 4 weeks.||||
33896422|NCT06329388|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial (RCT) with two parallel groups (treatment and control group).||||
33896423|NCT05128617|||COHORT||PROSPECTIVE|||||||
33896424|NCT04327648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896425|NCT00793923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33896426|NCT02242396|||COHORT||PROSPECTIVE|||||||
33896427|NCT03977077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896428|NCT04258618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896429|NCT03899740|||COHORT||PROSPECTIVE|||||||
33896430|NCT04649385|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896431|NCT06657339|||COHORT||PROSPECTIVE|||||||
33896432|NCT06133543|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33896433|NCT01600781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896434|NCT02942498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896435|NCT02688569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896436|NCT05240937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896437|NCT03466554|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33896438|NCT06448377|||COHORT||PROSPECTIVE|||||||
33896439|NCT06077799|||COHORT||RETROSPECTIVE|||||||
33896440|NCT02654925|||CASE_CONTROL||OTHER|||||||
33896441|NCT04029337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896442|NCT06090474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896443|NCT06478836|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33896444|NCT00202540|RANDOMIZED|PARALLEL||||DOUBLE||||||
33896445|NCT02035943|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33896446|NCT00949338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896447|NCT05994651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896448|NCT02622347|||OTHER||CROSS_SECTIONAL|||||||
33896449|NCT00101088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896450|NCT05854134|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896451|NCT01163422|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33979947|NCT04486196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979948|NCT02335801|||COHORT||PROSPECTIVE|||||||
33979949|NCT05676866|NA|SINGLE_GROUP||TREATMENT||NONE||Node positive breast cancer patients post neo adjuvant therapy||||
33896452|NCT01435512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896453|NCT00506389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896454|NCT01557725|||COHORT||PROSPECTIVE|||||||
33896455|NCT01691118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896456|NCT04295187|||OTHER||PROSPECTIVE|||||||
33896457|NCT04595955|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896458|NCT05827445|||COHORT||PROSPECTIVE|||||||
33979950|NCT00368953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979951|NCT00002595||||TREATMENT||||||||
33979952|NCT02849652|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33979953|NCT03765502|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33896459|NCT03455387|||COHORT||PROSPECTIVE|||||||
33896460|NCT03520049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896461|NCT01588080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979954|NCT02450981|NA|SINGLE_GROUP||||NONE||||||
33979955|NCT06433375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896462|NCT04387474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896463|NCT02455115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896464|NCT03414125|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Single Blind|Evaluate effect of offering choice of FIT or colonoscopy (n=2,000) compared to FIT alone (n=8,000) on one-time CRC screening completion, repeat screening, and follow-up of abnormal FIT results.|f|f|f|t
33896465|NCT02936895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896466|NCT04880317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896467|NCT03797287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896468|NCT01576471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896469|NCT04701411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896470|NCT00730093|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33979956|NCT03699644|||CASE_CONTROL||PROSPECTIVE|||||||
33979957|NCT00000949||||TREATMENT||NONE||||||
33979958|NCT02787278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33979959|NCT02850770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33979960|NCT04084483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979961|NCT06109103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979962|NCT04008784|||COHORT||PROSPECTIVE|||||||
33979963|NCT01658384|||COHORT||PROSPECTIVE|||||||
33896471|NCT00278824|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896472|NCT04807946|||COHORT||PROSPECTIVE|||||||
33896473|NCT02704429|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Part A with 12 weeks treatment and 12 weeks follow-up. Part B with 24 weeks treatment and 4 weeks follow-up.||||
33896474|NCT06114654|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33896475|NCT05144022|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"2 groups each undergoing one out of two conditions (high stress (bungee jump) or no stress (control))"||||
33896476|NCT02201823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896477|NCT06233292|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896478|NCT02732951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896479|NCT02395315|||COHORT||PROSPECTIVE|||||||
33896480|NCT02212418||CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33896481|NCT05741203|||COHORT||PROSPECTIVE|||||||
33896482|NCT02515695|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896483|NCT01517438|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
33896484|NCT01086683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896485|NCT05580289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomised|t|f|f|f
33979964|NCT03225196|||COHORT||CROSS_SECTIONAL|||||||
33979965|NCT01362998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979966|NCT02220868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979967|NCT02550223|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33979968|NCT03465566|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33979969|NCT01232634|||CASE_ONLY||PROSPECTIVE|||||||
33979970|NCT00018252|RANDOMIZED|||||||||||
33979971|NCT06014437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33979972|NCT01042483|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33979973|NCT04997343|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In this multicenter, longitudinal, interventional (for TMS-EEG) -observational (for clinical and radiological variables obtained according to clinical practice) case-control study, all participants will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity. These evaluations will be repeated according to clinical practice in patients taking Disease modifying therapies (DMTs) or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline. For the study, no hospital diagnostic equipment will be used, but machinery present in the research laboratories, for research use only, bearing the CE mark.||||
33979974|NCT02621775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33979975|NCT05375409|||COHORT||PROSPECTIVE|||||||
33979976|NCT04745026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33979977|NCT01076972|||COHORT||PROSPECTIVE|||||||
33979978|NCT01421706|RANDOMIZED|CROSSOVER||||NONE||||||
33979979|NCT03719222|||COHORT||RETROSPECTIVE|||||||
33979980|NCT01341366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979981|NCT06359808|||COHORT||CROSS_SECTIONAL|||||||
33979982|NCT03113006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979983|NCT02687048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979984|NCT05666752|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33979985|NCT02975466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025623|NCT06082193|||CASE_CONTROL||RETROSPECTIVE|||||||
34025624|NCT05949411|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34025625|NCT02462291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34025626|NCT06632405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025627|NCT06430931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre prospective non-inferior patient-preference study||||
33896486|NCT05707130|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be allocated to intervention groups by randomization. The patients in group A will be given gaze stabilization exercises and habituation exercises along with neck isometrics for 4 weeks. The patients in group B will be given neck isometrics for treatment of cervical spondylosis for 4 weeks.||||
33896487|NCT03619122|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34025628|NCT03571386|||COHORT||PROSPECTIVE|||||||
34025629|NCT03167346|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34025630|NCT02493192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34025631|NCT03083652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34025632|NCT03196635|NA|SINGLE_GROUP||SCREENING||NONE||||||
34025633|NCT01882972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34025634|NCT06163391|NA|SINGLE_GROUP||TREATMENT||NONE||6 cohorts, multiple-dose escalation, Bayesian optimal interval design (BOIN) trial||||
34077824|NCT01796028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896488|NCT04721314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All investigators are blinded to patient randomization. To assess subject blinding, participants are asked at 1 month and 12 month follow up if they believed that their pacemaker lower rate was changed.|Patients are randomized to either a personalized pacemaker lower heart rate setting based on a resting heart rate algorithm or to the conventional pacemaker lower rate setting of 60bpm.|t|f|t|f
33896489|NCT04939818|||COHORT||CROSS_SECTIONAL|||||||
33896490|NCT05299892|NA|SINGLE_GROUP||TREATMENT||NONE|"Participants will be blind as to whether the Speech Enhancer feature is activated or deactivated."|"One group of participants will be assessed unaided and aided with Phonak Audeo P or Phonak Naida P hearing aids with Speech Enhancer off, on at moderate, and on at strong settings."||||
33896491|NCT02519231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896492|NCT04648371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Centrally administered, computer based generation scheme. Release of assignments only after consent and eligibility, and required baseline data collected. Inability to predict future assignments from past assignments. Creation of an audit trail for the assignment. Balanced Random Assignments to Treatment will be used to generate treatment assignment schedule in a random permuted block design. A file specifying the treatment allocation of each randomization ID will be stored with a member independent of the study. Then, the independent member will access the randomization ID and will access the treatment allocation and program tDCS. The randomization ID will be noted in the CRF but the allocation will not be accessed unless there is an SAE that requires breaking of the blind or the study is complete. In order to ensure that blinding has been maintained, participants and raters will be asked as each patient exits the trial to state what treatment they believe each participant was given.||t|t|t|t
33896493|NCT03369847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896494|NCT04911153|||OTHER||PROSPECTIVE|||||||
33896495|NCT04227444|||CASE_ONLY||PROSPECTIVE|||||||
33896496|NCT02638012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896497|NCT03547050|||CASE_CONTROL||OTHER|||||||
33896498|NCT03400293|||COHORT||CROSS_SECTIONAL|||||||
33896499|NCT03716791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Double-blind placebo controlled randomized controlled trial|t|f|t|t
33896500|NCT04939493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33896501|NCT01987544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896502|NCT00756002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896503|NCT04494165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The measurements and evaluations of the patients were conducted by an independent surveyor (assessor-blind) to ensure that the study was double-blind. Massage application, the main intervention of the study, was carried out by another nurse who was trained on this subject.|3x2 (experiment, control and placebo group x pre-test post-test) split plot design|t|f|f|t
33896504|NCT05593432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study will include a 16 week double-blind period followed by a 16 week open-label period.|t|t|t|f
33896505|NCT05088148|||CASE_CONTROL||PROSPECTIVE|||||||
33979986|NCT03818802|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This protocol will employ a blinded design so that the participant, study personnel, and investigators will not know subject group assignment status. The unblinding would be done by contacting the research pharmacy. While the safety of the subject always comes first, it is still important to seriously consider if unmasking/unblinding the study therapy is necessary to ensure a subject's safety. The unmasking/unblinding will happen only when there is a serious adverse event; in this case this event will be logged in the specific Case Report Form for Serious Adverse Event (SAE) that is part of this protocol. However, in cases where unmasking/unblinding was not associated with an SAE, such actions will be reported in a same timeline requirements for reporting of SAEs.|The investigators will enroll 48 subjects (24 placebo vs. 24 NR) considering a dropout rate of 20%. Patients will be screened at outpatient clinic visit by the research team before the enrollment. For those subjects interested and qualified it will be offered participation in this trial. Once consent has been obtained baseline values will be established and subjects will begin treatment and followed for 4.5 months. After 4.5 months, a structured exercise regimen will be implemented in addition to the NR/placebo treatment and the patients will be followed for 6 weeks more, completing 6 months.|t|f|t|f
33979987|NCT00060905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33979988|NCT06127498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33979989|NCT02786238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33979990|NCT00847548|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33979991|NCT05475353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33979992|NCT01611389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33979993|NCT04465409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33979994|NCT00331578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33979995|NCT01701726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979996|NCT01229852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896506|NCT05315440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor doesn't know allocation concealment|randomized controlled trial|f|f|f|t
33896507|NCT04289883|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Double-blind|A double-blind, randomised crossover design with four arms divided into two parts.|t|t|t|t
33896508|NCT00142103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896509|NCT06482879|||OTHER||PROSPECTIVE|||||||
33979997|NCT03535168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part 1: Sequential parallel-group Part 2: Two-arm crossover|t|t|t|t
33896510|NCT01836315|||COHORT||PROSPECTIVE|||||||
33896511|NCT04866472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomization to Control: Video-Laryngoscope and GlideRite Rigid Stylet vs Intervention: Video-Laryngoscope with TCI Articulating Device|t|f|f|f
33896512|NCT04889677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33896513|NCT02981212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896514|NCT02691273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896515|NCT00658333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896516|NCT01082757|||COHORT||PROSPECTIVE|||||||
33896517|NCT02058381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896518|NCT02299934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896519|NCT04707872|||COHORT||PROSPECTIVE|||||||
33896520|NCT02189382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896521|NCT01707875|||CASE_ONLY||PROSPECTIVE|||||||
33896522|NCT04411238|||OTHER||PROSPECTIVE|||||||
33896523|NCT03409302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind (subject, outcome assessor)||t|f|t|f
33896524|NCT03008551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896525|NCT04653662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896526|NCT05961826|||COHORT||OTHER|||||||
33896527|NCT05952830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896528|NCT04605627|||COHORT||PROSPECTIVE|||||||
33896529|NCT06345040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896530|NCT04913805|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|all personnel will be masked except for the IDS pharmacist dispensing the drugs|3 interventions will be randomized and administered in a double-blind fashion|t|t|t|t
33896531|NCT04745442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896532|NCT06069063|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896533|NCT05762341|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Number of groups 2 (experiment, control), number of measurements 2 (pretest, posttest),|t|f|f|f
33896534|NCT05361096|RANDOMIZED|PARALLEL||OTHER||SINGLE||Explanatory sequential design, one of the mixed-method designs, was used.|f|f|f|t
33896535|NCT00784407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896536|NCT05277012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study participants will receive 3 treatments (Treatment A, B and C) sequentially during the Treatment Period 1, 2, and 3.~Treatment A: etrumadenant capsule in fasted state Treatment B: etrumadenant tablet in fasted state Treatment C: etrumadenant tablet in fed state Each treatment will be separated by a washout period of 7 days."||||
33896537|NCT00501319|||CASE_ONLY||PROSPECTIVE|||||||
33896538|NCT04215094|||CASE_CONTROL||PROSPECTIVE|||||||
33979998|NCT03072680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33979999|NCT03834805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980000|NCT02623166|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33980001|NCT06058728|||COHORT||PROSPECTIVE|||||||
33980002|NCT02456493|||COHORT||PROSPECTIVE|||||||
33980003|NCT04352361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980004|NCT05229757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The individuals included in the study and their families were not informed about which group they belonged to.||t|t|f|f
33980005|NCT06497153|||COHORT||PROSPECTIVE|||||||
33980006|NCT03204526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980007|NCT03184441|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980008|NCT04460105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980009|NCT02368405|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Study allocation was placed in concealed envelopes by research volunteer who was not otherwise involved in the study.||f|f|f|t
33980010|NCT01513083||PARALLEL||TREATMENT||NONE||||||
33980011|NCT02720510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980012|NCT00755326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896539|NCT00023348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896540|NCT00487812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896541|NCT06020469|||CASE_ONLY||RETROSPECTIVE|||||||
33896542|NCT05056714|||COHORT||PROSPECTIVE|||||||
33896543|NCT00474253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896544|NCT02870673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896545|NCT02655861|||CASE_ONLY||PROSPECTIVE|||||||
33896546|NCT02928419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896547|NCT00630032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896548|NCT04295902|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33896549|NCT02857712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896550|NCT03381040|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896551|NCT00004415||||TREATMENT||||||||
34077825|NCT04035824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33896552|NCT05337124|||CASE_ONLY||PROSPECTIVE|||||||
33896553|NCT03322137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896554|NCT03378687|||COHORT||RETROSPECTIVE|||||||
33896555|NCT01802944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896556|NCT04371510|NA|SINGLE_GROUP||OTHER||NONE||PredictCOVID-D study. Covid-19 chronic haemodialysis patients with moderate symptoms||||
33896557|NCT01598181|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33896558|NCT00984711|||COHORT||PROSPECTIVE|||||||
33896559|NCT00682968|||OTHER||OTHER|||||||
33896560|NCT06221111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|concealed allocation; blinded provision of assigned medication through research pharmacy|randomized, double-blind placebo-controlled trial of rimegepant at doses and route of administration approved by the FDA for the prophylaxis of migraine headache.|t|t|t|t
33896561|NCT03666767|||COHORT||PROSPECTIVE|||||||
33896562|NCT00735358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896563|NCT00292773|||||PROSPECTIVE|||||||
33896564|NCT00895492|||CASE_ONLY||PROSPECTIVE|||||||
33896565|NCT00893607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896566|NCT06163235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896567|NCT01144637|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896568|NCT00716521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33896569|NCT05926206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896570|NCT00731029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33896571|NCT01024244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896572|NCT03540017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896573|NCT05449392|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Blinding will be achieved by masking and packaging the products in an identical fashion. Investigational product will be filled in empty Aluminum Ointment Tubes 15 g (Supplied via HealthCareLogistics, Item # 10201-01). The empty Aluminum Ointment Tubes are sterilized by gamma irradiation and have protective inner (epoxy phenolic) coating to prevent ointments from sticking to the sides and reacting with the aluminum.~Each tube will be filled with approximately 15 g of the Neosporin ointment investigational product, or Vaseline Petroleum Jelly its matching placebo, and labeled in a blinded fashion.~Patient or clinicians requesting unblinding will contact the principal investigator (PI)."|Run-in cohort to test optimal sampling and storage conditions: For 6 participants, the investigator will test 50:50 with Neosporin vs Placebo participant nasal sampling and shipping protocol to evaluate signal to noise of interferon-stimulated genes (ISG) measures. If needed, we will rerun the power calculations.|t|f|t|f
33896574|NCT03045146|||CASE_ONLY||PROSPECTIVE|||||||
33896575|NCT05136391|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896576|NCT06187818|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980013|NCT00197210|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33980014|NCT02010762|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33980015|NCT04788238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors and data analysts will be blinded to the group allocation until the whole data analyses are completed. They will also not be involved in any part of the treatment administration. Furthermore, participants will be advised not to disclose their group assignment during data collection.|Participants will be equally allocated to the intervention and control group, following a randomization schedule generated by an independent statistician who has no access to the subjects. The randomization list will be sealed in sequentially numbered opaque envelopes. Participants will be informed of the group allocation after the submission of written consent and completion of the baseline assessments.|f|f|f|t
33980016|NCT06224725|||OTHER||PROSPECTIVE|||||||
33980017|NCT01052090|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33980018|NCT03929536|||COHORT||RETROSPECTIVE|||||||
33980019|NCT03189888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980020|NCT03451201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised Clinical Trial, 3 parallel groups: HIIT ( High-Intensity Interval Training) MCT (moderate intensity continuous training) and Sedentary Control Group.||||
33980021|NCT05266248|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33980022|NCT02626949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980023|NCT00379756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767816|NCT04170868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The videos will be evaluated in a split-exposure clinical trial, whereby outpatients will be randomly assigned access to one of the two proof-of-concept videos for unlimited viewing. After ten days of access, the patients will spend an additional ten days without video access. The first ten-day procedure will then be repeated once over, with each participant now gaining access to the opposing proof-of-concept video. Clinical impairment data along with patient perspectives will be gathered at each transition junction for use in pre- and post-exposure analyses. The investigators hope to find meaningful improvements in patient functioning-along with a positive reception to the video format-such as to warrant further clinical investigation.||||
33767817|NCT02340520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767818|NCT04760730|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blinded (participant-blinded study)||t|f|f|f
33767819|NCT04176159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The subjects will be randomized into 2 groups: an intervention group, which will participate in a program based on the combination of motor imagery and work oriented to the motor task; and a control group, which will carry out their usual school routine.|f|f|f|t
33767820|NCT02254837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767821|NCT04551196|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|Single-center, randomized, open-label, non-inferiority treatment pilot study||||
33767822|NCT01899066|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767823|NCT03813212|||COHORT||PROSPECTIVE|||||||
33767824|NCT02108145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767825|NCT04662671|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind, sham-controlled|The study will be conducted as a randomized, double-blind, sham-controlled study in SARS-CoV-2 infected individuals with outpatient COVID-19. Subjects will be randomized 2:1 RD-X19 to Sham Device treatment arms.|t|t|t|t
33767826|NCT01523340|||CASE_ONLY||PROSPECTIVE|||||||
33767827|NCT02075021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767828|NCT05449886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767829|NCT05097118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767830|NCT00401102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767831|NCT04096573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767832|NCT02774603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33767833|NCT06379113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767834|NCT01110343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767835|NCT02117232|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33767836|NCT05546541|||CASE_CONTROL||PROSPECTIVE|||||||
33767837|NCT02733302|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33767838|NCT04453241|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767839|NCT02409303|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33767840|NCT05699915|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33767841|NCT05531474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767842|NCT03958240|NA|SINGLE_GROUP||OTHER||NONE||||||
33767843|NCT01305096|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33767844|NCT01872637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767845|NCT00758160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801337|NCT03748186|NA|SEQUENTIAL||TREATMENT||NONE||The study is a modified 3+3 dose escalation study with a dose expansion. Dose escalation is in advanced ovarian cancer patients with relapsed or refractory disease to standard approved therapy. Dose expansion includes 2 cancer populations, ovarian cancer and endometrial cancer. The ovarian cancer expansion cohorts are Cohort A and Cohort C. Cohort A is a dose ranging design with randomization into 2 dose levels of STRO-002, 4.3 mg/kg and 5.2mg/kg. Cohort C is a single dose cohort design, STRO-002 5.2 mg/kg with prophylactic pegfilgrastim. Dose expansion in endometrial cancer (Cohort B) is a single dose cohort design, STRO-002 5.2 mg/kg. Endometrial subjects with prior pelvic irradiation will start treatment of STRO-002 at 4.3 mg/kg with step up to 5.2 mg/kg.||||
33896577|NCT05631951|RANDOMIZED|PARALLEL||TREATMENT||NONE||"30 patients were included and divided randomly into two equal groups:~* Group (A) will undergo BTM~* Group (B) will undergo BT~Methods:~I. Preoperative evaluation~II. Operative interventions:~A. Pre-operative:~B. Operative interventions~* first step~  • resection of infected bone~* Second step:~(A) Group A cement spacer and external fixator were applied then removal of cement spacer and metaphyseal osteotomy done (B)Group B~* external fixator was applied then metaphyseal osteotomy done C. Post-operative~* bone transport was started after latency of 7 days (from osteotomy) at rate of 1mm per day in 4 increments per day (rhythm of 0.25 mm every 6 hours) until reaching docking site."||||
33896578|NCT04674163|NA|SINGLE_GROUP||OTHER||NONE||||||
33896579|NCT02717702|||COHORT||PROSPECTIVE|||||||
33896580|NCT02429505|||CASE_ONLY||PROSPECTIVE|||||||
33896581|NCT05387161|||OTHER||PROSPECTIVE|||||||
33896582|NCT02298244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896583|NCT05742620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980024|NCT03678636|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||100 patients positive for BPA will be randomized to intervention or control treatment. It is anticipated approximately 200-250 patients will be tested assuming a prevalence of BPA of 40-50%.||||
33980025|NCT00449878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980026|NCT06137677|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33801338|NCT03431922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801339|NCT01030107|||CASE_ONLY||PROSPECTIVE|||||||
33801340|NCT02300675|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896584|NCT05193812|||COHORT||PROSPECTIVE|||||||
33896585|NCT04560127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801341|NCT03210454|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization occurs at the farmer's association level.||||
33801342|NCT02740283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801343|NCT03336905|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33801344|NCT02421159|NA|SINGLE_GROUP||OTHER||NONE||||||
33801345|NCT05444426|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33801346|NCT06252168|||CASE_ONLY||CROSS_SECTIONAL|||||||
33801347|NCT03671551|||COHORT||PROSPECTIVE|||||||
33801348|NCT00552201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896586|NCT05575518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896587|NCT02512796|||CASE_CONTROL||PROSPECTIVE|||||||
33801349|NCT04718909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801350|NCT01541436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33801351|NCT03855397|NA|SINGLE_GROUP||OTHER||NONE||||||
33801352|NCT04705675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants didn't know which group they were allocated. The participants will be blind when they attend breastfeeding education.|The study was designed to be parallel group, randomized controlled study (1:1). Power was calculated using the GPower 3.1 program. In the power analysis performed at a confidence interval of 95% and a margin of error of plus/minus 5%, sample size was calculated as a total of 304 mothers with 152 in the study group and 152 in the control group.A total of 304 mothers were evenly and homogeneously assigned to both groups.|t|f|f|f
33896588|NCT00006061||||TREATMENT||||||||
33896589|NCT02534337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896590|NCT04467112|||COHORT||CROSS_SECTIONAL|||||||
33896591|NCT05523492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896592|NCT04283877|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Double-blinding of participants and investigator, with independent investigator in charge of placebo and drug|Single Group Assignment|f|f|t|f
33896593|NCT02599012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896594|NCT00077662|||COHORT||PROSPECTIVE|||||||
33896595|NCT05079438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33896596|NCT05442385|||COHORT||PROSPECTIVE|||||||
33896597|NCT01910506|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33896598|NCT03554590|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896599|NCT05940337|||COHORT||CROSS_SECTIONAL|||||||
33896600|NCT03982225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896601|NCT02262130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801353|NCT03928522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patient will not know which antibiotic cement group they are in||t|f|f|f
33801354|NCT03306368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801355|NCT01913314|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801356|NCT02334436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801357|NCT03348722|||COHORT||PROSPECTIVE|||||||
33801358|NCT02742571|||||PROSPECTIVE|||||||
33801359|NCT04980274|||COHORT||RETROSPECTIVE|||||||
33801360|NCT04146519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801361|NCT01401023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801362|NCT00213733|||CASE_ONLY||PROSPECTIVE|||||||
33896602|NCT00509886|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33896603|NCT03563248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896604|NCT01341912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896605|NCT02408250|||OTHER||PROSPECTIVE|||||||
33896606|NCT06435715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors were not involved during the intervention process. Respondents were also asked not to inform the outcome assessor of the measures they received.|This study used a parallel Randomized Controlled Trial (RCT) with a 1:1 ratio.|f|f|f|t
33896607|NCT05691062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to fusion device.|Prospective randomized clinical trial with two cohorts.|t|f|f|f
33896608|NCT01519843|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896609|NCT03746197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33896610|NCT00257751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896611|NCT01773031|||CASE_ONLY||PROSPECTIVE|||||||
33896612|NCT06489964|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896613|NCT01158612|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33896614|NCT01438983|||COHORT||RETROSPECTIVE|||||||
33896615|NCT04715347|||COHORT||RETROSPECTIVE|||||||
33896616|NCT03067311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896617|NCT05946863|||COHORT||PROSPECTIVE|||||||
33896618|NCT01417260|||COHORT||PROSPECTIVE|||||||
33896619|NCT00408278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896620|NCT05475873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33896621|NCT04901507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896622|NCT03848520|||COHORT||CROSS_SECTIONAL|||||||
33896623|NCT03636828|||COHORT||PROSPECTIVE|||||||
33896624|NCT02270177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896625|NCT04769843|||CASE_ONLY||CROSS_SECTIONAL|||||||
33896626|NCT02837172|||CASE_CONTROL||OTHER|||||||
33896627|NCT02429648|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33896628|NCT00203346|||||PROSPECTIVE|||||||
33896629|NCT03291379|NA|SINGLE_GROUP||TREATMENT||NONE||1 mL BTG-002814 containing 100 mg vandetanib||||
33896630|NCT00729014|||||RETROSPECTIVE|||||||
33896631|NCT03951987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The randomization was in the ratio 1:1.||||
33896632|NCT02850250|||CASE_ONLY||PROSPECTIVE|||||||
33896633|NCT05755789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896634|NCT01046318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896635|NCT02616653|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|t|t|f
33896636|NCT00366236|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33896637|NCT05162235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896638|NCT05139524|||OTHER||OTHER|||||||
33896639|NCT03724708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomised computer generated table and closed envelope system|randomized controlled trial|t|f|f|f
33896640|NCT05990530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896641|NCT00256555||CROSSOVER||TREATMENT||NONE||00||||
33896642|NCT00735423|||COHORT||CROSS_SECTIONAL|||||||
33896643|NCT00844883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896644|NCT05751408|||OTHER||OTHER|||||||
33896645|NCT01421368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896646|NCT03062917|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896647|NCT04074993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896648|NCT01695629|||COHORT||PROSPECTIVE|||||||
33980027|NCT05770726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980028|NCT02204969|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33980029|NCT02979353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33980030|NCT02377336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980031|NCT00682305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980032|NCT04366141|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This will be a prospective, open-label, randomized controlled trial in which patients will be randomly allocated to two study groups on a 1:1 basis into:~1. COVID-19 barrier box Intervention group: Anesthesiologists will use a COVID barrier box during intubation.~2. Control group: Anesthesiologists will not use a COVID barrier box during intubation. Standard intubation procedures will be followed for intubation.~A block randomization strategy, using a computer-generated sequence of random numbers, will be used. Randomization will occur preoperatively if consented patients meet the eligibility criteria and provide informed consent."||||
33980033|NCT03219398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33980034|NCT01566071|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33980035|NCT00101582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980036|NCT00536900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980037|NCT04195815|||CASE_ONLY||PROSPECTIVE|||||||
33896649|NCT04300725|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|• Randomization will occur after informed written consent has been obtained. Treatment randomization will be performed using a block randomization approach with block sizes of 10 individuals. A list will be created using www.sealedenvelope.com, and these will be placed in numbered envelopes to be opened after patient consent by the intern resident.||f|t|f|f
33896650|NCT03490786|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation||||
33896651|NCT04285034|||COHORT||PROSPECTIVE|||||||
33896652|NCT02171169|||COHORT||RETROSPECTIVE|||||||
33896653|NCT03202121|||OTHER||PROSPECTIVE|||||||
33896654|NCT04121910|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33896655|NCT05914363|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single Group Assignment||||
33896656|NCT05726695|||CASE_CONTROL||PROSPECTIVE|||||||
33896657|NCT03682796|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896658|NCT02764619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896659|NCT03466762|||OTHER||CROSS_SECTIONAL|||||||
33896660|NCT03219125|||CASE_CONTROL||PROSPECTIVE|||||||
33896661|NCT02456623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896662|NCT02085577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896663|NCT00410891|NA|SINGLE_GROUP||OTHER||NONE||||||
33896664|NCT03251690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896665|NCT01938170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896666|NCT02046135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896667|NCT01581190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896668|NCT04481100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896669|NCT05115318|||CASE_ONLY||PROSPECTIVE|||||||
33896670|NCT00582231|||CASE_ONLY||PROSPECTIVE|||||||
33896671|NCT06334133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896672|NCT00469508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896673|NCT01225406|||COHORT||OTHER|||||||
33896674|NCT00765583|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33896675|NCT01647763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767846|NCT05724056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In order to maintain the blinding of the Investigator and his team, both products will be placed into identical boxes (blinding-box), identified only by a randomization number, without any indication of product identity or randomization arm.~Each patient will be randomly assigned a randomization number, allocating him/her to either Idroflog® or Sodium Hyaluronate 0.18% (1:1) in accordance with a central randomisation table generated using a validated computer-program. Randomisation will be stratified per center and performed using a permuted random block design."|Participants will be enrolled equally and randomly into either treatment group: Idroflog® or Sodium Hyaluronate 0.18% (Vismed®). Once randomized, participants will receive the intervention for 90 days, and will be followed up at 30 days, 60 days, and 90 days.|f|f|t|t
33767847|NCT02494921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980038|NCT03208543|NA|SINGLE_GROUP||TREATMENT||NONE||Patients meeting inclusion criteria will be enrolled to receive seven treatment sessions with thermotherapy (HECT-CL device) and will be reassessed during follow up visits at day 15, 30, 60, 90 and 180||||
33980039|NCT03795363|||COHORT||PROSPECTIVE|||||||
33767848|NCT05059054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Comparison between the exercise program and insole program.|t|f|t|t
33980040|NCT00048646|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33980041|NCT05028842|||COHORT||RETROSPECTIVE|||||||
33980042|NCT05367310|||OTHER||PROSPECTIVE|||||||
33980043|NCT05020847|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This will be an open, randomized controlled trial aimed at testing the effectiveness of three therapeutic diet regimens during the first phase of hospital management of children with complicated SAM admitted to CREN, Bobo Dioulasso.~Children aged 6 to 59 months hospitalized in the pediatric department or other services of the Bobo Dioulassso CHUSS, and admitted to the CREN for complicated SAM (WHZ \< -3 SD and/or MUAC \< 115 mm and/or the presence of nutritional edema) will be randomly assigned to receive:~1. Standard F75;~2. Alternative F75 without CMV (mainly containing corn flour, sugar, powdered milk and oil); and~3. Alternative F75 with CMV (includes most minerals and vitamins like F75 and F100)."||||
33980044|NCT01504737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980045|NCT00571428|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33980046|NCT01345149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980047|NCT03673488|||CASE_ONLY||PROSPECTIVE|||||||
33980048|NCT06496061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33980049|NCT01134523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980050|NCT03503448|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980051|NCT04418726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33980052|NCT03987009|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33980053|NCT02457429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980054|NCT04048148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and their parents / guardians and investigators will be masked to their lens assignment. Test spectacles will be of similar appearance to control spectacles and will not be easily identified without specialized equipment. Test and control spectacles will be assigned a code (A or B) by the clinical coordinator and stored in a secure location.|This is a mono-center, randomized, double-masked, cross-over study to evaluate if novel design lens can slow down the progression of myopia. A total of 120 healthy children aged between 8 years to 13 years with myopia (-0.75D to -4.75D) meeting the inclusion and exclusion criteria will be recruited. These children will be randomized to wear test lenses followed by control lenses (Group 1) or to wear control lenses followed by test lenses (Group 2). At the end of the 12 month period, all participants will wear test lenses for another 6 months. All children will be followed at 3-monthly intervals for 1.5 years to monitor for changes in axial length and 6-monthly for changes in cycloplegic autorefraction. The cross-over design allows to compare treatment effects between the two groups at 6 months, 12 months and at 18 months. In addition, at the end of the study, the treatment effects can be compared within subject as each subject will have worn both lenses and serves as his/her control.|t|f|t|f
33980055|NCT00825708|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33980056|NCT02296775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980057|NCT01643837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33980058|NCT00805558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980059|NCT01893957|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980060|NCT05586022|||COHORT||PROSPECTIVE|||||||
33980061|NCT04834037|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
33980062|NCT00175357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980063|NCT02384174|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33980064|NCT01004211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980065|NCT06356675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980066|NCT03689790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980067|NCT03103100|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33980068|NCT04637074|||COHORT||PROSPECTIVE|||||||
33980069|NCT02689908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980070|NCT02679001|||OTHER||CROSS_SECTIONAL|||||||
33980071|NCT03651323|||COHORT||RETROSPECTIVE|||||||
33767849|NCT00474721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33767850|NCT02941068|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767851|NCT05920525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767852|NCT05828849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767853|NCT04859894|||CASE_ONLY||PROSPECTIVE|||||||
33767854|NCT03297008|||COHORT||CROSS_SECTIONAL|||||||
33767855|NCT06547398|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised to Adaptive radiotherapy or standard radiotherapy, 2:1 randomisation.||||
33767856|NCT04861870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767857|NCT04386226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-Blind|Double-Blind, Randomized, Control|t|f|t|f
33980072|NCT02620345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980073|NCT04605107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33980074|NCT03127137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant will be blinded to group assignment. Outcome assessor will also be blinded to the randomization.|Prospective Randomized Controlled Trial using control arm plus 2 arm experimental (placebo and active drug)|t|f|f|t
33980075|NCT01196052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980076|NCT03832400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded as to which dosing arm the subjects are assigned.|This is a Phase 1b, placebo-controlled, multiple dose pilot study.|f|f|f|t
33980077|NCT03006016|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33980078|NCT03180866|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The subject will act as their own control as one target plaque will receive treatment and one will not. This information will not be made available to the Investigators or the bio-statistician.||f|f|t|t
33980079|NCT03160352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980080|NCT05327699|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33767858|NCT03103230|NA|SINGLE_GROUP||OTHER||NONE||||||
33980081|NCT00000406|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33980082|NCT06440564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767859|NCT04926012|||CASE_CONTROL||PROSPECTIVE|||||||
33980083|NCT06080061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077826|NCT03983954|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||NAP dose-escalation cohorts with a standard 3+3 design. A sentinel patient is recruited at each dose level in the first dose-escalation part. NAP is given for up to 3 cycles in the dose escalation parts and up to 6 cycles in the MTD expansion part.||||
34077827|NCT02936778|||CASE_CONTROL||PROSPECTIVE|||||||
34077828|NCT02380365|||COHORT||PROSPECTIVE|||||||
33980084|NCT03399526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980085|NCT00741663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980086|NCT01641445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980087|NCT01774890|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33980088|NCT05436756|NA|SINGLE_GROUP||OTHER||NONE||||||
33980089|NCT04012697|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Baseline data collection is performed prior to randomization and group assignment. Data collection at each of the following Time points is performed by research assistants who are blinded to the participant's group assignment. Investigators are likewise blinded to the group assignment of participants. Participants are not blinded given the impracticality of blinding assignment to the group receiving peer support vs. receiving usual care.|Pragmatic randomized controlled superiority trial with parallel intervention and usual care groups.|f|f|t|t
33980090|NCT05939674|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34077829|NCT01463787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077830|NCT02246738|||COHORT||PROSPECTIVE|||||||
34077831|NCT02216383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077832|NCT05668897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077833|NCT02821429|||COHORT||PROSPECTIVE|||||||
34077834|NCT04957043|||COHORT||RETROSPECTIVE|||||||
34077835|NCT01844037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077836|NCT03708445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The conventional staining method and new staining method will be performed in cytology specimens obtained from same patient.||||
33980091|NCT00732290|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33980092|NCT01567137|||CASE_ONLY||PROSPECTIVE|||||||
33767860|NCT00023842|RANDOMIZED|||TREATMENT||NONE||||||
33767861|NCT03015116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980093|NCT05194358|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33980094|NCT03413046|||CASE_CONTROL||PROSPECTIVE|||||||
33980095|NCT05701371|||COHORT||PROSPECTIVE|||||||
33980096|NCT01985802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980097|NCT05710978|NA|SINGLE_GROUP||OTHER||NONE||||||
33980098|NCT02857270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980099|NCT05924529|||COHORT||PROSPECTIVE|||||||
33980100|NCT01124396|||COHORT||PROSPECTIVE|||||||
33980101|NCT02187965|||CASE_ONLY||CROSS_SECTIONAL|||||||
33980102|NCT00001849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparison of results in patients receiving similar imaging scans||||
33980103|NCT04912349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077837|NCT01055015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077838|NCT03660748|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is open label, single center, uncontrolled pilot study of 20 participants divided into 2 groups of 10; each group will receive a different dose of MET-3. Each group will have 4-6 females, 4-6 participants with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9 kg/m.||||
34077839|NCT05430425|||CASE_ONLY||PROSPECTIVE|||||||
34077840|NCT00500448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077841|NCT06324877|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"1. Primary objective: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain.~2. Secondary objectives:~   * Determine to what extent the beneficial effects ongoing of NR on NFl translate to clinical efficacy in patients with A-T.~  * Type 1 Interferon (INFs) epigenetic signature specifically the cGAS-STING pathway."||||
34077842|NCT03507855|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33896676|NCT03669133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study biostatistician and Investigational Drug Services pharmacist will randomize subjects and will provide study drug|Group A: Vitamin E 800 IU/daily for 24 weeks. (total of 28 subjects) Group B: Matching placebo for 24 weeks (total of 28 subjects)|t|t|t|f
33896677|NCT04382261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896678|NCT01725763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896679|NCT04974307|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33980104|NCT04957108|||OTHER||CROSS_SECTIONAL|||||||
33980105|NCT02064595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980106|NCT01357603|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33980107|NCT00678366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33980108|NCT05524103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980109|NCT05883176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980110|NCT05052164|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33980111|NCT05075603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980112|NCT01850420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980113|NCT04122430|||OTHER||RETROSPECTIVE|||||||
33980114|NCT03312530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980115|NCT00775177|RANDOMIZED|CROSSOVER||||NONE||||||
33980116|NCT00922909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33980117|NCT05783284|||OTHER||RETROSPECTIVE|||||||
33980118|NCT00841100|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33980119|NCT04088214|NA|SINGLE_GROUP||TREATMENT||NONE||case series||||
33980120|NCT06387147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind Gentamicin + Metronidazole versus placebo|t|t|t|t
33980121|NCT01624376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980122|NCT03680898|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980123|NCT03190577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980124|NCT05491083|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Phase Ib: Patients with advanced solid tumors will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 6-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~* Phase II: Up to a total of 33 patients with advanced triple negative breast cancer will be enrolled."||||
33980125|NCT00406913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33980126|NCT04921774|||COHORT||PROSPECTIVE|||||||
33980127|NCT03120078|||COHORT||PROSPECTIVE|||||||
33980128|NCT04183881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980129|NCT01751347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33980130|NCT01390363|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33896680|NCT01318616|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33896681|NCT03517436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980131|NCT00116922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33980132|NCT03064022|||COHORT||RETROSPECTIVE|||||||
33980133|NCT04917978|||COHORT||RETROSPECTIVE|||||||
33980134|NCT02138279|||COHORT||PROSPECTIVE|||||||
33980135|NCT03344445|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||simple compare of information gain between traditional visit and video-assisted visit|f|f|f|t
33980136|NCT01882140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33980137|NCT00002662|RANDOMIZED|||TREATMENT||NONE||||||
33980138|NCT01864330|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33980139|NCT05123690|RANDOMIZED|PARALLEL||TREATMENT||NONE|Statistical analysis will be done seperately|Allocation is to one of two arms||||
33896682|NCT01962662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896683|NCT03019549|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33896684|NCT01252966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896685|NCT00167908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980140|NCT03633890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980141|NCT03943056|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Blinded Study||t|t|t|t
33980142|NCT00169533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980143|NCT04182737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is conceived as single blinded: only the patients will be not aware of the group allocation.|The study is designed as a multicentre, national, interventional, randomized, single-blinded, prospective, investigator sponsored, two arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned to IgM titer-based treatment or flat treatment group in a ratio 1:1. A block randomisation will be used with variable block sizes (block size 4-6-8), stratified by centre. Central randomisation will be performed using a secure, web-based, randomisation system. The allocation sequence will be generated by the study statistician using computer generated random numbers.|t|f|f|f
33896686|NCT05325164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33896687|NCT03322683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind researcher|RANDOMIZED CLINICAL TRIAL WITH BLIND EVALUATION BY THIRD PARTIES, LONGITUDINAL AND PROSPECTIVE.|f|f|t|f
33896688|NCT05646550|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33896689|NCT01861197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896690|NCT03946267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Authors involved in clinical data collection and measurement of outcome variables are not been directly involved in the patients' surgery and are masked to the randomization process|Patients assigned to undergo inverted flap surgery with infracyanine green or with brilliant blue G using the sealed-envelope randomization technique. The interventional study model consists of a randomized controlled trial study design.|t|f|f|t
33896691|NCT05190575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896692|NCT04415138|||CASE_CONTROL||PROSPECTIVE|||||||
33896693|NCT05097911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767862|NCT06285942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An interim-analysis will be performed on the primary endpoint when at least 50% of patients will have been randomized and completed the 6 months follow-up. The interim-analysis will be performed by an independent statistician, blinded for the treatment allocation. The statistician will report to the independent data and safety monitoring board||f|f|f|t
33896694|NCT01495026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896695|NCT05778318|||COHORT||RETROSPECTIVE|||||||
33896696|NCT01823562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896697|NCT02320331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896698|NCT03751202|RANDOMIZED|CROSSOVER||OTHER||SINGLE||One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33896699|NCT01079715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33896700|NCT04285723|||CASE_ONLY||RETROSPECTIVE|||||||
33896701|NCT04510259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980144|NCT00991445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980145|NCT00523796|||CASE_ONLY||RETROSPECTIVE|||||||
33980146|NCT02695732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980147|NCT05699629|||COHORT||PROSPECTIVE|||||||
33980148|NCT04314869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980149|NCT02328690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980150|NCT01717976|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34077843|NCT06379152|||COHORT||PROSPECTIVE|||||||
33767863|NCT04525625|||COHORT||PROSPECTIVE|||||||
33767864|NCT01832103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896702|NCT04454814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077844|NCT00299065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33767865|NCT06487819|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33767866|NCT02397265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767867|NCT02468934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896703|NCT03196713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Pragmatic RCT|f|f|f|t
33896704|NCT06128837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767868|NCT00194480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896705|NCT02729129|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33896706|NCT05032508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33980151|NCT04003779|NA|SINGLE_GROUP||OTHER||NONE||Using virtual reality and ergonomic measures, we will sequentially adjust features of the hospital room to determine the most stable gate in frail elderly patients.||||
33980152|NCT01240005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980153|NCT00113347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980154|NCT00864864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980155|NCT04137679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33980156|NCT00825227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980157|NCT04033952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33980158|NCT03061734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980159|NCT00537147|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33980160|NCT06441578|||COHORT||PROSPECTIVE|||||||
33980161|NCT02166138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33980162|NCT05334771|||COHORT||PROSPECTIVE|||||||
33980163|NCT02171052|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980164|NCT03965858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980165|NCT05063409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980166|NCT01255878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980167|NCT05717036|||CASE_ONLY||CROSS_SECTIONAL|||||||
33980168|NCT00277381|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33980169|NCT01677078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33980170|NCT04642950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980171|NCT00241917|RANDOMIZED|PARALLEL||||NONE||||||
33980172|NCT01473849|||COHORT||PROSPECTIVE|||||||
33980173|NCT00352690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980174|NCT03131037|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33980175|NCT03563105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Vascular Occlusion Test||||
33980176|NCT02228382|NA|||TREATMENT||NONE||||||
34077845|NCT00508950|NON_RANDOMIZED|SINGLE_GROUP||||||||||
34077846|NCT03007303|||CASE_CONTROL||PROSPECTIVE|||||||
34077847|NCT05914350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34077848|NCT04656613|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34077849|NCT05591157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||clinical study is a prospective, open, single-center study to evaluate the performance and accuracy of the ECG and heart rate calculation of the CSF-3 investigational Device.||||
34077850|NCT02529930|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077851|NCT03740763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Care Provider and Participants ar not masked. Data analysis of accelerometer data is masked (outcome assessor).||f|f|f|t
34077852|NCT05121610|||COHORT||PROSPECTIVE|||||||
34077853|NCT04504110|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077854|NCT04575220|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study evaluating fitness before and after home based rehabilitation||||
34077855|NCT00483535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077856|NCT05756881|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34077857|NCT02975180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34077858|NCT04851132|NA|SINGLE_GROUP||TREATMENT||NONE||RT + Durvalumab||||
34077859|NCT06102317|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34077860|NCT02050334|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33980177|NCT06309706|||CASE_ONLY||CROSS_SECTIONAL|||||||
34077861|NCT01839747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077862|NCT02440503|||COHORT||CROSS_SECTIONAL|||||||
34077863|NCT01741246|||||PROSPECTIVE|||||||
34077864|NCT05200273|NA|SINGLE_GROUP||TREATMENT||NONE|None (open Label)|Non Randomised||||
34077865|NCT02214030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077866|NCT02575417|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077867|NCT00975377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34077868|NCT03925142|RANDOMIZED|CROSSOVER||OTHER||SINGLE||This is a 16-week randomized, cross-over, controlled, single-blind study. During weeks 1 and 11, participant's usual, unrestricted dietary intakes will be assessed. At week 2, they will be randomized and assigned to consume either the controlled lacto-ovo vegetarian diet or beef diet for the first 5-week dietary intervention during weeks 2-6. They will consume the other diet during weeks 12-16. Two fasting-state serum samples and one stool samples will be collected during study weeks 1,6,11, and 16.|f|f|f|t
34077869|NCT03528551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077870|NCT06305975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077871|NCT00676403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077872|NCT01825200|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34077873|NCT00510614|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34077874|NCT01001910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077875|NCT01877161|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33896707|NCT04037085|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective observational open-label trial (Part 1)||||
33896708|NCT02306278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896709|NCT03455543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active and sham devices will look identical. Participants and site staff will be blind to the randomization.|Two parallel groups, active device group versus sham device group. Subjects will be randomized 1:1 at baseline and treat with active PEMF or sham for 4 months.|t|t|t|t
33896710|NCT04643041|NA|SINGLE_GROUP||TREATMENT||NONE||patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer||||
34077876|NCT00142649||||PREVENTION||||||||
34102993|NCT04487821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896711|NCT02220374|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33896712|NCT06004661|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants confirmed for enrollment in IRT will be stratified in one of the three cohorts based on eGFR calculated (MDRD formula) at screening:~* Cohort A: normal renal function eGFR \>= 90 mL/min,~* Cohort B: moderate renal impairment eGFR \>= 30 to =\< 59 mL/min~* Cohort C: severe renal impairment eGFR \>= 15 to =\< 29 mL/min."||||
33896713|NCT05004467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Neither the subjects assigned to the groups nor the researchers who measured the variables knew which group they belonged to.~Patients will be randomly assigned through GraphPad Software's QuickCals application (La Joya, CA, USA) to one of the 2 study groups"|"Study design:~A randomized, longitudinal, experimental, prospective, parallel and double-blind clinical trial will be carried out in which both the study subject and the researcher who made the measurements do not know which treatment group they belong to.~Participants The sample was composed of 42 healthy patients residing in the Community of Madrid, all of whom were personally recruited for the study. All of them will have two different manual therapy techniques (Mulligan and placebo) for acute or subactute neck pain. All patients will read the information sheet that explains what the study will consist of, as well as the informed consent form, which they will voluntarily sign before the intervention.~Each group will be given a different sentence: one group will attempt to influence with a positive expectation, another with a neutral expectation, and yet another will attempt to influence with a negative expectation."|t|f|f|t
33896714|NCT03331211|||CASE_ONLY||PROSPECTIVE|||||||
33896715|NCT03194425|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896716|NCT05190835|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33896717|NCT01409889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767869|NCT02043262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33767870|NCT04977518|||COHORT||RETROSPECTIVE|||||||
33896718|NCT01776268|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33896719|NCT01568411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896720|NCT00847561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33896721|NCT06057571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896722|NCT05324215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896723|NCT05962307|||COHORT||RETROSPECTIVE|||||||
33896724|NCT03858582|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33896725|NCT03156244|||COHORT||PROSPECTIVE|||||||
33896726|NCT01091350|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33896727|NCT00728338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896728|NCT01815398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896729|NCT05006443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896730|NCT01389128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33896731|NCT05508425|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33896732|NCT00759577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896733|NCT01506791|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896734|NCT05087056|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind study. Participants and study evaluators will be unaware of vaccine administered.||t|t|t|t
33896735|NCT06374810|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants in group 2 were told that the trial was full but actually they were just placed in the placebo control group.|"Participants were randomly assigned to either the breathwork group or they were told that they had been placed on a waitlist and that they would participate in the 2nd cohort, which would take place after the 1st 6-week program had been completed.~Participants in the breathwork groups were also given a 10 minute guided conscious connected breathwork recording. They were advised to do this daily to support the integration of their process. This was not mandatory. At the end of the study participants were asked how often they used the guided self-practice. The frequency of use of the self-practice was used a covariate."|t|f|f|f
33896736|NCT03616743|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial.||||
33896737|NCT00542698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896738|NCT04407507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33896739|NCT04014907|||CASE_ONLY||PROSPECTIVE|||||||
33767871|NCT01694810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33767872|NCT05158881|||COHORT||PROSPECTIVE|||||||
33767873|NCT02107248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896740|NCT02772380|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||||Subjects who are undergoing a standard of care procedure will also undergo the ASD2 research procedure involving placing an investigational lead in the substernal space to gather electrograms during induced ventricular arrhythmias for future research/development.||||
33896741|NCT00542815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896742|NCT03929042|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients currently on underarm brace treatment will be eligible for participation in our study. For those that agree to participate, a AP/lat standing X-ray and force measurements of the brace on the rib and loin hump will be taken. They will be then be asked to wear a customised postural correction girdle 24 hours after they have taken off the brace. The same study assessments will be conducted.~Patients whose forces and radiological Cobb correction are comparable between the two methods of treatment will be given a choice to either continue the hard brace or wear the posture correction girdle."||||
33767874|NCT00708305|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33767875|NCT03246243|||COHORT||PROSPECTIVE|||||||
33767876|NCT05012449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896743|NCT00033735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980178|NCT04835493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"1. Randomization will be achieved by blinded study staff using an automatic number generator that allows for stratification and blocking.~2. Individuals entering and obtaining study data will be blinded to study arm~3. Data will be collected prior to randomization for blinding purposes. Month-12 clinical data will be obtained in-person for both arms by nurses blinded to the study arm e.g., different nurses than those in the group visits, and chart review will be conducted for ADA measurements and for other clinical data if individuals from either study arm do not show.~4. Blinded research assistants will gather HbA1c, blood pressure, cholesterol, and BMI data for both arms quarterly until 36-months from baseline."||f|f|f|t
33767877|NCT00727818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33896744|NCT01607021|||CASE_ONLY||PROSPECTIVE|||||||
33896745|NCT04862416|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Study groups will be assigned sequentially to low and high doses of R0.6C Vaccine. Within each dose group, participants will be assigned randomly (1:1) to one of two adjuvant arms (either Alhydrogel alone or Alhydrogel + Matrix-M).||||
33896746|NCT04575129|||OTHER||PROSPECTIVE|||||||
33980179|NCT04259229|RANDOMIZED|PARALLEL||SCREENING||SINGLE||For this investigator-blinded, randomized, parallel design study, 100 participants (60 to finish; n=30/group) will complete a 10-week study period, which includes a 2-week baseline testing period (no diet control), followed by an 8-week controlled diet period (Figure 1). In order to define the effects of adding mushrooms to a healthy dietary pattern on fasting blood glucose and insulin concentrations and blood pressures, we will provide a Mediterranean-style diet devoid of mushrooms as the control diet for this study. Questionnaires assessing depression/anxiety, perceived quality of life, and mood will be administered and the results will provide a foundation to power future, more robust, studies.|f|f|t|f
33980180|NCT06114732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980181|NCT05944107|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33980182|NCT03988127|||COHORT||PROSPECTIVE|||||||
33980183|NCT01229020|||COHORT||PROSPECTIVE|||||||
33980184|NCT04193566|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Group allocation is concealed to patients as well as investigators. 60 sequentially numbered, opaque, sealed envelopes will be produced by Glostrup Apotek. All persons involved in the conduct of the study are blinded to the randomization code. Randomization codes and envelopes are stored securely at the study site available only for the unblinded site staff in charge of randomizing subjects and dispensing study products to subjects. Sealed codes are marked according to randomization code and distributed according to a pre-distributed order. Should unblinding of a study participant be necessary because of an emergency, a dedicated person at Steno Diabetes Center Copenhagen, not involved in the study, will perform the procedure. Alternatively, the Principal investigator will be able to perform unblinding|Randomized, double blinded, placebo-controlled, cross-over intervention study|t|f|t|f
33980185|NCT00281138|||COHORT||CROSS_SECTIONAL|||||||
33980186|NCT03332693|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33980187|NCT00252980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980188|NCT03395106|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Statisticians completing the analysis of the primary outcome will be blinded.|Factorial design 2x2|f|f|f|t
33980189|NCT03977051|||OTHER||PROSPECTIVE|||||||
33980190|NCT03361228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980191|NCT05781282|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33980192|NCT00686049|||COHORT||PROSPECTIVE|||||||
33980193|NCT03307200|||COHORT||PROSPECTIVE|||||||
33980194|NCT00003898|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980195|NCT02219165|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33980196|NCT05493176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33980197|NCT03348670|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|No-placebo and random and double blind|"* The usual approach group (high dose)~* The study approach group (low dose)"|t|t|t|t
33980198|NCT03393650|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33980199|NCT00925626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980200|NCT06354803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The drawing procedure was conducted by a researcher without disclosure to the participants, ensuring unbiased allocation. Moreover, both the assessor and statistician remained blinded throughout the assessment period, unaware of the group assignments.|45 participants with gestational age below 28 weeks|t|t|t|t
33980201|NCT02401126|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33896747|NCT01444391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896748|NCT03976232|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33896749|NCT04463030|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Randomized, placebo-controlled, single blind, cross-over trial|f|f|t|f
33980202|NCT02329756|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study drug and placebo will be prepared by Investigational Pharmacy, and with similar appearing packaging and syringes. The Investigational Pharmacy will maintain the randomization table and allocation list. Participants, care providers, investigators and outcomes assessors will remain blinded until after data analysis completed, unless unblinding required in case of clinical emergency, per the unblinding procedures within the protocol.||t|t|t|t
33980203|NCT02354742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980204|NCT04494659|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Repeated oral doses of Rifampicin on the pharmacokinetic profile of a single dose of Famitinib.||||
33896750|NCT01633060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980205|NCT03093324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980206|NCT02716870|||OTHER||OTHER|||||||
34077877|NCT05208333|NA|SINGLE_GROUP||TREATMENT||NONE||We conducted a cross-sectional study among 960 pupils aged 3-15 years from Kindergartens, primary schools and secondary schools to describe the characracteristics, and determine the factors related to Toxocariasis infection. After that, we identified infected children from 960 children, we choose 146 infected children who are as sampling for intervention with treatment of Albendazole. Then, we evaluate the effectiveness of Albendazole treatment by follow-up these 146 infected children for 6 months.||||
34077878|NCT04565548|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessors will not participate in group allocation or intervention delivery.||f|f|f|t
33896751|NCT04663620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34077879|NCT00002223||||TREATMENT||||||||
34077880|NCT05904613|||CASE_ONLY||RETROSPECTIVE|||||||
34077881|NCT04474964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767878|NCT04359030|||OTHER||PROSPECTIVE|||||||
33896752|NCT01336101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896753|NCT00437905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896754|NCT04566536|||COHORT||PROSPECTIVE|||||||
33896755|NCT06156098|||COHORT||PROSPECTIVE|||||||
33896756|NCT00190463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896757|NCT01023529|||CASE_ONLY||PROSPECTIVE|||||||
33896758|NCT01370070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896759|NCT00231478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896760|NCT02180386|NA|SINGLE_GROUP||OTHER||NONE||||||
33896761|NCT00812110|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33896762|NCT03155451|||CASE_CONTROL||PROSPECTIVE|||||||
33896763|NCT04664491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33896764|NCT02680288|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33896765|NCT03429647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896766|NCT03028493|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Three individuals not involved in intervention delivery will complete pre-post measures.||f|f|f|t
33896767|NCT00003018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896768|NCT00649961|NA|SINGLE_GROUP||OTHER||NONE||||||
33896769|NCT06656949|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study design is a two-arm, randomized, controlled trial.||||
33896770|NCT02567695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980207|NCT00496444|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980208|NCT01979081|||CASE_CONTROL||PROSPECTIVE|||||||
33980209|NCT02802436|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33980210|NCT01967108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077882|NCT03546712|||OTHER||CROSS_SECTIONAL|||||||
34077883|NCT04243629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a two-way, randomized, open-label, controlled, crossover trial to compare the following strategies:~(i) Rapid insulin-plus-Pramlintide closed-loop delivery~(ii) Rapid insulin-plus-Placebo closed-loop delivery"||||
34077884|NCT02590055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896771|NCT02990338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896772|NCT02453841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896773|NCT02624700|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33896774|NCT02026388|||COHORT||PROSPECTIVE|||||||
33896775|NCT03085069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896776|NCT06040177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896777|NCT03614390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896778|NCT03078881|||COHORT||PROSPECTIVE|||||||
33896779|NCT06270225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980211|NCT01402908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980212|NCT03160677|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34025635|NCT04767191|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|The two drugs being assessed are already approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatments for malaria. The study is to assess the continued efficacy of the drugs.||||
33896780|NCT00201201|RANDOMIZED|PARALLEL||||NONE||||||
33896781|NCT00367809|RANDOMIZED|PARALLEL||||NONE||||||
33896782|NCT06049316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896783|NCT03271710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896784|NCT05736315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33896785|NCT05766956|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33896786|NCT01912118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33896787|NCT04603378|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34025636|NCT05896644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025637|NCT03925259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants were masked as to their allocation to either full treatment or treatment with the self-as-context component removed.|The design was a pilot, randomised and controlled dismantling trial. Ethical approval was granted to conduct the trial (ref: 144363) and was contingent on adverse events being monitored in the arms. Participants were randomised to either full-ACT (i.e. the full hexaflex approach) or ACT-SAC (i.e. ACT minus the self-as-context component of the hexaflex). Participants were blind to their allocation. ACT process measures were completed at assessment, final therapy session and at 6-week follow-up and the outcome measures were taken on a session-by-session basis and at 6-week follow-up.|t|f|f|f
34025638|NCT06379685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind|Phase I, controlled, comparative, controlled, comparative.|t|f|f|t
34077885|NCT01105520|||COHORT||PROSPECTIVE|||||||
34077886|NCT03040167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077887|NCT05592938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896788|NCT04767880|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Participants will be blinded to the intervention and placebo in the laboratory setting.~Quadruple (Participants, care providers, investigators and outcome assessors) Participants, care providers, investigators and outcome assessors will be blinded to the placebo and varying doses of whey in the home setting."|Singleblind, randomized, crossover design|t|f|f|f
33896789|NCT00802477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33896790|NCT03227926|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase.~Patients resulting molecularly eligible at the RML checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated in the Trial Phase with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason (See Section 9.2.3) whichever comes first."||||
33896791|NCT02123329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896792|NCT01450540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896793|NCT00216008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33896794|NCT01300221|||COHORT||PROSPECTIVE|||||||
33896795|NCT04323501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An experimental pilot study, randomized, controlled and is single-blind, without drug and medical device.|f|f|t|f
33896796|NCT05286294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896797|NCT03873597|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre feasibility, parallel, randomised controlled trial||||
33896798|NCT00368368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896799|NCT04519528|||COHORT||OTHER|||||||
33896800|NCT03224962|||OTHER||OTHER|||||||
33896801|NCT05221190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896802|NCT02803216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896803|NCT03448835|NA|SINGLE_GROUP||TREATMENT||NONE||single group, open label||||
33896804|NCT02985801|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896805|NCT03304951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896806|NCT01827501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896807|NCT01486693|||COHORT||RETROSPECTIVE|||||||
33896808|NCT04920487|||COHORT||RETROSPECTIVE|||||||
33896809|NCT05815953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computer generated block randomization for each participating surgeon. The envelopes are sequentially numbered, opaque and sealed. The surgeon is not blinded, but the patient and the physiotherapist that do the clinical follow-ups are.||t|t|f|t
33896810|NCT01815684|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33896811|NCT01880346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33980213|NCT03622866|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Subjects who receive a permanent implant will be randomly assigned in a 1:1 ratio to one of the two sequences of treatment. Randomization schedules for each site will be prepared by the contract research organization (CRO) statistician and uploaded into a role-limited module of the study database. In order to avoid any potential bias, each site will designate an unblinded coordinator (UC). The UC, Nuvectra field personnel (FP) and the CRO will be unblinded to the treatment group. The participant and other site staff will be blinded to the treatment group.|During the Treatment Phase of the study, all subjects will receive both treatments under a crossover design. Subjects will undergo 12 weeks of treatment in each group with a 1-week washout between groups.|t|t|t|f
33980214|NCT02232100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980215|NCT00771537|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33980216|NCT00005349|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33980217|NCT02296515|||CASE_ONLY||PROSPECTIVE|||||||
33980218|NCT05194748|||OTHER||PROSPECTIVE|||||||
33980219|NCT02792205|||COHORT||PROSPECTIVE|||||||
33980220|NCT02356471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980221|NCT02445664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33980222|NCT02583503|||COHORT||PROSPECTIVE|||||||
33980223|NCT05083299|||OTHER||PROSPECTIVE|||||||
33980224|NCT01259869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980225|NCT05925595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded (participant)|Parallel Assignment|t|f|f|f
33980226|NCT01975064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33980227|NCT01586247|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33980228|NCT01469364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980229|NCT01663480|||CASE_ONLY||PROSPECTIVE|||||||
34077888|NCT04009265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077889|NCT05399199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34077890|NCT02539017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077891|NCT02239640|||COHORT||PROSPECTIVE|||||||
34077892|NCT01553110|||CASE_CONTROL||PROSPECTIVE|||||||
34077893|NCT03255356|||COHORT||PROSPECTIVE|||||||
34077894|NCT03618446|||COHORT||RETROSPECTIVE|||||||
34077895|NCT06086379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to treatment group assignment.|Two group randomized controlled trial|f|f|f|t
34077896|NCT03852589|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33896812|NCT00308620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896813|NCT04332549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33896814|NCT05076708|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33896815|NCT00005037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896816|NCT04231981|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label, single-arm||||
33896817|NCT03540095|RANDOMIZED|PARALLEL||TREATMENT||NONE|We are unable to mask the patient or provider for this study. The interventions are inherently similar, but different, thus making it impossible to blind.|There are two arms. Our 60 patients will be randomized to either of the two arms and studied in parallel.||||
33896818|NCT04970680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participant will have the block while anaesthetized, the care provider will do the block either blindly or using ultrasonic, the outcome assessor will not know which one have which technique|two groups, each will have peristyloid glossopharyngeal block, one with the help of ultrasound technology and the other blindly|t|f|f|t
33896819|NCT04219306|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||The study has been designed as a prospective, blinded, randomized clinical trial (RCT). Each call where the machine learning model suspects a cardiac arrest is by lot (1:1) randomized to either alert on dispatchers' screen or no alert on dispatchers' screen|t|t|f|t
33896820|NCT01025609|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33896821|NCT03411070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896822|NCT00707577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896823|NCT01037712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896824|NCT06428773|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33896825|NCT03943381|||COHORT||PROSPECTIVE|||||||
33896826|NCT02528695|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33896827|NCT02047552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767879|NCT01333540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896828|NCT02604966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896829|NCT04844190|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Study||||
33896830|NCT01914133|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33896831|NCT05059197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33896832|NCT02236624|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33896833|NCT02197962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896834|NCT05134623|||COHORT||PROSPECTIVE|||||||
33896835|NCT04020432|||OTHER||PROSPECTIVE|||||||
33896836|NCT05412329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896837|NCT01499576|NA|SINGLE_GROUP||SCREENING||NONE||||||
33896838|NCT05343195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896839|NCT04837040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896840|NCT02646904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896841|NCT04967846|||COHORT||CROSS_SECTIONAL|||||||
33896842|NCT02386423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896843|NCT04107220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896844|NCT01137435|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980230|NCT02294812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980231|NCT05198050|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A randomized controlled trial|t|f|f|f
33980232|NCT02423902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980233|NCT01301014|||COHORT||PROSPECTIVE|||||||
33980234|NCT06346210|||COHORT||RETROSPECTIVE|||||||
33980235|NCT01575522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980236|NCT00552331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980237|NCT05994222|||CASE_ONLY||PROSPECTIVE|||||||
33980238|NCT01106326|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33980239|NCT02512978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980240|NCT05818696|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Raters completing the outcome assessments will be blind to condition.|All participants receive both interventions but the order in which a participant receives the interventions is randomized.|f|f|f|t
33980241|NCT03095222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980242|NCT02958709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980243|NCT02976207|||COHORT||PROSPECTIVE|||||||
33896845|NCT04754373|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33980244|NCT01124149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980245|NCT01684553|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33980246|NCT00118105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980247|NCT00044226|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33896846|NCT05281315|||COHORT||RETROSPECTIVE|||||||
33896847|NCT06231108|||CASE_ONLY||PROSPECTIVE|||||||
33896848|NCT04219267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33896849|NCT00463437|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980248|NCT05233280|||COHORT||PROSPECTIVE|||||||
33980249|NCT05054868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980250|NCT01678547|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33980251|NCT02909140|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33980252|NCT02226458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980253|NCT01279356|||COHORT||PROSPECTIVE|||||||
33980254|NCT06457945|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33980255|NCT02388763|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33980256|NCT01756937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980257|NCT06350656|||OTHER||PROSPECTIVE|||||||
33980258|NCT05814848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980259|NCT02719249|||COHORT||PROSPECTIVE|||||||
33980260|NCT04043871|||CASE_ONLY||PROSPECTIVE|||||||
33896850|NCT01050777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33896851|NCT04252417|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Open label, Parallel-group, Single oral dose|t|t|t|t
33896852|NCT02471963|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33896853|NCT06481358|||OTHER||OTHER|||||||
33896854|NCT00198705|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33980261|NCT02683122|||COHORT||PROSPECTIVE|||||||
33980262|NCT00220701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980263|NCT01274364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896855|NCT02715648|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980264|NCT04839367|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33980265|NCT02835482|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980266|NCT00290147|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|Open Label|||||
33980267|NCT02129348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients were randomized to lithium or placebo, 1:1, stratified by site, for 12 weeks. Randomization, developed by the statistician and executed by the NYSPI pharmacy, was stratified within each site by the presence of psychosis (NPI score ≥4 on delusions or hallucinations) with randomization sequences balanced in blocks of four.~All study personnel and patients were masked to treatment assignment. After the final study visit, a psychiatrist independent of the study was unmasked and clinically treated the patient while study personnel remained blind."|Participants were outpatients and recruited primarily from memory clinics and physician referrals at all four sites. Salient inclusion criteria were a diagnosis of possible or probable Alzheimer's disease by National Institute on Aging (NIA) criteria, score ≥4 on the Neuropsychiatric Inventory (NPI) domain score for agitation/aggression, Folstein Mini Mental State Exam (MMSE) range 5-26, and availability of an informant. Patients with current major depression or suicidality, alcohol/substance dependence in the prior 6 months, bipolar or other psychotic disorder, and specific neurological disorders were excluded.|t|t|t|f
33980268|NCT00494975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980269|NCT00507897|||||PROSPECTIVE|||||||
33980270|NCT05589311|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33980271|NCT04304963|||COHORT||CROSS_SECTIONAL|||||||
33980272|NCT01648842|||CASE_CONTROL||PROSPECTIVE|||||||
33980273|NCT00940368|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33980274|NCT04028453|||COHORT||OTHER|||||||
33980275|NCT03394209|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a adaptive study, which include two steps.~1st step: 1600mg BID on day 1, followed by 600mg BID for 9 days. Sample size: 15 PK analysis: If the proportion of patients with a minimum observed plasma trough concentration above the MEC (20μg/ml) at all measured time points after the second dose is greater than or equal to 80% then the dose is considered adequate and the study will be completed. If not, then a second patient cohort will be recruited and will receive favipiravir 1800mg BID on day 1, followed by favipiravir 800mg BID for 9 days. Sample size: 15"||||
33980276|NCT05597345|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, open-label, phase 2, single-arm clinical trial of selinexor in patients with intermediate to high-risk smoldering multiple myeloma. Intermediate-risk patients will start enrolling after 5 high-risk smoldering myeloma patients have been enrolled and received 1-2 cycles of treatment. Patients will receive selinexor 40mg orally weekly for up to 12 cycles. Each cycle will be 28 days in length. Patients will receive treatment up to 1 year and continue in follow-up for 2 years after completion of the treatment period.||||
33980277|NCT04055402|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33980278|NCT03248063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980279|NCT02566824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980280|NCT02339766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980281|NCT05527756|||COHORT||PROSPECTIVE|||||||
33980282|NCT02256007|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two treatment sessions during an inpatient rehabilitation stay. Part 1 is the screening (Montreal Cognitive Assessment and the Boston Diagnostic Aphasia Examination). Assessments will be given to make sure patient is eligible for the study. If eligible, will complete part 2-paper and pencil tasks and video game tests.||||
33980283|NCT06062537|||COHORT||PROSPECTIVE|||||||
33980284|NCT02999178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33980285|NCT03425968|||CASE_CONTROL||PROSPECTIVE|||||||
33980286|NCT06241378|||CASE_CONTROL||RETROSPECTIVE|||||||
33980287|NCT05390437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33896856|NCT03228186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896857|NCT06394622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896858|NCT01277575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896859|NCT01933984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896860|NCT04353947|||COHORT||CROSS_SECTIONAL|||||||
33980288|NCT03623048|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33980289|NCT01512407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980290|NCT02415023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980291|NCT00125307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980292|NCT03825900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34077897|NCT05577728|||COHORT||RETROSPECTIVE|||||||
34077898|NCT02373150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980293|NCT03378466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980294|NCT05017857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980295|NCT02622945|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33980296|NCT00973700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980297|NCT04238442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980298|NCT02848326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33980299|NCT04900584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980300|NCT03797664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Dose-escalating, Randomized, Double-Blinded,. Placebo-Controlled|t|t|t|t
34077899|NCT02185417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077900|NCT05007119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077901|NCT04206345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077902|NCT02104895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077903|NCT03087838|||COHORT||PROSPECTIVE|||||||
33896861|NCT05924477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All trial participants will be masked to their tube locations. The primary outcome accessors who grade specular microscopy images at the PRC, perform IOP measurements at each clinical center, or conduct the MDS analysis at the Metagenomic RNA Deep Sequencing (RNA-seq) Center will also be masked to tube locations. Due to the nature of the surgical intervention, the surgeon, the technician taking specular microscopy and AS-OCT images, and the graders at the PRC who will perform AS-OCT measurements will not be masked to the tube locations. However, the graders of AS-OCT images will be masked to the purpose of the study and will be different from the graders of specular microscopy images.|A prospective 1:1 randomized, parallel design, double-masked clinical trial. Stratification is by clinical center and type of surgery (GDD alone vs GDD combined with phacoemulsification).|t|f|f|t
33896862|NCT00666185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33896863|NCT02823912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896864|NCT04732377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33896865|NCT02037945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896866|NCT05426343|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33896867|NCT03456765|||COHORT||PROSPECTIVE|||||||
33896868|NCT05004012|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Four groups of participants will be studied: gastroparesis, functional dyspepsia, gastroparesis patients s/p G-POEM, and healthy controls.||||
33896869|NCT00831051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896870|NCT04373122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896871|NCT05510986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33896872|NCT04047030|||CASE_CONTROL||PROSPECTIVE|||||||
33896873|NCT01211691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980301|NCT06423066|||COHORT||PROSPECTIVE|||||||
33980302|NCT04743258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980303|NCT06189768|||CASE_ONLY||RETROSPECTIVE|||||||
33980304|NCT04023409|||COHORT||CROSS_SECTIONAL|||||||
33980305|NCT03155048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980306|NCT04259177|||CASE_CONTROL||OTHER|||||||
33980307|NCT01278849|NA|PARALLEL||TREATMENT||NONE||||||
33896874|NCT03442803|NA|SINGLE_GROUP||OTHER||NONE||||||
33980308|NCT01626664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980309|NCT03627585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980310|NCT05497414|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Two groups (healthy vs major depression) are studied under two conditions (rested vs sleep deprivation).||||
33980311|NCT03708211|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34077904|NCT05033249|||COHORT||RETROSPECTIVE|||||||
34077905|NCT01425736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077906|NCT02436863|||COHORT||PROSPECTIVE|||||||
34077907|NCT04845997|||COHORT||PROSPECTIVE|||||||
34077908|NCT03166020|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34077909|NCT06223295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077910|NCT00763360|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34077911|NCT03041389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The rater of outcomes questionnaires is blinded.|Randomized (1:1 ratio), single-blind, parallel-group, controlled study|f|f|f|t
34077912|NCT05056961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Two parallel groups~1. the first without respiratory distress symptoms~2. the second with respiratory distress symptoms (for example, supra-clavicular and thoracic-abdominal asynchronies...)"||||
33896875|NCT05164328|||COHORT||PROSPECTIVE|||||||
34077913|NCT02490774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896876|NCT00982605|||CASE_CONTROL||PROSPECTIVE|||||||
33896877|NCT05782088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896878|NCT05597566|||CASE_ONLY||OTHER|||||||
33896879|NCT03317587|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33896880|NCT02363400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896881|NCT06070610|NA|CROSSOVER||TREATMENT||NONE||Patients cross over from test treatment (T) to reference treatment (R) (two periods, fixed sequence).||||
33896882|NCT00500071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896883|NCT01422057|||COHORT||PROSPECTIVE|||||||
33896884|NCT06255886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is partially blinded. There is blinding in relation to the placebo arm and the proton pump inhibitor arm.||t|t|t|f
33896885|NCT06082778|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33896886|NCT00863187|NON_RANDOMIZED|PARALLEL||||NONE||||||
33896887|NCT01057264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896888|NCT01513018|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33896889|NCT05667519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33980312|NCT00531505|||COHORT||PROSPECTIVE|||||||
33980313|NCT03840057|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Initial management of UGIB would be performed by the primary team without interference from the investigator. If a gastroenterology consult were placed by the primary team, the endoscopist on-call would evaluate the patient per routine care. If an early endoscopy is deemed appropriate and necessary based on the patient's clinical status, the participant is registered to a central electronic database, which would assign participants to the intervention arm or the placebo arm using a permuted block randomization process. The appropriate medication or placebo is prepared and distributed by the central inpatient pharmacy. The investigator, the endoscopist, the study participant, and the primary team are all blinded to the assignment.|The study is comprised of two intervention arms, namely the azithromycin arm and the metoclopramide arm, as well as one placebo arm. The two interventions would be studied sequentially in order to simplify the logistical challenges of the blinding and placebo-control processes. The current study is comprised to two parts. During Part 1 of the study, participants are randomized to either azithromycin 500mg intravenous infusion or equivalent volume of 0.9% sodium chloride infusion in a 2-to-1 ratio. During Part 2 of the study, participants are randomized to either metoclopramide 10mg intravenous injection or equivalent volume of 0.9% sodium chloride injection in a 2-to-1 ratio. The 0.9% sodium chloride arm from the two parts of the study are pooled together to form the placebo arm during final analysis.|t|t|t|t
33980314|NCT04500509|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind placebo controlled trial|double blind placebo controlled trial|t|t|t|t
33980315|NCT05007795|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980316|NCT04285749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980317|NCT01296126|||||OTHER|||||||
33980318|NCT02899338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980319|NCT00148681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980320|NCT01444703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33980321|NCT02227862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980322|NCT01434693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980323|NCT04117841|||COHORT||PROSPECTIVE|||||||
33980324|NCT06342076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Prospective randomize study|Prospective randomize study||||
33980325|NCT04915352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980326|NCT01192646|RANDOMIZED|PARALLEL||||NONE||||||
33980327|NCT02921737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980328|NCT00527800|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33980329|NCT01993875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980330|NCT01007500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33980331|NCT05227625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980332|NCT05890066|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a parallel-group randomized control trial with 2 arms. Arm 1 includes patients who will be treated by traditional multi-port laparoscopic surgery. Aim 2 includes patients who will be treated by single-port laparoscopic surgery. All patients are randomized using computer-generated sequences with allocation ratio 1:1. This is a non-blinded study where all patients and surgical teams know the treatment option.||||
33980333|NCT00005938||||TREATMENT||||||||
33980334|NCT01909869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980335|NCT02158832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980336|NCT00921193|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980337|NCT04635618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-arm randomized clinical trial , including professionals and students from essential services suffering from high levels of anxiety, depression, and irritability symptoms during the COVID-19 outbreak randomized 1:1:1: to the Cognitive Behavioral Brief-Telepsychotherapy group (B-CBT, four sessions), Brief Interpersonal Telepsychotherapy (B-IPT, four sessions) or Telepsychoeducation group (a single session psychoeducation group plus weekly personalized pre-recorded videos for 4 weeks).||||
33980338|NCT03263637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicentre, open-label, first in human, non-randomized, dose-escalation study including an intra-subject ramp-up. The study will consist of two, parallel dose escalation arms||||
33980339|NCT04558151|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized-controlled single-center trial, non-blinded||||
33980340|NCT06247657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980341|NCT06269276|||OTHER||CROSS_SECTIONAL|||||||
33980342|NCT02349165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980343|NCT02636907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980344|NCT01239251|||CASE_ONLY||PROSPECTIVE|||||||
34077914|NCT01023607|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34077915|NCT01783743|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34077916|NCT01048541|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34077917|NCT00732927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077918|NCT06086977|||COHORT||PROSPECTIVE|||||||
34077919|NCT05013216|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33980345|NCT05577793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Because of the nature of the intervention, double-blinding was not possible in this study.|This study used a randomized controlled trial. A parallel trial design was used describing three different experimental groups (Therapeutic Touch, Mother's Voice, and Therapeutic Touch+Mother's Voice) and a control group.|t|f|f|f
34077920|NCT06522815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077921|NCT04438408|||COHORT||PROSPECTIVE|||||||
34077922|NCT04178304|NA|SINGLE_GROUP||TREATMENT||NONE|the Assessor doing the musculoskeletal ultrasound will be masked to the radiographic grading of knee osteoarthritis, the clinical condition and the improvement following prolotgerapy.|Sixty knees with primary knee osteoarthritis will be included in the study, plain X-ray for the affected knee, followed by musculoskeletal ultrasound assessment will be done. The intervention: 1. a single intra-articular injection of 6 mL of 25% dextrose through infero-medial or infero-lateral approach will be done. 2. extra-articular injections will be done at major tender tendons and ligaments through 15 skin punctures using peppering technique and placing a possible total of 22.5 mL of 25% dextrose. Both intra and extra-articular injections will be done at 1, 5, 9, and 13 weeks intervals. Follow up will be done at 24 weeks after the last injection both clinically and ultrasounographicly.||||
34077923|NCT03345381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34077924|NCT03936088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34077925|NCT01824888|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34077926|NCT00607776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077927|NCT03202420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077928|NCT04564001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077929|NCT00001989|RANDOMIZED|||TREATMENT||||||||
33980346|NCT01703832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980347|NCT00458848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980348|NCT05733572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double masking (patients and outcome assessors)|This is a phase 2a study intended to demonstrate the superiority over placebo of 10 days' treatment with CHF6467 in significantly improving the field of vision of children and young adults with optical pathway glioma, 12 weeks after the start of treatment.|f|f|t|t
33980349|NCT02246920|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33980350|NCT05701202|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33980351|NCT05232708|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980352|NCT02073643|||COHORT||PROSPECTIVE|||||||
33980353|NCT03855475|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33980354|NCT06148909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33980355|NCT04898296|||OTHER||PROSPECTIVE|||||||
33767880|NCT03075501|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33980356|NCT05575271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33980357|NCT02236715|||COHORT||PROSPECTIVE|||||||
33980358|NCT05871736|||CASE_ONLY||PROSPECTIVE|||||||
33980359|NCT02210767|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33980360|NCT02344992|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33980361|NCT04892979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980362|NCT01867385|||||OTHER|||||||
33980363|NCT02636400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980364|NCT06452160|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
33980365|NCT03249584|NA|SINGLE_GROUP||TREATMENT||NONE||Enrollment/Baseline visit, OsteoCool procedure visit and 5 post-procedure visits (3 days, 1 week, 1-, 3-, and 6-month clinic visits) and a final post-procedure study visit (12 months) for a total of 8 study related visits.||||
33980366|NCT03255421|||COHORT||PROSPECTIVE|||||||
33980367|NCT02545153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980368|NCT02173704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980369|NCT00493168|||||PROSPECTIVE|||||||
33980370|NCT00692029|||COHORT||PROSPECTIVE|||||||
33980371|NCT00193622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980372|NCT00059852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980373|NCT03038737|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33980374|NCT05834231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33980375|NCT05282160|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
33980376|NCT00659607|||||PROSPECTIVE|||||||
33980377|NCT05532085|||OTHER||PROSPECTIVE|||||||
33980378|NCT00726700|RANDOMIZED|PARALLEL||TREATMENT||||||||
33980379|NCT02285738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980380|NCT04345965|||COHORT||PROSPECTIVE|||||||
33980381|NCT04326998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980382|NCT06431451|||CASE_ONLY||PROSPECTIVE|||||||
33980383|NCT00114426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33980384|NCT06235398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980385|NCT03252470|||COHORT||PROSPECTIVE|||||||
33980386|NCT01826383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980387|NCT01132976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33980388|NCT03902171|||CASE_ONLY||PROSPECTIVE|||||||
33767881|NCT00819065|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33980389|NCT05319665|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The study will consist of two phases. During the first phase, the participants will be the control group and will have the standard-of-care. During the second phase, the participants will be the interventional group and will have a head-mounted display airing a live video of their newborn filmed by a 2D 360° camera to enable a visual and auditory contact.||||
34077930|NCT05554497|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot project with a single arm to assess the effectiveness of a new platform to deliver a mindfulness curriculum.||||
34077931|NCT04275063|||OTHER||RETROSPECTIVE|||||||
33980390|NCT03605043|||COHORT||RETROSPECTIVE|||||||
33980391|NCT00193141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077932|NCT06047639|||CASE_CONTROL||PROSPECTIVE|||||||
34077933|NCT00973258|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34077934|NCT06235112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled trial of two arms, involving notification to providers (vs non-notification)|f|f|f|t
34077935|NCT03224793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077936|NCT01045005|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077937|NCT05885451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34077938|NCT01119690|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34077939|NCT01622933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077940|NCT05008796|||COHORT||PROSPECTIVE|||||||
34077941|NCT02277327|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34077942|NCT04428385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Interviewers assessing outcomes and statisticians will be blinded to arm assignment||f|f|f|t
34077943|NCT02507492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077944|NCT03698292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077945|NCT06230497|||COHORT||PROSPECTIVE|||||||
33980392|NCT02434055|||CASE_ONLY||PROSPECTIVE|||||||
33980393|NCT03199274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980394|NCT03318796|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm open label registry||||
33980395|NCT01308593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980396|NCT05269381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980397|NCT00154102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980398|NCT04133376|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33980399|NCT03140007|RANDOMIZED|CROSSOVER||OTHER||SINGLE|prospective, multi-center, randomized controlled, post market study|prospective, multi-center, randomized controlled, post market study|t|f|f|f
33980400|NCT06202716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980401|NCT05067764|RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, prospective, therapeutic, comparative, randomized controlled open-label, superiority, multicenter, national study.||||
33980402|NCT01762748|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077946|NCT06397430|NON_RANDOMIZED|PARALLEL||OTHER||NONE||prospective, longitudinal, parallel study||||
34077947|NCT05835661|||OTHER||OTHER|||||||
34077948|NCT01904890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077949|NCT03485599|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34077950|NCT03102970|||CASE_ONLY||PROSPECTIVE|||||||
34077951|NCT04512807|||CASE_ONLY||RETROSPECTIVE|||||||
34077952|NCT03902613|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34077953|NCT01982695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077954|NCT00345917|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34077955|NCT03278821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34077956|NCT04318704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077957|NCT00370617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077958|NCT06070090|NA|SINGLE_GROUP||OTHER||NONE||An intention-to-treat approach will be used to approximate real-world conditions wherein results will be included even if a participant decides not to participate in the group acupuncture session.||||
34077959|NCT02029131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33767882|NCT01114867|||CASE_CONTROL||PROSPECTIVE|||||||
33767883|NCT05863286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33896890|NCT05946330|RANDOMIZED|PARALLEL||TREATMENT||NONE||Allocation to the intervention will be performed by simple randomization technique in a 1:1 ratio. The intervention group will receive individual nutrition education actions with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up. The group The control will receive the usual care at the Outpatient Clinic. The collection of clinical, anthropometric, sociodemographic and food consumption data will be carried out during the nutrition consultations, as well as the application of the NLS-Br Nutritional Literacy questionnaire to verify literacy. During the nutrition consultation A 24-hour recall will be carried out to collect information on food consumption.||||
33896891|NCT04133324|||CASE_CONTROL||PROSPECTIVE|||||||
33896892|NCT02164565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896893|NCT03895138|RANDOMIZED|PARALLEL||OTHER||NONE||"Subjects with CABG or open heart valve surgery will be enrolled in the study. They will be randomized to receive one of the following treatments:~1. Standard Glucommander Protocol (SGP)~2. Optimized Glucommander (OGM)"||||
33980403|NCT02563197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980404|NCT00458900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980405|NCT00957814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980406|NCT04668105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980407|NCT00547677|NON_RANDOMIZED|||TREATMENT||||||||
33767884|NCT01793974|||CASE_CONTROL||PROSPECTIVE|||||||
33767885|NCT05429164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767886|NCT03976895|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767887|NCT00077636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767888|NCT00997256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767889|NCT05064982|||CASE_ONLY||PROSPECTIVE|||||||
33896894|NCT01302275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33896895|NCT04952727|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Subjects who have been primed with one dose or two doses of inactive SARS-CoV-2 vaccine will be recruited and randomized at a 1:1 ratio to receive abooster dose of inactive SARS-CoV-2 vaccine or recombinant SARS-CoV-2Ad5 vectored vaccine|t|f|t|t
33896896|NCT01574781|||||PROSPECTIVE|||||||
33896897|NCT04284644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33896898|NCT06510426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients at high risk for the development of neuroinvasive WNV disease (age 70 and older or immunocompromised patients) or patients presenting with neurologic symptoms of encephalomyelitis will be randomized to receive the study drug or placebo.|t|t|t|f
33896899|NCT05164965|||COHORT||PROSPECTIVE|||||||
33896900|NCT04119908|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34025639|NCT00501098|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34077960|NCT05975814|NA|SINGLE_GROUP||TREATMENT||NONE|each implant receives either a straight or a concave abutment. The patient is not aware of the type of abutment.|clinical study||||
34077961|NCT05235152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research assistant and treating therapist will be blinded to baseline evaluation results. Given that for this type of intervention it is impossible to blind the treating physiotherapists and participants, only the investigator, evaluator and statistician will be blinded.|A parallel-group randomized-controlled trial with four evaluation sessions over 26 weeks (baseline, week 6 \[mid-intervention\], week 12 \[end of intervention\], week 26) and 16 visits over 12 weeks to the Valcartier Health Centre for the intervention.|f|f|t|t
34077962|NCT00666302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33896901|NCT03719573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotherapist assessing function status.||f|f|f|t
34077963|NCT00902577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34077964|NCT03557593|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomized, stepped-wedge cluster trial.||||
34077965|NCT04110431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34077966|NCT05782803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34077967|NCT05670743|NA|SINGLE_GROUP||TREATMENT||NONE||This is a topical agent where the active ingredients are applied to the teeth and eventually swallowed and may be absorbed through the GI tract or excreted. Minimal amounts are absorbed through the oral mucosa. Serum concentrations of silver and fluoride will be be proportional to the dose of silver and fluoride administered topically to the teeth as part of Advantage Arrest.||||
34077968|NCT05443373|||COHORT||CROSS_SECTIONAL|||||||
34077969|NCT01967459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077970|NCT04528316|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental controlled randomization using Block Stratified Randomized Software program, after obtaining informed consent from illegible patient or his caregiver.||||
34077971|NCT04161235|||COHORT||PROSPECTIVE|||||||
34077972|NCT01686945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077973|NCT00628563|||||RETROSPECTIVE|||||||
34077974|NCT04213664|||OTHER||OTHER|||||||
34077975|NCT04254536|||CASE_ONLY||PROSPECTIVE|||||||
34077976|NCT00319709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34077977|NCT05060575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33896902|NCT01400646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077978|NCT01122069|||CASE_ONLY||PROSPECTIVE|||||||
34077979|NCT05865223|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34077980|NCT03119597|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the participants nor the researchers will be aware of which participants are receiving treatment or placebo. Participants and their parents will be debriefed on the last test day.|participants will be assigned to either a Placebo or Blueberry (treatment) drink, in parallel for the duration of the study|t|f|t|f
33896903|NCT05668156|||OTHER||OTHER|||||||
33896904|NCT00190086|||DEFINED_POPULATION||OTHER|||||||
33896905|NCT02032628|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896906|NCT04902248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896907|NCT05316363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care providers were not involved in any data analysis and the investigator was also blind to the assignment and outcomes assessment.|Randomized into two groups: Standard asthmatic care with OMT intervention and standard asthmatic care with no OMT.|f|t|t|f
33980408|NCT05129852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The researchers massaged the abdomen with sage oil for 30 minutes, and 30 minutes after the massage, VAS evaluation and blood pressure, body temperature, and pulse rate measurements were performed again.~VAS pain scores were also evaluated in the Reiki group (30 participants) when the pain started. The participants experienced pain on the first 3 days of their menstruation. Their blood pressure, body temperature, and pulse rate were also measured. Reiki was applied by a researcher with a Reiki certificate. Thirty minutes after the Reiki application, VAS evaluation and blood pressure, body temperature, and pulse rate measurements were repeated. This application was repeated for two menstrual periods.~Similarly, in the control group (30 participants), VAS pain scores were evaluated when the pain started on the first three days of their menstruation, and their blood pressure, body temperature, and pulse rate were measured. No application was performed; they were only asked to rest."|Three groups with alternative therapy is a randomized controlled trial|t|f|f|f
33980409|NCT03328260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980410|NCT03879239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This was a double blind, placebo controlled study and both the participant and the investigator were masked. The study investigators, sponsors and participants were all blinded throughout the study. A research pharmacist/investigator who was not involved with evaluating patients or conducting the study, provided training to the participants and dispensed the correct study arm allocation. This individual had no other role in the study.|The study design initially comprised 3 arms: 2 active vibrating capsule arms (Modes A and B) and 1 placebo arm. Based on the analysis of the first pre-define phase of the study, active mode B was discontinued and the trial was completed using mode A. Therefore, study results are available only for active A and Placebo arms.|t|f|t|f
34077981|NCT00917826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077982|NCT01754519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077983|NCT03977012|||CASE_ONLY||PROSPECTIVE|||||||
34077984|NCT00913341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34077985|NCT03641261|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34077986|NCT05178823|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33896908|NCT04773769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077987|NCT04375163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor-blind randomized control trial. A masked assessor conducted the measurements.|26 Tae Kwon Do athletes performed a vigorous exercise program on the isokinetic dynamometer twice in a period of 10 days, each time on a different extremity. In this way two groups of 26 individuals each were created, with the same individuals alternating. In the massage group (ME) a sport massage was applied between the sets while in the control group (NME) the break was passive. knee flexion and extension ROM, thigh circumference, and creatine kinase (CK) levels in blood plasma were measured before and after each test while L-DOMS was measured 24, 48, 72 and 96 hours after the exercise.|f|f|f|t
33767890|NCT03853317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767891|NCT01844115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767892|NCT02796963|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33767893|NCT02261090|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767894|NCT00421226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33767895|NCT03355963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767896|NCT02674490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767897|NCT00553202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767898|NCT05436964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767899|NCT01403441|NA|SINGLE_GROUP||TREATMENT||NONE||Precision radiotherapy is delivered on Day 1 using the Cyberknife System to Brodmann area cingulate 25.||||
33767900|NCT01058434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767901|NCT05472337|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized comparison between colchicine versus no colchicine in terms of microvascular coronary reperfusion and infarct size in patients with acute coronary syndrome.||||
33767902|NCT03936738|||COHORT||PROSPECTIVE|||||||
33896909|NCT04757363|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label, nonrandomized, single-institution, phase II study of nivolumab in combination with FOLFOX and regorafenib as first-line therapy in patients with metastatic esophagogastric adenocarcinoma.||||
33896910|NCT02088034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896911|NCT05978869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33896912|NCT06346405|||CASE_ONLY||PROSPECTIVE|||||||
33896913|NCT03129438|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Blind assessment of secondary outcomes at 6 months||f|f|f|t
33896914|NCT05415280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896915|NCT05485103|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33896916|NCT02586207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896917|NCT01283620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896918|NCT01486238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33896919|NCT02620540|||CASE_ONLY||PROSPECTIVE|||||||
33896920|NCT03157557|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33896921|NCT06388369|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The first patients are enrolled - without randomization - into the Safety Cohort to assess whether the treatment regime under investigation, i.e. Ipilimumab (3mg/kg) + \[177Lu\]Lu-PSMA-617 RLT (7,4 GBq), is appropriately tolerated as per dose escalation algorithm.~If it is established that Ipilimumab (3mg/kg) + \[177Lu\]Lu-PSMA-617 RLT (7,4 GBq) is appropriately tolerated, patients will be randomized into the two arms of the Analysis Cohort:~* Arm A: Ipilimumab + \[177Lu\]Lu-PSMA-617 RLT~* Arm B: \[177Lu\]Lu-PSMA-617 RLT"||||
33896922|NCT03615027|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This clinical trial has a sigle arm: all the dyads will go through the four visits.||||
33896923|NCT05934760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Due to the nature of exercise interventions, it is not possible to blind the participants or investigators.|||||
33896924|NCT01565486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896925|NCT00248677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896926|NCT03237208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980411|NCT03151278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980412|NCT02803242|||COHORT||OTHER|||||||
33980413|NCT06159803|||COHORT||PROSPECTIVE|||||||
33896927|NCT02330991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896928|NCT04896177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896929|NCT04956484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896930|NCT05567328|NA|SINGLE_GROUP||OTHER||NONE||||||
33896931|NCT05066815|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33767903|NCT06436937|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767904|NCT04719663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants will be blinded to the congruency condition. Outcome assessors (diagnosticians) will be blinded to treatment allocation and the congruency condition (both at the pre-measurement and at the post-measurement). The clinicians (care providers) who deliver the illness explanation and treatment rationale will be blinded to the participants' treatment allocation up to the point at which the respective treatment is delivered. This means that the clinician provides the treatment rationale (biological / psychological) without knowledge of whether a congruent or incongruent treatment will be delivered afterwards. The staff members who deliver the treatment (care providers) will be different to the clinician who delivers the rationales. Thus the treatment will be delivered without knowledge of whether a congruent or incongruent illness explanation was given.||t|t|f|t
33767905|NCT00974701|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767906|NCT01688960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767907|NCT00158210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33767908|NCT02300285|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767909|NCT03017144|||CASE_ONLY||PROSPECTIVE|||||||
33767910|NCT04499339|NA|SEQUENTIAL||TREATMENT||NONE||||||
33767911|NCT00204269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767912|NCT03091673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33767913|NCT00329121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767914|NCT01633216|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767915|NCT00073879||||TREATMENT||||||||
33767916|NCT03951935|||COHORT||CROSS_SECTIONAL|||||||
33767917|NCT01212406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767918|NCT06522243|RANDOMIZED|PARALLEL||TREATMENT||NONE||waitlist randomized controlled trial||||
33767919|NCT02784470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767920|NCT00446940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767921|NCT00549887|||COHORT||PROSPECTIVE|||||||
33767922|NCT05208619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33767923|NCT04872244|NA|SINGLE_GROUP||TREATMENT||NONE||patients who have isthmocele due to previous cesarean section and suffering from postmenstrual spotting bleeding||||
33767924|NCT03150524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767925|NCT06140563|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33767926|NCT00965796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767927|NCT02084719|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33767928|NCT05185596|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33767929|NCT04362657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767930|NCT00002163||||TREATMENT||DOUBLE||||||
33767931|NCT02674360|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33767932|NCT01183650||PARALLEL||BASIC_SCIENCE||NONE||||||
33767933|NCT00844740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767934|NCT04389333|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators recruited 40 patients who have related symptom and healthy people mainly from outpatient clinic or hostipal health examination center. After fully understanding the procedure of nc-MCE，patients with informed consent were randomly divided into MCE group and nc-MCE group(1:1) by using a stratified block randomization(block size four)||||
33767935|NCT01351428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767936|NCT01196884|||CASE_CONTROL||PROSPECTIVE|||||||
33767937|NCT04130334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33767938|NCT00282815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767939|NCT03676920|NA|SINGLE_GROUP||OTHER||NONE|There is only one arm and patients will know they are testing the intervention. Physicians will not be told explicitly which of their patients are enrolled in the study but they may see patients with the intervention (either on an iPad or in a printed version).|"The research tests the feasibility of an application-based (app) communication intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions during clinical interactions, and associated measures."||||
33767940|NCT04080310|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33767941|NCT01619046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767942|NCT00406419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33767943|NCT01532505|||CASE_CONTROL||PROSPECTIVE|||||||
33767944|NCT04180241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization process is initiated after general anesthesia is induced and the group affiliation will be determined by opening of a sealed envelope specifying the group assignment. The information of group allocation is stored in a closed envelope kept in a locked archive until the study is completed.|POEM with division all the esophageal muscle layers compared to deviding only the inner circular muscle layer of the esophagus.|t|f|t|t
33767945|NCT03804190|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33767946|NCT01472913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767947|NCT03539367|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33767948|NCT05806268|||COHORT||RETROSPECTIVE|||||||
33767949|NCT05145946|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33767950|NCT03826511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767951|NCT05296096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33767952|NCT03917810|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomised crossover design||||
33767953|NCT02885727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767954|NCT00079456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767955|NCT03221062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767956|NCT05774990|||COHORT||RETROSPECTIVE|||||||
33767957|NCT04735042|||COHORT||PROSPECTIVE|||||||
33767958|NCT01155830|||COHORT||PROSPECTIVE|||||||
33896932|NCT01039168|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896933|NCT00555945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896934|NCT05811910|||OTHER||CROSS_SECTIONAL|||||||
33896935|NCT00982722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33896936|NCT06117592|||COHORT||RETROSPECTIVE|||||||
33896937|NCT05965570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896938|NCT02997930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896939|NCT04713319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and care providers were fully blinded.|Altogether a 25 day study with first four days non-blinded with water. There after 0-control blood samples. After the 0-control blinded treatments for 21 days (3 weeks). Study group apparently healthy 50-60 year old males and females (N=27).|t|t|f|f
33980414|NCT04112082|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33767959|NCT00786890|||CASE_ONLY||PROSPECTIVE|||||||
33767960|NCT03395834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896940|NCT04937257|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcome raters were two independent nurse educators, blinded to the study protocol and interventions. An encrypted folder contained outcome videos, each with a unique number, containing no known information that may disclose the study arm.||f|f|f|t
33896941|NCT02316444|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33896942|NCT02428140|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33896943|NCT05207462|NA|SINGLE_GROUP||TREATMENT||NONE||Prolonged exposure will be offered in a massed format with a total of nine 60 minutes sessions of imaginal exposure and processing and five 2 hour group session with psychoeducation, rationales and in vivo exposure during one treatment week followed by three individual 60 minutes sessions 2, 4 and 8 weeks afterwards.||||
33980415|NCT05277753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980416|NCT01723449|||COHORT||PROSPECTIVE|||||||
33980417|NCT00105196|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33980418|NCT02480465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980419|NCT01722448|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33980420|NCT00055978|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33980421|NCT00002012||||TREATMENT||DOUBLE||||||
33767961|NCT06626048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767962|NCT00014196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767963|NCT02714101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767964|NCT01393080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767965|NCT01113658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767966|NCT03534765|||COHORT||PROSPECTIVE|||||||
33767967|NCT04930237|||CASE_CONTROL||PROSPECTIVE|||||||
33980422|NCT01881048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767968|NCT05404880|||COHORT||PROSPECTIVE|||||||
33767969|NCT05685823|||COHORT||PROSPECTIVE|||||||
33980423|NCT01436422|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33980424|NCT05559996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980425|NCT03380819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980426|NCT02173236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980427|NCT04963192|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A prospective clinical study, conducted at the Verdun Hospital, in patients with a chronic respiratory pathology (OSA or COPD), including an integrated management at home using connected devices, during 6 months||||
33980428|NCT01635842|||COHORT||PROSPECTIVE|||||||
33980429|NCT00182442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980430|NCT03532685|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33980431|NCT06367452|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33980432|NCT06277193|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34077988|NCT05293782|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|Crossover Assignment|t|f|f|t
34077989|NCT04022317|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind||t|f|t|f
33896944|NCT05661383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be block randomized (1:1) to receive either iTBS active combined with an olfactory stimulation or TBS active alone. Computer generated random numbers will be used to generate the allocation sequence. The allocation sequence will be handled by an independent person from the Administrative Department of the Hospital and will be unavailable to those who enroll and assign patients. Patients will be blind to their treatment assignment. Moreover, the medical doctors who will administer the clinical scales and the researchers that will analyze the data will be blinded to the allocation.|This is a prospective, single-center, randomized, double-blind, parallel-group controlled trial with two arms|t|f|t|t
33896945|NCT04590612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33896946|NCT04045912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33896947|NCT01684826|NON_RANDOMIZED|||TREATMENT||NONE||||||
33896948|NCT01165008|NA|SINGLE_GROUP||TREATMENT||||||||
33896949|NCT01496014|||COHORT||PROSPECTIVE|||||||
33896950|NCT03025581|RANDOMIZED|PARALLEL||||NONE||||||
33896951|NCT02728934|||COHORT||PROSPECTIVE|||||||
33980433|NCT03305237|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33980434|NCT05851131|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33980435|NCT03700242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980436|NCT02441972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980437|NCT00535808|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980438|NCT05873023|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33980439|NCT02597543|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33980440|NCT01471522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980441|NCT04468802|||CASE_ONLY||PROSPECTIVE|||||||
33980442|NCT00643877|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980443|NCT02841826|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980444|NCT04533022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980445|NCT00977288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980446|NCT06091878|||COHORT||RETROSPECTIVE|||||||
33980447|NCT03163875|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980448|NCT06089538|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33980449|NCT02486822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980450|NCT04527809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants, researchers and outcome assessors will remain blind throughout the study. To ensure proper blinding, the researcher responsible for that, will configurate the code of the tDCS device to sham or active before the proper application. It will be no difference between the devices for sham or active application of the tDCS.|The participants will undertake a single session of non-immersive VR tasks and tDCS-active or tDCS-sham.|t|f|t|f
33980451|NCT00005576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980452|NCT02164838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980453|NCT02029105|||CASE_ONLY||RETROSPECTIVE|||||||
33980454|NCT02080923|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a brief motivational interview-style intervention. Adolescents ages 15-19 years old who visit the emergency department and screen positive for physical or sexual dating abuse perpetration participate in a \~45 minute brief intervention and receive up to three booster calls in the subsequent 6 weeks.||||
33896952|NCT03880643|||CASE_ONLY||RETROSPECTIVE|||||||
33980455|NCT04472390|||COHORT||RETROSPECTIVE|||||||
33980456|NCT04182009|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33980457|NCT03220867|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33980458|NCT05939180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980459|NCT05282485|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study will recruit 144 women living with HIV and their HIV-exposed uninfected children (72 will receive the interventional product and 72 will receive the placebo). All of the women in the study will have breastfed or are currently breastfeeding their children.|t|t|t|t
33980460|NCT01362725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980461|NCT03535207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077990|NCT04851106|||COHORT||PROSPECTIVE|||||||
34077991|NCT00338741|||CASE_CONTROL||PROSPECTIVE|||||||
34077992|NCT01681758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34077993|NCT03478371|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34077994|NCT00103285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34077995|NCT00059228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34077996|NCT03513016|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34077997|NCT01828970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34077998|NCT04758195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34077999|NCT05934474|||CASE_ONLY||PROSPECTIVE|||||||
34078000|NCT01716663|||||PROSPECTIVE|||||||
33767970|NCT05081505|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single group trial, according to the pre-test result of the exercise stage of the change questionnaire, they were divided into the maintenance phase group (MP, N=15) and under the maintenance phase group (MPb, N=15). All subjects joined the community-based physical fitness exercise course for 24 weeks. To quantify the effect of this intervention method on functional fitness and exercise persistence of the elderly, this study analyzed the related exercise behavior changes of MPb and MP elderly.||||
33767971|NCT02561143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33767972|NCT06130813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled trial|t|f|f|f
33767973|NCT05194189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The participants in treatment group receive intravenous megadose vitamin C. The participants in control group receive 5% glucose injection with same volume.|t|f|f|t
33896953|NCT05696340|||OTHER||OTHER|||||||
33896954|NCT04350203|||COHORT||RETROSPECTIVE|||||||
33896955|NCT01553409|||COHORT||PROSPECTIVE|||||||
33896956|NCT02862795|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33896957|NCT02260011|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33896958|NCT03065530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896959|NCT01441154|||COHORT||PROSPECTIVE|||||||
33896960|NCT05124938|||CASE_CONTROL||RETROSPECTIVE|||||||
33896961|NCT02916446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980462|NCT03252964|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980463|NCT01648166|||CASE_CONTROL||PROSPECTIVE|||||||
33980464|NCT01479400|||CASE_CONTROL||PROSPECTIVE|||||||
33896962|NCT02851446|||CASE_CONTROL||PROSPECTIVE|||||||
33896963|NCT05879939|||COHORT||PROSPECTIVE|||||||
33980465|NCT03528200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896964|NCT01558687|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33980466|NCT01173042|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33980467|NCT02075437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980468|NCT02031978|||COHORT||PROSPECTIVE|||||||
33896965|NCT01784471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33896966|NCT06443034|||COHORT||RETROSPECTIVE|||||||
33896967|NCT05841459|||OTHER||CROSS_SECTIONAL|||||||
33896968|NCT01613612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33896969|NCT00834119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896970|NCT02375776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896971|NCT03983941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33896972|NCT01783405|||CASE_CONTROL||RETROSPECTIVE|||||||
33896973|NCT02189265|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33896974|NCT06498908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subjects won't be told which group they were assigned. Care providers will be told which group subject is assigned/|Nitrous Oxide vs Oxygen|t|f|f|f
33896975|NCT06507020|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33896976|NCT04403438|||COHORT||PROSPECTIVE|||||||
33896977|NCT01400828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33896978|NCT04471220|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33896979|NCT04098380|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33896980|NCT06266637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33980469|NCT02548637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980470|NCT05582460|||COHORT||PROSPECTIVE|||||||
33980471|NCT02780336|||CASE_CONTROL||PROSPECTIVE|||||||
33980472|NCT04701632|||OTHER||RETROSPECTIVE|||||||
33980473|NCT05117424|||COHORT||PROSPECTIVE|||||||
33980474|NCT00323193|RANDOMIZED|PARALLEL||||NONE||||||
33980475|NCT01144936|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33980476|NCT04845165|||COHORT||PROSPECTIVE|||||||
33980477|NCT01101425|||CASE_ONLY||PROSPECTIVE|||||||
33980478|NCT04813263|||COHORT||PROSPECTIVE|||||||
33980479|NCT01139164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980480|NCT05319990|||COHORT||PROSPECTIVE|||||||
33980481|NCT05020548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33980482|NCT04647604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980483|NCT03174119|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33980484|NCT06141070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078001|NCT02665247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078002|NCT05778474|||COHORT||CROSS_SECTIONAL|||||||
33896981|NCT02634515|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33896982|NCT03497689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896983|NCT04761185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33896984|NCT00760292|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980485|NCT05877170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980486|NCT02041169|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980487|NCT01790568|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078003|NCT05659147|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be prospectively recruited to one or more of four prospective imaging aims (Aims 1-4). All participants who enroll in any imaging Aim will have their images used for Aim 5 (image analysis aim) which will also include a retrospective component.||||
34078004|NCT00037986|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078005|NCT02996071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078006|NCT02881658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078007|NCT03154580|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34078008|NCT00002935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078009|NCT01131715|||OTHER||OTHER|||||||
34078010|NCT02955953|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34078011|NCT01464190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078012|NCT02052986|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33980488|NCT02572921|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33980489|NCT05575414|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33980490|NCT05618470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980491|NCT00928369|||CASE_ONLY||RETROSPECTIVE|||||||
34078013|NCT00608400|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34078014|NCT02209363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078015|NCT02137941|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34078016|NCT01549665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078017|NCT05943353|NA|SINGLE_GROUP||OTHER||NONE||||||
34078018|NCT05418465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078019|NCT01608880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980492|NCT00304447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980493|NCT01622998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980494|NCT01743378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980495|NCT00662753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980496|NCT02005536|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980497|NCT03325114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980498|NCT03980288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980499|NCT03974256|RANDOMIZED|CROSSOVER||OTHER||NONE||Interventional study, multicenter, randomized, cross-over, open, at risk and minimal constraints||||
33980500|NCT04774432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980501|NCT03201302|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980502|NCT06315426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078020|NCT06080516|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33980503|NCT00431691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980504|NCT04631770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980505|NCT05893264|||COHORT||PROSPECTIVE|||||||
33980506|NCT03955536|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Inclusion criteria 25-70 age range Undergoing open heart surgery Hemodynamically stable Ambulatory No advanced vision defect The physician authorized by the operating physician for participation in the exercise Patients who agreed to participate in the study. Exclusion criteria The presence of pulmonary, neurological, musculoskeletal disease limiting participation in exercise training Patients at high risk (ejection fraction below 40 percent) Dissectant aneurysm Patients who cannot be cooperative in verbal and / or auditory terms Psychological and / or perceptual cooperative patients|"randomized controlled trial 3 groups~1. Group routine cardiac rehabilitation program (RCRP)~2. Group RCRP and inspiratory muscle training~3. Group RCRP and virtual reality application"|t|f|f|f
33980507|NCT02812849|||COHORT||PROSPECTIVE|||||||
33980508|NCT04466085|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33980509|NCT03143400|RANDOMIZED|PARALLEL||OTHER||NONE|Open|||||
33980510|NCT01101230|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33980511|NCT05435300|||CASE_ONLY||PROSPECTIVE|||||||
33980512|NCT03227445|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This will an open-label study and blinding will not be performed.|Subjects will be randomized to receive a placebo ELLIPTA inhaler QD or a placebo DISKUS BID with placebo HandiHaler QD inhaler at Visit 1 and Visit 2 in a cross-over manner followed by Preference Questionnaire 1 or 2||||
33980513|NCT06252025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33980514|NCT04540640|NA|SINGLE_GROUP||OTHER||NONE||A pilot study assessing the feasibility of procedures and preliminary safety of study device and perfusion solution.||||
34078021|NCT03936569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980515|NCT00355628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980516|NCT05303909|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a double blind placebo controlled trial|Subjects will be randomized in a 1:1 ratio to receive either a single dose of IV gentamicin at dose of 5 mg/kg or 0.9% normal saline placebo on Day 0 in a double-blind fashion, followed by YF17D vaccination 30 minutes later.|t|f|t|f
33980517|NCT00460304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980518|NCT02164279|||COHORT||PROSPECTIVE|||||||
33980519|NCT00917657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980520|NCT05467306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980521|NCT02798484|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980522|NCT03508622|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pilot intervention using retrospective control group.||||
33980523|NCT01779323|||COHORT||PROSPECTIVE|||||||
33980524|NCT01936922|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980525|NCT06240390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Simple Blind, Evaluator||f|t|t|t
33980526|NCT05273866|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Crossover Assignment|t|f|f|f
33980527|NCT01188746|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980528|NCT00760266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980529|NCT02092922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078022|NCT02115100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078023|NCT01707641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980530|NCT04900090|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33980531|NCT00620009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980532|NCT00528853|||CASE_ONLY||PROSPECTIVE|||||||
34025640|NCT06600269|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025641|NCT03372291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025642|NCT05972174|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33896985|NCT03187379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33896986|NCT00002993||||TREATMENT||||||||
33896987|NCT04267237|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33896988|NCT04758793|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33896989|NCT02179632|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33896990|NCT00733655|||COHORT||PROSPECTIVE|||||||
33896991|NCT03701503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33896992|NCT03443024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33896993|NCT05366608|||COHORT||PROSPECTIVE|||||||
33896994|NCT05782855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33896995|NCT03154138|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33896996|NCT04668378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||It is a single blind, parallel arms study|f|f|f|t
33896997|NCT03366714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33896998|NCT02131701|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33896999|NCT02462161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897000|NCT02243566|||COHORT||PROSPECTIVE|||||||
33897001|NCT00983775|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33897002|NCT02788539|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33897003|NCT00082823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897004|NCT04538950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897005|NCT01613092|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33897006|NCT01592825|||COHORT||PROSPECTIVE|||||||
33897007|NCT03744234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33897008|NCT00080210|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897009|NCT05339516|||COHORT||CROSS_SECTIONAL|||||||
33897010|NCT02435628|||COHORT||PROSPECTIVE|||||||
33897011|NCT03942614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33897012|NCT03694522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded (participant, treating physician)||t|f|t|f
33897013|NCT00248950|NON_RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33897014|NCT01994577|||COHORT||PROSPECTIVE|||||||
33897015|NCT03933501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897016|NCT03485612|||COHORT||PROSPECTIVE|||||||
33897017|NCT01904175|||CASE_ONLY||PROSPECTIVE|||||||
33897018|NCT04429932|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33897019|NCT01495819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897020|NCT00392873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897021|NCT03419702|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33980533|NCT03657056|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"Participants will be recruited from the normal population of patients being treated for temporal lobe epilepsy Massachusetts General Hospital.~Patients identified as candidates for temporal lobe surgery by the clinical team will be notified via a letter that has been signed by a physician representative of the practice of their eligibility for the study. An administrator will follow-up on the letter with a phone call. The physician of potential participants will be notified of their eligibility for the study, and be provided with a copy of the consent form. A total of 3 participants will be enrolled in the project."||||
33980534|NCT00153803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980535|NCT01509300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980536|NCT06191900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897022|NCT00841724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897023|NCT02822365|||CASE_ONLY||CROSS_SECTIONAL|||||||
33897024|NCT00378729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897025|NCT04735029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Envelope|Group 1: Heat pack group; Group 2: Thermal Gun group|t|t|f|f
33897026|NCT01064089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897027|NCT04243044|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33897028|NCT01259739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33897029|NCT05399693|||COHORT||PROSPECTIVE|||||||
33897030|NCT02054832|||COHORT||PROSPECTIVE|||||||
33897031|NCT04677270|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33897032|NCT00986778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897033|NCT04332419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897034|NCT01142648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897035|NCT05937711|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome measures were assessed by investigators who were blinded to each patient's group.||f|f|f|t
33897036|NCT00480961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897037|NCT05450068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study is single-blinded as the participants are unaware of the treatment given to them.||t|f|f|f
33897038|NCT00515125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897039|NCT03913910|||CASE_CONTROL||PROSPECTIVE|||||||
33897040|NCT02886312||||SUPPORTIVE_CARE||||||||
33897041|NCT05109390|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This was a 3-part study, each part is a fixed-sequence with 2 periods.||||
33897042|NCT03507933|||CASE_ONLY||RETROSPECTIVE|||||||
33897043|NCT05446246|||CASE_CONTROL||RETROSPECTIVE|||||||
33897044|NCT04150458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897045|NCT01701700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897046|NCT03623750|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, uncontrolled, Phase Ib clinical study||||
33897047|NCT05012566|RANDOMIZED|PARALLEL||TREATMENT||NONE||monocenter, no treated controlled group, randomized clinical trial||||
33897048|NCT05791916|||COHORT||PROSPECTIVE|||||||
33897049|NCT02117089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897050|NCT03910699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897051|NCT01293435|||||RETROSPECTIVE|||||||
33897052|NCT05957562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (participants will choose from sealed closed envelopes)|This randomized controlled study conducted to assess the technical feasibility and surgical outcomes of one stage surgical repair, either with Azygos vein preservation or with Azygous vein disconnection, in newborns diagnosed with Esophageal Atresia and tracheoesophageal fistula. It includes 64 neonates with TOF/EA who will be randomly divided (using the sealed closed envelope method) into two equal groups, each group will include 34 neonatal patients|t|f|f|f
33897053|NCT03335124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33897054|NCT00718133|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897055|NCT02437838|||OTHER||PROSPECTIVE|||||||
33980537|NCT00002579|RANDOMIZED|||TREATMENT||||||||
33980538|NCT03755609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980539|NCT02031393|||CASE_CONTROL||PROSPECTIVE|||||||
33980540|NCT00595608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33980541|NCT02530762|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33897056|NCT04861038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897057|NCT00227461|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897058|NCT00624338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897059|NCT01901328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897060|NCT01682915|||OTHER||OTHER|||||||
33897061|NCT01523444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897062|NCT06513468|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||The enrolled study participants will be randomized to receive either the standard personal health care (routine diabetes health education services) or a standard group health education (DESMOND) session|t|t|t|t
33897063|NCT05089565|||CASE_CONTROL||PROSPECTIVE|||||||
33897064|NCT03591822|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33897065|NCT02329925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897066|NCT00575796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025643|NCT02609074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025644|NCT00237653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025645|NCT04679701|||CASE_ONLY||PROSPECTIVE|||||||
33897067|NCT03968510|||CASE_CROSSOVER||PROSPECTIVE|||||||
33897068|NCT03600116|||CASE_ONLY||PROSPECTIVE|||||||
33897069|NCT06499571|||COHORT||OTHER|||||||
33897070|NCT04630314|||COHORT||RETROSPECTIVE|||||||
33897071|NCT04613011|||COHORT||PROSPECTIVE|||||||
33897072|NCT03118843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897073|NCT00857610|||COHORT||PROSPECTIVE|||||||
33897074|NCT04775043|||COHORT||PROSPECTIVE|||||||
33897075|NCT03376828|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Prospective||||
33897076|NCT05691725|||COHORT||RETROSPECTIVE|||||||
33897077|NCT03617393|||COHORT||PROSPECTIVE|||||||
33897078|NCT03004846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897079|NCT01845077|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897080|NCT02950129|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33897081|NCT03071432|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Non-diabetic patients, n=15 Diabetic patients with cardiovascular autonomic neuropathy, n=15 Diabetic patients without cardiovascular autonomic neuropathy, n=15||||
33897082|NCT06512493|||COHORT||PROSPECTIVE|||||||
33897083|NCT03984526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897084|NCT00576914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897085|NCT02657642|||COHORT||PROSPECTIVE|||||||
33980542|NCT05323864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A double-blind randomized controlled crossover trial with two groups of participants will be conducted. One group will be a group of psychiatric patients and the other group will be a group of healthy controls. The study will follow a crossover design with random allocation of condition order (i.e., normobaric hypoxia or sham hypoxia).|t|t|f|f
33980543|NCT00005778|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33897086|NCT00337532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980544|NCT04347837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980545|NCT04281563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data were analyzed by a researcher who was not informed of the intervention group assignment.||f|f|t|f
33980546|NCT05126056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078024|NCT05857722|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will recruit and enroll 120 male/120 female youth (N=240) aged 18-30 from several communities in Bogotá using stratified selection for gender balance; and then randomize youth to receive Jóvenes Capibara within entrepreneurship training (N=120) or to a waitlist condition (N=120). Waitlisted youth will be eligible to receive the intervention after 6-month follow-up data collection.||||
33897087|NCT02660697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897088|NCT05717322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897089|NCT01573468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897090|NCT05873530|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33897091|NCT00206518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897092|NCT00540540|||CASE_ONLY||PROSPECTIVE|||||||
33897093|NCT03035812|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical and biological evaluation before and after an oral alkalinization||||
33897094|NCT00820638|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33897095|NCT04484129|||COHORT||PROSPECTIVE|||||||
33897096|NCT03250520|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33897097|NCT05704530|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Three distinct patient groups are defined, depending on the therapeutic scenario patients undertake. Patient management is standard of care. No investigational medicinal product (IMP) is involved.~Trial is considered low interventional due to addition of extra blood samples, otherwise would be observational."||||
33980547|NCT01894178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980548|NCT00906425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897098|NCT02190591|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897099|NCT02506777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897100|NCT00006812||||TREATMENT||||||||
33897101|NCT05272514|||OTHER||PROSPECTIVE|||||||
33897102|NCT05076968|||COHORT||PROSPECTIVE|||||||
33897103|NCT04711421|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33897104|NCT05784389|NA|SINGLE_GROUP||TREATMENT||NONE||"Single Group Assignment~Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up)."||||
33897105|NCT02283944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897106|NCT01666132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897107|NCT00276289|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897108|NCT03877744|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||randomized non-inferiority trial|f|f|f|t
33980549|NCT04018625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intervention versus treatment as usual.|t|f|f|t
33980550|NCT01893905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980551|NCT02556944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980552|NCT03629093|||COHORT||PROSPECTIVE|||||||
33980553|NCT06242405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980554|NCT01575223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33980555|NCT05063500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078025|NCT02300623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078026|NCT01759706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078027|NCT03434210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor would not known the arm, and forbiden to ask and comminicate with patients about the intervention.||f|f|f|t
34078028|NCT00371956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078029|NCT01307813|NA|SINGLE_GROUP||OTHER||NONE||||||
34078030|NCT01374022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078031|NCT03286218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34078032|NCT04071782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078033|NCT03669601|RANDOMIZED|PARALLEL||TREATMENT||NONE||Continuous and intermittent administration schedule.||||
34078034|NCT01393145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078035|NCT05468255|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34078036|NCT02823353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897109|NCT00196937|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897110|NCT01655407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897111|NCT03663244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897112|NCT05087186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897113|NCT00288210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897114|NCT06670482|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Randomized, cross-over, non-blinded|f|f|f|t
33897115|NCT03927040|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33897116|NCT02424487|||COHORT||PROSPECTIVE|||||||
33980556|NCT05265806|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind mixed experimental design|t|f|t|t
33980557|NCT00323349|RANDOMIZED|FACTORIAL||||NONE||||||
33980558|NCT00131703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33980559|NCT03960970|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pregnant patients admitted to Labor and Delivery unit between June 2019 and July 2020 will be randomized to received either standard prophylaxis or azithromycin and cephalosporin for preoperative prophylaxis after inclusion and exclusion criteria are met and informed consent for participation is signed.||||
33980560|NCT04752748|||CASE_CONTROL||PROSPECTIVE|||||||
34078037|NCT00199628|||COHORT||PROSPECTIVE|||||||
34078038|NCT06301919|||COHORT||RETROSPECTIVE|||||||
34078039|NCT02118103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33980561|NCT05019469|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980562|NCT05986383|||OTHER||PROSPECTIVE|||||||
33980563|NCT03567642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980564|NCT06521983|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33980565|NCT05488197|||OTHER||RETROSPECTIVE|||||||
33980566|NCT01130688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980567|NCT05193019|||OTHER||PROSPECTIVE|||||||
33980568|NCT05773183|||CASE_CROSSOVER||PROSPECTIVE|||||||
33980569|NCT04688697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980570|NCT03344510|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will be an open label split-body crossover trial, using healthy adult volunteers recruited from the faculty, staff and student body of the University of Pennsylvania, and from the University City area of Philadelphia. Participants will be randomized to one of three anatomic sites deemed relevant: the nasofacial sulcus, the lateral forehead, and the upper back. Participants will then be randomized to receive injection with the KAD first or second. They will receive one injection with and one injection without the interventional device, in a randomized order.||||
33980571|NCT05209009|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33980572|NCT01988922|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33980573|NCT00004769|||CASE_CONTROL||PROSPECTIVE|||||||
33980574|NCT00147030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980575|NCT02279797|||COHORT||RETROSPECTIVE|||||||
33980576|NCT03340727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Sample size for this trial will be flexible: the trial will be stopped for efficacy or futility based on pre-determined statistical thresholds or based on study drug availability.|t|t|t|t
33980577|NCT01295372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980578|NCT01541280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980579|NCT05942703|||CASE_CONTROL||PROSPECTIVE|||||||
33980580|NCT04700254|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980581|NCT02930005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980582|NCT02995057|||||PROSPECTIVE|||||||
33980583|NCT01572948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025646|NCT04030715|NON_RANDOMIZED|FACTORIAL||OTHER||NONE|no masking|Use the two-categorical variable , eradicate success or failure ,as a dependent variable, and analyze the influential factors by logistic regression.And then the statistically significant influencing factors like gastric mucosal pathology are obtained.We build a predictive model of the outcome of Hp eradication therapy based on significant influencing factors. The difference with p 0.05 is statistically significant.||||
34025647|NCT03638726|RANDOMIZED|PARALLEL||OTHER||SINGLE|Preoperative and postoperative assessment will be done by a masked observer.|Randomized clinical study|f|f|f|t
34078040|NCT02488226|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34078041|NCT03993483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The histochemistry and ultrasonography were analyzed by blinded study investigators|One arm and one leg of each participant were randomized to lift with heavier loads while the other arm and leg of each participant were randomized to lift with lighter loads for 10 weeks.|f|f|f|t
33839231|NCT05554211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Each solution (topical saline irrigation vs. TxA) will be prepared by the hospital pharmacy on the day of the procedure and given a blinded code number so that the surgeons and study's investigators will be blinded to which breast received which solution. A randomization table will be used to determine whether the right or left breast receives TxA for each patient. Each wound, whether treated with the control agent of TxA, will be irrigated with gentamicin.~The labeling and volume of both the TxA and control irrigation syringes will be visually identical for blinding purposes with the exception of the label indicating whether the syringe is for the right or left breast. Two pharmacy staff members will check the breast assignment on the label against the randomization table. Each label will contain the patient's subject ID number and the study protocol number."|In a within-subjects design, one breast will receive normal saline control and the contralateral breast will receive tranexamic acid.|f|f|t|f
33839232|NCT01860326|NA|SINGLE_GROUP||||NONE||||||
33897117|NCT06197607|RANDOMIZED|PARALLEL||OTHER||SINGLE|participants will get separate treatment protocols and possible effort will be put to mask the both groups about their treatment.|Randomised control trial will be conducted with sample size 20. 20 participants will be included in the study. There will be 10 individuals who will receive hand exercises along with sensory stimulation to improve hand grip strength and manual ability and 10 Individuals who will only receive hand exercises to improve hand grip strength and manual ability. Grip strength and will be analyzed using hand dynamometer. For manual dexterity, box and block test will be used. Grip strength and manual dexterity will be analyzed before and after the intervention.Group A individuals will only receive hand exercises to improve hand grip strength and manual ability. Group B individuals will receive hand exercises along with sensory stimulation to improve hand grip strength and manual ability.|t|f|f|f
34025648|NCT02568839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025649|NCT05060744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Clinical trial with CE marked medical device under normal conditions of use.|t|f|f|f
34025650|NCT02153463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078042|NCT06278805|||COHORT||CROSS_SECTIONAL|||||||
34078043|NCT00735345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078044|NCT03472131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767974|NCT05534880|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants will not be aware of the intention of each of the immersion conditions, and will be randomized through a program for each of the conditions, by a researcher external to the research, and sorted through an opaque envelope, the participants and the researcher, not will know in which condition they will be allocated, only on the day of the draw, each participant will be allocated in the condition and the researcher will not be aware of which condition the participant will be immersed in (condition 01 - video only) or (condition 02 - video associated with binaural beat) .|The study will be a double-blind randomized controlled clinical trial, with university students of both sexes in the city of Parnaíba - PI, volunteers who present cybersickness will be evaluated, those who meet the admission criteria will be randomized and allocated and will be immersed in three conditions, in these conditions the volunteers will be immersed in VR to induce symptoms, where bimodal conditions will be analyzed and compared to analyze the variable electrophysiological activity and the influence of multisensory conditions.|t|t|t|f
33767975|NCT03034122|||COHORT||PROSPECTIVE|||||||
33767976|NCT02467413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767977|NCT05222854|||COHORT||RETROSPECTIVE|||||||
33767978|NCT00779584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33767979|NCT06391216|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Healthy medical students are assigned|t|f|t|t
33767980|NCT00741715|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33767981|NCT01121172|||CASE_CONTROL||PROSPECTIVE|||||||
33767982|NCT01710917|||COHORT||PROSPECTIVE|||||||
33767983|NCT01478113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33767984|NCT01044342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33767985|NCT06609499|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A single digit number will be allocated to each of the two studied devices i.e. 1 for the flexible-tip bougie and 2 for the standard gum elastic bougie. Each study participant will be asked to randomly give a number (either 1 or 2) and will then be given the corresponding tracheal tube introducer to use. The maximum number of intubation attempts is limited to three per device.||t|f|f|f
33767986|NCT03961880|||CASE_ONLY||PROSPECTIVE|||||||
34078045|NCT03262779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This a phase II study employing a Simon two-stage design. If there is at least one response or prolonged stability (\> 24 weeks) using immune related Response Criteria (irRC) appreciated in the first 10 patients who initiate trial therapy, a total of 40 patients will be enrolled. An additional 10 patients with acquired resistance to anti-PD-1 axis therapy will be enrolled in an exploratory cohort receiving the same therapy.||||
34078046|NCT02048150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33767987|NCT04686279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078047|NCT04912843|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1: Dose-Finding: open label；12 subjects Part 2: First Stage: safety run-in phase: open label；6 subjects Part 2: Second Stage: randomized, double-blind, sham-injection; 90 subjects.|"Part 1: Dose-Finding At the dose-finding part, the principle is that the Safety Review Committee (SRC) will determine whether to make dose adjustment based on the safety data of the starting dose in Part 1. The recommended dose (safe and effective dose) of the Part 2 study will be determined jointly by the SRC, IDMC, sponsor and the drug regulatory authority after the interim analysis in Part 1 is completed.~Part 2 :~First Stage: safety run-in phase:~The safety run-in phase of Part 2 will enroll 6 evaluable subjects (including at least 1 minor subject aged ≥ 12 years and \< 18 years) aged ≥ 12 years and ≤ 75 years at the dose determined in Part 1, namely 4.5 x 109 vg, 0.05 mL eye/dose (high dose) and monitor the safety for at least 6 weeks. If there is no new safety concern evaluated by the SRC, the randomized, double-blind, sham-injection control study can be initiated.~Second Stage: randomized, double-blind, sham-injection control study."|t|t|t|t
34078048|NCT00980824|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34078049|NCT00433550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078050|NCT03449355|||OTHER||CROSS_SECTIONAL|||||||
34078051|NCT05434455|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34078052|NCT00492154|||COHORT||PROSPECTIVE|||||||
34078053|NCT01200706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078054|NCT02244671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078055|NCT03625557|||COHORT||PROSPECTIVE|||||||
34078056|NCT04987112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078057|NCT05511298|||COHORT||PROSPECTIVE|||||||
34078058|NCT00746226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078059|NCT02262910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078060|NCT05656170|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|Prospective placebo controlled clinical trial|t|t|t|t
33767988|NCT04261660|||CASE_CONTROL||PROSPECTIVE|||||||
33767989|NCT06503679|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33767990|NCT00477906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33767991|NCT02049710|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33767992|NCT06286514|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33767993|NCT02384967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33767994|NCT03008720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33767995|NCT02970253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33767996|NCT00393523|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33767997|NCT06226428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Controlled pilot clinical trial, with randomized assignment to two treatment groups, the cyclo-ergometry program group and the usual treatment group (parallel). The randomization will be carried out by blocks and will be kept in the Clinical Epidemiology Unit. When the physician has a patient available to enter the study, a call will be made to the Clinical Epidemiology Service where a randomization code and the group to which he/she has been assigned will be indicated.||||
33767998|NCT00507221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33767999|NCT01254890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768000|NCT00730314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768001|NCT00932334|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33768002|NCT04049292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768003|NCT01665833|||||RETROSPECTIVE|||||||
33768004|NCT06459895|||CASE_CONTROL||PROSPECTIVE|||||||
33768005|NCT01205321|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768006|NCT05738460|||COHORT||PROSPECTIVE|||||||
33768007|NCT02277470|||COHORT||PROSPECTIVE|||||||
34025651|NCT05002439|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be made by clusters, being every cluster a different Primary Care center in order to avoid contamination. Randomization on a 1:1 relationship between groups.||||
34025652|NCT00002678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025653|NCT04810065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025654|NCT05123183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025655|NCT03709979|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34025656|NCT01119664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025657|NCT05026697|||COHORT||PROSPECTIVE|||||||
34025658|NCT05418244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897118|NCT00889356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897119|NCT02981472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897120|NCT04503980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897121|NCT00054769|||||PROSPECTIVE|||||||
33897122|NCT00776737|||||PROSPECTIVE|||||||
33897123|NCT03690791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897124|NCT06374641|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Partners Innovate UK and Mitocholine Ltd will also be masked. Masking will be performed by an individual outside of the research group.|Trials will be randomised and counterbalanced to remove any trial-order effect.|t|f|t|t
33897125|NCT03530163|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be masked from knowing whether they are performing the Respiratory Muscle Training or sham training.||t|f|f|f
33897126|NCT00377962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897127|NCT06244927|||CASE_ONLY||RETROSPECTIVE|||||||
33897128|NCT00002516||||TREATMENT||||||||
33897129|NCT06232915|||COHORT||PROSPECTIVE|||||||
33897130|NCT00850512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897131|NCT03580057|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33897132|NCT02124798|NA|SINGLE_GROUP||OTHER||NONE||||||
33897133|NCT02024256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897134|NCT00581503|||CASE_ONLY||PROSPECTIVE|||||||
33897135|NCT04238845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897136|NCT02458976|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33897137|NCT01532453|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897138|NCT03563534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897139|NCT02466529|||CASE_ONLY||RETROSPECTIVE|||||||
34025659|NCT02193334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025660|NCT03490760|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm Phase II||||
34025661|NCT02027428|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025662|NCT06633952|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34025663|NCT01357148|||COHORT||RETROSPECTIVE|||||||
33897140|NCT03792009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897141|NCT00707226|||CASE_CONTROL||PROSPECTIVE|||||||
33897142|NCT06235346|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897143|NCT06067477|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Recruited participants will be randomised to take 400,1000, or 2000 IU for 12 weeks.|t|f|t|f
33897144|NCT04076566|||COHORT||PROSPECTIVE|||||||
33897145|NCT04707248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33897146|NCT01405079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897147|NCT02004964|||OTHER||PROSPECTIVE|||||||
33897148|NCT01258439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897149|NCT00671151|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33897150|NCT00863954|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33897151|NCT05614947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897152|NCT04943211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897153|NCT00629824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897154|NCT00863668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33897155|NCT02952716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33897156|NCT03879590|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768008|NCT03298503|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33768009|NCT06158308|||OTHER||RETROSPECTIVE|||||||
33768010|NCT04346550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study objective is to compare the frequency of pain and mean hospital stay in patients with and without drain insertion, following laparoscopic cholecystectomy for acutely inflamed gallbladder.||||
33768011|NCT02447835|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33768012|NCT05788276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, Double blinded, placebo controlled interventional study|t|t|t|t
33768013|NCT01532817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897157|NCT05267028|||OTHER||PROSPECTIVE|||||||
33897158|NCT01926886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897159|NCT01707147|||OTHER||PROSPECTIVE|||||||
33897160|NCT01917422|||CASE_CONTROL|||||||||
33768014|NCT01949376|||CASE_CONTROL||PROSPECTIVE|||||||
33897161|NCT02739139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897162|NCT00787007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34025664|NCT05517538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Split-Face: comparing two neurotoxin injection techniques, conventional palpation vs. EMG-guided injection.~Follow up using EMG analysis and Glabellar Merz Scales"||||
33768015|NCT03389607|||COHORT||PROSPECTIVE|||||||
34025665|NCT02950649|||COHORT||PROSPECTIVE|||||||
33768016|NCT01496534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768017|NCT03075904|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33768018|NCT00694421|||COHORT||CROSS_SECTIONAL|||||||
33768019|NCT02475525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33768020|NCT01252121|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897163|NCT04442529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897164|NCT01809366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897165|NCT04933630|||CASE_ONLY||PROSPECTIVE|||||||
33897166|NCT02655198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897167|NCT04722978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Gemcitabine combined with carboplatin plus moxifloxacin or placebo|t|t|t|t
33897168|NCT04788563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysts will be blinded.|Randomized controlled trial with patient preference arms|f|f|f|t
33897169|NCT00066781|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025666|NCT03601130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768021|NCT05386251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The same providers will deliver both treatment arms and so it will be difficult to fully mask the providers to which group is active (based on their natures). However, participants will be told that both groups are active and outcomes assessors will not be informed about group membership.|Students are randomized in a 1:1 allocation ratio to the active treatment of the control group. Participants will be randomized to the strategies or peer support groups using a stratified randomization procedure that randomizes within grade level (i.e., middle school or high school). After 20 students are randomized to a group, the group will be scheduled to begin.|t|f|f|t
33768022|NCT02652182|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33768023|NCT03378843|||COHORT||PROSPECTIVE|||||||
33768024|NCT03324711|NA|SINGLE_GROUP||OTHER||NONE||||||
33768025|NCT04745299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897170|NCT03771872|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33897171|NCT06430255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768026|NCT01868035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768027|NCT05385094|||COHORT||RETROSPECTIVE|||||||
33768028|NCT00641173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33768029|NCT06457100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization sequence was generated by a computer and handed over in sealed opaque sequentially numbered envelopes. The envelope was opened by anaesthetist not involved in the study and drugs were dispensed as per the allocation card. The configured drugs were then handed over to experienced anaesthetists who were not aware of the subgroups|In the esmolol group, 0.5 mg/kg esmolol was injected before the induction of anesthesia, and the injection was completed within 1 min, followed by continuous intravenous pumping of esmolol 50 ug/(kg-min) until the end of surgery.|t|f|t|t
33768030|NCT04797325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768031|NCT05878782|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A randomized, controlled, superiority trial in 3 parallel arms||||
33768032|NCT00720174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768033|NCT02918240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768034|NCT01241253|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33768035|NCT05684562|||CASE_CONTROL||PROSPECTIVE|||||||
33768036|NCT06354335|||COHORT||PROSPECTIVE|||||||
33768037|NCT04771338|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Virtual Reality Job Interview Training \& character strength training (KF-STRIDE)|f|f|f|t
33768038|NCT00766896|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33768039|NCT00569803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33768040|NCT03054688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897172|NCT02448550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897173|NCT00337636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897174|NCT01777633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897175|NCT01940718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897176|NCT00249561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897177|NCT01576081|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897178|NCT01701791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897179|NCT00332657|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33768041|NCT04444687|||CASE_CONTROL||PROSPECTIVE|||||||
33768042|NCT00692406|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768043|NCT01077726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768044|NCT02101918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768045|NCT02214576|||COHORT||PROSPECTIVE|||||||
33897180|NCT00000110||||TREATMENT||SINGLE||||||
33897181|NCT04728854|||COHORT||PROSPECTIVE|||||||
33897182|NCT05850377|||COHORT||PROSPECTIVE|||||||
33768046|NCT01629056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33768047|NCT03298620|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A dental team (dentist and dental hygienist) assessed the outcome measure at baseline and after the two months RCT trial. A neutral dentist implements the intervention after baseline registration. Toothbrushes used in the intervention period is hidden to the dental team during assessments at the end of the RCT period.|Randomized Clinical trial|f|f|t|t
33768048|NCT04905108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768049|NCT02314988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768050|NCT03987230|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each participant receives 6 different interventions in random order||||
33768051|NCT03777865|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768052|NCT01186614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768053|NCT03893825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768054|NCT02247804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768055|NCT02110524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839233|NCT03145012|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy individuals will be asked to take ranitidine for 6 weeks to determine the effect on peripheral blood immune cells.||||
33839234|NCT06441253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33839235|NCT05010876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Prospective, randomized, double-blind, multicentre, prospective study of three parallel groups of patients.|t|f|t|f
33839236|NCT02226861|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839237|NCT00821262|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33839238|NCT02693704|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33839239|NCT02222870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839240|NCT02168348|||CASE_ONLY||PROSPECTIVE|||||||
33839241|NCT06399562|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33839242|NCT03223831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Recruited patients would not be informed of the type of stent that was inserted|Recruited patients would be randomized to receive either uncovered duodenal stents or partially covered duodenal stents.|t|f|f|f
33768056|NCT03457272|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study consists of two intervention and two control departments. The intervention consists of a risk assesment to ensure systematic and standardized identification of patients in risk of clinical deterioration and a decision support algorithm. Actions are undertaken on the basis of the standardized decision support and when a patient is determined to be at risk escalation plans are activated. As part of the intervention, huddles are conducted and patients at risk are interdisciplinarily discussed.||||
33768057|NCT05731284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking: Participants and study examiners performing the postoperative assessment will remain masked to the intervention assignment for the study duration, unless a medical indication for unmasking is identified.||t|t|f|f
33768058|NCT05202990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768059|NCT00595972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768060|NCT02057289|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768061|NCT03671733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768062|NCT01965964|||CASE_ONLY||PROSPECTIVE|||||||
33768063|NCT03218696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|According to a predertermined list, the two products are provided in identical bottles and cartons appropriately labelled so as to ensure respect of the randomization list as well as blinding of all study participants.|Parallel randomized double blind|t|t|t|t
33768064|NCT01348776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768065|NCT01267981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33768066|NCT04868643|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768067|NCT01413672|||||PROSPECTIVE|||||||
33768068|NCT00543660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768069|NCT01837290|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33768070|NCT05639621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768071|NCT03214289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768072|NCT02712671|||COHORT||PROSPECTIVE|||||||
33897183|NCT03940105|RANDOMIZED|CROSSOVER||PREVENTION||NONE||tightly-controlled, randomized cross-over design||||
33897184|NCT01905735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897185|NCT01631162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897186|NCT01243931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897187|NCT04225754|||COHORT||PROSPECTIVE|||||||
33897188|NCT00654927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897189|NCT02108730|||COHORT||PROSPECTIVE|||||||
33897190|NCT04429750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897191|NCT03767738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897192|NCT06396481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897193|NCT00813475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897194|NCT04901338|||CASE_ONLY||RETROSPECTIVE|||||||
33897195|NCT06511531|||COHORT||RETROSPECTIVE|||||||
33897196|NCT03038724|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The study investigator will not know which arm each patient is assigned to.|Randomised, single-blind study|f|t|t|f
33897197|NCT04685148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897198|NCT04880174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897199|NCT00133744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897200|NCT06097806|||OTHER||PROSPECTIVE|||||||
33897201|NCT04516902|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"Double-blind, placebo-controlled, 4-period cross-over design with four treatment conditions:~1. 100 μg LSD+MDMA placebo~2. LSD placebo +100 mg MDMA~3. 100 μg LSD + 100 mg MDMA~4. LSD placebo+ MDMA placebo"|t|t|t|f
33897202|NCT04526587|||COHORT||PROSPECTIVE|||||||
33897203|NCT00793585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897204|NCT06313216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither participant nor the outcome assessor know the group distribution|The present study included 63 participants, aged 20 to 45, with teeth that needed to be extracted. After Kafrelsheikh University research ethics committee approval, patients were randomized into 3 groups: group I patients underwent immediate implantation with duoteck membrane, while group II was grafted by autogenous demineralized tooth graft, but group III was grafted with autogenous demineralized tooth graft with autogenous demineralized tooth plate Clinically, pink aesthetic score (PES), midfacial mucosal alterations (MFMA), stability quotient of dental implants (SQDI) were observed at baseline, six and twelve months after implantation. Moreover, baseline, 6- and 12-months alterations of radiographic horizontal buccolingual ridge width (HBLRW), facial marginal bone level (FMBL), peri-implant Density of bone (PIDB) and peri-implant vertical bone defect depth (PIVBDD) changes were assessed using cone beam computed tomography (CBCT).|t|f|f|t
33897205|NCT05935709|||COHORT||PROSPECTIVE|||||||
33897206|NCT04803812|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33897207|NCT02119130|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33897208|NCT00954577|||CASE_CROSSOVER||PROSPECTIVE|||||||
33897209|NCT04020874|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|statistician|pre-test, post-test, quasi-experimental|f|f|t|f
33897210|NCT03148028|||COHORT||OTHER|||||||
33897211|NCT05401071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897212|NCT03707093|NA|SEQUENTIAL||TREATMENT||NONE||||||
33897213|NCT02350543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897214|NCT04847115|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospecitve, randomized trial||||
33897215|NCT01232725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897216|NCT02608164|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33897217|NCT00310505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897218|NCT05753111|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Blinding: To avoid bias, treatment arms will be blinded to Investigators/Trial staff/participants, as follows: the supplement will be manufactured, packaged and labelled in such a way that the visual appearance, nor the smell and/or touch of the supplement can be distinguished from the placebo. Supplements are delivered to the participants by a member of the research group that is not involved in any of the experimental procedures or analyses. Furthermore, to maintain the blind, the supplement and placebo will follow the same administration route and process.|Double-blind, placebo-controlled, crossover trial design|t|f|t|f
33897219|NCT01850797|||CASE_ONLY||PROSPECTIVE|||||||
33897220|NCT04055649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897221|NCT03348202|||OTHER||OTHER|||||||
33897222|NCT00233571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897223|NCT02357992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897224|NCT03665155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a phase I/II study with the goal to assess the feasibility of using the anti-CD38 monoclonal antibody daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma.||||
33897225|NCT01472237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33897226|NCT02838030|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897227|NCT00725738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897228|NCT02750566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897229|NCT04837911|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The spirometers have been purchased with charitable donations, that's why we have 35 of them.||||
33897230|NCT04063761|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33897231|NCT03931837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897232|NCT02919293|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33897233|NCT03844438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897234|NCT05558345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897235|NCT01458769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897236|NCT06123416|||COHORT||CROSS_SECTIONAL|||||||
33897237|NCT05370157|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897238|NCT01979744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897239|NCT02232438|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33897240|NCT05817721|||COHORT||RETROSPECTIVE|||||||
33897241|NCT04036760|||CASE_CONTROL||PROSPECTIVE|||||||
33897242|NCT05465681|NA|SINGLE_GROUP||PREVENTION||NONE||HR20013 for injection combined with dexamethasone||||
33897243|NCT06203808|||COHORT||PROSPECTIVE|||||||
34024503|NCT04523935|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|"The best and most reliable form of research is a double-blind, placebo-controlled study that would eliminate the power of suggestion and prevent bias when patients' outcomes are evaluated thereby improving the reliability of clinical trial results.~Our study was double-blind initially for 110 days until the 70th day of treatment (Figure. 1, Figure. 2.). The caregiver of the participant, the research nurse, and the outcome data collecting nurse were not aware of the drug or drug combination and the dosage. There was no contact between the research nurse, the pharmacist preparing the medicines, and the outcome data collecting nurse. The caregiver of the participant was unaware of other participants' details.~Later, it was an open-label study for 290 days because double blinding for the total period of 400 days may not serve any additional purpose but increases the dropout risk."|There was an initial placebo run-in period. This clinical trial was a prospective, single-center, interventional, with initial placebo-control, double-blind for initial 110 days, open-label for the next 290 days, fixed-sequence, two-treatment, two-period, crossover clinical trial. The placebo run-in period (15 days) was followed by the placebo period (15 days). After a washout period (10 days), drug treatment (360 days) was started depending on the clinical findings and investigations.|t|t|f|t
33897244|NCT01722006|||CASE_ONLY|||||||||
33897245|NCT05265351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with confirmed or suspected diaphragm dysfunction undergoing transdiaphragmatic pressure measurement in response to phrenic neurostimulation as part of their follow-up or diagnostic. During this examination, ultrafast ultrasound imaging will be performed in diaphragm to capture elicited responses to assess the relationship between the variables derived from the ultrasound of the diaphragm and the variables usually measured during the evaluation of the transdiaphragmatic twitch pressure.||||
33897246|NCT03477916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897247|NCT01642537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897248|NCT00730743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897249|NCT02363647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897250|NCT04237883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parallel cluster randomized trial. Groups will be clustered at the clinic level taking into consideration total Clinical FTE, Primary Care network group, and baseline HM completion rates.|t|f|f|f
33897251|NCT02146846|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33897252|NCT05914779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897253|NCT00486980|RANDOMIZED|PARALLEL||||DOUBLE||||||
33897254|NCT02198144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897255|NCT04457921|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33897256|NCT03921372|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078061|NCT06428266|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients from the consultation of the Oculoplastics Department of the Institute of Ophthalmology Conde de Valenciana I.A.P, between July 2021 and July 2022 who met the inclusion and exclusion criteria were enrolled"||||
34078062|NCT01439113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897257|NCT04255134|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a randomized, open label trial|||||
33897258|NCT02330029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897259|NCT02818634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897260|NCT00191529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897261|NCT02450253|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33897262|NCT02880358|||COHORT||PROSPECTIVE|||||||
33897263|NCT01307150|||CASE_CROSSOVER||PROSPECTIVE|||||||
33897264|NCT00405041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897265|NCT01519115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897266|NCT04511299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33897267|NCT01047787|||CASE_CROSSOVER||PROSPECTIVE|||||||
33897268|NCT01820910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897269|NCT03578406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897270|NCT03832231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897271|NCT03299023|||COHORT||PROSPECTIVE|||||||
33897272|NCT03603132|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33897273|NCT05584826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897274|NCT02856737|NA|SINGLE_GROUP||OTHER||NONE||||||
33897275|NCT04893850|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit a group of caregivers in which the caregiver meets the current criteria for elevated symptoms of psychological distress as measured by a score of 9 and above on the Patient Health Questionnaire 9-item. Eligible caregivers (mothers, fathers, guardians) will be randomly assigned to one of two intervention arms, which will occur concurrently over 16-weeks. One arm will incorporate intervention materials from Dialectical Behavior Therapy (DBT) and parent skills training, while another will provide community family support services as usual.||||
33897276|NCT01521845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33897277|NCT01169545|||||CROSS_SECTIONAL|||||||
33897278|NCT01220778|RANDOMIZED|PARALLEL||||||||||
33980584|NCT06393088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"All individuals participating in the trial will be assigned a participant number. Subsequently all clinical records and reports will reference only the participant number, ensuring that participants remain anonymous.~Because of the low number of trial participants, only paper records will be maintained for all clinical and personal data. Records will be kept in locked storage and physical access will only be on a need to know basis. A participants' personal data correlating the participating individuals name and the trial participants Identifying Number will only be available to the principal investigator, clinical staff, and the trial administrator. All analytics will be performed on securely encrypted devices using only data masked or redacted of any personal information."|The trial will compare results between two groups; the first will be treated using the invisa-RED Technology IR REHAB and the second group with a sham device. The trial will be conducted employing a single blind study methodology; participants will not know to which trial group they have been assigned. Participants will undergo six (6) therapy sessions each using a homogeneous 15 minute protocol. At each of the therapy sessions; the participant will be asked to record their pain level before the treatment session and then in the same manner after the treatment using a Visual Analog Scale (VAS). The results from the two groups will be statistically analyzed to determine the efficacy of the invisa-RED Technology IR REHAB as an adjunctive therapy for musculoskeletal pain. Any medical errors will be included in the statistical analysis.|t|f|f|f
33980585|NCT02238145|||COHORT||PROSPECTIVE|||||||
33980586|NCT01327196|||OTHER||CROSS_SECTIONAL|||||||
33980587|NCT05411692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078063|NCT03273959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator who will apply the tests at the beginning and end of the hospital stay will be blinded. The evaluator who will apply the tests at the beginning and end of the hospital stay will be blinded. Another health professional who will participate in the research will apply the protocol of supervised exercises in patients who are randomized to the intervention group.|Patients will be randomized into two groups: control and intervention.|f|f|t|f
34078064|NCT04362202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078065|NCT06122402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34078066|NCT03838939|RANDOMIZED|FACTORIAL||TREATMENT||NONE|no masking|||||
34078067|NCT03249428|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Research staff analyzing the data and members of the data and safety monitoring committee will be blinded to the treatment. allotment.|3-yr multi-centre pragmatic Randomized Controlled Trial (RCT) to compare effectiveness of nicotine e-cigarettes (e-cigs) (with counseling) with peer-led PROMPT strategy (nicotine replacement therapy (NRT) and counseling) for tobacco dependence in the inner city population.|f|f|t|t
34078068|NCT04043429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897279|NCT02764840|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33897280|NCT01096667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897281|NCT04866836|NA|SINGLE_GROUP||TREATMENT||NONE||To observe and evaluate the effectiveness and safety of tislelizumab combined with radiotherapy in the treatment of patients with advanced biliary malignancies.||||
33897282|NCT05572099|||CASE_ONLY||PROSPECTIVE|||||||
33897283|NCT02255838|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|A blinded investigator will view the bronchoscopy video and evaluate. The blinded investigator will use the same criteria the investigator who did the procedure used (Un-blinded) for the evaluation. Video will not indicate which scope was used and only indicate if it is the right or left lung they are viewing. Research coordinator will keep separate a file indicating which scope was used.|The disposable aScope IV bronchoscope will be compared to the re-usable bronchoscope||||
33897284|NCT01791530|||COHORT||PROSPECTIVE|||||||
33897285|NCT00681681|||COHORT||PROSPECTIVE|||||||
33897286|NCT02650310|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33897287|NCT03580447|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33897288|NCT04439669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant does not know whether the stimulation is sham or active. The doctor or nurse giving the stimulation knows the target and whether the stimulation is sham or active. The RN and the clinician (conducting screening and 1 month clinical visit) do not know the stimulation type or target until month 3, when the code is opened.|"The patients are first randomized to receive either sham stimulation or right S2 for three week period (10 stimulation sessions). Thereafter, a 3 month followup period (clinical checkup at a research visit at 1 month, RN structured telephone interviews at 2 and 3 months). If pain ≥5/10 at 3 month interview, the patient is offered an open label nrTMS treatment phase, in which the protocol depends on the first protocol of the RCT phase."|t|f|t|t
33897289|NCT03446131|||COHORT||PROSPECTIVE|||||||
33897290|NCT04292938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will be blinded as to the dietary regimen followed by the patient|Randomised controlled single blind|f|f|f|t
33897291|NCT03843580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897292|NCT03047005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897293|NCT02707757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897294|NCT02215265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897295|NCT05632172|||COHORT||PROSPECTIVE|||||||
33897296|NCT05752318|||COHORT||PROSPECTIVE|||||||
33897297|NCT03389334|NA|SINGLE_GROUP||OTHER||NONE||||||
33897298|NCT06114082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897299|NCT03237403|||COHORT||RETROSPECTIVE|||||||
33897300|NCT05880914|||OTHER||PROSPECTIVE|||||||
33897301|NCT01416181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897302|NCT05545397|||COHORT||PROSPECTIVE|||||||
33897303|NCT00503971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897304|NCT04758143|||COHORT||PROSPECTIVE|||||||
33897305|NCT03014869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897306|NCT03887572|||CASE_CONTROL||PROSPECTIVE|||||||
33897307|NCT06272214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897308|NCT01887444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897309|NCT03095105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897310|NCT00174941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897311|NCT00816439|||||PROSPECTIVE|||||||
33897312|NCT03949777|NA|SINGLE_GROUP||PREVENTION||NONE||A single group of subjects will undergo diagnostic, screening or surveillance colonoscopy.||||
33897313|NCT05927909|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897314|NCT00184990|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33897315|NCT01873950|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897316|NCT01718717|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897317|NCT02818010|||COHORT||PROSPECTIVE|||||||
33897318|NCT03527043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897319|NCT05347056|||CASE_CONTROL||OTHER|||||||
33897320|NCT02542345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897321|NCT06023914|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The physiotherapist responsible for carrying out the strength assessments will be blind to which patient has the pathological condition and who is the healthy individual.|The model of strength assessments will be performed randomly. After the individual has performed the first evaluation, he will be evaluated in sequence with the other technique.|f|f|f|t
33897322|NCT03644121|||COHORT||RETROSPECTIVE|||||||
33897323|NCT05780281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897324|NCT02346448|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33897325|NCT03020511|NA|SINGLE_GROUP||OTHER||NONE||||||
33897326|NCT00858832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897327|NCT04379583|||CASE_ONLY||CROSS_SECTIONAL|||||||
33897328|NCT04163783|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897329|NCT05325619|||COHORT||RETROSPECTIVE|||||||
33897330|NCT00670111|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33897331|NCT01134510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897332|NCT03631329|||COHORT||PROSPECTIVE|||||||
33897333|NCT02902809|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33897334|NCT03037294|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33897335|NCT00008788|||DEFINED_POPULATION||CROSS_SECTIONAL|||||||
33897336|NCT05914883|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomized to screening with continuous ECG screening for 3-7 days, or control/standard of care||||
33980588|NCT04526496|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33980589|NCT04180007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980590|NCT02499666|||COHORT||PROSPECTIVE|||||||
33980591|NCT02070185|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33897337|NCT05822869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897338|NCT04373083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897339|NCT04394169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Visits 1,2, and 3 will be carried out by an investigator with sufficient training in questionnaires. This investigator will not participate on the intervention or the evaluation of the results.~The intervention will be performed by two researchers (Pain Physician and psychologist). This researcher will not participate in the questionnaire and basal data collection visits or results analysis.~Researchers who analyze the results will not participate in the questionnaire and basal data collection or program intervention."|Randomized, controlled, single-blind, and single-center clinical trial that will include patients who have been admitted to intensive care of our hospital due to COVID-19 disease.|f|f|t|f
33897340|NCT01509027|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33897341|NCT05499195|||COHORT||CROSS_SECTIONAL|||||||
33897342|NCT02532842|||COHORT||RETROSPECTIVE|||||||
33980592|NCT00085696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980593|NCT01697878|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33980594|NCT05911139|||COHORT||PROSPECTIVE|||||||
33980595|NCT00912288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980596|NCT06423222|||CASE_ONLY||CROSS_SECTIONAL|||||||
33980597|NCT02845128|||COHORT||PROSPECTIVE|||||||
33980598|NCT03009448|||CASE_ONLY||RETROSPECTIVE|||||||
33980599|NCT05308043|||COHORT||PROSPECTIVE|||||||
33897343|NCT05714371|||COHORT||RETROSPECTIVE|||||||
33897344|NCT03185676|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897345|NCT00479466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897346|NCT04603248|NA|SINGLE_GROUP||OTHER||NONE||||||
33897347|NCT03586804|||OTHER||PROSPECTIVE|||||||
33897348|NCT03450772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897349|NCT02365077|||CASE_CONTROL||PROSPECTIVE|||||||
33897350|NCT02436239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897351|NCT04352660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897352|NCT03255278|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"The clinical trial study of the GamTBvac vaccine against the tuberculosis is a comparative placebo-controlled study with a two-fold increase of an applied dose among healthy volonteers aged 18-49 years."|t|f|f|f
33897353|NCT00806117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"After radical surgery, eligible patients with risk pathological factors were randomize to three groups.~Radiotherapy: Group A underwent 50 GY pelvic RT alone. Radiotherapy and drugs: Group B received concurrent weekly cisplatin and RT (CCRT).~Radiotherapy and drugs: Group C received paclitaxel and bolus cisplatin every three weeks for two cycles before RT, followed by two cycles of chemotherapy (SCRT)."|f|f|f|t
33897354|NCT01050660|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897355|NCT05987670|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Open label cluster randomised controlled trial||||
33897356|NCT00548314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897357|NCT02396147|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980600|NCT05098379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980601|NCT01775592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980602|NCT04569682|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33768073|NCT03684720|RANDOMIZED|PARALLEL||OTHER||SINGLE|The groups will be masked, until the day of the teaching session, so the investigator won't know, which group he assigns participants to, when enrolling them. The raters who will score the participants, will have no knowledge of which group the participant belongs to.|The study is a randomized experimental study comparing 2 groups, a control and an intervention. One group will receive traditional instructional teaching (control) and the other will receive guided-discovery-learning (intervention). Both groups will undertake the same tests after the teaching session.|f|f|f|t
33768074|NCT06489691|NA|SINGLE_GROUP||OTHER||NONE||Each highlander with HAPH will perform a 6 MWT at 3200 m and at 760 m according to a prospective study design||||
33768075|NCT01672203|||CASE_CONTROL||PROSPECTIVE|||||||
33768076|NCT00344006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768077|NCT00147225|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33768078|NCT02593305|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33768079|NCT02891044|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768080|NCT00416260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768081|NCT04111523|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Parallel, Placebo control|t|t|t|t
33768082|NCT02384655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768083|NCT04639089|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure~Secondary end point :~Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test"|t|t|t|f
33768084|NCT05198193|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33768085|NCT04471779|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Persons conducting follow-up surveys via computer-assisted telephone interviews will be masked with respect to participant randomization group|The investigators estimate that 2171 people will participate in the Baseline Survey, of whom 400 will be randomized and included in the follow-up study. Half of those in the follow-up study will be randomized to receive information about their risk of Alzheimer's disease based on Latino ethnicity, family history, and APOE genotype, and half will be randomized to receive information about their risk based on ethnicity and family history alone.|f|f|f|t
33897358|NCT02082561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897359|NCT06084780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897360|NCT05071508|||COHORT||PROSPECTIVE|||||||
33897361|NCT00738725|||COHORT||PROSPECTIVE|||||||
33897362|NCT04015557|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897363|NCT02488278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897364|NCT02035384|||COHORT||PROSPECTIVE|||||||
33980603|NCT02199548|||COHORT||PROSPECTIVE|||||||
33980604|NCT03614195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980605|NCT00404131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33980606|NCT02445456|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980607|NCT06061666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980608|NCT02529280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33980609|NCT04568408|||COHORT||PROSPECTIVE|||||||
33980610|NCT03895684|NA|SINGLE_GROUP||TREATMENT||NONE||This single arm study will utilize an accelerated dose escalation, followed by a conventional 3+3 dose escalation phase to achieve maximum tolerated dose (MTD).||||
33980611|NCT01220830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980612|NCT04165954|||OTHER||RETROSPECTIVE|||||||
33980613|NCT01357707|||FAMILY_BASED||PROSPECTIVE|||||||
33980614|NCT00876200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980615|NCT05331222|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm proof-of-concept study||||
33980616|NCT02769637|||CASE_CROSSOVER||PROSPECTIVE|||||||
33980617|NCT01880970|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33980618|NCT00590395|NA|SINGLE_GROUP||OTHER||NONE||||||
33980619|NCT02771015|RANDOMIZED|PARALLEL||||NONE||||||
33897365|NCT03059589|||CASE_ONLY||PROSPECTIVE|||||||
33897366|NCT00636818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897367|NCT05641454|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33897368|NCT06102161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897369|NCT01742923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33897370|NCT00260000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897371|NCT06265896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897372|NCT03466710|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33897373|NCT00482846|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980620|NCT01151826|||COHORT||PROSPECTIVE|||||||
34024504|NCT04264026|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site, open-label study||||
33897374|NCT05219565|RANDOMIZED|PARALLEL||PREVENTION||NONE||Using restricted randomization criteria, eighty clusters will be randomized 1:1 to either the intervention arm (ATSBs deployed throughout the cluster) or the control arm. The clusters will be followed in parallel for two years. In year one the first and second cohort were enrolled and followed up over 6 months each. In year 2, the third cohort was enrolled and followed up over 1 year.||||
33768086|NCT00985543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768087|NCT01197820|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768088|NCT05351619|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study will be conducted in three phases; preparation, implementation, and evaluation.~Implementation phase~* For nurses:~  * Nurses' demographic characteristics will be collected by using part I of tool I.~ * Critical care nurses' practice of the oral care bundle will be observed by using part II of tool I.~* For patients:~  * An initial assessment will be carried out for all MV patients in selected ICUs on admission to confirm that they are free from exclusion criteria.~ * Patients' characteristics and health-relevant data will be collected by the PI on the first day of admission using part I of tool II.~ * Assessment of the occurrence of VAP will be done for both groups on the first, third, and sixth days of the patient's admission to the ICU by using part II of tool II.~ * An oral assessment scale will be carried out for both groups on the first, third, and sixth days of patient admission by using part III of tool II."||||
33768089|NCT04910815|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33768090|NCT00279656|RANDOMIZED|PARALLEL||ECT||NONE||||||
33768091|NCT00967213|NA|SINGLE_GROUP||||NONE||||||
33768092|NCT04395859|||COHORT||PROSPECTIVE|||||||
33768093|NCT03178955|||CASE_ONLY||PROSPECTIVE|||||||
33768094|NCT03767634|||COHORT||RETROSPECTIVE|||||||
33768095|NCT02952664|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768096|NCT00517075|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33768097|NCT03661996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768098|NCT03326817|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Comparing the control group and intervention group||||
33768099|NCT00179790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768100|NCT04182230|||OTHER||PROSPECTIVE|||||||
33768101|NCT02391441|||CASE_CONTROL||PROSPECTIVE|||||||
33768102|NCT02638623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33768103|NCT05268484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768104|NCT04765241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study team, with the exception of the study coordinator, will be blinded to reduce bias.||f|f|t|t
33768105|NCT05289284|||COHORT||PROSPECTIVE|||||||
33768106|NCT01337830|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33768107|NCT00814996|||CASE_CONTROL||PROSPECTIVE|||||||
33768108|NCT02245763|||COHORT||PROSPECTIVE|||||||
33768109|NCT00171132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33768110|NCT01904851|||COHORT||OTHER|||||||
33768111|NCT02208570|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33768112|NCT00383240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768113|NCT02770508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768114|NCT05988164|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|An independent statistician researcher, not directly involved in collecting patient data, will analyze the data to mask the investigator's influence.|There is an intervention group and a control group. Twenty-five participants participated in the intervention and 25 in the control group. Patients in the intervention group will be given eye masks and asked to sleep with them|f|f|t|f
33768115|NCT02914379|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768116|NCT01112514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768117|NCT02317224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897375|NCT01695369|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33897376|NCT00749632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897377|NCT01668758|||||OTHER|||||||
33897378|NCT06070129|||OTHER||PROSPECTIVE|||||||
33768118|NCT03415958|||COHORT||PROSPECTIVE|||||||
33768119|NCT06121960|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Person with expertise in the practice of TCAI. (at least 6 months, in order to be able to control the depth of the trance and to have a motor control allowing the realization of a spirometry)|Prospective, monocentric, non-randomized, open-label study.||||
33768120|NCT04658186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768121|NCT01025934||||TREATMENT||||||||
33768122|NCT00580996|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33897379|NCT04021472|NA|SINGLE_GROUP||PREVENTION||NONE||One-group trial||||
33897380|NCT03844971|NA|SINGLE_GROUP||TREATMENT||NONE|Single grouped study|Case series A trial will be carried out in hospital of oral and maxillofacial surgery department faculty of dentistry||||
33897381|NCT02817607|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768123|NCT03855410|RANDOMIZED|PARALLEL||PREVENTION||NONE||To test the preliminary efficacy of S4E, we will conduct a stage 1 randomized control trial (RCT) and use a mixed between/within-subjects design with two levels of intervention (S4E and Attention-Matched Control) as the between-subjects factor and a repeated measure assessment at 30 days post-Baseline as the within-subject factor.||||
33768124|NCT03860038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897382|NCT04230538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897383|NCT01336426|||CASE_ONLY||PROSPECTIVE|||||||
33897384|NCT02924792|||CASE_CONTROL||PROSPECTIVE|||||||
33897385|NCT00408681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33897386|NCT00430040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897387|NCT01938625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897388|NCT03681860|RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open label trial as it will not be possible to blind either volunteers or clinic staff to the allocation. However, laboratory staff will be blinded to the allocation of the volunteers as they undertake the immunological assays.|||||
33897389|NCT04453150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897390|NCT00968344|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Intervention: leucine|t|f|t|f
33897391|NCT02662439|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33897392|NCT01208181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897393|NCT01984814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980621|NCT00551499|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Comparing effect of CRT in patients with and without CSA + comparing effect of AOP in combination with CRT in patients with CSA|t|f|f|f
33980622|NCT03423849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980623|NCT04218903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33980624|NCT06234163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33980625|NCT02001948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980626|NCT04787822|||COHORT||PROSPECTIVE|||||||
33980627|NCT04008979|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||32 subjects to be randomized to treatment with either immediate release aspirin or PL-ASA at one of two doses (325 mg or 650 mg) administered orally. After completion of the first treatment and a minimum of a two week washout period(14-17 days) subjects are to cross over and receive treatment with the alternative compound at the same dose level.|f|f|t|t
33980628|NCT01909557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980629|NCT03097393|||CASE_ONLY||RETROSPECTIVE|||||||
33980630|NCT02151032|||CASE_CONTROL||PROSPECTIVE|||||||
33980631|NCT01807208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33980632|NCT04114448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33980633|NCT01471847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980634|NCT02737436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33980635|NCT03883906|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980636|NCT00849953|||COHORT||PROSPECTIVE|||||||
33980637|NCT02420210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980638|NCT01781637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980639|NCT05894577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
33980640|NCT00000482|RANDOMIZED|||PREVENTION||DOUBLE||||||
33980641|NCT02929979|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33980642|NCT04872257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Our randomization and blinding process is in charge by a nurse who is not part of the study. A pharmacy school laboratory (not part of the study) randomly assigned the intervention and placebo to each patient (1-20) as treatment A or B. This information was delivered in a sealed envelope, in which only the nurse had access to. Neither the participants, investigators and outcome assessor, nor the data analyst know which patient is receiving the experimental treatment.||t|f|t|t
33980643|NCT04033809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980644|NCT00821028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980645|NCT03371290|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33980646|NCT01170286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980647|NCT06021821|RANDOMIZED|PARALLEL||OTHER||NONE||Three-group study.||||
33980648|NCT01989091|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33980649|NCT04374084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980650|NCT01651702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980651|NCT01891409|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980652|NCT00818883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024505|NCT03121287|||COHORT||PROSPECTIVE|||||||
33897394|NCT04978753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078069|NCT02160912|||CASE_CROSSOVER||PROSPECTIVE|||||||
33897395|NCT04476264|||CASE_ONLY||RETROSPECTIVE|||||||
33897396|NCT02821286|||COHORT||PROSPECTIVE|||||||
33897397|NCT00380159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897398|NCT05824208|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897399|NCT03932955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897400|NCT03431935|||COHORT||PROSPECTIVE|||||||
33897401|NCT05374356|RANDOMIZED|PARALLEL||OTHER||SINGLE|All patients will be assessed by the study investigator for presence/absence of delirium on postoperative days 1,2 \& 3, as well as routine nursing assessment by the delirium assessment tool CAM-ICU, routinely done by nursing staff. Chart reviews will be conducted to confirm any additional incidence of delirium. The data collectors will not be aware whether the patient had a spinal anesthetic or not.|Patients will be randomized to either general anesthesia (GA) or HSA + GA.|f|f|f|t
33897402|NCT05814029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation and mobilization will be performed by two different investigators. The investigator who will make the evaluations will not know in which group the participants are.|There will be three separate groups in the study. The individuals in the group will be completely different individuals. Each group will receive a different intervention. One of the groups will be the control group|f|f|t|f
33897403|NCT05683132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded from group assignment and the treatment content. Participants will be blinded to the content of the treatment arm to which they are not assigned.||t|f|f|t
33897404|NCT02723435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897405|NCT02699775|||OTHER||PROSPECTIVE|||||||
33897406|NCT04555213|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 Dose Escalation: 400mg, 600mg, 800mg, 1200mg \& 1800mg Part 2 Dose Expansion : Recommended Phase 2 Dose||||
33897407|NCT04345549|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33897408|NCT02154971|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897409|NCT00184288|||CASE_ONLY||PROSPECTIVE|||||||
33897410|NCT03264040|||COHORT||PROSPECTIVE|||||||
33897411|NCT05047588|||CASE_ONLY||CROSS_SECTIONAL|||||||
33897412|NCT03605901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Post-operative data will be collected by blinded staff. Patient daily pain based on the analog scale of 0-10 post-operative for the first 72 hours, total opioid usage, length of stay, time to get out of bed.|Subjects will be randomly assigned to one of two different protocols by a designated study team member based on a computer generated randomization table. Randomization will occur on the day of surgery. Randomization will be 1:1.|f|f|f|t
33897413|NCT02968030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897414|NCT05776537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897415|NCT01634347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897416|NCT05187169|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open-label, randomized, 2-way, 2-period crossover, Food Effect study.||||
33897417|NCT02708823|||COHORT||PROSPECTIVE|||||||
33897418|NCT05128240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Interventions are given as 1g bovine capsules of equal size, weight and appearance, and provided in identical bottles with a coded label.|Placebo controlled, double blind intervention study.|t|f|t|t
34078070|NCT03981016|NA|SINGLE_GROUP||OTHER||NONE||||||
33897419|NCT06511388|||COHORT||PROSPECTIVE|||||||
33897420|NCT04299269|NA|SINGLE_GROUP||OTHER||NONE||||||
33897421|NCT03476850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Prospective randomized double-blinded trial to compare TAP block versus QL block for pain management in living donor nephrectomy patients. Participants will be blinded to the type of block received and physicians will be blinded both intra- and post-op regarding which block patients received. The team who performs the block will know which block the patient received. No one else involved in the care of the patient will know. The surgery team will not know, and the primary (in the OR) anesthesia team will not know. None of the providers involved in post-operative care of the patient will know.||t|t|f|t
33897422|NCT04631718|||COHORT||PROSPECTIVE|||||||
33897423|NCT01344122|RANDOMIZED|PARALLEL||||NONE||||||
33897424|NCT02169076|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34078071|NCT06100536|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34078072|NCT02260960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34078073|NCT00484770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34078074|NCT03128450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078075|NCT05259826|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Data derived from patients with food hypersensitivity will be compared with data of healthy controls||||
34078076|NCT01484080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078077|NCT03854331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34078078|NCT04652557|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34078079|NCT01328639|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078080|NCT01838239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897425|NCT00820040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078081|NCT04534517|NA|SINGLE_GROUP||TREATMENT||NONE|Participant is masked to the brand of the devices|||||
34078082|NCT04249947|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label, 3 + 3 design of dose-escalating cohorts with open label, dose expansion at RP2D||||
34078083|NCT04852250|||OTHER||PROSPECTIVE|||||||
34078084|NCT00480090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078085|NCT00098241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078086|NCT02948829|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078087|NCT04106908|||CASE_ONLY||PROSPECTIVE|||||||
34078088|NCT01676493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078089|NCT06455657|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The study is of a semi-separate type and all women can be trained.|The study is of a semi-separate type and all women can be trained.||||
34078090|NCT05811988|||OTHER||RETROSPECTIVE|||||||
33897426|NCT00849212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897427|NCT04124367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897428|NCT04132726|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33897429|NCT02786862|NA|SINGLE_GROUP||OTHER||NONE||||||
33897430|NCT01774448|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33897431|NCT03906877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897432|NCT03877406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897433|NCT04008212|||COHORT||PROSPECTIVE|||||||
33897434|NCT05738980|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897435|NCT03851861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A prospective intervention study in which participants with diagnosed Parkinson's disease are instructed to follow the Mediterranean diet for a 5-week intervention period.||||
33897436|NCT00981435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980653|NCT06314503|NA|SINGLE_GROUP||TREATMENT||NONE||This study has a first-in-human, prospective, open-label, non-randomized, three-center, single-arm design.||||
33980654|NCT03486990|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single ascending dose followed by repeat dose.||||
33897437|NCT04396457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897438|NCT02842814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897439|NCT02165488|||COHORT||PROSPECTIVE|||||||
33897440|NCT00364910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897441|NCT00982163|||COHORT||PROSPECTIVE|||||||
33897442|NCT00474227|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897443|NCT02609477|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33980655|NCT03579771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980656|NCT01631422|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33980657|NCT05773079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980658|NCT00379340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980659|NCT02581345|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34024506|NCT02097680|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34024507|NCT00000326||CROSSOVER||TREATMENT||DOUBLE||||||
34024508|NCT06300320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024509|NCT03072979|||COHORT||PROSPECTIVE|||||||
34024510|NCT05456555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024511|NCT02045147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024512|NCT02182635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024513|NCT03215186|||COHORT||PROSPECTIVE|||||||
34024514|NCT00541879|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024515|NCT05585879|NA|SINGLE_GROUP||OTHER||NONE||Multicenter, Prospective, Consecutive Series, Pragmatic Clinical Trial||||
34024516|NCT03583684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34024517|NCT04823975|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33897444|NCT04585763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897445|NCT00000790||PARALLEL||TREATMENT||||||||
33897446|NCT02628379|||CASE_ONLY||PROSPECTIVE|||||||
33897447|NCT00156728|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897448|NCT03303599|||COHORT||PROSPECTIVE|||||||
33897449|NCT00219180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33897450|NCT00404040|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33897451|NCT05079035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897452|NCT01864135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897453|NCT01872351|||CASE_ONLY||RETROSPECTIVE|||||||
33897454|NCT02614846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897455|NCT03659435|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33897456|NCT00932464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897457|NCT06673355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897458|NCT03299504|||COHORT||RETROSPECTIVE|||||||
33897459|NCT02221427|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33897460|NCT02986451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897461|NCT00964418|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897462|NCT04100421|||COHORT||RETROSPECTIVE|||||||
33897463|NCT03737864|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33897464|NCT04520789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897465|NCT06394063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897466|NCT04169477|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33897467|NCT02741531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897468|NCT03069638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897469|NCT02489630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897470|NCT00262106|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897471|NCT00411515|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897472|NCT00069121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897473|NCT02016807|||COHORT||PROSPECTIVE|||||||
33897474|NCT02803034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980660|NCT05017298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The Phase 2 study is a randomized, double blind and placebo control study conducted initially in a single clinic facility.|t|t|t|t
33980661|NCT01001845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024518|NCT01283035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897475|NCT06370247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897476|NCT05812378|||COHORT||PROSPECTIVE|||||||
33897477|NCT02621385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897478|NCT03177252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33897479|NCT01755481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897480|NCT00244218|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33897481|NCT04652024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33897482|NCT00947154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897483|NCT03348683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study drug and placebo will be randomized and mixed to appear identical by the Mount Sinai Investigational Drug Service (IDS). The randomization code will be kept by the lead pharmacist of the IDS until completion of the trial, at which point data will be unmasked.||t|t|t|f
33897484|NCT01900548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897485|NCT02139410|||COHORT||PROSPECTIVE|||||||
33980662|NCT06051240|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Identical-looking placebo is used. S-lithium levels are masked by using a separate lab service and sham values for placebo group.|Randomization is based on whether or not the study participant had received radiotherapy to the whole brain (CSI) or only part of it (focal irradiation). Within each of these two arms there is a predetermined block randomization with a 2:1 lithium:placebo ratio.|t|t|t|t
33897486|NCT02694029|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897487|NCT02162979|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33897488|NCT00545818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980663|NCT00076102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980664|NCT02392793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980665|NCT04168463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|N/A not possible|Stepped-wedge, cluster randomised control trial||||
33980666|NCT03116386|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Run-in period then 6 months control period and then 6 months experimental period with activation of all the functions of Etolya-F® (the device used in the study)||||
33980667|NCT05602064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102994|NCT05908084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"the study team at each site, including the surgeon performing the AVF creation or HAV implantation, the operating room staff, the dispensing pharmacist, and the Principal Investigator will be unblinded to treatment allocation.~Members of the Data Monitoring Committee and the Clinical Evaluation Committee, as well as members of the CRO staff may be unblinded to treatment assignment to perform their functions.~All Sponsor staff, with exception of Medical Monitor, Safety Scientist, and the HAV Inventory Supply and Tracking group, will remain blinded to treatment allocation while the study is in progress."|Randomized 1:1 to either the HAV or the AVF treatment arm.|f|f|f|t
33897489|NCT00964795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897490|NCT04509089|NA|SINGLE_GROUP||OTHER||NONE||||||
33897491|NCT01113528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897492|NCT00376688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897493|NCT02844738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897494|NCT01720771|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897495|NCT00465569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897496|NCT01626040|||CASE_ONLY||PROSPECTIVE|||||||
33897497|NCT04161677|||CASE_ONLY||CROSS_SECTIONAL|||||||
33897498|NCT03530540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897499|NCT01287117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897500|NCT02054650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897501|NCT00388739|RANDOMIZED|FACTORIAL||TREATMENT||NONE|patients will be randomized to a control and intervention group. Randomization will occur utilizing assignment by a randomized number table. The randomization scheme will then be packaged into sealed envelopes concealed to the educational interventionist at the time of enrollment. Once the patient is enrolled, the interventionist will open the sealed envelope revealing assignment to intervention or control.|This was a health outcomes intervention trial that utilized a randomized clinical trial (non-placebo controlled) with two separate arms. All patients received steroids and bronchodilators, but then were randomized to either no intervention or to Pulmicort respules||||
33897502|NCT01065480|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897503|NCT01057303|||CASE_ONLY||RETROSPECTIVE|||||||
33897504|NCT05131971|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study.|Participants will be randomized to receive either GSK3888130B or placebo in single ascending dose cohorts.|t|f|t|f
33897505|NCT02105298|||||PROSPECTIVE|||||||
33897506|NCT04118361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897507|NCT01383122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897508|NCT05333718|||COHORT||PROSPECTIVE|||||||
33897509|NCT00095121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897510|NCT01457339|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33897511|NCT05750667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Probands will be randomized to one of the two active implementation strategy arms (Penn Medicine, Family Heart Foundation; n=220 each) or usual care (n=360).||||
33897512|NCT04778761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research team collecting study outcomes will be blinded to group assignment||f|f|f|t
33897513|NCT06283251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33897514|NCT04135625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Control Group - with no chickens gifted and no INA training sessions||t|f|f|f
33897515|NCT01317849|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33897516|NCT03052153|||CASE_ONLY||RETROSPECTIVE|||||||
33897517|NCT02951923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897518|NCT04653415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants of the study are blinded to receive methylprednisolone with gabapentin (the study group) or placebo (the controls group). Only nurse knows if administer drug or placebo. Both outcome assessor and investigator are blinded.|two groups: the study and controls|t|f|t|t
33897519|NCT01606488|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34102995|NCT05861401|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33768125|NCT06163352|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients with pressure injury (n=64) and patients without pressure injury (n=84)||||
33768126|NCT04263298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768127|NCT04018989|||COHORT||PROSPECTIVE|||||||
33768128|NCT02289989|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33768129|NCT02654093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33768130|NCT00983489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768131|NCT02890238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897520|NCT03604614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897521|NCT02490540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897522|NCT06482060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897523|NCT05084846|||COHORT||PROSPECTIVE|||||||
33897524|NCT05986656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897525|NCT06330753|NA|SINGLE_GROUP||TREATMENT||NONE|Participants (patients and providers) will be de-identified|This is a prospective study designed to explore the acceptability, intervention appropriateness of trauma-informed care plans and the feasibility of trauma-informed care plans by patients and members of the health care team||||
33897526|NCT00668967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897527|NCT01015443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897528|NCT00539721|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897529|NCT03962049|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33980668|NCT00254956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980669|NCT01395186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980670|NCT05393960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980671|NCT02673580|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102996|NCT02577575|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34102997|NCT04614441|||COHORT||PROSPECTIVE|||||||
34102998|NCT00619242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102999|NCT05289453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103000|NCT06458166|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980672|NCT01350765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33980673|NCT01735630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980674|NCT02877186|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33980675|NCT03232008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33980676|NCT06242288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980677|NCT05570149|||COHORT||PROSPECTIVE|||||||
34078091|NCT05947253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group A 20 participants received Buyteko breathing technique while Group B 20 participants received active cycle of breathing technique and session of 35min will be given 5 days per week and data will be collected by using St. George's respiratory questionnaire for determining the quality of life and Borg's dyspnea scale for measuring breathlessness. participant and investigator are blind|make 2 groups Patients who will meet the inclusion criteria will be recruited by convenient sampling technique and allocated in two groups by simple randomization process. First Group A 20 participants received Buyteko breathing technique while Group B 20 participants received active cycle of breathing technique and session of 35min will be given 5 days per week and data will be collected by using St. George's respiratory questionnaire for determining the quality of life and Borg's dyspnea scale for measuring breathlessness.|t|f|t|f
34078092|NCT03293745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980678|NCT02464709|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33980679|NCT00927992|||COHORT||CROSS_SECTIONAL|||||||
33980680|NCT04817709|||COHORT||PROSPECTIVE|||||||
33980681|NCT03309709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980682|NCT04916938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980683|NCT00193284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980684|NCT00005520|||COHORT||PROSPECTIVE|||||||
33980685|NCT03011684|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980686|NCT02143765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980687|NCT03174756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The treatment codes of the study were not accessible to the investigators and to the examiner until the data were analyzed|A double-blind randomized controlled trial with 75 participants was conducted. Participants were assigned using block randomization in five groups: HOCl 0.025% and 0.05%, CHX 0.12% and 0.2% and sterile water as placebo. Participants were instructed to use each rinse solution for 30 seconds after dental prophylaxis. Samples of saliva were taken at baseline and after 30 seconds, 1, 3.5 and 7 hours to assess substantivity establishing the bacterial viability by the fluorescence method.|t|t|t|t
33897530|NCT03591952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomly allocated into intervention (gravity-driven) and control (suction-driven) groups by opening an opaque study envelope just prior to starting the procedure containing group assignment. Participants will be blinded to the use of gravity VS. suction drainage to prevent knowledge of their group assignment from biasing their pain assessments.||t|f|f|f
33897531|NCT00121225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897532|NCT02859701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078093|NCT05529537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078094|NCT06523959|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pragmatic randomized controlled, parallel group, open-label trial with a 1:1 randomization (block randomization) ratio.||||
34078095|NCT05239663|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34078096|NCT04352309|||COHORT||PROSPECTIVE|||||||
34078097|NCT06311058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This is a double-blinded randomized controlled trial.|Subjects are randomized to 1 of 3 intervention groups|t|t|t|t
34078098|NCT02260817|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078099|NCT06474156|||CASE_CROSSOVER||PROSPECTIVE|||||||
34078100|NCT01090180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078101|NCT03024983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34078102|NCT04416997|||OTHER||OTHER|||||||
33897533|NCT02031900|||CASE_ONLY||PROSPECTIVE|||||||
33897534|NCT00768378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897535|NCT00532259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897536|NCT00603044|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897537|NCT02189330|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33897538|NCT06064318|||COHORT||RETROSPECTIVE|||||||
33897539|NCT02131428|||COHORT||PROSPECTIVE|||||||
33897540|NCT06281873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897541|NCT02372162|||OTHER||PROSPECTIVE|||||||
33897542|NCT01596205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33897543|NCT00003270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897544|NCT02798523|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33897545|NCT05374941|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33897546|NCT03520179|||COHORT||CROSS_SECTIONAL|||||||
34078103|NCT00097214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078104|NCT01445249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078105|NCT05881655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078106|NCT00102596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897547|NCT01243593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897548|NCT02606786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897549|NCT01215630|||COHORT||CROSS_SECTIONAL|||||||
33897550|NCT06346912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078107|NCT00798811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078108|NCT00818584|NON_RANDOMIZED|PARALLEL||||NONE||||||
34078109|NCT04659707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897551|NCT06476080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897552|NCT05733481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897553|NCT03499054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized hemodialysis patients in hospital|f|f|t|f
33897554|NCT04369339|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|outcomes assessor blind to clinical data and cytology results|prospective cohort study comparing the immediate colposcopy findings among women with HrHPV other than HVPV16/18 and negative cytology|f|f|f|t
33897555|NCT05879263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|By the nature of the intervention(intermittent or continuous administration of enteral nutrition) is impossible to mask it to participats, care provider or investigators.|"The patients wil be allocated to expriemental group or control group using a simple randomization sequence.~There is an allocation concealment using sealed opaque envelopes Duration: From February 2022 to complete sample number."||||
33897556|NCT00217438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078110|NCT02027610|||COHORT||CROSS_SECTIONAL|||||||
34078111|NCT05348720|||COHORT||RETROSPECTIVE|||||||
34078112|NCT01845779|NA|SINGLE_GROUP||OTHER||NONE||||||
34078113|NCT01553565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078114|NCT01655316|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34078115|NCT04131920|||COHORT||PROSPECTIVE|||||||
34078116|NCT02053493|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34078117|NCT03999502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078118|NCT01474850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34078119|NCT04020653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078120|NCT03234036|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Part 1 of the study will be open label and thus not be blinded. Part 2 of the study will be single blinded because of the unavailability of matching placebo tablets. The Principal Investigator and the subject will be completely blinded to specific treatment assignment.|The randomization number will determine the allocation of treatment sequences (ABC or BAC) for Part 1, and of treatment (GSK2838232 without RTV or placebo) for Part 2. Allocation to treatment for Part 1A or Part 1B (with Part 2 being fixed) will be according to a predetermined random order.|t|f|t|f
34078121|NCT06611982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078122|NCT06446414|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078123|NCT03685734|||COHORT||PROSPECTIVE|||||||
34078124|NCT02584283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897557|NCT06295783|||COHORT||PROSPECTIVE|||||||
34078125|NCT03041636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078126|NCT04662112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078127|NCT02782741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078128|NCT01274351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078129|NCT04622917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078130|NCT01372046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078131|NCT01756989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078132|NCT06310811|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will be treated with RD06-04 cell injections in a single group||||
34078133|NCT01437618|||COHORT||PROSPECTIVE|||||||
34078134|NCT00971867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078135|NCT04936503|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078136|NCT02049736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078137|NCT04253340|NA|SINGLE_GROUP||OTHER||NONE||||||
34078138|NCT00346749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078139|NCT03239678|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897558|NCT02388230|||COHORT||PROSPECTIVE|||||||
34078140|NCT05919550|||CASE_CONTROL||RETROSPECTIVE|||||||
34078141|NCT01081613|||COHORT||PROSPECTIVE|||||||
34078142|NCT02554760|NA|SINGLE_GROUP||OTHER||NONE||||||
34078143|NCT06173479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled, single-blind experimental design with a pretest-posttest control group|t|f|f|f
34078144|NCT04153279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078145|NCT05720559|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078146|NCT03103191|||CASE_CONTROL||PROSPECTIVE|||||||
34078147|NCT04838847|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078148|NCT04691128|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34078149|NCT01124812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078150|NCT00498680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078151|NCT00019461||||TREATMENT||||||||
34078152|NCT00616551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078153|NCT02700048|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34078154|NCT03335800|NA|SINGLE_GROUP||SCREENING||NONE||||||
34078155|NCT04567940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34078156|NCT02671253|||COHORT||PROSPECTIVE|||||||
34078157|NCT01368263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078158|NCT05353088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078159|NCT06354322|||CASE_CONTROL||PROSPECTIVE|||||||
34078160|NCT03721224|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078161|NCT03686072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078162|NCT01439646|||||RETROSPECTIVE|||||||
34078163|NCT05093556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078164|NCT02322749|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34078165|NCT05133323|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078166|NCT02653157|||COHORT||PROSPECTIVE|||||||
34078167|NCT00186342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078168|NCT01409239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078169|NCT06193174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078170|NCT00002610|NON_RANDOMIZED|||TREATMENT||||||||
34078171|NCT01882296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078172|NCT04710719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be aware of which injection they will be receiving in follow up treatment for their keloid (TAC alone or TAC/5FU)|2 cohort arms, single blinded; 1=TAC alone, 2=TAC+5FU|t|f|f|f
34078173|NCT01571180|||COHORT||PROSPECTIVE|||||||
34078174|NCT01239394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078175|NCT04536662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103001|NCT01081574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980688|NCT05077566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768132|NCT01671748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980689|NCT04423237|||CASE_CONTROL||RETROSPECTIVE|||||||
33980690|NCT02684344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980691|NCT03432845|||COHORT||PROSPECTIVE|||||||
33980692|NCT01062256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33980693|NCT00845156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980694|NCT01247948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980695|NCT06369805|||COHORT||CROSS_SECTIONAL|||||||
33980696|NCT02007122|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980697|NCT00141466|RANDOMIZED|PARALLEL||||SINGLE||||||
33980698|NCT00189709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980699|NCT01210001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33980700|NCT04112537|||COHORT||RETROSPECTIVE|||||||
33980701|NCT05571878|NA|SEQUENTIAL||BASIC_SCIENCE||NONE|Participants will be blinded to the order of the intranasal spray condition (insulin or placebo).|The study will follow a single blind, crossover design wherein each participant will complete an MRI based protocol of brain insulin action. After an overnight fast, fasting bloodwork will be obtained, followed by two MRI scans: one with intranasal placebo and one with intranasal insulin challenge (80 IU; 40 IU per nostril). Between scans they will have a short break and be asked to complete a cognitive assessment. Participants with depression will complete a 6-month follow-up visit to track changes in metabolic health, illness severity, and cognitive function.||||
33980702|NCT01384786|||COHORT||RETROSPECTIVE|||||||
33980703|NCT01208363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980704|NCT01402947|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980705|NCT01935440|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33980706|NCT00090857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078176|NCT06376487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Patient will not know the flow rate sequence used during the assessment|A prospective clinical study to evaluated four different flow rate in infants with bronchiolitis using high flow nasal cannula||||
34078177|NCT06612008|||COHORT||PROSPECTIVE|||||||
33980707|NCT02060110|||||PROSPECTIVE|||||||
33980708|NCT05823207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The first group will be determined as the experimental group that inhales sage essential oil, and the second group will be determined as the control group. 2 group||||
33980709|NCT00002260||||TREATMENT||NONE||||||
33980710|NCT01272336|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33768133|NCT04776759|||COHORT||PROSPECTIVE|||||||
33768134|NCT05544552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33768135|NCT00634985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980711|NCT02175264|||CASE_ONLY||PROSPECTIVE|||||||
33980712|NCT05046548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
34078178|NCT01803659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078179|NCT00710255|||COHORT||PROSPECTIVE|||||||
34078180|NCT00026780|||COHORT||PROSPECTIVE|||||||
34078181|NCT03492437|NA|CROSSOVER||OTHER||NONE||||||
34078182|NCT02871674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078183|NCT00248469|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34078184|NCT03169478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078185|NCT03385785|||COHORT||PROSPECTIVE|||||||
34078186|NCT00356109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078187|NCT02151617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34078188|NCT00601315|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078189|NCT02410863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078190|NCT01569126|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34078191|NCT06249516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34078192|NCT06080009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-centre interventional study on biological sample||||
34078193|NCT02464137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078194|NCT01145664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078195|NCT02427854|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34078196|NCT02935569|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078197|NCT06225973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The Sponsor, Investigators and study staff will be masked during the randomization process and throughout the study. The study site will have the capacity to unmask participants in an emergency.~Following completion of the study, the randomization code will be unmasked once all data has been entered into the study database for every subject and the database has been locked."||t|t|t|f
34078198|NCT01904110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078199|NCT02307903|||COHORT||PROSPECTIVE|||||||
34078200|NCT02000050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078201|NCT01654770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078202|NCT01505413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078203|NCT00163865|||COHORT||CROSS_SECTIONAL|||||||
34078204|NCT01162889|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34078205|NCT05995834|||OTHER||PROSPECTIVE|||||||
34078206|NCT02214940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34078207|NCT01014247|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33897559|NCT04341610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind placebo-controlled|Double-blind placebo-controlled|t|t|t|t
33897560|NCT00003937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897561|NCT04403737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33897562|NCT02629393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897563|NCT01674764|||COHORT||PROSPECTIVE|||||||
33897564|NCT01903915|||CASE_CONTROL||PROSPECTIVE|||||||
33897565|NCT02234011|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897566|NCT03064282|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897567|NCT06297304|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All volunteers will receive a physical activity and sedentary management intervention.||||
33897568|NCT01112215|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897569|NCT02526849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897570|NCT01676116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897571|NCT01325493|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33897572|NCT03275870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897573|NCT04282928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897574|NCT00188448|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897575|NCT00989703|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33897576|NCT05275413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33897577|NCT05960955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897578|NCT00453752|||DEFINED_POPULATION||PROSPECTIVE|||||||
33897579|NCT04652362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be informed about the contents of the two different programmes and therefore will be blind to group allocation. Randomisation, questionnaire and intervention delivery will be fully automated through the Qualtrics platform and therefore researchers will also be blind to group allocation.|Participants will be randomly allocated to either the growth mindset intervention or the supportive therapy control condition.|t|f|t|t
33897580|NCT00989326|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897581|NCT03654547|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation arm followed by Dose Expansion arm||||
33897582|NCT00690872|NON_RANDOMIZED|||TREATMENT||NONE||||||
33897583|NCT01046149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897584|NCT03429556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897585|NCT00004909|||COHORT||RETROSPECTIVE|||||||
33897586|NCT03235908|||COHORT||PROSPECTIVE|||||||
33897587|NCT01401140|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33897588|NCT03963544|||COHORT||PROSPECTIVE|||||||
33897589|NCT05758038|||COHORT||PROSPECTIVE|||||||
33897590|NCT00064701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897591|NCT02838550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078208|NCT00239070|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34078209|NCT04013295|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34078210|NCT02987296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34078211|NCT06229223|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078212|NCT02412124|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078213|NCT04838002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078214|NCT05864534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078215|NCT05458986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078216|NCT05694858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34078217|NCT02571140|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078218|NCT00087100||||TREATMENT||NONE||||||
34078219|NCT01026948|||COHORT||PROSPECTIVE|||||||
34103002|NCT03241550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980713|NCT03375593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|study medication will be masked to participant and investigator. Medication will be dispensed by pharmacy in identical blister packs|participants will be randomized to receive either the narcotic hydrocodone with acetaminophen or a combination of acetaminophen plus ibuprofen for post-fracture pain|t|f|t|f
33980714|NCT03661528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ANNEXA-I is a randomized, open-label study with blinded adjudication on primary efficacy and safety outcomes, including death and thrombotic events.||f|f|f|t
33980715|NCT02601495|||CASE_ONLY||PROSPECTIVE|||||||
33980716|NCT05084001|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33768136|NCT01225913|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||To Better Understand the Mechanism(s) of Airflow Limitation During Exacerbation of Asthma||||
33768137|NCT01129531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897592|NCT02217735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897593|NCT06342167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897594|NCT01738399|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33897595|NCT01479205|||CASE_CONTROL||PROSPECTIVE|||||||
33897596|NCT05710874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897597|NCT05572125|||COHORT||PROSPECTIVE|||||||
33897598|NCT01639482|||CASE_CONTROL||PROSPECTIVE|||||||
33897599|NCT04141618|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897600|NCT03321812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897601|NCT05631925|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33897602|NCT00129077|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33897603|NCT04427657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897604|NCT06005506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33897605|NCT01812304|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33897606|NCT01980446|NA|SINGLE_GROUP||OTHER||NONE||||||
33897607|NCT01793207|||CASE_CONTROL||PROSPECTIVE|||||||
33897608|NCT02830373|||CASE_ONLY||PROSPECTIVE|||||||
33897609|NCT03925207|||COHORT||RETROSPECTIVE|||||||
33897610|NCT02182037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33897611|NCT01690832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897612|NCT06013787|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants were made aware through the informed consent that 1/2 of the communities would be receiving a video intervention. Care providers (community health workers who delivered the video intervention) were trained in it so were not blinded. Outcomes assessor was investigator|Cluster-matched randomized trial, by community, with 5 intervention communities and 5 control communities||||
33897613|NCT01606722|||COHORT||PROSPECTIVE|||||||
33897614|NCT01744899|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897615|NCT01828125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33897616|NCT06209957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective, interventional, comparative double-blinded study.|t|t|f|f
33897617|NCT02589587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897618|NCT00293280||||TREATMENT||NONE||||||
33897619|NCT05041543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897620|NCT00152373|RANDOMIZED|PARALLEL||||DOUBLE||||||
33897621|NCT05599217|||CASE_CONTROL||PROSPECTIVE|||||||
33897622|NCT01277146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897623|NCT02537860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897624|NCT02226068|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33897625|NCT01962454|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33897626|NCT02238613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897627|NCT06206876|NA|SEQUENTIAL||TREATMENT||NONE||||||
33897628|NCT01199341|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897629|NCT06011070|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33897630|NCT03957083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biased coin up-and-down design.|t|t|t|t
33897631|NCT01749059|||COHORT||PROSPECTIVE|||||||
33897632|NCT01293669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897633|NCT02048878|||CASE_CONTROL||PROSPECTIVE|||||||
33897634|NCT03461926|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This study will employ a prospective, 2-group, repeated measure (2x5), randomized controlled trial design. All participants will be randomized into either a 6-week HAPA-treatment (SB-related planning + text messages intervention) or waitlisted control (no treatment) condition. All primary outcomes will be assessed at four time points (baseline, 2, 4, and 6 weeks), and again at a two-week follow-up (8 weeks). Action and coping planning and action control towards reducing workplace sitting time will be assessed at the same time points. Secondary outcome assessments (i.e., work- and health-related outcomes) will occur pre- (baseline) and post-intervention (6 weeks).||||
33897635|NCT04934202|||COHORT||PROSPECTIVE|||||||
33897636|NCT06099054|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomised to either group:~Group I (Intervention group): in which pleural effusion will be drained using pigtail catheter under US guidance.~Group II (Control group): in which pleural effusion will be drained using ICT"||||
33897637|NCT03020693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33897638|NCT04329936|||COHORT||PROSPECTIVE|||||||
33897639|NCT03993743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897640|NCT00652821|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33897641|NCT04050748|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34078220|NCT06523010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The evaluator and the researcher administering the intervention will be different. The interventions will be administered to participants randomly.|The patients enrolled in the study will receive placebo talocrural joint traction and talocrural joint traction in a randomized sequence. The order of the interventions will be determined by flipping a coin.|t|f|f|t
34078221|NCT03152617|||COHORT||PROSPECTIVE|||||||
33897642|NCT00947102|||COHORT||PROSPECTIVE|||||||
34078222|NCT05499884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078223|NCT04868019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Complete history and examination will be carried out while patients will be screened for enrollment. After taking informed consent, eligible patients will be selected and divided into two groups A and B by lottery method.|Groups A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment.|t|f|f|f
34078224|NCT01921803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078225|NCT04965181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34078226|NCT01573000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078227|NCT01329146|||COHORT||PROSPECTIVE|||||||
34078228|NCT04396626|||COHORT||RETROSPECTIVE|||||||
34078229|NCT02903342|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078230|NCT04260516|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups are followed up for study parameters for 3 months one group is the intervention group and the other is the control group||||
34078231|NCT02405767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897643|NCT03158584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897644|NCT03550339|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897645|NCT03888495|RANDOMIZED|PARALLEL||OTHER||NONE|The intervention involved attendance at training workshops, so once randomization was completed by the biostatistician, random assignments had to be revealed.|||||
33897646|NCT04244825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897647|NCT05619848|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33897648|NCT03338231|||OTHER||RETROSPECTIVE|||||||
33897649|NCT05284110|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The researcher who will perform the vascular analysis will be blinded to the allocation order.|Participants with rheumatoid arthritis will attend the laboratory at Liverpool John Moores University on 2 occasions. During these visits, they will be submitted to the intervention or the control and will also undertake a series vascular tests prior- and post-intervention/control.|f|f|f|t
33897650|NCT00814710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33897651|NCT01430247|NA|SINGLE_GROUP||SCREENING||NONE||||||
33897652|NCT03312855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||with 2 doses (80 and 160 mg) of Revacept versus placebo|t|t|t|t
33897653|NCT02411123|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33897654|NCT01745055|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897655|NCT03856450|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897656|NCT04364217|NA|SINGLE_GROUP||OTHER||NONE||||||
33897657|NCT01724606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897658|NCT01094483|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33897659|NCT00850499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897660|NCT00715715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897661|NCT01152138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078232|NCT02085200|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33897662|NCT00563940|||CASE_ONLY||PROSPECTIVE|||||||
33897663|NCT00852930|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33897664|NCT02786537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897665|NCT05123287|||COHORT||PROSPECTIVE|||||||
33897666|NCT04323189|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Neither subjects, nor the investigator or key study personnel will know drug randomization until after data analyses are completed.|blinded 2:2 crossover, placebo-controlled|t|t|t|t
34078233|NCT06158217|||COHORT||PROSPECTIVE|||||||
33897667|NCT03048448|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33897668|NCT02393092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897669|NCT01824602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33897670|NCT05444244|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33897671|NCT03163238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33897672|NCT00165737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897673|NCT03294304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897674|NCT02355093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897675|NCT02203552|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33897676|NCT03260023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897677|NCT02623361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897678|NCT02956889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897679|NCT05821543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897680|NCT04165395|RANDOMIZED|PARALLEL||PREVENTION||NONE||Computer generated set of random numbers to determine group allocation with a ratio of 1:1||||
33897681|NCT00661765|RANDOMIZED|CROSSOVER||||NONE||||||
33897682|NCT04318574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897683|NCT03994640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind study: for patients and researchers|two groups parallel study: experimental and control group|t|t|f|f
33897684|NCT04396912|||COHORT||PROSPECTIVE|||||||
33897685|NCT04942548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897686|NCT00002676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897687|NCT06487884|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33897688|NCT03410147|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||A single blind, randomized, crossover monocentric study in a cohort of adult healthy volunteers|t|f|f|f
33897689|NCT02947750|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33897690|NCT05822856|||COHORT||CROSS_SECTIONAL|||||||
34078234|NCT02725658|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34078235|NCT01759953|RANDOMIZED|PARALLEL||||NONE||||||
33897691|NCT03396081|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33897692|NCT03244371|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33897693|NCT00221676|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897694|NCT06402253|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This study is organized around a 3-month digital music composition intervention for teenagers between 13 and 16 years old. This main music intervention will be compared with an active digital visual-art (i.e., photography) intervention, whose content is planned in parallel with the music one, and a passive no-intervention control group. The interventions will be administered in 24 sessions, with two 1-hour classes per week. Active interventions will cover both basic structural concepts (around music or photography, in each case) that will allow the participants to expand their understanding and appreciation of these kind of artistic stimuli; as well as hands-on experience in specific software for music / photography composition and edition (i.e., Soundtrap, Photoshop). Passive control participants will be monitored for 3-months and offered to complete one of the trainings after completing the study.~All groups will complete evaluations before and after the 3-month interventions."||||
33897695|NCT00881829|||CASE_ONLY||PROSPECTIVE|||||||
33897696|NCT05859958|||COHORT||RETROSPECTIVE|||||||
33897697|NCT02039388|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897698|NCT03047538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897699|NCT03866551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897700|NCT01604564|||COHORT||PROSPECTIVE|||||||
33897701|NCT01959360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897702|NCT01554215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897703|NCT02464319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897704|NCT00946270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The first 21 participants received pomalidomide 3.0 mg/day on a 21 day schedule. Due to poor tolerance the study was suspended and amended to treat 20 participants with pomalidomide 0.5 mg/day continuously for 28 days. The study was amended to treat an additional 29 participants with pomalidomide 0.5 mg/day for 28 days plus prednisone.||||
33980717|NCT05389943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|participants and care giver will be blind in this study|Randomized control trial on OPD patients (female age above 50) postmenopausal. the effect of vitamin D supplement on these women's bone density.|t|t|f|f
33980718|NCT00003078|RANDOMIZED|||TREATMENT||||||||
33980719|NCT03400930|||COHORT||PROSPECTIVE|||||||
33980720|NCT02925364|||COHORT||CROSS_SECTIONAL|||||||
33980721|NCT01424644|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33980722|NCT05318157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980723|NCT05778513|||CASE_CONTROL||PROSPECTIVE|||||||
33980724|NCT05178407|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The two study groups will receive different bouillon formulations in packaging that is identical except for the study group code. Linkage between the study group codes and bouillon formulations will be known only to the bouillon producer and independent codekeepers, and not to the investigators, data collection staff, or participants.||t|t|t|t
33980725|NCT06198374|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Parallel Assignment randomized, double-blind, placebo-controlled|t|t|t|t
33980726|NCT00605930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078236|NCT00874913|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34078237|NCT00917124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34078238|NCT00734643|||CASE_ONLY||PROSPECTIVE|||||||
34078239|NCT01898247|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|f|t
34078240|NCT01132183|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33897705|NCT05349461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33897706|NCT02873221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897707|NCT03138915|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897708|NCT06133010|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33897709|NCT06010810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078241|NCT01507116|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34078242|NCT06410716|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Random number table||||
34078243|NCT05200585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078244|NCT00224302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078245|NCT01494805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078246|NCT00919646|||CASE_ONLY||PROSPECTIVE|||||||
33768138|NCT03879603|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Subjects were randomized into:~WEVEE vaccine alone (Group 1, Group 3, and Group 5) or, WEVEE vaccine mixed with alum (Group 2, Group 4, and Group 6, respectively).~The study started by randomizing subjects to get a dose of 6 mcg in Group 1 or Group 2. Safety data were reviewed after 2 weeks to make sure this vaccine dose had no safety concerns before subjects were randomized to get the next dose of 30 mcg in Group 3 or Group 4. Safety data were reviewed again to make sure the 30 mcg vaccine dose had no safety concerns before subjects were randomized to the 60 mcg dose in Group 5 or Group 6.~A total of 30 subjects were randomized among the 6 groups."||||
33768139|NCT00596024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33768140|NCT00697008|||COHORT||PROSPECTIVE|||||||
33768141|NCT06268444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768142|NCT05168813|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768143|NCT00946868|||CASE_ONLY||PROSPECTIVE|||||||
33768144|NCT00175461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768145|NCT03457285|NA|SINGLE_GROUP||TREATMENT||NONE|No masking will take place|All participants will receive the same intervention||||
33768146|NCT01547520|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33768147|NCT02014090|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33768148|NCT04538924|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34078247|NCT05460546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078248|NCT03955510|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33768149|NCT05147519|||COHORT||PROSPECTIVE|||||||
33768150|NCT00796432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768151|NCT02796274|||CASE_ONLY||RETROSPECTIVE|||||||
33768152|NCT05083260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078249|NCT03879499|||COHORT||PROSPECTIVE|||||||
34078250|NCT05767489|||COHORT||PROSPECTIVE|||||||
34078251|NCT05288114|NA|SINGLE_GROUP||OTHER||NONE||||||
34078252|NCT02262650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078253|NCT02825914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078254|NCT02480738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078255|NCT02552108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078256|NCT03578627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078257|NCT03207191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078258|NCT04694001|NA|SINGLE_GROUP||OTHER||NONE||||||
34078259|NCT00577772|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078260|NCT04253158|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34078261|NCT03871036|RANDOMIZED|PARALLEL||TREATMENT||NONE||A run-in safety phase will be followed by a non-comparative 3-arm randomized study with a Simon's 2-stage optimal design. Run-in safety phase will start with an increasing dose of tremelimumab in combination with paclitaxel. In the final part of the run-in safety phase, patients will be randomized to receive paclitaxel with either regular dose tremelimumab in combination with durvalumab, or a high dose tremelimumab. If no unexpected toxicity occurs, the experimental phase of the study will start, randomizing patients over 3 arms. The best arm will be expanded based on a Simon's 2-stage optimal design.||||
33768153|NCT01280318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768154|NCT02058290|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768155|NCT00539643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768156|NCT01880372|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33768157|NCT01161693|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768158|NCT03001232|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33768159|NCT06004596|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897710|NCT01399346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33897711|NCT03413644|||COHORT||PROSPECTIVE|||||||
34078262|NCT03664115|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, Randomized, Controlled, Prospective, Open label, Phase II study.||||
34078263|NCT06234540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33980727|NCT04791150|NA|SINGLE_GROUP||SCREENING||NONE||||||
33768160|NCT04373915|RANDOMIZED|PARALLEL||OTHER||NONE||This is a single site prospective cohort study. Participants will be block randomized to standard rounding or availability of remote rounding based on their medical care team in the NICU. Parents using remote rounding will be compared to those who do not utilize remote rounding.||||
33768161|NCT05847322|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Single centre controlled human Bordetella pertussis colonisation study. Intervention: nasal challenge with Bordetella pertussis.||||
33768162|NCT01040767|RANDOMIZED|PARALLEL||||NONE||||||
33768163|NCT06296914|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768164|NCT03176589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|tube without resistance is given to patients. Randomization order is given after the analysis.|Positive expiratory pressure (PEP) therapy|f|t|f|t
33768165|NCT01872949|||COHORT||PROSPECTIVE|||||||
33768166|NCT01233882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980728|NCT02048306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980729|NCT00677365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768167|NCT02053025|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33768168|NCT04441723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768169|NCT01332890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768170|NCT02569359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768171|NCT00811746|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33768172|NCT04097405|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Double Blind, placebo controlled||t|t|t|f
33768173|NCT01982214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768174|NCT03380780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768175|NCT03806868|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33768176|NCT04408027|NA|SINGLE_GROUP||TREATMENT||NONE||The current study will leverage an adapted virtual-care cognitive behavioural therapy program for children with anxiety (VC-CBT). The VC-CBT protocol will involve 12 sessions (of one hour in duration) delivered by a CBT therapist using PHIPA (Personal Health Information Protection Act) compliant Zoom. An initial session will review therapy goals and psychoeducation about anxiety. Sessions 2 and 3 will focus on feeling identification and will introduce relaxation strategies. Sessions 4 and 5 will introduce cognitive distortions and restructuring strategies. Sessions 6 and 7 will introduce exposure tasks. Sessions 8 to 11 will involve practicing cognitive restructuring skills and completing exposures. The final session will review relapse prevention. Parents will participate in the first and last sessions, as well as join at the end of each session for a brief review of the skills learned during the session.||||
33768177|NCT01550835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768178|NCT05867485|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33768179|NCT02936713|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33768180|NCT04015115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897712|NCT03317808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33897713|NCT04336176|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Proof of concept study comparing the ability to redistribute forefoot pressure using a new foot offloading device compared to usual standard care. The sample will be purposively selected taken from a local population of active diabetic foot ulcer patients. The measurements will be taken from patients wearing usual standard of care, sham shoe (closest to barefoot or baseline pressures) and the PulseFlow DF boot. The measurements from each patient will be collated to compute pti averages for the comparison||||
33897714|NCT00315601|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33897715|NCT02187640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897716|NCT03823638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897717|NCT05852522|||OTHER||OTHER|||||||
33897718|NCT01593748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897719|NCT02984475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897720|NCT05449288|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33897721|NCT01919411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897722|NCT00003248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897723|NCT01805115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980730|NCT00932750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980731|NCT02569073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33980732|NCT05425888|||CASE_CONTROL||PROSPECTIVE|||||||
33980733|NCT04500470|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind placebo randomized controlled trial|double blind placebo randomized controlled trial|t|t|t|t
33980734|NCT05748288|||CASE_CONTROL||PROSPECTIVE|||||||
33980735|NCT00414297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980736|NCT00258271||||TREATMENT||||||||
33980737|NCT00301756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980738|NCT00613470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33980739|NCT03377881|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two-step design with a first step using paired design for blood-analysis and a second step using randomisation between prostate biopsy strategy. Repeated screening using individualised screen intervals for participants randomised to the experimental (MRI) arm and without prostate cancer diagnosed.||||
33980740|NCT01375166|||CASE_CONTROL||PROSPECTIVE|||||||
33897724|NCT05585853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was planned as a prospective, two-armed (1:1), randomized controlled experimental study. This randomized controlled trial will be reported according to the CONSORT guidelines.|f|f|f|t
33897725|NCT02011503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897726|NCT03868722|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization has to occur within 42 days after the first tests for screening were performed. Patients will be randomly assigned to treatment vs observation through 1:1 randomization process with stratification according to country, TP53 aberration status and IGHV mutational status. Treatment or observation period has to be initiated within 14 days after randomization.||||
33897727|NCT06034730|||CASE_CONTROL||PROSPECTIVE|||||||
33897728|NCT06463912|||CASE_ONLY||CROSS_SECTIONAL|||||||
33980741|NCT02401386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980742|NCT05960409|||OTHER||PROSPECTIVE|||||||
34078264|NCT01645059|||COHORT||CROSS_SECTIONAL|||||||
33768181|NCT04557527|RANDOMIZED|PARALLEL||TREATMENT||NONE|randomisation software|Patient will be recruited into||||
33768182|NCT05904860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants of the study are not informed in which group they are placed. The placement of the group is selected through the sealed envelope method.|total two groups are formed with 22 participants in each group. One is the treatment group which will receive backward gait training. The other is the control group receiving forward gait training. Pre-intervention outcomes are measured. Followed by mid-protocol outcome measurement after 2 weeks and end-protocol measurement after 4 weeks.|t|f|f|f
33768183|NCT00132379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768184|NCT03622203|||COHORT||PROSPECTIVE|||||||
33768185|NCT02542540|RANDOMIZED|PARALLEL||||NONE||||||
33768186|NCT01086566|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33768187|NCT06053060|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34078265|NCT02955303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897729|NCT05421754|NA|SINGLE_GROUP||OTHER||NONE||Patients will use ANNE Sleep system with Home Sleep Testing (HST) during one night followed by three subsequent nights with the ANNE Sleep system alone.||||
33897730|NCT02852369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897731|NCT05337943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33897732|NCT06388720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897733|NCT05980026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897734|NCT04611477|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33897735|NCT01450137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897736|NCT05771571|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Only researchers knew the type of the meal consumed by each participant.|Participants were randomly divided into control and interventional group. In the first study period, the control group consumed the meal with the refined olive oil and the interventional group received the meal with the novel, functional olive oil, enhanced with 10% w/w orange peel extract. After a washout week participants were crossed over and consumed the meals in reverse.|t|f|f|f
33897737|NCT00292123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897738|NCT04642664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897739|NCT03069339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897740|NCT02032875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897741|NCT01367743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897742|NCT03312010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects and assessors randomized to HF blinded Subjects and assessors randomized to sham blinded|Prospective, partially double-blinded, randomized|t|f|t|t
33897743|NCT05348369|||OTHER||RETROSPECTIVE|||||||
33980743|NCT06484114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Both the obesity research center team (obesity specialist/endocrinologist, blinded study coordinator, obesity research study staff) and the study participant are blinded to the treatment through the 48-week follow-up visit. The Sponsor (except for unblinded Sponsor personnel \[see below\]) is blinded to the treatment through the 24-week follow-up visit.|Randomized, Double-Blind, Sham-Controlled, Multicenter|t|t|f|t
33897744|NCT05222802|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33897745|NCT00385333|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897746|NCT04801914|||COHORT||PROSPECTIVE|||||||
33980744|NCT02201225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33980745|NCT00954915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980746|NCT06375408|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The random number table method was used for randomization, and the envelope method was used for randomization. The random serial number was stored in an airtight envelope, an envelope was opened when a patient was admitted.||t|t|t|t
34078266|NCT00922870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078267|NCT01705977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897747|NCT04071665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897748|NCT05041764|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897749|NCT01821963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897750|NCT00826605|||COHORT||RETROSPECTIVE|||||||
33897751|NCT02797561|||COHORT||PROSPECTIVE|||||||
33897752|NCT02086773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980747|NCT06210269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinding. The colored oral capsules for both study groups will have an identical appearance preventing both specific smell and taste; all drugs will be manufactured with identical labelling. Patients randomly assigned to antibiotics will receive oral moxifloxacin 400 mg once daily for seven days. The patients randomly assigned to placebo will receive an identical once daily oral administration and treatment duration of seven days. If the patient is suspected of not responding to the administered treatment based on clinical findings, the patient will undergo laparoscopic appendectomy based on the decision by the surgeon on call and the reasons for proceeding to appendectomy are recorded. Surgical findings and histopathological examination of the removed appendix will be used to confirm the diagnosis.||t|t|t|f
34078268|NCT01697839|||CASE_ONLY||PROSPECTIVE|||||||
33980748|NCT01317927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980749|NCT03179345|RANDOMIZED|CROSSOVER||OTHER||||||||
33980750|NCT01601678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980751|NCT02404948|||COHORT||PROSPECTIVE|||||||
33980752|NCT05226169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980753|NCT05436002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980754|NCT06150495|||COHORT||PROSPECTIVE|||||||
33980755|NCT04462458|||COHORT||PROSPECTIVE|||||||
33980756|NCT04359641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768188|NCT00997724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768189|NCT00460148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768190|NCT01177839|||CASE_ONLY||PROSPECTIVE|||||||
33768191|NCT01361620|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33980757|NCT04753788|||OTHER||PROSPECTIVE|||||||
34078269|NCT04608045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768192|NCT01551316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768193|NCT03580616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768194|NCT03643146|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768195|NCT00786201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980758|NCT03467165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study||||
34078270|NCT04809441|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33980759|NCT01826123|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768196|NCT01024647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768197|NCT04404608|||COHORT||PROSPECTIVE|||||||
33768198|NCT03568721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33768199|NCT05756452|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"Investigators will enroll partecipants who have had an acute coronary syndrome (3 months ± 15 days before enrollment) followed up at the Cardiology Unit of the participating centers.~Based on the coronary angiography results, partecipants will be divided into two groups:~1. patients with ACS and obstructive CAD;~2. patients with ACS without CAD, in a 1:1 ratio."||||
33768200|NCT03836508|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33768201|NCT00688090|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078271|NCT05875740|||COHORT||PROSPECTIVE|||||||
33768202|NCT05721443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980760|NCT05479630|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"A prospective quasi-experimental study will be conducted using a pre (intervention group only) - post-test design.~In the pre-test only adolescents in the intervention group will be examined as baseline. During the post-test adolescents and parents of both the intervention group and control group will be examined in order to investigate differences between them and to better determine the influence of the intervention on the outcomes."||||
33980761|NCT00016419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980762|NCT01044732|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|Open Label|||||
33980763|NCT01126736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078272|NCT02634073|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34078273|NCT00991081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078274|NCT01204203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078275|NCT00324922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768203|NCT02712697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768204|NCT04316390|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33768205|NCT02235701|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768206|NCT03211481|||COHORT||PROSPECTIVE|||||||
33768207|NCT06624722|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33768208|NCT05264233|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33980764|NCT05554653|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blinded (investigators and participants). A lab member external to the investigation will code items for the intervention.|Crossover to receive LEAA or Carbohydrate placebo. Unilateral leg exercise to give 4 outcome. (1) LEAA-EX; (2) LEAA-REST; (3) PLACEBO-EX; (4) PLACEBO-REST|t|f|t|t
34078276|NCT03541291|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33768209|NCT00896623|||OTHER||RETROSPECTIVE|||||||
33768210|NCT01166490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768211|NCT00181090|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768212|NCT04866862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768213|NCT05115019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768214|NCT04296474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768215|NCT03857841|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33768216|NCT01122004||||TREATMENT||||||||
33768217|NCT01100047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33768218|NCT04097834|||COHORT||PROSPECTIVE|||||||
33768219|NCT01141270|RANDOMIZED|CROSSOVER||||NONE||||||
33768220|NCT02984423|||COHORT||PROSPECTIVE|||||||
33768221|NCT00220961|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33768222|NCT05165953|||COHORT||RETROSPECTIVE|||||||
33768223|NCT01751815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768224|NCT05888948|||COHORT||RETROSPECTIVE|||||||
33980765|NCT00352261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980766|NCT03048500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980767|NCT05898919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33980768|NCT00683202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33980769|NCT01283919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768225|NCT04438941|||CASE_ONLY||OTHER|||||||
33768226|NCT00144872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768227|NCT00823420|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768228|NCT00101309||||TREATMENT||||||||
33768229|NCT00632164|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768230|NCT00514553|||||PROSPECTIVE|||||||
33768231|NCT02440594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768232|NCT05083624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980770|NCT00728949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980771|NCT04111731|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomised, controlled multi-centre pilot study. Forty participants with persistent atrial fibrillation will have an equal chance of being randomised to receive either of two treatment techniques of pulmonary vein isolation:~Cryoballoon (Group 1) or Radiofrequency ablation (Group 2). Subsequently, all patients will undergo a repeat procedure 2 months later to assess for reconnections requiring further treatment.~In Group 2 participants, there will also be lesions made to the back wall of the heart (left atrial posterior wall isolation)."||||
33980772|NCT04066309|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two implants (one of each group) will be placed on each subject at the same stage.||||
33980773|NCT04999553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study doctors and raters obtaining outcome measures will be blind to treatment assignment.|This is a two-arm multicenter parallel, clinician-blinded randomized non-inferiority trial|f|f|t|t
33980774|NCT03401112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
33980775|NCT02183064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980776|NCT02097290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980777|NCT04653844|||OTHER||RETROSPECTIVE|||||||
33980778|NCT01578837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980779|NCT00463606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980780|NCT04205942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980781|NCT03681509|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33980782|NCT03865654|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33980783|NCT04461665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||4 months old or 6 months old breastfeeding infants||||
33980784|NCT01288664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980785|NCT01051232|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33980786|NCT04422626|||COHORT||PROSPECTIVE|||||||
33980787|NCT03542422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980788|NCT02122796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980789|NCT05261685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024519|NCT04762498|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Screening period up to 35 days, followed by 4-week methotrexate (MTX) tolerability run-in. Treatment consists of pegloticase IV Q4 Wks dose for a total of 6 infusions (24 Weeks) with co-administered weekly oral MTX. Optional extension treatment (24-48 weeks) will be available for 6 more infusions (total of 12). Study will consist of Cohort 1: 16 mg pegloticase, co-administered with weekly doses of oral MTX; and, potential Cohort 2: 24 to 32 mg pegloticase, co-administered with weekly doses of oral MTX and/or potential infusion duration reduction to 60 min.||||
34024520|NCT05875311|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The characteristics of the interventions do not allow the study to be blinded either for the patient or for the professional. However, the analyses and surveys will be performed in a masked manner without the assigned group being identified by the investigators who carry out the examinations.|Pragmatic, open-label, prospective, parallel-group study|f|f|f|t
34024521|NCT03194841|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024522|NCT03601481|||OTHER||RETROSPECTIVE|||||||
34024523|NCT05435287|||COHORT||PROSPECTIVE|||||||
34024524|NCT05148260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024525|NCT06251492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024526|NCT04540679|RANDOMIZED|PARALLEL||OTHER||NONE||prospective experimental trial with two sets of participants a) Inpatients being randomized to one of two groups with pre-post assessments and b) outpatients being non-randomized with pre-post assessments||||
34024527|NCT05528471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024528|NCT02516943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024529|NCT04129671|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34024530|NCT04201886|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34024531|NCT01977274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024532|NCT05748106|||CASE_ONLY||PROSPECTIVE|||||||
33768233|NCT06356727|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective multicenter single-arm experimental study. The study aims to perform a functional study of the coronary microcirculation with pressure guides, in patients with new diagnoses of dilated cardiomyopathy and clinical indication for coronary angiography. Following this, a multiparametric imaging study with transthoracic echo cardiography will be performed. 12 months after the optimization of medical therapy, the patient will receive a clinical, laboratory and instrumental re-evaluation of transthoracic cardiac color Doppler. The primary endpoint is the recovery of left ventricular function on cardiac imaging. Follow up will continue up to 5 years from enrollment through telephone contacts, outpatient visits and review of clinical data.||||
33768234|NCT02285595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768235|NCT00947037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768236|NCT02798029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768237|NCT05095129|||OTHER||PROSPECTIVE|||||||
33768238|NCT00346801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768239|NCT00291434|||DEFINED_POPULATION||OTHER|||||||
33768240|NCT05304923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33768241|NCT04978259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768242|NCT00049400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768243|NCT00902941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33768244|NCT01091623|RANDOMIZED|PARALLEL||||NONE||||||
33768245|NCT03695341|||COHORT||RETROSPECTIVE|||||||
33768246|NCT05713760|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open Label Study||||
33768247|NCT01989286|||CASE_CONTROL||PROSPECTIVE|||||||
33768248|NCT03472573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768249|NCT03949660|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768250|NCT02388074|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33768251|NCT05310396|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33768252|NCT03717662|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33768253|NCT00874653|||COHORT||PROSPECTIVE|||||||
33768254|NCT06255821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768255|NCT00671632|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33768256|NCT00747318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768257|NCT04293523|||COHORT||PROSPECTIVE|||||||
33768258|NCT06175273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768259|NCT03427489|||CASE_CONTROL||PROSPECTIVE|||||||
33768260|NCT00188682|||COHORT||CROSS_SECTIONAL|||||||
33768261|NCT04216979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33768262|NCT02959671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768263|NCT05950269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be blind for the researchers involved in the post-telemonitoring assessments. Also, the data will be analyzed by a researcher who is not involved in the interventions or the assessments.||f|f|t|t
33768264|NCT00195390|||CASE_ONLY||PROSPECTIVE|||||||
33768265|NCT00157651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768266|NCT02761889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768267|NCT05325957|||COHORT||PROSPECTIVE|||||||
33768268|NCT02997839|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33768269|NCT04004572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768270|NCT00745212|||COHORT||PROSPECTIVE|||||||
33768271|NCT06385002|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33768272|NCT01549522|||||RETROSPECTIVE|||||||
33768273|NCT00633737|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33768274|NCT03855163|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the study group assignment is kept hidden from the data-analysts and manuscript writers after allocation|cluster-randomized controlled trial|f|f|t|f
33980790|NCT00000588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Chronic dose according to condition:~1. Reducing the body iron burden to near-normal levels in non- transfusion-dependent patients with iron-loading anemias (requires chelate- induced iron excretion of at least 0.10 to 0.20 mg Fe/kg/day);~2. Maintaining near-normal body iron stores in transfusion-dependent patients who have previously been well-chelated with chronic subcutaneous or intravenous desferrioxamine (requires chelate-induced iron excretion of at least 0.25 to 0.40 mg Fe/kg/day);~3. Reducing the body iron burden to near-normal levels in iron-loaded, transfusion-dependent patients (requires chelate-induced iron excretion greater than 0.40 mg Fe/kg/day)."||||
33980791|NCT04112030|||CASE_ONLY||PROSPECTIVE|||||||
33980792|NCT00113425|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33768275|NCT01234649|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33768276|NCT02459184|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33768277|NCT02892682|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33768278|NCT04278417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768279|NCT02307513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768280|NCT06624410|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Anesthesia providers, nurse providers, and surgical providers will be masked. The outcome assessor will be masked. The subject and their parent cannot be masked, due to the nature of the study. We will request of our subjects and parents/guardians to not inform their pre-operative nurse as to their allocation.||f|t|t|t
33768281|NCT03207217|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33768282|NCT04801745|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33768283|NCT05484583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768284|NCT00579982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768285|NCT02888067|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33768286|NCT00335725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33768287|NCT05445856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768288|NCT03948087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Wound assessments will be determined in a blinded capacity by utilizing the Photographic Wound Assessment Tool. Photos of individual study participant's wounds will be taken and then assigned a non-identifying marker prior to being submitted by the wound assessor.|Participants will be randomly assigned to an interventional group (vacuum rigid removable dressing) vs a non-interventional group (standard of care control group of soft dressing application).|f|f|f|t
33768289|NCT06450574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980793|NCT02480764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980794|NCT06403319|||COHORT||RETROSPECTIVE|||||||
33980795|NCT05916664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33980796|NCT00003797||||TREATMENT||||||||
33980797|NCT00921336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768290|NCT05855902|||COHORT||CROSS_SECTIONAL|||||||
33980798|NCT03386422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33980799|NCT04370665|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a prospective, single-center, single-arm, open-labelled study to enroll six (6) patients with Parkinson's disease for three biweekly deliveries of Cerezyme® to the unilateral putamen corresponding to the most affected side using Exablate and Definity®-induced BBB opening. This is a dose escalation study. Each subject will be followed for three months after the final procedure.||||
33980800|NCT01468090|||COHORT||PROSPECTIVE|||||||
33980801|NCT05540509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Staff completing assessments were blind to participants' study condition|prospective, convergent mixed-methods, randomized group design|f|f|f|t
33980802|NCT00890877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980803|NCT05750680|||CASE_CONTROL||PROSPECTIVE|||||||
34024533|NCT02083718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024534|NCT06165601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024535|NCT05734430|||COHORT||PROSPECTIVE|||||||
34024536|NCT05833698|||CASE_CONTROL||PROSPECTIVE|||||||
33980804|NCT05993156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial Parallel group, two arm, equivalent trial with 1:1 allocation ratio.|f|f|f|t
33897753|NCT03610412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Random assignment of groups and blinding:~All participants will be submitted to the selection of a sealed envelope which will have a numerical code previously defined by a third party for each intervention group.~The total number of envelopes required to complete the minimum number of participants (28) will be divided according to sex in two boxes, there will be 14 envelopes for men and 14 envelopes for women, with numerical codes that identify the bottle of intervention treatment that should receive the participant during the intervention period. They will be divided into 7 blinded codes for cinnamomum cassia group and 7 for placebo to complete the size of each subsample. Chance guarantees blinding, neither the participant nor the researcher will know the type of treatment. The database for the blinded statistical analysis will be completed. The blind man will be removed once the statistical analysis has been completed."|"Controlled clinical trial, of two parallel groups, double blind, with random assignment and control group.~Process:~Visit 1 / Day -7: Period of scrutiny, study information, consent signature, clinical history, anthropometry, baseline laboratory tests.~Visit 2 / Day 0: Start the intervention period, simple random assignment for study groups, delivery of medication, general recommendations of diet and exercise.~Visit 3 / Day 30 - Visit 4 / Day 60: Adherence to treatment, taking laboratory tests, evaluation of adverse events, general recommendations of diet and exercise, general recommendations of diet and exercise will be evaluated.~Final Visit / Day 90 ± 7: Anthropometric measurements will be taken, laboratory tests will be taken, treatment adherence and adverse events will be evaluated, end of the intervention period."|t|f|t|f
33897754|NCT02333838|NA|SINGLE_GROUP||OTHER||NONE||||||
33897755|NCT04889703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897756|NCT02200107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897757|NCT01042301|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33897758|NCT03995771|||COHORT||PROSPECTIVE|||||||
33897759|NCT02875951|||COHORT||PROSPECTIVE|||||||
33897760|NCT04146532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Note. 135 of an originally intended 200 participants had been enrolled at the time of cessation of research activities due to COVID-19 research closures. Therefore, the intended sample was increased to 270 to allow comparison between pre-COVID and post-COVID participants.|t|t|f|f
33897761|NCT02634112|||CASE_ONLY||PROSPECTIVE|||||||
33897762|NCT02861365|||COHORT||PROSPECTIVE|||||||
33897763|NCT01178918|||COHORT||PROSPECTIVE|||||||
33897764|NCT03328039|||COHORT||PROSPECTIVE|||||||
33897765|NCT05394077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897766|NCT04478422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897767|NCT04853329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33897768|NCT02287246|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33897769|NCT02104180|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980805|NCT01199861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980806|NCT00193037|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980807|NCT01919190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980808|NCT01740661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33980809|NCT01520948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980810|NCT02523105|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980811|NCT02707848|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33980812|NCT04638153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Anthropometric Measurements Assessor||f|f|f|t
33897770|NCT02791152|||COHORT||PROSPECTIVE|||||||
33897771|NCT06196840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897772|NCT02376439|||COHORT||CROSS_SECTIONAL|||||||
33897773|NCT02677740|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33897774|NCT03168061|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33897775|NCT00844077|||CASE_ONLY||PROSPECTIVE|||||||
33897776|NCT03759652|||COHORT||RETROSPECTIVE|||||||
33897777|NCT02417415|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Patients were blinded to the intervention|randomized, 2-arm crossover study (heat vs. sham)|t|f|f|f
33897778|NCT06511154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (outcomes assessor) single (outcomes assessor) the evaulation of the patients will be carried out by a blinded investigator.|Parallel Assingment dual parallel group design|f|f|f|t
33897779|NCT05644730|NA|SINGLE_GROUP||TREATMENT||NONE||Early feasibility safety study||||
33897780|NCT00736281|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33897781|NCT05585372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33897782|NCT02467764|||||RETROSPECTIVE|||||||
33897783|NCT01183858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897784|NCT00117078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897785|NCT05335122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor, Study Coordinator, Investigator|Parallel: Participants are assigned to one of three groups in parallel for the duration of the study|t|f|f|t
33897786|NCT02443844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078277|NCT04804176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study was divided into three groups, which were control group, group A and group B.Groups A and B received different treatment modalities on the same device.|t|f|f|f
34078278|NCT06387758|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34078279|NCT01973218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34078280|NCT03353324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34078281|NCT01950299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897787|NCT05727774|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897788|NCT03624998|NA|SINGLE_GROUP||SCREENING||NONE||||||
33897789|NCT01165229|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33897790|NCT00124540|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33897791|NCT01912885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33897792|NCT04207073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Controlled Study||||
33897793|NCT01507246|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897794|NCT06489678|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33897795|NCT00393458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897796|NCT00283829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897797|NCT05000801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897798|NCT04723537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897799|NCT05096169|RANDOMIZED|PARALLEL||OTHER||NONE|Open Label|Individuals will be divided into two groups. Group 1 will receive clomiphene citrate at a dose of 25mg daily and will take one-half of a 50mg tablet daily. Group 2 will receive clomiphene citrate at a dose of 50mg every other day and will take one 50mg tablet every other day.||||
33897800|NCT02045537|||CASE_CONTROL||RETROSPECTIVE|||||||
33897801|NCT02233725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897802|NCT04181281|||COHORT||CROSS_SECTIONAL|||||||
33897803|NCT03191175|||OTHER||PROSPECTIVE|||||||
33897804|NCT00887081|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34078282|NCT04619784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078283|NCT03902769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||One arm open study||||
33897805|NCT05859815|||COHORT||PROSPECTIVE|||||||
34078284|NCT04386902|||CASE_ONLY||PROSPECTIVE|||||||
34078285|NCT03158961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078286|NCT03017222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078287|NCT00468117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078288|NCT00003677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897806|NCT01470339|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33897807|NCT03436589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants who were recruited at the same time and location were assigned to the same treatment group to prevent knowledge of different treatment groups in the study.|Parallel-arm intervention with inactive control group and intervention group|t|f|f|f
34103003|NCT04491110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The masking is performed by assigning a mobile phone with headphones and an accelerometer to the carers of the control and intervention group and with the instruction not to mention what they heard to the evaluator; in this sense the participants do not know if they belong to the control or intervention group. However those who listen to music can conclude that it is an intervention group by themselves.||f|t|f|f
34103004|NCT06691022|||OTHER||CROSS_SECTIONAL|||||||
34103005|NCT06057103|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34103006|NCT06057025|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768291|NCT06131996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768292|NCT06447064|||CASE_CONTROL||RETROSPECTIVE|||||||
33897808|NCT02928640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897809|NCT01522495|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897810|NCT02082184|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33897811|NCT04706598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897812|NCT04724590|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Prospective study||||
33897813|NCT05153005|||COHORT||PROSPECTIVE|||||||
33980813|NCT00721604|||CASE_ONLY||PROSPECTIVE|||||||
33980814|NCT03925870|NA|SEQUENTIAL||TREATMENT||NONE||||||
33980815|NCT03354026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Our randomized program was completed by the key research laboratory of clinical research from the Traditional Chinese medicine Hospital of Guangdong Province. We design 306 cases into three groups: Group A, B, C in the proportion of 1:1:1. Group A is the experimental group used RBS, which include 8 herbals. Group B is the experimental group used PBS, which include all the herbals in Group A except Leech and Tabanus, rhubarb. Group C is a placebo group. This study adopts a stratified random sampling method and intra slice randomization on the basis of using PROC PLAN progress on SAS V9.2. On the other hand, this trial measures and the control measures will be made blind doubly. The surface of the opaque random envelopes will indicate the information of the test name, hospital name and the entry sequence number of patient. The research process of incorporating patient, dispensing medicine depending on the random envelopes and ect will all be supervised by the researchers each other.||t|t|t|t
33768293|NCT03152045|RANDOMIZED|PARALLEL||OTHER||NONE||"Interventional: to evaluate the effect of Feedback Guides on clinician-adolescent communication about hight-risk behaviors.~Control: standard of care"||||
33768294|NCT00070993|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33768295|NCT03923010|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768296|NCT05742230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980816|NCT01316562|||COHORT||CROSS_SECTIONAL|||||||
33980817|NCT03156062|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024537|NCT02218801|||COHORT||PROSPECTIVE|||||||
34024538|NCT02676583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34024539|NCT01504529|||COHORT||RETROSPECTIVE|||||||
34024540|NCT04618783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024541|NCT02926482|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024542|NCT01200992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024543|NCT04932057|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34024544|NCT05557032|||CASE_ONLY||PROSPECTIVE|||||||
33897814|NCT05982977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Since acupuncture intervention could not blind subjects and investigators, evaluators and statisticians were secretly grouped to avoid measurement bias as much as possible|This study was a parallel, randomized controlled trial. Qualified subjects were numbered according to the inclusion order and randomly assigned to the swallowing training treatment group and the acupuncture combined swallowing training treatment group in a 1:1 ratio.|f|f|f|t
33897815|NCT03730896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random assignment to dry needle group or control group with standard manual therapy interventions||t|f|f|f
33897816|NCT00233779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897817|NCT04079777|||CASE_ONLY||PROSPECTIVE|||||||
33897818|NCT02693964|||CASE_CONTROL||PROSPECTIVE|||||||
33897819|NCT04964726|NA|SINGLE_GROUP||OTHER||NONE||||||
33897820|NCT01843322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897821|NCT00208468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768297|NCT03146910|||COHORT||PROSPECTIVE|||||||
33897822|NCT05343910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel Assignment|f|f|t|f
33897823|NCT03887832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33897824|NCT05337449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||for both the intervention group and control group, the procedure and follow up will be done parallel to each other|t|f|f|t
34024545|NCT00237965|RANDOMIZED|PARALLEL||||SINGLE||||||
34024546|NCT05792579|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34078289|NCT05398406|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Cases; under the age of 20 - over 60, emerge and bleeding, outside the ASAI-II functional status, undergo surgery other than laparoscopic cholecystectomy, refused to participate in the study, allergic to local anesthetic agents, with a body mass index (BMI) \>30, have contraindications for regional anesthesia (sepsis, local infection, coagulopathy, heart disease, hypovolemia, cases that do not want regional anesthesia), pregnant were not included in the study.Twenty patients in each group and a total of 60 patients were included the study by power analysis. According to the randomized, single-blind, closed-envelope method, patients were randomly divided into three groups.|randomized, single-blind, closed-envelope method|t|f|f|f
33768298|NCT05100719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||LION is a two-armed, randomized, double-blind, placebo-controlled, two-phase clinical trial. In the first phase, we will enroll 100 patients, the allocation ratio will be 1:1 (50 patinets in each arm). Then, an interim analysis will be performed to determine the appropriate sample size. During the interim analysis, if there is already significant difference (p\<0.0294) between the arms, the recruitment will be considered completed; otherwise, recruitment will continue until the desired sample size is reached. If there is no hope for ascertaining significance, the study will be stopped.|t|t|t|t
33768299|NCT02870504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768300|NCT03290573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768301|NCT02762344|||COHORT||PROSPECTIVE|||||||
33768302|NCT02779595|||COHORT||PROSPECTIVE|||||||
33768303|NCT01915433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897825|NCT01614457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897826|NCT01282814|RANDOMIZED|CROSSOVER||||NONE||||||
33897827|NCT02285010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897828|NCT06345781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897829|NCT00722605|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078290|NCT03547323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768304|NCT03758027|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a randomized control trial with an experimental and control group. There will be a total of 96 participants, 48 in each group. For research question, a 2 X 3 repeated measures MANOVA will be conducted.||||
33897830|NCT05054946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897831|NCT06417684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897832|NCT05345522|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33897833|NCT05292677|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33897834|NCT05812508|||COHORT||PROSPECTIVE|||||||
33897835|NCT03689738|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33897836|NCT00634673|NON_RANDOMIZED|PARALLEL||||NONE||||||
33897837|NCT01532661|||COHORT||PROSPECTIVE|||||||
33897838|NCT01708564|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897839|NCT01089777|||CASE_ONLY||PROSPECTIVE|||||||
33897840|NCT04817540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897841|NCT03169283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33897842|NCT02362438|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33897843|NCT00813228|RANDOMIZED|PARALLEL||TREATMENT||||||||
33897844|NCT02907944|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33897845|NCT03550950|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33897846|NCT02373930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078291|NCT04414852|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33768305|NCT03581877|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a prospective randomized interventional study. Patients referred to Southside hospital will be consented to take part in the study. After obtaining written informed consent, investigators will subsequently enroll 158 consecutive patients (aged\> 18 years) randomized in a serial 1:1 allocation for either low dose PLST or ACDT for submassive pulmonary embolism.||||
33897847|NCT05337722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33897848|NCT00009867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897849|NCT03063255|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Sixty subjects with be randomized to the obturator block or neuromuscular block arm upon enrollment, using randomized permutated blocks of six.||||
33897850|NCT03542552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078292|NCT04281082|||COHORT||PROSPECTIVE|||||||
33897851|NCT05780840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33897852|NCT05922683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Randomisation will be carried out using sealed envelopes, using a randomisation code prepared by the trial statistician, which will be stratified by study centre. Each woman who gives consent will be given a trial identification (TID) number which will match the number on the randomisation envelopes.~The trial will be blinded with an identical placebo (microcrystalline cellulose, prepared by Mendes SA, Lugano). Samples will be run and analysed using TID only, with all data cleaning and re-assays carried out blinded. The trial statistician will unblind lab data once databases are finalised."||t|t|t|f
33897853|NCT00002365||||TREATMENT||NONE||||||
33897854|NCT01300143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897855|NCT04194931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897856|NCT00002187||PARALLEL||TREATMENT||||||||
33897857|NCT04468672|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician will be blinded to participant group and condition.|This is a mixed design with two participant groups (between-subject), day and night workers, each being exposed to 4 levels of food portion size (within-subjects factor)|f|f|f|t
33897858|NCT04606121|||CASE_ONLY||RETROSPECTIVE|||||||
34024547|NCT06524453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024548|NCT00062985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024549|NCT04007653|||COHORT||PROSPECTIVE|||||||
34024550|NCT04170751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, care givers and outcomes assessors are blinded. The investigator should not be included in the blind because the drug must be rate controlled during investigations.|Patients enrolled were divided into norepinephrine (group N) and vasopressin (group V) by random random numbers. The ratio of each group should be 1: 1.|t|t|f|t
34024551|NCT01421511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768306|NCT03485430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768307|NCT01216293|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33768308|NCT02095795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33768309|NCT02852018|||OTHER||OTHER|||||||
33768310|NCT03259529|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be 2 parts in this study. In Part 1, the safety of combination treatment will be evaluated prior to expansion of enrollment to evaluate treatment effect in Part 2. The arms in Part 1 include 3 different dosage regimens of gemcitabine (500 / 700 / 1000). Part 2 of the study will further characterize the safety and evaluate the antitumor activity of drug combination by enrolling patients at the recommended dose schedule determined in Part 1.||||
33768311|NCT01561092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768312|NCT05510635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768313|NCT00592319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768314|NCT01537679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768315|NCT02936037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"PART 1:~Total duration of Part 1 is 27 months. The randomized double-blind placebo-controlled period ranges from 15 to 27 months depending upon the randomization date of an individual patient.~Once the last month 15 evaluation of the study has been completed, patients will switch to the active drug at the next planned visit. Participants and study personnel will remain blinded as to the original treatment assignment.~Maximum duration of double-blind period per patient will be no longer than 27 months.~PART 2:~At the last evaluation of Part 1 (Visit 11/Month 27) all participants will be offered active treatment in an open label extension for 39 additional months (From V11/M27 to V18/M66).~The purpose of the active drug extension is to further define the safety of MD1003."|t|t|t|t
33768316|NCT02041247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768317|NCT02106013|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33768318|NCT05417451|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768319|NCT05668936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768320|NCT03083392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768321|NCT04062435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768322|NCT01515189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768323|NCT05992714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Investigator)|Parallel Assignment experimental model using randomized pretest and posttest with control group|t|f|t|f
33768324|NCT05523245|||COHORT||PROSPECTIVE|||||||
33768325|NCT04121039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768326|NCT00152763|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33768327|NCT04714437|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33768328|NCT01391351|NON_RANDOMIZED|PARALLEL||||NONE||||||
33897859|NCT06512974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will evaluate the efficacy of NeuroTrainer cognitive training for improving attention and executive function in students with ADHD and sub threshold ADHD, divided into intervention and control groups. Participants, aged 11-17, will be randomly assigned to use NeuroTrainer or receive standard educational activity. Primary outcomes include attention and executive function improvements, while secondary outcomes assess ADHD symptoms and academic performance. Data will be collected at baseline, midpoint, post-intervention and 6-month follow-up.|f|f|f|t
33897860|NCT05266638|||COHORT||RETROSPECTIVE|||||||
33897861|NCT02669563|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897862|NCT01768299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33897863|NCT04259710|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Stage 1: Comparison of intervention groups to pedometer only group. Stage 2: Comparison of intervention with implementation intentions to intervention alone||||
33897864|NCT02426086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Initially single-blind; treatments unmasked after 1st Interim Analysis and continued as open-label treatment.||t|f|f|f
33897865|NCT04507074|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33768329|NCT01821430|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33897866|NCT01515072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768330|NCT06296615|||CASE_CONTROL||PROSPECTIVE|||||||
33768331|NCT03930134|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33768332|NCT01709305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768333|NCT00004475|||FAMILY_BASED||PROSPECTIVE|||||||
33897867|NCT05165394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897868|NCT03156153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768334|NCT05423522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind period followed by an open-label trial period. The double-blind will be maintained throughout the double-blind period treatment (except exceptional unblinding in emergency situations for reasons of patient safety).|A prospective, multicenter, with a first randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period to evaluate the clinical safety and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's disease: a proof-of-concept study.|t|t|t|t
33768335|NCT02960763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768336|NCT02169037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768337|NCT02895568|||OTHER||CROSS_SECTIONAL|||||||
33768338|NCT04737772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A single arm pilot followed by a 2 arm randomized control trial|t|f|t|t
33897869|NCT05448534|||COHORT||PROSPECTIVE|||||||
33768339|NCT03458559|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized between~* radium-223-chloride intravenously, for a total of 6 administrations (every 4weeks)~* rhenium-188-HEDP intravenously for a total of 3 administratrions (every 8 weeks)"||||
33768340|NCT03037879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768341|NCT05443087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078293|NCT00269152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768342|NCT01920503|||COHORT||PROSPECTIVE|||||||
33768343|NCT06109090|||COHORT||PROSPECTIVE|||||||
33768344|NCT05535140|||OTHER||PROSPECTIVE|||||||
33768345|NCT01566630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768346|NCT05664139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768347|NCT02887989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897870|NCT01765712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768348|NCT00390455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768349|NCT01759615|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33768350|NCT05408143|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768351|NCT03160300|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33768352|NCT01031472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768353|NCT00774137|||COHORT||PROSPECTIVE|||||||
33768354|NCT04976595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768355|NCT04544228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768356|NCT02872727|||COHORT||CROSS_SECTIONAL|||||||
33768357|NCT05943314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768358|NCT05149781|||CASE_CONTROL||PROSPECTIVE|||||||
33897871|NCT06270992|||CASE_CONTROL||PROSPECTIVE|||||||
33897872|NCT05565924|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33897873|NCT00519623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897874|NCT01916577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897875|NCT04170140|||OTHER||CROSS_SECTIONAL|||||||
33897876|NCT02884115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897877|NCT05777525|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Parallel treatment design and double-blind|t|f|t|f
33897878|NCT01267435|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33897879|NCT02190487|||COHORT||RETROSPECTIVE|||||||
33897880|NCT04706390|||COHORT||PROSPECTIVE|||||||
33897881|NCT02424669|NON_RANDOMIZED|PARALLEL||||NONE||||||
33897882|NCT03714841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|f|t|t
33897883|NCT00123201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33897884|NCT06510842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897885|NCT04537637|||COHORT||PROSPECTIVE|||||||
33897886|NCT01772979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897887|NCT00651040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33897888|NCT00656214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897889|NCT05340400|||OTHER||CROSS_SECTIONAL|||||||
33897890|NCT05899725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897891|NCT01916369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897892|NCT00969722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897893|NCT05624372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897894|NCT01108991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33897895|NCT01993355|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33980818|NCT03654625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Baseline (pre-intervention) outcome measures will be completed at the first visit to the lab at Ryerson University. Participants will then be randomly assigned to one of the following conditions: (1) standard written exposure, (2) enhanced written exposure or (3) neutral writing. All participants will write at the lab for 30 minutes on each of 4 days. The 4 writing sessions will be spaced and take place within a 2-week period. During the 2-week intervention period and the three days following the intervention period, participants will track their worry and mood twice per day. With the exception of the Modified Behavioural Avoidance Test, which will only be assessed at pre-intervention and 1 month follow-up , all other outcomes will be reassessed at post-intervention, 1-week and 1-month follow-up. An additional assessment of excessive worry will occur at mid-intervention, and additional assessments of Perceived Probability, Cost and Coping Questions will occur at each writing session.|t|f|f|f
33980819|NCT06150976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980820|NCT03970564|||COHORT||PROSPECTIVE|||||||
33980821|NCT01806688|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized crossover|t|f|f|f
33980822|NCT04003090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980823|NCT02330848|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33980824|NCT00119886|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34078294|NCT01837251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078295|NCT01987180|||CASE_CONTROL||PROSPECTIVE|||||||
33897896|NCT00784069|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33897897|NCT01943448|||CASE_ONLY||PROSPECTIVE|||||||
33897898|NCT03232112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An un-blinded nurse will be responsible for carrying out the randomization of the patients in REDCap. When randomization is carried out, the nurse will ensure that the patient gets the treatment that he/she is allocated to. Patients, investigators, other care givers performing assessments and persons performing data analysis will remain blinded from the time of randomization until time of database unlock. In order to maintain the blinding of the patients, the nurse will prepare the injection in a separate room and the patients will be blindfolded as the injection is given.|Double-blinded, randomized, placebo-controlled.|t|f|t|t
33897899|NCT05003245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897900|NCT06177613|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33897901|NCT02809248|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33897902|NCT04166396|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33897903|NCT06017323|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33897904|NCT01845389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897905|NCT05417529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33897906|NCT03115255|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33897907|NCT00758615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897908|NCT03909685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The current study aims to recruit 45 Johns Hopkins graduate students (initially from Carey Business School) with at least mild depressive and/or anxiety symptoms who will be consented and enrolled in a five-week study. There are two study arms: (1) the intervention arm and (2) a waitlist control arm. During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy. The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm.||||
33897909|NCT00836563|||CASE_ONLY||PROSPECTIVE|||||||
33897910|NCT03091556|||COHORT||PROSPECTIVE|||||||
33897911|NCT06077981|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||"Randomization shall consist of 30 patients, of which:~15 will be from the hydroxyethylamide Group, where the submucosal endoscopic dissection will be performed with submucosal injection of hydroxyethylamide.~15 will be from the Hyaluronic acid group (TS-905 Blue Eye), where the submucosal endoscopic dissection with submucosal injection of hyaluronic acid (TS-905 Blue Eye) will be performed."|t|f|t|f
33897912|NCT03378440|||COHORT||PROSPECTIVE|||||||
33897913|NCT03525977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078296|NCT02114619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34078297|NCT02025192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078298|NCT04182958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897914|NCT01403129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33897915|NCT04107012|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33897916|NCT00469235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980825|NCT05290181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||68 female students with PMS who met the inclusion criteria will be divided into groups using a simple random method. There will be 34 female students in the intervention group and 34 female students in the control group.In order to prevent interaction between the intervention and control group students in the randomization, the places where the students stay (home, dormitory rooms) will be taken into account. A support program including pilates exercises and sending text messages will be applied to the students in the intervention group for 8 weeks. Online pilates exercises will be done 2 days a week and individual short messages will be sent to their smartphones via the Whatsapp application 3 days a week.||||
33980826|NCT06227247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We plan to randomize 40 participants 1:1 to the M4M intervention vs usual GDM care (UC)||||
33980827|NCT02019810|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33980828|NCT04448223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980829|NCT05126732|||COHORT||PROSPECTIVE|||||||
33980830|NCT02786030|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33980831|NCT01720264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980832|NCT03437148|NA|SINGLE_GROUP||OTHER||NONE|NO MASKING|||||
33980833|NCT04534010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980834|NCT02767232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980835|NCT02916290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980836|NCT03185065|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind|randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind, multicenter trial of 3 commonly used medications for treatment of Multiple Sclerosis related fatigue versus placebo in fatigued subjects with MS.|t|t|t|t
33980837|NCT05459727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the characteristics of the intervention in this trial, it would be impossible to blind the enrolled participants. However, the investigators and outcomes assessors will be blinded. Allocation to arms will be concealed in an envelope and revealed to the stomatologist and patient before delivering the first treatment. Other investigators like outcomes assessors and staff involved in the data collection and analyses will be masked.||f|f|t|t
33980838|NCT00057109|||||PROSPECTIVE|||||||
33980839|NCT00045877||||TREATMENT||||||||
33980840|NCT00318994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980841|NCT00766688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980842|NCT01626079|RANDOMIZED|PARALLEL||TREATMENT||NONE|614 in the Randomized Group for COAPT Trial and 162 Subjects in the COAPT CAS Group|||||
33980843|NCT05293054|||COHORT||PROSPECTIVE|||||||
33980844|NCT06015126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980845|NCT03604419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980846|NCT03935711|||OTHER||CROSS_SECTIONAL|||||||
33980847|NCT02448927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980848|NCT04247308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two group pre-test post-test design|t|t|f|f
34078299|NCT02077998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078300|NCT03969940|||COHORT||PROSPECTIVE|||||||
34078301|NCT00857662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078302|NCT04086810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078303|NCT05943366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Given the nature of the intervention, participants and researchers will be unblinded.|Prior to completing baseline measures, participants will be randomised in a 1:1 ratio to receive the intervention (KOKU-Nut) or to the control group and receive usual care. Randomisation will be undertaken by a separate member of the research team using the Sealed Envelope randomisation service.||||
34078304|NCT06432478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078305|NCT00246454|||OTHER||OTHER|||||||
33980849|NCT01494506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980850|NCT00553280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980851|NCT03806439|||COHORT||CROSS_SECTIONAL|||||||
34078306|NCT04390646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicentric randomized double-blind clinical trial|t|t|t|f
34078307|NCT04441346|||COHORT||PROSPECTIVE|||||||
34078308|NCT00914407|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078309|NCT04915560|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Percentage of valid data obtains from a professional performing an industrial cleaning task wearing a connected T-shirt.||||
34078310|NCT01369264|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34078311|NCT00789503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078312|NCT04321577|||OTHER||PROSPECTIVE|||||||
34103007|NCT02025010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103008|NCT06686524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103009|NCT05530538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839243|NCT04144712|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The current study will be carried on preterm infants admitted to the Neonatal Intensive Care Unit (NICU), Ain Shams University 80 Patients divided into two groups each group will contain 40 subjects Group sample sizes of 40 and 40 achieve 83% power to detect a difference of -7.0 regarding frequency of apnea attacks between the null hypothesis that both group means are 9.0 and the alternative hypothesis that the mean of group 2 is 16.0 with known group standard deviations of 3.7 and 5.2 and with a significance level (alpha) of 0.05000 using a two-sided Mann-Whitney test assuming that the actual distribution is uniform|t|t|f|f
33980852|NCT04219566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Subject, Nursing staff, Co-coordinators, Outcomes Assessor and any other study staff who have contact with the subject)||t|t|t|t
33980853|NCT03269305|||OTHER||PROSPECTIVE|||||||
33980854|NCT02270970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980855|NCT00738803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980856|NCT03169348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980857|NCT03933956|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-arm open-label intervention study||||
33839244|NCT00218608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839245|NCT04154553|||COHORT||PROSPECTIVE|||||||
33839246|NCT00319800|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897917|NCT01101074|||COHORT||PROSPECTIVE|||||||
33897918|NCT05319535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel cluster-randomized trial (parallel-CRT): used in pragmatic evaluations of health program or policy interventions, where half the clusters (in this case, VA medical centers) are randomly assigned to two interventions: Foundational REP (active comparator) vs. Enhanced REP (experimental).||||
33897919|NCT05058872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33897920|NCT03852212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897921|NCT00933946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897922|NCT06239311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897923|NCT02975648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33897924|NCT05968950|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, cohort||||
33897925|NCT00775307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33897926|NCT03901378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897927|NCT01455727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897928|NCT00182065|||||PROSPECTIVE|||||||
33897929|NCT00579904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897930|NCT02777463|||COHORT||PROSPECTIVE|||||||
33980858|NCT01190748|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33980859|NCT04734288|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single-arm cohort intervention study||||
33980860|NCT00071162|||FAMILY_BASED||RETROSPECTIVE|||||||
33980861|NCT03255148|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33980862|NCT00006106||||TREATMENT||||||||
33980863|NCT03893539|NA|SINGLE_GROUP||OTHER||NONE||||||
33980864|NCT03405402|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33980865|NCT01465477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980866|NCT00677196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980867|NCT03157622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980868|NCT00264797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980869|NCT02402348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33980870|NCT02079753|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33980871|NCT04172649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33980872|NCT03370068|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33980873|NCT05991726|||OTHER||PROSPECTIVE|||||||
33980874|NCT04867252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33980875|NCT06484933|||OTHER||PROSPECTIVE|||||||
33980876|NCT00002994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980877|NCT03299296|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||single blind, sequentially simple randomized controlled clinical trial|t|f|f|f
33980878|NCT02391064|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33980879|NCT03732105|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839247|NCT01793844|||CASE_CONTROL||PROSPECTIVE|||||||
33839248|NCT04654572|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34078313|NCT05476393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is erector spinae plane block group. The second one is thoracal paravertebral block group.|t|f|f|t
34078314|NCT03427710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Adaptive design allowing modifications in single and multidose arms|t|f|t|f
33839249|NCT03192462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is designed as a fixed-dose pilot study to evaluate the safety and feasibility and efficacy of up to 6 intravenous infusions of multiTAA-specific T cells in pancreas cancer patients with metastatic, locally advanced unresectable, or resectable disease.||||
34078315|NCT04149444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078316|NCT05916898|||CASE_ONLY||PROSPECTIVE|||||||
34078317|NCT01750658|||CASE_CROSSOVER||PROSPECTIVE|||||||
34078318|NCT01064271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768359|NCT03335930|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"1. Participants were randomly assigned to one of three exercise times (morning/08:00-10:00, afternoon/14:00-16:00 evening/18:00-20:00).~2. Training protocol: Treadmills were used for the aerobic exercise training. Participants received supervised exercise training three times per week on alternate days for 12 weeks at the medical centre.~3. All participants followed this training protocol and maintained their usual lifestyles. The duration of each training session was 30 minutes and took place 1 to 2 hours after a meal.~4. The intensity of the training was set at 60% VO2max (approximately equal to 72% HRmax) obtained from the GXT.~5. During each session of the 30-minute aerobic exercise training, the patient's heart rate was maintained at 72% of heart rate maximal on treadmill. Appropriate speed and grade were used to achieve the target heart rate being tracked by the heart rate monitor and to accurately control the required exercise intensity."||||
33768360|NCT05050266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized type 3 hybrid implementation-effectiveness trial||||
33768361|NCT01727492|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33768362|NCT04020159|||COHORT||PROSPECTIVE|||||||
33768363|NCT01762423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768364|NCT05126043|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768365|NCT01381952|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
33768366|NCT05492812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768367|NCT05176782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768368|NCT05763082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768369|NCT02280057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33768370|NCT04381260|||OTHER||OTHER|||||||
33768371|NCT01588990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768372|NCT03218761|||COHORT||PROSPECTIVE|||||||
33768373|NCT03377868|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Observational study of a cohort of patients with amyotrophic lateral sclerosis compared to a parallel cohort of healthy age and sex matched subjects||||
33768374|NCT01261143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768375|NCT00773058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768376|NCT01452984|||COHORT|||||||||
33768377|NCT01719224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768378|NCT05822843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33768379|NCT04766814|||CASE_CONTROL||PROSPECTIVE|||||||
33897931|NCT01226667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897932|NCT04154540|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33897933|NCT01418755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897934|NCT04887311|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33897935|NCT01335646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897936|NCT00870493|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33897937|NCT04210570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33897938|NCT00900848|||COHORT||RETROSPECTIVE|||||||
33897939|NCT01571986|||OTHER||PROSPECTIVE|||||||
33980880|NCT00674999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980881|NCT04343690|NA|SINGLE_GROUP||OTHER||NONE||||||
33768380|NCT02586337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768381|NCT02206698|||COHORT||PROSPECTIVE|||||||
33768382|NCT01392222|||FAMILY_BASED||PROSPECTIVE|||||||
33768383|NCT00285181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33768384|NCT02168790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768385|NCT05088837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent individual randomly appointed to all participants to either group (A) (n=20) or group (B) (n=20) by numbers that were picked from the closed envelopes.|Group (A) (Control group): consisted of 20 patients, they received muscle energy technique for 12 sessions, 3 sessions / week. Group (B) (Study group): consisted of 20 patients, they received alternative heat and ice for another 20 minutes /session (10 minutes for each).|f|f|f|t
33768386|NCT01672164|||COHORT||PROSPECTIVE|||||||
33768387|NCT01083940|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33980882|NCT02707653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897940|NCT03811951|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The University of Illinois Hospital and Health Sciences System Investigational Drug Service (IDS) randomizes treatment order to study subjects and prepares drug product and placebo. All other roles, including participant, investigator, and non-IDS study personnel are masked from treatment order.||t|f|t|f
33897941|NCT06092502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33897942|NCT06075615|||COHORT||PROSPECTIVE|||||||
33897943|NCT03675399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Exercise sessions were delivered by a physiotherapist who was not involved in the assessments.||f|f|t|f
33897944|NCT03350711|||CASE_ONLY||OTHER|||||||
33897945|NCT03976830|||COHORT||PROSPECTIVE|||||||
33897946|NCT02400346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897947|NCT00621933|||COHORT||PROSPECTIVE|||||||
33768388|NCT03642301|||COHORT||PROSPECTIVE|||||||
33897948|NCT03322657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33897949|NCT02554643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897950|NCT02906046|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33897951|NCT05907915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897952|NCT05070338|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33897953|NCT00920309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897954|NCT04886765|NA|SEQUENTIAL||TREATMENT||NONE||||||
33897955|NCT01478347|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33897956|NCT01050062|||CASE_ONLY||PROSPECTIVE|||||||
33980883|NCT00583700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980884|NCT00212069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980885|NCT05796310|||COHORT||PROSPECTIVE|||||||
33897957|NCT04169828|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic RCTs use alternative designs to establish effectiveness of a treatment strategy in usual care. Pragmatic trials aim to include all subjects in whom the treatment may be used and are conducted under the usual conditions of practice to demonstrate effectiveness under real word circumstances. Patients enrolled in a pragmatic trial are more representative because eligibility criteria are less strict.||||
33897958|NCT02309710|NA|SINGLE_GROUP||||NONE||||||
33897959|NCT02812680|||CASE_CONTROL||PROSPECTIVE|||||||
33897960|NCT04364932|||COHORT||RETROSPECTIVE|||||||
33897961|NCT04024410|||COHORT||PROSPECTIVE|||||||
33897962|NCT00283712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33897963|NCT00746538|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33897964|NCT02201810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897965|NCT06148610|||COHORT||PROSPECTIVE|||||||
33897966|NCT00739128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897967|NCT02914626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33897968|NCT05771922|||COHORT||PROSPECTIVE|||||||
33897969|NCT00298532|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33768389|NCT05800782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told whether they are in the experimental or control conditions and all conditions will require discriminating faces.|There will be a pre assessment, 6 weeks of training/active control, then an immediate post assessment, and finally an assessment after a 12-week no-contact period|t|f|f|f
33768390|NCT01048606|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33768391|NCT06380634|NA|SINGLE_GROUP||SCREENING||NONE|The groups were randomized into 2 groups using a web-based randomization program (http://www.randomizer.org). The researcher included pregnant women who met the inclusion criteria in the outpatient clinics on certain days of the week, in accordance with the randomization process.|The research was conducted in a prospective pre-test, post-test based randomized controlled experimental research design.||||
33768392|NCT00748124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768393|NCT02366936|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768394|NCT04930328|||OTHER||RETROSPECTIVE|||||||
33768395|NCT05092243|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33768396|NCT00807521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33768397|NCT01715337|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33897970|NCT06464406|RANDOMIZED|CROSSOVER||OTHER||SINGLE|It is not possible to mask the participant or data collection personnel from the conditions because the Virtual Reality condition requires that the headset be worn. Metabolic data and resulting outcomes (i.e. VO2peak value) will be analyzed by independent research assistants who will be blinded to the condition under which the data were gathered.|This study will use a repeated-measures crossover model in which each participant completes the two conditions of the maximal exercise test (Control and Virtual Reality) in a randomized, counterbalanced order.|f|f|f|t
33897971|NCT00939263|||COHORT||PROSPECTIVE|||||||
33897972|NCT02660554|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33897973|NCT05784792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Case-Control study|f|t|t|f
33897974|NCT05191082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, parallel, superiority, randomized clinical trial with a 3 months of follow-up|t|f|f|t
33897975|NCT04422587|||COHORT||OTHER|||||||
33897976|NCT05568745|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is impossible because of the nature of the device studied.|Multi-center, randomized, controlled, open-label therapeutic trial with two parallel arms.||||
33897977|NCT04562337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897978|NCT02628730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897979|NCT00051844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33897980|NCT05249595|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The central objective of this study is to validate a new neuromuscular interface that combines surface electromyography and ultrasound imaging to predict human ankle joint voluntary strength or movement intent under isometric and dynamic conditions. The secondary objective is to design control algorithms for a powered ankle exoskeleton and functional electrical stimulation with the consideration of human voluntary strength or movement intent that is estimated from the surface electromyography and ultrasound imaging-based interface.~This study is performed with two sets of subjects: people with neurological disorders and people without any neurological disorders. (why have parallel groups)"||||
33897981|NCT03513380|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33897982|NCT03607682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768398|NCT04890717|||COHORT||PROSPECTIVE|||||||
33768399|NCT00956696|||CASE_ONLY||PROSPECTIVE|||||||
33768400|NCT01464008|||CASE_ONLY||RETROSPECTIVE|||||||
33768401|NCT01397435|||CASE_CONTROL||PROSPECTIVE|||||||
33768402|NCT03786120|||COHORT||PROSPECTIVE|||||||
33768403|NCT04023149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768404|NCT00115219|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33897983|NCT02273973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33897984|NCT01843556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33897985|NCT05246410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980886|NCT04855786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768405|NCT03444935|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Crisis Clinicians who consent individuals for participation will be masked from randomization. The randomization process will be completed by a different staff member separate from the Crisis Clinician to prevent allocation bias.|Participants are randomized to one of two groups: intervention or control. Participants will receive a set number of follow-up phone calls based on the group to which they are randomized.|t|f|f|f
33768406|NCT01468896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768407|NCT02761460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768408|NCT01926522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33768409|NCT04091360|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind||t|f|t|f
33768410|NCT05256693|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768411|NCT01057108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768412|NCT00810082|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768413|NCT01634074|||COHORT||PROSPECTIVE|||||||
33768414|NCT04192630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768415|NCT05250258|||COHORT||PROSPECTIVE|||||||
33768416|NCT04022460|||COHORT||CROSS_SECTIONAL|||||||
33768417|NCT00798031|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768418|NCT03467308|||CASE_CONTROL||PROSPECTIVE|||||||
33768419|NCT03096301|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||It is a prospective trial of clinical and economic analysis. It will include 45 patients to evaluate the effectiveness of the treatments with low-intensity laser and occlusal plate for muscle pain in patients with TMD||||
33768420|NCT06367387|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Participants will be stratified by recruitment clinic and dose of buprenorphine at enrollment (≤16 mg vs \>16 mg) and randomized in 2x2 factorial design: 1) either to PSM or Usual Care, and then 2) either to POD or standard buprenorphine dosing. The randomization schema will be generated by the TREETOP Data Core using a stratified permuted block design and will be integrated into the web-based data collection and management system (REDCap).||||
33768421|NCT04334421|||COHORT||PROSPECTIVE|||||||
33768422|NCT05147168|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768423|NCT03780270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768424|NCT03648593|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||randomized intervention trial with waiting list control||||
33768425|NCT04258085|||COHORT||PROSPECTIVE|||||||
33768426|NCT00341653|||COHORT||CROSS_SECTIONAL|||||||
33768427|NCT01442272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768428|NCT04597502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded placebo controlled||t|t|t|f
33768429|NCT01033292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33897986|NCT03040050|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|The rPCR results will be provided to the clinical provider for the Interventional group participants. The rPCR results will not be provided to the clinic provider for the control group participants.||f|t|t|f
33897987|NCT04230577|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|After consent/screening participant is randomized by computer into Group 1 or Group 2 in blocks of 10. The participant, investigator and outcome assessor is blinded to Group.|This study is a blinded, randomized, sham-controlled, partial-crossover study with 2 groups (n=10 per group (Sham, Real); ages 18-65). Participants are randomized by computer into group 1 or 2, in blocks of 10. At-home LED intervention is self-administered 3 times per week (20 minutes), for two 5-week series, with a one month break between series. All participants receive a Real Series of treatment at some point during the study.|t|f|t|t
33897988|NCT02799940|||COHORT||PROSPECTIVE|||||||
33897989|NCT05518786|||COHORT||PROSPECTIVE|||||||
33897990|NCT03941548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33897991|NCT03477188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants didn't know taking which exercise treatment methods.|Experimental, Randomized Controlled Study|t|f|f|f
33897992|NCT02648230|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33897993|NCT02521350|||COHORT||PROSPECTIVE|||||||
33897994|NCT00211523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33897995|NCT01343615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33897996|NCT06034223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single blinded study in which participants will be alocated in two groups using simple random sampling.|the participants are divided into two groups, control group will recieve conventional physical therapy and experimental group will recieve proprioceptive training with conventional physcial therapy.|t|f|f|f
33897997|NCT03392129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897998|NCT05969080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33897999|NCT00030758|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33898000|NCT01115712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898001|NCT00939172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898002|NCT00663858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898003|NCT02559505|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33898004|NCT05766449|||COHORT||RETROSPECTIVE|||||||
33898005|NCT01767233|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898006|NCT01309126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898007|NCT01274767|||COHORT||PROSPECTIVE|||||||
33898008|NCT01269034|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898009|NCT02767050|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980887|NCT01921023|||CASE_ONLY||PROSPECTIVE|||||||
34078319|NCT04645563|||CASE_CONTROL||RETROSPECTIVE|||||||
34078320|NCT05867758|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial of a Group intervention with international college students||||
34078321|NCT06312865|||OTHER||CROSS_SECTIONAL|||||||
34078322|NCT03933449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078323|NCT06140433|NA|SINGLE_GROUP||SCREENING||NONE||||||
34078324|NCT05329857|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34078325|NCT05620589|||COHORT||PROSPECTIVE|||||||
34078326|NCT04902781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078327|NCT02970383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078328|NCT04918654|||COHORT||PROSPECTIVE|||||||
34078329|NCT00315445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078330|NCT02957357|||COHORT||OTHER|||||||
34078331|NCT00757393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898010|NCT03484026|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Consumption of BioFe in a single cohort of up to 8 subjects with iron deficiency.||||
33898011|NCT00565955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898012|NCT00205192|||CASE_CONTROL||PROSPECTIVE|||||||
33898013|NCT02280811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898014|NCT05300529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898015|NCT03746262|||COHORT||PROSPECTIVE|||||||
33898016|NCT02625038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898017|NCT04350515|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33898018|NCT03338556|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind||t|t|t|t
33898019|NCT01381523|||COHORT||RETROSPECTIVE|||||||
33898020|NCT02758795|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33898021|NCT02660658|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33898022|NCT03703531|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33898023|NCT01968876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898024|NCT06512298|||COHORT||PROSPECTIVE|||||||
33898025|NCT03692273|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The provider and patient will know which area is randomized to the three treatments. The assessors of the primary and secondary outcomes will be blinded to which treatment was provided to each of the three areas within the study scar.|Patients will receive all three interventions (laser, 0.5mm punch biopsy, and no treatment) within their study scar.|f|f|f|t
33898026|NCT05533125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898027|NCT00591383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898028|NCT04850950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898029|NCT03444025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898030|NCT00616473|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898031|NCT01001585|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33898032|NCT03541577|||COHORT||PROSPECTIVE|||||||
33898033|NCT04545307|NA|SINGLE_GROUP||TREATMENT||NONE||PRP clot loaded of BM-MSC in order to regenerate dental pulp tissue, placed in the root canal of an immature tooth from a patient with pulp necrosis and chronic apical periodontitis||||
33898034|NCT01292772|||OTHER||PROSPECTIVE|||||||
33898035|NCT05178134|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Other parts will be blinded except unblinded person who prepares the doses|A randomized, placebo controlled phase 2|t|t|t|f
33898036|NCT04562324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34078332|NCT02346708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078333|NCT01621386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078334|NCT00523913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078335|NCT01808274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078336|NCT04522648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34078337|NCT02391025|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078338|NCT05150431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078339|NCT03255460|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078340|NCT02965404|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34078341|NCT01601769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078342|NCT00262652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980888|NCT02433678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980889|NCT02170688|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33980890|NCT05951049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980891|NCT01997203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980892|NCT06059326|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33980893|NCT01740609|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33980894|NCT02716025|||CASE_CONTROL||PROSPECTIVE|||||||
33980895|NCT05372666|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Latin square randomization for test products following reference treatment (as per standard protocol)|t|t|t|t
33980896|NCT04852003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR0410 injection compared with placebo and morphine|t|t|t|t
33980897|NCT03553160|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33980898|NCT00201305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980899|NCT06198881|||COHORT||RETROSPECTIVE|||||||
33980900|NCT01490944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33980901|NCT06083337|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants of the VIRDICT study will be randomized either to standard of care management or high-dose atorvastatin +/- colchicine.||||
33980902|NCT05865639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33980903|NCT00414531|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33980904|NCT03831048|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980905|NCT01789164|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980906|NCT02115646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980907|NCT03057392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980908|NCT02154321|||OTHER||CROSS_SECTIONAL|||||||
33980909|NCT00275353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33980910|NCT05799781|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980911|NCT03299400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All eligible patients who have given informed consent will attend the ophthalmology clinic for screening.~Patient will undergo general anaesthesia for prone spinal surgery. The degree of inclination was set prior to the start of the case and independently confirmed using a goniometer. Patients will be placed in the prone position on a Jackson Spine table.~Once positioned, the head is carefully placed on the GentleTouch prone positioning pillow of the appropriate size.~Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface. The output of the sensor expressed in voltage, and can be analysed in real time points corresponding to the intraoperative events."||||
33980912|NCT05556109|||CASE_CONTROL||OTHER|||||||
34078343|NCT01605864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078344|NCT05486416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blinded, 2:1 ratio of HSK3489 and Propofol respectively|Surgical pre-induction analgesia|t|f|f|f
34078345|NCT00902070|||||PROSPECTIVE|||||||
34078346|NCT04751695|NA|SINGLE_GROUP||SCREENING||NONE||||||
34078347|NCT01666561|RANDOMIZED|CROSSOVER||||NONE||||||
33768430|NCT03767985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research orthoptist that does the orthoptic examinations is masked to the randomization.|Participants are randomized to either the standard patching therapy or the dichoptic video game therapy.|f|t|f|f
33768431|NCT05281003|NA|SINGLE_GROUP||TREATMENT||NONE||Pembrolizumab in combination with chemotherapy (Paclitaxel plus Cisplatin, TP regimen)||||
33980913|NCT02689297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33980914|NCT02782624|RANDOMIZED|CROSSOVER||||NONE||||||
33980915|NCT00591643|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980916|NCT06315179|||COHORT||PROSPECTIVE|||||||
33980917|NCT05474248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33980918|NCT02945215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980919|NCT01666730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980920|NCT01171690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078348|NCT01360723|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078349|NCT02379494|||COHORT||PROSPECTIVE|||||||
34078350|NCT06187831|||COHORT||OTHER|||||||
34078351|NCT04008225|||COHORT||PROSPECTIVE|||||||
33768432|NCT01352143|||CASE_CONTROL||PROSPECTIVE|||||||
33980921|NCT03934073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980922|NCT01867723|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33980923|NCT03842306|||COHORT||PROSPECTIVE|||||||
33980924|NCT05124574|||COHORT||PROSPECTIVE|||||||
33980925|NCT04276883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled|phase III, randomized, double-blind, placebo-controlled|t|t|t|t
33980926|NCT05735977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single centre cohort study using consecutive patients. No comparison group.||||
33980927|NCT05675332|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33980928|NCT01051505|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33980929|NCT01441609|||CASE_CONTROL|||||||||
33980930|NCT04249973|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33980931|NCT00872079|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33980932|NCT01045096|RANDOMIZED|PARALLEL||||NONE||||||
33980933|NCT03213886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980934|NCT01214226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980935|NCT02005965|||COHORT||PROSPECTIVE|||||||
33980936|NCT04031300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980937|NCT01548677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980938|NCT00001805||||TREATMENT||||||||
33980939|NCT05669768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078352|NCT06135844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be divided into two groups: Control Group (mineral oil) and the Treatment Group (hand sanitizer). Each group will be asked to apply the product to the HSV-1 lesion. Sample Inclusion Criteria: For the purpose of this study participants must be in the early prodromal stage of an HSV-1 outbreak (less than 24 hours from initial symptom), with the visible manifestation of a lesion, 18 years or older, capable of following daily treatment instructions, willing to complete a daily journal and willing to come to either clinic twice for photos during the duration of the lesion (day 3 and when the lesion has healed or the crust has fallen off the lesion).||||
34078353|NCT06163001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078354|NCT03589807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078355|NCT01832181|||COHORT||PROSPECTIVE|||||||
34078356|NCT04958876|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33898037|NCT04977505|||COHORT||RETROSPECTIVE|||||||
34078357|NCT00497432|||CASE_CONTROL||PROSPECTIVE|||||||
34078358|NCT04449965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator will be blinded to whether or not the patients are receiving either active treatments or placebo, and assignments will be concealed throughout the study. The patients will know if they are in the nasal gel spray or rinse group but will be blinded to whether or not they are receiving the active treatment or placebo if they are randomized into the rinse group.||t|f|t|f
34078359|NCT04776408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During this period, all patients were total sedation using continuous infusion, to prevent any spontaneous breathing .All patients were ventilated using a ventilator|Moderate to severe ARDS patient on mechanical ventilation in Far Eastern Memorial Hospital MICU|t|f|f|f
34078360|NCT01967160|||COHORT||PROSPECTIVE|||||||
34078361|NCT03736655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078362|NCT04789408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078363|NCT03810157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078364|NCT01105104|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34078365|NCT00705094|||CASE_CONTROL||PROSPECTIVE|||||||
34078366|NCT05447065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34078367|NCT00001475||||TREATMENT||||||||
33898038|NCT06364748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898039|NCT05237544|||OTHER||OTHER|||||||
33898040|NCT00091793|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898041|NCT02185469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898042|NCT02403206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898043|NCT00001737||||TREATMENT||||||||
33898044|NCT06008379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34078368|NCT00215891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078369|NCT05554029|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34078370|NCT03666442|NA|SINGLE_GROUP||TREATMENT||NONE||a group of patients receive 4 cycle of Xelox chemotherapy, MRI,TRUS, DE,endoscopy, blood DNA test,before, between and after chemotherapy was compared to detect the effect of chemotherapy in 2 cycles.||||
34078371|NCT04152681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078372|NCT02479555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078373|NCT01299350|RANDOMIZED|PARALLEL||||NONE||||||
34078374|NCT06276374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078375|NCT04018495|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078376|NCT06277297|||COHORT||RETROSPECTIVE|||||||
34078377|NCT01598805|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33768433|NCT03331627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|"1. intratympanic gel injection followed by 12 weeks oral treatment~2. intratympanic gel injection followed by 12 weeks oral treatment placebo~3. intratympanic gel injection placebo followed by 12 weeks oral treatment placebo"|t|f|t|f
33768434|NCT04878016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled|t|t|t|f
33768435|NCT01440127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768436|NCT03470714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768437|NCT03350659|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label clinical trial.||||
33768438|NCT05240833|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768439|NCT02319733|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768440|NCT00235443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768441|NCT03986710|||COHORT||PROSPECTIVE|||||||
33768442|NCT06109506|||COHORT||RETROSPECTIVE|||||||
33768443|NCT03609125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768444|NCT00734214|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768445|NCT05464576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants receive the same intervention||||
33768446|NCT04959149|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33768447|NCT04501302|||OTHER||PROSPECTIVE|||||||
33768448|NCT05505253|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768449|NCT03771157|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768450|NCT02318719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33768451|NCT01296490|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768452|NCT02569450|||COHORT||PROSPECTIVE|||||||
33768453|NCT03329820|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768454|NCT06155084|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33768455|NCT06211387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768456|NCT02380508|RANDOMIZED|PARALLEL||||NONE||||||
33768457|NCT02859467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768458|NCT03523182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768459|NCT03675074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768460|NCT01781260|||COHORT||PROSPECTIVE|||||||
33768461|NCT05928715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768462|NCT02587559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33768463|NCT00061230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33768464|NCT01696318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078378|NCT00856791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768465|NCT05261503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33768466|NCT00849082||||TREATMENT||||||||
33768467|NCT00240526|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768468|NCT06488521|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33768469|NCT05859633|||CASE_ONLY||PROSPECTIVE|||||||
33768470|NCT04070677|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078379|NCT04620577|||COHORT||PROSPECTIVE|||||||
34078380|NCT05010213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective randomized controlled clinical trial|f|f|f|t
33768471|NCT05964881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768472|NCT04514471|RANDOMIZED|PARALLEL||OTHER||NONE||Open label, between-subject, randomized multi-center pilot study||||
33768473|NCT01154894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768474|NCT00002536||||TREATMENT||||||||
33768475|NCT03240341|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768476|NCT01562002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768477|NCT04711070|||COHORT||PROSPECTIVE|||||||
33768478|NCT06241690|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768479|NCT02394041|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33768480|NCT03790514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768481|NCT02450864|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33768482|NCT02761174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768483|NCT02430818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768484|NCT05671367|||COHORT||RETROSPECTIVE|||||||
33768485|NCT01247519|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33768486|NCT02822560|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33768487|NCT04867876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768488|NCT05605717|||OTHER||CROSS_SECTIONAL|||||||
33768489|NCT05276063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768490|NCT04736017|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The study is a randomized, double-blind, sham-controlled cross-over trial.|t|t|f|t
33768491|NCT05713812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768492|NCT05697549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768493|NCT03683966|||COHORT||PROSPECTIVE|||||||
33768494|NCT02810730|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768495|NCT04071119|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33768496|NCT00380120|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768497|NCT06320522|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33768498|NCT00812513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768499|NCT06323811|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||5 groups of patients (MINOCA, myocarditis, Takotsubo cardiomyopathy, SCAD, NSTEMI) will undergo CMR with 3D perfusion in the acute setting (within 10 days after the event) and post convalescence (after 3 months)|f|f|t|f
33768500|NCT01287637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768501|NCT00957788|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768502|NCT04636606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768503|NCT00612703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768504|NCT01293188|||COHORT||PROSPECTIVE|||||||
33768505|NCT01828190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768506|NCT02414022|||OTHER||PROSPECTIVE|||||||
33768507|NCT05576363|||COHORT||PROSPECTIVE|||||||
33768508|NCT02335086|||COHORT||PROSPECTIVE|||||||
33768509|NCT03621722|RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient will be randomly assigned to a group based on their primary symptoms. The RN will be communicating with the patient for assessments, administering medications, and submitting results collected into the EPIC system.|Patients receiving Elequil Aromatabs(treatment cohort) and patients receiving Standard of care (control cohort). In addition, patients will be receiving PRN antiemetic or PRN anxiolytics||||
33768510|NCT02749058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768511|NCT05634720|NA|SINGLE_GROUP||TREATMENT||NONE||We will include both patients planned to undergo surgery before chemotherapy, as well as patients planned to receive systemic chemotherapy before surgery. This will allow us to test the safety and feasibility of adding single-dose neoadjuvant HA chemotherapy prior to surgery across the real-world treatment strategies employed in typical clinical practice. All patients receive HA chemotherapy in addition to standard-of-care surgery and systemic chemotherapy, so as not to withhold the treatment approach currently associated with best outcomes.||||
33768512|NCT00478764|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768513|NCT04835896|NA|SEQUENTIAL||TREATMENT||NONE||||||
33768514|NCT04192513|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This study is Observer Blinded|"A randomized, observer-blinded, vehicle controlled, single dose application, dose escalating bilateral comparison study of DBI-001 Gel vs. Placebo in the patients with Atopic Dermatitis (AD) affecting the antecubital areas and/or posterior popliteal areas.~Subjects meeting the inclusion/exclusion criteria and having moderate to heavy growth of S. aureus from a sample collected at screening from an area of dermatitis on at least one arm or at least one leg will be enrolled into the study. Microbiological samples will be collected from all the designated sites on the arms or leg and all subjects will be treated with a single application of the assigned test articles applied by the unblinded treating investigator at the baseline visit."|f|f|f|t
33768515|NCT05343117|||COHORT||OTHER|||||||
33768516|NCT04033172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768517|NCT01243073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768518|NCT02532959|||CASE_ONLY||PROSPECTIVE|||||||
33768519|NCT05561062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|t|f|f
33768520|NCT05407532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||90 patients will be recruited and randomly assigned to three groups: the oral care group, the oral management group, and the standard care group.|t|f|f|t
33768521|NCT03786796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768522|NCT04177381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33980940|NCT05839613|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The design of this study is a two parallel arms, followed during 12 months, randomized (1:1 ratio) as follow:~* 200 patients in the experimental group with PG/TDM intervention (PG/TDM group).~* 200 patients in Control group with the SOC group."||||
33980941|NCT01408966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980942|NCT01653626|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
33980943|NCT02715869|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33980944|NCT05670171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768523|NCT05054127|||COHORT||PROSPECTIVE|||||||
33768524|NCT03169192|||COHORT||PROSPECTIVE|||||||
33768525|NCT02257255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33768526|NCT03959592|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Double-blind, placebo-controlled trial|t|f|t|f
33768527|NCT04563390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial with two treatment conditions and one WL control condition.|t|f|f|f
33768528|NCT03320460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Control group will be treated with clobetasol propionate 0.05% gel for 30 consecutive days and the laser device will be positioned over the lesion but will be switched off to mask the treatment. The experimental group will be treated with placebo gel for 30 consecutive days to mask the treatment and patients will receive laser treatment twice a week during 1 month for PBM|Control group Experimental Group|t|f|t|t
33768529|NCT02157857|||COHORT||RETROSPECTIVE|||||||
33980945|NCT04206644|||OTHER||CROSS_SECTIONAL|||||||
33980946|NCT03286348|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33980947|NCT00242346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33980948|NCT00041808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33980949|NCT04639765|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33980950|NCT03407365|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980951|NCT00556127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980952|NCT00448175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768530|NCT02384317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980953|NCT05554770|||OTHER||PROSPECTIVE|||||||
33980954|NCT03538587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33980955|NCT01669538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980956|NCT00322257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980957|NCT06002048|||COHORT||CROSS_SECTIONAL|||||||
33980958|NCT01541150|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980959|NCT04014049|||COHORT||RETROSPECTIVE|||||||
33980960|NCT03859388|||COHORT||PROSPECTIVE|||||||
33980961|NCT02396875|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33980962|NCT00628888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980963|NCT05129098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33980964|NCT03772496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33980965|NCT03417128|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33980966|NCT02051309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980967|NCT00377871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980968|NCT03280797|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33980969|NCT02359331|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33980970|NCT01913990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980971|NCT03229005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33980972|NCT04661748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33980973|NCT05944705|||CASE_CONTROL||PROSPECTIVE|||||||
33980974|NCT00659321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768531|NCT06471244|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768532|NCT05805683|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel Assignment|t|f|t|t
33980975|NCT02603783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33980976|NCT02231645|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33980977|NCT06114706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel groups each with different interventions.||||
33980978|NCT06261866|||COHORT||PROSPECTIVE|||||||
33980979|NCT01843608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980980|NCT04012632|||CASE_CONTROL||RETROSPECTIVE|||||||
33980981|NCT00998023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33980982|NCT01505205|||COHORT||PROSPECTIVE|||||||
33980983|NCT02514265|||COHORT||PROSPECTIVE|||||||
33721250|NCT04212247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed if they will receive WBT or the control condition. At the end of the study they will receive this information.|This is a pilot study, designed as a randomized (1:1) controlled trial, comparing WBT vs a control condition. The patients will receive a baseline assessment to confirm the diagnosis of systemic sclerosis, then socio-demographic information, information on pharmacological/non-pharmacological treatments, on the history of medical diseases and on the psychological status will be collected. Thereafter, the subjects will be randomly assigned to WBT or to a control condition. The subjects will be re-assessed at the end of session 4, 8 of treatment, and at 6-month follow-up.|t|f|f|f
33768533|NCT04691713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768534|NCT00406458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768535|NCT05518760|||CASE_CONTROL||PROSPECTIVE|||||||
33980984|NCT06412549|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The first phase of the project included 554 participants (baseline sample) and the second phase included 746 participants (intervention sample). Totaling 1,300 patients with external ventricular drain and/or intracranial pressure monitoring catheter.||||
33898045|NCT04188158|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Intervention Group: Neoadjuvant chemotherapy + surgery + adjuvant chemotherapy~* Control group: surgery + adjuvant chemotherapy"||||
33898046|NCT00861042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980985|NCT03187678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33980986|NCT03443778|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33980987|NCT04697394|||COHORT||PROSPECTIVE|||||||
33980988|NCT02710201|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33980989|NCT03157388|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||15 patients with alcoholic hepatitis will be consecutively included and compared to a historical cohort of AH patients||||
33980990|NCT00477347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33980991|NCT04137393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33980992|NCT02696070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980993|NCT00996671|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33980994|NCT02592967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898047|NCT04982913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898048|NCT03019055|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study is divided into two phases. Phase 1 and Phase 1b. Phase 1: consists of 2 cohorts; dose escalation and dose expansion. The CAR-T cells were given over 2 days.~In the phase 1 portion, there will be a dose escalation cohort to determine the safe CAR-20/19-T cell dose in patients with CLL/SLL and NHL. Once the desired dose has been identified there will be a 6 patient dose expansion phase at the specified dose level.~Phase 1b: In the Phase 1b portion of the study, we will test the safety of unfractionated CAR-T cells utilizing the safe dose identified in the phase 1 portion (2.5 x 10\^6 cells/kg)."||||
33898049|NCT03147027|||OTHER||PROSPECTIVE|||||||
33898050|NCT01893177|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898051|NCT01738035|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33898052|NCT00960557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898053|NCT00783289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898054|NCT03502746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898055|NCT03160144|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
33898056|NCT01539629|||CASE_ONLY||PROSPECTIVE|||||||
33898057|NCT02944747|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||4 parallel arm superiority community based randomized control trial||||
33898058|NCT06108479|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33980995|NCT01261078|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33980996|NCT05214768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33980997|NCT06007456|||OTHER||PROSPECTIVE|||||||
33898059|NCT06411184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898060|NCT04526977|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898061|NCT06289725|||COHORT||PROSPECTIVE|||||||
33898062|NCT04705480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898063|NCT00193843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898064|NCT01164501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898065|NCT03431948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be enrolled in parallel based on physician preference and slot availability.||||
33898066|NCT00502060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898067|NCT05734937|NA|SINGLE_GROUP||OTHER||NONE||||||
33898068|NCT01513915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898069|NCT03373786|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33898070|NCT06244186|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||Participants were randomly assigned to either the placebo or probiotics group, receiving continuous administration for 12 weeks. Measurements of weight, BMI, and body fat were taken on days 0, 28, 56, and 84 of the treatment period. Additionally, 15 mL of fasting blood was drawn on both the first and 84th day.|t|t|f|f
33898071|NCT01859351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898072|NCT01598818|||OTHER||PROSPECTIVE|||||||
33980998|NCT01973049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33980999|NCT03257085|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the low-carbohydrate, high-fat and high-carbohydrate, moderate-fat diets masking is not feasible.|Randomised pilot study||||
33981000|NCT01840969|||CASE_ONLY||PROSPECTIVE|||||||
33981001|NCT02793453|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33981002|NCT02501057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981003|NCT04757090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981004|NCT03096821|||OTHER||PROSPECTIVE|||||||
33981005|NCT00969566|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981006|NCT00683293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981007|NCT02679183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33981008|NCT00569062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981009|NCT01022047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981010|NCT04799028|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study is a double-blinded study. The identity of specific product will be masked to subjects, support staff, investigators and sponsor's personnel except the manufacture and quality unit at Nestle (production factory).||t|f|t|t
33981011|NCT04665947|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a first-in-human 3 + 3 study design to identify dose limiting toxicity and recommended phase 2 dose||||
33981012|NCT04208503|||COHORT||PROSPECTIVE|||||||
33981013|NCT05587556|||CASE_ONLY||RETROSPECTIVE|||||||
33981014|NCT00081783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981015|NCT05339100|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981016|NCT06268522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Behavioral|f|t|t|t
33981017|NCT02506582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981018|NCT05097326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981019|NCT01870180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33981020|NCT03605238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981021|NCT06160037|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Those involved in conducting assessments of study participants have been masked to treatment assignment for the 30-year period following study enrollment during pregnancy.|Longitudinal cohort study|f|f|f|t
33981022|NCT03889756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be told what medication they are receiving; physicians absent from the infusion paradigm will perform blinded clinical efficacy ratings.|Phase 1 is a double-blind, midazolam-controlled parallel design trial; Phase 2 is an open extension.|t|f|f|t
33981023|NCT05240196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Patients will be randomised to the following groups;~1. Control~2. Binaural music~3. Non binaural music"||||
33981024|NCT05681208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33981025|NCT05907616|NA|SINGLE_GROUP||OTHER||NONE||||||
33981026|NCT00020345||||TREATMENT||||||||
33981027|NCT01061125|||CASE_CONTROL||PROSPECTIVE|||||||
33981028|NCT00757874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981029|NCT04947748|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33981030|NCT04902157|||COHORT||PROSPECTIVE|||||||
33981031|NCT03165552|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33981032|NCT06225232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981033|NCT02183571|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981034|NCT06182020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981035|NCT00584298|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33898073|NCT00055198|NON_RANDOMIZED|||TREATMENT||NONE||||||
33981036|NCT04855981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|whole-body vibration and aerobic exercise|t|f|f|t
33898074|NCT04901897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33898075|NCT04512079|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study participants will be randomized in a 1:1:1 fashion to 1 of 3 arms:~1. Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min)~2. Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)~3. Apixaban (5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)"||||
33898076|NCT04993742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Coded histopathology slides will be sent to pathologist for evaluation with only a study number|The study is a repeated measures, longitudinal design||||
33898077|NCT06060730|||OTHER||RETROSPECTIVE|||||||
33898078|NCT04054908|||COHORT||PROSPECTIVE|||||||
33898079|NCT06334835|||COHORT||PROSPECTIVE|||||||
33898080|NCT06201299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981037|NCT04986332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three parallel non-randomized groups||||
33981038|NCT01391793|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981039|NCT03388320|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33981040|NCT02351154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981041|NCT00708019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981042|NCT06233383|||OTHER||CROSS_SECTIONAL|||||||
33981043|NCT02171754|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981044|NCT02854579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981045|NCT05211297|||COHORT||PROSPECTIVE|||||||
33768536|NCT05960383|||COHORT||PROSPECTIVE|||||||
33768537|NCT03586206|||COHORT||PROSPECTIVE|||||||
33768538|NCT01572246|||COHORT||PROSPECTIVE|||||||
33839250|NCT04915092|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Families in the control arm will receive a newsletter|Families in the intervention arm will receive the app|t|f|f|f
33839251|NCT05775172|||COHORT||PROSPECTIVE|||||||
33839252|NCT02900547|||||PROSPECTIVE|||||||
33839253|NCT05656014|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898081|NCT02813538|||CASE_ONLY||PROSPECTIVE|||||||
33721251|NCT03913884|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33839254|NCT02627118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839255|NCT04692077|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839256|NCT00508989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839257|NCT05727215|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839258|NCT02859077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839259|NCT00004877||||TREATMENT||||||||
33839260|NCT01112436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839261|NCT05486312|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, exploratory, single-arm study to evaluate the overall effects of use of an abbreviated version of CT-155 in adults diagnosed with schizophrenia||||
33839262|NCT04206423|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839263|NCT06156553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839264|NCT04706689|||COHORT||PROSPECTIVE|||||||
33839265|NCT06319742|||COHORT||PROSPECTIVE|||||||
33839266|NCT05740813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839267|NCT04196192|||COHORT||RETROSPECTIVE|||||||
33839268|NCT03895047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839269|NCT01436552|||COHORT||PROSPECTIVE|||||||
33839270|NCT03642847|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33839271|NCT02956837|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33839272|NCT01492751|||COHORT||PROSPECTIVE|||||||
33839273|NCT03137719|||COHORT||PROSPECTIVE|||||||
33839274|NCT06179121|||COHORT||PROSPECTIVE|||||||
33839275|NCT00161369|||DEFINED_POPULATION||PROSPECTIVE|||||||
33839276|NCT04544150|||CASE_ONLY||PROSPECTIVE|||||||
33839277|NCT05413239|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33839278|NCT05369429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33839279|NCT05226936|||COHORT||PROSPECTIVE|||||||
33839280|NCT06437951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839281|NCT04518280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768539|NCT03678259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|open-label|The first three patients enrolled in the trial (Part 1) will take part in a dose-escalation study and will receive a single IV dose 11.1 MBq (0.3 mCi; n = 1), 37 MBq (1 mCi; n = 1) or 74 MBq (2 mCi; n = 1) of 124I-p5+14 Injection. The trial then will be opened to include another 54 patients who will receive a single IV bolus injection of 2 mCi 124I-p5+14 Injection. Every patient participating will receive \< 2 mg of peptide p5+14. The study comprises five parts.In Part 2, the trial will enroll SA patients with confirmed AL, ATTR, ALECT2, or other forms of amyloidosis.In Part 3, the trial will study asymptomatic subjects with genetically confirmed mutation of the transthyretin gene.Part 4 will include five healthy control subjects.Part 5 will recruit previously enrolled subjects from Parts 2 or 3 who received a 2 mC dose of 124I-p5+14 Injection and had images confirming the presence of abnormal amyloid deposits for a second exposure to 124I p5+14 Injection and second PET/CT scan.||||
34078381|NCT04362124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Double-blind trial. The blinding of the investigational vaccine will be maintained using an opaque label for the two products (vaccine and placebo).~The subjects, who collect the data (e.g., investigator and coordinator) and who evaluate the data (e.g., statistician) will be blinded. One or more pharmacists/vaccine administrators designated from the facility will not be blinded. These designated unblinded individuals will maintain the blindness of the investigational vaccine and will not be involved in evaluating the safety of the subjects."|"A multicenter, double-blind, randomized, phase III clinical trial, divided into two groups (vaccine and placebo) using a 1: 1 allocation ratio.~The treatment allocation will be performed according to random code."|t|t|t|t
34078382|NCT05660096|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cerebral palsy patients will undergo gait analysis without the sleeve in the first phase of the study. The same patients will then under gait analysis with the sleeve in the second phase of the study.||||
33768540|NCT01925261|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33898082|NCT02396862|||COHORT||PROSPECTIVE|||||||
33898083|NCT00789204|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33898084|NCT02225886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898085|NCT00379938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33898086|NCT02990884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33898087|NCT05890391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The female individuals were randomly divided into the TRE or ERD groups in an unbiased manner using a computer-generated block randomisation list.|t|t|t|t
33898088|NCT00852644|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants to receive Cyberknife radiation therapy in 4 doses over two weeks. Dose will be determined using a dose-escalation plan.||||
33898089|NCT01166269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898090|NCT00334750|||COHORT||PROSPECTIVE|||||||
33898091|NCT03309670|||CASE_ONLY||RETROSPECTIVE|||||||
33898092|NCT00546351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898093|NCT05171738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898094|NCT03590561|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33898095|NCT02067221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898096|NCT03796741|||COHORT||PROSPECTIVE|||||||
33898097|NCT00928915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898098|NCT06398392|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898099|NCT01430195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898100|NCT04307966|||COHORT||PROSPECTIVE|||||||
33898101|NCT02739412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898102|NCT00330824|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33981046|NCT02398071|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33981047|NCT01402037|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981048|NCT04978532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981049|NCT06443307|||COHORT||PROSPECTIVE|||||||
34078383|NCT05362708|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Methodology of virtual reality hypnosis prevents masking participants and experimenter.|Patients who are not interested will be considered as a control group.||||
34078384|NCT00987168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078385|NCT05707416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768541|NCT01529671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981050|NCT01553838||CROSSOVER||DIAGNOSTIC||NONE||||||
33981051|NCT05833386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981052|NCT03597490|||COHORT||PROSPECTIVE|||||||
33981053|NCT02381171|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33981054|NCT00663507|||||PROSPECTIVE|||||||
33721252|NCT00503308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33768542|NCT04105972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768543|NCT01827254|||COHORT||RETROSPECTIVE|||||||
33768544|NCT01391143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768545|NCT02238197|||COHORT||PROSPECTIVE|||||||
33768546|NCT03103022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768547|NCT00095823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768548|NCT01996072|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768549|NCT00280137|||||PROSPECTIVE|||||||
33981055|NCT05868447|||COHORT||PROSPECTIVE|||||||
33768550|NCT04261179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981056|NCT05938556|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be randomly assigned to receive either four months of group coaching or treatment as usual. After fourth months of the assigned treatment, the two arms will switch for another four months of either group coaching or treatment as usual.||||
33981057|NCT03091296|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981058|NCT02472522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33981059|NCT02684578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981060|NCT02796664|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981061|NCT00770510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981062|NCT02385396||PARALLEL||TREATMENT||NONE||||||
33981063|NCT05437809|NA|SINGLE_GROUP||OTHER||NONE||||||
33981064|NCT00762307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078386|NCT05894213|||OTHER||CROSS_SECTIONAL|||||||
34078387|NCT02926963|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078388|NCT00989222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078389|NCT02136537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078390|NCT05743153|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078391|NCT03280407|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open label, randomized phase II screening trial allocating eligible patients to either standard treatment for rectal cancer or experimental preoperative combination chemotherapy.||||
34078392|NCT02709148|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078393|NCT02582476|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34078394|NCT01268852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking was done with generated cmputer randomisation and sealed opaque enveloppes|Compare treatment between two appliance systems|f|f|t|t
34078395|NCT06426667|||COHORT||PROSPECTIVE|||||||
34078396|NCT02396225|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981065|NCT00813046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981066|NCT03213119|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33981067|NCT05639062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981068|NCT00665730|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33981069|NCT06497322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized controlled intervention (1:1 randomization). Specifically, 1 control group (usual care) and 1 intervention group (HIIT aerobic training), both receiving neoadjuvant therapy (immunochemotherapy) by infusion, as follows; Paclitaxel 80mg/m2 q1w x12, carboplatin 1.5 AUC q1w x12, pembrolizumab 200mg q3w x4, followed by epirubicin 90mg/ m2 q3w x 4, cyclophosphamide 600mg m2 q3w x 4, pembrolizumab 200mg q3w x 4. The intervention period (oncologic therapy + exercise intervention) is approximately 6 months (including screening phase and baseline data collection, tao), data collection after three months (ta1), after completion of neoadjuvant therapy (\~six months ta2), during which participants will complete the exercise intervention + oncologic treatment on site. Surgery will take place 2-3 weeks later.|f|f|f|t
33981070|NCT05064462|||COHORT||PROSPECTIVE|||||||
33981071|NCT01820026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981072|NCT02844803|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33981073|NCT05933005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This clinical trial is conducted using a double-blind design, requiring both the evaluators and participants to maintain blindness. The randomization table is prepared by an independent statistician who seals each copy of the randomization table separately after the allocation of the investigational device and control device.||t|t|t|f
33981074|NCT01287013|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981075|NCT03909659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33981076|NCT02582541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981077|NCT02886468|NA|SINGLE_GROUP||OTHER||NONE||||||
33981078|NCT05064319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981079|NCT01570699|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981080|NCT00620763|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33981081|NCT00012857|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33981082|NCT04827771|||COHORT||RETROSPECTIVE|||||||
33981083|NCT00365300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078397|NCT05291624|||COHORT||PROSPECTIVE|||||||
34078398|NCT02894333|||OTHER||CROSS_SECTIONAL|||||||
34078399|NCT02314858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078400|NCT06238024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078401|NCT02233218|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34078402|NCT05901337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||f|f|f|t
34078403|NCT05974566|||COHORT||RETROSPECTIVE|||||||
34078404|NCT05726487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33981084|NCT01581970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768551|NCT01053754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981085|NCT03618953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981086|NCT04442165|||COHORT||PROSPECTIVE|||||||
33981087|NCT02057848|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33981088|NCT03482063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomised, placebo-controlled, double-blind, parallel groups design|t|t|t|t
33981089|NCT03619005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981090|NCT03482440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33981091|NCT06233409|||COHORT||PROSPECTIVE|||||||
33981092|NCT04069637|||CASE_CONTROL||PROSPECTIVE|||||||
33981093|NCT03746093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981094|NCT06263348|NA|SINGLE_GROUP||TREATMENT||NONE||The marketed product - Dorzagliatin tablet (HuaTangNing®) is used as the study drug. During this study, the dosage and administration of Dorzagliatin tablets will be completely in accordance with the investigator's judgment based on the package insert and the patient's condition.||||
33981095|NCT03897088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981096|NCT02025465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981097|NCT02977026|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34078405|NCT01981668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078406|NCT04349566|||CASE_CONTROL||PROSPECTIVE|||||||
34078407|NCT05172713|||CASE_CONTROL||RETROSPECTIVE|||||||
34078408|NCT05344222|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An external investigator was assigned to perform randomization. Containing the type of treatment to be used inside, unidentified envelopes were drawn among the participants, resulting in two groups.||t|t|f|t
34078409|NCT00799084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078410|NCT02481076|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078411|NCT03690713|||COHORT||PROSPECTIVE|||||||
34078412|NCT05988567|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34078413|NCT04226417|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34078414|NCT05959265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078415|NCT04191889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078416|NCT01289886|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33768552|NCT04545216|||COHORT||PROSPECTIVE|||||||
34024552|NCT03546920|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|This is a feasibility trial.|Step wedge design. Randomization occurred at the facility level. Facilities are randomized to the order of starting accrual in control phase and then transitioning to intervention phase once control sample has accrued.||||
34024553|NCT02549586|NA|SINGLE_GROUP||TREATMENT||NONE||Pt are receiving everolimus in combination with autologous stem cell transplant to induce tolerance||||
33768553|NCT04021992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768554|NCT03933332|||COHORT||PROSPECTIVE|||||||
33768555|NCT04100460|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Study personnel will remain blinded to the sequence assigned to subjects throughout the study. A set of sealed unblinding envelopes will be provided to the Clinical Investigator for use in an emergency situation where a subject's health is at risk.|The study is a randomized, placebo-controlled, crossover, singe-center trial with one screening visit and 3 test periods separated by minimum 2 - week washout periods.|t|f|t|f
33768556|NCT01325649|||CASE_CONTROL||PROSPECTIVE|||||||
33768557|NCT01267253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768558|NCT01642082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768559|NCT04825444|||COHORT||PROSPECTIVE|||||||
33768560|NCT02109198|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33768561|NCT00472771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024554|NCT03761264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024555|NCT03929276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024556|NCT01808820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024557|NCT04472793|||CASE_CONTROL||PROSPECTIVE|||||||
34078417|NCT05036213|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||This is a randomized, double-blind, placebo-controlled, cross-over design. This means that all subjects will complete both supplementation phases in a randomized order.|t|f|t|f
34103010|NCT03796286|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The study site will be provided pre-packaged, sealed containers of control (a bar with no fiber) and active study products (a bar with 10 grams of fiber and a bar with 20 grams of fiber). Each product container will be labeled with the lot number, expiration date, and blinded product code.|Randomized, controlled, three-treatment, crossover trial with one screening/baseline visit and three test visits. At each testing visit, the study product (a bar) will be consumed with water.|t|t|t|t
33768562|NCT01493960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768563|NCT03452605|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33768564|NCT05444400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768565|NCT01642069|||COHORT||RETROSPECTIVE|||||||
33768566|NCT04940182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo.|Two groups (Group A and Group B) in a 1:1 ratio: Group A - investigational product; Group В - Placebo.|t|f|t|f
33768567|NCT06468072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768568|NCT01255943|||COHORT||PROSPECTIVE|||||||
33768569|NCT00003379||||TREATMENT||||||||
33768570|NCT03239405|||OTHER||OTHER|||||||
33768571|NCT03118375|||COHORT||PROSPECTIVE|||||||
33768572|NCT03895736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768573|NCT05126979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33768574|NCT00330512|||COHORT||RETROSPECTIVE|||||||
33768575|NCT04573413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768576|NCT00172081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898103|NCT04677842|||COHORT||OTHER|||||||
33898104|NCT00465738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898105|NCT00550238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898106|NCT06587568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898107|NCT04282577|||COHORT||CROSS_SECTIONAL|||||||
33898108|NCT04475094|||CASE_ONLY||PROSPECTIVE|||||||
33898109|NCT04229147|||COHORT||CROSS_SECTIONAL|||||||
33898110|NCT00346515|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33898111|NCT04553887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898112|NCT05308108|||COHORT||PROSPECTIVE|||||||
33768577|NCT01967056|||COHORT||PROSPECTIVE|||||||
33768578|NCT01421485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33768579|NCT01085565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898113|NCT01998646|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33898114|NCT01914718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898115|NCT05413694|NA|SINGLE_GROUP||OTHER||NONE||||||
33898116|NCT05127772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898117|NCT05045053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|computer based masking||t|f|f|f
34024558|NCT03190330|NA|SINGLE_GROUP||OTHER||NONE||||||
33898118|NCT01240018|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33898119|NCT05621512|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomization||||
33898120|NCT01557010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078418|NCT03988933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a partially double-blinded trial. Participation in control arm will be open label while participation in the two intervention arms will be double-blinded.|"Participants will be randomized 1:1:1 to be in control arm or in one of the two intervention arms.~Intervention arms:~Arm 1: 60 doses daily self-administered rifampin at 20 mg/kg (2R20 - maximum 1200 mg/day).~Arm 2: 60 doses daily self-administered rifampin at 30 mg/Kg (2R30) - maximum 1800 mg/day).~Comparator:~Arm 3 (standard): 120 doses daily self-administered rifampin at 10mg/kg (4R10maximum 600mg per day)."|t|t|t|f
34078419|NCT02546648|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34078420|NCT05998681|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|This study was designed as a randomized controlled trial|This study was designed as a randomized controlled trial|t|f|f|f
34078421|NCT02557399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078422|NCT03934671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078423|NCT02043288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078424|NCT04025541|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078425|NCT04145856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078426|NCT06492434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33898121|NCT00998101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898122|NCT04950231|||CASE_ONLY||PROSPECTIVE|||||||
34078427|NCT04637841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078428|NCT01854749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078429|NCT03744442|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34078430|NCT01896193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078431|NCT03049878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, split-mouth, placebo-controlled, double-blind clinical trial|t|f|t|t
34078432|NCT02417753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078433|NCT03904420|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34078434|NCT02738112|||COHORT||PROSPECTIVE|||||||
34078435|NCT03136718|||CASE_ONLY||PROSPECTIVE|||||||
34078436|NCT02862080|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078437|NCT04381780|NA|SINGLE_GROUP||TREATMENT||NONE||Open pilot study||||
34078438|NCT01361750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078439|NCT05989022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparison between both modalities in single patients||||
33898123|NCT03088150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898124|NCT04950738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||multicenter parallel arm double-blind randomized control trial|t|t|t|t
33898125|NCT00282802|||COHORT||PROSPECTIVE|||||||
34078440|NCT02175225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078441|NCT01534728|||CASE_ONLY||PROSPECTIVE|||||||
34078442|NCT00526318|RANDOMIZED|||TREATMENT||||||||
34078443|NCT00432900|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078444|NCT03658551|||CASE_CONTROL||PROSPECTIVE|||||||
34078445|NCT00822289|||COHORT||PROSPECTIVE|||||||
34078446|NCT03740269|||OTHER||OTHER|||||||
34078447|NCT00028717|RANDOMIZED|||TREATMENT||||||||
34078448|NCT04657939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078449|NCT01623921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078450|NCT05421065|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34078451|NCT06514079|NA|SINGLE_GROUP||TREATMENT||NONE||Pediatric patients aged less than 14 years, with refractory benign esophageal strictures and received a dilatation therapy without triamcinolone injections were included in our study||||
34078452|NCT04148547|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34078453|NCT05343663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33721253|NCT01136850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33898126|NCT04416516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078454|NCT02291029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34078455|NCT00438074|||CASE_ONLY||PROSPECTIVE|||||||
33898127|NCT01570491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33898128|NCT03291002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, cohort-based, dose escalation and expansion study||||
33898129|NCT02785757|NA|SINGLE_GROUP||OTHER||NONE||||||
33898130|NCT02214589|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33898131|NCT05400460|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective randomized cohort of patients with anterior cruciate ligament rupture assigned to three procedures and followed up two years after surgery.In this trial, patients diagnosed with anterior cruciate ligament rupture in the outpatient clinic were randomly assigned to the following three procedures: central axial single-bundle reconstruction (CASBR), anatomical single-bundle reconstruction (ASBR), and double-bundle reconstruction (DBR).|t|t|t|t
33898132|NCT03078361|RANDOMIZED|PARALLEL||SCREENING||NONE||After completion of baseline assessments, participants will be randomized so that the study personnel are unaware of the intervention assignment at the time of the baseline assessment.||||
34024559|NCT00867503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024560|NCT02552303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34024561|NCT04129359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Cluster RCT in general practices, which will recruit successive pregnant women. All practices will receive training in data recording and assessment, and half will receive additional training in use of the online intervention. Our original sample size calculation required 1,000 participants, in 100 clusters of 10 participants per practice. This would allow us to detect a difference of two points in the SDQ Total Difficulties Scale score (an effect size of 0.3) with 90% power at a 2.5% significance level assuming the intraclass correlation coefficient was 0.06. We continued to recruit practices until COVID-19 restrictions prevented further recruitment of practices. We then made a decision to increase the cluster size, allowing participating practices to recruit up to 30 participants. We were also able to adjust our original estimate of the intra-class correlation coefficient based on our baseline data from 0.06 to 0.02 allowing us to reduce our target sample size from 1000 to 624.|f|f|f|t
34024562|NCT00255710||||SUPPORTIVE_CARE||NONE||||||
34024563|NCT04939194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024564|NCT04075591|NA|SINGLE_GROUP||OTHER||NONE||wavefront-guided LASIK monovision treatment||||
34024565|NCT03634865|||COHORT||RETROSPECTIVE|||||||
34024566|NCT01789723|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024567|NCT02066948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34024568|NCT04336943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024569|NCT01329549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024570|NCT05393518|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024571|NCT04648202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024572|NCT03038841|||OTHER||PROSPECTIVE|||||||
34024573|NCT06430398|||CASE_CONTROL||PROSPECTIVE|||||||
34024574|NCT01085721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024575|NCT04851535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024576|NCT01724086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024577|NCT03052010|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024578|NCT06369597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024579|NCT00593411|||COHORT||PROSPECTIVE|||||||
34024580|NCT00148005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024581|NCT05953090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024582|NCT00822718|||||PROSPECTIVE|||||||
34024583|NCT01758588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34024584|NCT04840537|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024585|NCT00999427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024586|NCT01279083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024587|NCT05312450|||COHORT||PROSPECTIVE|||||||
34024588|NCT04102280|NA|SEQUENTIAL||TREATMENT||NONE||prospective, open, controlled, cross-over (with randomized treatment sequences), interventional, multi-center||||
34024589|NCT03521739|||COHORT||PROSPECTIVE|||||||
34024590|NCT02485119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024591|NCT02459535|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024592|NCT02529644|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34024593|NCT05138991|NA|SINGLE_GROUP||SCREENING||NONE||||||
34024594|NCT01085396|||||PROSPECTIVE|||||||
34024595|NCT06399653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Devices will be masked to ensure both the research team involved in data collection and participants are blinded (double-blind study design). An unblinded member of the research team, not involved in data collection and subject contact, will assign randomization, provide device identification number, and keep the key linking condition to identification numbers.|Participants will be randomly assigned to receive either active or placebo stimulation, and will receive identical instructions on use of the device. Participants will remain in the same condition assigned at baseline and will be instructed to self-administer nVNS/sham at home for 7 days (2 mins bilaterally, 2x per day) and return for a follow-up visit. Stimulation will be administered by the examiner during a functional MRI scan during the baseline and the follow-up visit.|t|f|t|t
34024596|NCT01239134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024597|NCT03996629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024598|NCT04773301|RANDOMIZED|PARALLEL||TREATMENT||NONE||Low-intervention clinical trial||||
34078456|NCT05029687|NA|SINGLE_GROUP||TREATMENT||NONE||Study transitioned from a randomized controlled trial to a single group study. The total participants enrolled in the trial include all aspects of the study (including qualitative focus groups and interviews).||||
34078457|NCT03049826|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078458|NCT04073719|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Prospective randomized sample of 36 patients, in a nested cross over design.||||
34078459|NCT02361775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078460|NCT03492229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34078461|NCT00317746|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078462|NCT02121795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078463|NCT06109389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34078464|NCT03333980|||OTHER||CROSS_SECTIONAL|||||||
34078465|NCT05426408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The investigators who will perform the evaluation of the CMR investigations will be blinded to all clinical data.|Patients will be their own controls||||
34078466|NCT03179735|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34078467|NCT04321902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34078468|NCT05628701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The CRUISE study is a prospective, non-randomized, non-blinded, multi-center, controlled trial on satisfaction, QoL, function, and complications between IRA and IPAA and permanent stoma among adult UC patients subjected to subtotal colectomy||||
34078469|NCT04294537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078470|NCT06449469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078471|NCT05588986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078472|NCT03603197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078473|NCT06524986|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group underwent a program that aimed to enhance self-efficacy through computer games for a duration of 5 weeks, whereas the control group received regular nursing care.||||
34078474|NCT05510258|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two groups control and experimental included|f|t|f|f
34078475|NCT06359262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981098|NCT05261464|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|We blinded both investigators and patients using encapsulated drugs distribute from Siriraj's dispensary and randomly assign to our patients. These encapsulated drugs then were sealed from humidity and kept at temperature below 25 degree celsius . These drugs will not be kept for more than 1 week after encapsulated. These encapsulated were assigned according to serial number generate from nQuery program by pharmacist Siriraj's dispensary. In each package, the number from first to fourth encapsulated drugs were assigned from Siriraj's dispensary in order to prescribe to patient when HR can not reach target prior to CCTA.|"1. Extract patients who undergo routine Computed Tomography Coronary Angiography (CCTA) with heart rate (HR) \> 60 bpm at rest~2. Enroll patients using Inform consent from the first date of study period until reach the required sample size~3. Randomize patients to 1:1:1 using 6 block randomization by nQuery program~4. Assign sequential encapsulated drugs distribute from Siriraj's dispensary to patients according to randomization and protocol prior to CCTA.~5. Assigned encapsulated until patient reaches target HR or until full dose according to each drugs protocol prior to CCTA.~6. Continuous monitor blood pressure and heart rate every 15 minutes and closed observe side effects and complication until at least 1 hr after finish CCTA.~7. Review medical record and CCTA results, then fill in case record forms."|t|t|t|f
33981099|NCT04782648|||COHORT||RETROSPECTIVE|||||||
33981100|NCT02012920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078476|NCT00245024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981101|NCT04804800|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This study presents three groups of patients :~* The control group : The patients benefit from the care recommended by the HAS, relaxation times and body scan.~* The experimental group 1 : The patients benefit from the care recommended by the HAS, the virtual reality program and relaxation times and body scan.~* The experimental group 2 : The patients benefit from the care recommended by the HAS, the virtual reality program, the multi-sensory remediation and relaxation times and body scan."||||
33768580|NCT01265407|||FAMILY_BASED||PROSPECTIVE|||||||
33981102|NCT00733330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981103|NCT03707379|||COHORT||PROSPECTIVE|||||||
33981104|NCT02430870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981105|NCT01737190|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768581|NCT01684995||PARALLEL||TREATMENT||||||||
33768582|NCT03696875|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1: Matched-pair cluster randomized clinical trial. Phase 2: a quasi-experimental study.||||
33768583|NCT03393338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33768584|NCT03085251|NA|SINGLE_GROUP||OTHER||NONE||||||
33768585|NCT04422639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981106|NCT05270005|||COHORT||PROSPECTIVE|||||||
33981107|NCT01398384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981108|NCT05109546|||CASE_ONLY||RETROSPECTIVE|||||||
33981109|NCT05096780|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double-blinded||t|t|t|t
33981110|NCT02230007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981111|NCT02968186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981112|NCT05284890|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981113|NCT03365726|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33981114|NCT04908332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The infant-mother dyads will not be Know that there are two different interventions in each group. This leads to greater adherence to treatment.~The researchers: there will be two research assistants who will receive capacity regardless of the group of participants they are going to train, the main researcher will not carry out the training to the mothers and will be blinded.~The nursing assistant in charge of weighing the baby and the pediatrician who determines the time of the kangaroo position. They will be blinded."|Two interventions groups of 34 each, participated in the study. The first group received Nursing intervention Kangaroo Baby Massage KBM at home and the second group received Kangaroo position KP at home, the KBM will start when the infant arrives at home until they leave the kangaroo position. The KP will measure since the baby arrive at home until leave the kangaroo position.|t|t|t|t
33981115|NCT03354104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981116|NCT01011361|||COHORT||PROSPECTIVE|||||||
33981117|NCT03748082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33981118|NCT02011607|||CASE_ONLY||PROSPECTIVE|||||||
33981119|NCT06143722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized, prospective phase II trial.|f|f|f|t
33981120|NCT02082353|||COHORT||OTHER|||||||
33981121|NCT05829122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981122|NCT02645526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981123|NCT05334849|||COHORT||PROSPECTIVE|||||||
33981124|NCT04514198|||COHORT||PROSPECTIVE|||||||
33981125|NCT02475083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33981126|NCT01210456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981127|NCT05887297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly allocated to either intervention group or waitlist control. Intervention group will receive CBT-I intervention following randomisation. Waitlist control group will receive CBT-I after all measures have been completed.||||
33981128|NCT01444443|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981129|NCT05919966|||COHORT||RETROSPECTIVE|||||||
33981130|NCT03338972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898133|NCT04924725|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||The samples in each group will be sent for rapid onsite cytology evaluation (ROSE) and pathology evaluation. If diagnosis could be made after ROSE, the procedure will be stopped. Otherwise, the FNB with be repeated for at most six times in each group. In conventional group, if the diagnosis could be made within three times of FNB, we will inject Sonazoid and record the enhance pattern of the pancreatic lesion. If the diagnosis still undetermined, the patient will receive CEH-EUS-guided FNB as cross-over test.|t|f|f|t
33898134|NCT05629962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898135|NCT04804852|||COHORT||PROSPECTIVE|||||||
33898136|NCT00419250|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981131|NCT06028607|NA|SINGLE_GROUP||OTHER||NONE||All service users will be approached for inclusion in feasibility||||
33981132|NCT02590185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981133|NCT06004726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981134|NCT01091090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981135|NCT00643578|RANDOMIZED|CROSSOVER||||NONE||||||
33981136|NCT00394108|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981137|NCT04038060|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Sequential multiple assignment randomized trial (SMART)|f|f|t|f
33981138|NCT04842045|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial of a single 25 mg dose of psilocybin combined with repeated boluses of midazolam in medically and psychiatrically healthy volunteers.||||
33981139|NCT04762056|||OTHER||PROSPECTIVE|||||||
33981140|NCT00936260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981141|NCT02304588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981142|NCT00462852|RANDOMIZED|||TREATMENT||||||||
33981143|NCT03200067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981144|NCT05008822|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33981145|NCT01014728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981146|NCT01938482|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33981147|NCT02834611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981148|NCT05324735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981149|NCT04428541|NA|SINGLE_GROUP||OTHER||NONE||||||
33981150|NCT00665821|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33981151|NCT01695551|||COHORT||PROSPECTIVE|||||||
33981152|NCT04529746|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Participants were randomized on a 1-1 basis to receive either the EVERYbody Project or be on the waitlist control list (assessment-only control).||||
33981153|NCT00406848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981154|NCT00699322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981155|NCT05376683|RANDOMIZED|FACTORIAL||OTHER||NONE||"This is a 3 armed study.~1. Control = SOC, 15 participants~2. CURATE.AI (device)+telemonitoring= 15 participants.~3. Telemonitoring without CURATE.AI= 15 participants. The rationale for the 3rd arm is that the process of telemonitoring itself can result in behavior change and affect blood pressure."||||
33981156|NCT02268799|||CASE_ONLY||PROSPECTIVE|||||||
33981157|NCT00180817|||||OTHER|||||||
33981158|NCT03299907|||OTHER||CROSS_SECTIONAL|||||||
33981159|NCT03487107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981160|NCT01675557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981161|NCT05756530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981162|NCT00319358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981163|NCT06459388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981164|NCT03594032|||COHORT||PROSPECTIVE|||||||
33981165|NCT04524065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33981166|NCT04860219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981167|NCT02298322|NA|SINGLE_GROUP||OTHER||NONE||||||
33981168|NCT06361498|NA|SINGLE_GROUP||OTHER||NONE||||||
33981169|NCT00881270|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981170|NCT02539485|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33981171|NCT01716078|||COHORT||PROSPECTIVE|||||||
33981172|NCT00784264|||||PROSPECTIVE|||||||
33981173|NCT01994525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981174|NCT04452734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981175|NCT04448678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will not know who is receiving additional health insurance navigation or standard navigation. The outcome assessor will also be blinded to which participants received health insurance navigation. Blinding for the outcome assessor will be kept throughout the entirety of the analysis. Groups will be identified for analysis with ambiguous categories such as group 1 and group 2.||t|f|f|t
33981176|NCT00263965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33981177|NCT02664584|||COHORT||CROSS_SECTIONAL|||||||
33981178|NCT06485375|||CASE_ONLY||PROSPECTIVE|||||||
33981179|NCT05015348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981180|NCT05904509|||CASE_ONLY||RETROSPECTIVE|||||||
33981181|NCT01551095|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981182|NCT01452451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981183|NCT03209752|||COHORT||PROSPECTIVE|||||||
33981184|NCT00515645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981185|NCT01376843|||CASE_CROSSOVER||PROSPECTIVE|||||||
33981186|NCT01386047|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33981187|NCT01451762|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981188|NCT02352298|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33981189|NCT02101541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981190|NCT01704742|||COHORT||PROSPECTIVE|||||||
33768586|NCT05813626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768587|NCT02183870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768588|NCT00676975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768589|NCT00953914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768590|NCT03961113|||COHORT||PROSPECTIVE|||||||
33721254|NCT04021589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768591|NCT05591560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768592|NCT03032874|||COHORT||PROSPECTIVE|||||||
33768593|NCT05394233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768594|NCT02969031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768595|NCT02010697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768596|NCT00265707|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33768597|NCT00247819|||||PROSPECTIVE|||||||
33768598|NCT02498379|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768599|NCT00781534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33768600|NCT02221856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768601|NCT00128011|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33768602|NCT01127906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33768603|NCT04837001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||All subjects who fulfill all study eligibility criteria will be randomized and dosed with study drug or placebo.|t|t|t|t
33768604|NCT03812211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768605|NCT03599986|||OTHER||PROSPECTIVE|||||||
33768606|NCT04542408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33768607|NCT04421742|||COHORT||PROSPECTIVE|||||||
33768608|NCT03491748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768609|NCT01598428|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33768610|NCT03804996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768611|NCT01430767|||COHORT||PROSPECTIVE|||||||
33768612|NCT05443425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768613|NCT01803841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768614|NCT03176095|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind||t|t|t|f
33768615|NCT06312293|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33768616|NCT05374759|||COHORT||PROSPECTIVE|||||||
33981191|NCT02851251|||COHORT||PROSPECTIVE|||||||
33981192|NCT01754025|||FAMILY_BASED||PROSPECTIVE|||||||
33981193|NCT03830164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981194|NCT02745522|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33981195|NCT03190486|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"20 men and 20 women : group non parent 20 father and 20 mother : group parent"||||
33981196|NCT00524758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981197|NCT00149500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33981198|NCT05891990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981199|NCT05745688|||CASE_ONLY||RETROSPECTIVE|||||||
33981200|NCT01774123|||CASE_CONTROL||PROSPECTIVE|||||||
33981201|NCT05128981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078477|NCT01102712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768617|NCT02831829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768618|NCT02275247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33768619|NCT00611117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|t|f|f
33768620|NCT00624325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768621|NCT01908673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768622|NCT01630590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768623|NCT05394363|||COHORT||PROSPECTIVE|||||||
33768624|NCT04173312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Infusion will be the same for both groups. One will have analgesic and one will have saline.|Randomized control trial|t|f|t|f
33768625|NCT06451315|||COHORT||RETROSPECTIVE|||||||
33768626|NCT04667845|||COHORT||PROSPECTIVE|||||||
33768627|NCT06234488|||COHORT||RETROSPECTIVE|||||||
33768628|NCT01596283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768629|NCT04000659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this investigation, neither the investigator nor the subject can be blinded to the treatment group assignment due to the implant's distinctive form that can be detected on radiographs; however, the randomization assignment will not be disclosed to the subject until after surgery is performed.|A total of 180 subjects will be enrolled and randomized using a 2:1 ratio (Episealer: Microfracture). Within each site, subjects will be randomized into one of the two study arms using a blocked randomization scheme with varying block sizes.|t|f|f|f
33768630|NCT00872014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768631|NCT02252458|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33768632|NCT04316728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768633|NCT03013686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768634|NCT06099951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768635|NCT01803230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768636|NCT00684086|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33981202|NCT05104983|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This trial will employ a randomized, double-blind, placebo-controlled multisite design to evaluate the safety and efficacy of early sirolimus treatment to prevent or delay seizure onset in TSC infants.|t|t|t|f
33981203|NCT04382937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981204|NCT04848948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981205|NCT00002725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981206|NCT00482521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981207|NCT00929500|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33981208|NCT00528242|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981209|NCT02962297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981210|NCT01578694|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981211|NCT03914066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981212|NCT05901948|||COHORT||PROSPECTIVE|||||||
33981213|NCT00620490|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078478|NCT04891666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34078479|NCT03286387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721255|NCT06202391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721256|NCT02284711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768637|NCT01782040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768638|NCT04394520|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized to one of five introduction and consent combinations: 1) standard introduction and standard consent mode (active opt-in and active opt-out); 2) modified introduction language and standard consent mode; 3) modified introduction language and active opt-in consent; 4) modified introduction language and active opt-out consent; or 5) modified introduction language and passive opt-in consent. This randomization will occur at the beginning of the survey.|f|f|f|t
33768639|NCT03273140|RANDOMIZED|PARALLEL||OTHER||NONE|Assessor blinding is not possible as the researcher is involved in the whole process from recruitment to data analysis as part of her doctorate study. However, a research assistant (RA) will assist in arranging the sequence of the envelopes as part of allocation concealment, double-checking of the data entry and analysis of the report. To highlight, the RA will also not know which is the 'control' and 'intervention' group, as both groups will be de-identified as group A and B during the process of data entry and analysis.|The study adopted a randomized controlled trial (RCT) design, comparing between intervention group (receiving GDEP) and control group (current practice). In this study, the RCT study design allows comparison between the intervention (GDEP), which will then prove the hypotheses and serves to address the aim of this study.||||
33768640|NCT00317174|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768641|NCT04789213|||COHORT||RETROSPECTIVE|||||||
33768642|NCT02132533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768643|NCT03176043|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33768644|NCT05392140|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||The research was organized in an experimental design with pre-test post-test control group.|t|f|f|t
33768645|NCT03389841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721257|NCT06490263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721258|NCT03163550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721259|NCT04711473|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33768646|NCT06217887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768647|NCT00125593|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768648|NCT00098254|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768649|NCT05412459|||COHORT||PROSPECTIVE|||||||
33768650|NCT03579797|||COHORT||CROSS_SECTIONAL|||||||
33768651|NCT05913284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study syringes containing the drug solution will be of identical appearance and with blind labelling so that the primary care team and the patient will be blinded to the treatments. An independent assessor blinded to the study will be responsible for the data analysis|The patients are randomized to receive either methadone 0.2mg/kg (maximum dose of 20mg) or equipotent dose of morphine, added to a syringe containing saline made up to 50ml in total. Randomization will be carried out by an independent investigator, on the day before operation, from pre-prepared envelops each containing the group assignment of either methadone or morphine group. The group assignment will be done by sequence generation with computer models.|t|t|f|f
33768652|NCT02906202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768653|NCT04823559|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768654|NCT00630214|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768655|NCT06210451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768656|NCT00739895|||CASE_CONTROL||PROSPECTIVE|||||||
33768657|NCT02501213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768658|NCT02529397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768659|NCT02127320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768660|NCT04599686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768661|NCT04529603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768662|NCT04848181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33768663|NCT02492672|||OTHER||PROSPECTIVE|||||||
33898137|NCT06513104|NA|SEQUENTIAL||TREATMENT||NONE||||||
33898138|NCT02332915|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33898139|NCT03551886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33898140|NCT04125745|NA|SINGLE_GROUP||TREATMENT||NONE||One-arm, open-label||||
33898141|NCT04686890|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33898142|NCT01535937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898143|NCT04825873|||COHORT||OTHER|||||||
33898144|NCT04720352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898145|NCT05741073|||COHORT||CROSS_SECTIONAL|||||||
33898146|NCT00687050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981214|NCT03180606|||CASE_CONTROL||PROSPECTIVE|||||||
33981215|NCT01351688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981216|NCT01747603|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981217|NCT04508998|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981218|NCT03676738|||COHORT||PROSPECTIVE|||||||
33981219|NCT01327963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981220|NCT05593965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33768664|NCT02394899|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33768665|NCT01613027|||COHORT||PROSPECTIVE|||||||
33768666|NCT03008421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768667|NCT03900377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768668|NCT00974519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768669|NCT02495896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768670|NCT03053921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768671|NCT03791385|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Children with ASD ages 4-16 years||||
33768672|NCT04650971|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|For blinding purposes the Placebo was made with the corresponding labelling of the study drug.|The dose cohorts were included into the study based on evaluation of the safety results performed by the Data Safety Monitoring Committee. 2 doses of vaccine/placebo were used in the study. The volunteers randomized to the study group received intranasally 0.5 ml of the vaccine/placebo (0.25 ml in each nostril) as nasal aerosol stray twice with an interval of 3 weeks.|t|f|t|f
33768673|NCT06187571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768674|NCT05115409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768675|NCT01863979|||COHORT||RETROSPECTIVE|||||||
33768676|NCT01413217|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33768677|NCT02364232|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33768678|NCT06495255|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants are blinded to the supplement.|Two or more interventions, each alone and in combination, are evaluated in parallel|t|f|f|f
33768679|NCT04874376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768680|NCT05730738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomization was done by a research randomization, The copy of the randomization table of patients to the 2 groups was kept with 2 different personnel not working on the study.|Patients diagnosed with MS will be evaluated for inclusion and exclusion criteria using the selected screening scales. Eligible patients will be randomly assigned to one of two groups: dalfampridine ER 10mg twice daily group and placebo group for 12 consecutive weeks.|t|t|t|t
33768681|NCT00428064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768682|NCT04151875|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor will be masked about the group of the participant during the measuring the outcome ..|"-Interventions Intervention Group (I) Extraction treatment group. Bonding all cases will be performed by the principal investigator, then premolars extraction will be done, then installing the 1st alignment wire.~Comparator group (C):~Non-extraction group. Same orthodontist will bond all the cases and install the 1st alignment wire."|f|f|f|t
33768683|NCT02354859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768684|NCT04955704|||OTHER||RETROSPECTIVE|||||||
33768685|NCT06236360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Investigators/care providers will be masked, while investigators performing nutritional interventions will not.||f|t|t|t
33768686|NCT04380896|||COHORT||PROSPECTIVE|||||||
33768687|NCT02223247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768688|NCT03403777|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, open-label, multi-centre trial to assess efficacy (as measured by 12-week progression-free survival) of AVELUMAB in patients with refractory germ cell tumors (GCTs). The Simon optimal 2-stage design (see statistical section) will be used. See section 6 (Statistical Considerations) for specific details.||||
33768689|NCT04958447|||CASE_ONLY||PROSPECTIVE|||||||
33981221|NCT01498848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33981222|NCT03913806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||phase I/II safety and dose-finding study||||
33981223|NCT00376922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981224|NCT00803920|||COHORT||PROSPECTIVE|||||||
33768690|NCT02141958|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33768691|NCT05889819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants at the treatment and control groups received cookies supplementation during 4 weeks.|One treatment group received almond orange potato cookies during 4 weeks. One control group received almond potato cookies during 4 weeks.|t|f|f|f
33768692|NCT01360567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768693|NCT03835637|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33768694|NCT00296387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33768695|NCT00280891|||||RETROSPECTIVE|||||||
33768696|NCT01097915|||COHORT||PROSPECTIVE|||||||
33768697|NCT01382940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768698|NCT00034840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33768699|NCT03119610|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33768700|NCT03001713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768701|NCT01463293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768702|NCT01432015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768703|NCT05534321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768704|NCT05833516|||CASE_CONTROL||PROSPECTIVE|||||||
33768705|NCT04595734|||COHORT||RETROSPECTIVE|||||||
33981225|NCT02216071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981226|NCT01631565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981227|NCT00740493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981228|NCT00469586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981229|NCT02017964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981230|NCT01492400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078480|NCT00144599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981231|NCT02395822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981232|NCT05602688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33981233|NCT05039502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981234|NCT03133195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind, placebo-controlled|The patients will be randomized in 1:1 ratio to receive Teriparatide or placebo|t|t|t|t
34078481|NCT02597517|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078482|NCT03901846|NA|SINGLE_GROUP||OTHER||NONE||||||
34078483|NCT03310242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078484|NCT02133391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34078485|NCT04030741|RANDOMIZED|PARALLEL||TREATMENT||NONE|The individual who evaluates the outcome(s) of interest|After permission from the ethical review board (ERB), Children diagnosed with acute appendicitis and fulfilling the inclusion and exclusion criteria will be included in the study after taking informed consent from parents. All the patients inducted in the study will be randomly divided into two groups: Non-operative treatment (group A) and operative treatment (group B), using computer generated number. Total sample size is 180 patiens and duration is 3 to 6 months.||||
34078486|NCT00165503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078487|NCT04121338|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Since this is a single arm study, no masking will be performed|10 patients with chronic GI dysmotility, chronic nausea/vomiting and feeding intolerance requiring G-J feeding and considered for Celiac Ganglion resection||||
34078488|NCT02003300|||||PROSPECTIVE|||||||
33981235|NCT02606565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981236|NCT00003123||||TREATMENT||||||||
34078489|NCT00129441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981237|NCT05400148|||COHORT||PROSPECTIVE|||||||
33981238|NCT05224895|||COHORT||PROSPECTIVE|||||||
33981239|NCT03150602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981240|NCT00473356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981241|NCT03664908|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33981242|NCT02632136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33981243|NCT04506866|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981244|NCT01934673|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33768706|NCT04294394|||OTHER||PROSPECTIVE|||||||
33981245|NCT03097120|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981246|NCT03695926|NA|SINGLE_GROUP||OTHER||NONE||||||
33981247|NCT04218188|||COHORT||PROSPECTIVE|||||||
33981248|NCT03576846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subject will not know the content of the other arm. The care provider cannot be blinded, as he/she will be performing the treatment. The investigator performing the measurements will not be aware of the treatment allocation, and the analyses will be masked for group allocation|Subjects will be randomized into two arms: 1: stretching exercises only, 2: stretching exercises and Spinal Manipulative Therapy|t|f|t|t
33981249|NCT05166265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981250|NCT02178722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981251|NCT03815981|||COHORT||CROSS_SECTIONAL|||||||
33981252|NCT04981938|||COHORT||RETROSPECTIVE|||||||
33981253|NCT02287545|||CASE_CONTROL||PROSPECTIVE|||||||
33981254|NCT00569374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981255|NCT02027909|||CASE_CONTROL||PROSPECTIVE|||||||
33721260|NCT05451147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Controlled, Parallel Group Trial.||||
33981256|NCT02927509|||COHORT||PROSPECTIVE|||||||
33981257|NCT02613156|||COHORT||PROSPECTIVE|||||||
33981258|NCT00813293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981259|NCT02771548|||COHORT||PROSPECTIVE|||||||
33981260|NCT04589910|NA|SINGLE_GROUP||SCREENING||NONE||||||
33981261|NCT05809765|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants were divided into the first group of patients undergoing hemodialysis every Monday, Wednesday, and Friday and the second group undergoing dialysis every Tuesday, Thursday, and Saturday. The experimental group and the control group were randomly assigned by a coin toss. The investigators conducted the study for eight weeks and investigated the effects of respiration training on the improvement of heart rate variability, anxiety, and quality of life in hemodialysis patients.||||
33981262|NCT05293249|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Dose escalation||||
33981263|NCT02272764|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33981264|NCT00982553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981265|NCT00710229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33981266|NCT04637048|||COHORT||OTHER|||||||
33981267|NCT01302496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981268|NCT04205201|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Generated by pharmaceutical companies.||t|t|f|f
33981269|NCT03512405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981270|NCT06381609|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981271|NCT05106166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This prospective studies that measure the effectiveness of occupational therapy intervention. Randomized controlled trials (RCT) are prospective studies that measure the effectiveness of a new intervention or treatment. Participants are recruited and randomly assigned to either the intervention or the comparator group. It is important to ensure that at the time of recruitment there is no knowledge of which group the participant will be allocated to; this is known as concealment. It is examined whether there is any difference in the results of the study intervention and also the intervention and control group are compared.|f|f|t|f
33981272|NCT03107468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent outcome assessors who do not know allocation result will participate in the outcome assessment.||f|f|f|t
33981273|NCT03341481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To mask intervention the placebo was used. In this case, the placebo was prepared as a blend of sucrose, apple fiber and natural aroma caramel by subcontractor of the producer, accordingly to the GMP (number of sachets prepared 1534). Placebo sachets were in the same size sachets as the product and could be hardly distinguished in term of color, taste or texture and flavor. To the end of the trial patients and medical staff were blinded which sachet contained active product. People responsible for the data clean-up and statistics were partially blinded since theyhad to know which patients were in the same treatment group.|Treatment was given to the mothers assigned to the galactogogue group, whereas a placebo was given to those assigned to the placebo group. Each patient randomized to either treatment or placebo group received 28 sachets for 14 days of the trial.|t|t|t|f
33981274|NCT00041509|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981275|NCT04431947|||COHORT||PROSPECTIVE|||||||
33981276|NCT06329947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981277|NCT00679965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981278|NCT01273181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981279|NCT03536624|NA|SINGLE_GROUP||PREVENTION||NONE|no masking|||||
33981280|NCT04599699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981281|NCT00762086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33981282|NCT04338126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy prepares medications that are coded|Randomized, placebo-controlled, double blind comparison|t|t|t|t
33981283|NCT06485258|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981284|NCT01417078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981285|NCT01751152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981286|NCT02328443|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981287|NCT00330538|||DEFINED_POPULATION||PROSPECTIVE|||||||
33981288|NCT00302705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981289|NCT00811668|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33981290|NCT03946501|||CASE_ONLY||RETROSPECTIVE|||||||
33981291|NCT05688306|||COHORT||PROSPECTIVE|||||||
33981292|NCT03970122|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinded|Dose escalation, parallel assignment|t|f|t|f
34078490|NCT00741312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34078491|NCT03572673|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33981293|NCT03831451|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Subjects will be randomized to a brief face-to-face stroke preparedness intervention compared to a healthy lifestyle stroke risk reduction intervention. After completing the outcome assessment, subjects will have the opportunity to receive the intervention that they were not initially randomized too.||||
33981294|NCT04745962|||CASE_ONLY||PROSPECTIVE|||||||
33981295|NCT02016612|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078492|NCT00379145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078493|NCT00806845|||COHORT||CROSS_SECTIONAL|||||||
34078494|NCT00964028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768707|NCT04152850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768708|NCT01426282|RANDOMIZED|PARALLEL||||NONE||||||
33768709|NCT04938115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768710|NCT00799734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768711|NCT04930107|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33768712|NCT02735837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768713|NCT01544582|||COHORT||PROSPECTIVE|||||||
33768714|NCT04005937|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Effects of spasticity on consecutive H-reflex response in patients with hemiplegia||||
33768715|NCT02017808|||COHORT||PROSPECTIVE|||||||
33768716|NCT04780217|NA|SEQUENTIAL||TREATMENT||NONE||||||
33768717|NCT02365974|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33768718|NCT02137291|||OTHER||PROSPECTIVE|||||||
33768719|NCT03487718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768720|NCT06476626|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33768721|NCT04932382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981296|NCT01483352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981297|NCT00858156|NON_RANDOMIZED|PARALLEL||||NONE||||||
33981298|NCT03948347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981299|NCT06484231|||COHORT||PROSPECTIVE|||||||
33981300|NCT06374615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981301|NCT03577626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078495|NCT05728138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078496|NCT01428843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981302|NCT04453202|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33981303|NCT04617769|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33981304|NCT05806203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078497|NCT00750763|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34078498|NCT02743364|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078499|NCT00678353|||CASE_ONLY||PROSPECTIVE|||||||
34078500|NCT02343367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34078501|NCT02770911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078502|NCT00241007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34078503|NCT01098084|NA|SINGLE_GROUP||||||||||
34078504|NCT02104427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078505|NCT02397941|||COHORT||PROSPECTIVE|||||||
34078506|NCT00000399|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34078507|NCT05618314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078508|NCT00039624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078509|NCT03139552|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Subjects were blind to the differences in recipes when taste testing.|Subjects were asked to taste test 3 versions of test items (in randomized order) and provide a liking score for each.|t|f|f|f
34078510|NCT00180089|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34078511|NCT05526547|||OTHER||RETROSPECTIVE|||||||
34078512|NCT04823780|||COHORT||PROSPECTIVE|||||||
34078513|NCT02812589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078514|NCT01331369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078515|NCT02410447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078516|NCT06350734|||COHORT||PROSPECTIVE|||||||
34078517|NCT01031303|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34078518|NCT02731378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078519|NCT00524524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078520|NCT03573037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078521|NCT05262816|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34078522|NCT05251350|||CASE_ONLY||OTHER|||||||
34078523|NCT01491425|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078524|NCT00397748|||||OTHER|||||||
34078525|NCT01099358|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34078526|NCT05313724|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078527|NCT00750113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768722|NCT01216891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768723|NCT06026722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078528|NCT00667329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078529|NCT00012025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078530|NCT01149655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34078531|NCT01610037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078532|NCT05108701|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel, two-arm, randomised pilot trial comparing Individual MBCT with Individual CBT||||
34078533|NCT01102309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078534|NCT00652912|RANDOMIZED|CROSSOVER||||NONE||||||
34078535|NCT01367015|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34078536|NCT03255369|||COHORT||PROSPECTIVE|||||||
34078537|NCT04232930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|This is not a blinded study as both the participant and the care provider will be able to listen to the music if the subject is assigned into the music group.|Prospective randomized trial||||
33981305|NCT00156247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981306|NCT02292745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981307|NCT00731081|||COHORT||PROSPECTIVE|||||||
33981308|NCT02367209|||CASE_CONTROL||PROSPECTIVE|||||||
33981309|NCT04177290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981310|NCT02441478|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33981311|NCT02348385|||CASE_CONTROL||PROSPECTIVE|||||||
33981312|NCT05745805|||COHORT||PROSPECTIVE|||||||
33981313|NCT01238237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981314|NCT02446626|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981315|NCT00162123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981316|NCT00455351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981317|NCT05885165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33981318|NCT01768806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981319|NCT04629404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981320|NCT01223365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078538|NCT05246891|||COHORT||RETROSPECTIVE|||||||
34078539|NCT00243763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078540|NCT04936516|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34078541|NCT03205293|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized control program trial, pre-post study||||
34078542|NCT04845334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078543|NCT05474183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078544|NCT03902093|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078545|NCT02614781|||COHORT||PROSPECTIVE|||||||
34078546|NCT00564941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078547|NCT04503967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078548|NCT05282628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078549|NCT05837273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078550|NCT03155659|||COHORT||PROSPECTIVE|||||||
34078551|NCT04810988|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither participants nor study therapists will be blinded to participant condition, as it is not feasible to blind to whether or not someone is receiving therapist support.|Eligible, consented participants will be immediately randomized to one of two arms and remain in that arm for the duration of the study.||||
34078552|NCT00737100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33768724|NCT01425593|||CASE_ONLY||PROSPECTIVE|||||||
33768725|NCT04814849|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33768726|NCT01146574|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33768727|NCT04358796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are unaware to the ATA in chamber and to oxygen levels in their mask.|two groups being tested in parallel. The first group in HBOT environment. The second group in a SHAM environment.|t|f|f|f
33768728|NCT03333174|RANDOMIZED|CROSSOVER||TREATMENT||NONE||(b) The first 24h of the data collection will be the baseline data. Over the next 72h, we will evaluate 3 interventions in a cross-over manner: Intervention 1 (24-48h of data), Intervention 2 (48-72h), and Intervention 3 (72-96h; same as intervention 1). Initial intervention will be by random assignment (computer-generated). The intervention will be to provide oxygen either by nasal cannula or by servo-controlled oxygen environment, followed by cross-over to other intervention for 24h, and then back to original intervention.||||
33768729|NCT01698086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33768730|NCT00064025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768731|NCT03136835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981321|NCT00799656|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33768732|NCT02300337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839282|NCT06033898|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33981322|NCT02458482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839283|NCT01636245|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33839284|NCT03432442|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33839285|NCT01711853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839286|NCT01038219|||CASE_ONLY||PROSPECTIVE|||||||
33981323|NCT05398822|||COHORT||RETROSPECTIVE|||||||
33981324|NCT00391105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33981325|NCT03476460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981326|NCT03362437|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33981327|NCT02319148|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33981328|NCT05203393|||COHORT||CROSS_SECTIONAL|||||||
33981329|NCT05978479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients in the intervention group (experimental group) will receive a hemodialysis training booklet and face-to-face training using the Teach Back Method in three sessions held every other day. The routine care and treatment of the control group will be continued."||||
33981330|NCT00716495|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33981331|NCT01078025|||COHORT||PROSPECTIVE|||||||
33981332|NCT03110003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981333|NCT01638988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981334|NCT04433871|||COHORT||PROSPECTIVE|||||||
33981335|NCT00007436||||TREATMENT||||||||
33981336|NCT02066922|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33981337|NCT03920137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981338|NCT03923179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981339|NCT02665143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981340|NCT01690494|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33981341|NCT02983110|||COHORT||PROSPECTIVE|||||||
33981342|NCT02717390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981343|NCT01372579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981344|NCT01390337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981345|NCT01799798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981346|NCT05210322|||COHORT||OTHER|||||||
33981347|NCT01292330|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981348|NCT02707978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981349|NCT01987271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981350|NCT02749513|NA|SINGLE_GROUP||OTHER||NONE||||||
33981351|NCT00812734|||OTHER||OTHER|||||||
33981352|NCT04493723|||OTHER||OTHER|||||||
33981353|NCT04709809|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Data driven analysis||||
33981354|NCT03187002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981355|NCT01382719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981356|NCT05703048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A computer system will be used for randomization by creating a list of number each number referred to one of the two groups. Block randomization will be used to ensure equality of the groups. Each number will be sealed in an opaque envelope. Then, each patient will be asked to choose one of the envelopes and give it to an anesthesiologist who compared it to the computer-generated list and hence assigned her to one of the two groups. The anesthesiologist, participant and outcomes Assessor will be blinded to the collected data until the end of the study and administered the medication.|"In group A (dexmedetomidine group): 35 patients will be received dexmedetomidine (Precedex; Abbott Laboratories, North Chicago, Illinois, USA) (vial = 2 ml) 100 mcg/ml at bolus dose of 1 mcg /kg slowly infused over 10 min, then continuous infusion by a rate of 0. 5 mcg /kg/h., infused by a syringe pump. infusion stopped immediately upon extubation.~In group B (Esmolol group): 35 patients will be received i.v. received a loading dose of esmolol 0.5 mg/kg in 30 mL isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min. infusion stopped immediately upon extubation."|t|t|t|t
33981357|NCT05961930|||OTHER||PROSPECTIVE|||||||
33981358|NCT02010879|||COHORT||PROSPECTIVE|||||||
33981359|NCT02372630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981360|NCT01900730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981361|NCT03463278|||COHORT||PROSPECTIVE|||||||
33981362|NCT03973177|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A Pilot Prospective, Randomized, Crossover Trial. (Block randomization scheme with 2:1 allocation (phenol neurolysis : perineural steroid injection) The crossover will occur in subjects who received the steroid injection who did not achieve adequate pain relief at 3 months.||||
33981363|NCT00376623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981364|NCT04233320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981365|NCT05203536|||COHORT||PROSPECTIVE|||||||
33981366|NCT05702424|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33981367|NCT05290194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981368|NCT04067102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981369|NCT01845363|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33981370|NCT06496542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33981371|NCT05289232|||COHORT||PROSPECTIVE|||||||
33981372|NCT06430437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981373|NCT00152035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981374|NCT03414749|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Treatment was unknown to outcome assessors. Participant were unaware of what the treatment would be and how it may / may not impact the outcome.|This study used a randomized, crossover experimental design over three days of testing.|t|f|f|t
33981375|NCT00924326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33981376|NCT01787708|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33981377|NCT05777707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981378|NCT02193880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981379|NCT05652725|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arm|t|f|t|f
33981380|NCT03272048|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33981381|NCT03129425|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34078553|NCT06280443|||COHORT||PROSPECTIVE|||||||
34078554|NCT01137513|||COHORT||PROSPECTIVE|||||||
34078555|NCT06119230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078556|NCT02245815|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078557|NCT04511897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078558|NCT02895269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33839287|NCT03745898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981382|NCT06344624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Using the block randomization technique, the sampled students will be split into two groups: the CBT group and the laughter group. Six will be the block size. Excel will be used to create blocks (allocation concealment) and random numbers will be generated by an assistant researcher who does not attend therapy sessions. The purpose of the program is to support mental health and evaluate its effectiveness; students will not be informed about which group they are in (participant blinding).~Research data will be coded as A and B and entered into the computer database by someone other than the researchers conducting the therapy sessions, and statistical analysis will be performed using this coding (statistician blinding)."|A randomized controlled trial with a pretest-posttest design|t|f|f|t
33981383|NCT05250245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981384|NCT03694665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981385|NCT01320696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33981386|NCT06048146|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981387|NCT00757406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981388|NCT00139178|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981389|NCT05335408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study optometrists (who will perform the examinations)|"The study design is a single-center, double masked, prospective randomized clinical study. The study will be conducted at the University Eye Clinic Maastricht of the Maastricht University Medical Centre+ (MUMC+) in the Netherlands.~The study consists of two study groups: Vario-group (implantation with the Acunex® Vario IOL) and the Vivity-group (implantation with the Alcon AcrySof® IQ Vivity® IOL). A total of 32 patients will be randomized into either the Vario-group or the Vivity-group at a 1:1 ratio. Patients and study-optometrists will be masked. Surgeons are impossible to mask, due to the difference in (optical) design between both IOLs. Patients will receive standard cataract extractions by experienced surgeons."|t|f|f|f
33981390|NCT01488149|||COHORT||PROSPECTIVE|||||||
33981391|NCT00366509|||CASE_CONTROL||PROSPECTIVE|||||||
33981392|NCT00266006|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33981393|NCT03416647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981394|NCT01522664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981395|NCT00000957||||PREVENTION||DOUBLE||||||
33981396|NCT03131310|||CASE_ONLY||OTHER|||||||
33981397|NCT03006419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981398|NCT06451861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981399|NCT00832377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078559|NCT05550350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, Randomized, Double-masked, Placebo-controlled,Parallel-design, Multicenter Study|t|f|t|t
34078560|NCT04980014|||COHORT||PROSPECTIVE|||||||
34078561|NCT06336421|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|statistics expert||f|f|f|t
34078562|NCT03159936|NA|SINGLE_GROUP||TREATMENT||NONE||Tofacitinib citrate will be administered twice a day starting on Day 1 at the Baseline Visit. Subjects will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.||||
34078563|NCT04423471|||COHORT||PROSPECTIVE|||||||
34078564|NCT02498678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078565|NCT00275522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078566|NCT03804268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078567|NCT03741374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078568|NCT00983502|||COHORT||PROSPECTIVE|||||||
33981400|NCT03637582|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33981401|NCT01221376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981402|NCT00854100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981403|NCT00002349|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34078569|NCT06469957|||COHORT||PROSPECTIVE|||||||
34078570|NCT03539094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the intervention because they will not know the group assignment.|Randomized controlled clinical trial|f|f|f|t
34078571|NCT05598060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078572|NCT00821275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078573|NCT03366857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants don´t know the randomized oxygen concentration. The postoperative follow up will be performed by a blinded research fellow.||t|f|f|t
34078574|NCT02886923|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34078575|NCT02532374|NA|SINGLE_GROUP||OTHER||NONE||||||
34078576|NCT04834401|||COHORT||PROSPECTIVE|||||||
34078577|NCT03747393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparative effectiveness parallel-group randomized controlled clinical trial|f|f|f|t
33839288|NCT01109511|RANDOMIZED|PARALLEL||PREVENTION||||||||
33981404|NCT00595166|||COHORT||PROSPECTIVE|||||||
33981405|NCT01876706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981406|NCT06389409|||COHORT||PROSPECTIVE|||||||
33981407|NCT02977520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981408|NCT00755196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981409|NCT03729297|NA|SINGLE_GROUP||TREATMENT||NONE||"3 cohorts:~* adenoid cystic carcinoma~* salivary duct carcinoma~* other subtypes of salivary gland cancer~sample size: The Simon two-stage design will be used, The first stage consists of 9 patients per cohort ((1) SDC, (2) ACC) evaluable for response. If 0 responses out of the first 9 evaluable patients are observed, the study will be stopped. In any other situation, the study will be continued until 17 patients are evaluable for response per cohort. If ≤2 responses are observed the study will accept the null hypothesis. If \>2 responses are observed, the null hypothesis will be rejected. In the third cohort (other SGC) 9 patients will be included to evaluate the efficacy of cabozantinib in other subtypes of c-MET positive SGC. Because different subtypes are included in this cohort, these results are hypothesis forming but will not be used for statistical analysis. Therefore, this study cohort will be closed after the first stage with 9 patients."||||
33981410|NCT00346814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981411|NCT05853484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981412|NCT00306371|||DEFINED_POPULATION||PROSPECTIVE|||||||
33981413|NCT02625454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981414|NCT05340010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981415|NCT04062409|||CASE_CONTROL||PROSPECTIVE|||||||
33981416|NCT02216903|||COHORT||PROSPECTIVE|||||||
33981417|NCT00759928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981418|NCT03846388|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981419|NCT02503943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981420|NCT04587466|||COHORT||PROSPECTIVE|||||||
33981421|NCT00048126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981422|NCT03845790|NA|SINGLE_GROUP||OTHER||NONE||Pharmacokinetic study||||
33981423|NCT01790581|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33981424|NCT00003422|RANDOMIZED|||TREATMENT||||||||
33981425|NCT01472601|||COHORT||PROSPECTIVE|||||||
33981426|NCT02520505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981427|NCT06496646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33981428|NCT06376448|||COHORT||PROSPECTIVE|||||||
33981429|NCT03724123|||COHORT||RETROSPECTIVE|||||||
33981430|NCT04774757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981431|NCT05842109|||CASE_CONTROL||PROSPECTIVE|||||||
33981432|NCT04662996|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Intervention: blood sample at inclusion. primary purpose: to better understand resistance mechanisms to prostate cancer treatment.|t|t|t|t
33981433|NCT01148082|||COHORT||PROSPECTIVE|||||||
33981434|NCT02779543|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078578|NCT00216593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34078579|NCT02245165|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34078580|NCT02982863|||COHORT||RETROSPECTIVE|||||||
33981435|NCT06325189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was single-blinded, as assessors of the study were kept blind to the intervention group to which the participant was allocated.|In this parallel-group randomized controlled trial (RCT), post-angioplasty patients will be assigned to either the control group (receiving standard medication) or the experimental group (receiving medication along with aerobic interval training). The study aims to evaluate the impact of aerobic interval training on fatigue levels and functional performance in these patients.|f|f|f|t
33981436|NCT03741348|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33981437|NCT05328804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with severe ITP will be randomly assigned to three groups: rhTPO group, Herombopag Group, Herombopag combined with rhTPO group.||||
33981438|NCT02597998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981439|NCT06006364|||OTHER||PROSPECTIVE|||||||
33981440|NCT00425672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981441|NCT02830022|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078581|NCT03330509|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"A stepped-wedge design will be used for this study, unblinded due to practical challenges of blinding. There will be 4 teams (clusters) within the DMO inpatient service, each comprising a team of senior consultant physicians, middle level and junior doctors, and oncology nurses. This follows current team structures. During the intervention period, a palliative care physician and nurse will join the team as integrated members.~The study will be conducted over 20 months from November 2017 to June 2019, with each cluster crossing over from 'usual care' to 'spark intervention' at 4-month intervals. Each cluster will be randomly assigned a specific timing of crossing over."||||
33981442|NCT03998865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will be not aware of the type of provisional abutment used in their treatment. Retrieved samples will be codified in order to mask them for the metagenomic analysis.|Participants will be randomly assigned to one of two groups: PEEK or Titanium provisional-abutments. A sample of the niche microbiota will be retrieved prior to implant placement (t0) and two months after provisional abutment (crown) connection (t1).|t|f|f|t
33981443|NCT00694551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981444|NCT01084460|||COHORT||RETROSPECTIVE|||||||
33721261|NCT05701410|NA|SINGLE_GROUP||SCREENING||NONE||||||
33721262|NCT06018259|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721263|NCT02152579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839289|NCT03586934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33839290|NCT03846440|||OTHER||CROSS_SECTIONAL|||||||
33839291|NCT03660423|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33839292|NCT01336049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839293|NCT00901953|||CASE_CONTROL||PROSPECTIVE|||||||
33839294|NCT00072501|RANDOMIZED|||SCREENING||||||||
33839295|NCT01696955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839296|NCT05056597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839297|NCT02416453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33839298|NCT02885584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33839299|NCT00271310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839300|NCT05129046|||COHORT||PROSPECTIVE|||||||
33839301|NCT01405729|||COHORT||CROSS_SECTIONAL|||||||
33839302|NCT03744013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||post market prospective, multi-center study||||
33839303|NCT02694367|||CASE_CONTROL||PROSPECTIVE|||||||
33839304|NCT01046929|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839305|NCT01823705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839306|NCT04592159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981445|NCT01521988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981446|NCT00008736|NON_RANDOMIZED|||TREATMENT||||||||
33981447|NCT06202196|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This clinical study is a multicenter, open-label, randomized in two parallel groups of patients: an experimental group specific plan for the prevention of risks related to epilepsy and a control group usual consultations with the neurologist and the usual TPE sessions"||||
33981448|NCT04095871|||COHORT||PROSPECTIVE|||||||
33981449|NCT04882670|||COHORT||RETROSPECTIVE|||||||
33981450|NCT05733715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981451|NCT00995553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33981452|NCT05948891|||COHORT||PROSPECTIVE|||||||
33981453|NCT05427656|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||We will study a total of 30 participants, 10 in each of 3 age cohorts 18-29, 30-59 and 60-89, with equal numbers of male and female participants in each cohort.||||
33981454|NCT00604500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981455|NCT04175548|||CASE_ONLY||RETROSPECTIVE|||||||
33981456|NCT05283005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981457|NCT00973648|||COHORT||CROSS_SECTIONAL|||||||
33981458|NCT06486610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33981459|NCT02513797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981460|NCT05554809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor are not aware of the participants group allocation at time of measurement of outcome measures||f|f|f|t
33981461|NCT03119480|||COHORT||PROSPECTIVE|||||||
33981462|NCT04154033|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33981463|NCT06261892|NA|SINGLE_GROUP||SCREENING||NONE||||||
33981464|NCT02853279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981465|NCT02067793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981466|NCT03904303|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33981467|NCT04351516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981468|NCT04792944|||OTHER||RETROSPECTIVE|||||||
33981469|NCT05589415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33981470|NCT05642494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33981471|NCT05552781|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation and Expansion||||
33981472|NCT05853328|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to one of two test groups. After being randomized to the SM+ arm or the EM arm, patients will receive one initial maneuver from a physician, then subsequently performe self-maneuvers at home three times in the morning, three times at noon and three times in the evening.||||
33981473|NCT05513742|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately 37 patients will be enrolled into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled, for a total of approximately 84 patients.||||
33981474|NCT02510547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981475|NCT03533465|NA|SINGLE_GROUP||TREATMENT||NONE||The first aim of this study will involve a comparison of baseline psychiatric symptoms and subjective and objective measures of sleep, with specific attention to REM, in adults with CG compared to 25 healthy controls. 10 of these adults with CG who complete AIM 1 will participate in Complicated Grief Treatment (CGT).||||
33981476|NCT03983564|||COHORT||PROSPECTIVE|||||||
33981477|NCT02463695|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981478|NCT06123520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981479|NCT05252130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981480|NCT00886171|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981481|NCT02096510|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981482|NCT00620048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981483|NCT02993549|||COHORT||PROSPECTIVE|||||||
33981484|NCT02936856|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981485|NCT03021538|||COHORT||PROSPECTIVE|||||||
33981486|NCT02652026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981487|NCT04988984|||CASE_ONLY||PROSPECTIVE|||||||
33981488|NCT01415700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981489|NCT06354504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981490|NCT02719223|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33981491|NCT01094067|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33981492|NCT04732195|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981493|NCT05061290|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33981494|NCT01940770|||COHORT||PROSPECTIVE|||||||
33981495|NCT00242788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981496|NCT04179045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981497|NCT01705769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981498|NCT00006734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078582|NCT03395626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, placebo-controlled, parallel-group|t|t|t|f
34078583|NCT05530772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981499|NCT03947242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078584|NCT03580070|||OTHER||RETROSPECTIVE|||||||
34078585|NCT00270452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078586|NCT05968144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be blinded when possible (e.g., salivary cortisol concentration)||f|f|f|t
34078587|NCT00345267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898147|NCT04201912|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Selection of patients by grading the patients according to criteria patients without periodontal and systemic involvement(control), patients classified as stage 2 periodontitis without systemic involvement(test group1), patients classified as stage 2 Periodontitis with systemic disease(Type 2 diabetes)||||
33898148|NCT03329872|||COHORT||PROSPECTIVE|||||||
34078588|NCT03606564|||CASE_ONLY||CROSS_SECTIONAL|||||||
34078589|NCT00962312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078590|NCT00866905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078591|NCT02421692|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34078592|NCT00791999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898149|NCT04918173|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33898150|NCT04718064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898151|NCT05037331|||CASE_CONTROL||PROSPECTIVE|||||||
33898152|NCT05395169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33898153|NCT02307968|||CASE_CONTROL||PROSPECTIVE|||||||
33898154|NCT02234622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898155|NCT04215549|||OTHER||CROSS_SECTIONAL|||||||
33898156|NCT03974919|||COHORT||RETROSPECTIVE|||||||
33898157|NCT04891601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078593|NCT05194462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898158|NCT00722176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898159|NCT01543308|||CASE_CONTROL||PROSPECTIVE|||||||
33981500|NCT01287923|||COHORT||OTHER|||||||
33981501|NCT01479738|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33981502|NCT03787680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981503|NCT03725605|NA|SINGLE_GROUP||TREATMENT||NONE||LTX-315 and TILs||||
33981504|NCT04999709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981505|NCT03597334|||COHORT||PROSPECTIVE|||||||
33898160|NCT01863862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898161|NCT05939323|||OTHER||CROSS_SECTIONAL|||||||
33898162|NCT05674773|||COHORT||RETROSPECTIVE|||||||
33898163|NCT00844246|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33898164|NCT04215692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33898165|NCT04567836|||COHORT||PROSPECTIVE|||||||
33898166|NCT05606705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898167|NCT00059761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898168|NCT00298571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898169|NCT00753922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898170|NCT05368675|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33981506|NCT00000961||PARALLEL||TREATMENT||||||||
33981507|NCT04978649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078594|NCT03275207|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||paitents undergoing breast or thoracic surgery|t|f|t|f
34078595|NCT04414007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34078596|NCT06442605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078597|NCT03008811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768733|NCT03412162|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Post-doctoral scholar conducting the statistical data analyses will be provided with de-identified data and will not be informed of which condition is which. Rather, they will be provided with a neutral and randomly assigned set of names identifying each condition: Condition 1 and Condition 2.|Two conditions will be tested: an ethnic-racial identity promotion intervention, and academic skills promotion control condition.|f|f|f|t
33768734|NCT04806230|||COHORT||PROSPECTIVE|||||||
33768735|NCT03285295|NA|SINGLE_GROUP||SCREENING||NONE||"Evaluation of assay performance characteristics.~Participants:~* Alinity s HBsAg: 17987~* Alinity s HTLV I/II: 17685~* Alinity s Anti-HCV: 17904~* Alinity s HIV Ag/Ab Combo: 19571~* Alinity s Anti-HBc: 16776~* Alinity s Chagas: 16958"||||
33768736|NCT02482636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768737|NCT00514046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768738|NCT02699541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768739|NCT02374190|||COHORT||PROSPECTIVE|||||||
33768740|NCT02324764|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33768741|NCT05468515|||COHORT||PROSPECTIVE|||||||
33768742|NCT04290065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33768743|NCT03072381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768744|NCT00198601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768745|NCT02009696|||CASE_ONLY||PROSPECTIVE|||||||
33768746|NCT03431051|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768747|NCT05095090|||COHORT||PROSPECTIVE|||||||
33768748|NCT05819853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768749|NCT02406209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33768750|NCT03292146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33768751|NCT00405704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768752|NCT06481449|||COHORT||RETROSPECTIVE|||||||
33768753|NCT04469699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768754|NCT06489665|||OTHER||OTHER|||||||
33898171|NCT01151150|||COHORT||PROSPECTIVE|||||||
33898172|NCT05593601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898173|NCT03247998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor who will analyze the outcome variables for this study (consciousness, motor function, sensation, speech, coordination, standard of care follow up assessments etc.) that may be impacted by choice of anesthesia/analgesia will be blinded to the treatment group of the participants to ensure unbiased reporting.|There will be two arms of this study. In the first arm, the patients who meet the inclusion criteria of the study will be randomized to receive general anesthesia during endovascular treatment for stroke. In the second arm of the study, patients will receive general sedation during endovascular treatment.|f|f|f|t
33898174|NCT03388970|RANDOMIZED|PARALLEL||TREATMENT||NONE|patient and family members|||||
33898175|NCT02347358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078598|NCT01587885|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768755|NCT03903679|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768756|NCT05371119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|BFR inflated 20 mmHg|The procedure will consist of 6 weeks of training with or without partial vascular occlusion (depending on group A or group B) at the rate of 3 sessions per week (for a total of 18 training sessions).|t|f|f|f
33768757|NCT00004221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768758|NCT00082602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768759|NCT00829608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898176|NCT04031014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two blinded protocols are available on the device, neither investigators, participants or care providers will know the active treatment arm|Active and sham arms 1:1 run in parallel|t|t|t|f
33898177|NCT03351673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898178|NCT03504033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This trial will be performed double-blinded. After randomization neither the patients nor the investigator of the baseline assessment and the postoperative assessment will be aware of the treatment allocation. The intraoperative anesthesiologist will not be blinded, due to feasibility and safety reasons.|Single-center, controlled, double-blinded, randomized, two-arm parallel, interventional clinical trial|t|f|t|t
33898179|NCT03777930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||200 patients with advanced tumors with a predicted survival period of ≥2 months were selected, including 100 patients with chemotherapy indications (50 patients were divided into chemotherapy group and 50 patients were divided into chemotherapy combined with TH and MG group according to the random principle) and 100 patients without chemotherapy indications (50 patients were randomly divided into the best supportive treatment group and 50 patients were randomly divided into the best supportive treatment group with TH and MG according to the random principle). The chemotherapy alone group and the best supportive treatment group were the control group. The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks.|f|f|f|t
33898180|NCT05653908|NA|SINGLE_GROUP||SCREENING||NONE||||||
33981508|NCT04400123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Treatment group TR Intervention: Drug: famitinib malate, new formulation; Intervention: Drug: famitinib malate, old formulation.~Treatment group RT Intervention: Drug: famitinib malate, old formulation; Intervention: Drug: famitinib malate, new formulation."||||
33981509|NCT00667524|||COHORT||RETROSPECTIVE|||||||
33981510|NCT01888081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981511|NCT03119935|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981512|NCT04797130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and outcome assessors are blinded for treatment (control group: usual care physiotherapy treatment versus intervention group: usual care physiotherapy treatment and Hospital Fit 2.0 use)|Randomized Controlled Trial|f|f|t|t
33981513|NCT05483153|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981514|NCT04349592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded trial||t|t|t|t
33981515|NCT05267366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981516|NCT00605709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981517|NCT02417636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981518|NCT02186730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981519|NCT03356821|NA|SINGLE_GROUP||TREATMENT||NONE||A phase I/II, open-label, single-arm, single-center intervention study in the NICU at the Wilhelmina children's Hospital / University Medical Centre in Utrecht of (near-)term newborns ≥36 weeks of gestation within the first week of onset of presenting clinical symptoms.||||
33981520|NCT04999670|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will not be made aware which method of fascial closure group they will be in, and investigators will also be blinded to the method of fascial closure as they approach participants to fill in their follow-up questionnaires.|Participants will be randomised into one of three groups based upon the method of fascial closure prior to their caesarean section.|t|f|t|f
33981521|NCT05629884|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981522|NCT05872178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33981523|NCT00607230|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33981524|NCT06360913|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"3 groups:~1. Control subjects~2. Confirmed patients (rare diseases)~3. Suspected patients (rare diseases)"||||
33768760|NCT01231243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33768761|NCT01722721|||CASE_ONLY||PROSPECTIVE|||||||
33768762|NCT03149263|||OTHER||PROSPECTIVE|||||||
33768763|NCT05780502|||COHORT||PROSPECTIVE|||||||
33768764|NCT03508336|||COHORT||PROSPECTIVE|||||||
33768765|NCT04076020|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768766|NCT02743286|RANDOMIZED|CROSSOVER||||NONE||||||
33768767|NCT00924469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768768|NCT00419653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768769|NCT04874324|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34078599|NCT02357225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078600|NCT01417468|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34078601|NCT00956085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078602|NCT00684398|||||PROSPECTIVE|||||||
33768770|NCT01973491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768771|NCT03869645|||COHORT||PROSPECTIVE|||||||
33768772|NCT01855581|||||RETROSPECTIVE|||||||
33768773|NCT02079584|||COHORT||PROSPECTIVE|||||||
33768774|NCT02413190|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768775|NCT05151042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768776|NCT05808530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33768777|NCT02302950|||OTHER||RETROSPECTIVE|||||||
33768778|NCT01143532|||COHORT||OTHER|||||||
33768779|NCT06165081|||COHORT||RETROSPECTIVE|||||||
33898181|NCT05612997|||COHORT||CROSS_SECTIONAL|||||||
33898182|NCT04349930|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-masked (patient and provider)|Double-masked, placebo-controlled randomized trial|t|t|t|t
33898183|NCT03656887|||COHORT||PROSPECTIVE|||||||
34078603|NCT03457428|||CASE_ONLY||PROSPECTIVE|||||||
34078604|NCT05580484|||COHORT||RETROSPECTIVE|||||||
34078605|NCT00535652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898184|NCT02545374|RANDOMIZED|PARALLEL||||NONE||||||
33898185|NCT04132544|RANDOMIZED|PARALLEL||OTHER||NONE||Interventional multicenter and open, randomized study in parallel groups comparing two arms||||
33898186|NCT05477771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898187|NCT04632147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly divided into two groups as pranayama group and control group.||||
33898188|NCT00001081||PARALLEL||TREATMENT||||||||
33898189|NCT03928470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898190|NCT03914352|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33898191|NCT01418872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33898192|NCT00299377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33898193|NCT00893711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078606|NCT04825665|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34078607|NCT02492802|||COHORT||PROSPECTIVE|||||||
34078608|NCT05733663|||COHORT||RETROSPECTIVE|||||||
34078609|NCT06520813|||CASE_ONLY||PROSPECTIVE|||||||
34078610|NCT04102293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078611|NCT00715403||||TREATMENT||||||||
34078612|NCT05684341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078613|NCT03495063|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This protocol uses a crossover design. The subject sample is randomized. Subjects will serve as their own controls as they will be asked to intake both the natural and synthetic caffeine at two different occasions.|t|f|t|f
34078614|NCT03905083|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078615|NCT02937480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078616|NCT05562531|||CASE_ONLY||PROSPECTIVE|||||||
34078617|NCT02828488|||COHORT||RETROSPECTIVE|||||||
34078618|NCT02713178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34078619|NCT01895803|||FAMILY_BASED||PROSPECTIVE|||||||
34078620|NCT05681117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In order to eliminate bias, the data of the study were collected and recorded by an unbiased researcher (co-researcher) who did not know the researcher-trained groups. The statistics of the research were made by an independent statistician who did not know the groups.|Randomized controlled (parallel group) experimental research design in the research pre-test-post-test order|f|f|t|t
33981525|NCT01419106|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33981526|NCT01437501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33981527|NCT03963063|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33981528|NCT00920764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981529|NCT00270764|||COHORT||PROSPECTIVE|||||||
33981530|NCT04480073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981531|NCT01123681|||CASE_CONTROL||PROSPECTIVE|||||||
33981532|NCT02107300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33981533|NCT00950625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33981534|NCT00005856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981535|NCT01382290|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981536|NCT04268732|||COHORT||CROSS_SECTIONAL|||||||
33981537|NCT05000840|||CASE_CONTROL||PROSPECTIVE|||||||
33981538|NCT02293668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981539|NCT01863303|||COHORT||PROSPECTIVE|||||||
33981540|NCT00032903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981541|NCT06318702|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33981542|NCT01218165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981543|NCT02359981|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33981544|NCT00893256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981545|NCT03322709|||CASE_CONTROL||PROSPECTIVE|||||||
34078621|NCT00350883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078622|NCT04737525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078623|NCT05358899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, care provider, investigator, and outcome assessor will be blind to the intervention except the treatment provider.|Randomized Quadro-blind clinical trial|t|t|t|t
34078624|NCT00327340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078625|NCT05001607|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Recruited anesthesiologists will sequentially perform all four methods of pulmonary blockade on an intubating manikin. The method order will be randomized to control for a learning effect.||||
34078626|NCT01997008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34078627|NCT04327921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant will not be aware of study condition of the participants.|Once the baseline interview is complete, the principal investigator, who is not involved in conducting assessments, will randomize eligible participants to one of two study conditions. Urn randomization will be used to ensure the groups are balanced on gender and Fagerström Test of Nicotine Dependence (FTND) score. The Research Assistant will not be informed of treatment condition assignment. All participants will be scheduled for a week 1 session with a study nurse within one week of the baseline appointment. The nurse will use a detailed counseling manual to ensure standardization of treatment delivery.|f|f|f|t
34078628|NCT01127100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078629|NCT04321772|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The samples analysed were masked by a number without any indication of the arm.|Same subjects serve as both the test and control arms which allows for within-subject comparison. Using a within-person design, participants trained each lower limb on separate days under two different training stimulus (HIIRT) and traditional training (TRT)|f|f|f|t
33981546|NCT06295653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33981547|NCT01400022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981548|NCT00483899|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981549|NCT05116670|||COHORT||RETROSPECTIVE|||||||
33981550|NCT01215409|||CASE_ONLY||PROSPECTIVE|||||||
33981551|NCT02225145|||COHORT||PROSPECTIVE|||||||
33981552|NCT01901666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981553|NCT02392065|||COHORT||PROSPECTIVE|||||||
33981554|NCT01424839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981555|NCT00076050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981556|NCT02072538|||COHORT||PROSPECTIVE|||||||
33981557|NCT06246474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33981558|NCT05954325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|Double-blinded, randomized, sham-controlled trial|t|f|t|f
33981559|NCT04462406|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33981560|NCT03052309|||COHORT||PROSPECTIVE|||||||
33981561|NCT01876576|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33981562|NCT03018834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768780|NCT06280456|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33768781|NCT02653040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33768782|NCT02405117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768783|NCT06199947|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898194|NCT03509506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898195|NCT00229840|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898196|NCT00204386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898197|NCT04271163|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Pilot Study||||
33898198|NCT00839163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898199|NCT00848991|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33898200|NCT05227573|||COHORT||PROSPECTIVE|||||||
33898201|NCT00098631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898202|NCT02453399|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33898203|NCT03985137|||OTHER||PROSPECTIVE|||||||
33898204|NCT05767541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078630|NCT05245383|NA|SINGLE_GROUP||SCREENING||NONE||||||
34078631|NCT05684848|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34078632|NCT03363646|||COHORT||PROSPECTIVE|||||||
34078633|NCT05357846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078634|NCT00924924|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33898205|NCT03399890|||COHORT||PROSPECTIVE|||||||
33898206|NCT06295926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898207|NCT03952286|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Group 1 receives the intervention: ED-Initiated School-based Asthma Medication Supervision (school and home asthma medication supervision). Group 2 receives usual care (home asthma medication supervision).||||
33898208|NCT04075227|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants were randomized into 2 groups. Group 1 were treated with subconjunctival 5-FU injection and topical 0.2% loteprednol etabonate while group 2 were treated with subconjunctival 5-FU injection and topical 0.1% dexamethasone (CD-oph: dexamethasone sodium phosphate 1 mg/mL, chloramphenicol 5 mg/mL, tetrahydrozaline hydrochloride 0.25 mg/mL).||||
33898209|NCT00680732|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34078635|NCT05909540|||COHORT||PROSPECTIVE|||||||
34078636|NCT01861132|||COHORT||PROSPECTIVE|||||||
34078637|NCT02063113|NA|SINGLE_GROUP||OTHER||NONE||||||
34078638|NCT01089127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078639|NCT02619617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
34078640|NCT05235932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078641|NCT00275171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078642|NCT05178472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078643|NCT04113291|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078644|NCT01333423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078645|NCT01324947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768784|NCT05692453|||COHORT||PROSPECTIVE|||||||
34078646|NCT02276963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078647|NCT02557724|||CASE_CONTROL||PROSPECTIVE|||||||
34078648|NCT01753713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078649|NCT01551966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078650|NCT05406700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078651|NCT03880136|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33768785|NCT05542407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898210|NCT05058378|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898211|NCT05539053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898212|NCT03708692|||OTHER||PROSPECTIVE|||||||
33898213|NCT05992779|||CASE_ONLY||RETROSPECTIVE|||||||
33898214|NCT01720667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898215|NCT03393351|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||A stepped wedge design, a variant of the cluster randomized controlled trial feasible to evaluate interventions in routine implementation, will be used. Participating clinics will receive the multifaceted implementation program in a randomized sequence.||||
33898216|NCT01689506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898217|NCT05180669|RANDOMIZED|PARALLEL||TREATMENT||NONE||Both groups will be enrolled at the same time through, with group designated by randomization, and monitored through the 12-week RCT as well as follow ups at 1-, 3-, and 6-months post enrollment.||||
33898218|NCT01300936|||CASE_CONTROL||PROSPECTIVE|||||||
33898219|NCT05546788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three groups of patients with periodontitis, Group I received plain gel Group II received chlorhexidine gel Group III received hydroxylated polymethoxy flavones solid dispersion gel|f|t|t|f
33898220|NCT05893082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898221|NCT02052453|||COHORT||PROSPECTIVE|||||||
33898222|NCT06292481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898223|NCT06508983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stage 1#Open-label Stage 2#Double-blind|"This Study consists of Stage 1 and Stage 2.~Stage 1 ：Single group. Subjects will receive SG301 Injection in combination with pomalidomide and dexamethasone.~Stage 2：Parallel. Subjects will be randomized to receive SG301 Injection in combination with pomalidomide and dexamethasone or placebo in combination with pomalidomide and dexamethasone."|t|t|t|t
33898224|NCT00662870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898225|NCT02317731|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33898226|NCT02525172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898227|NCT00929630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898228|NCT03339427|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33898229|NCT00521963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898230|NCT02194296|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898231|NCT00934063|||COHORT||PROSPECTIVE|||||||
33898232|NCT05090345|||COHORT||PROSPECTIVE|||||||
33898233|NCT05573685|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Single blind, randomized into 3:1 ratio (3 DiNaMo Study Apps of 4 indications: 1 Digital Control App)||t|f|t|t
33898234|NCT01380093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33898235|NCT00188994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898236|NCT03285529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898237|NCT03679494|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33898238|NCT02024464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898239|NCT02232815|||COHORT||PROSPECTIVE|||||||
33898240|NCT05978895|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-randomized intervention with a single arm. Study participants received new adapted canteen menus according to the nutritional and sensory needs of the target population.||||
33898241|NCT00887042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898242|NCT02897908|||CASE_ONLY||PROSPECTIVE|||||||
33898243|NCT04786210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898244|NCT01079923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33898245|NCT05227846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898246|NCT06365333|||COHORT||RETROSPECTIVE|||||||
33898247|NCT02420652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898248|NCT03489291|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single-dose, single-arm, multi-center trial||||
33898249|NCT06021743|||COHORT||PROSPECTIVE|||||||
33898250|NCT06067113|||CASE_CONTROL||PROSPECTIVE|||||||
33898251|NCT03863496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898252|NCT05561621|||COHORT||PROSPECTIVE|||||||
33898253|NCT04436913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898254|NCT04819672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768786|NCT05713734|||CASE_CONTROL||PROSPECTIVE|||||||
33768787|NCT04491123|||CASE_ONLY||PROSPECTIVE|||||||
33768788|NCT06341426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The first dose will be randomized and blinded (1mg psilocybin versus 25mg psilocybin), while the second dose will be open-label (25mg psilocybin).|Participants will be randomized to two groups for the first dosing session in a 1:1 allocation: 1) non-psychedelic/placebo dose (psilocybin 1mg) or 2) psychedelic dose (psilocybin 25mg). All participants will receive a psychedelic dose (psilocybin 25mg) for their second dosing session.|t|t|t|t
33768789|NCT01874106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768790|NCT03804515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768791|NCT05433402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768792|NCT06062940|||COHORT||PROSPECTIVE|||||||
33768793|NCT03475719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, single-dose, two-treatment, two-sequence, two-way crossover study||||
33768794|NCT03408834|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33768795|NCT06115850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768796|NCT03643653|||COHORT||PROSPECTIVE|||||||
33768797|NCT02726061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768798|NCT03135704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768799|NCT02089581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898255|NCT03685656|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33898256|NCT04655586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, clinical events committee members will be blind to treatment assignment. Investigator assessing outcomes will be blinded wherever possible.|investigational product compared to active comparator|t|f|f|t
33898257|NCT01868269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981563|NCT01353469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981564|NCT00321139|||||PROSPECTIVE|||||||
33981565|NCT00051025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33981566|NCT05901857|||OTHER||RETROSPECTIVE|||||||
33981567|NCT00630305|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33981568|NCT03994432|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981569|NCT04494867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981570|NCT00276757|RANDOMIZED|||TREATMENT||||||||
33981571|NCT01866449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981572|NCT01459874|||COHORT||PROSPECTIVE|||||||
33981573|NCT02091882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981574|NCT00575406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981575|NCT05385068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981576|NCT00973193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981577|NCT01203878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981578|NCT00679367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768800|NCT03567954|||OTHER||PROSPECTIVE|||||||
33768801|NCT02951351|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33768802|NCT03240939|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33768803|NCT00723424|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768804|NCT06161805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researchers and participants will not be informed on the nature of the treatment until the trial is fully completed, and the database is locked. Only the clinical pharmacist who prepares the study medication will be aware of the treatment allocation.|1:1 randomization|t|t|t|f
33898258|NCT00043225|||COHORT||OTHER|||||||
33898259|NCT01215318|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|randomly assigned to either modified or unmodified tampons||t|f|t|f
33898260|NCT00677781|||COHORT||PROSPECTIVE|||||||
33898261|NCT04946344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||30 ambulatory, community-dwelling persons that meet the ACR clinical criteria for knee osteoarthritis|f|f|f|t
33898262|NCT06414122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898263|NCT01410591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981579|NCT03450070|NA|SINGLE_GROUP||OTHER||NONE||||||
33981580|NCT04189003|||COHORT||RETROSPECTIVE|||||||
33981581|NCT00004825||||TREATMENT||||||||
33898264|NCT01171521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981582|NCT04453462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981583|NCT04328532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective interventional clinical cohort study, monocentric, controlled, open.||||
33981584|NCT02735174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981585|NCT05577845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981586|NCT01408199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981587|NCT02852980|||COHORT||RETROSPECTIVE|||||||
33981588|NCT00118547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981589|NCT04729660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33981590|NCT05247658|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Self-controlled trial: each patient serves as his or her own control. After bilateral PRK procedure, patients will receive both treatments, one treatment in each eye.||||
33981591|NCT04349735|NA|SINGLE_GROUP||TREATMENT||NONE||comparison of three methods of assessment of inhaltion technique||||
33981592|NCT05091385|||CASE_ONLY||RETROSPECTIVE|||||||
33981593|NCT04661878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981594|NCT00386009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898265|NCT00772850|||COHORT||RETROSPECTIVE|||||||
33898266|NCT03750838|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898267|NCT06479005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|open label|Monocentric prospective interventional feasibility study||||
33898268|NCT05175859|||COHORT||RETROSPECTIVE|||||||
33898269|NCT05101707|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||CIMT plus taVNS||||
33898270|NCT00014742|RANDOMIZED|||TREATMENT||||||||
33981595|NCT03741595|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898271|NCT01591590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898272|NCT01568944|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33898273|NCT01334112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898274|NCT03145129|||CASE_CONTROL||PROSPECTIVE|||||||
33898275|NCT05634564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898276|NCT04605679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898277|NCT02801357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898278|NCT06433427|||OTHER||CROSS_SECTIONAL|||||||
33898279|NCT01075425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898280|NCT05840705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898281|NCT00914342|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898282|NCT00782080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981596|NCT03688126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The U.S. POINTER Coordinating Center (CC) is divided into two distinct entities: the Administrative and Clinical Operations CC and the Data CC. Investigators and staff within the Administrative and Clinical Operations CC will be masked to outcomes data. Investigators and staff within the Data CC will be unmasked to intervention assignment and outcomes. In the clinic, examiners, data entry staff, and the study clinician will be masked to intervention assignment.||f|t|t|t
33981597|NCT00993252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981598|NCT05442866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981599|NCT01829308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981600|NCT03663803|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33981601|NCT04175964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33981602|NCT03261323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981603|NCT05901922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups, an application and a control group, will be used. Social skills training will be applied to one of the two groups with schizophrenia and not to the other group.|f|f|f|t
33981604|NCT02985593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981605|NCT05380271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981606|NCT05723809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981607|NCT01149629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768805|NCT01350622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839307|NCT01093469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33839308|NCT01225653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839309|NCT04832659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839310|NCT01706705|NA|SINGLE_GROUP||OTHER||NONE||||||
33839311|NCT06417710|||COHORT||PROSPECTIVE|||||||
33839312|NCT00567840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839313|NCT04707664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|This Phase 2b, multicenter, placebo-controlled, double-blind study will randomize approximately 500 adult patients who are symptomatic with mild or moderate COVID-19 (as defined in the FDA Guidance Document: Covid-19: Developing Drugs and Biological Products for Treatment or Prevention, May 2020) who are at high risk for progression to more severe disease. Patients will be randomized in a 1:1 ratio to inhaled sargramostim plus standard of care (SOC) or placebo plus SOC. Enrollment of patients who have completed a COVID-19 vaccination regimen or participated in a COVID-19 vaccine clinical trial will be capped at approximately 100 patients.|t|f|t|f
33839314|NCT01597843|RANDOMIZED|PARALLEL||||NONE||||||
33839315|NCT03752177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839316|NCT00270192|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33839317|NCT03423927|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants who agree to participate in the intervention are assigned in the experimental group, whereas participants who do not agree to participate in the intervention, but agree to answer the questionnaires, are assigned in the control group||||
33839318|NCT00911768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839319|NCT05548972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839320|NCT02380053|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839321|NCT01425619|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33839322|NCT05845203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839323|NCT02071277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839324|NCT03718377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839325|NCT03944655|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33839326|NCT00022945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839327|NCT05168462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839328|NCT03455998|||COHORT||PROSPECTIVE|||||||
33839329|NCT04954326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768806|NCT05185518|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will use the novel port for insulin injections for 3 days and will use standard subcutaneous sites for 3 days (in random order).||||
33768807|NCT05284305|||COHORT||RETROSPECTIVE|||||||
33768808|NCT02693834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768809|NCT03681795|NON_RANDOMIZED|PARALLEL||OTHER||NONE||compare PET-evaluated glutamaergic system activity (\[18F\]-FNM) between patients with Gilles de la Tourette and healthy volunteers paired in sex, age and manual laterality||||
33768810|NCT03044262|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898283|NCT05578521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898284|NCT04302272|||COHORT||PROSPECTIVE|||||||
33898285|NCT05942690|NA|SINGLE_GROUP||OTHER||NONE||||||
33898286|NCT00813839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898287|NCT06070038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study will consist of a wait list control trial, with one group assigned to receive the intervention immediately, and one group assigned to act as a control group before receiving the intervention after data collection is completed. The model also includes a stopping rule, such that 12-month follow-up data will not be collected if there is no significant effect of the intervention on the primary outcome (i.e. leisure time PA) at the 3-month follow-up.||||
33898288|NCT01689389|||COHORT||PROSPECTIVE|||||||
33898289|NCT06184581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blinded two-armed, parallel randomized trial|f|f|f|t
33898290|NCT05739708|NA|SINGLE_GROUP||OTHER||NONE||||||
33898291|NCT04526522|||COHORT||PROSPECTIVE|||||||
33898292|NCT02846077|||COHORT||PROSPECTIVE|||||||
33898293|NCT06511661|||CASE_CONTROL||RETROSPECTIVE|||||||
33898294|NCT03797443|NA|SINGLE_GROUP||TREATMENT||NONE||Ascorbic Acid Paclitaxel Protein Bound Cisplatin Gemcitabine||||
33898295|NCT00098059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898296|NCT00251069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898297|NCT02677779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898298|NCT03991637|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33898299|NCT04430348|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33898300|NCT02862210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898301|NCT04425850|||COHORT||PROSPECTIVE|||||||
33898302|NCT06449625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized 1:1|t|t|t|t
33898303|NCT05712668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 100 patients will be enrolled and randomized if they meet the inclusion criteria. Fifty patients allocated will be allocated to receive pre-operative counseling via standard face-to-face care and 50 patients allocated to receive standard pre-operative counseling with the addition of asynchronous telemedicine.||||
33898304|NCT01804855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898305|NCT00765479|RANDOMIZED|||TREATMENT||DOUBLE||||||
33898306|NCT00482001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33898307|NCT04358978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898308|NCT04671680|||COHORT||PROSPECTIVE|||||||
33898309|NCT03865342|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33898310|NCT03229577|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33898311|NCT06059937|||COHORT||RETROSPECTIVE|||||||
33898312|NCT03852225|||COHORT||PROSPECTIVE|||||||
33898313|NCT03041623|||COHORT||PROSPECTIVE|||||||
33898314|NCT04909021|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|The study is single-mask. Study participants and their parent(s)/guardian(s) will not know their child's study assignment; investigators, site staff, and site pharmacists will remain unmasked.|1st 5 subjects will be in Group 1 and randomized to investigational vaccine (IP) Dosage 1 or placebo. Safety Monitoring Committee (SMC) will review Group 1 data to Day 15 to allow dose escalation. Next 10 subjects will be in Group 2 and randomized to IP Dosage 2 or placebo. SMC will review Group 2 data to Day 15 to allow dose escalation. Next 12 enrolled subjects will be in Group 3 and randomized to IP Dosage 3 or placebo. SMC will review Group 3 data to Day 15 to allow dose escalation. Next 12 subjects will be in Group 4 and randomized to IP Dosage 4 or placebo. SMC will review Group 4 data to Day 15 to allow dose escalation. Next 12 subjects will be in Group 3a and randomized to IP Dosage 3 or placebo; if meet criteria will receive 2nd dose IP or placebo 28 days after 1st dose. Final 12 subjects will be in Group 4a and randomized to IP Dosage 4 or placebo; if meet criteria will receive 2nd dose IP or placebo 28 days after 1st dose.|t|f|f|f
33898315|NCT01088412|||COHORT||PROSPECTIVE|||||||
33768811|NCT00038441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768812|NCT02676323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768813|NCT05290610|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single group prospective feasibility study on adult epilepsy patients evaluating whether study tasks and workflow are feasible||||
33768814|NCT00869882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768815|NCT03093857|||OTHER||PROSPECTIVE|||||||
33768816|NCT01628627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768817|NCT03301688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768818|NCT02631421|||COHORT||CROSS_SECTIONAL|||||||
33768819|NCT06106815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768820|NCT05707013|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive traditionally fabricated orthotics or HP Arize 3D-printed orthotics for treatment of plantar fasciitis.||||
33768821|NCT01800708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768822|NCT04057911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768823|NCT00738452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768824|NCT01665287|||CASE_ONLY||PROSPECTIVE|||||||
33768825|NCT01448954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768826|NCT03954158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768827|NCT01324479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768828|NCT00836173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768829|NCT02543021|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33768830|NCT01336881|||||RETROSPECTIVE|||||||
33768831|NCT02581176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768832|NCT03179943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768833|NCT05905991|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33768834|NCT03247374|RANDOMIZED|PARALLEL||TREATMENT||NONE||simple randomization into two groups||||
33768835|NCT02294110|||COHORT||PROSPECTIVE|||||||
33768836|NCT05351060|NA|SINGLE_GROUP||PREVENTION||NONE||The study will include up to 10 patients with autoimmune diseases, including either scleroderma, rheumatoid arthritis, or osteoarthritis, which may include the elderly. The study will compare pre and post-evaluation measures for each individual participant through a multiple time series design.||||
33768837|NCT01073839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768838|NCT00794001|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33768839|NCT00189111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768840|NCT06170736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768841|NCT00595829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768842|NCT00852670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768843|NCT03644355|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cross-sectional, randomized controlled trial||||
33768844|NCT00837525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768845|NCT03747770|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Age range of subjects: 13 up to 18 years of age~* Vaccination - grade 8: 13 to less than 15 years of age~* Behavioral questionnaire: grade 8 (as above) and 15-18 years of age for baseline (unvaccinated) and Year 2 and Year 4 cross-sectional surveys post vaccination~* Urine collection: 15-18 years of age for baseline (unvaccinated) and Year 2 and Year 4 cross-sectional surveys post vaccination~* Blood collection: grade 8 (as above) and 15-18 years of age for Year 2 and Year 4 cross-sectional surveys post vaccination"||||
33768846|NCT01912781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33768847|NCT02293837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768848|NCT01311362|||CASE_CONTROL||PROSPECTIVE|||||||
33898316|NCT05329792|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.||||
33898317|NCT02551172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898318|NCT02424539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898319|NCT06510335|NA|SINGLE_GROUP||OTHER||NONE|The study includes a single arm. Participants did not know the market name of the products they used. Products were packaged in plain bottles with the instruction label affixed.|||||
33898320|NCT03263598|||COHORT||PROSPECTIVE|||||||
33898321|NCT04831944|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33898322|NCT01479725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898323|NCT04926155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898324|NCT01944215|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898325|NCT03831503|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This study will adhere to a dose escalation scheme. There are five cohorts for Study ZIKA-dMAb 01. Participants (n=6 per cohort) will be administered INO-A002 at four dose levels: 0.5, 1, 2, and 4 mg DNA/dose.||||
33898326|NCT02774707|||||CROSS_SECTIONAL|||||||
33898327|NCT05838417|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33898328|NCT00519532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898329|NCT02441803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981608|NCT01027780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981609|NCT03760211|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33981610|NCT02627209|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981611|NCT03347903|||COHORT||PROSPECTIVE|||||||
33981612|NCT00907998|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33981613|NCT01820923|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33981614|NCT02410928|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768849|NCT00721656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33768850|NCT00840372|||COHORT||PROSPECTIVE|||||||
33768851|NCT01646684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768852|NCT00227760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768853|NCT05645289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768854|NCT00717678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768855|NCT04707131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768856|NCT05493982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768857|NCT05611411|||OTHER||PROSPECTIVE|||||||
33768858|NCT06448455|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768859|NCT01560260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768860|NCT00216762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768861|NCT00726349|||COHORT||PROSPECTIVE|||||||
33768862|NCT01791634|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768863|NCT02069756|||COHORT||PROSPECTIVE|||||||
33768864|NCT04361032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768865|NCT02265081|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768866|NCT05315284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768867|NCT03229434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|pseudonymes||f|f|f|t
33768868|NCT06267443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768869|NCT03462706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768870|NCT02095964|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33768871|NCT00986115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33768872|NCT04536571|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33768873|NCT04996199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768874|NCT05680675|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768875|NCT01002664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768876|NCT02035813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768877|NCT01200030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898330|NCT01666522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898331|NCT00599651|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898332|NCT00097266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898333|NCT05751525|||CASE_CONTROL||RETROSPECTIVE|||||||
33898334|NCT01809236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898335|NCT04776343|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898336|NCT03608956|||COHORT||PROSPECTIVE|||||||
33898337|NCT04508309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898338|NCT03855254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33898339|NCT02367612|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33898340|NCT03697239|NA|SINGLE_GROUP||TREATMENT||NONE||Ascorbic Acid Paclitaxel Protein Bound Cisplatin Gemcitabine||||
33898341|NCT05159765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898342|NCT03303430|||CASE_ONLY||PROSPECTIVE|||||||
33898343|NCT01843712|||COHORT||CROSS_SECTIONAL|||||||
33898344|NCT02682329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898345|NCT03077295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33898346|NCT04600999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898347|NCT04205422|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33898348|NCT05863936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898349|NCT05513976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR4640 VS. Placebo|t|t|t|t
33898350|NCT01625169|NA|SINGLE_GROUP||||NONE||||||
33898351|NCT01855555|||COHORT||PROSPECTIVE|||||||
33898352|NCT01826669|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33898353|NCT06244966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparative study of two collection methods for blood samples||||
33898354|NCT01243476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898355|NCT04261621|||CASE_ONLY||PROSPECTIVE|||||||
33898356|NCT02207387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898357|NCT02584985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981615|NCT01455961|||||RETROSPECTIVE|||||||
33768878|NCT03672513|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33768879|NCT04337060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33898358|NCT01466114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898359|NCT06459752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981616|NCT03365037|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open, parallel controlled, non inferiority clinical trial design was used in this trial.Objective to evaluate the safety and effectiveness of electret static physiotherapy film in Beijing Youshilin science and Technology Development Co., Ltd.The patients were followed up after receiving the electret static physiotherapy film, and the treatment and complication rate of the patients were observed after the electret static physiotherapy film was attached to the patient.The data were compared between the experimental group and the control group.||||
34103519|NCT06688357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is triple blinded. One of the co-investigators not involved in participant contact created a color-coded randomization schedule that mapped onto the active vs sham conditions. The randomization schedule was used to assign participants to one vs another color group. The devices were color coded. As such, the project coordinator, research assistants, and the PI were unaware of the participant's intervention status other than color assignment. All statistical analyses were done blindly using the color code for groups.|randomized, sham controlled|t|f|f|t
33768880|NCT01278108|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33768881|NCT03847623|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33768882|NCT03550586|||CASE_CONTROL||PROSPECTIVE|||||||
33981617|NCT03210636|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33981618|NCT00072124|RANDOMIZED|||TREATMENT||||||||
33981619|NCT02869646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981620|NCT04513379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981621|NCT05383222|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|Participants|Participants complete 2 tasks, the order of which is randomised.||||
34103520|NCT01293864|||CASE_ONLY||PROSPECTIVE|||||||
33768883|NCT00944281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103521|NCT02307877|||CASE_CONTROL||PROSPECTIVE|||||||
34103522|NCT02771145|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768884|NCT00325936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768885|NCT05854212|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes will be automatically obtained from the food bank database.|Food agencies will be randomized to one of two interfaces on the online food bank ordering platform.|f|f|f|t
33768886|NCT01414413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981622|NCT03553823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded outcome assessor assessed subjects on each visit for target plaque TCS, PASI, IGA, BSA, ppIGA, PSSI, NAPS.|This was a 16-week, randomized, open-label, parallel-group, active-control study comparing secukinumab 300 mg s.c. versus guselkumab 100 mg s.c. in subjects with plaque psoriasis who had an inadequate response to ustekinumab.|f|f|f|t
33981623|NCT02589171|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768887|NCT00000343||||TREATMENT||||||||
33768888|NCT06624501|||COHORT||PROSPECTIVE|||||||
33839330|NCT06181253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103523|NCT02465814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103524|NCT06679907|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, comparative, unblinded, randomized, controlled, prospective, parallel-arm multicenter superiority clinical trial||||
34103525|NCT00938080|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33981624|NCT03943433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33981625|NCT06261229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981626|NCT05532332|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, two-way crossover, open-label, laboratory blind, bioequivalence study||||
33981627|NCT06547944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981628|NCT02087371|||COHORT||PROSPECTIVE|||||||
33981629|NCT03100305|||COHORT||PROSPECTIVE|||||||
33981630|NCT02869425|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33981631|NCT03056781|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34103526|NCT01627106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839331|NCT04444934|||COHORT||RETROSPECTIVE|||||||
33839332|NCT04625959|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||MOST: multiphase optimization strategy|t|f|f|f
33839333|NCT05723757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an exploratory, intra-individual, prospective, mono-site study. This study is a category 2 study (interventional research with minimal risks and constraints).||||
33839334|NCT02049853|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839335|NCT03559062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839336|NCT00223509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839337|NCT06358248|||COHORT||RETROSPECTIVE|||||||
33839338|NCT00767390|||CASE_ONLY||PROSPECTIVE|||||||
33839339|NCT01637077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33839340|NCT01480063|||COHORT||PROSPECTIVE|||||||
33898360|NCT00201851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898361|NCT03478683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a phase 4 double blind study, which will use a triple dummy design for dosing.|This is a parallel group study. Eligible subjects will be randomized in a ratio of 1:1 to receive either FF/UMEC/VI single inhaler triple therapy or multiple inhaler triple combination therapy (budesonide/formoterol plus tiotropium) during the treatment period.|t|f|t|f
33898362|NCT01581411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898363|NCT00950417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898364|NCT01703312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898365|NCT01367132|||COHORT||PROSPECTIVE|||||||
33898366|NCT00003565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078652|NCT06420388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study employed a double-blind masking approach to minimize potential bias. Patients, surgeons, and outcome assessors were blinded to treatment allocation. The randomization scheme was generated by a third party not involved in patient care, and sealed envelopes containing the allocation were opened only after the haemorrhoidectomy procedure was completed. The study gels were packaged identically to maintain blinding. Unblinding occurred only after data analysis was completed. This double-blind design ensured that knowledge of treatment allocation did not influence postoperative care, patient-reported pain scores, or the assessment of outcomes.|This study is a single-center, randomized, double-blind, controlled clinical trial comparing the efficacy of 2% lidocaine gel versus a non-anaesthetic lubricant gel control in reducing postoperative pain and analgesic consumption following haemorrhoidectomy. Patients were randomly assigned in a 1:1 ratio to either the intervention group receiving 5 mL 2% lidocaine gel three times per day postoperatively or the control group receiving 5 mL of a non-anaesthetic water-based lubricant gel.|t|t|t|t
33768889|NCT04299477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"25 patients with periodontitis (P) and osteoporosis (group 1), 25 systemically healthy patients with P (group 2) and 25 systemically and periodontally healthy individuals (group 3) were enrolled in this study.~Individuals were periodontally examined at baseline, 1 month and 3 months following the non-surgical periodontal therapy.~Participants in group 1 and 2 received non-surgical periodontal therapy including supra- and subgingival scaling, and root planning.Patients were advised and instructed to perform oral care twice a day, use interdental toothbrushes once a day regularly. No scaling and root planning was performed in the group 3."||||
33768890|NCT02947698|||CASE_CONTROL||RETROSPECTIVE|||||||
33981632|NCT02918994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981633|NCT06361225|||CASE_ONLY||PROSPECTIVE|||||||
33981634|NCT04697498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981635|NCT03587649|NA|SINGLE_GROUP||OTHER||NONE||||||
33981636|NCT04738032|||OTHER||OTHER|||||||
33981637|NCT03472365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981638|NCT02962570|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981639|NCT03784664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33981640|NCT05552001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981641|NCT00486109|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33981642|NCT03281109|||CASE_ONLY||PROSPECTIVE|||||||
33981643|NCT04155281|||CASE_ONLY||PROSPECTIVE|||||||
33981644|NCT00720265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981645|NCT04933825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981646|NCT04332302|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078653|NCT05459415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078654|NCT01677741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078655|NCT03984344|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Researcher unable to be blinded as stimulation site is dependent on the participants allocation to intermittent or continuous TBS.|Participants will be randomly allocated to one of three treatment arms: continuous TBS or intermittent TBS or sham TBS.|t|f|f|f
34078656|NCT01691378|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||After enrollment, participants were randomized to either receive the WtoH Intervention first, or Waitlist Control. After Time 2, the Waitlist Control arm crosses over and has the opportunity to participate in the WtoH Intervention.|f|f|f|t
34078657|NCT00032448|RANDOMIZED|PARALLEL||||NONE||||||
34078658|NCT03281772|||CASE_ONLY||PROSPECTIVE|||||||
34078659|NCT03361852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients will receive 4 weekly doses of rituximab. Afterwards, will receive either NeoVax alone (first 5 patients) or NeoVax in combination with pembrolizumab (5 patients)||||
34078660|NCT00360425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34078661|NCT04214210|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33768891|NCT00575068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981647|NCT04538170|||CASE_CONTROL||RETROSPECTIVE|||||||
33981648|NCT01671514|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33981649|NCT00527423|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33981650|NCT01206257|||COHORT||PROSPECTIVE|||||||
33981651|NCT04569942|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, controlled trial||||
33981652|NCT05301465|||COHORT||PROSPECTIVE|||||||
33981653|NCT00543686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981654|NCT00083785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981655|NCT04303364|||COHORT||PROSPECTIVE|||||||
33981656|NCT01674530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981657|NCT00731926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981658|NCT00242866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33981659|NCT03940001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981660|NCT04586088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981661|NCT00024453|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33981662|NCT00047606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34078662|NCT02766348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078663|NCT04179877|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The control municipalities are unaware of this project, and are thus masked to the study.|Naturalistic controlled trial with one municipality (Bodø) as treatment group and 10 similar municipalities without IPS services as controls.||||
33768892|NCT06072820|NA|SINGLE_GROUP||OTHER||NONE||||||
33768893|NCT01317290|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768894|NCT03298438|||COHORT||PROSPECTIVE|||||||
33768895|NCT05009706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33768896|NCT02390843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768897|NCT00561444|||CASE_ONLY||PROSPECTIVE|||||||
33768898|NCT01200537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768899|NCT00367913|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33768900|NCT01267591|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898367|NCT06367270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898368|NCT05110248|||OTHER||CROSS_SECTIONAL|||||||
33898369|NCT05421377|||COHORT||PROSPECTIVE|||||||
33898370|NCT05121246|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33898371|NCT00949650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898372|NCT03750162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898373|NCT01821248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898374|NCT03126227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2:1 randomization to AR101 or placebo|t|t|t|f
33898375|NCT02604719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898376|NCT02124850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898377|NCT05552638|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre/Post-test design||||
33898378|NCT01635569|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898379|NCT04064710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898380|NCT01803165|||COHORT||PROSPECTIVE|||||||
33898381|NCT02066662|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33898382|NCT03084159|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33898383|NCT03894540|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33898384|NCT03689231|||COHORT||RETROSPECTIVE|||||||
33768901|NCT06437730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768902|NCT02887417|||COHORT||PROSPECTIVE|||||||
33768903|NCT04048252|||CASE_ONLY||PROSPECTIVE|||||||
33768904|NCT02153359|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33768905|NCT00412035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768906|NCT00749801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33768907|NCT03585491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768908|NCT00291655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33768909|NCT05716841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768910|NCT03864120|||CASE_ONLY||CROSS_SECTIONAL|||||||
33768911|NCT01536145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768912|NCT03942913|||COHORT||PROSPECTIVE|||||||
33898385|NCT01483404|||CASE_ONLY||PROSPECTIVE|||||||
33898386|NCT01498510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898387|NCT01070355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898388|NCT03939910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898389|NCT04760548|||OTHER||OTHER|||||||
33898390|NCT04577768|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled trial (RCT)|t|f|f|f
33898391|NCT01746602|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33768913|NCT00012181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768914|NCT06108089|||COHORT||PROSPECTIVE|||||||
33768915|NCT00350701|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33768916|NCT01937637|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768917|NCT02556905|||CASE_ONLY||PROSPECTIVE|||||||
33768918|NCT05428462|||COHORT||RETROSPECTIVE|||||||
33768919|NCT03869515|||CASE_ONLY||PROSPECTIVE|||||||
33768920|NCT02894996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768921|NCT03740880|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups: 1 groups of patients receiving an early trigger (14mm), the other group receiving a late trigger (17mm)||||
33768922|NCT03066570|NA|SEQUENTIAL||TREATMENT||NONE||Randomized replicated sequential single-case design.||||
33768923|NCT05532241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Groups were labeled as I-IV, appliance is fixed on teeth and visible for both participants and care providers. Mouthwash is also visible. Outcome assessor does not know wether patient was in mouthwash group, but he sees the type of appliance. Microbiologist and statisticians are not aware of the group affiliation.|2 types of appliances and 2 experimental conditions|f|f|f|t
33768924|NCT00599989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768925|NCT02283437|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessors are blind to the group assignment and intervention received by the participants|Repeated-measures, three-arm design|f|f|f|t
33768926|NCT01427361|||OTHER||PROSPECTIVE|||||||
33768927|NCT06374537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768928|NCT03532893|||COHORT||PROSPECTIVE|||||||
33768929|NCT04355559|||CASE_CONTROL||RETROSPECTIVE|||||||
33768930|NCT01465503|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33768931|NCT00397267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768932|NCT04879316|||COHORT||PROSPECTIVE|||||||
33768933|NCT02735733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33768934|NCT04110366|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33768935|NCT00210119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768936|NCT04639778|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multi-centre, randomised, open, controlled study||||
33768937|NCT00798564|||OTHER||CROSS_SECTIONAL|||||||
33768938|NCT00602186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33768939|NCT02085343|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33768940|NCT00657514|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33768941|NCT03677882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768942|NCT04015102|||CASE_ONLY||PROSPECTIVE|||||||
33768943|NCT04114240|||OTHER||PROSPECTIVE|||||||
33768944|NCT02732860|||COHORT||PROSPECTIVE|||||||
33768945|NCT05348408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33768946|NCT05951725|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33768947|NCT00630058|RANDOMIZED|PARALLEL||||NONE||||||
33768948|NCT03241524|NA|SINGLE_GROUP||PREVENTION||NONE||Perineal floor muscle performance and participants' sexual functions were evaluated in three successive situations: (1) Initial evaluation; (2) after 4 weeks (intermediate evaluation), and (3) 8 weeks (final evaluation) from the start of the training program.||||
33768949|NCT03377790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768950|NCT04353193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind||t|f|f|f
33768951|NCT01073410|||CASE_CONTROL||PROSPECTIVE|||||||
33768952|NCT02406989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768953|NCT01342185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768954|NCT01931579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768955|NCT01783353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768956|NCT00004430|RANDOMIZED|||TREATMENT||||||||
33768957|NCT04970095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768958|NCT04874064|||COHORT||PROSPECTIVE|||||||
33768959|NCT01989559|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33768960|NCT05125393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33768961|NCT02476214|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33768962|NCT05539196|||COHORT||PROSPECTIVE|||||||
33768963|NCT01953770|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33768964|NCT02215330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768965|NCT01035333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768966|NCT02054312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768967|NCT02439177|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33768968|NCT01022073|||COHORT||PROSPECTIVE|||||||
33768969|NCT00110760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768970|NCT03438240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33768971|NCT04827134|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study|This is a randomized, single-dose, 2-cohort, 2-period crossover study.||||
33768972|NCT00452413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768973|NCT01474460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768974|NCT02381743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33768975|NCT01040286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33768976|NCT04451343|||COHORT||PROSPECTIVE|||||||
33768977|NCT04278430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The care provider were masked and the pre-post testing was performed by different therapist unaware of the assignment of children.||t|t|f|t
33768978|NCT04809792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33768979|NCT05341375|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33768980|NCT02151019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768981|NCT03230422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|residents, fellows and attending with different level of experience||t|f|f|f
33768982|NCT00315913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768983|NCT01014221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768984|NCT04324294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33768985|NCT03729921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33768986|NCT01988896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33768987|NCT02921373|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33768988|NCT02973360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768989|NCT06176820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33768990|NCT05246319|||COHORT||RETROSPECTIVE|||||||
33768991|NCT00519636|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33898392|NCT01372891|||CASE_CONTROL||PROSPECTIVE|||||||
33898393|NCT01224899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981663|NCT01075711|||COHORT||PROSPECTIVE|||||||
34078664|NCT00577317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34078665|NCT05357534|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34103527|NCT06687772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103528|NCT00827307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898394|NCT05533554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Simple, dynamic randomization will be carried out, balancing the groups based on sex (Female/Male). The masking will be single blind, where the researcher will know which participants will make up each group, said information will not be known to the participant.|Experimental methodology with experimental group and control group on waiting list.|t|f|f|t
33898395|NCT02967523|||CASE_ONLY||OTHER|||||||
33898396|NCT02924753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898397|NCT06073314|||OTHER||PROSPECTIVE|||||||
33898398|NCT05951127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898399|NCT01775566|||CASE_CROSSOVER||PROSPECTIVE|||||||
33898400|NCT05426044|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33898401|NCT00927680|||FAMILY_BASED||PROSPECTIVE|||||||
34078666|NCT02692807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This is only for the RCT Study - the double-blinded study. The HARP study consists of only a prospective longitudial study With same outcome measure and follow-ups; hence, given 3 arms. The below Allocation and Number of Subjects is ONLY for the RCT part of the study"|The RCT part of the HIPARTI Study has 2 arms, but there is also a prospective longitudinal study of those who are either not willing to participate in the RCT, or where the study takes part in collaborating countries were there is ONLY the prospective longitudial ongoing (Australia). This part of the study is the HARP study. The HIPARTI consists on one RCT trial eith two parallel arms, and one prospective cohort, the HARP study.|t|f|f|t
34078667|NCT04866966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078668|NCT01908868|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898402|NCT03088605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078669|NCT02155192|||COHORT||RETROSPECTIVE|||||||
34078670|NCT05989555|||COHORT||PROSPECTIVE|||||||
34078671|NCT04758728|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103529|NCT06309433|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898403|NCT03000738|||COHORT||PROSPECTIVE|||||||
33898404|NCT02569489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898405|NCT02862912|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
33898406|NCT01857986|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33898407|NCT03180762|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33898408|NCT03790735|||COHORT||CROSS_SECTIONAL|||||||
33898409|NCT02612597|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898410|NCT01663129|||COHORT||PROSPECTIVE|||||||
33898411|NCT02533622|||COHORT||PROSPECTIVE|||||||
33898412|NCT02911987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33898413|NCT02012816|NA|SINGLE_GROUP||||NONE||||||
33898414|NCT05858411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898415|NCT02846675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898416|NCT02708511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898417|NCT06223425|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33898418|NCT00222079|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33898419|NCT03803345|||OTHER||PROSPECTIVE|||||||
33898420|NCT05347654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898421|NCT02143271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898422|NCT06292312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (outcomes assesor) The evaluation of the patients will be carried out by a blinded investigator.|dual parallel group design|f|f|f|t
33898423|NCT06153381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898424|NCT00058799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898425|NCT05815238|||OTHER||PROSPECTIVE|||||||
33898426|NCT03863938|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898427|NCT04236453|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33898428|NCT02097199|||||PROSPECTIVE|||||||
33898429|NCT06320951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103530|NCT06019728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103531|NCT06613685|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Phase 2 of the study has 2 periods: Randomized and Extension, which are both open label.~Phase 3 of the study has 2 periods: Randomized Period which would be double-blind (at least Week 96), followed by an Extension Period which will be Open-label."||t|f|t|f
33768992|NCT03267290|NA|SINGLE_GROUP||OTHER||NONE||||||
33898430|NCT00837681|||COHORT||PROSPECTIVE|||||||
33898431|NCT00397956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898432|NCT06261528|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an open label, single arm, single center phase 1 research study designed to generate safety data, biomarker data, and preliminary efficacy data to reduce fatigue in patients with progressive MS, to include PPMS and SPMS||||
33898433|NCT00944944|||COHORT||PROSPECTIVE|||||||
33898434|NCT02146781|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898435|NCT05057624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33898436|NCT04150432|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Consecutive patients will participate in the study||||
33898437|NCT05449808|||OTHER||CROSS_SECTIONAL|||||||
33898438|NCT05295277|||COHORT||RETROSPECTIVE|||||||
33898439|NCT03089567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898440|NCT00000249|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981664|NCT03267745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Sachets with the supplement will be blinded to the participant, and research assistants. Outcomes assessors will be blinded to condition as well.|2 groups of 10 each will be randomized to receive amino acid supplementation or placebo for 28 days during which they will have one leg immobilized by a removable brace.|t|t|f|t
33981665|NCT00983710|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33981666|NCT00843323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981667|NCT01436032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981668|NCT02845895|||COHORT||PROSPECTIVE|||||||
33981669|NCT04348162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33898441|NCT02241018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898442|NCT02344940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898443|NCT02572037|||COHORT||PROSPECTIVE|||||||
33898444|NCT01215539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898445|NCT03340805|RANDOMIZED|PARALLEL||OTHER||NONE|Study participants, care provider, investigator, and outcomes assessor will not be masked to intervention allocation.|Single-center, open-label, randomized pragmatic clinical trial||||
33898446|NCT05459805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898447|NCT04698408|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33898448|NCT06399549|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898449|NCT06456723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981670|NCT03716141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981671|NCT04251390|||CASE_ONLY||PROSPECTIVE|||||||
33981672|NCT02757248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898450|NCT02686801|||COHORT||PROSPECTIVE|||||||
33898451|NCT04031261|||OTHER||OTHER|||||||
33768993|NCT06364241|||OTHER||CROSS_SECTIONAL|||||||
33768994|NCT05422456|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33768995|NCT06014619|||COHORT||RETROSPECTIVE|||||||
33768996|NCT03337321|||COHORT||CROSS_SECTIONAL|||||||
33768997|NCT00885573|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
33768998|NCT00082537|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33768999|NCT05046535|||COHORT||CROSS_SECTIONAL|||||||
33769000|NCT01415843|||COHORT||PROSPECTIVE|||||||
33769001|NCT03716622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769002|NCT00692640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769003|NCT00437021|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33769004|NCT02377960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769005|NCT00538096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769006|NCT00466674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769007|NCT04403958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769008|NCT01483157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769009|NCT02692950|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33769010|NCT03303677|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization into one of three treatment arms||||
33769011|NCT00131859|||CASE_CONTROL||PROSPECTIVE|||||||
33769012|NCT05230979|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769013|NCT02299258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769014|NCT04398693|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of acetate and butyrate in a sachet with a powder that must be dissolved in a glass of liquid during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study. Afterwards, endothelial function studies, evaluating the vasodilation mediated by flow (flow-mediated dilation-FMD), and peripheral and central hemodynamics are also performed before and after the two treatment periods.|t|t|f|f
33769015|NCT02518724|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33769016|NCT04282213|||CASE_CONTROL||PROSPECTIVE|||||||
33769017|NCT00674115|RANDOMIZED|CROSSOVER||||NONE||||||
33769018|NCT04397523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769019|NCT05391321|NA|SINGLE_GROUP||OTHER||NONE|The order of the questionnaires tested will be randomized in each bundle according to the random method. Each bundle will receive a randomization number which will not be known to the patient or the principal investigator.|women will have to answer the 4 sexual quality of life questionnaires. the order of the 4 questionnaires will be randomized||||
33769020|NCT06183086|||COHORT||PROSPECTIVE|||||||
33769021|NCT00087789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769022|NCT02274376|||COHORT||PROSPECTIVE|||||||
33769023|NCT05818059|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis.|"After enrolment, each subject will be assessed according to sequence AB (assessment by clinician #1 without CAD and assessment by clinician #2 with CAD) or sequence BA (assessment by clinician #1 with CAD and assessment by clinician #2 without CAD). Allocation to sequence AB or BA will be performed using a computer-generated random assignment list (with a 1:1 ratio), and assignments will be included in sealed opaque envelopes sequentially numbered.~Clinicians cannot be masked to the assessment method (with or without CAD) and cannot be masked to the further assessment (referral for microbiological diagnosis with stool and sputum Xpert) due to care process. However, the statistician will be masked to the assessment during data analysis."|f|f|f|t
33769024|NCT02534532|||||CROSS_SECTIONAL|||||||
33769025|NCT05892523|||CASE_ONLY||PROSPECTIVE|||||||
33769026|NCT04219722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded during the first 12 weeks of the study.|"Study performed in two steps:~* From 0 to 12 weeks: randomized, single-blind, placebo-controlled study~* From 12 to 52 weeks: open label, treatment only study"|t|f|f|f
33769027|NCT01266447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769028|NCT01289041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769029|NCT01643941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33769030|NCT05150587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769031|NCT04963673|||COHORT||PROSPECTIVE|||||||
33769032|NCT02934113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769033|NCT05553158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two arms in this study: control arm and interventional arm. Participants in the control arm will have pelvic vein embolization and participants in the interventional arm will have compression therapy.||||
33769034|NCT03301961|||CASE_ONLY||PROSPECTIVE|||||||
33769035|NCT03984032|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33769036|NCT04785326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769037|NCT01213173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981673|NCT00396526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769038|NCT05692895|||OTHER||RETROSPECTIVE|||||||
33769039|NCT05739032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769040|NCT01802463|||||PROSPECTIVE|||||||
33769041|NCT02546154|||COHORT||PROSPECTIVE|||||||
33769042|NCT05781893|||COHORT||PROSPECTIVE|||||||
33769043|NCT05016037|NA|SINGLE_GROUP||OTHER||NONE||||||
33769044|NCT01229982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769045|NCT02461875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981674|NCT01284205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981675|NCT05285085|||OTHER||RETROSPECTIVE|||||||
33981676|NCT00601302|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981677|NCT00144625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981678|NCT06025448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and health personnel examining the participants will be blinded. It will not be possible to blind the surgeons due to the nature of the intervention.||t|f|f|t
33981679|NCT01674582|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981680|NCT01340430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981681|NCT00995410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898452|NCT00149214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898453|NCT03283839|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898454|NCT04316481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Continued Access||||
33898455|NCT05387330|||COHORT||PROSPECTIVE|||||||
33769046|NCT04711603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898456|NCT02066090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898457|NCT00002423||||TREATMENT||||||||
33898458|NCT00643045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898459|NCT06498375|||COHORT||PROSPECTIVE|||||||
33769047|NCT01811940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898460|NCT04932590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898461|NCT06340412|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||A randomized, double-blinded, controlled, crossover trial|t|f|t|t
33769048|NCT01074749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898462|NCT06511427|||COHORT||PROSPECTIVE|||||||
33898463|NCT05036538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeons, neurologists, and neuropsychologists who will be involved in the assessment of outcome variables will be blinded for randomization status. The intervention sessions will be conducted by a psychological supervisor who is not involved in the evaluation of outcome parameters to ensure blinding.|Randomized controlled intervention study|f|f|t|t
33898464|NCT04347928|||COHORT||PROSPECTIVE|||||||
33769049|NCT06175117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898465|NCT02440724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769050|NCT05317546|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33898466|NCT06304441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898467|NCT02962635|||COHORT||PROSPECTIVE|||||||
33898468|NCT02471417|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33769051|NCT02468609|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33769052|NCT04459559|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed trial is designed as an explorative, open label, non-randomised, uncontrolled clinical trial.||||
33769053|NCT05295563|||COHORT||PROSPECTIVE|||||||
33769054|NCT03870178|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33769055|NCT04572919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33769056|NCT06386029|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, non-blinded intervention trial||||
33769057|NCT01324219|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33898469|NCT04036565|||COHORT||PROSPECTIVE|||||||
33769058|NCT01614977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769059|NCT01168063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769060|NCT04658303|||COHORT||PROSPECTIVE|||||||
33769061|NCT02385578|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33769062|NCT03341650|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769063|NCT00700674|||CASE_CONTROL||PROSPECTIVE|||||||
33769064|NCT04096989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839341|NCT03258320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the participants and care providers will be blind to the agents, but the investigators will be aware of and keep track of the whole regime and agents.|Chemotherapy (single agent of CDMS) will be performed 45 days before surgery for patients who are diagnosed with prostate cancer without distant metastasis. The chemotherapy using CDMS will done for 4 cycles within 30 days after first diagnosis of prostate cancer.|t|t|f|f
33839342|NCT00002377||PARALLEL||TREATMENT||||||||
33839343|NCT05674162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The participants are masked to existence of different conditions, not to the measurement of their data.|Single group, repeated measures model.||||
33898470|NCT02527304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898471|NCT06104683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898472|NCT00003995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898473|NCT00291304|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33898474|NCT04704076|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33898475|NCT05509608|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"This study is structured with two Arms (Aims).~For the first Arm (Aim 1) of this study, subjects (n=10) wear two ERG sensors, a new contact lens electrode and an FDA approved contact lens electrode, one after the other. The signal quality of the recorded ERG responses obtained with each sensor will be compared. Comparison of signal quality will help in assessing the functionality of the new contact lens electrode.~For the second Arm (Aim 2) of this study, subjects (n=10) will wear the two ERG sensors at the same time, one in each eye. After 20, 40 and 60 minutes of wear, each eye will be examined for irritation using standard clinical scales. Observing for ocular irritation will help determine the effect of the devices on the participants."||||
33898476|NCT00974779|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33898477|NCT01975025|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898478|NCT02558023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898479|NCT02409498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33769065|NCT04147767|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|All trial investigators will be blinded to the intervention, except for the CI. The CI will keep a record of interventions administrated. All trial participants and outcome assessors will be blinded to the intervention. Each food product has the same flavour and taste, as well as the same packaging to ensure blinding in maintained throughout study.|Enrolled participants will undergo 1:1 simple randomisation by the CI, to either Experimental arm or placebo arm.. Evaluations after intervention will be made at the end of the first 8 weeks of intervention (Day 56; 8th week) and at the end of the second 8 weeks intervention (Day 140; 20th week). Since a wash out period between the two food products consumption is provided, another evaluation after wash out period (Day 84; 12th week) will be performed. The wash out period consist in a 4 weeks food products free period, where will be ask to participants to maintain their usual dietary and life style habits excluding the consumption of any yoghurt drinks.|t|f|t|t
33769066|NCT02891122|||COHORT||PROSPECTIVE|||||||
33769067|NCT02099435|||COHORT||PROSPECTIVE|||||||
33981682|NCT06025838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention occurs entirely online. All assessment occurs via survey software. Participants do not interact with other participants and are not fully informed of the nature of the intervention and thus do not know if they are in an active condition.|Participants are either assigned to a control (no intervention) condition or to one where they receive positive feedback and are encouraged to specific, positive behavior.|t|t|t|t
33981683|NCT01674556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769068|NCT03710213|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33769069|NCT04925596|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster randomized trial|t|f|f|f
33769070|NCT04661475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|.A double blind, placebo controlled, randomized Feasibility Study|Parallel Assignment|t|f|t|t
33769071|NCT04443179|||CASE_CONTROL||PROSPECTIVE|||||||
33769072|NCT06382285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will include 50 patients who underwent a knee replacement surgery, who will be randomized to 2 groups. 6 hours after surgery the two groups will be connected to a prolonged block pump. One group will receive the peripheral block ropivacaine 0.2% according to the protocol of 8-10 cc per hour up to 24 hours after surgery. The second group will receive saline according to the same protocol|t|f|t|f
33769073|NCT02459249|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33769074|NCT02140346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769075|NCT02106689|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769076|NCT05983926|NA|SEQUENTIAL||TREATMENT||NONE||||||
33769077|NCT04992936|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33721264|NCT05020392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was a pragmatic clinical trial in which patients were divided into two groups, one receiving anti-CD19 CAR-T cells infusion, the other group receiving anti-CD19 CAR-T cells infusion and concurrent oral BTK inhibitor.||||
33721265|NCT06421779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Children aged 4 to 10 years for whom a skin prick test has been decided.|A Prospective parallel group randomized controlled trial.|t|f|f|f
33721266|NCT05757661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769078|NCT00517465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769079|NCT05885113|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||This study will be a single center, single-blinded, two-arm before-and-after trial to test the feasibility of IDC vs. SOC in newborns with CHD after newborn open-heart surgery.|f|f|f|t
33769080|NCT02678689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839344|NCT03912662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839345|NCT04148781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839346|NCT01193413|||CASE_CONTROL||PROSPECTIVE|||||||
33839347|NCT02402153|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33839348|NCT04749680|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, controlled, multicentre, interventional||||
33839349|NCT01549834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839350|NCT03422575|RANDOMIZED|CROSSOVER||OTHER||NONE||This was a bioequivalence study.||||
33839351|NCT00195065|||||PROSPECTIVE|||||||
33839352|NCT02927353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839353|NCT04779762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded||f|f|t|f
33839354|NCT02690753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839355|NCT00391703|RANDOMIZED|PARALLEL||||NONE||||||
33721267|NCT03577743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721268|NCT04563169|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial||||
33721269|NCT05888246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721270|NCT02984189|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33721271|NCT03951740|NA|SINGLE_GROUP||OTHER||NONE|Masking not applicable|This is a single-center validation study with a comparative design. Accuracy and responsiveness of two wrist-worn activity trackers will be assessed. 39 patients (19 with coronary artery disease with preserved left ventricular ejection fraction and 19 with heart failure with reduced left ventricular ejection fraction) will be included.||||
33769081|NCT06317064|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Group 1: Controls 10 females with no dysmenorrhea participated as controls. Group 2: NSAIDS All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."||||
33769082|NCT00808301|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33769083|NCT03161119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721272|NCT05068128|||CASE_ONLY||PROSPECTIVE|||||||
33721273|NCT01287897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721274|NCT02081079|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721275|NCT00003147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721276|NCT01319903|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33721277|NCT00225251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721278|NCT03375801|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE|"first 164 patients will not receive the decision aid, they will only fill out the questionnaires.~The next 164 patients will receive the decision aid and will be asked to fill out the same questionnaires."|Pre- and post intervention study.||||
33721279|NCT00602576|RANDOMIZED|PARALLEL||TREATMENT||NONE||4 arm parallel phase II study Arms A and B are randomized to different schedules of temozolomide Arm C is prior temozolomide-refractory patients Arm D is brain metastases patients||||
33721280|NCT05245760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721281|NCT03065244|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721282|NCT00049101||||TREATMENT||NONE||||||
33721283|NCT05431959|NA|SINGLE_GROUP||TREATMENT||NONE||immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.||||
33721284|NCT02850315|||COHORT||CROSS_SECTIONAL|||||||
33721285|NCT05387655|||CASE_CONTROL||PROSPECTIVE|||||||
33721286|NCT01650038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769084|NCT02490891|NA|SINGLE_GROUP||OTHER||NONE||||||
33769085|NCT03934632|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33769086|NCT03313219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769087|NCT00890058|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769088|NCT02186509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769089|NCT04737213|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective inclusion patients with colorectal lung metastases. Al injected with SGM-101.||||
33769090|NCT03987256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients will have blood puncture. Then, the research coordinator will prepare either an opaque syringe of saline solution or of PRP. At the end of the needling procedure, the investigator will inject the content of the opaque syringe.|In both groups, needling will be performed. Half of the patients will receive PRP (platelet-rich plasma).|t|t|t|t
33769091|NCT02770001|||OTHER||OTHER|||||||
33769092|NCT00003458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769093|NCT02872961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769094|NCT01209481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769095|NCT05238532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769096|NCT00665990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769097|NCT02020499|||COHORT||PROSPECTIVE|||||||
33769098|NCT02138747|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33769099|NCT04978610|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"After informed consent and assent have been obtained and the patient has successfully met the screening criteria, the patient will be enrolled. The study will commence upon the enrollment of approximately 20 participants, at which point participants will be randomized into the Virtual ACT or waitlist (control) group. The intervention group will begin vACT immediately, while the waitlist receive no intervention during the same 6-week time frame. Both groups will take the same baseline questionnaires and post-questionnaires (post, 1 month, and 3 month). After the vACT intervention group finishes, another 6-week vACT session will be offered to the waitlist. The waitlist group will fill out a post-therapy questionnaire again after their 6-weeks. The parents of both groups will fill out a baseline questionnaire and post questionnaires.~The investigators will repeat this protocol until 144 participants or 72 caregiver-child dyads."||||
33769100|NCT01292174|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33769101|NCT04103424|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be asked to complete 2 screening visits to determine eligibility. If participants remain eligible, they will be asked to complete 2 metabolic study visits, 1 before and 1 after 2 weeks of supervised exercise training on a stationary bike.||||
33769102|NCT05051332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Investigational Group : CartiLife® Procedure: Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm\^3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.~Active comparator: Microfracture Surgery Procedure : Microfracture surgery, performed by arthroscopy after the joint is cleaned of calcified cartilage, will be conducted using an awl or drill to create tiny fractures in the subchondral bone plate."|f|f|f|t
33769103|NCT00185510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769104|NCT05056064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769105|NCT04385160|||COHORT||OTHER|||||||
33769106|NCT00592046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769107|NCT01097213|||COHORT||PROSPECTIVE|||||||
33769108|NCT01539174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769109|NCT05099913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769110|NCT03448432|||COHORT||PROSPECTIVE|||||||
33769111|NCT02207517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769112|NCT05000489|||COHORT||OTHER|||||||
33769113|NCT04362137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769114|NCT02977884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769115|NCT00552773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769116|NCT00195715|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769117|NCT01987830|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769118|NCT00432510|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769119|NCT01738893|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33769120|NCT01082172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769121|NCT02608489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769122|NCT00624715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33769123|NCT02811016|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33769124|NCT05539521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769125|NCT05284019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898480|NCT06170255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769126|NCT00782977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33769127|NCT02161861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769128|NCT02559609|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33769129|NCT03926065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33769130|NCT01681498|||COHORT||PROSPECTIVE|||||||
33769131|NCT05228093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769132|NCT02119741|||CASE_ONLY||PROSPECTIVE|||||||
33769133|NCT00022217||||TREATMENT||||||||
33898481|NCT05475691|||COHORT||PROSPECTIVE|||||||
33898482|NCT04432441|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups. Experimental group realizes a therapeutic physical exercise program for scapulo-humeral stabilitation, and the other group (control group) the same program with electrostimulation. The programme consisted of a two-part sequence of isometric prone push-up, being it an optimal position for periscapular stability exercises.||||
33898483|NCT03227861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769134|NCT00603629|||CASE_ONLY||PROSPECTIVE|||||||
33769135|NCT02182219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769136|NCT03316417|||COHORT||OTHER|||||||
33769137|NCT00941538|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33769138|NCT01486615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898484|NCT00637728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898485|NCT03450889|||COHORT||PROSPECTIVE|||||||
33898486|NCT00072189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898487|NCT04102891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33898488|NCT05446298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898489|NCT01351519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898490|NCT03667131|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participant, care provider, investigator and outcomes assessor.|Randomized, double blind, controlled, parallel groups clinical trial.|t|t|t|t
33898491|NCT03808207|RANDOMIZED|PARALLEL||OTHER||SINGLE|The lipid profile will be assessed by an external investigator who is blind for the dietary advices and choices of the single patient. Milk samples are assigned a progressive numerical code.|Blind randomized clinical trial|f|f|f|t
33898492|NCT01683500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981684|NCT01195298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981685|NCT04692610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"218 patients were included in the analysis.~Each group had a different protocol:~Group A - Postoperative Group received stoma education and stoma care after surgery beginning from the postoperative day-1; Group B - Pre- and Postoperative Group received stoma education both before surgery and on the postoperative day-1. They received stoma care postoperatively as usual; Group C - Prehabilitation Group received the same protocol as Group B, however in addition they were prehabilitated with a water-filled stoma pouch (250 ml) 48 hours before surgery (Figure 2). These pouches were not removed until surgery, and EST nurse preoperatively taught the patients how to manage the stoma pouch with similar standards as the usual postoperative stoma-care.~The goal of the present study was to evaluate the stoma self-care ability, anxiety, depression and QoL of patients who underwent colorectal surgery and faecal diversion, and focusing on the effect of prehabilitation."|t|f|f|t
33981686|NCT01313416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981687|NCT00003666|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981688|NCT04234256|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33981689|NCT06496035|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible due to evident use or nonuse of device, and documentation in patient's chart.|Patients will be assigned to experimental group performing exercise with blood flow restriction, or to the control group performing exercises without the device||||
33981690|NCT01064349|||COHORT||RETROSPECTIVE|||||||
33981691|NCT01200043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769139|NCT01794117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769140|NCT02608762|||COHORT||PROSPECTIVE|||||||
33769141|NCT03446105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned (stratified by age and sex) to one of the treatment conditions in a 2:1 ratio (2 to intervention: 1 to attention control).||||
33769142|NCT00713414|||COHORT||PROSPECTIVE|||||||
33769143|NCT04482426|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769144|NCT01149213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769145|NCT01458990|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||PPI withdrawal (decompensated patients only) and PPI initiation (compensated and decompensated patients)||||
33898493|NCT02977091|||COHORT||PROSPECTIVE|||||||
33898494|NCT03537690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898495|NCT01130415|||COHORT||RETROSPECTIVE|||||||
33898496|NCT01195168|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898497|NCT00502710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898498|NCT06122337|||CASE_ONLY||PROSPECTIVE|||||||
33898499|NCT03224533|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898500|NCT05417828|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898501|NCT03767010|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, open-label study||||
33898502|NCT02273115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898503|NCT00645242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898504|NCT06407518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898505|NCT03921229|NA|SINGLE_GROUP||OTHER||NONE||||||
33769146|NCT03497494|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"All patients enrolled in this study underwent laparoscopic sleeve gastrectomy. According to the starting point of resection to pylorus distance and whether to the strengthen suture of esophageal hole, the cases were randomly divided into 6 groups:~G1: 2 cm away from the pylorus edge, without hiatal suture; G2: 4 cm away from the pylorus edge, without hiatal suture; G3: 6 cm away from the pylorus edge, without hiatal suture; G4: 2 cm away from the pylorus edge, with hiatal suture G5: 4 cm away from the pylorus edge, with hiatal suture; G6: 6 cm away from the pylorus edge, with hiatal suture;"|t|t|t|f
33769147|NCT06020664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator-Blinded Study|A total of 30 subjects will be randomized 1:1 to receive either NOX1416 + SOC or Placebo + SOC (15 per group).|f|f|f|t
33769148|NCT04370743|||OTHER||CROSS_SECTIONAL|||||||
33769149|NCT04178512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769150|NCT04694729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769151|NCT02418975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33769152|NCT02083003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769153|NCT00543400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769154|NCT04017390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Randomization will be to one of four groups: 1.) Theraworx foam alone; 2.) Theraworx foam plus night time splint; 3.) Placebo foam alone; 4.) Placebo foam plus night time splint.~Theraworx Foam is an FDA registered (NDC 61594-001-02) topical agent (active ingredient: magnesium sulfate superficia 6 x 0.05% HPUS) for muscle cramp and spasm relief."|t|f|t|f
33898506|NCT01963637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898507|NCT01847547|||COHORT||RETROSPECTIVE|||||||
33769155|NCT06291675|||COHORT||PROSPECTIVE|||||||
33769156|NCT00047983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769157|NCT05842460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769158|NCT06016270|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33769159|NCT02104830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33769160|NCT01950442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769161|NCT03154359|||COHORT||PROSPECTIVE|||||||
33769162|NCT02931890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769163|NCT05622890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769164|NCT02191384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769165|NCT03396432|RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistician will be blinded at the time of data analysis.|Prospective, randomized, multi-center parallel group trial|f|f|f|t
33769166|NCT04443764|||OTHER||PROSPECTIVE|||||||
33769167|NCT04140825|||COHORT||PROSPECTIVE|||||||
33981692|NCT00669630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981693|NCT03971825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769168|NCT03464604|||CASE_CONTROL||PROSPECTIVE|||||||
33769169|NCT06024629|||COHORT||RETROSPECTIVE|||||||
33769170|NCT05448586|||CASE_CONTROL||RETROSPECTIVE|||||||
33769171|NCT03499379|||COHORT||PROSPECTIVE|||||||
33769172|NCT03341871|||COHORT||PROSPECTIVE|||||||
33769173|NCT00026520||||TREATMENT||||||||
33769174|NCT00581802|||COHORT||PROSPECTIVE|||||||
33769175|NCT02483013|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33769176|NCT04660019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769177|NCT03621293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769178|NCT03547284|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33769179|NCT06207370|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33769180|NCT05763992|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open-label, two-arm, comparative, randomized phase II study||||
33769181|NCT05430048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded|comparing Preoperative Nasal Desmopressin versus Oral Bisoprolol for Controlling Bleeding and Improving Surgical Field during Unilateral Functional Endoscopic Sinus Surgery|t|t|f|t
33769182|NCT05091866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769183|NCT03769805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769184|NCT06148675|||CASE_ONLY||RETROSPECTIVE|||||||
33769185|NCT06029491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769186|NCT06335251|||CASE_ONLY||PROSPECTIVE|||||||
33769187|NCT02199821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769188|NCT05635318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33769189|NCT01850082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769190|NCT02780622|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33769191|NCT01265823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769192|NCT01756560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769193|NCT02210819|||COHORT||PROSPECTIVE|||||||
33769194|NCT00853281|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769195|NCT02133924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769196|NCT04610762|||COHORT||PROSPECTIVE|||||||
33769197|NCT00141882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769198|NCT00363194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769199|NCT02526056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769200|NCT03784092|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769201|NCT05565235|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|patient doesn't know which type of drugs given to him in the block , and the investigator who collect postoperative data also doesn't know which type of drugs used in the block||t|f|t|f
33769202|NCT00263120|||COHORT||CROSS_SECTIONAL|||||||
33769203|NCT05445817|||COHORT||PROSPECTIVE|||||||
33769204|NCT04896125|||CASE_CONTROL||PROSPECTIVE|||||||
33769205|NCT06083675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769206|NCT02519647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33981694|NCT05353452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981695|NCT01148095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769207|NCT00563849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769208|NCT02381990|||COHORT||PROSPECTIVE|||||||
33981696|NCT00860223|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769209|NCT05222438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769210|NCT03406702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769211|NCT00754975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769212|NCT00003048|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33769213|NCT01950273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769214|NCT00057187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769215|NCT02104635|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||||||||
33769216|NCT06429332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment allocation is on a site-level and not on an individual level. The allocation is not blinded. Follow-up clinical outcome assessors, who have no prior association with the study and are unaware of the patients' allocation to either the intervention or control arm, will contact the participant by telephone at 6 months. At the initiation of contact, study subjects will be urged not to disclose their treatment allocation.|"international multicentre, batched, cluster. Patients are not randomized, hospitals will be randomized.~In each batch, hospitals are randomized into two groups according to the timing of the intervention (Care Bundle) over 3 phases (usual care, randomized evaluation, post-implementation follow-up):~Phase 1 - baseline routine data collection, training and formative study (assess context and local resources, support adjustment of the protocol into local pathways) Phase 2 - start intervention implementation in the intervention group, data collection for comparison with usual care in the control group Phase 3 - all hospitals implement the intervention, data collection for quality improvement, assess sustainability and integration"|f|f|f|t
33769217|NCT01434433|||COHORT||RETROSPECTIVE|||||||
33769218|NCT02524132|NA|SINGLE_GROUP||||NONE||||||
33769219|NCT01451736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769220|NCT03636035|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33769221|NCT01584492|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33898508|NCT02557503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898509|NCT03531229|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||36 Subjects are planned for enrolment, with 6 subjects per cohort. The subjects will be randomized to Lu AF76432 or placebo in a 4:2 ratio per cohort. A maximum of 2 additional cohorts of young healthy men will be permitted thereby allowing investigation of a maximum of 48 subjects|t|f|t|f
34078672|NCT05355285|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There are 4 subject groups for this study: 1) T1DM without current depressive symptoms with no history of major depressive disorder; 2) T1DM with current depressive symptoms and with a history of major depressive disorder; 3) Non-diabetic controls without current depressive symptoms and with no history of major depression; 4) Non-diabetic controls with current depressive symptoms and with major depression history. For all subjects, MRS brain glutamate is assessed during basal euglycemia, and for a subset of subjects per group, during an acute hyperglycemic clamp. To control for potential confounding effects of hyperinsulinemia, brain glutamate is also assessed during a euglycemic hyperinsulinemic clamp in a subset of controls (group 3).||||
34078673|NCT00846144|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078674|NCT04195711|||COHORT||PROSPECTIVE|||||||
34078675|NCT03587064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078676|NCT05739604|||COHORT||PROSPECTIVE|||||||
34078677|NCT05757817|NA|SINGLE_GROUP||OTHER||NONE||||||
34078678|NCT03686553|||COHORT||RETROSPECTIVE|||||||
33898510|NCT00002042||||TREATMENT||DOUBLE||||||
33898511|NCT00705510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898512|NCT03988712|||COHORT||RETROSPECTIVE|||||||
33898513|NCT02755636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898514|NCT02334969|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33898515|NCT02221661|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898516|NCT06116344|||CASE_CONTROL||RETROSPECTIVE|||||||
33898517|NCT00643539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898518|NCT06673004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898519|NCT04837885|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33898520|NCT04630015|||COHORT||PROSPECTIVE|||||||
34078679|NCT03980262|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Twenty-four churches will participate and each church will be randomly assigned to treatment or control condition. 1) treatment: lifestyle and parenting intervention for parents with a complementary age-appropriate lifestyle curriculum for children and strategies to improve the church health environment (HCHF+); or 2) active control: financial literacy curricula (Money Smart) for parents and children. Churches will receive the alternate program after 12-month data collection for their initial program. This is for community-engaged approach and will also facilitate program evaluation for both the intervention and comparator conditions.||||
34078680|NCT03776474|||CASE_CONTROL||PROSPECTIVE|||||||
34078681|NCT01466738|NON_RANDOMIZED|PARALLEL||||NONE||||||
34078682|NCT04028726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34078683|NCT00006877||||TREATMENT||||||||
34078684|NCT02882126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898521|NCT00542828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898522|NCT03427775|||COHORT||PROSPECTIVE|||||||
33898523|NCT04507217|NA|SINGLE_GROUP||TREATMENT||NONE||Tislelizumab Combined with Pemetrexed/ Carboplatin||||
33898524|NCT06060080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898525|NCT03205787|NA|SINGLE_GROUP||OTHER||NONE||||||
33898526|NCT02864303|NA|SINGLE_GROUP||OTHER||NONE||||||
33898527|NCT05702944|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients in control group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In the case group, there is no drug to be taken."||||
33898528|NCT00168012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898529|NCT03288467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898530|NCT04325815|||COHORT||PROSPECTIVE|||||||
33898531|NCT01720251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898532|NCT05783258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898533|NCT05632497|||CASE_CONTROL||PROSPECTIVE|||||||
33898534|NCT04265989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33898535|NCT01235533|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898536|NCT02494908|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34078685|NCT03021811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078686|NCT03464435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078687|NCT05876325|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34078688|NCT06489912|||COHORT||PROSPECTIVE|||||||
34078689|NCT02844166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078690|NCT01028781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078691|NCT01005953|||CASE_ONLY||PROSPECTIVE|||||||
34078692|NCT05568134|||COHORT||PROSPECTIVE|||||||
34078693|NCT05460949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078694|NCT03514719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Patients with early stage disease (stage Ia(≥T1b)-IIIa) undergo pre-treatment PET-imaging and 2 cycles of neo-adjuvant avelumab treatment. Followed by surgical resection of the tumor.~Patients with stage IIIb-IV NSCLC will undergo pre-treatment PET-imaging in only part 1 of the study, and receive avelumab treatment 10mg/kg q2w until disease progression or treatment toxicity"||||
34078695|NCT02938572|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34078696|NCT03628118|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34078697|NCT01640548|||COHORT||RETROSPECTIVE|||||||
34078698|NCT02364388|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34078699|NCT01393873|||COHORT||PROSPECTIVE|||||||
34078700|NCT00431301|||CASE_CONTROL||PROSPECTIVE|||||||
34078701|NCT03535363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981697|NCT04578158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981698|NCT01517594|||||PROSPECTIVE|||||||
33981699|NCT01985893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981700|NCT05760872|||COHORT||PROSPECTIVE|||||||
33981701|NCT03389438|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental arm: autologous Tcm cells immunotherapy. participants who were treated with autologous Tcm cells immunotherapy.~No intervention arm: participants who were treated with no autologous Tcm cells immunotherapy."||||
33981702|NCT01471093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981703|NCT00301769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981704|NCT01094197|||CASE_ONLY||CROSS_SECTIONAL|||||||
34078702|NCT03940872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078703|NCT03191552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Observational Model: Cohort Time Perspective: Prospective Randomized controlled trial|f|f|t|t
34078704|NCT00306046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078705|NCT01724151|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078706|NCT02892617|||COHORT||PROSPECTIVE|||||||
34078707|NCT05055726|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter, international, open label, single-group study||||
34078708|NCT03551847|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078709|NCT04916652|||CASE_CONTROL||PROSPECTIVE|||||||
34078710|NCT02339103|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078711|NCT02892396|||COHORT||PROSPECTIVE|||||||
34078712|NCT05796713|||COHORT||CROSS_SECTIONAL|||||||
34078713|NCT00109993|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078714|NCT03442725|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34078715|NCT04477369|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078716|NCT04930926|||COHORT||PROSPECTIVE|||||||
33981705|NCT02589223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981706|NCT03548389|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental study||||
33981707|NCT03206866|||OTHER||OTHER|||||||
33981708|NCT02857088|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33981709|NCT02303548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981710|NCT03313609|||COHORT||PROSPECTIVE|||||||
33981711|NCT03731598|||COHORT||PROSPECTIVE|||||||
33981712|NCT00419770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981713|NCT00822926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981714|NCT04107974|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients and interventional radiologists cannot be blinded to the procedure as the follow up and performing the procedure for gastropexy versus non-gastropexy is different.|Randomized controlled trial comparing gastropexy to non-gastropexy for quality of life and complications.|f|f|f|t
33981715|NCT04988061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981716|NCT04949698|||CASE_CONTROL||RETROSPECTIVE|||||||
33981717|NCT00910364|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33981718|NCT05687630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981719|NCT03843593|||COHORT||PROSPECTIVE|||||||
33981720|NCT01054534|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981721|NCT01366508|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981722|NCT05904730|NA|SINGLE_GROUP||TREATMENT||NONE||The starting dose of Axitinib is 5 mg BID administered orally with food.||||
33981723|NCT00414466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898537|NCT02850198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898538|NCT05460507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898539|NCT02641704|||COHORT||PROSPECTIVE|||||||
33898540|NCT02873546|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898541|NCT01237548|||CASE_CONTROL||PROSPECTIVE|||||||
33898542|NCT03379571|||COHORT||PROSPECTIVE|||||||
33898543|NCT00745030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898544|NCT06498271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898545|NCT03846362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898546|NCT00542347|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898547|NCT04302181|NA|SINGLE_GROUP||TREATMENT||NONE|Masked clinical diagnostic assessor for the CAPS-5|A small open-label treatment study||||
33898548|NCT02767570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898549|NCT04872985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898550|NCT03565107|||OTHER||OTHER|||||||
33898551|NCT00077987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898552|NCT00294593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898553|NCT03320148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the new model of care and comparison, it is not possible to blind the patients or health care providers. Since the primary outcomes are self-reported outcome measures, the assessor is also not blind to the intervention.|This is a pilot cluster randomized controlled trial randomizing 4 sites to the PT-led primary care model for back pain or usual care model||||
33898554|NCT01943097|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33898555|NCT05508568|||COHORT||PROSPECTIVE|||||||
33898556|NCT05966701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898557|NCT06209697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|For the randomization process, patients were provided with slips of paper bearing numbers starting from 1, assigned based on the order of admission by the admitting physician. Subsequently, they were directed to the appropriate nurse. The outpatient clinic nurse assigned red clover treatment to subjects with an odd-numbered slip and placebo to those with an even-numbered slip. The nurse documented the medication assigned to each patient, while the researchers and subjects remained blinded to this information|The study included postmenopausal women who had naturally entered menopause and had applied to the outpatient clinics of Istanbul Medipol University Internal Medicine or Gynecology Departments with symptoms of menopause. Other inclusion criteria were: having a history of amenorrhea for at least 12 months, being aged 45-55, having received a diagnosis of dyslipidemia (at the present admission or within the past 3 months), not receiving treatment for dyslipidemia, absence of other chronic diseases, having a follicle stimulating hormone level of \>40 pg/mL and having a body mass index (BMI) of \<30 kg/m2.The subjects were divided into two groups: red clover and placebo groups.|t|f|t|t
33898558|NCT00395785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898559|NCT05763940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel treatment group participants will be randomly assigned either the experimental interventions;||||
33898560|NCT02770287|NA|SINGLE_GROUP||TREATMENT||NONE|Independent reviewer to identify the four-month photograph of the mons pubis and labia as compared to the baseline (untreated photo).|||||
33898561|NCT01505062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898562|NCT00447421|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898563|NCT05652660|NA|CROSSOVER||OTHER||NONE||||||
33898564|NCT05863429|||OTHER||OTHER|||||||
33898565|NCT04073212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Concealed allocation|Randomized controlled trial with 2 arms or treatment groups|f|f|f|t
33898566|NCT04910750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33898567|NCT05429814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Outcomes Assessor)|Parallel Assignment prospective randomized controlled clinical trial|t|f|f|t
33898568|NCT05528276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898569|NCT04966130|||COHORT||PROSPECTIVE|||||||
33898570|NCT00184847|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33898571|NCT04293848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Sequentially numbered, opaque, sealed envelopes will be used as a mechanism for allocation concealment. The allocation sequence will be generated on a remote workplace by a specialist not participating on enrollment and assigning participants to intervention.|t|f|t|t
33898572|NCT00241111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898573|NCT00678496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898574|NCT04440241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Test group: submerged healing Control group: non-submerged healing treatment of peri-implantitis using guided bone regeneration with a bone substitute and a resorbable membrane.|f|f|t|t
33898575|NCT04964401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33898576|NCT04649853|||CASE_CONTROL||PROSPECTIVE|||||||
33898577|NCT06128941|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33981724|NCT00165594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981725|NCT02609464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981726|NCT03593577|||COHORT||RETROSPECTIVE|||||||
33898578|NCT03463317|RANDOMIZED|PARALLEL||PREVENTION||NONE||Event-driven group-sequential design, non-inferiority test, if significant followed by superiority test||||
33898579|NCT04092036|||COHORT||PROSPECTIVE|||||||
33898580|NCT02053246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898581|NCT03045380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981727|NCT03802370|NA|SINGLE_GROUP||TREATMENT||NONE||single arm groups||||
33898582|NCT04222621|||COHORT||PROSPECTIVE|||||||
33898583|NCT03548428|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, Phase II, prospective, multicentric, randomized study 2:1, 2 arm study||||
33898584|NCT04194593|||CASE_ONLY||RETROSPECTIVE|||||||
33981728|NCT05583318|||COHORT||PROSPECTIVE|||||||
33981729|NCT02012244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33898585|NCT00027131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898586|NCT02312986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898587|NCT04673903|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention group will be instructed to include the Copenhagen adduction exercise into their warm up before training session (3 times per week) during one season (6 months).The control group will practice their usual warm up.~Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions."||||
33898588|NCT02633111|||COHORT||PROSPECTIVE|||||||
33898589|NCT00152256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898590|NCT00077233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898591|NCT05294042|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33981730|NCT04317066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981731|NCT04091971|NA|SINGLE_GROUP||OTHER||NONE||Depressed adults with current major depressive disorder||||
33981732|NCT04766281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to receive either MLC901 or placebo|t|t|t|t
33981733|NCT06096740|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|As participants will necessarily be aware of their arm assignment, symptom raters (research assistants) and study therapists will be blinded to participant arm assignment to reduce risk of ascertainment bias.|Randomization will be stratified based upon baseline presence/absence of MDD and will occur using pre-specified block randomization with randomly-sized blocks of either 4 or 6 to ensure near-equal distribution of participants with and without comorbid MDD between the two arms over time, while avoiding the ability for study personnel to predict treatment assignment of the next participant. Blocks will involve various orderings of participant assignment, each block will be assigned a number, and a random list generator will then order the block sequences prior to the start of the study. This will ensure equal numbers of participants with and without MDD are assigned to each treatment condition and limit predictability of assignment.|f|t|f|t
33898592|NCT01040832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981734|NCT00909402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981735|NCT05523271|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33981736|NCT02353169|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33981737|NCT03021720|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33981738|NCT05561426|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33981739|NCT03006965|||COHORT||OTHER|||||||
33981740|NCT01087970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981741|NCT06023147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981742|NCT03256942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898593|NCT03104244|||COHORT||PROSPECTIVE|||||||
33898594|NCT03682588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomised electronically generated randomisation table. Secret allocation (sealed opaque envelopes).|Randomized controlled trial|f|f|f|t
33898595|NCT01275248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898596|NCT04883073|RANDOMIZED|PARALLEL||TREATMENT||NONE||monocentric single side blinded randomized controlled trial||||
33898597|NCT04654325|NA|SINGLE_GROUP||OTHER||NONE||||||
33898598|NCT06046508|||COHORT||PROSPECTIVE|||||||
33981743|NCT04826809|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33981744|NCT04329208|||CASE_ONLY||PROSPECTIVE|||||||
33981745|NCT01828996|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33981746|NCT01851577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33981747|NCT03649048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981748|NCT05614570|||CASE_CONTROL||PROSPECTIVE|||||||
33981749|NCT03931642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898599|NCT06672250|||CASE_ONLY||CROSS_SECTIONAL|||||||
33981750|NCT00421577|||||OTHER|||||||
33981751|NCT01278056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981752|NCT04751448|||CASE_ONLY||PROSPECTIVE|||||||
33981753|NCT00378690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981754|NCT04423705|||OTHER||PROSPECTIVE|||||||
33981755|NCT06362486|||COHORT||PROSPECTIVE|||||||
33981756|NCT00331526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981757|NCT00486837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981758|NCT05293847|NA|SINGLE_GROUP||TREATMENT||NONE|Individuals who perform telerehabilitation applications and evaluate the results are different.|Pre and post-intervention evaluations were compared in this study.||||
33981759|NCT00405314|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981760|NCT00625443|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981761|NCT03043547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981762|NCT04088773|||CASE_CONTROL||PROSPECTIVE|||||||
33981763|NCT05975853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33981764|NCT05699005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and datamanagement responsible for statistical analysis will be blinded of the patient allocation group until the study completion||t|f|f|t
33981765|NCT04450043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981766|NCT01449630|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33981767|NCT02522806|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981768|NCT04734184|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33981769|NCT00004579||||PREVENTION||DOUBLE||||||
33981770|NCT02770963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769222|NCT05974579|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups will be enrolled: 8 healthy subjects and 4 patients with ALS This is non-randomized, all participants will receive the same dose of radiotracer||||
33769223|NCT00375141|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33898600|NCT00213018|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33898601|NCT05914753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898602|NCT04155385|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized two-arm clinical trial.||||
33898603|NCT04701086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator Masked, unmasked Pharmacist|PROSPECTIVE, MULTICENTRE, INVESTIGATOR-MASKED, PARALLEL-GROUP, ACTIVE-CONTROLLED, RANDOMISED, NON-INFERIORITY STUDY|t|t|t|t
33898604|NCT05888337|||COHORT||PROSPECTIVE|||||||
33981771|NCT05339802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981772|NCT04234100|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981773|NCT06305416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769224|NCT00744315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769225|NCT04239729|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned with equal likelihood to receive the website and coaching immediately or to wait for 12 weeks before using the website.||||
33769226|NCT02783118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33769227|NCT03662360|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The enrolled patients will be randomized following the 4 blocks random schema (AABB, ABAB, BBAA, BABA, ABBA, BAAB).~A repetition of the first 4 blocks will be perform up to 32 patients:~AABB, ABAB, BBAA, BABA AABB, ABAB, BBAA, BABA"||||
33769228|NCT04759742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769229|NCT04496843|||CASE_CONTROL||PROSPECTIVE|||||||
33981774|NCT03761290|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981775|NCT03123237|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078717|NCT04266899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078718|NCT05775601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769230|NCT00664820|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33769231|NCT00707213|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769232|NCT03545113|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33769233|NCT04107623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769234|NCT05626972|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Clinical outcome at day 90 will be obtained by centralized telephone call of the mRS in a blinded manner by certified personnel of the Catalan Stroke Program.||f|f|f|t
33769235|NCT02565004|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33898605|NCT03830138|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898606|NCT02729961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898607|NCT03676309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental drawing Phase II prospective, randomized, comparative, vs placebo study|t|f|t|f
33898608|NCT01210937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078719|NCT04915235|||OTHER||PROSPECTIVE|||||||
34078720|NCT01351818|||COHORT||PROSPECTIVE|||||||
34078721|NCT00006015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078722|NCT03760224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078723|NCT01522781|||COHORT||PROSPECTIVE|||||||
34078724|NCT03723434|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||PAS will be applied to two cortical targets at different asynchronies to modulate connectivity. PAS may selectively increase or decrease effective connectivity depending on the asynchrony. Negative asynchronies are expected to decrease effective connectivity, whereas positive asynchronies to increase it.||||
34078725|NCT06107998|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only the person who intubates the patient and inflates the cuff using a method will know what the procedure is.||t|f|t|t
34078726|NCT01219712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078727|NCT01484951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078728|NCT00766324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078729|NCT06326190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078730|NCT00887484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078731|NCT00505050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769236|NCT04683523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769237|NCT06442644|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33769238|NCT01797341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769239|NCT06393218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769240|NCT01015807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33769241|NCT03152513|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769242|NCT00002456||||SUPPORTIVE_CARE||||||||
33769243|NCT03577574|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33769244|NCT04602897|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The cough group patients were asked to cough a forced cough during different steps of IUD insertion||||
33769245|NCT01673074||||TREATMENT||||||||
33769246|NCT01938105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981776|NCT03985670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with local advanced esophageal squamous cell carcinoma receive two cycle of neoadjuvant chemotherapy and PD-1 antibody in the same day or chemotherapy followed by PD-1 antibody, and then surgery||||
34078732|NCT05781867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078733|NCT00465517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769247|NCT04075799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769248|NCT05764291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants for both the intervention and control arms will be recruited simultaneously using cluster design to minimise contamination between intervention and control group participants. At the end of the 10-week intervention period, participants in the waitlist control arm will receive access to the intervention.||||
33769249|NCT04845035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769250|NCT04711460|||COHORT||RETROSPECTIVE|||||||
33769251|NCT03519698|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33721287|NCT03679780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject has one control site and three experimental sites concurrently tested within the same study using intradermal microdialysis on the dorsal forearm.||||
33769252|NCT01512875|||CASE_ONLY||PROSPECTIVE|||||||
33769253|NCT06624332|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33769254|NCT04394091|||COHORT||PROSPECTIVE|||||||
33769255|NCT01728805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769256|NCT02023879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking during the double-blind treatment period|A double-blind treatment period of 24 weeks (3 parallel arms) followed by an open-label extension period (single arm)|t|t|t|f
33981777|NCT01295853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981778|NCT00284674|RANDOMIZED|PARALLEL||||NONE||||||
33981779|NCT02507427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981780|NCT05045118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33981781|NCT00868010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981782|NCT05020925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981783|NCT02321384|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33721288|NCT02814123|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721289|NCT00001758||||TREATMENT||||||||
33721290|NCT00017992||||TREATMENT||||||||
33769257|NCT05197257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981784|NCT03931876|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33981785|NCT04095117|||COHORT||PROSPECTIVE|||||||
33981786|NCT04659421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981787|NCT00330447|||COHORT||PROSPECTIVE|||||||
33981788|NCT01257009|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078734|NCT04378712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078735|NCT04789382|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33769258|NCT03984019|NA|SINGLE_GROUP||SCREENING||NONE||This is an exploratory study to determine whether cardiac changes occur after radiation treatment. Patients are treated following standard clinical practice, with additional diagnostic investigations. The study design is therefore a cohort study.||||
33898609|NCT00200681|RANDOMIZED|PARALLEL||||NONE||||||
33769259|NCT00000517|RANDOMIZED|||PREVENTION||||||||
34078736|NCT02702089|||COHORT||PROSPECTIVE|||||||
33769260|NCT05719623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769261|NCT01380990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769262|NCT02070120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769263|NCT02964715|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33769264|NCT04310943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769265|NCT03759613|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33769266|NCT01176604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769267|NCT06489574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will be randomized using a computer-generated list of random numbers, which will be sealed in closed envelopes. Patients will be randomly allocated to one of two groups; Group I will receive dexmedetomidine, while Group II (R) will receive fentanyl. An anesthesiologist who is not involved in the data collection team will perform all thoracic epidural infusion. Intra- and postoperative data will be collected by an anesthesiologist or intensivist who is blinded to the study protocol. So, both the patients and data collector were blinded to group assignment.||t|f|f|t
33769268|NCT00786526|||CASE_ONLY||PROSPECTIVE|||||||
33769269|NCT02361060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769270|NCT05625919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769271|NCT02571205|||CASE_ONLY||PROSPECTIVE|||||||
33769272|NCT05991973|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33769273|NCT03758118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33769274|NCT03813550|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769275|NCT03135457|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Masking of investigator is not possible due to nature of intervention.|Open-label, prospective cross-over randomized controlled trial.|t|t|f|f
33769276|NCT00217880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769277|NCT00743990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769278|NCT04655079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization, monitoring and data management will be performed locally. Randomization will be performed using an online list randomizer (random.org). The study coordinator will generate the random allocation sequence before enrollment. Then, one sub-investigator will perform clinical evaluations and another one will administer the treatment.|Participants will be recruited and randomized in two parallel group: group 1 will receive anodal left dlPFC tDCS (real tDCS) and group 2 will receive sham stimulation for 5 days/week for 2 consecutive weeks, in a 2:1 ratio, respectively. Each participant will undergo a clinical evaluation at baseline (T0), immediately after 2 weeks of either real or sham tDCS (T1), at 45-day (T2) and at 3-month follow up (T3) from baseline. PSP phenotypes will be uniformly distributed between treatment arms (ie, =Richardson's syndrome versus non-Richardson's syndrome=1:1).|t|t|f|t
33769279|NCT03384953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769280|NCT01885273|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
13113728|NCT06416423|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33769281|NCT05619913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769282|NCT03331133|||COHORT||PROSPECTIVE|||||||
33769283|NCT00130793|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33898610|NCT03040583|||COHORT||PROSPECTIVE|||||||
33898611|NCT06340594|||COHORT||RETROSPECTIVE|||||||
33769284|NCT02444988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769285|NCT01999062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769286|NCT06280287|||COHORT||PROSPECTIVE|||||||
33769287|NCT03545815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769288|NCT04015791|||CASE_CONTROL||PROSPECTIVE|||||||
33769289|NCT01207050|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33898612|NCT01733706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898613|NCT01912040|||COHORT||PROSPECTIVE|||||||
33898614|NCT02817438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898615|NCT02978014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898616|NCT00969618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898617|NCT00173953|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898618|NCT02574299|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33898619|NCT04696406|||COHORT||PROSPECTIVE|||||||
33898620|NCT04893837|||COHORT||PROSPECTIVE|||||||
33898621|NCT00772967|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33898622|NCT04936880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898623|NCT00550628|||COHORT||PROSPECTIVE|||||||
33898624|NCT06331585|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898625|NCT01031095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898626|NCT02864875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898627|NCT00810160|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898628|NCT03990948|||COHORT||CROSS_SECTIONAL|||||||
34078737|NCT03759080|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"there are two arms :1. proprioceptive neuromuscular facilitation (PNF) group ,2 mental practice (MP) group.~PNF group: 30 individuals, these subjects received PNF training. PNFMP: 30 individuals, these subjects receivedMP. training program has been administered for every group for 12 sessions over 4 weeks with 3 x 45 min training sessions per week."||||
34078738|NCT04460768|||OTHER||RETROSPECTIVE|||||||
34078739|NCT03169569|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization immediately after ESD|All procedures were performed according to the standard procedure sequence in the hemostatic powder group and control group. The Only difference between two groups was hemostatic powder (Endo-clot™) application after standard hemostasis using hemostatic forceps in the hemostatic powder group. For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.|f|f|t|f
33981789|NCT00552669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078740|NCT03227718|||COHORT||PROSPECTIVE|||||||
34078741|NCT04575246|||OTHER||CROSS_SECTIONAL|||||||
34078742|NCT01403558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078743|NCT04478318|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769290|NCT03992885|NA|SINGLE_GROUP||TREATMENT||NONE||EGFR-positive patients with metastatic non-squamous non-small cell lung cancer who did not progress after pemetrexed combined with platinum chemotherapy||||
33981790|NCT04109222|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981791|NCT01121276|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981792|NCT02702817|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078744|NCT02068638|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34078745|NCT05031442|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants are randomized to start with either reference or investigational product. The type of product is masked for the participant but since there are slight differences between the products the masking cannot be ensured.|Subjects use one product for 5 days and then switch to another product for 5 days. One of the products is the investigational product and one is the reference product.||||
33769291|NCT03115749|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34078746|NCT04222816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized, open label, parallel group, active controlled clinical trial|f|f|f|t
33769292|NCT01474616|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33769293|NCT00525603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769294|NCT06211062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded||t|f|t|f
33769295|NCT00073437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769296|NCT00099450|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34078747|NCT00537888|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34078748|NCT06106230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomize controlled trial|t|f|t|f
34078749|NCT01162044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078750|NCT04425070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||ATG-010 + ICE ATG-010 + GEMOX ATG-010 + Tislelizumab||||
33769297|NCT00459303|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33769298|NCT02327819|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33769299|NCT00043888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078751|NCT02979782|||COHORT||PROSPECTIVE|||||||
34078752|NCT00694525|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078753|NCT04058509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078754|NCT00144443|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34078755|NCT02904044|||CASE_CONTROL||PROSPECTIVE|||||||
34078756|NCT00248209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078757|NCT01534273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34078758|NCT03011866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078759|NCT05390008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078760|NCT02626598|||CASE_ONLY||PROSPECTIVE|||||||
33981793|NCT04892511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981794|NCT00375700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981795|NCT01194492|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981796|NCT01613911|||CASE_ONLY||CROSS_SECTIONAL|||||||
33981797|NCT06223347|||CASE_ONLY||PROSPECTIVE|||||||
33981798|NCT03830125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078761|NCT00621101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34078762|NCT00734292|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34078763|NCT00767572|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34078764|NCT06164977|NA|SINGLE_GROUP||TREATMENT||NONE||Single group consists of study participants who where treated for chronic total coronary occlusion with bioresorbable scaffolds||||
34078765|NCT00338091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769300|NCT00749385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33769301|NCT06495437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769302|NCT00936221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769303|NCT05106985|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Single case experimental design: Multiple Baseline Design||||
33769304|NCT00454428|RANDOMIZED|PARALLEL||||NONE||||||
33769305|NCT05243576|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769306|NCT03856996|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33769307|NCT04878419|NA|SINGLE_GROUP||OTHER||NONE||||||
33769308|NCT05064553|||OTHER||PROSPECTIVE|||||||
33769309|NCT05714995|||COHORT||PROSPECTIVE|||||||
33769310|NCT03656731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All physical tests will be conducted by masked health care professionals.|Participants will be randomized 1:1 to the intervention group and control group|f|f|f|t
33769311|NCT03863197|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Randomized controlled trial with waitlist control group|f|f|f|t
33769312|NCT01590771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769313|NCT05844761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will undergo radiotherapy using motion management techniques: Triggered Imaging with TrueBeam for prostate cancer, Synchrony with Radixact for prostate cancer, and Synchrony with Radixact for lung cancer. Dosimetric coverage will be assessed after treatment based on the accuracy of the motion management techniques and compared with dose coverage without motion management. After interim analysis, Planning target volume (PTV) will be reduced based on dosimetric accuracy in each arm.||||
33769314|NCT00572624|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769315|NCT04903834|||COHORT||RETROSPECTIVE|||||||
33769316|NCT02992522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769317|NCT03355105|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769318|NCT00636792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769319|NCT02572843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981799|NCT05504603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024599|NCT03485365|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double blind study. Participant and investigator will be masked.|Participants will be randomized in 3:1 ratio to receive GSK3858279 and placebo in sequential manner in Part A. In Part B, participants will be randomized in parallel groups to receive either GSK3858279 or placebo.|t|f|t|f
34024600|NCT05485987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024601|NCT02686138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024602|NCT02024113|||CASE_CONTROL||PROSPECTIVE|||||||
33981800|NCT04574648|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study participants, outcomes assessors, and study investigators will be blinded to treatment allocation. Community pharmacists cannot be blinded to the intervention, as we are studying the change in pharmacists' dispensing behavior due to the provision of new information. The information will only appear for patients in the experimental arm.|We will conduct a triple-blind randomized controlled trials. We will enrol consecutive eligible patients presenting to the emergency department with an adverse event due to non-adherence to prescribed outpatient medication. Randomization is implemented in the ActionADE application. Randomization will be equal (1:1) and stratified by site and age (\< 80, ≥ 80). A statistician otherwise uninvolved in the study will generate a list of treatment assignments using permuted blocks of varying sizes for each stratum. ActionADE will store the randomization list for each stratum. Once eligibility has been determined, the application will allocate the patient to the next available assignment within the stratum.|t|f|t|t
33981801|NCT04048005|||COHORT||RETROSPECTIVE|||||||
33981802|NCT02853162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981803|NCT00122629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33981804|NCT00064753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981805|NCT03289156|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33981806|NCT04810416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcome assessor will be masked to the participant's assigned activity and participants will be masked to the exact outcome measures.|Participants will be randomly assigned to one of the parallel four groups|t|f|f|t
34078766|NCT02515903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078767|NCT05225948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898629|NCT05133427|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a multicenter (two-center), open-label study in humans (hospital outpatients). The study is not comparative with respect to the two study groups; however, it is aimed to pool data if the study groups are statistically comparable.~The investigation is performed prior to CE mark to confirm safety and performance of the System ONE-M device when used as intended, i.e. as an non-invasive method to remove non-nodular basal cell carcinoma by 20 MHz high intensity focused ultrasound."||||
33898630|NCT00327639|||DEFINED_POPULATION||OTHER|||||||
33898631|NCT00213603|||COHORT||PROSPECTIVE|||||||
33898632|NCT01691729|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981807|NCT02607878|||COHORT||PROSPECTIVE|||||||
33981808|NCT00169195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981809|NCT03178500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898633|NCT06382688|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33898634|NCT04661319|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33981810|NCT02730078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981811|NCT01949194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981812|NCT04671004|||COHORT||PROSPECTIVE|||||||
33981813|NCT05697471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981814|NCT01670695|||COHORT||PROSPECTIVE|||||||
33981815|NCT03463369|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33981816|NCT03959878|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33981817|NCT04470791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of the participants and interventionists was impossible, but the data analyst was blinded.|A randomized pilot study was performed that included patients of both genders and over 18 years old with a snakebite of envenomation grade II who were admitted to the Clinical Toxicology Service of the Hospital Juárez de México.|f|f|t|t
33981818|NCT06148480|||CASE_CONTROL||PROSPECTIVE|||||||
33981819|NCT02892500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981820|NCT05687864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981821|NCT04168788|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981822|NCT04283084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981823|NCT02462330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981824|NCT04341740|NA|SINGLE_GROUP||OTHER||NONE||Patients enrolled on this study in either the Renal Cell Carcinoma cohort or the Urothelial Carcinoma cohort will undergo the same procedures of bone marrow aspiration and blood draw.||||
33981825|NCT04887077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research assistants collecting data will be blinded to the treatment allocation. Double blinding is nevertheless not possible in such interventions because allocation concealment is impossible for participants.|Prospective, randomized, controlled with two parallel arms.|f|f|t|t
33981826|NCT04882332|||CASE_CONTROL||PROSPECTIVE|||||||
33981827|NCT02456714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981828|NCT06126848|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33898635|NCT02908477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898636|NCT01231191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33898637|NCT03952650|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33898638|NCT00770861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981829|NCT02077270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33981830|NCT05723588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will receive either active repetitive transcranial magnetic stimulation (rTMS) or sham rTMS. Participants and the PI, who provides the rTMS will be blinded to this condition.||t|t|t|f
34078768|NCT05337176|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769320|NCT04432064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be single-blind masking as the experimenter will need to know which intervention to run on the participant.|One group of 20 participants will receive active TI-NDBS and another group of 20 participants will receive sham TI-NDBS. A third group of 20 participants will receive traditional transcranial direct current stimulation (tDCS).|t|f|f|f
33769321|NCT04744181|||CASE_CONTROL||PROSPECTIVE|||||||
33769322|NCT05247827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769323|NCT05340218|NA|PARALLEL||DIAGNOSTIC||NONE||||||
33769324|NCT04764929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769325|NCT01484795|RANDOMIZED|CROSSOVER||||NONE||||||
33769326|NCT01015313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769327|NCT04760990|||COHORT||PROSPECTIVE|||||||
33769328|NCT05063305|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33769329|NCT04161807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769330|NCT01639794|||COHORT||PROSPECTIVE|||||||
33769331|NCT05438225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33769332|NCT05353959|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769333|NCT02172456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769334|NCT04330014|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33769335|NCT05565313|||COHORT||RETROSPECTIVE|||||||
33769336|NCT00252213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33769337|NCT05672303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33769338|NCT05075343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769339|NCT02768415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769340|NCT01127217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769341|NCT05246072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769342|NCT01405755|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769343|NCT01574430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898639|NCT02277132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981831|NCT01566318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721291|NCT04846660|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were blindly assigned to the intervention or control group and were blind to the level of production pressure they were exposed to. They were also blinded to the purpose of the study until completion.||t|f|f|f
33721292|NCT00333866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721293|NCT06032247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721294|NCT03272607|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Medical chart abstracts compiled at discharge (including any subsequent visits within 30 days) will be combined with the patient telephone interview into a case summary report which will be reviewed independently by two trained and blinded clinician reviewers who will be made up of pharmacists and physicians from each study site (but who will not adjudicate any patients from their own site).|"The duration of the project will be a total of (approx.) 96 weeks. This is a stepped wedge cluster randomized trial study design (see PDF attachment entitled MedSafer, Figure 1 - note start date will be August 2017 not July 2016). The intervention component will be administered sequentially to six (6) clusters (by city). A randomly selected single cluster will move from control data collection to intervention data collection every 200 patients or roughly every 12 weeks (96 total weeks), which will be followed by 12 weeks to complete follow up and another 36 to analyze data.~Please see PDF attachment entitled MedSafer, Figure 2 which refers to both parts of the study (quality improvement and follow up components). It describes the follow up component of the study (a 30-day telephone follow-up to ascertain adverse drug events- please note the gray-shaded boxes refer to the Quality Improvement Project-Part 1)."|f|f|f|t
33721295|NCT02838680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898640|NCT00903916|||CASE_ONLY||PROSPECTIVE|||||||
33898641|NCT02214173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33898642|NCT05212246|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898643|NCT02447107|||COHORT||PROSPECTIVE|||||||
33898644|NCT01520922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898645|NCT02989948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898646|NCT03551899|||OTHER||PROSPECTIVE|||||||
33898647|NCT05065021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898648|NCT01121406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898649|NCT01954290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898650|NCT01903148|||COHORT||CROSS_SECTIONAL|||||||
33721296|NCT04435015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721297|NCT03020407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721298|NCT01161914|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33721299|NCT03295253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721300|NCT01746927|||CASE_ONLY||PROSPECTIVE|||||||
33721301|NCT04364308|||COHORT||PROSPECTIVE|||||||
33721302|NCT00010465|RANDOMIZED|||TREATMENT||DOUBLE||||||
33721303|NCT05771233|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study design employed is a randomized clinical trial (RCT), analytical, longitudinal and prospective, with a 4 months follow-up.||||
33721304|NCT03659591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721305|NCT03019939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33721306|NCT04725760|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33721307|NCT03359044|||COHORT||PROSPECTIVE|||||||
33721308|NCT00417807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721309|NCT00555607|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33721310|NCT05325879|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33898651|NCT00673673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898652|NCT00316901||||DIAGNOSTIC||||||||
33898653|NCT05564624|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33898654|NCT00638846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898655|NCT00871858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898656|NCT02688855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33981832|NCT00828048|||CASE_CONTROL||PROSPECTIVE|||||||
33981833|NCT00429364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981834|NCT02139553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981835|NCT05155306|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981836|NCT00979732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898657|NCT05413447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking the clinicians of the control group assignment is done to optimally capture local practice. Masking of the intervention group is not feasable as patients and healthcare workers will know whether they are receiving normal care or digital care. Outcome measures are determined beforehand.|Randomized controlled trial||||
33898658|NCT00493389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898659|NCT00735332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898660|NCT02188446|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33898661|NCT00404768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898662|NCT03478124|||COHORT||OTHER|||||||
33898663|NCT05484063|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||It is a quasi-experimental design study.||||
33898664|NCT06399081|||CASE_CONTROL||RETROSPECTIVE|||||||
33721311|NCT00530933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898665|NCT01520792||CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33898666|NCT00483951|||COHORT||PROSPECTIVE|||||||
33898667|NCT05615714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33898668|NCT05027269|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33898669|NCT01415440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two treatment arms plus sample of healthy controls, who were assessed at one time point|t|t|t|t
33898670|NCT04359953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898671|NCT00158977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898672|NCT06662539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898673|NCT06481189|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33898674|NCT03828292|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study.|Participants will receive GSK2857916 monotherapy during Part 1 (Dose escalation) of the study on a once every 21 days schedule. During Part 2, participants will receive GSK2857916 given in combination with Bortezomib/Dexamethasone on a once every 21 days schedule (Arm A) or with Pomalidomide/Dexamethasone on a once every 28 days schedule (Arm B).||||
33981837|NCT00454909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33981838|NCT02024087|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33981839|NCT04334590|||COHORT||PROSPECTIVE|||||||
33981840|NCT00946803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981841|NCT03388307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981842|NCT03202914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|During the original MDRD Study, clinical center personnel as well as study participants were masked to the results of the outcome assessment during the follow-up period.|"The present study consists of a secondary data analysis of the MDRD Study. Planned analyses will be limited to participants with available stored specimens.~The original MDRD Study was a 2 x 2 factorial study design, in which individuals were randomized to amounts of protein and phosphorus intake and levels of blood pressure control. In this secondary data analysis, we will analyze metabolites according to level of protein intake and will adjust for the blood pressure intervention."|f|f|f|t
33981843|NCT00984295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981844|NCT03861065|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33981845|NCT04008498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981846|NCT02468739|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33981847|NCT04351204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981848|NCT01917838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981849|NCT00939653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981850|NCT05184842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981851|NCT04504396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981852|NCT03571048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981853|NCT04980001|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will have access to the FOCUS TIC-COM intervention. The health care providers at the family medicine clinic within MLK-OPC will be trained to implement FOCUS TIC-COM with children who are overweight or obese. The investigators plan to survey and perform focus groups with health care providers and the parents / caregivers of children who were identified as overweight or obese by their doctor.||||
33981854|NCT00849459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981855|NCT01507857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34024603|NCT02418481|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34024604|NCT02111928|||COHORT||PROSPECTIVE|||||||
33981856|NCT03708835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The result will be evaluated by the statistician|Types of interventions that are applied to stroke patients and caregivers based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training.|f|f|f|t
33981857|NCT00281866|NON_RANDOMIZED|||TREATMENT||||||||
33981858|NCT03884166|||CASE_CONTROL||PROSPECTIVE|||||||
34078769|NCT02786992|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33981859|NCT05987371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981860|NCT05865353|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33981861|NCT04699149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|rTMS protocol either sham or real|blinded randomised clinical trial|t|f|f|f
33981862|NCT05541874|||COHORT||RETROSPECTIVE|||||||
33981863|NCT01719406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981864|NCT00987181|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981865|NCT00086762|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981866|NCT04415229|||CASE_ONLY||RETROSPECTIVE|||||||
33981867|NCT03420300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981868|NCT01706471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981869|NCT01407536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981870|NCT00000462|RANDOMIZED|PARALLEL||TREATMENT||||||||
33981871|NCT05192330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This randomized controlled study will conduct at Ondokuz Mayis University Training and Research Hospital, Obstetrics and Gynecology polyclinic between January 2022 and June 2022. The CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting randomised controlled trials (RCTs) has been used to describe the methods.|t|f|f|f
33981872|NCT04264065|||COHORT||PROSPECTIVE|||||||
33981873|NCT03077516|||COHORT||PROSPECTIVE|||||||
33981874|NCT03675828|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078770|NCT05660278|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33981875|NCT04088760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769344|NCT05240274|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Both the patient and the study team will be blinded to the treatment intervention. The clinical team will also be blinded.~Pharmacy staff who dispense the IMP will not be blinded, nor will Sponsor Office staff responsible for reporting unblinded SUSAR reports to the MHRA."|Single site, placebo controlled, double blind randomised clinical trial|t|t|t|t
33769345|NCT01424436|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769346|NCT05053217|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769347|NCT00566358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769348|NCT01593904|||CASE_CONTROL||RETROSPECTIVE|||||||
33769349|NCT06103708|||COHORT||CROSS_SECTIONAL|||||||
33769350|NCT01026714|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33769351|NCT05769751|||COHORT||RETROSPECTIVE|||||||
33769352|NCT01995019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769353|NCT05319561|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The Practical, Robust Implementation and Sustainability Model (PRISM) is an expansion of the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) model. Briefly, PRISM expands RE-AIM to further consider key contextual factors related to implementation, evaluation and dissemination of health services programs. The investigators will use PRISM and RE-AIM to inform implementation, evaluation and maintenance of the intervention as the investigators seek to disseminate the VAST beyond the 2 pilot sites||||
33769354|NCT04981522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blind cluster randomized controlled trial (c-RCT)|Research design of the study shall consists of two-arms, single-blind cluster randomized controlled trial (c-RCT). While Randomized Control Trial (RCT) shall consists of two groups: Active Treatment (AT) and Delayed Treatment Control (DTC).|t|t|f|t
33769355|NCT01410825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769356|NCT01805882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769357|NCT04737317|||COHORT||PROSPECTIVE|||||||
33769358|NCT02452866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769359|NCT02222519|||CASE_CONTROL||PROSPECTIVE|||||||
33769360|NCT06019013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769361|NCT03324399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769362|NCT01849120|||CASE_ONLY||PROSPECTIVE|||||||
33769363|NCT01717183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769364|NCT04949139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769365|NCT05666544|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33769366|NCT02231437|||COHORT||PROSPECTIVE|||||||
33769367|NCT01564745|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769368|NCT02359019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769369|NCT04946955|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Within the framework of the project, the beneficiary public is the population of young adults and adolescents between 11 and 25 years old likely to connect to a mobile application and an associated website dedicated to the prevention of psychological suffering and suicide.||||
33898675|NCT02778997|||CASE_ONLY||PROSPECTIVE|||||||
33898676|NCT03078491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981876|NCT04318665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981877|NCT03043924|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33721312|NCT05387733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769370|NCT04220671|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33769371|NCT04237974|||OTHER||PROSPECTIVE|||||||
33769372|NCT06489093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769373|NCT01360268|||COHORT||PROSPECTIVE|||||||
33769374|NCT00296842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33769375|NCT05880953|NA|SINGLE_GROUP||OTHER||NONE||||||
33769376|NCT02224482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33769377|NCT05623137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the treatments, only the participants will be blinded to the objectives of the study.||t|f|f|f
33769378|NCT04109742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, clinical staff, and data monitoring committee will not have knowledge of the interventions assigned to individual participants.|The comparison of two different doses (500mg/qd and 1g/qd) of a phosphatidylcholine-curcumin complex supplement, to matching placebo|t|t|t|f
33769379|NCT00258440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769380|NCT06257719|||COHORT||RETROSPECTIVE|||||||
33769381|NCT02124551|||OTHER||PROSPECTIVE|||||||
33769382|NCT05912114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769383|NCT05439577|||COHORT||PROSPECTIVE|||||||
33769384|NCT04555512|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769385|NCT02611310|||COHORT||PROSPECTIVE|||||||
33769386|NCT05858203|||COHORT||PROSPECTIVE|||||||
33769387|NCT00996580|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33769388|NCT01923428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769389|NCT01170884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33898677|NCT01359982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898678|NCT00295893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769390|NCT05216926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are blinded to to group allocation, sensor and plasma glucose.||t|f|f|f
33981878|NCT06090149|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pre/post study||||
33769391|NCT00675727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898679|NCT03162718|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators propose a mixed methods,16 single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device. The proposed study of 30 patients scheduled for lung cancer surgery will identify the strengths, weaknesses, and utility of this approach.||||
33898680|NCT03117933|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised open label trial with 3 arms, stratified for prior PARP use, prior anti-angiogenic use and BRCA status.||||
33898681|NCT01296386|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898682|NCT04419506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898683|NCT02459171|||COHORT||PROSPECTIVE|||||||
33898684|NCT00004934|RANDOMIZED|||TREATMENT||||||||
33898685|NCT00986193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898686|NCT04855877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Patient, anesthesiologist and surgeon are blinded|Double blinded prospective randomized controlled trial|t|t|t|t
33898687|NCT05861947|NA|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation 3+3 Design"||||
33898688|NCT05248958|||OTHER||CROSS_SECTIONAL|||||||
33981879|NCT01247116|||COHORT||PROSPECTIVE|||||||
33898689|NCT02348047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898690|NCT03167697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898691|NCT06513637|||CASE_ONLY||PROSPECTIVE|||||||
33898692|NCT05981521|||COHORT||RETROSPECTIVE|||||||
33981880|NCT02879682|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||preoperative Mapping|t|t|t|t
33981881|NCT05427383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33981882|NCT01459328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981883|NCT03809026|||CASE_CONTROL||PROSPECTIVE|||||||
33981884|NCT05316922|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, non-blinded, randomised two cohorts study||||
33981885|NCT05734222|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|"4. The comparison groups will include patients who underwent retromuscular plastic surgery followed by aspiration drainage of the prosthesis bed. When analyzing the results, the presence of obesity and coagulopathy will be taken into account, CT and ultrasound examination will be carried out. Special attention will be paid to the presence and volume of liquid formations in the implant bed.~5. Immediate results will be evaluated up to 1 year Criteria for evaluating immediate results: treatment time, pain syndrome, the presence of seromas and hematomas, their infection and suppuration.~6. Long-term results will be evaluated in terms from 1 to 1.5 years. Evaluation criteria: the presence of recurrent hernia, the presence of late complications - fistulas, seromas requiring drainage, pain syndrome."|"The study will include patients with postoperative ventral hernias of median and lateral localization and an average hernial gate width from 4.1 to 15 cm (W2-W3 according to the EHS classification).. The size of the hernial gate is determined by CT. The estimated number of patients is 60-80. 25-30 patients with median-lateral ventral postoperative hernias and 35-50 patients with median hernias are expected.~2. The control group is retrospective. It will include patients who have been operated on for POVG in the surgical department No. 1 of the KPH during the last 3 years (25-35) and 5-10 patients who will be operated on within the next 6-8 months.~3. The established group - patients who will be operated on in the surgical department No. 1 of the KPH over the next 1.5 - 2 years, using the developed techniques."||||
33981886|NCT03729310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will not have access to what treatment each cavity received through randomization. The information will be available should an emergency arise that would require the treating physician to know this information in order to best treat the subject. The subjects right to access this information will be reinstated when the study period is over (12 weeks after surgery).|Each subject will have both treatments (Propel and Nasopore), with one treatment on one side and the other treatment on the opposite side. The treatment for the right and left cavity will be selected in a randomized fashion (using opaque envelopes to assign each treatment to a respective ethmoid cavity).|t|f|f|f
33981887|NCT02550574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981888|NCT06484647|||CASE_CONTROL||PROSPECTIVE|||||||
33981889|NCT04085107|||COHORT||CROSS_SECTIONAL|||||||
33981890|NCT03090932|||CASE_CONTROL||PROSPECTIVE|||||||
33981891|NCT02458638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981892|NCT00115882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981893|NCT02149888|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33981894|NCT01453556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981895|NCT05047107|||CASE_ONLY||PROSPECTIVE|||||||
33981896|NCT04671888|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981897|NCT01097408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769392|NCT03497884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33769393|NCT00624663|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33769394|NCT00903669|||CASE_ONLY||PROSPECTIVE|||||||
33769395|NCT04931459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Study ACU-001 is a placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple escalating doses of intravenous ACU193. A two-part single-ascending dose (SAD)/multiple-ascending dose (MAD) study design will be conducted in a population of individuals with early AD (MCI or mild dementia due to AD).|t|t|t|t
33769396|NCT04375982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects are asked to provide venous and capillary blood samples which are not being taken as part of routine care||||
33769397|NCT02963051|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33769398|NCT04066985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither investigators, outcomes assessor, youth, nor parents will know the condition assigned to the youth.|All adolescent participants will be provided a study identifier and prompted to complete self-report questionnaires. Subsequently, a random number generator (embedded within Mindlogger, a Child Mind Institute developed data collection application) will be used to assign participants to one of three intervention conditions.|t|f|t|t
33769399|NCT04789577|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33769400|NCT04202744|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769401|NCT05942638|||COHORT||PROSPECTIVE|||||||
33769402|NCT04083963|NA|SINGLE_GROUP||TREATMENT||NONE||Carboplatin plus paclitaxel followed by doxorubicin and cyclophosphamide||||
33769403|NCT04759521|||COHORT||PROSPECTIVE|||||||
33769404|NCT04155437|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898693|NCT01426386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898694|NCT00414440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769405|NCT01500746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769406|NCT05808335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769407|NCT06042868|NA|PARALLEL||OTHER||NONE||||||
33769408|NCT04854538|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33769409|NCT04009005|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor blinded to study arm.|Comparison of the intervention arm to standard of care.|f|f|f|t
33769410|NCT02600624|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769411|NCT03183557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769412|NCT04753671|||COHORT||PROSPECTIVE|||||||
33769413|NCT02329106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33769414|NCT06309030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769415|NCT02926664|||COHORT||PROSPECTIVE|||||||
33898695|NCT01095861|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898696|NCT01158950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33898697|NCT02024581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898698|NCT02832492|||COHORT||PROSPECTIVE|||||||
33898699|NCT01580475|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33981898|NCT04220151|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33981899|NCT03339856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898700|NCT03900676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)|Parallel Assignment|t|t|t|f
33898701|NCT03050463|||CASE_CONTROL||PROSPECTIVE|||||||
33898702|NCT03401606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898703|NCT03697369|||CASE_ONLY||PROSPECTIVE|||||||
33898704|NCT00177346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898705|NCT02437669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898706|NCT05836961|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898707|NCT00754767|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33898708|NCT01850381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898709|NCT00922935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898710|NCT05744986|||CASE_ONLY||PROSPECTIVE|||||||
33898711|NCT00525343|||COHORT||RETROSPECTIVE|||||||
33898712|NCT01030042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898713|NCT01388400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898714|NCT02127762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898715|NCT03167619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898716|NCT01073189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898717|NCT06221644|||CASE_CONTROL||PROSPECTIVE|||||||
33898718|NCT06407362|||CASE_ONLY||PROSPECTIVE|||||||
33898719|NCT03761745|||COHORT||PROSPECTIVE|||||||
33898720|NCT02246270|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33898721|NCT03358628|||COHORT||PROSPECTIVE|||||||
33898722|NCT02894515|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898723|NCT05146622|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33898724|NCT04373369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898725|NCT03053349|||COHORT||PROSPECTIVE|||||||
33898726|NCT01596595|||CASE_ONLY||PROSPECTIVE|||||||
33898727|NCT06512090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981900|NCT02020707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981901|NCT02472184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33981902|NCT03905486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981903|NCT06360627|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33981904|NCT02208492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981905|NCT01050647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981906|NCT01212874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981907|NCT01980862|||COHORT||PROSPECTIVE|||||||
33981908|NCT04165148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981909|NCT05406349|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898728|NCT02808715|||CASE_CONTROL||PROSPECTIVE|||||||
33898729|NCT01583647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898730|NCT02333539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981910|NCT01740219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981911|NCT03947138|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33981912|NCT05536518|NA|SINGLE_GROUP||OTHER||NONE||||||
33981913|NCT01320306|||OTHER||RETROSPECTIVE|||||||
33981914|NCT04127045|||COHORT||PROSPECTIVE|||||||
33981915|NCT01050803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33981916|NCT02161848|||||CROSS_SECTIONAL|||||||
33981917|NCT05299047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981918|NCT01052116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33981919|NCT05655832|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981920|NCT05915403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078771|NCT02672176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34078772|NCT02269839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898731|NCT01906840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898732|NCT01594099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898733|NCT04296292|||OTHER||PROSPECTIVE|||||||
33898734|NCT06477341|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898735|NCT01363505|||CASE_CONTROL||PROSPECTIVE|||||||
33898736|NCT00443560|||CASE_CONTROL||RETROSPECTIVE|||||||
33898737|NCT00847717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898738|NCT06265948|||COHORT||PROSPECTIVE|||||||
33898739|NCT04885049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898740|NCT01793545|||COHORT||PROSPECTIVE|||||||
33898741|NCT04558008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33898742|NCT05751005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This was a double blind study, in which investigators were not unblinded until all primary data end points were statistically analyzed. One person who was not involved in the study maintained the key until investigators were ready to be unblinded.|Two different doses of collagen peptides versus placebo.|t|f|t|t
33898743|NCT03937986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33898744|NCT05306678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33898745|NCT05216991|||COHORT||PROSPECTIVE|||||||
33898746|NCT01197573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898747|NCT02517879|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898748|NCT02153515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898749|NCT05347732|||COHORT||PROSPECTIVE|||||||
33898750|NCT03680677|||COHORT||PROSPECTIVE|||||||
33898751|NCT04294589|||COHORT||PROSPECTIVE|||||||
33898752|NCT04292847|NA|SINGLE_GROUP||OTHER||NONE||||||
33898753|NCT05441046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898754|NCT03784430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898755|NCT00163540|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33898756|NCT00854048|||CASE_CROSSOVER||PROSPECTIVE|||||||
33898757|NCT04627350|||COHORT||PROSPECTIVE|||||||
33898758|NCT01787591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33898759|NCT02263664|||||PROSPECTIVE|||||||
33898760|NCT04827537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898761|NCT03466944|||COHORT||PROSPECTIVE|||||||
33898762|NCT05252520|NA|SEQUENTIAL||OTHER||NONE||||||
33898763|NCT02263365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898764|NCT02439385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898765|NCT03213639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898766|NCT04075604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898767|NCT04187001|||OTHER||OTHER|||||||
33898768|NCT00495846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898769|NCT02007239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898770|NCT01607723|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33898771|NCT00539344|NA|SINGLE_GROUP||||NONE||||||
33898772|NCT01264315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898773|NCT00642616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898774|NCT04512729|||COHORT||PROSPECTIVE|||||||
33898775|NCT00599586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981921|NCT05124184|||COHORT||RETROSPECTIVE|||||||
33981922|NCT00305045|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33981923|NCT02194998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981924|NCT04280757|||COHORT||OTHER|||||||
33981925|NCT06196801|||COHORT||PROSPECTIVE|||||||
33981926|NCT00912353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33981927|NCT01406795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981928|NCT05330754|||COHORT||CROSS_SECTIONAL|||||||
33981929|NCT01931033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078773|NCT01436487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078774|NCT00057291|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078775|NCT01082744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078776|NCT04554589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898776|NCT06143579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898777|NCT05332899|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898778|NCT03553017|||CASE_ONLY||CROSS_SECTIONAL|||||||
33898779|NCT05346757|NA|SINGLE_GROUP||SCREENING||NONE||Once the participant accepts to participate in the study, a fecal sample collection kit will be delivered together with the sample collection instructions. The sample must be collected at home before starting bowel preparation, more specifically between 24-72 hours before the day that colonoscopy is scheduled. Both miRNA expression and FIT will be analyzed in a central laboratory (Hospital Clinic of Barcelona) from the same fecal sample.||||
33898780|NCT05835258|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Crossover, Randomized, Triple-Blind Study|t|t|t|t
33898781|NCT06513520|||COHORT||PROSPECTIVE|||||||
33898782|NCT01268397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898783|NCT06365476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33898784|NCT04033679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Participant randomly assigned to receive either TDCS stimulation or sham stimulation.|t|f|f|t
33898785|NCT01172171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898786|NCT06156202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898787|NCT01678846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898788|NCT03576872|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33898789|NCT05542615|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a real-life, open-label, proof of concept trial to assess the safety and efficacy of two daily doses of pirfenidone (KitosCell® LP), in patients with compensated liver cirrhosis.||||
33898790|NCT04685473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898791|NCT01503931|||CASE_CONTROL||PROSPECTIVE|||||||
33898792|NCT06076330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898793|NCT04864795|||COHORT||PROSPECTIVE|||||||
33898794|NCT05333562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898795|NCT01837082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898796|NCT04329949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898797|NCT06405204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898798|NCT06669325|||COHORT||PROSPECTIVE|||||||
33898799|NCT01174784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898800|NCT02776930|||COHORT||PROSPECTIVE|||||||
33898801|NCT02726867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898802|NCT01753518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898803|NCT03424551|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898804|NCT06193083|||CASE_ONLY||PROSPECTIVE|||||||
33898805|NCT04086940|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||prospective randomized controlled study|t|t|t|t
33898806|NCT00148629|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33898807|NCT06667804|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized cotrolled clinical trial||||
33898808|NCT03604328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078777|NCT02937623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078778|NCT06141785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention with a historical control cohort.||||
34078779|NCT01217827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33898809|NCT02232789|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33898810|NCT00058370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898811|NCT04580602|||CASE_CONTROL||PROSPECTIVE|||||||
33898812|NCT05518591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898813|NCT02502422|NA|SINGLE_GROUP||SCREENING||NONE||||||
33898814|NCT04601272|||COHORT||RETROSPECTIVE|||||||
33898815|NCT04460027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33898816|NCT04685603|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein|t|f|t|f
33898817|NCT02446366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898818|NCT00574977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898819|NCT02156700|||COHORT||CROSS_SECTIONAL|||||||
33898820|NCT02997189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33898821|NCT03906695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898822|NCT01845025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898823|NCT06045572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pivotal, prospective, controlled study (comparison with genetic tests, histopathological / immunohistochemical analysis) to evaluate the safety and performance of VTM as a diagnostic test in breast cancer.||||
33898824|NCT01019408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898825|NCT00232570|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898826|NCT04430582|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898827|NCT02340104|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898828|NCT03976856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898829|NCT05590403|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind for Cohort 1 (Day1-Day 31) and single-blind afterwards and open-label for Cohort 2||t|t|t|t
33898830|NCT03868553|||COHORT||CROSS_SECTIONAL|||||||
33898831|NCT02240628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898832|NCT04272125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981930|NCT04963309|||COHORT||RETROSPECTIVE|||||||
33981931|NCT02820922|||||RETROSPECTIVE|||||||
33981932|NCT00487500|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33981933|NCT04734665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981934|NCT01358565|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33981935|NCT00565448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981936|NCT01001208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981937|NCT04420923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981938|NCT01926548|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33898833|NCT00510692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33898834|NCT04936425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded as to which study arm they are in, in order to avoid any bias they may have.||t|f|f|f
33898835|NCT04968561|||COHORT||RETROSPECTIVE|||||||
33898836|NCT02061995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898837|NCT04550507|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33898838|NCT01284556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981939|NCT00411203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33981940|NCT04305145|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981941|NCT03988270|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized study with two arms: Intervention arm with a pre-fistula placement exercise program versus a control arm with no prefistula placement exercise||||
33981942|NCT05556590|||COHORT||PROSPECTIVE|||||||
33981943|NCT03474510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33981944|NCT04426799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||: A randomized, pre-test-post-test design was carried out to examine the effectiveness of lemon essential oil in reducing test anxiety in first-year students of the Faculty of Medical Sciences of a private university in Istanbul.|f|f|t|f
33981945|NCT05210738|||COHORT||RETROSPECTIVE|||||||
33981946|NCT03727568|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33898839|NCT02227407|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33898840|NCT03927976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33898841|NCT05255614|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33898842|NCT04623931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898843|NCT00252863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898844|NCT01382069|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33981947|NCT00591630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981948|NCT01652001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33981949|NCT05425381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All student participants in the study will be assigned an alpha-numeric code to de-identify their cases. The codes and relevant identifiers will be maintained by a data specialist in the school districts and not shared with the researchers at any point.|The study will compare the ISFE model against co-located PBIS and SMH services-an approach commonly used in schools, particularly when community-based mental health clinicians are contracted for services. Thus, schools will be randomly assigned to the experimental conditions before systemic changes are implemented, beginning in the fall of 2022.|t|f|f|f
33981950|NCT02866188|||CASE_ONLY||PROSPECTIVE|||||||
33981951|NCT04792749|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33981952|NCT06398678|||CASE_CONTROL||RETROSPECTIVE|||||||
33981953|NCT01051570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981954|NCT01168505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981955|NCT06486480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33981956|NCT00769964||||TREATMENT||||||||
33981957|NCT05227820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981958|NCT05371444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The outcomes assessors will not now the arm to which each participant corresponds||f|t|t|t
33981959|NCT05386589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981960|NCT02300090|||OTHER||OTHER|||||||
33981961|NCT02465567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769416|NCT05142670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects in the experimental group underwent 20 minutes of task-oriented training individualized by the gravity perception following 30 minutes of regular physical therapy. The training in the control group received 20 minutes of visual feedback treatment program following 30 minutes of regular physical therapy.|t|f|f|t
33769417|NCT02312674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769418|NCT05565274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The hospital Pharmacist will prepare the drugs in both arms where the first arm will be 2 ml of 100mg tramadol in 5 ml syringe and 2ml of 600mg Paracetamol in 5 ml syringe as well. The second arm will be 2ml of 30mg pentazocine in 5ml syringe plus 2ml of water for injection. Both arms of the medications will be pre-packed in opaque envelopes and labelled by the pharmacist as either A or B who will take no further part in the study. These will be assigned based on the randomized outcome. The randomization list will be on the possession of research assistant who will take no further part in the study after randomly assigning participants to the study arms till the end of the study.|"Randomized"|t|t|t|t
33769419|NCT03978026|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Participants will be recorded by technicians and results stored anonymously for traitement|"Participant is evaluated in 4 situations :~* nap in a bed~* nap on a car sit~* nap in the Sombox~* no nap sitting on a car sit"|f|f|t|f
33769420|NCT05865457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769421|NCT00361361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769422|NCT04583683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769423|NCT04093141|NA|SINGLE_GROUP||TREATMENT||NONE||Patients in the study will be compared to data from clinical registry.||||
33769424|NCT03816241|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Participants are assigned to 1 out of 4 possible anecdotes; Control, Framing, Norms, Combination.|t|f|t|f
33769425|NCT01719900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769426|NCT00968721|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769427|NCT04563806|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33769428|NCT04830605|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a single-case experimental design with multiple baselines. This means the participants have different baseline lengths but the same intervention and follow-up period and that they all receive the same intervention. The baseline and intervention period serves as two study conditions, a control (baseline) and a treatment condition (intervention) with N equally spaced measurement occasions. The baseline length is randomly assigned to the participants and serves as each participants' own control-condition. This makes it possible to have a small number of participants. If the intervention shows effect a change in the anxiety level will be detected during the intervention period regardless of when the intervention-period was initiated.||||
33981962|NCT03230149|||CASE_ONLY||PROSPECTIVE|||||||
33981963|NCT00709553|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33981964|NCT04677764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded author to group allocation collected the outcome measures at baseline and after 12 weeks of intervention period.||f|f|f|t
33981965|NCT00507234|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33981966|NCT02107690|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981967|NCT03595657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078780|NCT00159315|RANDOMIZED|CROSSOVER||||NONE||||||
33981968|NCT05324436|||COHORT||PROSPECTIVE|||||||
33981969|NCT05083598|||COHORT||PROSPECTIVE|||||||
33981970|NCT02366949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981971|NCT00167505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33981972|NCT01412580|||FAMILY_BASED||PROSPECTIVE|||||||
33981973|NCT04625114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded placebo controlled||t|t|t|f
33981974|NCT05452226|NA|SINGLE_GROUP||TREATMENT||NONE||small, prospective cohort study where every participant receives the study intervention||||
33981975|NCT03246100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"Patients will be randomized within practices to one of 3 arms:~1. Standard of care control~2. Autodialer (3 reminders)- with brief education message + practice name + practice phone # (see autodialer scripts)~3. Mailed reminder (3 reminders)-- with brief education message + practice name + practice phone # (see postcards)"|t|f|f|f
33981976|NCT04064632|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients are randomly allocated into two arms:~The control arm continues the baseline therapy based on 3 drugs (2 NRTIs) for 24 weeks and then will be switched to receive rilpivirine and cobicistat/darunavir co-formulated tablets (a tablet day).~The experimental arm receives rilpivirine and cobicistat/darunavir coformulated tablets at randomization."||||
33981977|NCT03422211|||COHORT||PROSPECTIVE|||||||
33981978|NCT01844219|||COHORT||RETROSPECTIVE|||||||
33981979|NCT04791670|||COHORT||PROSPECTIVE|||||||
34024605|NCT02927366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898845|NCT04054713|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Participant will be initially allocated in either group without knowing its initial manoeuver|A clinical trial will be carried out, including all those patients older than 18 years who go to perform a superior endoscopy with diagnosis of Barrett's esophagus where patients will be randomized into two groups, one of acetic acid and the other of the Seattle protocol as a method Initially and subsequently, a second endoscopy will be performed with the opposite method and the histopathological results of both groups will be compared.|t|f|f|f
33898846|NCT00358592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33898847|NCT04786288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||simple and stratified randomization method (experiment, control and placebo group x pre-test post-test)|t|f|f|f
33898848|NCT00249886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898849|NCT05793073|||OTHER||RETROSPECTIVE|||||||
33898850|NCT00749099|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33981980|NCT05094713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Crossover randomized controlled trial|t|f|f|t
33981981|NCT03423225|NA|SINGLE_GROUP||SCREENING||NONE||||||
33981982|NCT05526118|||COHORT||PROSPECTIVE|||||||
33981983|NCT06054581|||OTHER||CROSS_SECTIONAL|||||||
33981984|NCT00921648|||CASE_ONLY||RETROSPECTIVE|||||||
33981985|NCT03733509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Total blind (patient, physicians, outcome assessors and statistician) Closed envelope by independent randomizer is given to physician assistant. The assistant prepares randomly allocated placebo or local anesthetic. Group is coded so that statistician is also blind|Two arm, randomly assigned|t|t|t|t
33981986|NCT04115280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33981987|NCT04864548|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE|This is an open-label trial, however in order to minimise volunteer adverse event reporting bias by volunteers, study participants will be kept blinded to swab results for as long as possible.|||||
33898851|NCT04103918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898852|NCT03077048|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33898853|NCT05976737|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33898854|NCT05321953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898855|NCT03063073|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33898856|NCT04410783|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a prospective, before-and-after study, and there will be no randomization process.||||
33898857|NCT04952012|||CASE_CONTROL||RETROSPECTIVE|||||||
33898858|NCT03690414|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The study treatments will be labelled as A, B and C at the Pharmacy. The masked study products will then be sent to the study coordinator to dispense|Children aged between 6 to 13 years old. Myopia with spherical equivalent of -0.50D or worse with cylinder of -2.00D or less|t|t|t|t
33898859|NCT02062177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898860|NCT05896176|||COHORT||PROSPECTIVE|||||||
33898861|NCT00500097|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33898862|NCT01304862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898863|NCT01878071|||||CROSS_SECTIONAL|||||||
33898864|NCT04859491|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The primary investigator will not be blinded to the treatment groups. However, both the research assistants responsible for administering the experimental protocol (aerobic interval and time to exhaustion testing) and the participants will be.|Participants will be randomized to one of three groups: isocaloric carbohydrate (1.2 g/kg of body weight), carbohydrate-protein (0.8 g/kg body weight carbohydrate + 0.4 g/kg body weight protein), or placebo (flavored water). All three beverages will have a similar appearance and taste and participants will be blinded to the contents. All beverages will contain the same volume of fluid (1 liter).|t|f|f|t
33981988|NCT04751578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33981989|NCT06307925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33981990|NCT06138184|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33981991|NCT01135927|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33981992|NCT00191295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33898865|NCT01274377|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898866|NCT03566966|||CASE_CONTROL||PROSPECTIVE|||||||
33898867|NCT05182515|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is an open-label, randomized, multicenter, concurrent, parallel-group, standard of care controlled, to evaluate the safety and efficacy of plasma exchange (PE) in patients with anti-interferon autoantibodies, intensive care admitted for severe or critical symptoms of respiratory illness caused by Coronavirus disease 2019 (COVID-19) defined as Life-threatening by the WHO scale, using a group-sequential adaptive design.~Approximately 50 participants will be randomized 1:1 to the Investigational or Control arm. Participants randomized to the Investigational arm will receive plasma exchanges (PE) for nearly three days in addition to standard of care (SOC), while participants in the Control arm will receive SOC only. The first plasma exchange session occurs within the first 120 hours of ICU admission.~Two interim analyses are planned."||||
33898868|NCT01525511|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981993|NCT05216081|NA|SINGLE_GROUP||SCREENING||NONE||||||
33981994|NCT00822874|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33981995|NCT01767428|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33981996|NCT04768179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33981997|NCT03509103|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33981998|NCT02375906|||COHORT||CROSS_SECTIONAL|||||||
33981999|NCT01449071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982000|NCT03732443|||COHORT||PROSPECTIVE|||||||
33982001|NCT05287438|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Group A will receive results based on standard culture and Group B will receive results based on NGS||||
33982002|NCT02068248|||||RETROSPECTIVE|||||||
33982003|NCT04066166|||COHORT||CROSS_SECTIONAL|||||||
33982004|NCT03317548|||CASE_CONTROL||RETROSPECTIVE|||||||
33982005|NCT03986177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33982006|NCT04643938|||CASE_ONLY||PROSPECTIVE|||||||
33982007|NCT03836066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982008|NCT00003237||||TREATMENT||||||||
33982009|NCT03500861|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33982010|NCT02808065|||COHORT||PROSPECTIVE|||||||
33982011|NCT02262377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982012|NCT03079271|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33982013|NCT03029936|||OTHER||CROSS_SECTIONAL|||||||
33982014|NCT01474564|||COHORT||PROSPECTIVE|||||||
33982015|NCT01974999|||COHORT||RETROSPECTIVE|||||||
33982016|NCT04744909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982017|NCT01563965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33982018|NCT04784598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Group 1- (n=40) The participant allocated to the insoles group adapted to flip-flops and classified as having a neutral foot according to the FPI-6 will receive a flip-flop with a horseshoe-type foot element on both feet to maintain symmetry between the limbs.~If the participant is classified with the foot pronated or supinated, only the painful foot will be modified since the symmetry of the limbs will not be modified. Participants with pronated foot will receive the medial wedge as a pedal element; already the participants with supinated foot, the lateral wedge. All elements will be 3mm and produced with EVA Shore 32.~• Group 2- The control group (n=40) will receive a slipper with a 2.5mm EVA cover (Shore A 32) identical to the one used by the intervention group, but without corrective par."|t|f|t|t
33982019|NCT05627141|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33982020|NCT03559023|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33982021|NCT00359164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982022|NCT01460797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982023|NCT02598479|||CASE_ONLY||PROSPECTIVE|||||||
34078781|NCT05355467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078782|NCT03337815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078783|NCT04264780|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34078784|NCT00203801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982024|NCT04170309|||COHORT||RETROSPECTIVE|||||||
33982025|NCT03804359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982026|NCT04539197|||COHORT||PROSPECTIVE|||||||
33982027|NCT05732766|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34078785|NCT03123081|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single Blind (Subject)||t|f|f|f
34078786|NCT06244368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078787|NCT03957785|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982028|NCT01223612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982029|NCT02766075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33982030|NCT04764565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||single-blind crossover|t|f|f|f
33982031|NCT01041456|||COHORT||RETROSPECTIVE|||||||
34103532|NCT06081244|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label.|This is a multicentre, interventional, prospective, two-arm, randomised, open-label, neoadjuvant, phase-II-trial evaluating the efficacy and safety of SG alone vs. SG+PEM in low-risk early TNBC in pre- and postmenopausal women.||||
34103533|NCT06410131|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33982032|NCT04109469|||COHORT||RETROSPECTIVE|||||||
33982033|NCT03657979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982034|NCT02473640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982035|NCT03165058|||CASE_CONTROL||PROSPECTIVE|||||||
33982036|NCT03488784|||COHORT||PROSPECTIVE|||||||
33982037|NCT00519142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982038|NCT04712422|||CASE_CONTROL||PROSPECTIVE|||||||
33982039|NCT01042886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982040|NCT01724502|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33982041|NCT05564247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Testers will remain blinded to group assignment throughout the study. A Research Coordinator (Quebec site) will coordinate T2 and T3 assessments for both groups.|A three-site, single-blind randomized controlled trial (RCT)|t|t|f|f
33982042|NCT00465010|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982043|NCT04829227|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33982044|NCT02748161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982045|NCT02942953|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982046|NCT06304701|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study is part of category 2 of research involving humans and which corresponds to an interventional study with minimal risks and constraints. The patient is asked to return to carry out this study.||||
33982047|NCT04719000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982048|NCT04191980|||COHORT||RETROSPECTIVE|||||||
33982049|NCT06431906|||CASE_ONLY||PROSPECTIVE|||||||
33982050|NCT00503152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982051|NCT04926883|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33982052|NCT02631629|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982053|NCT02445300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982054|NCT04995822|||COHORT||PROSPECTIVE|||||||
34078788|NCT03318198|RANDOMIZED|CROSSOVER||OTHER||NONE||We conducted a 9-month randomized, cross-over trial on an inpatient medicine teaching service where 22 faculty provided either: 1) direct supervision where attendings joined work rounds on established (previously admitted) patients or 2) standard supervision where attendings were available, but did not join work rounds. Each faculty member participated in both arms in random order. The primary safety outcome was rate of medical errors. Resident education was evaluated via a time motion study to assess resident participation on rounds and surveys to measure resident and attending educational ratings.||||
34078789|NCT03429101|NA|SINGLE_GROUP||TREATMENT||NONE||"* Part 1: Dose Finding To determine the MTD/MAD of poziotinib in combination with the standard dose of T-DM1 by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~* Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 of the study to further evaluate the safety and efficacy."||||
34078790|NCT06160336|NA|SINGLE_GROUP||OTHER||NONE||||||
34078791|NCT01560247|||COHORT||PROSPECTIVE|||||||
34078792|NCT02208076|||COHORT||OTHER|||||||
33982055|NCT05835791|||COHORT||PROSPECTIVE|||||||
34078793|NCT00467519|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078794|NCT02783612|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34078795|NCT04743622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078796|NCT00426881|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33982056|NCT05813548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982057|NCT03596190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982058|NCT00826930|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33982059|NCT01396278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982060|NCT00444197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33982061|NCT06150326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome is the area of the wound, which will be measured by 3 nurses blinded to the study arm, using a layer of the wound.|Randomized, controlled, parallel arms, single-blinded, single-center study|f|f|f|t
33982062|NCT01922648|||COHORT||PROSPECTIVE|||||||
33982063|NCT01918800|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33982064|NCT05542108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcomes assessors are blind to the group assignment of the infant. Care provider (Parents and Research staff supporting parents in intervention can not be masked to the group assignment).|Two intervention groups, Randomised Controlled Trial|f|f|t|t
33982065|NCT06088420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103534|NCT06649721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898869|NCT05677945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This research will be a double-blinded study, where the patient (participant) and the outcome assessor will be blinded to the treatment group (to avoid detection, reporting and assessment bias).~When a patient agrees to participate in the trial, an envelope will be drawn by one of the residents present at the clinic and name, telephone number and patient's I.D. will be written on it. Those selected envelops will be opened at treatment visit after performing access cavity to choose which material should be used. Randomization and allocation concealment will be performed by the co-supervisor to avoid selection bias. The participant will not be aware of which treatment modality he will be receiving.~Principal investigator will not be blinded due to differences in preparation of the mix."||t|f|t|t
33982066|NCT03144700|||OTHER||OTHER|||||||
33982067|NCT02587962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982068|NCT02024321|||CASE_CONTROL||PROSPECTIVE|||||||
33982069|NCT00401804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982070|NCT01316445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982071|NCT03841188|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33982072|NCT03807141|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33982073|NCT01069926|NA|SINGLE_GROUP||||NONE||||||
33982074|NCT00028691|RANDOMIZED|||TREATMENT||||||||
33982075|NCT06215079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982076|NCT04520386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982077|NCT05999006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982078|NCT02379247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982079|NCT00844948|||COHORT||PROSPECTIVE|||||||
34024606|NCT03058432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Concurrent cisplatin based chemoradiotherapy versus radiotherapy alone||||
34024607|NCT05787301|||COHORT||RETROSPECTIVE|||||||
33719868|NCT03359447|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Outcomes assessor: the outcomes are defined by hemoglobin and ferritin (corrected by CRP), also genomic instability is defined by a laboratory result such as comet assay. The members of the laboratory will receive labeled specimens with a code unrelated to the allocated arm.~The investigators that will analyze the data will not carry out the study. All the clinical data will be obtained by the care providers."|Two main arms: weekly vs daily iron supplementation. Infants who are exclusively breast fed will be randomized into three groups: no iron supplementation, weekly iron supplementation and daily iron supplementation. Infants that are partially fed with infant formula will be randomized into two groups: weekly iron supplementation and daily iron supplementation.|f|f|t|t
33719869|NCT02760667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719870|NCT06430203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024608|NCT02598687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024609|NCT02388360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024610|NCT01844232|NA|SEQUENTIAL||TREATMENT||NONE||All subjects will begin treatment with arbaclofen at 20 milligrams (mg) per day (2 X 10 mg) for two weeks, then increase to 30 mg per day (2 X 15 mg) for two weeks, and then increase to 40 mg per day (2 X 20 mg) based on the Dose Escalation Criteria. Once the subject reaches the Maintenance Dose, they will remain on that dose for approximately 1 year. The Maintenance Dose is the highest tolerated dose, not to exceed 40 mg per day.||||
34024611|NCT04937114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34024612|NCT01178216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024613|NCT01801631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024614|NCT02888483|||OTHER||CROSS_SECTIONAL|||||||
34024615|NCT00106743|||COHORT||PROSPECTIVE|||||||
34024616|NCT03928730|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33769429|NCT04581902|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A third party assessor will conduct a biweekly MADRS clinician rating to assess depression symptoms.|This will be a parallel-groups, stratified interventional study to investigate methods of optimizing clinical care in patients diagnosed with MDD.|f|f|f|t
33769430|NCT01763788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769431|NCT01113619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769432|NCT02301637|||||PROSPECTIVE|||||||
33769433|NCT06289790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and nursing staff will be blinded to the performed intervention. PI and performing anaesthesiologist will not be blinded.||t|t|f|f
33769434|NCT01702818|||OTHER||CROSS_SECTIONAL|||||||
33898870|NCT04696744|||COHORT||PROSPECTIVE|||||||
33898871|NCT01319760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898872|NCT03270787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898873|NCT05185232|||COHORT||PROSPECTIVE|||||||
33898874|NCT00488943|||COHORT||PROSPECTIVE|||||||
33898875|NCT04086043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898876|NCT01959204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898877|NCT04512885|||OTHER||PROSPECTIVE|||||||
33898878|NCT05581719|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34078797|NCT05648799|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study was conducted as open to the Participant and the Investigator. However, collected blood samples were blinded to an analytical laboratory specialist.|two-stage study: 1 stage - two-period escalating dose study involved two sequential cohorts of 6 healthy volunteers. 2 stage - randomized comparative study with hypothesis of superior efficacy in parallel groups.||||
33898879|NCT02857465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898880|NCT04652258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898881|NCT05537428|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33898882|NCT04541823|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33898883|NCT00907725|RANDOMIZED|PARALLEL||||NONE||||||
33898884|NCT03721328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898885|NCT05609422|RANDOMIZED|PARALLEL||TREATMENT||NONE||The selected subjects will be divided into two groups of equal numbers (control and study).||||
33898886|NCT00609440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898887|NCT00090285|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33898888|NCT02764866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898889|NCT00233636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078798|NCT03279809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33982080|NCT03382548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to the study, as they will not be informed of the treatment duration and likely to be sedated and unaware of the treatment regimens. Investigators will be blinded during the assessment of the participants for clinical stability based on the above-described criteria to minimise observer bias. Once conditions for stopping antibiotics are satisfied, the investigator will be unblinded and contact the primary physicians to stop antibiotics. The physicians will remain blinded until they are informed that the participant is suitable to stop antibiotics. Independent assessors, who are assigned to determine pneumonia recurrences, will be blinded from the randomisation arms. This will be achieved by blinding all study details, including randomisation arms, for participants with potential recurrences from these independent assessors.|Randomisation will be done via stratified block randomisation by the study sites to ensure participants with similar characteristics such as gender and age are distributed equally in the intervention and control groups. Randomisation will be done with a computer programme with a seed to allow reproducibility. Randomisation will be done with a 1:1 ratio. To prevent predictability of the random sequence, generation of the randomisation sequence is performed by an independent statistician and details of the randomisation generation is unavailable to all investigators. Randomisation will be allocated using sequentially numbered opaque envelopes. Fitness criteria for randomisation must be met prior to randomisation.|t|f|t|f
33982081|NCT02777060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982082|NCT01619800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33982083|NCT02865408|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982084|NCT01128686|||COHORT||RETROSPECTIVE|||||||
33982085|NCT01387737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982086|NCT00095212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982087|NCT01130025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982088|NCT02788448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982089|NCT00048581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982090|NCT02544594|RANDOMIZED|PARALLEL||TREATMENT||NONE||Best medical therapy versus best medical therapy + ECLS in the treatment of cardiogenic shock complicating acute myocardial infarction||||
33982091|NCT01399736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982092|NCT04840251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982093|NCT03025594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982094|NCT06315062|||CASE_ONLY||RETROSPECTIVE|||||||
33982095|NCT00376948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982096|NCT01706536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982097|NCT04549844|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982098|NCT01938586|||CASE_CONTROL||PROSPECTIVE|||||||
33982099|NCT04010331|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33982100|NCT00023309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982101|NCT00957151|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982102|NCT03756857|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open, randomized, parallel, two-arm trial||||
33982103|NCT00148304|||COHORT||CROSS_SECTIONAL|||||||
33982104|NCT00370006|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982105|NCT04473170|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (open-label)|"Parallel assignment involving two groups of participants:~* Group A (Experimental arm): Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.~* Group B (No investigational intervention arm): COVID-19 standard care."||||
33982106|NCT00996320|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33982107|NCT04759248|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single arm, Simon 2-stage, multicenter phase II study evaluating treatment with atezolizumab in combination with trastuzumab and vinorelbine in patients with locally advanced or metastatic PAM50 non-luminal/HER2+ BC refractory to trastuzumab based therapy and anti-HER2 ADC treatment.||||
33982108|NCT05585866|||COHORT||RETROSPECTIVE|||||||
34078799|NCT05401565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078800|NCT03241095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34078801|NCT02909790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078802|NCT05090202|||COHORT||PROSPECTIVE|||||||
34078803|NCT03025113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078804|NCT06046677|||COHORT||PROSPECTIVE|||||||
34078805|NCT00260013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34078806|NCT06211556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm open-label parallel group randomized controlled trial||||
34078807|NCT01145365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678565|NCT05278351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678566|NCT03687463|||COHORT||PROSPECTIVE|||||||
33678567|NCT00228176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678568|NCT01412489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33769435|NCT03558958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769436|NCT01824914|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33769437|NCT05429437|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34103535|NCT05852990|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients with Non-Small Cell Lung Cancer and EGFR Mutation receiving first or second generation-TKI therapy.||||
33678569|NCT01294098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33769438|NCT02076867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769439|NCT03436160|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Blinding is not necessary in this study|Subjects will be randomized to one of three groups to receive 100 mcg Carbon-14 radio labeled WR826647, WR909388, or WR909390||||
33769440|NCT00863889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33678570|NCT04947852|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34103536|NCT05378763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678571|NCT00637949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103537|NCT00677300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678572|NCT00545272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678573|NCT03776006|||COHORT||PROSPECTIVE|||||||
33678574|NCT05090800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33678575|NCT01343641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33678576|NCT04257188|||CASE_CONTROL||PROSPECTIVE|||||||
33678577|NCT03133884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898890|NCT05285852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678578|NCT01566084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33678579|NCT03718091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678580|NCT05103852|NA|SINGLE_GROUP||OTHER||NONE||||||
33678581|NCT04571671|||COHORT||RETROSPECTIVE|||||||
33678582|NCT02720172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33678583|NCT04583059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33769441|NCT03396536|||CASE_CONTROL||PROSPECTIVE|||||||
33769442|NCT04734535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|data blinding to Sponsor, Independent Data Monitoring Committee, FDA reviewer|Prospective, Randomized, Controlled, Multicenter, Clinical Investigation|f|f|f|t
33769443|NCT00183456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33769444|NCT03714022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769445|NCT01352702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769446|NCT04366219|||OTHER||OTHER|||||||
33769447|NCT02909023|||COHORT||PROSPECTIVE|||||||
33769448|NCT01435057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769449|NCT00237484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769450|NCT04392232|NA|SINGLE_GROUP||TREATMENT||NONE||Non-Randomized, single arm study of convalescent plasma treatment of covid 19.||||
33769451|NCT03694457|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
33769452|NCT02851160|||||RETROSPECTIVE|||||||
33898891|NCT01524289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898892|NCT02556762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103538|NCT03307590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33678584|NCT01080781|||||PROSPECTIVE|||||||
33678585|NCT01102998|||COHORT||PROSPECTIVE|||||||
33678586|NCT04432727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678587|NCT05167695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33678588|NCT04125953|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized clinical trial|f|f|t|t
33678589|NCT04513626|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This study is an open label, randomized, switch study, over 96 weeks, in which virally suppressed patients on a stable combined ART regimen will be randomized (2:1) to an immediate switch to doravirine/raltegravir (immediate switch group) or to the maintaining of their current ART followed by a switch to doravirine/raltegravir at W48 (delayed switch group). Patients will be followed during 96 weeks.~The randomization will be stratified on gender and antiretroviral regimen at inclusion (Dual therapy or more)."||||
33678590|NCT06179602|||COHORT||OTHER|||||||
33678591|NCT02093052|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33678592|NCT02070198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33678593|NCT03568188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678594|NCT02846298|||COHORT||PROSPECTIVE|||||||
33678595|NCT03006861|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33678596|NCT02520089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33678597|NCT02429180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33678598|NCT02365233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678599|NCT00074698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678600|NCT01980589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678601|NCT02027649|||CASE_CONTROL||PROSPECTIVE|||||||
33678602|NCT03225040|||COHORT||CROSS_SECTIONAL|||||||
33678603|NCT01736761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678604|NCT04554836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769453|NCT04358341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769454|NCT05263076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769455|NCT03938064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769456|NCT02601586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769457|NCT00937170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769458|NCT03600038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769459|NCT01658709|||COHORT||PROSPECTIVE|||||||
33769460|NCT03319524|||COHORT||PROSPECTIVE|||||||
33769461|NCT00424853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769462|NCT00594906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769463|NCT02368002|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33769464|NCT05611905|||OTHER||PROSPECTIVE|||||||
33898893|NCT03029962|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33898894|NCT04438135|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE||Repeated Open Application test|t|f|t|t
33898895|NCT00987766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898896|NCT06191068|||COHORT||PROSPECTIVE|||||||
34103539|NCT02133677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103540|NCT05947890|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34103541|NCT03389100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Study subjects will receive a single injection of 18F-MK6240 for tau positron emission tomography (PET) imaging two times, separated by an interval between 18 and 30 months.||||
34103542|NCT05852470|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be masked to the IOLs that have been previously implanted in the subject until the end of the study.||f|f|f|t
34103543|NCT06687421|||COHORT||PROSPECTIVE|||||||
33769465|NCT04478084|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind: the participant (or legally acceptable representative) and the Investigator remain unaware of the treatment assignments throughout the study. An unblinded qualified trial staff member will prepare and administer the appropriate vaccine but will not be involved in the immunogenicity and safety evaluations.||t|t|t|t
33769466|NCT01862458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769467|NCT02925260|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769468|NCT03915119|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769469|NCT01197989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33769470|NCT04177914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769471|NCT05766072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769472|NCT00073385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769473|NCT03713372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769474|NCT00969345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769475|NCT04876885|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study looks at two groups. First, it directly measures response of COVID-19 vaccine hesitancy in the general public to education videos on COVID-19 vaccine development, validation, and dissemination. Second, it surveys two stakeholder groups - healthcare professionals and public health professionals to better understand their evaluation of COVID-19 vaccine education needs in the general public, based on their interpretation of commonly asked questions, best practices in health promotion, and evaluation of information already available.||||
33769476|NCT03276663|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open-label, two-arm||||
33769477|NCT06489340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769478|NCT02415920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33769479|NCT02110446|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33769480|NCT06044220|RANDOMIZED|PARALLEL||PREVENTION||NONE||intervention and control group||||
33769481|NCT03963323|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33769482|NCT06297681|||COHORT||CROSS_SECTIONAL|||||||
33769483|NCT02120885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33769484|NCT04439006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769485|NCT01446263|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33769486|NCT03853122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are not aware of the allocation group of the participants|Randomized controlled trial, with two parallel groups (control and intervention)|f|f|f|t
33769487|NCT04912596|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33769488|NCT06316505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33769489|NCT05713682|||COHORT||RETROSPECTIVE|||||||
33769490|NCT05284292|NA|SINGLE_GROUP||OTHER||NONE||||||
33769491|NCT02401958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769492|NCT06625554|||OTHER||PROSPECTIVE|||||||
33769493|NCT00761917|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898897|NCT04244045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898898|NCT03921892|RANDOMIZED|PARALLEL||OTHER||NONE||Using a block randomization generator, participants will be randomized into either in-person or on-line parenting education that will take place over a two week period of time.||||
33898899|NCT06668831|||COHORT||PROSPECTIVE|||||||
33898900|NCT03248466|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||diabetic foot ulcer which Wagner classification at 2-3 grade.|f|f|f|t
33898901|NCT01483573|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33898902|NCT06212440|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||open-label, prospective, single-institution, 3-arms expended randomized study||||
33898903|NCT06213701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The groups will be randomized to one of three groups in a 2:2:1 ratio.|t|f|f|t
33898904|NCT00994370|||CASE_ONLY||PROSPECTIVE|||||||
33898905|NCT02690896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898906|NCT05519943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769494|NCT01563978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769495|NCT03151395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769496|NCT01677780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769497|NCT05428904|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33769498|NCT01984190|||COHORT||PROSPECTIVE|||||||
33769499|NCT04287959|RANDOMIZED|PARALLEL||TREATMENT||NONE||Given this is a pilot study, a recruitment target has not been set. Instead the study will aim to assess recruitment success which will inform a larger multicentre trial if deemed feasible||||
33769500|NCT01846598|||COHORT||PROSPECTIVE|||||||
33769501|NCT06108115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769502|NCT01465139|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33769503|NCT04691297|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769504|NCT05096676|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"Youth with autism participated in a randomized, double-blind placebo-controlled trial. Participants visited the lab for two sessions. In one of the sessions, they received oxytocin, and in the other, they received the placebo. Intranasal doses of 40 international units of oxytocin (IU)/mL were prepared by the Maayan-Haim pharmacy, Israel. We used age-dependent dosing such that participants aged 13-18 years received a dose of 24 IU (3 puffs to each nostril), and younger participants (aged 12 years) received 16 IU. Typically-developing youth underwent the same experimental procedure but did not receive oxytocin or placebo due to ethical constraints in Israel."|t|t|t|f
33769505|NCT06124482|NA|SINGLE_GROUP||OTHER||NONE||"Two target populations will be included in this clinical investigation :~* 60 patients requiring primary Total Knee Arthroplasty~* 32 patients requiring revision Knee Arthroplasty.~In this clinical investigation, it was not possible to realize a double-blinding for practical reasons. Nevertheless, a collection of the primary outcome (score KSS) will be realized blindly to the surgeon in charge of the patient by an intervener not involved in the medical care of the patient, who did not participate in the intervention and did not collect the preoperative KSS score."||||
33769506|NCT01234766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769507|NCT00582491|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33678605|NCT02489422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769508|NCT01752595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769509|NCT04857112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769510|NCT05972733|NA|SINGLE_GROUP||PREVENTION||NONE||Single-arm, Open-label Trial||||
33769511|NCT02826018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769512|NCT01735357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33678606|NCT02558647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants are randomized to CBT-I or a potential active comparator (PE). Follow-up data is primarily self-report; data on sick leave etc is objective data obtained form national registers, with investigators are blinded to participant identity.|This is a parallel-group superiority RCT comparing internet-delivered CBT-I (a Norwegian language version of SHUTi) with online patient education about sleep (PE).|t|f|t|f
33769513|NCT03760744|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33769514|NCT03488524|NA|SINGLE_GROUP||TREATMENT||NONE||This an open-label extension study to CENTAUR (AMX-3500)||||
33769515|NCT00951509|||COHORT||PROSPECTIVE|||||||
33678607|NCT03531632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769516|NCT00004736||||TREATMENT||||||||
33769517|NCT05193084|||OTHER||RETROSPECTIVE|||||||
33769518|NCT00216320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769519|NCT02066532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769520|NCT00039156||||TREATMENT||NONE||||||
33769521|NCT00361075|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33769522|NCT01228344|||OTHER||OTHER|||||||
33769523|NCT03509792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769524|NCT02378402|||CASE_ONLY||PROSPECTIVE|||||||
33769525|NCT04485650|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||"In the study, 30 patients were assigned to the music group, 30 patients were assigned to the group that received sedation and 30 patients were assigned to a group that was not sedated, all occurred in a randomized controlled way.~The music were chosen by a researcher under guidance of an expert and grouped as relaxing, classical, mystical, and Turkish folk music. One of them was chosen by the patients following the application of spinal anesthesia in the music group. Sedation (Dormicum) was performed to the sedated group after spinal anesthesia based on the height and weight data and the doctor's decision. The patients in the non-sedated group were followed without any procedure (sedation and music)."|f|f|t|f
33769526|NCT02045433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769527|NCT01250119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769528|NCT04529720|||COHORT||CROSS_SECTIONAL|||||||
33769529|NCT01436123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33678608|NCT02463890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33678609|NCT05632588|||CASE_ONLY||RETROSPECTIVE|||||||
33678610|NCT03881761|NA|SINGLE_GROUP||TREATMENT||NONE||transfusion of CD19/CD20 bispecific CAR-T cells 24-72 hours after completion of FC regimen pretreatment||||
33678611|NCT04608903|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Sulforaphane group or Placebo group. Thus, 52 participants with CKD under conservative treatment will be recruited at the Renal Nutrition Clinic of UFF and 70 patients under regular HD treatment|t|t|t|t
33678612|NCT01242813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769530|NCT02030912|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33769531|NCT04532021|||CASE_CONTROL||PROSPECTIVE|||||||
33769532|NCT01114750|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33769533|NCT01335113|||COHORT||PROSPECTIVE|||||||
33769534|NCT02211534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769535|NCT02951559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic study||||
33769536|NCT04975828|||COHORT||RETROSPECTIVE|||||||
33769537|NCT05686525|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will randomize approximately 220 patients with an anticipated 10% dropout (N = 200). The study will assign patients in a 1:1 manner to either Arm 1: TUMT or Arm 2: PAE.||||
33769538|NCT04842864|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769539|NCT00277589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769540|NCT04750993|||OTHER||CROSS_SECTIONAL|||||||
33769541|NCT04415697|||COHORT||RETROSPECTIVE|||||||
33769542|NCT02313818|NA|SINGLE_GROUP||TREATMENT||NONE||Variable length Cognitive Processing Therapy||||
33769543|NCT04639518|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Two sequential sub-studies||||
33769544|NCT03312179|||CASE_CONTROL||PROSPECTIVE|||||||
33769545|NCT05890898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769546|NCT01864863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769547|NCT06028581|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33769548|NCT02654223|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33769549|NCT01745315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769550|NCT04013490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769551|NCT02795260|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33769552|NCT05232435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The trial has 3 groups|f|f|t|t
33769553|NCT05285254|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769554|NCT04213313|||CASE_CONTROL||PROSPECTIVE|||||||
33769555|NCT04307498|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, one-group, exploratory clinical study.||||
33769556|NCT01863043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769557|NCT00423852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769558|NCT04356339|||COHORT||PROSPECTIVE|||||||
33769559|NCT03695016|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and their referring physician will be aware of participant randomization. Only the intervention coach, who will also notify the participants of their assignment will be aware of the assignments; other study staff and the investigator will be masked.|3 month wait-listed control trial in which participants are randomized to immediate intervention or intervention after 3 months.|f|f|t|t
33769560|NCT02096614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33678613|NCT00440791|||||PROSPECTIVE|||||||
33982109|NCT02268032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33982110|NCT01357278|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33982111|NCT03622138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33982112|NCT03182322|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33982113|NCT06001034|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1: Aerobic exercise plus occlusive tool. Group 2: Aerobic exercise without occlusive tool.||||
33982114|NCT04403880|||COHORT||OTHER|||||||
33982115|NCT01174680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982116|NCT02828709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678614|NCT03457064|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33678615|NCT03246997|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are enrolled in the study and randomly assigned to the immediate intervention or the delayed intervention group. Participants in the immediate intervention group will receive the intervention for 6 months with a 6-month and 12-month follow-up starting from day one of enrollment. Participants in the delayed intervention group will receive the intervention beginning 6 months after enrollment with a 6-month and 12-month follow-up starting from day one of enrollment.||||
33678616|NCT04620213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678617|NCT02711241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678618|NCT03060122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33678619|NCT05194371|||COHORT||RETROSPECTIVE|||||||
33678620|NCT02029300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678621|NCT01697280|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33678622|NCT01558128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678623|NCT01583829|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33678624|NCT02168036|||CASE_ONLY||CROSS_SECTIONAL|||||||
33678625|NCT04478344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678626|NCT01395524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678627|NCT04723264|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33678628|NCT05867589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33678629|NCT03954340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|all will be blinded to sham or treatment|Subjects will undergo either EEG NFB treatment with the iRemember System or a sham treatment|t|t|t|f
33678630|NCT00824837|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33678631|NCT00848562|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33678632|NCT05468073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33678633|NCT00001196|||COHORT||PROSPECTIVE|||||||
33678634|NCT05908565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33678635|NCT02691585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33678636|NCT02447237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678637|NCT00651079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33678638|NCT01529905|||COHORT||PROSPECTIVE|||||||
33678639|NCT06085456|||COHORT||RETROSPECTIVE|||||||
33678640|NCT01806701|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33678641|NCT03730402|RANDOMIZED|PARALLEL||OTHER||SINGLE|single-blind study|prospective randomized control trial|t|f|f|f
33678642|NCT00612105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678643|NCT05634993|||COHORT||PROSPECTIVE|||||||
33678644|NCT04592718|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33678645|NCT04769700|||COHORT||CROSS_SECTIONAL|||||||
33678646|NCT03049241|||OTHER||PROSPECTIVE|||||||
33678647|NCT00294619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678648|NCT00096356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33678649|NCT06293976|NA|SINGLE_GROUP||OTHER||NONE||||||
33678650|NCT02852187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678651|NCT02888496|||CASE_CONTROL||PROSPECTIVE|||||||
33678652|NCT04207541||SEQUENTIAL||PREVENTION||NONE|Participant does not know which group they are assigned to.|Recruit control group first then interventional group.||||
33769561|NCT01984424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898907|NCT02532543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898908|NCT01887834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898909|NCT01623466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898910|NCT05508152|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33898911|NCT04408157|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding not possible as passive control arm and using self-report outcomes.|Two-arm parallel randomised-controlled trial with nested qualitative study||||
33898912|NCT01486680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33898913|NCT03054727|||COHORT||PROSPECTIVE|||||||
33898914|NCT04920448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898915|NCT01225068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33898916|NCT00095303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982117|NCT03026270|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33982118|NCT02738242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982119|NCT03432897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982120|NCT02665013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33982121|NCT02774928|||COHORT||PROSPECTIVE|||||||
33769562|NCT02494206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769563|NCT05689086|||COHORT||PROSPECTIVE|||||||
33769564|NCT05521295|||CASE_CONTROL||PROSPECTIVE|||||||
33769565|NCT04205929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo-controlled Computer-generated randomization schema||t|f|t|t
33769566|NCT02150265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898917|NCT03560895|||COHORT||PROSPECTIVE|||||||
33898918|NCT01451671|||CASE_CONTROL||PROSPECTIVE|||||||
33898919|NCT04382651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898920|NCT03179124|||CASE_CONTROL||PROSPECTIVE|||||||
33898921|NCT05060250|||COHORT||PROSPECTIVE|||||||
33898922|NCT01098968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898923|NCT04220892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898924|NCT04923971|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will perform hand-dexterity tasks in three different ambient temperatures 1) 0C 2) -10C, and 3) -20C surrogate (-10C with 3m/s wind speed to simulate -20C conditions)||||
33898925|NCT00046826||||TREATMENT||NONE||||||
33898926|NCT02167477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898927|NCT00018863|RANDOMIZED|||TREATMENT||DOUBLE||||||
33898928|NCT01586663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898929|NCT04214795|||COHORT||PROSPECTIVE|||||||
33982122|NCT01079988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103544|NCT06002698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103545|NCT05370209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769567|NCT06050291|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-Label, Single-Dose, Randomized, Two-Treatment, Two-Period, Two-Sequence, Crossover Study||||
33898930|NCT03671369|||COHORT||PROSPECTIVE|||||||
33898931|NCT02486068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898932|NCT01652196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898933|NCT01731288|||OTHER||RETROSPECTIVE|||||||
33898934|NCT01979510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898935|NCT00971321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33898936|NCT03205969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33898937|NCT06296810|||CASE_ONLY||PROSPECTIVE|||||||
33898938|NCT06207344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33898939|NCT01815567|||CASE_CONTROL||PROSPECTIVE|||||||
33898940|NCT00247325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33898941|NCT06058234|||COHORT||PROSPECTIVE|||||||
33982123|NCT03992066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982124|NCT03365375|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982125|NCT05462561|NA|SINGLE_GROUP||TREATMENT||NONE||"5 total:~* 1 patient will be accrued for feasibility, and monitored for a period of 3 months.~* If successful, defined as the absence of life-threatening complication, including allograft rejection requiring explantation, and adequate bladder storage, accrual of the remaining 4 patients will ensue."||||
33982126|NCT01297036|RANDOMIZED|CROSSOVER||||NONE||||||
33982127|NCT02686333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982128|NCT05515926|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33982129|NCT05830019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982130|NCT01416766|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33982131|NCT00017953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982132|NCT03469297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982133|NCT04772105|RANDOMIZED|PARALLEL||TREATMENT||NONE||one investigational medicine with two different dose groups||||
34103546|NCT00583206|||CASE_ONLY||PROSPECTIVE|||||||
34103547|NCT01628770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769568|NCT04175353|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33769569|NCT00224523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769570|NCT02204293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769571|NCT04264234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Placenta previa cases will be followed up at 28th gestational week and evaluated at 32nd week by vaginal ultrasonography and MRI and this follow-up will continue until delivery.||||
33769572|NCT03379064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769573|NCT01133574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769574|NCT01018563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769575|NCT00462046|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33769576|NCT01235130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769577|NCT04376294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769578|NCT02357680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33769579|NCT05171868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769580|NCT02355522|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33769581|NCT03112200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon will be blinded to the treatment group until the time of surgery to avoid potential selection bias during the screening process. The subject will be blinded to the treatment group. The research coordinator will consult the central randomization list to determine which group the subject is in. Subjects may be randomized prior to surgery to allow for OR set-up. However, randomization should be performed as close to the time of surgery as possible to reduce the risk of randomization failures due to cancelled procedures.|A stratified blocked randomization will be used to assign subjects to either Subchondroplasty with arthroscopy or to arthroscopy alone in a 2:1 ratio. Individual sets of blocks will be determined within study site and lesion polarity status (unipolar vs. bipolar).|t|f|f|f
33769582|NCT01673360|||COHORT||PROSPECTIVE|||||||
33769583|NCT01284140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769584|NCT04738890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769585|NCT01340911|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33769586|NCT04366570|||COHORT||PROSPECTIVE|||||||
33769587|NCT05728593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers were not blinded to group assignments and interventions. However, the participants were blinded about the purpose of the study and the groups they were in.||t|f|f|f
33769588|NCT02174874|||COHORT||PROSPECTIVE|||||||
33898942|NCT03778229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Under Protocol versions 1-6 the study model was single arm (open-label).~Starting protocol version 7 patients will be randomised in a double blinded manner to receive savolitinib in combination with osimertinib or savolitinib with placebo to osimertinib with crossover option upon disease progression assessed by Investigator."|t|t|t|t
33898943|NCT00853905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898944|NCT05051085|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33898945|NCT01804595|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33898946|NCT00252850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33898947|NCT00084786||||TREATMENT||||||||
33898948|NCT01214512|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33898949|NCT00222846|RANDOMIZED|PARALLEL||||NONE||||||
33898950|NCT04713345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot, single-center, prospective, randomized, open-label, superiority study with 2 parallel groups (1: 1): experimental group (Virtual Reality) versus control group (Relaxation).||||
33982134|NCT05512026|NA|SINGLE_GROUP||TREATMENT||NONE|Patients will be de identified and assigned a designated number for inclusion in case report forms. Source documents will contain patient information and assigned study participant number.|"Up to 30 subjects Fifteen subjects will be enrolled in this study and undergo water-aided colonoscopy with the Poseidon System. If the Primary Endpoint and Secondary Endpoint 1 are achieved in the first 15 subjects, the study will be complete.~If the Primary Endpoint or Secondary Endpoint 1 are not achieved, changes to the device design will be made and this protocol will be conducted again in a second group of 15 subjects with updated device."||||
33982135|NCT00500487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103548|NCT06105645|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103549|NCT05741372|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33678657|NCT01606865|||COHORT||PROSPECTIVE|||||||
33982136|NCT05367388|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The treatment sequence will be determined using a 2×2 crossover design. This study includes an adaptive design feature of variable sample size.||||
33982137|NCT03117569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982138|NCT05532527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678662|NCT00744302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769589|NCT03313115|||COHORT||PROSPECTIVE|||||||
33769590|NCT06274164|||CASE_CONTROL||PROSPECTIVE|||||||
33769591|NCT01475916|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33678663|NCT03816540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Same intervention will be applied to FXTAS-affected and unaffected (comparison) participants.||||
33769592|NCT05924282|||COHORT||RETROSPECTIVE|||||||
33769593|NCT00852137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769594|NCT05080673|RANDOMIZED|PARALLEL||OTHER||NONE||Surveillance||||
33769595|NCT01108510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769596|NCT06004284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be given exercise practices along with ergonomics training.|f|f|f|t
33769597|NCT02109796|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33769598|NCT05065385|||COHORT||CROSS_SECTIONAL|||||||
33769599|NCT04263090|NA|SEQUENTIAL||TREATMENT||NONE||"Dose-escalating Phase I study followed by a Phase 2a dose-expansion phase.~Rigosertib escalation will occur with three dose levels: Dose D1: 280mg twice daily, Dose D2: 560mg qAM, 280mg qPM, Dose D3: 560mg twice daily. Nivolumab will be dosed at the standard fixed dose of 240mg."||||
33769600|NCT02802319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769601|NCT01017653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769602|NCT05094193|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33769603|NCT05559437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||To investigate the effectiveness of ultrasound guided Ilioinguinal/Iliohypogastric ( II/IH) block compared to ultrasound guided Posterior Quadratus Lumborum (PQL) block in patients subjected to inguinal hernia repair.|t|f|t|t
33769604|NCT00828906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769605|NCT06038903|||COHORT||CROSS_SECTIONAL|||||||
33769606|NCT02571621|||CASE_ONLY||RETROSPECTIVE|||||||
33769607|NCT01018641|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33769608|NCT05490693|||OTHER||OTHER|||||||
33769609|NCT04911062|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Optional Part B will be randomized, blinded, active-controlled.|||||
33769610|NCT04867785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769611|NCT04255082|||COHORT||PROSPECTIVE|||||||
33769612|NCT02861391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769613|NCT01004250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769614|NCT06122532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769615|NCT05716789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769616|NCT01335295|NA|SINGLE_GROUP||||NONE||||||
33769617|NCT00599547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769618|NCT01808976|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769619|NCT04180839|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33678669|NCT02631473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678670|NCT01865552|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33769620|NCT03548064|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33769621|NCT04421937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769622|NCT03712540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769623|NCT00211601|RANDOMIZED|PARALLEL||||NONE||||||
33769624|NCT00457028|||COHORT||RETROSPECTIVE|||||||
33769625|NCT03636945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769626|NCT01247493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769627|NCT03514407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769628|NCT00335205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33678672|NCT04705181|||OTHER||RETROSPECTIVE|||||||
33678673|NCT02771496|||COHORT||PROSPECTIVE|||||||
33678674|NCT04411563|||COHORT||PROSPECTIVE|||||||
33678675|NCT03425474|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33678676|NCT04305067|NA|SINGLE_GROUP||OTHER||NONE||||||
33678677|NCT05750199|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769629|NCT04132570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33769630|NCT05896917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33769631|NCT00479089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769632|NCT02600182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33769633|NCT01290536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982139|NCT03132727|||COHORT||PROSPECTIVE|||||||
33982140|NCT05395247|||COHORT||PROSPECTIVE|||||||
33982141|NCT03165019|||CASE_CONTROL||PROSPECTIVE|||||||
33982142|NCT04517019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982143|NCT03188770|||COHORT||PROSPECTIVE|||||||
33982144|NCT06424145|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33982145|NCT04223440|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982146|NCT01727271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982147|NCT02177981|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33982148|NCT06301698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769634|NCT02004743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33769635|NCT01770990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982149|NCT01002638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769636|NCT01242176|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982150|NCT02175706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982151|NCT04549883|NA|SINGLE_GROUP||PREVENTION||NONE||single-group, pretest-posttest clinical trial||||
33982152|NCT03902496|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The active and sham lenses will have tints calibrated such that the optical density, that is the overall darkness of all study lenses, will be the same. All study lenses will appear to have the same overall light-blocking effect to study subjects."|A total of 50 subjects will be randomized into one of two treatment groups in a one-to-one ratio. After three weeks, and following a one-week washout period, subjects will be given spectacles from the other treatment group|t|t|t|f
33982153|NCT03171493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982154|NCT06287905|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Simple randomization|observational comparative|t|f|f|f
33982155|NCT02768064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982156|NCT02543671|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33982157|NCT01925092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982158|NCT02015390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982159|NCT00219830|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982160|NCT02426710|RANDOMIZED|PARALLEL||TREATMENT||NONE||RAndomization to ICE or no ICE||||
33982161|NCT00748228|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33982162|NCT00005006|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982163|NCT00866593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982164|NCT02702960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982165|NCT03661047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, stratified, randomized clinical trial|t|t|t|t
33982166|NCT03303937|||COHORT||PROSPECTIVE|||||||
33982167|NCT01188837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982168|NCT00204139|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982169|NCT02835261|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33982170|NCT04842162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective non-randomized bicentric study||||
33982171|NCT03608878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982172|NCT01781286|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34103550|NCT04544631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers and nurses did not know the group assignment until immediately prior to intervention. Following the dressing change procedure, a second researcher, blinded to the group assignment, asked participants a post-assessment that included questions about child and guardian perceived pain and subjective VR experience.|A prospective, three-group between subject randomized controlled trial|f|f|t|t
33769637|NCT05646992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769638|NCT00084734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769639|NCT02562963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982173|NCT05354232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Soterix devices allow for effective and automated double-blinding.|Subjects will be randomized during the first study visit to the 2mA, 1mA, or sham conditions. Subjects will not change dose throughout study.|t|t|t|t
33769640|NCT00398775|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33769641|NCT00362102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769642|NCT00385450|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33769643|NCT01277536|||COHORT||PROSPECTIVE|||||||
33769644|NCT02158637|||CASE_ONLY||PROSPECTIVE|||||||
33769645|NCT02765490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769646|NCT01839968|||CASE_ONLY||PROSPECTIVE|||||||
33769647|NCT05012215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769648|NCT01586338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769649|NCT02693340|||COHORT||PROSPECTIVE|||||||
33769650|NCT04035655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Electrophysiological evaluation of a routine care intervention: single session of left dorso-lateral transcranial direct current stimulation||||
33769651|NCT00404534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769652|NCT04596787|||COHORT||RETROSPECTIVE|||||||
33769653|NCT01607385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769654|NCT05183737|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||The study is a longitudinal randomized, double-blind, placebo-controlled clinical trial with patients with CKD undergoing hemodialysis. Patients will be randomized and divided into two groups: intervention group, which will receive microcapsules containing 250mg of propolis and 250mg of turmeric, twice a day, for 12 weeks, and placebo group, which will receive for the same amount of capsules containing arabic gum and cornstarch.|t|f|t|t
33982174|NCT06194422|||COHORT||PROSPECTIVE|||||||
33982175|NCT00448097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982176|NCT05570084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982177|NCT03382002|||COHORT||PROSPECTIVE|||||||
33982178|NCT01493752|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33719871|NCT03509025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719872|NCT00338689|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33721313|NCT02401880|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33769655|NCT05142410|||CASE_CONTROL||RETROSPECTIVE|||||||
33769656|NCT05857579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769657|NCT02894320|||OTHER||CROSS_SECTIONAL|||||||
33769658|NCT05364619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982179|NCT05558891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982180|NCT02465697|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33982181|NCT02157220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103551|NCT02091960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103552|NCT06627595|||COHORT||PROSPECTIVE|||||||
34103553|NCT04674306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103554|NCT06407427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33721314|NCT01799616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721315|NCT00390533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721316|NCT00772707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769659|NCT00380341|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769660|NCT03117517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33769661|NCT04848662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769662|NCT04396223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769663|NCT06528561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769664|NCT03711864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769665|NCT02677363|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33769666|NCT05866250|||COHORT||PROSPECTIVE|||||||
33769667|NCT02066350|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769668|NCT03930914|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33898951|NCT03453086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|•Patients will be randomly allocated to one of the two groups by sealed closed envelop technique|"Although thoracic epidural analgesia is the gold standard technique after breast surgery paravertebral block (PVB) has become a potential alternative approach. However, both techniques may be associated with serious complications such as pneumothorax, total spinal anaesthesia and inadvertent intravascular injection. Recently since the advent of ultrasound (US) in anaesthetic practice several interfascial plane blocks have been described. Serratus plane block is a novel interfascial plane block which can provide analgesia after breast surgery.~The serratus anterior plane block is an interfascial plane block where the local anaesthetics are injected superficial to serratus anterior at the 5th rib level in the mid axillary line. The serratus plane block is a progression from Blanco's et al work with the Pecs I and II blocks by making the technique easier in its application using single injection and to lower the potential side-effects"|t|t|f|f
33898952|NCT05491642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33898953|NCT06641765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, prospective, randomized controlled study.||||
33898954|NCT03306771|||CASE_CONTROL||PROSPECTIVE|||||||
33898955|NCT02887963|||OTHER||CROSS_SECTIONAL|||||||
33898956|NCT01541605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898957|NCT01300377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33898958|NCT02795910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33898959|NCT06668870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33898960|NCT01052285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898961|NCT01613235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33898962|NCT00609271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33898963|NCT04727112|||COHORT||CROSS_SECTIONAL|||||||
33898964|NCT01599351|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898965|NCT01300117|||COHORT||PROSPECTIVE|||||||
33898966|NCT03339102|||COHORT||PROSPECTIVE|||||||
33898967|NCT01893788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982182|NCT04232605|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||"Phase one: In a randomized, single-blind, multiple-ascending-dose finding pilot study we investigate the safety and tolerability of GLP-1 on three healthy volunteers. The following GLP-1 doses will be given intravenously ( 1.5, 2.0 and 2.5 picomol/kg/min) over 20 min. The dose with considerable dilatory effect will be chosen for main study.~Phase 2 and 3:The study is a double-blinded, placebo-controlled, randomized crossover study. It involves two arms, GLP-1 and placebo. Each participant will in a randomized order receive placebo or GLP-1 intravenous infusion over 20 min on the two experiment days.~The study consists of two separate substudies, one for healthy volunteers and one for migraine patients. The substudies are otherwise identical."|t|t|t|f
33982183|NCT02166216|||COHORT||PROSPECTIVE|||||||
33982184|NCT04125706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Two parallel groups will receive two different locally delivered antibiotics|t|t|t|t
33982185|NCT03437356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982186|NCT02123979|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33721317|NCT03629821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups design where one group receives treatment and the other not in the same period of time.|f|f|t|t
33721318|NCT00999557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33721319|NCT04017273|||OTHER||PROSPECTIVE|||||||
33721320|NCT05087147|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians|||||
33721321|NCT05779878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721322|NCT05688241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center open-label, non-randomized phase I/II study.||||
33721323|NCT03742609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33721324|NCT01046734|||CASE_ONLY||PROSPECTIVE|||||||
33721325|NCT03012347|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33721326|NCT02959645|||CASE_ONLY||CROSS_SECTIONAL|||||||
33721327|NCT01144442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721328|NCT02105610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721329|NCT01361438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721330|NCT05451862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721331|NCT02576561|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33721332|NCT02068443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721333|NCT02174055|||CASE_ONLY||PROSPECTIVE|||||||
33721334|NCT02492620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721335|NCT01802528|||COHORT||RETROSPECTIVE|||||||
33721336|NCT03307720|RANDOMIZED|PARALLEL||TREATMENT||NONE||IVF patients enrolled either to HCG or agonist trigger ovulation induction||||
33721337|NCT00575913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721338|NCT02711046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721339|NCT05750355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721340|NCT01002469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721341|NCT00856895|||OTHER||CROSS_SECTIONAL|||||||
33721342|NCT01328821|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33721343|NCT04016376|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to 1 of 3 groups (approximately n=500 patients per group) of standard of care preoperative nerve blocks consisting of either: i) PVB, ii) serratus+PECS-1, or iii) PVB+PECS-1. Each group will receive ropivacaine or bupivacaine +/- clonidine (0.5 - 1 mcg/kg not to exceed a total of 100 mcg) +/- dexamethasone (up to 4 mg) in one of three routine nerve block approaches prior to surgical procedure as is current standard of care.||||
33721344|NCT01382446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721345|NCT04171973|RANDOMIZED|CROSSOVER||OTHER||NONE|Neither patients nor evaluators can be unaware of which group they are in.|It is a pilot, prospective, monocentric, controlled, randomized, open-arms, open-ended, minimal risk and minimal constraint study (RIPH category 2).||||
33769669|NCT05571995|RANDOMIZED|PARALLEL||PREVENTION||NONE||single blinded cluster randomised controlled trial||||
33769670|NCT04453514|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33769671|NCT02352662|||COHORT||PROSPECTIVE|||||||
33982187|NCT05533502|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single Blind Study (Investigator only)|A block-randomized, within-subject, two-day, crossover design examining acute (0-4 h) postprandial changes in different gut hormone concentrations and bone remodeling biomarkers in 12 healthy, young adults following ingestion of a combination plant-based protein and marine-based multi-mineral supplement or control.|f|f|t|f
33982188|NCT04392271|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982189|NCT05332015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982190|NCT02989688|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33982191|NCT02914730|||COHORT||CROSS_SECTIONAL|||||||
33982192|NCT00205049|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33769672|NCT01137136|||COHORT||PROSPECTIVE|||||||
33769673|NCT04494217|||COHORT||PROSPECTIVE|||||||
33769674|NCT03880318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982193|NCT02246478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982194|NCT02301676|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33769675|NCT05971134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33769676|NCT03434613|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|This study will conduct to evaluate the efficacy of liver fat lowering and safety of rosuvastatin 5mg alone or in combination with rosuvastatin 5mg / ezetimibe 10mg for 6 months.||||
33769677|NCT01703702|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33769678|NCT05756543|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769679|NCT06208345|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The treating physicians are kept blind to the treatment allocation.|Single-blind randomized controlled parallel-group clinical trial|f|t|t|f
33769680|NCT00332215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769681|NCT05158439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982195|NCT02947243|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982196|NCT03083171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982197|NCT02242292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982198|NCT01185808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982199|NCT04335578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is an Investigator-blind and participant-blind study.||t|t|t|t
33982200|NCT02244034|||COHORT||RETROSPECTIVE|||||||
33982201|NCT06266052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982202|NCT01522352||PARALLEL||||NONE||||||
33982203|NCT05352386|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33898968|NCT03749642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The present study will be performed in double blind conditions. During the study neither the Investigator nor the patient will be aware of the treatment assigned.|Randomized, double-blind, placebo and reference controlled, placebo unbalanced, double-dummy, dose finding, parallel group, multicentre, international, prospective study|t|t|t|t
33898969|NCT03502135|NA|SINGLE_GROUP||TREATMENT||NONE||Single-Arm, unblinded trial.||||
33898970|NCT00372164|||CASE_CONTROL||RETROSPECTIVE|||||||
33898971|NCT00539786||PARALLEL||DIAGNOSTIC||NONE||||||
33898972|NCT04072770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33898973|NCT03518515|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33898974|NCT03854487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982204|NCT02724800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33982205|NCT01024439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982206|NCT04038710|||CASE_ONLY||PROSPECTIVE|||||||
33898975|NCT05121337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors will not know randomization assignment. Investigators will not know randomization assignment. Participants and the nutritionist/dietitian interventionist will need to know randomization assignment in order to carry out the intervention.|Individual level, parallel, randomized trial|f|f|t|t
33898976|NCT04779021|||COHORT||RETROSPECTIVE|||||||
33769682|NCT05643963|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33898977|NCT01150110||||TREATMENT||||||||
33898978|NCT03127020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982207|NCT01379664|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33982208|NCT03228693|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33982209|NCT05328141|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33982210|NCT04922424|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participant, PI and RA will not know whether the participant is taking the atorvastatin or placebo. Supervising physician will know.|Baseline testing, then each condition (group) will receive atorvastatin or placebo, followed by washout. Then receive the other condition.|t|f|t|t
33982211|NCT03004300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982212|NCT05471817|NA|CROSSOVER||BASIC_SCIENCE||NONE||||||
33982213|NCT01856309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982214|NCT05469009|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33982215|NCT00628199|||COHORT||PROSPECTIVE|||||||
33982216|NCT05520788|||COHORT||OTHER|||||||
34024617|NCT06232798|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, singelcenter, single-arm clinical study to evaluate the safety and efficacy of PFA/RF catheter or PFA catheter for the treatment of persistent atrial fibrillation||||
33769683|NCT05285202|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||Twelve clusters or study regions (of which eight will be randomized to receive interventions) will be defined according to the catchment areas of twelve participating Ugandan district hospitals/major health centers. Eight study areas will receive a total of six 4-month intervention periods (alternating between the facility-based and the hotspot focused strategy, for three periods of each type) over a four-year period, with a 4-month wash-out period after each intervention period. Four additional areas will be used as control sites; the only involvement of participants in these sites will be through retrospective collection of de-identified data.|f|f|t|f
33769684|NCT04315246|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive up to five cycles of intracerebroventricular 177Lu-DTPA-omburtamab. Safety and efficacy will be investigated during treatment and follow-up period.||||
33769685|NCT06159413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sixty LBP participants will be divided into three groups in a 1:1:1 ratio, 20 in each group (control group, stabilizing exercises, and virtual reality rehabilitation system). All three groups received training three days per week throughout the Six-week treatment session.|Randomized, double-blinded controlled study.|t|f|f|f
33769686|NCT04718714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33769687|NCT06012864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|closed envelope|Patients divided into two groups (group A: modified supine PNL, group B: prone PNL)|t|f|f|f
33769688|NCT05891418|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33769689|NCT05882084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Astaxanthin vs Placebo|t|f|t|t
33769690|NCT04622137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769691|NCT02351440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769692|NCT03126032|||CASE_CONTROL||PROSPECTIVE|||||||
33769693|NCT01183702|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769694|NCT01333085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769695|NCT03452176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33769696|NCT01627119|||CASE_ONLY||RETROSPECTIVE|||||||
33769697|NCT03452020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769698|NCT05046977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769699|NCT01520389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769700|NCT00773955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769701|NCT06343337|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|The individual who evaluates the salivary pH and flow rate.||f|f|f|t
33769702|NCT02527967|||COHORT||PROSPECTIVE|||||||
33769703|NCT04387539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769704|NCT03324737|RANDOMIZED|PARALLEL||PREVENTION||NONE|The subjects who participate in the study may be seeing the doctors or allied health professionals involved in this study at the clinic. However, recruitment will not be done by them though they will help to improve the awareness of such a study to their patients. There will be no coercion involved as the subjects have the full autonomy to decide if they wish to participate.|"A prospective Randomized Control Trial will be conducted to compare an INTERACTIVE SMARTPHONE APP versus STANDARD care to optimize post-delivery weight in women with recent GDM. The aim is to reduce diabetes and cardiometabolic risk.~During the antenatal period, subjects will be informed about the study during regular NUH nurse-led dietary counseling sessions. After delivery, women will be offered the opportunity to join the study. Informed consent will be obtained before discharge from hospital post-delivery. An appointment will be given for the first study visit at 6 weeks post-delivery."||||
33769705|NCT04517422|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All study staff, including the Principal Investigator and the persons performing the subject assessments, will be blinded during the study. Sealed individual treatment code envelopes will be kept at the clinic to be able to break the code if any emergency occurs, as judged by the Investigator|Randomized controlled trials. 300 subjects (18-60 years old) will be allocated to receive a combination of Lactobacillus plantarum CECT 30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and P. acidilactici CECT 7483 (branch one) or placebo (branch two)|t|t|t|t
33769706|NCT05486429|||CASE_ONLY||RETROSPECTIVE|||||||
33769707|NCT04756011|||COHORT||CROSS_SECTIONAL|||||||
33769708|NCT04521517|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will use implementation science, evaluated using a randomized control trial involving mothers coming for day 1, 6week and 10th-week vaccination of their neonate in the selected health centers, by allocating mothers randomly in two arms (the intervention and non-intervention). Mothers in the intervention arm will get thorough counseling on post-partum Family planning, will be provided with FP pamphlets in addition to the routine immunization service, while mothers from the control arms will get the routine immunization service for their babies.||||
33769709|NCT05540743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769710|NCT00203905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769711|NCT01421589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769712|NCT03885856|||COHORT||RETROSPECTIVE|||||||
33769713|NCT03263234|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33769714|NCT04880161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769715|NCT02757521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769716|NCT04980716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982217|NCT05885139|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Active Comparator: Active Active sessions will last 1 hour each. The following parameters will be used for electric stimulation: low frequency (20 Hz), low current intensity (2 mA), with a small pulse width of 25-170 microseconds. Sham Comparator: Sham In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.|t|f|t|t
33982218|NCT04418388|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33982219|NCT02404194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982220|NCT01902680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982221|NCT04040348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769717|NCT04542226|||COHORT||PROSPECTIVE|||||||
33982222|NCT01661452|||||CROSS_SECTIONAL|||||||
33982223|NCT01604850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982224|NCT02898909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982225|NCT01692405|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982226|NCT02303678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982227|NCT02300805|||CASE_ONLY||PROSPECTIVE|||||||
33982228|NCT01458405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982229|NCT05567614|||COHORT||PROSPECTIVE|||||||
33982230|NCT03223233|||COHORT||CROSS_SECTIONAL|||||||
33982231|NCT00790959|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982232|NCT04963725|||COHORT||PROSPECTIVE|||||||
33982233|NCT00113789|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33898979|NCT03928873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients will be randomized to each group. All participants are blinded to the treatment groups. All of the outcome will be followed by an assistant who is blinded to the allocation.|"Our pilot experiment on safety and effectiveness of Extracorporeal shock wave therapy (ESWT), we choose the two energy doses of ESWT for experiment:~1. Low energy ESWT (1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks)~2. High energy ESWT (1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks) In order to realize the effectiveness of ESWT on trigger finger, we will enroll a placebo group in which all participants will receive ESWT probe treatment with only vibration without transferring energy once per week for 4 weeks."|t|f|f|t
33898980|NCT04789785|||CASE_CONTROL||PROSPECTIVE|||||||
33898981|NCT02226016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33898982|NCT01417286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898983|NCT06152601|NA|SINGLE_GROUP||OTHER||NONE||||||
33898984|NCT01717846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33898985|NCT05774470|||COHORT||PROSPECTIVE|||||||
33898986|NCT01645930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33898987|NCT03517722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33898988|NCT04332692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769718|NCT02855164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose finding, 3-part (Parts A, B, and C), adaptive design study to assess the safety, tolerability, and efficacy of six doses of tropifexor as compared to placebo in subjects with NASH. Each study part had a screening period followed by a double-blind, randomized, treatment period, and a post-treatment follow-up period.~This study was extended based on safety and efficacy results in Part A and available long-term toxicology coverage; Part C was added to explore 48 weeks of treatment at higher doses with paired biopsies in F2/3 NASH patients."|t|t|t|f
33898989|NCT05460780|NA|SINGLE_GROUP||OTHER||NONE||||||
33898990|NCT01533155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33898991|NCT03613428|NA|SINGLE_GROUP||TREATMENT||NONE||Open label dosing cohorts will evaluate oral ruxolinitib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).||||
33898992|NCT00153166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33898993|NCT03811600|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33898994|NCT06509100|NA|SINGLE_GROUP||OTHER||NONE||||||
33898995|NCT02396407|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33898996|NCT02436798|||OTHER||PROSPECTIVE|||||||
33898997|NCT00470327|||OTHER||PROSPECTIVE|||||||
33898998|NCT00683553|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33898999|NCT04419415|RANDOMIZED|FACTORIAL||PREVENTION||NONE||2x2 design||||
33899000|NCT03156777|||CASE_ONLY||PROSPECTIVE|||||||
33899001|NCT04939896|||OTHER||PROSPECTIVE|||||||
33899002|NCT06382753|||COHORT||RETROSPECTIVE|||||||
33899003|NCT06163781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899004|NCT00108810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899005|NCT04789824|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single-blind, randomized-controlled|f|f|f|t
33899006|NCT05195359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Single-blinded Randomized Waitlist Controlled Trial|f|f|t|t
33899007|NCT06438367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769719|NCT03072758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769720|NCT04612816|||OTHER||PROSPECTIVE|||||||
33769721|NCT00242203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769722|NCT02489825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33769723|NCT03029247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769724|NCT04226729|||OTHER||CROSS_SECTIONAL|||||||
33769725|NCT01763528|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33769726|NCT00588263|||COHORT||PROSPECTIVE|||||||
33769727|NCT00641186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769728|NCT05286515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769729|NCT05690360|||COHORT||PROSPECTIVE|||||||
33769730|NCT04318756|||COHORT||PROSPECTIVE|||||||
33769731|NCT02906085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33769732|NCT05225233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769733|NCT05056090|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized, multicenter, open label trial||||
33769734|NCT03607981|||CASE_ONLY||PROSPECTIVE|||||||
33769735|NCT03897205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769736|NCT06109844|||CASE_ONLY||PROSPECTIVE|||||||
33769737|NCT02858765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769738|NCT01563796|||CASE_CONTROL||PROSPECTIVE|||||||
33769739|NCT02817620|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33769740|NCT01989598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769741|NCT06031168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769742|NCT00439166|NON_RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33769743|NCT06611098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769744|NCT01947296|||CASE_CONTROL||PROSPECTIVE|||||||
33769745|NCT02164097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769746|NCT00946179|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769747|NCT00467922|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33769748|NCT06469411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study was a triple-blinded study. In this way, the doctor introduced the patients to receive secretome/distilled water and was not aware of the grouping. Participating volunteers did not know about receiving secretome, distilled water, or other drugs. Secretome and distilled water were placed in similar and coded vials. In addition, the placebo (distilled water) was identical in appearance (shape and color), taste, and smell with secretome. In addition, due to the coding of patients and the lack of clarity in the grouping of patients, the data analyzer were be also blinded.|In this clinical trial study, 60 patients with GvHD, who were referred to Shahid Qazi Hospital in Tabriz, were randomly divided into 2 groups of 30 people, and the intervention and control groups received secretome and distilled water by injection, respectively. The method of blinding was tripleblinded and all the names and personal information of the patients was coded at the time of data collection and remain completely confidential.|t|t|t|t
33769749|NCT00162643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769750|NCT01354106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33769751|NCT03559439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769752|NCT04522713|NA|SINGLE_GROUP||TREATMENT||NONE|Psychological intervention, self-report outcomes|Prospective single-group cohort study||||
33769753|NCT02626702|||OTHER||PROSPECTIVE|||||||
33769754|NCT00519896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769755|NCT00440089|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33769756|NCT03350113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769757|NCT00817804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769758|NCT03263182|||COHORT||PROSPECTIVE|||||||
33769759|NCT03603392||SEQUENTIAL||TREATMENT||NONE||two groups (experimental and control) randomly assigned||||
33769760|NCT03918538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33769761|NCT00841516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33769762|NCT04571463|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769763|NCT05208385|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33769764|NCT00701337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769765|NCT03431090|NA|SINGLE_GROUP||TREATMENT||NONE||The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.||||
33769766|NCT02349724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769767|NCT03304860|NA|SINGLE_GROUP||SCREENING||NONE||||||
33769768|NCT03459703|RANDOMIZED|PARALLEL||TREATMENT||NONE|Statistical analyses will be performed blinded.|||||
33769769|NCT02696330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769770|NCT02105636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769771|NCT01473381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769772|NCT02429245|||||RETROSPECTIVE|||||||
33769773|NCT00554333|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769774|NCT04813757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|We assume participants will not be able to differentiate between the upward rotation focused intervention and the control intervention. Furthermore, the examiner performing baseline and outcome assessment will be unaware of the group allocation while performing these assessments.|Randomized controlled trial|t|f|f|t
33769775|NCT02851836|NA|SINGLE_GROUP||||NONE||||||
33769776|NCT02629068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769777|NCT03022240|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769778|NCT02274649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Interviewer collecting outcomes data was not aware of group assignment||f|f|f|t
33769779|NCT05235763|RANDOMIZED|PARALLEL||OTHER||SINGLE||Upon recruitment, patients are randomized 1:1 to either intervention or control group. The study arms run in parallell for the twelve weeks.|t|f|f|f
33899008|NCT05431686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study will include the intervention group participating in the SMA visits (n=20)||||
33899009|NCT02844608|NA|SINGLE_GROUP||OTHER||NONE||||||
33899010|NCT02308280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899011|NCT00565500|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33899012|NCT01161836|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33899013|NCT03186469|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Data collector will be blinded as to which arm study participants are enrolled||f|f|f|t
33899014|NCT02106208|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33899015|NCT06672016|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899016|NCT00757523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899017|NCT02609711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899018|NCT00004346||||TREATMENT||||||||
33899019|NCT04097288|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Single center, randomized, double-blind, placebo controlled, three period cross over phase I study|t|t|t|t
33899020|NCT01365767|||CASE_ONLY||CROSS_SECTIONAL|||||||
33899021|NCT00534846|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33899022|NCT03271840|||COHORT||PROSPECTIVE|||||||
33899023|NCT03176212|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33899024|NCT06510478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34024618|NCT03706014|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial involving a contact-equivalent control group||||
34024619|NCT00177359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34024620|NCT02875652|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024621|NCT04349943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024622|NCT01505153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024623|NCT06175988|||COHORT||CROSS_SECTIONAL|||||||
34024624|NCT05381714|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769780|NCT04282590|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33769781|NCT06305689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769782|NCT04043637|||CASE_ONLY||PROSPECTIVE|||||||
33769783|NCT00661258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769784|NCT01790321|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33769785|NCT01617005|||COHORT||PROSPECTIVE|||||||
33982234|NCT05677698|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Massage will be done for 4 weeks and 2 times a week (8 massages will be given to a person in total). Experimental groups: The researcher will add 2 drops of aromatic oil to 5 cc almond oil and give hand and arm massage to the participants for 30 minutes. Peppermint oil will be used in the first experimental group, lemon oil in the second experimental group and only almond oil in the control group. The fragrance to be used before starting the application will be given to the women by giving them a sniff.Placebo Group: Hand and arm massage will be performed for 30 minutes by the researcher using only almond oil. Three groups will be formed from women with menopausal symptoms. 1st group will be given a massage with Mint, 2nd group Lemon, 3rd group (placebo group-almond oil) and menopausal symptoms, happiness, peace and aging anxiety symptoms will be evaluated between the groups. All groups will be pre-tested before the procedure. 4. At the end of the massage, the test will be repeated.|t|f|f|f
33982235|NCT04059965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982236|NCT02291900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33982237|NCT04714047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769786|NCT03892369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Three matched groups. Group A: participants diagnosed with alcohol dependence, group B: participants with a father diagnosed with alcohol dependence, and C: a healthy control group.||||
33769787|NCT04048759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33769788|NCT05060718|||COHORT||PROSPECTIVE|||||||
33769789|NCT06479681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769790|NCT03687450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769791|NCT04248465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769792|NCT02591680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769793|NCT04648163|||COHORT||RETROSPECTIVE|||||||
33769794|NCT01539863|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33769795|NCT02245100|||CASE_ONLY||PROSPECTIVE|||||||
33769796|NCT03244241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769797|NCT05881135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769798|NCT01643746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769799|NCT00798486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769800|NCT05913856|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33769801|NCT02770092|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769802|NCT03662997|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective RCT using a crossover design to evaluate safety and efficacy. The study will be conducted in an outpatient setting of an academic clinical center. There will be two participant groups: those with VLU and those with DFU. Approximately 50% of the participants will be in the VLU group and 50% of the participants in the DFU group. Treatment sequence will be randomized so that a fair distribution is achieved. Each participant will receive a 2-week treatment with one of the three dressings followed by a 2-week treatment period with a second dressing (i.e. each participant will receive treatment with two different dressings, either the Bordered Five-Layer Foam Dressing and the Hydropolymer Foam Dressing, or the Bordered Five-Layer Foam Dressing and the Hydrocellular Multi-Layer Foam Dressing) using a cross-over (repeated measures) design, with a total of four study arms.||||
33769803|NCT05878223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants||t|f|f|t
33769804|NCT01184001|RANDOMIZED|CROSSOVER||||NONE||||||
33982238|NCT06234670|||COHORT||RETROSPECTIVE|||||||
33982239|NCT02048111|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33769805|NCT02600858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33769806|NCT04839042|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33769807|NCT05815732|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be assessed before and after the intervention with physical exercise and personalized lifestyle advice.||||
33769808|NCT02918929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769809|NCT01117753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769810|NCT06345937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is not possible to blind participants to their assigned intervention. Care providers are not involved. The outcome assessors for any assessments involving potential for subjectivity in data collection or analysis will be blinded to group assignment.|3-arm parallel-group randomized controlled trial|f|f|f|t
33769811|NCT02011256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769812|NCT04204772|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"12 healthy volunteers will be enrolled to determine the two most palatable and tolerable AC combinations. There will be a total of 4 combinations (2 AC doses and 2 solutions) in stage 1. Each participant will drink an assigned combination every day for 3 consecutive days (Monday, Tuesday, Wednesday, M/T/W) and switch to a different assigned combination M/T/W the following week. AC solution assignments will be defined before the study using a balanced incomplete block design"||||
33769813|NCT04553263|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33769814|NCT05905887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769815|NCT00029575||||TREATMENT||||||||
33769816|NCT00347100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769817|NCT04661072|||COHORT||RETROSPECTIVE|||||||
33769818|NCT00900081|||COHORT||PROSPECTIVE|||||||
33769819|NCT01567943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769820|NCT04914052|||COHORT||PROSPECTIVE|||||||
33769821|NCT03257293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33769822|NCT00003143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024625|NCT00961948|||CASE_ONLY||PROSPECTIVE|||||||
34024626|NCT03240835|||CASE_ONLY||PROSPECTIVE|||||||
34024627|NCT01026987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024628|NCT01914861|||COHORT||PROSPECTIVE|||||||
34024629|NCT05337371|||CASE_ONLY||PROSPECTIVE|||||||
34024630|NCT00576316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024631|NCT04197817|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33839356|NCT05702385|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will enroll oncologists, interventional gastroenterologists, and primary care providers practicing in the US. Participants are randomly assigned to either control, intervention 1, or intervention 2 arms upon enrollment. All eligible and consented participants will complete two rounds of three patient simulations.~Intervention 1 and intervention 2 arms only will receive educational material about the diagnostic test in between these two rounds. Intervention 1 arm participants only will receive the test results whether they select it or not, and Intervention 2 participants will receive the test results only if they select it in the second round of simulated cases"||||
33839357|NCT02890251|||COHORT||CROSS_SECTIONAL|||||||
33839358|NCT01777165|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33839359|NCT05427227|||COHORT||PROSPECTIVE|||||||
33839360|NCT01133418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33839361|NCT03799913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839362|NCT05424146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839363|NCT06199869|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839364|NCT00782392|||COHORT||CROSS_SECTIONAL|||||||
33839365|NCT04190836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839366|NCT03381339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|examiners will be unaware of which toothbrush has been assigned to each subject|3 month home use parallel-arm design to assess the efficacy of powered toothbrush use in the treatment of gingivitis in a moderate sized population, n=70.|f|f|t|f
33839367|NCT04615195|||COHORT||PROSPECTIVE|||||||
33839368|NCT06349447|RANDOMIZED|PARALLEL||TREATMENT||NONE||308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group.||||
33839369|NCT03201510|||COHORT||PROSPECTIVE|||||||
33839370|NCT02357602|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33839371|NCT01618747|||COHORT||PROSPECTIVE|||||||
33839372|NCT01385748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839373|NCT02930395|||||CROSS_SECTIONAL|||||||
33839374|NCT04033965|||COHORT||RETROSPECTIVE|||||||
33839375|NCT04617314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678914|NCT01458093|||COHORT||PROSPECTIVE|||||||
33678915|NCT05454449|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33678916|NCT05339867|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Only the participants will be blinded to their assigned group. Immediately after participants have completed their baseline assessment, study staff will open a sealed envelope to identify the participants' group assignment.||t|f|f|f
33678918|NCT01146457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678919|NCT00616499||||TREATMENT||NONE||||||
33678920|NCT00641511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678921|NCT01423188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33678922|NCT02551796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678923|NCT04101838|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant will be blinded to which vaccine they receive until immediately after vaccination.||t|f|f|f
33678924|NCT01643785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769823|NCT05351138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The children to be included in the study will be randomized into two groups as the TENS group (TG) and the massage group (MG) after the first day evaluations are completed. Randomization will be done with the www.randomizer.com site. The groups of children determined according to the order of participation will be placed in opaque envelopes and the envelopes will be closed. On the second day, the physiotherapist, who will apply the treatments, will do the application according to the group that comes out of the envelope.|Children between the ages of 5-18, diagnosed with CP with LUTD who met the inclusion criteria will be included in the study. Sample size of the study is calculated as 54. All evaluations of the participants will be done by the specialist physiotherapist who made the evaluations would not know which treatment method was applied to the participants and would be a blind evaluator.|f|f|f|t
33769824|NCT02952911|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769825|NCT01424059|||CASE_CONTROL||PROSPECTIVE|||||||
33769826|NCT04505995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769827|NCT01258660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769828|NCT02869113|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33769829|NCT02397460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33769830|NCT01088529|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769831|NCT05653271|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33678926|NCT01410357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33678930|NCT06329193|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33769832|NCT03108963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769833|NCT02778191|||COHORT||RETROSPECTIVE|||||||
33769834|NCT02694484|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769835|NCT03957135|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled clinical trial||||
33769836|NCT01143623|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33769837|NCT06061874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769838|NCT04736550|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||In the pilot trial (R61 Phase), the investigators will use a multi-phase optimization trial (MOST) approach to help identify which components of the exercise and psychotherapy for pain treatment program are viable and worth retaining in the planned fully powered trial (R33 Phase). In the R61 Phase/Pilot Trial, the investigators will have two intervention components: 1) exercise with 3 levels ('assisted', voluntary, none/treatment as usual (TAU); and, 2) psychotherapy for pain (I-STOP) with 2 levels (Yes/I-STOP, No/TAU). All participants will receive also receive the treatment as usual at their residential drug treatment program and any medication assisted treatment (MAT). This corresponds to a 2\^1 x 3 1 full factorial with six experimental conditions.|f|t|f|t
33769839|NCT02018237|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33769840|NCT06449885|||CASE_ONLY||PROSPECTIVE|||||||
33678933|NCT02659774|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33678934|NCT00155519|||DEFINED_POPULATION||OTHER|||||||
33678935|NCT03534440|||COHORT||PROSPECTIVE|||||||
33678936|NCT00970385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678938|NCT03923244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Descriptive study, interventional research involving the human person at risk and with minimal constraints (type 2), prospective, with longitudinal cohort follow-up, mono-centric||||
34024632|NCT00834496|||COHORT||PROSPECTIVE|||||||
33678940|NCT04135170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a double blinded, non-inferiority register-based multicenter randomized controlled trial study. To ensure blinding of the patients, all patients are operated by the same surgical method and the type of cement is unknown to the patients. In this study, blinding of the surgeon is not possible because the surgeon recognizes the cement type and has to document the type of cement in the registration form. We believe the primary endpoint of this trial is not likely to be influenced by the surgeon knowledge of the cement used in the index surgery. The data analyst will be blinded for groups until the entire trial analysis has been completed to minimize the risk of bias that may be introduced during the statistical analysis because of the selective use and reporting of statistical tests.|Patients undergoing full-cemented primary TKA in any Norwegian hospitals are eligible for participation irrespectively of the diagnosis leading to TKA. and randomly assigned to receive ALBC (control group) or plain bone cement (experimental group).|t|f|f|t
33678941|NCT01905787|||CASE_ONLY||RETROSPECTIVE|||||||
33678942|NCT02886208|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33678944|NCT02631993|||COHORT||RETROSPECTIVE|||||||
33678945|NCT04242667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33678946|NCT01128621|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33678947|NCT02044107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33678948|NCT06297772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678949|NCT02968537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678950|NCT04986592|||OTHER||PROSPECTIVE|||||||
33678951|NCT05350956|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33678953|NCT01033149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678954|NCT05860270|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Random number will be generated by statistician who is not involved in the study, and will be masked to all participants, caregivers, investigators and outcomes assessors. Only the drug dispensing personnel will have the decoding table. When an eligible patient is enrolled, he/she will be given a sequential patient number, according to block randomization. Such a patient number indicated its group allocation. The drug dispensing personnel will offer the corresponding drug, however with a random drug number. Serial Serum 25- hydroxy-Vitamin D levels, obtained every three months, will be declassified at the end of the study (24 months after enrollment), or till the occurrence of death, permanently transfer to hemodialysis, loss of follow-up, or withdrawal from the study, whichever comes first.|Eligible patients on PD at one month after being cured from an episode of peritonitis will be enrolled and randomized 1:1 into two groups, includingthe intervention group administered Cholecalciferol (produced by Xymogen Company) 4000 U (2 capsules) per day, and the control group administered placebo 2 capsules per day.|t|t|t|t
33678957|NCT04368078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678960|NCT03757390|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33678961|NCT03085849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678962|NCT03632954|||COHORT||PROSPECTIVE|||||||
33678963|NCT06466408|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|groups -enzyme and -placebo single blind|groups -enzyme and -placebo|t|f|f|f
33678964|NCT03460509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678965|NCT00629967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899025|NCT04881877|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Analysts will be blinded until all data have been captured and the primary analysis programs have been verified. Likewise, all reasonable attempts will be made to keep other non-monitor staff blinded during the course of the study. The statistician analyzing the data will not be blinded. Due to slight differences related to colour of the study products, it will not be possible to blind participants and clinic staff associated with the project|The study is a randomized cross-over trial to evaluate the functional performance of two new male condoms compared to a control latex male condom.|f|f|f|t
33899026|NCT01192451|||COHORT||PROSPECTIVE|||||||
33899027|NCT02477098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899028|NCT05574543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899029|NCT01441544|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33899030|NCT01815437|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33899031|NCT03835338|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment Arm - PVI, LAA Isolation and WATCHMAN LAAC Implantation Control Arm - PVI||||
33899032|NCT05113524|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33899033|NCT01396525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899034|NCT01170156|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899035|NCT01373905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899036|NCT05597046|||OTHER||OTHER|||||||
33899037|NCT03816163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899038|NCT01154725|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899039|NCT05453253|RANDOMIZED|PARALLEL||PREVENTION||NONE||Considering 20% loss of follow-up and sampling failures at 14 days post 2nd OCV, the aim is to enroll 152 participants per arm for the analysis. Thus 456 (3\*152) participants will be recruited. Also, participants with a blood sampling failure at baseline (pre-1st OCV) will be replaced and withdrawn before randomization. Thus 456 (3\*152) participants with an appropriate blood sample at baseline will be randomisedecruited.||||
33899040|NCT00881205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899041|NCT06158672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899042|NCT03385668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024633|NCT05199090|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33678966|NCT01452100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33678967|NCT05724693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024634|NCT05187130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34024635|NCT00858481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024636|NCT04751929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769841|NCT00026897||||TREATMENT||||||||
33678968|NCT01528267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33678969|NCT01425580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33678970|NCT06023836|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly divided into 2 groups and will be treated with ESWT or Dry needling.||||
33678971|NCT04800770|||COHORT||CROSS_SECTIONAL|||||||
33678972|NCT00340899|||COHORT||PROSPECTIVE|||||||
33678974|NCT00966914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678975|NCT05176457|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33678976|NCT03554694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both intervention and placebo products are similar in colour, texture, and taste. A third party, independent of the daya-to-day research coordinator, will randomise treatments.|Crossover Assignment Randomised Double-blind Cross-over design with 4-6 weeks of prebiotics intervention and 4-6 weeks of placebo intervention. The first intervention phase will be followed by a 3 week wash-out period prior to the second intervention phase.d.|t|f|t|f
33678977|NCT00065429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33678979|NCT02630901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678980|NCT02855541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33678983|NCT04546984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678984|NCT05966337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a single-center, randomized, controlled, double-blind clinical trial, in which participants and outcome evaluators were blinded.|Pacients will be divided into 3 groups (CPAP group - CPAP + usual physical therapy care, BiPAP group - BiPAP + usual physical therapy care, and Control group - usual physical therapy care) in a 1:1 allocation ratio. Control group will receive the usual physiotherapy treatment, as kinesiotherapy protocol. Treatment will be administered twice a day, starting in the ICU and progressing to the ward. In the CPAP group, nasal CPAP at 10cmH2O will be administered for 1 hour, twice a day, using an approved device. In BiPAP group, nasal BiPAP with IPAP of 13cmH2O and EPAP of 8cmH2O will be administered for 1 hour, twice a day, using an approved device. The NIV sessions will be conducted during the 5 days of hospitalization, both in the ICU and the ward. After the fifth day, patients in intervention groups will undergo reassessment using the same assessment instruments as before.|t|f|f|t
33678985|NCT03117439|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33678986|NCT05544669|||CASE_ONLY||RETROSPECTIVE|||||||
33678987|NCT02123914|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33678988|NCT01849744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33678989|NCT04267900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33678990|NCT03338322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33678991|NCT06492499|||COHORT||RETROSPECTIVE|||||||
33678992|NCT02490969|||CASE_ONLY||PROSPECTIVE|||||||
33678993|NCT00458029|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized trial||||
33678994|NCT04873232|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33678995|NCT00742664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33678997|NCT04782206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded||t|t|t|t
33678998|NCT03931135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679001|NCT00081094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679002|NCT02161692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679003|NCT04381182|NA|SINGLE_GROUP||OTHER||NONE||||||
33679004|NCT05354453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679005|NCT04010578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||One group will receive a MK-7 and vitamin D3 supplementation and the control group will receive a placebo.|t|t|t|t
33679006|NCT03595618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679007|NCT00103233|RANDOMIZED|||TREATMENT||||||||
33679009|NCT05747040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769842|NCT00586079|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769843|NCT00089895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769844|NCT04722861|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769845|NCT02660762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982240|NCT05169554|RANDOMIZED|PARALLEL||TREATMENT||NONE||"BLMs4BU study is a Phase II, randomized, controlled open label non-inferiority, multi-centre trial, with two treatment arms:~* Standard \[RC8\]: rifampicin plus clarithromycin (RC) therapy for 8 weeks; and~* Investigational \[RCA4\]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.~Randomization will be stratified by lesion category categories I, II or III, using a fixed block size within each strata."||||
33982241|NCT02339233|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982242|NCT00050297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982243|NCT04212949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982244|NCT00517647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982245|NCT03484325|||OTHER||PROSPECTIVE|||||||
33982246|NCT05575180|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33679010|NCT03947476|||COHORT||PROSPECTIVE|||||||
33679011|NCT00913458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679012|NCT05239429|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679013|NCT00252252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769846|NCT05410236|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33769847|NCT02207374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982247|NCT03727100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|Clonidine Micropellet vs Sham-Control|t|f|t|t
33982248|NCT01422538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982249|NCT00448695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982250|NCT05696639|||COHORT||RETROSPECTIVE|||||||
33982251|NCT00291057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679015|NCT03517345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679016|NCT04792242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||case control|f|f|f|t
33679017|NCT04849702|||CASE_ONLY||PROSPECTIVE|||||||
33679018|NCT03905044|||OTHER||RETROSPECTIVE|||||||
33679019|NCT02292914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982252|NCT03306160|||COHORT||PROSPECTIVE|||||||
33982253|NCT02102425|||CASE_CROSSOVER||PROSPECTIVE|||||||
33982254|NCT03759678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The primary evaluation of the Clinical Impression of Change in Severity (CI-CS; Primary Endpoint) will be performed by two independent neurologists whose assessments are based on videos of patient's performance on either the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or the 8 Meter Walk Test (8MWT) taken at each visit.|Patients will be assessed during three study phases: a baseline period (with or without a study run-in), a treatment period, and a washout period.|f|f|f|t
33982255|NCT04736771|||OTHER||RETROSPECTIVE|||||||
33679020|NCT04549402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679021|NCT04385693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679022|NCT03350269|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33679023|NCT01096628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679024|NCT00877123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769848|NCT03249376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769849|NCT03225521|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant-time point is randomized between intervention or no intervention (delivery of a contextually tailored activity suggestion or no suggestion; planning or no planning)||||
33769850|NCT05765097|NA|SINGLE_GROUP||TREATMENT||NONE||"The study was conducted in two phases: one subject only participated in one of the phases.~In phase 1, the semi-closed-loop open source AP system was used to treat the subjects, and the nurse manually entered the initial basal and the bolus instruction for three meals into the system according to the doctor's advice. When the Phase 1 trial is completed, all subjects have no serious adverse events and have been evaluated and confirmed by participants, the phase 2 trial can proceed. In phase 2, the full closed-loop open source AP system was used to treat the subjects. The nurses manually entered initial basal into the system according to the doctor's advice to start treatment, and the open source AP system automatically gave infusion instructions for boluses.Each phase will enroll up to 10 subjects."||||
33769851|NCT00057603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769852|NCT04948879|||COHORT||RETROSPECTIVE|||||||
33769853|NCT05751538|||COHORT||PROSPECTIVE|||||||
33769854|NCT02978989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769855|NCT02341144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33769856|NCT03675243|||COHORT||PROSPECTIVE|||||||
33769857|NCT04887181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769858|NCT04651270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769859|NCT04804813|||COHORT||PROSPECTIVE|||||||
33769860|NCT00839774|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33769861|NCT02952573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769862|NCT04974814|RANDOMIZED|PARALLEL||TREATMENT||NONE||The clinical study will be a prospective open label randomized controlled trial||||
33769863|NCT01037959|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33769864|NCT02546063|RANDOMIZED|CROSSOVER||||NONE||||||
33769865|NCT05178264|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769866|NCT00859092|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769867|NCT02935868|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769868|NCT05668364|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized controlled study||||
33769869|NCT01758861|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33769870|NCT03691389|||FAMILY_BASED||RETROSPECTIVE|||||||
33769871|NCT06144944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769872|NCT03161314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33769873|NCT03117465|RANDOMIZED|PARALLEL||TREATMENT||NONE||All the hemiplegic patients were mainly derived from stroke recovery periodical inpatients from September 2015 to September 2016 in rehabilitation unit of shenzhen nanshan district people's hospital, Guangdong Province,China. All subjects were told in detail about the risks and signed informed consent before the experiment.||||
33769874|NCT06001281|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33679025|NCT06426459|||CASE_CONTROL||OTHER|||||||
33679026|NCT03363113|||CASE_ONLY||RETROSPECTIVE|||||||
33679028|NCT01757145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679030|NCT03279289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679031|NCT00375401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679032|NCT03741387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679033|NCT03222778|||CASE_CONTROL||PROSPECTIVE|||||||
33679034|NCT00798278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679035|NCT06277843|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm non-randomized trial||||
33679036|NCT04909476|||COHORT||PROSPECTIVE|||||||
33679037|NCT05771883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679038|NCT01875198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679039|NCT01550653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33679040|NCT00086268|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679042|NCT05676918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679043|NCT06304467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679044|NCT06086197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679045|NCT03343353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Volunteers will be randomized into groups:~Group Sham= 35 Group red LED= 35 Group infrared LED = 35"|f|f|t|t
33679046|NCT02661763|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33679047|NCT02522624|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33679048|NCT03354143|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33679049|NCT02809716|||CASE_ONLY||PROSPECTIVE|||||||
33679050|NCT05033405|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||The study was conducted by using a prospective randomized single-blind clinical trial model.|t|t|f|f
33679051|NCT02607605|||CASE_ONLY||PROSPECTIVE|||||||
33679052|NCT04405557|||CASE_ONLY||PROSPECTIVE|||||||
33679054|NCT00740935|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33679055|NCT01774656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679056|NCT00842907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679057|NCT03976804|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33679058|NCT05788289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679059|NCT04921813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||rondomized controlled trail|t|f|f|f
33679061|NCT02825797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679062|NCT00912236|||COHORT||CROSS_SECTIONAL|||||||
33679063|NCT05371847|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33679064|NCT04523727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679065|NCT04269083|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, multicenter, randomized phase II study||||
33679067|NCT00659347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679068|NCT03772288|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33679069|NCT04211220|NA|SINGLE_GROUP||OTHER||NONE||A decision support software||||
33679070|NCT00005815||||TREATMENT||||||||
33769875|NCT03437928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839376|NCT05785923|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679071|NCT06531434|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive an induction chemotherapy regimen consisting of 4-8 cycles of docetaxel, cisplatin, and fluorouracil. It is followed by concurrent chemoradiotherapy if down-stage had been achieved by induction chemotherapy.||||
33679075|NCT04414735|RANDOMIZED|PARALLEL||PREVENTION||NONE||Unicentric, randomized, open study.||||
33679076|NCT05975398|||COHORT||PROSPECTIVE|||||||
33899043|NCT04354051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899044|NCT05293938|||COHORT||RETROSPECTIVE|||||||
33899045|NCT02243176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899046|NCT02333045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899047|NCT01137630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899048|NCT05335525|||OTHER||PROSPECTIVE|||||||
33679077|NCT05891639|||CASE_CROSSOVER||PROSPECTIVE|||||||
33679078|NCT04107389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"I intend to use a wait-list control group, whereby following admission to the unit, consenting patients will be randomised to an intervention group which will begin Art Therapy sessions in due course, or to a wait-list control group for a minimum of two weeks and a maximum of six weeks. The intervention group members will receive the Art Therapy intervention, while the waitlist control group are fully aware of the research and are waiting to receive it at a later date.~The waitlist participants will be made fully aware that if they are discharged before therapy has become available to them, or if they reach the maximum term of 6 weeks on the waiting list, then they may not receive the intervention. Participants who reach the maximum term of 6 weeks on the waiting list while waiting for therapy availability will be withdrawn from the research. This maximum six week term is based upon the six week average duration of patient stay within the unit."||||
33899049|NCT01004107|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33899050|NCT01788085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899051|NCT03406195|NA|SINGLE_GROUP||TREATMENT||NONE||We will perform episodic memory task before and after the TMS session||||
33679079|NCT04284462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Same packaging for all (cans). Color and flavor matched.||t|t|t|t
33839377|NCT04151589|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33839378|NCT01183039|RANDOMIZED|PARALLEL||||NONE||||||
33839379|NCT01260818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839380|NCT02749097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839381|NCT02687035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839382|NCT01205022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839383|NCT00022737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839384|NCT05970705|RANDOMIZED|PARALLEL||TREATMENT||NONE||controlled, randomized||||
33839385|NCT03749135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomized, double blind, placebo controlled|This is a Phase 2a multicenter, randomized, double blind, placebo controlled, parallel group, two-arm, proof-of-concept investigator-initiated trial|t|t|t|t
33899052|NCT02806427|||OTHER||PROSPECTIVE|||||||
33899053|NCT04230850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The people collecting the data will not be aware of which intervention group the subjects were allocated to.|A parallel design typically compares two or more treatments. Participants are randomly assigned to one of the groups, treatments are administered, and then the results are compared. In this study, individuals will be placed in one of three groups: static stretching group, dynamic cupping group, or stretching group.|f|f|t|t
33899054|NCT03991793|||CASE_CONTROL||PROSPECTIVE|||||||
33899055|NCT03505866|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The intervention was started in February and March, 2015 and was completed six month later. The program comprises of psychosocial support/peer counseling, ART adherence support and counseling, basic health care, and referral for further care. The support team comprises of a community health worker, a trained HIV-positive person, and a social worker.||||
33899056|NCT05617092|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33899057|NCT04751279|||CASE_ONLY||PROSPECTIVE|||||||
33899058|NCT03952130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899059|NCT03726216|||COHORT||PROSPECTIVE|||||||
33899060|NCT00002669|RANDOMIZED|||TREATMENT||||||||
33899061|NCT04241003|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33899062|NCT05056480|||COHORT||PROSPECTIVE|||||||
33899063|NCT06511609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679081|NCT00227708||||TREATMENT||NONE||||||
33679082|NCT02560506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679083|NCT02850471|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33679084|NCT00322972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679085|NCT02338232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679086|NCT05844475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33679087|NCT00027833|RANDOMIZED|||TREATMENT||NONE||||||
33679088|NCT05307198|NA|SINGLE_GROUP||TREATMENT||NONE||The pCR rate of neoadjuvant chemoradiotherapy is about 20% (null hypothesis). Assuming that the pCR of the RAIC scheme in this study would be in the range of 15%-35%. Using Simon's two-stage design, a total of 37 patients would provide 80% power at a one sided 5% alpha level. Considering the drop rate of 10%, 38 patients would be included (64 cases to be screened) in this study. 10 cases (17 cases were screened) and 28 cases (47 cases were screened) would be included in the first and second stages, respectively. If the number of patients with pCR in the first stage is less than 2, the study will be terminated. If the number of patients with pCR in the first stage is more than 2, a second-stage trial will be performed. If the total number of patients with pCR is more than 9, the effective remission rate of the RAIC regimen is considered to be acceptable.||||
33679090|NCT02998632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679092|NCT05367258|||COHORT||RETROSPECTIVE|||||||
33679093|NCT05423353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679094|NCT01136187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679095|NCT03796520|||CASE_ONLY||PROSPECTIVE|||||||
33679096|NCT01630278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679097|NCT05411627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679098|NCT04356261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intervention condition is randomly assigned and the intervention delivery is digital, through a smartphone app. Senior members of the research team will have a record of the participants randomized to each condition but the delivery of all intervention content is automated within the mobile app. Junior members of the research team responsible for tracking participants and sending follow-up survey reminders will not be aware of participant condition assignment.||t|f|f|f
33679099|NCT05423223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679100|NCT04039100|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679101|NCT02773784|||COHORT||PROSPECTIVE|||||||
33679102|NCT04740645|||COHORT||RETROSPECTIVE|||||||
33679104|NCT02372734|||COHORT||CROSS_SECTIONAL|||||||
33679105|NCT01543581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679106|NCT00974584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679107|NCT00486811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679110|NCT00795678|||CASE_ONLY||PROSPECTIVE|||||||
33679111|NCT00000679||||TREATMENT||DOUBLE||||||
33679112|NCT04924439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Small papers with 40 experiments and 40 controls were folded and put into closed, sealed, opaque envelopes, then all the envelopes were put in a bag and mixed. The women were asked to choose one envelope from the bag, and it was determined whether the experimental or control group they were included in before the application. The women in the study did not know which of the experimental and control groups they were included in, and the statistical analysis was planned double-blind, as an independent statistician apart from the researchers did it.~Statistical analysis of the research was carried out independently by a statistician."|randomized controlled trial|t|f|f|t
33769876|NCT03482817|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, non-randomized, single-sequence study||||
33899064|NCT00360022|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33899065|NCT00172380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899066|NCT05171530|NA|SEQUENTIAL||TREATMENT||NONE||||||
33899067|NCT04462042|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is an open label, multi-centre, randomised phase II study. 100 patients with anal carcinoma (including carcinoma of the perianal skin) will be randomised in 1:1 ratio to treatment delivered with photons or protons||||
33899068|NCT01667744|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33899069|NCT02252978|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33982256|NCT01891266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982257|NCT06282705|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Semi-randomised, matched model.||||
33982258|NCT00115726|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078808|NCT03973580|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The randomized assignment procedure will be conducted solely by the PI. All other research staff and participants will be blind to the assigned condition throughout the course of the study. The PI will use a random number generator in Excel to assign a number 1-10 for each participant. The number will be given to the study coordinator, who notes the number in the participant's file. Participants will be assessed by the coordinator or other research staff. The research staff goes to each participant's home to conduct the ABM training protocol, where the number noted in this participant's file will be entered at the start of the training task to assign the participant to either the ABM task or the control task. The PI will not run the tasks. In communicating with participants, the terms baseline, outcome, and training will not be used.|Sixty adolescents will be randomly assigned to an active ABM task (n=30) or a control task (n=30) in parallel for the duration of the study.|t|f|f|t
34078809|NCT02358148|||COHORT||PROSPECTIVE|||||||
34078810|NCT02576392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34078811|NCT00727376|||COHORT||PROSPECTIVE|||||||
34078812|NCT04723459|RANDOMIZED|PARALLEL||PREVENTION||NONE||Sequential Assignment||||
34078813|NCT01848574|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34078814|NCT02447419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679113|NCT05457621|NA|SINGLE_GROUP||TREATMENT||NONE||Participants attend 7 visits (screening visit, inclusion visit, 4 intermediate visits, final visit) and make a visit by phone call at Day48 hours. They apply the investigational product once daily (evening) for 2 months on the whole face and the accompanying product twice daily for 3 months on the whole face.||||
33679114|NCT04796181|||OTHER||PROSPECTIVE|||||||
33679115|NCT06036693|||COHORT||OTHER|||||||
33982259|NCT05865691|||CASE_CONTROL||PROSPECTIVE|||||||
33679116|NCT01596062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679117|NCT04370340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679119|NCT02036151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33679120|NCT00146484|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679121|NCT00458770|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33679122|NCT04303728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982260|NCT00054106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982261|NCT04663360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking is not possible due to cluster randomisation.|Participating GP practices will be randomised into an intervention and control arms.||||
33679123|NCT00109603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679124|NCT02553252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679125|NCT00187603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679126|NCT03371888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded study|An intervention performed in experimental group and control group|t|t|f|f
33679128|NCT04229732|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33679129|NCT00514852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679130|NCT06095648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679132|NCT05811234|||COHORT||PROSPECTIVE|||||||
33982262|NCT00764985|||COHORT||PROSPECTIVE|||||||
33982263|NCT00945165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982264|NCT01293422|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982265|NCT02911597|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33982266|NCT02965326|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33679133|NCT01714791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679134|NCT04812847|||COHORT||PROSPECTIVE|||||||
33679136|NCT04693052|||OTHER||OTHER|||||||
33679140|NCT01541397|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679143|NCT02968056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769877|NCT03029260|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33769878|NCT02708589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33769879|NCT02685371|||CASE_ONLY||PROSPECTIVE|||||||
33982267|NCT01769183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982268|NCT06280690|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a single center prospective, non-randomized phase 2 proof of concept study, on the performance of SGM-101 to discriminate T1RC/HGD from LGD in patients that will be scheduled for endoscopic local en-bloc resection in the Leiden University Medical Centre (LUMC).||||
33982269|NCT02063893|||CASE_CONTROL||PROSPECTIVE|||||||
33982270|NCT02996656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982271|NCT01535859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982272|NCT00944203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982273|NCT04562662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982274|NCT00660426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982275|NCT02066207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982276|NCT03499171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982277|NCT03282838|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33679147|NCT03069729|||CASE_CONTROL||PROSPECTIVE|||||||
33982278|NCT01536626|||COHORT||PROSPECTIVE|||||||
33982279|NCT00905125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33982280|NCT05522062|||COHORT||PROSPECTIVE|||||||
33982281|NCT05966571|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839386|NCT04513067|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation study composed of 2 stages. Single agent in Stage 1 (as defined as arm 1) and combination therapy in Stage 2 (as defined in arm 2)||||
33982282|NCT05710341|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Given the nature of the interventions, participants, and the investigators responsible for delivering the interventions will be unblinded throughout the trial. However, all researchers performing the laboratory analyses and data analyses will be blinded to the interventions that the participants received until after the data analysis has been performed.|prospective, mono-centre, randomised, controlled, crossover study|f|f|f|t
33982283|NCT01465295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982284|NCT05455073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982285|NCT02136095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982286|NCT00388544|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|f|t
33982287|NCT05738525|||COHORT||PROSPECTIVE|||||||
33982288|NCT01709032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982289|NCT02329678|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33982290|NCT04922112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982291|NCT04259528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982292|NCT01159132|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34024637|NCT00592618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024638|NCT03903211|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024639|NCT03624686|||OTHER||PROSPECTIVE|||||||
33839387|NCT01125033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839388|NCT06118580|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Placebo drink (without alcohol)||t|f|f|t
33839389|NCT05022433|||COHORT||PROSPECTIVE|||||||
33839390|NCT01976247|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33839391|NCT04396249|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33839392|NCT02895932|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839393|NCT01682551|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33839394|NCT05408247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind design||t|t|t|t
33839395|NCT00798291|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33839396|NCT04340661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839397|NCT03941600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839398|NCT03838731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839399|NCT02345109|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33839400|NCT04339712|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Treatment with tocilizumab or anakinra||||
33839401|NCT00341861|||CASE_CONTROL||RETROSPECTIVE|||||||
33839402|NCT01830647|||COHORT||PROSPECTIVE|||||||
33839403|NCT01436253|||COHORT||PROSPECTIVE|||||||
33839404|NCT01400360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839405|NCT05712551|||OTHER||OTHER|||||||
33839406|NCT00340249|||COHORT||RETROSPECTIVE|||||||
33839407|NCT06507280|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33839408|NCT02180373|||COHORT||PROSPECTIVE|||||||
33839409|NCT06018662|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"Control group (138 patients): The medications selection and dosage will be performed according to the department policy without using the application.~Intervention group (138 patients): The physicians use the application for appropriate medications selection and dosage calculation."|t|t|f|f
33839410|NCT05857254|||COHORT||PROSPECTIVE|||||||
33839411|NCT04686149|||COHORT||PROSPECTIVE|||||||
33839412|NCT00868153|||COHORT||PROSPECTIVE|||||||
33839413|NCT00561145|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33839414|NCT00396695|||DEFINED_POPULATION||OTHER|||||||
33839415|NCT00195962|||CASE_ONLY||PROSPECTIVE|||||||
33839416|NCT00910377|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33839417|NCT02489968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839418|NCT05880108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to treatment allocation/group assignment|Weight Loss Program (Diet and Exercise)|f|f|f|t
33839419|NCT01622062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839420|NCT02668276|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33839421|NCT03570723|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants were blinded to the procedure performed.|The study was single-blind randomized controlled trial carried out in a tertiary University Hospital between June 2018to June 2021. Investigators included patients scheduled for CS due to complete placenta previa. They were randomly allocated to the group (I) managed by stepwise uterine devascularization, group (II) managed by A glove-loaded Foley's catheter tamponade. The primary outcome was the amount of intraoperative estimated blood loss.|t|f|f|f
33839422|NCT05163795|||COHORT||RETROSPECTIVE|||||||
33769880|NCT03250351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|As masking techniques, the people responsible for randomization of intervention in each group, the evaluation of subjects and data collection, the analysis of data will be independent. Participants are also masked, since we think they are unable to distinguish between NDG and CG interventions.|Two groups: Experimental group \& Control group|t|f|t|t
33769881|NCT01540396|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33769882|NCT06310603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33769883|NCT05072522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769884|NCT05177003|||COHORT||CROSS_SECTIONAL|||||||
33769885|NCT00472186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769886|NCT00071240|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769887|NCT05735457|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33769888|NCT03622385|||COHORT||OTHER|||||||
33769889|NCT06376643|RANDOMIZED|PARALLEL||OTHER||SINGLE|It will not be possible to blind study participants to study arm allocation due to the nature of the intervention(s), but they will be blinded to study objectives. The statistician will be blinded regarding the allocation of participants to the study arms for results analysis.|Open-label, prospective, multicenter, cluster randomized controlled clinical trial|f|f|f|t
33769890|NCT02310893|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33769891|NCT04515199|||COHORT||PROSPECTIVE|||||||
33769892|NCT01247441|||COHORT||RETROSPECTIVE|||||||
33769893|NCT03219424|||COHORT||PROSPECTIVE|||||||
33769894|NCT02655471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769895|NCT00385853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769896|NCT01269814|||CASE_ONLY||PROSPECTIVE|||||||
33769897|NCT04859530|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33769898|NCT04684641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769899|NCT02910986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33769900|NCT02406313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769901|NCT01322438|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769902|NCT00002214||||TREATMENT||||||||
33769903|NCT06384378|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33769904|NCT02190916|||COHORT||CROSS_SECTIONAL|||||||
33769905|NCT05344989|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33769906|NCT03418935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33769907|NCT04967625|NA|SINGLE_GROUP||TREATMENT||NONE||Anti-PD-1 antibody sintilimab combined With anti-angeogensis inhibitor anlotinib for extensive stage disease small cell lung cancer after failure of first line standard therapy||||
33769908|NCT01486758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769909|NCT03192540|NA|SINGLE_GROUP||OTHER||NONE||||||
33769910|NCT02307747|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33769911|NCT00505167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33769912|NCT04777929|||CASE_ONLY||PROSPECTIVE|||||||
33769913|NCT00718367|||COHORT||RETROSPECTIVE|||||||
33769914|NCT00649389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769915|NCT00836654|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769916|NCT02162992|||CASE_CONTROL||PROSPECTIVE|||||||
33769917|NCT05389527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769918|NCT02999711|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33769919|NCT03940235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769920|NCT04186650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024640|NCT00999323|||COHORT||PROSPECTIVE|||||||
34024641|NCT06632392|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34024642|NCT00700297|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33769921|NCT05085535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A triple blinding will be carried out: 1) of the patient, 2) of the collaborator who performs the data collection, 3) of the computer data analyst.~The physiotherapist who performs the intervention of manual therapy, exercise teaching and pain education, it is impossible to blind him."|It is a study of the randomized clinical trial|t|f|t|t
34024643|NCT06633328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982293|NCT05682118|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The sample size was calculated using effect size (Cohen's d) for the effectiveness of the dynamic coronary roadmap system for the guidance of the iFR and FFR. The effect size was assumed to be 0.4, which is a small to medium effect size. The sample size of 113 participants for each group was estimated to provide 90% power with a 2-sided type I error of 0.05.~This is a single-center randomized study and will be conducted in 226 patients with 50-90% coronary artery stenosis on angiography. Afterward, randomly assigned, 113 patients will be tested using the roadmap system, and 113 patients will be tested without using the roadmap system. Methods for measuring FFR and iFR and all PCI will use standardized testing and procedure methods."||||
33982294|NCT01180569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769922|NCT00584805|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33982295|NCT05081258|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, longitudinal, randomized, clinical trial||||
33769923|NCT00566943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982296|NCT00403039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982297|NCT00076947|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33769924|NCT04950556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly divided into two groups (control and exercise) for treatment.|f|f|f|t
33769925|NCT06056986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769926|NCT03664219|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Atrophied posterior mandible||||
33769927|NCT00653263|||CASE_ONLY||PROSPECTIVE|||||||
33769928|NCT03966612|||COHORT||PROSPECTIVE|||||||
33982298|NCT01582672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982299|NCT06212453|NA|SINGLE_GROUP||TREATMENT||NONE||Targeted Microwave Ablation||||
33982300|NCT05165056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982301|NCT05968209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33982302|NCT00006495||||TREATMENT||DOUBLE||||||
33982303|NCT05826262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982304|NCT04887142|||CASE_CONTROL||PROSPECTIVE|||||||
33982305|NCT03127904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome evaluators and data scientists will be blinded regarding randomization. Blinding will be ensured by asking investigators at the end of the trial if investigators knew the arm to which each subject was going to be allocated prior to opening the envelope.||f|f|t|f
33679150|NCT03478293|NA|SINGLE_GROUP||TREATMENT||NONE|Single (Outcomes Assessor)|||||
33679151|NCT04064125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679153|NCT00554281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679154|NCT05728099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the whole study protocol, patients did not receive information about testing the SpiroGym app. They will receive information that we are testing two types of expiratory muscle strength training programs. Outcomes assessors are blinded to treatment group.|Participants are randomly assigned to either the experimental or the active control group. A simple computer-generated random allocation sequence was completed before study initiation.|t|f|f|t
33679156|NCT01323855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679157|NCT04734197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679158|NCT04578652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and research team will be blinded to the type of intervention allocated to each arm until the end of the study. Concealment will be protected by secure, password protected website. The group not on MET (fiber alone) will receive a placebo pill. The group not on fiber will also receive a placebo, composed of the same base solution without added fibers.||t|f|t|f
33679160|NCT03977740|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33679161|NCT00717236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679163|NCT04605991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679164|NCT04643145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679167|NCT06238102|||CASE_CONTROL||RETROSPECTIVE|||||||
33679168|NCT01764139|||COHORT||PROSPECTIVE|||||||
33679170|NCT00910299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679171|NCT05576545|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33679172|NCT04120311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982306|NCT02347501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982307|NCT01374750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982308|NCT02138669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982309|NCT01523626|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982310|NCT04499170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental research project to detect an immediate effect of a technique on postural balance measures.||||
33982311|NCT03613259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982312|NCT03816371|RANDOMIZED|PARALLEL||OTHER||SINGLE|Group allocation was concealed using individual sealed opaque envelopes that were numbered in sequential order. As individuals were enrolled in the study, the next envelope in the sequence was extracted and the participant was assigned to the groups accordingly. All the researchers except for the clinical nurse who positioned the patients according to randomization list and patients were blinded from group assignment.|This study was conducted as a prospective, single-center, parallel, three arm (1:1:1), randomized controlled trial at the Endocrine Surgery Clinic of a university hospital in Turkey.|t|f|f|f
33982313|NCT05286957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982314|NCT02218580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982315|NCT00048958|||OTHER||PROSPECTIVE|||||||
33982316|NCT02911805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33982317|NCT03749369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024644|NCT02187692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024645|NCT04035915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024646|NCT04522817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024647|NCT00386633|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024648|NCT03769714|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024649|NCT04463797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024650|NCT03047330|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024651|NCT00013091||||TREATMENT||SINGLE||||||
34024652|NCT04132700|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024653|NCT00767624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024654|NCT01507766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024655|NCT00324727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34024656|NCT03680612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34024657|NCT00076076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34024658|NCT03812549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024659|NCT04610879|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||The trial is a phase IV randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention. We have used a factorial trial design as this approach enables the efficient simultaneous investigation of anti-epileptic drug (AED) (carbamazepine; levetiracetam; no AED) and sleep behaviour intervention (vs standard care) by including all participants in both analyses. In a factorial trial it is also possible to consider both the separate effects of each intervention and the benefits of receiving both interventions together (for example levetiracetam and sleep intervention).||||
34024660|NCT00400595|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024661|NCT06243965|||COHORT||RETROSPECTIVE|||||||
33769929|NCT02938936|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33769930|NCT02540395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769931|NCT05315830|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33769932|NCT00909103|||CASE_CONTROL||PROSPECTIVE|||||||
33769933|NCT00710112|||COHORT||PROSPECTIVE|||||||
33839423|NCT04627922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind masking||t|f|t|f
34024662|NCT06232330|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be randomized clinical trial used to evaluate the effect of task-oriented training on balance in spastic hemiplegic cerebral palsied children. Subjects with hemiplegic Cerebral Palsy meeting the inclusion and exclusion criteria will be divided into two groups using non-probability sampling techniques.||||
34024663|NCT03813615|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This protocol is a single-center, open-label, phase 0 / 1 a/b study of preoperative aerobic training in patients with untreated solid tumors. This study design allows for the enrollment of patients with various types of cancer. This study will target patients with prespecified solid malignancies.||||
33839424|NCT00081822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839425|NCT00846807|||COHORT||PROSPECTIVE|||||||
33839426|NCT04356534|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, interventional and randomized open label trial involving 40 patients with COVID-19 who are in respiratory distress, with the criteria that all require oxygen therapy and have radiological evidence of pneumonia, 20 of whom will receive a transfusion of convalescent patient plasma plus routine care, compared to 20 COVID-19 patients who will receive routine care alone.||||
33839427|NCT01249846||||TREATMENT||||||||
33839428|NCT05440253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839429|NCT03842540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||SpeakOut: Empowering Teen to Teen Social Communication About Highly Effective Contraception (Also Known As: The Share Health Study: Teen Social Connections and Health) (Phase 2)|f|f|f|t
33839430|NCT00002539|RANDOMIZED|||TREATMENT||||||||
33839431|NCT00959686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839432|NCT04033302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839433|NCT01229605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839434|NCT05573633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839435|NCT01973153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839436|NCT00897793|||COHORT||PROSPECTIVE|||||||
34024664|NCT01381666|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34024665|NCT04869215|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34024666|NCT04666805|||OTHER||RETROSPECTIVE|||||||
34024667|NCT03032016|||COHORT||PROSPECTIVE|||||||
34024668|NCT06582056|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024669|NCT05444257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024670|NCT03795038|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective, multicentric, open, interventional, cross-over with randomization||||
34024671|NCT03734939|||OTHER||CROSS_SECTIONAL|||||||
33899070|NCT06672887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not be blinded, as it was hard to devise a placebo intervention, and the standard care (no access to the MiLES intervention) was obviously different from the intervention (access to the MiLES intervention).|A non-blinded RCT. The investigators will include employer-employee with cancer dyads, and will compare an intervention group, in which the employer will get access to the MiLES intervention, with a control group, in which both the employee and employer will receive care as usual.|f|f|f|t
33899071|NCT00001761||||TREATMENT||||||||
33679176|NCT05006742|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective randomized trial to assess diagnostic accuracy and safety of cryobiopsy using two different transbronchial biopsy techniques. Included patients are 1:1 randomized to receive either cryobiopsy (CB study arm) or forceps biopsy and cryobiopsy within the same session (FB-CB study arm). Both, forceps biopsy and cryobiopsy are performed according to official recommendations. The biopsies will be scored for ACR according to the ISHLT criteria (A0 - A4) by 3 pathologists. A subgroup analysis in the FB-CB study arm will compare FB and CB of the same patient in order to prevent second bronchoscopy due to inconclusive histological result of FB and lung function decline being suspicious for ACR.||||
33899072|NCT04640597|||COHORT||PROSPECTIVE|||||||
33899073|NCT04145947|||COHORT||PROSPECTIVE|||||||
33899074|NCT05182333|||CASE_CONTROL||RETROSPECTIVE|||||||
33899075|NCT03076567|||OTHER||OTHER|||||||
33899076|NCT01318902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899077|NCT06216886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"After the initial round of botox, all participants will be randomized to either onabotA or saline. The randomization will performed by a provider who is not a care provider or proceduralist.~The patient will be blinded, the proceduralist will be blinded and the care provider will be blinded. Data will be stored and not reviewed by research team until the study closes."|This will be a randomized controlled trial of onabotulinumtoxinA versus Saline intradermal injections into the affected trigeminal distributions. The RCT will be enriched with all participants being initial responders to a preliminary round of onatbotulinumtoxinA.|t|t|t|f
33899078|NCT00105729|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899079|NCT02514057|||COHORT||PROSPECTIVE|||||||
33899080|NCT04048239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899081|NCT02759822|||COHORT||PROSPECTIVE|||||||
33899082|NCT00783510|||COHORT||PROSPECTIVE|||||||
33899083|NCT06402773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899084|NCT01839994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899085|NCT00261638|||DEFINED_POPULATION||OTHER|||||||
33982318|NCT04992052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of the principal investigator and operating staff is not possible. However, all attempts will be made to keep this information from the hospital staff caring for the patients in the postoperative period. The patient and the postoperative hospital staff will be blinded to the treatment arm. The OR staff will be trained not to discuss this information with the patient. During the transition of care from the OR to the Post Anesthetic Care Unit (PACU) the treatment arm will not be included in the verbal patient report. The lack of this information is not required to effectively manage the patient in the postoperative period and will not affect patient care. Postoperatively medical care is managed by the hospitalist, medical doctors specializing in the care of hospitalized patients.|"Arm 1 Bone wax applied to the exposed cancellous surfaces of the bone (treatment group).~Arm 2 No bone wax. This group will serve as the control arm."|t|t|f|f
33982319|NCT00999037|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33982320|NCT05179681|||COHORT||RETROSPECTIVE|||||||
33982321|NCT04971668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33982322|NCT02460159|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982323|NCT01355081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982324|NCT03002779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078815|NCT03744897|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Subjects are blinded to wether group they will be allocated Assessor will be blinded and the investigator not involved in subjects assessment will perform the hypnosis.|"1. Hypnotic analgesia + a-tDCS~2. Hypnotic analgesia + s-tDCS~3. Hypnotic analgesia~4. a-tDCS"|t|f|f|t
34078816|NCT01493245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078817|NCT06392035|RANDOMIZED|PARALLEL||OTHER||DOUBLE||In the research, an experiment and a control group will be selected.|t|f|f|t
34078818|NCT01800045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078819|NCT05970250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982325|NCT05570903|||COHORT||PROSPECTIVE|||||||
34024672|NCT02055664|RANDOMIZED|PARALLEL||||DOUBLE||||||
34024673|NCT02074618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024674|NCT06634147|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Multicenter Randomized Clinical Trial||||
33899086|NCT04024228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind: the participant and the Investigators remained unaware of the treatment assignments throughout the study. An unblinded qualified trial staff member administered the appropriate vaccine but were not involved in the immunogenicity and safety evaluations.|Participants randomized in each group were stratified by age (60 to 64 years of age; 65 years of age and older).|t|t|t|t
33899087|NCT04301453|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33899088|NCT00787735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899089|NCT01385943|||CASE_ONLY||CROSS_SECTIONAL|||||||
33899090|NCT01954628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899091|NCT01488981|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33899092|NCT00162877|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899093|NCT06510465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899094|NCT06148519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899095|NCT03027037|||COHORT||PROSPECTIVE|||||||
33899096|NCT05721261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899097|NCT01668069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899098|NCT03598777|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33899099|NCT05948878|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33899100|NCT01917825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899101|NCT02017249|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33899102|NCT00131443|RANDOMIZED|PARALLEL||||DOUBLE||||||
33899103|NCT02609893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899104|NCT00071773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899105|NCT04507750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899106|NCT04634123|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Split mouth design|t|f|f|t
33899107|NCT04930250|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The test products are coded by group coding (A - E).|Randomised controlled, double-blind, full crossover study conducted in an acute setting. 20 subjects will receive 5 test products, over 5 separate test visits in a crossover design.|t|t|t|t
33899108|NCT02282332|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899109|NCT06442241|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33899110|NCT02433249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33899111|NCT00390923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899112|NCT05719064|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33899113|NCT03391492|||CASE_CONTROL||PROSPECTIVE|||||||
33899114|NCT04984135|||CASE_ONLY||PROSPECTIVE|||||||
33899115|NCT04243369|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33899116|NCT03953638|||COHORT||PROSPECTIVE|||||||
33899117|NCT02599467|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33899118|NCT03863392|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33899119|NCT06126445|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Examiner blinded to toothbrush used.|single use, examiner blinded, randomized, two-period, cross-over|f|f|t|f
33899120|NCT00957645|||COHORT||PROSPECTIVE|||||||
33899121|NCT05176028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Hotpack, interferential current and exercise program were applied to the control group (n=15), the fascia technique was applied to the treatment group (n=15) in addition to the control group program for 2 weeks with 2 sessions per week.|f|f|f|t
33899122|NCT02640612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899123|NCT05837260|||COHORT||PROSPECTIVE|||||||
33899124|NCT02477865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899125|NCT04370249|||CASE_ONLY||RETROSPECTIVE|||||||
33899126|NCT01924715|||CASE_CONTROL||RETROSPECTIVE|||||||
33899127|NCT06483893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899128|NCT03320512|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The trial will consist of a three-arm RCT to test intervention efficacy among young men who have sex with men (YMSM) and young transgender women who have sex with men (YTWSM) who are starting PrEP or are non-adherent to PrEP. Study arms will include P3, P3+, and standard of care (SOC). Participants will be recruited from seven cities. The investigators will enroll up to 240 participants and randomize them 1:1:1 to receive P3, P3+, or SOC. Assessments will be completed at months 0, 3, and 6.||||
33899129|NCT06379295|||COHORT||CROSS_SECTIONAL|||||||
33982326|NCT03619746|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|All participants in the study (i.e., patients and physicians) will be aware of what arm of the study they are in.|"Pre-Post Study Design with Non-Pharmacologic Intervention~Patient in first arm of study will be treated by physicians who have not yet received educational training. Patients in the second arm of the study will be treated by physicians who went through the educational training."||||
33982327|NCT04910230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33982328|NCT00324168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982329|NCT06403761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982330|NCT01491880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078820|NCT03160391|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Although the type of intervention provided was explicit (dance or music), participants, intervention providers, and outcomes assessors were not aware of the study hypotheses or predicted effects for each intervention. Hence they did not know whether they were in a treatment or control group.||t|t|f|t
33899130|NCT05033210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistical analysis will be masked, this means that the statistician will not know the treatment groups until the end of the analysis. In addition, this person will not be involved in the choice of the participants, the administration of the intervention, in study assessments or in data entry.|After screening and baseline assessments, participants will be randomised to either the treatment group (n=105) or the comparison group (n=105), with an equal probability of assignment to each group (allocation ratio 1:1). The trial is a single-blind RCT (i.e. outcome assessors are blind to treatment allocation). Randomisation will be carried out through computerised software (Castor EDC) using limited block size (e.g. 6-12 participants per block) and will be performed by an independent person who is not involved in the assessment.|f|f|f|t
34078821|NCT02799147|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078822|NCT02731300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078823|NCT04295577|||COHORT||OTHER|||||||
33769934|NCT06420674|NA|SINGLE_GROUP||PREVENTION||NONE|Masking is not applicable in this study as it includes only one condition.|This study will be offered to all women undergoing artificial inseminations in two public hospitals.||||
33769935|NCT03648151|||COHORT||RETROSPECTIVE|||||||
33769936|NCT01987596|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33899131|NCT06384339|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899132|NCT06664567|||OTHER||PROSPECTIVE|||||||
33899133|NCT04036266|||CASE_ONLY||RETROSPECTIVE|||||||
33899134|NCT03881163|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||All the subjects enrolled in the study will receive the same treatment with the investigational medicinal product (IMP), i.e. NAC, 300 mg/ 3 mL solution injection as single dose and multiple dose regime. Single dose of IMP will be administered under fasting conditions on day 1 at 08:00 ±1 h. Multiple doses (5) of IMP will be administered twice a day (b.i.d.) on days 4 and 5 at 08:00 ±1 h and 20:00 ±1 h and one dose will be administered on day 6 at 08:00 ±1.||||
33899135|NCT01623687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899136|NCT01663350|||COHORT||PROSPECTIVE|||||||
33899137|NCT03046238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33899138|NCT02018250|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33899139|NCT06668506|||CASE_ONLY||PROSPECTIVE|||||||
33899140|NCT03320733|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33899141|NCT05089305|NA|SINGLE_GROUP||TREATMENT||NONE||Open-ended, uncontrolled clinical trial in 35 patients||||
33899142|NCT04634643|||COHORT||PROSPECTIVE|||||||
33899143|NCT02128490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899144|NCT05144178|||COHORT||RETROSPECTIVE|||||||
33899145|NCT02167555|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33899146|NCT02133937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899147|NCT02498223|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899148|NCT05358886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899149|NCT05590299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899150|NCT05313230|||OTHER||PROSPECTIVE|||||||
33899151|NCT04705298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899152|NCT01674426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899153|NCT00552305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899154|NCT03094247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899155|NCT01716169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899156|NCT06512987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33899157|NCT05386433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982331|NCT05613894|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A standard 3+3 dose escalation design will be used to identify the MTD and/or recommended dose and schedule for the subsequent expansion phase. The study will test 2 dose levels of cabozantinib with the option to dose reduce to dose level -1.||||
33982332|NCT06129227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a single-blinded RCT. The assessor will be blinded during assessments. The participants and investigators (trainers) are not possible to be blinded as it is an exercise intervention.|After stratification according to gender and walking speed, the participants will be randomly allocated to one of three groups: (1) dual-task training, (2) single-task training, and (3) control intervention, using a 1:1:1 allocation ratio.|f|f|f|t
33982333|NCT02073604|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33982334|NCT06030505|||CASE_CONTROL||PROSPECTIVE|||||||
33982335|NCT03025880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078824|NCT02931760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078825|NCT03984084|||OTHER||OTHER|||||||
34078826|NCT04534998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078827|NCT04010409|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078828|NCT05835141|||COHORT||CROSS_SECTIONAL|||||||
34078829|NCT00000860|||NATURAL_HISTORY|||||||||
34078830|NCT03215069|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078831|NCT00619788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078832|NCT03212040|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Comparison of 14 vs 16 gauge needles||||
33899158|NCT00686205|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33899159|NCT03332953|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33899160|NCT03011242|||CASE_CONTROL||PROSPECTIVE|||||||
33899161|NCT03540121|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33899162|NCT00005860||||TREATMENT||||||||
33899163|NCT04814823|||CASE_ONLY||PROSPECTIVE|||||||
33899164|NCT01507194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33899165|NCT01119040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899166|NCT04606615|||COHORT||CROSS_SECTIONAL|||||||
33899167|NCT03805880|||COHORT||PROSPECTIVE|||||||
33899168|NCT01565746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899169|NCT05134974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899170|NCT04358250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679178|NCT04653467|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE||Part 1: a randomized, double-blind, single ascending dose (SAD), Part 2: a randomized, double-blind, multiple ascending dose (MAD) escalation and Part 3 and 4: an open-label, randomized, crossover rBA and food-effect (FE) part.|t|t|t|t
33982336|NCT04862702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The assistant supervisor is the one who will generate the random sequence, assign the participants to the intervention or control groups and the only one who knows whether A or B represents the intervention or the control.~The operators will enroll the participants after they find the eligible ones and confirm with the assistant supervisor."||t|f|f|t
33982337|NCT00389064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982338|NCT01165671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982339|NCT02433106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33982340|NCT00214422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982341|NCT03977649|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study treatments will be all identical in packaging, labeling, schedule of administration, appearance, taste and odor|"After a run-in phase of 4 weeks, patients will be randomized, according to a 1:1 ratio, to a 24 weeks of treatment, as follow:~* Sequence 1: A/B~* Sequence 2: B/A where: A=monthly subcutaneous erenumab 140 mg for 12 weeks; B=monthly subcutaneous masked placebo for 12 weeks."|t|t|t|t
33982342|NCT03010098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982343|NCT03386019|NA|SINGLE_GROUP||TREATMENT||NONE||There will be a total of 4 different time points where outcome measures will be assessed including: baseline, immediately after pre-conditioning, immediately after treatment and 10 minutes after treatment. Once the participant completed the assessment of one treatment, another assessment session from one of the two remaining treatments will be scheduled in the following week, and the data collections for all three treatments will be finished in three consecutive weeks. This could ensure that all participants receive similar training schedules with similar training intensity within a fixed time period.||||
34078833|NCT03428334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078834|NCT01151306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078835|NCT04022330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34078836|NCT03612466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078837|NCT03117634|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, 2-arm, Non-inferiority, interventional study||||
34078838|NCT04065243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Body weight and other anthropometric data are not masked.||f|f|f|t
34078839|NCT04070014|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33679180|NCT05884749|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The P2C model is an outreach peer support model aimed at facilitating CI for individuals living with concurrent disorders following homelessness. This approach uses relationship-building and engagement in meaningful activity facilitated by peer support specialists (PSS) in concert with occupational therapy (OT) and social work (SW) consultation. This model includes four distinct components: 1) peer support delivered in a community space dedicated to the program or community locations at a maximum ratio of 10:1; 2) OT and SW offering consultation to PSSs and service users; 3) a weekly support meeting for PSSs, OT and SW aimed at providing a venue for problem-solving through complex cases and providing mutual emotional support in the context of service delivery with a complex population; and 4) opportunities for social enterprise (developing ideas for income generation) within the community space.||||
33679182|NCT05923216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679183|NCT02462642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33679185|NCT01473680|||COHORT||PROSPECTIVE|||||||
33679186|NCT02537795|||OTHER||PROSPECTIVE|||||||
33679188|NCT03140059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33679190|NCT05307913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679191|NCT04914260|||COHORT||PROSPECTIVE|||||||
33769937|NCT03375125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization list will by assembled by independient organization not related with participant, care provider, investigators or sponsors. eCRF will include randomization selection|Randomized controlled trial, double blind allocation concealment, parallel assignment|t|t|t|t
33679196|NCT01293071|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33679199|NCT03598114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33769938|NCT00474929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769939|NCT00255658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982344|NCT00385593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078840|NCT01635660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078841|NCT00941850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078842|NCT04685993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078843|NCT04583605|||CASE_CONTROL||RETROSPECTIVE|||||||
34078844|NCT05897242|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Any outcome evaluator who has direct contact with participants will be blinded to treatment assignment.||f|f|f|t
34078845|NCT05800756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078846|NCT00168571|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078847|NCT03303495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078848|NCT04089254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-Randomized Design||||
34078849|NCT03906812|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The study statistician will be blinded to study arm assignment.|Comparative effectiveness - on admission, eligible, low-risk patients will be individually assigned to either unmonitored floor admission or floor admission with telemetry.|f|f|f|t
34078850|NCT03177148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||After two years of intervention arm study, the usual care arm will receive MI training.||||
33679200|NCT00661518|||CASE_CONTROL||PROSPECTIVE|||||||
34078851|NCT05184959|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34078852|NCT04941534|||COHORT||PROSPECTIVE|||||||
34078853|NCT04767464|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078854|NCT04828031|NA|SINGLE_GROUP||TREATMENT||NONE||Open label prospective clinical trial with vitamin D 50,000 IU PO every week for 12 weeks in patients with inflammatory bowel disease (IBD) with 25(OH)D ≤ 25 ng/mL||||
34078855|NCT02277028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078856|NCT03535961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078857|NCT00879801|||COHORT||PROSPECTIVE|||||||
34078858|NCT02500316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078859|NCT02374320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078860|NCT05695742|||COHORT||PROSPECTIVE|||||||
34078861|NCT04238377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34078862|NCT04419857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078863|NCT00452439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679202|NCT01801345|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33679203|NCT04408378|||CASE_CONTROL||RETROSPECTIVE|||||||
34078864|NCT04846270|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34078865|NCT00289276|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34078866|NCT02418234|||CASE_ONLY||PROSPECTIVE|||||||
34078867|NCT05071534|||OTHER||PROSPECTIVE|||||||
33679205|NCT04279106|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33679206|NCT05167240|||OTHER||RETROSPECTIVE|||||||
33679207|NCT03618355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy. With a single site screening patients into the cohorts at a rate of 3 patients every 6 weeks (4 weeks dosing and 2 weeks safety assessment), a new cohort will start approximately every 6 weeks. Therefore, if each cohort of 3 patients are pre-screened and there are no dose limiting toxicities (DLT), the 4th and final dose cohort will be enrolled at approximately 18 weeks. Each patient will be on study for 6 months; therefore, 10-11 months will be the shortest time for trial completion. Given unforeseen delays, we anticipate the trial to take approximately one year to complete.||||
33679212|NCT04167878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 5 couple， 10 patients will be assigned into investigational (n=5) and control groups (n=5).||||
33679215|NCT05621525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679216|NCT04526821|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33679218|NCT02675556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899171|NCT03450850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078868|NCT00140062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078869|NCT06532981|||OTHER||PROSPECTIVE|||||||
34078870|NCT02371681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34078871|NCT05504096|NA|SINGLE_GROUP||OTHER||NONE||||||
34078872|NCT00575354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679220|NCT01875679|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34078873|NCT02525016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078874|NCT01919164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078875|NCT00563121|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078876|NCT04751760|||CASE_ONLY||PROSPECTIVE|||||||
34078877|NCT02821494|NA|SINGLE_GROUP||OTHER||NONE||||||
34078878|NCT03533218|||OTHER||CROSS_SECTIONAL|||||||
34078879|NCT02204670|||COHORT||PROSPECTIVE|||||||
34078880|NCT04582292|||OTHER||CROSS_SECTIONAL|||||||
34078881|NCT05271565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients and the legal guardians will be blinded|Monocentric randomized pilot controlled trial with 2 groups: interventional (oligomeric formula) and control (polymeric)|t|f|f|f
34078882|NCT02457195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899172|NCT01429649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899173|NCT00956644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899174|NCT05895851|||CASE_CONTROL||RETROSPECTIVE|||||||
33899175|NCT02900677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33899176|NCT02449564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899177|NCT03396549|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Only the assistant delivering tDCS will not be blind to conditions.|Cross-over blind. All get sham and real tDCS.|t|f|f|t
33899178|NCT00154505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899179|NCT02128581|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33899180|NCT00640783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899181|NCT06637540|NA|SINGLE_GROUP||OTHER||NONE||||||
33899182|NCT03854955|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899183|NCT04233346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899184|NCT02257606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899185|NCT03375710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899186|NCT05295329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33899187|NCT02645318|||CASE_ONLY||PROSPECTIVE|||||||
33899188|NCT00065910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899189|NCT00641940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899190|NCT04569539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899191|NCT03890224|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Rescue2-monitor is an open-label, prospective randomized, controlled, superiority clinical trial, performed in patients with hypercapnic chronic obstructive pulmonary disease post-acute hypercapnic exacerbation. Four arms (distributed between groups at a ratio of 1:1:1:1) will be compared: no home NIV 'hospital NIV' (control group) versus any of 3 modalities of home NIV (experimental groups). The 3 experimental treatments are Nocturnal home NIV 'non-targeted home NIV', Nocturnal home NIV with high monitoring 'targeted home NIV', and 'rescue home NIV'.||||
33899192|NCT02851654|||CASE_ONLY||PROSPECTIVE|||||||
33899193|NCT00165568|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33899194|NCT06091423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899195|NCT00676039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899196|NCT01478750|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33899197|NCT02113748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899198|NCT03557372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899199|NCT01435525|||COHORT||PROSPECTIVE|||||||
33679223|NCT06530979|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33679225|NCT06219798|||COHORT||RETROSPECTIVE|||||||
33679226|NCT00936728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899200|NCT04273243|||CASE_ONLY||PROSPECTIVE|||||||
33899201|NCT01105338|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33899202|NCT06062173|||OTHER||OTHER|||||||
33899203|NCT00600002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899204|NCT02463591|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33899205|NCT00456937|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33769940|NCT03411824|||COHORT||PROSPECTIVE|||||||
33769941|NCT01232465|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33769942|NCT05222425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679230|NCT05504967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, controlled, double-blind clinical trial|t|t|t|t
33679232|NCT05984069|||COHORT||PROSPECTIVE|||||||
33679233|NCT00692536|RANDOMIZED|PARALLEL||||NONE||||||
33679234|NCT04734678|||COHORT||OTHER|||||||
33679235|NCT00600119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679236|NCT01139008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33679237|NCT02255435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679238|NCT04498481|||COHORT||RETROSPECTIVE|||||||
33679240|NCT02862756|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33679244|NCT01926340|||CASE_CONTROL||PROSPECTIVE|||||||
33679247|NCT04579887|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33769943|NCT05389020|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33769944|NCT03034213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769945|NCT05089058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769946|NCT04555590|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an implementation study of the H-HOPE Intervention. The team uses a Stepped-Wedge Design for Implementation.||||
33769947|NCT02055573|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33769948|NCT03039543|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33679248|NCT06266793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679249|NCT00004040||||TREATMENT||||||||
33679250|NCT04915950|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33679251|NCT02576184|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Biologic mesh Synthetic mesh|t|f|f|t
33679253|NCT02735824|||CASE_ONLY||PROSPECTIVE|||||||
33679256|NCT04500847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacist will not be masked. All investigators will be masked until the end of the study.||t|t|t|t
33679257|NCT04475705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single blind controlled trial|t|f|f|f
33679259|NCT01437306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33679262|NCT05451485|||COHORT||PROSPECTIVE|||||||
33769949|NCT02071550|||CASE_CONTROL||PROSPECTIVE|||||||
33769950|NCT03650660|||CASE_ONLY||PROSPECTIVE|||||||
33769951|NCT00040092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769952|NCT05787938|||CASE_ONLY||CROSS_SECTIONAL|||||||
33769953|NCT05900219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769954|NCT00976482|||COHORT||PROSPECTIVE|||||||
33899206|NCT00796783|||CASE_ONLY||PROSPECTIVE|||||||
33899207|NCT06443112|||COHORT||RETROSPECTIVE|||||||
33899208|NCT04853797|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33899209|NCT04208373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899210|NCT05906446|NA|SINGLE_GROUP||OTHER||NONE||||||
33899211|NCT02583152|||COHORT||PROSPECTIVE|||||||
33899212|NCT02859415|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33899213|NCT03867253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899214|NCT01652833|||OTHER||CROSS_SECTIONAL|||||||
33899215|NCT06205134|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"To evaluate the comparative bioavailability and pharmacodynamic response between:~A. Epinephrine injection, USP auto-injector 0.3 mg for intramuscular (IM) injection B. FMXIN002 epinephrine microspheres powder for nasal application, 3.6 mg and C. FMXIN002 epinephrine microspheres powder for nasal application, 4 mg and after a single-dose administration to healthy adults~Secondary Objective:~To evaluate the safety and tolerability of the study treatments"||||
33899216|NCT02247830|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33899217|NCT03992235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The patients will randomize into 2 group|t|f|f|f
33899218|NCT00345371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899219|NCT02514070|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33899220|NCT04865081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899221|NCT01970150|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33899222|NCT03865069|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study will be completed over 2 consecutive 12-hour periods in randomly assigned sequence of automatic oxygen control with Volume Guarantee ventilation (VG) ® and automatic FiO2 control without VG®.Once consent has been obtained, the team will complete the trial registration/randomisation form and access the web based randomisation service at http://www.sealedenvelope.com to obtain unique trial number and assignment of intervention. Before logging onto the website to randomise the following information must be available: Infant's gestation age, Oxygen requirement (Yes/No), Ventilated(Yes/No).||||
33899223|NCT03534271|||COHORT||PROSPECTIVE|||||||
33899224|NCT03989063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are randomly assigned to one of the two parallel groups receiving either external or internal attentional focus instructions for the same balance task. Participants will be blinded to this group assignment until final debriefing.|Participants are randomly assigned to one of the two conditions receiving either external or internal attentional focus instructions for the same balance task. After a washout period of at least 1 month, the participant will repeat the experiment with instruction not previously received (i.e. if the participant received the internal focus instruction during the first phase, he/she will receive the external focus instruction in the second phase).|t|f|f|f
33982345|NCT04751669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo tablets with the same external aspect than the dietary supplement, the same administration route, containing only the excipients|A double-blind, placebo-controlled, randomized clinical trial|t|t|t|t
33982346|NCT04320173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982347|NCT04875793|RANDOMIZED|PARALLEL||SCREENING||NONE||List of health centres that randomly allocated to receive the intervention||||
33982348|NCT03227198|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982349|NCT03470220|||COHORT||PROSPECTIVE|||||||
33982350|NCT00715065|||CASE_CONTROL||PROSPECTIVE|||||||
33982351|NCT03589534|NA|SINGLE_GROUP||OTHER||NONE||||||
33982352|NCT00252811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982353|NCT05463653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is a physical therapist independent of the research team, who is blind to the treatment assignment|Two arms parallel design, randomized assignment, outcomes-assessor blind to the assignment|f|f|f|t
33982354|NCT06140264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982355|NCT01405222|||COHORT||PROSPECTIVE|||||||
33982356|NCT02256293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982357|NCT02533362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982358|NCT02629757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982359|NCT02195245|NON_RANDOMIZED|PARALLEL||||NONE||||||
33982360|NCT01539915|NA|SINGLE_GROUP||||||||||
33982361|NCT01410630|||CASE_ONLY||RETROSPECTIVE|||||||
33679264|NCT04086498|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Raw data are encoded with 3 letters assigned to each treatment (A, B and C). Investigators and outcomes assessor do not have access to the waiting (letter-treatment)|It is single blind, parallel arms study|f|f|t|t
33769955|NCT03375632|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33769956|NCT03648203|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is using a single arm, single site, pre-post assessment interventional design, with no control group. Because this is a pilot study, all subjects will receive the intervention.||||
33769957|NCT06184490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769958|NCT00924560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769959|NCT05244343|||OTHER||CROSS_SECTIONAL|||||||
33769960|NCT00195169|||COHORT||PROSPECTIVE|||||||
33769961|NCT06110741|||COHORT||PROSPECTIVE|||||||
33769962|NCT01010477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679269|NCT05592860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33769963|NCT00282360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33769964|NCT05762536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769965|NCT02780986|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33769966|NCT00450320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769967|NCT01317875|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769968|NCT03191357|||COHORT||PROSPECTIVE|||||||
33769969|NCT04772885|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|randomized double blind (for Parts A and B only)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption|t|t|t|t
33769970|NCT00723333|||COHORT||RETROSPECTIVE|||||||
33769971|NCT00042796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769972|NCT05731882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769973|NCT05099016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33769974|NCT00018005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33769975|NCT03766893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769976|NCT02901093|||OTHER||PROSPECTIVE|||||||
33769977|NCT04186676|||CASE_ONLY||PROSPECTIVE|||||||
33769978|NCT04017429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33769979|NCT03376802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33769980|NCT02609659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769981|NCT05438030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33769982|NCT04114136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33769983|NCT03124628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33769984|NCT00192140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769985|NCT03634137|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants were assigned to receive either a 16 mg bioresorbable afamelanotide implant from the previous manufacturing process or a 16 mg bioresorbable afamelanotide implant from the optimized final manufacturing process.||||
33769986|NCT06123572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomly assigned in as 1:1 ratio to receive either test product A or B.|This is a Randomized, Interventional, Prospective, Double Blind, Two Arm, Comparative, Parallel, Placebo-Controlled, Safety and Efficacy Study|t|f|t|f
33769987|NCT00157274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33769988|NCT01647308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33769989|NCT04526405|||COHORT||PROSPECTIVE|||||||
33769990|NCT03826589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33769991|NCT04752891|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33769992|NCT02125123|RANDOMIZED|PARALLEL||||NONE||||||
33769993|NCT02228473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33769994|NCT04136652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the doctor who performs the laser procedure knows which treatment the participant gets. The data analyzer will also know, in data analyses after all treatments are done.||t|t|f|f
33769995|NCT04906109|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33769996|NCT06421753|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||SCED : Single Case Experimental Design Each patient is his own control Patient will be randomised to receive FES-cycling with SDSS or standard electrical stimulation|t|f|f|f
33769997|NCT05271838|RANDOMIZED|PARALLEL||TREATMENT||NONE||"At baseline patients are randomized to either a dietary protein intake of 2 g/kg/day (achieved by nutritional counseling and protein supplementations) or standard care (No nutritional counseling or protein recommendation are given) under admission and three weeks after discharge.~Furthermore patients with a magnesium retention level \>25% are further randomized to receive either magnesium acetate oral mixture (0,5 mmol/ml) 20 ml x 3 daily (30 mmol/day) or not receiving magnesium supplement for three weeks."||||
33769998|NCT01160120|NA|SINGLE_GROUP||OTHER||NONE||||||
33769999|NCT02327273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33770000|NCT04188236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770001|NCT04743375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770002|NCT01432535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982362|NCT03626649|NA|SINGLE_GROUP||TREATMENT||NONE||The DIAMOND FASTR-AF study is a prospective, single-arm trial being performed at multiple centers in Europe.||||
33982363|NCT00481520|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33770003|NCT06076473|||OTHER||RETROSPECTIVE|||||||
33770004|NCT03799679|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single arm, two-stage Simon Design study for women with Triple Negative Breast Cancer. Patients will treated by Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in Combination with Cyclophosphamide.||||
33770005|NCT03802162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982364|NCT01268865|||COHORT||PROSPECTIVE|||||||
33679274|NCT02258776|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33982365|NCT02392364|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982366|NCT03476980|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Neurodevelopmental providers will be blinded to the randomization of the toddler during the examination.|Neurodevelopmental assessments will be done at 2 years of corrected age (22-26 months) for subjects who were randomized at birth to receive either delayed cord clamping or umbilical cord milking as part of the PREMOD2 trial. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.|t|t|t|t
33982367|NCT00941837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33982368|NCT03546777|||CASE_CROSSOVER||PROSPECTIVE|||||||
33982369|NCT01384461|||COHORT||PROSPECTIVE|||||||
33982370|NCT01743508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33982371|NCT02084004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982372|NCT04271722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982373|NCT04015843|||COHORT||PROSPECTIVE|||||||
33982374|NCT00769041|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33982375|NCT01887145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982376|NCT03991494|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982377|NCT05719090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33982378|NCT02970110|||CASE_ONLY||PROSPECTIVE|||||||
33982379|NCT00442390|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982380|NCT01924078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982381|NCT05723445|NA|SEQUENTIAL||TREATMENT||NONE||Single dietary treatment with a meal-delivery phase and free-living conditions phase, as well as a run-in period as a control||||
33982382|NCT06440447|||COHORT||RETROSPECTIVE|||||||
33982383|NCT02032888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982384|NCT00239421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982385|NCT01286662|||COHORT||RETROSPECTIVE|||||||
33982386|NCT05701670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34078883|NCT03248869|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||"A/B testing is a randomized statistical experiment with intervention and control study arms, A and B. New users, as of December 2015, will be stratified and randomized to different daily survey formats in order to test differences in daily survey participation rates. Since this was a mobile app based study, a first of its kind - which was available in the App store, it was possible to recruit widely in large numbers. Therefore, even though this was a feasibility study, the sample size was large."||||
33679277|NCT06390072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This basic experimental pilot study involved a randomized cross-over design of two brief interventions with a 1:1 allocation ratio||||
33679278|NCT06006767|||OTHER||OTHER|||||||
33679279|NCT00694278|||CASE_ONLY||CROSS_SECTIONAL|||||||
33899225|NCT06326151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The work of sequencing, randomisation, recruitment and allocation of the trial sample will be carried out by research staff who are not involved in the assessments or interventions of each group, thus avoiding any potential bias in the trial.~Participants will also be blinded and will not know which group they have been allocated to and therefore which intervention they will receive. In order to minimise any contamination between groups, the assessment process will be carried out by external research staff who will perform the measurements and who have been previously trained and educated to avoid subjective bias in the process, as they will be unaware of the intervention group to which they have been assigned, thus masking the blinded assessment by third parties in the clinical trial. In addition, the researchers responsible for the statistical analysis of the trial will be blinded in order to increase the rigour of the trial process and thus the scientific quality."||f|f|f|t
33679280|NCT03041831|||OTHER||CROSS_SECTIONAL|||||||
33679282|NCT03802058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679283|NCT01392118|||CASE_CONTROL||RETROSPECTIVE|||||||
33899226|NCT02369510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33899227|NCT02642861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679284|NCT01009372|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679286|NCT05867641|NA|SINGLE_GROUP||TREATMENT||NONE||Pragmatic interventional trial including a three-week home-based intervention and one-week follow-up.||||
33679287|NCT03692819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In addition to concealment of randomization, the investigator responsible for the procedures of periodontal therapy (periodontal debridement) and the researcher responsible for the measurements will not know which treatment each group will receive, characterizing the blindness of the study.|Parallel Assignment Prospective double-blind randomized controlled clinical study with a 90-days follow-up.|f|t|t|t
33679288|NCT02067975|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33899228|NCT06315881|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33679290|NCT02583217|||CASE_CONTROL||PROSPECTIVE|||||||
33679291|NCT03264118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth design. One side of mouth is test and the other is control side.|t|f|f|t
33679292|NCT03035877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770006|NCT02314741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899229|NCT06097585|||CASE_CONTROL||RETROSPECTIVE|||||||
33770007|NCT01272882|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770008|NCT04654546|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Scan of abdominal organs of participants as detailed in the study protocol||||
33770009|NCT01606956|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
33770010|NCT03358329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770011|NCT06275659|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33770012|NCT02181972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770013|NCT00722995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770014|NCT02838628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899230|NCT00994565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899231|NCT03403244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899232|NCT02672956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899233|NCT02552407|||OTHER||RETROSPECTIVE|||||||
33899234|NCT01099033|||CASE_CONTROL||PROSPECTIVE|||||||
33899235|NCT00479362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33899236|NCT03954171|NA|SINGLE_GROUP||OTHER||NONE||||||
33899237|NCT04427592|NA|SINGLE_GROUP||TREATMENT||NONE||Investigators conducting prospective study for management of placenta accreta spectrum including diagnosis and uterine sparing surgery.||||
33770015|NCT02941393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770016|NCT02857660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770017|NCT04708301|||COHORT||PROSPECTIVE|||||||
33899238|NCT00449059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899239|NCT00121732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899240|NCT02718846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770018|NCT00115362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770019|NCT00735449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33679293|NCT01934647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679294|NCT03876236|||COHORT||PROSPECTIVE|||||||
33679295|NCT01590381|||COHORT||PROSPECTIVE|||||||
33679296|NCT00288899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33679297|NCT02403466|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34078884|NCT05385198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679298|NCT03927482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will be blind to the participant's randomization assignment||f|f|f|t
33679299|NCT03149744|||COHORT||PROSPECTIVE|||||||
33679300|NCT02674204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679301|NCT00043342|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33679302|NCT05174182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants: Participants are blinded to the actual contents of the two interventions before being allocated, and will remain blinded to the contents of the parallel intervention. They are also blinded to the superiority framework.~Care provider: Therapists delivering an intervention will likewise be blinded to the contents of the parallel intervention, and to the superiority framework.~Outcomes assessors: Staff collecting objective outcome data are blinded to group allocation of participants."|The trial is a single-center pragmatic, double-blinded randomized controlled superiority trial, with a two-group parallel arm design and 1:1 group allocation ratio.|t|t|f|t
33679303|NCT03406741|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679304|NCT02297347|||CASE_ONLY||PROSPECTIVE|||||||
33679305|NCT01409070|||COHORT||RETROSPECTIVE|||||||
33770020|NCT03562260|NA|SINGLE_GROUP||TREATMENT||NONE||only 1 group in children who received the bipolar release||||
33770021|NCT05859802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Subjects were blinded and randomized into 2 groups; Group 1 received physical therapy for 12 weeks while taking Dalfampradine 10 mg two times day and Group 2 received physical therapy while taking a placebo pill two times a day.~Both investigators that were preforming the testing and treatment were blinded as to subject group assignment."||t|t|t|t
33770022|NCT04845295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33770023|NCT00886262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770024|NCT05334823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770025|NCT02240719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770026|NCT04797819|||COHORT||PROSPECTIVE|||||||
33770027|NCT04788030|||CASE_ONLY||RETROSPECTIVE|||||||
33770028|NCT01313611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770029|NCT06226142|RANDOMIZED|PARALLEL||OTHER||NONE||Enrolled patients will be randomized in a 1:1:1 ratio to ultrasound or bronchoscopy or ultrasound-bronchoscopy percutaneous dilatational tracheostomy.||||
33770030|NCT04783064|||OTHER||PROSPECTIVE|||||||
33770031|NCT02359591|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33770032|NCT04041479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Human subjects in the proposed protocol will be randomized to receive a) biotype-guided rTMS to the left DLPFC or to the DMPFC; b) rTMS targeted to the opposite site; and c) standard-of-care left DLPFC rTMS. The dosage and method of delivery of rTMS are as follows: intermittent theta burst stimulation (iTBS) will be delivered at 120% of the resting motor threshold. It will be administered in triplet 50 Hz bursts, repeated at 5 Hz with a duty cycle of 2 s on and 8 s off, for a total of 600 pulses per session and a total duration of 3 min 9 s. Participants will receive screening and diagnostic interviews, phenotypic assessment (including demographic information, cognitive assessments, and behavioral functioning), structured clinical interviews, and magnetic resonance imaging (including structural and functional MRI).|t|t|t|t
33770033|NCT02807740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770034|NCT01428674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770035|NCT04755439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|non|Single center prospektif clinical research||||
33770036|NCT05957757|NA|SINGLE_GROUP||TREATMENT||NONE||To study the safety and efficacy of RC48 combined with Tislelizumab in HER2 expression high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.||||
33770037|NCT02571439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770038|NCT06155175|||COHORT||RETROSPECTIVE|||||||
33770039|NCT06529549|||COHORT||PROSPECTIVE|||||||
33770040|NCT00798356|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33770041|NCT02286271|||COHORT||PROSPECTIVE|||||||
33770042|NCT04142060|NA|SINGLE_GROUP||TREATMENT||NONE||an exploratory, open-label, non-randomized, two-cohort, multicenter, prospective, phase II study which evaluates the effect of enzalutamide on proliferation||||
33770043|NCT05789862|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33770044|NCT04041752|NA|SINGLE_GROUP||PREVENTION||NONE|No masking|All participants complete the same conditions||||
33770045|NCT02218385|||||PROSPECTIVE|||||||
33899241|NCT04101422|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33899242|NCT02648815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899243|NCT01154946|||CASE_CONTROL||RETROSPECTIVE|||||||
33899244|NCT05914220|||COHORT||PROSPECTIVE|||||||
33899245|NCT01200511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899246|NCT03048097|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|images will be interpreted without identification|A comparison will be made between initial images, and images taken 2 weeks later of the same group of individuals.||||
33899247|NCT04628871|||CASE_ONLY||PROSPECTIVE|||||||
33899248|NCT05084547|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899249|NCT00889291|||COHORT||OTHER|||||||
33899250|NCT01464697|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33899251|NCT00667277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899252|NCT01737164|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899253|NCT05296057|NA|SINGLE_GROUP||TREATMENT||NONE||As this is a pilot study, a control will not be included. Findings from this pilot will inform methods for a subsequent larger clinical trial that will include a control group.||||
34078885|NCT04422938|||COHORT||RETROSPECTIVE|||||||
34078886|NCT05026944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34078887|NCT03964389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants receive TEN sessions, but do not know that one of the groups will receive extra information|two-armed randomized trial|t|f|f|t
34078888|NCT00969228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982387|NCT02290171|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982388|NCT01965522|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33982389|NCT06171139|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33982390|NCT01474122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982391|NCT04702971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078889|NCT00994942|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078890|NCT05242237|||COHORT||PROSPECTIVE|||||||
34078891|NCT01832337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34078892|NCT00780975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078893|NCT04485377|||COHORT||CROSS_SECTIONAL|||||||
34078894|NCT01328964|||COHORT||RETROSPECTIVE|||||||
34078895|NCT04833777|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The surgeon administering the local anesthetic will not be blinded, however the participant and the research nurse (measuring outcomes) will be.|The study model for the primary outcome will be single group (patients randomized to one of two anesthetic types). However, select patients who wish to have bilateral carpal tunnel release will be entered into a crossover model, such that they will be randomized for their first surgery and receive the other type of anesthetic for their second surgery.|t|f|f|t
34078896|NCT04105517|||COHORT||RETROSPECTIVE|||||||
34078897|NCT04502446|NA|SEQUENTIAL||TREATMENT||NONE||||||
34078898|NCT00002535||||TREATMENT||||||||
34078899|NCT05605405|||OTHER||CROSS_SECTIONAL|||||||
34078900|NCT00002192||||TREATMENT||||||||
34078901|NCT00712452|NON_RANDOMIZED|PARALLEL||||NONE||||||
34078902|NCT02570698|||COHORT||PROSPECTIVE|||||||
34078903|NCT03584607|||CASE_CONTROL||PROSPECTIVE|||||||
34078904|NCT05628753|||COHORT||PROSPECTIVE|||||||
34078905|NCT05190874|||CASE_ONLY||OTHER|||||||
34078906|NCT00352937|||COHORT||PROSPECTIVE|||||||
34078907|NCT03984396|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A pragmatic cluster randomized educational intervention with a delayed control.||||
34078908|NCT00781053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078909|NCT02779569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078910|NCT02757729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078911|NCT01077323|||COHORT||RETROSPECTIVE|||||||
34078912|NCT03121105|||COHORT||RETROSPECTIVE|||||||
34078913|NCT01259947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078914|NCT00487903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078915|NCT00377637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078916|NCT01953562|||COHORT||PROSPECTIVE|||||||
34078917|NCT02667340|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34078918|NCT00480571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34078919|NCT06293274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34078920|NCT02667925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078921|NCT03001947|||COHORT||PROSPECTIVE|||||||
34078922|NCT03280459|||COHORT||PROSPECTIVE|||||||
33679306|NCT00167778|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33982392|NCT02086188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982393|NCT03376165|||COHORT||PROSPECTIVE|||||||
33982394|NCT02495857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982395|NCT00245609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982396|NCT04714307|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33982397|NCT05841225|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34078923|NCT04448119|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078924|NCT03040271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078925|NCT03851770|NA|SINGLE_GROUP||OTHER||NONE||Patients participating will be asked to come to the Neurophysiology Department of Saint Luc Clinic to peform the laryngeal evoked motor potential.||||
34078926|NCT05735704|||COHORT||PROSPECTIVE|||||||
34078927|NCT05673447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078928|NCT00094991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34078929|NCT00847600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34078930|NCT04668417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34078931|NCT03512522|RANDOMIZED|PARALLEL||TREATMENT||NONE||A patient preference randomized controlled trial (RCT) will be used for this study. Participants will be randomly assigned to be enrolled in the online group or workbook group, or be placed on a twelve-week wait list control, which will serve as a control group to control for the influence of time on symptom change between groups.||||
34078932|NCT00275886|||CASE_CONTROL||OTHER|||||||
34078933|NCT05793021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078934|NCT03308422|||CASE_ONLY||CROSS_SECTIONAL|||||||
34078935|NCT04773223|||COHORT||PROSPECTIVE|||||||
34078936|NCT00827788|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34078937|NCT01334294|||COHORT||PROSPECTIVE|||||||
34078938|NCT02605200|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33982398|NCT05685979|||CASE_ONLY||PROSPECTIVE|||||||
33982399|NCT00322465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982400|NCT01538251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982401|NCT02562365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982402|NCT06328348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33982403|NCT04173754|||CASE_CONTROL||PROSPECTIVE|||||||
33982404|NCT01488630|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33982405|NCT00304083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982406|NCT05607238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982407|NCT04332627|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33770046|NCT01225822|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33770047|NCT03819777|||OTHER||PROSPECTIVE|||||||
33770048|NCT02611544|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE|Participants were blinded to study hypotheses.|||||
33770049|NCT03354637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770050|NCT05085743|||CASE_ONLY||RETROSPECTIVE|||||||
33770051|NCT02351882|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33770052|NCT00953420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770053|NCT02967263|||COHORT||PROSPECTIVE|||||||
33770054|NCT05002374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770055|NCT05568836|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33679307|NCT02942940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679308|NCT04503408|||OTHER||PROSPECTIVE|||||||
33679309|NCT03838094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33679310|NCT06455969|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33679311|NCT03183154|||OTHER||OTHER|||||||
33679312|NCT05900206|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel, two arms for cycles 1-3. Further treatment (cycles 4-6) decided by molecular intrinsic subtype.||||
33679313|NCT00000682|RANDOMIZED|||TREATMENT||||||||
33679314|NCT03118661|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679315|NCT01737593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33679316|NCT00132977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679317|NCT04960839|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33679318|NCT05827471|||COHORT||OTHER|||||||
33679319|NCT06069440|NA|SINGLE_GROUP||OTHER||NONE||||||
33679320|NCT05122702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679321|NCT01604733|||||CROSS_SECTIONAL|||||||
33679322|NCT03642340|||OTHER||PROSPECTIVE|||||||
33679323|NCT04811534|||CASE_ONLY||PROSPECTIVE|||||||
33770056|NCT01676025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770057|NCT01927731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770058|NCT02720289|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33770059|NCT01528644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33770060|NCT00003050||||TREATMENT||||||||
33770061|NCT01159223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770062|NCT00796536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770063|NCT06317350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770064|NCT02796287|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770065|NCT01535131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33679324|NCT00770575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679325|NCT00106509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679326|NCT04204876|||COHORT||PROSPECTIVE|||||||
33679327|NCT04944680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Because of the different therapies, it is not possible to mask the participant. It was possible to mask the group allocation for routine rehabilitation therapist. However, the difference is obvious between Transcranial Direct Current Stimulation and motor imagery. Outcome measure is conducted by a physician who is blinded to group assignment.|The four parallel groups are as follows: control group, Transcranial Direct Current Stimulation group, motor imagery group, Transcranial Direct Current Stimulation and motor imagery group. Patients are randomly assigned to each group with block randomization.|f|t|f|t
33679328|NCT05337020|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33770066|NCT00165295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770067|NCT00180713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770068|NCT02184663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33770069|NCT04005703|||COHORT||CROSS_SECTIONAL|||||||
33770070|NCT01939782|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33770071|NCT01213043|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33770072|NCT03321513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770073|NCT02596022|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33719873|NCT03324854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomisation for allocation the type of mesh for each patient was realized with numbers generated by computer with the program R version 3.0.2 with the simple function.~The participant and the outcomes assessor did not know the type of mesh."|The simple size for pilot study was been calculated in 20 patients, according with Browne for not knowing the variability of the treatment. 10 patients in the group of Polypropylene mesh (Prolene ®) and , and 10 patients in the group of mesh of PEBD (mosquito net).|t|f|f|t
33770074|NCT03125590|||OTHER||PROSPECTIVE|||||||
33770075|NCT01231685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770076|NCT06247332|||COHORT||RETROSPECTIVE|||||||
33770077|NCT03929926|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33770078|NCT01484236|||OTHER||CROSS_SECTIONAL|||||||
33770079|NCT02892487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33770080|NCT05950854|||COHORT||PROSPECTIVE|||||||
33770081|NCT04208360|||CASE_ONLY||PROSPECTIVE|||||||
33770082|NCT04585490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770083|NCT03259282|||CASE_ONLY||RETROSPECTIVE|||||||
33770084|NCT04249336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Statistician will be masked.||t|f|t|t
33770085|NCT00720408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839437|NCT05084053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899254|NCT04752813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899255|NCT03233477|||COHORT||PROSPECTIVE|||||||
33899256|NCT03411733|||COHORT||PROSPECTIVE|||||||
33899257|NCT03644992|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33899258|NCT04315363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33899259|NCT06250842|||COHORT||PROSPECTIVE|||||||
33899260|NCT04361110|||CASE_CONTROL||RETROSPECTIVE|||||||
33899261|NCT01611077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899262|NCT05203965|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33899263|NCT04176822|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||There are 3 independent working groups.||||
33899264|NCT06673030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899265|NCT04977544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899266|NCT05102981|||CASE_CONTROL||PROSPECTIVE|||||||
33899267|NCT04510727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899268|NCT03693027|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33899269|NCT05881850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistical expert who performs the randomization of the study and the statistical expert who evaluates the pre- and post-intervention data obtained in the study are different from each other.|The research will be conducted in a pre-test-post-test order, as a randomized controlled experimental.|f|f|f|t
33899270|NCT04905329|||COHORT||PROSPECTIVE|||||||
33899271|NCT02450669|||COHORT||PROSPECTIVE|||||||
33899272|NCT00125203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33899273|NCT01982110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899274|NCT04057963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
33899275|NCT02597595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33899276|NCT01887210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33899277|NCT01867346|||||PROSPECTIVE|||||||
33899278|NCT04820985|||COHORT||PROSPECTIVE|||||||
33982408|NCT00617305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982409|NCT03260465|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomised single-center study with 2 treatment arms.||||
33982410|NCT00046527|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982411|NCT01879137|||COHORT||PROSPECTIVE|||||||
33679329|NCT05952752|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients in each study category will be equally and randomly assigned to receive either DEXA or DEXM using computer generated random tables and sealed envelopes. Independent researchers who aren't aware of the scope of the study will be assigned to assess and report patient outcome. Used medications will be prepared in similar packages to secure adequate blinding.|"The estimated sample size for each group was 164 patients. We added 10 % of patients as expected dropout rate. So, the final sample size will be 191 patients per group. Sample size was calculated using G Power 3.1.6.9 (Kiel University, Germany).~The present study will include American Society of Anesthesiology (ASA) I-II women scheduled for elective CS under intrathecal anesthesia. All patients will be instructed, prepared and monitored according the standard guidelines.~Preoperative medications will include IV granisetron 1gm and ranitidine 50mg. Spinal anesthesia will be accomplished using 10-12 mg of 0.5% hyperbaric bupivacaine. When adequate level of anesthesia is guaranteed, CS is started under appropriate hemodynamic monitoring. Once the baby is delivered, 10 IV units of oxytocin will be administered. Patients in the studied groups will receive either or intravenous DEXM 10 µg (Sween et al., 2021) or IV infusion of DEXA 8 mg (Esmat et al., 2021)."|t|t|t|t
33679330|NCT05289401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679331|NCT04382989|||COHORT||PROSPECTIVE|||||||
33899279|NCT01660165|||COHORT||PROSPECTIVE|||||||
33899280|NCT04306042|||CASE_ONLY||PROSPECTIVE|||||||
33899281|NCT03961646|||COHORT||RETROSPECTIVE|||||||
33899282|NCT03836638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899283|NCT04348721|||OTHER||PROSPECTIVE|||||||
33899284|NCT00410371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899285|NCT05971329|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||ZetaFuse Bone Graft||||
33899286|NCT05659121|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899287|NCT05126615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33899288|NCT03398772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33899289|NCT04446585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study, treatment allocation is not masked to rescuers or patients. The steering committee will, during the study, receive information on total numbers of arrests and overall success of providing defibrillation. The steering committee will not receive information on whether defibrillation took place in areas allocated to intervention or no intervention. Only the safety committee will have access to all information.||f|f|f|t
33899290|NCT03342443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982412|NCT01376102|||||PROSPECTIVE|||||||
33982413|NCT02648620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982414|NCT00182806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982415|NCT05070611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982416|NCT02573584|||COHORT||PROSPECTIVE|||||||
34078939|NCT00170209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982417|NCT06213844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982418|NCT00176306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982419|NCT01833052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33982420|NCT01696097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982421|NCT02337309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982422|NCT04849520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective randomized controlled trial|t|f|f|f
33982423|NCT06125483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982424|NCT02788565|||COHORT||CROSS_SECTIONAL|||||||
33982425|NCT05440539|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized clinical trial||||
33982426|NCT02589964|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33982427|NCT00360360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982428|NCT04181190|||COHORT||RETROSPECTIVE|||||||
33982429|NCT01606605|||COHORT||RETROSPECTIVE|||||||
33982430|NCT05546983|||CASE_ONLY||RETROSPECTIVE|||||||
33982431|NCT01513070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982432|NCT02635243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
33982433|NCT02324803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982434|NCT05567874|||COHORT||RETROSPECTIVE|||||||
33982435|NCT03621800|RANDOMIZED|PARALLEL||OTHER||NONE||This is a study with an experimental research design. Randomized clinical trial, parallel, prospective and monocentric.||||
33982436|NCT06260488|NA|SINGLE_GROUP||OTHER||NONE||||||
33982437|NCT06346223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A single-blinded, parallel-group, randomized-controlled trial (RCT) design.|t|f|f|f
33982438|NCT01888263|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982439|NCT03515967|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982440|NCT02726230|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33982441|NCT01520623|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33982442|NCT02359305|||CASE_ONLY||RETROSPECTIVE|||||||
34078940|NCT02861508|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33679332|NCT01199367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679333|NCT03195400|||COHORT||PROSPECTIVE|||||||
33679334|NCT05178368|||CASE_CONTROL||PROSPECTIVE|||||||
33679335|NCT00798759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679336|NCT04268823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679337|NCT03316911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679338|NCT01785862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982443|NCT04815083|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|In Part B, the participant and pathologist will be blind to treatment arm allocation for the duration of the study. The surgeon will be blind to treatment arm allocation up until the time that standard of care resection is complete. The blind will be broken during the surgical procedure after the surgeon declares standard of care resection complete.|Part A of the study is open-label. All patients in Part A will receive the investigational drug and will undergo standard of care breast conserving surgery (BCS) followed by fluorescence-guided resection. Part B of the study is randomized and placebo controlled; patients will be randomized to receive placebo + standard of care BCS alone or PD G 506 A + SoC BCS followed by fluorescence-guided resection.|t|f|f|t
33982444|NCT02904837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982445|NCT00803803|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982446|NCT04901221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982447|NCT04331665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982448|NCT03884439|||CASE_ONLY||OTHER|||||||
34078941|NCT04039620|||COHORT||PROSPECTIVE|||||||
34078942|NCT05556148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679339|NCT04981613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679340|NCT01024309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679341|NCT02060916|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33839438|NCT03771105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|crossover parallel|||||
33839439|NCT02609672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33839440|NCT06092567|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blinded study in which the participant and the outcome assessor masked.|In this study, participants allocated in two groups by Consecutive non-random sampling technique|t|f|f|t
33839441|NCT00223301|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33839442|NCT01318798|||COHORT||RETROSPECTIVE|||||||
33839443|NCT00153985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839444|NCT01699113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33839445|NCT01244750|||COHORT||OTHER|||||||
33839446|NCT00447564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839447|NCT05422053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770086|NCT04361513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants does not know the nature of the injected material. Syringe was colored to cover it|Group received nerve block and another group received steroid|t|f|f|f
33770087|NCT00783471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770088|NCT03006198|||COHORT||PROSPECTIVE|||||||
33770089|NCT01806155|||COHORT||PROSPECTIVE|||||||
33770090|NCT00170937|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33770091|NCT04662918|||OTHER||PROSPECTIVE|||||||
33770092|NCT00275691|||||PROSPECTIVE|||||||
33770093|NCT05414838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770094|NCT02649387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770095|NCT00911105|||COHORT||PROSPECTIVE|||||||
33770096|NCT05843890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770097|NCT04029558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33770098|NCT04832386|||OTHER||CROSS_SECTIONAL|||||||
33770099|NCT01494714|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
33770100|NCT01097395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770101|NCT02917265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770102|NCT03511872|RANDOMIZED|PARALLEL||OTHER||SINGLE|Two blinded 10-year experienced professionals in emergency training (trainers in the Syrian resuscitation council) are asked to evaluate students' skills independently A third assessor who is also professional in emergency training is asked to resolve conflict judgments between live and camera assessment when existed.|A randomized controlled trial with blinded assessors on medical students from the pre-clinical years (1st to 3rd years in Syria) at Syrian Private University. Students are randomly assigned to peer-led or to professional-led training group for one-day-course of basic life support skills.|f|f|f|t
33770103|NCT01381835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770104|NCT00346996|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33770105|NCT00807690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770106|NCT00253279|||CASE_CONTROL||PROSPECTIVE|||||||
33770107|NCT03423875|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"To prevent outcome assessment bias, research staff will be masked as to the randomization status of participants until after they have completed and recorded gold-standard delirium assessments of delirium using the Confusion Assessment Method .~Similarly, ED physicians will be blinded to the gold standard assessments of delirium made by research assistants as well as the results of the PrEDICT test scores when they make their baseline clinical assessments of delirium. ED Physicians will also remain masked until they have recorded their discharge plan. The intervention focuses on the impact of revealing the result of the PrEDICT game scores on ED physicians' recognition of delirium, so randomization status must be revealed to them."||t|f|f|t
33770108|NCT00001495||||TREATMENT||||||||
33770109|NCT01049061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770110|NCT00004220||||TREATMENT||||||||
33770111|NCT00745641|||CASE_CONTROL||PROSPECTIVE|||||||
33770112|NCT02381002|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33770113|NCT03728114|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33770114|NCT02500212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770115|NCT00305864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770116|NCT05596357|||COHORT||PROSPECTIVE|||||||
33770117|NCT04666922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770118|NCT03480139|||COHORT||PROSPECTIVE|||||||
33770119|NCT00744237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770120|NCT04896944|||COHORT||RETROSPECTIVE|||||||
33770121|NCT05179044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899291|NCT03402763|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|All patients and researchers are aware if the patient receives a handout or watches the ACP video.|Participants will (1) be given either a short informational handout on the process and choices involved in advanced care planning or (2) be shown a less 6 minute video describing CPR, breathing tube placement and mechanical breathing support in addition to the general process of advanced care planning.||||
33899292|NCT05430659|||OTHER||RETROSPECTIVE|||||||
33899293|NCT00199186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899294|NCT00793104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899295|NCT02277886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899296|NCT01300286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899297|NCT03789188|||COHORT||OTHER|||||||
33899298|NCT04060992|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Observational study design, prospective cohort study||||
33899299|NCT02062931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899300|NCT04945993|||OTHER||PROSPECTIVE|||||||
33899301|NCT04127136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899302|NCT03742804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899303|NCT00827203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899304|NCT03497962|||COHORT||PROSPECTIVE|||||||
33899305|NCT01910662|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33899306|NCT06512324|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33899307|NCT01786018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899308|NCT02725385|||CASE_CONTROL||PROSPECTIVE|||||||
33899309|NCT05414968|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||16 participants will be recruited (8 pre-neuropathic, 8 neuropathic) to evaluate device feasibility through 10 sessions spread over 14 days.||||
33899310|NCT05197101|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899311|NCT01009112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899312|NCT00021866|||FAMILY_BASED||PROSPECTIVE|||||||
33899313|NCT02700581|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33982449|NCT03456570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33982450|NCT02865746|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33770122|NCT04367402|||CASE_CONTROL||RETROSPECTIVE|||||||
33770123|NCT04723160|||CASE_CONTROL||PROSPECTIVE|||||||
33770124|NCT03939039|||COHORT||PROSPECTIVE|||||||
33770125|NCT05522751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770126|NCT04443387|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||double blinded randomized study|f|f|t|f
33770127|NCT00730301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770128|NCT04560205|NA|SINGLE_GROUP||TREATMENT||NONE||quasi-experimental||||
33770129|NCT02983162|||COHORT||CROSS_SECTIONAL|||||||
33770130|NCT02487940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770131|NCT03691285|RANDOMIZED|PARALLEL||TREATMENT||NONE|To avoid selection bias and ensure adequate allocation concealment, their treatment group will only be revealed for each participant after the assessment of the baseline outcomes, which will occur after the delivery and regular use of the new set of conventional dentures. Since full blinding for the two interventions is not possible for those involved with treatment management and collection of data, only those collecting and analyzing clinical data from masticatory performance tests will be unaware of the assigned treatment.|Comparative effectiveness of two competing strategies for the edentulous mandible using implants||||
33982451|NCT02045927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982452|NCT04920877|NA|SINGLE_GROUP||PREVENTION||NONE||Patients followed with a central catheter in the intensive care unit||||
33982453|NCT01767298|RANDOMIZED|CROSSOVER||||NONE||||||
33982454|NCT03435705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33982455|NCT04577495|||COHORT||RETROSPECTIVE|||||||
33982456|NCT04294108|||COHORT||PROSPECTIVE|||||||
33982457|NCT05689463|NA|SINGLE_GROUP||OTHER||NONE||||||
33982458|NCT02187432|||COHORT||PROSPECTIVE|||||||
33770132|NCT03496818|||CASE_CONTROL||PROSPECTIVE|||||||
33770133|NCT04489615|||OTHER||PROSPECTIVE|||||||
33770134|NCT04894461|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770135|NCT02584855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770136|NCT04906369|||COHORT||PROSPECTIVE|||||||
33770137|NCT00678990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770138|NCT04393740|||COHORT||CROSS_SECTIONAL|||||||
33770139|NCT05016011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770140|NCT02406885|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770141|NCT06428838|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized (1:1), controlled trial with standard of care (SoC) as control arm.|t|f|f|f
33770142|NCT02452021|||CASE_ONLY||PROSPECTIVE|||||||
33770143|NCT05171140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770144|NCT02746757|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33770145|NCT02715895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33770146|NCT03535584|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770147|NCT05624723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770148|NCT05361603|||COHORT||PROSPECTIVE|||||||
33770149|NCT03901469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33770150|NCT00002499||||TREATMENT||||||||
33770151|NCT03225846|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33770152|NCT03262090|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The aim of the present preliminary study was to determine the safety and efficacy of of intraoperative infusion of dexmedetomidine (DEX) that would prevent postoperative EA and ED in children undergoing day surgery with desoflurane anesthesia. Subjects who underwent day surgery were stratified into two age groups as follows: low to 3 years, and 3-9 years. Then they were randomly assigned to receive one of six doses of intravenous dexmedetomidine: 0,0.2, 0.4, 0.6, 0.8 ,1.0ug/kg before skin incision.|f|t|t|t
33770153|NCT02123537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770154|NCT02520180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770155|NCT04479241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770156|NCT04808128|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770157|NCT06106035|NA|SINGLE_GROUP||TREATMENT||NONE||All individuals will be on a low-fat vegan diet for the duration of the study.||||
33770158|NCT02134119|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33770159|NCT01416896|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33770160|NCT06130163|||CASE_CONTROL||RETROSPECTIVE|||||||
33770161|NCT02544269|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33770162|NCT03881033|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33770163|NCT06180941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33770164|NCT03753711|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770165|NCT00128622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770166|NCT05950022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient does not know which technique he will benefit from, the surgeon will proceed with the surgery and will therefore be informed of the result of the randomization|Interventional, comparative, randomized study, in 2 parallel groups, single-blind|t|f|f|f
33770167|NCT00289237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770168|NCT00324012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770169|NCT04363385|NA|SINGLE_GROUP||PREVENTION||NONE||Collection of blood samples in a cohort of Covid-19 patients||||
33770170|NCT05774496|||COHORT||RETROSPECTIVE|||||||
33770171|NCT01042899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770172|NCT01886638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770173|NCT02821832|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770174|NCT00004399|RANDOMIZED|||PREVENTION||||||||
33770175|NCT02223065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33770176|NCT05691348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982459|NCT01616602|RANDOMIZED|PARALLEL||||SINGLE||||||
33982460|NCT03085056|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 12 patient pilot study that will evaluate the combination of the MEK inhibitor trametinib with paclitaxel in anaplastic thyroid cancer.||||
33982461|NCT03659656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982462|NCT01132963|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33982463|NCT01954264|NA|SINGLE_GROUP||OTHER||NONE||||||
33982464|NCT02541149|||CASE_CONTROL||PROSPECTIVE|||||||
33982465|NCT05060315|||COHORT||OTHER|||||||
33982466|NCT01959256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982467|NCT04661397|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33770177|NCT01717105|||COHORT||PROSPECTIVE|||||||
33770178|NCT05937009|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33770179|NCT04013958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Eligible patients will be randomized according to a blocked randomization scheme WWW.RANDOMIZATION.COM , which permits assignment of the participant to either group A or group B (the IM ketamine+IV morphine group or IV ketamine+IV morphine with IM saline (placebo) group.~Eligible patients will be divided in equal proportions (50 in group A and 50 in group B)."|t|t|f|t
33770180|NCT05667571|||COHORT||CROSS_SECTIONAL|||||||
33770181|NCT05399251|||CASE_ONLY||CROSS_SECTIONAL|||||||
33770182|NCT02795975|||COHORT||CROSS_SECTIONAL|||||||
33770183|NCT01578096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770184|NCT05039177|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770185|NCT05402800|||COHORT||CROSS_SECTIONAL|||||||
33770186|NCT05253690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The obstetrician evaluating labor progress is blinded for type of intervention|Randomized control trial|f|f|f|t
33770187|NCT00765427|NA|SINGLE_GROUP||||NONE||||||
33770188|NCT04123964|||CASE_ONLY||RETROSPECTIVE|||||||
33770189|NCT02176941|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33770190|NCT01355419|||COHORT||PROSPECTIVE|||||||
33770191|NCT06274580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770192|NCT00107744|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The randomization assignment list was generated by a computer program that could only be accessed by the study data coordinator. Apart from the data coordinator, all research personnel, including investigators, study coordinators, and BP technicians, and the study participants were unaware of treatment assignment.|The trial participants were assigned to take 40 g/d soy protein, milk protein, or carbohydrate supplementation each for 8 weeks in a random order. A 3-week washout period was implemented between the interventions.|t|f|t|t
33770193|NCT04674774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770194|NCT05755230|||COHORT||PROSPECTIVE|||||||
33770195|NCT04141072|||COHORT||PROSPECTIVE|||||||
33770196|NCT05295303|RANDOMIZED|PARALLEL||TREATMENT||NONE||To assess efficacy of home-based remote monitoring in post-myocardial infarction patient for improving guideline directed treatment utility, compared between subjects with home-based remote monitoring and management care (Interventional group) and conventional care (Control group).||||
33770197|NCT03251560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||half of the participants will receive Fuke Qianjin capsule, the other half participants will receive placebo|t|f|t|f
33770198|NCT05391022|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770199|NCT00518713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770200|NCT03687268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982468|NCT04545762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770201|NCT01422681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33770202|NCT00373932|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33770203|NCT00779558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770204|NCT04506996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were randomized after they completed the study's baseline assessment. The randomization sequence was designed to balance treatment groups by gender of the participants. Allocation was concealed from the data collectors, and was determined using a randomization module in REDCap, a survey website. The data collectors were not blinded to the randomization results after the completion of the baseline survey.|Parallel, superiority randomized controlled trial|f|f|t|f
33770205|NCT06250543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were randomized to receive 20 intradetrusor injections of either 300 U AbobotulinumtoxinA or 100 U IncobotulinumtoxinA. They were further randomized to receive either local anesthesia (40 ml of 1% lidocaine solution) or placebo before botulinum toxin injection.|t|f|f|f
33770206|NCT03049657|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33770207|NCT00049686||||TREATMENT||NONE||||||
33770208|NCT01219595|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33770209|NCT02709642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770210|NCT01388192|||CASE_ONLY||PROSPECTIVE|||||||
33770211|NCT03571984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770212|NCT05404867|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33770213|NCT03953729|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33770214|NCT02438150|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33770215|NCT01304082|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33770216|NCT01717443|||COHORT||PROSPECTIVE|||||||
33770217|NCT03178084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33770218|NCT00089713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770219|NCT01157741|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33770220|NCT05787795|||COHORT||PROSPECTIVE|||||||
33770221|NCT03741244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770222|NCT00962585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770223|NCT01163903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770224|NCT02801474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770225|NCT00417014||||TREATMENT||NONE||||||
33770226|NCT01782963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770227|NCT03909997|||COHORT||RETROSPECTIVE|||||||
33770228|NCT06380660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770229|NCT04611113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770230|NCT05170308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33770231|NCT05582213|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33770232|NCT03213496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data of outcomes will be evaluated by statisticians.|Adult patients programmed for elective non-cardiac surgery, prior informed consent, will be randomized to an intervention (prescription of a programed walking) in the period of 2-3 weeks before surgery or will be assigned to a control group/conventional care.|f|f|t|t
33770233|NCT02049060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770234|NCT05100836|||COHORT||PROSPECTIVE|||||||
33899314|NCT05569577|RANDOMIZED|PARALLEL||TREATMENT||NONE|In the current study, none of patients, investigators and designers is marked.|We have two cohorts in the current study and patients are randomly assigned to either cohort of additional hCG injection or not.||||
33899315|NCT06664034|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single arm pilot hybrid type I trial||||
33899316|NCT03556696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Monocentric prospective randomized controlled clinical trial~* arm 1: medical device automatically administering remifentanil, guided by expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)~* arm 2 : standard practice : remifentanil is administered using a target controlled device using a pK/pD model of Minto"|t|f|f|f
33982469|NCT01112280|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982470|NCT04511403|||OTHER||CROSS_SECTIONAL|||||||
33982471|NCT00465881|||||PROSPECTIVE|||||||
33982472|NCT01961141|||CASE_ONLY||RETROSPECTIVE|||||||
33982473|NCT04055337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982474|NCT00163605|NON_RANDOMIZED|PARALLEL||||NONE||||||
33982475|NCT00081952|RANDOMIZED|PARALLEL||TREATMENT||||||||
33982476|NCT02780570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982477|NCT04185909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982478|NCT06404307|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33982479|NCT05699278|||CASE_CROSSOVER||PROSPECTIVE|||||||
33982480|NCT04542603|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982481|NCT02721264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982482|NCT06320977|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33982483|NCT06495697|||CASE_ONLY||RETROSPECTIVE|||||||
33982484|NCT04343066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982485|NCT05416164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982486|NCT03318471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982487|NCT04190693|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Treatment or Placebo|Long-term follow-up (LTFU), no study treatment administered.|t|t|t|f
33982488|NCT01941966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982489|NCT04456426|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33982490|NCT01698476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982491|NCT02932696|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982492|NCT01246830|||CASE_CONTROL||PROSPECTIVE|||||||
33982493|NCT01469767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982494|NCT04626856|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33982495|NCT01762085|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982496|NCT06180512|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33770235|NCT01265095|||CASE_ONLY||PROSPECTIVE|||||||
33982497|NCT04484545|||COHORT||RETROSPECTIVE|||||||
33982498|NCT05797558|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded, prospective, multi-center,randomized, controlled trial.||||
33982499|NCT00547781|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982500|NCT05137925|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will randomize participants to an eight-week virtual group-based Mindfulness-based Cognitive Therapy intervention or to a treatment as usual control condition.||||
33982501|NCT03205254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized two-way crossover design||||
33982502|NCT02885077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770236|NCT05849532|NA|SINGLE_GROUP||TREATMENT||NONE||Single group design to compare the effects of functional electrical stimulation on gait, balance control, physical activity and fall risk in individuals with chronic stroke||||
33770237|NCT04221061|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770238|NCT02089815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770239|NCT04037995|||COHORT||PROSPECTIVE|||||||
33770240|NCT04912141|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, double-blind, placebo-controlled, multicenter, phase 2, dose-finding.|t|t|t|t
33770241|NCT04898842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839448|NCT01174069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839449|NCT02993523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839450|NCT04588129|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33839451|NCT02582294|||OTHER||RETROSPECTIVE|||||||
33839452|NCT03774615|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, uncontrolled, monocenter, phase IV study||||
33839453|NCT06242769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839454|NCT05675813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839455|NCT01606410|||COHORT||CROSS_SECTIONAL|||||||
33839456|NCT04471831|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The identification and selection of participants will be done by none of investigators. Allocation into group will also be done by none of the investigators. Outcome assessment will be done by none of the investigators. Participants will not be privy to another group|This clinical controlled study will involve a minimum of 30 stroke survivors who is positive for coronavirus (CoViD-19) admitted into different isolation centres in Nigeria|t|t|t|t
33839457|NCT04553055|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33679342|NCT05439213|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomised, double-blind, prospective, multicentre study in two parallel groups of 85 patients comparing two concentrations of adrenaline in arthroscopic irrigation fluid (0.33 mg/L vs 1 mg/L|t|f|t|t
33679343|NCT03870958|RANDOMIZED|PARALLEL||PREVENTION||NONE||This two-arm, parallel group, patient-randomized controlled, superiority trial will have treatment provided in schools. Schoolchildren (age 6-9), presenting at least one MIH molar (n molars = 195,) will have random allocation to treatment with or without the application of a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).||||
33679344|NCT00670943|||COHORT||PROSPECTIVE|||||||
33982503|NCT04672291|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|This study consists of 2 treatment groups. Study subjects will be assigned by chance to a treatment group. Group 1 receives the study drug; group 2 receives the placebo. Neither the study subject or the study team will know the group assignments. There will be a 4 out 5 chance of receiving the study drug and 1 out 5 chance of receiving the placebo.|Intranasal Poly-ICLC (Hiltonol®) or Placebo|t|t|t|t
33679345|NCT06212258|||CASE_CONTROL||PROSPECTIVE|||||||
33679346|NCT03897439|RANDOMIZED|PARALLEL||TREATMENT||NONE||"African American smokers randomized to OPT (n=196) will receive high intensity smoking cessation counseling, nicotine patch (NP), and up to two pharmacotherapy optimizations \[varenicline (VAR), bupropion (BUP) plus NP\] based on verified smoking status at Weeks 2 and 6.~African American smokers randomized to enhanced UC (n=196) will receive the same high intensity counseling and NP with no optimizations in pharmacotherapy."||||
33679347|NCT06529978|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770242|NCT05970835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors and data analysts will remain blinded to participant´s allocation group.|This will be a single-blinded, parallel two-arm group randomised, controlled, superiority trial with a 3 months of intervention period in real thermal treatment conditions, in Caldelas- Amares, Portugal. The target population will be recruited among the patients who use the thermal environment in Caldelas- Amares.|t|f|f|t
33770243|NCT04343443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770244|NCT03402373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double Blind, Randomized|Double Blind, Randomized, Placebo-Controlled|t|t|t|t
33770245|NCT04175418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33770246|NCT03593993|||CASE_ONLY||PROSPECTIVE|||||||
33679349|NCT05612932|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770247|NCT03109340|RANDOMIZED|PARALLEL||TREATMENT||NONE||Women with overweight and obesity were assigned to two groups: supervised treadmill walking (Group I) or walking with ECE PEDO (Group II).||||
33982504|NCT06294080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Data collection carried out by RAs blinded to participants' group allocation Statistician blinded to the group and test parameters|Random Controlled Trial: Blind|f|f|t|t
33770248|NCT04232189|||OTHER||OTHER|||||||
33770249|NCT03228017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770250|NCT00910637|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33770251|NCT04484766|||COHORT||PROSPECTIVE|||||||
33770252|NCT03331029|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single Center interventional study||||
33770253|NCT05230862|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33770254|NCT06421909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33982505|NCT04706104|||CASE_CONTROL||PROSPECTIVE|||||||
33982506|NCT01543880|||COHORT||RETROSPECTIVE|||||||
33982507|NCT04932252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982508|NCT03005522|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33679350|NCT05120557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients recruited will receive routine care for liver assessment followed by an exam using the device subject of the research.||||
33982509|NCT00262964|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33982510|NCT00894283|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33982511|NCT03109132|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||TRIPLE|This is a double-blind, order randomized study. All cannulas will be numbered. The investigators, the outcomes assessors and the subjects will be blind to the identity of the cannulas. The order of which the subjects will assess the cannulas will be randomized.|This is randomnized crossover study. Every subject will assess all cannulas in randomized order.|t|f|t|t
33982512|NCT00030446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982513|NCT04182152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982514|NCT03963206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679351|NCT06394167|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33679352|NCT05253001|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||An experiment was developed in the current study. A total of 40 women from a medical hospital in northern Taiwan were recruited as the participants. The study groups mobile chatbot approach to improving prenatal education. The controp group was a traditional approach to prenatal education.|t|f|f|f
33770255|NCT01175772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770256|NCT02572817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770257|NCT05498896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770258|NCT06475287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770259|NCT03122756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33770260|NCT02574676|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33770261|NCT00910520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770262|NCT01123460|||OTHER||RETROSPECTIVE|||||||
33770263|NCT01584830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770264|NCT02342925|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33770265|NCT04586777|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33770266|NCT04657523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982515|NCT05506462|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm||||
33982516|NCT04177368|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33982517|NCT02038608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34078943|NCT04454359|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Isocaloric placebos of same taste and texture as the experimental supplements|Randomized, placebo-controlled, double-blinded pilot trial|t|t|t|t
34078944|NCT03006536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078945|NCT00831116|||COHORT||PROSPECTIVE|||||||
33679353|NCT04274998|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33679354|NCT04085939|||COHORT||PROSPECTIVE|||||||
33679355|NCT00004913||||TREATMENT||||||||
33770267|NCT01383057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770268|NCT00003220||||TREATMENT||||||||
33770269|NCT00904150|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33770270|NCT01034579|NON_RANDOMIZED|PARALLEL||||NONE||||||
33770271|NCT02813967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770272|NCT00547911|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899317|NCT02734550|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||investigator-initiated prospective, multicenter, randomized, open, and parallel group study||||
34078946|NCT03320707|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34078947|NCT00631293|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33679356|NCT03540550|NA|SINGLE_GROUP||OTHER||NONE||||||
33679357|NCT04911192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679359|NCT01203644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770273|NCT03338205|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33770274|NCT04561011|NA|SINGLE_GROUP||TREATMENT||NONE||Participants in will receive a guided online cognitive behaviour therapy program||||
33770275|NCT01556815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770276|NCT02550873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770277|NCT01448421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770278|NCT01133860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770279|NCT03229616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770280|NCT06390930|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||randomized, blinded, placebo-controlled, cross-over with repeated measures|t|f|f|t
33770281|NCT02783820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770282|NCT04814563|||COHORT||RETROSPECTIVE|||||||
33770283|NCT00284765|RANDOMIZED|PARALLEL||||NONE||||||
33770284|NCT03387514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study is a single cohort study without randomization or stratification.||||
33770285|NCT04229680|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single-blinded|All participants will complete each arm.|t|f|f|f
33770286|NCT02684903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770287|NCT01941550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770288|NCT01254565|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33770289|NCT04503538|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33899318|NCT01139866|||OTHER||PROSPECTIVE|||||||
33899319|NCT02598713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899320|NCT06394999|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899321|NCT00446212|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33899322|NCT04431869|||COHORT||PROSPECTIVE|||||||
33899323|NCT04727216|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will be blinded to which stimulation program they are receiving during each 2 week cycle. The Investigator who is also the care provider will be blinded to both the stimulation they are receiving and the sequential order they are given in. The outcomes assessor will be blinded to the sequential order of the stimulation programs each participant receives.|Subjects will undergo 3 sequential 2-week dosing stimulation programs \[1.) continuous, 2.) 1 minute on: 1 minute off, and 3.) 1 minute on: 2 minutes\] in randomized order and double blinded fashion for a total of 6 consecutive weeks.|t|t|t|t
33899324|NCT05149755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899325|NCT02001350|||COHORT||CROSS_SECTIONAL|||||||
33899326|NCT03341403|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Only Phacobel which provide the pills will have the knowledge of the pills codes.|randomized double blind placebo control study|t|t|t|t
33899327|NCT01619228|||COHORT||PROSPECTIVE|||||||
34078948|NCT04060953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078949|NCT02907567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770290|NCT04703803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A member of the research team who doesn´t know whether the participant is in the intervention or control group will be responsible for the reassessment (after 72 hours and 1 week) to measure the outcomes|Randomized, comparative, single-blinded interventional study|f|f|f|t
33770291|NCT05345288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know if there are in the intervention or control group until the completion of the study. The PI will know since she will have to assign the online activities.|The intervention group will complete the prescribed computerized cognitive training while the control group will complete the control games that are not cognitive training and offered through the BrainHQ website as well.|t|f|f|f
33770292|NCT01865123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33770293|NCT00873301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770294|NCT01609530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using sealed envelope assignment, the participant will be placed in study Arm 1 or 2. The investigator will not be masked because the investigator will administer the standard of care cryotherapy or the experimental laser treatment. The outcome assessor will be masked to study group assignment for gathering data from trial participants.|Randomized Clinical Trail of standard cryotherapy compared with laser treatment|t|f|f|t
33770295|NCT05320016|||CASE_ONLY||PROSPECTIVE|||||||
33770296|NCT02669303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770297|NCT05666414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770298|NCT04987190|||COHORT||RETROSPECTIVE|||||||
33770299|NCT00871351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770300|NCT00249093|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
33770301|NCT04434924|||COHORT||CROSS_SECTIONAL|||||||
33770302|NCT03868241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770303|NCT00159978|||COHORT||PROSPECTIVE|||||||
33770304|NCT06251258|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33770305|NCT00932646|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33770306|NCT01257256|||CASE_ONLY||CROSS_SECTIONAL|||||||
33770307|NCT05694975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, multi-center, randomized, single-blind, placebo-controlled clinical trial|t|f|f|f
33770308|NCT04174235|||COHORT||PROSPECTIVE|||||||
33679360|NCT03456882|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double blinde study.|Multicenter, randomized, double-blind, placebo-controlled, parallel group, add-on phase II trial. ALS Patients who meet the study's inclusion/exclusion criteria and sign the Informed Consent Form will be enrolled. A total of 142 subjects will be randomly assigned to receive treatment with either RNS60 or placebo while concomitantly taking riluzole (50 mg tablet t.i.d.). RNS60 or placebo will be administered intravenously once a week as well as inhaled via nebulization every morning in the remaining six days of each week for 24 weeks. Blood samples for biomarker analysis will be collected on day 1, week 4, w12, and w24. Safety and preliminary efficacy will be assessed by way of physical exam, vital signs and AEs. Changes in disability and quality of life will be assessed using the ALSFRS-R scale, FVC and ALSAQ-40 scale. Each patient will be followed up for a maximum period of 48 weeks (24-week treatment + 24-week follow up) or until death or tracheostomy, whichever occurs first.|t|t|t|t
34078950|NCT03511677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo insole||t|f|f|t
34078951|NCT01061606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078952|NCT03983538|||CASE_ONLY||PROSPECTIVE|||||||
34078953|NCT01460732|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34078954|NCT00637403|NON_RANDOMIZED|PARALLEL||||NONE||||||
34078955|NCT01159574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078956|NCT06402383|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34078957|NCT05415189|||COHORT||RETROSPECTIVE|||||||
33679361|NCT01617226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679362|NCT01666340|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679364|NCT04495205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patient and the statistician are masked||t|f|f|t
33679365|NCT05667077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679366|NCT03206281|||CASE_CONTROL||PROSPECTIVE|||||||
33679367|NCT00831818|||CASE_CONTROL||PROSPECTIVE|||||||
33679368|NCT02284841|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33679372|NCT01331889|||COHORT||PROSPECTIVE|||||||
33679373|NCT06251531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679374|NCT03836001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study.|This is an investigator-initiated, single-center, randomized, double-blind, placebo-controlled, parallel-arm trial evaluating the effects of serlopitant at 5 mg by mouth daily on EB-related itch.|t|t|t|t
33679375|NCT03115502|||COHORT||PROSPECTIVE|||||||
33679377|NCT04070911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||RANDOMIZED CONTROLLED STUDY GROUP|t|f|f|f
33899328|NCT05282706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be assigned to an arm based upon the symptoms they are experiencing prior to their therapy session. If a patient reports nausea symptom, they will be assigned to the peppermint fragrance or a placebo. The randomization will be conducted in a 1:2 ratio, one placebo to two experimental. If a patient reports pain symptom, they will be assigned to the lavender or mandarin fragrance or placebo. The randomization will be conducted in a 1:2 ratio, one placebo to two experimental. The experimental group will then be randomized to a 1:1 ratio between lavender and mandarin. For those that refuse the aromatherapy patch will be asked to serve as a control and receive usual care with no patch.|Three interventional and one control arm|t|f|f|f
15130075|NCT03738982|NA|SINGLE_GROUP||OTHER||NONE||Device Feasibility study||||
33899329|NCT04870177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899330|NCT03385356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1000 IU/day of Vitamin D vs 4000 IU of Vitamin D /day; IU (international units)|t|t|t|f
33899331|NCT03927729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899332|NCT02524080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899333|NCT01251523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33899334|NCT03270085|RANDOMIZED|PARALLEL||OTHER||TRIPLE|30 subjects with irritable bowel syndrome and diarrhea and bile acid malabsorption will be randomized into 15 people per group in 4-week double-blind, parallel-group trial to Colesevelam or placebo.|This is the third specific aim of a program on IBS-D with increased fecal bile acid excretion.|t|t|t|f
33899335|NCT03672617|||COHORT||PROSPECTIVE|||||||
33899336|NCT04065763|||CASE_ONLY||PROSPECTIVE|||||||
33899337|NCT04740866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899338|NCT04740749|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33899339|NCT06353646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899340|NCT02319772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899341|NCT05616234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899342|NCT03002493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899343|NCT03952364|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33899344|NCT04596813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899345|NCT03113331|||COHORT||PROSPECTIVE|||||||
33899346|NCT02723630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899347|NCT03103750|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a within-subject, two-day four-scan, randomized, double-blind, placebo-controlled study design.|t|f|t|f
34078958|NCT02819570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34078959|NCT03539276|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|It was unlikely that participants could foresee whether or when their medications have been reviewed or modified.|Pre-post study|t|f|f|f
34078960|NCT02992925|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34078961|NCT00151333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33899348|NCT01319955|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33899349|NCT01392690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679378|NCT05638919|||COHORT||PROSPECTIVE|||||||
33679379|NCT03672929|||COHORT||PROSPECTIVE|||||||
33679380|NCT05981781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the patients , outcome assessors and care providers are not informed with the block type done.|Double blinded randomized study|t|t|f|t
33679383|NCT05484700|||COHORT||RETROSPECTIVE|||||||
33982518|NCT03411330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Prospective randomized double blinded clinical study on humans|"The investigators hypothesize that, the addition of hyaluronidase may affect the quality of the block by enhancing the spread of the local anaesthetics through the facial planes and thus, reaching the target nerves more easily, rapid and effective that may provide better effective block in short duration and lasting for longer duration. This effect will be measured in terms of stress response and  analgesic quality Total sample size of 64 patients randomly allocated into two equal groups. According to study Hyaluronidase in sub-Tenon's anesthesia for phacoemulsification that was done and published in International Journal of Ophthalmology (2012) to detect difference in post-operative pain between those patients receiving Lidocaine only versus Lidocaine and hyaluronidase, sample size of 29 patients per group is needed with confidence level 95% power of the study 80% \& type I error 0.05. Sample size calculation was done using Medcalc Software version 15.4."|t|f|t|f
33679384|NCT00732836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982519|NCT03475771|||COHORT||RETROSPECTIVE|||||||
33982520|NCT05165680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded as neither the subjects nor the investigators are aware of the treatment assignment until the end of the trial|Sixty anemic obese premenopausal women, their ages will range from 30 to 40 years. The participants will be selected from General Zagazig Hospital. All participants will be randomly assigned into two groups equal in number; Experimental group and control group. Experimental group will receive a program of aerobic exercise, low caloric diet rich in iron, vitamin c, and folate for 3 times per week and Iron supplements for 12 weeks , while control group will only receive low caloric diet rich in iron, vitamin c, and folate for 3 times per week and Iron supplements for 12 weeks . Participants' demographic data will be collected as marital status, length of menstrual cycle, level of income, level of education, occupation.|t|f|t|f
33982521|NCT04513964|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33982522|NCT05266430|||CASE_CONTROL||PROSPECTIVE|||||||
33982523|NCT02524197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982524|NCT05267236|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment vs. Control Group Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.||||
33982525|NCT01056965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982526|NCT00615069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982527|NCT04559347|RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine (a long acting local anesthetic) to Ropivacaine (0.5% followed by 0.2% infusion using a catheter) in patients undergoing video assisted thoracoscopic (VAT) surgery.||||
33982528|NCT02027714|||||CROSS_SECTIONAL|||||||
33982529|NCT04053348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679385|NCT02908490|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33679386|NCT00361634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679388|NCT01376687|||COHORT||PROSPECTIVE|||||||
33679389|NCT01964768|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33679390|NCT03414892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679391|NCT02410343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679392|NCT00508781|||||OTHER|||||||
33679396|NCT02672696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679397|NCT04891640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679398|NCT06353022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679399|NCT04109508|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679401|NCT03351036|||COHORT||PROSPECTIVE|||||||
33679402|NCT03537469|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The subjects and operators who performed TMS were blinded to the type of stimulation applied, we then employed a randomized double-blind sham-controlled crossover design.||t|t|t|t
33770309|NCT05764226|NA|SINGLE_GROUP||TREATMENT||NONE|An off-label use of an open label single arm before and after treatment comparison clinical study|An open label single arm before and after treatment comparison clinical study||||
33899350|NCT02523586|||CASE_CROSSOVER||PROSPECTIVE|||||||
33899351|NCT02097836|NA|SINGLE_GROUP||TREATMENT||NONE|Gross Motor Function Measure Outcome was masked for temporal order and video scored by reviewers who were not involved in data collections or intervention.|||||
33899352|NCT00361725|||CASE_CONTROL||OTHER|||||||
33899353|NCT04265534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, placebo controlled||t|t|t|t
33899354|NCT03042949|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Subjects will have their blood pressure measured by standard plethysmography and with a new optical device||||
33899355|NCT01207544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899356|NCT01355432|||COHORT||PROSPECTIVE|||||||
33899357|NCT00565422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899358|NCT05870475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899359|NCT03425656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899360|NCT04923373|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients (n=105) were randomly divided into two groups: telerehabilitation group (n=54) - 42 women and 12 men and control group (n=51) 40 women and 11 men - direct physiotherapist supervised group.||||
33899361|NCT05418946|||COHORT||RETROSPECTIVE|||||||
33899362|NCT02896725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Healing status for primary and secondary outcomes are adjudicated by blinded review of photographs of healed reference ulcer site or unhealed reference|Participants allocated to receive either keratin dressing or usual care dressing|f|f|f|t
33899363|NCT01434225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899364|NCT02792777|||OTHER||PROSPECTIVE|||||||
33899365|NCT05669885|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33899366|NCT06378710|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33899367|NCT05073289|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Patients with a diagnosis of mental disorder in the psychiatry clinic|Randomized Control Experimental Research|t|f|f|f
33899368|NCT04599790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899369|NCT00200148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899370|NCT02658695|||CASE_CONTROL||PROSPECTIVE|||||||
33899371|NCT01333618|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33899372|NCT04298346|||CASE_CONTROL||PROSPECTIVE|||||||
33899373|NCT01379586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899374|NCT01412931|||CASE_CONTROL||PROSPECTIVE|||||||
33899375|NCT05216263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899376|NCT02385123|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899377|NCT05841849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899378|NCT02509338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899379|NCT03060577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899380|NCT04111367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899381|NCT06335940|||COHORT||PROSPECTIVE|||||||
33899382|NCT02359123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899383|NCT05074784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized into control group or intervention group.|f|t|t|t
33899384|NCT00270920|RANDOMIZED|PARALLEL||||NONE||||||
33899385|NCT04334148|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind|Double blind, placebo-controlled, randomized clinical trial.|t|t|t|f
33899386|NCT02904564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899387|NCT01750021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33899388|NCT03925844|||COHORT||PROSPECTIVE|||||||
33899389|NCT00942201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899390|NCT03827876|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33899391|NCT05429515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are divided into two groups: (1) chemotherapy combined with HFR-SUPRA (2) chemotherapy combined with hemodialysis||||
33899392|NCT01936246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33899393|NCT03738124|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33899394|NCT04795180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"1 treatment arm open label~1 treatment arm double-blind~1 treatment arm double-blind"||t|f|t|f
33899395|NCT01819961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899396|NCT02599389|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899397|NCT02997124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899398|NCT01363895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899399|NCT02879500|||OTHER||PROSPECTIVE|||||||
33899400|NCT03715257|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33899401|NCT06377995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33899402|NCT01821677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899403|NCT05566275|||COHORT||CROSS_SECTIONAL|||||||
33899404|NCT05418361|||OTHER||PROSPECTIVE|||||||
33899405|NCT05066893|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899406|NCT03901183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770310|NCT04232098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899407|NCT05796089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899408|NCT00997685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899409|NCT05275829|||COHORT||PROSPECTIVE|||||||
33899410|NCT00102037|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33899411|NCT05065424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982530|NCT00073177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982531|NCT03657160|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33899412|NCT03709433|NA|SINGLE_GROUP||TREATMENT||NONE|No masking will be used.|All participants will receive the same active treatment (acceptance and commitment therapy groups and a mobile app)||||
33899413|NCT00310245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899414|NCT00679562|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33982532|NCT04764916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Surgeons and patients will be blinded to study arm until 2 week post-operative visit. Anesthesiology and their staff will not be blinded.|One study group receives standard bupivacaine. One group receives liposomal bupivacaine (Exparel). All other study procedures are identical|t|t|t|t
33982533|NCT04061005|RANDOMIZED|PARALLEL||OTHER||NONE|RCT-HSP-CSP|||||
33982534|NCT05859386|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first group will be a single group aimed at initial intervention refinement. The second group will be randomized to either receive the intervention or enter a wait-list control condition.||||
33982535|NCT01384838|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33982536|NCT01962337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982537|NCT03328936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982538|NCT04365309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982539|NCT06174857|||COHORT||PROSPECTIVE|||||||
33982540|NCT06311942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982541|NCT04235881|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The experimental study was developed through a randomized controlled clinical trial, with simple random probabilistic sampling. With a pre-post design, the variables measured in the participants before performing the mindfulness training were measured again at the end of the program, eight weeks later, in order to compare the values of both measurements.||||
33982542|NCT04341285|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) within 24 hours Control intervention: Insertion of Extracorporal Membrane Oxygenation (ECMO) as rescue therapy following failure of conventional therapy for ARDS. This conventional therapy will be standardized to reduce bias.~Duration of intervention per patient: varies, depending on severity of pulmonary compromise Follow-up per patient: 90days or until hospital discharge Accompanying measures: Serum Samples and bronchoscopy samples of patients included into the trial for secondary analysis of inflammatory parameters and potential biomarkers"||||
34078962|NCT03200548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The three acupressure formulas will be labeled acupressure set A, set B, and set C. Acupressure educators, outcome assessors, study participants, and study investigators (who will not interact with any of the study participants) will be blinded as to acupressure allocation. Only after data analysis is completed will the randomization code be unblinded. Those randomized to usual care will know that they are not receiving acupressure."|The investigators propose to perform a randomized, single-blind parallel clinical trial. This will be parallel design with four arms (relaxing acupressure plus usual care, stimulating acupressure plus usual care, sham acupressure plus usual care and usual care alone) for persistent fatigue in SLE.|t|t|f|t
34078963|NCT00209391|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679403|NCT05045989|NA|SINGLE_GROUP||PREVENTION||NONE|N/A process evaluation, single group intervention|Process evaluation of a SARS-CoV-2 testing participation uptake scheme in a single group of students living in two halls of residence.||||
33899415|NCT04154982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers, involved in the assessment of NAC efficacy, are blinded to randomization process; thus, they do not know whether the patients are in the NAC or in the control groups.||f|f|f|t
33899416|NCT01836601|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33679404|NCT03127332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679407|NCT02237534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679408|NCT05466370|||COHORT||RETROSPECTIVE|||||||
33679409|NCT02081859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679410|NCT05896436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679412|NCT00666484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679413|NCT00935246|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982543|NCT01395030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679414|NCT04915378|||COHORT||PROSPECTIVE|||||||
33679415|NCT03873740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679416|NCT00250146|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33770311|NCT01476436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33982544|NCT02581748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982545|NCT01743326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770312|NCT05860725|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33770313|NCT00814515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770314|NCT05643417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770315|NCT04095572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Pragmatic, parallel arm, superiority, multicentre, randomised trial with blinded treating physicians, patients and outcome assessors|t|f|t|t
33770316|NCT02491892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982546|NCT06403930|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||This study evaluated the accuracy of different obturator materials using Bland-Altman analysis and assessed patient satisfaction with obturators in post-maxillectomy patients using the obturator functioning scale, addressing functional and aesthetic issues caused by maxillofacial tumor surgeries that impact patients' quality of life and social well-being.|f|f|f|t
33982547|NCT02992093|||||PROSPECTIVE|||||||
33982548|NCT05956678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|CMHC providers (i.e., the study participants) are blind to group allocation.|CMHC providers are cluster-randomized to either Standard TranS-C or Adapted TranS-C by their CMHC of employment.|t|f|f|f
33982549|NCT04019678|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33982550|NCT02272777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982551|NCT02342054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982552|NCT03900624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single Arm Treatment Group with a Prospective, Comparative Cohort Receiving Standard Care||||
33982553|NCT05452447|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33982554|NCT01190293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982555|NCT01821144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33982556|NCT02011204|||COHORT||PROSPECTIVE|||||||
33982557|NCT00320112|RANDOMIZED|PARALLEL||||NONE||||||
33982558|NCT06011122|||COHORT||RETROSPECTIVE|||||||
33982559|NCT05047003|||COHORT||PROSPECTIVE|||||||
33982560|NCT04250662|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Device settings|"A single blind, randomized control, exploratory trial to assess the acute effects of tDCS and guided imagery in women with chronic pelvic pain. Qualified individuals will be randomized 1:1:1:1 to receive 1 session of one of the following treatments:~* 20 minutes of active tDCS with 25 minutes of guided imagery~* 20 minutes of active tDCS with no guided imagery~* 20 minutes of sham tDCS with 25 minutes of guided imagery~* 20 minutes of sham tDCS with no guided imagery"|t|f|f|f
33982561|NCT03444116|||CASE_CONTROL||OTHER|||||||
33982562|NCT02109042|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982563|NCT02127281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982564|NCT03272022|||COHORT||PROSPECTIVE|||||||
33982565|NCT05867576|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The study design is an unblinded, waitlist-controlled, randomised controlled trial (RCT). Randomisation will be conducted using established randomisation software RedCap. Researchers will not be blind to trial arm allocation.|Randomised controlled trial of 6-12 sessions of ACT versus waitlist control. Waitlist control will involve a delay in the offer of ACT sessions for 12 weeks.||||
33982566|NCT01889836|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982567|NCT04062890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the pharmacist and the principle investigator will know the treatments designated to a patient.|Patients will be treated with a placebo or vigabatrin|t|t|t|f
33679421|NCT05813223|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open label, single arm, mechanism of disease study||||
33679422|NCT01646333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679423|NCT04015375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, Randomised|A multi-center, double-blind, randomized, three-arm, placebo-controlled, parallel-group study|t|t|t|t
33679425|NCT01936090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770317|NCT02773706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770318|NCT03079505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770319|NCT02443025|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770320|NCT06131541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The present clinical trial was single-blinded one as the evaluator and the statistician were both blinded. While both the implantologist or the participant were not blinded as the interventions were dissimilar.|single-center, prospective, single-blinded, randomized parallel two-arm controlled clinical trial|f|f|t|t
33770321|NCT05690542|||CASE_CONTROL||PROSPECTIVE|||||||
33770322|NCT02836327|||CASE_CONTROL||PROSPECTIVE|||||||
33770323|NCT02221323|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770324|NCT05891821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770325|NCT00030433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770326|NCT00267423|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33770327|NCT02839122|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33770328|NCT06192615|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982568|NCT02491346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679426|NCT05019118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The masking process will be triple blind, that is, both the participating women, the research staff (including those in charge of delivering the products and the one who performs and interprets the measurements), as well as the analyst, won't know at any time what group belong to patients. All the products in the study (Únicla dairy) as well as their respective placebos (conventional FEIRACO equivalent products) will maintain a similar format and labeling, with the organoleptic characteristics of dairy products being very similar. Masking will be opened at the time that the last data interpretation of the last subject included was made and before starting the statistical analysis|Randomized, masked and controlled nutritional intervention study|t|t|t|t
33982569|NCT02865564|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33982570|NCT01311804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679427|NCT01920100|||COHORT||PROSPECTIVE|||||||
33982571|NCT01130623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679428|NCT02149849|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33679431|NCT02797002|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33770329|NCT05987501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770330|NCT01985477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770331|NCT02129816|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33770332|NCT03165006|||COHORT||RETROSPECTIVE|||||||
33770333|NCT05927376|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33770334|NCT04588896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770335|NCT06320496|||OTHER||PROSPECTIVE|||||||
33770336|NCT01410461|||COHORT||PROSPECTIVE|||||||
33770337|NCT04639921|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|double blind performed by food provider|Diagnostic double blind randomized placebo controlled food challenge with cross over|t|t|t|f
33770338|NCT01342887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770339|NCT01273532|RANDOMIZED|CROSSOVER||||NONE||||||
33770340|NCT00818909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770341|NCT04598737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982572|NCT01504698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982573|NCT05369247|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33770342|NCT04139915|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33770343|NCT02512510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770344|NCT01982396|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33770345|NCT04276662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1, open-label, parallel design, single-dose PK study||||
33770346|NCT03343860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770347|NCT06098495|||COHORT||PROSPECTIVE|||||||
33899417|NCT05807828|RANDOMIZED|PARALLEL||OTHER||SINGLE|The personnel that will assess the cup inclination and stem version will not know the group assignment of the participants|All participants will be randomized to the VR simulation or control group for cup inclination and stem version assessment by a computerized random number generator. The VR group will perform implantation on sawbones after VR education and the control group without VR education.|f|f|f|t
33899418|NCT05975307|NA|SINGLE_GROUP||TREATMENT||NONE||This Phase 2 trial uses a single-arm, Simon's two-stage design.||||
33899419|NCT02040246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899420|NCT00919022|||COHORT||PROSPECTIVE|||||||
33899421|NCT06449261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A two-group, parallel-arm, single-blinded, randomized clinical trial|f|f|f|t
33899422|NCT02937610|||COHORT||PROSPECTIVE|||||||
33899423|NCT01777438|||CASE_CONTROL||PROSPECTIVE|||||||
33770348|NCT02326116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33770349|NCT05271682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770350|NCT02854358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770351|NCT03499626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770352|NCT01950117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770353|NCT02312180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899424|NCT02628223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33899425|NCT05099991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982574|NCT01330498|||CASE_ONLY||RETROSPECTIVE|||||||
33982575|NCT00470769|||DEFINED_POPULATION||OTHER|||||||
33982576|NCT02552342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982577|NCT00693966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982578|NCT00816504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982579|NCT01472393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982580|NCT01336660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982581|NCT02997098|||COHORT||OTHER|||||||
33982582|NCT00002654|RANDOMIZED|||TREATMENT||||||||
33982583|NCT02348983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982584|NCT05989893|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982585|NCT05763238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982586|NCT00999050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982587|NCT03619408|||COHORT||PROSPECTIVE|||||||
33770354|NCT06063902|||COHORT||PROSPECTIVE|||||||
33770355|NCT00458679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770356|NCT03169270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770357|NCT04358419|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33770358|NCT03209401|NA|SEQUENTIAL||TREATMENT||NONE||"The Phase Ia portion of the trial will be conducted in a 3+3 design, enrolling patients in cohorts of 3 patients each to insure safety and tolerability.~There will be a Phase Ib expansion cohort including 20 patients to further assess the efficacy of niraparib plus carboplatin, using the RP2D and schedule from Phase Ia."||||
33770359|NCT00936520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770360|NCT02297971|||CASE_ONLY||PROSPECTIVE|||||||
33899426|NCT01316289|||CASE_CONTROL||PROSPECTIVE|||||||
33899427|NCT04346225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899428|NCT02887144|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33982588|NCT02528760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982589|NCT04200417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982590|NCT02482246|||CASE_ONLY||PROSPECTIVE|||||||
33982591|NCT04751734|||CASE_CONTROL||PROSPECTIVE|||||||
33982592|NCT01729377|||COHORT||PROSPECTIVE|||||||
33899429|NCT05585385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|Backward Walking Training and Balance Training|t|f|f|t
33899430|NCT01269567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982593|NCT00526786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982594|NCT00659464|||CASE_ONLY||PROSPECTIVE|||||||
33982595|NCT01087476|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33982596|NCT00863746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982597|NCT00077948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982598|NCT01417390|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33982599|NCT01059903|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33982600|NCT05573620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know that two different treatments were delivered.|"Randomization assigned participants to 3 arms:~* in vivo exposure~* virtual reality~* waiting list"|t|f|f|f
33982601|NCT02291562|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33982602|NCT05847205|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single arm, single-center||||
33982603|NCT03396523|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34078964|NCT00634478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078965|NCT01321671|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34078966|NCT04606303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078967|NCT02717195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34078968|NCT06508086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679432|NCT01507064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679433|NCT04175990|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33679434|NCT01996839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679436|NCT06128265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized and unblinded||||
33679437|NCT02395172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679438|NCT00496600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679439|NCT05526300|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679440|NCT05282602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679444|NCT05047289|||CASE_ONLY||PROSPECTIVE|||||||
33679445|NCT00333944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679446|NCT02385656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679448|NCT06532240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679449|NCT01542424|||COHORT||PROSPECTIVE|||||||
33679450|NCT04247542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Vancomycin capsules will be over-encapsulated to have identical appearance to ibezapolstat capsules. Placebo capsules will be used to enable a double-dummy, double-blind design.|In Segment 2B, approximately 64 patients will be randomly assigned in a 1:1 fashion to ibezapolstat or the standard of care positive control, vancomycin.|t|t|t|t
33679451|NCT01998568|||CASE_ONLY||CROSS_SECTIONAL|||||||
33679452|NCT01840657|||CASE_ONLY||PROSPECTIVE|||||||
33679455|NCT00295386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679456|NCT02482831|||COHORT||PROSPECTIVE|||||||
33679457|NCT04802122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679458|NCT04602234|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Among the 151 patients included, 111 LUS were performed (LUS group)||||
33679460|NCT01473368|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33679461|NCT01425463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34078969|NCT02042469|||COHORT||CROSS_SECTIONAL|||||||
34078970|NCT04779112|||CASE_ONLY||RETROSPECTIVE|||||||
34078971|NCT05759637|||COHORT||CROSS_SECTIONAL|||||||
34078972|NCT00363558|||NATURAL_HISTORY||RETROSPECTIVE|||||||
34078973|NCT02837926|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33679462|NCT05356156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679463|NCT05318742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33679464|NCT03523598|RANDOMIZED|PARALLEL||TREATMENT||NONE|Triple (Participant, Investigator, Outcomes Assessor)|||||
33679470|NCT04478864|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33679472|NCT05227092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679476|NCT02204124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be blinded to the assigned operating technique.||t|f|f|f
33679478|NCT03126344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679479|NCT05364333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33679480|NCT02710955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770361|NCT05521594|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679484|NCT04371302|||COHORT||CROSS_SECTIONAL|||||||
33679485|NCT01980485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770362|NCT01768754|||COHORT||PROSPECTIVE|||||||
33770363|NCT00238420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679491|NCT00621335|||||PROSPECTIVE|||||||
33679494|NCT04663490|||COHORT||RETROSPECTIVE|||||||
33770364|NCT06055192|||OTHER||OTHER|||||||
33770365|NCT01226810|||CASE_ONLY||CROSS_SECTIONAL|||||||
33899431|NCT03653715|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The Principal Investigator and Clinical Research Technicians, because they handle the contact lenses both in and out of their packaging, are not masked.|This single center study is a device feasibility, two-arm, double-masked (participants and outcomes assessor), repeated measures, cross-sectional design. Each participant is tested with the four (4) study devices (i.e., contact lenses), one (1) test lens and three (3) control lenses, in randomized order. Participants are masked to each lens they wear.|t|f|f|t
33899432|NCT05901181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||study design Applications of women will be received by making announcements of the research and laughter yoga trainings through posters hung in the center of the district to menopausal women in the 45-60 age group in the district. After the applications, menopausal women who meet the research criteria and volunteer to participate in the research will be randomly assigned to the intervention and control groups by drawing lots to determine which group they will be in.||||
33770366|NCT01339988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770367|NCT02265029|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33770368|NCT00179699|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33770369|NCT04422366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33770370|NCT02037828|||OTHER||PROSPECTIVE|||||||
33770371|NCT01193543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770372|NCT05790226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770373|NCT01961596|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33770374|NCT06036563|||COHORT||PROSPECTIVE|||||||
33770375|NCT02989896|||COHORT||PROSPECTIVE|||||||
33770376|NCT06172218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770377|NCT02707419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770378|NCT06353659|||COHORT||PROSPECTIVE|||||||
33770379|NCT02710994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899433|NCT05645666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899434|NCT04068389|||COHORT||PROSPECTIVE|||||||
33899435|NCT00674934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899436|NCT02195115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899437|NCT01902160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899438|NCT03032887|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33899439|NCT04820478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo-controlled study, using a placebo with similar look and taste in similar bottles; the study is double-blinded, i.e. patients and study personnel are masked||t|t|t|t
33899440|NCT01221545|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33899441|NCT04336150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33899442|NCT02439762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899443|NCT00855712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899444|NCT02510599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078974|NCT03110354|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open label|||||
34078975|NCT01585337|||CASE_ONLY||PROSPECTIVE|||||||
34078976|NCT02737761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078977|NCT00255619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078978|NCT01559662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679503|NCT03267485|||COHORT||PROSPECTIVE|||||||
33679504|NCT00815555|||||RETROSPECTIVE|||||||
33770380|NCT06026527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770381|NCT02737956|||COHORT||RETROSPECTIVE|||||||
33770382|NCT04088474|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|a randomized, double-blind, placebo-controlled clinical study|a randomized, double-blind, placebo-controlled clinical study|t|f|f|f
33899445|NCT06480045|RANDOMIZED|PARALLEL||OTHER||NONE||70 patients with ASA I-II, between the ages of 18-75, who were scheduled for mastectomy surgery were included in the study. An anesthesiology resident under the supervision of senior anesthesiologist, performed a PECS II block with AI-integrated USG or conventional USG (Group AI-USG and Group USG) after randomization. Block was performed after induction of general anesthesia. Patient data in terms of hemodynamic changes in the intraoperative period, opioid consumption, and postoperatively hemodynamics, pain scores (VAS), postoperative opioid (tramadol administered with a patient-controlled analgesia pump) and, if necessary, rescue analgesic agent (non-steroidal antiinflammatory agent) consumption were monitored in the post-anesthesia care unit, and at postoperative 6., 12. and 24.hours.||||
33899446|NCT03427840|||COHORT||PROSPECTIVE|||||||
33679510|NCT00941629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679512|NCT06297785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899447|NCT00385086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899448|NCT06077422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899449|NCT01618955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899450|NCT01415960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899451|NCT00744159|||CASE_CONTROL||PROSPECTIVE|||||||
33899452|NCT04902118|||COHORT||RETROSPECTIVE|||||||
33899453|NCT01252888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899454|NCT00004081||||TREATMENT||NONE||||||
33899455|NCT00444210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33899456|NCT03644797|||COHORT||RETROSPECTIVE|||||||
33899457|NCT01675037|||COHORT||PROSPECTIVE|||||||
33899458|NCT00358891|||CASE_CONTROL||PROSPECTIVE|||||||
33899459|NCT01542372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899460|NCT04883489|||COHORT||CROSS_SECTIONAL|||||||
33982604|NCT04606420|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Since this is a behavioral intervention, it is not possible to blind the participant and the care provider from whether or not they are receiving the intervention. However, everyone involved in testing patients (Outcome Assessors) is blinded to group assignment.|"In this randomized crossover design, 51 patients with early Alzheimer's disease were randomly-assigned to one of two groups. After baseline testing, the first group receives the lifestyle program for 20 weeks (via Zoom since 2/20 due to COVID-19). The second group does not and is a randomized control group during this phase. Both groups are re-tested after 20 weeks. Then, the second group crosses over and receives this program for 20 weeks and the first group continues the program for 20 additional weeks. After 40 weeks, both groups are re-tested again. Patients initially randomly assigned to the control group will receive the intervention for a total of 40 weeks and then be re-tested.~Due to challenges in recruiting patients, including Covid-19, we recently terminated recruitment after 51 patients were recruited. This decision was based on recruitment and funding issues, without review of any of the data. This trial will continue until all 51 patients have completed it."|f|f|f|t
33982605|NCT04949620|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||The first stage investigates the efficacy of the online REThink therapeutic game in comparison with monitoring in the prevention of emotional disorders for 4 weeks. In the second stage, for the non-responders to the intervention, the online parenting intervention will be implemented, while the other groups will be monitored for other 4 weeks.|t|f|f|f
33982606|NCT02674477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982607|NCT02222155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982608|NCT00992771|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33982609|NCT03382756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982610|NCT00931099|||COHORT||PROSPECTIVE|||||||
33982611|NCT05417100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078979|NCT02329847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078980|NCT04020211|||COHORT||PROSPECTIVE|||||||
34078981|NCT00842634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679514|NCT05922800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statisticians and outcome assessors will be blinded to the allocation.||f|f|t|t
33679515|NCT05471713|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33679516|NCT00512629|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33679519|NCT01488513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679520|NCT05539989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33679521|NCT01644747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679522|NCT04183361|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33982612|NCT05436509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982613|NCT05909124|||CASE_CONTROL||RETROSPECTIVE|||||||
33982614|NCT01122485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982615|NCT01228409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982616|NCT01884090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33982617|NCT00002889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982618|NCT01762709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33982619|NCT00949312|||COHORT||PROSPECTIVE|||||||
33982620|NCT05306470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679526|NCT01277003|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33679528|NCT06514989|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33679529|NCT01567839|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33679530|NCT04668027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679531|NCT03847441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679532|NCT04489069|NA|SINGLE_GROUP||OTHER||NONE||||||
33679533|NCT05122598|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33679534|NCT05843786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679535|NCT00130975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679536|NCT02881567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679537|NCT02128685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679538|NCT03260049|||CASE_ONLY||RETROSPECTIVE|||||||
33679539|NCT04572152|NA|SEQUENTIAL||TREATMENT||NONE|Open label|||||
33679540|NCT01646164|||COHORT||RETROSPECTIVE|||||||
33679541|NCT05960292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679542|NCT05229497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679543|NCT01685398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33679544|NCT02069275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679545|NCT02983279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679546|NCT03581461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679547|NCT03826784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679548|NCT03087799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679549|NCT04931888|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679550|NCT05424770|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33679551|NCT03314571|||COHORT||PROSPECTIVE|||||||
33679552|NCT06333600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679553|NCT05143788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679554|NCT05396716|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The stimulator is put in an opaque box||t|t|t|t
33679555|NCT05545280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679556|NCT03219775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679557|NCT03153384|||CASE_CONTROL||PROSPECTIVE|||||||
33679558|NCT02303392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679559|NCT05363254|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33679560|NCT06212037|||COHORT||PROSPECTIVE|||||||
33982621|NCT05221242|NA|SINGLE_GROUP||TREATMENT||NONE|two observers will evaluate clinically patient's restorations using the modified USPHS criteria and the FDI criteria. Observers will be blinded to the type of luting agent used for the restoration with ceramic partial laminate veneers|In this study, two different luting resin cements will be used to bond ceramic partial laminate veneers. This is a randomized split mouth clinical trial, in which only maxillary anterior teeth will be treated with partial veneers (maximum 6 teeth, upper incisors and canines. This zone is called sector 2). For this purpose, sector 2 will be divided in two sides (right and left), and randomization will be performed to select a conventional resin cement or a preheated resin composite luting agent as the material of choice for the right or left side of the mouth to bond ceramic partial laminate veneers for every recruited patient. Number of participants is related to the number of restorations.||||
33982622|NCT05128812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33679561|NCT01585675|||OTHER||PROSPECTIVE|||||||
33679562|NCT01661842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679563|NCT06173180|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants were randomized into two groups and underwent surgery.||||
33679564|NCT03851172|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation concealment will be achieved by masking the bottles of the different agents which will be used in the study. All agents will be added to non-labeled bottles, then they will be labeled by the supervisor (who will not participate in eye drops administration) as bottle (1), bottle (2) and bottle (3). The most junior researcher will be responsible for the eye drops administration, for whom the different agents are not known.||t|t|f|f
33679565|NCT03525964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The posterior site of the achilles tendon region is covered by dark tape during the functional assesments.|Prospective|f|f|f|t
33679566|NCT00156936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679567|NCT00190255|||COHORT||PROSPECTIVE|||||||
33679568|NCT04756336|NA|SINGLE_GROUP||TREATMENT||NONE||Consecutive case series||||
33679569|NCT05918471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgeons, investigators, outcome assessors, and data analysts will be blinded to treatment allocation to limit measurement bias|This is a multi-center, blinded, parallel pilot RCT.|f|t|t|t
33679570|NCT00660686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33679571|NCT03171103|||CASE_ONLY||PROSPECTIVE|||||||
33982623|NCT03967730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982624|NCT03088670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679572|NCT00308464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679573|NCT01929941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679574|NCT03310307|RANDOMIZED|PARALLEL||TREATMENT|||Double blind|||||
33679575|NCT04986358|NA|SINGLE_GROUP||OTHER||NONE||Patient cohorte||||
33679576|NCT04529356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679577|NCT02227940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679578|NCT02512484|||COHORT||PROSPECTIVE|||||||
33679579|NCT05451316|||COHORT||PROSPECTIVE|||||||
33679580|NCT02252341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679581|NCT06012994|||COHORT||RETROSPECTIVE|||||||
33679582|NCT04206280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33679583|NCT06001359|||COHORT||CROSS_SECTIONAL|||||||
33679584|NCT00319072|RANDOMIZED|PARALLEL||ECT||NONE||||||
33679585|NCT01717053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679586|NCT04705493|||CASE_ONLY||CROSS_SECTIONAL|||||||
33679587|NCT00892801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679588|NCT04781933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679589|NCT00075192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679590|NCT00123643|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33679591|NCT06058208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In this randomized controlled study, block randomization method, which is one of the fixed probability randomization methods, was used in randomization. Each of the experimental and control groups was represented by one of the letters A, B, C. In the creation of the 6-block (2A, 2B, 2C) design for 54 samples and three groups; Using the permutation method, the assignment of 9 blocks out of 90 block options was carried out through the random numbers table on the www.random.org site. Which of the experimental and control groups will match the letters A, B, C; It was determined by the lottery method drawn by hand by the independent clinical nurse from the study. As a result of the draw, A: smell, B: smell + video, C: represented the control group."|f|f|t|f
33679592|NCT02980809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679593|NCT05193032|||COHORT||RETROSPECTIVE|||||||
33679594|NCT04055428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679595|NCT01433250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679596|NCT04164511|||CASE_CONTROL||PROSPECTIVE|||||||
33770383|NCT05512728|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Categorical variables will be assessed using the chi-square or Fischer's exact test where appropriate. Normally distributed data will be presented as the mean (SD). Midazolam consumption and hemodynamic variables with a normal distribution will be analyzed using two-way analyses of variance with repeated measures and Dennett's post hoc test as appropriate. Data that are not normally distributed (by the Kolmogorov-Smirnov test) are presented as the median (range) and will be analyzed with the Kruskal-Wallis test as appropriate. The software SPSS v15.0 for Windows (SPSS, Inc, Chicago, IL, United States) will be used for statistical analysis|f|t|f|f
33770384|NCT01156077|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33770385|NCT04343222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33770386|NCT05907577|||CASE_CONTROL||RETROSPECTIVE|||||||
33770387|NCT05724914|||COHORT||RETROSPECTIVE|||||||
33770388|NCT02088827|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33770389|NCT04283344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770390|NCT04672109|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33770391|NCT03876938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770392|NCT04657549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients in active arms don't know if they are in tonsillectomy or tonsillotomy group||t|f|f|f
33770393|NCT03623880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770394|NCT05330130|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33770395|NCT02788006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770396|NCT04188483|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33770397|NCT01161004|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33770398|NCT04516421|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After random assignment, the external researcher newly assigned a subject ID to each participant. All other study personnel and participants remained blinded to the identity codes throughout the course of the study. When participants withdrew from or completed the study, researchers were provided with the participants' identities, and the participants were told what supplement they had received.|Then eligible participants is invited to attend this randomized, double-blind, placebo-controlled,2-parallel-group trial, and concealed allocation and intention-to-treat (ITT) analysis were applied, and randomly assigned to the experimental and control group in the ratio of 1:1 for the 12-week trial. and intervention.|t|t|f|f
33770399|NCT00000143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770400|NCT05134714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Assignment|t|f|f|t
33770401|NCT02942680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770402|NCT03795467|||COHORT||RETROSPECTIVE|||||||
33770403|NCT01591460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770404|NCT06257901|||OTHER||CROSS_SECTIONAL|||||||
33770405|NCT03088020|||COHORT||PROSPECTIVE|||||||
33770406|NCT03504735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770407|NCT00763399|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33770408|NCT03971812|||OTHER||PROSPECTIVE|||||||
33770409|NCT04694482|||CASE_CONTROL||RETROSPECTIVE|||||||
33770410|NCT02268318|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33770411|NCT04328558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is clavipectoral fascia plane block group. The second one is no intervention control group.|t|f|f|t
33770412|NCT04882761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770413|NCT04343482|||COHORT||PROSPECTIVE|||||||
33982625|NCT02895048|||CASE_CONTROL||PROSPECTIVE|||||||
33982626|NCT02393482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982627|NCT03996109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33770414|NCT00250848|||COHORT||OTHER|||||||
33770415|NCT00675506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770416|NCT05858489|||CASE_CONTROL||PROSPECTIVE|||||||
33770417|NCT00791921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770418|NCT04445155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||For clarity, each intervention group was separate and not comparable to other intervention groups.||||
33679597|NCT04610281|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33679598|NCT03800394|||COHORT||CROSS_SECTIONAL|||||||
33679599|NCT02586441|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679600|NCT00960726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679601|NCT05237206|NA|SINGLE_GROUP||TREATMENT||NONE||non-comparative, open-label, basket-design study||||
33679602|NCT05901077|||COHORT||OTHER|||||||
33679603|NCT05207345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|f|f|t|t
33679604|NCT03310060|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33770419|NCT03702101|||OTHER||PROSPECTIVE|||||||
33770420|NCT01572324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770421|NCT02899871|||CASE_CONTROL||PROSPECTIVE|||||||
33770422|NCT03436134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770423|NCT00453310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770424|NCT01061437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770425|NCT05174104|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33770426|NCT04297241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770427|NCT00504296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770428|NCT02954900|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770429|NCT03882671|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770430|NCT04864613|||COHORT||PROSPECTIVE|||||||
33770431|NCT00000990||||TREATMENT||DOUBLE||||||
33770432|NCT01232309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33770433|NCT01625624|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33770434|NCT00214032|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33770435|NCT06139991|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Since this is a double-blind study, so the investigator, all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.|This is a Partial-replicate, 3-period Cross-over study.|t|t|t|f
33770436|NCT02649322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33770437|NCT01873547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||cell therapy or rehabitation treatment|f|f|f|t
33770438|NCT03926585|||COHORT||CROSS_SECTIONAL|||||||
33770439|NCT02222896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33982628|NCT05266521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982629|NCT01975207|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33982630|NCT06368037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982631|NCT05420805|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor)|This is a 29-week pilot, single site, randomized, cross-over trial of alpha-lactalbumin + sodium butyrate + inulin + fructo-oligosaccharides vs. sodium butyrate + zinc oxide. Periods I and II of the randomized study are 12 weeks long together with a 4 week washout period.|f|f|t|t
33982632|NCT00003186||||DIAGNOSTIC||||||||
33679605|NCT01024621|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33679606|NCT05020015|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study has 2 Parts: Part 1 is composed of dose escalation followed by dose expansion and Part 2.||||
33679607|NCT04381039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679608|NCT04830098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33679609|NCT04682119|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33679610|NCT03849391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770440|NCT04539119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770441|NCT04266041|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33770442|NCT03498326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770443|NCT04420546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33770444|NCT00512551|||CASE_ONLY||PROSPECTIVE|||||||
33770445|NCT03591757|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with hATTR mutations conferring leptomeningeal amyloidosis.||||
33770446|NCT03073460|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770447|NCT05106153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33770448|NCT00167336|||||PROSPECTIVE|||||||
33770449|NCT01409421|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33770450|NCT03743337|||OTHER||OTHER|||||||
33770451|NCT00063817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770452|NCT05686915|||CASE_ONLY||PROSPECTIVE|||||||
33770453|NCT04089306|||CASE_ONLY||RETROSPECTIVE|||||||
33770454|NCT01627080|||COHORT||PROSPECTIVE|||||||
33770455|NCT02831309|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33770456|NCT01882595|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33770457|NCT02343588|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33770458|NCT03174574|||FAMILY_BASED||PROSPECTIVE|||||||
33679611|NCT00874926|||COHORT||PROSPECTIVE|||||||
33679612|NCT00067938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679613|NCT00000485|RANDOMIZED|||PREVENTION||||||||
33770459|NCT05994261|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Randomized, controlled study of long-term maintenance Cereset Research after an initial 4-session intervention bolus versus usual care control following an initial 4-session intervention bolus.||||
33770460|NCT01134133|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770461|NCT06038812|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33770462|NCT02881190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770463|NCT00245375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770464|NCT03164915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770465|NCT06429358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised Controlled Trial|t|f|f|f
33770466|NCT02216747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770467|NCT03030547|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33770468|NCT03859687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770469|NCT02632019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770470|NCT00857441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770471|NCT00030368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770472|NCT05359185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982633|NCT03110302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982634|NCT01848301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982635|NCT02958111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982636|NCT03097900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982637|NCT03923465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982638|NCT01790204|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33679614|NCT03673397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679615|NCT00726401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679616|NCT02870322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679617|NCT04953988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679618|NCT05668611|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a two-phase cohort study that will determine the ability of MOH nurses to accurately integrate echocardiographic screening for rheumatic heart disease into primary healthcare clinics in Uganda.||||
33679619|NCT03246386|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Comparing a 2 groups of obese subjects vs 1 group of non-obese subjects.||||
33679620|NCT06031389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33679621|NCT02268929|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33770473|NCT04927039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770474|NCT02391870|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770475|NCT01714102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770476|NCT05838274|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33770477|NCT00981825|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33770478|NCT06244121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant, investigator)||t|f|t|f
33770479|NCT06393686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RANDOMIZED CONTROLLED TRIAL||||
33899461|NCT03903055|||COHORT||PROSPECTIVE|||||||
33899462|NCT05730608|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33899463|NCT05574972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899464|NCT05263843|||COHORT||PROSPECTIVE|||||||
33899465|NCT04706546|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33899466|NCT04847830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomisation for the site receiving the additional test procedure (laser) will be carried out between baseline and visit 2. The randomisation will be carried out by Postgraduate Students independent of the study. Random permuted block sizes of 4 will be employed. The centralised randomisation service 'Sealed envelope' will be used for randomisation and to ensure allocation concealment. A sealed envelope will be enclosed with the patient's notes by personnel not directly involved in the study. The therapist will only be informed about treatment allocation by opening the envelope following completion of non-surgical therapy (when the laser will need to be employed on the test site). No minimization or stratification is planned. The randomisation code will only be revealed after statistical analysis. The randomisation will be done by a different postgraduate student who will be masked and is not involved in the study.|non-surgical periodontal therapy with or without laser adjunct|t|f|t|t
33899467|NCT01274897|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33899468|NCT05126095|||COHORT||PROSPECTIVE|||||||
33899469|NCT02195648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor will be blinded to group allocation. Additionally, analysis blinding will be performed to group allocation.||f|f|t|t
33899470|NCT04063683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899471|NCT00367471|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899472|NCT04138667|NA|SINGLE_GROUP||OTHER||NONE||Patients with breast cancer related lymphedema who will undergo complex decongestive phase 1||||
33899473|NCT02964104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679622|NCT01929499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679623|NCT02895126|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679624|NCT05061043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was single blinded in which subjects were managed to be masked of treatment options available for other groups. Clinicians and assessors could not be blinded due to apparently very different procedures of two groups.||t|f|f|f
33679625|NCT01883453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679626|NCT00954096|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33679627|NCT05846607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679628|NCT01464281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679629|NCT02747472|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33679630|NCT05867979|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a single-center molecular biology pilot study on a single group of 20 patients with a disorder of sex development and inconclusive molecular diagnosis.~The 20 blood samples from patients with severe or moderate DSD, with an inconclusive diagnosis will benefit from the Optical Genome Mapping."||||
33679631|NCT02721953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679632|NCT03271645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679633|NCT00726843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679634|NCT01210040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33679635|NCT06530433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Not possible to mask participants and care provider. Outcome is assessed by a device. Analyst will be masked.|||||
33679636|NCT01906944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679637|NCT00668733|||COHORT||PROSPECTIVE|||||||
33679638|NCT02338882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679639|NCT01853488|||CASE_CONTROL||PROSPECTIVE|||||||
33679640|NCT03317054|||OTHER||PROSPECTIVE|||||||
33679641|NCT03504046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679642|NCT00892840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679643|NCT03118908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679644|NCT03400267|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial, with randomization to either paracetamol intravenously or fentanyl.||||
33679645|NCT00757328|||CASE_ONLY||RETROSPECTIVE|||||||
33679646|NCT05195983|||COHORT||PROSPECTIVE|||||||
33679647|NCT02113397|||COHORT||PROSPECTIVE|||||||
33679648|NCT04727021|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679649|NCT03390114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary investigator is blinded to the treatment assignment|10-week, randomized, controlled, single-blinded, two-arm, parallel group, pilot trial at a single center|f|f|t|f
33679650|NCT03220451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679651|NCT02975232|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33679652|NCT01267357|||CASE_CONTROL||RETROSPECTIVE|||||||
33679653|NCT04206241|||COHORT||PROSPECTIVE|||||||
33770480|NCT05138484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Each clinical record was coded by number, group and each group was assigned a color, which was stamped on the bottle of each mouthwash (bottles were of the same appearance).~The masking mechanisms through coding by number, group and color, ensured that the patients did not know the specific mouthwash they received; examiners E.A and A.N were limited only to assessing the clinical aspects; and the data analysis was performed with the database using numerical coding. Only researcher B.B was aware of the real assignment by color, with its corresponding study group and number."|"Two examiners recorded the data: sex, age, hygiene habits, systemic diseases, use of drugs and smoking.~Clinical examination and registration of clinical indexes: Basic Periodontal Examination, Gingival Bleeding Index, Bacterial plaque index.~Another investigator performed, through simple randomization, the patient's assignment to one of the three parallel study groups:~G.1 (Positive control 0.12% chlorhexidine digluconate) G.2 (Negative control vehicle mouthwash) G.3 (experimental group 10% mouthwash of M. sylvestris extract). To each patient was delivering a 150 ml bottle with the corresponding mouthwash. The indications for posology were: rinse with 10 ml of mouthwash for 1 minute in the mouth, every 12 hours for 7 days. To the follow-up of the intervention, was made telephone calls at least once a day to remember the rinse.~The re-evaluation was performed 7 days after the first appointment."|t|t|t|f
33770481|NCT04524572|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33770482|NCT04346641|||CASE_ONLY||RETROSPECTIVE|||||||
33770483|NCT01288456|||CASE_CONTROL||PROSPECTIVE|||||||
33679654|NCT03736915|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The senior author (T.O.H.P) will perform all injection, and are given three pieces of paper before ever injection, to silently give information on tumescent technique, fingers sequence, syringe-needle combinations sequence and the solution used. Subjects are seated comfortably, behind a screen with a small opening large enough to introduce the tested hand. Both hands are placed on the supine position on the table. Seating positions and hand positions are designed somewhat ergonomics and comfort, to avoid creating bias due to positional discomfort. They could not see any of the procedure and won't know which syringe-needle combinations is used.|: A randomized single-blinded controlled trial is designed for 30 adult male healthy subjects to compare the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. The injection will be SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc. Subjects are required to rate two check-point of VAS at the timing of needle puncture and just right after the completion of the infiltration. Upon the completion of each finger, the subject is also asked to give response to seri of questions regarding the procedures and their preferences. At the end of all injections, subject is asked to rate his preference of syringe and needle combination.|t|f|f|t
33679655|NCT00311584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679656|NCT01198613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33679657|NCT00756912|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33770484|NCT03122262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770485|NCT05108584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899474|NCT05394545|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A Randomized, Phase II, Open-Label Study Evaluating the Nu-V3 Cranial Nerve Stimulation Treatment Device in Patients with Chronic Pain, Anxiety, Depression, and/or Sleeplessness||||
33679658|NCT06529926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33679659|NCT01807390|||COHORT||PROSPECTIVE|||||||
33679660|NCT01317550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33679661|NCT02923921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679662|NCT02434588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679663|NCT00274833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679664|NCT02494063|||COHORT||PROSPECTIVE|||||||
33770486|NCT06241196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33770487|NCT00000342||PARALLEL||TREATMENT||DOUBLE||||||
33770488|NCT04315623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770489|NCT00250172||||TREATMENT||||||||
33770490|NCT02597933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770491|NCT02969980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770492|NCT01147211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899475|NCT04770272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899476|NCT03161418|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33899477|NCT02413983|||COHORT||PROSPECTIVE|||||||
33899478|NCT00169468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899479|NCT00764894|||COHORT||RETROSPECTIVE|||||||
33899480|NCT02142062|||COHORT||PROSPECTIVE|||||||
33899481|NCT04430530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899482|NCT06667505|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Patients, meeting the inclusion criteria of either awaiting or with a recently implanted ICD, will be invited to participate by a member of the clinical team in Belfast Health and Social care Trust (BHSCT) or Golden Jubilee National Hospital (Clydebank). If the patient is interested in participating, they will be invited to nominate a family member.~Once patients and family member / caregiver provides written informed consent will be randomly allocated to receive the intervention (Choice ICD APP and BHF booklet) or usual care."||||
33899483|NCT00000681||||TREATMENT||NONE||||||
33899484|NCT03518957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899485|NCT01526226|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33899486|NCT02896140|||COHORT||PROSPECTIVE|||||||
33899487|NCT04486521|||OTHER||PROSPECTIVE|||||||
33899488|NCT05701852|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899489|NCT02081469|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE||Tenofovir 300mg QD. Two arm: 6 month and 12 month.|f|f|t|f
34078982|NCT03262077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34078983|NCT01810224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770493|NCT05901415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A modified semi-supine position of combined anterior lumbar and lateral sacral plexus block|f|t|f|t
33770494|NCT02641951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33770495|NCT04913818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||To examine the feasibility and preliminary effect of a partnering exercise program on the health outcomes of the PwD and their family caregivers||||
33899490|NCT00446394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899491|NCT04012411|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33982639|NCT05065229|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|A computer-generated random number sequence will be obtained to determine which probe is attached to which foot. The sequence will be kept in opaque, sequentially numbered envelopes that will be opened just before the probes are attached to the feet of the participant. The clinical team nurse who will record the oxygen saturation readings will be blinded to which probe is attached to which foot by covering the feet securely after the probes have been attached. The probes will be designated as A and B. The study statistician will be blind to which probe is A and which is B until all data analyses are completed.|Parallel group, randomised study|t|t|t|t
33982640|NCT04828720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque envelope|In patients with inadequate zone of attached gingiva, treatment planned for FGGs to augment keratinized tissue dimensions in the mandibular incisor area.|f|f|f|t
33982641|NCT06035445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study uses a stepped-wedge, delayed implementation randomized clinical trial design, to measure the effectiveness of the interventions compared to standard of care.||||
33982642|NCT05371665|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33982643|NCT00902109|||COHORT||PROSPECTIVE|||||||
33982644|NCT05706337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982645|NCT01085825|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982646|NCT04526210|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34078984|NCT00614874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679665|NCT05389852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|dexmedetomidine or placebo prepared by Lausanne University Hospital Pharmacy|Patients undergoing forearm or hand surgery under supraclavicular brachial plexus block, receiving either additional intravenous dexmedetomidine or placebo|t|t|t|t
33679666|NCT02382484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679667|NCT01624246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679668|NCT02102659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679669|NCT01860729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679670|NCT00946218|||CASE_ONLY||RETROSPECTIVE|||||||
33679671|NCT04504851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679672|NCT03370705|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Multicentric open-label controlled trial||||
33679673|NCT01381562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679674|NCT02081885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899492|NCT05852210|||OTHER||CROSS_SECTIONAL|||||||
33899493|NCT05110586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899494|NCT01481246|||COHORT||PROSPECTIVE|||||||
33899495|NCT00632593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899496|NCT05221125|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33899497|NCT00941980|||COHORT||PROSPECTIVE|||||||
33899498|NCT03352856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Double-blind, cross-over, randomly allocated, placebo controlled|t|t|t|t
33679675|NCT02130102|||CASE_ONLY||PROSPECTIVE|||||||
33679676|NCT04622943|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33679677|NCT02123251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679678|NCT06491368|||COHORT||PROSPECTIVE|||||||
33679679|NCT00294762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679680|NCT03478865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679681|NCT01988701|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33679682|NCT00147550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679683|NCT00213993|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33899499|NCT04927650|||COHORT||PROSPECTIVE|||||||
33899500|NCT04591288|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All the clinical assessments will be performed by masked Physical Therapist.|"It is a randomized controlled two-treatment group clinical trial. We randomly assign subjects to either an FES-Treadmill group, a Treadmill-Only group, or a Control group. The FES-Treadmill group will undergo an FES-assisted treadmill training protocol. The Treadmill-Only group will undergo the same protocol without FES assistance. The control group will not receive treatment. Additionally, following their no-treatment period, we will randomize control group subjects into one of the two treatment groups. This design allows us greater power to identify treatment group differences while accommodating parents who might ordinarily not want their child to participate in a non-treatment group. Initially, each group will consist of 14 subjects. Following crossover, the FES-Treadmill and Treadmill-Only groups will consist of 21 subjects while the control group remains 14 subjects."|f|f|f|t
33899501|NCT01425866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899502|NCT05278793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899503|NCT01702012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899504|NCT00085969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899505|NCT05643300|||OTHER||CROSS_SECTIONAL|||||||
33982647|NCT03283254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The person administering the outcome measures is blind to participant group.|Two groups: One receives PREPP prevention intervention and the other group receives Enhanced Treatment as Usual (psychoeducation about Postpartum Depression, referral and monitoring)|f|f|f|t
33982648|NCT03705897|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33982649|NCT00206583|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982650|NCT04697745|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33982651|NCT03494322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised phase II study with safety run in||||
33679684|NCT05288062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679685|NCT06155019|||COHORT||RETROSPECTIVE|||||||
33679686|NCT00538083|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33679687|NCT03101553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33679688|NCT01762137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679689|NCT03320551|NA|SINGLE_GROUP||OTHER||NONE||||||
33679690|NCT06071429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679691|NCT00586092|NA|SINGLE_GROUP||||NONE||||||
33679692|NCT02603666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679693|NCT05246865|RANDOMIZED|PARALLEL||OTHER||NONE||A prospective human in-vivo physiology study||||
33679694|NCT01741402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679695|NCT05037435|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective randomized double-blind placebo-controllable.|t|f|t|f
33679696|NCT02208687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679697|NCT00091325||||PREVENTION||NONE||||||
33770496|NCT02476097|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33899506|NCT02481765|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||HD-tDCS (High definition transcranial direct current stimulation)||||
33899507|NCT00144300|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33899508|NCT00350064|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33899509|NCT03551028|NA|SINGLE_GROUP||SCREENING||NONE||||||
33770497|NCT01033786|||COHORT||RETROSPECTIVE|||||||
33770498|NCT01934400|||CASE_ONLY||PROSPECTIVE|||||||
33770499|NCT01568827|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33770500|NCT04726475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770501|NCT06309095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770502|NCT01168674|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33679698|NCT03467685|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Subjects will be asked to close their eyes prior to the vibration anesthetic device (VAD) being applied to their skin. Only the user will know whether the VAD will be on or off based on the result of a random number generator. This will prevent anticipatory changes on the subjects side. The subject will be aware of the intervention after the device is turned on or left in the off position.|"Subjects will be randomly assigned into one of two groups:~Group 1: Vibratory anesthetic device (VAD) is in the OFF mode Group 2: VAD is in the ON mode~We will use a random number generator to place patients into one of the two groups."|t|f|f|f
33679699|NCT06432283|||COHORT||PROSPECTIVE|||||||
33679700|NCT00948220|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33679701|NCT04644315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679702|NCT00779259|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770503|NCT02864043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770504|NCT02054078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770505|NCT02435771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982652|NCT04107454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is designed as a randomized placebo-controlled study|t|f|f|f
33982653|NCT05451446|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blind participants. They will not be told which group they are randomized to.|Between subjects, single-blind|t|f|f|f
33982654|NCT00025896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982655|NCT02841488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982656|NCT05325047|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33982657|NCT05856903|||CASE_ONLY||PROSPECTIVE|||||||
33982658|NCT00581646|||CASE_ONLY||PROSPECTIVE|||||||
33982659|NCT00488748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982660|NCT05566015|NA|SINGLE_GROUP||OTHER||NONE||||||
33982661|NCT04549584|||COHORT||PROSPECTIVE|||||||
33982662|NCT04136899|||COHORT||CROSS_SECTIONAL|||||||
33679703|NCT02433028|||COHORT||PROSPECTIVE|||||||
33679704|NCT05929573|||COHORT||PROSPECTIVE|||||||
33679705|NCT05030285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to what arm the participant is allocated to.|Participants will be randomised (1:1 ratio) to either the Tele-CBT intervention or usual care (Control) arm.|f|f|f|t
33770506|NCT02501759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770507|NCT03136796|||COHORT||PROSPECTIVE|||||||
33770508|NCT01194882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770509|NCT00651443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982663|NCT03415997|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33982664|NCT03094312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982665|NCT04138732|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33982666|NCT01822548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679706|NCT01916291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679707|NCT00995566|||COHORT||PROSPECTIVE|||||||
33679708|NCT00763503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679709|NCT03254459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679710|NCT02116530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33679711|NCT04140760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Study is double blind design||t|f|t|f
33679712|NCT00934648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679713|NCT02220088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679714|NCT04314791|||COHORT||PROSPECTIVE|||||||
33770510|NCT05630664|||COHORT||PROSPECTIVE|||||||
33770511|NCT03923218|||OTHER||CROSS_SECTIONAL|||||||
33770512|NCT03435601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770513|NCT03132623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770514|NCT03606941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33770515|NCT02443662|||CASE_ONLY||PROSPECTIVE|||||||
33770516|NCT05677737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33770517|NCT03319186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770518|NCT02415686|||CASE_CONTROL||PROSPECTIVE|||||||
33770519|NCT03204695|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770520|NCT05540093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|permuted block randomization|high power pain threshold ultrasound and traditional therapy|f|f|f|t
33770521|NCT04213586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33770522|NCT02171182|||COHORT||PROSPECTIVE|||||||
33982667|NCT01798212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899510|NCT06457438|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking will be used in the study.|The study subjects and their samples will be divided into two study groups.||||
33899511|NCT02202603|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33899512|NCT01858883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899513|NCT01483846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899514|NCT00249262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899515|NCT04744415|||COHORT||OTHER|||||||
33899516|NCT05916638|||COHORT||PROSPECTIVE|||||||
33899517|NCT01791439|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33899518|NCT06513598|||COHORT||PROSPECTIVE|||||||
33899519|NCT03143595|||COHORT||PROSPECTIVE|||||||
33899520|NCT03584802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899521|NCT06329453|||COHORT||PROSPECTIVE|||||||
33899522|NCT05447962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899523|NCT00377299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899524|NCT04061707|||COHORT||PROSPECTIVE|||||||
33899525|NCT03378206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899526|NCT04354025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899527|NCT05864040|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33899528|NCT00744367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899529|NCT00243893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899530|NCT04797975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899531|NCT01364610|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33899532|NCT05450861|RANDOMIZED|PARALLEL||OTHER||SINGLE|using scalp conditioning solution without target composition||t|f|f|f
33899533|NCT06246825|||COHORT||PROSPECTIVE|||||||
33899534|NCT04704765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Using an experimental randomized controlled trial approach. The experimental group receiving abdominal breathing training, and control group without training. The effectiveness assessment used the Beck anxiety inventory, required to be completed by both the experimental group and control group. This study performed the pre-and-post assessments. This study performed the pre-test before the implementation of abdominal breathing training, and performed the post-test at Week 4 and Week 8 the end of abdominal breathing training.||||
33899535|NCT03307447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899536|NCT04096937|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33899537|NCT04735900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899538|NCT06658808|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will have a stepped wedge design with 3 cycles of implementation (in successive years) across 9-12 villages total, depending on need and feasibility to achieve our needs. In each village, we will collect baseline data and follow-up data on knowledge, attitudes, and behavior related to suicide prevention from participants and non-participants. Participants will also provide data on these topics after each learning circle they attend and non-participants will be given a monthly survey each month for 5 months as the learning circles occur. Intervention participants will be self-selecting.||||
33899539|NCT00215501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899540|NCT04568174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The SAD phase is open label and MAD is randomized, dose escalation, double blind (patient and investigator blinded), placebo-controlled|Single Group in SAD and parallel in MAD|t|f|t|t
33899541|NCT02617121|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33899542|NCT04237051|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33899543|NCT05484986|||OTHER||CROSS_SECTIONAL|||||||
33899544|NCT02688010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33899545|NCT02102230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899546|NCT01563510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899547|NCT00875420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899548|NCT03401489|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33899549|NCT04159727|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33899550|NCT04170621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899551|NCT04835272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899552|NCT03618225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899553|NCT06085391|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33899554|NCT00720707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899555|NCT05488301|||COHORT||PROSPECTIVE|||||||
33899556|NCT01094899|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33899557|NCT04260724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899558|NCT00878228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770523|NCT02055703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770524|NCT06117748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33770525|NCT00933842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770526|NCT03696277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899559|NCT05082870|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Research Coordinator and Statistician analyzing the data will be blinded to group allocation.||f|f|f|t
33899560|NCT02328716|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33899561|NCT03825042|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study treatment was assigned through envelopes randomization system: the site was provided with sealed envelopes, numbered in progressive number starting from R-001, containing the treatment kit to be assigned to the subject. The Investigator will open the first available envelope in progressive order. Inside the envelope there will be the kit number of the treatment to be assigned to that subject.|9-weeks double-blind, randomized, placebo-controlled, parallel-arm superiority study|t|t|t|t
33899562|NCT04002323|||OTHER||PROSPECTIVE|||||||
33899563|NCT01416610|||COHORT||PROSPECTIVE|||||||
33899564|NCT03611140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PD and placebo interventions were packaged identically in appearance, both the researcher and the participant did not know what type of maneuver was assigned. The packages were distributed by a person outside the study who was the same person who performed the randomization|In the first stage, the participants with metabolic syndrome consumed a reduced-energy diet tailored to provide a 500 kcal/d deficit as recommended by NIH with respect to their habitual diet for 15 days. In the second stage, the participants continued to consume the reduced energy diet with the addition of a combination of functional foods (dietary portfolio; DP). The DP provided 200 kcal that were subtracted from the diet. The kcal, appearance, and flavor were similar in DP and P. The DP and P were given in a package in a dehydrated form ready to be dissolved in water. The DP was divided into two packages, the first package contained 30 g of DP o P given in the breakfast and dissolved in 250ml and the second package was given at the dinner time and contained 30 g of P and DP dissolved in 250 mL of water.|t|f|t|f
33899565|NCT01373554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982668|NCT04752462|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33982669|NCT03581422|||CASE_CONTROL||RETROSPECTIVE|||||||
33982670|NCT02357186|||COHORT||PROSPECTIVE|||||||
33982671|NCT00735904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982672|NCT03938922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982673|NCT03546842|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33982674|NCT04048369|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33982675|NCT02376348|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33982676|NCT02011776|||CASE_CONTROL||PROSPECTIVE|||||||
33982677|NCT04737200|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34078985|NCT04212767|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, parallel-arm, randomized controlled trial||||
34078986|NCT02147613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770527|NCT01474447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770528|NCT05723848|||COHORT||PROSPECTIVE|||||||
33770529|NCT02493218|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33770530|NCT02193802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770531|NCT01533714|NA|SINGLE_GROUP||TREATMENT||NONE||RA0089 is a single arm study, however, analysis will also be performed according to the original treatment arms of the parent study NCT01463059 (RA0083).||||
33770532|NCT00313911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770533|NCT04908124|RANDOMIZED|PARALLEL||PREVENTION||NONE||The personal lubricants will be tested in a 5-arm parallel-design, where subjects will be randomised to an arm/lubricant. This follows an initial tolerance phase conducted in a sub-set of the population which will be tested in a 5-arm parrallel design,where subjects will be randomised to an arm/lubricant. Note: subjects participating in the both the tolerability and treatment phases will be enrolled into an arm for each which includes the same IP/lubricant throughout both phases.||||
33770534|NCT03069560|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770535|NCT02500875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770536|NCT01003184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770537|NCT06114563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|f|t
33770538|NCT05938725|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770539|NCT00255697|||COHORT||CROSS_SECTIONAL|||||||
33770540|NCT02875561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770541|NCT03655522|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||This was a double-blind, placebo-controlled, randomized, single ascending dose, sequential group study. Each subject participated in only 1 treatment period.|t|f|t|f
33982678|NCT06222749|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Neither participants nor investigators will know at which time point the participant will receive intranasal oxytocin and placebo. The nasal sprays will be prepared by independent members of the university hospital Tübingen.|The investigators will assess the effects of oxytocin administration on reward processing and metabolism using a double-blind randomized cross-over design. In a within subject design, participants will get receive both oxytocin and placebo (both conditions) at different time points (approximately 4 weeks apart). After drug/placebo administration we will assess cerebral blood flow and functional connectivity at rest (via functional magnetic resonance imaging (fMRI)) during an effort-based decision-making task.|t|f|t|t
33982679|NCT02192047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33982680|NCT03482427|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will test our intervention compared to usual care (control)||||
33982681|NCT01374919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982682|NCT02539589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982683|NCT01264120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982684|NCT00001748||||TREATMENT||||||||
33982685|NCT05788861|||CASE_ONLY||PROSPECTIVE|||||||
33982686|NCT03608215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||active, sham|t|f|t|t
33982687|NCT01220076|NA|SINGLE_GROUP||SCREENING||NONE||||||
33982688|NCT00242021|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33679715|NCT05638789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|66 patients with CBD stone will be divided into two groups which is Group A(EST+EPLBD) (33 cases) and Group B (EST alone) (33 cases). Randomization will be done using computer software for sequence generation and was stratified with 1:1 allocation using random block sizes of 6 and 8 to Group A or Group B. The allocation concealment mechanism was developed by preparing 88 sealed and opaque envelopes. Each envelop contain one allocation sequence which is generated by computer software. Data collection officer will randomly open one of the envelop each time one patient recruited and will need to follow the allocation sequences inside the envelop in order to determine whether the patient to be Group A or Group B patient. This is single blinded study whereby the participant is blinded but the endoscopist is not blinded.|EST alone versus EST + EPLBD group|t|f|f|f
33679716|NCT05554562|||COHORT||PROSPECTIVE|||||||
33679717|NCT03360864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679718|NCT05853003|||OTHER||CROSS_SECTIONAL|||||||
33679719|NCT05070780|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33679720|NCT01394640|||COHORT||PROSPECTIVE|||||||
33679721|NCT02619539|||COHORT||PROSPECTIVE|||||||
33679722|NCT00060359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679723|NCT02114658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679724|NCT05414734|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33679725|NCT00097149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679726|NCT04160975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33679727|NCT06255197|||COHORT||OTHER|||||||
33679728|NCT00985920|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33679729|NCT03658876|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33679730|NCT04120298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679731|NCT04144127|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33679732|NCT00988650|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33679733|NCT01529775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679734|NCT05392413|||CASE_ONLY||PROSPECTIVE|||||||
33679735|NCT01944280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33679736|NCT05365685|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33679737|NCT04671446|||CASE_CONTROL||PROSPECTIVE|||||||
33679738|NCT02537288|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33679739|NCT03031002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679740|NCT04732390|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33679741|NCT01879644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679742|NCT00491088|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33679743|NCT01757158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679744|NCT01811056|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679745|NCT01191567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679746|NCT04359381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent person randomly assigned to all participated subjects to either group (A) (n=30) or group (B) (n=30) by chosen numbers from closed envelopes having numbers that the number generator were chosen randomly.|The study was designed as a randomized controlled trial.|f|f|t|f
33679747|NCT03584581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679748|NCT00361933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679749|NCT04263584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770542|NCT04328818|||COHORT||PROSPECTIVE|||||||
33770543|NCT05050214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982689|NCT04721652|||CASE_ONLY||PROSPECTIVE|||||||
33982690|NCT01434121|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33679750|NCT03010371|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The current clinical trial is a sequential RCT. In the first stage, it compares the effectiveness of the Positive Psychotherapy for Cancer with one of the most proved Cognitive-Behavioral Psychotherapies in Cancer, which is the Cognitive Behavioral Stress Management (CBSM). In the other stage, the common presential version of the Positive Psychotherapy is compared with its online version.|f|t|t|t
33982691|NCT05193279|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982692|NCT02602925|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled non-inferiority study||||
33982693|NCT04675580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33982694|NCT02492568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982695|NCT01450085|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33982696|NCT04509180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982697|NCT01806805|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33982698|NCT04109521|RANDOMIZED|PARALLEL||OTHER||NONE|Due to the nature of the intervention, it will not be possible to mask allocation to the researchers and the participants. Masking will only be done at analysis stage, meaning that analysis will be done without revealing group allocation (A/B) and by someone who is not knowledgeable about the allocation of clusters to treatment or control. Masking will only be broken after the primary analyses have been completed.|"A two-arm cluster-randomized, non-masked, community-based trial will be used to estimate the effectiveness of the MoreMilk intervention. A baseline and an endline survey will be done for each arm with 12 months in between; the same vendors and households will be surveyed at baseline and endline.~The unit of randomization is a cluster of 1 to 5 vendors and the households consuming milk from those vendors. Study clusters will be randomly assigned to one of two arms: (1) Treatment arm: Training, certification, and marketing scheme for milk vendors; (2) Control arm: Delayed intervention (implemented after endline survey)."||||
33982699|NCT01823965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982700|NCT04271826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679751|NCT02970682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982701|NCT03142360|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment group is randomly assigned to start taking 120 mcg of Berasil. On the other hand, the control group does not take anything.||||
33982702|NCT04489264|||COHORT||PROSPECTIVE|||||||
33982703|NCT00002549|RANDOMIZED|||TREATMENT||||||||
33982704|NCT02171793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33679752|NCT04655196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770544|NCT00231270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770545|NCT01141335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33770546|NCT05022602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770547|NCT06194253|||COHORT||RETROSPECTIVE|||||||
33770548|NCT05314556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770549|NCT01582880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770550|NCT01373710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770551|NCT05225402|||OTHER||PROSPECTIVE|||||||
33770552|NCT00274170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770553|NCT03758820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|randomization of patients|parallel group assignment|t|f|f|f
33770554|NCT02165904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770555|NCT05200936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33770556|NCT05917951|||COHORT||OTHER|||||||
33770557|NCT02374593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982705|NCT04949932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770558|NCT05903690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770559|NCT00925782|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982706|NCT03310190|||COHORT||PROSPECTIVE|||||||
33770560|NCT05392387|||COHORT||PROSPECTIVE|||||||
33770561|NCT00363896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899566|NCT03313024|||COHORT||PROSPECTIVE|||||||
33899567|NCT02137551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899568|NCT05129839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899569|NCT02355912|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33899570|NCT02696746|||COHORT||CROSS_SECTIONAL|||||||
33899571|NCT00045838||||TREATMENT||||||||
33899572|NCT03976401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899573|NCT01898312|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33899574|NCT00477451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899575|NCT02519764|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33899576|NCT06668428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The research will be conducted as a two-group, parallel, randomized, controlled experimental study with a pretest-posttest design.|t|f|f|t
33899577|NCT03163030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899578|NCT02596880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899579|NCT01790061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899580|NCT03114618|||COHORT||PROSPECTIVE|||||||
33899581|NCT04760132|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The design is an open-labelled, non-randomised, parallel group, phase IV study with historical controls.||||
33899582|NCT06375798|||COHORT||PROSPECTIVE|||||||
33899583|NCT05253807|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants enrolled in this study will be assigned to 1 of 2 cohorts: Cohort A (squamous NSCLC) will enroll approximately 100 participants, and Cohort B (nonsquamous NSCLC) will enroll approximately 25 participants.||||
33899584|NCT03442127|NA|SINGLE_GROUP||OTHER||NONE||||||
33899585|NCT02893254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899586|NCT03328611|||COHORT||PROSPECTIVE|||||||
33899587|NCT02796989|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33899588|NCT06485544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899589|NCT04052958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33899590|NCT00669773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899591|NCT04204681|||CASE_CONTROL||PROSPECTIVE|||||||
33899592|NCT00953121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899593|NCT03438422|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33899594|NCT02955186|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33679753|NCT04863183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Center for Advanced Therapies will send a pre-filled syringe with the 5 cc of solution without any difference in its external appearance, regardless of the content, according to the previously randomization.|Controlled, randomized, double-blind clinical trial comparing CELLISTEM-OA and active comparator (triamcinolone acetonide).|t|t|t|f
33679754|NCT00859027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, placebo controlled trial.|t|f|t|f
33679755|NCT00732940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679756|NCT04554056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33679757|NCT02909387|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33679758|NCT04248621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679759|NCT02346773|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33679760|NCT00505778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33679761|NCT00955305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679762|NCT04405466|||COHORT||PROSPECTIVE|||||||
33679763|NCT02300636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679764|NCT06278428|||CASE_ONLY||PROSPECTIVE|||||||
33770562|NCT03623932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective study, monocentric, controlled, randomized, open-label||||
33770563|NCT01842087|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33770564|NCT04152785|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33770565|NCT04055168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982707|NCT03480425|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982708|NCT02183688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982709|NCT00175617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982710|NCT04901962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982711|NCT06077526|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon recruitment and completion of informed consent, participants will be randomly assigned following a stratified randomization schedule to either Group A or B using online randomization software. A stratified randomization schedule was selected to balance the group assignments based on the covariate of sex. A team member who will have no contact with participants will obtain and employ the randomization schedule.||||
33982712|NCT04659798|||COHORT||PROSPECTIVE|||||||
33679765|NCT04260139|||COHORT||PROSPECTIVE|||||||
33679766|NCT02767297|NON_RANDOMIZED|PARALLEL||||NONE||||||
33679767|NCT00287417|||CASE_ONLY||PROSPECTIVE|||||||
33679768|NCT03002467|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33679769|NCT04294056|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679770|NCT03069521|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33679771|NCT04735640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679772|NCT05330884|RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-inferiority randomised trial||||
33679773|NCT00824733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679774|NCT03157700|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Factorial design in which participants are randomly assigned to treatment and control groups. The control is a delayed intervention condition, receiving the intervention after the treatment condition is completed.||||
33679775|NCT06356428|||OTHER||PROSPECTIVE|||||||
33679776|NCT00748852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679777|NCT05035602|||COHORT||RETROSPECTIVE|||||||
33679778|NCT01534858|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679779|NCT01956344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33679780|NCT01295879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679781|NCT01104532|RANDOMIZED|CROSSOVER||||NONE||||||
33770566|NCT01713790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770567|NCT00861926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770568|NCT00556374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33770569|NCT03784352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33770570|NCT00631384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33839458|NCT04563039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a double blinded study in which study subjects will not be informed of their treatment allocation through the index procedure. In assessing stone fragmentation using a CT image as defined in the primary endpoint, an independent radiologist will conduct the assessment and will be blinded to the treatment allocation of each subject's CT image.|t|f|f|t
33839459|NCT00293189|||CASE_CONTROL||PROSPECTIVE|||||||
33839460|NCT06390527|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839461|NCT02319473|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33839462|NCT03880253|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33839463|NCT00725335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839464|NCT03004053|||COHORT||PROSPECTIVE|||||||
33839465|NCT01435772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839466|NCT03442946|||OTHER||RETROSPECTIVE|||||||
33839467|NCT02405598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839468|NCT03462862|RANDOMIZED|PARALLEL||OTHER||TRIPLE||2 parallel groups one group will receive RPD with PEEK denture base and the other will get Bre Flex denture base material|t|t|f|t
33839469|NCT00012493|||DEFINED_POPULATION||PROSPECTIVE|||||||
33839470|NCT06533319|NA|SINGLE_GROUP||TREATMENT||NONE|All study components will be blind to individuals in charge of the study, with the exception of the prescribing clinician and primary investigator.|Multi-site, prospective cohort study at Idaho county jails with quantitative methods and survey.||||
33839471|NCT01285700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839472|NCT04343976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||t|f|f|f
33839473|NCT03019640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839474|NCT04385706|NA|SINGLE_GROUP||TREATMENT||NONE||One group pre-test post-test design to evaluate a coaching model||||
33839475|NCT00487955|||DEFINED_POPULATION||OTHER|||||||
33839476|NCT02944929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33839477|NCT04265326|||OTHER||PROSPECTIVE|||||||
33839478|NCT01640639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839479|NCT04142268|||CASE_CONTROL||PROSPECTIVE|||||||
33839480|NCT04589728|||CASE_ONLY||OTHER|||||||
33839481|NCT02833597|||COHORT||RETROSPECTIVE|||||||
33982713|NCT04836000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Randomized|t|f|f|t
33982714|NCT04142970|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33982715|NCT01598701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33982716|NCT02456779|||CASE_CONTROL||PROSPECTIVE|||||||
33679782|NCT03330392|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33679783|NCT06251401|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33679784|NCT04136119|||OTHER||PROSPECTIVE|||||||
33770571|NCT04386590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will evaluate a de-identified database with the interventions labeled as 1 and 2.|Twenty Veterans between the ages of 50 and 70 years with moderate COPD, will be randomly allocated to two equal groups. Group 1: 'sham' manual therapy plus pulmonary rehabilitation program; Group 2: Chiropractic manual therapy group plus the same pulmonary rehabilitation program (CMT+PR). Participants in both groups will undergo 8 treatment sessions over a 4 week period plus an additional assessment session at week 8. All sham manual therapy and CMT will be delivered just prior to pulmonary rehabilitation.|f|f|f|t
33770572|NCT02840396|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33770573|NCT03820167|||CASE_CONTROL||PROSPECTIVE|||||||
33770574|NCT03051490|RANDOMIZED|PARALLEL||TREATMENT||NONE|unblinded to treatment randomization; blinded to primary efficacy variable|||||
33770575|NCT01404611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770576|NCT05078346|||COHORT||PROSPECTIVE|||||||
33770577|NCT05593211|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition.||||
33770578|NCT04690374|||COHORT||OTHER|||||||
33770579|NCT05206864|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33770580|NCT01321398|||COHORT||PROSPECTIVE|||||||
33770581|NCT02786173|||COHORT||PROSPECTIVE|||||||
33770582|NCT05990413|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33770583|NCT04547426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|We use non-alcoholic or alcohol containing wine and regular or nicotine free snuff||t|f|f|f
33770584|NCT01426490|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33770585|NCT01053637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770586|NCT03056859|||CASE_ONLY||PROSPECTIVE|||||||
33899595|NCT01145105|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33899596|NCT04612764|||OTHER||CROSS_SECTIONAL|||||||
33899597|NCT04149522|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||2 study arms - 20 women to receive Mepitel film on medial aspect of breast, 20 women to receive Mepitel film on lateral aspect of breast||||
33899598|NCT06428760|||COHORT||PROSPECTIVE|||||||
33899599|NCT03467022|||OTHER||PROSPECTIVE|||||||
33899600|NCT05336773|||COHORT||RETROSPECTIVE|||||||
33899601|NCT05195879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33679785|NCT03582709|||COHORT||PROSPECTIVE|||||||
33770587|NCT01634958|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33770588|NCT05955521|NA|SINGLE_GROUP||SCREENING||NONE||||||
33770589|NCT05312437|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Those randomized to intervention arm will have the intervention BPA prompt. Those randomized to the control arm will not have an associated BPA prompt. Risk predictions for all participants in study settings will be visible in eStar flowsheets for equipoise.||t|f|f|f
33770590|NCT01971606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33770591|NCT03162757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770592|NCT05044975|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33839482|NCT04115072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839483|NCT02084199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839484|NCT02493062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839485|NCT00747240|||COHORT||PROSPECTIVE|||||||
33839486|NCT02395731|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33839487|NCT00249938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839488|NCT03729427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839489|NCT05212753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839490|NCT04043897|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with a diagnosis of microscopic colitis will receive open-label rifaximin 550mg tid x 4 weeks.||||
33839491|NCT04238013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33839492|NCT06203353|||COHORT||PROSPECTIVE|||||||
33839493|NCT02028325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839494|NCT04792177|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups for the duration of the study. 50% of participants will be assigned to the intervention group while the other 50% will be assign to a waitlist control condition. The waitlist group will have access to the intervention after 6 months.||||
33899602|NCT00211822|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899603|NCT04665544|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899604|NCT00723658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899605|NCT01395485|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33899606|NCT00893789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899607|NCT03787433|||COHORT||PROSPECTIVE|||||||
33899608|NCT05114889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899609|NCT02049528|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33899610|NCT05785338|||COHORT||RETROSPECTIVE|||||||
33899611|NCT01694654|||COHORT||RETROSPECTIVE|||||||
33899612|NCT00463970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899613|NCT03505242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899614|NCT04374656|||COHORT||PROSPECTIVE|||||||
33899615|NCT04730323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899616|NCT02011022|NON_RANDOMIZED|PARALLEL||||NONE||||||
33899617|NCT02242539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899618|NCT01525394|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33982717|NCT00073060|||CASE_CONTROL||PROSPECTIVE|||||||
33982718|NCT01239121|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33679786|NCT03972891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"An independent biometrician created forty envelopes (i.e., 20 blue and 20 white envelopes) for group allocation. Each envelope was filled with the group assignment (intervention break or continuous therapy) and signed by the biometrician. White envelopes will only be used when all blue envelopes are opened to ensure that 20 group-balanced children can be used for interims analysis. Each envelope pack (white \& blue) consisted of 10 intervention (therapy break) and control (continuous therapy) groups. The group allocation take place after inclusion of the child in the study. The non-transparent envelope is randomly drawn and opened by the speech therapist. The randomisation result, the name of the child and the date of the assignment will be documented in the case report form (CRF). The CRFs and the envelop will be handed over to the study director at regular intervals, whereby the biometrician is not informed about the allocation of the study."|Study Design: randomized control trial, single-blinded Time Perspective: prospective|t|t|f|t
33679787|NCT03900689|||COHORT||PROSPECTIVE|||||||
33679788|NCT03063047|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33679789|NCT02338570|NA|SINGLE_GROUP||OTHER||NONE||||||
33679790|NCT00613912|||CASE_ONLY||PROSPECTIVE|||||||
33679791|NCT01557634|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679792|NCT02578576|||CASE_CONTROL||PROSPECTIVE|||||||
33679793|NCT05107752|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||All participants receive cognitive processing therapy during weeks 1 and 2. Participants will be randomly allocated to receive SGB during or 3 months after CPT.|f|f|f|t
33679794|NCT04182464|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The use of identical capsules will allow the blinding, the capsules will be deposited in bottles numbered sequentially according to the enrollment process and neither the participants nor the researches will know the content of the capsules or the group assigned.|Triple-blind, parallel, placebo-controlled, randomized clinical trial.|t|t|t|t
33679795|NCT02476656|||COHORT||PROSPECTIVE|||||||
33679796|NCT01809587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679797|NCT00001012||||TREATMENT||NONE||||||
33679798|NCT00566202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33679799|NCT04532580|||CASE_CONTROL||RETROSPECTIVE|||||||
33679800|NCT00305929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679801|NCT04475198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33679802|NCT04810689|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Study participants will be randomized to 1 of 2 arms: XFBD granules or placebo|t|f|t|t
33679803|NCT01795768|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679804|NCT05919706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was conducted as a randomized controlled experimental study with pretest-posttest-follow-up test.||||
33679805|NCT01261780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33679806|NCT05887778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679807|NCT05668988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679808|NCT02979860|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33679809|NCT00701402|||COHORT||CROSS_SECTIONAL|||||||
33679810|NCT03800017|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33679811|NCT01127789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679812|NCT02495571|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679813|NCT01054833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679814|NCT03007810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679815|NCT02432352|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33679816|NCT02908542|||COHORT||OTHER|||||||
33679817|NCT00943449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679818|NCT01816945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679819|NCT05787600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The products will be packaged in such a way that they are not recognizable neither by the operator, nor by the patient. Each package will be assigned a number that in turn will refer to the type of the product. The association between the number and type of the product will be collected by another operator according to the association carried out by a dedicated software. The operator who will deliver the product will be informed about the type only at the end of the treatment.|54 subjects with plaque induced gingivitis, caused by accumulation of plaque, will be selected and enrolled in this study. Subsequently, subjects will be equally divided and randomly allocated for three groups, each group received a similar number of subjects (n=18) with a 1:1:1 allocation.|t|f|t|f
33679820|NCT06298942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679821|NCT00781573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679822|NCT03007004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679823|NCT06453434|||OTHER||PROSPECTIVE|||||||
33679824|NCT03444480|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33679825|NCT00129662|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33839495|NCT05230953|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective intervention study, to test the effect of a 4th dose, by comparing the immune response before and after the 4th dose, given to 150-200 volunteers, as well as comparing their responses with (1) a control group of individuals vaccinated with 3 doses but without the 4th. (2) a similar group vaccinated with BNT162b2 as a 4th dose||||
33839496|NCT04043143|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigators will use an electronic randomization scheme created so that the principal investigator and statistician can remain blind to assignment.|The investigators will test this tool prospectively for Cesarean section patients anticipated to use about half or less of the usually prescribed amount of opioid pain pills randomized equally to prescription tool intervention or no intervention (prescription as usual).|t|f|t|f
33982719|NCT02360462|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33839497|NCT05083845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839498|NCT04196634|||COHORT||PROSPECTIVE|||||||
33839499|NCT01598077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839500|NCT04127097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839501|NCT06310889|||COHORT||PROSPECTIVE|||||||
33839502|NCT00135473|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33982720|NCT02683967|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33679826|NCT05094518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The intervention group cluster will use the HERA application to receive appointment reminders. The Informed and Non-Informed Control groups will not be using the HERA application.||||
33679827|NCT02660138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679828|NCT00949494|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33679829|NCT01877876|||||PROSPECTIVE|||||||
33679830|NCT04277806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The randomized allocation was concealed in double-enclosed, opaque, sealed and sequentially numbered envelops and opened when the infant was found to be eligible by the neonatal team in the NICU.|Randomized controlled study. Standard group: old protocol. Intervention group: New protocol.|t|f|f|t
33982721|NCT05979779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a Phase 2, randomized, parallel-group, placebo-controlled, double-blind study where subjects will be randomized to one of 3 HU6 dose levels or placebo.|t|t|t|t
33982722|NCT04583852|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33982723|NCT05286593|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"All participants will receive a standard high flow rate weight based bolus of Rb-82 and a low flow rate weight based infusion of Rb-82. The bolus and infusion doses will be administered randomly at rest and stress however the bolus is considered the gold standard.~In addition, under resting conditions, participants will also receive a third dose of Rb-82 that is either a bolus or low flow rate (assigned randomly)."||||
33982724|NCT05470556|||COHORT||CROSS_SECTIONAL|||||||
33679831|NCT01671579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679832|NCT00575341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679833|NCT00154323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679834|NCT01937429|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33679835|NCT04955600|||FAMILY_BASED||PROSPECTIVE|||||||
33679836|NCT00995033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679837|NCT02358291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679838|NCT03755544|||COHORT||PROSPECTIVE|||||||
33679839|NCT03176537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo|"Placebo and TRT groups"|t|t|t|t
33679840|NCT05187273|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33679841|NCT00966875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679842|NCT05948865|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33679843|NCT05941871|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this trial blinding of experimenters will not be possible as they will have to administer the chronotype diet in the intervention group|Randomised and controlled trial with 2 arms of intervention||||
33679844|NCT01128764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679845|NCT05563870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679846|NCT03935568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679847|NCT00685009|||CASE_CONTROL||PROSPECTIVE|||||||
33679848|NCT00002671||||TREATMENT||||||||
33679849|NCT06007807|||COHORT||OTHER|||||||
33679850|NCT03835416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Those responsible for outcomes assessment will be blinded from group treatment arm to every extent possible.|Two-armed Randomized Controlled Trial. Control group follows RDA-level (0.8 g/kg bw/d)protein weight loss diet. Protein follows higher protein (1.2 g/kg bw/d) weight loss diet with balanced protein at each meal.|f|f|f|t
33839503|NCT02840578|||COHORT||PROSPECTIVE|||||||
33839504|NCT04239599|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a randomized Radiation trial|||||
33839505|NCT03695484|||CASE_CONTROL||PROSPECTIVE|||||||
33839506|NCT00004572|||DEFINED_POPULATION|||||||||
33839507|NCT01110408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839508|NCT04850664|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Evon Medics will perform randomization of participants stratified by sex at site level. Site staff and participants will be blinded to treatment assignment.|t|t|t|t
33839509|NCT06007196|||OTHER||PROSPECTIVE|||||||
33839510|NCT02756533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33839511|NCT03330145|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33839512|NCT05908552|||OTHER||PROSPECTIVE|||||||
33839513|NCT05610124|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|True double blinding is not feasible in these study designs. Inherent differences in taste, smell, look and preparation of the various treatments are conspicuous and thus not possible to double-blind. This study is an ad libitum study to simulate a mealtime at home.|"Study Design:~The experiment follows a randomized, cross-over, repeated measures acute trial design."|t|f|f|f
33839514|NCT04732351|||CASE_CONTROL||PROSPECTIVE|||||||
33839515|NCT04689945|||COHORT||PROSPECTIVE|||||||
33839516|NCT05564000|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The principal investigator (outcomes assessor) does not know who participate in this study.|experimental and control group|f|f|f|t
33839517|NCT01368471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839518|NCT02209753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839519|NCT00448526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839520|NCT03462004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33770593|NCT06339125|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||An observational cohort, mixed-methods study design will be conducted to determine the impact and effectiveness of usual care and three different fall prevention strategies that exceed the standard of care on three inpatient units at MGH over one year. Unit 1 will employ streaming analytics and the MGH algorithm only, Unit 2 will employee Inspiren's AUGI computer visualization only and Unit 3 will employ the combined streaming analytic/MGH algorithm and Inspiren's AUGI device. Unit 4, the control unit, will serve as an internal comparison group from the same institution. In addition to the study interventions all four units will continue to maintain usual MGH evidence-based practice, standards of care for fall prevention.||||
33770594|NCT02787200|||||CROSS_SECTIONAL|||||||
33770595|NCT02111213|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The primary study design (involving 245 randomized participants) was a 2-arm non-inferiority randomized trial comparing the effects of physical activity advice delivered by human advisors vs. a computer-based advisor|f|f|f|t
33770596|NCT02319343|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33770597|NCT03656458|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor was not aware regarding the allocation of participants to study groups.||f|f|f|t
33770598|NCT01003639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770599|NCT02530138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770600|NCT00462436|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33770601|NCT01148342|RANDOMIZED|CROSSOVER||OTHER||||||||
33770602|NCT06476795|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||We will use a two-arm escalation design||||
33770603|NCT02979626|||COHORT||CROSS_SECTIONAL|||||||
33770604|NCT00827151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770605|NCT02625194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33770606|NCT04831008|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33770607|NCT02934360|||COHORT||PROSPECTIVE|||||||
33770608|NCT03019120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770609|NCT01636375|||CASE_CONTROL||PROSPECTIVE|||||||
33770610|NCT03906513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770611|NCT01916499|||CASE_ONLY||PROSPECTIVE|||||||
33770612|NCT00974636|RANDOMIZED|CROSSOVER||||NONE||||||
33770613|NCT06459791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Methodology: RIPH 1, Phase II, multi-center, single-arm, non-randomized study||||
33770614|NCT03535051|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||A total of 152 lesions in different areas of the body were evaluated in the study. Seventy six lesions received the combination treatment and 76 received topical tacrolimus alone. Forty six lesions were in the head and neck region, 40 were acral in location, 36 were in the upper and lower limbs, 22 lesions were over bony prominences and 8 lesions were present on the trunk.|t|f|f|f
33770615|NCT01805193|||COHORT||CROSS_SECTIONAL|||||||
33770616|NCT00464035|RANDOMIZED|CROSSOVER||||NONE||||||
33770617|NCT06386081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment will be blinded to the participants and research team.||t|f|t|t
33770618|NCT03051126|||COHORT||PROSPECTIVE|||||||
33770619|NCT00505726|||CASE_ONLY||PROSPECTIVE|||||||
33770620|NCT00241137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770621|NCT01505751|||CASE_ONLY||RETROSPECTIVE|||||||
33770622|NCT05648084|||COHORT||PROSPECTIVE|||||||
33770623|NCT01654237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770624|NCT03380832|||CASE_ONLY||CROSS_SECTIONAL|||||||
33770625|NCT03388112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982725|NCT05240222|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|All personnel involved in this study were masked, including the participating teachers, investigators, trainers who deliver the SC-PIES or meeting, and staff who collected the outcome data.|This is a triple-blind parallel randomized controlled trial. Specifically, teachers from a diverse urban district were recruited and randomly assigned to either the treatment (SC-PIES) or active control condition (administrative meeting). Based on the condition assigned, teachers received the SC-PIES (or met with administrators) before EBP training. The investigators assessed teachers' ITI, intervention fidelity, and youth behavioral outcome (academic engagement as an incompatible behavior to externalizing disorders) before treatment, immediately after training, and six weeks afterward.|t|t|t|t
33982726|NCT05696470|||COHORT||PROSPECTIVE|||||||
33982727|NCT04443660|||COHORT||PROSPECTIVE|||||||
33982728|NCT00172055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982729|NCT01809171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982730|NCT05354648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33982731|NCT04231084|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||f|t|t|t
33982732|NCT03663478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982733|NCT04603209|||COHORT||PROSPECTIVE|||||||
33899619|NCT06337370|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|In order to guarantee the objectivity and impartiality of the research team, randomization will be accompanied by blinding. A single-blind trial is proposed in which the participants during the conduct of the study will be unaware of their assignment to the experimental or control groups; likewise, the research assistants who perform the pre and post measurement will be unaware of their assignment to the groups; there will be specific assistants for the pre measurement and specific assistants for the post measurement with each group. Candidates will be invited to participate in the study, explaining to them that it is a randomized study in which they may be assigned to a specific intervention group, that their assignment will only be random, that neither the research team nor the treating health team will be able to interfere with their assignment and that this will be revealed to them once the study is completed.|"CDSMP is a group-based chronic disease self-management education intervention comprised of 2.5-hour sessions, including time for a break and snack. The maximum number of participants per session ranges from 12 to 16. In total the program consists of 6 sessions that take place once a week for a total duration of 6 weeks. The development of each of the sessions is standardized and scripted; two group leaders previously trained by a Master Trainer, who in turn was trained to train leaders with Stanford University, guide the sessions. In the case of the present study, the main researcher and a nursing professional with experience in health education will receive the training from a Master Trainer of the program. Participants receive the book Taking Control of Your Health at the beginning of the program."|t|t|f|t
33899620|NCT01341873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33899621|NCT00984789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899622|NCT00865501|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34078987|NCT04190355|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group 1: 2 ml of 5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.~Group 1: 2 ml of 5.25% Cloraxid gel/ distilled water will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation. The tip of the cannula will be adjusted to reach two-thirds of the working length."||||
33899623|NCT03614715|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33899624|NCT01525212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899625|NCT00025649||||TREATMENT||||||||
33899626|NCT04392011|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33899627|NCT00319904|||COHORT||PROSPECTIVE|||||||
33899628|NCT04076761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34078988|NCT04865861|||COHORT||PROSPECTIVE|||||||
33899629|NCT02165540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899630|NCT00129714|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899631|NCT06667128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078989|NCT02977793|||COHORT||PROSPECTIVE|||||||
34078990|NCT02723188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34078991|NCT04605237|||COHORT||PROSPECTIVE|||||||
34078992|NCT02083796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34078993|NCT00871156|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34078994|NCT02471573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34078995|NCT01331811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899632|NCT00884143|||CASE_ONLY||RETROSPECTIVE|||||||
34078996|NCT00707044|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34078997|NCT04052607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34078998|NCT05702580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Laboratory personnel responsible for the microbiological and biochemical analysis will be blinded to the identity of the paired samples.|All participants will undergo both thoracentesis techniques; the standard and the experimental pre-aspiration agitated fluid techniques||||
34078999|NCT04385498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079000|NCT02993835|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34079001|NCT05645510|||COHORT||PROSPECTIVE|||||||
34079002|NCT06433167|||CASE_CONTROL||PROSPECTIVE|||||||
34079003|NCT04470973|||COHORT||PROSPECTIVE|||||||
34079004|NCT01088633|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079005|NCT01660009|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34079006|NCT01630135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079007|NCT06431464|||CASE_CONTROL||PROSPECTIVE|||||||
34079008|NCT04771845|||COHORT||RETROSPECTIVE|||||||
34079009|NCT02437578|||COHORT||PROSPECTIVE|||||||
34079010|NCT05171010|||OTHER||RETROSPECTIVE|||||||
34079011|NCT02365350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079012|NCT03806543|||CASE_ONLY||RETROSPECTIVE|||||||
34079013|NCT04601740|||COHORT||PROSPECTIVE|||||||
34079014|NCT01766362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079015|NCT02160795|||COHORT||RETROSPECTIVE|||||||
34079016|NCT01537237|||CASE_CONTROL||PROSPECTIVE|||||||
34079017|NCT02012400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079018|NCT01699048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079019|NCT01513993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34079020|NCT02530112|||COHORT||PROSPECTIVE|||||||
34079021|NCT03505372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079022|NCT04552600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Randomized, Double-masked, Placebo-controlled phase 1b/2a study|f|t|f|f
34079023|NCT05793749|RANDOMIZED|PARALLEL||PREVENTION||NONE||Random grouping (A:B=3:1): A: intervention group; B: nonintervention group||||
34079024|NCT02274922|||COHORT||PROSPECTIVE|||||||
34079025|NCT04438525|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34079026|NCT00260988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079027|NCT02037724|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34079028|NCT00918983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079029|NCT02254772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079030|NCT06164457|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Pre-post intervention||||
34079031|NCT04103190|||CASE_ONLY||CROSS_SECTIONAL|||||||
34079032|NCT03708263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079033|NCT03734393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079034|NCT01827969|NA|SINGLE_GROUP||||NONE||||||
34079035|NCT03787823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079036|NCT05344846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33899633|NCT01566838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899634|NCT03471910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33899635|NCT03599908|||COHORT||RETROSPECTIVE|||||||
33899636|NCT01101724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33899637|NCT01750710|||OTHER||CROSS_SECTIONAL|||||||
33899638|NCT02603640|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899639|NCT06227923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33899640|NCT04634669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899641|NCT04965714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899642|NCT04442581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899643|NCT03626051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33899644|NCT06665568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899645|NCT02739477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899646|NCT00294346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33899647|NCT01754896|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899648|NCT03334214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079037|NCT03457389|RANDOMIZED|PARALLEL||TREATMENT||NONE||One experimental group and one control group||||
34079038|NCT00596271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34079039|NCT00003740||||TREATMENT||||||||
34079040|NCT04105179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079041|NCT00270101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33679851|NCT06299488|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|This study is not blinded. Participants consume the intervention on alternating weeks. All participants receive the intervention|Participants will complete a 5-week study consisting of screening assessments, baseline scales and surveys, objective digital measure, 2 weeks of product use (1 week on - 1 week off - 1 week on), scales and surveys, and end of study assessments and surveys. This is a remote observational study that will use the People Science app-based data collection platform Consumer Health Learning and Organizing Ecosystem (CHLOE) for study participants to report their assessments and collect objective sleep data from personal wearable devices. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.||||
33679852|NCT04380064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679853|NCT03196388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679854|NCT02678494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679855|NCT06248047|||COHORT||PROSPECTIVE|||||||
33679856|NCT00407901|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33679857|NCT01206322|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33679858|NCT03511742|||COHORT||PROSPECTIVE|||||||
33679859|NCT03698344|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33679860|NCT02811874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33679861|NCT03268421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Non-pharmacologic trial comparing behavioral and exercise-based treatments|f|f|t|t
33679862|NCT00712400|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33679863|NCT01700439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679864|NCT01332461|||COHORT||RETROSPECTIVE|||||||
33679865|NCT02885571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33679866|NCT03683732|||CASE_ONLY||PROSPECTIVE|||||||
33679867|NCT03094507|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33679868|NCT05040113|NA|SINGLE_GROUP||OTHER||NONE||||||
34079042|NCT04847024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parecoxib + acetaminophen vs Dexketoprofen + acetaminophen in patient receiving neuraxial analgesia for pain after caesarean section.|t|t|t|t
34079043|NCT00261105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679869|NCT01256190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679870|NCT04606680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679871|NCT04958954|||COHORT||RETROSPECTIVE|||||||
33679872|NCT06153680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679873|NCT00446680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679874|NCT03950921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention-control study design||||
33679875|NCT05731011|||COHORT||PROSPECTIVE|||||||
33679876|NCT00223782|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33679877|NCT02743611|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33679878|NCT01765959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679879|NCT04193462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33679880|NCT01683097|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679881|NCT00951613|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679882|NCT02634190|||COHORT||OTHER|||||||
33679883|NCT02812498|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33679884|NCT01605630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982734|NCT04344847||SEQUENTIAL||TREATMENT||NONE|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.|With institutional review board approval from Zagazig University Hospitals 338. A double-centre prospective study was conducted on prospectively collected data of all morbidly. 17 patients in Zagazig University Hospitals, Faculty of Medicine, Egypt and 321 patients done in bariatric surgery excellence unit in a tertiary hospital in Riyadh-KSA.||||
33982735|NCT06114251|||COHORT||RETROSPECTIVE|||||||
33982736|NCT00500474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33982737|NCT02226185|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33770626|NCT06306950|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Upon arrival in the emergency department, the randomization envelope was opened, and patients were assigned into either active treatment (intervention) or usual care (control) groups with cerebral oximetry monitoring using NIRS bilaterally (Root; Prime Medical Corporation, MASIMO, USA).|In a prospective study, 80 patients were randomized to either application of near-infrared reflectance spectroscopy (NIRS) monitoring with active display or attempt to make an intervention to keep regional cortical cerebral oxygen saturation (rSO2) ≥ 55% by increased cardiac output, mean arterial pressure, and adjusting the ventilator to hypoventilation (PaCO2 40-45 mmHg) (exclude in radiographic brain herniation) (intervention, n = 40), compared with usual care (n = 40). Clinical outcomes were assessed by a blind observer. Data collection comprised of patients' demographic data, intervention process, and outcomes of treatment assessed by modified Rankin scale (mRS) followed up at 1 year.|t|t|t|f
33770627|NCT02116920|||CASE_ONLY||PROSPECTIVE|||||||
33982738|NCT02970656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982739|NCT04770883|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is an open labelled, randomized, controlled clinical trial, with a ratio 2:2:1.||||
33982740|NCT02704182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770628|NCT03281278|||COHORT||PROSPECTIVE|||||||
33770629|NCT04683302|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|coded (e)crf's and anonymized and coded ultrasound clips|randomized clinical trial (RCT)|t|f|f|t
33770630|NCT00856934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770631|NCT04908683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33770632|NCT02137538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770633|NCT00410631|RANDOMIZED|||TREATMENT||NONE||||||
33982741|NCT01985347|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33982742|NCT06447883|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33982743|NCT00994669|||CASE_CONTROL||PROSPECTIVE|||||||
33982744|NCT01175616|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982745|NCT06157710|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982746|NCT01929122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33982747|NCT05926479|||OTHER||PROSPECTIVE|||||||
33982748|NCT04745546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982749|NCT01716793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982750|NCT04074174|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982751|NCT02059746|||COHORT||PROSPECTIVE|||||||
33679885|NCT00042471|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679886|NCT03488511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679887|NCT01689493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982752|NCT06158516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Arm A: surufatinib Arm B: placebo|t|t|t|t
34079044|NCT00380536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679888|NCT00978757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679889|NCT04025333|||CASE_ONLY||PROSPECTIVE|||||||
33679890|NCT00786435|||CASE_CONTROL||PROSPECTIVE|||||||
33679891|NCT04540510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients randomized to the OPEP therapy added to standard pneumonia care OR standard pneumonia care..|t|f|f|f
33679892|NCT02547961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679893|NCT03002090|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33679894|NCT02155114|||COHORT||CROSS_SECTIONAL|||||||
33679895|NCT01251536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679896|NCT01342237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679897|NCT05402605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679898|NCT05697185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679899|NCT00109590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679900|NCT02414529|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33679901|NCT03462511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33679902|NCT00117052|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679903|NCT05734417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679904|NCT02553356|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679905|NCT05286645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899649|NCT06316323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects that participated in this study were randomly allocated to two groups; Group A and Group B. Group A subjects were treated with 38% SDF and Group B subjects were treated with 5% NaF varnish. The randomisations of the subjects were done using a sealed envelope. Sequentially numbered, opaque sealed envelopes (SNOSE) method was used for the allocation concealments. This study was conducted in a non-blinded manner, as it was deemed impossible to blind the subjects. The treatment solutions utilized in this study were clearly distinct, with the SDF solution comprising a two-step process, while NaF varnish only required a single step. Additionally, the treatments exhibited different colors and textures. Consequently, the principal investigator had to closely supervise the treatment of each group. Due to the risk of blackish staining associated with SDF, parents and children were not blinded and were informed of the treatment they would receive.|one group received silver diamine fluoride treatment, and another group received sodium fluoride varnish treatment|f|f|f|t
33679906|NCT03179202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679907|NCT02379689|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33679908|NCT05761795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33679909|NCT03924557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized, controlled, parallel arm study.||||
33679910|NCT00748020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679911|NCT05716672|||COHORT||PROSPECTIVE|||||||
33679912|NCT00006233||||TREATMENT||NONE||||||
33899650|NCT05083208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899651|NCT06022679|||OTHER||OTHER|||||||
33899652|NCT01501149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899653|NCT01982201|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33899654|NCT00884507||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899655|NCT01236885|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33899656|NCT02281058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899657|NCT04635735|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I/II, single arm, open label trial.||||
33899658|NCT00873444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899659|NCT03526640|RANDOMIZED|PARALLEL||PREVENTION||NONE||Block randomized design||||
33982753|NCT03087747|||COHORT||PROSPECTIVE|||||||
33982754|NCT01654783|||COHORT||PROSPECTIVE|||||||
33982755|NCT00921622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||vitamin C compared with vitamin D in prospective clinical trial|t|f|t|f
33679913|NCT01221285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679914|NCT03086187|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33679915|NCT02724540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679916|NCT04320758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770634|NCT02058420|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33770635|NCT03910348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899660|NCT05013528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither subjects nor the investigator who is assessing the patient are aware of the treatment assignment until the end of the study||t|f|f|t
33899661|NCT03109002|||COHORT||RETROSPECTIVE|||||||
33899662|NCT00918723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982756|NCT04046211|NA|SINGLE_GROUP||SCREENING||NONE||||||
33982757|NCT06367400|||COHORT||PROSPECTIVE|||||||
33982758|NCT02144753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33982759|NCT02812732|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33982760|NCT03815669|||COHORT||PROSPECTIVE|||||||
33982761|NCT00190814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982762|NCT03357003|||COHORT||PROSPECTIVE|||||||
33982763|NCT03627780|||CASE_CONTROL||PROSPECTIVE|||||||
33982764|NCT04822402|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982765|NCT04734145|||COHORT||PROSPECTIVE|||||||
33982766|NCT03327779|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33982767|NCT04047147|||COHORT||PROSPECTIVE|||||||
33982768|NCT03104101|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33982769|NCT02767310|RANDOMIZED|CROSSOVER||||NONE||||||
33679917|NCT04635800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open-label; no masking|The primary objective of this open-label study is to evaluate the initial safety, tolerability, and pharmacokinetics (PK) of single IVT doses of MHU650 in up to 24 patients. The screening period will be up to 60 days. A single dose of MHU650 will be administered at Baseline / Day 1 in the study eye. The follow up period will last until Day 60 / end of study (EOS). A post study safety phone contact call will occur 30 days after the EOS visit. A total of up to 4 cohorts may be enrolled, with an additional optional lower or intermediate cohort of 6 participants.||||
33679918|NCT03101111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"All subjects will receive two intramuscular injections on day 0 and 28 and one subcutaneous injection on day 0.~Subjects randomized to verum will receive MV-CHIK intramuscularely on days 0 and 28 and placebo subcutaneously in the contralateral arm on day 0.~Subjects randomized to the comparator will receive MMR-vaccine subcutaneously on day 0 and placebo (dummy injection) intramuscularely on days 0 and 28 in the contralateral arm."|Prospective, comparator controled, randomized, double-blinded, interventional, safety study|t|t|t|t
33679919|NCT02527577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679920|NCT04958395|||CASE_ONLY||PROSPECTIVE|||||||
33679921|NCT02122068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679922|NCT04295031|||CASE_ONLY||CROSS_SECTIONAL|||||||
33679923|NCT05048511|||CASE_CONTROL||RETROSPECTIVE|||||||
33679924|NCT02509234|||CASE_ONLY||RETROSPECTIVE|||||||
33679925|NCT01158001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679926|NCT03428919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770636|NCT02415998|||COHORT||PROSPECTIVE|||||||
33770637|NCT05280405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770638|NCT05775835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770639|NCT02878070|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33770640|NCT00674635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770641|NCT02904291|||CASE_ONLY||PROSPECTIVE|||||||
33770642|NCT00062621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770643|NCT03051659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770644|NCT05816148|||COHORT||CROSS_SECTIONAL|||||||
33770645|NCT02237339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770646|NCT01980901|||COHORT||PROSPECTIVE|||||||
33770647|NCT05620030|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33770648|NCT05287230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770649|NCT04470219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33770650|NCT04924140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770651|NCT02407002|||COHORT||PROSPECTIVE|||||||
33770652|NCT02025920|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770653|NCT01760200|||||RETROSPECTIVE|||||||
33770654|NCT01339364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33770655|NCT02561351|||COHORT||PROSPECTIVE|||||||
33770656|NCT00306904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770657|NCT03765762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33770658|NCT03524313|||COHORT||PROSPECTIVE|||||||
33899663|NCT06408090|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33770659|NCT01849796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770660|NCT01933503|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33899664|NCT00163137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33899665|NCT01928030|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33899666|NCT04374994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33899667|NCT02658656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899668|NCT03419234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899669|NCT06547112|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will comprise 2 cohorts enrolled sequentially, each with 10 subjects. The first 10 patients will be enrolled to Cohort 1, and the next 10 patients will be enrolled to Cohort 2.||||
33899670|NCT04841668|||COHORT||PROSPECTIVE|||||||
33899671|NCT01596829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33899672|NCT01801397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899673|NCT01688648|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33899674|NCT05247177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899675|NCT04441931|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33899676|NCT04174963|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899677|NCT01309425|RANDOMIZED|CROSSOVER||||NONE||||||
33899678|NCT02601781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899679|NCT06509516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The same intervention, a programme of the Modified Sleeper-Stretch, will be applied on two different groups||||
33899680|NCT03780517|NA|SEQUENTIAL||TREATMENT||NONE||||||
33899681|NCT01595204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899682|NCT05839626|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33899683|NCT04859127|||COHORT||CROSS_SECTIONAL|||||||
33899684|NCT05346562|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33899685|NCT01962636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899686|NCT00006452||||TREATMENT||||||||
33899687|NCT06057129|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33899688|NCT02747667|||COHORT||RETROSPECTIVE|||||||
33899689|NCT03667677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899690|NCT05804162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33899691|NCT03758677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899692|NCT00745316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899693|NCT03940170|||OTHER||PROSPECTIVE|||||||
33982770|NCT05986448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982771|NCT03806803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|LFMT and LSFF appear identical. Randomization is performed by lab staff not involved in any aspect of treatment administration or care.|double blind randomized|t|t|t|t
33982772|NCT02654912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982773|NCT01627457|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982774|NCT06191939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982775|NCT00480350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982776|NCT00006194|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33982777|NCT03100630|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33982778|NCT02392897|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33982779|NCT05050448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982780|NCT05087693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Drug condition (placebo or salbutamol) will be double blinded Air quality condition (ozone or filtered air) will be single blinded||t|f|t|f
33982781|NCT06039982|||COHORT||PROSPECTIVE|||||||
33982782|NCT02120443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982783|NCT01852435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982784|NCT02435745|||CASE_CONTROL||PROSPECTIVE|||||||
33982785|NCT06347042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079045|NCT00179140|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34079046|NCT02053285|||COHORT||PROSPECTIVE|||||||
34079047|NCT05739318|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34079048|NCT01406093|||COHORT||RETROSPECTIVE|||||||
34079049|NCT00230048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079050|NCT06274970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079051|NCT01042418|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34079052|NCT02842047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079053|NCT02614989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079054|NCT01656083|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079055|NCT06165211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34079056|NCT05038930|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All analysis will be done by a statistician blinded to the intervention or sedentary protocol. Stored data will be named according to patient ID, assigned a letter according to the protocol and a number according to the measurement phase (e.g. ID1011A2).|This study is designed as a cross-over study with patients randomly assigned to (1) an initial intervention protocol on the first day and with a passive sedentary protocol on the second, or (2) an initial passive sedentary protocol on the first day followed by an intervention protocol on the second day.|f|f|t|f
34079057|NCT01228591|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079058|NCT02456194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079059|NCT04125979|RANDOMIZED|PARALLEL||TREATMENT||NONE||120 patients were divided into two groups. One group retained the pulmonary vagus nerve and the other group severed the vagus nerve.||||
34079060|NCT06396949|||CASE_CONTROL||PROSPECTIVE|||||||
34079061|NCT05868590|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34079062|NCT03658291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079063|NCT02567383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079064|NCT03021746|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079065|NCT03339063|||COHORT||PROSPECTIVE|||||||
34079066|NCT03714763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982786|NCT02087904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982787|NCT02185690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079067|NCT05282511|||COHORT||RETROSPECTIVE|||||||
34079068|NCT03065647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079069|NCT04155463|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Study participants will take part in a two-week dietary intervention. All participants will receive one week of organic food and one week of conventional food, randomized to order.||||
34079070|NCT05677711|||COHORT||PROSPECTIVE|||||||
34079071|NCT04036487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079072|NCT02168959|RANDOMIZED|PARALLEL||||NONE||||||
34079073|NCT01394289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079074|NCT05116917|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be enrolled in the study to treatment with nivolumab, ipilimumab and radiation in combination with influenza vaccine, until 30 participants have been treated.||||
34079075|NCT04822714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants was blinded during the recruitment and allocation via electronic consent format and the intervention conducted through mobile intervention|This study is a single blind, multiple center parallel, randomized control trial (RCT) design incorporate individual treatment to all the participants with the mobile career competencies intervention aim to enhance the career competencies among the participants|t|f|f|f
34079076|NCT00274742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079077|NCT03118934|RANDOMIZED|PARALLEL||OTHER||SINGLE|Subjects are unmasked to the study lenses that are dispensed, but will be masked to the fitting guides used to fit each eye.||t|f|f|f
34079078|NCT04513119|||OTHER||PROSPECTIVE|||||||
34079079|NCT00116948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33679927|NCT04471285|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The trial doctor will mark the woman's chart with a continuous number that will become her number in the trial, and she will then be referred to the acupuncturist. , she will receive an acupuncture treatment according to the randomized numbers for acupuncture V or acupuncture P. Approximately 30 minutes after the acupuncture treatment began, the woman will be asked once again to assess her level of pain. An improvement of 1.5 marks on the NRS scale is considered a positive response. Women whose response after 30 minutes of acupuncture is less than this will be given the opposite acupuncture treatment. Those who received V acupuncture will receive P acupuncture and those who received P acupuncture will receive V acupuncture. A woman will be called again if her pain is significantly worse. She will then receive the treatment that has been found most effective between the two acupuncture treatments she received previously.|f|f|f|t
33679928|NCT04195542|||OTHER||PROSPECTIVE|||||||
33679929|NCT06313788|RANDOMIZED|PARALLEL||OTHER||SINGLE|One group of the participants will be told that they are involved in a marketing survey and will be given a band-aid as a token of appreciation for their participation. This constitutes the mere possession group.||t|f|f|f
33679930|NCT06174142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In a randomized trial, two shock wave therapies for plantar fasciitis are tested. Group A gets high-frequency (15 Hz), Group B low-frequency (10 Hz, higher intensity), and Group C receives sham therapy. The study aims to measure pain relief and functional gains post six treatments, with follow-ups to assess benefits' persistence.|This randomized trial compares two shock wave therapy protocols in plantar fasciitis treatment against a sham control. Group A receives high-frequency therapy (15 Hz, intensity level 3), Group B low-frequency (10 Hz, intensity level 4), and Group C a sham treatment, all alongside physical therapy. The goal is to evaluate pain reduction and functional improvement after six sessions, with follow-up assessments to gauge effect durability.|t|f|f|f
33679931|NCT02923024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33679932|NCT01981577|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33679933|NCT00608946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679934|NCT06134011|||CASE_ONLY||OTHER|||||||
33679935|NCT00314002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679936|NCT05342038|NA|SINGLE_GROUP||OTHER||NONE||||||
33679937|NCT04440605|||COHORT||PROSPECTIVE|||||||
33679938|NCT04197310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679939|NCT04267601|||COHORT||PROSPECTIVE|||||||
33679940|NCT05158400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679941|NCT05956444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679942|NCT05469698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679943|NCT00391326|||CASE_CONTROL|||||||||
33679944|NCT02966054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33679945|NCT02043899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679946|NCT02663934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33679947|NCT04772326|||COHORT||PROSPECTIVE|||||||
33679948|NCT01547559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33679949|NCT03005184|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33679950|NCT02324634|RANDOMIZED|PARALLEL||TREATMENT||NONE|As this is a feasibility RCT, the outcome assessor has not been masked to treatment but would be in a subsequent pilot and definitive trial.|||||
33679951|NCT06431971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679952|NCT05037578|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33679953|NCT00870103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079080|NCT01956890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982788|NCT00429000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982789|NCT05233163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982790|NCT04753437|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33982791|NCT04119349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomized using an interactive Web-response system assigning patients in a 1:1 ratio to receive the extra counseling before first trimester assessment (intervention group) or nothing (control group). The allocation will be performed by the study manager. The maternal-fetal medicine specialist will be in charge of the participant's enrolment and will also perform the intervention to the corresponding randomized group.~This is an open-label study which means that the specialist and women will be aware of the allocation and intervention every time."||||
33679954|NCT02275884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33679955|NCT04034797|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33679956|NCT05683353|||CASE_CONTROL||PROSPECTIVE|||||||
33679957|NCT05456282|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants will randomly assigned to receive one of two alternative interventions (SHAM or AMPS) in the first session and the other intervention during the second visit. Participants will be assessed before and after each session.|t|f|f|t
33679958|NCT02507037|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33679959|NCT04048278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and the physicians performing the cases will be unaware of who receives lidocaine or placebo.|A prospective randomized placebo-controlled double blinded trial design will be used for the proposed study.|t|t|f|f
33679960|NCT02859805|||||PROSPECTIVE|||||||
33679961|NCT01361360|||CASE_CONTROL||PROSPECTIVE|||||||
33679962|NCT01067924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33679963|NCT02773108|||COHORT||PROSPECTIVE|||||||
33679964|NCT03961698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two or more groups in parallel for the duration of the study.||||
33679965|NCT00444678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679966|NCT04796064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679967|NCT03968939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. Benadryl + Melatonin Group + Sleep Hygiene Education~2. Sleep Hygiene Education Group~3. Control group (Usual Care)"||t|f|t|f
33679968|NCT06156709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679969|NCT00627575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679970|NCT03034239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33679971|NCT00076453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679972|NCT06250335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33679973|NCT06013813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982792|NCT01509248|||COHORT||PROSPECTIVE|||||||
33982793|NCT02226952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33982794|NCT01758276|||COHORT||RETROSPECTIVE|||||||
33982795|NCT00493142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982796|NCT01388465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33982797|NCT05922449|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Packet information is hidden in serially numbered, sealed and opaque envelopes for allocation hiding.~Due to the different anesthesia methods implemented in this study, the operators cannot achieve the blind method. The outcome assessor and data statisticians are blinded to the group assignment. If a major adverse event occurs during perioperative period that poses a serious threat to the safety of the subject and the anesthesiologist or attending physician deems it necessary to know the subject's grouping, an authorized blind person may open an emergency blind letter, record the time, cause and name of the blind person, and immediately report it to the supervisory board."|Randomized parallel controlled trial|f|f|t|t
33982798|NCT03164772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982799|NCT02992678|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33982800|NCT02751398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982801|NCT04525781|||CASE_CONTROL||RETROSPECTIVE|||||||
33982802|NCT02924038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982803|NCT01333150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33982804|NCT02218411||PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982805|NCT02994615|||CASE_CONTROL||PROSPECTIVE|||||||
33982806|NCT03157856|||COHORT||PROSPECTIVE|||||||
33982807|NCT04470934|||OTHER||PROSPECTIVE|||||||
33982808|NCT03105830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982809|NCT01911520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982810|NCT04680715|NA|SINGLE_GROUP||TREATMENT||NONE||radiotherapy treatment||||
33982811|NCT00540501|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982812|NCT01884740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982813|NCT00363506|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33982814|NCT06157749|||CASE_ONLY||PROSPECTIVE|||||||
33982815|NCT06305897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Proof of concept study concerning 3 prototypes of cyto-selective cryotherapy devices corresponding to a modified CE marked medical device (ref: 822-v1).|t|f|f|f
33982816|NCT00002345|RANDOMIZED|||TREATMENT||||||||
33982817|NCT02923388|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33982818|NCT05108571|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33679974|NCT02730195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982819|NCT06032533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors are recruited from another department, and have not been involved with subjects prior to the telephone interview. Participants and outcome assessors are blinded to subject intervention.|Participants are randomized to either daily treatment with remote ischemic conditioning or daily sham-treatment.|t|f|f|t
34079081|NCT03898622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study drug and placebo will be packaged and labeled on the basis of this randomization program, being letters both, for placebo or Levothyroxine, coding that only the third randomization investigator outside the study will know. The letters of the drugs will be preprinted on the study drug labels and will be assigned to double blind treatment as the subjects meet the requirements for the study Both groups treated with fasting medication (levothyroxine) (in the case of taking a drug that interacts with absorption, use of the drug is changed according to the specified hours, see Table 2) or fasting placebo according to the randomization 1: 1 3 months|Phase II study, type placebo controlled clinical trial, randomized of two arms, double blind, unicentric.|t|t|t|f
34079082|NCT01590108|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34079083|NCT01943981|||CASE_ONLY||PROSPECTIVE|||||||
34079084|NCT03131167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679975|NCT02649348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982820|NCT02978586|||COHORT||PROSPECTIVE|||||||
33982821|NCT03133364|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participants are randomized to the control group (C) and intervention group (I) using the programme Research randomizer. The main supervisor will manage the randomization.~Participants are blinded to whether they receive the control or intervention menu. Each menu will daily consist of a main meal and a between-meal."|"2-armed randomized controlled study which in total runs 12 weeks.~It has been calculated that 106 participants should be completed. With the risk of loss, 150 elderly are screened and invited to join the study, whereas 120 elderly should be included.~Fifty participants are randomized to receive a control menu for 12 weeks and fifty participants are randomized to receive an intervention menu for 12 weeks.~To enhance subject compliance and avoid treatment group contamination the randomization will be done in blocks where each of the 8 departments of the nursing home is randomized to either the Control or Intervention group."|t|t|t|f
33982822|NCT00929565|||CASE_CONTROL||PROSPECTIVE|||||||
33982823|NCT06063005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982824|NCT03607032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982825|NCT04148391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33982826|NCT03301285|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33982827|NCT01861262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982828|NCT03827863|||COHORT||PROSPECTIVE|||||||
33982829|NCT03820466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33982830|NCT01914497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982831|NCT00839605|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982832|NCT04309422|||COHORT||RETROSPECTIVE|||||||
34079085|NCT06160089|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a parallel group, randomized controlled trial (allocation ratio 1:1) with blinded outcome assessment where participants will be randomly assigned to one of the two study groups (iso-inertial or gravitational resistance training).|f|f|f|t
34079086|NCT04577989|||COHORT||RETROSPECTIVE|||||||
34079087|NCT04479839|||COHORT||PROSPECTIVE|||||||
34079088|NCT04996420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079089|NCT05362812|||COHORT||PROSPECTIVE|||||||
34079090|NCT04619017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single-center, open-label, single-arm, controlled mechanistic study. All participants will receive an investigational product.||||
34079091|NCT00967577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079092|NCT02438280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679976|NCT03845439|||COHORT||PROSPECTIVE|||||||
33679977|NCT02893579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33679978|NCT05397704|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group assignment||||
33679979|NCT02294968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982833|NCT05288127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982834|NCT00723528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33982835|NCT04206410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079093|NCT03403907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079094|NCT04052646|||CASE_ONLY||RETROSPECTIVE|||||||
34079095|NCT01093846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079096|NCT03546569|||COHORT||PROSPECTIVE|||||||
34079097|NCT03769649|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive the treatment and outcome will be followed||||
34079098|NCT01704755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079099|NCT00971477|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079100|NCT01768325|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34079101|NCT04988204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33679980|NCT06148649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679981|NCT03278119|||COHORT||PROSPECTIVE|||||||
33679982|NCT03686267|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33679983|NCT03148691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679984|NCT01004198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33679985|NCT02024152|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33679986|NCT05331417|||COHORT||PROSPECTIVE|||||||
33679987|NCT01838759|||COHORT||PROSPECTIVE|||||||
33679988|NCT00205920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33679989|NCT05324761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33679990|NCT04822805|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib , and being observed the disease-related outcomes of the patients.||||
33679991|NCT05228379|||COHORT||RETROSPECTIVE|||||||
33679992|NCT05337397|||COHORT||PROSPECTIVE|||||||
33679993|NCT00969982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770661|NCT06276127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While the treating physician, nurse, and the patient will not be blinded to the treatment, the investigator collecting data and the statistician analysing it will remain blinded to treatment allocations. This ensures unbiased data collection and analysis.|"* Study Design: Double-blind, randomized controlled trial.~* Participants: Patients with atrial fibrillation/flutter and rapid ventricular rate.~* Treatment Arms: Oral Bisoprolol vs. Intravenous Diltiazem.~* Randomization: Subjects randomly assigned to either treatment group.~* Primary Endpoint: Reduction of heart rate to a target level within a specific timeframe.~* Secondary Outcomes: Adverse effects, hospital admission rates, additional rate control needs.~* Objective: Compare effectiveness and safety of oral Bisoprolol to intravenous Diltiazem.~* Monitoring: Continuous observation of vital signs and electrocardiograms for safety."|f|f|t|t
33679994|NCT03034603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33679995|NCT03467100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679996|NCT01116778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33679997|NCT02101164|RANDOMIZED|CROSSOVER||||NONE||||||
33770662|NCT04761055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33679998|NCT02086032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33679999|NCT00979667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680000|NCT02587611|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33680001|NCT00749710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680002|NCT00608569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680003|NCT04892368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680004|NCT01859546|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680005|NCT05536388|||OTHER||PROSPECTIVE|||||||
33680006|NCT03348189|||OTHER||OTHER|||||||
33770663|NCT02115997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680007|NCT04293744|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33680008|NCT03513341|||COHORT||CROSS_SECTIONAL|||||||
33680009|NCT04844710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680010|NCT00568633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment assignment was based on availability of an HLA-matched donor.||||
33770664|NCT00027521||||TREATMENT||||||||
33770665|NCT05591469|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33770666|NCT00163891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33770667|NCT00072852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770668|NCT01888913|||COHORT||PROSPECTIVE|||||||
33770669|NCT02273193|||CASE_CONTROL||PROSPECTIVE|||||||
33770670|NCT06441058|||COHORT||RETROSPECTIVE|||||||
33770671|NCT04321993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770672|NCT02934477|||COHORT||PROSPECTIVE|||||||
33770673|NCT02240589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770674|NCT04773886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patient and statistician are masked about the treatment modality.|"Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated into 4 groups (15 each)~Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP: Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent."|t|f|f|t
33770675|NCT00812474|||CASE_CONTROL||PROSPECTIVE|||||||
33770676|NCT05843474|NA|SINGLE_GROUP||PREVENTION||NONE||a non-concurrent ABA multiple baseline design||||
33770677|NCT04833101|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33770678|NCT01784315|||||PROSPECTIVE|||||||
33770679|NCT02678520|RANDOMIZED|PARALLEL||||NONE||||||
33770680|NCT04915703|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|open|Non-blinded randomized controlled trial with 1:1 allocation||||
33770681|NCT05257759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982836|NCT06370221|||CASE_CONTROL||PROSPECTIVE|||||||
33982837|NCT03267628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double blinded|4 groups of 25 patients each. All patients will receive a spinal and a quadratus lumborum type 2 block. The groups will have a combination of ITM / QLB or both or neither.|t|t|t|t
33982838|NCT06199297|||COHORT||RETROSPECTIVE|||||||
33982839|NCT03169205|||COHORT||PROSPECTIVE|||||||
33982840|NCT05297032|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982841|NCT00213421|||CASE_ONLY||PROSPECTIVE|||||||
33982842|NCT03310697|NA|SINGLE_GROUP||SCREENING||NONE||Transverse prevalence study. For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.||||
33982843|NCT01974648|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33982844|NCT04885296|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33982845|NCT00428857|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982846|NCT01459003|RANDOMIZED|PARALLEL||||NONE||||||
33680011|NCT05795634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective study using baseline characteristics to predict outcomes||||
33680012|NCT06017999|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680013|NCT03254108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680014|NCT00618098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770682|NCT03220945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33770683|NCT03481790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770684|NCT03411889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982847|NCT01288131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982848|NCT05727137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982849|NCT05411926|||CASE_CONTROL||PROSPECTIVE|||||||
33680015|NCT05066542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The study is interventional Efficacy trial for people at risk for type 2 diabetes. Participants will be randomized into the traditional DPP curriculum or DPP + basketball. Certified NDPP coaches will deliver the curriculum.The Traditional arm will receive the standard NDPP curriculum. The intervention arm will receive the NDPP curriculum and participate in group based exercise sessions. Both groups will submit weekly activity reports.~Group evaluations are based on the percentage of participants achieving 5% weight loss at 12-months; self-reported dietary intake, physical activity and sleep time, HbA1c, fasting glucose, body composition, blood pressure, aerobic fitness, musculoskeletal fitness, quality of life, self-efficacy, motivation and depression symptoms at 12-months. Assessments will be conducted at baseline, 6 months, and at 12-months from study initiation. An additional 24-month measurement will be conducted to determine sustainability of program effects."|t|f|f|f
33982850|NCT05908864|||CASE_CONTROL||PROSPECTIVE|||||||
33982851|NCT00743548|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33982852|NCT03446248|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33982853|NCT04257474|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982854|NCT01653353|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33982855|NCT01055899|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33982856|NCT05527678|||COHORT||PROSPECTIVE|||||||
33982857|NCT03635359|||CASE_CONTROL||PROSPECTIVE|||||||
33982858|NCT02648880|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680016|NCT02971033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680017|NCT00206232|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33680018|NCT00114790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680019|NCT05714644|RANDOMIZED|PARALLEL||SCREENING||SINGLE||The Health Centers are randomized to FIT testing or Cologuard.|f|f|f|t
33680020|NCT05986201|||CASE_CONTROL||RETROSPECTIVE|||||||
33680021|NCT04244305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors were blinded to group allocation of the participants||f|f|f|t
33680022|NCT05251402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33680023|NCT04801264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680024|NCT05859737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33680025|NCT04773080|||CASE_ONLY||RETROSPECTIVE|||||||
33680026|NCT01753206|||||CROSS_SECTIONAL|||||||
33680027|NCT01734889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680028|NCT01362010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680029|NCT00027872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680030|NCT01561196|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33680031|NCT05165498|||CASE_ONLY||PROSPECTIVE|||||||
33680032|NCT02453815|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33982859|NCT04192006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33982860|NCT04929457|||COHORT||PROSPECTIVE|||||||
33982861|NCT00719316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982862|NCT01393678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982863|NCT01700621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982864|NCT02274129|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33982865|NCT05414760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982866|NCT00259012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982867|NCT04840264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982868|NCT00803764|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982869|NCT04158570|||CASE_CONTROL||PROSPECTIVE|||||||
33982870|NCT00817193|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982871|NCT02830386|||CASE_ONLY||PROSPECTIVE|||||||
33982872|NCT06327191|||COHORT||CROSS_SECTIONAL|||||||
33982873|NCT00893464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982874|NCT01722877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982875|NCT01492894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982876|NCT02436122|||COHORT||PROSPECTIVE|||||||
33982877|NCT04952558|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982878|NCT05480657|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label trial||||
33982879|NCT05090969|||CASE_ONLY||RETROSPECTIVE|||||||
33982880|NCT05621265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982881|NCT01855932|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33982882|NCT00085150||||TREATMENT||||||||
33982883|NCT01244126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982884|NCT04865952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||split-mouth design|t|f|f|t
33982885|NCT01454544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982886|NCT06031792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized prospective clinical study|t|f|f|f
33982887|NCT00812266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982888|NCT04439396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind randomized trial|randomized|t|t|t|f
33982889|NCT04227639|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33982890|NCT06115369|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The study will be designed as a 2 x 2 factorial randomized clinical trial. First, study patients will be randomized 1:1:1 to receive medically tailored meals (MTM) twice daily (N = 50) vs. weekly fresh produce box (N = 50) vs. a control arm (dietary counseling only) (N=50). In the second factorial intervention, participants will be randomized 1:1 to receive their food supplements in a conditional fashion, based on whether they attend a clinic visit and fill their meds (N =50) vs. receiving the intervention unconditionally (N =50). The intervention will be initiated within a week of hospital discharge and will continue for a period of 90 days.||||
33982891|NCT05142995|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33982892|NCT02193178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680033|NCT00165802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680034|NCT00921895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680035|NCT01464957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680036|NCT03534479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982893|NCT01083277|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33982894|NCT01139437|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33982895|NCT04680364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982896|NCT00915096|||CASE_ONLY||PROSPECTIVE|||||||
33982897|NCT02008565|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33982898|NCT06188091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor: Have no knowledge of the intervention the individual patient has received Participant, are asked to join after they meet the criteria's for inclusion, they know what intervention they get but no knowledge of the intervention in the other group Care Provider - know at the time for the first intervention right after drawing number 2 or 8|"All patients admitted to the hospital because of a knee problem are assign to a date of hospitalizing in random order by the secretary.~Once at the hospital the knee patients, who might be candidates for the enrollment of the study, will get the ROM of the knees measured by a blinded physiotherapist trained in measuring knee joint.~After joint measuring, there will be held a drawing from a bag which contains equal numbers marked either with a 2 or 8. The number is only known by the principal investigator and the 2 therapist who will introduce the patients to the exercises and instruct in the daily interval of doing the exercises (2 or 8). The therapist invites the patients which meets the inclusion criteria to take part in the study.~After 18 days of treatment the outcome assessors will once again measure the ROM on patients included in the study (same therapist that did the the first measuring of a specific patient)"|f|f|f|t
33982899|NCT03347032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33982900|NCT04362891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, Care Provider, Investigator, Outcome Assessor|Multicenter; triple blind; randomized; parallel; controlled trial with 4 treatment arms (4 different widely used commercially available HA soft tissue fillers with FDA approval status and/or CE-marking for cosmetic facial use).|t|t|t|t
34079102|NCT06195436|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For ethical reasons, it is methodologically inappropriate to randomize the study groups, so the protocol will adhere to the TREND guidelines (Transparent Reports of Non-randomized Evaluations \[for its acronym in English: Transparent reporting of reviews with nonrandomized Designs \]), which share several criteria with CONSORTs|"Conceptual definition: It is framed in a functional philosophical position, it is based on a new Theory of Language and Cognition; offers an alternative to traditional psychopathology: the functional dimension of Experiential Avoidance; and promotes basic research and controlled trials.~Operational definition: Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks."|t|f|f|t
34079103|NCT02164955|||COHORT||PROSPECTIVE|||||||
33680037|NCT02166944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680038|NCT05665192|||COHORT||PROSPECTIVE|||||||
33680039|NCT04829084|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||To Increase the attendance of patients with Diabetes Mellitus, for retinal screening at REMEH by providing health education intervention to selected physicians and establishing a referral pathway.|f|f|f|t
33680040|NCT04017195|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33680041|NCT00856011|||CASE_CONTROL||PROSPECTIVE|||||||
33680042|NCT05278598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33680043|NCT02029378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680044|NCT00316108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680045|NCT03941639|||CASE_ONLY||OTHER|||||||
33680046|NCT04176653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multiple Group Assignment|t|f|t|f
33680047|NCT03560518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680048|NCT06531980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A member of the research group will conduct the randomization|One group receives the digittal health intervention and one group receives treatment as usual|f|f|t|f
33680049|NCT04099394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680050|NCT01587768|||||RETROSPECTIVE|||||||
33680051|NCT04355585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|This is a double-blind study in which investigators, participants, site personnel, and laboratory staff will be blinded during the study. Only the research pharmacy will have access to randomization and treatment assignments.|Stratified randomization according to sex will be performed. Each group will be randomized to receive colchicine or placebo.|t|t|t|t
33680052|NCT03496779|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open label, multicenter phase 2 study. Patients treated with gemcitabine will receive brentuximab vedotin (GBv) for 4 cycles of induction.||||
33770685|NCT00171405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770686|NCT05947773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33770687|NCT01429506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770688|NCT04012203|||COHORT||PROSPECTIVE|||||||
33770689|NCT00818064|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33770690|NCT01757067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770691|NCT03688711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770692|NCT05834816|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single Group Assignment||||
33770693|NCT03290690|||COHORT||PROSPECTIVE|||||||
33770694|NCT05486234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33770695|NCT03999905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants were randomized into the intervention and control arm through computer-generated random numbers. the randomization was done by a neutral person. The investigators and the mystery patients were unaware of the members of the intervention arm or the control arm.|Participants are assigned into either arm of the study randomly. Participants in the intervention arm will receive educational training after baseline assessment while participants in the control group will receive the same training after the study had been completed.|f|t|t|f
33770696|NCT03713814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33770697|NCT02088775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770698|NCT03160482|||COHORT||CROSS_SECTIONAL|||||||
33680053|NCT01580137|||COHORT||PROSPECTIVE|||||||
33680054|NCT03059355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pilot phase is open-label. Randomized phase is blinded.||t|t|t|t
33680055|NCT02967978|||COHORT||PROSPECTIVE|||||||
33680056|NCT04023838|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized either conventional right radial approach or left distal radial approach.||||
33680057|NCT02155387|||CASE_CONTROL||PROSPECTIVE|||||||
33680058|NCT06022289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680059|NCT02604329|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33680060|NCT05873166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899694|NCT05102201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Allocation to treatment groups was concealed from participants until it was operationally required to begin intervention activities (ie, postbaseline data collection). Research assistants involved in data collection and data coding were masked to the other intervention groups through assignment of work to 1 group only, and by separate working locations. Intervention RAs were allocated to specific facilities, working with only one of the groups, and were masked to all outcome measurements, as were participants.|A randomized controlled trail, single-blind, two parallel groups, and repeated measures design|t|f|f|t
33899695|NCT02904967|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899696|NCT05170945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899697|NCT06510218|||OTHER||CROSS_SECTIONAL|||||||
33899698|NCT05202977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899699|NCT04791891|||COHORT||PROSPECTIVE|||||||
33899700|NCT02689648|||COHORT||PROSPECTIVE|||||||
33982901|NCT03581448|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Study falls under device feasibility: An intervention of a device product is being evaluated in a small clinical trial to determine the feasibility of the product; or a clinical trial to test a prototype device for feasibility and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial.||||
34079104|NCT03022591|||COHORT||RETROSPECTIVE|||||||
34079105|NCT02102048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079106|NCT04046068|||CASE_ONLY||PROSPECTIVE|||||||
34079107|NCT05366595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079108|NCT04545450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the research pharmacist was aware of the randomization results.||t|t|t|t
34079109|NCT00972959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079110|NCT03705702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All the measurements will be performed by a blinded professional, who will be masked from randomization and other results. For each test, the same investigator will be maintained before and after the intervention. The participants will know what treatment they will receive, but they don't will know what intervention belongs to the control group.||t|f|f|t
34079111|NCT01799447|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34079112|NCT06225492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079113|NCT02553343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680061|NCT03769610|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomly assigned to either inpatient or outpatient cervical ripening with a Foley catheter.||||
33680062|NCT06080568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680063|NCT04908943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and study team member who randomizes participants are blinded to participant responses at randomization. However, following assignment the blind is broken.||t|f|t|f
33680064|NCT02757638|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680065|NCT04670250|||COHORT||PROSPECTIVE|||||||
33680066|NCT02269540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680067|NCT05154305|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33680068|NCT05830617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33680069|NCT05315908|RANDOMIZED|PARALLEL||OTHER||NONE||Eligible patients who don't opt out will be randomized to one of two arms (automated call vs text messaging)||||
33680070|NCT02970240|||CASE_CONTROL||PROSPECTIVE|||||||
33680071|NCT03878433|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33680072|NCT04094415|||COHORT||PROSPECTIVE|||||||
33680073|NCT03190733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33899701|NCT02796144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899702|NCT03366311|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Prospective randomised crossover manikin study|t|f|f|f
33899703|NCT02660580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899704|NCT03914547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899705|NCT03977532|NA|SINGLE_GROUP||OTHER||NONE||||||
33899706|NCT02616822|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33899707|NCT03989687|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The evaluator will not have knowledge of which type of isolation was used when placing the sealants.|each patient is serving as their own control|f|f|f|t
33899708|NCT05167786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982902|NCT05805657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The assessment team will be blind to group allocation at post-treatment and six-month follow-up|CMHC sites will be cluster randomized to either Standard TranS-C or Adapted TranS-C. Then within each CMHC site, patients will be randomized to either TranS-C or to Usual Care followed by Delayed Treatment (UC-DT).|f|f|f|t
33982903|NCT03578068|||COHORT||PROSPECTIVE|||||||
33982904|NCT04359849|||COHORT||RETROSPECTIVE|||||||
33982905|NCT02745925|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34079114|NCT02309086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079115|NCT03795480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079116|NCT04627194|||COHORT||RETROSPECTIVE|||||||
34079117|NCT01032564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079118|NCT01350817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079119|NCT03765060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34079120|NCT02148393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680074|NCT02836639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680075|NCT00472680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680076|NCT02785770|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33680077|NCT05083780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680078|NCT05179343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants will be randomised at the baseline visit to either the active (tAN) or sham (sham-tAN) device arm of the trial at a ratio 2:1 ratio.|t|t|t|t
33899709|NCT00006669||||TREATMENT||||||||
33899710|NCT01065428|||COHORT||PROSPECTIVE|||||||
33899711|NCT04293250|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||latent growth modeling using structural equation model,||||
33899712|NCT01686984|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079121|NCT02491138|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680079|NCT02465554|||COHORT||PROSPECTIVE|||||||
33680080|NCT03763513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680081|NCT01030666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680082|NCT02243462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680083|NCT01853839|||CASE_ONLY||PROSPECTIVE|||||||
33770699|NCT06091618|RANDOMIZED|PARALLEL||TREATMENT||NONE||"prospective, randomized clinical study.~Exclusion criteria~* Major psychiatric and somatic diseases and the use of drugs that affect sexual function~* Patients with ejaculatory dysfunction or no ejaculation~* Patients with documented or suspected prostate cancer~* Patients with neurogenic bladder, voiding dysfunction, urethral strictures, and malignancies of the upper or lower urinary tract,~* Prostates sized more than 80 CC, severe comorbidities or high surgical risk patients."||||
33770700|NCT04410887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770701|NCT03935464|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot Randomized Trial||||
33770702|NCT03898180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study was unblinded with Amendment 3.||t|f|t|t
33770703|NCT02304328|||CASE_CONTROL||PROSPECTIVE|||||||
33770704|NCT06222008|||CASE_ONLY||PROSPECTIVE|||||||
33770705|NCT03890536|||COHORT||PROSPECTIVE|||||||
33770706|NCT01099735|||CASE_ONLY||PROSPECTIVE|||||||
33770707|NCT01534455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770708|NCT05192772|||COHORT||PROSPECTIVE|||||||
33899713|NCT02634164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33770709|NCT03116503|NA|SINGLE_GROUP||SCREENING||NONE||Describe the number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.||||
33899714|NCT04641546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33899715|NCT06105957|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33899716|NCT03575468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982906|NCT04164745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982907|NCT05506280|||OTHER||RETROSPECTIVE|||||||
33982908|NCT00366899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680084|NCT00561860|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33899717|NCT05687760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33680085|NCT03199755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680086|NCT05452083|||COHORT||PROSPECTIVE|||||||
33680087|NCT02660840|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680088|NCT00588861|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680089|NCT03417713|||COHORT||PROSPECTIVE|||||||
33680090|NCT00488254|||COHORT||RETROSPECTIVE|||||||
33680091|NCT00215176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680092|NCT05525078|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680093|NCT05953441|RANDOMIZED|PARALLEL||OTHER||SINGLE|The simulation-based assessment videos were sent for rating by 2 assessors, who were blinded to the groupings.|Prospective 2-arm randomized controlled trial with a pretest-posttest study design|f|f|f|t
33680094|NCT06154577|||COHORT||PROSPECTIVE|||||||
33680095|NCT01501838|||COHORT||PROSPECTIVE|||||||
33680096|NCT02615626|||COHORT||PROSPECTIVE|||||||
33680097|NCT02962843|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770710|NCT04921514|NA|SINGLE_GROUP||OTHER||NONE||40 participants (20 patients and 20 relatives)||||
33770711|NCT06488560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33770712|NCT04379466|||COHORT||PROSPECTIVE|||||||
33770713|NCT02662803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770714|NCT00128245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770715|NCT03422458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899718|NCT06007170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899719|NCT05821504|RANDOMIZED|PARALLEL||OTHER||NONE||Two groups performed different types of high-intensity interval training||||
33899720|NCT03953534|||COHORT||PROSPECTIVE|||||||
33899721|NCT02482220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899722|NCT04561388|NA|SINGLE_GROUP||OTHER||NONE||||||
33899723|NCT04693247|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Tester and subject for BCVA are masked as to which device and trial frames are from.||t|f|f|f
33899724|NCT00050713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899725|NCT05816356|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, two-way crossover||||
33899726|NCT05197244|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm randomized controlled trial||||
33770716|NCT03754361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||the mode of urgent dialysis will choose by patient guided by nephrologist, the HD group will receive the standard traditional treatment: from induction HD to regular HD. The PD group will receive the APD daily.||||
33770717|NCT03987568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770718|NCT02708602|||COHORT||RETROSPECTIVE|||||||
33770719|NCT01663974|||COHORT||PROSPECTIVE|||||||
33770720|NCT04517370|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33770721|NCT00845871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770722|NCT02330419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770723|NCT00125099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770724|NCT02244099|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33770725|NCT01099540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899727|NCT00418405|||DEFINED_POPULATION||PROSPECTIVE|||||||
33899728|NCT02952742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33899729|NCT06672094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899730|NCT04391868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899731|NCT06474793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899732|NCT04988607|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 1:1, the experimental arm is osimertinib plus bevacizumab, while the control arm is osimertinib monotherapy||||
33899733|NCT04736810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982909|NCT04157348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982910|NCT05451030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982911|NCT03049488|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33982912|NCT00074906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899734|NCT04278729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899735|NCT06661265|||CASE_ONLY||RETROSPECTIVE|||||||
33899736|NCT05167292|||COHORT||PROSPECTIVE|||||||
34079122|NCT03194009|RANDOMIZED|PARALLEL||PREVENTION||NONE||Primary health care clinics will be allocated to one of the two arms of the intervention. A) lifestyle modification, B) Metformin and lifestyle modification||||
33680098|NCT03700684|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data files are coded to mask group assignment, session ID, and testing condition.|Participants are stratified by voice severity and assigned to one of three groups: Lee Silverman Voice Treatment (intervention), SpeechVive (intervention), or non-treatment control group (control).|f|f|f|t
33680099|NCT05141877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33680100|NCT00119093||PARALLEL||TREATMENT||NONE||||||
33680101|NCT05272345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33680102|NCT02749474|||COHORT||PROSPECTIVE|||||||
33680103|NCT02618213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680104|NCT05901844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Blind assessment: Researchers using Raman analyzer during surgery are not aware of the subjects' preoperative diagnostic results, while researchers conducting paraffin pathology examinations after surgery are not aware of the subjects' preoperative diagnostic results and the diagnostic results of Raman analyzer.|The same sample was diagnosed using Raman spectroscopy and paraffin pathology, respectively. Calculate the sensitivity and specificity of a Raman analyzer using paraffin pathological results as the gold standard.||||
33680105|NCT05014633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33680106|NCT05047419|||CASE_CONTROL||PROSPECTIVE|||||||
33680107|NCT00495040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680108|NCT06341790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899737|NCT04534894|||CASE_CONTROL||PROSPECTIVE|||||||
33899738|NCT05010681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899739|NCT03210285|||CASE_CONTROL||OTHER|||||||
33899740|NCT03533790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899741|NCT01501344|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899742|NCT03068572|||CASE_CONTROL||PROSPECTIVE|||||||
33899743|NCT00413569|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33899744|NCT06436313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680109|NCT03635411|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Assessing Safety and Tolerability|t|t|t|f
33680110|NCT01705067|||CASE_ONLY||OTHER|||||||
33680111|NCT01853618|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33680112|NCT05661084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, sham controlled|Randomized, sham-controlled, double-blinded, parallel-arm trial|t|f|t|t
33680113|NCT06398743|||COHORT||PROSPECTIVE|||||||
33680114|NCT01103089|||CASE_ONLY||RETROSPECTIVE|||||||
33680115|NCT03463200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680116|NCT05873400|||COHORT||PROSPECTIVE|||||||
33680117|NCT05648669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680118|NCT05391178|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A 12-week prospective pilot study involving a total of 15 patients, including five patients diagnosed with alopecia areata (AA), five patients diagnosed with polymorphous light eruption (PMLE), and five patients diagnosed with psoriasis||||
33680119|NCT01989468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680120|NCT05605951|||COHORT||PROSPECTIVE|||||||
33899745|NCT05717738|||COHORT||OTHER|||||||
33899746|NCT06672848|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blind patients and postoperative follow-ups will not know which group the patient is in the study.|randomized double blinding|t|t|f|f
33899747|NCT05910463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899748|NCT06630832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33899749|NCT05604105|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33899750|NCT05409885|||CASE_CONTROL||PROSPECTIVE|||||||
33899751|NCT02240498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899752|NCT00908297|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899753|NCT03331341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899754|NCT06517810|||CASE_CONTROL||PROSPECTIVE|||||||
33899755|NCT01713348|RANDOMIZED|PARALLEL||||NONE||||||
33899756|NCT04906005|RANDOMIZED|PARALLEL||OTHER||TRIPLE|To ensure that administration of the IMP is carried out under double-blind conditions, an unblinded team (nurse, technician or physician) will be responsible for preparing and administrating the IMP(s). This person will ensure non-disclosure of information.||t|t|t|f
33899757|NCT02119208||PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33899758|NCT03498872|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33899759|NCT01564654|||CASE_ONLY||RETROSPECTIVE|||||||
33680121|NCT05723471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680122|NCT02249637|||CASE_CONTROL||RETROSPECTIVE|||||||
33680123|NCT05873127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33680124|NCT05732402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680125|NCT01260740|||OTHER||CROSS_SECTIONAL|||||||
33680126|NCT04066712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680127|NCT04451213|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680128|NCT01967498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680129|NCT04193514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770726|NCT05175534|||COHORT||RETROSPECTIVE|||||||
33899760|NCT02365857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899761|NCT04649281|NA|SINGLE_GROUP||SCREENING||NONE||||||
33899762|NCT03272477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899763|NCT05964738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899764|NCT06390618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the data are collected, a randomized controlled double-blind study will be conducted by ensuring the blindness of the evaluator and the statistician. Blinding will be achieved by assigning numbers to randomized patients and keeping the evaluator and statistician from knowing which patient is in which group.|According to randomization, they will be divided into 3 groups: aerobic exercise group (AE), combined exercise (CE) group in which biopsychosocial exercise is performed in addition to aerobic exercise, and control group (C).|f|f|t|t
33899765|NCT00092911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33899766|NCT05770414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899767|NCT02250040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899768|NCT04819425|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Cluster and Crossover||||
33899769|NCT00676559|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33899770|NCT05331365|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Patients who have undergone ankle ligamentoplasty 4 months ago will be included in the study.~Healthy volunteers will be selected on a voluntary basis at the request of the investigators in the population of patients undergoing rehabilitation by physiotherapists at the investigation sites and with no history of knee or ankle problems."||||
33899771|NCT04372355|NA|SINGLE_GROUP||TREATMENT||NONE||T2DM patients with DFU and HbA1c \> 8.5%||||
33899772|NCT05640986|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33899773|NCT00959244|||COHORT||PROSPECTIVE|||||||
33899774|NCT04129723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899775|NCT00077181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899776|NCT03471221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Outcomes Assessors include clinical research assistants and laboratory personnel. Laboratory personnel will be blinded. Clinical research assistants collecting surveys and specimens will not be blinded.||f|f|t|t
33899777|NCT02652819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899778|NCT01541254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899779|NCT02065440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899780|NCT05078034|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized control trial||||
33899781|NCT03626415||PARALLEL||BASIC_SCIENCE||NONE||Recruitment for subjects with moderate and mild hepatic impairment (Cohorts 1 and 2) will initiate first and these subjects will be enrolled in parallel.||||
33899782|NCT01462292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899783|NCT02551848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899784|NCT02652429|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Extension||||
33899785|NCT00652093|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33899786|NCT02395679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982913|NCT03265080|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Personalized immunotherapy treatment design||||
33982914|NCT06218680|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||RCT|t|f|t|t
33982915|NCT01449266|NA|SINGLE_GROUP||||NONE||||||
33982916|NCT04354558|||COHORT||PROSPECTIVE|||||||
33982917|NCT02268422|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33982918|NCT00983684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982919|NCT03930498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982920|NCT04622657|NA|SEQUENTIAL||OTHER||NONE||||||
33982921|NCT04221425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770727|NCT04572256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770728|NCT04562103|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33770729|NCT01532180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770730|NCT00393744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680130|NCT05705089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation sequence concealment and blinded outcome adjudication|1:1 open-label parallel group randomized controlled trial with concealed allocation sequence and blinded outcome adjudication|f|f|f|t
33680131|NCT03096587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded and will not know the group he is in.||t|f|f|f
33680132|NCT01232803|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33680133|NCT01606917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33770731|NCT01556763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33770732|NCT02857803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770733|NCT04853901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770734|NCT04653298|||COHORT||PROSPECTIVE|||||||
33770735|NCT04758234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33899787|NCT04399278|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|A randomization sequence by permuted blocks (random block sizes) with an allocation of 1:1 will be generated by a computer program (Stata software, version 15, StataCorp, College Station, US) The group assignment will be concealed until arrival in the operating room so that only the anesthesiologist in charge of the patient will aware to the randomization group|"The EEO test will be performed by interrupting the mechanical ventilation at end-expiration over 15 and 30 seconds using the end-expiratory hold button available on the anesthesia ventilator. Each occlusion will be separated by 1 minute to allow a return to the baseline value.~Hemodynamic variables will be recorded before and immediately after each EEO procedure, and after a fluid challenge (4 ml/kg of 0.9% saline over 5 minutes).~Fluid responders will be defined by an increase in stroke volume ≥15% 1 min after the end of the fluid challenge."|t|f|t|t
33899788|NCT01812720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899789|NCT02029430|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899790|NCT00609128|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33899791|NCT03065673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899792|NCT00010023||||TREATMENT||||||||
33899793|NCT00943878|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33899794|NCT05021614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899795|NCT02996305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899796|NCT04245124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Primary Aim: Difference in Cognitive and Neurophysiological Function between SMART and TCR. Multilevel mixed-effect modeling will be conducted for Aim 1 with treatment modality (SMART vs. TCR) as the independent variable. This approach will take into consideration between-subject variance based on randomized group, as well as within-subject variance for repeated measures. Primary analyses will be based on intention to treat, and we will leverage the statistical power of multilevel modeling to handle missing follow-up data. Outcome will be assessed as change in GDS over time. A significant p-value of 0.05 will be used to assess the main effects.|t|f|f|f
33899797|NCT05067660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible study participants are randomized at the time of recruitment by an algorithm in a 1:1 ratio to receive either stereotactic ablative radiotherapy (SABR) or current standard-of-care template-based salvage radiotherapy.|Randomized controlled pilot trial|t|f|f|f
33899798|NCT03626467|NA|SINGLE_GROUP||TREATMENT||NONE||A phase IV, open-label and single-arm clinical trial||||
33899799|NCT04735185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We are trying to determine whether intradiscal injection of autologous BMC (bone marrow-derived mesenchymal stem cells) will decrease pain and improve function compared with intradiscal steroid.|f|f|f|t
33899800|NCT04971811|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33899801|NCT05372705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33899802|NCT06074172|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor)|Two-arm Case-Crossover|t|t|f|t
33899803|NCT05822999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|This is a randomized, double-blinded design, with seven points of measurement. The subjects will receive either the WELT-IP app or sham app.|t|f|t|f
33899804|NCT02035423|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33899805|NCT05910593|||CASE_ONLY||CROSS_SECTIONAL|||||||
33899806|NCT04381000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899807|NCT00816946|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33899808|NCT01718314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899809|NCT02405312|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33982922|NCT03412357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680134|NCT04195971|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680135|NCT05622747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680136|NCT06123013|NA|SINGLE_GROUP||OTHER||NONE||||||
33680137|NCT01160419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680138|NCT05864092|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Masking and randomization is not possible due to the nature of the virtual reality goggles.|The study has two separate arms. A control arm will be a retrospective chart analysis of patients (100 anticipated) ages 6-21 with sickle cell VOC, and the trial arm will be an interventional prospective convenience sampling of patients (100 anticipated) admitted to the emergency department ages 6-21 with sickle cell VOC who will receive VR in addition to standard medical therapy.||||
33680139|NCT00118495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680140|NCT01143740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680141|NCT05736029|||OTHER||PROSPECTIVE|||||||
33680142|NCT00393510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680143|NCT00321126|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33680144|NCT04832100|||CASE_CONTROL||PROSPECTIVE|||||||
33770736|NCT05817669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized to receive efgartigimod 10 mg/kg or placebo in a 2:1 ratio, respectively. All participants will receive efgartigimod IV 10 mg/kg or placebo once weekly for 24 weeks during the treatment period||t|t|t|f
33770737|NCT03459313|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770738|NCT02161601|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770739|NCT05122572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770740|NCT01740011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680145|NCT00391209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770741|NCT00613613|||COHORT||PROSPECTIVE|||||||
33770742|NCT01974466|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33680146|NCT04586387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Participants will not be able to tell the difference if they are being given active vs sham stimulation but will receive both.|||||
33680147|NCT00408941|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33680148|NCT04431674|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single-Centre, Single-Arm, Non-Randomized, Phase-I MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest Wall and Breast Cancer||||
33680149|NCT02730793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680150|NCT03112954|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|blind treatment|cohort study.||||
33680151|NCT00411580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680152|NCT01806662|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33680153|NCT01144299|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680154|NCT00794898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680155|NCT02763943|NA|SINGLE_GROUP||PREVENTION||||||||
33680156|NCT00934843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33680157|NCT00357760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680158|NCT00761644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680159|NCT06151080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680160|NCT00220922|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33680161|NCT01037192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680162|NCT05624333|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33680163|NCT04981873|||OTHER||CROSS_SECTIONAL|||||||
33680164|NCT05464953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680165|NCT01385397|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33680166|NCT02216110|||COHORT||RETROSPECTIVE|||||||
33680167|NCT05401058|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680168|NCT01719744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680169|NCT00977847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680170|NCT04698096|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680171|NCT02635932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680172|NCT01217307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680173|NCT02325869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680174|NCT05185206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, investigator and outcome assessor will be blinded to the treatment modalities.|A split mouth study design which checks the post operative sensitivity with cention-n(commercially available restorative material) using conventional steel bur and polymer bur using Visual Analog scale.|t|f|t|t
33680175|NCT01779817|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33680176|NCT03751657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33680177|NCT03140215|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680178|NCT04858191|||OTHER||PROSPECTIVE|||||||
33680179|NCT01491113|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33680180|NCT00753740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680181|NCT00003388||||TREATMENT||||||||
33680182|NCT01876940|RANDOMIZED|PARALLEL||||NONE||||||
33680183|NCT05738590|||COHORT||CROSS_SECTIONAL|||||||
33680184|NCT03494491|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33899810|NCT02756455|||CASE_ONLY||PROSPECTIVE|||||||
33899811|NCT01359540|||CASE_CONTROL||PROSPECTIVE|||||||
33899812|NCT01364467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899813|NCT06372639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899814|NCT02988986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899815|NCT02067312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899816|NCT01435993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899817|NCT06672328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899818|NCT00003820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899819|NCT03009695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899820|NCT03507400|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||waiting list control study||||
33680185|NCT03505840|||COHORT||PROSPECTIVE|||||||
33680186|NCT00052624||||TREATMENT||NONE||||||
33680187|NCT02906982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680188|NCT02207946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680189|NCT05128708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||all participants underwent right hemicolectomy using combined medial and caudal approach and divided into 2 groups group I had open surgery and group II had laparoscopic surgery||||
33680190|NCT00799851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680191|NCT00038389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680192|NCT03310762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The allocation sequence will be concealed from the study staff responsible for screening and enrolling participants in serially numbered, opaque, sealed envelopes.|This is an individually randomized, three-arm parallel group design randomized control trial with equal allocation in the two treatment groups and control group. Children in intervention group A will receive the simple silicon bracelets, children in intervention group B will receive the bracelets developed by Alma Sana Inc. and children in the Control group will not receive any intervention.||||
33680193|NCT02739178|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33680194|NCT05970354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33680195|NCT06472076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680196|NCT03167281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680197|NCT04642157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899821|NCT01331395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899822|NCT06217159|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A randomized single-blind crossover design will be used to test 2 conditions. Participants will consume 60 mL of a supplement containing 0.6g/kg body weight of the ketone monoester (\[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate) in both conditions, and their PetCO2 will be maintained in the normocapnic conditions or not maintained in the poikilocapnic condition, in a randomized order.|t|f|f|t
33899823|NCT04310137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will be unaware of in which group the participant was randomized.|Randomized Controlled Trial|f|f|f|t
33680198|NCT05562401|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The hydrating drinks will be placed in containers labeled as treatments 1 and 2 by a person in charge external to the project, where neither study subjects nor the main researcher will know the type of drink they will be receiving because both will have the same or similar appearance and taste.|Two groups of subjects will be formed that will be randomized by the type of treatment they will receive, which will be the same during the 4 interventions of the study.|t|f|t|f
33680199|NCT00000590|RANDOMIZED|||PREVENTION||DOUBLE||||||
33680200|NCT02602756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study with 2 differents dosages of proton therapy|t|f|f|f
33680201|NCT06240364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33680202|NCT02872506|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33680203|NCT02754700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680204|NCT06148844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Control group will receive conventional pre-operative preparation and intervention group will receive pre-operative preparation designed with interactive robot by researchers|Two group with conventional therapy control group|t|f|f|t
33680205|NCT01018784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680206|NCT03963167|||COHORT||PROSPECTIVE|||||||
33899824|NCT06512428|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation Phase:~Dose 1: simmitinib 4mg QD plus irinotecan liposome 70 mg/m\^2 every 2 weeks; Dose 2: simmitinib 6mg 3 weeks on 1 week off plus irinotecan liposome 70 mg/m\^2 every 2 weeks; Dose 3: simmitinib 6mg QD plus irinotecan liposome 70 mg/m\^2 every 2 weeks;~Randomized controlled study Phase:~Randomly assigned to the following 3 groups at 1:1:1 ratio, including simmitinib plus irinotecan liposome, irinotecan liposome, and irinotecan."||||
33899825|NCT02213757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33680207|NCT04104126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899826|NCT02094105|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899827|NCT06672276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899828|NCT02475460|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33899829|NCT01770353|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33899830|NCT04946110|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899831|NCT02412007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33899832|NCT05186532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33899833|NCT04252807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Study investigators and outcome assessors will be blind to the allocations status of participants. To ensure blinding, participants will be instructed to not disclose their allocation during assessment.~Fidelity of masking will be ensured by having assessors guess the allocation status of participants at the end of assessments."|Single blind, two arm, individual randomized controlled trial|f|f|t|t
33899834|NCT03419533|||COHORT||CROSS_SECTIONAL|||||||
33899835|NCT02542449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899836|NCT03412227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be masked to the treatment conditions.|Randomized Clinical Trial, stratified by principal youth diagnosis (anxiety or depression).|f|f|f|t
33899837|NCT00928980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899838|NCT03380949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are not informed about the group assignement (intervention takes place in general anesthesia). Outcome assessors are persons without knowledge on former treatment in intervention/control group.|Participants are assigned to intervention groups by chance|t|f|f|t
33899839|NCT03411603|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33899840|NCT00100555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33899841|NCT00816218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33899842|NCT05422144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899843|NCT05983302|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33982923|NCT01020734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982924|NCT00976664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982925|NCT05317078|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33982926|NCT02506309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982927|NCT05137483|||OTHER||CROSS_SECTIONAL|||||||
33982928|NCT03639311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study, thus no masking.|This is an Intervention Model, with parallel assignment, where the primary purpose of the study is, treatment, with 2 arms and no masking.||||
33982929|NCT04944537|||OTHER||CROSS_SECTIONAL|||||||
33982930|NCT02359617|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33982931|NCT03560544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680208|NCT05633030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Group A: 50 patients will be operated using UAS during flexible ureteroscopy. Group B: 50 patients will be operated using PCN during flexible ureteroscopy.|f|f|f|t
34079123|NCT03577249||SEQUENTIAL||TREATMENT||NONE||45 patients with end stage renal disease will be treated with dialysis solution A (standard of care: acetate-buffered) for 3 months then with solution B (acetate-free, citrate buffered, otherwise identical to solution A) for 3 months and then with solution A for the final 3 months||||
34079124|NCT05032144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079125|NCT00583310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079126|NCT03934216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982932|NCT05486637|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking is involved.|This is a prospective design involving human subjects who are children and adults with cochlear implants or with normal hearing. Participants will perform two kinds of tasks: 1) listening tasks in which participants listen to speech or nonspeech sounds and make a judgment regarding the emotion in the sound and 2) speaking tasks, in which participants will read aloud a list of simple sentences in a happy way and a sad way or converse with a member of the research team, in which participants retell a picture book story or describe an activity of their choosing. Participants' speech will be recorded, analyzed for its acoustics, and also used as stimuli for listening tasks. Child participants will also be invited to perform tests of cognition, vocabulary, and theory of mind. All participants will be invited to participate in all studies, with no assignment. The order of tests will be randomized as appropriate to avoid order effects.||||
33982933|NCT01026077|||COHORT||PROSPECTIVE|||||||
34079127|NCT05358691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, multicenter, phase 1 study to evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation Durvalumab therapy in patients with locally advanced Stage III NSCLC. The Phase 1a part will include dose escalations or de-escalation in three dose cohorts and a dose-limiting toxicity observation period. The Phase 1b part will be an expansion phase with twelve participants (including those enrolled at the MTD) at the recommended Phase 2 dose (RP2D) or the maximum tolerated dose level.||||
34079128|NCT05680610|||COHORT||PROSPECTIVE|||||||
34079129|NCT04880109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079130|NCT04861844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33899844|NCT03333369|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"For the randomization of the intervention and placebo the Research Randomizer on www.randomizer.org will be used. The randomization will be performed by the Kantonsapotheke in Zurich. The generated list of condition sequences will be stored at there. The list will not be accessible for study members who are associated with the assessment. The Boxes containing the cachets will be labelled with the subject number and A or B for the first or second session, respectively as well as with the ID of the study. The cachets will be prepared and labelled at the Kantonsapotheke in Zurich. DA and placebo will be provided in identical cachets. The blinding will be broken only after a subject has completed both experimental sessions or in case of an acute reaction during the session."|"Each subject in the group will participate in two test sessions, separated by at least one week. All sessions will start at 15:30.~In a double-blind within-design procedure, participants will be randomly assigned to receive either a cachet of a dual-release formulation of 200 mg levodopa/50 mg benserazide (a peripheral L-dihhydroxyphenylalanine-decarboxylase inhibitor) or a placebo in the first session. In the second session they will receive the other intervention."|t|t|t|f
33899845|NCT06667440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33899846|NCT05295160|RANDOMIZED|PARALLEL||TREATMENT||NONE||Obese people with type 2 diabetes with a duration of less then 4 years will be compared with people with type 2 diabetes for more than 8 years regarding their capability to achieve remission of type 2 diabetes in response to a weight loss of 15kg achived using very low calorie intake||||
33899847|NCT02185599|||OTHER||OTHER|||||||
33899848|NCT01620996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899849|NCT06513767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982934|NCT02234050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899850|NCT05760625|||OTHER||CROSS_SECTIONAL|||||||
33982935|NCT04590300|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33982936|NCT02522234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982937|NCT01312922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982938|NCT03814239|||COHORT||RETROSPECTIVE|||||||
34079131|NCT00628407|||CASE_ONLY||PROSPECTIVE|||||||
34079132|NCT03536195|||COHORT||PROSPECTIVE|||||||
34079133|NCT05798351|||COHORT||CROSS_SECTIONAL|||||||
34079134|NCT02570347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079135|NCT06522464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be randomized control trial in which non probability convenient sampling will be used. Two groups of age 6 - 12 years old CP hemiparetic children having the ability to grasp and release light objects, with an extension of at least 20° of the wrist and 10° of the metacarpophalangeal joints of the fingers (from full flexion of the affected hand will be formed in which participants will be randomly divided. Group A will follow the mCIMT Protocol with additional cross education will be given and group B will follow the mCIMT Protocol.|t|f|f|f
34079136|NCT06385171|||COHORT||PROSPECTIVE|||||||
34079137|NCT02016768|||COHORT||PROSPECTIVE|||||||
33680209|NCT00222950|||DEFINED_POPULATION||OTHER|||||||
33680210|NCT02874170|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33680211|NCT04838717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680212|NCT00924040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680213|NCT05698875|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be randomised to test each of the three test meals on two separate occasions with a control meal (usual breakfast meal) for each test meal. Randomisation will be achieved using a Latin square randomisation. The tool used for this will be http://www.jerrydallal.com/random/randomize.htm. Randomisation will be done in a block of four.||||
33680214|NCT01426542|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33680215|NCT05864456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680216|NCT02896322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680217|NCT05510271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33680218|NCT02524483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680219|NCT00445237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680220|NCT01923051|||COHORT||PROSPECTIVE|||||||
33680221|NCT02880956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680222|NCT01116856|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two phases, the first for overweight, and the second for obese people||||
33680223|NCT01303224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982939|NCT03329027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982940|NCT04165564|||COHORT||PROSPECTIVE|||||||
33982941|NCT02994186|||COHORT||PROSPECTIVE|||||||
33982942|NCT00163826|||COHORT|||||||||
33680224|NCT03649308|RANDOMIZED|PARALLEL||TREATMENT||NONE||After split-thickness skin graft procedure, the participants are assigned to either conventional treatment or negative pressure wound therapy group in parallel for the duration of the study.||||
33982943|NCT05754008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study team will conduct a patient-level randomized, parallel-group pragmatic trial of usual care vs. the AURORA care strategy among Latinx members (ages 18-44), recently diagnosed with T2D with a diagnosis HbA1c ≥8% (n=102/study arm). Outcomes assessed at 6 months post-enrollment will include HbA1c changes, medication initiation and adherence, and changes in patient-reported measures (e.g., self-efficacy).||||
33680225|NCT00349700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079138|NCT03301402|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34079139|NCT00349141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34079140|NCT02567188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079141|NCT03064113|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33680226|NCT06088602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Anaesthesiologist performing intervention is unblinded|"The patients will be randomized to 2 groups with 22 in each.~Sham cryo (sham-group): Postoperative sham cryoneurolysis of the lower extremity.~Cryoneurolysis (cryo-group): Postoperative cryoneurolysis of the superficial genicular nerves, i.e., the infrapatellar branches of the saphenous nerve (ISN) and the anterior femoral cutaneous nerve (AFCN)."|t|t|t|t
33680227|NCT03317327|NA|SINGLE_GROUP||TREATMENT||NONE||Exploratory||||
33680228|NCT02879487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680229|NCT05095532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a randomized, controlled clinical trial in which CP patients scheduled for TP-IAT who meet the study criteria and consented will be randomized into three groups. One group will receive islet transplantation alone (n=14). The other two groups will receive islets plus BM-MSCs at two different doses (20x10\^6/patient, or 50x10\^6/patient, n=14 in each group).|f|t|f|t
33680230|NCT01873469|||COHORT||PROSPECTIVE|||||||
33680231|NCT05737615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680232|NCT04062903|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will employ a randomised waitlist trial design with mixed methods using a co-productive participatory approach.||||
33680233|NCT02815826|||COHORT||PROSPECTIVE|||||||
33680234|NCT00254579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680235|NCT01465685|NA|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33680236|NCT04369261|||OTHER||PROSPECTIVE|||||||
33680237|NCT03508791|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33680238|NCT02901327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680239|NCT02491944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680240|NCT05427877|NA|SINGLE_GROUP||OTHER||NONE||||||
33680241|NCT00222131|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33680242|NCT03982134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680243|NCT00308581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680244|NCT00488358|||CASE_ONLY||PROSPECTIVE|||||||
33680245|NCT03856281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680246|NCT04605614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680247|NCT01932879|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33680248|NCT03349398|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33680249|NCT06025136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analyse is going to be completed by a independent researcher.|The research will be conducted using randomized controlled, experimental type and single-blind research methods. For this purpose, after the data are collected, they will be coded as A and B groups, so the researcher who will make the research statistics will analyze the data without knowing the study and control groups. Randomization method will be used to determine the groups. For this, the patients who meet the study criteria and volunteer will be assigned to the groups using the randomization program 'Random Allocation Software 2.0' according to the order of hospitalization.|f|f|f|t
33680250|NCT03610100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680251|NCT05046197|||OTHER||RETROSPECTIVE|||||||
33680252|NCT05922670|NA|SINGLE_GROUP||PREVENTION||NONE||Behavioral health-Works (BH-Works) is a systems-level, multicomponent suicide prevention program designed for youth populations. The program includes two primary components, comprehensive web-based behavioral health screening (BHS), and an electronic referral system. This project will adapt and import this program into lesbian, gay, bisexual, transgender, and queer (LGBTQ) organizations. This project builds upon robust partnerships with two diverse LGBTQ organizations in Philadelphia, Pennsylvania and in rural Roanoke, Virginia and their behavioral health partners.||||
33680253|NCT05766358|||CASE_CONTROL||PROSPECTIVE|||||||
33680254|NCT04352426|||OTHER||PROSPECTIVE|||||||
33680255|NCT01800461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680256|NCT04114162|||OTHER||PROSPECTIVE|||||||
33680257|NCT05471583|||COHORT||PROSPECTIVE|||||||
33770743|NCT04020003|NA|SINGLE_GROUP||TREATMENT||NONE||Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% s50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over.||||
33770744|NCT06317519|||COHORT||PROSPECTIVE|||||||
33770745|NCT06392685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770746|NCT01428804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770747|NCT05504213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770748|NCT03860064|||CASE_CONTROL||PROSPECTIVE|||||||
33770749|NCT05092425|||CASE_ONLY||PROSPECTIVE|||||||
33770750|NCT03694301|||COHORT||PROSPECTIVE|||||||
33770751|NCT06238063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33770752|NCT05871931|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Controlled Study|t|f|f|t
33770753|NCT00452179|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33770754|NCT04170296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680258|NCT00535964|||COHORT||PROSPECTIVE|||||||
33680259|NCT03156647|||CASE_ONLY||PROSPECTIVE|||||||
33680260|NCT01037894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680261|NCT02816827|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33680262|NCT04330729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680263|NCT02141477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680264|NCT00427401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680265|NCT03439683|||OTHER||CROSS_SECTIONAL|||||||
33680266|NCT00564057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770755|NCT01478763|||COHORT||PROSPECTIVE|||||||
33770756|NCT04672889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770757|NCT06360003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770758|NCT04976569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770759|NCT05274308|||OTHER||PROSPECTIVE|||||||
33770760|NCT00791115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770761|NCT00839917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770762|NCT05904743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770763|NCT00670696|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33770764|NCT05655104|||COHORT||PROSPECTIVE|||||||
33899851|NCT05567978|||COHORT||PROSPECTIVE|||||||
33899852|NCT00004177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899853|NCT00005963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899854|NCT04663035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899855|NCT04369352|||COHORT||PROSPECTIVE|||||||
33899856|NCT01213810|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33899857|NCT03311685|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33899858|NCT01458340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33899859|NCT03550144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33899860|NCT00538733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899861|NCT00258544|||COHORT||OTHER|||||||
33899862|NCT01098396|||CASE_ONLY|||||||||
33899863|NCT00379730|RANDOMIZED|PARALLEL||TREATMENT||||||||
33899864|NCT02522910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899865|NCT03705494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33899866|NCT00971646|||COHORT||PROSPECTIVE|||||||
33899867|NCT03440112|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participant, Investigator||t|t|t|f
33899868|NCT04331730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899869|NCT01977144|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33899870|NCT01092442|||COHORT||PROSPECTIVE|||||||
33899871|NCT05721625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899872|NCT05328843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899873|NCT01859429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33899874|NCT00476931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33899875|NCT05587985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899876|NCT01883310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899877|NCT02810002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899878|NCT01846546|||CASE_ONLY||PROSPECTIVE|||||||
33899879|NCT02365532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680267|NCT03160794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770765|NCT04320615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770766|NCT03681483|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label, multi-institution study of RO5126766 (CH5127566) in patients with KRAS mutant NSCLC.||||
33770767|NCT06365606|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants and the healthcare providers are not aware of the syphilis status.||t|t|f|f
33770768|NCT05028491|||CASE_ONLY||PROSPECTIVE|||||||
33770769|NCT02587689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770770|NCT02323503|||COHORT||PROSPECTIVE|||||||
33770771|NCT00846833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770772|NCT01227408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899880|NCT02435173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Part I of the study was a non-randomized, open-label, within-patient up-titration dose-finding part in 6 participants with APDS/PASLI. Part II was a randomized, subject, investigator and sponsor-blinded, placebo-controlled, fixed dose part investigating 31 participants with APDS/PASLI.|t|t|t|f
33899881|NCT06316661|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899882|NCT06142747|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899883|NCT06351410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The 6 types of Contact Lenses used will be labeled as A, B, C, D, E, and F by a co-investigator and will be fitted on the participant's eye randomly.|18 participants will be fitted with 2 types of lenses on either eye at one time. There will be a 2-week wash-off period before another 2 set of fittings with another 4 types of lenses.||||
33899884|NCT05376202|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33899885|NCT00810329|||COHORT||PROSPECTIVE|||||||
33899886|NCT00145340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680268|NCT03619057|||COHORT||PROSPECTIVE|||||||
33680269|NCT05630391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33680270|NCT05324904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33680271|NCT06085976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33680272|NCT04220879|||CASE_CONTROL||OTHER|||||||
33680273|NCT02061943|||CASE_ONLY||PROSPECTIVE|||||||
33680274|NCT00326651|||NATURAL_HISTORY||OTHER|||||||
33680275|NCT03353740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680276|NCT03243409|||CASE_ONLY||RETROSPECTIVE|||||||
33680277|NCT06084975|||COHORT||RETROSPECTIVE|||||||
33680278|NCT00588029|||CASE_CONTROL||PROSPECTIVE|||||||
33680279|NCT03629275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680280|NCT02051933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680281|NCT05271500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770773|NCT05270317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will be conducted on 18 skeletally immature patients who are suffering Bone loss problems either posttraumatic, post-tumor resection or post-infection that requires bone grafting, attending the Pediatric orthopedic Surgery Department in king Hussein Medical center.|t|f|f|f
33680282|NCT03772002|NA|SINGLE_GROUP||SCREENING||NONE||||||
33680283|NCT02171910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33680284|NCT01788813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899887|NCT05200351|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be randomly assigned to one of the five pre-defined baseline lengths (2-6 weeks) to increase the internal validity of the design with a 1:1 allocation using permuted blocks of random sizes.||||
33899888|NCT03295422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899889|NCT00846612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899890|NCT04837404|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicentre, randomized investigator-initiated trial with a superiority design||||
33899891|NCT02732912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised, investigator-blinded, parallel group design|f|f|t|f
33899892|NCT01729832|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33899893|NCT01848444|||COHORT||PROSPECTIVE|||||||
33899894|NCT06671912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899895|NCT00187161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899896|NCT00436670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899897|NCT02176967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899898|NCT00475449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899899|NCT04651777|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, open-label pilot study||||
33899900|NCT03988114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899901|NCT05047393|||COHORT||PROSPECTIVE|||||||
33899902|NCT01326286|||COHORT||PROSPECTIVE|||||||
33899903|NCT02928237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899904|NCT00722059|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899905|NCT04668846|||OTHER||PROSPECTIVE|||||||
33899906|NCT01326962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899907|NCT05017831|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Any study team member who is assessing for outcomes will not know which participant/family is in which group.|Random assignment to one of two groups.|f|f|f|t
33899908|NCT00520689|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33899909|NCT04333290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899910|NCT00883428|||||CROSS_SECTIONAL|||||||
33899911|NCT06039917|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33982944|NCT04526964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This RCT will be conducted at four established cardiac centers in Germany. Participants will be assigned to either intervention or control using a 1: 1 randomization scheme. Block-randomization will be performed by a professional from the study coordinating center not being involved into the clinical care for patients. The group assignment is non-blinded to the professionals involved in order to enable the intervention to be carried out adequately. Participants in the control group (CGr) receive standard follow-up procedures (care as usual). The intervention group (IGr) receive self-management support and skills training based on the modular self-management curriculum post-implant and during regular outpatient follow-up. The self-management training program will be supplemented by a smartphone-based application. The intervention lasts for 3 months followed by a 9-month follow-up period per participant. Based on power calculations the inclusion of 142 patients is anticipated.||||
33982945|NCT05334147|||COHORT||PROSPECTIVE|||||||
33680285|NCT00710125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680286|NCT02423967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680287|NCT00864916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680288|NCT01054547|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33680289|NCT01757340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680290|NCT06127446|||CASE_ONLY||OTHER|||||||
33680291|NCT01725659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680292|NCT03908489|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The statistician, clinical and radiographic outcomes assessors will be blinded in this study.|same patient will one molar indicated for vital pulpotomy on one side and on contralateral side|f|f|t|t
33680293|NCT06081322|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33680294|NCT04772638|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Cluster RCT with a waitlist control||||
33680295|NCT00998127|||COHORT||PROSPECTIVE|||||||
33680296|NCT00755209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680297|NCT00313183|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33680298|NCT04411784|||CASE_CONTROL||RETROSPECTIVE|||||||
33680299|NCT00179491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33680300|NCT03104660|NA|SINGLE_GROUP||TREATMENT||NONE||CE certified mitral valve repair systems||||
33680301|NCT04938297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680302|NCT04375657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||TRIIM-X is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration.|f|f|f|t
33680303|NCT03081156|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33982946|NCT03136666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982947|NCT03648944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982948|NCT02879877|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33770774|NCT01223222|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33770775|NCT02746575|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770776|NCT01977001|||CASE_ONLY||PROSPECTIVE|||||||
33770777|NCT06170749|||COHORT||OTHER|||||||
33770778|NCT06266702|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33770779|NCT00309608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33770780|NCT02991235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33770781|NCT03917160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770782|NCT01700673|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770783|NCT01221324|||COHORT||RETROSPECTIVE|||||||
33770784|NCT04268953||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33770785|NCT04739683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770786|NCT05504382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"children suffering from juvenile idiopathic arthritis/oligoarthritic (mainly the knee joint) will participate in the study.~All children will be randomly assigned into 2 groups of equal numbers A, B using sealed envelopes, 21 children for each group.~* Study group A: will receive especially electrical acupuncture on the knee joint~* Study group B: will receive naproxen phonophoresis on the knee joint"|Randomized Clinical Trial|t|f|f|f
33770787|NCT05261932|||CASE_CONTROL||PROSPECTIVE|||||||
33770788|NCT06529354|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33770789|NCT01421082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770790|NCT06414564|NA|SEQUENTIAL||TREATMENT||NONE||||||
33770791|NCT04561141|||OTHER||CROSS_SECTIONAL|||||||
33899912|NCT05198167|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this type of study, the aim is to guarantee internal validity by minimizing possible biases, which is why it is important to guarantee the randomization process and the measurement of variables with objectivity criteria. This type of clinical trial does not allow masking the person who performs the intervention, nor the person who measures the main outcome variable, since given the type of patient and the specific care required, it is not possible for a professional outside the patient's care to carry out the assessment of the patient. Blinded analysis of the patients will be guaranteed.|"* Group A: Application of hyperoxygenated fatty acids.~* Group B: Protection of pressure areas with hydrocolloid dressing."|f|f|f|t
33899913|NCT02983838|||CASE_CONTROL||PROSPECTIVE|||||||
33899914|NCT02725177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899915|NCT02646436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899916|NCT03224026|||COHORT||PROSPECTIVE|||||||
33899917|NCT04165265|NA|SINGLE_GROUP||TREATMENT||NONE||Case-control trial||||
33899918|NCT03955029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33899919|NCT00552799|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33899920|NCT02850614|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33899921|NCT02812030|||COHORT||PROSPECTIVE|||||||
33899922|NCT01398254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899923|NCT00480194|||CASE_ONLY||PROSPECTIVE|||||||
33899924|NCT04986527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899925|NCT01736683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899926|NCT03039777|||COHORT||PROSPECTIVE|||||||
33899927|NCT01589094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899928|NCT02120586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33899929|NCT06229678|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants, and investigators will be blinded to the randomization|A randomized (2:1) placebo controlled double blind study|t|f|t|f
33899930|NCT02256449|||COHORT||PROSPECTIVE|||||||
33899931|NCT02275572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899932|NCT03946306|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients will not know which treatment they will receive|The patients will be divided in 2 groups: Group 1: (control group) 5,25% NaOCl with syringe needle irrigation alone. Group 2: 5,25% NaOCl with syringe needle irrigation, activated with sonic system EDDY (VDW, Munich, Germany)|t|f|f|f
33899933|NCT01251575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899934|NCT03705923|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770792|NCT05393362|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The researchers who perform the assessments and analyzes of the data will be blinded.|Randomized crossover clinical trial at the Hospital Regional Universitario of Malaga|f|f|t|t
33770793|NCT02910518|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33770794|NCT03722719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33899935|NCT03945331|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33899936|NCT02383394|||COHORT||RETROSPECTIVE|||||||
33899937|NCT03033108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899938|NCT01056107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899939|NCT03963297|||COHORT||PROSPECTIVE|||||||
33899940|NCT01601015|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33899941|NCT00881920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899942|NCT01430728|||COHORT||PROSPECTIVE|||||||
33899943|NCT02786459|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33899944|NCT04330625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899945|NCT00974662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899946|NCT00242177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33899947|NCT04733729|||COHORT||CROSS_SECTIONAL|||||||
33982949|NCT05844722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982950|NCT00208026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982951|NCT03693430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982952|NCT02326610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982953|NCT03581526|||COHORT||PROSPECTIVE|||||||
33770795|NCT04840888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33770796|NCT05159206|NA|SINGLE_GROUP||TREATMENT||NONE||One group of patients undergoing total hip arthroplasty with a new technique of preoperative templating, per-operative navigation and postoperative migration analysis.||||
33770797|NCT00975572|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33770798|NCT02797223|||CASE_ONLY||CROSS_SECTIONAL|||||||
33770799|NCT01738022|NA|SINGLE_GROUP||OTHER||NONE||||||
33770800|NCT03577808|||COHORT||PROSPECTIVE|||||||
33770801|NCT02140294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899948|NCT04311905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded||t|f|f|f
33899949|NCT02672839|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33899950|NCT03020186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899951|NCT02614794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking applied only during the Double-blind phase of the trial. The Unblinded Phase is open-label.||t|t|t|t
33899952|NCT03488992|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33899953|NCT01370954|||COHORT||PROSPECTIVE|||||||
33899954|NCT04975048|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Masking was applied for those who collected blood samples, physical examination data, and assessed laboratory outcomes. People who were masked did not participate in the routine management meetings of the trial.||f|t|f|f
33899955|NCT04250805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899956|NCT06522854|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator and Outcomes Assessor) The only unmasked person will be the pharmacist who dispenses the study medication--sildenafil 50 mg or identical placebo.|Parallel Assignment Double blinded, placebo controlled, 1:1 parallel allocation, randomized feasibility trial|t|t|t|t
33899957|NCT04685330|||COHORT||PROSPECTIVE|||||||
33899958|NCT05322460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899959|NCT04445077|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33899960|NCT01728259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899961|NCT04958564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33899962|NCT00234117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33899963|NCT04715750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33899964|NCT05657977|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Just one researcher has to blinded.|The one-group, pretest, posttest research design.|f|f|t|f
33899965|NCT00003641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899966|NCT02720068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899967|NCT01103050|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33899968|NCT04760652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Rater blinded|"Esketamine:All participants will receive esketamine for MDSI (Major depression with suicidal ideation) as part of their standard care. The protocol will adhere to the FDA label for this product and the FDA-registered trials.~CBT:Half of participants will be randomized to the CBT intervention, which will consist of an in-person and computer-based component (based on Good Days Ahead). In total, this will consist of 20 total sessions given over 16 weeks (the first 4 weeks of CBT will have sessions twice weekly; thereafter sessions will be held weekly).~TAU only:Participants not randomized to CBT will undergo treatment as usual (TAU). These patients will undergo standard, post-hospitalization clinical treatments, which may include physician visits and psychotherapy (except for formal CBT)."|f|f|f|t
33899969|NCT04251312|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33899970|NCT00307229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899971|NCT04634539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899972|NCT02976831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33899973|NCT04397055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blinded to which oil they are receiving|8 week parallel feeding trials of diets rich in Cottonseed oil or Olive Oil|t|f|f|f
33899974|NCT01347164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33899975|NCT02217462|||COHORT||PROSPECTIVE|||||||
33899976|NCT01312155|||CASE_CONTROL||PROSPECTIVE|||||||
33899977|NCT01348919|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33899978|NCT01851473|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33899979|NCT00827619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899980|NCT02708212|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33899981|NCT02768129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33899982|NCT04722172|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, multicenter clinical trial.||||
33982954|NCT01285037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982955|NCT01014065|||COHORT||PROSPECTIVE|||||||
33680304|NCT05373888|||COHORT||PROSPECTIVE|||||||
33680305|NCT01627834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680306|NCT04618510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Masked Randomized Study||t|f|f|f
33680307|NCT06022471|||COHORT||PROSPECTIVE|||||||
33770802|NCT00204659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770803|NCT03045393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899983|NCT05084989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part1: double blinded Part2: observer-blinded|Part1: 2 arms Part2: 2 arms|t|t|t|t
33899984|NCT02333331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33899985|NCT01656616|||COHORT||RETROSPECTIVE|||||||
33899986|NCT05081622|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33899987|NCT05921448|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) . Encryption will be through a website (REDCap).|"2-arm randomized, placebo-controlled, multicenter, parallel group intervention study in patients aged between 18-49.~Participants will be randomly allocated to one of four treatment groups.~Conducted in adherence with Good Clinical Practice (GCP)."|t|t|t|t
33899988|NCT02278146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33899989|NCT03500107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899990|NCT06673420|||OTHER||CROSS_SECTIONAL|||||||
33899991|NCT03451825|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33899992|NCT04807582|||COHORT||PROSPECTIVE|||||||
33899993|NCT03008512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33899994|NCT04010422|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33899995|NCT03403972|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33899996|NCT00641147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33899997|NCT02214758|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33899998|NCT01974180|||CASE_CONTROL||PROSPECTIVE|||||||
33899999|NCT01753544|||CASE_ONLY||PROSPECTIVE|||||||
33900000|NCT01378663|||||RETROSPECTIVE|||||||
33900001|NCT02378753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900002|NCT00258154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900003|NCT05515562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982956|NCT01342328|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33770804|NCT03306043|NA|SINGLE_GROUP||TREATMENT||NONE||A single group of subjects will receive 300 mg SC mepolizumab every 4 Weeks.||||
33770805|NCT02843958|NA|SINGLE_GROUP||||NONE||||||
33770806|NCT02976597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770807|NCT02341456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770808|NCT06369025|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33770809|NCT00429494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770810|NCT01062412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770811|NCT02520999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33770812|NCT05914831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770813|NCT00552786|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33770814|NCT01760746|||CASE_CONTROL||PROSPECTIVE|||||||
33900004|NCT05689827|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33900005|NCT03154450|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33900006|NCT02163369|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33900007|NCT03172650|||CASE_CONTROL||PROSPECTIVE|||||||
33900008|NCT03088423|||CASE_ONLY||RETROSPECTIVE|||||||
33900009|NCT04044534|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33900010|NCT05761327|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention Group 1: Mediterranean Diet Intervention Group 2: Mediterranean Diet + Curcumin Supplementation Intervention Group 3: Mediterranean Diet + Resveratrol Supplementation||||
33900011|NCT00798512|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900012|NCT06513260|||COHORT||PROSPECTIVE|||||||
33900013|NCT05616390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900014|NCT00330629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900015|NCT00772395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900016|NCT06671691|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Treatment tolerance will be the basis for allowing us to progress to the next dose level.~Dose-limiting toxicity (DLT) will be defined as a G3-G4 toxicity or G2 in cases of hypo/hyperpigmentation according to the CTCAE v5.0 scale, assessing the following items: induration, ulceration, pruritus, pigmentation changes, and fatigue. If, at 3 months post-RT at the initial dose level, none of the patients present a DLT, three new patients will receive RT at the next dose level. However, if any patient in a group presents a DLT, three additional patients will be added at the same dose level. Dose escalation will continue up to 30Gy unless \>33% of patients in a single dose group experience a DLT.~If \>33% of patients at a dose level experience a DLT, the study will end, and the dose level immediately below this will be selected to design the phase II of the study."||||
33900017|NCT01652677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900018|NCT03004014|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33900019|NCT01756976|||COHORT||PROSPECTIVE|||||||
33900020|NCT00917410|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33900021|NCT05336370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The two vagus nerve stimulation arms are double-blinded, both for the participants and the outcome assessor, whilst the hypnosis arm is not possible to blind.|The HypnoPain trial is designed as an experimental randomized controlled, statistician blinded superiority trial with three parallel groups|t|f|t|t
33900022|NCT00621023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900023|NCT03614624|NA|SINGLE_GROUP||PREVENTION||NONE|No masking description|All the healthy volunteers who consent to participate in the study, and who are eligible according to the protocol will have an clinical examination, an electrocardiogram and an echocardiography with two devices.||||
33900024|NCT05627193|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessor determining the patient satisfaction will be blinded to the type of follow up. This will be ensured by restricting the information available to accessor to only the name and contact number of the patient. The assessor will therefore have no access to the electronic health record of the patient on HIS and will not be able to determine the type of follow up of the patient.|Pre-operative randomization will be carried out and patients will be allocated to either of the two groups this will be done by 'Computerized block randomization'.|f|f|f|t
33982957|NCT00242060|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982958|NCT06344832|||COHORT||PROSPECTIVE|||||||
33770815|NCT06044363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Open trial|a single center, open-label, randomized, controlled trial|t|f|f|f
33770816|NCT05327335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Reference group: A total of 60 older adults without mobility difficulties will be recruited for need assessment, robot adoption, mobility assessment, and manipulability assessment. Each session will last for around 3 hours.~Intervention group: A total of 120 older adults from out-patient clinic and/or elderly community service units will be recruited for user studies in three phases, with 60 people in each phase. Subjects to be recruited in Phase 2 and Phase 3 need to meet the following inclusion and exclusion criteria: (1) aged 65 or older; (2) SARC-F score (measurement of sarcopenia) equal to or over 4; (3) SPPB score less than 11; (4) moderate mobility impairment, i.e., ADL between 6 and 12; (5) capable of clear communication; and (6) no cognitive impairment. Participants will use the robotics system and integrated environment to perform daily self-care to uncover problems in functionality, usability, and acceptance of the robotic device prototype."||||
33770817|NCT02307110|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770818|NCT01216176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079142|NCT05952921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The rinses will be coded to avoid any bias and the codes will not be broken before the study ends. Patients will be randomly assigned to receive a rinse bottle identified as solution A or B. These bottles will be identical in terms of shape, color and material. Neither the subject nor the dentists will be informed about the group assignment. The principal investigator who does not participate in the treatment or data collection will have access to a closed envelope with the allocation information."||t|t|t|t
33770819|NCT05078528|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770820|NCT01857830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33770821|NCT02971059|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33770822|NCT02767635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770823|NCT00706784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770824|NCT05262426|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33770825|NCT02521324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770826|NCT05039034|||OTHER||CROSS_SECTIONAL|||||||
33770827|NCT04919187|||COHORT||PROSPECTIVE|||||||
33770828|NCT03018743|||CASE_ONLY||PROSPECTIVE|||||||
33770829|NCT04166929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770830|NCT01288781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33770831|NCT02013973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770832|NCT03307915|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33770833|NCT03118544|||CASE_ONLY||PROSPECTIVE|||||||
33770834|NCT04328363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33770835|NCT05045911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770836|NCT01447849|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33770837|NCT03381508|||COHORT||RETROSPECTIVE|||||||
33770838|NCT02831179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770839|NCT03434236|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33770840|NCT01706965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770841|NCT01406717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770842|NCT05542732|NA|SINGLE_GROUP||SCREENING||NONE||A sample size of twelve subjects was planned in both the non-invasive study and invasive study, as recommended by the FDA Guidance for Industry and FDA Staff Pulse Oximeters - Premarket Notification Submissions \[510(k)s\]. Of these subjects, at least a minimum of 2 subjects or 15% of the analyzed population needed to have a dark skin pigmentation and at least 30 % of one gender is preferred.||||
33770843|NCT06488794|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33770844|NCT04243889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770845|NCT01427335|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33770846|NCT02701751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33770847|NCT01069068|||CASE_ONLY||PROSPECTIVE|||||||
33770848|NCT01594177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770849|NCT03948425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770850|NCT05172830|||COHORT||OTHER|||||||
33770851|NCT03752762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770852|NCT01698658|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770853|NCT02913521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33770854|NCT04221750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo controlled||t|f|t|t
33770855|NCT02710760|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33770856|NCT04961736|||CASE_CONTROL||PROSPECTIVE|||||||
33770857|NCT04757467|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||f|t|t|t
33770858|NCT01705275|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33770859|NCT05471258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are not familiar with diathermy, and will lie prone while receiving treatment. They will also be cited on different days of the week to the experimental group.~The therapist assessing the outcome measures does not know which group the patients belong to, and will be supervised by the principal investigator so that they do not ask any questions about it."|Once the study is over, the control group will have the opportunity to receive radiofrequency treatment for three weeks.|t|f|f|t
33770860|NCT04513457|||COHORT||RETROSPECTIVE|||||||
33770861|NCT03414697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33770862|NCT01807221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770863|NCT05693493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33770864|NCT01898520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770865|NCT03121534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770866|NCT01830881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770867|NCT00005991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770868|NCT03748979|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33770869|NCT04772690|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33770870|NCT05438615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900025|NCT01690949|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33900026|NCT01466725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680308|NCT06393556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Care provider measuring the primary outcome scale at T2 was not aware of the intervention given at T0/1. Statistical data analysis initially was prepared not knowing which group was the intervention group.|1:1 randomization|f|t|f|t
33680309|NCT02091505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680310|NCT04754217|||COHORT||PROSPECTIVE|||||||
33680311|NCT04753424|||CASE_ONLY||PROSPECTIVE|||||||
33680312|NCT01348477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33680313|NCT03798119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680314|NCT01097031|||||PROSPECTIVE|||||||
33680315|NCT03337919|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, phase II, multi-centre study. It will use an Ahern single stage design with independent trials steering committee review to monitor for safety and efficacy.||||
33680316|NCT05028361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33680317|NCT01697410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680318|NCT03270826|||OTHER||CROSS_SECTIONAL|||||||
33680319|NCT02879331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900027|NCT02975154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33680320|NCT00839176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680321|NCT02642744|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680322|NCT03596541|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33680323|NCT03165604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be given the same drink (water) in different packaging||t|t|f|f
33680324|NCT02335814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680325|NCT03553992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680326|NCT01239992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680327|NCT00154089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680328|NCT01870934|||||PROSPECTIVE|||||||
33680329|NCT02285036|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33680330|NCT00551928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680331|NCT05977738|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||open label, dose-finding, 3+3-like dose-escalation study design||||
33680332|NCT00489125|||COHORT||PROSPECTIVE|||||||
33680333|NCT05662800|||CASE_ONLY||CROSS_SECTIONAL|||||||
33680334|NCT02409030|||OTHER||PROSPECTIVE|||||||
33680335|NCT02058823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33680336|NCT03689309|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33680337|NCT06156293|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Pragmatic stepped wedge design - over 4 months, 18 sites enter trial at 1 month intervals.||||
33680338|NCT02194257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680339|NCT05170867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680340|NCT05949034|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33680341|NCT00536211|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33680342|NCT02551991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680343|NCT02613273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680344|NCT06199583|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680345|NCT04567901|||CASE_CONTROL||RETROSPECTIVE|||||||
33680346|NCT04550377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900028|NCT05303675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900029|NCT02060825|||CASE_ONLY||PROSPECTIVE|||||||
33900030|NCT03630068|||COHORT||RETROSPECTIVE|||||||
33900031|NCT00988962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900032|NCT05760456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900033|NCT02511080|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33900034|NCT05337605|||COHORT||PROSPECTIVE|||||||
33900035|NCT03453749|NA|SINGLE_GROUP||TREATMENT||NONE||5 consecutive adult patients with severe head trauma will receive treatment||||
33900036|NCT05391763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the observer for drain volume are both blinded for their assigned breast randomization. The surgeon(s) and coordinating researcher will not be blinded, and are therefore not allowed to measure the drain production.||t|t|f|f
34079143|NCT03663296|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34079144|NCT05035251|||CASE_CONTROL||PROSPECTIVE|||||||
33680347|NCT05898529|||COHORT||PROSPECTIVE|||||||
33680348|NCT04446390|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680349|NCT01608022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680350|NCT04036318|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33680351|NCT04801927|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680352|NCT02325843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680353|NCT05972525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The group of hip and knee surgeons at Vejle, Odense, and Svendborg hospitals will be randomized 1:1 either to continue standard consultation or to practice SDM supported by the in-consultation PtDA.||||
33680354|NCT02299518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680355|NCT02672020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680356|NCT03219658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680357|NCT02799251|||COHORT||PROSPECTIVE|||||||
33680358|NCT03754439|||COHORT||PROSPECTIVE|||||||
33680359|NCT03519542|||COHORT||PROSPECTIVE|||||||
33680360|NCT06405945|||COHORT||PROSPECTIVE|||||||
33680361|NCT00422084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33900037|NCT02325999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900038|NCT03373812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900039|NCT02398123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900040|NCT00116311|||DEFINED_POPULATION||OTHER|||||||
33900041|NCT05798962|||COHORT||PROSPECTIVE|||||||
33900042|NCT04312997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900043|NCT06218589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900044|NCT06533384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900045|NCT05775406|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33900046|NCT02132338|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900047|NCT06207877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079145|NCT05534139|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33982959|NCT05037006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For each patient, an opaque envelope will be prepared, sealed and numbered sequentially containing the group to which the patient will be allocated. A list of randomized computer-generated numbers (www.random.org) will be used for this purpose. No surgeon, members of the nursing team, anesthesiologist involved in anesthesia or data collection will be aware of the dose of neostigmine to be administered. The type of anesthesia (inhalation or venous) will not be covered. An anesthesiologist not involved in the study will be responsible for preparing the solution containing neostigmine and atropine (diluted with saline solution until complete 20 mL) according to the group to which each patient belongs. Syringes (20 mL) will be similar and identified only with a label with the word reversal."|Prospective, randomized, clinical trial|t|t|t|f
33982960|NCT02804737|||COHORT||PROSPECTIVE|||||||
33982961|NCT01760408|||||PROSPECTIVE|||||||
33982962|NCT04408365|||COHORT||PROSPECTIVE|||||||
33982963|NCT02754622|||COHORT||PROSPECTIVE|||||||
33982964|NCT04354532|||CASE_ONLY||RETROSPECTIVE|||||||
33982965|NCT03818230|||COHORT||PROSPECTIVE|||||||
33680362|NCT00168792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680363|NCT01566214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33680364|NCT02745145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680365|NCT03337828|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33680366|NCT05334056|||CASE_ONLY||PROSPECTIVE|||||||
33680367|NCT04714775|||COHORT||PROSPECTIVE|||||||
33680368|NCT04476173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680369|NCT03726450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680370|NCT02727231|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680371|NCT05614856|||COHORT||PROSPECTIVE|||||||
33680372|NCT06294210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A group of students will be using the mobile app and wrist-monitor to support their wellbeing while a control group of students will be followed at the same time who will not be using the app or wearable. The survey wellbeing, stress, and sleep scores will be compared between these groups.||||
33680373|NCT03758755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680374|NCT05784285|NA|SINGLE_GROUP||TREATMENT||NONE|All assessors will be blinded to the time point in which the intervention begins and to the chosen activity.|A 22-week interrupted time series design with multiple baselines across 150 youth with physical disabilities stratified by sex and severity will be employed.||||
33680375|NCT03543488|||COHORT||RETROSPECTIVE|||||||
33680376|NCT00662532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33680377|NCT03860558|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33680378|NCT04828772|||COHORT||RETROSPECTIVE|||||||
33680379|NCT04987359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33680380|NCT02490345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680381|NCT00097981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680382|NCT03943537|NA|SINGLE_GROUP||OTHER||NONE||||||
33680383|NCT02415842|||COHORT||RETROSPECTIVE|||||||
33680384|NCT06273137|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be randomized 1:1 to either receive PAT upon enrollment or after a waitlist period.||||
33982966|NCT01124929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33982967|NCT03716011|NA|SINGLE_GROUP||TREATMENT||NONE||the EXCROSSAL stent in CAD patients with 3-month DAPT or 12-month DAPT||||
33982968|NCT03991026|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated to one of 2 groups: a control group or the intervention group.||||
33680385|NCT05711446|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680386|NCT02483767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680387|NCT01510457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680388|NCT06025045|||CASE_ONLY||RETROSPECTIVE|||||||
33680389|NCT04882345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680390|NCT05418309|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33680391|NCT00118456|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982969|NCT05719545|||COHORT||PROSPECTIVE|||||||
33982970|NCT00610090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900048|NCT03183635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900049|NCT05018338|||COHORT||PROSPECTIVE|||||||
33680392|NCT03259620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680393|NCT03124667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33680394|NCT02788279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680395|NCT05729867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680396|NCT01455909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770871|NCT03893864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participants of the interventional group know they are taking a nutritional supplementation in study to improve health condition. Only the outcome evaluators, blood analisis, exercise testing data processing, muscle biopy analisys do not know if the samples come from control or interventional group|Interventional study of 22 subjects, 12 under supplemental intervention and 10 as control subjects. Both groups are similar subjects with same characteristics and condition. The interventional group will receive a supplementaction of CoQ10 (100 mg) during one month, the Control group nothing.|f|t|f|t
33770872|NCT04286230|||COHORT||PROSPECTIVE|||||||
33900050|NCT02721004|||CASE_ONLY||CROSS_SECTIONAL|||||||
33900051|NCT02094846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900052|NCT00053612|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33900053|NCT01704872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900054|NCT01690234|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33900055|NCT05886192|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33900056|NCT03070132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900057|NCT06361459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||three study groups: group that does not smoke, group that smokes and stops, group that smokes and does not stop||||
33900058|NCT02924675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900059|NCT02357277|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33900060|NCT01972425|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33900061|NCT01450371|||||PROSPECTIVE|||||||
33900062|NCT05243329|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33900063|NCT06672289|||OTHER||PROSPECTIVE|||||||
33900064|NCT01986205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900065|NCT04044547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900066|NCT01842464|||COHORT||RETROSPECTIVE|||||||
33900067|NCT05652192|NA|SINGLE_GROUP||TREATMENT||NONE||SBRT for metastatic diseases combined with systemic therapy with GP chemotherapy plus PD-1 antibody||||
33900068|NCT03728361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900069|NCT03524872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The devices will have the same shape and will be delivered to the surgeon unlabeled in an identical sterile envelope.||t|t|t|t
33900070|NCT03183921|||COHORT||PROSPECTIVE|||||||
33900071|NCT05107414|||COHORT||RETROSPECTIVE|||||||
33900072|NCT02031146|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33900073|NCT03606746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900074|NCT01548664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982971|NCT04558905|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"This a non-inferiority and cross-over study, with a planned follow-up of 16 months, with 2 intervention arms:~Intervention 1: Patients assigned to 6 months of usual medical care model, followed by 4 months of a control period, and finally 6 months of hybrid medical care model.~Intervention 2: Patients assigned to 6 months of hybrid medical care model, followed by 4 months of a control period, and finally 6 months of usual medical care model."||||
33982972|NCT02778230|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33982973|NCT01475396|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33900075|NCT05015361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Remimazolam Tosilate compared with Propofol Injection|t|t|t|t
33900076|NCT05522114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900077|NCT00114907|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33900078|NCT02773992|||COHORT||PROSPECTIVE|||||||
33900079|NCT01835327|||CASE_CONTROL||PROSPECTIVE|||||||
33900080|NCT05352217|||COHORT||PROSPECTIVE|||||||
33900081|NCT03123523|||CASE_CONTROL||PROSPECTIVE|||||||
33900082|NCT05025488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900083|NCT05014074|NA|SINGLE_GROUP||OTHER||NONE||||||
33900084|NCT01714583|||||RETROSPECTIVE|||||||
33900085|NCT01161524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900086|NCT03987399|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33900087|NCT02467114|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33982974|NCT06310460|||COHORT||PROSPECTIVE|||||||
33982975|NCT03585530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982976|NCT01434108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33982977|NCT00724256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33982978|NCT05173207|||COHORT||PROSPECTIVE|||||||
33680397|NCT06282458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind|"Subjects will be randomized to the three treatment arms (GLP-1 receptor agonist plus either enobosarm 3mg dose group, enobosarm 6mg dose group, or placebo group) in a 1:1:1 fashion. All patients randomized into this study will be medically indicated for use of GLP-1 receptor agonist for weight management. NOTE: First dose of GLP-1 receptor agonist will be Day 1 of this study.~The primary efficacy endpoint of the study will be the change from baseline in total lean mass at 4 months (112 days). Subjects will continue enobosarm (or matching placebo) monotherapy treatment from Day 112 to Day 196 to assess the effect of enobosarm on total lean mass, total muscle mass, maintenance of weight loss, and rebound fat gain after discontinuation of GLP-1 receptor agonists. A safety follow-up visit will occur approximately 30 days after last dose of study drug."|t|t|t|f
33680398|NCT02917811|||COHORT||PROSPECTIVE|||||||
33680399|NCT00403572|||COHORT||PROSPECTIVE|||||||
33680400|NCT02045030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680401|NCT05055492|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design.||||
33680402|NCT03135418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both group will recevie conventional stroke rehabilitation. Intervention group will receive a Oculus Rift+Leap motion tracking supported upper extremity activities and control group will receive a sham virtual reality on focusing visual scenes without interaction.~Outcomes will be recorded by physical therapist using SPSS and groups would not be specified with letter. Statistical analysis will be conducted by another researcher who does not aware of groups given numbers on SPSS."|Patients' information and contact will be obtaioned from neurologist and willing participant's gender, age and stroke onset data will be processed with a random number generator. Patients will divide into two groups as intervention and control with a normal distrubution of gender, age and stroke onset.|t|f|f|t
33680403|NCT04683601|||CASE_ONLY||RETROSPECTIVE|||||||
33680404|NCT01185353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680405|NCT02445547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680406|NCT00539175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680407|NCT04610957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680408|NCT00540618|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33680409|NCT03812237|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients were blinded to treatment until their 2 week post-operative visit.|Prospective, Randomized, Controlled Trial||||
33680410|NCT02777320|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33680411|NCT04628377|||CASE_CONTROL||PROSPECTIVE|||||||
33680412|NCT04850508|||CASE_CONTROL||PROSPECTIVE|||||||
33680413|NCT06131476|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33680414|NCT06476639|RANDOMIZED|PARALLEL||OTHER||NONE||"A phase II, open label, multicentre, three-group, randomised clinical trial.~240 eligible females aged 18 or older with clinically stage 1b or 2 vulvar cancer will receive a bilateral groin node ultrasound up to 30 days prior to planned surgery:~Participants with normal/negative baseline groin ultrasounds will be randomly assigned to two groups (2:1 randomisation). The Intervention group will receive bilateral groin node ultrasound every 2 months and clinical examinations every 3 months (groin lymph nodes are not removed). The Standard Group will undergo upfront full groin LND or sentinel node biopsy (SNB) based on clinician choice (according to local clinical practice management guidelines).~Participants with suspicious/indeterminate baseline groin ultrasound (third group) will receive an upfront full groin LND or SNB, consistent with the current standard treatment, according to local clinical practice management guidelines."||||
33680415|NCT02192424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680416|NCT03495583|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised controlled trial in which breastfed infants were randomised (equal groups) either to introduce 6 allergenic foods (cow's milk, egg, wheat, peanut, sesame, fish) from 3 months of age or to continue exclusive breastfeeding until about 6 months of age.||||
33680417|NCT02321670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680418|NCT01989208|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33680419|NCT06329284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Newly pregnant normotensive (NT) women with singleton fetus||||
33680420|NCT01942850|||||PROSPECTIVE|||||||
33680421|NCT02224885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680422|NCT00313781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680423|NCT05423860|||COHORT||OTHER|||||||
33680424|NCT03704753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised and double blinded.|t|t|t|t
33680425|NCT03602560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770873|NCT04410328|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1: Aggrenox plus standard care. Participants will receive Aggrenox (Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), 2 times daily (FDA-recommended dose) starting on the day of enrollment for a total of 2 weeks.~Arm 2: Standard care. Participants will receive standard care starting on the day of enrollment for a total of 2 weeks.~The investigators will perform a randomized, 2-arm, open-label single-site pilot study to evaluate the effect of oral Aggrenox (Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally), on clinical outcomes in patients with SARS-CoV-2. In this research proposal, the investigators will randomly assign 132 consenting participants with diagnosis of SARS-CoV-2 to two treatment groups: 1) Aggrenox (Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally) + standard care and 2) standard care alone. Participants will be screened, enrolled, receive treatment and followed for 28 days."||||
33770874|NCT04343781|||COHORT||CROSS_SECTIONAL|||||||
33770875|NCT06381817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900088|NCT06672159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All included ambulance stations will perform one of the two procedures for six months followed by a crossover for six months.||||
33900089|NCT03886077|||CASE_CONTROL||PROSPECTIVE|||||||
33900090|NCT06251388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900091|NCT02522481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900092|NCT03193905|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900093|NCT01654575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900094|NCT01070615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900095|NCT01743027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900096|NCT00379483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982979|NCT00828035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33982980|NCT04556240|||CASE_ONLY||PROSPECTIVE|||||||
33770876|NCT03154840|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||6x3 Crossover Study||||
33680426|NCT00546598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770877|NCT04713085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770878|NCT04621136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770879|NCT04466423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Groups labeled 1 or 2 with random order assignment."|Two-arm randomized controlled trial|f|f|f|t
33680427|NCT03666156|||COHORT||CROSS_SECTIONAL|||||||
33680428|NCT01123993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680429|NCT06166121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680430|NCT01253811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680431|NCT06374043|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized placebo-controlled double-blind cross-over trial with repeated administration (i.e., a series of N=1 trials).|t|t|t|f
33680432|NCT02400164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680433|NCT02577887|||COHORT||PROSPECTIVE|||||||
33680434|NCT06531967|||COHORT||PROSPECTIVE|||||||
33680435|NCT00648050|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33770880|NCT01488864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770881|NCT05765188|||CASE_CONTROL||RETROSPECTIVE|||||||
33770882|NCT05727033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The person in charge of analyzing the data collected in the study will not know if the participants belong to the intervention group or the control group, which will be identified with an alphanumeric code.|Cluster randomised clinical trial with the control group, unblinded and with pre-intervention, end-of-intervention and post-intervention assessments six months after the intervention. A 1:1 allocation ratio is established.|f|f|f|t
33770883|NCT04658628|||COHORT||PROSPECTIVE|||||||
33770884|NCT01983137|||COHORT||PROSPECTIVE|||||||
33770885|NCT03862703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Randomized controlled trial.|f|t|f|t
33770886|NCT00785538||SEQUENTIAL||TREATMENT||NONE||||||
33770887|NCT05136911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The principal investigator will be responsible for randomization and the outcome assessor (research assistant) will be blinded to group allocation. The research assistant will collect all outcome data at 6 weeks from the intervention and usual care group.|A pragmatic two-arm parallel 6-week randomized controlled Trial|f|f|f|t
33770888|NCT01248962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770889|NCT00196989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770890|NCT04139447|||COHORT||PROSPECTIVE|||||||
33770891|NCT02811900|||COHORT||PROSPECTIVE|||||||
33770892|NCT01741064|||COHORT||RETROSPECTIVE|||||||
33770893|NCT00557622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770894|NCT01440582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770895|NCT04570345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770896|NCT06218134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770897|NCT03492619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770898|NCT00726284|||COHORT||PROSPECTIVE|||||||
33770899|NCT02423590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770900|NCT01729897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770901|NCT00664703|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33770902|NCT05245799|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33770903|NCT02893683|||OTHER||CROSS_SECTIONAL|||||||
33770904|NCT00464919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770905|NCT05088967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770906|NCT04532437|||COHORT||PROSPECTIVE|||||||
33770907|NCT05858320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33770908|NCT06059534|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33770909|NCT04018898|||OTHER||PROSPECTIVE|||||||
33770910|NCT02413684|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33770911|NCT00127413|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33770912|NCT05420324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770913|NCT05853757|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Proof of science/concept, Single-arm, Single-blind||||
33770914|NCT02390063|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33770915|NCT00074243||||TREATMENT||||||||
33770916|NCT01749501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33770917|NCT01952964|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33770918|NCT01863641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770919|NCT01730014|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33770920|NCT02612896|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33770921|NCT06240858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770922|NCT02127827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770923|NCT02691351|||COHORT||PROSPECTIVE|||||||
33770924|NCT02827786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770925|NCT00485056|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33770926|NCT00977405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33770927|NCT04435392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770928|NCT01368211|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33770929|NCT00451841|||COHORT||PROSPECTIVE|||||||
33770930|NCT04956263|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blinded, randomized|"During the No Treatment Period prior to the baseline MMTT performed on Day -2, subjects will be randomized 1:1:1:1:1:1 to one of six Treatment Sequences A/B/C, A/C/B, B/C/A, B/A/C, C/B/A or C/A/B:~* Treatment A is YG1699 10 mg~* Treatment B is YG1699 25 mg~* Treatment C is dapagliflozin 10 mg"|t|t|t|t
33770931|NCT03567993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33770932|NCT00341068|||COHORT||CROSS_SECTIONAL|||||||
33770933|NCT00007475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900097|NCT00304590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680436|NCT00225264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680437|NCT02700633|||COHORT||RETROSPECTIVE|||||||
33680438|NCT00633542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770934|NCT05177575|||COHORT||PROSPECTIVE|||||||
33770935|NCT06265883|||COHORT||RETROSPECTIVE|||||||
33770936|NCT01190332|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33680439|NCT05607212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680440|NCT00003544||||TREATMENT||||||||
33680441|NCT00347373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680442|NCT05046327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680443|NCT04308200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study was a single blinded and randomized controlled trial. All children included in the study were evaluated by a single evaluator who was blind to therapy at baseline and at the end of treatment. The study was completed with a total of 30 individuals, 15 in the CO-OP+ neurodevelopmental therapy (NDT) and 15 in the NDT group. Both groups received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity and postural reactions. All children who met the inclusion criteria using GMFCS and MACS were evaluated with sociodemographic data, activity daily log, COPM and PEDI. The CO-OP group received twelve sessions of intervention, with the baseline and end of treatment assessments, each lasting approximately one hour.|f|f|f|t
33680444|NCT00329056|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33680445|NCT05109455|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33680446|NCT03664349|||COHORT||PROSPECTIVE|||||||
33900098|NCT01411410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680447|NCT03968640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter two-arm prospective, randomized, double-blind, placebo-controlled clinical trial. 290 eligible burn patients admitted to military/civilian hospitals to be enrolled within 48 hours after severe burn injury (20%-70% TBSA burn) \& randomly assigned to either CoQ10 (n=145) or Placebo (n=145) groups. Patients in the CoQ10 group to receive loading dose of CoQ10 (1,800 mg/day) for 4 weeks and then maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge. Allocation-concealed placebo will be used as an appropriate control.|t|t|t|t
33900099|NCT00639067|||COHORT||PROSPECTIVE|||||||
33900100|NCT03195790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors, PI, and some co-investigators will be blinded to group assignment.|Randomized controlled trial|f|f|t|t
33900101|NCT06429631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The person doing the statistical analysis will not know which is the experiment and which is the control group.|parallel group single-blind randomized control trial|t|f|f|f
33900102|NCT06178510|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33900103|NCT05358834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33982981|NCT00537225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Home-based exercise|t|f|f|f
33680448|NCT03421769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680449|NCT05908643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680450|NCT02256397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680451|NCT02024178|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680452|NCT00711178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680453|NCT00358345|||COHORT||PROSPECTIVE|||||||
33680454|NCT03940768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680455|NCT03462433|||COHORT||PROSPECTIVE|||||||
33680456|NCT01066390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680457|NCT04871191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680458|NCT02991664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680459|NCT05324644|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study is a randomized and case-control study.||||
33680460|NCT01270802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680461|NCT04129151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680462|NCT00323817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680463|NCT01943253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680464|NCT03708393|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Independent Readers blinded to mass diagnosis|"This will be a controlled, blinded, multi-reader, multi-case (MRMC) study using a sequential design. The study will include 5-12 independent readers depending on qualifications and availability.~Imagio (IUS+OA) Training to be completed prior to any reads taking place. Read 1 is immediately followed by Read 2 within the same read session.~Read 1 (Control): Mammogram (if available) + History + IUS (stills and videos provided), IUS Probability of Malignancy (POM) and BI-RADS scored and the data form locked.~Read 2 (Test): Mammogram (if available) + History + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). An interim IUS POM and BI-RADS is recorded as well as a combined Imagio (IUS+OA) POM and BIRADS Pre and Post SenoGram on separate data forms."|f|f|f|t
33680465|NCT03733990|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation, six dose levels||||
33680466|NCT00002280||||TREATMENT||NONE||||||
33680467|NCT02251964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680468|NCT04580810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680469|NCT00705744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33680470|NCT02690571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33680471|NCT01677429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33680472|NCT05279391|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33680473|NCT04204980|NA|SEQUENTIAL||TREATMENT||NONE||"* Step I: dose-escalation 3 patients treated weekly during four weeks with 4 mg/kg of daratumumab, then 3 patients treated weekly during four weeks with 8 mg/kg of daratumumab, then 3 patients treated weekly four weeks with 16 mg/kg of daratumumab~* Step II: expansion cohort to 13 patients (with 10 new patients included and the last 3 patients from the step I) with eight weekly doses of 16 mg/kg daratumumabProvide"||||
33680474|NCT01062178|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680475|NCT04128631|||OTHER||PROSPECTIVE|||||||
33680476|NCT00108108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680477|NCT00720018|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680478|NCT03276455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680479|NCT03986372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900104|NCT05483972|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900105|NCT06377098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only person who will be unmasked will be the pharmacist who will dispense the study medication--either sildenafil 50mg or identical placebo|Double blinded, placebo-controlled, 1:1 parallel allocation, randomized feasibility trial|t|t|t|t
33900106|NCT00824538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900107|NCT05466110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680480|NCT05617313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982982|NCT01063543|||COHORT||PROSPECTIVE|||||||
33680481|NCT06146231|NA|SINGLE_GROUP||OTHER||NONE||This study is designed as a pivotal, prospective, multicentric, interventional, open-label, single-arm, non-randomized and pre-market clinical investigation.||||
33680482|NCT01779791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680483|NCT03642483|||COHORT||PROSPECTIVE|||||||
33770937|NCT03781115|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Double Blind Masking: The participant and the investigator are both blinded.|The investigators will first conduct a dose-response evaluation of the anti-psychotic drug ziprasidone (Geodon) (20, 40, or 60 mg tablet) or olanzapine (Zyprexa®) (2.5, 5, 7.5, or 10 mg tablet) in non-psychiatric ill control individuals to determine the dosage that promotes sedation in individuals versus a placebo. The evaluation will comprise of a physical examination, drug/pregnancy screenings and sleepiness questionnaires. Once the dosage of the anti-psychotic medication is determined new healthy subjects will be recruited to ingest the medication and have an electroencephalogram (EEG) recording taken. If the dosage of medication does not show an effect on the EEG the investigators will ask the individual to come back on a different day so the next higher dose of medication can be given. Once a the healthy subject's EEG shows an effect new control subjects and individuals with a diagnosis of schizophrenia will be recruited.|t|f|t|f
33770938|NCT05826522|||OTHER||PROSPECTIVE|||||||
33770939|NCT00358150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770940|NCT03781232|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33770941|NCT06138275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770942|NCT00615394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770943|NCT05214014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770944|NCT01993823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33770945|NCT04825821|||CASE_CONTROL||PROSPECTIVE|||||||
33770946|NCT03915080|NA|SINGLE_GROUP||OTHER||NONE||||||
33770947|NCT00322608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33770948|NCT03768999|||COHORT||PROSPECTIVE|||||||
33900108|NCT03518840|NA|SINGLE_GROUP||TREATMENT||NONE||All patients receive an SIJ belt.||||
33900109|NCT05295615|NA|SINGLE_GROUP||TREATMENT||NONE||Active treatment||||
33900110|NCT06065722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double Blind||t|f|t|f
33982983|NCT01245322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982984|NCT02603250|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982985|NCT04879888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982986|NCT03554707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33982987|NCT00150462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33982988|NCT01099943|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33770949|NCT05740761|||OTHER||PROSPECTIVE|||||||
33770950|NCT02758574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770951|NCT02790593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770952|NCT05024149|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33770953|NCT04315415|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject enrolled will receive implantation of both Silk Voice and control material.||||
33770954|NCT00114309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770955|NCT06208072|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Enrolled patients will be randomized into two arms. One arm will receive treatment with Irbesartan 150mg once daily and the second arm will receive treatment with Eplerenone 25mg twice daily. Blood pressure response will be assessed after 8 weeks. For both arms peptide differences will be assessed through proteomic analysis in responders and non responders in each individual arm.||||
33770956|NCT03050437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770957|NCT02905123|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33982989|NCT02421952|||CASE_ONLY||CROSS_SECTIONAL|||||||
33982990|NCT06202443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33770958|NCT03770013|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind study.|A prospective Randomized Interventional double-blind study.|t|t|t|t
33770959|NCT02811094|NA|SINGLE_GROUP||OTHER||NONE||||||
33770960|NCT01275196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900111|NCT03120910|NA|SINGLE_GROUP||OTHER||NONE||||||
33900112|NCT01933672|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33900113|NCT04372589|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, Bayesian adaptive randomized controlled trial||||
33900114|NCT02218203|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33900115|NCT04666961|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with extensive ductal carcinoma in situ with an indication for mastectomy receiving neoadjuvant hormone therapy with Tamoxifen (non-menopausal patients) or Anastrozole (postmenopausal patients)||||
33900116|NCT00035815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900117|NCT01644045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900118|NCT06563388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900119|NCT05721885|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Group A: standard treatment group, standard anti-tumor treatment, clinicians in accordance with the NCCN anti-tumor treatment guidelines.~Group B: peri-radiotherapy nutrition management group, standard anti-tumor therapy combined with peri-radiotherapy nutrition management."||||
33900120|NCT01690962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33982991|NCT01076452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982992|NCT03455348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982993|NCT02763111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33982994|NCT05319938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33982995|NCT04761965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33982996|NCT04347642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33982997|NCT02202850|||COHORT||PROSPECTIVE|||||||
33982998|NCT05890157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33982999|NCT02733120|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33983000|NCT06132698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983001|NCT05564819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983002|NCT05402852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects were randomly assigned to the EuBone® capsule treatment group or placebo control group in a 2:1 ratio.|t|t|t|f
33900121|NCT06027983|NA|SEQUENTIAL||TREATMENT||NONE||"This is a single arm, open-label, phase Ib safety lead in, followed by phase II study. The phase Ib segment will be carried out in a standard 3+3 dose escalation design. In the phase II, dose expansion will be carried out to a total of 10 patients at recommended phase II dose in both phase Ib and II.~Phase Ib: Patients with advanced solid tumors will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 6-30 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~Phase II: Up to a total of 10 patients with HER2+ advanced breast cancer will be enrolled.~For patients who are in Dose level 3 - 5 will require additional Trastuzumab,erythropoietin beta and Lymphodepletion."||||
33900122|NCT04272853|||COHORT||PROSPECTIVE|||||||
33900123|NCT01172288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900124|NCT02095730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900125|NCT06658002|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The treating and examining doctors and all participants will be masked to the identity of the medication in each group. The study drug will be labeled A, B ,C D, E, F with two letters to each treatment group. The only people who will not be masked is the pharmacist at Pondicherry who relabels the medications with the study drug code and maintains the master key of which drug belongs to which study label, the data analyst responsible for generating the randomization code, and a United States study coordinator who is responsible for relabeling protocol and training. The study coordinator at Aravind will not be informed of the master key but will be aware of the study drug allocation name as he/she will be dispensing study drug to the participant. The study coordinator at Aravind will review the drops with the patient each visit. The participants will be informed to not show the examining doctor any of the medications. The study doctors will not ask to see the study medications.|"This is a randomized controlled trial in which participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1% or CsA 2% or placebo for 4 weeks. In cases of bilateral fungal keratitis, if both eyes fit inclusion criteria, the eye with worse acuity will be randomized.~The primary outcome is Best Corrected Visual Acuity (BCVA) at 3 months."|t|t|t|t
33900126|NCT02718677|||OTHER||OTHER|||||||
33900127|NCT03391011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900128|NCT00335712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900129|NCT02984878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900130|NCT02742389|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33900131|NCT04211545|NA|SINGLE_GROUP||OTHER||NONE||||||
33900132|NCT02685150|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33900133|NCT01757457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900134|NCT00761124|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33900135|NCT04345939|||COHORT||PROSPECTIVE|||||||
33900136|NCT01223248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900137|NCT05286151|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900138|NCT06211348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900139|NCT02795156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900140|NCT00003139|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33900141|NCT03425799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900142|NCT04640246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900143|NCT05509257|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33900144|NCT02989727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900145|NCT04967430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900146|NCT06672640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The evaluators were blinded to the intervention details of the participants.||f|f|f|t
33900147|NCT03418246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and participants are blinded to restoration used.|One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer). The second group will be treated with Biodentine that will be placed near the gum line.|t|f|t|f
33900148|NCT00940927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900149|NCT05390632|||CASE_CONTROL||PROSPECTIVE|||||||
33900150|NCT05065138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900151|NCT05126225|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator.||||
33770961|NCT02339701|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33770962|NCT00994474|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
33900152|NCT03691558|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Treatment and control were masked with A and B|It is single blind, parallel arms study|f|f|f|t
33900153|NCT02941731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900154|NCT04943900|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33900155|NCT04091867|NA|SINGLE_GROUP||TREATMENT||NONE||This study will be enrolled using a 3+3 model. All patients will receive a fixed loading dose of 10 mg/kg to be followed by the assigned dose level during the concurrent phase. The 3+3 design model applies only to the concurrent phase. An expansion cohort of 6 patients will be added for testing biological endpoints.||||
33900156|NCT01190605|||CASE_ONLY||CROSS_SECTIONAL|||||||
33983003|NCT04528420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983004|NCT04347746|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33770963|NCT03600558|||COHORT||RETROSPECTIVE|||||||
33770964|NCT02338518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983005|NCT04200482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983006|NCT04104165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983007|NCT02164448|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33983008|NCT01815073|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770965|NCT05943418|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized Control Trial with an intervention arm and a control arm.|t|f|t|t
33900157|NCT01962259|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900158|NCT05677789|||COHORT||PROSPECTIVE|||||||
33983009|NCT05251025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983010|NCT05738382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masked for BG2109 dose groups and open for the active controlled group.||t|t|t|t
33983011|NCT01697696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983012|NCT05040230|||COHORT||PROSPECTIVE|||||||
33900159|NCT05020184|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|randomized, double-blind, placebo-controlled|The study design is a multicenter, prospective, randomized, double-blind, placebo-controlled, crossover trial of oral cimetidine 800mg twice daily versus placebo|t|t|t|t
33900160|NCT03768401|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33900161|NCT04828876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Yoga and control group|This study is an experimental study with pre-test and post-test control groups.|t|f|f|f
33900162|NCT05783401|||COHORT||PROSPECTIVE|||||||
33900163|NCT01373645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900164|NCT02492711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900165|NCT00015249||||DIAGNOSTIC||DOUBLE||||||
33900166|NCT03915691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900167|NCT04188366|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33900168|NCT06672302|||CASE_CONTROL||PROSPECTIVE|||||||
33900169|NCT04535011|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"Study Phase 1: The investigators will evaluate whether PPKAY with personalized text booster or PPKAY with standard text booster will reduce the quantity or frequency of alcohol use, the number of binge drinking events or the number of alcohol-related consequences based on the Drinker Inventory of Consequences (DrInC) compared to usual care.~Study Phase 2: The investigators will evaluate whether PPKAY alone is an inferior supplement to PPKAY plus standard or personalized text booster"|f|f|t|t
33900170|NCT01419171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900171|NCT03798561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part A: Double blinded, with exception of unblinded dispensing pharmacist Part B: Double blinded|Phase 1, multicenter, double-blind, vehicle-controlled, randomized ascending doses trial.|t|f|t|f
33900172|NCT01549847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900173|NCT03852342|||COHORT||RETROSPECTIVE|||||||
33900174|NCT03267329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900175|NCT04741243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was done by sealed envelope||t|f|f|t
33900176|NCT03763279|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The patient and the epidemiology nurse, who will assess the presence of SSI, will be blinded to the treatment assigned.~The surgeon is masked to the assignment prior to consenting and enrolling the patient and initiating the surgery."||t|f|f|t
33900177|NCT03170284|||COHORT||PROSPECTIVE|||||||
33900178|NCT05452746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor blinded to treatment allocation|Randomized single blinded controlled trial|f|f|f|t
33900179|NCT02584569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900180|NCT05650229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900181|NCT04749108|RANDOMIZED|PARALLEL||TREATMENT||NONE||Drug: Induction chemotherapy - modified FOLFIRINOX regimen Other: Early tumor response evaluation by MRI volumetry Radiation: Radiochemotherapy Cap 50 Procedure: Radical proctectomy with total mesorectal excision||||
33900182|NCT06671535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900183|NCT02627950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900184|NCT00677144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900185|NCT01252329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900186|NCT04868240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single-blinded two-arm RCT with parallel-groups (1:1 allocation ratio).|f|f|f|t
33900187|NCT04797286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900188|NCT06562816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900189|NCT02797041|||CASE_ONLY||RETROSPECTIVE|||||||
33900190|NCT04675346|||COHORT||CROSS_SECTIONAL|||||||
33900191|NCT05706467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects who met the inclusion criteria received two kinds of non-invasive positive pressure ventilation treatment, namely, non-invasive continuous positive pressure ventilation and non-invasive high-frequency oscillatory ventilation.||||
33983013|NCT01058278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983014|NCT03796806|||CASE_ONLY||PROSPECTIVE|||||||
33983015|NCT00098826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983016|NCT03236207|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33983017|NCT02932345|||CASE_CONTROL||RETROSPECTIVE|||||||
33983018|NCT03920657|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single arm, phase II, study designed to look whether early intervention with low dose DFX improves clinical outcome of patients with MDS.||||
33900192|NCT04128098|||COHORT||PROSPECTIVE|||||||
33900193|NCT04729127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900194|NCT03421223|||CASE_CONTROL||PROSPECTIVE|||||||
33900195|NCT02688075|||COHORT||PROSPECTIVE|||||||
33983019|NCT03395444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983020|NCT01728922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|similar appearance of placebo and active drug|double-blind, dose ranging, two doses of vitamin D, randomised parallel groups with placebo arms in clinically isolated syndrome and heathy control participants|t|t|t|t
33983021|NCT01247545|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33983022|NCT01851733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983023|NCT01515826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33900196|NCT01686503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33900197|NCT01927562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983024|NCT01646788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983025|NCT05350137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983026|NCT03338660|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|the assesor of platelet function and the PI will be blinded to group.|crossover study of various storage infusions techniques with each subject receiving various fluids aliquots.|f|f|t|t
33900198|NCT05067777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33900199|NCT05387590|NA|SINGLE_GROUP||OTHER||NONE||||||
33900200|NCT04953455|||OTHER||PROSPECTIVE|||||||
33900201|NCT01810991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900202|NCT03538392|||CASE_ONLY||PROSPECTIVE|||||||
33900203|NCT01104389|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33900204|NCT04180410|NA|SINGLE_GROUP||OTHER||NONE||No-randomized,no-comparative study||||
33900205|NCT02675517|||COHORT||PROSPECTIVE|||||||
33900206|NCT03120338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blind||f|f|f|t
33680484|NCT03839043|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A randomization schedule for each strata will be generated by the biostatistician using variable length blocks of size 2 or 4 to ensure that the number of subjects assigned to each of the 2 intervention groups remains balanced within each strata. Using these randomization schedules, a computer application program will be used that allows the study personnel to enroll a patient into the trial and obtain the appropriate treatment assignment. The computer application will assign this patient the next sequential treatment assignment for the admission status, and update the randomization dataset accordingly.Once treatment assignment is determined, study personnel will deliver the assigned intervention. The patient will be blinded to treatment assignment to the extent of not knowing the goal of the intervention a priori.|"Two hypotheses will be tested using a randomized controlled trial of 200 cigarette smokers scheduled for elective surgery that are willing to maintain temporary abstinence from cigarettes. Using a validated decision aid, subjects stratify according to intended duration of abstinence and randomize within each stratum to receive either a quit for a bit or a quit for good intervention. Both stratums employ a Short Message Service (SMS or text) to deliver extended follow-up and assess engagement, e.g. subject response to text requests (ex. # of cigarettes smoked). The quit for a bit intervention targets abstinence in the first 7 days after surgery, and has an option of receiving continued messages. Both interventions can continue messages beyond day 30. We will assess treatment engagement outcomes and the continuation rate. We will also obtain biochemically-confirmed abstinence data on the morning of surgery and 30 days post-surgery, as well as self-reported abstinence."|t|f|f|f
33680485|NCT01376518|||OTHER||PROSPECTIVE|||||||
33680486|NCT00562315|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33680487|NCT06518434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680488|NCT04732013|||COHORT||PROSPECTIVE|||||||
33900207|NCT06672679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680489|NCT05212545|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680490|NCT03027544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680491|NCT03137745|||OTHER||PROSPECTIVE|||||||
33680492|NCT03708354|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Placebo softgels will be of the same size/color as the active softgels.|dietary supplement|t|f|t|t
33900208|NCT02418403|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33900209|NCT06029712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900210|NCT02293343|||CASE_CONTROL||PROSPECTIVE|||||||
33900211|NCT06020976|||CASE_ONLY||CROSS_SECTIONAL|||||||
33900212|NCT01742351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900213|NCT02558946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983027|NCT05022056|||COHORT||RETROSPECTIVE|||||||
33983028|NCT01570322|||COHORT||PROSPECTIVE|||||||
33983029|NCT02567838|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33680493|NCT00486655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983030|NCT03203447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33680494|NCT01414348|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33680495|NCT03436758|||CASE_ONLY||PROSPECTIVE|||||||
33680496|NCT01030640|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33680497|NCT00107640|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33680498|NCT02972385|||COHORT||PROSPECTIVE|||||||
33900214|NCT05362162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33900215|NCT03701789|NA|SINGLE_GROUP||OTHER||NONE||||||
33900216|NCT03177577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900217|NCT02132390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900218|NCT04573777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900219|NCT02141308|||CASE_CONTROL||PROSPECTIVE|||||||
33983031|NCT00878397|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33680499|NCT01046435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33680500|NCT00870584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900220|NCT03115385|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33900221|NCT02935738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900222|NCT01632878|||COHORT||PROSPECTIVE|||||||
33900223|NCT02351037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900224|NCT03968445|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900225|NCT00693719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900226|NCT04538352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900227|NCT01057628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900228|NCT06669741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Randomized, Double-Blind, Placebo-Controlled Clinical Investigation|t|f|t|f
33900229|NCT04777955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|closed envelope procedure|Group 1, core stabilization exercises group; Group 2, core stabilization exercises + electrical stimulation group; Group 3, core stabilization exercises + kinesiological banding group.|t|f|f|f
33900230|NCT04110834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33900231|NCT00984659|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33900232|NCT04450914|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Mixed method, hybrid implementation-effectiveness (Type III) step-wedge clustered randomized trial||||
33900233|NCT02814214|||COHORT||PROSPECTIVE|||||||
33900234|NCT02819596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900235|NCT03648645|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900236|NCT03974178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983032|NCT01101802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983033|NCT04286802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983034|NCT06134778|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983035|NCT04172454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983036|NCT05280262|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No blinding on trial|||||
33983037|NCT05498805|RANDOMIZED|PARALLEL||TREATMENT||NONE||radiation||||
33983038|NCT04925648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, non-randomised pilot study||||
34079146|NCT01769677|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079147|NCT01305564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079148|NCT00713804|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34079149|NCT00532363|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079150|NCT04518917|NA|SINGLE_GROUP||OTHER||NONE||||||
34079151|NCT05990725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079152|NCT01747369|||CASE_ONLY||PROSPECTIVE|||||||
34079153|NCT01491022|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33983039|NCT04929626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator was aware of the intervention being provided. Others were masked including the participant and care provider.|Eligible patients were divided in two groups. In group A, patients received 3 back-to-back nebulization with Ventolin solution only using nebulizer machine and face mask after every 20 minutes for 60 minutes. In group B, patients were divided into 3 subgroups and each subgroup received both Ventolin and MgSO4 with three different doses after every 20 minutes for 60 minutes|t|t|f|f
34079154|NCT04826627|||COHORT||PROSPECTIVE|||||||
33983040|NCT05141097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079155|NCT01811537|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34079156|NCT05486884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Score mRS will be measured by a psychologist during a telephone interview 180 days after inclusion. The psychologist will be blinded to the randomization arm|Prospective, multicenter, randomized, controlled, open study|f|f|f|t
34079157|NCT01043978|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34079158|NCT04536714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079159|NCT02605759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079160|NCT04996966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079161|NCT04561648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients that are planned to go to an invasive coronary artery angiography with good radial pulse and using the TRA are going to be randomized to two groups. One will receive the standard UFH dose and the other will receive the prespecified high dose (per Kg of body weight) of UFH.|t|t|f|f
34079162|NCT00667641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079163|NCT04752371|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34079164|NCT04463810|||COHORT||PROSPECTIVE|||||||
34079165|NCT00232557|RANDOMIZED|PARALLEL||||NONE||||||
34079166|NCT00993551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079167|NCT00661089|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34079168|NCT02033759|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34079169|NCT01619865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The Octreoscan and 68Ga-DOTA-tyr3-Octreotide PET scans are read independently by two certified nuclear medicine physicians for discordant positive lesions.|||||
34079170|NCT04486118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079171|NCT06413966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Participants (Double-blinded) and Assessor (nurse who will be assigned for collecting perioperative and postoperative results after surgery)~* After obtaining informed consent and the patient's agreement to participate in the study, the patients will be allocated block sizes of four and computer-generated random numbers in sequential order within opaque envelopes that are sealed. The allocation process follows a 1:1 ratio.~* Those sealed envelopes were kept by the researcher. On the day of operation, after video-assisted thoracoscopic blebectomy/bullectomy will be done, a randomized envelope will be opened by the scrub nurse to determine which additional method would be used between partially absorbable mesh and apical pleurectomy."||t|f|f|t
34079172|NCT02349035|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079173|NCT00006193|RANDOMIZED|||TREATMENT||||||||
34079174|NCT01508988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079175|NCT00789321|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34079176|NCT03643718|||COHORT||PROSPECTIVE|||||||
34079177|NCT06529341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34079178|NCT01645982|||CASE_ONLY||PROSPECTIVE|||||||
34079179|NCT02671851|||COHORT||RETROSPECTIVE|||||||
34079180|NCT01204736|||COHORT||RETROSPECTIVE|||||||
34079181|NCT00141518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079182|NCT05003544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079183|NCT03735823|||COHORT||PROSPECTIVE|||||||
34079184|NCT02242123|||CASE_CONTROL||PROSPECTIVE|||||||
34079185|NCT02787577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079186|NCT04350827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blinded randomized comparative trial.|t|f|f|t
34079187|NCT00296855|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079188|NCT06139172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079189|NCT03301636|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079190|NCT04623866|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
34079191|NCT03926104|||COHORT||PROSPECTIVE|||||||
34079192|NCT00194129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079193|NCT05186129|RANDOMIZED|CROSSOVER||OTHER||NONE||open label, randomized, single-dose, 2 way cross-over study||||
34079194|NCT03567473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study personnel (including study nurses, coordinators, investigators, data management staff, and statistical team), health care staff providing patient care, and patients/families will be blinded to the study group assignment.||t|t|t|t
34079195|NCT03312374|||COHORT||PROSPECTIVE|||||||
34079196|NCT06401707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34079197|NCT01702467|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33983041|NCT02592161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983042|NCT06413290|||CASE_ONLY||PROSPECTIVE|||||||
33983043|NCT06292871|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will employ a randomized controlled trial design, with GDM patients from KKH randomly assigned to either the intervention or control group. Randomization will be conducted via the electronic randomization list.||||
33680501|NCT00413985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770966|NCT05071274|NA|SINGLE_GROUP||TREATMENT||NONE||This proof of Concept study serves to evaluate the efficacy and tolerability of Microneedling with SkinPen in female and male Subjects with facial Acne Vulgaris, ages 18 through 45. Overall assessment of clinical outcome and safety will be based on clinic visits. The Investigator will apply an objective and precise assessment, the Lesion Count of inflammatory and non-inflammatory lesions. The Investigator will also perform the IGA assessment. Subjects will be dispensed a Diary to record any new Adverse Events between visits. Subjects will be encouraged to contact the Study Investigator if any adverse events arise.||||
33983044|NCT05297266|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, interventional. Sixty patients (80 injured extremities) will receive tissue CO2 monitoring in the replanted extremity after traumatic amputation replant surgery.||||
33770967|NCT03084939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983045|NCT05847062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients will be randomized to assign them to one or another study group, which will be carried out by an independent assistant, who will generate a random sequence that will be unknown to the investigators. Each patient will be given a sealed and numbered envelope to choose from, in which the randomized group in which he/she has been included will be determined. The study will be blinded for the patient and rehabilitator but not for the surgeon|This is an experimental, prospective, unblinded, randomized, comparative clinical trial between patients carrying two types of prosthetic implants with a different biomechanical design based on medialization or lateralization of the center of rotation of the inverted prosthesis.|t|f|t|t
33770968|NCT04771858|||COHORT||PROSPECTIVE|||||||
33770969|NCT01579253|||COHORT||PROSPECTIVE|||||||
33770970|NCT06241261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770971|NCT04156152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The masking will be done by concealing the two main faces of the dentifrice container with a white adhesive and this will be delivered in sealed packages, all of the same color and shape.|A randomized clinical trial will be conducted to compare the clinical efficacy in reducing dentinal hypersensitivity in patients treated with dentifrices based on hydroxyapatite / 5% potassium nitrate / sodium monofluorophosphate 1450 ppm and 5% potassium nitrate / 1426ppm sodium fluoride, during an evaluation period of 8 weeks.|t|t|f|f
33983046|NCT05575219|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33770972|NCT00823732|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33770973|NCT01468922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33770974|NCT00787592|||COHORT||PROSPECTIVE|||||||
33770975|NCT00035698|||COHORT||CROSS_SECTIONAL|||||||
33770976|NCT03077373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33770977|NCT01495182|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33770978|NCT01479686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33770979|NCT01397565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33770980|NCT02583568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33770981|NCT06255093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be self-triaged to one of two study arms: (1) Pre-surveys only (did not meet referral criteria based on screening assessment) and receive online mental wellness education and anxiety treatment options information; (2) Pre-surveys, meet referral criteria, referred to a program, post-surveys. Post-surveys will occur at the end of the out-of-school program, or 4 months after joining the program (whichever comes first).||||
33900237|NCT03484533|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33900238|NCT02673112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900239|NCT06282172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900240|NCT02873715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Assessor will be blinded to the families group assignment. Coaches will be back up assessor. Coach 1 will be an assessor for families assigned to Coach 2, Coach 2 will collect measures for families assigned to Coach 3, and Coach 3 will collect measures for families assigned to Coach 1. Thus, coaches will not collect height and weight measures for families from their caseload.~Although not possible to guarantee that coaches are blind to condition for families that are not in their caseload due to the families not being blinded, use of a standard protocol (see Appendix C) ensures objective and reliable measurement of the primary outcome. Assessors will be blind to prior heights/weights, further protecting against assessment bias."||f|f|t|t
33900241|NCT03668548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All parties will be masked from the intervention.|The study will be a randomised controlled pilot trial. Participants will complete testing at baseline and after 10 weeks.|t|t|t|t
33983047|NCT02259270|||OTHER||RETROSPECTIVE|||||||
33983048|NCT02609139|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33983049|NCT02961309|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33983050|NCT02359474|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983051|NCT02859662|||COHORT||PROSPECTIVE|||||||
33983052|NCT02203448|||COHORT||PROSPECTIVE|||||||
33983053|NCT05729061|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33983054|NCT04983706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983055|NCT01658293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983056|NCT01161615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983057|NCT00854308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983058|NCT03443765|||COHORT||PROSPECTIVE|||||||
33983059|NCT03859466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The masking is performed using opaque envelopes that are opened by an assistant at the end of the CABG procedure after the bypasses are fully established.|This study investigates the safety and performance characteristics of the Direct Epicardial Shockwave Therapy System (DESWT) as applied with the Cardiac Shockwave Probe (CSP) vs. Sham treatment|t|t|t|t
33983060|NCT02700464|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33983061|NCT01066806|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983062|NCT00952406|||COHORT||PROSPECTIVE|||||||
33983063|NCT02808702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983064|NCT00481780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983065|NCT03300934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983066|NCT00338481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983067|NCT03688373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983068|NCT02693210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33680502|NCT04866745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assignment to the MT and MT placebo group will be only known by the technician from the external device manufacturer who programs the coded MT equipment. The coded MT equipment will be programmed in such a way that the physical therapist that applies the intervention will enter the code for each participant without knowing the group to which the patient is assigned. Therefore, the therapists that apply the intervention will only know the assignment to the MW group. For the blinding of the subjects, the same protocol will be followed in the placebo treatment as in the experimental group (number of sessions, application area, and device). The researchers who perform the recruitment, the participants, the researcher who will perform the assessments and the analysis of the data, and the therapists who will apply the exercise program will be blinded.|Double-blinded, sham-controlled, randomized clinical trial.|t|f|t|f
33680503|NCT01374100|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33680504|NCT03291834|||COHORT||RETROSPECTIVE|||||||
33680505|NCT05179174|||CASE_CONTROL||PROSPECTIVE|||||||
33680506|NCT05022667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33680507|NCT04427826|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I / IIa prospective, monocentric and open therapeutic study||||
33680508|NCT05014737|||COHORT||PROSPECTIVE|||||||
33680509|NCT05160142|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group pretest-poshest study design||||
33680510|NCT03729271|NA|SINGLE_GROUP||TREATMENT||NONE|The study drug will be open label. However, the order of the breath tests that are performed (glucose and lactulose) will be blinded to the participant and the person performing the breath sample, and the results of the breath test.|||||
33680511|NCT01771809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680512|NCT06227182|||COHORT||PROSPECTIVE|||||||
33680513|NCT02364336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680514|NCT01640574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680515|NCT03693560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All enrolled patients will be mentioned as two groups; Group I (n=40) are patients who the endocrinologist prescribed them vildagliptin plus their metformin to control their blood sugar level. Group II (n=40) are patients who the endocrinologist prescribed them glimepiride plus their metformin.|t|f|t|f
33680516|NCT00811642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680517|NCT05202964|||COHORT||PROSPECTIVE|||||||
33680518|NCT04671732|||COHORT||PROSPECTIVE|||||||
33680519|NCT06093074|NA|SINGLE_GROUP||OTHER||NONE||This is a feasibility trial evaluating the feasibility and acceptability of a planned randomized controlled trial. Therefore, no control group will be included in this feasibility study.||||
33680520|NCT04271618|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33680521|NCT02069964|||COHORT||PROSPECTIVE|||||||
33680522|NCT06242353|||COHORT||PROSPECTIVE|||||||
33770982|NCT03988010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomise double blind placebo- controlled study|Patients randomly allocated to two treatment groups: Amantadine Sulphate group (Group I) and the placebo group (Group II). Participants will receive two doses of amantadine sulphate in the form of three-hour infusions. The first infusion will be administered 8 hours before the operation and the second infusion will be terminated just before the operation.|t|t|f|f
33770983|NCT02189096|||COHORT||PROSPECTIVE|||||||
33770984|NCT05287568|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open label, dose escalation phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.||||
33770985|NCT02258464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770986|NCT01991249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33770987|NCT01046461|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33770988|NCT00404482|||COHORT||RETROSPECTIVE|||||||
33900242|NCT04560101|||CASE_ONLY||PROSPECTIVE|||||||
33900243|NCT06666855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33900244|NCT03331172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900245|NCT00006246||||TREATMENT||||||||
33900246|NCT05888714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33900247|NCT00002828||||TREATMENT||||||||
33900248|NCT05191329|||COHORT||PROSPECTIVE|||||||
33900249|NCT01212328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900250|NCT02848885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33983069|NCT04096703|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983070|NCT02079766|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33680523|NCT04374227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person running the force plate and its analysis was blind to who was in the treatment group and who was not because the analysis and treatments were given in different rooms.|The subjects were randomized into treatment or control groups. The treatment group for week 1 completed two measurements (before and after) and one treatment. Week 2 the treatment group received a treatment. Week 3 the treatment group received a treatment. Week 2 they completed one measurement. The control group completed two measurements and an assessment during week 1. They completed an assessment during weeks 2 and 3, and then completed a measurement during week 4.|f|f|f|t
33680524|NCT01597167|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33680525|NCT05251389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||a randomized double-blind intervention trial|t|t|t|t
33680526|NCT01175681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33680527|NCT00620932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680528|NCT05921045|||CASE_CROSSOVER||PROSPECTIVE|||||||
33900251|NCT04171128|||CASE_ONLY||PROSPECTIVE|||||||
33900252|NCT04453956|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33900253|NCT03340740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The medication and placebo doses will be prepared in the pharmacy at the study site and provided to the investigators in deidentified bottles.||t|t|t|t
33900254|NCT06021795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900255|NCT06511414|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||randomized controlled trial||||
33900256|NCT02734732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983071|NCT00654264|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983072|NCT03291548|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double Blind: researcher and particiapant unaware of the intervention assignment||t|f|t|f
33680529|NCT05413824|||CASE_ONLY||RETROSPECTIVE|||||||
33680530|NCT02775929|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33680531|NCT04764474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680532|NCT04641338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680533|NCT02844062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900257|NCT02602431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900258|NCT03021525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900259|NCT01717612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900260|NCT03241173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900261|NCT02414295|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33900262|NCT02795598|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33983073|NCT02967159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983074|NCT01780415|||COHORT||OTHER|||||||
33983075|NCT02183415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983076|NCT06130371|||COHORT||CROSS_SECTIONAL|||||||
33983077|NCT02344784|||CASE_ONLY||CROSS_SECTIONAL|||||||
33983078|NCT05353764|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33983079|NCT04406441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33983080|NCT02298465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33983081|NCT05449249|NA|SINGLE_GROUP||PREVENTION||NONE||single-arm, prospective, monocentric, interventional study||||
33983082|NCT03855332|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||Randomised, double-blind, placebo and active controlled, crossover design|t|t|t|t
33983083|NCT02661529|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33983084|NCT05632770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983085|NCT00122798|||DEFINED_POPULATION||PROSPECTIVE|||||||
33983086|NCT06399822|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983087|NCT05735925|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983088|NCT02005705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983089|NCT04570904|||COHORT||PROSPECTIVE|||||||
33983090|NCT03733925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983091|NCT02729376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983092|NCT00555230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983093|NCT01033565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983094|NCT01034280|||CASE_ONLY||CROSS_SECTIONAL|||||||
33983095|NCT00440297|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983096|NCT03615300|||COHORT||PROSPECTIVE|||||||
33983097|NCT00905853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983098|NCT02305823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983099|NCT05586256|||COHORT||OTHER|||||||
33983100|NCT03769285|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983101|NCT01565096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983102|NCT01771705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983103|NCT03750097|NA|SINGLE_GROUP||OTHER||NONE||||||
33983104|NCT03599505|||OTHER||PROSPECTIVE|||||||
33680534|NCT00327821|RANDOMIZED|PARALLEL||||NONE||||||
33680535|NCT01870323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680536|NCT01248104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680537|NCT00926315|NA|SINGLE_GROUP||||NONE||||||
33900263|NCT03072511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900264|NCT02345161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900265|NCT02410369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900266|NCT04570449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900267|NCT06511726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900268|NCT00036218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900269|NCT01984112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900270|NCT03727711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900271|NCT01738139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983105|NCT00686959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983106|NCT01709474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983107|NCT03101878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983108|NCT01475448|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983109|NCT03151057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, investigator|Idelalisib 100mg or placebo twice daily, starting day +90 (+-/ 10 days) after transplant until day +270.|t|f|t|f
33983110|NCT00998374|||CASE_ONLY||PROSPECTIVE|||||||
33983111|NCT00867542|||||RETROSPECTIVE|||||||
33983112|NCT04085029|||CASE_ONLY||PROSPECTIVE|||||||
33983113|NCT04353791|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33983114|NCT01781598|||COHORT||PROSPECTIVE|||||||
33983115|NCT02719522|||COHORT||PROSPECTIVE|||||||
33983116|NCT04351074|RANDOMIZED|PARALLEL||TREATMENT||NONE||group A (39 patients): Patients underwent intersphincteric ligation of fistulous track (LIFT) group B (39 patients): Patients underwent fistulectomy.||||
33983117|NCT01798836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983118|NCT04843878|||CASE_ONLY||PROSPECTIVE|||||||
34024675|NCT04494984|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|A Double-blind, Placebo-controlled, sealed-envelope based. Access to unblinded interim results will be limited to the DMC and unblinded statistician|"This study will be an adaptive phase 2/3 investigation. First, 12 subjects will be randomly assigned to receive 1 of the 2 treatment regimens (study drug or placebo) in a 1:1 ratio. After the first 6 subjects have been enrolled and have completed 24 hours post treatment of 2nd dose, the IDMC will review the safety data and will inform whether to continue with staggered enrollment. Randomization ratio for subjects in the following stage will be 1:1. The independent data monitoring committee (IDMC) will review safety data after 12, 24, 48 and 96 patients have been enrolled in each arm. The study will then enroll a total of 121 patients in each arm. An interim analysis will be performed after 80% of recruitment has been reached (n=194). The IDMC will analyze the rate of events in the group under standard of care."|t|t|t|t
33680538|NCT03201081|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||A quasi-experimental design (2x2) was developed, dividing the participants into two groups; one experimental and one control. In this design, an initial measurement prior to the intervention (pre-test) and a measurement after the intervention (post-test) were conducted. The sampling was natural and intentional.|f|f|t|f
33680539|NCT03083444|||COHORT||PROSPECTIVE|||||||
33680540|NCT00428584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680541|NCT04006626|||COHORT||RETROSPECTIVE|||||||
33680542|NCT04837326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized-controlled experimental study was performed to evaluate the effect of white noise, embracing and facilitated tucking on pain during heel lance blood sampling in newborns.||||
33680543|NCT06139627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680544|NCT02885116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680545|NCT02605291|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33680546|NCT01049945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680547|NCT04231552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680548|NCT04170972|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"A case-control study with two groups of participants with different genetic background on the TBC1D4 gene:~1. Homozygote carriers of a p.Arg684T TBC1D4 gene-variant~2. None carriers (matched controls) of the p.Arg684T TBC1D4 gene-variant"||||
33680549|NCT00401687|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680550|NCT03616054|||COHORT||PROSPECTIVE|||||||
33680551|NCT00895102|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33680552|NCT02607748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680553|NCT03829423|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Retrospective breast MRI datasets with all personal patient information removed||f|t|f|f
33680554|NCT02595645|NA|SINGLE_GROUP||SCREENING||NONE||||||
33680555|NCT00274092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680556|NCT01222156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900272|NCT06038448|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||parallel into two groups, each urinary catheter balloon size 10mL and 5mL|t|f|f|f
34079198|NCT05532215|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"A hospital's pharmacist/pharmacologist will manufacture the misoprostol tablets at doses of 200 mcg each as well as the placebo tablets (which will contain vitamin B complex excipient only). The misoprostol tablets and placebo tablets will be indistinguishable. Envelopes will be pre-packed, sealed and outwardly labelled by a hospital's pharmacist/pharmacologist who will take no further part in the study.~Each pre-packed envelope will contain three 200 mcg misoprostol tablets for the misoprostol arm or three placebo tablets (which will contain vitamin B complex excipient only) for the placebo arm.~The randomization list will be in the possession of a research assistant who will take no further part in the study after randomly allocating the participants to the study arms, till the end of the study."||t|t|t|t
34079199|NCT00374478|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34079200|NCT01397136|||COHORT||PROSPECTIVE|||||||
34079201|NCT03400527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079202|NCT00388791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34079203|NCT02652663|||COHORT||RETROSPECTIVE|||||||
34079204|NCT03930628|||COHORT||PROSPECTIVE|||||||
34079205|NCT06086990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Outcome assessors, investigators and analysts will be kept unaware of treatment allocation. However, due to the characteristics of the intervention, it is not possible to mask participants.|Participants will be randomly allocated in a 1:1 fashion to receive the smartphone application or usual follow-up care.|f|t|t|t
34079206|NCT02361866|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34079207|NCT02238730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079208|NCT05036941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079209|NCT03999255||SEQUENTIAL||TREATMENT||NONE||||||
34079210|NCT03159585|NA|SINGLE_GROUP||TREATMENT||NONE||a single-center, open, single (or fractional) dose of safety and tolerability||||
34079211|NCT02250313|||CASE_CONTROL||PROSPECTIVE|||||||
34079212|NCT01914393|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34079213|NCT04157010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079214|NCT04735705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079215|NCT00003039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079216|NCT05324319|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34079217|NCT03308669|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34079218|NCT04045756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900273|NCT01144546|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34079219|NCT02564276|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34079220|NCT02391051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079221|NCT05485922|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34079222|NCT05554107|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079223|NCT03908788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079224|NCT06338306|||COHORT||PROSPECTIVE|||||||
34079225|NCT04604834|RANDOMIZED|CROSSOVER||TREATMENT||NONE|No blinded study.|Subjects will be selected based on inclusion and exclusion criteria. A thorough ophthalmologic evaluation will be carried out before starting any treatment (baseline). Subjects will be randomly assigned to one of the treatment groups and receive the corresponding treatment for 4 weeks. At the end of week 4, subjects will switch treatment groups (crossover) and receive the new treatment for 4 more weeks. At the end of week 8, subjects will start the last treatment for 4 more weeks. Ophthalmologic evaluations will be performed every 4 weeks.||||
33680557|NCT02452827|||CASE_CONTROL||PROSPECTIVE|||||||
33680558|NCT01087788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680559|NCT01022398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33900274|NCT04524741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 40 patients with atrial fibrillation were scheduled to receive left atrial appendage occlusion, which were divided into two groups. The operation was performed under the guidance of intracardiac echocardiography and left atrial appendage radiography, respectively (allocation ratio 1:1).|t|f|f|t
34079226|NCT04797208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079227|NCT00838097|||||PROSPECTIVE|||||||
34079228|NCT03988153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, placebo-controlled, randomized parallel clinical trial|t|t|f|f
33983119|NCT06131502|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"In the first stage, patients will not be randomized and neither patients nor evaluators will be blinded as to treatment status. A period of 6 months of best medical treatment (BMT) prior to the capsulotomy treatment will ensure that the patients are clinically stable and compliant with the study set-up.~If no safety stop rules occur at the end of the first stage, we will submit an IDE supplement to the FDA providing evidence of safety and requesting continuation. The second stage would then proceed pending the receipt and review/approval of that supplement. The second stage is focused on efficacy. In stage II, patients will be randomized, and both patient and evaluators will be blinded as to treatment status. The patients will be treated by BMT plus MRgFUS or BMT plus sham for 12 months. Parallel BMT along with the sham and MRgFUS periods would decrease protocol violations or drop-outs."|In the first stage of the study, participants with severe, treatment resistant OCD (n=10) will be recruited in two centers (Harvard and Stanford) and treated with best medical care (BMT) for 6 months. Thereafter, they will receive the ExAblate MRgFUS procedure and then another BMT for 12 months. In the second stage of the study, participants with moderate to severe OCD (n=56) will be recruited in a multi-center study and treated with BMT plus real or sham MRgFUS for 12 months. Thereafter, those who received sham MRgFUS and did not improve will receive real MRgFUS and then treated with BMT for another 12 months.|t|f|f|t
33680560|NCT03909594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized double blind study - - All the pharmacist and research manager||t|t|t|t
33680561|NCT06151509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33680562|NCT04625296|||COHORT||PROSPECTIVE|||||||
33680563|NCT05426499|||COHORT||PROSPECTIVE|||||||
33680564|NCT03027791|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33680565|NCT02480946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900275|NCT03670173|NA|SINGLE_GROUP||TREATMENT||NONE||multi-center, single-arm, open-label, non-blind||||
33900276|NCT04370262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double-Blind Comparative Trial|t|t|t|f
33680566|NCT04963101|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680567|NCT04696211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33680568|NCT03927560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680569|NCT04796870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680570|NCT02834845|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33680571|NCT00210158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680572|NCT02868827|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680573|NCT02081066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33680574|NCT00527891|||COHORT||PROSPECTIVE|||||||
33680575|NCT00514748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680576|NCT03351205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680577|NCT01723644|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33680578|NCT03225859|NA|SINGLE_GROUP||TREATMENT||NONE|As everyone in the study will receive the same intervention, no masking is being employed|The study non-randomized, open-trial pilot test of the intervention with twelve Veterans who will all receive the study intervention.||||
33680579|NCT00647569|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33680580|NCT03685890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a randomized placebo controlled double blind trial. Patients will be randomized to ILP with nivolumab or ILP with placebo. Active follow-up for 3 years.|t|t|t|t
33680581|NCT03834558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Investigator: The persons who make the data analysis and decide whether a patient has experienced an outcome of interest will be masked.~Outcome assessors: The persons who assess patients and provide outcome data will be masked."|"This project is based on an, longitudinal, prospective, controlled, randomized, intervention study and blind for the researchers responsible for the study. Thus, the subjects participating in the study will be divided into 2 groups, one of which will perform the mixed exercise program (intervention group, IG), and another that will follow their daily routine without added exercise (control group, CG).~Each group will have 2 measurements in which the corresponding variables will be evaluated: A) before the start of the intervention, B) at 6 months (at the end of the intervention)"|f|f|t|t
33680582|NCT00735579|||COHORT||PROSPECTIVE|||||||
33680583|NCT02989987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900277|NCT06131203|||CASE_CONTROL||PROSPECTIVE|||||||
33900278|NCT05464277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To avoid selection bias, the allocation sequence will be blinded from researchers involved in patient enrolment. Although study subjects will be unaware of the assigned group, blinding of treating clinicians is not considered feasible.|"Enrolled patients will be randomly allocated using opaque sealed envelopes to either intermediate normal oxygen or high normal oxygen group. The asymptomatic maximal procedure, with an allocation ratio of 1:1 and a maximum tolerated imbalance of 2 will be used to randomize subjects."|t|f|f|t
33900279|NCT02858388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900280|NCT00414622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900281|NCT05579626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900282|NCT01332032|||||PROSPECTIVE|||||||
33900283|NCT05384743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900284|NCT01334125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900285|NCT00312377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900286|NCT01147965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900287|NCT05105243|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-blind. placebo-controlled.|"For the single-dose regimen, approximately 40 healthy male or female participants will be enrolled in 1 of 5 single-dose cohorts (designated as S1 through S5, respectively) in an ascending fashion. Each cohort will consist of 8 participants randomized to CVN766 or placebo, whereby 6 participants will receive a single oral dose of CVN766 suspension, and 2 participants will receive a matching placebo suspension under overnight fasted conditions.~For the multiple-dose regimen, approximately 24 healthy male and female participants age 18 to 50 years old will be enrolled in 1 of the 3 multiple-dose cohorts (designated as M1 through M3, respectively) in an ascending fashion. The dose levels planned to be studied in the multiple-dose regimen are 45, 125, and 250 mg CVN766 for multiple-dose cohorts M1 through M3, respectively."|t|t|t|f
33900288|NCT02129764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900289|NCT00236561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900290|NCT05857956|NA|SINGLE_GROUP||OTHER||NONE||||||
33983120|NCT00902876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983121|NCT00758186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983122|NCT04810377|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective study that evaluates EUS-guided gastroenterostomy in a group of participants with diagnosis of malignant gastric outlet obstruction. Patients are sequentially recruited as diagnosed.||||
33983123|NCT06219473|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients were classified into three main groups:~Group 1 (Study group) It includes eight patients seeking for implant placement in the upper anterior areas and implants will be placed with the application of fascia lata allograft membrane.~Group 2 (Study group) It includes eight patients seeking for implant placement in the upper anterior area and implants will be placed with the application of PRF.~Group 3 (Control group) It includes eight patients seeking for single implant placement at the upper anterior area and those patients will be received their implants with subepithelial connective tissue graft."||||
33983124|NCT01307098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900291|NCT03461965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be recruited from University Hospitals Department of Dermatology MMS Clinics at the Cleveland Medical Center, Chagrin Highlands and Westlake Locations. These patients will be randomly assigned to a control (50%) or experimental group (50%) prior to the onset of the study protocol.||||
33900292|NCT05662358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33900293|NCT02713750|||COHORT||PROSPECTIVE|||||||
33900294|NCT00265941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900295|NCT06565624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983125|NCT01205295|||COHORT||PROSPECTIVE|||||||
33900296|NCT04763382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Because the initiative of the study is based on education. While obtaining informed consent, the purpose and content of the study were explained to the participants. For this reason, the trainees know that they are in the experimental group, and those who do not receive training in the control group.|The caregivers in experimental group of study were given health training on CIC application, and after the training, the guide booklet was delivered to the participants, the android phone application. After discharge of three urinalysis, three phone calls and home visit. The data collection tools applied to aregivers in experimental group as a pre-test were also applied post-test and retention test. The same data collection tools were applied to control group for pre-test. The caregivers in the control group were not trained, android applications were not installed on their phones, home visits. With the routine practice given in the hospital, he was provided with CIC training. However, one month after discharge, he was asked to give urinalysis once a month for three consecutive months. Urinalysis was taken three times in total. Data collection tools, which were applied as a pre-test when they gave the second urinalysis, were applied again as a post-test.||||
33900297|NCT05073770|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33900298|NCT04444791|||COHORT||PROSPECTIVE|||||||
33900299|NCT06408792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900300|NCT05728801|||COHORT||PROSPECTIVE|||||||
33900301|NCT03862378|||COHORT||PROSPECTIVE|||||||
33900302|NCT05301348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900303|NCT03873207|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized two cohort (device or SOC) pilot study||||
33900304|NCT06602024|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33900305|NCT02536482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900306|NCT04624932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocations will be concealed to the researchers at participant assignment and data analysis.||f|f|t|t
33900307|NCT00239460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900308|NCT05552612|||COHORT||PROSPECTIVE|||||||
33900309|NCT03215472|RANDOMIZED|PARALLEL||TREATMENT||NONE||3-month randomized controlled trial to test the initial feasibility of DASH Cloud, a digital health intervention for women at risk for CVD||||
33900310|NCT06671704|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Stepped wedge randomized controlled trial|t|f|f|f
33900311|NCT02544984|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33900312|NCT06672952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study employs a double-blind design to ensure that participants, investigators, and outcome assessors remain unaware of the group assignments. All supplements (placebo and both doses of CITRAPEAK®) are provided in identical capsules, containing either 400 mg of cellulose (placebo), 200 mg of CITRAPEAK® with 200 mg of cellulose, or 400 mg of CITRAPEAK®. Each participant is assigned a unique randomization code, which is used to label the capsules, maintaining blinding throughout the study. Only the study designated unblinded personnel have access to the randomization key, ensuring that the blinding remains intact for all other study staff.||t|f|t|t
33900313|NCT02244697|||CASE_CROSSOVER||PROSPECTIVE|||||||
33900314|NCT03383367|NA|SINGLE_GROUP||SCREENING||NONE||A prospective interventional study to evaluate the impact of a reminder sent by the Adémas-69 organization to improve coloscopy surveillance and compliance with recommendations for high risk of colorectal cancer people.||||
33900315|NCT00489983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900316|NCT00302237|||CASE_CONTROL||PROSPECTIVE|||||||
33900317|NCT01920139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900318|NCT01177215|||COHORT||PROSPECTIVE|||||||
33900319|NCT03911570|||CASE_CONTROL||RETROSPECTIVE|||||||
33900320|NCT01095484|||CASE_ONLY||PROSPECTIVE|||||||
33900321|NCT01566344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900322|NCT02725255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33900323|NCT04500288|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single center prospective Pilot Study||||
33900324|NCT06136338|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental group： intervention + routine care Control group：routine care||||
33900325|NCT05043610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded|A single-blinded, randomized, multicenter trial.|f|f|f|t
33900326|NCT02517515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900327|NCT02927223|NA|SINGLE_GROUP||OTHER||NONE||||||
33900328|NCT04655612|||COHORT||PROSPECTIVE|||||||
33983126|NCT03245086|||CASE_CONTROL||PROSPECTIVE|||||||
33983127|NCT04754178|||CASE_CONTROL||PROSPECTIVE|||||||
33900329|NCT04340869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900330|NCT01874704||PARALLEL||SCREENING||SINGLE|||t|f|f|f
33983128|NCT01787058|||COHORT||PROSPECTIVE|||||||
33983129|NCT03084081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900331|NCT03940781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and assessors blinded|30 participants with moderate or severe OSA (AHI≥15) were randomized into intervention group (N=15) and control group (N=15).|t|f|f|t
33900332|NCT06358885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||A two-arm cluster-randomized implementation trial comparing two strategies to scale-up an evidence-based brief alcohol intervention (BAI), in Vietnam, examining the mechanisms of BAI scale-up and the impact of experiential BAI (EBAI) on clinic staff. The two implementation approaches are facilitation only (FAC) and facilitation plus an experiential brief alcohol intervention (EBAI+FAC).|f|f|t|t
33900333|NCT06653634|RANDOMIZED|PARALLEL||TREATMENT||NONE||Researcher initiated, randomized controlled, 3-arm, parallel group, national, multicenter clinical trial||||
33900334|NCT03211078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900335|NCT03809546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33900336|NCT03940573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900337|NCT00471380|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33900338|NCT02127112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900339|NCT02252952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900340|NCT02585804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900341|NCT05485636|||COHORT||RETROSPECTIVE|||||||
33900342|NCT03063385|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33900343|NCT06672861|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33900344|NCT02512016|NA|SINGLE_GROUP||OTHER||NONE||||||
33900345|NCT05776459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900346|NCT06302322|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33900347|NCT05269849|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33900348|NCT06260150|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33900349|NCT05138120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33900350|NCT01327430|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33900351|NCT03741881|||COHORT||PROSPECTIVE|||||||
33900352|NCT05324943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900353|NCT00824694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900354|NCT00950781|||OTHER||PROSPECTIVE|||||||
33900355|NCT06472570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900356|NCT06673160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33900357|NCT01556919|||CASE_ONLY||PROSPECTIVE|||||||
33900358|NCT04530825|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900359|NCT02004340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900360|NCT06652100|||COHORT||PROSPECTIVE|||||||
33900361|NCT04980183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900362|NCT01673880|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900363|NCT05092581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900364|NCT05920096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900365|NCT04536324|||CASE_ONLY||PROSPECTIVE|||||||
33900366|NCT05859620|||COHORT||PROSPECTIVE|||||||
33900367|NCT01516801|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33900368|NCT00974129|||COHORT||PROSPECTIVE|||||||
33900369|NCT05932810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900370|NCT05707065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33900371|NCT01483092|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33900372|NCT04468750|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a quasi-experimental, single-subject AB design.||||
33900373|NCT01773395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33900374|NCT01330381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900375|NCT02021968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33900376|NCT01956643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900377|NCT00730704|||CASE_ONLY||PROSPECTIVE|||||||
33983130|NCT06213688|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983131|NCT05833594|||CASE_CONTROL||PROSPECTIVE|||||||
33900378|NCT04509856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900379|NCT03739983|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective Simon two-stage study design||||
33900380|NCT05946681|||COHORT||CROSS_SECTIONAL|||||||
33900381|NCT05552716|||CASE_CONTROL||RETROSPECTIVE|||||||
33983132|NCT04245566|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized controlled study||||
33983133|NCT01624064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33770989|NCT03394261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The Patient Decision Aid for Medication Assisted Therapy (PtDA-MAT) will be pilot-tested by patients and clinicians during actual visits with OUD patients to assess its acceptability and feasibility. We will track patients receiving PtDAT-MAT using their clinical and administration data over a 3-month period and compare outcomes to those of treatment admissions during the 3 months prior to the pilot testing to assess preliminary outcomes associated with PtDAT-MAT.||||
33770990|NCT05925738|||COHORT||PROSPECTIVE|||||||
33770991|NCT00850044|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33770992|NCT04571632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770993|NCT00139022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770994|NCT04799860|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A pre-post-intervention design with control group will be used to evaluate intervention uptake and implementation process effectiveness from the perspective of managers, primary care professionals, patients, and organisation. Primary care settings in central Sweden will be supported in implementing a guideline-based health-promoting way of working including screening of life-style habits, measures taken according to evidence based recommendations and documentation. Strategies will include interactive education sessions, external and internal facilitators, audit and feedback, and tools from theories of leading change; tailored according to contextual and participant needs.||||
33983134|NCT06155630|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33770995|NCT05561348|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)||t|f|f|t
33770996|NCT05989165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33770997|NCT06071520|||COHORT||RETROSPECTIVE|||||||
33770998|NCT03652194|||COHORT||OTHER|||||||
33770999|NCT06198296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771000|NCT00161096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771001|NCT03549234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771002|NCT05223842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771003|NCT00111254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771004|NCT00715741|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33771005|NCT00406471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983135|NCT00968552|||CASE_ONLY||PROSPECTIVE|||||||
33900382|NCT03607734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900383|NCT02004990|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983136|NCT01655628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983137|NCT02172365|||OTHER||RETROSPECTIVE|||||||
33983138|NCT01702584|||COHORT||PROSPECTIVE|||||||
33983139|NCT05525026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983140|NCT03456947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900384|NCT02251730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771006|NCT00917267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900385|NCT02100553|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900386|NCT03725046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33900387|NCT01269125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900388|NCT01825434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900389|NCT00472927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900390|NCT05450055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Sixty patients were expected to participate in a centralized randomized study method divided into two groups of 30 patients per group: the intraperitoneal analgesic group and the normal saline control group.|t|t|t|t
33900391|NCT05736731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900392|NCT02021422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900393|NCT05279937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded randomized|10mL of 1% Lidocaine (Control) or 5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).|t|f|t|f
33900394|NCT02762864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900395|NCT04442620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900396|NCT00002445||||TREATMENT||DOUBLE||||||
33900397|NCT00831519|||CASE_CONTROL||PROSPECTIVE|||||||
33900398|NCT04098926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900399|NCT01009775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900400|NCT01496261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900401|NCT00000637||||TREATMENT||DOUBLE||||||
33900402|NCT04722133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900403|NCT00893503|||COHORT||PROSPECTIVE|||||||
33900404|NCT03807973|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33900405|NCT04319237|||CASE_ONLY||PROSPECTIVE|||||||
33900406|NCT02987673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983141|NCT04131751|||OTHER||PROSPECTIVE|||||||
33983142|NCT00281125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983143|NCT02781727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983144|NCT02873910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983145|NCT02637232|||OTHER||PROSPECTIVE|||||||
33900407|NCT06287047|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. Prior to surgery the appropriate numbered envelope will be opened by the nurse, the card inside will determine the patient group.|81 patients meeting the inclusion criteria will be randomly divided into three equal groups: Group A (n=27): Conventional epidural. Group B (n=27): Dural puncture epidural with 25-gauge spinal needle. Group C (n=27): Dural puncture epidural with 27-gauge spinal needle.|t|f|t|f
33900408|NCT04701281|NA|SINGLE_GROUP||TREATMENT||NONE||"Single arm, two cohorts:~Cohort 1: 1st line patients, RAS mutant; Cohort 2: pre-treated or refractory patients, no specific mutation"||||
33900409|NCT02322307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33900410|NCT04366271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680584|NCT04568824|RANDOMIZED|PARALLEL||TREATMENT||NONE|The only masking is done at the level of data analysis, as it is readily evident to participants and those monitoring which group the participants are in.|This is a parallel intervention design with crossover elements (control group is offered the intervention after completion of the control intervention). We will evaluate a reading intervention of interest in comparison to a math control.||||
33680585|NCT01398917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900411|NCT05205239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900412|NCT04952883|||COHORT||PROSPECTIVE|||||||
33900413|NCT04910412|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33900414|NCT06468410|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomly assigned to one of three groups:~1. 60-minute Hatha Yoga group (60mHY, n=21)~2. 30-minute Hatha Yoga group (30mHY, n=21)~3. Control group (CG, n=21)"||||
33900415|NCT00318708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900416|NCT02562196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900417|NCT06359249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900418|NCT02434887|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33900419|NCT03475394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900420|NCT04850911|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All members of the study team will be blinded to the condition a participant is allocated to with the exception of the team member responsible for administering the drug/placebo.|Participants will be assigned to receive either ketamine or placebo. Ketamine is not being administered for treatment purposes, the purpose is to understand the mechanisms underpinning its effects.|t|f|t|f
33900421|NCT01355991|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900422|NCT01009463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900423|NCT06508996|||COHORT||PROSPECTIVE|||||||
33900424|NCT04115397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900425|NCT04756895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900426|NCT00883194|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33900427|NCT03959618|||COHORT||PROSPECTIVE|||||||
33900428|NCT00623155|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33900429|NCT06671652|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983146|NCT02578953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983147|NCT00191022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983148|NCT05940662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983149|NCT02550340|||COHORT||PROSPECTIVE|||||||
33983150|NCT01279460|||COHORT||PROSPECTIVE|||||||
33680586|NCT02551510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983151|NCT03898297|||OTHER||CROSS_SECTIONAL|||||||
33983152|NCT05688514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983153|NCT02441309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024676|NCT05024864|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Outcomes assessors will be blinded to randomized assignment of screening/observation period.|Cluster randomized, crossover, registry-based clinical trial|f|f|f|t
34024677|NCT05250011|||OTHER||PROSPECTIVE|||||||
33680587|NCT01431638|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled||||
33680588|NCT03776370|||COHORT||PROSPECTIVE|||||||
33680589|NCT05574855|||CASE_CONTROL||PROSPECTIVE|||||||
33900430|NCT03838250|NA|SINGLE_GROUP||TREATMENT||NONE||A single-dose injection of autologous bone marrow-derived mesenchymal stem cells (Cellgram™) will be administered to the patient by an experienced interventional radiologist.||||
33900431|NCT00398528|||||PROSPECTIVE|||||||
33900432|NCT01618656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900433|NCT05661136|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Postanesthesia care unit nurses assess primary outcome and will not know the group assignment~Sample size was calculated for the primary outcome of difference between the groups in maternal temperature on arrival to the post-anesthesia care unit. We calculated the a priori sample size, WinPepi, based upon a prior publication that compared Active-Warming versus No-Warming, mean(standard deviation) 35.9(0.5)0 C versus 35.5(0.5), power 90%, 0.05 two-sided significance (Cobb et al). For clinical significance we calculated sample size with a mean difference of 0.50 C, with SD 0.5, power 90%, two sided significance with potential for 10% dropouts, total 66 women, 33 per group, and without dropouts, 22 per group total 44 women."|two arms: lower body forced air warming versus none|f|f|f|t
33900434|NCT02044484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900435|NCT03977389|||COHORT||RETROSPECTIVE|||||||
33680590|NCT03834649|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33680591|NCT05031039|||OTHER||RETROSPECTIVE|||||||
33680592|NCT05637060|RANDOMIZED|CROSSOVER||OTHER||NONE|Only Analysts will be kept blind|A single center, open label, randomized, single-dose, two period, two-way, cross-over study. Subjects will receive one single dose per treatment period separated by a wash-out period of 7 days.||||
33680593|NCT04028271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900436|NCT01570725|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33900437|NCT00391638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900438|NCT04762355|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33900439|NCT06658132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900440|NCT01709877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900441|NCT00530699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900442|NCT04807153|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33900443|NCT02243124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900444|NCT01104129|||CASE_CONTROL||PROSPECTIVE|||||||
33900445|NCT05930249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33900446|NCT05101421|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This will be a single arm and open-labelled prospective study||||
33900447|NCT02973672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900448|NCT02891993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33900449|NCT06220344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33900450|NCT06207175|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Sponsor, investigators and biostatisticians will remain blinded to subject allocation||t|f|t|f
33900451|NCT06335238|||CASE_ONLY||PROSPECTIVE|||||||
33900452|NCT04272307|||CASE_ONLY||PROSPECTIVE|||||||
33900453|NCT06338449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the data is obtained, the person analyzing the data will not know the specific grouping and participant information. The groups will be replaced by Group A, B, C, D, and the participants will be indicated by their IDs.|"The specific exercise plan and grouping are as follows:~Participants were randomly (Using an electronic random number generator) divided into four groups: control group (Control), aerobic training group (AT), resistance training group (RT), and combined aerobic and resistance training group (AT + RT), with each group consisting of 10 individuals, totaling 40 participants. All participants were young adults aged between 18 and 21 years old."|f|f|f|t
34024678|NCT02535871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34079229|NCT06360328|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group = direct laryngoscopy Intervention group = video laryngoscopy||||
33680594|NCT05893953|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33680595|NCT01790243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680596|NCT02329340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680597|NCT00168129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680598|NCT04335305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680599|NCT01490801|||COHORT||RETROSPECTIVE|||||||
33680600|NCT05948384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680601|NCT00883688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680602|NCT04605705|||CASE_CONTROL||PROSPECTIVE|||||||
33680603|NCT05641389|||COHORT||PROSPECTIVE|||||||
33680604|NCT05872854|NA|SINGLE_GROUP||TREATMENT||NONE||The goal of this clinical trial is to assess the benefit of continuous treatment with open label synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks).||||
33680605|NCT02656225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33680606|NCT03545971|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33680607|NCT05567549|||CASE_ONLY||OTHER|||||||
33680608|NCT00383474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680609|NCT00899496|||OTHER||PROSPECTIVE|||||||
33680610|NCT05111301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, prospective clinical trial||||
33680611|NCT00950885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33680612|NCT00689260|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33983154|NCT03512366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind trial .The patient will not be revealed about the technique being performed. The investigator who will follow up the patients post operatively in the out-patient clinic will also be blinded about the procedure performed on the patient.|"DESARDA'S NO MESH REPAIR:~It will be performed according to the surgical technique described by Dr. Desarda. A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure the aponeurotic strip to the inguinal ligament inferiorly , and the strip will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence as it gives additional strength to the weakened internal oblique and transverses abdominis muscles."|t|f|t|f
33983155|NCT05007288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983156|NCT03583606|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983157|NCT02377622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983158|NCT01976286|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33983159|NCT00822497|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33983160|NCT02750124|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983161|NCT05915702|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|The site staff in charge of the preparation and administration of study intervention will be unblinded and will not be involved in any evaluation of safety and efficacy. The site staff in charge of conducting all other study procedures as per the schedule of activities (SoA) will remain blinded to the study intervention administered.||t|t|t|t
33680613|NCT03980353|||OTHER||CROSS_SECTIONAL|||||||
33680614|NCT04497883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680615|NCT00233909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680616|NCT03152006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33680617|NCT03541915|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680618|NCT02057328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680619|NCT01830400|||||PROSPECTIVE|||||||
33680620|NCT03777462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771007|NCT04193748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical outcomes were assessed by an investigator masked about the treatment modality that has been used||f|t|f|t
33900454|NCT06672913|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Multi-center, prospective pre and post training interventional clinical study. The effect of a standardized skin-to-skin contact application, which is initiated early and applied regularly, on clinical outcomes for preterm infants born at less than 32 weeks of gestation will be investigated.~Intervention: Teoritical and practical education on skin to skin contact to ensure the application of Turkish Neonatal Society skin to skin contact protocol."||||
33771008|NCT01666054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900455|NCT02042131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33900456|NCT00360516|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33900457|NCT04045223|||COHORT||PROSPECTIVE|||||||
33900458|NCT00083824|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33900459|NCT06673394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900460|NCT01633242|||||PROSPECTIVE|||||||
33983162|NCT05313698|||CASE_ONLY||PROSPECTIVE|||||||
33983163|NCT01405690|||COHORT||PROSPECTIVE|||||||
33983164|NCT05494567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983165|NCT06165562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients, medical staff responsible for measuring outcome variables, surgeons, and nurses in the recovery room and wards will be blinded. This blinding approach ensures that both medical staff and patients remain unaware of the assigned group throughout the study.|Prospective, single-blinded, parallel-group, randomized clinical study|f|f|t|t
33983166|NCT03358849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983167|NCT01682083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983168|NCT05918263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Principle investigators blinded to block size||f|f|t|f
33983169|NCT02732210|||COHORT||PROSPECTIVE|||||||
33983170|NCT05214001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983171|NCT00138515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983172|NCT03333291|NA|SINGLE_GROUP||TREATMENT||NONE||Open pilot study||||
33983173|NCT04286009|||CASE_ONLY||PROSPECTIVE|||||||
33983174|NCT05412173|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33983175|NCT01072708|NA|SINGLE_GROUP||OTHER||NONE||||||
33983176|NCT02588677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983177|NCT01807637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983178|NCT03643328|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983179|NCT00278018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983180|NCT02252731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983181|NCT02253797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983182|NCT03726788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only pharmacists and radiologists know the patient's randomizing arm.||t|t|t|t
33771009|NCT06489054|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Experimental group and control group|f|f|f|t
33771010|NCT01042990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771011|NCT04981132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771012|NCT04788069|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33771013|NCT00099723|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33771014|NCT04114851|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|control group will be masked so that the monitor index will not be seen by the caregiver/investigator.|RCT|f|f|t|f
33771015|NCT03651232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771016|NCT02769065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900461|NCT02112266|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33900462|NCT03341468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33900463|NCT01855789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900464|NCT00602628||||DIAGNOSTIC||NONE||||||
33680621|NCT04745260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A non-blinded researcher (physician) will determine the group to which the patient is assigned and order the medication(s) according to the assigned group. A separate blinded researcher (physician) will then perform the laceration repair, mYPAS, and post-procedure evaluations. The non-blinded researcher, nurse, parent, and patient will be advised not to disclose which medication(s) were administered to ensure blinding of the provider performing the laceration repair and assessment.||t|t|t|t
33680622|NCT02331095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680623|NCT03817047|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a cluster-randomized trial with three parallel arms||||
33771017|NCT03653663|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|All members of the investigative team as well as the patients are blinded to treatment until all subjects have completed the study.|Double-blind, randomized crossover study of placebo vs. 20 mg simvastatin for 8 weeks with a 4 week washout in between|t|t|t|t
33983183|NCT04408404|||COHORT||RETROSPECTIVE|||||||
33983184|NCT00741871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983185|NCT00202982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983186|NCT02731157|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33983187|NCT00760110|||COHORT||PROSPECTIVE|||||||
33983188|NCT01141426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983189|NCT00471926|||DEFINED_POPULATION||OTHER|||||||
33983190|NCT03657329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Dreem||||
33983191|NCT00847678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983192|NCT03447678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983193|NCT03629249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983194|NCT04475965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor responsible for the outcome measures was blinded to the subjetc´s treatment assignment. The assessor was not present in the room while the treatment was delivered. He returned once the treatment was completed to perform the measurements.|Participants were randomly assigned to groups by using a random number table. This procedure was conducted by an external assessor. The allocation concealment strategy included the use of sealed-opaque and consecutively numbered envelopes.|f|f|f|t
33983195|NCT05110677|||OTHER||PROSPECTIVE|||||||
33983196|NCT00056160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983197|NCT02080611|||CASE_ONLY||CROSS_SECTIONAL|||||||
33983198|NCT05488613|||COHORT||RETROSPECTIVE|||||||
33983199|NCT03046602|||COHORT||PROSPECTIVE|||||||
33983200|NCT01675102|||COHORT||PROSPECTIVE|||||||
33983201|NCT02019056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983202|NCT00855738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983203|NCT00677118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983204|NCT02419456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33983205|NCT03704220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079230|NCT05237726|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three groups randomized to receive DVT prophylaxis either enoxaparin 30 mg every 12 hours, enoxaparin 40 mg once daily and unfractionated heparin 5000 units every 8 hours||||
34079231|NCT02946359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680624|NCT04754945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680625|NCT01608256|||COHORT||CROSS_SECTIONAL|||||||
33680626|NCT00201162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33680627|NCT02160132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680628|NCT04903470|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The participant will not know the intended effect of the drug or the drug name.|In this crossover study, the subjects receive from one drug up to a sequence of drugs such as atropine and edrophonium to study the effect on defecatory mechanisms.|t|f|f|f
33680629|NCT04955678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680630|NCT01253707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983206|NCT03095846|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33983207|NCT03000296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983208|NCT00862550|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33983209|NCT04089982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||2-arm randomized, placebo-controlled trial|t|t|t|t
33983210|NCT04063358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983211|NCT05526950|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The model consists of a randomized controlled in human patients using a cytokine adsorption device.~Lung transplant recipients are randomized to either the treatment group which undergoes cytokine adsorption using the medical device compared to the control group which has not received the cytokine adsorber."||||
34024679|NCT04762849|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are randomly allocated to one of two groups:~Experimental surgical bariatric procedure in the first (A) group: patients will undergo the laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (MGB/OAGB+SMR); Active comparator surgical bariatric procedure in the second (B) group: patients will undergo the laparoscopic one anastomosis gastric bypass (MGB/OAGB) without band: standard surgery."||||
34024680|NCT01143766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34024681|NCT05997732|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete three pharmacological conditions, and serve as their own controls.||||
34024682|NCT04261907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079232|NCT03087734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079233|NCT02296489|||CASE_CONTROL||PROSPECTIVE|||||||
33680631|NCT01640431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33680632|NCT03470727|NA|SINGLE_GROUP||TREATMENT||NONE||prospective comparison study||||
33680633|NCT02891928|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771018|NCT03698760|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study is a single-center controlled study (Jewish General Hospital, Montreal, Quebec, Canada), consisting of two groups of subjects: a control group and a group of subjects with mild Alzheimer's disease.||||
33771019|NCT01865617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079234|NCT01705080|||COHORT||PROSPECTIVE|||||||
33680634|NCT01007630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680635|NCT05330715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680636|NCT00906971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771020|NCT05429359|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33771021|NCT05011916|RANDOMIZED|PARALLEL||TREATMENT||NONE||4||||
33771022|NCT04191070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771023|NCT04014478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771024|NCT05936203|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover clinical trial||||
33771025|NCT01554943|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771026|NCT03612518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33771027|NCT03909802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants are masked from knowing the intervention given.|The researcher will assess the obtained information relating to the patient having DFU and make a list of potentially eligible participants. Those who met the criteria will be random using research randomizer application. The participants will be provided an information sheet in the course of study objectives. Also, this objective will be informed to the owner of wound care clinics for improving the current treatment. Afterward, those who have a willingness to take part in this study will be interviewed to re-assess the eligible inclusion criteria. If they met with the criteria, they will be asked to sign informed consent, provide their home address and a convenient phone number as well. Prior to the study implementation, each eligible participant will be randomly assigned to determine whether he or she will be included either into an experimental or control group. This process will utilize a research randomizer application and the result will be protected by the researcher only.|t|f|f|f
33771028|NCT02258932|||COHORT||PROSPECTIVE|||||||
33771029|NCT02922985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771030|NCT03217734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771031|NCT04623411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The control and intervention group will be formed by randomization. The intervention and control group will be defined as group 1 and group 2 for statistical analysis. Data analysis will be evaluated and reported by the statistician. Also the statistician will be blind.|This was pretest-posttest design, randomized controlled trial.|t|f|f|f
33983212|NCT04031131|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Blinded to assessors and patients|The trial will be a randomised control trial blinded to patient and assessor (the clinician collecting data at 4 hours, 72 hours and 1 month after the procedure. Randomisation will be achieved by a computer software. Administrators will be aware of which group the patient being treated is in. Half of the patients (n=30) will receive the intervention treatment (Instillagel topical anaesthetic) and lubricating gel (standard of care), the other half will receive the standard of care alone (lubricating gel) (n=30) before the procedure. The standard of care is to use no form of analgesia, with K-Y gel only being used as a lubricant. Researchers will be asked to apply the allocated treatment 5-10 minutes before the procedure. The primary end points will be: patient recruitment rate, patient acceptability, surgeon acceptability, patient retention. The secondary endpoints will be: pain scores using the 10-point visual analogue scale.|t|f|f|t
33983213|NCT04167410|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33983214|NCT06312371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33983215|NCT04519437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983216|NCT04556565|||COHORT||PROSPECTIVE|||||||
33983217|NCT04322500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Prospective comparative pilot study with two groups randomly divided|f|t|t|t
33983218|NCT05980156|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory technicians processing samples will be blinded to participant's study arm.|Students were randomized to three arms in the original trial. In this follow-on study, students will remain in their study arms. Arm 1 which previously received intermittent screening-and-treatment will now receive intermittent preventive treatment with sulfadoxine-pyrimethamine plus chloroquine. Arm 2 which received intermittent preventive treatment with dihydroartemisinin-piperaquine will again receive intermittent preventive treatment with dihydroartemisinin-piperaquine. Arm 3 the control arm will continue as a control. Females 10 years and older (potentially post-menarche) in Arms 1 and 2 will receive chloroquine alone.|f|f|f|t
33983219|NCT03490773|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983220|NCT04196322|||COHORT||PROSPECTIVE|||||||
33983221|NCT02515422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33983222|NCT04464798|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983223|NCT03100903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983224|NCT05815056|RANDOMIZED|PARALLEL||TREATMENT||NONE|the participation in one of the 2 arms is determined randomly just before the implantation|1 arm with anaesthetic drugs vs hypnosis induced by virtual reality||||
33983225|NCT03481205|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33983226|NCT04978766|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"An external collaborator will create the allocation sequence for each of the two participating health centers (stratified randomization). Two independent research assistants will prepare the allocation in sequentially numbered, opaque, sealed and stapled envelopes. Aluminium foil inside each envelope will be used to render the envelope impermeable to intense light. This will allow the allocation sequence to be concealed from the researcher assessing participants at baseline. Once baseline assessment is completed, the next consecutively numbered envelope will be opened to reveal the participant's allocation.~Treatment for the experimental group will be provided by two different researchers who will not participate in outcome assessment.~A different researcher (outcome assessor), blind to the allocation sequence, to the participant's allocation and to the participant's baseline scores, will complete the participants' assessments during posttest."|All participants will take baseline measures. After baseline, each participant will be randomly assigned to the control or the experimental group. At posttest, all measures taken at baseline will be evaluated again in all participants.|f|f|f|t
33983227|NCT00280904|||COHORT||PROSPECTIVE|||||||
33983228|NCT01973348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983229|NCT02437279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983230|NCT05888870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983231|NCT01481805|||COHORT||RETROSPECTIVE|||||||
33983232|NCT06078956|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33983233|NCT04510285|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm pilot study of adjuvant pembrolizumab + trastuzumab.||||
33983234|NCT01409486|||COHORT||PROSPECTIVE|||||||
33983235|NCT05087134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983236|NCT02829970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983237|NCT02682602|||COHORT||CROSS_SECTIONAL|||||||
33983238|NCT02188641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983239|NCT06495905|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Intervention, observational, Propensity Matching Analysis study||||
33983240|NCT05375201|NA|PARALLEL||TREATMENT||NONE||||||
33983241|NCT03863730|RANDOMIZED|PARALLEL||PREVENTION||NONE|Pathologist will perform outcome assessment blinded|Patients will be randomized 1:1 to receive Profermin Plus® versus a general FSMP, Fresubin®, for 24 weeks.||||
33983242|NCT01771965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983243|NCT00448578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983244|NCT03968549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983245|NCT04966455|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33983246|NCT03205553|RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective double-arm study designed to evaluate the tolerability of direct peritoneal resuscitation (DPR) in neonates with gastroschisis. The experimental arm (DPR group) will receive adjuvant DPR with standard treatment for gastroschisis (staged silo closure). The control arm (SoC group) will receive standard treatment for gastroschisis only. All subjects will be placed in a silo shortly after birth and within 2 hours of admission to the NICU and subsequently serially reduced in silo with umbilical tape until the bowel contents are at the level of fascia and deemed suitable for closure.||||
33983247|NCT06427057|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983248|NCT05177588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective, interventional, randomized controlled, open label study. The study sample will include heart failure patients with pre-diabetes|f|f|f|t
33983249|NCT02209480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983250|NCT04835246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983251|NCT03555305|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33983252|NCT05641103|||COHORT||OTHER|||||||
33983253|NCT03806777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Dose finding||||
33680637|NCT06286709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind|Phase IIa, multi-centre, randomised, placebo-controlled, single-blinded, parallel group, clinical trial|t|f|t|f
33680638|NCT03323788|||COHORT||PROSPECTIVE|||||||
33680639|NCT03322319|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680640|NCT05614934|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-labeled, prospective, three-arm, parallel-group, non-placebo Randomized controlled clinical trial||||
33680641|NCT04083625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680642|NCT00228215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680643|NCT06079229|||COHORT||PROSPECTIVE|||||||
33680644|NCT01793870|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33680645|NCT05870982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, parallel-arm clinical trial|f|f|t|f
33680646|NCT01402427|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33680647|NCT03021161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33680648|NCT00368199|||COHORT||PROSPECTIVE|||||||
33680649|NCT02835040|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33680650|NCT01463007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680651|NCT04415242|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33680652|NCT01466829|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680653|NCT06531889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680654|NCT01351779|||COHORT||PROSPECTIVE|||||||
33771032|NCT05867264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33771033|NCT01565005|||CASE_CONTROL||PROSPECTIVE|||||||
33771034|NCT00976703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983254|NCT02895711|||OTHER||PROSPECTIVE|||||||
33680655|NCT02303418|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33680656|NCT05381493|||COHORT||RETROSPECTIVE|||||||
33680657|NCT05402371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|blinded, placebo controlled, randomized|t|t|t|t
33680658|NCT05342480|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study PTSD trauma treatment||||
33680659|NCT00035113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680660|NCT01122056|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33680661|NCT01004276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680662|NCT06417983|||CASE_ONLY||PROSPECTIVE|||||||
33680663|NCT05795998|||OTHER||CROSS_SECTIONAL|||||||
33771035|NCT00820820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33983255|NCT03099174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983256|NCT00076934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983257|NCT04041843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680664|NCT04333303|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"1. Investigators will be blinded towards group allocation. There is as risk of unblinding of investigators, therefore we will determine true blinding status at follow-up.~2. Outcomes Assessors will be consequently blinded with regard to group assignment until the statistical analysis plan is finalized."|Of the anticipated 44 nursing homes entering randomisation, half (22) will be allocated to the ACP intervention, the others continue with usual care.|f|f|t|t
33983258|NCT00126932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983259|NCT02636959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983260|NCT03397862|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Blinding will occur at package level.|Induction Phase will consist of application of the once-weekly TDS for 3 consecutive weeks to the same skin site, followed by a rest period of 2 weeks. The TDS application site will be visually scored for skin irritation approximately 30 minutes following each patch removal and prior to the next patch application. The Challenge Phase will consist of 2 days of TDS application followed by 3 days of visual scoring of TDS application site following TDS removal. Subjects meeting the guidance criteria for Re-Challenge phase will continue with a rest period of 4-8 weeks, followed by 2-day TDS application and a 3-day visual scoring of the TDS application site following TDS removal.|t|t|t|t
33983261|NCT03252353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983262|NCT03460951|||CASE_CONTROL||PROSPECTIVE|||||||
33983263|NCT05498480|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33680665|NCT03663556|||CASE_ONLY||PROSPECTIVE|||||||
33983264|NCT05374590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680666|NCT05636800|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label study, however, there is a blinded site investigator at each site who will not be aware of the AK lesions that are randomized to treatment. The blinded site investigator will assess resolution and reoccurrence of the AK lesions. Photos of the AK lesions will be taken and these will be reviewed by three independent blinded assessors to assess cosmetic outcomes.|||||
33680667|NCT00146432|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33680668|NCT00353756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680669|NCT03203993|||CASE_CROSSOVER||PROSPECTIVE|||||||
33680670|NCT02828670|||CASE_CONTROL||PROSPECTIVE|||||||
33680671|NCT01418508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680672|NCT04457622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33680673|NCT06392373|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double blinded randomized crossover design|t|f|t|t
33680674|NCT02630043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771036|NCT04901364|||COHORT||RETROSPECTIVE|||||||
33771037|NCT01297530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771038|NCT01674933|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983265|NCT03618147|||COHORT||OTHER|||||||
33983266|NCT01346397|||CASE_CONTROL||PROSPECTIVE|||||||
33983267|NCT01389102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771039|NCT01812005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771040|NCT04676711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Study drug: GFH312 and placebo In part Ia, subjects will be randomized and dosed in different cohorts in single dose. In part Ib, one of the cohorts will selected as food effect cohort with washout period of part Ia.~In part II, subjects will be randomized and dosed in different cohorts in multiple doses."|t|t|t|f
33771041|NCT00451568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900465|NCT05734872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900466|NCT03546374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900467|NCT00955240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900468|NCT01373177|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33900469|NCT06598397|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A full factorial randomized controlled trial using Multiphase Optimization STrategy (MOST) with 4 component interventions, each at 2 levels (off/on), for a total of 16 component conditions.||||
33900470|NCT01258829|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33900471|NCT05153408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900472|NCT06316089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900473|NCT03312946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983268|NCT04657770|NA|SINGLE_GROUP||TREATMENT||NONE||All enrollees will receive telerehabilitation.||||
33983269|NCT03588624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983270|NCT04976426|||CASE_CONTROL||PROSPECTIVE|||||||
33983271|NCT00397488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983272|NCT05000619|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will not be informed specifically of their assignment to different arms throughout the study. Providers who conduct appointments will not be randomized to study arms or informed of patient assignment.||t|t|f|f
33983273|NCT05493930|||COHORT||RETROSPECTIVE|||||||
33983274|NCT01934621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983275|NCT05537051|NA|SEQUENTIAL||TREATMENT||NONE||||||
33983276|NCT00882180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983277|NCT03124420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|open labeled, randomized control trial.|Group A: 7-day triple therapy for patients fail to achieve intraluminal eradication Group B: 14-day triple therapy for patients fail to achieve intraluminal eradication|f|f|t|f
33983278|NCT04423263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983279|NCT01532674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983280|NCT01944267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983281|NCT02377947|||OTHER||OTHER|||||||
33983282|NCT04213690|||CASE_ONLY||PROSPECTIVE|||||||
33983283|NCT03206177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983284|NCT03952143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983285|NCT01071122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983286|NCT00951925|||COHORT||OTHER|||||||
33983287|NCT04770961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33983288|NCT05363878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983289|NCT02697331|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33983290|NCT03649971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983291|NCT03202576|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Evaluate the securement of the Nasogastric tube either by standard securement or using a Nasal Bridal securement method.||||
33983292|NCT04633109|||CASE_CONTROL||PROSPECTIVE|||||||
33983293|NCT03295669|||OTHER||PROSPECTIVE|||||||
33983294|NCT02008305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983295|NCT01361802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983296|NCT04403425|||COHORT||PROSPECTIVE|||||||
34024683|NCT03876262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be assigned to four groups: annual ivermectin; annual moxidectin; biannual ivermectin; or biannual moxidectin|t|t|t|t
34024684|NCT05871723|||COHORT||CROSS_SECTIONAL|||||||
34024685|NCT01990482|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024686|NCT04244578|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34024687|NCT06165952|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024688|NCT06634316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024689|NCT05373004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The trial will be double-blinded including both participants and health care providers to minimize the risk of bias. The blinding of outcome adjudicators and data collectors is unlikely to matter since the study outcomes are objective.||t|t|f|f
34024690|NCT04471025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|After completion of the block, a single blinded observer recorded demographic data and evaluated the block characteristics|single-center, prospective, randomized into two goups: Jedi grip versus conventional double operator technique|f|f|f|t
33680675|NCT05990595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The clinical trial adopts a randomized cross-over trial, the experimental group to eat white rice with adlay and the control group to eat white rice. Participants in the project were randomly divided into two groups, group A and B, with 30 people in each group. Group A eat 200 gm cooked adlay with white rice to replace their carbohydrates; Group B ate a box of 200 grams of white rice per day. After the first run of study, all participants resume to the original regular diet for two weeks, and then switch groups for crossover trial after the two-week washout period. In the experiment, during the crossover experiment, group A and group B replaced the experimental ingredients, that is, the original white rice group was replaced by adlay with white rice, and the original adlay and white rice group was replaced with white rice for a period of two weeks.||||
33680676|NCT02113800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680677|NCT01837459|||COHORT||PROSPECTIVE|||||||
33680678|NCT02150694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33680679|NCT04685161|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups are used One using fibre post placement And the other using surgical extrusion||||
33680680|NCT02910505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680681|NCT05596383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The study was divided into two groups, the intervention group and the control group. The intervention group received vitamin D 5000 IU/day for 6 months and the control group received a placebo (contains microcrystalline, calcium carbonate, sodium starch) for 6 months|t|t|t|t
33900474|NCT03877185|||COHORT||PROSPECTIVE|||||||
33900475|NCT02457052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33900476|NCT04764032|||COHORT||PROSPECTIVE|||||||
33900477|NCT03271255|RANDOMIZED|PARALLEL||TREATMENT||NONE||Head-to-head comparison of apatinib versus bevacizumab plus sencond-line chemotherapy regimen FOLFIRI for treatment of metastatic colorectal cancer||||
33900478|NCT04022369|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33900479|NCT06302634|||COHORT||PROSPECTIVE|||||||
33900480|NCT04580719|||OTHER||PROSPECTIVE|||||||
33900481|NCT05965713|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study staff will screen participants virtually or in person for eligibility after completing the informed consent process and documentation. After screening for study eligibility has occurred, the initial EEG screening will take place for all individuals who meet the criteria for the study as to ensure no preference to subjects with optimal signals for use of the IpsiHand. Once EEG screenings have been completed, the participant will be randomly assigned to Group 1 (BCI treatment) or Group 2 (standard of care treatment group). Each group will complete a daily therapy regimen. In Group 1 (BCI group)- will complete daily BCI therapy. In Group 2 (standard of care)- individuals will complete standard of care therapy program daily for 12 weeks provided by an occupational therapist.||||
33900482|NCT00402350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900483|NCT02976467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900484|NCT05712031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900485|NCT06672796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised controlled|f|f|t|t
33900486|NCT02348567|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33900487|NCT02547194|||||PROSPECTIVE|||||||
33900488|NCT02965703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33900489|NCT05153395|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900490|NCT05250115|||COHORT||PROSPECTIVE|||||||
33983297|NCT06302374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|"In the phase I part of the study, a total of 94 healthy subjects will be enrolled. The 94 healthy adult subjects will be enrolled into 7 cohorts sequentially. Each participant will receive a single IM dose of GR2001 or placebo or HTIG according to the cohort in which they were enrolled. After injection (Day 0), participants will remain in the study site for observation up to Day 1. The phase I part will last for 105 days following the assessments of safety, PK, PD and ADA.~In the phase II part of the study, a total of 108 healthy subjects will be enrolled. The 108 healthy subjects will be randomly assigned to the experimental group and the control group based on a ratio of 1:1:1:2:2:2.The phase II part will last for 105 days following the assessments of safety, PK, PD and ADA."|t|f|t|f
33983298|NCT03894605|||OTHER||PROSPECTIVE|||||||
34024691|NCT02315430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680682|NCT04307615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33680683|NCT03948477|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double-blinded|Double-blinded, randomised, crossover trial, phase II, stratified by the chemotherapy regimen|t|t|t|f
33680684|NCT03894007|RANDOMIZED|PARALLEL||TREATMENT||NONE||Both arms start with four cycles of docetaxel/paklitaxel+carboplatin+trastuzumab+pertuzumab. Thereafter arm A receives three cycles of epirubicin+cyclophosphamide+atezolizumab and arm B receives epirubicin+cyclophosphamide.||||
33680685|NCT04335214|NA|SINGLE_GROUP||OTHER||NONE||one to one interviews||||
33680686|NCT02721394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680687|NCT06289205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This will be a single-blind study in which the subjects will be unaware of the intervention. Blinding will be maintained by ensuring that subjects are unaware of the dosing regimens they are receiving.|Using lottery methods patients will be divided into two groups with 60 subjects in each group. Group 1 will be regarded as control group and per operative methotrexate infusion will be used by mixing 75 mg of methotrexate into one litre of BSS solution. Group 2 will be regarded as the study group and will receive 500 µg of intra-silicon oil methotrexate at the end of the surgery and then at 1st, 2nd, 3rd , 4th and 6th post operative weeks.|t|f|f|f
33771042|NCT01967264|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33771043|NCT03607903|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study is double blind. Investigator, study staff, and subjects, are blinded until study closure. Investigational drug and matching placebo are indistinguishable and will be packaged similarly. Injection site assessments will be performed by (a) study-independent physician(s). The study physician will administer the injection, thus unblinded to type of injection. This physician will not reveal the route of administration to others. The investigator receives sealed emergency codes to be broken in case of emergency situations. If the identity of study drug administered needs to be known to manage the subject's condition i.e., in case of a medical emergency or in the case a SUSAR occurs, the treatment emergency code for that subject may be broken and the study drug identified. All such occurrences should be documented in the study file. Just prior to database lock unused emergency code labels will be checked and a statement that all are intact (or not) is made on database lock form.|This is a double blind, placebo controlled, double-dummy study.|t|f|t|t
33771044|NCT05921071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized control|t|t|f|t
33771045|NCT06048757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771046|NCT02582164|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33771047|NCT00822003|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33771048|NCT05303896|||CASE_ONLY||CROSS_SECTIONAL|||||||
33771049|NCT01556074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771050|NCT00284089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771051|NCT01601444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771052|NCT00001626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771053|NCT01812538|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33771054|NCT05054712|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33771055|NCT05047562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33771056|NCT04676009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771057|NCT02282319|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33771058|NCT04575649|||COHORT||PROSPECTIVE|||||||
33771059|NCT00895843|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33771060|NCT00593320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771061|NCT03810313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A masked evaluating investigator was responsible for all aspects of the study except the injections and the safety assessment following the injections. An unmasked treating investigator performed the injections and assessed patient safety following the injections.||t|f|t|t
33771062|NCT01775930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771063|NCT03729011|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients will be randomly allocated to receive either inhalation anaesthesia or TIVA. Permuted-block randomization will be used to allocate subjects to one of the study groups. Sequentially numbered sealed opaque envelopes will contain the treatment code, to be opened in the morning of surgery. Patients will be unaware of group assignment. All the statistical analyses will be performed by the biostatistician not involved in treatment allocation.|t|f|f|f
33771064|NCT05239416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771065|NCT02690636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680688|NCT03714269|NA|SINGLE_GROUP||OTHER||NONE||||||
33680689|NCT04113590|NA|SINGLE_GROUP||OTHER||NONE||||||
33680690|NCT02065388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33680691|NCT01258569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680692|NCT02379130|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33680693|NCT00947440|RANDOMIZED|CROSSOVER||||NONE||||||
33680694|NCT04841187|||COHORT||PROSPECTIVE|||||||
33771066|NCT06345222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Case control study||||
33771067|NCT03570125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771068|NCT01226979|NA|SINGLE_GROUP||TREATMENT||NONE||High-Dose-Rate Endorectal Brachytherapy (HDRBT)||||
33771069|NCT01755520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900491|NCT06508567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900492|NCT03421847|||CASE_CONTROL||OTHER|||||||
33900493|NCT03946566|||OTHER||PROSPECTIVE|||||||
33900494|NCT04476771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900495|NCT01385696|RANDOMIZED|CROSSOVER||||NONE||||||
33900496|NCT00955110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33900497|NCT00313677|||COHORT||PROSPECTIVE|||||||
33900498|NCT03085732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680695|NCT05903209|||CASE_CONTROL||RETROSPECTIVE|||||||
33680696|NCT00338182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680697|NCT04806867|||COHORT||RETROSPECTIVE|||||||
33771070|NCT06261463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Research Assistants (RAs) who will collect both qualitative and quantitative data will be blind to the condition in which study participants are randomized.|The investigators will conduct a randomized controlled trial with refugee families from Arabic-speaking refugee families from the Middle East (n=74). Half of the participants will be randomized to receive CAFES2 and half will be randomized to the enhanced control condition where they will receive ongoing access to services through partner organizations and healthy lifestyle materials.|f|f|f|t
33680698|NCT05900440|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33680699|NCT03459690|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective trial enrolling healthy volunteers, including novice meditators and experienced meditators. Subjects will undergo an EEG at baseline and again after 6 weeks. During the 6 weeks, subjects will be asked to meditate twice a day, 12 minutes each time.||||
33680700|NCT01489241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33680701|NCT00243646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771071|NCT05197790|NA|SINGLE_GROUP||OTHER||NONE||||||
33771072|NCT05467917|||COHORT||PROSPECTIVE|||||||
33771073|NCT02443103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771074|NCT02762383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771075|NCT01743690|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33771076|NCT05140811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771077|NCT03754101|||COHORT||PROSPECTIVE|||||||
33771078|NCT00002215||||TREATMENT||DOUBLE||||||
33771079|NCT05689814|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Masking versus no fixative control will not be possible, however, clinical outcomes assessors will be masked to the two different investigational denture fixative products|The denture fixative cream formulations will be tested in a 3-arm cross-over-design, where subjects will be randomised to a sequence including the two intervention (denture fixative) arms and a control (no fixative) arm.|f|f|f|t
33680702|NCT00837733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771080|NCT00960102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680703|NCT02667353|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33680704|NCT00561977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771081|NCT01435044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680705|NCT01291485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33680706|NCT05049317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771082|NCT01342029|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33680707|NCT00401180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680708|NCT00129311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33680709|NCT06481280|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"Masking only applies to the 1st part of the study : during this part all parties (participant, care provide, investigator and outcomes assessor) will be blinded.~The 2nd study part is open-label , there is no masking during this phase"|"The first part of the study consists in a double-blind placebo-controlled food challenge (DBPCFC) during which all patient will receive the test formula and a placebo, in a randomised order.~During the second part of the study, all patients will be fed the test formula (open-label phase)."|t|t|t|t
33771083|NCT06413550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33680710|NCT02845219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771084|NCT05401370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771085|NCT03585114|NA|SINGLE_GROUP||TREATMENT||NONE||Fifteen men will be recruited from Columbia University Medical Center.||||
33771086|NCT03200301|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33771087|NCT03171558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771088|NCT02337478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771089|NCT01791452|||||PROSPECTIVE|||||||
33771090|NCT04047381|||OTHER||PROSPECTIVE|||||||
33771091|NCT05366049|RANDOMIZED|PARALLEL||OTHER||TRIPLE|single blind|randomized controlled trial|f|t|t|t
33680711|NCT01794338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680712|NCT00303368|||OTHER||RETROSPECTIVE|||||||
33771092|NCT04291235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33771093|NCT04911257|||COHORT||PROSPECTIVE|||||||
33771094|NCT01764373|NA|SINGLE_GROUP||||NONE||||||
33771095|NCT01425164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771096|NCT03863743|RANDOMIZED|PARALLEL||PREVENTION||NONE||164 patients will be randomized to either the control group or the experimental group. Patients will be randomized immediately following the signed consent.||||
33771097|NCT05794282|||COHORT||RETROSPECTIVE|||||||
33771098|NCT03969082|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33771099|NCT00368862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771100|NCT01715623|||COHORT||PROSPECTIVE|||||||
33771101|NCT06077916|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33771102|NCT02792985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33900499|NCT06120738|||OTHER||CROSS_SECTIONAL|||||||
33771103|NCT02349568|||COHORT||PROSPECTIVE|||||||
33771104|NCT02155959|||COHORT||PROSPECTIVE|||||||
33771105|NCT04730921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771106|NCT00431639|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33771107|NCT02383511|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33771108|NCT03765463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771109|NCT02377713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680713|NCT05637814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Non-invasive measurements of oxygenation and perfusion will be measured with pulse oximeters and a machine learning algorithm to improve sensitivity of CCHD screening.||||
33771110|NCT04974541|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33900500|NCT04799782|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33900501|NCT04596657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900502|NCT06274359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Caregivers will be assigned randomly to receive a series of digital stories by text message or to receive usual care.|f|f|t|f
34024692|NCT02111603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771111|NCT02663375|||CASE_ONLY||PROSPECTIVE|||||||
33771112|NCT01821443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771113|NCT02513992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771114|NCT01886963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771115|NCT02500485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771116|NCT05509543|RANDOMIZED|CROSSOVER||TREATMENT||NONE|In order to prevent distortion (bias) affecting test results during sample analysis, this clinical trial shall not be disclosed to analysis manager and analyst until the specimen analysis is completed.|||||
33771117|NCT01077362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771118|NCT02731313|||CASE_ONLY||CROSS_SECTIONAL|||||||
33771119|NCT05764239|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The DEP (Part 1) and OLE (Part 3) were open label, and the RWP (Part 2) was double blinded.|This was a Phase 2b/3 adaptive study design.|t|t|t|t
33771120|NCT03395210|NA|SEQUENTIAL||TREATMENT||NONE||||||
33771121|NCT00829361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771122|NCT04533776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771123|NCT05597800|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study type: Phase 2 - Interventional Trial Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID syndrome||||
33771124|NCT02806284|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771125|NCT05733819|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will complete a 6MWT without RAS and then complete a 6MWT with RAS||||
33771126|NCT02951910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771127|NCT00102050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771128|NCT02076685|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33771129|NCT04545294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The allocation concealment was further ensured by the administration of tACS using study mode of the device in which a five-digit numerical code specific to individual participant was entered into the device (Eldith DC stimulator Plus, NeuroConn, Ilmenau, Germany) that resulted in either active or sham stimulation, i.e., the researcher got the randomization code and a unique five-digit numerical code for an individual participant from the study coordinator while tACS administrator entered the code for study mode into the device. The study coordinator had continuous access to the randomization list and unblinded the study after the final visit of the last participant. Not until the unblinding of the trial did the participants, tACS administrators, researchers and clinical raters know the actual stimulation types."||t|t|t|t
33771130|NCT03009890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771131|NCT00432835|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33900503|NCT03876340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Controlled double blinded study. Patients and outcomes assessors will be masked to intervention.|Two parallel arms: group A will receive treatment as usual, group B will receive treatment as dictated by a clinical decision algorithm (PLoS ONE 2018:13(11):e0206477).|t|f|f|t
33900504|NCT05738616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900505|NCT00152412|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33900506|NCT01665781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900507|NCT06235151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900508|NCT02140320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33900509|NCT06096194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two types of eggs. Control egg and fortified egg (vitamin D3-enhanced egg), only the researcher in charge of eggs production was not blinded|Randomized Double Blind field trial|t|t|f|t
33771132|NCT01282320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900510|NCT01679834|||COHORT||PROSPECTIVE|||||||
33900511|NCT00425438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771133|NCT02334527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771134|NCT03906981|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33771135|NCT05476991|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33771136|NCT01682564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900512|NCT05557474|||COHORT||PROSPECTIVE|||||||
33900513|NCT02940665|||COHORT||PROSPECTIVE|||||||
33900514|NCT00875771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900515|NCT04098614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigator/study personnel inform the participant regarding which arm they have been assigned and inform a recovery coach if the participant is randomized to the intervention arm.|f|f|f|t
33900516|NCT01534832|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33900517|NCT06273865|||COHORT||CROSS_SECTIONAL|||||||
33900518|NCT02360943|||COHORT||PROSPECTIVE|||||||
33900519|NCT06671132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900520|NCT04286308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33900521|NCT03188211|RANDOMIZED|PARALLEL||OTHER||SINGLE||cluster randomized controlled trial|f|f|f|t
33900522|NCT00003881||||TREATMENT||||||||
33900523|NCT01823653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900524|NCT04842344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900525|NCT04372329|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33900526|NCT02612714|NA|SINGLE_GROUP||||NONE||||||
33900527|NCT06673108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900528|NCT06513780|||COHORT||OTHER|||||||
33983299|NCT06433674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The intervention will be two parallel groups. one Group receiving Zinc Sulfate. The other group receiving Placebo|t|t|t|t
33983300|NCT04707040|NA|SINGLE_GROUP||TREATMENT||NONE|The investigator who performed the outcome measures were blind to the groups, and did not know if the participant was actually a healthy control, or a patient with ADHD.|||||
33983301|NCT02099981|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983302|NCT03401996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983303|NCT05539222|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33983304|NCT02738190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34024693|NCT02879851|||||PROSPECTIVE|||||||
33900529|NCT06662188|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multicenter, open-label, first-in-human (FIH), single-dose, dose-escalation, safety, tolerability, and clinical activity of JAG201. A traditional 3+3 design strategy will be implemented for dose escalation from the 1st cohort to the 2nd cohort.||||
33900530|NCT04674137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For blinding purposes the Placebo was made with the corresponding labelling of the study drug.|At Visit 3, Week 0 all patients were randomized into 2 groups in 1:1 ratio (35 patients to group of XC8 100 mg and 35 patients to Placebo group).|t|f|t|f
33983305|NCT01544127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900531|NCT03662464|||COHORT||PROSPECTIVE|||||||
33900532|NCT03562780|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33680714|NCT01871480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680715|NCT06493292|||COHORT||PROSPECTIVE|||||||
33680716|NCT01595022|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33680717|NCT02206178|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33680718|NCT05623462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680719|NCT01395784|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33680720|NCT03560700|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33680721|NCT00186953|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33680722|NCT00878436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680723|NCT05901389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||lidocaine will be injection by electronic analgesic pump, and the pulse infusion speed is 1ml / 30min, and 2ml / h for continuous infusion|t|f|f|f
33680724|NCT00910507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680725|NCT02524600|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680726|NCT02226679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900533|NCT05717920|NA|SINGLE_GROUP||TREATMENT||NONE|Part 1 is an open-label trial.|||||
33900534|NCT03935646|NA|SINGLE_GROUP||TREATMENT||NONE||This is a mixed (within-subjects and between-subjects) design. ADHD and comparison participants will complete outcome measures at baseline and at two counter-balanced experimental sessions (placebo, Adderall).||||
33900535|NCT05941052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900536|NCT03562221|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33983306|NCT01506466|NA|SINGLE_GROUP||||NONE||||||
33983307|NCT05378126|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983308|NCT06250010|||COHORT||OTHER|||||||
33680727|NCT01888432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This was a 24-month, multicenter, open-label, randomized, controlled study. It included the extension to the 24-month, randomized, controlled, open-label CRAD001H2307 study in recipients of living donor liver transplants in Japan.|f|t|f|f
33680728|NCT00347256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680729|NCT00917293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983309|NCT04786184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment|A prospective RCT: In Phase I, participants will be randomized 1:1 to one of two groups: CALM Breathing (N = 25) and Wait-List control (N = 25). In Phase II, both groups will be offered Columbia University's 10-week PR program (care as usual). Access to timely initiation of PR will be facilitated. We will use a hybrid design to evaluate feasibility and acceptability.|f|f|f|t
33983310|NCT00604877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983311|NCT05376007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and investigators will be masked at pre-test assessment only||f|f|f|t
33983312|NCT05163093|||COHORT||PROSPECTIVE|||||||
33983313|NCT03785548|||COHORT||PROSPECTIVE|||||||
33983314|NCT03020043|||COHORT||PROSPECTIVE|||||||
33983315|NCT01463761|||COHORT||PROSPECTIVE|||||||
33983316|NCT02815319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983317|NCT00959660|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33983318|NCT05194722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983319|NCT01038791|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33983320|NCT04742478|||COHORT||PROSPECTIVE|||||||
33983321|NCT05364632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluations will be conducted blindly, that is, by an evaluator who will not be directly involved in the intervention.||f|f|t|t
33900537|NCT04908072|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Video recordings of procedures will be allocated a random 7-digit number, and subsequently stored onto an encrypted computer, and a separate encrypted hard drive. This random number will be the only identifiable information available when the simulation/surgical procedure is assessed, thus masking the assessor to the participant's intervention/control arm.~Recordings will be converted to an MP4 format, and coded. At CyberSight, the recording will be renamed as a randomly generated seven-digit number (e.g. 6253815). The code sheet will be generated by an independent statistician and only be known to them and the CyberSight administrator. Once assessors are notified that the video is ready for marking, this random number will be the only identifiable information available when the simulation/surgical procedure is assessed, thus completely masking the assessor to the participant's intervention/control arm and personal identity."|This research program involves a prospective, investigator-masked education-intervention randomized controlled study of intensive virtual reality (VR) simulation-based surgical education of ophthalmologists in China, Ethiopia, India, Mongolia, Bangladesh, the UK and USA. Participants will be randomized, and surgical competency will be assessed at baseline and 1-month between groups. Competency will be assessed at baseline, using artificial eyes. Both groups will perform three full MSICS cases using model eyes at baseline. At one-month post intervention, both groups will again perform three full MSICS using model eyes (main outcome).|f|f|t|t
33900538|NCT04552119|||COHORT||PROSPECTIVE|||||||
33900539|NCT00043147|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33900540|NCT03806569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants will not know, in which of the arms they are; the outcomes assessor did not know the patients study-arm|monocentric, parallel group randomized superiority study - one arm with new intervention, other arm with well established relaxation treatment|t|t|f|t
33900541|NCT06669442|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33900542|NCT03891277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Two nearly identical tablet forms of Ferrous iron (0.2g Ferrous iron and matching placebo) with almost the same size, color and smell will be used in this research.||t|t|t|t
33900543|NCT03494725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33900544|NCT05789004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983322|NCT05290311|||COHORT||PROSPECTIVE|||||||
33983323|NCT03438253|||COHORT||PROSPECTIVE|||||||
33983324|NCT00778505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983325|NCT06164782|||OTHER||CROSS_SECTIONAL|||||||
33983326|NCT00011570|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983327|NCT06327607|||CASE_CONTROL||PROSPECTIVE|||||||
33983328|NCT04807621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983329|NCT02680626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983330|NCT05342285|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983331|NCT00350246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983332|NCT00874237|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind, double dummy||t|t|t|t
33983333|NCT00812357|||COHORT||PROSPECTIVE|||||||
33983334|NCT00672178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983335|NCT06119841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983336|NCT00206544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983337|NCT06491524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983338|NCT03962023|||COHORT||PROSPECTIVE|||||||
33900545|NCT05803564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900546|NCT05739617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900547|NCT03910959|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The study has a randomized, controlled cross-over design.|f|f|f|t
33983339|NCT01167309|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33983340|NCT02039362|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33983341|NCT05797571|||COHORT||CROSS_SECTIONAL|||||||
33983342|NCT00969800|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33983343|NCT01824537|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33983344|NCT01165905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983345|NCT01861210|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33983346|NCT03148704|||COHORT||PROSPECTIVE|||||||
33983347|NCT05924763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983348|NCT01096420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983349|NCT02598882|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983350|NCT05731297|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983351|NCT00430287|||COHORT||PROSPECTIVE|||||||
33983352|NCT02511626|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983353|NCT02763085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983354|NCT05873881|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Factorial 1: Placebo controlled. Factorial 2: Prospective Randomized Open Blinded End-point (PROBE) design|Factorial 1: Colchicine 0.5 mg daily or placebo Factorial 2: Thiamine 300mg daily or no thiamine|t|f|f|t
33983355|NCT00134394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983356|NCT01276730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983357|NCT01763385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983358|NCT04734964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33900548|NCT06006728|||CASE_ONLY||RETROSPECTIVE|||||||
33900549|NCT03745339|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33900550|NCT01325467|||CASE_ONLY||PROSPECTIVE|||||||
33900551|NCT05575804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900552|NCT03323307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900553|NCT05624944|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900554|NCT05013060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900555|NCT02949661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33900556|NCT03074305|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open label, two-arm, randomized controlled trial||||
33900557|NCT00455546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33900558|NCT05581576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983359|NCT01709760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33983360|NCT05584943|||COHORT||RETROSPECTIVE|||||||
33983361|NCT01367340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983362|NCT03828734|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33983363|NCT04192526|||CASE_CONTROL||PROSPECTIVE|||||||
33983364|NCT04920708|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients starting standard of care CDK4/6 inhibitors and fulvestrant will have ctDNA assessment at Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15).~Patients with high ctDNA levels at C1D15 will be randomised in a 1:1 ratio to palbociclib + fulvestrant (comparison arm) or palbociclib + fulvestrant + ipatasertib (interventional arm).~Patients with ctDNA suppressed at C1D15 will continue standard of care, fulvestrant+CDK4/6 inhibitor (observational arm). The first 100 patients of this group will be followed for PFS, OS and ctDNA collection.~Patients with no detectable ctDNA at screening will continue on standard of care. The first 50 of this group will be followed for PFS, OS, time to next treatment, and time to chemotherapy."||||
33983365|NCT00533663|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33983366|NCT04857125|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|The statistician will be blinded from the groups, when assessing the primary outcome.||f|f|f|t
33983367|NCT04342481|||COHORT||PROSPECTIVE|||||||
33983368|NCT01643005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983369|NCT00054873||||TREATMENT||||||||
33983370|NCT03737578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||this is an interventional, pragmatic study with minimal risks, exposed / unexposed, prospective, longitudinal, multicentric and national conducted in metropolitan France||||
33983371|NCT02223741|||COHORT||PROSPECTIVE|||||||
33983372|NCT00075543||||TREATMENT||||||||
33983373|NCT05056077|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33983374|NCT01735409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983375|NCT00055315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900559|NCT02742740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33900560|NCT04143971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900561|NCT06663371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There is no specific relevant model to refer to for use.|t|f|f|f
33900562|NCT02583750|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33900563|NCT03634046|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor do not know all the information about the data origin and the group.|Subjects were recruited comparatively into two groups (percutaneous transforaminal endoscopic discectomy (PTED) group and Radiofrequency Ablation (RA) group). The follow-up time points are 7 days, 1 month, 6 months and 12 months post-operation in both groups, respectively.|f|f|f|t
33900564|NCT06075004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective randomized comparison between two analgesic techniques|t|f|f|t
33983376|NCT00819741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983377|NCT01237522|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983378|NCT01167205|RANDOMIZED|PARALLEL||||SINGLE||||||
33983379|NCT00384852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983380|NCT02647164|||CASE_ONLY||PROSPECTIVE|||||||
33983381|NCT03706989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Only one group of cardiac patients divided in sub-groups according to their age.||||
33983382|NCT00488865|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33983383|NCT00814463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983384|NCT01085045|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33983385|NCT03079128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983386|NCT05625022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983387|NCT00986297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680730|NCT01331421|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680731|NCT02614521|||OTHER||PROSPECTIVE|||||||
33680732|NCT00930137|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33680733|NCT03263650|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All participants will receive 6 cycles of cabazitaxel and carboplatin before being randomized 2:1 to olaparib maintenance versus observation.||||
33680734|NCT02117128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33680735|NCT00088556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680736|NCT02172534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680737|NCT01713933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680738|NCT04936984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All subjects were to receive a transdermal patch containing 300 μg abaloparatide for 4,5 and 7 minutes in 4 separate periods.||||
33680739|NCT06434987|||COHORT||PROSPECTIVE|||||||
33680740|NCT06414785|||CASE_ONLY||RETROSPECTIVE|||||||
33900565|NCT06671002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both study staff performing outcome assessment and data analysis will be masked to treatment assignment.|Both study staff performing outcome assessment and data analysis will be masked to treatment assignment.|f|f|f|t
33983388|NCT02853682|||COHORT||PROSPECTIVE|||||||
33680741|NCT02081755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680742|NCT04195776|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33680743|NCT03570463|||COHORT||PROSPECTIVE|||||||
33680744|NCT00523367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680745|NCT04813003|||OTHER||PROSPECTIVE|||||||
33900566|NCT03341104|||COHORT||RETROSPECTIVE|||||||
33900567|NCT06166134|||OTHER||CROSS_SECTIONAL|||||||
33900568|NCT04404400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900569|NCT03690024|||CASE_ONLY||PROSPECTIVE|||||||
33900570|NCT03000114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900571|NCT03564249|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33900572|NCT03650439|||COHORT||PROSPECTIVE|||||||
33900573|NCT03224637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33900574|NCT00298662|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900575|NCT02267785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900576|NCT03025711|||COHORT||RETROSPECTIVE|||||||
33900577|NCT01719445|||COHORT||PROSPECTIVE|||||||
33900578|NCT04689646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) Participants will be partially blinded. Participants in the usual care arm will be blinded to the specifics of the interventions. Participants in Mind-Body Intervention 2 arm will be blinded to the specifics of the interventions. Intervention participants will be blinded to the specifics of the intervention until after they have been randomized into that arm. Data analysis will be conducted by persons who are completely blinded.|Mind-Body Intervention 1, Mind-Body Intervention 2 and Usual Care|t|f|f|t
33900579|NCT02162745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900580|NCT05777811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly assigned to either the Vertically Coronally Advanced Flap (n=25) group or the Free Gingival Graft (n=25) group by one of the authors, with an allocation ratio of 1:1, using a computer-generated program after the successful completion of Phase I periodontal treatment. One calibrated author applied the surgical technique and recorded all clinical variables. The surgeon opened the labeled envelope containing the intervention name.||f|t|f|t
33900581|NCT06332963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Equal groups parallel randomized clinical trial||||
33900582|NCT04246229|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33900583|NCT03396471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839521|NCT05842642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Upon acceptance, each participant will be assigned a treatment group. Before starting the intervention, all the subjects will go to the UAH physiotherapy center for a first visit with the first examiner where personal data will be collected and sociodemographic, psychometric and functional variables will be assessed.~At the end of said evaluation, a second examiner gave them the steps to follow to carry out the study. In addition, you will be given a document with a table that will be your migraine diary that you must fill in every day from the start of treatment until the day of the last assessment."|Two groups, a control group and an experimental group. In the control group, a treatment of the cervical region will be done for 6 weeks, once a week, and they will be taught some exercises to do at home. And in the experimental group, the treatment of the control group will be done plus an additional intervention in the oculomotor region together with some specific exercises.|t|f|f|f
33900584|NCT02333955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900585|NCT00400387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900586|NCT05979012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900587|NCT02917863|RANDOMIZED|CROSSOVER||||NONE||||||
33900588|NCT01784549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900589|NCT01849848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900590|NCT00828386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900591|NCT00683189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900592|NCT05331989|||CASE_CONTROL||PROSPECTIVE|||||||
33900593|NCT06133777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900594|NCT02391727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900595|NCT00570739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900596|NCT06179212|||CASE_ONLY||PROSPECTIVE|||||||
33900597|NCT02057237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900598|NCT05534334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900599|NCT00933335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900600|NCT06512701|||OTHER||CROSS_SECTIONAL|||||||
33900601|NCT02803372|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900602|NCT00302601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900603|NCT02732158|NA|SINGLE_GROUP||OTHER||NONE||||||
33900604|NCT02114203|RANDOMIZED|||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33900605|NCT02104310|||COHORT||PROSPECTIVE|||||||
33900606|NCT06672185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33900607|NCT06661759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33900608|NCT02903511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900609|NCT04440917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900610|NCT06513221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900611|NCT02946229|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study is designed to collect data from a ultrasound device being used to evaluate feasibility of next generation algorithms for ultrasound data processing and does not test any health outcome. All eligible adults (aged 18 or older) will contribute case data from a convenience sample of maintenance hemodialysis population available at the study site and consistent with feasibility assessment of the technology. A relatively large feasibility population is used due to the need to test feasibility of multiple features across variations within this population.||||
33900612|NCT01354691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900613|NCT03049540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33900614|NCT02525224|NA|SINGLE_GROUP||OTHER||NONE||||||
33900615|NCT04490954|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33983389|NCT03171155|NA|SINGLE_GROUP||TREATMENT||NONE||Implantation of the XPro System||||
33983390|NCT00714740|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33983391|NCT00724230|||||PROSPECTIVE|||||||
33983392|NCT01351506|||COHORT||PROSPECTIVE|||||||
33983393|NCT00715702|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983394|NCT02735122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983395|NCT02648347|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor was blinded during the study|||||
33983396|NCT02335840|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33900616|NCT04248257|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33983397|NCT05078138|NA|SEQUENTIAL||PREVENTION||NONE||Longitudinal study design||||
33983398|NCT06011538|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||To evaluate the potential efficacy of additional on-line, patient education for SDD LH in achieving SDD compared to standard information giving. In addition, the utility and acceptability of patient information will be assessed as well as the impact on patient satisfaction and recovery.|t|t|t|t
33983399|NCT02649803|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983400|NCT03151473|||COHORT||PROSPECTIVE|||||||
33983401|NCT02502110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983402|NCT04236960|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33983403|NCT00219323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024694|NCT05151354|||COHORT||PROSPECTIVE|||||||
34024695|NCT05971940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024696|NCT05336383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024697|NCT02263950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024698|NCT01616030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024699|NCT05574608|NA|SEQUENTIAL||TREATMENT||NONE||Evaluate the safety of JD023 injection.||||
34024700|NCT05549609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024701|NCT00650208|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33900617|NCT00173134|||||OTHER|||||||
33900618|NCT01538173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900619|NCT06064682|||COHORT||PROSPECTIVE|||||||
33900620|NCT00942708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900621|NCT02827552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900622|NCT04581187|||COHORT||PROSPECTIVE|||||||
33900623|NCT00072969||||TREATMENT||||||||
33900624|NCT02933515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900625|NCT00670917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33900626|NCT04848974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900627|NCT02061137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900628|NCT04618705|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel non-randomized study.||||
33900629|NCT02202811|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33900630|NCT04418583|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective case-control study wherein participants are their own control||||
33900631|NCT05641623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Monitor|Double-blind|t|t|t|t
33900632|NCT05823493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900633|NCT03376490|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33900634|NCT06160635|||COHORT||OTHER|||||||
33900635|NCT01964365|RANDOMIZED|CROSSOVER||||NONE||||||
33900636|NCT00388752|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900637|NCT00772460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900638|NCT05679726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33900639|NCT00501852|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33900640|NCT01919372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983404|NCT03966365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding will correspond to the principal investigator and coinvestigator. In addition, the statistical analysis will be carried out in a blinded manner for the final analysis. Blinding can not be guaranteed in the subject.~The masking will be done through the secondary container. The primary packaging will not be masked by the morphological difference between them. The sponsor and the research center will have two blind / non-blind teams.~They will be identified by means of identical labels. Which, in accordance with current and applicable regulations, must contain at least:~* Name, address and telephone number of the sponsor.~* Pharmaceutical form and route of administration.~* Lot Number.~* Caption Exclusively for clinical studies~* Date of Expiry"|Phase I clinical trial, controlled, parallel group, double blind, randomized.|f|f|t|t
33983405|NCT05070676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A newly developed mobile application will be developed to help pedodontists in orthodontic diagnosis, and treatment of dentoalveolar, or skeletal deformations||||
33983406|NCT01701024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771137|NCT03989635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a subject and investigator-blinded study. Subjects, investigators and all site staff will remain blinded to study treatment throughout the study.~Unblinding a single subject at site for safety reasons (if necessary for subject management) will occur via an emergency system in place at the site.~The identity of the treatments will be concealed by the use of study drugs that are all identical in packaging, labeling, schedule of administration, appearance, and odor.~The sponsor may be unblinded to the study treatment at any time, especially in case of a safety concern."|"This is a non-confirmatory, mode-of-action, placebo-controlled, parallel group, randomized, subject and investigator blinded study in 48 moderate to severe asthma patients, who are on at least medium dose ICS, with or without other asthma controller and with elevated sputum eosinophils count of ≥ 2% of the total cell count from an induced sputum specimen and a peripheral eosinophil count ≥ 250 cells/μL of blood. They should be on standard of care asthma medications for 4 weeks prior to screening with no past or current medical history of other chronic or severe pulmonary diseases. Randomized patients will be treated with fevipiprant or matching placebo for up to 98 days. A group of 10 healthy subjects will also be recruited to examine baseline levels of prostaglandins and DP2-related biomarkers and compare them to biomarker data from asthma patients at baseline and after therapy with fevipiprant.~Healthy volunteers will not receive study treatment.~."|t|t|t|f
33771138|NCT05592080|||CASE_CONTROL||PROSPECTIVE|||||||
33771139|NCT03337880|||CASE_CONTROL||PROSPECTIVE|||||||
33771140|NCT04081298|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33771141|NCT01644474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771142|NCT05690789|||COHORT||CROSS_SECTIONAL|||||||
33771143|NCT04905732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After documenting parental consent, these ventilated infants with BPD were randomly assigned to either NHFOV or NCPAP using a table of random numbers and sealed opaque envelopes when they were eligible for extubation. Blinding to doctor was not possible due to the nature of the intervention, is not necessary to participant.|After documenting parental consent, the ventilated infants with BPD were randomly assigned to either NHFOV or NCPAP|f|f|t|t
33771144|NCT02290366|NA|SINGLE_GROUP||TREATMENT||NONE||Brachytherapy, using Cesium 131||||
33771145|NCT03180216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771146|NCT03859375|||COHORT||PROSPECTIVE|||||||
33771147|NCT04140890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be masked.|The treatment group will receive healthy habit intervention, and the control group will receive attention control.|f|f|f|t
33771148|NCT03525574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839522|NCT05914051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33839523|NCT03863977|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A blinded physician prepared the study medications in color coded syringes.|60 patients will be divided into two groups according to the dose of dexamethasone added to bupivacaine in the TAP block, I - group ( Group D4 ) 4mg of dexamethasone will be added II - group ( Group D8 ) 8mg of dexamethasone will be added. III-group(control) bupivacaine alone|t|t|t|t
33839524|NCT00616590|||COHORT||PROSPECTIVE|||||||
33839525|NCT03033940|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839526|NCT00763464|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839527|NCT00249964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900641|NCT05094440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900642|NCT02263339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900643|NCT03495505|NA|SINGLE_GROUP||TREATMENT||NONE||20 patients will be recruited into this feasibility study with a 6 month follow-up. There will be no blinding nor randomisation.||||
33900644|NCT02089737|||COHORT||PROSPECTIVE|||||||
33900645|NCT03246035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33900646|NCT04493749|||COHORT||PROSPECTIVE|||||||
33900647|NCT01411540|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33900648|NCT03359421|||COHORT||OTHER|||||||
33900649|NCT01401244|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900650|NCT06187415|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33900651|NCT02805699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33900652|NCT00432133|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33983407|NCT00946166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34079235|NCT00190424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900653|NCT05440955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be maintained at several levels: participants, research staff members including investigators and data analysts. If different from the investigator, care providers will be also blinded to intervention. Blinding for the tDCS condition will be achieved for the research staff members who will administer the tDCS by the use of a randomization code (see details in §16c) and for the participants by ensuring identical appearance and sensation for both active and sham conditions. Outcome assessments, imaging and biological data will be collected and analysed by research staff members blind to group assignment and different from the staff member who will administer the tDCS.|The present study is designed as a superiority, double-blind, parallel-group, sham-controlled randomized clinical trial with an allocation ratio of 1:1.|t|t|t|t
33771149|NCT04398784|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The blueberry treatment and placebo powders have been supplied by the U.S. Highbush Blueberry Council; packets are labeled either alpha or omega. The treatment powder is a freeze-dried whole blueberry powder, and the placebo is a color- and flavor-matched powder which has been used in previous trials. Only an unblinded research assistant will have knowledge of which label corresponds to blueberry or placebo. That research assistant will be in charge of: (1) Before each appointment, distributing appropriate treatment or placebo packets into closable boxes with a number corresponding to each participant. Care-providers will give closed boxes to participants at the time of assessment. (2) Re-labeling all collected data and samples with a participant code number, and sorting into appropriate groups for analysis by blinded researchers.|This study will utilize a randomized, double-blind, placebo-controlled, crossover design. 60 participants with depression will be randomized into either the placebo first or blueberry first group. Randomization will be based on outcomes from behavioral measures (Major Depression Inventory and GAD-7) and a physiological measure (C-reactive protein levels) in appointment 0. The first arm will consist of 12 weeks of daily treatment and baseline (pre-intervention), mid-intervention and post-intervention assessments. Next there will be a four week washout period, after which patients will switch treatments, and the second arm will commence--identical to the first in structure. Further, the study is a repeated measures design with each participant's baseline measures serving as her or his own control.|t|t|t|t
33771150|NCT00079443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771151|NCT00175968|RANDOMIZED|CROSSOVER||ECT||SINGLE||||||
33771152|NCT04329858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771153|NCT05164731|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33771154|NCT04288674|||CASE_CONTROL||RETROSPECTIVE|||||||
33771155|NCT02746822|||CASE_ONLY||PROSPECTIVE|||||||
33771156|NCT03232320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771157|NCT02429921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771158|NCT06294015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771159|NCT01026675|||COHORT||PROSPECTIVE|||||||
33771160|NCT00948883|||CASE_CONTROL||PROSPECTIVE|||||||
33771161|NCT03849716|||COHORT||PROSPECTIVE|||||||
33771162|NCT03665883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, assessors and investigators will be blinded on patient group.|the effect on seroma formation and output of pre-peritoneal drain after TEP by monoploar diathermy or blunt dissection approach will be studied|t|f|t|t
33771163|NCT03550430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771164|NCT05892835|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The attitude and knowledge about CPR were measured before and after the educational intervention.||||
33771165|NCT02936622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771166|NCT05799300|||COHORT||RETROSPECTIVE|||||||
33771167|NCT05242575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771168|NCT01602978|||COHORT||PROSPECTIVE|||||||
33771169|NCT06383195|||OTHER||CROSS_SECTIONAL|||||||
33771170|NCT01340313|||||PROSPECTIVE|||||||
33771171|NCT00395915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900654|NCT03356314|||COHORT||RETROSPECTIVE|||||||
33900655|NCT05659615|||OTHER||PROSPECTIVE|||||||
33900656|NCT00180115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900657|NCT03823768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900658|NCT05746910|||CASE_ONLY||CROSS_SECTIONAL|||||||
33900659|NCT03133897|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33771172|NCT06187350|||COHORT||PROSPECTIVE|||||||
33771173|NCT02008968|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771174|NCT01405794|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33771175|NCT01570543|||CASE_ONLY||CROSS_SECTIONAL|||||||
33983408|NCT05440903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The investigators and majority of study staff are blinded. The only individuals who are unblinded to a participant's conditions do not conduct data collection nor interact with participants beyond assigning participants to a condition and explaining the protocol for MT or control app training.~Participants are aware of their condition, but do not know that the protocol is being measured as the variable of interest, nor that other participants are assigned to different conditions."|Between-groups study design|t|f|t|t
33983409|NCT01497652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983410|NCT05324150|||CASE_ONLY||PROSPECTIVE|||||||
33983411|NCT03336411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983412|NCT03611478|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This is a triple-blind trial, with randomisation being conducted by a disinterested third party. Unblinding will not occur until data analysis is complete.|Half the participants will receive the probiotic formulation while the other half will receive placebo.|t|f|t|t
33983413|NCT00819507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900660|NCT01089725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900661|NCT00803088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900662|NCT05286398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900663|NCT03016715|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33900664|NCT02521246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900665|NCT05205707|||COHORT||CROSS_SECTIONAL|||||||
33900666|NCT06511505|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33900667|NCT03966586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33900668|NCT04681664|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33900669|NCT00450463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900670|NCT00708877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900671|NCT06450028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant will not know which anesthetic they received on each side of their jaw. The care provider, who will be administering the anesthetic intraoperatively, will know which anesthetic is being administered on each side of the participant's jaw. The outcomes assessor will not know which anesthetics was administered on each side of the participant's jaw.|Participants will be randomly assigned to one of two groups. Group 1 will receive 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine on the left side of their jaw and 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine on the right side of their jaw. Group 2 will receive 10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine on the right side of their jaw and 6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine on the left side of their jaw.|t|f|f|t
33900672|NCT00804440|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900673|NCT01536912|||CASE_ONLY|||||||||
33900674|NCT01709799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900675|NCT03515798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900676|NCT05283707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33900677|NCT01160367|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33900678|NCT02769871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33900679|NCT02203370|||CASE_ONLY||PROSPECTIVE|||||||
33900680|NCT00155051|||DEFINED_POPULATION||OTHER|||||||
33900681|NCT06103552|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single arm, cohort study.||||
33900682|NCT03636594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900683|NCT02234401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33900684|NCT00836160|||||PROSPECTIVE|||||||
33900685|NCT06246552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900686|NCT06574828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983414|NCT02688257|||COHORT||PROSPECTIVE|||||||
33983415|NCT01284439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983416|NCT05457101|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33983417|NCT03416777|RANDOMIZED|PARALLEL||PREVENTION||NONE|In this trial blinding of participants and investigators will not be possible because of obvious differences between the intervention diets|Randomized parallel open dietary intervention study with 3 arms of intervention||||
33983418|NCT02932878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983419|NCT01503697|||COHORT||CROSS_SECTIONAL|||||||
33983420|NCT01162226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983421|NCT06121193|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983422|NCT04548440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983423|NCT00840138|||COHORT||PROSPECTIVE|||||||
33983424|NCT03616106|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will use a single group pretest-posttest design to evaluate if using infographics during clinic visits can lead to improved patient outcomes.||||
33983425|NCT01474668|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983426|NCT04712071|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group, single dose, open-label study||||
33983427|NCT06383962|||COHORT||PROSPECTIVE|||||||
33983428|NCT01390844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983429|NCT00336479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983430|NCT01870856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983431|NCT01464970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983432|NCT02355431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900687|NCT04164667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33900688|NCT04776369|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||"Patients will be randomly assigned to 4 groups:~* Group A: 30 patients will receive IV lidocaine 4 mg/kg (Tan, 2019) in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.~* Group B: 30 patients will receive IV magnesium sulfate 30mg/kg in 50 ml volume over 30 min. plus IV saline 50 ml after induction of anesthesia.~* Group C: 30 patients will receive IV lidocaine 4 mg/kg in 50 ml volume over 30 min. plus IV magnesium sulfate 30mg/kg in 50 ml volume over 30 min. after induction of anesthesia.~* Group D (control group): 30 patients will receive IV saline 50 ml plus IV saline 50 ml over 30 min. after induction of anesthesia."|t|t|f|f
33900689|NCT01134484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900690|NCT05602467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The active group would receive 2 stimulation programs, each set last 12-week. Participants would receive 3 sessions/week in the first 2 weeks and then 1 session/week in the subsequent 10 weeks. A total of 32 sessions (16 sessions per set) of TPS will be delivered, each lasting 30 minutes.~The control group will be recruited with the same recruitment criteria. They would receive treatment-as-usual (TAU) in the outpatient clinic without TPS intervention given."||||
33900691|NCT04589494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|tramadol or morphine||t|t|f|t
33680746|NCT05731050|NA|SEQUENTIAL||TREATMENT||NONE||A total of at least 6 patients (maximum of 10) with documented PNH and at least 3 months of Soliris treatment prior to Screening will be enrolled at the study site. The total duration of study term participation for all subjects will be up to 22 weeks, including a screening period of up to 8 weeks, a 12-week treatment period, and 2 weeks of a washout period. All subjects will receive a dose of 15 mg/kg NM8074 every two weeks with a total of 6 doses, from Day 1 to Day 84 during the treatment period. No more than two subjects will be dosed in a single day.||||
33680747|NCT02858817|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33900692|NCT00842517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680748|NCT04008927|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Effectiveness-implementation hybrid study type 2. This study design will simultaneously allow assessing the effectiveness of the model, using the percentage of HCV cure as criteria, and the feasibility by measuring potential obstacles during implementation.||||
33680749|NCT00045981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900693|NCT04729530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900694|NCT05265013|NA|SINGLE_GROUP||TREATMENT||NONE||ASP-1929 Photoimmunotherapy Combined With Pembrolizumab||||
33900695|NCT06672120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The principal investigator, who will assess outcomes, will be blinded to group allocation. Patients will be randomized by a staff member. Data analysis will be done by a professional statistician.|Patients diagnosed with TNBC and scheduled for immuno-chemotherapy will be randomized (1:1) into an intervention group receiving combined endurance and resistance training and a control group receiving standard exercise recommendations.|f|f|t|t
33900696|NCT03358862|||CASE_ONLY||OTHER|||||||
33900697|NCT06085365|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33900698|NCT04452526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900699|NCT00355589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900700|NCT02511574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900701|NCT06570213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Random assignment of eligible participants will occur in two steps using a custom computer randomization algorithm. First, participants will be randomly assigned to receive either two active SGB injections or two placebo saline injections. In the second stage of random assignment, participants will be randomly assigned to receive 1-week of CPT or daily symptom monitoring.~As there will only be three treatment conditions of this study (SGB+CPT, SGB+Daily Monitoring, and Placebo Injection+CPT), individuals that are randomly assigned to the placebo injection group in the first stage of random assignment will automatically be assigned to receive CPT."|t|f|t|t
33900702|NCT01903434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33983433|NCT02726581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983434|NCT06061146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983435|NCT03152656|||CASE_ONLY||PROSPECTIVE|||||||
33983436|NCT05405725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680750|NCT00182585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680751|NCT02878252|||OTHER||CROSS_SECTIONAL|||||||
33680752|NCT02793622|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680753|NCT01525992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983437|NCT02472366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983438|NCT01561274|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33983439|NCT06336291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983440|NCT00590408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983441|NCT02605395|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33983442|NCT05372406|||COHORT||RETROSPECTIVE|||||||
33983443|NCT05741437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983444|NCT04361266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded ultrasound assessment|prospective randomized control trial|f|f|t|f
33983445|NCT02131129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983446|NCT03773848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024702|NCT05229003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were first enrolled into cohort A, and when the efficacy of cohort A reached a certain percentage, the enrollment of cohort B started then.||||
34024703|NCT06599580|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34024704|NCT04918485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024705|NCT06393946|||COHORT||PROSPECTIVE|||||||
33900703|NCT03110822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"There are 4 study parts: Dose escalation and expansion (Study Part 1), Ruxolitinib/Methylprednisolone Arm (Study Part 2), Expanded Eligibility Criteria (Study Part 3), and High Dose (Study Part 4).~The first 49 subjects will be enrolled into the Ruxolitinib, Lenalidomide and Methylprednisolone treatment arm (Study Part 1).~Subjects in Study Part 2 will receive Ruxolitinib and Methylprednisolone until confirmed disease progression. Lenalidomide will be added to the treatment once disease progression is confirmed.~Subjects in Study Part 3 will receive Ruxolitinib, Lenalidomide and Methylprednisolone treatment.~Subjects in Study Part 4 will receive high-dose Ruxolitinib and Methylprednisolone treatment."||||
33900704|NCT04019496|||CASE_CONTROL||PROSPECTIVE|||||||
33680754|NCT03320824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680755|NCT03417401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900705|NCT00675285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900706|NCT00306891|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900707|NCT05418608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33900708|NCT04593498|||COHORT||PROSPECTIVE|||||||
33900709|NCT05523635|||COHORT||PROSPECTIVE|||||||
33900710|NCT01522651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900711|NCT05670119|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study is a single-center parallel-group randomized controlled clinical trial. Participants who accepted to participate in the study and met the inclusion criteria will be assigned to the intervention (n=35) or control group (n=35) according to the computer-based randomization table.|f|f|f|t
33900712|NCT04901026|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33900713|NCT03980158|||COHORT||PROSPECTIVE|||||||
33900714|NCT02820610|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33900715|NCT05045755|||COHORT||PROSPECTIVE|||||||
33900716|NCT03631667|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Deidentified samples will be analyzed by AMS at Lawrence Livermore National Laboratory and the pharmacokinetics determine at Pacific Northwest National Laboratory.||f|f|f|t
33900717|NCT00090649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900718|NCT03158545|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33900719|NCT04416776|||COHORT||PROSPECTIVE|||||||
33900720|NCT00554957|||COHORT||CROSS_SECTIONAL|||||||
33900721|NCT02553915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All the above were blinded to the interventions. Placebo and EPA capsules had identical appearances.|Study compared 3 dosing regimens of eicosapentaenoic acid (EPA), 1 g/day, 2 g/day, and 4 g/day versus an inactive placebo.|t|t|t|t
33900722|NCT06671145|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33900723|NCT00635531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900724|NCT01160146|||CASE_CONTROL||RETROSPECTIVE|||||||
34024706|NCT01324505|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34024707|NCT05810584|||CASE_ONLY||RETROSPECTIVE|||||||
34024708|NCT00052299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024709|NCT01398215|||COHORT||PROSPECTIVE|||||||
33680756|NCT03452475|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised 1:1:1 to one of the three treatment arms||||
33680757|NCT02907840|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680758|NCT04998968|||COHORT||PROSPECTIVE|||||||
33839528|NCT04747223|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are masked to group assignment. Investigators are blinded to participant's group at follow-ups.||t|f|t|f
33839529|NCT01638390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839530|NCT04448626|||OTHER||RETROSPECTIVE|||||||
33839531|NCT00417053|NON_RANDOMIZED|||TREATMENT||NONE||||||
33839532|NCT01918592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839533|NCT04288505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839534|NCT01922388|||CASE_ONLY||PROSPECTIVE|||||||
33839535|NCT06160687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839536|NCT05439889|||CASE_ONLY||PROSPECTIVE|||||||
33839537|NCT02895919|||CASE_ONLY||PROSPECTIVE|||||||
33839538|NCT03811990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, non-blinded, control trial||||
33839539|NCT02445651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|This is an Open Label study. Randomization will occur via a 2:1 ratio of the NAC group and the waitlist control groups using the method of random permuted blocks with random block sizes without stratification. 28 subjects in the NAC arm and 14 subjects have been enrolled in the standard of care arm.|||||
33839540|NCT00003933||||DIAGNOSTIC||||||||
33839541|NCT01653938|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33839542|NCT04149431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind randomized placebo controlled study|This is a multi-center, double-blind, randomized phase III-IV clinical trial in parallel groups to evaluate the efficacy and safety of Derinat versus Placebo in patients with acute upper respiratory tract infection.|t|t|t|t
33839543|NCT04160442|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33839544|NCT06331390|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33839545|NCT02498782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839546|NCT01132820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839547|NCT02974400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839548|NCT02282553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839549|NCT05284630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839550|NCT02690116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33839551|NCT03176264|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib study, safety run-in (N=\~6 pts) followed with an expansion (N=\~86 pts). One single arm: PDR001 in combination with bevacizumab and mFOLFOX6||||
33839552|NCT01016847|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33839553|NCT05269953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The member of the research team performing allocation will not be involved in the collection or processing of measurement outcomes (questionnaire/ video data). This same researcher will also be responsible for assigning participants to interventions by programming the MNS devices to deliver sham/active stimulation. This member of the research team will be responsible for creating and maintaining a document which links each participants unique ID with the condition they have been assigned to.~All other members of the research team, participants and legal guardians will be blind to sham/active group allocation. Participants in the waitlist group and their carers will not be blind to the group they have been allocated to. Participants allocated to the waitlist group will not be blind to the stimulation type they will receive (i.e., all participants initially allocated to the waitlist group will go on to receive active rhythmic MNS at the conclusion of their participation)."|"Participants will be randomly allocated into three groups (ratio: 1:1:1): active stimulation, sham stimulation and waitlist (no stimulation).~Those in the waitlist group would receive treatment as normal, prior to an open label phase of receiving active stimulation."|t|t|t|t
33839554|NCT05679804|||CASE_ONLY||PROSPECTIVE|||||||
33839555|NCT00515723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839556|NCT05235282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839557|NCT04797910|||COHORT||PROSPECTIVE|||||||
33839558|NCT05988944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839559|NCT02434757|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839560|NCT02639455|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33839561|NCT00140010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839562|NCT04223544|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33839563|NCT00271206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839564|NCT04646863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839565|NCT01968889|||COHORT||PROSPECTIVE|||||||
33839566|NCT01504776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839567|NCT00041652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839568|NCT01495572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839569|NCT05003492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839570|NCT03132675|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded Independent Central Review|"Cohort 1A_Locally advanced/metastatic melanoma: pathological diagnosis of unresectable or metastatic melanoma with progression on pembrolizumab or nivolumab, confirmed according to RECIST v1.1. BRAF V600 mutation-positive melanoma could have received standard of care targeted therapy for advanced or metastatic disease (eg, BRAF/MEK inhibitor, alone or in combination) prior to enrolling on this study; however, progression is not required.~Cohort 1B_Locally advanced/metastatic melanoma: Subjects will be enrolled in order to collect safety data using the GenPulse generator. Eligibility for enrollment will be the same as that for Cohort 1A.~Cohort 2_Locally advanced/metastatic melanoma with prior exposure to ipilimumab alone or in combination with nivolumab (or other drug(s)/agent(s)): Eligible subjects will be those with pathological diagnosis of unresectable or metastatic melanoma who have been exposed to ipilimumab alone or in combination with nivolumab (or other drug/agent)"||||
33839571|NCT00587691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839572|NCT03177239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839573|NCT06114849|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33839574|NCT02892643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839575|NCT00113451|||DEFINED_POPULATION||PROSPECTIVE|||||||
33983447|NCT06085300|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will be randomly assigned to one of three conditions: monolingual recast therapy delivered in English, monolingual recast therapy delivered in Spanish, or bilingual therapy (Spanish+English). Schools are randomly assigned to first treatment target (conditional adverbial clause; complement clause). The investigators use a cross-over design such that all children eventually receive treatment for all targets. Pretesting will be completed for both targets in both languages. Children will be stratified based on bilingual proficiency (Spanish-dominant, English-dominant, Balanced) and randomly assigned to language of intervention. Children will receive 16 hours of recast therapy. After, both structures will be tested in both languages again. Then, treatment target will switch but language of intervention will remain the same, and children will receive an additional 16 hours of treatment for the second structure. At post-test, both structures will be tested in both languages.|f|f|f|t
33983448|NCT03965377|NA|SINGLE_GROUP||PREVENTION||NONE||teen parents and parents to be will be randomly assigned to game play (4 vs 1) to assess the effectiveness of the computer game to decrease time to identifying home hazards, improve identification of resolutions of hazards, and time to identify home hazards under distraction conditions||||
33680759|NCT04545970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will occur by assignment to either the active group or placebo group using a randomization table prepared prior to the start of the study by a non-participating staff member at the office of the investigator. Subjects will be assigned a number in numerical order as enrolled. The unblinded staff member will take a set of products from one of two groups of labeled active product vs. placebo and fill in the patient number and distribution date on the bottles to be dispensed to the subject.|Randomized, double-blind, placebo-controlled|t|f|t|f
33983449|NCT05620225|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Subjects and clinical study staff (with the sole exception of the Blinding Operator) will be blinded to study treatment.~Steps for setting up the device are extremely similar whether the patient is in the Sham or Active groups. The following steps must be completed before the patient or the Operator have entered the room for their session. Please avoid any unnecessary interactions with the patient, Operator or any other Clinic personnel in the performance of these tasks.~The primary security method for protecting the Blind is strict utilization of Medrio and the special permissions granted by the Sponsor for the conduct of Blinding and Unblinding subjects."|"Prospective, controlled, double blinded, randomized, multi-center clinical trial in which up to 80 subjects diagnosed with painful diabetic neuropathy will be randomized 3:1 into one of two treatment groups:~1. Axon Therapy plus CMM (AT+CMM)~2. Sham plus CMM (Sham+CMM)"|t|t|t|f
33983450|NCT04647266|||COHORT||RETROSPECTIVE|||||||
33983451|NCT01213901|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33983452|NCT03232437|||OTHER||CROSS_SECTIONAL|||||||
33983453|NCT02307734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680760|NCT00985036|||CASE_CONTROL||PROSPECTIVE|||||||
33983454|NCT06433141|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33983455|NCT00014105||||TREATMENT||||||||
33983456|NCT05119439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983457|NCT00216463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983458|NCT01614730|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33983459|NCT06214208|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33983460|NCT01433809|||COHORT||PROSPECTIVE|||||||
33983461|NCT05567965|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33983462|NCT02804204|||CASE_ONLY||PROSPECTIVE|||||||
33983463|NCT03673293|||COHORT||PROSPECTIVE|||||||
33983464|NCT02069665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983465|NCT02904577|||COHORT||PROSPECTIVE|||||||
33983466|NCT00595062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079236|NCT00756626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680761|NCT04347603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079237|NCT00826553|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34079238|NCT01518647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079239|NCT05251272|||COHORT||PROSPECTIVE|||||||
34079240|NCT05030649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079241|NCT06297512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079242|NCT01219543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079243|NCT05089578|||OTHER||CROSS_SECTIONAL|||||||
34079244|NCT00372424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680762|NCT06065098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinical research coordinators and laboratory technicians who assess health-related outcomes will be blinded to intervention assignment. Study physicians who review serious adverse events and unanticipated problems will also be blinded to intervention assignment.|Cluster-randomization of 42 churches in New Orleans, Louisiana to two arms|f|f|f|t
33680763|NCT02720107|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33680764|NCT03699969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680765|NCT02015221|RANDOMIZED|PARALLEL||||NONE||||||
34079245|NCT00928434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079246|NCT04864743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079247|NCT02664142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079248|NCT00163566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079249|NCT03565354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34079250|NCT01500798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680766|NCT01336400|||CASE_ONLY||PROSPECTIVE|||||||
33680767|NCT05304780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34079251|NCT05743530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079252|NCT01091922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34079253|NCT05705830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079254|NCT04040517|||CASE_ONLY||CROSS_SECTIONAL|||||||
34079255|NCT03781466|RANDOMIZED|PARALLEL||PREVENTION||NONE|A randomized clinical trial open label|A randomized clinical trial||||
34079256|NCT03013400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079257|NCT03191851|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079258|NCT00120692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079259|NCT05822817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33900725|NCT06393114|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||During the run-in phase, participants consume their habitual diet. Subsequently, participants are randomized to incorporate one of the study products into their habitual diet for three weeks. The amount of the products to be consumed is 4-6 dl/day, with the precise amount being determined based on the participants' energy requirements. After the three-week diet period, participants will return to their habitual diet, followed by another three-week period during which they will consume the alternate intervention product. The overall duration of the study will be 12 weeks for each participant.||||
33900726|NCT06143163|||COHORT||RETROSPECTIVE|||||||
33900727|NCT03511638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||a multicenter, controlled, randomized, monocular trial of Bausch \& Lomb DVisc40 (test) OVD compared to the currently marketed Alcon VISCOAT® (control) OVD|t|t|t|t
33900728|NCT03305042|||OTHER||CROSS_SECTIONAL|||||||
33900729|NCT02050932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900730|NCT02289755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900731|NCT01253460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900732|NCT05218889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900733|NCT05917379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900734|NCT04059809|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participant and care provider will be blinded regarding the status of photobiomodulation device (if switched on or off).|Randomized single blind controlled trial|t|t|f|f
33900735|NCT05026229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900736|NCT00810797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900737|NCT01001494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900738|NCT01011062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33900739|NCT04446143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subject randomization will use permutated blocks and assignments in concealed consecutively numbered envelops. Those in the mindfulness medication group will listen to an audio-taped mediation, which takes 10 mins to complete, where as the control group will be seated in a quiet empty room where they wait for 10 min.||||
33900740|NCT06074510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900741|NCT04822922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 parallel group with different doses of UC-MSC||||
33900742|NCT04151004|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900743|NCT00778323|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33900744|NCT02413255|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33900745|NCT00029796|RANDOMIZED|||TREATMENT||DOUBLE||||||
33900746|NCT01483040|NA|SINGLE_GROUP||SCREENING||NONE||||||
33900747|NCT04281927|||CASE_CONTROL||PROSPECTIVE|||||||
33900748|NCT03442426|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We have proposed a strong quasi-experimental alternative with inclusion of a usual care group of patients prior to initiation of the intervention. Specifically, our study will use a quasi-experimental control group design with pre-test and post-test. Our control group will receive usual care, and the intervention group will receive the proposed intervention (screening, care coordination and individual care plans, engagement in decision making, and technology support). The usual care group will be followed for 6 months after study entry (baseline period). Once completed, the intervention will be implemented and recruitment for the intervention group will begin. The intervention group will also be followed for 6 months after study entry (intervention period). We will be able to compare the intervention group with the usual care group.||||
33900749|NCT06140407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900750|NCT06421961|||OTHER||OTHER|||||||
33900751|NCT03756012|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33900752|NCT03268174|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|AO+ Mist (or placebo) are supplied in white 100mL metered spray bottles. Test products are blinded and labeled for application to the LEFT or RIGHT side of the body|This is a bilateral study. Each subject will apply appropriately labeled test product to the left and right arm.|t|t|t|t
33900753|NCT06515223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900754|NCT02610023|||COHORT||PROSPECTIVE|||||||
33900755|NCT03838848|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Cohort A, B and C are carried out in sequence, a Scientific Monitoring Committee (SMC) will decide whether to enter the next group (A to B, B to C).~Cohort D: 1L NSCLC (EGFR-sensitive mutation (Ex19del or L858R), progression after at least one line treatemtn of EGFR TKIs, and no prior systemic platinum-containing chemotherapy); Cohort E: ≥ 2L NSCLC (failure or intolerance of 1L platinum-doublet chemotherapy; and failure of PD-1/PD-L1 checkpoint inhibitor therapy);"||||
33900756|NCT05212532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label study will include 2 cohorts, non-ICU hospitalized and ICU hospitalized patients||||
33900757|NCT02342171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900758|NCT05398874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33900759|NCT01713985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900760|NCT01460836|||||RETROSPECTIVE|||||||
33900761|NCT06513429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680768|NCT05908006|||CASE_ONLY||PROSPECTIVE|||||||
33680769|NCT06210360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680770|NCT05705635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680771|NCT00866229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983467|NCT05753605|||COHORT||PROSPECTIVE|||||||
33983468|NCT01817062|||COHORT||RETROSPECTIVE|||||||
33983469|NCT01883271|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33983470|NCT05134792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33983471|NCT01976377|||CASE_CONTROL||RETROSPECTIVE|||||||
33983472|NCT03828058|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study will be a prospective, randomized, open label study comparing Envarsus XR with twice daily prograf.||||
33983473|NCT05791032|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983474|NCT04503993|NA|SINGLE_GROUP||SCREENING||NONE||||||
34079260|NCT05648903|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two modes of remote care delivery are used (one-to one and group).||||
34079261|NCT03080740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079262|NCT02981940|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079263|NCT03065491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079264|NCT05406414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079265|NCT03648788|||OTHER||PROSPECTIVE|||||||
34079266|NCT01024114|||CASE_ONLY||PROSPECTIVE|||||||
34079267|NCT04460326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079268|NCT02076204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079269|NCT04817332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079270|NCT02048722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079271|NCT05525351|||COHORT||PROSPECTIVE|||||||
34079272|NCT01935999|NA|SINGLE_GROUP||||NONE||||||
34079273|NCT04625335|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34079274|NCT02986464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079275|NCT05209659|||OTHER||PROSPECTIVE|||||||
34079276|NCT04839744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079277|NCT02643641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079278|NCT03250689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079279|NCT01288599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079280|NCT03529500|||COHORT||CROSS_SECTIONAL|||||||
34079281|NCT05430165|||COHORT||PROSPECTIVE|||||||
34079282|NCT00194935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079283|NCT01848106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079284|NCT02667600|||COHORT||PROSPECTIVE|||||||
34079285|NCT03043586|||COHORT||RETROSPECTIVE|||||||
34079286|NCT05537701|||COHORT||PROSPECTIVE|||||||
34079287|NCT03592888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079288|NCT01492348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34079289|NCT05447143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079290|NCT03869372|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects will act as their own controls: The investigators will assess measures of autonomic function at baseline and in response to various modes of TMS exposure.||||
34079291|NCT04577105|||COHORT||RETROSPECTIVE|||||||
34079292|NCT04938076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded randomized control trial|Double blinded randomized control trial|t|t|t|t
34079293|NCT04598620|||CASE_ONLY||PROSPECTIVE|||||||
33900762|NCT02760602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33900763|NCT06298097|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33900764|NCT03336840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900765|NCT04247932|||COHORT||PROSPECTIVE|||||||
33900766|NCT02875522|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900767|NCT05421897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900768|NCT06158841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900769|NCT04959019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study utilizes a randomized delayed intervention study design. Participants are randomized to a 6-week exercise program (intervention), or to a 6-week delay (no-intervention control) prior to beginning the exercise program.|f|f|t|t
33983475|NCT05067647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983476|NCT03056937|||CASE_CONTROL||PROSPECTIVE|||||||
33983477|NCT03769844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, sequential, dose- and route of administration-finding study that will be conducted in sequential cohorts of children with sepsis-induced MODS||||
33983478|NCT01063556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079294|NCT02745652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079295|NCT02534168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079296|NCT01634646|NA|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34079297|NCT03070795|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079298|NCT01561417|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34079299|NCT00904007|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079300|NCT03397784|||CASE_CONTROL||PROSPECTIVE|||||||
34079301|NCT00869505|||CASE_CONTROL||RETROSPECTIVE|||||||
34079302|NCT00678418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079303|NCT00778596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079304|NCT00580957|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33680772|NCT00002501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079305|NCT01954849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079306|NCT02379013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079307|NCT01943487|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079308|NCT05673356|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group: Clinical trials with a single arm.||||
34079309|NCT03308240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups will be studied: an experimental group (patient and caregiver) receiving one magic therapy session within the hospitalization period and a control group (patient and caregiver) who will receive standard child life therapies.||||
34079310|NCT02672098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079311|NCT04369833|||COHORT||PROSPECTIVE|||||||
34079312|NCT05222555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079313|NCT01781962|||COHORT||PROSPECTIVE|||||||
33983479|NCT02457520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983480|NCT02019290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983481|NCT02612337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983482|NCT01202448|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983483|NCT04725708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33983484|NCT05292651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||single-center, prospective, single blinded randomized clinical trial|f|t|f|t
33983485|NCT04807270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983486|NCT03408119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983487|NCT02175238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983488|NCT05437549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983489|NCT05526573|||CASE_ONLY||PROSPECTIVE|||||||
33983490|NCT06496516|||COHORT||PROSPECTIVE|||||||
33983491|NCT01748630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983492|NCT06146153|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33983493|NCT00711464|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33983494|NCT02158182|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983495|NCT06101225|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Data will be collected from children by independent researchers, blinded to group allocation at the three data points: before the beginning of the intervention (T0), immediately after the intervention (T1), and at follow-up (T2). In the intermediate data collection (TInt) blindness to group allocation is not possible, because data collection will be performed during the intervention. Outcome's assessors will be blinded to group assignment in all data analysis times.|"The RCT design includes 3 conditions to which classes (3rd and 4th graders) will be randomly allocated: the experimental group will receive MindRegulation intervention (a) relaxation and guided imagery with Socioemotional Leaning; the alternative condition group will receive relaxation intervention (b); and the waiting list control group will be involved in the regular school activities, with no intervention (c).~Interventions (a and b) will be held during 15 minutes in class, 3 school days per week, for 5 months. Data on all measures of the study will be collected at 4 data points: before the intervention (T0), during the intervention (TIntermediate); immediately after the intervention end (T1), and at follow-up (T2), 6 months after the intervention end, for the experimental (a) and alternative condition (b) groups. After follow-up, the waiting list control group will receive intervention (a), for 5 months, after which a post-intervention measurement will be performed."|f|f|t|t
33983496|NCT01388270|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983497|NCT02501005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983498|NCT01837654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983499|NCT03098108|NA|SINGLE_GROUP||TREATMENT||NONE||CCPT arm||||
33680773|NCT01671527|||CASE_CONTROL||PROSPECTIVE|||||||
33680774|NCT00361413|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33983500|NCT00594347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983501|NCT04773470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983502|NCT01215266|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33983503|NCT00784823|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 + 3 Dose Escalation||||
33983504|NCT01524653|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33983505|NCT01370408|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33680775|NCT00933218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33839576|NCT00458952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839577|NCT02517177|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983506|NCT05848245|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983507|NCT04274686|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983508|NCT04512547|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34079314|NCT05563337|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Physician who will perform the renal arteriography and renal denervation in case of randomization in the renal denervation group will be different from the cardiologist who will follow the patient throughout the study in order to keep the double blind"||t|f|f|t
33771176|NCT03746977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcome assessors were not aware of the status of the participants and were not allowed to ask correspondingly. Each of the participants were blinded according to the treatment and intervention. Participants of the three study groups were not in contact.|Randomized controlled parallel group design with 3 study arms|t|f|f|t
33771177|NCT00003284||||TREATMENT||||||||
33771178|NCT02357043|NA|SINGLE_GROUP||OTHER||NONE||||||
33771179|NCT04324255|||COHORT||RETROSPECTIVE|||||||
33771180|NCT03524456|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771181|NCT02424552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771182|NCT04980768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771183|NCT03410914|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771184|NCT05768516|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants and general practitioners will not be blinded to their group. No outcome will be measured be an external assessor (patients will fill out questionnaires at home). The statistical analysis will be blinded.|Two-arms parallel pilot study. Two healthcare centres (one for each arm) have been selected for their convenience.|f|f|f|t
33771185|NCT03093519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771186|NCT05927064|||COHORT||RETROSPECTIVE|||||||
33771187|NCT05874271|NA|SINGLE_GROUP||OTHER||NONE||||||
33771188|NCT03655873|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33771189|NCT04877574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33771190|NCT01708889|NON_RANDOMIZED|PARALLEL||||NONE||||||
33771191|NCT02406118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771192|NCT01443975|||COHORT||PROSPECTIVE|||||||
33771193|NCT06398028|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multicentric low-intervention phase IV clinical trial of preoperative ICG administration for intraoperative detection of liver tumors||||
33771194|NCT00579540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771195|NCT04572529|||COHORT||PROSPECTIVE|||||||
33771196|NCT00469781|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33771197|NCT01899274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771198|NCT03518528|||COHORT||PROSPECTIVE|||||||
33771199|NCT00151918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771200|NCT05399992|||COHORT||PROSPECTIVE|||||||
33771201|NCT05297617|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, national, multicenter, single-arm, interventional, non-threshold crossing phase II study evaluating a therapeutic de-escalation that limits adjuvant hormone therapy to 2 years of aromatase inhibitor||||
33900770|NCT01371123|||CASE_CONTROL||PROSPECTIVE|||||||
33900771|NCT05826353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900772|NCT06167369|||COHORT||PROSPECTIVE|||||||
33900773|NCT00538603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900774|NCT00006168|RANDOMIZED|||TREATMENT||DOUBLE||||||
33900775|NCT06570902|||COHORT||PROSPECTIVE|||||||
34079315|NCT02749344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900776|NCT06572267|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33900777|NCT01041573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900778|NCT05555069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079316|NCT03148262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079317|NCT05175781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34079318|NCT01508247|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34079319|NCT01414998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079320|NCT06076031|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34079321|NCT05232552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079322|NCT01232790|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34079323|NCT05481801|||COHORT||RETROSPECTIVE|||||||
34079324|NCT05763927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680776|NCT04453943|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The central objective of this study is to validate new algorithms that coordinate between functional electrical stimulation (FES) and the exoskeleton during sitting-to-standing, walking, and standing-to-sitting movements. The secondary objective is to optimize the algorithms as well as assess their ability to reduce FES-induced muscle fatigue by using ultrasound imaging as a sensing modality.~This study is performed with two sets of subjects: people with spinal cord injury and people without disability."||||
33680777|NCT00565929|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33680778|NCT06299410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680779|NCT02174588|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33680780|NCT06047951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study population will consist of adult men and women with a CTA-proven UIA under 7 mm who were advised to not undergo treatment because of its low rupture risk. The sample will consist of consecutively enrolled patients seen for a vascular neurosurgical consult or follow-up in the outpatient clinic of participating centers. All eligible patients will be offered to participate in the study at the next follow-up. Enrolled patients will then decide if they want to undergo SRS or if they prefer to continue being managed expectantly. Patients who decide to undergo SRS will be treated with radiosurgery according to the study protocol, while patients who decline SRS will be enrolled in a control, prospective, observational cohort with the same follow-up protocol as the SRS cohort. Furthermore, patients harbouring multiple UIAs will only be treated for one lesion. There will be no randomization or blinding.||||
33680781|NCT02387476|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680782|NCT05880290|NA|SINGLE_GROUP||OTHER||NONE||Single group: gynaecological examination in lateral decubitus, conventional repositioning if unsuccessful||||
33680783|NCT05874570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680784|NCT02094768|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33680785|NCT02105753|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680786|NCT00183729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680787|NCT04287543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680788|NCT05303662|||CASE_ONLY||PROSPECTIVE|||||||
33680789|NCT05579951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33771202|NCT05769699|NA|SINGLE_GROUP||OTHER||NONE||||||
33771203|NCT04181424|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33839578|NCT03750929|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33839579|NCT05613777|NA|SINGLE_GROUP||TREATMENT||NONE||Fixed sequence: Run in period-Reference-Treatment||||
33839580|NCT00513708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33839581|NCT05576376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each patient will be randomly assigned to his group using quick Calcs methodfor randomization (https://www.graphpad.com/quickcalcs/randomize1/) either group A (plantar fascia open release) or group B (Plantar fascia endoscopic release) or group C( calcaneal osteotomy)|We aim to achieve 35% percentage difference between both techniques with 80% power at a 5% (two-sided) significance level with alpha error 5%. For this power, a sample size of 54 patients will be required with assuming 10% drop out. So, a total of 60 patients will be enrolled (30 patients in each arm).|f|f|f|t
33839582|NCT04425590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open label|Eligible subjects were randomly allocated to receive any of the following regiments: standard therapy consists of aspirin 100 mg once daily, atorvastatin 20 mg once daily, vitamin B12 100 mg three times daily (control group) or standard therapy and DLBS1033 3 times daily (experimental group).||||
33839583|NCT06430229|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33839584|NCT03045705|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33839585|NCT00675532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839586|NCT04914598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079325|NCT00183651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079326|NCT04687852|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial||||
34079327|NCT04521556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34079328|NCT00417664|||COHORT||RETROSPECTIVE|||||||
34079329|NCT01339039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079330|NCT00250822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079331|NCT06103305|||COHORT||CROSS_SECTIONAL|||||||
33839587|NCT01352819|||COHORT||PROSPECTIVE|||||||
33839588|NCT02757677|||COHORT||PROSPECTIVE|||||||
33839589|NCT03185884|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33839590|NCT01373580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839591|NCT06378736|||CASE_CONTROL||PROSPECTIVE|||||||
33771204|NCT05330741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|By random generator|Designed Physical Therapy program, Whole Body Vibration and, Gravity Force Stimulation|t|f|f|t
33771205|NCT04284761|NA|SINGLE_GROUP||TREATMENT||NONE||Biolen bicalutamide implant||||
33771206|NCT00000782||||TREATMENT||DOUBLE||||||
33771207|NCT05388994|NA|SINGLE_GROUP||TREATMENT||NONE||prospective||||
33771208|NCT05036889|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33771209|NCT05774405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771210|NCT06489392|||OTHER||RETROSPECTIVE|||||||
33771211|NCT02762981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771212|NCT01448720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771213|NCT02265224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771214|NCT02099630|||COHORT||PROSPECTIVE|||||||
33771215|NCT04440644|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33771216|NCT03601104|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33771217|NCT01159535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771218|NCT03632434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771219|NCT03971864|||COHORT||PROSPECTIVE|||||||
33771220|NCT03775408|||COHORT||PROSPECTIVE|||||||
33771221|NCT02867969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33771222|NCT01266993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900779|NCT04125823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900780|NCT05115201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33900781|NCT00945191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900782|NCT03078517|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33900783|NCT01749735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900784|NCT02231203|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33900785|NCT01120327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900786|NCT03720080|||COHORT||PROSPECTIVE|||||||
33900787|NCT00060086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900788|NCT01418768|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900789|NCT02293681|||COHORT||PROSPECTIVE|||||||
33900790|NCT03649854|||CASE_CONTROL||PROSPECTIVE|||||||
33900791|NCT02075996|||COHORT||PROSPECTIVE|||||||
33900792|NCT03910192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33900793|NCT00759473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33900794|NCT04049188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900795|NCT05157282|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know if they receive real or sham stimulation|Transcutaneous electrical spinal stimulation (TESS)|t|f|f|f
33900796|NCT02747628|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33900797|NCT02501356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33900798|NCT00950027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33900799|NCT05144542|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33900800|NCT02091011|||COHORT||PROSPECTIVE|||||||
33900801|NCT03687034|NA|SINGLE_GROUP||TREATMENT||NONE||This study consists of dose escalations that follow the standard 3+3 design, proceeding until the maximum tolerated dose is attained. The treatment period for patients in this study at each dose will be one year.||||
33900802|NCT02679066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983509|NCT01988909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983510|NCT05342597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33771223|NCT03343405|RANDOMIZED|PARALLEL||TREATMENT||NONE||A between groups repeated measure experimental design. Participants that met inclusion criteria and were interested in continuing with the study were randomized to either the treatment or wait-list group. Participants randomized to the treatment group were provided with 10 online program modules provided weekly over 10 weeks. After 10-weeks the wait-list group had the opportunity to participate in the intervention protocol if they desire. All participants will be asked to complete pre-, mid-, post-, f/u- intervention questionnaires.||||
33771224|NCT03743363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33771225|NCT02718534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983511|NCT02770625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680790|NCT03365388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation of the subjects will be conducted by the blind researchers. The IMP administration of the subjects will be conducted by non blind researchers or legal staff authorized by the principal investigator (PI)|The patient was diagnosed with periarthritis of shoulder|f|f|f|t
33680791|NCT05373056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There are two groups, the control group and the experimental group. In the control group, only the conventional exercise program for epicondylar muscles will be performed and the experimental group will also perform a scapular exercise program. Group assignment is randomized using the G\* POWER software program.|t|f|f|t
33680792|NCT06314893|||CASE_CONTROL||PROSPECTIVE|||||||
33680793|NCT01606215|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33680794|NCT01008241|||OTHER||OTHER|||||||
33771226|NCT01954524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771227|NCT00982982|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33771228|NCT03393403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33771229|NCT01419860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33680795|NCT02929498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771230|NCT06141304|NA|SINGLE_GROUP||TREATMENT||NONE||Plerixafor plus donor lymphocyte infusion for patients with relapsed acute leukemia||||
33771231|NCT00110513|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771232|NCT06531148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a randomized controlled clinical trial with split-mouth technique|f|t|f|f
33900803|NCT05372315|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each subject's participation is expected to last for approximately 1 month and will be required to complete six scheduled visits over the course of the study period: Baseline (Screening Visit), Operative Visit/Insertion Day (Day 0), Day 1, Day 8, Day 14 and Day 30.||||
33900804|NCT02297893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900805|NCT02973646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900806|NCT01769404|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33900807|NCT06141408|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900808|NCT03827148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The investigators, data collectors, study observers, data entry operators and data analysis statistician will be blinded to the allocation. The patients in the control group will be blinded to pharmacists as they would not know if the person they find in the room is a pharmacist or, a data collector. Similarly, the data collector would not know if the patient belong to IG or CG. However, the patients enrolled in intervention group will not be blinded to the pharmacist considering the nature of intervention yet, the pharmacist will be blinded to the outcome assessment so that there will be less likelihood of intervention bias.|This study is a randomized single-blind parallel trial. The patients who participate in this study after signing of consent would be randomly assigned to either control group (CG), i.e., usual care or intervention group (IG), i.e., pharmaceutical care. The allocation ratio will be 1:1. The participants in the intervention group would be counselled by pharmacist, provided a disease education literature and would have access to pharmacist for 90 days via telephone. The participants in the control group would received usual care without pharmacist intervention.|t|t|t|t
33900809|NCT05635838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized 1:1 to 1 of 2 treatment groups (ruxolitinib 1.5% cream BID or vehicle cream BID).|t|t|t|t
33983512|NCT05941481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983513|NCT05724810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active and sham cards do not differ in appearance, and both coils are enclosed within the same helmet, enabling double-blind administration.|After enrollment, participants will be randomized between-subjects to active dTMS or sham.|t|t|t|t
33983514|NCT02628834|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33983515|NCT01157091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983516|NCT01311908|||CASE_CONTROL||PROSPECTIVE|||||||
33983517|NCT01118247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983518|NCT02620670|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33983519|NCT01168557|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983520|NCT01589783|||COHORT||CROSS_SECTIONAL|||||||
33983521|NCT02468778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680796|NCT06405971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To ensure the reliability of the research results, a study committee consisting of 5 members will be formed. The committee comprised a 2-member data safety monitoring committee and a 3-member clinical event review committee. These committee members were blinded to the treatment group assignments. Any disagreements were resolved by a third member of the clinical events adjudication committee. All five committee members reviewed and resolved any discrepancies through consensus.|Simple randomized controlled trial|t|t|t|t
33680797|NCT01947062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680798|NCT00930748|||COHORT||PROSPECTIVE|||||||
33680799|NCT02931708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983522|NCT01938547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680800|NCT04253054|||COHORT||PROSPECTIVE|||||||
33680801|NCT04042246|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33680802|NCT01317108|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33680803|NCT03377140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680804|NCT01512667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680805|NCT00739089|||CASE_CONTROL||PROSPECTIVE|||||||
33680806|NCT04316403|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33680807|NCT06081088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33680808|NCT00062231|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33983523|NCT04829162|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Investigator was blind to condition throughout data accrual.|We conducted a 2 (parent with versus without obesity) x 2 (child with versus without obesity) x 2 (daughter versus son) x 2 (mother versus father) between-subjects experiment. Participants were randomly assigned to one of 16 conditions. However, only five a priori hypotheses were tested.|f|f|t|f
33983524|NCT04371042|||COHORT||OTHER|||||||
33983525|NCT01192230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983526|NCT01231490|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33983527|NCT01732978|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983528|NCT03744715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983529|NCT05312697|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33983530|NCT05606562|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33983531|NCT01609322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983532|NCT01450462|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33680809|NCT00443196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680810|NCT00352573|||COHORT||PROSPECTIVE|||||||
33680811|NCT05668390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680812|NCT01724619|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680813|NCT04121078|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33680814|NCT04286997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680815|NCT00270842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680816|NCT00594711|||CASE_CONTROL||PROSPECTIVE|||||||
33680817|NCT02023060|||COHORT||PROSPECTIVE|||||||
33680818|NCT04865926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33680819|NCT01071707|||CASE_ONLY||PROSPECTIVE|||||||
33680820|NCT01768429|RANDOMIZED|PARALLEL||||NONE||||||
33680821|NCT03599375|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with recurrent or refractory CD19+ ALL receive CD19 CAR T-cell immunotherapy.||||
33680822|NCT03865888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Evaluation of the effect of topical application of Tacrolimus 0.03% (FK506) eye drops versus Cyclosporine 0.05% eye drops in treatment of dry eye in Secondary Sjogren Syndrome.|t|f|f|f
33680823|NCT01155167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680824|NCT06363266|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE||Using a stepped care approach, TEMPO will be provided across two intervention stages with variations on timing (initial vs. delayed) and intensity (self-directed vs. guided). All dyads will continue to access usual care (a co-intervention measure is included).|f|f|t|t
33680825|NCT03223181|||CASE_CROSSOVER||PROSPECTIVE|||||||
33680826|NCT04933370|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33680827|NCT00917644|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33680828|NCT01297777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680829|NCT00935155|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33680830|NCT04635605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a phase 2 proof of concept, randomized, placebo controlled, single blind clinical trial on the efficacy of Methylene Blue against SARS-CoV-2 infection in patients with recently diagnosed SARS-CoV-2 infection|f|t|t|t
33680831|NCT02342418|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680832|NCT02254564|||CASE_CONTROL||PROSPECTIVE|||||||
33680833|NCT04208113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33680834|NCT04950868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680835|NCT00448396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680836|NCT05229861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of the principal investigator and research assistant towards group allocation is ensured by a unique subject identification code given to each participant.|Single-centre Randomized Controlled Trial (RCT)|f|f|t|t
33680837|NCT02753088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680838|NCT01911910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680839|NCT02069067|||COHORT||PROSPECTIVE|||||||
33680840|NCT00909207|||CASE_ONLY||PROSPECTIVE|||||||
33680841|NCT04631094|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680842|NCT03273218|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33680843|NCT01860183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680844|NCT02366533|||COHORT||PROSPECTIVE|||||||
33680845|NCT01239719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680846|NCT06277453|||COHORT||RETROSPECTIVE|||||||
33680847|NCT00883519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680848|NCT04546828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680849|NCT02129842|||CASE_ONLY||PROSPECTIVE|||||||
33680850|NCT04110652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33680851|NCT00248963|RANDOMIZED|PARALLEL||ECT||NONE||||||
33680852|NCT03827915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, randomized controlled, superiority trial, with two parallel groups, conducted in one academic medical center||||
33680853|NCT02366364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680854|NCT05775523|||COHORT||PROSPECTIVE|||||||
33680855|NCT06533995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33680856|NCT00513825|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33680857|NCT05254145|||COHORT||PROSPECTIVE|||||||
33680858|NCT02685059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680859|NCT03530709|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33680860|NCT05429775|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33680861|NCT05343468|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This single-arm repeated measures design examined the effects of a software device as an intervention, permitting the participants to serve as their own controls.||||
33983533|NCT06151678|||OTHER||OTHER|||||||
33983534|NCT03025945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983535|NCT04437862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983536|NCT03799029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant are blind on their group assignation. Investigator are blind on group assignation|will compare the ADHD group with a control group including healthy participants .The experimental study uses a pseudo-randomized, double-blind, controlled multi-center design.Participants will be assigned to an experimental group (cognitive training ) or in a control active group.|t|f|t|f
33983537|NCT03933748|||COHORT||PROSPECTIVE|||||||
33900810|NCT06637917|||COHORT||PROSPECTIVE|||||||
33983538|NCT01273337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900811|NCT03932136|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983539|NCT03678038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983540|NCT04587778|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33983541|NCT01194609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983542|NCT05527626|||CASE_ONLY||RETROSPECTIVE|||||||
33983543|NCT02883452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983544|NCT02349893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983545|NCT03437304|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33983546|NCT04611789|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33983547|NCT03222765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Two groups (linagliptin vs placebo) double-blind Two groups (metformin \& metformin+linagliptin) single-blind|Randomized, parallel , single-blind, placebo controlled|t|t|t|t
33983548|NCT02152566|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983549|NCT02221765|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33983550|NCT03918486|||CASE_ONLY||PROSPECTIVE|||||||
33983551|NCT04874545|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33983552|NCT00002905||||TREATMENT||||||||
33983553|NCT05140070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the same appearance of the mousse (with and without active substance)|randomize, double blind, intervention vs control|t|t|t|t
33983554|NCT04013425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983555|NCT02911662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983556|NCT05699980|||OTHER||PROSPECTIVE|||||||
33680862|NCT00095147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680863|NCT05157802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680864|NCT00436540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680865|NCT05873907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33680866|NCT01489813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33680867|NCT02361476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33900812|NCT05972967|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33900813|NCT01904461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900814|NCT01011205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900815|NCT04095208|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33900816|NCT00580697|||COHORT||PROSPECTIVE|||||||
33680868|NCT00510653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900817|NCT00851110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900818|NCT04317222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900819|NCT01853228||SEQUENTIAL||TREATMENT||NONE||||||
33900820|NCT06080750|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33900821|NCT02413515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983557|NCT02555111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983558|NCT02264106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983559|NCT05245643|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective multicenter study: interventional cohort for surgical treatment (deep brain stimulation) in severe and resistant Anorexia Nervosa||||
33983560|NCT01190163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983561|NCT03165968|||COHORT||PROSPECTIVE|||||||
33983562|NCT04449666|||CASE_CONTROL||PROSPECTIVE|||||||
33983563|NCT05626894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983564|NCT02155205|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33983565|NCT02615847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983566|NCT00535860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983567|NCT00667862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983568|NCT02266264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34024710|NCT04480021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34024711|NCT01782430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024712|NCT00358410|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34079332|NCT00286572|||COHORT||PROSPECTIVE|||||||
34079333|NCT00667563|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33983569|NCT04231838|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Study Arms and Randomization Plan Participants who were eligible and consent to take part will be randomized to either continuing smoking their own cigarette brand (Arm A) or switching to using C-F NDS (Arm B).~The randomization sequence will be computer generated, with an allocation ratio of 1:2 (Arm A: Arm B) to compensate for an estimated 50% success rate (defined as combined smoking abstinence rate + \>80% smoking reduction rate) in the long term (more details in the section about Sample Size Calculation). The randomization scheme will be provided to clinical sites via a web-based application set up by the CRO. The staff randomizing the participant will access the web-based application when the participant is with them, entering their participant identification number, date of birth and initials into the program. The allocation will be immediately provided by the program/software."||||
33983570|NCT01377805|||CASE_ONLY||RETROSPECTIVE|||||||
34079334|NCT00405171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079335|NCT03025633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33680869|NCT02828215|||COHORT||PROSPECTIVE|||||||
33680870|NCT01046409|||CASE_ONLY||CROSS_SECTIONAL|||||||
33680871|NCT04320030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multicentric, open prospective study||||
33680872|NCT02126475|||CASE_CONTROL||PROSPECTIVE|||||||
33680873|NCT01075191|||COHORT||PROSPECTIVE|||||||
33680874|NCT05366400|||COHORT||CROSS_SECTIONAL|||||||
33680875|NCT00330161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680876|NCT05293899|||COHORT||PROSPECTIVE|||||||
33680877|NCT05412589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680878|NCT04486300|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33680879|NCT05336604|||COHORT||PROSPECTIVE|||||||
33680880|NCT02320201|NA|SINGLE_GROUP||OTHER||NONE||||||
33680881|NCT01062373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680882|NCT03168958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drugs will be prepared by the operating room pharmacy. All patients and care providers will be blinded to group assignment|Patients will be randomized to receieve either methadone or saline-control|t|t|t|t
33680883|NCT00668993|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33680884|NCT01949467|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33680885|NCT04516395|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||According to the model, it divided into two parts - retrospective chart review and prospective data collection. Single independent patient group will be divided two parts depending on over a period of time. The patients in the retrospective part received a standard treatment become a control group, while the patients in the prospective part received the intervention become an experimental group.||||
33680886|NCT05806489|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33680887|NCT01588756|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771233|NCT01193582|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33771234|NCT04415385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771235|NCT04504318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33771236|NCT01217489|||CASE_ONLY||PROSPECTIVE|||||||
33771237|NCT05141981|||OTHER||CROSS_SECTIONAL|||||||
33771238|NCT05199909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771239|NCT00354133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771240|NCT05005949|||COHORT||PROSPECTIVE|||||||
33771241|NCT00135746||CROSSOVER||TREATMENT||DOUBLE||||||
33771242|NCT03743662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771243|NCT01737060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771244|NCT02538679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771245|NCT05461014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079336|NCT05456204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079337|NCT02060500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079338|NCT01611623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771246|NCT01026909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771247|NCT01824563|||COHORT||PROSPECTIVE|||||||
33771248|NCT00802828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771249|NCT00902889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771250|NCT02038764|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33771251|NCT05501171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a double-blind multi-site randomized efficacy trial of two mobile apps: DreAMLand versus CERENA in 180 patients with AML. Patients will be recruited from 5 sites and randomized in 1:1 fashion, stratified by study site, to DreAMLand versus CERENA. The study investigators and clinicians caring for these patients will be blinded to the study group assignment.||f|t|t|f
33771252|NCT03005093|||COHORT||PROSPECTIVE|||||||
33680888|NCT03673423|||OTHER||CROSS_SECTIONAL|||||||
33680889|NCT04255394|||CASE_CONTROL||RETROSPECTIVE|||||||
33680890|NCT00021372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680891|NCT05132803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680892|NCT03350438|||COHORT||CROSS_SECTIONAL|||||||
33771253|NCT06023355|||COHORT||PROSPECTIVE|||||||
33771254|NCT01504451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771255|NCT00721643|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33771256|NCT01454050|||CASE_ONLY||PROSPECTIVE|||||||
33771257|NCT02631811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771258|NCT04864041|||COHORT||PROSPECTIVE|||||||
33771259|NCT00099593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771260|NCT02327624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983571|NCT03194412|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"The group of participants involved to the study:~* n=60 ( at least 30) to diet /nutritional - intervention group 1~* n=60 ( at least 30) to physical activity - intervention group 2~* n=60 ( at least 30) to comprehensive therapy (diet/nutritional+physical activity training) - intervention group 3~* n=30 (at least 15) formal and informal caregivers of elderly - intervention group 4~* n=60 ( at least 30) to control group without intervention - group 5~Evaluation process:~* Screening Evaluation (stage 1)- investigated within 0~* Baseline Evaluation (stage 2) - after 3 months from 0~* Final Evaluation (stage 3) - after 6 months from 0 Professionals involved in the interventions: physicians, general practitioners, physiotherapists, rehabilitation professionals, educators, nurses, volunteers, nutrition consultant."||||
33983572|NCT06083389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33983573|NCT04029610|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33771261|NCT05627401|||COHORT||RETROSPECTIVE|||||||
33771262|NCT01777243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771263|NCT00482222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771264|NCT04399187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33771265|NCT02701946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771266|NCT04325464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900822|NCT04520698|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The study will use a stepped-wedge non-randomized trial design with 16 sites in two states (Indiana and Maryland). The study team will compare process and outcomes of the UPLIFT-AD intervention vs. usual care. The intervention will be implemented consecutively over 36 months, with staggered roll-out at 4 sites (2 per state) approximately every 6 months.||||
33900823|NCT04185467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessor blinded.|"Design: Two-site, assessor blinded, two-arm superiority randomised controlled trial.~Setting: Participant recruitment from the affiliated hospital of Nantong University and the first affiliated hospital of Nanjing Medical University~Procedure:~Randomisation: Randomisation list devised by independent statistician; carried out using the REDCap randomisation function to ensure allocation concealment. Following consent and assessment, participants are randomised 1:1. Lung cancer with stage I-IIIA and treatment type is surgery +/- adjuvant treatment."|f|f|f|t
33900824|NCT05942274|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We propose to validate these smartwatch ECG functions to support FDA submissions||||
33680893|NCT03872076|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33680894|NCT05600530|||OTHER||CROSS_SECTIONAL|||||||
33680895|NCT01120782|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33680896|NCT02617901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983574|NCT00653471|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33983575|NCT03204266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983576|NCT01835080|||COHORT||PROSPECTIVE|||||||
33983577|NCT00885456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33983578|NCT02924883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983579|NCT02648607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983580|NCT06340139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983581|NCT06266806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||A randomized controlled experimental study|t|f|f|t
33983582|NCT02679053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983583|NCT00060307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983584|NCT00202319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983585|NCT00913705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079339|NCT06172231|RANDOMIZED|PARALLEL||TREATMENT||NONE||Both group will be recruited concurrently. Both group will receive treatment.||||
34079340|NCT00454961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079341|NCT01438138|||COHORT||RETROSPECTIVE|||||||
34079342|NCT00072410|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34079343|NCT01967680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079344|NCT02355717|||COHORT||PROSPECTIVE|||||||
34079345|NCT01713205|||COHORT||PROSPECTIVE|||||||
34079346|NCT04348708|||COHORT||PROSPECTIVE|||||||
34079347|NCT03994978|||COHORT||PROSPECTIVE|||||||
34079348|NCT03615313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079349|NCT02697643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34079350|NCT01791595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079351|NCT05721664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||A prospective, true experimental, and comparative research design will be used in the current study. The type of true experiment that will be conducted is (pretest-posttest control). The study will compare the current traditional in-service training with developed (EBNTP) regarding the care of mechanically ventilated patients. True-experiment is research design where the researcher initiates an experimental treatment, randomly assigns test units and treatments to the experimental group, and use of control group|t|f|t|f
34079352|NCT03949595|||CASE_ONLY||RETROSPECTIVE|||||||
34079353|NCT05222165|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1b: Rolling 6 design, 3 cohorts Phase 2: Single Group Assignment||||
33771267|NCT03257423|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients are enrolled in conjuction with APPAC II (NCT03236961) and APPAC III (NCT 03234296) trials, all patients with uncomplicated or complicated acute appendicitis are evaluated for MAPPAC enrollment. MAPPAC study groups: complicated acute appendicitis (samples: rectal swabs, serum, removed appendix), APPAC II patients in two groups according to APPAC II randomized antibiotic therapy (uncomplicated acute appendicitis, samples: rectal swabs, serum and in cases of antibiotic treatment failure or appendicitis recurrence also removed appendix), APPAC III patients in two groups according to APPAC III randomized group of antibiotc or placebo therapy (uncomplicated acute appendicitis, samples: rectal swabs, serum and in cases of antibiotic or placebo treatment failure or appendicitis recurrence also removed appendix), and patients with uncomplicated acute appendicitis declining to participate in APPAC II or III trials undergoing appendectomy||||
33771268|NCT00393900|||COHORT||PROSPECTIVE|||||||
33771269|NCT04412252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771270|NCT00339703|||CASE_ONLY||PROSPECTIVE|||||||
33771271|NCT04663568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771272|NCT01611818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771273|NCT06013332|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33771274|NCT02293525|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33771275|NCT03133949|||CASE_CONTROL||RETROSPECTIVE|||||||
33983586|NCT01944930|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33983587|NCT00186706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33983588|NCT00343278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983589|NCT03514771|NA|SINGLE_GROUP||TREATMENT||SINGLE|Efficacy evaluations of photographs will be performed by two trained and experienced evaluators who are blinded to which side of the face has been treated, and which side of the face has not been treated.|All subjects will have one side of the face (Right-Left) treated with the laser and the other side will be untreated to act as a control.|f|f|f|t
33983590|NCT03262012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33983591|NCT04874389|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983592|NCT02134405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983593|NCT03827174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The outcomes assessors are blinded to study condition during all measurements. Participants and providers of the return to work coordination intervention are blinded until a rehabilitation plan has been completed. Thereafter allocation to study condition is disclosed and the other components of the behaviour change ability programme are provided to those in the experimental group.||t|t|f|t
33983594|NCT01546766|||CASE_CONTROL||PROSPECTIVE|||||||
33983595|NCT02799108|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079354|NCT04530045|||COHORT||PROSPECTIVE|||||||
34079355|NCT04488445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34079356|NCT03794492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079357|NCT00920842|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079358|NCT01241422|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34079359|NCT01716806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079360|NCT00197093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34079361|NCT06237933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079362|NCT02461537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079363|NCT03645642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079364|NCT00532545|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079365|NCT01816321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079366|NCT02404051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079367|NCT02378389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079368|NCT06459310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34079369|NCT01231477|||CASE_CONTROL||PROSPECTIVE|||||||
33983596|NCT06364280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The trial uses a Bayesian Adaptive Sequential Platform Trial (BASIC-PT) framework.~The study interventions are strategies of prehospital airway management: \[BVM-only\], \[BVM followed by SGA\] and \[BVM followed by ETI\].~The trial will be organized and executed in two successive stages. In Stage I of the trial, EMS personnel will alternate between two strategies: \[BVM-only\] or \[BVM followed by SGA\]. The \[winner of Stage I\] will advance to Stage II based upon results of Bayesian interim analyses. In Stage II of the trial, EMS personnel will alternate between \[BVM followed by ETI\] vs. \[Winner of Stage I\].~The interventions will be quasi-randomized using alternate day assignment."||||
33983597|NCT05088005|||COHORT||PROSPECTIVE|||||||
33983598|NCT05554822|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33983599|NCT01351220|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33900825|NCT02513940|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33900826|NCT00622934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983600|NCT05100381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983601|NCT01269801|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983602|NCT00641394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33983603|NCT00173771|||DEFINED_POPULATION||PROSPECTIVE|||||||
33983604|NCT04321564|||COHORT||PROSPECTIVE|||||||
33983605|NCT02076022|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983606|NCT02939729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33983607|NCT02563808|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33983608|NCT04161365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983609|NCT05406791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33983610|NCT01695720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983611|NCT06302530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"To reduce bias, the study will use double-blind blinding. Patients will not know the group to which they have been assigned. In addition, the assessors performing the ankle range of motion measurements by goniometry will be blinded to each patient's treatment group.~Randomization to each group will be performed using opaque sealed envelopes that will be opened in the operating room just prior to surgery. Neither the surgeon nor the patient will know the assignment until that time.~The statistical analysis will also be performed in a blinded manner, without the statistician knowing the intervention received by each group. Only after the analysis will the groups be unblinded.~In this way, the aim is to reduce the possibility of knowledge of the assigned treatment influencing the evaluation of the results, both on the part of the patients and of the evaluators and analysts."||t|f|t|f
33983612|NCT05733884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33983613|NCT06037122|||COHORT||RETROSPECTIVE|||||||
33983614|NCT04719949|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983615|NCT01263704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983616|NCT05320679|||COHORT||PROSPECTIVE|||||||
33983617|NCT01366079|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983618|NCT05800652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In this study, the analysis of the data was conducted by an independent statistician who does not know the intervention and control group appointment. In addition, students were not explained in which group they were in and they were blinded.Simple random randomization was used in the appointment of the students in the sample group to experimental and control groups.|"Study has been planned as a type of randomized controlled intervention type with pre -test and monitoring patterns, one of the quantitative research methods. 40 mentees/first year students (experimental = 20; control = 20) and 20 mentors/fourth year students were included in the study. Simple random randomization was used in the appointment of the students in the sample group to experimental and control groups. Mentors were randomly matched with the mentees assigned to the experimental group.12 -week mentoring program was applied to the mentees by the mentors. In the collection of research data, Personal Information Form, General Self -Qualification Scale, Self -Confidence Scale and Perceived Stress Scale were used. The measurements were taken 3 times:pre test, post-test and 3-months post-test."|t|f|f|t
33983619|NCT00006370||||TREATMENT||||||||
33983620|NCT03496922|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will not be told which cigarettes (ventilated or unventilated) are which.|||||
33983621|NCT00467220|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983622|NCT01700244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983623|NCT06366477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983624|NCT03616990|RANDOMIZED|PARALLEL||OTHER||NONE||Individually-randomized, two-group parallel study||||
33983625|NCT00880568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983626|NCT03026348|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983627|NCT02071719|||COHORT||PROSPECTIVE|||||||
33983628|NCT00890526|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33983629|NCT05963321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983630|NCT02461771|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33983631|NCT06327022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33983632|NCT01964092|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983633|NCT02828917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983634|NCT03292653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983635|NCT03280394|||COHORT||PROSPECTIVE|||||||
33983636|NCT04188106|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single group study.||||
33983637|NCT01010542|RANDOMIZED|||TREATMENT||SINGLE|||t|f|f|f
33900827|NCT01083563|||COHORT||PROSPECTIVE|||||||
33900828|NCT00217477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900829|NCT03940144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care providers and investigators in the operating room could not be blinded due to the presence of the cardiac index trending monitor. The postoperative assessors were blinded to the allocation.|goal-directed fluid therapy guided by stroke volume variation and cardiac index using FloTrac/Vigileo monitor|t|f|f|t
33900830|NCT04148430|NA|SEQUENTIAL||TREATMENT||NONE||||||
33900831|NCT03667651|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be blinded to the group of allocation and will have no contact with the participants aside from the assessment of outcomes at six-weeks and 12-months|A single blinded study design will be used|f|f|f|t
33900832|NCT00607360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680897|NCT03579602|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Central Pathology assessment and Central Radiology post-operative MRI assessment will be blinded to study arm and fluorescence data.~Central Fluorescence assessment will be blinded to study arm."|Subjects will be randomized 1:10 to 1 of 2 study arms. Subjects in arm 1 (\~9% of subjects) will not receive tozuleristide but will undergo neurosurgery and imaging will be performed with the Canvas. Subjects in arm 2 (\~91% of subjects) will receive tozuleristide and will undergo neurosurgery and imaging will be performed with the Canvas.|f|f|f|t
33680898|NCT05146102|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The interventiongroup is offered organized interprofessional sessions, once a month, for six months at their workplace. In the the controlgroup, organized interprofessional sessions are not planned at the wards.||||
33680899|NCT05052931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900833|NCT03115645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster randomized controlled trial|f|f|f|t
33900834|NCT03191292|||COHORT||RETROSPECTIVE|||||||
33900835|NCT05720078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900836|NCT03211130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33900837|NCT03090737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900838|NCT03792919|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to 2 groups. Group 1: Stop current anti-HBV neucleos(t)ides treatment, Group 2: Keep on current anti-HBV nucleus(t)ides treatment||||
33900839|NCT03763487|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||50 patients and 30 healthy blood donor||||
33900840|NCT01350700|||COHORT||OTHER|||||||
33900841|NCT05497505|||COHORT||PROSPECTIVE|||||||
33900842|NCT05537181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900843|NCT05367804|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy male and female adult subjects (n=39) will be recruited to take part in an evaluation study to determine the amount of dietary protein intake which influences gut-protein-derived metabolites production. The study consists of 8 weeks with weekly visits and the subjects will consume an isolated plant-protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase. Faecal samples will be used to answer the main outcome of gut metabolites and microbiota profile. And the blood and urine samples to measure health status and compliance (protein intake markers). Questionnaires will be used to access gastrointestinal symptoms and bowel movement, physical activity level and dietary intake.||||
33900844|NCT05437094|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900845|NCT01803802|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33900846|NCT04133753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33900847|NCT02714946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900848|NCT02556086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900849|NCT02224846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900850|NCT04498910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900851|NCT02135640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900852|NCT06403345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079370|NCT01462630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079371|NCT00261755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079372|NCT06044103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079373|NCT02898857|||||RETROSPECTIVE|||||||
34079374|NCT02306369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079375|NCT01439035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079376|NCT01960101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079377|NCT04581434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079378|NCT05751798|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34079379|NCT03865030|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||the participants are divided into 2 groups: psoriatic patients and healthy volunteers.||||
34079380|NCT05817162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The distribution of intervention is performed by attributing a code for each patient. Each code will have been previously distributed randomly between PRP + Ropicavaine and PRP only. The codes are kept closed singularly in an envelope. Before treatment, the nurse will ask the patient to choose an envelope. At this moment, the envelope is placed on a table, and the patient writes his name. Alone, the nurse opens the envelope and sees the code and the indication of PRP or PRP + Ropivacaine. Then, she will prepare, in her room, isolated from the whole team, one 3cc syringe with PRP or PRP + 1cc ropivacaine (7.5mg/ml), depending on the code. Once the code is attributed to the patient, she will deliver a tray with the prepared syringe for treatment. After finishing the arthrocentesis, the doctor injects the chosen treatment. Daily for one week, the patient answers a questionnaire, and at the end of the postoperative week, each patient will be blinded evaluated with a clinical examination.|For this randomized clinical trial an appropriate number of sealed envelopes will be prepared: 15 for PRP and 15 for PRP + Ropivacaine. Patients with inclusion criteria will be seen in an orofacial pain session and assessed for pain using the VAS scale, by scoring the degree of pain between 0 (absence of pain) and 10 (maximum pain). Then the patients are proposed for TMJ arthrocentesis.|f|f|t|f
34079381|NCT03561896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079382|NCT04881344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079383|NCT02548377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079384|NCT00457730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34079385|NCT05192265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants were assigned into one of the two treatment groups according to a pre-generated randomization code. Children randomized to Pyramax™ received three doses of pyronaridine-artesunate granules or tablets manufactured by Shin Poong Pharmaceuticals, Seoul, Korea depending on their body weights. Pyramax granules come in sachets with each containing 60mg of pyronaridine/20mg of artesunate while Pyramax tablets contain 180mg pyronaridine/60mg artesunate. Study participants randomized to Coartem™ received the standard six-dose regimen of AL dispersible tablets (Coartem™, Novartis pharma) twice daily according to body weights.||||
34079386|NCT02670369|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079387|NCT03440619|NA|SINGLE_GROUP||OTHER||NONE||||||
34079388|NCT00164138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079389|NCT04585802|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079390|NCT03498521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079391|NCT03165773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34079392|NCT02885038|||COHORT||RETROSPECTIVE|||||||
34079393|NCT02444494|||COHORT||PROSPECTIVE|||||||
33900853|NCT00275379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900854|NCT03388125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900855|NCT05870007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900856|NCT02267577|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Participants enrolled in the study will have their blood pressure measured multiple times with both the GE Dinamap Procare commercial blood pressure monitor and Sphygmo, the experimental blood pressure monitoring device.||||
33900857|NCT00785746|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33900858|NCT04556604|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33900859|NCT00218244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900860|NCT06530849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900861|NCT04579393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900862|NCT05187195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900863|NCT06211283|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33900864|NCT02021812|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33900865|NCT05420012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be assigned with equal allocation to the intervention and control groups using block randomization to ensure a balance in sample size across groups over time.|Randomized double-blind, placebo-controlled study in patients with heart failure \[HF\] with reduced ejection fraction \[HFrEF\].|t|f|t|f
33900866|NCT06125795|||COHORT||PROSPECTIVE|||||||
33900867|NCT05424692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33900868|NCT02909296|||COHORT||RETROSPECTIVE|||||||
33900869|NCT01895010|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33900870|NCT04083222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900871|NCT04916197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983638|NCT01860105|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33983639|NCT02167165|||CASE_CONTROL||PROSPECTIVE|||||||
33983640|NCT02747615|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33983641|NCT06387186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983642|NCT00773422|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33983643|NCT00842595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983644|NCT02548403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33983645|NCT02493270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983646|NCT03884088|NA|SINGLE_GROUP||SCREENING||NONE||||||
33983647|NCT02088463|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33983648|NCT02370719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983649|NCT05037760|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33983650|NCT01427023|||COHORT||CROSS_SECTIONAL|||||||
33983651|NCT01513486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983652|NCT02171637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983653|NCT05712005|||COHORT||PROSPECTIVE|||||||
33983654|NCT06449742|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983655|NCT05761626|||COHORT||RETROSPECTIVE|||||||
33983656|NCT03149653|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33983657|NCT04092647|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a 1:1 randomized double blinded placebo controlled trial.|t|f|t|f
33983658|NCT03326271|||COHORT||RETROSPECTIVE|||||||
33983659|NCT04336696|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|guuartor of study, only participant|prospective cohort study|t|f|t|f
33983660|NCT02114047|||OTHER||PROSPECTIVE|||||||
33983661|NCT01581450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33983662|NCT00685477|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33983663|NCT01425710|||CASE_CONTROL||PROSPECTIVE|||||||
33983664|NCT05059249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983665|NCT00213304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983666|NCT03733600|||COHORT||RETROSPECTIVE|||||||
33983667|NCT04991090|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation of lymph node metastasis||||
33983668|NCT05106465|||COHORT||PROSPECTIVE|||||||
33983669|NCT00562445|||CASE_ONLY||PROSPECTIVE|||||||
33983670|NCT05681247|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33983671|NCT01194388|||OTHER||PROSPECTIVE|||||||
33983672|NCT06022237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983673|NCT01642342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983674|NCT02011932|||COHORT||PROSPECTIVE|||||||
33983675|NCT04913376|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised controlled trial with stratification.||||
33983676|NCT00316745|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983677|NCT01785368|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983678|NCT04346927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983679|NCT04469270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983680|NCT00050778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983681|NCT02293083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983682|NCT03117257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983683|NCT02346097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983684|NCT00012948|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33983685|NCT02064088|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33983686|NCT04857541|||CASE_CROSSOVER||PROSPECTIVE|||||||
33983687|NCT04325100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|A blinding procedure was used for the evaluation of the Brief Negative Symptom Scale: interviews were recorded and each video or sound recording was evaluated at the end of the study by one (or two) independent evaluator who was unaware of the recordings' assessment time.|||||
33983688|NCT00106548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983689|NCT02401334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983690|NCT00223197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983691|NCT02146261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983692|NCT01428830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983693|NCT00227136|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33983694|NCT03415802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983695|NCT04903600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33983696|NCT03955237|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 different type of fluid||||
34024713|NCT05209594|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the intervention, it is not possible to have blinded conditions. Most school-based prevention programs of this type are not blinded.|GSA members (students in grades 9 to 12) will be assessed in one of two arms. The intervention arm includes GSAs that will implement the Healthy Relationships Program (HRP) for two-spirit, lesbian, gay, bisexual, trans, queer, intersex, and asexual (2SLGBTQIA+) youth. The comparison arm will be GSAs where standard GSA programming is delivered.||||
34024714|NCT04320342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680900|NCT05845697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind, randomized control|t|f|f|t
33680901|NCT02895425|||COHORT||PROSPECTIVE|||||||
33680902|NCT04880902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680903|NCT02065427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33680904|NCT04036292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33680905|NCT01388556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680906|NCT02248675|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33680907|NCT01638442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33680908|NCT03320876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680909|NCT05497271|||COHORT||PROSPECTIVE|||||||
33680910|NCT05133960|||CASE_ONLY||OTHER|||||||
33900872|NCT04297163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||4-weeks randomized with parallel groups study.||||
33900873|NCT02894190|||COHORT||PROSPECTIVE|||||||
33680911|NCT04443374|||CASE_ONLY||CROSS_SECTIONAL|||||||
33680912|NCT00830908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680913|NCT01265264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680914|NCT06334406|||COHORT||PROSPECTIVE|||||||
33680915|NCT01887054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680916|NCT06471387|||CASE_CONTROL||PROSPECTIVE|||||||
33680917|NCT02956590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680918|NCT02380300|||COHORT||PROSPECTIVE|||||||
33680919|NCT03498053|NA|SINGLE_GROUP||OTHER||NONE||Not-randomized crossover study with a single group||||
33680920|NCT03995329|NA|SINGLE_GROUP||OTHER||NONE||||||
33680921|NCT03645343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680922|NCT00470509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680923|NCT05661747|NA|SINGLE_GROUP||TREATMENT||NONE|No masking is possible, as each child will serve as their own control in using the mouthguard, and their progress will be compared to their measurements prior to beginning the trial.|The patient will serve as their own control.||||
33680924|NCT05152225|||COHORT||PROSPECTIVE|||||||
33680925|NCT03162900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33680926|NCT00724321|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33680927|NCT01957670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680928|NCT04708171|||COHORT||PROSPECTIVE|||||||
33680929|NCT05506228|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680930|NCT00828100|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680931|NCT00322985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680932|NCT02087267|||COHORT||PROSPECTIVE|||||||
33680933|NCT00660881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680934|NCT00170001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33680935|NCT02176746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33680936|NCT05631002|||CASE_CONTROL||PROSPECTIVE|||||||
33680937|NCT05258188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Our study will be single-blinded, outcome assessor-blinded. The assessor will be blinded to avoid being biased during the outcome assessment.||f|f|f|t
33680938|NCT03591770|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33680939|NCT00000939||||TREATMENT||NONE||||||
33680940|NCT03287271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680941|NCT00679445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680942|NCT00894959|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33680943|NCT01708096|RANDOMIZED|PARALLEL||||NONE||||||
33680944|NCT03997227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33680945|NCT02594995|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33680946|NCT02801266|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33680947|NCT05222672|||COHORT||PROSPECTIVE|||||||
33680948|NCT03550300|||COHORT||PROSPECTIVE|||||||
33680949|NCT06055738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680950|NCT04493528|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Each participant receive two anesthesia methods randomly. Total 8 arms, 4 groups, each group will recruit 6 participants. Incase of drop out, a total of 30 participant will be enrolled.|Randomized split-mouth cross-over clinical trial.|f|f|t|t
33680951|NCT00602199||||TREATMENT||NONE||||||
33680952|NCT02316509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680953|NCT02518464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680954|NCT04285840|NA|SINGLE_GROUP||OTHER||NONE||||||
33680955|NCT03441217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900874|NCT06469658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33900875|NCT04435769|||COHORT||RETROSPECTIVE|||||||
33900876|NCT01410019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680956|NCT00825253|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33680957|NCT00551304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33680958|NCT06518590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771276|NCT00859508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771277|NCT03063970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessor otherwise uninvolved in the study.|Feasibility Randomised Controlled Trial|f|f|f|t
33771278|NCT03086915|||COHORT||RETROSPECTIVE|||||||
33771279|NCT06177301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771280|NCT00206388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771281|NCT05119413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900877|NCT02291380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900878|NCT03044665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900879|NCT01441167|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900880|NCT05294848|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel random assignment to 3 arms in 1:1:1 ratio.|t|f|f|f
33900881|NCT04886830|||COHORT||RETROSPECTIVE|||||||
33900882|NCT04021862|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33900883|NCT05810779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900884|NCT04044638|RANDOMIZED|PARALLEL||OTHER||SINGLE||The sample consisted of 14 women, which were divided into two groups: young group (YG = 7) and middle age group (MAG = 7).|f|f|t|f
33900885|NCT05738512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900886|NCT01471873|||CASE_CONTROL||PROSPECTIVE|||||||
33900887|NCT02421380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900888|NCT03078101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983697|NCT03232372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind study The RX examiner and the person performing the resonance frequency measurements would be independent of the surgeons who placed the implants.|"To randomize we will use the application created by a computer programmer that generates random numbers.~In each jaw, each edentulous space will be randomly assigned (A, B, C, D, ..). Following the alphabetical order to each letter will be assigned randomly the connection to use, as detailed below:~* 2 edentulous spaces: A: c. External or c. Internal (random) B: the one that is pending (The type of internal connection (crestal or infracrestal) will be chosen at random.)~* 3 edentulous spaces: A: c. External, c. Crestal or infracrestal internal B: randomly choose between the two remaining options C: the one that is pending"|t|f|f|f
33983698|NCT02865538|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33983699|NCT06046846|RANDOMIZED|PARALLEL||OTHER||NONE||Single centred feasibility randomised controlled trial (RCT)||||
33983700|NCT03875755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33983701|NCT01206153|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33983702|NCT05737992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research project collaborator who is not informed about grouping of participants will obtain outcome measurements of the functional tests. Outcome adjudicators and data analysts will be kept blinded to the allocation. Moreover, all investigators, staff, and participants will be kept masked to outcome measurements and trial results.|Participants will be randomly allocate to intervention group or control group and will be examined in the same way|f|f|f|t
33983703|NCT00041496|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33983704|NCT03335761|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33900889|NCT02280005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900890|NCT04174157|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33900891|NCT02117050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900892|NCT02012972|||COHORT||PROSPECTIVE|||||||
33900893|NCT06670638|||OTHER||PROSPECTIVE|||||||
33900894|NCT00004184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900895|NCT04996576|NON_RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|t|f|f
33900896|NCT02707094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900897|NCT04424498|||COHORT||RETROSPECTIVE|||||||
33900898|NCT04765462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900899|NCT03690518|RANDOMIZED|PARALLEL||OTHER||NONE||Cardiac rehabilitation||||
33900900|NCT03890276|RANDOMIZED|PARALLEL||OTHER||SINGLE|Jhpiego data analysts will be blinded to which participants were in which arm.|This is a quasi-experimental two-arm study that is a formative, pre- and post-training assessment of healthcare providers who receive the training intervention. In the experimental arm, participants (health care providers) will receive training supplemented with videos. In the comparison arm, participants (heath care providers) will receive training with no video. Participants come from 36 health facilities. There are 18 health facilities sending participants, per study arm.|f|f|f|t
33900901|NCT05163808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|2 treatment Groups (Study Drug and Placebo)|t|t|t|t
33900902|NCT06263166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33900903|NCT04597138|||CASE_ONLY||PROSPECTIVE|||||||
33900904|NCT01706289|||CASE_CONTROL||PROSPECTIVE|||||||
33983705|NCT05336708|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
33983706|NCT03206619|||COHORT||PROSPECTIVE|||||||
33983707|NCT03973983|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983708|NCT06062914|||COHORT||RETROSPECTIVE|||||||
33983709|NCT03426241|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983710|NCT01702948|||||RETROSPECTIVE|||||||
33983711|NCT03635125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||12-week Amlodipine background treatment phase followed by a 4-week Low dose Nebivolol/Metoprolol treatment phase and a 4-week high dose Nebivolol/Metoprolol treatment phase||||
33983712|NCT03832257|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983713|NCT04121364|NA|SINGLE_GROUP||TREATMENT||NONE||Non randomized, single arm, objective performance criteria study||||
33983714|NCT01683032|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33983715|NCT01500876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983716|NCT05999669|||COHORT||PROSPECTIVE|||||||
33983717|NCT05454553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33983718|NCT05086783|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Due to the nature of the intervention, the participants and the surgical coach will not be blinded. The participants will be informed of their assignment after completing the first attempt. The staff surgeon in the operating room for each attempt will be blinded. The experienced laparoscopists who will be scoring the videos will be blinded to the group allocation and the attempt number.|Participants will be randomized to the intervention (video-based coaching plus standard surgical teaching following the master-apprentice model) or the control (standard surgical teaching following the master-apprentice model)|f|t|t|t
33983719|NCT02109354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33983720|NCT05110209|||COHORT||RETROSPECTIVE|||||||
33983721|NCT00545545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983722|NCT04487262|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective cluster-randomized parallel study||||
33983723|NCT00881088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33983724|NCT03979703|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33983725|NCT06128811|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The statistician will be blinded|It is a split-mouth randomized clinical trial. And both sides fissure sealants will be provided at the same appointment by the same trained and calibrated dentist|f|f|t|f
33983726|NCT02870920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983727|NCT02987985|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33983728|NCT02603224|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34024715|NCT03860051|||COHORT||PROSPECTIVE|||||||
33900905|NCT05152446|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900906|NCT02499965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33900907|NCT02202681|NA|SINGLE_GROUP||OTHER||NONE||||||
33900908|NCT06494176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900909|NCT05690633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900910|NCT04163198|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33900911|NCT00124423|||CASE_ONLY||PROSPECTIVE|||||||
33900912|NCT01377467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900913|NCT04169607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33900914|NCT03700892|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The e-liquids will be maintained by an individual not active in the study procedures or analysis.|Controls will not be randomized and will not receive the study intervention.|t|f|f|t
33900915|NCT04661618|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data is anonymized|Randomised-Control Trial|f|f|t|f
33900916|NCT01100021|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33983729|NCT04517162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind Placebo-controlled Clinical Trial|t|t|t|t
33983730|NCT01469026|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33983731|NCT03866330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33983732|NCT00002166||PARALLEL||TREATMENT||||||||
33983733|NCT04277026|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with a waitlist control group||||
33983734|NCT00171821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983735|NCT01908725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983736|NCT06041061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Blinds for randomized subjects and drug coding blinds will be generated and stored by an independent third party. Immunogenic subgroup blind maintenance: The subgroup information shall not be disclosed to the testing personnel. The serological test results report of the immunogenic subgroup shall be received by non-blind personnel independent of the project team, and the personnel designated by the data management unit shall be responsible for checking the blind data. Before the study is unblinded, the serum results should not be disclosed to the relevant personnel to ensure the blindness of serological test results.~In order to ensure the implementation of the blind method, iDMC will be established in this experiment. At the time of the interim analysis, iDMC was responsible for completing the primary efficacy markers and safety assessment, while the sponsors, investigators, and project staff of the trial remained blind."|Recombinant 14-Valent Human Papillomavirus Vaccine (Types 6,11,16,18,31,33,35,39, 45,51,52,56,58,59) （Insect Cell）|t|f|t|f
33983737|NCT04000100|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33983738|NCT05701215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983739|NCT04339894|||COHORT||PROSPECTIVE|||||||
33983740|NCT00881556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983741|NCT01184196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983742|NCT03432247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983743|NCT05326659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983744|NCT02218905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983745|NCT01064570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983746|NCT03004105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983747|NCT00172458|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33983748|NCT04594278|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983749|NCT05037422|||OTHER||OTHER|||||||
33983750|NCT03436225|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983751|NCT03262688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, legal guardian and study personnel involved in the assessment of efficacy and safety are blinded to treatment.|Randomized, controlled|t|f|f|t
33983752|NCT02243930|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33983753|NCT05031884|||CASE_CONTROL||PROSPECTIVE|||||||
33983754|NCT06351683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded. Pharmacy will randomize and dispense capsules.||t|t|t|t
33983755|NCT06185777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983756|NCT02910037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983757|NCT03962673|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants are receiving the same treatment of which the UVB dose is adjusted for the participants Fitzpatrick skin type.||||
33900917|NCT04979208|||COHORT||RETROSPECTIVE|||||||
33900918|NCT03000452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900919|NCT04696835|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33900920|NCT06650163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900921|NCT00865254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900922|NCT06671431|||COHORT||RETROSPECTIVE|||||||
33900923|NCT02297217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900924|NCT04211324|||OTHER||OTHER|||||||
33900925|NCT02269319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900926|NCT00970294|NA|SINGLE_GROUP||||NONE||||||
33983758|NCT05778448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33900927|NCT06387238|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients With Metastatic Hormone Sensitive Prostate Cancer, will receive pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.||||
33900928|NCT06028776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The investigators will use a classic RCT approach, although participants randomized into the control group will be offered the intervention afterwards (hence, termed control-waitlist group).|f|f|t|t
33900929|NCT02163330|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900930|NCT05069363|NA|SINGLE_GROUP||TREATMENT||NONE||A feasibility study designed as a single centre and single-armed trial with embedded qualitative component||||
33771282|NCT00445263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771283|NCT02323035|NA|SINGLE_GROUP||OTHER||NONE||||||
33680959|NCT05633303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||For all the studies performed all patients will have a bipolar voltage map created in sinus rhythm. If patients are not in sinus rhythm at the start of the procedure, they will undergo DC cardioversion (DCCV) to achieve sinus rhythm. Low voltage zones (LVZs) will be defined as sites with a voltage \<0.5mV on bipolar voltage map. If patients have ≥30% of LVZs in the LA body excluding the PVs and mitral valve annulus, they will be classified as patients with underlying LVZs whilst those with a proportion of LVZs of \<30% will be defined as those without LVZs. The study protocol undertaken will be decided based on whether the patient has underlying LVZs or not.||||
33680960|NCT00254267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680961|NCT04670627|||CASE_CONTROL||PROSPECTIVE|||||||
33771284|NCT04003662|||COHORT||PROSPECTIVE|||||||
33680962|NCT00958438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680963|NCT04251676|||COHORT||RETROSPECTIVE|||||||
33680964|NCT01449942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680965|NCT02929043|||COHORT||PROSPECTIVE|||||||
33680966|NCT04565327|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771285|NCT00536068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771286|NCT04672356|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771287|NCT04280718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771288|NCT02934516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771289|NCT01778062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771290|NCT05390138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor did not aware of which groups the patients belongs to.|This is a 2-group randomisation controlled trial with 4-month and 12-month follow-up. The Experimental group will receive 4S intervention in relation to self-management and the Control group will receive general hygiene information.|f|f|f|t
33771291|NCT05424445|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the study, comparing the same drug but in different preparations, blinding is not deemed feasible.|||||
33771292|NCT00880321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771293|NCT05666375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771294|NCT01349413|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33771295|NCT02165085|||CASE_CONTROL||PROSPECTIVE|||||||
33771296|NCT01903408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771297|NCT02557906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771298|NCT01664936|||COHORT||PROSPECTIVE|||||||
33900931|NCT05819346|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33900932|NCT05671120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900933|NCT03300453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900934|NCT00231062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900935|NCT02636790|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33900936|NCT00775372|RANDOMIZED|CROSSOVER||||NONE||||||
33900937|NCT00746772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33900938|NCT06670027|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||Group A will receive a family voice message and Group B will be received nature sound|t|f|f|f
33900939|NCT02393651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900940|NCT05090358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900941|NCT01343719|RANDOMIZED|PARALLEL||||DOUBLE||||||
33900942|NCT01038492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900943|NCT04759911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900944|NCT05718076|||COHORT||PROSPECTIVE|||||||
33900945|NCT04838912|NA|SINGLE_GROUP||TREATMENT||NONE||Fifteen teenagers aged 13-17 years with an active ASD diagnosis and experiencing life interference anxiety symptoms will be divided into 3 groups and treated with the Cool Kids AST anxiety program||||
33900946|NCT02751307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900947|NCT02875210|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900948|NCT01568580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900949|NCT01469923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33900950|NCT02383719|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33900951|NCT02047487|||CASE_CONTROL||PROSPECTIVE|||||||
33900952|NCT04291014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a 16-week, randomized, phase II, parallel-group, dose-selection clinical trial of LT in participants with PD and co-existing sleep disruption using a comparative selection trial design.|f|f|f|t
33900953|NCT04472104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those doing data analysis are blind|3-year, randomized, unblinded, two-site, controlled trial of 8 weekly sessions of group Mindfulness-Based Cognitive Therapy for sexuality (MBCT-S) vs. 8 weekly sessions of a sex education treatment.|f|f|f|t
33900954|NCT00573131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900955|NCT00492921|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33900956|NCT02286141|||||PROSPECTIVE|||||||
33900957|NCT03094702|||COHORT||PROSPECTIVE|||||||
33900958|NCT06671288|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized controlled trial having two groups. One group will receive (interventional group) balloon-blowing exercises with abdominal \& lumbar core muscles activation position.~and the other group (control group) will receive Diaphragmatic breathing exercise."||||
33900959|NCT05869344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All participants (n=28) were randomly assigned by a staff member who had no contact with them into either a group receiving BPH treatment (5 g) or a placebo group. In this study, participants were blinded to treatment and received either BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage or the placebo (120 mL non-caloric commercial beverage).|A randomized, placebo-controlled clinical trial was carried out in 28 adults (65% female) to evaluate the effect of 5 g of BPH on postprandial glucose and insulin levels. After determining the participants metabolic status, the subjects were classified as either normal glucose tolerance (n=14) or prediabetes (n=14). Consequently, seven subjects with NGT and seven subjects with prediabetes were included in each treatment group (BPH or placebo).|t|t|t|f
33900960|NCT03633071|||COHORT||PROSPECTIVE|||||||
33900961|NCT02884466|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33983759|NCT00430196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983760|NCT00436553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33900962|NCT01765647|NA|SINGLE_GROUP||TREATMENT||NONE||All participants received open label AGY, a natural health product||||
33900963|NCT03045484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33900964|NCT00754429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900965|NCT04988893|||COHORT||PROSPECTIVE|||||||
33900966|NCT00779038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900967|NCT01804205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33900968|NCT03366844|NA|SINGLE_GROUP||TREATMENT||NONE||"Single Arm with Two Cohorts~1. Cohort 1: High-risk, ER-positive and HER2-negative breast cancer patients with primary tumors measuring at least 2cm~2. Cohort 2: TNBC patients with primary tumors measuring at least 2cm"||||
33983761|NCT01318499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983762|NCT00731705|||CASE_ONLY||PROSPECTIVE|||||||
33983763|NCT01722474|NA|SINGLE_GROUP||SCREENING||NONE||||||
33983764|NCT02627924|||CASE_ONLY||PROSPECTIVE|||||||
33983765|NCT04869787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983766|NCT05594472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A self controlled study on 2 contralateral comparative skin lesions|f|f|f|t
33983767|NCT06197529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33983768|NCT03248362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants \& primary researchers will be blinded to group allocation|A pragmatic, multicentre, placebo controlled randomised parallel group trial|t|f|t|t
33983769|NCT04336930|||COHORT||PROSPECTIVE|||||||
33983770|NCT04499729|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will utilize a pragmatic, system-wide rollout quality improvement evaluation design. Data from patients in the Rush Collaborative Care service will be used beginning Dec 1, 2019. The first care manager will begin offering IntelliCare as part of the collaborative care service in September, 2020, and one additional care manager will begin offering IntelliCare to patients every 3 months||||
33983771|NCT00611819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983772|NCT04470180|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983773|NCT02313688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983774|NCT02549651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983775|NCT03236753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983776|NCT02726425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983777|NCT06118593|||COHORT||PROSPECTIVE|||||||
33983778|NCT06064136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983779|NCT03115840|||COHORT||PROSPECTIVE|||||||
33983780|NCT05754632|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A single randomized control trial will compare the use of exercises augmented with BFRT with quantitative measurements of strength and patient-reported outcomes. A total of 40 youth and adolescent patients undergoing a surgical procedure for ACLR and subsequent physical therapy at our institution will be recruited for this study.~Patients will be randomized into one of two groups using computer randomization for allocation: the intervention group receiving BFRT as part of physical therapy, and the control group will follow the institution's standard ACLR rehabilitation protocol. Both groups will follow a time- and criterion-based standardized rehabilitation protocol. The primary outcomes will be isometric and isokinetic knee peak torque and limb symmetry indices. Secondary outcomes will be quadriceps hypertrophy via mid-thigh circumference and patient-reported outcomes."||||
33983781|NCT06048419|NA|SINGLE_GROUP||TREATMENT||NONE||prospective cohort||||
34024716|NCT06362694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024717|NCT00003577|RANDOMIZED|||TREATMENT||||||||
33680967|NCT01239732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33680968|NCT02996058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33680969|NCT03409978|||CASE_ONLY||PROSPECTIVE|||||||
33680970|NCT04592952|NA|SINGLE_GROUP||OTHER||NONE||||||
33680971|NCT01278927|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33680972|NCT02061319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680973|NCT00182481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33680974|NCT04203277|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention effectiveness on improving vaccination rates will be evaluated using a SW-CRT. 36 Eight practices (clusters) will eventually be randomized to receive the IVY intervention over a 13-month study period. Patients are clustered within practices, and outcomes will be assessed on cross-sectional samples of individuals at each practice at 13 discrete, monthly time points. There will be a baseline block of two months where all practices will be in the control group (Figure 3). Following this, two practices will be randomly assigned to receive the intervention (Group 1). Two months after initiation of IVY in Group 1, two practices will be randomly assigned to receive the intervention in Group 2. This will be continued for 4 total Groups. There will be a five-month block after implementing IVY in all practices where data will continue to be collected after all have been assigned to receive the intervention.||||
33680975|NCT03359018|NA|SINGLE_GROUP||TREATMENT||NONE||Every patients will received apatinib 500mg or 250mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects||||
33680976|NCT02683590|NA|SINGLE_GROUP||OTHER||NONE||||||
33680977|NCT05139511|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Clinical experimental controlled trial, double-blind in which participants will be randomized into 2 groups: a study group and a control group|t|f|t|f
33680978|NCT03032302|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33680979|NCT03160313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33680980|NCT01238627|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33680981|NCT01447667|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33680982|NCT01576159|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33680983|NCT00304213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33680984|NCT04316910|||CASE_CONTROL||PROSPECTIVE|||||||
33680985|NCT04249232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|Parallel assignment with randomization|t|t|t|t
33680986|NCT04612608|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention arm will undergo a protocol of 4x per day bed elevation to 60 degrees for 30 minutes.||||
33900969|NCT06408194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900970|NCT06397261|||CASE_ONLY||PROSPECTIVE|||||||
33983782|NCT06091007|RANDOMIZED|PARALLEL||OTHER||NONE||Group 1: participants take 200 mg of magnesium citrate daily for 4 weeks. Group 2: participants take 400 mg of magnesium citrate daily for 4 weeks.||||
33983783|NCT03447717|NA|SINGLE_GROUP||TREATMENT||NONE||patients meeting the inclusion criteria are included||||
33983784|NCT01359566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983785|NCT03951532|||COHORT||RETROSPECTIVE|||||||
33983786|NCT01568476|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33983787|NCT04000217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983788|NCT01077596|||CASE_CONTROL||RETROSPECTIVE|||||||
33983789|NCT04459273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33983790|NCT01346527|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983791|NCT04191993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983792|NCT01536405|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33983793|NCT01958463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983794|NCT02100228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983795|NCT03038048|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33983796|NCT01866319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983797|NCT04391062|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33983798|NCT00148837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33983799|NCT05188742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Treatment sequence: randomized with 1:1 ratio to either Sequence A or Sequence B Sequence A: mirabegron 50mg monotherapy x 8 weeks -\> multi-modal combination treatment x 4 weeks -\> TTNS monotherapy x 8 weeks Sequence B: TTNS monotherapy x 8 weeks -\> multi-modal combination treatment x 4 weeks -\> mirabegron 50mg monotherapy x 8 weeks||||
33983800|NCT00614952|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33983801|NCT00533273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983802|NCT06000709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33983803|NCT02297932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983804|NCT00906165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983805|NCT03621579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983806|NCT03557762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33983807|NCT00167739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983808|NCT03892694|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Sham controlled.|Prospective, multi-centre, randomised, blinded, sham controlled trial with 1:1 randomisation. Sham-control arm subjects are eligible to receive treatment after the 6-month visit.|t|t|f|t
33983809|NCT05768048|||COHORT||PROSPECTIVE|||||||
33680987|NCT01215929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33680988|NCT04097951|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33680989|NCT04363190|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33680990|NCT05680116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33983810|NCT05851937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983811|NCT01245907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983812|NCT04366401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two-arm, double-blind, randomized clinical trial in balanced blocks of six months of intervention will be developed in a group of 50 individuals (25 for the intervention group -IG-,25 for the control group -CG-). The GC will receive conventional dietary advice on an individual basis. In the IG, an individual diet-nutrition education program with high prebiotic and probiotic content will be established. Data on psychopathological status (PANSS and PSP scales), and blood tests (haemogram, lipid profile, etc.),at the beginning, after three and six months. The estimate of intestinal microbiota and the usual nutritional pattern will be assessed at baseline and at six months, using a stool test and a validated food frequency questionnaire, respectively. To assess the degree of adherence, IG participants will fill in a specific weekly record of the main dishes/foods consumed. Anthropometric parameters will be analysed monthly (BMI, blood pressure, heart rate, abdominal perimeter).|t|t|f|f
33983813|NCT03264898|||COHORT||CROSS_SECTIONAL|||||||
33983814|NCT01503307|||CASE_ONLY||PROSPECTIVE|||||||
33983815|NCT02982408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983816|NCT03642548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A placebo-controlled double-blind randomized study||t|t|t|t
33983817|NCT05996510|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983818|NCT05612724|NA|SINGLE_GROUP||OTHER||NONE||Pilot study to assess feasibility of testing asymptomatic dental patients for SARS-CoV-2 antigen using Rapid Antigen point-of-care testing||||
33983819|NCT04018339|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33983820|NCT05039190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||To confirm the efficacy of HBM9161 subcutaneous injection for the treatment of gMG in Chinese patientsTreatment|t|t|t|t
33983821|NCT04970992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983822|NCT05352360|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will help to compare the effects of pilates Exercises with kinesiotaping and on other hand the effects of muscle energy technique with kinesiotaping for improving pain||||
33983823|NCT00185705|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33983824|NCT02498847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33983825|NCT04406753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983826|NCT00535951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983827|NCT03524469|||COHORT||PROSPECTIVE|||||||
33680991|NCT04618627|||OTHER||PROSPECTIVE|||||||
33680992|NCT03489746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All data will be analysed anonymously|Cluster randomized controlled trial at practice level|f|f|t|t
33680993|NCT05232409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33680994|NCT05377697|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33983828|NCT00000229||||TREATMENT||||||||
33983829|NCT00233597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983830|NCT03659006|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33983831|NCT03184480|||COHORT||PROSPECTIVE|||||||
33983832|NCT06485999|||CASE_ONLY||RETROSPECTIVE|||||||
33983833|NCT01421030|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33983834|NCT00071591|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33983835|NCT05968066|||COHORT||PROSPECTIVE|||||||
33771299|NCT00855868|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33680995|NCT03355469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Each subject will be randomly assigned to receive low intensity exercise training + placebo, high intensity exercise training + placebo, or these exercise programs with metformin.|t|t|t|t
33680996|NCT06029257|||COHORT||PROSPECTIVE|||||||
33680997|NCT05027360|||COHORT||RETROSPECTIVE|||||||
33680998|NCT04451876|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33680999|NCT02929654|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33681000|NCT00291213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771300|NCT01395043|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33771301|NCT00387257|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33771302|NCT00268619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771303|NCT00953095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33771304|NCT01476917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771305|NCT01226628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771306|NCT05348343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771307|NCT01551303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33771308|NCT06110845|||COHORT||PROSPECTIVE|||||||
33771309|NCT05273086|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized controlled trial|f|t|t|t
33771310|NCT04963972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771311|NCT05745480|||OTHER||OTHER|||||||
33771312|NCT06144268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771313|NCT05391360|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33771314|NCT03551808|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33771315|NCT03017235|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33771316|NCT02123290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771317|NCT00004203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771318|NCT05903430|||COHORT||PROSPECTIVE|||||||
33771319|NCT05216224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded placebo drug is packaged to match the active study drug and will be stored under the same conditions.|Randomized, double-blind, placebo-controlled study|t|t|t|t
33771320|NCT05266651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771321|NCT01119339|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33771322|NCT00854295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771323|NCT03119337|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will conduct a prospective, un-blinded, randomized control trial (RCT) among VMMC clients in a 1:1 ratio of control to intervention. Study participants and clinic staff are not masked to treatment.||||
33771324|NCT02067637|||CASE_CONTROL||PROSPECTIVE|||||||
33771325|NCT03912220|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33771326|NCT06031909|||COHORT||PROSPECTIVE|||||||
33771327|NCT01868074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771328|NCT00900575|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33900971|NCT00537940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33900972|NCT02313480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900973|NCT06369428|||COHORT||RETROSPECTIVE|||||||
33900974|NCT00649298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900975|NCT05263882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900976|NCT04575350|||COHORT||RETROSPECTIVE|||||||
33900977|NCT00537745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900978|NCT03774017|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33900979|NCT06430554|||COHORT||PROSPECTIVE|||||||
33900980|NCT00997412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33900981|NCT02719483|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983836|NCT05804890|||CASE_CONTROL||PROSPECTIVE|||||||
34024718|NCT06633341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681001|NCT02617485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681002|NCT03254576|||COHORT||PROSPECTIVE|||||||
33681003|NCT05662670|NA|SEQUENTIAL||TREATMENT||NONE||||||
33681004|NCT05702346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681005|NCT00770380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681006|NCT03014999|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33681007|NCT04645121|||CASE_CONTROL||PROSPECTIVE|||||||
33681008|NCT05120063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33681009|NCT02449746|RANDOMIZED|PARALLEL||OTHER||NONE|open label|||||
33681010|NCT03328884|NA|SINGLE_GROUP||TREATMENT||NONE||This is an international, prospective, open-label, multicenter, single arm, two-stage Simon Design phase II clinical trial||||
33681011|NCT01688206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681012|NCT01022008|NA|SINGLE_GROUP||OTHER||NONE||||||
33771329|NCT04702100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|instrument assisted soft tissue mobilization and integrated neuromuscular inhibition technique|t|f|f|t
33771330|NCT03352063|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomly assigned to either the sitting plus exercise or walking plus exercise.||||
33771331|NCT06229184|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33771332|NCT02578225|||COHORT||PROSPECTIVE|||||||
33771333|NCT04160611|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two randomized groups receiving midazolam/not receiving midazolam premedication before oocyte aspiration procedures as part of IVF procedures||||
33839592|NCT02532127|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33839593|NCT00645177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839594|NCT05864651|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33839595|NCT05355740|||CASE_ONLY||PROSPECTIVE|||||||
33839596|NCT00733252|||CASE_ONLY||RETROSPECTIVE|||||||
33839597|NCT00292422|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33839598|NCT02963948|||OTHER||PROSPECTIVE|||||||
33839599|NCT00770900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839600|NCT01007110|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33839601|NCT01030393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839602|NCT03270800|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33900982|NCT06288386|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Split-mouth design|t|f|f|t
34024719|NCT02045589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681013|NCT03877640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Three blinded protocols available on the device, so care provider will not know to which treatment subject is randomized. Active treatment is not blinded for use in open label portion of study.|Active and sham arms 2:1 run parallel. Upon completion, sham patients repeat visits with open label treatment.|t|t|t|f
33681014|NCT00511940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681015|NCT05595759|RANDOMIZED|PARALLEL||OTHER||SINGLE|"In this study, the names of the patients hospitalized in the two wards will be sorted and numbered in alphabetical order. After the numbering process, the patients will be selected to the experimental and control group by using the https://www.randomizer.org/ site by an independent specialist.~In this study, the names of the patients hospitalized in the two wards will be sorted and numbered in alphabetical order. After the numbering process, the patients will be divided into an experimental and control group using the https://www.randomizer.org/ site by an independent specialist."|randomized controlled trial|t|f|f|f
33681016|NCT02901665|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771334|NCT03288389|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants will be randomized by a nurse consultant into placebo and supplement arms and will be masked from lead investigator, physician participants and research nurse coordinator. Placebo and Product will be in identical white numbered bottles and look, feel, taste and smell the same. Data will be collected independently online by a specialty company and after the trial is completed, it will be transferred to an independent statistical unit at the University of California, Irvine for analysis and at that time the code will be broken for analysis purposes.|The purpose of this study is to determine the clinical effectiveness of an all-natural, patented, Food and Drug Administration (FDA)-approved oral lipid nutritional supplement (NTFactor Lipids) on reducing pain, fatigue and other symptoms and improving quality of life in Fibromyalgia and other related conditions. The investigators will evaluate the efficacy of a dietary product called NTFactor Lipids made by Nutritional Therapeutics, Inc. of New York on pain, fatigue and gastrointestinal symptoms as well as quality of life indicators in adult male and female subjects. The addition of NTFactor Lipids to the diet is expected to improve cellular energy function, decrease fatigue and pain and lower the severity of other symptoms and improve quality of life indicators in Fibromyalgia patients. This study will be a randomized, placebo-controlled, cross-over study.|t|t|t|f
33771335|NCT03764358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33771336|NCT03165162|NA|SINGLE_GROUP||OTHER||NONE||||||
33771337|NCT05989321|||COHORT||RETROSPECTIVE|||||||
33771338|NCT03698864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771339|NCT04559490|||COHORT||PROSPECTIVE|||||||
33771340|NCT04883593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771341|NCT01614574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771342|NCT03477786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33771343|NCT04360122|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase III, randomized, open labelled, clinical trial on one hundred adult healthy healthcare workers||||
33771344|NCT03509376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapist doing the clinical examinations at different phases of the study|Patients are randomised to a suture repair or suture with mesh repair|f|f|f|t
33771345|NCT02446093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900983|NCT06145490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"The study entails two sessions with a cross-over design. Participants will be randomized to start with either the caffeine condition or the placebo condition.~The study includes two arms: (a) participants with Panic Disorder (anticipated n = 50) and (b) Healthy controls (anticipated n = 50). Both arms (Panic Disorder and Healthy controls) will complete both conditions with the two sessions (caffeine and placebo condition) in randomized order."|t|f|t|f
33900984|NCT02973815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33900985|NCT00680420|||COHORT||PROSPECTIVE|||||||
33900986|NCT05767957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Control group: rehabilitation physiotherapy by physiotherapist using conventional technique alone.~Intervention group: rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies."|t|f|t|f
33900987|NCT04007029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900988|NCT01948934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900989|NCT01223911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33900990|NCT05485012|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33983837|NCT05083221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||In this single-blind, randomized controlled trial, older adults aged 65 years or older with hearing impairment will be randomized into either the intervention group (Hear-Talk-Activity intervention group) or the control group (waitlist control group)|f|f|f|t
33983838|NCT00059865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983839|NCT05237310|RANDOMIZED|CROSSOVER||SCREENING||NONE||"Subjects will be randomized to one of four groups (arms), Group A1, A2, B1 and B2:~Group A1: Subjects will undergo standard colonoscopy immediately followed by CAD-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session). Group A2: Subjects will undergo CAD-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session). Group B1: Subjects will undergo standard colonoscopy immediately followed by combined CAD-EYE and G-EYE colonoscopy (both procedures performed by the same endoscopist in the same sedation session). Group B2: Subjects will undergo combined CAD-EYE and G-EYE colonoscopy immediately followed by standard colonoscopy (both procedures performed by the same endoscopist in the same sedation session)."||||
33983840|NCT01726205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983841|NCT00704821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983842|NCT04154579|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial utilizing a mixed methods, pre-post intervention, and parallel group analysis.||||
33983843|NCT03799653|||COHORT||PROSPECTIVE|||||||
33771346|NCT00453102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771347|NCT00759772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771348|NCT02589041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983844|NCT04873310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In all the assessments, the principal investigator and research assistants will be blind to the trial arm where the schools/students were allocated||f|f|t|t
33983845|NCT05818709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983846|NCT00558857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771349|NCT04724356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771350|NCT02392884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771351|NCT00334867|RANDOMIZED|||TREATMENT||||||||
33771352|NCT02450773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33900991|NCT06672562|RANDOMIZED|PARALLEL||TREATMENT||NONE|Data analysts will be masked as to treatment arms.|||||
33983847|NCT01033305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983848|NCT01097993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983849|NCT02775357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33983850|NCT01314417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983851|NCT01176071|||COHORT||RETROSPECTIVE|||||||
33983852|NCT01603862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983853|NCT05752994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33983854|NCT06179056|||CASE_ONLY||CROSS_SECTIONAL|||||||
33983855|NCT02258620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771353|NCT03629990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771354|NCT02930564|NA|SINGLE_GROUP||OTHER||NONE||||||
33771355|NCT03115008|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771356|NCT03198793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771357|NCT02085837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33771358|NCT02479035|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33771359|NCT01874093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771360|NCT04263792|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771361|NCT03308760|||COHORT||PROSPECTIVE|||||||
33983856|NCT02185872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983857|NCT04547517|||COHORT||CROSS_SECTIONAL|||||||
33983858|NCT00862979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983859|NCT00639028|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983860|NCT03687515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983861|NCT02818842|||COHORT||PROSPECTIVE|||||||
33983862|NCT03638739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33983863|NCT04971226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33900992|NCT03641300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized into the study using a permuted block method with a random number generator. The study statistician will prepare the randomization scheme. The block size will be fixed and study personnel will be blinded to the randomization block size|The study is a randomized, double blind, parallel-group clinical trial with two treatment arms conducted at three academic institutions: the Temerty Centre for Therapeutic Brain Intervention based at CAMH in Toronto, ON; the Ontario Shores Centre for Mental Health Sciences in Whitby, Ontario; and UBC Hospital based at the University of British Columbia in Vancouver, BC. CAMH aims to recruit 40 participants. Parkwood Institute and UBC Hospital aim to recruit 30 participants each.|t|t|f|t
33900993|NCT00312351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33900994|NCT02698423|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33983864|NCT01805934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983865|NCT01265225|||CASE_ONLY|||||||||
33983866|NCT01248247|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983867|NCT05246462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were blinded to treatment allocation. The investigator delivered the intervention and, therefore, could not be blinded to allocation.|This study was conducted between 25 March-15 December 2019 as a single-blind randomized controlled trial.|t|f|f|f
33983868|NCT01944332|NA|SEQUENTIAL||TREATMENT||NONE||||||
33983869|NCT03770598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Non-Distressed patients will be randomized to receive intervention or standard of care.~Distressed patients will be randomized to receive intervention or standard of care"||||
33983870|NCT06273033|||OTHER||RETROSPECTIVE|||||||
33983871|NCT00443716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079394|NCT05191966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Sealed opaque envelopes containing study participation numbers will be used to assign each patient. A researcher not involved in patient follow-up will use the web-based Research Randomizer (Urbaniak and Plous 2013) tool to give each participation number to a random group with a 1:1 ratio.~A nurse not an active investigator in the study will have each participant choose an envelope containing the study participation number. They will inform the anesthetist who will administer the block/blocks about which group the patient is in immediately before administration. Researchers, patients, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program, 'Research Randomizer (Urbaniak and Plous 2013)'.|t|t|t|t
34079395|NCT01205347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079396|NCT05181098|||COHORT||PROSPECTIVE|||||||
34079397|NCT04940156|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33681017|NCT03911102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33983872|NCT00667095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983873|NCT00534443|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33681018|NCT00601952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681019|NCT03917524|||COHORT||PROSPECTIVE|||||||
33681020|NCT03759808|NA|SINGLE_GROUP||TREATMENT||NONE||An open trial will be conducted in patients with persistent post-concussion symptoms compared to non-injured controls in order to determine whether the intervention (controlled breathing and cognitive behavioral therapy for anxiety) improves parasympathetic, HPA axis activity and cerebral blood flow, and whether improvement in parasympathetic and HPA axis activity predicts reduction in PPCS symptoms. We will compare baseline evaluations to the evaluation conducted after brief CBT and controlled breathing training to demonstrate the feasibility of normalizing parasympathetic, and HPA axis activity via this intervention. If we obtain the predicted results in the current study we will design a much larger study to identify the mechanisms of change. Healthy, non-injured control participants will provide normative data on all measures except for concussion-relevant outcomes.||||
33983874|NCT00765622|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33983875|NCT05502978|NA|SINGLE_GROUP||OTHER||NONE||||||
33983876|NCT02758665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983877|NCT03435081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983878|NCT00874887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33983879|NCT00709566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33983880|NCT04083846|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33983881|NCT01895296|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33983882|NCT03874871|||COHORT||PROSPECTIVE|||||||
33983883|NCT05843279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A physiotherapist outside the study was in charge of carrying out the first evaluation in the first week of life of the infant. Another physiotherapist was in charge of applying the physiotherapy intervention. After completion of the intervention, all infants were reassessed by another physiotherapist outside the study.|Myofunctional Therapy is performed in one group and a breastfeeding session is performed in another group.|t|f|t|t
33983884|NCT04453878|||OTHER||PROSPECTIVE|||||||
33681021|NCT03743077|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079398|NCT03946059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|"Investigators will assess for each subject whether they have any guess, a priori, as to hypothesized effects of the iTBS vs. cTBS protocols (improve, impair or no change on cognition). Participant/care provider will know which stimulation is being applied (iTBS, cTBS based on labels A \& B), but will not know the hypothesized effects of these two protocols. iTBS and cTBS protocols will be masked as treatment A and treatment B, prior to handing the data over to PI/outcomes assessor. Analyses will thus be performed to assess whether treatment A or treatment B has an effect on cognition; and whether there are differences between these treatment protocols."|The investigators will test the effects of two different interventions (iTBS, cTBS) on cognitive control. Each participant will receive both interventions, labeled A \& B, separated a week apart.|t|t|t|t
34079399|NCT03374839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079400|NCT04703985|||COHORT||PROSPECTIVE|||||||
34079401|NCT02740842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079402|NCT04265521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681022|NCT05071651|||COHORT||PROSPECTIVE|||||||
34079403|NCT02410408|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34079404|NCT01153919|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33681023|NCT02061527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681024|NCT00256971|||||PROSPECTIVE|||||||
33681025|NCT01696162|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33681026|NCT03561532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant and the treating personnel are blinded of the randomization result.|Participants are randomized in two groups to receive in colonoscopy either a fecal suspension made of their own feces or a fecal suspension of a healthy donor.|t|t|t|t
33681027|NCT02165241|||CASE_CONTROL||PROSPECTIVE|||||||
33681028|NCT00205907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681029|NCT00796926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681030|NCT03499964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681031|NCT02108015|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681032|NCT04503187|||COHORT||PROSPECTIVE|||||||
33681033|NCT00769327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681034|NCT01337999|||COHORT||PROSPECTIVE|||||||
33681035|NCT01604993|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33681036|NCT05599477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681037|NCT03310333|RANDOMIZED|PARALLEL||TREATMENT||NONE|open|||||
33681038|NCT00198887|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33681039|NCT00603642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681040|NCT03015480|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33681041|NCT01100476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681042|NCT00400803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681043|NCT02143050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681044|NCT00710762||PARALLEL||PREVENTION||||||||
33681045|NCT03284918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681046|NCT03725462|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33681047|NCT04564300|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||We will compare the recovery in a group of oral contraceptive users to a group of women not using oral contraceptives||||
33681048|NCT04951323|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681049|NCT02285062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681050|NCT04043598|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double-blind randomized|Multi-center investigator-initiated randomized-controlled double blind clinical trial comparing to already established treatment protocols.|t|t|t|t
33681051|NCT02581150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681052|NCT00317278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33681053|NCT00853996|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681054|NCT02074891|||COHORT||PROSPECTIVE|||||||
33681055|NCT02586506|NA|SINGLE_GROUP||OTHER||NONE||||||
33681056|NCT04392700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681057|NCT03515954|||COHORT||PROSPECTIVE|||||||
33681058|NCT02184455|NA|SINGLE_GROUP||TREATMENT||NONE||Diabetic type I/II patients with chronic ulcer present||||
33681059|NCT05981976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681060|NCT03740893|RANDOMIZED|PARALLEL||OTHER||NONE||"Window of opportunity (WOP), open-label, multi-centre, phase IIa trial comprising multiple non-comparative treatment cohorts with patient allocation via randomisation.~The trial consists of two parts: a post-neoadjuvant chemotherapy preoperative WOP component (PART 1); and a post-operative component (PART 2)."||||
33681061|NCT01974739|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33681062|NCT04966858|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatments are not to be blinded, since both the patients and clinicians who work with this population are highly skilled at estimating kcal and would be able to determine group assignment by simply viewing meal trays.|Participants will be recruited upon hospital admission at the University of California, San Francisco (UCSF) and Stanford and randomly assigned to Individualized Caloric Refeeding (ICR) or Higher Calorie Refeeding (HCR) for the duration of the hospitalization. Treatment ends at hospital discharge with open follow-up for one year. Participants followed daily in hospital and at 3mo, 6mo, 9mo, and 12mo post-discharge.||||
33681063|NCT02787486|||FAMILY_BASED||PROSPECTIVE|||||||
33681064|NCT00189774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681065|NCT00543244|||CASE_ONLY||CROSS_SECTIONAL|||||||
33681066|NCT06427083|||CASE_ONLY||PROSPECTIVE|||||||
33771362|NCT01248520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33771363|NCT02848612|||COHORT||RETROSPECTIVE|||||||
33771364|NCT01917305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079405|NCT04096846|||COHORT||PROSPECTIVE|||||||
34079406|NCT03856372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079407|NCT00898430|||CASE_ONLY||PROSPECTIVE|||||||
34079408|NCT05944575|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be told if the location of the clip electrode will be for active taVNS or for sham-taVNS.|Treatment for each patient will crossover (after one week) from an active taVNS to an inactive sham-taVNS treatment or vice versa (depending on randomization).|t|f|f|f
33681067|NCT05297318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|patients and care providers did not know the whether the hypotension prediction index use during the operation.|The patients receive elective major gastrointestinal surgery with older than 65 years old. These patients have divided into two groups, including with/without HPI guided. The intraoperative hypotension incidence has been measured.|t|t|f|f
33681068|NCT00858572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681069|NCT06272227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681070|NCT03513107|||CASE_ONLY||CROSS_SECTIONAL|||||||
33681071|NCT06261281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33681072|NCT06492655|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681073|NCT02691871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681074|NCT03457779|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Patients with TNBC will receive \[1,2-13C\]-glucose IV to prior to undergoing a biopsy of their breast cancer and blood collection to allow for in depth evaluation.||||
33681075|NCT01213576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771365|NCT03349372|||COHORT||RETROSPECTIVE|||||||
33771366|NCT05473091|||CASE_CONTROL||RETROSPECTIVE|||||||
33771367|NCT02144519|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771368|NCT01829893|RANDOMIZED|CROSSOVER||||NONE||||||
33771369|NCT05433896|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33771370|NCT01501916|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33771371|NCT04149041|||CASE_ONLY||RETROSPECTIVE|||||||
33771372|NCT03625505|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771373|NCT04448236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Assessor for the primary outcome (maximum voluntary isometric contraction, MVIC) of knee extension, functional outcomes(6-minute walk test, Short Physical Performance Battery), will be blinded to the allocated study group.|"Participants are randomized into one of the two treatment groups by drawing enclosed envelops which contain the random allocation of participants to intervention group (training with BFR-device and control group (training without the device). The envelopes are opened after inclusion for the individual participant only.~Stratification of participants into two groups by maximum voluntary isometric contraction (MVIC) at baseline before randomization will be done. The cutoff for the stratification will be determined from the data in the recent service."|f|f|f|t
33771374|NCT03621982|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771375|NCT02096133|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33771376|NCT00822315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771377|NCT00204308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771378|NCT04998695|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Oils were provided in unlabelled bottles (only differed in the colors of stoppers)|"After a 3-week run-in, healthy and at risk (hypercholesterolemic) volunteers were randomly allocated to one of each arm.~Each intervention stage lasted 4 weeks and was separated by a 3-week wash-out."|t|f|f|f
33771379|NCT05200637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with true coronary bifurcation lesions will be randomized to undergo two-stent DK-crush technique with Orsiro or Xience. Another parallel prospective registry will enroll patients with bifurcation lesions treated with provisional one-stent strategy.||||
33771380|NCT01990820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771381|NCT02930642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771382|NCT02444234|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771383|NCT02818660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771384|NCT00060463|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771385|NCT06526702|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Single-center, randomized, crossover study with 24 participants. The study will investigate the effect of high-flux hemodialysis (using the FX CorDiax 100 dialyzer) and post-dilution HDF (using the FX CorDiax 1000 dialyzer) on the intradialytic kinetics of selected cardiac biomarkers. The study will not be blinded, but the order of the interventions will be randomized. The two dialysis sessions will be conducted on the same weekday. Between the two interventions, the patient will have a wash-out period of 1-3 weeks with standard dialysis treatment.||||
33771386|NCT01598974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771387|NCT04136535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771388|NCT03900143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33900995|NCT05582837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No masking: care provider|Participants will be assigned to a study group by chance (like a coin flip) rather than by a medical decision made by the researchers. There are two arms in the study (treatment group which consists of nortriptyline + topiramate, control group which consist of hydrochlorothiazide plus triamterene with placebo), and participants enrolling in the trial will be randomly assigned in a 1:1 fashion to one of the arms. The participant will remain in the same arm for the duration of the study (8 weeks). There may be multiple participants in each arm who are undergoing the study at the same time (parallel model).|t|f|t|t
33900996|NCT01408537|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33900997|NCT03088904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33771389|NCT01898143|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33771390|NCT01054872|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33771391|NCT00955734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771392|NCT04027205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771393|NCT03781713|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"To evaluate the impact of the tool on the time of stabilization of patients, two groups will be compared: the first will be composed of patients who did not triggered triggers and the second by patients who triggered triggers and had interventions.~For the calculation of the stabilization time, the long-term risk rating of the Epimed Performance software will be used, which allows us to estimate the length of ICU stay of the patients individually using more than 60 variables."||||
33771394|NCT04704401|||COHORT||PROSPECTIVE|||||||
33771395|NCT04939311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771396|NCT01674257|||COHORT||PROSPECTIVE|||||||
33771397|NCT05700006|||COHORT||PROSPECTIVE|||||||
33900998|NCT05435248|NA|SEQUENTIAL||TREATMENT||NONE||||||
33900999|NCT02696512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901000|NCT04957498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901001|NCT04249453|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901002|NCT01645280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901003|NCT04985708|||COHORT||PROSPECTIVE|||||||
33901004|NCT06040567|||OTHER||PROSPECTIVE|||||||
33901005|NCT02947451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33901006|NCT00364039|RANDOMIZED|PARALLEL||||DOUBLE||||||
33901007|NCT06071286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901008|NCT05217862|||CASE_ONLY||PROSPECTIVE|||||||
33901009|NCT05099601|NA|SINGLE_GROUP||TREATMENT||NONE||Each side of the patients' face will be randomly allocated to either topical silymarin 0.7% and microneedling or topical silymarin 0.7% alone.||||
33901010|NCT00894530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901011|NCT04368130|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33901012|NCT02112318|||COHORT||PROSPECTIVE|||||||
33901013|NCT02247206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901014|NCT02935881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901015|NCT00354068||||TREATMENT||||||||
33901016|NCT03414567|||OTHER||OTHER|||||||
33901017|NCT05746780|||CASE_ONLY||RETROSPECTIVE|||||||
33901018|NCT06585930|||OTHER||PROSPECTIVE|||||||
33901019|NCT04562623|||COHORT||PROSPECTIVE|||||||
33901020|NCT01418222||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901021|NCT02061007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901022|NCT05014282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901023|NCT01382563|||CASE_ONLY||OTHER|||||||
33901024|NCT03870022|NA|SINGLE_GROUP||OTHER||NONE||||||
33901025|NCT05533242|NA|SEQUENTIAL||TREATMENT||NONE||A modified 3+3 design is used. The applied dose of Lu-177-labeled-6A10Fab-fragments to the resection cavity will be escalated in three cohorts until the maximum tolerated dose (MTD) is determined.||||
33901026|NCT02035072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901027|NCT03067558|||CASE_ONLY||PROSPECTIVE|||||||
33901028|NCT06672354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901029|NCT00677963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901030|NCT06594406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901031|NCT06229366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901032|NCT03454139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33901033|NCT06449105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33901034|NCT03873350|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participants will be masked, meaning they will not know if they are given living or sterilized kombucha. The control group consuming water will know that they are the control group.|The participants will be divided into three groups in which one is given living kombucha, one heat-sterilized kombucha (placebo group) and one regular tap water (control group).|t|f|t|f
33901035|NCT06512857|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901036|NCT06633497|||COHORT||PROSPECTIVE|||||||
33901037|NCT05068596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901038|NCT02961764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771398|NCT03417882|NA|SINGLE_GROUP||TREATMENT||NONE||The study will follow a Simon two-stage design \[1\] with up to 64 subjects enrolled. All subjects will receive GRN-1201 at a dose of 3.0 mg per peptide in combination with 75 µg sargramostim (Leukine®) and 200 mg pembrolizumab.||||
33901039|NCT00487279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983885|NCT03065582|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33983886|NCT03966560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective controlled clinical trial||||
33983887|NCT01909076|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983888|NCT02987491|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33983889|NCT04331847|||OTHER||CROSS_SECTIONAL|||||||
33983890|NCT02137993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983891|NCT01270919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983892|NCT03549364|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771399|NCT03817346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blinde|Single ascending dose|t|t|t|f
33901040|NCT00193362|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901041|NCT03417258|||OTHER||CROSS_SECTIONAL|||||||
33901042|NCT04295304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901043|NCT04095416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two arms, one interventional group and one control. Interventional group receives compression wraps and standard medical care, control group only receives standard medical care|f|f|t|t
33901044|NCT04805372|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Students and teachers are not blinded, but researchers and data evaluators are blinded.|Before the allocation, the instructor led the trainees to watch the demonstration video of the central vein operation and explained the main points of the operation at least 5 times.Before the operation, trainees should complete the operation-related test questions. And trainees should complete at least one central venipuncture model training and one actual operation under the personal guidance of the instructor before allocation.They will then be assigned to review a video of an expert performing central vein operation (VD alone), or both the expert video and a video of their own most recent operation(VD+VF), before returning to do another central vein operation. This will be repeated for a total of 5 central vein operation encounters and 5 video reviews.In the second week, each trainee completed at least 5 independent operations under the supervision of the instructor.|f|f|t|t
33901045|NCT00000960||||TREATMENT||||||||
33901046|NCT00338936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901047|NCT03804346|||COHORT||PROSPECTIVE|||||||
33901048|NCT03995407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel 2-arm pilot randomized controlled trial|f|f|f|t
33983893|NCT04863586|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33983894|NCT00567177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771400|NCT00450515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771401|NCT06102031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901049|NCT02502630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901050|NCT01399827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983895|NCT02624557|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33983896|NCT04753710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983897|NCT02210390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983898|NCT03571880|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983899|NCT04785677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771402|NCT05887284|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind clinical trial.||t|f|t|t
33771403|NCT00028314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771404|NCT03732586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomly assigned to one of the two treatments. The randomization is done through a computer generated system. The labelling will be done by a pharmacist or similar. Envelopes with randomization listings will be stored in a secure environment within the Hospital. Blinding should be maintained throughout the study. The randomization code should not be broken during the course of the study unless it is necessary for the safety of the subjects, as judged by the investigator. The date, time and reason for unmasking must be recorded, along with the researcher's signature. The rupture of the study blind will be done once the database has been blocked. The study will be double-blind, which means that neither the patients nor the study site staff will have access to the randomization code until the code is broken.|Randomized, Double-blind clinical trial.|t|f|f|f
33771405|NCT03967405|||COHORT||PROSPECTIVE|||||||
33771406|NCT01315275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771407|NCT02353832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681076|NCT03741478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants will be masked to:~1. Knowing whether they were assigned to the olanzapine or placebo conditions~2. Knowing whether they were assigned to the intranasal insulin or intranasal placebo conditions.~Investigators will only be masked to the randomization of placebo or olanzapine for the participants, but will know whether the participant receives intranasal insulin or intranasal placebo. In the Cognitive Arm, a separate staff member who is unaware of drug condition will administer cognitive assessments."|"This study will follow a single-blind, crossover design wherein each participant will participate in all of the possible treatment combinations including:~Cognitive Arm:~1. Intranasal placebo and placebo~2. Intranasal placebo and olanzapine~3. Intranasal insulin and placebo~4. Intranasal insulin and olanzapine~Metabolic Arm:~1. Intranasal placebo and placebo~2. Intranasal insulin and placebo~3. Intranasal insulin and olanzapine"|t|f|t|f
33681077|NCT01287182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681078|NCT00102401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33681079|NCT04329624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681080|NCT01680198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681081|NCT01402336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681082|NCT05446831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681083|NCT03775538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Randomised, Double-Blind, Active Treatment|t|t|t|t
33681084|NCT05857553|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681085|NCT04326101|||CASE_ONLY||PROSPECTIVE|||||||
33681086|NCT03708575|||OTHER||RETROSPECTIVE|||||||
33681087|NCT00752440|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33681088|NCT02185976|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33771408|NCT01948362|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33771409|NCT05960877|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33771410|NCT00245336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771411|NCT06030453|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33771412|NCT02208882|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33771413|NCT02999620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33771414|NCT00004003||||TREATMENT||||||||
33771415|NCT05287334|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group assignment. Approx 10-15 voluntary blood donors.||||
33771416|NCT01622348|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33771417|NCT05445024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771418|NCT00950937|||CASE_CONTROL||PROSPECTIVE|||||||
33771419|NCT02556515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079409|NCT01991964|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33681089|NCT04241978|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681090|NCT01073046|||CASE_CONTROL||PROSPECTIVE|||||||
33771420|NCT00762684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771421|NCT04162990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771422|NCT00387166|||COHORT||PROSPECTIVE|||||||
33771423|NCT02092038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771424|NCT05345457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771425|NCT04436796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771426|NCT03102658|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33771427|NCT02636894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771428|NCT04534335|||COHORT||CROSS_SECTIONAL|||||||
33901051|NCT04098601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator/study personnel inform the participant regarding which arm they have been assigned and inform a recovery coach if the participant is randomized to the intervention arm.||f|f|f|t
33901052|NCT00857246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901053|NCT06130384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be masked. The assistant instilling the eyedrop will be masked to which eyedrop is used for each eye.|All patients will receive both bromfenac 0.09% in the study eye and artificial tears in the control eye. Patients will be randomized to determine whether their right or left eye is the study eye.|t|t|f|f
33901054|NCT00389415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901055|NCT04116034|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||up to 10 subjects will be enrolled to evaluate feasibility and safety of thealfapump DSR system||||
33901056|NCT00466752|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33901057|NCT02094469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901058|NCT06672224|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33983900|NCT01520909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681091|NCT04273880|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double-blind.||t|f|t|t
33681092|NCT00181636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681093|NCT03224559|||COHORT||PROSPECTIVE|||||||
33681094|NCT04276558|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-masked: dose and nature of the product|The study will have an initial period of dose escalation followed by a parallel recruitment period. Randomisation in the first 24 patients will be sequential and after, patients will be randomised to all 4 treatment arms.|t|t|t|f
33771429|NCT01493661|||||CROSS_SECTIONAL|||||||
33771430|NCT00000390||||TREATMENT||||||||
33771431|NCT06116214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771432|NCT03757806|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized controlled trial will be conducted. Participants will be randomized to the control group or intervention group.~The control group will receive usual care only (e.g., pharmacologic treatment), whilst the experimental group will receive an individualized home-based physical activity program at home (LiFE4D) in addition to usual care."||||
33771433|NCT03022838|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33771434|NCT02391935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771435|NCT00494936|||COHORT||PROSPECTIVE|||||||
33771436|NCT02213055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771437|NCT00266474|||COHORT||CROSS_SECTIONAL|||||||
33771438|NCT05851924|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm, phase II study.||||
33771439|NCT03514264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After 6 months the results will be evaluated by two independent professionals, who did not participate in the interventions and are not aware of the allocation. The evaluation will be performed by means of tomography and clinical examination|A randomized, interventional, prospective, unicentric, double blind clinical trial.|f|f|f|t
33771440|NCT06328166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771441|NCT02604836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771442|NCT01087723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901059|NCT03414918|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Study 1: We will enroll consecutive hypertensive patients with PA, who need to undergo adrenal vein sampling (AVS) before being referred for adrenalectomy, according to current guidelines12.~Study 2: Regardless of the results of study 1, we will recruit consecutive referred hypertensive patients undergoing screening for secondary hypertension. This is because to prove unambiguously the role of macrolides in the screening of mutated APA we must enroll a population of patients with and without PA and with/without the different gene mutations so far identified in APA."||||
33901060|NCT04578145|NA|SINGLE_GROUP||SCREENING||NONE||"Stratified randomization was carried out in 23 priority districts involved.~Kind of HIV testing offered for FSW intervention group is difference with those, in control group. Both HIV blood test and self-testing are implemented in the intervention group while it is just HIV blood test provided for the control one. For assisted in the intervention group, FSW been reached is offered HIV blood test at least 3 times at stages of outreaching process, before answering the eligibility questions and before watching the guided OFT self-testing video. If she receives, she will be accompanied to take the test in health facilities. If she refuses, she will be offered to perform or continue to take OFT self-testing. For unassisted, FSW only has an option to undertake OFT self-testing. The FSW accesses the link on website (www.teman-kita.org) and registers herself independently without assistance of outreach workers (OW) who usually offer HIV blood test."||||
33901061|NCT02047123|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33901062|NCT00598130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901063|NCT05247580|||COHORT||PROSPECTIVE|||||||
33901064|NCT05034783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079410|NCT04622566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079411|NCT04817306|||CASE_CONTROL||PROSPECTIVE|||||||
33771443|NCT04206137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771444|NCT02351596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771445|NCT00167986|||CASE_CONTROL||PROSPECTIVE|||||||
33771446|NCT05103813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771447|NCT04039074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771448|NCT01801553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771449|NCT02230150|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771450|NCT00008047|RANDOMIZED|||TREATMENT||NONE||||||
33771451|NCT04681677|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, prospective, multi-center, non-randomized, historical control, non-inferiority study of subjects treated with single fraction, Intra-Operative Radiation Therapy at the time of maximal resection for recurrent GBM. Treatment with Bevacizumab will be initiated 28-56 days after surgery depending on surgical wound healing assessment at the discretion of the treating investigator.||||
33901065|NCT05600712|NA|SINGLE_GROUP||OTHER||NONE||Participants who have been implanted with REDAPT Sleeved Stem||||
33901066|NCT03741439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and who analyzes the data are blind to randomization.|Randomized controlled trial|t|t|f|t
33901067|NCT00601289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901068|NCT01122810|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901069|NCT06671860|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33901070|NCT02950623|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33901071|NCT05632250|NA|SINGLE_GROUP||TREATMENT||NONE||Post Market Clinical Follow Up Study||||
33901072|NCT04760795|||CASE_ONLY||PROSPECTIVE|||||||
33901073|NCT01342640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901074|NCT00178412|RANDOMIZED|PARALLEL||||NONE||||||
33901075|NCT06671067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901076|NCT01292395|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33901077|NCT04459910|||CASE_ONLY||RETROSPECTIVE|||||||
33901078|NCT03733678|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are masked in some interventions related to the workings of the tablet-based decision-support tool, but not to the price discounts they receive for the contraceptive methods.|"The study independently experiments with two aspects of the health provider-client relationship:~1. First, a tablet-based counseling app that is used by the provider gives random discounts to clients - separately for LARCs and SARCs.~2. Second, the tablet-based app presents recommendations to the client sequentially (i.e. the top-ranked method, followed by the next one if that recommendation is declined by the client, etc.) vs. simultaneously (i.e. presenting the top recommendations to the client all at once and asking her to choose which one to discuss further)."|t|f|f|f
33901079|NCT03281590|||OTHER||OTHER|||||||
33901080|NCT01421849|NA|CROSSOVER||TREATMENT||NONE||||||
33901081|NCT00649519|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33901082|NCT02213003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901083|NCT03057873|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double-blind||t|t|t|t
33901084|NCT01276847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771452|NCT00179348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771453|NCT05502224|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Each individual is his own control. It is therefore a longitudinal data collection.||||
33771454|NCT00991614|||CASE_ONLY||PROSPECTIVE|||||||
33771455|NCT00415974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771456|NCT02006420|||COHORT||PROSPECTIVE|||||||
33771457|NCT05776082|||COHORT||PROSPECTIVE|||||||
33771458|NCT03399149|||COHORT||PROSPECTIVE|||||||
33771459|NCT02726399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771460|NCT06294691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771461|NCT03901599|||CASE_ONLY||PROSPECTIVE|||||||
33771462|NCT02947464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771463|NCT03904342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771464|NCT06449014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771465|NCT03289481|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Masking will be done by the pharmacy. Active and placebo lozenges will look identical.|Double-blind, placebo controlled crossover study|t|t|t|t
33901085|NCT06673290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901086|NCT06125210|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Intervention group: The bundle treatment plan was:1) After receiving mechanical ventilation for \<7 days, three of the following four items of intensive bedside rehabilitation were initiated: ① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.~2) Receive mechanical ventilation \<14 days, start the target-oriented nutrition program, including: (1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks.~3) Receiving mechanical ventilation \<21 days, tracheotomy transition to home mechanical ventilation (HMV), special diseases (central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy."|t|t|t|t
33901087|NCT03527901|||COHORT||CROSS_SECTIONAL|||||||
33901088|NCT06181617|||COHORT||PROSPECTIVE|||||||
33901089|NCT01084252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901090|NCT01726777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771466|NCT00806520|||COHORT||PROSPECTIVE|||||||
33771467|NCT01196221|||COHORT||PROSPECTIVE|||||||
33771468|NCT01992549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771469|NCT05292196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771470|NCT02037867|||COHORT||PROSPECTIVE|||||||
33771471|NCT01638468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901091|NCT00336492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901092|NCT00717470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901093|NCT02367092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901094|NCT04892446|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33901095|NCT03841877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901096|NCT03393962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901097|NCT05866822|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901098|NCT00702312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901099|NCT05933278|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901100|NCT06658119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901101|NCT05980000|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized on a 2:1 basis to Arm 1 or Arm 2.||||
33901102|NCT01868087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901103|NCT01105351|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33901104|NCT00756977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079412|NCT04421040|NA|SINGLE_GROUP||PREVENTION||NONE||Patients with TTR-wt cardiac amyloidosis will be monitored with an implantable loop recorder to determine frequency of atrial and ventricular arrhythmias. After 6 months the device will be explanted unless required for further clinical monitoring.||||
34079413|NCT00444119|||DEFINED_POPULATION||OTHER|||||||
34079414|NCT01721538|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34079415|NCT00246584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079416|NCT02299440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901105|NCT00984230|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33901106|NCT01619618|||OTHER||OTHER|||||||
33901107|NCT06559059|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33901108|NCT00660140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901109|NCT00325572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079417|NCT01505777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079418|NCT01765296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901110|NCT06080347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33901111|NCT00001246|||COHORT||PROSPECTIVE|||||||
33901112|NCT03670862|||CASE_ONLY||PROSPECTIVE|||||||
33901113|NCT00117338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901114|NCT06633302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33901115|NCT06512480|||COHORT||OTHER|||||||
33901116|NCT05554900|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator who perform the operations cannot be blinded because of the use of manual techniques.||f|t|f|t
33901117|NCT04277702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079419|NCT04210986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079420|NCT06470490|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34079421|NCT03028142|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34079422|NCT03160716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079423|NCT00870454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079424|NCT00999505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901118|NCT00447954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901119|NCT00267254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901120|NCT02948595|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33901121|NCT06672523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901122|NCT06290505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901123|NCT03845998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901124|NCT02438072|NA|SINGLE_GROUP||||NONE||||||
34079425|NCT01150630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079426|NCT02360514|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33901125|NCT02914743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901126|NCT02908802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901127|NCT06431542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901128|NCT05552599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901129|NCT05584423|||COHORT||PROSPECTIVE|||||||
33901130|NCT00065975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901131|NCT00128206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901132|NCT01205243|||OTHER||PROSPECTIVE|||||||
33901133|NCT05431465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901134|NCT06319898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901135|NCT05498623|||COHORT||PROSPECTIVE|||||||
33901136|NCT05196698|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901137|NCT00148590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33901138|NCT00728416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901139|NCT00982956|||CASE_CONTROL||PROSPECTIVE|||||||
33901140|NCT03826953|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study is to determine the feasibility of a nurse led allergy clinic, delivered by specialist allergy nurse in primary care, using a hub and spoke model for the delivery of the clinic, the hub being the 'host' centre of GP practice and the spokes being the local / neighbouring GP practices that refer into the 'host' centre. Participants will be identified and recommended through their usual health care provider and referred into the clinic. Data will be collected through a mixed methods approach using questionnaires, interviews and national and locally held data to evaluate the effectiveness of the clinic.||||
33901141|NCT03515980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901142|NCT05457530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901143|NCT00758862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901144|NCT03905434|||COHORT||PROSPECTIVE|||||||
33681095|NCT04118257|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33681096|NCT03707275|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681097|NCT02651909|||COHORT||PROSPECTIVE|||||||
33681098|NCT04097587|NA|SINGLE_GROUP||PREVENTION||NONE||A clustered randomized controlled study with a parallel-group design.||||
33681099|NCT01499368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681100|NCT03483064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681101|NCT05991544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33681102|NCT01371279|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33681103|NCT05195060|||COHORT||PROSPECTIVE|||||||
33681104|NCT00945906|NA|SINGLE_GROUP||||NONE||||||
33771472|NCT06391814|NA|SINGLE_GROUP||TREATMENT||NONE||single patient||||
33771473|NCT03796013|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771474|NCT04705220|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The test product MERIVA® is formulated in tablets indistinguishable from those of its correspondent placebo, with a completely indistinguishable appearance even in packaging.|This is a double-blind, randomized, single-center clinical trial. Patients enrolled will be randomized in a 1:1 ratio between groups and sexes to receive the test product MERIVA® (Group A) or its correspondent placebo (Group B).|t|f|t|f
33681105|NCT03540251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33771475|NCT01962025|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771476|NCT01848834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771477|NCT05585190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33771478|NCT04126096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Skin testing||||
33771479|NCT01936129|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771480|NCT03731130|||COHORT||PROSPECTIVE|||||||
33771481|NCT01910727|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771482|NCT05269537|||COHORT||PROSPECTIVE|||||||
33771483|NCT06109415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomized in a 2:1 ratio to HTX-011 or bupivacaine HCl, respectively. All subjects will receive a scheduled postoperative non opioid multimodal analgesic (MMA) regimen.|t|f|f|t
33771484|NCT05922163|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33771485|NCT04758221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771486|NCT04548531|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Patients will not be given any information on their assigned arm. Statistician will be blinded to the assignment when analyzing the results.|Two-armed randomized control trial|f|f|f|t
33771487|NCT02640976|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33771488|NCT03806946|||CASE_CONTROL||RETROSPECTIVE|||||||
33771489|NCT05112341|||CASE_CONTROL||PROSPECTIVE|||||||
33771490|NCT04190875|||COHORT||OTHER|||||||
33771491|NCT03116243|||OTHER||CROSS_SECTIONAL|||||||
33771492|NCT02225821|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771493|NCT03125941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771494|NCT05450445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33901145|NCT01852344|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33901146|NCT01677611|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33901147|NCT05536648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The dental investigator who perform the oral health assessment for dentition status and plaque status was blinded during the intervention.|single blinded randomized control trial|f|f|t|f
33901148|NCT05188235|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33681106|NCT04458324|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||Subjects are assigned to one of four groups with equal chance: 1. NIV + Buspar, 2. NIV + placebo, 3. sham NIV + Buspar, or 4. sham NIV + placebo|t|f|t|f
33771495|NCT04380818|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33771496|NCT06012565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Statistician and Safety Review Committee are not blinded. Sponsor is blinded.||t|t|t|f
33771497|NCT05583851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33771498|NCT04256590|||CASE_CONTROL||PROSPECTIVE|||||||
33771499|NCT01936610|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33771500|NCT02223117|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33771501|NCT03193060|||CASE_CONTROL||PROSPECTIVE|||||||
33771502|NCT04809896|||COHORT||RETROSPECTIVE|||||||
33771503|NCT06364592|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33771504|NCT00663962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771505|NCT03663777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771506|NCT00871819|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33771507|NCT04048499|||OTHER||PROSPECTIVE|||||||
33771508|NCT03993899|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: the patient and the investigator don't know the strategy|"two arms A and B:~Arm A: patient's fitting with strategy FS4 --\> 15 days use --\> tests and patient's fitting with strategy HDCIS --\> 15 days use --\> tests~Arm B: patient's fitting with strategy HDCIS --\> 15 days use --\> tests and patient's fitting with strategy FS4 --\> 15 days use --\> tests"|t|f|t|f
33771509|NCT00832338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771510|NCT05082896|||CASE_CONTROL||PROSPECTIVE|||||||
33771511|NCT00371527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901149|NCT01145391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33901150|NCT04320303|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901151|NCT05697991|||COHORT||PROSPECTIVE|||||||
33901152|NCT06166576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901153|NCT01330446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901154|NCT00009594||||DIAGNOSTIC||||||||
33901155|NCT01244802|||OTHER||CROSS_SECTIONAL|||||||
33901156|NCT00296283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901157|NCT05804110|||OTHER||CROSS_SECTIONAL|||||||
33901158|NCT00985452|RANDOMIZED|FACTORIAL||||NONE||||||
33901159|NCT04548947|NA|SINGLE_GROUP||PREVENTION||NONE||prospective, multi-endoscopist, single center, clinical study at tertiary referral center (CHUM)||||
33983901|NCT01345045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983902|NCT05328986|||COHORT||PROSPECTIVE|||||||
33983903|NCT01689792|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33771512|NCT03264391|||CASE_ONLY||CROSS_SECTIONAL|||||||
33771513|NCT01254175|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33771514|NCT04259775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771515|NCT00991822|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33771516|NCT06249620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33771517|NCT04524728|||COHORT||PROSPECTIVE|||||||
33771518|NCT00245011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771519|NCT04854850|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label clinical trial||||
34079427|NCT04241549|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771520|NCT04432402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771521|NCT03219450|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771522|NCT03729596|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation will use a 3+3+3 design to identify an MAD or MTD, followed by a Cohort Expansion.||||
33771523|NCT03428568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771524|NCT05793710|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Double (Participant, Outcomes Assessor) Blinded to group membership, research assistants collected data from both groups.||t|f|f|t
33771525|NCT02291224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771526|NCT00865891|RANDOMIZED|CROSSOVER||||NONE||||||
33771527|NCT01479491|||CASE_ONLY||RETROSPECTIVE|||||||
33771528|NCT04942912|||CASE_ONLY||RETROSPECTIVE|||||||
33771529|NCT06487767|||CASE_ONLY||PROSPECTIVE|||||||
33771530|NCT02930213|||CASE_ONLY||PROSPECTIVE|||||||
33771531|NCT00389090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771532|NCT00883103|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771533|NCT02333734|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33901160|NCT05887856|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"It would be a single blinded study the assessor will be blinded to the type of group to which patient belongs.~Blinding will be ensured by sharing the data only with relevant study team members, The assessor will read out instruction before beginning of the interview requesting the enrolled patients not to mention the tools used for pre-operative education and to answer only the questions being asked."|"Pre-operative randomization after enrollment will be carried out and patients will be allocated either to the intervention group or to the non-intervention group by 'computerized block randomization'. Research Randomizer software, a free to use software will be used for this. Patients will be randomized either into the intervention group or into non-intervention group."|f|t|t|t
33771534|NCT02136498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901161|NCT04522752|||COHORT||PROSPECTIVE|||||||
33771535|NCT02809508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33771536|NCT05966376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771537|NCT01001780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771538|NCT04961320|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33771539|NCT03871049|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33771540|NCT03518658|||COHORT||PROSPECTIVE|||||||
33771541|NCT05261750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33771542|NCT02372123|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33771543|NCT02753725|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771544|NCT04345198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771545|NCT02591420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771546|NCT01226173|||CASE_ONLY||PROSPECTIVE|||||||
33771547|NCT03508804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771548|NCT03146858|NA|SINGLE_GROUP||PREVENTION||NONE||Once patients have been recruited into the trail, they will undertake the first of 4 blood samples. Following the samples the PPCI treatment with begin. The enoxaparin infusion will be set up when the treatment begins. At the end of the PPCI treatment the second blood sample will obtained. The enoxaparin infusion will be commenced after a kidney function check has been performed. The third blood sample will be taken 3 hours into the infusion, and the 4th sample taken at the end of the 6 hour infusion. A 12 hour clinical follow up will then be performed and will mark study completion for the patient.||||
33771549|NCT03148847|||CASE_ONLY||RETROSPECTIVE|||||||
33771550|NCT02475291|||CASE_ONLY||PROSPECTIVE|||||||
33771551|NCT01464255|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33901162|NCT01248806|||CASE_ONLY||RETROSPECTIVE|||||||
34079428|NCT05333913|||COHORT||PROSPECTIVE|||||||
34079429|NCT03151850|||COHORT||PROSPECTIVE|||||||
34079430|NCT04263259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not informed about the nature of the mobile-delivered intervention or their assignment to the intervention or control condition.||t|f|f|f
34079431|NCT05581147|||COHORT||RETROSPECTIVE|||||||
34079432|NCT05023122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079433|NCT01316718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771552|NCT00252590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771553|NCT04022889|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771554|NCT05294874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771555|NCT03488290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers doing outcome assessment will be kept blind to the group allocations|This will be a two arm study: 1) LTP Plus TF-CBT added to TAU 2) Treatment as usual (TAU)|f|f|f|t
33681107|NCT03970356|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigators will perform a pragmatic cluster randomised controlled trial (cRCT). The targeted population consists of frail elderly residents of residential care homes and nursing homes attended by general practitioners. The clusters (care home + general practitioners) are assigned to intervention- or control group. In the intervention group, an antibiotic stewardship intervention is actively implemented at the level of the general practitioners and caregivers in the homes.~The study has two measurement periods; a baseline period (5 months) and a follow-up period (7 months). In between there is an implementation period in which the intervention (i.e. active implementation) is started in the intervention homes \[no measurements are taken\]."||||
33771556|NCT01023880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771557|NCT00462579|||COHORT||RETROSPECTIVE|||||||
33771558|NCT01972334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901163|NCT02831868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901164|NCT01899144|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33681108|NCT02842034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901165|NCT06513715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901166|NCT04983901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901167|NCT02075346|||CASE_ONLY|||||||||
33901168|NCT02227381|||COHORT||PROSPECTIVE|||||||
33901169|NCT00564629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33983904|NCT03138330|||COHORT||CROSS_SECTIONAL|||||||
33983905|NCT00354198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983906|NCT02666300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33983907|NCT05807932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983908|NCT01983761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681109|NCT05406193|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33681110|NCT04119271|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681111|NCT00345332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681112|NCT05291169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized to Omeza Combination therapy and SOC Vs SOC alone||||
33771559|NCT01466296|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771560|NCT06339294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33771561|NCT06255847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771562|NCT00023790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771563|NCT00229476|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33771564|NCT05266664|||COHORT||PROSPECTIVE|||||||
33681113|NCT02817399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33771565|NCT04870619|||COHORT||PROSPECTIVE|||||||
33771566|NCT05744024|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Randomization will not be blinded since both the provider and patient know if the patient will be wearing the VR system or headphone with audio during wound care or not wearing the VR system or headphone with audio.|||||
33771567|NCT00627068|||COHORT||PROSPECTIVE|||||||
33771568|NCT04669912|||COHORT||PROSPECTIVE|||||||
33983909|NCT03283943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983910|NCT03027830|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33983911|NCT03601962|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomized, double blind, placebo controlled, cross over study|t|t|t|t
33771569|NCT03507543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771570|NCT01346761|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33771571|NCT05419882|||COHORT||PROSPECTIVE|||||||
33771572|NCT02670538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901170|NCT05956574|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33901171|NCT06666998|||COHORT||PROSPECTIVE|||||||
33901172|NCT05385614|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33901173|NCT00395122|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983912|NCT05426005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771573|NCT00714350|||||PROSPECTIVE|||||||
33771574|NCT00078104||||TREATMENT||||||||
33771575|NCT01554982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771576|NCT03467438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The manufacturer will provide packages of the investigational medical product/placebo that are indistinguishable. Every package have a code written on it; only the manufacturer knows whether that code refers to the IMD or placebo.||t|f|t|f
33901174|NCT05345496|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901175|NCT05440760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Subjects will be placed into four treatment-sequence groups in a 1:1:1:1 allocation ratio via permuted block randomization with randomized block sizes of four or eight.|f|f|f|t
33901176|NCT00693355|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33901177|NCT01892917|||OTHER||PROSPECTIVE|||||||
33901178|NCT00999752|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901179|NCT05537363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983913|NCT04921462|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33983914|NCT05479110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983915|NCT01930227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33983916|NCT02728102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983917|NCT01558141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983918|NCT05201716|||OTHER||PROSPECTIVE|||||||
33983919|NCT05614960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983920|NCT00566800||||TREATMENT||NONE||||||
33983921|NCT01550900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983922|NCT01868529|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33983923|NCT06316921|||CASE_CONTROL||RETROSPECTIVE|||||||
33983924|NCT01390493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983925|NCT04993664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983926|NCT03343795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983927|NCT03104166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983928|NCT03887663|||COHORT||PROSPECTIVE|||||||
33983929|NCT01288352|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681114|NCT02081248|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681115|NCT01467687|RANDOMIZED|CROSSOVER||||NONE||||||
33901180|NCT04763265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eligible subjects will be randomized at Baseline (Day 0) to Group A or B in a 1:1 randomization scheme. Investigators and subjects will be blinded to the treatment administered and will evaluate the severity of glabellar lines independently. The subjects should perform their assessment independently and ideally before the investigator, to ensure they are not biased by the investigator. The same investigator must complete the Baseline assessments and FWS at Week 4 (primary endpoint assessments) for a given subject.|Multi-center, randomized, double-blind, comparator-controlled study. The study will take place in the EU, US and Canada. The benefit of participation in this study is the expected reduction in the severity of glabellar frown lines. All subjects will benefit from free medical screenings and follow up.|t|f|t|t
33901181|NCT06605066|||CASE_ONLY||PROSPECTIVE|||||||
33901182|NCT02448823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681116|NCT00984620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901183|NCT02662309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901184|NCT03088241|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter (2-12 centers), parallel-group (1:1 allocation), open-label, superiority, prospective randomized clinical study||||
33901185|NCT03711019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Individuals blinded to their acute course of treatment will continue to receive the convulsive therapy to which they responded in in a blinded fashion.|"The study will involve a parallel-group clinical trial with three treatment arms conducted at the Centre for Addiction and Mental Health (CAMH) in Toronto, ON, Ontario Shores Centre for Mental Health Sciences in Whitby, ON and UBC Hospital in Vancouver, BC.~The investigators plan to enroll up to 105 participants to ensure 70 participants receive a complete course of continuation therapy following MST, RUL-UB ECT, or bitemporal ECT and anticipate enrolling up to 60 participants who will receive an acute course of bitemporal ECT as part of our secondary exploratory outcome over 48 months."|t|t|f|t
33901186|NCT01341509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901187|NCT04590729|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||three-by-three crossover design|t|f|t|t
33901188|NCT03488940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901189|NCT00072722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901190|NCT00923091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901191|NCT03048864|||CASE_ONLY||PROSPECTIVE|||||||
33901192|NCT02158221|NON_RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33901193|NCT06670131|||OTHER||PROSPECTIVE|||||||
33901194|NCT04224558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901195|NCT06671444|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||single dose||||
33901196|NCT02463123|||COHORT||PROSPECTIVE|||||||
33901197|NCT05574816|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901198|NCT02207192|||CASE_CROSSOVER||PROSPECTIVE|||||||
33983930|NCT03212222|RANDOMIZED|CROSSOVER||SCREENING||NONE||Patient randomly assigned to either be screened first with standard clinic technique or cell phone application. Patient is then screened with other method.||||
33983931|NCT00765648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983932|NCT01798732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983933|NCT02215083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983934|NCT06078878|NA|SEQUENTIAL||OTHER||NONE||||||
33983935|NCT02186925|||COHORT||PROSPECTIVE|||||||
33983936|NCT04095247|||CASE_CROSSOVER||PROSPECTIVE|||||||
33983937|NCT00909493|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33983938|NCT02701114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901199|NCT05828940|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind|randomised double-blind|t|f|t|f
33901200|NCT00001542||||TREATMENT||||||||
33983939|NCT00005025||||TREATMENT||||||||
34024720|NCT05239507|||CASE_ONLY||RETROSPECTIVE|||||||
34024721|NCT01434082|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33681117|NCT00522925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681118|NCT00533793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681119|NCT05062954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681120|NCT03351101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, bilateral, d o u b l e - masked, 1-month study with two parallel groups|t|t|t|f
33681121|NCT04235413|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681122|NCT01193257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681123|NCT03051620|||COHORT||PROSPECTIVE|||||||
33681124|NCT02490020|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33681125|NCT06082973|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Device: closed-loop control algorithm with a dual-hormone configuration versus a single-hormone configuration with rescue carbohydrate recommendations for glucose control during an unannounced 30-min aerobic exercise session and a meal challenge.||||
33681126|NCT04751214|||OTHER||RETROSPECTIVE|||||||
33681127|NCT03077087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681128|NCT03636841|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681129|NCT02447627|||COHORT||PROSPECTIVE|||||||
33681130|NCT04292522|||COHORT||RETROSPECTIVE|||||||
34024722|NCT00299286|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34024723|NCT03127683|NA|SINGLE_GROUP||OTHER||NONE||"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."||||
34024724|NCT00760851|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024725|NCT06625632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024726|NCT02944305|||COHORT||RETROSPECTIVE|||||||
34024727|NCT01544179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024728|NCT04460482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Offline data analyzis are being performed without knowing which intervention group the patients are from|Eligible patients randomized to NIRS-guided or standard angiographic-guided intervention with DES|f|f|t|t
34024729|NCT01046786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024730|NCT03067597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681131|NCT05292547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681132|NCT01306929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681133|NCT01836276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681134|NCT00385476|||CASE_CONTROL||PROSPECTIVE|||||||
33681135|NCT01710540|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33681136|NCT02508558|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33681137|NCT06470568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The kinesiologists performing the assessments will be blind to the intervention. The blinding will extend to the data analysis team.||f|t|f|t
33681138|NCT05613712|||COHORT||PROSPECTIVE|||||||
33681139|NCT01650870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33681140|NCT01306578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681141|NCT05168501|NA|SINGLE_GROUP||OTHER||NONE||This study is an unblinded reproducibility assessment to assess variability of the ventilatory response to Duffin's rebreathing procedure. The lead-in reproducibility assessment will have up to 10 healthy volunteer participants.||||
33681142|NCT05403398|NA|SINGLE_GROUP||OTHER||NONE||||||
33681143|NCT00523263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681144|NCT04175119|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33681145|NCT05763745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681146|NCT01496937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681147|NCT02242422|||COHORT||RETROSPECTIVE|||||||
33681148|NCT04328207|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The investigators are masked as to which group the patient is in.|In the first half of enrollment in the program there will be no financial incentive offered to any patients. In the second half of enrollment, all patients needing referral will be notified that they will receive a payment upon the completion of their referral visit.|f|f|t|t
33681149|NCT03387488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771577|NCT02142920|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33771578|NCT01482650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771579|NCT04980235|||CASE_ONLY||RETROSPECTIVE|||||||
33771580|NCT00612404|||COHORT||PROSPECTIVE|||||||
33771581|NCT00366860|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33771582|NCT01903343|||COHORT||PROSPECTIVE|||||||
33771583|NCT04406337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771584|NCT00119119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771585|NCT04169581|||COHORT||RETROSPECTIVE|||||||
33771586|NCT00003095|||COHORT||PROSPECTIVE|||||||
33771587|NCT04842994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839603|NCT05006118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839604|NCT01413503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901201|NCT04046484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).~In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.~In both treatment groups, subjects will be provided the best available standard of care."|t|t|t|t
33901202|NCT04745832|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1: Rituximab plus Zandelisib~Arm 2: Rituximab plus chemotherapy (CHOP or Bendamustine)"||||
33901203|NCT06318923|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901204|NCT00492622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901205|NCT00729430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901206|NCT01507545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901207|NCT04050007|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33901208|NCT02227212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901209|NCT04634968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33901210|NCT02235285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901211|NCT03096028|||COHORT||CROSS_SECTIONAL|||||||
33901212|NCT06671951|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33901213|NCT05087823|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901214|NCT06016621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants involved in data collection will be blinded to treatment allocation for the entire duration of the study. Success of blinding will be verified by asking assessors if they inadvertently found out about the treatment allocation - instances of unblinding will be recorded using a case report form with details including information on who was unblinded, the source of the unblinding and the reason for the unblinding.|"Assessor-blind, multi-centre, pragmatic, two-arm, randomised controlled trial in which participants will be randomly allocated to either:~1. Twice-weekly 30 minute-sessions of one to one improvisational music therapy over 12 weeks, in addition to support as usual.~2. Support as usual control group."|f|f|f|t
33901215|NCT03245476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||corticoid injection + physiotherapy with a focus on manual therapy and home-exercises versus corticosteroid injection + physiotherapy with focus on education and supported home exercises|f|f|f|t
33901216|NCT03260738|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33681150|NCT02337231|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33839605|NCT01788293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33839606|NCT03431753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839607|NCT01589159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839608|NCT00690599|||||RETROSPECTIVE|||||||
33839609|NCT06046417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839610|NCT05905107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839611|NCT00286988|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33901217|NCT03370367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901218|NCT00719173|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33901219|NCT00150033|||||PROSPECTIVE|||||||
33901220|NCT02584621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34024731|NCT03676348|||COHORT||PROSPECTIVE|||||||
34024732|NCT01269333|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34024733|NCT01397643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024734|NCT00226174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771588|NCT06230302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the trial period, neither the researcher nor the research subjects know the randomization information of the research subjects. In principle, the randomization code is maintained and stored by the researcher.~In general, double blinding should not be lifted until all research subjects have completed the test and the data is locked. However, in the case of an emergency such as a health problem of a research subject during intervention, double blinding may be lifted at the discretion of the researcher. In this case, the research person must contact the principal investigator as quickly as possible.~The date, time, and reason for lifting double blinding must be documented in an appropriate location in the case record and supporting documents. A copy of the double-blind code release confirmation document received from the principal investigator must be kept in the supporting documents."|Double-blind randomized controlled trial|t|t|t|t
33681151|NCT01255748|||COHORT||PROSPECTIVE|||||||
33681152|NCT05299853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681153|NCT02843997|NA|SINGLE_GROUP||||NONE||||||
33681154|NCT01030081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681155|NCT00029510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681156|NCT00366093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681157|NCT01561898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771589|NCT04009551|||COHORT||RETROSPECTIVE|||||||
33771590|NCT05595421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study outcomes are measured by clinical raters blinded to the arms and interventions.|A three arm/group parallel interventional study model.|f|f|f|t
33771591|NCT01929330|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771592|NCT00262288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771593|NCT04466618|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33771594|NCT00239785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771595|NCT03555578|||COHORT||PROSPECTIVE|||||||
33771596|NCT02361593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771597|NCT02835443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771598|NCT00858221|||COHORT||RETROSPECTIVE|||||||
33771599|NCT02036515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771600|NCT03681262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized open label parallel group||||
33771601|NCT06286579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"One blinded (when possible) independent assessor"|Randomised controlled trial of parallel group design.|f|f|f|t
33771602|NCT00003534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901221|NCT00231920|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33901222|NCT02432092|||COHORT||PROSPECTIVE|||||||
33901223|NCT06511011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901224|NCT00872898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901225|NCT02167204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901226|NCT01407562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901227|NCT02734121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901228|NCT00765258|||CASE_ONLY||PROSPECTIVE|||||||
33901229|NCT05182203|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901230|NCT04309721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901231|NCT02165852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33983940|NCT05026671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and the healthcare worker who will perform preoperative and postoperative visit will be blinded to randomized study group.||t|f|f|t
33983941|NCT04022798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental group: Group A (NM, LSE and rESWT) and Control group: Group B (LSE and rESWT).|t|f|f|f
33983942|NCT04213326|||COHORT||PROSPECTIVE|||||||
33983943|NCT02373319|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33983944|NCT05856604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Experimental group = Improvisational Music Therapy Active control group = Storytelling activity|t|f|f|t
33983945|NCT04258982|||OTHER||PROSPECTIVE|||||||
33983946|NCT06391983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681158|NCT05273502|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is an educational program, so that, the intervention group will know that will receive some educational and behavioral activities, and the control group will know that they will not receive any kind of activities.|Randomized Controlled Trial (cluster)|f|f|f|t
33681159|NCT02451371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681160|NCT00125346|RANDOMIZED|||TREATMENT||DOUBLE||||||
33771603|NCT05921721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771604|NCT03948867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The cohort will be divided into two arms based on the initial screening TCD result: 1) those who have a normal initial screening TCD and will be an observation/control cohort; and 2) those who have an elevated initial screening TCD (either conditional or abnormal TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule||||
33771605|NCT06174974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data will be collected and coded by the nurse researcher. Data will be analyzed by an independent statistician. The study groups will be disguised as A and B. The statistician will not know the groups. In addition, the statistical expert will not see the data of the experimental group regarding satisfaction.|"The patients in the experimental group will be informed by the researcher in the training room in the ward 1 day before the operation (verbal permission was obtained) with an educational presentation on intensive care unit stressors.~Patients in the control group will not be given preoperative training on intensive care unit stressors by the researcher. Patients in the control group will receive standard care\*."|f|f|f|t
33771606|NCT03050398|NA|SINGLE_GROUP||OTHER||NONE||||||
33771607|NCT03619941|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33771608|NCT05667259|||COHORT||RETROSPECTIVE|||||||
33771609|NCT00353444|||||PROSPECTIVE|||||||
33901232|NCT05219279|||COHORT||PROSPECTIVE|||||||
33901233|NCT00990015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33983947|NCT05983562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33983948|NCT04511273|||OTHER||PROSPECTIVE|||||||
33983949|NCT03744364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681161|NCT00329849|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33681162|NCT02224196|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33681163|NCT04704362|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Trainees and their patients will not be told which arm the trainee was in. Outcome assessors will also be blinded to arm.|This is a non-randomized controlled trial comparing training and supervision as usual with training and supervision using a competency-based approach.|t|t|f|t
33681164|NCT00392145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901234|NCT06253780|||CASE_ONLY||PROSPECTIVE|||||||
33901235|NCT01546220|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33983950|NCT03044171|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33983951|NCT01691508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33983952|NCT03252028|||COHORT||PROSPECTIVE|||||||
33983953|NCT04211493|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are not aware of the study hypothesis.|The study has a randomised placebo-controlled crossover design. Every participant exercises two training-sessions (experimental-condition, placebo-condition) in randomized order with one week fade-out phase inbetween.|t|f|f|f
33983954|NCT02019940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983955|NCT00938171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33983956|NCT05717309|||COHORT||RETROSPECTIVE|||||||
33983957|NCT04287322|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|The research assistants were blinded of aim of study, group allocations and interventions.|Quasi-experimental design|f|f|f|t
33983958|NCT01027143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079434|NCT03147872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and care providers will be masked as to which embryo is randomized to each condition. Investigators will be masked until the data are analyzed.|Randomized Controlled Trial|t|t|t|f
34079435|NCT00314158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079436|NCT04191707|||COHORT||RETROSPECTIVE|||||||
33681165|NCT02452931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681166|NCT05985460|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681167|NCT01331252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33681168|NCT00907452|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771610|NCT01454830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771611|NCT06285617|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prednisone||||
33901236|NCT00970203|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901237|NCT05928026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901238|NCT05709756|||CASE_ONLY||PROSPECTIVE|||||||
33983959|NCT06222645|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33983960|NCT04364568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||prospective, monocentric, etiological cohort study|f|f|t|f
33983961|NCT04203030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983962|NCT00207857|||||PROSPECTIVE|||||||
33983963|NCT03687736|NA|SINGLE_GROUP||OTHER||NONE||||||
33983964|NCT00128154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34079437|NCT03798743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771612|NCT05334121|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33771613|NCT03139838|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33771614|NCT05272423|||COHORT||PROSPECTIVE|||||||
33771615|NCT05950503|||COHORT||PROSPECTIVE|||||||
33901239|NCT00455858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901240|NCT03245788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking occurs.|There will be 12 groups in each arm which reflects the 12 different cancer types.||||
33901241|NCT05595473|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33901242|NCT03370081|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33901243|NCT06257004|||CASE_CONTROL||PROSPECTIVE|||||||
34079438|NCT05070013|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|To mitigate subject bias, subjects will be blinded with respect to which stimulation type they are assigned in each week.|All subjects will experience all 3 DBS stimulation conditions (one condition per week, 3 consecutive weeks): adaptive stimulation, open-loop stimulation (standard clinical stimulation therapy) and no stimulation (control). The order in which each subject is assigned to a condition will be randomized.|t|f|f|f
34079439|NCT05954052|NA|SINGLE_GROUP||OTHER||NONE||||||
34079440|NCT04448275|RANDOMIZED|PARALLEL||TREATMENT||NONE||"control group which received conventional selected exercise program in form of Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise~and study group received the same exercise training program in addition to Neurodynamics Nerve flossing three times per week for three successive months"||||
34079441|NCT03197948|||COHORT||PROSPECTIVE|||||||
34079442|NCT00709332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079443|NCT00773357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079444|NCT00013507|RANDOMIZED|CROSSOVER||||NONE||||||
34079445|NCT02779491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34079446|NCT02395068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079447|NCT00434031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079448|NCT03361462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079449|NCT00948090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079450|NCT05781672|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079451|NCT00559234|||||PROSPECTIVE|||||||
34079452|NCT01157845|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079453|NCT04549662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079454|NCT05824013|||COHORT||PROSPECTIVE|||||||
34079455|NCT02177929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079456|NCT00952666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079457|NCT01753960|||CASE_CONTROL||PROSPECTIVE|||||||
33771616|NCT01722318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771617|NCT01487304|||COHORT||PROSPECTIVE|||||||
33771618|NCT04094701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Investigators propose two standardized prescribing patterns across all teams. The first would be the control postoperative prescribing pattern and the second would be the experimental opioid reduced prescribing pattern. Patients will not be informed if their postoperative prescriptions are part of the control or opioid reduced prescribing pattern. Of note, patients will be allowed to cross over from the opioid reduced experimental group to the standard of care control group if they have breakthrough pain following surgery.|t|f|f|f
33771619|NCT01625936|NA|SINGLE_GROUP||TREATMENT||||||||
33901244|NCT03714412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079458|NCT01820663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079459|NCT01661738|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34079460|NCT05626309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079461|NCT04998864|||CASE_ONLY||PROSPECTIVE|||||||
34079462|NCT06051526|||COHORT||PROSPECTIVE|||||||
33901245|NCT01716494|||COHORT||PROSPECTIVE|||||||
33901246|NCT03461692|||COHORT||PROSPECTIVE|||||||
34079463|NCT01746537|||COHORT||PROSPECTIVE|||||||
34079464|NCT02198846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079465|NCT02432885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079466|NCT03476421|||COHORT||PROSPECTIVE|||||||
34079467|NCT02597777|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
34079468|NCT00347750|||||PROSPECTIVE|||||||
34079469|NCT00901342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901247|NCT05314348|NON_RANDOMIZED|PARALLEL||OTHER||NONE||12 MND/ALS patients and 13 healthy controls to be assessed at a single time-point each||||
34079470|NCT00555074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681169|NCT05330910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Allocation concealment will be achieved via a central computer-generated random assignment, that will only be made known to the surgeon after the patient is induced on table prior to surgery. Participants from both institutions (SKH, SGH) will be within the same pool for block randomization, to ensure allocation concealment. Access or knowledge about the sequence of the randomization, will not be made known to the PI, Co-Is or mentor, and is only held by protocol administrator.~Patient will be blinded to the randomization, and will only be told of the group of allocation at the end of completion of the study, at 1-year, after their postoperative endoscopy at 1-year. Outcomes assessor for primary outcomes at 1-year endoscopy will also be blinded to the initial surgery that was performed."|"This study will be a double institution, double-blinded, randomized controlled trial, involving surgeons from the Upper Gastrointestinal and Bariatric Service, Department of General Surgery, Sengkang General Hospital (SKH) as well as the Department of Upper Gastrointestinal and Bariatric Surgery, Singapore General Hospital (SGH).~Randomization will be performed by block randomization, with each block of 4. Block randomization was selected given the small study size, to ensure equal representation in both arms of the study."|t|f|f|t
33681170|NCT03853824|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participating sites will be randomised to normal postoperative care, or increased postoperative surveillance. Randomisation will be stratified according to the level of the surgical facility and the expected weekly surgical case-load. Participating sites which have been randomised to increased surveillance will need to provide increased surveillance to surgical patients with a predicted increased postoperative risk as determined by the ASOS risk stratification tool.~Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers."||||
33681171|NCT04935645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681172|NCT05757258|||COHORT||PROSPECTIVE|||||||
33681173|NCT04662970|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681174|NCT00400036|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33681175|NCT02154828|||COHORT||PROSPECTIVE|||||||
33681176|NCT06146270|||COHORT||PROSPECTIVE|||||||
33681177|NCT01027806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681178|NCT01357850|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33681179|NCT02191215|||COHORT||PROSPECTIVE|||||||
33681180|NCT01325662|||COHORT||PROSPECTIVE|||||||
33681181|NCT00463021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681182|NCT04621383|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33681183|NCT05895526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. Group A (Application of 5% sodium fluoride varnish)~2. Group B (Self etch dentin adhesive)"|t|f|t|f
33681184|NCT03648866|||OTHER||PROSPECTIVE|||||||
33681185|NCT04220593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901248|NCT06673329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901249|NCT04111822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901250|NCT06092398|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901251|NCT04795440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The oocytes will be randomly assigned to one of the two study groups, and only the person who microinjects them will know which group each oocyte belongs to.|Prospective and interventional|t|t|t|t
33901252|NCT00375934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901253|NCT01512524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901254|NCT03446547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901255|NCT06443879|||COHORT||PROSPECTIVE|||||||
33901256|NCT06672614|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Considering that the hot water immersion protocol will be easily perceptible to the participants, it will not be possible to blind them from their group assignment. Also, the investigators will be required to set the water temperature for the immersion protocol following each exercise session, so they will also be aware of group assignments during the intervention.|||||
33901257|NCT06248320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33901258|NCT01915875|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079471|NCT04958070|||COHORT||PROSPECTIVE|||||||
34079472|NCT06215235|||CASE_ONLY||OTHER|||||||
33681186|NCT00681356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33681187|NCT02687867|||COHORT||RETROSPECTIVE|||||||
33681188|NCT00862797|||COHORT||PROSPECTIVE|||||||
33983965|NCT04548453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, non-significant risk||||
33983966|NCT01258725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33983967|NCT00563264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983968|NCT02405325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33681189|NCT03283605|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Single group assignment||||
33983969|NCT01310660|||COHORT||PROSPECTIVE|||||||
33983970|NCT00006264||||TREATMENT||||||||
33983971|NCT03583593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|It is a double blind study, that is, neither the researcher nor the patient knows if he takes placebo or the active tablet.||t|f|t|f
33983972|NCT06215352|||COHORT||PROSPECTIVE|||||||
33983973|NCT01037283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681190|NCT03483129|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomised into either the intervention or the control group. Participants in INT will receive a 15 minute one to one consultation with a nurse at their general practice. The consultation will provide the participant with information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide. Participants will have the opportunity to discuss pre-diabetes with a nurse and ask any questions they may have. Participants placed in CON will not receive the consultation and will only attend visits to the WARU. A subgroup of participants will also be randomised for additional physical activity monitoring.||||
33983974|NCT06394505|||OTHER||PROSPECTIVE|||||||
33983975|NCT00162669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983976|NCT03187145|||COHORT||PROSPECTIVE|||||||
33983977|NCT02713022|||COHORT||PROSPECTIVE|||||||
33983978|NCT05133778|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, double-blind, placebo-controlled parallel trial|t|f|t|t
33983979|NCT01393288|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34079473|NCT03434639|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079474|NCT00221013|RANDOMIZED|PARALLEL||||NONE||||||
34079475|NCT02805283|||COHORT||CROSS_SECTIONAL|||||||
33771620|NCT05408923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Irrisept can be differentiated visually from normal saline. Patients will be informed in the consent that they will be blinded to the treatment they are randomized to throughout the study.|"Patients will be randomized preoperatively to the study group (Irrisept) versus the control group (sterile saline irrigation).~Standard betadine and/or chloraprep solution will be used to prep the patient.~Control group will get normal saline for irrigation throughout the case while study group will be irrigated with the Irrisept solution intermittently throughout the procedure per surgeon discretion.~No Vancomycin powder will be used in both groups at the time of closure. Standard closure will be performed."|t|f|f|f
33771621|NCT00840996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771622|NCT01219803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33771623|NCT03219203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771624|NCT00153946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983980|NCT01026623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983981|NCT03047265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33983982|NCT03656185|||COHORT||RETROSPECTIVE|||||||
33983983|NCT01853553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33983984|NCT06518343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double blind masking|Crossover Assignment|t|f|t|t
33983985|NCT05909579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983986|NCT03146247|NA|SINGLE_GROUP||OTHER||NONE||||||
33983987|NCT06254677|||COHORT||RETROSPECTIVE|||||||
33983988|NCT03827044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33983989|NCT05711771|||CASE_ONLY||RETROSPECTIVE|||||||
33983990|NCT01652794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983991|NCT00005722|||NATURAL_HISTORY|||||||||
33983992|NCT05983874|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33983993|NCT05774860|||COHORT||PROSPECTIVE|||||||
33983994|NCT01270503|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33983995|NCT03106610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33983996|NCT00791947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33983997|NCT04832399|||COHORT||PROSPECTIVE|||||||
33983998|NCT02884232|||COHORT||PROSPECTIVE|||||||
34024735|NCT01658501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079476|NCT03976752|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34024736|NCT00037024||||OTHER||||||||
34024737|NCT03429400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024738|NCT04430478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|QVA analysis will be performed by an investigator blinded to the volume flow analysis outcomes.|The study will include consecutive patients undergoing fluoroscopically-guided percutaneous balloon angioplasty due to dysfunctional AVF. Intraprocedural volume flow measurements will be obtained just prior to the procedure and after each balloon dilation. Volume flow measurements will be correlated with digital subtraction angiography quantitative vessel analysis (QVA) performed by an independent investigator blinded to the volume flow analysis outcomes. Follow up DUS imaging including volume-flow assessment will be set at 24h, 6, and 12 months, while fistulograms with QVA analysis will be performed at 6 and 12 months.||||
34079477|NCT02473185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34079478|NCT03793569|RANDOMIZED|PARALLEL||PREVENTION||NONE||Control group and intervention group. Intervention group will participate in peer discussion group.||||
34079479|NCT04163848|||OTHER||PROSPECTIVE|||||||
34079480|NCT05397197|NA|SINGLE_GROUP||OTHER||NONE||||||
34079481|NCT01477762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34079482|NCT01010737|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34079483|NCT02799563|RANDOMIZED|FACTORIAL||||NONE||||||
34079484|NCT03788694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079485|NCT04360460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34079486|NCT00433472||||DIAGNOSTIC||||||||
34079487|NCT00143338|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771625|NCT01254305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681191|NCT05397782|NA|SINGLE_GROUP||PREVENTION||NONE||A single group of women with recurrent symptomatic UTI will be studied longitudinally while using the intervention system. Results will be compared with historical controls.||||
33681192|NCT01491594|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771626|NCT03752619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771627|NCT00229619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771628|NCT05672004|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Recipients of ProMuscle are not the target group within this study. Healthcare professionals are the participants of the study, they know that they received the implementation toolbox once they switched to the intervention group|stepped wedge cluster trial and mixed methods process analysis||||
33771629|NCT00003792||||TREATMENT||||||||
33771630|NCT01880762|||CASE_ONLY||PROSPECTIVE|||||||
33771631|NCT01079624|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33771632|NCT02791555|||CASE_CONTROL||PROSPECTIVE|||||||
33771633|NCT04461925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental: stem cells therapy + treatment in according with approved by Ukrainian Health Ministry COVID-19 clinical protocol Experimental Group 1: Subjects with severe COVID-19 pneumonia shall be received three infusions of cryopreserved allogeneic P-MMSCs (1 million cells/kg body weight) at 2-days intervals: Day 1, Day 4, Day 7.~Control Group: treatment in according with approved by Ukrainian MoH COVID-19 clinical protocol."||||
33771634|NCT06387589|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33771635|NCT02738671|||COHORT||CROSS_SECTIONAL|||||||
33771636|NCT01812382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771637|NCT05601921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771638|NCT03106519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771639|NCT05102591|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants, research staff, and clinical staff, including the investigator, research assistant, research nurse, and attending physician, will remain blind to the study interventions.|The investigators will carry out a pilot randomized controlled trial (RCT) to determine the feasibility and acceptability of implementing a double-dummy, crossover RCT protocol.|t|t|t|f
33771640|NCT01614847|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33771641|NCT02766998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771642|NCT03937323|||CASE_CONTROL||PROSPECTIVE|||||||
33771643|NCT01900054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771644|NCT00282230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901259|NCT02016066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901260|NCT01204112|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901261|NCT02681887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33901262|NCT01347567|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33901263|NCT06311240|||COHORT||PROSPECTIVE|||||||
33901264|NCT06448780|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The first cohort of 8 infants will receive a lower loading dose of caffeine. Following a safety review, an additional 8 infants will receive a higher loading dose.||||
33901265|NCT02162875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901266|NCT02765412|||CASE_CONTROL||PROSPECTIVE|||||||
34024739|NCT05228028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33771645|NCT03864926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771646|NCT01264029|RANDOMIZED|PARALLEL||PREVENTION||||||||
33771647|NCT01898975|||CASE_ONLY||PROSPECTIVE|||||||
33771648|NCT06453018|NA|SINGLE_GROUP||TREATMENT||NONE||Children aged 6 to 17 years of age with positional OSA (POSA) will receive the positional therapy.||||
33771649|NCT05558943|||COHORT||OTHER|||||||
33771650|NCT02214823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771651|NCT00441051|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33771652|NCT06348537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771653|NCT01830192|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771654|NCT02654795|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771655|NCT01700348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33771656|NCT00064272|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33771657|NCT00650494|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771658|NCT04658732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomly allocated by a computer-generated table into one of the study groups; the randomization sequence will be concealed in sealed opaque envelopes.|Randomized double blinded study.|t|t|f|f
33771659|NCT01729728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771660|NCT00307099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901267|NCT04021784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is blinded to the medical device until after surgery. This is done to prevent selection bias through withdrawal. Patients are unblinded post-operatively, to enable accurate patient counseling with radiographs, on which the implant can be clearly seen.|Half of the patients will be implanted with SDS system, the other half will be implanted with NEMOST.|t|f|f|f
33901268|NCT04283461|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33901269|NCT01864577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901270|NCT02446639|||CASE_ONLY||PROSPECTIVE|||||||
33901271|NCT04099446|||CASE_ONLY||PROSPECTIVE|||||||
34024740|NCT01860677|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33983999|NCT03067207|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|This study will be a single-blinded study (investigators only). Participants will be coded using Arabic numerals. A research assistant will receive all questionnaires and cortisol samples. Mindfulness facilitators will be unaware of participant identification numbers. Participants will be assigned to one of four groups (experimental arm) or to one of two groups (feasibility arm) following a computer-generated randomization list (permuted block design, using blocks of two or four). The allocation sequence will be generated by a statistician not otherwise involved in the project and passed on to a research assistant after patient identification data has been collected (ensuring that the investigators are kept blind to the allocation of each participant). Allocation sequence will be password-protected and only accessible by the statistician and research assistant.|The study will be conducted as a longitudinal randomized non-inferiority trial comparing two arms: an experimental arm and feasibility arm. Participants living close enough to commit to in-person sessions will be entered in the experimental arm of the study. The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. At the end of the recruitment period, once participants have been placed in the experimental and feasibility arms, two separate randomizations will take place. The first randomization (experimental arm) will serve to assign participants to one of the four experimental groups and the second randomization (feasibility arm) will assign participants to one of the two feasibility groups.|f|f|t|f
33984000|NCT05034653|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This study applying mixed study method that consists of two parts: quantitative and qualitative. The quantitative part involved allocating participants into two intervention arms; combined Intermittent Fasting and Healthy Plate (IFHP) group and Healthy Plate (HP) group, and measuring the outcomes at baseline, 3-month and 6-month. On the other hand, the qualitative part aimed to explore the facilitators and barriers that enable or admonish the success of weight loss in the IFHP group through Focused Group Discussion that was conducted at month 6.||||
33984001|NCT03453125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901272|NCT05227651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901273|NCT03849560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33984002|NCT01123265|||CASE_CONTROL||PROSPECTIVE|||||||
33984003|NCT01759901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984004|NCT03321578|||CASE_ONLY||CROSS_SECTIONAL|||||||
33771661|NCT05453981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771662|NCT02087150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984005|NCT02947230|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33984006|NCT04567186|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34079488|NCT06213558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901274|NCT02943551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34079489|NCT06160765|||CASE_CONTROL||OTHER|||||||
33901275|NCT04210713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
34079490|NCT01826942|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079491|NCT01276158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079492|NCT05782075|||COHORT||PROSPECTIVE|||||||
34079493|NCT03912038|||COHORT||PROSPECTIVE|||||||
34079494|NCT05638282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771663|NCT00429260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079495|NCT00533871|||DEFINED_POPULATION||OTHER|||||||
34079496|NCT00804453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771664|NCT03905590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33771665|NCT06146309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901276|NCT00477373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901277|NCT04681846|||CASE_ONLY||PROSPECTIVE|||||||
33901278|NCT01048515|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33901279|NCT02797873|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901280|NCT04635644|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33901281|NCT06672835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The intervention study model is parallel where participants will be randomly assigned to the experimental group (n=16) and the active comparator group (n=16).|t|f|f|f
33901282|NCT02013934|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33901283|NCT06035380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|f|f|f|t
33901284|NCT03005535|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34079497|NCT03920085|NA|SINGLE_GROUP||OTHER||NONE||||||
34079498|NCT04956471|||CASE_ONLY||PROSPECTIVE|||||||
34079499|NCT02840266|||CASE_ONLY||PROSPECTIVE|||||||
34079500|NCT02233426|||CASE_CONTROL||RETROSPECTIVE|||||||
34079501|NCT02635308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079502|NCT04798157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901285|NCT06299007|||COHORT||RETROSPECTIVE|||||||
33681193|NCT04316975|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects will undergo a standard of care (SOC) esophagogastroduodenoscopy (EGD). At this visit, research biopsies will be obtained - 4 research biopsies at the midpoint of current Barrett's Esophagus (BE) OR slides will be cut from clinical Endoscopic Mucosal Resection (EMR). Slides will be analyzed for mutational load (ML) analysis and gastroenterologist (GI) pathologist diagnosis for the presence of adenocarcinoma or degrees of dysplasia. ML will be correlated to the pathology diagnosis on this research biopsy. Subjects will then undergo (Endoscopic Eradication Therapy) EET per routine standard of care at the treating institution until Complete Eradication of Intestinal Metaplasia (CEIM) is achieved. Subjects will be followed (data collection only) during treatment period until CEIM is achieved. After subjects reach CEIM, four additional research biopsies will be collected, from the midpoint of previous BE site.||||
33681194|NCT02079818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681195|NCT06385067|||CASE_ONLY||PROSPECTIVE|||||||
33901286|NCT05113004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multi-center, prospective, randomized, double blinded|t|t|t|f
33901287|NCT02307526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901288|NCT03246269|||COHORT||PROSPECTIVE|||||||
33901289|NCT04805931|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Prospective, randomized controlled, parallel groups trial|t|f|f|f
33901290|NCT05237882|NA|SINGLE_GROUP||TREATMENT||NONE||A non-concurrent multi-variate baseline single-case experimental design (SCED) including 6 children and 6 adolescents with their parents. Baseline periods randomized between 5-15 days||||
33901291|NCT03391518||PARALLEL||BASIC_SCIENCE||NONE||||||
33901292|NCT06671028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901293|NCT06671236|NA|SEQUENTIAL||TREATMENT||NONE||||||
33901294|NCT06513195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901295|NCT02905773|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33901296|NCT06123429|NA|SINGLE_GROUP||OTHER||NONE||Single pilot group, up to 40 patients will enroll and all will receive intervention.||||
33681196|NCT00307008|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33681197|NCT05738343|||CASE_ONLY||PROSPECTIVE|||||||
33681198|NCT05282056|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The random assignment is done automatically by the CAD system and is not visible to the patient. The radiologist obviously sees which cases have CAD analysis and which not.|CAD outputs are turned off for randomly chosen 50% of patients, which represent the control group. The other 50% are analysed using CAD|t|f|f|f
33681199|NCT05580445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681200|NCT00802113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681201|NCT02610101|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33681202|NCT04658940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681203|NCT03697135|||OTHER||PROSPECTIVE|||||||
33681204|NCT01352260|||COHORT||PROSPECTIVE|||||||
33681205|NCT02086643|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33681206|NCT00838864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681207|NCT06129617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681208|NCT03680235|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681209|NCT05084729|||OTHER||PROSPECTIVE|||||||
33681210|NCT02762227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681211|NCT05814302|||CASE_ONLY||PROSPECTIVE|||||||
33681212|NCT05205473|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33681213|NCT02250001|||CASE_ONLY||OTHER|||||||
33901297|NCT06667336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901298|NCT05000606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984007|NCT00353353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33984008|NCT01768858|||COHORT||PROSPECTIVE|||||||
33984009|NCT04335396|||COHORT||PROSPECTIVE|||||||
33984010|NCT00279357|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984011|NCT02601482|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984012|NCT05789602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33984013|NCT02883335|||COHORT||PROSPECTIVE|||||||
33984014|NCT05009225|||COHORT||PROSPECTIVE|||||||
33984015|NCT01988974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984016|NCT00535054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681214|NCT05944172|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33681215|NCT01982968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681216|NCT02057588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681217|NCT04678076|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking procedure will be applied.|Single dose, open-label, randomised, two-period, two-way cross-over, two-stage bioequivalence study.||||
33681218|NCT04582123|NA|SEQUENTIAL||TREATMENT||NONE||||||
33681219|NCT02925416|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33681220|NCT00321581||||TREATMENT||||||||
33681221|NCT02726542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681222|NCT03852680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681223|NCT02653703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33681224|NCT01369329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681225|NCT01552798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681226|NCT01788410|||COHORT||PROSPECTIVE|||||||
33681227|NCT02600871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681228|NCT04375319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681229|NCT04925856|NA|SINGLE_GROUP||OTHER||NONE||||||
33681230|NCT04874051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The experimental group is treated through a sensor-based devices in a virtual environment, while the control group is treated through conventional physiotherapy for balance rehabilitation|f|f|t|t
33681231|NCT01605500|||CASE_ONLY||PROSPECTIVE|||||||
33901299|NCT04433520|||OTHER||PROSPECTIVE|||||||
33901300|NCT05180305|||CASE_ONLY||PROSPECTIVE|||||||
33901301|NCT02836886|||OTHER||PROSPECTIVE|||||||
33901302|NCT03554681|||COHORT||PROSPECTIVE|||||||
33901303|NCT04175912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901304|NCT01771094|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33901305|NCT00850772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901306|NCT05151744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984017|NCT00989924|||CASE_ONLY||CROSS_SECTIONAL|||||||
33681232|NCT01167387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681233|NCT04218565|NA|SINGLE_GROUP||TREATMENT||NONE||Golimumab is approved for the treatment of several inflammatory diseases, the self-control study aims to evaluate the response to GOL in refractory BDU.||||
33681234|NCT02802046|||CASE_CONTROL||RETROSPECTIVE|||||||
33681235|NCT03842982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901307|NCT02958137|||COHORT||PROSPECTIVE|||||||
33901308|NCT03228251|||COHORT||CROSS_SECTIONAL|||||||
33901309|NCT02420964|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681236|NCT00213694|||||PROSPECTIVE|||||||
33681237|NCT04870697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33681238|NCT05885308|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33681239|NCT00998244|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33681240|NCT04821505|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a single-blind randomized controlled trial with all data collection personnel and investigators blinded to subjects' treatment status. The study coordinator does not collect data but receives subjects assigned treatment and then to informs them of their treatment group|Meditation (Transcendental Meditation, TM) was employed as a lifestyle modification strategy compared to a health education control with exercise and dietary recommendations but with no stress management component|f|f|t|t
33681241|NCT01044329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33681242|NCT04810780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681243|NCT02967757|||COHORT||RETROSPECTIVE|||||||
33681244|NCT00771589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681245|NCT04215757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681246|NCT00813540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681247|NCT00843778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681248|NCT01697540|||CASE_ONLY||PROSPECTIVE|||||||
33681249|NCT01392651|||CASE_CONTROL||RETROSPECTIVE|||||||
33681250|NCT05676775|||COHORT||PROSPECTIVE|||||||
33681251|NCT01922401|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33681252|NCT03229343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Experimental arm : supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.~Non interventionnel arm: only pneumological consultation performed at M0, M3 and M6."||||
33681253|NCT02025153|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681254|NCT05370703|||OTHER||PROSPECTIVE|||||||
33771666|NCT01566786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901310|NCT04843111|||COHORT||PROSPECTIVE|||||||
33901311|NCT03418038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901312|NCT04346394|NA|SINGLE_GROUP||OTHER||NONE||||||
33901313|NCT01579201|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33901314|NCT01782599|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901315|NCT00340327|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33901316|NCT00296348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901317|NCT00122499|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33901318|NCT02988804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901319|NCT05696366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind|Each participant will receive 12-week insulin-adjunctive treatment with both: (1) SGLTi (sotagliflozin 200 mg PO each day) + Placebo and (2) SGLTi + GRA (volagidemab 35 mg subcutaneously each week), in a random-order, cross-over design with a 14-week washout period between treatment periods.|t|f|t|f
33901320|NCT02743637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901321|NCT04100070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective randomized parallel groups open study||||
33901322|NCT04085510|NA|SINGLE_GROUP||SCREENING||NONE||||||
33901323|NCT06451237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor responsible for the follow up (assessing primary and secondary measures) during the treatment and maintenance phases was blinded to the line of treatment used.|Interventional study on 3 parallel groups, with random assignment and longitudinal follow up, conducted in two phases (treatment and maintenance).|f|f|t|t
33901324|NCT02714205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901325|NCT03656640|||CASE_ONLY||PROSPECTIVE|||||||
33681255|NCT03372759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681256|NCT04712240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participant, care giver, investigator and outcomes assessor will be aware that all participants are wearing a portable respiration rate monitor whose measurements will be compared to the gold standard of capnography|Participants will wear a portable respiration rate monitor that records respiration rate continuously while their respiration rate is also concurrently monitored and recorded using capnography (gold standard)||||
33681257|NCT02358356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771667|NCT00569361|NA|SINGLE_GROUP||SCREENING||NONE||||||
33901326|NCT01500174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901327|NCT06298292|||CASE_CONTROL||PROSPECTIVE|||||||
33901328|NCT03184701|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33901329|NCT05396118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901330|NCT06404008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Only the statistician will be blinded to study group|||||
33901331|NCT03076008|||COHORT||PROSPECTIVE|||||||
33901332|NCT02172222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901333|NCT01232946|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901334|NCT02887846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901335|NCT04055935|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||split mouth study design, side intervention and other side for control|f|f|f|t
33901336|NCT03671083|||COHORT||PROSPECTIVE|||||||
33901337|NCT05730439|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33901338|NCT04770155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33901339|NCT00427661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901340|NCT02136394|||COHORT||PROSPECTIVE|||||||
33901341|NCT06333847|||COHORT||PROSPECTIVE|||||||
33901342|NCT02060708|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33901343|NCT04692493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901344|NCT00668525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901345|NCT06666361|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33901346|NCT06671158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901347|NCT00001332||||TREATMENT||||||||
33901348|NCT06228183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33901349|NCT01818375|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33901350|NCT01687231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901351|NCT04832438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901352|NCT01662973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901353|NCT05983367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized 1:1|t|t|t|t
33901354|NCT06019143|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33901355|NCT02717546|||OTHER||PROSPECTIVE|||||||
33901356|NCT05929326|||CASE_ONLY||CROSS_SECTIONAL|||||||
33901357|NCT04390815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33901358|NCT02847611|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33901359|NCT02752308|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33901360|NCT03803046|||COHORT||PROSPECTIVE|||||||
33901361|NCT01635933|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33901362|NCT06672211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33901363|NCT03133481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The first two groups will have 50 participants each (100 total) the Adductor Canal Nerve Catheter group and the Femoral Nerve Catheter, group. Participants will be randomized using block randomization. The blocks will be assigned randomly based on computer generated numbers."|t|f|f|f
33901364|NCT05658029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901365|NCT06027320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33901366|NCT02028572|||CASE_ONLY||CROSS_SECTIONAL|||||||
33901367|NCT04950985|||COHORT||PROSPECTIVE|||||||
33901368|NCT00780000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901369|NCT02265211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901370|NCT03947879|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984018|NCT03164889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984019|NCT04584268|RANDOMIZED|PARALLEL||TREATMENT||NONE||cluster randomized controlled trial||||
33901371|NCT06470958|||COHORT||PROSPECTIVE|||||||
33901372|NCT00866294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901373|NCT00000711||||TREATMENT||NONE||||||
33901374|NCT06673381|||CASE_ONLY||PROSPECTIVE|||||||
33901375|NCT00695994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901376|NCT03087253|||COHORT||PROSPECTIVE|||||||
33901377|NCT05032976|||COHORT||PROSPECTIVE|||||||
33901378|NCT02368444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901379|NCT04976075|||COHORT||PROSPECTIVE|||||||
33901380|NCT00247481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901381|NCT01971879|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33901382|NCT05738213|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33901383|NCT02613572|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901384|NCT06672510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984020|NCT05343143|NA|SINGLE_GROUP||TREATMENT||NONE||single arm investigational clinical trial||||
33984021|NCT02898545|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33984022|NCT06373705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"After consent to participate in the study, patient will be entered into a random allocation sequence for standard of care (SOC) or cardiac simulator groups.~Patient and surgeon will both be notified which group they have been assigned to."|"1:1 randomization to either receive standard of care on the fly surgical planning discussion as is current practice or assisted surgical planning discussion with the aid of computer simulation."||||
33984023|NCT03916094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984024|NCT00827853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984025|NCT03734497|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomised||||
33901385|NCT04210973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984026|NCT00803478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984027|NCT00824148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984028|NCT02172105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984029|NCT00183807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984030|NCT01297348|||CASE_CONTROL||RETROSPECTIVE|||||||
33984031|NCT00119379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901386|NCT00765869|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901387|NCT01494038|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33901388|NCT00308295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901389|NCT03070912|||COHORT||PROSPECTIVE|||||||
33901390|NCT04251585|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All participants, care providers, investigators, and outcomes assessors are masked.|"Participants will be randomly assigned to one of 3 treatment groups or the placebo group.~* 20 international units twice daily (n=7)~* 40 international units twice daily (n=7)~* 80 international units twice daily (n=9)~* placebo (n=7)"|t|t|t|t
33901391|NCT04876664|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901392|NCT00435539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901393|NCT03312673|||COHORT||PROSPECTIVE|||||||
33901394|NCT02749721|NA|SINGLE_GROUP||OTHER||NONE||||||
33901395|NCT05215210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Supplements will be labeled A and B by a scientist who is not involved in this trial.||t|t|t|f
33901396|NCT01668238|||||CROSS_SECTIONAL|||||||
33901397|NCT04483362|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079503|NCT03173417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901398|NCT04522102|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33901399|NCT03189225|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901400|NCT02179307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901401|NCT05032833|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33901402|NCT00870272|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901403|NCT00941772|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901404|NCT05501444|NA|SINGLE_GROUP||TREATMENT||NONE||The project is carried out as a pilot study||||
33901405|NCT06671639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901406|NCT06304272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double blinded, parallel, non-inferiority trial|t|t|f|f
33901407|NCT01276015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901408|NCT04710940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After completing the informed consent, study staff will enter the participant's information into pre-populated REDCap identification numbers. This will assign allocation based on the randomization table. Using this technique, participants will be blinded to allocation. However, research staff will not be blinded to provide personalized training for intervention and control. The investigator will be blinded to randomization for all participants during the study.|"The purpose of this study is to develop and usability test a patient-centric intervention designed to improve implementation of diabetes self-management training. To accomplish this, 3 specific aims will be completed.~Aim 1 - Retrospective data from the UMass Medical School EHR data repository will be analyzed to identify different clusters of patients with diabetes.~Aim 2 - To facilitate a patient-centric design of the DM-BOOST intervention, Patient Research Expert Panel (PREP) members (n\</=10) will be recruited from various patient types identified in Aim 1 (Aim 2a), participate in Community Engagement Studios to inform intervention conceptualization (Aim 2b) and usability test the intervention (Aim 2c).~Aim 3 - The intervention will be pilot tested in n\</=70 patients with type 2 diabetes (T2D). Participants will be randomized to either intervention or comparison groups."|t|f|t|f
33901409|NCT06672705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901410|NCT03131297|NA|SINGLE_GROUP||OTHER||NONE||||||
33984032|NCT04691830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a comparative intervention study comparing the effect of prosodic rehabilitation in addition to the traditional language and auditory training on prosodic skills of hearing impaired children in comparison to traditional language and auditory rehabilitation alone.|t|f|f|t
33984033|NCT00830401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984034|NCT03343730|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33984035|NCT01621165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984036|NCT03051204|||CASE_ONLY||PROSPECTIVE|||||||
33984037|NCT00380445|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33984038|NCT00994253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984039|NCT05218798|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|All subjects will be blinded for group allocation during testing procedures, including coaches (care provider), soldiers (participants) investigators, and outcomes assessors.|Crossover randomized validation study|t|t|t|t
33984040|NCT02956772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079504|NCT05665868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34079505|NCT05078983|||COHORT||PROSPECTIVE|||||||
34079506|NCT02849587|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|Product will be dispensed from the Research Pharmacy. All assessors, investigators, and participants are blinded to the THC content.|Participants will be randomized to smoke a cannabis cigarette containing placebo (.02%), 5.9% or 13.4% THC.|t|f|t|t
34079507|NCT00930462|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34079508|NCT00370500|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079509|NCT01222104|||COHORT||PROSPECTIVE|||||||
33984041|NCT04497181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984042|NCT00939003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079510|NCT02651870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901411|NCT00813956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984043|NCT00464048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33984044|NCT03685565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental group: Dermabond with underlying steristrips. Control group: Dermabond alone|f|f|t|t
33984045|NCT00278980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984046|NCT02304809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984047|NCT00404430|||COHORT||PROSPECTIVE|||||||
33984048|NCT00721747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984049|NCT04886973|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The groups will receive the treatment simultaneously||||
34079511|NCT05306847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079512|NCT04577638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079513|NCT05282147|NA|SINGLE_GROUP||SCREENING||NONE||||||
34079514|NCT02869763|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34079515|NCT03506048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901412|NCT00856752|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33901413|NCT00827268|NA|SINGLE_GROUP||TREATMENT||NONE||This is a repeated probe design study.||||
33901414|NCT05392322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901415|NCT05885685|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901416|NCT03829189|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Arm 1: inulin; minimum of 14 days wash-out; 14 days placebo Arm 2: 14 days placebo; minimum of 14 days wash-out; 14 days placebo|t|f|t|f
33901417|NCT02005523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901418|NCT04388735|||COHORT||PROSPECTIVE|||||||
33901419|NCT01819688|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33901420|NCT06575621|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Non-randomized intervention||||
33901421|NCT06113666|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants are in theory blinded to which group they are allocated to. However, it is not possible to blind completely as it is easy for the patients to see if they are receiving active, interactive treatment or are allocated into the control group with patient education.|||||
33901422|NCT03461289|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi||||
33901423|NCT06408831|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||two groups with control group without training||||
33901424|NCT05740007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901425|NCT03083951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient does not know the group to which it has been assigned.|Randomized controlled trial, single blind (the patient does not know the group to which it has been assigned) of patients undergoing laparoscopic sigmoid colon cancer resection. In all patients a lymphadenectomy with a high ligation of the Lower Mesenteric Artery will be performed. In patients in group 1A, lymphadenectomy will also include the lymphogranular tissue that accompanies the inferior mesenteric vein from its origin (complete mesocolon excision). In patients in group 1B, a conventional lymphadenectomy will be performed only from the origin of the inferior mesenteric artery without including the lymphatic tissue of the origin of the inferior mesenteric vein.|t|f|f|f
33901426|NCT02116972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901427|NCT06180551|||CASE_ONLY||PROSPECTIVE|||||||
33901428|NCT03635190|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, multi-center, non-randomized single-arm study||||
33901429|NCT04144881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901430|NCT00887445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901431|NCT02292381|||COHORT||PROSPECTIVE|||||||
33901432|NCT03453060|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33901433|NCT02185170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901434|NCT06248008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901435|NCT01950884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901436|NCT01631357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901437|NCT00318838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901438|NCT04227977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901439|NCT03684083|||CASE_CONTROL||PROSPECTIVE|||||||
33901440|NCT01118143|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901441|NCT02071628|||COHORT||PROSPECTIVE|||||||
33901442|NCT01562769|||CASE_CROSSOVER||PROSPECTIVE|||||||
33984050|NCT02385409|||COHORT||PROSPECTIVE|||||||
33984051|NCT02711852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984052|NCT03060694|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33984053|NCT00860405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984054|NCT05677204|||COHORT||PROSPECTIVE|||||||
33984055|NCT02435225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984056|NCT01841866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984057|NCT00936871|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33901443|NCT00053820|RANDOMIZED|||TREATMENT||NONE||||||
33901444|NCT01938222|||COHORT||PROSPECTIVE|||||||
33901445|NCT03223727|||COHORT||PROSPECTIVE|||||||
33901446|NCT02465034|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984058|NCT01095692|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984059|NCT01185821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking continued during the double blind period of extension only.|This extension study was originally set up as a 2 year dose-blinded extension study to maintain blinding of ongoing Core study. Study was later amended to include a subsequent Open-Label treatment phase after Core study was unblinded. During the Dose-Blinded phase of the extension study patients received the same dose from the Core study. Patients who received placebo in Period 1 during the Core Study were equally randomized to 1 of the 3 active doses of siponimod used during Period 1 (0.5, 2.0, or 10 mg) and patients who received placebo in Period 2 were equally randomized to 1 of the 2 active doses of siponimod used during Period 2 (0.25 mg or 1.25 mg).|t|t|t|t
33984060|NCT00336622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984061|NCT04510077|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984062|NCT00488774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984063|NCT05123495|||COHORT||PROSPECTIVE|||||||
33984064|NCT01758627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984065|NCT03726866|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984066|NCT02455492|||COHORT||RETROSPECTIVE|||||||
33984067|NCT02763865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984068|NCT01110005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984069|NCT05101044|NA|SINGLE_GROUP||TREATMENT||NONE||An uncontrolled open trial approach will be used in which all participants receive the ABBT intervention.||||
33984070|NCT06364709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681258|NCT04944056|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental Group received compression mobilization with Conventional Physiotherapy and the control group received Conventional Physiotherapy||||
33681259|NCT02632123|||COHORT||PROSPECTIVE|||||||
33681260|NCT00266786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681261|NCT05461378|||COHORT||PROSPECTIVE|||||||
33771668|NCT02890914|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33771669|NCT06488391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771670|NCT02101099|||CASE_ONLY||PROSPECTIVE|||||||
33771671|NCT00850720|||CASE_ONLY||PROSPECTIVE|||||||
33771672|NCT04443933|||COHORT||PROSPECTIVE|||||||
33771673|NCT04934774|NA|SEQUENTIAL||TREATMENT||NONE||||||
33771674|NCT01672450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771675|NCT05923593|NA|SINGLE_GROUP||OTHER||NONE||||||
33771676|NCT05403203|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33771677|NCT04388930|||COHORT||PROSPECTIVE|||||||
33771678|NCT05353543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771679|NCT03708419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771680|NCT03326089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants are blindly randomized to receive oxygen or not during rehabilitation.||t|f|t|f
33771681|NCT03173443|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
33771682|NCT05418777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771683|NCT00931450|RANDOMIZED|||TREATMENT||DOUBLE||||||
33771684|NCT01734850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771685|NCT04985734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cohort of patients||||
33984071|NCT05448430|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||f|t|f|t
33984072|NCT01386294|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681262|NCT00653432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681263|NCT00023699||||TREATMENT||||||||
33681264|NCT02068898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901447|NCT03576677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is double-blinded; hence neither patients nor investigators are aware of the treatment assignment throughout the study period. 2 unblinded study nurses at each site will perform randomization and prepare study medication blinded to the rest of the research team.|"This is a prospective multi-center, double-blinded, placebo controlled, randomized study in patients with advanced chronic heart failure. Patients who meet the eligibility criteria will be randomized in a 1:1 ratio for treatment with 6 hours infusion of either (i) levosimendan 0.2 µg/kg/min or (ii) placebo (sterile 5% dextrose).~At baseline an upright ergometer maximal exercise test is performed to determine max workload and pVO2 (Test 0). Based on this test 50% of pVO2 with corresponding workload (watt) is calculated (submax).~At Day 0 patients will perform a supine ergometer maximal exercise test (Test 1) with simultaneous invasive hemodynamic measurement by Swan-Ganz catheter. Subsequently, patients will receive 6 hours infusion of study medication.~At Day 5 (4-6 days after infusion of study medication) patients will repeat the supine ergometer maximal exercise test (Test 2) with simultaneous invasive hemodynamic measurements."|t|t|t|t
33901448|NCT06320197|||COHORT||RETROSPECTIVE|||||||
33901449|NCT01676376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984073|NCT05478395|||COHORT||CROSS_SECTIONAL|||||||
33984074|NCT06181071|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33984075|NCT03481998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984076|NCT04249271|||COHORT||PROSPECTIVE|||||||
33984077|NCT05782647|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cuffless (watch type) BP monitor and standard beat-to-beat monitoring device||||
33984078|NCT02104960|||COHORT||PROSPECTIVE|||||||
33984079|NCT04181853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants wil be making exercise. It is not possible to make participants blinded to the study.|The study has 3 arms|f|f|t|t
33984080|NCT00292851|||COHORT||PROSPECTIVE|||||||
33984081|NCT02024646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984082|NCT06086574|||COHORT||PROSPECTIVE|||||||
33984083|NCT01530880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681265|NCT04954248|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681266|NCT02251548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681267|NCT02524613|||CASE_ONLY||PROSPECTIVE|||||||
33681268|NCT04634045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681269|NCT01517360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681270|NCT02718170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681271|NCT04184388|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33681272|NCT05516563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A feasibility randomised controlled trial|f|f|f|t
33771686|NCT00160160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771687|NCT01933386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771688|NCT04374500|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"In protocol 1, each participant was examined once. Leptin was given intraarterially in the forearm in increasing doses and forearm blood flow (FBF) was measured. No masking, no randomisation.~In protocol 2, each participant was examined twice and they got either leptin or saline intraarterially in the forearm at least 2 weeks apart, and the order was randomised. Concomitantly, they got four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) intraarterially in a randomised order.~In protocol 3, each participant was examined once and the three vasodilatators (substance P, acetylcholine, and sodium nitroprusside) were given intraarterially in the forearm in a randomised order."||||
33771689|NCT03194074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33771690|NCT00742105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771691|NCT05027737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multi-centre, assessor-blind, parallel-groups (1:1), pragmatic, randomized controlled trial|f|f|t|t
33984084|NCT02830516|||CASE_CROSSOVER||PROSPECTIVE|||||||
33984085|NCT03027115|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to 1 of 2 possible arms, control and treatment||||
33984086|NCT00487669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984087|NCT03192696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984088|NCT00620022|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34024741|NCT05506995|||CASE_ONLY||PROSPECTIVE|||||||
33901450|NCT04097717|RANDOMIZED|PARALLEL||OTHER||NONE||This study is a randomized controlled trial in which participants will be assigned to one of two groups (intervention arm or usual care arm) in parallel for the duration of the study. All participants will be asked to complete assessments at three separate time points \[immediately after using the decision aid (for those in the intervention arm) when participants are less than 24 weeks gestation (Time 1); in the 3rd trimester between 32-36 weeks gestation (Time 2); and three months postpartum (Time 3)\].||||
33901451|NCT04888221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901452|NCT03148171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901453|NCT03424109|||COHORT||RETROSPECTIVE|||||||
33901454|NCT06671990|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33901455|NCT02090582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901456|NCT05760937|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33901457|NCT06093880|||OTHER||PROSPECTIVE|||||||
33901458|NCT03210077|||COHORT||PROSPECTIVE|||||||
33901459|NCT05077189|||CASE_CONTROL||PROSPECTIVE|||||||
33901460|NCT02047877|||COHORT||PROSPECTIVE|||||||
33901461|NCT02026271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901462|NCT01346137|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33901463|NCT02852694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901464|NCT04929873|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||transdynation for real-time pressure monitoring||||
33901465|NCT03232723|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33901466|NCT01183546|||CASE_ONLY||PROSPECTIVE|||||||
33901467|NCT00891657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901468|NCT04086134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901469|NCT02951130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901470|NCT06201572|||OTHER||OTHER|||||||
33901471|NCT05873140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901472|NCT03953560|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Design Cohorts study in consecutive patients with objectively confirmed PE.||||
33901473|NCT03596125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901474|NCT00823329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901475|NCT05847972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The groups will be arranged randomly and the masking technique to be used will the single blind procedure. The random allocation to each group will be made just by the software Epidat version 4.2 of the Galician Health Service (link: https://www.sergas.es/Saude-publica/EPIDAT?idioma=es).||t|f|f|f
33901476|NCT06350162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901477|NCT03134963|||CASE_CONTROL||PROSPECTIVE|||||||
33901478|NCT05184764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled|t|t|t|f
33901479|NCT06666296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33901480|NCT00537823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901481|NCT00607828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901482|NCT05665985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The capsule form between the drug and the placebo was the same, there was no drug name label on the drug packaging, and only a number was given on the drug packaging.|This study was a Randomized Controlled Trial (RCT) with 30 research samples divided into two groups, containing 15 samples each for the treatment group and 15 for the control group. The treatment group was given Moringa oleifera extract of 40.50 mg/KGBW/day, while the control group was given a placebo for 30 days. The degree of disease activity (DAS28-CRP, DAS28-LED) was assessed before and after the intervention. Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days. Inclusion criteria are Female patients, 18-60 years, who met the RA criteria according to the ACR / EULAR 2010 and VAS\> 3. Exclusion criteria are Pregnant, using Methylprednisolone\> 8 mg per day, using NSAIDs, and having comorbidities|t|f|t|f
33901483|NCT04383977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901484|NCT03176966|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33901485|NCT04570891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984089|NCT05275205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This study is double-masked, masking patients and investigators to treatment assignment. In addition to this, any Clinical Research Organization and Sponsor team members who are actively engaged with the site will be masked.~The injector will be unmasked. Some additional roles at the site, Clinical Research Organization and Sponsor levels are unmasked."||t|f|t|f
33984090|NCT02881255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984091|NCT05487274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901486|NCT01003587|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33901487|NCT00659685|RANDOMIZED|CROSSOVER||||NONE||||||
33901488|NCT02292134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901489|NCT03311178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901490|NCT00987259|||COHORT||RETROSPECTIVE|||||||
33901491|NCT03324256|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33901492|NCT05788068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901493|NCT02606773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901494|NCT04824872|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33901495|NCT03152864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984092|NCT02939092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984093|NCT01035060|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901496|NCT06043323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901497|NCT06583395|||COHORT||PROSPECTIVE|||||||
33984094|NCT04768517|||COHORT||PROSPECTIVE|||||||
33984095|NCT00234078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984096|NCT00516880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984097|NCT01828697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024742|NCT05372640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024743|NCT01182376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33984098|NCT03314688|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The following study personnel will be masked to participant study arm: the staff performing DXA scan and blood processing/biomarker evaluation. The staff performing clinic measures, study staff reviewing forms and entering data, the PI and Co-Is, the statistician, study manager, and interventionists (study dieticians) will be unblinded.||f|t|f|t
33984099|NCT00856388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901498|NCT06385496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901499|NCT00795626|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901500|NCT05385705|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|"This is an open label, multi-center, proof of concept, phase Ib trial.~A total of 6 patients will be included in the safety lead-in phase. If signs of both clinical and biological activity are seen, and no more than 1 TLT is observed in those first 6 patients, the study will expand with 14 additional patients (expansion phase)."||||
33901501|NCT03208192|RANDOMIZED|PARALLEL||TREATMENT||NONE||"two groups will be compared. Group 1: liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).~Group 2: liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)"||||
33901502|NCT06012604|NA|SINGLE_GROUP||TREATMENT||NONE||intervention group control group||||
33901503|NCT06445335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984100|NCT06022302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Overall, there are two parallel arms (low- and high-fiber diet) to which the participants will be randomized with an allocation ratio 1:1. In each arm participants will be exposed to a crossover design where participants in random order will continue on the meal intervention alone (control) or receive Movicol (a laxative) along with the meal intervention to shorten intestinal transit time.||||
33681273|NCT01311635|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33681274|NCT00043329|||||RETROSPECTIVE|||||||
33901504|NCT02430792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33901505|NCT05868967|NA|SINGLE_GROUP||OTHER||NONE||A single-center, single-dose, open-label design||||
33901506|NCT01452425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901507|NCT00685178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901508|NCT02094079|||COHORT||RETROSPECTIVE|||||||
33901509|NCT04308265|||CASE_ONLY||PROSPECTIVE|||||||
33901510|NCT02444169|||COHORT||RETROSPECTIVE|||||||
33901511|NCT04773041|||COHORT||CROSS_SECTIONAL|||||||
33901512|NCT00517686|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33901513|NCT06249126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984101|NCT00631826|||CASE_ONLY||PROSPECTIVE|||||||
33681275|NCT01348711|||COHORT||PROSPECTIVE|||||||
33681276|NCT04367051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681277|NCT03746288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681278|NCT03265964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681279|NCT03721029|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33681280|NCT02412813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901514|NCT03279237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901515|NCT04119323|||CASE_ONLY||PROSPECTIVE|||||||
33901516|NCT03528252|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization by sealed envelopes, opened in private. Allocation sequence and envelopes provided by external agent. Participants are instructed not to discuss intervention outside household. No more than one (randomly selected) participant per household allowed.|Two identical parallel groups|t|t|t|f
33901517|NCT05762822|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Power calculation resulted in n=18 for the primary endpoint. We plan to include n= 20 to ensure statistical power and take dropouts, missing values etc into account.~Washout period of minimum 3 days."|t|f|t|f
33901518|NCT00750347|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33901519|NCT01088815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901520|NCT01539265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901521|NCT05895318|||COHORT||CROSS_SECTIONAL|||||||
33901522|NCT00067522|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33901523|NCT02214979|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901524|NCT04308369|NA|SINGLE_GROUP||OTHER||NONE||interventional study with minimal risk. Ony blood collection done during study to determinate biological marker level||||
33901525|NCT03398408|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901526|NCT01067638|RANDOMIZED|||TREATMENT||DOUBLE||||||
33901527|NCT06649903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a randomized controlled study.|f|f|f|t
33901528|NCT01301612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901529|NCT02194881|||COHORT||RETROSPECTIVE|||||||
33901530|NCT03514472|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"In the study 34 of ages between 13-30 years divided into 2 age groups (below and above 18) were selected (excluding pregnant and lactating women) and were intervened with value added supplement  Moringa oleifera for a period of three months."||||
33901531|NCT04494711|NA|SINGLE_GROUP||PREVENTION||NONE||Mixed Methods||||
33901532|NCT06667466|||COHORT||PROSPECTIVE|||||||
33901533|NCT03254667|||COHORT||PROSPECTIVE|||||||
33901534|NCT01713036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901535|NCT04362267|||COHORT||CROSS_SECTIONAL|||||||
33901536|NCT04877782|||OTHER||CROSS_SECTIONAL|||||||
33901537|NCT01352377|||COHORT||RETROSPECTIVE|||||||
33901538|NCT06671379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901539|NCT01347684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901540|NCT05315310|NA|SINGLE_GROUP||TREATMENT||NONE||Single intervention arm||||
33901541|NCT01332435|||COHORT||RETROSPECTIVE|||||||
33901542|NCT03699345|||CASE_ONLY||PROSPECTIVE|||||||
33901543|NCT04089124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||repair zone II cut flexor of hand under GA and Walant|f|f|f|t
33901544|NCT01206595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901545|NCT03882840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901546|NCT03415074|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Eligible patients will enter a run-in phase (3 mo), when mild protein diet (0.8g/kg dry ideal bw) will be initiated and compliance will be evaluated twice monthly.~Those who will prove compliant during the run-in phase and still fulfill the selection criteria will be randomized 1:1 (computer-generated numbers) to receive the low protein diet (0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential amino-acids (Ketosteril 1 tb/10 kg dry bw) or to continue the mild protein restriction (0.8 g/kg-day)."||||
33901547|NCT06369324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33901548|NCT06673407|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||This trial uses a 2-variable full factorial design within the Multiphase Optimization Strategy (MOST) framework. Participants will be assigned to one of four study conditions involving 5.5-7.5-hours of workshops (depending on study condition) conducted over 3 in-person group sessions. Study conditions will vary depending on whether they 1) include self-compassion (i.e., common humanity) enhancements, and 2) are led by peer co-facilitators.|t|f|f|f
33901549|NCT03549624|||COHORT||PROSPECTIVE|||||||
33901550|NCT06014814|||CASE_CONTROL||PROSPECTIVE|||||||
33901551|NCT03660904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|only the investigator knew the procedure and the media provided for each case|"Group 1 blastocysts were vitrified with the Vit (home made) HM according to shady grove protocol using open system on cryotop vit. device and thawed with gradual thawing technique using HM thawing media according to Kuwayama protocol.~Group 2 blastocysts were cryopreserved with the Global Fast Freeze Kit using open system on cryotop vit. device and thawed using Global fast thaw kit. Blastocysts were assessed immediately for survival, subsequently cultured for 6-8 h, assessed for survival and expansion, then transferred and the percentages of Positive hCG, clinical pregnancy, implantation, multiple pregnancy and abortion were recorded."|f|t|t|f
33984102|NCT00096265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984103|NCT00057239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901552|NCT05700240|||COHORT||RETROSPECTIVE|||||||
33901553|NCT04533763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901554|NCT05823506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024744|NCT03096912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024745|NCT00714610|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024746|NCT04142112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901555|NCT01134887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024747|NCT04502420|||COHORT||PROSPECTIVE|||||||
34024748|NCT05097794|NA|SINGLE_GROUP||OTHER||NONE||One-sequence, 3-period study.||||
34024749|NCT05470205|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901556|NCT05134298|||COHORT||PROSPECTIVE|||||||
33901557|NCT02901262|||COHORT||PROSPECTIVE|||||||
33901558|NCT06671080|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||In the study, quantitative evaluation tests will be conducted and numerical data will be obtained.||||
34024750|NCT05200598|||COHORT||PROSPECTIVE|||||||
34024751|NCT04569669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901559|NCT06672653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33901560|NCT05314582|||CASE_CONTROL||PROSPECTIVE|||||||
33901561|NCT02277210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901562|NCT01616615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901563|NCT00844298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901564|NCT00021853||||TREATMENT||||||||
33901565|NCT00816972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984104|NCT03423056|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:~* Week 1: heart rate target: 50% of maximum heart rate~* Week 2: heart rate target: 60% of maximum heart rate~* Week 3: heart rate target: 70% of maximum heart rate~* Week 4: heart rate target: 60% of maximum heart rate~The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist.~The post intervention aerobic capacity will be measured at week 3 and 4 with the 6-minute walk test."||||
33984105|NCT00022386||||SUPPORTIVE_CARE||||||||
33984106|NCT06064799|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33984107|NCT00431600|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984108|NCT03929393|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33984109|NCT05335863|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossed, controlled and randomized clinical trial||||
33984110|NCT02867930|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33984111|NCT06372457|||COHORT||RETROSPECTIVE|||||||
33984112|NCT04776525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681281|NCT00727441|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681282|NCT05585593|||COHORT||PROSPECTIVE|||||||
33681283|NCT01410617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681284|NCT01819285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681285|NCT06394362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33681286|NCT01698307|RANDOMIZED|PARALLEL||TREATMENT||NONE||algorithm||||
33681287|NCT02470637|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33681288|NCT03189056|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33681289|NCT02631382|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33901566|NCT04257461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901567|NCT04448249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901568|NCT02947139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901569|NCT02316119|||CASE_CONTROL||PROSPECTIVE|||||||
33681290|NCT01375075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901570|NCT06403774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||TWO DIFFERENT BOWEL PREPARATION METHODS WILL BE COMPARED IN PATIENTS WHO WILL HAVE HEMORRHOIDECTOMY||||
33901571|NCT01278628|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33901572|NCT03237845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Participant|Randomized Controlled Trial|t|t|t|f
33901573|NCT02508714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901574|NCT00865462|RANDOMIZED|CROSSOVER||||NONE||||||
33901575|NCT00364546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901576|NCT00149929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901577|NCT04494009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33984113|NCT03274830|||CASE_ONLY||PROSPECTIVE|||||||
33984114|NCT02866422|||||CROSS_SECTIONAL|||||||
33681291|NCT02571907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681292|NCT00628043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681293|NCT00435253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984115|NCT03902028|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33984116|NCT01591447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984117|NCT03369730|||CASE_ONLY||PROSPECTIVE|||||||
33681294|NCT00745589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681295|NCT04685174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681296|NCT01090895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681297|NCT03343418|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33681298|NCT06270758|||CASE_CONTROL||PROSPECTIVE|||||||
33681299|NCT02219802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681300|NCT04130308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681301|NCT04673279|||COHORT||CROSS_SECTIONAL|||||||
33681302|NCT03001271|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33681303|NCT01286961|||CASE_ONLY||PROSPECTIVE|||||||
33681304|NCT00300742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681305|NCT04012671|||COHORT||PROSPECTIVE|||||||
33681306|NCT06492681|||COHORT||PROSPECTIVE|||||||
33681307|NCT02289716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681308|NCT01624311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681309|NCT04763681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participating couples are randomized to either immediately receive the Internet-delivered Couple HOPES intervention or to a delayed intervention group, where they receive access to Couple HOPES 8 weeks later.|f|f|f|t
33681310|NCT06370715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681311|NCT01666847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681312|NCT01564056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681313|NCT01456624|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33681314|NCT04075812|NA|SINGLE_GROUP||OTHER||NONE||Single arm, open-label, non-controlled prospective intervention||||
33681315|NCT00952380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681316|NCT01057875|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33681317|NCT03841747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681318|NCT05188157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681319|NCT03207373|NA|SINGLE_GROUP||SCREENING||NONE||||||
33681320|NCT00583713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681321|NCT01718340|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33681322|NCT02162407|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681323|NCT02083549|||CASE_ONLY||PROSPECTIVE|||||||
33681324|NCT06024512|||CASE_ONLY||OTHER|||||||
33681325|NCT03554811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33681326|NCT05449015|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33681327|NCT01253954|||CASE_ONLY||PROSPECTIVE|||||||
33771692|NCT02183428|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771693|NCT01418040|||COHORT||PROSPECTIVE|||||||
33771694|NCT01706224|||COHORT||CROSS_SECTIONAL|||||||
33771695|NCT04577742|||COHORT||RETROSPECTIVE|||||||
33839612|NCT03101462|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized to one of two different groups to receive either licensed inactivated influenza vaccine (IIV) or licensed live attenuated influenza vaccine (LAIV) from the 2010-2011 season.||||
33839613|NCT02121964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839614|NCT03848039|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33681328|NCT02126345|||COHORT||PROSPECTIVE|||||||
33681329|NCT00340574||||TREATMENT||||||||
33681330|NCT03940183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681331|NCT00532675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681332|NCT00061412|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33681333|NCT02431260||SEQUENTIAL||TREATMENT||NONE||||||
33681334|NCT03538171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681335|NCT01237483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681336|NCT02880696|RANDOMIZED|PARALLEL||||NONE||||||
33681337|NCT02585661|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33681338|NCT06076291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681339|NCT00348608|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681340|NCT01816451|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33681341|NCT04685239|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||controlled randomized trial||||
33681342|NCT00275132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681343|NCT00985829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681344|NCT04209985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients are randomly assigned to receive health coaching or usual care. Patients assigned to usual care have access to all existing resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider. Patients in the health coaching arm have access to all usual care resources. In addition, they will be assigned an unlicensed, trained health coach who will call them up to five times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers.||||
33681345|NCT03643536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A prospective controlled before-after study||||
33839615|NCT02152943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839616|NCT02929277|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984118|NCT04589091|||OTHER||RETROSPECTIVE|||||||
33984119|NCT02516657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984120|NCT04455581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984121|NCT02648334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984122|NCT00998556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984123|NCT02072486|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984124|NCT04071860|||OTHER||PROSPECTIVE|||||||
33984125|NCT05332925|||OTHER||PROSPECTIVE|||||||
33984126|NCT00996788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771696|NCT05642546|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind study (subjects and on-site medical/nursing staff at the study site are blinded to study drug/dose assignment). The pharmacy staff preparing the investigational products will not be blinded to NM8074 study drug assignment, but all other site staff, including the Investigator, will be blinded. Unblinding should only be considered for the safety of the subject.|Eligible subjects who meet the inclusion/exclusion criteria will be randomized on Day 1 to either NM8074 or placebo. The sentinel pair in each of the 5 dose cohorts will be randomized in a 1:1 ratio to receive NM8074 or placebo. The remaining subjects will be randomized in a 5:1 ratio to NM8074 to placebo. Dose escalation will occur in sequential cohorts once safety has been evaluated in the prior cohort.|t|f|t|f
33771697|NCT06420102|||CASE_CONTROL||PROSPECTIVE|||||||
33771698|NCT00759824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771699|NCT02479997|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33771700|NCT03580356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigator staff and personnel performing the study assessments remained blinded to the identity of the treatment from the time of randomization until final database lock. The study drug was prepared by an independent unblinded pharmacist (or authorized delegate) and administered by an independent unblinded study drug administrator. Neither the unblinded pharmacist nor the unblinded study drug administrator was involved in any assessments.|This was a Phase III multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.|t|t|t|f
33771701|NCT05642273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771702|NCT01358448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771703|NCT04336423|||COHORT||PROSPECTIVE|||||||
33771704|NCT04683289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771705|NCT06355713|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771706|NCT00273962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771707|NCT04934137|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33771708|NCT00035503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771709|NCT01427621|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33771710|NCT03745794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771711|NCT04002180|||COHORT||PROSPECTIVE|||||||
33771712|NCT03498014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771713|NCT03936296|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||To perform standard transrectal prostate biopsy and MR guided MR-US fusion prostate biopsy in the 2 randomized patient group||||
33771714|NCT01257139|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771715|NCT02693886|||CASE_ONLY|||||||||
33771716|NCT03693716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771717|NCT03008122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33771718|NCT00991159|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33771719|NCT02868580|NA|SINGLE_GROUP||TREATMENT||NONE||Safety and Tolerability open label||||
33771720|NCT00061620|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771721|NCT03936413|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||See protocol||||
33771722|NCT03253770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771723|NCT00654329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771724|NCT05297721|||OTHER||CROSS_SECTIONAL|||||||
33771725|NCT06379230|||OTHER||RETROSPECTIVE|||||||
33771726|NCT01165840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771727|NCT01622712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771728|NCT03753607|||CASE_CONTROL||PROSPECTIVE|||||||
33771729|NCT02632786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771730|NCT01079689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33771731|NCT05741970|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Examiner who recorded the clinical indexes was blinded to the systemical status of the patients and the periodontologists who were responsible for patients periodontal treatment were not blinded because of the anesthesia applied to hypertension patients and the precautions needed to be taken.||f|f|f|t
33771732|NCT00004811||||TREATMENT||||||||
33771733|NCT06475560|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||two-armed prospective clustered case-crossover randomized controlled trial||||
33771734|NCT05387486|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33771735|NCT06488768|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An investigator blinded to the volunteer's opioid status will perform all the sensory and motor tests after thorough instruction in this procedure. Only the primary investigator will have the knowledge of opioid status.|A volunteer blinded matched case-control study.|f|f|t|f
33901578|NCT06519877|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Sachets of soluble corn fiber and placebo will be prepared and assigned randomization numbers by the investigational pharmacist at the San Francisco VA Health Care System. Participants, study staff, and those involved in outcome assessment will be blinded to the group assignment throughout the study.|Participants will be randomized into one of two groups at a 1:1 ratio in random permutated blocks of size 6. Each group will undergo 2 phases of intervention with soluble corn fiber 20g/day for 4 weeks and placebo (maltodextrin) for 4 weeks, with 4-weeks of washout in between. Group 1 will receive soluble corn fiber first followed by placebo, whereas group 2 will receive placebo first followed by soluble corn fiber. Outcomes will be assessed at the end of each intervention phase.|t|t|t|t
33901579|NCT05414123|||COHORT||PROSPECTIVE|||||||
33901580|NCT01184989|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901581|NCT03109951|NA|SINGLE_GROUP||OTHER||NONE|Open label|Single group||||
33984127|NCT05113966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984128|NCT00413764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984129|NCT06111703|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33984130|NCT01971619|||CASE_ONLY||PROSPECTIVE|||||||
33984131|NCT00804063|||CASE_CONTROL||PROSPECTIVE|||||||
33984132|NCT03936530|||CASE_ONLY||PROSPECTIVE|||||||
33984133|NCT01371162|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33984134|NCT05341622|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33984135|NCT02198586|||COHORT||PROSPECTIVE|||||||
33984136|NCT02214264|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984137|NCT03488186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901582|NCT03223038|||COHORT||PROSPECTIVE|||||||
33901583|NCT03345212|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901584|NCT05963698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Events Adjudication Committee is blinded to intervention assignment.|Randomized Controlled Trial|f|f|f|t
33901585|NCT05974189|||COHORT||RETROSPECTIVE|||||||
33901586|NCT01663740|RANDOMIZED|||OTHER||NONE||||||
33901587|NCT03727594|||COHORT||PROSPECTIVE|||||||
33901588|NCT03348631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901589|NCT05592223|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901590|NCT00112138|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33681346|NCT04477278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33901591|NCT05808088|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||One group receives the intervention at inclusion, the other group is a control group, but crosses over to intervention halfway through the study.||||
33901592|NCT00863629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901593|NCT02350829|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901594|NCT06068725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the study, groups were determined by block randomization. The randomization list was created by block randomization according to New York Heart Association (NYHA) classification.|It consists of two groups, application and control, and three follow-ups.|t|f|f|t
33901595|NCT01277289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984138|NCT00229645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681347|NCT02489929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681348|NCT02058524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681349|NCT04133207|||COHORT||RETROSPECTIVE|||||||
33681350|NCT01699347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681351|NCT02365142|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681352|NCT03337789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681353|NCT04590833|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33681354|NCT00842413|||COHORT||PROSPECTIVE|||||||
33681355|NCT03647189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681356|NCT04552145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33681357|NCT03661879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|Five (5) cohorts are planned. In each cohort, subjects will be randomised in a 3:1 manner to receive either: 1) NNC9204-1706: 9 subjects or 2) Placebo (NNC9204-1706): 3 subjects|t|t|t|t
33681358|NCT03749980|||COHORT||OTHER|||||||
33681359|NCT00790309|||CASE_CONTROL||PROSPECTIVE|||||||
33681360|NCT01578824|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33681361|NCT05627778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681362|NCT02458937|||COHORT||PROSPECTIVE|||||||
33681363|NCT06125470|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Strengthened technical capacity of healthcare workforce to provide quality gender-responsive SRH /FP services to women of reproductive age, youth and adolescents. .~Increased availability of quality gender-responsive materials, equipment and appropriate infrastructure for FP/SRH Enhanced ability of district and provincial health authorities to maintain adequate and sustainable supplies of FP commodities Improved knowledge and attitudes regarding FP/SRH amongst male and female community members Enhanced ability of local community structures, institutions and leaders to identify and respond to gender and social barriers to utilization of FP/SRH services."||||
33681364|NCT02811523|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33681365|NCT05925543|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33901596|NCT04988126|||CASE_CONTROL||PROSPECTIVE|||||||
33901597|NCT04913324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|18 month follow-up assessment will be completed by a blinded clinician||f|f|f|t
33984139|NCT02327130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984140|NCT04795609|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33984141|NCT05165537|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984142|NCT01678638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984143|NCT02417805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33984144|NCT01604694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984145|NCT04132778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Physician blinded to the allcocated treatment; AsthmaTuner or traditional treatment.|RCT with two arms, Asthmatuner or traditional asthma management, during at least 6 months. Thereafter, the study continues to be observational from 6- 12 months.|f|f|t|f
33984146|NCT02409693|||COHORT||RETROSPECTIVE|||||||
33984147|NCT00445003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984148|NCT03603314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079516|NCT00241202|RANDOMIZED|PARALLEL||||NONE||||||
34079517|NCT01507181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681366|NCT05056428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33681367|NCT02142387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681368|NCT06476054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33681369|NCT00239135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681370|NCT01414920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681371|NCT04135105|||OTHER||OTHER|||||||
33771736|NCT00684268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901598|NCT02077322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33901599|NCT02798081|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901600|NCT04583865|||COHORT||PROSPECTIVE|||||||
33901601|NCT06244381|||COHORT||RETROSPECTIVE|||||||
33901602|NCT01666873|||COHORT||PROSPECTIVE|||||||
33901603|NCT03687177|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33901604|NCT00799097|||COHORT||PROSPECTIVE|||||||
33901605|NCT06487494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901606|NCT05101291|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm, open label investigation on the hemodynamic effect of fractional spinal anaesthesia as measured by lithium dilution cardiac output monitoring||||
33901607|NCT02795767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901608|NCT05335083|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33901609|NCT02236585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984149|NCT02566278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984150|NCT00649025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984151|NCT00020826|||CASE_ONLY||PROSPECTIVE|||||||
33984152|NCT05921955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984153|NCT05430698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984154|NCT03804762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681372|NCT02997241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33984155|NCT02934347|||CASE_CONTROL||PROSPECTIVE|||||||
33984156|NCT05381766|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984157|NCT05070286|||COHORT||PROSPECTIVE|||||||
33984158|NCT06086951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomisation procedure will be implemented using sequentially numbered, opaque, and sealed envelopes containing number cards (1=intervention, 2=control). This procedure will be carried out by a clerical staff member who has no involvement in the research activities, using a set of random numbers generated by a statistician. The randomisation process will remain concealed from the research team.~Research Assistant (RA), blinded to the subject selection, will open the envelopes only after informed consent is obtained. Parents who have been randomised will be sent a secure link via email to assess the materials based on their study groups. All outcomes will be assessed through self-reports using the online tools embedded within the Pai.ACT application."|Two-arm Randomised Controlled Trial (RCT) with a repeated-measures parallel-group design|f|f|t|t
33984159|NCT05814926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984160|NCT05932095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcome assessors were blinded to the group allocation of the participants.|This study is a 12-week, randomized controlled trial. Patients with anxiety state are randomized to either TCM Daoyin intervention group or health education control group.|f|f|f|t
33681373|NCT01453387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681374|NCT04598191|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither participants, all care providers, investigators nor outcomes assessors know the treatment allocations.|Patients are divided into 2 groups, who are administered aerosolized iloprost through a nebulizer connected to the inspiratory limb of the respiratory system, or who are administered same volume of normal saline at the same time and in the same manner.|t|t|t|t
33681375|NCT06530472|||COHORT||PROSPECTIVE|||||||
33681376|NCT04434846|||COHORT||CROSS_SECTIONAL|||||||
33681377|NCT06172985|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33681378|NCT04113369|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33681379|NCT06411171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33681380|NCT04891393|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33681381|NCT03140358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized control trial|t|t|t|t
33681382|NCT01825772|||COHORT||CROSS_SECTIONAL|||||||
33681383|NCT02557477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681384|NCT06138730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681385|NCT06505733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The statistician will be blinded in the study. The researcher will not be blinded because he/she is the implementer. However, the researcher will open the envelope created by the statistician just before the application and learn which group the mother is in. In order to prevent bias in the evaluation of the data, the groups will be coded as A and B, and the data will be analysed by an independent statistician. After the analysis and interpretation of the data is completed, the codes of the intervention and control groups will be revealed.|group who received companion training, group who did not receive training|t|f|f|t
33681386|NCT00973297|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681387|NCT04985344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681388|NCT02776202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681389|NCT02593136|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771737|NCT04171830|NA|SINGLE_GROUP||SCREENING||NONE||This study is a non-randomized hybrid implementation-intervention comparative trial using pre- and post-implementation methods with an embedded qualitative component pre- and during intervention.||||
33771738|NCT03953404|||COHORT||PROSPECTIVE|||||||
33771739|NCT04929366|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33771740|NCT05480332|||CASE_ONLY||PROSPECTIVE|||||||
33771741|NCT04864821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901610|NCT06051695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901611|NCT02453412|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901612|NCT05115461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901613|NCT04469894|||COHORT||PROSPECTIVE|||||||
33901614|NCT04491396|NA|SINGLE_GROUP||TREATMENT||NONE|The study is not blinded.|Mixed methods model||||
33901615|NCT03642795|||CASE_ONLY||PROSPECTIVE|||||||
33901616|NCT04933097|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984161|NCT02819934|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984162|NCT04661384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984163|NCT02381210|||CASE_CONTROL||PROSPECTIVE|||||||
33984164|NCT05833581|NA|SINGLE_GROUP||OTHER||NONE|For the 6-minute walk test the technician performing the test is masked. The remainder of the data is not masked.|A prospective cross-sectional study in the ambulatory care settings that manages adult patients with chronic heart failure (both heart failure with reduced ejection fraction \[HFrEF\] and heart failure with preserved ejection fraction \[HFpEF\]).||||
34024752|NCT03460314|||CASE_ONLY||PROSPECTIVE|||||||
34024753|NCT05342779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681390|NCT01012674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681391|NCT03005873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681392|NCT00043550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681393|NCT00000776||||TREATMENT||DOUBLE||||||
33771742|NCT01831414|RANDOMIZED|CROSSOVER||||NONE||||||
33771743|NCT03669094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is an interventional randomized, multicenter, double-blind, placebo-controlled, parallel-group study|t|t|t|t
33771744|NCT05995613|||COHORT||PROSPECTIVE|||||||
33771745|NCT00197301|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33901617|NCT05213598|||COHORT||PROSPECTIVE|||||||
33901618|NCT06671808|||COHORT||RETROSPECTIVE|||||||
33901619|NCT06457048|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Outcomes will be compared between a prospsective post-intervention cohort enrolled for this study and a historical pre-intervention cohort.||||
33901620|NCT00396227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901621|NCT04535570|||OTHER||PROSPECTIVE|||||||
33901622|NCT00022711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901623|NCT01965548|||COHORT||RETROSPECTIVE|||||||
33901624|NCT03662022|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomized trial in which villages are assigned to one of four intervention groups||||
33984165|NCT03518281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All parties, except an outside person not involved in the study, will be blinded to the treatment conditions|Randomized, Double-Blind, Placebo Controlled|t|t|t|t
33984166|NCT03239509|||COHORT||RETROSPECTIVE|||||||
33984167|NCT02312700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33984168|NCT03681145|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33984169|NCT02602041|||COHORT||PROSPECTIVE|||||||
33984170|NCT01739101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984171|NCT00560443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984172|NCT01237990|||CASE_ONLY||PROSPECTIVE|||||||
33984173|NCT03329326|||COHORT||CROSS_SECTIONAL|||||||
33984174|NCT03006445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984175|NCT06079645|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, randomized pilot study involving 20 participants with genital LEA, refractory to the use of high-potency topical corticosteroid therapy. In this investigation.~The vulvas will be randomized as right side and left side"||||
33984176|NCT03613922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984177|NCT05029843|||COHORT||CROSS_SECTIONAL|||||||
33984178|NCT00401947|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33681394|NCT04646564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681395|NCT06225908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33771746|NCT05569824|||COHORT||PROSPECTIVE|||||||
33771747|NCT04364321|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A pragmatic parallel group randomized trial comparing single dose clonazepam with intermittent oral diazepam for prevention recurrent febrile seizures|f|t|t|t
33984179|NCT01636609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984180|NCT04881903|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will use the Mobile Intervention for Suicidal Thoughts (MIST) intervention for 4 weeks, followed by the Mobile Intervention for Reducing Anger (MIRA) for another 4 weeks.||||
33681396|NCT03355547|||COHORT||PROSPECTIVE|||||||
33681397|NCT05269121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681398|NCT05163015|||CASE_ONLY||PROSPECTIVE|||||||
33681399|NCT02152644|||COHORT||CROSS_SECTIONAL|||||||
33681400|NCT04690439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single : outcome assessor|prospective randomized, controlled cross-over trial|f|f|f|t
33681401|NCT04978519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681402|NCT05867732|||COHORT||OTHER|||||||
33771748|NCT05724901|||COHORT||PROSPECTIVE|||||||
33771749|NCT00849680|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33771750|NCT01054196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771751|NCT04888481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771752|NCT01792362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771753|NCT02067351|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33901625|NCT01943630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901626|NCT02758145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901627|NCT04018170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901628|NCT06003816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901629|NCT02076672|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901630|NCT05112185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984181|NCT05962879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33984182|NCT01346163|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984183|NCT02512393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984184|NCT00911898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984185|NCT02412215|NA|SINGLE_GROUP||||NONE||||||
33984186|NCT00720330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984187|NCT01582126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33984188|NCT05300139|||COHORT||PROSPECTIVE|||||||
34024754|NCT05180201|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Allocation concealment and blinding of participants, study personnel, and investigators.|Randomized, placebo-controlled, parallel-design multi-arm trial|t|t|t|t
34024755|NCT03536533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901631|NCT02229149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901632|NCT01188798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901633|NCT04095910|RANDOMIZED|PARALLEL||PREVENTION||NONE||None (open label)||||
33901634|NCT01294254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901635|NCT02432677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901636|NCT00399802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901637|NCT00370656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901638|NCT05327530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901639|NCT01952015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901640|NCT04172831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901641|NCT01266148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901642|NCT03264638|RANDOMIZED|PARALLEL||TREATMENT||NONE||One third of participanta will receive Dingkun Dan Pills, one third of participanta will receive Diane-35 Pills, and the another third will receive Dingkun Dan pills and Diane-35 in combination.||||
33901643|NCT02226614|NA|SINGLE_GROUP||||NONE||||||
33901644|NCT00023907||||TREATMENT||NONE||||||
33901645|NCT06512766|||COHORT||RETROSPECTIVE|||||||
33901646|NCT01288378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901647|NCT06673342|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A convenience sample of 100 participants will be enrolled for the study. Selection of participants will concur to a written consent primarily based on voluntary agreement. For each participant the following procedures will be performed:~1. Record a thorough health history from each subject regarding past and present family health conditions and demographic information including demographic information, including age, gender, and race/ethnicity.~2. For the control group an oral examination to visually assess the DMFT scores will be performed and added sugar consumption will be calculated using the online application, Sugar Intake Calculator, with no additional nutritional counseling tool utilized.~3. For the intervention group, an oral examination to visually assess the DMFT scores will be performed and added sugar consumption will be calculated using the online application, Sugar Intake Calculator, with the intervention of Stephan's curve as a nutritional tool."||||
33901648|NCT06067646|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901649|NCT00029315|RANDOMIZED|||TREATMENT||DOUBLE||||||
33901650|NCT03403101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901651|NCT05476549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34024756|NCT04355065|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is prospective, unicentric, ramdominated, superiority with a control group and with a sample of 105 patients diagnosed with ADHD and pharmacologically stable.||||
34024757|NCT00866879|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024758|NCT06332989|||COHORT||PROSPECTIVE|||||||
34024759|NCT01476332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024760|NCT05189444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024761|NCT06332495|||CASE_ONLY||PROSPECTIVE|||||||
34024762|NCT02634359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024763|NCT00205803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34024764|NCT00338312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024765|NCT02122900|||CASE_ONLY||PROSPECTIVE|||||||
34024766|NCT02391129|||COHORT||RETROSPECTIVE|||||||
34024767|NCT04928079|||CASE_ONLY||PROSPECTIVE|||||||
34024768|NCT01186484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024769|NCT02594085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34024770|NCT00154869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024771|NCT00111826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34024772|NCT04719455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024773|NCT05011747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024774|NCT05742932|||COHORT||PROSPECTIVE|||||||
34024775|NCT06349174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024776|NCT06621004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34024777|NCT05524961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects will be explained that the study aims to test the efficacy of the different modalities of non-pharmacological treatments for depression including bright light therapy and the negative ion generator, without mentioning which one is the placebo. An independent outcome assessor will be blinded to the treatment allocation throughout the study.|Randomized placebo- and active-controlled trial|t|f|f|t
34024778|NCT02264912|||COHORT||PROSPECTIVE|||||||
34024779|NCT00855543|||COHORT||PROSPECTIVE|||||||
34024780|NCT02329535|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024781|NCT06633575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024782|NCT06632717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024783|NCT04511598|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34024784|NCT03640286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34024785|NCT06633770|||CASE_CONTROL||PROSPECTIVE|||||||
34024786|NCT02382861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024787|NCT02326441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024788|NCT00497861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984189|NCT06341322|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Participants will be randomized to either control (no reminder screening invitation) or one of three treatments (standard reminder letter, behaviorally informed reminder letter, behaviorally informed letter with home testing kit included).|t|f|f|f
33984190|NCT00528606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984191|NCT03366805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Care provider is not informed of which patient education video(s) the patient was provided, unless that patient initiates a conversation with the provider regarding the video.|prospective, randomized clinical trial|f|t|f|f
33984192|NCT02403765|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33984193|NCT03233646|||CASE_CONTROL||PROSPECTIVE|||||||
33984194|NCT00841178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984195|NCT05636241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33984196|NCT01067885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984197|NCT01772537|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33984198|NCT02325141|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984199|NCT00584922|||COHORT||PROSPECTIVE|||||||
33984200|NCT01381705|||OTHER||RETROSPECTIVE|||||||
33984201|NCT06015997|||CASE_ONLY||PROSPECTIVE|||||||
33984202|NCT00724477|||COHORT||RETROSPECTIVE|||||||
33984203|NCT00377390|||COHORT||PROSPECTIVE|||||||
33984204|NCT00408070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984205|NCT02400957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33984206|NCT01658228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984207|NCT01178619|||CASE_CONTROL|||||||||
33984208|NCT04184180|||COHORT||PROSPECTIVE|||||||
33984209|NCT04097730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984210|NCT02670057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984211|NCT04484493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984212|NCT04444557|||COHORT||PROSPECTIVE|||||||
33771754|NCT05048368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is divided into four cohorts: healthy subjects in cohort A and C, mild liver function impairment subjects in cohort B, and moderateliver function impairment subjects in cohort D. Cohorts A and B, C and D should be matched in terms of gender, age, and body mass index (BMI).||||
33771755|NCT02456337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984213|NCT05525871|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33984214|NCT01746329|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33984215|NCT00280553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984216|NCT01612520|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984217|NCT04572386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984218|NCT00189293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984219|NCT02613000|||COHORT||PROSPECTIVE|||||||
33984220|NCT05561335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984221|NCT02731365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984222|NCT02535494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33984223|NCT06124235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984224|NCT02566928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984225|NCT05189405|||COHORT||RETROSPECTIVE|||||||
33984226|NCT03968718|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33984227|NCT03239990|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomize Controlled Trial with intervention and control groups (TAU)||||
33984228|NCT06061471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984229|NCT06231147|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984230|NCT02646397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984231|NCT03071029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681403|NCT04105478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Based on the sample calculation the investigators intend to include a total number of 122 patients of which the first 56 patients will be studied using MB-RSA and DXA. The patients are allocated into two groups of equal of size:~1. The un-cemented Comprehensive Nano stemless shoulder arthroplasty (intervention group)~2. The un-cemented Comprehensive stemmed total shoulder arthroplasty (control group)~The randomization is done in the operating theater just after the perioperative evaluation of the bone-stock and the rotator cuff. The randomization sequence will be computer generated. The patients will be randomized using stratified, block randomization."|t|f|t|f
33681404|NCT02245425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681405|NCT00022347||||TREATMENT||||||||
33681406|NCT04634305|||COHORT||PROSPECTIVE|||||||
33771756|NCT00000830|||NATURAL_HISTORY|||||||||
33771757|NCT05929261|||COHORT||CROSS_SECTIONAL|||||||
33771758|NCT01521325|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33771759|NCT03413410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681407|NCT00510432|||COHORT||PROSPECTIVE|||||||
33771760|NCT03664037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33771761|NCT02754414|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33771762|NCT00153335|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33771763|NCT05752422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771764|NCT00165867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681408|NCT04196387|||CASE_ONLY||RETROSPECTIVE|||||||
33681409|NCT01719211|||OTHER||PROSPECTIVE|||||||
33681410|NCT03608150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681411|NCT05120921|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The statistician will be blinded to which group patients were allocated to.|The first group of patients will receive standard osteopathic management. The second group will receive biopsychosocially informed osteopathic management.|f|f|f|t
33681412|NCT04896970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681413|NCT06068426|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681414|NCT00195208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681415|NCT00390026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681416|NCT00007059||||TREATMENT||||||||
33771765|NCT00249496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771766|NCT05515029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771767|NCT06077435|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A Randomized Controlled Trial.||||
33771768|NCT01209338|RANDOMIZED|PARALLEL||||NONE||||||
33771769|NCT00284999|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33771770|NCT03657927|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33681417|NCT03997292|||COHORT||PROSPECTIVE|||||||
33681418|NCT03206788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681419|NCT03936452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681420|NCT04363151|||OTHER||RETROSPECTIVE|||||||
33681421|NCT03618589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33681422|NCT03219710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681423|NCT05874206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681424|NCT00853970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681425|NCT01901796|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33681426|NCT02890108|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33771771|NCT01364727|NA|SINGLE_GROUP||OTHER||NONE||||||
33771772|NCT00154063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901652|NCT00812071|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33901653|NCT06447181|||COHORT||RETROSPECTIVE|||||||
33771773|NCT02385617|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33771774|NCT02155556|||COHORT||PROSPECTIVE|||||||
33901654|NCT00778999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901655|NCT03847337|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33901656|NCT04806087|||CASE_ONLY||CROSS_SECTIONAL|||||||
33901657|NCT01927146|||CASE_ONLY||RETROSPECTIVE|||||||
33901658|NCT00089180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33901659|NCT06649747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901660|NCT06512376|||COHORT||PROSPECTIVE|||||||
33901661|NCT03817944|||COHORT||PROSPECTIVE|||||||
33901662|NCT04073823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33901663|NCT02310633|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33901664|NCT04275752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901665|NCT00713869|||CASE_CONTROL||PROSPECTIVE|||||||
33901666|NCT04804956|||COHORT||PROSPECTIVE|||||||
33901667|NCT01174914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901668|NCT05504330|||COHORT||PROSPECTIVE|||||||
33771775|NCT02464930|||CASE_CONTROL||PROSPECTIVE|||||||
33771776|NCT04763538|||COHORT||PROSPECTIVE|||||||
33771777|NCT03598218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771778|NCT03016117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771779|NCT01061918|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33771780|NCT00786474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771781|NCT04456582|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771782|NCT00878475|||COHORT||PROSPECTIVE|||||||
33771783|NCT04906590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771784|NCT02951650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771785|NCT04334785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681427|NCT02889744|RANDOMIZED|PARALLEL||OTHER||SINGLE|Primary and secondary outcomes were assessed by an investigator blinded to this study.|"From the results of previous studies, we assumed that the mean difference in rSO2 at 72 h between the 36℃ or 33℃ groups would be 3% with 4% of standard deviation. By a referral (2015-0207) to the Medical Research Collaborating Center (MRCC) of SNUH/SNUMC, a sample size of at least 58 (29 per group) was calculated with a power of 0.8 and a significance level of 0.05. Considering an unexpected loss of 15%, the study was planned for 66 participants.~Randomization was performed by the 4, 6-block randomization method at the MRCC SNUH/SNUMC web-site (http://mrcc.snu.ac.kr)."|f|f|f|t
33681428|NCT06401629|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Owing to the pragmatic trial design, providers will not be blinded to randomization. All outcome assessors will be blinded until randomization is completed for all patients.|This study will be designed as a multicentre, two-arm, parallel, pragmatic, randomized controlled trial conducted at two participating hospitals in Qatar. This design allows for an assessment of interventions in real-world settings and offers practical insights into the clinical utility of different diagnostic criteria. All pregnancies will be randomly assigned to the NPRP or IADPSG approach (1:1 ratio) at their first prenatal visit using an electronically generated random assignment procedure; this assignment will be provided to the lab within CERNER at the time of reporting GDM screening results (typically done at 24-28 weeks' gestation). If screening was ordered more than once, the same assigned result type will be presented to providers each time.|t|f|f|t
33681429|NCT03815578|NA|SINGLE_GROUP||OTHER||NONE||||||
33681430|NCT05446337|||OTHER||OTHER|||||||
33681431|NCT00164476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681432|NCT02642224|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681433|NCT04006600|||OTHER||RETROSPECTIVE|||||||
33771786|NCT01927718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771787|NCT04198740|||OTHER||PROSPECTIVE|||||||
33771788|NCT03479749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33771789|NCT01355874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771790|NCT04765293|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor was blinded concerning participants therapy model and results.||f|f|f|t
33771791|NCT00649493|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771792|NCT00338793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771793|NCT04957732|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization methodology was controlled by the site.||||
33771794|NCT04725630|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators will be blinded to group allocation during data collection.||f|f|t|f
33771795|NCT02950935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771796|NCT02023216|||CASE_ONLY||PROSPECTIVE|||||||
33771797|NCT02834572|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33771798|NCT01474837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771799|NCT05663983|||COHORT||OTHER|||||||
33771800|NCT00001493||||TREATMENT||||||||
33771801|NCT03079193|||CASE_CONTROL||PROSPECTIVE|||||||
33771802|NCT05976113|||COHORT||RETROSPECTIVE|||||||
33771803|NCT03587350|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33771804|NCT00312858|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771805|NCT01165710|||COHORT||PROSPECTIVE|||||||
33984232|NCT01719731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984233|NCT04646213|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33984234|NCT00816569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984235|NCT05717257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to the treatment or control group||||
33984236|NCT00914420|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33984237|NCT05528263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024789|NCT03916783|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Due to insufficient sample size, the intervention (Aim 3) was not implemented. The enrolment number specified is for Aim 2.||||
34024790|NCT04708548|||OTHER||CROSS_SECTIONAL|||||||
34024791|NCT00103220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771806|NCT03001401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771807|NCT02053428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771808|NCT04037241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771809|NCT04039178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sham device appears as real device. Only randomizer which is a third party, is unblinded. First 4 patients are non randomized|Prospective, randomized, double blinded, sham device controlled study|t|t|t|t
33771810|NCT03522987|NA|SINGLE_GROUP||TREATMENT||NONE||Epileptologist-driven medication treatment intervention for anxiety and depression, carried out directly in the epilepsy clinic during a regularly scheduled visit and supported by advanced practice provider (APP).||||
33771811|NCT00188318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771812|NCT03862651|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33771813|NCT03040687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901669|NCT00576693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901670|NCT01448551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901671|NCT05955027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigational drug and the investigational drug placebo shall be provided by the sponsoring unit or its designated unit; Ensure that the placebo looks, tastes, and weighs similar to the test drug and marked for clinical trials; The test drug and placebo shall be blinded by the sponsor or its designated unit for each trial group.||t|t|t|t
33901672|NCT06151015|RANDOMIZED|PARALLEL||PREVENTION||NONE|Whilst participants will not be actively told which arm they have been allocated to, they are likely to be aware that their energy requirement has not been met if they have been allocated to the calorie restricted group.|Pilot, randomised, parallel trial||||
33901673|NCT00882713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024792|NCT01208636|||COHORT||CROSS_SECTIONAL|||||||
34024793|NCT02195661|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024794|NCT04851873|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive a single administration of OAV101||||
34024795|NCT00905710|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681434|NCT00477841|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33681435|NCT05885178|||COHORT||RETROSPECTIVE|||||||
33681436|NCT04922047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681437|NCT01213667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681438|NCT04623125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681439|NCT05779371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Blinded to group membership, research assistants collected data from both groups.||t|f|t|t
33681440|NCT01101308|RANDOMIZED|CROSSOVER||||NONE||||||
33681441|NCT00935090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||PET scans will be performed to show the distribution throughout the body of substances containing a small amount of radioactive material.||||
33681442|NCT04656899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33681443|NCT02732301|||COHORT||PROSPECTIVE|||||||
33681444|NCT02336126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681445|NCT05012670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681446|NCT01024725|||||PROSPECTIVE|||||||
33681447|NCT00000477|RANDOMIZED|||PREVENTION||||||||
33771814|NCT00214903|||COHORT||PROSPECTIVE|||||||
33771815|NCT00794820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771816|NCT00278785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33771817|NCT01159639|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771818|NCT04930458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771819|NCT04239456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group assignments will be concealed and assessments and interventions will be conducted by trained staff blinded to each other's findings and data.|This study is a double-blind randomized clinical trial. Participants will be randomly assigned to a treatment group or wait-list control group.|t|f|f|t
33771820|NCT03694015|RANDOMIZED|PARALLEL||TREATMENT||NONE||Simple randomization with stratification will be used to randomly assign patients to either Arm 1 or Arm 2 in a 1:1 ratio using a computer-generated randomization scheme.||||
33771821|NCT04641195|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||The effect of both interventions (vitamin D or zinc) will be investigated simultaneously using a factorial design.|t|t|t|t
33771822|NCT04142814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771823|NCT05685771|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33901674|NCT03796169|NA|SEQUENTIAL||SCREENING||NONE||||||
33681448|NCT03255629|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Study medication will be provided in vials which are labeled with randomization information only but not contents of vial.|A randomization scheme will be devised to assign half the subjects to receive glucagon during their first challenge visit and the other half to receive vehicle during their first challenge visit. At their second challenge subjects will be assigned to the product not received during their first challenge. The label will include a subject randomization number and information as to which vial should be administered during the first challenge and which should be administered during the second challenge.|t|t|t|t
33681449|NCT03251131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681450|NCT00813943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681451|NCT00368290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681452|NCT01403948||SEQUENTIAL||TREATMENT||NONE||||||
33681453|NCT03141996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681454|NCT04445389|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Phase 1: Open-label, Dose escalation (3-arms) Phase 2a: Randomized, Double-blinded, Placebo-controlled|t|f|t|f
33681455|NCT03262311|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33681456|NCT02973373|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33681457|NCT02121665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771824|NCT04327908|||CASE_ONLY||PROSPECTIVE|||||||
33771825|NCT03604263|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33771826|NCT06142435|||COHORT||PROSPECTIVE|||||||
33771827|NCT02161328|||CASE_ONLY||PROSPECTIVE|||||||
33771828|NCT02125032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771829|NCT00099489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33771830|NCT02473887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771831|NCT06524505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771832|NCT05518422|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33771833|NCT00211237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771834|NCT04453501|||COHORT||RETROSPECTIVE|||||||
33771835|NCT03562351|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will implement an intervention jointly with our simulation program to determine the most effective training model: verbal instructions, instructional video, or use of a mannequin. Caregivers will undergo a training curriculum, and 90 caregivers (30 assigned to each educational model) will be matched into three groups and assigned to participate in one of three educational models in the SIM Center.||||
33771836|NCT05998772|||CASE_CROSSOVER||PROSPECTIVE|||||||
33901675|NCT03766997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901676|NCT04363307|||COHORT||PROSPECTIVE|||||||
33901677|NCT02561377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901678|NCT05297305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Key personnel not collecting data will perform randomization and inform surgeon of the group assignment, keeping data collection blinded. The participant will also remain blinded to their assignment.|Prospective randomized double-blind trial of two active comparators.|t|f|f|t
33901679|NCT04467541|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901680|NCT00499993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901681|NCT05259046|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, data collectors, and investigators are blinded of the allocation throughout the study period. The randomization list is generated and kept by a statistician employed at the Center for Clinical Research and Prevention, but not involved in the trial. Kappa Bioscience AS, Oslo, Norway, keeps the randomization list for labelling of investigational products. The randomization list will be made available to one DSMB member if safety concerns arise during the study period.|Participants will be randomized in a double-blinded manner 1:1 to MK-7 tablets or placebo tablets. Randomisation is conducted in blocks of 6 using computer generated random numbers. A total of 450 participants will be enrolled (225 in each group).|t|t|t|t
33681458|NCT04552678|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Assessors who collect data from children are blind to study condition.|The study utilizes a 2x4 factorial design with 16 conditions. Classrooms are the unit of randomization. Classrooms are randomized into 1 of 16 conditions that vary based on whether or not the following treatments are turned on or off: Healthy Eating Classroom Curriculum; Active Play Classroom Curriculum; Self-Regulation Classroom Curriculum; Enhanced Parent Education. All classrooms receive a Food Literacy curriculum.|f|f|f|t
33681459|NCT01065324|||COHORT||PROSPECTIVE|||||||
33681460|NCT00289159|||DEFINED_POPULATION||PROSPECTIVE|||||||
33681461|NCT06227598|||COHORT||CROSS_SECTIONAL|||||||
33681462|NCT03530657|||COHORT||PROSPECTIVE|||||||
33681463|NCT00167492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681464|NCT04204070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33771837|NCT04262102|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Single blinding. Participants will not know in which dietary group they belong to (Standard diet or High fruit and vegetable diet). We will give them dietary advice depending on their eating habits.|After completing the first questionnaire, researchers will allocate each participant into one of the groups (standard diet or high fruit and vegetable diet) depending on their eating habits. Then, when participants' children start with the complementary feeding (spoon-fed or baby-led) chosen by their parents, two new groups will be created. Participants will be allocated to those two new groups depending on the complementary feeding style they have chosen for their children. Therefore, the study will follow the factorial model, created by the following groups: standard diet and spoon-feeding (group 1), standard diet and baby-led weaning (group 2), high fruit and vegetable diet and spoon-feeding (group 3), and high fruit and vegetable diet and baby-led weaning (group 4).|t|f|f|f
33771838|NCT01366651|NA|SINGLE_GROUP||||NONE||||||
33771839|NCT00881036|||COHORT||PROSPECTIVE|||||||
33771840|NCT00253786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771841|NCT00326768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901682|NCT02399878|||COHORT||PROSPECTIVE|||||||
33901683|NCT06257407|||OTHER||PROSPECTIVE|||||||
33901684|NCT02172612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901685|NCT00164905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901686|NCT05131321|||OTHER||PROSPECTIVE|||||||
33901687|NCT04638127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33901688|NCT06671314|||COHORT||RETROSPECTIVE|||||||
33681465|NCT05905744|||CASE_ONLY||PROSPECTIVE|||||||
33901689|NCT02504892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901690|NCT03942328|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901691|NCT01650779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901692|NCT01556633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901693|NCT05664685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For the anonymization of the sequence, the research team will delegate the generation of the random sequence and the numbering of the containers to a team that has no participation or knowledge of the design of the study, the collection or analysis of data.~The research team will deliver 204 containers with the intervention or control (102 of each) to 1 member of the UC Pharmacology and Toxicology Program. They will generate the randomization sequence, number the containers according to their result and keep the record of the randomization sequence until the data collection is finished, and the statistical analysis is done then the blind opens."|Randomized, multicenter, controlled, double-blind clinical trial with two parallel arms. The control group will receive the current Standard Triple Therapy for the eradication of H. pylori. It consists in omeprazole + amoxicillin + clarithromycin for 14 days. The intervention group will be administered Quadruple Therapy with Bismuth, that consists in esomeprazole + amoxicillin + metronidazole + bismuth subsalicylate for 14 days|t|t|t|f
33901694|NCT06008171|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients with an indication for treatment of field therapy for actinic keratosis will be consulted with patient decision aid or without patient decision aid (conventional)||||
33901695|NCT03836521|||COHORT||PROSPECTIVE|||||||
33901696|NCT01707823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024796|NCT02473523|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024797|NCT05194098|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This double-blind sham-controlled crossover study combines case-control and within-subjects design.|t|f|t|f
34024798|NCT03961490|||OTHER||PROSPECTIVE|||||||
34024799|NCT04257149|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771842|NCT05993286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were randomly assigned to one of three groups: psychoeducation only (the active control group), exposure therapy with psychoeducation, and sound therapy with psychoeducation. All participants were assessed at baseline, and then at 3rd and 6th weeks. All of them received psychoeducation at study intake. A random one third received no further active treatment, one third received exposure, and one third received sound therapy.|t|f|f|f
33771843|NCT02229643|||CASE_ONLY||PROSPECTIVE|||||||
33771844|NCT03003546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771845|NCT05908890|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33771846|NCT04219254|NA|SINGLE_GROUP||TREATMENT||NONE|open label|Phase 1/2a, dose escalation, consecutive-cohort, open-label study trial of BI-1206 in combination with pembrolizumab||||
33771847|NCT02663414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771848|NCT01115491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771849|NCT01213862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771850|NCT00065468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771851|NCT03942562|||COHORT||PROSPECTIVE|||||||
33771852|NCT01492179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024800|NCT00598572|NA|SINGLE_GROUP||OTHER||NONE||||||
34024801|NCT03037437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024802|NCT01775449|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34024803|NCT02837848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34024804|NCT00045864||||TREATMENT||||||||
34024805|NCT00735306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024806|NCT04790708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024807|NCT04061031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681466|NCT05522842|||CASE_CONTROL||PROSPECTIVE|||||||
33681467|NCT03105466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681468|NCT04668261|||COHORT||PROSPECTIVE|||||||
33681469|NCT01230177|||CASE_ONLY||PROSPECTIVE|||||||
33681470|NCT02108340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681471|NCT04458688|||CASE_CONTROL||PROSPECTIVE|||||||
33681472|NCT05262348|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681473|NCT03946722|RANDOMIZED|PARALLEL||TREATMENT||NONE|It will not be possible to perform blinding due to the difference in frequency of administration of medication between the two protocols, therefore an open label method will be used.|This is a prospective, randomised controlled trial with two parallel arms. Frozen thawed embryo transfer takes approximately 6 weeks in a standard protocol, including a one week period of downregulation. Downregulation will be extended by five weeks in the modified protocol compared to the standard protocol. Participants will be followed up until the pregnancy outcome is determined, maximum 9 months after embryo transfer.||||
33681474|NCT02536261|||CASE_ONLY||PROSPECTIVE|||||||
33681475|NCT03740984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Single blinded. The participant knows which group intervention is being used (music, hypnosis or standard care). This is being told while listening to the Intervention. All care Providers only know which colour mp3 player is being used (white, orange or black)."|"Prospective randomised Trial:~Intervention 1 = hypnosis (hypnotherapy), Intervention 2 = Music therapy; Intervention 3 (Standard care)"|f|t|t|t
33681476|NCT02588001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681477|NCT03276169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers will participate in the operation to record operative parameters such as LA pressure. Other researchers including follow-up personnel and the ultrasonic data analyst are uninformed about the random situation of the patients (patient information is recorded according to the random number. Random numbers corresponding to the random allocation list are stored in the research center. After follow-up of the last patient is completed, the random allocation list is published by the random number designer; and the designer does not participate in the data collection and statistics.)|A total of 105 patients with persistent atrial fibrillation(AF), who are persistented more than one year and planned to undergo surgical treatment, will be allocated into two groups. These patients will receive left atrial appendage closure, radiofrequency ablation under the guidance of 3D mapping and left atrial appendage closure combined with radiofrequency ablation, respectively (allocation ratio, 1:1:1).|t|f|f|t
33681478|NCT03073551|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The control group will receive diabetes treatment and education as per standard of care.~The intervention group will receive diabetes treatment and education as per standard of care, and will also be given a Wii game console to bring home."||||
33681479|NCT05288907|||CASE_ONLY||PROSPECTIVE|||||||
33681480|NCT05062434|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a pilot study for cardiac electrophysiologists at 3 Veterans Integrated Service Networks.||||
33901697|NCT06672757|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Stepped wedge|f|f|t|t
33901698|NCT00636623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901699|NCT05783869|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901700|NCT03969433|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33901701|NCT06265558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901702|NCT04083144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901703|NCT00418886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901704|NCT05367960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901705|NCT03807765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901706|NCT02727114|||COHORT||CROSS_SECTIONAL|||||||
33901707|NCT01203462|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33901708|NCT06672432|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Biostatisticians will be blinded to the study groups, ensuring that all results are analyzed and interpreted without bias.||t|t|t|t
33901709|NCT02958163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901710|NCT03047460|||COHORT||PROSPECTIVE|||||||
33901711|NCT04294784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901712|NCT03071406|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned in a 1:1 ratio to Arm A (nivolumab + ipilimumab), or Arm B (nivolumab + ipilimumab + SBRT).||||
33901713|NCT04542291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901714|NCT02897635|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33901715|NCT06511856|||COHORT||OTHER|||||||
33901716|NCT06128512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will not know which group they are assigned to - either the intervention or placebo group. Sham auricular acupuncture (Sham-AA) will be administered similarly to AA but without the use of needles.~The physician administering the treatments will be aware of the group assignments but will not be involved in result assessment or data analysis. Those responsible for outcome evaluation and data analysis will not know the treatment allocations."||t|f|t|t
33901717|NCT03199092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901718|NCT03120403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|using opaque sealed envelopes containing computer generated randomization schedule, the opaque sealed envelopes are sequentially numbered that were open before application of anesthetic plan.|intratehcal injection of drug( morphine).|t|f|t|f
33901719|NCT02355379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901720|NCT01070303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901721|NCT03340493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded core laboratory adjudication of the primary outcome. NIHSS and mRS (secondary outcomes) performed by blinded assessor.|Patients will receive either intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over \~10 seconds) or intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over \~10 seconds).|f|f|f|t
33901722|NCT06340737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901723|NCT00611130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771853|NCT03181126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771854|NCT02304250|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771855|NCT00303082|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33771856|NCT01272713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771857|NCT00196274|||||PROSPECTIVE|||||||
33771858|NCT03424720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771859|NCT02597205|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771860|NCT05771584|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2, open label, randomized, early proof-of-concept study||||
34079518|NCT03563573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The scoring of the lidocaine test is masked, using the coded identity of the tastes. The scoring will be done during the visit by the Scoring and Randomization Specialist so that the patient can be assigned to an intervention or control group to maintain equal numbers in treatment versus control groups. To prevent bias, the Scoring and Randomization Specialist will not be involved in any of the ADHD assessment steps and the patients will not be told about their lidocaine status until after all study testing is done. The subjects and other study personnel such as those doing the ADHD testing will be told not to discuss what they could or couldn't taste. Having scored the lidocaine test, the Scoring and Randomization Specialist will assign subjects to Intervention versus Control using a 1-to-1 allocation.|"The trial will have 2 arms, lidocaine sensitive (effective) and lidocaine insensitive (ineffective). The sample will be enriched to have 50% in each arm. Within each arm, subjects will be randomized on a 1-to-1 allocation to the treatment or control groups.~The investigators will adopt an iterative approach of testing of batches of subjects because (1) the frequency of lidocaine-insensitivity is only known approximately, (2) the frequency may be unevenly distributed across ethnic groups, and (3) the exact effect size of the potassium is not known, though reported to be high in off-label use in clinical settings with more chronic administration.~At the end of testing 40 patients, the results will be analyzed for statistical significance. (1) If the results are statistically significant with a 95% confidence, the testing may stop with the first batch of 40 subjects. (2) If not, sequential, iterative batches of 20 subjects will be tested, and the results reanalyzed."|t|t|t|t
34079519|NCT02765152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079520|NCT00042913|RANDOMIZED|||TREATMENT||||||||
34079521|NCT01767818|||COHORT||PROSPECTIVE|||||||
34079522|NCT06022328|||COHORT||RETROSPECTIVE|||||||
34079523|NCT00026091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079524|NCT05662020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Sponsor, investigators and biostatisticians will remain blinded to subject allocation.|A total of 2,750 participants were enrolled in this study: 9-14 years (2 doses) group was administrated with investigational vaccine on 0 Day, 6th month, and 9-19 years (3 doses) group was administrated with investigational vaccine on 0 Day, 2nd month and 6th month. Both of these two group are of non-randomized, open label design; 20-26 years (3 doses) group was randomized at a 1: 1 ratio to receive the investigational vaccine or the positive control, respectivelyon 0 Day, 2nd month and 6th month.|t|f|t|f
34079525|NCT05401994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079526|NCT01758497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771861|NCT05926128|NA|SINGLE_GROUP||TREATMENT||NONE||multicentre, open-label, uncontrolled trial||||
33771862|NCT01565200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771863|NCT01714973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771864|NCT00170404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901724|NCT00413816|||DEFINED_POPULATION||OTHER|||||||
33901725|NCT01388010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33901726|NCT00258583|||COHORT||OTHER|||||||
33901727|NCT01374581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901728|NCT05132738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901729|NCT00339079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901730|NCT03469193|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901731|NCT03153397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901732|NCT02260414|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33901733|NCT02016742|RANDOMIZED|CROSSOVER||||NONE||||||
33901734|NCT02575313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901735|NCT02970851|||COHORT||PROSPECTIVE|||||||
33901736|NCT02400112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901737|NCT03245632|||CASE_CONTROL||PROSPECTIVE|||||||
33901738|NCT01516450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33901739|NCT00051688||||TREATMENT||||||||
33901740|NCT00005474|||COHORT||PROSPECTIVE|||||||
33901741|NCT05834959|NA|SINGLE_GROUP||PREVENTION||NONE||"A two-part education and practical program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury. SPSS software will be used to analyze mean differences between self-report questionnaire scores regarding low back pain/dysfunction at baseline and post-program using paired t-tests (p\<0.05). Paired t-tests will be used to determine if there is a statistical difference in back injury rates at Seven Oaks Hospital one year post-program, compared to previous years. The results of the post-program survey will be summarized using descriptive statistics. Information from baseline movement confidence questionnaires will also be summarized using descriptive statistics and compared pre and post programming.~\*Note: Before t-test analyses is performed the distribution of scores will be checked to determine if they are normal. If not, non-parametric tests equivalent to paired t-tests will be used."||||
33901742|NCT06672367|RANDOMIZED|PARALLEL||TREATMENT||NONE||It will involve two groups. Experimental group involves balance training combined with gaze stability exercises for the treatment of mild cognitive impairment and the control group involves only balance training for the treatment of mild cognitive impairment.||||
33771865|NCT04670926|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33771866|NCT04192214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771867|NCT04106479|||COHORT||RETROSPECTIVE|||||||
33901743|NCT02617758|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771868|NCT02406261|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771869|NCT02141659|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771870|NCT02807246|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771871|NCT00323713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681481|NCT05453734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
33681482|NCT04698577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and their parents were blind to group allocation.|This is a two arm, single-blind, pilot cluster randomised study. Participants were randomly allocated to the attention training group or active control group based on class groups (three class groups of fourth-class students and one class group of fifth-class students).|t|f|f|f
34079527|NCT01711112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681483|NCT02905396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079528|NCT02569892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079529|NCT03875001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079530|NCT01975493|||OTHER||PROSPECTIVE|||||||
34079531|NCT01786057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079532|NCT06444750|||CASE_CONTROL||PROSPECTIVE|||||||
34079533|NCT00412841|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34079534|NCT03016169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079535|NCT01876108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34079536|NCT00596908|||COHORT||PROSPECTIVE|||||||
34079537|NCT00622024|||||PROSPECTIVE|||||||
34079538|NCT00458003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079539|NCT03885414|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline||||
34079540|NCT05157659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079541|NCT04718597|||CASE_CONTROL||RETROSPECTIVE|||||||
34079542|NCT04268407|RANDOMIZED|PARALLEL||TREATMENT||NONE||thyroid nodules, plan for transoral thyroidectomy||||
34079543|NCT06205784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34079544|NCT01911416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079545|NCT03100409|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34079546|NCT05218200|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The researcher collecting data does not know the characteristics of the groups.|randomized controlled experimental research|f|f|t|f
34079547|NCT05852093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079548|NCT00003381|||CASE_ONLY||PROSPECTIVE|||||||
34079549|NCT06448962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079550|NCT06355661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Double-blind, Randomized, Placebo-Controlled|t|t|t|t
34079551|NCT03720678|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation||||
34079552|NCT00937963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079553|NCT04028362|||COHORT||PROSPECTIVE|||||||
33681484|NCT05974462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single Blind, Investigator-initiated, Randomized Controlled Trial|t|f|f|f
33681485|NCT04197453|||COHORT||PROSPECTIVE|||||||
33681486|NCT04837352|||OTHER||PROSPECTIVE|||||||
33681487|NCT02447224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681488|NCT00000803||||TREATMENT||DOUBLE||||||
33681489|NCT03149367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901744|NCT04076072|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Randomization and data storage will occur in RedCap. Patients will be randomized the day of surgery by a masked study coordinator. The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from patients and investigator staff. A patient randomization list will be produced by the IRT provider using a validated system that automates the random assignment of patient numbers to randomization numbers. These randomization numbers are linked to the different treatment arms. The randomization scheme for patients will be reviewed and approved by a member of the Randomization Group.|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.|t|t|t|f
33901745|NCT01742962|||COHORT||CROSS_SECTIONAL|||||||
33901746|NCT05196932|||CASE_ONLY||PROSPECTIVE|||||||
33901747|NCT01479049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901748|NCT06578650|||COHORT||PROSPECTIVE|||||||
33901749|NCT00001693||||TREATMENT||||||||
33901750|NCT04067531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901751|NCT00178321|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33901752|NCT00013039|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33901753|NCT04386265|||CASE_ONLY||PROSPECTIVE|||||||
33901754|NCT03425565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901755|NCT02123147|||COHORT||PROSPECTIVE|||||||
34079554|NCT05583097|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomization 1:1 in blocks of 10.||||
34079555|NCT03151382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079556|NCT03924323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079557|NCT03003234|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079558|NCT06195644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079559|NCT01359930|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34079560|NCT06225843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079561|NCT05821387|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||5 SAD Cohorts. Each SAD cohort will enroll 8 participants randomized 6 active:2 placebo to receive single doses of Lucid-21-302. For SAD cohort with food effect, all 8 participants will receive Lucid-21-302.|t|f|t|t
34079562|NCT02763774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34079563|NCT04042571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079564|NCT00739648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079565|NCT03332186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079566|NCT03504618|||CASE_ONLY||CROSS_SECTIONAL|||||||
34079567|NCT06367088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079568|NCT01645150|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079569|NCT00692575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079570|NCT03649451|||OTHER||PROSPECTIVE|||||||
34079571|NCT05169619|||OTHER||CROSS_SECTIONAL|||||||
34079572|NCT04995068|||COHORT||RETROSPECTIVE|||||||
34079573|NCT02779140|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34079574|NCT05719896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079575|NCT02553642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079576|NCT04542980|||CASE_CONTROL||RETROSPECTIVE|||||||
33984238|NCT04075461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon, theater staff and patient cannot be blinded due to the nature of two very different types of surgery. However, the assessors will be blinded for type of surgery.|The study is designed as a national pragmatical RCT including all patients with an undisplaced FNF and a NMS score of 5 and above. The standard treatment in Denmark is internal fixation and the patients are randomized to arthroplasty or IF. The steering group have assessed the pragmatic attitude of the design and the study reaches 5 points in 7 of the 9 domains (Figure 1) (9). Reporting is performed accordingly to the extension of the CONSORT statements for pragmatical RCT (17). Using the PRECIS-2 we scored the study to 43 points out of 45 possible.|f|f|f|t
33984239|NCT02466594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33984240|NCT03136380|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33984241|NCT04970368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984242|NCT05192850|||COHORT||RETROSPECTIVE|||||||
33984243|NCT01947218|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33984244|NCT00626184|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33984245|NCT03686033|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The study consists of a randomized double-blind design in Treatment Periods 1, 2, and 3, followed by an open-label Treatment Period 4.|The study consists of a crossover design in Treatment Periods 1, 2, and 3, followed by an open-label Treatment Period 4.|t|t|t|t
33984246|NCT03225456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33984247|NCT01900964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984248|NCT05422170|||COHORT||PROSPECTIVE|||||||
33984249|NCT01789385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984250|NCT02419937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984251|NCT03354221|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33984252|NCT03800251|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who are fasting according to the guidelines and agree to partake in the study will, on the day of their elective LSCS, be given a 400ml carbohydrate drink at least 2hrs before their scheduled theatre time and will then have their gastric volume assessed at 15min intervals for 2hrs to determine how long it takes for the ingested fluid to leave the stomach.||||
33984253|NCT00614471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984254|NCT03872505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984255|NCT05178095|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984256|NCT06213506|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||Data will be collected in an observer-blind manner.|t|t|t|t
33984257|NCT00378131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984258|NCT01313949|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33984259|NCT03048812|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcome assessment will be blinded for assessment which treatment (O-Ring \\Equator) is provided|Participants are randomized to the AB sequence receive treatment A in the first period and treatment B in the second period, whereas experimental units that are randomized to the BA sequence receive treatment B in the first period and treatment A in the second period|f|f|f|t
33984260|NCT01903317|||COHORT||PROSPECTIVE|||||||
34079577|NCT06410300|||OTHER||PROSPECTIVE|||||||
34079578|NCT02310217|||OTHER||CROSS_SECTIONAL|||||||
34079579|NCT01431248|||COHORT||PROSPECTIVE|||||||
34079580|NCT05124522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079581|NCT00311493|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34079582|NCT04151069|||CASE_CONTROL||PROSPECTIVE|||||||
34079583|NCT03533751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079584|NCT03819400|||CASE_ONLY||PROSPECTIVE|||||||
34079585|NCT01526785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681490|NCT01037088|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34079586|NCT05701813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation is performed by the nutraceutical supplier. Neither the participant, nor the investigator, nor the care provider, nor the outcome analyzer knows which arm the patient is assigned to.|The children will be randomized into two arms, receiving either a mixture of inositols or placebo, for a period of 3 months.|t|t|t|t
34079587|NCT03276598|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The placebo tablets and drugs are packed in similar gelatin capsules.|The design of the study is a randomized placebo-controlled cross-over study. The study starts with a run-in placebo period lasting for four weeks. The four monotherapy treatment periods last for four weeks and they are separated by placebo periods lasting also for four weeks. Randomization occurs after the first placebo period in blocks of 24 (all possible drug sequences).|t|t|t|t
34079588|NCT05350020|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33984261|NCT05801497|||COHORT||PROSPECTIVE|||||||
33984262|NCT01423760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984263|NCT00158171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984264|NCT05857098|||OTHER||PROSPECTIVE|||||||
33984265|NCT05313425|||CASE_ONLY||PROSPECTIVE|||||||
33984266|NCT05881421|||COHORT||PROSPECTIVE|||||||
34079589|NCT01831895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079590|NCT02174757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079591|NCT01518569|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34079592|NCT03515863|||CASE_CONTROL||PROSPECTIVE|||||||
33681491|NCT01583556|||COHORT||PROSPECTIVE|||||||
33681492|NCT05874167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681493|NCT04441190|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33681494|NCT03771079|||COHORT||RETROSPECTIVE|||||||
34079593|NCT03790410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33681495|NCT00812760|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33681496|NCT03067298|||COHORT||PROSPECTIVE|||||||
33681497|NCT00125125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681498|NCT04427332|||COHORT||PROSPECTIVE|||||||
33681499|NCT00833417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681500|NCT03717272|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33681501|NCT01484288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681502|NCT00622271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984267|NCT05599295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984268|NCT01474798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984269|NCT02794974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984270|NCT05151588|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Induction treatment with docetaxel, cisplatin, 5-FU and tazemetostat followed by surgery or radical chemoradiation and maintenance tazemetostat||||
33984271|NCT04641130|NA|SINGLE_GROUP||OTHER||NONE||||||
33984272|NCT05708105|||COHORT||PROSPECTIVE|||||||
34079594|NCT03883243|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Patients are evenly divided into the telecoaching group or usual care group according to owning a smartphone and their affinity with it.|Prospective non-randomised controlled pilot study. 16 patients will be included in the intervention group and 16 patients will be included in a matched control group receiving only usual care.||||
34079595|NCT03026946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079596|NCT02310074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079597|NCT03545945|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized control trial||||
34079598|NCT03020485|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34079599|NCT04805671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator, participant and sponsor personnel involved in study intervention and study evaluation will be unaware of the intervention assignments. Investigators will remain blinded to each participant's assigned study treatment throughout the course of the study.|Randomized, double-blind, placebo controlled|t|t|t|t
34079600|NCT02144701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079601|NCT05006378|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE||This is a placebo-controlled complete crossover study with 3 treatments: (A) placebo, (B) chamomile extract capsule, and (C) chamomile tea. Every participant will receive all three treatments. There are 6 possible sequences of treatment (ABC, ACB, BAC, BCA, CAB, CBA). Blocked randomization lists for sequence assignment will be computed using statistical software. Each participant will be randomly assigned one of the six treatment sequences using REDCap software. Carryover effects will be minimized by maintaining a consistent washout time of 1 week between treatments. Blood sampling will be conducted immediately before and after the treatment weeks.|t|f|t|f
34079602|NCT02314728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079603|NCT01262144|||CASE_ONLY||RETROSPECTIVE|||||||
34079604|NCT02547753|||COHORT||PROSPECTIVE|||||||
34079605|NCT00297648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079606|NCT03772808|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079607|NCT06077344|||COHORT||PROSPECTIVE|||||||
33681503|NCT03970408|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33681504|NCT03756493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681505|NCT05934058|||CASE_CONTROL||RETROSPECTIVE|||||||
33681506|NCT04844151|||COHORT||OTHER|||||||
33681507|NCT02783079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681508|NCT04226170|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|The only unblinded study member will be the pharmacist|randomized to ondansetron + pyridostigmine or placebo+ pyridostigmine in a 3:1 ratio.|t|t|t|t
33681509|NCT00324298|RANDOMIZED|||TREATMENT||||||||
33681510|NCT02043340|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33681511|NCT05090176|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE||randomized control trial, double blind|t|f|t|f
33681512|NCT00787904|||CASE_CONTROL||PROSPECTIVE|||||||
33681513|NCT04645433|||COHORT||RETROSPECTIVE|||||||
33681514|NCT02412514|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681515|NCT00732004|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33771872|NCT03016793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771873|NCT02459080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771874|NCT02571465|||CASE_ONLY||PROSPECTIVE|||||||
33771875|NCT00271414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771876|NCT03627611|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33771877|NCT00660920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839617|NCT03511690|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Randomization schedules will be developed by the biostatistician and administered by an individual (staff) not involved in the study analyses so that the statistician will be blinded to the allocation. This method will ensure unbiased results.|Participants are randomized to an immediate or delayed arm|f|f|f|t
33839618|NCT01888549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839619|NCT04760262|||CASE_CONTROL||PROSPECTIVE|||||||
33839620|NCT04584476|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839621|NCT01543542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839622|NCT03648359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839623|NCT04339660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33839624|NCT02807610|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33839625|NCT04571190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Group affiliation will be concealed for the researcher performing the statistical analyses. Participants will be informed that the overall purpose of the study is to examine the feasibility, acceptability and effect of prenatal MBSR and they are thus not blind to group allocation.|The design is a single-center feasibility trial comparing prenatal MBSR as add on to usual care with usual care alone. Participants will be randomized in a 1:1 ratio to an intervention or waitlist control group. Participants in the waitlist control group will be offered participation in a MBSR program after a three months follow-up period. Mindfulness training in the control group will thus be initiated postnatal.|f|f|f|t
33839626|NCT05167890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839627|NCT02294357|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839628|NCT06128096|||COHORT||PROSPECTIVE|||||||
33839629|NCT01083953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33839630|NCT04993469|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment Single centre open label prospective||||
33839631|NCT01049867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839632|NCT01601522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839633|NCT04014738|||CASE_ONLY||RETROSPECTIVE|||||||
33839634|NCT00757224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839635|NCT06051110|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839636|NCT02963675|||COHORT||RETROSPECTIVE|||||||
33771878|NCT06460415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To control possible measurement biases in the present study, the following measures will be taken: all treatment sessions will be administered by the same trained and experienced researcher, to ensure that the treatment is homogeneous among the volunteers. The evaluators who will apply the scales, scores and questionnaires will be blinded to the allocation of volunteers to the groups under study. The sealed envelope method will be used for confidential allocation. Each envelope containing the allocated treatment will be sealed and numbered sequentially.|"GPBM group - will receive application in 8 points (4 red and 4 infrared) in the vulvar region and 8 points (4 red and 4 infrared) in the intravaginal pelvic floor region of PBM and will be evaluated in the pre-intervention, post-intervention and in follow-ups of 15, 30, 90 and 180 days~GS group - will receive simulation of PBM application in the same number of vulvar and intravaginal points, in the same places where it was applied in the GPBM group. and will be evaluated pre-intervention, post-intervention and in follow-ups of 15, 30, 90 and 180 days"|t|f|t|t
33771879|NCT01706211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33771880|NCT04425993|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681516|NCT06243523|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This study is mixed methods research that combines both exploratory mixed and nested action research phases of a multi-phase mixed design. In the first phase; It is planned to develop a stress management psychoeducation program based on Neuman's Systems Model based on the literature. In the second phase; It is planned to conduct technical action research based on the radical structuralist paradigm, one of the types of action research.~It was planned to use the criterion sampling method, one of the purposeful sampling methods, in determining the sample of the research. The psychoeducation program will be implemented in six sessions with individual interviews lasting approximately 45-60 minutes, three times a week for the spouses of patients in intensive care."||||
33771881|NCT06290921|||COHORT||RETROSPECTIVE|||||||
33771882|NCT04287192|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators will conduct a non-randomized control trial to understand the impact of the intervention. For each site (Sinai Health System and THP - both Mississauga and Credit Valley sites) and each service, half of the participating wards will be designated as control while the other half will be designated as intervention. The investigators will collect baseline data from all wards (control and intervention) during phase 1 while co-design is on-going and the intervention has not been deployed. During phase 2, after co-design is complete, the co-designed technology intervention and workflow will be rolled out to only the intervention wards. The investigators will then collect data (identical to what was collected at baseline) from all wards (control and intervention) to understand the impact of technology by examining the differential change between control and intervention wards (difference in difference approach).||||
33771883|NCT06488703|||COHORT||RETROSPECTIVE|||||||
33771884|NCT01377415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771885|NCT02722317|||||RETROSPECTIVE|||||||
33771886|NCT01162408|||COHORT||PROSPECTIVE|||||||
33771887|NCT04396353|||COHORT||CROSS_SECTIONAL|||||||
33839637|NCT02658877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839638|NCT00757627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681517|NCT05481957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681518|NCT05395793|||COHORT||PROSPECTIVE|||||||
33681519|NCT05293392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33681520|NCT03452748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|no masking|all excised membranes will be examined with FTIR spectroscopy, there will be no control group||||
33839639|NCT01120873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839640|NCT01757951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839641|NCT05410093|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33839642|NCT01908153|||COHORT||CROSS_SECTIONAL|||||||
33839643|NCT01763593|||CASE_ONLY||PROSPECTIVE|||||||
33901756|NCT06673121|||COHORT||PROSPECTIVE|||||||
33901757|NCT03025919|||OTHER||CROSS_SECTIONAL|||||||
34079608|NCT04214587|||CASE_CONTROL||PROSPECTIVE|||||||
34079609|NCT02100046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079610|NCT04727957|||CASE_CONTROL||RETROSPECTIVE|||||||
34079611|NCT00313729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079612|NCT00629031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984273|NCT04350580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The double blinding will be provided by the hospital pharmacy of each establishment with the help of opaque sleeves to mask the product packaging and should be returned to the pharmacy when empty.|The participant will be randomized to either the group of treatment with IVIG or the placebo group. Participants in the treatment group will receive infusions of polyvalent immunoglobulins for 4 consecutive days. Participants in the placebo group will receive an equivalent volume of sodium chloride 0.9% for the same duration.|t|t|f|f
33984274|NCT04591405|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A randomized, double-blind, placebo-controlled design|t|t|t|t
33681521|NCT05322044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984275|NCT00122577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984276|NCT02758691|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33984277|NCT05130554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984278|NCT02605148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33984279|NCT00914394|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33984280|NCT03365297|NA|SINGLE_GROUP||TREATMENT||NONE||Single centre, single arm open labelled Phase II window study||||
33984281|NCT00063856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984282|NCT05662163|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33984283|NCT03850639|RANDOMIZED|PARALLEL||TREATMENT||NONE|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.||||
33984284|NCT03751605|||COHORT||PROSPECTIVE|||||||
33984285|NCT06284538|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984286|NCT04455126|NA|SINGLE_GROUP||TREATMENT||NONE||This was an open-label, non-randomized clinical study that aimed to assess the ocular signs and symptoms in 60 eyes of 30 newly diagnosed Egyptian glaucoma patients receiving preservative-free tafluprost eye drops.||||
33984287|NCT02865122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984288|NCT02142556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984289|NCT06123533|||OTHER||OTHER|||||||
33984290|NCT03736382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984291|NCT00322803|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33984292|NCT05275179|||COHORT||PROSPECTIVE|||||||
33984293|NCT03139019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984294|NCT01386593|RANDOMIZED|CROSSOVER||||NONE||||||
33984295|NCT02006173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984296|NCT05099822|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33984297|NCT06203522|||COHORT||RETROSPECTIVE|||||||
33984298|NCT00858923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984299|NCT05883956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984300|NCT02623543|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33984301|NCT03488667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984302|NCT01221155|||COHORT|||||||||
33984303|NCT03927066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984304|NCT03806062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984305|NCT02393157|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984306|NCT01316549|||OTHER||PROSPECTIVE|||||||
33984307|NCT01576042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984308|NCT05257746|||COHORT||PROSPECTIVE|||||||
33984309|NCT05910632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Hidden and opaque envelope technique.||f|f|t|t
33984310|NCT00468286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079613|NCT02365662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079614|NCT01022333|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34079615|NCT04584515|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681522|NCT02805504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681523|NCT06342739|||CASE_ONLY||PROSPECTIVE|||||||
33681524|NCT05712486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double- blind||t|f|f|t
33681525|NCT01147627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681526|NCT04717830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681527|NCT05832775|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33681528|NCT02907476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771888|NCT05148832|NA|SINGLE_GROUP||TREATMENT||NONE||67 Covid-19 patients with symptoms of ageusia and anosmia were recruited (that their covid infection was confirmed by using PCR).||||
33771889|NCT06243848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771890|NCT02980796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33771891|NCT01321762|||COHORT||PROSPECTIVE|||||||
33771892|NCT04465058|||OTHER||PROSPECTIVE|||||||
33771893|NCT04403802|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33984311|NCT01745783|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984312|NCT02337218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984313|NCT06370780|NA|SINGLE_GROUP||OTHER||NONE|N/A - all participants get the app|||||
33984314|NCT00161564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984315|NCT02874300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984316|NCT03739749|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multiple group assignment||||
33984317|NCT05634772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984318|NCT01003002|||COHORT||PROSPECTIVE|||||||
33984319|NCT01793194|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984320|NCT02828904|||COHORT||RETROSPECTIVE|||||||
33984321|NCT00004359||||TREATMENT||||||||
33984322|NCT02219945|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"6 groups:~1) 20 TB patients 2) 20 non-TB patients (alternative diagnosis) 3) 20 patients with chest symptoms - non-TB 4) 7 MDR-TB patients 5) 20 healthy controls 6) 300 subjects suspected to have pulmonary tuberculosis - follow-up for 2.5 years"||||
33681529|NCT02278523|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33681530|NCT00734747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681531|NCT02536183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681532|NCT02006095|||COHORT||PROSPECTIVE|||||||
33681533|NCT00205270|||COHORT||PROSPECTIVE|||||||
33681534|NCT02536404|RANDOMIZED|PARALLEL||TREATMENT||||||||
33681535|NCT03430076|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33771894|NCT01615341|||COHORT||PROSPECTIVE|||||||
33771895|NCT02400359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771896|NCT05276843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771897|NCT01129336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771898|NCT01693003|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681536|NCT00852514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901758|NCT05344092|NA|SINGLE_GROUP||OTHER||NONE||Participants will be provided with VetEd (the Veteran student support mobile app) and log-in information, to utilize at home over a four-week period. During that time, they will be provided with instructions on how to use the app. Participants will be asked to complete at least two in-app tasks per week, including for example setting up an educational roadmap, tracking course assignments, learning about successful study strategies, completing a coping exercise, and finding information related to GI Bill benefits.||||
33901759|NCT04714463|||COHORT||PROSPECTIVE|||||||
33681537|NCT05050591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901760|NCT02466269|||CASE_ONLY||RETROSPECTIVE|||||||
33681538|NCT01420276|||||PROSPECTIVE|||||||
33681539|NCT02623231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33901761|NCT03558321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901762|NCT04880057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681540|NCT04013243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33681541|NCT00458224|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681542|NCT03016143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33901763|NCT04670653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33901764|NCT01179763|||CASE_ONLY||PROSPECTIVE|||||||
33901765|NCT00193310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681543|NCT01737229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681544|NCT01811264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33681545|NCT01827683|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33681546|NCT00108368|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33771899|NCT00801424|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33901766|NCT05032443|||OTHER||PROSPECTIVE|||||||
33901767|NCT01988038|||COHORT||PROSPECTIVE|||||||
33901768|NCT03407391|||COHORT||PROSPECTIVE|||||||
33901769|NCT04912128|||CASE_CONTROL||RETROSPECTIVE|||||||
33901770|NCT02796950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33901771|NCT01125891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901772|NCT00092547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33901773|NCT02564822|||OTHER||CROSS_SECTIONAL|||||||
33984323|NCT05693597|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group I (control): Patients will not receive any prophylactic intervention, as there is no standard of care for prophylaxis to the radiation induced dermatitis (RID).~Group II (Topical intervention): Patients will receive Imtenan ® N. sativa oil apply 1.5 mls; twice daily; not sooner than 2 hours before and after radiation therapy; from day 1 of radiation therapy till the end.~Group III (Oral intervention): Patients will receive Baraka ® N. sativa gelatin capsules; 40mg/Kg/day; from day 1 of radiation therapy till the end"||||
34079616|NCT04858204|||COHORT||RETROSPECTIVE|||||||
34079617|NCT01635452|||CASE_ONLY||PROSPECTIVE|||||||
34079618|NCT04708158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079619|NCT02823470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079620|NCT02730611|||COHORT||PROSPECTIVE|||||||
34079621|NCT01613261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079622|NCT05057689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34079623|NCT05830760|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34079624|NCT05874232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34079625|NCT01719549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079626|NCT02992119|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized 7 groups||||
34079627|NCT02421354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079628|NCT05341024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079629|NCT05455827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079630|NCT02486692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079631|NCT01730807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079632|NCT01144780|||COHORT||PROSPECTIVE|||||||
34079633|NCT04238936|||CASE_CONTROL||PROSPECTIVE|||||||
34079634|NCT00890448|||CASE_CONTROL|||||||||
34079635|NCT03154086|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34079636|NCT02589145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079637|NCT00455169|||COHORT||PROSPECTIVE|||||||
34079638|NCT00001512||||TREATMENT||||||||
34079639|NCT04549493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079640|NCT04353726|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after study design||||
34079641|NCT01535924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079642|NCT05066191|||COHORT||PROSPECTIVE|||||||
34079643|NCT01401595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079644|NCT04381078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34079645|NCT00954681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079646|NCT05514730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be unaware of whether they are assigned to the experimental or control condition. Research assistants collecting data will similarly be unaware of the participant's condition during assessment.|Two conditions will be employed, PBT and treatment-as-usual, and participants will be randomly assigned to condition using a blocked randomization procedure balancing for gender and age.|t|f|f|t
34079647|NCT02758834|||COHORT||PROSPECTIVE|||||||
34079648|NCT02833896|||COHORT||RETROSPECTIVE|||||||
34079649|NCT02001701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681547|NCT06449274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681548|NCT00004082||||TREATMENT||||||||
33681549|NCT01495312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681550|NCT03459391|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Blinding was carried out by using Placebo equivalent to XC221 tablets without active substance and the corresponding labeling of the study drug.|The dose cohorts were included into the study subsequently based on preliminary safety results evaluation performed by the Data Safety Monitoring Committee. 2 doses of XC221/placebo (60 mg and 200 mg) were used in the study.The duration of exposure to the study drug was 6 days in each cohort: Day 1, once, at the step of single administration, and then in 6 days, daily, 1 time a day for 5 days at the step of multiple administration.|t|f|t|f
33681551|NCT01873521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681552|NCT03986931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research interns conducting baseline and exit data collection will be blinded so that they do not influence responses.||f|f|t|f
33681553|NCT03838809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33681554|NCT02338908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681555|NCT05088473|||COHORT||RETROSPECTIVE|||||||
33681556|NCT02604537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681557|NCT03601234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681558|NCT02683746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681559|NCT00879008|||COHORT||PROSPECTIVE|||||||
33681560|NCT05551247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681561|NCT06097390|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681562|NCT03507114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Folow-up interviews will be carried out by a different team of assessors (blinded to the treatment condition)||f|f|f|t
33681563|NCT03837522|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33681564|NCT04125251|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participants, LSB providers and the outcomes assessors will not be having knowledge regarding the outcomes being assessed.|The intervention and the assessment will be carried out parallel in the intervention and the control arm.|t|t|f|t
33681565|NCT02621840|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681566|NCT01055652|NA|SINGLE_GROUP||||NONE||||||
33681567|NCT06066229|||OTHER||PROSPECTIVE|||||||
33681568|NCT01246817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681569|NCT06376903|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33681570|NCT06435065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681571|NCT03455790|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33681572|NCT04669418|||CASE_CONTROL||PROSPECTIVE|||||||
33681573|NCT00000496|RANDOMIZED|||PREVENTION||DOUBLE||||||
33681574|NCT03430453|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33681575|NCT01943357|NA|SINGLE_GROUP||OTHER||NONE||||||
33681576|NCT02384057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681577|NCT06102330|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The first half of families at each site will be enrolled in the 'usual care' arm, the second half enrolled in the 'intervention' arm||||
33681578|NCT03763565|||COHORT||RETROSPECTIVE|||||||
33681579|NCT00002339||||TREATMENT||||||||
33681580|NCT02482779|||OTHER||PROSPECTIVE|||||||
33681581|NCT01556412|||COHORT||PROSPECTIVE|||||||
33681582|NCT02208063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681583|NCT02876250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681584|NCT04479319|||CASE_ONLY||RETROSPECTIVE|||||||
33681585|NCT04063800|||COHORT||RETROSPECTIVE|||||||
33681586|NCT05099094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681587|NCT00725842|||COHORT||PROSPECTIVE|||||||
33681588|NCT00479271|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||||||
33681589|NCT01397734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681590|NCT04605367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"This is a double-blind study for the tDCS part. Participant will be blind to the type of stimulation (sham or real tDCS). The experimenter will be also blind to the type of stimulation using the study mode implemented in the stimulator device that encodes sham and real stimulation mode using predefined numeric codes."||t|f|f|t
33681591|NCT02188901|NA|SINGLE_GROUP||SCREENING||NONE||||||
33681592|NCT00796445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681593|NCT04769180|||CASE_CONTROL||RETROSPECTIVE|||||||
33681594|NCT01109732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681595|NCT00947505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681596|NCT00125398|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681597|NCT03540719|||COHORT||PROSPECTIVE|||||||
33681598|NCT05617495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681599|NCT04424329|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33681600|NCT02292901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681601|NCT04948931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Three groups: Lavender aromatherapy group, rosemary aromatherapy group and control group||||
33681602|NCT00885820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681603|NCT00083252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681604|NCT04271644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681605|NCT01328366|||COHORT||PROSPECTIVE|||||||
33681606|NCT05828927|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681607|NCT01765478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681608|NCT02004288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33681609|NCT02965768|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double-blind trial. An encrypted and password-protected database will contain (1) information about individual group assignment, and (2) blister pack codes (medication will be dispensed in blister packs by investigators based on these codes). An investigator not involved with data collection or participant interactions will randomly assign individuals to the treatment group and provide blister pack ID codes for each individual.||t|t|t|t
33681610|NCT02085031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681611|NCT05767567|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33681612|NCT05186415|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681613|NCT00385190|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33681614|NCT03234140|||COHORT||RETROSPECTIVE|||||||
33681615|NCT04040491||PARALLEL||TREATMENT||NONE||50 patients for newly diagnosed group and 50 patients for relapse/refractory group.||||
33681616|NCT00449306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33984324|NCT01138436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984325|NCT06149130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681617|NCT04404218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinding, using placebo pills.|Prospective, double-blinded, placebo-controlled, randomized, multicentre clinical trial|t|t|t|t
33681618|NCT04049409|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33681619|NCT04290728|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled clinical trial||||
33681620|NCT03640780|||OTHER||CROSS_SECTIONAL|||||||
33681621|NCT02735889|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33681622|NCT03115281|||COHORT||PROSPECTIVE|||||||
33681623|NCT00415298|RANDOMIZED|||TREATMENT||||||||
33681624|NCT05277337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681625|NCT00307320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681626|NCT03495609|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681627|NCT04660838|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33681628|NCT00167297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681629|NCT04933643|||CASE_CONTROL||PROSPECTIVE|||||||
33681630|NCT00545129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681631|NCT02841878|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33681632|NCT01984762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681633|NCT02805270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33681634|NCT05577520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Small particle group (SPG n=10): MSA using 250 to 1000 µm size ABBM particles (Osteodens®, Pharmatrix, Argentina) as bone substitute.~Large particles group (LPG n=10): MSA using 1000 to 2000 µm size ABBM particles (Osteodens®, Pharmatrix, Argentina) as bone substitute."|t|f|f|f
33681635|NCT04233918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681636|NCT00220779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681637|NCT04124497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681638|NCT02341937|||COHORT||PROSPECTIVE|||||||
33681639|NCT00216905|||CASE_ONLY||CROSS_SECTIONAL|||||||
33681640|NCT04272112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33681641|NCT04348968|||COHORT||OTHER|||||||
33681642|NCT05223153|||CASE_CONTROL||PROSPECTIVE|||||||
33681643|NCT05417152|||OTHER||PROSPECTIVE|||||||
33681644|NCT04783688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Study is a measurement of subjects performing normal tasks in a controlled environment, with physiological measurements||||
33681645|NCT00046800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681646|NCT06005324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33681647|NCT01302132|NA|SINGLE_GROUP||||NONE||||||
33681648|NCT06361342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681649|NCT00755300|||COHORT||PROSPECTIVE|||||||
33681650|NCT01209104|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681651|NCT05892380|||COHORT||PROSPECTIVE|||||||
33771900|NCT04720963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771901|NCT00878358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771902|NCT05179941|NA|SINGLE_GROUP||OTHER||NONE||||||
33771903|NCT02246829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771904|NCT04081519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33681652|NCT05059288|NA|SINGLE_GROUP||OTHER||NONE||||||
33681653|NCT01970904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681654|NCT02247648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771905|NCT04691882|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771906|NCT06344611|||COHORT||PROSPECTIVE|||||||
33681655|NCT02603965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33771907|NCT02691104|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33771908|NCT03382600|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33771909|NCT06278116|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33771910|NCT05854329|RANDOMIZED|PARALLEL||PREVENTION||NONE||Immersive and Non immersive Virtual Reality||||
33771911|NCT01865864|||COHORT||PROSPECTIVE|||||||
33771912|NCT00990301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33771913|NCT04786470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771914|NCT00975455|||CASE_ONLY||PROSPECTIVE|||||||
33771915|NCT00492934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771916|NCT03552705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded RCT||t|t|t|t
33681656|NCT01203852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681657|NCT01100957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681658|NCT02856360|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33681659|NCT04137107|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33681660|NCT06328478|||COHORT||PROSPECTIVE|||||||
33771917|NCT03747289|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the investigator will check all the participants without knowing to which group they are assigned to||f|f|t|f
33984326|NCT03962348|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Feasibility and Acceptability Study||||
33984327|NCT04320849|||OTHER||PROSPECTIVE|||||||
33984328|NCT00585689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984329|NCT02068105|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984330|NCT02550678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984331|NCT00010647|RANDOMIZED|||TREATMENT||||||||
33984332|NCT02126137|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984333|NCT05298267|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be monitored for 4 weeks. Halfway through the monitoring period, participants will be asked to turn on the DNDWD feature on their phone.||||
33984334|NCT05165381|||OTHER||PROSPECTIVE|||||||
33984335|NCT01482377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984336|NCT05136183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984337|NCT03593980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984338|NCT04738084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analyst will be blind to study group|Patients randomized to one of two groups, the Meru Health Program which is a 12 week program or a 12-week waitlist control group|f|f|f|t
33984339|NCT04831749|||OTHER||CROSS_SECTIONAL|||||||
33984340|NCT01641380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33984341|NCT01544361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984342|NCT02975141|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33984343|NCT04000815|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||In this study, there are three groups. Group 1:Women between 18-40 age, Group 2:Perimenopausal women (40-49 years), Group 3: Postmenopausal women.|f|f|t|f
33984344|NCT05240495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|This study was a three-armed controlled superiority trial in which two internet-based interventions for stress-related disorder: (a) cognitive-behavioural therapy (iCBT; n=61) and (b) work-focused iCBT (W-iCBT; n=61) that integrated work aspects early into the treatment, were compared against a wait-list control group (n=60). The study followed the CONSORT guidelines \[45\]. Sample size was estimated on the basis of previous controlled trials on iCBT for chronic stress (e.g., Persson Asplund et al., 2018), with the aim of detecting an effect size of Cohens'd=0.50 on the primary outcome Shirom-Melamed Burnout Questionnaire (see Measures), at post assessment, based on a power of 0.80 in a two-tailed test with 0.05 significant level. Self-reported outcome assessments were collected at pre- and post-treatment (ten weeks) and at a 6- and 12-month follow-up.|t|f|f|f
33681661|NCT05667415|RANDOMIZED|PARALLEL||TREATMENT||NONE||Combination regimen of disulfiram and cisplatin for gastric cancer and standard cisplatin regimen for gastric cancer||||
33984345|NCT01292720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984346|NCT05651230|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33984347|NCT00747864|||COHORT||RETROSPECTIVE|||||||
33984348|NCT00086996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984349|NCT01591785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984350|NCT02616809|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33984351|NCT02678286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681662|NCT01538784|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33681663|NCT02819232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681664|NCT05411575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681665|NCT00275821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681666|NCT06121245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Pharmacy prepared placebo.|Randomized, double-blind, placebo-controlled, crossover study|t|f|t|f
33771918|NCT00268931|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33771919|NCT02999893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901774|NCT02722577|||COHORT||PROSPECTIVE|||||||
33901775|NCT03531268|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||All subjects meeting inclusion/exclusion criteria will undergo pharmacogenomic testing. The group for which testing is thought to have clinical utility will be compared to the group for which testing is thought to have no clinical utility.||||
33901776|NCT06094712|NA|SINGLE_GROUP||OTHER||NONE||||||
33901777|NCT06434740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901778|NCT03463265|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33901779|NCT06244602|||CASE_ONLY||CROSS_SECTIONAL|||||||
33901780|NCT02138110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901781|NCT05057312|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33901782|NCT06672692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants are not provided investigational results and will only be provided with routine standard of care diagnostics results.|||||
33901783|NCT06668363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data analysts will be masked.||f|f|t|t
33901784|NCT05699447|||COHORT||RETROSPECTIVE|||||||
33901785|NCT06425744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901786|NCT04239404|||COHORT||PROSPECTIVE|||||||
33984352|NCT00359905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984353|NCT02696694|||COHORT||PROSPECTIVE|||||||
33681667|NCT02362828|||COHORT||PROSPECTIVE|||||||
33901787|NCT00856427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901788|NCT00178594|||OTHER||PROSPECTIVE|||||||
33901789|NCT02768909|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901790|NCT03372954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901791|NCT06274333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33901792|NCT03426215|||CASE_ONLY||PROSPECTIVE|||||||
33901793|NCT03671863|||COHORT||RETROSPECTIVE|||||||
33901794|NCT04611464|||CASE_ONLY||CROSS_SECTIONAL|||||||
33984354|NCT03020641|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33771920|NCT04384458|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is a open-blind, randomised trial.||||
33984355|NCT02722980|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33984356|NCT00003528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984357|NCT04836078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33984358|NCT02263092|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33984359|NCT03123471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984360|NCT01135797|||COHORT||RETROSPECTIVE|||||||
33984361|NCT02778165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33984362|NCT03101995|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II open, single arm, national, non-randomized clinical trial; to evaluate safety of gemcitabine in patients with locally advanced cervical cancer and renal dysfunction, referring to the INCAN.||||
33984363|NCT04769648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects randomized for week 0 - week 12; subjects, investigators and study staff will be masked through week 24.|12 weeks randomized 1:1 active to placebo. At 12 weeks, placebo group crosses over to active drug. At week 24, all subjects can opt in to an open-label phase.|t|t|t|t
33984364|NCT01333332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984365|NCT01807793|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34079650|NCT05117060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The outcome assessor is considered to be the person/people who will assess the outcome of the data/study and will in this study therefore be the sponsor.~To ensure masking across the interventions, each dose of treatment in the LEO 152020 tablet - Dose regimen 2 and LEO 152020 tablet - Dose regimen 3 arms will consist of a combination of LEO 152020 and LEO 152020 placebo tablets. In these arms, placebo will be used as a masking aid and is therefore considered neither a control nor an intervention."||t|f|t|t
33984366|NCT00857623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984367|NCT04857697|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079651|NCT05968313|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34079652|NCT05433467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681668|NCT04686058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33681669|NCT04604132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681670|NCT03625908|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients will be assigned by use of OCT-guidance or angiography-guidance for stent implantation.||||
33681671|NCT02858700|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681672|NCT02585570|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681673|NCT05173545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681674|NCT00484744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33681675|NCT04643600|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||The research will be organized as a cross-sectional study that will include patients, smokers and non-smokers, who are undergoing medical rehabilitation or medically programmed vacation in the Special Hospital for Medical Rehabilitation Daruvarske toplice|f|f|t|f
33681676|NCT04951167|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Pregnant women will be randomly divided into 4 groups using the closed envelope method. The person who prepares the study drugs and follows the study will be different and unaware of the study.||t|f|t|f
33681677|NCT06343857|||COHORT||PROSPECTIVE|||||||
33681678|NCT04232969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.|t|t|t|t
33681679|NCT00093444||||TREATMENT||||||||
34079653|NCT02509377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681680|NCT04319497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681681|NCT02439359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681682|NCT00483132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681683|NCT06393335|NA|SEQUENTIAL||TREATMENT||NONE||||||
33681684|NCT05536128|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, phase II study||||
34079654|NCT04085601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079655|NCT03745053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The members of the Event Adjudication Committee and the Core Lab will be blinded to the patient assignment.|Randomized multi-centre controlled trial|f|f|f|t
34079656|NCT04772066|||COHORT||PROSPECTIVE|||||||
34079657|NCT05556603|||CASE_CONTROL||PROSPECTIVE|||||||
34079658|NCT00313690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079659|NCT00699777|RANDOMIZED|CROSSOVER||||NONE||||||
34079660|NCT03708471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079661|NCT02599532|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681685|NCT06046742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681686|NCT04988191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681687|NCT01252667|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In part 1, patients are treated at each dose in cohorts of three and observed for any dose limiting toxicities. In Part 2, patients are treated at the maximum tolerated dose established in Part 1.||||
33681688|NCT01337102|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33771921|NCT04217993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771922|NCT01912222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771923|NCT05203575|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||f|f|t|t
33771924|NCT01079143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771925|NCT03143335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33771926|NCT03389685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771927|NCT00462644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771928|NCT06168591|||COHORT||PROSPECTIVE|||||||
33771929|NCT01097460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771930|NCT02124876|||COHORT||PROSPECTIVE|||||||
33771931|NCT05634122|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel-group, randomized controlled trial||||
33771932|NCT00226473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984368|NCT01979341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984369|NCT02865356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984370|NCT03410862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984371|NCT01423526|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33984372|NCT04697017|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33681689|NCT01762020|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|within patient randomization. One half of breast received Cavilon and other receives standard of care treatment. Care provider is blinded as to portion receiving treatment.|within patient randomization of Cavilon skin spray|f|t|f|f
33681690|NCT00395343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681691|NCT01479283|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33681692|NCT06403488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681693|NCT03387111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681694|NCT01517191|||CASE_CONTROL||PROSPECTIVE|||||||
33681695|NCT00042341|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681696|NCT05145270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All the participants will be 1:2:2 randomly assigned to different intervention groups including escitalopram, escitalopram plus sulforaphane (SFN) , and escitalopram plus repetitive transcranial magnetic stimulation (rTMS).|f|f|f|t
33681697|NCT00456443|||DEFINED_POPULATION||OTHER|||||||
33681698|NCT00000481|RANDOMIZED|||PREVENTION||||||||
33681699|NCT05323825|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33681700|NCT03894371|NA|SINGLE_GROUP||TREATMENT||NONE||Thermage FLX System||||
33681701|NCT00030004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681702|NCT02491229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681703|NCT06356467|||COHORT||RETROSPECTIVE|||||||
33681704|NCT03339297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681705|NCT05270447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Study|t|f|f|f
33681706|NCT00819793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681707|NCT00494767|RANDOMIZED|PARALLEL||TREATMENT||||||||
33681708|NCT04769999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681709|NCT03565367|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901795|NCT06504550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be Randomized clinical trial in which non probability convinient sampling will be used.Two groups of 8 to 12 years of age will be formed in which participants will be randomly divided.In Group A Schroth exercises will be conducted that consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles.In Group B Klapp group will be treated with klapp exercises. In each session, a sequence of 8 postures of Klapp method will be carried out|t|f|f|f
33901796|NCT05441969|||COHORT||PROSPECTIVE|||||||
33681710|NCT00709709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681711|NCT05796830|RANDOMIZED|PARALLEL||OTHER||SINGLE||This studyis a single-center and randomized controlled clinical trial. Patients who accepted to participate in the study and met the inclusion criteria will be assigned to the intervention (n= 35) or control group (n= 35) according to the computer- based randomization table.|f|f|f|t
33681712|NCT02396160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681713|NCT05212857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681714|NCT02694757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681715|NCT05240443|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-centre, open-label, parallel-arm feasibility randomized controlled trial with blinded endpoint assessment.||||
33681716|NCT02011139|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33681717|NCT02682979|||OTHER||RETROSPECTIVE|||||||
33681718|NCT05488756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33681719|NCT05873660|||COHORT||CROSS_SECTIONAL|||||||
33681720|NCT02346890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681721|NCT00680238|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33681722|NCT02331901|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901797|NCT05437029|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33901798|NCT06352216|||COHORT||PROSPECTIVE|||||||
33681723|NCT03023839|||COHORT||PROSPECTIVE|||||||
33901799|NCT05930873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901800|NCT06673173|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33901801|NCT00576498|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33681724|NCT00265148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681725|NCT00642889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901802|NCT01597193|NON_RANDOMIZED|||TREATMENT||NONE||||||
33901803|NCT05829720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33901804|NCT03340441|||COHORT||PROSPECTIVE|||||||
33901805|NCT01477632|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901806|NCT06544863|||COHORT||PROSPECTIVE|||||||
33901807|NCT04900662|||OTHER||PROSPECTIVE|||||||
33901808|NCT06529185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901809|NCT00593112|NON_RANDOMIZED|PARALLEL||||NONE||||||
33901810|NCT03704051|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33984373|NCT01885039|||CASE_ONLY||CROSS_SECTIONAL|||||||
33984374|NCT00416520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984375|NCT01415557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33984376|NCT05310097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984377|NCT03172351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984378|NCT01942863|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34079662|NCT04247516|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized controlled trial will be developed with three groups. After obtaining informed consent from parents/caregivers, participants meeting criteria will be randomly assigned to one condition. The control group (CG) will not have access to the online platform, i.e. no intervention. The intervention group 1 (IG1) will receive on a weekly basis tasks and activities on the online platform to promote SR and SE, as well as chapters of the narrative. The intervention group 2 (IG2) will receive the same tasks and materials as IG1 but embedded with Gamification Strategies.||||
34079663|NCT04954521|||OTHER||PROSPECTIVE|||||||
33984379|NCT02236247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984380|NCT01013025|||COHORT||CROSS_SECTIONAL|||||||
33984381|NCT01529060|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34079664|NCT02307227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079665|NCT05438277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079666|NCT01878032|||CASE_CONTROL||PROSPECTIVE|||||||
34079667|NCT05775627|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34079668|NCT03722706|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34079669|NCT01690507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079670|NCT02586376|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34079671|NCT00424281|||DEFINED_POPULATION||OTHER|||||||
33984382|NCT04702828|||CASE_ONLY||CROSS_SECTIONAL|||||||
33984383|NCT01960569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984384|NCT04350086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984385|NCT01974297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984386|NCT01661114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984387|NCT02561793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984388|NCT02336165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079672|NCT01753609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079673|NCT05932758|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34079674|NCT00852813|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34079675|NCT01128296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079676|NCT01663402|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34079677|NCT00742911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079678|NCT04787367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patient will be unaware of when they received the block. The nursing assistants checking the pain score will also be unaware of the timing of the block.|This is a single blinded, prospective study designed to determine optimal timing of TAP block in laparoscopic gastric sleeve patients. Patients will randomly be assigned to the early intra-operative TAP block group or the late intra-operative TAP block group.|t|f|f|f
34079679|NCT06330376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective randomized clinical study with 2 arms|f|f|f|t
34079680|NCT01450319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079681|NCT05229328|||CASE_CONTROL||PROSPECTIVE|||||||
34079682|NCT02692586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079683|NCT02644278||SEQUENTIAL||TREATMENT||NONE||||||
34079684|NCT05397353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079685|NCT05731700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079686|NCT03573635|NA|SINGLE_GROUP||OTHER||NONE||||||
34079687|NCT03503279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34079688|NCT03863860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079689|NCT03429348|RANDOMIZED|PARALLEL||OTHER||NONE||Working with firefighters during training fire exercises, Dr. Jeff Burgess and his study team will compare a chemical commonly excreted in firefighter urine samples after firefighting to assess the value of adding sauna to rehab post-fire. Firefighter heart rate and temperature will be monitored using a core body temperature/heart rate monitor data recorder. Urine will be collected for 12 hours immediately before the scheduled training fire and for 12 hours afterwards. After the fire, the firefighter will perform the standard rehab. During this time, the University of Arizona (UA) study team will randomly select half of the firefighters to an additional sauna rehab and the other half of the firefighters to no additional rehab. Dermal (skin) wipe samples will be taken off the calf, arm, and neck before the fire, before standard rehab, and after sauna/no additional treatment. A post-fire survey will be administered.||||
34079690|NCT05390606|RANDOMIZED|PARALLEL||OTHER||NONE||A longitudinal open label randomized controlled trial.||||
34079691|NCT05868317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984389|NCT05245357|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Lentil and Control meals were designed to be comparable in taste and appearance. The meals are prepared and coded prior to receipt by the research team. Randomization is for order of coded meals.|The design is 2 x 2 crossover design, where the overweight and obese adults without Type 2 Diabetes will be randomized into Control or Lentil|t|f|t|f
33984390|NCT00262223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33984391|NCT03733197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Mixed Methods Approach|t|f|f|f
33984392|NCT00449566|||CASE_CONTROL||PROSPECTIVE|||||||
33984393|NCT04448106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and evaluators|The Phase 2 study is an open-label, 6 arms, randomized, control group clinical study conducted in multiple clinical facilities.|t|f|f|t
33984394|NCT04607863|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33681726|NCT06058988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984395|NCT00283699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984396|NCT00537030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079692|NCT02652637|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34079693|NCT05704868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984397|NCT00986245|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984398|NCT02389491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33984399|NCT00000221||CROSSOVER||TREATMENT||DOUBLE||||||
33984400|NCT02189941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984401|NCT05267691|||COHORT||RETROSPECTIVE|||||||
33984402|NCT04700774|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|It will not be known to participants whether they receive standard BA or mBA.|Participants will be randomized to active treatment or a 10-week waitlist followed by active treatment (BA or mBA). The active treatment is also based upon randomization, where individuals will receive either standard BA or mBA, and will be followed for 6 months post treatment.|t|f|f|f
34079694|NCT02437760|||CASE_CONTROL||PROSPECTIVE|||||||
33681727|NCT01264575|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33984403|NCT01770938|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33984404|NCT04225663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984405|NCT01516983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984406|NCT03803800|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"All subjects involved (participants, care providor, asessor) are blinded to the supplementation (beta-alanine vs placebo).~Outcome assessors are blinded to the exercise intervention (classic vs periodized training)"|Four intervention groups following either 12 weeks of 'classical' moderate intensity cardiovascular exercise therapy (n=40) or periodized exercise therapy (n=40), with (MSβclassic, n=20; MSβperiod, n=20) or without (MSclassic, n=20; MSperiod, n=20) β-alanine supplementation|t|t|t|t
33984407|NCT00606151|||CASE_CONTROL||PROSPECTIVE|||||||
34079695|NCT03962608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo|"Randomized (1:1) to:~* Standard medical treatment + Yaq-001 (8 g/ day) - n= 35~* Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day) - n= 35"|t|t|t|t
34079696|NCT00916552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079697|NCT00974311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079698|NCT05793515|||COHORT||PROSPECTIVE|||||||
33681728|NCT06449365|RANDOMIZED|PARALLEL||OTHER||NONE||randomized control||||
33681729|NCT04718545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079699|NCT03240419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33681730|NCT01466257|||OTHER||RETROSPECTIVE|||||||
33681731|NCT00370045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681732|NCT00084890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681733|NCT03619967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Experimental: Arm 1: Multispectral Imaging Per current standard of care for patients with breast cancer, three different tracers will be injected in the patient: technetium radiocolloid, indocyanine green and methylene blue. The surgeon will identify the location of the sentinel lymph node per standard of care by using a handheld gamma-probe and by visual inspection of the wound site. During this same time period, fluorescent signals from the underarm surgical wound site will be recorded with the bio-inspired multispectral camera.||||
34079700|NCT02791854|||OTHER||PROSPECTIVE|||||||
34079701|NCT02975401|||COHORT||PROSPECTIVE|||||||
34079702|NCT00115310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34079703|NCT03179358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079704|NCT02031523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079705|NCT00165126|||CASE_ONLY||PROSPECTIVE|||||||
33681734|NCT00518960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079706|NCT01975558|||CASE_CONTROL||PROSPECTIVE|||||||
34079707|NCT03472911|||CASE_ONLY||PROSPECTIVE|||||||
33984408|NCT05070260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study (respectively Part 1 and 2).|t|t|t|f
33984409|NCT05044221|||COHORT||PROSPECTIVE|||||||
33984410|NCT01975688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984411|NCT03499847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|subjects will be interviewed over the telephone 6 weeks after initial intervention by a blinded assessor to assess outcomes|"3-arm, randomised control trial~1. Active Intervention group (n=65) Counselling provided Pamphlet given~2. Passive Intervention group (n=65) Pamphlet given~3. Control group (n=65) Neither counselling nor pamphlet given"|f|f|f|t
33984412|NCT04660656|||CASE_ONLY||PROSPECTIVE|||||||
34079708|NCT05211440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Supplement and placebo supplements will be provided to the clinic in blindly coded containers. The code was generated by parties not responsible for data collection, analysis, or interpretation.||t|f|t|t
34079709|NCT03114293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Rater blinded.|Short, randomised waiting-group controlled explorative studies of a behavioural intervention.|f|f|t|t
34079710|NCT01775670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079711|NCT00502567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079712|NCT00965107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079713|NCT01558219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079714|NCT02311829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079715|NCT04831034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079716|NCT05439746|NA|SINGLE_GROUP||TREATMENT||NONE|The primary outcome assessment in this trial will be assessed by digital photography of the wounds as assessed by study team members who are blinded to the randomization.|||||
33984413|NCT00800137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984414|NCT05730166|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33984415|NCT00830232|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33984416|NCT04037969|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participants and investigators are masked as to which lens is assigned to each eye.||t|f|t|f
33984417|NCT01306630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079717|NCT05793593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079718|NCT02205125|||COHORT||PROSPECTIVE|||||||
34079719|NCT06040359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079720|NCT05310669|||COHORT||PROSPECTIVE|||||||
34079721|NCT04799925|||CASE_CONTROL||PROSPECTIVE|||||||
34079722|NCT05728736|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34079723|NCT01461642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079724|NCT00458315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079725|NCT02224625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34079726|NCT05945238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33681735|NCT00102778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681736|NCT04966910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984418|NCT06123728|||COHORT||PROSPECTIVE|||||||
33984419|NCT00006027|RANDOMIZED|||TREATMENT||||||||
33984420|NCT01021670|||COHORT||PROSPECTIVE|||||||
33984421|NCT05364307|||CASE_ONLY||PROSPECTIVE|||||||
34079727|NCT04966286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34079728|NCT02923765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079729|NCT04251078|||COHORT||PROSPECTIVE|||||||
34079730|NCT03259152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079731|NCT02570386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079732|NCT02230891|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079733|NCT06524388|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34079734|NCT02733718|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34079735|NCT02655003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079736|NCT01937897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079737|NCT00128661|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34079738|NCT03479112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079739|NCT03540693|||OTHER||OTHER|||||||
34079740|NCT04062695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo controlled parallel group for 12 weeks followed by 12 weeks open label|t|t|t|t
34079741|NCT03319771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079742|NCT06550843|||CASE_CONTROL||RETROSPECTIVE|||||||
34079743|NCT04249427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079744|NCT05114434|||COHORT||PROSPECTIVE|||||||
34079745|NCT02262897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079746|NCT01155817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079747|NCT04389528|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||double-blind randomized study|t|t|t|t
33984422|NCT00699491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984423|NCT00021463||||TREATMENT||||||||
33984424|NCT00662740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984425|NCT03314298|NA|SINGLE_GROUP||PREVENTION||NONE||open labelled pharmacokinetic study||||
33984426|NCT00425256|RANDOMIZED|PARALLEL||||DOUBLE||||||
33984427|NCT00374335|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33984428|NCT03291925|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, open-label trial.||||
33984429|NCT02560194|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33984430|NCT05853666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants enrolled in the study will be allocated based on whether the NICU is in the control or intervention condition on their admission date. Blinding to the intervention at the participant level (i.e., standard care or CNH+) is not possible. Although an attention control website was considered, this was not implemented to ensure the findings are relevant against existing standard care (i.e., no eHealth component). Blinding is not possible at the unit level due to the shift in communication that will occur (e.g., virtual rounds). Blinding will occur during data analyses by using an external statistician not familiar with the group allocations. Examiners completing the 18-month neurodevelopment outcomes work at arm's length to the NICU with no or little knowledge of ongoing NICU studies.|The CONNECT study is an unblinded multicentre stepped wedge cluster randomized controlled trial guided by a Hybrid-1 design examining the effectiveness and implementation of CNH+ compared to usual care (control) across four Canadian NICUs. All sites will begin in the control period (baseline). Every 5 months, one site will be randomized to CNH+ using a stepped wedge design allowing for 4 sites with 5 measurement steps.||||
33984431|NCT06392594|||COHORT||PROSPECTIVE|||||||
33984432|NCT04228744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984433|NCT05491226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984434|NCT04593628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984435|NCT04327375|||COHORT||RETROSPECTIVE|||||||
33984436|NCT01998217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079748|NCT03685604|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||"The intervention will be conducted as an open-label cluster-randomized cross-over multicenter trial with an allocation ratio of 1:1.~The departments of surgery of the 3 study sites will be randomized center-wise in clusters by month to use CHX or PI. The products will be switched over according to the computer-generated randomization list."|f|f|f|t
34079749|NCT01537224|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079750|NCT03637608|||COHORT||RETROSPECTIVE|||||||
34079751|NCT02099513|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34079752|NCT03691636|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized clinical trial||||
33984437|NCT00727961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079753|NCT02895035|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34079754|NCT02405819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079755|NCT02295072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34079756|NCT02974868|RANDOMIZED|||TREATMENT||TRIPLE||The first 24 weeks are parallel. The single-blind extension period will have a segment for non-responder and a withdrawal/retreatment segment for responder. The cross-over extension period is parallel for non-responders.|t|f|t|t
34079757|NCT00132535|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34079758|NCT05327582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079759|NCT06268834|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
34079760|NCT05296707|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34079761|NCT05107219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079762|NCT02344316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079763|NCT03477292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized trial|t|f|t|t
34079764|NCT05240235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771933|NCT03317379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Since this is a behavioral intervention, participants, care providers, and investigators are aware of each patient's randomization. Outcomes are assessed electronically.|Randomization occurs at the beginning of each individual's participation in the study. Participants are randomized to one condition and not re-randomized during any portion of the study||||
33771934|NCT04994041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984438|NCT01134848|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33984439|NCT03786965|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984440|NCT03115242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984441|NCT01732172|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984442|NCT01392430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34079765|NCT03171259|||COHORT||PROSPECTIVE|||||||
34079766|NCT04426942|||COHORT||PROSPECTIVE|||||||
34079767|NCT02576132|||COHORT||RETROSPECTIVE|||||||
34079768|NCT06167941|||OTHER||RETROSPECTIVE|||||||
34079769|NCT05493293|NA|SINGLE_GROUP||TREATMENT||NONE|For participants who enroll directly from Study NBI-921352-FOS2021, the study will include a Blinded Dose Conversion Period (1 week) before proceeding to the Open-Label Treatment Period.|||||
34079770|NCT06223230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34079771|NCT06125093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079772|NCT05032014|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The random assignment of patients was performed by Nanchang Medical University with a computer-generated random number code. Patients were randomly distributed in a 1:1 ratio to receive probiotics or a placebo (the block size was known only to the statistician). The drug was distributed and packaged in accordance with random numbers, and the documents stating the parameters, such as the blinding codes for the seeds of the random numbers, the block length, and the random numbers, were sealed in envelopes||t|t|t|t
34079773|NCT04054401|NA|SINGLE_GROUP||TREATMENT||NONE||Single group||||
34079774|NCT02527629|||OTHER||PROSPECTIVE|||||||
34079775|NCT05407285|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Crossover Assignment In this crossover design, participants will be administered both dosages of CBD and placebo during participation in the study. Participant will be randomly assigned to one of ten pre-determined sequences with a CBD or placebo product at 5 dosages (0 mg, 20 mg, 50 mg, 100 mg and 200 mg). Participants will be randomized based on a completely balanced 5 by 5 latin square.|t|t|t|t
34079776|NCT00003713||||TREATMENT||||||||
34079777|NCT02408510|||CASE_ONLY||CROSS_SECTIONAL|||||||
34079778|NCT01209403|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34079779|NCT03545750|||CASE_CONTROL||RETROSPECTIVE|||||||
34079780|NCT00863915|RANDOMIZED|CROSSOVER||||NONE||||||
34079781|NCT04042584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079782|NCT01396083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079783|NCT00243009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079784|NCT03081247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079785|NCT00913549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079786|NCT01223833|||||PROSPECTIVE|||||||
34079787|NCT00475137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079788|NCT03187743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079789|NCT03825588|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|During the RCT, the independent evaluator (IE) will be blinded to the assigned condition and will take the following steps to preserve the blind: participants and families will be asked not to share with the IE which condition they are assigned to; at staff meetings when cases are reviewed, IEs will not be present; IEs will be asked to guess what the treatment assignment is at the end of each interview, and they will notify the project coordinator if they become unblinded. Participants will complete complementary self-report forms that will not be influenced by interviewer bias.|Investigators will randomize 240 hospitalized suicidal adolescents with a history of a suicide attempt or ideation with plan to one of 4 conditions in a 2 by 2 design: (1) ASAP + BRITE; (2) BRITE + TAU (treatment as usual); (3) ASAP + TAU; or (4) TAU alone to determine the single and additive effects of ASAP and BRITE on suicide attempts in the subsequent six months.|f|f|f|t
34079790|NCT04756622|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase III, randomized, open label and multi-center study.||||
34079791|NCT00303030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079792|NCT02144870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34079793|NCT04929899|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34079794|NCT06139926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34079795|NCT00910234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34079796|NCT00960193|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34079797|NCT03692429|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34079798|NCT01555658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901811|NCT06556810|NA|SINGLE_GROUP||TREATMENT||NONE||Hospitalized patients with acute decompensated heart failure will be treated with an intravenous dose of IC14 and evaluated for safety, pharmacokinetics/pharmacodynamics, and preliminary clinic response||||
34079799|NCT02897557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901812|NCT01205490||||BASIC_SCIENCE||SINGLE|||f|f|f|t
34079800|NCT01940965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079801|NCT00669318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079802|NCT05775419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079803|NCT02419807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901813|NCT03425110|||COHORT||PROSPECTIVE|||||||
34079804|NCT02945826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079805|NCT05062096|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34079806|NCT06515899|||COHORT||PROSPECTIVE|||||||
34079807|NCT02909010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079808|NCT04830566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079809|NCT06338566|||COHORT||PROSPECTIVE|||||||
34079810|NCT03163641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Used a masked reading center to review the corneal defect staining.||f|f|f|t
34079811|NCT02171546|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079812|NCT06448052|NA|SINGLE_GROUP||TREATMENT||NONE||a single-group, open-label, phase I/II clinical trial||||
34079813|NCT03570216|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single group prospective study.||||
34079814|NCT04997603|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Fitbit accelerometers are distributed to both groups, student athletes and non-athletes who continue to live their lives as usual during the 2 week monitoring.||||
34079815|NCT01706562|||COHORT||RETROSPECTIVE|||||||
34079816|NCT00001057||||TREATMENT||||||||
34079817|NCT01362764|RANDOMIZED|CROSSOVER||||NONE||||||
33771935|NCT06080230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33771936|NCT05239871|||CASE_CONTROL||RETROSPECTIVE|||||||
33771937|NCT00407784|||DEFINED_POPULATION||PROSPECTIVE|||||||
33771938|NCT01253122|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33771939|NCT02276378|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33901814|NCT05215327|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All study staff, and subjects will be blinded to which vaccine the subject will receive, except for an un-blinded vaccinator. This individual will not inform the study team or the subjects which vaccine they administered to the subject. The un-blinded vaccinator will not participate in any other study activities. If the study vaccine is provided in a blinded manner, then research staff will be able to administer the vaccine, and an un-blinded vaccinator will not be necessary. The pharmacy will be un-blinded and will have a record of which vaccine was given to each subject.|The primary goal of this study is to compare influenza vaccine immunogenicity and safety between two doses of HD-QIV and two doses of SD-QIV in a population of lung transplant recipients. The study will be powered on a comparison of the primary immunogenicity outcome. A nominal level of α = 0.05 (two-sided) will be used to determine statistical significance|t|t|t|t
33901815|NCT05174637|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33901816|NCT04995744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901817|NCT02349230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901818|NCT02442999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901819|NCT02487745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901820|NCT06027086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901821|NCT02295891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901822|NCT04979572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34079818|NCT01996371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079819|NCT04471701|||COHORT||CROSS_SECTIONAL|||||||
34079820|NCT00953030|RANDOMIZED|||||NONE||||||
34079821|NCT04517292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079822|NCT06368310|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33984443|NCT05138848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data collection and data reduction will be performed by sleep technicians and staff who are blind to study hypotheses and the randomization assignment.|Participants will be randomized to one of two intervention groups. The active group will limit their time in bed for 4 weeks by following a consistent sleep schedule with 85% time in bed compared to their baseline time in bed. The control group will not limit their time in bed, but will be asked to maintain their typical sleep schedule consistent with their baseline time in bed.|f|f|f|t
33984444|NCT00815763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984445|NCT02780687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984446|NCT04813705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984447|NCT04819633|||CASE_CONTROL||PROSPECTIVE|||||||
33984448|NCT05926570|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||evaluate the effect of cinacalcet on insulin like growth factor-1 in pediatric patients with ESRD on regular hemodialysis||||
33984449|NCT00115843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984450|NCT01985308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984451|NCT01561807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984452|NCT00928525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984453|NCT06359132|||COHORT||PROSPECTIVE|||||||
33984454|NCT00890981|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33984455|NCT01197339|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33984456|NCT00242970|||CASE_CONTROL||PROSPECTIVE|||||||
33984457|NCT00159302|||OTHER||PROSPECTIVE|||||||
33984458|NCT00614289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984459|NCT01591122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984460|NCT04825132|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Longitudinal case-control study||||
33984461|NCT00301366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079823|NCT02731196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079824|NCT04454008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator was unaware of the subjects' treatment status||f|f|f|t
34079825|NCT02189668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079826|NCT00229671|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We performed a prospective cohort study of patients under age 21 from 6 office practices. Data collection methodologies included duplicate prescription review, 2 surveys, and chart review. All data were reviewed for medication errors, including those with the potential for harm (near misses) and those that actually caused harm (preventable ADEs). In addition, data were reviewed for harm from medications that were not associated with an error (nonpreventable ADEs). All ADEs were further characterized according to types and potential prevention strategies.||||
34079827|NCT05716347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079828|NCT05815134|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34079829|NCT00572091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079830|NCT02981030|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33771940|NCT02492646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33771941|NCT01158430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771942|NCT06381440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial|f|f|f|t
33901823|NCT02221076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901824|NCT03178461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization two 2 groups according to temperature of IV fluids. One group will receive room temperature fluids and the other group will receive body temperature fluids.||||
33901825|NCT05755867|||OTHER||PROSPECTIVE|||||||
33901826|NCT03278730|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The objective is to evaluate, whether p-Tyr supplementation reduces the ICU mortality of the patients with sepsis comparing to placebo group|t|t|t|t
33901827|NCT06672783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901828|NCT00243776|||COHORT||PROSPECTIVE|||||||
33901829|NCT05559086|||COHORT||PROSPECTIVE|||||||
33901830|NCT00450866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901831|NCT00909090|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Two arms: nutritional supplement vs. placebo.|t|t|t|t
33901832|NCT00916721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901833|NCT05574504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901834|NCT00281411|||COHORT||PROSPECTIVE|||||||
33901835|NCT05568043|RANDOMIZED|FACTORIAL||PREVENTION||NONE||2x2 with 2 intervention delivery methods (virtual vs. in-person) and 2 implementation support mechanisms (virtual mentoring vs. virtual mentoring plus co-design)||||
33901836|NCT02641899|NA|SINGLE_GROUP||OTHER||NONE||||||
33901837|NCT00210561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33901838|NCT00204633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984462|NCT01799330|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33984463|NCT03797547|||COHORT||PROSPECTIVE|||||||
34079831|NCT01346865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079832|NCT00254514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079833|NCT03603522|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Participants will have a screening period followed by 28 days treatment with BioGaia DSM17938 or placebo, followed by a washout period and will then crossover to the opposite treatment received in the first part of the study.|t|t|t|t
34079834|NCT04806022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34079835|NCT04658264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079836|NCT06029881|||CASE_ONLY||PROSPECTIVE|||||||
34079837|NCT06139848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079838|NCT01086670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079839|NCT01909700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079840|NCT05340335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079841|NCT06327412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"A total of 35 patients with primary stage 2 and 3 lower extremity lymphedema, aged 18-65, who apply to the lymphedema outpatient clinic and meet the criteria of the International Society of Lymphology, will be included. Patients participating in the study will be randomized into 2 groups: aerobic exercise group (Group 1) and home exercise group (Group 2). According to randomization, 18 patients will be included in one group and 17 patients in the other.~Cardiopulmonary exercise test (CPET), 30-second-stand-sit test (30s-CST), 6-minute walk test (6MWT), Lymphedema Circumference and Volume Measurement, Bioimpedance Measurement, Lower Extremity Functional Scale (LEFS), Lymphedema Life Impact Scale ( LLIC), Hospital Depression and Anxiety Scale (HADS), Numerical Rating Scale (NRS) forms will be filled in the cardiopulmonary rehabilitation unit of Kayseri City Hospital in the 0th, 4th and 16th weeks."|t|f|f|t
34079842|NCT05562869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079843|NCT02718664|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079844|NCT00226369|RANDOMIZED|PARALLEL||||DOUBLE||||||
34079845|NCT05813418|NA|SINGLE_GROUP||OTHER||NONE||||||
34079846|NCT00239148|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34079847|NCT04486261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34079848|NCT06417970|||CASE_ONLY||CROSS_SECTIONAL|||||||
34079849|NCT00683423|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34079850|NCT02976311|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34079851|NCT03101150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079852|NCT01265498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34079853|NCT00236054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34079854|NCT04240808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079855|NCT03137810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079856|NCT01650857|||COHORT||PROSPECTIVE|||||||
34079857|NCT01944358|||COHORT||PROSPECTIVE|||||||
33901839|NCT05046210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants from the identified communities were randomly assigned to experimental group or control group using random table.|A randomized controlled trial (RCT) was conducted. The participants recruited from aboriginal communities in Eastern Taiwan. Data collecting time was from 2019 to 2020. Participants from the identified communities were randomly assigned to experimental group or control group using random table.|t|f|f|f
33901840|NCT06483633|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33901841|NCT00547937|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33901842|NCT03321929|NA|SINGLE_GROUP||OTHER||NONE||||||
33901843|NCT01571674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901844|NCT05905328|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The Phase 1b portion of the study is an open-label, dose-escalating, safety and pharmacokinetic (PK) study of multiple ascending doses of CTO1681 in patients with Diffuse Large B-cell Lymphoma who receive commercially available CD19-directed CAR T-cell therapy.||||
33901845|NCT06340555|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901846|NCT04546256|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33901847|NCT01056523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901848|NCT06672978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901849|NCT05187338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901850|NCT02097667|||COHORT||PROSPECTIVE|||||||
33901851|NCT06453551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901852|NCT06438276|||COHORT||PROSPECTIVE|||||||
33901853|NCT04928365|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901854|NCT05111249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This was a randomized double blind study. Participants were planned to be randomized in an equal randomization rate among the open treatment arms, and then in a 4:1 ratio for active vs. placebo within each arm.|"The study design used a staggered cohort approach, allowing safety and tolerability of lower doses to be assessed before randomizing subjects to higher doses.~At the time of the Cohort Gating Assessments (CGAs), all available data was reviewed from a safety and dose finding perspective by an independent Sponsor team to support the decision to open the next cohort. The independent Data Monitoring Committee (DMC) reviewed the data separately. The decision to open a new cohort was planned to be made by the Sponsor in consultation with the DMC."|t|t|t|t
33901855|NCT00401583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901856|NCT00602862|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984464|NCT00624065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984465|NCT02125370|||||CROSS_SECTIONAL|||||||
33984466|NCT00899483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984467|NCT00473486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984468|NCT06425679|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33984469|NCT03753425|||COHORT||PROSPECTIVE|||||||
33984470|NCT03702894|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The subjects and the investigator will not be blinded towards the identity of the study products. However, analysts will be blinded towards identity of the study products administered.||f|f|f|t
33984471|NCT04140188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681737|NCT05365945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The trial was a randomized, double-blinded study, 10 days duration. The patients were divided into two groups: study and control and were subjected to different therapies (independent variables). The study group consisted of 30 people. Their physiotherapy was based on exercises that heavily employed the core muscles to equalize tension and strength, according to the NDT Bobath concept. The control group also consisted of 30 patients. They underwent classical neurological rehabilitation. All patients were examined twice. The first time after admission to the Rehabilitation Clinic, and the second time after 10 days of therapy. Assessment games were used for the study, which is the software of the Armeo®Spring device and proprietary tests, wall and abacus (dependent variables)."|t|t|f|f
33681738|NCT04805489|NA|SINGLE_GROUP||OTHER||NONE||||||
33681739|NCT04879147|||CASE_ONLY||PROSPECTIVE|||||||
33681740|NCT00536029|||DEFINED_POPULATION||PROSPECTIVE|||||||
33771943|NCT05033743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771944|NCT06095232|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33771945|NCT02290717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771946|NCT03753217|NA|SINGLE_GROUP||OTHER||NONE||||||
33901857|NCT05790304|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be enrolled within the following groups based on their CP classification score as determined at screening:~* Group 1: Matched-control healthy participants with normal hepatic function.~* Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).~* Group 3: Participants with severe hepatic impairment (CP Class C, score of 10 to 15)."||||
33901858|NCT06274489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901859|NCT05517759|||CASE_ONLY||CROSS_SECTIONAL|||||||
33901860|NCT01712438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901861|NCT04908137|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33901862|NCT01048125|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901863|NCT04746092|||CASE_CONTROL||PROSPECTIVE|||||||
33984472|NCT01382641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984473|NCT04135820|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33984474|NCT00197769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984475|NCT04883216|||CASE_ONLY||PROSPECTIVE|||||||
33984476|NCT00448994|||CASE_ONLY|||||||||
33984477|NCT02248597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984478|NCT05596877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33984479|NCT01645839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984480|NCT00567762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984481|NCT03195374|||COHORT||PROSPECTIVE|||||||
33984482|NCT04350970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One single COPD group performed 3 differents tests, Control exercise, VNI exercise and HFNT exercise on different days.||||
33984483|NCT05016063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984484|NCT03720262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the surgeon performing the follow-up are masked for the allocation|Randomized controlled trial|t|f|f|t
33984485|NCT04190043|||COHORT||PROSPECTIVE|||||||
33984486|NCT01974141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984487|NCT00875030|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33984488|NCT05477030|RANDOMIZED|PARALLEL||OTHER||NONE||Open label randomized controlled trial||||
33984489|NCT04006171|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984490|NCT02475954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984491|NCT04462926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984492|NCT00715377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984493|NCT05343637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984494|NCT05792774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984495|NCT00351845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984496|NCT05502484|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized multiple baseline design with staggered starts (randomized allocation to a baseline length of 4, 6, or 8 weeks) before starting the treatment (integrative Dialectical Behavioural Therapy).||||
33984497|NCT04334798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984498|NCT06518785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Due to the objectives of the study, the identity of LIFU treatments will not be known to research staff performing the data analysis or participants.|This is a single-center, double-blind, controlled, randomized, complete block, 2-period crossover pilot trial.|t|f|f|t
33984499|NCT04840797|||CASE_ONLY||PROSPECTIVE|||||||
33984500|NCT00254644|||CASE_CONTROL||PROSPECTIVE|||||||
33984501|NCT04500353|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking of caregivers not feasible due to the nature of the intervention|Randomised parallel group study||||
33984502|NCT04649411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079858|NCT02165683|||CASE_ONLY||PROSPECTIVE|||||||
34079859|NCT03474796|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34079860|NCT05572645|||COHORT||RETROSPECTIVE|||||||
34079861|NCT02725320|||COHORT||PROSPECTIVE|||||||
34079862|NCT02266446|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial||||
33681741|NCT01156064|||CASE_CONTROL||PROSPECTIVE|||||||
33681742|NCT01455402|||COHORT||PROSPECTIVE|||||||
33681743|NCT01794195|NON_RANDOMIZED|PARALLEL||||NONE||||||
33681744|NCT02776748|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33681745|NCT02521896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771947|NCT02293174|||COHORT||PROSPECTIVE|||||||
33771948|NCT02668237|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771949|NCT02372058|NA|SINGLE_GROUP||SCREENING||NONE||||||
33771950|NCT03423160|||CASE_CONTROL||PROSPECTIVE|||||||
33771951|NCT02666963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984503|NCT01474551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984504|NCT02554370|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33984505|NCT06158451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33984506|NCT00846495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33984507|NCT01371786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984508|NCT03642769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079863|NCT00236002|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33984509|NCT05427643|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681746|NCT03473548|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Single-center, un-blinded, feasibility, methods comparison, and non-inferiority study||||
33984510|NCT03623230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Three groups involved. One control group and two nerve block groups with different drug concentration|t|t|t|f
33984511|NCT04625348|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984512|NCT02962726|||CASE_CONTROL||PROSPECTIVE|||||||
33984513|NCT00319735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079864|NCT03059914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079865|NCT02900352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079866|NCT01703494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079867|NCT04928781|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arm study, with a control arm and intervention arm. The control arm will consist of a retrospective chart review will be conducted to create a randomly selected cohort of patients that meet inclusion and exclusion criteria and did not receive smoking cessation counseling to serve as the control arm. The intervention arm will prospectively enroll to be provided with smoking cessation counseling.||||
34079868|NCT03799614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34079869|NCT01401322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079870|NCT01100853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681747|NCT05681559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681748|NCT03527342|||COHORT||PROSPECTIVE|||||||
33681749|NCT00436501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681750|NCT00300430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681751|NCT03907839|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33681752|NCT03405038|||OTHER||RETROSPECTIVE|||||||
33681753|NCT03929094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984514|NCT00119015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984515|NCT02836847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984516|NCT03607097|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079871|NCT06251141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079872|NCT01129401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681754|NCT01594801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681755|NCT01436617|||||PROSPECTIVE|||||||
33681756|NCT02433431|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33984517|NCT05757271|||COHORT||PROSPECTIVE|||||||
33984518|NCT06265922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant masking as patients will be divided into two groups High frequecy cerebellar repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation by placing the coil in perpendicular way away from the cerebellum.~Care provider masking as the physical therapist treating patients will be blind from the application of repetitive transcranial magnetic stimulation"||t|t|f|f
33984519|NCT01813006|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33984520|NCT05878730|||CASE_CONTROL||PROSPECTIVE|||||||
33984521|NCT00001862||||TREATMENT||||||||
33984522|NCT01555411|||COHORT||PROSPECTIVE|||||||
33984523|NCT00472394|||||OTHER|||||||
33984524|NCT06324682|||COHORT||PROSPECTIVE|||||||
34079873|NCT04779424|||COHORT||PROSPECTIVE|||||||
34079874|NCT06087770|NA|SEQUENTIAL||TREATMENT||NONE||||||
34079875|NCT03365661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079876|NCT04122638|||COHORT||PROSPECTIVE|||||||
34079877|NCT01543568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079878|NCT04591639|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|As above|The observational component of the study will have 4 cohort of participants (patients with type 2 diabetes without heart failure, patients with heart failure with or without diabetes and healthy volunteers) The randomised controlled trial component of the study will have 2 groups of patients - heart failure with or without type 2 diabetes|t|t|t|t
34079879|NCT03874832|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079880|NCT01341015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984525|NCT04690166|||OTHER||PROSPECTIVE|||||||
33984526|NCT03116659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984527|NCT01856426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984528|NCT01360970|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33771952|NCT00992160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771953|NCT03375684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33771954|NCT04376697|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-arm, open label feasibility study||||
33771955|NCT03335891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771956|NCT00436176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33771957|NCT04532242|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33771958|NCT03043222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771959|NCT06048796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A cluster randomized crossover design with two treatment arms (early cessation from sedation and TTM vs standard care).||||
33771960|NCT04806412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, non-randomized, cohort study||||
33771961|NCT01805765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771962|NCT05447793|||CASE_CONTROL||PROSPECTIVE|||||||
33771963|NCT05774028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771964|NCT03299062|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33771965|NCT02814110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771966|NCT01101139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771967|NCT06315764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group (A):~It consists of twenty female patients suffering from hypertension who underwent medical treatment as well as peddler training three times per week for eight weeks. After four weeks of treatment (post-1) and another four weeks of treatment, the post evaluation was used (post-2).~Group (B):~This group consisted of twenty female patients suffering from hypertension who received the same drugs as group (A) as well as reflexology three times per week for eight weeks"|t|f|f|f
33771968|NCT01497405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33771969|NCT03836898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33771970|NCT02225158|||COHORT||PROSPECTIVE|||||||
33771971|NCT00074074|RANDOMIZED|||TREATMENT||NONE||||||
33901864|NCT02099643|||COHORT||PROSPECTIVE|||||||
33901865|NCT06256575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects de-identified, all study staff blinded, all product labeled with number assignment, randomization performed by computer, number assignment conveyed to blinded study staff via computer.|This is a parallel study of two (2) arms in which participants receive different interventions. Participants are randomized and assigned to the treatment or placebo arm at the beginning of the trial. They continue in that arm throughout the length of the trial.|t|t|t|t
33901866|NCT06005714|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33901867|NCT03330691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984529|NCT04794322|||COHORT||CROSS_SECTIONAL|||||||
33984530|NCT01743547|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33984531|NCT00757809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984532|NCT01233505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984533|NCT01155986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079881|NCT02150928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079882|NCT01056692|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33984534|NCT03341585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984535|NCT03109977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984536|NCT00218205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984537|NCT00609830|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34079883|NCT04478058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be offered to take part in either live or online Cognitive Behavioural Therapy for a 12 week period.||||
34079884|NCT01288313|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34079885|NCT05718349|||COHORT||PROSPECTIVE|||||||
34079886|NCT03836027|||COHORT||PROSPECTIVE|||||||
33771972|NCT06313996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33771973|NCT02590068|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34079887|NCT03713684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079888|NCT02626416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079889|NCT02754232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681757|NCT04598256|||OTHER||PROSPECTIVE|||||||
33681758|NCT03472547|NA|SINGLE_GROUP||OTHER||NONE||All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).||||
33681759|NCT05520164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The two separate clinicians conducting the assessment were masked to allow for impartiality.|The study is a randomized controlled trial.|f|f|f|t
33771974|NCT03895437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be randomly assigned to treatment with TOL-3021 or placebo in a 2:1 fashion|t|t|t|f
33771975|NCT01236703|||COHORT||RETROSPECTIVE|||||||
33771976|NCT03972774|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33771977|NCT02533258|||CASE_ONLY||RETROSPECTIVE|||||||
33771978|NCT04039503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771979|NCT00414232|||CASE_ONLY||PROSPECTIVE|||||||
33771980|NCT01128062|||CASE_ONLY||PROSPECTIVE|||||||
33771981|NCT00894582|||COHORT||PROSPECTIVE|||||||
33771982|NCT04558203|||COHORT||PROSPECTIVE|||||||
33771983|NCT02965118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771984|NCT03210688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771985|NCT04397302|||CASE_ONLY||PROSPECTIVE|||||||
33771986|NCT03871270|||OTHER||PROSPECTIVE|||||||
33771987|NCT04763083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33771988|NCT05911490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33771989|NCT04924764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33771990|NCT03646903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33771991|NCT05148624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33771992|NCT00284375|||OTHER||PROSPECTIVE|||||||
33771993|NCT05229172|||COHORT||PROSPECTIVE|||||||
33771994|NCT00975221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33771995|NCT04475848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33771996|NCT00391014|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33771997|NCT01630343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33771998|NCT03263143|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33771999|NCT04238403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772000|NCT02904109|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33772001|NCT02905019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33772002|NCT04084782|||CASE_ONLY||PROSPECTIVE|||||||
33772003|NCT06281262|||COHORT||PROSPECTIVE|||||||
33772004|NCT04454905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772005|NCT03990363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772006|NCT03729895|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty-four patients diagnosed with OSAS in different degrees,who cannot tolerate continuous positive air pressure use and reject a surgical approach, were treated with adjustable customized oral appliances and evaluated with cone-beam computed tomography and polysomnography.||||
33772007|NCT03820531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"DNA-mutation analysis by Next Generation Sequencing is performed to identify IPMN pancreas cysts with LGD versus HGD/Carcinoma.~Controls: non-neoplastic pancreas cysts and chronic pancreatitis with main duct dilation"||||
33772008|NCT04822935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772009|NCT04679103|NA|SINGLE_GROUP||TREATMENT||NONE|NAP|Interventional||||
33772010|NCT02019602|NA|SINGLE_GROUP||OTHER||NONE||||||
33772011|NCT00722813|||CASE_CONTROL||PROSPECTIVE|||||||
33772012|NCT00719303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901868|NCT00205972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901869|NCT02383329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901870|NCT00339963|||COHORT||RETROSPECTIVE|||||||
33901871|NCT02341755|||COHORT||PROSPECTIVE|||||||
33901872|NCT01059604|||COHORT||PROSPECTIVE|||||||
33901873|NCT03988751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33901874|NCT03078985|NA|SINGLE_GROUP||TREATMENT||NONE|This an Open Label study.|||||
33901875|NCT00901602|||CASE_ONLY||PROSPECTIVE|||||||
33901876|NCT01926379|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34079890|NCT00351585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681760|NCT03713177|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33681761|NCT01446614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681762|NCT01324518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681763|NCT04752644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681764|NCT06158529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681765|NCT02702297|||COHORT||PROSPECTIVE|||||||
33772013|NCT03324542|||CASE_ONLY||RETROSPECTIVE|||||||
33772014|NCT03010579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772015|NCT04958928|||COHORT||PROSPECTIVE|||||||
33772016|NCT02886546|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33772017|NCT01033773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772018|NCT05989867|||COHORT||CROSS_SECTIONAL|||||||
33772019|NCT05451381|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901877|NCT06480071|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The nasal mucosa was decongested with oxymetazoline nasal spray 0.5mg/ml 2 sprays eacg nostril to achieve maximum nasal decongestion and to investigate if this promotes the physical performance during heavey exercise.||||
33901878|NCT01326598|||COHORT||RETROSPECTIVE|||||||
33901879|NCT06267001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901880|NCT01612793|||CASE_ONLY||PROSPECTIVE|||||||
33901881|NCT05308095|NA|SINGLE_GROUP||OTHER||NONE||||||
33901882|NCT05646771|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the intervention.||||
34079891|NCT00247468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079892|NCT02484144|||||PROSPECTIVE|||||||
34079893|NCT02874001|||||PROSPECTIVE|||||||
33772020|NCT05078684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, attending staff, and outcome assessors will not know whether the patient received the actual LGSB or a sham (placebo) procedure. The sham procedure will consist of subcutaneous application of a small amount (1ml) of the local anesthetic drug to the region of expected LGSB procedure.|Randomization 1:1 for active treatment vs. sham procedure|t|t|f|t
33772021|NCT01276249|||COHORT||PROSPECTIVE|||||||
33772022|NCT03978390|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33681766|NCT01491438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772023|NCT00618462|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33772024|NCT00159601|||CASE_CONTROL||PROSPECTIVE|||||||
33772025|NCT02861677|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33772026|NCT01840319|||CASE_ONLY||RETROSPECTIVE|||||||
33772027|NCT02328976|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772028|NCT03012789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772029|NCT03070184|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33772030|NCT03558464|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of the intervention package compared to the control package prevents a double-blind study design and thus, only the outcome assessors (data collectors) and the study statistician can be blinded to the group assignment.|Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study|f|f|f|t
33772031|NCT00267111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772032|NCT00231998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772033|NCT01118130|||CASE_CONTROL||RETROSPECTIVE|||||||
33772034|NCT00000206||||TREATMENT||DOUBLE||||||
33681767|NCT03457441|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681768|NCT02031328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681769|NCT05134129|||COHORT||PROSPECTIVE|||||||
33681770|NCT03249662|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33681771|NCT03356704|||COHORT||RETROSPECTIVE|||||||
33681772|NCT04613843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, counterbalanced, crossover design||||
33681773|NCT03290001|||COHORT||PROSPECTIVE|||||||
33681774|NCT05302453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681775|NCT02030431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681776|NCT04835831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681777|NCT02624947|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33681778|NCT01214057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681779|NCT03897140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681780|NCT00832832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772035|NCT02484560|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772036|NCT00627042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772037|NCT01654822|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33772038|NCT03132493|||COHORT||RETROSPECTIVE|||||||
33772039|NCT03901560|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33772040|NCT03266341|||CASE_ONLY||PROSPECTIVE|||||||
33681781|NCT02578719|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772041|NCT02450019|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33772042|NCT05092048|||CASE_ONLY||PROSPECTIVE|||||||
33772043|NCT02029040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772044|NCT02043730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772045|NCT00447044|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33772046|NCT06333990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772047|NCT02398058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772048|NCT00874289|||COHORT||PROSPECTIVE|||||||
33772049|NCT05133466|||COHORT||OTHER|||||||
33772050|NCT06477367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33772051|NCT04399239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772052|NCT00988351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984538|NCT04471272|NA|SINGLE_GROUP||TREATMENT||NONE||"* Study population: RFA using gradual RF energy delivery mode with Octopus electrodes~* Control group: Over a period of two years from 2017 to 2018, the patients who performed RFA for HCC using octopus electrodes and the maximum high-frequency energy transfer mode technique were collected. After performing propensity score matching analysis using variables of liver function values, the same number of controls are selected and set."||||
33681782|NCT03386045|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
33681783|NCT02270996|||COHORT||PROSPECTIVE|||||||
33772053|NCT02528435|||COHORT||CROSS_SECTIONAL|||||||
33772054|NCT06106074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772055|NCT06050356|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|"Phase 1a is open label~Phase 1b is double-blind, randomised, and placebo controlled"|"Phase 1a proceeds as sequential dosing to determine early safety signals (Arms 1, 2, 3, 4a, and 4b).~Phase 1b proceeds as parallel assignment. Participants are randomised to one of four treatment arms (H107e/CAF®10b; H107e/CAF®10b + BCG; BCG; placebo)."||||
33772056|NCT06529900|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33772057|NCT06232174|||COHORT||CROSS_SECTIONAL|||||||
33772058|NCT05552274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
33772059|NCT00515398|||CASE_ONLY||CROSS_SECTIONAL|||||||
33772060|NCT03432949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772061|NCT00044460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772062|NCT01820533|||CASE_ONLY||CROSS_SECTIONAL|||||||
33772063|NCT01702389|NA|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33772064|NCT00833222|||COHORT||PROSPECTIVE|||||||
33772065|NCT03751163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772066|NCT00100139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772067|NCT00028860||||TREATMENT||||||||
33772068|NCT01246661|||||PROSPECTIVE|||||||
33772069|NCT02865057|||COHORT||PROSPECTIVE|||||||
33772070|NCT04712474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772071|NCT01806519|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33772072|NCT01178437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681784|NCT03163602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33681785|NCT01785173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901883|NCT05546996|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Phase A: EVD drainage will be monitored by a digital video recorder capturing images of CSF dripping through the EVD drainage system graduated drip chamber.~Phase B: The EVD flow rate will be measured with FlowSense over a 20-minute period (FlowSense Flow Rate) (physician and patient blinded to device data), with patients receiving standard-of-care imaging and clinical observation. Simultaneously, a digital video recorder will be used to record video of CSF dripping through the EVD drainage system graduated drip chamber."||||
33681786|NCT03250364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||5 goups: Multilayer bandage group; Double compression bandage group; Cohesive bandage group; Adhesive compression bandage group; Kinesiotaping bandage group|f|f|t|t
33681787|NCT01886027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681788|NCT00402233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681789|NCT00000724||||TREATMENT||NONE||||||
33681790|NCT04887376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
33901884|NCT00230490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681791|NCT01151943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901885|NCT02911363|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33901886|NCT05223738|||CASE_CONTROL||PROSPECTIVE|||||||
33901887|NCT05186558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984539|NCT03099538|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center, exploratory, open-label, single-arm design study of 12 patients with BP. Treatment naïve and treatment refractory patients with BP will be treated with Ixekizumab. Patients who are non-responders, to physician choice standard of care, will undergo a washout period and will be enrolled in the study.||||
33984540|NCT03982485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901888|NCT05774691|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel Assignment|t|t|f|t
33984541|NCT02332148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984542|NCT03120117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984543|NCT01625884|||COHORT||CROSS_SECTIONAL|||||||
33984544|NCT03313349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants in the study are allocated to each arm by using randomization system. After determining which of the three school Units the student will attend, the participants are distributed in to one of the two arms at each school (UP \& ENP).~It is not possible to fully blind parents and students as they have to give informed consent. Teachers and social workers will be kept blind to allocation as far as possible . They are not directly involved in the treatment measured in this study, even though they play a great part in it. The blindness of the teachers and social workers is important as they will be providing the ratings used in the analyses."|"Design: A pragmatic RCT designed according to CONSORT guidance (CONSORT, 2010) to compare UP and ENB.~Students, attending the schools, were randomly allocated to either UP or ENP according to a one-to-one ratio. Outcome measures (see below) were collected at pre-intervention (T1), post-intervention (T2 - 3 months post randomization) and follow up (T3 - 6 months post randomization). If possible, the a last follow up (T4 - 12 months post randomization)."|t|t|f|t
33984545|NCT05333159|||COHORT||PROSPECTIVE|||||||
33984546|NCT03291769|||COHORT||PROSPECTIVE|||||||
33984547|NCT04321850|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The patient and the investigator will be blinded; for this, the 50 mg zinc and placebo tablets will be similar in size, color, shape, weight and taste; the bottles will be classified into codes A and B, which in turn will have the same shape, size and color. All of the above will be done through the Pharmaceuticals GREMAR S.A. de C.V., which is a Mexican company that has a line of food supplements located in Mexico City.~An independent investigator (who will be blinded for the purpose of the study) will be requested to receive the medications (zinc / placebo) prepared by the Pharmaceuticals GREMAR S.A. of C.V., so that it provides to the principal investigator only the bottles coded as A and B. At the end of the intervention, the independent investigator will be asked to reveal the coding of the medications to determine which group (Group 1 placebo or Group 2 zinc) corresponds to treatment A and B respectively."|The subjects will be randomized to designate them in the control group (Group1 placebo) or intervention group (Group 2 zinc). The zinc / placebo intervention will be administered orally in tablets of 50-100 mg / day, from day 1 of chemotherapy until the end of the consolidation phase (2 to 2.5 months).|t|t|t|f
33984548|NCT01301573|||COHORT||PROSPECTIVE|||||||
33984549|NCT02476799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984550|NCT06542016|||OTHER||PROSPECTIVE|||||||
33984551|NCT01580384|||COHORT||PROSPECTIVE|||||||
33984552|NCT03550625|||COHORT||RETROSPECTIVE|||||||
33984553|NCT04355104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33984554|NCT01358097|||CASE_CONTROL||PROSPECTIVE|||||||
33984555|NCT01533805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984556|NCT03316001|||CASE_CONTROL||RETROSPECTIVE|||||||
33984557|NCT02506933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33984558|NCT00300911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984559|NCT02140060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984560|NCT03095625|||CASE_CONTROL||PROSPECTIVE|||||||
33984561|NCT04368624|||CASE_CONTROL||PROSPECTIVE|||||||
33984562|NCT00429481|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33984563|NCT00905840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984564|NCT03606603|||OTHER||RETROSPECTIVE|||||||
33984565|NCT00275730|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33984566|NCT03343522|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33681792|NCT03095196|||COHORT||RETROSPECTIVE|||||||
33681793|NCT04468529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is planned to conduct the study in several domestic clinical research sites at the same time. A total of 140 subjects will be enrolled, including 70 subjects in the investigational drug group and 70 subjects in the control group.|This is a multi-center, randomized, double-blind, standard therapy based, placebo-controlled parallel study.|t|f|f|f
33681794|NCT03037645|NA|SEQUENTIAL||TREATMENT||NONE||||||
33681795|NCT02108678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681796|NCT02907190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33681797|NCT01648556|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984567|NCT02640183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984568|NCT00388024|||COHORT||PROSPECTIVE|||||||
33984569|NCT04176029|||COHORT||PROSPECTIVE|||||||
33984570|NCT03496623|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984571|NCT04250064|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681798|NCT04918056|||COHORT||RETROSPECTIVE|||||||
33681799|NCT00353860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681800|NCT00793273|||COHORT||PROSPECTIVE|||||||
33681801|NCT00593242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681802|NCT01375855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681803|NCT01431209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681804|NCT02333864|||CASE_ONLY||PROSPECTIVE|||||||
33681805|NCT01892384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33681806|NCT00639652|||COHORT||PROSPECTIVE|||||||
33681807|NCT00947791|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patient, doctor and rater are masked (triple masked). Only the research pharmacist is unblinded.||t|f|t|f
33681808|NCT01122264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681809|NCT00972140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681810|NCT06072898|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||This study will use a 2-group one-way delayed-start (AB/BB) design, with one group receiving placebo at the first visit and the investigational drug at second, and another group receiving the investigational drug at both visits.|t|t|t|t
33681811|NCT01928745|||COHORT||PROSPECTIVE|||||||
33681812|NCT06005129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681813|NCT02610504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681814|NCT00835731|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33681815|NCT00875589|||CASE_CONTROL||PROSPECTIVE|||||||
33681816|NCT03610529|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The study participants will be using both the experimental device and the control device simultaneously throughout the study participation. The participant will thereby act as its own control.||||
33681817|NCT02358317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772073|NCT05706792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"This was a 16-week randomized, parallel, single-blind, controlled, clinical trial. After assessments for eligibility patients were randomly assigned to two groups of equal size: a treatment group that received three times a week one session per day of 20 minutes in the NSC Relax for relaxation program and a control group that did not participate in the activity mentioned for the treatment group, but received, at the same time and duration, the care and activities that were part of the daily routines of the center.~The 16-week study extension included a first pre-treatment period of 2 weeks' duration prior to the start of the intervention to establish the baseline, followed by a second 12-week treatment period with the use of the NSC and, finally, a third post-treatment period conducted 2-week after completion of the intervention."|f|f|t|t
33772074|NCT06206980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33772075|NCT04131283|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33772076|NCT02508766|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33772077|NCT06017687|NA|SINGLE_GROUP||OTHER||NONE||||||
33681818|NCT01409343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681819|NCT03970044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681820|NCT01122550|||CASE_ONLY||PROSPECTIVE|||||||
33681821|NCT05798468|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both the teacher who will perform the intervention and the evaluator of the study will be blinded.||f|f|t|t
33681822|NCT01193296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681823|NCT02516540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681824|NCT00166556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681825|NCT05145218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681826|NCT06316999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681827|NCT04148144|||COHORT||PROSPECTIVE|||||||
33681828|NCT00078169||||TREATMENT||||||||
33681829|NCT00746200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681830|NCT04124744|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33681831|NCT04831632|||OTHER||CROSS_SECTIONAL|||||||
33681832|NCT04982003|NA|SINGLE_GROUP||TREATMENT||NONE||single group, pre- post-test design||||
33681833|NCT04138225|||COHORT||OTHER|||||||
33681834|NCT02213406|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
33681835|NCT00435045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681836|NCT03445156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2 (controller type) x 3 (video game type) factorial design. Participants used either a regular or gun shaped controller while playing a non-shooting, non-humanoid shooting, or humanoid shooting game.||||
33681837|NCT02000908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33772078|NCT00872430|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33772079|NCT02803320|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33772080|NCT06401759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33772081|NCT04059393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772082|NCT00517660|||CASE_CONTROL||PROSPECTIVE|||||||
33772083|NCT02664779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33901889|NCT06382493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901890|NCT02168946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded adjudication committee||f|f|f|t
33901891|NCT04933812|NA|SINGLE_GROUP||PREVENTION||NONE||Intervention Arm||||
33901892|NCT02228512|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901893|NCT03749681|||COHORT||RETROSPECTIVE|||||||
33901894|NCT06673433|||CASE_CONTROL||PROSPECTIVE|||||||
33901895|NCT03634072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomly assigned to one of two groups. One will undergo PVR with catheter or surgery (whichever is most appropriate ). The other group will continue with medical management.|Subjects will be randomized to PVR or no PVR|f|f|t|f
33901896|NCT06430268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901897|NCT05174806|RANDOMIZED|PARALLEL||TREATMENT||NONE||Topical Pravibismane (MBN-101) versus Standard of Care (SOC); 2:1 ratio.||||
33984572|NCT02592226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984573|NCT04044326|NA|SINGLE_GROUP||TREATMENT||NONE||microwave ablation||||
33984574|NCT05723900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984575|NCT03931239|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984576|NCT02511782|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33984577|NCT01110473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984578|NCT04407962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|f|t|t|t
33984579|NCT03289286|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33901898|NCT06671015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with systolic heart failure admitted to the CICU or MICU at Yale New Haven Hospital who require IMV for \>24 hours.||||
33984580|NCT02715622|||COHORT||PROSPECTIVE|||||||
33984581|NCT01028469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984582|NCT00423761|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34079894|NCT03933163|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will be randomised between receiving resveratrol in period 1 and placebo in period 2, or placebo in period 1 and resveratrol in period 2.|Double-blind, randomised, placebo-controlled 2-period crossover trial of 2g/day of micronised resveratrol versus placebo. Participants will be randomised in terms of the order in which they received micronised resveratrol and placebo.|t|t|t|t
34079895|NCT05442060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901899|NCT06439914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079896|NCT03150082|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This will be an open-label study. Hence, masking will not be performed.|Crossover assignment: Subjects will receive treatment in one of the two sequences; Treatment A (GR37547 tablet) followed by Treatment B (ciprofloxacin reference tablet) or vice versa separated by a washout period of at least 7 days and not more than 14 days.||||
34079897|NCT04630977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Every participant will be randomized to any of the groups. The principal investigator will be blinded for the supplement and allocation of the participants until the end of the analysis of the results after the intervention. Therefore, an external and third researcher will send the supplements to every participant and will keep the record of the randomised allocation of each of them until the end of the analysis of the last outcomes assessments collection.|"One group will intake a pre-workout multi-ingredient supplement. The second group will intake an isocaloric placebo containing only carbohydrates.~The third group (control) will take a non-caloric placebo."|t|f|t|t
34079898|NCT02433847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079899|NCT06200935|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34079900|NCT06177288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079901|NCT00507936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079902|NCT03031340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901900|NCT00336193|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33681838|NCT04910308|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33681839|NCT03526588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681840|NCT01779219|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33681841|NCT05299983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33681842|NCT01917656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681843|NCT01883856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901901|NCT00597558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901902|NCT02553603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33901903|NCT01818557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901904|NCT06116591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901905|NCT02500030|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33681844|NCT01029405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681845|NCT00446160|||CASE_ONLY||RETROSPECTIVE|||||||
33681846|NCT00782470|||COHORT|||||||||
33901906|NCT02601001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901907|NCT06658899|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigator, Subject, Outcomes Assessor, and Sponsor Blinded; placebo-controlled|3-period randomized 3-sequence study|t|t|t|t
33901908|NCT04174131|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33901909|NCT06435156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984583|NCT00540020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33984584|NCT04977245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of this study, masking is not possible. Participants and researchers must be aware of which arm they are in.|Two groups of 20 participants. Group 1 is the control arm (online, self-guided stress reduction course) and group 2 is the intervention arm (MBSR group.)||||
33984585|NCT00531856|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33984586|NCT04702178|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33681847|NCT05383001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681848|NCT00382642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681849|NCT02181270|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33681850|NCT01198522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681851|NCT02821663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681852|NCT03561688|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The study design is a cross over study. Patients is instructed in using a placebo FO for one month and receive a custom-made FO, which they will be using for one month.||||
33901910|NCT01066416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901911|NCT03515538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901912|NCT01569204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984587|NCT02374996|||COHORT||CROSS_SECTIONAL|||||||
33984588|NCT04597463|NA|SINGLE_GROUP||TREATMENT||NONE||Endometrial injury in RIF patients||||
33984589|NCT03122457|NA|SINGLE_GROUP||TREATMENT||NONE||Application of clindamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel to treat perimenstrual acne||||
33984590|NCT02979015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984591|NCT04719702|||COHORT||PROSPECTIVE|||||||
33984592|NCT01476085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984593|NCT03861845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984594|NCT05172622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984595|NCT05063786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984596|NCT05486780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33984597|NCT01625065|||CASE_CROSSOVER||PROSPECTIVE|||||||
33984598|NCT02753335|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984599|NCT03533270|||CASE_ONLY||RETROSPECTIVE|||||||
33984600|NCT01924091|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33984601|NCT01675232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33984602|NCT05353790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Four one-week meal plans for each Active and Control intervention will be developed and given twice in random order to allow for a partially controlled dietary regimen.||t|f|f|f
33984603|NCT01765114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984604|NCT04816838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984605|NCT02325531|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Clinics were randomized and data was collected at the clinic level, there was no data collected at the participant level.||||
33984606|NCT00266266|||COHORT||PROSPECTIVE|||||||
33984607|NCT01532141|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984608|NCT04222881|||OTHER||PROSPECTIVE|||||||
33984609|NCT00183794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984610|NCT01874756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984611|NCT06402539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33984612|NCT00323882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984613|NCT06115889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Trained research assistants will collect the data blinded to group assignment.||f|f|f|t
33984614|NCT06031857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind RCT in which just participants were unaware of intervention they are given|Single blind RCT|t|f|f|f
33984615|NCT04651803|||COHORT||RETROSPECTIVE|||||||
33984616|NCT01225809|||||RETROSPECTIVE|||||||
33984617|NCT03004209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984618|NCT01772030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984619|NCT01122147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984620|NCT01949662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33984621|NCT03834870|NA|SINGLE_GROUP||SCREENING||NONE||||||
33984622|NCT01461850|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned (1:1 ratio) to undergo either PDS followed by systemic adjuvant chemotherapy, or NACT followed by IDS. Random assignment will be centralised at the Institutional clinical trial center using a block-randomisation computer-generated list (maximum allowable percentage deviation = 10%). Allocation will be concealed to patients and investigators. Patients and investigators will not be masked to group assignment.||||
33984623|NCT01612871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984624|NCT03766620|||COHORT||PROSPECTIVE|||||||
33984625|NCT03100396|||COHORT||PROSPECTIVE|||||||
33984626|NCT02933931|||COHORT||PROSPECTIVE|||||||
33984627|NCT02313571|||COHORT||RETROSPECTIVE|||||||
33984628|NCT03380377|NA|SINGLE_GROUP||TREATMENT||NONE||All ten patients enrolled will receive study medication (Clazakizumab, Vitaeris, Inc, Vancouver, Canada, B.C)||||
33984629|NCT04192422|||COHORT||PROSPECTIVE|||||||
33984630|NCT03141840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects are randomly assigned to treatment or placebo groups by a predetermined algoritm using sealed envelopes.|Double blind randomized controlled trail comparing ABL01 and placebo.|t|t|t|t
33984631|NCT05194839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33984632|NCT06354166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|open-label study|Interventional, randomised (1:1 ratio), single-centre study||||
33984633|NCT03764748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079903|NCT02337491|RANDOMIZED|PARALLEL||TREATMENT||NONE||There is a safety lead-in before the start of the randomized phase 2 study.||||
34079904|NCT04611100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34079905|NCT02256696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079906|NCT01644721|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079907|NCT02308800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079908|NCT01139996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34079909|NCT00313846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079910|NCT01586234|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079911|NCT06321822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079912|NCT06434935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079913|NCT02062437|||COHORT||RETROSPECTIVE|||||||
33984634|NCT01592578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984635|NCT05267405|||COHORT||PROSPECTIVE|||||||
33984636|NCT00587470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079914|NCT02200146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079915|NCT02212262|||CASE_CONTROL||PROSPECTIVE|||||||
34079916|NCT02597309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079917|NCT05742334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984637|NCT02661295|NA|SINGLE_GROUP||OTHER||NONE||This study will be designed as a single arm, prospective, experimental trial of 45 hemodialysis patients. Patients on hemodialysis at least 6 months and receiving a phosphate binder with serum phosphorus levels between 2.5 and 8.0 mg/dL, normal serum calcium levels, and on maintenance iron therapy are potentially eligible. Participants will receive ferric citrate after at least a 2 week washout period from previous phosphate binders if phosphorus is ≥ 5.5 mg/dl, calcium is within the normal range and ferritin ≥ 200 and \< 600 ng/ml. Ferric citrate will be titrated to maintain serum phosphorus and calcium within acceptable levels. Inflammatory markers and lipid levels will be tested at 0, 3, and 6 months.||||
33984638|NCT05125601|||COHORT||PROSPECTIVE|||||||
33984639|NCT05385679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984640|NCT04934917|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33984641|NCT03097783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984642|NCT06147765|||OTHER||OTHER|||||||
33984643|NCT03124966|NA|SINGLE_GROUP||OTHER||NONE||||||
33984644|NCT05644743|||OTHER||PROSPECTIVE|||||||
33984645|NCT04132908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984646|NCT03337386|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984647|NCT02076763|||COHORT||PROSPECTIVE|||||||
33984648|NCT03247920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicenter prospective randomized controlled non-inferiority trial|f|f|f|t
33984649|NCT04068441|||COHORT||PROSPECTIVE|||||||
33984650|NCT04355468|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33984651|NCT01457053|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33984652|NCT01822847|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33772084|NCT03636360|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be aware that the lighting conditions will vary during their visits, but will not be aware of the nature of the difference in the lights.||t|f|f|f
33984653|NCT04969757|NA|SINGLE_GROUP||OTHER||NONE||||||
33984654|NCT04091256|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm: Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.||||
33901913|NCT01747330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901914|NCT03595215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901915|NCT00577330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901916|NCT01013883|||COHORT||RETROSPECTIVE|||||||
33901917|NCT01456832|||CASE_ONLY||RETROSPECTIVE|||||||
33901918|NCT05743543|NA|SINGLE_GROUP||OTHER||NONE||||||
33901919|NCT06394219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33901920|NCT06065956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33901921|NCT00247390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901922|NCT03337841|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33901923|NCT00374907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901924|NCT06095284|||COHORT||OTHER|||||||
33901925|NCT02894983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901926|NCT01686204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33901927|NCT04050904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective single-arm open pilot study||||
33901928|NCT03176186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901929|NCT05636085|||CASE_ONLY||PROSPECTIVE|||||||
33901930|NCT02404831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901931|NCT02232646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901932|NCT00184054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901933|NCT02251223|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33901934|NCT00098345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901935|NCT00974337|||||CROSS_SECTIONAL|||||||
33901936|NCT01900275|||COHORT||PROSPECTIVE|||||||
33901937|NCT06070233|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33901938|NCT04798417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901939|NCT02556879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33901940|NCT04624633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984655|NCT04058288|||COHORT||PROSPECTIVE|||||||
33984656|NCT03668704|||CASE_ONLY||RETROSPECTIVE|||||||
33984657|NCT00803491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33984658|NCT04067180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901941|NCT06619990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901942|NCT04373980|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33901943|NCT05227274|||OTHER||PROSPECTIVE|||||||
33901944|NCT00091390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901945|NCT05359627|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33901946|NCT03465475|||CASE_CONTROL||PROSPECTIVE|||||||
33901947|NCT04618861|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901948|NCT00806780|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33901949|NCT03494803|||CASE_CONTROL||RETROSPECTIVE|||||||
33901950|NCT04874038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33901951|NCT02983292|||COHORT||OTHER|||||||
33901952|NCT04792996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901953|NCT02008240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901954|NCT01969175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901955|NCT05868642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901956|NCT03138850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33984659|NCT00233194|||COHORT||PROSPECTIVE|||||||
33984660|NCT04301791|||COHORT||CROSS_SECTIONAL|||||||
33984661|NCT00431197|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
34079918|NCT03781726|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984662|NCT03257722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is an open labeled, single arm, interventional study combining standard pembrolizumab (MK-3475, trade name: Keytruda) with investigational agent, idelalisib (trade name: Zydelig) in non-small cell lung cancer (NSCLC). The study will enroll patients in two phases: a dose finding/tolerability assessment phase and an efficacy assessment phase.~The Phase 1b (modified 3+3 dose escalation) assessment will determine the safe dose of idelalisib in combination with pembrolizumab that down-regulates the activity of T-regulatory function (Treg).~The Phase 2 efficacy assessment will enroll patients to detect whether idelalisib added to pembrolizumab at the phase 2 recommended dose (P2RD) will result in further objective response."||||
33984663|NCT02822820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984664|NCT01838720|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984665|NCT02152332|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33984666|NCT05776303|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomize 240 individuals in 8-10 worksites to either Good Bowls alone or Good Bowls + Phone App nudges at a 1:1 allocation ratio. Initial assignment will be followed for four months, after which the groups will crossover for the subsequent four months.||||
33984667|NCT03328676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Phase II, Randomized, Double-blind, Placebo-controlled Trial|t|t|t|f
33984668|NCT01861379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984669|NCT02468258|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33984670|NCT01303549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984671|NCT04910126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984672|NCT01707134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984673|NCT02380807|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33984674|NCT03597711|RANDOMIZED|PARALLEL||TREATMENT||NONE||Once consent is obtained, patients will be randomized to either 24G non-safety cannula, 24G safety or 26G safety cannula. Each patient can enter the study a maximum of three times providing 90 episodes of cannulation.||||
34079919|NCT04512963|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"SAD Phase including Food Interaction:~This is a randomized, double-blind, placebo-controlled, dose-escalating study in healthy volunteers. Participants will be assigned to 1 of up to 6 cohorts and will be randomized within each cohort to Progerinin or placebo at 3:1 ratio.~Following the completion of the SAD phase, if study stopping criteria (SSC) is not met, then participants in cohort 5 and 6 will cross-over to the fed part of the study following a 7 day washout period. If SSC is achieved in the SAD phase, then the previous dose will be in the Food Interaction phase.~MAD Phase:~This is a randomized, double-blind, placebo-controlled, dose-escalating study in healthy volunteers. If SSC is not met in the SAD phase, then participants will be assigned to 1 of 2 cohorts and will be randomized within each cohort to Progerinin or placebo at 3:1 ratio. If SSC is achieved in the SAD phase, then the previous two doses will be used as the 2 cohorts in the MAD phase."|t|t|t|t
34079920|NCT03814564|||COHORT||PROSPECTIVE|||||||
34079921|NCT03322293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded study, as the subject cannot be blinded to treatment. Disease assessments and aminolevulinic acid (ALA) application will be performed by the blinded investigator. History, concomitant medications, randomization, light exposure, symptom assessment, and Skindex-16 will be administered by the unblinded study coordinator.|Randomized (1:1:1), single-blind controlled trial with parallel group design|f|f|t|f
34079922|NCT03834363|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|For both morphine retard capsules as fentanyl patches there is a placebo available. Participants will be treated in each period with both tablets and a patch. (morphine capsules+placebo patch, placebo capsules+fentanyl patch, placebo capsules+ placebo patch.)|Crossover, double blind, double dummy Randomized Controlled Trial|t|t|t|t
34079923|NCT04391478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34079924|NCT02987699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079925|NCT03583658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079926|NCT02392078|||COHORT||PROSPECTIVE|||||||
34079927|NCT00788385|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34079928|NCT05562752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Study consists of 2 parts with the participants in part 2 being recruited from Placebo non-responders in Part 1."|t|t|t|t
34079929|NCT00243919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079930|NCT02559037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079931|NCT02996916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079932|NCT03921736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Postmenopausal women with, untreated essential hypertension were recruited to the study. The control group consisted of 40 postmenopausal women with normal blood pressure.|f|f|t|f
34079933|NCT06100796|||COHORT||RETROSPECTIVE|||||||
34079934|NCT00452374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079935|NCT01394536|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34079936|NCT03025321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079937|NCT02815306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984675|NCT04403997|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33984676|NCT01126125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33984677|NCT03064880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984678|NCT00188253|||COHORT||PROSPECTIVE|||||||
33772085|NCT01881269|||COHORT||PROSPECTIVE|||||||
33984679|NCT02823522|||COHORT||PROSPECTIVE|||||||
33984680|NCT04305782|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33984681|NCT01532297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984682|NCT02963025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984683|NCT04315662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984684|NCT01012934|RANDOMIZED|CROSSOVER||||NONE||||||
33984685|NCT03146130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34079938|NCT03261076|NA|SINGLE_GROUP||TREATMENT||NONE||This study uses a multiple baseline design, in which participants enter into the single-arm intervention at different times, yet have data collected at all time points. Approximately one third of participants will have their entry into the intervention shifted later by one week, and approximately another third will have their entry shifted by two weeks. This will happen on a rotating basis. All individuals will receive progress monitoring during the weeks that the other individuals are receiving intervention and/or assessments. The multiple baseline design allows for all individuals to receive the study intervention, and still provides a mechanism for monitoring change (or lack thereof) during non-intervention periods before and after intervention.||||
34079939|NCT04726735|||CASE_ONLY||RETROSPECTIVE|||||||
33984686|NCT04419311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and physiatrists performing isokinetic measurements were blinded to group allocation.|Patients were randomized in a 1:1 ratio via computer-generated randomization using Microsoft Excel 2016 (Microsoft Corporation, Seattle, WA, USA) to be allocated in the UC insert or PS insert group before the TKA operation (Figure 1). Unblinded senior resident implemented the randomization. Patients and physiatrists performing isokinetic measurements were blinded to group allocation.|t|f|t|f
33984687|NCT05179993|||OTHER||PROSPECTIVE|||||||
33984688|NCT06363747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control--\[GLP-1 agonist +/- DM2 meds + medical management + nutritional/behavioral counseling\] Experimental---\[Optifast + GLP-1 agonist + medical management + nutritional/behavioral counseling\]||||
33984689|NCT05558930|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||A randomized double-blinded, sham-controlled, crossover study design is used to investigate the effects of bilateral cerebellar iTBS on patients with prolonged DOC in a VS/UWS or in a MCS state. We prospectively recruit 44 patients in VS/UWS or MCS state. Each patient will receive bilateral cerebellar iTBS and sham stimulation in random order, one session per day for 5 consecutive days, separated by a 5-day washout. TMS is performed by personalized neuro-navigation to target the cerebellar dentate nucleus. The primary research outcome is whether bilateral cerebellar iTBS, as compared to sham stimulation, will improve consciousness (as measured by changes in CRS-R total scores) in VS/UWS and MCS patients. Secondary research outcome is evaluated by Electroencephalogram(EEG), CRS-R subscore, and Glasgow Outcome Scale-Extended(GOSE) score at 3 and 6 months of enrollment.|t|t|t|f
33984690|NCT01165385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984691|NCT05232877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The intervention group will follow sessions of tDCS combined with a simultaneous cognitive training on tablet.~he control group will follow cognitive training with a combined sham tDCS. Intervention will last for 4-week with 3 sessions per week (12 sessions)."|t|f|f|t
33984692|NCT00873132|||COHORT|||||||||
33984693|NCT00144534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984694|NCT00674505|NA|SINGLE_GROUP||||NONE||||||
33984695|NCT03269409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Cytori Celution 800/GP System to process ADRC from lipoaspirate at the point of care.|t|t|t|t
33984696|NCT01496183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33984697|NCT01938339|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984698|NCT02225301|NA|SINGLE_GROUP||OTHER||NONE||||||
33984699|NCT00053287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984700|NCT03637556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||open-label, two-period cross-over||||
33984701|NCT02724462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33984702|NCT04873011|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33984703|NCT00283361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984704|NCT01878825|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984705|NCT01792635|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33772086|NCT02481102|||COHORT||PROSPECTIVE|||||||
33772087|NCT03309163|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33772088|NCT03685032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study drugs based on a sequentially numbered list were prepared in the same way. These drugs had similar characteristics, including clear color and no observable particles, and were loaded into syringes labeled for each group. The attending anesthesiologists, anesthetic nurses, and ward nurses, as well as the patients were blinded to the computer-generated randomization lists.|"Double-blinded randomized control trial was conducted. The investigators allocated patients into two arm.~The study group (Gr. D) received intraoperative dexamethasone 4 mg iv and ondansetron 4 mg iv, whereas the control group (Gr. N) received placebo (0.9% normal saline 1 ml iv and 0.9% normal saline 2 ml iv)"|t|t|t|t
33772089|NCT01013974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772090|NCT05408000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772091|NCT02811289|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33772092|NCT04781647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772093|NCT05574621|||COHORT||PROSPECTIVE|||||||
33772094|NCT05488938|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The orthopedic surgeons who will evaluate the participants' Cobb's angle will be blinded concerning the group to which each participant was assigned.||f|f|f|t
33772095|NCT04565756|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33772096|NCT01313923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772097|NCT03803020|||CASE_ONLY||PROSPECTIVE|||||||
33772098|NCT04095104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|At baseline, each participant will be randomized 1:1 to either 12 weeks of phentermine, topiramate and standard of care or 12 weeks of phentermine placebo, topiramate placebo, and standard of care. This randomization will be blinded to the participant, investigator, care providers, and outcomes assessor for the duration of the study.|Two-arm parallel assignment where the experimental arm will receive active drugs + standard of care and the control arm will receive placebo drugs + standard of care.|t|t|t|t
33772099|NCT02250521|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772100|NCT03145805|||COHORT||PROSPECTIVE|||||||
33772101|NCT03489005|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33772102|NCT05586854|NA|SINGLE_GROUP||TREATMENT||NONE||interventional, prospective, multicentre, longitudinal, non-comparative study.||||
33772103|NCT04503382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772104|NCT00592514|||COHORT||PROSPECTIVE|||||||
33984706|NCT06278077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All involved personnel at the investigational site, the Sponsor (except production unit) and the CRO (except independent biostatistician for performing the randomization) will be blinded during the trial. The Investigator keeps the sealed treatment code envelopes throughout the course of the trial for the individual patients and must not break the code without a valid reason (e.g., in case of emergency).|Randomized, double-blind, active- and placebo-controlled confirmatory clinical trial|t|t|t|t
33984707|NCT01667679|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984708|NCT02301325|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33984709|NCT06171360|||COHORT||PROSPECTIVE|||||||
33984710|NCT00000171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984711|NCT03995420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to treatment allocation (single blind)|Randomized Controlled Trial|f|f|f|t
33984712|NCT03880266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984713|NCT03080597|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33984714|NCT03471078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33984715|NCT05380895|||COHORT||RETROSPECTIVE|||||||
33984716|NCT00161356|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33772105|NCT04930666|||OTHER||CROSS_SECTIONAL|||||||
33772106|NCT04265443|||CASE_CONTROL||PROSPECTIVE|||||||
33772107|NCT01015222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772108|NCT02773264|||COHORT||PROSPECTIVE|||||||
33772109|NCT02809586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33772110|NCT00114842|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33772111|NCT02619227|RANDOMIZED|PARALLEL||||NONE||||||
33772112|NCT05699902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Interventional|t|t|t|t
33772113|NCT02456974|||OTHER||PROSPECTIVE|||||||
33772114|NCT01315405|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33772115|NCT03758638|RANDOMIZED|PARALLEL||PREVENTION||NONE||Healthy Eating \& Active Living Taught at Home (HEALTH) embeds content related to healthy eating and activity within Parents as Teachers (PAT)'s existing home visits.||||
33772116|NCT01777594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772117|NCT00548041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772118|NCT01267825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772119|NCT02926547|||OTHER||CROSS_SECTIONAL|||||||
33772120|NCT03461250|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33772121|NCT01731587|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772122|NCT04519541|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized||||
33772123|NCT06336499|||CASE_CONTROL||RETROSPECTIVE|||||||
33772124|NCT02532322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772125|NCT02535559|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33772126|NCT01818141|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|||||
34079940|NCT00249834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079941|NCT03640169|NA|SINGLE_GROUP||OTHER||NONE||||||
34079942|NCT03132545|||CASE_CONTROL||PROSPECTIVE|||||||
34079943|NCT03269201|||CASE_ONLY||CROSS_SECTIONAL|||||||
34079944|NCT00909064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079945|NCT00793689|||COHORT||PROSPECTIVE|||||||
34079946|NCT00581737|||COHORT||PROSPECTIVE|||||||
34079947|NCT01891214|||COHORT||PROSPECTIVE|||||||
34079948|NCT01663389|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34079949|NCT05545475|||COHORT||PROSPECTIVE|||||||
34079950|NCT04918862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Computer-generated sequence will be used for randomization and opaque envelopes will be used for concealment|210 patients were recruited and allocated randomly to receive either granisetron 1.0mg (n =105) or granisetron 3.0mg (n =105). The two groups were compared regarding: demographic data of the patients, hemodynamic parameters including mean arterial pressure and heart rate and percentage of patients with no complain of postoperative nausea and vomiting at first 24 hours.|t|f|f|f
34079951|NCT02889068|||COHORT||CROSS_SECTIONAL|||||||
33772127|NCT04902560|||COHORT||PROSPECTIVE|||||||
33772128|NCT00019006||||TREATMENT||||||||
33772129|NCT01169181|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772130|NCT00393094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772131|NCT03958630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33772132|NCT05368506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772133|NCT03514862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772134|NCT05517720|NA|SINGLE_GROUP||OTHER||NONE||||||
33772135|NCT05969522|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772136|NCT01597661|||CASE_CONTROL||RETROSPECTIVE|||||||
33772137|NCT03289390|||COHORT||PROSPECTIVE|||||||
33772138|NCT02610218|||COHORT||PROSPECTIVE|||||||
33772139|NCT01887314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33772140|NCT06119906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772141|NCT02916004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772142|NCT02500979|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33772143|NCT00993317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772144|NCT00519259|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33772145|NCT02569320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772146|NCT03296618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772147|NCT01419145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772148|NCT05555862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind, placebo-controlled|Double blind, placebo controlled randomized trial|t|f|t|f
33772149|NCT00192621|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772150|NCT03831828|||COHORT||RETROSPECTIVE|||||||
33772151|NCT02091869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772152|NCT04797169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two conditions in a parallel design including a 12-month intervention. Participants will be openly-enrolled over the course of 12-months until the recruitment goal of 600, 300 in each group, is reached.||||
33772153|NCT02509351|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772154|NCT02774408|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772155|NCT02210962|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772156|NCT02488382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772157|NCT05805111|||CASE_ONLY||PROSPECTIVE|||||||
33772158|NCT04276090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with unresectable colorectal liver metastases (arm 1) and unresectable intrahepatic cholangiocarcinoma (arm 2), will undergo hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. All patients will receive hepatic artery infusion floxuridine, and then individual arms will receive disease-specific systemic chemotherapy.||||
33772159|NCT03472092|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Behavioral therapy assignment is known to the treating therapist/care provider. Placebo and amitriptyline are double blinded. Participant will be aware they are either assigned to behavioral or pill therapy.|Mechanistic/basic science project seeking to identify the neural mechanisms by which youth with migraine improve in response to preventive treatment.|t|f|t|t
33772160|NCT02221895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772161|NCT06306560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772162|NCT04762329|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33772163|NCT02053194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33772164|NCT01244139|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33772165|NCT01219621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772166|NCT04732715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772167|NCT06245265|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984717|NCT02281305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984718|NCT02702102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984719|NCT03182114|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33984720|NCT01049607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984721|NCT03503422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984722|NCT04298177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a two-arm, single-blind, single-center, randomized controlled trial.|t|f|f|f
33984723|NCT01885455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33984724|NCT01705522|||COHORT||PROSPECTIVE|||||||
33984725|NCT05253105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33984726|NCT00237003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681853|NCT05095012|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Each site will be randomized to a start date. Once a site starts the clinical pathway, the clinical pathway tools (assessment, education and referral tools) will be utilized by staff in that particular emergency department. Patients and parents will be unaware of clinical pathway.|The project will involve a stepped wedge time series design to evaluate the implementation of the Maternal Newborn and Child Health clinical pathway for the acute care of pediatric concussion.||||
33681854|NCT05566483|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized control trial||||
33681855|NCT02486341|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681856|NCT04223492|NA|SINGLE_GROUP||OTHER||NONE||||||
33681857|NCT00720447|NON_RANDOMIZED|||TREATMENT||||||||
33681858|NCT00849316|||COHORT||PROSPECTIVE|||||||
33681859|NCT01517971|||COHORT||RETROSPECTIVE|||||||
33681860|NCT04486417|||OTHER||PROSPECTIVE|||||||
33681861|NCT01952483|||COHORT||PROSPECTIVE|||||||
33681862|NCT05309876|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants get access to the tool or get assigned to a control group without access||||
33681863|NCT03229174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681864|NCT04057716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The assessor will be blinded to sleep condition in order to obtain unbiased estimates of study outcomes (e.g., weight, eating behavior).|Participants will be instructed to restrict or expand their sleep for one week each within a randomized crossover design, separated by a one week wash-out period.|f|f|f|t
33681865|NCT04479371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded as to which block they received|Two arms with one receiving liposomal bupivacaine in their penile block vs one receiving standard bupivacaine|t|f|f|f
33681866|NCT00265356|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33681867|NCT01837576|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
33681868|NCT02930980|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33681869|NCT00334178|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681870|NCT02612831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681871|NCT00760799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33681872|NCT03450356|||OTHER||PROSPECTIVE|||||||
33772168|NCT03989791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772169|NCT00423111|||NATURAL_HISTORY||OTHER|||||||
33984727|NCT03322111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681873|NCT01336361|||CASE_ONLY||CROSS_SECTIONAL|||||||
33681874|NCT03978793|||CASE_CROSSOVER||PROSPECTIVE|||||||
33681875|NCT05154968|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Partially blind||t|f|f|f
33772170|NCT05435235|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33772171|NCT05652855|NA|SINGLE_GROUP||TREATMENT||NONE||Single group contains two study parts||||
33772172|NCT05973084|||COHORT||PROSPECTIVE|||||||
33772173|NCT02310126|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33772174|NCT01872780|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33772175|NCT00287469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772176|NCT01779011|||COHORT||PROSPECTIVE|||||||
33772177|NCT00574990|||||PROSPECTIVE|||||||
33772178|NCT01173640|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984728|NCT04165239|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The study will be a double-blind, randomised, placebo-controlled, multi-centre, three-way cross-over study. Twenty-seven subjects, with a confirmed mitochondrial DNA tRNALeu(UUR) 3243A\>G mutation and with clinical signs of mitochondrial disease including attentional dysfunction, and fulfilling pre-defined cardiac exclusion criteria, will be randomised over three treatment sequences as assigned by Latin-square. Each group will have 3 treatment periods of 28 days each, separated by 14-day washout periods between treatments. During the 28-day treatment periods, subjects will receive bid oral administration of 50 mg KH176,100 mg KH176, or placebo in the sequence as applicable for the group.|t|t|t|t
33681876|NCT00333346|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681877|NCT04518995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681878|NCT02265198|||CASE_CONTROL||PROSPECTIVE|||||||
33681879|NCT02848443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681880|NCT01642875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681881|NCT04311593|||COHORT||PROSPECTIVE|||||||
33681882|NCT05055089|||CASE_ONLY||RETROSPECTIVE|||||||
33681883|NCT01689428|||COHORT||PROSPECTIVE|||||||
33984729|NCT06410222|||COHORT||RETROSPECTIVE|||||||
33984730|NCT03992586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33984731|NCT01307722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984732|NCT04940962|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33984733|NCT04389320|||COHORT||CROSS_SECTIONAL|||||||
33681884|NCT02878057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984734|NCT03497897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984735|NCT03334825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized controlled trial||||
33984736|NCT01579357|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33681885|NCT05519293|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation and Expansion||||
33681886|NCT03005210|RANDOMIZED|CROSSOVER||||NONE||||||
33984737|NCT02420444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33984738|NCT02003547|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984739|NCT05832996|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33984740|NCT00550537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984741|NCT00004562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984742|NCT05214560|||CASE_ONLY||PROSPECTIVE|||||||
33984743|NCT01926821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984744|NCT04452656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blindness will be achieved by patient codes which will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A physician not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anaesthesiologist who is expert in doing the Erector spinae plane block in patients included within the block group. This expert anaesthesiologist will not be involved in collecting data but another anaesthesia doctor will be responsible for patient management and collecting the intraoperative and postoperative data.||t|t|t|t
33984745|NCT01026363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984746|NCT02527278|||COHORT||RETROSPECTIVE|||||||
33984747|NCT00002804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984748|NCT02092805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984749|NCT02039908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984750|NCT01672515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984751|NCT03189173|NA|SINGLE_GROUP||TREATMENT||NONE|"Supplemental oxygen versus air assignment nights will be blinded to participants, but will be known by the investigator. Oral appliances will be open label."|Subjects will receive mandibular advancement, supplemental oxygen, mandibular advancement plus supplemental oxygen, and no treatment in randomized order. On nights without supplemental oxygen, subjects will be administered sham (air, single blinded). Oral appliance use will not be masked.||||
33984752|NCT05149118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33984753|NCT03351335|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33984754|NCT05820685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984755|NCT01832259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33984756|NCT01319123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984757|NCT04705714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984758|NCT05956366|||COHORT||PROSPECTIVE|||||||
33984759|NCT03610113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984760|NCT05641064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization and study drug preparation by person(s) not involved in patient care, data gathering or outcome evaluation. Group allocation kept in sealed opaque envelope until all data gathered.||t|t|t|f
33984761|NCT01352663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984762|NCT03789019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984763|NCT00501345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984764|NCT00808171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33681887|NCT05779774|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Premises are unaware of the pseudo patrons sent in for data collection.||t|f|f|f
33681888|NCT05622409|||COHORT||OTHER|||||||
33681889|NCT00571584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681890|NCT03086564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681891|NCT06240767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681892|NCT01244490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681893|NCT03994029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681894|NCT03720392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681895|NCT04246931|||COHORT||CROSS_SECTIONAL|||||||
33681896|NCT00450008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681897|NCT04022733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681898|NCT00797966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33681899|NCT04320862|||COHORT||PROSPECTIVE|||||||
33681900|NCT03034187|||COHORT||PROSPECTIVE|||||||
33681901|NCT06309550|||COHORT||PROSPECTIVE|||||||
33681902|NCT02728427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681903|NCT03492008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681904|NCT06092125|||COHORT||PROSPECTIVE|||||||
33681905|NCT05950152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681906|NCT02527200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681907|NCT05258370|||CASE_ONLY||PROSPECTIVE|||||||
33681908|NCT05370183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681909|NCT00774176|||OTHER||OTHER|||||||
33681910|NCT04592484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681911|NCT02228616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681912|NCT01584544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33681913|NCT01577290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772179|NCT02456389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901957|NCT05829577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Administration of assessment will be done by(individuals blinded of the outcome assessor) as an Independent evaluators, whose trained in the administration of study assessments, will conduct the pre-intervention, re assessment and post intervention assessments and this therapist will be blinded for intervention and control group, and thire qualification as follow : highly experienced therapist who has been licensed to practice occupational therapy for a mean of 10 years, and who had experience with working with children with ASD (mean = 5 years). also were trained on conducting these standardized assessment and certified on Wee FIM|Single blind one center randomized control trial (RCT) with one arm :control group will receive Individual Sensory integration / sensory processing and daily life skills training , treatment group will receive Individual Sensory integration / sensory processing and daily life skills training training combined with EF strategies both groups will receive 1 session individual OT/week for 45 min for 14 weeks .|f|f|f|t
33901958|NCT06673303|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33901959|NCT06048016|NA|SINGLE_GROUP||TREATMENT||NONE||Group 1 : 68 Periodontitis Patients, providing scaling and root plaining . Group 2:68 healthy individuals.||||
33901960|NCT06663046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901961|NCT00389077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901962|NCT01541722|||COHORT||PROSPECTIVE|||||||
33901963|NCT02563873|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33901964|NCT00898053|||COHORT||PROSPECTIVE|||||||
33901965|NCT04453267|||OTHER||PROSPECTIVE|||||||
33901966|NCT05308485|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33901967|NCT04844671|||COHORT||OTHER|||||||
33901968|NCT01359826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901969|NCT04630340|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Feasibility Trial||||
33901970|NCT05377905|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, comparative 2-cohort design||||
33901971|NCT02234115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901972|NCT05154214|||COHORT||PROSPECTIVE|||||||
33901973|NCT00632034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901974|NCT03384511|NA|SINGLE_GROUP||TREATMENT||NONE||Apatinib at oral dose of 250 mg twice daily (500 mg/day) for a minimum of 30 days||||
33901975|NCT00038194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901976|NCT04164212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984765|NCT02590159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984766|NCT02129426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33984767|NCT02209428|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984768|NCT04277325|RANDOMIZED|PARALLEL||TREATMENT||NONE||Couples will be randomly assigned to one of two groups: intervention or waitlist.||||
33984769|NCT04601792|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.|randomized, double-blind, crossover comparisons of individualized herbal decoction with control decoction within individual patients. Each N-of-1 trial has 3 pairs of treatment periods. The duration of each treatment period will be 4 weeks.|t|t|t|t
33984770|NCT04987619|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The order in which the participants will consume one supplement or another will be assigned randomly and double blind by an external collaborator to the research team, who will be responsible for coding the bottles.|The experimental procedure will consist of three visits, separate from each other by one week, to achieve the total elimination of any effects caused by BJR as well as the optimal recovery of the participants.|t|f|t|f
33984771|NCT00889109|||CASE_CONTROL||PROSPECTIVE|||||||
33984772|NCT04269460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33984773|NCT06131853|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33984774|NCT01363765|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984775|NCT02817841|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984776|NCT01639222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984777|NCT00000966||||TREATMENT||||||||
33681914|NCT03995251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681915|NCT03643978|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in an intervention group that reviews a decision aid and a control group that does not.||||
33681916|NCT00289523|||CASE_CONTROL||PROSPECTIVE|||||||
33681917|NCT05726877|NA|SINGLE_GROUP||OTHER||NONE||||||
33681918|NCT02618356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772180|NCT05701722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772181|NCT05389969|||OTHER||CROSS_SECTIONAL|||||||
33772182|NCT02498730|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33772183|NCT01759680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772184|NCT05231564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment||||
33772185|NCT03269448|||OTHER||CROSS_SECTIONAL|||||||
33772186|NCT05047796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each participant will be randomly assigned to the intervention group or placebo group by an independent study evaluator. Data will be secretly allocated through sealed, opaque envelopes. After the randomization process, the participant will be evaluated by a researcher who will not have knowledge about the distribution of the groups.||t|f|f|t
33772187|NCT03753282|||COHORT||RETROSPECTIVE|||||||
33772188|NCT02465021|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33772189|NCT03877705|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The operator will be blinded to material and assessors will be blinded to the material assignment.|Geriatric bedridden patients|f|f|t|t
33772190|NCT03410238|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33772191|NCT00493337|RANDOMIZED|PARALLEL||||NONE||||||
33772192|NCT02320786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772193|NCT05104918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant would be randomly allocated to either of the two interventional groups||t|f|f|f
33901977|NCT06672029|NA|SINGLE_GROUP||TREATMENT||NONE||retrospective study||||
33901978|NCT06344520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||three groups as intervention, exercises group non- exercises group and scham||||
33901979|NCT00722540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33901980|NCT04375631|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33901981|NCT04591665|||CASE_ONLY||PROSPECTIVE|||||||
33984778|NCT04324580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984779|NCT03995030|||OTHER||PROSPECTIVE|||||||
33681919|NCT06162390|NA|SEQUENTIAL||PREVENTION||NONE|This is one arm non-randomized approach. Since it is a sequential approach of medication administration, the anesthesiologist and patients were blinded to whatever dose was given.|||||
33681920|NCT05624047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33681921|NCT05015985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|During all the procedure, the anesthetist performing the locoregional anesthesia and the intravenous hypnotic administration, is blinded about the patient group and music program.|"In this study, the investigators compare a specific program of music therapy to an usual music support by playlist. The specific program MUSIC-CARE is administered through a hardware and software, consisting of a modern tablet. The Music-Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians.~Music-Care utilizes the U technique designed to gradually relax the listener. Initially, the objective is to represent the patient's state of tension by stimulating musical rhythm of 80-95 beats per minute (bpm). Then, it gradually falls into a relaxed state via a gradual reduction in musical tempo (40-80 bpm), orchestral size, frequencies, and volume (descending arm of the U)."|f|t|f|t
33681922|NCT02976220|NA|SINGLE_GROUP||OTHER||NONE||||||
33681923|NCT06491966|||COHORT||RETROSPECTIVE|||||||
33681924|NCT03678870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772194|NCT03668730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772195|NCT04199715|NA|SINGLE_GROUP||PREVENTION||NONE|N/A. Investigator and patient will know that the patient received the Heplisav-B vaccine.|"A total of 18 patients will be entered into the study including 3 evenly sized groups of 6 as follows:~* Group A patients on tumor necrosis factor alpha or interleukin inhibitor therapy for underlying chronic inflammatory disorders~* Group B patients on chemotherapy for solid organ malignancy~* Group C patients are either recipients of livers from anti-HBc positive donors or are patients transplanted for chronic hepatitis B infection without recurrent hepatitis B at the time of enrollment"||||
33772196|NCT05683522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is subomohyoid plane block group. The second one is combination of costaclavicular with superficial cervical plexus block.|t|t|f|t
33772197|NCT05740358|||COHORT||PROSPECTIVE|||||||
33772198|NCT02044419|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33772199|NCT06100380|||CASE_CONTROL||PROSPECTIVE|||||||
33772200|NCT04625647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772201|NCT05706181|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|With the exception of a research nurse, all research personnel are blinded.||t|f|t|t
33772202|NCT05342116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Endoscopists will be blinded to the patients' assigned arm.|A randomised controlled trial with 3 arms: (1) Fasting 6 hours prior to endoscopy, (2) Allow up to 400ml of water up to 2 hours before endoscopy, (3) Carbohydrate loading with Preload 400ml at least 2-4 hours before endoscopy.|f|f|f|t
33772203|NCT02441920|||COHORT||CROSS_SECTIONAL|||||||
33772204|NCT01467258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772205|NCT00719602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33772206|NCT02220335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772207|NCT04610151|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||The study was conducted with patients undergoing lower extremity operations between April 2018 and May 2019 at the Necip Fazıl City Hospital (Kahramanmaraş, Turkey) as a pretest-posttest study with a quasi-experimental design and a control group.|f|t|f|f
33772208|NCT01039350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772209|NCT05859711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772210|NCT03318211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772211|NCT02241720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772212|NCT03615209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33772213|NCT05372679|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, non-randomized, open-label clinical study||||
33772214|NCT02705040|||COHORT||PROSPECTIVE|||||||
33772215|NCT02774265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901982|NCT06671886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|PACT teams will be randomized to the intervention or control arms of the study. Patients will not be individually recruited or randomized for the cluster-randomized trial.|The study is a cluster-randomized trial to test the effectiveness of the NCCP intervention relative to Usual Care on patient-level clinical process outcomes. The unit of randomization will be the PACT team enrolled into the NCCP or usual care. Outcome assessments will be conducted at 6 and 12 months.|t|f|f|f
33984780|NCT05226923|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33901983|NCT04103372|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"Multicentre, stepped-wedge cluster randomised trial. This pilot study will run for 9 months and utilise a stepped wedge cluster randomised controlled trial design (including transition period). Sites will enter data from the diagnostic and treatment pathways of all rectal cancer patients who are eligible for primary surgical treatment, eg those radiologically staged as less than or equal to T3b or with confirmed as less than or equal to pT2N0 pathological staging.~Prior to the trial opening the participating sites will be randomly allocated a number, which will determine the number of months the site will remain in the control and then subsequently the intervention phase of the trial."||||
33984781|NCT02903888|||COHORT||CROSS_SECTIONAL|||||||
33984782|NCT02254174|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33984783|NCT01725698|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33984784|NCT06047665|||COHORT||PROSPECTIVE|||||||
33984785|NCT02006160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984786|NCT05220683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984787|NCT04329988|||COHORT||PROSPECTIVE|||||||
33984788|NCT01364194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984789|NCT00756080|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33984790|NCT05397093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984791|NCT03314870|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984792|NCT00893386|||COHORT||PROSPECTIVE|||||||
33984793|NCT03748303|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label study||||
33984794|NCT03131362|||COHORT||PROSPECTIVE|||||||
33984795|NCT05088252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33984796|NCT02127450|||CASE_CONTROL||PROSPECTIVE|||||||
33984797|NCT03018249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33984798|NCT01713465|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33984799|NCT02499718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984800|NCT06248853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|Graston technique and exercise program|f|f|t|t
33984801|NCT03938402|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33984802|NCT00795015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984803|NCT00556790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984804|NCT01607645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984805|NCT00987948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984806|NCT02993991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984807|NCT05170009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984808|NCT03084822|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984809|NCT03893318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study Drug|a randomized, triple-blind, placebo-controlled trial of intravenous lidocaine in the management of surgery performed for adolescent idiopathic scoliosis.|t|t|t|t
33984810|NCT00155545|NON_RANDOMIZED|PARALLEL||||NONE||||||
33984811|NCT02089997|||COHORT||PROSPECTIVE|||||||
33984812|NCT03141047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984813|NCT06209567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984814|NCT02374853|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33984815|NCT01303848|||||PROSPECTIVE|||||||
33984816|NCT01678066|||COHORT||PROSPECTIVE|||||||
33984817|NCT05605301|NA|SEQUENTIAL||TREATMENT||NONE||"Subjects will be given 2DG orally during a single day of dosing at one of three sequential dose levels (a single dose of 40 mg for Dose Level 1, a single dose of 60 mg for Dose Level 2, or 60 mg bid for Dose Level 3). The total dose will not exceed 120 mg/day, or 60 mg maximum.~as a single dose"||||
33984818|NCT03701256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984819|NCT01620853|||COHORT||RETROSPECTIVE|||||||
33984820|NCT02413320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984821|NCT01397292|||COHORT||PROSPECTIVE|||||||
33984822|NCT04763005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984823|NCT01757600|||CASE_ONLY||RETROSPECTIVE|||||||
33984824|NCT04608253|||COHORT||RETROSPECTIVE|||||||
33984825|NCT00649753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984826|NCT01321190|||CASE_ONLY||CROSS_SECTIONAL|||||||
33984827|NCT00282048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984828|NCT01564511|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33984829|NCT02424266|||CASE_CONTROL||PROSPECTIVE|||||||
33984830|NCT05647031|||OTHER||OTHER|||||||
33901984|NCT01817608|||COHORT||PROSPECTIVE|||||||
33901985|NCT02850679|||COHORT||RETROSPECTIVE|||||||
33901986|NCT02979067|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33901987|NCT03964415|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33901988|NCT01804361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33681925|NCT03453372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participating patients will be blinded to treatment assignment and to the ongoing results of the study; they will remain blinded to their assignment throughout the study period. All the staff involved in the pre- and post-treatment evaluation of patients will be also blinded. The evaluation of patients will be performed by physicians not involved in the treatment to ensure double blinding.|Double-blind placebo-controlled randomized clinical trial|t|f|t|f
33681926|NCT03859973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681927|NCT02165501|||COHORT||PROSPECTIVE|||||||
33681928|NCT00005862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681929|NCT00558688|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33681930|NCT03782831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33901989|NCT05384054|||COHORT||PROSPECTIVE|||||||
33772216|NCT04543370|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33772217|NCT00861796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772218|NCT06189430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Research data were collected by one-on-one and face-to-face interviews using data collection tools and the statistician was blinded. Hrobjartsson et al. (2013) report that blinding the person performing the statistical analysis, which is frequently preferred in non-pharmaceutical research, has positive effects in terms of reducing bias in effect size estimates and is also useful if the measurements are subjective. It is emphasized that blinding those who measure subjective data, which can only be obtained from the individual and which generally constitute the main criteria of nursing studies, is a feasible and preferable method. For this reason, the data in our study was collected by another research assistant outside the study. For all tests performed, individuals were given nicknames and data entries were made.|This study was planned as a randomized controlled, double-blind and experimental study to evaluate the effect of vinyasa yoga on frailty and anthropometric measurements in elderly individuals.|f|f|t|t
33772219|NCT02874664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772220|NCT05276323|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||We conducted a randomized trial comprising children aged 2-18 diagnosed with mild to moderate AD, with an IGA of 2-3 and BSA of 1%-10%, including 30 patients, 20 using Med-D-Cream and 10 as controls using Hydrocortisone 1% cream. Patients applied creams for 2 weeks and were then followed for two weeks to measure clinical responses.||||
33772221|NCT05189509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772222|NCT04800757|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized||||
33772223|NCT05542992|||COHORT||PROSPECTIVE|||||||
33772224|NCT03137602|NA|SINGLE_GROUP||OTHER||NONE||||||
33772225|NCT00573950|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33772226|NCT03881059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigative site staff, the Sponsor, and Participant will remain blinded to treatment assignment with the exception of an unblinded pharmacist, an unblinded study drug administrator (Part B), and an unblinded site monitor.||t|f|t|f
33772227|NCT00451217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772228|NCT05299879|||COHORT||PROSPECTIVE|||||||
33772229|NCT01845948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33772230|NCT05716737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772231|NCT00664664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772232|NCT04827290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772233|NCT02743793|||COHORT||PROSPECTIVE|||||||
33901990|NCT00619541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33901991|NCT05589181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In trial 1 neither the investigator nor the participant will be blinded to group assignment. In Trial 2, participants, Investigators and site personnel with the exception of the investigational drug pharmacist will be blinded to group assignment.|The design of Trial 1 and Trial 2 will be described separately. Trial 1 is a prospective test of the safety and tolerability of 32 mg of BUP as an induction dose (split dosing over 30-60 minutes with 4 hours of post-induction monitoring) with the recommended BUP induction dose (12mg, also split over 60 minutes). Trial 2 is a four-site pilot RCT (n=20x4) conducted in the ED, that will test the efficacy, safety and tolerability of the high BUP dose (selected in Trial 1) as an induction dose (split dosing over 30-60 min) compared to standard BUP induction dose (up to 12mg) also split over 30-60 min. The four sites participating in the Trial 2 RCT are, (1) Mount Sinai Hospital Emergency Department, (2) Mount Sinai Beth Israel Emergency Department, (3) Barnes Jewish Hospital Emergency Department and (4) Rhode Island Hospital Emergency Department.|t|t|t|t
33901992|NCT01955174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33901993|NCT01950936|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33901994|NCT03015272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33901995|NCT04263922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681931|NCT04860908|||COHORT||PROSPECTIVE|||||||
33681932|NCT06299254|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33681933|NCT03391193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681934|NCT03717428|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Effect of self-weighing to prevent age-related weight gain||||
33681935|NCT05767879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681936|NCT02375789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772234|NCT02755454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772235|NCT04025203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33901996|NCT02160340|||CASE_ONLY||PROSPECTIVE|||||||
33901997|NCT04548661|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Pragmatic, multicentre, participant and adjudicator-blinded, three-arm randomized controlled trial|t|f|f|t
33984831|NCT05689762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984832|NCT06327243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know if they are receiving the actual Kinesio Taping (KT) treatment or a sham taping. The KT will be applied following the correct standards for the rectus femoris muscle, including appropriate stretching. Conversely, the placebo taping will be applied horizontally across the muscle fibers without any stretching. The therapists applying the tape will know which treatment each participant is allocated to ensure that the application of either the real KT or the placebo taping aligns with the study's protocol.|In a randomized and single-blinded approach, participants are divided into two groups. One group receives actual Kinesio taping, while the other undergoes a sham procedure, with neither group aware of their specific treatment type to ensure unbiased results.|t|f|f|f
33681937|NCT04090775|NA|SINGLE_GROUP||TREATMENT||NONE||Male subjects greater than 18 years of age with histologically-proven cancer of the prostate with at least one imaging- or histologically -proven metastasis to lymph nodes or bone.||||
33984833|NCT03538405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984834|NCT04384978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A 12-month pilot study will be comprised of two groups of people diagnosed with mild Alzheimer's disease and related dementia for a total of 80 senior subjects. Subjects will be randomly assigned to two groups: Group 1 users will play games with and administered by Ryan, 2-3 times a week and 30-minutes per day. Group 2 (Active Control Group) will play solitary games and activities but will have to interaction with Ryan. The team will measure the changes and improvement in the social/emotional well-being of these two groups and eventual changes in the cognitive/memory functions of elderly people living in the similar environment.||||
33984835|NCT01327690|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33681938|NCT05254743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681939|NCT02027129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33681940|NCT02151773|||COHORT||PROSPECTIVE|||||||
33681941|NCT02230969|||COHORT||PROSPECTIVE|||||||
33681942|NCT05532423|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|As it is a double blind study, participants and investigators for this study will be blinded to the intervention they are receiving.|The design is a single group randomized crossover trial, with individuals with metabolic syndrome receiving both the active nitrate rich juice and the placebo juice, randomized in order.|t|f|t|f
33681943|NCT04465201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681944|NCT05840042|||COHORT||PROSPECTIVE|||||||
33681945|NCT06215768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33681946|NCT00430183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681947|NCT05475301|||COHORT||OTHER|||||||
33681948|NCT01733212|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681949|NCT04672707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681950|NCT04337710|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33681951|NCT04721561|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33681952|NCT03137667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigator is not aware of the allocation at the level of the patient. In addition, the investigator is not involved in vaccine verification (data collection involving patient-level vaccination status)||f|f|t|f
33681953|NCT06036004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study participants, study team (i.e., study nurses, study physicians, study psychologists), and further outcome assessors will be blinded after assignment to interventions.|double-blind randomised placebo-controlled trial: participants will be randomly assigned 1:1 to receive either treatment with intranasal OXT or intranasal placebo|t|f|t|t
33681954|NCT01235598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681955|NCT00545870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33681956|NCT01515020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681957|NCT00104598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33681958|NCT01236547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33681959|NCT04112238|||CASE_ONLY||PROSPECTIVE|||||||
33681960|NCT03844711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33681961|NCT00816023|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33681962|NCT03830905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681963|NCT04962256|||COHORT||PROSPECTIVE|||||||
33681964|NCT00384683|||CASE_CONTROL||PROSPECTIVE|||||||
33681965|NCT04049682|||COHORT||PROSPECTIVE|||||||
33681966|NCT04120103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33681967|NCT00853216|RANDOMIZED|CROSSOVER||||NONE||||||
33681968|NCT03070743|||COHORT||PROSPECTIVE|||||||
33681969|NCT00344890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681970|NCT01975324|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33681971|NCT02512627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33681972|NCT05855876|||COHORT||PROSPECTIVE|||||||
33681973|NCT02032043|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33681974|NCT03706547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681975|NCT02728713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33681976|NCT04248725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized (1:1), single blind parallel-group trial comparing a telehealth pain self-management intervention, adapted to address employment issues (E-TIPS), to a waitlist control in adults with physical disabilities and chronic pain who are employed.|f|f|f|t
33681977|NCT02649829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681978|NCT01503671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33681979|NCT03965000|||FAMILY_BASED||PROSPECTIVE|||||||
33681980|NCT02213133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772236|NCT06092541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients, in the database, will be identified as group A and B; Once the study and the compilation of the database have been completed, this will be delivered to the results evaluation team which will therefore be blinded, not being able to recognize whether group A and B belong to control or intervention.|Single-blind, randomized clinical pilot study with masked third-party assessment. Patients will be assigned to the two groups (pericervical analgesia / nitrous oxide) through the sealed envelope method.|t|f|f|t
33772237|NCT03922802|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33772238|NCT02926508|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33772239|NCT01515345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772240|NCT06321250|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772241|NCT03147066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772242|NCT04123327|||OTHER||OTHER|||||||
33772243|NCT01839357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772244|NCT03241264|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33772245|NCT03953144|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label, single-arm feasibility trial.|This study is a single centre, prospective clinical trial evaluating the safety and feasibility of adding 3D anatomical reconstructions and real-time intraoperative planning using Synapse 3D software added to NIF-guided targeted segmental resection. It is anticipated that 32 participants will be enrolled within a 1-year period. Enrollment will take place at St. Joseph's Healthcare Hamilton. All patients enrolled will be evaluated until their first scheduled follow-up appointment (within 30 days post-surgery).||||
33772246|NCT04221815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772247|NCT06022718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Low dye bandage technique was used with a 3.8 cm wide rigid band (Leuko® Sportstape Premium, Germany) for rigid taping. RT was performed on both feet in the subtalar neutral position while participants in the prone position with their heels and feet out of the bed. The taping protocol described elsewhere was followed. To optimise rigid tape adhesion, feet were washed and dried before taping. To increase consistency, the same researcher (MU) applied all taping.||||
33772248|NCT05324501|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two cohort 3+3 design. Between 4-18 patients per cohort.||||
33772249|NCT01945567|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33772250|NCT03047174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772251|NCT04444375|||OTHER||PROSPECTIVE|||||||
33772252|NCT01055093|||COHORT||PROSPECTIVE|||||||
33772253|NCT00264472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984836|NCT02461823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984837|NCT01488786|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33984838|NCT00818545|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33984839|NCT05859841|RANDOMIZED|PARALLEL||TREATMENT||NONE||15 pt listen to music, 15 receives standard treatment, care and rehabilitation||||
33984840|NCT00723476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984841|NCT01835093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984842|NCT05789238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984843|NCT04624412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984844|NCT03061526|||COHORT||RETROSPECTIVE|||||||
33984845|NCT04004091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984846|NCT03195491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984847|NCT01944800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984848|NCT02404662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33984849|NCT03370549|RANDOMIZED|PARALLEL||TREATMENT||NONE||We employed a two-arm randomized clinical trial to test the preliminary feasibility, safety, and efficacy for AWARE intervention comparing the AWARE intervention group (n=48) with the wait-list group (n =48).||||
33984850|NCT03393728|NA|SINGLE_GROUP||TREATMENT||NONE||Open label Before and After design||||
33984851|NCT01163825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984852|NCT00482794|||COHORT||OTHER|||||||
33984853|NCT03049384|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups in parallel for the duration of the study.||||
33984854|NCT01201460|||COHORT||CROSS_SECTIONAL|||||||
33984855|NCT00716248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984856|NCT03070808|||OTHER||PROSPECTIVE|||||||
33984857|NCT03507335|||CASE_CONTROL||PROSPECTIVE|||||||
33984858|NCT02047071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984859|NCT03608722|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33984860|NCT02620891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984861|NCT05792397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984862|NCT03846765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984863|NCT03699020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984864|NCT06346730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The sample will divide into intervention and control groups||||
33984865|NCT04699747|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Drug: F-18 3F4AP PET scan||||
33984866|NCT02560844|||COHORT||PROSPECTIVE|||||||
33984867|NCT06036082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized control study|f|f|f|t
33984868|NCT04720638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984869|NCT06095076|||COHORT||PROSPECTIVE|||||||
33984870|NCT01933373|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984871|NCT05778422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were allocated to groups using a random sequence of numbers generated by computer using the Randomizer® program (www.random.org). The number of patients and the groups to which they would belong were randomly drawn. These numbers were placed in envelopes numbered from 1 to 40, which were drawn on the day of the consultation.|Group 1 - pulsed radiofrequency Group 2 - bupivacaine|f|f|f|t
33984872|NCT05487547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984873|NCT00524264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681981|NCT05319873|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase Ib: Sequential assignment to increasing doses of ribociclib with fixed doses of tucatinib and trastuzumab.~Phase II: Randomized assignment to 3 parallel arms."||||
33984874|NCT06034119|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A group of participants post-stroke and neurotypical controls will be recruited for this study. All individuals will perform all conditions||||
33984875|NCT05611216|||COHORT||RETROSPECTIVE|||||||
33984876|NCT01416584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984877|NCT02363634|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33984878|NCT00633399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079952|NCT03309553|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The randomization assignments will be kept confidential within the study team until hearing screening day, when masking the referral process assignment will no longer be possible. All outcome assessors, including audiologists and ear, nose, and throat (ENT) surgeons reading telemedicine consults within the Alaska Native healthcare system and study team members performing medical record abstraction, will be masked to intervention allocation. Study team members who read telemedicine consults as a part of their clinical responsibilities will abstain from reading any study-related consults. The results of the school screen, mHealth screen, and audiometric assessments will also be masked, such that study team members performing the mHealth screen or audiometric assessment will be masked to the other results.||f|f|f|t
33984879|NCT03002597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984880|NCT03497247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984881|NCT02687074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984882|NCT00184600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984883|NCT06214364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation concealment: allocation sequence will be generated by an independent investigator. Group code number will be placed in sealed envelopes, that will be opened by another investigator, ignoring which code corresponds with each intervention.|This is parallel randomized triple-blind controlled trial with two groups: experimental group will be administered active anodal tDCS and control group, with sham tDCS.|t|t|t|t
34079953|NCT00683228|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34079954|NCT00532909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079955|NCT05974254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients will be under sedation in the operating room and will not be aware of which treatment group they are in.~The PACU team and outcomes assessor will not be aware of patient group assignment."|Randomized controlled trial Group 1 - acupuncture treatment Group 2 - no acupuncture treatment 70 patients per group|t|f|f|t
34079956|NCT02345005|||COHORT||PROSPECTIVE|||||||
34079957|NCT05573763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079958|NCT03272243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34079959|NCT02283879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079960|NCT02914834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079961|NCT06245642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34079962|NCT03131284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34079963|NCT00232700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34079964|NCT01861067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079965|NCT01302405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079966|NCT03087305|||COHORT||PROSPECTIVE|||||||
33681982|NCT02787239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681983|NCT05349201|||COHORT||RETROSPECTIVE|||||||
33681984|NCT01120743|||COHORT||PROSPECTIVE|||||||
33681985|NCT03364829|NA|SINGLE_GROUP||TREATMENT||NONE||single group with comparisom before and after intervention||||
33681986|NCT02031965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33681987|NCT00711516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681988|NCT01210417|||CASE_ONLY||PROSPECTIVE|||||||
33681989|NCT03626818|||COHORT||PROSPECTIVE|||||||
33984884|NCT01346007|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984885|NCT02116153|||CASE_ONLY||PROSPECTIVE|||||||
33681990|NCT04307342|||CASE_ONLY||PROSPECTIVE|||||||
33681991|NCT00281658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984886|NCT00099047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33984887|NCT05941403|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33984888|NCT04953832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33984889|NCT03536130|RANDOMIZED|PARALLEL||OTHER||NONE||Allocation: randomization 1 to 1 Endpoint classification: efficacy study Masking: Open label Intervention model: parallel assignment Primary purpose: supportive care||||
33984890|NCT03079050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984891|NCT01387022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079967|NCT04041102|||COHORT||PROSPECTIVE|||||||
34079968|NCT00130130|||CASE_ONLY||PROSPECTIVE|||||||
34079969|NCT05261165|||COHORT||RETROSPECTIVE|||||||
34079970|NCT00021723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34079971|NCT00331565|NON_RANDOMIZED|PARALLEL||||NONE||||||
34079972|NCT03010826|||CASE_CONTROL||PROSPECTIVE|||||||
34079973|NCT03428100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33681992|NCT05170776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|this trial has three groups; one experimental and two groups control.|f|f|t|t
33681993|NCT02284932|||COHORT||PROSPECTIVE|||||||
33681994|NCT06105671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33681995|NCT01488123|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33681996|NCT01428947|||CASE_ONLY||PROSPECTIVE|||||||
33681997|NCT00207896|||COHORT||PROSPECTIVE|||||||
33681998|NCT02995369|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33984892|NCT00938834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984893|NCT06283186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34079974|NCT03627325|||OTHER||PROSPECTIVE|||||||
34079975|NCT02899611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079976|NCT00905242|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772254|NCT01776684|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772255|NCT02796781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772256|NCT05909319|||COHORT||PROSPECTIVE|||||||
33772257|NCT00108121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772258|NCT03760822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772259|NCT05895058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772260|NCT03100565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will be blinded to the methods used for pain relief.||t|f|f|f
33772261|NCT03657381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772262|NCT04537897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772263|NCT02843880|||COHORT||PROSPECTIVE|||||||
33772264|NCT03406793|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772265|NCT05155592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772266|NCT03826134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772267|NCT06524245|||COHORT||PROSPECTIVE|||||||
33984894|NCT02809469|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33984895|NCT02373826|||COHORT||RETROSPECTIVE|||||||
33772268|NCT04210193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772269|NCT02032173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772270|NCT03820791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33772271|NCT03656484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772272|NCT00243555|||DEFINED_POPULATION||OTHER|||||||
33772273|NCT04418414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772274|NCT01680458|||CASE_ONLY||PROSPECTIVE|||||||
33772275|NCT00896129|||CASE_ONLY||CROSS_SECTIONAL|||||||
33772276|NCT05532020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772277|NCT05778331|||COHORT||PROSPECTIVE|||||||
33772278|NCT03271268|||COHORT||PROSPECTIVE|||||||
33772279|NCT00183443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33772280|NCT03246425|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33772281|NCT04455334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772282|NCT02646306|||CASE_CONTROL||RETROSPECTIVE|||||||
33772283|NCT04086979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Some outcomes were observed by coders unaware of the participant's intervention condition. Other outcomes were reported by participants who were aware of their intervention condition.|Participants were randomly assigned to one of two interventions: Parental Friendship Coaching (PFC) or Coping with ADHD through Relationships and Education (CARE)|f|f|f|t
33772284|NCT00547105|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single arm phase II pilot trial. Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib. Maintenance erlotinib will continue until disease progression uncontrollable by SBRT, intolerable toxicity, or death.||||
33772285|NCT00649740|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33772286|NCT06441825|||COHORT||PROSPECTIVE|||||||
33772287|NCT01049074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772288|NCT00158522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772289|NCT03780595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772290|NCT04827563|||CASE_CONTROL||PROSPECTIVE|||||||
33984896|NCT03707912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984897|NCT00138060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984898|NCT02134834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772291|NCT01428921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772292|NCT00011024|RANDOMIZED|||TREATMENT||||||||
33772293|NCT03675841|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33772294|NCT00609141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772295|NCT02248961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772296|NCT03954496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33772297|NCT05139641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33984899|NCT01467765|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33984900|NCT02305706|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33681999|NCT00528970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682000|NCT04858971|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682001|NCT04136444|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33682002|NCT02539056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682003|NCT04401020|NA|SEQUENTIAL||TREATMENT||NONE||||||
33682004|NCT01625260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33901998|NCT05370248|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participants are blinded to which group they belong and they have given consent to that.~The person assigning patients to each group is the research assistant. The person setting the mechanical ventilator is the anesthesiology resident. The person assessing outcome with ultrasound is radiology department staff, who does not know which group the patient belong.~The person assessing outcome of interleukin is laboratory personnel, who does not know which group the patient belong.~The person collecting and freezing data into worksheet is the research assistant.~The person analyzing final data is the primary investigator."|Patient was divided into group A and B. Group A received tidal volume of 6 ml/kg and group B received tidal volume of 10 ml/kg.|t|f|t|t
33901999|NCT05014698|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902000|NCT05416606|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this study, a hybrid technique, that combines two types of techniques using the same cutting current and technological setup, will be proposed enucleation of the prostate gland with the plasma vaporization electrode and resection with a TURis cutting loop. This technique is defined as transurethral vapor enucleation and resection of the prostate (TVERP) comparing it with open prostatectomy.||||
33902001|NCT05506371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All biopsies were reviewed by the same pathologist, blinded to experimental group affiliation of biopsies|Randomized controlled short-term clinical trial|f|f|f|t
33902002|NCT02270632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33902003|NCT02004652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33902004|NCT03922399|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|evaluating in different medical groups|Patients with major burn scar, after lasers treatment for three years Evaluation tool: questionnaires, sonography, HRV||||
33902005|NCT04889495|||CASE_ONLY||PROSPECTIVE|||||||
33902006|NCT00118170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902007|NCT03291782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902008|NCT05565677|||COHORT||PROSPECTIVE|||||||
33682005|NCT02101697|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33682006|NCT00473122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682007|NCT00002952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682008|NCT03587285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682009|NCT03131427|||COHORT||PROSPECTIVE|||||||
33682010|NCT05275361|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682011|NCT00146783|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33682012|NCT00668356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682013|NCT03632486|||COHORT||PROSPECTIVE|||||||
33682014|NCT01872325|||COHORT||PROSPECTIVE|||||||
33682015|NCT00353470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682016|NCT00357591|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682017|NCT04861493|||OTHER||CROSS_SECTIONAL|||||||
33682018|NCT06021860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682019|NCT03317301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682020|NCT03938753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682021|NCT00123890||||DIAGNOSTIC||NONE||||||
33682022|NCT01863589|||||PROSPECTIVE|||||||
33682023|NCT00213473|||COHORT||PROSPECTIVE|||||||
33682024|NCT05800431|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The evaluators of all the results and the main caregivers of the participating patients will be masked.||t|t|f|f
33682025|NCT02386189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|For one of the outcomes (laboratory duplication) the assessor is blind to group assignment.||f|f|f|t
33682026|NCT05099224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The data (questionnaire and blood samples) were collected by three research assistants with at least 10 years nursing experiences who were not involved in any other parts of the study.~Also, the participants were randomly assigned equally to the study groups using a computerized random numbers procedure carried out by a research assistant who was not involved in any other parts of the study"|Randomized controlled Trial (pretest-posttests, two-group, randomized design)|f|f|f|t
33682027|NCT04456231|||COHORT||PROSPECTIVE|||||||
33682028|NCT03131830|||OTHER||PROSPECTIVE|||||||
33682029|NCT03893890|||CASE_ONLY||PROSPECTIVE|||||||
33772298|NCT04675112|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772299|NCT06231290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33902009|NCT01461031|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33902010|NCT02650778|||OTHER||PROSPECTIVE|||||||
33772300|NCT03067103|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Patients admitted for tonsillectomy were randomized into 3 groups by means of sealed envelopes. The envelope selected by the caregiver will be open by the registered nurse, who will prepare the infiltration. Neither the surgeon, anesthesiologist the caregiver nor the patient will see what is inside the envelope. The register of the envelope number and patient data will be done by the statistical group|Patientes will be seleted to receive peritonsillar injection of Tramadol, Ketamine or Placebo before tonsillectomy prospective, double-blind, placebo controlles|t|t|t|f
33772301|NCT01785628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33772302|NCT05275751|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE||"Factorial: There are 4 treatments (TRPV1-, TRPA1-, TRPM3- and chloride channel inhibition). These will be applied in all possible combinations (16). Each healthy volunteer will receive 8 of these 16 combinations in a sequence defined by a Williams square (Hinkelmann, K., and Kempthorne, O. (2005). Design and Analysis of Experiments Vol. 2 - Advanced Experimental Design (Wiley))~Randomized: Volunteers will be randomly assigned to a pre-specified sequence.~Placebo-controlled: One of the 16 combinations includes none of the three treatments, i.e., can be regarded as placebo control.~Adaptive: Due to the complex study design, a priori assumptions about the distribution and correlation of data could not be made reliably. Therefore, after 16 volunteers, the responsible bio-statistician will simulate how much more patients are necessary to detect the a priori defined effect size with the until then observed data"|t|t|f|t
33772303|NCT00743587|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33984901|NCT00062790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772304|NCT03159650|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34079977|NCT04600869|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study examined the effects of an oncofertility education program on decisional conflict in nurses caring for breast cancer patients and patients with breast cancer.||||
33772305|NCT05716321|||OTHER||PROSPECTIVE|||||||
33772306|NCT04435119|||COHORT||RETROSPECTIVE|||||||
33772307|NCT03816891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 2a (completed): 2 arms; Phase 2b (enrolling): 5 arms (4 arms during Double Blind Period and 1 arm during Open Label Extension)|t|t|t|t
33772308|NCT00425217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772309|NCT00345787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772310|NCT01356901|||COHORT||PROSPECTIVE|||||||
33772311|NCT00956280|||CASE_ONLY||PROSPECTIVE|||||||
33772312|NCT00821132|||FAMILY_BASED||OTHER|||||||
33772313|NCT04446910|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a hybrid 1 effectiveness-implementation design in which the investigators will test a theory-driven digital health (i.e., SMS text-messaging) treatment engagement intervention while also collecting data on the text messaging platform's potential implementation and adoption within juvenile justice and behavioral health settings.||||
33772314|NCT03789643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772315|NCT03354520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902011|NCT00227877|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||In this before-/after- quasi-experimental trial, all sites first completed a treatment-as-usual phase with assessments only, followed by all sites undergoing training and completing a subsequent intervention phase.||||
33902012|NCT02307305|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33902013|NCT06135818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort||||
33902014|NCT05878444|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Samples will be coded and they will not know the pacient personal/sociodemographic data.|We will try the probiotic in normal weight and overweight/obese people|f|f|f|t
33902015|NCT05161962|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33902016|NCT04904042|NA|SINGLE_GROUP||OTHER||NONE||||||
33902017|NCT05725148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902018|NCT04977999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized parallel two group design.||||
33902019|NCT01109706|||OTHER||PROSPECTIVE|||||||
33902020|NCT04565561|||COHORT||PROSPECTIVE|||||||
33902021|NCT05405543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902022|NCT05694078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902023|NCT01277224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902024|NCT05208983|||COHORT||PROSPECTIVE|||||||
33902025|NCT05458232|||COHORT||PROSPECTIVE|||||||
33902026|NCT04507308|NA|SINGLE_GROUP||TREATMENT||NONE|All participants are completing the same study procedure.|All participants are completing the same study procedure.||||
33902027|NCT04256746|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|"The coded and un-coded randomization schedule was generated by the bio-statistician of CRO.~The person involved in the preparation of the test product was not involved in any other activities related to the study."|Randomized, balanced incomplete block design dose response study of efficacy,|t|t|t|t
33902028|NCT05958303|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33902029|NCT04355117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984902|NCT02698982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33984903|NCT06314737|||COHORT||RETROSPECTIVE|||||||
33984904|NCT00164671|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33984905|NCT02134080|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984906|NCT01219322|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
33984907|NCT03447262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984908|NCT05813340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984909|NCT02845739|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984910|NCT02133105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984911|NCT04963491|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33984912|NCT03365115|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33984913|NCT01163591|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33984914|NCT00971256|||CASE_CONTROL||RETROSPECTIVE|||||||
33984915|NCT03004820|NA|SINGLE_GROUP||PREVENTION||NONE||Patients will receive remote ischemic conditioning||||
33984916|NCT01167530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984917|NCT03611374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984918|NCT04645615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984919|NCT01856205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33682030|NCT03848299|NA|SINGLE_GROUP||PREVENTION||NONE||"The objective is to investigate the post-meal glucose response variations between individuals in function of their individual factors such as their microbiome composition or their lifestyle.~All participants of the main cohort will have to follow a standardized diet during the first meal of the day from the second to the seventh day of the study participation.~All participants will follow the same diet, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies."||||
33682031|NCT00100334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33682032|NCT05169476|||COHORT||PROSPECTIVE|||||||
33682033|NCT03679442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682034|NCT01037621|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33682035|NCT01513200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33682036|NCT03616223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682037|NCT01038869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682038|NCT03207165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study participants, treating medical team and research team will be blinded to randomization; the pharmacy staff, CCU nurses and allied healthcare team members will not be blinded to the randomization.|Consecutive patients admitted to the Coronary Care Unit (CCU) at the Ottawa Heart Institute from start of study (tentatively set for August 2017 with anticipated end date of June 2020) and identified by the treating medical team as requiring initiation of inotrope therapy will be screened and randomized based on the healthcare team's clinical assessment of predominantly LV or RV systolic dysfunction (biventricular dysfunction will be assigned to predominantly LV dysfunction). All decisions to initiate inotrope therapy will be made by the primary care team with no involvement from the research team.|t|t|t|t
33682039|NCT03478436|RANDOMIZED|PARALLEL||OTHER||NONE||parallel groups to compare outcomes between fed and fasting conditions||||
33682040|NCT02402725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682041|NCT00019994||||TREATMENT||NONE||||||
33682042|NCT03105544|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33682043|NCT03751254|NA|SINGLE_GROUP||OTHER||NONE||||||
33682044|NCT05101200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682045|NCT03497598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682046|NCT02397018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079978|NCT04270461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682047|NCT02270853|NA|SINGLE_GROUP||SCREENING||NONE||||||
33682048|NCT03341780|||COHORT||PROSPECTIVE|||||||
34079979|NCT03556995|||COHORT||RETROSPECTIVE|||||||
33682049|NCT03657771|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, prospective, parallel||||
33682050|NCT03505398|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33682051|NCT00649597|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33682052|NCT03726385|||COHORT||PROSPECTIVE|||||||
33772316|NCT05754138|||COHORT||PROSPECTIVE|||||||
33772317|NCT03938948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772318|NCT05913375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772319|NCT00005973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772320|NCT03134378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized-double blinded Clinical Trials||t|t|t|t
33772321|NCT05886686|||COHORT||PROSPECTIVE|||||||
33772322|NCT01222611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902030|NCT06518863|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33902031|NCT06392789|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33772323|NCT04181541|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators propose a randomized, controlled, non-inferiority study comparing management of medical abortion by either nurse midwives or physicians for women undergoing induced abortion at a gestational ages \> 13 weeks.||||
33902032|NCT00623012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079980|NCT02911649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772324|NCT04205175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772325|NCT06526377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772326|NCT01993537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772327|NCT01718236|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33772328|NCT02397486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772329|NCT00002720|RANDOMIZED|||TREATMENT||||||||
33772330|NCT05172882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772331|NCT03786094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772332|NCT03450213|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33772333|NCT02550132|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902033|NCT04431999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Controlled, Randomized, Open Labe Therapeutic Trial||||
33902034|NCT03512223|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902035|NCT06671678|||CASE_ONLY||RETROSPECTIVE|||||||
33902036|NCT00002056||||TREATMENT||DOUBLE||||||
33902037|NCT04509700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902038|NCT04102839|||FAMILY_BASED||OTHER|||||||
33902039|NCT06512311|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33902040|NCT06488326|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33902041|NCT03216265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902042|NCT05218447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All clinical and study specific assessments will be completed by trained assessors blinded to group allocation. Clinical assessments will be completed by a physical therapist (e.g., WISCI-II, SCIM). Study specific assessments (e.g., FSS, actigraphy, TMS) will be conducted by study staff and investigator. Subjects will not be blinded to group allocation.|Subjects will be randomly assigned into one of 4 gait training groups: usual care (UC) gait training only; high frequency RGT - 4 sessions/week for 6 weeks; moderate frequency RGT - 3 sessions/week for 8 weeks; or low frequency RGT - 2 sessions/week for 12 weeks|f|t|t|t
34079981|NCT00511810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682053|NCT00337220|||COHORT||PROSPECTIVE|||||||
33682054|NCT04619160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The surgeon and participant are blinded for randomization. The anesthesiologist is unblinded.||t|t|f|f
33682055|NCT03786627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Physical therapist, investigator, and assessor will be blinded to the group assignment. This process will be handled by the research coordinator.|Subjects with impaired lumbopelvic control will be randomly assigned to either combined NMES with motor control training group, or motor control training alone group using randomly generated number in concealed envelopes.|f|t|t|t
33682056|NCT03642704|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective non-comparative study of mother-child pairs whose mother is HIV-infected and received less than 4 weeks of antiretroviral therapy before birth or whose HIV infection has been diagnosed at birth. Assess the operational efficacy of a strategy combining early diagnosis and preventive antiretroviral treatment systematically reinforced from the birth among infants at high risk of infection with HIV.||||
33682057|NCT05355493|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33682058|NCT00506532|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682059|NCT03127098|NA|SEQUENTIAL||TREATMENT||NONE||ETBX-011 immunization was administered by subcutaneous (SC) injection. ALT-803 will be administered by SC injection.||||
33682060|NCT00045942|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682061|NCT01801371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682062|NCT03190044|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Placebo and 'verum' pills have the similar shape and colour.||f|t|f|f
33682063|NCT06449937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682064|NCT04240795|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Tightly controlled cross-over study design with three arms.|t|f|f|f
33682065|NCT00854412|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682066|NCT00189410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682067|NCT03418103|||COHORT||PROSPECTIVE|||||||
33682068|NCT03231683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772334|NCT02870946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772335|NCT01254487|||COHORT||PROSPECTIVE|||||||
33772336|NCT02068534|||OTHER||RETROSPECTIVE|||||||
33772337|NCT02915341|||OTHER||OTHER|||||||
33772338|NCT02640599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772339|NCT04285437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772340|NCT01112605|||||CROSS_SECTIONAL|||||||
33772341|NCT02464111|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33772342|NCT02912156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772343|NCT05140187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772344|NCT03329313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|simple blind||t|f|f|f
33772345|NCT03952455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772346|NCT04515563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772347|NCT01154049|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33772348|NCT00519675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772349|NCT02167152|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33772350|NCT02953093|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33772351|NCT02392767|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33772352|NCT02908854|NA|SINGLE_GROUP||OTHER||NONE||||||
33772353|NCT01372358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772354|NCT00655551|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772355|NCT02637050|||COHORT||PROSPECTIVE|||||||
33772356|NCT06106841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772357|NCT05918315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772358|NCT01978275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33772359|NCT00505180|||DEFINED_POPULATION||PROSPECTIVE|||||||
33772360|NCT02698280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772361|NCT04724720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double-Blind Comparative Placebo Controlled Trial|t|t|t|f
33772362|NCT02726776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33772363|NCT00936494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772364|NCT05853874|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial with two parallel arms. The intervention group will receive a nutritional protocol and the control group will receive the standard of care||||
33772365|NCT03414788|NA|SINGLE_GROUP||OTHER||NONE||||||
33902043|NCT03902405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902044|NCT01882023|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33902045|NCT02138578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902046|NCT00707018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984920|NCT05187949|||OTHER||CROSS_SECTIONAL|||||||
33984921|NCT01980693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984922|NCT03600376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Ryanodex (dantrolene sodium) for injectable suspension plus Standard of Care|t|t|f|f
33984923|NCT03723395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682069|NCT00108875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682070|NCT04514783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682071|NCT00003001||||TREATMENT||||||||
33682072|NCT03174002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682073|NCT02168387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682074|NCT02769897|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33682075|NCT02914028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33682076|NCT05045937|||COHORT||PROSPECTIVE|||||||
33682077|NCT00329901|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33682078|NCT02229656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772366|NCT03868293|NA|SINGLE_GROUP||OTHER||NONE||||||
33772367|NCT00374972|||||PROSPECTIVE|||||||
33772368|NCT02314221|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772369|NCT00781742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984924|NCT03085576|||COHORT||PROSPECTIVE|||||||
33984925|NCT01918397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33984926|NCT03469505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984927|NCT01886326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33984928|NCT04554134|||COHORT||RETROSPECTIVE|||||||
33682079|NCT05917431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682080|NCT06272175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682081|NCT01802918|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33682082|NCT00732901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33682083|NCT05184010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33682084|NCT05024643|||COHORT||RETROSPECTIVE|||||||
33682085|NCT02310009|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33682086|NCT01273311|||||PROSPECTIVE|||||||
33772370|NCT04213989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligible patients will be randomized to conservative care or Flexitouch Plus and conservative care at Screening. Subjects have up to 60 days to acquire treatment through commercial means and commence treatment. Follow-up will take place 3-4 weeks after treatment commences.||||
33772371|NCT05828225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772372|NCT01622101|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33902047|NCT04397133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the assessor who will investigate the results and the investigator who will perform the MIP and 6-minutes walking test will be blinded to the randomization|three armed study with two interventions and one control group intervention group 1: inspiratory muscle training applied for 4 week intervention group 2: inspiratory muscle training applied for 8 week control group : will get sham intervention|f|f|t|t
33902048|NCT06672497|||COHORT||PROSPECTIVE|||||||
33902049|NCT01623778|||COHORT||PROSPECTIVE|||||||
33902050|NCT01947673|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33902051|NCT04709276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682087|NCT05219071|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682088|NCT00000931||PARALLEL||PREVENTION||||||||
33682089|NCT03518476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33902052|NCT03761953|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a pilot single-arm study consisting of 15 patients evaluating the use of oritavancin in the final consolidation phase (last two weeks of treatment) of systemic infections with Staphylococcus aureus (S. aureus) in opioid users.||||
33902053|NCT00770185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902054|NCT01221298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902055|NCT04660903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902056|NCT03546478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902057|NCT00000530|RANDOMIZED|||TREATMENT||||||||
33984929|NCT03161405|NA|SINGLE_GROUP||OTHER||NONE||||||
33984930|NCT01273805|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||There were 2 arms in this study because the study was amended to evaluate a second cohort of patients treated at a higher dose using the same two-stage statistical design.||||
33984931|NCT00721305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682090|NCT02650921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682091|NCT04571528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Single-blind, parallel-group, randomized controlled trial|f|f|t|t
33984932|NCT03743753|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The plastic surgeon will be blinded to participant's group allocation. The data analyst will also be blinded. They will be presented the data without group identification (i.e., Group A and Group B).||f|t|f|t
33984933|NCT04915534|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Patients are allocated to the cuff pressure groups via block randomization|prospective, randomized, controlled, single-blinded|t|f|f|f
33984934|NCT01514617|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33984935|NCT04414072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||surgeries|t|f|f|f
33984936|NCT04166552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (intracohort)|This is a dose escalation double-blind intracohort trial starting with Cohorts 1 and 2 commencing in parallel and then Cohorts 3 and 4 commencing in parallel|t|f|t|f
33984937|NCT02414152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984938|NCT00000697||PARALLEL||TREATMENT||||||||
33984939|NCT03895957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984940|NCT00385125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984941|NCT01310647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984942|NCT00563966|||FAMILY_BASED||PROSPECTIVE|||||||
33984943|NCT01448057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33984944|NCT01300494|||CASE_ONLY||PROSPECTIVE|||||||
33984945|NCT05029297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients will receive one of the two interventions (CAPSAICIN topical solution and cream) during the initial phase of the study of 8 weeks and receive the other intervention during the second phase of the study of 8 weeks. Both phases will be separated in a 4 week washout period.||||
33984946|NCT01061866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984947|NCT00004907||||TREATMENT||NONE||||||
33984948|NCT04811183|||COHORT||PROSPECTIVE|||||||
33984949|NCT01734265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984950|NCT02937701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33984951|NCT03009669|||CASE_ONLY||PROSPECTIVE|||||||
33984952|NCT03872947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984953|NCT05565664|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33984954|NCT00763763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984955|NCT02495545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682092|NCT03886545|||COHORT||PROSPECTIVE|||||||
33682093|NCT04308031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984956|NCT05644340|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33682094|NCT00839033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682095|NCT01165762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682096|NCT02788162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682097|NCT04992858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682098|NCT03062254|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682099|NCT03843346|||COHORT||PROSPECTIVE|||||||
33682100|NCT03753581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Masking of the researchers: the assignment of participants to the groups will be carried out by a researcher who will not apply the interventions and will not collect the outcome variables. The interventions will be carried out by researchers different from those who will perform the evaluations of the outcome variables.~Masking of the participants: it will be done using the same electrodes and microcurrent devices in both groups. In the placebo stimulation, the device will emit a luminous signal of operation as well as the devices of the intervention group, however, it will be manipulated and tested with an oscilloscope to ensure that it does not emit microcurrents. The participants of both groups will not perceive any sensation of current, since the electrical stimulation with microcurrents is below the sensitive threshold."||t|t|f|t
33682101|NCT04620798|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Because we are attempting to assess the impact of having knowledge about a participants' antibody test result on their engagement in protective behaviors to avoid SARS-CoV-2 infections, the intervention information will be masked from the participant and the investigators.|Participants will be randomized to receive their antibody test results either within a day of the test or after a four-week waiting period in order to assess whether receiving the results of an antibody test changes protective behavior to avoid SARS-CoV-2 infections.|t|f|t|f
33682102|NCT03215433|||COHORT||PROSPECTIVE|||||||
33682103|NCT00948584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682104|NCT00322621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682105|NCT02278536|||COHORT||PROSPECTIVE|||||||
33682106|NCT06235255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682107|NCT04087330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682108|NCT04612101|||COHORT||PROSPECTIVE|||||||
33984957|NCT04000464|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and Post study model||||
33984958|NCT02950207|||COHORT||PROSPECTIVE|||||||
33984959|NCT02157636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984960|NCT05728385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984961|NCT00148772|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33984962|NCT01545830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33984963|NCT03495622|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster Randomized Controlled Trial||||
33984964|NCT05311501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33984965|NCT00189956|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33984966|NCT02057705|||COHORT||PROSPECTIVE|||||||
33984967|NCT05331066|||OTHER||PROSPECTIVE|||||||
33984968|NCT04715477|||CASE_CONTROL||PROSPECTIVE|||||||
33984969|NCT05397028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984970|NCT06455579|NA|SINGLE_GROUP||OTHER||NONE||||||
33984971|NCT01623726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33984972|NCT00985257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33984973|NCT06080321|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33984974|NCT02597101|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33984975|NCT03596372|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33984976|NCT03762564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984977|NCT00485771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33984978|NCT04901377|||COHORT||PROSPECTIVE|||||||
33984979|NCT04681703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33984980|NCT05633485|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33984981|NCT00759447|||CASE_CONTROL||PROSPECTIVE|||||||
33984982|NCT01666470|||COHORT||CROSS_SECTIONAL|||||||
33984983|NCT04997122|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Oils were provided in unlabelled bottles (only differed in the colors of stoppers)|"After a 3-week run-in, healthy and at risk (hypercholesterolemic) volunteers were randomly allocated to one of each arm.~Eas intervention stage lasted 4 weeks and was separated fy a 3-week wash-out."|t|f|f|f
33984984|NCT00881322|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33984985|NCT03288883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33984986|NCT03601637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33984987|NCT04566848|||CASE_CONTROL||PROSPECTIVE|||||||
33984988|NCT05343078|NA|SEQUENTIAL||TREATMENT||NONE||In the single-dose protocol, hemodialysis participants will take the experimental drug immediately prior to the dialysis session. In the multiple-dose protocol, volunteers will take the drug daily in the morning for one week.||||
33984989|NCT01987011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33984990|NCT01556308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33984991|NCT05074030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33984992|NCT00194753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984993|NCT01109862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33984994|NCT05225597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were unaware of the group in which they were assigned. The person evaluating the results did not know which result belonged to which group.|This study consisted of three groups: epinephrine group, carbachol group, and control group.|t|f|f|t
33682109|NCT00482339|||||OTHER|||||||
33682110|NCT01976039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682111|NCT03593473|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Participants will receive a nasal insufflation bottle of oxytocin intranasal spray or placebo intranasal spray manufactured to mimic oxytocin nasal spray.|Non-pregnant women will be randomized to either 24 IU of nasal OT or placebo. The Investigational Drug Service will use a random number generator to prepare a randomization table.|t|t|t|t
33682112|NCT01809470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33682113|NCT00158132|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33682114|NCT03848871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682115|NCT02658591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33682116|NCT04541277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682117|NCT02975362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682118|NCT02014870|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33682119|NCT02104037|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682120|NCT02328053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682121|NCT01546272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682122|NCT00423787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682123|NCT00830778|RANDOMIZED|||TREATMENT||||||||
33682124|NCT05810077|||CASE_ONLY||CROSS_SECTIONAL|||||||
33682125|NCT02012868|||COHORT||PROSPECTIVE|||||||
33682126|NCT03516474|||CASE_CONTROL||PROSPECTIVE|||||||
33682127|NCT00770146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682128|NCT00708084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682129|NCT02523469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682130|NCT04395950|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33682131|NCT05014061|RANDOMIZED|PARALLEL||OTHER||NONE||Single center, open-label, randomized controlled trial||||
33772373|NCT04024787|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized controlled trial. Participants with chronic insomnia are randomized to either immediate cognitive-behavioural therapy or a 3-month wait-list period using a 1:1 allocation ratio. Randomization is conducted with block sizes of 4 participants. Randomization results are contained in sealed opaque envelopes that are opened in the presence of the participants after the completion of the pre-treatment assessment. A second assessment will be conducted after the treatment or waiting period. A follow-up assessment is conducted 12 months after the completion of the post-treatment assessment. A group of good sleepers, matched on age and gender with the insomniacs, will also be recruited and assessed at baseline only to provide a normative reference group.||||
33772374|NCT02810691|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33772375|NCT00124774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772376|NCT00077350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772377|NCT00507741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772378|NCT06247670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772379|NCT00259818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772380|NCT01933347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772381|NCT05721573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
33772382|NCT00287248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772383|NCT00736073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772384|NCT05955456|||COHORT||PROSPECTIVE|||||||
33772385|NCT06359600|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33772386|NCT01620736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772387|NCT02984956|||COHORT||PROSPECTIVE|||||||
33772388|NCT02384005|NA|SINGLE_GROUP||SCREENING||NONE||||||
33772389|NCT03108287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772390|NCT04430296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772391|NCT03069820|NA|SINGLE_GROUP||SCREENING||NONE||||||
33772392|NCT04768933|NA|SINGLE_GROUP||OTHER||NONE||||||
33772393|NCT05980429|RANDOMIZED|PARALLEL||OTHER||NONE||Participants were enrolled from the surgery staff at a quaternary care hospital after signing informed consent and were randomized using block randomization (1:1:1) to one of 3 groups: (1) 30 minutes of prescribed musical intervention at bedtime (PM), (2) 30 minutes of self-selected music listening at bedtime (PS), or (3) unaltered, normal bedtime routine, as a control (C).||||
33682132|NCT00263861|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33682133|NCT00672659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682134|NCT00588159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682135|NCT01128023|||COHORT||PROSPECTIVE|||||||
33682136|NCT04081259|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682137|NCT01406405|||CASE_CONTROL||PROSPECTIVE|||||||
33682138|NCT03719534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682139|NCT02880085|||CASE_CROSSOVER||PROSPECTIVE|||||||
33682140|NCT03493932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682141|NCT06306872|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be randomly assigned 1:1 to arms A (Sequence A) or arms B (Sequence B) to receive a single dose of ABSK-011 orally in two separate doses, spaced at least 4 days apart. Among them, subjects in sequence A will be given ABSK-011 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) and ABSK-011 200 mg (100 mg capsule \*2) on an empty stomach in the morning of the first day of cycle 1 (C1D1) and the first day of cycle 2 (C2D1), respectively. Subjects in sequence B will be given ABSK-011 new formulation 200 mg (100 mg capsule \*2) and ABSK-011 old formulation 220 mg (100 mg capsule \*2 and 20 mg capsule \*1) on an empty stomach in the morning of Cycle 1 day (C1D1) and cycle 2 day (C2D1), respectively.||||
33682142|NCT00272714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682143|NCT06436664|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33682144|NCT03706924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33682145|NCT04083729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|percutaneous mitral commissurotomy|predictors of Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy|t|f|f|f
33682146|NCT03769584|||COHORT||RETROSPECTIVE|||||||
33682147|NCT05721807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682148|NCT04371874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682149|NCT02226744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772394|NCT05406037|||CASE_CONTROL||PROSPECTIVE|||||||
33772395|NCT03172741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind placebo controlled||t|f|t|t
33772396|NCT00079794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772397|NCT06195124|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772398|NCT05437042|||CASE_ONLY||RETROSPECTIVE|||||||
33772399|NCT04308538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772400|NCT01603420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772401|NCT05506267|||CASE_ONLY||PROSPECTIVE|||||||
33772402|NCT03680040|||COHORT||PROSPECTIVE|||||||
33902058|NCT03778255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The procedure is listed as follows:~1. Recruiting endometrial cancer patients undergoing hysterectomy with or without bilateral adnexectomy, pelvic and para-aortic lymph node resection from July 2018 to June 2020.~2. Selecting the Standard-compliant patients according to the inclusion and exclusion criteria and letting them sign an informed consent form.~3. Numbering the above patients and collecting their clinical data.~4. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~5. Identifying and removing sentinel lymph nodes.~6. Completing the hysterectomy with or without bilateral adnexectomy, pelvic and para-aortic lymph node resection~7. Staining all nodes using hematoxylin-eosin staining.~8. Calculating the sensitivity, negative predictive value, etc."||||
33772403|NCT02166918|||||CROSS_SECTIONAL|||||||
33772404|NCT03300375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Permuted block randomization with block sizes of four will made by means of a computer algorithm to ensure balanced group sizes and allocation concealment.|Two group, parallel study|t|f|f|f
33772405|NCT00000611|RANDOMIZED|||PREVENTION||||||||
33772406|NCT06270420|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Longitudinal Pilot study||||
33772407|NCT06545396|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33772408|NCT01711138|||CASE_CONTROL||PROSPECTIVE|||||||
33772409|NCT01450787|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33772410|NCT01095705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33902059|NCT06673225|||COHORT||PROSPECTIVE|||||||
33984995|NCT02324725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33984996|NCT03295474|||COHORT||PROSPECTIVE|||||||
33984997|NCT02336854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772411|NCT05293288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33772412|NCT01214551|||OTHER||PROSPECTIVE|||||||
33902060|NCT05811572|||OTHER||CROSS_SECTIONAL|||||||
33902061|NCT05509894|||COHORT||PROSPECTIVE|||||||
33902062|NCT04275310|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33902063|NCT06671522|||OTHER||PROSPECTIVE|||||||
33902064|NCT04222725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902065|NCT05634512|||CASE_ONLY||PROSPECTIVE|||||||
33902066|NCT02255591|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33984998|NCT02403791|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33984999|NCT04125576|||COHORT||PROSPECTIVE|||||||
33985000|NCT05854602|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|"Participants and researchers will be blinded to condition at enrolment and baseline assessment.~Randomization takes place after baseline assessment (T0), by drawing a number (1-34, corresponding to condition 1-34) from a sealed envelope, by a researcher who has no contact with any of the study participants.~Care providers cannot be blinded to participants' condition. At T2/4/6/12, Participants will be blinded to the conditions that exist in the study, but are aware of whether they received one or more intervention components.~Independent researchers and clinicians blinded to participants' condition and timepoint (T0/6/12) will code video recordings of the parent-child interaction task and parental stories about children's anxiety."|A Factorial Experiment with 34 conditions|t|f|f|f
33985001|NCT03611894|||CASE_ONLY||RETROSPECTIVE|||||||
33985002|NCT01889498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079982|NCT06410664|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the nature of the intervention, nurses can't be blinded to allocation (the frequency of HME exchange), but are strongly inculcated not to disclose the allocation status of the participant at the follow-up assessments. As the ICU is paperless and fully computerised, the data in the computer can be acquired and analysed by the researchers without having access to information about the allocation.|Eligible patients will be recruited in the medical-surgical ICU at Královské Vinohrady University Hospital (FNKV), managed under an intensivist-led closed ICU, with a 1:1 nurse-to-patient ratio and randomised in equal proportions between HME filter exchange every 72 hours versus daily HME filter exchange arm.|f|f|t|t
34079983|NCT02728232|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34079984|NCT03499808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079985|NCT00710931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34079986|NCT01734447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34079987|NCT04500444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34079988|NCT04482049|||CASE_ONLY||PROSPECTIVE|||||||
34079989|NCT04406467|||CASE_ONLY||RETROSPECTIVE|||||||
34079990|NCT04579978|||COHORT||PROSPECTIVE|||||||
34079991|NCT02499107|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33772413|NCT03741205|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Participating physicians will recruit patients meeting the inclusion and exclusion criteria. Upon completion of screening and enrollment procedures study participants will be randomly assigned to one of two groups using a randomized call-in system: treatment or standard of care.~Demographics will be obtained for both groups during this initial clinic visit. The treatment group will be prescribed the Brain Sentinel® SPEAC System for use in the home environment. Study Participants in the standard of care group will be given standard care."||||
34079992|NCT03167242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772414|NCT01551251|||COHORT||RETROSPECTIVE|||||||
33772415|NCT02247414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772416|NCT06112613|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34079993|NCT00743756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34079994|NCT04472221|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental||||
34079995|NCT03444844|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34079996|NCT00596219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34079997|NCT00173966|||DEFINED_POPULATION||OTHER|||||||
34079998|NCT02964130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34079999|NCT03994913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772417|NCT04672512|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33772418|NCT01815814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772419|NCT00955006|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33772420|NCT02777502|||CASE_ONLY||PROSPECTIVE|||||||
33772421|NCT01369056|RANDOMIZED|PARALLEL||||NONE||||||
33772422|NCT01652820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772423|NCT03227484|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33772424|NCT01130883|||||PROSPECTIVE|||||||
33772425|NCT06197243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772426|NCT01997320|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33772427|NCT01448044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772428|NCT03864289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772429|NCT02899546|||COHORT||PROSPECTIVE|||||||
33772430|NCT03546361|NA|SEQUENTIAL||TREATMENT||NONE||||||
33772431|NCT00321334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772432|NCT00967018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772433|NCT03653416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772434|NCT02218489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772435|NCT03529422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772436|NCT00118144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772437|NCT04241575|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33902067|NCT00163722|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902068|NCT00703807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902069|NCT00722345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902070|NCT02917486|||CASE_CONTROL||PROSPECTIVE|||||||
33902071|NCT01511146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902072|NCT04859803|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|double||t|t|f|f
34080000|NCT04348526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080001|NCT02248324|||CASE_CONTROL||PROSPECTIVE|||||||
34080002|NCT01656044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080003|NCT02592447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080004|NCT02661230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902073|NCT01719081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902074|NCT06395142|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080005|NCT05724303|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33772438|NCT01649596|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label.|||||
33772439|NCT01060020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772440|NCT04555915|||CASE_CONTROL||PROSPECTIVE|||||||
33772441|NCT02805361|||COHORT||PROSPECTIVE|||||||
33772442|NCT04443439|||CASE_CONTROL||PROSPECTIVE|||||||
33902075|NCT06242340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080006|NCT00146562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772443|NCT01225835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772444|NCT00199030|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arms; Allocation by stratification||||
33772445|NCT01574547|||CASE_CONTROL||PROSPECTIVE|||||||
33772446|NCT02653014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772447|NCT02605161|||CASE_CONTROL||PROSPECTIVE|||||||
33772448|NCT00747058|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33772449|NCT03896451|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33772450|NCT02342184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772451|NCT01402258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772452|NCT00002793|RANDOMIZED|||TREATMENT||||||||
33772453|NCT06078930|||CASE_CONTROL||PROSPECTIVE|||||||
33772454|NCT06381362|||COHORT||PROSPECTIVE|||||||
33985003|NCT03928886|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE||Each subject will undergo her regularly scheduled full-field digital mammography imaging exam per standard practices at the investigational site. Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam. Both the laterality (right/left breast) to which compression modes are assigned and the mode of compression to start with will be randomized across all subjects. Hence, approximately one quarter of women will use patient-assisted compression as first option on the right breast, another quarter will use patient-assisted compression as first option on the left breast, a third quarter will use standard compression as first option on the right breast and the last quarter will use standard compression as first option on the left breast. The randomization schedule will be generated by Epidemiology and Evaluation Department of the Hospital and provided to the study staff prior to start of enrollment.|f|f|t|t
33772455|NCT05385328|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33985004|NCT04535843|||COHORT||PROSPECTIVE|||||||
33985005|NCT02357732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985006|NCT00940810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985007|NCT02275637|||COHORT||PROSPECTIVE|||||||
33985008|NCT02148484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985009|NCT00318812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772456|NCT01542541|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985010|NCT01916317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985011|NCT01140581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985012|NCT00191763|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985013|NCT00377416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985014|NCT02877147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985015|NCT03521856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985016|NCT01054027|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33985017|NCT01029340|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985018|NCT03024918|||COHORT||PROSPECTIVE|||||||
33985019|NCT02238678|||COHORT||PROSPECTIVE|||||||
33985020|NCT05757765|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985021|NCT04859920|||COHORT||PROSPECTIVE|||||||
33985022|NCT06132074|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985023|NCT00576056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985024|NCT03063814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985025|NCT00553228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985026|NCT03851965|||COHORT||PROSPECTIVE|||||||
33985027|NCT00698230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985028|NCT05934071|||COHORT||OTHER|||||||
33985029|NCT05946460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080007|NCT03391102|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34080008|NCT05619731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two arms||||
34080009|NCT01015326|||COHORT||PROSPECTIVE|||||||
33985030|NCT05087524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985031|NCT00218530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33985032|NCT04605094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080010|NCT05700734|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34080011|NCT01251042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080012|NCT01447407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985033|NCT01054898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33985034|NCT04109417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080013|NCT03321721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients are randomized after informed consent evaluation of cosmetic outcome at 4m is blinded to researchers|randomized, parallel group, comparative study|f|f|f|t
33985035|NCT01185548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985036|NCT04937101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985037|NCT05076305|||COHORT||PROSPECTIVE|||||||
33985038|NCT01423006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985039|NCT03475030|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985040|NCT03447860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34080014|NCT01687114|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080015|NCT05259488|||CASE_CONTROL||RETROSPECTIVE|||||||
34080016|NCT00004547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080017|NCT04752254|||CASE_ONLY||RETROSPECTIVE|||||||
34080018|NCT05469126|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33772457|NCT01761786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772458|NCT01235975|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772459|NCT01618396|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33772460|NCT02100540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772461|NCT00431002|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33772462|NCT00488215|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33772463|NCT02311322|||COHORT||PROSPECTIVE|||||||
33772464|NCT03786484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772465|NCT01287793|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33985041|NCT06075173|||COHORT||PROSPECTIVE|||||||
33985042|NCT06396026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Drug: TLL-018 Drug: Placebo|t|t|t|f
34080019|NCT03212001|||OTHER||OTHER|||||||
33772466|NCT01471158|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33985043|NCT00351676|NON_RANDOMIZED|PARALLEL||||NONE||||||
33985044|NCT01684241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080020|NCT01039467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080021|NCT04794920|||COHORT||PROSPECTIVE|||||||
34080022|NCT00230243|||||RETROSPECTIVE|||||||
34080023|NCT00899834|||CASE_ONLY||PROSPECTIVE|||||||
34080024|NCT00782197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080025|NCT02397616|||COHORT||RETROSPECTIVE|||||||
34080026|NCT04566068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080027|NCT03991390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080028|NCT00955500|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34080029|NCT01619852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34080030|NCT04126304|||COHORT||PROSPECTIVE|||||||
33902076|NCT04151563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985045|NCT03985865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33985046|NCT02063841|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33985047|NCT02770820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985048|NCT04383431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985049|NCT03552250|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33902077|NCT04925544|NA|SINGLE_GROUP||TREATMENT||NONE||"Two stage phase 2 single arm trial with three strata:~1. EBV related NPC subjects receiving VK 2019~2. EBV related lymphoma subjects receiving VK 2019~3. EBV related PTLD subjects receiving VK 2019"||||
34080031|NCT06238427|||COHORT||PROSPECTIVE|||||||
34080032|NCT02427841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080033|NCT00421278|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080034|NCT00026247|NA|SINGLE_GROUP||TREATMENT||NONE||The outcomes of the study will be adverse event analysis and pain relief.||||
34080035|NCT00742794|||COHORT||RETROSPECTIVE|||||||
33902078|NCT01187212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902079|NCT00001269||||TREATMENT||||||||
33902080|NCT00658970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080036|NCT05623410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080037|NCT04488913|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Stepped-Wedge Cluster Randomized|f|f|f|t
34080038|NCT06115174|RANDOMIZED|PARALLEL||OTHER||NONE||"The design of this study is a randomized, controlled parallel clinical trial which will be conducted on 44 patients with metastatic colorectal cancer. The duration of the study will be one year to determine progression free survival (PFS) and the overall survival (OS). Patients will be recruited from Medical Oncology Department, Oncology Centre, Mansoura University, Mansoura, Egypt. The patients will be randomized using sealed envelope method into the following two groups:~Group I (Control group; n=22) which will receive FOLFOX (leucovorin, fluorouracil, oxaliplatin) or XELOX (oxaliplatin + capecitabine) ± target therapy (Bevacizumab).~Group II: (Pentoxiphylline group; n=22) which will receive the same FOLFOX or XELOX regimen ± target therapy (Bevacizumab) in addition to Pentoxiphylline 400 mg twice daily."||||
34080039|NCT03625726|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||Exploratory, cross-sectional, case-control pathophysiology study, based on ex vivo treatment of blood samples.||||
34080040|NCT02959502|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34080041|NCT00430846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080042|NCT00447772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080043|NCT00065299|NON_RANDOMIZED|||TREATMENT||NONE||||||
34080044|NCT04309032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34080045|NCT05848037|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms with patients randomised into treatment arm (cymactive device) and routine standard of care arm (foley-type device).||||
34080046|NCT06109012|||CASE_ONLY||PROSPECTIVE|||||||
34080047|NCT03175497|NA|SINGLE_GROUP||TREATMENT||NONE||This study is comprised of two stages. The 1st stage will follow the traditional 3+3 dose-escalation design in patients with advanced solid tumor The 2nd phase will be conduced in Gastric cancer patients, primarily for PK data collection||||
34080048|NCT04083560|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080049|NCT05541939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080050|NCT06437925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34080051|NCT02016443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080052|NCT02250339|||COHORT||PROSPECTIVE|||||||
34080053|NCT02925858|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080054|NCT02594319|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33902081|NCT03321617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Identity of medications will be blinded having every subject take an equal number of pills (using identical looking tables of placebo)|Double-blind, randomized, phase 1b, multiple dose trial|t|f|t|t
33985050|NCT03929822|||COHORT||PROSPECTIVE|||||||
33985051|NCT04386759|||COHORT||OTHER|||||||
33985052|NCT01934478|||CASE_ONLY||PROSPECTIVE|||||||
33985053|NCT02479893|||CASE_CONTROL||PROSPECTIVE|||||||
33985054|NCT00718926|||CASE_CONTROL|||||||||
33985055|NCT00307697|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33985056|NCT01060618|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080055|NCT01837836|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080056|NCT03257436|NA|SINGLE_GROUP||OTHER||NONE||||||
34080057|NCT01365130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772467|NCT02120989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772468|NCT04091906|NA|SINGLE_GROUP||OTHER||NONE||||||
33772469|NCT02404493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33772470|NCT02951299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772471|NCT01224808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772472|NCT01832415|||COHORT||PROSPECTIVE|||||||
33772473|NCT05743192|||OTHER||RETROSPECTIVE|||||||
33772474|NCT01914029|||CASE_ONLY||PROSPECTIVE|||||||
33772475|NCT00859131|RANDOMIZED|PARALLEL||||NONE||||||
33772476|NCT03403257|||COHORT||PROSPECTIVE|||||||
33772477|NCT01958762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33772478|NCT06424379|||COHORT||RETROSPECTIVE|||||||
33772479|NCT04198532|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772480|NCT03584893|||COHORT||OTHER|||||||
33772481|NCT04001140|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33772482|NCT04507360|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||TRIPLE||The investigators will conduct focus groups applying user-centered design strategies to identify and co-build potentially effective engagement strategies for particular client subtypes. The investigators anticipate enrolling 10,000 Mental Health America consumers in Study 1 (the sequential multiple assignment randomized trial; SMART), with a subset of 250 participating in Study 2, a randomized controlled trial of an Artificial Intelligence (AI)-assisted self-help tool compared to a non-AI self help tool and to psychoeducational materials only control group.|t|t|f|t
33772483|NCT04250961|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All results (wound culture and photographs) were sent to an Infection Control Committee who was masked as to the patient grouping for evaluation.|A Prospective, Randomized Controlled Trial|t|f|f|f
33772484|NCT00422799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772485|NCT01915199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772486|NCT03589729|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772487|NCT01914978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772488|NCT03126305|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33772489|NCT06443203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled clinical trial|f|t|f|f
33772490|NCT05244590|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772491|NCT05332951|||COHORT||PROSPECTIVE|||||||
33772492|NCT06118775|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, pragmatic, parallel-group, controlled clinical trial will be conducted with two patient groups. Our hypothesis is that using EaDyn as a hemodynamic tool to guide vasopressor weaning can reduce the duration of vasopressor support. Patients meeting the inclusion criteria will be randomly assigned to one of the two groups using computer-generated random numbers in a 1:1 ratio. In the first group, termed 'EaDyn weaning arm' (EaDyn), dynamic arterial elastance will be used as a tool for vasopressor weaning. In the second group, named 'PAM weaning arm,' mean arterial pressure will be used as the tool for vasopressor weaning. Due to the study's methodological characteristics, blinding of participants and investigators regarding group assignment will not be possible. Lastly, the study will be conducted on an intention-to-treat basis.||||
33772493|NCT06740799|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking,|||||
33772494|NCT05752643|RANDOMIZED|PARALLEL||SCREENING||NONE|Due to the nature of the intervention, participants will know to which arm they have been allocated. So, it would not be possible to blind either the participants or healthcare professionals|Non-blinded randomized controlled non-inferiority trial||||
33772495|NCT01449721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772496|NCT01438671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772497|NCT04041180|||OTHER||PROSPECTIVE|||||||
33772498|NCT02635087|||COHORT||PROSPECTIVE|||||||
33772499|NCT05929365|||COHORT||PROSPECTIVE|||||||
33772500|NCT00675324|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33772501|NCT05086822|NA|SINGLE_GROUP||TREATMENT||NONE||A dose-escalation（3+3 design） and expansion study||||
33772502|NCT05515718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772503|NCT04447820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772504|NCT05545969|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentre, open label, clinical trial||||
33772505|NCT03186326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772506|NCT03922828|||COHORT||PROSPECTIVE|||||||
33772507|NCT00794625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772508|NCT04485676|||OTHER||RETROSPECTIVE|||||||
33772509|NCT04814875|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772510|NCT03990714|RANDOMIZED|PARALLEL||TREATMENT||NONE||The IVEA-study is a prospective multicenter randomized trial with two parallel groups being done IA or EA in laparoscopic right hemicolectomy for right colon neoplasia.||||
33772511|NCT01751113|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33772512|NCT05985993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33772513|NCT04625478|||COHORT||RETROSPECTIVE|||||||
33772514|NCT00152490|RANDOMIZED|PARALLEL||||DOUBLE||||||
33772515|NCT03737513|||CASE_ONLY||RETROSPECTIVE|||||||
33772516|NCT01896115|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33772517|NCT01394250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772518|NCT03947359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Healthy volunteers||||
33772519|NCT00560131|||CASE_CONTROL||PROSPECTIVE|||||||
33772520|NCT04815486|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The clinical trial will follow an AB/BA crossover design with a counterbalanced assignment, in which the first 50% of the sample will be assigned to order AB and the second 50% to order BA. The washout period between therapies A and B will be always a month.||||
33772521|NCT05466903|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33772522|NCT00767104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772523|NCT06184360|||COHORT||RETROSPECTIVE|||||||
33772524|NCT04977947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Families will be assigned to either the treatment or control condition (standard care).|f|f|f|t
33902082|NCT03085810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902083|NCT06362408|||COHORT||PROSPECTIVE|||||||
33902084|NCT04806568|RANDOMIZED|PARALLEL||OTHER||SINGLE||Patients will wear a smartwatch and will be randomly assigned to either the cognitive intervention, or the active control group, stratified by age, sex, education and cognition.|f|f|f|t
33985057|NCT04786080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is not possible to blind parents enrolled in the study and Qualtrics will automatically inform parents of their group allocation. Blinded members of the research team and the senior statistician will not be given access to the Qualtrics system or the data in order to remain blinded until after the analysis is complete. We do not anticipate any serious harms associated with taking part in the intervention, therefore there will be no need to unblind any blinded staff during the study. The junior statistician will be unblinded throughout.|SPARKLE is a two-arm superiority parallel group randomised controlled trial (RCT) embedded in an existing large self-selected community cohort - Co-SPACE. Co-SPACE parents aged ≥18, who have children aged 4-10 years, will be invited to take part in the SPARKLE trial. Those who consent to SPARKLE will be randomised 1:1 to either Parent Positive or FAU. Outcome measures will be collected according to the Co-SPACE schedule at baseline (T1), which will be the Co-SPACE survey data obtained immediately prior to randomisation, and then at one month (T2) and two months (T3) post-randomisation.|f|f|t|t
33985058|NCT02209922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985059|NCT02196675|||COHORT||PROSPECTIVE|||||||
34080058|NCT03588130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding of subjects, study team on sites (e.g. investigators, study nurses etc.) and sponsor team to the assigned treatment will be employed between EX-02 arm and Gel Vehicle arm. Since the NSSOC appearance and dosing regimen are different from that of IMP (EX-02 or Gel vehicle), treatment with NSSOC arm can not be masked to study team or sponsor.||t|t|t|t
34080059|NCT03765606|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double-blinded|Randomised double-blinded crossover|t|f|t|t
34080060|NCT05865912|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34080061|NCT03416348|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|For Aim 1 there will be no masking. Aim 2, recruitment methods will be by convenience sampling. Subjects in Aim 1 reporting an HDSS of 2 or greater and additional subjects as needed from the U of U or VA clinics with HDSS of 2 or greater will be invited to participate in this crossover study. Subjects will be randomized equally to two sequence arms by a random number generator. The first arm will receive in sequential order every 3 weeks: Aluminum Chloride, a placebo of ethyl alcohol base, Aluminum Chloride, and placebo. The second arm will receive in sequential order every 3 weeks: placebo, Aluminum Chloride, placebo, and Aluminum Chloride. Each condition will last for 3 weeks, which will allow enough time for the Aluminum Chloride and placebo to demonstrate their respective effects. The first week of each period will also serve as a sufficient washout for the previous period. The total trial length, then, will be 12 weeks.|For the two aims of the study, subjects will be recruited from the amputee clinics held at the Salt Lake VA Medical Center or the University of Utah. Combined, these clinics serve approximately 500 patients and see approximately 75 new patients each year. Based on the investigators work, which showed 66% of patients with HDSS scores of 2 or greater, we will have a potential pool of up to 330 eligible patients for the studies that follow. We expect to enroll approximate equal numbers from both sites for each of the aims of this study.|t|f|t|f
34080062|NCT02347046|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080063|NCT05387876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators and outcomes assessors are masked to intervention group assignments using a researcher outside the study that maintains the study codes and IDs|Double blind placebo controlled randomized intervention of vitamin supplementation|t|f|t|t
34080064|NCT01087164|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34080065|NCT02483884|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902085|NCT02446652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902086|NCT04449432|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Comparing intervention to active control|t|t|t|t
33902087|NCT05582577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902088|NCT00173576|||||OTHER|||||||
33902089|NCT03238248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985060|NCT01409278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985061|NCT03586726|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33985062|NCT01886261|||COHORT||PROSPECTIVE|||||||
33902090|NCT04359446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985063|NCT04564482|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682150|NCT04253886|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Randomization will be done using computer generated number and concealed using sequentially numbered, sealed opaque envelope.|"Either the Fekry Oral Airway Intubator (Ameco Tech, Cairo, Egypt) or the Ovassapian Fibreoptic Intubating Airway (Kendall Sheridan, Argyle, NY) will be inserted into the mouth in random order, and the patient's lungs ventilated by bag and facemask with 100% oxygen and 1-1.5% isoflurane. Blinding will be impossible in this study as the operator has to see the airway through the fibrescope in order to perform the assessment.~After confirmation of full neuromuscular blockade, a bronchoscope with a preloaded tracheal tube will be then inserted through the airway for bronchoscopic assessment."|t|f|t|f
33682151|NCT02815280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682152|NCT00959400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682153|NCT05673174|||CASE_ONLY||PROSPECTIVE|||||||
33682154|NCT04518189|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized trial|double blind randomized trial|t|t|t|t
33682155|NCT00691119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33682156|NCT06421129|||COHORT||RETROSPECTIVE|||||||
33682157|NCT05926375|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The experiment lasted for 20 weeks, including 8 weeks self-controlled phase, 8 weeks supplement phase and 4 weeks washout period. In self-controlled phase would intake 400\~500 kcal breakfast and in supplement phase consume one servings of jelly high protein supplement with 100\~200 kcal food at breakfast. Subjects were randomly divided into first intervention group and post intervention group. The first intervention group used HINEX Jelly as daily breakfast during the first to 8th weeks of the experiment, the 9th to 12th week is the wash out period, the 13th to the 20th week is the selfcontrol period; the post-intervention group is in the first to the 8th week of self-control period,the 9th to 12th week is the wash out period, and the 13th to the 20th week is used HINEX Jelly as daily breakfast, as well as maintained their regular diet and medication, but do exercise lifestyle modification during 20-week experimental period."||||
33682158|NCT04645277|||CASE_CONTROL||PROSPECTIVE|||||||
33682159|NCT05094973|NA|SINGLE_GROUP||TREATMENT||NONE||This study included 15 patients with Class II molar relationship and Class II canine relationship treated using Carriere Motion Appliance®.||||
33682160|NCT06506591|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|SAD and MAD ：Double (Participant,Investigator) FE：Open Label||t|f|t|f
33682161|NCT01676467|||COHORT||CROSS_SECTIONAL|||||||
33682162|NCT05184400|||COHORT||PROSPECTIVE|||||||
33682163|NCT00204438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682164|NCT00736515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682165|NCT05272319|||COHORT||OTHER|||||||
33682166|NCT02242591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682167|NCT01954927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682168|NCT01150344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682169|NCT03220698|||CASE_CONTROL||PROSPECTIVE|||||||
33682170|NCT00389402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682171|NCT01779271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682172|NCT04045418|||COHORT||PROSPECTIVE|||||||
33682173|NCT04919447|||COHORT||PROSPECTIVE|||||||
33682174|NCT02984943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682175|NCT05234450|||CASE_ONLY||PROSPECTIVE|||||||
33682176|NCT00538785|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682177|NCT02236351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682178|NCT06473610|||COHORT||PROSPECTIVE|||||||
33682179|NCT02434471|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33682180|NCT03489954|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33682181|NCT03373227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682182|NCT02884700|||COHORT||RETROSPECTIVE|||||||
33682183|NCT03862508|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682184|NCT04800952|NA|SINGLE_GROUP||OTHER||NONE||||||
33682185|NCT00634738|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33682186|NCT04023929|||COHORT||PROSPECTIVE|||||||
33682187|NCT05951465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682188|NCT05911594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682189|NCT02762773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682190|NCT01643031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682191|NCT00998218|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33682192|NCT02819908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682193|NCT06071728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682194|NCT01520428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682195|NCT01575977|||OTHER||PROSPECTIVE|||||||
33682196|NCT02980952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33682197|NCT05292300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682198|NCT01204723|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33682199|NCT02122783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33682200|NCT03810729|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33682201|NCT05507359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33682202|NCT02232880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682203|NCT05382000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Once the patient's consent has been obtained, the patient will be assessed sequentially in the same triage space. Initially, a nurse will classify the patient in the triage box using the MAT system according to the usual practice. Then, another professional from the center, trained in the use of the Mediktor Hospital ® tool, and who has not been present in the conventional sorting, will perform the advanced IA triage in the same space, both professionals being blind to the result of each of the tools.~Attention in the Emergency Service Once the sequential triage is completed, the patient will return to the Gynecology and Obstetrics Emergency Room. The patient's care will be performed according to usual clinical practice, following the triage assessment performed with the MAT system."||||
33682204|NCT01014923|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33682205|NCT03739229|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682206|NCT02822547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682207|NCT01822314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682208|NCT00282347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682209|NCT03430713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682210|NCT00002975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682211|NCT04444830|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, non-blinded, randomized control trial.||||
33682212|NCT02181517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682213|NCT00557817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682214|NCT02986997|||OTHER||RETROSPECTIVE|||||||
33682215|NCT05076864|||COHORT||PROSPECTIVE|||||||
33682216|NCT05661188|NA|SINGLE_GROUP||TREATMENT||NONE||The TIRANUS trial is a Phase II, single-arm, open-label, non randomized, non controlled, proof-of-concept clinical trial of atezolizumab and tiragolumab in concomitancy with standard chemoradiotherapy (RT, 5-FU, and Cisplatin) as first-line in localized squamous cell carcinoma of the anal canal.||||
33682217|NCT00815854|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33682218|NCT02248688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682219|NCT00986284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682220|NCT05441878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682221|NCT05181280|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants are randomized into either the intervention group (body image messaging) or control group (infant feeding messaging).|t|f|f|f
33682222|NCT02390791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33682223|NCT05652023|||CASE_ONLY||PROSPECTIVE|||||||
33682224|NCT02870023|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33682225|NCT02647450|||COHORT||RETROSPECTIVE|||||||
33682226|NCT01361061|||COHORT||PROSPECTIVE|||||||
33682227|NCT02224118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682228|NCT03605602|||COHORT||PROSPECTIVE|||||||
33682229|NCT00001068|RANDOMIZED|PARALLEL||TREATMENT||||||||
33682230|NCT00729469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772525|NCT05601713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be informed of the study interventions before providing informed consent but will be masked to the specific trial until exposure (i.e., participants will not know the cooling intervention before the trial or during baseline measurements). Data will be blinded prior to analysis.|Participant will complete 3 simulated extreme heat event exposures in random order: i) no cooling intervention (control); ii) lower limb water immersion; and iii) lower limb water immersion with application of cool wet towel to the neck.|t|f|f|t
33682231|NCT04882969|NA|SINGLE_GROUP||TREATMENT||NONE|No masking.|Each participating subject will serve as his or her baseline control and will receive up to two (2) treatments per month for 3 months with Thulium laser and post-laser treatment topically applied Kerafactor.||||
33772526|NCT05364918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682232|NCT00980161|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682233|NCT01742455|||COHORT||PROSPECTIVE|||||||
33682234|NCT00407381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682235|NCT04600011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot feasibility study, non-controlled||||
33682236|NCT02744742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682237|NCT04095585|||CASE_ONLY||OTHER|||||||
33682238|NCT01712958|||COHORT||RETROSPECTIVE|||||||
33682239|NCT02775019|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682240|NCT05808634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682241|NCT05563038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Scrambler Group and Non-scrambler group||||
33682242|NCT00537615|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682243|NCT00855270|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080066|NCT03283735|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"This phase of the study is expected to start in September 2019 and will last for 6 months.~Two groups will be created with a minimum of 190 patients each, one of which will be composed from patients from the region of Aveiro, Coimbra and Guarda and the other from patients from the region of Castelo Branco, Leiria and Viseu. In the intervention group the investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy. The information given in this group will result from the knowledge obtained in phase II in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group."|t|f|t|f
34080067|NCT00570401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080068|NCT04784234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking of GlaucoCetin and identical Placebo was provided by Guardian Health Sciences, Inc. Labeling has been conducted by non-clinical study team personnel in Glaucoma Research Center at Wills Eye Hospital.|Study aims to enroll 50 patients within each intervention arm (GlaucoCetin vs Placebo). Within the intervention arm there will be one group with Central visual field defects and one group with Peripheral visual field defects.|t|t|t|t
34080069|NCT00643760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33902091|NCT06331728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the exception of the single sentinel participants for each cohort who will be single blinded (participant blinded), the study will be designed as a double-blind study thus the Investigator, site staff (other than pharmacists), sponsor, sponsors delegates (if applicable) and participants are all blinded to treatment.|Randomized, double-blind, placebo-controlled, single ascending dose study with single blind sentinel period|t|t|t|t
33902092|NCT02677701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080070|NCT05427435|NA|SINGLE_GROUP||PREVENTION||NONE||prospective single arm monocentric evaluation study||||
34080071|NCT02915146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080072|NCT02882334|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34080073|NCT00965133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080074|NCT03732027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080075|NCT00955799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080076|NCT02028598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080077|NCT01905618|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34080078|NCT03499782|||COHORT||RETROSPECTIVE|||||||
34080079|NCT01187732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34080080|NCT01026025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080081|NCT02493972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080082|NCT03199352|||OTHER||PROSPECTIVE|||||||
34080083|NCT01620645|||COHORT||PROSPECTIVE|||||||
34080084|NCT02172027|||CASE_ONLY||PROSPECTIVE|||||||
34080085|NCT00509717|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34080086|NCT04744818|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33902093|NCT01797432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902094|NCT00978575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902095|NCT02558699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33902096|NCT01479088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902097|NCT03721081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33902098|NCT03645252|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33902099|NCT05176847|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33902100|NCT04791969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, placebo controlled 2b clinical trial|2:1 Naltrexone with EMI vs. Placebo with EMI|t|t|t|f
33902101|NCT00002221||||TREATMENT||||||||
33985064|NCT01583569|||CASE_CONTROL||RETROSPECTIVE|||||||
33985065|NCT00006226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985066|NCT03569761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The investigators will use a two-group randomized controlled trial to achieve our aims. Participants (n=120) will be randomized to view the AI culturally-adapted decision aid or an attention-control (i.e., food safety) video. The study flow diagram (Figure 2) indicates the recruitment, randomization, and assessment process.Our research to develop and evaluate the decision aid is approved by the Lumbee Tribal Council and the institutional review board (IRB) at the University of North Carolina at Chapel Hill.|t|f|f|f
33985067|NCT05437744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985068|NCT00761020|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985069|NCT01416246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985070|NCT02058498|NA|SINGLE_GROUP||||NONE||||||
33985071|NCT03037372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985072|NCT06460025|||COHORT||CROSS_SECTIONAL|||||||
33985073|NCT04035603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985074|NCT05160350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33985075|NCT00422747|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985076|NCT02392000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985077|NCT05868564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985078|NCT03148886|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985079|NCT05078996|||OTHER||CROSS_SECTIONAL|||||||
33985080|NCT00126906|RANDOMIZED|PARALLEL||ECT||NONE||||||
33985081|NCT01814462|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985082|NCT04274114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985083|NCT01038856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985084|NCT00750594|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33985085|NCT01606540|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33985086|NCT00081848||||TREATMENT||||||||
33772527|NCT05551481|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33772528|NCT01645371|||CASE_ONLY||CROSS_SECTIONAL|||||||
33772529|NCT06375135|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||We will enroll 250 adults Latino MSM with HIV with suboptimal ART adherence and randomize (1:1) into two arms: TXTXT (n=125) or TXTXT + e-Navigation (n=125). Those in Arm 1 who continue to have suboptimal adherence (\<90% pills taken) at 3-months will be re-randomized (1:1) to continue TXTXT or add e-Navigation; those in Arm 2 who have suboptimal adherence will be re-randomized (1:1) to continue TXTXT + e-Navigation or add EMA support. At 6-months, the intervention arms will cease to receive any intervention components and be followed for an additional 6-months.||||
33772530|NCT06161103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772531|NCT04387838|||COHORT||PROSPECTIVE|||||||
33902102|NCT04737122|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm1: LM-061 single agent escalation Arm2: LM-061 combination escalation||||
33902103|NCT06673082|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||one group will receive oral Zinc therapy while the other group will recieve placebo|t|t|t|t
33902104|NCT01863758|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33902105|NCT05279469|||CASE_ONLY||RETROSPECTIVE|||||||
33902106|NCT03728127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902107|NCT06107062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902108|NCT05678790|NA|SINGLE_GROUP||TREATMENT||NONE||Case Study||||
33902109|NCT06555094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902110|NCT02575482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902111|NCT06512038|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902112|NCT05941182|||CASE_ONLY||PROSPECTIVE|||||||
33902113|NCT01144689|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902114|NCT00107107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902115|NCT02426268|||COHORT||PROSPECTIVE|||||||
33902116|NCT03873129|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Phase 2 is single group trial of A-CHESS when implemented in 2 high-volume HIV clinics, providing evidence describing the effectiveness and durability of an mHealth strategy for maintaining viral suppression among patients with substance use disorders treated with ART.||||
33902117|NCT01563692|||COHORT||PROSPECTIVE|||||||
33902118|NCT06322433|||COHORT||PROSPECTIVE|||||||
33902119|NCT03397485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985087|NCT02108509|||CASE_ONLY||PROSPECTIVE|||||||
33985088|NCT01275586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985089|NCT00770718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985090|NCT00003040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985091|NCT01311245|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33985092|NCT04720664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985093|NCT04567147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080087|NCT01626846|||COHORT||CROSS_SECTIONAL|||||||
33902120|NCT05141526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding participants is not possible due to the nature of the interventions. Individuals independent from the study and blinded to groups (e.g. statistician), will conduct the randomization and analyses while a research assistant, instructed not to discuss treatments with participants, will conduct the testing sessions.|(1) non-restrictive, satiating intervention (P1) followed by a continuation of this intervention (P2); (2) conventional restrictive intervention (-500 kcal/d) (P1) followed by a non-restrictive satiating intervention (P2); (3) control group that follows minimal healthy guidelines (P1) followed by recommended weight maintenance strategies (P2). \*P1=phase 1; P2=phase 2|f|f|t|t
33902121|NCT00126451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985094|NCT05645471|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study aims to test the impact of the adapted Together After Cancer intervention using a cluster randomized controlled trial (cRCT), with individuals nested within couples and randomization occurring at the couple level to see if it is more effective than usual care (UC).||||
33985095|NCT02222805|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33772532|NCT02947607|||COHORT||PROSPECTIVE|||||||
33985096|NCT06000280|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The techinician who performed the exams (Optical Coherence Tomography and Visual Field)|"This is a randomized, prospective and comparative clinical trial. Both the surgeon (the only one) and the technician responsible for the exams were blinded to the study groups. The patients (one or both eyes) included were from the glaucoma outpatient clinic of the Fundação Banco de Olhos de Goiás (FUBOG) or the Reference Center in Ophthalmology (CEROF) of the Federal University of Goiás (UFG) between the years 202 and 2022. All patients with glaucoma with indication for Trab with MMC and in clinical use of any PA eye drops (latanoprost, travoprost, bimatoprost or tafluprost) in the eye to be operated on for at least 6 months were considered for inclusion.~The study adhered to the principles of the Declaration of Helsinki and was authorized by the Research Ethics Committee of the UFG, under the Certificate of Presentation for Ethical Appreciation NUMBER 40055620.8.1001.5083. All those included voluntarily agreed to participate by signing the Free and Informed Consent Form."|f|f|t|t
33985097|NCT00527657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985098|NCT05304481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772533|NCT05811429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772534|NCT06330636|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Allocation coded A and B, with independent researcher determining allocation and making up the test breakfasts for the study team.|Randomised, placebo controlled cross over design|t|f|t|t
33772535|NCT00469365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33772536|NCT03017989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772537|NCT06233123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33772538|NCT03188900|||CASE_CONTROL||PROSPECTIVE|||||||
33772539|NCT01150578|||COHORT||PROSPECTIVE|||||||
33772540|NCT02264496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772541|NCT03053674|RANDOMIZED|PARALLEL||PREVENTION||NONE||Case-control study||||
33772542|NCT03650595|NA|SINGLE_GROUP||TREATMENT||NONE||24 Month, Prospective, Interventional, Open-label Single-Arm Effectiveness Study||||
33772543|NCT00259376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772544|NCT04124874|||OTHER||CROSS_SECTIONAL|||||||
33902122|NCT06513793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes are recorded remotely by the participant, online using the Qualtrics platform.|This is a pilot randomised controlled trial with two arms; psychological intervention versus waiting list control. The control arm participants will be offered the intervention following the end of the waiting list period.|f|f|f|t
33902123|NCT02797366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902124|NCT00478660|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33902125|NCT00316446|||||PROSPECTIVE|||||||
33902126|NCT06285162|||COHORT||PROSPECTIVE|||||||
33902127|NCT04634162|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Patients, research staff and laboratory personnel will be blinded to treatment assignments. Masking and randomization of medications (cangrelor and placebo) will be performed by our institutional research pharmacy.|The Switching Antiplatelet Therapy-5 (SWAP-5) study will be a prospective, randomized, double-blind, placebo controlled, cross-over PK and PD investigation|t|t|t|t
33902128|NCT00277472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985099|NCT04904861|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985100|NCT03764709|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective, randomized, controlled, open-label, monocentric study for the evaluation of two different settings of critically ill patients recovered in Internal Medicine unit (IMU) and subsequently sent to subacute managed care unit or to earlier discharge, in order to evaluate the effectiveness of a wireless monitoring of clinical conditions vs. a traditional clinical monitoring on outcomes (critical adverse events, clinical exacerbations).||||
33985101|NCT03621930|||COHORT||PROSPECTIVE|||||||
33985102|NCT02816788|NA|SINGLE_GROUP||TREATMENT||NONE|No masking.|Single group, within subjects comparison. Pre- and post-intervention comparisons.||||
33985103|NCT05492630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985104|NCT01887262|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985105|NCT00003939||||TREATMENT||||||||
33985106|NCT00987805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985107|NCT00705536|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33985108|NCT00202605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33985109|NCT03012178|||COHORT||PROSPECTIVE|||||||
33772545|NCT00671996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772546|NCT05409274|||COHORT||PROSPECTIVE|||||||
33772547|NCT03398915|||COHORT||PROSPECTIVE|||||||
33985110|NCT05481840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Participants, care provider and investigator are not blinded, this is impossible concerning the nature of the intervention.~Outcome assessor will be blinded."|"This is a cluster randomized trial with a intervention group and waiting list group.~Six organization will participate. They will be divided into one of the three couples. Within this couple randomization will take place at organization level, resulting in one organization receiving the intervention and a parallel group continuing regular continence care. The couples will start the research consecutively, after the previous couple finished the research (hence stepped). Due to the nature of the intervention (smart continence products) the randomization is not blinded."|f|f|f|t
33985111|NCT02154997|||CASE_CONTROL||PROSPECTIVE|||||||
33985112|NCT01367457|||CASE_ONLY||RETROSPECTIVE|||||||
33985113|NCT01493635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985114|NCT00629590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985115|NCT00539266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985116|NCT00995241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985117|NCT04414605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985118|NCT02576730|||COHORT||RETROSPECTIVE|||||||
33772548|NCT01189890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772549|NCT03086824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772550|NCT05372887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772551|NCT01219530|||||PROSPECTIVE|||||||
33772552|NCT04089774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33772553|NCT04138030|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33772554|NCT01478815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772555|NCT01799720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33772556|NCT03555604|||OTHER||CROSS_SECTIONAL|||||||
33772557|NCT03511079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|There will be no blinding in this study.|There will be two groups. The intervention group will listen to music each night several days before and after surgery. The control group will not listen to music each night around the time of surgery.||||
33772558|NCT04103554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772559|NCT03171168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is the only one masked in the study. Assessor is independent of the randomization, trial coordination, and care providers.|Single blinded (evaluator), single-center, randomized controlled trial. Interventional and Control group with option for Control group to Cross over.|f|f|f|t
33772560|NCT03993405|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33772561|NCT01918293|RANDOMIZED|PARALLEL||||NONE||||||
33772562|NCT06450587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772563|NCT01875861|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33772564|NCT00724425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772565|NCT00912821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772566|NCT00818415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772567|NCT04842396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772568|NCT03587805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772569|NCT04402593|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Study will enroll 15 subjects to a twice a week Music Therapy intervention (modified Heidelberg Model of Neuro-Music Therapy) for 3 weeks (6 sessions total).||||
33772570|NCT00367393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772571|NCT05316168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772572|NCT02733042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Within Arms A, B, and C participants on the dose-finding part were enrolled sequentially according to a 3+3 design. All treatment arms were to be open for enrollment at study start except in the US, where Arm D was to enroll depending on the availability of treatment slots and following the completion of assessment of responses from the combination therapy arms.||||
33772573|NCT03518736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772574|NCT04845932|||COHORT||PROSPECTIVE|||||||
33772575|NCT04767360|NA|SEQUENTIAL||TREATMENT||NONE||clinical sequential two-period crossover-design study||||
33772576|NCT01414218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772577|NCT03074110|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33772578|NCT01625195|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33772579|NCT06410846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772580|NCT03428815|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33772581|NCT03197103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772582|NCT00115375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772583|NCT00963989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772584|NCT06007079|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33772585|NCT01471067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772586|NCT00355407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772587|NCT04447443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772588|NCT04912622|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Control group: 110 individuals with healthy retina Patient group: 95 individuals with diseased retina Exclusion: age \< 18y, pregnancy, epilepsy, no informed consent||||
33772589|NCT00886470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772590|NCT01633086|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33772591|NCT01152541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772592|NCT02565355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772593|NCT00095030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772594|NCT05480033|RANDOMIZED|PARALLEL||PREVENTION||NONE||Imagination is linked to human creativity. Imagery is how we animate and design an object, situation and/or entity by redefining it and concretising it in our minds. In other words, imagery is the ability to create an idea or image in our minds.||||
33772595|NCT00436579|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772596|NCT01544621|||CASE_ONLY||PROSPECTIVE|||||||
33772597|NCT06376318|||COHORT||OTHER|||||||
33772598|NCT04600297|NA|SINGLE_GROUP||TREATMENT||NONE||Cases of one missing posterior tooth to be restored with 3D printed resin composite posterior FDP||||
33772599|NCT06134934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772600|NCT02881177|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33772601|NCT06291532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772602|NCT00687661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33772603|NCT01750593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772604|NCT03549611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will not be made aware which treatment regimen they are receiving and neither will the attending urologist.||t|f|f|f
33772605|NCT03929419|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33772606|NCT06738004|||COHORT||PROSPECTIVE|||||||
33772607|NCT01548014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772608|NCT02827214|||COHORT||PROSPECTIVE|||||||
33772609|NCT02796547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772610|NCT05457816|||COHORT||PROSPECTIVE|||||||
33772611|NCT05823337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772612|NCT04685733|||COHORT||RETROSPECTIVE|||||||
33772613|NCT02323893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772614|NCT04831762|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33772615|NCT04161417|NA|SINGLE_GROUP||SCREENING||NONE||The study is seen as interventional as patients may have more tissue taken at diagnositic biopsy than if they were not part of the trial or may have an extra biopsy if there is not enough material available from their diagnostic biopsy.||||
33772616|NCT00271869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772617|NCT01822353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772618|NCT06531135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33772619|NCT03380884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772620|NCT01081353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682244|NCT00940472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682245|NCT04538209|||CASE_ONLY||PROSPECTIVE|||||||
33682246|NCT01718418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33682247|NCT03970980|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33682248|NCT00619320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682249|NCT04842032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682250|NCT02898285|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33682251|NCT00289055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682252|NCT03154229|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomized controlled trial.||||
33682253|NCT04582825|||COHORT||PROSPECTIVE|||||||
33682254|NCT04929717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33682255|NCT01634256|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33682256|NCT03438721|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33682257|NCT02727530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33682258|NCT04180384|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||For 1 dosing week (at least 1 week following the paclitaxel capsule PK sampling period, ie, at Week 5 or later), a subgroup of 8 participants (Group B) will receive Oraxol as HM30181 plus a tablet formulation of paclitaxel. For the remainder of the study, Group B participants will receive the current clinical capsule formulation of paclitaxel. This will allow for comparison of the bioavailability of these 2 formulations with minimal impact on safety or activity.||||
33682259|NCT02943083|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33682260|NCT04645498|||COHORT||PROSPECTIVE|||||||
33682261|NCT04109339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682262|NCT01317316|||||PROSPECTIVE|||||||
33682263|NCT04851093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682264|NCT00928590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682265|NCT00617669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682266|NCT04002518|||COHORT||PROSPECTIVE|||||||
33682267|NCT00923364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682268|NCT02685475|||COHORT||PROSPECTIVE|||||||
33682269|NCT02491359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772621|NCT00249249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772622|NCT03011515|||COHORT||PROSPECTIVE|||||||
33772623|NCT04493918|NA|SINGLE_GROUP||TREATMENT||NONE|Participants do not know which treatment they receives. Outcome assessor is a radiologist|||||
33772624|NCT02100111|||CASE_CONTROL||RETROSPECTIVE|||||||
33772625|NCT06370338|||COHORT||PROSPECTIVE|||||||
33772626|NCT00000174|RANDOMIZED|||TREATMENT||DOUBLE||||||
33985119|NCT05309122|||COHORT||RETROSPECTIVE|||||||
33985120|NCT02712827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772627|NCT00209274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772628|NCT03783481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772629|NCT04662502|||COHORT||PROSPECTIVE|||||||
33682270|NCT02747979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772630|NCT02260089|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772631|NCT05280847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33772632|NCT04366206|||COHORT||PROSPECTIVE|||||||
33772633|NCT01397929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772634|NCT03454217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772635|NCT01429519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682271|NCT02872220|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33682272|NCT02216812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682273|NCT00990418|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682274|NCT06208956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682275|NCT00910624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682276|NCT02222025|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682277|NCT05266573|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682278|NCT00520585|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33682279|NCT02848729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682280|NCT01986777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682281|NCT03345966|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Bmi-1 antibody using immunohistochemistry and PCR|f|f|f|t
33682282|NCT00131924||||TREATMENT||NONE||||||
33682283|NCT06259071|||OTHER||PROSPECTIVE|||||||
33682284|NCT00317291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772636|NCT02092818|||COHORT||PROSPECTIVE|||||||
33902129|NCT05610891|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: CLR 131 is a radio-iodinated therapy comprising a core phospholipid ether (PLE) analogue radiolabeled with iodine-131. CLR 131 exploits the tumor-targeting properties of PLEs to provide targeted delivery of radiation to malignant tumor cells and minimizes radiation exposure to normal tissues.||||
33902130|NCT02203838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902131|NCT05495399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902132|NCT00711451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902133|NCT00918762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902134|NCT02547337|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33902135|NCT00759304|||COHORT||PROSPECTIVE|||||||
33902136|NCT00068887|||||PROSPECTIVE|||||||
33902137|NCT06670924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Data were collected by an independent database administrator and stored in a password-protected Microsoft Excel file. The data files were not accessible to the surgical team or to residents or ancillary staff involved in postoperative care.|The investigators conducted a two-group, parallel-design, pragmatic study of 70 consecutive patients with clinically localised (pT1-pT2) PCa undergoing primary open RP by a well-experienced single surgical team at Dr Lutfi Kirdar City Hospital as a tertiary care institution .The optimal sample size for this study was calculated to be 70 patients (35 patients in each arm) by the power calculation (α = 0.05, β = 0.1, power: 90%) The subjects were randomly assigned to one of two treatment groups using a simple randomization procedure that involved computer-generated random numbers in Microsoft Excel.|t|t|t|f
33902138|NCT06338696|||OTHER||PROSPECTIVE|||||||
33902139|NCT01348178|||COHORT||RETROSPECTIVE|||||||
33902140|NCT05310383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682285|NCT06200025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two groups with a conventional control group|f|f|f|t
33902141|NCT06313905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double-blind randomized study|t|t|f|t
33682286|NCT06280001|||COHORT||PROSPECTIVE|||||||
33682287|NCT02226133|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682288|NCT06492837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682289|NCT04868630|||CASE_ONLY||PROSPECTIVE|||||||
33682290|NCT02826720|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682291|NCT04548843|NA|SEQUENTIAL||TREATMENT||NONE||"The study will involve two sequential cohorts:~Cohort 1: 3 patients will be administrated with Dose 1 The dosing interval between patients will be at minimum 2 weeks. Two (2) weeks after the 3rd patient has received MNV-BM-PLC, the Data safety monitoring board (DSMB) will convene to review accumulated safety data. The DSMB will make a recommendation whether to proceed with the 4th patient administration.~Cohort 2: 3 patients will be administrated with Dose 2 The dosing interval between patients will be at minimum 2 weeks."||||
33682292|NCT04803123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682293|NCT01090583|||COHORT||PROSPECTIVE|||||||
33682294|NCT06139042|||CASE_CONTROL||PROSPECTIVE|||||||
33682295|NCT00154947|||CASE_CONTROL||PROSPECTIVE|||||||
33682296|NCT04012489|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33682297|NCT03660137|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive both RSL and MOLLI-guided lumpectomy surgery||||
33682298|NCT00164697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682299|NCT02893462|||COHORT||PROSPECTIVE|||||||
33682300|NCT01606657|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682301|NCT05448820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682302|NCT00028145|||COHORT||PROSPECTIVE|||||||
33682303|NCT03209674|||COHORT||PROSPECTIVE|||||||
33682304|NCT05375773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682305|NCT05940454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682306|NCT04623424|||COHORT||PROSPECTIVE|||||||
33682307|NCT06394934|||COHORT||PROSPECTIVE|||||||
33682308|NCT00918073|||COHORT||PROSPECTIVE|||||||
33682309|NCT02866955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682310|NCT06226532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. Group SL: 10%lidocaine spray total 8 puffs at laryngoscopes blade and endotracheal tube cuff.~2. Group IL: 2% lidocaine intravenous 1.5 mg/kg, not exceed 80 mg equally to spray group."|t|f|f|t
33682311|NCT04583709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682312|NCT02296138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682313|NCT02642497|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33682314|NCT00766753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682315|NCT06450119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33682316|NCT03964558|NA|SINGLE_GROUP||OTHER||NONE||||||
33682317|NCT02248558|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33682318|NCT03910920|||COHORT||PROSPECTIVE|||||||
33682319|NCT00243607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682320|NCT05145738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Care providers, investigators and outcome assessors will be blind to avatar versus no avatar conditions||f|t|t|t
33682321|NCT02066987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682322|NCT01094392|||CASE_ONLY||PROSPECTIVE|||||||
33682323|NCT03253419|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||To evaluate the use of the Home for Life mobile application to examine home safety and perceived fall risk and actual falls within 2 weeks of hospital discharge for participants who have undergone hip replacement surgery.||||
33682324|NCT00004904||||TREATMENT||||||||
33682325|NCT00957125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682326|NCT05947292|||CASE_ONLY||PROSPECTIVE|||||||
33682327|NCT03154892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682328|NCT03346473|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33682329|NCT01265654|||CASE_ONLY||RETROSPECTIVE|||||||
33682330|NCT01328444|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33682331|NCT04163289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682332|NCT03879343|||CASE_CONTROL||PROSPECTIVE|||||||
33682333|NCT05946304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682334|NCT06299371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682335|NCT03446144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Masked||t|t|t|f
33682336|NCT01800175|NON_RANDOMIZED|PARALLEL||||NONE||||||
33682337|NCT02654964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902142|NCT05275218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33902143|NCT04871321|||COHORT||PROSPECTIVE|||||||
33902144|NCT02876224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33682338|NCT01482390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682339|NCT03480464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682340|NCT03562767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research staff conducting the psychological, physical, outcome assessments, and study analyses will be blinded to participant's group allocation. To minimize bias, participants in the intervention group will be asked to refrain from disclosing their group assignment to study staff who collect data and questionnaires. Due to the overt nature of the CT-CB approach, the investigators and participants in the intervention group will not be blinded.|Three groups of subjects with uncontrolled diabetes Type 2 will be followed longitudinally for 3 months|f|f|f|t
33682341|NCT02217774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682342|NCT02188693|||CASE_CONTROL||PROSPECTIVE|||||||
33682343|NCT05153889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682344|NCT00005767|||NATURAL_HISTORY||CROSS_SECTIONAL|||||||
33682345|NCT06321367|||COHORT||PROSPECTIVE|||||||
33682346|NCT00515424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33682347|NCT03763526|||COHORT||PROSPECTIVE|||||||
33772637|NCT06208722|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Investigator and Outcomes Assessor will be blinded to allocation. Both arms will be described as interventions (educational versus behavioral). At the end of the trial children will be able to access the app in the other arm free of charge. The Outcomes Assessor (Statistician) will be masked to group assignment and unblinded only after the final analyses are completed.|Participants will be randomly selected in the experimental and the control arm. Participants in the experimental arm will use the experimental app while those in the control arm will use the control app. Participants will receive all surveys in the same format and frequency in both arms.|f|f|t|t
33682348|NCT01814280|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33772638|NCT03859336|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective 3 day open-label device trial across all subjects, with 1 day single-blinded sham pre- and post-treatment||||
33682349|NCT05814276|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will attend ten sessions on the non-pharmacological therapies' methodology and implementation.||||
33772639|NCT03857581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772640|NCT03315819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772641|NCT01558076|||COHORT||CROSS_SECTIONAL|||||||
33772642|NCT04668287|NA|SINGLE_GROUP||OTHER||NONE||Open-Label Pilot Study||||
33772643|NCT06510491|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772644|NCT05000528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772645|NCT01185054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772646|NCT04619342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772647|NCT00976079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772648|NCT04089371|||COHORT||PROSPECTIVE|||||||
33772649|NCT01804816|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772650|NCT04815213|NA|SINGLE_GROUP||OTHER||NONE||||||
33772651|NCT05153759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902145|NCT02112604|||COHORT||PROSPECTIVE|||||||
33902146|NCT01332526|||CASE_CONTROL||PROSPECTIVE|||||||
33902147|NCT00362388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33902148|NCT02961647|||COHORT||RETROSPECTIVE|||||||
33902149|NCT00818038|||COHORT||PROSPECTIVE|||||||
33902150|NCT04751331|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33902151|NCT02817542|||COHORT||PROSPECTIVE|||||||
33985121|NCT06309901|||OTHER||CROSS_SECTIONAL|||||||
33985122|NCT01043380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985123|NCT02795000|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33985124|NCT05928481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized controlled single-blind experimental study|t|f|f|f
33985125|NCT03802682|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33985126|NCT02683837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985127|NCT01199848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33985128|NCT05403684|RANDOMIZED|PARALLEL||PREVENTION||NONE||The proposed study is a non-blinded randomized controlled trial with a 1:1 parallel allocation of infants to higher-volume feedings (200-240 ml/kg/day) or usual-volume feedings (140-180 ml/kg/day) using computer-generated random-block sequences.||||
33985129|NCT03821545|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33985130|NCT04385771|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial examining COVID-patients requiring vv-ECMO therapy (+/- cytokine adsorption)||||
33985131|NCT05633745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985132|NCT03667183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985133|NCT02321566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985134|NCT00544180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985135|NCT04374448|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective Case-Series and Feasibility Study||||
33682350|NCT02572739|||CASE_ONLY||CROSS_SECTIONAL|||||||
33682351|NCT04564638|||OTHER||OTHER|||||||
33682352|NCT00715143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682353|NCT00918996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682354|NCT04036123|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682355|NCT04914013|||CASE_ONLY||PROSPECTIVE|||||||
33682356|NCT05410756|||CASE_CONTROL||PROSPECTIVE|||||||
33682357|NCT00927940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682358|NCT03090048|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33985136|NCT04353557|||CASE_ONLY||PROSPECTIVE|||||||
33682359|NCT00665314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772652|NCT03973138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772653|NCT04869683|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Health services research and follow up DMS||||
33772654|NCT01364402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772655|NCT04215185|NA|SINGLE_GROUP||OTHER||NONE||Non-anaesthetized subjects in the ICU (Intensive Care Unit) or in the CICU (Cardiac Intensive Care Unit) with arterial line placement in the radial artery.||||
33985137|NCT05286203|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33985138|NCT03368755|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33985139|NCT02651753|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985140|NCT05035355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985141|NCT03283345|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985142|NCT04863768|||COHORT||RETROSPECTIVE|||||||
33985143|NCT03546205|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985144|NCT05683730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985145|NCT02388620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985146|NCT05885893|||OTHER||OTHER|||||||
33985147|NCT05735639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985148|NCT00414765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985149|NCT03214991|||COHORT||PROSPECTIVE|||||||
33985150|NCT01546545|||CASE_ONLY||PROSPECTIVE|||||||
33985151|NCT04285359|||COHORT||PROSPECTIVE|||||||
33985152|NCT04550065|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33985153|NCT04759885|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Endoscopist-blinded|A randomized, parallel-group study.|f|f|f|t
33985154|NCT01513434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985155|NCT02329197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985156|NCT04507425|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into 1 of 3 interventions: nasal cannula, high flow nasal cannula, and high flow nasal cannula plus noninvasive ventilation within each of two groups: patients admitted to ICU without being intubated OR intubated patients undergoing an extubation.||||
33985157|NCT02743130|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33985158|NCT00002361||||TREATMENT||||||||
33985159|NCT01281501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985160|NCT02215161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985161|NCT00038675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985162|NCT00737490|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33985163|NCT01030848|||COHORT||PROSPECTIVE|||||||
33985164|NCT00155116|||DEFINED_POPULATION||OTHER|||||||
33682360|NCT01797406|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33682361|NCT03676101|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33682362|NCT04657107|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682363|NCT03547115|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1, open-label, 3 + 3 dose escalation study to determine the safety and preliminary efficacy of voruciclib alone or in combination with venetoclax.||||
33682364|NCT04391985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985165|NCT00020397||||TREATMENT||NONE||||||
33985166|NCT02575222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985167|NCT02372305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985168|NCT00465764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985169|NCT04132622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985170|NCT04758130|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985171|NCT03627091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682365|NCT05424432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682366|NCT03030742|||COHORT||PROSPECTIVE|||||||
33682367|NCT00000750||||TREATMENT||||||||
33772656|NCT03128918|||OTHER||PROSPECTIVE|||||||
33985172|NCT02380989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985173|NCT01114022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985174|NCT00877032|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33985175|NCT03783793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985176|NCT02692547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985177|NCT01037114|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33985178|NCT02881385|||CASE_CROSSOVER||PROSPECTIVE|||||||
33985179|NCT03452501|||COHORT||PROSPECTIVE|||||||
33985180|NCT00890422|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33985181|NCT03402503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985182|NCT05231837|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parks will be randomized to one of two conditions for a period of two years. Individual measures of physical activity and behavior will be collected among children and parents who reside in the neighborhoods that are served by each park. Children and parents will be enrolled for two years and measured at baseline, six, twelve and twenty-four months.||||
33985183|NCT01029379|||COHORT||PROSPECTIVE|||||||
33985184|NCT06073548|||COHORT||PROSPECTIVE|||||||
33985185|NCT01846845|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33985186|NCT03756272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study patient and outcome assessor are blinded|Randomized controlled trial|t|f|f|t
33985187|NCT04924868|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985188|NCT00319345|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33985189|NCT05786274|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985190|NCT05352087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985191|NCT00661596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985192|NCT05205759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080088|NCT00861133|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080089|NCT03634943|||COHORT||PROSPECTIVE|||||||
33985193|NCT05328180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study nurse prepares the anaesthetic solution in advance, without reporting the contents to the surgeon or assisting nurses. The solution is labelled so that the surgeon doesn't know which solution is used. The used solution is recorded on a data pool and revealed only after the data analysis is made. Neither the investigators or outcome assessors have access to the randomized treatment before data has been analysed.|Two concurrent study groups|t|t|t|t
33985194|NCT05452798|||COHORT||RETROSPECTIVE|||||||
33985195|NCT04487132|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control trial design will be used in this study to examine the impact of school-based intervention on motivation towards physical activity and psychosocial outcomes among adolescents. In trials with randomized and controlled design the effects of the study (school based intervention and psychosocial outcomes) are compared with those of a control group and the participants are randomly assigned to the two groups. In this interventional model Active physical education lessons and physical education plan will be carried out which includes, Physical activities 10 -15 minutes daily or at least 5 days in a week during the school timings.||||
33772657|NCT05363137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33772658|NCT03062098|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33902152|NCT04524975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Dose blinding will be performed using Placebo. Patient will receive 3 vials labeled for study drug administration as follows: 1 capsule in the morning, afternoon, and evening.~Package numbers were assigned via IWRS. Thus, during the Study Treatment period, neither the patient nor the Investigator knew the group to which the patient was allocated. Single blinding was performed during the Placebo Run-in and Follow-up periods."|This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging pilot study to assess the efficacy and safety of CD-008-0045 in patients with GAD. The primary study objective is to select the dosage regimen for CD-008-0045 (20 mg BID or TID) based on preliminary assessment of its efficacy versus placebo according to frequency of treatment response at Week 8 in patients with GAD. Treatment response is considered as ≥ 50% decrease of the Hamilton Anxiety Rating Scale (HARS) total score from baseline.|t|f|t|f
33902153|NCT04988516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902154|NCT02150642|||COHORT||PROSPECTIVE|||||||
33902155|NCT02616029|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902156|NCT04001751|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33902157|NCT05673603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985196|NCT05479383|||COHORT||PROSPECTIVE|||||||
33985197|NCT03101540|NA|SINGLE_GROUP||TREATMENT||NONE||A single group model was used: pregnant women.||||
33985198|NCT00358449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985199|NCT04767477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985200|NCT04121286|NA|SEQUENTIAL||TREATMENT||NONE||Proposed dose Cohorts Cohort A：1mg Cohort B：2mg Cohort C：4mg Cohort D: 6mg Cohort E：8mg||||
33985201|NCT03222817|NA|SINGLE_GROUP||SCREENING||NONE||||||
33985202|NCT00725998|||OTHER||OTHER|||||||
33985203|NCT05291702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985204|NCT02804945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985205|NCT02670005|||COHORT||RETROSPECTIVE|||||||
33985206|NCT06349967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985207|NCT01938066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985208|NCT01029470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985209|NCT04016532|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985210|NCT04175379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, care givers and outcomes assessors are blinded. The investigator should not be included in the blind because they need to adjust the ventilator settings.|Random sampling using random numbers is divided into three groups, and the ratio of each group is 1: 1: 1.|t|t|f|t
33985211|NCT04033471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||epidural bupiviacain|t|f|f|t
33985212|NCT00306462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985213|NCT03878719|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985214|NCT03433430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985215|NCT02903901|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33985216|NCT00216983|||CASE_CROSSOVER||PROSPECTIVE|||||||
33985217|NCT00002132||||TREATMENT||DOUBLE||||||
33985218|NCT01533298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772659|NCT02444585|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33772660|NCT02790216|||CASE_ONLY||PROSPECTIVE|||||||
33772661|NCT03381014|||COHORT||PROSPECTIVE|||||||
33772662|NCT01359618|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33772663|NCT03734159|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772664|NCT03722264|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|"Opalseal and TransbondXT are identical in color, consistency and application allowing random assignments as well as patient blinding.~The outcomes assessor will also be blinded to the groups assignments."|Participants have at least two teeth planned for extraction on either side of the mouth. The study will use a split-mouth design with random assignments for intervention (OpalSeal) on one tooth.|t|f|f|t
34080090|NCT05289700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomisation will be double-blinded: neither the patient nor physician caring for the patient will be informed of the strategy. Only the Hyperbaric Chamber team, in charge of the session, will be informed of the treatment arm which has been attributed.|Intervention is a treatment with Hyperbaric Oxygen Therapy in Hyperbaric chamber. Placebo is entry in hyperbaric chamber but without oxygen and with a minimal pression. Within 4 hrs (or at the latest 12 hrs) of their initial consultation at their hospital's ED, patients who have agreed to participate in the study will be randomised between the HBOT intervention group (2 ATA, 95 min, FIO2=1) and the placebo group (1.3 ATA, 95 min, FIO2=0.21). Patients undergo a first session (HBOT/placebo) in the hyperbaric chamber and then return to their ward.|t|f|t|t
34080091|NCT01748968|||COHORT||RETROSPECTIVE|||||||
34080092|NCT01065818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080093|NCT02351947|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080094|NCT03467451|||OTHER||RETROSPECTIVE|||||||
34080095|NCT05104385|||COHORT||PROSPECTIVE|||||||
33682368|NCT00713310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682369|NCT06506487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34080096|NCT03830268|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||10 young and 10 older participants undergoing six separate but identical metabolic visits (interventions)||||
34080097|NCT01164202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682370|NCT04504058|||COHORT||PROSPECTIVE|||||||
33682371|NCT01439815|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33682372|NCT02565134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682373|NCT05373069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682374|NCT03265223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blinding was done i.e. neither the operating surgeon nor the investigator and nor the patient knew to which study group patient belong to.|Three study groups: Controls received no drug, intraperitoneal group received drug along right hemidiaphragm and in gallbladder fossa while intraincisional group received drug by infiltration at trocar site|t|t|t|f
33682375|NCT05785481|||COHORT||PROSPECTIVE|||||||
33902158|NCT03762252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33902159|NCT03095534|NA|SINGLE_GROUP||PREVENTION||NONE||Single group with pretest and posttest||||
33902160|NCT01696877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902161|NCT01764178|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33902162|NCT00443430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902163|NCT06208709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Groups in which participants are randomized into will be unknown to the investigators evaluating the outcome data.|"Participants will be randomized into one of two treatment arms:~Arm 1 - CASA device arm; Arm 2 - Standard of care (SOC) arm~In both arms participants are being given a treatment for CTS. Throughout the intervention, participants wear their device daily while they sleep and then record their response within a daily journal. Additionally, participants are contacted weekly to answer weekly questionnaires related to their symptoms and hand function."|f|f|f|t
33902164|NCT00004429|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33902165|NCT03424330|RANDOMIZED|CROSSOVER||OTHER||NONE||"The study will employ a randomized, controlled crossover study design.~The study comprises two stages:~* Stage 1: ReX-C Intervention in which subjects will use ReX-C to receive medication.~* Stage 2: Control, in which Treatment as Usual (TAU). All subjects enrolled for the study will participate in both stages in a randomized crossover mode."||||
33902166|NCT04036136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682376|NCT05003271|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups pre-post assessment (pilot/feasibility study)||||
33682377|NCT03841084|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase II, registry-based, multicentre, parallel group randomised controlled trial.~(Data retrieved from the EXCEL national clinical registry)"||||
33682378|NCT00425178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682379|NCT05828641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome accessors will be blinded to the study. They will not know which group is supination-flexion group or hyperpronation group from the data set. Group names will be included in the dataset as group 1 and group 2.|This study is designed as parallel group randomized controlled trial.|f|f|f|t
33682380|NCT05568940|||COHORT||PROSPECTIVE|||||||
33772665|NCT03854240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient and the anesthesiologist who will evaluate postoperative pain will be blinded to the procedure.|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position|t|f|f|t
33772666|NCT03393143|||COHORT||OTHER|||||||
33772667|NCT02961855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772668|NCT04814927|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants at each site will receive one of four marketed, approved contraceptive products for the duration of the study.|f|f|f|t
33772669|NCT00556348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772670|NCT00000942||||PREVENTION||DOUBLE||||||
33772671|NCT03441113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772672|NCT01009047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772673|NCT06196580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a single-center, randomized, double blind, three-period, and three-group parallel design trial, consisting of three groups (group A、 group B and placebo group).|t|f|t|f
33772674|NCT01047475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772675|NCT02444299|||COHORT||PROSPECTIVE|||||||
33772676|NCT06145022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772677|NCT04227860|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Post-exercise training assessment will be done by an investigator not involved in the study and unaware of the grading of KOA or of the pre-exercise assessment.||f|f|t|f
33772678|NCT04539379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33772679|NCT01978340|||||PROSPECTIVE|||||||
33772680|NCT04751175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To preserve the masking of the study, the randomization system has been carried out by the pharmacy service personnel using the EPIDAT 4.0 program and only the personnel responsible for the pharmacy will know the randomization tables and codes. The main investigator will have the emergency codes in case of need by contacting the pharmacy service|Single-center, controlled, prospective and randomized clinical trial, phase IV, to determine the effect of perioperative intravenous administration of ketamine and dexamethasone in patients undergoing lumbar arthrodesis|t|f|t|f
33772681|NCT01028521|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33772682|NCT00715507|||||PROSPECTIVE|||||||
33772683|NCT03815279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An investigator initiated, academic, non-randomized, open-label phase 2 study that will assess carfilzomib, lenalidomide and dexamethasone regimen as treatment in patients with intermediate-risk (not carfilzomib) or high-risk SMM or active MM.||||
33772684|NCT04866511|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will adopt a Single Case Design (SCD) methodology, and specifically a naturalistic, sequential measurement, mixed-method AB design.~SCDs are an idiographic method that allows for the analysis and interpretation of change at the level of the individual, rather the group. As such, SCDs typically aim to measure the change occurring in the individual's behaviour or symptoms by comparing the baseline, the intervention and the follow-up phases in terms of trends and variability (Parsonson \& Baer, 1986). Furthermore, SCDs lend themselves to an in-depth exploration of process and outcome of therapy in applied settings, and, particularly when experimental, allows for drawing causal inferences about effectiveness. This is in line with the objectives of this study, which aims to answer questions about both outcomes and processes of change within NET."||||
33772685|NCT02169947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772686|NCT04788290|||OTHER||PROSPECTIVE|||||||
33772687|NCT06174935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772688|NCT05303038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772689|NCT03647839|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label, multicentre, parallel phase II study designed to assess the efficacy of the combination of nivolumab and BNC105 and the combination of nivolumab and BBI-608. Patients with microsatellite stable adenocarcinoma of colorectal origin that is not resectable are eligible and will be randomised in the ratio of 1:1 using permuted block randomisation with stratification by screening ECOG performance status (0 or 1) to receive either nivolumab and BNC105 or nivolumab and BBI-608.|This is an open-label, multicentre, parallel phase II study designed to assess the efficacy of the combination of nivolumab and BNC105 and the combination of nivolumab and BBI-608. Patients with microsatellite stable adenocarcinoma of colorectal origin that is not resectable are eligible and will be randomised in the ratio of 1:1 using permuted block randomisation with stratification by screening ECOG performance status (0 or 1) to receive either nivolumab and BNC105 or nivolumab and BBI-608.||||
33772690|NCT05251441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33772691|NCT01263184|||COHORT||PROSPECTIVE|||||||
33772692|NCT03195920|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm trial with the Enhanced Lithotripsy System||||
33772693|NCT05377086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772694|NCT01449214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772695|NCT01752413|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33772696|NCT05681403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772697|NCT01388374|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33772698|NCT02624206|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33772699|NCT01628211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682381|NCT00319267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682382|NCT06189235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682383|NCT03253562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682384|NCT00266864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985219|NCT01019889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985220|NCT04166032|NA|SINGLE_GROUP||SCREENING||NONE||||||
33985221|NCT00360997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985222|NCT03726151|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33985223|NCT04682145|||COHORT||RETROSPECTIVE|||||||
33985224|NCT01951794|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33985225|NCT00565032|||COHORT||PROSPECTIVE|||||||
33985226|NCT00003332||||TREATMENT||||||||
33772700|NCT00134927|||COHORT||PROSPECTIVE|||||||
33985227|NCT05867095|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33772701|NCT06362239|||COHORT||PROSPECTIVE|||||||
33772702|NCT03614884|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm randomized controlled trial (RCT) will be conducted to evaluate the proposed online intervention. Eligible participants will be randomized to either the online integrated gambling and smoking treatment condition, or the gambling only (i.e., control) condition.||||
33772703|NCT05008159|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and interventionists are not blinded. All data collectors will be independent of the study and blinded to treatment allocation. Statisticians will be blinded to treatment allocation.|Type II hybrid effectiveness-implementation RCT|f|f|t|t
33772704|NCT00871793|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33772705|NCT05718648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772706|NCT02169895|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33772707|NCT00035945||||TREATMENT||||||||
33772708|NCT02793635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772709|NCT03543722|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33772710|NCT02846558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772711|NCT03179631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomized, double-blind, placebo-controlled,72-week study and its 72-week open-label extension|This study describes the randomized, double-blind, placebo-controlled, 72-week study and its 72-week open-label extension|t|t|t|t
33772712|NCT02237378|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772713|NCT03146481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772714|NCT01605734|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902167|NCT03977402|||OTHER||PROSPECTIVE|||||||
33902168|NCT05409976|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, multicenter, non-randomized, single-arm study.||||
33902169|NCT06671964|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Educational sessions~2. Anthropometric measurements~3. Questionnaire"||||
33902170|NCT02152423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902171|NCT05334589|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients were divided into intervention and control groups using the block randomization method.||||
33902172|NCT04834986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902173|NCT03577821|||COHORT||PROSPECTIVE|||||||
33902174|NCT00320671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902175|NCT00719810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985228|NCT04441463|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985229|NCT04834271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985230|NCT03127631|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33985231|NCT02683083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985232|NCT03462654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized into either the iLiFE or gLiFE arm of the study.|f|f|f|t
33985233|NCT02923635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772715|NCT04478227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772716|NCT00050089|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33772717|NCT05576805|||COHORT||RETROSPECTIVE|||||||
33772718|NCT05008692|||COHORT||PROSPECTIVE|||||||
33772719|NCT03749460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772720|NCT00164853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772721|NCT01800149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772722|NCT04642469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind and open-label||t|t|t|t
33902176|NCT03069768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33902177|NCT03851341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902178|NCT04663867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902179|NCT02844205|||CASE_ONLY||PROSPECTIVE|||||||
33902180|NCT06004115|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|placebo preparation by the pharmacy|double blind crossover design|t|t|t|t
33902181|NCT02037919|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985234|NCT01739959|||||PROSPECTIVE|||||||
33985235|NCT03552692|NA|SINGLE_GROUP||TREATMENT||NONE||"Study design This is an open-label, multi-center, single arm phase II trial, with a two-stage design, to evaluate the activity and safety of ABT-199 single agent in patients with BCL-2 pos R/R PTCL-NOS, AITL, TFH.~A pre-screening evaluation of immunohistochemical positivity of BCL-2 will be performed in the relapse biopsy, if available, or otherwise in the initial biopsy. BCL-2 evaluation will be centralized (FIL Laboratories). Only patients with a percentage of BCL-2 positive tumor cells ≥ 25% will be included onto the study. Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest. The primary objective of the study is ORR which will be evaluated after 3 cycles of treatment."||||
33985236|NCT01540760|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33985237|NCT02867280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985238|NCT03885362|NA|SINGLE_GROUP||PREVENTION||NONE|Blinded CGM but not Libre|||||
33985239|NCT05281822|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985240|NCT04520464|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Patients will be randomly selected by two sequences which will be used for diagnostic and positive patients will be referred for colposcopy and biopsy.||||
33985241|NCT02017223|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33985242|NCT02170311|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985243|NCT00760448|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985244|NCT00314886|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985245|NCT01196260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33772723|NCT02480686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772724|NCT05640076|||COHORT||RETROSPECTIVE|||||||
33985246|NCT04092751|RANDOMIZED|CROSSOVER||OTHER||NONE||"Subjects will be randomized to a treatment sequence (AB or BA) in a crossover fashion with a minimum 10-day washout period between treatments~Treatment A = Single oral 20-mg dose of PRA on Day 1 AM. Treatment B = Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later."||||
33985247|NCT05315739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985248|NCT04764214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985249|NCT01049334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985250|NCT01794065|||COHORT||PROSPECTIVE|||||||
33985251|NCT05507801|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single (Participants)||t|f|f|f
33985252|NCT06340256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33985253|NCT04005859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985254|NCT00420238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985255|NCT06370182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985256|NCT05899855|||CASE_CROSSOVER||PROSPECTIVE|||||||
33985257|NCT05689905|||COHORT||PROSPECTIVE|||||||
33985258|NCT02303808|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33985259|NCT06391606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985260|NCT01090713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985261|NCT03050944|||CASE_CONTROL||PROSPECTIVE|||||||
33985262|NCT04821986|||OTHER||CROSS_SECTIONAL|||||||
34080098|NCT06204497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The masking in this study is inappropriate because the patients in the SDT group do not have an abdominal stoma.|The patients who were enrolled will either undergo ileostomy or SDT after the removal of the rectal tumor, which will be decided by chance.|f|f|f|t
34080099|NCT02515630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080100|NCT00032591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080101|NCT05179304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080102|NCT03205150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080103|NCT04102618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080104|NCT01586052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682385|NCT01246908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682386|NCT03594942|||COHORT||CROSS_SECTIONAL|||||||
33682387|NCT04858178|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682388|NCT03355482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682389|NCT06113380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682390|NCT02454361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682391|NCT03661476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682392|NCT00717704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682393|NCT01900912|RANDOMIZED|PARALLEL||||NONE||||||
33682394|NCT03079570|||COHORT||CROSS_SECTIONAL|||||||
33682395|NCT01781273|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33682396|NCT01271582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682397|NCT01034891|||COHORT||RETROSPECTIVE|||||||
33682398|NCT00535288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682399|NCT00889616|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682400|NCT06190054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682401|NCT04043624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682402|NCT02789267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772725|NCT02328196|||COHORT||CROSS_SECTIONAL|||||||
33772726|NCT04228328|||OTHER||CROSS_SECTIONAL|||||||
33772727|NCT02036190|||COHORT||PROSPECTIVE|||||||
33772728|NCT03800966|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33772729|NCT04157686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772730|NCT02324023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772731|NCT05733806|||COHORT||PROSPECTIVE|||||||
33772732|NCT01216982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33772733|NCT01576055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772734|NCT00641849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33772735|NCT02300389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985263|NCT04544878|||COHORT||PROSPECTIVE|||||||
33985264|NCT03177486|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33985265|NCT05977049|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will be placed in a virtual Takotsubo Support Group once enrolled in the study.||||
33985266|NCT00060749||||TREATMENT||||||||
33985267|NCT00485472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985268|NCT00007852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985269|NCT00465270|RANDOMIZED|PARALLEL||PREVENTION||NONE||AMPLATZER PFO Occluder||||
33985270|NCT00978822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985271|NCT01790347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985272|NCT01796886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985273|NCT06291792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985274|NCT03203863|||OTHER||CROSS_SECTIONAL|||||||
33985275|NCT05551780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080105|NCT02511301|NA|SINGLE_GROUP||SCREENING||NONE||||||
34080106|NCT06425796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double Blind: two or more parties are unaware of the intervention assignment||t|f|t|f
34080107|NCT01838538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080108|NCT01556620|||COHORT||PROSPECTIVE|||||||
34080109|NCT03981471|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34080110|NCT02271113|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34080111|NCT01939314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080112|NCT01502085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080113|NCT05619666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080114|NCT02573714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080115|NCT00691522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080116|NCT02990403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985276|NCT03443986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple: a researcher shall be exclusively responsible for the evaluations and reevaluations not having knowledge of what intervention~group the patient will enter. The patient will be allocated among three groups. After the final evaluations, all data will be analyzed by another researcher directed solely to that purpose. Therefore, there will be a triple blinding (researcher, patient and statistician)."|Three groups: resistance training associated with whole body vibration (G1), resistance training associated with vibration sham; (G2) and control group-guidelines about foot care (GC)|t|t|t|f
33985277|NCT05745870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985278|NCT01017848|||CASE_ONLY||RETROSPECTIVE|||||||
33985279|NCT02071875|||COHORT||PROSPECTIVE|||||||
33985280|NCT03929900|||COHORT||PROSPECTIVE|||||||
33985281|NCT01854008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33985282|NCT04807374|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomized interrupted time series||||
33985283|NCT01358422|||COHORT||PROSPECTIVE|||||||
33985284|NCT02945891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985285|NCT06493266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985286|NCT05619783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985287|NCT02964260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985288|NCT05961423|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Control group: laparoscopic surgery Interventional group: robotic surgery||||
33985289|NCT03064334|||OTHER||OTHER|||||||
33985290|NCT00768742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985291|NCT04504526|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985292|NCT04115332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985293|NCT00724542|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33682403|NCT06257602|||COHORT||PROSPECTIVE|||||||
33682404|NCT03354793|||COHORT||RETROSPECTIVE|||||||
33682405|NCT04224688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators are blinded to the treatment code, they will see the platelet values.||t|t|t|t
33682406|NCT05736575|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682407|NCT05763589|||COHORT||PROSPECTIVE|||||||
33682408|NCT00811213|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33682409|NCT06305884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682410|NCT04641689|RANDOMIZED|FACTORIAL||PREVENTION||NONE||2 x 2||||
33682411|NCT05024292|||COHORT||PROSPECTIVE|||||||
33682412|NCT03997045|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33682413|NCT02294760|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33682414|NCT01765309|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33682415|NCT02535572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682416|NCT05933109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682417|NCT00875134|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682418|NCT00238602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682419|NCT01075633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682420|NCT01088607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682421|NCT01675089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682422|NCT06119958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682423|NCT01612845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33682424|NCT04659512|||COHORT||PROSPECTIVE|||||||
33682425|NCT05772351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682426|NCT02211911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682427|NCT00315757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682428|NCT06472986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682429|NCT02946931|||COHORT||PROSPECTIVE|||||||
33682430|NCT01410851|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33682431|NCT00721253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682432|NCT01114230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682433|NCT05308940|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33682434|NCT01106092|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33682435|NCT00773045|||||PROSPECTIVE|||||||
33682436|NCT01659801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682437|NCT02230488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682438|NCT03381534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33682439|NCT00003296||||TREATMENT||||||||
33682440|NCT00650481|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33682441|NCT00456144|||CASE_ONLY||PROSPECTIVE|||||||
33682442|NCT00606047|||COHORT||PROSPECTIVE|||||||
33682443|NCT02307253|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682444|NCT00627952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682445|NCT06165458|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33682446|NCT04111562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682447|NCT01743001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682448|NCT03127982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical staff participating in the intervention are unaware of the group membership of the subjects; either experimental or wait-list.|Allocation: Randomized Intervention Model: Parallel Assignment Single Blind|f|t|f|t
33682449|NCT04121351|||CASE_ONLY||CROSS_SECTIONAL|||||||
33772736|NCT03449537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772737|NCT05611970|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional multi-clinic study where each participant serves as her own control.||||
33772738|NCT05501769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682450|NCT03206164|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Methods: We will convert the evidence based HealthMatters Train the Trainer Workshop for Instructors, synchronous, live webinar training course into HealthMatters@24/7, an asynchronous, e-learning training course for staff to plan, conduct, and evaluate the HealthMatters Program for people with IDD in residential and day/employment community-based organizations (CBOs).~Design. We will utilize a two-group (Table 1) pre-test/post test quasi-experimental design wherein the Experimental Group will receive HealthMatters@24/7 training and the Control Group will receive the customary real-time (live) webinar training (HealthMatters Train the Trainer Workshop)."||||
33682451|NCT01715597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682452|NCT00362180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682453|NCT05628259|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding was provided that included inclusion criteria and agreement to participate in the study.|This study is a parallel group randomized controlled study.|t|f|f|f
33682454|NCT00626470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682455|NCT01143805|RANDOMIZED|CROSSOVER||||NONE||||||
33682456|NCT04118452|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33682457|NCT00745849|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33682458|NCT00736047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682459|NCT04676256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682460|NCT05939778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682461|NCT05433623|||OTHER||CROSS_SECTIONAL|||||||
33682462|NCT04693143|NA|SINGLE_GROUP||OTHER||NONE|"A). Primary outcome for assessment of participants who need mechanical ventilation(MV) and MV duration.~B). Secondary outcomes will include assessment of participants accordingly, Pediatric Intensive Care Unit (PICU) stay , days of need for vasoacitive drugs infusion , incidence of new infections ,and PICU mortality."|A randomized controlled open-label clinical trial||||
33682463|NCT03131401|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33985294|NCT01916408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772739|NCT06458829|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Stepped-Wedge Cluster Randomized Trial. Six community centers will be included. There will be three steps for intervention implementation. Tat each step, two centers will be randomly assigned to receive intervention, other centers will serve as control group or maintain post-intervention status.||||
33772740|NCT00517426|NA|SINGLE_GROUP||||NONE||||||
33772741|NCT01448525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985295|NCT02272556|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33772742|NCT05386186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772743|NCT02693912|||CASE_CONTROL||PROSPECTIVE|||||||
33772744|NCT03059693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Sponsor will send all washout and test products in compliance with current Good Manufacturing Practices directly to the clinical facility prior to the start of the study. Study procedures will be in place to ensure double-blind administration of study treatments. Access to the randomization code will be strictly controlled. The quantity of all study material shipped to the clinical facility will be documented on the shipping and receiving form included within the shipment. Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, care provider, outcomes assessor, research staff, or patients. Packaging and labeling of test and control treatments will be identical to maintain the blind. Products will be identified with the codes generated by the randomization.||t|t|t|t
33772745|NCT03428282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772746|NCT05819905|||COHORT||RETROSPECTIVE|||||||
33772747|NCT04876560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33772748|NCT02329600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772749|NCT05377840|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this prospective, single center, randomized treatment study, participants will be screening for anxiety and depression in a Crohn's disease population using the Generalized Anxiety Disorder (GAD) questionnaire and the Patient Health Questionnaire (PHQ). Subjects with GAD scores of ≥8 will be considered to have anxiety and those with a PHQ score of ≥10 will be considered to have depression. All subjects with screening questionnaire scores positive for anxiety or depression will be randomized to treatment with either cognitive behavioral therapy (CBT) or Sudarshan Kriya Yoga (SKY).||||
33772750|NCT02112058|RANDOMIZED|PARALLEL||||NONE||||||
33772751|NCT04045639|||COHORT||PROSPECTIVE|||||||
33772752|NCT01562847|||CASE_CONTROL||PROSPECTIVE|||||||
33772753|NCT04305899|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772754|NCT04273503|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Behavioral intervention||||
33772755|NCT04825860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772756|NCT03897101|||CASE_CONTROL||PROSPECTIVE|||||||
33772757|NCT06204328|RANDOMIZED|PARALLEL||OTHER||NONE|The computer-generated simple random sampling technique will be used to select the caregiving burden of study participants for both the intervention and control groups.|||||
33772758|NCT03603015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single pilot group all receiving the same tests||||
33772759|NCT05140213|||COHORT||RETROSPECTIVE|||||||
33772760|NCT05706987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772761|NCT01816763|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33772762|NCT02593539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772763|NCT05165875|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial design is a multicentre, randomized controlled, assessor blinded, 2 arm 1:1 superiority trial.||||
33772764|NCT05471869|||COHORT||RETROSPECTIVE|||||||
33772765|NCT05856240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772766|NCT00881010|||CASE_CONTROL||PROSPECTIVE|||||||
33985296|NCT04386278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each group in this study includes a different device iteration that is being investigated in parallel.||||
33985297|NCT04472078|||COHORT||CROSS_SECTIONAL|||||||
33985298|NCT03229018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985299|NCT03478397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985300|NCT01552447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985301|NCT01451047|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33985302|NCT02918877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985303|NCT05082779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080117|NCT05720416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34080118|NCT01926028|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682464|NCT05265780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682465|NCT01857596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682466|NCT06016023|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682467|NCT03104816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682468|NCT04717206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33682469|NCT02811276|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33682470|NCT00331110|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682471|NCT05555173|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33682472|NCT00965965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33682473|NCT03843619|||COHORT||PROSPECTIVE|||||||
33682474|NCT04811300|||FAMILY_BASED||PROSPECTIVE|||||||
33902182|NCT04470752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both study drug and Placebo have identical packaging (brown glass bottle) and labeling (Capsaicin or Placebo). Both use the same liquid suspension, same colour, and consistency..||t|t|t|t
33902183|NCT01283828|||COHORT||PROSPECTIVE|||||||
33902184|NCT03023410|||COHORT||PROSPECTIVE|||||||
33902185|NCT04223167|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||The individuals were identified by collecting the age, weight, height, BMI, caffeine and energy drink consumption habit information by applicant acceptance questionnaire. Based on the applicant acceptance questionnaire 12 subjects were low-habitual caffeine consumers with an estimated daily intake of approximately 130 mg caffeine and named as energy drink 2 (ED2) group, 12 subjects were high-habitual caffeine consumers with an estimated daily intake of approximately more than 200 mg caffeine and named as energy drink 3 (ED3) group, while 24 subjects were caffeine naive (energy drink 1 (ED1) (n=12) and Control (n=12)) .|t|f|t|t
33902186|NCT05187533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902187|NCT01022853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902188|NCT01780389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902189|NCT00797927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902190|NCT00864292|||CASE_CONTROL||PROSPECTIVE|||||||
33902191|NCT04561817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"For non-altered patients- An interim analysis is scheduled when the number of enrolled patients reaches 14. The research team will stop the trial for futility if 2 or less than 2 patients respond. When the total number of patients reaches the maximum sample size of 25, the research team will reject the null hypothesis and conclude that the treatment is promising if the number of responses are greater than 6; otherwise the research team will conclude that the treatment is not promising.~For altered patients-An interim analysis is scheduled when the number of enrolled patients reaches 8. The research team will stop the entire trial of two cohorts for futility if 1 or less than 1 patients respond. When the total number of patients reaches the maximum sample size of 14, the research team will reject the null hypothesis and conclude that the treatment is promising"||||
33902192|NCT02151539|||CASE_ONLY||PROSPECTIVE|||||||
33902193|NCT00974077|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33902194|NCT01112501|||CASE_CONTROL||PROSPECTIVE|||||||
33902195|NCT05404854|||COHORT||PROSPECTIVE|||||||
33902196|NCT03201653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||SURGICEL group comparisons to traditional group (each performed at a nominal alpha of 0.05 and power of 0.80) in a 2:1 allocation ratio|t|t|f|t
33902197|NCT04388657|||COHORT||PROSPECTIVE|||||||
33902198|NCT00740506|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33902199|NCT02406872|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33902200|NCT00170157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080119|NCT02653365|||COHORT||PROSPECTIVE|||||||
34080120|NCT02151357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080121|NCT06435975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682475|NCT04884451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682476|NCT06229171|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33682477|NCT01613170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682478|NCT04044144|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignment||||
33682479|NCT01529801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33682480|NCT01889381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902201|NCT00005592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902202|NCT01081210|||OTHER||PROSPECTIVE|||||||
33902203|NCT01582724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985304|NCT05618405|||COHORT||PROSPECTIVE|||||||
33985305|NCT01733511|||COHORT||PROSPECTIVE|||||||
33985306|NCT05119270|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"3 groups will be compared:~* Group 1: 30 participants suffering from cataract who are candidates for femtosecond laser assisted cataract surgery~* Group 2: 30 participants suffering from cataract who are candidates for traditional cataract surgery with the Active Sentry handpiece~* Group 3: 30 participants suffering from cataract who are candidates for traditional cataract surgery with the OZil handpiece"||||
33985307|NCT04567056|||CASE_CONTROL||PROSPECTIVE|||||||
33985308|NCT01675622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985309|NCT05213273|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized nutritional intervention clinical trial of 2 parallel groups, in which 150 healthy adults between 18 and 65 years will be recruited.||||
33985310|NCT00164892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33985311|NCT02062580|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33985312|NCT00258947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985313|NCT04200014|||CASE_ONLY||RETROSPECTIVE|||||||
33682481|NCT01975857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682482|NCT05128422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682483|NCT04357288|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33682484|NCT03712423|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, open-label, single centre immune-PET study with \[89Zr\]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of \[89Zr\]-Df-CriPec® docetaxel||||
33682485|NCT01855373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33682486|NCT02428127|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33902204|NCT04034979|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||4 phases||||
34080122|NCT02539992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080123|NCT04000178|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080124|NCT00072384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080125|NCT05689359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080126|NCT05757414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080127|NCT05646368|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||f|t|t|t
34080128|NCT04650074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080129|NCT03069872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080130|NCT02664077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080131|NCT02037672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080132|NCT00471497|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682487|NCT05930015|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 200 people tested were randomly divided into 4 groups of 50 each during the intervention phase, with three groups carrying out a intervention||||
33682488|NCT00197158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33682489|NCT02745418|||OTHER||CROSS_SECTIONAL|||||||
33682490|NCT00321646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682491|NCT05599568|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682492|NCT06173115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682493|NCT03865797|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682494|NCT05441657|||CASE_CONTROL||RETROSPECTIVE|||||||
33682495|NCT02222753|||COHORT||PROSPECTIVE|||||||
33682496|NCT03045224|||COHORT||PROSPECTIVE|||||||
33682497|NCT01180179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682498|NCT00355836|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33682499|NCT06237192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682500|NCT01716962|||COHORT||PROSPECTIVE|||||||
33682501|NCT00814216|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33682502|NCT02823639|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33682503|NCT03985878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682504|NCT03207438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33772767|NCT04375696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772768|NCT04441424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772769|NCT00864838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772770|NCT02411591||SEQUENTIAL||TREATMENT||NONE||||||
33772771|NCT02622633|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33902205|NCT05503134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902206|NCT06162026|NA|SINGLE_GROUP||SCREENING||NONE||||||
33902207|NCT05016128|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34080133|NCT04463134|||COHORT||PROSPECTIVE|||||||
34080134|NCT05383326|||COHORT||PROSPECTIVE|||||||
34080135|NCT04873089|||OTHER||OTHER|||||||
34080136|NCT01116921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080137|NCT05812950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once data collection is complete, the data will be blinded by one of the principal investigators. This allows for blinded analysis by the outcome assessor.|All participants start with CBT-E phase 1 and 2. If not improved enough with regard to eating disorder symptoms (following EDE-Q pre- and post measure comparison) in the first phase, they will be included in the RCT. When included they will be randomly assigned to either the CBT-E continuation condition or the GST condition.|f|f|f|t
34080138|NCT05669118|||CASE_ONLY||PROSPECTIVE|||||||
34080139|NCT00471484||||TREATMENT||NONE||||||
34080140|NCT01487083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080141|NCT01690182|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34080142|NCT02923700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682505|NCT04742413|||COHORT||PROSPECTIVE|||||||
33682506|NCT03458598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The intra-operative anesthesiologist, surgeon and outcomes assessor are blinded to group allocation||t|t|f|t
33682507|NCT04880330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682508|NCT04963842|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33682509|NCT00832039|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33682510|NCT03431727|||COHORT||PROSPECTIVE|||||||
33682511|NCT04665869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33772772|NCT00734513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772773|NCT05601492|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant will not know that the electronic cap adapter is actually recording the opening of the medication bottle.|Randomization 1:1:1|t|f|f|f
33772774|NCT04410679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772775|NCT01349660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772776|NCT02531295|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772777|NCT04594551|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772778|NCT01121718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This study does not involve any masking.|This is an experimental study. All study subjects will receive the same intervention.||||
33772779|NCT05644405|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33772780|NCT05376592|||COHORT||PROSPECTIVE|||||||
33772781|NCT04893070|||CASE_CONTROL||PROSPECTIVE|||||||
33772782|NCT02325713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772783|NCT05769270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080143|NCT03937115|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34080144|NCT02411240|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080145|NCT00995839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080146|NCT02390154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080147|NCT02728063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080148|NCT06459713|||OTHER||RETROSPECTIVE|||||||
34080149|NCT00831220|||CASE_CONTROL||PROSPECTIVE|||||||
34080150|NCT03511768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080151|NCT02938702|||COHORT||PROSPECTIVE|||||||
34080152|NCT01046864|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34080153|NCT05385146|RANDOMIZED|PARALLEL||PREVENTION||NONE|patients who signed inform consent are randomized into qigong group and control group|randomized||||
33902208|NCT01808703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902209|NCT02749370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902210|NCT00317070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902211|NCT00620204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902212|NCT06242925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, matched, interventional prospective cohort study compared to historical cohort.||||
33902213|NCT02891746|||COHORT||PROSPECTIVE|||||||
33902214|NCT00318201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902215|NCT06574269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902216|NCT00126464|RANDOMIZED|||TREATMENT||||||||
33902217|NCT00471471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902218|NCT05348850|||OTHER||CROSS_SECTIONAL|||||||
33902219|NCT02273310|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902220|NCT00068952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902221|NCT05114863|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33902222|NCT04606511|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902223|NCT06468774|||CASE_CONTROL||PROSPECTIVE|||||||
33902224|NCT03279510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985314|NCT01548248|||COHORT||PROSPECTIVE|||||||
33985315|NCT04256122|||CASE_CONTROL||RETROSPECTIVE|||||||
33985316|NCT01629069|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985317|NCT01162603|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33985318|NCT01552499|RANDOMIZED|PARALLEL||||NONE||||||
33985319|NCT02438722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985320|NCT04337320|||COHORT||RETROSPECTIVE|||||||
33985321|NCT01448798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33985322|NCT03478748|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Both investigators and participants knew about the intervention and who were involved.|The model is an oral health education package that covers the following aspects: (i) cognitive component (for example, the provision of basic oral health knowledge using an anticipatory guidance technique); (ii) psychomotor component (for example, the demonstration of basic oral health skills such as toothbrushing skills with a hands-on practical); and (iii) attitude component (activities that help to improve the children's attitude towards oral health). Children (along with their older siblings and mothers) in the study group were required to make six-monthly visits to the dental clinic in the three-year study period. Those in the control group received the conventional Ministry of Health programme.||||
33985323|NCT00008515||||TREATMENT||||||||
33985324|NCT03567174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized trial||||
33985325|NCT02647580|||CASE_ONLY||CROSS_SECTIONAL|||||||
33985326|NCT00825110|||COHORT||PROSPECTIVE|||||||
33985327|NCT00696020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985328|NCT01932086|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985329|NCT00738868|NON_RANDOMIZED|||TREATMENT||||||||
33772784|NCT01628302|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33985330|NCT03982862|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33772785|NCT04972981|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985331|NCT04441970|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
33985332|NCT04738071|||COHORT||OTHER|||||||
33985333|NCT02078986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985334|NCT00002911|RANDOMIZED|||TREATMENT||||||||
34080154|NCT00018317|RANDOMIZED|||TREATMENT||NONE||||||
34080155|NCT03598400|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34080156|NCT00729521|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34080157|NCT01285661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080158|NCT04331288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080159|NCT02178904|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080160|NCT05020041|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34080161|NCT05762367|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|MRI will be pseudo-anonymised and blindly analyzed|20 patients with IIH and 20 volunteers paired on age (20-40 yo) and gender will be prospectively enrolled in the study|f|f|t|t
34080162|NCT05029908|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33772786|NCT00247624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772787|NCT04888637|||OTHER||OTHER|||||||
33902225|NCT06672588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized into the study using a permuted block method with a random number generator. The study statistician will prepare the randomization scheme. The block size will be fixed and study personnel will be blinded to the randomization block size.|The study is a randomized, double blind, parallel-group clinical trial with two treatment arms conducted at two academic institutions. The aim is to recruit 80 participants in the hope of having 50 participants complete the study.|t|t|f|t
33902226|NCT06274112|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||All participants will receive each dose of TMS in a counterbalanced order (AB or BA)|t|f|f|f
33985335|NCT01486147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985336|NCT00403715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33985337|NCT05883943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985338|NCT01012635|||COHORT||PROSPECTIVE|||||||
33985339|NCT01876875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985340|NCT03860415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985341|NCT00267644|||COHORT||PROSPECTIVE|||||||
33985342|NCT06064422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985343|NCT01460147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985344|NCT00318461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985345|NCT04043884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985346|NCT04089735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985347|NCT05357898|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985348|NCT03393286|||COHORT||PROSPECTIVE|||||||
33985349|NCT05813678|||COHORT||PROSPECTIVE|||||||
33985350|NCT00377754|||||PROSPECTIVE|||||||
33985351|NCT01596166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33985352|NCT02436057|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985353|NCT03363503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985354|NCT05235321|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In this study, 3 eye pressure measurements will be made in the upright position (standard GAT, fixed force GAT, upright applanating prototype) and 1 in the supine position (supine applanating prototype).||||
33985355|NCT06349538|||COHORT||PROSPECTIVE|||||||
33985356|NCT00550563|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985357|NCT01880593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985358|NCT01470482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985359|NCT02146495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985360|NCT06387771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985361|NCT05166447|||COHORT||PROSPECTIVE|||||||
33985362|NCT04038801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985363|NCT02546817|||CASE_ONLY||PROSPECTIVE|||||||
33985364|NCT03857061|||COHORT||PROSPECTIVE|||||||
33985365|NCT00018733|RANDOMIZED|||TREATMENT||DOUBLE||||||
33985366|NCT05599438|||CASE_CONTROL||PROSPECTIVE|||||||
33985367|NCT05495997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985368|NCT01182415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985369|NCT05054348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose escalation, dose expansion and dose randomization||||
33985370|NCT05223426|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single blind masking: the research personnel performing the outcome assessments at baseline, between the intervention (two months) and after the intervention (four months) will be blinded to groups' intervention order. Participants will be aware of the order in which they receive the intervention.||f|f|f|t
34080163|NCT05105074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34080164|NCT03393182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Prospective, randomized, multi-center trial that comparing surgical complications and Quality of Life between Totally laparoscopic distal gastrectomy and Laparoscopy-assisted distal gastrectomy in Korea."|f|f|f|t
34080165|NCT01870713|||CASE_CONTROL||PROSPECTIVE|||||||
33772788|NCT03179800|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33985371|NCT00771485|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33985372|NCT01397630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985373|NCT02411552|||COHORT||PROSPECTIVE|||||||
33985374|NCT00511069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985375|NCT00830206|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33985376|NCT00481338|NA|SINGLE_GROUP||||NONE||||||
33985377|NCT00662571|||CASE_CONTROL||RETROSPECTIVE|||||||
33985378|NCT01330186|||CASE_ONLY||PROSPECTIVE|||||||
34080166|NCT00383201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34080167|NCT01088971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080168|NCT01885013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080169|NCT04710212|||COHORT||PROSPECTIVE|||||||
33985379|NCT02739997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985380|NCT02898493|||CASE_ONLY||CROSS_SECTIONAL|||||||
33985381|NCT01689181|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33985382|NCT05283070|||COHORT||PROSPECTIVE|||||||
33985383|NCT01273974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985384|NCT03564561|||COHORT||PROSPECTIVE|||||||
33985385|NCT01852617|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985386|NCT01253590|||COHORT||PROSPECTIVE|||||||
33985387|NCT01875952|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33985388|NCT01929642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682512|NCT00475423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985389|NCT01511939|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985390|NCT04054232|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The primary investigator will not be involved in the randomization process or in the process of collecting outcome data. Once data collection is complete, an independent investigator not involved in the trial will confirm study endpoints.|Patients with a high risk of having undiagnosed PAD will be identified using an EHR-based PAD screening tool. Fifty total patients meeting inclusion criteria will be randomized to either the intervention arm - primary treating physician notified about high risk of undiagnosed PAD - or the control arm - no notification provided. Physician notification will include suggestions to refer the patient to vascular medicine and/or order ankle brachial index (ABI) testing. If a patient is found to have PAD diagnosed by ABI the patient and provider will be notified and provided guidelines from the American Heart Association regarding management of PAD.|f|f|t|t
33985391|NCT02058797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985392|NCT05752734|||COHORT||PROSPECTIVE|||||||
33985393|NCT04990817|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33682513|NCT02793648|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33682514|NCT05699473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|"The randomization list will be drawn up before the beginning of the study by a person not related to the study and stored confidentially. Every effort will be made to maintain the blind during the study.~The labelling will not show any difference (including batch number and use-by date) between the test and the comparative products.~During the whole study and in the absence of unblinding, neither the investigators, service providers, nor the participant will be aware of the product they test or can deduce the group they belong to.~The unblinding will occur after the database locking, at the end of the study. The unblinding will be in charge of the person responsible for the randomization list.~Whether an emergency unblinding procedure may occur (i.e., SAE), the date and the reason for the unblinding will be indicated in the electronic Case Report Form (e-CRF) and the source document of the study."|Prospective, monocentric, double-blind, randomized, cross-over bioavailability study|t|t|t|t
33682515|NCT05772052|||COHORT||CROSS_SECTIONAL|||||||
33682516|NCT06074042|||COHORT||PROSPECTIVE|||||||
33682517|NCT02299973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772789|NCT04866914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772790|NCT00862953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772791|NCT06115096|||CASE_ONLY||CROSS_SECTIONAL|||||||
33772792|NCT01450280|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772793|NCT03413358|RANDOMIZED|PARALLEL||TREATMENT||NONE||These subjects will be randomized (1:1) to treatment group or control group.||||
33772794|NCT02892942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772795|NCT01463917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772796|NCT03841981|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33772797|NCT04228549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33772798|NCT00002354||||TREATMENT||DOUBLE||||||
33772799|NCT05581238|||COHORT||RETROSPECTIVE|||||||
33772800|NCT02471404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772801|NCT02050022|||CASE_CONTROL||PROSPECTIVE|||||||
33772802|NCT04747275|RANDOMIZED|CROSSOVER||OTHER||NONE||Phase 4, single-center, pilot, randomized, open-label, cross-over study||||
33772803|NCT01163747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772804|NCT02868437|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772805|NCT05015673|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double blind|Double-blind, Placebo-controlled, Randomized, 3-period, 3-treatment Crossover|t|t|t|t
33772806|NCT04151693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Research group, 35-40 participants (8 sessions in 4 months) Control group (health and lifestyle counselling), 35-40 participants (6 sessions in 3 months)|f|t|f|f
33772807|NCT00518141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772808|NCT05611697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are allocated to surgical treatment 2 weeks before surgery and blinded to treatment allocation until the first postoperative day.|Patients are randomized in a 1:1 ratio to sleeve gastrectomy or SASI. The randomization list will contain block sizes of 4 and 6 in random order, stratified by study center.|t|f|f|f
33772809|NCT04499417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Outcomes Assessors are not aware of the study hypothesis / the condition.|The study has a randomised placebo-controlled parallel design (two arms: experimental-condition, sham-condition).|t|f|f|t
33772810|NCT06415786|||CASE_ONLY||PROSPECTIVE|||||||
33772811|NCT04404621|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33772812|NCT02023138|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33772813|NCT04645524|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33772814|NCT04888702|NA|SINGLE_GROUP||OTHER||NONE||all patients undergo clinical evaluation and wear Actimyo device in daily living to evaluate their improvement under treatment.||||
33772815|NCT05542381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study design is a double-blinded placebo-controlled experiment, as the patient and the investigator recording the pain scores will not know which treatment arm the patient is assigned to (negative control or experimental group).|Double-blinded placebo-controlled design|t|f|t|t
33772816|NCT03435458|RANDOMIZED|PARALLEL||OTHER||SINGLE||The study is a randomized, multicentre, open-label, controlled trial comparing association of balloon catheter plus oral prostaglandin E1 versus oral prostaglandin E1 alone to induce labor in a 1:1 randomization of nulliparous obese women.|f|f|f|t
33772817|NCT04615208|||COHORT||PROSPECTIVE|||||||
33985394|NCT02220166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772818|NCT02164162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33772819|NCT02878213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772820|NCT02982720|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
33772821|NCT02228525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772822|NCT05601635|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33772823|NCT02030275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772824|NCT03410290|||COHORT||PROSPECTIVE|||||||
33772825|NCT03902938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772826|NCT00358215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772827|NCT02265380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772828|NCT02791490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772829|NCT00910806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772830|NCT00867490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772831|NCT04293809|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772832|NCT06403839|||COHORT||PROSPECTIVE|||||||
33772833|NCT03706157|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33772834|NCT02040090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33772835|NCT05640167|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33772836|NCT00259324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772837|NCT05784662|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||RCT||||
33772838|NCT04375670|||COHORT||OTHER|||||||
33902227|NCT04549038|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 randomized, non-blinded, controlled||||
33902228|NCT01099826|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33902229|NCT01426048|||CASE_ONLY||RETROSPECTIVE|||||||
33902230|NCT05535673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902231|NCT02133014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902232|NCT03633643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||single-dose application of Cotrimoxazole compared to a 3-day application of Cotrimoxazole|t|f|t|t
33902233|NCT01079793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080170|NCT06005363|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participants receive randomized allocation to BIS, DEX, or usual care group before VP shunt surgery. Outcome assessor evaluate the preoperative and postoperative cognitive function, delirium status, and evaluate glymphatic function with functional MRI.|Two interventional group with BIS group and DEX group all receive BIS monitoring, and DEX group receive dexmedetomidine infusion.|t|f|f|t
34080171|NCT03388424|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33772839|NCT04333173|||COHORT||RETROSPECTIVE|||||||
34080172|NCT03323593|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34080173|NCT05976789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Repeated Measures with two treatment groups|f|f|f|t
34080174|NCT03451981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080175|NCT04378335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772840|NCT03202030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772841|NCT05298462|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In this study we aim to evaluate the accuracy of this new test, in patients and in hospital staff with a history of COVID-19 symptoms||||
33772842|NCT06039228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772843|NCT00662493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772844|NCT00240838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772845|NCT02552433|||COHORT||PROSPECTIVE|||||||
33772846|NCT00502996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772847|NCT06210763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772848|NCT02836613|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33772849|NCT02044237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33772850|NCT00002015||||TREATMENT||NONE||||||
33772851|NCT03499574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised Controlled Trial|f|f|f|t
33772852|NCT00787722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902234|NCT03094936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902235|NCT02153242|||CASE_ONLY||PROSPECTIVE|||||||
33902236|NCT03345862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080176|NCT03003910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080177|NCT01207947|||CASE_ONLY||PROSPECTIVE|||||||
34080178|NCT01662544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080179|NCT04020367|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33772853|NCT01995357|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33772854|NCT00489723|||DEFINED_POPULATION||PROSPECTIVE|||||||
33772855|NCT03851913|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902237|NCT00734929|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33772856|NCT02337205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772857|NCT02218021|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33772858|NCT05184738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772859|NCT01651936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772860|NCT03652480|||COHORT||PROSPECTIVE|||||||
33772861|NCT02242240|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772862|NCT05752812|||COHORT||PROSPECTIVE|||||||
33772863|NCT05197686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Groups are designed by web randomizer.||f|f|t|f
33902238|NCT01589120|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33902239|NCT04955743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33985395|NCT00864097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985396|NCT05831462|RANDOMIZED|PARALLEL||TREATMENT||NONE||cvbnm-89||||
33985397|NCT01826409|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985398|NCT00373217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985399|NCT05134220|||CASE_CROSSOVER||PROSPECTIVE|||||||
33985400|NCT01845870|||CASE_CONTROL||RETROSPECTIVE|||||||
33985401|NCT04128943|||COHORT||PROSPECTIVE|||||||
33985402|NCT02755714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985403|NCT06312488|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985404|NCT06016894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985405|NCT05380024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985406|NCT04795154|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|"The participant was pregnant women\> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg, who was approved as the subject of research and sign in the informed consent.~The care provider was a midwife who was competent in yoga exercise, pregnancy care services, as well as competent phlebotomies.~Investigator was the authors in this research."|This study was an experimental study that used pre and post-test designs in a single group. pre-group wasn't got yoga exercise, and post group was got yoga exercise was 30 minutes every 2 weeks for two months (4 times treatment). Yoga exercises technique used stretching and posture exercises (asanas) combined with deep breathing (pranayama) and meditation, to unify body, mind, and spirit (Babbar S, Parks-Savage AC, Chauhan SP, 2012). We obtained 24 samples from pregnant women\> 20 weeks who had blood pressure level which was 130/80 mmHg to 140/90 mmHg got fouth times yoga exercise during pregnancy. This study was carried out in September 2020. Every each subject was measured the hypertension level by systolic and diastolic blood pressure, the protein level in urine, as well as blood platelets. The research was carried out in several public health centers where was Puskesmas Pembina and two clinics of midwives practice in Palembang city from September to November 2020.|t|t|t|f
33985407|NCT01864174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985408|NCT04314505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985409|NCT02126800|||||PROSPECTIVE|||||||
33985410|NCT05872217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A prospective randomized controlled trial of pre-post study design with two months follow-up evaluation will be used.|"intervention Control Group: Children in this group will receive conventional UE therapeutic program for about 60 minutes/3session per week.~Children in this group will receive the same conventional UE therapeutic program as control group in addition to virtual reality session using fully-immersive VRapeutic software gaming technology (Archeeko module) for 30 min/3sessions/week for 8 weeks."|t|t|f|t
33985411|NCT02609295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33985412|NCT05835622|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||After screening visit, patients are randomised between two Arms. Patients in Arm A start with experimental phase and after a wash-out period start the control phase (without exoskeleton). Patients randomised in Arm B start with the control phase and after the wash-out period start the experimental phase. After that, all patients have a follow-up period.||||
33985413|NCT01616498|||CASE_CONTROL||PROSPECTIVE|||||||
33985414|NCT05005494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Patient, anesthesiologist and surgeon are blinded|Double blinded prospective randomized controlled trial|t|t|t|t
33985415|NCT01004237|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33985416|NCT05068648|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33985417|NCT05439109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The primary investigator will provide the information regarding the portion of endotracheal to be kept below the vocal cords to the care provider after measuring the dimensions of the trachea topographically. After tube placement, the tube tip to carina distance will be measured in both topographical and intubation guide mark technique.|All enrolled patients will be intubated by either topographical landmarks of individual tracheal dimensions or by the conventional intubation guide method.|t|f|f|t
33985418|NCT03518905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are blinded either to sham or treatment and unblinded after 24 weeks after final examination|randomized sham-controlled|t|f|f|f
33985419|NCT04050930|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||each volunteer will participate to the whole protocol, that is 5 recording sessions, which, except the first session, will be organized in a random order for each volunteer||||
33985420|NCT01585259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985421|NCT00075478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985422|NCT03170622|||COHORT||PROSPECTIVE|||||||
33985423|NCT05992805|||CASE_ONLY||PROSPECTIVE|||||||
33985424|NCT01789177|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985425|NCT01305122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985426|NCT02190877|||COHORT||RETROSPECTIVE|||||||
33985427|NCT02642068|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33985428|NCT04666311|||COHORT||PROSPECTIVE|||||||
34080180|NCT00036764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985429|NCT05163132|||CASE_ONLY||PROSPECTIVE|||||||
33985430|NCT03148808|NA|SINGLE_GROUP||TREATMENT||NONE||NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.||||
33985431|NCT01211652|||COHORT||CROSS_SECTIONAL|||||||
34080181|NCT03363971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33772864|NCT05312515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||In order to ensure randomization in the study, a random numbers table was created by dividing into two groups out of 238 samples by taking 10% more than the number of samples determined on the site https://www.randomizer.org/. In order to avoid bias, the assignment of women to the intervention and control groups according to the randomization list will be determined by a midwife working in the clinic, who is not one of the study authors. In the study, the CONSORT scheme will be followed during the application.|t|t|t|f
33772865|NCT02102464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772866|NCT01951092|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33772867|NCT06159296|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study is double blind. The participants will not know whether the machine they use delivers hydroxy or placebo gas. The PI and outcome assessors will also not know which machine delivers hydroxy or placebo gas to participants during the running of the study. A collaborator will be in charge of blinding for the study.|Participants will be randomly assigned a machine that delivers either hydroxy or placebo gas in the first three weeks of the study. Those who receive placebo in the first three weeks will receive hydroxy in the last three weeks following a minimum of a 3 week washout period. Those who receive hydroxy in the first three weeks will receive placebo in the last three weeks.|t|f|t|f
33772868|NCT05592535|||COHORT||RETROSPECTIVE|||||||
33772869|NCT00422370|RANDOMIZED|PARALLEL||||DOUBLE||||||
33772870|NCT03638635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participant and the floor nursing staff recording pain scores will be blinded to the assigned intervention.|Participants are randomized to receive either standard bupivacaine or liposomal bupivacaine.|t|f|f|t
33772871|NCT05851911|||COHORT||PROSPECTIVE|||||||
33772872|NCT02922673|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33772873|NCT03407261|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33772874|NCT04220918|||COHORT||PROSPECTIVE|||||||
33772875|NCT01518660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772876|NCT03113721|||COHORT||PROSPECTIVE|||||||
33985432|NCT00635492|||COHORT||PROSPECTIVE|||||||
33772877|NCT00652262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772878|NCT00275496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772879|NCT02169219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772880|NCT04183673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33772881|NCT00305682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772882|NCT06153940|||COHORT||PROSPECTIVE|||||||
33772883|NCT02981485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772884|NCT04176133|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772885|NCT03935217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||For primary phase of study, patients were randomly assigned in a 1:1 ratio to either Solosec or Placebo.|t|t|t|t
33772886|NCT03154203|||COHORT||PROSPECTIVE|||||||
33772887|NCT05554146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||We will observe participants who are enrolled in one of 4 arms in a partnering study over 14 weeks.|t|t|t|t
33772888|NCT06207396|||CASE_ONLY||PROSPECTIVE|||||||
33985433|NCT01741844|||CASE_ONLY||PROSPECTIVE|||||||
33985434|NCT01530620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985435|NCT03571893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to participant treatment condition.|Participants will be randomly assigned to one of two conditions, with assessments occurring prior to randomization, at 3 months and 12 months. Participants will be referred to either Weight Watchers or provided DIY resources. Study staff will not deliver intervention.|f|f|f|t
33985436|NCT04943029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772889|NCT00372333|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772890|NCT02560740|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33985437|NCT05309941|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants are not aware of the condition they are assigned to.|Participants attend a single study visit and are randomized to view one of two nutrition education videos.|t|f|f|f
33985438|NCT02418637|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33985439|NCT04551261|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985440|NCT05207956|RANDOMIZED|PARALLEL||TREATMENT||NONE||After consenting to participate in the trial, participants will be randomized in pairs to one of the two study arms.||||
33985441|NCT04141202|||COHORT||PROSPECTIVE|||||||
33985442|NCT00365534|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34080182|NCT04071379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomized, double blind, 2 arms parallel group, prospective intervention study This study will do the lot to lot consistency and will be compared to registered product|Subjects neonates: Randomized, double blind, 2 arms parallel groups, prospective intervention Study|t|f|t|f
34080183|NCT06394583|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34080184|NCT03547609|NA|SINGLE_GROUP||OTHER||NONE||||||
34080185|NCT01241279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080186|NCT00002424||||TREATMENT||DOUBLE||||||
34080187|NCT02359461|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34080188|NCT04283786|||COHORT||CROSS_SECTIONAL|||||||
34080189|NCT01883895|NA|SINGLE_GROUP||TREATMENT||NONE||three treatment design, all participants will perform two exercise sessions (isometric exercise, concentric exercise), as well as a control session in a randomized manner. (This is not a cross-over design as each participant will have their own randomized order of sessions of exercise \& control sessions.)||||
34080190|NCT00838071|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080191|NCT04601727|||COHORT||PROSPECTIVE|||||||
34080192|NCT04100616|||CASE_ONLY||PROSPECTIVE|||||||
34080193|NCT01095835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080194|NCT01051921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080195|NCT06363643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080196|NCT04787705|||COHORT||PROSPECTIVE|||||||
34080197|NCT03671070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080198|NCT00735007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080199|NCT01304797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080200|NCT05310864|||OTHER||CROSS_SECTIONAL|||||||
34080201|NCT01341496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080202|NCT04064112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080203|NCT03786380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772891|NCT05975866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Before the start of the study, the set of cans containing the relevant capsules will be coded as A and B by someone other than the researcher so that the researcher does not know the type of capsule received by the patients. The cans containing the relevant capsules will be delivered to the patients on a monthly basis, and they will be asked to take one tablet with cold water every day (morning, noon, and night with the main meals). Also, the curcumin placebo will be similar to the curcumin supplement in terms of size, shape, color, appearance, smell, and drug distribution cans.|The study subjects are Hashimoto's patients who, if they wish to participate in this research, a written consent form will be obtained from the patients at the beginning of the study. The patients will be classified according to age and sex. Then, using Stratified Block Randomization, patients will be placed in one of two intervention or placebo groups. The intervention will last 12 weeks, and the anti-inflammatory diet will be personalized based on each person's calorie intake. Patients will be asked to take one tablet with cold water daily (morning, noon, and night with the main meals). Also, the curcumin placebo in size, shape, color, appearance, smell, and dispensing cans of the drug will be similar to the curcumin supplement.|t|t|t|t
33772892|NCT04246203|||COHORT||PROSPECTIVE|||||||
33772893|NCT00431977|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33772894|NCT02605382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772895|NCT03701009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772896|NCT02547571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772897|NCT03490903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772898|NCT02065570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080204|NCT02208544|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34080205|NCT05733130|||COHORT||PROSPECTIVE|||||||
34080206|NCT03273478|||COHORT||PROSPECTIVE|||||||
34080207|NCT00449163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080208|NCT02182310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34080209|NCT02564367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080210|NCT01954589|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34080211|NCT05839717|||COHORT||PROSPECTIVE|||||||
34080212|NCT02215850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080213|NCT01339871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080214|NCT04363060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080215|NCT04790695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080216|NCT04609514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080217|NCT01245101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080218|NCT05762237|||COHORT||RETROSPECTIVE|||||||
34080219|NCT05252403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080220|NCT04271124|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34080221|NCT05645926|||COHORT||OTHER|||||||
34080222|NCT03557177|||COHORT||PROSPECTIVE|||||||
34080223|NCT05543538|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34080224|NCT00920153|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080225|NCT02577536|||COHORT||PROSPECTIVE|||||||
34080226|NCT03843372|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All of participants will be randomly allocated into two groups as random number table. The first group will ongoing CPAP therapy in first night and high flow nasal cannula in the second night. The second group will oppositely performed high flow nasal cannula in first night and CPAP in second night.||||
34080227|NCT06479382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080228|NCT01224275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080229|NCT06333730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34080230|NCT03728062|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34080231|NCT02016989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080232|NCT04669431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080233|NCT03849534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator is blinded to treatment that is performed by a specialist in orofacial pain. The patient is instructed to not reveal the treatment to the investigator|"Non-inferiority study with two patient arms that are randomized to one of three different treatment arms.~75 children with TMD myalgia are randomized to one of three treatment arms 75 children with TMD arthralgia are randomized to one of three treatment arms"|f|f|t|f
34080234|NCT02059837|||CASE_ONLY||RETROSPECTIVE|||||||
33682518|NCT04517279|RANDOMIZED|PARALLEL||TREATMENT||NONE||The model is a cluster randomized controlled trial with randomization at the team level.||||
33682519|NCT06090292|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The subject will be blind to stimulation condition (sham/active TUS). The assessor for the finger accelerometry will be blind to stimulation condition (sham/active TUS). The UPDRS examination will be video-recorded and blindly assessed by a research team member.||t|f|f|t
33772899|NCT04453670|||CASE_ONLY||PROSPECTIVE|||||||
33682520|NCT05546593|||OTHER||CROSS_SECTIONAL|||||||
33682521|NCT02812888|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682522|NCT04152993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902240|NCT03809572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Given the use of group therapy, participants and interventionists cannot be blinded to group assignment. The study is designed to minimize the extent to which study staff, aside from interventionists and the primary Study Coordinator(s), are aware of group assignment. The Study Coordinator(s) needs to know group assignment because they will inform participants of their group assignment and will be the main point of contact for participants throughout the study, as to reduce risk of participants revealing their group assignment to other study staff. Participants will be informed that only the Study Coordinator(s) and interventionists, if applicable, are aware of their group assignment. Therefore, in order to ensure the integrity of the research study, they should refrain from discussing their group assignment with other staff members.|The study is a randomized, control trial with an intervention arm, Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnant women (Dimidjian, Goodman, et al., 2016), and treatment as usual (TAU) arm. The study will be blinded to staff (except for the study coordinator(s) and interventionists), but participant blinding is not possible due to the nature of the intervention. Participants will be randomized using a stratified block design after initial eligibility determination. Randomization will be stratified based on current depressive symptoms and current stress levels.|f|f|t|t
33682523|NCT01589770|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Individuals specialized in cMRI performed the analyses and were blinded to disease status of participants.|All participants underwent cardiac MRI(cMRI) using a 1.5 tesla Siemens Magnetom Avanto scanner to compare left ventricular structure and Left atrium size.|f|f|f|t
33682524|NCT01615497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902241|NCT02369835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33682525|NCT00866008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902242|NCT03110042|||COHORT||PROSPECTIVE|||||||
33985443|NCT05417230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985444|NCT03661593|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Masking done by a third person following computer randomization||f|f|t|t
33985445|NCT03666585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682526|NCT03033147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682527|NCT02656680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682528|NCT04407572|||CASE_CONTROL||PROSPECTIVE|||||||
33772900|NCT04113330|||OTHER||PROSPECTIVE|||||||
33985446|NCT02629094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985447|NCT05317052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985448|NCT01804777|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33682529|NCT02917057|||COHORT||RETROSPECTIVE|||||||
33682530|NCT03520127|||COHORT||PROSPECTIVE|||||||
33772901|NCT01439087|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33772902|NCT06264934|||CASE_ONLY||PROSPECTIVE|||||||
33772903|NCT04392440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33682531|NCT03400956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682532|NCT05631678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682533|NCT00595374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682534|NCT05535205|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33682535|NCT01574001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682536|NCT06087419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682537|NCT05196711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682538|NCT00471614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772904|NCT02329990|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33772905|NCT05495061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33772906|NCT00865111|RANDOMIZED|CROSSOVER||||NONE||||||
33772907|NCT02604732|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33772908|NCT06089421|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33772909|NCT03085550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772910|NCT00406120|||CASE_ONLY||RETROSPECTIVE|||||||
33772911|NCT03962595|||OTHER||PROSPECTIVE|||||||
33772912|NCT05285826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772913|NCT04723251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772914|NCT00253539|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33772915|NCT00875849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772916|NCT05758155|RANDOMIZED|PARALLEL||OTHER||SINGLE|"İn this study, the names of the patients nursing student in the two wards will be sorted and numbered in alphabetical order. After the numbering process, the patients will be selected to the experimental and control group by using the www.randomizer.org/ site by an independent specialist."|randomized controlled trial|t|f|f|f
33682539|NCT00000375|RANDOMIZED|||TREATMENT||SINGLE||||||
33682540|NCT03670420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772917|NCT02753530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772918|NCT01721395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772919|NCT00206960|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33772920|NCT04034186|||CASE_ONLY||RETROSPECTIVE|||||||
33772921|NCT00403975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33772922|NCT00972387|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33772923|NCT06548685|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33772924|NCT00245596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772925|NCT04730063|||COHORT||PROSPECTIVE|||||||
33772926|NCT05595330|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33772927|NCT04883983|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772928|NCT01863602|||||PROSPECTIVE|||||||
33772929|NCT03266471|||CASE_CONTROL||PROSPECTIVE|||||||
33772930|NCT05643482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized between HBOT and control group with a 1:1 allocation ratio, stratified by decade of age and gender via computer generated block randomization with block size of four.|t|t|t|t
33772931|NCT00581113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902243|NCT04498858|||COHORT||PROSPECTIVE|||||||
33902244|NCT03501355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33902245|NCT05477238|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Monocentric, cross-sectional and comparative study||||
33902246|NCT05348005|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"cross-over clinical study to evaluate the effectiveness of TENS units on the management of endometriosis flare-related pain. Subjects will participate in a 3-month baseline period (no TENS unit use for endometriosis flares) and then cross-over to a 3-month treatment period (TENS unit use for endometriosis flares)."||||
33902247|NCT01378390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902248|NCT00147108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902249|NCT03401177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33902250|NCT03390231|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label study with all subjects received SCE therapy.|In this project, the optimized SCE therapy for diabetes will be tested in a prospective, single-arm, open-label, single-center study||||
33902251|NCT04379518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902252|NCT06611631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33902253|NCT05101213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902254|NCT06005493|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study consists of individual modules each evaluating the safety and tolerability of AZD5863 dosed as monotherapy:~* Module 1: AZD5863 intravenous administration~* Module 2: AZD5863 subcutaneous administration~Modules 1 and 2 each consist of two parts: Part A, Dose Escalation and Part B, Dose Expansion."||||
33902255|NCT03997474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902256|NCT03538873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902257|NCT02077062|||CASE_CONTROL||PROSPECTIVE|||||||
33902258|NCT05574101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902259|NCT03320629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902260|NCT03846297|||COHORT||PROSPECTIVE|||||||
33902261|NCT00564707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902262|NCT04594694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902263|NCT06512220|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33902264|NCT03280550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902265|NCT04300218|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Multicenter parallel-group add-on superiority randomized controlled trial (RCT) comparing an active treatment condition (iCBT-I plus CAU) to CAU alone||||
33772932|NCT01425632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985449|NCT00913406|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33985450|NCT02478957|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33985451|NCT02121886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985452|NCT01486121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985453|NCT02644434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985454|NCT01458808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985455|NCT04572659|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080235|NCT04356937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects who meet all inclusion criteria and none of the exclusion criteria will be randomized 2:1 to tocilizumab or placebo.|Prospective, multi-center, randomized,double blind, placebo-controlled trial|t|f|t|f
34080236|NCT03538080|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080237|NCT00652444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080238|NCT00659087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34080239|NCT02419599|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34080240|NCT04343352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Researchers and family will know about all the details of the study. Verbal and written permission will be obtained from families.|The research is a randomized controlled experimental study. Pretest - posttest with control and application group||||
34080241|NCT03880747|||COHORT||PROSPECTIVE|||||||
33772933|NCT02126787|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33772934|NCT02231372|||COHORT||PROSPECTIVE|||||||
33772935|NCT04161599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33772936|NCT02258685|||COHORT||CROSS_SECTIONAL|||||||
33772937|NCT01013935|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33772938|NCT03941314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772939|NCT04716413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772940|NCT06355908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902266|NCT02458612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902267|NCT02571179|NA|SINGLE_GROUP||TREATMENT||NONE||Intranasal fentanyl||||
33902268|NCT06673251|||CASE_CONTROL||PROSPECTIVE|||||||
33902269|NCT04962165|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33902270|NCT03482310|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33902271|NCT05781399|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Parts A, B, and D are blinded. Part C is open-label.|The study will be conducted in 4 parts: Parts A, B, C, and D. This study will be seamless, meaning various study parts could begin while other parts are still ongoing, but dose escalation will occur only after satisfactory review of safety and tolerability data from a minimum of 6 participants completing through Day 3, and available PK data.|t|t|t|t
33985456|NCT05259241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-center, prospective, observational study||||
33985457|NCT05027841|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33985458|NCT02992938|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985459|NCT05049226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Unblinded study staff will be responsible for preparing study products (in accordance with the randomly determined assignment), administering the study vaccine, and handling all drug accountability procedures. These personnel will not participate in the other aspects of the clinical trial, to help ensure the integrity of the blind at the site. Unblinded staff will retrieve a participant's randomization assignment after being informed by the PI or designee that a participant is eligible for randomization. They will prepare study vaccine (AZ or PF) with dose (full or half dose) based on the participant's randomization||t|f|t|f
33985460|NCT05400785|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33772941|NCT00645216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985461|NCT00006365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080242|NCT03669588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080243|NCT00908765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080244|NCT02785393|RANDOMIZED|CROSSOVER||||DOUBLE|||t|t|f|f
34080245|NCT01325350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080246|NCT03456466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|TQB2303 and Rituximab|t|f|t|t
34080247|NCT03601169|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34080248|NCT02104661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772942|NCT05856474|||COHORT||OTHER|||||||
33772943|NCT01304043|||COHORT||PROSPECTIVE|||||||
33772944|NCT05409196|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
33772945|NCT00746317|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33772946|NCT04096807|||COHORT||PROSPECTIVE|||||||
33772947|NCT02075190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33772948|NCT01961713|||CASE_ONLY||PROSPECTIVE|||||||
33772949|NCT02916992|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33902272|NCT03065803|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33902273|NCT01963052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902274|NCT05699460|||COHORT||PROSPECTIVE|||||||
33902275|NCT03893929|||COHORT||PROSPECTIVE|||||||
33902276|NCT04284917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902277|NCT06480929|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902278|NCT06673134|||COHORT||PROSPECTIVE|||||||
33902279|NCT02377934|||CASE_ONLY||PROSPECTIVE|||||||
33902280|NCT06443281|||COHORT||CROSS_SECTIONAL|||||||
33902281|NCT02777840|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902282|NCT01123304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080249|NCT03918811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the intervention, blinding of the subject and the operators responsible for extubation is not possible. The person in charge of data statistical analysis and the evaluator who assess and record outcome measures will be blinded to the allocated intervention.|superiority|f|f|t|t
34080250|NCT02324751|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34080251|NCT02145455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080252|NCT00545025|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33772950|NCT05217823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080253|NCT06461169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the study, blinding will be performed only in the assignment-randomisation to groups and statistical analysis of the results.|Block randomisation will be used to ensure that the number of patients in each group is balanced. Patients will be divided into two groups, each group consisting of at least 30 people, by a statistician who is not involved in the study, using a table of random numbers.|f|f|f|t
33902283|NCT03199911|RANDOMIZED|PARALLEL||PREVENTION||NONE|Randomization to one of two intervention arms (i.e. antibiotic ointment vs. placebo artificial tear ointment) will be performed prior to study recruitment by REDCap software. Patients' randomization assignments will be revealed at the initial pre-operative visit or at time that procedure consent is obtained; the study team will not be aware of a subject's randomization assignment prior to that time.|Patients will be randomized to one of two intervention arms (i.e. antibiotic ointment vs. placebo artificial tear ointment) and will not at any point cross over to the other arm.||||
33985462|NCT03858777|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985463|NCT03020615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33985464|NCT03503578|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985465|NCT05279482|||COHORT||RETROSPECTIVE|||||||
33985466|NCT04272060|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"All patients are being asked to undergo a research CT scan in addition to the clinically prescribed invasive coronary angiogram (each patient is the patient's own control for the diagnostic test)"||||
33985467|NCT00517530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985468|NCT02074605|||CASE_CONTROL||PROSPECTIVE|||||||
33985469|NCT01361048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985470|NCT00846274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985471|NCT04328597|||COHORT||PROSPECTIVE|||||||
33985472|NCT05649228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Labeling codes will be used for a double-blind procedure. Packaging is done by Chorda Pharma.|"Each subject will be given two of either:~1. vehicle cream containing 0.25% capsaicin palmitate~2. vehicle cream containing 0.10% non-palmitated capsaicin~3. vehicle cream alone (placebo)"|t|f|t|f
34080254|NCT02312960|NA|SINGLE_GROUP||OTHER||NONE||||||
34080255|NCT05222880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080256|NCT05810701|RANDOMIZED|PARALLEL||TREATMENT||NONE||Rancomized clinical trial Combined observational study||||
34080257|NCT01684176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682541|NCT04705844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, Double-Blind, Placebo-Controlled|Subjects will be randomized to receive a single dose of adalimumab or placebo. Subjects will receive standard care of therapy (per study site written policies or guidelines) together with adalimumab or matching placebo.|t|t|t|t
33682542|NCT03363022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772951|NCT05773131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772952|NCT04550273|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33772953|NCT01490203|||COHORT||PROSPECTIVE|||||||
33772954|NCT00788255|||CASE_ONLY||PROSPECTIVE|||||||
33902284|NCT01301911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902285|NCT04072640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902286|NCT03991377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical raters carrying out evaluations will be blind to the participants' research condition. Patients will not be blind to treatment as a sham alternative to EMDR therapy is impossible due to its use of bilateral stimulation.|This is a multicenter phase II rater-blinded randomized controlled trial with two parallel branches, EMDR + TAU and TAU, of 80 FEP patients who have a history of psychological trauma, even if they do not currently meet DSM-V criteria for PTSD.|f|f|f|t
33902287|NCT02397720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902288|NCT05661565|||OTHER||PROSPECTIVE|||||||
33902289|NCT02392546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33902290|NCT02828319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902291|NCT00790296|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33902292|NCT05894993|||COHORT||PROSPECTIVE|||||||
33902293|NCT03649776|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33902294|NCT02195037|||COHORT||PROSPECTIVE|||||||
33902295|NCT05703503|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33902296|NCT01834326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902297|NCT00552539|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33902298|NCT06293898|NA|SEQUENTIAL||TREATMENT||NONE||||||
33902299|NCT04182191|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985473|NCT04953234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985474|NCT01050088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33902300|NCT01298440|||CASE_ONLY||PROSPECTIVE|||||||
33985475|NCT02591927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985476|NCT02004509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985477|NCT00406068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985478|NCT00798447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985479|NCT00907413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985480|NCT01278550|||COHORT||PROSPECTIVE|||||||
33985481|NCT03871920|||COHORT||PROSPECTIVE|||||||
33985482|NCT05013112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080258|NCT01274533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682543|NCT02102503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33682544|NCT03093584|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33682545|NCT01115192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682546|NCT03452449|||COHORT||PROSPECTIVE|||||||
33682547|NCT01230203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682548|NCT02867553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772955|NCT02226172|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33772956|NCT02915575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33902301|NCT00863733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902302|NCT04697147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neurocognitive assessors are blinded to which participants have received the intervention during their longitudinal visits.||f|f|f|t
33772957|NCT04196374|NA|SINGLE_GROUP||PREVENTION||NONE|There will be no masking all eligible individuals identified with an actionable genomic variant in an ACMG V2.0 gene will be notified.|Individuals who have had their DNA sequenced as part of TOPMed and are living will be notified if they have an actionable genomic result in an ACMG gene. There is no comparison group for this study.||||
33682549|NCT05858840|||COHORT||RETROSPECTIVE|||||||
34080259|NCT06339190|||COHORT||PROSPECTIVE|||||||
33682550|NCT00286559|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33682551|NCT00603486|||CASE_ONLY||PROSPECTIVE|||||||
33682552|NCT01453582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772958|NCT02381782|||COHORT||PROSPECTIVE|||||||
33772959|NCT05297916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||delayed enteral feeding ingroup 1 early enteral feeding in group 2|t|f|f|f
33772960|NCT03321604|||COHORT||PROSPECTIVE|||||||
33772961|NCT05470413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33772962|NCT04684927|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a prospective, single arm, non-randomized, new enrollment cohort study||||
33772963|NCT02054390|||COHORT||PROSPECTIVE|||||||
33772964|NCT03580460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 arm, RCT with waitlist control|f|f|t|f
33772965|NCT01529190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33772966|NCT06100601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Part 1) Case-control study Part 2) Randomized-controlled trial (3 arms)|f|f|f|t
33772967|NCT04070053|NA|SINGLE_GROUP||TREATMENT||NONE||"We will perform a before and after study to evaluate the feasibility and acceptability of the HRF and ARDS Pathway during its pilot implementation. All mechanically ventilated patients will enter the pathway during the one month implementation period and one year post-implementation period.~To assess Pathway feasibility we will collect patient data for two years and one month: one year immediately prior to implementation as well as one month during plus one year following implementation.~To assess acceptability of the pathway we will conduct a survey to clinicians who used the pathway."||||
33772968|NCT00936338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682553|NCT03609593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682554|NCT00170690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772969|NCT02635282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772970|NCT04448431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33772971|NCT05538481|||COHORT||CROSS_SECTIONAL|||||||
33772972|NCT03262701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682555|NCT01263912|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33682556|NCT01607827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33682557|NCT02427178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682558|NCT04469829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772973|NCT01503138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33772974|NCT02864511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772975|NCT04472780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled study|f|f|f|t
33772976|NCT03923361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772977|NCT05255484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33772978|NCT04181398|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Observational cohort study without blinding or randomization.||||
34080260|NCT05446961|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The groups will be randomized and blindly assigned to receive either the LCLT supplement (3 g per day that delivers 2 g elemental of L-carnitine) or placebo. Subjects from Cohort 2 will receive L-carnitine in addition to Standard of Care (SOC) therapy or placebo in addition tosStandard of care (SOC) therapy|A total of 274 subjects, will be prospectively enrolled into a pilot randomized, placebo controlled study in the two cohorts: Cohort 1: 220 healthy, SARS-CoV-2 negative, individuals (55 to 85 years old) with close contact (cohabit) to a person with newly acquired SARS-CoV-2 infection based on PCR detection and absence of antibody response; and, Cohort 2: 54 asymptomatic ( 18 to 85 years old) or symptomatic patients with mild COVID-19 that tested positive for COVID-19 by RT-PCR within the last 24 hours prior to the enrolment in the study.|t|t|t|t
33682559|NCT03471572|||COHORT||CROSS_SECTIONAL|||||||
33682560|NCT00456456|||DEFINED_POPULATION||OTHER|||||||
33682561|NCT01761032|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682562|NCT01967381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33682563|NCT00510965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682564|NCT02684890|||CASE_CONTROL||PROSPECTIVE|||||||
33682565|NCT03911843|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A cohort study was performed in 2017, in all T1D patients 1-18 years old with onset in the years 2014-2017. Supplementation with omega3 was proposed to all subjects with onset in 2017. Patients with onset in 2014-2015-2016 were enrolled only as control subjects. The work was performed on retrospectively collected data in medical records for patients with start of the disease in 2014-2016. Patients enrolled since 2017 have been studied prospectively.||||
33682566|NCT02990247|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33985483|NCT01936194|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33985484|NCT03728296||SEQUENTIAL||TREATMENT||NONE||||||
33682567|NCT05249335|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||multicenter, prospective, investigator single-blinded, randomized study|f|f|t|f
33682568|NCT04764682|||COHORT||PROSPECTIVE|||||||
33682569|NCT02706223|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33682570|NCT03240744|NA|SINGLE_GROUP||PREVENTION||NONE||Inactivated EV71 vaccine (KMB-17 cells)||||
33682571|NCT01622634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682572|NCT02730143|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682573|NCT00555308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682574|NCT03294577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Plinabulin is masked using a double-dummy design. Docetaxel/Doxorubicin/Cyclophasphamide administration is not masked.||t|t|t|f
33682575|NCT03866395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682576|NCT02306031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682577|NCT05550207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682578|NCT02842905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682579|NCT02437227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682580|NCT05480345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682581|NCT04193280|||CASE_ONLY||PROSPECTIVE|||||||
33682582|NCT02266953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682583|NCT02241889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682584|NCT04286217|||COHORT||PROSPECTIVE|||||||
33682585|NCT04133922|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject is studied 3 times in randomized order||||
33682586|NCT03896893|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Enrolled babies will be sequentially recruited to one of 4 study arms (see below).||||
33682587|NCT02349308|||||PROSPECTIVE|||||||
33682588|NCT00008450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682589|NCT06200142|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||(In)capacitated patients (all ages/both genders) with a clinical (and/or family) history and abnormal additional examination (physical (neurological)/ biochemical/ radiological/ genetic) suspicious for an IEM, without diagnosis.||||
33682590|NCT05753579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible patients were divided into two groups using the closed envelope method at a ratio of 1:1. The patients did not know which group they were in. This grouping was unknown to the radiologist performing the evaluation and the statistician performing the data analysis. Mobilization applications and other clinical tests were performed by the same physiotherapist in the study.|This study was designed as a double-blind randomized controlled clinical trial. In order to carry out the prospectively designed study, ethics committee approval was obtained from the Non-Interventional Clinical Research Ethics Committee of Muş Alparslan University with the decision numbered 21 taken at the meeting dated 29.12.2020 and numbered 15. Informed consent was obtained from all patients included in the study before the study.|t|f|f|t
33682591|NCT00021073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682592|NCT00754221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682593|NCT00709579|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33985485|NCT05841316|||COHORT||PROSPECTIVE|||||||
33985486|NCT03942120|||COHORT||PROSPECTIVE|||||||
33985487|NCT03609983|RANDOMIZED|FACTORIAL||SCREENING||NONE||A 3x2 mixed factorial design will be used, with a between-subject factor will of self-weighing group (daily weighing; weekly weighing; and no weighing control group) and within-subject factor will of time (prior to self-weighing and feedback and during self-weighing and feedback).||||
33985488|NCT05297630|||COHORT||PROSPECTIVE|||||||
33985489|NCT04756752|||COHORT||PROSPECTIVE|||||||
33985490|NCT01331187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985491|NCT01683721|||COHORT||PROSPECTIVE|||||||
34080261|NCT02164292|||COHORT||PROSPECTIVE|||||||
33985492|NCT04455230|NA|SINGLE_GROUP||OTHER||NONE||A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects with Fabry Disease||||
33985493|NCT03904966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure group concealment, randomization will be done by using opaque, sealed envelopes and the assessors will be blinded to|Parallel assignment|t|f|f|t
33985494|NCT04813718|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33985495|NCT04925817|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985496|NCT05994859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985497|NCT02406625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985498|NCT02160210|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33772979|NCT01346670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772980|NCT05221749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33772981|NCT03364439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772982|NCT05709691|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know in which group they are, oculomotor therapy will only be used in the experimental group.|128 participants were randomized to follow a physiotherapy online program for 6 weeks. Participants will not know in which group they are, oculomotor therapy will only be used in the experimental group. The results will be measured at the end of the study.|f|f|f|t
33772983|NCT02676986|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33772984|NCT03587792|||COHORT||PROSPECTIVE|||||||
33772985|NCT05034224|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigators performing the analysis of the data (post-hoc) and patients are blinded to the sequence of the interventions.|The study is a single-center, cross-over randomized trial to investigate the effect of coronary sinus occlusion on microvascular resistances.|t|f|t|f
33985499|NCT00357201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33985500|NCT03968796|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985501|NCT03901768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985502|NCT01406418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985503|NCT04869722|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All samples provided to the participant are labelled with 3 digit random codes|This study involves both a crossover design where each participant tastes different protein fortified products with an appropriate break between the tasting. It is also both a within and between groups design as the responses from the older volunteers will be compared with the younger volunteers. The study will be conducted single blind as it not feasible to blind the researcher. Each participant will attend 1 study visits and all products will be presented with random blinding codes.|t|f|f|f
33985504|NCT03827291|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare efficacy of a quadratus lumborum block performed with liposomal bupivacaine for pain relief after laparoscopic colectomy compared to a historical cohort who received thoracic epidural analgesia.||||
33985505|NCT04400617|||CASE_ONLY||CROSS_SECTIONAL|||||||
33985506|NCT01853527|||COHORT||PROSPECTIVE|||||||
33985507|NCT03838393|||COHORT||PROSPECTIVE|||||||
33985508|NCT05811689|||COHORT||CROSS_SECTIONAL|||||||
33985509|NCT01008878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985510|NCT03344055|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985511|NCT03379103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistical analysis will not open label for group allocation|"Patients will be allocated by means of a randomized table in 2 groups:~GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete~GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia"|f|f|f|t
33985512|NCT03617523|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study was partially randomized. Participants were assigned a vaccine group based on age. Participants in Groups 1, 2, and 5 were not randomly assigned, while participants in Groups 3 and 4 were randomly assigned.||||
33985513|NCT05122208|||CASE_CONTROL||RETROSPECTIVE|||||||
33985514|NCT01789294|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33772986|NCT03647020|||CASE_ONLY||RETROSPECTIVE|||||||
33772987|NCT00398398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772988|NCT06078592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33772989|NCT03000673|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33772990|NCT04005729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33772991|NCT00492843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772992|NCT02126436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772993|NCT05825664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33985515|NCT00678262|||CASE_CONTROL||PROSPECTIVE|||||||
33985516|NCT05541432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and outcome assessors will be masked to the group allocation of participants. Participants will be masked to the hypothesis of the study.|Participants will be randomized in a 1:1:1 ratio to one of three arms. Participants will perform exercise or control activities twice weekly for 12 months. Not all participants will start and end at the same time.|t|f|t|t
33985517|NCT05621941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772994|NCT02723279|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33772995|NCT01815736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33772996|NCT01973894|||COHORT||PROSPECTIVE|||||||
33772997|NCT02948348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33772998|NCT03660033|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Participants will be invited to the mother-child simulation centre at CHU Sainte-Justine for a 60 minute simulation session during which they will complete two neonatal resuscitation scenarios (one of pulseless VT and the other of PEA). They will be randomized to either having access or not to ECG monitoring during the resuscitations.||||
33772999|NCT00542503|||COHORT||PROSPECTIVE|||||||
33682594|NCT06396442|||COHORT||PROSPECTIVE|||||||
33682595|NCT00948467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682596|NCT01439698|||CASE_ONLY||PROSPECTIVE|||||||
33682597|NCT03635671|||COHORT||PROSPECTIVE|||||||
33682598|NCT03709576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682599|NCT03279393|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33682600|NCT01964040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33682601|NCT02478567|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33682602|NCT02545543|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682603|NCT02719561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682604|NCT01715129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682605|NCT05443139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are not aware that there are another experimental group and a control group. The conditions of the study are only known by the researcher and the Research Ethics Committee of the Universidad Autónoma de Ciudad Juárez.|"The Well-being Online study will implement a randomized controlled trial at five points for the intervention groups and six evaluation periods for the control group: 1)pretest, 2)middle of the treatment, 3) post-test, 4) follow up at 3 months and 5) follow up at six months. 6) Participants in the control group will be re-assigned to the intervention group after the post-waiting list period.~The study will implement a three-arm design (parallel group), comparing:~1. Interactive Intervention Group ,~2. Intervention delivered through PDF files.~3. Control group."|t|f|f|f
33682606|NCT00485524|||COHORT||RETROSPECTIVE|||||||
33682607|NCT00567255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682608|NCT03999775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985518|NCT05345236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773000|NCT05081375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Blinding will be done by research pharmacist. Nurse Manager will also be un-blinded.|Blinded, Controlled, Randomized, Safety Study|t|t|t|f
33985519|NCT06562413|||CASE_CONTROL||PROSPECTIVE|||||||
33985520|NCT03584139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773001|NCT00549419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773002|NCT04430335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773003|NCT03983902|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel assignment||||
33773004|NCT05967104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773005|NCT03237962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985521|NCT02605928|NA|SINGLE_GROUP||OTHER||NONE||||||
33985522|NCT04189250|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33985523|NCT00135941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985524|NCT01394562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985525|NCT01889719|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33985526|NCT03079765|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985527|NCT03233724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985528|NCT05387447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773006|NCT03006627|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682609|NCT04169971|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a single-centre, prospective, randomised controlled trial. Patients will be invited to participate if they are due to undergo a procedure for which they will require spinal anaesthesia and if they meet the inclusion criteria and none of the exclusion criteria. They will not be required to make any additional hospital visits and will be asked to give their informed consent prior to the procedure. Half of the participants will receive music from the start of surgery until completion of the operation and the other half will serve as the 'control group' and will receive no headphones or music. The anxiety of participant's during the operation will be assessed through a VAS and they will be asked questions about their experience afterwards. The anxiety scores from the two groups will be compared, as will their responses to the questions about their experience, in order to elucidate whether the music produced any differences in anxiety or experience.||||
33682610|NCT05228847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33682611|NCT04309799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682612|NCT00574964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682613|NCT03355690|||COHORT||PROSPECTIVE|||||||
33682614|NCT06433596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682615|NCT05049083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A single-centre, single-dose, random, open, two-period, cross-over relative bioavailability study.||||
33773007|NCT03941743|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33773008|NCT02589392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33682616|NCT00680719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773009|NCT00312975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773010|NCT01054690|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33773011|NCT02032667|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33773012|NCT02485275|||COHORT||PROSPECTIVE|||||||
33773013|NCT05909228|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682617|NCT01233518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682618|NCT05428878|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682619|NCT00466492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682620|NCT05146453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the physicians placing the nerve blocks will not be blinded to the treatment group. The post-operative care team including the nurses doing pain assessments and management will be blinded to group allocation.||t|t|f|t
33682621|NCT05347147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators and other site personnel, patients, contract research organisation and Sponsor personnel will be blinded regarding the treatment during the randomised period.|This will be a placebo-controlled, double-blind, multi-centre clinical trial in approximately 240 randomised patients with IIH.|t|t|t|t
33682622|NCT00545285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682623|NCT01658813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682624|NCT06518850|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33682625|NCT01293227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682626|NCT04191083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33682627|NCT05639244|RANDOMIZED|CROSSOVER||OTHER||NONE||The investigators will include 20 adult patients. Participants will be randomised to a 2 week time restricted eating (TRE) period or a 2 week period in which they consume their regular diet within an unrestricted time period. Participants will be crossed over to the other treatment arm after a 6 weeks wash-out period.||||
33682628|NCT05852041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|A read will completed for the PET portion of the examination by a nuclear medicine trained radiologist who is blinded to the mpMRI portion of the exam.|||||
33682629|NCT03769376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned (1:1) to one of two treatment groups (Bio-Oss® or Salvin-Oss®) at the time of surgery through random selection of sealed envelopes. The outcome assessor for histological samples will not be aware of which group the participant was in until code unlocked.|Patients will be randomly assigned (1:1) to one of two treatment groups (Bio-Oss® or Salvin-Oss®) at the time of surgery through random selection of sealed envelopes.|f|f|f|t
33682630|NCT03138993|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33682631|NCT02935751|||COHORT||PROSPECTIVE|||||||
18403134|NCT06625476|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The study consists of Part A and Part B which both are double blinded. Participants Investigators and Clinical Unit staff are all blind to treatment allocation. There will be an unblinded pharmacist to prepare the study treatment.||t|t|t|f
33682632|NCT06013215|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682633|NCT03905252|||CASE_ONLY||PROSPECTIVE|||||||
33682634|NCT03681223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will be blinded to their assignment, investigators will not be blinded.|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to either Restorelle® or Vertessa® Y sacrocolpopexy according to a computer-generated randomization.|t|f|f|f
33682635|NCT02779361|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682636|NCT04109001|||COHORT||OTHER|||||||
33682637|NCT01561534|||COHORT||PROSPECTIVE|||||||
33773014|NCT01736358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33773015|NCT05660044|||OTHER||PROSPECTIVE|||||||
33773016|NCT00466258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773017|NCT06737315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773018|NCT06268041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773019|NCT06740006|||OTHER||RETROSPECTIVE|||||||
33773020|NCT06463028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773021|NCT04240756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773022|NCT06738368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773023|NCT03806465|||OTHER||PROSPECTIVE|||||||
33773024|NCT00001309|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902303|NCT05646641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902304|NCT05618080|||COHORT||OTHER|||||||
33902305|NCT04967755|NA|SINGLE_GROUP||TREATMENT||NONE||one group received ordinal treatment and other group combination Jing-Si-Herbal-Tea and ordinal treatment||||
33902306|NCT03397420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902307|NCT06550050|||COHORT||OTHER|||||||
33773025|NCT00197028|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33773026|NCT05093751|||CASE_ONLY||RETROSPECTIVE|||||||
33902308|NCT04374903|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects who are enrolled in the study will be randomly assigned to any of the study arms, A or B~Study Arm A (HCQ \& AZ): Subjects will receive HCQ 600mg PO X 10 days and AZ PO 250mg DAILY X 10 days.~Study Arm B (HCQ+SIR): Subjects will receive HCQ 600mg PO X 10 days and SIR 4mg PO X 1 day then 2mg PO DAILY X 9 days"||||
33985529|NCT04715152|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33682638|NCT05245448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682639|NCT06032845|NA|SINGLE_GROUP||TREATMENT||NONE||cryoablation, Tislelizumab, Lenvatinib||||
33682640|NCT02958683|||CASE_CONTROL||PROSPECTIVE|||||||
33773027|NCT05264493|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Williams Square Study Design with 6 sequences||||
33773028|NCT03677063|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773029|NCT03684005|NA|SINGLE_GROUP||OTHER||NONE||||||
33773030|NCT04842279|||COHORT||PROSPECTIVE|||||||
33773031|NCT02765555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773032|NCT01817634|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773033|NCT01155388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773034|NCT02917044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773035|NCT04203927|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33773036|NCT01388127|||COHORT||PROSPECTIVE|||||||
33773037|NCT02769611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773038|NCT01369173|RANDOMIZED|CROSSOVER||||NONE||||||
33902309|NCT00693134|||CASE_CONTROL||PROSPECTIVE|||||||
33902310|NCT06099873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study|t|t|t|t
33902311|NCT01901133|NON_RANDOMIZED|PARALLEL||||NONE||||||
33902312|NCT00184470|||||RETROSPECTIVE|||||||
33902313|NCT06672055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985530|NCT02345941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985531|NCT04817774|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33985532|NCT05528744|||OTHER||CROSS_SECTIONAL|||||||
33682641|NCT02257762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682642|NCT00303589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682643|NCT02122601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682644|NCT04622800|NA|SEQUENTIAL||TREATMENT||NONE||||||
33682645|NCT04563832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Control group: standardized respiratory management.~* Experimental group: same program, associated with the daily use of a hyperinsufflation technique."||||
33682646|NCT01943474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682647|NCT00655915|||COHORT||PROSPECTIVE|||||||
33682648|NCT00940667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682649|NCT02879045|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682650|NCT05972226|||COHORT||PROSPECTIVE|||||||
33682651|NCT05247528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682652|NCT04689412|||CASE_CONTROL||PROSPECTIVE|||||||
33682653|NCT00002805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682654|NCT01997112|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33682655|NCT00255424|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682656|NCT05218954|||COHORT||RETROSPECTIVE|||||||
33682657|NCT03337672|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33682658|NCT04540978|||COHORT||PROSPECTIVE|||||||
33682659|NCT06163677|||COHORT||PROSPECTIVE|||||||
33682660|NCT00813969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682661|NCT01263262|||COHORT||PROSPECTIVE|||||||
33682662|NCT06434402|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773039|NCT02672163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773040|NCT05318846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multicenter, randomized, double-blind, placebo-controlled, phase IIa clinical trial|t|t|t|t
33773041|NCT01187290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773042|NCT00919893|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33773043|NCT05974553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcomes assessors are blind to participant study condition. Participants, study providers, and investigators will not be blind to study condition.|Multisite clinical trial with parallel experimental design|f|f|f|t
33773044|NCT01797796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33773045|NCT03866642|||COHORT||RETROSPECTIVE|||||||
33773046|NCT03509922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773047|NCT01402167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682663|NCT02480036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682664|NCT05520710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blinded to randomization|Participants will be randomized to either the Therapy (n=30) or Education Group (n=30). At the conclusion of therapy (for the Therapy Group) or after three weeks (for the Education Group), participants will be re-administered the outcome measures. The outcome measures using the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) will then be compared during data analysis between the two groups.|f|f|f|t
33773048|NCT02552680|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33773049|NCT02254850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33773050|NCT05291884|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33682665|NCT01150669|||CASE_ONLY||RETROSPECTIVE|||||||
33773051|NCT01818934|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33682666|NCT03573011|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"Original phase 2 trial (44 subjects)~The assigned \[18F\]PSMA-11 dosing group will be blind to the recruiting physicians, the patient the staff member(s) while planning the \[18F\]PSMA-11 scanday of the patient, and the nuclear medicine physicians interpreting the images.~Next to the clinical trial coordinators, also the staff members responsible for the preparation of the individual \[18F\]PSMA-11 dose and the IV injection of this dose are aware of the dose group (2.0 ± 0.2 or 4.0 ± 0.4 MBq/kg body weight), which means that they are NOT blinded. However, these staff members do not carry out any further study specific handlings.~Extension phase 2 trial (22 subjects):~masking is not applicable for this part of the phase 2 trial."|"Original phase 2 (44 subjects) Concerning the dose of \[18F\]PSMA-11, half of the patients in the phase 2 study will be injected with 2.0 ± 0.2 MBq/kg bodyweight. The other half will be injected with 4.0 ± 0.4 MBq/kg body weight. Randomization of patients to one of these two groups will be performed using a block randomization design with block sizes of two, four, and six.~Extension phase 2 (22 subjects):~For this part of the phase 2 study, all patients will be injected with 2.0 ± 0.2 MBq/kg bodyweight \[18F\]PSMA-11. No Randomisation or masking is applicable for this group of 22 subjects."|t|f|t|t
33682667|NCT00128505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902314|NCT04914130|||CASE_CONTROL||PROSPECTIVE|||||||
33985533|NCT01448902|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33682668|NCT02723487|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33682669|NCT02823444|||COHORT||PROSPECTIVE|||||||
33682670|NCT02524834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682671|NCT03933995|||OTHER||PROSPECTIVE|||||||
33682672|NCT02556164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682673|NCT04572360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both patients and investigators will be blinded to the assigned groups. Patients will be allocated at a ratio of 1:1:1:1, the randomization will be carried out by Statistical Analysis System 9.3 (SAS 9.3) statistical software. (Descript how the blinding works here) One copy of the blind codes will be held by the project responsible unit. The statistician will be blinded throughout the study.|A triple-blinded, randomized, parallel groups, controlled clinical trial. A total of 172 eligible patients will be randomized 1:1:1:1 into four groups: cardiorespiratory exercise plus Chinese herbal medicines group, cardiorespiratory exercise group, Chinese herbal medicines group and waiting list group for 12-week (3 months) with 12-week follow-up period.|t|f|t|t
33682674|NCT00134420|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682675|NCT06224920|||COHORT||PROSPECTIVE|||||||
33682676|NCT05055245|||COHORT||PROSPECTIVE|||||||
33682677|NCT01598142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682678|NCT00654147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682679|NCT05772988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682680|NCT06225180|||COHORT||RETROSPECTIVE|||||||
33682681|NCT00228982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682682|NCT05053373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A central randomized system of clinical research (provided by the Clinical Evaluation Center of the Chinese Academy of Traditional Chinese Medicine) will be used for randomization. When eligible subjects are enrolled, randomized personnel from each center will log on to the central random online system to apply for a randomized number. Then the participants will be randomly assigned to PFMT+EA group or PFMT+sham EA group at a ratio of 1:1 to one of four hospitals. The following individuals in the trial will be blinded: 1) participants, this will be achieved by using sham EA procedure; (2) Evaluators, evaluation and record of measurements will be conducted by the evaluators who do not know the grouping situation; (3) Statisticians, group allocation will not be revealed until the statistical analyses are completed.||t|f|f|t
33682683|NCT03787043|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33682684|NCT05596097|NA|SINGLE_GROUP||TREATMENT||NONE||According to the initial treatment plan of the patients, the patients were divided into R-CHOP and R-chemo groups. Both groups received zanubrutinib maintenance therapy after induction and consolidation therapy reached the maximum curative effect. With event-free survival (EFS) as the primary endpoint, partial remission (PR) to CR conversion rate, progression-free survival (PFS), and overall survival (OS) as secondary endpoints, adverse events (AEs) were assessed. ) incidence and related mechanisms during the study period.||||
33682685|NCT04774211|||COHORT||PROSPECTIVE|||||||
33682686|NCT05904301|||COHORT||PROSPECTIVE|||||||
33682687|NCT06164821|NA|SINGLE_GROUP||TREATMENT||NONE||5 cases with transfusion burden\<7.5 units/24 weeks, and 5 cases with transfusion burden 7.5-15 units/24 weeks||||
33682688|NCT03777527|||COHORT||PROSPECTIVE|||||||
33682689|NCT02489916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682690|NCT05503745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each participant will be randomized in one of the two experimental conditions by allocation concealment. In particular, randomized-permuted blocks will be used. The research team will be also blind to the randomized allocation. Group allocation will remain concealed until the end of the assessment stage.|A parallel-group randomized controlled trial design will be used in order to compare CBT-E (n = 10) condition to combined MIT/CBT-F (n = 10). Patients in both conditions will receive 20 weekly sessions of either CBT-E or CBT-F+MIT. Repeated follow-up will be collected up to 24 months. The study is run in an private outpatient clinic specialized in eating disorder treatment. We will evaluate acceptability in terms of session attendance and number of completers and preliminary outcomes.|f|f|f|t
33773052|NCT05796960|||COHORT||RETROSPECTIVE|||||||
33773053|NCT00326690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773054|NCT01409746|||COHORT||PROSPECTIVE|||||||
33773055|NCT01932138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33773056|NCT01034241|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33773057|NCT04275180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773058|NCT00003320||||TREATMENT||||||||
33773059|NCT04719936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Inferior capsulotomy in bipolar hemiarthroplasty will be performed in 25 patients.~As control group, historical group of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020 will be included. A total of 5500 patients are to be included in multicenters."||||
33773060|NCT00356486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773061|NCT05506865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33773062|NCT04103320|||COHORT||PROSPECTIVE|||||||
33773063|NCT00474175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773064|NCT04786522|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33773065|NCT03816592|||CASE_CONTROL||RETROSPECTIVE|||||||
33773066|NCT01182727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773067|NCT01306721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33773068|NCT04837521|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 is Single Group. However Phase 2 is parallel comparison to self-guided and therapist-delivered versions of the UP-5||||
33773069|NCT03620682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773070|NCT01389063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773071|NCT00255229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773072|NCT02869269|||CASE_ONLY||PROSPECTIVE|||||||
33773073|NCT06358872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants, community health workers delivering the intervention, and team members supervising the program will not be masked. One biostatistician and one data analyst will remain unmasked to prepare the randomization sequence. Masked personnel include outcome assessors as well as the biostatistician and data analyst conducting the data analyses.|The intervention will involve biannual oral azithromycin MDA to children 1-59 months old distributed by community health workers. The Centre de Santé Integré (CSI) will be randomized to receive azithromycin MDA or delayed treatment in a stepped wedge design for the first 2 years. The delayed intervention arm will receive usual care for the first 2 years, then will receive the intervention for the next 2 years.|f|f|f|t
33773074|NCT04099381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is prospective, non-randomized (open-label) with control group study. In total, the study will involve 150 patients in three groups. The first and second groups will receive transfusions of umbilical cord blood hematopoietic cells, with varying degrees of selection for the genes of the HLA system. The third group will be the control group. In the control group, 50 patients with similar pathology will be examined, comparable in age, sex and degree of disorder of the type of para-copies against the background of standard therapy."||||
33773075|NCT04315714|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This will be a randomized, controlled trial crossover design, evaluating a yoga intervention, delivered online/virtually via Zoom, with a wait-list control condition for 6 weeks. Study participants will be crossed over to the alternative intervention for an additional 6 weeks, with total intervention time of 12 weeks. Twenty participants with irritable bowel syndrome (IBS) and 20 healthy controls (HC) will be recruited; 10 participants with IBS will be randomized to the yoga intervention at the beginning of the trial, and 10 participants with IBS randomized to the waitlist control condition. Likewise, 10 HC participants will be randomized to the yoga intervention at the beginning of the trial, and 10 HC will be randomized to the waitlist control condition.||||
33773076|NCT05759312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773077|NCT03242603|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the feasibility, safety and effectiveness of anti-GD2 in combination with expanded, activated NK cells in research participants with Neuroblastoma||||
33773078|NCT02025452|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33773079|NCT01454180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773080|NCT05969938|||COHORT||PROSPECTIVE|||||||
33773081|NCT02359383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773082|NCT01501422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773083|NCT02551744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773084|NCT02255630|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33773085|NCT04394741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773086|NCT04376229|||CASE_ONLY||PROSPECTIVE|||||||
33773087|NCT00341172|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33773088|NCT05372237|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33985534|NCT01435265|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985535|NCT05278481|RANDOMIZED|FACTORIAL||OTHER||NONE||3 x 2 factorial design||||
33985536|NCT02351466|||COHORT||PROSPECTIVE|||||||
33985537|NCT03878654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773089|NCT03298607|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo controlled|2 months treatment with (Food Supplement - Serelys PMS)|t|t|t|t
33773090|NCT04401553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33682691|NCT01633593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773091|NCT03250026|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomised controlled trial; randomisation on primary care centre level||||
33773092|NCT06275048|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33682692|NCT00135174|||COHORT||PROSPECTIVE|||||||
33682693|NCT02444000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682694|NCT03487601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be randomized to either active or sham tDCS and will undergo 5 consecutive treatments of daily tDCS beginning the Monday following the first day of their on-study chemotherapy cycle. Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days. Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.|The proposed feasibility trial is a randomized, sham-controlled, double-blind experiment.|t|f|f|f
33682695|NCT04825197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682696|NCT04725357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682697|NCT03395119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Both participant and investigators are blinded for the assignment of dietary supplementation of fish oil, olive oil or control.||t|f|t|f
33682698|NCT04585503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682699|NCT04989452|||COHORT||PROSPECTIVE|||||||
33682700|NCT02376959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682701|NCT04422340|||COHORT||OTHER|||||||
33773093|NCT04861662|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773094|NCT03048032|||COHORT||PROSPECTIVE|||||||
33773095|NCT01245868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773096|NCT00230321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773097|NCT01162941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773098|NCT05606315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773099|NCT05073744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773100|NCT01215708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773101|NCT03739320|||CASE_CROSSOVER||PROSPECTIVE|||||||
33773102|NCT01952301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773103|NCT01905579|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773104|NCT05802160|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33773105|NCT00838643|||COHORT||PROSPECTIVE|||||||
33773106|NCT01454492|||CASE_CONTROL||PROSPECTIVE|||||||
33773107|NCT00570661|NA|SINGLE_GROUP||TREATMENT||NONE|Not applicable. The study was open label.|||||
33773108|NCT01423864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773109|NCT01493830|||CASE_ONLY||RETROSPECTIVE|||||||
33773110|NCT03541642|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Women participants will be randomized to condition upon consent based on a random numbers table. Intervention arm will get enhanced intervention with customized messages and counseling/text messaging; control arm will get basic intervention with medical counseling and text message reminders."||||
33773111|NCT01387503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773112|NCT05310032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773113|NCT04681430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The camostat mesylate and its placebo group will be double blinded while the CP and its placebo will be open label.|"The study is a multicenter trial that will be conducted in approx. 10 - 15 centers in Germany.~At each center, patients will be randomized into four groups: two treatment groups and two control groups. The randomization rate in this study is two to one (2:1) in favor to therapy, i.e.~included patients have twice the chance to receive interventional therapy than placebo / SoC."|t|t|t|t
33773114|NCT02810119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773115|NCT05192980|NA|SINGLE_GROUP||OTHER||NONE||||||
33773116|NCT01915147|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33773117|NCT06475469|NA|SINGLE_GROUP||SCREENING||NONE||||||
33773118|NCT05217069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773119|NCT01466764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773120|NCT05649488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773121|NCT04017702|||CASE_CONTROL||PROSPECTIVE|||||||
33773122|NCT02697006|||CASE_ONLY||PROSPECTIVE|||||||
33773123|NCT02963688|||CASE_ONLY||RETROSPECTIVE|||||||
33773124|NCT00780936|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33773125|NCT01957696|||COHORT||PROSPECTIVE|||||||
33773126|NCT02506959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773127|NCT04453059|||OTHER||RETROSPECTIVE|||||||
33902315|NCT04389801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo group Will receive glucose 5% over 4 hrs infusion|Desferal group An initial dose of 1000 mg should be administered at a rate NOT TO EXCEED 15 mg/kg/hr. This may be followed by 500 mg over 4 hours for two doses. Depending upon the clinical response, subsequent doses of 500 mg may be administered over 4-12 hours.|t|f|f|f
33682702|NCT05248828|||CASE_ONLY||PROSPECTIVE|||||||
33682703|NCT03556488|||COHORT||PROSPECTIVE|||||||
33682704|NCT00232869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682705|NCT00692354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682706|NCT05570331|||COHORT||PROSPECTIVE|||||||
33773128|NCT00549822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682707|NCT00977301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682708|NCT05824143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682709|NCT05895916|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682710|NCT06371820|||COHORT||PROSPECTIVE|||||||
33682711|NCT01073462|||COHORT||PROSPECTIVE|||||||
33682712|NCT00689442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682713|NCT03314246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682714|NCT03597646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682715|NCT00260364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682716|NCT06363305|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The capsules will be placed into solid white color bottles, and labeled discreetly by a third party not directly involved with the research.|Parallel: Participants are randomly assigned to one of two groups in parallel for the duration of the study|t|f|t|t
33682717|NCT00225927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682718|NCT05987176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682719|NCT05999604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682720|NCT02853799|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773129|NCT06413641|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomized 1:1:1 to post-CTA usual care follow up in general practice or one of two intervention strategies (low or high intensity intervention). Patients randomized to the intervention groups will be invited to an individualized video-based or ambulatory consultation by a special trained nurse within 2 weeks from the index CTA test."||||
33682721|NCT00663949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773130|NCT04695158|||COHORT||PROSPECTIVE|||||||
33682722|NCT03513445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blind study in which participants are unaware of whether or not they received a peri-incisional injection of pain medication during their surgery.||t|f|f|f
33682723|NCT06419530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773131|NCT05193721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773132|NCT01397058|||COHORT||PROSPECTIVE|||||||
33773133|NCT01927692|||CASE_ONLY||PROSPECTIVE|||||||
33773134|NCT02398162|||COHORT||PROSPECTIVE|||||||
33682724|NCT05191056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773135|NCT03157024|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33773136|NCT04956861|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33773137|NCT02618057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773138|NCT01604811|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33773139|NCT02710058|||COHORT||PROSPECTIVE|||||||
33773140|NCT00729690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773141|NCT05636137|||OTHER||CROSS_SECTIONAL|||||||
33773142|NCT01928225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682725|NCT00613067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773143|NCT04131959|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open, multi-center, single arm study||||
33773144|NCT05221203|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33682726|NCT06455267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773145|NCT00798174|NA|SINGLE_GROUP||TREATMENT||NONE||Single group undergoing crossover in therapy (defibrillation testing with two different device configurations).||||
33773146|NCT01272986|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773147|NCT03230864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773148|NCT04760015|||CASE_CONTROL||RETROSPECTIVE|||||||
33773149|NCT02685592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682727|NCT02398279|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33682728|NCT02882152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682729|NCT02384642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682730|NCT06448416|||COHORT||RETROSPECTIVE|||||||
33682731|NCT01592656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682732|NCT00273533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33682733|NCT01300533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773150|NCT05602337|||COHORT||PROSPECTIVE|||||||
33682734|NCT00729846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773151|NCT02328157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682735|NCT00178503|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33773152|NCT00914537|||COHORT||PROSPECTIVE|||||||
33773153|NCT00003384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773154|NCT02269943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773155|NCT06362343|||COHORT||PROSPECTIVE|||||||
33773156|NCT01378520|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33773157|NCT00487786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682736|NCT02373371|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773158|NCT04001764|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773159|NCT04829435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773160|NCT06002061|NA|SINGLE_GROUP||TREATMENT||NONE||This study has been designed as a single group study, in which recruited patients who suffer from obstructive sleep apnea (OSA) will undergo one sleep study that will evaluate the effectiveness of applying brief air pressure maneuvers in activating the upper airway muscles.||||
33902316|NCT01065129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902317|NCT02612090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33682737|NCT00737399|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33682738|NCT04834960|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a 'pre-post' study design, where the intervention is designed and implemented by the regular non-research clinical staff. This intervention has four components that are described in the 'intervention' section.||||
33682739|NCT00129909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682740|NCT02153879|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33682741|NCT02470715|||OTHER||OTHER|||||||
33682742|NCT04134403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Prospective Parallel Randomized Controlled clinical Study|t|t|t|t
33682743|NCT04571983|||COHORT||PROSPECTIVE|||||||
33682744|NCT01397097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682745|NCT03739242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682746|NCT00130247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682747|NCT00488709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773161|NCT03945110|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Consenting participants meeting eligibility criteria will join the intervention arm of trial; participants not meeting eligibility criteria and/or unwilling to receive intervention but consenting for data collection on bladder health measures for the study duration will join the non-intervention (standard care only) arm of trial.||||
33773162|NCT01330264|||||PROSPECTIVE|||||||
33773163|NCT00289770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902318|NCT05255562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985538|NCT01536574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773164|NCT03874780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773165|NCT01644396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773166|NCT02382237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773167|NCT05073068|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants will receive a code so that the person in charge with the data quality check and the data analyses will be blinded to the interventions.||f|f|f|t
33773168|NCT05693467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33773169|NCT03649269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Voluntary subjects were assigned sequentially into two treatment groups: 1) fibrate (bezafibrate) 200 mg/day, and 2) PC-300 tea, one cup half an hour before eating.||||
33773170|NCT00005108||||TREATMENT||||||||
33773171|NCT03059160|NA|SINGLE_GROUP||TREATMENT||NONE||open label study with one doze||||
33773172|NCT06349122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773173|NCT00679484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773174|NCT03646227|||CASE_ONLY||PROSPECTIVE|||||||
33773175|NCT01157143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773176|NCT03656393|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33773177|NCT03664739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|As a double-blinded study, the investigators, the site staff, the sponsor, and the clinical monitors will not be aware of the treatment assigned to the individual study subjects|Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study|t|t|t|t
33773178|NCT02398682|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33773179|NCT04792606|||COHORT||PROSPECTIVE|||||||
33773180|NCT06445855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Women to be included in the study will be divided into two groups after randomization. The first group will be the experimental group and the second group will be the waiting group. The experimental group will receive 8 weeks of interpersonal relationship-based online psychotherapy.|One waiting group and one experimental group|t|f|f|t
33773181|NCT00696163|||CASE_ONLY||PROSPECTIVE|||||||
33773182|NCT02667444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773183|NCT05744882|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33773184|NCT00237055|||||PROSPECTIVE|||||||
33773185|NCT03486899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773186|NCT05744050|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Repeated measures|t|f|f|f
33773187|NCT01154023|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33773188|NCT06494319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The first 10 participants will do the treatment via the canvas classroom virtually and participate in user experience interviews to improve the quality of the treatment and improve the user experience.Next, the second group of 10 participants will do the treatment with the canvas classroom aided by a mobile health application.These participants will also participate in user experience interviews to improve the quality of the treatment and improve the user experience.||||
33773189|NCT02441205|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33773190|NCT00065416|RANDOMIZED|PARALLEL||TREATMENT||||||||
33773191|NCT04773574|NA|SINGLE_GROUP||OTHER||NONE||||||
33773192|NCT01899118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773193|NCT05715450|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort||||
33985539|NCT05388318|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial with 2 groups (intervention and control).||||
33985540|NCT00530725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985541|NCT03890471|RANDOMIZED|PARALLEL||OTHER||NONE||We will conduct a randomized controlled trial comparing a provider-initiated preoperative telephone call plus usual clinic counseling to usual clinic counseling alone in women planning pelvic reconstructive surgery for SUI and/or POP.||||
33773194|NCT06132672|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Recruit, enroll, and collect baseline data from 144 Hispanic/Latino Gay, Bisexual and Other Men Who Have Sex With Men (HLMSM), including 16 Community-Based Peer Navigators (known as Navigators) and their social network members (n=8 unique social network members per leader). Navigators (coupled with their social networks) will be randomly assigned to intervention (n=8 Navigators; n=64 social network members) or delayed-intervention (n=8 Navigators; n=64 social network members) groups. Navigators in the intervention group will be trained and supported for 12 months of implementation across years 3 and 4; those in the delayed-intervention group will be trained in year 5||||
33773195|NCT06529601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773196|NCT00550173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773197|NCT02585037|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33773198|NCT03044353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773199|NCT00274911||||TREATMENT||NONE||||||
33773200|NCT05267314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773201|NCT00931138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773202|NCT03837613|||COHORT||PROSPECTIVE|||||||
33773203|NCT01971580|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33773204|NCT03376503|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33773205|NCT00438867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773206|NCT02610712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773207|NCT03203668|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773208|NCT06121518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773209|NCT03319030|||COHORT||CROSS_SECTIONAL|||||||
33773210|NCT01941004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773211|NCT01132638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773212|NCT06410378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The patients will be divided randomly by a computer-generated randomization table into three equal groups|t|t|t|t
33773213|NCT04057820|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|The protocol study team will assure blinding of the electronically performed follow-up questionnaires through the use of a centralized computer scoring system. However, it will not be possible to blind responses to questionnaires that are performed with the assistance of research personnel at the participating sites. The protocol study team will note the method of questionnaire completion and will evaluate for bias in this context.|Stepped-wedge cluster randomized controlled trial with transition period.All sites start with usual care and are transitioned to using the ESC tool|f|f|f|t
33773214|NCT04088318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33773215|NCT06171906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773216|NCT02377830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985542|NCT05940909|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33985543|NCT00239616|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985544|NCT06272331|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33985545|NCT05697419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985546|NCT06217614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not know the intervention in each group|"(Manuka honey-green tea) will topically be applied to the oral mucosa as oral rinse 3 times per day.~Patients will be instructed not to swallow (Manuka honey-green tea) mouth rinse."|f|f|f|t
33985547|NCT03387176|||COHORT||PROSPECTIVE|||||||
33985548|NCT03047317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985549|NCT05125419|||CASE_ONLY||CROSS_SECTIONAL|||||||
33985550|NCT03536715|||OTHER||PROSPECTIVE|||||||
33985551|NCT03169595|||CASE_ONLY||RETROSPECTIVE|||||||
33985552|NCT05075447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985553|NCT01560169|||||PROSPECTIVE|||||||
33773217|NCT05107245|||CASE_CONTROL||PROSPECTIVE|||||||
33773218|NCT06352268|||COHORT||PROSPECTIVE|||||||
33773219|NCT06381037|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Quantitative, observational and longitudinal study with three measurements (pre-intervention, post-intervention and monitoring).||||
33773220|NCT03444220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773221|NCT06077669|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33773222|NCT04098640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773223|NCT02702349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773224|NCT00625235|RANDOMIZED|PARALLEL||TREATMENT||||||||
33773225|NCT02769299|||COHORT||PROSPECTIVE|||||||
33773226|NCT05475938|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group underwent psychological evaluation, drawing analysis and psychotherapy intervention before and after chemotherapy and surgery, while the control group only underwent psychological evaluation without drawing analysis and psychotherapy intervention.||||
33773227|NCT03963882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||patients diagnosed with locally advanced cervical cancer of stage IB2 to IIB (FIGO 2009 system)||||
33773228|NCT00588718|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33773229|NCT01361685|||OTHER||PROSPECTIVE|||||||
33773230|NCT01280240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33773231|NCT00109551|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33773232|NCT05779839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be randomly assigned to two different arms of the study: one where the algorithm matches individuals and one where matches are randomly assigned.|t|f|t|f
33773233|NCT03111758|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33773234|NCT02595177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773235|NCT00656916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773236|NCT03904537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773237|NCT05279430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773238|NCT02060292|||CASE_CONTROL||PROSPECTIVE|||||||
33773239|NCT03376841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773240|NCT01282476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773241|NCT02117882|||CASE_CONTROL||PROSPECTIVE|||||||
33773242|NCT02220686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773243|NCT00472537|||CASE_CONTROL||PROSPECTIVE|||||||
33985554|NCT00833339|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33985555|NCT01459185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080262|NCT03352076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985556|NCT01591603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682748|NCT03161587|||CASE_ONLY||CROSS_SECTIONAL|||||||
33682749|NCT03029884|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|There will be assigned active intervention and non-active intervention periods for each patient throughout phase 2 and 3 of the study. The participant will not know if he/she is in the active or non-active period of the phase.|All participants (phantom limb and thalamic pain) will participate in the same three phase study to test open-loop DBS vs closed-loop DBS vs Sham DBS|t|f|f|f
33985557|NCT04546334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* The patients will be blinded to their groups and a sham block will be performed.~* An anesthesia resident who will not participate in the study and have no subsequent rule in it will help in the preparation of local anesthetic mixtures under strict aseptic precautions.~* An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in collection of the data of measurements."||t|f|t|t
33985558|NCT01133470|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080263|NCT06233786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080264|NCT05412004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080265|NCT06204562|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34080266|NCT06006156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment assignments will be sealed in opaque envelopes that will be opened during the surgery. The treatment assignment will be disclosed to the surgeon after the elevation of the alveolar mucosal flaps and prior to the preparation of the recipient sites.|The study is a split-mouth randomized controlled trial. One implant with a converging collar with micro threads or a diverging polished collar will be installed in each patient according to randomization in the esthetic region of the upper jaw ( between the second premolars ). It will be restored with individual crowns after three months of healing. Both implants will be placed with the rough margin of \~1 mm subcrestally.|t|t|t|t
33682750|NCT02891785|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33682751|NCT03691740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study group assignments will be placed in an opaque envelope which will be kept in the designated research area on Labor and Delivery. After informed consent is obtained, the coordinator will take one of the envelopes to determine the study group. The coordinator will not communicate with the care provide or the investigator regarding study group assignment.|Randomized clinical trial|f|t|t|t
33682752|NCT03454009|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682753|NCT06080139|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||f|t|f|t
33682754|NCT04183751|||OTHER||CROSS_SECTIONAL|||||||
33682755|NCT04744376|||COHORT||PROSPECTIVE|||||||
33682756|NCT04595994|NA|SEQUENTIAL||TREATMENT||NONE||unique arms for each possible dose||||
33682757|NCT03320525|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33682758|NCT05557825|||CASE_ONLY||RETROSPECTIVE|||||||
33682759|NCT02400411|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33682760|NCT02085642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682761|NCT01246154|||CASE_CONTROL||PROSPECTIVE|||||||
33682762|NCT00439049|||OTHER||PROSPECTIVE|||||||
33682763|NCT06131528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773244|NCT03782896|||CASE_ONLY||CROSS_SECTIONAL|||||||
33985559|NCT05207709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682764|NCT02700334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682765|NCT02510638|||COHORT||RETROSPECTIVE|||||||
33985560|NCT05277025|||COHORT||CROSS_SECTIONAL|||||||
33985561|NCT02833389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985562|NCT01305018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985563|NCT04793347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080267|NCT03546673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34080268|NCT05892237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773245|NCT03805256|||CASE_CONTROL||PROSPECTIVE|||||||
33773246|NCT04022642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080269|NCT02472730|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080270|NCT01666483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080271|NCT02204943|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080272|NCT03098680|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33902319|NCT04160403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|the data about socioeconomic status did not be announced|prospective cohort study||||
33773247|NCT00491725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773248|NCT04683471|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33773249|NCT01482949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773250|NCT01060995|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33773251|NCT04235868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773252|NCT04635501|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33773253|NCT02430922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773254|NCT02977065|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33773255|NCT00658736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773256|NCT05359835|NA|SINGLE_GROUP||TREATMENT||NONE||Six adult patients aged 18 to 65 who meet diagnostic criteria for Gadolinium Deposition Disease and study inclusion criteria, and are free of exclusion criteria will be enrolled.||||
33773257|NCT02698436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773258|NCT03666910|||CASE_CONTROL||RETROSPECTIVE|||||||
33902320|NCT02192710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902321|NCT02832440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33902322|NCT03819946|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The endoscopists performing the follow up endoscopy test will be 'blinded' to the randomization of the trial participant, to minimise bias.|This is a randomized clinical trial with 1:1 randomization to the study protocol or the control. The study group will have esophageal protection utilising the esophageal cooling device. The control group will have standard esophageal protection, using an esophageal temperature probe.|f|f|f|t
33902323|NCT00373841|||COHORT||OTHER|||||||
33773259|NCT01890902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773260|NCT04690296|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33773261|NCT02631083|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33773262|NCT02701322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773263|NCT02989363|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33773264|NCT06451575|||CASE_CONTROL||PROSPECTIVE|||||||
33773265|NCT02646111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773266|NCT03844321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773267|NCT05050474|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33773268|NCT02878304|||COHORT||PROSPECTIVE|||||||
33773269|NCT04736589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773270|NCT01013532|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33773271|NCT02339389|||COHORT||PROSPECTIVE|||||||
33773272|NCT04800523|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33773273|NCT04607473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773274|NCT00893568|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33902324|NCT05905822|||COHORT||PROSPECTIVE|||||||
33902325|NCT06095674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902326|NCT01793181|||CASE_CONTROL||PROSPECTIVE|||||||
33902327|NCT06094777|NA|SEQUENTIAL||TREATMENT||NONE||||||
33902328|NCT01638689|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985564|NCT06459271|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants (patients with newly diagnosed and recently recurred ovarian cancer) will receive the intervention.||||
33985565|NCT00957450|||COHORT||PROSPECTIVE|||||||
33985566|NCT01661686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985567|NCT02998138|||COHORT||PROSPECTIVE|||||||
33985568|NCT01802086|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33985569|NCT00746798|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985570|NCT01566396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985571|NCT02512952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985572|NCT04055805|||COHORT||PROSPECTIVE|||||||
33985573|NCT02107092|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985574|NCT02549092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985575|NCT02105103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985576|NCT02898168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985577|NCT05242432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Cohort 1: adults aged 60 years and older Cohort 2: adults aged 20 to 59 years at high-risk of severe RSV disease|t|f|t|f
33985578|NCT05598658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985579|NCT00261066|||COHORT||PROSPECTIVE|||||||
33985580|NCT02024932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985581|NCT05959681|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective observational cohort study.||||
33985582|NCT05098886|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985583|NCT02533479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985584|NCT03922906|NA|SINGLE_GROUP||SCREENING||NONE||||||
33985585|NCT05527548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985586|NCT00675935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985587|NCT02639741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985588|NCT01271530|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33985589|NCT03193177|||COHORT||CROSS_SECTIONAL|||||||
33985590|NCT03786822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomized in a 2:1 fashion|"Condition or Disease: Paroxysmal atrial fibrillation~Procedure: Cryoballoon Pulmonary Vein Isolation"|f|f|f|t
33985591|NCT02841800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985592|NCT03867994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the patients were selected randomly and divided for three groups prospectively. the design was single-blinded randomized controlled study at which the researcher was aware by the allocation of the groups while the patients were blinded.|This prospective study is intended to evaluate if carvedilol has any potential protective effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following cardiac catheterization in patients with moderate to high risk for CIN.|t|f|f|f
33985593|NCT05818839|||OTHER||CROSS_SECTIONAL|||||||
33985594|NCT04092023|RANDOMIZED|PARALLEL||OTHER||SINGLE||A six month and two-arm parallel randomized control trial is employed|f|f|f|t
33985595|NCT04239833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All trial personnel and participants were masked to treatment allocation, until unblinding due to progression disease or other Criteria of termination.|Participants are randomly assigned to SH-1028 tablets arm or Gefitinib arm based on the mutation condition of EGFR (L858R or 19Del) and brain metastases (yes or no). The rate of SH-1028 tablets arm to Gefitinib arm is 2:1.|t|t|t|f
33985596|NCT00392847|RANDOMIZED|PARALLEL||||NONE||||||
33902329|NCT04830748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to study hypotheses and informed only about comparing different programs of treatment of knee osteoarthritis. After randomization, participants will only be provided with details of the program they will be undertaking.|"2 groups~The first group will include 20 patients and will receive therapeutic exercises in the form of stretching and strengthening exercises of the knee.~The second group will include 20 patients and will receive the same exercise program of the first group preceded by continuous mechanical traction of the knee."|t|f|f|t
33985597|NCT00199277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985598|NCT01981720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985599|NCT04495647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||frail older people (n=10) pre-post; robust older (n=10) and young (n=10) reference groups with identical intervention||||
33985600|NCT03143920|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot study to test feasibility of treating patients with chronic inflammatory conditions of the urinary bladder with hyperbaric oxygen therapy.||||
33985601|NCT01086241|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33773275|NCT00589550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773276|NCT00504465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985602|NCT03974438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will not be aware of the treatment given. The randomization will take place right before the procedure begins. The treatment will be given to the skin covering the spine and the patients will be placed in the supine position. They will therefore not know whether or not they are receiving the actual acupuncture or the sham procedure.~The investigator will not be present at the procedures and will not have access to patients records and data until after the trial is complete.~The outcomes are measured using validated questionnaires. They will be assessed by the investigator at the time of project completion."|The participants will be divided into two groups, group A, the intervention group, will receive SDN in the area of pain. Group B, the control group will receive a sham procedure.|t|f|t|t
33985603|NCT00130988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985604|NCT01848938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985605|NCT03752528|||CASE_ONLY||PROSPECTIVE|||||||
33985606|NCT00783861|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985607|NCT04300673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985608|NCT05161611|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33985609|NCT02993380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985610|NCT00286754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985611|NCT04234685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized using a computer generated random number generator. The allocation sequence will be recorded on cards placed in sealed, opaque envelopes. Allocation will be concealed until after the initial assessment is completed. At this point the research assistant (physiotherapist) will open the sealed envelope, which will indicate either Group A or Group B, then initiate the phototherapy session by pressing on the corresponding button for Group A or B, which will deliver the appropriate phototherapy intensity for the respective group.|Double (patient and investigator) blind, parallel group, pilot randomized control trial with 1:1 allocation ratio to HIPL Therapy™ or placebo control.|t|t|t|t
33773277|NCT04110873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773278|NCT02501135|||COHORT||RETROSPECTIVE|||||||
33773279|NCT01102179|||||CROSS_SECTIONAL|||||||
33773280|NCT02694640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773281|NCT00698321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682766|NCT02635646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33773282|NCT00873093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985612|NCT02972047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985613|NCT02341261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985614|NCT00669942|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33985615|NCT02173418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985616|NCT00000190||||DIAGNOSTIC||||||||
33985617|NCT01054586|||COHORT||PROSPECTIVE|||||||
33985618|NCT01710657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985619|NCT03749512|||COHORT||RETROSPECTIVE|||||||
33985620|NCT03735251|||COHORT||PROSPECTIVE|||||||
33985621|NCT03981341|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open label treatment for 3 months in two parallel groups (post menopausal women without and with sleep apnea)||||
33985622|NCT05662111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized placebo-controlled double blind trial using etidronate versus placebo|t|t|t|t
33985623|NCT03674489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Each subject will be randomized to one of three groups:~* Neurodynamic Slider Mobilization~* Neurodynamic Tensioner Mobilization~* Sham Neurodynamic Mobilization~Outcomes will be assessed immediately prior to and immediately following the intervention."|t|f|f|t
33985624|NCT01723748|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33985625|NCT04314362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33985626|NCT04511507|||COHORT||PROSPECTIVE|||||||
34080273|NCT00617357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080274|NCT06154304|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33902330|NCT06673056|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, placebo-controlled, double-blind, crossover, multi-center, study with 1:1 randomization of IB1001 plus SOC for 12-weeks versus placebo plus SOC for 12-weeks, followed by open-label extension study.|t|t|t|t
33902331|NCT03948282|||COHORT||PROSPECTIVE|||||||
33902332|NCT03879863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902333|NCT03874221|||COHORT||PROSPECTIVE|||||||
33902334|NCT00906256|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33902335|NCT06139380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|We will blind medication administrator, care provider, and assessor in addition to the patients.|2-group parallel double blind randomized controlled trial|t|t|t|t
33902336|NCT03859999|||COHORT||RETROSPECTIVE|||||||
33902337|NCT06102460|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Neither the participant or investigator will know what treatment has been given until un-blinding at the completion of the study.|All participants will complete all 4 interventions with at least a 1 week wash out period in between.|t|f|t|f
33985627|NCT03214822|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Masking of care providers is not feasible since the procedures of preparation for HMF and H2MF are different. Outcome assessors (personnel analyzing microbiome profiles and oxidative stress biomarkers) will be masked.|Using a randomized, controlled, un-blinded parallel design we will enroll 30 VLBW premature neonates (birth weight \< 1250 grams, gestational age 26+0 to 30+0 weeks) from the NICU at the Health Sciences Centre Children's Hospital in Winnipeg, MB, Canada. Currently, H2MF is not routinely used in this population at this centre.|f|f|t|t
33985628|NCT05964777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985629|NCT03672604|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A Phase 1, first-in-human, double-blind, randomized, placebo-controlled, single-ascending followed by multiple-dose study|t|t|t|t
33985630|NCT05254301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985631|NCT03586700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985632|NCT03677622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985633|NCT05675215|||COHORT||OTHER|||||||
34080275|NCT00435617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080276|NCT02729337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902338|NCT03100331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902339|NCT02714634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902340|NCT02563184|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902341|NCT05174572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985634|NCT02373098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A 6-month, multicenter, prospective, interventional, single arm, open label study investigating the effects of fingolimod administered according to local label recommendations on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients||||
33985635|NCT02149745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985636|NCT01993030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985637|NCT03548675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prescribing physicians will be unblinded for the genotype and the resulting metabolization phenotype. Outcome assessments will be performed by blinded researchers and the patients themselves (self-assessments).|This study is a randomized controlled clinical trial.|f|f|f|t
33985638|NCT03286465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985639|NCT02703948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985640|NCT03493347|NA|SINGLE_GROUP||TREATMENT||NONE||multiple baseline single case experimental design||||
33985641|NCT01895205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985642|NCT02098876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080277|NCT03048045|||COHORT||RETROSPECTIVE|||||||
34080278|NCT02184104|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34080279|NCT01545388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080280|NCT02800837|||CASE_ONLY||PROSPECTIVE|||||||
34080281|NCT05660629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33985643|NCT05404386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the study, participants will be left unaware of whether they are in the study or control group (single-blind masking).||t|f|f|f
33985644|NCT04844489|NA|SINGLE_GROUP||OTHER||NONE||||||
33985645|NCT04490941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33985646|NCT04485923|||CASE_CONTROL||PROSPECTIVE|||||||
33985647|NCT05747391|||CASE_CROSSOVER||PROSPECTIVE|||||||
33985648|NCT05033834|||COHORT||PROSPECTIVE|||||||
33985649|NCT00352820|||CASE_ONLY||PROSPECTIVE|||||||
33985650|NCT01860027|||COHORT||PROSPECTIVE|||||||
33985651|NCT01231022|||COHORT||CROSS_SECTIONAL|||||||
33985652|NCT02902991|||COHORT||PROSPECTIVE|||||||
33985653|NCT03045250|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33985654|NCT04786106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The curvature and length assessments will be performed without knowledge as to pre-treatment measurements.||f|f|f|t
33985655|NCT04525365|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pleural suction under sedation vs Tube Thoracostomy without pleural suction||||
33985656|NCT05380609|||COHORT||RETROSPECTIVE|||||||
34080282|NCT03918057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080283|NCT02429050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080284|NCT03497871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080285|NCT04383301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Intracorneal ring segment (ICRS) followed by accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)||||
34080286|NCT04827277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682767|NCT04473235|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33682768|NCT04661761|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Determination of salivary flow rate chewing Paraffin pellets (manufactured by Aurosan GmbH) for 7 minutes. At a later timepoint determination of salivary flow rate chewing Saliva-Check Buffer (manufactured by GC Europe) for 7 minutes.||||
33682769|NCT00591110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682770|NCT05517278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080287|NCT01278342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682771|NCT02878356|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33682772|NCT00802815|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33682773|NCT06174168|||OTHER||PROSPECTIVE|||||||
33682774|NCT02279407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682775|NCT05967039|||CASE_CONTROL||RETROSPECTIVE|||||||
33682776|NCT06401811|||OTHER||PROSPECTIVE|||||||
33682777|NCT00594945|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682778|NCT04805879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682779|NCT02744950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682780|NCT06034990|||OTHER||CROSS_SECTIONAL|||||||
33682781|NCT04185597|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||cluster-randomized controlled trial||||
33682782|NCT02991989|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773283|NCT04122560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparing a 2 groups of obese subjects vs 1 group of non-obese subjects||||
33773284|NCT05379140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080288|NCT04869592|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34080289|NCT05203640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080290|NCT05732376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080291|NCT03928054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33682783|NCT06504745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention group: peer education Control group: instruction education||||
33682784|NCT05744440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682785|NCT05986084|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682786|NCT05905614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773285|NCT03379714|||CASE_ONLY||PROSPECTIVE|||||||
33773286|NCT02145793|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33773287|NCT06115902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773288|NCT03150680|||COHORT||PROSPECTIVE|||||||
33773289|NCT01804894|||COHORT||PROSPECTIVE|||||||
33773290|NCT05993195|||COHORT||RETROSPECTIVE|||||||
33985657|NCT04473105|||OTHER||PROSPECTIVE|||||||
33985658|NCT06200220|||COHORT||RETROSPECTIVE|||||||
33985659|NCT02059525|||CASE_CONTROL||PROSPECTIVE|||||||
33985660|NCT01641068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080292|NCT01270035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080293|NCT05869370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773291|NCT00004286|RANDOMIZED|||TREATMENT||DOUBLE||||||
33773292|NCT04873622|NA|SINGLE_GROUP||OTHER||NONE||||||
33773293|NCT05536674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33773294|NCT05462652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773295|NCT02708238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773296|NCT01088308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773297|NCT05401630|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33773298|NCT01352234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773299|NCT05758363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773300|NCT04349410|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|As FMTVDM is an absolute quantification method, which cannot be influenced by human error or bias, the final determinant of success or failure of treatment cannot be influenced. However, given the pandemic, medical, nursing, technologist and other healthcare providers will NOT be blinded to data. The availability of the data will allow real time assessment and decision making by the clinicians involved in the care of the patient.|"Measurement of CoVid-19 pneumonia (CVP) and inflammation will be made using a patented method (FMTVDM #9566037 and adjunct USPTO submissions deemed covered by USPTO under the original patent #9566037).~Following FMTVDM measurements, patients will be randomized into one of eleven treatment arms - others may be added as information becomes available. Forty-eight to 72-hours later - providing adequate time for treatment effect - FMTVDM will be repeated.~Patients with improvement in FMTVDM will be maintained on their original treatment. FMTVDM measured treatment failure will result in a change to another arm of treatment. FMTVDM measurement showing no change will be treated by adding an additional treatment arm to patient care. Sequential FMTVDM studies will be carried out.~Simultaneous Immune and ventilatory RX. Ventilatory support per ARDS protocol. Applicable blood tests and PCR will be included."|f|f|t|f
33773301|NCT04261738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Control exposure followed by Hyperbaric Oxygen exposure||||
33773302|NCT00915902|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33773303|NCT06043063|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33773304|NCT02118714|NA|SINGLE_GROUP||OTHER||NONE||||||
33773305|NCT04384679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773306|NCT03751540|||CASE_CONTROL||RETROSPECTIVE|||||||
33773307|NCT01580098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773308|NCT00695682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773309|NCT03575689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The PI will be the blinded assessor. The choice of which patient gets a Doyle splint will be randomized using the sealed envelope system mentioned above.~The randomization will be balanced to ensure that both arms have patients with extensive surgeries as well as isolated NSRs"|"There will be two possible scenarios resulting from randomization: All patients will undergo septoplasty using quilting technique.~A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.~B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same."|f|f|f|t
33773310|NCT00802659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773311|NCT05211375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773312|NCT03318952|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33773313|NCT00562068||||TREATMENT||NONE||||||
33773314|NCT06398340|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33773315|NCT00823550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773316|NCT00088205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773317|NCT02166151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985661|NCT00941174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985662|NCT04821401|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The medical assistant conducting clinical visits will receive two binders with sets of sequentially numbered, Kit Assignment Forms (n = 50) - one binder for men and one binder for women. For each new participant, the assistant will enter the participant identification # on the next Kit Assignment Form which contains the Kit # to be assigned to the new participant. The kits (contain either the dietary supplement or the placebo) were assigned either dietary supplement or placebo per the order of the randomization list generated by www.randomization.com|This is a randomized, double-blind, placebo-controlled trial in adult men ages 45-75 years and postmenopausal women up to age 75 years|t|t|t|f
33985663|NCT01379222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985664|NCT03735030|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080294|NCT06021327|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomized using a computer-generated list of random numbers, which will be sealed in closed envelopes. Patients will be randomly allocated to one of two groups; Group I (E) will receive a US-guided ESPB, while Group II (R) will receive a US-guided RLB. An anesthesiologist who is not involved in the data collection team will perform all nerve blocks. Intra- and postoperative data will be collected by an anesthesiologist or intensivist who is blinded to the study protocol.||t|f|t|f
34080295|NCT03044314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773318|NCT06098924|||CASE_ONLY||CROSS_SECTIONAL|||||||
33773319|NCT04052230|||COHORT||PROSPECTIVE|||||||
33773320|NCT02584764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773321|NCT01260857|||||PROSPECTIVE|||||||
33773322|NCT01085929|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902342|NCT03477630|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, cohort, prospective controlled, randomized study with one year of follow-up.||||
33902343|NCT01183962|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985665|NCT04544787|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"All OPV-vaccinated participants will receive one of the nOPV2 candidates candidates in a single blind manner and all IPV- vaccinated participants will receive one of the nOPV2 candidates or placebo in a double-blinded manner.~For the study duration participants and blinded study staff responsible for safety evaluation of IPV participants will not have any information of what has been administered. As the placebo can be distinguished from the vaccine candidates in packaging and color, reception of the vaccines, dose preparation and administration will be done by a team of unblinded study personnel. Appropriate measures will be taken at the site to ensure blinding of subjects and blinded team for the duration of the study."|"In this partial-blind study participants will be randomized into one of the following groups:~OPV-vaccinated adults:~* 1 dose of nOPV2 candidate 1 (Group 1);~* 2 doses of nOPV2 candidate 1 (Group 2);~* 1 dose of nOPV2 candidate 2 (Group 3);~* 2 doses of nOPV2 candidate 2 (Group 4);~IPV-only vaccinated adults:~* 2 doses of nOPV2 candidate 1 (Group 5);~* 2 doses of nOPV2 candidate 2 (Group 6);~* 2 doses of placebo (Group 7).~The first 100 OPV-vaccinated participants will be randomly assigned 1:1 to Groups 3 (1 dose) and 4 (2 doses) to receive nOPV2-c2. The second 100 OPV-vaccinated participants will be randomly assigned 1:1 to Groups 1 (1 dose) and 2 (2 doses) to receive nOPV2-c1. IPV-vaccinated adults will be enrolled in parallel and randomly assigned 2:1 to Group 6 (2 doses of nOPV2-c2) or Group 7 (2 doses of placebo), until Group 6 enrollment is complete, when 2:1 randomization will be continued for Group 5 (2 doses of nOPV2-c1) and Group 7 (2 doses of placebo)."|t|t|t|t
33985666|NCT02212847|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985667|NCT03639662|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985668|NCT03748953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902344|NCT00062738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902345|NCT00394914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33902346|NCT00803244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902347|NCT03531957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902348|NCT00551655|||COHORT||RETROSPECTIVE|||||||
33902349|NCT05456100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33902350|NCT02119104|||CASE_ONLY||PROSPECTIVE|||||||
33902351|NCT06249542|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33902352|NCT06664515|||CASE_ONLY||PROSPECTIVE|||||||
33902353|NCT02572206|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902354|NCT00397228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902355|NCT00890968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985669|NCT02597660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33985670|NCT01565902|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985671|NCT04438707|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Pilot study designed by a randomized controlled trial in two parallel intervention groups|f|f|t|t
33985672|NCT04529863|||COHORT||RETROSPECTIVE|||||||
33985673|NCT01903161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33985674|NCT00453362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985675|NCT00431730|NON_RANDOMIZED|PARALLEL||||NONE||||||
33985676|NCT05351918|||CASE_CONTROL||PROSPECTIVE|||||||
33985677|NCT02378571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985678|NCT03243487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants and study staff cannot be blinded to the treatment arm to which they are randomized. Data analysis will be blinded and conducted without revealing the treatment group assignment.|After undergoing screening and enrollment, participants will be assigned to either standard care follow-up or to the patient adherence monitoring service (PAMS).|f|f|f|t
33985679|NCT03002077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985680|NCT04475861|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33985681|NCT02841033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985682|NCT02562378|NA|SEQUENTIAL||TREATMENT||NONE||||||
33985683|NCT03671447|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Stepped Wedge design with cluster-randomization of sites to 3 sequence groups (switching groups). Hereby, sites cross over to the intervention condition sequentially in a random order."||||
33985684|NCT01820208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773323|NCT05939817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This double blind, randomized controlled trial (RCT) is carried out according to CONSORT statement. Identical syringes containing the substances were prepared by laboratory staff, in which the researchers were not informed of the syringe contents, in accordance to computerized block randomization. Data processing was then carried out by other statisticians and clinicians.|Patients were screened initially by measuring the length and thickness of the keloids using a ruler. Patients who met the study inclusion criteria were randomly divided into 3 groups. Each patient in the groups was given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure. Group 1 was given UC-MSC 2 million cells/mL/cm3, group 2 was given UC-CM 1 mL/cm3, and group 3 was given TA 40 mg/mL/cm3.|t|t|t|t
33773324|NCT03124030|||COHORT||PROSPECTIVE|||||||
33773325|NCT03188614|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33773326|NCT01710774|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773327|NCT05827666|RANDOMIZED|CROSSOVER||OTHER||SINGLE|As the study is a single-blind crossover design, the randomization of the protein type will be blinded to the participants only. For each liquid meal, beverages will be provided in opaque bottles, and the caloric content of the beverages will be the same.|Using a single-blind randomized counterbalanced crossover design, participants will complete four metabolic trials providing one of the four isoenergetic (equal calories) beverages: 2% milk (MILK), soy 'milk,' (SOY), almond 'milk,' (ALMOND), or rice 'milk' (RICE) following a bout of variable-intensity exercise. The caloric content of the beverages is based on 0.3 g/kg FFM 2% milk.|t|f|f|f
33773328|NCT02313896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773329|NCT05814757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Masked Investigator)|Parallel: Participants are assigned to one of three groups in parallel for the duration of the study|t|f|t|f
33773330|NCT02711176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773331|NCT03542448|||COHORT||PROSPECTIVE|||||||
33773332|NCT01496508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33773333|NCT05291013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773334|NCT06237374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The CHWs will be blinded to treatment assignment and informed that they are taking part in a study to understand the CHW experiences and their communication with patients.|This is a cluster randomized trial with baseline covariate adjustment and stratification. The randomization unit is the Community Health Unit (CHU), the administrative unit in which community health workers (CHWs) are organized in the study region. The randomization will be stratified by geographic unit (wards) and whether a health facility is located in the ward. The following baseline characteristics will be measured and adjusted for in the main analysis of primary outcomes to increase statistical efficiency: 1) age, 2) gender, 3) language, 4) years of work experience, 5) vaccine beliefs, and 6) self-reported preparedness to educate patients about vaccination.|t|f|f|f
33773335|NCT05185128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Participants in both the ASD and SSD groups will engage in approximately three hours of diagnostic, behavioral, and social cognition testing and one hour of MRI scanning both pre- and post-treatment. Additionally, TD participants will undergo two MRI scanning and behavioral assessment sessions approximately 16-weeks apart without enrolling in the PEERS program, to serve as controls.||||
33773336|NCT04100200|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33773337|NCT02019563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773338|NCT03657264|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||Williams design for a 4\*4 cross over|t|f|t|t
33773339|NCT00634322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33773340|NCT06301659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33773341|NCT03365505|||COHORT||PROSPECTIVE|||||||
33773342|NCT01091428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773343|NCT01558674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773344|NCT00007293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33773345|NCT01265030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773346|NCT03529786|||OTHER||RETROSPECTIVE|||||||
33902356|NCT03984760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902357|NCT01595646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902358|NCT03029403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902359|NCT04902950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Randomization of the patient is performed by the Pharmacist and entered into REDCap. Access to Patient Group and distributed drug (saline vs TXA) is restricted to the Pharmacist and the Study Coordinator.|"This study will be double-blinded. Participating patients will be randomized to receive normal saline (control group) or tranexamic acid (study population) on the day of surgery by the pharmacist. Normal saline is the current standard of care.~Each group will have 10 participants. Group 1 will undergo application of three normal saline soaked lap sponges to the surgical site. Group 2 will undergo application of three TXA soaked lap sponges to the surgical site. The lap sponges will be removed after three minutes and measurements will be taken for the study.~After discharge, post-operative drain output will be monitored and recorded by the patient on a provided drain documentation sheet. This does not differ from the current standard of care regarding drain output recordings."|t|t|t|f
33902360|NCT05429684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902361|NCT01133639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902362|NCT03288974|||COHORT||PROSPECTIVE|||||||
33902363|NCT04471740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Patients will not be informed of the final treatment decided|Patients diagnosed of normal-pressure hydrocephalus will undergo sleep studies to rule our sleep apnea. Those with sleep apnea will be treated for this condition and we will see if the hydrocephalus symptoms improve|t|f|f|f
33902364|NCT01016483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902365|NCT02253875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902366|NCT02574312|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902367|NCT02575794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902368|NCT00259805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902369|NCT04649710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682787|NCT06255678|||COHORT||PROSPECTIVE|||||||
33682788|NCT05116527|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||All subjects will receive both study drug and placebo.|t|t|t|t
33682789|NCT00156156|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33682790|NCT01555385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33902370|NCT05955859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682791|NCT03712007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902371|NCT02211495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902372|NCT01430221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33902373|NCT06672744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902374|NCT05571150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902375|NCT05611463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902376|NCT06671613|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Multi-center, open label, phase 2, randomized (partial crossover design) study evaluating the feasibility of FMD in stage IV NSCLC patients receiving single agent checkpoint inhibitors. Participants will be randomized 1:1 in blocks of 3. There is no blinding or stratification. Patients with high PDL1 NSCLC will be randomized to two arms: (Arm 1) 3 cycles of RD+PD1 inhibitors followed by 3 cycles of FMD+PD1 inhibitors or (Arm 2) 3 cycles of FMD+PD1 inhibitors.||||
33902377|NCT04137172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33902378|NCT06166706|||COHORT||PROSPECTIVE|||||||
33902379|NCT02175667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33902380|NCT01371838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985685|NCT01526330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985686|NCT05662865|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Proof-of-concept, single-group, study design||||
33985687|NCT00175058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985688|NCT03352271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985689|NCT04704505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985690|NCT03949179|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33985691|NCT03437694|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomized in a 1:1 ratio to either the intervention or control group.||||
33985692|NCT03649841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985693|NCT03265977|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Random numbers generated by IWRS; Stratified by site. Syringes are masked with a translucent colored label, in order to maintain the study blind.|Participants will be enrolled in two cohorts. Within each cohort participants will be randomized in a 1:1 ratio to receive either H56:IC31 (5 ug H56/500 nmol IC31) or placebo intramuscularly (IM) on Days 0 and 56.|t|t|t|f
33985694|NCT03991260|||COHORT||PROSPECTIVE|||||||
33985695|NCT02087514|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33985696|NCT02235662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985697|NCT01684657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985698|NCT02744820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985699|NCT00380198|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33985700|NCT00433147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985701|NCT01739075|||COHORT||PROSPECTIVE|||||||
33985702|NCT02669745|||OTHER||PROSPECTIVE|||||||
33985703|NCT00209625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985704|NCT04186208|||CASE_ONLY||PROSPECTIVE|||||||
33985705|NCT06440499|||COHORT||PROSPECTIVE|||||||
33985706|NCT05998265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985707|NCT01442857|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33985708|NCT06163079|||COHORT||RETROSPECTIVE|||||||
33985709|NCT03350347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985710|NCT06236893|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33985711|NCT04621552|||CASE_CONTROL||RETROSPECTIVE|||||||
33985712|NCT00362765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985713|NCT02231749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985714|NCT04146766|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||wait list control group RCT||||
33985715|NCT03703791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985716|NCT00179361|||COHORT||PROSPECTIVE|||||||
33985717|NCT01778517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985718|NCT00089661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985719|NCT04340011|||OTHER||PROSPECTIVE|||||||
33985720|NCT01246076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985721|NCT00035581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985722|NCT01885052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33682792|NCT00146055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682793|NCT00277082|||COHORT||PROSPECTIVE|||||||
33682794|NCT01401998|||COHORT||RETROSPECTIVE|||||||
33985723|NCT03648658|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985724|NCT05156619|||COHORT||PROSPECTIVE|||||||
33985725|NCT02791880|||COHORT||PROSPECTIVE|||||||
33682795|NCT01126047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682796|NCT01634425|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682797|NCT01669057|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682798|NCT04503733|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33682799|NCT01917877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682800|NCT02047344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682801|NCT01449643|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33682802|NCT06154278|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-center, non-randomized, pilot study of Imdusiran (AB-729) in virally suppressed adults with chronic hepatitis B on oral antiviral therapy.||||
33682803|NCT05260541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682804|NCT01528865|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682805|NCT04284631|||CASE_ONLY||CROSS_SECTIONAL|||||||
33682806|NCT02622906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682807|NCT02437123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682808|NCT04348227|||COHORT||OTHER|||||||
33682809|NCT02058745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682810|NCT06221527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double(Participant, Outcome Assessor)|comparison between healing properties using hyaluronic acid topical application and not using it in parasymphyseal fracture|t|f|f|t
33682811|NCT01413347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682812|NCT06192810|||COHORT||RETROSPECTIVE|||||||
33682813|NCT04631991|||CASE_CONTROL||PROSPECTIVE|||||||
33682814|NCT01343901|||COHORT||PROSPECTIVE|||||||
33682815|NCT04838808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682816|NCT06103331|||COHORT||OTHER|||||||
33682817|NCT05457582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the participants nor the investigators are aware of the treatment assignment until the end of the trial|Participants are randomly (at a ratio of 1:1) assigned to PCSK9 inhibitor plus high-intensity statin or placebo plus high-intensity statin group, and then the results at 1 year, 2- or 3-year are compared|t|f|t|t
33682818|NCT03449784|||COHORT||PROSPECTIVE|||||||
33682819|NCT05594615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682820|NCT05884801|NA|SEQUENTIAL||TREATMENT||NONE||||||
33682821|NCT04985396|RANDOMIZED|PARALLEL||TREATMENT||NONE||A hospital-based randomized clinical trial study will be carried out to compare the efficacy of steroid injection with PRP injection in the treatment for Plantar Fasciitis. Participants will be randomized in a 1:1 ratio, and assigned to steroid injection and PRP injection group through computer generated block randomization.||||
33682822|NCT04385329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682823|NCT01097200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682824|NCT02183753|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33682825|NCT05459090|||CASE_ONLY||RETROSPECTIVE|||||||
33682826|NCT02434601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682827|NCT02186301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682828|NCT04389437|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682829|NCT05805878|||OTHER||CROSS_SECTIONAL|||||||
33682830|NCT04156542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researchers entered school cafeterias to collect student tray waste data. When students asked why the researchers were there, researchers indicated their purpose was to learn more about the National School Lunch Program.|We randomly assigned the six participating schools to either be a control school (N=1) or a treatment school (N=5). Each of the treatment schools administered a single intervention, but at different times. In our fifteen-week study, one school implemented the intervention for five weeks after five weeks of baseline data collection. Once this school completed the five weeks with the treatment, it removed the intervention and collected five more weeks of post-intervention data. In the other four schools, we staggered intervention implementation. The first school implemented the intervention on the first day of the study. The next school implemented the intervention after three weeks of collecting baseline data. The next school implemented the intervention after six weeks of collecting baseline data. Lastly, the final school implemented the intervention after nine weeks of collecting baseline data.|t|f|f|f
33682831|NCT02562118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682832|NCT03038477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682833|NCT02446171|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33682834|NCT06422234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682835|NCT00331552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682836|NCT05205577|NA|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33773347|NCT05233722|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant will be blinded upon receiving the drug. 4-5 researchers will conduct various measurements on the subject upon each experimental day. Only the clinical responsible will know which drug is administered, while the remaining researchers will be blinded.||t|f|t|f
33773348|NCT01695122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773349|NCT02812212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773350|NCT00972179|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The cohorts will enroll sequentially: enrollment to the subsequent cohort (ie, next higher dose) will proceed only after the previous dose is determined to be safe and well tolerated by a blinded review of available safety data conducted on day 43 of the previous cohort. Within each dose cohort, participants will be randomized 3:1 to receive tezepelumab or placebo.|t|f|t|f
33773351|NCT03537261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773352|NCT05392075|||COHORT||RETROSPECTIVE|||||||
33773353|NCT02415075|||COHORT||CROSS_SECTIONAL|||||||
33773354|NCT02488694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773355|NCT04584606|||CASE_ONLY||RETROSPECTIVE|||||||
33773356|NCT02724787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773357|NCT04405726|||CASE_ONLY||OTHER|||||||
33773358|NCT06043596|RANDOMIZED|PARALLEL||PREVENTION||NONE||This research project will use an individual randomized controlled trial design in which youth recruited from social media ads will be randomized 1:1 into the experimental condition (about sexual health) and the control condition (about general health).||||
33773359|NCT01649128|||COHORT||PROSPECTIVE|||||||
33773360|NCT04299802|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unable to blind procedures as they require different types of devices, procedures and settings.|Randomized Clinical Trial tracking Platelet-Rich Plasma injection vs. Percutaneous Ultrasonic Tenotomy for up to 1 year||||
33773361|NCT06739928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773362|NCT03575637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902381|NCT06672874|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants in this single-group study will receive the same intervention, Fermented Papaya Preparation (FPP). Each participant will serve as their own control, allowing comparisons between their baseline (pre-FPP) driving performance and subsequent assessments following FPP administration. Participants will complete three assessments in a high-fidelity driving simulator at baseline, short-term (within 24 hours post-FPP), and long-term (after 8 weeks of FPP use) to evaluate changes in cognitive functions and driving performance over time.||||
33902382|NCT03551418|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33902383|NCT05585437|||COHORT||RETROSPECTIVE|||||||
33902384|NCT04646317|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and care provider do not know about the interventions|Randomised control trial|t|t|f|f
33902385|NCT00855530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902386|NCT04701255|RANDOMIZED|PARALLEL||TREATMENT||NONE||40 human eyes undergoing phacoemulsification with intraocular lens implantation||||
33902387|NCT01518699|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-dummy technique was used to mask the treatments. The test product is a gel and the positive control is a tablet. The active test product was administered with placebo positive control, while the active positive control was administered with placebo test product. The placebo group received both placebos.||t|t|t|t
33902388|NCT02177669|||COHORT||PROSPECTIVE|||||||
33902389|NCT00680004|||COHORT||PROSPECTIVE|||||||
33902390|NCT00914628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902391|NCT01362400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902392|NCT01294345|||COHORT||CROSS_SECTIONAL|||||||
33902393|NCT05876572|NA|SINGLE_GROUP||OTHER||NONE||||||
33902394|NCT05823558|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33902395|NCT04038775|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The first 25 patients are placed into the intervention group (recommended volunteering by their provider) and the next 25 patients are placed into the control group (not recommended volunteering).||||
33902396|NCT01716260|||COHORT||PROSPECTIVE|||||||
33902397|NCT03640897|RANDOMIZED|PARALLEL||PREVENTION||NONE||A monocentric, prospective, randomized, comparator controlled, parallel groups study conducted under paediatric control.||||
33902398|NCT05342974|NA|SINGLE_GROUP||OTHER||NONE||||||
33902399|NCT01260181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682837|NCT00663247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682838|NCT01459289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33773363|NCT01301768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33773364|NCT04026282|RANDOMIZED|PARALLEL||TREATMENT||NONE||When patients enter this study, they will be randomly assigned to GnRH-ant group or GnRH-a group at ratio1:1 by the randomization schedule generated by a computer program.||||
33773365|NCT06624072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773366|NCT06080737|||COHORT||PROSPECTIVE|||||||
33773367|NCT06739213|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, controlled, open-label, multicenter, Phase II clinical trail, randomized 1:1 to receive either SYHA1813 (experimental group) or investigators' choice (control group).||||
33773368|NCT00516750||||TREATMENT||NONE||||||
33773369|NCT06739798|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33773370|NCT03918239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773371|NCT04817917|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773372|NCT03218215|||COHORT||CROSS_SECTIONAL|||||||
33773373|NCT01503541|||||RETROSPECTIVE|||||||
33773374|NCT06392061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773375|NCT05781490|NA|SINGLE_GROUP||OTHER||NONE||||||
33773376|NCT04295746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773377|NCT04267575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773378|NCT02300480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773379|NCT06275672|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped-wedge cluster randomized trial to randomize 18 schools into six cohorts of three schools incrementally.||||
33773380|NCT04438096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773381|NCT06465121|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773382|NCT06218732|||CASE_CROSSOVER||PROSPECTIVE|||||||
33773383|NCT04130711|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773384|NCT01714596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773385|NCT02341911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773386|NCT03979261|||COHORT||PROSPECTIVE|||||||
33773387|NCT02360839|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33773388|NCT06418958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773389|NCT00552474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773390|NCT05165602|||OTHER||PROSPECTIVE|||||||
33773391|NCT04063579|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773392|NCT00643500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773393|NCT00351923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773394|NCT06223477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded limited to the outcome assessment|split-mouth, prospective, single-center, single-blinded, two-arm randomized clinical trial with a 1:1 allocation ratio.|f|f|f|t
33773395|NCT06691282|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773396|NCT01813032|||CASE_CONTROL||PROSPECTIVE|||||||
33773397|NCT00075569|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel design||||
33773398|NCT02427555|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33773399|NCT06053177|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33773400|NCT04902170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773401|NCT02369315|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33773402|NCT06712121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773403|NCT02826148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773404|NCT02743000|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33773405|NCT02933190|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33773406|NCT00101569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773407|NCT00014690||||TREATMENT||||||||
33773408|NCT03821701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773409|NCT01907074|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33773410|NCT00478608|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33773411|NCT06066489|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A prospective, quasi-experimental, pre- and post-study with a one month baseline period; one month intervention period and three months post-intervention period||||
33773412|NCT01495221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773413|NCT06374069|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33773414|NCT03004664|||COHORT||PROSPECTIVE|||||||
33773415|NCT06738147|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773416|NCT02120846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773417|NCT06527651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773418|NCT05332574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902400|NCT00923910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080296|NCT01851941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080297|NCT04322032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080298|NCT01195350|||COHORT||PROSPECTIVE|||||||
34080299|NCT01251952|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080300|NCT05266469|||COHORT||OTHER|||||||
34080301|NCT01876524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34080302|NCT01585883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080303|NCT01518803|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
34080304|NCT00126919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080305|NCT04319393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34080306|NCT02889224|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34080307|NCT02072642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080308|NCT05633433|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080309|NCT05720637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080310|NCT03490955|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34080311|NCT00130507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080312|NCT01711697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080313|NCT05253014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080314|NCT05336266|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34080315|NCT02563899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080316|NCT04069715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This was a randomized, placebo-controlled, double-blind, parallel study with a 4-week therapeutic lifestyle change diet (TLC) run-in period and a 12-week supplementation period.|t|f|t|f
34080317|NCT06286917|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34080318|NCT06220617|||CASE_CONTROL||PROSPECTIVE|||||||
34080319|NCT01483638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080320|NCT02704312|NA|SINGLE_GROUP||OTHER||NONE||||||
34080321|NCT04210297|||COHORT||CROSS_SECTIONAL|||||||
34080322|NCT02044042|||COHORT||RETROSPECTIVE|||||||
34080323|NCT00488423|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
34080324|NCT04481139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080325|NCT05938218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In this intervention, VR glasses with an information module are utilized, lasting approximately 25 minutes. This intervention takes place in the waiting room prior to the actual physician-patient conversation and complements the usual care provided through brochures||||
33773419|NCT05043311|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"This is a randomized, double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety, tolerability and immunogenicity of SCTV01C (A Bivalent Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Variants) in healthy population aged ≥18 years previously vaccinated with mRNA vaccine against COVID-19.~In the study, participants receive 20 µg dose or placebo, 40 µg dose or placebo."|t|t|t|f
34080326|NCT03299101|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A novel a novel, multifaceted, home-based prehabilitation intervention designed to improve functional capacity and postoperative outcomes for frail Veterans anticipating cardiothoracic surgery. Prehabilitation will include: (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.||||
34080327|NCT01834547|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34080328|NCT06518980|||COHORT||PROSPECTIVE|||||||
34080329|NCT03685162|||COHORT||PROSPECTIVE|||||||
34080330|NCT06555445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773420|NCT05013996|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||open label multicenter randomized controlled trial||||
33773421|NCT05266040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized clinical trial|t|t|t|t
33773422|NCT02746081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773423|NCT05421520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Experimental: novices with AI-assisted system Control：without AI-assisted system||||
33773424|NCT01674595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902401|NCT00922545|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902402|NCT01332929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902403|NCT01286844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902404|NCT01495546|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33902405|NCT02976493|||CASE_ONLY||PROSPECTIVE|||||||
33902406|NCT01196910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902407|NCT06399705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researchers and most study personnel (including those from the QOL follow-up center and events assessors, clinical events committee and angiographic core laboratory) will be blinded to allocated treatment.||f|f|f|t
33902408|NCT06219720|||COHORT||PROSPECTIVE|||||||
34080331|NCT01616043|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34080332|NCT02696395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080333|NCT02236000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080334|NCT04887649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34080335|NCT03469115|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Adolescents aged 13-17 will be divided into two groups according to BMI (body mass index)||||
34080336|NCT04254510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080337|NCT04310722|||CASE_ONLY||PROSPECTIVE|||||||
34080338|NCT02354287|||COHORT||PROSPECTIVE|||||||
34080339|NCT01071174|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34080340|NCT03826017|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34080341|NCT04345276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080342|NCT05750758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080343|NCT01239797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080344|NCT04722029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080345|NCT02991365|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34080346|NCT00000638||PARALLEL||PREVENTION||||||||
34080347|NCT04824807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080348|NCT05246722|||COHORT||OTHER|||||||
34080349|NCT02404545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080350|NCT00395993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773425|NCT04678869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised trial of prophylactic ciprofloxacin (10mg/kg BD, enteral/IV) versus standard of care during the neutropenic period of induction (with an internal pilot study) in patients aged 1-17 years with de-novo ALL treated on ALLTogether-1. Exclusion||||
33773426|NCT06082622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773427|NCT02826564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773428|NCT05853978|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33773429|NCT01948271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773430|NCT00941278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773431|NCT04267614|||OTHER||RETROSPECTIVE|||||||
33773432|NCT06738628|||CASE_ONLY||PROSPECTIVE|||||||
33773433|NCT00000700||PARALLEL||TREATMENT||||||||
33773434|NCT00437125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773435|NCT03209713|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773436|NCT02572336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773437|NCT05629442|||COHORT||PROSPECTIVE|||||||
33773438|NCT02291289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773439|NCT00416871|RANDOMIZED|||TREATMENT||NONE||||||
33773440|NCT01982162|||COHORT||PROSPECTIVE|||||||
33773441|NCT04779164|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Both patients with and without diabetes mellitus was evaluated in terms of pain and ultrasonographic femoral cartilage thickness.||||
33773442|NCT00697554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773443|NCT02712112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773444|NCT06740877|||COHORT||PROSPECTIVE|||||||
33902409|NCT00003530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902410|NCT01233219|||COHORT||PROSPECTIVE|||||||
33902411|NCT04807569|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33902412|NCT01415622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902413|NCT02517112|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902414|NCT00401973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902415|NCT02540174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33902416|NCT04177654|||COHORT||CROSS_SECTIONAL|||||||
33902417|NCT05028023|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This single arm Interventional Study is a comparative clinical trial with the form of before and after intervention (apneic oxygenation), in every participant. During the phases of before and after intervention, parameters of regional cerebral oxygen saturation, peripheral oxygen saturation, arterial blood gases and haemodynamics are recorded in both conditions.||||
33902418|NCT05111119|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33902419|NCT01797029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902420|NCT00590681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902421|NCT03699839|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33902422|NCT03898583|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The trial will be assessor-blinded with random assignment of the 2 microarray patches containing calcipotriol and betamethasone dipropionate, the vehicle (microarray patches without active substance) and the active comparator.|Intra-individual comparison of all treatments|f|f|t|f
33902423|NCT03078673|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33902424|NCT03975972|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902425|NCT06378073|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902426|NCT04385030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902427|NCT00849693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902428|NCT04608097|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33902429|NCT00416767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902430|NCT05805969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective, dual-arm, randomized controlled trial|f|f|f|t
33902431|NCT00097422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902432|NCT03702257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773445|NCT04299282|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized 1:1 for 10 in the treatment group and 10 in the control group, shall be enrolled||||
33773446|NCT00440180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773447|NCT03552718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773448|NCT05947123|||COHORT||RETROSPECTIVE|||||||
33773449|NCT06740175|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902433|NCT06569537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33902434|NCT00839098|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33902435|NCT03242759|||COHORT||PROSPECTIVE|||||||
33902436|NCT01651260|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33902437|NCT01511289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902438|NCT00956241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902439|NCT04860713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985726|NCT00483626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985727|NCT03787030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A nurse blinded to the treatment applied will evaluate the healing of chronic anal fissure and quantify pain||f|f|f|t
33985728|NCT02631772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985729|NCT01185886|||COHORT||OTHER|||||||
33985730|NCT02694731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773450|NCT06736600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773451|NCT01836458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773452|NCT04843865|NA|SINGLE_GROUP||TREATMENT||NONE||A quasi-experimental design||||
33773453|NCT06739252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773454|NCT06739967|||COHORT||PROSPECTIVE|||||||
33773455|NCT05838521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773456|NCT06052566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773457|NCT06198426|NA|SEQUENTIAL||TREATMENT||NONE||||||
33773458|NCT06559475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773459|NCT06397287|||COHORT||PROSPECTIVE|||||||
33773460|NCT05645003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773461|NCT04277741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participant will be blind to the condition that they are in.||t|f|f|f
33773462|NCT06737081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773463|NCT06124690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients with persistent atrial fibrillation are included in the study. They are randomized into three diffrenet treatment arms depending on the presence of left atrial fibrosis.|t|f|f|t
33773464|NCT06508021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773465|NCT02689791|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33773466|NCT04701593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33773467|NCT06103669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773468|NCT03809637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773469|NCT06740227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773470|NCT05744921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773471|NCT05617547|||COHORT||CROSS_SECTIONAL|||||||
33773472|NCT00532805|||COHORT||PROSPECTIVE|||||||
33773473|NCT02460081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773474|NCT02270073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773475|NCT05903911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||130 participants randomized to intervention and 130 to waitlist control|t|f|f|f
33773476|NCT06741345|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Multiple ascending dose study will enroll three cohorts sequentially. An optional fourth cohort may be enrolled. The food effect study follows a randomized, balanced, single-dose, two-treatment (i.e., fed versus fasted), two-period, crossover design.||||
33773477|NCT06738693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773478|NCT06739265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773479|NCT01285193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773480|NCT01770249|NA|SINGLE_GROUP||OTHER||NONE||||||
33773481|NCT06195046|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|patient and Investigator will not know whether the subject has BAT turned on or off during each of the 3 month follow-up intervals|double-blind cross-over study design|t|f|t|f
33773482|NCT02178436|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I is completed, due to Dose Limiting Toxicities (DLT).||||
33773483|NCT03673371|||COHORT||PROSPECTIVE|||||||
33773484|NCT03878537|||COHORT||PROSPECTIVE|||||||
33773485|NCT06740500|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773486|NCT05655195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773487|NCT06056999|||COHORT||PROSPECTIVE|||||||
33773488|NCT03103932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The assigned care pathway will not be revealed to the participant NTproBNP levels will not be revealed to care providers for the group randomized to usual care.|single blind, strategy based, randomized trial consisting of two main study arms|t|t|f|f
33773489|NCT05176080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773490|NCT05015660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded outcome adjudication|Prospective open-label randomized controlled trial (1:1) with blinded outcome adjudication|f|f|f|t
33773491|NCT06736652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33773492|NCT02284919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773493|NCT03294213|||COHORT||PROSPECTIVE|||||||
33773494|NCT06738030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomly assigned to active transcranial stimulation or sham stimulation groups.|t|f|t|f
33773495|NCT05115474|||CASE_ONLY||PROSPECTIVE|||||||
33773496|NCT02825953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773497|NCT06117995|||COHORT||PROSPECTIVE|||||||
33773498|NCT05785611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773499|NCT02071563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773500|NCT04489589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773501|NCT05400018|||CASE_ONLY||RETROSPECTIVE|||||||
33773502|NCT00344188|||COHORT||PROSPECTIVE|||||||
33773503|NCT06736847|||COHORT||PROSPECTIVE|||||||
33773504|NCT04340843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773505|NCT06428383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773506|NCT06740019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985731|NCT06195670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773507|NCT03316261|||COHORT||CROSS_SECTIONAL|||||||
33773508|NCT06740396|||COHORT||PROSPECTIVE|||||||
33773509|NCT05559658|||COHORT||CROSS_SECTIONAL|||||||
33773510|NCT01634711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773511|NCT02212938|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773512|NCT06738615|||COHORT||PROSPECTIVE|||||||
33773513|NCT02919943|||COHORT||PROSPECTIVE|||||||
33773514|NCT04381767|||CASE_ONLY||RETROSPECTIVE|||||||
33773515|NCT05290597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773516|NCT05827822|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33773517|NCT04350476|NA|SINGLE_GROUP||SCREENING||NONE||"This is a non-randomized study. Based on clinical assessment, patients will be provided with the following home monitoring system: VitalConnect Vital Sign Patch (San Jose, California) This patch provides continuous real-time monitoring of cardiac telemetry, heart rate, respiratory rate and oxygen saturation. Duration of monitoring is typically up to 7 days.~This patch is applied to the upper left side of the chest wall, attached with a hypoallergenic adhesive material. (This device is FDA approved for this indication)."||||
33773518|NCT06740136|NA|SINGLE_GROUP||OTHER||NONE||Intervention model||||
33773519|NCT01326793|NA|SINGLE_GROUP||SCREENING||NONE||||||
33773520|NCT06558110|||COHORT||CROSS_SECTIONAL|||||||
33773521|NCT06129760|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, prospective, unblinded cohort study to establish feasibility that will provide the basis for larger prospective studies using wearables. The results from this study will be used to refine the actigraphy signatures and analysis pipelines to be used in future prospective studies that will proactively identify health changes in participants with glioblastoma.||||
33773522|NCT03760471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773523|NCT02800824|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33773524|NCT06741358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773525|NCT02606747|||COHORT||PROSPECTIVE|||||||
33773526|NCT03997162|||CASE_ONLY||PROSPECTIVE|||||||
33773527|NCT01628380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773528|NCT06738238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773529|NCT02311374|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33773530|NCT02312505|NA|SINGLE_GROUP||||NONE||||||
33773531|NCT06424288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985732|NCT04128826|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Independent individual outcome assessor will not know participants belongs to which group.||f|f|f|t
33773532|NCT00776100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773533|NCT06736834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33773534|NCT05575674|||CASE_ONLY||RETROSPECTIVE|||||||
33773535|NCT06737952|||COHORT||PROSPECTIVE|||||||
33773536|NCT01310868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773537|NCT06739018|||CASE_CROSSOVER||PROSPECTIVE|||||||
33773538|NCT06738173|||COHORT||CROSS_SECTIONAL|||||||
33773539|NCT02190760|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33773540|NCT03370926|||COHORT||PROSPECTIVE|||||||
33773541|NCT06740903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773542|NCT04989530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985733|NCT04619186|||COHORT||PROSPECTIVE|||||||
33985734|NCT04656223|||COHORT||PROSPECTIVE|||||||
33985735|NCT05445310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985736|NCT00520130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985737|NCT04971772|||COHORT||PROSPECTIVE|||||||
33985738|NCT04089592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient meeting the inclusion criteria will be randomly allocated divided into two groups by chit paper method A, B (30 participants in each group).|RCT, Double-blind, Randomized control trial|t|t|t|f
33985739|NCT06067243|||COHORT||PROSPECTIVE|||||||
33985740|NCT01901705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985741|NCT01503736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985742|NCT02727010|||CASE_CONTROL||PROSPECTIVE|||||||
33985743|NCT04078932|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985744|NCT02973763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985745|NCT03276247|||COHORT||CROSS_SECTIONAL|||||||
33985746|NCT00954395|||COHORT||PROSPECTIVE|||||||
33985747|NCT01375660|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33985748|NCT01590485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985749|NCT00239278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33985750|NCT01822483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985751|NCT00034684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985752|NCT03756662|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, open-label, single arm, multicenter||||
33985753|NCT03158675|NA|SINGLE_GROUP||TREATMENT||NONE||"• Methods:-~-In each patient: The lesions on one side of the body will be randomly allocated to group A, and the lesions on the other side to group B.~Group A: will be treated with fractional CO2 laser combined with topical corticosteroid and UVB-NB.~Group B: will be treated with topical corticosteroid and UVB-NB."||||
33985754|NCT01232647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985755|NCT01884766|||OTHER||PROSPECTIVE|||||||
33985756|NCT00369447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985757|NCT05566860|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985758|NCT04937348|||CASE_CONTROL||PROSPECTIVE|||||||
33985759|NCT04627038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985760|NCT00274937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985761|NCT05863962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985762|NCT06203717|NA|SINGLE_GROUP||OTHER||NONE||||||
33985763|NCT02627066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985764|NCT06377657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants were blinded for the supplementation.||t|f|f|t
33985765|NCT01882257|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985766|NCT03613337|||CASE_CONTROL||RETROSPECTIVE|||||||
33985767|NCT00526734|RANDOMIZED|||TREATMENT||NONE||||||
33985768|NCT02030353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33985769|NCT06426004|RANDOMIZED|FACTORIAL||OTHER||NONE||The investigators will develop three layers of interventions that involve educational elements about NPH and evaluate which provides the most benefit including referrals to NPH related care. 1) Patients identified from the first part of the study with possible NPH symptoms will receive intervention 2) Patients, and the Primary Care Providers (PCPs) receive intervention, and 3) patients, and PCP receive intervention and with additional community health workers (CHWs) assisting providers with managing the patient care including referrals, addressing socioeconomic barriers, transportation to receive care.||||
33985770|NCT01845662|||COHORT||RETROSPECTIVE|||||||
33985771|NCT01378039|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33985772|NCT05066438|||COHORT||PROSPECTIVE|||||||
33985773|NCT01183585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080351|NCT04946812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a prospective, single-blind, parallel-group randomized control trial to assess the feasibility and safety of SBTM in preventing falls and improving gait and balance, as well as its efficacy compared to TM training. The assessor will be blinded to their randomization. Patients will not be blinded to the intervention, and will be informed about the rationale of the study.|Split-belt treadmill (Grail systems®, by Motek, Netherlands)|f|f|f|t
34080352|NCT04418362|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33773543|NCT06737159|||COHORT||PROSPECTIVE|||||||
34080353|NCT06323759|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This intervention is based on a pedagogical engineering that proposes a favorable learning environment more adapted than the courses already offered in preparing for parenthood and promoting breastfeeding||||
33773544|NCT06737965|||CASE_CONTROL||PROSPECTIVE|||||||
33773545|NCT03309124|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33773546|NCT05048394|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33773547|NCT06034197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773548|NCT06737133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902440|NCT06341569|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||"This study uses a multiple-group design to investigate various psychosocial aspects of physical therapy students and to explore the potential benefits of breathing techniques as a well-being-promoting intervention. The study involves three groups:~Intervention group: second-year physical therapy students participating in a 14-week breathing techniques program.~Control group: second-year physical therapy students who do not participate in the program but complete the same questionnaires.~Comparison groups: 1st, 2nd, and 3rd year physical therapy students participating in assessments only."||||
33902441|NCT01009385|RANDOMIZED|PARALLEL||||NONE||||||
33902442|NCT06339229|||COHORT||RETROSPECTIVE|||||||
33902443|NCT04818450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902444|NCT04811677|||COHORT||CROSS_SECTIONAL|||||||
33985774|NCT02234661|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985775|NCT00582673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985776|NCT01778205|||COHORT||PROSPECTIVE|||||||
33985777|NCT02264054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985778|NCT03872674|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patients will be randomly allocated to 2 groups using computer-generated randomization method. Neither participants nor physicians will be blinded to the groups because of organizational reasons|Arm 1: standard nasal cannula group Arm 2: high-flow humidified oxygen-delivery system (OptiFlow THRIVE) group||||
33985779|NCT03824119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985780|NCT00807196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985781|NCT03352089|||CASE_CONTROL||PROSPECTIVE|||||||
33985782|NCT06043843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985783|NCT03879915|||COHORT||PROSPECTIVE|||||||
33985784|NCT02120937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773549|NCT00673634|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33773550|NCT00344370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902445|NCT01210950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902446|NCT01581112|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902447|NCT04947566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33902448|NCT04083911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902449|NCT02417220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33902450|NCT01086059|||COHORT||PROSPECTIVE|||||||
33902451|NCT06672380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902452|NCT01053624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902453|NCT05090150|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Participants are first randomly assigned to two interventions:either best clinic practices or best clinic practices with a conditional lottery incentive. This stage lasts 6 months. Participants who do not meet the criteria for non-response will continue in the assigned intervention arm. Non-responders will be rerandomized to continue in the clinic intervention arm (standard of care), community ART (smart lockers), or home delivery.||||
33902454|NCT02183298|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33902455|NCT06050434|||COHORT||PROSPECTIVE|||||||
33902456|NCT03068026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a randomized crossover trial. The two exercise modalities will be separately assessed in different groups of patients, but within each group the intervention (VitaBreath) will be compared to control (pursed-lip breathing).||||
33902457|NCT03622411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902458|NCT02626052|||COHORT||PROSPECTIVE|||||||
33985785|NCT03550781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985786|NCT02140398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985787|NCT01259583|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33773551|NCT00432679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773552|NCT01165346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773553|NCT00391456|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33985788|NCT01304641|||COHORT||RETROSPECTIVE|||||||
33985789|NCT02821897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080354|NCT03266900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080355|NCT02818855|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33773554|NCT05057832|||CASE_ONLY||PROSPECTIVE|||||||
33985790|NCT03013634|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985791|NCT00851526|||COHORT||RETROSPECTIVE|||||||
33985792|NCT01804803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985793|NCT04794140|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33985794|NCT05123222|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||This study will include 4 cohorts of 14 ZIKV and DENV-naïve non-pregnant female and male subjects, 18 - 40 years of age (total: up to 56 subjects). Within each cohort, 10 subjects will receive ZIKV and 4 subjects will receive a placebo on Study Day 0. Cohorts 1 and 2 (Dose = 10\^2 PFU) will be enrolled first and will enroll only women. Cohorts 3 and 4 (Dose = 10\^2 PFU) will enroll men.|t|t|t|t
33985795|NCT04667091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinding will be used in which only the researcher doing the study knows which treatment or intervention the participant is receiving until the trial is over.||t|f|f|f
33985796|NCT02495467|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33985797|NCT00251979|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33985798|NCT02420834|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33985799|NCT04117997|||CASE_ONLY||PROSPECTIVE|||||||
34080356|NCT02071459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985800|NCT00382694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33773555|NCT06737211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773556|NCT02035215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985801|NCT02187562|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985802|NCT00783367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985803|NCT02884141|||COHORT||PROSPECTIVE|||||||
33985804|NCT00518518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985805|NCT03292354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All investigators who assess the image quality will be blinded to the assigned contrast media protocol. Only the technicians who complete the scan and injection protocol will be unblinded for the contrast media protocol chosen.||f|f|t|t
33985806|NCT06421870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985807|NCT02458469|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33985808|NCT01602653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33985809|NCT04891744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985810|NCT04254718|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34080357|NCT01651364|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34080358|NCT01614470|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34080359|NCT04100928|||OTHER||CROSS_SECTIONAL|||||||
33773557|NCT06206746|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Control arm has the option to crossover to receive the May Health procedure after completion of the 3 month primary endpoint visit.||||
34080360|NCT02001571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773558|NCT06738940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773559|NCT00670462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773560|NCT02456818|||COHORT||PROSPECTIVE|||||||
34080361|NCT04332406|||COHORT||RETROSPECTIVE|||||||
33773561|NCT05668858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080362|NCT01022203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080363|NCT00600093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080364|NCT05934006|||COHORT||CROSS_SECTIONAL|||||||
33773562|NCT03358979|||OTHER||PROSPECTIVE|||||||
33773563|NCT06574425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773564|NCT06741137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080365|NCT00749398|||COHORT||PROSPECTIVE|||||||
33773565|NCT05586737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773566|NCT05865418|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessor will be blinded to the group assignment.|Adolescents with cerebral palsy will be randomly assigned to two unique exercise regimen and no exercise/standard-of-care group.|f|f|f|t
33773567|NCT05055648|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, non-blinded, international multicenter, randomized phase III study||||
33773568|NCT06739499|||COHORT||PROSPECTIVE|||||||
33773569|NCT06737718|||CASE_CONTROL||PROSPECTIVE|||||||
33773570|NCT05530837|||COHORT||RETROSPECTIVE|||||||
33773571|NCT06739642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773572|NCT00658671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773573|NCT06027775|||COHORT||RETROSPECTIVE|||||||
33773574|NCT04765592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773575|NCT02918890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773576|NCT00982150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773577|NCT02978313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773578|NCT00806624|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773579|NCT06738186|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773580|NCT00771693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33773581|NCT00864370|||COHORT||PROSPECTIVE|||||||
33773582|NCT03223272|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, dose titration study||||
33773583|NCT04439487|||COHORT||PROSPECTIVE|||||||
33773584|NCT06736795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985811|NCT05611593|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Group Assignment||||
33985812|NCT02057458|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985813|NCT02951962|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080366|NCT00225745|||CASE_CONTROL||RETROSPECTIVE|||||||
34080367|NCT00346957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080368|NCT03351712|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Single subject design and group design combined||||
34080369|NCT03251365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"After explaining the treatment to develop once informed of the characteristics of pancreatic cancer to the patient, we will explain in detail the clinical trial that we are going to develop. After obtaining the informed consent, authors will start the randomly distribution of patients A list of randomization to 42 patients will be developed by a computer program that simulates the extraction procedure of numbered balls and the correlative allocation to each of the codes.~Randomization is by block, thereby ensuring a balanced number of subjects per treatment. Then a scrambling code in which randomly assigned treatment to each code will be developed.~The randomization code and study randomization list shall be kept only for the person that will carry the allocation of treatments.Randomization of patients will be performed centrally. Each patient is assigned to a sequential number of the centralized list of inclusion and appropriate treatment."|Characteristics of the Trial: This is a randomized,interventional, multidisciplinary study,phase II-III, involving several Services as General Surgery, Pathology, Oncology, Pharmacy, Gastroenterology and Radiology at the University General Hospital of Ciudad Real and the Faculty of Medicine, and Translational Research Unit,HGUCR.The study is opened to the incorporation of other centers that increase the power of the obtained results.|t|f|t|f
34080370|NCT06403826|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080371|NCT00264147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080372|NCT02735031|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34080373|NCT03667768|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Split-mouth design|t|t|f|f
34080374|NCT02697214|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33902459|NCT05911958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080375|NCT05829499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080376|NCT04804761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The types of treatment, either real or sham EA, will be kept confidential to all parties, including subjects, endodontist, data collector and data analyst, and it will only be reviewed to the acupuncturist right before the EA session.|Twenty subjects will be recruited from IMU Oral Health Centre, Bukit Jalil who come for endodontic treatment due to symptomatic irreversible pulpitis between April 2020 to April 2022.|t|t|f|t
34080377|NCT03632564|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34080378|NCT02048800|||COHORT||PROSPECTIVE|||||||
34080379|NCT02198638|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080380|NCT02590666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080381|NCT00100399|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33902460|NCT03938662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902461|NCT05897957|||COHORT||PROSPECTIVE|||||||
33902462|NCT06649955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902463|NCT02100657|NA|SINGLE_GROUP||OTHER||NONE||||||
33902464|NCT00341315|||COHORT||PROSPECTIVE|||||||
33902465|NCT06132490|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The patient and the pain nurses will be blind to the intervention due to the study design.||t|f|f|f
33902466|NCT04199754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects will receive contrast enhanced CBCT prior to RT treatment.||||
33902467|NCT06671509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Non-randomized|Single dose||||
33902468|NCT03533478|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33902469|NCT02426242|||COHORT||PROSPECTIVE|||||||
33902470|NCT04319289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902471|NCT03125642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902472|NCT02856789|||OTHER||PROSPECTIVE|||||||
33902473|NCT06672003|||OTHER||CROSS_SECTIONAL|||||||
33902474|NCT05541692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902475|NCT03708003|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, single-arm, open-label, phase-II trial.||||
33902476|NCT03863444|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study subjects will be divided into the experimental group and control group. In order to avoid the contamination between the control group and the experimental group due to the simultaneous empty space and information sharing, the control group will be recruited in the study in the first two months. After control group recruitment, we will recruit the intervention group and provide prenatal education.||||
33902477|NCT06475222|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Study 1 is single group model, study 2 is parallel model, and study 3 is crossover model.|f|f|t|t
33902478|NCT06662994|NA|SINGLE_GROUP||TREATMENT||NONE||Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.||||
33902479|NCT02060396|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33902480|NCT01369693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33902481|NCT02267499|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902482|NCT03005782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080382|NCT03308552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080383|NCT02862301|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080384|NCT00933725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080385|NCT05726435|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Program is used to make random selection and grouping of participants in two groups: experimental one receiving fiber and control one, receiving placebo. A research assistant who is not involved in study (neither design nor implementation) will pack prebiotic/placebo daily doses (20 grams/day) and provide nutritionist who is one of the investigators with doses for each participant. Only when the study is completed and all results processed will the information on who received fiber/placebo be released.|Double-blind study of defined prebiotic supplementation for active basketball players investigating fiber effect on microbiota composition and delayed feeling of fatigue. There are two arms, active one receiving prebiotic fibre and control one receiving placebo. Each arm contains 7 randomly selected participants who signed informed consent and will receive supplementation during 4 weeks in total while being in the same training camp and under same training conditions.|f|f|t|t
34080386|NCT02460289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985814|NCT05651126|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators are blinded to the drug condition|Case-Control comparison using repeated-measures cross-over design. Each participant receives each one of the three pharmacological probes in separate visits (i.e., placebo, psilocybin low dose and psilocybin higher dose), with the order of administration being pseudorandomized (to prevent order effects).|t|f|t|f
33985815|NCT00794963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902483|NCT02255786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985816|NCT01499147|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985817|NCT02093494|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985818|NCT01900080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985819|NCT05912062|||COHORT||PROSPECTIVE|||||||
33985820|NCT04432233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985821|NCT03041025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985822|NCT00396279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985823|NCT01846585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985824|NCT06089018|||CASE_CONTROL||PROSPECTIVE|||||||
33985825|NCT01300390|||CASE_ONLY||PROSPECTIVE|||||||
33985826|NCT05595694|||OTHER||RETROSPECTIVE|||||||
33902484|NCT06671418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985827|NCT01313273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985828|NCT05174325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985829|NCT00260039|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33985830|NCT03743961|||COHORT||PROSPECTIVE|||||||
33985831|NCT02097550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902485|NCT00155285|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33985832|NCT03509545|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985833|NCT04753905|||COHORT||CROSS_SECTIONAL|||||||
33902486|NCT03453463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor are not aware of participant status and are nor allowed to ask correspondingly||f|f|f|t
33902487|NCT03664817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, Randomized, Controlled||||
34080387|NCT03729050|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33902488|NCT04827056|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Apart from the Research Pharmacists, all others engaged with this study (participants and study team) will be masked to the drug sequence.|All participants will be randomized to receive BXCL501 40µg, 80µg or placebo in a modified crossover randomization scheme in which all participants will receive each possible study drug assignment but must receive 40µg before receiving the higher dose (80µg).|t|t|t|f
33985834|NCT00949481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985835|NCT01108094|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985836|NCT00538421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985837|NCT04138147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33985838|NCT01587209|||CASE_ONLY||PROSPECTIVE|||||||
33985839|NCT04898361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985840|NCT06242119|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080388|NCT06369558|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34080389|NCT02890316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080390|NCT04705818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"4 independant single-arm, phase II trials, based on 2-stage Simon's optimal design:~* cohort A: pancreatic cancer~* cohort B: not MSI-H or MMR-deficient colorectal cancer~* cohort C: metastatic solid tumor with positive interferon gamma signature and/or prensece of tertiary lymphoid structure~* cohort D: soft-tissue sarcoma"||||
34080391|NCT05971771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Products will be delivered in forms that it will not be discernable (to participant, investigator, or care provider) as to which product is active or placebo|A double-blind, placebo controlled, parallel designed study in healthy subjects|t|f|t|t
34080392|NCT05606861|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34080393|NCT01172613|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33902489|NCT03935477|||COHORT||PROSPECTIVE|||||||
33902490|NCT04002453|||CASE_ONLY||PROSPECTIVE|||||||
33902491|NCT01227915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33902492|NCT00198159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902493|NCT02590679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902494|NCT01370798|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080394|NCT05637034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080395|NCT04640922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised, double-blind placebo-controlled multi-centre study|t|t|t|t
33902495|NCT04094506|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33902496|NCT03093012|||OTHER||PROSPECTIVE|||||||
33902497|NCT00759512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33773585|NCT06741085|RANDOMIZED|PARALLEL||TREATMENT||NONE||After 3 months of TKI therapy, eligible patients are randomized to either continuing drug therapy alone with salvage interventions at progression (SOC) vs continuing drug therapy with addition of consolidative SRS of radiographically visible brain lesions (intervention). Randomization will be stratified by receipt of TKI monotherapy vs. TKI combination therapy (e.g. with concurrent chemotherapy) as first line systemic therapy.||||
33773586|NCT01662622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773587|NCT06737237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Clinical Research Coordinator||t|t|f|t
33773588|NCT06736639|||CASE_CONTROL||RETROSPECTIVE|||||||
33773589|NCT03888508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single Blind Randomized Controlled Parallel Design trial|f|f|f|t
33773590|NCT04451135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773591|NCT06737432|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|Monitoring 3-4 months prior to intervention or use of the software.|||||
33773592|NCT01388530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773593|NCT01896089|||COHORT||PROSPECTIVE|||||||
33773594|NCT03604913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33773595|NCT04944225|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|It is not possible to blind clinicians or study staff to hospital allocation because the appropriate pain/opioid management must be transparently applied upon entry to the intervention phase of the study, and therefore the unit of randomization is at the hospital level. Outcome adjudicators will be blinded and patients will remain blinded.|"Stepped-Wedge Cluster Randomized Trial. In this trial, the unit of randomization is the cluster (i,e each of the hospital) and the unit of analysis is the patient.This will entail the roll out of the intervention in a randomized fashion and sequential crossover of clusters from control to intervention until all clusters are exposed."|t|f|f|t
33773596|NCT05256381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773597|NCT06442072|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33773598|NCT06737757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773599|NCT06122181|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33773600|NCT06741124|||CASE_CONTROL||RETROSPECTIVE|||||||
33773601|NCT01180972|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33773602|NCT04855487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Adolescents/young adults with cancer will participate in a 5-week online expressive storytelling intervention. They will independently create digital stories about themselves while their target audiences are their primary nurses. They will then participate in weekly online meetings with nursing research staff, during which they introduce their stories and discuss their reflections. In the final session, they will create a one-page or five-slide story to share with their primary nurses, if they want.||||
33773603|NCT06168851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773604|NCT06273579|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Double (Participant, Expert Instructor)~Both study participants and expert instructors are blinded to group assignments and study outcomes."|Randomized Controlled Trial|t|f|f|t
33773605|NCT04251702|||COHORT||PROSPECTIVE|||||||
33773606|NCT03957915|NA|SEQUENTIAL||TREATMENT||NONE||"This Phase 1 Study is an open-label, non-randomized, dose escalation, safety, efficacy, pharmacokinetic, and pharmacodynamic evaluation study of INA03 administered as a single agent IV infusion every 2 weeks to patients ≥18 years of age with R/R AML, MLL, or ALL.~The study will be performed in 2 parts: a Dose Titration for Day 1 study (Part 1) followed by a Dose Escalation Part (Part 2) of INA03 used as monotherapy."||||
33773607|NCT06740045|NA|SINGLE_GROUP||TREATMENT||NONE||"The proposed design is a 24-week pilot study to investigate the histo-inflammatory and remodeling profiles and clinical outcomes of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) patients with Severe Asthma (SA) treated with Tezepelumab. The investigators plan to recruit approximately 10 subjects with (CRSwNP) and severe asthma as a proof of concept study. Eligible subjects will be requested to participate in the study for a maximum of 24 weeks, during which subjects will remain on their existing standard of care therapy. At Visit 2 (week 0), subjects will receive either add-on Tezepelumab (210 mg) during the 24-week treatment period. Study medication will be administered subcutaneously (SC) every 4 weeks for a total of 6 doses."||||
33773608|NCT06738134|||COHORT||PROSPECTIVE|||||||
33773609|NCT02862275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773610|NCT06293482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773611|NCT06364358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33773612|NCT06369961|||CASE_ONLY||RETROSPECTIVE|||||||
33773613|NCT05028010|NA|SINGLE_GROUP||PREVENTION||NONE|No masking will be done.|This is a quasi-experimental study aimed to look at the impact of model-based education on the improvement of nutrition promotion.||||
33902498|NCT05786261|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33902499|NCT00568789|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33902500|NCT01748695|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985841|NCT05468021|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants will not be aware if they are assigned to an educational intervention nor control group. All will be assessed equally.|Participants are assigned to one of two groups in parallel for the duration of the study. 193 participants will be assigned to an educational intervention group and 193 will be assigned to a control group.|t|f|f|f
33985842|NCT04986878|RANDOMIZED|PARALLEL||TREATMENT||NONE|A computer-generated randomization table will be used for patient allocation to one of the two study groups, The SACB group, and the CACB group. Randomization was done in blocks of 10 patients each. Patients' assignments were written in a sealed envelope that was only open after the patient consents to the study.|The target population of this study will be patients undergoing primary total knee arthroplasty at Aswan l and Assiut university hospitals||||
33773614|NCT03360279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The IVUS interpreter and follow-up evaluators are masked.||f|f|f|t
33773615|NCT01335308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773616|NCT05071066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773617|NCT06740812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773618|NCT05176704|||COHORT||CROSS_SECTIONAL|||||||
33773619|NCT06633016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study participants, Investigator, and study site staff, Sponsor will be blinded to treatment assignments (ABX-002 or placebo solution).||t|f|t|f
33773620|NCT06349200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773621|NCT03502733|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33773622|NCT06741111|||COHORT||RETROSPECTIVE|||||||
33985843|NCT00616408|||COHORT||RETROSPECTIVE|||||||
33773623|NCT06740656|||CASE_ONLY||RETROSPECTIVE|||||||
33773624|NCT04266795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773625|NCT03813095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple Blind||t|t|t|f
33902501|NCT00878046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902502|NCT01469052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902503|NCT00135434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902504|NCT03751709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902505|NCT03281226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985844|NCT03919370|||COHORT||PROSPECTIVE|||||||
33985845|NCT00003114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985846|NCT05920343|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind placebo-controlled study||t|t|t|f
33985847|NCT02676024|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33985848|NCT00892086|||COHORT||PROSPECTIVE|||||||
33985849|NCT00424047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773626|NCT03941574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773627|NCT02954575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902506|NCT04853667|||FAMILY_BASED||PROSPECTIVE|||||||
33902507|NCT03912467|||COHORT||RETROSPECTIVE|||||||
33902508|NCT04726267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902509|NCT03507140|||COHORT||PROSPECTIVE|||||||
33985850|NCT05769725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985851|NCT01616225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773628|NCT00165022|||COHORT||CROSS_SECTIONAL|||||||
33773629|NCT00433576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773630|NCT05219799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902510|NCT05451121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902511|NCT06611605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|t|f|f|f
33902512|NCT02272205|||COHORT||RETROSPECTIVE|||||||
33902513|NCT04965012|RANDOMIZED|PARALLEL||TREATMENT||NONE||A three-arm RCT will be conducted to evaluate the proposed online intervention. Eligible participants will be randomized to the CBT with MET condition, the CBT without MET condition, or the psychoeducational control (i.e., control) condition.||||
33902514|NCT05814575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33985852|NCT00885144|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33985853|NCT00717405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985854|NCT06231784|NA|SINGLE_GROUP||TREATMENT||NONE||LUMINA IOL||||
33985855|NCT02815527|||COHORT||PROSPECTIVE|||||||
34080396|NCT04361084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This feasibility study involves staff within the host Trust. Staff booking into the training will select available dates. These dates have been randomly assigned (not visible on booking to participants) to do traditional or virtual reality simulation training. Only on attending the actual training day will participants find out which training allocation they will undertake.||||
34080397|NCT03831776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902515|NCT05348187|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Specimens from advanced NSCLC and CRC patient tumor samples, will be extracted and tested with the therascreen® KRAS RGQ PCR Kit. The sample KRAS G12C mutation status, if known by a previous testing method, will be blinded to device investigation site personnel at NeoGenomics.|||||
33902516|NCT01628991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902517|NCT05209568|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a multi-center study of immune responses to gluten in persons with celiac disease and healthy controls. All participants will have baseline blood drawn to assess immune responses at baseline in addition to four hours after a single oral dose of gluten.||||
33902518|NCT04442048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902519|NCT06672172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080398|NCT01455623|||COHORT||PROSPECTIVE|||||||
33902520|NCT02829112|||COHORT||RETROSPECTIVE|||||||
33902521|NCT00571272|||COHORT||PROSPECTIVE|||||||
33902522|NCT02698592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902523|NCT01764646|RANDOMIZED|PARALLEL||TREATMENT||NONE||5 x 7.25 Gy delivery in 2 alternative time Schedule: over 9 days every other treatment or over 28 days once a week||||
33902524|NCT01984593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080399|NCT00973583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902525|NCT01863563|NA|SINGLE_GROUP||TREATMENT||NONE||Quickclot||||
33902526|NCT05885256|||COHORT||PROSPECTIVE|||||||
33902527|NCT02687113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902528|NCT05812846|||COHORT||PROSPECTIVE|||||||
33902529|NCT02318394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902530|NCT04304222|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|2 study team clinicians are the designated care providers to the participants hence they are masked together with the participants. One of the masked clinicians is the Principal investigator.|"Participants are randomized into 2 sequence:~1. To receive the conventionally made denture framework then the 3D printed denture framework~2. To receive the 3D printed denture framework then the conventionally made denture framework"|t|t|f|t
33902531|NCT03528044|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||In this study, patients undergoing bariatric surgery will be assessed at baseline and after bariatric surgery. We intend to analyze the changes in this repeated and dependent measurements. The other group will be undisturbed during the follow up except for clinical assessments and MRI imaging.||||
33902532|NCT01396408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902533|NCT05217381|||COHORT||RETROSPECTIVE|||||||
33902534|NCT06411899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33682839|NCT05934669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A double blind randomized study. Except for the pharmacist, all treating ED physicians, nurses, patients, patients' caregivers/guardians, ancillary staff, and data analysts will be blinded to the medication administered to the patient. The medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.|After patient enrollment, a nurse will assign a chronological number from 1 to 90. The pharmacist will randomly divide all 90 subjects into 3 even groups to receive either medication A, B, or C. The pharmacist will dispense the medication in a 1ml syringe to the chronological number provided in the order. The nurse will fill out a mYPAS scale to assess the patient's anxiety level and then administer the medication. After 30 minutes, the physician will determine subject readiness and perform laceration repair. The patient's vitals will be monitored every 5 minutes. At the end of the procedure, both the physician and the parent will answer a question using a Likert scale and the nurse will fill out another mYPAS scale. After the procedure, the patient will be monitored in the ED for any adverse effects and will be discharged home once the patient meets established discharge criteria. The nurse will document the time the patient is discharged.|t|t|t|t
34080400|NCT04458519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Investigator responsible for product allocation and blinding is not in contact with study participant and will only be made aware of the process of their evolution in case of emergency.~Study personel in daily contact with the patient are unaware of the patient treatment assignement and are thus blinded."|Single-blinded, randomized, prospective trial|f|t|f|t
33682840|NCT04539743|||COHORT||PROSPECTIVE|||||||
33682841|NCT02243423|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33682842|NCT04308187|||COHORT||CROSS_SECTIONAL|||||||
33682843|NCT05696028|||COHORT||PROSPECTIVE|||||||
33682844|NCT03452527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682845|NCT01579812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773631|NCT06739915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data identified by clinic allocation will be blinded to the PI and co-investigators and study statistician until completion of comparative analysis. There will be no other blinding.||f|f|t|f
33773632|NCT05113264|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773633|NCT06716528|||COHORT||PROSPECTIVE|||||||
33773634|NCT05562960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773635|NCT06736977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33773636|NCT00213330|||CASE_CONTROL||PROSPECTIVE|||||||
33773637|NCT06738069|||OTHER||CROSS_SECTIONAL|||||||
33773638|NCT06739395|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773639|NCT06739226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773640|NCT06097377|||CASE_CONTROL||PROSPECTIVE|||||||
33902535|NCT01314287|||COHORT||PROSPECTIVE|||||||
33902536|NCT03835208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each patient will follow the HMK and LMK diet in a period of 2x3 days in randomized order with a four day washout between. The order of the two diets will be assigned randomly.||||
33902537|NCT00934531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33902538|NCT03434132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902539|NCT03559985|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Paracetamol 500 mg capsules (Doliprane® 500 mg) will remain packaged in their blister packs of origin. The necessary quantity of capsules will be packaged in a box labelled at the corresponding period (period 1 or 2).~Lactose capsules (placebo) of the same size and colour as the Paracetamol capsules (Doliprane® 500 mg) will be bought by the CHU Pharmacy from Clermont-Ferrand. The capsules will then be blistered; the necessary quantity of capsules placebo will be packaged in the same box used for paracetamol, labelled at the time of the treatment (period 1 or 2)."|After a week of pre-selection (D-6 to D0), each patient will receive successively in random order each of the 2 products (paracetamol and placebo) with one wash-out period of 7 days between each administration.|t|t|t|t
33902540|NCT02278185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33902541|NCT03177876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080401|NCT02815085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34080402|NCT02017301|||COHORT||PROSPECTIVE|||||||
34080403|NCT01927094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080404|NCT00669175|||CASE_ONLY||PROSPECTIVE|||||||
34080405|NCT00002125||||TREATMENT||||||||
34080406|NCT05653232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080407|NCT04702464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773641|NCT02576834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773642|NCT05697939|||COHORT||PROSPECTIVE|||||||
33773643|NCT05678673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773644|NCT01824472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773645|NCT05921630|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773646|NCT06741150|NA|SEQUENTIAL||TREATMENT||NONE||3+3 dose climb||||
33773647|NCT04667468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||permuted block design|f|f|f|t
33682846|NCT05424783|||COHORT||PROSPECTIVE|||||||
33682847|NCT01924429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33682848|NCT00169858|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773648|NCT04048070|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with chronic rhinosinusitis undergoing ESS were prospectively assigned to one of five groups; ERAS groups with postoperative intravenous Flubiprofen Axetil or analgesia pump, traditional care with Flubiprofen Axetil or analgesia pump (NERAS groups), or traditional care without postoperative intravenous analgesia group (control).||||
33985856|NCT04854330|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Independent technician|The proposed study design will be a randomised placebo-controlled, double-blind, crossover study.|t|f|t|t
33773649|NCT05874492|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomisation will be carried out by the coordinating centre by telephone. This methodology will maintain the investigator's blindness, the coordinating centre will ask the patient not to talk to the investigator about her treatment during follow-up visits.|"2 groups:~* Immediate spa therapy: the patient carries out the spa therapy soon after the enrolment in the study~* Late spa therapy: the patient carries out the spa therapy after the 6-month follow up visit"|f|f|t|f
33773650|NCT04361474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients with persistent hyposmia related to a SARS-CoV-2 infection|Patients with persistent hyposmia related to a SARS-CoV-2 infection|t|f|f|f
33773651|NCT04426006|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33773652|NCT04345874|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized trial where family child care home providers are randomized to either nutrition or environmental health technical assistance intervention. Interventions are matched for time and contact.||||
33773653|NCT06737341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33773654|NCT03316612|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The all details of groups assignment are arranged and controlled by the research designers. The color, shape, and external packaging of the bilberry extract and placebo are consistent (brown oval tablets). Each bottle of tablets will be marked with the name (or identify number) of the participants by research designers. Thus, the grouping of participants is blind to the rest of the researchers (like outcomes assessors).||t|f|f|t
33773655|NCT06728332|||COHORT||PROSPECTIVE|||||||
33773656|NCT06688786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773657|NCT04574154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized trial|f|f|f|t
33773658|NCT06527079|||COHORT||PROSPECTIVE|||||||
33773659|NCT04345913|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33773660|NCT05958407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773661|NCT06738862|||CASE_CONTROL||PROSPECTIVE|||||||
33773662|NCT06104124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985857|NCT03957239|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The participants, investigators, and anyone else involved with the study will remain blinded for its entirety.|A randomized, double-blind, placebo-controlled crossover in which participants receive one of the study beverages (cranberry or cranberry-flavored) for a 2-week intervention period each will be used.|t|f|t|t
33985858|NCT06326762|||COHORT||RETROSPECTIVE|||||||
33985859|NCT02301910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985860|NCT02331394|NA|SINGLE_GROUP||OTHER||NONE||This is a feasibility study designed to see if the main study can be done.||||
33985861|NCT04060147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985862|NCT04709926|||COHORT||PROSPECTIVE|||||||
34080408|NCT04881812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients with a CTO who are eligible for PCI will be randomized in a 1:1 ratio to additional DCB treatment or stenting of residual disease.|t|f|f|f
34080409|NCT04967053|||COHORT||RETROSPECTIVE|||||||
34080410|NCT01855958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773663|NCT05143957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773664|NCT02014792|||CASE_ONLY||CROSS_SECTIONAL|||||||
33773665|NCT05987618|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The technician scoring the sleep recordings investigating the objective effect of oral appliance treatment with or without elastic bands, will be blinded to which treatment modality the patients are using.||f|f|f|t
33773666|NCT01347853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773667|NCT01564719|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Assessors of metabolic syndrome indicators did not know participants' treatment group.|The investigators used a randomized, multiple baseline design in which 3 cohorts were randomly assigned to start date, thereby creating 2 waiting cohorts. Cohort 1 immediately received the intervention; Cohort 2 waited one year and then received the intervention. Cohort 3 waited two years and then received the intervention. Data were collected from Cohorts 2 and 3 while waiting.|f|f|f|t
33773668|NCT05548959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773669|NCT01398436|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773670|NCT06738264|||COHORT||PROSPECTIVE|||||||
33773671|NCT06479720|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33773672|NCT04063111|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33773673|NCT05509712|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33902542|NCT04207112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33773674|NCT00652925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985863|NCT04270448|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33773675|NCT01430312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33985864|NCT02630121|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33985865|NCT04543760|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33985866|NCT05207280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind clinical trial|Randomized, parallel, multicenter, double-blind clinical trial with two treatment arms|t|f|t|f
33773676|NCT06272019|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||the participant will use iodine gargle in 2 method|f|f|f|t
33773677|NCT03312465|||COHORT||OTHER|||||||
33773678|NCT03903796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902543|NCT06672107|||CASE_CROSSOVER||PROSPECTIVE|||||||
33902544|NCT01221051|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902545|NCT05009472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985867|NCT04826679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985868|NCT01115465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985869|NCT04877080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985870|NCT02816905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33985871|NCT03228719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985872|NCT05986357|||CASE_CONTROL||PROSPECTIVE|||||||
33985873|NCT06366906|||CASE_CONTROL||RETROSPECTIVE|||||||
33985874|NCT06378242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985875|NCT03962686|||CASE_CONTROL||PROSPECTIVE|||||||
33985876|NCT01510730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902546|NCT00149825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33902547|NCT06037538|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902548|NCT00042081|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33902549|NCT01659944||CROSSOVER||BASIC_SCIENCE||NONE||||||
33902550|NCT02606877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902551|NCT04489524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902552|NCT06421246|||COHORT||PROSPECTIVE|||||||
33902553|NCT06672315|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients aged 18 years or older who have experienced out-of-hospital cardiac arrest (OHCA) due to non-traumatic causes||||
33985877|NCT04615793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080411|NCT00871234|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34080412|NCT02820077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34080413|NCT02174107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902554|NCT00196495|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33902555|NCT00598962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902556|NCT04232501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33902557|NCT02940886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902558|NCT00612846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902559|NCT06671847|NA|SINGLE_GROUP||OTHER||NONE||||||
33902560|NCT05924360|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33902561|NCT03251976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985878|NCT05139797|||COHORT||PROSPECTIVE|||||||
33985879|NCT03446339|||CASE_ONLY||PROSPECTIVE|||||||
33985880|NCT02874586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985881|NCT01836341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985882|NCT06013618|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985883|NCT06024993|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"During analysis the groups (flow-controlled ventilation and volume-controlled ventilation) will be blinded.~Participants know that they will be exposed to both modes of ventilation, but are unaware of the randomized sequence (FCV-VCV or VCV-FCV).~It is impossible to mask the investigators delivering the intervention."|Crossover volume-controlled ventilation and flow-controlled ventilation|t|f|f|t
34080414|NCT02831582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33985884|NCT02124434|||COHORT||PROSPECTIVE|||||||
33773679|NCT06170957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Study|t|f|f|f
33902562|NCT06380517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902563|NCT05427682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902564|NCT01175239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902565|NCT01502436|||CASE_CONTROL||RETROSPECTIVE|||||||
33902566|NCT00244205|||CASE_CONTROL||PROSPECTIVE|||||||
33902567|NCT03964012|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind||t|t|t|t
33902568|NCT03698162|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902569|NCT04681287|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with advanced HER2 positive breast cancer who had received at least paclitaxel, trastuzumab and TKIs (lapatinib or Pyrotinib) at least in the past were included in this study,Efficacy and safety of combination of inetetamab and PD-1 inhibitor combined with chemotherapy (including albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine or aribrin).||||
33902570|NCT02625519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902571|NCT04652492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902572|NCT04016493|||OTHER||PROSPECTIVE|||||||
33902573|NCT00418262|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33902574|NCT06287424|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible subjects will be stratified based on Screening mean PPD (above or below 2mm), mean GBI (above or below 0.44), mean age (above or below 45 years old), gender (male or female) and tobacco use (yes or no). Within strata, subjects will be randomly assigned to one of the treatment groups using an encoded program. This assignment process and the distribution of test products will be conducted in a protected area that will ensure blinding of the examiner to the identity of the test products.|4 Regimen parralel groups|t|f|f|f
33902575|NCT06672263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902576|NCT05913557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants self-selected to receive the therapy or not receive the therapy. Researchers and providers were also made aware of treatment group as they would then set up assessments and first treatment session.|Participants were either in a healthy group that did not receive treatment but did complete a baseline assessment or in one of two clinical groups. The first clinical group completed a baseline assessment, received 4 months of Radically Open Dialectical Behavior Therapy (RO DBT) treatment, then completed a follow-up assessment. The non-treatment clinical received no treatment (but could complete any other ongoing treatment as usual (TAU) treatment) and completed a baseline assessment and a subset also completed a follow-up assessment.||||
33902577|NCT02526615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902578|NCT00693381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902579|NCT04003155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902580|NCT02481518|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34080415|NCT06465017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902581|NCT05292222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902582|NCT00081289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902583|NCT01782183|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33902584|NCT06082947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902585|NCT04038372|||COHORT||PROSPECTIVE|||||||
33902586|NCT00121810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902587|NCT05208112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902588|NCT06255977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902589|NCT00915967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902590|NCT00392002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902591|NCT03106272|||CASE_ONLY||PROSPECTIVE|||||||
33902592|NCT03356847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902593|NCT05595382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33902594|NCT03116529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902595|NCT06671275|NA|SEQUENTIAL||TREATMENT||NONE||||||
33902596|NCT06672419|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this trial, the outcome assessors will be blinded to the group assignment of participants to minimize bias during data collection and analysis. While both participants and care providers are aware of the group assignments (open-label), the outcome assessors will not know which intervention the participants received to ensure unbiased assessment of the primary and secondary outcomes.|This study employs a parallel-group randomized controlled trial (RCT) design. Participants will be randomly assigned to one of two groups: the intervention group, which will receive AI-guided exercise and pain neuroscience education through a tele-rehabilitation platform, or the control group, which will receive standard care for fibromyalgia, including pharmacological treatment and general physical activity recommendations. The study will use a 1:1 randomization ratio and will be conducted remotely. Randomization will be performed using a computer-generated allocation sequence to ensure unbiased group assignment.||||
33902597|NCT04183257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902598|NCT01742221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902599|NCT04296630|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Pragmatic cluster randomized controlled trial|t|f|t|t
33902600|NCT04755400|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The Hospital Pharmacy, Herning Hospital, generates the randomization list. A copy of the list is kept at the Medical Research department.~Patients are randomized to receive either potassium nitrate or placebo (Potassium chloride). The Hospital Pharmacy, Gødstrup Hospital, will blind both treatments."|double-blinded, placebo-controlled, crossover study|t|t|t|f
33902601|NCT05828160|||OTHER||PROSPECTIVE|||||||
33902602|NCT04552236|||COHORT||PROSPECTIVE|||||||
33902603|NCT06312007|RANDOMIZED|PARALLEL||OTHER||NONE||Intervention semi seated position Control side lying position||||
33902604|NCT05365295|NA|SINGLE_GROUP||SCREENING||NONE||||||
33902605|NCT01378754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902606|NCT00184639|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902607|NCT05330442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not know which are patients within health centers are assigned to because they will be independent of the participant recruitment coordinators.|Matched pairs of health centers/FQHCs will be randomized to either CoCM alone or to CoCM+WET.|f|f|f|t
33902608|NCT05496426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902609|NCT03897712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33682849|NCT04743570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682850|NCT02984072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985885|NCT02494544|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Site staff that is performing functional testing on subject is blinded to what implant the patient has.||f|f|f|t
33985886|NCT01650974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33985887|NCT00991965|||COHORT||PROSPECTIVE|||||||
33985888|NCT00322166|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33985889|NCT02277847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985890|NCT04582318|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33985891|NCT01882855|||CASE_ONLY||CROSS_SECTIONAL|||||||
33985892|NCT04503174|||COHORT||PROSPECTIVE|||||||
33985893|NCT04191005|||OTHER||OTHER|||||||
33985894|NCT03481647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will not be aware of the care/treatment given to the other group|Intervention group: intensified oral care programme Control group: conventional oral care|t|f|f|f
33985895|NCT03301948|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Single blind, counterbalanced, crossover trial|t|f|f|f
33985896|NCT05070572|||COHORT||PROSPECTIVE|||||||
33985897|NCT00076622|||COHORT||PROSPECTIVE|||||||
33985898|NCT00496964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985899|NCT00660647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985900|NCT00726739|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985901|NCT02746484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682851|NCT02133170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33682852|NCT00004644||||TREATMENT||||||||
33682853|NCT03102190||SEQUENTIAL||TREATMENT||NONE||||||
33682854|NCT05179707|||COHORT||PROSPECTIVE|||||||
33682855|NCT04095676|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Randomized, controlled study~* Not blinded (open label)~* National multicenter study"||||
33682856|NCT05277948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682857|NCT00533754|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33682858|NCT05690256|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and those analyzing outcomes will be blinded to study assignment. Given the nature of the intervention, participants and their healthcare providers will be unblinded to their assignment.|non-randomized controlled trial (prospective cohort study)|f|f|t|t
33682859|NCT04074291|||COHORT||CROSS_SECTIONAL|||||||
33682860|NCT03849573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33902610|NCT00181688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902611|NCT04515485|||CASE_ONLY||PROSPECTIVE|||||||
33902612|NCT06550674|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33902613|NCT01264133||FACTORIAL||TREATMENT||NONE||||||
33902614|NCT05757999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation numbers will be placed in opaque envelopes and opened by an anesthesiologist (not participating in the study)who will also prepare the study solutions. The solutions used in the study are similar in physical appearance and an investigator not included in the study will prepare the solutions.|Patients will be allocated to one of two groups: a saline placebo group (n=50) or a magnesium group (n=50). The patients will be pretreated with either an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) or a magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) 10 min. before induction of anesthesia. Allocation numbers will be placed in opaque envelopes and opened by an anesthesiologist (not participating in the study)who will also prepare the study solutions.|t|t|t|t
33902615|NCT04664660|||CASE_CONTROL||RETROSPECTIVE|||||||
33985902|NCT01714180|||CASE_CONTROL||PROSPECTIVE|||||||
33985903|NCT03605030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33985904|NCT00492960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Randomized, double-blind, placebo Controlled, dose ranging, multicenter Study|t|f|t|f
33985905|NCT00410774|NON_RANDOMIZED|||TREATMENT||NONE||||||
33985906|NCT03922230|||COHORT||CROSS_SECTIONAL|||||||
33985907|NCT00831428|||OTHER||CROSS_SECTIONAL|||||||
33985908|NCT03241784|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous infusion of expanded T-regulatory lymphocytes during early and late phases of ALS disease in patients with varying rates of disease progression.||||
33985909|NCT04290845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants will be blinded as to who is receiving Relief-Hybrid and who is receiving Usual Care.||f|f|f|t
33985910|NCT04758260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985911|NCT00772941|||CASE_ONLY||PROSPECTIVE|||||||
33985912|NCT01372345|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985913|NCT00989274|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985914|NCT00257673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33985915|NCT01967485|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33985916|NCT01286090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985917|NCT00770445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682861|NCT03269162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682862|NCT02661178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33682863|NCT04179409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682864|NCT02830438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682865|NCT00722371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682866|NCT01926327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682867|NCT01642732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682868|NCT05477472|||CASE_ONLY||PROSPECTIVE|||||||
33902616|NCT02665442|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902617|NCT03400670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985918|NCT05757245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985919|NCT00509561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985920|NCT01061021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33985921|NCT02664805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985922|NCT05003635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985923|NCT02219620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985924|NCT05258474|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33985925|NCT00579761|||CASE_ONLY||RETROSPECTIVE|||||||
33902618|NCT00213369|||||PROSPECTIVE|||||||
33902619|NCT01422304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33985926|NCT04005677|||COHORT||PROSPECTIVE|||||||
33985927|NCT02086747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33902620|NCT05930925|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33985928|NCT03073330|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33985929|NCT05294094|RANDOMIZED|PARALLEL||OTHER||SINGLE||intervention group vs. control group|f|f|f|t
33902621|NCT00317941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902622|NCT00893594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985930|NCT02287675|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33985931|NCT06470880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985932|NCT05668520|||CASE_ONLY||PROSPECTIVE|||||||
33985933|NCT02769715|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33985934|NCT05372926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All patients were randomly allocated into two groups using the block randomization technique (blocks of eight patients) in a 1:1 ratio. In group A, a high-intensity constant work-rate endurance test using Venturi mask (VM) was performed on first, and a test using high-flow nasal canulae oxygen therapy (HFNC) was performed next. In group B, a high-intensity CWRET using HFNC was performed first, and a test using VM was performed next.||||
33985935|NCT01789905|||CASE_ONLY||RETROSPECTIVE|||||||
33985936|NCT03637153|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low altitude and High altitude||||
33985937|NCT03970421|||COHORT||PROSPECTIVE|||||||
33985938|NCT00905931|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985939|NCT00760630|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33985940|NCT01513174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985941|NCT04370821|||COHORT||PROSPECTIVE|||||||
33985942|NCT02247752|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33985943|NCT03375463|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Part A, B and D are not blinded. Part C is blinded to Participant and Investigator||t|f|t|f
33985944|NCT03852082|||COHORT||PROSPECTIVE|||||||
33985945|NCT02496416|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985946|NCT03211403|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33985947|NCT03839303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33985948|NCT00065312||||TREATMENT||||||||
33985949|NCT03847350|||OTHER||PROSPECTIVE|||||||
33985950|NCT05607264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985951|NCT02667405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33985952|NCT01859364|||||PROSPECTIVE|||||||
33985953|NCT00493831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682869|NCT01958827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682870|NCT04796987|||OTHER||RETROSPECTIVE|||||||
33682871|NCT06329128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were divided in two groups. One groups will get electrotherapy, exercise(home programme) and manuel therapy intervention. One group will be the control group. Control group will get electrotherapy and exercise (home programme).|f|f|f|t
33682872|NCT02148900|||CASE_CONTROL||PROSPECTIVE|||||||
33682873|NCT00004393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33682874|NCT01429337|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33682875|NCT01411553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33682876|NCT00076375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33682877|NCT03899636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682878|NCT02395302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682879|NCT02906384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682880|NCT02052414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682881|NCT02104388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902623|NCT02019381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33902624|NCT02666911|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33902625|NCT01025778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902626|NCT02384369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985954|NCT06486129|NA|SINGLE_GROUP||TREATMENT||NONE||Clinically stable patients with OHS and severe hypercapnia during the daytime, referred to the tertiary clinic for the initiation of long-term NIV to alleviate chronic respiratory failure were consecutively enrolled to the study||||
33985955|NCT00495222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985956|NCT02479503|||OTHER||OTHER|||||||
33985957|NCT05354479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both investigator and outcome assessor will be blinded.|Double blinded Randomized control trial|f|f|t|t
33985958|NCT05378724|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A prospective, multi-center, stepped-wedge cluster-randomised trial will be performed to investigate the effectiveness of Hospital Fit. Additionally, a process evaluation will be performed using semi-structured interviews and questionnaires in patients and focus-group interviews in healthcare professionals.||||
33985959|NCT04513730|NA|SINGLE_GROUP||TREATMENT||NONE||"A device originally designed with the function of keeping the user in a comfortable position of pelvic suspension, in dorsal decubitus, with fixation in the popliteal region and ankles was built to promote lumbar traction. The device is designed in auto CAD software with 2d technical representations and 3d electronic model. It consists of a structure of PVC pipes and fittings and padded material at the support points. The structure design was based on anthropometric models according to Felisberto and Paschoarelli (2000).~Participants belonging to both groups will receive information about the procedures performed including the objectives, risks and benefits and study protocol Participants belonging to the intervention group will be submitted to 10 pelvic suspension technique sessions using the functional prototype of the device."||||
33985960|NCT03183037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three - arm pilot randomized controlled trial|t|f|f|t
33985961|NCT05906732|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33985962|NCT01036360|||||PROSPECTIVE|||||||
33985963|NCT04373278|||COHORT||RETROSPECTIVE|||||||
33985964|NCT04065035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Prior to the start of the study, Stephens will generate 2 randomization lists (1 for biopsy subjects and 1 for non-biopsy subjects) to establish treatment assignment to 1 arm (left or right) with the other arm untreated (receiving a placebo). Each list will first be created by concatenating blocks of size of 4 subjects, 2 with left arm treated/right arm untreated and 2 with right arm treated/left arm untreated. The lists will then be randomized by variables from 2 independent uniform distributions: 1 to randomize subjects within block and 1 to randomize blocks. After the randomization lists are created, treatment arm will be assigned to each subject number accordingly.|Split Body, randomized, and placebo controlled|t|f|t|f
33985965|NCT02023853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985966|NCT00711360|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985967|NCT04381962|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study. However, while the study is in progress, access to tabular results by allocated treatment allocation will not be available to the research team, patients, or members of the Steering Committee (unless the DSMC advises otherwise).|Open label, Two-arm, Randomised Superiority Trial||||
33985968|NCT04258150|NA|SINGLE_GROUP||TREATMENT||NONE||Initially, patients will be enrolled in the study to treatment with ipilimumab, nivolumab and tocilizumab in combination with SBRT, until 30 patients have been treated (Part A: Lead-in). This Part A: Lead-in involves Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark.||||
33985969|NCT01638377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985970|NCT03852147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985971|NCT05713994|||COHORT||PROSPECTIVE|||||||
33985972|NCT01165086|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33985973|NCT01356693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33985974|NCT03163680|||COHORT||RETROSPECTIVE|||||||
33985975|NCT00383097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985976|NCT05683665|||COHORT||RETROSPECTIVE|||||||
33985977|NCT04782232|||COHORT||PROSPECTIVE|||||||
33985978|NCT01982318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985979|NCT05113147|||OTHER||CROSS_SECTIONAL|||||||
33985980|NCT00965874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33985981|NCT03168633|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33985982|NCT04088422|||COHORT||PROSPECTIVE|||||||
33985983|NCT02685462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33985984|NCT02760368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33985985|NCT04011345|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|This is a double-blind clinical trials, so neither participants nor medical care providers will be aware of the participants group assignment in order to limit bias, changes in dietary habits, or medical treatment. The outcomes assessor will also be unaware of participant assignment in order to limit bias in analysis of samples.|This research project will consist of a clinical trial in which children with SCD are randomly selected to initially receive 1 mg per day of folic acid (the current standard dose) or a placebo for a 12-week period. Following that, each participant will have a 12 week wash-out period and then treatments are reversed (folic acid supplement or placebo) for 12 weeks. No controls are included in the study as each participant serves as their own control during periods of no supplementation.|t|t|t|t
34080416|NCT01890655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080417|NCT05879965|||COHORT||PROSPECTIVE|||||||
34080418|NCT01405560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080419|NCT03851263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080420|NCT03733366||CROSSOVER||OTHER||NONE||||||
33773680|NCT06731452|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33985986|NCT06324838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This randomized controlled trial will incorporate blinding procedures, with the understanding that due to the nature of this interventional surgical study, the operating surgeon cannot be blinded. However, rigorous measures will be implemented to ensure blinding of both patients and all other participants involved in patient treatment. The description of the surgery within the patient chart will follow a standardized format, with the exception of the resection details. Where the two treatment methods diverge, a predefined, standardized text referencing the study will be inserted.|Blinded multicenter randomized controlled clinical trial (RCT).|t|t|f|f
33985987|NCT05239754|NA|SINGLE_GROUP||TREATMENT||NONE||"Arms Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support.~Assigned Interventions Primary services: Participants receive 16 hours of 24/7 Dads curricula and at least 2 hours of career readiness workshops over the course of 9 weeks. Participants also receive ongoing job readiness support and post-employment support."||||
33985988|NCT04577846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33985989|NCT06189274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33985990|NCT02045160|||CASE_ONLY||PROSPECTIVE|||||||
33985991|NCT04202874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, surgeon, anesthesiologist, scrub nurse and outcome assessors will be blinded. The operating room circulating nurse, who will be providing the substance, will be unblinded. The investigators will be unblinded after data collection.|Eighty women above the age of 18 and undergoing a midline laparotomy for a suspected gynecologic malignancy will be randomized to undergo a bilateral surgeon-administered Tranversus abdomens plane block with either 40ml of 0.25% bupivacaine or an equal volume of saline administered equally over both sides (placebo), prior to fascial closure. Forty patient will receive bupivacaine, and 40 patients will receive the placebo.|t|t|f|t
34080421|NCT03604939|NA|SINGLE_GROUP||SCREENING||NONE||35,000 households in 228 villages, among which women between 30 to 60 years residing in the villages of the block are eligible to participate||||
34080422|NCT04754997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were divided in three groups. Two groups will get two different intervention. One group will be the control group.|f|f|f|t
33682882|NCT04474548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33682883|NCT01319331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682884|NCT05513118|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33682885|NCT00234247|||||PROSPECTIVE|||||||
33682886|NCT01782001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33682887|NCT00562666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682888|NCT02163343|||COHORT||RETROSPECTIVE|||||||
33682889|NCT03873675|||COHORT||PROSPECTIVE|||||||
33682890|NCT01578512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773681|NCT05249296|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33773682|NCT06097637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773683|NCT06737458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773684|NCT06714552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Statistician, Principal Investigator||t|f|f|f
33773685|NCT05818189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subjects will not know which intervention is favored for improving gait automaticity and the researchers analyzing the data will not know which intervention group subjects were randomly assigned.|60 participants with PD from Aim I, will be randomized into one, of two, cueing interventions: 1) personalized, step-synchronized tactile cueing and 2) tactile cueing at fixed intervals as an active control group. We will analyze the immediate effects of the cueing intervention on gait automaticity. In addition, we will explore the feasibility and potential benefits of independent use of tactile cueing during a week in daily life for a future clinical trial.|t|f|t|t
33773686|NCT06671093|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33985992|NCT05186662|||COHORT||RETROSPECTIVE|||||||
33985993|NCT04784520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985994|NCT05026567|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33985995|NCT00021528|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33985996|NCT04905017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33985997|NCT02909478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33985998|NCT02646865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33985999|NCT01542190|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986000|NCT00911781|||COHORT||RETROSPECTIVE|||||||
33986001|NCT00704691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986002|NCT04086030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986003|NCT03173391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986004|NCT00781586|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33986005|NCT01390233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986006|NCT05001022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986007|NCT02285894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986008|NCT02517684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986009|NCT01249222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986010|NCT05701930|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Single (Participant) symptom management, life quality|pecha kucha training|t|f|f|f
33986011|NCT03645785|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||All subjects will collect 4 urine samples on Day1 and Day 4. On day 2, 3 and 4 all subjects will drink a bottle of water with True Lemon and collect another 4 urine samples on day 4||||
33986012|NCT06323876|||COHORT||PROSPECTIVE|||||||
33682891|NCT05628688|||CASE_ONLY||PROSPECTIVE|||||||
33682892|NCT01629199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682893|NCT01844167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682894|NCT00246571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773687|NCT06294678|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986013|NCT00857935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986014|NCT01305226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986015|NCT03537872|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986016|NCT06455982|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be compared to themselve (i.e. pre-intervention and post-intervention) The intervention will be 2 months of reduced carbohydrate menu combined with a ketogenic supplement (MCT)||||
33986017|NCT03227302|||COHORT||PROSPECTIVE|||||||
33986018|NCT05564897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986019|NCT01278732|||||PROSPECTIVE|||||||
33986020|NCT01328561|||||PROSPECTIVE|||||||
33986021|NCT02738723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080423|NCT04356157|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||"The three interventions to be implemented and evaluated in the research plan are designed to assess the involvement of MI at individual level, interpersonal/network, community-level, Health System and structural level according to ecological model.~The study is articulated in three phases: pre-intervention, intervention and post-intervention analyses. In the pre-intervention analysis, the baseline situation of the three participating centres will be evaluated. The aim of this phase is to set a starting point in order to weigh the relative effect of each intervention to be studied. In each clinical centre baseline data will be collected. In order to evaluate the effect of the interventions, the same indicators will be measured in pre-and in post-intervention phase. The enrollment of participants will be consecutively based on the order of patient appointments."||||
34080424|NCT03504215|NA|SINGLE_GROUP||PREVENTION||NONE||Group assignments. Both groups are evaluated before and after a 14 week supervised exercise (aerobic and resistance training) intervention.||||
34080425|NCT03242941|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately 15 subjects with AF indicated for ablation of the pulmonary vein will be enrolled in the study. Participants will attend the Baseline visit and the Procedure visit. The baseline visit can be on the same day as the ablation procedure. Since it is an acute study, no follow-up visit will occur. The research procedure will be performed during an already scheduled ablation procedure. Subjects will be enrolled over a period of approximately 18 months||||
34080426|NCT05859568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080427|NCT02739217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080428|NCT03819517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34080429|NCT03959007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34080430|NCT02523430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080431|NCT01064479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080432|NCT06515756|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients were blinded and were unaware of the specific treatment protocol. Participants were then randomly assigned to the four groups in a 1:1 ratio using a computer algorithm program (http:// randomizer.org)||t|f|f|f
34080433|NCT03446040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080434|NCT06197360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33682895|NCT05018351|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Persons are randomly assigned to receive either:~A) treatment as usual (TAU-IC), which is Integrated Care services with Thresholds, OR B) peer navigator program (PNP), which includes in-vivo support with managing physical health and wellness at least weekly"||||
33682896|NCT00534742|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33682897|NCT04176601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682898|NCT01890720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682899|NCT04857229|||OTHER||PROSPECTIVE|||||||
33902627|NCT06274346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sixty male and female geriatric patients had chronic knee osteoarthritis were chosen the outpatient clinic of faculty of physical therapy, Delta University for science and technology. education, occupation and duration of complaints of each patient. All were evaluated at the beginning of the treatment (week 0), at the endpoint of the treatment (week 4).|Patients were randomly assigned into two groups through computer software. We put sixty patients on the software program and the program assigned them randomly. s exercise, straight leg raise, prone knee bending, side lying hip abduction, prone hip extension with 5 seconds hold and a rest interval of 2 seconds for 10 repetitions for each exercise for a period of 4 weeks, 3 days per week was given. Second group was treated by retrowalking exercises in addition to physical therapy interventions including short wave diathermy and strengthening exercise such as static quadriceps exercise, dynamic quadriceps exercise, straight leg raise, prone knee bending, side lying hip abduction, prone hip extension with 5 seconds hold and a rest interval of 2 seconds for 10 repetitions for each exercise for a period of 4 weeks, 3 days per week was given., which were given 3 times/week for 4 consecutive weeks.|t|f|f|f
33902628|NCT02734992|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33902629|NCT03787004|RANDOMIZED|PARALLEL||TREATMENT||NONE|Part 1: Open Label Part 2: Double-Blind|||||
33902630|NCT03881124|||COHORT||RETROSPECTIVE|||||||
33902631|NCT04056130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902632|NCT03982459|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33902633|NCT05603286|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33986022|NCT03552393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986023|NCT01279486|||COHORT||PROSPECTIVE|||||||
33986024|NCT01674166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986025|NCT01954394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986026|NCT00102440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33986027|NCT02407275|NA|SINGLE_GROUP||SCREENING||NONE||||||
33986028|NCT05122650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986029|NCT02865005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986030|NCT03185039|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33986031|NCT01757470|||COHORT||PROSPECTIVE|||||||
33986032|NCT03717350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Similar appearance of study drug of both arms||t|t|t|t
33986033|NCT05197322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, 2 arm phase II trial||||
33986034|NCT00793663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986035|NCT03216577|||CASE_CONTROL||PROSPECTIVE|||||||
33986036|NCT01623362|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33986037|NCT03003871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33682900|NCT06432296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080435|NCT02163161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34080436|NCT04521595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080437|NCT01095497|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34080438|NCT06183034|NA|SINGLE_GROUP||OTHER||NONE||||||
34080439|NCT02499016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080440|NCT03451396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080441|NCT03711435|||CASE_CONTROL||PROSPECTIVE|||||||
34080442|NCT03482050|NA|SEQUENTIAL||TREATMENT||NONE||Dose-escalating, four subject-groups clinical study; a single treatment administration of AstroRx, administered in an escalating low, medium and high dose or two consecutive administrations of the medium dose separated by an interval. AstroRx will be administered by intrathecal (spinal) injection to subjects with ALS at the early disease stage.||||
34080443|NCT02770638|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34080444|NCT01042470|||CASE_CONTROL||PROSPECTIVE|||||||
34080445|NCT06192940|||COHORT||PROSPECTIVE|||||||
34080446|NCT00584584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080447|NCT05731310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080448|NCT02039258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682901|NCT00954252|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33682902|NCT02933671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33682903|NCT01456767|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34080449|NCT00117169|RANDOMIZED|PARALLEL||||DOUBLE||||||
34080450|NCT03610893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34080451|NCT04284254|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34080452|NCT00217282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080453|NCT04354935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentric Naturalistic Study||||
34080454|NCT04140409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080455|NCT05414851|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Laboratory personnel will not know which dietary phase each subject has completed, but otherwise blinding is not possible.|All subjects will consume two separate diets, with a 4-6 washout in between. They will be randomized 1:1 to determine which diet they start with.|f|f|f|t
34080456|NCT00000798||||PREVENTION||DOUBLE||||||
34080457|NCT05643391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080458|NCT00572845|NA|SINGLE_GROUP||||NONE||||||
34080459|NCT00350441|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34080460|NCT03328481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34080461|NCT05426590|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34080462|NCT06252935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080463|NCT00496340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080464|NCT00706680|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080465|NCT04811157|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized|t|t|t|f
34080466|NCT04979481|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Teens and young adults enrolled in the study received either: 8 weeks of BRAVE text messages or 8 weeks of STEM text messages; and then crossed over to the other arm and received the next set of messages.||||
33902634|NCT04615390|||COHORT||PROSPECTIVE|||||||
34080467|NCT04494646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All patients, investigators, site personnel, laboratories, and study personnel with direct involvement in the conduct of the study or their designees will be blinded to treatment assignments. To prevent potential bias, appropriate measures will be taken to ensure the blind is maintained for the patients and personnel mentioned previously. To maintain the blind, investigators will distribute blinded study drug treatment to patients as directed by the IWRS system. Investigators and patients will not be blinded to dose level, but will be blinded to treatment assignment (i.e., bardoxolone methyl vs. placebo).||t|t|t|f
34080468|NCT01753349|||COHORT||PROSPECTIVE|||||||
33902635|NCT05198986|||CASE_ONLY||PROSPECTIVE|||||||
33902636|NCT01795469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902637|NCT02881307|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Ultrasonographer and joint assessor are blinded to the diet intervention and to each others assessments.|Randomized Controlled Clinical Trial|f|t|t|t
33902638|NCT06520072|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. The ORGANIZATION SAMPLE has a 2-arm parallel cluster-randomized control trial design, with an attention control design. The clusters are the partner community-based organizations where participants are recruited/enrolled by study staff. The cluster is the level of randomization (not individuals).~2. The INDIVIDUAL SAMPLE has a 2-arm parallel randomized control trial design, with an attention control design. The individual parent/guardian as the level of randomization (no clusters). After completing the Baseline Survey (Parts 1 and 2), each individual parent/guardian will be randomized to the Intervention Arm or Control Arm.~Both: Parents/guardians will be asked to use the assigned app for 8-weeks. Next, they will complete the Follow Up Survey, then they have the option to download the other app, if interested. For both arms, usage of the CHEW app will be tracked for up to 20 weeks after the date of study enrollment."||||
33902639|NCT06186336|||COHORT||PROSPECTIVE|||||||
33902640|NCT05044169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902641|NCT02110108|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Each patient receives a single wavelength treatment on one side of their face, and a double wavelength on the other side of their face.||||
33902642|NCT02018510|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902643|NCT03428191|||CASE_ONLY||PROSPECTIVE|||||||
33902644|NCT00053846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33902645|NCT01562015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902646|NCT01347697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902647|NCT03268304|||COHORT||PROSPECTIVE|||||||
33902648|NCT06671574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33902649|NCT06284421|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33682904|NCT05164107|NA|SINGLE_GROUP||OTHER||NONE||||||
33682905|NCT04268602|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled study|f|f|f|t
33682906|NCT02775240|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33682907|NCT04278274|||COHORT||PROSPECTIVE|||||||
33682908|NCT05938049|||COHORT||PROSPECTIVE|||||||
33682909|NCT02173262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682910|NCT03441672|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986038|NCT03855579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773688|NCT06677203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902650|NCT04936139|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, parallel and multi-centric non-pharmacological clinical trial||||
33902651|NCT03869073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Upon enrolling in the study participants will be randomized into one of three possible treatment arms: 420mg single dose at baseline, 840mg single dose at baseline, or placebo|t|t|f|t
33902652|NCT01758016|||COHORT||PROSPECTIVE|||||||
33902653|NCT01771679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902654|NCT03510143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants cannot know the Neoveil apply in their surgery|Neoveil applied // Neoveil non-applied|t|f|f|f
33902655|NCT01447173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902656|NCT03663985|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33902657|NCT05260255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902658|NCT06671249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902659|NCT05197868|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33902660|NCT06166069|||COHORT||RETROSPECTIVE|||||||
33902661|NCT00744055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902662|NCT00122772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986039|NCT04527575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Masking in Phase 2|Simple, blind, placebo-controlled, randomized study involving healthy volunteers|t|f|t|f
33902663|NCT02892097|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33986040|NCT05820958|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The investigators were blinded to the results in that way that questionnaires serving as outcome measures were filled up online and results were recorded in the online database. This process was fully automatic. The investigators were unaware of the results until the base was 'opened' after the completion of the study.~After the completion of the study, the control group was selected from participants of our previous, observational study based on a non-random, matched sampling method. this procedure was completed by one of the investigators. Then, the data were sent to the outcomes assessor with the names of the groups coded. The assessor was unaware of the roles of the two groups in the study."|"In this project, we tested the effect of a single intervention, i.e. intensification of tactile contact between mother and newborn, in the group of volunteers.~The equivalent control group was selected from participants of our previous, observational study based on a non-random, matched sampling method."|f|f|t|t
33986041|NCT05398718|||COHORT||OTHER|||||||
33902664|NCT00569920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902665|NCT06554496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902666|NCT06580119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The participants will be assigned to Group A or Group B. Intervention Group A will be provided the in-person intervention and Group B will be provided the virtual.~During Phase 1, Group A will receive the intervention and Group B will act as the control group. During Phase 2, Group B will receive the intervention."||||
33902667|NCT03854162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902668|NCT01245894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33902669|NCT02749487|||COHORT||RETROSPECTIVE|||||||
33902670|NCT02680301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33902671|NCT02401178|||OTHER||PROSPECTIVE|||||||
33902672|NCT05326893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study was conducted as a randomized, single-blind, sham-controlled clinical trial.|t|f|f|f
33902673|NCT02746679|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902674|NCT00828867|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33902675|NCT04174885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902676|NCT05372575|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33902677|NCT00447213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902678|NCT03623269|||COHORT||RETROSPECTIVE|||||||
33902679|NCT03246477|||COHORT||RETROSPECTIVE|||||||
33902680|NCT02147938|||COHORT||PROSPECTIVE|||||||
34080469|NCT02615886|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34080470|NCT01413724|||COHORT||CROSS_SECTIONAL|||||||
34080471|NCT03884335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080472|NCT04207905|||COHORT||PROSPECTIVE|||||||
33902681|NCT03372057|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33902682|NCT06338059|||OTHER||CROSS_SECTIONAL|||||||
33902683|NCT03569514|||COHORT||RETROSPECTIVE|||||||
33902684|NCT06671600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly divided into either the treatment group who will receive OMT and the sham group who will receive light touch.|t|f|f|f
33902685|NCT03285009|NA|SINGLE_GROUP||PREVENTION||NONE|Masking not possible as individual treatment is given|||||
33902686|NCT02523677|||COHORT||PROSPECTIVE|||||||
33902687|NCT00052429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902688|NCT01202110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902689|NCT04249895|||CASE_ONLY||PROSPECTIVE|||||||
33902690|NCT01753752|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33902691|NCT06314906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773689|NCT03226457|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-Blind|6 week period of Investigational Medicinal Product (Empagliflozin 25 mg od) or placebo. A 2 week washout period will then be observed, followed by the second arm with a further 6 week period of placebo or IMP. At week 1 and week 6 of each arm, detailed Renal Physiology Test days will be performed.|t|t|t|t
33986042|NCT04910178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986043|NCT02155465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986044|NCT06118970|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986045|NCT03113422|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773690|NCT00445601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986046|NCT05210062|||CASE_ONLY||PROSPECTIVE|||||||
33986047|NCT00000194||||TREATMENT||DOUBLE||||||
33986048|NCT02400047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986049|NCT01557712|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33986050|NCT02543203|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33986051|NCT04500873|||OTHER||CROSS_SECTIONAL|||||||
33986052|NCT04507711|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33986053|NCT00936169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986054|NCT00532090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986055|NCT05004194|NA|SINGLE_GROUP||TREATMENT||NONE||An open label non-randomized pilot trial||||
33986056|NCT00929929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986057|NCT05391685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33986058|NCT04615091|||COHORT||PROSPECTIVE|||||||
33986059|NCT03375853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986060|NCT03122990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986061|NCT05880056|NA|SINGLE_GROUP||TREATMENT||NONE||The subject will initially administer once daily 5 mg bisoprolol (Nerkardou) oral dissolvable film (ODF) for 2 weeks. After the assessment of the subject being a responder, study medication will be maintained till week 12. Response will be assessed for each patient every 2 weeks and dose-titration will be done based on the response and PI decision at any visit. Then, for responders, once daily 5 mg bisoprolol (Nerkardou) oral dissolvable film (ODF will be administered for the subsequent 2 weeks. For non-responders once daily 10 mg bisoprolol (Nerkardou) oral dissolvable film (ODF) will be administered for the subsequent 2 weeks. Non responders patients on 10 mg will be shifted to other alternatives according to their merit and those patients will be included to intention to treat.||||
33986062|NCT02055963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33986063|NCT03186456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986064|NCT02772289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986065|NCT00267592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986066|NCT04349917|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The pharmacy that provides the drug/placebo works from a randomized subject order defining whether each subject received drug first or placebo first. Only the pharmacists know this order, and the drug and placebo look identical to the participants and the investigators.|Randomized, double-blind, placebo-controlled, crossover design. Each subject with ADHD participates in two sessions, one on drug and one on placebo (order randomized ). Both subjects and experimenters are blind to the order.|t|f|t|f
33986067|NCT00864591|||COHORT||PROSPECTIVE|||||||
33986068|NCT00537979|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986069|NCT04078022|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33986070|NCT01667185|||COHORT||PROSPECTIVE|||||||
33986071|NCT00004314||||TREATMENT||||||||
33986072|NCT01848340|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33986073|NCT04929886|||CASE_CONTROL||PROSPECTIVE|||||||
33986074|NCT06321991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To avoid bias, treatment arms will be blinded to Investigators, Trial staff, participants,.. as follows: vitamin E creme will be packaged and labelled in such a way that the visual appearance, nor the smell and/or touch of the creme can be distinguished from placebo (Vaseline).|Simple random allocation will be ensured by the principal investigators' designated staff (study nurse of IORT), who will not be involved in recruiting trial participants, medical care, drug administration or follow-up, through the generation of a random numbers table with computer software program. A randomization list will be prepared by the Sponsor's designated staff, not involved in recruiting Trial participants, medical care, drug administration or follow-up.|t|t|t|f
33986075|NCT04464330|||CASE_CONTROL||PROSPECTIVE|||||||
33986076|NCT00904553|||CASE_ONLY||PROSPECTIVE|||||||
33986077|NCT03197207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986078|NCT05619289|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986079|NCT03653260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986080|NCT01939717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986081|NCT04723810|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33986082|NCT02548897|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33986083|NCT00496548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986084|NCT05617222|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The assessors will be without knowledge of which leg has received neuromuscular electrical stimulation and which leg was control|Participants are subjected to 5 days bed rest. One leg will receive 3/daily neuromuscular electrical stimulation. The contralateral leg will serve as control-leg undergo disuse only.|f|f|f|t
33986085|NCT06003634|||COHORT||OTHER|||||||
33986086|NCT00362024|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33986087|NCT04506502|NA|SINGLE_GROUP||OTHER||NONE||||||
34024808|NCT04922320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research assistant (RA) conducting baseline evaluations will not access any randomization procedures, leaving that RA blinded during the evaluation.|All consented participants who complete baseline assessment will be randomized into the PPC or UC groups. Randomization will be blocked and stratified by PCP to assure balance in the number of patients assigned to two study arms by enrolled PCP. Within each clinician, the investigators will use random blocks of 4 and 6. Blocking ensures half will be randomized to PPC and half to UC. Varying block size makes the sequence of assignments more difficult to predict. The random numbers will be generated in SAS PROC PLAN. The research assistant (RA) conducting baseline evaluations will not access any randomization procedures, leaving that RA blinded during the evaluation.|f|f|f|t
33986088|NCT05172219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|"Participants: The patients were not informed of other portal messages. The portal message they received (if it had a link to asynchronous care or not and if it was sent by physician or system) was determined by random assignment.~Care Providers: After reviewing patients for exclusion criteria, the physicians were not informed which intervention group patients were assigned. They knew who was selected for the study and then those patients were randomly assigned to intervention groups by computerized randomization system.~Investigators: The data was extracted from the EHR and de-identified prior to sharing it with the investigators. Therefore, the investigators were blind to patients and patient assignment.~Outcomes Assessor: Outcomes were assessed only from de-identified data."|The model was a 2 (link to survey) × 2 (message source) experimental design; therefore, we had two factors that created four treatment conditions.|t|t|t|t
33986089|NCT03048526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33986090|NCT01840735|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33986091|NCT00010205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080473|NCT06023966|||COHORT||PROSPECTIVE|||||||
33902692|NCT06049420|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be able to opt-in to the protocol for adjunctive treatment, and their outcome measures will be assessed relative to similar patients that do not opt-in to the intervention (standard care).||||
33773691|NCT00927043|||COHORT||PROSPECTIVE|||||||
33773692|NCT04857190|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33773693|NCT03314623|||COHORT||PROSPECTIVE|||||||
33773694|NCT00674882|||OTHER||OTHER|||||||
33773695|NCT04938167|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized assignment to Standard arm (target preductal SpO2 91% to 95%) or Intervention arm (target preductal SpO2 95% to 99%)||||
33773696|NCT04431687|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773697|NCT03396731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will be blinded to the study participants and what treatment they are receiving.||f|f|f|t
33773698|NCT04069221|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Part1: Open label, one treatment Part 2: Open-label, randomized, single-dose, 3-way cross-over study||||
33902693|NCT03567499|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This will be a double-blinded (Sponsor unblinded) study in which the subjects and site staff (Pharmacist unblinded to prepare study drug) will be blinded for the duration of the study|This study will consist of two parts, Part A and a conditional Part B. Part A is designed as a randomized double-blinded, 3 period, placebo-controlled, repeat-dose, cross-over study. The decision to initiate Part B will be made based on an evaluation of data from Part A which will include an overall assessment of safety, PK and PD. Part B will also employ a randomized, double-blind, repeat dose, cross-over study design and will follow the same assessments and procedures as Part A.|t|f|t|f
33902694|NCT05477680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773699|NCT01557972|||COHORT||PROSPECTIVE|||||||
33773700|NCT01854294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773701|NCT03355365|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Compassionate crossover design|t|t|t|t
33773702|NCT03285113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902695|NCT02133235|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33902696|NCT00234104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33902697|NCT02399475|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33986092|NCT06263972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024809|NCT06296927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a randomized controlled two-group study.||||
34024810|NCT03902886|||CASE_CONTROL||RETROSPECTIVE|||||||
34024811|NCT04608123|||COHORT||RETROSPECTIVE|||||||
34024812|NCT04496284|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34024813|NCT05290727|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The study and control products will lack any identification label, except that concerning the assignment code. The product together with the instillation instructions will be delivered in a sealed envelope which will contain an identification label of the assignment code.|Low intervention level, prospective, crossover, double masked, randomized, single center clinical trial|t|t|t|t
34024814|NCT03578367|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment arms 1 - 4 randomized; New Treatment arm 5 (asciminib single agent cohort) not randomized||||
34024815|NCT04821700|||COHORT||PROSPECTIVE|||||||
34024816|NCT05551663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34024817|NCT04087681|||COHORT||PROSPECTIVE|||||||
34024818|NCT02723747|||CASE_ONLY||PROSPECTIVE|||||||
34024819|NCT00237640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024820|NCT03363386|RANDOMIZED|PARALLEL||PREVENTION||NONE||The sample of study consists of patients with Type 2 Diabetes Mellitus (DM) got diagnosed at least 6 months and who referred to Fitness Center in Pendik Arif Nihat Asya Kültür Merkezi Istanbul Turkey by a medical doctor between December 2016- March 2017. The study included in 30 patients (24F, 6M) with T2DM. The patients who met inclusion criteria are divided into two groups||||
34024821|NCT05396235|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34024822|NCT03251339|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34024823|NCT06262451|||CASE_ONLY||PROSPECTIVE|||||||
34024824|NCT03013855|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024825|NCT00904579|||COHORT||RETROSPECTIVE|||||||
34024826|NCT01790477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024827|NCT03815734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024828|NCT06322602|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024829|NCT04204291|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024830|NCT04471129|RANDOMIZED|PARALLEL||TREATMENT||NONE|No applicable|sequential assignment||||
34024831|NCT05612373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
34024832|NCT01824043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024833|NCT00117832|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34024834|NCT00409448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902698|NCT01322607|RANDOMIZED|PARALLEL||||NONE||||||
34080474|NCT05868135|||COHORT||PROSPECTIVE|||||||
34080475|NCT02718872|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33902699|NCT05598996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a 12-month parallel-group randomized controlled trial.|f|f|t|t
33902700|NCT01624129|||CASE_ONLY||PROSPECTIVE|||||||
34080476|NCT05447273|||COHORT||PROSPECTIVE|||||||
34080477|NCT00764101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080478|NCT03606811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34080479|NCT02420535|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33682911|NCT00002167||PARALLEL||TREATMENT||||||||
34080480|NCT01918501|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080481|NCT05128838|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34080482|NCT00582465|||COHORT||PROSPECTIVE|||||||
33682912|NCT03708562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682913|NCT03590184|||CASE_ONLY||RETROSPECTIVE|||||||
33682914|NCT02461472|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33682915|NCT05473585|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will complete 4 experimental sessions. At each session, they will receive a different combination of e-cigarette and combusted cigarette.||||
33682916|NCT05206656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682917|NCT01260675|||OTHER||OTHER|||||||
33682918|NCT04399746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Relation 3:1 in Combination:Control groups||||
33682919|NCT03044600|||COHORT||PROSPECTIVE|||||||
33682920|NCT05491460|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682921|NCT06534892|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an extension and crossover study.||||
33682922|NCT00223236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682923|NCT01659879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33682924|NCT00282464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682925|NCT00318942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682926|NCT06102018|||COHORT||PROSPECTIVE|||||||
33682927|NCT04607798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682928|NCT05647278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682929|NCT05579743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be computer randomized 1:1 to receive wound care monitoring using remote diabetic foot ulcer (DFU) monitoring technology or standard in-person monitoring for 12 weeks||||
33682930|NCT02051075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682931|NCT00395057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682932|NCT05282914|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33682933|NCT04673110|||COHORT||RETROSPECTIVE|||||||
33682934|NCT03196700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682935|NCT02793856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682936|NCT03581890|||COHORT||PROSPECTIVE|||||||
33682937|NCT04537780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"randomized, prospective placebo controlled study that will be conducted on 44 patients who fulfill the selection criteria and will be classified randomly into two groups.~Group 1 (Control group n= 22): Patients will receive Placebo once daily at bedtime.~Group 2 (Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime. The treatment duration will be 12 weeks."|t|f|t|f
33682938|NCT04911374|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study. 45 female subjects recruited, 35 to 65 years, Fitzpatrick skin type I-VI, with mild to moderate droopy eyelids, moderate crow's feet wrinkles, and moderate global photodamage.||||
33682939|NCT05811845|||OTHER||PROSPECTIVE|||||||
33682940|NCT04234724|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773703|NCT02688374|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33682941|NCT00430131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682942|NCT01523470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682943|NCT01009840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682944|NCT02643056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682945|NCT02160002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682946|NCT05910671|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773704|NCT01945762|||COHORT||PROSPECTIVE|||||||
33773705|NCT00205231|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773706|NCT06417190|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label||||
33773707|NCT01000376|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902701|NCT02739698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33902702|NCT03262493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33902703|NCT02158143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902704|NCT02261480|||CASE_CONTROL||PROSPECTIVE|||||||
33902705|NCT03952923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902706|NCT01052012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902707|NCT04153812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902708|NCT05378789|NA|SINGLE_GROUP||OTHER||NONE||||||
33902709|NCT00477529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902710|NCT02295930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902711|NCT04709861|||COHORT||PROSPECTIVE|||||||
33902712|NCT02229994|||COHORT||PROSPECTIVE|||||||
33902713|NCT04086303|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||young handball players ≥10 years sport age adult handball players ≤10 years sport age|f|f|t|f
33902714|NCT05986539|||CASE_CONTROL||PROSPECTIVE|||||||
34080483|NCT04527042|||CASE_ONLY||PROSPECTIVE|||||||
34080484|NCT06040814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080485|NCT00646698|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34080486|NCT01135693|||||RETROSPECTIVE|||||||
34080487|NCT03695146|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34080488|NCT01753882|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34080489|NCT04524689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080490|NCT02228252|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34080491|NCT02820168|||COHORT||PROSPECTIVE|||||||
34080492|NCT02917174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34080493|NCT02510937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902715|NCT01272180|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33986093|NCT05488808|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Blinding is achieved by inserting a card into the rTMS stimulator which determines whether the patient receives active or sham stimulation, making both participant and investigator blind towards group allocation. Care providers are also blinded to treatment allocation. Main efficacy analyses will be performed blinded without identification of participants and group allocation.|Patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial (RCT) with a 2 x 2 cross-over design, receiving both active and placebo stimulation. Patients are randomly assigned in a 1:1 ration to one of two counterbalanced arms: either they first receive active rTMS and then sham rTMS after a 9 week washout period, or the first receive sham rTMS and then active rTMS after 9 weeks of washout.|t|t|t|t
33986094|NCT00546897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986095|NCT01452022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986096|NCT04299594|||CASE_ONLY||PROSPECTIVE|||||||
33902716|NCT03884348|||CASE_ONLY||RETROSPECTIVE|||||||
33902717|NCT00184912|RANDOMIZED|PARALLEL||||DOUBLE||||||
33902718|NCT05502848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902719|NCT01126619|||||PROSPECTIVE|||||||
33902720|NCT02463266|||CASE_ONLY||OTHER|||||||
33902721|NCT01004146|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902722|NCT02298517|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33902723|NCT00514449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902724|NCT00554294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902725|NCT02267512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902726|NCT04982549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902727|NCT00541359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986097|NCT06266260|||COHORT||PROSPECTIVE|||||||
33986098|NCT03863418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986099|NCT00722124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986100|NCT03202277|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33986101|NCT02996682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986102|NCT03979079|||COHORT||RETROSPECTIVE|||||||
33986103|NCT01287910|NA|SINGLE_GROUP||||NONE||||||
33986104|NCT04702945|||COHORT||OTHER|||||||
33986105|NCT01707420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986106|NCT02147925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986107|NCT04667494|NA|SINGLE_GROUP||TREATMENT||NONE||Outcome measures will be evaluated before and after intervention with sonotherapy.||||
33986108|NCT05168670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986109|NCT03928197|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986110|NCT06362772|||COHORT||RETROSPECTIVE|||||||
33986111|NCT02202486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986112|NCT00383656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986113|NCT03656783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986114|NCT02600286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986115|NCT06009146|||COHORT||PROSPECTIVE|||||||
33902728|NCT02405039|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33902729|NCT06498102|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were randomly divided into a control (n=17) and time-restricted feeding (TRF) group (n=17).|"Two groups: Control (n=17) and time-restricted feeding (TRF) group (n=17)~Thirty-four healthy recreationally active males who habitually undergo cycling, running, soccer 2-3 times per week volunteered to participate in this randomized controlled study."|t|f|f|f
33902730|NCT03288584|||CASE_CONTROL||PROSPECTIVE|||||||
33902731|NCT02571361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986116|NCT00581971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986117|NCT01956786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986118|NCT01272453|||CASE_CONTROL||PROSPECTIVE|||||||
33986119|NCT02433977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986120|NCT04960163|||COHORT||PROSPECTIVE|||||||
33986121|NCT06295211|||COHORT||RETROSPECTIVE|||||||
34024835|NCT05255848|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024836|NCT02668588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024837|NCT00908310|NA|SINGLE_GROUP||||NONE||||||
34024838|NCT00901212|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34024839|NCT01385449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024840|NCT06290908|||CASE_CONTROL||PROSPECTIVE|||||||
34024841|NCT01090752|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34024842|NCT05052047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024843|NCT02916667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33682947|NCT03861494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The who Advanced Practice Registered Nurse performing the outpatient follow up visits at one and six months will remain blinded to the enrollment of each participant.||f|t|f|f
33682948|NCT06333197|RANDOMIZED|PARALLEL||TREATMENT||NONE||ALL Patients diagnosed with Extra Capsular Fracture of Mandibular Condyle amenable for surgery.||||
33773708|NCT06737848|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33682949|NCT03655002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682950|NCT04672954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This trial is designed to have three parts. Part 1: single-blind, randomized, placebo-controlled. Part 2: open-label, non-randomized. Part 3: open-label, randomized.|t|f|f|f
33682951|NCT05208918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682952|NCT01661582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33682953|NCT04630574|||CASE_ONLY||PROSPECTIVE|||||||
33773709|NCT04019600|||COHORT||CROSS_SECTIONAL|||||||
33773710|NCT03982888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902732|NCT02887105|||COHORT||PROSPECTIVE|||||||
33902733|NCT05299827|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33902734|NCT02151500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902735|NCT01781026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902736|NCT01281995|||||PROSPECTIVE|||||||
33902737|NCT04806581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Sequential Assignment||||
33902738|NCT01105741|||COHORT||PROSPECTIVE|||||||
33902739|NCT05268094|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study staff and participants' families will be aware of treatment group due to the nature of the interventions.|Participants will be randomized to receive either an SPS or DAS. Overall randomization will be 1:1 to each treatment arm, with block randomization will be performed by center and by single vs. two ventricle status||||
33902740|NCT06003751|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Placebo sham||t|f|f|f
33902741|NCT01225393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902742|NCT06483100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902743|NCT01062399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902744|NCT01376739|||CASE_ONLY||PROSPECTIVE|||||||
33902745|NCT02729311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902746|NCT05241171|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33902747|NCT04181203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902748|NCT01810367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902749|NCT05970055|||OTHER||CROSS_SECTIONAL|||||||
33902750|NCT04728971|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33902751|NCT02508727|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33902752|NCT00805883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902753|NCT04270851|||COHORT||PROSPECTIVE|||||||
33902754|NCT06340204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902755|NCT06119178|||COHORT||RETROSPECTIVE|||||||
33902756|NCT00973908|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902757|NCT00638066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33902758|NCT01485679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902759|NCT03809065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33902760|NCT03851679|||COHORT||RETROSPECTIVE|||||||
33902761|NCT05700344|||OTHER||PROSPECTIVE|||||||
33902762|NCT01302041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902763|NCT04973228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902764|NCT02166528|||CASE_CONTROL||PROSPECTIVE|||||||
33902765|NCT03334370|||CASE_CONTROL||PROSPECTIVE|||||||
33986122|NCT05875142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will know what group they are in. When data is sent to the statistician for analysis it will be coded in the groups (e.g., 123) without informing which is which. This masks (or blinds) him to the condition.|Conduct a pilot study of 3 levels of digital training (Level 1 - Digital tutorial only \[T\]; Level 2 - Tutorial \& digital training materials for self-study \[TM\]; Level 3 - Tutorial, digital materials, feedback and coaching \[TMC\]) to establish feasibility, acceptability, and examine the effects of training on CRAFT knowledge, fidelity, and treatment entry and retention.|f|f|f|t
33986123|NCT01629433|||COHORT||PROSPECTIVE|||||||
33682954|NCT01190423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773711|NCT02074540|||CASE_ONLY||PROSPECTIVE|||||||
33773712|NCT00601718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773713|NCT06720389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773714|NCT05209074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773715|NCT02829710|||||RETROSPECTIVE|||||||
33773716|NCT06737224|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized crossover, within-subject, repeated measures|f|f|f|t
33773717|NCT05463614|||COHORT||RETROSPECTIVE|||||||
33773718|NCT02971384|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773719|NCT06737471|||OTHER||PROSPECTIVE|||||||
33773720|NCT04266093|||COHORT||PROSPECTIVE|||||||
33773721|NCT05672849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773722|NCT05583448|||COHORT||OTHER|||||||
33986124|NCT03713333|RANDOMIZED|SEQUENTIAL||SCREENING||TRIPLE|Treating physicians and clinical practitioners will not be concealed to the randomized allocation of individual clinics or the patients that are seen in these encounters. Physicians in the interventional group will participate in conducting technology-enabled visitations before and after a patient encounter and therefore are not blinded to the assessment. For the standard care group handheld imaging and remote patient monitoring will not be performed after the patient-physician encounter. Principal investigators, outcome adjudicators, and statisticians are blinded to randomization, device findings, and treatment decisions.|Pragmatic, multisite, cluster randomized trial comparing point of care and remote patient monitoring with digital health devices and handheld imaging to standard-care|f|t|t|t
33986125|NCT04320147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986126|NCT04395417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients and the researcher who were responsible for the analyzing of the data were blinded to the randomization results.|Parallel Assignment|t|f|f|f
33986127|NCT01039961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986128|NCT05431166|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Wait list Control||||
33986129|NCT01846923|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33682955|NCT04791527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682956|NCT04486898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants and treatment provider are aware of group assignment due to the nature of biobehavioral intervention. A single-blinded design will be adopted because outcome assessors will be blinded to the group allocation and interventions employed in the two groups. The outcome assessors will not be allowed to disclose participant grouping or to discuss the details of participants. The researcher will not discuss participant-related research data with the outcome assessors.|This will be a randomized controlled trial with single-blinded, two-arm parallel study. Data will be collected between August to December 2020. A structured questionnaire will be used to collect data on demographics, burnout, depression, stress, and anxiety. We will enroll nurses from the General units of Leroj Atama Memorial Hospital in Majuro, Marshall Islands. The invitation to participate will be communicated by the Chief Nursing Officer and baseline assessment will be given by a trained study interviewer for participant recruitment|f|f|f|t
33682957|NCT05444998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682958|NCT02688322|NA|SINGLE_GROUP||OTHER||NONE||||||
33682959|NCT01488344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682960|NCT01247298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682961|NCT03737227|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Fundamental research with 11 male participants in one study arm, all performingflexion and extension of the lumbar spine during cinematographic recordings twice.||||
33773723|NCT00001813|||CASE_CONTROL||PROSPECTIVE|||||||
33773724|NCT06741319|||COHORT||PROSPECTIVE|||||||
33773725|NCT05870787|||COHORT||PROSPECTIVE|||||||
33773726|NCT02548559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33986130|NCT00312663|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33682962|NCT00338975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33682963|NCT01650012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33682964|NCT05861622|NA|SINGLE_GROUP||OTHER||NONE||||||
33682965|NCT03313232|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33773727|NCT06738706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773728|NCT01295346|||COHORT||PROSPECTIVE|||||||
33773729|NCT00656461|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773730|NCT02348437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773731|NCT06739564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773732|NCT04769713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A technologist will either load up a syringe with ropivacaine or with saline. He will be the only one knowing what was put in the syringe. The operator will inject the content of the syringe at the location of the hepatic hilar nerve block, not knowing what is being injected.|Prospective Randomized Double-Blinded Trial|t|t|t|t
33773733|NCT06393127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773734|NCT06237309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773735|NCT03285451|||OTHER||PROSPECTIVE|||||||
33773736|NCT03989089|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33773737|NCT00967174|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33773738|NCT06527430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773739|NCT02490696|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773740|NCT00320476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773741|NCT00904228|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33773742|NCT06738758|||COHORT||PROSPECTIVE|||||||
33773743|NCT03873246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773744|NCT04396925|||COHORT||PROSPECTIVE|||||||
33773745|NCT01038674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773746|NCT06740526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773747|NCT06738160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773748|NCT06738199|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|lab staff that did the analysis and lead author that performed statistical analyses||t|f|t|t
33773749|NCT04860843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986131|NCT04893005|||OTHER||CROSS_SECTIONAL|||||||
33986132|NCT04470557|||OTHER||CROSS_SECTIONAL|||||||
34024844|NCT02338804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024845|NCT04467450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024846|NCT05375071|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33682966|NCT01479218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682967|NCT02369601|||COHORT||PROSPECTIVE|||||||
33682968|NCT01268280|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33682969|NCT00918060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33682970|NCT04677478|||COHORT||PROSPECTIVE|||||||
33682971|NCT00151203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682972|NCT05117918|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33682973|NCT00726141|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33682974|NCT04822142|||COHORT||PROSPECTIVE|||||||
33682975|NCT00594425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682976|NCT01698710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682977|NCT05378698|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open-randomized treatment study involving state of the art technique such as imaging mass spectrometry, classical mass spectroscopy and proteomics in patients treated with Tralokinumab during 16 weeks||||
33682978|NCT04740905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33682979|NCT02836509|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33682980|NCT04062500|||COHORT||PROSPECTIVE|||||||
33902766|NCT06671223|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"In this study, a double-blind design is implemented to ensure data integrity and reduce bias. The following roles are masked:~Participants: Participants are not informed to which treatment group they have been assigned (corticosteroid infiltrations or conservative treatment).~Investigators: Investigators evaluating clinical outcomes, including pain measurement and foot function, are blinded to the treatment group assignment of participants.~Healthcare Providers: The professionals administering the infiltrations are masked regarding treatment assignment, as a third party, not involved in the study, will be responsible for performing the infiltrations.~Data Monitors: Data monitors monitoring the safety and integrity of the study are also blinded to treatment assignments until final analysis of the results is completed."|"Participants will be randomly assigned to one of two groups:~Intervention group: They will receive corticosteroid infiltrations under ultrasound guidance.~Control group: They will receive conservative treatment that may include physiotherapy and recommendations for foot care, without infiltrations."|f|f|t|f
33682981|NCT00274924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902767|NCT02717767|||OTHER||PROSPECTIVE|||||||
33902768|NCT03291197|NA|SINGLE_GROUP||OTHER||NONE||Open label preliminary study testing the tolerability of the procedure.||||
34080494|NCT00945646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902769|NCT05483543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080495|NCT02201862|||CASE_CONTROL||PROSPECTIVE|||||||
34080496|NCT03903263|||COHORT||CROSS_SECTIONAL|||||||
34080497|NCT06216418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080498|NCT05437601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigators will not know which arm patients have been assigned to or if they receive placebo or astaxanthin|Patients will be randomized to receive either 12 mg astaxanthin capsules or placebo capsules for 8 weeks|t|f|t|f
34080499|NCT03832283|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients randomized to MyChart will not be blinded to the intervention. Patients who are randomized to usual screening will not be informed about the intervention arm and, thus, will be blinded to trial assignment. PCPs will not be informed of the randomization; however, they will receive results whenever their patients complete the CAT-MH via MyChart.|||||
34080500|NCT00703300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080501|NCT03988361|||COHORT||PROSPECTIVE|||||||
34080502|NCT01719380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080503|NCT03398473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34080504|NCT00723229|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080505|NCT04270812|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group open trial.||||
33682982|NCT01268579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682983|NCT00288743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33682984|NCT05853731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33682985|NCT03469869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Giving a spesific personal menu through android apps, one group with balance diet menu, and the other with balance and sustainable diet menu. Only di IT knows which person get which type of menu|One group balance diet One group balance and sustainable diet|t|t|t|t
33682986|NCT05583513|||CASE_ONLY||PROSPECTIVE|||||||
33682987|NCT00743236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33682988|NCT01710410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33682989|NCT00256477|RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
33682990|NCT01568528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33682991|NCT03026101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33682992|NCT01997242|||COHORT||PROSPECTIVE|||||||
33682993|NCT04644367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principle investigator, co-investigators will analyze and interpret the data, but will be blinded to the group allocation (single-blind). The principle investigator, co-investigators will restrict discussion of the study's outcomes with the research assistants who will be aware allocation, and who will be involved in data entry or collection.|A prospective, single-blind, randomized control trial of 40 individuals with early-stage PD (Hoehn \& Yahr stages 1 to 3).|f|f|f|t
33682994|NCT01848782|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33682995|NCT01514162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682996|NCT01054183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682997|NCT00936689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773750|NCT06739070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33773751|NCT01115023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773752|NCT02651285|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33773753|NCT06139263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33773754|NCT06676540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773755|NCT06740487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33682998|NCT02810444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33682999|NCT05790161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|doubleblind regarding treatment no blinding regarding sleep manipulation|Within-Design regarding treatment (caffeine vs. placebo). Between-Design regarding sleep manipulation (sleep restriction vs. sleep manipulation)|t|f|t|f
33683000|NCT02156245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773756|NCT06290102|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773757|NCT05239793|NA|SINGLE_GROUP||OTHER||NONE||||||
33773758|NCT06731049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773759|NCT00283465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773760|NCT04674969|||COHORT||PROSPECTIVE|||||||
33773761|NCT05746429|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773762|NCT06697197|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33773763|NCT05511740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33773764|NCT02991690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773765|NCT06741293|||CASE_CONTROL||PROSPECTIVE|||||||
33773766|NCT04853862|||COHORT||PROSPECTIVE|||||||
33773767|NCT06738420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773768|NCT00319605|||||RETROSPECTIVE|||||||
33773769|NCT02262260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683001|NCT00207324|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33683002|NCT03896347|||CASE_ONLY||PROSPECTIVE|||||||
33683003|NCT01107379|||COHORT||PROSPECTIVE|||||||
33902770|NCT04986293|NA|SINGLE_GROUP||OTHER||NONE||||||
33902771|NCT05342831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|None (Open Label)|Parallel Assignment||||
33902772|NCT00590083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902773|NCT02077049|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33902774|NCT05864157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to group allocation||f|f|f|t
33902775|NCT04132752|RANDOMIZED|PARALLEL||TREATMENT||NONE||33 children with obstetric brachial plexus palsy (OBPP) were randomized into control or intervention groups. Both groups parents were informed about OBPP, given home exercise and exercise diary. Intervention group was called via phone weekly in order to motivate and answer questions. Children's functional scores and parents motivation was measured.||||
33902776|NCT06671977|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Healthy individuals and individuals with current major depression will participate in 2 dosing sessions separated by 4 weeks, during which they will receive placebo, low dose DMT, medium dose DMT, low dose THC and medium dose THC. Subjects will be prepared for the dosing session and also debriefed after each dosing session|t|t|f|t
33902777|NCT01553539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902778|NCT05476692|||COHORT||PROSPECTIVE|||||||
33902779|NCT00469014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986133|NCT04476329|RANDOMIZED|PARALLEL||TREATMENT||NONE|This trial will not be masked, subjects will know which arm they are randomly assigned to.|"Arm A will initiate Cycle 1 treatment at 80mg daily of regorafenib escalating up to but not exceeding 160mg daily at 40mg per week increments.~Arm B will initiate Cycle 1 treatment at 160mg daily of regorafenib."||||
33986134|NCT01873586|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986135|NCT02779894|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986136|NCT03207880|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33986137|NCT04056182|NA|SINGLE_GROUP||TREATMENT||NONE||open label treatment||||
33986138|NCT03338075|||COHORT||RETROSPECTIVE|||||||
33986139|NCT01399034|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33683004|NCT04360278|||COHORT||PROSPECTIVE|||||||
33683005|NCT02555280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683006|NCT00171470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683007|NCT03149848|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 2-period crossover study in healthy adults||||
33683008|NCT04365101|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I will evaluate the safety and efficacy of multiple doses of CYNK-001 (Days 1,4, and 7) in 14 patients.~Phase II will utilize a randomized, open-label design; multiple doses of CYNK-001 will be compared to the control group: Best Supportive Care. Up to 72 patients will be included in the Phase II portion of the study with a 1:1 randomization ratio."||||
33683009|NCT00371553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683010|NCT00004581||||TREATMENT||||||||
33683011|NCT00409331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683012|NCT03529071|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be provided with a Question Prompt Sheet to use at their nephrology clinic visit.||||
33683013|NCT02825290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33683014|NCT01282970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683015|NCT04577157|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single-blinded The investigators will be blinded.|It is a parallel-design, intention-to-treat, two-arm, randomized controlled trial, six months of duration with intervention module intervention pre-test and post-test evaluations to assess the effectiveness of mHealth application using Multi-aid-package intervention(voice, written message, and multimedia picture) to improve adherence to medication in hypertensive patients in Lahore, Pakistan. Participants will be assigned to the two groups in a parallel fashion in a ratio of 1:1. The intervention group will be given a reminder module intervention and control group with standard care (as per being practiced routinely in the hospitals).|f|f|t|f
33683016|NCT00918125|||COHORT||PROSPECTIVE|||||||
33683017|NCT02864901|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33683018|NCT00599131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683019|NCT00949767|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33683020|NCT00139867|RANDOMIZED|CROSSOVER||||NONE||||||
33683021|NCT02335671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683022|NCT03653871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683023|NCT04994470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware of the assigned intervention group|Participants are assigned to two groups in parallel for the duration of the study|t|f|f|f
33683024|NCT03444532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33683025|NCT05349253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683026|NCT02338336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683027|NCT00266669|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33683028|NCT05579067|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A- the use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft for ACL reconstruction (anterior cruciate ligament) of the knee joint;~B- the use of Hamstring muscle tendon autograft (Semitendonus and slender muscle) taken from the lower leg of the same limb and used as a graft for ACL reconstruction (anterior cruciate ligament) of the knee joint"||||
33683029|NCT02855151|||COHORT||CROSS_SECTIONAL|||||||
33683030|NCT00522132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683031|NCT01603524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773770|NCT06241703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and bedside nurses cannot be blinded, but the attending physicians and the medical ultrasound doctor will be blinded. The medical team will ensure that the patients and bedside nurses keep the group assignment confidential from the attending physicians and the medical ultrasound doctor. Unblinding will occur when the patient is discharged, and any instances of premature unblinding will be recorded. Additionally, the data analysts involved in this study will be blinded.||f|f|t|t
33683032|NCT02139059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683033|NCT04411381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33683034|NCT05026190|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683035|NCT00492063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33683036|NCT05783427|||CASE_CONTROL||PROSPECTIVE|||||||
33683037|NCT04802629|||OTHER||PROSPECTIVE|||||||
33683038|NCT00146159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683039|NCT03829878|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33683040|NCT03996369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683041|NCT04062136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683042|NCT00497809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683043|NCT05541887|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33683044|NCT06161896|||COHORT||PROSPECTIVE|||||||
33683045|NCT03099343|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33683046|NCT01391884|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33683047|NCT00373438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683048|NCT01909791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683049|NCT00897338|||COHORT||PROSPECTIVE|||||||
33683050|NCT01479426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33683051|NCT02969408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683052|NCT00002289||||TREATMENT||DOUBLE||||||
33773771|NCT06737926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773772|NCT06740253|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Study participants will be asked to use a placebo IVR to determine safety and acceptability for 14 days.||||
33773773|NCT05646979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The randomized experiment was designed as a control study.|f|f|f|t
33773774|NCT06690424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The enrolled patients and the data collectors were blinded to the grouping status||t|f|f|t
33773775|NCT06740370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773776|NCT00615433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773777|NCT06737679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773778|NCT06737250|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical study is conducted as an open, single-arm study targeting a patient population with rare diseases for which there is no distinct standard of care treatment.||||
33773779|NCT06739278|||COHORT||RETROSPECTIVE|||||||
33773780|NCT06738875|||COHORT||PROSPECTIVE|||||||
33773781|NCT06738524|NA|SINGLE_GROUP||PREVENTION||NONE||"The research was conducted in two stages. In the first stage, the Pittsburgh Sleep Quality Index and Digital Addiction Scale were applied to all students. In the second stage, the experimental and control groups were created by analyzing the scores of the students from the Digital Addiction Scale for the intervention study. It was calculated with the power analysis that 42 participants should be included in the study. 21 participants were randomly assigned to the intervention group and 21 participants to the control group by lot. Blood samples were taken from the students assigned to the intervention and control groups before the training and their orexin-A levels were measured. Then, the digital addiction combating training program was applied to the intervention group. After the training program was completed, a post-test was applied to both groups and orexin-A levels were measured again."||||
33773782|NCT06293911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773783|NCT01689740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33902780|NCT02221739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902781|NCT01892969|||COHORT||PROSPECTIVE|||||||
33902782|NCT04444700|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label) Blinding of participants, clinical research staff, and clinicians is not possible due to the nature of the intervention. However, the biostatisticians will be blinded at the data analysis phase.|This study is a 2-arm, parallel, pragmatic, multi-centre, open-label randomized controlled trial to determine the effect of therapeutic anticoagulation on the composite outcome of ICU admission, mechanical ventilation and/or death in hospitalized patients with COVID-19.||||
33902783|NCT01391091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902784|NCT04579081|||CASE_CONTROL||PROSPECTIVE|||||||
33902785|NCT03693365|||CASE_ONLY||PROSPECTIVE|||||||
33902786|NCT04128657|||COHORT||PROSPECTIVE|||||||
33902787|NCT02967848|||COHORT||PROSPECTIVE|||||||
33902788|NCT01894516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683053|NCT00412373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683054|NCT03473080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902789|NCT05851846|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||What list of participants||||
33902790|NCT05913076|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33902791|NCT05006807|||CASE_ONLY||PROSPECTIVE|||||||
33902792|NCT04559906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Assignment|t|f|f|t
33683055|NCT00600834|||COHORT||PROSPECTIVE|||||||
33683056|NCT01947907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683057|NCT05642650|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33683058|NCT00542438|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683059|NCT00669409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683060|NCT03689907|||COHORT||PROSPECTIVE|||||||
33902793|NCT02028689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33902794|NCT06106425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33902795|NCT01252784|||CASE_ONLY||PROSPECTIVE|||||||
33902796|NCT01847144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33902797|NCT02169635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902798|NCT01696409|||COHORT||PROSPECTIVE|||||||
33683061|NCT00178529|RANDOMIZED|PARALLEL||OTHER||SINGLE||||||
33683062|NCT04306991|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Each patient will be auscultated twice:~* during a febrile episode (body temperature \>38.5°C)~* after resolution of fever (body temperature \< 37.5°C)"||||
33683063|NCT03093688|NA|SINGLE_GROUP||TREATMENT||NONE||treatment group: receive twice cell infusions in one course of treatment.||||
33683064|NCT04642001|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33683065|NCT02642549|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683066|NCT04972643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33683067|NCT00329446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683068|NCT04379492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683069|NCT03923803|||OTHER||CROSS_SECTIONAL|||||||
33683070|NCT00917215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683071|NCT06074731|||COHORT||PROSPECTIVE|||||||
33683072|NCT03635580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773784|NCT02903589|||||CROSS_SECTIONAL|||||||
33773785|NCT04678336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773786|NCT02671721|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33902799|NCT05419154|NA|SINGLE_GROUP||TREATMENT||NONE||pragmatic, multi-center, multi-surgeon, prospective outcome study||||
33902800|NCT01224873|||COHORT||PROSPECTIVE|||||||
33902801|NCT01072279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902802|NCT04487847|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Explorative study of 18F-PSMA-1007 PET to detect prostate cancer||||
33902803|NCT01827540|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33902804|NCT03918642|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-Group Parallel Comparison Trial||||
33902805|NCT05734781|||OTHER||PROSPECTIVE|||||||
33902806|NCT04329923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study|There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms|t|t|t|f
33902807|NCT01878006|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Bliniding|Crossover study - participants receive active and placebo treatments in randomized order.|t|f|t|f
33902808|NCT06671561|||COHORT||PROSPECTIVE|||||||
33902809|NCT00434460|||COHORT||PROSPECTIVE|||||||
33902810|NCT02204540|RANDOMIZED|CROSSOVER||||NONE||||||
33986140|NCT05038657|NA|SINGLE_GROUP||TREATMENT||NONE||This study uses a Simon's 2-Stage optimal design with best ORR (% with a confirmed partial or complete response by RECIST v1.1) at a minimum of 12 weeks from commencing treatment as the primary endpoint.||||
33986141|NCT00977522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33986142|NCT04416230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research assistants scoring participant pain were blinded to group.|"The intervention consisted of a massage given by a licensed massage therapist on each of seven consecutive days beginning on the day of surgery (Day 1). The massage included 30 minutes of Swedish massage on the infant's accessible upper extremities, lower extremities, head, face, and back. Standard precautions were used, including proper hand hygiene and the use of gloves when needed for infection control.~Infants randomized to the comparison group received a 30 minute quiet time (QT) period during which non-essential caregiving tasks were restricted. During QT, clinicians were asked to avoid direct clinical caregiving activities, i.e. activities requiring physical contact with the infant."|f|t|f|t
33986143|NCT02576353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33986144|NCT03544008|||OTHER||OTHER|||||||
33986145|NCT00925119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986146|NCT03589170|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33986147|NCT03348423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, double-dummy||t|t|t|t
33986148|NCT02962934|||CASE_ONLY||PROSPECTIVE|||||||
33986149|NCT04504240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986150|NCT05621226|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
33986151|NCT05770063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33773787|NCT06185946|||OTHER||PROSPECTIVE|||||||
33773788|NCT06740630|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Observer-blind study.||t|f|t|f
33986152|NCT01753895|||CASE_CONTROL||PROSPECTIVE|||||||
33986153|NCT00518830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986154|NCT02224742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986155|NCT04458701|||CASE_ONLY||PROSPECTIVE|||||||
33986156|NCT04444713|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33986157|NCT00000661||||TREATMENT||NONE||||||
33986158|NCT05454111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986159|NCT01066143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986160|NCT03283137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986161|NCT06331247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors will be masked from the assignment of the participants.|This is a two-arm parallel design, with one arm being the control arm (usual medical care) and the other being the intervention arm (MIND diet intervention + usual medical care).|f|f|f|t
33986162|NCT01404988|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34024847|NCT01679717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024848|NCT00642252|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34024849|NCT00134004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024850|NCT00252200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024851|NCT03645707|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (Florida Hospital IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group. However, in this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."||||
34024852|NCT04766164|||COHORT||CROSS_SECTIONAL|||||||
34024853|NCT02489253|||CASE_CONTROL||PROSPECTIVE|||||||
34024854|NCT04138823|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024855|NCT02687529|||CASE_CONTROL||PROSPECTIVE|||||||
34024856|NCT03909269|||CASE_CONTROL||PROSPECTIVE|||||||
34024857|NCT02558530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024858|NCT06579534|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Fall prevention education before discharge is an inevitable measure. Participants accepted such measures but did not know that this study involved differentiated health education methods.|Control and Experimental group|t|f|f|f
34024859|NCT02787408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024860|NCT05249452|||COHORT||PROSPECTIVE|||||||
34024861|NCT00871273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024862|NCT06522633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Open label|In patients under regular treatment with opioids referred to the motility unit for dysphagia, esophageal manometry is performed and if they present an OIED, the morphine is removed and the manometry is repeated to evaluated if OIED was resolved with the suspension of opioid||||
34024863|NCT05349643|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
34024864|NCT05656872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34024865|NCT05467696|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34024866|NCT01578616|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34024867|NCT05496491|RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no blindness at the level of the patient, the treating physicians (surgeon, oncologist, radiotherapist) and the researcher who will record the data.|The study will employ a prospective, parallel randomized-controlled design||||
34024868|NCT04711902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024869|NCT00001705||||TREATMENT||||||||
34024870|NCT04208958|NA|SINGLE_GROUP||TREATMENT||NONE||"This study was designed to help determine the safety and effectiveness of the study drug, VE800, in combination with nivolumab in patients with advanced/metastatic cancer.~The following cohorts of patients with advanced/metastatic cancer were enrolled:~* Melanoma~* Gastric/gastroesophageal junction (GEJ) adenocarcinoma~* Colorectal cancer (microsatellite-stable) (CRC-MSS)"||||
33773789|NCT05792839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Repair of ventral hernia with hernioplasty or abdominoplasty.|f|f|f|t
33773790|NCT02988206|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33773791|NCT06741332|||COHORT||PROSPECTIVE|||||||
33773792|NCT03733093|||COHORT||PROSPECTIVE|||||||
33773793|NCT03726021|NA|SINGLE_GROUP||TREATMENT||NONE||"Experimental: Irinotecan,Oxaliplatin, and S1~* S1 will be administered orally days 1 and 14 of a 21 day cycle~* Irrinotecan 165 mg/m2 and Oxaliplatin 85mg/m2 will be administered IV days 1 of a 21 day cycle."||||
33773794|NCT06737705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773795|NCT06739824|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773796|NCT02850328|NA|SINGLE_GROUP||OTHER||NONE||||||
33902811|NCT04940598|RANDOMIZED|PARALLEL||PREVENTION||NONE||In a longitudinal study design, 40 participants with chronic SCI will be randomly assigned to one of the two study groups (HIIT and control) in a 1:1 ratio. Randomization will be performed using the block randomization method, Randomization will be performed using the block randomization method. A randomization list will be generated and assignments will be placed into closed envelopes and given to each study participant. Participants will be assessed at baseline and 16-wks post HIIT or control||||
33902812|NCT02948231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902813|NCT03556722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|Two-arm parallel assignment involves two groups of participants. One group receives r-TMS, and the other group receives sham placebo r-TMS.|t|t|t|t
33902814|NCT06497725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33902815|NCT01972477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902816|NCT01198444|||COHORT||PROSPECTIVE|||||||
33902817|NCT04385901|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and care providers will know which group they are in, but data will be deidentified and blinded prior to analysis or viewing by the primary investigator|Patients receiving care through the program developed by the University of Missouri Healthcare system will, if willing, return for follow up testing and be compared against a matched group that did not receive the rehabilitative treatment to see if there are short or long term differences.|f|f|t|t
33902818|NCT06169748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33902819|NCT06671821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902820|NCT00592150|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33902821|NCT00739297|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33902822|NCT06410053|||COHORT||PROSPECTIVE|||||||
33902823|NCT06311630|||CASE_ONLY||PROSPECTIVE|||||||
33902824|NCT06597955|||OTHER||OTHER|||||||
33902825|NCT02495077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902826|NCT02974946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902827|NCT06336824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902828|NCT04109443|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33902829|NCT03855917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902830|NCT05011422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902831|NCT04756089|RANDOMIZED|PARALLEL||OTHER||NONE||This is a pilot feasibility and acceptability study of a randomized clinical trial of pregnant women at 36 weeks of gestation and greater randomized to one of two arms at Yale New Haven Hospital: (1) breast stimulation by hand or with a breast pump versus (2) exogenous intravenous oxytocin infusion (standard of care, control). The pilot study will be randomized since one of the goals is to evaluate whether the idea of randomization would be acceptable to patients.||||
33902832|NCT00991172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33902833|NCT04376346|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902834|NCT02868502|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33902835|NCT01438710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902836|NCT02807116|NA|SINGLE_GROUP||OTHER||NONE||||||
33902837|NCT06671925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902838|NCT00717353|||CASE_ONLY||CROSS_SECTIONAL|||||||
33902839|NCT04674852|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33902840|NCT00430781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986163|NCT05410301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Cohort 1 - Main study group consisting of patients with rGBM and Cohort 2 - Substudy group consisting of a participating unaffected partners of patients with rGBM||||
33773797|NCT03481738|||COHORT||PROSPECTIVE|||||||
33773798|NCT06737406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will be a single-center, parallel, randomized, double-blind, placebo-controlled trial. Patients who meet eligibility criteria will be randomized (1:1:1) to one of 3 groups. Group A will receive 5% fluorouracil cream and 0.005% calcipotriol ointment. Group B will receive 5% fluorouracil cream and a placebo ointment in identical tubes in terms of color and scent and with identical usage instructions to calcipotriol. Group C will receive 0.005% calcipotriol ointment and a placebo cream in identical tubes with identical instructions to fluorouracil. All patients applied a thin layer of ointment and cream to the affected area (palmoplantar) twice daily for 3 consecutive weeks (21 days).|t|t|t|t
33773799|NCT04047004|NA|SINGLE_GROUP||OTHER||NONE||Prospective, multicenter, non-randomized, non-blinded, open-label||||
33986164|NCT04023539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A simple blinding (participants blinded to the belonging group). The person who will randomize the participants will not be involved in the recruitment of participants. This will be done when we have the total sample of participants.|Randomized Controlled Trial This is a simple blind randomized clinical trial with patients with type 2 diabetes, the subjects will be divided into two groups, the intervention supplemented with 2 g daily of cinnamomum zeylanicum orally (capsules) and the control group with a placebo. There will be a follow-up of 3 months every two weeks to measure the variables of interest in the study.|t|f|f|f
33773800|NCT06739551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773801|NCT06738095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773802|NCT01621958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33773803|NCT06350097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773804|NCT06187038|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33773805|NCT05479994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773806|NCT01851395|||COHORT||PROSPECTIVE|||||||
33773807|NCT04416581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773808|NCT06696326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773809|NCT06657183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773810|NCT06739187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773811|NCT05580640|NA|SINGLE_GROUP||TREATMENT||NONE||For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system.||||
33773812|NCT00471250|||OTHER||PROSPECTIVE|||||||
33773813|NCT03639285|||COHORT||OTHER|||||||
33773814|NCT00675545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902841|NCT02257814|RANDOMIZED|PARALLEL||||NONE||||||
33902842|NCT03488810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902843|NCT00693212|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33902844|NCT00153634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986165|NCT05963178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986166|NCT01665209|RANDOMIZED|CROSSOVER||||NONE||||||
33986167|NCT03609034|||OTHER||CROSS_SECTIONAL|||||||
33986168|NCT01534520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986169|NCT06347562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986170|NCT05076253|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Group A: Ivermectin Group B: Placebo|a randomized ,double blind,placebo,controlled trial|t|t|t|f
33902845|NCT04051567|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33902846|NCT01856946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902847|NCT03550716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization will be performed when the patient is asleep.|"Trial type:~Clinical randomized multi-center controlled trial~Randomization:~Block randomization is performed with the use of a computer generated block randomization list~Participants:~Patients with NOA undergoing fertility treatment"|t|f|f|f
33902848|NCT00616239|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33902849|NCT04135261|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation (Part 1) followed by Dose expansion (Part 2)||||
33683073|NCT06059131|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization is performed by an independent statistical service. The randomization list will be transferred to the hospital pharmacy. The pharmacists will be responsible for the delivery of the capsules (placebo vs. verum). Neither the investigator nor the participant will be aware of the treatment. The code will be unmasked at the end of the study.|2 arms : placebo vs verum|t|t|t|f
33683074|NCT03189290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902850|NCT05801523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902851|NCT06585670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33902852|NCT03476551|||CASE_ONLY||PROSPECTIVE|||||||
33902853|NCT01437631|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902854|NCT03090191|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902855|NCT05207436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902856|NCT04792138|||COHORT||PROSPECTIVE|||||||
33902857|NCT01139723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33902858|NCT00530712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902859|NCT00370149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902860|NCT05154747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902861|NCT00611078|||CASE_CONTROL||PROSPECTIVE|||||||
33902862|NCT06119698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902863|NCT00644540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902864|NCT05690594|||COHORT||RETROSPECTIVE|||||||
33902865|NCT01601392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902866|NCT04904146|||OTHER||PROSPECTIVE|||||||
33902867|NCT05519761|||COHORT||RETROSPECTIVE|||||||
33902868|NCT04221451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902869|NCT00942877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902870|NCT04341844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902871|NCT04604730|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sequential assignment||||
33902872|NCT06477016|||CASE_ONLY||PROSPECTIVE|||||||
33902873|NCT04356105|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of poor ovarian responders to be given two different induction protocols at the same time duration of the study||||
33902874|NCT05116982|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33902875|NCT04175197|||COHORT||PROSPECTIVE|||||||
33902876|NCT01605305|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33902877|NCT04578717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical evaluation of NCCLs restorations was conducted by two trained and calibrated examiners.The examiners and patients were blinded to the group assignment.|A hundred teeth with NCCLs meeting the inclusion criteria were randomly assigned into four experimental groups (n=25); A: air-abrasion + Etch\&rinse, B: air-abrasion + Self-etch, C: Etch\&rinse and D: Self-etch.|t|f|f|t
33902878|NCT02901717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902879|NCT06056739|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33902880|NCT05799144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902881|NCT01894282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902882|NCT06671769|NA|SINGLE_GROUP||TREATMENT||NONE||"The Natural Heart Health Supplement Trial is designed as a single-arm treatment study, where participants will serve as their own controls. This innovative approach, termed a Signal Phase study at Efforia, aims to evaluate the potential efficacy and safety of an experimental natural heart health supplement over a 3-month period. Participants will consume a daily dose of the supplement, which is administered in a chocolate-flavored powdered format. The primary objective is to assess the impact of the supplement on key heart health biomarkers, including Total Cholesterol, HDL-C, LDL-C, Triglycerides, and High-Sensitivity C-reactive protein (hs-CRP). By utilizing this methodology, the study will provide preliminary insights into the supplement's effects, offering a directional indication of potential positive results."||||
33902883|NCT05242588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Priticipant,Care provider and investigators are masked in this study|Parallel|t|t|t|f
33902884|NCT01854567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902885|NCT01891747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902886|NCT00690937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902887|NCT00003356||||TREATMENT||||||||
33902888|NCT04412603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A pilot randomized clinical trial was performed with simple blind and randomization of block assignmen.|f|f|f|t
33902889|NCT00858767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902890|NCT04953637|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902891|NCT01182129|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33902892|NCT01224353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902893|NCT00174057|||CASE_CONTROL||OTHER|||||||
33902894|NCT00498446|||||PROSPECTIVE|||||||
33902895|NCT06238999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-Mouth Design|t|f|f|t
33902896|NCT03568006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is not possible to mask physiotherapists and patients, so the only masking will be for researchers and evaluators||f|f|t|t
33902897|NCT01140542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902898|NCT01188018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902899|NCT06362161|||COHORT||OTHER|||||||
33902900|NCT04813679|||COHORT||PROSPECTIVE|||||||
33902901|NCT02225223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902902|NCT02659345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33902903|NCT05942534|||COHORT||PROSPECTIVE|||||||
33902904|NCT06132763|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902905|NCT06036108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902906|NCT03561285|||COHORT||CROSS_SECTIONAL|||||||
33902907|NCT03418662|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33902908|NCT00203645|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33902909|NCT04156646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080506|NCT03675646|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Only ICU personnel was blinded to the method used|Patient elicited for open prostatectomy or open nephrectomy were given intrathecal morphine in normal saline before induction to general anaesthesia (GA) or GA only. After surgery, time to the first opioid request, total opioid consumption during first 24 hours and 48 hours after surgery and opioid side effects were noticed.|f|f|f|t
34080507|NCT06308471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Professional nurses who evaluate nutrition do not know which group they belong to in the study.~They do not know which group the premature babies are in due to their age."|Baby massage was applied to the intervention group (20) of the study, and oral stimulation was applied with the Fucile protocol to the control group (20).|t|f|f|t
34080508|NCT05211934|||COHORT||PROSPECTIVE|||||||
34080509|NCT01710020|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080510|NCT05991310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The days in which the neurologist will be on or off the mobile stroke unit will be randomly determined. Randomization will be stratified by nurse category (Nurse Practitioner versus Clinical Nurse Consultant) with an adaptive component to balance the number of patients reviewed in person or via telemedicine within each nurse category. The randomized schedule will be generated in a rolling fashion on a weekly basis.||||
34080511|NCT04995913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33902910|NCT02690467|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902911|NCT05496803|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33902912|NCT03062033|||COHORT||PROSPECTIVE|||||||
33902913|NCT03290300|||COHORT||PROSPECTIVE|||||||
33902914|NCT06622109|||COHORT||PROSPECTIVE|||||||
33902915|NCT06498063|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33902916|NCT01250067|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902917|NCT02046564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902918|NCT03078725|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients will be randomized to two groups, one receiving glyburide and one receiving metformin.||||
33902919|NCT02265146|||COHORT||PROSPECTIVE|||||||
33902920|NCT05820295|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33902921|NCT00723840|||COHORT||PROSPECTIVE|||||||
33902922|NCT02927171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33902923|NCT02952547|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33902924|NCT06326229|||COHORT||CROSS_SECTIONAL|||||||
33902925|NCT00791128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902926|NCT03822403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33683075|NCT00403169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683076|NCT01605149|||CASE_ONLY||PROSPECTIVE|||||||
33683077|NCT02362568|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33902927|NCT06672068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902928|NCT03493503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902929|NCT03779932|||CASE_ONLY||CROSS_SECTIONAL|||||||
33902930|NCT04036058|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two-arm parallel assignment: the 10 participating units will be randomized; at each site, one unit will be randomized to the intervention group and one unit to the control group so that 5 units will enact the universal gloving intervention and 5 units will continue standard of care gloving practices.||||
33902931|NCT05209243|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Interventional arm: STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment~* Control arm: STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment~Patients will be stratified according to prior local treatment (yes/no) or the new imaging technique used (Choline vs PSMA PET/TC)."||||
33902932|NCT01732263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902933|NCT02754947|||COHORT||RETROSPECTIVE|||||||
33902934|NCT03435029|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902935|NCT04523792|NA|SINGLE_GROUP||TREATMENT||NONE||The study is designed to examine feasibility of SUBLOCADE on outpatient treatment engagement compared to historical and concurrent control groups.||||
33902936|NCT06253559|||OTHER||RETROSPECTIVE|||||||
33902937|NCT04128592|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33902938|NCT03808714|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention - smoking cessation program delivered by Community Health Worker with pharmacological support by a specialist at the university Control - Alabama Quitline||||
33902939|NCT03446170|RANDOMIZED|FACTORIAL||PREVENTION||NONE|The study tests the effects of graphic cigarette warning labels and packaging regulations, therefore it is unmasked.|The experimental design is a 2 (graphic warning message framing: gain versus loss) by 2 (cigarette packaging: standardized, plain or branded) factorial design. An unexposed control group is also included.||||
33902940|NCT03486535|||COHORT||PROSPECTIVE|||||||
33902941|NCT05334784|NA|SINGLE_GROUP||TREATMENT||NONE||"Upon completion of enrollment in the pivotal study, enrollment in Continued Access Protocol will begin.~ECP Pivotal enrolled 256 subjects and Impella ECP Continued Access Protocol anticipates to enroll up to 300 subjects"||||
33902942|NCT05216211|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33902943|NCT05407298|||OTHER||PROSPECTIVE|||||||
33683078|NCT03205592|||COHORT||PROSPECTIVE|||||||
33902944|NCT01209208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986171|NCT03539003|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. sevoflurane group~2. desflurane group~3. total intravenous anesthesia group"||||
33986172|NCT04327453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33986173|NCT02131805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683079|NCT01238588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683080|NCT00849836|||CASE_CONTROL||PROSPECTIVE|||||||
33902945|NCT04340830|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902946|NCT00005628||||TREATMENT||||||||
33902947|NCT05354284|||COHORT||PROSPECTIVE|||||||
33902948|NCT00199511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683081|NCT00815178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902949|NCT03662152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of data was blinded to statistics investigator||f|f|f|t
33902950|NCT05462587|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33902951|NCT04023812|||COHORT||PROSPECTIVE|||||||
33902952|NCT04291300|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II pilot study, single centre, two cohorts. Cohort 1: Patients with R/M ACC Cohort 2: Patients with R/M SDC||||
33902953|NCT02424370|||OTHER||PROSPECTIVE|||||||
33902954|NCT00450606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33902955|NCT05797350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902956|NCT00381316|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902957|NCT01221233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902958|NCT02890771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902959|NCT00552825|||COHORT||RETROSPECTIVE|||||||
33986174|NCT05970653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986175|NCT02281591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986176|NCT04017156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The two recipient sites will be selected prior the surgery, while the type of site preparation will be randomly decided. The randomization will be performed electronically (randomization.com) by a researcher neither involved in the selection of the patients nor in installation of the devices (DB). Sealed opaque envelopes will be prepared and opened at the time of surgery by an author not involved in the surgery (DB). Surgeon and patients will be blinded.|Clinical Trial|t|f|t|t
33986177|NCT05516056|NA|SINGLE_GROUP||TREATMENT||NONE||prospective and cross sectional study||||
33986178|NCT02640521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986179|NCT00736970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986180|NCT06189833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902960|NCT04815629|||COHORT||RETROSPECTIVE|||||||
33902961|NCT02064218|||COHORT||PROSPECTIVE|||||||
33902962|NCT05032157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33902963|NCT05159583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are randomly assigned to treatment arms by People Power. Identical systems are self-installed by caregivers in all homes regardless of treatment arm. Initiating the features of the system appropriate to the assigned treatment arm is done remotely by a member of the People Power staff following the installation. All participants complete the same questionnaires at the same intervals.||f|f|t|f
33902964|NCT01380496|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33902965|NCT00033839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33902966|NCT05588492|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33902967|NCT02392208|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33902968|NCT01073072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902969|NCT04556331|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33902970|NCT03509753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33902971|NCT05019183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Patients will be randomized into 2 arms:~* Experimental arm: patients will beneficiate from a training program in an immersive environment (virtual reality)~* Control group: patients will beneficiate from a training program in a real (non-virtual) environment"|f|f|f|t
33902972|NCT00898261|||OTHER||RETROSPECTIVE|||||||
33902973|NCT05064345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902974|NCT03903029|||CASE_ONLY||PROSPECTIVE|||||||
33902975|NCT05221294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33902976|NCT03197675|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986181|NCT05704881|||CASE_ONLY||PROSPECTIVE|||||||
33986182|NCT05527223|||COHORT||PROSPECTIVE|||||||
33986183|NCT01159860|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33986184|NCT02848924|||COHORT||RETROSPECTIVE|||||||
33986185|NCT04249830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986186|NCT00714090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986187|NCT05342740|||CASE_CONTROL||PROSPECTIVE|||||||
33986188|NCT03059966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986189|NCT04535830|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open-label, randomized controlled trial. The investigators plan to recruit 200 persons with type 2 diabetes diagnosed within six months. Participants will be randomly assigned (1:1) to either use of a flash glucose monitoring system(FSL) or self-monitoring blood glucose(SMBG) . All participants need to wear the flash glucose monitoring sensor at baseline and at the end of the experiment for data analysis.During the three months of experiment,participants at the FSL group will wear a flash glucose monitoring sensor for 14 days and have a care visit every month,while people at SMBG group will monitor their glucose by pricking a finger at home and receive a care visit every month as well.~The primary outcome is the between-group difference in mean HbA1c at 3 months. Meanwhile,researchers want to know whether differences in glucose variability and diabetes-specific distress between two groups."||||
33986190|NCT06082154|||OTHER||PROSPECTIVE|||||||
33986191|NCT00208403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986192|NCT01066182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986193|NCT05817747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||On all participants the dialogue support tool will be used and will thereafter be put into either of two treatment-arms (surgical, or non-surgical treatment)||||
33986194|NCT02478190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986195|NCT02217293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986196|NCT01125059|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33986197|NCT03776422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986198|NCT00892892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986199|NCT02007031|||||CROSS_SECTIONAL|||||||
33986200|NCT01327222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986201|NCT00567320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33986202|NCT04721795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assesor is blinded to treatment groups|Randomised|f|f|f|t
33986203|NCT02502474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986204|NCT03570905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986205|NCT03953950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986206|NCT05805865|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator blinded to group||f|f|t|f
33986207|NCT05165823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902977|NCT06427681|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33986208|NCT00276133|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33986209|NCT01042522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986210|NCT05884762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The occupational therapist who will include and do the sessions will be open. The assessors who will test motor functions during the assessments will be blind||t|f|t|t
33986211|NCT00242398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33986212|NCT01677962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986213|NCT01169883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33986214|NCT04195022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080512|NCT02287038|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|randomized, double-blind, placebo-controlled, and cross-over trial|A small prospective, 10-week, fixed-dose, randomized, double-blind, placebo-controlled, and cross-over trial of atomoxetine as an add-on medication to other therapies in Veterans with comorbid ADHD/PTSD.|t|t|t|t
34080513|NCT03940833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080514|NCT03561454|||CASE_ONLY||PROSPECTIVE|||||||
33902978|NCT04064684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33902979|NCT06184919|||OTHER||PROSPECTIVE|||||||
33902980|NCT01376830|||COHORT||PROSPECTIVE|||||||
33902981|NCT04384640|||COHORT||PROSPECTIVE|||||||
33902982|NCT04918940|NA|SINGLE_GROUP||OTHER||NONE||||||
33902983|NCT00598533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33902984|NCT02444637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902985|NCT05023486|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986215|NCT06366009|||COHORT||PROSPECTIVE|||||||
33773815|NCT04134845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study statistician will generate the allocation schedule but will remain blinded to the treatment assignment as well as the study staff physician's. The research clinician will not be blinded.|84 participants will be randomly assigned in a 2:1 ratio to treatment (dantrolene) or control (placebo). A computer-generated randomization list will be prepared by the study statistician using the stratified permuted block randomization, where block size varies randomly from 4 or 6 to ensure overall balance across treatment arms. Randomization will be stratified by 1) documented CAD with prior infarct, 2) amiodarone use within the past 21 days defined as chronic oral use or \>5 grams cumulative, 3) LVEF \<35%. Enrollment will be evenly distributed across the two study arms by the stratification factors|t|f|t|f
33773816|NCT02438774|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773817|NCT06292533|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773818|NCT00027690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773819|NCT06741098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33902986|NCT03731416|RANDOMIZED|PARALLEL||OTHER||SINGLE|Each patient will be given a code by the researcher and the observers will be blind to which group this case belong.|The patients will be randomly divided into 2 equal groups|f|f|t|f
33773820|NCT03537053|NA|SINGLE_GROUP||OTHER||NONE||a single group feasibility study||||
33773821|NCT06736353|||COHORT||PROSPECTIVE|||||||
33773822|NCT03626038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773823|NCT06741215|||COHORT||RETROSPECTIVE|||||||
33773824|NCT06117774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773825|NCT04091776|NA|SINGLE_GROUP||SCREENING||NONE||||||
33773826|NCT05843448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773827|NCT04704661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773828|NCT03448393|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33773829|NCT06280963|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||group one will receive muscle energy technique group two will receive posterior innominate mobilization group three will receive conventional treatment ( TENS , US , stertching exercises and strenghening exercises )|t|f|f|f
33773830|NCT05968885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33773831|NCT03959774|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773832|NCT06467175|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773833|NCT06737861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"interventional study model for this study is a parallel-group randomized controlled trial (RCT). This model involves two distinct groups:~Intervention Group: Participants receive both Buerger exercises and Whole Body Vibration (WBV) therapy.~Control Group: Participants receive only Buerger exercises without WBV therapy. Each participant is assigned randomly to one of these groups, ensuring that comparisons between the combined therapy and single therapy are unbiased. This parallel structure means each group undergoes its specific intervention throughout the study period without crossover to the other group's intervention. This approach helps assess the distinct and combined effects of the two therapies on pain, balance, and lower limb perfusion in patients with diabetic peripheral neuropathy."|f|f|f|t
33773834|NCT06739135|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Drivers with DPN will be randomly assigned to either the intervention group or the control group.~Drivers with no diagnosed DPN will be assigned to the No/Low DPN group."||||
33773835|NCT05690776|||COHORT||OTHER|||||||
33902987|NCT02225067|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33902988|NCT05173272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902989|NCT03903198|||COHORT||PROSPECTIVE|||||||
33902990|NCT03524365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33902991|NCT01810146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33902992|NCT01977534|||CASE_ONLY||PROSPECTIVE|||||||
33902993|NCT02865044|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33902994|NCT06287125|||CASE_CONTROL||PROSPECTIVE|||||||
33902995|NCT03925428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33902996|NCT01898546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33902997|NCT04122768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients in the control group will receive a sham version of the smartphone application|1:1 randomization. Patients who are active at baseline will not be randomized but will be followed up in a cohort study.|t|f|f|f
33902998|NCT03609229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33902999|NCT03850249|||COHORT||RETROSPECTIVE|||||||
33903000|NCT01892254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33903001|NCT02910856|||COHORT||PROSPECTIVE|||||||
33986216|NCT04587570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986217|NCT02785003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986218|NCT06317103|||CASE_CONTROL||RETROSPECTIVE|||||||
33986219|NCT04463602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986220|NCT06275061|||COHORT||PROSPECTIVE|||||||
33986221|NCT03705065|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986222|NCT04827732|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986223|NCT02943447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986224|NCT04739566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986225|NCT03290781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986226|NCT01878292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986227|NCT06231745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33986228|NCT01942746|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33986229|NCT04713137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33986230|NCT02286076|||CASE_CONTROL||PROSPECTIVE|||||||
33986231|NCT05922826|||COHORT||OTHER|||||||
33986232|NCT05326841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a double blinded randomized controlled trial. Subjects were allocated in each treatment arm using permuted block randomization, with a block size of four and concealed code lists. Investigators, doctors, and subjects were blinded to treatment allocation (double blind).|There are two groups : cholecalciferol group( intervention group) which get cholecalciferol 5000 iu/day for 12 weeks and saccharum lactis group ( placebo group) which get saccharum lactis for 12 weeks|t|t|t|t
33986233|NCT01046474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33986234|NCT03983057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986235|NCT00965185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986236|NCT03719898|NA|SINGLE_GROUP||TREATMENT||NONE||Refractory or relapsed ALK positive ALCL patients who may or my not have previously received treatment with any ALK inhibitor for any indication||||
33986237|NCT00468598|||COHORT||PROSPECTIVE|||||||
33986238|NCT05632874|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773836|NCT06739655|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since our intervention is the change in breast cancer sequence to preoperative radiotherapy and immediate breast reconstruction, it is impractical/unethical to blind patients, care providers, or investigators. The main outcomes will be self-evaluations from the patients (PROMs) or registered by the investigator and is therefore not blinded either. The assessment of the photographs by an external expert panel however, can and will be blinded.|Multicenter phase 3 (non-pharmacological) randomized controlled trial, with a parallel design and a 1:1 assignment ratio.||||
33986239|NCT05984251|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33986240|NCT03808064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986241|NCT01619930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773837|NCT05345184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986242|NCT03625856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is a double-blind, randomized controlled trial. Subjects will be randomly allocated into two groups and each one will receive the supplement (Chlorella Vulgaris) or placebo for 8 weeks. To prevent selection bias, the study participants, investigators and the laboratory staff will be all blinded to treatment assignment.|Subjects will be randomly allocated into two groups; Chlorella and placebo groups.|t|t|t|f
33986243|NCT01900340|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33986244|NCT03153930|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete a randomized crossover study with 2 conditions: sitting continuously for 3 hours vs. interrupting sitting with 3-minute moderate intensity walking breaks every 30 minutes for 3 hours. A subset will then complete a free-living component wearing a continuous glucose monitor that will consist of habitual activity vs. interrupting periods of 30+ sedentary minutes with short activity breaks.||||
33986245|NCT01518972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986246|NCT00478179|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33986247|NCT02426762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33986248|NCT03430869|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33986249|NCT00569153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986250|NCT04040426|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Human Split Thickness Skin Graft Allograft (Theraskin™) in the Treatment of Diabetic Foot Ulcers||||
33986251|NCT04915053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Random number of samples|Three measurements, initial, middle, and final.|t|t|t|f
33986252|NCT03401918|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986253|NCT01387633|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33986254|NCT02053701|||OTHER||OTHER|||||||
33986255|NCT04990180|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Mixed methods observational and feasibility study||||
33986256|NCT04165330|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical Trial||||
33986257|NCT03196570|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33986258|NCT02052947|NA|SINGLE_GROUP||SCREENING||NONE||||||
33986259|NCT06560580|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33986260|NCT06278545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986261|NCT05985317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986262|NCT03784937|||COHORT||PROSPECTIVE|||||||
33903002|NCT03465852|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study participants will be randomly assigned to the intervention or the wait list comparison arm|The intervention study uses an intervention arm and a wait list comparison (control) arm|f|f|f|t
33986263|NCT01394497|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33903003|NCT05075785|||COHORT||PROSPECTIVE|||||||
33903004|NCT05436808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903005|NCT01398397|||CASE_ONLY||RETROSPECTIVE|||||||
33986264|NCT01334645|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33986265|NCT00838149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986266|NCT03672266|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986267|NCT05162664|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|In total, three investigators are involved. One is in charge for the screening process, and is not blinded for the status of the participants. The second investigator, i.e. the outcome assessor, is blinded for the status of the participants, and performs the clinical assessments (NOT the questionnaires). A third senior researcher is supervising the process.|Cross-sectional study, in which patients with migraine are gender- and age matched to healthy controls, and undergo a pain protocol.|f|f|f|t
33986268|NCT04714294|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||SAD: planned 48 arms. 12 subjects each arm (Active: placebo=3:1) MAD: planned 36 arms. 12 subjects each arm (Active: placebo=3:1)|t|t|t|t
33986269|NCT02169115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986270|NCT01029522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986271|NCT02851992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986272|NCT01841554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986273|NCT03220802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986274|NCT02848742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986275|NCT00637741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986276|NCT01577303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986277|NCT01857167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33986278|NCT01618097|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986279|NCT03809130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986280|NCT00804180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986281|NCT00473330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986282|NCT05764330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986283|NCT06268197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986284|NCT01543360|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986285|NCT03266263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986286|NCT02681263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080515|NCT05584995|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080516|NCT02484014|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34080517|NCT05325996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080518|NCT03292510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A 2-group mixed methods stratified randomized controlled trial following CONSORT criteria is proposed. Group allocation will be concealed and outcome evaluation blinded|"Experimental: GO-OUT program An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 10 weeks.~Intervention: Other: GO-OUT program Active Comparator: Task-oriented outdoor walking workshop An outdoor walking workshop with stations to learn various outdoor walking skills and information.~Intervention: Other: Task-oriented outdoor walking workshop"|f|f|f|t
34080519|NCT06059040|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A parallel randomized controlled design will be used in this study.||||
34080520|NCT03220308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773838|NCT02322177|||COHORT||CROSS_SECTIONAL|||||||
33773839|NCT01309490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903006|NCT03207828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants: blind to hypothesis and blind regarding which conditions they have been assigned. To mask the condition, participants of both arms will receive the experimental intervention. Control participants will need to wait to receive the intervention. Control participants will know that the time waiting to be attended can vary among participants (and that even participants in the experimental group may have to wait). They also would know that (while waiting to be intervened) participants will need to attend to a series of assessments, and that five month is the longest period they will need to wait. Care providers: blind to all the study aspects but not to its aims. Investigators: blind to the subject treatment assignment and the outcomes. Outcomes assessors: blind to all aspects. Interventionist: blind to hypothesis and outcomes. Research assistant: blind to everything but not to aims and implementation.|Patients with Fibromialgia and mayor depression will be randomized to two treatment conditions.|t|t|t|t
33903007|NCT05967195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903008|NCT03805295|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33903009|NCT01288040|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903010|NCT06173752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903011|NCT00950352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903012|NCT00767195|||CASE_CONTROL||PROSPECTIVE|||||||
33903013|NCT04952389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903014|NCT02502877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33903015|NCT02868125|||COHORT||PROSPECTIVE|||||||
33903016|NCT06080113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903017|NCT06096233|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33903018|NCT05132465|||COHORT||PROSPECTIVE|||||||
33903019|NCT03037320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903020|NCT00650429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903021|NCT01185652|||COHORT||PROSPECTIVE|||||||
33903022|NCT03690258|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Researches collecting data will be blinded of participant allocation.|Variable load exercise, non-pharmacological intervention|f|f|t|f
33903023|NCT05000580|||COHORT||RETROSPECTIVE|||||||
33903024|NCT05986344|||COHORT||PROSPECTIVE|||||||
33903025|NCT05882162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33903026|NCT02157272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903027|NCT05024838|||COHORT||RETROSPECTIVE|||||||
33903028|NCT03851744|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33903029|NCT01978912|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903030|NCT03723564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903031|NCT03445039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All of the patients will be divided into four groups by using randomization tables. The assignment will be concealed from the clinical operators until the beginning of implant surgery. The outcome examiners will be kept blinded to the assignment.||f|f|t|t
33903032|NCT03713723|||COHORT||PROSPECTIVE|||||||
33903033|NCT00458250|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33903034|NCT02328846|||COHORT||PROSPECTIVE|||||||
33903035|NCT00916604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903036|NCT03271827|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33903037|NCT01411397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903038|NCT01673048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903039|NCT02573103|||COHORT||PROSPECTIVE|||||||
33903040|NCT01413178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903041|NCT00802165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903042|NCT01105403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903043|NCT00692705|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33903044|NCT03587909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33903045|NCT05336227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessors will be blinded to group allocation (data entry and analysis personnel).|One group that immediately receives the intervention. Another group that waits before receiving the same intervention.|f|f|f|t
34080521|NCT01668836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080522|NCT02970955|||COHORT||PROSPECTIVE|||||||
34080523|NCT02244684|||COHORT||PROSPECTIVE|||||||
34080524|NCT00748878|||COHORT||PROSPECTIVE|||||||
34080525|NCT02708134|||COHORT||PROSPECTIVE|||||||
34080526|NCT00903643|||CASE_CONTROL||PROSPECTIVE|||||||
34080527|NCT05022498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34080528|NCT04541355|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34080529|NCT03485443|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The postoperative assessment following the anesthesiologist, nurse and parents were blind during the entire study group||f|f|t|f
33773840|NCT05365113|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Exploratory study testing in cross-sectional design two alveolar recruitment maneuvers referenced in practice, in patients under general anesthesia and intubated under controlled ventilation, in operating room|t|f|f|f
33773841|NCT04715087|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33773842|NCT06192355|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33773843|NCT06379750|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33773844|NCT06737809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683082|NCT02973880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All daily study products will be manufactured in indistinguishable single dose plastic vials, labeled in accordance with hour of administration. In accordance with the double-blind design of the study, daily treatment for patients randomized to group A (NETILDEX™ ophthalmic gel), will be of 2 doses of active treatment and 2 doses of indistinguishable placebo. For blinding purposes, Group B (NETILDEX™ eye drops solution) medications labels will consist in an aluminum envelope for each dose of the daily treatment, containing indistinguishable plastic vials of NETILDEX™ eye drops solution. Tertiary packaging (patient's treatment supply) will be a carton box appropriately labeled, containing 16 secondary packages (aluminum envelopes - each envelope containing 5 vials for each treatment time dose), containing enough plastic vials to allow the patient to complete the whole study treatment.|Two treatment arms, test group versus active-comparator (control) group, treated in parallel.|t|t|t|f
33683083|NCT00509262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773845|NCT06566313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773846|NCT00555789|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773847|NCT06284070|||CASE_ONLY||PROSPECTIVE|||||||
33773848|NCT06740032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773849|NCT06053814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773850|NCT06739811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773851|NCT03368924|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903046|NCT05174689|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The micro RNA profile of patients with known EIA and house dust mite allergy and patients with EIA without allergic sensitization are compared to the micro RNA profile of healthy controls||||
33903047|NCT01512368|NA|SINGLE_GROUP||||NONE||||||
33903048|NCT00492401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903049|NCT06494904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is a multi-site double-blind, double-dummy randomized clinical trial. Only the DSC staff overseeing the random assignment schedule, a few designated CCC staff, and the central research staff preparing the study medication will be unblinded; all other study personnel and participants will remain blinded to treatment arm until the nationwide completion of the trial and the database is formally locked. Detailed information on the study procedures regarding the double-blinding will be contained in a standalone Blinding Management Plan and Study Site Blinding Plan. A DSMB will review study data throughout the course of the trial in a blinded fashion (e.g., masked treatment assignments), however they can request to be unblinded at any time.||t|t|t|f
33903050|NCT01731691|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33903051|NCT02760407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903052|NCT00751101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986287|NCT03680248|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||10 non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) and 10 non-obese non-diabetic subjects with increased hepatic fat content (more than 5% of hepatic fat) will undergo series of six experiments - changes of liver fat content will be measured at time 0, 3 and 6 hours after specific dietary interventions||||
33986288|NCT03585790|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33986289|NCT02452164|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33986290|NCT05013372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986291|NCT02495415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986292|NCT03388671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The data collection personnel and the patients' guardians will be blinded to the group assignment.|The aim of this study will be to investigate the safety and analgesic efficacy of Transversus Abdominis Plane (TAB) Block versus psoas blocks. Both blocks will be administered surgically and guided by the laparoscopy screen in children undergoing laparoscopic surgery.|t|f|f|t
33986293|NCT03666728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986294|NCT03682341|||CASE_CONTROL||PROSPECTIVE|||||||
33986295|NCT02994810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986296|NCT02608788|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33986297|NCT01683682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986298|NCT05710562|||OTHER||CROSS_SECTIONAL|||||||
33986299|NCT00648947|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33986300|NCT06370507|||CASE_CROSSOVER||PROSPECTIVE|||||||
33986301|NCT06471985|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33683084|NCT01463137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683085|NCT03643471|||CASE_CONTROL||PROSPECTIVE|||||||
33683086|NCT04372056|||COHORT||PROSPECTIVE|||||||
33683087|NCT02009384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683088|NCT03048136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683089|NCT00806013|||CASE_CONTROL||PROSPECTIVE|||||||
33773852|NCT06015880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773853|NCT00545142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773854|NCT06737796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773855|NCT02373696|||COHORT||PROSPECTIVE|||||||
33773856|NCT05753748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773857|NCT06350084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33773858|NCT00439179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773859|NCT06740123|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 30 patients, including 15 systemically healthy patients older than 18 years of age, with Stage 2 periodontitis and periodontal/peri-implant pockets between 5-8 mm on the contralateral side, who applied to Kütahya Health Sciences University, Faculty of Dentistry, Department of Periodontology, will be included in the study. Patients with periodontal/peri-implant pockets will be evaluated in a total of four groups after non-surgical periodontal treatment, two different groups, one side of the patients will be the test group and the other side will be the control group. All patients will be randomly allocated to the study groups using the sealed envelope method.|t|f|f|t
33903053|NCT05827146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986302|NCT03945422|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive the treatment and outcome will be followed||||
33986303|NCT02548234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986304|NCT01705301|||COHORT||PROSPECTIVE|||||||
33986305|NCT02621996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986306|NCT03079466|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34080530|NCT03854578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080531|NCT01455870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080532|NCT03904823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080533|NCT06279078|||COHORT||RETROSPECTIVE|||||||
34080534|NCT02603198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080535|NCT01198652|||CASE_ONLY||RETROSPECTIVE|||||||
34080536|NCT06404437|||OTHER||PROSPECTIVE|||||||
33773860|NCT05830266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080537|NCT02505958|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33986307|NCT01413581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080538|NCT01798563|||CASE_CONTROL||PROSPECTIVE|||||||
34080539|NCT01739140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683090|NCT00196183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683091|NCT01910077|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683092|NCT00253708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The study was designed to assess the feasibility and effectiveness of massage for patients with cancer-related pain|f|f|t|t
33683093|NCT02856191|NA|SINGLE_GROUP||||NONE||||||
33683094|NCT00706498|NA|SINGLE_GROUP||TREATMENT||||||||
33773861|NCT03528928|NA|SEQUENTIAL||OTHER||NONE|The patient was not allowed to see the ultrasound screen|Surface electrical stimulation, Elitone by Elidah, Inc.||||
33773862|NCT01784913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773863|NCT05832229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The drug manufacturer and bottler will be unblinded, as will a few members of the Scientific and Data Coordinating Center. All other study team members will remain blinded.|This study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial, of 20mg (or 10mg for participants of East Asian ancestry) of rosuvastatin by mouth, once daily. Participants will be randomized (1:1) to either once daily placebo or once daily rosuvastatin.|t|t|t|t
33773864|NCT03713255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (participant, care provider, investigator, outcomes assessor)|Prospective, randomized, quadruple-blinded, three arm parallel group clinical trial.|t|t|t|t
33986308|NCT03864575|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's two-stage Minimax design||||
33986309|NCT00837486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986310|NCT04468503|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33986311|NCT01773330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986312|NCT01439880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986313|NCT04101591|||COHORT||PROSPECTIVE|||||||
33986314|NCT03790345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Proof of concept 12-week prospective, randomized, double-blind, controlled trial|t|t|t|t
33986315|NCT04825808|||COHORT||RETROSPECTIVE|||||||
33986316|NCT01209390|||COHORT||PROSPECTIVE|||||||
33986317|NCT03281460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986318|NCT00437853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986319|NCT05562518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986320|NCT00355797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986321|NCT05000658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986322|NCT00609960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33986323|NCT03912337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986324|NCT03961425|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Clinical Outcomes are assessed by ICU physicians and the intraoperative strategy is not disclosed|Random allocation in 1:1:1 to either NO CO2, CO2 with non specific cannula, CO2 with dedicated diffuser|f|f|f|t
33986325|NCT03462524|||COHORT||RETROSPECTIVE|||||||
33986326|NCT02625077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080540|NCT05846750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080541|NCT01836068|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080542|NCT00918372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33683095|NCT02781740|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33683096|NCT00704275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683097|NCT03605953|||COHORT||PROSPECTIVE|||||||
33683098|NCT04065165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683099|NCT03869801|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33773865|NCT03875911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986327|NCT02120547|NON_RANDOMIZED|PARALLEL||||NONE||||||
33986328|NCT00812162|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683100|NCT05679843|||COHORT||RETROSPECTIVE|||||||
33986329|NCT03194139|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33986330|NCT05396859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986331|NCT05107323|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33986332|NCT03562091|||COHORT||PROSPECTIVE|||||||
33986333|NCT03105141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33986334|NCT03232294|||COHORT||PROSPECTIVE|||||||
34080543|NCT01100502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080544|NCT01738100|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34080545|NCT04346953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33683101|NCT03470532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33683102|NCT03415776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080546|NCT03687983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080547|NCT03042845|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080548|NCT06138197|||COHORT||PROSPECTIVE|||||||
34080549|NCT05181371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080550|NCT00413023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34080551|NCT01418339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080552|NCT06138210|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34080553|NCT01019161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080554|NCT06282991|||CASE_ONLY||OTHER|||||||
34080555|NCT03037515|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080556|NCT04217291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080557|NCT00125450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080558|NCT02207062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080559|NCT03481452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986335|NCT03544411|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This study was a clinical trial with cross over study design, random allocation, and double blindness to compare changes in antioxidant, glucose, cholesterol and triglyceride levels supplemented with 15 ml / day of olive oil (KZ) with supplementation of 15 ml / day of bran oil (KB). Provision of oil for 4 weeks in a row. During the 2-week interval not being treated (wash out). After the wash out period cross-over by exchanging olive oil supplementation to rice bran and vice versa for 4 consecutive weeks.|t|t|t|t
33986336|NCT00887263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986337|NCT03886935|||CASE_CONTROL||PROSPECTIVE|||||||
33986338|NCT01372033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986339|NCT01114815|||CASE_ONLY||RETROSPECTIVE|||||||
33986340|NCT03287310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multi-center, double-blind study in which subjects will be allocated to five cohorts. The subjects in each cohort will be randomized to receive GSK3511294 and placebo in a ratio of 3:1. In each cohort, dosing will be staggered: one subject will receive GSK3511294 and one subject will receive placebo at least 72 hours before the remaining subjects in that cohort are dosed. The remaining subjects will be dosed if the review of all safety data up to 72 hours after dosing of the first two subjects in each cohort is satisfactory.|t|f|t|f
33986341|NCT06233747|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped wedge pilot study, in which 2 hospitals will be randomized to begin implementation of I-CARE at 2 different times within the 17-month study period. Both sites begin with an initial 3-month period of treatment-as-usual and the research team collects all outcome measures during this period, then 1 hospital will crossover to launch the I-CARE intervention and the other will launch 2 months later (continuing to provide treatment-as-usual in the interim). This may be considered a form of a parallel cluster study, in which one of the two hospitals is initially randomized to I-CARE while the other remains in the baseline/treatment-as-usual state.||||
33986342|NCT04342559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, non-comparative clinical study.||||
33986343|NCT05218772|||OTHER||CROSS_SECTIONAL|||||||
33986344|NCT06510634|||COHORT||PROSPECTIVE|||||||
34080560|NCT01195779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080561|NCT01256528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080562|NCT04125069|||COHORT||PROSPECTIVE|||||||
34080563|NCT01746719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080564|NCT06424808|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33683103|NCT05982067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the character of the intervention and control group in this study (the mindfulness-based PE vs health education), it is impossible to blind participants. The interventionist (the qualified mindfulness instructor and sport coach) is also unrealizable to be blinded. To reduce the allocation bias as much as possible, the following personnel will be blinded: the research assistants who are responsible for the participants recruitment, the research assistants who perform the randomization and the assessor who collect data.||f|f|t|t
33683104|NCT02831907|||COHORT||PROSPECTIVE|||||||
33683105|NCT00791973|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33683106|NCT03126552|NA|SINGLE_GROUP||OTHER||NONE||||||
33773866|NCT05539690|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33773867|NCT06738680|||CASE_ONLY||PROSPECTIVE|||||||
33903054|NCT05360615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903055|NCT00003210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903056|NCT04239235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be told which condition they are in.|Two-arm RCT where participants are randomly assigned to intervention or control.||||
33903057|NCT05253352|||COHORT||PROSPECTIVE|||||||
33903058|NCT01852864|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903059|NCT00164424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33903060|NCT06567106|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and outcomes assessors are blinded to the experimental condition.|Each participant is randomly assigned to receive either ultrasound intervention at varying intensities or sham control.|t|f|f|t
33903061|NCT04829643|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903062|NCT02983981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903063|NCT06343207|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||A Randomized Controlled Trial|f|f|t|f
33903064|NCT02740153|||COHORT||PROSPECTIVE|||||||
33903065|NCT06007430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903066|NCT01654562|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33903067|NCT04990544|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33903068|NCT00911664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903069|NCT04761497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903070|NCT03474718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Second offsite investigator will assess the patient for clinical improvement and will be unaware of the patient's randomization assignment.||t|f|t|f
33903071|NCT01236222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33903072|NCT05062317|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903073|NCT04652687|||CASE_ONLY||PROSPECTIVE|||||||
33903074|NCT04311476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33903075|NCT00299884|||CASE_CROSSOVER||PROSPECTIVE|||||||
33903076|NCT02199522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903077|NCT03330743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903078|NCT06591819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903079|NCT00751881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903080|NCT00546819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33903081|NCT04632329|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||f|t|f|t
33903082|NCT00777465|||COHORT||PROSPECTIVE|||||||
33903083|NCT01461577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903084|NCT01257126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903085|NCT01832311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903086|NCT04670146|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903087|NCT06513325|||COHORT||PROSPECTIVE|||||||
33903088|NCT02163408|||COHORT||PROSPECTIVE|||||||
33903089|NCT02963077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080565|NCT02147171|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683107|NCT02192840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683108|NCT00991952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683109|NCT05198375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683110|NCT03011892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683111|NCT03253471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773868|NCT06740279|||COHORT||PROSPECTIVE|||||||
33773869|NCT04687631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773870|NCT06255236|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773871|NCT03855878|||COHORT||PROSPECTIVE|||||||
33773872|NCT06608966|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The PI of the study is masked to treatment condition. Outcome assessors for the NIH toolbox measure will also be masked.|The proposed study will involve a multi-center randomized controlled clinical trial using a factorial design to simultaneously assess the impact of two behavioral treatment components: 1) Epilepsy Journey web-based modules and 2) Epilepsy Journey telehealth sessions with a therapist.There are four treatment arms for the current study, including 1) Epilepsy Journey web-based modules, 2) Epilepsy Journey web-based modules and telehealth with a therapist, 3) Telehealth with a therapist, and 4) Treatment as Usual.|f|f|t|t
33773873|NCT03133663|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773874|NCT01969162|||COHORT||PROSPECTIVE|||||||
33773875|NCT06739044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773876|NCT03638687|||COHORT||PROSPECTIVE|||||||
33773877|NCT06259162|NA|SINGLE_GROUP||SCREENING||NONE||||||
33773878|NCT06727539|||CASE_CONTROL||RETROSPECTIVE|||||||
33773879|NCT06739707|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Study medication will be supplied in labelled vials,clearly identifying the contents and indicating that the product is an investigational drug. An unblinding pharmacist at the clinical site will be responsible for the appropriate amount of vials to be dispnsed to each subject according to the randomization scheme. A blinded nurse will draw the correct amount of study medication into a syringe based on the subject's assigned arm, and administer the injection to the subject.|"Dosing will be in 7 dose cohorts. Cohorts 1 through 6 will be comprised of six subjects in each cohort using 4:2 (active: placebo) randomization. Thus, there will be four subjects receiving drug and two receiving placebo in each cohort. Cohort 7 will comprise 18 Obese subjects, in which 12 subjects will receive MD-18 and six will receive placebo. A total of 54 subjects will be enrolled in this study, with 36 receiving MD-18 and 18 receiving placebo. There is no need to wait for the completion of one cohort (Day 28) before proceeding to the next. Once all subjects for Cohort 1 have been recruited, the site should begin recruitment for Cohort 2, even while Cohort 1 is still ongoing. This process should continue for subsequent cohorts.~The highest dose that is safe and tolerable in all subjects will be determined as the Maximum Tolerable Dose ."|t|f|t|f
33773880|NCT03927768|||COHORT||PROSPECTIVE|||||||
33773881|NCT00925340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773882|NCT04052022|||CASE_CONTROL||PROSPECTIVE|||||||
33773883|NCT05616871|||COHORT||PROSPECTIVE|||||||
33773884|NCT06740617|||OTHER||CROSS_SECTIONAL|||||||
33773885|NCT06740357|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33773886|NCT01544114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773887|NCT06740578|||COHORT||PROSPECTIVE|||||||
33773888|NCT02862847|||CASE_CONTROL||PROSPECTIVE|||||||
33773889|NCT06292546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773890|NCT06739694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773891|NCT04821141|RANDOMIZED|PARALLEL||PREVENTION||NONE|Only designated biostatistician is aware of randomization assignment until after a subject is enrolled and assigned, Then assignment is unblinded and agents are open-label.|Randomization to immediate 6 months of BZA+CE versus wait list for 6 months followed by option to receive 6 months of BZA+CE.||||
33773892|NCT06739668|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE||Randomization, 2:1, Active to Sham|t|t|t|t
33773893|NCT00604786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33773894|NCT01281553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773895|NCT03869060|NA|SINGLE_GROUP||OTHER||NONE||||||
33773896|NCT06134362|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33773897|NCT06029530|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|De-identified bottles will be sent to the sites with randomization codes. The key will be kept at the data coordinating center.|Participants will receive one of three concentrations of atropine (0.01%, 0.03%, or 0.05%)|t|t|t|t
33773898|NCT03981536|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33773899|NCT06737666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773900|NCT03728192|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study comprised of two groups A (Hela) and group B ( H357) . Each group was further subdivided into 3 subgroups- A1 -Untreated cells, A2- mangosteen treated cells and A3- cells treated with standard drug. Group B was divided into B1- Untreated cells, B2- mangosteen treated cells and B3 -cells treated with the standard drug healthy periodontium. Test group: (Chronic periodontitis patients) comprised of 25 participants with signs of clinical inflammation and bone los||||
33773901|NCT05524675|||COHORT||PROSPECTIVE|||||||
33773902|NCT02250495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773903|NCT01727518|||COHORT||PROSPECTIVE|||||||
33773904|NCT01843075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773905|NCT00355017|RANDOMIZED|PARALLEL||||NONE||||||
33903090|NCT05164276|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33903091|NCT03472534|NA|SINGLE_GROUP||OTHER||NONE||Cumulative irritancy patch test (CIPT) procedure. All subjects received once daily applications of 0.2mL of diacerein 1% ointment under occlusive patch for 21 days.||||
33683112|NCT00128323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683113|NCT02866851|NA|SINGLE_GROUP||OTHER||NONE||||||
33683114|NCT04695613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986345|NCT04133623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double dummy||t|t|t|f
33986346|NCT03988803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986347|NCT04860804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683115|NCT00965198|||CASE_CROSSOVER||PROSPECTIVE|||||||
33683116|NCT05610189|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683117|NCT03657303|||CASE_CONTROL||PROSPECTIVE|||||||
33683118|NCT02339220|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33986348|NCT04630327|||CASE_ONLY||PROSPECTIVE|||||||
34080566|NCT01320397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903092|NCT04879446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The group in which the patients were included was determined by pulling the closed envelope just before the surgery. Test side was determined by tossing a coin after the implant cavities were prepared but before the implants were placed. The examiners who carried out the measurements and analyzes were unaware of the study and the groups.|This is a split-mouth design study. This study evaluating the effects of advanced platelet-rich fibrin and concentrated growth factor liquids on dental implant osseointegration was planned as a randomized, clinical controlled and prospective study. A total of 32 patients included in our study were divided into two groups of 16. It was planned to apply 2 implants to each patient and to evaluate each patient as one side as the control and the other as the study group. In other words, while there was a study group and a control group in the CGF group, there was also a study group and a control group in the A-PRF group. The implants were placed symmetrically to the right and left of the midline by the same physician provided that they were in the same jaw.|t|t|t|t
33986349|NCT04370769|||COHORT||CROSS_SECTIONAL|||||||
33986350|NCT02188953|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33986351|NCT01624363|||CASE_ONLY||PROSPECTIVE|||||||
33986352|NCT05608447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33986353|NCT04181905|||OTHER||CROSS_SECTIONAL|||||||
33986354|NCT02276339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986355|NCT06037772|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Informed consent form was obtained from the participants|pretest-posttest, randomized controlled experimental design with experimental and control groups|t|f|t|f
33986356|NCT04197765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024871|NCT04839484|RANDOMIZED|PARALLEL||OTHER||SINGLE|A blinded evaluator at each site who does not know what patient was treated with what product (per side) scores the patient. Photographic reviewers are also blinded to treatment.|Parallel assignment to product to different sides of face, per randomization code. At 12 months subjects may be retreated only with study product (partial cross over potential)|f|f|f|t
34080567|NCT05146752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903093|NCT00644319|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34080568|NCT02101762|||COHORT||PROSPECTIVE|||||||
33903094|NCT05582122|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33903095|NCT00380484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903096|NCT01943279|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33903097|NCT00987051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903098|NCT02712684|||COHORT||PROSPECTIVE|||||||
33903099|NCT00195559|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33903100|NCT02039271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903101|NCT02231216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903102|NCT00562510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33903103|NCT05090540|||COHORT||PROSPECTIVE|||||||
33903104|NCT05844527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903105|NCT02279329|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903106|NCT01123447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903107|NCT00003369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903108|NCT04346823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903109|NCT00000579||FACTORIAL||TREATMENT||||||||
34024872|NCT02826512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024873|NCT03749486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024874|NCT04605874|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be informed that they will be supplied with study cigarillos, but will be unaware of their randomization condition, 2 cigarillos per pack versus 4 cigarillos per pack.|This project will recruit current cigarillo users to a 20-day, randomized, parallel design protocol. After a 5-day period of smoking their own preferred brand of cigarillos, participants will begin a 15-day experimental period when they will be randomized to one of two conditions, 2 cigarillos per pack versus 4 cigarillos per pack, to examine how quantity per pack affects use patterns, including daily consumption and cigar smoking topography.|t|f|f|f
34024875|NCT02565537|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024876|NCT06376851|||COHORT||CROSS_SECTIONAL|||||||
34024877|NCT00002070||||TREATMENT||||||||
34024878|NCT06410235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34024879|NCT05856630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024880|NCT00383305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024881|NCT03214393|||COHORT||PROSPECTIVE|||||||
34024882|NCT02304133|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34024883|NCT05939583|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34024884|NCT02213289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024885|NCT02602600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024886|NCT00850863|||CASE_CONTROL||PROSPECTIVE|||||||
34024887|NCT00195338|||COHORT||PROSPECTIVE|||||||
34024888|NCT02709291|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34024889|NCT06549712|NA|SINGLE_GROUP||OTHER||NONE||||||
34024890|NCT00351884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024891|NCT01593943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024892|NCT02076490|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34024893|NCT06633198|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024894|NCT02695173|||COHORT||RETROSPECTIVE|||||||
34024895|NCT06498635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024896|NCT03609320|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This single-arm study embedded within a 2-arm cluster RCT will test the difference in the rate of missed opportunities pre- and post-implementation of a 3-component intervention including communication skills, performance feedback, and prompts. These three interventions will be implemented together in practices that previously received standard of care.||||
34024897|NCT04808219|||CASE_ONLY||PROSPECTIVE|||||||
34024898|NCT03915418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024899|NCT02518672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024900|NCT01140399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986357|NCT03696394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single-blinded. Group I and II subjects will be blinded as to whether they have received BioCartilage® in addition to Microfracture or Microfracture alone, as per standard of care. Investigators will be aware of the assigned treatment on the patients. Subjects will be aware of their assigned treatment after their surgery.|Participants are assigned to one of two groups. Group I consists of 5 patients receiving Microfracture as per standard of care (Control Group). Group II consists of 10 patients receiving Microfracture with BioCartilage® (Investigational Group).|t|f|f|f
33986358|NCT01633450|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33986359|NCT04546282|||CASE_CONTROL||RETROSPECTIVE|||||||
33986360|NCT03212573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Nurse evaluating postoperative pain is blinded to the protocol applied||f|f|f|t
33986361|NCT05396963|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants are instructed not to disclose the supplement they are taking to their trainers, investigator, or outcome assessor.||f|t|t|t
33986362|NCT00603187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986363|NCT00007722|||CASE_ONLY||PROSPECTIVE|||||||
33986364|NCT01935076|||COHORT||PROSPECTIVE|||||||
33986365|NCT02350647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080569|NCT00215917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34080570|NCT03814863|||OTHER||PROSPECTIVE|||||||
34080571|NCT06122350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The research was planned as a cross section (pre-test post-test, experimental and control group) randomized controlled study.|t|f|f|t
34080572|NCT03874793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician will not know the group assignment until blind is broken. Statistician randomizes the groups. Principal investigator will not know group assignment until blind is broken.|treatment groups will consist of a minimum of 4 participants (preferably 5-8). The statistician will randomize the groups once a sufficient number of participants have enrolled to ensure desired group size.|f|f|t|t
34080573|NCT06144515|||COHORT||PROSPECTIVE|||||||
34080574|NCT01348126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080575|NCT04587817|||CASE_ONLY||PROSPECTIVE|||||||
34080576|NCT06051877|||COHORT||PROSPECTIVE|||||||
34080577|NCT03767842|||COHORT||PROSPECTIVE|||||||
33683119|NCT06284629|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and physicians will be blinded to device and app data in the control group. Blinding of the group allocation is not possible due to the investigated device.|||||
33683120|NCT00401388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One treatment arm: Perifosine. Three groups related to sarcoma subtype: histologically or cytologically confirmed diagnosis of (a) chondrosarcoma, (b) alveolar soft part sarcoma and (c) extra-skeletal myxoid chondrosarcoma.||||
33683121|NCT04869748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single blind randomized controlled trial study|f|f|f|t
33683122|NCT00455832|||COHORT||PROSPECTIVE|||||||
33683123|NCT06000267|||OTHER||PROSPECTIVE|||||||
33903110|NCT03061968|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33903111|NCT04354753|||CASE_ONLY||RETROSPECTIVE|||||||
33903112|NCT01713400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903113|NCT06173492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903114|NCT05113823|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33903115|NCT06043310|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33903116|NCT04337138|||COHORT||RETROSPECTIVE|||||||
33903117|NCT04981340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903118|NCT05819632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903119|NCT01950078|||||PROSPECTIVE|||||||
33903120|NCT06237842|||COHORT||CROSS_SECTIONAL|||||||
33903121|NCT05301049|||COHORT||RETROSPECTIVE|||||||
33903122|NCT03464097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903123|NCT00224107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903124|NCT05078567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903125|NCT01810159|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|We used an R software random number generator to randomly assign eligible participants to either CC or usual care. We used a concealed randomization protocol where neither participant nor researcher (outside of the statistician doing the randomization) was aware of the randomization until after the baseline interview. None of the participants or providers was blinded to treatment allocation after randomization. Interviewers were blinded to treatment allocation||f|f|f|t
33903126|NCT03570229|||CASE_ONLY||PROSPECTIVE|||||||
33903127|NCT05347914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903128|NCT02573805|||CASE_CONTROL||PROSPECTIVE|||||||
33903129|NCT01508078|||OTHER||CROSS_SECTIONAL|||||||
33903130|NCT04364672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903131|NCT04905914|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose escalation design||||
34080578|NCT02280330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34080579|NCT06114680|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080580|NCT06420531|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34080581|NCT01611675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903132|NCT01176851|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903133|NCT01544595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986366|NCT05223894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903134|NCT00186238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903135|NCT00784251|||CASE_ONLY||PROSPECTIVE|||||||
33903136|NCT03074175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903137|NCT04016363|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986367|NCT01814930|RANDOMIZED|PARALLEL||||NONE||||||
33986368|NCT04711980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683124|NCT06246942|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will not be informed of the asynchrony value for each visit. The order of asynchronies is randomized.|PAS will be applied to two cortical targets at a minimum of 3 different asynchronies to modulate connectivity. PAS may selectively increase or decrease effective connectivity depending on the asynchrony. Negative asynchronies are expected to decrease effective connectivity, whereas positive asynchronies to increase it. All participants will be stimulated with all 3 asynchronies (on different visits).||||
33683125|NCT05408793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind. Participants and interventionists will be blinded to the random allocation to either the verum TPS group or the sham TPS group.|This is a randomized, double-blinded, sham-controlled trial.|t|f|t|f
33683126|NCT03348592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a 28 week study. Participants take no treatment for 8 weeks, followed by 12 weeks on the pre-biotic p-inulin, followed by no treatment for 8 weeks. The treatment arms are no treatment and the pre-biotic p-inulin. Inulin is derived from chicory root fiber.||||
33683127|NCT06082401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683128|NCT02648633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683129|NCT01850927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683130|NCT02663726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683131|NCT00002543||||TREATMENT||||||||
33683132|NCT00345644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683133|NCT03878693|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33683134|NCT04457388|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683135|NCT00497042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683136|NCT00506636|||NATURAL_HISTORY||OTHER|||||||
33683137|NCT06300593|||COHORT||PROSPECTIVE|||||||
33683138|NCT01162798|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33903138|NCT05914272|||COHORT||PROSPECTIVE|||||||
33683139|NCT03448874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single blinded. The subject will be blinded to the treatment arm; however, by nature of the type of the proposed study, blinding of the investigator/ surgeon is not feasible. In order to minimize bias, subjects will be randomized during the surgery upon confirmation of the intra-operative exclusion criteria. This will ensure that the surgeon will not know prior to surgery and until completion of anastomosis creation, whether or not Seal-G MIST will be used.|Controlled, Randomized, single blind study|t|f|f|f
33683140|NCT05367375|||COHORT||PROSPECTIVE|||||||
33773906|NCT06422793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blinded from their treatment group to minimize placebo effect, although they may later recall NG tube presence/removal if they belong in the NG group. Surgeons and anesthesiologists will not be blinded, as the nature of the study is not conducive to a double-blinded method.|This is a prospective study for all patients undergoing orthognathic surgery who meet inclusion criteria. If they choose to enroll, they will be randomized into one of two study groups using a random treatment sequence determined on www.randomization.com. This randomization sequence is stratified with a 1:1 (No NG: NG in at beginning of surgery and removed in PACU) allocation using random block sizes of 6 to ensure balance among groups in 14 blocks. Participants will be sequentially assigned to the next protocol group listed by the random generator at the time of enrollment.|t|f|f|f
33773907|NCT06391229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773908|NCT06606886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773909|NCT06740721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773910|NCT05740475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773911|NCT00521872|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33773912|NCT03679013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773913|NCT06543914|||COHORT||PROSPECTIVE|||||||
33773914|NCT06741202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be allocated to either MMG or PCGT|Conduct a pilot randomized controlled trial with men MST survivors (n=32), randomized to the MMG or Present-Centered Group Therapy (PCGT; control condition) (four cohorts: 2 experimental, 2 control). Investigate engagement (session attendance) as well as recovery-oriented outcomes (agency, hope, belongingness, shame-reduction) and psychological symptoms (PTSD, MDD, suicidality) assessed at pre-, immediate post-, and 6-month post-intervention.|t|f|f|f
33773915|NCT01274130|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33903139|NCT01264991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33903140|NCT00991627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903141|NCT01563588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903142|NCT06523777|||COHORT||PROSPECTIVE|||||||
33903143|NCT06275165|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Participants were divided into an experimental group and a control group. experimental group: received acupressure for 5 days in addition to regular care.~control group: received regular postoperative care."|f|f|f|t
33903144|NCT03777956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903145|NCT05938881|||COHORT||PROSPECTIVE|||||||
33903146|NCT04462848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903147|NCT06673186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986369|NCT01517854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986370|NCT00488800|||||PROSPECTIVE|||||||
33986371|NCT05279040|||CASE_ONLY||PROSPECTIVE|||||||
33986372|NCT03983486|||CASE_ONLY||OTHER|||||||
33986373|NCT02979522|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986374|NCT04591717|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986375|NCT02054845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986376|NCT03067753|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986377|NCT02883413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986378|NCT01666899|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33986379|NCT05023044|||COHORT||PROSPECTIVE|||||||
33986380|NCT02973685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986381|NCT06144918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986382|NCT06388122|||COHORT||PROSPECTIVE|||||||
33986383|NCT05855577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigators that visit the patient and perform Gait Analysis are Blind|25 M-PD (H\&Y\< 2.5) and 25 S-PD (H\&Y \> 2.5) patients with idiopathic PD will be enrolled sequentially in the randomized double-blind, double-dummy study.|t|f|t|f
33986384|NCT00946374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33773916|NCT05694715|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33773917|NCT05638880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773918|NCT01191684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683141|NCT04322370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Occupational hand therapists will be blinded to the use of VersaWrap.||f|t|f|f
33773919|NCT06736756|||CASE_ONLY||CROSS_SECTIONAL|||||||
33773920|NCT01722916|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33773921|NCT02787720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33903148|NCT05144295|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients assigned to lubiprostone will receive a dose based on their weight at the time of enrollment. patients weighing \<50 kg and ≥ 50 kg will be given lubiprostone at doses of 8 mg TID and 24 mg BID, respectively.~Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and large volume of fluid.~The control group will receive the conventional therapy (lactulose 1 mL/kg, once or twice daily (maximum 60 mL/day), or Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years.~Both arms will receive the treatment for 12 weeks followed by 4 weeks follow-up after the end of treatment (week 16)."||||
33683142|NCT04313647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||MSCs-exosomes||||
33683143|NCT05973149|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33683144|NCT02398149|||COHORT||CROSS_SECTIONAL|||||||
33683145|NCT04097782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33683146|NCT03523169|||COHORT||PROSPECTIVE|||||||
33683147|NCT04514354|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33683148|NCT01144130|||||PROSPECTIVE|||||||
33683149|NCT01227629|RANDOMIZED|PARALLEL||PREVENTION||||||||
33683150|NCT01445548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773922|NCT03241043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903149|NCT02989077|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33903150|NCT02796404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903151|NCT03344497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33903152|NCT00909285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903153|NCT01823796|||CASE_CONTROL||PROSPECTIVE|||||||
33903154|NCT04599816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33903155|NCT01541592|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33903156|NCT00615706|||||CROSS_SECTIONAL|||||||
33903157|NCT02980835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903158|NCT04790006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683151|NCT03613272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective multicentre cohort study.The main study content is comparative study of the curative effect of extended thymectomy performed through the subxiphoid-right video-thoracoscopic approach with double elevation of the sternum versus intercostal video-thoracoscopic approach, divided into subxiphoid and intercostal groups. Communicating with the surgeon and patients who meet the inclusion criteria, decide whether to enter the subxiphoid or intercostal group. Subxiphoid group with subxiphoid-right video-thoracoscopic approach under double elevation of the sternum in extended thymectomy , intercostal group with traditional intercostal video-assisted thoracoscopic surgery in extended thymectomy.||||
33683152|NCT01447212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903159|NCT01475292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903160|NCT04795804|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33903161|NCT06497647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903162|NCT01361529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903163|NCT05468086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903164|NCT06672965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33903165|NCT03991624|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33903166|NCT02093975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903167|NCT04281212|||COHORT||PROSPECTIVE|||||||
33903168|NCT03698240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903169|NCT01073592|||COHORT||PROSPECTIVE|||||||
33903170|NCT00049413||||TREATMENT||NONE||||||
33903171|NCT05121597|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single blinded||t|f|f|t
33903172|NCT01968044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903173|NCT05111834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903174|NCT03717324|||COHORT||PROSPECTIVE|||||||
33903175|NCT03253198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903176|NCT01825044|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33903177|NCT05553379|||OTHER||OTHER|||||||
33986385|NCT04805411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986386|NCT02284750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683153|NCT03971877|||CASE_ONLY||CROSS_SECTIONAL|||||||
33683154|NCT00997113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683155|NCT04976270|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33683156|NCT00970775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33773923|NCT04765865|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33773924|NCT05967130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773925|NCT02826304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773926|NCT05899543|||CASE_CROSSOVER||PROSPECTIVE|||||||
33773927|NCT00259493|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33773928|NCT02818075|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33986387|NCT03649594|||COHORT||PROSPECTIVE|||||||
33986388|NCT05203562|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33986389|NCT01184183|||COHORT||PROSPECTIVE|||||||
33986390|NCT04295122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986391|NCT03086473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participant and participant's parents, medical care providers, and investigators will remain masked to the randomization.|Each participant is assigned to one of two arms of the study.|t|t|t|f
33986392|NCT05812781|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986393|NCT01464112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683157|NCT04280809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33773929|NCT02640651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683158|NCT03133962|NA|SINGLE_GROUP||OTHER||NONE||||||
33683159|NCT03206996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-subjects design (baseline, treatment and follow-up)||||
33683160|NCT00933413|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33683161|NCT02975583|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33773930|NCT06738303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773931|NCT02895490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903178|NCT01300780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33986394|NCT02146118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683162|NCT04011371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683163|NCT01913587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683164|NCT03277820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Investigator does not know which subjects administered probiotics||f|f|t|f
33683165|NCT04269382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683166|NCT01098669|||COHORT||CROSS_SECTIONAL|||||||
33683167|NCT01931215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|pharmacy providing identical sets of study drugs and placebo, computerized random sequence generation, sequence held by the pharmacy until study completion|treatment versus placebo|t|t|t|t
33683168|NCT02487342|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33683169|NCT00869778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683170|NCT05425316|||CASE_CONTROL||PROSPECTIVE|||||||
33683171|NCT04572555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33683172|NCT01129583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683173|NCT02298335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683174|NCT05387499|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33903179|NCT03746574|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to intervention or control occuring at the level of clinic. All participants within a clinic are assigned to same group||||
33903180|NCT01873664|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903181|NCT00001056||||PREVENTION||DOUBLE||||||
33903182|NCT00611793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903183|NCT05914311|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33903184|NCT04736524|||COHORT||PROSPECTIVE|||||||
33903185|NCT02457897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903186|NCT01187420|||COHORT||PROSPECTIVE|||||||
33903187|NCT06272253|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903188|NCT01283581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903189|NCT00184405|||COHORT||PROSPECTIVE|||||||
33903190|NCT06111573|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33903191|NCT01764503|||||PROSPECTIVE|||||||
33903192|NCT05061888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903193|NCT01380405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903194|NCT03115801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903195|NCT05547555|||COHORT||PROSPECTIVE|||||||
33903196|NCT04277572|||OTHER||PROSPECTIVE|||||||
33903197|NCT06342297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903198|NCT04283032|||CASE_CONTROL||PROSPECTIVE|||||||
33903199|NCT01589198|||CASE_CONTROL||PROSPECTIVE|||||||
33903200|NCT05840289|||COHORT||RETROSPECTIVE|||||||
33903201|NCT02414321|||COHORT||CROSS_SECTIONAL|||||||
33903202|NCT01008930|NA|SINGLE_GROUP||SCREENING||NONE||||||
33903203|NCT01455571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903204|NCT04461847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903205|NCT03080922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903206|NCT05782218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33903207|NCT05477966|||COHORT||RETROSPECTIVE|||||||
33903208|NCT05606822|||COHORT||PROSPECTIVE|||||||
33903209|NCT04575662|NA|SINGLE_GROUP||TREATMENT||NONE||STAR treatment||||
33903210|NCT01142323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903211|NCT06286930|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33903212|NCT01918215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903213|NCT02050854|||COHORT||CROSS_SECTIONAL|||||||
33903214|NCT06298773|||COHORT||PROSPECTIVE|||||||
33903215|NCT01497418|||COHORT||OTHER|||||||
33986395|NCT02170506|NA|SINGLE_GROUP||||NONE||||||
33986396|NCT03834883|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33986397|NCT06441097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986398|NCT04398745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study.|||||
33986399|NCT02712086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080582|NCT04794257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both participants and outcomes assessor will be blinded to the respective group assignment.|A prospective, randomized study with 2 arms: i-IONM vs. NeveTrend mode (n=132 patients and 264 nerves at risk, each). Patients referred to the Department of Endocrine Surgery, Third Department of General Surgery, Jagiellonian University Medical College in Krakow, for first-time thyroid surgery from April 1, 2021 onwards will be registered. Eligible patients with either benign or malignant thyroid disease will be assessed for the study. The study will be approved by the Institutional Review Board (Bioethics Committee of the Jagiellonian University).|t|f|f|t
34080583|NCT01285843|RANDOMIZED|||TREATMENT||NONE||||||
34080584|NCT05324306|NA|SINGLE_GROUP||OTHER||NONE||||||
34080585|NCT05560503|||CASE_CONTROL||RETROSPECTIVE|||||||
34080586|NCT01719250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080587|NCT05558397|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group: oral route morphine Intervention group: epidural route morphine||||
34080588|NCT01143285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903216|NCT06151756|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A randomized controlled trial was designed. According to randomization in a computer environment of 200 students who meet the criteria for inclusion in the study, the intervention and control group were divided into two groups. This study was conducted in a university faculty of health sciences nursing department students with the aim of examining the impact of video mobile application-supported teaching utilized in nursing skills training on students' academic success, problem solving and critical thinking levels.||||
34080589|NCT02991391|||COHORT||PROSPECTIVE|||||||
34080590|NCT05747066|||COHORT||PROSPECTIVE|||||||
34080591|NCT04503317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34080592|NCT04091165|||CASE_ONLY||PROSPECTIVE|||||||
34080593|NCT05030844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding was provided that included inclusion criteria and agreement to participate in the study.|This study is a parallel group randomized controlled study|t|f|f|f
33683175|NCT00646932|NON_RANDOMIZED|PARALLEL||||NONE||||||
33683176|NCT03028337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903217|NCT00427388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903218|NCT03121352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986400|NCT04361786|||CASE_ONLY||PROSPECTIVE|||||||
33986401|NCT04309201|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33986402|NCT00111098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986403|NCT04881968|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|A physician's treatment assignment will be masked during analysis.|We will email the Uniform Resource Locator (URL) to download the App with encouragement to play the game, including positive feedback from participants in the efficacy study. Receipt of the email will be our measure of intervention delivery. Each hospitalist 'crosses over' from control to intervention at a single time point.|f|f|f|t
33986404|NCT05675735|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986405|NCT00269776|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33986406|NCT01844674|NA|SINGLE_GROUP||OTHER||NONE||||||
33986407|NCT03581435|||CASE_CONTROL||PROSPECTIVE|||||||
34080594|NCT00644761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080595|NCT03092752|||COHORT||RETROSPECTIVE|||||||
34080596|NCT04474340|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080597|NCT02873767|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34080598|NCT03472209|||CASE_CONTROL||PROSPECTIVE|||||||
34080599|NCT02976519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080600|NCT02267941|||CASE_CONTROL||RETROSPECTIVE|||||||
34080601|NCT02464124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080602|NCT02501824|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080603|NCT03242369|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080604|NCT02639871|||OTHER||PROSPECTIVE|||||||
34080605|NCT05116436|||FAMILY_BASED||OTHER|||||||
33683177|NCT03796845|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients submitted to surgery for breast cancer will be allocated into two groups: Intervention (upper limbs no-limited movement with amplitude above 90º for flexion and abduction of shoulder) and Control (upper limbs limited movement at maximum 90º amplitude flexion and abduction of shoulder, until withdrawal surgical points).||||
33903219|NCT04303585|||COHORT||PROSPECTIVE|||||||
33903220|NCT02377310|||COHORT||PROSPECTIVE|||||||
33903221|NCT02632058|||COHORT||RETROSPECTIVE|||||||
33903222|NCT01494961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903223|NCT00002826||||TREATMENT||||||||
33903224|NCT02461732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903225|NCT01735110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903226|NCT02772497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903227|NCT04258553|||CASE_CONTROL||PROSPECTIVE|||||||
33986408|NCT01912898|||COHORT||PROSPECTIVE|||||||
33986409|NCT03001063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986410|NCT04152174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080606|NCT04355364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Dornase alfa will be administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days, using a vibrating mesh nebulizer. The remainder of the management will be performed in accordance with good practice, including mechanical ventilation (protective ventilation, PEEP \> 5 cmH2O, tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure \< 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2\<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.tracheal balloon pressure checking every 4 hours or automatic device, 30° head of the bed elevation, tidal volume 6-8mL/kg, plateau pressure \< 30cmH2O), neuromuscular blockers if necessary, prone position if PaO2/FiO2\<150, early enteral nutrition, glycemic control, a sedation protocol based on the RASS score.|t|f|f|f
34080607|NCT05918536|||CASE_ONLY||PROSPECTIVE|||||||
34080608|NCT00344058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080609|NCT05676229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomised, triple-blind, placebo-controlled trial|t|t|t|t
34080610|NCT03113045|NA|SINGLE_GROUP||PREVENTION||NONE|The observer will not be made aware of the time that the patient will sit.|||||
34080611|NCT03017092|NA|SINGLE_GROUP||OTHER||NONE||||||
34080612|NCT01582113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080613|NCT04643132|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34080614|NCT04722107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080615|NCT05883696|||COHORT||CROSS_SECTIONAL|||||||
34080616|NCT01541709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080617|NCT00015613|||DEFINED_POPULATION||OTHER|||||||
33903228|NCT05217979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903229|NCT01312792|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33903230|NCT04838444|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903231|NCT04789746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903232|NCT05112523|||COHORT||PROSPECTIVE|||||||
33903233|NCT06232122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903234|NCT01636869|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903235|NCT04323709|||COHORT||RETROSPECTIVE|||||||
33903236|NCT01678807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903237|NCT03151525|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized parallel two-arm prospective open-label study||||
33903238|NCT06570954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers who conduct baseline and follow-up visits will be blinded to the condition to which the patient has been assigned. The statistician and data manger will be blinded to waiting period the patient got assigned to when analyzing data. The PI and therapists will be blinded to participant's baseline target scores.|Participants 19 years and older with PNES will be prospectively enrolled. Participants will be randomly assigned to one of three conditions: no wait, 3-month waiting period, 6-month waiting period after which they will receive 12 sessions of Retraining and Control Therapy (ReACT).|f|f|t|t
33903239|NCT00005029||||TREATMENT||||||||
33903240|NCT06250153|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33903241|NCT04344171|||COHORT||PROSPECTIVE|||||||
33903242|NCT01558089|||COHORT||PROSPECTIVE|||||||
33903243|NCT02492750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903244|NCT03465735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903245|NCT00428727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903246|NCT03468023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Non-inferiority trial aimed at comparing the non inferiority of a short arm cast (below elbow cast) as opposed to a long arm cast (below elbow cast) in terms of fracture reduction maintenance ratio.~The sample size was selected as the highest required to test all non-inferiority thresholds and considering a drop-out percentage of 15%. Continuous values of all radiological parameters were used in order to keep results objective and reproducible.~At the end of recruitment observed drop-out percentage was 26%."|f|f|t|t
33903247|NCT02844504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903248|NCT04864977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903249|NCT03267095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080618|NCT03663270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computer generated random list|Randomized two arm study with two groups|t|t|f|t
34080619|NCT05554016|||CASE_CONTROL||PROSPECTIVE|||||||
34080620|NCT02026999|||CASE_CONTROL||PROSPECTIVE|||||||
34080621|NCT05911217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080622|NCT06107114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080623|NCT00617552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080624|NCT02408848|||COHORT||PROSPECTIVE|||||||
34080625|NCT03017807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080626|NCT04500808|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34080627|NCT03209479|||COHORT||PROSPECTIVE|||||||
34080628|NCT03939104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate- mefloquine+piperaquine (AS-MQ+PPQ) and the ACTs artemether-lumefantrine+placebo (AL+PBO), artesunate-mefloquine+placebo (AS-MQ+PBO) (with single-low dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria to assess and compare their efficacy, safety, tolerability.|t|f|f|f
34080629|NCT01284894|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080630|NCT04654741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080631|NCT02062138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34080632|NCT00738712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080633|NCT03856138|||CASE_CONTROL||PROSPECTIVE|||||||
34080634|NCT02442596|||COHORT||PROSPECTIVE|||||||
34080635|NCT03619473|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34080636|NCT01618968|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903250|NCT00784784|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903251|NCT02021123|NA|SINGLE_GROUP||OTHER||NONE||||||
34080637|NCT00828711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080638|NCT04264572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|A computer-generated list of random numbers will be prepared in advance by the study biostatistician and loaded into a REDCap randomization tool to ensure the research staff are blinded to assignment pre-randomization. It is not feasible to blind participants and clinic staff to assignment post enrollment; however, HbA1c is an objective outcome, and as such lack of blinding should not be a significant limitation.|Enrolled patients with HbA1c\>8% will be randomized to 1 of 3 arms: 1) MTM; 2) MTM + tele- MNT; or 3) usual care in a 1:1:1 ratio using random permuted blocks stratified by HbA1c (\>8 to \<10 vs. \>10) and hospital discharge site (inpatient vs ED). The size of any particular block will be randomly selected and only known by the study biostatistician. This stratification approach was selected as investigators hypothesize that the interventions may have differential effects based on how poorly controlled an individual's DM is at baseline, as well as the degree of acute decompensation of the patient at time of enrollment.||||
34080639|NCT03817606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants will not know which posterior lumbar cage they receive.|Parallel randomized controlled trial|t|f|f|f
34080640|NCT05898035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This a randomized prospective clinical study|t|f|f|f
33903252|NCT06031467|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33903253|NCT01588574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903254|NCT01256619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903255|NCT01162369|||COHORT||PROSPECTIVE|||||||
33903256|NCT00005398|||COHORT||PROSPECTIVE|||||||
33903257|NCT00968578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33903258|NCT06598007|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903259|NCT01951482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903260|NCT06671340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903261|NCT05839990|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903262|NCT04897412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903263|NCT04382976|||COHORT||PROSPECTIVE|||||||
33903264|NCT00144105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903265|NCT01752517|||COHORT||PROSPECTIVE|||||||
33903266|NCT03141307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33903267|NCT06321484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903268|NCT03742492|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33903269|NCT02596347|||CASE_ONLY||CROSS_SECTIONAL|||||||
33903270|NCT03662334|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33903271|NCT01949493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903272|NCT01170377|||COHORT||PROSPECTIVE|||||||
33903273|NCT04818164|||COHORT||PROSPECTIVE|||||||
33903274|NCT05641376|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33903275|NCT02025972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903276|NCT06667557|||COHORT||PROSPECTIVE|||||||
33903277|NCT05283083|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking|An open label randomized controlled trial||||
33903278|NCT02778880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903279|NCT06172257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903280|NCT05257473|||COHORT||OTHER|||||||
33903281|NCT01114711|||COHORT||OTHER|||||||
33903282|NCT01369719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903283|NCT04523285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903284|NCT01116245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903285|NCT03754946|||COHORT||PROSPECTIVE|||||||
33903286|NCT06286852|||CASE_CONTROL||PROSPECTIVE|||||||
33903287|NCT01302769|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903288|NCT00772512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33903289|NCT02484573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903290|NCT05022992|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33903291|NCT01675921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33903292|NCT00929578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903293|NCT03303885|||OTHER||CROSS_SECTIONAL|||||||
33903294|NCT06378658|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33903295|NCT05707845|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Two groups pre-test post-test design.~* In this study the patients will be randomly assigned into two equal groups (20 patients for each group).~  (a) Group A: (control group):~* Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs). (b) Group B: (Study group):~* Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).~* Physical therapy program weight reduction by diet program in the form of caloric restriction, in combination to aerobic exercise in the form of using treadmill 30 minutes /3 times a week for 12 weeks."||||
33903296|NCT05035186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903297|NCT05895175|||OTHER||PROSPECTIVE|||||||
33903298|NCT00000581|RANDOMIZED|||PREVENTION||||||||
33903299|NCT01903239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903300|NCT02595060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903301|NCT06203678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33903302|NCT04110249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903303|NCT05106972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903304|NCT03415464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903305|NCT04495764|||COHORT||PROSPECTIVE|||||||
33903306|NCT00354549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903307|NCT01809990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903308|NCT01032785|||CASE_ONLY||PROSPECTIVE|||||||
33683178|NCT02310087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|no other masking|Eighty infertile men with OAT were randomly assigned to receive either daily 16 mg of astaxanthin and 40 mg of vitamin E in capsules or placebo. At baseline and after three months of treatment semen quality was assessed according to the WHO guidelines. The sperm concentration, motility and morphology were determined by standard microscopic analyses. Sperm DNA fragmentation was evaluated using a TUNEL assay . Mitochondrial membrane potential was measured by means of 3,3'-dihexyloxacarbocyanine iodide (DiOC6) staining as an indicator of mitochondrial membrane integrity and the mitochondrial potential capacity to generate ATP by oxidative phosphorylation. The serum level of FSH was measured by a solid-phase, two-site chemiluminescent immunometric assay.|t|t|t|f
33683179|NCT02645838|RANDOMIZED|PARALLEL||||NONE||||||
33683180|NCT03907618|||CASE_CONTROL||PROSPECTIVE|||||||
33683181|NCT04145843|||COHORT||PROSPECTIVE|||||||
33683182|NCT03991546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two study groups. The intervention group and the control group that does not receive the intervention.||||
33683183|NCT04548492|||CASE_CROSSOVER||PROSPECTIVE|||||||
33683184|NCT06065111|||COHORT||PROSPECTIVE|||||||
33683185|NCT01347489|||||PROSPECTIVE|||||||
33683186|NCT03856268|||COHORT||CROSS_SECTIONAL|||||||
33683187|NCT01981057|||CASE_CROSSOVER||PROSPECTIVE|||||||
33683188|NCT02299778|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33773932|NCT06740734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Intervention The pregnant women who were randomly included in the study and control groups by going to the clinic during the study period by the researcher will first fill out the Informed Volunteer Consent Form and Pregnant Identifier Form (Pregnant Identifier Information-Labor and Episiotomy Follow-up Form first 8 questions).~Implementation process~* Group 1; Stress ball~* Group 2 Expressive touch after cesarean~* Control Group will be given routine care.~Study Group 1: Sterile Stress ball during mediolateral episiotomy repair for pregnant women who received stress ball application. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hand (Ozen et al., 2023).~Group 3 -Those who received expressive touch During mediolateral episiotomy repair, expressive touch will be applied to one of the mother's hands by the researcher for an average of 15-20 minutes (Association, 2023.).~In the Control Group The women in the control group receiv"|t|t|f|t
33773933|NCT01635361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33773934|NCT06736717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773935|NCT02499328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773936|NCT06740097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773937|NCT06129409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Drug vs Placebo|t|f|t|f
33773938|NCT06740461|||COHORT||CROSS_SECTIONAL|||||||
33773939|NCT04570735|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33773940|NCT03685708|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33773941|NCT00974103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773942|NCT03860779|||COHORT||PROSPECTIVE|||||||
33773943|NCT05914649|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participants and the person administering the cognitive testing will be blinded to the volume of saline infused (999 mL or 50 mL).|Participants will complete both the active and placebo arms of the study in a random order.|t|f|f|t
33773944|NCT06011876|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33773945|NCT06046443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33773946|NCT05468775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773947|NCT05714085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773948|NCT06740344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is an unblinded study as it is not possible to blind the provider to the type of mask hold. However, the operators will be blinded to the respiratory function monitor measurements feedback. This will be achieved by obscuring the colour sensor with brown, opaque tape and covering the Monivent screen. The outcome assessor will be blinded to the group allocation.|Parallel group randomised controlled trial|f|f|f|t
33773949|NCT01233167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773950|NCT04898894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773951|NCT06526754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|he random allocation sequence was implemented using sequentially numbered, opaque sealed envelopes, each containing a card indicating group assignment. An independent administrative staff member, not involved in enrollment or treatment, prepared the envelopes. To conceal the allocation sequence, envelopes were stored in a secure, locked cabinet accessible only to the study coordinator, who was not involved in patient evaluations or surgeries. This maintained clinician blindness to allocations, preserving the integrity of the randomization process. Third-party medical staff, blinded to group allocation, evaluated the outcomes to ensure objective assessment.|This study involves three phases. Phase one focuses on developing and validating 3D-printed liver models. Phase two optimizes the 3D reconstruction process using AI-assisted segmentation. Phase three is a randomized controlled trial comparing surgical outcomes using physical 3D models versus digital simulations.|t|t|t|t
33903309|NCT05895279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903310|NCT02669927|||COHORT||PROSPECTIVE|||||||
33903311|NCT06671197|||CASE_CONTROL||PROSPECTIVE|||||||
33903312|NCT01754688|||OTHER||PROSPECTIVE|||||||
33903313|NCT02530944|||COHORT||PROSPECTIVE|||||||
33903314|NCT00212238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903315|NCT06672731|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080641|NCT03961867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080642|NCT01856738|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33683189|NCT03176017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773952|NCT06446609|||COHORT||PROSPECTIVE|||||||
33773953|NCT00654693|||COHORT||PROSPECTIVE|||||||
33773954|NCT05203510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773955|NCT06637436|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33903316|NCT00829166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903317|NCT04802356|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, open label, non-randomized single arm clinical trial||||
33903318|NCT03752853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903319|NCT00546858|||CASE_ONLY||PROSPECTIVE|||||||
33903320|NCT02711748|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34080643|NCT05015036|||COHORT||PROSPECTIVE|||||||
34080644|NCT02630862|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34080645|NCT03248596|||CASE_ONLY||PROSPECTIVE|||||||
34080646|NCT02174302|||||PROSPECTIVE|||||||
34080647|NCT05294861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In a crossover design, the effects of YesMdiet and of NoMdiet on overall glycemia and Gut Microbiome will be assessed in the participants in random order||||
34080648|NCT03508778|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34080649|NCT02097498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34080650|NCT03776448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and researchers involved directly in collecting data (ex. Measuring blood pressure or interviewing subjects) will be unaware of the allocation status and thus blinded. However, statistical analysts and those who will provide the participants with the intervention/placebo will be aware of the allocation status. All interventions (black seed oil and charcoal softgels) will be supplemented in neutral identical containers. Each participant will receive a container labeled with his or her specific identification code and containing the intervention for the arm to which he or she has been allocated.||t|f|t|f
34080651|NCT04892069|||COHORT||RETROSPECTIVE|||||||
34080652|NCT00598728|||COHORT||RETROSPECTIVE|||||||
34080653|NCT04849793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|First of all, the names of all students will be listed alphabetically for the selection of 196 nursing students in the research population and 52 nursing students who will be the sample. Numbers between 1-196 will be written in front of each student in the ordered student list. 52 nursing students will be determined by randomization created in computer environment by an independent researcher who is not included in the study. A total of 52 students in the sample group determined by randomization will be separated according to the A and B groups created by the same statistician in computer environment.|Prospective, parallel, two-arm randomized controlled clinical trial|t|f|f|f
34080654|NCT03638128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080655|NCT00524927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080656|NCT00308945|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34080657|NCT01959113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080658|NCT00967304|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080659|NCT02344329|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33683190|NCT03928093|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All investigators, assessors and participants will be blinded to the intervention. The randomization will be done by the research pharmacist. Unblinding before the study completion is allowed only in case of serious adverse events.|there two treatment periods in the study. All of the study participants will receive pregabalin treatment during one of these two 10-week treatment periods, and placebo - during the other one.|t|t|t|t
33683191|NCT02776319|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33683192|NCT05428124|||CASE_ONLY||RETROSPECTIVE|||||||
33683193|NCT05394493|||COHORT||RETROSPECTIVE|||||||
33773956|NCT05883631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683194|NCT01642628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683195|NCT03956043|||COHORT||PROSPECTIVE|||||||
33683196|NCT05306821|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683197|NCT02240277|||COHORT||PROSPECTIVE|||||||
33683198|NCT05849961|||COHORT||OTHER|||||||
33683199|NCT02723045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773957|NCT05801562|||COHORT||OTHER|||||||
33773958|NCT00485576|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33773959|NCT03351998|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33773960|NCT05389332|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Aim 1: Interviews with ten to twelve health care providers and community leaders for a 30-60 minute interview via Zoom and recorded.~Aim 2: We anticipate recruiting four focus groups (2 English, 2 Spanish) with six to eight participants each for a 60-minute audio-recorded focus group. Ten to twelve individual interviews for a 30-60 minute interview via Zoom and recorded.~Aim 3: A single-arm design: participants will receive WhatsApp messages about skin cancer for three months. The participants will need to complete a survey with the same questions in the pre-survey along with the acceptability and feasibility measures at three-month and six-month follow-ups.~Aim 4: A pilot RCT comparing two groups: skin cancer and physical activity and nutrition information. Survey at baseline, three-month and six-month follow-ups."||||
33773961|NCT03257995|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33773962|NCT01990300|||COHORT||PROSPECTIVE|||||||
33773963|NCT01991197|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33773964|NCT02701582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33773965|NCT01592695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33773966|NCT05195593|||COHORT||PROSPECTIVE|||||||
33773967|NCT06738576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33773968|NCT06738394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773969|NCT05886777|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33773970|NCT02822170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773971|NCT06739200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33773972|NCT01084590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33773973|NCT06326463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773974|NCT03140917|||OTHER||PROSPECTIVE|||||||
33773975|NCT04627727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773976|NCT03292042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33773977|NCT06740188|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33773978|NCT04575935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33773979|NCT00954018|||OTHER||PROSPECTIVE|||||||
33773980|NCT05776979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773981|NCT04920149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33773982|NCT06738459|||COHORT||RETROSPECTIVE|||||||
33773983|NCT06309680|||COHORT||PROSPECTIVE|||||||
33773984|NCT06435273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33773985|NCT05235295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33773986|NCT04241874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33773987|NCT00466934|||||PROSPECTIVE|||||||
33773988|NCT06738121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683200|NCT03726996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080660|NCT00380172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683201|NCT05757232|||COHORT||RETROSPECTIVE|||||||
33683202|NCT02814487|||CASE_ONLY||PROSPECTIVE|||||||
33683203|NCT05062395|||COHORT||PROSPECTIVE|||||||
34080661|NCT01307787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34080662|NCT02324686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080663|NCT04110821|||OTHER||PROSPECTIVE|||||||
34080664|NCT01980433|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34080665|NCT04835545|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34080666|NCT04078464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The order the participants participate in the 3 experimental conditions will be randomly assigned.||||
34080667|NCT04606693|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34080668|NCT04531865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080669|NCT01179607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080670|NCT00144677|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34080671|NCT01831869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683204|NCT02619773|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33683205|NCT06129513|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33683206|NCT00157287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33683207|NCT04707859|||COHORT||PROSPECTIVE|||||||
33683208|NCT06437431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683209|NCT05735210|NA|SINGLE_GROUP||OTHER||NONE||||||
33683210|NCT00176189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683211|NCT04399460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683212|NCT04967040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683213|NCT06280014|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33683214|NCT01685645|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33683215|NCT00590928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683216|NCT02622997|NA|SINGLE_GROUP||SCREENING||NONE||All participants will take two cervico-vaginal self-samples using flocked swabs and then a further cervicao-vaginal self-sample using a HerSwab collection device.||||
33683217|NCT01516333|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33683218|NCT00740376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683219|NCT05585944|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683220|NCT04176042|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All 28 participants will be randomized to one of two 4-week tracks (N=14 each).|4-WEEK TRACKS All 28 participants will be randomized to one of two 4-week tracks (N=14 each). The study design (crossover) dictates that all participants must complete a questionnaire at identical time points; therefore, participants in track 2 will perform a baseline questionnaire at the same time as track 1 participants perform a baseline questionnaire for their intervention. Also, participants in track 1 will complete the follow up at the same time as track 2 participants perform a baseline questionnaire for their intervention.|t|f|f|f
33683221|NCT05292898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683222|NCT05787990|||COHORT||PROSPECTIVE|||||||
33683223|NCT00621621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683224|NCT04130737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683225|NCT05315869|||CASE_CONTROL||RETROSPECTIVE|||||||
33683226|NCT00202527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683227|NCT06339476|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||In the overall study population of 56 subjects recruited from, Sivas Cumhuriyet University Faculty of Medicine Research and Practice Hospital, Gynecology and Obstetrics Clinic, divided into two groups: irregular menstrual cycle (n=28) and regular menstrual cycle control group (n=28). While those who met the criteria for menstrual irregularity were included, those with another gynecological disease (PCOS, endometriosis, etc.) and additional diseases (diabetes, insulin resistance, cancer, heart disease, etc.) were excluded from the study. All participants provided written informed consent before participating in the study. Participants were asked to report the average length of their menstrual cycle over the past six months, as well as the consistency of cycle length. Menstrual regularity was assessed by self-report using a standardized questionnaire.|t|f|t|f
33683228|NCT00214604|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33683229|NCT01894568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683230|NCT04108117|||CASE_CONTROL||RETROSPECTIVE|||||||
33683231|NCT02202330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33683232|NCT04803682|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683233|NCT05221502|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Trial 323-201-00006 is a multicenter, phase 2b/c, open-label, randomized, dose-finding trial in subjects with DS-TB. Following a screening period of up to 14 days, eligible subjects will be randomized on~Day -1 or predose Day 1 in a ratio of 1:2:2:1 to one of the following treatment arms:~Arm 1: DLM (300 mg once daily \[QD\]) + BDQ (400 mg QD x 2 weeks, then 200 mg thrice-weekly \[TIW\]) + OPC-167832 (10 mg QD) for 17 weeks~Arm 2: DLM (300 mg QD) + BDQ (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (30 mg QD) for 17 weeks~Arm 3: DLM (300 mg once daily \[QD\]) + BDQ (400 mg QD x 2 weeks, then 200 mg TIW) + OPC-167832 (90 mg QD) for 17 weeks~Arm 4: RHEZ for 8 weeks followed by 18 weeks of rifampin and isoniazid (for a total of 26 weeks)~Randomization will be stratified by HIV status (yes or no) and presence of bilateral cavitation on screening chest x-ray (yes or no). After the end of the treatment period, subjects will be followed until 12 months postrandomization."||||
33683234|NCT01249898|||COHORT||PROSPECTIVE|||||||
33683235|NCT02996032|||COHORT||PROSPECTIVE|||||||
33683236|NCT03650946|||COHORT||PROSPECTIVE|||||||
33683237|NCT03381729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683238|NCT01585519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683239|NCT06427304|||CASE_ONLY||PROSPECTIVE|||||||
33683240|NCT06332742|||COHORT||PROSPECTIVE|||||||
33683241|NCT03830723|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, prospective, dose-finding, single centre pilot study.||||
33683242|NCT03468569|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683243|NCT02665403|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33773989|NCT06498713|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty at Yale New Haven Hospital at St. Raphael's Campus.||||
33773990|NCT06643377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33773991|NCT06741020|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive A combination of Oxaliplatin, Calcium folinate, 5-Fluorouracil and Adebrelimab with transhepatic arterial infusion.||||
33773992|NCT06308081|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to 1 of 2 conditions: SGM-tailored anti-vaping messages versus non-tailored messages. Block randomization will achieve balance across the two conditions based on age group, gender identity, sexual orientation, race, ethnicity, and prior use. Both conditions will receive repeated exposure of messages within their assigned condition daily for 4, up to a total of 24 messages over the course of the study. Messages will be delivered using texting to participants mobile phones. We will record participants' self-reported engagement to the messages at the follow-up survey (after measuring the study outcomes). Participants will be asked to complete a baseline survey comprising vaping susceptibility and characteristics, surveys at 1-, 2-, 3-, and 4-weeks follow-up to measure vaping susceptibility.||||
33773993|NCT05781386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33773994|NCT05560646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903321|NCT00001259|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33903322|NCT03112837|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33903323|NCT01527604|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33683244|NCT05488821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683245|NCT02038270|||OTHER||RETROSPECTIVE|||||||
33683246|NCT01374035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33683247|NCT03158792|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33683248|NCT02642588|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773995|NCT06396377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized parallel-arm trial.||||
33773996|NCT06738784|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33773997|NCT06387199|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomized placebo-controlled crossover 2x3 factorial designed trial|t|t|t|t
33773998|NCT01617395|||COHORT||PROSPECTIVE|||||||
33773999|NCT06723899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a cluster randomised control trial. One group will receive the intervention and the other group will receive standard care|f|f|f|t
33774000|NCT06739109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774001|NCT04879498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774002|NCT03314649|||COHORT||PROSPECTIVE|||||||
33774003|NCT02845687|||COHORT||PROSPECTIVE|||||||
33774004|NCT06487533|||COHORT||PROSPECTIVE|||||||
33774005|NCT05009992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774006|NCT05851690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774007|NCT06736704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903324|NCT03553238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903325|NCT00480753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33903326|NCT00782808|||COHORT||PROSPECTIVE|||||||
33903327|NCT02831491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903328|NCT06672393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903329|NCT05619211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903330|NCT01600131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34080672|NCT02631447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080673|NCT00126594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080674|NCT01842269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683249|NCT00000460|||COHORT||PROSPECTIVE|||||||
33683250|NCT04315584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All 5 study subjects will undergo the same procedures.||||
33683251|NCT05015413|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A will receive shock wave therapy Group B will receive low level laser therapy||||
33683252|NCT05850494|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This study is double blinded with regard to treatment (MDI administered with 2 different propellants \[Treatment A or B\]), ie, the sponsor, the investigator, all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.|"The purpose of this study is to assess bronchospasm potentially induced by hydrofluoroolefin (HFO) metered dose inhaler (MDI) as compared with hydrofluoroalkane (HFA) MDI in participants with asthma, well controlled or partially controlled on treatment for asthma, including, low-dose inhaled corticosteroid (ICS) daily or low-dose ICS/formoterol as needed (not approved in the US), or short-acting beta2-agonists (SABA) as needed, or low-dose ICS whenever SABA as needed is used.~Study details include:~* The study duration will be up to 37 days.~* The treatment duration will be 1 day for each treatment period.~* The visit frequency will be approximately every 1 week."|t|t|t|t
33683253|NCT05503901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683254|NCT04918342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be assigned to either exercise individually with a physical therapist or in a group.|f|f|f|t
33683255|NCT04549207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683256|NCT02644681|||COHORT||PROSPECTIVE|||||||
33683257|NCT02737033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683258|NCT05507788|NA|SINGLE_GROUP||TREATMENT||NONE|Efforts will be taken to mask the conditions to the participants.|The convenience sample of 15 individuals will each complete the test protocol under the 3 seating conditions in random order.||||
33683259|NCT05313776|||CASE_CONTROL||PROSPECTIVE|||||||
33683260|NCT00534313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683261|NCT02758405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683262|NCT01147133|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33683263|NCT01215916|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683264|NCT06276738|||COHORT||PROSPECTIVE|||||||
33683265|NCT04397770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683266|NCT05214079|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33683267|NCT04987944|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
33683268|NCT02133443|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080675|NCT03909048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, statistician, and outcomes assessor are blinded.||t|f|f|t
33986411|NCT04967794|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"The clinical trial is a simple blind study in which the sample will be randomized into three groups, whose participants will be blinded to the types of intervention"|The study population will be divided into three groups that will receive the intervention by communication platform, teleconsultation platform in health and in person.all individuals participating in the group will receive toothbrushing guidelines as a preventive measure for the development of dental caries|t|f|f|f
33683269|NCT03940976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986412|NCT00489112|RANDOMIZED|PARALLEL||||NONE||||||
33986413|NCT01312415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986414|NCT00401089|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33986415|NCT02767921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683270|NCT03450330|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation||||
33683271|NCT05537870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible patient were randomly assigned by the computer random number generator to either intervention or control group. Several methods were used to maintain the treatment blindly, including segregation of assessment and treatment staff and instructions to patients to avoid discussion of treatment assignment with the independent evaluators.||t|f|f|f
33683272|NCT02811627|NA|SINGLE_GROUP||OTHER||NONE||||||
33683273|NCT03381833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683274|NCT03673761|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33683275|NCT05070546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33683276|NCT00573729|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33683277|NCT01962038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683278|NCT03874429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|investigator-masked||f|f|t|f
33683279|NCT00684047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683280|NCT04821362|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||A prospective, experimental, randomized controlled trial.||||
33774008|NCT04215393|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33774009|NCT05546190|||OTHER||OTHER|||||||
33774010|NCT06129695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each patient will be given a code by the researcher and the observers will be blind to which group this case belong. Patients, radiographic outcome assessor and statistician will be blinded.|"1. Randomized Controlled Clinical Trial.~2. Parallel group study.~3. Allocation Ratio 1:1."|t|f|f|t
33774011|NCT06739876|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants in the intervention group will wear a device and will either receive motivational support via social media or not. The control group will not wear a device during the intervention phase.|f|f|f|t
33986416|NCT04184518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986417|NCT00749177|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33986418|NCT04198844|||COHORT||RETROSPECTIVE|||||||
33986419|NCT03192930|||COHORT||PROSPECTIVE|||||||
33986420|NCT04718506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986421|NCT04928300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33986422|NCT02775565|||OTHER||RETROSPECTIVE|||||||
33986423|NCT02942264|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986424|NCT01447615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986425|NCT04960722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986426|NCT06057922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986427|NCT06169358|||OTHER||CROSS_SECTIONAL|||||||
33986428|NCT00557752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986429|NCT03254771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open label|||||
33986430|NCT03171285|||CASE_ONLY||RETROSPECTIVE|||||||
33986431|NCT02682784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33986432|NCT04394676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Prospective, Randomized Trial|t|t|t|f
33986433|NCT03210480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multicenter, prospective study.||||
33986434|NCT03326180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986435|NCT04593134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33986436|NCT01880814|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34080676|NCT01805895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080677|NCT04547881|||COHORT||PROSPECTIVE|||||||
33683281|NCT05694377|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The person analysing the outcomes will be blinded to the subjects allocation to the groups.|two arms repeated measures control design|f|f|f|t
33683282|NCT05857280|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33683283|NCT02840084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986437|NCT02634437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080678|NCT03583957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080679|NCT01774591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683284|NCT00423527|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33683285|NCT03740815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683286|NCT02673541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683287|NCT01770444|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33683288|NCT01782469|||CASE_ONLY||PROSPECTIVE|||||||
33683289|NCT01565304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683290|NCT02203201|||CASE_CONTROL||PROSPECTIVE|||||||
33683291|NCT00977457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683292|NCT03055364|||CASE_ONLY||PROSPECTIVE|||||||
33683293|NCT06286176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683294|NCT00000128|RANDOMIZED|||TREATMENT||||||||
33683295|NCT04757428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683296|NCT04674540|||CASE_ONLY||CROSS_SECTIONAL|||||||
33683297|NCT00873873|||COHORT||PROSPECTIVE|||||||
33683298|NCT00950677|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33683299|NCT03869268|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not applicable for this trial as this is an open label study.|This trial is a randomised controlled hybrid parallel-group and crossover study.||||
33683300|NCT03802214|||CASE_CONTROL||PROSPECTIVE|||||||
33774012|NCT06186128|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33774013|NCT04917549|||OTHER||CROSS_SECTIONAL|||||||
33774014|NCT05099679|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774015|NCT00002474||||TREATMENT||NONE||||||
33774016|NCT05580458|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774017|NCT00253409|RANDOMIZED|||TREATMENT||||||||
33903331|NCT04239560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A gel that has an active ingredient in boron with a gel that does not have a substance and is used as a placebo is completely identical in terms of the shape and size of the container, and the gels themselves do not differ in terms of odor and color, and are completely indistinguishable. (This action was taken by the pharmaceutical company). The important point is that the patient is told that the gel used for the patient may be medication or medication. Clinicians and blind patients will be blinded.|The aim of the study was fully described to the eligible subjects and informed consent was gathered. Afterwards, the patients were assigned into the intervention and placebo groups. In the intervention and placebo groups, subjects received daily a gel containing 3% sodium pentaborate pentahydrate and gel free of any chemical treatment respectively 15 minutes before the radiotherapy session. As the gels were used on the target areas of the patients by the researchers, there was no compliance problem in this study. Afterwards, the study's outcomes were examined at 25th day of treatment for the patients in two groups.|t|t|f|f
33903332|NCT01019590|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33903333|NCT04191278|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of three study conditions: 1) varenicline alone; 2) varenicline + mobile health app; 3) varenicline + mobile health app + contingency management||||
33903334|NCT02144220|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33903335|NCT00879268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903336|NCT03177837|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33903337|NCT06361745|NA|SINGLE_GROUP||TREATMENT||NONE||UTAA09 injection||||
33774018|NCT02336581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774019|NCT04127084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774020|NCT06692335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774021|NCT05575115|||COHORT||PROSPECTIVE|||||||
33774022|NCT05443126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774023|NCT04317716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The facilitators of the fall prevention program will not be involved in the usual care of the participants. The intervention will take place online. Control-group participants will receive a brochure about falls and fall risk factors, sent by mail. Baseline and follow-up assessments will be performed by blinded evaluators.|Participants will be stratified for ambulation level (ambulatory/non-ambulatory) and a 1:1 allocation ratio of blocks of 4 will be used.|f|f|f|t
33774024|NCT04324463|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, parallel group, factorial, randomized controlled trial||||
33774025|NCT06674603|||COHORT||PROSPECTIVE|||||||
33774026|NCT02348320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774027|NCT06038227|||COHORT||PROSPECTIVE|||||||
33774028|NCT06585787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903338|NCT04059133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903339|NCT02769260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33903340|NCT06351215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903341|NCT03290638|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986438|NCT06105034|||COHORT||PROSPECTIVE|||||||
33683301|NCT00006212||||TREATMENT||||||||
33683302|NCT02937584|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33683303|NCT03289520|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683304|NCT05758701|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||In a standard polyenergetic CT procedure, 100 ml of iodinated contrast is used. Two cohorts of patients will be assessed, the first being given a 1/3rd reduction (33 ml). If satisfactory, a second cohort with 1/4th the standard dosage (25 ml) will be assessed. If unsatisfactory, the IV contrast dose will be increased to 1/2 (50 ml)||||
33683305|NCT02921061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683306|NCT01229462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683307|NCT03343756|||OTHER||OTHER|||||||
33683308|NCT00481975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683309|NCT00592774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683310|NCT03302182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33774029|NCT05955274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomly assigned to one of two groups|f|f|f|t
33774030|NCT06740565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774031|NCT05597267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774032|NCT05966805|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986439|NCT04680962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986440|NCT01959750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33986441|NCT03681964|||COHORT||PROSPECTIVE|||||||
33986442|NCT03226054|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective Cohort||||
34080680|NCT03856697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683311|NCT03048383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774033|NCT05898412|||COHORT||RETROSPECTIVE|||||||
33774034|NCT00692055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33774035|NCT06577935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986443|NCT01891578|||COHORT||PROSPECTIVE|||||||
33986444|NCT04692194|||COHORT||RETROSPECTIVE|||||||
33986445|NCT01058148|||||PROSPECTIVE|||||||
33986446|NCT06204991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986447|NCT04176094|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A cluster-randomized crossover trial will compare 16h vs. 24h overnight schedules for residents completing an ICU rotation.||||
33774036|NCT05295433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774037|NCT06737029|||COHORT||PROSPECTIVE|||||||
33774038|NCT06077643|||COHORT||PROSPECTIVE|||||||
33774039|NCT05826132|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled trial|t|f|f|f
33774040|NCT06504589|||COHORT||PROSPECTIVE|||||||
33774041|NCT02653924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774042|NCT03620903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774043|NCT05432206|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33774044|NCT05066061|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled, open-label, three-arm parallel, single-center therapeutic trial.||||
33774045|NCT05707650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774046|NCT03458429|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the safety and tolerability of 12 once monthly transfusions of GMFFP (Granulocyte - Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma harvested from young, healthy donors), given to older, frail individuals who are at risk due to unhealthy aging and who will then have a subsequent 12-month follow-up period.||||
33774047|NCT05623969|||COHORT||PROSPECTIVE|||||||
33774048|NCT06585150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774049|NCT05953038|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will be blinded with respect to dose only.|Each participant will be given one of 25, 50, 75, 100, 125, 150, 175 or 200 micrograms of lysergic acid diethylamide (LSD) equivalent as freebase.||||
33774050|NCT06739434|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774051|NCT06740331|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||participants are assigned to one of two or more groups in parallel for the duration of the study||||
33774052|NCT06740747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774053|NCT03109197|||FAMILY_BASED||PROSPECTIVE|||||||
33774054|NCT05554341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774055|NCT06741189|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774056|NCT06560320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This prospective, randomised controlled study.|f|f|f|t
33774057|NCT06238401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774058|NCT02298205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774059|NCT01182168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774060|NCT01823614|||COHORT||CROSS_SECTIONAL|||||||
34080681|NCT03523065|||COHORT||PROSPECTIVE|||||||
33986448|NCT04380610|||COHORT||PROSPECTIVE|||||||
33774061|NCT06375941|||OTHER||PROSPECTIVE|||||||
33774062|NCT01139905|NA|SINGLE_GROUP||||NONE||||||
33774063|NCT01880060|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33774064|NCT03763396|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774065|NCT02243631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774066|NCT04679376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774067|NCT06738017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774068|NCT06740786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774069|NCT05143866|NA|SINGLE_GROUP||OTHER||NONE||Feasibility with pre post assessment||||
33774070|NCT01208415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774071|NCT06472128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774072|NCT04868435|||COHORT||PROSPECTIVE|||||||
33774073|NCT02378818|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33774074|NCT01010217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774075|NCT05412342|||COHORT||PROSPECTIVE|||||||
33774076|NCT05246930|||COHORT||PROSPECTIVE|||||||
33774077|NCT06738966|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774078|NCT02719899|||COHORT||PROSPECTIVE|||||||
33986449|NCT01049893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986450|NCT06420986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986451|NCT05508932|||COHORT||PROSPECTIVE|||||||
33774079|NCT06737042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774080|NCT06444048|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participants, investigators, study personnel performing any study-related assessments following study product administration, and laboratory personnel will be blinded to treatment assignments.||t|t|t|f
33774081|NCT05776927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All site staff, including pharmacist will be blinded. All sponsor staff will be blinded.|A double-blind, randomized, parallel-group, active controlled study.|t|t|t|t
33774082|NCT05437575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|t|f|f
33774083|NCT05399485|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774084|NCT06738667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774085|NCT05135169|||COHORT||PROSPECTIVE|||||||
33774086|NCT04826757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomised, controlled, cluster trial. the project is multicentered.||||
33774087|NCT01337648|||CASE_ONLY||PROSPECTIVE|||||||
33774088|NCT05097287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774089|NCT00696085|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33774090|NCT06740162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774091|NCT01960205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774092|NCT02638610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986452|NCT02792426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33986453|NCT04325256|||OTHER||CROSS_SECTIONAL|||||||
33986454|NCT02486900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986455|NCT00100776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33986456|NCT03525860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986457|NCT01629381|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33986458|NCT02601794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986459|NCT02246322|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33986460|NCT03857295|||COHORT||RETROSPECTIVE|||||||
33986461|NCT03261310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986462|NCT05084066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33986463|NCT02149693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33986464|NCT02340897|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986465|NCT02453386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683312|NCT04033588|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, multi-centre, non-comparative, post-market clinical follow-up study||||
33683313|NCT05977881|NA|SINGLE_GROUP||PREVENTION||NONE||The study interventional model is at the community level; the intervention will be offered in all areas in which the cohort will be recruited.||||
33774093|NCT00488241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774094|NCT01058330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774095|NCT05961813|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open, controlled clinical trial.||||
33774096|NCT01083160|||CASE_ONLY||PROSPECTIVE|||||||
33774097|NCT06740214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33774098|NCT06737588|||OTHER||PROSPECTIVE|||||||
33774099|NCT01356173|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774100|NCT03308578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33774101|NCT01776398|||CASE_CONTROL||PROSPECTIVE|||||||
33774102|NCT01811017|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774103|NCT02502305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903342|NCT05555030|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open-label, prospective study to evaluate the sensitivity and specificity of the iCura COVID-19 Antigen Rapid Home Test when a lay person conducts the test on themselves or another study participant. Potential subjects will be those presenting for COVID-19 testing. The study will evaluate the performance of the iCura COVID-19 Antigen Rapid Home Test by comparing it to a high sensitivity EUA SARS-CoV-2 RT-PCR assay to calculate both the positive percent agreement (PPA, or sensitivity) and the negative percent agreement (NPA, or specificity).||||
33903343|NCT00008164||||TREATMENT||||||||
33903344|NCT00795067|||CASE_ONLY||PROSPECTIVE|||||||
33903345|NCT05762939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903346|NCT00063648|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33903347|NCT03392519|||CASE_ONLY||CROSS_SECTIONAL|||||||
33986466|NCT05857891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986467|NCT02196766|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33986468|NCT04546074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683314|NCT06009185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683315|NCT05979545|RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary aim is to quantify the combined effect of a PCR-based rapid microbiology diagnostic system and locally adapted antibiotic stewardship on patients with infections due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales. The combined effect of diagnostics and appropriate antibiotic is the primary focus in the RAPID trial as they are closely interlinked.||||
33683316|NCT01322776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683317|NCT05380362|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33683318|NCT04810728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683319|NCT04892056|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinding of the principal investigator was not possible due to the nature of the interventions. However, the outcome assessor was blinded to the interventions and all digital models were unidentified during outcome assessment.||f|f|f|t
33683320|NCT05273073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This was a 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial in post-gestational diabetes women. Participants were randomly received either placebo or 30 billion colony forming units of probiotics (HEXBIO® Microbial Cell Preparation, MCP® BCMC® Strains) consist of six viable microorganisms of Lactobacillus and Bifidobacteria strains, twice daily for 12-week.|t|f|t|f
33683321|NCT05830110|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals.|t|f|t|f
33683322|NCT03550846|||COHORT||PROSPECTIVE|||||||
33683323|NCT05946434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683324|NCT02530047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683325|NCT02820532|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33683326|NCT06210932|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33683327|NCT04678687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683328|NCT05207189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683329|NCT06074770|||OTHER||CROSS_SECTIONAL|||||||
33683330|NCT02236182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683331|NCT05624710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|open label study|||||
33683332|NCT03290482|||COHORT||PROSPECTIVE|||||||
33683333|NCT04155411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683334|NCT01704612|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683335|NCT02965092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683336|NCT00852371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774104|NCT06686797|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33774105|NCT05085288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33774106|NCT06738082|||COHORT||PROSPECTIVE|||||||
33774107|NCT06605703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774108|NCT05329766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903348|NCT00416351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903349|NCT06024330|||CASE_ONLY||CROSS_SECTIONAL|||||||
33986469|NCT03527147|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986470|NCT04039594|||COHORT||PROSPECTIVE|||||||
33986471|NCT04186182|NA|SINGLE_GROUP||TREATMENT||NONE||This is a feasibility trial evaluating the feasibility and acceptability of a planned randomized controlled trial. Therefore, no control group will be included.||||
33986472|NCT05494671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||interventional case series||||
33986473|NCT00638625|||COHORT||PROSPECTIVE|||||||
33986474|NCT02261857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683337|NCT01685333|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683338|NCT00942071|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986475|NCT02758496|||COHORT||RETROSPECTIVE|||||||
33683339|NCT03626298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33683340|NCT04585971|||CASE_ONLY||PROSPECTIVE|||||||
33774109|NCT06390267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All study investigators and personnel delivering assessments will be blind to whether patient is assigned to an active or sham tAN group. This will ensure a non-biased assessment of post-stressor performance. All participants will be blinded to whether they are receiving active or sham tAN. Participants will complete a blinding effectiveness questionnaire at the conclusion of the study. To maintain the blind, all participants will be informed that you may or may not perceive stimulation, meaning you may receive benefits without any perception of stimulation."|This study is designed as a randomized, double-blind, sham-controlled trial in sixty healthy, able-bodied participants. Participants will be randomized to one of four treatment groups in a 1:1:2:2 ratio. Twice as many participants will be randomized to the acute treatment active tAN and acute treatment sham tAN arms (Groups 3 and 4) compared to the prophylactic treatment group arms (Groups 1 and 2).|t|t|t|t
33986476|NCT00260650|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986477|NCT04272632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986478|NCT01559324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986479|NCT03600480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33683341|NCT04903821|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986480|NCT02360982|||COHORT||PROSPECTIVE|||||||
33986481|NCT00613145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986482|NCT03283722|||COHORT||PROSPECTIVE|||||||
33986483|NCT06559579|||COHORT||RETROSPECTIVE|||||||
33986484|NCT00800709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986485|NCT00934934|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33986486|NCT01086254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986487|NCT00151047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986488|NCT05184426|||COHORT||CROSS_SECTIONAL|||||||
33986489|NCT03152981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683342|NCT01390064|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683343|NCT03874260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683344|NCT02150902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683345|NCT06220890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683346|NCT01429909|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683347|NCT04140032|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33683348|NCT03780023|||CASE_ONLY||PROSPECTIVE|||||||
33683349|NCT03651388|||FAMILY_BASED||OTHER|||||||
33683350|NCT03848156|||CASE_CONTROL||PROSPECTIVE|||||||
33683351|NCT03469778|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33683352|NCT02201342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683353|NCT05937464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683354|NCT01006603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683355|NCT01821573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683356|NCT05607069|||COHORT||PROSPECTIVE|||||||
33683357|NCT00391183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683358|NCT02069340|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33774110|NCT06736613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774111|NCT06737523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774112|NCT02390765|||COHORT||PROSPECTIVE|||||||
33774113|NCT06738927|||COHORT||RETROSPECTIVE|||||||
33774114|NCT00398177|||COHORT||PROSPECTIVE|||||||
33774115|NCT05552976|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study; however, any review of aggregate study data by the Sponsor will be performed in a blinded manner.|This is a two-stage inferentially seamless design.||||
33774116|NCT06720168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774117|NCT06396338|||COHORT||PROSPECTIVE|||||||
33774118|NCT05348876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774119|NCT06346067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774120|NCT03149341|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33774121|NCT06469307|||COHORT||PROSPECTIVE|||||||
33774122|NCT02127905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774123|NCT04039945|||COHORT||PROSPECTIVE|||||||
33774124|NCT06736964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double ( participant, Outcome Assessor)|parallel assignment|f|f|t|t
33774125|NCT05622201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A proof-of-concept study: a multicenter, placebo-controlled, double-blinded, add-on intervention study|t|t|t|t
33774126|NCT05539963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774127|NCT06521463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33774128|NCT02309606|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33774129|NCT06738888|||COHORT||PROSPECTIVE|||||||
33774130|NCT01015014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774131|NCT05118204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774132|NCT00865644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774133|NCT06649201|||COHORT||PROSPECTIVE|||||||
33774134|NCT03496415|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774135|NCT06728241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774136|NCT04983979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind randomised clinical trial.|A Multi site, placebo controlled, double blind randomised clinical trial.|t|t|t|t
33774137|NCT03847779|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33774138|NCT01132196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903350|NCT03540368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will receive standard treatment equally||t|f|f|f
33903351|NCT01571882|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33903352|NCT04678167|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Only the investigator carrying out the follow-up consultations is blind.~After examination by the ENT specialist (otorhinolaryngologist) who will diagnose vestibular neuritis, the patient will be randomized into one of three groups. The clinical follow-up will be performed by another practitioner, who will not know in which arm the patient is included (the patient will come to the consultation without his glasses). Only the practitioner who realized the randomization and the patient will have information about the arm in which they are located."|The randomization list is established by the Brest CHRU data management unit before the start of the trial. Based on a ratio (1:1:1) with stratification on the center.|f|f|t|f
33903353|NCT00348972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33903354|NCT03304483|NA|SINGLE_GROUP||SCREENING||NONE|Before and after the race|athletes participating in the ultra marathon running||||
33903355|NCT04372693|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Online Distance Learning with certain principals will be implemented for the study group and control group who learned by Traditional Classroom-Based will be selected retrospectively as baseline data, students' perception and achievement will be measured for both.||||
33903356|NCT01284179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903357|NCT04501653|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be aware that they are receiving either psilocybin or methylphenidate at each medication imaging session, but will not be told in what order they will receive study medication (psilocybin first versus methylphenidate first).|"Participants will undergo a baseline imaging session, followed by a blinded drug session with psilocybin 25mg, or methylphenidate (MTP) 40mg. Participants will then have a between imaging session without medication, followed by another medication imaging session with the agent not used in the first medication session. This will be followed by a final imaging session without medication."|t|f|f|f
33903358|NCT01432314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903359|NCT00509873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903360|NCT02818153|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903361|NCT05026658|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33903362|NCT01784510|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33903363|NCT05689528|||COHORT||PROSPECTIVE|||||||
33903364|NCT05563532|||OTHER||CROSS_SECTIONAL|||||||
33903365|NCT05926089|||CASE_ONLY||CROSS_SECTIONAL|||||||
33903366|NCT02385695|||CASE_CONTROL||PROSPECTIVE|||||||
33903367|NCT00417612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774139|NCT06739031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774140|NCT04165161|RANDOMIZED|CROSSOVER||OTHER||NONE||For each patient the 4 tests will be performed in a randomized order to limit bias||||
33774141|NCT03923296|||CASE_CONTROL||PROSPECTIVE|||||||
33774142|NCT01235182|||COHORT||PROSPECTIVE|||||||
33774143|NCT06728982|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized into two groups:~Group A: Patients will receive standard chemoradiotherapy(CRT).~Group B: Patients will self-administer 1000mg of metformin twice daily by mouth:~1. beginning 1-2 weeks before standard CRT.~2. during standard CRT.~3. until 30 days after the end of standard CRT."||||
33774144|NCT04065282|NA|SINGLE_GROUP||TREATMENT||NONE||neoadjuvant chemotherapy sintilimab plus XELOX||||
33774145|NCT06401031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774146|NCT04665297|RANDOMIZED|PARALLEL||PREVENTION||NONE|Given nature of study, blinding is not feasible.|Nonblinded, two-arm cluster randomized controlled trial for 12 months. At 12 months, control arm crosses into the intervention, and both arms receive the intervention for an additional 12 months (total of 24 months)||||
33774147|NCT00709592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774148|NCT06673095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774149|NCT05656443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774150|NCT06435949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33683359|NCT04926402|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33683360|NCT06433856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33683361|NCT06092229|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"randomised to either palpation or ultrasonography~The participants are thus randomised to use either palpation or to use ultrasonography to DIAGNOSE the position of the cricothyroid membrane"||||
33774151|NCT03179189|||COHORT||PROSPECTIVE|||||||
33774152|NCT06219343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774153|NCT06527040|||COHORT||PROSPECTIVE|||||||
33774154|NCT06736678|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774155|NCT05731947|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1a dose escalation portion of the study will employ a Rolling 6 trial design, followed by a Phase 1b signal-seeking portion, and a Phase 2 randomized (2:1) signal confirmation portion.~Phase 1: Non-randomized; Phase 2: Randomized"||||
33774156|NCT06008808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774157|NCT05672082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774158|NCT02874066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774159|NCT02475213|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774160|NCT06541704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774161|NCT03557489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33774162|NCT06738212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A sample will be divided into two groups, each group will have 21 participants. The group A will be given Aerobic exercise and Group B will be given Aviva exercises.|f|f|f|t
33774163|NCT05444673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774164|NCT03942874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774165|NCT05585307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774166|NCT06739512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774167|NCT05437276|||CASE_ONLY||PROSPECTIVE|||||||
33774168|NCT05521048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774169|NCT04019119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The system of randomization for the participants is through an external computer system.|Two groups study. One group with intervention (app mobile program); second group as control. At the end of the intervention, the control group receives advice of demonstrated effectiveness in the intervention to comply with the ethical principles.|f|f|f|t
33774170|NCT02813460|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33774171|NCT06305962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774172|NCT06014385|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33774173|NCT06738836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774174|NCT06738251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774175|NCT04266171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774176|NCT06740318|NA|SINGLE_GROUP||TREATMENT||NONE||Motivational enhancement therapy in three sessions within three months from diagnosis are applied in addition to standard of care.||||
33774177|NCT03377673|||CASE_ONLY||PROSPECTIVE|||||||
33774178|NCT01681368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683362|NCT04738318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treating physician and patient will be blinded to the treatment assignment.||t|t|t|f
33903368|NCT05754827|||COHORT||PROSPECTIVE|||||||
33903369|NCT00599430|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33903370|NCT00818142|||COHORT||PROSPECTIVE|||||||
33903371|NCT04645797|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1 Dose Escalation||||
33774179|NCT05468125|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"patients will be randomly allocated by a computer software program (www. Randmizer.org) and allocation sequence will be done by opaque closed envelope.~Data will be collected by a separate anesthesiologist not sharing in the study and blinded to the technique being used."||t|f|t|f
33774180|NCT06161753|NA|SINGLE_GROUP||TREATMENT||NONE||mixed-methods single cohort study||||
33774181|NCT03763188|||COHORT||OTHER|||||||
33774182|NCT04773249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Clinician)|Parallel Assignment|f|f|t|f
33774183|NCT02736110|||CASE_ONLY||PROSPECTIVE|||||||
33774184|NCT06098079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Sponsor will be blinded||t|t|t|t
33774185|NCT01186328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774186|NCT05482516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774187|NCT06605599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774188|NCT00564590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683363|NCT05506605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683364|NCT02220699|||CASE_ONLY||CROSS_SECTIONAL|||||||
33683365|NCT04052802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683366|NCT05896280|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33683367|NCT04839562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683368|NCT02983318|||OTHER||CROSS_SECTIONAL|||||||
33683369|NCT02042820|||CASE_CONTROL||PROSPECTIVE|||||||
33683370|NCT05069701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683371|NCT01789931|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683372|NCT02073383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683373|NCT05171452|||COHORT||PROSPECTIVE|||||||
33683374|NCT04173598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Comparative, prospective, randomized, study including two groups of (patient / caregiver) dyads:~* An intervention group consisting of a dyad (patient + family carer) benefiting in addition to the usual treatment from the intervention for the family carer.~* a group consisting of a dyad (patient + caregiver) with usual care (control group)."||||
33683375|NCT00981942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683376|NCT01646866|||COHORT||PROSPECTIVE|||||||
33683377|NCT03081546|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33683378|NCT01845623|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33683379|NCT04650061|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The patient is informed that he participates in a study to test the efficacy of different care plans, but he is not informed if he belongs to the experimental or to the control group (standard of care)|A multi-centre randomized, controlled trial (RCT)|t|f|f|f
33683380|NCT05053932|||COHORT||PROSPECTIVE|||||||
33683381|NCT02816567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33683382|NCT00289029|RANDOMIZED|PARALLEL||||DOUBLE||||||
33683383|NCT03507530|||COHORT||PROSPECTIVE|||||||
33683384|NCT00115323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683385|NCT01753050|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33903372|NCT01721369|||COHORT||PROSPECTIVE|||||||
33903373|NCT00719732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903374|NCT04462692|||CASE_ONLY||PROSPECTIVE|||||||
33903375|NCT00004697|RANDOMIZED|||TREATMENT||DOUBLE||||||
33903376|NCT03053089|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Stage 1: 6 adults will be given a single dose, assigned to 0.3, 1.0 or 3.0 mg/kg (with cohort assignment based on order of study entry)~Stage 2: up to 15 children will be given repeat weekly doses for 26 weeks, assigned to 1.0, 3.0 and 6.0 or 9.0 mg/kg (with cohort assignment based on order of study entry). Early term"||||
33903377|NCT05070949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903378|NCT05782413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903379|NCT05807022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903380|NCT00000289||||TREATMENT||DOUBLE||||||
33903381|NCT06131645|||COHORT||RETROSPECTIVE|||||||
33683386|NCT01650129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986490|NCT02038621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683387|NCT00053898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683388|NCT04942457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to mask a fasting intervention for the participant or the study personel. Therefore only outcome assessors are masked.|There are 2 parallel groups following different nutritional regimes. Additionally Qualitative Interviews with Patients and Doctors/Medical Staff.|f|f|f|t
33683389|NCT04564131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683390|NCT00714571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33683391|NCT05171725|||COHORT||OTHER|||||||
33683392|NCT01935310|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33683393|NCT00432601|RANDOMIZED|PARALLEL||||NONE||||||
33903382|NCT02468089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903383|NCT06024005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903384|NCT03880227|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will be paired based on key demographic criteria and assigned to one of two stimulation locations (rTPJ or dmPFC), participants will then complete active and sham stimulation sessions in a randomized, counterbalanced order approximately one week apart.|t|f|f|t
33903385|NCT00024297||||SUPPORTIVE_CARE||||||||
33903386|NCT01073748|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33903387|NCT01420107|||CASE_ONLY||PROSPECTIVE|||||||
33903388|NCT04497246|||COHORT||PROSPECTIVE|||||||
33986491|NCT00416845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33986492|NCT00316186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986493|NCT00834795|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33683394|NCT03273569|NA|SINGLE_GROUP||PREVENTION||NONE||Women with placenta accreta at the time of Cesarean delivery||||
33683395|NCT03550859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683396|NCT04980326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Outcomes assessor will not know whether a single participant was allocated to the experimental or to the control arm. That will be done by assigning random values toe the variable arm in the dataset."|Participants will be allocated to the experimental or the control arm with a 1:1 ratio. Participants in the experimental arm will first received the step 1 of the stepped-care program, namely the Doing What Matters self-guided program. If they still report significant levels of psychological distress, as measured by the K-10 scale, 1 week after DWM, they will be invited to step 2, an individual intervention namely Problem Management Plus (PM+). If they do not report significant levels of psychological distress, they will not receive further interventions, but will be asked to complete the remaining assessments.|f|f|f|t
33683397|NCT03705936|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33683398|NCT00296608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683399|NCT04156516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683400|NCT02982512|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683401|NCT00396539|||||PROSPECTIVE|||||||
33683402|NCT05782816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683403|NCT03466593|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. A prospective cohort compared to historical controls~2. A randomized, controlled, intervention study."||||
33683404|NCT03758885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683405|NCT05694143|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||A cluster randomized controlled trial design|t|f|f|f
33683406|NCT00052442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683407|NCT01811667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903389|NCT01201369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903390|NCT01780558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683408|NCT00890045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683409|NCT02203175|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
33683410|NCT01642810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683411|NCT03844295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Only patient will be blind. He doesn't know if INSPIRE therapy was activated or not|Monocentric, prospective, controlled, patient single-blind study|t|f|f|f
33683412|NCT02048241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683413|NCT05806827|||CASE_CONTROL||PROSPECTIVE|||||||
33683414|NCT04594057|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683415|NCT05165589|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Part 1: 3 subjects for 4 days included to collect initial data for algoritm development for device feasibility evaluation Part 2: 10 subjects for 7 days included to evaluate device feasibility||||
33683416|NCT01120067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683417|NCT06324227|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33683418|NCT01407003|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33683419|NCT06213675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683420|NCT04308733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blind||t|f|f|f
33683421|NCT03467009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33683422|NCT06191783|||COHORT||PROSPECTIVE|||||||
33683423|NCT02436980|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683424|NCT00727532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683425|NCT02671916|||COHORT||PROSPECTIVE|||||||
33774189|NCT04232748|||COHORT||PROSPECTIVE|||||||
33774190|NCT06736665|RANDOMIZED|PARALLEL||TREATMENT||NONE||Once the presence of a calcified nodular lesion is confirmed and the patient meets the inclusion criteria without any exclusion criteria, the patient will be randomized to one of the two treatment techniques being evaluated in the study (OA vs. IVL) in a 1:1 ratio. A stratified randomization will be implemented based on the type of calcified nodule (eruptive or non-eruptive) to ensure equal proportions of each type between the two treatment groups.||||
33774191|NCT06738511|NA|SINGLE_GROUP||SCREENING||NONE|Laboratory Technicians|||||
33774192|NCT05649072|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33774193|NCT06739759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33774194|NCT05730218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774195|NCT06738849|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group will switch to the interventional device after the first three months of the study||||
33903391|NCT06396156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903392|NCT04408521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33903393|NCT06672926|||COHORT||PROSPECTIVE|||||||
33683426|NCT01766700|RANDOMIZED|PARALLEL||||NONE||||||
33683427|NCT05255185|NA|SEQUENTIAL||TREATMENT||NONE||||||
33683428|NCT01001299||PARALLEL||TREATMENT||NONE||||||
33683429|NCT04191460|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33774196|NCT05348889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774197|NCT06735040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients in the groups did not have information with regard to which group they were included in.|Randomised, sham-controlled study|t|f|f|t
33774198|NCT01987063|||COHORT||PROSPECTIVE|||||||
33774199|NCT00003944||||TREATMENT||||||||
33774200|NCT04037384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774201|NCT03084419|NA|SINGLE_GROUP||TREATMENT||NONE||"The investigators will perform a small clinical trial to assess the feasibility of performing a larger randomised controlled trial.~Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.~Participants will sign informed consent at visit 1 (screening visit). There is then a 28 day window before treatment starts at visit 2 (baseline). Each participants participation in the trial is estimated to last 28 weeks from visit 1."||||
33774202|NCT03626974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774203|NCT06685146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33774204|NCT06737783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774205|NCT06739317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774206|NCT02339649|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33774207|NCT03763162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774208|NCT06737835|||COHORT||PROSPECTIVE|||||||
33774209|NCT03114072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Consenting participants will be randomized (by www.randomizer.org) to either intervention/control condition. The intervention- and control glasses will be covered in the same looking wrapping, done by a third person, which will blind the investigator as well.||t|f|t|f
33774210|NCT02981225|||COHORT||PROSPECTIVE|||||||
33774211|NCT06736925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Several co-investigators and undergraduate researchers will remain masked throughout the trial.|One group will be randomly assigned to take DHA+EPA, while the other group will be randomly assigned to take the placebo, organic soybean oil. Both groups will received identical stimuli of 20 soccer headings per session for a total of 2 sessions.|t|f|t|f
33903394|NCT02674607|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33903395|NCT03215888|||CASE_CONTROL||PROSPECTIVE|||||||
33683430|NCT05439070|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33683431|NCT05820997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683432|NCT03157570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33683433|NCT01993836|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33683434|NCT03774823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is not aware which group they will be randomized into upon entering the study|One group receives treatment with RF and PEMF while the second group receives treatment with ultrasound|t|f|f|f
33683435|NCT02608333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683436|NCT05048069|||CASE_ONLY||PROSPECTIVE|||||||
34080682|NCT03521557|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be assessed at baseline prior to randomization. Once baseline assessments are completed, participants will be randomized to one of 2 study groups. Interventions will occur at a different site than assessments to avoid unmasking. At the post test and follow-up assessment time points, participants will be instructed not to divulge their group assignment to their assessor (the same individual that assessed them at baseline).|2 group x 3 time interval|f|f|f|t
33683437|NCT01106417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded study. The study participants will be blinded to the study randomisation assignment and study treatment they receive. In addition, every effort will be made by the Sponsor and Investigator to maintain the study blind. Treatment assignment will occur in sequential chronological order according to a central master list of random assignments prepared by the study statistician (master randomization list).|"Subjects received treatment in one of two parallel arms.~Treatment Arm 1; NeoFuse (a biologic, consisting of STRO-3 immunological selected allogeneic Mesenchymal Precursor Cells, derived from adult bone marrow mononucleated cells) with Mastergraft Matrix (a medical device that is compression resistant and embedded with Mastergraft Granules). Subjects received 10 million Neufuse cells per treated cervical interbody level involved in the fusion. Either 2 or 3 levels were involved for a total of either 20 million or 30 million Neofuse cells.~Treatment Arm 2; Mastergraft Granules (medical device made of medical grade combination of hydroxyapatite and beta-tricalcium phosphate)."|t|f|f|f
33683438|NCT00001131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683439|NCT03505931|||CASE_ONLY||PROSPECTIVE|||||||
33903396|NCT04758117|||COHORT||PROSPECTIVE|||||||
33683440|NCT03037723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683441|NCT04038203|||COHORT||PROSPECTIVE|||||||
33683442|NCT01492946|||COHORT||RETROSPECTIVE|||||||
33683443|NCT00159822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774212|NCT02215928|||OTHER||OTHER|||||||
33774213|NCT03306407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774214|NCT06008756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33774215|NCT04463784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774216|NCT01369953|||||PROSPECTIVE|||||||
33774217|NCT04579120|||OTHER||PROSPECTIVE|||||||
33903397|NCT02559232|||COHORT||CROSS_SECTIONAL|||||||
33903398|NCT01615003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903399|NCT00830427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903400|NCT04553276|||CASE_ONLY||PROSPECTIVE|||||||
33903401|NCT02345369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33903402|NCT06077058|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33903403|NCT00815165|||CASE_CONTROL||PROSPECTIVE|||||||
33903404|NCT02025699|||COHORT||PROSPECTIVE|||||||
33903405|NCT03949582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Double-Blind Crossover Randomised Controlled Trial|t|f|t|t
33903406|NCT04761380|||COHORT||CROSS_SECTIONAL|||||||
33903407|NCT00500149|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33903408|NCT05772091|||COHORT||RETROSPECTIVE|||||||
33903409|NCT02293434|||COHORT||PROSPECTIVE|||||||
33903410|NCT02815631|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
33903411|NCT04476537|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33903412|NCT02088216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903413|NCT01198418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774218|NCT06738641|RANDOMIZED|PARALLEL||OTHER||NONE|This is an open trial.|Randomized controlled parallel study with pre- and post-measures||||
33774219|NCT02326844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774220|NCT02771210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Double-blind|t|t|t|t
33774221|NCT03714997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded outcomes assessment at each measures phase|Parallel design randomized controlled trial|f|f|f|t
33774222|NCT02749695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903414|NCT05616949|RANDOMIZED|PARALLEL||TREATMENT||NONE||A parallel group randomized design is used. Participants will be randomized to receive treatment as usual (TAU) or the Peer Recovery Support Services (PRSS) intervention with a focus on MOUD retention. Individuals in the PRSS intervention group will receive all components of TAU plus additional peer-delivered recovery support services to aimed at enhancing retention in MOUD treatment. The plan is to recruit 50 total individuals. If there is significant drop out. Randomization will occur in a 1:1 ratio by flipping a coin, and will be conducted using stratified block randomization using random block sizes. Gender is the only stratification variable. Study staff involved with recruitment will be blinded to the participant's condition until after randomization. After randomization, the participant and study staff will all know if the participant was randomized to TAU or to PRSS. The intervention period is 24-weeks with follow ups at weeks 36 and 52.||||
33903415|NCT05920850|NA|SINGLE_GROUP||SCREENING||NONE||||||
33903416|NCT02239094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903417|NCT03819244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903418|NCT02241850|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33903419|NCT04522427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903420|NCT02985125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986494|NCT01926912|||COHORT||PROSPECTIVE|||||||
33774223|NCT06475716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Semi-structured interviews will be administered by researchers blind to randomization allocation at baseline, 10 and 22 weeks after randomization. Self-report data will be collected via a secure online platform, so it will help avoid ascertainment bias in the measurement of outcomes.|Participants will be randomized to the immediate treatment group or delayed treatment control group. The immediate treatment group will receive the intervention immediately after randomization. The delayed treatment group will receive the intervention 22 weeks after randomization.|f|f|f|t
33774224|NCT01414530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774225|NCT00895973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774226|NCT03027713|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33774227|NCT00324714|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33774228|NCT06549595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774229|NCT05111613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774230|NCT04814186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774231|NCT06615986|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33774232|NCT00932490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33774233|NCT06738979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774234|NCT06738498|||COHORT||PROSPECTIVE|||||||
33774235|NCT04676230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are assigned to two groups in parallel for the duration of the study|t|f|t|f
33903421|NCT03955848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774236|NCT02690402|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774237|NCT04105920|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single Blind||t|f|t|f
33774238|NCT06739408|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33774239|NCT05423717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774240|NCT02506621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774241|NCT06739577|||CASE_CONTROL||PROSPECTIVE|||||||
33774242|NCT02204228|||COHORT||PROSPECTIVE|||||||
33774243|NCT06739174|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33774244|NCT05292391|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33774245|NCT01991444|||CASE_ONLY||PROSPECTIVE|||||||
33774246|NCT01544491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774247|NCT06740604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774248|NCT02522975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903422|NCT05074095|||OTHER||RETROSPECTIVE|||||||
33903423|NCT04497220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774249|NCT05586191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774250|NCT06739603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774251|NCT05339035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33903424|NCT05933291|||COHORT||PROSPECTIVE|||||||
33903425|NCT03686202|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903426|NCT05135975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903427|NCT00843622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903428|NCT02033980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903429|NCT03605134|||COHORT||PROSPECTIVE|||||||
33903430|NCT05181917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903431|NCT02124720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903432|NCT04846153|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Physicians enrolling the study are exclusively assigned to Human-based Quantification.||||
33903433|NCT02615106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986495|NCT01190930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986496|NCT03707171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986497|NCT04055584|||CASE_ONLY||PROSPECTIVE|||||||
33986498|NCT00069797|||COHORT||CROSS_SECTIONAL|||||||
33986499|NCT01467622|||COHORT||PROSPECTIVE|||||||
33986500|NCT02096718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986501|NCT04799444|||COHORT||PROSPECTIVE|||||||
33986502|NCT01221922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986503|NCT03888430|||COHORT||PROSPECTIVE|||||||
33986504|NCT05763147|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986505|NCT05748886|||COHORT||PROSPECTIVE|||||||
33986506|NCT06139666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Papers with equal numbers of either E for Exparel or B for Bupivacaine will be allocated to envelopes and shuffled for randomization. At the time of selection, the patient will be identified and allocated to their respective group dependent on what letter they get. This will take place in the preoperative visit and will be communicated to the anesthesia team prior to block taking place by the data spreadsheet so that the surgeon will be blinded to what treatment took place."|Prospective, double-blinded (surgeon and patient) randomized therapeutic trial|t|f|t|f
33986507|NCT05497362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blinded|t|f|f|t
33986508|NCT05242705|||OTHER||CROSS_SECTIONAL|||||||
33986509|NCT06523114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774252|NCT06736873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33903434|NCT03887637|||COHORT||PROSPECTIVE|||||||
33903435|NCT01816646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903436|NCT00716729|||||PROSPECTIVE|||||||
33903437|NCT05649124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903438|NCT01272271|||COHORT||RETROSPECTIVE|||||||
33903439|NCT05099757|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903440|NCT05064995|||CASE_CONTROL||PROSPECTIVE|||||||
33903441|NCT05061225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903442|NCT06014905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903443|NCT06672770|RANDOMIZED|PARALLEL||TREATMENT||NONE||"MS patients will be divided into 3 groups as functional inspiratory muscle training (FIMT) group (n=21), basic inspiratory muscle training (IMT) group (n=21) and Control (CT) group (n=21) by block randomization with the randomization program https://www.studyrandomizer.com/."||||
33903444|NCT04895059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903445|NCT04648878|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|participants will be instructed to not reveal which treatment arm they have been assigned to||f|t|f|f
33903446|NCT06097936|||COHORT||OTHER|||||||
33903447|NCT06565338|||OTHER||PROSPECTIVE|||||||
33903448|NCT04281537|||COHORT||CROSS_SECTIONAL|||||||
33903449|NCT05331664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903450|NCT02572661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903451|NCT06511869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903452|NCT06337851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a prospective randomized controlled trial|t|f|f|f
33903453|NCT04982614|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903454|NCT01937208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903455|NCT04457726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986510|NCT01659580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986511|NCT02195193|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33986512|NCT02363803|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33986513|NCT02589808|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986514|NCT02045550|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33986515|NCT02409953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986516|NCT03106662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986517|NCT01759940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986518|NCT06145386|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986519|NCT00861406|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986520|NCT00384917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986521|NCT02099747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683444|NCT05214053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683445|NCT00686634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683446|NCT05026814|||COHORT||PROSPECTIVE|||||||
33683447|NCT01153776|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683448|NCT02108262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683449|NCT00575835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683450|NCT05098977|||COHORT||PROSPECTIVE|||||||
33683451|NCT00851968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683452|NCT02009605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683453|NCT03841578|NA|SINGLE_GROUP||SCREENING||NONE||10 healthy subjects (controls) undergoing organoleptic assessment and gastrointestinal motility study||||
33683454|NCT00005646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683455|NCT01027390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33683456|NCT00231556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683457|NCT03511898|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33683458|NCT03233880|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blind|randomized, double blinded controlled trial|t|t|f|f
33683459|NCT04664894|||OTHER||CROSS_SECTIONAL|||||||
33683460|NCT04418401|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683461|NCT02299739|||COHORT||RETROSPECTIVE|||||||
33683462|NCT05709132|RANDOMIZED|PARALLEL||OTHER||SINGLE||Waitlist randomized controlled trial|f|f|t|f
33683463|NCT00469170|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33683464|NCT03951168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33683465|NCT02671162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683466|NCT00749814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683467|NCT04840030|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The Gipuzkoa GOIZ ZAINDU - GO-ON study is a two year randomized, controlled trial to evaluate the effectiveness of multi-component lifestyle and dementia risk factor intervention in preventing cognitive decline in older adults with cognitive frailty.|t|t|f|t
33683468|NCT04715334|NA|SINGLE_GROUP||TREATMENT||NONE||pre and post intervention comparison||||
33986522|NCT03955757|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study team data analyst will be provided with blinded data.||f|f|f|t
33774253|NCT06736782|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A multi-site quasi-experimental study is planned to evaluate the feasibility, acceptability, and effectiveness of a Self-Empowerment Care model tailored for frail older adults in Hong Kong. Participants will be allocated into one intervention group and one control group, with the intervention group receiving a 12-week program focused on hydration, exercise, dietary support, and defecation care. This model, rooted in Nordic re-enablement principles and adapted in Japan, aims to enhance participants' independence in activities of daily living (ADLs) and quality of life (QOL).||||
33774254|NCT06539052|||OTHER||OTHER|||||||
33774255|NCT06741046|||COHORT||RETROSPECTIVE|||||||
33986523|NCT02865850|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor was blinded during the study|||||
33986524|NCT02291263|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986525|NCT04768309|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986526|NCT01708824|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33986527|NCT02247115|||COHORT||PROSPECTIVE|||||||
33986528|NCT01875315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986529|NCT03943238|NA|SINGLE_GROUP||TREATMENT||NONE||In this phase 1 study, a conditioning regimen of Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donr CD34+, T cell and Recipient T regulatory Cell Transfusion in Human Leukocyte Antigen Mismatched Living Donor Kidney Transplantation will be studied||||
33774256|NCT06737328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774257|NCT06720012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774258|NCT03530046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774259|NCT03257592|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33903456|NCT03332004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In the selected patients, after a first white light visual inspection, 0.25 mg/(kg BW) ICG were injected intravenously. After 5 to 30 minutes a second inspection of the abdomen and pelvis in Near Infrared vision was made. All the visualized lesions were carefully described pre and post the Indocyanine Green injection, removed and listed||||
33903457|NCT05262595|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33903458|NCT00384280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903459|NCT05638711|||COHORT||RETROSPECTIVE|||||||
33903460|NCT03856073|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33903461|NCT06512467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986530|NCT05112367|||COHORT||RETROSPECTIVE|||||||
33986531|NCT04701541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986532|NCT01815879|||CASE_ONLY||RETROSPECTIVE|||||||
33986533|NCT01781325|RANDOMIZED|PARALLEL||||NONE||||||
33903462|NCT00479804|||COHORT||PROSPECTIVE|||||||
33903463|NCT02213198|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33903464|NCT00179920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903465|NCT05590949|||COHORT||PROSPECTIVE|||||||
33903466|NCT02948777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903467|NCT03395340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33986534|NCT06035107|||COHORT||PROSPECTIVE|||||||
33986535|NCT02170922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903468|NCT04292119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903469|NCT05319951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33903470|NCT06306638|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903471|NCT02379910|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33903472|NCT00691197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903473|NCT04803708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903474|NCT01459107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986536|NCT06131086|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the reading is blind|Randomized clinical trail|f|f|f|t
33986537|NCT04781205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Paired cluster randomization of 40 clinics into 20 intervention and 20 usual care. Randomization from among a couple of similar clinics||||
33986538|NCT05838703|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33986539|NCT02108119|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986540|NCT06122363|||CASE_CONTROL||RETROSPECTIVE|||||||
33986541|NCT02307981|||CASE_CONTROL||PROSPECTIVE|||||||
33986542|NCT00314990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33986543|NCT02616133|||OTHER||PROSPECTIVE|||||||
33986544|NCT06123130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903475|NCT00225368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903476|NCT00698126|||||PROSPECTIVE|||||||
33903477|NCT02527876|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33903478|NCT02806765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33903479|NCT01024465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080683|NCT03509168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicenter-randomized single blind controlled trial with a (1:1) allocation ratio.|t|t|f|f
34080684|NCT05535608|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34080685|NCT03848559||SEQUENTIAL||OTHER||NONE||||||
34080686|NCT01768780|NA|SINGLE_GROUP||OTHER||NONE||||||
34080687|NCT00179855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080688|NCT05570552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080689|NCT00169676|||COHORT||PROSPECTIVE|||||||
34080690|NCT02778217|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34080691|NCT02125890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080692|NCT04911348|||COHORT||RETROSPECTIVE|||||||
34080693|NCT01639352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080694|NCT05316064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080695|NCT02187783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080696|NCT02142816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33903480|NCT04367337|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34080697|NCT03893578|NA|SINGLE_GROUP||TREATMENT||NONE||Device: Synecor Conveyor System||||
34080698|NCT01030146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080699|NCT03159598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The study is semi-blind in that patients will not be told which treatment they are receiving. If the patient is assigned to one of the drains groups, she will know post-operatively that she has drains, but she will not know if TissueGlu was utilized. The doctor will be aware of what treatment the patient is receiving, as he or she will administer the drug"|This study has three parallel groups. One experimental and two control groups|t|f|f|f
34080700|NCT06028789|||CASE_CONTROL||PROSPECTIVE|||||||
34080701|NCT01243918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080702|NCT05511857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080703|NCT03531723|||OTHER||PROSPECTIVE|||||||
34080704|NCT03318263|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080705|NCT02783170|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080706|NCT04935203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34080707|NCT02179125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080708|NCT00409981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34080709|NCT04670536|||COHORT||OTHER|||||||
33774260|NCT00338767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080710|NCT05337761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study participants will not know if they are receiving the intended intervention or not, since the control arm will also be receiving some messages|Cluster randomized trial|t|f|f|f
34080711|NCT03674268|||OTHER||PROSPECTIVE|||||||
34080712|NCT02624999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080713|NCT02358057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080714|NCT02773498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34080715|NCT01255215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080716|NCT05570448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34080717|NCT00860275|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080718|NCT00528424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080719|NCT03385213|||CASE_CONTROL||RETROSPECTIVE|||||||
34080720|NCT02935556|||CASE_CONTROL||PROSPECTIVE|||||||
34080721|NCT00004244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080722|NCT03472638|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33903481|NCT06667284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903482|NCT03058458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903483|NCT05189015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903484|NCT04030403|||OTHER||PROSPECTIVE|||||||
33903485|NCT01841008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903486|NCT06524882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903487|NCT01148056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903488|NCT01380756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903489|NCT02295098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903490|NCT00004778|RANDOMIZED|||TREATMENT||DOUBLE||||||
33903491|NCT01869244|||COHORT||PROSPECTIVE|||||||
34080723|NCT03594929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080724|NCT00103454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080725|NCT00374010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34080726|NCT01682980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34080727|NCT00350077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080728|NCT02938364|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34080729|NCT00802711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080730|NCT03735615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||10 patients with stable chronic obstructive lung disease (COPD) stage 3 and 4 according to GOLD guidelines (www.goldcopd.org), recruited from outpatient ward of the Lung Department at St Olav University Hospital. Control group of 10 age-matched but otherwise healthy subjects||||
33774261|NCT06734455|||COHORT||RETROSPECTIVE|||||||
33774262|NCT06740968|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Please note that because the most logical interventional study model is a single arm study the study team can't select a masking option. Please note that Participants, Investigators, and Outcomes Assessors will be blinded to active vs. sham stimulation (with the exception of one study investigator that pre-configures the randomization schedule, and this person will not be involved in any assessments/outcomes).|Participants will all receive the same treatments, however, visits 3 through 7 will have order of conditions (types of stimulation) randomized.||||
34080731|NCT04637243|||OTHER||RETROSPECTIVE|||||||
33683469|NCT03255070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a 2-part, Phase 1, open-label study will administer the IMP, ARX788 by IV infusion every 3, 4 or 6 weeks. Sequential dose escalation cohorts are planned using a 3+3 design. A cohort may be expanded to collect additional data if recommended by Safety Monitoring Committee based on comprehensive reviews of safety, tolerability and PK data to determine RP2D.~Phase 1a will determine the recommended Phase 2 dose (RP2D) in subjects with advanced cancer whose HER2 test results are in situ hybridization (ISH) positive or immunohistochemistry (IHC) 3+.~Phase 1b will assess anticancer activity and safety in advanced cancer."||||
34080732|NCT00388648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683470|NCT06131762|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the reading is blind|Randomized control trail|f|f|f|t
33683471|NCT06131671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683472|NCT03888638|||COHORT||RETROSPECTIVE|||||||
33683473|NCT02666157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683474|NCT02977182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683475|NCT01604278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683476|NCT03458715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774263|NCT04857372|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774264|NCT05040256|||CASE_ONLY||RETROSPECTIVE|||||||
33774265|NCT06712719|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33774266|NCT00001416||||TREATMENT||||||||
33774267|NCT00239018|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33774268|NCT06740695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33774269|NCT06525935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774270|NCT05526235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33774271|NCT06739863|||COHORT||PROSPECTIVE|||||||
33774272|NCT02885519|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33774273|NCT06475196|||COHORT||PROSPECTIVE|||||||
33774274|NCT06739304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774275|NCT06737185|NA|SINGLE_GROUP||OTHER||NONE||||||
33774276|NCT02942004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774277|NCT01121640|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33774278|NCT04708288|||COHORT||PROSPECTIVE|||||||
33774279|NCT06739889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774280|NCT04838626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All participants will receive \[18F\]CTT1057 for PET/CT scan imaging, and surgery will be performed up to 6 weeks after \[18F\]CTT1057 PET for pathology assessment of the tissue specimens.~Additional pharmacokinetics (PK) assessments will be performed on the date of imaging in a subset of approximately 10 patients at the same site."||||
33774281|NCT00272766|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774282|NCT00113893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774283|NCT06737978|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33774284|NCT01379820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774285|NCT06682143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774286|NCT06737302|||COHORT||PROSPECTIVE|||||||
33774287|NCT01039714|||COHORT||PROSPECTIVE|||||||
33774288|NCT03930186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774289|NCT05773365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774290|NCT06368440|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33774291|NCT06173362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774292|NCT06737419|||COHORT||RETROSPECTIVE|||||||
33774293|NCT06738563|||OTHER||PROSPECTIVE|||||||
33774294|NCT06737536|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|f|t|f
33774295|NCT01163149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774296|NCT06737575|||COHORT||PROSPECTIVE|||||||
33774297|NCT03010735|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774298|NCT06739902|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774299|NCT04299633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774300|NCT06723392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel-arm, double-blind, placebo-controlled, 2:1 allocation, randomized controlled trial|t|f|f|f
33774301|NCT03879694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774302|NCT06740266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774303|NCT05457283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774304|NCT06712459|||COHORT||RETROSPECTIVE|||||||
33774305|NCT01990170|||COHORT||PROSPECTIVE|||||||
33774306|NCT00226564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774307|NCT06728449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double- Blinded|After the approval from the relevant authorities from The University of Lahore and Hospital, individuals meeting the ATP III criteria for metabolic syndrome (n = 330) will be selected for inclusion after taking consent. The selected participants will be randomly divided into control and 4 experimental groups. Anthropometric measurements, socio-economic status, nutrient intake and biochemical tests as fasting blood sugar level, triglyceride and cholesterol levels will be taken at beginning (0 day) and 60 days.|t|t|f|f
33774308|NCT00680550|||||PROSPECTIVE|||||||
33903492|NCT04083742|||COHORT||PROSPECTIVE|||||||
33903493|NCT01382589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903494|NCT02101606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080733|NCT05471011|||COHORT||PROSPECTIVE|||||||
34080734|NCT06454474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080735|NCT02456727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080736|NCT02533700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683477|NCT05724043|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not receive information about who is included in the intervention- and control group, respectively. They will only receive information that is relevant for their participation. The chosen study design (C-RCT) facilitates this masking by reducing the possibility of contamination between the groups.|A pragmatic cluster randomized controlled trial (C-RCT) will be employed to assess effects of SmartJournal usage as specified in the study objectives. Nursing homes located in Rogaland, Norway, will be recruited and randomly assigned to an intervention group and a control group. Nursing homes in the intervention group will be provided with tablets containing SmartJournal and receive training and follow-up throughout the intervention period. Nursing homes in the control group will continue with existing oral care routines. The intervention will last for 12 weeks.|t|t|f|f
33683478|NCT02158364|||COHORT||PROSPECTIVE|||||||
33683479|NCT00830791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683480|NCT04108351|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33986545|NCT02900391|||COHORT||PROSPECTIVE|||||||
33683481|NCT04054947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683482|NCT02837081|RANDOMIZED|PARALLEL||||NONE||||||
33683483|NCT03954678|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683484|NCT00862420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683485|NCT01791959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683486|NCT02972476|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33683487|NCT02083198|||COHORT||RETROSPECTIVE|||||||
33683488|NCT02051699|||||PROSPECTIVE|||||||
33683489|NCT01908946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683490|NCT01135667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683491|NCT02935829|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33774309|NCT06627647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind masking|"Arm A: Rilvegostomig in combination with platinum-based doublet chemotherapy followed by rilvegostomig monotherapy plus pemetrexed in maintenance.~Arm B: Pembrolizumab in combination with platinum-based doublet chemotherapy followed by pembrolizumab monotherapy plus pemetrexed in maintenance."|t|t|t|t
33774310|NCT03122886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774311|NCT05489705|||COHORT||PROSPECTIVE|||||||
33774312|NCT06626399|||CASE_CONTROL||RETROSPECTIVE|||||||
33774313|NCT04163991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774314|NCT06739447|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Patients admitted to the Pediatric Trauma Unit in the Emergency Department and Pediatric Patients who have undergone an appendectomy||||
33774315|NCT06739941|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774316|NCT05415137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774317|NCT06199076|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33774318|NCT06719700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774319|NCT06737003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled study on 90 preterm neonates with Respiratory distress syndrome(RDS) in need for noninvasive ventilation during their first 3 days of life. They were randomized into 3 groups; Nasal high frequency oscillatory ventilation (NHFOV),Vapotherm and Continuous positive air way pressure(CPAP) groups; 30 neonates for each group. Haemodynamic changes were assessed by echocardiography, pelviabdominal and transcranial ultrasounds during and after discontinuation of device .|t|f|f|f
33986546|NCT04829045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33683492|NCT04384367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683493|NCT05886985|NA|SINGLE_GROUP||TREATMENT||NONE||MatriPlax||||
33683494|NCT01621815|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683495|NCT04628533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683496|NCT04647981|||OTHER||PROSPECTIVE|||||||
33683497|NCT04140123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683498|NCT02409914|||COHORT||CROSS_SECTIONAL|||||||
33683499|NCT00493857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683500|NCT05391191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774320|NCT00783120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774321|NCT06736769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774322|NCT00742196|||CASE_CONTROL||RETROSPECTIVE|||||||
33774323|NCT03206060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774324|NCT05375136|||COHORT||PROSPECTIVE|||||||
33774325|NCT06737900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"there were total of 52 participants and were randomly assigned to two different groups. Group A received proprioceptive neuromuscular facilitation technique and Group B received jandas approach of stretching and strengthening.~The aim of this study was to study the Effects of Jandas approach versus Proprioceptive Neuromuscular Facilitation technique on pain, disability, range of motion, endurance and quality of life in patients with lower crossed syndrome"|t|f|t|f
33774326|NCT05443620|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||All participants will receive both treatments: (1) High load and (2) No load. This at to separate study visits.|f|f|f|t
33774327|NCT05125042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774328|NCT01080963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774329|NCT01005628|||CASE_ONLY||PROSPECTIVE|||||||
33683501|NCT04457895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683502|NCT05818605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, controlled, blinded|f|f|t|f
33774330|NCT06699797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774331|NCT06377761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Random parallel grouping|t|t|t|t
33986547|NCT04769622|||COHORT||CROSS_SECTIONAL|||||||
33986548|NCT02109250|||CASE_ONLY||OTHER|||||||
33986549|NCT02313064|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33986550|NCT04025450|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this trial, patients will be randomly assigned to chidamide+VRD group or VRD group, and then treated with the corresponding regimen, and their safety and efficacy will be evaluated.||||
33986551|NCT04357639|||COHORT||PROSPECTIVE|||||||
33986552|NCT00807794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986553|NCT01960374|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986554|NCT01888822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903495|NCT05874245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|All are blinded|The study will be a prospective randomized double-blind study. Patients will be randomized into three groups using a closed envelope technique in sequentially numbered opaque envelopes that will be opened by an anesthesiologist not involved in the study|t|t|t|t
33903496|NCT02855814|||COHORT||CROSS_SECTIONAL|||||||
33903497|NCT03647943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|One arm of this study is a sham condition; both tDCS and sham tDCS conditions are blinded to participants and study assessor/s.||t|f|t|t
33903498|NCT04069767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a parallel trial. After baseline assessment, the participants will be randomly assigned to one of two trial arms, A and B, in a 1:1 ratio.|t|f|f|t
33683503|NCT05863598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization will be conducted using a randomization list. As soon as a participant is eligible after providing baseline data and a clinical interview, the assessment staff will ask the coordinator to check what condition the participant should be assigned to based on the randomization list. The participants will be informed. At follow-ups, the assessors will not be aware of the intervention condition of each participants.|This is randomized controlled trials. Participants will be randomized to the active prevention program, or to a placebo (expressive writing). The intervention is brief (four weeks only). Recruitment of the participants (n=644) will take one year (anticipated)After the intervention, they will receive a booster session and will be followed up every 6 months, for 36 months post-intervention.|f|f|f|t
33683504|NCT00133978|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33683505|NCT01070147|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683506|NCT02799420|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683507|NCT04898205|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All participants will be blind to whether they receive supplemental oxygen or air during the first 8 sessions.|This study entails 24 treatment sessions. The first 8 sessions involve four experimental conditions: 1) exercise + oxygen (treatment), exercise + air (active control), oxygen only (active control), air only (placebo). Pre-treatment testing will then be repeated, after which all participants will crossover to 16 sessions of exercise + oxygen.|t|f|f|f
33683508|NCT05212129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment Arm A is masked (double-blinded). Treatment Arm B is not masked.|Participants enrolled in either Treatment Arm A (randomized to active vs sham therapy) or Treatment Arm B at the same time throughout the enrollment process.|t|t|t|t
33683509|NCT00435500|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33774332|NCT04341350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33774333|NCT06383845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Erector spinae plane block VS intravenous lidocaine.|t|t|f|f
33903499|NCT04493619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903500|NCT03948204|||CASE_CONTROL||PROSPECTIVE|||||||
33903501|NCT00038259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903502|NCT01524211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Zenith t-Branch Subject Cohort: All eligible subjects will receive treatment with the investigational t-Branch Endovascular Graft. (Total 225 subjects)~Terumo Arch Branch Cohort: All eligible subjects will receive treatment with the investigational Terumo Arch Branch Endovascular Graft. (Total 10 Subjects)"||||
33903503|NCT05652868|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903504|NCT00363025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903505|NCT01401088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903506|NCT01089868|||COHORT||PROSPECTIVE|||||||
33903507|NCT01039649|||CASE_ONLY||PROSPECTIVE|||||||
33774334|NCT06737393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903508|NCT04644575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||It is a 3-arm study with single intervention||||
33903509|NCT00064662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903510|NCT03141801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903511|NCT00688493|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33903512|NCT06339996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903513|NCT00479440|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33903514|NCT02991950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903515|NCT06667089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33903516|NCT03327922|RANDOMIZED|FACTORIAL||OTHER||SINGLE||At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).|f|f|f|t
33903517|NCT06573814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903518|NCT05743023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903519|NCT05337267|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33903520|NCT02408146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903521|NCT03388177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The project uses a blinded rater to assess the primary outcome measure of symptoms of depression|Randomized controlled trial|f|f|f|t
33903522|NCT01379443|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33986555|NCT03184753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986556|NCT01286922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986557|NCT03727828|||COHORT||PROSPECTIVE|||||||
33986558|NCT00060918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33986559|NCT02308722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986560|NCT04888819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986561|NCT03543462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator check the random list only when the patients is enrolled.|Patients affected by advanced stage ovarian cancer with diaphragmatic involvement. When diaphragmatic resection is performed the patients are randomized to proceed with chest drain positioning or not|f|f|t|f
33986562|NCT00984126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986563|NCT02273622|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33986564|NCT02514941|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33986565|NCT00312897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986566|NCT03829397|||CASE_ONLY||OTHER|||||||
33986567|NCT05860647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986568|NCT01334632|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33986569|NCT03217903|NA|SINGLE_GROUP||SCREENING||NONE||||||
33986570|NCT00486395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903523|NCT03870581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know whether they were assigned to AI-SMART group or Human-SMART group.||t|f|f|f
33903524|NCT02549677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903525|NCT00631722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903526|NCT00716404|||CASE_ONLY||PROSPECTIVE|||||||
33903527|NCT05498753|||COHORT||PROSPECTIVE|||||||
34080737|NCT04872088|RANDOMIZED|PARALLEL||OTHER||NONE||Non-blinded cluster randomized controlled trial||||
34080738|NCT00104936|RANDOMIZED|||TREATMENT||||||||
34080739|NCT03080935|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34080740|NCT04514900|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A 2x2 randomized controlled pilot study will be conducted which randomly allocates 73 individuals with overweight or obesity to an online weight control program and varies whether they receive asynchronous social support (discussion board) vs synchronous plus asynchronous social support (weekly video chat + discussion board) and varies whether the type of feedback which they receive on their self-monitoring (detailed vs basic) in a factorial study. All participants will receive the core 16-week online interactive behavioral weight loss program (iREACH) and will be followed for 4 months with monthly surveys and weight ascertainment.||||
34080741|NCT03846934|||CASE_ONLY||PROSPECTIVE|||||||
34080742|NCT01122498|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080743|NCT05465902|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34080744|NCT00016536||CROSSOVER||PREVENTION||||||||
34080745|NCT02112942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683510|NCT04822584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This is a double-blind study. To preserve the blinding of the study, a minimum number of sponsor personnel will see the randomization table and treatment assignments before the study is complete.~All study assessments will be performed by study personnel who are blinded to the patient's treatment group.~Except in clinical circumstances where unblinding is required, the patients, investigators, sponsor study team, and any personnel interacting directly with patients or investigative sites will remain blinded to baricitinib and placebo assignment until after completion of the Double-Blinded Treatment Period."|This is a multicenter, randomized, non-comparative, phase II proof-of-concept trial involved patients with progressive vitiligo and uses one of the most common regimens in this phase of study. Assessment of the experimental treatment efficacy will be estimated only on the results obtained in the experimental treatment arm (baricitinib 4 mg/day + narrowband UVB TL01 arm).|t|f|t|f
33683511|NCT03492840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683512|NCT06059352|||COHORT||PROSPECTIVE|||||||
33683513|NCT05334095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774335|NCT05784714|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33774336|NCT06740513|||COHORT||PROSPECTIVE|||||||
33774337|NCT00368446|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33903528|NCT00915811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903529|NCT04942418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903530|NCT05033444|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Participants will be randomized in a 3:1 ratio of PRV-002 and Placebo.~The following controls will be employed to maintain the double-blind status of the study:~Nasal Spray containing active drug and placebo will be indistinguishable in appearance~Randomization list will be provided to the study center pharmacist for dispensing purposes and kept in the pharmacy, accessible to the pharmacist and authorized personnel only~PK results for the SRC between cohorts will be presented in a blinded fashion."|Randomized, double-blind, placebo-controlled, single ascending dose, multi-cohort study.|t|t|t|t
33903531|NCT05772650|||COHORT||PROSPECTIVE|||||||
33903532|NCT02925221|||COHORT||PROSPECTIVE|||||||
33903533|NCT03807999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903534|NCT05632939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080746|NCT03552991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080747|NCT01463995|||COHORT||PROSPECTIVE|||||||
34080748|NCT00671788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080749|NCT05508373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080750|NCT02755506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080751|NCT00037050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080752|NCT05900375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34080753|NCT01061996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080754|NCT04394598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34080755|NCT03466632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34080756|NCT05797025|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34080757|NCT01505283|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34080758|NCT00421239|||CASE_CONTROL||RETROSPECTIVE|||||||
34080759|NCT05502770|||COHORT||PROSPECTIVE|||||||
34080760|NCT01085643|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34080761|NCT01738945|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34080762|NCT01053741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33903535|NCT06313281|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|f|t
33903536|NCT02369224|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33903537|NCT02101411|||CASE_CONTROL||PROSPECTIVE|||||||
33903538|NCT01051388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33903539|NCT05091801|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903540|NCT03059563|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33903541|NCT00716937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903542|NCT03729869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903543|NCT01083290|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33903544|NCT02379416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903545|NCT05536453|||COHORT||RETROSPECTIVE|||||||
33903546|NCT03013751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903547|NCT01340287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33903548|NCT01627756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33903549|NCT01417728|||CASE_ONLY||PROSPECTIVE|||||||
33903550|NCT05632133|RANDOMIZED|PARALLEL||TREATMENT||NONE||We assessed CGRP before and after treatment in two groups of episodic migraine patients; the first group (the lacosamide group) received Ibuprofen 200-400 mg as a treatment for acute migraine attacks and 50 mg lacosamide Bid for 3 months, and the second group (control group) received only Ibuprofen 200-400 mg as a treatment for acute migraine attacks||||
33903551|NCT02692053|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33903552|NCT02778776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903553|NCT04545112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903554|NCT01270646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903555|NCT03008590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33903556|NCT06361277|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33903557|NCT06660212|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Participants and investigators in this 2x2 factorial clinical trial will be blinded through a process of random allocation managed by a third-party investigator who is not involved in the direct administration of treatments or outcome assessments. This third-party investigator will use a computerized randomization system to assign participants to one of the four treatment groups.|2x2 factorial|t|t|t|t
33903558|NCT04985773|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, multi-center, single arm clinical study.||||
33986571|NCT01518439|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986572|NCT02445339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986573|NCT01348789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986574|NCT02344381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33986575|NCT01969747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33986576|NCT01446094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986577|NCT01950611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683514|NCT05307367|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"WP1+2: longitudinal research design of 80 patients with newly diagnosed non-small cell lung cancer, over 12 weeks registration of biomedical variables incl. blood samples, physical performance, body composition, and patient- and caregiver-reported outcomes. On a subgroup in WP2 (n=40) obtaining skeletal muscle biopises, adipose tissue (AT) biopsies, and peripheral blood samples before and after 12 weeks of 1st line treatment. In WP2 40 healthy matched controls will be assessed as well.~WP3: a interventional study where 24 patients in active treatment for NSCLC will participate in a 8 weeks one-leg exercise training. The design has an important advantage that the contralateral leg is an untrained control. In WP3 24 healthy matched controls will be assessed as well."||||
33683515|NCT06055335|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33683516|NCT00782431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33683517|NCT04334018|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33840467|NCT05119842|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will consist of two parts to assess safety, and effectiveness of the investigational device.~Part A (Safety): In total 8 patients will be enrolled sequentially in three groups (N=1, N=2, N=5). An interval of at least 7 days between the groups will be left to allow the safety board to review individual patient's safety and demographic data. After completion of the first four patients and all three groups in Part A, an independent Data Safety Monitoring Board (DSMB) will recommend the initiation of study Part B based on the review of the safety data.~Part B: In Part B of the study, the remaining 22 patients of the study will be enrolled non-sequentially.~Part A and B (Effectiveness Population) will include: The part A patients will also be used for the confirmatory testing of the primary endpoint. At the end of the study safety of the investigational device will be assessed on patients of part A and B together."||||
33903559|NCT02682888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33903560|NCT02458651|||COHORT||PROSPECTIVE|||||||
33903561|NCT03611309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986578|NCT03968601|||COHORT||PROSPECTIVE|||||||
33986579|NCT00679640|||COHORT||PROSPECTIVE|||||||
33986580|NCT02723721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986581|NCT01324193|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986582|NCT00650793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683518|NCT04409639|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, nonrandomized phase 2 trial||||
33683519|NCT00807573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903562|NCT00002195||PARALLEL||TREATMENT||||||||
33903563|NCT01526187|||COHORT||PROSPECTIVE|||||||
33903564|NCT00897559|||COHORT||RETROSPECTIVE|||||||
33903565|NCT02135601|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33903566|NCT03799003|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903567|NCT03388983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The orthopedic surgeons, outcome assessor and statistician will be blinded to the group allocation of participants.|A single-blinded randomized controlled trial|f|t|t|t
33903568|NCT04883385|||COHORT||RETROSPECTIVE|||||||
33903569|NCT00288470||||TREATMENT||||||||
33903570|NCT03399539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903571|NCT03835052|||COHORT||PROSPECTIVE|||||||
33986583|NCT03694782|||CASE_CONTROL||PROSPECTIVE|||||||
33986584|NCT05041127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986585|NCT02543632|||CASE_CONTROL||PROSPECTIVE|||||||
33986586|NCT01921062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986587|NCT01950637|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33774338|NCT06602479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"This study will be performed in a double-blind manner (ie, investigator and participant blind). The responsible personnel preparing IP at the site will have access to participants' unblinded treatment assignments.~The IRT/RTSM will provide to the investigators or pharmacists the kit identification numbers to be allocated to the participant at the dispensing visit."|"This is parallel-group, participant and investigator blinded, treatment study. Approximately 1020 participants will be screened to achieve 408 randomised to study intervention and 366 evaluable participants.~Study Arms:~* The aCGRP-N cohort includes 5 arms (placebo and 4 active dose levels).~  * A total of 288 participants will be randomized in this cohort.~ * After 64 participants total have been randomised on a 1:1 basis to either MEDI0618 Dose A or placebo, 3 lower dose arms will be initiated and include 56 participants each. Alongside the lower dose arms, 28 participants will be concomitantly allocated to the Dose A and 28 participants to the placebo arms. At this point, an adaptive randomisation will be used to allow concurrent completion of the study for all arms.~* The aCGRP-IR cohort includes 2 arms (placebo and one active dose level). -2 arms of 60 participants each; 1 will receive MEDI0618 Dose A, and 1 will receive placebo randomised on a 1:1 basis."|t|f|t|f
33774339|NCT06740058|||COHORT||OTHER|||||||
33774340|NCT06736886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33774341|NCT06170307|||CASE_CONTROL||RETROSPECTIVE|||||||
33683520|NCT05999760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|each patient was not informed about material of received prosthesis||t|f|f|f
33683521|NCT04200040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683522|NCT04738305|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683523|NCT05581901|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33683524|NCT03257917|||COHORT||CROSS_SECTIONAL|||||||
33683525|NCT05466487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903572|NCT04316572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33683526|NCT02556476|||COHORT||PROSPECTIVE|||||||
33683527|NCT01857557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683528|NCT02217527|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Crossover of active JNJ vs. placebo for 2 weeks each, involving 1 week of dose run-up and 1 week of attempting to quit each day on that drug condition. A one-week washout separates these drug conditions, which are administered in counter-balanced order.|t|f|t|t
33683529|NCT06458218|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33683530|NCT03189498|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33683531|NCT05060809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683532|NCT03588962|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683533|NCT01695278|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774342|NCT06050915|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33774343|NCT05134389|||OTHER||CROSS_SECTIONAL|||||||
33774344|NCT05367440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903573|NCT01025245||PARALLEL||PREVENTION||NONE||||||
33903574|NCT06316167|||CASE_ONLY||RETROSPECTIVE|||||||
33903575|NCT06138847|||CASE_CONTROL||RETROSPECTIVE|||||||
33903576|NCT05934799|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33903577|NCT04134104|||CASE_ONLY||CROSS_SECTIONAL|||||||
33903578|NCT04713358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903579|NCT02813330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33903580|NCT03797495|||COHORT||OTHER|||||||
33903581|NCT02517047|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33903582|NCT04644419|||COHORT||PROSPECTIVE|||||||
33903583|NCT02413398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903584|NCT04020237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986588|NCT03598374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients, care provides, investigators and outcome assessors are blinded for the treatment: Inositol + Folic acid versus Folic acid alone. The treatment allocation is identified by code number before the study start, and will be revealed only after data analysis.|Randomized multi centre double-blind controlled trial|t|t|t|t
33986589|NCT06359847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986590|NCT02260830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986591|NCT00001865||||TREATMENT||||||||
33986592|NCT04847323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of the principal investigator and participants was not be possible due to the nature of the interventions. Nonetheless, the outcome assessor was blinded for the periodontal and patient perception variables.|"This was a 2-arm parallel randomized controlled trial. Therefore, the selected patients were randomly divided into two groups.~Group 1: Bonded V-bend retainers. Group 2: Vacuum-formed retainers. Randomization was performed through sequentially numbered, opaque envelopes prepared by a colleague independent of the study."|f|f|f|t
33986593|NCT06133725|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33986594|NCT04395677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986595|NCT01961973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986596|NCT03557632|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will use a between-groups, randomized controlled experimental design to test the effects of Virtual Reality Cue Exposure Therapy (VRCET) compared to Relapse Prevention Drug Education (RPDE) on self-reported drug craving, physiological reactivity (i.e., Galvanic Skin Conductance \[GSC\] and heart rate \[HR\]), craving coping skills, and drug use among Mexican American IDUs and NIDUs with heroin as their primary drug of choice (see design below). All participants who are former IDU will not be randomized and will complete the VRCET protocol.||||
33986597|NCT04111263|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double-blinded||t|f|t|t
33986598|NCT01118312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33986599|NCT01139034|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33986600|NCT01113424|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33986601|NCT00622414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986602|NCT04123080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986603|NCT02485847|||COHORT||PROSPECTIVE|||||||
33986604|NCT06390501|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33986605|NCT01107366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986606|NCT00507663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986607|NCT00441467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986608|NCT06237023|NON_RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|f|t|t
33986609|NCT06250491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683534|NCT04839575|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The PI, CRA and study biostatistician will be masked until database lock.|A two-period crossover design will be used where the treatment sequences will be assigned at random.|t|f|t|f
33986610|NCT01802853|RANDOMIZED|CROSSOVER||||NONE||||||
33986611|NCT00415363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986612|NCT01263860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683535|NCT03254615|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Experimental, analytical, longitudinal, and prospective designs will be employed. The assignment will be conducted by each school.||||
33683536|NCT02639858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986613|NCT01862627|||CASE_ONLY||RETROSPECTIVE|||||||
33683537|NCT00773227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683538|NCT04939506|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683539|NCT00571402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683540|NCT03615508|NA|SINGLE_GROUP||OTHER||NONE||Single arm, intervention trial.||||
33774345|NCT06738732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986614|NCT03072563|||COHORT||PROSPECTIVE|||||||
33774346|NCT06715241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774347|NCT00816660|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33840468|NCT06228716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The individual and the independent observer participating in the subcutaneous biological drug administration skill evaluation were enabled to participate in the evaluation process with a blinding method.|The research was carried out with a pretest-posttest randomized controlled experimental design to evaluate the effect of the training given by the hybrid simulation method to individuals who self-administer subcutaneous biological drugs on application skills and anxiety levels.|t|f|f|f
33986615|NCT04422769|||COHORT||PROSPECTIVE|||||||
33986616|NCT02286817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33986617|NCT05710393|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33986618|NCT04794283|||COHORT||PROSPECTIVE|||||||
33986619|NCT00441831|||CASE_CONTROL||RETROSPECTIVE|||||||
33986620|NCT01229618|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986621|NCT01268709||||TREATMENT||||||||
33986622|NCT04207203|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||In the first 3 weeks, stabilization phase, SZC will be prescribed to normalize plasma potassium to 3.5 to 5.0 mml/L, and a diet with energy 25-35 kcal/kg/day and protein 0.6 to 0.8 g/kg/day and with low K content will be prescribed. At the end of the first 3 weeks, the patients will initiate a healthy diet containing 3700 to 4000 mg/potassium for 3 weeks (healthy diet phase). A food basket containing fruits, vegetables, whole grains, nuts, white meat, fish and eggs in amounts adequate for the patient will be provided. Serum K will be monitored to promote serum K between 3.5 to 5.0 mmol/L and adjustments in the dose of SZC will be performed according to the drug label. During stabilization and healthy diet phases, serum K will be measured every 72 hours until serum K is normalized and after that, once per week.||||
33986623|NCT01882647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986624|NCT03660384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986625|NCT03934047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986626|NCT03325192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subject assignment will be done using randomly generated assignment tables based on stratification by tumor type (Lung, Breast, Other) and assigned 1:1 using random permuted blocks of 4.~Subjects will be blinded to their group assignment to minimize bias on follow up surveys.~Physicians evaluating the patient during the initial visit and on subsequent postprocedure followup will be blinded to subject assignment. The provider responsible for placement of the catheter and delivery of the pleurodesis agent or placebo will not be involved in post procedure followup care~All treatment physicians will follow prespecified protocols in deciding on adequate pleurodesis and timing of IPC removal."|Prospective, Randomized, Controlled, Double Blinded, Parallel Design, Trial|t|f|t|t
33840469|NCT01245374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840470|NCT00154531|||CASE_CONTROL||OTHER|||||||
34080763|NCT00029822|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33683541|NCT03718975|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33683542|NCT00400296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683543|NCT02602678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683544|NCT01086839|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33683545|NCT05542745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683546|NCT02386670|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33683547|NCT02723071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903585|NCT01369810|||||RETROSPECTIVE|||||||
33903586|NCT00402974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33903587|NCT03920852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903588|NCT03102775|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|While the leaders and family-coordinators are aware of whether the office has been randomized to experimental or control group offices, the families are masked for this information. they are only aware of participating in a family project, but not if experimental or control condition.|Cluster-randomized study. After baseline at office leader and family coordinator level as well as administrative data for families in target group, offices have been randomized to experimental and control group offices. The HOLF-model is implemeted in experimental group offices, while control group offices implement local family projects. Effects on families are analysed on the four main follow-up areas: employment, housing, financial situation and the social situation of the children.|t|f|f|f
33903589|NCT05706519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33903590|NCT02315729|||COHORT||PROSPECTIVE|||||||
33903591|NCT05163561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study is designed as a double-blind (observer blind) study. Observer-blind means that during study, the participants and the study personnel responsible for the evaluation of any study endpoints (e.g. safety and immunogenicity) will be unaware of the IP administered. The IP preparation and administration will be done by designated unblinded personnel who will not participate in any of the clinical study evaluations. Unblinded study personnel will prepare/reconstitute the IP out of view of the participant as well as the site staff. Considering the fact that the IP are likely to have distinct appearances, even when drawn into syringes, the syringes will be masked with an opaque wrapping before administration. After administration, the unblinded study personnel will complete accountability label on the carton and store the used products at designated area.|Study participants aged 6 to 8 weeks will be enrolled and randomized into 1:1:1:1 ratio to receive either the SII inactivated Salk polio vaccine (adsorbed) from one of the three lots (Lot A or Lot B or Lot C) or the Sii licensed inactivated poliovirus vaccine (IPV).|t|t|t|t
33903592|NCT00002191||||TREATMENT||DOUBLE||||||
33903593|NCT01024673|||COHORT||PROSPECTIVE|||||||
33903594|NCT04389606|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33903595|NCT04076449|||COHORT||PROSPECTIVE|||||||
33903596|NCT02703116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683548|NCT06036147|RANDOMIZED|FACTORIAL||TREATMENT||NONE|"Outcomes are all assessed via self-report so masking of research team is not necessary.~Participants and interventionists cannot be masked as to what intervention the participants receiving."|Youth are randomized into one of 8 pathways which are all combinations of three intervention approaches.||||
33903597|NCT04146584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903598|NCT06300619|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants know that there are 2 Pilates groups, but not which group is under investigation vs. the comparison group.||t|f|f|f
33903599|NCT02110121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903600|NCT00014573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903601|NCT01946048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903602|NCT06146218|NA|SINGLE_GROUP||OTHER||NONE||||||
33903603|NCT01588197|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33683549|NCT00498667|||COHORT||RETROSPECTIVE|||||||
33683550|NCT00646243|||COHORT||PROSPECTIVE|||||||
33683551|NCT04825353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683552|NCT04353804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The result of this randomization will be double-blinded, both to the study personnel and participants. All participants will access the computerized cognitive rehabilitation software (or control programs) via the same mechanism. Only specific support staff provided by our industry partner for purposes of training participants on the devices will have knowledge of the participant's randomization category other than the biostatisticians.|The RETURN-III study will randomize medical and surgical VA ICU survivors to either 12-weeks of intervention using Computerized Cognitive Rehabilitation (CCR), or control of non-specific computer games.|t|t|t|t
33683553|NCT05671809|||CASE_CONTROL||PROSPECTIVE|||||||
33683554|NCT01382147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683555|NCT01987921|||COHORT||PROSPECTIVE|||||||
33683556|NCT04902300|||CASE_ONLY||CROSS_SECTIONAL|||||||
33683557|NCT00204555|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33683558|NCT02674854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683559|NCT03787381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683560|NCT05987488|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Quadruple||t|t|t|t
33683561|NCT05909800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, caregivers, investigators, outcome assessors, and the person responsible for the statistical analysis will be blinded to the intervention until completion of the study.|Participants will be randomly assigned to two groups, receiving either phenofibrate at a dose of 160 mg or placebo, orally, once daily, for 12 months. All study participants will be followed up for up to 12 months after the start of the intervention. Study visits at month 3, 6, 9 and 12 will be coordinated with diabetes outpatient clinic visits.|t|t|t|t
33683562|NCT05823740|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33903604|NCT00921505|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33903605|NCT01095250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903606|NCT00849303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33903607|NCT00279903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903608|NCT02075255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903609|NCT02143518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33903610|NCT02662686|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33903611|NCT01842893|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33903612|NCT03718104|||COHORT||PROSPECTIVE|||||||
33903613|NCT04822363|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33903614|NCT04937894|||COHORT||PROSPECTIVE|||||||
33903615|NCT03591029|||CASE_ONLY||PROSPECTIVE|||||||
33903616|NCT01779986|||COHORT||PROSPECTIVE|||||||
33903617|NCT02625662|||COHORT||PROSPECTIVE|||||||
33903618|NCT02645305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903619|NCT03516799|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Non-randomized trial across four time points at one study site||||
33683563|NCT04158193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903620|NCT03744169|||CASE_ONLY||PROSPECTIVE|||||||
33683564|NCT04531774|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683565|NCT05449470|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Patients (in both arms) who schedule an appointment will receive a letter containing information on the objectives and procedures of the study and an invitation to participate. For patients in the intervention arm, the invitation letter will also include a printed QPL and a link to the Patient portal. At this point, the Patient portal will only provide information on their upcoming visit as well as educational material regarding falls prevention.~At the falls clinic the assessments will be carried out as usual. In the intervention group, the physician will use the CDSS during the consultation. Consultations in the control group are carried out as usual. After the consultation, patients and their caregivers (if applicable) will be asked to fill out a set of questionnaires. After the visit to the falls clinic, patients in the intervention group will be able to review their consultation with the physician and their estimated fall risk in the patient portal."|t|f|f|f
33683566|NCT02689102|||CASE_ONLY||CROSS_SECTIONAL|||||||
33683567|NCT06206954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators (with exception of statistician) will be masked to study condition. Outcome assessors and all staff engaging directly with participants will be masked to study condition, except those staff who are sending intervention content.|Parallel cluster randomized|f|f|t|t
33774348|NCT06183515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study included a total of 81 pediatric patients who were 0 to 12 years of age, classified as II and III according to the American Society of Anesthesiologists (ASA), and who underwent elective subglottic balloon dilation under general anesthesia due to acquired or congenital subglottic stenosis.Patients were randomized into two groups through computer-generated randomization into two groups: Group non-CPAP (Control, n=41) and Group CPAP (n=40).During the postoperative period, the CPAP group received Fi02:0.6 and 8 to 12 mmHg of nasal CPAP, or CPAP was initiated through the tracheostomy cannula. The non-CPAP group received Fi02:0.6, and oxygen support was provided at a rate of 3 liters per minute (L/min) either via mask for those who were extubated or through a T-piece for those with a tracheostomy cannula.|t|f|f|f
33903621|NCT02082067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903622|NCT04205591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Bone augmentation procedures using autogenous cortical plates or xenograft cortical plates were carried on, both using autogenous bone chips to fill the resulting gap. Patients included in this clinical trial were randomly allocated by a blinded assistant in two groups: Autogenous Cortical Plates (ACP) and Xenograft Cortical Plates (XCP). Random allocation of participants to intervention groups was performed using a computerized random number generated by the GraphPad- QuickCalc software (GraphPad Soft- ware Inc., La Jolla, CA) As a result, 9 patients were randomly assigned to de ACP group and 9 to the XCP group. All surgeries were performed by the same oral surgeon (JT).|16 patients referred for implant placement and with insufficient bucco-lingual (BL) alveolar bone width (\<4 mm) were included in the study.. Patients included in the clinical trial were randomly allocated by a blinded assistant in two groups: in the autogenous cortical plate group (ACP), and xenogeneic cortical plate group (XCP).|t|f|t|f
33903623|NCT01165801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33903624|NCT00161304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903625|NCT05875935|NA|SINGLE_GROUP||SCREENING||NONE||||||
33903626|NCT06029816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Fourteen patients each had three mutation sites and 42 patients were co-enrolled||||
33903627|NCT01518192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903628|NCT05655546|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33683568|NCT02225613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683569|NCT01191216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683570|NCT01510288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683571|NCT03789409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33683572|NCT03526380|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33683573|NCT01059929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683574|NCT03257709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683575|NCT03885167|||CASE_CONTROL||PROSPECTIVE|||||||
33683576|NCT02246712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683577|NCT01637519|||COHORT||PROSPECTIVE|||||||
33683578|NCT01863654|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33683579|NCT00427180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683580|NCT02342093|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33683581|NCT05194566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, investigator and outcomes assessor are all blinded. Designated research team members will be unblinded in order to manage computerized procedure.|The study will employ a between-subject randomized sham-controlled design.|t|t|t|t
33683582|NCT03967691|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Only subjects will be masked regarding order of saline and tocilizumab infusion.|The study is designed in a placebo-controlled crossover manner, consisting of a screening visit and three study visits/study days. the Subjects will be infused with saline (placebo) on two of the study days and tocilizumab on one of the study days.|t|f|f|f
33683583|NCT05315011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33683584|NCT04260932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683585|NCT00577525|||CASE_CONTROL||PROSPECTIVE|||||||
33683586|NCT00694538|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33683587|NCT04199702|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683588|NCT02359175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683589|NCT02916121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683590|NCT02472509|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683591|NCT01032473|||CASE_CONTROL||PROSPECTIVE|||||||
33903629|NCT01625728|||CASE_CONTROL||PROSPECTIVE|||||||
33903630|NCT00002442||||TREATMENT||NONE||||||
33903631|NCT02075918|||CASE_ONLY||PROSPECTIVE|||||||
33903632|NCT00216021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903633|NCT02002078|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|t|f|f
33903634|NCT05636865|||OTHER||RETROSPECTIVE|||||||
33683592|NCT06252077|NA|SINGLE_GROUP||TREATMENT||NONE||body weight loss||||
33683593|NCT00881543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33903635|NCT05945485|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33903636|NCT06448884|||OTHER||CROSS_SECTIONAL|||||||
33903637|NCT01254604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080764|NCT05469945|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking possible: the patient and the provider are well aware of yes or no wearing of compressive garments.|Randomized controlled trial evaluating the added value of CC2 compressive garments in stage 0-1 LLL||||
34080765|NCT03514550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34080766|NCT00534027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080767|NCT05441800|||COHORT||PROSPECTIVE|||||||
34080768|NCT00004293||||TREATMENT||||||||
34080769|NCT02185274|||COHORT||PROSPECTIVE|||||||
34080770|NCT00653393|RANDOMIZED|CROSSOVER||||NONE||||||
34080771|NCT02238808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683594|NCT04367571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683595|NCT00767182|||COHORT||PROSPECTIVE|||||||
33683596|NCT05944328|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33683597|NCT02507960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683598|NCT00521300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683599|NCT01092832|NON_RANDOMIZED|||TREATMENT||NONE||||||
33683600|NCT06086015|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33683601|NCT05484687|NA|SINGLE_GROUP||OTHER||NONE||||||
33683602|NCT01455987|||COHORT||RETROSPECTIVE|||||||
33683603|NCT02535780|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683604|NCT02698995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683605|NCT02444624|||CASE_CONTROL||PROSPECTIVE|||||||
33683606|NCT00385164|||COHORT||PROSPECTIVE|||||||
33683607|NCT05331079|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33683608|NCT05834595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683609|NCT01716871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683610|NCT02276027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683611|NCT00222716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683612|NCT01407653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683613|NCT02447705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683614|NCT01323920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683615|NCT03703401|||COHORT||PROSPECTIVE|||||||
33683616|NCT00777751|||CASE_ONLY||PROSPECTIVE|||||||
33683617|NCT04434378|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||One group will be randomized to tamsulosin and the second group randomized to placebo|t|t|t|t
33683618|NCT02819778|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683619|NCT06505720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683620|NCT04585009|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part A will be a single ascending dose escalation study consisting of two sequential cross-over cohorts (Cohorts 1 and 2) in healthy participants. Part B is a repeat dose study consisting of two parallel cohorts (Cohort 3 and 4) in healthy participants. Part C is a repeat dose study consisting of one cohort (Cohort 5) in participants with asthma.|t|f|t|f
33683621|NCT03811808|||COHORT||PROSPECTIVE|||||||
33683622|NCT00666289|||FAMILY_BASED||OTHER|||||||
33683623|NCT00604370|||CASE_CONTROL||RETROSPECTIVE|||||||
33683624|NCT02577393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683625|NCT01251640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683626|NCT04671472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683627|NCT04248959|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683628|NCT04865523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774349|NCT00165360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774350|NCT05880589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33774351|NCT05683236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33774352|NCT02833662|NA|SINGLE_GROUP||SCREENING||NONE||||||
33774353|NCT04840602|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33774354|NCT06740110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080772|NCT05654571|||COHORT||PROSPECTIVE|||||||
33774355|NCT06739005|||COHORT||PROSPECTIVE|||||||
33840471|NCT04297631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840472|NCT01361542|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33840473|NCT01934790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840474|NCT01648673|||COHORT||PROSPECTIVE|||||||
33840475|NCT00002475||||TREATMENT||||||||
33840476|NCT06507462|||OTHER||RETROSPECTIVE|||||||
33840477|NCT02474719|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33840478|NCT00557557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840479|NCT00384735|||COHORT||PROSPECTIVE|||||||
33840480|NCT01570959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33840481|NCT00802347|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33840482|NCT06249958|||COHORT||RETROSPECTIVE|||||||
33840483|NCT00605332|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33840484|NCT02042027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683629|NCT05622162|NA|SINGLE_GROUP||TREATMENT||NONE|"The blind readers of PET/CT examinations with Investigational product (18F-JK-PSMA-7) and with Comparator (18F-fluorocholine) will be blinded to any clinical data of patient.~The analysis of images obtained with IMP (18F-JK-PSMA-7) and with Comparator (18F-fluorocholine) will be performed by two independent off-site experts blinded to any patient´s clinical data, using the defined grid (Appendix I). Discrepancies between results of the two observers will be recorded by the clinical manager and a consensus reading with third expert will be organized. This reading will be used for determination of imaging performances.~Wash-out period of at least one month is ensured between reading of examinations with Investigational product (18F-JK-PSMA-7) and with Comparator (18F-Fluorocholine) for each blind reader."|Prospective, multicentric, comparative (controlled), phase III study of diagnostic performance with blind reading and standard of truth.||||
33683630|NCT05869357|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33774356|NCT03981445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This trial is an open-label, un-blinded study. Given the pragmatic nature of the trial, participants, providers and research staff will not be blinded. Research and clinical staff will be blinded to the randomization procedure to prevent predictions about participant assignment.Research and clinical staff will initially be blinded to arm assignment to avoid bias, but after baseline the research and clinical staff will not be blinded.|This trial is an open-label, multi-site, multi-center, randomized, controlled,superiority trial with two parallel treatment arms. The study is a type-1 hybrid effectiveness implementation study. Participants will be randomized to the on-site integrated care with adherence counselling treatment or the off-site referral to specialized care group with patient navigation in a 1:1 ratio using a permuted-block randomization scheme.|f|f|f|t
33903638|NCT01943539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903639|NCT03750110|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will use a pragmatic, parallel-group, open, randomized controlled trial design||||
33903640|NCT04718519|||COHORT||CROSS_SECTIONAL|||||||
33903641|NCT00907140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903642|NCT00607646|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33903643|NCT03952312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33903644|NCT04196842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Blinded until intervention is assigned to subject||t|f|t|t
33903645|NCT01654497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903646|NCT02698761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33903647|NCT03172507|||CASE_CONTROL||PROSPECTIVE|||||||
33903648|NCT02159092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903649|NCT04463160|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33903650|NCT04705597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Multicenter, Randomized, Double-blind, Placebo-controlled|t|t|t|t
33903651|NCT06182033|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33903652|NCT00726323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903653|NCT03919890|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blinded||t|f|t|f
33903654|NCT02205385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903655|NCT03310684|||COHORT||PROSPECTIVE|||||||
33903656|NCT06442709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903657|NCT04788199|||CASE_CONTROL||RETROSPECTIVE|||||||
33903658|NCT01844700|RANDOMIZED|PARALLEL||||NONE||||||
33903659|NCT04655677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903660|NCT06192446|||OTHER||CROSS_SECTIONAL|||||||
33903661|NCT04676139|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|A randomized controlled clinical trial||||
33903662|NCT06190912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903663|NCT01271478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903664|NCT02805907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903665|NCT05892185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903666|NCT02735317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986627|NCT04023461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|At the time of patient recruitment, they were randomly assigned to ablation or medical therapy (antiarrhythmic drug arm) according to a 1:1 stratified randomization list locked into a computer system.|All patients in clinical treatment arm had to keep on antiarrhythmic drug for AF rhythm control strategy|f|t|f|t
33986628|NCT03571997|||CASE_ONLY||RETROSPECTIVE|||||||
33986629|NCT01819597|NA|SINGLE_GROUP||TREATMENT||NONE||EDAS surgery for Intracranial atherosclerosis. Non-futility design||||
33986630|NCT04230083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33986631|NCT05783505|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter stepped wedge cluster randomized controlled trial||||
33986632|NCT03555747|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
33986633|NCT00801970|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33986634|NCT00961168|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33986635|NCT05951660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33986636|NCT01537640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986637|NCT01886768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986638|NCT02543554|||OTHER||OTHER|||||||
33986639|NCT02466880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986640|NCT01638520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986641|NCT03886571|||COHORT||PROSPECTIVE|||||||
33903667|NCT06439719|||CASE_CONTROL||PROSPECTIVE|||||||
33903668|NCT03611400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The participants, investigators, and anyone else involved with the study will remain blinded for its entirety.|A randomized, double-blind, placebo-controlled crossover in which participants receive one of the study supplements (probiotic or placebo) for a 3-week intervention period each will be used.|t|f|t|t
33903669|NCT02125929|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33903670|NCT02971696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903671|NCT04740593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will only have access to coded data, which cannot be traced back to the individual participants, from the electronic Case Report Forms in Castor, a cloud-based clinical data management platform.||f|f|f|t
33903672|NCT01671436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683631|NCT01005121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683632|NCT00212940|RANDOMIZED|PARALLEL||||NONE||||||
33683633|NCT04064008|||COHORT||RETROSPECTIVE|||||||
33683634|NCT00167869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33683635|NCT02778360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903673|NCT05005559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33903674|NCT01520324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903675|NCT05876650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903676|NCT00763685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33903677|NCT00003068||||TREATMENT||||||||
33903678|NCT01299597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903679|NCT00250471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903680|NCT00077623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903681|NCT02975869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903682|NCT02092415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903683|NCT05480137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33903684|NCT05938088|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33683636|NCT03040570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683637|NCT00573287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683638|NCT00859638|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683639|NCT00637143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683640|NCT00891956|||||PROSPECTIVE|||||||
33683641|NCT02858544|||COHORT||RETROSPECTIVE|||||||
33683642|NCT02280122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33683643|NCT05264948|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33683644|NCT01961583|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683645|NCT03315091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683646|NCT00918008|||COHORT||PROSPECTIVE|||||||
33683647|NCT05023369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33774357|NCT02158624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774358|NCT06740071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774359|NCT02202694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774360|NCT06632678|||OTHER||OTHER|||||||
33903685|NCT01888354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903686|NCT02004054|||CASE_ONLY||CROSS_SECTIONAL|||||||
33903687|NCT05921916|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Single center, randomized, double-blind, placebo-controlled clinical study.|t|f|t|f
33903688|NCT00268112|||||RETROSPECTIVE|||||||
33903689|NCT02393599|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33903690|NCT00221845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903691|NCT02688114|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903692|NCT00733512|||COHORT||RETROSPECTIVE|||||||
33986642|NCT01393366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986643|NCT03243630|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The participant and medical professional will be blinded to the condition per day.|Mixed-effects models will be used to test the study hypotheses. These models allow for different numbers of observations per subject, use all available data on each subject, and are unaffected by randomly missing data.|t|f|t|f
33986644|NCT05314023|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986645|NCT04115150|||COHORT||RETROSPECTIVE|||||||
33986646|NCT02995005|NA|SINGLE_GROUP||PREVENTION||NONE|No masking, just one interventional group.|Single group study.||||
33774361|NCT03075293|||COHORT||RETROSPECTIVE|||||||
33774362|NCT01585922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774363|NCT05416775|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicenter, open-label, dose-finding and efficacy-expansion phase Ib/II study. The first stage is for dose finding, using modified 3+3 design; the second stage is for dose confirmation and efficacy expansion through randomization.||||
33774364|NCT04973046|||CASE_ONLY||RETROSPECTIVE|||||||
33774365|NCT02053779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33774366|NCT06725212|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33774367|NCT06740201|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986647|NCT00509730|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33986648|NCT01280149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986649|NCT00498082|||||PROSPECTIVE|||||||
33986650|NCT04267627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Three-arm trial evaluating CARING delivered over telemedicine vs. CARING delivered face-to-face vs. usual care||||
33986651|NCT00448903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683648|NCT06008912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and his/her caregivers will allocate in study via computer based randomisation, and will not know about his/her and also other participants group in study.|"Experimental model of study consist from three arm.~* First Arm: Patients will take aerobic exercise training in 3 days per week, and 7 days per week calisthenic exercises for upper extremity, lower extremity and trunk, for 8 weeks.~* Second Arm: Patients will take aerobic exercise training in 3 days per week, for 8 weeks.~* Third Arm: Patients will take physical activity recommendations, and just screening after 8 weeks."|t|t|f|f
33683649|NCT03712709|||COHORT||CROSS_SECTIONAL|||||||
33683650|NCT04397666|NA|SINGLE_GROUP||OTHER||NONE||||||
33683651|NCT03361943|||OTHER||OTHER|||||||
33683652|NCT02311218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33683653|NCT04170478|NA|SINGLE_GROUP||OTHER||NONE||||||
33683654|NCT03893253|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Trained evaluators will rate a series of videos but will be blinded to which arm of the study participants are from.|Participants randomized to one of three groups : early booster, late booster, or no booster (control group)|f|f|f|t
33683655|NCT03906916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683656|NCT05398081|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33683657|NCT04104269|||COHORT||PROSPECTIVE|||||||
33683658|NCT05073094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774368|NCT06097156|||COHORT||CROSS_SECTIONAL|||||||
33774369|NCT06588608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33774370|NCT06741306|||COHORT||CROSS_SECTIONAL|||||||
33986652|NCT01764347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986653|NCT04992234|||COHORT||PROSPECTIVE|||||||
33986654|NCT00886275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024901|NCT05287256|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo controlled, double blind drug administration|A within-subjects design. At the time of study randomization, participants will be assigned to complete Sub-Study 1 followed by Sub-Study 2, or vice versa, using a counter-balanced randomization sequence. The order in which dose conditions are administered within each sub-study will be randomized across participants because there are too many drug conditions to fully counterbalance dosing within sub-studies at the proposed sample size.|t|t|f|f
33683659|NCT01836874|||CASE_ONLY||PROSPECTIVE|||||||
33683660|NCT01470989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683661|NCT04924413|NA|SINGLE_GROUP||TREATMENT||NONE||L-TIL and Tislelizumab||||
33683662|NCT04865874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized clinical trial|t|f|f|t
33683663|NCT02899078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683664|NCT05634447|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683665|NCT01966432|NA|SINGLE_GROUP||SCREENING||NONE||This is a single group, non-randomized, pilot study that explores the feasibility of applying SBIRT to adult with high-risk diabetes.||||
33683666|NCT00645255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683667|NCT02303236|||COHORT||PROSPECTIVE|||||||
33683668|NCT05623865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person who evaluates the outcome criteria and the person who makes the interventions are different. The person who evaluates the outcome criteria is blind.|Randomized controlled trial|f|f|f|t
33683669|NCT01486043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774371|NCT06226077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention is a 6-week (4-week intervention, 1- week pre/post actigraphy measurement) 2-armed randomized control trial with the sleep extension intervention in one arm, and then an education contact control in the second arm.||||
33774372|NCT06074900|||COHORT||PROSPECTIVE|||||||
33774373|NCT03464214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774374|NCT04873778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|t|f|f|f
33774375|NCT06442020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774376|NCT06084104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774377|NCT05417789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774378|NCT05907928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33774379|NCT06441227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903693|NCT04936672|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Try not to allow communication and contact between participants in each group. Researchers do not participate in training. Researchers do not disclose more research information. Data collection and entry should be operated by professional personnel.|There are four groups, 1 control group, and 3 intervention groups. Three intervention groups include the brisk walking group, the Tai Chi Chuan group, and their combination group.||||
33903694|NCT01790438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903695|NCT06066918|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||allocation will be sequential. 2 patients will be in the study group, followed by one patient at the control group.||||
33903696|NCT04355338|||COHORT||PROSPECTIVE|||||||
33903697|NCT00163553|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33903698|NCT04487860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903699|NCT04269512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903700|NCT05602597|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33903701|NCT03714386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683670|NCT01595945|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33683671|NCT05410951|||COHORT||PROSPECTIVE|||||||
33683672|NCT03523923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study uses masked outcome assessments; research staff members who collect outcome data from participants at 4 and 8 months must be unaware of participants' treatment group allocation.|Randomized, 1:1 controlled trial effectiveness study comparing Collaborative Care (CC) to usual care (UC) to reduce pain interference among outpatients in our UW Medicine TBI clinics who have chronic pain, including headache, and meet other eligibility criteria.|f|f|f|t
33683673|NCT00407680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683674|NCT01962168|||COHORT||PROSPECTIVE|||||||
33683675|NCT01937104|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683676|NCT04850781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This is a Phase 1 pilot feasibility study that uses an embedded, pragmatic randomized clinical trial design.|f|f|t|t
33683677|NCT01252693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683678|NCT05201456|||COHORT||PROSPECTIVE|||||||
33903702|NCT06149884|||COHORT||RETROSPECTIVE|||||||
33903703|NCT04239274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683679|NCT01494389|||CASE_CONTROL||PROSPECTIVE|||||||
33683680|NCT03665818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683681|NCT00594724|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683682|NCT01436162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683683|NCT05828810|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a multicentre, pragmatic, open label, 2-arm parallel-group Vanguard feasibility RCT.||||
33683684|NCT03066973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683685|NCT00320957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683686|NCT04687176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683687|NCT00203814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683688|NCT00775203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774380|NCT06035237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33774381|NCT05698654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774382|NCT03821415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentre, randomised, double-masked, parallel-group, placebo-controlled Phase II study|t|t|t|t
33903704|NCT00474630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024902|NCT05708092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the follow up data collector will be blinded to the randomization assignment of all participants. At the beginning of each interview, the participant will be instructed to not share whether they were assigned to a NRF or SOC.||f|f|t|f
34024903|NCT00235209|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024904|NCT06336395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080773|NCT04541563|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"This is a fully remote trial. Participants will be randomized in ProofPilot, and only the fulfillment center will know whether the participant is in the placebo or control arm.~Participants will be unblinded at week 4 at the crossover."|"This is a fully remote trial where participants engage at home in the study using the ProofPilot study platform. All potential participant enrollment data, including proof of identity via government ID will be reviewed by licensed medical professionals in the participant's state prior to their full enrollment.~Participants will be randomized into an immediate or delayed treatment arm. The immediate treatment arm participants will be shipped an active Fisher Wallace device limited to Level 2 output even if a participant raises the dial beyond that. The participant will remain with the active device for the full 8 weeks."|t|t|t|t
34080774|NCT05157217|||CASE_CONTROL||OTHER|||||||
34080775|NCT02643875|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34080776|NCT02110979|RANDOMIZED|PARALLEL||||NONE||||||
33683689|NCT03702244|RANDOMIZED|PARALLEL||OTHER||NONE||Participants who meet all inclusion criteria and none of the exclusion criteria will be randomized in a ratio of 1:1 within a clinical center to either a precision evaluation strategy or usual care using an interactive web or voice-based system (IXRS). Randomization will be stratified by intended first test if randomized to usual care and by classification as minimal vs. elevated risk by the minimal risk model. The randomization scheme within a clinical center will be carried out by the method of random permuted block design with variable block size||||
33683690|NCT04896450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The histologist is blinded to the study protocol|Patients undergo GTR procedure, after they are randomly allocated either to test (with OTM) or control group (without OTM)|f|f|f|t
33903705|NCT03627455|||COHORT||PROSPECTIVE|||||||
33903706|NCT04590937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903707|NCT00056212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903708|NCT04360330|NA|SEQUENTIAL||TREATMENT||NONE||||||
33903709|NCT05055661|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33903710|NCT05801926|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Everyone eventually gets the intervention, it is the order that is randomized. The outcome is gait quality measured directly from the sensor and is not affected by observers.|Individual, blocked, stepped-wedge||||
33903711|NCT03893903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903712|NCT04743414|NA|SEQUENTIAL||OTHER||NONE||||||
33903713|NCT01221675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903714|NCT04942483|||OTHER||PROSPECTIVE|||||||
33903715|NCT03098381|||COHORT||PROSPECTIVE|||||||
33903716|NCT01135485|||CASE_CONTROL||PROSPECTIVE|||||||
33903717|NCT04080115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903718|NCT01000064|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33903719|NCT06208046|||COHORT||RETROSPECTIVE|||||||
34024905|NCT05127915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data will be reviewed by the Outcomes Assessor for futility at 25% and 50% enrollment. Subsequently at 75% enrollment, the Outcomes Assessor will conduct an interim assessment for potentially stopping the study with overwhelming efficacy of the filter cohort.||f|f|f|t
34024906|NCT05174195|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective||||
34024907|NCT00506792|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34024908|NCT00087620||||TREATMENT||||||||
34024909|NCT02974179|||COHORT||PROSPECTIVE|||||||
33903720|NCT03455881|||COHORT||PROSPECTIVE|||||||
33903721|NCT00404404||||TREATMENT||NONE||||||
34080777|NCT05235438|NA|SEQUENTIAL||TREATMENT||NONE||This study is to observe the dose-limiting toxicity (DLT) of the patients and to determine the maximal tolerance dose(MTD) and recommended dose for expansion (RDE) to observe the AE including relationship and severity of IMM27M based on CTCAE 5.0||||
34080778|NCT01499810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903722|NCT04367701|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33903723|NCT05117710|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Quadruple masking|Parallel-arm, double-blind, randomised, placebo-controlled|t|t|t|t
33903724|NCT04760314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903725|NCT01344811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903726|NCT00164762|||DEFINED_POPULATION||PROSPECTIVE|||||||
33903727|NCT04018287|||CASE_CONTROL||PROSPECTIVE|||||||
33903728|NCT05283915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080779|NCT04080726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|multicenter, randomized, double-blind, parallel group study|t|f|t|f
34080780|NCT02541617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080781|NCT06182059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080782|NCT02175121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080783|NCT05905432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33903729|NCT01902797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080784|NCT00823134|NA|SINGLE_GROUP||SCREENING||NONE||||||
34080785|NCT00558545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080786|NCT05871307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080787|NCT02373865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080788|NCT03217591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Phase 2, randomized, double-blind, placebo-controlled, parallel-group study|t|t|t|f
34080789|NCT03161301|||COHORT||CROSS_SECTIONAL|||||||
34080790|NCT02163395|NA|SINGLE_GROUP||OTHER||NONE||||||
34080791|NCT01706367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34080792|NCT06429865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903730|NCT04922125|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single-blind|A single-blind, randomised crossover design with one arm.|t|f|f|f
33903731|NCT04479501|||COHORT||RETROSPECTIVE|||||||
34080793|NCT01952652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080794|NCT00763581|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080795|NCT01507350|||COHORT||PROSPECTIVE|||||||
34080796|NCT04702152|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34080797|NCT01494818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33683691|NCT01405066|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33683692|NCT02506985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683693|NCT01197443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080798|NCT01460303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080799|NCT01033500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683694|NCT02956902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683695|NCT00639743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683696|NCT05974423|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be assigned to one of the following groups:~* Group 1:~  1. Oxycodone 5 mg 1 tablet every 6 hours PRN~ 2. Tylenol 1000 mg every 8 hours~ 3. Ibuprofen 600 mg every 6 hours as needed for pain~* Group 2 (Experimental Group) will not be sent home with an oxycodone prescription. They will be sent home with the following prescriptions. If this does not manage their pain, they will call the resident on call who will reach out to the PI. The PI will then electronically send in a prescription of oxycodone to their pharmacy if required. The PI or operating surgeon (co-investigators) will be available 24/7 to do this. They will be sent home with these two prescriptions:~  1. Tylenol 1000 mg every 8 hours~ 2. Ibuprofen 600 mg every 6 hours as needed for pain"||||
33683697|NCT00266877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683698|NCT05530018|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683699|NCT04443595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683700|NCT02983097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683701|NCT00998777|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33683702|NCT00647829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683703|NCT00472758|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34080800|NCT01249911|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080801|NCT02499055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080802|NCT05867381|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|A sham filter will be used in the control, to replace HEPA filter in the intervention group. Participants and investigators will be blinded to the intervention type, only investigators who will prepare air filters for intervention will be unblinded for the real air filter type.||t|f|t|f
34080803|NCT02294279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080804|NCT01198002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080805|NCT02171000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683704|NCT02204761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683705|NCT00695201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683706|NCT04280770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each of the recruited patients were assigned a study number and randomized in accordance with a simple block randomization scheme.|Fifty participants were assigned and divided into two groups. Participants without RD after SO removal was recruited into group A-NRD, and participants with RD after SO removal was recruited into group B-RD.|t|t|f|t
33683707|NCT04234633|||CASE_ONLY||PROSPECTIVE|||||||
33683708|NCT01904773|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33683709|NCT04505501|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is unblinded.|||||
33683710|NCT01220544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683711|NCT03824509|||CASE_CONTROL||RETROSPECTIVE|||||||
33683712|NCT03633877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Every patient will have each tape on each side of the mouth, with Hy-Tape® on one side and DuraporeTM on the other side according to the randomization schema.|t|f|f|t
34080806|NCT05098080|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Eight healthy subjects will be in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg). For each dose cohort, six subjects will be administered Hutrukin and two will be administered placebo and the study will not proceed to the next dose level unless the tested dose level has been deemed to have acceptable tolerability and safety. Subjects will undergo blood sampling at multiple time points up to 28 days. Subjects will also be evaluated for the development of anti-drug antibodies (ADA).~Dose escalation will utilize a 6+2 design with sentinel dosing and doses will be explored in cohort of 8 subjects (6 active drug and 2 placebo). There are two sub-groups, the first is comprised of one subject receiving Hutrukin and one subject receiving placebo, the second sub-group is comprised of five subjects receiving active drug and one subject receiving placebo. A 24-hour observation window will be given before enrolling the subjects in the second sub-group."||||
34080807|NCT04746638|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34080808|NCT04065490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Valeda Light Delivery System|t|t|t|t
34080809|NCT00904475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080810|NCT03518359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants do not know that the investigator is testing mindfulness. Participants only will be told that they will be learning stress-reduction skills for physicians.|Randomized, partially-blinded.|t|f|f|t
34080811|NCT01037426|NA|SINGLE_GROUP||PREVENTION||NONE||Patients were their own control and number of falls was compared in the year before and after Pacemaker implant||||
34080812|NCT04737733|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A non-equivalent control group design with a historical control group||||
34080813|NCT03657069|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34080814|NCT04237948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the examiner who did the ratings were blind to the type of tDCS delivered, which was applied by another blinded experimenter.|Two randomized double blind groups will be evaluated. Both group will undergo physical rehabilitation. The real arm group will undergo real cerebellar tDCS while the placebo-arm will undergo a sham stimulation|t|f|t|f
34080815|NCT00477763|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34080816|NCT00018824|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34080817|NCT03089463|||COHORT||PROSPECTIVE|||||||
34080818|NCT03401047|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a prospective interventional cohort study. Women with PCOS and controls will receive identical treatment (transdermal estradiol) and will be monitored using the same surveillance protocol. The study does not involve randomization, and it is not blinded.||||
34080819|NCT04777981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|This is a randomized, double blind, placebo-controlled trial. Patients will be randomized to CBDRA60 supplement or placebo.|t|f|t|f
34080820|NCT01561937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080821|NCT00119574|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34080822|NCT03105037|||CASE_CROSSOVER||PROSPECTIVE|||||||
34080823|NCT06446934|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, single-arm, interventional pre-post design study||||
34080824|NCT04553666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients in the intervention Arm will receive 800 mg Epigallocatechin gallate (EGCG) + 250mg Ascorbic Acid||||
34080825|NCT02706288|NA|SINGLE_GROUP||OTHER||NONE||||||
34080826|NCT05524064|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm prospective study||||
33774383|NCT06266364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All are blinded in the RCT (Randomized Controlled Trial) phase. However, sites will need to have an unblinded programmer who is only programming the device and not collecting outcomes data|1:1 randomization of active stimulation vs. sham stimulation for 12 sessions post randomization, followed by up to 12 sessions of open label active stimulation for all participants|t|t|t|t
33840485|NCT03514316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The observer who performed all the measurements was blinded to the group assignment. The study was blinded in regard to the statistical analysis: blinding was obtained by eliminating from the elaboration file every reference to patient group assignment.|a prospective three-arm parallel group randomized clinical trial with 1:1:1 allocation ratio|f|f|f|t
33840486|NCT02120287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840487|NCT04264377|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33840488|NCT05884177|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33840489|NCT05852665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840490|NCT05222204|NA|SINGLE_GROUP||TREATMENT||NONE||two cohort: cohort A (first-line) and cohort B (post-line)||||
33840491|NCT04365231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840492|NCT01161992|||COHORT||OTHER|||||||
33840493|NCT04398667|||CASE_ONLY||RETROSPECTIVE|||||||
33840494|NCT03620539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34080827|NCT01897337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33840495|NCT05105776|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Galvanic stimulation is masked (sham vs active)||t|f|f|t
33840496|NCT01934764|||||PROSPECTIVE|||||||
33840497|NCT00429013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840498|NCT01529320|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33840499|NCT03312023|RANDOMIZED|PARALLEL||TREATMENT||NONE|Ten potential subjects for Groups C and D will be randomized in a 1:1 fashion.|Open-label Study, multi-arm||||
33840500|NCT01549704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840501|NCT01290276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840502|NCT05350046|NA|SINGLE_GROUP||OTHER||NONE||||||
33840503|NCT03916406|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33840504|NCT04849767|||OTHER||CROSS_SECTIONAL|||||||
33683713|NCT05792657|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Each participant will be randomly assigned (1:1:1:1) to one intervention group, HIGH, MEDIUM, LOW or CONTROL following a simple computer-based randomization program. All participants included in the study will conduct the baseline assessments before the randomization procedure. The study design will not allow for further masking of study participants or the exercise professional (caregivers to the interventions). Those from the research group involved in inclusion of the participants or follow-up measurements will not have access to the group allocation list. Further, all measurements will be completed and plotted without the research group information of group allocation. The statistical analyses will be done in SPSS, following a predefined analysis plan and before unmasking the study arms.|||||
33683714|NCT04278105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683715|NCT00328302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683716|NCT01440543|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33683717|NCT00321087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683718|NCT02050178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683719|NCT01335802|||CASE_CONTROL||PROSPECTIVE|||||||
33683720|NCT05662709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor blinded for treatment groups.|"Controlled clinical trial, 2 groups of patients undergoing tooth extraction, allocated to:~* Test group: alveolar ridge preservation with L-PRF~* Control group: spontaneous healing of the socket"|f|f|f|t
33683721|NCT05117671|||COHORT||RETROSPECTIVE|||||||
33683722|NCT00865423|RANDOMIZED|CROSSOVER||||NONE||||||
33683723|NCT00600145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683724|NCT04474028|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33683725|NCT01073501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33683726|NCT03505710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683727|NCT02233478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33774384|NCT04082429|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised to concizumab PPX/no PPX/ assigned into non-randomised arms, based on treatment before trial. Upon restart, patients randomised to arms 1/2 before pause will enter arm 4. Patients allocated to arms 3 \& 4 before pause will re-enter initially allocated arm. Randomisation into arms 1/2 will be restarted with new patients. Main part is completed when patient completed 24 wks (excluding screening) in arm 1 or 32 wks (excluding screening) in arms 2-4. After main part, patients will have offer to continue in extension (ext.) part and receive treatment with product until concizumab is commercially available in their countries or until 21-Apr-26 at latest. Patients will be in ext. part for up to 257 (arms 2-4) or 265 wks (arm 1) for up to additional 128 (arms 2-4) or 136 wks (arm 1). Patient will receive last dose at home on day prior to visit 26a. Follow-up part will start on visit 26a and lasts for 7 wks and include reporting of bleeding episodes until visit 27a.||||
33774385|NCT06729112|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33774386|NCT05012111|||COHORT||PROSPECTIVE|||||||
33774387|NCT06738589|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33774388|NCT05039229|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774389|NCT06731699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774390|NCT06730672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774391|NCT05280548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903732|NCT05452161|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A prospective randomized controlled trial, comparing 3 modes of intervention. A single-center study conducted at the Musculoskeletal Department of the University of Lausanne The control group receives the standard care in place in the department, including only a group information session (1/3 of the sample).~Intervention group A receives, in addition to a group information session, an individualized preparation and education session (2/3 of the sample).~Intervention group B receives, in addition to a group information session, an individualized preparation and education session, and a remote postoperative follow-up (1/2 of group A = 1/3 of the sample).~Patients are randomly assigned to their group based on their order of arrival. Hip and knee surgery patients are randomized separately, to keep the same proportions in each of the three groups. Block randomisation will be carried out."||||
33903733|NCT05922852|||COHORT||RETROSPECTIVE|||||||
33903734|NCT00349791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903735|NCT00592358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903736|NCT06164795|||COHORT||PROSPECTIVE|||||||
33903737|NCT02627846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903738|NCT05057949|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903739|NCT01317394|||CASE_ONLY||RETROSPECTIVE|||||||
33903740|NCT00048906||||TREATMENT||||||||
33903741|NCT05305261|||COHORT||PROSPECTIVE|||||||
33903742|NCT02491658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903743|NCT03105154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient will be randomized sequentially to Prevena alternating with standard of care dressing||||
33683728|NCT05604183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"The diagnosis of Amyloidosis (biomarker of Alzheimer's disease) is made based on the normal patient care consisting of the neurologist assessment and the Cerebro-Spinal Fluid analysis.~This diagnosis is used as golden standard for the model based on retinal images and cognitive test results."|||||
33683729|NCT05653531|NA|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33683730|NCT00559494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683731|NCT06221657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683732|NCT04316702|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|randomization by computer, the patient and her primary care physician will know the treatment received. Any side effects during therapy will be reported to the care providers and nurses and physicians unrelated to the study. Investigators and outcome assessors will not know the patient's arm.|randomized controlled trial using conventional pharmacotherapy treatment compared to hyperbaric oxygen therapy|f|f|t|t
33683733|NCT05602896|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33683734|NCT01890629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683735|NCT03934190|||CASE_ONLY||RETROSPECTIVE|||||||
33683736|NCT01768884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683737|NCT01492543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683738|NCT05616689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683739|NCT04591860|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The primary objective of the present trial is to compare the hiatal hernia recurrence rate between three different methods of cruroplasty in large hiatal hernias: hiatal closure with sutures versus pledgeted sutures versus absorbable mesh (Phasix™ST mesh).~The study includes patients who are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia. A large hiatal hernia is defined as \> 5cm in manometry or gastroscopy or at least 1/3 of the stomach lying intrathoracically. The primary study endpoint is defined as the hernia recurrence rate, objectively assessed by gastroscopy. After inclusion in the study, patients will be followed up 6 months, 1 year, 3 years and 5 years after the operation using standardized questionnaires and gastroscopy."||||
33774392|NCT01315106|||COHORT||PROSPECTIVE|||||||
33774393|NCT03232138|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind||t|t|t|t
33774394|NCT04890834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774395|NCT04802954|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683740|NCT00212017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is an open and blinded-endpoint study|Prospective, randomised, open, blinded-endpoint study|f|f|f|t
33683741|NCT00871507|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33683742|NCT04355728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinding Trial|The trial has two groups, each with 12 subjects (n=24). All eligible subjects will be randomized to either the treatment group or standard of care, and randomization will be stratified by ARDS severity.|t|t|t|f
33683743|NCT02739633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683744|NCT00369629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683745|NCT00729391|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683746|NCT04551313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774396|NCT06068049|||COHORT||OTHER|||||||
33774397|NCT06602726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774398|NCT05671835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774399|NCT04981509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774400|NCT05443048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774401|NCT06679270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774402|NCT05971251|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation based on Dose escalation guidelines.||||
33774403|NCT06458153|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The single group model involves assessing the neural basis of multiple behavioral tasks in three cohorts. Cohort 1 is neurotypical adults. Cohort 2 is people with post-stroke cerebellar lesions. Cohort 3 is a group of control participants that will be matched to Cohort 2. The behavioral interventions are overlapping between cohorts, though Cohort 1 will complete additional sessions.||||
33774404|NCT06740669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33774405|NCT06720714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774406|NCT06741072|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Healthy volunteers, patients, and site staff evaluating the patients will be blinded to treatment assignment.||t|f|f|t
33774407|NCT05553938|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Double-blind|Double blind placebo controlled, with crossover for placebo patients to active drug at 6 weeks. (At 6 weeks, participants are unblinded, and participants who received placebo will receive study drug.)|t|t|t|f
34080828|NCT01181973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33774408|NCT04418037|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774409|NCT04706507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774410|NCT06229080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774411|NCT03815656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903744|NCT05547373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903745|NCT01486316|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33903746|NCT00205504|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903747|NCT01829789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903748|NCT00872833|||COHORT||PROSPECTIVE|||||||
33903749|NCT04980911|||COHORT||RETROSPECTIVE|||||||
33903750|NCT06270797|||COHORT||PROSPECTIVE|||||||
34080829|NCT03854942|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33903751|NCT03050268|||FAMILY_BASED||PROSPECTIVE|||||||
33903752|NCT06203145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903753|NCT03159754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903754|NCT02874794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903755|NCT01347918|||CASE_CONTROL||PROSPECTIVE|||||||
33903756|NCT00973830|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33903757|NCT03751189|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33903758|NCT03237260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903759|NCT06070623|||COHORT||CROSS_SECTIONAL|||||||
33903760|NCT03531372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903761|NCT01976533|||COHORT||RETROSPECTIVE|||||||
33903762|NCT01751646|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34080830|NCT03984942|||COHORT||PROSPECTIVE|||||||
34080831|NCT01064414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080832|NCT00808223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080833|NCT02194972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080834|NCT05436990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080835|NCT00254865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080836|NCT05696067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080837|NCT05705011|||COHORT||PROSPECTIVE|||||||
34080838|NCT01241474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34080839|NCT02390271|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080840|NCT03048617|||CASE_ONLY||PROSPECTIVE|||||||
34080841|NCT05801003|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized controlled trial||||
34080842|NCT03662126|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34080843|NCT04536363|RANDOMIZED|PARALLEL||TREATMENT||NONE|There are no masking techniques in assigning treatment to patients, as this is an open study. Nor is any procedure for urgently opening emergency codes applicable. The statistical analysis will be carried out without the epidemiologist in charge knowing or being able to identify the group of origin of the patients (control / intervention). To guarantee this, the data of the patients will be reported to the epidemiologist without any identification data and through a code whose sole knowledge at the time of delivery will be the responsibility of the principal investigator. Interim comparisons and analysis will be carried out for mortality and adverse events in the following follow-up stages according to the number of patients achieved: 20%, 40%, 60%, 80% and final.|"Study type: Open randomized clinical trial. Study phase: Phase II Design: Experimental in parallel Two management groups Intermediate analysis will be carried out when completing 20%, 40%, 60% and 80% of the planned sample. All adjusted statistical analysis will be carried out conditionally, predicting the effect of the stratification of the randomization process.~The statistical analysis will be carried out in accordance with the principle of intention to treat"||||
34080844|NCT01705041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080845|NCT05444699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080846|NCT00145886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080847|NCT04284865|NA|SINGLE_GROUP||OTHER||NONE||||||
34080848|NCT02415543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080849|NCT03846869|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective Cohort Study||||
33683747|NCT05677672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Phase 1 was a non-randomized, single-arm, multicenter, dose-escalation clinical trial design.~Phase 2 was a randomized, double-masking , multicenter, blank control, dose-extended clinical trial design."|t|f|f|t
33903763|NCT05964725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In the whole clinical research process, the subjects and researchers participating in the efficacy and safety evaluation should be in a blind state, that is, neither of them knows the specific intervention measures given to the subjects. For participant, the treatment equipment is exactly the same between the two groups. Also, 10 seconds sham stimulation at the beginning of treatment is set in the control group for minimizing risk of participants being able to guess treatment allocation. The randomized allocation is completed by a unified randomization center. Therefore, the investigators in each center just know A or B for the allocation information of each participant. For outcomes assessors, they are only responsible for baseline and follow-up assessment during the study."|Participants in the included studies were randomized 1:1 by statisticians. The statistician will number the subjects using a computer-generated random number table, then arrange them in order of number size, and then randomly divide the subjects into random blocks of length 2 or 4 to complete the randomization.|t|t|t|t
33903764|NCT01442129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903765|NCT03896399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903766|NCT01674543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34080850|NCT04112576|||COHORT||PROSPECTIVE|||||||
33683748|NCT02593071|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33683749|NCT01556347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683750|NCT01823588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33683751|NCT03235635|||COHORT||PROSPECTIVE|||||||
33683752|NCT00884767|NON_RANDOMIZED|||TREATMENT||||||||
33683753|NCT03812627|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33683754|NCT02385227|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33683755|NCT00245219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903767|NCT00034112|RANDOMIZED|||TREATMENT||||||||
33903768|NCT05883267|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Children will be randomized to one of two interventions for diabetes management: group 1 will use VR glasses first and group 2 will listen to vocal-guided affective imagery first (audio). After 1 month, the interventions will be crossed over.||||
34080851|NCT04398680|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study.|||||
34080852|NCT05059340|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080853|NCT00374348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080854|NCT02900742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774412|NCT06741059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Study Design: This study follows a parallel design with three groups:~Experimental Group: Participants in this group receive the active intervention (e.g., Transcutaneous Electrical Nerve Stimulation - TENS).~Placebo Group: Participants in this group receive a placebo treatment (e.g., a sham TENS treatment or a non-active intervention).~Control Group: Participants in this group receive no intervention or the standard treatment.~Blinding: A single-blind design is used in this study, meaning only the participants do not know which group they are assigned to. The research team is aware of the group assignments. This approach helps prevent the participants' expectations from influencing the results."|This design allows for direct comparison of the active intervention, placebo, and no intervention (control), evaluating the impact of the treatment on the outcomes.|t|f|f|f
33774413|NCT06271616|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903769|NCT04797013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||multicenter, prospective, randomized, open label, blinded-endpoint (PROBE)，Parallel controls，Non-inferiority|f|f|f|t
33903770|NCT02401256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903771|NCT00355004|RANDOMIZED|||SCREENING||||||||
33903772|NCT06513273|||CASE_ONLY||PROSPECTIVE|||||||
33903773|NCT02839746|||COHORT||PROSPECTIVE|||||||
33903774|NCT01573208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903775|NCT03625219|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Cohort A Open label: 4 groups of 10 subjects Cohort B Double-Blind: 1 group of 20 subjects|t|t|t|t
33903776|NCT05978297|||COHORT||PROSPECTIVE|||||||
33903777|NCT03490669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-Label||||
33903778|NCT01168804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903779|NCT02644083|||COHORT||PROSPECTIVE|||||||
33903780|NCT03132246|||COHORT||PROSPECTIVE|||||||
33903781|NCT01485783|||CASE_ONLY||PROSPECTIVE|||||||
33903782|NCT03679481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903783|NCT06559137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized after consent is obtained and will not know if they receive a single-shot peripheral nerve block. Due to current standard of care procedures, all patients will consent to receiving a peripheral nerve block despite their randomized group.||t|f|f|f
33903784|NCT04576351|||COHORT||PROSPECTIVE|||||||
33903785|NCT06175312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will typically be unaware of the conditions presented, though because these involve manipulations of stimuli or task demands, they may be aware of the manipulation. This is not expected to impact the primary outcome measures (e.g., BOLD signal activation patterns).|This is a basic science study in which all participants will participate in all task conditions within each experiment (repeated-measures design).||||
33903786|NCT01481571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903787|NCT01680224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903788|NCT03043365|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33903789|NCT04122157|||COHORT||PROSPECTIVE|||||||
33903790|NCT00886821|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33903791|NCT03907722|||OTHER||CROSS_SECTIONAL|||||||
33903792|NCT01797783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903793|NCT04296136|||COHORT||OTHER|||||||
33903794|NCT04072237|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33903795|NCT00309777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33903796|NCT03412630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903797|NCT00410280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903798|NCT03041376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903799|NCT02723162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33903800|NCT00306436|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33903801|NCT00864227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903802|NCT01892527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903803|NCT04272905|||COHORT||CROSS_SECTIONAL|||||||
33903804|NCT01445743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33903805|NCT04525222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Any outcome evaluator who has direct contact with participants will be blinded to treatment group assignment||f|f|f|t
33903806|NCT00972998|NA|SINGLE_GROUP||||NONE||||||
33903807|NCT00664274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903808|NCT01254396|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33903809|NCT02209597|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The randomization table will be generated by the Barnes-Jewish Hospital Investigational Pharmacy. Each subject will be assigned the next available number. Subjects, investigators, and all study team members will be blinded to drug treatment. In the case of dropouts (either subject- or investigator-initiated), subjects will be replaced, to provide the required number of subjects.|Each participant receives the 4 drugs in sequence (sequence is randomized).|t|t|f|f
33903810|NCT06671405|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||DDI study, open label, fixed sequence||||
33903811|NCT00282490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903812|NCT06321744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33903813|NCT02133378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903814|NCT01058577|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903815|NCT01140516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903816|NCT00120796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903817|NCT06671834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903818|NCT00815984|||COHORT||RETROSPECTIVE|||||||
33903819|NCT01568905|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33903820|NCT06175507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903821|NCT06416839|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903822|NCT06247540|NA|SEQUENTIAL||TREATMENT||NONE||||||
33903823|NCT03792269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903824|NCT06375330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903825|NCT06457763|||COHORT||PROSPECTIVE|||||||
33903826|NCT04516616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080855|NCT06460259|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34080856|NCT01524666|||CASE_ONLY||PROSPECTIVE|||||||
33774414|NCT05565560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774415|NCT06740942|||COHORT||PROSPECTIVE|||||||
33774416|NCT06739850|||COHORT||CROSS_SECTIONAL|||||||
33774417|NCT06258837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not practical or feasible to maintain blinding among the surgeons performing the procedures or the clinical staff caring for patients in the perioperative setting. Given this, it is unlikely that blinding could be maintained among parents or caregivers of patients, therefore there will be no attempt to blind caregivers to the treatment assignment. However, the sleep medicine collaborators who will be reviewing and scoring postoperative PSGs will be instructed not to review the medical record so as to ensure blinding to treatment assignment.|"Participants will be recruited from pediatric otolaryngology clinics. The study will be introduced to caregivers of children with small tonsils and a history of sleep disordered breathing/OSA who are referred for surgery and meet the inclusion and exclusion criteria noted. If current or recent PSG testing demonstrates OSA, they will be invited to participate.~Randomization will be done. Patients will be randomized to either the personalized DISE-directed surgery or the standard AT after collection of baseline measures and pre-op PSG. Allocation will be made by using a computer-generated randomization scheme. Caregivers will be advised of the outcomes and risks of different surgical procedures included in DISE-directed surgery and informed consent will be obtained. All patients will be planned for overnight observation to monitor for safety and perioperative complications."|f|f|f|t
33774418|NCT04494113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080857|NCT06165432|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Assessment of objective pain using Sound, Eye and Motor scale will be done by a single outcome assessor who will be blinded about the intervention technique.|Cross sectional comparative split mouth study|f|f|f|t
33774419|NCT06595238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774420|NCT03212170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33774421|NCT06148935|||COHORT||PROSPECTIVE|||||||
33774422|NCT04605770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774423|NCT06235892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774424|NCT04729049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Care provider (anaesthetist) will know the type of anaesthesia performed. Outcome assessor (physician visiting the patient postoperatively) and investigator (study design and data analysis) will not know the type of anaesthesia performed.|Cases vs control|t|f|t|t
33774425|NCT06694584|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774426|NCT06097260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080858|NCT05366166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080859|NCT05081388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase1/Phase2/Phase3|t|t|t|t
33774427|NCT03971253|||COHORT||PROSPECTIVE|||||||
33774428|NCT06738108|||COHORT||RETROSPECTIVE|||||||
33774429|NCT00401674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774430|NCT06561854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774431|NCT02699697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774432|NCT04262141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774433|NCT03701100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA.|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). An extracephalic positions were used for the reference electrodes (cathodes) in order to avoid confounding effects from inhibitory cathodal effects at other cortical sites. The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 milliampere (mA) (current density=1.14 A/square meter) for 20 min, twice-daily on 5 consecutive weekdays (total charge density=2736 C/square meter).|t|f|f|t
33774434|NCT06154512|||COHORT||PROSPECTIVE|||||||
33774435|NCT06738771|||COHORT||PROSPECTIVE|||||||
33774436|NCT05567796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774437|NCT04612049|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33774438|NCT04431011|||COHORT||CROSS_SECTIONAL|||||||
33774439|NCT04170634|||CASE_ONLY||PROSPECTIVE|||||||
33774440|NCT06739837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774441|NCT04997148|||COHORT||OTHER|||||||
33774442|NCT03865420|||FAMILY_BASED||PROSPECTIVE|||||||
33774443|NCT06287463|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774444|NCT06558253|NA|SEQUENTIAL||TREATMENT||NONE||||||
33774445|NCT05104775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774446|NCT02523040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774447|NCT04581824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and study staff may only be blinded to study treatment.||t|t|f|f
33774448|NCT02315612|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903827|NCT00073593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024910|NCT05636514|NA|SINGLE_GROUP||TREATMENT||NONE||A phase 1, open-label, 3+3 dose escalation, multicentre study. All participants will receive a fixed dose of ASTX727, with escalation and de-escalation of the dose of defactinib. Enrolled participants will receive one cycle of ASTX727 alone (pre-phase) followed by five cycles of ASTX727 in combination with defactinib (combination phase). Participants with stable or responding disease by IWG criteria will be eligible to proceed to a continuation phase of monotherapy with ASTX727.||||
34024911|NCT00168818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33774449|NCT04969835|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study will follow a standard 3+3 dose escalation design in Phase 1a to evaluate the safety, tolerability, and MTD of two AVA6000 administration schedules (Q3W and Q2W). The Phase 1b dose expansion regimen was selected based upon completion of the Phase 1a portion.||||
33774450|NCT06408298|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33774451|NCT04594005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774452|NCT06461013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33774453|NCT04200391|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will receive a very low carbohydrate diet for 12 weeks and undergo a glucagon challenge during weeks 5-12 to assess glycemic response.||||
33774454|NCT03487822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The co-investigators performing assessments will be blind to the participant's arm.||f|f|t|f
33774455|NCT06116656|||COHORT||PROSPECTIVE|||||||
33774456|NCT06539741|||CASE_CONTROL||PROSPECTIVE|||||||
33774457|NCT05443347|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33774458|NCT06610032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774459|NCT05250804|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34024912|NCT05386030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024913|NCT02635113|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024914|NCT04462211|NA|SEQUENTIAL||TREATMENT||NONE||||||
33774460|NCT02675491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774461|NCT04493034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774462|NCT06734819|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33774463|NCT04909034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774464|NCT06072807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774465|NCT06735079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903828|NCT03996538|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Metformin and placebo tablets will be identical. Participants and researchers will not know treatment allocation.||t|f|t|f
34024915|NCT01059344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903829|NCT02242149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903830|NCT02046915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903831|NCT05032053|||COHORT||PROSPECTIVE|||||||
33903832|NCT00042185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903833|NCT02967120|||COHORT||PROSPECTIVE|||||||
33903834|NCT06295510|||CASE_CONTROL||RETROSPECTIVE|||||||
33903835|NCT03077945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants will be randomized to the intervention or control condition, blocked by age and level of motivation to quit smoking.|t|f|f|f
33903836|NCT04964921|||COHORT||CROSS_SECTIONAL|||||||
33903837|NCT00472342|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33903838|NCT02707289|||OTHER||RETROSPECTIVE|||||||
33903839|NCT06530628|||COHORT||PROSPECTIVE|||||||
33903840|NCT01949064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33903841|NCT00724035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903842|NCT03292627|||CASE_CONTROL||PROSPECTIVE|||||||
33903843|NCT05040178|||COHORT||OTHER|||||||
33903844|NCT03634215|||COHORT||PROSPECTIVE|||||||
34024916|NCT01797237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024917|NCT01085201|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024918|NCT01729403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903845|NCT05441150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33903846|NCT00478972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903847|NCT01883245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903848|NCT01853124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903849|NCT04436510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903850|NCT00592501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903851|NCT00764842|||COHORT||RETROSPECTIVE|||||||
33903852|NCT05995522|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"All participants were given an identical vial, with an invention similar in shape, color, and consistency.~The groups were named group A and group B."|Clinical trial parallel design. Two groups with intervention, one with supplementation and other with placebo|t|f|t|f
33903853|NCT02467452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903854|NCT01455077|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33903855|NCT00126542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903856|NCT00775775|||CASE_ONLY||PROSPECTIVE|||||||
33903857|NCT02109003|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33683756|NCT01471431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683757|NCT02620371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33683758|NCT03765970|||CASE_ONLY||PROSPECTIVE|||||||
33683759|NCT03034668|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
33683760|NCT02725489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683761|NCT01135563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903858|NCT02175563|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33903859|NCT02409420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903860|NCT04370028|||COHORT||PROSPECTIVE|||||||
33903861|NCT04536415|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080860|NCT04576650|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33903862|NCT03545152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34024919|NCT04086407|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Subject data is randomized to Investigator|||||
34024920|NCT02287155|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024921|NCT06633315|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"The children were randomly divided into three groups using a random number table method:~The low-dose dexmedetomidine group ( DL group,n = 30) ， Group DL received dexmedetomidine 2.5 μ g/kg nasal drops, The high-dose group of dexmedetomidine (DH group),received dexmedetomidine 3 μ g/kg nasal drops The combination group (DE group, n=30). received dexmedetomidine 2 μ g/kg nasal drops plus esketamine 0.5 mg/kg nasal drops.~Record the Modified Vigilance/Sedation (MOAA/S) Scale score, Mask Acceptance Scale (MAS) score, one-time medication success rate, and number of salvage medication cases 30 minutes after nasal drip. Record the vital signs of four groups of patients during the examination process, including their basic"|t|f|t|t
34024922|NCT05808920|||COHORT||OTHER|||||||
34080861|NCT01516723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080862|NCT05625685|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||"Will employ two interventions as part of a sequential multiple-assignment randomized trial (SMART).~First-stage intervention - Participants are randomized to one of two arms, QuitBuddy (a novel smoking cessation app) or Control.~Participants will be randomized again after reaching a predefined tailoring variable, operationalized as biochemically verified 24h smoking abstinence within 1-week from target quit date (TQD).~Second-stage intervention - Social determinants of health (SDoH) intervention.~Participants are randomized to receive either a digital SDoH intervention (powered by findhelp.org and integrated into QuitBuddy) or will receive an emailed list of social service providers in their Zip Code (standard care control)."|t|f|f|t
34080863|NCT02614638|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34080864|NCT02306200|||CASE_CONTROL||PROSPECTIVE|||||||
34080865|NCT01951144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34080866|NCT02158689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080867|NCT01248897|||CASE_ONLY||PROSPECTIVE|||||||
34080868|NCT05013411|||OTHER||PROSPECTIVE|||||||
34080869|NCT05720598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with histopathologically confirmed, locally advanced adenocarcinoma of the stomach scheduled for staging laparoscopy by the multidisciplinary team will be classified for enrollment into this study.||||
34080870|NCT00101244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080871|NCT05328427|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34080872|NCT00761228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080873|NCT02674139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080874|NCT05497752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080875|NCT01994213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080876|NCT03559634|RANDOMIZED|PARALLEL||OTHER||NONE||Feasibility trial||||
34080877|NCT03539107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34080878|NCT00726609|||CASE_ONLY||PROSPECTIVE|||||||
34080879|NCT04913246|||COHORT||PROSPECTIVE|||||||
33683762|NCT01138176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903863|NCT03808272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903864|NCT02279589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903865|NCT02538146|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34080880|NCT01791985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683763|NCT06044766|NA|SINGLE_GROUP||OTHER||NONE||||||
33683764|NCT05945862|NA|SINGLE_GROUP||PREVENTION||NONE||Health Promotion and Disease Prevention||||
33903866|NCT00985881|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33903867|NCT02693353|||COHORT||PROSPECTIVE|||||||
33903868|NCT02027688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903869|NCT03799315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903870|NCT00358189|||||PROSPECTIVE|||||||
33903871|NCT05182502|NA|SINGLE_GROUP||TREATMENT||NONE|Photos will be evaluated in randomized blinded pairs pre- and post-treatment|Treatment of subjects with a device for facial rejuvenation and blinded comparison of pre- and post-treatment photos.||||
33903872|NCT06162676|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||intervention vs. usual care (control)|f|f|f|t
34024923|NCT01499459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683765|NCT06080724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants were up to age of 12 years so they automatically got masked. outcome assessors were the teams of doctor working in outpatient department were also masked|A randomized control trial study was conducted on patients of haemangiomas of pediatric age group coming to pediatric surgery ward, KEMU/Mayo hospital, Lahore. Patients were randomized in two study groups A and B. The Lottery method was used for allocation of patients where the patient was given allocated treatment regimen after opening the sealed envelope. Each group contained 57 of patients. Patients in the group A were given intralesional bleomycin combined with dexamethasone and in the group B intralesional bleomycin alone after taking aseptic and antiseptic measures. T|t|f|f|t
33683766|NCT01845103|||COHORT||PROSPECTIVE|||||||
33683767|NCT01467635|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33683768|NCT00528541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683769|NCT06052098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683770|NCT05545046|||CASE_ONLY||PROSPECTIVE|||||||
33683771|NCT06114524|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683772|NCT02496676|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33683773|NCT02195414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683774|NCT00002165||||TREATMENT||||||||
34080881|NCT01477307|||OTHER||PROSPECTIVE|||||||
33683775|NCT02178839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683776|NCT00604214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683777|NCT03338959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683778|NCT01143389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683779|NCT03680456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||interventional randomized doubleblind, Placebo controlled|t|f|t|f
33683780|NCT03007888|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33683781|NCT04774458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683782|NCT00503945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683783|NCT00410137|||DEFINED_POPULATION||PROSPECTIVE|||||||
33774466|NCT06529094|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The RE-AIM (Reach, Efficacy, Adoption, Implementation, and Maintenance) framework will guide this study to assess implementation. For this study, Reach is the proportion of the outpatient SCI population that complete the CAPP-FIT. Efficacy is success rate, measured as reduction in incidence of CAPrIs, CAPrI-associated hospitalizations, and patient and provider satisfaction. Adoption is the degree that sites use the CAPP-FIT. Implementation is the extent to which the CAPP-FIT is implemented as intended. Maintenance is the extent to which CAPP-FIT is maintained over time.||||
33774467|NCT06740292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were allocated in a 1:1 ratio using an on-site computer software system with concealed allocation through sequentially numbered, opaque, sealed envelopes (SNOSE). Group A was treated with InterFlex plates, and Group B with conventional miniplates||f|f|t|f
33774468|NCT06073340|||COHORT||PROSPECTIVE|||||||
34080882|NCT02389959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774469|NCT05806346|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|placebo-controlled|randomized prospective double-blind placebo-controlled multicenter non-inferior|t|t|t|t
33774470|NCT05006716|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774471|NCT01807143|||COHORT||RETROSPECTIVE|||||||
34080883|NCT04088162|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080884|NCT03102762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized double blind placebo control ( RDBPC) study.|t|t|f|f
34080885|NCT00863707|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34080886|NCT02051517|||COHORT||CROSS_SECTIONAL|||||||
33774472|NCT04742205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903873|NCT00151411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34080887|NCT02512887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33683784|NCT01850576|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33774473|NCT05301907|||OTHER||CROSS_SECTIONAL|||||||
33774474|NCT06630325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774475|NCT05780723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774476|NCT06373497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903874|NCT06671743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903875|NCT02314208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34080888|NCT04054830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34080889|NCT05405985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080890|NCT04188600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The analysis of the results will be blind for the investigator|"The selected patients will be randomly distributed in one of the two arms (Libicare® / active-control), in a 2:1 ratio according to a randomization list. The kits containing the study treatment (Libicare®) and the active-control will be numbered with a randomization code according to this unique list and will be distributed to the consultations.~Patients will not know the treatment and only the researchers and team investigator assigned to the study will know the treatment assigned.~A second randomization list (ratio 1:1) will be generated for Libicare® responding patients, at 12 weeks in order to assign two sub-groups: continue Libicare® treatment or observation without Libicare® treatment."|t|f|t|f
34080891|NCT02888834|||COHORT||RETROSPECTIVE|||||||
33903876|NCT02004405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903877|NCT04450355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor not involved in this study will investigate the outcomes. The patient will be not informed of the infusion of nefopam by not attaching an identifiable label so that it cannot be distinguished from normal saline.|A prospective randomized double-blinded study|t|f|f|t
34080892|NCT05200169|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, non-randomized, single-dose, single-period study||||
34080893|NCT03369574|||COHORT||PROSPECTIVE|||||||
34080894|NCT01441141|||CASE_CONTROL||OTHER|||||||
34080895|NCT01067586|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080896|NCT01198912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080897|NCT05810896|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Investigators will use a pre-test post-test model.||||
33903878|NCT03572192|||OTHER||PROSPECTIVE|||||||
33903879|NCT05321797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903880|NCT04347811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080898|NCT02532504|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33986655|NCT03606278|RANDOMIZED|PARALLEL||OTHER||SINGLE|For the performance and evaluation score of the adherence of the teams to the resuscitation protocols, a review of the literature was performed, and the modified version of the validated Neonatal Resuscitation Performance Evaluation (NRPE) tool was considered (1). Given that this instrument did not consider behavioral and leadership aspects, a checklist of individual performance and performance by profession was constructed in each of the scenarios that included cognitive/technical and behavioral aspects. This checklist was applied by a reviewer blinded to the assignment of the type of debriefing by reviewing the video of the participation of the groups in the scenarios.|The study participants were randomly assigned to the type of debriefing (oral or video), stratified by the type of health professional. For this randomization, the random function of Excel was used, sorting the participants in a random number order and assigning the first half to the oral group and the other half to the video-assisted group. For the conformation of the teams, a second randomization was performed, in which the professionals within an assigned group (oral or video-assisted) were randomized to form a resuscitation team. In this randomization, Excel's random function was also used, sorting the patients in a random number order and assigning the one that was ordered first to team 1, the second to team 2, and so on, each team had three professions: pediatrician, professional nurse, and respiratory therapist. The same team was maintained during the participation of each scenario.|f|f|f|t
33986656|NCT01228461|||COHORT||RETROSPECTIVE|||||||
33683785|NCT00344942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683786|NCT04056767|||COHORT||PROSPECTIVE|||||||
33683787|NCT00960583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683788|NCT04381988|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This is a randomized (1:1), double-blind, placebo-controlled phase II clinical trial.|t|t|t|f
33683789|NCT05216666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
33683790|NCT01607203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683791|NCT05022511|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33683792|NCT00718562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683793|NCT05059899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774477|NCT06580587|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903881|NCT03438630|||CASE_CONTROL||OTHER|||||||
33903882|NCT02971644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903883|NCT02014532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903884|NCT05675280|||COHORT||RETROSPECTIVE|||||||
33903885|NCT01428102|||CASE_ONLY||PROSPECTIVE|||||||
33903886|NCT02788916|||COHORT||RETROSPECTIVE|||||||
33903887|NCT04738045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903888|NCT05360186|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33903889|NCT00854932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903890|NCT00100373|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33903891|NCT05564598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903892|NCT05279794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33903893|NCT03749993|NA|SINGLE_GROUP||SCREENING||NONE||||||
33903894|NCT02291315|||CASE_CROSSOVER||PROSPECTIVE|||||||
33903895|NCT05152147|RANDOMIZED|PARALLEL||TREATMENT||NONE||multi-cohort, open-label, multicenter study||||
33903896|NCT04995965|||CASE_ONLY||RETROSPECTIVE|||||||
33903897|NCT00758303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903898|NCT05203133|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||"Participants will complete a 5-day free-living baseline assessment period (days -5 to -1) and two consecutive 5-day periods (days 1 - 10, with a final assessment on the morning of day 11) of controlled exercise to increase oxidative capacity (3 days of aerobic exercise per period, 15 kcal/kg FFM/day energy expenditure cycling) and energy intake.~This will achieve states of energy balance (EB; energy availability - EA - 45 kcal/kg of fat free mass (FFM)/day), required for weight maintenance (days 1 - 5), followed by energy deficit (ED; EA 10 kcal/kg FFM/day), required for weight loss on days 6 - 10."||||
33903899|NCT03832868|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Clinic sites will be block-randomized to eliminate contamination induced by individual-level randomization for a system-level intervention. Each site will rotate on a monthly basis whether the decision aid is administered pre- or post-office visit, and this will be applied to all ICD patients. Each site will have a minimum of 2 months exposure to each arm. No blinding will occur."||||
33903900|NCT01240993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33903901|NCT02406781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903902|NCT04708145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903903|NCT03718494|||COHORT||PROSPECTIVE|||||||
33903904|NCT02160977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33903905|NCT03616769|||COHORT||PROSPECTIVE|||||||
33903906|NCT03207256|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903907|NCT06554210|||COHORT||RETROSPECTIVE|||||||
33903908|NCT03239808|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, multicenter, randomized clinical trial. It has two strata: for age (≥or\< 75 years old) and for KrU (≥or\< 5,5 ml/min/1.73m2). It is controlled through usual clinical practice.~Intervention consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression."||||
33903909|NCT02857023|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33986657|NCT04108572|NA|SINGLE_GROUP||PREVENTION||NONE||Non-randomised feasibility study of an infant feeding intervention and implementation strategy, with embedded process evaluation and economic evaluation||||
33986658|NCT02080845|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33986659|NCT05218486|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33986660|NCT03337997|NA|SINGLE_GROUP||TREATMENT||NONE|CT scans and PET scans will be read by two radiologists and concensus obtained. The two radiologists will be unaware of prior chemo, patient age, original tumor size.|Patients with biopsy-proven adenocarcinoma of the head of the pancreas deemed to be resectable by a multi-disciplinary team will be invited to participate.||||
33986661|NCT03352518|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33986662|NCT04989374|||COHORT||PROSPECTIVE|||||||
33986663|NCT02645409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986664|NCT00578552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33986665|NCT01645995|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33986666|NCT04888572|||COHORT||RETROSPECTIVE|||||||
33986667|NCT05839470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986668|NCT05033847|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33986669|NCT04713709|RANDOMIZED|CROSSOVER||OTHER||NONE||Open-label, single-dose, randomized, two-period, two treatment, two-sequence, crossover, comparative bioavailability study||||
33986670|NCT00003674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986671|NCT01770262|||COHORT||CROSS_SECTIONAL|||||||
33986672|NCT00588874|||CASE_ONLY||CROSS_SECTIONAL|||||||
33986673|NCT05879471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986674|NCT03429920|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Both the participants and the investigators will not be aware of which powder is the active powder and which one is the placebo. Only the Principle Investigator will be made aware.|This dietary intervention trial is a randomized, 2x2 crossover design with 24 subjects in free-living conditions.There will be a two week run-in (acclimation period), after which subjects will be randomized to receive either Q CAN powder or placebo powder for 12 weeks. Following a two week wash out period, subjects will be switched over to the alternate treatment.|t|f|t|f
33986675|NCT01019603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33986676|NCT01291121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986677|NCT00431912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986678|NCT00103623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986679|NCT01471041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986680|NCT05952661|||COHORT||PROSPECTIVE|||||||
33986681|NCT04513418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33986682|NCT04007640|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683794|NCT06457672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683795|NCT03219463|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33683796|NCT01373827|||COHORT||PROSPECTIVE|||||||
33774478|NCT05679921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774479|NCT06364319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774480|NCT05610280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774481|NCT03498079|||OTHER||PROSPECTIVE|||||||
33774482|NCT02021461|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33986683|NCT02377778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986684|NCT02832752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986685|NCT00527098|||CASE_CONTROL||PROSPECTIVE|||||||
33986686|NCT04407806|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Prospective, single-site||||
33986687|NCT06018532|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33986688|NCT00725803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986689|NCT02105779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683797|NCT05242796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind randomized clinical trial|t|f|f|t
33683798|NCT05463198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683799|NCT04486001|NA|SINGLE_GROUP||TREATMENT||NONE||single group comparison with cohort of contemporaneous non-treated patients.||||
33683800|NCT02350751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683801|NCT02097017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683802|NCT00732043|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986690|NCT03015584|||COHORT||PROSPECTIVE|||||||
33986691|NCT03958422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Random, controlled, single blind|t|f|f|t
33986692|NCT05481320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The active treatment is a REACH VN phone intervention, a culturally adapted version of REACH VA, a multicomponent dementia family caregiver support intervention that includes psychoeducation, stress reduction, problem-solving, and skill-building.|f|f|f|t
33986693|NCT04598074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33986694|NCT04100486|||OTHER||PROSPECTIVE|||||||
33986695|NCT02195050|||COHORT||CROSS_SECTIONAL|||||||
33986696|NCT02184026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903910|NCT04927988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33903911|NCT01873742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903912|NCT02974257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33903913|NCT00641043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33903914|NCT00882869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903915|NCT00123357|||||PROSPECTIVE|||||||
33903916|NCT00229372|RANDOMIZED|PARALLEL||||SINGLE||||||
33903917|NCT05872425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903918|NCT05694819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903919|NCT01319929|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33903920|NCT01499238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903921|NCT00147628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33903922|NCT03722680|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo arm: The patient will be taken on tablet (placebo :50 mg, film-coated tablet) Posology, administration and duration of treatment will be equivalent to riluzole group.|Riluzole arm: The patient will be taken one tablet (riluzole 50 mg, film-coated tablet) twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).|t|t|t|t
33903923|NCT00787332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903924|NCT06200467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel group design trial, with moxifloxacin as positive control in a nested cross-over in healthy male and female subjects with overweight/obesity.|t|t|t|t
33903925|NCT05703828|||COHORT||PROSPECTIVE|||||||
33903926|NCT01907529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903927|NCT02805088|NON_RANDOMIZED|PARALLEL||||NONE||||||
33903928|NCT05165329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33903929|NCT05955092|||CASE_ONLY||CROSS_SECTIONAL|||||||
33903930|NCT02158858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903931|NCT05323552|||COHORT||PROSPECTIVE|||||||
33986697|NCT01381653|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33986698|NCT03252509|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre a post interventional study, in patients with head and neck neoplasms, eligible for an outpatient procedure.||||
33986699|NCT03119025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986700|NCT01332864|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34024924|NCT06043687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024925|NCT02954991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024926|NCT06194760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024927|NCT05801718|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024928|NCT04667754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024929|NCT06359288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Double blinding was used in the study. For this purpose, the participants were not specified in which group they belonged to the research. Therefore, a separate informed consent form was prepared for each group. In order to avoid bias in the analysis of the research data, statistician blinding was also applied.~While coding the research data, the research groups were coded as A and B, and the statistician was prevented from knowing which letter represented which group."|The study was conducted experimentally with a pre-test and post-test control group.|t|f|f|t
34024930|NCT02483208|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34024931|NCT04438993|||COHORT||PROSPECTIVE|||||||
34024932|NCT01931696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024933|NCT02008435|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34024934|NCT04060095|||COHORT||PROSPECTIVE|||||||
34024935|NCT00911027|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34024936|NCT06632249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be a single-blind clinical trial; the evaluators of the primary outcomes will be blinded, unaware of the group allocation to ensure the objectivity of the assessments. The data analysis will remain blinded to ensure that the researcher in charge is unaware of the experimental conditions, thus maintaining the impartiality of the analysis. However, the participants will be aware of their allocation group, as they will experience the different versions of the VR game 'Move Sapiens®'; one group will perform the exergame, with HIIT physical exercise, while the other will participate using a joystick, without physical exercise, which will prevent blinding of the volunteers. The training monitoring team, due to operational necessity, will also not be blinded.||f|f|t|t
34024937|NCT04617522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024938|NCT02341391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024939|NCT06632808|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34024940|NCT06498440|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||This study is a Phase 4 single-centre randomized controlled trial (RCT) at the Hamilton Regional Eye Clinic, St. Joseph's Healthcare Hamilton. It aims to compare postoperative treatments following Selective Laser Trabeculoplasty (SLT) in open-angle glaucoma patients. Participants are randomly assigned to one of three groups: ketorolac alone, ketorolac with fluorometholone, or no treatment (control). The primary outcome is the change in intraocular pressure (IOP) from baseline to one year post-SLT, with secondary outcomes including visual acuity, inflammation, and patient-reported discomfort. Follow-up assessments occur at 1 hour, 1 week, 1 month, 3 months, 6 months, and 1 year. The study follows CONSORT guidelines and has ethical approval from the Hamilton Integrated Research Ethics Board (HiREB). The goal is to provide reliable data on effective postoperative management strategies, enhancing clinical practice in glaucoma treatment.|f|f|f|t
34080899|NCT00004862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080900|NCT05084976|||OTHER||OTHER|||||||
34080901|NCT01021397|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34080902|NCT03455517|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, prospective, interventional, single arm study||||
34080903|NCT00541242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080904|NCT01126099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080905|NCT06438211|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33903932|NCT02816762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080906|NCT02539251|||OTHER||CROSS_SECTIONAL|||||||
34080907|NCT04072029|||COHORT||PROSPECTIVE|||||||
34080908|NCT06316635|||OTHER||PROSPECTIVE|||||||
34080909|NCT03135314|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34080910|NCT00747916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080911|NCT05306990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080912|NCT06521970|||OTHER||CROSS_SECTIONAL|||||||
34080913|NCT04610229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903933|NCT06532461|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants are randomized to start first with 3 or 7 days infusionsset and cross-over after 4 months. Further they are randomized to either Novorapid og humalog insulin||||
33903934|NCT05741164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903935|NCT02345434|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33903936|NCT02948192|||COHORT||PROSPECTIVE|||||||
33903937|NCT02186795|||CASE_CONTROL||RETROSPECTIVE|||||||
33903938|NCT03471429|||COHORT||PROSPECTIVE|||||||
33903939|NCT04665258|||CASE_ONLY||PROSPECTIVE|||||||
33903940|NCT03321292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group(A) 130 pregnant women diagnosed with IUGR will receive L-arginine and Acetylesalicylic acid 75mg Group(B) 130 pregnant women diagnosed with IUGR will receive Acetylesalicylic acid 75mg|t|f|f|f
33903941|NCT02630277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33903942|NCT05941884|||CASE_CONTROL||OTHER|||||||
33903943|NCT05591443|||COHORT||PROSPECTIVE|||||||
33903944|NCT01595256|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33903945|NCT04210791|||COHORT||OTHER|||||||
33903946|NCT01789073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33903947|NCT02533960|||COHORT||PROSPECTIVE|||||||
33903948|NCT04848363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blindness. The Principal Investigator performing the blockade knows the randomization group. The anesthesiologist, postoperative pain assessor, and study participant do not know the randomization group.|"Distribution: randomized Intervention model: parallel distribution 2 groups~* Control group: patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. Before surgery will be performde bilateral blockade of the QL muscle with normal saline.~* Study group: patients receiving general anesthesia with propofol, fentanyl and cisatracurium for induction and sevoflurane, fentanyl and cisatracurium for maintaining anesthesia. Patients receiving postoperative multimodal intravenous analgesia with paracetamol, ketoprofen, tramadol, and trimeperidine. The QL blockade will be performed under ultrasound guidance using 20 ml of a solution of levobupivacaine 2.5 mg / ml."|t|t|f|t
33903949|NCT06671470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single dose||||
33903950|NCT06183606|||CASE_ONLY||RETROSPECTIVE|||||||
33903951|NCT03103269|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33903952|NCT02778048|||OTHER||RETROSPECTIVE|||||||
33903953|NCT06171880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903954|NCT03102736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both participants and research staff (aside from pharmacy) will be blinded||t|f|t|t
33903955|NCT01570738|||OTHER||PROSPECTIVE|||||||
33903956|NCT04305093|||OTHER||RETROSPECTIVE|||||||
33903957|NCT00604448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903958|NCT05891743|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33903959|NCT05673135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903960|NCT00582803|||CASE_ONLY||PROSPECTIVE|||||||
34024941|NCT00676780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024942|NCT00701961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024943|NCT05005312|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34024944|NCT02167854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024945|NCT01053000|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024946|NCT01496300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024947|NCT06149806|||COHORT||PROSPECTIVE|||||||
34024948|NCT06633692|NA|SINGLE_GROUP||OTHER||NONE||Pre- and post-assessment of the pelvic blood flow in response to simulated microgravity||||
34024949|NCT06633432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using SPSS 25.0 software, random numbers from 001 to 316 were generated through a computer and randomly assigned in a 1:1 ratio to either the acupuncture group or the sham acupuncture group. The group information is sealed in opaque envelopes numbered randomly. Qualified subjects will be randomly assigned numbers in descending order of enrollment, without skipping numbers. Before implementing acupuncture and moxibustion, the acupuncture and moxibustion shall open the envelope allocated with the corresponding random number of the subject and conduct acupuncture and moxibustion according to the grouping information in the envelope. However, there was no communication between the acupuncture and moxibustion and other researchers and study patients about this study. Patients, attending anesthesiologists, surgeons, and data collectors (doctors responsible for evaluating sleep variables in the sleep laboratory) are all unaware of group allocation.||t|f|t|f
34024950|NCT01942889|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34024951|NCT02454127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024952|NCT05853744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Sequentially numbered and sealed opaque envelopes method was used to carry out the randomization and allocation.~These were done by a different doctor from the one caring for the patient in the peri-operative period."||t|t|t|t
34024953|NCT03277118|||COHORT||PROSPECTIVE|||||||
34024954|NCT05180916|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled trial||||
34024955|NCT00009815||||TREATMENT||||||||
33986701|NCT03067818|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The individual that conducts the tests of arm movement will be unaware of which brain area was stimulated.|Each participant will receive stimulation targeting each brain area. The order in which the stimulation sites are targeted for each participant is randomized and there is a washout period of several weeks between each treatment.|f|f|f|t
33986702|NCT03596944|||OTHER||RETROSPECTIVE|||||||
33986703|NCT05668780|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Using a step-wedge design with 20 PCCs, the investigators will conduct a Type 3 Hybrid implementation trial||||
33986704|NCT02508883|||COHORT||PROSPECTIVE|||||||
33986705|NCT06350669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The patients will be randomly assigned to either the intervention group (app-assisted vestibular rehabilitation) or the control group (standard vestibular rehabilitation/no app)"|f|f|f|t
33986706|NCT04048317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986707|NCT01786785|||OTHER||PROSPECTIVE|||||||
33986708|NCT01208545|||COHORT||PROSPECTIVE|||||||
33986709|NCT04808557|RANDOMIZED|PARALLEL||TREATMENT||NONE||Volunteers will have buttons bonded on the vestibular surfaces of elements 1.4,1.5,1.6. Then, they will be randomly divided into two groups: Trial Group will use Biorepair Total Protection toothpaste for home oral care, whereas Control Group will use Sensodyne Repair \& Protect for home oral care.||||
33986710|NCT04430569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986711|NCT00657553|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986712|NCT02289963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986713|NCT04395222|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33986714|NCT03682263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986715|NCT06225076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33986716|NCT01688609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986717|NCT01082523|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33986718|NCT04826874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||within-individual and randomized control design|t|f|f|f
33986719|NCT03374462|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33986720|NCT05638971|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080914|NCT02479750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986721|NCT04910425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080915|NCT02112695|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34080916|NCT00735709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986722|NCT04847544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986723|NCT03426722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986724|NCT03967223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|||||
33986725|NCT05312827|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A 4-year pan-Canadian stakeholder-oriented, mixed-method implementation-effectiveness design will be used. TIPS will be implemented in all sites in a same region during the same month, and sequentially introduced across all regions, 2 months apart. An interrupted time series (ITS) was selected to assess primary implementation outcomes (obj. 1), as recommended for research in real-world settings. An ITS consists of observing the same dependent variables over time, with a break in the series of observations corresponding to the introduction of an intervention. If the intervention is effective, a change in the series' pre- and post-intervention averages will be observed.||||
33986726|NCT02914600|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants received blinded treatment during different phases in the study.||t|f|t|f
34080917|NCT03834311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080918|NCT02746835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34080919|NCT02781324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34080920|NCT06424522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080921|NCT04221334|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Product Code: XX Brush twice daily (morning and evening) for at least 2 minutes each time Cover the entire length of bristles with toothpaste|Parallel Assignment|f|t|t|t
34080922|NCT01321034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080923|NCT00001104||PARALLEL||TREATMENT||||||||
34080924|NCT00746551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080925|NCT03548077|NA|SINGLE_GROUP||PREVENTION||NONE||Quasi-experimental, pre-post study design||||
34080926|NCT00234624|||DEFINED_POPULATION||PROSPECTIVE|||||||
34080927|NCT02988700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34080928|NCT00005868||||TREATMENT||||||||
34080929|NCT01204671|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080930|NCT04245969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34080931|NCT03345641|||COHORT||PROSPECTIVE|||||||
34080932|NCT02113514|||CASE_CONTROL||PROSPECTIVE|||||||
34080933|NCT05246657|||OTHER||PROSPECTIVE|||||||
34080934|NCT05704816|||COHORT||PROSPECTIVE|||||||
34080935|NCT02017977|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34080936|NCT03335995|||COHORT||PROSPECTIVE|||||||
34080937|NCT02572453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are enrolled onto one of three parallel, non-comparative arms by disease type; treatment regimens are the same for each arm.||||
34080938|NCT06485960|||COHORT||PROSPECTIVE|||||||
34080939|NCT04925557|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Analysts had no knowledge of study drug assignment and if a subject as a patient or HC.||f|f|f|t
34080940|NCT04844216|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Injectors will be unblinded. All subjects, investigators (in charge of clinical examination, assessment of local tolerance, live and on photograph assessment of nasolabial folds severity), as well as technicians (in charge of photographs and measurement of roughness) will be blinded.|Within-subject study with treatment of one nasolabial fold with the investigational medical device and treatment of the other nasolabial fold with a comparator (another medical device).|t|f|t|t
34080941|NCT05356221|||CASE_ONLY||CROSS_SECTIONAL|||||||
34080942|NCT05986123|NA|SINGLE_GROUP||OTHER||NONE||||||
33683803|NCT04240080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33683804|NCT05063071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683805|NCT00252941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683806|NCT02969603|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683807|NCT05476484|||COHORT||RETROSPECTIVE|||||||
33683808|NCT04982601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774483|NCT03167216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Comparison of mast cell tryptase levels and changes in symptom scores after treatment with cromolyn sodium and cetirizine hydrochloride||||
33774484|NCT04487717|||COHORT||PROSPECTIVE|||||||
33774485|NCT04842682|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Within each group, participants will be randomized in a double blind manner to active intervention or placebo in a 5:1 ratio. Randomization will be stratified by group.~All groups will be double-blind until W6. Formal individual unblinding (with communication of individual volunteer allocation to active vs. placebo) will only performed at the end of the W48 visits of all participants in a given group.~Long term follow-up to study the persistence of immune responses at W76 will be unblinded.~The second part of the trial will be single blind. Allocation of the use of the unadjuvanted vs. adjuvanted CD40. HIVRI.Env boost will be randomized. Randomisation will be stratified by the initial group (Solo or Combi with its dose level)."|Multicenter double-blind placebo controlled phase I dose-escalation trial to evaluate different dose levels of CD40.HIVRI.Env (adjuvanted with Hiltonol®) alone and in co-administration with DNA-HIV-PT123|t|t|t|t
33774486|NCT03869736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986727|NCT04975334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986728|NCT00305786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986729|NCT04616066|RANDOMIZED|PARALLEL||OTHER||NONE||This is a parallel, prospective, interventional and randomized trial involving 80 patients with type 2 diabetes. They will be randomised to either 60g of dates or 60g of raisins (amount split and given as a mid-morning and mid-afternoon snack) for 3 months.||||
33986730|NCT02620930|||COHORT||PROSPECTIVE|||||||
33986731|NCT06162793|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Quasi-experimental design||||
33986732|NCT06147596|||COHORT||PROSPECTIVE|||||||
33986733|NCT02089685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986734|NCT03916497|||COHORT||CROSS_SECTIONAL|||||||
33986735|NCT00421850|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33986736|NCT02864615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986737|NCT02042664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986738|NCT00906594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986739|NCT01630733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986740|NCT05239819|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study population will be randomized and separated in two groups, Intervention and Usual care group.||||
33986741|NCT04609722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33986742|NCT02561585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986743|NCT02459951|||CASE_ONLY||PROSPECTIVE|||||||
33986744|NCT00773253|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683809|NCT05856591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683810|NCT00002642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683811|NCT04812288|||OTHER||CROSS_SECTIONAL|||||||
33683812|NCT02257801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33683813|NCT00618553|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33683814|NCT03175055|NA|SINGLE_GROUP||OTHER||NONE||||||
33683815|NCT03483922|||CASE_CONTROL||RETROSPECTIVE|||||||
33683816|NCT00294710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33683817|NCT00167856|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33683818|NCT05062993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683819|NCT00040846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683820|NCT01104376|NA|SINGLE_GROUP||SCREENING||NONE||||||
33683821|NCT02253927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683822|NCT03029637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683823|NCT02398994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774487|NCT05499130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774488|NCT05177523|||COHORT||PROSPECTIVE|||||||
33774489|NCT06085625|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774490|NCT05658341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This will be a pragmatic two-arm (ADA intervention versus control/usual care) cluster randomized controlled trial.|f|f|f|t
33774491|NCT06565650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be instructed not to show or discuss the properties of the assigned Investigational Product (IP) and/or their experience with the IP with other subjects and not to show or discuss the IP with the Investigator or site personnel other than the dedicated dosing coordinator, unless instructed to do so.||f|f|t|f
33774492|NCT06121050|NA|SINGLE_GROUP||OTHER||NONE||Patients who can be visited by their pets||||
33903961|NCT06440590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double (Investigator, Outcomes Assessor) Patients and physicians allocated to each intervention group were aware of the allocation; however, the data analysts and the outcome assessors were kept blinded to the allocation.|An independent doctor created the randomization sequence using Excel 2016 (computerized random numbers) with a 1:1 allocation via random block sizes of 2, 4, and 6; he assigned the sample numbers equally to each group and assigned the block. Patients and physicians allocated to each intervention group were aware of the allocation; however, the data analysts and the outcome assessors were kept blinded to the allocation. The investigators prospectively carried out this study on 30 patients with quadrilateral plate fractures between February 2022 and June 2023 that met our inclusion criteria. The independent doctor allocated the 30 cases to two groups: Group A (15 cases): supra-pectineal quadrilateral buttress plating, group B (15 cases): Infra-pectineal plating|f|f|f|t
33903962|NCT04944979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683824|NCT04125264|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patient located in experimental group will be treated with ITU. Patient located in control group will be treated with the same protocoll of ITU without intensity.|Randomized, Non-probabilistic and Superiority Controlled Clinical Trial.||||
33683825|NCT05599776|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a 2 arm, 1:1 randomized, controlled, single-center trial adhering to Standard Protocol Items: Recommendation for Interventional Trials (SPIRIT) guidelines. The study will be carried out at Coxa Hospital for Joint Replacement (Tampere, Finland), a university-affiliated publicly funded orthopaedic hospital specializing in joint replacement surgery.||||
33683826|NCT06391190|NA|SINGLE_GROUP||TREATMENT||NONE||single arm||||
33683827|NCT04204499|||OTHER||OTHER|||||||
33683828|NCT00547001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683829|NCT05854927|||COHORT||PROSPECTIVE|||||||
33683830|NCT05407740|||COHORT||RETROSPECTIVE|||||||
33683831|NCT04058171|||COHORT||CROSS_SECTIONAL|||||||
33683832|NCT03986073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683833|NCT04111978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683834|NCT05337033|NA|SINGLE_GROUP||TREATMENT||NONE||Open label tolerability trial||||
33683835|NCT01868919|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33683836|NCT03557996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participant-outcome assessor)|patient will receive either silver diamine fluoride or sodium fluoride varnish|t|f|f|t
33683837|NCT01464905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33683838|NCT01185301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683839|NCT02677311|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33683840|NCT03567317|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33683841|NCT01343823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683842|NCT01413633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683843|NCT00392379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683844|NCT00041587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683845|NCT02518880|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33903963|NCT00593086|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33683846|NCT05714319|||COHORT||OTHER|||||||
33683847|NCT03426982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"After randomization, the patients must be monitored using either anti-Xa activity or aPTT.~Only that specific test should be prescribed by the ward, and only that the corresponding test result be given by the laboratory."||||
33683848|NCT04814238|||COHORT||OTHER|||||||
33683849|NCT05765773|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33774493|NCT06419361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774494|NCT04606433|NA|SEQUENTIAL||TREATMENT||NONE||||||
33774495|NCT06411756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774496|NCT05082025|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774497|NCT02945722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33903964|NCT05470582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33903965|NCT06157697|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33903966|NCT02296840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33903967|NCT03962998|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33903968|NCT05715086|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, non-blinded, randomized controlled trial with two study arms.||||
33986745|NCT04694586|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective||||
33986746|NCT02989233|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33986747|NCT03388203|||COHORT||RETROSPECTIVE|||||||
34080943|NCT02007902|||COHORT||PROSPECTIVE|||||||
34080944|NCT00552695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34080945|NCT04564911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080946|NCT01809756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080947|NCT02244983|||COHORT||PROSPECTIVE|||||||
34080948|NCT01575080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34080949|NCT02124824|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34080950|NCT00103948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34080951|NCT02247466|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34080952|NCT03528148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomize control trials|t|f|f|f
34080953|NCT05799846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34080954|NCT04925102|||COHORT||PROSPECTIVE|||||||
34080955|NCT01944657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080956|NCT02373267|||COHORT||PROSPECTIVE|||||||
34080957|NCT05197816|NA|SINGLE_GROUP||TREATMENT||NONE||"Evaluation of symptomatology on and off adaptive deep brain stimulation"||||
34080958|NCT04693793|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will enroll specialist physicians, specifically cardiologists and pulmonologists, practicing in the US. Participants are randomly assigned to either a control, intervention 1, or intervenion 2 arm upon enrollment. All eligible and consented participants will complete two rounds of three patient simulations.~The intervention 1 and intervention 2 arms only will receive educational material about the Janssen test in between these two rounds. Intervention 1 arm participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it in the second round of simulated cases."||||
33986748|NCT00448019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903969|NCT04673409|||CASE_CONTROL||PROSPECTIVE|||||||
33903970|NCT06224543|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two interventional groups: Group A: 0.01 mmol/kg GV, Group B: 0.025 mmol/kg GV. Both groups also receive GV standard dose (0.1 mmol/kg) that serves as the clinical image set for the participant and as comparator.||||
33986749|NCT05371392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986750|NCT04018365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986751|NCT06279910|||CASE_CONTROL||RETROSPECTIVE|||||||
33986752|NCT01637298|||COHORT||PROSPECTIVE|||||||
33986753|NCT04446559|RANDOMIZED|PARALLEL||OTHER||NONE||Once the patient is included and the randomization is made, the positioning method will be applied for only one period of 3 hours (if optimal tolerance) and arterial gasometry in relation to the main objective will only be performed on this occasion. For the rest of the stay, the patient will benefit from the usual examinations and positioning techniques in the corresponding ICU.||||
33903971|NCT01157858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903972|NCT02091622|RANDOMIZED|PARALLEL||||NONE||||||
33903973|NCT00393289|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33903974|NCT05224622|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986754|NCT06151730|||COHORT||PROSPECTIVE|||||||
33986755|NCT04564560|||CASE_ONLY||RETROSPECTIVE|||||||
33986756|NCT04526782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, multicenter, multi-cohort Phase 2 study of the combination of encorafenib and binimetinib in patients with previously treated and untreated BRAFV600E-mutant NSCLC.||||
33683850|NCT03315052|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Comparison of standard immunosuppression to immunosuppression incorporating budesonide in place of prednisone||||
33683851|NCT04929665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683852|NCT03693729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33683853|NCT04652739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33683854|NCT01143233|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33683855|NCT01566812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33683856|NCT02890615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33683857|NCT01623674|||||PROSPECTIVE|||||||
33903975|NCT02033551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903976|NCT03378401|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683858|NCT04732000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683859|NCT03707028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683860|NCT05680805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683861|NCT03367247|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Clinical research assistant blinded to randomized study arms; will conduct structured interview at baseline, prior to randomization, and 4 weeks post randomization +/- 2 weeks.|"Phase I: Single-arm study with up to 20 ovarian cancer patients and their informal caregivers run-in.~Phase II: Two-arm pilot RCT with 60 gynecologic or gastrointestinal cancer patients and their informal caregivers (30 dyads in each arm)."|f|f|f|t
33683862|NCT02558829|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|This was an open label trial. No masking with regard to the Growth Hormone Stimulation Tests (GHSTs) performed was done. However, Data Review Committee/Sponsor/Project Management was masked towards the Growth Hormone (GH) values as results fo both tests. GH values were provided to the investigator only after both GHSTs had been performed, to avoid bias.|||||
33683863|NCT04426760|||CASE_ONLY||PROSPECTIVE|||||||
33986757|NCT01510262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33986758|NCT06517979|||COHORT||PROSPECTIVE|||||||
33986759|NCT04624620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986760|NCT03851939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986761|NCT04914962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patient will receive a restoration with superior function, esthetics, and excellent clinical performance|t|f|f|t
33774498|NCT06646627|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33903977|NCT05164952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903978|NCT06255990|||COHORT||PROSPECTIVE|||||||
33903979|NCT00259025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33903980|NCT06254469|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33903981|NCT02275026|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33903982|NCT02137434|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33986762|NCT04100733|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33986763|NCT00239863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986764|NCT01560767|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33986765|NCT05908266|||CASE_CONTROL||PROSPECTIVE|||||||
33986766|NCT01853657|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33986767|NCT04718025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986768|NCT02214615|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33986769|NCT00651820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33986770|NCT02069080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683864|NCT06080672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Group 1: Students, whose first records (plaque index, gingival index) are taken after the examination by the periodontology specialist, will be taught how to brush their teeth with the Modified Bass Technique and how to use dental floss/interdental brush. Students will then be asked to brush their teeth.~Group 2: The students, whose initial records (plaque index, gingival index) are taken after the examination by the periodontology specialist, will be taught how to brush their teeth with the Modified Bass Technique and how to use dental floss/interdental brush. After staining the teeth with a plaque disclosing agent, they will be shown in the mirror. Then the students will then be asked to brush their teeth."||||
33683865|NCT00207597|||NATURAL_HISTORY||PROSPECTIVE|||||||
33683866|NCT04122456|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33683867|NCT01700868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33683868|NCT01940978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683869|NCT05172479|||COHORT||PROSPECTIVE|||||||
33683870|NCT03036475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683871|NCT03521895|||COHORT||RETROSPECTIVE|||||||
33683872|NCT00634270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683873|NCT00424255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683874|NCT06372743|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a dual-centre two-arm, open-label randomized controlled trial (RCT). Patients are randomized with a one-to-one allocation into two parallel groups.||||
33683875|NCT02925533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683876|NCT03330002|||COHORT||PROSPECTIVE|||||||
33683877|NCT03768557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683878|NCT00481507|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683879|NCT02294942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683880|NCT04513561|||COHORT||PROSPECTIVE|||||||
33774499|NCT05877196|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Sequential, Multiple Assignment, Randomized Trial|f|f|t|t
33774500|NCT03817502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774501|NCT04495751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a double blind study. Only the investigational pharmacists and the statisticians will be unblinded. The blind will be maintained until the study is complete.||t|f|t|f
33774502|NCT06342375|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33903983|NCT06044753|RANDOMIZED|PARALLEL||OTHER||SINGLE|Masking of parents and patients, until entering the operation theatre|Paediatric Patients age 4 to 12 .|t|f|f|f
33903984|NCT01208662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903985|NCT00657761|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33903986|NCT02349906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903987|NCT00087204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33903988|NCT02062151|NA|SINGLE_GROUP||OTHER||NONE||||||
33903989|NCT03313271|||COHORT||OTHER|||||||
33903990|NCT01646008|||||PROSPECTIVE|||||||
33903991|NCT05312905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be included in the study and randomly divided into two groups using block randomization in Microsoft Excel-RANDOMISE 'RAND(WS)' function.||t|f|f|f
33903992|NCT01914445|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33903993|NCT00256828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33903994|NCT01157871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33903995|NCT06020326|||COHORT||RETROSPECTIVE|||||||
33903996|NCT06498297|||CASE_ONLY||RETROSPECTIVE|||||||
33903997|NCT03196050|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33903998|NCT02860468|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33903999|NCT02339025|||OTHER||CROSS_SECTIONAL|||||||
33904000|NCT04907604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||It will conduct a stepped wedge cluster randomized trial with randomization on the company level, each company representing one cluster. The design involves random and sequential crossover of clusters from control to intervention until all clusters are exposed. Data collection continues throughout the study so that each cluster contributes observations under both control and intervention observation periods. This design was selected in order to retain the power of randomization while offering all companies enrolled in the trial the desirable intervention.|f|f|t|f
33904001|NCT04900805|||OTHER||CROSS_SECTIONAL|||||||
33904002|NCT02619240|||CASE_ONLY||PROSPECTIVE|||||||
33986771|NCT02600403|||COHORT||PROSPECTIVE|||||||
33986772|NCT01016028|||CASE_ONLY||PROSPECTIVE|||||||
33904003|NCT02286011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904004|NCT06671327|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33904005|NCT05233267|||COHORT||PROSPECTIVE|||||||
33904006|NCT05716607|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-center, randomized, open-label, two-period cross-over trial||||
33904007|NCT04338022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904008|NCT01729364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904009|NCT00832715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904010|NCT04920474|||CASE_ONLY||RETROSPECTIVE|||||||
33904011|NCT04303390|RANDOMIZED|PARALLEL||TREATMENT||NONE||50% of study patients will be assigned to first generation cephalosporin while the other 50% will be assigned to the second generation cephalosporin. 50% of the entire study participants will be assigned to 24 hour therapy while the other 50% will be assigned to 48 hours||||
33904012|NCT03334578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904013|NCT02199977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904014|NCT04637321|||OTHER||RETROSPECTIVE|||||||
33904015|NCT03664986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The group you get randomized to will be chosen by chance, like flipping a coin. Neither you nor the study doctor will choose what group you will be in. You will have an equal chance of being in either group. Neither you nor the nurses nor anesthesiologist will know which group you will be in. However, your study doctor will know.||t|f|f|f
33986773|NCT03909945|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after study intervention||||
33986774|NCT03135834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986775|NCT01162694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986776|NCT00683098|||CASE_ONLY||PROSPECTIVE|||||||
34080959|NCT02988011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683881|NCT04164693|RANDOMIZED|PARALLEL||PREVENTION||NONE||The enrolled patients will be randomly assigned to either the anticoagulant group or the control group. Patients in the anticoagulant group will receive a low-dose subcutaneous injection of low molecular weight heparin for the prevention of AVF thrombosis, starting 12-24 hours after the surgery. For patients weighing less than 80kg, enoxaparin sodium 4000IU will be administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU will be administered every 12 hours. After discharge, these patients will be switched to oral low-dose warfarin for anticoagulation, with a daily dose of 1.25mg (half tablet) on dialysis days and 2.5mg/day on non-dialysis days. Patients with significantly excessive body weight may be considered for a daily dose of 2.5mg, with a total treatment duration of 4 weeks. Patients in the control group will not receive anticoagulants postoperatively, but both groups will routinely receive antiplatelet therapy.||||
34080960|NCT04400461|||COHORT||CROSS_SECTIONAL|||||||
34080961|NCT05880797|||COHORT||PROSPECTIVE|||||||
33683882|NCT02319356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33683883|NCT02528721|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33683884|NCT01223443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683885|NCT00882570|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683886|NCT05895799|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomized controlled waitlist design|f|f|t|t
33683887|NCT04352153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683888|NCT04668612|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized open-label single-center crossover clinical study||||
33683889|NCT00280111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683890|NCT00576680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683891|NCT04597060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683892|NCT03893344|||CASE_CONTROL||PROSPECTIVE|||||||
33683893|NCT04787523|||COHORT||RETROSPECTIVE|||||||
33683894|NCT03393533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgical procedures were always performed by the same surgeon and assistant, who was unaware of the group that belonged to the patient, as well as the patient himself. This randomization was performed involving numbers and envelopes, being only the investigator's knowledge.|"The sample will consist of 32 lower third molars, semi-inclusively or included. This study will be a randomized, blind, controlled, split-mouth clinical trial, divided into two groups simultaneously, namely:~Group I (16 teeth) - without therapeutic banding on the face, after the third molar extraction.~Group II (16 teeth) - with therapeutic banding on the face, after the third molar extraction."|f|t|f|f
33904016|NCT04011436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|SNOSE: Sequentially Numbered, Opaque Sealed Envelopes. The forty subjects of the experimental procedure were assigned to the two intervention groups from three steps: 1. A paper / charcoal sheet was placed on an Assignation paper marked with Group A or Group B, 2. Then they were lined with aluminum foil, also rectangular and 3. They were finally inserted in a white envelope which was sealed with glue. Forty of these envelopes were made, twenty for Group A and the other half for Group B, after that, they were mixed in a cardboard box and then enumerated one by one at random until the 40 envelopes were completed. Each envelope was delivered in order of numbering to each of the patients who were entering the treatment. The investigator directed the strengthening program and another Physical Therapist addressed the tests.|Experimental study type controlled clinical trial, designed to evaluate the effect of two muscle strengthening programs in people with patellofemoral pain syndrome (Group A: Exercises for core, hip and knee and Group B: exercises for hip and knee).|t|f|t|t
33904017|NCT02747043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904018|NCT02131467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904019|NCT01072864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33904020|NCT01477216|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33904021|NCT01454089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904022|NCT05468450|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Blinding of participants and investigators is not possible because of the obvious differences between the two treatments (a single mid-calf injection versus multiple injections for tumescent anaesthesia/laser precautions etc...).~A blind third-party check was carried out, only at 3 years, and those assessors were completely independent of the study and blinded."|multicentre-RCT (11 centres) comparing ultrasound-guided-foam sclerotherapy (UGFS) and Endovenous Laser Ablation (EVLA) for treating small saphenous veins (SSV) insufficiency||||
33904023|NCT00174746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904024|NCT02145767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33904025|NCT04197297|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will undergo CT and MRIs before and after radiation therapy.||||
33986777|NCT04000386|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant) Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Single blind controlled trial between participants, drug preparing team, doctors, investigators, and outcome assessors.|Parallel Assignment|t|f|f|f
33986778|NCT04481815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986779|NCT05860686|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Double blind randomized clinical trial|f|f|f|t
33986780|NCT01804270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986781|NCT01940341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986782|NCT05703438|NA|SINGLE_GROUP||TREATMENT||NONE||The study was conducted by providing a daily calorie deficit of 500-600 kcal to the usual intake of each participant. The study was conducted for 8 weeks. Examination of metabolic biomarkers is carried out before and after the diet intervention is administered.||||
33986783|NCT03397056|||COHORT||PROSPECTIVE|||||||
33986784|NCT00724191|||CASE_ONLY||PROSPECTIVE|||||||
33986785|NCT01216839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986786|NCT01549080|||CASE_CONTROL||PROSPECTIVE|||||||
34024956|NCT05738317|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with advanced non-squamous non-small cell lung cancer after first-line immunotherapy progression||||
34024957|NCT04855149|||COHORT||PROSPECTIVE|||||||
34024958|NCT05713851|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group 1: Dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days.~Group 2: Standard of care strategy, patients will receive the usual treatment for their pathology according to the judgment of their treating physician and the Institutional practices, without receiving any of the interventional drugs, but blood and urinary samples will be taken to determine the biomarkers at the times established in the schedule."||||
33683895|NCT05832554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33683896|NCT03920904|||COHORT||PROSPECTIVE|||||||
33683897|NCT01525199|||CASE_CONTROL||RETROSPECTIVE|||||||
33683898|NCT00177047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683899|NCT01257360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683900|NCT06409793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The proposed intervention will provide one group of adolescents with a combined accelerometer and heart rate monitor, alongside exercise counselling. The accelerometer will be used to support the youngsters achieve a personalised daily PA goal. The heart rate monitor will then be used to support adherence to an individualised and co-created home-based exercise programme.~A second group will receive exercise counselling only."||||
33683901|NCT05337904|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A clinical trial with four periods will be performed: pre-treatment, Intervention and follow-up, Cross-over period, and Recoveryoriented intervention.|f|f|f|t
33683902|NCT00735189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33683903|NCT04607278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and investigators are double-blinded|The 8-week randomized, double-blind, parallel-group, placebo-controlled study|t|f|t|f
33683904|NCT02488876|||COHORT||PROSPECTIVE|||||||
33683905|NCT05409378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683906|NCT00535574|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33683907|NCT01819818|||COHORT||PROSPECTIVE|||||||
33683908|NCT00075270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33683909|NCT02217072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774503|NCT05952024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904026|NCT05351086|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|A computerized randomization scheme will be created and shall be considered blinded (as per the following). The randomization is available only to the clinical research unit pharmacy staff that are preparing the drug who will not be involved in any other aspect of the study including administration of the drug. It will not be made available to the subjects, site PI, or members of the staff responsible for the monitoring and evaluation of study assessments.|Double Dummy, Double-blind|t|t|t|t
33683910|NCT01247805|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683911|NCT06046352|||COHORT||RETROSPECTIVE|||||||
33683912|NCT00204243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774504|NCT06739980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774505|NCT05882266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomisation will be done by an independent researcher using block randomisation. No one except the independent researcher will know which group were assigned for each code. The file containing the info for each code will be kept by the independent researcher in Beacon Hospital.|"This is a non-weight loss interventional study. This study employed a single-blinded, randomised controlled, parallel design to compare the effect of plant-based omega-3 versus standard dietary therapy among individuals with CVD risk for 12 weeks. The randomisation will be done by an independent researcher. The intervention study had comprised two groups:~* Treatment group: Receive standard dietary therapy and plant-based omega-3 supplemental beverage consumed once daily during breakfast.~* Control group: Receive only standard dietary therapy"|t|f|t|t
33774506|NCT06029010|||COHORT||RETROSPECTIVE|||||||
33774507|NCT05229874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774508|NCT06495996|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774509|NCT06726954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple||t|t|t|t
33904027|NCT01193790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904028|NCT05031325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024959|NCT01194817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774510|NCT05491343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774511|NCT05658835|||COHORT||PROSPECTIVE|||||||
33774512|NCT03418896|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||simple one arm intervention study||||
33774513|NCT06738823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774514|NCT02907554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774515|NCT06739590|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants remained unaware of the trial purpose and assessment metrics, only that they would be learning and practicing the anatomical structures and surgical planning of hepatobiliary surgery.|Stratified Randomized Block Design|t|f|f|f
33774516|NCT06571669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774517|NCT06206694|||COHORT||CROSS_SECTIONAL|||||||
33774518|NCT06739681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33774519|NCT06730958|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33774520|NCT05313191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase: Registry, Phase I, Phase II Study Design/Methodology: Cohort-defined, single arm prospective study||||
33774521|NCT06249984|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Blinded study products|Within-subjects factorial design|t|f|f|f
33774522|NCT00059748|||COHORT||PROSPECTIVE|||||||
33774523|NCT04090398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774524|NCT03394365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904029|NCT06442917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904030|NCT04185610|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33904031|NCT01641315|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33904032|NCT02299908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33904033|NCT00573326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904034|NCT01799746|||CASE_CROSSOVER||OTHER|||||||
33904035|NCT04550546|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904036|NCT01775046|||COHORT||PROSPECTIVE|||||||
33904037|NCT00996710|||FAMILY_BASED||OTHER|||||||
33904038|NCT02183545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904039|NCT01565629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904040|NCT06535399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904041|NCT03789773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904042|NCT01193725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904043|NCT00723112|||CASE_CONTROL||PROSPECTIVE|||||||
34024960|NCT03803787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904044|NCT05280015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||After randomization, subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy pr placebo during 12 weeks. The microbiotherapy is GynMDD developped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.|t|t|t|t
33904045|NCT05967234|NA|SINGLE_GROUP||OTHER||NONE||Study participants will be clients at local WIC agency sites where the telehealth solution is offered||||
33683913|NCT00007007|NA|SINGLE_GROUP||OTHER||NONE||||||
33683914|NCT05421650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904046|NCT03474003|||COHORT||PROSPECTIVE|||||||
33904047|NCT00176566|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33904048|NCT03925441|||COHORT||PROSPECTIVE|||||||
33904049|NCT00328263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33904050|NCT00319618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904051|NCT02518178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904052|NCT02385032|RANDOMIZED|CROSSOVER||||NONE||||||
33904053|NCT02636764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904054|NCT00004154|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33904055|NCT03849469|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904056|NCT01785953|||CASE_ONLY||RETROSPECTIVE|||||||
33904057|NCT03633578|NA|SINGLE_GROUP||OTHER||NONE||||||
33904058|NCT02328573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683915|NCT00105053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904059|NCT04691596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were randomized into four different study groups||t|f|f|f
33904060|NCT01467739|RANDOMIZED|PARALLEL||||NONE||||||
33904061|NCT01801046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904062|NCT06098885|||CASE_CONTROL||RETROSPECTIVE|||||||
33904063|NCT03943667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904064|NCT01225783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904065|NCT01495390|||CASE_ONLY||PROSPECTIVE|||||||
33683916|NCT06435559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683917|NCT05551442|||COHORT||RETROSPECTIVE|||||||
33986787|NCT05707962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As soon as parental consent has been obtained the baby will be allocated to one arm of the study using randomly shuffled sealed brown envelopes containing the allocation arm|All babies with moderate or severe Hypoxic Ischemic Encephalopathy fulfilling the inclusion criteria will be randomized to receive either the standard treatment (oxygen and fluid therapy along with anticonvulsants if required) plus 3.0 ml/kg of 10% dextrose water given over 30 minutes, three dose given 24 hours apart or to receive standard treatment PLUS three doses of Magnesium Sulphate infusion given over 30 minutes at 250 mg/kg per dose given 24 hours apart. The volume of infusion shall be adjusted with 10% dextrose water to make it|t|t|f|f
33986788|NCT04540523|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33986789|NCT03128905|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is used. All involved know the identity of the intervention assignment.|||||
33986790|NCT02238990|||COHORT||PROSPECTIVE|||||||
33683918|NCT05905003|||COHORT||PROSPECTIVE|||||||
33683919|NCT00904410|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683920|NCT02703428|||COHORT||PROSPECTIVE|||||||
33683921|NCT00081861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683922|NCT02582177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683923|NCT06112873|||COHORT||OTHER|||||||
33683924|NCT02125604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683925|NCT00169442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683926|NCT05243173|||COHORT||PROSPECTIVE|||||||
33683927|NCT05713669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A Total of 20 residents will be recruited (10 residents in the intervention arm; 10 residents in the control arm). One resident in each pair will be randomized to participate in a follow up encounter in the post-ICU clinic with the patient that residents have cared for (intervention) and one will have no follow up encounter (control). There will be 10 patients enrolled for the study and will not be randomized into any arm. Outcomes are based on the residents only.||||
33683928|NCT00412672|||COHORT||PROSPECTIVE|||||||
33683929|NCT00480948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33683930|NCT03947554|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33683931|NCT01532193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683932|NCT03160547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33683933|NCT01221740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683934|NCT05958693|||COHORT||PROSPECTIVE|||||||
33904066|NCT03628469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial with 1:1 randomization stratified for risk of hospital admission and region||||
33904067|NCT05470309|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33904068|NCT06238765|||COHORT||PROSPECTIVE|||||||
33904069|NCT03393845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904070|NCT01010841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904071|NCT01287234|NA|SINGLE_GROUP||||NONE||||||
33904072|NCT05638386|||CASE_CONTROL||RETROSPECTIVE|||||||
33904073|NCT05837312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904074|NCT03344328|||COHORT||RETROSPECTIVE|||||||
33904075|NCT03952546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of the principal investigator and operating staff is not possible. However, all attempts will be made to keep this information from the hospital staff caring for the patients in the postoperative period. The patient and the postoperative hospital staff will be blinded to the treatment arm. The OR staff will be trained not to discuss this information with the patient. During the transition of care from the OR to the Post Anesthetic Care Unit (PACU) the treatment arm will not be included in the verbal patient report. The lack of this information is not required to effectively manage the patient in the postoperative period and will not affect patient care. Postoperatively medical care is managed by the hospitalist, medical doctors specializing in the care of hospitalized patients.||t|t|f|f
33904076|NCT06392984|||CASE_CONTROL||PROSPECTIVE|||||||
33986791|NCT01244620|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33986792|NCT05565053|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Comparing the efficacy of erector spina plan block and trigger point injection in patients with myofascial pain syndrome|t|f|f|f
33683935|NCT00586664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33683936|NCT05860010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33683937|NCT01498094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683938|NCT01433276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683939|NCT04161768|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683940|NCT01425047|||COHORT||PROSPECTIVE|||||||
33683941|NCT02710162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683942|NCT04935450|||COHORT||PROSPECTIVE|||||||
33683943|NCT00782938|||CASE_CONTROL||PROSPECTIVE|||||||
33683944|NCT04466722|||COHORT||PROSPECTIVE|||||||
33683945|NCT00216164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683946|NCT00738036|||COHORT||PROSPECTIVE|||||||
33683947|NCT06070220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33683948|NCT04875247|||COHORT||PROSPECTIVE|||||||
33683949|NCT00886652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683950|NCT03288792|NA|SINGLE_GROUP||SCREENING||NONE||||||
33683951|NCT05651204|||CASE_CONTROL||PROSPECTIVE|||||||
33683952|NCT02261025|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33683953|NCT03976869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683954|NCT03551925|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a randomized controlled trial using a pretest-posttest control group design to allow for comparison between a treatment as usual (TAU) group supporting medication adherence and a TAU group that receives an additional occupational therapy intervention.||||
33683955|NCT01574833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33683956|NCT04503915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683957|NCT06193798|||OTHER||PROSPECTIVE|||||||
33683958|NCT02849353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683959|NCT02426489|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33683960|NCT03232125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, care provider and investigator are blinded to group assignment.|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction. In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.|t|t|t|f
33683961|NCT01673152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683962|NCT03024580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683963|NCT03515291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683964|NCT04925154|||CASE_CONTROL||OTHER|||||||
33683965|NCT06531590|||COHORT||PROSPECTIVE|||||||
33683966|NCT06485115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904077|NCT05898503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33904078|NCT01219244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33904079|NCT01382186|||COHORT||PROSPECTIVE|||||||
33904080|NCT01936649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683967|NCT05291468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The study population will be divided in 4 groups Group A consists of patients with C. Acnes present in their tissue Group B consists of patients without C. Acnes present in their tissue 50% of patients in each group will be treated with antibiotics and 50% with placebo.~Study duration is 4 months"|t|t|t|f
33683968|NCT04897139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683969|NCT03027284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33683970|NCT03961477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each subject in both groups was positioned in prone lying and the area to be treated was exposed. The IF group which included 30 subjects received IF. The IF current was increased gradually according the subject's condition with comfortable tingling sensation.||t|f|f|t
33683971|NCT03978143|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33683972|NCT03675464|||COHORT||PROSPECTIVE|||||||
33683973|NCT04883723|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||During the data collection, 120 individuals who met the inclusion criteria and were selected with the randomization list created on the computer constituted the sample of the study.|t|f|f|f
33683974|NCT06388044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683975|NCT03235180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683976|NCT05853796|||CASE_CONTROL||PROSPECTIVE|||||||
33683977|NCT02924519|||COHORT||PROSPECTIVE|||||||
33683978|NCT03680742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683979|NCT04340219|||COHORT||PROSPECTIVE|||||||
33683980|NCT03725423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683981|NCT03014882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683982|NCT00734955|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33904081|NCT01776099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904082|NCT03280732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904083|NCT00061308|NON_RANDOMIZED|||TREATMENT||NONE||||||
33904084|NCT02288975|||CASE_CONTROL||PROSPECTIVE|||||||
33904085|NCT01315015|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33904086|NCT04710589|||COHORT||PROSPECTIVE|||||||
33904087|NCT02421120|NA|SINGLE_GROUP||OTHER||NONE||||||
33904088|NCT04534062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only participant will be blinded|randomized controlled trial|t|f|f|f
33904089|NCT03005847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904090|NCT04196036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904091|NCT01641016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904092|NCT06032676|||COHORT||PROSPECTIVE|||||||
33904093|NCT02222727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904094|NCT03612141|||COHORT||PROSPECTIVE|||||||
33986793|NCT04444479|NA|SINGLE_GROUP||OTHER||NONE|No masking will be used in the study|The study subjects enrolled in the study will be assigned to one study group. No randomization is performed.||||
33986794|NCT05997147|||COHORT||RETROSPECTIVE|||||||
33986795|NCT00868374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986796|NCT03222063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986797|NCT04425447|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774525|NCT06736730|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Jackson, MS will be divided into 9 clusters (with defined geographic boundaries and know population totals) and those clusters will undergo randomization for activation. 3 clusters will be activated each year for three years and those living in the activated clusters will receive the interventions upon activation. Results from participants living in active clusters will be compared to those not in active clusters until at the end of the three years study period all clusters will be activated.||||
33986798|NCT05844553|||COHORT||OTHER|||||||
33986799|NCT02381834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986800|NCT05552833|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||12 COPD will undergo the intervention in one arm and 12 healthy, age and BMI matched individuals will undergo the same intervention.||||
33683983|NCT03889301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be assigned to experimental or control group.|f|f|t|f
33683984|NCT01534182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683985|NCT04069364|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33774526|NCT02928094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33774527|NCT05656105|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774528|NCT04504136|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33683986|NCT00708253|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33774529|NCT02275416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774530|NCT05876377|||COHORT||RETROSPECTIVE|||||||
33774531|NCT06173349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774532|NCT06739382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683987|NCT02325973|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683988|NCT06236191|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcome assessor assessing sleep data will be blinded|Crossover trial using Balaam's design|f|f|f|t
33683989|NCT02758379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33683990|NCT00821509|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33683991|NCT00693862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33683992|NCT05843227|||COHORT||PROSPECTIVE|||||||
33774533|NCT06728085|NA|SEQUENTIAL||PREVENTION||NONE||Hybrid Type II, stepped-wedge cluster randomized trial||||
33774534|NCT05325866|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774535|NCT05773781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33774536|NCT06506773|||COHORT||PROSPECTIVE|||||||
33774537|NCT03656549|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation study||||
33774538|NCT05748600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986801|NCT02469805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986802|NCT04561622|||CASE_CONTROL||PROSPECTIVE|||||||
33986803|NCT04809961|||COHORT||CROSS_SECTIONAL|||||||
33986804|NCT01300091|||COHORT||PROSPECTIVE|||||||
33986805|NCT06560515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986806|NCT00171886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986807|NCT05261737|||CASE_ONLY||PROSPECTIVE|||||||
33774539|NCT06062576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774540|NCT00632710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33774541|NCT06649006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774542|NCT06184256|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774543|NCT05797740|||COHORT||OTHER|||||||
33774544|NCT06634836|||CASE_ONLY||PROSPECTIVE|||||||
33774545|NCT06319222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774546|NCT06739460|||CASE_CONTROL||PROSPECTIVE|||||||
33774547|NCT05141487|||OTHER||PROSPECTIVE|||||||
33774548|NCT02988128|||COHORT||PROSPECTIVE|||||||
33774549|NCT06050252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774550|NCT06112418|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized, open blinded endpoint (PROBE), event-driven pragmatic trial||||
33839644|NCT03969134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Fifty volunteers receive a single intramuscular dose of ChAd63 KH 7.5x1010vp and 50 placebo. Investigators and the participant will be blinded. A pharmacist and nurse will prepare the injections. There will be stratification between patients aged 12-17, and patients aged 18-50, to ensure balanced randomisation. The pharmacist will be told which age strata the patient is in by a nurse, and will prepare the injection with the study nurse. There will be two series of sealed envelopes, one for each of the adolescent and adult cohorts. These envelopes will have external labelling, with the cohort, and successive cohort patient numbering. Each envelope contains randomisation to VACCINE or SALINE. The vaccine and placebo injections will be prepared in blacked-out syringes labelled with patient cohort number. The study nurse will take the prepared injection to the clinical team for administration. The syringe will be further labelled with the patient's initials, date and time of injection.|Randomised, double blinded, placebo controlled|t|t|t|t
33986808|NCT00532974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986809|NCT06020924|||CASE_CONTROL||RETROSPECTIVE|||||||
33986810|NCT03113786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986811|NCT03190005|||CASE_CONTROL||PROSPECTIVE|||||||
33986812|NCT02109692|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33986813|NCT04036422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary investigator will be blind to the treatment received by the patients and will carry out all patient evaluations before and after the treatment program is completed.|The patients will be randomized into one of two groups (fifteen patients in each group) using the Random Allocation Software. All patients will receive a one hourly 'one-on-one' session of physiotherapy five days a week to a total of twenty hours (four weeks) which includes strengthening, balance and walking exercises. In addition to this, one group will receive half and hour of conventional occupational therapy which includes task based exercises aimed at improving upper arm dexterity, coordination and strength seven days a week to a total of twenty eight hours (four weeks), whereas patients in the other group will receive half an hour of Rejoyce computerized exercise to a total of twenty eight hours (four weeks).|f|f|t|t
33986814|NCT06234358|||COHORT||RETROSPECTIVE|||||||
33986815|NCT00921440|||COHORT||PROSPECTIVE|||||||
33986816|NCT06025188|||COHORT||RETROSPECTIVE|||||||
33986817|NCT03141671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986818|NCT00950989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986819|NCT05229445|NA|SINGLE_GROUP||TREATMENT||NONE||Single group open label||||
33986820|NCT00465439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839645|NCT02924090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839646|NCT00046306|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33986821|NCT02043327|||CASE_CONTROL|||||||||
33986822|NCT01425060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986823|NCT01223820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986824|NCT01604902|||CASE_ONLY||PROSPECTIVE|||||||
33986825|NCT02137135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33986826|NCT00381225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986827|NCT04472156|NA|SINGLE_GROUP||TREATMENT||NONE||Outcomes will be evaluated with women who have a mosaic embryo transferred||||
33986828|NCT04045262|||CASE_ONLY||PROSPECTIVE|||||||
33986829|NCT05640531|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33986830|NCT02128386|||COHORT||PROSPECTIVE|||||||
33986831|NCT01828528|||COHORT||PROSPECTIVE|||||||
33986832|NCT00942318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986833|NCT02010320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986834|NCT02704286|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986835|NCT02035306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986836|NCT03075553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986837|NCT00318045|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33986838|NCT00732563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986839|NCT02481830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986840|NCT00180986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986841|NCT02071797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986842|NCT04657965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986843|NCT01884519|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986844|NCT00938951|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33986845|NCT00328926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986846|NCT04012112|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33986847|NCT04215822|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986848|NCT06141317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986849|NCT01751048|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34080962|NCT03585270|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study will be performed in a double-blind fashion. The investigator, study personnel, subjects, clinical research associates (CRAs), sponsor personnel, and vendor / Contract Research Organization (CRO) personnel involved in the conduct of the study will remain blinded to the study treatment received by the subjects during the double-blind treatment period until study closure||t|t|t|t
34080963|NCT03551795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839647|NCT00936572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33839648|NCT01731223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839649|NCT05937555|||OTHER||RETROSPECTIVE|||||||
33839650|NCT00573898|||||PROSPECTIVE|||||||
33839651|NCT04371523|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither the participant, nor the investigators, study coordinators, adjudicator, and data analysts will know if the subject is receiving the hydroxychloroquine or placebo.|Parallel two-armed, multi-centred, blinded, stratified, superiority, randomized controlled trial|t|t|t|t
33839652|NCT05034406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839653|NCT00737503|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33839654|NCT05459155|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Prospective pre-post mixed methods hybrid type 2 effectiveness-implementation study||||
33839655|NCT03614260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839656|NCT05959798|||COHORT||PROSPECTIVE|||||||
33839657|NCT05549492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||to determine if TAP block treatment, either with or without buprenorphine, affected patients having inguinal hernias repaired|t|f|f|f
33839658|NCT01907867|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839659|NCT06092320|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants will not know the specific pediatric resuscitation simulation they will be completing.~Simulation reviewers will not know which arm of the intervention the participants are in."||t|f|f|t
33839660|NCT03008798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33986850|NCT01644253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986851|NCT02095782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986852|NCT03904563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986853|NCT02002754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986854|NCT04642274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33986855|NCT05974163|||COHORT||PROSPECTIVE|||||||
33986856|NCT04742283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986857|NCT01218672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986858|NCT00863083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986859|NCT05767619|||COHORT||PROSPECTIVE|||||||
33986860|NCT01613040|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33986861|NCT06078072|||CASE_ONLY||PROSPECTIVE|||||||
33986862|NCT01328093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986863|NCT05672433|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33986864|NCT06334445|||CASE_ONLY||PROSPECTIVE|||||||
33986865|NCT03959605|||CASE_CONTROL||PROSPECTIVE|||||||
33986866|NCT02388191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33986867|NCT05294471|||COHORT||PROSPECTIVE|||||||
33986868|NCT06012097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986869|NCT00270777|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33986870|NCT01341821|||||RETROSPECTIVE|||||||
33986871|NCT04927208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986872|NCT01633047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986873|NCT03978923|||CASE_CROSSOVER||PROSPECTIVE|||||||
34080964|NCT01035749|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080965|NCT00518570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33986874|NCT01376167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33683993|NCT04093063|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In order to judge the effectiveness of intervention, participants in the intervention and control groups will perform a microsuturing task at the beginning and at the end of the study to grade surgical skills. Before each grading session, subjects will watch video instructions on how to perform microsurgical suturing. The subjects' microsurgical manipulations will be video-recorded. The video-recordings will be rated by 2 ophthalmologists, including the main investigator, masked to the identity of the subject (intervention vs control) and time of recording (either before or after intervention). Videos were muted, and subjects were instructed to wear gloves in order to ensure anonymity.|"This study is a single-center, prospective, randomized, controlled trial. After obtaining consent, recruited participants were asked to perform a microsurgical task. Their attempt was video-recorded for a pre-assessment. After completion of the video-recorded pre-assessment, participants were randomized to either the intervention or the non-intervention control group by flip of a coin. Subjects in the intervention group were tasked to build a micro-stellated icosahedron using a detailed instruction manual. Subjects in the control group had no specific task for two weeks.~All subjects in both groups were required to return in two weeks for a second in-person meeting. At the second meeting, their attempt at completing a microsurgical task was video-recorded for a post-assessment, using similar instruments and set-up as those used two weeks prior."|f|f|t|t
33904095|NCT02378428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904096|NCT01893593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904097|NCT03760380|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Phase 1 All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)~Phase 2 Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use."||||
33904098|NCT05604612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986875|NCT05206344|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33986876|NCT00437658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986877|NCT02406898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904099|NCT01652378|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986878|NCT06036498|||COHORT||PROSPECTIVE|||||||
33986879|NCT00451412|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33986880|NCT04988763|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33986881|NCT06558877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33986882|NCT00444847|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33986883|NCT04459585|NA|SEQUENTIAL||TREATMENT||NONE||||||
33986884|NCT00056134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986885|NCT01757886|||COHORT||PROSPECTIVE|||||||
33986886|NCT01414972|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33683994|NCT05675683|||COHORT||RETROSPECTIVE|||||||
33683995|NCT02844686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33683996|NCT03460743|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participant- and observer-blind, the vaccine will be administered by a non-blinded vaccinator that will not participate in the clinical evaluation.|"Visit 1: screening visit, baseline blood sampling and administration of the study vaccine that can be performed on Day 0.~Visit 1A and 2: Remote follow up contacts on day 2 and 7 post-vaccination. Visit 3: i. Follow up and blood sampling (for the 1-dose group); ii. Visit 3A, follow-up and application of the second dose of the vaccine (for the corresponding group); iii. Visit 3B, follow-up and blood sampling for the 2-dose group. The visits occur on Day 28.~Months 3, 4, 5: Remote Contacts for safety tracking Visit 4: Remote contact for study closure and safety tracking at Month 6"|t|f|t|f
33683997|NCT02540889|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33904100|NCT05544825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33904101|NCT02470013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904102|NCT00341952|||CASE_CONTROL||RETROSPECTIVE|||||||
33904103|NCT03303339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904104|NCT06554613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904105|NCT00854529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904106|NCT01177150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904107|NCT06499090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33904108|NCT05640232|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind, Double-dummy.||t|t|t|t
33904109|NCT02416687|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33904110|NCT01463852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904111|NCT01236729|||COHORT||CROSS_SECTIONAL|||||||
33904112|NCT00004033||||TREATMENT||||||||
33904113|NCT00734409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904114|NCT04963218|||COHORT||RETROSPECTIVE|||||||
33986887|NCT01292590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904115|NCT01225263|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33904116|NCT03026504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904117|NCT02565823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904118|NCT00426751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904119|NCT00807547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904120|NCT03492450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33986888|NCT04920929|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized control||||
33986889|NCT02433639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986890|NCT03313622|||CASE_ONLY||PROSPECTIVE|||||||
33986891|NCT05287061|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group clinical trial, experimental group with psychological intervention versus control group without intervention||||
33986892|NCT05930964|||CASE_ONLY||CROSS_SECTIONAL|||||||
33986893|NCT05357417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986894|NCT03429634|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33986895|NCT00220415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33986896|NCT05075798|||COHORT||RETROSPECTIVE|||||||
33986897|NCT00665145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986898|NCT03276715|||COHORT||PROSPECTIVE|||||||
33986899|NCT00641420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986900|NCT02442063|NA|SINGLE_GROUP||||NONE||||||
33986901|NCT04934618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986902|NCT03459807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774551|NCT05396625|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The eligible and consenting child-caregiver dyads will be randomized into one of eight experimental conditions. The randomization will be performed by the Project Director immediately following the baseline visit. A secure, web-based, password-protected database built on a REDCap (Research Electronic Data Capture) platform will be used to randomize participants into the 8 experimental conditions and to manage recruitment; eligibility assessment; scheduling and tracking of baseline and follow-up assessments; and sending intervention reminders. All data collectors (or interviewers) will receive a highly structured and intensive interview training conducted by the PIs. Data collectors and outcome assessors will be masked to participants' intervention group assignment.|"The study will use a randomized design and apply MOST approach to test and compare the three intervention components: a) a family-strengthening intervention; b) mental health screening and referral for treatment; and c) economic empowerment in the form of Child Savings Accounts /CDAs.~There are three factors (intervention components) and each factor has two levels. This is a 2\*2\*2, or 2 by 3, factorial design and, therefore, the study will have eight different experimental conditions or groups (2 by 3=8). The eligible and consenting child-parent dyads (N=400) will be randomly assigned to one of eight study groups (50 dyads per group), determining how many and which intervention components participants will receive. Given this design, half of the sample (n=200) will receive each intervention component (e.g., families assigned to Groups 1-4 will receive the family strengthening intervention and will be compared to families from Groups 5-8). All participants will receive Usual Care."|f|f|f|t
33774552|NCT04602429|||COHORT||PROSPECTIVE|||||||
33774553|NCT05315167|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 is a Phase 1, open label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024. Upon completing Phase 1 and depending on data obtained, dose expansion may proceed in Phase 2 to confirm the tolerability and efficacy of the RP2D of PRJ1-3024 .||||
33774554|NCT00967863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774555|NCT05519085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774556|NCT05376267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be blinded to the treatment assignment of the participant.|Bayesian Adaptive Design|f|f|f|t
33774557|NCT05053503|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|All study investigators will be blind to patient treatment group assignment. Furthermore, each clinical site will use qualified COWS assessors that will be blind to randomization group assignment. This will ensure a non-biased assessment of opioid withdrawal symptoms. Information regarding study intervention will be withheld from the blinded COWS assessors. All participants will be blinded to their group assignment during acute detox treatment (Phase I). Participants will not be unblinded to their Phase I treatment until study exit, which may occur at the end of Phase II for participants who continue in the study. Participants will not be blinded to their treatment group during Phase II.|This is a prospective, randomized, controlled, multi-center, clinical trial in which participants with a history of dependence on prescriptive or non-prescriptive opioids will be randomized 2:1 into one of four treatment groups during Phase I (acute detoxification). Phase I will occur during the participant's treatment in a residential detox center. Participants will have the option to continue into Phase II of the trial at the conclusion of their stay in the residential detox treatment program. In Phase II, participants will be re-randomized 1:1 into one of two treatment groups.|t|t|t|t
33774558|NCT02642471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774559|NCT06729775|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33839661|NCT00214552|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33839662|NCT00499967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839663|NCT05594602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33839664|NCT06035302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839665|NCT03495973|||COHORT||PROSPECTIVE|||||||
33839666|NCT01715883|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839667|NCT01372397|||CASE_ONLY||PROSPECTIVE|||||||
33839668|NCT04688177|||OTHER||CROSS_SECTIONAL|||||||
33839669|NCT01277692|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33986903|NCT04742790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric prospective longitudinal study||||
33986904|NCT05719922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986905|NCT03610035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986906|NCT02364063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986907|NCT03226522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986908|NCT04065867|||COHORT||PROSPECTIVE|||||||
33839670|NCT00615875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839671|NCT00378430|||||PROSPECTIVE|||||||
33839672|NCT02472145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839673|NCT03392168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Cohort 1 was open label. Cohort 2 was double blind.||t|f|t|f
33839674|NCT02796768|||COHORT||PROSPECTIVE|||||||
33839675|NCT04949529|||COHORT||PROSPECTIVE|||||||
33839676|NCT06224790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839677|NCT03523026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839678|NCT04351035|||COHORT||CROSS_SECTIONAL|||||||
33839679|NCT00281060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33683998|NCT05112276|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33683999|NCT04840836|||COHORT||PROSPECTIVE|||||||
33684000|NCT00830076|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33684001|NCT03920540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684002|NCT04382664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684003|NCT05008978|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33684004|NCT05700643|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33684005|NCT00409305|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33684006|NCT02417493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684007|NCT01456975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33684008|NCT04061993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33684009|NCT02846220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684010|NCT03989869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684011|NCT04964193|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, single blind, two-period, single dose, crossover study with three weeks washout period in 24 healthy female subjects under fasting condition.|t|f|t|f
33839680|NCT01424813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839681|NCT00949377|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33839682|NCT02086318|||COHORT||PROSPECTIVE|||||||
33839683|NCT02050880|||COHORT||PROSPECTIVE|||||||
33839684|NCT04941053|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839685|NCT06126679|RANDOMIZED|PARALLEL||TREATMENT||NONE||80 children are recruited for this study and they randomize either to an intervention group or a control group with standard care. Intervention group receive intensive, family-based diet and physical activity counseling, deliver by a multidisciplinary team of a pediatrician, a nurse and a clinical nutritionist. Control group do not receive any lifestyle intervention during the study. The inclusion criteria are weight-for-height ≥+40% or ≥+30% and increasing and age of 6-12 years. All participants fill out the study questionnaires and plasma samples are taken at baseline and at 12 months. Outcome variables will be compared between intervention and control groups.||||
33839686|NCT00863681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839687|NCT00737477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839688|NCT00288002|RANDOMIZED|||TREATMENT||NONE||||||
33839689|NCT02912546|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33839690|NCT00258739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839691|NCT03695653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986909|NCT04678882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986910|NCT02071303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33986911|NCT06264024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986912|NCT02462317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33986913|NCT02134964|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33684012|NCT04598399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In order to limit measurement and attrition biases, the patient will be kept unaware of the hypotheses concerning the details of the evaluated programs (MBRP or control) and the program expected to be superior||f|f|f|t
33684013|NCT04764266|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33986914|NCT03407781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In the first stage, a small proportion of participants receive preoperative 68Ga-IRDye800-BBN PET/CT and then||||
33986915|NCT04612140|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in the study.|The study subjects will be randomized into one of the two study arms.||||
33684014|NCT03109912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33684015|NCT04599179|||COHORT||PROSPECTIVE|||||||
33684016|NCT05421884|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684017|NCT01722695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684018|NCT00923988|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684019|NCT04048733|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33684020|NCT02095132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684021|NCT03331510|||COHORT||PROSPECTIVE|||||||
33684022|NCT02331160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684023|NCT04482023|||CASE_ONLY||CROSS_SECTIONAL|||||||
33684024|NCT03387384|||CASE_ONLY||PROSPECTIVE|||||||
33684025|NCT05955976|||CASE_ONLY||PROSPECTIVE|||||||
33684026|NCT04303923|||COHORT||RETROSPECTIVE|||||||
33684027|NCT04526548|||COHORT||PROSPECTIVE|||||||
33684028|NCT01829243|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33684029|NCT03952390|||CASE_CONTROL||PROSPECTIVE|||||||
33684030|NCT02550977|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684031|NCT01797770|||||PROSPECTIVE|||||||
33684032|NCT01444092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684033|NCT06515535|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33684034|NCT01695876|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33684035|NCT00893620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684036|NCT02915874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684037|NCT03957460|||COHORT||PROSPECTIVE|||||||
33684038|NCT03096041|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind||t|f|f|f
33684039|NCT01976988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684040|NCT04942197|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33684041|NCT03716570|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33904121|NCT04523779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome data will be collected by independent evaluators (IEs) who will be blinded to randomization. All IEs will be based in Houston, with direct oversight by Dr. Cully. IEs will undergo training and calibration on all study measures and be regularly reassessed for quality.|Cognitive behavioral therapy (CBT) is an evidence-based practice (EBP) for all types of anxiety disorders including generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder. The proposed bCBT treatment for anxiety was specifically designed for use within VA PCMHI settings and uses a patient-centered approach to increase engagement while addressing the mental health needs of anxious Veterans. Emphasis was placed on maximizing intervention potency and minimizing intensity and duration to improve implementation value and alignment with VA PCMHI requirements. The intervention directly addresses challenges to delivery of CBT providing 1) a brief, practical model of care to address multiple anxiety conditions consistent with the PCMHI model (e.g. 4-6 sessions; measurement-based care), and 2) a clinically potent intervention that includes exposure-based skills.|f|f|f|t
33904122|NCT05366933|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904123|NCT04250493|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904124|NCT02096939|||CASE_CONTROL||PROSPECTIVE|||||||
33904125|NCT06353971|NA|SEQUENTIAL||TREATMENT||NONE||"This is an open-label, single ascending dose, Phase 1b/2a trial.~Cohort 1 follows a 3+3 design and will be treated with a single 40mg dose. Cohort 2 will be treated with a single 120mg dose. Cohort 3 will be treated with a single 180mg dose."||||
33904126|NCT00303342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904127|NCT06190002|||CASE_ONLY||RETROSPECTIVE|||||||
33904128|NCT03671759|NA|SINGLE_GROUP||OTHER||NONE||||||
33904129|NCT00088010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904130|NCT05137522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904131|NCT01479790|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33904132|NCT01748448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904133|NCT05952219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33904134|NCT04195074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904135|NCT04272619|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904136|NCT06048003|||COHORT||PROSPECTIVE|||||||
33904137|NCT03249896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective, randomised, controlled, parallel-group, single centre study. Study subjects will be randomised into either the intervention or the control arm in a 1:1 ratio. The randomisation will be stratified by ethnicity (Chinese or non-Chinese) and pre-pregnancy BMI (BMI of \<25kg/m2 or ≥25kg/m2), and will be performed using computer-generated randomisation.||||
33904138|NCT06490965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904139|NCT00464100|||CASE_CONTROL||PROSPECTIVE|||||||
33904140|NCT03691012|||COHORT||PROSPECTIVE|||||||
33904141|NCT04938141|||COHORT||PROSPECTIVE|||||||
33904142|NCT03312140|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study to evolve the effect ot the treatment by comparing data before and after the treatment within the same patients||||
33904143|NCT03271008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Following informed consent participants are randomised into one of the device groups and general anaesthesia is induced. Primary intubation attempt is carried out with the randomised device. We do not disclose the result of randomisation with our participants prior to anaesthesia induction. Participants are already in surgical anaesthesia with muscle relaxation during the intubation attempt. As providers are the users of the intubation device masking is not possible in this regard. During outcome assessment we plan not to disclose which device was used for a certain group.||t|f|f|t
33904144|NCT03454048|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904145|NCT05989620|||COHORT||OTHER|||||||
33904146|NCT04471103|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A two-group parallel randomised trial||||
33904147|NCT01016405|||CASE_ONLY||PROSPECTIVE|||||||
33904148|NCT03855306|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33986916|NCT06007781|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Subjects will be allocated (2 to1) into one of two trial arms, Arm 1 - One dose of HIL-214; Arm 2 - One dose of placebo.|t|t|t|t
33986917|NCT03011294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986918|NCT02486445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986919|NCT00407394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904149|NCT06533644|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904150|NCT04795713|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904151|NCT00515463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904152|NCT02517944|||CASE_CONTROL||PROSPECTIVE|||||||
33904153|NCT05828446|NA|SINGLE_GROUP||SCREENING||NONE||single center interventional prospective study||||
33904154|NCT03894904|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33904155|NCT02058355|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33904156|NCT06274138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33986920|NCT02012153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986921|NCT00849901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986922|NCT06082791|||COHORT||PROSPECTIVE|||||||
33986923|NCT02422264|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684042|NCT03821844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The principal investigator is blinded to random assignment of nursing homes to treatment or control conditions|The investigator's primary outcome (staff report of resident agitated and aggressive behaviors) will be evaluated using a parallel design. Some secondary outcomes will be tested with a stepped wedge design.|f|f|t|f
33684043|NCT04575597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684044|NCT05251129|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Open-label, randomized controlled trial|f|f|f|t
33684045|NCT00782587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684046|NCT00105365|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684047|NCT01325792|||COHORT||PROSPECTIVE|||||||
33684048|NCT05779384|||COHORT||PROSPECTIVE|||||||
33684049|NCT04661098|NA|SINGLE_GROUP||TREATMENT||NONE||Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)||||
33684050|NCT03357939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684051|NCT02772198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684052|NCT05461573|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"All subjects enrolled in the study will participate in Part A of the study and receive the experimental drug LPRI-CF113 (drospirenone). Part A will investigate the efficacy, safety, and tolerability of LPRI-CF113.~A subgroup of subjects that are age 18-45 and without further exclusion criteria to Part B will be enrolled in Part B of the study. Part B of the study will investigate the effects of LPRI-CF113 on bone mineral density."||||
33684053|NCT02879396|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684054|NCT00471809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33684055|NCT00716833|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33684056|NCT00880464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684057|NCT01699971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684058|NCT06129357|||OTHER||CROSS_SECTIONAL|||||||
33684059|NCT01858818|||COHORT||PROSPECTIVE|||||||
33684060|NCT06029517|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684061|NCT01109056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684062|NCT04905498|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33684063|NCT04098055|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33684064|NCT02312687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684065|NCT06409832|||CASE_ONLY||PROSPECTIVE|||||||
33684066|NCT04957433|||COHORT||RETROSPECTIVE|||||||
33684067|NCT02262182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33684068|NCT03935113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684069|NCT03243708|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Step-Wedge Randomized controlled trial (RCT)||||
33684070|NCT06173310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684071|NCT05606003|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774560|NCT04917796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization will occur before the baseline assessments are administered. Each site will randomize its own patients through RedCap. Once the patient is randomized, the site acupuncture team will be notified via RedCap alert in order to provide the appropriate treatment. Patients and non-acupuncturist members of the study team will be blinded to which acupuncture group the patient was assigned. The acupuncturists and one clinical research coordinator will be the only ones unblinded. The clinical research coordinator will be unblinded in order to assist acupuncturists to confirm randomization. This clinical research coordinator will not be the primary research coordinator in the study and will not have direct contact with the patient. The rest of the study coinvestigators and staff will remain blinded.||t|f|f|f
33774561|NCT05912543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33774562|NCT04842890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774563|NCT05918328|RANDOMIZED|PARALLEL||TREATMENT||NONE|Non|Patients who meet the inclusion criteria were randomly divided into TCbHP group and Nab-PH+pyrrolitinib group in a 1:1 ratio.||||
33774564|NCT06232902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774565|NCT06738381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774566|NCT00001471|||COHORT||PROSPECTIVE|||||||
33774567|NCT04548778|||COHORT||CROSS_SECTIONAL|||||||
33774568|NCT05268887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33774569|NCT03935854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774570|NCT04772989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904157|NCT02088944|||CASE_CONTROL||PROSPECTIVE|||||||
33904158|NCT01214616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904159|NCT02605733|||COHORT||PROSPECTIVE|||||||
33904160|NCT01766427|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904161|NCT03785197|||COHORT||PROSPECTIVE|||||||
33904162|NCT05254522|||OTHER||PROSPECTIVE|||||||
33904163|NCT03824977|||COHORT||PROSPECTIVE|||||||
33684072|NCT05256706|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33684073|NCT02968862|||COHORT||PROSPECTIVE|||||||
33684074|NCT01031420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684075|NCT02402738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684076|NCT04057989|||OTHER||RETROSPECTIVE|||||||
33684077|NCT00126880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684078|NCT03056599|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684079|NCT00268580|NON_RANDOMIZED|PARALLEL||||NONE||||||
33684080|NCT00068133|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33774571|NCT06720961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33774572|NCT04724018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774573|NCT05882578|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Doesn´t exist. Patients were allocated depending their preferences|control trial||||
33774574|NCT06487273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"modified Zelen method: participants in the control group will not be aware of another group using the SIMEOX -\> only one group is blinded~A blinded adjudication committee will review the outcome for one primary endpoint (exacerbations)."|"Interventional, prospective, randomised according to modified Zelen method in two steps, controlled, multi-sites clinical investigation~2 groups : comparison of SIMEOX + remote Physiotherapy + standard of care versus remote Physiotherapy + standard of care"|t|f|f|f
33904164|NCT06283095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904165|NCT05464485|||COHORT||RETROSPECTIVE|||||||
33684081|NCT01894412|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33684082|NCT05767476|||COHORT||PROSPECTIVE|||||||
33684083|NCT04555967|||COHORT||PROSPECTIVE|||||||
33684084|NCT05519995|||COHORT||CROSS_SECTIONAL|||||||
33684085|NCT05143710|||CASE_ONLY||RETROSPECTIVE|||||||
33684086|NCT01262352|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33684087|NCT02603796|||COHORT||PROSPECTIVE|||||||
33684088|NCT05504876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684089|NCT00998062|||||RETROSPECTIVE|||||||
33684090|NCT05268627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33684091|NCT04998136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33684092|NCT05047445|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label, uncontrolled study.||||
33684093|NCT04382820|||COHORT||CROSS_SECTIONAL|||||||
33684094|NCT00913692|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33684095|NCT06298682|||OTHER||OTHER|||||||
33684096|NCT04559529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|During Visit 2, participants will be randomly assigned to an intervention arm in which they will receive two 250mg LEV capsules or two placebo capsules. Both the participant and the research team will be blinded to which arm each participant is in. During Visit 3, the participant will undergo cross-over and receive either two 250mg LEV capsules or two placebo capsules (whichever intervention they did not receive in Visit 2).|2-way crossover, double-blind, randomized controlled study|t|t|t|f
33684097|NCT01874678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684098|NCT03487692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33684099|NCT03757013|||COHORT||RETROSPECTIVE|||||||
33904166|NCT01682369|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904167|NCT04037358|RANDOMIZED|PARALLEL||TREATMENT||NONE||RAdium-223 and SABR Versus SABR (Stereotactic Ablative Radiotherapy)||||
33904168|NCT04579068|NA|SINGLE_GROUP||SCREENING||NONE||||||
33904169|NCT00445055|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33904170|NCT05196997|||CASE_ONLY||CROSS_SECTIONAL|||||||
33904171|NCT00192517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904172|NCT03136211|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled trial||||
33904173|NCT00202410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904174|NCT02553720|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 201 patients were randomized with 100 to the Aquatic Group and 101 to the Control Group. At 24 months, 91 patients had completion of evaluation in the Aquatic Group and 90 patients in the Control Group.||||
33904175|NCT01001533|||COHORT||PROSPECTIVE|||||||
33904176|NCT04220047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33904177|NCT00890630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904178|NCT00352781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904179|NCT02658162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904180|NCT05082571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986924|NCT00234286|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33986925|NCT00436163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986926|NCT00142662|RANDOMIZED|||PREVENTION||||||||
33986927|NCT01868191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986928|NCT02957097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986929|NCT03069586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33986930|NCT02480322|||CASE_CONTROL||RETROSPECTIVE|||||||
33684100|NCT02785237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684101|NCT00956098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904181|NCT00247910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904182|NCT01588301|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33904183|NCT03839433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904184|NCT04357093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904185|NCT06110234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Assessors are blind in the clinical trials. Participants know that there are different training programs but they ignore the purpose of each one.|Older participants are randomly assigned to one of two intervention conditions (Episodic Specificity Induction ; Associative Memory)|t|f|f|t
33904186|NCT02335450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904187|NCT01818791|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33904188|NCT02546856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33986931|NCT02803398|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33986932|NCT05086562|||COHORT||PROSPECTIVE|||||||
33986933|NCT03620747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080966|NCT04184401|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34080967|NCT06482164|NA|SINGLE_GROUP||SCREENING||NONE||||||
34080968|NCT02084511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34080969|NCT05982327|||CASE_ONLY||PROSPECTIVE|||||||
34080970|NCT01187316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34080971|NCT03297190|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Four arms: (1) SMS only; (2) SMS + interpersonal; (3) interpersonal only; (4) none||||
34080972|NCT03313739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34080973|NCT00517608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080974|NCT02115984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080975|NCT05334667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The trial will be planned that neither the doctors (investigator) nor the patients will be aware of the group allocation.|Comparison between using CRRT versus plasmapheresis in the management of aluminum phosphide poisoning and effect on mortality rate.|t|t|t|t
34080976|NCT00465530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34080977|NCT02112253|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34080978|NCT03434483|||CASE_CONTROL||PROSPECTIVE|||||||
34080979|NCT04879017|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm dose escalation and two-arm expansion study in patients with metastatic UM||||
34080980|NCT01988467|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34080981|NCT04602286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||4 x (2) mixed design, with training (mindfulness vs specific sham mindfulness vs general sham mindfulness vs book listening control, between subjects) and time (pre-treatment vs post-treatment, within-subjects) as factors.|t|t|t|t
34080982|NCT06527690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34080983|NCT06257732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080984|NCT05299866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34080985|NCT02436824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986934|NCT00505570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986935|NCT02897375|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986936|NCT05690217|||CASE_CONTROL||PROSPECTIVE|||||||
33986937|NCT03769922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986938|NCT02345395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33986939|NCT00115128|||COHORT||PROSPECTIVE|||||||
34080986|NCT02943772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34080987|NCT05453851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080988|NCT00825123|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34080989|NCT04204005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-centre, double-blind, placebo-controlled, randomised study.|t|f|t|f
33986940|NCT01083784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986941|NCT01900626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684102|NCT00631761|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684103|NCT03589209|||COHORT||RETROSPECTIVE|||||||
33774575|NCT06083948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double blinded, clinical trial|t|t|t|t
33904189|NCT03753568|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects are monitored first before the intervention and then during the intervention.||||
33904190|NCT05605327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904191|NCT04708964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33904192|NCT05611684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904193|NCT05228912|||COHORT||PROSPECTIVE|||||||
33904194|NCT03578354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904195|NCT04866667|||COHORT||PROSPECTIVE|||||||
33904196|NCT01830452|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33904197|NCT02134704|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33904198|NCT03135028|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904199|NCT04724486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684104|NCT03956719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684105|NCT03652623|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684106|NCT06425627|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33684107|NCT05720754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masked examiner for all clinical assessments will not involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the three groups.||f|t|t|t
33684108|NCT04139746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684109|NCT02900144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684110|NCT03419975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684111|NCT01022827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684112|NCT04999852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684113|NCT05033990|||COHORT||PROSPECTIVE|||||||
33684114|NCT04739176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684115|NCT04998201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684116|NCT02110602|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33684117|NCT04930380|||CASE_CONTROL||RETROSPECTIVE|||||||
33684118|NCT00245778|||CASE_CONTROL||OTHER|||||||
33684119|NCT06520969|NA|SINGLE_GROUP||OTHER||NONE||Endometrium and cervical cancer patients that will be operated in Istanbul University School of Medicine, Dept. of Obstetrics and Gynecology, Division of Oncology will be included. Anatomic details such as the presence, number of superficial and deep uterine veins, calibers, anatomical relationships with hypogastric arteries and veins, ureters, vesicouterine ligaments will be described systematically and bilaterally for every consenting women after pelvic spaces are opened before pelvic lypmhadenectomy and hysterectomy. All regarding information will be photographed for every patient bilaterally and recorded on data sheet.||||
33684120|NCT00093665||||TREATMENT||NONE||||||
33774576|NCT06257277|||COHORT||PROSPECTIVE|||||||
33774577|NCT06474182|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33774578|NCT06737731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904200|NCT04962321|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study to examine acceptability, feasibility, and explore clinical responses related to wellness behaviors and quality of life.||||
33904201|NCT05521685|||COHORT||RETROSPECTIVE|||||||
33986942|NCT03644693|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||The study design for this nutritional intervention protocol is a randomized, double blind, placebo controlled crossover study. Each patient will receive both nutritional formulation and placebo formulation, with a washout period between each arm. The dietary backgrounds will differ among patients. Acceptable diets include three basic diets: ketogenic diet (i.e. conventional 4:1 or 3:1, modified Atkins), low glycemic index diet (LGIT), and standard American diet (regular diet).|t|t|t|t
33986943|NCT04694391|||CASE_CONTROL||PROSPECTIVE|||||||
33904202|NCT01311206|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33986944|NCT06093802|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33774579|NCT05039554|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33774580|NCT00670735|||COHORT||PROSPECTIVE|||||||
33774581|NCT06737094|||COHORT||PROSPECTIVE|||||||
33774582|NCT06738602|||COHORT||PROSPECTIVE|||||||
33774583|NCT04507841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904203|NCT02325505|||COHORT||PROSPECTIVE|||||||
33904204|NCT05713305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33904205|NCT00409630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904206|NCT06115577|||CASE_CONTROL||PROSPECTIVE|||||||
33904207|NCT02645448|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33904208|NCT01147731|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904209|NCT01792986|NA|SINGLE_GROUP||OTHER||NONE||||||
33904210|NCT05453370|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, two-arm randomized controlled trial design, which will employ an intervention condition (CALMA app) and a control condition (Treatment as usual -TAU) with a 3-month follow-up for each participant||||
33904211|NCT06329362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904212|NCT05182229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904213|NCT03444363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The results of the study were evaluated in a blinded manner|This study was designed as a randomized, controlled.|t|f|t|f
33904214|NCT02190435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904215|NCT02095353|||CASE_CROSSOVER||PROSPECTIVE|||||||
33904216|NCT01836055|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904217|NCT04969393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904218|NCT04289103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904219|NCT02532868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986945|NCT00304603|||CASE_CONTROL||RETROSPECTIVE|||||||
33986946|NCT03723993|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33986947|NCT02265783|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33986948|NCT01602419|||CASE_ONLY||PROSPECTIVE|||||||
33986949|NCT02424097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33986950|NCT00029198|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33986951|NCT01768533|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33986952|NCT02642367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33904220|NCT04222127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904221|NCT04908189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080990|NCT02536937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080991|NCT02087774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904222|NCT05857202|||COHORT||PROSPECTIVE|||||||
33904223|NCT06693726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904224|NCT02089386|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904225|NCT03475407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904226|NCT00328198|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904227|NCT05815121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, parallel goup, single|t|f|f|f
33904228|NCT05524272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33904229|NCT02238405|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904230|NCT04686734|||COHORT||PROSPECTIVE|||||||
33904231|NCT04093323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904232|NCT02719418|||COHORT||PROSPECTIVE|||||||
33904233|NCT05873413|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33904234|NCT02243527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33904235|NCT05065944|||COHORT||PROSPECTIVE|||||||
33904236|NCT03119038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904237|NCT04195451|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33904238|NCT01930734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34080992|NCT05861830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34080993|NCT04630184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The reserarch assistant (for assesement) will be blind of the group allocation, as well as the kinesiologist (but not the psychologist).||f|t|f|t
34080994|NCT03582384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080995|NCT05383378|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The study consists of 2 parts, a single ascending dose (SAD) part, and a multiple ascending dose (MAD) part.|t|f|t|t
34080996|NCT03440476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention is an online program, not an individual, so masking is not necessary. Similarly, the same online survey is deployed in all follow-up assessments regardless of condition, and data are not collected by individuals, so masking is not necessary.||t|f|f|f
34080997|NCT00372138|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34080998|NCT05770713|||COHORT||RETROSPECTIVE|||||||
33684121|NCT05988502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The random sequence of numbers was separately and sequentially stored in sealed, opaque envelopes that were opened in front of the participants in the predetermined order, which determined their group.The participants do not know their own group, the researcher knows the participant's group and intervenes according to the participant's group, and the outcomes Assessor conducts the outcomes assessment without knowing the participant's group|The participants were randomized into two groups by a research team not involved in the study intervention or data collection. The randomization process was accomplished through a computer-generated sequence of random numbers, and permuted block randomization was employed with four in each block. The random sequence of numbers was separately and sequentially stored in sealed, opaque envelopes that were opened in front of the participants in the predetermined order, which determined their group allocation.the auricular acupressure (AA) group was given auricular acupressure for two weeks and the control group received usual care for heart failure during the same study period. Data were collected consisted of three repeated measurement time points at baseline, Week 1, and Week 2.|t|f|f|t
33684122|NCT06312696|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Participants with chronic mechanical neck pain will be recruited and randomized into one of three groups: 1) No Treatment, 2) Light Massage (pseudo- sham), and 3) Spinal Manipulative Therapy. Using a repeated measures study design, metrics of quality of spinal motion will be compared before and after the prescribed intervention.|f|f|f|t
33684123|NCT03405779|||COHORT||PROSPECTIVE|||||||
33684124|NCT00636350|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684125|NCT01311869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33684126|NCT05795478|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33684127|NCT05898997|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|The patients included in the study were between the ages of 15 and 80 and were classified into 5 groups based on their visual field defect levels.||||
33684128|NCT05371873|||COHORT||PROSPECTIVE|||||||
33684129|NCT01254942|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33684130|NCT00527488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904239|NCT02829346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904240|NCT06300970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904241|NCT03142997|||CASE_CONTROL||PROSPECTIVE|||||||
33904242|NCT04961801|NA|SEQUENTIAL||TREATMENT||NONE||||||
33904243|NCT04027465|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomixed controlled trial||||
33904244|NCT05316077|||OTHER||PROSPECTIVE|||||||
33904245|NCT05159232|RANDOMIZED|PARALLEL||TREATMENT||NONE||non-probability consecutive sampling||||
33904246|NCT00992446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904247|NCT03723265|||COHORT||PROSPECTIVE|||||||
33904248|NCT03335631|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904249|NCT03010423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34080999|NCT03208816|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||a non-pharmacological, telephone-delivered, symptom management program for chemotherapy patients.||||
34081000|NCT04974073|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|t|f|t
34081001|NCT05098873|||CASE_CONTROL||PROSPECTIVE|||||||
33684131|NCT01945710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904250|NCT02950662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904251|NCT06664450|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904252|NCT00740025|||CASE_CONTROL||PROSPECTIVE|||||||
33904253|NCT05911009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double-blind, randomized, parallel group, placebo controlled, multicentric|t|f|t|f
33904254|NCT00436215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904255|NCT00085540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904256|NCT02480075|||COHORT||PROSPECTIVE|||||||
33904257|NCT05979090|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33684132|NCT04241679|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm study of 10 patients with no serviceable hearing due to small or medium sized vestibular schwannomas undergoing translabyrinthine resection.||||
33684133|NCT03549793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator are neurologists, blinded to the treatment received by the patient|Participants are randomly assigned to experimental group or control group. Both of the groups undergo a rehabilitation treatment. The experimental group undergoes 4-week MIRT (Multidisciplinary Intensive Rehabilitation Treatment) + dance therapy. The control group undergoes 4-week MIRT (Multidisciplinary Intensive Rehabilitation Treatment) + exercises|f|f|t|f
33684134|NCT03779243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|t|f|f
33904258|NCT05762744|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were not informed whether the nurse was administering saline or exenatide injections.|Research participants all received the same two interventions (saline or exenatide) but the order of the interventions was randomized.|t|f|f|f
33904259|NCT03677089|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Sites were randomized in a stepped-wedge design with 5 clusters (2 sites per cluster) and a staggered start over a 1-year period. Staggering the start allowed for some control for potential temporal trends, as well as allowing the core team to focus on working with each site to ensure smooth startup of the training program at each site.~All participants received the intervention."||||
33904260|NCT00293072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904261|NCT02654106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904262|NCT02354170|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33904263|NCT04892862|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||PROSPECTIVE CLİNİCAL TRİAL|t|f|f|f
33904264|NCT00231985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904265|NCT03267472|||CASE_CONTROL||RETROSPECTIVE|||||||
33904266|NCT03381092|||COHORT||PROSPECTIVE|||||||
33904267|NCT05257577|||COHORT||PROSPECTIVE|||||||
33904268|NCT03626753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904269|NCT02097888|||COHORT||CROSS_SECTIONAL|||||||
33904270|NCT00876980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904271|NCT01941368|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33904272|NCT04884620|||COHORT||PROSPECTIVE|||||||
33904273|NCT02389946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904274|NCT03551145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The examiners will be blinded. Envelopes will be prepared by a research assistant not involved as clinician or examiner. The clinicians involved will have no access to the data collection sheets or the group allocation, whilst the examiners will have no access to the patients' treatment notes or group allocation. The examiners will be blinded with regards to the participant treatment assignments. The measures will include no access to the dental records as to which treatment has been assigned. The patients are not to reveal their treatment assignment to the examiners. Unblinding is expected when patients present with adverse outcomes during the course of the study, e.g., emphysema.|Multi-centre randomized clinical trial (2 centres) with the duration of 102 weeks for the evaluation of efficiency on the new collagen xenograft (Muco-Graft®) in comparison to the autologous connective tissue graft for the augmentation of keratinized mucosa and gaining hygienic access to the implants diagnosed with peri-implantitis|f|f|t|t
33904275|NCT05431582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904276|NCT05927389|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904277|NCT06403384|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33904278|NCT03566537|||CASE_CONTROL||PROSPECTIVE|||||||
33904279|NCT01604486|||||RETROSPECTIVE|||||||
33904280|NCT00889577|||COHORT||CROSS_SECTIONAL|||||||
33904281|NCT06536985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The first author will use randomizer.org for randomization. Recruitment without informing the subjects of study participation and group allocation to blind the subjects. And the allocation is also concealed for researchers in charge of data collection and processing.||t|f|f|t
33904282|NCT01149278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904283|NCT02664246|||COHORT||RETROSPECTIVE|||||||
33904284|NCT04008862|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Longitudinal design, participants serve as their own control.||||
33904285|NCT03735693|||COHORT||PROSPECTIVE|||||||
33904286|NCT05283538|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904287|NCT02146807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33904288|NCT02791789|NA|SINGLE_GROUP||||NONE||||||
33684135|NCT04438070|RANDOMIZED|PARALLEL||SCREENING||NONE||Cluster randomized multi-center trial||||
33904289|NCT04339946|||CASE_ONLY||PROSPECTIVE|||||||
33904290|NCT02322723|||COHORT||PROSPECTIVE|||||||
33904291|NCT04388644|||CASE_ONLY||RETROSPECTIVE|||||||
33904292|NCT02247661|||COHORT||PROSPECTIVE|||||||
33904293|NCT02794831|||CASE_CONTROL||PROSPECTIVE|||||||
33904294|NCT03520023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904295|NCT05499988|||COHORT||PROSPECTIVE|||||||
33904296|NCT06333470|||COHORT||CROSS_SECTIONAL|||||||
33904297|NCT00524745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904298|NCT03819283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904299|NCT05243550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904300|NCT06472505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904301|NCT00907478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081002|NCT05924165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Operating surgeon will be blinded to treatment arm intraoperatively (will not be blinded postoperatively)||f|f|t|f
34081003|NCT00566085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081004|NCT01682252|||||PROSPECTIVE|||||||
34081005|NCT00984412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081006|NCT04655417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081007|NCT01200329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081008|NCT01088555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081009|NCT01657396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904302|NCT03701165|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort non-randomized trial.||||
34081010|NCT03368807|||OTHER||PROSPECTIVE|||||||
34081011|NCT05604365|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081012|NCT04512989|||COHORT||PROSPECTIVE|||||||
34081013|NCT00221819|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081014|NCT06037317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081015|NCT03600831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081016|NCT01208272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081017|NCT03384589|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group 1: 3 doses of PCV13 (2, 4, 12 months), 2+1 Group 2: 2 doses of PCV13 (2, 12 months), 1+1||||
33904303|NCT06474741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33904304|NCT04618497|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be enrolled on a convenience basis. After being seen and screened by investigators, patients who meet all inclusion and non-exclusion criteria will be enrolled and randomized 1:1 by drawing from equal preset numbers of envelopes. Patients will receive either inhalational methoxyflurane or intramuscular ketorolac. Patients and investigators are not blinded to the treatment due to the nature of drug administration.||||
33904305|NCT03306069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors involved in data analysis will not be aware of the arm to which the participants were allocated (single-blinded masking).|Parallel Assignment parallel-group, randomized-controlled study|f|f|f|t
34081018|NCT05567081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081019|NCT05133115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No-blinded participant groups and personnel (research team).|"Eligible schools will be randomly allocated either to an intervention group or control. The clusters were school classrooms (grades 6, 7). For each grade (and 7) there will be several classrooms (clusters) depending of the schools.The randomization procedure will be performed in two steps. First, the schools will be randomly allocated either to an intervention group or control by the external researcher using computer-generated random numbers; second, the external researcher will randomize the intervention group into the different school-levels.~According to the minimum estimated sample size (70 participants/group) and knowing that there are 25 to 30 students per classroom, we will need a minimum of three clusters (classrooms) per group."||||
34081020|NCT04332263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized through data generated by a computer program containing the coded distribution (Randomizer, USA). The software takes into account one of the main objectives of randomization, which is to prevent the researcher from identifying which intervention will be performed on each patient. A researcher blinded to the study will do the generation of the sequence of numbers, after the patients' selection by the inclusion and exclusion criteria. The numbers sequence used for randomization will be kept confidential until the exact moment of the beginning of the intervention. In addition, a second blinded researcher, who will not be aware of the subjects' names in the three experimental groups, will perform the data analysis.|The present study is a randomized controlled trial, which followed the recommendations proposed by the CONSORT Statement|t|f|t|t
34081021|NCT01307956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081022|NCT04545801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34081023|NCT03398694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081024|NCT04102137|||COHORT||CROSS_SECTIONAL|||||||
34081025|NCT02386852|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081026|NCT02812186|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34081027|NCT00800358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081028|NCT02654639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081029|NCT02203266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684136|NCT05027295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904306|NCT05518344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684137|NCT02475824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33684138|NCT00376818|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684139|NCT04276727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Gel tubes will be supplied with similar labelling, identified by blinded drug pack numbers which can be linked to the treatment allocation if an emergency need arises. The menthol and placebo gels have a similar blue colour and both have a minty odour.|Randomised, double-blind placebo controlled|t|f|t|t
33684140|NCT01375283|||COHORT||PROSPECTIVE|||||||
33684141|NCT03894722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684142|NCT02974751|||CASE_ONLY||PROSPECTIVE|||||||
33684143|NCT05532670|||OTHER||PROSPECTIVE|||||||
33684144|NCT04321785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33684145|NCT00476671|||COHORT||CROSS_SECTIONAL|||||||
33684146|NCT00352352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33904307|NCT04157660|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33904308|NCT04458038|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904309|NCT01707212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33904310|NCT02660424|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33904311|NCT03225755|||COHORT||PROSPECTIVE|||||||
33904312|NCT02847936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904313|NCT04215081|NA|SINGLE_GROUP||TREATMENT||NONE||SCI Level T4-L5 or, C7-T3 with ASIA D||||
34081030|NCT01689597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081031|NCT05130437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081032|NCT01565213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081033|NCT00994305|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34081034|NCT00068276||||TREATMENT||NONE||||||
34081035|NCT02806713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081036|NCT03364881|||CASE_ONLY||PROSPECTIVE|||||||
33684147|NCT00674154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684148|NCT04430075|||COHORT||PROSPECTIVE|||||||
33684149|NCT03443947|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774584|NCT06736821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This study was included16 severely atrophied maxillary sinus, with alveolar bone height less than 4mm, that need sinus augmentation and delayed implant placement. all patients was enrolled randomly and distributed into 2 groups (via : http://www.randomizer.org) :~Group A: sinus membrane elevation was done using lateral window technique and filled with the mixture of melatonin and xenograft.~Group B: sinuses membrane was elevated and filled with with xenograft. After 6 months, bone biopsies was collected from the augmented sinuses immediately before implant instalment in the same visit.~Initial CBCT was taken preoperatively and immediate postoperatively. Final CBCT was taken 6 months before implant placement to measure Bone density and bone height and width."|t|f|t|t
33774585|NCT06177067|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with relapsed or refractory acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) who meet the eligibility criteria.||||
33904314|NCT01950481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904315|NCT05506332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081037|NCT03175185|||CASE_CONTROL||RETROSPECTIVE|||||||
34081038|NCT04741438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684150|NCT00278915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684151|NCT01373671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684152|NCT04441762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||case-control trial|t|t|t|t
33684153|NCT06354556|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, open, single arm, fixed sequence||||
33684154|NCT01278654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33684155|NCT03306797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684156|NCT01649453|||CASE_ONLY||PROSPECTIVE|||||||
33684157|NCT05711303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomization will be carried out by computer-generated block-randomization lists. Subjects will be randomized to one of the two treatment groups, in blocks of 6. The randomization will be seeded, with the seed only available to the statistician generating the randomization list.|Subjects who successfully meet the eligibility criteria will be randomized on a 1:1 basis, to receive Superba Boost or Placebo.|t|t|f|t
33684158|NCT04050020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33774586|NCT06036641|||CASE_ONLY||CROSS_SECTIONAL|||||||
33774587|NCT05359731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|A research assistant (licensed anesthesiologist) will prepare the local anesthetic solutions and will add the study drug following the randomization order. The operator, patient and investigator assessing the block will be blinded to group allocation.||t|t|f|t
33774588|NCT05267821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, adaptively-randomized, double-blind, placebo controlled clinical trial|t|t|t|t
33774589|NCT04974099|NA|SINGLE_GROUP||OTHER||NONE||The intervention cohort includes patients, age 6-22 years old who have been diagnosed with CD, are naïve to anti-TNF medications and are scheduled to start infliximab (or infliximab biosimilar).||||
33774590|NCT06739291|NA|SEQUENTIAL||TREATMENT||NONE||||||
33774591|NCT02723591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774592|NCT05969002|||COHORT||PROSPECTIVE|||||||
33774593|NCT05560724|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Double-blind parallel group design.|t|f|t|f
33774594|NCT06474169|||CASE_CONTROL||PROSPECTIVE|||||||
33774595|NCT00170573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774596|NCT03677128|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Effects on outcomes when using mNavigator will be compared to historical controls (preceding mNavigator use). Number of participants below references those who will be consented prospectively to participate in the study.||||
33774597|NCT05693571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774598|NCT06738992|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774599|NCT03138512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774600|NCT06739954|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774601|NCT05573893|||COHORT||PROSPECTIVE|||||||
33774602|NCT05226663|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774603|NCT04551703|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients will randomize into two groups based on computer generating numbers. Group 1 will have the usual method of irrigation with normal saline during surgery whereas group 2 have irrigation with 1:100 000 adrenaline in normal saline. The solution will be prepared by the senior resident through adding one ampule of 0.1 percent adrenaline in one liter bag of normal saline, which made the adrenaline concentration in the solution 1:100 000. The investigators who collected the data will be blinded to the content of both preparations. Irrigation with either solution will be used during the procedure through a 20 mL syringe attached to an olive tip long curved suction.|t|t|t|f
33774604|NCT04953884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774605|NCT04056728|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774606|NCT06734975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774607|NCT04447989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug (sildenafil or placebo) will be prepared in the pharmacy by the unblinded pharmacist. Treatment cohort will be randomly assigned electronically and communicated to the pharmacist via the study portal. All other study staff and the patients/parents will be blinded to the treatment assignment.|Premature infants with severe BPD (inpatient in neonatal intensive care units) will be randomized in a dose escalating approach 3:1 (sildenafil: placebo) sequentially, into each of 3 cohorts. There will be approximately 40 randomized and dosed participants in each cohort for a total of up to 120 participants.|t|t|t|t
33774608|NCT06101290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774609|NCT05294731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774610|NCT04716881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904316|NCT00216359|||NATURAL_HISTORY||OTHER|||||||
33904317|NCT01988012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904318|NCT00282165|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33904319|NCT01044277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-Blind - GSH 500 mg/GSH 125 mg/Placebo||t|f|t|f
33904320|NCT03921281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33904321|NCT05527704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986953|NCT06561022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684159|NCT06144762|NA|SINGLE_GROUP||OTHER||NONE||||||
33684160|NCT04300959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684161|NCT01613976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684162|NCT01701518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684163|NCT02767362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684164|NCT05908058|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684165|NCT01535664|||COHORT|||||||||
33684166|NCT02166671|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684167|NCT02052765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774611|NCT05211869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will be randomized after enrollment into the study using REDCap. Study staff will notify CHWs of participant assignment to the intervention arm based on REDCap. Investigators, except the PI, and outcome assessors will remain blinded to arm assignment. The PI will not be able to be blinded because they will be required to do supervision and close oversight of the CHWs.|9-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care|f|f|t|t
33774612|NCT06738550|RANDOMIZED|PARALLEL||TREATMENT||NONE||control group with lactulose syrup 10 ml every 8 hours and nutritional intervetion intervention group with agave inulin 9 gr per day and nutritional intervetion||||
33774613|NCT05307900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774614|NCT06738290|||COHORT||PROSPECTIVE|||||||
33774615|NCT06612268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33774616|NCT05513001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774617|NCT06578455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized, Open-Label, Crossover||||
33774618|NCT06508164|||COHORT||PROSPECTIVE|||||||
33774619|NCT06140147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical team caring for participants will not be blinded due to the nature of the intervention. The participants and their family will not be actively informed about group allocation. The steering group, author group, trial statistician, outcome assessors, prognosticators, the trial coordinating team, manuscript writers and the data safety and monitoring committee will be blinded to group allocation.||t|f|t|t
33774620|NCT05608837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|BCVA examiner and study subjects will be masked||t|f|f|t
33774621|NCT06494540|||COHORT||PROSPECTIVE|||||||
33774622|NCT05639348|||COHORT||PROSPECTIVE|||||||
33774623|NCT06297265|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774624|NCT01351545|||OTHER||PROSPECTIVE|||||||
33774625|NCT05812144|NA|SINGLE_GROUP||OTHER||NONE||||||
33774626|NCT06232109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774627|NCT05800990|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33774628|NCT04988074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774629|NCT06716645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774630|NCT03806296|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33684168|NCT00000973||||TREATMENT||NONE||||||
33774631|NCT02287610|||COHORT||PROSPECTIVE|||||||
33774632|NCT02473757|||COHORT||PROSPECTIVE|||||||
33774633|NCT06513884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33774634|NCT03802981|||COHORT||PROSPECTIVE|||||||
33774635|NCT05220033|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774636|NCT06661031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The oral fluid testing pilot is a single-arm preliminary examination of remote oral fluid test feasibility and acceptability (anticipated n = up to 5).~The pilot randomized controlled trial is a parallel, 2-arm, trial with 1:1 randomized allocation to the MOMENT-V intervention versus Enhanced Care, stratified by sex (male vs. not male), race (Black or African American vs. not Black or African American), cannabis use frequency (daily vs. not daily), and site (Boston Children's Hospital Adolescent/Young Adult Medical Practice vs. Martha Eliot Health Center Adolescent Clinic) (anticipated n=60)."|f|f|f|t
33774637|NCT06740760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774638|NCT04064424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904322|NCT05606354|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups: interventional and Control. Both groups will receive one standard treatment which is exercises. interventional group will receive kinesio tape and control group will not receive any kinesio tape.||||
33986954|NCT05321446|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE|No masking required as outcomes are based on technology and performance tests.|The intervention is positive auditory feedback provided by the device for good wrist movement during completion of different functional tasks. Two different groups are assessed, one with the device and one without in a sequential pre-post design. The groups are not compared.||||
34081039|NCT06151808|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||30 subjects with non-cognitive impairment, 30 subjects with MCI due to AD， 30 subjects with mild to moderate AD.||||
34081040|NCT05435547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081041|NCT02280252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081042|NCT03035448|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34081043|NCT05322096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684169|NCT02355873|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||ST100 (AN69ST) to M100 (AN69), M100 to ST100|f|t|t|f
33684170|NCT06092047|NA|SINGLE_GROUP||TREATMENT||NONE||UTAA09 injection||||
33684171|NCT06177275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684172|NCT03553966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Multicenter, double-blind, randomized, active-controlled parallel-group study.|t|t|t|t
33684173|NCT02691598|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33684174|NCT01284257|||COHORT||PROSPECTIVE|||||||
33684175|NCT04113876|||OTHER||PROSPECTIVE|||||||
33684176|NCT01111929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684177|NCT05557318|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This clinical study is a prospective study to evaluate the sensitivity and specificity of the Ainos Flora Female Vaginal Health Tester in identifying vaginal infections. Potential subjects will be patients in the gynecological clinic. The study will evaluate the performance of the Ainos Flora Female Vaginal Health Tester by comparing it to the conventional real-time polymerase chain reaction (RT-PCR) and culture methods for the diagnosis of vaginitis to calculate both sensitivity and specificity.||||
34081044|NCT03043196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904323|NCT04061798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be randomized using a computerized program (CASTOR EDC) with a random block size of a maximum of 8. The randomization will be stratified by participating centre. The participant is blinded to the allocated treatment.~Separate evaluation of results and if complications can be labelled as TEC, will be performed by an Independent Central Adjudication Committee. The 3 members of this Committee will be blinded to the allocated treatment.~Since the care provider and investigator have to do the ACT measuring, it is impossible to blind them to the allocated treatment."|"Intervention group:~Heparin is given to reach an ACT of 200-220 seconds. At the start of the procedure, before any heparin is given, a baseline ACT measurement is performed. 3-5 minutes before clamping of the aorta 100 IU/kg bodyweight of heparin is administrated intravenously. 5 minutes after administration of heparin, ACT measurement is performed.~Comparative group:~A single dose of 5 000 IU of heparin is given 3-5 minutes before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps."|t|f|f|f
33904324|NCT00006386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904325|NCT04407845|||COHORT||PROSPECTIVE|||||||
33904326|NCT01197638|||CASE_ONLY||PROSPECTIVE|||||||
33986955|NCT03700944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Twenty-seven allergic rhinitis patients, aged 18-45 year old, were randomized into 2 groups: control group (CON; n=14) and yoga group (YOG; n=13). The control group had normal life and the yoga group was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-test and post-test.|f|f|f|t
33904327|NCT04579055|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33904328|NCT00962065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904329|NCT04333433|||COHORT||PROSPECTIVE|||||||
33904330|NCT04716439|||COHORT||CROSS_SECTIONAL|||||||
33904331|NCT02058199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904332|NCT00701740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904333|NCT05616065|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904334|NCT01102855|||||PROSPECTIVE|||||||
33904335|NCT06020859|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33986956|NCT03333616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904336|NCT00273858|||COHORT||PROSPECTIVE|||||||
33986957|NCT03157362|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will not be informed of what condition they are assigned to. The research assistants who code the data will also not be informed of condition.|"Each participant will experience four conditions, in a random order, crossing near and far virtual environments, and social presence or no social presence."|t|f|f|t
33986958|NCT04664621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33986959|NCT05197634|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33986960|NCT02029326|||COHORT||PROSPECTIVE|||||||
33986961|NCT06561399|||COHORT||PROSPECTIVE|||||||
33986962|NCT01236677|||COHORT||PROSPECTIVE|||||||
33986963|NCT01079026|||COHORT||PROSPECTIVE|||||||
33986964|NCT04334174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986965|NCT02409979|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33986966|NCT05612867|||COHORT||RETROSPECTIVE|||||||
33986967|NCT02583763|||CASE_CONTROL||PROSPECTIVE|||||||
34081045|NCT00468585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081046|NCT02979821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081047|NCT03177395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081048|NCT04328337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34081049|NCT04621331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081050|NCT06108999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081051|NCT00945841|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33904337|NCT03042013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904338|NCT02706093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33986968|NCT03919058|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The outcome assessor will not know the code of the different regimes.|Participants will follow four regimes of 4 days each including a control, a sit less, a sit and an exercise regime. The order of the sit and sit less regimes will be randomized. Each activity regime will be followed by a wash-out period of 10 days during which subjects will continue their normal lifestyle.|f|f|f|t
34081052|NCT03641508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081053|NCT06265831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Hospitalized patients with a diagnosis of COPD will be randomized into two groups. The intervention group will have a hand fan applied to the face and be monitored for a week, and the control group will receive routine care at the clinic. Investigators will evaluate outcome measures.|Parallel group: two groups, an intervention group and a control group, receiving complementary therapy.|t|f|f|f
34081054|NCT02772666|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33904339|NCT02209233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904340|NCT00950612|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33904341|NCT04408092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||standard treatment of EPN includes repeat surgeries at (1) second-look surgery to remove residual tumor after first-look surgery at initial diagnosis, and (2) optimal debulking of recurrent tumor, providing a rare opportunity to measure the effect of experimental therapy directly in children's brain tumors. Ten patients each will be entered into the second-look and recurrence strata of this study.||||
33986969|NCT02026635|||COHORT||PROSPECTIVE|||||||
33986970|NCT03738605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986971|NCT03541941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33986972|NCT02613260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081055|NCT01995669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081056|NCT06522750|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34081057|NCT01443858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081058|NCT06144255|NA|SINGLE_GROUP||TREATMENT||NONE||Each volunteer will have 3 study visits, receiving a different study dose at each visit in randomized order as spelled out in the protocol.||||
34081059|NCT00863382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081060|NCT02642705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081061|NCT01283100|RANDOMIZED|CROSSOVER||||NONE||||||
34081062|NCT06053385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Participants will be randomized to either the melatonin lotion first or the placebo control lotion first, and then each participant will receive the other treatment second.|t|f|t|t
34081063|NCT00926250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34081064|NCT02765737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081065|NCT01755507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34081066|NCT00218751|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34081067|NCT03301389|||COHORT||PROSPECTIVE|||||||
34081068|NCT04233853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081069|NCT00109863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081070|NCT01596569|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|f|t|t
34081071|NCT01270477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081072|NCT05033626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684178|NCT00562900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081073|NCT03850717|||COHORT||RETROSPECTIVE|||||||
34081074|NCT04964115|||COHORT||CROSS_SECTIONAL|||||||
34081075|NCT06336785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081076|NCT05701709|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-A2102 single arm||||
34081077|NCT01726595|||COHORT||PROSPECTIVE|||||||
34081078|NCT00434824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081079|NCT00843141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081080|NCT03245281|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||According to the enrolment chronological order, each subject will be allocated to Diuretic Suspension group (DS), Diuretic Increase (DI) or Diuretic+MRA medication Suspension (DMS), which will define the medication regimen before the follow-up visit.||||
34081081|NCT02952651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081082|NCT03101306|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single site, non-randomised basic science study.||||
34081083|NCT05088772|||COHORT||PROSPECTIVE|||||||
33684179|NCT02967380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684180|NCT03121027|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34081084|NCT00224263|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33684181|NCT00065130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684182|NCT05046444|||CASE_ONLY||PROSPECTIVE|||||||
33684183|NCT01884727|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33684184|NCT05576974|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Open Label|"In Part 1 the single dose of 1 mg/kg of pegsitacianine given 6-100 hours prior to surgery will be used to image primary tumors in patients with HNSCC to evaluated to verify the diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes.~In Part 2, pegsitacianine the single dose of 1 mg/kg of given 6-100 hours prior to surgery will be used to in patients with unknown primary cancer of the head and neck. These patients typically undergo exam under anesthesia with a laryngoscopy as well as panendoscopy for identifying the source of the metastatic cancer found in the cervical nodes. Subjects for Part 2 may begin dosing at any time during Part 1 thus the two parts can run concurrently."||||
33684185|NCT04829578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684186|NCT05048550|RANDOMIZED|PARALLEL||OTHER||NONE||This is a single-centre randomised interventional study; a 3-arm parallel group, open-label clinical feasibility trial for a definitive RCT with equal arm allocation and a superiority design.||||
33684187|NCT01211431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684188|NCT03010436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684189|NCT04879602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774639|NCT05630014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774640|NCT06400472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774641|NCT06183684|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33774642|NCT04380051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||participants are assigned to one of two or more groups in parallel for the duration of the study|f|f|f|t
34081085|NCT01338324|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34081086|NCT04023396|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, follow-up study||||
34081087|NCT01219023|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34081088|NCT03477578|||CASE_CONTROL||OTHER|||||||
34081089|NCT06167408|||COHORT||RETROSPECTIVE|||||||
34081090|NCT03846401|||COHORT||PROSPECTIVE|||||||
34081091|NCT02824445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081092|NCT05913362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081093|NCT05755893|||CASE_CONTROL||RETROSPECTIVE|||||||
34081094|NCT05199246|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081095|NCT01126216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081096|NCT03813862|||COHORT||RETROSPECTIVE|||||||
34081097|NCT01062191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081098|NCT00496769|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33774643|NCT03618550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in transplant eligible patients with relapsed or refractory Hodgkin lymphoma following failure of 1-line of multi-agent chemotherapy.||||
33774644|NCT06737198|||COHORT||PROSPECTIVE|||||||
33774645|NCT05252754|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774646|NCT06486506|||COHORT||RETROSPECTIVE|||||||
33774647|NCT05389462|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774648|NCT06085807|||COHORT||PROSPECTIVE|||||||
33774649|NCT04478643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Monocentric, Parallel-Arm, Patient, Statistician, Operator and Examiner are blinded, RCT|t|t|t|t
33774650|NCT06696443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774651|NCT00339911|||CASE_ONLY||CROSS_SECTIONAL|||||||
33774652|NCT01134770|||COHORT||CROSS_SECTIONAL|||||||
34081099|NCT05380245|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A single dose, randomized, crossover, open-labeled and two sequence study with a two-week washout period, evaluated the impact of clarithromycin on the pharmacokinetics (PK) profile of voriconazole Pakistani healthy male volunteers.||||
34081100|NCT04418947|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE||Randomized, double-blind, factorial design|t|t|t|t
33684190|NCT06396182|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A (Study group): (Thirty participant) The program of treatment will be 3 times a week lasting for 8 weeks. A standardized 5- min warm-up phase will precede each session and 10-min cooling down phase after each session with the actual time of each session is 30 minute. 30 minutes of virtual reality cycling by fully immersive Head-Mounted Display virtual reality (Oculus Quest virtual reality (VR) headset with hand controller).~Group B (Control group): (Thirty participant) The program of treatment will be 3 times a week lasting for 8 weeks. A standardized 5- min warm-up phase will precede each session and 10-min cooling down phase after each session with the actual time of each session is 30 minute. 30 minutes of cycling session by traditional stationary bike."||||
33684191|NCT04465136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684192|NCT05357729|NA|SINGLE_GROUP||OTHER||NONE||||||
33684193|NCT03539809|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684194|NCT01450904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33684195|NCT05615935|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33684196|NCT04244812|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33684197|NCT01843647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684198|NCT04617431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684199|NCT04304547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684200|NCT01376440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684201|NCT02093351|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33684202|NCT06078800|NA|SEQUENTIAL||TREATMENT||NONE||||||
33684203|NCT04138979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684204|NCT05891756|||CASE_CONTROL||PROSPECTIVE|||||||
33684205|NCT03486275|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double-blinded randomized trial : Participants do not know their assignment group. The questionnaires, identical in both groups, were completed by the participants and blinded from their assignment group.|randomized trial comparing the learning provided by a week of access to the game Hygie or source articles|t|t|t|t
33684206|NCT05036473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The active drugs and placebo are labeled from the company and the study staff will give the drug to the subjects who are randomized.|"Active groups are the groups of Parkinson's disease patients who will receive WD-1603 tablets with 3 different dosages.~Placebo group is the group of Parkinson's disease patients who will receive the placebo-matching tablets."|t|f|t|f
33684207|NCT05503667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684208|NCT01481129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684209|NCT03937635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684210|NCT05364801|||OTHER||CROSS_SECTIONAL|||||||
33684211|NCT03320694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684212|NCT00559832|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33684213|NCT02490761|||COHORT||PROSPECTIVE|||||||
33684214|NCT01875224|RANDOMIZED|PARALLEL||||NONE||||||
33684215|NCT01315821|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33684216|NCT05704127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684217|NCT00789412|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684218|NCT01932892|||CASE_ONLY||CROSS_SECTIONAL|||||||
33684219|NCT00677053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684220|NCT04785690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Subjects will be seen at follow-up visits. A Masked Examiner must complete distance VA, near VA and stereoacuity testing at these visits. All procedures will be performed with the subject's current spectacle correction. If a subject currently wears spectacles but is not wearing them at the follow-up examination for whatever reason, testing must be performed in trial frames except for Visit 1 and Visit 5 visual acuity must ONLY be performed in current refractive correction glasses (not trial frames).~Prior to the Masked Examiner entering the room, subjects and parents should be instructed not to discuss their treatment with the Masked Examiner."|The EDC and data management will construct a Master Randomization List using a permutated block design stratified by initial visual acuity in the amblyopic eye and age which will specify the order of treatment group assignments. Randomization will be managed directly by the eCRF platform.|f|t|f|f
33684221|NCT00499057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684222|NCT03787979|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The assessor and investigator will be blinded to the random order. This process will be handled by the research manager.|Participants will be randomly assigned to either stretching exercise with lumbopelvic stiffening technique or lumbopelvic relaxing technique. They will be provided a 2-day wash-out period. Then, participants will cross-over to another technique.|f|f|t|t
33684223|NCT05997394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The experimental and control groups will be determined by randomization method by a person other than the researcher. Participants will not know which group they are in.|It is a semi-experimental type of study. It consists of two groups: experiment and control.|t|f|t|f
33684224|NCT01528540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684225|NCT00235170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684226|NCT04816409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684227|NCT01701752|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33684228|NCT00796887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684229|NCT03700541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684230|NCT04434170|||COHORT||PROSPECTIVE|||||||
33684231|NCT02473692|||OTHER||PROSPECTIVE|||||||
33684232|NCT01335022|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33986973|NCT05034055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986974|NCT04446676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups with endoprosthesis stabilisation with stem or sleeve.|f|f|t|f
33986975|NCT01370317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33986976|NCT05875597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33986977|NCT01654458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986978|NCT01331538|||||CROSS_SECTIONAL|||||||
33986979|NCT02139839|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33986980|NCT01762618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986981|NCT03921294|NA|SINGLE_GROUP||TREATMENT||NONE||single arm prospective open-label single-center study||||
33986982|NCT03331445|NA|SEQUENTIAL||TREATMENT||NONE||Open label safety study (COVID-19 Sub-study)||||
33684233|NCT00641316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684234|NCT00354185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684235|NCT01303003|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33684236|NCT01076127|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33684237|NCT02592642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684238|NCT02616601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684239|NCT04438564|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684240|NCT06036602|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomized 4:1 to receive the cAd3-Sudan Ebolavirus vaccine at 1.0 × 10\^11 PU dose or placebo at Day 1.|t|t|t|t
33684241|NCT06391528|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33684242|NCT00591578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684243|NCT03821662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684244|NCT03415386|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33684245|NCT04608461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684246|NCT06267378|||COHORT||PROSPECTIVE|||||||
33684247|NCT03571945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The attending anaesthesiologist will not be blinded to the method of administering GA (BIS or ETAG guided) and recovery immediately after extubation inside the OR. However, the postoperative evaluation of intraoperative awareness and patient recovery profile will be evaluated by an independent assessor blinded to the technique of GA.|"2000- patients aged 18-65 years scheduled for elective surgery under general anaesthesia will be randomly allocated to one of the following two groups:~Group I \[BIS Guided Group, n=1000\]: GA will be monitored and controlled with Bi-spectral index (BIS).~Group II \[ETAG Guided Group, n=1000\]: GA will be monitored and controlled with end-tidal anaesthesia gas concentration (ETAG)."|t|f|f|t
33684248|NCT05778383|RANDOMIZED|PARALLEL||OTHER||NONE||We are administering Zinc supplementation in the acute phase of SARS-CoV-2 infection||||
33684249|NCT03222492|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33684250|NCT02835053|||COHORT||RETROSPECTIVE|||||||
33684251|NCT00663442|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33684252|NCT05612412|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33684253|NCT05436873|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||There is only 1 treatment arm, as this is a feasibility study.||||
33684254|NCT03633240|||COHORT||PROSPECTIVE|||||||
33684255|NCT03857347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Data will be explored using the reliable and clinically significant change analysis (Morely, Williams \& Hussain, 2008). This analysis allows pre and post treatment scores to be compared to see if participants have achieved a level of difference that could be categorized as real and not due to measurement error. Furthermore this score can be helpful to determine if the change seen is clinically significant.||||
33684256|NCT02557074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684257|NCT03654573|NA|SINGLE_GROUP||OTHER||NONE||N= 50 Diagnostic and N= 20 Therapeutic||||
33684258|NCT00216866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684259|NCT05324488|||COHORT||PROSPECTIVE|||||||
33684260|NCT02817477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684261|NCT01653379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684262|NCT00164944|||CASE_CONTROL||PROSPECTIVE|||||||
33684263|NCT03660085|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study|t|f|f|f
33684264|NCT04626115|||OTHER||PROSPECTIVE|||||||
33684265|NCT02368184|||COHORT||PROSPECTIVE|||||||
33684266|NCT04718844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684267|NCT03813368|||COHORT||RETROSPECTIVE|||||||
33684268|NCT05383014|||OTHER||PROSPECTIVE|||||||
33684269|NCT02251522|||CASE_CONTROL||OTHER|||||||
33684270|NCT06001411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33684271|NCT00938886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684272|NCT04544215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684273|NCT05444140|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33986983|NCT04306107|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33986984|NCT03921463|||COHORT||PROSPECTIVE|||||||
33986985|NCT05957263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both participants and assessors will be blind for the treatment procedures|controlled, double-blinded, and randomized clinical trial|t|f|f|t
33986986|NCT04477005|||COHORT||PROSPECTIVE|||||||
33986987|NCT04135027|||COHORT||PROSPECTIVE|||||||
33986988|NCT05122286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33986989|NCT00599664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986990|NCT05746897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986991|NCT05132933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986992|NCT04167332|||COHORT||PROSPECTIVE|||||||
33986993|NCT00318383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33986994|NCT01804985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33986995|NCT01312220|||COHORT|||||||||
33986996|NCT00845715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33986997|NCT00091260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684274|NCT04320641|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"* who do not have regular periods (between 21-35 days),~* Has a psychiatric diagnosis,~* Having any gynecological disease (anornal uterine bleeding, fibroids, ovarian cyst etc.)~* Using contraceptive drugs,~* With tissue deformity in its extremities, Any health problems that may prevent physical exercise"||t|f|f|f
33684275|NCT04403009|||COHORT||CROSS_SECTIONAL|||||||
33684276|NCT02166177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684277|NCT00338897|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33684278|NCT01174433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684279|NCT00722085|||COHORT||RETROSPECTIVE|||||||
33684280|NCT03369678|||CASE_ONLY||CROSS_SECTIONAL|||||||
33684281|NCT02660008|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33684282|NCT02589600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33986998|NCT06016361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33774653|NCT06191159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized in equal numbers to have the initial skin incision made with either scalpel, standard electrocautery or PEAK PlasmaBlade. For skin incisions made with electrocautery or PEAK PlasmaBlade the surgeon will use the same equipment for the completion of the surgery. Patients who have initial skin incision with scalpel will be further randomized to have completion of the surgery with standard electrocautery or PEAK PlasmaBlade. Any patients with bilateral mastectomy will be randomized to the same surgical approach for both breasts.|t|f|t|t
33774654|NCT05591703|||CASE_ONLY||PROSPECTIVE|||||||
33774655|NCT03786016|NA|SINGLE_GROUP||OTHER||NONE||All participants will be exposed to the same condition.||||
33774656|NCT05580211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the Phase I, all participants are randomized to one of two treatment stimulation patterns. In Phase II, all participants will receive the same treatment pattern.||t|f|t|t
33774657|NCT06740240|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33774658|NCT06738810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||There will be a single group. Indeed, all type 2 diabetes with or without a hepatic check-up will be included in the study.||||
33774659|NCT04781231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participant in the group Usual care are unaware of the other groups, in order to avoir the Hawthorne effect.|||||
33774660|NCT06526286|||COHORT||PROSPECTIVE|||||||
33774661|NCT05185180|||COHORT||PROSPECTIVE|||||||
33774662|NCT06658457|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33774663|NCT06146335|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33986999|NCT05334173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded for the patient and to the surgeon up to the time of intervention|Randomized trial in blocks (1:1). Type 1 laparoscopic Gastric Bypass (150cm alimentary limb and 70cm biliopancreatic limb) or type 2 laparoscopic Gastric Bypass (70cm alimentary limb and 150cm biliopancreatic limb)|t|f|f|f
33987000|NCT01555086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987001|NCT04019834|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients and all study and hospital personnel will be blinded to randomization assignments except the regional anesthesia team.||t|t|t|f
33987002|NCT06405009|||COHORT||RETROSPECTIVE|||||||
33987003|NCT06485869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||non-randomized parallel two-arm comparative study with a group without virtual reality sessions and a group with virtual reality sessions||||
33987004|NCT01586611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987005|NCT00688363|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987006|NCT02513056|||CASE_CONTROL||PROSPECTIVE|||||||
33987007|NCT03828981|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized superiority trial||||
33987008|NCT01777347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987009|NCT01615198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987010|NCT01537861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987011|NCT00290030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987012|NCT02829762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987013|NCT04985474|||COHORT||PROSPECTIVE|||||||
33684283|NCT02575066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684284|NCT02165839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684285|NCT02955251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684286|NCT05585281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684287|NCT04232709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684288|NCT04564768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized controlled pilot study including qualitative and quantitative elements.|f|f|f|t
33684289|NCT05428189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Monocetric, single blinded, randomized clinical trial, parallel design.|f|f|t|f
33684290|NCT03121976|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33774664|NCT04158648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774665|NCT02709226|NA|SEQUENTIAL||TREATMENT||NONE||||||
33774666|NCT06739486|||OTHER||CROSS_SECTIONAL|||||||
33774667|NCT03770273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774668|NCT06738654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental Group: Breast-conserving surgery for breast cancer using single-port robotic surgery.~Control Group: Breast-conserving surgery for breast cancer using traditional open surgery."||||
33987014|NCT06309225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987015|NCT05599074|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after design||||
33774669|NCT06739538|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774670|NCT06638632|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is an iterative, user-centered design process. Therefore, patients and care partners will receive iterations of the decision aid as updates are made to it.||||
33774671|NCT01809288|||COHORT||CROSS_SECTIONAL|||||||
33774672|NCT06214156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774673|NCT06103955|NA|SINGLE_GROUP||TREATMENT||NONE||The primary aim is to carry out preliminary testing of the intervention and to use feedback from participants to make small changes to the intervention||||
33774674|NCT05508971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not practical or feasible to maintain blinding among the surgeons performing the procedures or the clinical staff caring for patients in the perioperative setting. Given this, it is unlikely that blinding could be maintained among parents or caregivers of patients, therefore there will be no attempt to blind caregivers to the treatment assignment. However, the sleep medicine collaborators who will be reviewing and scoring postoperative PSGs will be instructed not to review the medical record so as to ensure blinding to treatment assignment.|"Participants will be recruited from pediatric otolaryngology clinics. The study will be introduced to caregivers of children with DS and a history of sleep disordered breathing/OSA who are referred for surgery and meet the inclusion and exclusion criteria noted. If current or recent PSG testing demonstrates OSA, they will be invited to participate.~Randomization will be done. Patients will be randomized to either the personalized DISE-directed surgery or the standard AT after collection of baseline measures and pre-op PSG. Allocation will be made by using a computer-generated randomization scheme. Caregivers will be advised of the outcomes and risks of different surgical procedures included in DISE-directed surgery and informed consent will be obtained. All patients will be planned for overnight observation to monitor for safety and periop complications."|f|f|f|t
33774675|NCT06049407|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33774676|NCT06046222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774677|NCT06462443|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group assignment||||
33774678|NCT06534502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774679|NCT04875416|||COHORT||PROSPECTIVE|||||||
33774680|NCT06494488|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33774681|NCT04853251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774682|NCT06056830|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774683|NCT03883945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study medication will be administered by the Treating Investigator. Safety and efficacy measures will be evaluated by the masked Evaluating Investigator.|Randomized, double-blind, vehicle-controlled, parallel-group, dose-escalation study evaluating study medication versus vehicle in each of 4 sequentially enrolled cohorts|t|f|t|t
33774684|NCT00434837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987016|NCT00627419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987017|NCT00817661|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987018|NCT01038310|||CASE_ONLY||PROSPECTIVE|||||||
33987019|NCT06156644|NA|SINGLE_GROUP||OTHER||NONE||Single Arm||||
33987020|NCT05306639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987021|NCT05275985|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987022|NCT02272647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33987023|NCT05081466|||COHORT||PROSPECTIVE|||||||
33987024|NCT05531422|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33987025|NCT04755985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987026|NCT03110120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The patient where randomized by the investigator after inform consent was signed The investigator prepared the syringes named serratus and local with levobupivacaine 0.25 or saline according to randomization The care provider injected the prepared syringes respectively in the serratus plane or locally without knowing their contents The outcome assessor evaluated the post operative pain and the 3 months followup without knowing the randomization"|Compare the efficacy of the serratus plane block with local infiltration after thoracic robot-assisted surgery|t|t|f|t
33987027|NCT03401086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The KT group received Kinesio taping application, while the PG group received pressure garment (40-60 mmHg) for at least 15-18 hours per day through the study.||t|f|f|t
33987028|NCT01205425|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33987029|NCT01465581|||COHORT||PROSPECTIVE|||||||
33987030|NCT01207986|NA|SINGLE_GROUP||SCREENING||NONE||||||
33774685|NCT06738043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The allocation will be concealed using sequentially numbered, sealed envelopes. A nurse not involved in patient care will open the envelope after induction of anesthesia to assign patients to groups.|Patients will be randomized into three parallel groups: dexmedetomidine, ketamine, or control (placebo) groups, each receiving specific interventions based on the protocol.|t|t|t|t
33774686|NCT06582602|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33774687|NCT05966740|||COHORT||PROSPECTIVE|||||||
33774688|NCT05775094|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm.||||
33774689|NCT05632562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774690|NCT05130450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774691|NCT06420518|||OTHER||PROSPECTIVE|||||||
33774692|NCT05394519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774693|NCT02964611|||COHORT||CROSS_SECTIONAL|||||||
33774694|NCT05577702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774695|NCT06106828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774696|NCT05467735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33987031|NCT01476293|||CASE_ONLY||RETROSPECTIVE|||||||
34081101|NCT03944616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All nursing staff/phlebotomist collecting physical samples, and the lab analyzing the samples will be masked to the trial arm the participant is in. The biostatistician performing the final analyses will also be masked.|This study is testing the effect of commercial diet beverage intake on diabetes control parameters in free-living adults with type 2 diabetes in a randomized, two arm parallel trial with a run-in period of 2-weeks and an active intervention period of 24-weeks. We will recruit 200 patients with type 2 diabetes who are usual consumers of commercial diet beverages and randomize them to receive and consume either: 1) A commercial diet beverage of choice (3 servings or 24 oz. daily); or 2) Unflavored bottled water of choice (sparkling or plain) (3 servings or 24 oz. daily).|f|f|f|t
34081102|NCT01733277|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34081103|NCT01106131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081104|NCT00702780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081105|NCT02477592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081106|NCT04787848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34081107|NCT04027088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34081108|NCT03368664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081109|NCT03654417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081110|NCT04339049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081111|NCT04686916|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081112|NCT04627688|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081113|NCT03894995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081114|NCT00368251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081115|NCT02794129|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081116|NCT06302777|||CASE_ONLY||PROSPECTIVE|||||||
34081117|NCT01776554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34081118|NCT06127277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34081119|NCT02828865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081120|NCT02455128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081121|NCT02071485|||CASE_ONLY||PROSPECTIVE|||||||
34081122|NCT05985746|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081123|NCT06422728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, single-blind procedure will be applied to reduce biases. For this purpose, participants will be informed only about the general procedure of group therapy (e.g. general focus of the group therapy, number of sessions, duration of sessions, number of participants) but will not be informed about which intervention they receive and which group they are assigned.|This study will search the effectiveness of the unified protocol on anxiety disorders. For this purpose, there will be an intervention group (unified protocol will be applied) and a control group. The participants will be assigned randomly to the groups.|t|f|f|f
33987032|NCT04690881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987033|NCT06228963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987034|NCT02304211|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33987035|NCT01421381|||COHORT||PROSPECTIVE|||||||
33987036|NCT03430830|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987037|NCT04710381|NA|SINGLE_GROUP||PREVENTION||NONE|No masking will be used in the study|The study treatment (IMUNOR) will be administered to one group of study subjects only.||||
33987038|NCT01638741|||CASE_ONLY||PROSPECTIVE|||||||
33987039|NCT01854463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33987040|NCT00813592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987041|NCT01202734|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33987042|NCT01045161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987043|NCT02159183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987044|NCT00979303|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intent to treat use of non fluoroscopic mapping system with traditional fluoroscopic mapping system during elective catheter ablation in children 8-17 with normal cardiac anatomy||||
33987045|NCT05718245|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|A sham filter will be used in the control, to replace HEPA filter in the intervention group. Participants and investigators will be blinded to the intervention type, only specific investigator who will prepare air filter for intervention will be unblinded for the real air filter type.||t|f|t|f
33987046|NCT05538052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Alpha-numeric codes||t|t|t|t
33987047|NCT01523730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33987048|NCT01232426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987049|NCT04587557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987050|NCT03941925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684291|NCT02940106|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33987051|NCT02544672|NA|SINGLE_GROUP||||NONE||||||
33987052|NCT05858463|RANDOMIZED|PARALLEL||OTHER||NONE||comparison of 2 exercise training strategies||||
33987053|NCT00817960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987054|NCT00097383|NON_RANDOMIZED|||TREATMENT||||||||
33987055|NCT06038019|||OTHER||PROSPECTIVE|||||||
33987056|NCT03325426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987057|NCT06007937|NA|SEQUENTIAL||TREATMENT||NONE||||||
33987058|NCT05470972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684292|NCT02814500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081124|NCT00072449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081125|NCT00003012|RANDOMIZED|||TREATMENT||||||||
33987059|NCT03331497|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34081126|NCT02306889|RANDOMIZED|CROSSOVER||||NONE||||||
34081127|NCT01115452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987060|NCT05519683|RANDOMIZED|PARALLEL||TREATMENT||NONE|One quarter of participants will be in each arm. Those randomized to device arms will not be informed of their parameters. Those in the drug arm will be informed of their arm soon after randomization.|||||
33987061|NCT05810753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987062|NCT02188303|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33987063|NCT00520234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987064|NCT00904345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987065|NCT00127946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081128|NCT03053882|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|investigator||f|f|t|t
34081129|NCT03366662|||COHORT||PROSPECTIVE|||||||
34081130|NCT06514287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081131|NCT04393649|||COHORT||PROSPECTIVE|||||||
34081132|NCT01814007|NA|SINGLE_GROUP||OTHER||NONE||||||
34081133|NCT00325169|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34081134|NCT00100906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081135|NCT02184819|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33684293|NCT05999162|||COHORT||RETROSPECTIVE|||||||
33684294|NCT01903252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33684295|NCT03513081|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33684296|NCT05735769|||COHORT||RETROSPECTIVE|||||||
33684297|NCT05409560|||COHORT||PROSPECTIVE|||||||
33684298|NCT05513898|||COHORT||RETROSPECTIVE|||||||
33684299|NCT01670578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684300|NCT03814421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684301|NCT01082822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081136|NCT00583648|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34081137|NCT05883865|||COHORT||OTHER|||||||
34081138|NCT04746469|RANDOMIZED|PARALLEL||SCREENING||NONE||\~2500 patients who are overdue for average-risk CRC screening and are enrolled in UCLA Health biannual mailed FIT program will be randomized to either control (mailed FIT kit + standard messaging) or intervention (mailed FIT Kit + standard messaging + delayed automated phone reminder)||||
33987066|NCT05180253|||COHORT||PROSPECTIVE|||||||
33987067|NCT06561100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized into either the exercise or stretching condition in a 1:1 fashion. The outcome assessors will be blinded at all times while the intervention specialist (study trainers) will unblind themselves prior to the participants first intervention appointment.|Participants are randomized to one or more study arms and each study arm will be allocated a different intervention.|f|f|f|t
33987068|NCT04550585|||OTHER||PROSPECTIVE|||||||
33684302|NCT04250077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will know what group they are in. When we send the data to the statistician for analysis we can code the groups (e.g., 123) and not tell them which is which. This masks (or blinds) him to the condition.|Phase One of this project will develop and refine digital delivery of two modified CRAFT (Community Reinforcement and Family Training) interventions: automated and Group CRAFT protocol (CRAFT-A) and automated CRAFT protocol with live coaching (CRAFT-C) and assess the effectiveness of the adapted CRAFT protocols with WTV's business as usual model of Peer Support Forum (PEER). The goal of the project is to deliver an innovative and effective evidence-based behavioral intervention with consumer technology to an existing and growing online audience.|f|f|f|t
33987069|NCT05975697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is planned to be double-blind, and the patient and the evaluating physician will not know which patient is in the study group and which patient is in the control group. The walkers and the physiotherapist will not be blind.|Divided into two groups as experimental and control groups.|t|f|f|t
33987070|NCT05663411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987071|NCT03568565|RANDOMIZED|SEQUENTIAL||OTHER||NONE||The model is a partial/limited SMART design. Couples are initially randomly assigned to one of five groups - a waitlist control, the ePREP program (with and without a coach) and the OurRelationship program (with and without a coach). Following initial randomization, couples initially assigned to complete either program without a coach and who are not completing activities in a timely manner will be re-randomized to either continue without a coach or received a coach.||||
33987072|NCT03552744|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33684303|NCT00191087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684304|NCT02250833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684305|NCT01371032|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33684306|NCT00130312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684307|NCT05232370|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Three groups are made~1. - Control group: No treatment~2. - Tratment group: Enalapril~3. - Treatment group: Losartan"||||
33684308|NCT00311298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684309|NCT00783302|||CASE_ONLY||PROSPECTIVE|||||||
33684310|NCT00062816||||TREATMENT||||||||
33684311|NCT06294743|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Group-1, posterior tibial nerve neuroprolotherapy will be administered during the first two menstrual cycles, followed by oral acetaminophen (500mg) for the subsequent two menstrual cycles. Conversely.~Group-2, oral acetaminophen (500mg) will be given during the initial two menstrual cycles, followed by a transition to posterior tibial nerve neuroprolotherapy for the last two menstrual cycles."||||
33684312|NCT01190735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684313|NCT00728143|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33774697|NCT04214418|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The phase 1 portion of the study will be conducted using the time-to-event continue reassessment method (TITE-CRM) using four dose levels. The phase 2 portion of the study will use the recommended phase 2 dose for three cohorts with KRAS mutation - 1. Pancreatic adenocarcinoma; 2. Colorectal adenocarcinoma; and 3. Histology agnostic adenocarcinoma.||||
33774698|NCT06664957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774699|NCT06737146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774700|NCT06427941|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774701|NCT04280926|||COHORT||PROSPECTIVE|||||||
33774702|NCT04542499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774703|NCT06741267|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33774704|NCT04636710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774705|NCT04611516|||COHORT||PROSPECTIVE|||||||
33774706|NCT05847478|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33774707|NCT02698254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774708|NCT05882877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774709|NCT04585815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774710|NCT06444880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774711|NCT04630301|||CASE_ONLY||PROSPECTIVE|||||||
33987073|NCT04792450|||COHORT||PROSPECTIVE|||||||
33987074|NCT06089382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987075|NCT00429234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987076|NCT05622422|NA|SINGLE_GROUP||PREVENTION||NONE||mixed method||||
33987077|NCT05132985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987078|NCT01424293|NA|SINGLE_GROUP||OTHER||NONE||||||
33987079|NCT04188197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987080|NCT03706794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be informed that they will receive one of two educational interventions. The care provider is a smartphone application; the only person aware of the condition is the research assistant assigning participants to the smartphone application conditions. The investigator, research coordinator, and all other personnel including outcomes assessors will be unaware of condition."||t|f|t|t
33987081|NCT04941586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental group: Education in Pain plus Manual Therapy plus Exercises Control group: Manual Therapy plus Exercises|f|f|t|t
33987082|NCT03205241|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomised, placebo-controlled, double blind, crossover design study|t|f|t|f
33987083|NCT05212285|||CASE_CONTROL||PROSPECTIVE|||||||
33987084|NCT00512161|||||RETROSPECTIVE|||||||
33987085|NCT00061061|RANDOMIZED|||TREATMENT||DOUBLE||||||
33987086|NCT05518890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987087|NCT03689426|||CASE_ONLY||PROSPECTIVE|||||||
34081139|NCT05606601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded in that only the investigators (including the statistician) will be blinded to the treatment group assignment when examining the primary hypotheses.||f|f|t|f
33987088|NCT04171570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization to distal transradial access or conventional transradial access. Both techniques are standard of care.||||
33987089|NCT01433718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987090|NCT02241434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987091|NCT00925054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33987092|NCT03187158|||COHORT||CROSS_SECTIONAL|||||||
33987093|NCT02527447|||COHORT||PROSPECTIVE|||||||
33987094|NCT01216566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987095|NCT02775812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987096|NCT02050685|||COHORT||PROSPECTIVE|||||||
33987097|NCT00215410|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33774712|NCT03443323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774713|NCT05345197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774714|NCT06705192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774715|NCT05007730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774716|NCT05004233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774717|NCT05990426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is an unblinded two-arm randomized controlled trial to investigate the effects of alternate day fasting in ovarian and uterine cancer patients undergoing chemotherapy.||||
33774718|NCT06470659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774719|NCT02988960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774720|NCT06066580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904342|NCT00467909|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|The drink (nutritional item) was prepared daily, for each child individually, by mixing 65 g of the powder in 160 mL boiled water. The fortified products in the 4 treatment groups were each assigned a specific color code, which was displayed on the package, but were otherwise indistinguishable in color, appearance, and taste. The investigators, assessors of cognitive tests, and participants were blinded until the study was completed, all data were entered, and the initial analyses were performed.|In a 2-by-2 factorial, double-blind, randomized controlled trial, 598 children aged 6-10 y were individually allocated to 1 of 4 intervention groups to receive foods fortified with either 100% or 15% of the Recommended Dietary Allowance of micronutrients in combination with either 900 mg α-linolenic acid plus 100 mg docosahexaenoic acid or 140 mg α-linolenic acid for 12 mo. Anthropometric and biochemical assessments were performed at baseline and 12 mo. Cognitive performance was measured at baseline and at 6 and 12 mo.|t|t|f|f
33904343|NCT05915819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33904344|NCT02110134|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33904345|NCT02434315|RANDOMIZED|PARALLEL||||NONE||||||
33987098|NCT05331261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987099|NCT05764980|||COHORT||PROSPECTIVE|||||||
34081140|NCT01298947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774721|NCT06648759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subjects will be 2:1 randomized to the Vagal Nerve Stimulator Group or the Placebo Group, respectively.~A blinded study team member will use a standard, active device to establish the threshold of current required to stimulate the vagal nerve via an electrode placed on each side of the neck. The study device will be placed after surgery once an NG tube has been administered. This study device placement and adjustment may happen anywhere from the PACU to the hospital ward level, dependent on the NG tube placement timing, but it will be done in a private setting for confidential safeguards.~According to the standard operative procedure of the vagal stimulator, this current threshold is achieved by (1) increasing the current until the patient feels the sensation, and then (2) reducing the current until the patient no longer feels the current. When this is established, a research-specific device (either active or sham, based on the randomization assignment) will be connected to the elect"|Randomized clinical trial|t|t|t|f
33774722|NCT05601440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774723|NCT06555731|||COHORT||PROSPECTIVE|||||||
33904346|NCT05027022|||OTHER||CROSS_SECTIONAL|||||||
33987100|NCT05538416|||COHORT||OTHER|||||||
33987101|NCT04110236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study team member who will administer the follow-up study interviews will remain blinded to the group status throughout the duration of the study.||f|f|f|t
33987102|NCT03925532|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33987103|NCT02308475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987104|NCT03500003|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33987105|NCT04916418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987106|NCT04649593|RANDOMIZED|PARALLEL||TREATMENT||NONE||According to the clinic's memo, when the labor is found to be dystocic, the woman is asked about her participation in the study. If the woman admits participation, she is included in the project. This is also noted in her journal.||||
33987107|NCT05931315|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Triple|Randomized, double-blind, placebo-controlled trial|t|t|t|f
34081141|NCT02229591|||COHORT||PROSPECTIVE|||||||
34081142|NCT03534661|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-blinded for participants|Each participant receives 3 randomized treatments.|t|f|f|f
34081143|NCT02785198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34081144|NCT05564572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34081145|NCT01434446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081146|NCT02134093|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34081147|NCT02585453|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34081148|NCT00728494|||COHORT||PROSPECTIVE|||||||
33904347|NCT03025191|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684314|NCT00911885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684315|NCT05672667|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Each subject will receive 14 micrograms of oxytocin intravenously over 30 minutes and 102 micrograms of oxytocin intranasally.||||
33684316|NCT00743665|||COHORT||PROSPECTIVE|||||||
33904348|NCT01368939|||COHORT||PROSPECTIVE|||||||
33904349|NCT04349995|||COHORT||PROSPECTIVE|||||||
33904350|NCT05090410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904351|NCT02625142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33904352|NCT04547244|||COHORT||PROSPECTIVE|||||||
33987108|NCT05105945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The Logrank method was used to compare the difference in survival time between the two groups of patients. According to previous literature data, it is estimated that the DFS of the control group is 18 months. Assuming that the DFS of the test group can be extended to 21.6 months (corresponding HR=1.20), the test requires 1048 patients (524 in each group) to achieve α=0.05 This difference can be detected with 80% confidence at the (two-sided) significance level. The trial plans to enroll for 48 months, follow up for 60 months, and conduct a final analysis when 944 patients have tumor progression (recurrence or metastasis). It is estimated that the drop-off rate of patients in the experimental group and the control group is 10%, so 1164 (524×2÷0.9=1164) patients need to be enrolled in the final group.~Significance Level：0.05"|t|f|f|f
33684317|NCT02195011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684318|NCT00622778|||COHORT||PROSPECTIVE|||||||
33684319|NCT01686802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684320|NCT00912444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774724|NCT06448026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904353|NCT04138524|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility study, no control group||||
33987109|NCT00392665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987110|NCT02255097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987111|NCT03427164|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33987112|NCT02477202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987113|NCT05900635|RANDOMIZED|PARALLEL||TREATMENT||NONE|open labeled|Prospective, open-labeled, parallel, randomised controlled trial||||
33987114|NCT03019367|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"It is not possible to blind the delivering obstetrician, however all other caregivers will be blinded. The procedure will be documented as placental transfusion in the delivery summary or admission-progress notes and all study assessments whether primary (head US) or secondary (neurodevelopmental exams) will be performed by blinded team members."||f|t|t|t
33987115|NCT02927119|||||RETROSPECTIVE|||||||
33987116|NCT04724941|||COHORT||PROSPECTIVE|||||||
33987117|NCT00064974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987118|NCT02167386|RANDOMIZED|PARALLEL||PREVENTION||NONE||combination drug and behavioral intervention||||
33987119|NCT06009471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 200 patients with Parkinson's disease were enrolled in each center and randomly divided into control group (routine treatment) and observation group (routine treatment +rTMS).|t|f|f|f
33987120|NCT02937415|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987121|NCT01996527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987122|NCT04278391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33987123|NCT06148701|||COHORT||RETROSPECTIVE|||||||
33684321|NCT00314483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684322|NCT05926076|||CASE_CONTROL||RETROSPECTIVE|||||||
33684323|NCT05524116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For some of the outcomes that are not patient-reported, researchers collecting the at the post-intervention visit timepoint will be blinded to group allocation.|Parallel-arm randomized controlled trial|f|f|f|t
33684324|NCT02111278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33684325|NCT03302364|||COHORT||PROSPECTIVE|||||||
33684326|NCT04733794|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684327|NCT05202938|||CASE_CONTROL||PROSPECTIVE|||||||
33774725|NCT06191263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904354|NCT02538666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904355|NCT05663086|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33904356|NCT03074448|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33904357|NCT05953740|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double blind||t|f|t|t
33904358|NCT03579875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904359|NCT00798967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904360|NCT02551367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33904361|NCT05296421|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904362|NCT05001867|||CASE_ONLY||CROSS_SECTIONAL|||||||
33684328|NCT06401213|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33684329|NCT01358188|||CASE_CONTROL||PROSPECTIVE|||||||
33684330|NCT05107843|||CASE_ONLY||RETROSPECTIVE|||||||
33684331|NCT00635076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684332|NCT06514534|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label study||||
33684333|NCT06047184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Dose escalation phase: 6 dose levels are carried out, the starting dose of BEBT-209 is set to 25mg/day, and the accelerated titration method combined with the 3+3 mode is used for climbing research.~Phase Ib: According to the pharmacokinetics, safety and preliminary efficacy of BEBT-209 in the dose escalation phase, one dose was selected for the BEBT-209 monotherapy group, two doses were selected for the combination with letrozole group, and two doses were selected for the combination with fulvestrant group, and all five groups were continuously administered until disease progression or unacceptable toxicity or patient withdrawal or death."||||
33904363|NCT03690622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|masking for the drop instilled|randomised control trial|t|f|t|f
33904364|NCT00003859||||TREATMENT||||||||
33904365|NCT04444908|||COHORT||PROSPECTIVE|||||||
33904366|NCT05443958|||COHORT||RETROSPECTIVE|||||||
33904367|NCT05650450|||COHORT||PROSPECTIVE|||||||
33904368|NCT05715541|NA|SINGLE_GROUP||OTHER||NONE||||||
33904369|NCT03158649|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904370|NCT03147664|||CASE_CONTROL||PROSPECTIVE|||||||
33684334|NCT01373736||||DIAGNOSTIC||||||||
33684335|NCT00217464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684336|NCT01792570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684337|NCT00667173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684338|NCT02412488|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33684339|NCT05472701|RANDOMIZED|CROSSOVER||OTHER||SINGLE||SWAP-MEAT Athlete is a randomized crossover trial in which 12 recreational runners and 12 recreational resistance trainers are assigned to one of six possible diet orders. Each diet order contains three phases for four weeks each-Animal, Plant-Based Meat Alternatives (PBMA), and Whole Food Plant-Based (WFPB)-in random order.|f|f|f|t
33684340|NCT00314587|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684341|NCT01141062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684342|NCT03344523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684343|NCT02102256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684344|NCT06297252|NA|SINGLE_GROUP||OTHER||NONE||||||
33684345|NCT04762901|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33684346|NCT00081510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684347|NCT00473980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684348|NCT01597115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684349|NCT06272097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33684350|NCT04014374|||COHORT||OTHER|||||||
33684351|NCT03079544|||CASE_ONLY||OTHER|||||||
33684352|NCT00400608|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684353|NCT03603327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684354|NCT01998984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684355|NCT05915039|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"A faculty member without knowledge of the intervention and outcomes will randomize all subjects into 2 separate groups using random generated numbers from a computer software program:~1. Control Group - Group B - Will not receive the CAL module training for the first retest session (T1), but will for T2.~2. Experimental Group - Group A will complete the CAL module ahead of the first retest date (T1), but not for T2.~Allocation of subjects to each group will be concealed in envelopes so that no other researcher knows who was assigned to a particular group (allocation concealment). The faculty member who performs the randomization and allocation will be the only researcher with knowledge of group allocation. This individual will open the envelopes and send the corresponding CAL module training link at the time points designated above. This faculty member is not involved in the class and has no knowledge of the outcomes or training provided."|"This study will utilize a randomized crossover design. Students enrolled in this study will undergo traditional blood pressure training. The students will be randomly divided into 2 groups (control and experimental). All students will undergo baseline testing 2 weeks after the class. At 48 hours before the 2 month timepoint, the experimental group will complete a CAL module entitled: BP Measurement: Student Essentials. The control group will not undergo any retraining activities. All students will retest for accuracy, confidence, and knowledge. At the second 2 month mark, the control group will complete the CAL module and the experimental group will not. All students will retest for accuracy, confidence, and knowledge. All participants, the faculty teaching BP, and outcome assessors will be blinded from knowledge of groups throughout to reduce bias risk."|t|t|t|t
33684356|NCT03199443|||COHORT||PROSPECTIVE|||||||
33684357|NCT06451731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684358|NCT04772742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684359|NCT01145638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684360|NCT02364401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684361|NCT02004639|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33684362|NCT00828373|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33684363|NCT05049720|NA|SINGLE_GROUP||OTHER||NONE||||||
33684364|NCT06418464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684365|NCT03130647|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Repeated measures sham controlled||||
33684366|NCT01849887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684367|NCT05287360|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33684368|NCT04189471|||COHORT||PROSPECTIVE|||||||
33684369|NCT04449731|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33684370|NCT00057980||||TREATMENT||||||||
33684371|NCT05662566|||CASE_CONTROL||RETROSPECTIVE|||||||
33684372|NCT00958997|||CASE_CONTROL||PROSPECTIVE|||||||
33684373|NCT02201550|||CASE_ONLY||PROSPECTIVE|||||||
33684374|NCT04507373|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|Double Blind||t|t|t|f
33684375|NCT02409108|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33774726|NCT06740643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774727|NCT05774678|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774728|NCT05669664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774729|NCT05129020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each clinical site will have NICU nurses that will perform the Finnegan scale and be blind to the subjects' group designation. This will ensure a non-biased assessment of the Finnegan score, and importantly morphine dosing. Information regarding study intervention will be withheld from the blinded NICU nurses. NNNS assessors will also be blinded to information regarding study intervention to prevent biased NNNS scoring. All investigators will be blinded to subject treatment group.|This study is designed as a randomized, double-blind, sham-controlled, multi-center, clinical trial in which neonates diagnosed with Neonatal Opioid Withdrawal Syndrome (NOWS) will be randomized 1:1 into one of two treatment groups.|t|t|t|t
33774730|NCT03964571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774731|NCT04613635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774732|NCT06706739|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33684376|NCT04951297|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33684377|NCT04510636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774733|NCT05728944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked treatment will be used to reduce potential of bias during data collection and evaluation of clinical endpoints.|A multi-center, double masked, randomized, efficacy and safety study|t|t|t|t
33904371|NCT01220310|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33904372|NCT03684161|||CASE_CONTROL||PROSPECTIVE|||||||
33904373|NCT04866459|||OTHER||OTHER|||||||
33684378|NCT05402033|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33774734|NCT06737692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single-blind, meaning that the Outcomes Assessor and the researcher implementing the exercise program will be different individuals. The Outcomes Assessor will not be aware of which group the participants belong to.|A total of 40 participants aged 18 to 65, diagnosed with gastrointestinal cancer and cachexia, will be included in the study. Participants will be randomly assigned to the exercise group (aerobic and resistance training) or the control group (standard care), with 20 individuals in each group. The study will be single-blind, meaning the Outcomes Assessor will not know which group the participants belong to.|f|f|f|t
33904374|NCT06111326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774735|NCT06015282|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774736|NCT03958565|||OTHER||PROSPECTIVE|||||||
33684379|NCT01227824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774737|NCT06646848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective, randomized controlled trial|f|f|f|t
33684380|NCT05420753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684381|NCT05066555|||COHORT||PROSPECTIVE|||||||
33774738|NCT05727670|NA|SINGLE_GROUP||TREATMENT||NONE|development of a method for the treatment of extension of s with acceleration of treatment time|"At the first stage of our study, it is planned to examine patients aged 15-35 years. The examination will be carried out according to the scheme including the main (clarification of complaints, anamnesis collection, external examination, examination of the oral cavity and teeth) and additional examination methods (anthropometric examination of diagnostic models of dentition, cone-beam computed tomography of the head, orthopantomography, telerentgenography of the head, electrodontodiagnostics, determination of the area of occlusal contacts).~At the second stage of our study, it is planned to sample the results with the division of patients into the main and control groups. The main group will include patients who will receive orthodontic treatment according to the method we have proposed. The control group will include patients whose treatment will be carried out according to the standard method"||||
33774739|NCT05446870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774740|NCT06739161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774741|NCT06350071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33904375|NCT01594476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904376|NCT00403117|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|double-blind, placebo-controlled||t|f|t|f
33904377|NCT03610971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904378|NCT04393181|||COHORT||PROSPECTIVE|||||||
33904379|NCT04238663|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33904380|NCT00679159|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987124|NCT02911792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987125|NCT05954546|||COHORT||RETROSPECTIVE|||||||
33987126|NCT00752973|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987127|NCT05855785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987128|NCT02408302|RANDOMIZED|PARALLEL||||NONE||||||
33684382|NCT00386971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684383|NCT02847572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684384|NCT02924415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33684385|NCT00832910|||CASE_CONTROL|||||||||
33684386|NCT03340103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Pilot study, non-commercial, with food supplement, treated vs. control with a ratio 1: 1 double-blind. The identical vials, corresponding to placebo and active product, have an alphanumeric code without meaning for the operator, but that identifies the treaties from controls, in an anonymous document kept by the Statistical. The document will be placed in a sealed and anonymous envelope and it will be kept open by the statistician at the time of data analysis.|"Since birth, premature newborns, that are comply with the inclusion parameters, will be introduced and separated in two random groups (A and B).~All newborns, during the observation period, will be submitted to the blood collection (1 ml) from the umbilical cord and peripheral site (at the same time with the routine collections) on which there will be performed blood gas analysis and oxidative stress markers (TH and BAP)"|t|t|t|f
33684387|NCT02747433|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Single blind study.||f|f|f|t
33684388|NCT03934814|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33684389|NCT01476202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904381|NCT03702205|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33904382|NCT02445378|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33904383|NCT03143582|NA|SINGLE_GROUP||OTHER||NONE||This is an open-label pilot study examining the effects of exercise on mood, learning, memory, attention, stress, and sleeping habits.||||
33904384|NCT05393583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Blinding not possible|"2-armed study~* arm 1: outpatient hysterectomy (discharge the day of the operation)~* arm 2: inpatient hysterectomy (1 night hospital stay)"||||
33904385|NCT02561416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33987129|NCT04408794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987130|NCT02259283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987131|NCT00440453|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33987132|NCT00001703|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987133|NCT00319930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987134|NCT01521481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987135|NCT05293886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987136|NCT00223457|||DEFINED_POPULATION||OTHER|||||||
33987137|NCT03374605|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33987138|NCT05270733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987139|NCT03647215|||COHORT||PROSPECTIVE|||||||
33987140|NCT01093053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684390|NCT01027273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33987141|NCT03047486|||COHORT||PROSPECTIVE|||||||
33987142|NCT03059628|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987143|NCT06131437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987144|NCT00450190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987145|NCT05732857|RANDOMIZED|PARALLEL||TREATMENT||NONE||control arm: patients in which traditional laparoscopic trocar is used intervention arm: patients in which the valveless trocar is used||||
33774742|NCT04158154|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study applies an interrupted time series design.||||
33684391|NCT03134079|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Subjects were blind to what version (recipe) of the taste test item they were tasting.|Subjects were asked to taste test 3 versions of test items (in randomized order) and provide a liking score for each (tastings of each recipe were done on separate occasions separated by one week)|t|f|f|f
33684392|NCT06402994|||OTHER||CROSS_SECTIONAL|||||||
33684393|NCT04935671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blocked randomization technique has done via software|The study design will be prospective, randomized, open-labeled, blinded end-point trial for a period of 4-weeks.|f|f|f|t
33684394|NCT01787344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774743|NCT05597306|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation/de-escalation and dose expansion design.||||
33684395|NCT05535218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684396|NCT05272436|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This study aimed to explore:~* patients, clinicians, family members perceptions of the effect of IVR on ULMI rehabilitation (range of movement (ROM) recovery)~* patient perceptions of the usability, quality of live, acceptability, engagement with and enjoyment of IVR scenarios;~* occupational therapies perceptions about the usability and implications of the IVR technology within a patient rehabilitation at home.~Methods: This was a small-scale mixed methods (quantitative and qualitative) study.~Patients: paediatric patients recruited from Sheffield Children's Foundation Hospital Trust in England, UK, their parents, and an occupational therapist (OT) from the Sheffield Children's Foundation Hospital Trust for Burns, Plastics, and Orthopaedics participated in the study"||||
33684397|NCT05993013|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684398|NCT02735499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684399|NCT06271473|RANDOMIZED|PARALLEL||TREATMENT||NONE||"20 eyes of 20 patients will be divided randomly into 2 groups:~* Group (A): 10 eyes subjecting to vitrectomy + ILM peeling only~* Group (B): 10 eyes subjecting to vitrectomy + ILM peeling + planned foveal detachment via subretinal injection of ringer's solution."||||
33684400|NCT02760043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33684401|NCT00241501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33684402|NCT05937776|||COHORT||PROSPECTIVE|||||||
33684403|NCT06522984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684404|NCT05519332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684405|NCT03189381|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33684406|NCT04390932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Opaque sealed envelopes.||t|f|t|t
33684407|NCT04440423|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33684408|NCT00348933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774744|NCT01087320|||COHORT||PROSPECTIVE|||||||
33774745|NCT05022485|||CASE_CONTROL||PROSPECTIVE|||||||
33774746|NCT04975230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Both conditions will receive time-balanced sessions with the study team. Participants will not be told whether in the experimental condition or the condition delivering usual care until after the completion of the study.|Behavioral: Sleep self-management|t|f|f|f
33774747|NCT06739720|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned in a 1:1 ratio to either the intervention group or the waitlist group. The intervention group receives CP003 capsules (5 capsules once daily) for 6 weeks. The waitlist group undergoes a 6-week waiting period without any treatment.||||
33774748|NCT05151341|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33774749|NCT06609590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774750|NCT06734728|NA|SINGLE_GROUP||TREATMENT||NONE||Post-marketing, prospective, within-subject controlled clinical trial to evaluate the efficacy and safety of a medical product for the treatment of cold sores, over a period of 14 days or until the outbreak subsides. A group of 35 adult subjects was established, with the sample size determined statistically.||||
33684409|NCT01728233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774751|NCT05772104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774752|NCT06522165|||COHORT||RETROSPECTIVE|||||||
33774753|NCT05652205|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33904386|NCT01429012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904387|NCT05513612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904388|NCT00004640|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33904389|NCT04791397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904390|NCT05318625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904391|NCT02183467|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33684410|NCT05959980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684411|NCT00713232|||COHORT||CROSS_SECTIONAL|||||||
33904392|NCT06149312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904393|NCT05836012|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33904394|NCT03189576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987146|NCT00501397|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987147|NCT03733158|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33987148|NCT05125211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987149|NCT02504138|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987150|NCT02598323|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33987151|NCT01139320|||COHORT||RETROSPECTIVE|||||||
33987152|NCT04042363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients as well as ophthalmologists will be subject to the procedure of masking and will keep the blinding for the duration of the study. As a result, ophthalmologists examiners will not perform electrical stimulation sessions.~The persons in charge of the stimulation will be in open label and will ensure the inclusion, the follow-up of the patient throughout the study, the stimulation (SHAM or stimulation), the clinical and neurological examination as well as the collection of the treatments and the notification of the Adverse Events/Serious Adverse Events (AE/SAE)."||t|f|f|t
33987153|NCT03876769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987154|NCT01262469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987155|NCT02847650|RANDOMIZED|||TREATMENT||TRIPLE|||t|t|t|f
33987156|NCT05247463|||COHORT||OTHER|||||||
33987157|NCT00487565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987158|NCT02937870|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33987159|NCT01677494|||COHORT||PROSPECTIVE|||||||
33987160|NCT04739384|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987161|NCT02485522|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33987162|NCT00644345|||CASE_CONTROL||PROSPECTIVE|||||||
33684412|NCT01097083|RANDOMIZED|||TREATMENT||||||||
33987163|NCT06243835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987164|NCT06339515|NA|SINGLE_GROUP||OTHER||NONE||Universal Design Model for Learning||||
33987165|NCT03235388|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33684413|NCT05054660|NA|SINGLE_GROUP||OTHER||NONE||psychiatry outpatient using the investigator-developed-chatbot, and evaluate effectiveness, acceptability, usability, and adoption||||
33684414|NCT05587946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Effect of Virtual Reality Application Used During Endoscopy on Pain, Anxiety and Vital Signs: A Mixed Methods Study||||
33684415|NCT00859261|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33684416|NCT04363398|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants (teachers and students) are not aware of what arm they are randomized to. The primary investigators performing the analysis and overseeing all decisions are blinded to the schools receiving the comprehensive vs standard follow-up.|A Hybrid (effectiveness-implementation) Type 2 RCT design will be conducted. Teams will be randomized into either a comprehensive or standard intervention delivery group.|t|f|t|f
33684417|NCT01514786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33684418|NCT06208930|NA|SEQUENTIAL||TREATMENT||NONE||||||
33684419|NCT02430129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684420|NCT06275529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684421|NCT03304444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684422|NCT00657410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684423|NCT02605044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684424|NCT03726554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684425|NCT02732197|||COHORT||RETROSPECTIVE|||||||
33684426|NCT01136200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684427|NCT00184769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684428|NCT03279627|||OTHER||PROSPECTIVE|||||||
33684429|NCT01138878|||||CROSS_SECTIONAL|||||||
33684430|NCT00184171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684431|NCT05814354|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel model, randomized at a 1:1 ratio||||
33684432|NCT01294527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684433|NCT02106923|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684434|NCT01149954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684435|NCT01599143|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33774754|NCT06741241|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will complete surveys and receive virtual education sessions and not know if they are in control arm or intervention arm.|Participants will be randomly assigned to the eHealth promotora intervention where they will participate in a group education session of cervical cancer screening or a control group where they will participate in a group education session on healthy nutrition.|t|f|f|f
33774755|NCT06407063|||COHORT||OTHER|||||||
33987166|NCT00579670|||COHORT||PROSPECTIVE|||||||
33987167|NCT01667627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987168|NCT01275469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987169|NCT05048004|||COHORT||PROSPECTIVE|||||||
33987170|NCT01181622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987171|NCT05665062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987172|NCT03469219|||CASE_CONTROL||RETROSPECTIVE|||||||
33987173|NCT03122015|RANDOMIZED|PARALLEL||TREATMENT||NONE||This pilot study will include a group that will receive the intervention of distraction by the therapeutic clown (CT) and the other that will receive the standard treatment. The study will take place at St. Justine's Hospital, precisely at the infectious diseases clinic. Recruitment of participants will be by convenience from parents and children who will be eligible for study. The sample of this pilot project will contain approximately 24 children in addition to parents and the nurse who will perform the painful procedure.||||
33987174|NCT03092661|||COHORT||PROSPECTIVE|||||||
33987175|NCT03848507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987176|NCT02159950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987177|NCT03127826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Primary care providers will be unaware of risk stratification scores.||f|t|f|t
33987178|NCT04140877|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, contralateral eye study|t|f|t|t
33987179|NCT06065150|RANDOMIZED|PARALLEL||TREATMENT||NONE|non applicable|Multicentre randomized open-label controlled trial||||
33987180|NCT05048017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987181|NCT06097819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987182|NCT02128997|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987183|NCT04414917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham injection versus injection of local anesthetic as the Twin block|Prospective randomized blind clinical trial of patients undergoing lower third molar extraction/s to evaluate the ability of the Twin block (local anesthetic nerve block) on side of extraction to reduce post-operative pain and pain medication utilization monitoring with an active pill dispenser|t|f|f|t
33987184|NCT05249634|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive treatment with JATENZO||||
33987185|NCT06002230|||COHORT||RETROSPECTIVE|||||||
34081149|NCT01876095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34081150|NCT00944918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081151|NCT02192671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684436|NCT01640327|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774756|NCT06740825|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking.|||||
33684437|NCT02700503|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684438|NCT02763969|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33684439|NCT04636853|NA|SEQUENTIAL||TREATMENT||NONE||||||
33684440|NCT03785093|||FAMILY_BASED||PROSPECTIVE|||||||
33684441|NCT04729400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assesor|A specialist physician will be diagnosed the epicondylitis|t|f|f|f
33774757|NCT06028529|NA|SINGLE_GROUP||OTHER||NONE||Safety, tolerability, feasibility, methodological assessment, and sample characteristics with consideration of multiple staging and high patient variability towards the design of a future clinical efficacy study.||||
33774758|NCT06701617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774759|NCT00039689|||COHORT||PROSPECTIVE|||||||
33774760|NCT06740149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774761|NCT06738797|||CASE_ONLY||PROSPECTIVE|||||||
33774762|NCT06581627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774763|NCT04274543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to treatment group when analyzing data for publication.||f|f|f|t
33774764|NCT00686335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774765|NCT03785873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774766|NCT05737940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774767|NCT06729424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774768|NCT03625323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774769|NCT06636149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774770|NCT06644261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be unable to remain masked to treatment intervention. Procedurists will also be unable to remain masked.|Parallel prospective randomized non-inferiority trial with option for cross-over|f|f|t|t
33774771|NCT03702270|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||During the trial, randomization will occur using a stepped wedge cluster randomized controlled trial design. Medical units at VUMC will be assigned to clusters. A single cluster will be selected for intervention at the outset of the trial. Subsequent additional clusters will first contribute to the control group, and be selected to randomly cross over to the intervention group at regular intervals of 1 months.||||
33774772|NCT05959863|||CASE_CONTROL||PROSPECTIVE|||||||
33774773|NCT06275815|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33774774|NCT02902328|||COHORT||PROSPECTIVE|||||||
33774775|NCT06730685|||COHORT||PROSPECTIVE|||||||
33774776|NCT06644157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774777|NCT05645536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774778|NCT05457998|||COHORT||PROSPECTIVE|||||||
33774779|NCT06649149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Students will not know which group they are in. The data of the research will be entered by coding and the result evaluator will not know which group the students are in.|It is a randomized controlled trial in parallel groups.|t|f|f|t
33774780|NCT05960734|||OTHER||CROSS_SECTIONAL|||||||
33774781|NCT05459688|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients from Study CIN-107-124 who elect to participate in this study will continue treatment with 2 mg CIN-107 tablets QD after enrollment, starting at Visit 1 and concluding at EOT (Visit 7)||||
33987186|NCT05294081|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, multicentre, randomised, controlled, open-label, two-arm intervention study with a parallel group design.~Two parallel groups are formed, the intervention group receives 10 sessions of EXP therapy, the control group receives 10 sessions of CBT.~The assignment to the therapy methods is randomised. This is a multicentre study, the study will be conducted at 5 centres throughout Germany. A total of 380 patients will be included. Per study arm, 190 patients must be included."||||
33987187|NCT01787786|||COHORT||PROSPECTIVE|||||||
33987188|NCT03514420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987189|NCT01289262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987190|NCT05737836|||CASE_CROSSOVER||PROSPECTIVE|||||||
33987191|NCT04519749|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774782|NCT05271409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774783|NCT06483204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33774784|NCT06630234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774785|NCT05298904|||COHORT||PROSPECTIVE|||||||
33774786|NCT06740383|||COHORT||PROSPECTIVE|||||||
33774787|NCT06215586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774788|NCT06738485|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774789|NCT05129631|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33774790|NCT06094010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774791|NCT06056219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33774792|NCT05554367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774793|NCT04666129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774794|NCT06211036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774795|NCT06049797|||COHORT||PROSPECTIVE|||||||
33774796|NCT06148532|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33774797|NCT01282021|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33774798|NCT06736912|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33774799|NCT01313442|||COHORT||PROSPECTIVE|||||||
33774800|NCT03604978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987192|NCT01038947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987193|NCT03422770|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Analysis will be blinded|All participants will undergo 'echo', bloodtests and MRI. Participating patients will in addition undergo electrocardiogram (ECG/Holter ECG) and 6 min walking test.|f|f|f|t
33987194|NCT06181175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analysis is blind||f|f|t|f
33987195|NCT06181006|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33987196|NCT06559423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987197|NCT06328491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987198|NCT02950272|||COHORT||PROSPECTIVE|||||||
33987199|NCT04930796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987200|NCT01874561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987201|NCT02287051|||COHORT||PROSPECTIVE|||||||
33987202|NCT02925247|NA|SINGLE_GROUP||OTHER||NONE||||||
33987203|NCT04535076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33987204|NCT04992611|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE||Mechanistic clinical trial seeking to determine why there we have seen a difference in dietary response to sleep extension across chronotypes, with adolescent Morning Larks showing a dramatic protective effect not shared by Night Owls.|f|f|f|t
33987205|NCT02129491|||CASE_ONLY||PROSPECTIVE|||||||
34081152|NCT02109757|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33904395|NCT06672536|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34081153|NCT05303116|||COHORT||PROSPECTIVE|||||||
33904396|NCT01660841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904397|NCT00292292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904398|NCT05416229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||single-centre, randomised, double-blinded, placebo-controlled, 1:1 parallel-group clinical trial|t|t|t|t
33987206|NCT01452802|||COHORT||PROSPECTIVE|||||||
33987207|NCT04123808|NA|SINGLE_GROUP||TREATMENT||NONE|An occupational therapist independent to the study will review and score 2 outcome measures (Fugl-Meyer and Action Research Arm Test). The study coordinator will randomize the order of the videos for each participant, so that the outcome assessor will not know which time point they are scoring. In other words, the video-outcome assessor will be blinded to the order of the assessments as they are scoring them but will not be blinded to the intervention as all participants will be receiving the same intervention.|||||
33987208|NCT05324098|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33987209|NCT02974556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33904399|NCT06129994|||COHORT||PROSPECTIVE|||||||
33987210|NCT04975035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987211|NCT03914183|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized control study of control (current standard of care) versus mCPN intervention||||
34081154|NCT04113044|||COHORT||PROSPECTIVE|||||||
34081155|NCT00144430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081156|NCT00792285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904400|NCT01576861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33904401|NCT03336398|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33904402|NCT00619931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987212|NCT00287014|||||PROSPECTIVE|||||||
34081157|NCT05410678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081158|NCT02617615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081159|NCT00716456||PARALLEL||TREATMENT||NONE||||||
34081160|NCT02652169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987213|NCT05093309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33987214|NCT02393417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987215|NCT03673670|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The nebulizer cup will be obscured so the contents are not visible to the subject and the blinded study staff.||t|f|t|t
33987216|NCT00015626|RANDOMIZED|||TREATMENT||DOUBLE||||||
34081161|NCT01268163|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081162|NCT02076386|||OTHER||PROSPECTIVE|||||||
34081163|NCT04805268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081164|NCT03877913|||COHORT||PROSPECTIVE|||||||
34081165|NCT03622762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081166|NCT01423825|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34081167|NCT03227250|||COHORT||PROSPECTIVE|||||||
34081168|NCT05021640|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Participants, Investigators, site staff, the CRO staff, and the Sponsor Medical Monitor will be blinded to the randomization. Other members of the Sponsor staff will be unblinded for the duration of the study. Complete details will be presented in the Study Blinding Plan.||t|f|t|f
34081169|NCT05021653|||CASE_ONLY||PROSPECTIVE|||||||
34081170|NCT01934465|||COHORT|||||||||
34081171|NCT04347408|||CASE_CONTROL||PROSPECTIVE|||||||
34081172|NCT00400075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081173|NCT05784051|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The SUPPRESS study will be a national multicenter randomized open label trial using the PROBE study design (Prospective Randomized Open Blinded End-point).~Patients fulfilling the inclusion criteria (asymptomatic patients with frequent (\> 10%/day) PVCs and normal LVEF) and without any exclusion criteria that agree to enter the protocol will be randomized to:~1. Experimental group: 149 patients treated for PVCs with drug therapy and/or catheter ablation/ medical treatment including drug administration ± catheter ablation (Ablation can be performed if the PVC burden remain \>10% after 2 lines of AAD treatment).~2. Control group: 149 patients with therapeutic abstention or no treatment modification such as drug therapy/ Therapeutic abstention or no modification of therapy"||||
34081174|NCT01162733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081175|NCT03818152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081176|NCT06521177|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||A crossover trial where participants are randomized to receive either Hand Serum alone or Hand Serum with Glove in the first period, followed by the alternate intervention in the second period.||||
34081177|NCT00419536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081178|NCT01625468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081179|NCT06269302|||OTHER||CROSS_SECTIONAL|||||||
34081180|NCT05733897|||CASE_ONLY||RETROSPECTIVE|||||||
34081181|NCT01183364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081182|NCT01811732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081183|NCT03347383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904403|NCT01670851|||COHORT||PROSPECTIVE|||||||
33904404|NCT02284906|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904405|NCT01392989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904406|NCT06671795|||COHORT||PROSPECTIVE|||||||
33904407|NCT05232591|||CASE_ONLY||CROSS_SECTIONAL|||||||
33904408|NCT06279585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904409|NCT00002141||||TREATMENT||DOUBLE||||||
33904410|NCT04841629|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33904411|NCT03505697|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33684442|NCT01565343|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33684443|NCT00943943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684444|NCT05609812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684445|NCT01012648|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33684446|NCT05587049|||COHORT||PROSPECTIVE|||||||
33684447|NCT02715297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684448|NCT00703703|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33684449|NCT03025100|||COHORT||PROSPECTIVE|||||||
33684450|NCT02756988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684451|NCT04731857|||COHORT||RETROSPECTIVE|||||||
33684452|NCT00591461|||CASE_ONLY||PROSPECTIVE|||||||
33684453|NCT00001860||||TREATMENT||||||||
33684454|NCT05982951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The block will be performed by one investigator who is not participating in either data collection or analysis. Also the patient will be blinded .||f|f|t|t
33684455|NCT05552144|||COHORT||PROSPECTIVE|||||||
33684456|NCT02827656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684457|NCT02219243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684458|NCT03416062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684459|NCT04877509|||COHORT||OTHER|||||||
33684460|NCT03726398|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684461|NCT06367218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987217|NCT01353664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987218|NCT00479258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774801|NCT05594992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774802|NCT06097650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904412|NCT04003506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904413|NCT03255525|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33684462|NCT03149601|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684463|NCT04955080|||COHORT||PROSPECTIVE|||||||
33684464|NCT06095622|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33684465|NCT01820260|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Masking only for Part 2|Part 1 was an open-label, dose escalation. Part 2 was a randomised, double-blind, parallel group|t|t|t|t
33684466|NCT00130442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684467|NCT05541588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33987219|NCT04555889|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"* All babies wether they experience the intervention ofr not they can not tell to other peoples.~* Only The lab analyzer will be blind to the subject of study, other measurement can not be blind."|The impact of lung recruitment maneuver in 24-32 weekers with assist-control volume guarantee mode to their hemodynamic status and the incidence of Bronchopulmonary dysplasia|t|f|f|t
33987220|NCT00398515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987221|NCT02713321|||COHORT||RETROSPECTIVE|||||||
33987222|NCT02060760|||COHORT||PROSPECTIVE|||||||
33987223|NCT03324594|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Throughout the study, neither participating couples, clinic staff, research assistants or researchers are masked to condom assignment as there are observable differences on packaging and design between the test condom (WLC and WLM) and the control condom (durex-Together). However, statisticians, sponsors, and medical reviewers are masked until completion of the final report to minimize biases potentially emerge during data analyses and results reporting.||f|f|f|t
33987224|NCT05474365|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33987225|NCT04465864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group 1: intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)~Group 2: intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)"|t|f|f|f
33987226|NCT02982356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987227|NCT06223464|||CASE_CONTROL||PROSPECTIVE|||||||
33987228|NCT00240747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987229|NCT01152840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987230|NCT04264130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987231|NCT01123694|||CASE_ONLY||CROSS_SECTIONAL|||||||
33987232|NCT04533893|||OTHER||CROSS_SECTIONAL|||||||
33987233|NCT01401647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987234|NCT01111864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33684468|NCT00073853|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987235|NCT03622801|||CASE_CONTROL||RETROSPECTIVE|||||||
33987236|NCT00972218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987237|NCT03127085|||COHORT||PROSPECTIVE|||||||
33987238|NCT02160925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987239|NCT03850795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987240|NCT03965091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987241|NCT03202238|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33987242|NCT06192095|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987243|NCT02967107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987244|NCT01995591|||COHORT||PROSPECTIVE|||||||
33987245|NCT01273779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987246|NCT01845298|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987247|NCT02491905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987248|NCT04029272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987249|NCT01457716|RANDOMIZED|CROSSOVER||||NONE||||||
33987250|NCT03476265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987251|NCT05316428|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34081184|NCT02074202|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34081185|NCT04968678|||COHORT||PROSPECTIVE|||||||
33684469|NCT03271983|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33684470|NCT01351870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684471|NCT05470257|RANDOMIZED|PARALLEL||TREATMENT||NONE|Casting is an external treatment that cannot be masked from investigators or participants.|Two cohorts will be established. One will include patients casted in elbow extension. The other cohort will include patients casted in elbow flexion.||||
33684472|NCT06437704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684473|NCT03462901|NA|SINGLE_GROUP||TREATMENT||NONE||Fracture clavicle in adults||||
33684474|NCT06246955|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684475|NCT00035347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684476|NCT06397521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three techniques for aesthetic crown lengthening|f|f|t|t
33684477|NCT02915328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684478|NCT05849285|||COHORT||PROSPECTIVE|||||||
33774803|NCT05136651|RANDOMIZED|PARALLEL||TREATMENT||NONE||Waitlist-control design. Participants will be randomly assigned to receive either immediate treatment or treatment after a 2-month waiting period. The intervention received is the same in both conditions; only the timing differs.||||
33774804|NCT01031407|||COHORT||CROSS_SECTIONAL|||||||
33774805|NCT05784740|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33774806|NCT06170671|||COHORT||RETROSPECTIVE|||||||
33904414|NCT03344159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be blinded to study treatment for the duration of the study. Clinicians will also be blinded to study drug assignment. Evaluation of all study results will be done blinded to treatment randomization. Because of the double-blind design, safety laboratory tests, and monitoring of potential side effects will be performed for each participant for the duration of the trial, regardless of the treatment arm.|STAR-HF is a phase 4 single center, randomized, placebo controlled trial comparing spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated to matching placebo.|t|t|t|t
33904415|NCT04365816|||COHORT||PROSPECTIVE|||||||
33904416|NCT04704882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33904417|NCT00958568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904418|NCT03981575|||OTHER||PROSPECTIVE|||||||
33904419|NCT04844047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors were blinded to intervention||f|f|f|t
33904420|NCT04376268|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33904421|NCT04833075|NA|SINGLE_GROUP||OTHER||NONE||A low-interventional cross-sectional pharmacokinetic study.||||
33904422|NCT01753115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904423|NCT01128972|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34081186|NCT03540264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blind to the treatment assigned to indivivual patients.||f|f|f|t
34081187|NCT05802017|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
34081188|NCT02832778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081189|NCT00155714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081190|NCT01126892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081191|NCT04870996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081192|NCT03905733|||COHORT||PROSPECTIVE|||||||
34081193|NCT05374447|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The participant will be blinded to which group they were randomized to.|1:1 randomization to EBUS-TBNA alone or EBUS-TBNA and EBUS-IFB|t|f|f|f
34081194|NCT02560285|||COHORT||PROSPECTIVE|||||||
34081195|NCT00305162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081196|NCT00025389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081197|NCT02539069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081198|NCT05932888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684479|NCT06167343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33684480|NCT04357301|NA|SINGLE_GROUP||TREATMENT||NONE||Single prospective pilot study (12 patients)||||
33684481|NCT03286127|||CASE_ONLY||PROSPECTIVE|||||||
33684482|NCT01146860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684483|NCT02040675|||CASE_ONLY||PROSPECTIVE|||||||
33684484|NCT02919384|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33684485|NCT00252044|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33684486|NCT01535300|||CASE_ONLY||PROSPECTIVE|||||||
33684487|NCT05658523|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and those evaluating reactogenicity will be blinded to the vaccine allocation for the first 7 days following vaccination. After that, both clinical investigators and participants will be aware of their investigational product. Laboratory staff will remain blinded to the investigational product.|Study participants who have previously received 3 COVID-19 vaccines will be either randomised into one of two vaccine groups or be part of a self-selected control group. Randomised participants will receive a standard dose of either the bivalent Moderna or the protein-based Novavax vaccine. 200 non-randomised participants will be part of a control group and will not receive any COVID-19 vaccine.|t|f|t|f
33684488|NCT02789319|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33684489|NCT00555425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684490|NCT03272269|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-blind, placebo controlled||t|t|t|f
33684491|NCT01030601|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684492|NCT01197001|RANDOMIZED|CROSSOVER||||NONE||||||
33684493|NCT06053710|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684494|NCT02694432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684495|NCT04649580|||COHORT||CROSS_SECTIONAL|||||||
33684496|NCT03003299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684497|NCT02057042|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33684498|NCT02542930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684499|NCT05054842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SP2086 VS. Placebo|t|t|t|t
33774807|NCT05384561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081199|NCT01162616|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34081200|NCT05058989|||COHORT||RETROSPECTIVE|||||||
34081201|NCT03949881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684500|NCT01663077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684501|NCT02068768|||COHORT||PROSPECTIVE|||||||
33774808|NCT05522868|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Traditional 3+3 Dose Ascending design||||
33774809|NCT05008042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial with Three-month follow up|t|f|t|f
33774810|NCT04306367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774811|NCT05324371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774812|NCT06225297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study participants, community health workers, and study field staff will not be blinded to intervention assignment. However, the trial statistician and laboratory technicians carrying out subsequent analyses in reference laboratories will remain blinded.||f|f|f|t
33774813|NCT03759522|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774814|NCT02310399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081202|NCT06135181|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel-group, consecutive cohort, escalating single-dose study design|t|f|f|f
34081203|NCT05859217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081204|NCT01202500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081205|NCT03106688|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34081206|NCT00909168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081207|NCT03885908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The proposed study is a randomized controlled trial study.||||
34081208|NCT03143257|||COHORT||OTHER|||||||
34081209|NCT04621799|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective evaluation of a cohort of patients with a specific characteristic over time to see if they develop a particular endpoint or outcome based on a stated hypothesis||||
34081210|NCT03181152|||COHORT||PROSPECTIVE|||||||
34081211|NCT00764790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34081212|NCT03467074|||COHORT||PROSPECTIVE|||||||
34081213|NCT02383524|||COHORT||PROSPECTIVE|||||||
34081214|NCT01739881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081215|NCT00512590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081216|NCT01012427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081217|NCT04816916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081218|NCT00345488|||DEFINED_POPULATION||PROSPECTIVE|||||||
34081219|NCT05108766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081220|NCT01936766|||CASE_CONTROL||PROSPECTIVE|||||||
33774815|NCT06740994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081221|NCT00652847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081222|NCT02169440|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081223|NCT05337046|||COHORT||PROSPECTIVE|||||||
34081224|NCT04126434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904424|NCT03333785|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Improving Cancer Care Together through eOncoNote is a concurrent mixed-methods hybrid type I effectiveness-implementation study design. Effectiveness of eOncoNote will be assessed by a pragmatic randomized controlled trial with individual patient randomization and outcomes measured at the patient level. Implementation will be assessed using a mixed methods process evaluation involving key stakeholders to assess barriers and facilitators to implementation of the intervention.||||
33684502|NCT03168529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Subjects will be randomized at baseline, then at discharge dispensed a uniquely coded IP bottle. The randomization numbers to each IP bottle will be generated and maintained in an outside dataset or randomization key. The subject ID and corresponding randomization number, recorded in REDCap, will correlate which subjects are in each group, Ivabradine or placebo.~In the case of an emergent medical event, where the unblinding of a subject is deemed medically necessary by the study PIs, the unblinded study personnel will consult the randomization key to unblind study treatment. Once a subject has been unblinded, the date, time and reason(s) for un-blinding will be recorded in the source documents and eCRF."|Prospective, randomized (1:1), placebo-controlled, double blind, study of ivabradine (Corlanor®)|t|t|t|t
33904425|NCT00872716|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33904426|NCT06286280|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant will not be informed about group allocation|single-center, two-arm randomized-controlled prospective study|t|f|f|f
33904427|NCT06077630|||COHORT||RETROSPECTIVE|||||||
34081225|NCT04771910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||All AD patients will receive both treatments (verum and placebo). Verum cream will be applied on one side of the body (elbow or knee cavities), the placebo cream on the other side.|t|t|t|t
34081226|NCT02154139|||COHORT||PROSPECTIVE|||||||
34081227|NCT02852421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081228|NCT02427009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34081229|NCT01757041|||COHORT||PROSPECTIVE|||||||
34081230|NCT03954093|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33904428|NCT00538382|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34081231|NCT00020657|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34081232|NCT04748003|||COHORT||PROSPECTIVE|||||||
34081233|NCT02416661|||COHORT||PROSPECTIVE|||||||
34081234|NCT01257347|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34081235|NCT05093582|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34081236|NCT05321667|||COHORT||RETROSPECTIVE|||||||
34081237|NCT03035162|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081238|NCT05387616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081239|NCT03874442|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081240|NCT03102502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel: Patiants with coronary heart disease are assigned to two groups in parallel for the duration of the study.|f|f|f|t
34081241|NCT02100839|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34081242|NCT00830765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081243|NCT01058447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34081244|NCT00228579|||COHORT||PROSPECTIVE|||||||
33904429|NCT01639859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904430|NCT00417365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33904431|NCT06214949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33904432|NCT01496573|||CASE_ONLY||RETROSPECTIVE|||||||
33904433|NCT01531218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904434|NCT04221074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33904435|NCT04734756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904436|NCT02560701|||COHORT||RETROSPECTIVE|||||||
33904437|NCT06532383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants will be assigned to receive study intervention according to the assigned treatment group from the randomization scheme. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study. In order to maintain this blind, an otherwise uninvolved third party will be responsible for the preparation and dispensing of all study intervention and will endeavor to ensure that there are no differences in time taken to dispense or visual presentation, following randomization or dispensing. This third party will instruct the participant to avoid discussing the taste, dosing frequency, or packaging of the study intervention with the investigator.|randomized, double-blinded (investigator- and participant-blinded), sponsor-open, placebo-controlled, 4-period, crossover, interleaving, first in human single ascending oral dose|t|t|t|f
34081245|NCT03373214|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081246|NCT04122261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081247|NCT00003062||||TREATMENT||||||||
34081248|NCT02459522|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34081249|NCT03225638|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081250|NCT03278574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081251|NCT00277004|||COHORT||PROSPECTIVE|||||||
34081252|NCT03179072|||COHORT||CROSS_SECTIONAL|||||||
33684503|NCT03472443|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33684504|NCT00410709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081253|NCT05650203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081254|NCT04227912|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081255|NCT04829071|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34081256|NCT02577640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081257|NCT00121056|||||PROSPECTIVE|||||||
34081258|NCT02191488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081259|NCT00176046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081260|NCT00563771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081261|NCT03028181|||OTHER||RETROSPECTIVE|||||||
34081262|NCT04102826|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34081263|NCT03524716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081264|NCT00897117|||COHORT||PROSPECTIVE|||||||
34081265|NCT02558049|NA|SINGLE_GROUP||OTHER||NONE||||||
34081266|NCT00270673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081267|NCT04745728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081268|NCT00196703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904438|NCT05908383|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This clinical study is a double-blind study, in which participants such as clinical researchers, project managers, and project monitors are unaware of the random coding and drug administration groups of the subjects. Non-blind monitoring during the clinical study will be conducted by non-blind monitors. In addition, drug preparation will be carried out by non-blind researchers independent of this study. Analysis and testing personnel will also adopt blind analysis.||t|t|t|t
33904439|NCT04004507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987252|NCT03452319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessor will not be aware of which group the patients are included in.|A single blind, randomized, controlled, intervention study. Evaluation of the addition of increased physical activity and respiratory muscle training for patients undergoing thoracoabdominal esophagus resection compared to standard care|f|f|t|f
33987253|NCT02410486|||COHORT||PROSPECTIVE|||||||
33987254|NCT03243474|||CASE_CROSSOVER||PROSPECTIVE|||||||
33904440|NCT05037903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987255|NCT03268538|||COHORT||PROSPECTIVE|||||||
33987256|NCT00944424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987257|NCT01350557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33987258|NCT00422214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33987259|NCT04553133|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33987260|NCT06456580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987261|NCT02409472|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987262|NCT02236494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904441|NCT05900414|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904442|NCT03716063|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study was double-blind. According to the randomized results, the experimental group was given orally therapeutic granules, while the control group was given orally low-dose granules. Random sequence was generated by professional statisticians of group leader unit by statistical software. 350 subjects were divided into experimental group and control group according to the ratio of 1:1, 175 cases in each group. Random seeds and random sequences are stored as confidential data in opaque envelopes, and emergency envelopes are handed over to a third party to ensure that patients, researchers and outcome evaluators are unaware of the patient group before blindness is uncovered. After successful screening and signing the informed consent form, the patient can open a random envelope in turn and record the subject's name, hospital number and admission time on the envelope.|This study was double-blind. According to the randomized results, the experimental group was given orally therapeutic granules, while the control group was given orally low-dose granules.|t|t|f|f
33904443|NCT02083250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904444|NCT01901471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904445|NCT05420467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904446|NCT04555655|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33904447|NCT00434850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904448|NCT00672542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904449|NCT03502759|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904450|NCT03435653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904451|NCT03092687|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904452|NCT03014661|||COHORT||RETROSPECTIVE|||||||
33904453|NCT02926573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904454|NCT05975567|||COHORT||PROSPECTIVE|||||||
33904455|NCT02022423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Four groups are included in this study||||
33987263|NCT02435823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987264|NCT01502254|RANDOMIZED|PARALLEL||||NONE||||||
33987265|NCT03522545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987266|NCT03595917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987267|NCT01746017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33987268|NCT02440308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987269|NCT02822326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987270|NCT04568785|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987271|NCT03155425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987272|NCT03644264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, Randomised, Active-controlled, Parallel Group, Multicentre,||||
33987273|NCT03332485|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33987274|NCT05167760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987275|NCT03195205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987276|NCT06202794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After the website (https://www.randomizer.org) generates a number sequence, blind allocation will be performed using consecutively numbered opaque envelopes. The envelopes will be sealed and stored in a secure cabinet. The main investigator will perform sample randomization and blind assignment. The researcher in charge of administering the treatments will open the envelopes immediately prior to the intervention. The patient, researcher and assessor will have no knowledge about the treatment applied (blinding of assessor and subjects). Only the researcher who administers the intervention (active or sham TENS) will have knowledge of the treatment and will instruct the participant not to provide information on the sensation of electrical stimulus to the assessor measuring pain levels.|A two-arm, randomized, sham-controlled trial will be conducted with blinded assessors.|t|t|t|f
33987277|NCT03796949|||CASE_CONTROL||PROSPECTIVE|||||||
33987278|NCT00987103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987279|NCT00657332|||COHORT||PROSPECTIVE|||||||
33987280|NCT03037697|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33684505|NCT06416995|||CASE_CONTROL||PROSPECTIVE|||||||
33987281|NCT01986491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987282|NCT02449265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987283|NCT00933686|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33987284|NCT00000294||||TREATMENT||DOUBLE||||||
33987285|NCT06094517|||OTHER||PROSPECTIVE|||||||
33987286|NCT05424029|||COHORT||PROSPECTIVE|||||||
33987287|NCT05212766|||COHORT||PROSPECTIVE|||||||
33987288|NCT03609866|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33987289|NCT06541886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be masked to whether they are in the Standard CBT-I or Teen CBT-I condition, but they may be able to determine which group they are in based on the nature of the treatment materials. The treatment material in Teen CBT-I was designed for and with teens so we anticipate that it will be more noticeably teen-friendly. Participants assigned to the waitlist condition will know about this assignment as they will not receive treatment with a therapist during the 6-week active treatment period. Care providers, investigators, and outcome assessors will be aware of group assignment with the exception that the team member scoring actigraphy will be blind to the treatment condition.|This study has a parallel intervention study model in that participants are assigned to one of three groups in parallel for the duration of the study-either Standard CBT-I, Teen CBT-I, or waitlist control for at least 8 weeks of treatment.|t|f|f|f
33987290|NCT00770822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081269|NCT01121471|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34081270|NCT04682899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081271|NCT04140773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081272|NCT02037893|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34081273|NCT06143397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blinded||f|f|f|t
34081274|NCT02004223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081275|NCT01331317|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34081276|NCT05733325|||COHORT||PROSPECTIVE|||||||
34081277|NCT04850651|NA|SINGLE_GROUP||OTHER||NONE||Pyrotinib alone and then combination with fluconazole||||
34081278|NCT02389660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34081279|NCT06134635|||COHORT||PROSPECTIVE|||||||
34081280|NCT02728908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081281|NCT00104052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081282|NCT05190796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34081283|NCT03400449|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups randomized to counseling type.||||
34081284|NCT01190891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081285|NCT01041859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081286|NCT02446691|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34081287|NCT01838746|||COHORT||RETROSPECTIVE|||||||
34081288|NCT03115034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081289|NCT04288947|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Training of midwives on 4 respectful maternal care modules.||||
34081290|NCT03837717|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Infants and mothers will be randomly assigned to the holding condition occurring on the second versus the third day of hypothermia.~On the day of holding, four samples of saliva will be obtained; two from the mother (pre and post holding) and two from the infant (pre and post holding). The first sample will be collected prior to holding, and the second sample immediately at the end of holding before the infant is placed back in the bed.~On the day without holding, four additional samples of saliva will be obtained; two from the mother (pre and post not holding) and two from the infant (pre and post not holding)."||||
34081291|NCT02870647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081292|NCT04331626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081293|NCT02367300|||CASE_ONLY||PROSPECTIVE|||||||
33987291|NCT05133817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987292|NCT03919149|||COHORT||PROSPECTIVE|||||||
33987293|NCT00239577|RANDOMIZED|PARALLEL||PREVENTION||||||||
33987294|NCT01450189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987295|NCT04132011|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Feasibility study of an n-of-1, within-subject, crossover, randomized, double blind, placebo controlled case series|t|t|t|t
33987296|NCT05132166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987297|NCT05857085|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 therapeutic arms - adding empagliflozin or semaglutide to basic insulin treatment and control arm in type 1 diabetic patients||||
33987298|NCT02294253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987299|NCT01202422|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33987300|NCT01773590|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33987301|NCT04739020|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987302|NCT04263857|||OTHER||OTHER|||||||
33987303|NCT04797195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987304|NCT06303726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987305|NCT00132262|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34081294|NCT02611882|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34081295|NCT04405752|||CASE_CONTROL||RETROSPECTIVE|||||||
34081296|NCT04451772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081297|NCT03943628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34081298|NCT05517629|||OTHER||CROSS_SECTIONAL|||||||
34081299|NCT02945436|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34081300|NCT01116336|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34081301|NCT04228484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Double-blinded randomized placebo-controlled study|t|t|t|f
34081302|NCT05696964|NA|SINGLE_GROUP||TREATMENT||NONE||"All participating medical residents in the study will receive the same motivational interviewing training.~Patients of these medical residents will be recruited to provide data on their perceptions of their relationship with their physician, as well as health indicators, but there is no direct intervention for patients themselves. The target number of patients is 200."||||
34081303|NCT03093922|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized phase II study testing two different schedules of atezolizumab combined with gemcitabine and cisplatin chemotherapy (GC) in patients with metastatic urothelial carcinoma (mUC) who are eligible for cisplatin.||||
34081304|NCT04868669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|In this study, the blinding of the intervention is not feasible. However, the outcomes of the trial are objective in nature. Furthermore, the randomization and the statistical analysis will be carried out by someone unconnected to the allocation and enrollment process.|prospective, two-arm, parallel-group, equal allocation, open-label, community-based, cluster-randomized controlled trial||||
34081305|NCT02338817|||COHORT||PROSPECTIVE|||||||
34081306|NCT05171322|||COHORT||PROSPECTIVE|||||||
34081307|NCT03567408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081308|NCT03468842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will follow a randomized, double-blind, placebo-controlled design with 2 parallel prospective follow-up groups.|t|f|t|f
34081309|NCT06551428|||CASE_ONLY||CROSS_SECTIONAL|||||||
34081310|NCT03586310|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34081311|NCT01271647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081312|NCT00001781||||TREATMENT||||||||
34081313|NCT03106116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081314|NCT00542893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081315|NCT01054963|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
34081316|NCT03984708|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34081317|NCT04758806|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible for the study are consecutive consenting adult patients||||
33987306|NCT05408884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Those assigned to the Miracle Money condition are not notified that they have been selected to receive monthly income until after they have actively engaged in the Miracle Friends intervention.||t|f|f|f
33987307|NCT06192303|||COHORT||PROSPECTIVE|||||||
33987308|NCT00581139|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33987309|NCT02209571|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33987310|NCT05047822|||COHORT||RETROSPECTIVE|||||||
33987311|NCT00000310|RANDOMIZED|||TREATMENT||DOUBLE||||||
33987312|NCT01330576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987313|NCT02708693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987314|NCT02987439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987315|NCT02372149|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33987316|NCT06406608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081318|NCT06496451|||COHORT||PROSPECTIVE|||||||
34081319|NCT01309386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081320|NCT03387605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double Blind, Placebo Controlled single center study.|t|t|t|f
34081321|NCT01163552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081322|NCT01725685|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081323|NCT02642406|||CASE_ONLY||PROSPECTIVE|||||||
34081324|NCT05683106|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single|Assignment|f|f|t|t
34081325|NCT03257748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081326|NCT01228825|||||PROSPECTIVE|||||||
34081327|NCT00010257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081328|NCT01572402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34081329|NCT02627079|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081330|NCT00122434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081331|NCT00992862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081332|NCT03407313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081333|NCT05213299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||2-arm crossover design, randomized controlled trial.|t|f|f|t
34081334|NCT03423043|||COHORT||PROSPECTIVE|||||||
34081335|NCT03860636|||COHORT||PROSPECTIVE|||||||
34081336|NCT04576013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081337|NCT02524639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081338|NCT00061789||||TREATMENT||||||||
33684506|NCT00829985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684507|NCT01652300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33684508|NCT02317146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684509|NCT01537107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684510|NCT05438901|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|no masking|A single-group study was conducted before (1st arm) and after (2nd arm) administration of HT.||||
33684511|NCT02692898|||COHORT||RETROSPECTIVE|||||||
33684512|NCT06092060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684513|NCT03443557|||COHORT||CROSS_SECTIONAL|||||||
33684514|NCT05038345|||CASE_ONLY||RETROSPECTIVE|||||||
33684515|NCT03932006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774816|NCT04936321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Because all study procedures delivered online, neither study participants nor investigators. care providers, or outcomes assessors will have knowledge of the treatment assignment and thus this trial can be carried out as a double-blinded RCT.|The study design is a two arm, two-phase RCT. In Phase 1, the effects of internet-delivered CBT insomnia intervention will be compared to internet-delivered sleep education control. In Phase 2, all participants will receive internet-delivered CBT pain intervention.|t|t|t|t
33774817|NCT01265641|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33774818|NCT05348733|||COHORT||PROSPECTIVE|||||||
33774819|NCT06643169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33774820|NCT04922736|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single Group, open label,||||
33774821|NCT06362967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774822|NCT06738537|||OTHER||PROSPECTIVE|||||||
33774823|NCT05975099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081339|NCT06471439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||three different type one leg exercise intervention are apllied in patients with copd|t|f|f|f
34081340|NCT00455286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081341|NCT06212011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081342|NCT02999789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34081343|NCT05719181|NA|SINGLE_GROUP||SCREENING||NONE||two groups; first group with protein , second group without (control)||||
34081344|NCT00023868|RANDOMIZED|||TREATMENT||||||||
34081345|NCT00869869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081346|NCT00485862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081347|NCT01449565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081348|NCT06043466|NA|SEQUENTIAL||TREATMENT||NONE||||||
34081349|NCT06343116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081350|NCT01564004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081351|NCT04887467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081352|NCT05560620|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||2-group, randomized design|t|f|f|f
34081353|NCT06328972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081354|NCT01168895|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34081355|NCT06047977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081356|NCT02789501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34081357|NCT03555149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081358|NCT01269073|||COHORT||CROSS_SECTIONAL|||||||
34081359|NCT00521365|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081360|NCT02116868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081361|NCT01858870|||CASE_ONLY||RETROSPECTIVE|||||||
34081362|NCT03073928|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34081363|NCT01687634|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34081364|NCT03959657|||COHORT||RETROSPECTIVE|||||||
34081365|NCT04132037|||CASE_ONLY||PROSPECTIVE|||||||
34081366|NCT05758896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34081367|NCT03575702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081368|NCT01319136|||CASE_ONLY||CROSS_SECTIONAL|||||||
34081369|NCT01486069|||CASE_ONLY||PROSPECTIVE|||||||
34081370|NCT04076241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081371|NCT05328245|||COHORT||RETROSPECTIVE|||||||
34081372|NCT02334163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081373|NCT00244179|RANDOMIZED|PARALLEL||ECT||NONE||||||
34081374|NCT05257317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081375|NCT05294120|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, open-label, single-center, phase II, single-arm clinical trial.||||
34081376|NCT01799759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34081377|NCT02217748|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34081378|NCT02766647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34081379|NCT00249704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081380|NCT06342947|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34081381|NCT02623712|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33904456|NCT03999567|NA|SINGLE_GROUP||OTHER||NONE||"Thirty adults (18-65) with DSM-5 MDD will be enrolled at the BCDF Toronto, Ontario. All subjects will have their diagnosis confirmed by Mini International Neuropsychiatric Interview Version 6.0.~At baseline, data will be collected from all participants and will include demographics, comorbidities, medication history and concurrent medications. All subjects will be assessed symptomatically with the Montgomery and Asberg Depression Rating Scale (MADRS) as well as the Hamilton Anxiety Rating Scale (HAM-A), Snaith Hamilton Pleasure Scale (SHAPS) for anhedonia, as well as the paper and pencil version of the DSST at baseline and end of study (Day 7).~The DSST has been normed on the sex, age and gender. These norms will be used as reference. All subjects will complete the pencil and paper version of the DSST and complete the mobile app-based version of the DSST."||||
33987317|NCT04904120|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|"Archived tumor tissue will be tested for expression of the imaging target, melanocortin receptor sub-type 1 (MC1R). The qualified researcher who tests the sample, and the independent pathologist who reviews the results, will be blinded to a participant's identifying information and imaging results. Evaluators will not have access to the medical record.~A pool of three qualified readers will evaluate study images (PET/CT and SPECT/CT). Images and medical information given to the readers will not include a participant's identifying information. The reader pool will not know the sequence of imaging for a participant or have access to the medical record.~An independent medical physicist will validate imaging results and measurements of radiation absorbed and excreted by the participant's body. The physicist will be blinded to participant identifiers and demographics, as well as the sequence of imaging for a participant. The physicist will not have access to the medical record."||f|f|f|t
33987318|NCT01401803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987319|NCT04064892|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33987320|NCT00631956|||FAMILY_BASED||RETROSPECTIVE|||||||
34081382|NCT05367245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple, participants, care provider, investigators and outcome assessor will not have access to blinding. Only research pharmacist to distribute the drug or placebo and study coordinator to keep a confidential and secure records, will have access to the blinding.|"-Drug: Ca-Mg-Butyrate Take oral Capsule as directed (600 mg, two times a day for 18 weeks; 2x600 mg/day for 18 weeks) with food or without food.~Other name: Calcium-Magnesium Butyrate, BodyBio Cal-Mag Butyrate~-Drug: Placebo Take oral Capsule as directed (600 mg, two times a day for 18 weeks; 2x600 mg/day for 18 weeks) with food or without food.~Other Name: Sugar pill, inactive substance"|t|t|t|t
33904457|NCT00615940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904458|NCT06419036|||COHORT||RETROSPECTIVE|||||||
33904459|NCT01423240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904460|NCT06651697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904461|NCT03652415|||COHORT||PROSPECTIVE|||||||
33904462|NCT01420640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904463|NCT01636219|||COHORT||CROSS_SECTIONAL|||||||
33904464|NCT05803265|||OTHER||CROSS_SECTIONAL|||||||
33904465|NCT00976768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904466|NCT05215392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Randomized, Efficacy Study|t|f|t|f
33904467|NCT02725073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904468|NCT04014504|||CASE_CONTROL||RETROSPECTIVE|||||||
33904469|NCT02389413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904470|NCT02009137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904471|NCT01583192|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904472|NCT02471131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904473|NCT01360164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904474|NCT04621123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID-19 patients who are non-hospitalised. Subjects will be followed up to 60 days after infusion|t|f|t|f
33904475|NCT05782556|||COHORT||PROSPECTIVE|||||||
33904476|NCT02965534|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33904477|NCT06247592|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33904478|NCT03695523|RANDOMIZED|PARALLEL||OTHER||SINGLE|Children and childcare providers will be aware of whether or not they receive the intervention. However, research assistants who are collecting data will remain blind to each centre's group assignment.|Cluster randomized controlled trial|f|f|f|t
33904479|NCT05020938|||COHORT||RETROSPECTIVE|||||||
34081383|NCT06523712|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"In this study, masking, also known as blinding, refers to the practice of concealing the allocation of participants to intervention groups from outcome assessors and investigators involved in data collection and analysis.~Masking helps minimize bias that could occur if those assessing the outcomes are aware of the participants' assigned interventions. In this case, both the outcome assessors and investigators are masked, meaning they are unaware of which participants received the interactive oral care lessons (experimental group) and which participants were in the control group."|In a parallel intervention study model, participants are divided into two or more distinct groups, with each group receiving a different intervention or treatment simultaneously. In this study, participants are not randomized into two arms: the experimental group (Arm 1) and the control group (Arm 2). The experimental group receives the interactive oral care lessons, while the control group does not receive any intervention and continues with their regular oral hygiene practices. Both groups are assessed at baseline and post-intervention to compare outcomes and evaluate the effectiveness of the intervention. This study design allows for the direct comparison of outcomes between the intervention and control groups, enabling researchers to determine the impact of the intervention on oral hygiene knowledge, behavior, and plaque control.|f|f|t|t
34081384|NCT00171093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081385|NCT04350463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904480|NCT04766424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and outcomes assessors will not have access to the randomization table. Outcomes assessors will not be involved in the group assignments. Participants will be instructed to not tell outcomes assessors which group they are assigned to.||f|f|t|t
33987321|NCT04979429|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be blinded to randomization status.|Participants will be randomized to either receive the pain self-management sessions (PePS) or standard care (SC).|f|f|f|t
33987322|NCT02895763|||COHORT||PROSPECTIVE|||||||
34081386|NCT01172873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081387|NCT02672241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081388|NCT04802499|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34081389|NCT04993573|||CASE_ONLY||RETROSPECTIVE|||||||
34081390|NCT03709251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34081391|NCT04066933|||COHORT||OTHER|||||||
34081392|NCT06300034|||OTHER||CROSS_SECTIONAL|||||||
34081393|NCT03288168|||COHORT||RETROSPECTIVE|||||||
33684516|NCT04415970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"We aim to assign participants into one of two different sub-study designs:~1. Group A: Participants will float for 60 minutes, 2 times a week for 8 weeks or use the sleep pod for 60 minutes, 2 times a week for 8 weeks.~2. Group B: Participants will engage in a crossover design in which they will participate in both float and nap pod, each for two weeks at a time, twice. The order in which these participants engage in the two recovery modalities will be randomly assigned via statistical package R.~The only difference between Groups A and B is how often/frequent they engage in the two different modalities. Participants in group A will only do float or Metronap - participants in Group B will do both and alternate every two weeks."||||
33684517|NCT02849600|||COHORT||RETROSPECTIVE|||||||
33684518|NCT02513147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684519|NCT01155479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684520|NCT05421143|||COHORT||PROSPECTIVE|||||||
33684521|NCT02788877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684522|NCT02378805|||COHORT||CROSS_SECTIONAL|||||||
33684523|NCT05532696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684524|NCT03688529|||COHORT||PROSPECTIVE|||||||
33684525|NCT04707443|||COHORT||PROSPECTIVE|||||||
33684526|NCT03687164|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33684527|NCT02447783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33684528|NCT00825773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904481|NCT02834403|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904482|NCT03710785|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33904483|NCT00306566|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33904484|NCT00890812|||CASE_CONTROL||RETROSPECTIVE|||||||
33904485|NCT06062927|||COHORT||PROSPECTIVE|||||||
33987323|NCT04175808|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This was a partially double-blind study. In Part B, placebo and OM treatments were double-blinded, moxifloxacin treatment was open-label, and the core ECG laboratory was blinded to all treatment information. Except for the moxifloxacin treatment in 1 of 3 periods in Part B, treatment assignment was blinded to all participants, site personnel, the Medical Monitor, and Clinical Research Associates.||t|f|t|t
33684529|NCT05080244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684530|NCT01544088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684531|NCT00627146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684532|NCT01654913|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684533|NCT01119937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684534|NCT00409175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684535|NCT05703633|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, open label, proof-of-concept study, Phase 1-2a||||
33684536|NCT00159497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987324|NCT03500120|||CASE_CONTROL||PROSPECTIVE|||||||
33987325|NCT01569269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33987326|NCT03143686|||CASE_ONLY||PROSPECTIVE|||||||
33774824|NCT04261712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774825|NCT04612751|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose escalation and dose expansion model||||
33904486|NCT05896982|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Experimental 2x2 factorial design.||||
34081394|NCT00413543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081395|NCT06277674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081396|NCT00003146||||TREATMENT||||||||
34081397|NCT05415306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081398|NCT00975936|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34081399|NCT06365944|||COHORT||PROSPECTIVE|||||||
34081400|NCT02002546|||CASE_ONLY||PROSPECTIVE|||||||
34081401|NCT04712292|||COHORT||RETROSPECTIVE|||||||
34081402|NCT00254436|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34081403|NCT05343325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081404|NCT03433235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081405|NCT01443169|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34081406|NCT00482937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081407|NCT03593200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081408|NCT02588430|||CASE_ONLY||PROSPECTIVE|||||||
34081409|NCT02854917|||CASE_CONTROL||RETROSPECTIVE|||||||
34081410|NCT00137709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081411|NCT01576575||SEQUENTIAL||OTHER||NONE||||||
34081412|NCT04757155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081413|NCT03564470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081414|NCT00571623|||CASE_CROSSOVER||PROSPECTIVE|||||||
34081415|NCT05466721|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34081416|NCT02205372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081417|NCT05827276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessor will be blind to the usage of the life story questionnaire for study participants. Additionally, the participants will not be told the group they were allocated to.|Prospective Randomized Control Trial. Patients will be randomly allocated in two groups: (1) Control group, which will receive standard physical therapy care without LSQ use; and (2) Experimental group, where physical therapists will use the LSQ.|t|f|f|t
34081418|NCT00244049|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34081419|NCT00801372|||CASE_CONTROL||PROSPECTIVE|||||||
34081420|NCT02400801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081421|NCT04140565|||COHORT||PROSPECTIVE|||||||
34081422|NCT05983952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081423|NCT02728323|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34081424|NCT06319027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081425|NCT03457857|RANDOMIZED|PARALLEL||OTHER||SINGLE|"This study will be evaluator-blinded, so the PI/expert graders will not know which group (Group 1 or Group 2) each subject is in. Personnel dispensing the IPs or supervising IP use will not participate in the evaluation of subjects in order to minimize potential bias. IPs will be kept separate from the site personnel involved in assessing or evaluating the subjects, and subjects will be instructed not to discuss their assigned IPs with the PI/expert graders or other subjects.~To keep the evaluator blinded, the study staff will keep the grading forms separate from the bulk of the source documents so the evaluator will not have access to the sheets that indicate randomization and the study staff will instruct the subjects/LAR to not say anything about what product they are using."|"The duration of this trial will be approximately 5 weeks and will consist of a screening visit followed by an approximately 1-week (7-day) washout period; a 4-week (28 day) treatment period with visits conducted at baseline (Day 0, ± 2 days), week 2 (Day 14, ± 2 days), and week 4 (Day 28, ± 2 days); and a regression period with a visit 3-5 days after the week 4 visit.~During the one week washout period, subjects will use a commercial available Baby Wash at least 3x per week.~For the next 4 weeks, subjects will be randomly assigned to use one of two IP regiments. Subjects in Group 1 will use the Baby Wash \& Shampoo at least 3x per week, but no more than once daily. Subjects in Group 2 will use the Baby Wash \& Shampoo at least 3x per week, but no more than once daily, plus the Baby Lotion at least once daily. The lotion should be applied after bathing (as applicable).~At Visit 4, subjects will begin a 3-5 day regression period."|f|f|t|f
34081426|NCT02432339|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33684537|NCT03584945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Children ages 6-14 with OCD, obsessive compulsive symptoms, or healthy controls||||
33684538|NCT00000843||||TREATMENT||NONE||||||
33684539|NCT03403387|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Half of the participants will be randomized to receive the supplement and the other half will receive the placebo.|t|t|f|f
33684540|NCT01687374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684541|NCT03916107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684542|NCT05229198|||COHORT||PROSPECTIVE|||||||
33684543|NCT02425189|||FAMILY_BASED||PROSPECTIVE|||||||
33684544|NCT00005866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081427|NCT02277483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081428|NCT04195594|NA|SINGLE_GROUP||OTHER||NONE||Open-Label||||
34081429|NCT01053156|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34081430|NCT05276791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized study||||
34081431|NCT06123702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Capsules will be in opaque bottles and the experimenter will not see the contents of the bottle.|Participants will be randomly assigned to CBD or placebo.|t|f|f|t
33684545|NCT01155882|||COHORT||OTHER|||||||
33684546|NCT00924170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684547|NCT02140502|||COHORT||PROSPECTIVE|||||||
33684548|NCT01879579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904487|NCT03591796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||When the neonate had fulfilled the included criteria, selective HFOV or CMV were started immediately on the basis of the group assignment.|t|f|t|t
33904488|NCT01187797|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33904489|NCT02407574|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33904490|NCT02474017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904491|NCT00337298|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33904492|NCT01070550|||COHORT||PROSPECTIVE|||||||
33904493|NCT00933010|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33684549|NCT00129298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684550|NCT05009433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Due to the trial design and specificity of the interventions it is not possible to blind the study participants in terms of the allocation to the study groups. The HIIT and MICT groups will attend exercise sessions of high or moderate intesity, 3 times a week, while the comparative groups will not be subjected to any exercise intervention. However the data collectors and assessors will be blinded to the group allocation.|The study model is parallel in the two subgroups. The first subgroup consists of pregnant women who will be assigned to one of the three interventions: high intensity interval training program, moderate intensity continuous program or educational program on healthy lifestyle. The second subgroup will be age-matched nonpregnant women and they will be also assigned to the above three interventions. The pregnant women will be evaluated both in comparison to other pregnant women intervention groups and to the appropriate control non-pregnant groups.|f|f|t|t
33904494|NCT03395171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904495|NCT00498862|||DEFINED_POPULATION||OTHER|||||||
33904496|NCT00227279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33904497|NCT00277992|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33904498|NCT02241512|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33904499|NCT02793908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987327|NCT01838941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987328|NCT00891800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987329|NCT04123769|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987330|NCT00833651|||COHORT||PROSPECTIVE|||||||
33987331|NCT02647177|||CASE_ONLY||CROSS_SECTIONAL|||||||
33987332|NCT01188850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987333|NCT00163514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33987334|NCT03620175|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Outcomes Assessor is blinded to treatment groups and vehicle control.|Each patient receives each of the 4 treatment arms. It is closest to a single-subject design where each participant serves as their own control. The placement of treatments on each of the 4 wounds is randomized and assessed by a blinded outcomes assessor.|f|f|f|t
33987335|NCT01581658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987336|NCT00900718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987337|NCT02646124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987338|NCT06225609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987339|NCT00732082|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987340|NCT04628117|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial with two-parallel-group in stable continuous ambulatory peritoneal dialysis patients.||||
33987341|NCT04279353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987342|NCT01780870|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987343|NCT04907838|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33987344|NCT01790386|||||PROSPECTIVE|||||||
33987345|NCT02330380|||COHORT||PROSPECTIVE|||||||
33987346|NCT05305430|||COHORT||PROSPECTIVE|||||||
33987347|NCT04427748|||CASE_CONTROL||PROSPECTIVE|||||||
33987348|NCT05034757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33987349|NCT01868971|NA|SINGLE_GROUP||SCREENING||NONE||||||
33904500|NCT03137355|||CASE_ONLY||OTHER|||||||
33904501|NCT00931892|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33904502|NCT00000800||||TREATMENT||NONE||||||
33904503|NCT05186181|||CASE_ONLY||PROSPECTIVE|||||||
33987350|NCT03250286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987351|NCT05408897|||CASE_ONLY||PROSPECTIVE|||||||
33987352|NCT04253366|NA|SINGLE_GROUP||SCREENING||NONE||Clinical investigation with Medical Device class IIa||||
33987353|NCT03789994|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33987354|NCT01352091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987355|NCT05498857|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, randomized, double-blind and placebo-controlled trial|t|t|t|t
33904504|NCT03081325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904505|NCT01750476|||COHORT||PROSPECTIVE|||||||
33904506|NCT01708083|||COHORT||PROSPECTIVE|||||||
33904507|NCT01165203|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33904508|NCT03421990|||COHORT||PROSPECTIVE|||||||
33904509|NCT01050179|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904510|NCT04618393|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation followed by Cohort Expansion Phase at the RP2D.||||
33987356|NCT03439982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987357|NCT06560242|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987358|NCT04006522|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987359|NCT00500591|||CASE_ONLY||PROSPECTIVE|||||||
33987360|NCT00467662|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33684551|NCT00718237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33684552|NCT00635024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684553|NCT00185653|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684554|NCT04566445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcome Assessor). The overall objectives of the study are to evaluate the safety and efficacy (anatomical and functional visual outcomes) of two doses of GT005 in genetically defined subjects with GA due to AMD.|This is a Phase II, open-label, outcomes-assessor masked, multicentre, randomised, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.|t|t|t|t
33684555|NCT04739371|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33684556|NCT06309394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684557|NCT00459056|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33684558|NCT00914303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33684559|NCT00306111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774826|NCT06731062|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||"Induction period (3 weeks): the experimental and control product will be applied through a patch test on the participants' back for 3 consecutive weeks, with 3 weekly applications, with the first week being the primary irritation phase and the two consecutive weeks being the accumulated irritation phase.~Rest period (10 to 15 days): corresponds to the rest period, when participants will remain without any contact test applied to their back, which will follow the induction period, where there will be no application of the experimental and control product. Challenge period (3 days): the experimental and control product will be applied to the participants' back, in a naïve area. Products will be removed after 48 hours, with readings taking place after removal and approximately 24 hours after removal. This period corresponds to the sensitization phase."|f|f|f|t
33774827|NCT06734962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774828|NCT06035120|NA|SINGLE_GROUP||TREATMENT||NONE||The study is designed as a single-arm clinical trial in which eligible subjects with an identified fissure gap in the target lobe will be treated with the AeriSeal System to determine the rate of conversion from having collateral ventilation (CV+) to having little to no collateral ventilation (CV-). Subjects who convert to CV- status with AeriSeal will then undergo BLVR using Zephyr Valve per standard of care.||||
33774829|NCT04699188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774830|NCT05144061|NA|SINGLE_GROUP||TREATMENT||NONE||Single therapy of HRS2398||||
33904511|NCT05085548|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study includes a dose escalation arm, followed by an expansion arm at the ideal dose for participants with non-neuroendocrine pancreatic cancer.||||
33904512|NCT00390364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904513|NCT01564290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904514|NCT01671488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904515|NCT05222906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the open-label extended treatment period all participants will receive open label venglustat.|Double Dummy|t|t|t|t
33904516|NCT01132573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904517|NCT02206711|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33904518|NCT05305638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904519|NCT01171547|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33904520|NCT05463679|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Two-arm, multicenter, randomized, double-blind, placebo-controlled study in patients with vEDS receiving enzastaurin 500 mg once daily (QD) compared to placebo, in addition to background standard of care, followed by an OLE phase.~Approximately 260 patients with vEDS are planned to be randomized in a 1:1 ratio of enzastaurin or placebo. Patients will be enrolled in the study if they meet all eligibility criteria."|t|t|t|f
33987361|NCT02700750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987362|NCT04362566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will receive long acting local anesthetic or saline placebo postoperatively, they will be blinded to the arm they are in|Single-blind RCT|t|f|f|f
33987363|NCT05886101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987364|NCT03727620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987365|NCT02371343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987366|NCT00074230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684560|NCT03256890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will implement blinding of staff performing participant assessments and data analysts performing statistical analyses. The principal investigator will be blinded to group allocation, except for participants that he is involved with instructing in the MB-BP intervention (there are multiple instructors). The prinicipal investigator has no access to the master data file. Equipoise is emphasized for all staff who interact with participants.||f|t|t|t
33684561|NCT05154370|||COHORT||PROSPECTIVE|||||||
33684562|NCT00534469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684563|NCT01847807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684564|NCT04559711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two parallel arm superiority community based cluster randomized controlled trial||||
33684565|NCT00408044|||||PROSPECTIVE|||||||
33684566|NCT04644731|||COHORT||OTHER|||||||
33684567|NCT02067052|||CASE_CONTROL||PROSPECTIVE|||||||
33684568|NCT04959071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After informed, written consent, all selected cases were offered to pick up a slip from total mixed up slips (half-slips contained letter 'A' and other half slips contained letter 'B') and he/she was placed in that respective group.|Randomized control trial. After informed, written consent, all selected cases were offered to pick up a slip from total mixed up slips (half-slips contained letter 'A' and other half slips contained letter 'B') and he/she was placed in that respective group. In group A patients, VAC dressing was applied while in group B conventional dressing was applied. All patients were followed regularly by the single researcher and mean healing time was noted in every patient of both groups . This all data (age, gender, duration of ulcer, and size of ulcer, BMI, and healing time) was recorded on a specially designed Performa designed beforehand.|t|f|f|f
33684569|NCT02721771|||COHORT||PROSPECTIVE|||||||
33684570|NCT00356837|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684571|NCT00539760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684572|NCT02680678|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|the outcome accessor and care provider will be aware in which gropu the patient was|4 group of patients were sheduled to receive either kristalloid or kolloid two gropus before and two groups during anesthesia induction|t|f|t|t
33684573|NCT00374205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684574|NCT00969280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684575|NCT00276042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33684576|NCT00416897|RANDOMIZED|||TREATMENT||NONE||||||
33684577|NCT01415089|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684578|NCT00433264|||CASE_ONLY||PROSPECTIVE|||||||
33684579|NCT03997578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684580|NCT02864485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684581|NCT01584570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33684582|NCT03381157|||CASE_CONTROL||PROSPECTIVE|||||||
33684583|NCT01081548||PARALLEL||||NONE||||||
33684584|NCT00299468|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684585|NCT03252600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684586|NCT00817687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684587|NCT00098982||||TREATMENT||NONE||||||
33774831|NCT05238961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33774832|NCT03493113|||COHORT||RETROSPECTIVE|||||||
33774833|NCT00001281|||COHORT||PROSPECTIVE|||||||
33774834|NCT04876053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33774835|NCT00233272|||COHORT||PROSPECTIVE|||||||
33774836|NCT06666764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987367|NCT02355574|||COHORT||PROSPECTIVE|||||||
33987368|NCT02296008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987369|NCT01381848|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33987370|NCT01648582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987371|NCT03552081|NA|SINGLE_GROUP||OTHER||NONE||||||
33987372|NCT05852886|NA|SINGLE_GROUP||OTHER||NONE||First-in-human-use single arm clinical study to evaluate safety.||||
33987373|NCT05333341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987374|NCT04779320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987375|NCT02059070|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33987376|NCT04638452|NA|SINGLE_GROUP||OTHER||NONE||Epidemiology||||
33987377|NCT05069961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987378|NCT02957318|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33987379|NCT04899089|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33987380|NCT03678844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987381|NCT03290820|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients eligible are divided randomly. All the patients will receive concurrent chemoradiotherapy. The cases in the Experimental Group will receive daily aspirin of 75mg.||||
33987382|NCT01215981|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987383|NCT04908007|||OTHER||PROSPECTIVE|||||||
33987384|NCT05681130|||COHORT||PROSPECTIVE|||||||
33987385|NCT03702218|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987386|NCT05904821|||OTHER||CROSS_SECTIONAL|||||||
33987387|NCT03837249|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|One group - personal sleep monitoring data with-held then provided after the intervention period.|Comparative control - 3 group|t|f|f|f
33987388|NCT02909907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987389|NCT03756259|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684588|NCT00406627|||||PROSPECTIVE|||||||
33684589|NCT04918901|||CASE_ONLY||OTHER|||||||
33684590|NCT00584740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684591|NCT00870233|||COHORT||PROSPECTIVE|||||||
33774837|NCT04466059|||CASE_CONTROL||PROSPECTIVE|||||||
33774838|NCT04910087|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE||Prospective randomized double blinded study|t|t|t|t
33987390|NCT02303405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987391|NCT00006468|RANDOMIZED|||TREATMENT||NONE||||||
33987392|NCT01939756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081432|NCT00860639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081433|NCT04301856|||COHORT||PROSPECTIVE|||||||
33774839|NCT05992896|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33774840|NCT01375114|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33774841|NCT06473779|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Parallel-Group treatment study with 3 arms. Participants will be treated with tezepelumab Q4W from Week 0, with the last dose administered at Week 68||||
33987393|NCT01173692|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33987394|NCT06456918|||CASE_CONTROL||PROSPECTIVE|||||||
33987395|NCT05113693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987396|NCT04046783|||CASE_CONTROL||PROSPECTIVE|||||||
33987397|NCT04815759|||OTHER||CROSS_SECTIONAL|||||||
33987398|NCT02246166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987399|NCT04074915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684592|NCT00794027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684593|NCT00256282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684594|NCT02007538|||CASE_CONTROL||PROSPECTIVE|||||||
33684595|NCT02676128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684596|NCT03383653|||COHORT||PROSPECTIVE|||||||
33684597|NCT02962375|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33684598|NCT01437800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684599|NCT02179138|NA|SINGLE_GROUP||||NONE||||||
33684600|NCT02821143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684601|NCT01246466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684602|NCT06094985|||COHORT||PROSPECTIVE|||||||
33684603|NCT02299401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33684604|NCT00645710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684605|NCT01847131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684606|NCT06254196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33684607|NCT05426330|||COHORT||CROSS_SECTIONAL|||||||
33684608|NCT05635188|||COHORT||RETROSPECTIVE|||||||
33684609|NCT05955573|||CASE_ONLY||CROSS_SECTIONAL|||||||
33684610|NCT01552733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684611|NCT05959642|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33684612|NCT01824797|||COHORT||PROSPECTIVE|||||||
33684613|NCT02727543|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33684614|NCT06453057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684615|NCT05204303|||OTHER||PROSPECTIVE|||||||
33684616|NCT02583659|||COHORT||PROSPECTIVE|||||||
33684617|NCT03249467|||CASE_ONLY||PROSPECTIVE|||||||
33684618|NCT03725254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684619|NCT03742648|RANDOMIZED|PARALLEL||PREVENTION||NONE|There is no party who is masked|Participants are assigned to one of two or more groups in parallel for the duration of the study||||
33684620|NCT04601454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774842|NCT04193293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774843|NCT06736860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774844|NCT06713304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33774845|NCT06188208|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904521|NCT03621969|RANDOMIZED|CROSSOVER||OTHER||NONE||"Group 1 will receive:~1. two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,~2. then will rest for 2 weeks (weeks 3-4),~3. then will take the RePlay devices and tablet computer home for two weeks (weeks 5-6) for daily device therapy, followed by re-assessment.~Group 2 will receive:~1. two weeks of RePlay device therapy daily at home (they will take the devices and tablet home) (weeks 1-2), followed by re-assessment,~2. then will rest for 2 weeks (weeks 3-4),~3. then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."||||
33904522|NCT03387124|||COHORT||PROSPECTIVE|||||||
33904523|NCT01185535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904524|NCT01837147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904525|NCT06247696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33684621|NCT04613778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774846|NCT06739733|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33904526|NCT02055027|||COHORT||PROSPECTIVE|||||||
33904527|NCT03961919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904528|NCT02438436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904529|NCT01629667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904530|NCT02270398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987400|NCT05350891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987401|NCT00004905||||TREATMENT||||||||
33987402|NCT05382377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987403|NCT02566239|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987404|NCT00909610|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33987405|NCT06407622|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The thesis study was planned as a randomized controlled experimental study.||||
33684622|NCT02407652|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33684623|NCT01444807|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33684624|NCT00627614|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684625|NCT02842554|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33684626|NCT05733403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684627|NCT01687647|NA|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|f|t
33987406|NCT05321316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987407|NCT06107192|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|During the crossover trial of two diets, participants will receive the same foods during both arms. The intervention and control will be delivered by a beverage containing either the active component or a nutritionally equivalent control beverage with similar flavor. Participants will not be told the order of study arms they receive. Drinks will be labeled with a code by a different researcher than the team interacting with participants. The statistician will not know which code corresponds to which intervention until analysis is complete.||t|f|t|t
33987408|NCT06368869|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33987409|NCT01294917|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33987410|NCT02977260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33684628|NCT01671943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684629|NCT03539042|||COHORT||PROSPECTIVE|||||||
33684630|NCT02807311|||COHORT||RETROSPECTIVE|||||||
33684631|NCT04140227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684632|NCT05713708|||COHORT||RETROSPECTIVE|||||||
33684633|NCT04112589|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study consists of a dose escalation-dose finding part (phase I) and a phase II part.~Subjects will have an induction of 1 cycle, by an alloSCT (allogeneic hematopoietic stem cell transplantation) in CR/CRi, when possible, with up to 3 optional HiDAC (high dose Cytarabine ) consolidation cycles. All patients in CR/CRi will receive a maintenance schedule (12 months, 12 cycles).~The phase I portion will progress from starting level dose 1 (40mg 14 days) to level dose 2 (60 mg 14 days). De-escalation to level dose -1 (60mg 7 days) or level dose -2 (40mg 7 days) may be necessary to be explored.~Once the RP2D is established, the phase II will start."||||
33684634|NCT01467778|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33684635|NCT05535010|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684636|NCT05392933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684637|NCT00560521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684638|NCT02871882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684639|NCT02636140|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33684640|NCT04692727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The information of the individuals being treated will be hidden from the researcher who will make the MRI measurements.|Single blind randomized controlled study:Three parallel treatment groups; the control group received only exercise therapy, while the other two groups received two different taping treatments in addition to exercise therapy.|f|f|f|t
33684641|NCT06442631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Given the nature of the intervention (an educational platform), masking of participants is not feasible, but other key study members (and clinicians) will be blinded to the study assignment.||f|t|t|t
33774847|NCT06587035|||CASE_ONLY||PROSPECTIVE|||||||
33774848|NCT06464289|||CASE_CONTROL||RETROSPECTIVE|||||||
33987411|NCT04455139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987412|NCT00865592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987413|NCT03223961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||randomazed study||||
33987414|NCT06370754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987415|NCT02252133|RANDOMIZED|CROSSOVER||||NONE||||||
33987416|NCT00512421|||COHORT||PROSPECTIVE|||||||
33987417|NCT00204074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33987418|NCT04819490|||OTHER||OTHER|||||||
33987419|NCT00133822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33987420|NCT03083886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987421|NCT05932524|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus high-dose dexamethasone or high-dose dexamethasone alone. Each group requires 66 patients (considering 10% drop-off).||||
33987422|NCT05981989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987423|NCT04003350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987424|NCT04408144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987425|NCT04511910|||COHORT||RETROSPECTIVE|||||||
33987426|NCT01125137|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987427|NCT03700411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684642|NCT04259723|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33684643|NCT02040727|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33684644|NCT02634476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684645|NCT05748652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33684646|NCT02770209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081434|NCT04387123|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Vaginoscopy via Darwish sheet or without its use.||||
33684647|NCT02100709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684648|NCT05504772|||COHORT||PROSPECTIVE|||||||
33684649|NCT05694221|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33684650|NCT02324543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684651|NCT03088085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684652|NCT01348009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684653|NCT02655770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684654|NCT03748043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684655|NCT06259851|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Allocation to the Active rTMS/Sham rTMS group is randomized.|t|t|f|f
33684656|NCT03748615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774849|NCT03141528|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33774850|NCT00614198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33774851|NCT05956938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33774852|NCT06329518|NA|SINGLE_GROUP||OTHER||NONE||||||
33774853|NCT03866772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774854|NCT03027505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774855|NCT06741007|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33774856|NCT06134128|NA|SINGLE_GROUP||OTHER||NONE||||||
33904531|NCT05667428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904532|NCT06415578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904533|NCT05725369|||COHORT||PROSPECTIVE|||||||
33904534|NCT05447130|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904535|NCT04302883|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33904536|NCT04116632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33904537|NCT05929027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33904538|NCT03247907|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33904539|NCT03384849|||CASE_ONLY||PROSPECTIVE|||||||
33904540|NCT05433298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33684657|NCT02532166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904541|NCT00271440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904542|NCT01834313|||COHORT||CROSS_SECTIONAL|||||||
34081435|NCT01643330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081436|NCT02276469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081437|NCT05502627|||CASE_CONTROL||PROSPECTIVE|||||||
34081438|NCT02415530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33774857|NCT06736938|RANDOMIZED|PARALLEL||OTHER||NONE||Eligible patients may undergo flexible bronchoscopy based solely on clinical indications, with procedures classified as either interventional (e.g., laser therapy, ndotracheal/endobronchial debulking, visual biopsies, mucosal biopsies, or transbronchial biopsies guided by echo-endoscopy such as EBUS or EUS) or non-bioptic procedures, such as bronchial lavage, bronchoalveolar lavage, or endobronchial lavage. To ensure a balanced distribution of characteristics that could influence study outcomes, stratified block randomisation will be used. Patients will be stratified according to the type of bronchoscopic procedure (interventional vs simple), as the complexity and invasiveness of the procedure may influence the required depth of sedation. Within each group, block randomisation with a 1:1 ratio will be applied to ensure a consistent balance of patients recruited between treatment groups (Propofol+Pethidine or Midazolam+Pethidine).||||
34081439|NCT01536210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081440|NCT01851421|||CASE_CONTROL||PROSPECTIVE|||||||
34081441|NCT00057135|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081442|NCT03569501|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|f|t
34081443|NCT04229043|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects in each group will drink one of two drinks: water or sports drink. We will measure the changing volume in the stomach using ultrasound over the next 60 minutes.||||
34081444|NCT02343224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081445|NCT05777421|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive conventional physical therapy along with Natural apophyseal glides and the second will receive Natural Apophyseal Glides in addition to cranial base release with conventional physical therapy. Both groups will be recruited concurrently.||||
33684658|NCT01718977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684659|NCT05150639|||COHORT||PROSPECTIVE|||||||
33684660|NCT01457976|||||CROSS_SECTIONAL|||||||
33684661|NCT05763355|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33684662|NCT03431272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684663|NCT00023127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684664|NCT05954104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684665|NCT04492215|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The study is based on the participation of general practitioners in a training, the test is necessarily open for doctors. However patients will not know if their doctor has received training and will be blinded..|This study is a multicenter trial. Patients will be followed either by GPs from the interventional group who participated in motivational interviewing or by the control group who never participated. The distribution of general practitioners in the groups is done thanks random draw.|t|f|f|f
33774858|NCT05107401|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||Participants will be randomized to receive the digital crowdsourced intervention or standard of care (existing HIV informational materials). We will examine effects of the intervention on reducing HIV stigma and increasing HIV testing.|t|f|f|f
33774859|NCT06533098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774860|NCT06032416|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904543|NCT06519435|||CASE_ONLY||PROSPECTIVE|||||||
33904544|NCT02237495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33904545|NCT04961840|||COHORT||RETROSPECTIVE|||||||
33904546|NCT02644525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081446|NCT02306876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081447|NCT01614301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081448|NCT04605900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A pre and post-test analysis was performed.||||
34081449|NCT00073918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081450|NCT03537066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081451|NCT01510405|||COHORT||PROSPECTIVE|||||||
33684666|NCT05045950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684667|NCT03947411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684668|NCT01761071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33684669|NCT00118521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33684670|NCT05582954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent researcher who is not involved in the study will generate the random sequence using a computer random sequence generator. Randomisation will take place at an individual level, stratified by gender and the university where students study. Participants will be randomised into two groups (EsteemUp vs EsteemUp-G) with an allocation ratio of 1:1. We will conduct block randomisation with randomly varied block sizes (6 to 12 allocations per block) to prevent foreknowledge of intervention assignment. Allocation will be concealed from the study's researchers. It is not possible to mask personnel and participants to the treatment allocation because of the nature of the intervention.|The present study is a two-armed randomized controlled trial. This trial will be conducted in a university setting. A guided web-based intervention to improve self-esteem (EsteemUp) will be compared to a version of the same intervention with gamification elements (EsteemUp-G)|f|f|t|t
33684671|NCT02282878|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33904547|NCT04364074|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33904548|NCT02344693|||COHORT||PROSPECTIVE|||||||
33904549|NCT06347822|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33904550|NCT02832726|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33904551|NCT05247112|||CASE_ONLY||PROSPECTIVE|||||||
33904552|NCT02065908|||COHORT||PROSPECTIVE|||||||
33904553|NCT06532019|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33904554|NCT03593304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Experimental group: Medicine- Injection Mecobalamin (500mcg), Tablet Pyridoxine hydrochloride (25 mg) Placebo group: Injection normal saline (1ml), oral placebo pill|t|f|t|f
33904555|NCT00004048||||TREATMENT||||||||
33904556|NCT01531491|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33904557|NCT02268565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33904558|NCT06322823|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33904559|NCT01765764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904560|NCT03070457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904561|NCT02816710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904562|NCT01312428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987428|NCT04189146|NA|SINGLE_GROUP||OTHER||NONE||"This study only involves administration of electronic surveys at six different time points. These time points include: at the time of consent; after completing the Inner Engineering Online modules but before the in-person course begins; after the completion of the in-person (IECO) course; at 6 weeks; at 6 months and at 12 months. These surveys can take up to 15 minutes to complete. Electronic reminders will be sent to participants who have not completed these surveys within a week.~Additionally, participants must complete a two-minute compliance survey at the end of each week for 6 weeks after IECO completion. After these 6 weeks, this same two-minute compliance survey will be sent monthly until the end of the year. This survey is an important component of our data analysis, because it collects information on the frequency and duration of their routine practice."||||
33987429|NCT02079194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081452|NCT00757146|||||RETROSPECTIVE|||||||
33684672|NCT06363188|||CASE_ONLY||PROSPECTIVE|||||||
33684673|NCT06036446|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial of cerclage versus no cerclage in singleton high-risk pregnancies with a short TVU CL at 24-26 weeks of gestation.||||
33684674|NCT01659554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684675|NCT02320903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684676|NCT05820659|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684677|NCT01548144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684678|NCT04490928|||COHORT||RETROSPECTIVE|||||||
33684679|NCT00570232|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33684680|NCT03817450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684681|NCT01573884|||CASE_ONLY||PROSPECTIVE|||||||
33684682|NCT04861402|||CASE_CONTROL||PROSPECTIVE|||||||
33987430|NCT06234722|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Mixed crossover-factorial|t|f|t|f
33987431|NCT06144385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987432|NCT01516996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987433|NCT03892863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.|Patients will be randomly assigned to real or placebo (sham) stimulation.|t|f|t|t
33987434|NCT02529592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34081453|NCT04056208|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Crossover assignment|f|f|t|t
33987435|NCT01268085|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33987436|NCT06144190|||COHORT||RETROSPECTIVE|||||||
33987437|NCT05368870|||COHORT||RETROSPECTIVE|||||||
33987438|NCT03554577|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each participant will be treated with each sound changing principle (Noise Reduction principle (NR)) in a randomized order.|t|f|f|f
33987439|NCT01649011|||COHORT||PROSPECTIVE|||||||
33987440|NCT00854711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987441|NCT05025345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33987442|NCT04312165|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomization between Duramesh closure and standard suture closure||||
33987443|NCT04425928|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33987444|NCT03384602|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two intervention groups: Active I = Dalcroze Eurhythmic Program Active II: simple home exercise program Control group: no change in daily activities, no intervention|f|f|t|t
33987445|NCT01901783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987446|NCT01590420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987447|NCT01747317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987448|NCT03408691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind only in Test and Control arm open label in arm without intervention|Single-site exploratory randomized, controlled interventional trial with a parallel group design: double blind with Test and Control arm + open label arm without intervention.|t|f|t|f
33987449|NCT02508662|||COHORT||PROSPECTIVE|||||||
33987450|NCT06138457|||COHORT||PROSPECTIVE|||||||
33987451|NCT05667272|||CASE_CONTROL||RETROSPECTIVE|||||||
33987452|NCT01805583|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33987453|NCT02545803|NA|SINGLE_GROUP||OTHER||NONE||||||
33987454|NCT02615028|NA|SINGLE_GROUP||||NONE||||||
33987455|NCT05731674|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33987456|NCT00356785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987457|NCT03197883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987458|NCT04492553|NA|SINGLE_GROUP||TREATMENT||NONE||Cured lymphoma patients who suffer from hypogonadism identified in a previous study, Vitality-Obs, will be treated with testosterone replacement therapy for the duration of one year. Patients are treated after standard indication and in standard doses. All will receive the same treatment.||||
34081454|NCT00566488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081455|NCT03391752|||OTHER||PROSPECTIVE|||||||
34081456|NCT01471977|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34081457|NCT03541837|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective series case compared to a before group of consecutive patients||||
33684683|NCT01605578|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684684|NCT03544788|NA|SINGLE_GROUP||TREATMENT||NONE||Cirvo™ Therapy||||
33684685|NCT06234332|||COHORT||PROSPECTIVE|||||||
33684686|NCT05184439|||CASE_ONLY||PROSPECTIVE|||||||
33684687|NCT05010642|||COHORT||CROSS_SECTIONAL|||||||
33774861|NCT05105009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||all KDIGO stages and healthy volunteers (Kidney donors)||||
33774862|NCT06385210|NA|SINGLE_GROUP||OTHER||NONE||||||
33684688|NCT05527938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study personnel involved in the data assessment of the study are blinded to the patients' treatment assignment. The clinical doctors that deliver the study treatment are not blinded and are therefore uninvolved in the patients' data assessments related to this study. Data analysts are blinded to group allocation.|web-based intervention|t|f|f|f
33684689|NCT04054427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684690|NCT04121624|||COHORT||PROSPECTIVE|||||||
33684691|NCT02241096|NA|SINGLE_GROUP||OTHER||NONE||||||
33774863|NCT06469359|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Prospective study in healthy volunteers. Randomized, single-blind, cross-over trial|t|f|f|f
33684692|NCT03177629|RANDOMIZED|PARALLEL||TREATMENT||NONE||"treatment group vs control group Patients in treatment group will be treated with antibiotics for H. pylori eradication at visit 1.~Control group has 2 stage. Fot the 1st stage (for 3 months), the patient will be observed without any treatment. And at visit 4, at 2nd stage, they will be treated with the same regimen for H. pylori eradication."||||
33684693|NCT02620397|||||PROSPECTIVE|||||||
33684694|NCT03479645|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33684695|NCT04096183|NA|SINGLE_GROUP||OTHER||NONE||||||
33684696|NCT00695734|||CASE_ONLY||CROSS_SECTIONAL|||||||
33684697|NCT02095496|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33684698|NCT02078076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684699|NCT01710267|||COHORT||PROSPECTIVE|||||||
33684700|NCT06046521|||COHORT||PROSPECTIVE|||||||
33684701|NCT06251817|||OTHER||CROSS_SECTIONAL|||||||
33684702|NCT00458874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684703|NCT03121651|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Unblinded pilot study with 1 intervention arm||||
33684704|NCT00911001|||COHORT||PROSPECTIVE|||||||
33684705|NCT05252260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684706|NCT05340270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684707|NCT02230527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684708|NCT03255330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684709|NCT04187287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684710|NCT03229460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684711|NCT05871515|||COHORT||PROSPECTIVE|||||||
33904563|NCT01327339|||COHORT||PROSPECTIVE|||||||
33904564|NCT02242071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904565|NCT00000455|RANDOMIZED|||TREATMENT||||||||
33904566|NCT04282473|||CASE_CONTROL||PROSPECTIVE|||||||
33904567|NCT01283191|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684712|NCT01470443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684713|NCT04240678|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33684714|NCT05573412|||OTHER||OTHER|||||||
33684715|NCT06427343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Drug: Ferric Derisomaltose|f|f|f|t
33684716|NCT03375073|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized controlled trial, with a 1:1 allocation ratio|f|f|t|t
33684717|NCT03894176|||COHORT||PROSPECTIVE|||||||
33684718|NCT01368718|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33684719|NCT01771185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684720|NCT05918198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904568|NCT02832804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904569|NCT04558762|||COHORT||CROSS_SECTIONAL|||||||
33904570|NCT01783626|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33904571|NCT01681784|||COHORT||PROSPECTIVE|||||||
33904572|NCT02429596|RANDOMIZED|PARALLEL||||NONE||||||
33904573|NCT06498427|||COHORT||PROSPECTIVE|||||||
33904574|NCT00114114|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33904575|NCT03336138|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904576|NCT01706445|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33904577|NCT06693479|RANDOMIZED|PARALLEL||OTHER||NONE|Due to the nature of the intervention, neither the treating physiotherapist nor the participants can be blinded. Blinding of the evaluator is irrelevant as outcome data will either be collected online with self-reported questionnaires or by the device measuring physical work demands. The investigator and statistician will remain unaware of group assignments throughout.|||||
33904578|NCT02337504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904579|NCT01323673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904580|NCT02186327|RANDOMIZED|PARALLEL||||NONE||||||
33904581|NCT04323397|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Controlled Crossover Study||||
33904582|NCT04389476|||CASE_ONLY||PROSPECTIVE|||||||
33904583|NCT05566197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|masking is not feasible according to the study design.|The intervention will receive a package of dietary intervention + nutrition counseling, whereas the control group will receive only nutrition counseling.||||
33904584|NCT01729598|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33904585|NCT03990766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Two randomized arms|t|t|t|t
33904586|NCT04971044|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33904587|NCT03558932|||COHORT||PROSPECTIVE|||||||
33904588|NCT03828838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904589|NCT05272163|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants are blind to the purposes of the experiment but know about the manipulations of the conditions.|||||
33904590|NCT04217902|||OTHER||OTHER|||||||
33904591|NCT00353847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33904592|NCT02107391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904593|NCT02022683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904594|NCT03312491|||COHORT||PROSPECTIVE|||||||
33904595|NCT01285921|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33904596|NCT01219946|||CASE_ONLY||CROSS_SECTIONAL|||||||
33904597|NCT03747016|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33904598|NCT06162416|||CASE_ONLY||RETROSPECTIVE|||||||
33904599|NCT03869138|NA|SINGLE_GROUP||TREATMENT||NONE|Intervention provider and assessor were all blinded|||||
33904600|NCT02940054|||||PROSPECTIVE|||||||
33904601|NCT02983903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904602|NCT02157831|NA|SINGLE_GROUP||TREATMENT||||||||
33904603|NCT01959308|||||RETROSPECTIVE|||||||
33904604|NCT02909166|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33904605|NCT01943123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33904606|NCT04833933|||OTHER||CROSS_SECTIONAL|||||||
33904607|NCT04180436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904608|NCT06671041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904609|NCT00440128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081458|NCT03405727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081459|NCT04970212|||COHORT||PROSPECTIVE|||||||
34081460|NCT05807867|RANDOMIZED|PARALLEL||OTHER||SINGLE|Staff assessing all outcomes will be blinded to treatment assignment.|"1. Recruit 180 women to allow for 8% attrition post-intervention, with an added 8% during 4-month follow-up (below), to yield a final sample of N=151 expected to complete WMM or control (n=75 in each of 2 arms).~2. The investigators expect to recruit \~180 family members to allow for 16% attrition overall, to yield a final sample of N=151 expected to complete the stigma intervention or control (n=75 in each of the 2 arms, under assumption that attrition on average occurs at the same rate in each arm)."|f|f|f|t
34081461|NCT01368419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081462|NCT04077892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34081463|NCT01989858|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34081464|NCT01746862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081465|NCT05595135|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34081466|NCT01192737|||COHORT||PROSPECTIVE|||||||
34081467|NCT00524433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081468|NCT01563523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081469|NCT02869789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081470|NCT06017245|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34081471|NCT01290718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081472|NCT02121210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081473|NCT04149418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34081474|NCT06273761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081475|NCT01595373|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34081476|NCT03305718|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34081477|NCT01952379|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34081478|NCT00888875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081479|NCT02668640|||CASE_ONLY||PROSPECTIVE|||||||
34081480|NCT02351934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081481|NCT01219582|||COHORT||PROSPECTIVE|||||||
34081482|NCT03982524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081483|NCT02051296|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081484|NCT01299558|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34081485|NCT00191243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081486|NCT04131296|||COHORT||PROSPECTIVE|||||||
34081487|NCT03110107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081488|NCT06221176|NA|SINGLE_GROUP||SCREENING||NONE||||||
34081489|NCT03759925|RANDOMIZED|PARALLEL||OTHER||SINGLE|The principal investigators will be masked to whether participants were in the intervention or control arm.|180 participants will be randomized to the intervention (n=90) or control (n=90) groups, stratified by health care utilization (\<3 vs. \>=3 hospital admissions at ZSFGH) and food security ( zero affirmative answers vs. at least one affirmative answers on the US Department of Agriculture (USDA) 12-question food security screener). The intervention consists of providing home delivery of medically-appropriate food support and individual nutritional counseling over five months to patients at Zuckerberg San Francisco General admitted to the hospital with acute decompensated heart failure.|f|f|t|f
34081490|NCT00001567||||TREATMENT||||||||
34081491|NCT00677417|||CASE_ONLY||RETROSPECTIVE|||||||
34081492|NCT05870852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081493|NCT00927875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081494|NCT03034369|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33684721|NCT05774392|||COHORT||OTHER|||||||
33684722|NCT00781352|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33684723|NCT01930331|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684724|NCT04662827|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The masking is done by the pharmacological department also produces the placebos|doubleblind, placebo-controlled,prospective crossover study|t|t|t|t
33684725|NCT00310453|RANDOMIZED|PARALLEL||||DOUBLE||||||
33684726|NCT03274375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684727|NCT00817128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684728|NCT01889095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684729|NCT04147403|||COHORT||CROSS_SECTIONAL|||||||
33684730|NCT03390101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684731|NCT01341392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684732|NCT06530186|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33684733|NCT01653132|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33684734|NCT00484185|||COHORT||PROSPECTIVE|||||||
33684735|NCT00005001||||TREATMENT||DOUBLE||||||
33684736|NCT01518738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33684737|NCT01363414|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33684738|NCT01447680|||COHORT||PROSPECTIVE|||||||
33684739|NCT04617873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684740|NCT00941434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684741|NCT02539615|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33684742|NCT01758445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684743|NCT03442868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081495|NCT05507099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081496|NCT02962427|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34081497|NCT01111565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081498|NCT04554472|||CASE_ONLY||PROSPECTIVE|||||||
34081499|NCT02792504|||COHORT||PROSPECTIVE|||||||
34081500|NCT03111524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Principal investigator is blinded to the study. The researcher is able to observe while the research assistants are aware of who is in the control versus intervention groups.|10 schools are included. The schools are assigned to control versus intervention groups|t|f|t|f
34081501|NCT00483652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081502|NCT04861142|||COHORT||PROSPECTIVE|||||||
34081503|NCT06163118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33987459|NCT04057677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The proposed clinical study is a prospective, parallel two arm, randomized controlled trial||||
33987460|NCT05277779|||COHORT||PROSPECTIVE|||||||
33987461|NCT04728763|||OTHER||PROSPECTIVE|||||||
33987462|NCT01174225|RANDOMIZED|PARALLEL||PREVENTION||NONE||Flexi-T380(+) IUD Nova-T200 IUD||||
33904610|NCT03896867|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Group assignment will be blinded with the data set (Group A vs B) for review purposes - although it is important to note that true blinding of the providers (including on PI and Co PI) is impossible for this procedural study.||f|f|t|t
33987463|NCT04441216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987464|NCT02458586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33987465|NCT05510557|||COHORT||PROSPECTIVE|||||||
33987466|NCT06302686|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987467|NCT03959683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, multicenter, 2 arm, comparative trial|t|f|f|f
33987468|NCT04093037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"80 patients divided into 4 subgroups according to the value of manual Standard Break-Up-Time (SBUT):~* 0-5 seconds (very dry)~* 5-10 seconds (sec)~* 10-15 seconds (moderately dry)~* 15-20 seconds (normal)"||||
33987469|NCT01204294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987470|NCT03575403|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33987471|NCT03735485|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants did not know which treatment group they were in.|There were three study groups: 1. The control group: Participants in this group received only conventional physiotherapy treatment. 2. The shoulder mobilization group: Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques as treatment. The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises as treatment.|t|f|f|f
33904611|NCT00653796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904612|NCT00396188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904613|NCT04863287|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||"Randomized, partial-blind, placebo controlled, sequential, dose escalation study, consisting of four cohorts of 10 subjects. Each cohort will have a sentinel group consisting of 2 subjects randomized 1:1 to receive 2217LS or placebo. Sentinel subjects will be dosed first. If judged safe and well tolerated by the Principal Investigator (PI) and if the stopping rules have not been met, the remaining 8 subjects in the cohort will be randomized 7:1 to 2217LS or placebo, respectively and dosed no less than 24 hours after dosing of sentinel subjects has been completed.~For each cohort, safety and pharmacokinetic (PK) data will be reviewed by the PI, Independent Medical Monitor (IMM) and Sponsor prior to dosing the next cohort. A minimum of 7 days of safety data and available PK data from a minimum of 8 subjects from the preceding cohort must be reviewed. Dosing of the next cohort may proceed upon agreement between the PI, IMM and Sponsor, if the stopping rules have not been met."|t|t|t|f
33904614|NCT05242276|||CASE_CONTROL||PROSPECTIVE|||||||
33904615|NCT03994835|||COHORT||PROSPECTIVE|||||||
33904616|NCT05782101|||COHORT||PROSPECTIVE|||||||
33904617|NCT02773758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33904618|NCT00395096|||COHORT||PROSPECTIVE|||||||
33904619|NCT05162612|||CASE_ONLY||CROSS_SECTIONAL|||||||
33904620|NCT01924897|RANDOMIZED|||TREATMENT||||||||
33904621|NCT06201195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33904622|NCT00515008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904623|NCT05688267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33904624|NCT05573594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904625|NCT03692910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904626|NCT04490668|||CASE_CONTROL||RETROSPECTIVE|||||||
33904627|NCT02456116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904628|NCT01761955|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33904629|NCT05325138|||OTHER||OTHER|||||||
33904630|NCT04013581|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Prospective, open label, randomized, parallel, multicenter clinical trial||||
33904631|NCT03601338|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||pregnant women with history of unexplained fetal death||||
33904632|NCT02286115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904633|NCT03230175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904634|NCT03843658|||OTHER||PROSPECTIVE|||||||
33904635|NCT01464047|||CASE_ONLY||PROSPECTIVE|||||||
33904636|NCT04707144|||COHORT||PROSPECTIVE|||||||
33904637|NCT01943864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904638|NCT06692127|||COHORT||PROSPECTIVE|||||||
33904639|NCT06212895|||OTHER||CROSS_SECTIONAL|||||||
33904640|NCT03402867|NA|SINGLE_GROUP||TREATMENT||NONE||Deep dry needling||||
33904641|NCT01243606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904642|NCT06689735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904643|NCT03206034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind placebo controlled randomized control trial|t|f|t|t
33904644|NCT02003742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904645|NCT05776186|||COHORT||PROSPECTIVE|||||||
33904646|NCT04534426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904647|NCT03339648|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|All participants and study staff will be aware of which schools are in each arm.|During the measurement period, the experimental arm will receive the intervention while the control arm continues business as usual. After all data collection, the control arm will receive the intervention.||||
33904648|NCT03658330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904649|NCT04082767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33904650|NCT06435195|||COHORT||RETROSPECTIVE|||||||
33904651|NCT02354391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904652|NCT04788303|RANDOMIZED|PARALLEL||PREVENTION||NONE||Six schools will be randomly assigned to receive the full intervention (school meal, garden, and education), partial intervention (garden and education), or control (standard of care). Community workshops will also be provided to parents of adolescents in full and partial intervention schools.||||
33904653|NCT03739944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33904654|NCT00504166|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33904655|NCT05212194|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904656|NCT00783705|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33904657|NCT04237207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904658|NCT00674336|NA|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33904659|NCT02228278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904660|NCT04459299|||COHORT||PROSPECTIVE|||||||
33904661|NCT00299533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904662|NCT03153111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904663|NCT03814317|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated.||||
33904664|NCT01703819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904665|NCT02952066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904666|NCT01143597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904667|NCT03532555|RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants will be stratified by gestational age (23-24 wks, 25-26 wks, 27-29 wks) and then are randomized to receive supplemental oral zinc acetate or no zinc acetate.||||
33904668|NCT01856634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904669|NCT01745627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987472|NCT05852626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized clinical trial||||
33987473|NCT05549934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987474|NCT01559220|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33987475|NCT05070052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33987476|NCT02269995|||COHORT||PROSPECTIVE|||||||
33987477|NCT05906004|||COHORT||OTHER|||||||
33987478|NCT03548519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33987479|NCT00296647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987480|NCT00467896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987481|NCT02695797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987482|NCT02365454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987483|NCT04042285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987484|NCT03137108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987485|NCT02444715|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987486|NCT02356302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33987487|NCT06372353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987488|NCT01639092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987489|NCT02372266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987490|NCT02301975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987491|NCT04405570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987492|NCT02959580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987493|NCT03892408|RANDOMIZED|PARALLEL||PREVENTION||NONE|triple (Participant, Care Provider, investigator)|A prospective Randomized, open label Trial||||
33987494|NCT02447874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684744|NCT02273739|NA|SEQUENTIAL||TREATMENT||NONE||||||
33684745|NCT00817479|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33684746|NCT04739865|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33684747|NCT05106790|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Double-blinded|It's a 12-month factorial design, intention-to-treat, four-arm, double-blinded, multicentre, pragmatic randomized controlled trial with an intervention to assess the efficacy of mHealth and education support with peer counseling to improve treatment adherence and lower systolic blood pressure in hypertensive patients in three teaching hospitals in Lahore, Pakistan.|f|f|t|t
33684748|NCT00134784|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684749|NCT01773447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33684750|NCT04698850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684751|NCT05996991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Clinical Trial with three parallel arms|t|t|t|t
33684752|NCT04307875|||COHORT||CROSS_SECTIONAL|||||||
33684753|NCT04047927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684754|NCT03513848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904670|NCT03781193|||COHORT||PROSPECTIVE|||||||
33904671|NCT01096550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987495|NCT01517321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987496|NCT02028611|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33987497|NCT02371486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987498|NCT04461379|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, researchers (including members of the research team that will assess outcomes), and treating physicians or health personnel (should the patient require in-hospital management) will be blinded to the treatment group to which the patients were randomized. Only the personnel who apply the vaccine will not be blinded to the treatment group to which the patients were randomized (this personnel will not have any further contact with the patients or provide any other type of patient care).|"A randomized double-blinded clinical trial, using computer software, participants will be allocated between two groups:~Intervention: BCG vaccine intradermally 0.1 ml, equivalent to 0.075 mg of attenuated Mycobacterium bovis. (Tokio 172 strain). The application technique is based on the National Vaccination Manual version 2017.~Comparator: Placebo, intradermally 0.1 ml of NaCl 0.9%"|t|t|f|t
33987499|NCT02158663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987500|NCT01665586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33987501|NCT01922765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987502|NCT02849691|||COHORT||RETROSPECTIVE|||||||
33987503|NCT04058080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987504|NCT00901745|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33987505|NCT02130518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987506|NCT00469417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987507|NCT03919630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987508|NCT03905005|||COHORT||PROSPECTIVE|||||||
33904672|NCT04003636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904673|NCT00275405|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904674|NCT02897193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904675|NCT00824499||PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904676|NCT01790958|||CASE_CONTROL||RETROSPECTIVE|||||||
33904677|NCT03953586|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904678|NCT05680129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904679|NCT03020524|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904680|NCT00084682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904681|NCT01530399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904682|NCT05922267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904683|NCT01306058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904684|NCT00729118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904685|NCT01150071|||COHORT||PROSPECTIVE|||||||
33904686|NCT05724667|||OTHER||RETROSPECTIVE|||||||
33987509|NCT01688934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987510|NCT05910853|||OTHER||PROSPECTIVE|||||||
33987511|NCT02282189||CROSSOVER||TREATMENT||NONE||||||
33987512|NCT01136382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684755|NCT02555501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684756|NCT03835728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684757|NCT01367080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33684758|NCT06309888|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684759|NCT04656483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33684760|NCT01137162|||COHORT||PROSPECTIVE|||||||
33684761|NCT01687556|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33684762|NCT01167985|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33684763|NCT02045953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684764|NCT00084461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684765|NCT00290095|||CASE_ONLY||PROSPECTIVE|||||||
33684766|NCT06382883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684767|NCT05679427|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The sample size calculation is based on the Kaplan-Meier estimator and uses a log-rank test (Freedman, 1982; Machin et al., 2018). Assuming for the two groups a two-year LRFS of 95% and 85%, respectively, with alpha=0.05 and power of 80%, the total number needed to identify a significant difference between the two curves is 292 (test at 2 queues, 146 patients per group).~Calculations were performed with software (PASS 2021, v21.0.3). Assuming a 5% dropout, we expect to enroll 15 more patients in total, thus reaching a final number of 307."||||
33904687|NCT05993767|NA|SINGLE_GROUP||TREATMENT||NONE||An interventional, phase I/II, multicenter, single-arm study||||
33904688|NCT04292717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904689|NCT06137521|||COHORT||RETROSPECTIVE|||||||
33904690|NCT00365976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904691|NCT03605355|||COHORT||PROSPECTIVE|||||||
33904692|NCT02752867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904693|NCT03619148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 sub group will be recruited:~1. patient undergoing TOE~2. Staff volunteers"||||
33904694|NCT05682807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904695|NCT01666444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904696|NCT03510663|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33987513|NCT03292328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987514|NCT00449592|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987515|NCT00276926|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33987516|NCT06013293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987517|NCT01134094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987518|NCT00584025|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34081504|NCT03425669|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants will be randomized to placebo or stimulant medication during assessments. Participants will be unaware if they will get sham stimulation or SVS (but not the test administrator).|"Patients will be recruited from Child and Adolescent Psychiatry in Lund and Malmö. Typically developing children (TDC) and inattentive children without diagnosis will be recruited from schools.~All participants will perform a double-blind placebo cross over control study. ADHD participants will perform the entire test battery at three occasions with 2-3 weeks intermission in between tests. One occasion with placebo medication and sham SVS stimulation; one occasion with active SVS stimulation; and one occasion with active medication. TD children will only be tested twice and just perform under SVS vs. sham conditions.~Test battery: 1) Episodic memory will be tested trough Auditory Verbal Learning Test (AVLT) (e.g. Dige et al., 2008). 2) Visuo-spatial working memory will be tested through the Spanboard task (Westerberg et al., 2004). 3) Motor-neurological investigation. 4) A finger tapping task. 5) Evaluation of an iPhone auditory noise application in a normal school setting."|t|t|f|t
34081505|NCT00643201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684768|NCT06506370|||CASE_CONTROL||PROSPECTIVE|||||||
33684769|NCT01126671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684770|NCT05312918|||COHORT||PROSPECTIVE|||||||
33684771|NCT03190642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774864|NCT05419830|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The randomization envelopes will be prepared by the study statistician. Randomization and the intervention BBTI will be completed by research nurse and PI and the outcome assessor will be blinded to randomization.|In the proposed pilot study 30 community-dwelling older adults (aged \>65) who take at ≥1 daily non-diuretic antihypertensive medication, have a mean SBP \>135 mm Hg, and awaken ≥2 times nightly to void will be randomly assigned to one of the 3 groups of 10 participants each to 1) morning (am) HTN medication dosing, 2) BBTI with am HTN medication dosing, 3) nighttime non-diuretic HTN medication dosing (chronotherapy) for 6 weeks.|f|f|t|t
33774865|NCT06602232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774866|NCT05881005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774867|NCT03595787|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33987519|NCT05984030|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Participants are randomized 1:1 to Intervention Condition or Control Condition. The study will use blocked randomization stratified by county, with randomly ordered blocks of sizes 4 and 6.~All participants will be asked to complete baseline and quarterly assessments at 3- and 6-month follow-up. Participants who are enrolled into the study with sufficient follow-up time remaining in the funding period will also be asked to complete a 12-month assessment. Primary outcome measures are assessed at month 3. Secondary outcome measures are assessed at months 3 and 6."||||
33987520|NCT03383354|||COHORT||PROSPECTIVE|||||||
33987521|NCT06451783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Combined treatment group：Traditional Chinese medicine combined with manipulation treatment Control group：Oral control group medication|t|f|t|t
34081506|NCT02851602|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081507|NCT02398110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987522|NCT01344707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987523|NCT03494361|||OTHER||PROSPECTIVE|||||||
33987524|NCT03154645|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|visually identical pills|randomized double blind controlled trial|t|t|t|t
33987525|NCT03084471|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33987526|NCT01336322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987527|NCT02061891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987528|NCT01262833|||COHORT||PROSPECTIVE|||||||
33987529|NCT02496546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987530|NCT01320254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987531|NCT05244863|||OTHER||OTHER|||||||
33987532|NCT01972165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987533|NCT03657394|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Cluster Randomized Crossover|f|f|f|t
33987534|NCT06431321|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Research assistants and the statistician will be blinded until the analyses are completed. The randomisation process is concealed from research assistants in order to avoid experimenter bias. Complete statistical analysis plans will be prepared before the data is locked, and analysis tactics are predetermined. Until the data are finalised, the study statistician will not be aware of the treatment assignment|Each study arm will have 8 schools Schools will be randomly assigned to the study arm|t|f|f|t
33987535|NCT03141398|||COHORT||PROSPECTIVE|||||||
33987536|NCT04186260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will be performed at 0, 6, and 12-months post-intervention. To minimize the potential for bias, outcome assessors will be blinded to treatment condition.|The pilot study uses a small randomized-controlled trial (RCT) design that will be conducted in two phases. The first phase includes recruitment, screening, and baseline assessment procedures. The second phase will include PNPLA3 risk allele carriers (CG/GG genotype) with NAFLD, who will be assigned 2:1 to a NAFLD-specific weight loss intervention tailored for Mexican-American men, including informing them of their lifestyle and genetic risk, for 12-months compared to a wait-list control group.|f|f|f|t
33774868|NCT03935750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome assessors will be blinded to group allocation.|This trial will randomly assign 1236 ACL deficient patients at high risk of re-injury to anatomic anterior cruciate ligament reconstruction (ACLR) using bone patellar tendon bone (BPTB) or quadriceps tendon (QT) autograft with or without a lateral extra-articular tenodesis (LET) in a 1:1:1:1 ratio.|f|f|f|t
33774869|NCT06364163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33774870|NCT05667064|||COHORT||PROSPECTIVE|||||||
33774871|NCT06215911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081508|NCT00676923|||COHORT||PROSPECTIVE|||||||
34081509|NCT02425306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081510|NCT00293553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34081511|NCT00695123|||OTHER||PROSPECTIVE|||||||
34081512|NCT02980081|||COHORT||RETROSPECTIVE|||||||
34081513|NCT06147934|||CASE_ONLY||PROSPECTIVE|||||||
34081514|NCT02964624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081515|NCT05858983|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34081516|NCT02356120|||COHORT||PROSPECTIVE|||||||
34081517|NCT01099046|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34081518|NCT03142945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be advised of their group until they exit the study|Two randomized groups. One receiving traditional physical therapy treatments for patients with mechanical headaches. The other will receive an MDT- based approach.|t|f|f|f
34081519|NCT00731822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081520|NCT00529711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081521|NCT00059553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081522|NCT02273401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081523|NCT04216147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081524|NCT04070664|||COHORT||PROSPECTIVE|||||||
34081525|NCT03060408|||COHORT||RETROSPECTIVE|||||||
33904697|NCT03818438|||CASE_CONTROL||PROSPECTIVE|||||||
34081526|NCT04158869|||CASE_CONTROL||RETROSPECTIVE|||||||
34081527|NCT04222920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are kept ignorant of the group to which they have been assigned|Patients with rheumatoid arthritis treated with adalimumab for at least 28 weeks and a serum adalimumab concentration above 5 mg/L will be randomly assigned to dose reduction by extending their dosing interval aiming a drug level of 2 mg/L or aiming a drug level of 5 mg/L|t|f|f|f
33684772|NCT03563144|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a randomized parallel group study comparing the NANT Pancreatic Cancer Vaccine and standard therapy with respect to efficacy and safety in treatment naïve patients with pancreatic cancer. Patients will be stratified by ECOG status and then randomized 1:1 to receive either the NANT Pancreatic Vaccine (n\~532) or standard therapy with gemcitabine alone (ECOG 2; n\~266) or combined with nab-paclitaxel (ECOG 0-1; n\~266). Treatment may continue for up to 2 years or until documented progression (RECIST v 1.1) or unacceptable toxicity. Patients on standard therapy who progress or experience unacceptable toxicity may crossover to receive NANT Pancreatic Vaccine.||||
33904698|NCT03067662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904699|NCT06169865|||OTHER||CROSS_SECTIONAL|||||||
33904700|NCT05823909|||CASE_CROSSOVER||PROSPECTIVE|||||||
33904701|NCT03952897|||COHORT||PROSPECTIVE|||||||
33904702|NCT01842061|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33904703|NCT04569305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded means that patient will be unaware of his/her treatment method.||t|f|f|f
33904704|NCT00003264||||TREATMENT||||||||
33904705|NCT01208896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904706|NCT03632512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33904707|NCT04788719|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Preop Postop||t|f|f|f
33904708|NCT01585129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904709|NCT01123239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33987537|NCT05030363|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Open label|A 2-Period, Crossover, Single-Center Study||||
33987538|NCT05596435|||COHORT||PROSPECTIVE|||||||
33987539|NCT00725517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987540|NCT05222477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33987541|NCT00394810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081528|NCT03620513|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Four arms of study group with equal number of subjects in each group|t|t|f|t
33774872|NCT06128564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904710|NCT04499508|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-arm, single-center, post-market, real-world, investigator-initiated study.||||
33904711|NCT00471367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904712|NCT04911101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904713|NCT00278265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904714|NCT00187707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904715|NCT04770233|RANDOMIZED|PARALLEL||TREATMENT||NONE||Registry-based multi-center RCT. Centralized randomization through NNKLR stratified by participating centers. Allocation concealment secured by requiring registration into the NNKLR and the R-RCT before allocation is revealed.||||
33904716|NCT04994821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple Masking||t|t|t|t
33904717|NCT02509910|||COHORT||RETROSPECTIVE|||||||
33987542|NCT03502161|||COHORT||PROSPECTIVE|||||||
34081529|NCT04144192|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34081530|NCT03602105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081531|NCT00607243|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081532|NCT04858152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081533|NCT03041441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081534|NCT01748370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33987543|NCT01745120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987544|NCT01774435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987545|NCT06562023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33987546|NCT02465320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987547|NCT01216150|||COHORT||PROSPECTIVE|||||||
33987548|NCT00410865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987549|NCT02819323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987550|NCT00059670|RANDOMIZED|||TREATMENT||||||||
33987551|NCT06221319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987552|NCT06456593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987553|NCT01853566|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33987554|NCT00311441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33987555|NCT04391933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.||||
34081535|NCT00983372|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34081536|NCT03006562|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, single-institution, multi-surgeon, stratified randomized controlled trial. Randomization will be stratified into four groups by procedure approach (open or robotic) and whether patients elect to undergo a screening 30-day lower extremity Duplex (ultrasound or no ultrasound). Patients will then be randomized, within each of the strata, to the two arms (subcutaneous heparin versus no subcutaneous heparin).|f|f|f|t
33684773|NCT03450980|NA|SINGLE_GROUP||SCREENING||NONE|"Aim 1) In the comparison of the app against the ground truth the study staff will be masked to the ground truth value.~Aim 2) In comparison of the app against the clinical gold standards, the study staff making the clinical gold standard measures (prism alternating cover test and Modified Thorington test) will be masked to the app measurement.~Analyses: Study staff and statistician performing the analysis will be masked to which group data is from the app and which is from the ground truth and gold standard tests."|||||
33684774|NCT04329689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684775|NCT00344292|||CASE_CONTROL||RETROSPECTIVE|||||||
33684776|NCT05061680|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684777|NCT01840878|||CASE_CROSSOVER||PROSPECTIVE|||||||
33904718|NCT02951546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved. Also biochemical mechanisms that affect the metabolic flexibility need to be better clarified.~It is known that a dietary intervention and a physical personalized training, reduce either the hepatic fat content either insulin resistance.~Therefore, the aim of the study is to evaluate metabolic flexibility in obese NAFLD subjects taking in account the presence or absence of PNPLA3 and TM6SF2 polymorphism and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). The composition of gut microbiota will be also evaluated.~Finally, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested to comprehend whether and how healthy diets could operate in the clinical treatment of NAFLD and related conditions."||||
33684778|NCT02065271|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34081537|NCT02662569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081538|NCT05749016|NA|SINGLE_GROUP||TREATMENT||NONE|open label|The phase II trial included patients with histologically confirmed stage IIA to IIIC and HER2-positive primary invasive breast cancer from November 2021 to July 2023. Eligible patients received inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen every three weeks for a maximum of 6 cycles, followed by surgery. The primary endpoint was pathologic complete response (pCR; ypT0 ypN0) rate. Key secondary endpoints included near pCR (npCR) (residual breast disease \<1cm), objective response rate (ORR) and safety.||||
33684779|NCT05343533|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All supplements were blinded from participant and investigator by a third party|andomized, double-blind, placebo-controlled, parallel study design that will evaluate the ability of a probiotic to influence mood, depressive symptoms, anxiety, sleep quality, and other personality traits in a group of healthy men and women|t|f|t|f
33684780|NCT06245551|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33684781|NCT02483533|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33684782|NCT01891045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904719|NCT06444737|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33904720|NCT02610088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904721|NCT05094154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and providers will necessarily be unblinded, but outcomes will be analyzed by a blind assessor.|This study will be performed as a pragmatic, randomized controlled clinical trial with parallel group assignment.|f|f|f|t
33904722|NCT02848846|NA|SINGLE_GROUP||||NONE||||||
33904723|NCT02229864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904724|NCT00266110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904725|NCT02235753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904726|NCT03791346|||COHORT||RETROSPECTIVE|||||||
33904727|NCT01094340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904728|NCT01214434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904729|NCT01166672|||COHORT|||||||||
33904730|NCT01970579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904731|NCT06021652|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904732|NCT01109901|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904733|NCT06675799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904734|NCT00002263||||TREATMENT||||||||
33904735|NCT01935908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684783|NCT05883826|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33684784|NCT00162955|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904736|NCT03375658|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904737|NCT04397068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904738|NCT03471676|||COHORT||PROSPECTIVE|||||||
33904739|NCT01353833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33904740|NCT06286787|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904741|NCT05355363|NA|SINGLE_GROUP||PREVENTION||NONE||prospective, multi-endoscopist, single center, single group assignment||||
33904742|NCT04066556|||COHORT||PROSPECTIVE|||||||
33904743|NCT03229746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904744|NCT02025738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904745|NCT01720511|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33904746|NCT01554878|||||PROSPECTIVE|||||||
34081539|NCT03072550|NA|SINGLE_GROUP||TREATMENT||NONE||multi-center open-label study||||
34081540|NCT00004246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081541|NCT01317563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684785|NCT00777218|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33684786|NCT02734901|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33904747|NCT05438485|||COHORT||OTHER|||||||
33987556|NCT03522363|RANDOMIZED|PARALLEL||OTHER||NONE||Phase I, exploratory, prospective, mechanistic pilot clinical trial with two parallel follow-up groups that differ in the number of treament applications.||||
33987557|NCT05378360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987558|NCT04539470|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33987559|NCT04289532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081542|NCT01339312|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081543|NCT01317147|||CASE_ONLY||PROSPECTIVE|||||||
34081544|NCT02089347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081545|NCT05251584|NA|SINGLE_GROUP||PREVENTION||NONE||Single group: topical mupirocin ointment retrospective period compare with gentamicin prospective period||||
33684787|NCT04340427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684788|NCT05067231|||COHORT||PROSPECTIVE|||||||
33684789|NCT05353803|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33684790|NCT00706849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684791|NCT00740051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33684792|NCT03705273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684793|NCT02173028|||CASE_CONTROL||PROSPECTIVE|||||||
33684794|NCT02651181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684795|NCT02274038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684796|NCT04906915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684797|NCT04991818|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33684798|NCT00239525|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684799|NCT01326325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684800|NCT00360152|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33684801|NCT00003959||||TREATMENT||||||||
33684802|NCT03505827|||COHORT||PROSPECTIVE|||||||
33684803|NCT03486145|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Both the study investigators and the participants were blinded regarding supplement assignments, and the identity of the A and B supplements were not revealed to study investigators until all data analyses were complete."|Participants were stratified by age, height, weight, BMI, blood pressure and athletic status and randomly assigned to consume daily either the fruit and vegetable rich juice supplement (B) or prune juice (A; control treatment).|t|f|t|t
33684804|NCT02485678|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33684805|NCT05124418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684806|NCT03521804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774873|NCT05166811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Doses will be prepared ahead of time by an investigational pharmacist, arms will be identical in appearance, and clinicians administering the study drug will be blinded to the study arm the patient receives.|Randomized, double-blind, placebo-controlled trial|t|t|t|t
33774874|NCT05716763|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, randomized, single dose, two-sequence, two-period crossover study||||
33987560|NCT03680222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Different methods of protection of external branches of superior laryngeal nerve|t|f|f|f
33987561|NCT04589247|||COHORT||PROSPECTIVE|||||||
33987562|NCT05645367|||COHORT||CROSS_SECTIONAL|||||||
34081546|NCT02598453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081547|NCT06443294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684807|NCT03736239|||COHORT||PROSPECTIVE|||||||
33684808|NCT04506762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Prospective Controled||||
33684809|NCT00559182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684810|NCT06520475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774875|NCT06492512|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:1 for daily iron (ferrous sulfate) supplementation vs. every other day iron (ferrous sulfate) supplementation||||
33774876|NCT04843813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A 2-group parallel design will be employed to collect feasibility data on daily lutein supplementation over 4 months.|t|f|f|f
33774877|NCT06738355|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Clinic analysts will create a real-time list of patients due for an initial HPV vaccine dose. P/C of remaining C/A patients will be individually randomized to either Auto or Auto-Plus intervention or usual care (UC) in a 1:1:1 ratio. The PREVENT study will only target one child/adolescent per parent/caregiver (siblings will be excluded from intervention assessments). The investigators will use automated codes to manage interventions so that eligible patients get initial HPV vaccines on time and P/C are prompted to repeat vaccination, as recommended. The investigators will select a cohort of approximately 1,038 P/C patients from the 4 clinics, randomized to intervention arms (UC, Auto, and Auto-Plus). Intervention activities largely mimic clinic processes, and clinicians and participants will be unaware of which intervention study arm the P/C has been assigned.|"The investigators will use intervention mapping (IM) to plan each intervention step. The investigators will apply IM to develop and test HPV vaccination reminders for parents/caregivers (P/C). Bootcamp Translation (BCT) will engage diverse stakeholders using an iterative schedule of meetings. The BCT process will define the format and content of vaccination messages.~Intervention: The investigators propose a 3-arm RCT to compare rates of completing the next step in the HPV vaccination series at six months and completing the HPV vaccination series at 13 months between Auto, Auto-Plus, and UC arms. P/C of children/adolescents (C/A) who have not completed the series will be randomized 1:1:1 to study arms. Participants will be assessed for eligibility and enrolled, with a total participant time in the study of 13 months, for a total of 25 months of enrollment, participation, and follow-up."|t|t|f|f
33774878|NCT06509152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33987563|NCT02077465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987564|NCT00719745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987565|NCT02530905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987566|NCT00833157|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33987567|NCT01693263|||COHORT||PROSPECTIVE|||||||
33987568|NCT01265056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Care Provider and Investigator are all masked.||t|t|t|f
33684811|NCT06364293|||COHORT||PROSPECTIVE|||||||
34081548|NCT00889629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34081549|NCT05914181|||CASE_ONLY||CROSS_SECTIONAL|||||||
34081550|NCT03860740|||CASE_CONTROL||PROSPECTIVE|||||||
34081551|NCT01178294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684812|NCT05117957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684813|NCT05098275|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684814|NCT02678598|||COHORT||RETROSPECTIVE|||||||
34081552|NCT00286182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684815|NCT04034953|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33684816|NCT03673904|||CASE_ONLY||PROSPECTIVE|||||||
33684817|NCT00026611||||PREVENTION||DOUBLE||||||
33684818|NCT01028690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684819|NCT02484859|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33684820|NCT00005176|||FAMILY_BASED||PROSPECTIVE|||||||
33684821|NCT05184751|||COHORT||RETROSPECTIVE|||||||
34081553|NCT03025373|||CASE_CONTROL||PROSPECTIVE|||||||
34081554|NCT01784874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34081555|NCT00086671|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34081556|NCT02683629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081557|NCT02687854|||COHORT||RETROSPECTIVE|||||||
34081558|NCT03212716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34081559|NCT00230035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774879|NCT04622020|||COHORT||PROSPECTIVE|||||||
34081560|NCT02516072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081561|NCT04367298|||CASE_ONLY||PROSPECTIVE|||||||
34081562|NCT04478617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081563|NCT03068104|||COHORT||RETROSPECTIVE|||||||
34081564|NCT00950573|||COHORT||PROSPECTIVE|||||||
34081565|NCT04895917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684822|NCT01505647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33684823|NCT01663753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684824|NCT05413577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684825|NCT01781169|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774880|NCT05879068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774881|NCT05934448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774882|NCT06740708|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33774883|NCT05921760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081566|NCT05493566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684826|NCT03167450|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33684827|NCT01910311|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684828|NCT05553054|||COHORT||PROSPECTIVE|||||||
33684829|NCT03794882|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant is blinded to the treatment.|Parallel Assignment|t|f|f|f
33684830|NCT02239705|||CASE_CONTROL||PROSPECTIVE|||||||
33684831|NCT06198140|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33684832|NCT00704665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684833|NCT01644370|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33684834|NCT02044497|NA|SINGLE_GROUP||OTHER||NONE||||||
33684835|NCT04272138|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33684836|NCT06257043|||COHORT||PROSPECTIVE|||||||
33684837|NCT03044574|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized clinical study to assess efficacy and safety of intermittent pneumatic compression device (SCD) application in combined prevention of postoperative VTE in surgical patients at high and extremely high risk receiving graduated compression stockings and early/delayed prophylactic anticoagulation with low-molecular weight heparins.|f|f|f|t
33684838|NCT06154681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33684839|NCT02451618|||COHORT||PROSPECTIVE|||||||
33684840|NCT02128100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684841|NCT02697669|||CASE_ONLY||PROSPECTIVE|||||||
33684842|NCT03584529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684843|NCT02724670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684844|NCT06459232|||COHORT||RETROSPECTIVE|||||||
33684845|NCT06255366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684846|NCT05632744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774884|NCT05009979|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33774885|NCT05121038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774886|NCT06229236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients will be masked until randomization. Outcomes Assessor will be masked.||f|f|f|t
33904748|NCT04954469|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I:~Part I: 14 patients not infected with SARS-CoV-2 will receive an open-label 500 μl subcutaneous injection via needle and syringe of the study IMP (CoVAC-1).~Part II (optional): If there is an insufficient immune response measured by IFN-γ ELISpot in Part I of Phase I on day 28, an additional Part (Part II) of Phase I will start enrollment of 14 subjects receiving two open-label 500 μl subcutaneous injection via needle and syringe of the study IMP (CoVac-1) on d1 and d42.~Phase II (after an amendment to the protocol):~40 subjects will receive an open-label 500 μl subcutaneous injection via needle and syringe of the study IMP (CoVac-1) on d1 and, depending on the data collected in Phase I, a econd vaccination on d42 if necessary."||||
33904749|NCT03394859|||COHORT||PROSPECTIVE|||||||
33904750|NCT02436486|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081567|NCT06003036|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34081568|NCT02816294|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081569|NCT04547855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081570|NCT00439972|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081571|NCT06339775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081572|NCT02328612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081573|NCT03226444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-masked||t|t|t|f
34081574|NCT01930591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081575|NCT05190627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081576|NCT02659943|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34081577|NCT02850094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081578|NCT03353376|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34081579|NCT01976000|||CASE_CONTROL||PROSPECTIVE|||||||
33774887|NCT02724878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774888|NCT04298281|||COHORT||PROSPECTIVE|||||||
33904751|NCT02416908|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904752|NCT03179098|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34081580|NCT05882929|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (participant, outcomes assessor)|The research is a randomized controlled trial. In this parallel group study, there will be two intervention groups (watching cartoons and ball squeezing) and a control group.|t|f|f|f
34081581|NCT02891473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34081582|NCT02355678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081583|NCT04549194|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The pharmacist, carrying out the packaging and labelling of the treatment units, will ensure the blinding. Neither the participant nor the investigator will know what treatment is being administered.|"The study is composed of 2 groups, each of which is composed of 2 arms:~* External Operation group~  * L-Tyrosine arm~ * Placebo arm~* Rear Base group~  * L-Tyrosine arm~ * Placebo arm"|t|f|t|t
34081584|NCT02607813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081585|NCT00746005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081586|NCT04624763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34081587|NCT01358474|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34081588|NCT00015704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081589|NCT02139540|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34081590|NCT00354315|RANDOMIZED|PARALLEL||||NONE||||||
33774889|NCT06298552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081591|NCT00902655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081592|NCT01692119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34081593|NCT01165307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081594|NCT03839134|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33774890|NCT06727721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33774891|NCT06578728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient blinded.|Intra-subject randomized controlled trial|t|f|f|f
33774892|NCT06465043|||COHORT||PROSPECTIVE|||||||
33904753|NCT00084422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904754|NCT04024683|||CASE_CONTROL||RETROSPECTIVE|||||||
33904755|NCT04390698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33904756|NCT04073082|||CASE_CONTROL||RETROSPECTIVE|||||||
33904757|NCT00122746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904758|NCT00524095|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33904759|NCT05537324|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was a non-blinded randomized controlled trial, where participants were requited and enrolled to the study / intervention continuously over about two years. Half of the participants (26) in the experimental group and half of the participants in the control group||||
33904760|NCT03174860|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"The patients will be randomly divided into 2 groups:~Experimental group:~Diclofenac Potassium (50 mg, Cataflam) to be administered one hour before treatment.~Control group:~Placebo to be administered one hour before treatment."|t|t|t|t
33904761|NCT02052960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904762|NCT00602316||||DIAGNOSTIC||||||||
33904763|NCT01395303|||||RETROSPECTIVE|||||||
33904764|NCT05575713|||COHORT||PROSPECTIVE|||||||
33904765|NCT00344929|||DEFINED_POPULATION||PROSPECTIVE|||||||
33904766|NCT04646928|||COHORT||PROSPECTIVE|||||||
33904767|NCT01556945|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33904768|NCT03332667|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34081595|NCT00885118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081596|NCT04844320|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study was designed to include 3 groups of 30 patients and a total of 90 patients. 90 patients who underwent laparoscopic sleeve gastrectomy will be divided into 3 groups according to their postoperative weight gain. The first group will include patients who have lost more than 50% EWL postoperative weight, the second group will include patients who have lost 50 to 25% EWL postoperative , and the third group will include patients who have lost less than 25% EWL postoperative.~Patients in these 3 groups will be randomized on www.randomisor.org. In these 3 groups, cobb angle measurements will be made on the PA chest radiographs taken at the preoperative, postoperative 1st year and postoperative 2nd year controls. Patient satisfaction questionnaires will be conducted to compare pre- and postoperative complaints such as low back pain, back pain, and neck pain in all patients. The change in cobb angles will be determined according to the weight loss ratio (% EWL) of the patients."||||
34081597|NCT02866656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774893|NCT05274347|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904769|NCT03130101|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients with type 1 diabetes on insulin pump therapy will remain on their usual insulin regimen. However, we are testing percent basal rate reductions during exercise (e.g. 80% reduction, 50% reduction, and 100% reduction).||||
33904770|NCT04528082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The participants will be randomized to receive apremilast or placebo in the double-blind 12 week treatment phase. Then, the participants will all receive apremilast for a further 40 weeks in the active treatment phase. The participants will then complete the 30 days safety follow-up period after the last dose of apremilast in the active treatment phase.|t|t|t|t
33904771|NCT00722592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904772|NCT05015400|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33904773|NCT01889810|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081598|NCT02675205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081599|NCT04133948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081600|NCT00443833|||CASE_CONTROL||OTHER|||||||
34081601|NCT00624793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684847|NCT06229314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient's current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.|t|f|f|f
33684848|NCT01848431|||COHORT||PROSPECTIVE|||||||
33684849|NCT05204875|||COHORT||RETROSPECTIVE|||||||
33684850|NCT04937400|||COHORT||PROSPECTIVE|||||||
33684851|NCT02368925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684852|NCT02456480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684853|NCT02483871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684854|NCT04617301|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33721346|NCT04698031|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The two stroke neurologists reviewing the brain MRI scans will independently adjudicate the presence and number of SBIs for each patient by reviewing the initial and repeat scans, along with the medical history. Each adjudicator will maintain a log with the results and a study identification number while blinded to the platelet procoagulant levels and intervention arm distribution. The laboratory staff will be blinded to clinical, imaging and intervention data. The VA Research Pharmacy will dispense similar looking pills to ensure the double-blind nature of the intervention.|Patients admitted for stroke/TIA, with indication for antiplatelet therapy as secondary prevention (decision independent of the study and based on individual clinical decision for each patient by the treating physician), will be assigned to therapy with either clopidogrel or aspirin. Both medications are FDA approved for secondary prevention. Patients will be followed for 24 months and repeat brain MRI will be obtained at 24 months. These doses are part of the recommended guidelines for secondary stroke prevention. After randomization, an electronic prescription will be signed by the PI (flagged as part of the research protocol) for a 90-day supply with multiple refills. The medication will be delivered prior to discharge.|t|f|t|t
33774894|NCT06213272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be informed about study hypotheses. Outcome Assessors will be masked to participants' assigned condition. Treating therapists (care providers) will be masked to participants baseline and outcome scores.|Participants will be randomly assigned to one of the 2 intervention groups: combined aerobic exercise and phono-motor therapy, or combined light stretching and phono-motor therapy. Randomization will be stratified by aphasia severity.|t|t|f|t
33774895|NCT06738745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774896|NCT05520567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774897|NCT03951467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33774898|NCT04488055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33774899|NCT01834300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081602|NCT00875810|||||PROSPECTIVE|||||||
34081603|NCT06183138|||CASE_ONLY||CROSS_SECTIONAL|||||||
34081604|NCT02740816|||COHORT||CROSS_SECTIONAL|||||||
33774900|NCT06726044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study finally included 24 people after ACL reconstruction. All of them participated in 12 - week rehabilitation; SR - standard rehabilitation, SR+I - standard rehabilitation and inertial exercises||||
33774901|NCT04590326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904774|NCT00461266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904775|NCT01444521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904776|NCT04739124|||COHORT||PROSPECTIVE|||||||
33904777|NCT04825093|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, non-blinded controlled trial||||
33904778|NCT00246038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904779|NCT01775488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904780|NCT03806595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081605|NCT00290563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081606|NCT05002972|NA|SINGLE_GROUP||OTHER||NONE||||||
34081607|NCT01884883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904781|NCT00634543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904782|NCT03699982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904783|NCT06634901|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33904784|NCT02102061|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904785|NCT02084134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904786|NCT01270893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904787|NCT05329467|NA|SINGLE_GROUP||OTHER||NONE||||||
33904788|NCT06590454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Randomized Controlled Trial:~Pyrvinium (n=16) Placebo (n=16)"|t|t|t|f
33904789|NCT00011193|||COHORT||PROSPECTIVE|||||||
33904790|NCT03574467|||CASE_CONTROL||RETROSPECTIVE|||||||
33904791|NCT02508701|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33904792|NCT01080989|NA|SINGLE_GROUP||SCREENING||NONE||||||
33904793|NCT03836118|||COHORT||RETROSPECTIVE|||||||
33904794|NCT02341014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904795|NCT02174497|||COHORT||PROSPECTIVE|||||||
33904796|NCT04039828|NA|SINGLE_GROUP||TREATMENT||NONE||"Stratum 1: From 3 months to \<18 months= 175 Stratum 2: From 18 months to 59 months= 175~in total, 350 participants will be enrolled"||||
33904797|NCT02287792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904798|NCT01275261|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684855|NCT05542277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After all applicable screening assessments have been performed, patients who have met all inclusion criteria and none of the exclusion criteria will be randomly allocated to one of the two treatment groups (with ratio 1:1) and will receive a unique computer-generated randomization number. Site stratified block randomization will be used during the study. Blocks length will have random length (e.g., 4, 6, 8). In order to reduce bias as much as possible, the trial will be double-blinded, keeping Sponsor, all patients and the Investigator blinded to the treatment. The randomization list will not be available to blinded personnel (such as Principal Investigator) involved in the conduct and evaluation of the trial until the trial database is locked.|Multi-center, international, double-blind, randomized, controlled, prospective, clinical investigation, in which Patients undergoing Coronary Artery Bypass Grafting or valve replacement surgeries with a cardiopulmonary bypass, required plasma transfusion, will be randomized to receive a one-time infusion (up to 12 hours) of PDP (group A) or FFP (group B) with unlimited number of plasma units. The administration of plasma needs to be in line with the clinical practice and doctor decision. Furthermore, the main point is the patients with CABG/VRS that lost significant blood and need transfusion. Patients will be continuously monitored during transfusion and during stay in ICU. The assessment and additional test will be done at the admission to the ICU, 12 hours (±1) after procedure, 24 hours (±1) after procedure, 48 hours (±2) after procedure, at the discharge and 30±3 days after procedure.|t|t|t|t
33684856|NCT02508298|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33684857|NCT00480987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684858|NCT06335901|||COHORT||PROSPECTIVE|||||||
33684859|NCT04959656|||CASE_ONLY||RETROSPECTIVE|||||||
33684860|NCT00005690|||||PROSPECTIVE|||||||
33684861|NCT04461600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684862|NCT06148194|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|LiveSpo Navax and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax suspension are unrecognizable to investigators, trainers, child caregivers, children's parents, and children due to opaque plastic container. Only the PI and a data analyst are aware of the group codes.|Blind, randomized, and controlled clinical trial|t|t|t|f
33684863|NCT00357929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684864|NCT04484168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33684865|NCT04771065|||COHORT||RETROSPECTIVE|||||||
33684866|NCT01015001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684867|NCT02777749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33774902|NCT04111419|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomly divided into four groups, taking amlodipine/atorvastatin (5/10mg tablet) once a day or amlodipine/atorvastatin (5/20mg tablet) once a day or amlodipine/atorvastatin (5/10mg tablet)+allisartan (240mg/tablet) once a day or amlodipine/atorvastatin (5/20mg tablet)+allisartan (240mg/tablet) once a day.||||
33774903|NCT03682991|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a parallel group, open label randomized clinical trial, with blinded endpoint evaluation (PROBE design)||||
33774904|NCT06586606|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774905|NCT04875078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will be blinded to which hand was treated, and be the blinded assessor.|Treated hand compared to non-treated hand|f|f|t|f
33774906|NCT06348719|RANDOMIZED|PARALLEL||OTHER||NONE||"As part of this project, we are proposing an original approach by combining a randomized controlled trial with a prospective observational cohort and a retrospective cohort.~This research will therefore consist of 3 complementary studies :~A multicenter, parallel-group, open-label, randomized controlled superiority trial (ratio 1:1) comparing two groups:~* Group 1: laparoscopic robot-assisted hysterectomy~* Group 2: conventional laparoscopic hysterectomy A prospective cohort based on the randomized controlled trial A retrospective cohort"||||
33774907|NCT04970901|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904799|NCT05764798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904800|NCT03191396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904801|NCT01595750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904802|NCT03028025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33904803|NCT06074822|||OTHER||OTHER|||||||
33904804|NCT02657252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904805|NCT01807507|||CASE_ONLY||PROSPECTIVE|||||||
33904806|NCT05592470|||OTHER||CROSS_SECTIONAL|||||||
33904807|NCT05025072|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33904808|NCT03527615|||COHORT||RETROSPECTIVE|||||||
33904809|NCT01314235|||||PROSPECTIVE|||||||
33904810|NCT03397797|||COHORT||PROSPECTIVE|||||||
33904811|NCT03067896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904812|NCT02728635|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33904813|NCT01985685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904814|NCT06307080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987569|NCT00794456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987570|NCT04782765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987571|NCT06230770|||COHORT||PROSPECTIVE|||||||
33987572|NCT01310920|||CASE_CONTROL|||||||||
33987573|NCT02416726|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081608|NCT01009853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684868|NCT03744143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721347|NCT02084147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721348|NCT00641862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904815|NCT05170139|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will be given a bottle with either caffeine and carbohydrates or just carbohydrates.|Participants will be given a bottle with either caffeine and carbohydrates or just carbohydrates. All participants will complete ice-hockey specific athletic tests in both conditions.|t|f|t|f
33904816|NCT00175006|||||PROSPECTIVE|||||||
33904817|NCT03911674|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987574|NCT01854047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33987575|NCT02096783|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33987576|NCT04772807|||COHORT||PROSPECTIVE|||||||
33987577|NCT01171989|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987578|NCT00183521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987579|NCT05040880|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987580|NCT00287092|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987581|NCT00754117|||COHORT||PROSPECTIVE|||||||
33987582|NCT00827047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987583|NCT01220362|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33987584|NCT02776878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987585|NCT00910663|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33987586|NCT05250843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987587|NCT00772239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33987588|NCT06209320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081609|NCT03597737|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Patients will be informed of the condition they have been assigned to.|One condition||||
34081610|NCT00975416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081611|NCT01118052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721349|NCT06160973|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2 Factorial Design||||
33721350|NCT03558243|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator who will evaluate the primary end point will be blinded to which hemostatic technique the patient received.|Randomized clinical trial|f|f|f|t
33721351|NCT02127567|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33721352|NCT01465022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904818|NCT05615701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904819|NCT03974646|RANDOMIZED|PARALLEL||PREVENTION||NONE||patients fulfilling eligibility criteria and willing to participate will randomized after baseline assessment (1:1 allocation ration). A prior, an independent research assistant will prepare a computer-generated randomization schedule. The allocation numbers will be concealed in opaque sealed envelopes prepared by a research assistant. the envelopes will be accessible by the research assistant, only opening them after informed consent and baseline assessment have been obtained.||||
33904820|NCT02870452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33904821|NCT00700752|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33904822|NCT00841295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33987589|NCT02942615|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33987590|NCT02139826|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987591|NCT03682159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33987592|NCT03251430|||COHORT||PROSPECTIVE|||||||
33987593|NCT03636763|||CASE_CONTROL||RETROSPECTIVE|||||||
33987594|NCT01972204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987595|NCT00501553|||COHORT||PROSPECTIVE|||||||
33987596|NCT03423680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987597|NCT00803686|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34081612|NCT01215838|||COHORT||PROSPECTIVE|||||||
34081613|NCT04471961|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34081614|NCT06427499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081615|NCT05589896|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All patients will receive Ossium HPC, Marrow product. Study arms will be based on conditioning regimen.||||
33987598|NCT00633256|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33987599|NCT00561834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987600|NCT04561063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987601|NCT03135743|||COHORT||PROSPECTIVE|||||||
33987602|NCT00497263|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33987603|NCT02067624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987604|NCT05546138|||COHORT||PROSPECTIVE|||||||
33987605|NCT01214850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33987606|NCT06064331|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33987607|NCT04571658|||CASE_ONLY||PROSPECTIVE|||||||
34081616|NCT03464760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904823|NCT05932628|||COHORT||PROSPECTIVE|||||||
33904824|NCT02650284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904825|NCT06560918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904826|NCT00128726|||COHORT||PROSPECTIVE|||||||
33904827|NCT01244334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904828|NCT02807454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904829|NCT06069557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In our study, there are two groups, one control group and one experimental group. The control group will not be intervened. The experimental group will receive preoperative training about the postoperative intervention and the effect of the intervention will be evaluated in postoperative period.||||
33904830|NCT00075751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904831|NCT03499041|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33904832|NCT04077203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33904833|NCT02222129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904834|NCT05385718|||OTHER||OTHER|||||||
33904835|NCT03950102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904836|NCT02126644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904837|NCT03802422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904838|NCT03469245|||COHORT||PROSPECTIVE|||||||
33904839|NCT06512805|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33904840|NCT02892851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904841|NCT03201328|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904842|NCT02771808|||CASE_ONLY||PROSPECTIVE|||||||
33904843|NCT01805700|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33904844|NCT05777434|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive conventional physical therapy along with cervical stabilization exercises and the second will receive Scapulothoracic Stabilization Exercises in addition to Cervical Stabilization Exercises with conventional physical therapy. Both groups will be recruited concurrently.||||
33904845|NCT06385964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904846|NCT01441687|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33904847|NCT03837756|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The participant and all study personnel who directly interact with study participants are blinded to study arm designation.|"Participants will be randomized 1:1:1:1 in a blinded fashion to receive:~Arm A: Placebo and Placebo Arm B: Lefitolimod and Placebo Arm C: Placebo and 3BNC117+10-1074 Arm D: Lefitolimod and 3BNC117+10-1074"|t|f|t|f
33904848|NCT03711071|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All participating doctors will be blinded towards the explicit purpose and design of the study. ICE communication training will be offered to all participants: to the doctors in the intervention group as a true intervention at the beginning of the trial, and to the doctors in the control group as a pretend intervention at the end of the trial.|Cluster randomised parallel design: Randomization to ICE communication training will take place at the practice level with units of randomizations being single handed or group practices.|t|t|f|t
33904849|NCT06054451|||CASE_ONLY||PROSPECTIVE|||||||
33904850|NCT01877330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33904851|NCT02633072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904852|NCT01097616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904853|NCT06653010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904854|NCT01025180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904855|NCT06304948|||OTHER||OTHER|||||||
33904856|NCT01447056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904857|NCT01307995|||CASE_CROSSOVER|||||||||
33904858|NCT05030623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904859|NCT00089128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904860|NCT04466683|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized 2:1 to receive radiation therapy (2 different doses) or control (no radiation). Sixty subjects will be enrolled to 3 arms and the best dose chosen after enrolling 60 subjects. Randomization of an additional 40 subjects will be randomized 2:1 to receive radiation therapy (best dose) versus control with no radiation.||||
33904861|NCT06594523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904862|NCT03598231|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Cross-over of two sequences (2x2: AB / BA)|t|f|t|f
33904863|NCT05951153|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904864|NCT02050048|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904865|NCT00900133|||CASE_ONLY||CROSS_SECTIONAL|||||||
33904866|NCT02232516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904867|NCT01582282|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33904868|NCT06099717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group allocation|Randomized clinical trial|f|f|t|f
33904869|NCT03466346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|participants will be evaluated by an outcomes assessor that is not aware of which treatment the participant is receiving. This will be achieved by keeping the randomization key locked and accessible only to the study coordinator and investigators. Participants who are scheduled for assessments will be reminded not to spontaneously disclose their treatment modality to the outcomes assessor.|fluoxetine versus interpersonal psychotherapy (IPT) for treatment of Major Depressive Disorder (MDD) and/or Posttraumatic Stress Disorder (PTSD)|f|f|f|t
33904870|NCT04713020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33904871|NCT05946395|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomly divided by drawing lots into 2 groups. Group A will benefit from speech therapy and synchronous equipment, and group B will begin speech therapy after 3 months after the installation of the equipment.||||
33904872|NCT05413967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904873|NCT02676349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904874|NCT05927246|||COHORT||RETROSPECTIVE|||||||
33684869|NCT03889483|NA|SINGLE_GROUP||OTHER||NONE||"Participants will be divided into the following cohorts:~Cohort 1: 30 participants with persistent mTBI symptoms (duration greater than 6 weeks), as determined by the Investigator; Cohort 2: 30 participants who recovered quickly from mTBI (i.e., within approximately six weeks based on symptomatology), as determined by the Investigator; Cohort 3: 15 participants who have had multiple mTBIs (2 or more medically verified concussions over the last year); and Cohort 4: 30 participants who have never had a concussion. Participants in Cohorts 1-3 will be recruited 6-16 weeks post injury date.~After study enrollment, all participants undergo two NeuroCatch Platform assessments."||||
33684870|NCT02927405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33684871|NCT04637009|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33684872|NCT02784574|||OTHER||PROSPECTIVE|||||||
33904875|NCT00862381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904876|NCT01795040|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33904877|NCT02222987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904878|NCT06130631|||OTHER||RETROSPECTIVE|||||||
33904879|NCT01129791|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33904880|NCT00003386||||TREATMENT||||||||
33904881|NCT04013737|||OTHER||PROSPECTIVE|||||||
33904882|NCT02339298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33904883|NCT03556683|NA|SEQUENTIAL||TREATMENT||NONE||To access the efficacy of inhalation of 3% and 7% hypertonic saline||||
33904884|NCT01746992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904885|NCT05394272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Longitudinal, experimental qualitative and quantitative research project. Non-pharmacological, non- invasive, natural complementary therapy.|f|f|t|f
33904886|NCT00579735|||CASE_ONLY||RETROSPECTIVE|||||||
33904887|NCT04297566|||COHORT||RETROSPECTIVE|||||||
33904888|NCT05910021|||OTHER||RETROSPECTIVE|||||||
33904889|NCT00227149|||COHORT||PROSPECTIVE|||||||
33904890|NCT06688032|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinding was not possible due to the look and tast of the two cheeses|Design and randomization The study was performed as an open randomized stratified parallel group designed trial with two strata. Sex is used as a stratification factor. The two equal sized strata are chosen because of different OED of cheese for women and men, and because the dose-response study previously performed has shown different response in men and women. The participants were equally allocated (1:1) to either Jarlsberg or Norvegia cheese by block randomization.||||
33904891|NCT05794997|||COHORT||RETROSPECTIVE|||||||
33904892|NCT00382889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904893|NCT01773200|||COHORT||PROSPECTIVE|||||||
33904894|NCT02306772|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33904895|NCT02092389|||COHORT||PROSPECTIVE|||||||
33904896|NCT02605863|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904897|NCT02755740|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33904898|NCT00486226|||COHORT||PROSPECTIVE|||||||
33904899|NCT00279500|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with a confirmed history of advanced retinal degenerative disease and meeting the inclusion criteria listed will be considered as eligible participants in the study. Subjects who have a condition listed in the exclusion criteria will not be allowed to participate in the study. Eligible subjects with the above diagnoses will be recruited from the Doheny Eye Institute at the University of Southern California. Additionally, new subjects encountered in the clinic who fulfill the inclusion criteria will also be eligible to participate. Upon meeting the entry criteria, all subjects must sign an Informed Consent prior to enrollment in the study. Since the subjects are blind, an individual not associated with this study must read the informed consent to the subject. This person must sign the consent form as a witness to the informed consent process.||||
33904900|NCT04688567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The groups are predetermined based on the tool randomizer.org and blinded to the researcher assigning the participants to groups.||f|f|t|f
33904901|NCT03301480|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904902|NCT01858428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904903|NCT02205567|||CASE_ONLY||PROSPECTIVE|||||||
33684873|NCT03553030|||CASE_CONTROL||RETROSPECTIVE|||||||
33684874|NCT01569243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904904|NCT00020852||||TREATMENT||||||||
33904905|NCT01190657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904906|NCT06693856|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684875|NCT04779749|||CASE_CONTROL||RETROSPECTIVE|||||||
33904907|NCT05412186|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33904908|NCT05327478|||CASE_CONTROL||PROSPECTIVE|||||||
33904909|NCT01974674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904910|NCT00239200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33904911|NCT04893330|||OTHER||PROSPECTIVE|||||||
33904912|NCT01997567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904913|NCT00016861||||TREATMENT||||||||
33904914|NCT00718861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904915|NCT03636503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904916|NCT02074215|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33904917|NCT00312780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904918|NCT06553781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904919|NCT01062646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904920|NCT01883583|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33904921|NCT00627640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904922|NCT06430749|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33904923|NCT02540798|||COHORT||PROSPECTIVE|||||||
33904924|NCT06113354|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-arm registry||||
33684876|NCT06022484|||COHORT||CROSS_SECTIONAL|||||||
33684877|NCT03054129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684878|NCT04745273|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33684879|NCT06086262|||CASE_CONTROL||RETROSPECTIVE|||||||
33684880|NCT00744354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684881|NCT01072565|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33684882|NCT02739737|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33684883|NCT00014755||||TREATMENT||||||||
33684884|NCT05290623|||COHORT||RETROSPECTIVE|||||||
33684885|NCT02673047|||CASE_ONLY||PROSPECTIVE|||||||
33684886|NCT05778643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33684887|NCT02003274|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33684888|NCT00466687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684889|NCT06321341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684890|NCT03167567|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Women who will agree to be escorted by a medical clown during their first labor will be interviewed after delivery regarding their experience. Their answers will be compared to those of women whe were not escorted by a clown.||||
33684891|NCT04828473|NA|CROSSOVER||BASIC_SCIENCE||NONE||single group assessment||||
33684892|NCT02026570|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33904925|NCT03366740|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study design: This will be an open-labeled randomized controlled clinical trial with three treatment arms (3/4th strength rice suji, full strength rice suji with modification and GB mixed full strength rice suji). Investigators will prospectively screen, children \> 6 to 36 months of age admitted to the Dhaka hospital of icddr,b, with PD or developed PD during their treatment period and failed to respond with milk suji and enroll them for the study. Thereafter permuted block randomization technique will be followed to select treatment arms for each child.||||
33904926|NCT06309810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904927|NCT04076124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33904928|NCT04891250|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio.||||
33904929|NCT05466149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904930|NCT00003667|RANDOMIZED|||TREATMENT||||||||
33904931|NCT02005601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904932|NCT01095952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904933|NCT05415202|||COHORT||PROSPECTIVE|||||||
33904934|NCT01746667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904935|NCT05313919|||COHORT||PROSPECTIVE|||||||
33684893|NCT05683431|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, 'open label' study to examine the feasibility and potential target engagement (i.e. potential benefit) of a behavioral smartphone-based cognitive training program for individuals with bipolar I disorder. Participants with bipolar disorder are assessed before and after the 20 session/4 week intervention. In addition, a comparison group of healthy adults (without bipolar disorder) are assessed at a single time-point as a means of identifying baseline deficits associated with bipolar disorder. Participants in the healthy comparison group do not complete the intervention. (Thus, Number of Intervention Arms = 1.)||||
33684894|NCT03541876|||COHORT||PROSPECTIVE|||||||
33684895|NCT02554279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684896|NCT03055377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind placebo-controlled pharmacotherapy trial|1:1 parallel group allocation randomized placebo controlled trial|t|t|t|t
33684897|NCT04652414|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33684898|NCT03611842|||CASE_CONTROL||PROSPECTIVE|||||||
33684899|NCT00776685|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33684900|NCT04545944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684901|NCT02630199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721353|NCT01228357|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721354|NCT05461651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904936|NCT03070418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904937|NCT06513182|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33904938|NCT03391440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904939|NCT03120390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33904940|NCT01439529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904941|NCT00161824|RANDOMIZED|PARALLEL||||SINGLE||||||
33904942|NCT06636071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904943|NCT02273323|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33904944|NCT00520676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904945|NCT01492231|||OTHER||RETROSPECTIVE|||||||
33904946|NCT04919486|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33904947|NCT00049959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33904948|NCT05938439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987608|NCT05652543|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants ≥3 years old who has received the recommended dose and immunization procedure of domestically approved COVID-19 vaccine, Participants in each group (including the first 15 participants in Group A and sentry participants in groups B and C) will be randomly inoculated with either SCTV01E or placebo (normal saline) according to 4:1, i.e. 200 participants in each group will receive SCTV01E and 50 participants will receive placebo (normal saline).|t|t|t|t
33987609|NCT04156919|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33721355|NCT00091273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721356|NCT00171223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721357|NCT04751825|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT with Wait-List condition||||
33721358|NCT03287804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721359|NCT03101137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33987610|NCT03503318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987611|NCT06560164|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Study design: This is a non-inferiority, randomized controlled trial in patients receiving ECMO.~Study population: Patients, 18 years or older, receiving ECMO (see additional details below).~Randomization will be stratified by:~* Center;~* ECMO mode, divided by:~  * VV ECMO (or triple cannulation methods with primarily a pulmonary indication);~ * VA ECMO (or triple cannulation methods with primarily a cardiac indication or extracorporeal cardiopulmonary resuscitation \[ECPR\]).~Intervention:~1. Restrictive RBC transfusion threshold: in case the Hb transfusion trigger of 7.0 g/dL (4.3 mmol/L) is reached, 1 RBC unit at a time will be transfused.~2. Liberal RBC transfusion threshold: in case the Hb transfusion trigger of 9.0 g/dL (5.6 mmol/L) is reached, 1 RBC unit at a time will be transfused."||||
33987612|NCT00162474|NA|SINGLE_GROUP||OTHER||NONE||||||
33987613|NCT03985267|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33987614|NCT02536950|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33987615|NCT05992220|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, multicenter, open-label study||||
33987616|NCT03235128|||CASE_CONTROL||RETROSPECTIVE|||||||
33987617|NCT04882150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987618|NCT05902702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessor will receive anonymized data for analysis.|An investigator-initiated, multicenter, open label, three-arm randomized, controlled non-inferiority trial.|f|f|f|t
33987619|NCT01878344|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33987620|NCT00438945|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33987621|NCT01635322|||COHORT||PROSPECTIVE|||||||
33987622|NCT00528905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987623|NCT01881854|||COHORT||CROSS_SECTIONAL|||||||
33987624|NCT04417933|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33987625|NCT00184522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987626|NCT05115123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33987627|NCT03111719|||COHORT||CROSS_SECTIONAL|||||||
33987628|NCT05057650|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33987629|NCT00656305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081617|NCT01340690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The verum nutrional supplementation is completely masked and an appropriate Placebo is provided. Up to know, none of the above mentioned is unblinded"|We use the dietary supplementation like a medication and performed the study like a phase 3 medication study, because the dietary supplementation (verum) is available as special preparation in drug stores.|t|t|t|t
33721360|NCT00425867|||CASE_CONTROL||OTHER|||||||
33774908|NCT05586711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081618|NCT04644029|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"In Study Part 1, a double-blinding technique with in-house blinding will be used. ISL and FTC/TDF will be packaged identically relative to their matching placebos so that blind is maintained. The participant, the investigator, and Sponsor personnel or delegate(s) who are involved in the study intervention administration or clinical evaluation of the participants are unaware of the intervention assignments.~In Study Part 2, sponsor personnel not directly involved with blinded safety monitoring will be unblinded to participants' randomized study intervention in Part 1.~In Study Part 3, participants, investigators, and all Sponsor personnel will be unblinded to the participants' original randomized study intervention group."||t|t|t|f
34081619|NCT03566225|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34081620|NCT04897386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081621|NCT03290430|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||this is a quasi-experiment, with 4 intervention arms plus options for supplemental intervention support||||
34081622|NCT03263455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081623|NCT05145985|||COHORT||CROSS_SECTIONAL|||||||
33684902|NCT03475953|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a multicenter, prospective open-labeled phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Regorafenib given in combination with Avelumab (no dose escalation for Avelumab) in patients with advanced solid tumors followed by 17 phase II trials :~* to evaluate the association of Regorafenib at the RP2D with Avelumab in 16 distinct disease settings (advanced or metastatic tumors).~* to evaluate the association of a low-dose of regorafenib with avelumab in advanced or metastatic colorectal cancer"||||
33684903|NCT02126748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684904|NCT05045066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684905|NCT01077375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684906|NCT03819907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33684907|NCT05130671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684908|NCT01489384|||COHORT||PROSPECTIVE|||||||
33684909|NCT04616742|NA|SINGLE_GROUP||OTHER||NONE||||||
33684910|NCT02661711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684911|NCT04661254|NA|SINGLE_GROUP||OTHER||NONE||||||
33684912|NCT05697978|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|each patient in group received monofocal intraocular lens in both eyes||||
33774909|NCT06737614|||OTHER||CROSS_SECTIONAL|||||||
33774910|NCT06312020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774911|NCT05908175|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
33684913|NCT01622283|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33684914|NCT03603171|||CASE_CONTROL||PROSPECTIVE|||||||
33684915|NCT02239120|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33684916|NCT06098677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33684917|NCT05834855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, site personnel administrating infusions, and the treating and evaluating neurologist and study nurse will all be blinded|Multicenter randomized controlled double-blind non-inferiority trial in The Netherlands|t|t|t|t
33684918|NCT00278408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684919|NCT02778438|||CASE_CROSSOVER||PROSPECTIVE|||||||
33774912|NCT05537467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081624|NCT05696951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34081625|NCT03022006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081626|NCT06241911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33774913|NCT04143724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774914|NCT06492291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774915|NCT04658342|||CASE_CONTROL||PROSPECTIVE|||||||
33774916|NCT05627856|NA|SEQUENTIAL||TREATMENT||NONE||||||
33904949|NCT06650761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904950|NCT03174743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33684920|NCT05043376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684921|NCT03467152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684922|NCT01599364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684923|NCT05793229|||COHORT||PROSPECTIVE|||||||
33684924|NCT01995045|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33684925|NCT00746408|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684926|NCT01711385|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33684927|NCT03761797|||COHORT||PROSPECTIVE|||||||
34081627|NCT00160511|RANDOMIZED|PARALLEL||||DOUBLE||||||
34081628|NCT02672072|||OTHER||PROSPECTIVE|||||||
33684928|NCT01602133|NA|SINGLE_GROUP||||NONE||||||
33684929|NCT01185834|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33684930|NCT06531044|||OTHER||CROSS_SECTIONAL|||||||
33684931|NCT02692651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684932|NCT01293578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33684933|NCT03627390|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, single center, two arm||||
33684934|NCT02258984|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33684935|NCT04900064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will only be informed that they will be randomised between two different types of extended assessments, both of which are more extensive than regular healthcare. They will receive no information about the nature of the assessments or about different treatments following the assessments to avoid nocebo effects.|"Patients are randomised between a diagnostic assessment and a contextual assessment. Patients in the contextual assessment arm can only be treated with brief interventions whereas patients in the diagnostic assessment arm are offered guided self-help if deemed appropriate and otherwise gets brief interventions.~As such, patients are randomised between two arms. We have however included four arms below in order to be able to describe the primary and secondary analysis. The primary analysis is performed on all patients treated with self-help CBT in the arm where a diagnostic assessment is made, compared to patients in the contextual assessment arm that are found suitable for self-help CBT (based on screening data), but treated with brief interventions."|t|f|f|f
33684936|NCT01325220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684937|NCT06298344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind|t|f|t|f
33684938|NCT04318145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Part A: Single dose per subject, dose level ascension every 3 subjects. 5 dose levels are planned. An intermediate dose between planned doses may be chosen by the Sponsor/Investigator upon discussion after MTD is reached.~Part B: Single dose, dose chosen from Part A."||||
33684939|NCT05329038|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33684940|NCT04689438|||CASE_CONTROL||PROSPECTIVE|||||||
33684941|NCT00400153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33684942|NCT06099145|RANDOMIZED|PARALLEL||OTHER||NONE||This is an interventional, multicenter, randomized, controlled clinical study.||||
33684943|NCT00941577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684944|NCT02553668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33684945|NCT00511225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33684946|NCT00830869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33684947|NCT00004190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684948|NCT01920035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684949|NCT05958173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The products will be prepared in the Pharmacy Department and will be labeled with a code that does not allow its identification neither by the patient nor by the investigator who administers it.|Single-center, double-blinded, three-arm randomized clinical trial|t|f|t|f
33684950|NCT02523612|NA|SINGLE_GROUP||OTHER||NONE||||||
33684951|NCT02820701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684952|NCT01987947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33684953|NCT03139942|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33684954|NCT01625533|||COHORT||PROSPECTIVE|||||||
33684955|NCT03386877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684956|NCT01060345|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33904951|NCT03605004|||OTHER||RETROSPECTIVE|||||||
34081629|NCT04773028|||OTHER||PROSPECTIVE|||||||
34081630|NCT01626066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081631|NCT04795063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081632|NCT04718922|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34081633|NCT03835039|||COHORT||PROSPECTIVE|||||||
34081634|NCT04168034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33684957|NCT01574742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684958|NCT02592811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684959|NCT06339671|||COHORT||OTHER|||||||
33684960|NCT04095637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33684961|NCT05883670|||OTHER||PROSPECTIVE|||||||
33684962|NCT00208546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904952|NCT04921722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904953|NCT06692595|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33904954|NCT03059303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904955|NCT02021500|||OTHER||PROSPECTIVE|||||||
33904956|NCT01874782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987630|NCT03513822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The randomisation is done with R software. Each randomisation card is put in a sealed opaque envelope. The two products being transparent, it's impossible to differentiate the two products with identical packaging is a syringe of 50 cc Luer Lock Plastipack BD with a standard extension for syringe Luer Lock.~Both products will be prepared by an SSPI nurse who opens the envelope, the nurse does not participate in the study, the patient assessment investigator as well as the patient will remain blind about the administration of the product. Each syringe will be labeled for each patient with a special label without indication of the product The outcomes assessor, investigator and participant are blinded."|Interventional randomized placebo-controlled clinical trial. Adult, medullary injured (BM), with chronic neuropathic pain (DN). 4 groups: BM with DN with bedsore Ketamine Group versus Placebo Group BM with DN without bedsore group Ketamine versus Placebo Group Ketamine infusion 1 mg / kg IVSE over two hours versus Nacl perfusion 0.9%|t|f|t|t
33987631|NCT02587871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987632|NCT02907047||PARALLEL||||||||||
33987633|NCT04684901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987634|NCT02011295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987635|NCT05974397|||COHORT||RETROSPECTIVE|||||||
33987636|NCT02197260|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33987637|NCT00485394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987638|NCT03558945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987639|NCT00857103|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33987640|NCT06127797|||COHORT||PROSPECTIVE|||||||
33987641|NCT02688023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987642|NCT03625661|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||cohort study||||
33987643|NCT03480321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987644|NCT03838276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987645|NCT02886247|||FAMILY_BASED||PROSPECTIVE|||||||
33987646|NCT01601145|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33987647|NCT01308164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987648|NCT01922180|||COHORT||PROSPECTIVE|||||||
33987649|NCT02046746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987650|NCT01982981|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33987651|NCT01907334|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33987652|NCT04775745|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A classic 3+3 design will be used to establish the dose-limiting toxicity (DLT), MTD, and RP2D. Three to six subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-168 on a once or twice daily schedule for 28 days (a Cycle), starting at a dose of 100 mg/day. Once all subjects in a given cohort have reached Cycle 1 Day 28, these data will be reviewed by the Safety Review Committee (SRC) for decisions on dose escalation for a new dose cohort. Subjects will receive once-daily or twice-daily oral dose of LP-168 until disease progression, unacceptable toxicity, or a clinical observation satisfying another criterion for withdrawal from treatment is noted."||||
33987653|NCT06162169|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081635|NCT04377581|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34081636|NCT04768088|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will perform one-week training of single-leg falling techniques, a post-training assessment, a two-week break, and a retention assessment. A pre-training assessment will not be performed, and a control group will not be included because it will be unsafe for participants to fall on a hard surface without proper training of falling techniques.||||
33987654|NCT01278953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987655|NCT05008640|||COHORT||RETROSPECTIVE|||||||
33987656|NCT01668602|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Assignment to either Cohort 1 or Cohort 2 will occur simultaneously and will be based on the lab/personnel and subject schedules. Participants in Cohort 1 receive only FastFES. Participants in Cohort 2 will receive 3 sessions of FastFES and 3 sessions of fast walking without FES.||||
33987657|NCT02296177|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33987658|NCT01559428|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33987659|NCT03466866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Single blind, randomized controlled trial|f|f|t|t
33987660|NCT05375604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987661|NCT01038661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987662|NCT02659150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987663|NCT02534272|||COHORT||PROSPECTIVE|||||||
33987664|NCT04820920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987665|NCT03888794|||CASE_ONLY||PROSPECTIVE|||||||
33987666|NCT03251911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987667|NCT04062045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking the infusion mixture by using the same shape of the drug/placebo bottle and wrapping it into non-transparent sheath.|Prospective, randomized, double blind, placebo controlled|t|t|t|f
33987668|NCT00667212|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33987669|NCT05609539|||COHORT||PROSPECTIVE|||||||
33987670|NCT02227186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33987671|NCT05514392|||CASE_CONTROL||PROSPECTIVE|||||||
33987672|NCT05176522|||COHORT||CROSS_SECTIONAL|||||||
33987673|NCT04438239|||OTHER||PROSPECTIVE|||||||
33987674|NCT01416753|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987675|NCT04413266|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33987676|NCT05995470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33987677|NCT00268905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987678|NCT00067535|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33987679|NCT05729529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes|The main objective of this study was to evaluate the efficacy of lipoic acid over placebo in the management of BMS|t|f|t|f
33987680|NCT00322439|||COHORT||PROSPECTIVE|||||||
33987681|NCT00671320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987682|NCT01469650|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33987683|NCT05241808|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33987684|NCT05627739|||COHORT||PROSPECTIVE|||||||
33987685|NCT02888639|||COHORT||PROSPECTIVE|||||||
33987686|NCT00882505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987687|NCT01056666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987688|NCT03368508|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33987689|NCT05338047|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987690|NCT00251030|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987691|NCT02341547|||COHORT||PROSPECTIVE|||||||
33987692|NCT01676974|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33987693|NCT06311396|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33987694|NCT04175366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33987695|NCT04848844|||COHORT||PROSPECTIVE|||||||
33987696|NCT05198947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081637|NCT02477176|||CASE_CONTROL||PROSPECTIVE|||||||
34081638|NCT01819714|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34081639|NCT01100424|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34081640|NCT04574089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081641|NCT02816723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33684963|NCT05200819|||COHORT||CROSS_SECTIONAL|||||||
33684964|NCT03396757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684965|NCT02648828|||COHORT||PROSPECTIVE|||||||
33684966|NCT02394197|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987697|NCT04909190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987698|NCT02991404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33987699|NCT00519194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987700|NCT05926947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double blind randomized parallel study|t|t|t|t
33987701|NCT01040520|||COHORT||PROSPECTIVE|||||||
33987702|NCT01513954|||CASE_CONTROL||PROSPECTIVE|||||||
33987703|NCT06307639|||CASE_CONTROL||PROSPECTIVE|||||||
33987704|NCT02682238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987705|NCT05046860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987706|NCT04839276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants of the study know that they are being assigned to injection laryngoplasty procedures, but they didn't know whether PRF is being added to the autologous fat injection filler. The researchers are fully aware which participants are assigned to which procedures.|The intervention group will receive injection laryngoplasty with a combination of PRF and microlobular autograph fat, while the control group will receive injection laryngoplasty with microlobular autograph fat.|t|f|f|f
34081642|NCT01947348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081643|NCT04335435|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34081644|NCT00766766|RANDOMIZED|PARALLEL||||NONE||||||
34081645|NCT02649010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081646|NCT04497285|||OTHER||PROSPECTIVE|||||||
34081647|NCT00476814|||||PROSPECTIVE|||||||
34081648|NCT02414698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684967|NCT02697110|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33684968|NCT00297024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684969|NCT02029690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684970|NCT00924625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684971|NCT04089800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684972|NCT01927471|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33684973|NCT03381742|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684974|NCT01642121|||CASE_CONTROL||RETROSPECTIVE|||||||
33684975|NCT03089762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684976|NCT04651101|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33774917|NCT05616013|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|"In regard to bimagrumab and placebo-bimagrumab, the participants, Investigator and Sponsor will be blinded.~Due to semaglutide being pre-filled, packaged and labeled by manufacturer, it is not possible to blind semaglutide."|The study is designed to have three periods. The 48-week core treatment period has 9 treatment arms, with combinations of 3 semaglutide doses (none, 1.0 mg and 2.4 mg) and 3 bimagrumab doses (0, 10 and 30 mg/kg). The core treatment period is then followed by an open-label 24-week treatment extension period during which participants originally assigned to either placebo or bimagrumab 10 mg/kg will switch to bimagrumab 30 mg/kg. All other treatment assignments will remain the same. The extension period is then followed by a 32-week post-treatment period, during which all study treatments will be withdrawn from all arms.|t|f|t|f
33774918|NCT00650078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774919|NCT04660929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774920|NCT06075095|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This is a phase III, randomised, placebo-controlled, double-blind, multi-centre, 4-week, 3-way crossover pharmacodynamic study to assess the equivalence of BGF MDI HFO compared with BGF MDI HFA in participants with COPD.|t|t|t|t
33774921|NCT06739421|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33774922|NCT05252962|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|double-blind|The clinical study will be performed in a double-blind, randomized, monocentric cross-over design.|t|f|t|t
33774923|NCT03270111|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081649|NCT06333639|||CASE_CONTROL||PROSPECTIVE|||||||
34081650|NCT04214743|||COHORT||PROSPECTIVE|||||||
33774924|NCT05444504|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The investigators will compare two intervention models among women awaiting fistula surgery or whose surgery was unsuccessful: 1) a vaginal cup ('cup'), and 2) the cup attached via rubber tubing to a leg-secured urine collection bag ('cup+') for greater urine holding capacity (Table 1). Using a crossover design for efficiency, the investigators will randomize 100 participants to one of two sequences of leaking freely, cup, and cup+ at fistula centers in Ghana, Kenya, and Uganda, then re-randomize to continue using the cup or cup+ at home for up to 3 months. This design includes repeated measures of leakage (4 per participant, total obs=400), uses participants as their own controls, reduces the risk of confounding due to intervention order, and captures usual leaking variability through multiple measures.||||
33774925|NCT06740955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774926|NCT02422147|||COHORT||PROSPECTIVE|||||||
33774927|NCT04306315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pre-filled syringes with 210 mg (1.5 mL) brodalumab will be open-label. The packaging and labelling of the pre-filled syringes with 70 mg (0.5 mL) brodalumab or placebo will contain no evidence to distinguish brodalumab from placebo. It is not considered possible to distinguish between brodalumab and placebo visually; both solutions are colourless.||t|t|t|t
33774928|NCT05673304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774929|NCT06568458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774930|NCT04899310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774931|NCT06585631|RANDOMIZED|PARALLEL||PREVENTION||NONE||YBLMSM will be randomized (1:1) to intervention vs. Standard of Care (SOC) for each aim, using stratified randomization to yield balanced randomization between younger (15-19) and older (20-24) age groups. A separate stratum will be defined for each combination of covariates. To prevent a priori knowledge of treatment assignment among study/clinic staff, allocation will be concealed within the encrypted study data system. Participants will sign a release of medical information for HIV/SU/Mental Health Disorders outcomes. Visits occur at baseline (time 0), 3, 6, 9, and 12 months. Participants will complete an interviewer-administered, electronic baseline and quarterly surveys followed by the collection of samples for biologic measures. Survey assess individual, interpersonal, multi-level barriers to HIV prevention care and treatment in the community, and structural levels. The survey will identify varying severity of hazardous/harmful substance use and co-existing mental health needs.||||
33774932|NCT05990335|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Between subjects and within subjects mixed design, reflecting major variables of high/low group intervention/control.||||
33774933|NCT05378347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical Events Committee members as well as key sponsor team members will be blinded||f|f|f|t
34081651|NCT03342001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081652|NCT00998569|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33684977|NCT03780400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684978|NCT04334538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33684979|NCT03699475|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33904957|NCT06272383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is an internal double-blinded vanguard randomized controlled trial (RCT), which will be conducted at the Winnipeg Children's Hospital (WCH). Computerized randomization will be performed by a statistician at the George and Fay Yee Centre for HealthCare Innovation to generate the randomization list. Investigators will perform a computerized randomization stratified by age. Investigators will do a block randomization with random blocks of undisclosed block sizes over the seasons to ensure temporal distribution of croup cases is captured. Investigators will randomly assign patients to either the intervention or control in ratio 1:1. While croup is common between 6 months and 5 years, a typical croup affects children between 6 months and 3 years. Based on this, we will randomize such that this age category (6 months-3years) has almost similar distribution in each arm.|t|t|t|t
33904958|NCT03993353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904959|NCT03554499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33904960|NCT01723280|||CASE_CONTROL||PROSPECTIVE|||||||
33684980|NCT01817517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684981|NCT05301712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This clinical trial was planned for the purpose of re-evaluating ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage the efficacy and effects of naloxone hydrochloride.|t|t|t|t
33684982|NCT02199327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684983|NCT00791076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684984|NCT04148872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684985|NCT04265495|||OTHER||PROSPECTIVE|||||||
33684986|NCT00822809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684987|NCT04626141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33684988|NCT00675207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33684989|NCT00641927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33684990|NCT00612898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774934|NCT04963153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774935|NCT05475171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774936|NCT06060665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33774937|NCT06542588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33684991|NCT06388928|||CASE_ONLY||PROSPECTIVE|||||||
33684992|NCT04508543|||COHORT||PROSPECTIVE|||||||
33684993|NCT02183103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33684994|NCT05577273|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 arms: antibiotic prophylaxis vs no treatment||||
33684995|NCT02571738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33684996|NCT05336344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33684997|NCT00829933|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33774938|NCT05245513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33774939|NCT02616484|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33774940|NCT06446024|||COHORT||PROSPECTIVE|||||||
33774941|NCT06565221|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33774942|NCT06476834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774943|NCT06730074|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study will be conducted with 15 PD patients, aged 50-75||||
33684998|NCT06301243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33774944|NCT05678998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987707|NCT04004676|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and investigators will be blinded as an individual not involved in the project will assemble and distribute the treatment (drinks) according to a coding system that is kept confidential until the study is completed. Participants will complete the protocol three times and the treatment order will be systematically rotated to avoid any order effect. taste and texture of treatments will be matched and will be distribute in opaque bottles to keep participant blinded|This will be a double blind repeated measures cross over study. There will be two treatments involved: cabohydrate-ketone supplements and carbohydrates alone (placebo). Participants will complete the protocol twice and the treatment order will be systematically rotated to avoid any order effect. Design of the study is composed of a glycogen depleting exercise session, followed by 4 hours of recovery/supplementation, and a 20 km cycling time trial. All participants will arrive in a fasted state to the laboratory. a glycogen depleting exercise bout will be done followed by a 4 hour recovery period. during this 4 hours, participants will ingest the corresponding treatment for the first 2 hours. after recovery, they will perform a 20 km cycling time trial.|t|f|t|f
33987708|NCT00428298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774945|NCT04002830|NA|SINGLE_GROUP||TREATMENT||NONE||Type 3 Gaucher disease patients||||
33774946|NCT06023199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774947|NCT01518114|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33684999|NCT04573647|||COHORT||PROSPECTIVE|||||||
33685000|NCT00064298|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33685001|NCT01511055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685002|NCT01905423|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33685003|NCT02117206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33685004|NCT02702245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33685005|NCT00103727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685006|NCT05381337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685007|NCT03281993|||OTHER||PROSPECTIVE|||||||
33685008|NCT05980767|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33685009|NCT04178356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized|f|t|f|f
33685010|NCT02694718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685011|NCT00045474||||TREATMENT||||||||
34081653|NCT06465472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All Sponsor personnel will be blinded to study drug treatment until the 6-month treatment period data is unblinded for the primary analysis. To ensure that blinding will be maintained along the study, the following measures are implemented:~* the capsules are identical for both products~* all packaging items, bottles (primary packagings) and boxes (secondary, tertiary and quaternary packagings) are identical bearing similar study specific labels.~At the start of the open-label Period 2), in order to maintain the blind to treatment assignment, gradual initiation of treatment will be done in all patients over the first three days as follows: 30 mg/kg/day at Day1, 40 mg/kg/day at Day 2 and 50 mg/kg/day from Day 3 (with a maximum dose of 3,000 mg/day)."|"The study will be conducted in 2 periods: a 6-month, placebo-controlled, double-blind treatment period on which the primary endpoint will be evaluated (period 1) followed by a 6-month open-label treatment period with blind maintained on results (period 2).~Patients who benefit from the treatment after the first 12 months of study treatment will be proposed to enter the 4 years open-label extension (OLE) part of the study to continue to assess the long-term efficacy and safety of stiripentol."|t|t|t|t
34081654|NCT02979964|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33987709|NCT04394962|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Physician performing the embryo transfer will be blinded to the patient's group randomization||f|t|f|f
34081655|NCT00807066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987710|NCT01349374|NON_RANDOMIZED|PARALLEL||||NONE||||||
34081656|NCT01193946|||COHORT||PROSPECTIVE|||||||
34081657|NCT00084240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081658|NCT00914147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081659|NCT00685516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081660|NCT04064268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"In a randomized crossover design, eight healthy lean young men will undergo either:~i) Healthy conditions (overnight fast) + whey protein ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + whey protein iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + 3-OHB/whey protein"||||
34081661|NCT02530437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081662|NCT00005998||||TREATMENT||||||||
34081663|NCT04531124|||COHORT||PROSPECTIVE|||||||
34081664|NCT00379834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081665|NCT03071211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081666|NCT06525116|||CASE_ONLY||RETROSPECTIVE|||||||
33987711|NCT03804983|RANDOMIZED|PARALLEL||OTHER||NONE||This trial aims to demonstrate the safety and feasibility of using MyTDI to determine insulin parameters on the Closed Loop Control (CLC) Artificial Pancreas (AP) System t:slim X2 with Control-IQ technology for use both at ski camp and at home in adolescent patients with type 1 diabetes.||||
34081667|NCT00231023||||TREATMENT||||||||
34081668|NCT02358122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34081669|NCT03335592|||COHORT||RETROSPECTIVE|||||||
33987712|NCT02190929|||COHORT||CROSS_SECTIONAL|||||||
34081670|NCT05328960|||COHORT||RETROSPECTIVE|||||||
34081671|NCT02791256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081672|NCT02736617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081673|NCT01229878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33904961|NCT01320579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33904962|NCT06370702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904963|NCT05041192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33904964|NCT01819220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33904965|NCT03936439|||COHORT||RETROSPECTIVE|||||||
33904966|NCT00931957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33904967|NCT06693297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33904968|NCT01310595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33904969|NCT03083158|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33904970|NCT00523822|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33904971|NCT02612077|||COHORT||PROSPECTIVE|||||||
33904972|NCT02054533|||COHORT||PROSPECTIVE|||||||
33904973|NCT06323590|||COHORT||PROSPECTIVE|||||||
33987713|NCT04741620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33987714|NCT02553044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33904974|NCT00510588|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33904975|NCT01011881|||COHORT||PROSPECTIVE|||||||
33904976|NCT00250380|||COHORT||PROSPECTIVE|||||||
33904977|NCT04510922|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33904978|NCT03502707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33904979|NCT06298370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, double-blind, randomized clinical trial|t|f|f|f
33685012|NCT02302430|RANDOMIZED|PARALLEL||OTHER||TRIPLE||SOLO arm and ECHO arm -- Acquainted, Unacquainted|t|f|t|t
33904980|NCT03260335|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Case Experimental Design combining withdrawal (ABA) and multiple baseline design,||||
33904981|NCT02987478|||COHORT||PROSPECTIVE|||||||
33904982|NCT00282958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904983|NCT03591705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904984|NCT06438913|||CASE_ONLY||PROSPECTIVE|||||||
33904985|NCT00260741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33904986|NCT06152263|||CASE_CONTROL||PROSPECTIVE|||||||
33904987|NCT00480454|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33987715|NCT01369927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33987716|NCT05976386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987717|NCT05512442|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33987718|NCT00097617|||COHORT||PROSPECTIVE|||||||
33987719|NCT01395563|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987720|NCT00609674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987721|NCT03382925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each subject will be randomized into a group assignment in a 1:1 manner, #1 or #2, as outlined in the Methods section.||t|f|f|f
33987722|NCT00191204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987723|NCT04471610|RANDOMIZED|PARALLEL||OTHER||NONE||In the intervention arm serial measurement of NT-proBNP will be made available to the treating physician. A control group continuing to undergo care according to the 2016 ESC Guidelines will serve as comparator. Changes in NT-proBNP levels, safety laboratory parameters such as sodium, potassium, creatinine, HF medication, vital signs, body weight and BMI, QoL, length of hospital stay, NYHA functional class, adverse events, transfer to the Intensive Care Unit and mortality will be recorded in patients with ADHF.||||
33987724|NCT04459260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987725|NCT00004694|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33987726|NCT02412852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685013|NCT05325710|RANDOMIZED|PARALLEL||PREVENTION||NONE||Compare a group of patient with study-nurse specific regular follow-up versus standard follow-up in France||||
33685014|NCT00877773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685015|NCT01830023|||FAMILY_BASED||PROSPECTIVE|||||||
33685016|NCT01952782|NA|SINGLE_GROUP||OTHER||NONE||||||
33685017|NCT03733431|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33685018|NCT04485065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685019|NCT05043155|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685020|NCT04422275|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Blinded|2 x 2 factorial design|t|t|t|t
33685021|NCT02218476|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33774948|NCT04656652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904988|NCT03408080|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open trial. There is no masking.|||||
33904989|NCT03769740|||COHORT||PROSPECTIVE|||||||
33904990|NCT01668771|||||PROSPECTIVE|||||||
33904991|NCT03666143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33904992|NCT04220866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904993|NCT01729910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33904994|NCT05262400|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33987727|NCT04280263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33987728|NCT00305357|||COHORT||PROSPECTIVE|||||||
33987729|NCT00522886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987730|NCT02778815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33987731|NCT04907786|||OTHER||PROSPECTIVE|||||||
33987732|NCT05080322|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33987733|NCT00927303|||COHORT||PROSPECTIVE|||||||
33987734|NCT02017119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987735|NCT00830739|||||OTHER|||||||
34081674|NCT04258072|NA|SINGLE_GROUP||TREATMENT||NONE||"* Vactosertib\* 100-300 mg bid for 5 days~* Liposomal Irinotecan (Onivyde) 70mg/m2 on D1~* LV 200mg/m2 IV bolus on D1~* 5-FU 2400mg/m2 CIV over 46 hours on D1"||||
34081675|NCT01015027|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34081676|NCT04550078|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double-blinded||t|f|t|f
34081677|NCT02546011|||COHORT||PROSPECTIVE|||||||
34081678|NCT00542867|||||PROSPECTIVE|||||||
34081679|NCT02143817|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081680|NCT04232956|||COHORT||RETROSPECTIVE|||||||
33774949|NCT05568355|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33774950|NCT05567172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774951|NCT05649410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774952|NCT05642221|||COHORT||PROSPECTIVE|||||||
33904995|NCT04187222|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Treatment of peri-implant mucositis and maintenance care Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curves and polishing using a rubber bowl and polishing paste. In the Test Group the treatment session was completed by a professional topical application around the carboxymethylcellulose gel implants containing 109 CFLs of B. lactis HN019. The gel was applied sub and supragingivally. The patients then received commercial capsules containing the same bacteria and were instructed to dissolve the capsule contents in 20 mL of water and rinse for 30 to 60 seconds, followed by swallowing twice a day for 12 weeks. The control group received the same oral hygiene instructions, mechanical debridement and was treated with gel and placebo tablets. At 3 months postoperatively, the same local mechanical and chemical treatment was repeated for the Test and Control groups.|t|t|f|t
33904996|NCT04465617|||OTHER||RETROSPECTIVE|||||||
33904997|NCT01884285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685022|NCT03272984|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a parallel, open-label randomized controlled trial.||||
33685023|NCT04643301|NA|SINGLE_GROUP||OTHER||NONE||The study cohort will be compared to a retrospective matched cohort based on BMI before surgery, gender and type of surgery||||
33685024|NCT00400478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685025|NCT00828438|NA|SINGLE_GROUP||OTHER||NONE||||||
33685026|NCT00544089|||||PROSPECTIVE|||||||
33685027|NCT02281097|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33685028|NCT05838989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and care providers will not be blinded to the treatment group, but outcomes assessors will be blinded to the treatment group.|Participants will be randomized into one of three groups: stretching and prefabricated orthoses, orthoses alone, or a placebo treatment.|f|f|f|t
33685029|NCT02385136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685030|NCT02547883|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33685031|NCT05944978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685032|NCT04801940|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomisation will use equal probability between all active treatments a given patient is eligible for and Standard Care (SC) as the control arm (i.e. a patient that is eligible for two treatments and SC will be randomized 1:1:1 between the three arms).||||
33685033|NCT00624884|||CASE_CONTROL||PROSPECTIVE|||||||
33685034|NCT04396184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator assesses photographs without prior knowledge of intervention||f|f|f|t
33774953|NCT06641232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trial|t|t|t|f
33774954|NCT00984815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33774955|NCT04493853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Approximately 1000 participants are assigned to one of the two parallel groups (1:1 ratio) to receive either capivasertib or placebo, in combination with abiraterone on a background of ADT for the duration of the study.|t|t|t|t
33774956|NCT02617563|||COHORT||PROSPECTIVE|||||||
33774957|NCT04782375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33774958|NCT06178354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685035|NCT01211587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685036|NCT02598336|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685037|NCT01286831|NA|SINGLE_GROUP||OTHER||NONE||||||
33685038|NCT04676971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685039|NCT02968589|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33685040|NCT04837677|NA|SEQUENTIAL||TREATMENT||NONE||||||
33774959|NCT06740539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774960|NCT00597909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33774961|NCT04120805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33774962|NCT03519581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be masked to their treatment assignment. The research coordinator that performs the measurement of best corrected visual acuity will be masked to the treatment assignment. The reading center analyst responsible for reviewing and analyzing OCT and microperimetry reports will be masked to treatment assignment.||t|f|f|t
33774963|NCT04219709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized in a parallel design to receive a standard carbohydrate diet versus very low carbohydrate diet. Both of diet groups will undergo euglycemic-hypoglycemic insulin clamps and MRI studies to assess brain hypoglycemia tolerance. The standard diet group will undergo an additional euglycemic-hypoglycemic insulin clamp - with and without exogenous oral ketones in random order.||||
33774964|NCT06284694|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive active rTMS treatment.||||
33774965|NCT04872309|||COHORT||PROSPECTIVE|||||||
33685041|NCT03590431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|"Two of the three test drinks will consist of milk delivering extrinsic iodine or intrinsic iodine and will appear the same. These two milks will be labelled with A and B and masking will be applied to the participant only (single-blinded). The code will be held by the Study coordinator. However, for the water iodine-solution, blinding will not be possible."||t|f|f|f
33685042|NCT01706900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33685043|NCT00611871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685044|NCT01763242|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685045|NCT04716556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685046|NCT04002570|||CASE_CONTROL||PROSPECTIVE|||||||
33685047|NCT00006439|NA|SINGLE_GROUP||ECT||||||||
33774966|NCT06147401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The anesthetist in the operating room will be the only one who knows what treatment has been administered~Participant: the patient will not know the type of block he will be subjected to, because of he will already be subjected to neuraxial anesthesia.~Outcomes Assessor: a clinician external to the practice will evaluate the degree of residual paralysis after anesthesia and pain control Investigator: the statistician will not know which anesthetic technique was administered to which group"|A double-blind, randomized, controlled trial|t|t|t|t
33774967|NCT06204029|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33774968|NCT01658930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774969|NCT04134572|||COHORT||OTHER|||||||
33774970|NCT05073679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The Penn State Health IDS pharmacy will purchase Naltrexone 50mg tablets from a pharmaceutical wholesaler. The IDS pharmacy will purchase gelatin capsules and USP grade methylcellulose from a pharmacy supplier to be used for compounding the active and placebo capsules. For the active Naltrexone 50mg capsules, a Naltrexone 50mg tablet will be placed in an empty gelatin capsule with methylcellulose filler. The placebo capsules will be empty gelatin capsules filled with Methylcellulose.~Participants will be randomized using redcap at enrollment to either study article or placebo, and neither investigators nor care providers will be aware of which article the participants receive."|double-blind, placebo controlled randomized clinical trial|t|t|t|f
33774971|NCT04024761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774972|NCT06740084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774973|NCT06342310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33904998|NCT06480474|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will use a controlled randomized design with 3 conditions (1. Online program, 2. Online program and online forum, 3. Wait list). Participants will be assessed at 4 time points: before the beginning of the intervention (T0, baseline), at 4 weeks mid-treatment (T1), after the intervention, at 8 weeks (T2), and at the follow-up, that is 3 months post-intervention (T3).||||
33904999|NCT03287297|||COHORT||CROSS_SECTIONAL|||||||
33905000|NCT01733069|||COHORT||CROSS_SECTIONAL|||||||
33905001|NCT04742517|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33905002|NCT01048229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905003|NCT01492647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905004|NCT05221450|||COHORT||PROSPECTIVE|||||||
33905005|NCT02467595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33905006|NCT02826044|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33905007|NCT02702193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905008|NCT05118139|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905009|NCT04331158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To avoid any type of selection bias, the confidential allocation method will be through opaque envelopes, sealed and numbered consecutively. The randomization process will be carried out by an independent researcher who will not be involved in other study procedures. The group in which the participant will be allocated will be revealed to the researcher responsible for the consultations prior to the first intervention.|dry cupping group and dry cupping sham group|t|f|f|t
33905010|NCT04936451|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Monocentric, randomized in cross over in two arms, open||||
33905011|NCT03711552|||COHORT||PROSPECTIVE|||||||
33905012|NCT03564665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo|Randomized, Placebo Controlled, Single Blinded|t|f|f|f
33905013|NCT06124443|||CASE_CONTROL||PROSPECTIVE|||||||
33905014|NCT03604471|NA|SINGLE_GROUP||OTHER||NONE||||||
33905015|NCT04330508|||COHORT||PROSPECTIVE|||||||
33905016|NCT02090114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905017|NCT04142476|NA|SINGLE_GROUP||OTHER||NONE||||||
33905018|NCT00023985||||TREATMENT||||||||
33905019|NCT00004865||||TREATMENT||||||||
33774974|NCT03030261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774975|NCT06719635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33774976|NCT05685238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905020|NCT01835990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905021|NCT03155542|||CASE_CONTROL||RETROSPECTIVE|||||||
33905022|NCT00325442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905023|NCT02013193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905024|NCT04742153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905025|NCT00031577||||TREATMENT||||||||
33905026|NCT05644210|||COHORT||PROSPECTIVE|||||||
33905027|NCT00620620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905028|NCT02807909|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33905029|NCT00769704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905030|NCT01414088|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33905031|NCT00005999||||TREATMENT||||||||
33905032|NCT01048996|||CASE_CONTROL||PROSPECTIVE|||||||
33905033|NCT00193674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905034|NCT04869579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized double-blinded, placebo-controlled Phase 2 clinical trial to assess the efficacy of Selenium in the treatment of moderately-ill, severely-ill, and critically ill COVID-19 patients. The patients will be randomized in a 1:1 ratio to receive standard of care plus a loading dose of Selenium followed by continuous infusion for a total of 14 days, or standard of care plus a Saline-based placebo.|t|f|t|f
33685048|NCT00217321|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33685049|NCT00629278|RANDOMIZED|||TREATMENT||||||||
33685050|NCT02146144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685051|NCT04184986|||OTHER||PROSPECTIVE|||||||
33685052|NCT01173887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685053|NCT04520269|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open-label, lead in phase Ib dose confirmation, followed by phase II study with 2 parallel study cohorts.||||
33685054|NCT01673347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685055|NCT00259129|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33685056|NCT02480140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685057|NCT01935427|||||PROSPECTIVE|||||||
33685058|NCT02324127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685059|NCT00122733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685060|NCT05889260|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33685061|NCT00991068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685062|NCT06401187|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33685063|NCT02468271|||COHORT||PROSPECTIVE|||||||
33685064|NCT00298753|NON_RANDOMIZED|PARALLEL||||NONE||||||
33685065|NCT05389228|||COHORT||PROSPECTIVE|||||||
33685066|NCT01210703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33685067|NCT01915329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33685068|NCT05553743|||COHORT||PROSPECTIVE|||||||
33685069|NCT05113303|||CASE_CONTROL||RETROSPECTIVE|||||||
33685070|NCT03025789|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685071|NCT04168710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical team taking care of the patient as well as the patient will be blinded as to allocation to experimental or control group. The physician administering the block will also be blinded to the substance administered.||t|t|f|f
33685072|NCT00821444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33685073|NCT00813176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective randomized study|t|f|f|t
33685074|NCT03509415|||COHORT||PROSPECTIVE|||||||
33685075|NCT01295268|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33685076|NCT02403687|||CASE_ONLY||PROSPECTIVE|||||||
33685077|NCT01505504|||CASE_ONLY||RETROSPECTIVE|||||||
33685078|NCT01309893|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33685079|NCT01723696|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33685080|NCT00203281|||CASE_ONLY||PROSPECTIVE|||||||
33685081|NCT02963844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685082|NCT06345196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33685083|NCT01677390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685084|NCT04719832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685085|NCT05629000|||COHORT||PROSPECTIVE|||||||
33685086|NCT04284150|NA|SINGLE_GROUP||TREATMENT||NONE||patients with supraventricular tachycardia||||
33685087|NCT05324865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685088|NCT04686045|||OTHER||RETROSPECTIVE|||||||
33685089|NCT00124839|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33685090|NCT06054204|NA|SINGLE_GROUP||TREATMENT||NONE||single group assignment patients||||
33685091|NCT01254955|||COHORT||RETROSPECTIVE|||||||
33685092|NCT02682914|||COHORT||PROSPECTIVE|||||||
33685093|NCT03455907|||COHORT||PROSPECTIVE|||||||
33685094|NCT04013399|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33685095|NCT00912561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685096|NCT04368247|||CASE_ONLY||PROSPECTIVE|||||||
33685097|NCT05036811|||COHORT||RETROSPECTIVE|||||||
33685098|NCT06371183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who complaining of lower GI manifestations||||
33685099|NCT00540371|||CASE_ONLY||RETROSPECTIVE|||||||
33905035|NCT03586843|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33905036|NCT04151381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33905037|NCT02272621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987736|NCT03633474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Non-Neisseria spp. carriers will randomised in a ratio of 2:1 to receive either 10-5 cfu N. lactamica or PBS control using randomisation software, e.g. Sealed envelope (TM) available online.|Volunteers will be blinded to the inoculum type received (i.e. N. lactamica or PBS control) throughout the study duration. Nasal secretion and throat swabs will be taken to enable mucosal immune profiling and microbiome analyses to be performed. Subjects will be screened for nasopharyngeal N. meningitidis carriage -28 to -7 days (visit 1) and non-Neisseria spp. carriers will be challenged with either 105 cfu N. lactamica suspended in PBS or PBS only control (day 0, visit 2). Volunteers identified as carriers of N. meningitidis at visit 1 will be excluded from the study and will not progress to experimental human challenge. Biological samples (nasal secretion, microbiome swab and blood) will be collected from volunteers who progress to the challenge (visit 2, Day 0) and on days +7 (+/-3), +14 (+/-3) and +28 (+/-5) post-challenge. Nasal wash sampling will not be taken at the challenge visit (Day 0) but will be taken on days +7(+/-3), +14 (+/-3) and +28 (+/-5) post-challenge.|t|f|f|f
33987737|NCT05602103|||CASE_ONLY||RETROSPECTIVE|||||||
33987738|NCT06135857|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34081681|NCT06078215|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A prospective longitudinal study will be performed in ischemic stroke patients who:~1. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - control (group A),~2. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy plus Cerebrolysin (group B)~3. are not referred to reperfusion therapy nor Cerebrolysin (group C)."||||
34081682|NCT04443335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081683|NCT03010072|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34081684|NCT00327483|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34081685|NCT00617279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081686|NCT05641571|RANDOMIZED|PARALLEL||PREVENTION||NONE||The 3\~6 months home-based extremity exercise program will be intervened between newly diagnosed with breast cancer to the completion of chemotherapy. Participants have to perform a total of 50 minutes of exercise including the Ten Skilled Hand exercise fourth a day, 5 minutes each time and Buerger Allen exercise twice a day, 15 minutes each time. The observational group will need to record the extra exercise performed and the exercise prescription will be distributed after the study.||||
34081687|NCT03884881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081688|NCT03221114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to intervention assignment and will only collect clinical data at baseline, 8-, and 12-weeks.|Cluster-randomized control trial|f|f|f|t
34081689|NCT04573660|||COHORT||PROSPECTIVE|||||||
33905038|NCT01401855|||CASE_ONLY||CROSS_SECTIONAL|||||||
33905039|NCT01800604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905040|NCT02018614|||||CROSS_SECTIONAL|||||||
33905041|NCT05603910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905042|NCT02391168|||COHORT||PROSPECTIVE|||||||
33905043|NCT05492383|NA|SINGLE_GROUP||OTHER||NONE|Investigation participant number only|A prospective, non-randomized, single-arm, multicenter, clinical performance pivotal clinical investigation.||||
33905044|NCT01257217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905045|NCT06482645|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33905046|NCT01335815|||COHORT||PROSPECTIVE|||||||
33905047|NCT04210336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081690|NCT05073705|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||"Intervention condition. The empowerment and personal transformation (EPT) intervention~Control condition. The control condition will be standard of care. At the MRRH HIV clinic, ALHIV are identified for the transition to adult HIV care after careful consideration of factors that are individual specific. Under current standard of care, clinic visits are guided by a number of factors including the patient's age, clinical status, availability of school programs, distance from the clinic, and ability to afford transport fare to the clinic.~Randomization. Experimental procedures will be registered with ClinicalTrials.gov. Participants will be allocated to the treatment vs. control conditions in equal proportions in a parallel group design in which treatment assignment will be determined centrally using a computerized random number generator.~Randomization will be stratified by age (15-19 vs 20-24 years) and gender (male vs female)."|t|t|t|f
34081691|NCT06141252|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators aim to compare and evaluate the effects of therapeutic hypothermia versus standard care on clinical outcomes, such as survival rates and neurological function, in patients with out-of-hospital cardiac arrest complicating acute myocardial infarction.||||
34081692|NCT02069938|||CASE_ONLY||PROSPECTIVE|||||||
34081693|NCT00646724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081694|NCT02440269|||COHORT||PROSPECTIVE|||||||
34081695|NCT04500574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a single-center study to assess the safety and feasibility of delivering latanoprost using the latanoprost contact lens (L-CL) delivery system as a treatment for glaucoma or ocular hypertension. The study has two phases. Phase A is an open-label study with 5 participants; these individuals will wear the L-CL in one eye for one week during which time they will be closely followed with examinations for evaluation of safety. If the L-CL is found to be safe after review of the clinical data by a data and safety monitoring board, phase B will be initiated to assess the safety and effectiveness of delivering latanoprost through the L-CL. This is a double-masked double-dummy study. The L-CL arm will have the drug-eluting latanoprost contact lens (L-CL) and a sham drop, and the latanoprost arm will have a C-CL (no drug) with a nightly 0.005% latanoprost drop.|t|t|t|t
34081696|NCT05696145|||COHORT||PROSPECTIVE|||||||
34081697|NCT00325741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081698|NCT00687934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081699|NCT00006032||||TREATMENT||||||||
34081700|NCT04025216|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Parallel arms with sequential dose escalation||||
34081701|NCT06209632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081702|NCT06416631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081703|NCT01552746|||COHORT||PROSPECTIVE|||||||
34081704|NCT04781712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081705|NCT01210638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081706|NCT05885932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081707|NCT00745303|||CASE_CONTROL||PROSPECTIVE|||||||
34081708|NCT05497323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081709|NCT03190824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081710|NCT00995956|||COHORT||PROSPECTIVE|||||||
33905048|NCT04079556|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33905049|NCT02461485|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33905050|NCT01938820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905051|NCT03648996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905052|NCT04195750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905053|NCT03206944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905054|NCT04809727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients suffering after supracervical hysterectomy||||
33905055|NCT01985048|||COHORT||PROSPECTIVE|||||||
33905056|NCT02601885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905057|NCT00893113|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33905058|NCT01959867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905059|NCT03070730|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The study design is a double-dummy design. While during two of the three trial arms the patients take an active study drug and a placebo, there is also an arm where patients take only placebo."|t|f|t|t
33905060|NCT01519427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905061|NCT06047431|NA|SEQUENTIAL||TREATMENT||NONE||||||
33905062|NCT00149331|RANDOMIZED|PARALLEL||ECT||NONE||||||
33905063|NCT02615717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905064|NCT03518229|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33905065|NCT04743037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905066|NCT02154854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33905067|NCT05328778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905068|NCT02452970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905069|NCT00778752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905070|NCT06328075|||CASE_CONTROL||OTHER|||||||
33905071|NCT05572229|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905072|NCT05853458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905073|NCT01902407|||COHORT||PROSPECTIVE|||||||
33905074|NCT05258058|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33905075|NCT04845776|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants with ASD will receive the vitamin/mineral supplement||||
33905076|NCT04368065|||COHORT||PROSPECTIVE|||||||
33905077|NCT04748783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, placebo-controlled, double-blind prospective trial to test the efficacy and acceptability of 4 therapeutic, antiseptic mouth rinses to inactivate SARS-CoV-2 virus in saliva of COVID-19 positive patients|t|t|f|t
33905078|NCT01996319|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33987739|NCT00651586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987740|NCT05457231|NA|SINGLE_GROUP||OTHER||NONE||||||
33987741|NCT06223893|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomised 1:1 to receive either the standard of care or the CirrhoCare management system.||||
33987742|NCT01805505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987743|NCT01172977|||CASE_CONTROL||PROSPECTIVE|||||||
33987744|NCT04449315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987745|NCT01240291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987746|NCT04013919|||CASE_ONLY||PROSPECTIVE|||||||
33987747|NCT02356354|NA|SINGLE_GROUP||||NONE||||||
33987748|NCT04825535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One assessor will be blinded to the (2) comparison groups of all participants.|Online CBT intervention|f|f|f|t
33987749|NCT02783352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987750|NCT06045598|||COHORT||RETROSPECTIVE|||||||
33987751|NCT00359489|||DEFINED_POPULATION||PROSPECTIVE|||||||
33987752|NCT02152683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987753|NCT00002220||||TREATMENT||||||||
33987754|NCT04017494|||COHORT||PROSPECTIVE|||||||
33774977|NCT06392230|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33774978|NCT03941730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33774979|NCT06636864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905079|NCT05603624|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The two types of gloves used were labeled as Glove 1 and Glove 2 for data collection and analysis. The providers performing examinations and the patients knew the type of glove being used at the time of the study but data collection was deidentified and retrospective analysis was blinded to the investigating team until the study concluded."|Eligible and consented participants were randomized to receive all cervical examinations with sterile powder-free polyvinyl chloride exam gloves (current routine practice, control group) or clean powder-free nitrile exam gloves (nonsterile, experimental group). Neither the clinical providers performing the exam nor the participants were blinded to the glove type used, however, the researchers did not know which glove type was used while completing the retrospective data collection and analysis. All other obstetrical care provided to the participants was per ACOG guidelines and the only changes made to their care was the type of glove used for this study.|f|f|t|t
33905080|NCT00044044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905081|NCT04166045|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33905082|NCT01945931|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905083|NCT00110383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905084|NCT03792750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905085|NCT06586021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905086|NCT05775692|||COHORT||PROSPECTIVE|||||||
33905087|NCT00431860|||CASE_CONTROL||OTHER|||||||
33905088|NCT03640143|||COHORT||RETROSPECTIVE|||||||
33905089|NCT05846386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33905090|NCT03472482|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33987755|NCT03392454|||CASE_ONLY||PROSPECTIVE|||||||
34081711|NCT00125008|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081712|NCT00000320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905091|NCT04524936|||CASE_CONTROL||PROSPECTIVE|||||||
33905092|NCT04594408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Surgeons are blinded to group allocation as all IV bags will have labels appearing identical when turned away from the surgeon. Anesthetists are told not to reveal allocation to the surgeon as well. And patients will not be informed of their allocation.||t|t|t|t
33905093|NCT02886026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905094|NCT04656964|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33905095|NCT00744146|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33905096|NCT01543451|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33987756|NCT06101771|||CASE_CONTROL||PROSPECTIVE|||||||
33987757|NCT06560112|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33987758|NCT02010190|||COHORT||PROSPECTIVE|||||||
33987759|NCT02753959|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33987760|NCT03909620|NA|SINGLE_GROUP||SCREENING||NONE||||||
33774980|NCT05919264|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33774981|NCT06737263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33774982|NCT06481436|RANDOMIZED|PARALLEL||OTHER||NONE|This is a non-blinded study|Randomized Controlled Trial||||
33774983|NCT06501729|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||The couples in the control group will not kiss; they will only wait for the salivary pH to neutralize physiologically. The other couples will be divided into two groups: the group in which only one person in the couple consumes the sugary or fermented drink, and the group in which both people in the couple do so.|t|f|f|f
33774984|NCT06737068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33987761|NCT04932967|||CASE_ONLY||RETROSPECTIVE|||||||
33987762|NCT05824325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987763|NCT04057222|||COHORT||PROSPECTIVE|||||||
33987764|NCT01172145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987765|NCT00301691|RANDOMIZED|||PREVENTION||||||||
33987766|NCT04534166|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33987767|NCT02728856|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33987768|NCT02545205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987769|NCT04377009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987770|NCT00938106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987771|NCT04293757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987772|NCT05107505|||COHORT||PROSPECTIVE|||||||
33987773|NCT01299363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987774|NCT00001835||||TREATMENT||||||||
33987775|NCT02892253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34081713|NCT05185063|||COHORT||PROSPECTIVE|||||||
34081714|NCT01338896|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34081715|NCT05656300|||COHORT||PROSPECTIVE|||||||
34081716|NCT01382550|||COHORT||PROSPECTIVE|||||||
34081717|NCT01764841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081718|NCT03894358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081719|NCT04142333|NA|SINGLE_GROUP||SCREENING||NONE||||||
34081720|NCT03168217|||COHORT||RETROSPECTIVE|||||||
34081721|NCT04854239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were not aware whether implant were placed with a contra-angled handpiece or with a torque wrench. 3D implant position accuracy evaluation was performed blinded, randomization sequence was revealed after analysis.|Forty patients were treated; implant insertion with half-guided surgical protocol was utilized by surgical motor (20 patients, machine-driven group) or torque wrench (20 patients, manual group) in the maxilla.|t|f|f|t
34081722|NCT04149340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33774985|NCT06004388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33774986|NCT06409663|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839692|NCT03283475|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The sample will be divided into two groups:- - Control group which will include 60 adult individuals between 18 and 35 years old who have BMI between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences.~- Patient group which will include 40 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.~After assessment, one of the following techniques will be selected:-~* Liposuction only.~* thigh lift.~* Liposuction assisted thigh lift."||||
33839693|NCT00000920||||TREATMENT||||||||
33905097|NCT00000451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905098|NCT00606697|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33905099|NCT00687154|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905100|NCT06692530|||CASE_ONLY||CROSS_SECTIONAL|||||||
33905101|NCT06504082|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905102|NCT01431482|||COHORT||PROSPECTIVE|||||||
34081723|NCT02291978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081724|NCT03225365|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081725|NCT00603031|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33905103|NCT02369978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081726|NCT03530891|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because the two interventions requires different pre operative preparation, both the participants and investigators can't be blinded.|"* A Randomized clinical trial.~* Parallel group study.~* A trial will be carried out in hospital of Oral and Maxillofacial surgery department- Faculty of Oral and Dental Medicine Cairo University~* Equal randomization: participants with equal probabilities for intervention.~* Positive controlled: Both groups receiving treatment."||||
34081727|NCT01332825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34081728|NCT01057836|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34081729|NCT06088589|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685100|NCT03754231|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients recruited will be wearing the Aingeal device at a paediatric outpatient clinic setting.||||
33685101|NCT04845529|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33685102|NCT02502006|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33685103|NCT06209385|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation and dose expansion||||
33685104|NCT00976508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685105|NCT01643980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685106|NCT01216371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685107|NCT04370483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685108|NCT04770077|||OTHER||PROSPECTIVE|||||||
33685109|NCT05326724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685110|NCT01692847|||COHORT||PROSPECTIVE|||||||
33685111|NCT02045329|||CASE_ONLY||PROSPECTIVE|||||||
33685112|NCT05780268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685113|NCT05892796|||COHORT||PROSPECTIVE|||||||
33685114|NCT03710018|||COHORT||PROSPECTIVE|||||||
33685115|NCT01758289|||COHORT||PROSPECTIVE|||||||
33685116|NCT01129024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685117|NCT04995289|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33685118|NCT06091072|NA|SINGLE_GROUP||OTHER||NONE||One group to evaluate the feasibility of the proposed method.||||
33685119|NCT05682573|||COHORT||PROSPECTIVE|||||||
33905104|NCT02855593|||CASE_ONLY||PROSPECTIVE|||||||
33685120|NCT02741180|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33685121|NCT03539796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685122|NCT02205554|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33685123|NCT06381271|||COHORT||PROSPECTIVE|||||||
33685124|NCT01752036|NA|SINGLE_GROUP||TREATMENT||NONE||Post-Operative Stereotactic Radiosurgery||||
33685125|NCT00697580|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33685126|NCT02290431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685127|NCT01864356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905105|NCT00400491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905106|NCT05975580|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The investigational drugs and placebo capsules will look identical. University of California Irvine Medical Center Investigational Drug Service will dispense the masked study drugs in accordance with randomization. The study statistician who generates the randomization scheme and the research pharmacist who dispenses the study drugs are the only personnel who are unblinded to the randomized assignment. Investigators and all other study personnel and the study subjects will be blinded to the treatment assignment until subjects have completed all visits, all data have been entered, and the data file has been locked.|A total of 120 eligible subjects, with weight regain after bariatric surgery, will be initially randomized in a 3:3:2 ratio to daily treatment with topiramate (TPM) 50 mg or phentermine (PHEN) 7.5 mg or placebo. After 4 months, responders (those with ≥5% weight loss) will continue the same treatment, while nonresponders will be re-randomized to a higher dose of the same drug or phentermine/topiramate 7.5/50 mg combination (PHEN/TPM) during Months 5-12. All randomized subjects will receive lifestyle counseling throughout the study.|t|t|t|t
33905107|NCT00647842|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34081730|NCT01095172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685128|NCT06403475|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33685129|NCT01063933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685130|NCT00539201|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33685131|NCT01358279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685132|NCT04195191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The statistical analysis will be performed by a person who would be blinded to which arm were assigned the subjects.|cluster randomized controlled trial.|f|f|f|t
33685133|NCT03739788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081731|NCT04680832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081732|NCT00800046|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34081733|NCT01334086|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34081734|NCT04119934|||OTHER||PROSPECTIVE|||||||
33905108|NCT02081547|||COHORT||PROSPECTIVE|||||||
33905109|NCT00708994|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33905110|NCT00000650||||TREATMENT||NONE||||||
33905111|NCT06352437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905112|NCT04493710|||COHORT||CROSS_SECTIONAL|||||||
33905113|NCT04925414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905114|NCT01984476|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33905115|NCT01070784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905116|NCT06693843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905117|NCT06693895|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Observer-blind study.||t|f|t|f
33905118|NCT01959555|||||RETROSPECTIVE|||||||
33905119|NCT03823937|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33905120|NCT03223220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905121|NCT05585411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905122|NCT02031380|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33905123|NCT01074411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905124|NCT02422043|NA|SINGLE_GROUP||OTHER||NONE||||||
33905125|NCT01591018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33905126|NCT02995681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905127|NCT01505491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905128|NCT05758441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Trained research assistants who will collect data and survey measures are blinded to study condition of each participant.|For this community-based study, a stratified randomized-controlled clinical trial will evaluate MPBA+F among 7/8th grade children with overweight or obesity recruited during years 1 and 2 of the study from rural Appalachian counties. Stratification by biological sex to have equal numbers of males and females will occur. Investigators will recruit 288 children to participate. Half will be randomized to receive MPBA+F; the other half will receive a comparison program of 10 weekly, self-guided modules from mailed to their home. By following participants from the start of 7th grade (baseline) through the middle of 8th grade, longer-term effects on PA outcomes and body composition can be determined. Differences in outcomes are explored by examining sub-group differences on effects. A sub-set of parents from both study conditions will be recruited (72 parents from each condition) to provide child assessments of perceived PA behaviors and perceived child health.|f|f|f|t
33987776|NCT06440694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Controlled Pilot Trial comparing two groups - Colchicine 0.5 mg po once daily for 180 days vs Placebo 0.5 mg po once daily for 180 days.|t|t|t|t
33987777|NCT00053963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685134|NCT01908400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987778|NCT00909662|||CASE_CONTROL||PROSPECTIVE|||||||
33987779|NCT06217224|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Phase 3, randomized study with patients diagnosed with OS, enrolled at INCA, candidates for the Glato protocol (chemotherapy -doxorubicin, cisplatin, dexamethasone and MTX + surgery). Patients will be randomized through the computerized system to groups 1 or 2.~Randomization will be performed in permuted blocks."||||
33987780|NCT03730597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|blinded to purpose of study and to randomization|randomized study|f|f|f|t
33987781|NCT02119065|||CASE_ONLY||PROSPECTIVE|||||||
33987782|NCT00308048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987783|NCT05340140|||OTHER||OTHER|||||||
33987784|NCT01844375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33987785|NCT05445739|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33987786|NCT00594685|||CASE_ONLY||PROSPECTIVE|||||||
33987787|NCT04303663|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33987788|NCT03380754|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Research assistant who is not involved in any of the patients clinical care is responsible for randomization collection of data. All others are blinded to the groups involved.|Prospective, randomized, double blinded, placebo controlled trial|t|t|t|t
33987789|NCT01565876|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987790|NCT05557747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. mobilization and conventional physical therapy~2. autogenic muscle Energy Technique and conventional physical therapy~3. conventional physical therapy only"|t|f|f|t
33987791|NCT00610363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987792|NCT03236311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987793|NCT05584345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987794|NCT04309981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987795|NCT04541147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987796|NCT01597245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987797|NCT01181700|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33987798|NCT03369860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987799|NCT01839279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081735|NCT00176449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685135|NCT01753778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685136|NCT03350230|||CASE_CONTROL||PROSPECTIVE|||||||
33685137|NCT02269189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685138|NCT02695212|NA|SINGLE_GROUP||OTHER||NONE||||||
33685139|NCT06420258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each group allocation will be sealed in an opaque envelope with a code written on the outside. These sealed envelopes will be handed over to the researchers. When a study participant meets the inclusion and exclusion criteria upon entry into the study, they will be assigned a number. Subsequently, the corresponding envelope with the assigned number will be opened, and the intervention will be carried out according to the group allocation specified in the envelope. The treatment plan for each research participant will be determined by the generated random sequence.||t|t|f|f
33685140|NCT04710771|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685141|NCT04886440|||COHORT||RETROSPECTIVE|||||||
33685142|NCT00827931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685143|NCT01934543|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33685144|NCT03797313|||COHORT||PROSPECTIVE|||||||
33685145|NCT00779272|||COHORT||RETROSPECTIVE|||||||
33685146|NCT04259892|||COHORT||PROSPECTIVE|||||||
33685147|NCT03415529|||COHORT||RETROSPECTIVE|||||||
33685148|NCT03216928|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33685149|NCT00724880|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685150|NCT05575921|||COHORT||RETROSPECTIVE|||||||
33685151|NCT05056285|||CASE_ONLY||OTHER|||||||
33685152|NCT03396042|||COHORT||PROSPECTIVE|||||||
33685153|NCT03690336|||COHORT||RETROSPECTIVE|||||||
33685154|NCT05258669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|An unblinded pharmacist or another qualified individual will prepare and provide the syringe in a blinded manner to the study vaccine administrator (a trained and qualified study nurse, medical doctor, or otherwise qualified health care professional) who will perform the injection.|1:1 randomization ratio|t|t|t|t
33685155|NCT06514196|||COHORT||PROSPECTIVE|||||||
33685156|NCT02780323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905129|NCT03743558|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"First consultation: SHS questionnaire submission and clinical examination~* Realization of PV and analysis according to the standard criteria of the American Academy of Sleep Medicine~* Production of a video at home by the parents according to the following conditions, within 4 days around the PV/PSG :~* Second consultation~* Collection of the video and the result of the PV~* Study exit."||||
33905130|NCT01728272|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33905131|NCT04869956|RANDOMIZED|PARALLEL||TREATMENT||NONE||open, controlled, randomized clinical trial||||
33905132|NCT04736511|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Mono-centric comparative cross-sectional observational study with minimal risks and constraints.||||
33987800|NCT01425294|||OTHER||PROSPECTIVE|||||||
33987801|NCT06412016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Analytic database will not have any indication of intervention or control group assignment||f|f|f|t
33987802|NCT03797183|||COHORT||PROSPECTIVE|||||||
33987803|NCT06176326|NA|SINGLE_GROUP||OTHER||NONE||One-group Pretest-Posttest Experimental Method||||
33987804|NCT03429725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34081736|NCT02344823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685157|NCT03170232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685158|NCT05025748|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33685159|NCT05198544|NA|SINGLE_GROUP||TREATMENT||NONE||"This study is a multi-center, prospective trial designed to evaluate the use of HaM in Wagner grade 1 and 2 DFUs.~After screening, subjects are treated with weekly application of HaM and SOC for 8 weeks followed by SOC alone for the remainder of the 12-week trial period.~The standard of care in this study consists of offloading of the DFU using a total contact cast or fixed ankle walker, sharp debridement, infection management with the use of antiseptics and proper moisture balance."||||
33685160|NCT02149771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685161|NCT00266565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685162|NCT02802670|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685163|NCT04575792|||COHORT||RETROSPECTIVE|||||||
33685164|NCT00937885||PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685165|NCT00219544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685166|NCT03656471|||CASE_CONTROL||PROSPECTIVE|||||||
33685167|NCT02315443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839694|NCT06150092|||COHORT||PROSPECTIVE|||||||
33987805|NCT03244553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987806|NCT04113265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685168|NCT02728973|||CASE_CONTROL||PROSPECTIVE|||||||
33685169|NCT03347162|||COHORT||PROSPECTIVE|||||||
33685170|NCT03726567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who are undergoing bariatric surgery and control group who is having abdominal surgery for non-bariatric reasons||||
33685171|NCT02538861|||CASE_CONTROL||PROSPECTIVE|||||||
33685172|NCT02833714|||COHORT||PROSPECTIVE|||||||
33685173|NCT03239665|RANDOMIZED|PARALLEL||PREVENTION||NONE||The design is a randomized trial with randomization to PHARM or PEER performed at the program date level.||||
33685174|NCT06052215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33839695|NCT05963477|||COHORT||PROSPECTIVE|||||||
33839696|NCT03121820|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|two-way crossover||||
33839697|NCT02353364|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34081737|NCT03289338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081738|NCT02697071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081739|NCT01286129|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081740|NCT00072111||||TREATMENT||||||||
34081741|NCT01408706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081742|NCT04135404|||COHORT||CROSS_SECTIONAL|||||||
34081743|NCT04545073|||COHORT||OTHER|||||||
34081744|NCT00986414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081745|NCT00975728|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33905133|NCT04429425|RANDOMIZED|PARALLEL||PREVENTION||NONE|all patients undergoing colorectal surgery will be grouped consecutively as epidural anesthesia (EA) or non-EA|each patient will be randomly asigned to each group (EA or non-EA)||||
33905134|NCT00207987|||||PROSPECTIVE|||||||
33905135|NCT04743882|||CASE_ONLY||CROSS_SECTIONAL|||||||
33905136|NCT02944799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905137|NCT02111824|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33905138|NCT01383044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905139|NCT02154269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905140|NCT04452812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot, experimental, randomized, prospective, longitudinal, clinical study|t|t|f|f
33905141|NCT02782455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905142|NCT00000348||||TREATMENT||NONE||||||
33905143|NCT04592276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905144|NCT02385461|||COHORT||PROSPECTIVE|||||||
33905145|NCT00000849|RANDOMIZED|||TREATMENT||||||||
33905146|NCT02188121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905147|NCT02412644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905148|NCT04302389|NA|SINGLE_GROUP||TREATMENT||NONE||This project includes a one-arm trial to evaluate WW's new lifestyle modification program.||||
33905149|NCT03622164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905150|NCT01084616|||CASE_CONTROL||PROSPECTIVE|||||||
33905151|NCT02433210|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|||||
33905152|NCT01043523|||COHORT||RETROSPECTIVE|||||||
33905153|NCT04291417|||CASE_CONTROL||PROSPECTIVE|||||||
33774987|NCT03829631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of each intervention, blinding will not be feasible for participants. However, outcomes assessor and adjudicators, as well as the statistician, will be blinded to the actual allocation. The investigators will develop two interpretations of our results based on a blinded review of the primary outcome data (intervention A vs. intervention B). One scenario will assume intervention A was brace and the other will assume intervention A was routine recommendations. Only after our team has agreed that there will be no further changes in the interpretation of the scenarios will the randomisation code be broken, and the correct interpretation used in manuscript preparation.|This is a prospective, superiority, 1:1 parallel randomised control trial with concealed allocation. Superiority will be based on a minimally clinically significant difference of our primary outcome measure (Numerical Pain Rating Scale, a 0-10 point scale).|f|f|f|t
33774988|NCT05398770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33774989|NCT05681442|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a prospective multicentre, randomized, open-label comparative continuous vs. intermittent pivotal βL antibiotic infusion strategies and combination vs. monotherapy trial conducted with a 2X2 factorial design||||
33774990|NCT04867278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774991|NCT05109494|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized by the University of Wisconsin clinical trials team to conventional versus hypofractionated RT. Randomization will be blocked to maintain balance over time, with blocks randomly assigned to sizes of 4 or 6. The randomization will take into account receipt of immunotherapy, to allow for a balance of patients in both arms.||||
33774992|NCT05691283|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33774993|NCT03899103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774994|NCT05431010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774995|NCT06064877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind, Placebo-Controlled||t|t|t|t
33905154|NCT00541437|||||PROSPECTIVE|||||||
33905155|NCT01011192|||COHORT||PROSPECTIVE|||||||
33905156|NCT05265845|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33905157|NCT03976739|||OTHER||CROSS_SECTIONAL|||||||
33905158|NCT00036205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987807|NCT06334991|NA|SINGLE_GROUP||TREATMENT||NONE||The study is open label, for Refractory/ Relapsed Non-Hodgkin Lymphoma. Up to 10 subjects will receive at least 1 dose of study drug. The initial 3 subjects will receive study drug in a staggered fashion, with a 7 day interval between each subject to evaluate any toxicities.||||
33987808|NCT04618341|||OTHER||RETROSPECTIVE|||||||
33987809|NCT01541891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987810|NCT00152685|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34081746|NCT00854997|||COHORT||PROSPECTIVE|||||||
34081747|NCT04285463|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685175|NCT04528901|||COHORT||PROSPECTIVE|||||||
33685176|NCT05860101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685177|NCT01925989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33685178|NCT05088239|||CASE_ONLY||RETROSPECTIVE|||||||
33685179|NCT03067233|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685180|NCT01445626|||COHORT||RETROSPECTIVE|||||||
33685181|NCT04456153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685182|NCT05911282|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33685183|NCT04941742|||COHORT||PROSPECTIVE|||||||
33685184|NCT01503112|||COHORT||PROSPECTIVE|||||||
33685185|NCT02208778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685186|NCT05898269|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33685187|NCT00213824|||CASE_CONTROL||PROSPECTIVE|||||||
33685188|NCT01606878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685189|NCT05178745|||COHORT||PROSPECTIVE|||||||
33774996|NCT05676489|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905159|NCT04328623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905160|NCT00565695|||CASE_CONTROL||RETROSPECTIVE|||||||
33905161|NCT03907735|||CASE_CONTROL||PROSPECTIVE|||||||
33905162|NCT05600764|||COHORT||PROSPECTIVE|||||||
33905163|NCT04215991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905164|NCT01127425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905165|NCT02690480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905166|NCT02890082|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905167|NCT04246671|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905168|NCT04539301|||COHORT||PROSPECTIVE|||||||
34081748|NCT02423226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081749|NCT05444790|||CASE_CONTROL||PROSPECTIVE|||||||
33685190|NCT06185270|||COHORT||PROSPECTIVE|||||||
33685191|NCT04671953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685192|NCT00465309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685193|NCT04291001|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Randomization scheme: block randomization with block size of 4~Blinding protocol: This study will not be blinded as a pilot. The feasibility of the study, including clinic space limitations and provider time, relies on the same healthcare provider for implant insertion and ultrasound in many patients. All statistical analyses will be blinded to the statistician."||||
33774997|NCT06249334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33774998|NCT06360354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33774999|NCT05907707|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33775000|NCT06737276|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The researchers were blinded concerning the randomisation sequence and the allocation of participants to the interventions.|This study is a two-stage simultaneous parallel (CG) and crossover (EG1 and EG2) randomised controlled trial.|t|f|t|t
33905169|NCT02711670|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33905170|NCT06392828|||COHORT||PROSPECTIVE|||||||
33905171|NCT05053139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905172|NCT01818817|||||PROSPECTIVE|||||||
33685194|NCT03493659|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are assigned to either a sitting or a standing tutorial, where their learning will be measured.||||
33685195|NCT01692795|||COHORT||RETROSPECTIVE|||||||
33905173|NCT03630640|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical study phase II||||
33987811|NCT04444505|||OTHER||PROSPECTIVE|||||||
33685196|NCT01804829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685197|NCT01845987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685198|NCT00908739|||CASE_CONTROL||PROSPECTIVE|||||||
33685199|NCT05346445|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study was a prospective randomized clinical trial made in Mexican women diagnosed with postmenopause from the climacteric clinic of the regional hospital 1ro de Octubre-Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado (ISSSTE). Eligible participants were randomly selected in each consult to receive citalopram 20 mg/d or fluoxetine 20 mg/d for six months. The evaluation of the MRS score was done at the first consult and three and six months after medication. The institutional ethical committee of the hospital approved the study on May 20th, 2021, with registration number CONBIOETICA-09-CEI-012-20170421 and the internal registration number 122.2021. All participants provided written informed consent."||||
33685200|NCT04647487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33775001|NCT06155279|NA|SINGLE_GROUP||TREATMENT||NONE||"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."||||
33775002|NCT03630562|NA|SINGLE_GROUP||OTHER||NONE||||||
33775003|NCT05683418|NA|SINGLE_GROUP||TREATMENT||NONE||"TOS-358 Single Agent Arm:~Part 1(multiple ascending doses, QD or BID): locally advanced, recurrent or metastatic select solid tumors with PIK3CA mutation per local assessment; Part 2 (RP2D determined in Part 1) Patients with locally advanced, recurrent or metastatic select solid tumors with PIK3CA mutation per local assessment will be enrolled protocol defined groups"||||
33775004|NCT03653676|||COHORT||CROSS_SECTIONAL|||||||
33775005|NCT06183892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775006|NCT05464719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775007|NCT04006717|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33905174|NCT05572567|||COHORT||RETROSPECTIVE|||||||
33905175|NCT01417780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905176|NCT05366907|||OTHER||PROSPECTIVE|||||||
33905177|NCT01568190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905178|NCT04514367|NA|SINGLE_GROUP||TREATMENT||NONE||ANX005 administered for up to 22 weeks||||
33905179|NCT04048967|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster randomization of 23 preschools to the intervention group (professional development) and 23 to the control group (standard of care).|f|f|f|t
33905180|NCT05232097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905181|NCT05346224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel-Controlled|t|t|t|t
33905182|NCT01259297|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33905183|NCT03794726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905184|NCT05949814|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33905185|NCT06051279|||CASE_CONTROL||RETROSPECTIVE|||||||
33905186|NCT00800033|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33905187|NCT05436938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905188|NCT00886132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905189|NCT01870063|||COHORT||PROSPECTIVE|||||||
33905190|NCT01279135|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking. This is a open-label study.|Patients enrolled are randomized to either conventional arm or tomotherapy arm for treatment after stratification according to type of surgery the patient underwent and the indication of chemotherapy along with radiation||||
33905191|NCT00262262|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33905192|NCT04268862|||COHORT||CROSS_SECTIONAL|||||||
33905193|NCT04770168|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study employs a stepped wedge research design, allowing for both groups to receive the same cognitive behavioural therapy curriculum but during different time periods. Half the classes will receive the curriculum during the first half of the academic year and the rest of the classes will receive the curriculum during the second half of the academic year.||||
33905194|NCT03619980|||COHORT||OTHER|||||||
33905195|NCT03481764|||CASE_CONTROL||RETROSPECTIVE|||||||
33987812|NCT00000541|RANDOMIZED|FACTORIAL||PREVENTION||||||||
33987813|NCT04935411|||COHORT||PROSPECTIVE|||||||
33987814|NCT05279560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987815|NCT04763746|||COHORT||PROSPECTIVE|||||||
33987816|NCT06559254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987817|NCT06400355|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patients will be randomly assigned into two equal comparable groups using computer- generated random numbers in opaque closed envelopes, each of which will include 30 patients. Randomization will be done by statistician and each group of the patient will revealed only when the included patient is transferred to preanesthetic room.|The aim of this study is to test, whether mannitol infusion in will affect recovery pattern?|t|f|t|f
33987818|NCT04852380|||OTHER||PROSPECTIVE|||||||
33987819|NCT05376319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775008|NCT00798070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775009|NCT06736587|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33775010|NCT06501365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and Interventionists cannot be masked to group assignment. The Principal Investigator will remain masked. While most outcomes are patient-reported, Outcomes Assessors will be trained to remind participants not to disclose their group status during assessments.||f|f|t|t
33775011|NCT06381492|||CASE_CONTROL||PROSPECTIVE|||||||
33775012|NCT01812343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775013|NCT06723470|||CASE_CONTROL||PROSPECTIVE|||||||
33775014|NCT06632496|||CASE_ONLY||PROSPECTIVE|||||||
33775015|NCT04522843|||COHORT||RETROSPECTIVE|||||||
33775016|NCT04623502|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33775017|NCT02654379|||COHORT||RETROSPECTIVE|||||||
33987820|NCT04142918|||OTHER||CROSS_SECTIONAL|||||||
33987821|NCT04033705|||COHORT||PROSPECTIVE|||||||
33905196|NCT00920465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987822|NCT05571189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34081750|NCT00163059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34081751|NCT00111761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081752|NCT04599231|NA|SINGLE_GROUP||SCREENING||NONE||Prospective observational study||||
34081753|NCT03504800|||CASE_CONTROL||PROSPECTIVE|||||||
34081754|NCT02337062|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081755|NCT00134134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685201|NCT00188708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685202|NCT02519855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33685203|NCT03956069|||FAMILY_BASED||PROSPECTIVE|||||||
33685204|NCT00130351|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33905197|NCT04805021|||CASE_CONTROL||PROSPECTIVE|||||||
33905198|NCT03360149|||COHORT||RETROSPECTIVE|||||||
33905199|NCT04885244|||COHORT||PROSPECTIVE|||||||
33905200|NCT03688646|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33905201|NCT05413499|NA|SINGLE_GROUP||OTHER||NONE||||||
33905202|NCT05566756|||COHORT||PROSPECTIVE|||||||
33905203|NCT00763204|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|f|t
33905204|NCT06497426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33905205|NCT02928393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905206|NCT00114205||||TREATMENT||||||||
33905207|NCT00945750|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905208|NCT04877548|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33905209|NCT01883882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905210|NCT05845164|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"Only the study staff will have access to the randomization information and study participants in each arm will not be informed which arm they are in. The sham group will receive 10 seconds of .5mA at the initiation of each of the three ramp-ups, after which the current will be turned off. This is to maintain a blind trial."|"30 participants will be recruited and randomly placed in either the treatment or the sham group. The randomization ratio is 1:1. Each participant has an equal chance of being assigned to each condition and each participant will be assigned to a condition independently of the other participants. The sample is small (15 each group), so in order to ensure random assignment, we will assign a unique number to every participant of the study's sample. Then, we will use a lottery method to randomly assign each number to the control or experimental group.~Both the treatment and sham groups will participate in the ACT activity and the stop signal task which is administered at baseline and the final visit, but only the treatment group will receive tDCS."|t|f|f|f
33905211|NCT02094586|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33905212|NCT02183025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33905213|NCT02288728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905214|NCT00824486|RANDOMIZED|SINGLE_GROUP||||||||||
33905215|NCT01809262|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33905216|NCT02729454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905217|NCT01401829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905218|NCT04509128|||COHORT||PROSPECTIVE|||||||
33905219|NCT00363012|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905220|NCT02547077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905221|NCT00204893|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33905222|NCT02372903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905223|NCT02309736|||CASE_ONLY||OTHER|||||||
33905224|NCT00109733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905225|NCT04083040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905226|NCT00619684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905227|NCT05413473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905228|NCT01270672|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33905229|NCT01209754|||COHORT||PROSPECTIVE|||||||
33905230|NCT03883048|||COHORT||RETROSPECTIVE|||||||
33905231|NCT02776280|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33905232|NCT03939130|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33987823|NCT05514951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987824|NCT00878878|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33987825|NCT06502262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33905233|NCT05192057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987826|NCT03565133|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants and investigators will be blinded for the contents of the gastric capsule. Both cannot be blinded for the oral sham feeding||t|f|t|f
33905234|NCT05814770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905235|NCT06258629|||CASE_CONTROL||PROSPECTIVE|||||||
33905236|NCT05091060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905237|NCT02787512|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33905238|NCT00995735|||COHORT||PROSPECTIVE|||||||
33987827|NCT05914454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987828|NCT03767361|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33987829|NCT03660020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33987830|NCT06041815|||COHORT||PROSPECTIVE|||||||
33987831|NCT04370639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987832|NCT06562426|||CASE_ONLY||CROSS_SECTIONAL|||||||
34081756|NCT03636399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081757|NCT00121004|||COHORT||PROSPECTIVE|||||||
34081758|NCT05656196|NON_RANDOMIZED|PARALLEL||OTHER||NONE||30 dry eye syndrome subjects, 60 Sjögren's syndrome' dry eye subjects, and 10 non DES SJS Healthy Controls, NHC)||||
34081759|NCT02402517|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34081760|NCT04976816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081761|NCT02172976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081762|NCT04522219|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Phase 3b, prospective, Case-Control study||||
33987833|NCT04457284|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a two-stage design, single arm, phase II study.||||
33987834|NCT00385346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081763|NCT03158207|RANDOMIZED|CROSSOVER||OTHER||NONE||The sequence of standard vs Warters mask will be determined by random number generator. Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication. After grading mask ventilation the study intervention is complete and the remainder of surgical and anesthesia care will be based on the clinical needs and decisions of the care team.||||
34081764|NCT02776566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34081765|NCT06435013|||CASE_CONTROL||RETROSPECTIVE|||||||
34081766|NCT02121197|||COHORT||RETROSPECTIVE|||||||
34081767|NCT01213381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987835|NCT00287963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685205|NCT01955798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685206|NCT00168987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685207|NCT03603366|||COHORT||CROSS_SECTIONAL|||||||
33685208|NCT04272879|||COHORT||PROSPECTIVE|||||||
33987836|NCT05782634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081768|NCT04593381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081769|NCT05938712|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be allocated to treatment with either dapagliflozin 10 mg PO daily alone for 12 weeks or subcutaneous once weekly semaglutide up-titrated as tolerated every 4 weeks starting with 0.25 mg, then to 0.5 mg to 1 mg alone for 12 weeks, followed by a subsequent treatment period of combination therapy with dapagliflozin 10 mg PO daily plus maximally tolerated dose semaglutide (up-titrated every 4 weeks from 0.25 mg to 0.5 mg to 1 mg) subcutaneous once weekly.||||
34081770|NCT05194514|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081771|NCT05283434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-Blind Clinical Trial|t|t|t|f
34081772|NCT01542762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685209|NCT04519177|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33685210|NCT05320497|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a before-after study. Transparent cap SpyGlass and standard SpyGlass were performed on the same patient successively.||||
33685211|NCT02793843|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33685212|NCT02020720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775018|NCT04023422|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||All patients will receive the clinical intervention (CI). In a 2-factor, 2-level factorial design, patients will be randomized to one of four groups by home visitor (HV) and/or physician feedback(CF) intervention: CI + HV, CI + CF, CI + HV + CF, CI. Well-suited for the investigation of the separate components of an intervention, a factorial design permits simple and powerful comparisons between the two factors (home visitor (HV) and clinician feedback CF), cell specific contrasts (the addition of home visitors among patients who have no physician feedback), and the interaction of both interventions. Each patient will be followed over time, so that the additional power of the factorial design will complement the confounder control inherent in randomization plus longitudinal analysis.|f|f|t|f
33775019|NCT06191133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775020|NCT06410391|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33775021|NCT04755140|||COHORT||PROSPECTIVE|||||||
33775022|NCT06738953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Selective Preventive Intervention Study|t|f|f|f
33775023|NCT01508299|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775024|NCT06720311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775025|NCT06401538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775026|NCT06459011|||OTHER||CROSS_SECTIONAL|||||||
33775027|NCT05620914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775028|NCT06036121|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775029|NCT01780168|||COHORT||PROSPECTIVE|||||||
33775030|NCT05753189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-masked treatment will be used to reduce potential of bias during data collection and the evaluation of clinical endpoints.|A Multi-Center, Double-Masked Phase 3 Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects|t|t|t|f
33775031|NCT05643287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775032|NCT05331729|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33775033|NCT06119295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775034|NCT06739993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized-controlled Trial|t|f|f|f
33775035|NCT06397313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775036|NCT05656027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multi-center, double-masked, randomized, active-controlled, safety and efficacy study|t|t|t|t
33775037|NCT06718803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775038|NCT05906303|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Patient will receive either a mixture of caffeine and sodium benzoate dissolved in 500 cc normal saline or normal saline alone. A randomization schedule held by the OB team to determine which arm the patient falls into. The product will be prepared by pharmacy and sent to the labor floor. The infusion will be started once the patient is determined to be 10 cm in cervical dilation without notice to the patient.|Single Blind, Randomized control trial|t|f|f|f
33775039|NCT06340503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987837|NCT04366791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987838|NCT02096991|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33987839|NCT04979377|||COHORT||CROSS_SECTIONAL|||||||
33987840|NCT03792477|RANDOMIZED|CROSSOVER||OTHER||NONE||This is an open-label, randomized, 2-treatment, 2-period, single dose (200 mg), cross-over study, 2-part design to evaluate the bioequivalence and tolerability of a reformulated presentation of testosterone cypionate relative to a currently marketed and approved formulation||||
33987841|NCT00089193|RANDOMIZED|||TREATMENT||NONE||||||
33987842|NCT02976662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33987843|NCT04552418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987844|NCT04826653|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33987845|NCT05925621|||COHORT||PROSPECTIVE|||||||
33987846|NCT02443961|NA|SINGLE_GROUP||OTHER||NONE||||||
33987847|NCT06122298|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33987848|NCT06394635|||COHORT||PROSPECTIVE|||||||
34081773|NCT05415293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905239|NCT04997837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905240|NCT06132685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905241|NCT06692270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905242|NCT05104151|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study is a randomized, single-blind, single center, parallel study.||||
33905243|NCT03412422|||CASE_ONLY||PROSPECTIVE|||||||
33905244|NCT02018640|||COHORT||PROSPECTIVE|||||||
33905245|NCT05732155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label study assesses the safety and preliminary effectiveness of MDMA-assisted therapy in participants diagnosed with PTSD. The study will be conducted in at least 30 participants. A flexible dose of MDMA HCl followed by a supplemental half dose unless tolerability issues emerge or a participant declines, is administered during the Treatment Period with manualized therapy in three open-label monthly Experimental Sessions (2 Experimental Individual Sessions, and one Experimental Group Session). This \~18-week Treatment Period is preceded by three Preparatory Sessions. Each Individual Experimental Session is followed by three Integrative Sessions of non-drug psychotherapy. The Group Experimental Session is preceded by 2 Preparatory Group Sessions and followed by 3 Group Integrative Sessions.||||
33905246|NCT01651182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905247|NCT02991820|RANDOMIZED|PARALLEL||OTHER||||||||
33905248|NCT05952167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33905249|NCT00300872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905250|NCT02942550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905251|NCT03888300|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive standard physiotherapy as prescribed by the physician||||
33905252|NCT04577859|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participant is blinded to which esophageal probe is used (Esophageal cooling probe, \[ensoETM\] versus esophageal temperature monitoring probe) during their AF ablation, which is performed under general anesthesia.~This study includes an optional endoscopy. The endoscopist who performs the upper GI (gastrointestinal) endoscopy camera after the ablation procedure, is also blinded to the randomization."|Multi-center, prospective double-blind 1:1 randomized clinical trial|t|t|f|t
33905253|NCT05573165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Computerized randomization,|Prospective randomized controlled pilot study|f|f|t|t
33905254|NCT03360981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"arm 1 , diabetics treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy..~arm 2, diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.~arm 3, non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy."|t|f|f|f
33905255|NCT00211770|||COHORT||PROSPECTIVE|||||||
33905256|NCT04626219|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33905257|NCT04631471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Placebo controlled trial|t|t|t|t
33987849|NCT00813215|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33987850|NCT00776048|||CASE_CONTROL||PROSPECTIVE|||||||
33987851|NCT00982943|||CASE_ONLY||RETROSPECTIVE|||||||
33987852|NCT04146987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Outcome evaluators will be masked (blinded) and not involved with the study. The statisticians who will conduct the analyzes will also be masked to the treatment status until the analyzes are completed. Due to the types of interventions, it will not be possible to mask the participants and providers of the intervention.|"Patients will undergo a clinical evaluation, plain radiography, and magnetic resonance imaging to confirm the diagnosis of rotator cuff injury. At this moment, the type of lesion will be evaluated, as well as its size, retraction and the degree of fatty infiltration of the muscular belly, according to the Goutallier classification. The lesions will be classified as small (\<1cm); moderate (1-3cm); large (3-5cm) or very large (\> 5cm). All patients will undergo examinations and preoperative clinical evaluation.~Patients will be consecutively allocated to one of two proposed treatment methods: open rotator cuff repair or arthroscopic rotator cuff repair."|t|t|t|t
34081774|NCT03294642|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34081775|NCT05944835|||COHORT||RETROSPECTIVE|||||||
34081776|NCT03019848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081777|NCT01441986|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081778|NCT00763217|||COHORT||PROSPECTIVE|||||||
34081779|NCT02941315|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34081780|NCT02079662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34081781|NCT04549181|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Dyads (n = 60; 120 participants) will be trained to use a 4-step problem-solving process to collaboratively manage HF-related problems over 12 weeks.||||
34081782|NCT04588974|||CASE_CONTROL||PROSPECTIVE|||||||
33905258|NCT05219721|NA|SINGLE_GROUP||TREATMENT||NONE||"This study sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 0.5×10\^6 CAR-T/Kg, 1.0×10\^6 CAR-T/Kg, 2.0×10\^6 CAR-T/Kg, and subjects will receive a single infusion of CAR-GPRC5D/ single dose. Each dose group level will include 3-6 subjects, and the total number of subjects depends on increased dose levels. The estimated number of enrollment at this stage will be 9-18 cases in total. This study is to observe the characteristics of dose-limiting toxicity (DLT), pharmacokinetics, pharmacodynamics, and immunogenicity of CAR-GPRC5D in different dose groups. And to preliminarily observe the efficacy in small samples of patients with R/R MM or Plasma cell leukemia and confirm the recommended phase II dose (RP2D)."||||
33905259|NCT02850575|||CASE_ONLY||PROSPECTIVE|||||||
33905260|NCT01818167|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33905261|NCT03242928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905262|NCT02207530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905263|NCT00371033|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33905264|NCT06440304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905265|NCT03864744|||COHORT||PROSPECTIVE|||||||
33905266|NCT04805567|||COHORT||PROSPECTIVE|||||||
33905267|NCT03195634|||COHORT||PROSPECTIVE|||||||
33905268|NCT01671085|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33905269|NCT02350894|||COHORT||PROSPECTIVE|||||||
33905270|NCT00359814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905271|NCT01904877|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33905272|NCT02098317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905273|NCT01848821|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||OASIS|t|f|f|f
33905274|NCT01651130|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905275|NCT02582749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905276|NCT06032403|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The investigators start by including 100 participants (control group) who are attending the clinical. The control group will be followed for one year. After the control group has been followed for one year the investigators include 100 participants in the intervention group.||||
33905277|NCT04764123|||COHORT||PROSPECTIVE|||||||
33905278|NCT02829086|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905279|NCT03261154|||CASE_ONLY||RETROSPECTIVE|||||||
33905280|NCT02564120|||COHORT||PROSPECTIVE|||||||
33905281|NCT00357812|||||PROSPECTIVE|||||||
33987853|NCT06561737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study was single-blind and the participants were blinded.|This study was a randomized, single-blind, parallel group-controlled trial.|t|f|f|f
33987854|NCT01751594|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33987855|NCT02742935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987856|NCT05499572|||OTHER||PROSPECTIVE|||||||
33987857|NCT02514122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987858|NCT04821908|||OTHER||PROSPECTIVE|||||||
33987859|NCT02252120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987860|NCT01499628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987861|NCT03579095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Between and within groups model|t|t|t|t
33987862|NCT03763318|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part B will be blinded to all study staff that has direct access to the subjects and the sponsor. The site's pharmacist or designee will be unblinded to prepare the study drug.|Part A is an open label 3+3 dose escalation Part B is blinded and randomized 2:1|t|t|t|t
33987863|NCT03521765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33987864|NCT00344110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081783|NCT03490617|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33905282|NCT02664285|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33905283|NCT02979873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905284|NCT02099799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistant who assesses outcomes is blinded to randomization group.||f|f|f|t
33905285|NCT03137394|||COHORT||PROSPECTIVE|||||||
33905286|NCT01847638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33987865|NCT01133353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987866|NCT00005877||||TREATMENT||||||||
33987867|NCT03492372|||CASE_ONLY||PROSPECTIVE|||||||
33987868|NCT06099340|RANDOMIZED|PARALLEL||TREATMENT||NONE|Prospective Randomized Open Blinded End-point|||||
33987869|NCT04589195|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33987870|NCT02118532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987871|NCT03204539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33987872|NCT03522675|NA|SINGLE_GROUP||OTHER||NONE||||||
33987873|NCT04891120|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The statistician will be masked.|||||
33987874|NCT04157179|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All arms will receive the same study conditions.||||
33987875|NCT02070822|||CASE_ONLY||PROSPECTIVE|||||||
33987876|NCT03247972|||CASE_ONLY||PROSPECTIVE|||||||
33987877|NCT04480086|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33987878|NCT00974740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987879|NCT04643197|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2\*2 factorial design Primary randomization: Barbed suture vs. Non-barbed suture in fascia closure Secondary randomization: subcutaneous drain insertion vs. non-insertion The effect of secondary randomization is one of secondary objectives.|t|f|f|f
33987880|NCT03976635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987881|NCT01668264|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33905287|NCT00739778|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33905288|NCT02375698|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33987882|NCT02527382|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33987883|NCT04239872|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34081784|NCT04015739|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients will be treated the same way in the PRR and PSR cohorts:~Durvalumab 1.12 g IV on Day 1 Q3W Bevacizumab 15 mg/kg Day 1 Q3W Olaparib 300 mg bid po, continuously~Patients will be treated upon disease progression, unacceptable toxicity or consent withdrawal."||||
34081785|NCT05866913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the participants will be masked.|Control group. Experimental group 1. Experimental group 2.|t|f|f|f
33987884|NCT04393818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants will be blinded, as both the intervention and the control group will receive an App with information about management of mental health problems targeted at healthcare providers. The statisticians and outcome assessors (in this case the psychologists who will undertake the pre and post intervention psychological evaluations) will also be blinded. Only the PI and a research assistance will be unblinded.||t|t|f|t
33987885|NCT04074655|NA|SINGLE_GROUP||TREATMENT||NONE||In this study we do not need to label participants as healthy or demented; we only use the MoCA range between 7 to 25 to enroll participants. Many healthy adults do have some memory impairments and have a MoCA score less than 25 but still consider themselves healthy. Thus, we do not label anyone in this study as healthy or demented.||||
33987886|NCT00118664|||COHORT||PROSPECTIVE|||||||
33987887|NCT01481649|||COHORT||PROSPECTIVE|||||||
33987888|NCT02314403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987889|NCT05404594|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33987890|NCT06337721|RANDOMIZED|PARALLEL||PREVENTION||NONE||Will conduct a randomized controlled trial of the SPEAR intervention vs. control group.||||
33987891|NCT03676686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987892|NCT05332496|||COHORT||OTHER|||||||
33987893|NCT00066001|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33987894|NCT02147418|||CASE_CONTROL||PROSPECTIVE|||||||
33987895|NCT01675765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987896|NCT03281135|RANDOMIZED|PARALLEL||SCREENING||NONE||A cluster randomized trial will be conducted in the Health and Demographic Surveillance Site (HDSS) of Addis Ababa University, School of Public Health which is located in Butajira district. The study population consists of women aged 30-49 who are found among the catchment population of ten Kebele's(Smallest Administrative Unit). Each Kebele will have 2 or more clusters based on the community health workers structure and size. A total of 22 clusters will then be randomized in to two arms. A total of 1760 women will be grouped in to 22 clusters, each comprises 80 women.||||
33987897|NCT04692350|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33987898|NCT00830700|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33987899|NCT02042781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905289|NCT00682825|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33987900|NCT02284087|||OTHER||PROSPECTIVE|||||||
33987901|NCT00404989|||COHORT||PROSPECTIVE|||||||
33987902|NCT04605861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Regardless of treatment allocations, each subject receive the same total volume of investigational drug or placebo. All drug automatic injectors and kits, study drugs or placebo are identical in appearance and labels to blind subjects and investigators. This can minimize the bias of investigators and subjects on treatment evaluation.|This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. The total study duration is 34\~36 weeks, including 2-week screening, 6\~8-week dosage titration, 24-week stable treatment and 2-week safety follow-up.|t|f|t|f
34081786|NCT02481050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081787|NCT01583881|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081788|NCT00584389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34081789|NCT02658266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081790|NCT03531866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905290|NCT04772365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
33987903|NCT02178787|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33987904|NCT00404105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987905|NCT05084625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987906|NCT01334333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987907|NCT01662284|||CASE_ONLY||PROSPECTIVE|||||||
33987908|NCT05195762|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, all participants will apply NFX-179 gel for 12 weeks||||
33987909|NCT02442934|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33987910|NCT03186976|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a parallel group, open label randomized clinical trial, with blinded endpoint evaluation (PROBE design)||||
33987911|NCT02960568|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33987912|NCT02519491|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34081791|NCT05267210|||CASE_CONTROL||PROSPECTIVE|||||||
34081792|NCT00706004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987913|NCT02544386|||COHORT||PROSPECTIVE|||||||
33775040|NCT06368856|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Single-center, randomized, open-label pharmacokinetic study of mupirocin in 40 healthy subjects with 2 randomization :~* first randomization - single dose part : 50mg or 500mg of mupirocin~* wash-out: one month~* second randomization - repeated doses part: 50mg mupirocin twice a day or 50 mg 3 times a day 500mg mupirocin twice a day or 500mg mupirocin 3 times a day"||||
33775041|NCT04134858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental and control group||||
33775042|NCT06740591|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33905291|NCT06693375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Part A: In total 12 healthy male participants, or healthy female participants of non-childbearing potential, aged 18 to 50 years (inclusive), with a body mass index (BMI) of 18.5 to 30.0 kg/m2 will be considered for trial participation.~Part B: Male participants, or female participants of non-childbearing potential, aged \>18 years with primary rectal cancer (clinical stage T1-T4) planned for surgery with suspected spread to lymph nodes will be considered for trial participation.~In Part A, the following dose levels will apply. Each participant will be in one condition. Each condition will be examined by MMUS at 7hours, 24hours, 48hours \&72hours post dose:~* Condition1: Dose 1: 28 mg Fe (7 mg Fe/mL, 4 ml in total )~* Condition2: Dose 2: 56 mg Fe (3,5 mg Fe/mL, 16 mL in total)~* Condition3: Dose 2: 56 mg Fe (14 mg Fe/mL, 4 mL in total)~* Condition4: Dose 3: 112 mg Fe (14 mg Fe/mL, 8 mL in total)~In Part B, the dose level to be applied will be decided based on the outcome of Part A."||||
33905292|NCT06421415|||COHORT||PROSPECTIVE|||||||
33987914|NCT03373162|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905293|NCT02809417|||COHORT||PROSPECTIVE|||||||
33905294|NCT00058578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987915|NCT01963728|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Subjects will be randomized to~1. Insulin glargine (Lantus) or~2. Insulin isophane (NPH)"|||||
33987916|NCT03409133|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33987917|NCT00207090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987918|NCT04236401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33987919|NCT06355622|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33987920|NCT00002062||||TREATMENT||NONE||||||
33987921|NCT00397787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987922|NCT04478786|||OTHER||RETROSPECTIVE|||||||
33905295|NCT05026450|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33905296|NCT06295731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase 2: open label; Phase 3: double-blind||t|f|t|f
33905297|NCT01489787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905298|NCT05399758|||COHORT||PROSPECTIVE|||||||
33905299|NCT05809011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905300|NCT05567068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded.||t|t|f|f
33905301|NCT06332053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905302|NCT02811484|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33905303|NCT00295399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905304|NCT04541745|||COHORT||PROSPECTIVE|||||||
33987923|NCT00834522|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33987924|NCT03235739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Effect of Naloxegol on reversing opioid-related side effects in patients recovering from elective primary hip surgery under spinal anesthesia who will be randomly assigned to oral Naloxegol or placebo for two postoperative days or until the date of discharge, whichever occurs earlier. The design will be a randomized, double-blind, placebo-controlled trial of oral Naloxegol in adults having elective primary hip or knee surgery under spinal anesthesia. The study will be performed at the Cleveland Clinic hospitals.|t|t|t|f
33987925|NCT03174080|||OTHER||PROSPECTIVE|||||||
33987926|NCT03801980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987927|NCT06225622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987928|NCT00764777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33987929|NCT03233386|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33987930|NCT03108911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33987931|NCT00271752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33987932|NCT06092658|||COHORT||RETROSPECTIVE|||||||
33987933|NCT05644587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987934|NCT04982094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Business advisor participants will be randomised to the treatment or control group using block randomisation. This process will be conducted by an external organisation who the participants are members of, so the trial investigators are blind to what study arm the participants are randomised to. The external organisation will provide potential participants with a computer generated unique ID, then order the IDs from highest to lowest, divide the list in half and allocate a block to the treatment or control arm. Allocation concealment will be achieved because the external organisation will not be able to predict the unique ID allocated to each participant before they are randomised to a group. The outcome assessor will be blinded to the participants study arm for the preliminary analysis. There are no subjective measures in this study. The participants will be blinded to their study group before they agree to participate to avoid self-selection bias.|Randomised Controlled Trial|f|f|t|t
33987935|NCT06406491|||COHORT||PROSPECTIVE|||||||
33987936|NCT05879653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987937|NCT03192722|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987938|NCT04231422|||COHORT||PROSPECTIVE|||||||
33987939|NCT00485667|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33987940|NCT01524718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775043|NCT05586763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS ) will be done in the pre- medication, post medication 60 mins post intervention medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10 in three different positions (supine, sitting and standing). The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper as well as the need of eply manuver as rescue. Principle investigator in each centers will be responsible to collect the papers for analysis by end of each weeks.|A 3-arm multi-center, randomized, triple-blind, controlled study comparing three treatments for acute vertigo Arm I : IM Metoclopramid ( 10mg) Arm II : IM Promethazine (25mg) Arm III : IM prochloraperazine( 12.5mg)|t|t|f|t
33775044|NCT06737770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775045|NCT06529770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987941|NCT01702935|||||PROSPECTIVE|||||||
33987942|NCT01457300|||CASE_CONTROL||PROSPECTIVE|||||||
33987943|NCT00226317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775046|NCT00009243|||COHORT||PROSPECTIVE|||||||
33987944|NCT03021018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987945|NCT05631587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A two-arm, assessor-blinded RCT|f|f|f|t
33987946|NCT03808805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Phase 3, randomized prospective study, double blind-double placebo|t|f|f|f
33987947|NCT02059863|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33987948|NCT01472848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987949|NCT00798954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987950|NCT04138368|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987951|NCT05700565|||COHORT||PROSPECTIVE|||||||
33987952|NCT04826718|||OTHER||OTHER|||||||
33775047|NCT03729349|||COHORT||PROSPECTIVE|||||||
33775048|NCT05939518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33775049|NCT06253858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775050|NCT06555822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775051|NCT04574024|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||High-fiber supplement-treatment and non-treatment||||
33775052|NCT05544058|||OTHER||RETROSPECTIVE|||||||
33775053|NCT06738329|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33775054|NCT00570258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775055|NCT05138796|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|The investigators, study coordinators, study subjects, and the sponsor will be blinded to treatment assignment.|Part 1: a randomized, double-blind, single ascending dose (SAD) with Cohort 1-4 administered on a full stomach and Cohort 5 administered after a period of fasting Part 2: a randomized, double-blind, multiple ascending dose (MAD) escalation with Cohort 6-8 administered on a full stomach.|t|f|t|t
33905305|NCT05347589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987953|NCT05898607|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33987954|NCT04134091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects meeting the enrollment criteria will be randomly assigned to one of the three treatment arms. The randomization will be carried out by central assignment. The study is a blinded study; therefore all the randomization codes will be centrally maintained and no data from the randomization will be available to Sponsor, contract research organization (CRO) operations team, medical monitors, monitors or any site staff.|"Randomized in 1:1:1 ratio to receive one of the following treatments:~* Treatment A: Oral LPCN 1144 Formulation A~* Treatment B: Oral LPCN 1144 Formulation B~* Treatment C: Oral matching placebo"|t|t|t|t
33987955|NCT04953676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33987956|NCT04512092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987957|NCT03393208|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33987958|NCT05901090|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33987959|NCT02329262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33987960|NCT01175018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905306|NCT05628233|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33987961|NCT01004341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987962|NCT01718886|||COHORT||PROSPECTIVE|||||||
33987963|NCT05693337|||COHORT||PROSPECTIVE|||||||
33987964|NCT06526338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987965|NCT05016323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, multicenter, placebo-controlled, parallel groups, Phase II clinical trial|t|t|t|t
34081793|NCT03122171|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33987966|NCT05878483|NA|SINGLE_GROUP||OTHER||NONE||"Anticipated number of participants distribution:~Phase A: 1,500 participants (max) Phase B1: 374 participants Phase B2/C1: 1,500 participants (max) Phase C2: 8,744 participants Phase 0: 1,500 participants (max)~The Phases are sequential, reflective of technology development:~Phase B1 should be completed before Phase B2/C1 can start. Phase B2 should be completed before Phase C2 can start."||||
33775056|NCT00708838|||CASE_ONLY||PROSPECTIVE|||||||
33987967|NCT01237054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775057|NCT03888170|||COHORT||PROSPECTIVE|||||||
33987968|NCT05596279|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33987969|NCT01185691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775058|NCT06576479|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The participant takes a random envelope without seeing, which the researcher receives and is automatically assigned the group in which he will remain until satisfactorily finished.|The intervention group receives specialized oral nutritional supplements plus nutritional counseling, the control group only receives nutrition counseling. Both groups receive laboratory studies (blood and urine) as well as body composition analysis with the use of electronic bioimpedance.|f|f|t|f
33987970|NCT02900209|||COHORT||PROSPECTIVE|||||||
33987971|NCT00371722|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33775059|NCT03678441|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33987972|NCT02322983|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33987973|NCT05707507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987974|NCT05803603|NA|SINGLE_GROUP||TREATMENT||NONE||8 individuals will be recruited and followed for 12 months following the intervention. The intervention includes providing a $500 monthly housing stipend for six months and twelve months of social work support to find permanent housing. Individuals will be asked to provide information thought interviews and clinical records.||||
33987975|NCT04473807|NA|SINGLE_GROUP||OTHER||NONE||||||
33987976|NCT00193804|||COHORT||PROSPECTIVE|||||||
33987977|NCT01013467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987978|NCT01020396|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33987979|NCT04383886|||COHORT||PROSPECTIVE|||||||
33987980|NCT02124135|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33987981|NCT02960594|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33987982|NCT04877210|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33987983|NCT02256722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33987984|NCT02124122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33987985|NCT03871361|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective 0pen Label Interventional Proof-of-Concept Study||||
33987986|NCT03946891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33987987|NCT02695394|||COHORT||PROSPECTIVE|||||||
33987988|NCT03851250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33987989|NCT05332327|||COHORT||PROSPECTIVE|||||||
33987990|NCT00073307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34081794|NCT04483414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Unblinded, single arm imaging study||||
34081795|NCT05041400|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775060|NCT05800366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775061|NCT04008030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775062|NCT06345729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775063|NCT05247502|||COHORT||PROSPECTIVE|||||||
33987991|NCT02778451|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34081796|NCT06514352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34081797|NCT04321928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Subjects will be blinded to knowledge of the details of differences between the interventions.~Everyone else (outcome assessors, caregivers and data analysts) will be blinded regarding the allocation."|This is a randomized controlled, adaptive, two-arm, parallel trial. The target patient population consists of adults age above 60 years without confirmed COVID-19 infection or current hospitalization. The sample size calculation suggests that 7576 subjects (3788/ each arm) are required. The allocation ratio is 1:1. Eligible participants in the generalized health education intervention arm will receive healthy lifestyle advice according to World Health Organization (WHO) principles. On the personalized education arm, participants will receive detailed informative intervention regarding lifestyle changes based on their current habits.|t|f|f|t
34081798|NCT00006152||||TREATMENT||||||||
34081799|NCT00269724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081800|NCT05588531|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE||The whole trial is conducted by dose escalation from low to high.|t|t|t|f
34081801|NCT00267436|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34081802|NCT02696824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33987992|NCT04107675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind trial. Due to the different appearance of the 3 tested strengths of IMP, a full blinding of the study was not possible. Only the randomized study patients were blinded to study treatment assignment.||t|f|f|f
33987993|NCT00859534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33987994|NCT05137184|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking Statistician|||||
33987995|NCT01278095|RANDOMIZED|PARALLEL||||NONE||||||
33987996|NCT05807321|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33987997|NCT03655535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|randomized, placebo-controlled, double-blind||t|t|t|f
33987998|NCT02467205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33987999|NCT03918174|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After enrollment, subjects were randomly divided into the research group and into the control group. Both groups went through the same intake evaluation. On completion of the intervention, both groups were reevaluated and filled out a satisfaction questionnaire.~The research group alone filled out the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST) questionnaire, to measure the level of satisfaction attribute to assistive technologies, e.g., the innovative dart splint they exercised with."||||
33988000|NCT02352259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988001|NCT02821247|||COHORT||PROSPECTIVE|||||||
33988002|NCT00275600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081803|NCT04534751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Given blood products in each randomized arm have different physical differences, it is not possible to blind the treating health care providers to group assignment.~Clinicians not involved in the acute resuscitation period (MHP activations usually last under 4 hours) and outcome assessors will remain blinded by using a generic product label in the patient chart and/or the electronic product name (i.e., FiiRST-2 MHP pack 1 and pack 2, rather than specifying type of product used). The first pack will be sealed, and the treating health care providers will be instructed to refrain from opening the first pack until the decision is made to transfuse clotting factor replacement."|Prospective, multi-center, randomized, parallel-control, superiority study comparing administration of clotting factor concentrates with a standard massive hemorrhage protocol in severely bleeding trauma patients.|t|f|t|t
34081804|NCT06227650|||COHORT||RETROSPECTIVE|||||||
33775064|NCT01196130|||CASE_ONLY||PROSPECTIVE|||||||
34081805|NCT00371735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775065|NCT06688578|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Masked individuals will not know if sham or stim;~1. Participants will be masked.~2. The Post-doc/Research Coordinator running the study will be masked."|For each test participants will be assessed during stimulation with imperceptible random levels of electrical stimulation as well as during sham stimulation.|t|f|t|f
33775066|NCT06737874|||COHORT||PROSPECTIVE|||||||
33775067|NCT04818632|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775068|NCT06737510|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|N/A No masking|A two-arm parallel randomized controlled trial will be conducted to compare the effectiveness of a phone-based household emergency preparedness intervention with a mailed informational brochure on household emergency preparedness amongst a sample of World Trade Center Health Registry enrollees residing within New York City.||||
33775069|NCT01307280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905307|NCT00301067|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"3+3 dose escalation design study. (3) patients per dose stratum will be entered in the following cohorts:~Cohort 1 - Temozolomide and Calcitriol 0.2mcg/kg days 1 + 15~Cohort 2 - Temozolomide and Calcitriol 0.3 mcg/kg days 1 + 15~Cohort 3 - Temozolomide and Calcitriol 0.5 mcg/kg days 1 + 15~Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every 28 day cycle in each cohort.~If 1 patient experiences dose limiting toxicity (DLT) at any dose, that cohort will be expanded to 6 patients. If 2 patients experience DLT in that cohort, further dose escalation will cease and the cohort immediately preceding that cohort will be considered the maximum tolerated dose (MTD). Alternatively, if no more patients experience DLT, then dose will be escalated to the next cohort."||||
33905308|NCT00764972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905309|NCT00614003|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33905310|NCT03048240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905311|NCT00397280|||OTHER||CROSS_SECTIONAL|||||||
33905312|NCT01266707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905313|NCT02806778|||OTHER||PROSPECTIVE|||||||
33905314|NCT01868373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905315|NCT03465800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33905316|NCT04422756|||COHORT||PROSPECTIVE|||||||
33905317|NCT04241237|||COHORT||PROSPECTIVE|||||||
33905318|NCT00172744|||||PROSPECTIVE|||||||
33905319|NCT01856491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905320|NCT05791318|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||Randomized, triple blind, placebo controlled|t|t|t|t
33905321|NCT06521008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single blinded randomized controlled trial|t|f|f|f
33905322|NCT00269191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905323|NCT03114241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligible patients will be randomized 1:1 to one of the two groups: conventional care group or intervention group. No minimization procedures are used.||||
33905324|NCT03732768|NA|SINGLE_GROUP||PREVENTION||NONE||3+3 dose escalation study followed by an expansion cohort.||||
33905325|NCT02707705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33905326|NCT00667758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905327|NCT01893723|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33905328|NCT01037374|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33988003|NCT04433611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988004|NCT04810338|||COHORT||RETROSPECTIVE|||||||
33988005|NCT04849650|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|All parties will have knowledge of the interventions assigned to each subject.|"One group of subjects with renal impairment will receive 10mg IV Amisulpride followed 24 hours later by a 10mg oral dose.~One group of matched healthy subjects will receive 10mg IV Amisulpride followed 24 hours later by a 10mg oral dose."||||
33988006|NCT01116362|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988007|NCT05345665|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33988008|NCT04263649|||CASE_ONLY||PROSPECTIVE|||||||
33988009|NCT00054301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988010|NCT04163354|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinding is not possible as pink glass ionomer sealants will be placed on the primary molars of one of the groups.|"A parallel design model with 2 treatment arms:~1. NaF varnish: Application of a 5% NaF varnish (Duraphat, Colgate-Palmolive Ltd, Waltrop, Germany) on the occlusal surfaces of primary second molars and all other teeth, every 3 months during the study period;~2. GI sealant: Glass ionomer sealant (GC Fuji VII® (pink)) on all primary second molars included in the studies, with no further repair/replacement of the sealant"||||
33988011|NCT00076817|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33988012|NCT04405765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, 2-arm parallel assignment, randomized clinical trial. Stravix will be applied at initial visit with NPWT and will only be reapplied after 4 weeks if wound is not ready for grafting unless debridement is indicated.||||
33988013|NCT02468284|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988014|NCT00772161|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33988015|NCT01900691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081806|NCT03398096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081807|NCT01802385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081808|NCT04021966|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34081809|NCT05556993|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34081810|NCT03864081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081811|NCT03821129|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34081812|NCT01042340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081813|NCT05146778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be not aware of which type of anesthesia would be applied during operation.|"1. Control arm: Conventional Anesthesia with opioid~2. Interventional arm: Opiod-free Anesthesia with dexmedetomidine and lidocaine"|t|f|f|f
34081814|NCT02127658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905329|NCT03661541|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~x Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months x Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months x Group C: 12 subjects with zero outbreaks in the past 12 months Subjects in group A will receive 2% SADBE dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."||||
33905330|NCT04318743|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33905331|NCT03705104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905332|NCT02815397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905333|NCT01861340|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905334|NCT04650321|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm clinical trial.||||
33905335|NCT03851393|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905336|NCT01220752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905337|NCT00779727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905338|NCT05870501|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||A double-blind active-placebo crossover design will be used to study a single group of people with TRD to assess the effects of ketamine on brain networks activity versus an active placebo (midazolam). Participants will be randomised to receive three separate IV infusions of ketamine (0.5mg/kg) followed by three separate IV infusions of midazolam (0.045mg/kg), or three separate infusions of midazolam followed by three separate infusions of ketamine.|t|t|t|t
33905339|NCT05521997|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will occur on a 5:1 basis to experimental arm and control arm. The first 5 participants randomized to the experimental arm will be considered the safety lead-in.||||
33905340|NCT05339464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905341|NCT03298854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905342|NCT04875819|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33988016|NCT00630149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988017|NCT05439447|||COHORT||PROSPECTIVE|||||||
33988018|NCT01702987|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33988019|NCT04518059|||COHORT||PROSPECTIVE|||||||
33988020|NCT04416451|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, phase II study.||||
33988021|NCT05063903|||CASE_CONTROL||PROSPECTIVE|||||||
33988022|NCT00439634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988023|NCT04150627|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33988024|NCT01473953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988025|NCT06563011|NA|SINGLE_GROUP||SCREENING||NONE||||||
33988026|NCT04658745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081815|NCT00453375|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34081816|NCT00614510|||COHORT|||||||||
34081817|NCT05577416|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 0 'window of opportunity'/perioperative (Part A) followed by Phase 2 adjuvant treatment||||
34081818|NCT02842528|NON_RANDOMIZED|PARALLEL||||NONE||||||
33905343|NCT03988777|||COHORT||OTHER|||||||
33905344|NCT03299517|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33905345|NCT00390780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081819|NCT01166919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905346|NCT00138125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905347|NCT01394029|||COHORT||RETROSPECTIVE|||||||
34081820|NCT05333211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081821|NCT02118285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081822|NCT00368108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081823|NCT00506103|||DEFINED_POPULATION||PROSPECTIVE|||||||
34081824|NCT02376686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905348|NCT03983876|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, 2-arm parallel study of AVT02 (Administered via a PFS either manually via an autoinjector, in healthy adult subjects. The subjects in both arms will receive the same dose of AVT02, but in two different delivery modes.||||
33905349|NCT00370786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905350|NCT04005443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"In this study, two 68Ga-NODAGA-RGD PET scans will be performed for each patient included :~* The first PET will be carried out within a maximum of one month following the assessment initial ophthalmologic including OCT and measurement of visual acuity (M0);~* The second PET scan will be performed at the same time as the ophthalmic assessment including OCT and measurement of visual acuity (at M4), before the 5th intraocular injection antiangiogenic."||||
33905351|NCT04016883|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|double-blind masking|The study is a randomized controlled trial of parallel type (2 arms, with a ratio of 1: 1, and with a block size of 5), which consists of the following phases where necessary changes in the methods are described after to start the trial:|f|f|t|f
33905352|NCT03715569|||COHORT||PROSPECTIVE|||||||
33905353|NCT03351322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905354|NCT04996849|||COHORT||PROSPECTIVE|||||||
33905355|NCT02229968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905356|NCT05108324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This will be a randomized controlled trial - parallel group with the patients. It is a superiority trial.~study group are 10 patients receiving 2 zygomatic implants with 2 conventional implant in anterior region, while the control group are another 10 patients receiving 4 conventional implant 2 in anterior region and 2 in posterior region with immediate loading."||||
33905357|NCT01509586|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905358|NCT04973111|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33905359|NCT05515549|||CASE_CONTROL||PROSPECTIVE|||||||
33905360|NCT01158534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905361|NCT02362711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905362|NCT00177268|||OTHER||PROSPECTIVE|||||||
33905363|NCT03092492|||COHORT||PROSPECTIVE|||||||
33905364|NCT05378659|||COHORT||PROSPECTIVE|||||||
33905365|NCT00840437|||COHORT||PROSPECTIVE|||||||
33905366|NCT02305251|||OTHER||PROSPECTIVE|||||||
33905367|NCT01492114|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33905368|NCT06691217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a prospective, randomized, double-blind clinical trial of individuals with established coronary heart disease.|t|t|t|t
33905369|NCT00416637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081825|NCT02114021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34081826|NCT01963702|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905370|NCT06284928|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33905371|NCT01108809|||COHORT||PROSPECTIVE|||||||
33905372|NCT00854763|||COHORT||PROSPECTIVE|||||||
33905373|NCT04205903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905374|NCT03212547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants: The families of the MLP infants will remain blind to the group they belong to. Families will receive feedback on their infant's ADBB scores only after the final assessment (12 months).~Care providers: neonatologists who care for participants during the trial are aware if the participants enter to the experimental or control group.~Investigator: the principal investigator (JB) is also an external evaluator. He is an ADBB- trained psychologist who doesn't participate in the follow-up of any of the participants. He is blind to the ADBB scores of the ADB- trained neonatologists.~Outcome assessment: Regarding to the ADBB assessment, once the ADBB score is assigned, this data is collected by a study coordinator, also blind to the group category.~Data collection assessors: They are not trained in the ADBB scale, and don't have contact with the participants or their families."||t|f|t|t
33905375|NCT01869894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33905376|NCT03321240|||COHORT||PROSPECTIVE|||||||
33905377|NCT00717418|||COHORT||PROSPECTIVE|||||||
33905378|NCT05652374|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cross-over randomized controlled trial. Study is set-up as non-inferiority, parallel group trial, with a 1:1 randomization.||||
33905379|NCT03634605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33905380|NCT06346340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905381|NCT03567291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905382|NCT06503653|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33905383|NCT06446739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905384|NCT01759784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905385|NCT04581681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905386|NCT00575822|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34081827|NCT03918265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081828|NCT05813756|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34081829|NCT05469646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081830|NCT05540704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081831|NCT01041222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081832|NCT01339416|||COHORT||RETROSPECTIVE|||||||
33905387|NCT03691623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905388|NCT05185882|||CASE_ONLY||PROSPECTIVE|||||||
33905389|NCT02467907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905390|NCT00123526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905391|NCT01748396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905392|NCT02083445|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905393|NCT03742960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905394|NCT01005394|||CASE_ONLY||PROSPECTIVE|||||||
33905395|NCT06513364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905396|NCT05272059|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33905397|NCT03406949|NA|SINGLE_GROUP||TREATMENT||NONE||3+3+3 dose escalation design followed by Cohort Expansion Phase.||||
33905398|NCT03286166|||CASE_ONLY||RETROSPECTIVE|||||||
33905399|NCT06512363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905400|NCT04803786|||COHORT||PROSPECTIVE|||||||
33905401|NCT02507947|||CASE_ONLY||PROSPECTIVE|||||||
33905402|NCT00041236||||TREATMENT||NONE||||||
33988027|NCT02286739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33988028|NCT06252350|||COHORT||PROSPECTIVE|||||||
33988029|NCT00270322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33988030|NCT03928691|||COHORT||PROSPECTIVE|||||||
33988031|NCT06358053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988032|NCT00822822|||||PROSPECTIVE|||||||
33988033|NCT01746485|NA|SINGLE_GROUP||||NONE||||||
33988034|NCT00658762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988035|NCT01458561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988036|NCT04574102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|subjects will be masked to treatment|"This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design.~Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule V with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule)."|t|f|f|f
33988037|NCT01704677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988038|NCT05293145|NA|SINGLE_GROUP||TREATMENT||NONE||Primary Services Participants receive 14 hours of Survival Skills for Healthy Families curricula delivered over a series of 7 weekly workshops, or 16 hours of Survival Skills for Healthy Families curricula delivered over one weekend followed by 2 hours of a Reflections Workshop delivered two weeks later. Participants also receive support services delivered by Family Coaches and Career Coaches as needed.||||
33988039|NCT01224535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988040|NCT01508962|||COHORT||PROSPECTIVE|||||||
33988041|NCT04599439|||COHORT||PROSPECTIVE|||||||
33988042|NCT00163657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988043|NCT03753230|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33905403|NCT00449748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905404|NCT00876174|||COHORT||PROSPECTIVE|||||||
33905405|NCT05923905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905406|NCT00331786|RANDOMIZED|||PREVENTION||DOUBLE||||||
33905407|NCT02960958|||COHORT||CROSS_SECTIONAL|||||||
33905408|NCT03032068|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33905409|NCT00192894|||COHORT||PROSPECTIVE|||||||
34081833|NCT04119648|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open pilot trial of one treatment without control or comparison group.||||
33905410|NCT05482269|||COHORT||PROSPECTIVE|||||||
33905411|NCT03061123|||OTHER||CROSS_SECTIONAL|||||||
33905412|NCT04343885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905413|NCT01744847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905414|NCT04910971|||CASE_CROSSOVER||PROSPECTIVE|||||||
33905415|NCT01809561|||CASE_CONTROL||PROSPECTIVE|||||||
33905416|NCT05493956|RANDOMIZED|PARALLEL||TREATMENT||NONE||Consolidation chemoradiation||||
33905417|NCT00491114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905418|NCT01563627|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33905419|NCT04488692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905420|NCT03767205|NA|SINGLE_GROUP||OTHER||NONE||||||
33905421|NCT05979129|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33905422|NCT01034098|||COHORT||CROSS_SECTIONAL|||||||
33988044|NCT05648721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685213|NCT04653896|NA|SINGLE_GROUP||TREATMENT||NONE||We will conduct a functional mobility comparison between Keeogo and knee braces among participants with knee OA. A within-subject design is selected. We plan to have 2 or 3 1-hour sessions per week (up to 12 sessions) for tuning the Keeogo and letting the participants be familiar with the device. After that, participants will be evaluated through a series of mobility tests using their prescribed knee braces and Keeogo configured with tuned parameters, respectively. If participants can complete the mobility tests without their knee braces we will also collect these data. The functional mobility tests will include the 6 Minute Walk Test, Timed Up and Go, 13-step Stair Test, Pick up Penny from Floor Test, and Short Physical Performance Battery. The investigators expect to use two separate sessions to finish the evaluations. The order of using the Keeogo and their knee braces will be randomized. There will be a 10-min break between each test. Participants could request a longer break time.||||
33685214|NCT02115126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685215|NCT01908881|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33685216|NCT06104839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685217|NCT01226121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685218|NCT02599051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685219|NCT04896645|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685220|NCT05290376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The selected patients were stratified according to age, gender, years of mandibular edentulism, number of old non-satisfactory dentures (baseline criteria, table 1). Patients were assigned to one of 2 groups using a balanced randomization procedure to ensure comparability between groups regarding baseline characters;|Patients were randomly assigned into two equal groups. Group I (control): patients who would be delivered mandibular implant overdenture retained by two RTX locator attachments using conventional loading protocol. Group II (study): patients who would be delivered mandibular overdenture retained by two RTx locator attachments using early loading protocol.|t|f|f|t
33685221|NCT05023824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685222|NCT01166243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685223|NCT05384951|NA|SINGLE_GROUP||OTHER||NONE||Single group repeated measures design with 12 weeks of no intervention (control period) followed by 12 weeks of intervention.||||
33685224|NCT03167801|||CASE_CONTROL||PROSPECTIVE|||||||
33685225|NCT02420600|||COHORT||PROSPECTIVE|||||||
33685226|NCT05002920|||COHORT||RETROSPECTIVE|||||||
33685227|NCT05512468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685228|NCT05060939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33685229|NCT00541190|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33685230|NCT00445809|||COHORT||PROSPECTIVE|||||||
33685231|NCT01795066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685232|NCT03808987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants will be blind to the arm the participant has been randomly assigned to and to study hypotheses.|Child-Parent Psychotherapy|f|f|f|t
33775070|NCT05313893|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects received 2 doses of an inactivated quadrivalent influenza vaccine,4 weeks apart. Blood samples were obtained from children at 3 time points-before receipt of dose 1, 4 weeks after receipt of dose 1 and before dose 2, and4 weeks after dose 2.||||
33775071|NCT04283045|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775072|NCT06556823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775073|NCT02321085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775074|NCT05348395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775075|NCT06730360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905423|NCT05499442|||COHORT||PROSPECTIVE|||||||
33905424|NCT03912571|||COHORT||PROSPECTIVE|||||||
33905425|NCT01178684|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33905426|NCT01798706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905427|NCT04964830|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33905428|NCT02717689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905429|NCT01264965|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33988045|NCT05665686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34081834|NCT03915834|||COHORT||PROSPECTIVE|||||||
34081835|NCT01723072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685233|NCT05950243|||COHORT||PROSPECTIVE|||||||
33685234|NCT03361644|RANDOMIZED|PARALLEL||TREATMENT||NONE||2x3 repeated-measures randomized control trial.||||
33685235|NCT03413176|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685236|NCT05304091|||COHORT||PROSPECTIVE|||||||
33775076|NCT04100564|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stepped-wedge||||
33775077|NCT01629017|||CASE_CONTROL||PROSPECTIVE|||||||
33775078|NCT06738719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775079|NCT06431347|||COHORT||PROSPECTIVE|||||||
33775080|NCT06524804|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775081|NCT01222741|||FAMILY_BASED||PROSPECTIVE|||||||
33905430|NCT03254017|NA|SINGLE_GROUP||TREATMENT||NONE||all subjects will receive bilateral surgical implantation of DBS system.||||
33905431|NCT05148208|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33905432|NCT03277547|||COHORT||PROSPECTIVE|||||||
33905433|NCT01842568|||COHORT||PROSPECTIVE|||||||
33905434|NCT01033695|||||PROSPECTIVE|||||||
33905435|NCT03988816|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Placebo-controlled||t|t|t|t
33905436|NCT01289392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33905437|NCT05699616|||COHORT||RETROSPECTIVE|||||||
33905438|NCT03196297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905439|NCT02485366|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905440|NCT02057419|||OTHER||PROSPECTIVE|||||||
33988046|NCT00003484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988047|NCT02997150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988048|NCT01833182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081836|NCT01065753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081837|NCT04440501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081838|NCT00004700|RANDOMIZED|||TREATMENT||DOUBLE||||||
34081839|NCT01735604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081840|NCT00171249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685237|NCT04489901|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study was a randomized controlled clinical trial. To avoid bias, an impartial midwife who was working in the outpatient clinic on the day the data were collected and was not among the researchers asked each participant to select one of two closed envelopes that included the letters A (experimental group) or B (control group). The pregnant women were assigned to the experimental and control groups depending on the letter in the envelope they chose. Then, the researcher registered the participants in the experimental and control groups on a list. The obstetrician and pregnant women were informed about the procedure, but the obstetrician did not know which procedure would be applied to which pregnant woman. The pregnant women did not know why olive oil was being used. The participating women signed an informed consent form knowing that they could withdraw from the study at any time|Randomized controlled clinical trial|t|t|f|f
33685238|NCT03976180|RANDOMIZED|PARALLEL||OTHER||NONE||"This is a comparative randomized controlled superiority open-label multi-arm multi-stage (MAMS) trial. The study will use a multi-arm multi-stage (MAMS) trial design with three stages and four arms (one control arm and three intervention arms).~* Pilot stage: a formal safety/feasibility testing. Research arms will only continue to recruitment in the next stage if they have been shown to be both safe and feasible, although patient data from all patients and all stages will be included in the final analyses.~* Activity stage: an interim comparison of activity using the rate of VOC resolution without complication at day-5 as primary endpoint. At the end of this stage, an interim analysis will be used in order to select the most promising experimental treatment and compare it to control in the subsequent stage (pick the winner strategy).~* Efficacy stage: final comparison with secondary ACS at day-14 as the primary endpoint."||||
33685239|NCT04306679|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33775082|NCT05546411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775083|NCT02631603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775084|NCT06737744|NA|SINGLE_GROUP||OTHER||NONE||The recruitment of this study was conducted in accordance with a pre-established plan, which entailed the selection of a total of 50 participants who met the established inclusion and exclusion criteria. These participants were divided into groups of 7-10 individuals. Each participant was required to attend a minimum of 2 and a maximum of 4 different sessions. In each session, the participants were exposed to games with varying levels of difficulty and content, which were designed to develop the specified competencies and skills outlined in the CASEL model at different levels. The majority of these games were group games that involved low or moderate physical activity.||||
33775085|NCT04982653|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33775086|NCT01565018|RANDOMIZED|CROSSOVER||||NONE||||||
33775087|NCT04281498|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm open-label Study of Combined Ruxolitinib and Enasidenib in Patients with Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis with an IDH2 Mutation, Simons minimax design.||||
33988049|NCT02152163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Staff, including the principal investigator, study coordinator, and trauma nurses and the patients were blinded as to the treatment they received. In order to maintain the double-blind protocol, all IV bags had identical appearance and label.|, randomized, double-blind, parallel-group, placebo-controlled study. Eligible patients who signed the informed consent were randomized to either IV Ibuprofen (Caldolor®) or Placebo via a computer-generated randomization list.|t|t|t|f
33988050|NCT05051462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988051|NCT01467791|||CASE_ONLY||PROSPECTIVE|||||||
33775088|NCT06719661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775089|NCT06330961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33775090|NCT06639958|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905441|NCT05890638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905442|NCT00020930||||TREATMENT||||||||
33905443|NCT01300871|||CASE_ONLY||CROSS_SECTIONAL|||||||
33905444|NCT05924100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905445|NCT06004531|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33905446|NCT01555463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905447|NCT04149327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905448|NCT02457351|NA|SINGLE_GROUP||||NONE||||||
33905449|NCT06400602|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33988052|NCT01887548|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33988053|NCT01357863|||COHORT||PROSPECTIVE|||||||
33988054|NCT01945463|||COHORT||CROSS_SECTIONAL|||||||
33988055|NCT01863030|||CASE_ONLY||PROSPECTIVE|||||||
33988056|NCT05598476|||CASE_ONLY||PROSPECTIVE|||||||
33988057|NCT02609256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988058|NCT03112863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind randomized study comparing the effect of bakuchiol and retinoid|t|f|t|t
33988059|NCT03598101|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33905450|NCT01685294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905451|NCT00814840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905452|NCT06671171|||CASE_ONLY||PROSPECTIVE|||||||
33905453|NCT02402192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905454|NCT03017586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905455|NCT06534944|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pilot open-label clinical trial||||
33905456|NCT03067766|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905457|NCT02629497|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33905458|NCT03852888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905459|NCT03553329|||CASE_ONLY||RETROSPECTIVE|||||||
33905460|NCT01819922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33905461|NCT00938327|||COHORT||PROSPECTIVE|||||||
33905462|NCT05379322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905463|NCT00141635|||DEFINED_POPULATION||PROSPECTIVE|||||||
33905464|NCT03542240|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33905465|NCT03408873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905466|NCT06231940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The experimental group undergoes twice-weekly CDT sessions, including manual lymph drainage, pneumatic compression, and bandaging, while the control group receives no treatment.|t|t|t|f
33905467|NCT01559207|||COHORT||PROSPECTIVE|||||||
33905468|NCT04866420|||COHORT||CROSS_SECTIONAL|||||||
33775091|NCT06561555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685240|NCT01818947|||CASE_ONLY||RETROSPECTIVE|||||||
33775092|NCT02928497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775093|NCT00271622|||OTHER||CROSS_SECTIONAL|||||||
33685241|NCT04648969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685242|NCT01740505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685243|NCT04490330|||CASE_ONLY||PROSPECTIVE|||||||
33685244|NCT00210938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685245|NCT01923168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775094|NCT06727526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33775095|NCT06735924|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775096|NCT06195332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775097|NCT04028843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assigned stratified by maternal BMI and site|f|f|t|t
33775098|NCT03441074|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775099|NCT00001846|||OTHER||PROSPECTIVE|||||||
33775100|NCT05257642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775101|NCT06498128|||COHORT||OTHER|||||||
33775102|NCT06739369|||CASE_ONLY||CROSS_SECTIONAL|||||||
33775103|NCT06735859|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is a randomized, crossover clinical trial with a washout period and follow-up.||||
33775104|NCT06720610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775105|NCT01650675|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33775106|NCT03482674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775107|NCT05345912|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind Study|A randomized, double-blind, placebo-controlled, dose-escalation, crossover study|t|t|t|t
33775108|NCT02849574|||COHORT||PROSPECTIVE|||||||
33775109|NCT06393998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775110|NCT06739473|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33775111|NCT05180552|RANDOMIZED|PARALLEL||PREVENTION||NONE||This randomized control trial will use a quantitative, comparative approach using an experimental and control study group design to measure and compare the outcomes after the subjects are placed in either the HEALiX or wrist restraints.||||
33775112|NCT00033956|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33775113|NCT05309928|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study design is a prospective phase I pharmacokinetic study focused on dosing of 500 mg oral amoxicillin administration in pregnant women in the 2nd and 3rd trimester.||||
33775114|NCT05625425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|After recruitment, participants are randomly assigned to treatment arms. Participants and experimenters with whom participants interact during the experiments are blind to the purpose of the randomly-assigned arm. First-level analysis performed blind to participant's treatment arm.||t|f|f|t
33775115|NCT05088694|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905469|NCT02494349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905470|NCT01912872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905471|NCT05106660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905472|NCT06503302|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33905473|NCT02114632|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33905474|NCT02290639|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33905475|NCT00633828|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33905476|NCT01429246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905477|NCT04983940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988060|NCT00291681|||DEFINED_POPULATION||OTHER|||||||
33988061|NCT05416554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34081841|NCT02797834|||CASE_ONLY||PROSPECTIVE|||||||
34081842|NCT02607631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685246|NCT01927939|||CASE_ONLY||PROSPECTIVE|||||||
33685247|NCT00925743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685248|NCT00899080|||OTHER||RETROSPECTIVE|||||||
33685249|NCT01920646|RANDOMIZED|||||||||||
33685250|NCT03721770|||COHORT||PROSPECTIVE|||||||
33685251|NCT03398278|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33685252|NCT03403842|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33685253|NCT01449695|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685254|NCT04450810|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33685255|NCT02879149|||COHORT||PROSPECTIVE|||||||
33775116|NCT06741033|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33775117|NCT05056376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775118|NCT03092674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775119|NCT04832412|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775120|NCT02531880|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775121|NCT00669747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775122|NCT02343575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775123|NCT02742506|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33775124|NCT04963764|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Pilot Feasibility Study|t|t|t|t
33775125|NCT05834582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775126|NCT03562169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775127|NCT00747383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33775128|NCT05297903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905478|NCT00775359|RANDOMIZED|CROSSOVER||||NONE||||||
33905479|NCT02508168|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905480|NCT03483688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905481|NCT03827577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905482|NCT05392192|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33905483|NCT03245671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33905484|NCT03288779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905485|NCT05423158|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The investigators propose a randomized clinical trial evaluating the effects of HBCR alone (usual care) versus HBCR + d-Coaching. d-Coaching includes a private social media group, optimized Annie text messaging, VA Video Connect, and a wearable device.||||
33905486|NCT01207739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775129|NCT06737991|NA|SINGLE_GROUP||TREATMENT||NONE||On the group of children with chest burn, thoracic expansion exercises will be applied and VO2 Max will be monitored.||||
33775130|NCT05992909|||COHORT||PROSPECTIVE|||||||
33775131|NCT05175105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775132|NCT06633913|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775133|NCT06736808|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905487|NCT03026686|||COHORT||RETROSPECTIVE|||||||
33905488|NCT04993027|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33905489|NCT05667961|||CASE_CONTROL||RETROSPECTIVE|||||||
33905490|NCT01312350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905491|NCT05780853|||CASE_CONTROL||PROSPECTIVE|||||||
33905492|NCT05379023|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33988062|NCT05183204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988063|NCT05327608|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33988064|NCT01980823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988065|NCT00264394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988066|NCT01263353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081843|NCT02414282|||OTHER||PROSPECTIVE|||||||
34081844|NCT01053455|||CASE_CROSSOVER||PROSPECTIVE|||||||
34081845|NCT01629550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081846|NCT00949442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081847|NCT02227095|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34081848|NCT00203515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33905493|NCT00026468|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33905494|NCT01947374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905495|NCT01981122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33775134|NCT06188468|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775135|NCT02719847|||COHORT||PROSPECTIVE|||||||
33775136|NCT06737549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33775137|NCT05074693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775138|NCT06663020|||COHORT||PROSPECTIVE|||||||
33775139|NCT06728761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33775140|NCT06716957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905496|NCT06133829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The analyst will be masked to study allocation.||f|f|f|t
33905497|NCT01280123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905498|NCT06692959|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, Bayesian Optimal Design, single arm, one cohort, open label, multi-centre study of neoadjuvant PD-1 vaccine PD1-Vaxx and surgical resection in adult patients with operable MSI-high colorectal cancer.||||
33905499|NCT04037423|||COHORT||OTHER|||||||
33905500|NCT00156546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905501|NCT06593912|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study comparing two different immobilization protocols.||||
33905502|NCT03018782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905503|NCT02016157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905504|NCT01400971|||OTHER||PROSPECTIVE|||||||
33905505|NCT00174161|||DEFINED_POPULATION||OTHER|||||||
33905506|NCT06058780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905507|NCT06252610|||COHORT||PROSPECTIVE|||||||
33905508|NCT05427851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905509|NCT05579561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In a clinical study pilot project, compare vegetarian therapeutic carbohydrates restriction to the omnivore version, in the contexte of reverse type 2 diabetes symptoms||||
33905510|NCT03403491|RANDOMIZED|CROSSOVER||OTHER||NONE||Prospective, open-label, sham-controlled, observational study. Usual care run-in period (2 weeks) followed by random order 2 x 4-week crossover periods. Comparison is active pMp app \[+ digital weighing scales + BP monitor\] for 4 weeks vs. sham application for 4 weeks.||||
33905511|NCT04099901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Double-blind placebo-controlled randomized trial|t|t|t|t
33905512|NCT03319992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905513|NCT02352246|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33905514|NCT05131178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905515|NCT03394170|||OTHER||PROSPECTIVE|||||||
33905516|NCT03813563|||COHORT||RETROSPECTIVE|||||||
34081849|NCT02342626|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685256|NCT05579171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded Investigator will be unaware of which side received both treatments.|Enrolled subjects will be randomized to receive picosecond 755 nm Alexandrite laser treatment to either the left or right facial half. The subjects will then undergo full face radiofrequency microneedling (RFM).|f|t|t|f
33685257|NCT01673282|||COHORT||PROSPECTIVE|||||||
33685258|NCT04074239|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The operators at the medical helpline 1813 will triage children meeting the inclusion criteria by video every other day they are at work, and by telephone the other days. The children will hence be randomized to either video or telephone depending on what day they are calling and which operator they are talking to.||||
33685259|NCT00197990|||COHORT||PROSPECTIVE|||||||
33685260|NCT04612296|||COHORT||PROSPECTIVE|||||||
33685261|NCT00534261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685262|NCT03620656|||COHORT||PROSPECTIVE|||||||
33685263|NCT01667705|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685264|NCT06505811|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The assessors completing the in-home observations will not be apprised of treatment assignment.|"All eligible applicants will be entered into a lottery which will randomly select a total of 600 participants for the Pomona Household Universal Grant (HUG) program. Selected applicants will be assigned to one of the following groups (July 2024):~Treated Group - 250 applicants will receive 18 monthly payments in the amount of $500 each Comparison Group - 350 applicants will receive $20 stipend payments for a total of 18 months"|t|f|f|t
33685265|NCT06194019|||OTHER||CROSS_SECTIONAL|||||||
33685266|NCT04707547|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685267|NCT00738621|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33685268|NCT04597151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685269|NCT00211744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685270|NCT01073371|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33685271|NCT06020729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685272|NCT01489111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685273|NCT05592873|||OTHER||RETROSPECTIVE|||||||
33685274|NCT01877733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685275|NCT04722055|||COHORT||PROSPECTIVE|||||||
33685276|NCT00716950|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685277|NCT01781091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685278|NCT05399576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33685279|NCT02340273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685280|NCT00564538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685281|NCT00533091|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33775141|NCT02035787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775142|NCT04915612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775143|NCT06737107|||CASE_CONTROL||RETROSPECTIVE|||||||
33775144|NCT06209606|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a pilot, multicenter, open-label study evaluating the utility of using increases in serum BCMA \> 25% versus IMWG criteria to determine disease progression among patients with RRMM treated with ruxolitinib and methylprednisolone to determine when to add lenalidomide to the regimen. Subjects that were treated with ruxolitinib with methylprednisolone and showed disease progression will have lenalidomide added to their regimen. PD is defined by either change in sBCMA (≥ 25% increase from nadir) or by standard IMWG criteria, whichever occurs first. PD will be confirmed by two consecutive tests.||||
33775145|NCT06555783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775146|NCT05603819|||OTHER||CROSS_SECTIONAL|||||||
33775147|NCT01579019||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775148|NCT06374797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775149|NCT06153888|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||crossover- such as the same patient performs 1) a standard hemodialysis and one week later 2) an experimental hemodialysis (change in ultrafiltration time)||||
33775150|NCT02453087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988067|NCT03071666|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|We will randomize women in a 1:1 ratio. The vitamin B12 supplements and the placebos will be produced specifically for this trial and be identical in taste and appearance. Each woman will be assigned a packet of medicines according to her id number. This packet will only be labeled with general information about the study and a unique id number. The list that links the id number to the randomization code will be kept with the company that produces the intervention and the placebo, and with the scientist who will generate the randomization code. This scientist will otherwise not be involved in the study. None of the investigators will have access to this list until completion of data collection and cleaning of data for the main outcomes.||t|t|t|t
33988068|NCT00871754|||COHORT||PROSPECTIVE|||||||
33988069|NCT01852747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988070|NCT05379647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988071|NCT01571245|||COHORT||PROSPECTIVE|||||||
33988072|NCT03677492|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33988073|NCT01817985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988074|NCT01871662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081850|NCT01772602|||OTHER||OTHER|||||||
33685282|NCT03171428|||CASE_CONTROL||RETROSPECTIVE|||||||
33685283|NCT04106414|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an MSKCC investigator-initiated, single-center, randomized, open-label, phase 2 study to evaluate the activity of PD-1 inhibitor, Nivolumab alone with and without IDO-inhibitor, BMS-986205, in patients with recurrent or persistent endometrial carcinoma or endometrial carcinosarcoma.||||
33685284|NCT00983398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685285|NCT04514302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Parallel|t|t|t|t
33775151|NCT03851874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775152|NCT01941992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775153|NCT03231449|||COHORT||PROSPECTIVE|||||||
33988075|NCT00437138|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34081851|NCT06552117|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33685286|NCT02013583|||CASE_ONLY||OTHER|||||||
33988076|NCT06068530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988077|NCT05497921|NA|SINGLE_GROUP||TREATMENT||NONE|PI will not know which is the treatment or control hand.|Subjects will treat one hand while the contralateral hand acts as a control. At the end of 6 weeks the subject will be instructed to cease treatment of the test hand and commence treatment of the control hand for 6 weeks. Efficacy will be evaluated at 6 weeks after the beginning of the treatment and 12 weeks (end of crossover).||||
33988078|NCT02009462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988079|NCT01741948|||CASE_CONTROL||PROSPECTIVE|||||||
33988080|NCT01631383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685287|NCT04570059|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Parents are informed that the aim of the study was about the effect of complementary feeding recommendations on their child's eating behaviour but they are unaware of the focus on texture. They are also blinded to the group (intervention vs. control) to which they were allocated. This information is revealed to them after the end of the study. The principal investigator analyse the data without information on children allocation and groups effect are initially assessed without identification of participants.|Intervention run between 8 and 15 months of the children, randomisation of children within a control (n=30) or intervention group (n=30).|t|f|t|f
33685288|NCT02353143|NA|SEQUENTIAL||TREATMENT||NONE||The study included ascending doses in the range 0.1 mg/kg to 2.5 mg/kg. According to the Data Safety Review Board, doses to be sequentially tested are 0.1, 0.3, 0.6, 1, 1.7, 2.5 mg/kg single shot and 1.7, 2, and 3 mg/kg ramp up||||
33685289|NCT05193227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685290|NCT05911555|||CASE_ONLY||PROSPECTIVE|||||||
33685291|NCT04330105|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685292|NCT04479462|||COHORT||PROSPECTIVE|||||||
33685293|NCT00101829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685294|NCT01181401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685295|NCT02828891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685296|NCT00172159|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33685297|NCT03473418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685298|NCT00445016|||||PROSPECTIVE|||||||
33685299|NCT06173427|||CASE_ONLY||RETROSPECTIVE|||||||
33685300|NCT04288232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685301|NCT00476567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33775154|NCT01021163||PARALLEL||TREATMENT||||||||
33775155|NCT03944980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775156|NCT04314063|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33775157|NCT01783093|||CASE_ONLY||RETROSPECTIVE|||||||
34081852|NCT05380765|RANDOMIZED|PARALLEL||PREVENTION||NONE||wait-list control||||
33685302|NCT01047098|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33685303|NCT05841173|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Masking is used between 2 groups out of 5 (between the Product group and Placebo group). The investigated product and Placebo have comparable organoleptic properties and are packed in the same containers labelled as N1 or N2.~The participants are randomised for 5 arms. In the case of arms 1 and 2, they are prescribed to consume 2 doses of product per day without awareness of either it is the investigational product or a placebo (the investigational product or a placebo). Field investigators prescribe to participants product N1 or N2 according to group allocation without awareness of either it is the investigational product or a placebo."|Prospective randomised parallel arms double control interventional study|t|f|t|f
33685304|NCT02492737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685305|NCT04879524|||COHORT||PROSPECTIVE|||||||
33685306|NCT01813045|||COHORT||PROSPECTIVE|||||||
33685307|NCT03743974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685308|NCT03840720|||COHORT||CROSS_SECTIONAL|||||||
33685309|NCT05401396|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Each participant will on the first day of the trial be randomized either to swim in a pool immediately after lunch or to wait 30 minutes before swimming. The participants will do the opposite on the second day of the trial. The randomization will be done by throwing a dice.|f|f|f|t
33685310|NCT05301374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685311|NCT03811275|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The occupational therapist providing all of the functional assessments will be blinded to sequence of interventions provided.|All participants will receive both interventions (A and B) and will be randomly assigned to the sequence in which they receive them (AB or BA).|f|f|t|f
33685312|NCT00178880|||COHORT||PROSPECTIVE|||||||
33685313|NCT05138471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685314|NCT01067443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685315|NCT01067547|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775158|NCT05797519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775159|NCT06738446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775160|NCT02674243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775161|NCT05327010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775162|NCT06276491|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion study||||
33905517|NCT04006743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessment of the videos was blinded. PIPP score was measured by two specialist pain doctors who were blinded to the study purpose, and to the study group allocation.|This study was randomized controlled trial on the effects of combined and alone use of swaddling, expressed breast milk, and facilitated tucking on preterm infants before, during and after OGT insertion procedure. Preterm infants were randomly allocated before the OGT insertion by a neonatal nurse using a random closed envelope manner to one of the six groups: routine care group, swaddling, expressed breast milk, facilitated tucking, swaddling+expressed breast milk, and facilitated tucking+expressed breast milk group. After obtaining parental written consent, neonatal nurse who apply OGT insertion randomized the infant and learned the allocation group. The nurses could not be blinded to the allocation because of the nature of the intervention. However, nurses were blinded to the study hypotheses. Additionally, the outcome assessment of the videos was blinded.|f|f|f|t
33988081|NCT06537193|NA|SINGLE_GROUP||SCREENING||NONE||||||
33988082|NCT04254887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33988083|NCT02053857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988084|NCT00061321|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33988085|NCT00655590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775163|NCT04234048|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation oncology Phase 1 with extended cohort study (1b); Up to 46 patients for the whole study: up to 8 patients for accelerated phase 1a (single patient cohort) + up to 18 patients for standard phase 1a (3+3 design) + 20 patients for phase 1b at the maximum tolerated dose (MTD)||||
33775164|NCT04642885|||FAMILY_BASED||PROSPECTIVE|||||||
33775165|NCT06467357|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label, Sponsor-blinded study. To maintain the integrity of the study, Sponsor personnel directly involved in study conduct will not undertake or have access to efficacy data aggregated by treatment group prior to final data readout for the primary endpoint.|||||
33775166|NCT05035654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775167|NCT05884658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, multicenter, randomized, parallel-group, non-inferiority open superiority study|t|f|f|f
33775168|NCT05079919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775169|NCT06738433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775170|NCT01005654|||COHORT||PROSPECTIVE|||||||
33775171|NCT00781144|||CASE_ONLY||PROSPECTIVE|||||||
33775172|NCT04260126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905518|NCT05942651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be block randomized (1:1) to receive either active ccPAS4-ms or sham ccPAS100-ms. Computer generated random numbers will be used to generate the allocation sequence. The allocation sequence will be handled by an independent person from the Administrative Department of the Hospital and will be unavailable to those who enroll and assign patients. Patients will be blind to their treatment assignment. Moreover, the medical doctors who will administer the clinical scales and the researchers that will analyze the data will be blinded to the allocation.|This is a prospective, randomized, double-blind, parallel-group controlled trial with two arms.|t|f|t|t
33905519|NCT02097706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905520|NCT06554301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905521|NCT06402604|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group receives a 12-weeks standard online MBSR therapy, consisting of 8 weekly group meetings, one day silent retreat, and daily homework. A second group attends a 12-week aerobe training program which consists of HR-controlled training on a cycle trainer at 70-80% individual heart rate reserve (HRR) for 2 to 3 times per week. Finally, the time control (wait list) group will be asked to continue normal activities and lifestyle and won't undergo guided mindfulness therapy or exercise training during the 12 weeks study period.||||
33905522|NCT04854265|||OTHER||RETROSPECTIVE|||||||
33905523|NCT01571531|||OTHER||PROSPECTIVE|||||||
33905524|NCT00935857|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33988086|NCT00919230|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33988087|NCT01373593|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33905525|NCT05339308|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The participants will not be informed about the actual study purpose, while the main investigator will be blinded to the EXP or CON oil administration|Randomized controlled study|t|f|t|t
33905526|NCT06274411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33905527|NCT04923412|RANDOMIZED|PARALLEL||TREATMENT||NONE||"214 patients will be divided into two groups.~1. Control group (N=107): Effort to preserve the pulmonary branch of vagus nerve preservation is not made in this group during mediastinal lymph node dissection~2. Treatment group (N=107): Effort to preserve the pulmonary branch of vagus nerve preservation is made in this group during mediastinal lymph node dissection"||||
33905528|NCT03643432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised between usual care or the intervention arm which will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment. A sub sample of the population will undergo a qualitative study to assess acceptability of the intervention.||||
33905529|NCT05019703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905530|NCT02333240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905531|NCT03737149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a staged cohort study. In the first (pilot) cohort, all participating subjects will utilize the mymobility with Apple Watch platform. In the second (RCT) cohort, approximately 1,000 subjects will be randomized 1:1 to either the mymobility with Apple Watch platform or standard of care SOC. In the third (correlative analytics) cohort, all participating subjects will utilize the mymobility with Apple Watch platform.||||
33905532|NCT05791799|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33905533|NCT06215339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"While the patients were randomized; In order to keep the possibility of being affected by each other at a minimum level, the study was continued with the same application group in the same session group. For example; It's like working only with the robot cat group in the 08:00-12:00 session group on Mondays. In order to reduce the possibility of selection bias due to sample selection, single-stage cluster type random sampling, which is a subtype of random sampling, was used. In addition, before the study, patients were informed about the study and their consent was obtained."|using G\*Power 3.1.9.2. The sample size was deemed sufficient (experiment=30; control=30), and the study was concluded. Participants were selected using a lottery method, and data were collected through a singleblind randomization process.||||
33905534|NCT04254237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905535|NCT00887692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905536|NCT01377181|||CASE_CONTROL||PROSPECTIVE|||||||
33905537|NCT05704413|||COHORT||PROSPECTIVE|||||||
33905538|NCT03273075|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33905539|NCT05563077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care providers and outcomes assessors will be blinded to group allocation.|The sample of this study will be randomized in a 1:1:1 ratio (www.randomizer.org) based on a computer-generated random allocation sequence, and will be concealed using sequentially numbered, opaque, sealed envelopes to MIIT, MICT and control groups.|f|t|f|t
33905540|NCT00013598||||TREATMENT||||||||
33905541|NCT06245577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|mesh material||t|t|f|t
33988088|NCT05967715|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Only for the probiotics and placebo arms"||t|t|t|t
34081853|NCT04745117|||COHORT||PROSPECTIVE|||||||
34081854|NCT05821049|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Envelope Blinding Chits|A randomized, double blind, placebo controlled, parallel group|t|t|t|f
34081855|NCT04197271|||COHORT||PROSPECTIVE|||||||
33905542|NCT03670082|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905543|NCT04099056|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33905544|NCT02166593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905545|NCT05183581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905546|NCT06332144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905547|NCT02253667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905548|NCT00382096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685316|NCT04501029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905549|NCT01460641|||OTHER||PROSPECTIVE|||||||
33905550|NCT00611455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905551|NCT04592380|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33905552|NCT05329688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single blind (Participant)|single blind (Participant)|t|f|f|f
33905553|NCT03070977|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905554|NCT01120938|||CASE_CROSSOVER||PROSPECTIVE|||||||
33685317|NCT02372214|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33685318|NCT02073266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775173|NCT03237013|RANDOMIZED|PARALLEL||PREVENTION||NONE||At initial visit, participants were screened for study eligibility, consented, and randomized to a study condition. Participants first completed baseline assessment. Following, all participants completed intervention as determined by randomized assignment (i.e., control, facial morphing or mindfulness). At the initial visit, all subjects were assigned a subject ID number. Each subject ID was pre-assigned to a study condition, determined by an online randomization program, prior to recruitment. Each eligible participant had a 1/3 chance to be assigned to each of the three study conditions. Immediately after intervention, participants completed acute assessment, also consisting of self-report questionnaires. At the end of the initial visit, participants provided researchers a valid email address to be sent a subsequent follow-up survey. Approximately one month from the intervention date, participants received and completed the online follow-up survey.||||
33775174|NCT03744559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775175|NCT05311007|||COHORT||PROSPECTIVE|||||||
33775176|NCT05709535|||COHORT||PROSPECTIVE|||||||
33775177|NCT01190176|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33775178|NCT05561244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study is interventional, prospective, comparative, superiority, multicentric, randomised by cluster, in closed cohort.|f|t|f|f
33775179|NCT06165445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, parallel group trial|t|t|f|t
33685319|NCT04037878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient is randomized according to randomization block and sealed envelops. The investigator doesn't know what study group the patient is randomized into||t|f|t|f
33775180|NCT04543591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775181|NCT01902589|||COHORT||PROSPECTIVE|||||||
33775182|NCT06641323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33775183|NCT01778569|||CASE_ONLY||PROSPECTIVE|||||||
33775184|NCT06442761|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33775185|NCT06739746|||COHORT||CROSS_SECTIONAL|||||||
33775186|NCT06602193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905555|NCT05772715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33905556|NCT00918528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685320|NCT02380690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905557|NCT06639347|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-A2102 with antitumor therapy||||
33905558|NCT06024577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research staff collecting data will be masked to intervention|Randomized study to three arms: 1) walk intervention, 2) variety intervention, 3) progressive intervention|f|f|f|t
33905559|NCT05845047|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The study is to be conducted in a blinded assessor manner. The participants and the clinician performing the behavioral assessments will know the treatment assignment, as there is no way to mask the participants from this information. The PI will have access to the unblinded list of randomization codes and treatment assignments. Technicians who were not involved in any of the treatment sessions will review videos of all of the assessments and will score the participants without knowledge of treatment order assignment||f|f|f|t
33905560|NCT03027817|||COHORT||PROSPECTIVE|||||||
33905561|NCT02769572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988089|NCT03379467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The allocation sequence will be concealed from the study staff responsible for screening and enrolling participants in serially numbered, opaque, sealed envelopes.|This is an individually randomized, three-arm parallel group design randomized control trial with equal allocation in the two treatment groups and control group. The parents of infants in SMS and interactive reminder groups will receive 3-5 reminders for scheduled follow-up immunization visits. The difference in between SMS and interactive reminders is that parents in SMS reminders are not asked to respond back to SMS reminders. The infants in control group will carry out routine follow-ups without any added intervention.||||
33685321|NCT01312623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685322|NCT03575481|||COHORT||PROSPECTIVE|||||||
33685323|NCT01426789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33685324|NCT04106024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905562|NCT00916799|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33905563|NCT05943847|||COHORT||PROSPECTIVE|||||||
33905564|NCT03204838|||CASE_ONLY||PROSPECTIVE|||||||
33905565|NCT00863785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905566|NCT06111846|NA|SEQUENTIAL||TREATMENT||NONE||||||
33905567|NCT02775864|||COHORT||RETROSPECTIVE|||||||
33905568|NCT00369434|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33685325|NCT02898584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685326|NCT01522885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905569|NCT05590234|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33905570|NCT03183245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905571|NCT04933006|||COHORT||RETROSPECTIVE|||||||
33905572|NCT04005092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905573|NCT06380426|||COHORT||OTHER|||||||
33905574|NCT04701099|||COHORT||PROSPECTIVE|||||||
33775187|NCT05723614|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||One component of the intervention will focus on providing housing support for recently incarcerated people as well as family members of currently incarcerated people. The target sample size is about 1,400. The other component of the intervention is mental wellness training for neighborhood residents to participate in trauma-informed care training sessions.||||
33775188|NCT06737120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775189|NCT06737939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33775190|NCT01021033|||CASE_ONLY||CROSS_SECTIONAL|||||||
33775191|NCT05501704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775192|NCT06736951|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a step-wedge cluster randomized controlled trials in which hospital units will cross over from control to intervention phase in a randomly assigned sequence.||||
33775193|NCT05037097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Observer Blind|The study will evaluate 3 investigational vaccines in parallel.|t|t|t|t
33905575|NCT05367687|RANDOMIZED|PARALLEL||TREATMENT||NONE|Camrelizumab Plus Rivoceranib (Apatinib) compared with Camrelizumab|||||
33905576|NCT00004106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905577|NCT01278680|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33905578|NCT05126823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a three-arm randomized clinical trial, with a pre-post-follow-up repeated measures intergroup design.|t|t|f|t
33905579|NCT04255186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905580|NCT06177834|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33905581|NCT02136823|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33905582|NCT00909376|||COHORT||PROSPECTIVE|||||||
33905583|NCT02703792|||OTHER||OTHER|||||||
33905584|NCT02137772|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33905585|NCT04747808|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-comparative||||
34081856|NCT03953014|||OTHER||CROSS_SECTIONAL|||||||
33988090|NCT02606825|||CASE_ONLY||RETROSPECTIVE|||||||
33988091|NCT01203332|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33988092|NCT02996591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988093|NCT01783561|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33988094|NCT06381141|NA|SEQUENTIAL||TREATMENT||NONE||||||
34081857|NCT05107661|||CASE_CONTROL||PROSPECTIVE|||||||
34081858|NCT00349336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081859|NCT01278758|NA|PARALLEL||TREATMENT||NONE||||||
33905586|NCT01957267|||COHORT||PROSPECTIVE|||||||
33905587|NCT01506414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905588|NCT00246883||||TREATMENT||||||||
33905589|NCT03416582|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33905590|NCT06693219|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905591|NCT03251014|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33905592|NCT06109623|||CASE_CONTROL||RETROSPECTIVE|||||||
33905593|NCT01390701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905594|NCT05741385|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905595|NCT03803761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905596|NCT02868749|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33905597|NCT02505555|||||PROSPECTIVE|||||||
33905598|NCT00495664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988095|NCT00273026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988096|NCT04534790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988097|NCT01415232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988098|NCT02074020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988099|NCT03215693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988100|NCT02728674|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33988101|NCT05220657|||COHORT||CROSS_SECTIONAL|||||||
33988102|NCT05290961|||OTHER||PROSPECTIVE|||||||
33988103|NCT03203876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988104|NCT00283764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33988105|NCT00905346|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988106|NCT03692585|||OTHER||OTHER|||||||
33988107|NCT05917925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple-blind|A randomized parallel study will be conducted in which 80 subjects will be divided into 2 groups: COL) 10 g/d hydrolyzed collagen-based supplement; PLA) 10 g/d placebo (maltodextrin) for 12 weeks.|t|f|t|t
33988108|NCT00801164|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33988109|NCT04135235|||COHORT||PROSPECTIVE|||||||
33988110|NCT00298350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988111|NCT05333809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988112|NCT04988672|||COHORT||PROSPECTIVE|||||||
33988113|NCT06386887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants' cross-sectional skeletal muscle areas will be measured. Measurements will be performed on CT scans obtained within 4-6 weeks of treatment initiation (with a 7-day screening window) by a fellowship-trained, experienced radiologist and imaging specialist in consensus who will be blinded to participant clinical variables and treatment.|Two arm, randomized, controlled study.|f|f|f|t
33988114|NCT02017262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988115|NCT04230525|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988116|NCT04486339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905599|NCT02974062|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33905600|NCT04260022|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A total of 40 patients will be randomized at 3:3:2 ratio into one of the three dose cohorts (Cohorts A, B, and C): 30 mg every other day (QOD), 40 mg QOD and 50 mg QOD, with 15, 15, and 10 patients in Cohort A, B, and C.~For Cohort D: 14 to 22 Ph+ BCP ALL or CML LBP patients will be enrolled."||||
33905601|NCT06057818|||OTHER||OTHER|||||||
33905602|NCT01704781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33988117|NCT03675269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988118|NCT02554032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988119|NCT00949585|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33988120|NCT00858845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33988121|NCT04468867|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988122|NCT06333457|||CASE_ONLY||PROSPECTIVE|||||||
33988123|NCT04518631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33988124|NCT05114447|||COHORT||PROSPECTIVE|||||||
33988125|NCT00752297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988126|NCT00311974|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33988127|NCT02258347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988128|NCT01835860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988129|NCT03951363|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988130|NCT00834340|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33905603|NCT03865407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905604|NCT04926363|||CASE_CONTROL||RETROSPECTIVE|||||||
33905605|NCT02310958|||COHORT||PROSPECTIVE|||||||
33988131|NCT04770857|||COHORT||PROSPECTIVE|||||||
33988132|NCT02431494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905606|NCT03112798|||COHORT||PROSPECTIVE|||||||
33905607|NCT02316093|||CASE_CONTROL||PROSPECTIVE|||||||
33905608|NCT01094964|RANDOMIZED|||TREATMENT||NONE||||||
33905609|NCT02731040|||CASE_CONTROL||OTHER|||||||
33988133|NCT00159848|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33988134|NCT03197285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988135|NCT03368287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988136|NCT01419093|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33988137|NCT02384876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988138|NCT01027923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988139|NCT03105453|||COHORT||PROSPECTIVE|||||||
33988140|NCT01244022|||CASE_ONLY||PROSPECTIVE|||||||
33988141|NCT03165994|NA|SINGLE_GROUP||TREATMENT||NONE||Non-comparative, open-label pilot study||||
33988142|NCT04371133|||CASE_CONTROL||PROSPECTIVE|||||||
33988143|NCT03535896|NA|SINGLE_GROUP||OTHER||NONE||||||
33988144|NCT01223105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988145|NCT06293872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081860|NCT06148870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|As this is a double-masked, randomized controlled trial, both the investigators and subjects will be masked.|This is a one-year, mono-centre, randomized, double-masked, monocular cross-over Clinical Trial with the objective to test and compare the efficacy of the new lens design in slowing down the increase of axial length and controlling myopic progression. The subject starts by wearing Myopia Control Lens 1 (MCL1) in one eye, and Myopia Control Lens 2 (MCL2) in another eye. After 6 months, a new pair of study spectacles will be dispensed with MCL1 and MCL2 crossed over. At the end of the 1-year period, each eye would have worn both MCL1 and MCL2 for 6 months each. There will be a total of 7 study visits with follow up periods at 3 months, 6 months and 12 months|t|f|t|f
34081861|NCT02517658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081862|NCT02880254|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33988146|NCT04470115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988147|NCT03592953|RANDOMIZED|PARALLEL||OTHER||SINGLE|the primary endpoint is the scoring of non-technical skills on the video recording of the high fidelity simulation session. The raters are blinded of the allocation group of the participant.|Randomized trial with 3 groups: classical teaching, serious game with classical scenarios, serious game with specific scenarios|f|f|f|t
33988148|NCT01757392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988149|NCT03820310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081863|NCT01690663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081864|NCT06187636|||COHORT||PROSPECTIVE|||||||
33905610|NCT00469196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905611|NCT03054818|||COHORT||PROSPECTIVE|||||||
33988150|NCT04129346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33988151|NCT01762579|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33988152|NCT00834756|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988153|NCT00356239|||DEFINED_POPULATION||PROSPECTIVE|||||||
33988154|NCT05296304|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I, single-arm therapeutic study for patients with diffuse cutaneous T-cell lymphomas (CTCL).||||
33988155|NCT03491579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081865|NCT02133157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081866|NCT00598091|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081867|NCT05265702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081868|NCT02966834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905612|NCT00287833|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33988156|NCT00252720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988157|NCT03331289|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be randomized to one of four groups (20 per group): i) placebo; (ii) exenatide 5 ug subcutaneously; (iii) dapagliflozin (10 mg); and (iv) dapagliflozin 10 mg plus exenatide 5 ug||||
33988158|NCT02298647|||COHORT||PROSPECTIVE|||||||
33685327|NCT06119022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905613|NCT00677027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33988159|NCT01691456|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988160|NCT04438109|||CASE_ONLY||RETROSPECTIVE|||||||
33988161|NCT03289845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988162|NCT02489526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988163|NCT01074879|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33988164|NCT05394935|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All participant data and exercise arm will be anonymised and non-identifiable by the assessor.|Participants will complete multiple baseline assessments. Within the crossover model, participants will complete a baseline cerebrovascular assessment, followed by a random bout of acute exercise and then a post-exercise repeat of the baseline tests. Following a pre-designated washout, the participants will complete the same visit with the remaining exercise bout.|f|f|f|t
33988165|NCT01689311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988166|NCT04138186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988167|NCT02106156|||CASE_ONLY||PROSPECTIVE|||||||
33685328|NCT04690062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685329|NCT05880823|||COHORT||PROSPECTIVE|||||||
33988168|NCT00003980||||TREATMENT||||||||
33988169|NCT03660098|||CASE_ONLY||PROSPECTIVE|||||||
33988170|NCT04499963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a 6-month, widely inclusive, largely remote/virtual, single-center, open-label pilot trial utilizing a historical control group.||||
34081869|NCT04630678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The children in both groups were evaluated by the same physiotherapist who was blinded. The treatment was given by a different physiotherapist who has been working in the field of pediatric physiotherapy for ten years.|The children were randomized into two groups.The first group was received virtual reality therapy. The second group was received activity training. Both treatments were given three times a week for eight weeks.|f|f|f|t
33775194|NCT06728280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Given the study's design, blinding TMS operators will not be possible. Still, participants、staff responsible for participant assessments and data analysis will be blinded to treatment conditions and external to the clinic staff. Patients will be instructed not to reveal their group assignment to the raters. Patients will not be given the specifics of the treatment parameters and will be instructed not to talk to each other during the study period. Both treatments will be presented as effective to them. Lastly, the data management center will strictly control access to the randomization code.|randomized, double-blind,single-center, two-arm, parallel-group superiority trial|t|f|t|t
33905614|NCT06094179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase IB and Phase IIA of this study were double-blind trials. Neither the subject nor the investigator nor the sponsor's project team members were aware of the subject's treatment assignment. Supply of the investigational drug and placebo by the sponsor or designated unit. To reduce the likelihood of subjects being exposed to unnecessary risks while providing the necessary information for dosing escalation, discontinuation and selection, a Safety Management Committee (SMC) will be established to review the subject safety data as necessary.|This is a Phase IB/IIA clinical study of BAT6026 in patients with AD. The subjects were adults with moderate to severe atopic dermatitis (AD) whose disease was not adequately controlled by prior topical medications or for which topical medications were not appropriate. The first phase was the phase IB study, which was double-blind controlled by placebo in the group and consisted of 3 dose groups. After completing the dose escalation study, the phase IIA study was entered. The Phase IIA study was a randomized, double-blind, controlled, multicentering clinical trial with different dose groups and placebo groups. The primary endpoint was to explore the efficacy and safety of BAT6026 in patients with eczema area and severity index (EASI) of at least 75% lower than the baseline at week 16 after 4 treatment cycles. To provide the optimal dose for the phase III regimen.|t|f|t|f
33905615|NCT03686254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081870|NCT01146847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081871|NCT00785356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081872|NCT02920190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081873|NCT02528448|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081874|NCT03627832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PI Miller will not be blinded to block size or participant assignment because she will inform study therapists of participant assignment to conditions. However, PI Miller and study therapists will be blinded to assessment outcomes, and the assessment RA will be blinded to participant condition. All participants will be told that they will be assigned to one of two insomnia treatment conditions in order to blind them to condition assignment.|Participants will be assigned to receive either Cognitive Behavioral Therapy for Insomnia (CBT-I) or Sleep Hygiene.|t|f|f|t
34081875|NCT01133548|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081876|NCT04556760|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both participants and investigators will be blinded. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study. In order to maintain this blind, a third party will be responsible for the reconstitution and dispensation of all study interventions.||t|f|t|f
34081877|NCT00771368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081878|NCT02860936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685330|NCT03647787|||CASE_ONLY||RETROSPECTIVE|||||||
33685331|NCT02850133|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685332|NCT03047681|||CASE_CONTROL||PROSPECTIVE|||||||
33685333|NCT04691947|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33685334|NCT04970953|||COHORT||PROSPECTIVE|||||||
33685335|NCT06254820|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participant and Investigator. Investigator will be blinded in Part A of the study.|This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age|t|f|t|f
33685336|NCT06177574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685337|NCT02000154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685338|NCT00079131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685339|NCT05300373|||OTHER||PROSPECTIVE|||||||
33685340|NCT06245278|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685341|NCT01843335|||CASE_ONLY||PROSPECTIVE|||||||
33685342|NCT03303027|NON_RANDOMIZED|FACTORIAL||OTHER||SINGLE||The primary endpoint will be the score of two blinded reviewers using the patient observer scar assessment score at a three-month assessment visit.|f|f|f|t
33685343|NCT02726308|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33685344|NCT01789918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685345|NCT03986060|||COHORT||PROSPECTIVE|||||||
33685346|NCT05952271|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33685347|NCT06505408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, double-blind, placebo-controlled, parallel study in healthy women.|t|f|t|f
33685348|NCT03696927|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33685349|NCT04042935|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||3+3 Dose Escalation: Dose Level -2: ALA 300 mg daily Dose Level -1: ALA 600 mg daily Dose Level 1: ALA 600 mg BID Dose Level 2: ALA 600 mg TID||||
33685350|NCT05134532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685351|NCT05249218|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a prospective, randomised controlled study over 21 weeks in children to assess how Phe intake from fruits and vegetables (containing 76-100 mg Phe/100g) vs. animal sources will impact on blood Phe control. This will be followed by a 6 months extension study examining the 'unlimited' use of fruits and vegetables containing Phe 76-100 mg/100g on blood Phe control.||||
33685352|NCT04641520|||COHORT||PROSPECTIVE|||||||
33775195|NCT01400464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775196|NCT02919956|||COHORT||CROSS_SECTIONAL|||||||
33775197|NCT05972889|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33775198|NCT01859299|||CASE_CONTROL||PROSPECTIVE|||||||
33775199|NCT05388708|||COHORT||PROSPECTIVE|||||||
33685353|NCT00824070|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33775200|NCT06728254|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized controlled trial, with participants unequally allocated to test and control groups (factor 5) in clusters||||
33775201|NCT06741280|NA|SINGLE_GROUP||TREATMENT||NONE||Post-marketing, prospective, within-subject controlled clinical trial to evaluate the efficacy and safety of a medical product for the treatment of mouth sores, over a period of 14 days or until the end of the outbreak. A group of 35 adult subjects was established, with the sample size determined statistically. The treatment will consist of daily applications of the product as soon as a mouth sore appears until its complete disappearance or healing, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (maximum 3-4 applications).||||
33685354|NCT04498494|||CASE_CONTROL||RETROSPECTIVE|||||||
33775202|NCT03442023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988171|NCT03464240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33685355|NCT04411862|RANDOMIZED|PARALLEL||TREATMENT||NONE||Shams University Hospitals and Ain Shams Specialized Hospital outpatient Gastroenterology Clinics.||||
33685356|NCT03375229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685357|NCT00089674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685358|NCT03021174|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685359|NCT00001965||||TREATMENT||||||||
33685360|NCT03148119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685361|NCT05565417|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33685362|NCT04572438|||COHORT||PROSPECTIVE|||||||
33685363|NCT01511666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685364|NCT04426383|||COHORT||PROSPECTIVE|||||||
33685365|NCT02816931|||COHORT||PROSPECTIVE|||||||
33685366|NCT01011478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685367|NCT00017485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685368|NCT04748588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685369|NCT01981785|||CASE_CONTROL||PROSPECTIVE|||||||
33775203|NCT01105858|||COHORT||PROSPECTIVE|||||||
33775204|NCT05877885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775205|NCT06447805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Academic, investigator initiated, open-label pilot study with a randomized controlled trial (RCT) design and 3:1 allocation (3 intervention: 1 standard).|t|f|f|t
33775206|NCT04927364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775207|NCT06713239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective, randomized, open-label trial||||
33775208|NCT04436107|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775209|NCT05795842|||CASE_ONLY||PROSPECTIVE|||||||
33775210|NCT06729762|||COHORT||PROSPECTIVE|||||||
33775211|NCT06627179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775212|NCT05482932|||COHORT||CROSS_SECTIONAL|||||||
33905616|NCT02284399|||CASE_CONTROL||RETROSPECTIVE|||||||
33905617|NCT02963467|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33905618|NCT00475280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905619|NCT05402878|||COHORT||PROSPECTIVE|||||||
33905620|NCT03328130|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Five successive cohorts separated by DSMC assessments||||
33905621|NCT05847270|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33905622|NCT05029076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905623|NCT04473261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|empty capsule will be given as a placebo|Randomized, controlled, multi-armed, close-label, interventional study designed|t|t|t|t
33905624|NCT05791825|RANDOMIZED|PARALLEL||OTHER||NONE||The study employs a cluster-randomized design with two study arms, one of which will receive the intervention and the other of which will act as the control group. The study will employ repeated measures at pre- (baseline/time 1 assessment), post-intervention (time 2), and 3-month (time 3) follow-up points. The counterfactual will be a waitlisted control comparison condition and randomization to the intervention/control group will occur at the classroom level.||||
33905625|NCT00092144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905626|NCT05174052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double blind, placebo-controlled trial.|t|t|t|t
33905627|NCT04579588|||CASE_CONTROL||PROSPECTIVE|||||||
33905628|NCT05961592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905629|NCT00591227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905630|NCT04878640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905631|NCT03747172|||COHORT||PROSPECTIVE|||||||
33905632|NCT00629694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905633|NCT05894018|NA|SINGLE_GROUP||TREATMENT||NONE||Fluzoparib 150 mg Bid was given orally after meals for 2 months (60 days) in a continuous cycle 48 h after radioactive particle implantation. The maximum cumulative dosing period is 1 year. Tumor assessment was performed in each cycle. The first cycle is evaluated every month. Patients in partial remission (PR) or patients with stable disease (SD) will be supplemented with additional particle implantations (≤3) according to the dose prescribed by the physician, noting the need to discontinue the drug for at least 5 days prior to surgery and to continue oral Fluzoparib for 2 days after surgery until 6 months after the last particle implantation. Patients with intolerable toxicity or patient requested discontinuation or disease progression (PD) were withdrawn from the trial and entered into survival follow-up.||||
33905634|NCT05299710|||OTHER||PROSPECTIVE|||||||
33905635|NCT06692062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905636|NCT05228652|||COHORT||CROSS_SECTIONAL|||||||
33905637|NCT04547296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988172|NCT04671368|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The AI group, ordinary pathologists and gold standard group will not be informed of each other's results|All patients will be diagnosed by both AI and ordinary pathologists, thus performing a self-controlled study|f|f|f|t
33988173|NCT01279902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905638|NCT06401655|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot study will utilize a longitudinal concurrent mixed-methods research design that gathers and analyzes qualitative and quantitative data overtime about a new 10-session financial coaching program the investigators have developed. The data collected will be used to inform improvements to future related studies and programs for people living with brain injury.||||
33988174|NCT01173211|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33988175|NCT01680380|||CASE_ONLY||CROSS_SECTIONAL|||||||
34081879|NCT05789966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Staff without knowledge of participant information will create a computer-generated list that consists of blocks of six that contain two of each of the three groups per block in a random order. The randomisation list will be incorporated into a computer program that our staff will use for enrolment and automated random assignment of participants. Group allocation will be concealed from study staff until the 7-day pre-intervention period begins (to allow preparation of genetic risk estimates and/or calculate Fitbit step goals from baseline data) and concealed from participants until the intervention begins. Given the nature of the interventions, it is impossible for participants to be blinded to their group allocation; however, research staff analysing participants' deidentified data will remain blinded to participant group assignments.|parallel-group, open randomized controlled trial|t|f|t|f
33905639|NCT03127202|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33988176|NCT04415515|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988177|NCT05004116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a single institution phase 1/2 study of TPX-0005 (Repotrectinib) (capsule) when given in combination with irinotecan and temozolomide in pediatric and young adult patients (≥12 years old) with relapsed/refractory solid tumors, followed by a single institution phase 2 study to determine the overall response rate at the recommended phase 2 dose in primarily neuroblastoma and DSRCT patients.||||
33988178|NCT00851877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988179|NCT00988663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988180|NCT04645914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind through randomization|Two groups : consumers of cigarettes/e-cigarettes and non consumers of cigarettes/e-cigarettes|t|f|t|t
33988181|NCT01646554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081880|NCT04344119|||CASE_ONLY||PROSPECTIVE|||||||
34081881|NCT05256823|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomized block design will be used to randomly randomize the subjects to the test or control group at a rate of 3:1 with 4 as the block length. The SAS software will be used to generate a random number table and assign a unique random number to every subject eligible for screening before the first dose of the investigational product.||||
33685370|NCT00413088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685371|NCT01326559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685372|NCT01832168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685373|NCT06132581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This study is designed to be double-blind. Participants and the researchers are unaware of each participant's assignment until the completion of all data collection. This is accomplished using randomization codes. Furthermore, this study utilizes an active sham stimulation. This means that the active sham condition includes some stimulation, mimicking the skin sensations associated with tACS. In a previously concluded trial, participants in the delta-beta tACS, theta-gamma tACS, and active sham groups responded similarly to the blinding questionnaire, indicating that the active sham stimulation successfully blinded the participants.|Participants are randomized into one of three arms of the study: delta-beta tACS, control tACS in theta-gamma, or active sham tACS.|t|f|t|f
33685374|NCT04168632|NA|SINGLE_GROUP||PREVENTION||NONE||Three schools from one municipality in the Region Stockholm met inclusion criteria and were eligible to participate in the intervention. These schools all served the baseline followed by the new menu. Each period lasted four weeks.||||
33685375|NCT03042026|||CASE_CONTROL||PROSPECTIVE|||||||
33685376|NCT03123185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685377|NCT03516903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685378|NCT04783675|NA|SINGLE_GROUP||TREATMENT||NONE||Rituximab||||
33685379|NCT03444987|||CASE_CONTROL||PROSPECTIVE|||||||
33905640|NCT02096198|||COHORT||PROSPECTIVE|||||||
33905641|NCT03532971|||COHORT||OTHER|||||||
33905642|NCT06692881|||COHORT||PROSPECTIVE|||||||
33905643|NCT02143986|||COHORT||PROSPECTIVE|||||||
33905644|NCT05055739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905645|NCT06030765|||COHORT||PROSPECTIVE|||||||
33685380|NCT04577339|||COHORT||RETROSPECTIVE|||||||
33905646|NCT05805371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905647|NCT06385262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905648|NCT05922423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33905649|NCT02394444|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33905650|NCT06692582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be performed using a computer program. Only one member of the research group, who will also prepare the mouthwashes, will know the content of the randomization table or the type of mouthwash used by each individual. Identification codes will remain hidden from all other researchers and subjects until the final follow-up examinations. The packaging of the mouthwashes will be identical, and the active ingredients will not be distinguishable by color.||t|t|t|t
33905651|NCT01996345|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking in this study.|||||
33685381|NCT04615585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905652|NCT00863928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33905653|NCT06324487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33905654|NCT03234868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905655|NCT05552586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33905656|NCT03348657|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905657|NCT00002706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905658|NCT05614674|||COHORT||CROSS_SECTIONAL|||||||
33905659|NCT04338945|||COHORT||PROSPECTIVE|||||||
33685382|NCT00004071|RANDOMIZED|||TREATMENT||||||||
33905660|NCT03157635|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33905661|NCT05971290|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33905662|NCT00963521|NON_RANDOMIZED|||TREATMENT||||||||
33905663|NCT04062877|||COHORT||PROSPECTIVE|||||||
33905664|NCT00230386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905665|NCT03440372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685383|NCT02439333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905666|NCT05684978|NA|SINGLE_GROUP||OTHER||NONE||||||
33905667|NCT05646797|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905668|NCT03015350|||CASE_CONTROL||PROSPECTIVE|||||||
34081882|NCT05355558|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34081883|NCT03259958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685384|NCT04486274|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33685385|NCT00306007|||COHORT||PROSPECTIVE|||||||
33685386|NCT05378139|||OTHER||PROSPECTIVE|||||||
33685387|NCT05358340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685388|NCT05365854|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33685389|NCT00667446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685390|NCT04909151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685391|NCT00001162|||CASE_ONLY||PROSPECTIVE|||||||
33685392|NCT06516835|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patient will not be aware of the allocation|Two groups will be randomly allocated to ENF or IVF group|t|f|f|f
33685393|NCT02101112|RANDOMIZED|CROSSOVER||||NONE||||||
33685394|NCT03989739|||COHORT||RETROSPECTIVE|||||||
33685395|NCT02257671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685396|NCT02948101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685397|NCT06135194|||COHORT||PROSPECTIVE|||||||
33685398|NCT06273371|||COHORT||RETROSPECTIVE|||||||
33685399|NCT02553954|NA|SINGLE_GROUP||OTHER||NONE||||||
33685400|NCT01350544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33685401|NCT01115582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685402|NCT06067659|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Inclusion criteria for the study were diagnosis of calcaneal spur by a physician, being in the age range of 30-70 years, patient complaining of pain in the heel region, appearance of calcaneal protrusion in the radiographic image, no other treatment or medication (NSAI, steroids, other drugs, etc.) analgesics) and the patient volunteered to participate in the study. Exclusion criteria were those who received injection therapy to the foot area (corticosteroids or corticosteroids/anesthetics), those with a history of rheumatic disease, coagulopathy, thrombophlebitis, neoplasia, systemic inflammatory disease, and outpatient surgery in the last 3 months. No other treatment or medication (NSAI, steroids, other analgesics) will be used during the study period.|Crossover Assignment Factorial Assignment randomized controlled trial 3 groups|t|f|f|f
33685403|NCT01230775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33685404|NCT05634356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Parents are not informed of their group assignment.|We have a parallel design in which parent-infant dyads are assigned to either the intervention or to a random control group.|t|f|f|f
33685405|NCT00672204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685406|NCT02646202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685407|NCT01221844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685408|NCT01461057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905669|NCT03997422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081884|NCT00905996|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33905670|NCT01670630|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33905671|NCT01005472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905672|NCT04330235|||OTHER||PROSPECTIVE|||||||
33905673|NCT01547845|||CASE_ONLY||PROSPECTIVE|||||||
33905674|NCT05634590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905675|NCT00536731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905676|NCT03881917|||COHORT||PROSPECTIVE|||||||
33905677|NCT04814355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905678|NCT00502905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905679|NCT03338387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905680|NCT04018014|||COHORT||PROSPECTIVE|||||||
33905681|NCT00233220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905682|NCT01806870|NA|SINGLE_GROUP||OTHER||NONE||||||
33905683|NCT05910736|NA|SEQUENTIAL||PREVENTION||NONE||Stepped wedge||||
33905684|NCT02184416|||OTHER||OTHER|||||||
33905685|NCT01097330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905686|NCT01350778|||COHORT||PROSPECTIVE|||||||
33685409|NCT00983697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905687|NCT00959296|||COHORT||PROSPECTIVE|||||||
33905688|NCT03218852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33905689|NCT04051593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905690|NCT01348282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905691|NCT05942885|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905692|NCT04930640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33905693|NCT04561843|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33905694|NCT05690828|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905695|NCT01313026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905696|NCT01115946|RANDOMIZED|CROSSOVER||||NONE||||||
33905697|NCT04955145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905698|NCT04695730|RANDOMIZED|PARALLEL||TREATMENT||NONE|Statistician (data analyst) will be masked.|||||
33905699|NCT06693674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081885|NCT03523156|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixty-four kebeles (sub-districts) of Amhara will be randomized to receive annual mass treatment or annual mass treatment plus targeted treatment. One gott (village) per kebele will be selected and 50 children from each gott will be randomly selected.||||
33685410|NCT02792621|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33685411|NCT02755532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33685412|NCT05344755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685413|NCT04971330|||OTHER||OTHER|||||||
33685414|NCT00693875|||COHORT||PROSPECTIVE|||||||
33685415|NCT05979532|||COHORT||PROSPECTIVE|||||||
33905700|NCT02998892|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33905701|NCT01401426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081886|NCT05202834|||CASE_ONLY||PROSPECTIVE|||||||
34081887|NCT01811238|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34081888|NCT00830128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685416|NCT03643614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685417|NCT04048161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685418|NCT06521879|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned via simple randomization method (computer- generated random number sequence)||||
33685419|NCT05441306|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33905702|NCT02045277|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33685420|NCT00397943|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33685421|NCT03188042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685422|NCT00928122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685423|NCT04281238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905703|NCT02538237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905704|NCT06194201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905705|NCT03997539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905706|NCT06058494|||COHORT||PROSPECTIVE|||||||
33905707|NCT02916784|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33905708|NCT03572543|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33905709|NCT01653366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33905710|NCT05741593|||OTHER||PROSPECTIVE|||||||
33905711|NCT05718791|||COHORT||PROSPECTIVE|||||||
33905712|NCT02853331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905713|NCT01854983|||CASE_ONLY||PROSPECTIVE|||||||
33905714|NCT00493116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905715|NCT00669539|||COHORT||PROSPECTIVE|||||||
33905716|NCT06691529|||CASE_CONTROL||PROSPECTIVE|||||||
34081889|NCT04654013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study personnel assessing trial outcomes will be masked as to participants assignment, which will be simplified by the fact that there will be participants with and without glasses at both Intervention and Control. It is not ethical in this setting to provide Control participants with placebo treatment (glasses with zero power lenses), but participants will not be informed of either the overall design of the study or the explicit treatment intervention assignment.|1260 workers aged 30 years and above with uncorrected presbyopia will be randomized to receive free glasses within one week of undergoing vision assessment, or free glasses at the end of the study assessment (18 months after vision assessment).|f|f|t|t
34081890|NCT06380062|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33905717|NCT06692504|||COHORT||RETROSPECTIVE|||||||
33905718|NCT04857398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905719|NCT04960566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905720|NCT05650099|||CASE_ONLY||PROSPECTIVE|||||||
33905721|NCT06168864|||COHORT||RETROSPECTIVE|||||||
33905722|NCT06693869|||COHORT||RETROSPECTIVE|||||||
33905723|NCT03570840|||COHORT||CROSS_SECTIONAL|||||||
33905724|NCT02205970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|one arm study||t|f|f|t
33905725|NCT03864172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind study|Randomised controlled Trial|t|t|t|t
33905726|NCT04558645|||CASE_CONTROL||PROSPECTIVE|||||||
33905727|NCT01099839|RANDOMIZED|CROSSOVER||||NONE||||||
33905728|NCT03569423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, consecutive, nonrandomized case-control comparative study.||||
33905729|NCT06692244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905730|NCT05615597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905731|NCT06176963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905732|NCT06410781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|Radial Extracorporeal Shockwave Therapy and traditional therapy|f|f|t|t
34081891|NCT03614104|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34081892|NCT04388410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Encasement of plasma and saline bags with an identical material will be done in Blood bank|Randomized, double-blinded, multicenter, placebo-controlled study|t|t|t|t
34081893|NCT06293742|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081894|NCT05861375|||CASE_ONLY||PROSPECTIVE|||||||
34081895|NCT04415346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081896|NCT00568971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081897|NCT03447548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Randomized controlled trial with intervention versus active control|t|f|f|t
34081898|NCT02402374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081899|NCT03060473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind|Allocation: Randomized Intervention model: Parallel Assignment|f|f|f|t
34081900|NCT05224700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In all evaluations, the evaluators will be blind to the trial arm where the schools/students were allocated|Single-blinded, two-arm randomized controlled trial clinical|f|f|f|t
34081901|NCT04175171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081902|NCT03644017|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm treated with investigational device WRAPSODY Stent Graft||||
34081903|NCT05405790|||COHORT||RETROSPECTIVE|||||||
34081904|NCT04044118|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34081905|NCT00239720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34081906|NCT00481884|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34081907|NCT02806440|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34081908|NCT06394908|||OTHER||PROSPECTIVE|||||||
34081909|NCT00405301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081910|NCT05899530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Invisalign versus conventional expander|Expansion of maxillary arch by 2 different techniques including conventional expander in one group compared with expansion with clear aligner.|f|f|f|t
34081911|NCT05549596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081912|NCT06011863|||COHORT||CROSS_SECTIONAL|||||||
34081913|NCT01658280|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34081914|NCT00416273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081915|NCT02035540|||OTHER||PROSPECTIVE|||||||
34081916|NCT06458348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33685424|NCT03876301|||COHORT||PROSPECTIVE|||||||
33685425|NCT02600754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685426|NCT05356728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The doctors who examine the patients will not get any information about the choice of artificial tears in each eye.||f|f|t|f
33685427|NCT03761771|||CASE_ONLY||PROSPECTIVE|||||||
33905733|NCT06511986|||COHORT||OTHER|||||||
33905734|NCT05906316|||COHORT||PROSPECTIVE|||||||
33905735|NCT04530812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905736|NCT01583582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905737|NCT04559581|||COHORT||PROSPECTIVE|||||||
33905738|NCT00779090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33905739|NCT06074458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905740|NCT06026254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905741|NCT03479879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081917|NCT00743210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081918|NCT04773275|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort consecutive case series||||
34081919|NCT00259935|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081920|NCT00133198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34081921|NCT02625701|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Patients, clinical care givers and assessors are blinded to the the treatment (GDT or restrictive).~Sealed enveloppes contain the patient' identification number. A person not involved in the study prepare the enveloppes with the identification number.~Investigators who are assessing the postoperative study outcomes are blinded to the treatment arms"||t|f|f|f
34081922|NCT05117853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Simple blind (Only participant)|Single-center, comparative, randomized, single-blind, controlled trial against the gold standard of visual identification and viability evaluation.|t|f|f|f
33685428|NCT00005566||||DIAGNOSTIC||||||||
33685429|NCT06191211|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33685430|NCT00201370|||COHORT||RETROSPECTIVE|||||||
33685431|NCT05785910|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685432|NCT04473482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33685433|NCT03239561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685434|NCT00174772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905742|NCT00443404|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33905743|NCT02165631|||COHORT||PROSPECTIVE|||||||
33905744|NCT01052597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33905745|NCT04328064|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33905746|NCT03630614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Randomized, placebo and reference treatment controlled, multicenter, double blind, double dummy, parallel group, pivotal, phase III trial.|t|t|t|t
33905747|NCT05711667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33685435|NCT05897333|||CASE_CONTROL||PROSPECTIVE|||||||
33685436|NCT01837771|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685437|NCT02263170|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685438|NCT02095314|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33685439|NCT05148520|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685440|NCT05171829|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statistician masking|||||
33685441|NCT00600054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685442|NCT00593580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33685443|NCT00921245|||COHORT||PROSPECTIVE|||||||
33685444|NCT02323360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685445|NCT01302977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685446|NCT01649843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685447|NCT06224751|||OTHER||PROSPECTIVE|||||||
33685448|NCT04590248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685449|NCT00853268|RANDOMIZED|PARALLEL||||NONE||||||
33685450|NCT00064675|||COHORT||CROSS_SECTIONAL|||||||
33685451|NCT02764190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33685452|NCT02249845|||COHORT||PROSPECTIVE|||||||
33685453|NCT01931709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685454|NCT00158821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685455|NCT04309123|NA|SINGLE_GROUP||TREATMENT||NONE||Open label observational study||||
33685456|NCT05770674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685457|NCT05121571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685458|NCT03619811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685459|NCT05260346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double (Participant, Investigator)|Parallel assignment|t|f|t|f
33685460|NCT06398405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685461|NCT05810818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33685462|NCT00450385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685463|NCT02208401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33685464|NCT00479921|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33685465|NCT00001282||||TREATMENT||||||||
33685466|NCT05277480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685467|NCT04824716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33685468|NCT02707159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685469|NCT04387643|||OTHER||PROSPECTIVE|||||||
33685470|NCT00040456|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33685471|NCT05884632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685472|NCT06482242|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The research team will utilize a stepped wedge randomized clinical trial with 8 clinic/community sites, each recruiting 40 participants, for a total of 320 participants. Each site will transition from control (pre-intervention) to intervention (post-intervention) in a randomized, stepwise fashion. Sites are randomly assigned to different start times (in 4-week intervals) for the intervention, ensuring that every site eventually receives the intervention, while maintaining methodological rigor. From Weeks 0-4, baseline recruitment and pre-intervention survey administration will occur at all 8 sites. In Weeks 5-8 (Time Period 1), participants at Site 1 will start the intervention (each consented participant will be emailed a link to MBAL and the post-intervention survey upon completion.) In Weeks 9-12 (Time Period 2), participants at Site 2 will start the intervention, while Site 1 continues to recruit until 40 participants are enrolled in the study, and this pattern will continue.||||
33685473|NCT05384977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685474|NCT01089361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685475|NCT01991639|RANDOMIZED|PARALLEL||||NONE||||||
34081923|NCT06171893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single-arm, controlled, multicentre trial, will be conducted to validate to study objective. The study is divided into five iterative substudies of which the first four are aimed towards improving the application, based on the quantitative data from the smartwatch and the qualitative feedback of the users whilst also validating the recent version through assessing the interim study outcomes.||||
34081924|NCT02143232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34081925|NCT05010278|||OTHER||PROSPECTIVE|||||||
34081926|NCT00781846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081927|NCT00915174|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34081928|NCT02686853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081929|NCT03805594|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34081930|NCT01288690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081931|NCT03721757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081932|NCT01329198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Programming to be performed for this study by the programming investigator under the supervision of the PI|Prospective blinded staggered onset design|t|t|f|t
34081933|NCT02560168|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34081934|NCT00368628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081935|NCT03087864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081936|NCT03286920|||COHORT||PROSPECTIVE|||||||
34081937|NCT03073772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081938|NCT00535613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081939|NCT00001328||||TREATMENT||||||||
34081940|NCT02513550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081941|NCT00213681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081942|NCT05590169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081943|NCT00086190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34081944|NCT02431689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081945|NCT03246464|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controled clinical interventional trial||||
34081946|NCT02112214|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34081947|NCT05734261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each subject is his or her own control||||
34081948|NCT05862935|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The persons analyzing the data collected (investigators, statician) will not know to which group each person belongs.|Non-randomized controlled trial|f|f|t|t
34081949|NCT00402831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081950|NCT00626288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34081951|NCT02065180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34081952|NCT01549145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081953|NCT06325163|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34081954|NCT00344695|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34081955|NCT01376869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33685476|NCT01138943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33685477|NCT05623488|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905748|NCT04299399|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33905749|NCT04399967|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33905750|NCT03899896|||COHORT||PROSPECTIVE|||||||
33905751|NCT01723501|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33905752|NCT01461863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905753|NCT00406640|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33905754|NCT04632784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905755|NCT01373567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905756|NCT03958968|||COHORT||PROSPECTIVE|||||||
33905757|NCT06348420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905758|NCT03949049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33905759|NCT02515591|||COHORT||PROSPECTIVE|||||||
33905760|NCT05057585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This research was conducted as a prospective and experimental study|t|t|t|t
33905761|NCT01345786|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33905762|NCT06384807|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation followed by enrollment in signal-finding cohorts.||||
33905763|NCT04267562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905764|NCT03693287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients/Parents/Legal guardian will be masked. The statistician will be also masked when analyzing the data.||t|f|f|f
33905765|NCT04114994|||COHORT||PROSPECTIVE|||||||
34081956|NCT00611585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081957|NCT05426746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Site, Clinical Research Organization and Sponsor personnel are are blinded except for unblinded pharmacist staff, unblinded Project Manager, unblinded Monitor and unblinded statistician|First in human, randomized, double-blind, placebo-controlled, multi-cohort healthy volunteer trial|t|t|t|t
34081958|NCT03820401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34081959|NCT05956041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081960|NCT06405919|||COHORT||PROSPECTIVE|||||||
34081961|NCT03319498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|t|t|f|f
34081962|NCT03156075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34081963|NCT01525589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081964|NCT03256617|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Pre-post test design for the therapists followed by a prospective cohort of patients.~We anticipate 50 physical therapy providers and 150 patients for a total of 200 participants."||||
34081965|NCT05287789|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||pretest-posttest time series model with the different control group|f|f|t|t
34081966|NCT04074265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgeon, participant, and all nursing staff involved in recording post-operative outcomes will be blinded to treatment group allocation.|Patients will be assigned to either treatment/intervention group or placebo. All other aspects of care will be identical between the two groups.|t|t|t|f
34081967|NCT04733924|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33685478|NCT04344743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081968|NCT04577066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Phase 1 will be an open label trial, Phase 2 will be a double-blind trial.|"This trial has both a sequential as well as a parallel interventional study model.~The safety and tolerability of the GA2 parasite will be assessed in phase 1 by means of a sequential study model. There will be 2 cohorts, which will be recruited sequentially and exposed to increasing numbers of infected mosquito bites.~The preliminary protective efficacy of the GA2 parasite will be assessed in phase 2 by means of a parallel study model. There will be 3 groups of volunteers, who will be exposed to either GA2-infected, GA1-infected or uninfected mosquito bites."|t|f|t|f
33685479|NCT05578001|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685480|NCT06463275|||OTHER||PROSPECTIVE|||||||
33685481|NCT02127268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685482|NCT01610375|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33905766|NCT05872438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Comparison of screening for two hypothesis:~How many and what percentage of additional STI are diagnosed with the 3 sites sampling compared to the vaginal sampling alone?"||||
33905767|NCT00984802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685483|NCT02188043|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33685484|NCT01307020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685485|NCT00656071|||CASE_CONTROL||RETROSPECTIVE|||||||
34081969|NCT05572203|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33685486|NCT01280201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685487|NCT06112964|||COHORT||OTHER|||||||
33685488|NCT00801307|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33685489|NCT00923949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775213|NCT06565169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The PI and all personnel involved in the outcomes assessment will remain masked to study arm assignment until the end of the study, while the UNC site co-investigators will deliver training and feedback reports to intervention sites and will not be masked.||f|f|t|t
33775214|NCT00422721|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775215|NCT06739148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775216|NCT06631417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Study has 2 parts, participants cross over between 3 treatments||||
33775217|NCT02398747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775218|NCT06501794|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33775219|NCT06532747|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a 2-arm, parallel randomized controlled pilot trial designed to test the preliminary efficacy of a novel integrated lifestyle intervention for emerging adult (EA) women, compared to a developmentally adapted behavioral weight loss arm.|f|f|t|t
33775220|NCT05704322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial.||||
33775221|NCT04871919|||COHORT||PROSPECTIVE|||||||
33775222|NCT06734338|||COHORT||PROSPECTIVE|||||||
33905768|NCT01539837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905769|NCT03795155|||COHORT||PROSPECTIVE|||||||
33905770|NCT05314166|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33905771|NCT02890199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905772|NCT03009656|||CASE_ONLY||PROSPECTIVE|||||||
33775223|NCT02807805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775224|NCT06738901|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33775225|NCT05234177|||CASE_ONLY||PROSPECTIVE|||||||
33905773|NCT02112162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905774|NCT03013491|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905775|NCT04738513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33905776|NCT02697955|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33905777|NCT02020343|||CASE_CONTROL||PROSPECTIVE|||||||
33905778|NCT01757704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33905779|NCT00230581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33905780|NCT01697527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905781|NCT02805218|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33905782|NCT06554457|||CASE_ONLY||PROSPECTIVE|||||||
34081970|NCT06552208|||COHORT||RETROSPECTIVE|||||||
34081971|NCT03092427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081972|NCT02027025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081973|NCT03802552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34081974|NCT01763541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34081975|NCT00310986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081976|NCT01171378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081977|NCT03634319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."||||
34081978|NCT03516565|||CASE_CONTROL||PROSPECTIVE|||||||
34081979|NCT00177125|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34081980|NCT04895501|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34081981|NCT00463645|||DEFINED_POPULATION||PROSPECTIVE|||||||
34081982|NCT05458310|||COHORT||RETROSPECTIVE|||||||
34081983|NCT04789304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"As this is a Multiple Rising Dose (MRD) trial, blinded individuals will be aware of the current dose level.~All individuals are unblinded regarding the midazolam administration."||t|t|t|f
34081984|NCT06429904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905783|NCT02371733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33905784|NCT05904886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905785|NCT00188500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905786|NCT06514469|||CASE_CONTROL||PROSPECTIVE|||||||
33775226|NCT06714578|||OTHER||CROSS_SECTIONAL|||||||
33775227|NCT02712840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988182|NCT03175718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The operative team will remain blinded to the dressing until the time of application. Since wound failure requires the need of medical or surgical intervention, primary outcome of this study is not blinded. However, the treatment arm will be blinded to the Research Coordinator/Outcomes Assessor of secondary outcomes including scar assessment, QoL and Functional Assessment.|This is a Canadian multicenter superiority randomized clinical trial in patients who are scheduled to undergo surgical resection of a soft tissue sarcoma treated with either preoperative or postoperative radiation therapy and a primary closure. The participants are randomized to Incisional Negative Pressure Wound Therapy (Acelity) or conventional gauze dressing; the current standard of care.|t|f|f|t
33775228|NCT06357182|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The treatment plan starts with a 7 day monotherapy lead-in (Cycle 0 \[C0\]) and then proceeds to combination therapy in 28 day cycles. Disease will be assessed pre-treatment (Screening/Baseline), at the end of monotherapy, in C1 (and C2, if response is not observed in C1), and at the end of alternating cycles, thereafter. A disease assessment will also be conducted within 30 days of the last dose of IADA. Participants that do not achieve response after up to 2 cycles of the triplet regimen will be taken off treatment.||||
33775229|NCT03308903|||COHORT||CROSS_SECTIONAL|||||||
33775230|NCT01385722|||COHORT||PROSPECTIVE|||||||
33775231|NCT03863899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775232|NCT01398501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775233|NCT06719778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775234|NCT00075803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775235|NCT05257551|||CASE_ONLY||PROSPECTIVE|||||||
33775236|NCT06737172|||COHORT||PROSPECTIVE|||||||
33775237|NCT06739772|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33988183|NCT04140318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775238|NCT06177795|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||"For the Penn trial, primary care clinics will be randomized 2:1 to the intervention arm or control arm using covariate-constrained randomization. Patients identified as at high-risk for non-completion of breast cancer screening will be additionally randomized 1:1 at the individual level to receive an additional intensification nudge compared with the multi-component nudge intervention alone. Penn Medicine is expected to enroll approximately 15,000 patients.~For the UH trial, primary care providers will be randomized 1:1 to the intervention or control arm using covariate-constrained randomization. UH is expected to enroll approximately 6,416 patients."|f|f|t|t
33905787|NCT03891069|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A mix-methods study, including two focus groups (with patients and physiotherapists) and quantitative feasibility study, will performed. Physiotherapists and PD patients with a Hoehn Yahr Stage ≤ 2 (MED ON), ability to walk independently without risk of falling and a Mini-mental state score \> 24 will be included. The primary outcome will be patients' satisfaction with the games measured through a 7-point Likert scale. Secondary outcomes will include: games difficulty (7-point Likert scale), perceived effort (modified Borg scale), safety (number of adverse events) and functional mobility (Time up and Go test).||||
33905788|NCT03238144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905789|NCT01519570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905790|NCT04012268|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33905791|NCT02804802|||COHORT||PROSPECTIVE|||||||
33905792|NCT05375903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905793|NCT01253512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905794|NCT05666011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Investigator will be unaware of which arm received which treatment|Enrolled subjects will be randomized to combination treatment with IPL activation of SNA (i.e. intervention arm) versus IPL alone (i.e. control arm).|f|f|t|f
33905795|NCT00345553|||COHORT||PROSPECTIVE|||||||
33905796|NCT03791983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775239|NCT05723575|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775240|NCT06739525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33775241|NCT02055248|||COHORT||CROSS_SECTIONAL|||||||
33775242|NCT04607421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775243|NCT01117597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33905797|NCT00731445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905798|NCT06455787|NA|SINGLE_GROUP||TREATMENT||NONE||The investigation is a prospective, single arm, multi-center, interventional pivotal study.||||
33905799|NCT04160156|||COHORT||PROSPECTIVE|||||||
33905800|NCT03574896|||COHORT||PROSPECTIVE|||||||
33905801|NCT01863264|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33905802|NCT00373971|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33905803|NCT06326840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905804|NCT00364663|||DEFINED_POPULATION||OTHER|||||||
33905805|NCT03819179|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33905806|NCT03771144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775244|NCT05854836|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will randomize the ten 90-day court-mandated substance use disorder treatment cohorts to receive CHOICES-PLEAS (45 women) or brief advice and referral (45 women) over a 2.5 year period using a matching process before randomization to achieve balance between cohorts in the intervention and control groups. Ninety-day cohorts run sequentially. The treatment cohorts will be divided into two cells by program start time within the study period. The first 5 cohorts will be placed in cell one and the second 5 cohorts in cell two. Cohorts will be randomly selected within each of these two cells to be assigned to either the intervention or control group to ensure 5 cohorts will receive CHOICES-PLEAS (9 women per cohort, n=45) and 5 will receive brief advice and referral (9 women per cohort, n=45).||||
33775245|NCT03857711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905807|NCT03222479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Healthy individuals recruited through advertisement||||
33905808|NCT06692868|||CASE_ONLY||OTHER|||||||
33905809|NCT02152865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905810|NCT04747574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905811|NCT02284334|||CASE_CROSSOVER||PROSPECTIVE|||||||
33905812|NCT00867243|||COHORT||PROSPECTIVE|||||||
33905813|NCT06041529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905814|NCT03645837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905815|NCT06321536|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33905816|NCT03704883|||CASE_ONLY||PROSPECTIVE|||||||
33905817|NCT05878938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905818|NCT06631833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33905819|NCT00403702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33905820|NCT06684847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905821|NCT04841499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905822|NCT03614429|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparative experimental (interventional) controlled study||||
33905823|NCT02556645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905824|NCT03313505|||COHORT||PROSPECTIVE|||||||
33905825|NCT01175551|||COHORT||PROSPECTIVE|||||||
33905826|NCT04445467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905827|NCT00858702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905828|NCT03355625|||COHORT||PROSPECTIVE|||||||
33905829|NCT00112151|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33905830|NCT01983345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905831|NCT04489771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905832|NCT00216606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33905833|NCT01679145|||CASE_CONTROL||PROSPECTIVE|||||||
33905834|NCT00812916|||COHORT||PROSPECTIVE|||||||
33988184|NCT00858793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988185|NCT01549353|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33988186|NCT00263588|NON_RANDOMIZED|||TREATMENT||NONE||||||
34081985|NCT03043456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|"The study will be blinded regarding the statistician who is responsible for data analysis.~The participant patients will be blinded. The outcome assessor for patient satisfaction can be blinded during the questionnaire. On the other hand, Microbial count assessor will not be blinded during swab taking while the lab technician can be blinded. but The operator cannot be blinded."|prospective , parallel, randomized clinical trial|t|t|f|t
34081986|NCT02515435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34081987|NCT01305811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34081988|NCT04261140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34081989|NCT00225875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34081990|NCT05446285|||COHORT||PROSPECTIVE|||||||
34081991|NCT02092753|NON_RANDOMIZED|PARALLEL||||NONE||||||
34081992|NCT02198534|||COHORT||PROSPECTIVE|||||||
34081993|NCT04535427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34081994|NCT02814071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34081995|NCT02669706|||COHORT||PROSPECTIVE|||||||
34081996|NCT05985863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34081997|NCT01548807||||TREATMENT||||||||
34081998|NCT05847608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34081999|NCT04420091|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34082000|NCT01521000|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34082001|NCT03182309|||CASE_CONTROL||PROSPECTIVE|||||||
34082002|NCT00612820|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34082003|NCT05880706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082004|NCT02976883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082005|NCT01206465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082006|NCT03292016|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082007|NCT02138565|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082008|NCT06273488|||COHORT||PROSPECTIVE|||||||
34082009|NCT04176224|NA|SINGLE_GROUP||OTHER||NONE||||||
34082010|NCT04166071|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33988187|NCT04606628|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|One of the employees will distribute the capsules and know which of the group is placebo and intervention. Everyone else involved in the project will be blinded for this knowledge.|This study is a randomized double-blinded controlled trial and is considered as a pilot study.|t|t|t|t
33988188|NCT04926805|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988189|NCT03998605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988190|NCT02225314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988191|NCT00387686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988192|NCT05491798|||COHORT||PROSPECTIVE|||||||
33988193|NCT01779544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988194|NCT04106193|RANDOMIZED|CROSSOVER||SCREENING||NONE||Hybrid type II implementation-effectiveness design; stepped wedge||||
33988195|NCT00747565|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988196|NCT03781739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988197|NCT01114893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988198|NCT04807439|||COHORT||PROSPECTIVE|||||||
33988199|NCT01097577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988200|NCT05091645|||COHORT||PROSPECTIVE|||||||
33905835|NCT05774457|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|Masking does not apply.|Participants will be randomized to either traditional voice intervention in the clinic or to voice intervention using virtual reality. Pre- and post-intervention measures will be made regarding acquisition, retention, and transfer of voice skills in the two conditions.||||
33988201|NCT02514876|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33905836|NCT01501578|||CASE_CONTROL||RETROSPECTIVE|||||||
33988202|NCT02419898|||COHORT||PROSPECTIVE|||||||
33988203|NCT03388853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988204|NCT04093505|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||The two research questions are addressed in a 2 by 2 factorial design. Patients are upfront randomized for the two induction schedules (GO-147 versus GO-1, ratio 1:1) and for Glasdegib or Placebo (double blinded, ratio 1:1) as adjunct to consolidation therapy and as single agent 6 months maintenance therapy.|t|t|t|t
33988205|NCT02161445|||CASE_CONTROL||PROSPECTIVE|||||||
33988206|NCT02235935|||COHORT||PROSPECTIVE|||||||
33988207|NCT05435391|||COHORT||PROSPECTIVE|||||||
33988208|NCT03733730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1 completed prior to the initiation of Arm 2. Within each arm, IOL assignment was parallel.||||
33988209|NCT03944447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082011|NCT05036226|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be enrolled in sequence of dose levels.||||
33905837|NCT04532463|||OTHER||PROSPECTIVE|||||||
33905838|NCT03491163|||CASE_ONLY||PROSPECTIVE|||||||
33905839|NCT01454401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905840|NCT06569082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905841|NCT04840654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be an observer-blinded RCT. The surgeon, regional pediatric anesthesiologist, and operating room staff (anesthesiologists and nurses) will not be blinded to the treatment group. However, the patient and family, recovery room nurses, and study coordinator who collects the data from families will be blinded|Subjects will be randomized to 2 groups. One group will receive the Caudal block. The other group will receive the Pudendal block.|t|f|f|t
33905842|NCT00624130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33905843|NCT06374498|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905844|NCT04591314|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905845|NCT06097195|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33905846|NCT05556382|||COHORT||PROSPECTIVE|||||||
33905847|NCT01605396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082012|NCT03899727|||OTHER||CROSS_SECTIONAL|||||||
34082013|NCT02902835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082014|NCT04724746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685490|NCT01989260|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33685491|NCT02763592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685492|NCT05757362|NA|SINGLE_GROUP||OTHER||NONE||||||
33685493|NCT01924702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082015|NCT05768646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082016|NCT01805661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33685494|NCT02576769|||CASE_ONLY||PROSPECTIVE|||||||
33685495|NCT04074876|||COHORT||PROSPECTIVE|||||||
33685496|NCT00950261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685497|NCT05147779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685498|NCT05578027|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||A pilot study|t|f|f|f
33685499|NCT05011279|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685500|NCT04823416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685501|NCT04413227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685502|NCT01141777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33721361|NCT04846790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|All study team members and participants will be blind to group allocation with the exception of one research assistant who will not be involved in providing the intervention to the participants or data analysis. There is no outcome assessor, outcomes will be self-reported.|This is a Phase III, randomized controlled trial, whereby ninety healthcare workers will be randomized into one of three groups: Nature+Mindfulness (n=30), Nature only (n=30), and Control (n=30).|t|t|t|t
34082017|NCT01833676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082018|NCT02858466|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905848|NCT04913259|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33905849|NCT03517046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082019|NCT03463083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|An online randomization program (http://www.randomizer.org) will be used to generate random list and to allocate patients into the study groups. Random allocation numbers will be concealed in opaque closed envelops. The patient and investigator assessing study outcomes will all be blinded to the study groups allocation. The study drugs will be prepared by a separate investigator not involved in outcome assessment|"This double-blind, prospective, randomised clinically controlled study is designed to study the efficacy of epidural analgesia of dexmedetomidine and compare the analgesic effect of its epidural injection with bupivacaine versus fentanyl with bupivacaine in the post operative period of elective spine surgeries.~To determine if the epidural route provide an acceptable analgesia in spine surgeries and avoided the need for excessive IV analgesics. Also to determine whatever dexmedetomidine or fentanyl is more better neuroaxial adjuvant regarding providing early onset and prolonged analgesia and stable cardiorespiratory parameters."|t|t|f|f
34082020|NCT02707003|||COHORT||PROSPECTIVE|||||||
34082021|NCT04282174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The two myeloablative conditioning regimens are:~Regimen A: Hyperfractionated Total Body Irradiation/Thiotepa/Cyclophosphamide: 100 patients Regimen B: Busulfan/Melphalan/Fludarabine: 100 patients It is anticipated that the accrual will last five years. Patients will be followed for two years following transplantation."||||
34082022|NCT02683109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905850|NCT06368921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082023|NCT00643552|||COHORT||CROSS_SECTIONAL|||||||
34082024|NCT03704064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082025|NCT06473441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082026|NCT02321852|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34082027|NCT05438563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082028|NCT03609463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A researcher adequately trained in the administration of questionnaires and interviews, and blinded to the experimental allocation of patients, will carry out all the evaluations.||f|f|f|t
34082029|NCT04971499|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905851|NCT03242096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded QCA for primary outcome|"Experimental intervention: Predilatation of coronary ISR with POBA followed by a sirolimus coated SeQuent® SCB balloon balloon (sirolimus 4.0 μg/mm²)~Control intervention: Predilatation of coronary ISR with POBA followed by a paclitaxel coated SeQuent® Please balloon or SeQuent® Please NEO balloon (paclitaxel 3.0 μg/mm²)"|f|f|f|t
33905852|NCT06693401|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Physiotherapy Intervention rehabilitation program was implemented in both study groups in accordance to the usual physiotherapeutic rehabilitation approach through a programme according to the European and American Guidelines for Physical Therapy in Parkinson's Disease, with the purpose of improving balance and reducing the risk of falls, enhancing mobility and motor function, managing muscle stiffness and rigidity, addressing gait abnormalities, and providing education and support.~Occupational Therapy rehabilitation program was implemented only in the Intervention Group, through handbooks for handwriting occupational therapy exercises in Portuguese language, with exercises to be performed for about 45 minutes, three times a week. Each participant was offered a kit with all the materials needed to perform the handwriting and fine motor skills exercises (1 ping-pong ball, 1 anti-stress ball, 1 plastic coin, 2 rubber bands, 2 beans and 10 paper clips)."|f|f|f|t
33905853|NCT06691308|NA|SEQUENTIAL||TREATMENT||NONE||||||
33905854|NCT00259259|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33905855|NCT04449068|||COHORT||PROSPECTIVE|||||||
33905856|NCT03408847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will receive a bottle with experiental oil or placebo, consisting of commercial refined olive oil. No diffencences between the two bottles.|Pilot study|t|f|t|f
33905857|NCT06353945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905858|NCT03252639|||COHORT||PROSPECTIVE|||||||
33905859|NCT05346393|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment 1:1-randomization, parallel design, stratified by center and AKI stage.||||
33905860|NCT01372878|NA|SINGLE_GROUP||SCREENING||DOUBLE|||f|f|t|t
33905861|NCT00651118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905862|NCT06051253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905863|NCT00540176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905864|NCT00069095|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33905865|NCT00005022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905866|NCT03318107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905867|NCT05534555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905868|NCT00198341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905869|NCT06561958|||COHORT||PROSPECTIVE|||||||
33905870|NCT04015297|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33905871|NCT02583672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905872|NCT06282757|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33905873|NCT01082913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33905874|NCT05019235|||COHORT||RETROSPECTIVE|||||||
33905875|NCT02316470|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33905876|NCT06580067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905877|NCT06095973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||sequential|t|f|f|f
33905878|NCT04359823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905879|NCT03501706|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33905880|NCT04185324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Preschoolers are not aware of whether they receive zippering instruction using a standard teaching zippering vest or the modified one. The parents were not aware which group their child was put in. All children received extra practice with zippering, in both groups.|two cohort|t|t|f|f
33905881|NCT02844582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905882|NCT03549273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905883|NCT03960710|||COHORT||RETROSPECTIVE|||||||
33905884|NCT01676480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905885|NCT05314595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905886|NCT03543891|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33905887|NCT03170336|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||All patients need to be on an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) daily at least four weeks prior to the study. The baseline data would be recorded. Patients enrolled will receive either amiloride or hydrochlorothiazide first for 8 weeks.Then the patients will discontinue amiloride or hydrochlorothiazide for a washout for 4 weeks, but continue with ACEI(angiotensin-converting enzyme inhibitor ) or ARB. After that patients will cross over to receive another medication for another 8 weeks.|t|f|t|f
33905888|NCT05635084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33905889|NCT05269134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind||t|t|t|f
33905890|NCT06551324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905891|NCT00788658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905892|NCT06511713|||COHORT||CROSS_SECTIONAL|||||||
33905893|NCT05720611|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33905894|NCT01099410|||CASE_ONLY||PROSPECTIVE|||||||
33988210|NCT05288881|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Placebo-controlled single ascending dose study.|t|f|t|f
33988211|NCT03134222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988212|NCT01493466|||||PROSPECTIVE|||||||
33988213|NCT03327545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988214|NCT00020605||||SUPPORTIVE_CARE||||||||
33905895|NCT06692075|RANDOMIZED|PARALLEL||TREATMENT||NONE|Data and Safety Monitoring Committee|Two arms are designed. One is the total ECLS arm to start emergency ECMO supported cardiopulmonary resuscitation immediately after the arrival of eligible OHCA patients at the emergency department. The other is the standard ACLS arm to start standard ACLS cardiopulmonary resuscitation for at least 45 minutes from collapse and 119 call or at least 15 minutes after arrival at the emergency department.||||
33905896|NCT02911064|||COHORT||PROSPECTIVE|||||||
33905897|NCT05895825|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33905898|NCT02531269|||COHORT||RETROSPECTIVE|||||||
33905899|NCT00500045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905900|NCT01203904|||COHORT||PROSPECTIVE|||||||
33988215|NCT02593357|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988216|NCT01423994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988217|NCT03965286|||COHORT||PROSPECTIVE|||||||
33988218|NCT01139047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33988219|NCT03421834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988220|NCT03936556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988221|NCT05084677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988222|NCT01242774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988223|NCT02713425|NA|SINGLE_GROUP||OTHER||NONE||||||
33988224|NCT03212339|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905901|NCT04209868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be randomised on the day of surgery to the 'pre-PVB LA' or 'pre-PVB saline' arm, by a study investigator, with a 1:1 randomisation ratio using 'Sealed Envelope' (www.sealedenvelope.com) online software. Each subject will receive a unique randomization code in an envelope that will only be opened during the preparation of the pre-PVB injectate.~A non-blinded research nurse, will prepare the pre-PVB injectate in a standard syringe according to the allocation, labelled by participant number, in a theatre location concealed from the operating room and staff.~The anaesthetist, the surgeon and theatre team, recovery staff, and the researchers performing all the outcome assessments will be separate and blinded to the group allocation. The PVB catheter will be taped as normal before connecting the post-PVB LA infusion pump.~We have elected to perform an interventional placebo intervention as opposed to a sham control to minimize observer bias."|"The study will be conducted at Guy's Hospital, London, United Kingdom (UK), a large tertiary thoracic centre for London, Sussex, Kent and Berkshire. In 2015, 459 lung cancer resection operations were performed; 8% of all lung cancer resections in England.~Criteria for discontinuation/withdrawal or modifying allocated treatment:~* Participant request to withdraw from the study.~* Intraoperative identification of infection/tumour in paravertebral space~Patient recruitment Eligible patients will be identified in the catchment outpatient clinics 4-6 weeks before surgery. The participant information sheet (PIS) will be introduced in the standard surgical booklet given by the surgeon. At the preoperative assessment clinic 2-3 weeks before surgery, a face-to-face discussion with the research nurse will support the PIS; the opportunity to ask any questions and contact a PPI (Patient and Public Involvement) representative and will be given. Written informed consent will be obtained."|t|t|t|t
33988225|NCT01816490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905902|NCT03121742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33905903|NCT00057616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33905904|NCT01411293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33905905|NCT04794699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905906|NCT00158652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905907|NCT03968367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988226|NCT06066476|||CASE_ONLY||PROSPECTIVE|||||||
33988227|NCT00738049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33988228|NCT01512823|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33988229|NCT04737486|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind|Single and multiple ascending dose|t|t|t|t
33988230|NCT00789230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Suture versus mesh repair in umbilical hernia patients|t|f|t|t
33905908|NCT02460822|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33988231|NCT03427944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988232|NCT05641961|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33721362|NCT02747706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721363|NCT03533452|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blinded, randomized controlled, prospective|t|t|t|f
33721364|NCT02074995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721365|NCT00128947||||TREATMENT||||||||
33721366|NCT03238404|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a single-center, parallel, open-label randomized controlled trial.||||
33988233|NCT01313780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721367|NCT01340144|||CASE_CONTROL||PROSPECTIVE|||||||
33721368|NCT05339503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721369|NCT02758015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33721370|NCT05965024|||COHORT||PROSPECTIVE|||||||
33721371|NCT02794662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721372|NCT00878007|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33721373|NCT03318250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721374|NCT02306629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988234|NCT01074541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33988235|NCT03467399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988236|NCT01771939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988237|NCT04430985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988238|NCT00498381|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988239|NCT05978557|||COHORT||PROSPECTIVE|||||||
33988240|NCT03133533|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive either laparoscopic or robot-assisted repair of inguinal hernia.||||
33775246|NCT06042257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A masked investigational pharmacist or designee will dispense study product according to randomization treatment assignments. All other site staff as well as participants and parents/legal guardians will also be masked for up to 8 weeks while the study participant is receiving study product.~Participants, parents/legal guardians, site staff, and study administrators will be unmasked at the 8 week study visit.~Emergency unmasking may occur at any time throughout the study in the event that knowledge of the actual treatment is absolutely essential for further management of the participant."|Participants will be randomized 2:1 to GIR or placebo.|t|t|t|f
33775247|NCT06572930|||CASE_ONLY||PROSPECTIVE|||||||
33775248|NCT05144256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775249|NCT06137183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775250|NCT05785624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775251|NCT05195710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905909|NCT06693193|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33905910|NCT01551563|||COHORT||PROSPECTIVE|||||||
33905911|NCT05193097|||COHORT||PROSPECTIVE|||||||
33905912|NCT05942898|||COHORT||CROSS_SECTIONAL|||||||
33905913|NCT05734547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessments will be conducted by a clinician from the study group that will be blind to treatment condition||f|f|t|t
33905914|NCT03515603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|only surgeon knows the used technique, endocrinologist, patient and all involved medical staff is blinded|prospective randomized|t|t|f|f
33905915|NCT02353078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905916|NCT01517789|NA|SINGLE_GROUP||||NONE||||||
33905917|NCT00308542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905918|NCT04215354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Potential participants were informed that they will be randomly allocated in one of the three study groups: the magnet (BEMER) group, virtual reality (Wii) group or the placebo group.||t|f|f|f
33905919|NCT06194435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person conducting the statistical analysis will be unaware of group identities, she will perform the data analysis without knowledge of which group received which treatment.|"Study Design: This study utilizes a randomized controlled parallel-design approach to evaluate the effectiveness of telemedicine methods in treating RCS compared to traditional in-person methods.~Participants: The study will include 102 participants aged 40 to 60 years diagnosed with RCS, confirmed through shoulder MRI, and unresponsive to conservative treatments. They are randomly assigned to two groups.~Intervention Group/Telemedicine Group: Remote assessments, video exercise program, and virtual follow-ups.~Control Group: In-person assessments, exercise program, and follow-ups.~Data Collection: Comprehensive documentation of clinical diagnoses and demographics, informed consent, and outcome measures (Quick-DASH and Numeric-VAS) are collected.~Outcome Measures: The study assesses pain levels, functional recovery, and overall treatment outcomes.~Analysis: Statistical analysis is conducted to compare treatment effectiveness between the two groups."|f|f|f|t
33905920|NCT03225586|||COHORT||PROSPECTIVE|||||||
33905921|NCT06486922|NA|SINGLE_GROUP||PREVENTION||NONE||Sequential, single arm, intervention development study.||||
33905922|NCT02045316|||CASE_CONTROL||PROSPECTIVE|||||||
33905923|NCT02237807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905924|NCT05017285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient does not know which type of surgery is used|"A prospective randomised multicentre single-blind comparative study of two parallel groups of patients scheduled for HoLEP prostate resection:~Group 1 Conventional HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).~Group 2 Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum Each patient will be evaluated five times during the study (D0, M1, M3, M6, M12) The total duration of the study is 2 years (1 year of recruitment and 1 year of follow-up)."|t|f|f|f
33905925|NCT00235729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33905926|NCT03244891||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33905927|NCT04786301|||COHORT||PROSPECTIVE|||||||
33905928|NCT04537390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988241|NCT00125086|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33988242|NCT05451069|||OTHER||CROSS_SECTIONAL|||||||
33988243|NCT05669781|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE||Patients were randomized into a gum-metoclopramide (GM) group, a gum-only (G) group, a metoclopramide-only (M) group and a control (C) group. Patients in the GM group chewed gum and received intravenous metoclopramide, each 8 hourly. In the G group, patients chewed only gum while those in the M group received 10mg of intravenous metoclopramide only. To the C group, 10ml of intravenous sterile water for injection was given 8 hourly|f|t|t|t
33988244|NCT00019591||||TREATMENT||||||||
33988245|NCT06197009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
33988246|NCT02409355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988247|NCT04316884|||COHORT||PROSPECTIVE|||||||
33988248|NCT02813018|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33988249|NCT04970420|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33988250|NCT05369884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and investigators were masked to group assignment. An independent statistician was masked for the data analysis.||t|f|t|t
33988251|NCT04362020|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988252|NCT04834440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988253|NCT06416826|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33988254|NCT01684774|||CASE_CONTROL||PROSPECTIVE|||||||
33905929|NCT04830995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was done by sealed envelope|group (A) received HIIT and low diet for four weeks, 3 sessions weekly. While the control group received diet only.|t|f|t|f
33905930|NCT00935220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905931|NCT00392444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905932|NCT00144001|||COHORT||RETROSPECTIVE|||||||
33905933|NCT03927534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33905934|NCT01450930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905935|NCT05552378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905936|NCT03654248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905937|NCT04715724|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants will not be aware which baby doll they will be assessing prior to presentation within the simulation. Standardized patients (SP) will know which baby doll to present during the simulations, so they will not be masked. Following the simulation, the SP will indicate which dolls were used using a blinded numbering system that will be used for data analysis by investigators and outcomes assessors.|All participants will evaluate the Newborn Oral Assessment and Latch Simulator (NORALSim) and one of two other baby dolls: 1) a cloth doll with a puppet-style head where the user can control the opening and closing of the mouth, and 2) a rigid, plastic doll with a static open mouth. The order of presentation of the dolls between the two back-to-back simulations and the second baby doll will be randomized.|t|f|t|t
33905938|NCT00027040||||TREATMENT||||||||
33905939|NCT05071781|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||To assess the effect of the CRH on on duodenal mast cell count, eosinophil count, immune activation and mucosal permeability, gastric accommodation, gastric sensitivity to distension and gastric emptying time, an interventional study will be conducted in 20 healthy subjects. The study is designed as a double-blind randomized crossover study with at least 7 days between the different study days.|t|f|t|f
33905940|NCT01362712|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33905941|NCT04294264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905942|NCT00004297|RANDOMIZED|||TREATMENT||DOUBLE||||||
33905943|NCT00206115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33905944|NCT02691247|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33905945|NCT02703805|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33905946|NCT04141345|||COHORT||RETROSPECTIVE|||||||
33905947|NCT05077917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant, investigator, and the study team will be blinded to assignment of study drug or placebo. Only pharmacy and data committee will have key to drug assignment.|Double blind, placebo-controlled, randomized trial|t|f|t|f
33905948|NCT04484519|||OTHER||PROSPECTIVE|||||||
33905949|NCT02528669|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33905950|NCT05165810|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a non-blinded, randomized, factorial trial with a secondary adaptive randomization, designed to assess the effectiveness of three interventions (relative to standard care) to increase viral suppression among HIV-positive PWID in India.||||
33905951|NCT00637273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988255|NCT02538523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988256|NCT05318365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988257|NCT04024007|||COHORT||PROSPECTIVE|||||||
33988258|NCT02375685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988259|NCT00520923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988260|NCT03059615|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"2 stage study:~1. Dose Range Finder (4 treatment arms)~2. Dose Confirmation (1 chosen treatment arm)"||||
33988261|NCT04906863|||COHORT||PROSPECTIVE|||||||
33988262|NCT06265298|NA|SINGLE_GROUP||OTHER||NONE||transversal and fundamental study||||
33988263|NCT04857008|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33988264|NCT00079625||||TREATMENT||||||||
33988265|NCT03173547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo controlled|t|f|t|f
33988266|NCT05181566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988267|NCT06151691|||CASE_CONTROL||PROSPECTIVE|||||||
33988268|NCT00934050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988269|NCT03782779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33988270|NCT04553146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988271|NCT03010592|||OTHER||PROSPECTIVE|||||||
33988272|NCT03670017|NA|SINGLE_GROUP||OTHER||NONE||||||
33988273|NCT04302662|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential assignment: eligible patients will be receiving increased doses from lower, middle to upper range of MS1819-SD on top of a stable dose of PPEs||||
33988274|NCT05217472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988275|NCT00731978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33988276|NCT02827071|||CASE_ONLY||PROSPECTIVE|||||||
33988277|NCT06110377|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized study carried out on 60 men. Two techniques for administering dutasteride will be compared, injected by syringes or needles (mesotherapy) or needling using the MMP technique (through tattoo machines)||||
33988278|NCT06498700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988279|NCT04102319|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988280|NCT03751345|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the Open Trial, all participants will receive PW. In the RCT phase, adolescents will be randomly assigned to one of the two conditions. After completion of the baseline assessment, random assignment of adolescents using blocking and stratification will be automatically generated by the electronic data capture software REDCap. Random block sizes of assignments will be generated to prevent guessing of pending treatment assignments. Stratification will be used to ensure a balance on biological sex and disruptive behavior disorder severity (more of less than T=85), as indicated on the CBCL.||||
33988281|NCT05093491|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988282|NCT03405454|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 2:1 to receive either durvalumab at a dose of 1500mg every four weeks for a maximum of 24 months or physician's choice of chemotherapy||||
33988283|NCT01507337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988284|NCT06562777|||COHORT||PROSPECTIVE|||||||
33988285|NCT02081612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988286|NCT00993122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775252|NCT06739343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study follows a parallel group design, where eligible participants are randomly assigned to one of two independent intervention arms: the Phaco-Trabeculectomy group or the MSICS-Trabeculectomy group. Each group receives a distinct surgical intervention, and participants remain in their assigned groups throughout the study duration. Outcomes are measured and compared between the two groups to evaluate the relative effectiveness and safety of the interventions.|t|f|f|t
33905952|NCT04002440|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The study is not blinded, as the intervention does not provide an opportunity to blind either the physician or the patient. The PI will be masked to randomization and not involved in patient care or data collection. Statistical analyses will be conducted by Dr. Ronit Katz who is not an investigator for this trial and PI Dr.Joachim Ix after being provided secure study results.|Participants will be consented and then randomized to one of 2 modality groups; AMIA or HomeChoice PRO. Participants will receive PD care with randomized modality for 6 months, then cross-over to other modality for next 6 months. Nephrologists will see patients once a month. Each visit, the nephrologist will define the patient's desired dry weight (DW) at the subsequent visit. The primary end-point will be the average difference between actual DW vs. prescribed DW. The investigators envision a learning curve with each cycler change, and therefore have set the primary endpoint to average the final 3 visits, rather than using all 6 visits. All solutions and supplies will be from Baxter. Labs will be obtained monthly and quarterly per routine. Dialysis RN will review patients on AMIA twice a week and contact those off target DW and offer interventions to achieve prescribed DW. HomeChoice PRO will record data on a chip analyzed at the end of 6 months to evaluate compliance.||||
33988287|NCT03547622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988288|NCT01067963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988289|NCT01274039|||CASE_ONLY||PROSPECTIVE|||||||
33988290|NCT00100620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33988291|NCT01424761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33905953|NCT01150877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905954|NCT00835094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905955|NCT00728507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905956|NCT06077487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The study is double-blinded, meaning neither the study participants nor the study investigators will know which ketamine administration each participant is receiving.||t|t|t|f
33905957|NCT03755531|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The anesthetist was the person in charge for giving the allocated drug after labor of the baby at once. Otherwise the operating obstetricians, the care givers, investigators and the ouctcomes assessor were all blinded to the type of the injection.|Parallel Assignment|t|t|t|t
33905958|NCT02391623|RANDOMIZED|||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33905959|NCT05121077|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either the MCT or IT training group||||
33905960|NCT01881620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33905961|NCT04705025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33905962|NCT03511261|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|single blinded|four groups, each group with different formulations.|t|f|f|f
33905963|NCT03765346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33905964|NCT02134314|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33905965|NCT03663608|||COHORT||PROSPECTIVE|||||||
33905966|NCT00962923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905967|NCT05612035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|f|t|t
33905968|NCT01428011|||COHORT||PROSPECTIVE|||||||
33905969|NCT05238896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905970|NCT04992832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33905971|NCT04624893|||COHORT||RETROSPECTIVE|||||||
33905972|NCT01421290|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33905973|NCT06692426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905974|NCT03743584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical team responsible for the participant (physicians, nurses and others) and involved with direct patient care will not be blinded to allocation group due to the inherent difficulty in blinding the intervention and as temperature is a vital sign required for clinical care. Measures will be taken to ensure that the information about allocation will not disseminate beyond the immediate group of caregivers responsible for patient care. A blinded physician will evaluate the patient for Cardiac function at pre-specified time-Points after randomisation and make a statement on Cardiac function.||t|f|t|t
33905975|NCT05975775|||COHORT||PROSPECTIVE|||||||
33905976|NCT00113802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33905977|NCT00401622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905978|NCT03616080|NON_RANDOMIZED|PARALLEL||OTHER||NONE||all were ambulatory children with CP age 5-12 years old.||||
33905979|NCT05797896|||CASE_ONLY||PROSPECTIVE|||||||
33905980|NCT02676310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905981|NCT00012727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905982|NCT03458000|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33905983|NCT00585299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905984|NCT03224949|||CASE_CONTROL||PROSPECTIVE|||||||
33905985|NCT01465737|||CASE_ONLY||RETROSPECTIVE|||||||
33988292|NCT04808648|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988293|NCT03134586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988294|NCT04203147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33988295|NCT02255708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988296|NCT05281341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988297|NCT04018482|NA|SINGLE_GROUP||TREATMENT||NONE||A single cohort will have one eye (right) treated with Povidone Iodine (PI), and one eye (left) treated with Avenova.||||
33988298|NCT03760939|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33988299|NCT03977272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988300|NCT00849030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33905986|NCT04792151|||COHORT||PROSPECTIVE|||||||
33905987|NCT06693544|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33905988|NCT03505320|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be enrolled to receive zolbetuximab as monotherapy or in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab and in combination with FLOT in an unblinded fashion.||t|f|t|f
33905989|NCT02584634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905990|NCT04026503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are randomized through block permuted generated lists performed by the study biostatistician.|Participants are assigned to 8 week Live Long Walk Strong rehabilitation or 8 week wait list control then the LLWS rehabilitation program.|f|f|t|t
33905991|NCT04825275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905992|NCT06266286|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The investigators designes a randomized crossover, sham-controlled, double- blind trial to demonstrate the improvement of motor functions and cerebral palsy related symptoms following two weeks of daily sessions of active versus sham EXOPULSE Mollii suit. A two-week washout period should be enough to prevent a potential carry- over effect.~Two weeks after the end of this phase (phase 1), a second phase of this trial, an open label phase, will be proposed for all patients to understand the effects of EXOPULSE Mollii suit and will consist of six months of active stimulation (sessions performed on a daily basis with the same parameters used for the active session in phase 1) on cerebral palsy related symptoms.~Summary:~* Phase 1: randomized sham controlled crossover study (active versus sham condition)~* Phase 2: Open label study (active condition)"|t|t|f|t
33905993|NCT02444897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33905994|NCT02260193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33905995|NCT00991835|||COHORT||PROSPECTIVE|||||||
33905996|NCT06025292|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33905997|NCT06271369|||COHORT||RETROSPECTIVE|||||||
33905998|NCT02030561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33905999|NCT02761993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906000|NCT04716946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906001|NCT06499753|||COHORT||PROSPECTIVE|||||||
33906002|NCT00903461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906003|NCT05925816|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|Brief interventions are conducted online and thus largely masked. All assessment is also conducted through an online survey.||t|t|t|t
33906004|NCT02648048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906005|NCT04485169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||It was an interventional retrospective Propensity score matched (PSM) single centre based cohort study in Pak Emirates Military Hospital Rawalpindi (PEMH), Pakistan from 1st April to 30th June 2020. This study was carried out at the Department of Pulmonology and Critical care. PEMH is the largest Covid-19 designated hospital in the country. Data of all hospitalized patients is maintained by PEMH Covid-19 Research and evaluation cell. The study was approved by Institutional Review Board.||||
33906006|NCT06549686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906007|NCT06243757|||COHORT||PROSPECTIVE|||||||
33906008|NCT06692608|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33906009|NCT04133779|||COHORT||RETROSPECTIVE|||||||
33906010|NCT01221467|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906011|NCT01883128|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||Whole-body MRI and Focal salvage therapy|f|f|t|f
33906012|NCT02016417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906013|NCT01020292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906014|NCT06693557|||CASE_CONTROL||PROSPECTIVE|||||||
33906015|NCT05002192|||COHORT||RETROSPECTIVE|||||||
33906016|NCT01772342|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33906017|NCT02291835|||COHORT||PROSPECTIVE|||||||
33906018|NCT00830830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906019|NCT05433103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator and Outcomes Assessor will be blinded to group allocation|Randomized control trial with two groups.|f|f|t|t
33906020|NCT06135597|||COHORT||PROSPECTIVE|||||||
33988301|NCT01183910|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33988302|NCT00185458|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906021|NCT06693804|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33906022|NCT04116502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906023|NCT06692374|||COHORT||PROSPECTIVE|||||||
33685503|NCT02551952|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The randomization was performed using the website http://www.randomizer.org/form.htm, recorded on paper and stored in sealed opaque envelopes to be opened in the study room where volunteers would play the video game. The health professionals responsible for the game application were aware of the MentalPlus® game version arm just after openness of the envelopes. However, patients, neuropsychologists, and outcome assessors involved in the the study was kept blinded to the stratification group to which each patient belonged. The study groups were identified only after the evaluation of all patients and statistical analysis.|The study was conceived as a randomized, double-blind exploratory trial. It received the approval of the Ethics Committee for Research Project Analysis (CAPPesq) of the Clinical Board, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP).|t|f|t|t
33906024|NCT00130208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775253|NCT05601726|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design. It will consist in a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part.||||
33775254|NCT06740682|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33775255|NCT02367014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775256|NCT06560138|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-4602 injection only||||
33775257|NCT05471843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775258|NCT05540665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775259|NCT01155726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775260|NCT06724432|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||children were randomly assigned to oral supplementation with melatonin or placebo (5% dexstrose), before induction of an anesthesia for surgery|f|t|f|t
33775261|NCT05157204|||CASE_CONTROL||PROSPECTIVE|||||||
33775262|NCT06737640|||COHORT||PROSPECTIVE|||||||
33775263|NCT06276140|||COHORT||PROSPECTIVE|||||||
33775264|NCT05644561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775265|NCT05867108|||CASE_ONLY||RETROSPECTIVE|||||||
33775266|NCT06391242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775267|NCT06491862|||COHORT||RETROSPECTIVE|||||||
33775268|NCT06525220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775269|NCT00811148|||CASE_ONLY||PROSPECTIVE|||||||
33906025|NCT05838755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Click here to enter text.||t|f|t|f
33906026|NCT06030895|NA|SINGLE_GROUP||TREATMENT||NONE||100 hepatocellular carcinoma patients||||
33906027|NCT02574780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906028|NCT03285880|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Within-subject; participants/experimenters are aware of conditions|Within subject comparison of nap and wake conditions||||
33906029|NCT02954835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906030|NCT05635734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906031|NCT03585374|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomly assigned to Penthrox (test group) or standard analgesic treatment (comparison group). As per local clinical practice, the standard analgesic will vary according to pain intensity score measured by Numerical Rating Scale (NRS): morphine, in case of score ≥ 7 or paracetamol/ketoprofen in case of score 4-6. Penthrox treatment will be performed by inhalatory route and will last maximum 25 minutes. the standard of care will be administered by an intravenous drip lasting at maximum 10 minutes.||||
33906032|NCT03756974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906033|NCT00526864|||COHORT||PROSPECTIVE|||||||
33906034|NCT05727566|||CASE_ONLY||CROSS_SECTIONAL|||||||
33906035|NCT01391312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906036|NCT02821793|||COHORT||PROSPECTIVE|||||||
33988303|NCT01370733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988304|NCT01274988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988305|NCT03282162|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind within-subject design|t|f|t|t
33988306|NCT03239314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988307|NCT01051765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988308|NCT04263467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988309|NCT02432976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988310|NCT02807233|||COHORT||CROSS_SECTIONAL|||||||
33988311|NCT00359281|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33988312|NCT00229281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988313|NCT02970994|||COHORT||PROSPECTIVE|||||||
33988314|NCT03614845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988315|NCT05722990|||CASE_ONLY||PROSPECTIVE|||||||
33988316|NCT05729594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988317|NCT01879345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988318|NCT06376656|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cohort of older Malaysian adults will be recruited and assigned to one of the groups, either cognitive stimulation, physical activity, combined cognitive stimulation and physical activity, or non-intervention control.||||
33988319|NCT05732363|||OTHER||CROSS_SECTIONAL|||||||
33988320|NCT02700776|||COHORT||PROSPECTIVE|||||||
33988321|NCT05833425|||CASE_CONTROL||PROSPECTIVE|||||||
33988322|NCT06017713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988323|NCT02980822|||COHORT||PROSPECTIVE|||||||
33988324|NCT06093386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33988325|NCT00953498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906037|NCT05725798|||CASE_CONTROL||PROSPECTIVE|||||||
33906038|NCT06300762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two assessors are blinded to evaluate some outcomes||f|f|f|t
33906039|NCT02773914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33906040|NCT01898533|||CASE_ONLY||PROSPECTIVE|||||||
33906041|NCT02292199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33906042|NCT05943977|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33906043|NCT05239728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906044|NCT06611748|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||KeyGrip is an implantable peripheral nerve stimulator that is being studied for its ability to provide coordinated activation of innervated paralyzed muscles. KeyGrip will be configured to activate nerves of the upper extremity (arm and hand) in order to facilitate movements such as hand opening and/or closing. The study will evaluate participants; grasp strength and ability to manipulate standard objects with each participant serving as their own control, comparing stimulation ON vs. OFF.||||
33906045|NCT06062368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant will be unaware of the group they are participating in.|Individuals will be randomized to one of four groups, each with a different rate of entry into and exit out of the 7 Tesla MRI machine.|t|f|f|f
33906046|NCT05133505|||COHORT||RETROSPECTIVE|||||||
33906047|NCT06693596|||COHORT||PROSPECTIVE|||||||
33988326|NCT06042335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988327|NCT00038363|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33988328|NCT05757908|NA|SINGLE_GROUP||OTHER||NONE||Long-Acting Beta Agonist||||
33988329|NCT02424123|||COHORT||PROSPECTIVE|||||||
33988330|NCT03332745|||CASE_CONTROL||PROSPECTIVE|||||||
33988331|NCT05673317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The participant cannot be blinded as they will be using the application.~The investigator cannot be blinded as they have to provide the application to the patient, teach them how to use it, and perform their surveys about the application use.~The outcomes assessor and care provider will be blinded."|Control group received usual breastfeeding care (counseling by provider, access to lactation consultant, etc). Interventional received usual care plus the breastfeeding application introduced at the time of delivery or within 1 week postpartum.|f|t|f|t
33988332|NCT06503601|||COHORT||PROSPECTIVE|||||||
33988333|NCT05419661|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33988334|NCT02533973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082030|NCT04690465|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||Qualified participants who have signed a consent letter will be randomly assigned into three groups by a draw of lots, in a ratio of 1:1:1. The three groups will be 1) Intervention group: Resistance training (n = 40); 2) Active concurrent control group: Eight-form Yang-style Tai Chi program (n = 40); and 3) Non-treatment control group (n = 40).|t|f|f|t
33988335|NCT05234502|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988336|NCT03620591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33988337|NCT05732207|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Electrode location and duration of stimulation will be masked|AUD and age- and gender matched control participants will be tested under sham, cathodal, and anodal tDCS (in counterbalanced order)|t|f|t|f
33988338|NCT02045472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988339|NCT04786353|||COHORT||CROSS_SECTIONAL|||||||
33988340|NCT04207983|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part I (Safety cohort phase) - no randomization will take place; subjects will be consecutively assigned to one of two sequential safety cohort Regimens and receive two administrations of EYS606~Part II (Randomized comparison phase) - 1:1 randomization to either Treatment Arm A (Regimen 1 or 2 based upon recommendation by the DSMB, n=25) or Treatment Arm B (Regimen 3, n=25)"||||
33988341|NCT00471419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082031|NCT03049501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33685504|NCT04142879|||COHORT||PROSPECTIVE|||||||
33685505|NCT00548405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685506|NCT00141583|RANDOMIZED|CROSSOVER||||NONE||||||
33685507|NCT02363023|||COHORT||PROSPECTIVE|||||||
33988342|NCT01344291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988343|NCT01377779|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33988344|NCT00549718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988345|NCT02368639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988346|NCT01633645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685508|NCT05191264|||COHORT||PROSPECTIVE|||||||
33685509|NCT05415384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will blind patients to whether or not they underwent cryoneurolysis|The proposed study is a single center, prospective, randomized controlled trial evaluating the efficacy of adding cryoneurolysis for patients that meet indication for Surgical Stabilization of Rib Fractures (SSRF) and consent to surgical fixation|t|f|f|f
33685510|NCT00849927|||COHORT||PROSPECTIVE|||||||
33685511|NCT02347696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685512|NCT01284049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685513|NCT02292784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988347|NCT03708458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988348|NCT04280120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, care provider, investigator and outcome assessor will be unaware about the allocation. The therapist performing the initial assessment and the final assessment will be same but will be unaware about the patient assignment.|The study will include a minimum of 60 participants visiting the investigator's outpatient department from 2020-2021. The equal allocation procedure will be used based on the admission of the cases.|t|t|t|t
33988349|NCT01952522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988350|NCT05442021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed by clinicians at Hands on Diagnostics locations. Assessors will be blinded to which intervention participant has received.|Study will be divided into two randomly assigned groups - control and experimental. Control group will receive traditional e-stim treatment with TENS plus physical therapy. Experimental group will receive direct current e-stim treatment with the Neubie device plus physical therapy.|f|f|f|t
33988351|NCT02594358|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33988352|NCT06280183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor will be blind to the group allocation, and participants will be blind to group allocation|This is a randomized, single-blind study three arm study.|t|f|f|t
33988353|NCT04364126|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:1 parallel group study with baseline and follow-up measurements||||
33988354|NCT05277493|||COHORT||OTHER|||||||
33988355|NCT03361722|||COHORT||RETROSPECTIVE|||||||
33988356|NCT00854659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988357|NCT01971060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988358|NCT01498003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988359|NCT00645762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988360|NCT00006051||||TREATMENT||||||||
33988361|NCT03666026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33988362|NCT04032782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988363|NCT01383486|NON_RANDOMIZED|PARALLEL||||NONE||||||
33988364|NCT05041361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988365|NCT02516839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988366|NCT04236856|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-arm, international, multi- center, non-inferiority study to evaluate the effectiveness and safety of the CorPath GRX System for endovascular cerebral aneurysm embolization compared to historical controls.||||
33988367|NCT02773134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33988368|NCT04233385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A blinded research assistant will perform all outcomes assessments of objective functional measures. Participants will be told they are being randomized into two different types of massage, however, we will not refer to they myofascial massage as intervention or the light touch as active control"|Randomized Controlled Trial|t|f|f|t
33988369|NCT02055677|||||PROSPECTIVE|||||||
33988370|NCT06147622|RANDOMIZED|CROSSOVER||OTHER||NONE||open-label, randomized, 2-period, single dose, crossover study||||
33988371|NCT02406560|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33988372|NCT06310655|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive 5 fractions of proton radiotherapy for their cancer. At the time of each fraction, the initial pre-plan will be compared to the newly generated adapted plan, and the optimal treatment will be administered.||||
33988373|NCT01049997|||COHORT||PROSPECTIVE|||||||
33685514|NCT06040242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33685515|NCT03282331|RANDOMIZED|PARALLEL||TREATMENT|||open|||||
33685516|NCT03636698|||OTHER||PROSPECTIVE|||||||
33685517|NCT02614469|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685518|NCT01456377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685519|NCT01274260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685520|NCT03324581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685521|NCT01984905|||COHORT||PROSPECTIVE|||||||
33685522|NCT03777631|RANDOMIZED|PARALLEL||PREVENTION||NONE||The included patients were randomly allocated to two groups: (1) Standard medical treatment group and (2) Catheter ablation additional group.||||
33685523|NCT04224545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized double-blind controlled trial in two groups|t|t|t|f
33685524|NCT05480774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33685525|NCT00895011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685526|NCT01125787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685527|NCT01271790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685528|NCT04097743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33685529|NCT02311101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721375|NCT05352893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|On Day 1, eligible subjects will be randomized in a 1:1:1 ratio to receive a single intravenous (IV) high dose imsidolimab, low dose imsidolimab, or placebo.||t|t|t|t
33906048|NCT03380117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.||||
33906049|NCT02320799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906050|NCT00003207|NA|SINGLE_GROUP||TREATMENT||||||||
33988374|NCT00186251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988375|NCT05349435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988376|NCT04681534|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33988377|NCT04208724|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33988378|NCT03524781|||COHORT||PROSPECTIVE|||||||
33988379|NCT05310591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988380|NCT03755947|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, longitudinal, experimental, open, non-randomized and non-comparable study||||
33988381|NCT06561867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of clopidogrel or cilostazol by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 900 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included cilostazol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|The investigators will conduct a randomized controlled trial containing 2 arms; the ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg twice daily from the 2nd to the 90th day). The cilostazol arm will receive (a 200mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day).|f|f|t|t
33988382|NCT06219577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988383|NCT06561750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||After undergoing a BIODEX exercise program to induce muscle soreness, participants will be randomised into 2 groups; the control and the aspalathus linearis groups. The Control group will be subjected to water while the aspalathus linearis group will be subjected to the rooibos tea|t|f|t|f
33988384|NCT06558669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator is the individual responsible for overseeing the clinical trial. Masking the investigator means they are unaware of which treatment group participants belong to. This helps prevent bias in data collection, analysis, and interpretation.|My study model is Parallel, as I want to check which dose of fresh sugarcane juice has the best effect on liver health status after the consumption of fresh sugarcane juice for 90days, for this, participants has been divided into, one control and three treatments groups|f|f|t|f
33906051|NCT01111981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906052|NCT03606083|||COHORT||PROSPECTIVE|||||||
33906053|NCT04978376|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906054|NCT01284322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906055|NCT04933279|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33988385|NCT01342263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988386|NCT03081403|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988387|NCT02969486|||OTHER||PROSPECTIVE|||||||
33988388|NCT01721681|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33988389|NCT03820427|||COHORT||CROSS_SECTIONAL|||||||
33988390|NCT06218108|||COHORT||RETROSPECTIVE|||||||
33988391|NCT01072890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988392|NCT02935517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988393|NCT02146105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082032|NCT02704767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082033|NCT03070873|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|In the study the operation was performed by three surgeons, the patients received surgery by the doctor when the patients saw in the outpatient clinic.|"The investigators divided the patients randomly into three groups:~The group A was a total of 91 patients who accepted transvaginal hysterectomy and total pelvic floor reconstruction combined Perigee and Apogee polypropylene mesh(PA)；~The group B was a total of 97 patients who accepted transvaginal hysterectomy and total pelvic floor reconstruction with Gynecare prolift polypropylene mesh；~The group C was a total of 70 patients who accepted transvaginal hysterectomy and anterior and posterior vaginal wall repair without any mesh."|t|f|t|f
34082034|NCT05480124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants, study coordinator, and clinical assessor will be blind as to which session the participants receive active or sham treatment.||t|f|f|t
34082035|NCT00094445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685530|NCT04758000|NA|SINGLE_GROUP||PREVENTION||NONE||"1. Group 1 Localized osteosarcoma that have presented a response ≤ 60% to the pre-operatory chemotherapy.~   Is expected the enrolment of 37 patients as total population, in 44 months. The patients will be followed for 3 years, started from the date of enrolment. Metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified.~2. Group 2 Osteosarcoma and Ewing sarcoma patients with complete remission after the first relapse.~Is expected the enrolment of 30 patients as total population, in 24 months. Metformin will be administrated at the Group 2 for 1 year. If there is no toxicity verified or relapse, the patient should continue the treatment for other 2 year (in a total 3 years as maximum)."||||
33685531|NCT05477433|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685532|NCT00042029||||TREATMENT||||||||
33685533|NCT01354054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988394|NCT00214097|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"dose escalation, 3 possible dose groups, with one Phase II group based on MTD.~Per protocol, while waiting for safety data to mature for escalation, protocol permitted enrollment to continue on last dose that was already proven safe. Thus Arms one and two have more than 50 subjects each."||||
33988395|NCT00384163|||||RETROSPECTIVE|||||||
33988396|NCT03472105|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The aim of this study was to investigate if 7 days of dietary intake of New Nordic Renal Diet reduces the 24-hour urinary phosphorus excretion and other components of the phosphorus homeostasis in 18 moderate CKD patients compared to 7 days of habitual diet.||||
33988397|NCT03682653|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|individually randomized trial of azithromycin versus placebo to establish the efficacy and safety of administration of a dose of azithromycin during the neonatal period|t|t|t|t
33988398|NCT04037839|||OTHER||RETROSPECTIVE|||||||
33988399|NCT06029686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685534|NCT01002820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685535|NCT02456103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685536|NCT05604053|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive each level of visual cue type and motivation.||||
33685537|NCT01488474|||CASE_CONTROL||PROSPECTIVE|||||||
33685538|NCT04948086|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33685539|NCT03279471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants do not know what interventions others receive; med arm care providers don't know what interventions their patients receive; assessors don't know what treatments the participants they asses receive|3 Arm trial comparing manualized CBT/social skills training versus sertraline versus pill placebo|t|t|f|t
33685540|NCT01466543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685541|NCT05203042|||OTHER||CROSS_SECTIONAL|||||||
33685542|NCT02047318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685543|NCT00003798||||TREATMENT||||||||
33685544|NCT01133990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685545|NCT01086280|||COHORT|||||||||
33685546|NCT00420641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685547|NCT00002681||||TREATMENT||||||||
33685548|NCT05313152|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33685549|NCT01077752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685550|NCT04153734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685551|NCT01133028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685552|NCT00233831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685553|NCT01585012|NA|SINGLE_GROUP||||NONE||||||
33685554|NCT03195296|||CASE_ONLY||PROSPECTIVE|||||||
33685555|NCT01731873|||COHORT||PROSPECTIVE|||||||
33685556|NCT03533686|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who are enrolled in Aims 3 are part of a cross-over design. Participants in this group will be randomly assigned to either standard of care followed by Adhear, or Adhear followed by standard of care.||||
33685557|NCT01993095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685558|NCT03461354|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33685559|NCT03461679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||RCT|t|t|f|t
33685560|NCT02574572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685561|NCT02373501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685562|NCT03020446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685563|NCT03915860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685564|NCT05985564|||CASE_CONTROL||RETROSPECTIVE|||||||
33685565|NCT03440177|||CASE_ONLY||PROSPECTIVE|||||||
33685566|NCT00003409||||TREATMENT||||||||
33685567|NCT03347578|||COHORT||PROSPECTIVE|||||||
33685568|NCT05371171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685569|NCT01279239|||COHORT||PROSPECTIVE|||||||
33685570|NCT06184620|||OTHER||RETROSPECTIVE|||||||
33685571|NCT04976153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685572|NCT05837169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Given the nature of the intervention, the study will be open and participants will know which group they belong to. However, the statistician will be blinded in order to reduce the risk of introducing bias when interpreting the data.||f|f|f|t
33988400|NCT03670485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988401|NCT05004532|||OTHER||RETROSPECTIVE|||||||
33988402|NCT02834663|NA|SINGLE_GROUP||OTHER||NONE||||||
33988403|NCT04893291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988404|NCT05428020|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant (patient) will be blinded to whether they are receiving a short-term foley catheter or no foley.||t|f|f|f
33988405|NCT02889848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33988406|NCT01136174|RANDOMIZED|PARALLEL||||DOUBLE||||||
33988407|NCT03950089|||CASE_CONTROL||PROSPECTIVE|||||||
33988408|NCT00747162|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775270|NCT05389319|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Cohorts 1 to 5 will include a safety lead with 1 sentinel participant. If no safety issues occurred within the on-site monitoring period as assessed by the investigator and solicited during telephone visits, the next 2 participants in that dose cohort will be vaccinated. After an 48-hour observation period and assuming no safety issues were identified in these 2 participants, an additional 4 participants will be vaccinated. After a 48-hour observation period, and assuming that no safety problems were noted in these 4 participants, the remaining participants in the dosing group will be vaccinated. Each participant will be observed for at least 4 hours at the study center after Prime-2-CoV_Beta booster vaccination. After the last participant of each of the Cohorts 1 to 4 has completed 7 days of follow up after the Prime-2-CoV_Beta booster vaccination, all safety data will be reviewed by the safety review committee.||||
33775271|NCT06425029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will not be informed of their group assignment. The study team will have no knowledge of randomization sequence until all participants complete the study.|The primary endpoint is to assess the reduction in epileptiform activity (as defined by change in normalized RNS 'long episode' detection frequency) during the 14-day stimulus presentation block for three music pieces. 1) Music piece (A) previously shown to reduce interictal epileptiform discharges (IEDs)). 2) Music piece (B) (previously shown to not reduce IEDs in the same population despite rhythmic similarities), and 3) Music piece (C) - a selection from the participant's preferred musical style that is also matched for musical characteristics.|t|f|t|f
33775272|NCT06163547|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicentre randomised-controlled trial.||||
33775273|NCT01925781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775274|NCT05980949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775275|NCT02243397|||COHORT||PROSPECTIVE|||||||
33775276|NCT00737061|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988409|NCT01599728|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33988410|NCT03872596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a two-part, crossover study. In Part A, participants will be randomized into one of three treatment sequences, each receiving Seroquel immediate release (IR) 300mg, Quetiapine Formulation A 300mg and Quetiapine Formulation B 300mg. In Part B, participants will be randomized into one of two treatment sequences, each receiving Seroquel IR 25mg and Quetiapine 25mg, the formulation of which will be established in Part A.||||
33988411|NCT04195360|||COHORT||PROSPECTIVE|||||||
34082036|NCT01208285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082037|NCT05661448|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-randomized concurrent control design (NRCC) is proposed and will allow for a comparison between the two interventions using one (e.g., CR) as the active control for the other (e.g., MCT) and vice-versa, on intervention-specific primary outcomes.||||
34082038|NCT03011203|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34082039|NCT05765877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082040|NCT06207409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082041|NCT02735564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082042|NCT05690880|||OTHER||OTHER|||||||
34082043|NCT04018352|||OTHER||CROSS_SECTIONAL|||||||
34082044|NCT03416439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Lifestyle intervention program carried out by trained professionals versus standard, unstructured information given by the family physicians|f|f|f|t
34082045|NCT02646969|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34082046|NCT01458067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082047|NCT04433104|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082048|NCT04501250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|A double-blinded|Crossover Assignment two-way crossover|t|f|t|f
34082049|NCT01917279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775277|NCT05561764|NA|SINGLE_GROUP||OTHER||NONE||Open-label, descriptive, pharmacokinetic and outcome study||||
33775278|NCT06737822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775279|NCT02146950|||COHORT||PROSPECTIVE|||||||
33775280|NCT05215600|||COHORT||RETROSPECTIVE|||||||
33988412|NCT05458635|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082050|NCT04277208|||COHORT||PROSPECTIVE|||||||
34082051|NCT02204917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparative performance of contrast enhanced Voiding Urosonography (ceVUS) and Voiding Cystourethrography (VCUG) in the same participant and in the same session.||||
34082052|NCT02366416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988413|NCT02152397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988414|NCT02356978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988415|NCT03714685||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33988416|NCT00420303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988417|NCT06322420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988418|NCT04069286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988419|NCT05420896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988420|NCT03059186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082053|NCT01741077|||COHORT||CROSS_SECTIONAL|||||||
34082054|NCT03460678|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized into either the arm of Erlotinib 150 mg once daily, or the arm of Pemetrexed 500 mg/m2 administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects.||||
34082055|NCT02221752|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082056|NCT05754099|||OTHER||PROSPECTIVE|||||||
34082057|NCT03415152|||COHORT||PROSPECTIVE|||||||
34082058|NCT05260814|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control clinical trial||||
34082059|NCT03052777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082060|NCT02915939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34082061|NCT05702008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34082062|NCT04595058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082063|NCT04646382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Each volunteer is assigned a participant number that will be associated with a pot that will have all the product for the study.~The pot number is the same as the participant number."|Controlled, randomized, double-blind, parallel group nutritional intervention study.|t|t|t|t
34082064|NCT03980548|||OTHER||OTHER|||||||
33775281|NCT00186147|||COHORT||PROSPECTIVE|||||||
33775282|NCT06605170|||CASE_ONLY||PROSPECTIVE|||||||
33775283|NCT04421014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33775284|NCT06738056|||COHORT||PROSPECTIVE|||||||
33775285|NCT06728462|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||External comparator arm study|t|t|t|t
33775286|NCT06197295|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33906056|NCT02869867|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33906057|NCT06219928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906058|NCT01598584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33906059|NCT06693102|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are not randomized before all pre-assessment questionnaires and tests are completed.|||||
34082065|NCT03220841|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Randomised controlled trial||||
34082066|NCT02793986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34082067|NCT01577797|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34082068|NCT00569452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082069|NCT00717145|RANDOMIZED|CROSSOVER||||NONE||||||
34082070|NCT01204034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082071|NCT02749409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082072|NCT03717597|NA|SINGLE_GROUP||PREVENTION||NONE||While subjects will be enrolled in multiple groups, all subjects will receive the same intervention and will complete the same study activities.||||
34082073|NCT03129503|||CASE_CONTROL||PROSPECTIVE|||||||
33906060|NCT06313190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906061|NCT02498080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906062|NCT00950690|||OTHER||PROSPECTIVE|||||||
33988421|NCT04729881|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals are randomly allocated into control, intervention and specific exercise groups.||||
33988422|NCT04416386|||CASE_CONTROL||PROSPECTIVE|||||||
33988423|NCT02632344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988424|NCT03575234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988425|NCT04897321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988426|NCT02766881|||COHORT||PROSPECTIVE|||||||
33988427|NCT06074289|NA|SINGLE_GROUP||TREATMENT||NONE||consecutive sampling||||
33685573|NCT00622739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685574|NCT00005779||||TREATMENT||||||||
33685575|NCT05297435|||COHORT||PROSPECTIVE|||||||
33685576|NCT03023670|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33685577|NCT02309619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685578|NCT01233687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685579|NCT02036554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685580|NCT01050478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685581|NCT03018665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685582|NCT02752555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906063|NCT03874598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33988428|NCT00210587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988429|NCT05269901|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988430|NCT04813081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants were defined as two study groups: Test Group (TG) consists of patients have free gingival graft around dental implant patients and Control Group (CG) consists of patients have free gingival graft around the teeth.||||
33988431|NCT04195230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988432|NCT01456221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33988433|NCT06279286|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33685583|NCT03387644|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33685584|NCT03662243|||CASE_ONLY||PROSPECTIVE|||||||
33685585|NCT04144218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685586|NCT00171054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685587|NCT02994888|||COHORT||PROSPECTIVE|||||||
33685588|NCT04430205|||COHORT||RETROSPECTIVE|||||||
33906064|NCT06081621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906065|NCT00596518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906066|NCT02590016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906067|NCT06692777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34082074|NCT03226795|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34082075|NCT05182944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082076|NCT04788134|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34082077|NCT04950400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082078|NCT01669434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082079|NCT00324493|||DEFINED_POPULATION||PROSPECTIVE|||||||
34082080|NCT00697099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082081|NCT00869960|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33988434|NCT02656368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988435|NCT03468764|||CASE_ONLY||PROSPECTIVE|||||||
33988436|NCT03301363|||COHORT||PROSPECTIVE|||||||
33988437|NCT06314022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Patients who agree to participate in the study are randomized by a 1:1 block computer program (an attempt will be made to balance the groups according to the type of laxative) into two groups: group A: control group, which receives the standard information given in writing, and group B: APP group, which receives the standard information together with the mobile application individually adapted to the scheduled colonoscopy appointment and the type of laxative.~Patients scheduled for a screening colonoscopy will be contacted by telephone, those who agree to participate will be scheduled with the nurse, after giving their consent they are randomized. Group B will indicate how to download the APP and its management. The endoscopist performing the examination is blind for randomization and will assess colon cleansing according to the Boston Bowel Scale (Lai EJ. et al Gastroinest Endosc 2009)."|Each subject will be randomized into two groups according to the instructions given to perform the preparation of the colon prior to colonoscopy: group A: perform the preparation with the written instructions delivered in the consultation and group B: they will be given the instructions in writing and will also be indicated how to install the APP.|f|f|t|f
33988438|NCT04298918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988439|NCT04094103|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The supplement and placebo will be distributed to the individual by a member of the research team who is not involved with data collection or analysis.||t|f|t|f
33988440|NCT02193061|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33988441|NCT00523315|||COHORT||PROSPECTIVE|||||||
33988442|NCT04763239|||CASE_ONLY||PROSPECTIVE|||||||
33988443|NCT04977739|||CASE_CONTROL||PROSPECTIVE|||||||
33988444|NCT00668915|||COHORT||PROSPECTIVE|||||||
33988445|NCT05313217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Quasi-experimental single group laboratory study||||
33988446|NCT02252250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988447|NCT00001085||||TREATMENT||||||||
33988448|NCT00272597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988449|NCT05176015|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33988450|NCT04550013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to intervention allocation||f|f|f|t
33988451|NCT05166148|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988452|NCT00477945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988453|NCT00058955|NON_RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33988454|NCT01346735|||CASE_ONLY||PROSPECTIVE|||||||
34082082|NCT03244488|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34082083|NCT02801331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082084|NCT01762488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082085|NCT04650737|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"Both groups will receive Ultrasound guided ESPB before induction of general anesthesia~* Single shot group (A):(20 patients) Patients in this group will receive 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine.~* Continous infusion group (B):(20 patients) Patients in this group will receive 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs"|t|t|f|f
34082086|NCT02280434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082087|NCT04367961|||COHORT||RETROSPECTIVE|||||||
34082088|NCT04644406|||COHORT||PROSPECTIVE|||||||
34082089|NCT01326871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082090|NCT00546442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082091|NCT05423834|||COHORT||OTHER|||||||
34082092|NCT01364155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082093|NCT06202846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"* Plasma isolated from whole blood sampled on BCT strecl tube~* Whole blood sampled on heparin tube"||||
34082094|NCT04862338|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Exploratory interventional repeated-dose study, open-label, single-arm, single-center||||
34082095|NCT05100888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082096|NCT04836741|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082097|NCT03474224|||CASE_ONLY||PROSPECTIVE|||||||
34082098|NCT04126200|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be a dose exploration (DE) phase which will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with other anti-cancer treatments. A recommended Phase 2 dose (RP2D) for each combination treatment will be identified based on the safety and preliminary efficacy in DE. This will be followed by a cohort expansion (CE) phase which will evaluate the clinical activity of the combination treatment in comparison to belantamab mafodotin monotherapy in additional participants.||||
34082099|NCT04267497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Phase I, One-center, Prospective, Randomized and controlled study|t|f|f|f
34082100|NCT00733967|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34082101|NCT05804812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34082102|NCT06012136|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34082103|NCT03639168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082104|NCT02631005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988455|NCT04457674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988456|NCT05642286|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, multi center, single group target value design is adopted; 218 subjects who met the inclusion criteria and did not meet the exclusion criteria were planned to be included in the study, and the trial medical devices were used to assist surgery and complete follow-up, so as to evaluate the safety and effectiveness of the trial medical devices.||||
33988457|NCT04396015|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind placebo controlled|randomized, placebo control cross-over study, with an open label extension|t|t|t|t
33988458|NCT04915495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988459|NCT02071108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988460|NCT04138745|||CASE_CONTROL||PROSPECTIVE|||||||
33988461|NCT03323008|NA|SINGLE_GROUP||OTHER||NONE||||||
33988462|NCT00743964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906068|NCT03014934|||CASE_CONTROL||PROSPECTIVE|||||||
33988463|NCT00362596|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33988464|NCT02519361|||COHORT||PROSPECTIVE|||||||
33988465|NCT05081960|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988466|NCT05548647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Study 1 is a double-blind, placebo-controlled, randomized controlled, long-term treatment trial. Study 2 is a double-blind, medication withdrawal trial, re-randomized treatment trial.|t|t|t|t
33685589|NCT05201729|||COHORT||PROSPECTIVE|||||||
33685590|NCT01975831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775287|NCT06740422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775288|NCT04221542|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906069|NCT02384499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906070|NCT06618729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33906071|NCT05684159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will enroll a planned total of 12 patients as subjects for the trial, with extra enrollment if needed, at the discretion of the Investigator. All subjects will be assigned to either Cohort 1 or Cohort 2. Enrollment in Cohort 2 will occur after at least three patients in Cohort 1 have been evaluated for safety for 3 days after the first dose. No more than three patients will be dosed in a day. Safety data will be assessed and reviewed by the Sponsor and Study Investigators for dosed subjects prior to dosing of the rest of the study subjects. In Cohort 1, all 6 subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses. All 6 patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses followed by biweekly doses at 20 mg/kg for a total of 5 doses.||||
33906072|NCT03484000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33906073|NCT06692699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906074|NCT06488573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Control group vs intervention group|f|f|f|t
33906075|NCT03404414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|None (Open Label)|Single Group Assignment||||
33906076|NCT05361018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two-armed, randomized controlled design. Patients will then be assigned randomly either to the WBV group or the CAR group. Patients allocated to the WBV group receive a defined WBV exercise program twice a week in addition to their usual treatment. Patients in conventional aerobic and resistance exercise (CAR) group will receive a defined exercise program twice a week in addition to their usual treatment.||||
33906077|NCT02602236|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906078|NCT02972723|NA|SINGLE_GROUP||||NONE||||||
33906079|NCT02592304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906080|NCT01098955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906081|NCT03421288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906082|NCT03441191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906083|NCT06681740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33906084|NCT06687174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The trial was a double-blind design.||t|t|t|f
33906085|NCT03177135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906086|NCT00003753||||TREATMENT||NONE||||||
33906087|NCT02717871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906088|NCT00956475|||CASE_ONLY||CROSS_SECTIONAL|||||||
33906089|NCT01752569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906090|NCT06476184|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized 1:1:~* Experimental arm: Densification of the chemotherapy administration dose and dosing schedule of carboplatin-paclitaxel (carboplatin AUC 5 every 3 weeks on day 1 and paclitaxel 80 mg/m2 every week, on day 1, day 8, and day 15, with 3 week-cycles) for 3 cycles~  +/- combined with daily sub-cutaneous administrations of GCSF (Granulocyte Colony-Stimulating Factor) 30 MUI days 3 to 5, \& 10 to 12, \& 17 to 19 (at investigator discretion, as per standard of care)~* Standard arm: Continuation of the same 3-weekly carboplatin-paclitaxel, as administered during the neo-adjuvant chemotherapy +/- combined with peg-GCSF or GCSF daily sub-cutaneous administrations, at investigator discretion, as per standard of care.~Of note, bevacizumab addition in both arms is required in countries where it is available as per standard of care, according to country health coverage policy."||||
33685591|NCT05916911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775289|NCT04698889|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects allocated to receive one or more milk types in random order on different occasions, spaced by at least two weeks||||
33906091|NCT05240950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906092|NCT01915849|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33906093|NCT04626479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906094|NCT01084499|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33685592|NCT03504943|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33685593|NCT00084773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685594|NCT04687215|||CASE_ONLY||PROSPECTIVE|||||||
33685595|NCT03963401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685596|NCT03688425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685597|NCT06432868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906095|NCT06693427|||CASE_CONTROL||PROSPECTIVE|||||||
33906096|NCT03340077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906097|NCT00745264|RANDOMIZED|PARALLEL||||NONE||||||
33906098|NCT01142986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906099|NCT00521339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906100|NCT01129076|||||PROSPECTIVE|||||||
33988467|NCT01958450|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33988468|NCT04374487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988469|NCT04318821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants in each group will receive real (with energy output) or sham (without energy output) laser acupuncture. The feelings of participants in each group are not different. The care provider and outcomes assessor don't involve the random allocation and don't know if participants receive real laser acupuncture.||t|t|f|t
33685598|NCT04431089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775290|NCT06290206|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775291|NCT06482892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988470|NCT04131621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988471|NCT05271786|||COHORT||RETROSPECTIVE|||||||
33906101|NCT02645747|||OTHER||RETROSPECTIVE|||||||
33906102|NCT05624255|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906103|NCT05674747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906104|NCT04742465|NA|SINGLE_GROUP||OTHER||NONE||"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patient testers to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated character."||||
33906105|NCT00406315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906106|NCT06338865|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and post-anesthesia care unit nurses will be masked.||t|f|f|t
33906107|NCT05251935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906108|NCT01897415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906109|NCT02041351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906110|NCT03037957|||CASE_ONLY||PROSPECTIVE|||||||
33906111|NCT06207500|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic prospective controlled clinical trial||||
33906112|NCT04611126|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"18 patients are included in 3 steps, containing 6 patients each.~Step 1: 6 patients will be included. Ipilimumab wil not be administered pre-tumor harvest. If feasible and tolerable, as defined by no additional SAE/SAR compared to the previously completed pilot studies at CCIT-DK, the trial will move to Step 2~Step 2: 6 patients will be included. Ipilimumab will be administered once 2-6 weeks before tumor resection.~Step 3: If no additional SAE/SAR, compared to the previous completed study at CCIT-DK, is observed additional 6 patients can be included at Step Two. If on the other hand Step 2 is not found safe, additional 6 patients can be included at Step 1"||||
33906113|NCT02140918|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33906114|NCT00698516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906115|NCT02226510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906116|NCT02859545|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33906117|NCT01514669|||COHORT||CROSS_SECTIONAL|||||||
33906118|NCT04729452|||COHORT||OTHER|||||||
33906119|NCT01004549|||CASE_ONLY||CROSS_SECTIONAL|||||||
33906120|NCT02629081|||CASE_CONTROL||PROSPECTIVE|||||||
33906121|NCT01592851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33906122|NCT00984464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906123|NCT01495897|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33906124|NCT05816616|||COHORT||PROSPECTIVE|||||||
33906125|NCT04554030|||COHORT||PROSPECTIVE|||||||
33906126|NCT02461914|NA|SINGLE_GROUP||OTHER||NONE||||||
33906127|NCT04529551|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33906128|NCT01259492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988472|NCT01802320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988473|NCT02503293|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988474|NCT03982030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988475|NCT03094598|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988476|NCT03726892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988477|NCT00056667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988478|NCT04043377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988479|NCT02335658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082105|NCT06029764|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will use a simple randomization method to group patients who meet the inclusion criteria using a computer-generated randomization scheme.||||
34082106|NCT05828992|||CASE_ONLY||CROSS_SECTIONAL|||||||
34082107|NCT00721799|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082108|NCT02930785|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082109|NCT03925896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082110|NCT03961399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082111|NCT03037840|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082112|NCT02381236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082113|NCT01352078|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34082114|NCT01631448|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34082115|NCT01846858|||COHORT||PROSPECTIVE|||||||
33906129|NCT06692400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The lab technician who results the labs will be blinded.||f|f|t|f
34082116|NCT02281617|||CASE_ONLY||PROSPECTIVE|||||||
33906130|NCT06693635|||CASE_ONLY||RETROSPECTIVE|||||||
33906131|NCT02765477|||CASE_CONTROL||RETROSPECTIVE|||||||
34082117|NCT05489575|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A sham CPAP will be used.|Randomized, single-blind, crossover|t|f|f|f
33906132|NCT02028338|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33906133|NCT03819803|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with acute gastrointestinal graft-versus-host disease refractory to steroid treatment||||
33906134|NCT06665477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906135|NCT06692946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments were not conducted by a blinded independent assessor|A rater-blinded RCT conducted in an Italian Child Neuropsychiatry community service. The study included two groups: the experimental CPMT group where children and parents receiving both CPMT and TAU and TAU-CG, where children received only individual PI.|f|f|t|t
34082118|NCT05334862|NA|SINGLE_GROUP||TREATMENT||NONE||Skeletally immature patients over 2.5 years of age and less than 12 years of age who presented with pathologic tibia vara.( Langenskiöld type 1,2and 3) associated with intoeing.||||
34082119|NCT03471052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34082120|NCT03684408|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34082121|NCT05715619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082122|NCT02791269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082123|NCT03736486|||COHORT||CROSS_SECTIONAL|||||||
34082124|NCT00909844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906136|NCT03117049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906137|NCT06264518|||CASE_CROSSOVER||PROSPECTIVE|||||||
33906138|NCT00124267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906139|NCT05424900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906140|NCT02218788|||COHORT||RETROSPECTIVE|||||||
33906141|NCT04850040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906142|NCT02588846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients receive the intervention for comparison against retrospective matched cohort.||||
33906143|NCT01241513|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33906144|NCT03363828|||COHORT||PROSPECTIVE|||||||
33906145|NCT01449019|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33906146|NCT05060510|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a prospective evaluation of a program that is being implemented using a stepped-wedge, cluster randomized design.||||
33988480|NCT05388123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988481|NCT01636661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33988482|NCT02737046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988483|NCT00613522|||CASE_CONTROL||PROSPECTIVE|||||||
33988484|NCT02608177|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33988485|NCT03360305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data extractors will be blinded to the specific study arm each participant has been randomized to.||f|f|f|t
33988486|NCT00614250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988487|NCT01297179|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34082125|NCT01848171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082126|NCT00716612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082127|NCT04785417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082128|NCT05685121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082129|NCT01386606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082130|NCT04267978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||glioblastoma, lower-grade glioma||||
34082131|NCT02067858|NA|SINGLE_GROUP||OTHER||NONE||||||
34082132|NCT03664843|||CASE_ONLY||PROSPECTIVE|||||||
34082133|NCT00850291|||COHORT||PROSPECTIVE|||||||
34082134|NCT01911949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082135|NCT01899911|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34082136|NCT05359471|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This is single center, cross sectional study conducted at the Chronic Viral Illness Service (CVIS) of McGill University Health Center (MUHC). This is a pilot feasibility study with the aim of further exploring more options to conduct or facilitate similar studies in larger group.||||
34082137|NCT05619328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082138|NCT05067400|||COHORT||CROSS_SECTIONAL|||||||
34082139|NCT02960412|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34082140|NCT00348400|RANDOMIZED|PARALLEL||||SINGLE||||||
33775292|NCT03749902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685599|NCT01905215|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33685600|NCT01949337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685601|NCT01330017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685602|NCT06076278|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized controlled trial having two groups. One group will receive home based resistant training and the second will receive clinic based resistant training. Both groups will be recruited concurrently.||||
33685603|NCT06518265|||COHORT||OTHER|||||||
33685604|NCT01695161|||CASE_CONTROL||PROSPECTIVE|||||||
33685605|NCT03945175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775293|NCT06102863|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with endometrial cancer who met the inclusion criteria were randomly divided into the control group and the experimental group in a 1:1 ratio according to the random numbers generated in advance (no preset position, no specific object).||||
33685606|NCT02510755|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33685607|NCT00885001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685608|NCT01085500|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33775294|NCT06641089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775295|NCT04714905|||COHORT||PROSPECTIVE|||||||
33775296|NCT04708691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33775297|NCT02096120|||COHORT||PROSPECTIVE|||||||
33775298|NCT05345093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775299|NCT03746756|RANDOMIZED|PARALLEL||TREATMENT||NONE||Compares Screening, Brief Intervention and Referral to Treatment (SBIRT) as currently practiced at federal qualified health centers (FQHC) as a practice as usual comparison group vs. SBIRT+ Recovery Management Checkups for Primary Care at the time of referral and quarterly for 12 months.||||
33775300|NCT06136832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients are randomized into either controls or treatments upon being determined eligible. Control group does not receive education intervention prior to asking if they would like the vaccine. Treatment group does receive education intervention prior to asking if they'd like the vaccine.|t|f|f|f
33906147|NCT05813210|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, randomized, two-arm controlled, monocentric, national study.||||
33906148|NCT02937103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906149|NCT05458284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906150|NCT02379923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906151|NCT00000615||||PREVENTION||||||||
33906152|NCT05663723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Only outcome assessors and patients will be blinded to group allocation.|The intervention and control groups will be: Group A: Intervention group with the IV and V LED board. Group B: Intervention group with the IV, V and Violet LED board. Group C: Control group with the LED board without emitting light.|t|f|f|t
33906153|NCT02929992|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906154|NCT04855721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, double-dummy|There are 4 groups in the study; 1 with placebo and 3 with different AUR101 dosing regimens|t|t|t|t
33906155|NCT06475989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906156|NCT00793884|||COHORT||PROSPECTIVE|||||||
33906157|NCT06195280|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, non-randomized study||||
33906158|NCT03259542|NA|SINGLE_GROUP||OTHER||NONE||||||
33906159|NCT05638776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906160|NCT02124187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906161|NCT00055419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906162|NCT02599766|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906163|NCT00807898|||CASE_ONLY||CROSS_SECTIONAL|||||||
33906164|NCT06211504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906165|NCT05110898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33906166|NCT05507944|||COHORT||PROSPECTIVE|||||||
33906167|NCT03642015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33906168|NCT06553313|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33906169|NCT06350539|||OTHER||OTHER|||||||
33906170|NCT06692010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906171|NCT06693115|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33906172|NCT00813553|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33906173|NCT06259955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906174|NCT02678988|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906175|NCT02992470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33906176|NCT06621472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blind|t|f|f|t
33906177|NCT00384540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906178|NCT03955107|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a open-label, randomized controlled trial. The investigators plan to recruit 154 women with gestational diabetes at 24-28 weeks gestation. 77 subjects (Group 1) will be selected to undergo CGM every 4 weeks and another 77 subjects will be recruited to undergo usual antenatal care ,and last month undergo CGMS (Group 2).~The primary outcomes will be time in range of glycaemic control in the third trimester. The investigators also plan to assess changes to management made by the endocrinologist based on the additional information on glycemic control obtained from professional CGM use. The investigators also plan to compare hypoglycaemia and hyperglycaemia detection rates using the CGMS and fingerstick methods of glucose evaluation. Written and informed consent will be obtained in accordance with the principles of the Helsinki Declaration."||||
33906179|NCT01188044|||COHORT||PROSPECTIVE|||||||
33906180|NCT04509492|||CASE_ONLY||PROSPECTIVE|||||||
33906181|NCT05762185|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906182|NCT03531619|||COHORT||PROSPECTIVE|||||||
33906183|NCT06019780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33906184|NCT03938376|||COHORT||PROSPECTIVE|||||||
33906185|NCT01704248|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33906186|NCT06527378|||COHORT||RETROSPECTIVE|||||||
33906187|NCT04220528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906188|NCT04531319|||CASE_CONTROL||PROSPECTIVE|||||||
33906189|NCT04454996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906190|NCT03977597|||COHORT||PROSPECTIVE|||||||
33906191|NCT00138099|||DEFINED_POPULATION||PROSPECTIVE|||||||
33906192|NCT06594848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33906193|NCT01905397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906194|NCT06691880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906195|NCT04180059|NA|SINGLE_GROUP||TREATMENT||NONE||"Biological, T cell clone~A standard phase 1 dose-escalation study will be used:~Level 1: 1 x 10\^4 cells/kg of recipient, Level 2: 5 x 10\^4 cells/kg, Level 3: 25 x 10\^4 cells/kg, Level 4: 50 x 10\^4 cells/kg, Level 5: 100 x 10\^4 cells/kg.~After study of toxicity of the 4 injected patients, choice has been made to stop the CRM method to choose the dose and to test only 2 doses for each last patients : 100 x 10\^4 cells/kg (actual level 5) and 500 x 10\^4 cells/kg (choice based on compassionnal injections data at the level 5)"||||
33906196|NCT06114953|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental group: glucocorticoid, mizoribine, tacrolimus; Control group: glucocorticoid, mycophenolate mofetil.||||
33906197|NCT05998993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906198|NCT05528042|NA|SINGLE_GROUP||OTHER||NONE|All the parties will be aware of the study.|We carry out a multicentric, prospective clinical research, evaluating the performance of the COBOX device to the extent and within the framework of usual care. Heart rate and respiratory rate are measured when a patient arrives in the emergency room, also, given the high attendance of these services, it seemed to us to be an excellent place for this study. This measurement is carried out as part of the patient's care pathway using the reference process techniques for taking measurements via a CE marked device and a manual counting reference method. The inclusions of the patient consultant in the emergencies service allow you to quickly obtain a large number of inclusions, and also, a great variability of the constants revealed by the different pathological stages. This allows a large reproduction in the combination of clinical situations and allows validating the actions in different contexts||||
33906199|NCT01734993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988488|NCT03359356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988489|NCT01111461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988490|NCT05832411|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33988491|NCT01461421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988492|NCT00003647||||TREATMENT||||||||
33988493|NCT01820793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082141|NCT00516971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082142|NCT03242317|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082143|NCT03599596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34082144|NCT04968236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33906200|NCT06038097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906201|NCT06693492|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Longitudinal prospective cohort study with baseline and follow-up assessment||||
33906202|NCT05165576|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator applied the intervention. The participant and the outcomes assessors were blind as to which group participants were assigned.|Parallel assignment|t|f|f|t
33906203|NCT02361749|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33906204|NCT01232972|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906205|NCT04695847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906206|NCT04618692|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|The patients will be randomly allocated in the equal groups.İn group 1 biliary anastomosis will be performed using surgical loupes and İn group 2 biliary anastomosis will be performed using microscope.||||
33906207|NCT03629626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988494|NCT06461091|||COHORT||PROSPECTIVE|||||||
33988495|NCT01044485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988496|NCT04542356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988497|NCT05589363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33988498|NCT03377894|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33988499|NCT03125135|NA|SINGLE_GROUP||OTHER||NONE||||||
34082145|NCT00758446|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33685609|NCT06521450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685610|NCT05065554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685611|NCT04405232|||COHORT||PROSPECTIVE|||||||
33906208|NCT05904405|||OTHER||CROSS_SECTIONAL|||||||
33685612|NCT04325555|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33906209|NCT05520619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906210|NCT02713581|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33906211|NCT01617434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906212|NCT03237832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The pharmacist preparing the doses was unblended and was responsible for all drug accountability issues, including preparing, labeling, and dispensing study drug according to the randomization code provided. The unblinded pharmacists were responsible for maintaining the blind, consistent with protocol design, throughout the study. All documentation was filed in the Pharmacy Manual, and access to this manual was restricted to the unblinded pharmacists. The subjects, Principal Investigator, and all other personnel involved with subject assessments were blinded to the actual treatment assignments of the subjects (ARN-6039 or placebo) during the study.|Determine safety and tolerability of ARN-6039 ascending doses compared to placebo|t|t|t|t
33906213|NCT02606045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906214|NCT03765567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906215|NCT06322992|||COHORT||PROSPECTIVE|||||||
33906216|NCT06692348|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33906217|NCT05598931|||COHORT||PROSPECTIVE|||||||
33906218|NCT01175070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906219|NCT03872583|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Participants, physicians, outcome assessors and investigator will be blinded.|Randomized, controlled, double-blind trial|t|t|t|t
33906220|NCT06155682|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33906221|NCT03841149|||COHORT||PROSPECTIVE|||||||
33906222|NCT02126111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906223|NCT05377034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be performed in a double-blind manner. The investigators, monitoring team, site staff, and all patients will be blinded to the study treatments from the time of randomization until database lock. Biostatisticians involved in preparing the randomization and safety data analysis for Data and Safety Monitoring Board (independent to study statistician) will be unblinded.||t|t|t|t
33906224|NCT02120651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906225|NCT03830801|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33988500|NCT03663179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33988501|NCT01623791|||COHORT||PROSPECTIVE|||||||
33988502|NCT05646433|||COHORT||PROSPECTIVE|||||||
33988503|NCT00193115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988504|NCT03170323|RANDOMIZED|PARALLEL||TREATMENT||NONE||Drug: Mycophenolate mofetil, high dose steroid Drug: Cyclosporin, low dose steroid||||
33988505|NCT05253950|||OTHER||CROSS_SECTIONAL|||||||
33685613|NCT04138966|||COHORT||PROSPECTIVE|||||||
33685614|NCT06228911|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33906226|NCT04743635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All participants were treated with the Avéli device.||||
33906227|NCT03736083|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study team will enroll 52 consecutive new onset type 1 diabetes patients and stratify the subjects into two groups, age 4-10 vs 11-17, aiming for 26 subjects in each group. Participants will be randomized to one of the two groups using blocked randomization with random block sizes of 2 and 4, stratified by age (4-10 vs. 11-17).||||
33906228|NCT06333015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects and designated postoperative evaluator(s) will be masked to the IOLs assigned. The Investigator implanting the IOL and designated site personnel will be unmasked to the treatment assignment for a subject.|Approximately 224 subjects (448 eyes) will be enrolled in this study with plans to bilaterally implant approximately 112 subjects with each of the test and control IOLs.|t|f|f|t
33906229|NCT06693713|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33906230|NCT01937130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906231|NCT00114972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988506|NCT02627235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988507|NCT03816072|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Patients receive either propofol or sevoflurane to maintain anaesthesia. Both treatment groups receive the same phenylephrine and mechanical ventilation regimens.||||
33988508|NCT02563561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988509|NCT05137821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two group control and test group test group divided into four subgroups|f|f|t|f
33988510|NCT05952986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988511|NCT01003054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988512|NCT04435353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research involves single blinding (researcher statistician)|Prospective\\retrospective study|f|f|f|t
33685615|NCT06089369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906232|NCT04498429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988513|NCT01188681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906233|NCT06472895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988514|NCT00546988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988515|NCT02068820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988516|NCT01239017|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33988517|NCT01472341|||COHORT||PROSPECTIVE|||||||
33988518|NCT04908098|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were divided into two groups as study and control.||||
33988519|NCT03498794|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Comparison Between Ureteral Stent versus Percutaneous Nephrostomy in Obstructed infected kidney due to Ureteric calculi||||
33988520|NCT00019812||||TREATMENT||||||||
33988521|NCT00433225|RANDOMIZED|PARALLEL||||SINGLE||||||
33988522|NCT04079088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988523|NCT03218137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988524|NCT02880761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988525|NCT00941811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33988526|NCT04039334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988527|NCT00144014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906234|NCT06692751|||COHORT||PROSPECTIVE|||||||
33906235|NCT04922892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906236|NCT03697395|NA|PARALLEL||DIAGNOSTIC||NONE||Part 1-blood and bronch samples will be collected from subjects already undergoing procedures Part 2-blood, bronch samples and MRI will be performed on subject||||
33906237|NCT05163990|RANDOMIZED|PARALLEL||PREVENTION||NONE||"TEAS group: 10 minutes before intraspinal anesthesia, bilateral Neiguan points and Zusanli points are given dense wave transcutaneous acupoint electrical stimulation with the frequency of 10/50Hz. The intensity is based on the maximum tolerance of the participant, and the stimulation last until 30 minutes after subarachnoid administration.~Control group: Electrodes are connected at bilateral Neiguan points and Zusanli points 10 minutes before intraspinal anesthesia, but no transcutaneous acupoint electrical stimulation is given, the duration is the same as that of the TEAS group."||||
33906238|NCT04919993|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Phase IIa Proof-of-Concept Trial||||
33906239|NCT00782925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33906240|NCT02051244|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988528|NCT00859430|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988529|NCT00002053||||TREATMENT||DOUBLE||||||
33988530|NCT04507230|||COHORT||CROSS_SECTIONAL|||||||
33988531|NCT00440518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33988532|NCT00633451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988533|NCT02450682|RANDOMIZED|PARALLEL||||NONE||||||
34082146|NCT02739126|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34082147|NCT05393752|||COHORT||PROSPECTIVE|||||||
33906241|NCT03216551|||COHORT||PROSPECTIVE|||||||
34082148|NCT00217945|RANDOMIZED|||TREATMENT||||||||
34082149|NCT02932436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906242|NCT06189677|||COHORT||PROSPECTIVE|||||||
33906243|NCT05091489|||OTHER||CROSS_SECTIONAL|||||||
33906244|NCT02750813|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33906245|NCT02123017|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33906246|NCT03872401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906247|NCT01263535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906248|NCT00400933|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33906249|NCT04438603|||COHORT||PROSPECTIVE|||||||
33906250|NCT04832841|||COHORT||PROSPECTIVE|||||||
33906251|NCT04617613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33906252|NCT06510296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906253|NCT05601999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blinded||t|f|f|t
33988534|NCT01393054|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33988535|NCT04710862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly assigned to one of two conditions|t|f|f|t
33988536|NCT04598828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988537|NCT03974035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The investigators propose a double-blinded prospective comparative experimental study (patient and nurse). After the approval of the ethics committee of our hospital and the signed consent from each of the patients in the study, patients will be scheduled for bimaxillary osteotomy and will be randomly and prospectively assigned to one of the two groups with a plan to register up to 52 patients. Patients will not know the group that they have been assigned consecutively; and both the postoperative resuscitation nurses and the hospitalization nurses who will perform VAS records, opioid consumption, PONV and postoperative complications, will also be unaware of the analgesic treatment that the patient has received in the operating room. Patients will be assigned randomly to one group or another:|t|t|f|f
33685616|NCT00688207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685617|NCT00510380|||CASE_CONTROL||PROSPECTIVE|||||||
33685618|NCT05478629|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33685619|NCT04649372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685620|NCT04576338|||COHORT||CROSS_SECTIONAL|||||||
33685621|NCT04433143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685622|NCT02843737|||CASE_ONLY||PROSPECTIVE|||||||
33685623|NCT03332511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685624|NCT00335270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906254|NCT05795465|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|All subjects, investigators, and study personnel involved in the conduct of the study, including data management, will be blinded to treatment assignment with the exception of some designated personnel. The unblinded study personnel will not participate in study procedures or data analysis prior to unblinding of the study data to all study-related personnel.|Part 1 - Randomized, double-blind, dose escalation. Part 2 - Randomized, double-blind, placebo controlled, parallel group.|t|t|t|f
33906255|NCT03854591|||CASE_ONLY||PROSPECTIVE|||||||
34082150|NCT05540145|||COHORT||PROSPECTIVE|||||||
33906256|NCT05151653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906257|NCT01954121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906258|NCT03321786|||CASE_CONTROL||PROSPECTIVE|||||||
33906259|NCT02345642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906260|NCT04550442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906261|NCT06150105|||COHORT||RETROSPECTIVE|||||||
33906262|NCT06041672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906263|NCT05874219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906264|NCT04906239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33906265|NCT05301322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study is double-blinded.~The participant, study coordinator, and all site staff will be blinded.~The majority of sponsor staff will be blinded to study intervention allocation. All laboratory testing personnel performing serological assays or diagnostic assays will remain blinded to the study intervention assigned/received throughout the study."|Parallel|t|t|t|t
33906266|NCT06112340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906267|NCT03466320|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906268|NCT00339014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988538|NCT02198391|||COHORT||PROSPECTIVE|||||||
33988539|NCT02894424|||OTHER||PROSPECTIVE|||||||
33988540|NCT03117296|||COHORT||OTHER|||||||
34082151|NCT00161655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082152|NCT00171535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082153|NCT04735614|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The surgeon will not know the patients' group before or during the surgery. The outcome assessor won't know the group during the whole research.||f|t|t|t
33988541|NCT05381688|||COHORT||PROSPECTIVE|||||||
33988542|NCT03270462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988543|NCT01075893|||CASE_CONTROL||PROSPECTIVE|||||||
33988544|NCT04171583|||COHORT||PROSPECTIVE|||||||
33988545|NCT03006705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988546|NCT01433497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988547|NCT03531294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988548|NCT01746615|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33988549|NCT03224494|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988550|NCT05536739|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The model used is a repeated measures single arm study||||
33988551|NCT02975622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988552|NCT05017480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988553|NCT04850547|||OTHER||CROSS_SECTIONAL|||||||
33988554|NCT00820586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988555|NCT00612287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082154|NCT05601349|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Each cluster is conformed by one hospital of middle or higher attention level, the individuals in each cluster don´t know the intervention options, and the outcomes assessor either|Community based intervention study randomized by clusters. These studies are differentiated by the method of randomisation, in which a group of individuals is randomly assigned to an intervention as a group or cluster rather than as individuals.|t|f|f|t
34082155|NCT06472947|||COHORT||PROSPECTIVE|||||||
33685625|NCT00258843|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33988556|NCT04057872|NA|SINGLE_GROUP||OTHER||NONE||Consecutive Adults patients with vasoplegic septic shock with at least 2 organ dysfunction will receive TPE||||
33988557|NCT03145493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988558|NCT01921894|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33988559|NCT02235155|||COHORT||PROSPECTIVE|||||||
33988560|NCT02396966|||CASE_CONTROL||PROSPECTIVE|||||||
33988561|NCT00196651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988562|NCT04776330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988563|NCT04035395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were not told whether they had been randomized into the intervention or control group. However, when the participant was offered new intervention services, the participant could infer that they were part of the intervention group. Conversely, if a participant was only offered the standard intervention services, they could infer they were part of the control group.||t|f|f|f
33988564|NCT05213156|RANDOMIZED|FACTORIAL||SCREENING||QUADRUPLE||Participants were didvided in three groups: the control group, those who suffer from severe Dry Eye Disease and all other patients with Dry Eye Disease.|t|t|t|t
33988565|NCT02664103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988566|NCT00731783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988567|NCT05742971|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study population will be randomly divided into the intervention group (VR-group) or the standard care group.|The study population will be randomly divided into the intervention group (VR-group) or the standard care group. The intervention group can choose for an immersive guided relaxation VR experience or an interactive VR experience during the external version additional to the usual standard care. The participants randomised to the standard care group receive the usual standard care given during external version.|f|f|t|f
33988568|NCT05820893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomized to either maintaining their standard diet or taking the resistant potato starch prebiotic for 4 weeks.|f|f|t|t
33988569|NCT00454025|||COHORT||PROSPECTIVE|||||||
34082156|NCT02762032|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34082157|NCT01268995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082158|NCT01561443|||COHORT||PROSPECTIVE|||||||
34082159|NCT03712280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082160|NCT04447716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082161|NCT00308867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082162|NCT05263362|||COHORT||OTHER|||||||
33685626|NCT00672113|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33685627|NCT00645788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685628|NCT01348971|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33685629|NCT02896647|||OTHER||CROSS_SECTIONAL|||||||
33685630|NCT00918112|||CASE_CONTROL||PROSPECTIVE|||||||
33685631|NCT03096015|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subjects Group design||||
33685632|NCT04009083|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33685633|NCT01586273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685634|NCT01169597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685635|NCT03446261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906269|NCT04903548|||COHORT||PROSPECTIVE|||||||
33906270|NCT00978445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906271|NCT06238479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Only the dose optimization cohort is randomized.|||||
33906272|NCT04935879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study||t|t|t|t
33906273|NCT01613469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906274|NCT05222347|||COHORT||CROSS_SECTIONAL|||||||
33906275|NCT06108323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be assigned to one of two study groups by the person conducting the intervention.~All participants receive mental practice (real or sham) and the exercise program.~The evaluators are unaware of the assignment at all times."||t|f|t|t
33906276|NCT06692257|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33906277|NCT03719560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906278|NCT01772225|||COHORT||RETROSPECTIVE|||||||
33906279|NCT04030481|||CASE_CONTROL||PROSPECTIVE|||||||
33906280|NCT03123939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906281|NCT06281028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective, multicenter, randomized||||
33906282|NCT05669482|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34082163|NCT02666222|||COHORT||PROSPECTIVE|||||||
34082164|NCT03581006|||COHORT||PROSPECTIVE|||||||
34082165|NCT04176913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082166|NCT03122795|NA|SINGLE_GROUP||TREATMENT||NONE||Patients and donors who meet the inclusion criteria will be recruited and inclueded and put through the study in a cumulative fashion.||||
34082167|NCT02968524|||OTHER||PROSPECTIVE|||||||
34082168|NCT04161391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988570|NCT05900934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind, assessor-blinded and patient-blinded, randomized controlled study.|Arm 1: Myofascial Releasing Group Arm 2: Sham Myofascial Releasing Group|t|f|f|t
33906283|NCT04729959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988571|NCT02731534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906284|NCT01791868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988572|NCT01135446|RANDOMIZED|PARALLEL||||NONE||||||
33988573|NCT05524701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A randomised crossover trial with one group undergoing two conditions- a sleep restriction condition and a normal sleep condition.||||
33988574|NCT02906293|||CASE_ONLY||PROSPECTIVE|||||||
33988575|NCT06031766|||OTHER||CROSS_SECTIONAL|||||||
33988576|NCT02458625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988577|NCT04277390|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988578|NCT05492279|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|random allocation, open label|clinical trial randomized|t|t|t|t
33988579|NCT01483950|||COHORT||CROSS_SECTIONAL|||||||
33685636|NCT04706416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.||||
33685637|NCT04869553|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Controlled, randomised, open-label, cross-over, 3-sequence study (uniform design across time and sequence: ABC/BCA/CAB).~* Treatment A: Usual pain management of each ward~* Treatment B: Usual pain management on each ward and analgesic hypnotherapy during care~* Treatment C: Usual pain management of each ward and virtual reality session using a suitable headset."||||
33685638|NCT02119676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685639|NCT03313908|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33685640|NCT03271294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685641|NCT06023576|RANDOMIZED|PARALLEL||PREVENTION||NONE||This open-label, two-arm RCT will compare the effects of intensive versus standard SBP control in patients with BC and HTN receiving anthracycline-based treatment (with or without HER2-targeted therapy).||||
33685642|NCT02420782|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33906285|NCT06126705|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33906286|NCT06148233|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906287|NCT05815329|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomised controlled clinical study with follow up (experimental group and waiting list)||||
33906288|NCT04143542|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33906289|NCT00069082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906290|NCT04465370|||CASE_ONLY||PROSPECTIVE|||||||
33906291|NCT06692465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906292|NCT03345836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906293|NCT02117245|||CASE_ONLY||PROSPECTIVE|||||||
33906294|NCT00759486|||OTHER||PROSPECTIVE|||||||
33906295|NCT00832754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906296|NCT00581711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906297|NCT02313935|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906298|NCT03344731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33988580|NCT03079947|||COHORT||PROSPECTIVE|||||||
33988581|NCT06263959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988582|NCT04819594|NA|SINGLE_GROUP||OTHER||NONE||||||
33988583|NCT06241963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988584|NCT06056817|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33988585|NCT05230563|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33906299|NCT02743403|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33906300|NCT03275883|||COHORT||OTHER|||||||
33906301|NCT00200278|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33906302|NCT00034970|RANDOMIZED|FACTORIAL||ECT||NONE||||||
33906303|NCT06387719|||CASE_CONTROL||PROSPECTIVE|||||||
33906304|NCT03679208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906305|NCT05909345|||OTHER||OTHER|||||||
33906306|NCT00207376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906307|NCT02280681|||COHORT||CROSS_SECTIONAL|||||||
33906308|NCT06000722|||OTHER||PROSPECTIVE|||||||
33906309|NCT02407951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906310|NCT04483739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906311|NCT06692088|||CASE_CONTROL||PROSPECTIVE|||||||
33906312|NCT06203548|NA|SINGLE_GROUP||TREATMENT||NONE||Lifestyle intervention programme||||
33906313|NCT01842620|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33906314|NCT01990222|||CASE_ONLY||PROSPECTIVE|||||||
33906315|NCT00096096||||SUPPORTIVE_CARE||NONE||||||
33988586|NCT04024553|||COHORT||PROSPECTIVE|||||||
33988587|NCT02020915|||CASE_ONLY||RETROSPECTIVE|||||||
33988588|NCT02658045|||COHORT||PROSPECTIVE|||||||
33988589|NCT02849093|||COHORT||CROSS_SECTIONAL|||||||
33988590|NCT02104908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988591|NCT06504056|||COHORT||OTHER|||||||
33988592|NCT03829891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988593|NCT05570981|||CASE_CONTROL||PROSPECTIVE|||||||
33988594|NCT03055637|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33988595|NCT01959672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988596|NCT04595279|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988597|NCT03414593|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients who underwent surgery on both feet at the same time. One foot is performed before surgery and the other is performed after surgery.|t|f|f|t
33988598|NCT05228626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the participant and study clinicians and other data collectors will be blinded|Enrolled participants will be randomized to two trial arms. Arm1: the control arm will be composed of Standard of care for treating COVID-19 in Uganda as recommended by the ministry of Health plus the Placebo Arm 2: the Intervention arm will be composed of the intervention plus the standard of care for treating COVID-19 in Uganda as recommended by the ministry of Health|t|t|t|f
33988599|NCT02110953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988600|NCT02436447|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33988601|NCT00365846|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33685643|NCT00893815|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33685644|NCT05280483|RANDOMIZED|CROSSOVER||OTHER||NONE||In this study, a single oral dose of the tablet formulation administered under fed conditions will be compared to administration under fasted conditions to assess the effects of high-fat meal on the rate and extent of absorption and exposure.||||
33685645|NCT04560244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685646|NCT00661986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685647|NCT03032770|||COHORT||PROSPECTIVE|||||||
33685648|NCT03460015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685649|NCT03721445|||CASE_CONTROL||PROSPECTIVE|||||||
33685650|NCT01535976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33685651|NCT03660670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685652|NCT05664698|NA|SINGLE_GROUP||TREATMENT||NONE||One intervention (emotion regulation training) with three randomized pre-intervention baselines at different lengths.||||
33685653|NCT06391931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685654|NCT04517357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685655|NCT01809977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685656|NCT01963000|||COHORT||RETROSPECTIVE|||||||
33685657|NCT04153214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685658|NCT04941443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685659|NCT02150408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685660|NCT01216605|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33685661|NCT01908738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33685662|NCT00625703|NA|SINGLE_GROUP||OTHER||NONE||||||
33685663|NCT00649311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685664|NCT00227071|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33685665|NCT02712814|||COHORT||PROSPECTIVE|||||||
33988602|NCT02955641|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33906316|NCT06212557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be stratified by three characteristics: (1) buprenorphine or methadone, (2) history of MAT, and (3) stimulant use in past one month. Allocation to treatment groups will be randomly assigned by 1:1 allotment to either KIOS + TAU (treatment as usual) or KIOS sham + TAU with strata. Study staff will be blind to the condition to which the participant is assigned.|Randomized controlled 2 arm trial|f|f|t|f
33988603|NCT04950634|||COHORT||PROSPECTIVE|||||||
33988604|NCT00840606|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988605|NCT00707161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988606|NCT03126747|||COHORT||PROSPECTIVE|||||||
33988607|NCT03144505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988608|NCT01095315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988609|NCT06185322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The physiatrist who will initially assess, diagnose and collect outcome measures, will be blind to the study group of the patient.~The patient will not know whether they are receiving the detailed exercise program or conventional exercise program."||t|f|t|t
33988610|NCT04492774|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open label)|Parallel Assignment||||
33988611|NCT04819243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988612|NCT03520517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988613|NCT03206008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33988614|NCT05488834|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|A stepped-wedge cluster randomised trial will be used to roll-out the implementation of CPOT (intervention) in a random sequence across groups. When the study starts, all groups will not be exposed to the intervention (control group). The groups are randomised and switched to the intervention at a predetermined moment. At the beginning of the trial, every two ICUs will be clustered in one group, so four groups will be formed. The study will be conducted over six months. In the first month (month 1), all groups will be in the control period, and then at month 2, the intervention will be implemented to the first group over one month, while the other three groups are in the control arm.|A hybrid effectiveness-implementation design will be used in this study. This study will use type (III) hybrid effectiveness implementation strategy. The Critical Care Pain Observation Tool (CPOT) is a pain scale tool used to assess pain in critically ill patients who are incapable of reporting pain. CPOT will be implemented in the eight adult ICUs, and at the same time, data will be collected to measure the intervention's effectiveness.||||
34082169|NCT03821961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082170|NCT05034549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082171|NCT04082052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants will be randomized by Qualtrics and will be unknown to the investigator and the patient until data collection is complete||t|t|t|f
34082172|NCT03348605|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|"As this study is described as single blinded, the only entity of the trial not aware of the group or sequence of the participant is the participant itself.~The other personell involved in the trial needs to be aware of the position of the participant within the study so to apply the right measures.~In this case the participant is unaware of the fact whether his stimulation system is turned on or off."|"The primary outcomes are the changes in size and position over time and their timed occurrence after the amputation of these receptive fields as well as the inter-/intratester reliability in their detection.~The secondary outcomes are the change in selected gait parameters and phantom sensations through the application of the stimulating system (Phantom Stimulator (Cort X Sensorics, Spaichingen, Germany)).~The primary outcome is of mere descriptive nature. Therefore, no control group is created and the participants are not blinded or randomized.~For the secondary outcomes, every tested subject serves as its own control (cross over). The gait analysis as well as the questionnaire are performed three times. The two measurements after the first familiarization measurements are performed in a randomized order."|t|f|f|f
34082173|NCT00646828|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34082174|NCT05626569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082175|NCT00117234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082176|NCT04189016|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34082177|NCT04391257|NA|SEQUENTIAL||PREVENTION||NONE||||||
34082178|NCT04882696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082179|NCT00492297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685666|NCT02043600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685667|NCT05167552|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685668|NCT05224011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study is a single-arm study in which patient measurements will be obtained using both the investigational device-Boppli-as well as traditional blood pressure measurement collected via IAL.||||
33685669|NCT02538783|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33685670|NCT02249247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685671|NCT00852332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685672|NCT00907660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685673|NCT05710380|NA|SINGLE_GROUP||SCREENING||NONE||||||
33685674|NCT02677324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685675|NCT03532607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33906317|NCT06079476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906318|NCT00004747|RANDOMIZED|||TREATMENT||DOUBLE||||||
33906319|NCT04582500|||COHORT||PROSPECTIVE|||||||
33906320|NCT01637051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906321|NCT04180527|||CASE_CONTROL||RETROSPECTIVE|||||||
33906322|NCT05588362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators responsible for administering questionnaires and collecting visual outcomes will be masked to the treatment group of the participant. Both the research assistant and participant will be unmasked.|Prospective randomized control study|f|f|t|t
33906323|NCT01182857|||||PROSPECTIVE|||||||
33685676|NCT02392533|||COHORT||RETROSPECTIVE|||||||
33721376|NCT01218191|||CASE_ONLY||PROSPECTIVE|||||||
33721377|NCT03885713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721378|NCT02429518|||CASE_ONLY||PROSPECTIVE|||||||
33721379|NCT00336713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721380|NCT02208856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721381|NCT00311623|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33988615|NCT05935631|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-test and post-test of serum folate levels after using salt with folic acid in the same group of women, each serving as their own control.||||
33906324|NCT02545296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988616|NCT01860521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906325|NCT02959710|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33906326|NCT01295905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906327|NCT04667195|||COHORT||CROSS_SECTIONAL|||||||
33906328|NCT03521167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906329|NCT03519308|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906330|NCT01400334|||COHORT||PROSPECTIVE|||||||
33906331|NCT04874909|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33906332|NCT06017232|NA|SINGLE_GROUP||TREATMENT||NONE||The study design is a pre-post without a control group||||
33721382|NCT00847457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721383|NCT01748981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33721384|NCT04171687|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721385|NCT02167607|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33721386|NCT00894322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721387|NCT01275833|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33721388|NCT01266460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721389|NCT03160534|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Controlled Pilot Trial||||
33721390|NCT02937779|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33721391|NCT00002670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721392|NCT06288412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721393|NCT00644280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721394|NCT05494450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721395|NCT00637507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721396|NCT01782261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721397|NCT02246673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721398|NCT05271955|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33721399|NCT05194618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||comparative, randomized, double-blind, placebo-controlled, parallel groups study|t|t|t|t
33906333|NCT02285764|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33906334|NCT00038545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906335|NCT00367497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906336|NCT02896426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906337|NCT06217536|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906338|NCT02887534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906339|NCT05199532|||COHORT||PROSPECTIVE|||||||
33775301|NCT03877263|RANDOMIZED|PARALLEL||SCREENING||NONE|"Patients agreeing to participate in the study will be randomized by visit into a study group in a 1:1 fashion. Patients who participate during both their initial and third trimester (of pregnancy) will be randomized twice to a study group.~The randomization allocation schedule will be developed by biostatisticians from the OhioHealth Research \& Innovation Institute (OHRI), and will be hidden from the investigator until directly prior to enrollment to prevent bias. The clinical research coordinator will reveal the randomization allocation once patient is consented and enrolled into the study.~Due to the nature of the study, we cannot completed mask the investigator from the study group while taking the vaginal swabs."|||||
33775302|NCT00369811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775303|NCT05048238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775304|NCT04157790|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33775305|NCT00810641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775306|NCT02854215|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33906340|NCT06392100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The experimental group received mindfulness-based stress reduction measures, while the control group received conventional care measures.|The experimental group received mindfulness-based stress reduction intervention, while the control group received weekly line care messages from class instructors. Both groups took the post-test before the internship (T0), during the internship (T1), after the internship (T2), and one month after the internship (T3), a total of 4 times. The contents include psychological well-being scale; anxiety, depression, stress scale and mental toughness scale.|t|f|f|f
33906341|NCT01335568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906342|NCT02064439|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33906343|NCT06471140|||COHORT||PROSPECTIVE|||||||
33906344|NCT02402218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906345|NCT00633139|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906346|NCT02440178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906347|NCT03555539|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This study was to be conducted sequentially in 2 parts.~Part 1: Participants with moderate HI (based on Child-Pugh scores) were compared to demographically matched participants with normal hepatic function.~Following a review of PK and safety data from Part 1, a decision was to be made by the principle investigators and the sponsor whether to conduct Part 2 of this study, which was planned to enroll participants with severe and mild HI."||||
33906348|NCT02685384|||CASE_CONTROL||PROSPECTIVE|||||||
33906349|NCT00755352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988617|NCT03227497|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Independent researcher will perform statistical analyses, without prior knowledge on study treatment allocation.|"This study is a randomized, cross-over, controlled, 5-week nutritional intervention, investigating health effects of dietary intake of whole walnuts, as a replacement meal within habitual diet and lifestyle.~At the beginning of the study, half of the study subjects are randomly assigned to a treatment arm with walnut consumption, or control arm without study intervention. Treatment arm considers consumption of pre-packed 56 g of whole walnuts daily, as a replacement meal. After 5 weeks, study subjects are crossed, for additional 5 weeks. At the beginning of the study, all subjects are instructed to continue with their habitual diet and physical activity during the study period of 10 weeks."||||
33988618|NCT02132494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988619|NCT01199718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082180|NCT01483118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082181|NCT02984982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082182|NCT02048423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082183|NCT04566107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|||||
34082184|NCT03143361|||COHORT||PROSPECTIVE|||||||
33775307|NCT03093844|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 1/phase 2 study.||||
33775308|NCT05630989|||COHORT||OTHER|||||||
33906350|NCT02324530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906351|NCT01705353|||COHORT||PROSPECTIVE|||||||
33988620|NCT00852462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988621|NCT04533295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988622|NCT05799313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988623|NCT03065374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082185|NCT06516575|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34082186|NCT04987047|||COHORT||PROSPECTIVE|||||||
34082187|NCT01668420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082188|NCT04587804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082189|NCT01880827|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34082190|NCT06115018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082191|NCT06270641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34082192|NCT01645436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34082193|NCT02987010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082194|NCT05609669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082195|NCT01674725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082196|NCT01867008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906352|NCT05146232|RANDOMIZED|PARALLEL||OTHER||SINGLE|The anesthesiologist caring for the patient will be aware of the group assignments.While the person who is responsible for patient monitor recording and the patients will be blinded to the group assignments.|The rSO2 values will be recorded preoperatively, 1 min after anesthesia induction, and every 5 min during surgery. Arterial blood gases (ABG) will be measured in the fifth minute postinduction (t1), 30th minute postinsufflation (t2), and postextubation (t3), and correlation with rSO2 will be examined.|t|f|f|f
33906353|NCT04914988|||CASE_ONLY||PROSPECTIVE|||||||
33906354|NCT03464058|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Part 1 and 2 of the study are open-label and therefore blinding is not required. Part 3 of the study is double-blind.||t|f|t|t
33906355|NCT00376402|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33988624|NCT06562569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Veterans will be randomized to one of two groups that will receive vagal nerve stimulation|t|f|f|t
33988625|NCT01403194|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33988626|NCT00673647|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988627|NCT02807545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988628|NCT06554405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher who will evaluate the patients before and after treatment will not know which group the patients are in.|Participants will be grouped according to randomization into unilateral or bilateral intervention.|f|f|f|t
33988629|NCT01208077|||COHORT||PROSPECTIVE|||||||
33988630|NCT01458002|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33988631|NCT02347722|||COHORT||OTHER|||||||
33988632|NCT01887652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988633|NCT03149874|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Patient seuentially randomized to either vaccine||||
33988634|NCT05223322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Following baseline data collection, participants will be randomized into one of two study arms: intervention (exercise) and control (usual care). The investigators have three strata in this study: 1) race/ethnicity (NHW or Bl/AA), 2) anti-cancer therapy (ANTs, anti-Her2 treatments, or both), and 3) comorbidity profile (low vs. high). (High comorbidity level is defined as \>3 comorbidities that include hypertension, diabetes, hyperlipidemia, BMI 50+, renal failure, liver failure. It is possible there may be other comorbidities that may be identified based on physician feedback and patient approval). The investigators will employ blocked randomization within each site (MCW and UIC) that have their own stratified randomization sequence. Each patient will be randomized to a treatment arm (usual care or exercise) via MCW's OnCore Clinical Trials Management System at the MCW Clinical Trials Office.|||||
33988635|NCT02373397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33988636|NCT02355587|||COHORT||PROSPECTIVE|||||||
33988637|NCT04992507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906356|NCT05326399|||COHORT||PROSPECTIVE|||||||
33988638|NCT02655679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906357|NCT06693258|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE||Prospective, Comparative, Monocentric Study|t|f|f|t
33906358|NCT06691334|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906359|NCT02004756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906360|NCT06658613|||COHORT||PROSPECTIVE|||||||
33906361|NCT05057273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906362|NCT04304495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be randomly assigned (by the REDCap program) 1:1 to the intervention or usual care arm.||f|f|f|t
33906363|NCT00734422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906364|NCT06669104|||COHORT||PROSPECTIVE|||||||
33906365|NCT00906022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906366|NCT06291220|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906367|NCT01414816|||COHORT||PROSPECTIVE|||||||
33906368|NCT05907967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906369|NCT04868461|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|This is a single-blind study i.e. participants do not know the real purpose of the study. They are given a cover story. They are told about the real purpose of the study at the completion of this.|Tightly controlled cross-over study design with four arms.|t|f|f|f
33906370|NCT02325674|||COHORT||PROSPECTIVE|||||||
33906371|NCT01106534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906372|NCT00424580|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33906373|NCT00320385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906374|NCT01612572|||COHORT||PROSPECTIVE|||||||
33988639|NCT03375047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988640|NCT03129022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988641|NCT02598089|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33988642|NCT04956198|||CASE_ONLY||PROSPECTIVE|||||||
33988643|NCT03871166|||COHORT||RETROSPECTIVE|||||||
33988644|NCT04073394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988645|NCT01022463|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988646|NCT00112645||||TREATMENT||NONE||||||
34082197|NCT01328938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33906375|NCT05489133|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Primary objective is to test whether a psychological intervention with modified prolonged exposure (mPE) therapy is superior to treatment as usual (TAU) to prevent the development of PTSD.|f|f|t|t
33906376|NCT00430625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906377|NCT04286867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants are told they will receive information about strategies and tools to reduce alcohol consumption. The participants will not be told whether they are receiving the novel method for reducing alcohol consumption or previously developed and studies methods for reducing alcohol consumption.|Two groups are defined and compared in terms of primary outcome measures.|t|f|f|f
33906378|NCT05488561|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33988647|NCT02430272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33906379|NCT05746351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The participants will be divided into three equal groups ,one group will receive epidural analgesia with bupivacaine and dexmedetomidine, another Group will receive epidural analgesia with bupivacaine and fentanyl and the other Group will receive epidural analgesia with bupivacaine and Nalbuphine.||||
33906380|NCT04229446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The included statistician will do the first evaluation of the results|This is a cluster-randomized controlled trial including patients with dementia and pain living at different wards at nursing homes.|f|f|f|t
33988648|NCT04783051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988649|NCT05707676|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33988650|NCT01190865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988651|NCT02259972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33988652|NCT00979043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988653|NCT02779803|||COHORT||PROSPECTIVE|||||||
33988654|NCT03406494|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor will be independent from the study and blinded from patient allocations.|prospective, multicenter, assessor-blinded, randomized controlled trial|f|f|f|t
33988655|NCT00115960|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33988656|NCT04481919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple blinded study of guideline-based care compared with a protocolized diuretic strategy using urinary sodium|Two-arm comparison of structured usual care vs urinary sodium guided diuresis|t|t|t|t
33988657|NCT03863002|RANDOMIZED|PARALLEL||TREATMENT||NONE|both participants and the study team are unblinded to the treatment allocation|||||
33988658|NCT01583127|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33988659|NCT03065062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988660|NCT00001018||||TREATMENT||||||||
33988661|NCT03023150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082198|NCT04601220|||COHORT||PROSPECTIVE|||||||
34082199|NCT05709665|||COHORT||PROSPECTIVE|||||||
34082200|NCT04260620|||CASE_CONTROL||RETROSPECTIVE|||||||
34082201|NCT03778008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082202|NCT06151379|||CASE_ONLY||RETROSPECTIVE|||||||
34082203|NCT06184048|NA|SINGLE_GROUP||TREATMENT||NONE||"Recruitment will take place at the University of Utah Orthopedic Center by physician and study study staff members EMR chart review prior to patient visits.~The investigator plans to recruit a total of 30 participants to this project over a 24 month period of time."||||
34082204|NCT03652818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sponsor, patients, investigators and study staff involved in the protocol procedures or those involved in data collection, data entry, data analysis will be blinded.||t|f|t|f
34082205|NCT04572373|||COHORT||RETROSPECTIVE|||||||
33906381|NCT02429427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082206|NCT00713076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082207|NCT00988702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34082208|NCT03343548|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34082209|NCT05783934|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082210|NCT03416959|||CASE_ONLY||PROSPECTIVE|||||||
34082211|NCT06193772|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All eligible participants (n = 240) will be entered into IPDT. At week 3 in treatment, participants at risk of non-response will be identified using our open-source algorithm. Identified participants at risk will be randomized to either adapted treatment or continued IPDT as usual.||||
34082212|NCT01928771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082213|NCT00052104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34082214|NCT04232631|||CASE_ONLY||PROSPECTIVE|||||||
34082215|NCT04882371|||COHORT||RETROSPECTIVE|||||||
34082216|NCT01232283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082217|NCT03201991|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082218|NCT02202304|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082219|NCT01797393|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34082220|NCT01123655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082221|NCT06149702|RANDOMIZED|PARALLEL||OTHER||NONE||This feasibility randomised controlled trial is a 6-week study comparing the modified KOKU programme to usual care in community dwelling PwD and carers of PwD. After assessing participants for eligibility, they will be allocated randomly to either intervention group or control group. Assessments will be performed at baseline and 6 weeks post follow up||||
34082222|NCT02272530|||COHORT||PROSPECTIVE|||||||
34082223|NCT00956436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082224|NCT03817281|||CASE_ONLY||PROSPECTIVE|||||||
33906382|NCT02894047|||CASE_ONLY||PROSPECTIVE|||||||
33906383|NCT00553917|||CASE_ONLY||PROSPECTIVE|||||||
33906384|NCT05588895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988662|NCT04032977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the unblinded treating investigator and unblinded assistant will be unblinded to the treatment. The remainder of study/site personnel remain blinded.|Double-blind, randomized, controlled, multicenter clinical study|t|t|t|t
33988663|NCT03456518|||COHORT||PROSPECTIVE|||||||
33988664|NCT05221086|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33988665|NCT06118047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988666|NCT00731744|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988667|NCT02887339|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988668|NCT03848286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082225|NCT03311867|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34082226|NCT02510339|||COHORT||PROSPECTIVE|||||||
34082227|NCT02821533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082228|NCT00574262|||CASE_ONLY||PROSPECTIVE|||||||
34082229|NCT01082029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082230|NCT05130424|||OTHER||PROSPECTIVE|||||||
34082231|NCT04371016|NA|SINGLE_GROUP||TREATMENT||NONE|Analysis of data will be conducted by a statistician not involved in interventions at bedside|Interventional study evaluating the beneficial impact of verticalization of patients with ARDS on pathophysiological parameters||||
33988669|NCT03199547|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The active study drug and placebo will look identical and will not be identifiable. The study drugs will be allocated to the participants according to the randomisation number|This is a Phase III, double-blind, placebo controlled randomized clinical trial. Women attending the study health facilities in labour will be randomized to receive either a single dose of oral AZI (2g) or placebo (1:1)|t|f|t|t
33988670|NCT05703932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33988671|NCT03238781|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33988672|NCT00766168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988673|NCT05508659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988674|NCT00000261|NA|SINGLE_GROUP||||DOUBLE|||t|t|f|f
33988675|NCT03370250|||CASE_ONLY||RETROSPECTIVE|||||||
33988676|NCT05217524|||CASE_ONLY||PROSPECTIVE|||||||
33988677|NCT01173263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33988678|NCT05945030|||CASE_CONTROL||PROSPECTIVE|||||||
33988679|NCT00574327|||CASE_CONTROL||PROSPECTIVE|||||||
33988680|NCT04829981|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082232|NCT03129932|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|volunteers will receive placebo or gluten corn muffins that are similar in taste and appearance. Investigator does not know who is receiving placebo or gluten muffins. During analyses, each sample is coded to avoid volunteer or phase identification.|double-masked, crossover, randomized, controlled study|t|f|t|f
34082233|NCT00001305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082234|NCT04411615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082235|NCT06313463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082236|NCT05414214|||COHORT||PROSPECTIVE|||||||
33906385|NCT04154267|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will include 100 patients in this work. In the first 48 hours after transplantation 50 patients will be randomized in the protocol biopsy and noninvasive evaluation group and 50 patients for noninvasive evaluation only.||||
33906386|NCT04061980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906387|NCT00843297|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33906388|NCT06221631|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33906389|NCT02146989|||COHORT||CROSS_SECTIONAL|||||||
33906390|NCT02543398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906391|NCT06692712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906392|NCT06682962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient is masked to the treatment group he or she has been assigned to. The determination of the tolerance threshold and the programming of the stimulation parameters on the OkuStim 2 is carried out by unmasked members of the study team as it is impossible to program the OkuStim 2 without knowing the assignment of the patient to the study group. Examinations relating to the primary, secondary or exploratory endpoints are carried out only by masked team members.|Patients are assigned 1:1 to one of two different groups: Sham group (sham treatment) or TES group.|t|f|f|t
33906393|NCT02684240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906394|NCT02797106|||||CROSS_SECTIONAL|||||||
33906395|NCT00833248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906396|NCT02834312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906397|NCT04718987|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, single-arm clinical trial to enroll a total of 10 low- or favourable intermediate-risk prostate cancer patients.||||
33906398|NCT00953550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906399|NCT00844428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906400|NCT00668343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906401|NCT00524108|||COHORT||RETROSPECTIVE|||||||
33906402|NCT01635556|||COHORT||PROSPECTIVE|||||||
33906403|NCT02214199|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33906404|NCT04772183|||COHORT||PROSPECTIVE|||||||
33906405|NCT03023644|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33906406|NCT03611959|||COHORT||RETROSPECTIVE|||||||
33906407|NCT00540449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906408|NCT03613090|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Investigators will screen routine root canal treatment-seeking patients who present normally to clinic as potential study participants. The patients selected will be those who will require root canal therapy as a part of their routine dental care.~Participant will be randomly assigned to one or two groups:"||||
33906409|NCT00668291|||COHORT|||||||||
33906410|NCT04337450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906411|NCT03978494|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33906412|NCT01736202|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33906413|NCT03140800|||CASE_CONTROL||PROSPECTIVE|||||||
33906414|NCT06039254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082237|NCT04550117|NA|SINGLE_GROUP||OTHER||NONE||||||
34082238|NCT02047578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082239|NCT06100952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33906415|NCT02005653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906416|NCT01783522|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33906417|NCT02024711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082240|NCT01825824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082241|NCT01700803|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34082242|NCT01608165|RANDOMIZED|PARALLEL||||NONE||||||
33906418|NCT02740569|||COHORT||CROSS_SECTIONAL|||||||
33906419|NCT06692049|||COHORT||PROSPECTIVE|||||||
33906420|NCT05402501|||COHORT||PROSPECTIVE|||||||
33906421|NCT01911182|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33906422|NCT01356602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906423|NCT04770337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment. Neither the study investigator nor subject shall be notified of the treatment assignment.|multiple site, randomized, double blinded parallel-group controlled study|t|f|t|f
33906424|NCT04070378|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label treatment group.||||
33906425|NCT05024045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906426|NCT00016523|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33988681|NCT05168150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Double (Participant and Expert Rater)~Participants do not know the performance metrics used in calculation of their final composite-score, only that they will be learning and practicing technical skills used in neurosurgery while receiving feedback from an instructor or an intelligent system, in subpial tumor resection procedures.~Experts do not know to which group the video performance they are rating belongs, for the OSATS rating."|Randomized Control trial|t|f|f|t
33988682|NCT02193165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988683|NCT02834026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988684|NCT05352789|||OTHER||OTHER|||||||
33988685|NCT01723397|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33988686|NCT04009486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988687|NCT00505622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988688|NCT00054626|RANDOMIZED|||TREATMENT||||||||
33988689|NCT05345990|NA|SINGLE_GROUP||TREATMENT||NONE||Patients treated in two cohorts for 12 weeks with hepatitis B immunoglobulins||||
33988690|NCT00088829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988691|NCT02900443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082243|NCT03217409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082244|NCT03620448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082245|NCT03307174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082246|NCT04361656|||COHORT||PROSPECTIVE|||||||
34082247|NCT04222543|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Imaging results of HPV positive tumours are compared to imaging results of HPV negative tumours.||||
34082248|NCT04493606|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34082249|NCT02018133|||CASE_ONLY||PROSPECTIVE|||||||
34082250|NCT01493713|NA|SINGLE_GROUP||OTHER||NONE||||||
33988692|NCT01929863|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33988693|NCT03203980|||COHORT||PROSPECTIVE|||||||
33988694|NCT05314647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each participant will be assigned to a group based on a permuted block randomization stratified by participant self-reported sex. Participants may identify male, female or other. If other is selected, assignment as male or female for randomization purposes will be determined by a coin flip. Randomized block lists with a size of 4 will be prepared using a computer generated random number sequence, http://www.jerrydallal.com/random/assigndoc.htm#num (J. Kim \& Shin, 2014). Based on group placement, participants will be provided with Bottle A or Bottle B of gummies to last for the next 90 days.|randomized, double-blind, placebo controlled|t|f|t|t
33988695|NCT01880632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988696|NCT04030286|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33988697|NCT06250309|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Study investigators will be blinded as to the randomization for all participants until all study procedures are completed.|A total of 48 participants will be enrolled in this trial with two phases: Western Diet and Mediterranean Diet. Each participant will complete both phases, with a 6 week wash out period in between the phases. Each participant is randomized, in a 1:1 ratio, to one particular diet. When the first phase is completed, the wash out period begins. After completion of the wash out phase, the participant is crossed over into the other diet.|t|f|t|f
33988698|NCT06124014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988699|NCT05866991|||COHORT||PROSPECTIVE|||||||
33988700|NCT00550758|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33988701|NCT06452472|||COHORT||PROSPECTIVE|||||||
33988702|NCT06558903|||CASE_ONLY||RETROSPECTIVE|||||||
33988703|NCT00752635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33988704|NCT04873518|||FAMILY_BASED||PROSPECTIVE|||||||
33988705|NCT06278844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988706|NCT04032119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988707|NCT04927091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082251|NCT03353792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention consists of treatment with a CL/AP-enabled insulin pump/CGM combination; subjects in the control group will continue their usual diabetes care (insulin pump therapy) along with CGM recording .|The design is a single-site, parallel group, randomized clinical trail. Following enrollement and CGM documentation of hypoglycemia during the 4-week run-in period, study participants are randomized to intervention and control groups.|t|f|f|f
34082252|NCT04139252|||COHORT||PROSPECTIVE|||||||
34082253|NCT01408069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775309|NCT03756454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Upon conclusion of the surgical intervention, the Anesthesia or nursing team will administer the trial medication, Bezlotoxumab, or the placebo, normal saline. Dosing is planned to be ten milligrams per kilogram, which is standard dosing for therapeutic Bezlotoxumab approved for use by the U.S. Food and Drug Administration. This dose will be administered as a one-time single-infusion dose administered over the span of one hour. The placebo administration of normal saline will be at the same dosing with a single-infusion over one hour. The patient will receive standard of care post-operative management and the information obtained from standard-of-care lab draws will be assessed throughout their hospital stay. The patient will be seen and evaluated in clinic in the post-operative period at the one month follow-up and either in clinic or via telephone at their three month and six month follow-up.|Randomization will be performed per best common practice guidelines with a computer generated randomization process and hospital investigational pharmacy blinding processes into both a therapeutic arm (Bezlotoxumab) and a placebo (normal saline) arm of the study. All current standards of care will continue to be administered in these patients, regardless of their respective study arm. To control for the antibiotics administered, the patients will need to be stratified according to the standard-of-care antibiotics and balanced in regards to this variable. Current standard of care therapy at our institution for fulminant C. difficile colitis includes Vancomycin (both oral and rectal, if needed) and intravenous Metronidazole. Fulminant C. difficile colitis is defined, per our guidelines, as proven infection with hypotension/ shock, ileus, or megacolon.|t|t|t|f
34082254|NCT03628651|||COHORT||PROSPECTIVE|||||||
33775310|NCT02498743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33775311|NCT04509830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|randomized control trial|f|t|f|t
33775312|NCT06423599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Anonymized data will be analyzed|This is a investigator-initiated, parallel-group, 2-arm assessor-blinded, open-label, randomised, clinical trial|f|f|f|t
33906427|NCT04520113|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The principal investigators are blinded as to the assignment of treatment to participants||f|f|t|f
33906428|NCT01605071|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33906429|NCT00002206||||TREATMENT||DOUBLE||||||
33906430|NCT03115489|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906431|NCT02946710|||OTHER||RETROSPECTIVE|||||||
34082255|NCT01584713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082256|NCT04128917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082257|NCT02123381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906432|NCT06693908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906433|NCT03566108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906434|NCT00542685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906435|NCT05840770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906436|NCT03774745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo pills in opaque bottle|Randomized, double blind, placebo controlled trial|t|t|t|t
34082258|NCT01698359|||||PROSPECTIVE|||||||
34082259|NCT06080477|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm individually randomized trial||||
34082260|NCT05428956|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Participants will perform the spirometry after use of short acting bronchodilator with a spacer using both single breath and 5-tidal breath on two consecutive days. The investigator, care provider and outcome assessor will be masked for allocation. The spirometry will be performed by a respiratory technician not involved in patient care|All the patients will receive inhaled salbutamol using two techniques during lung function testing on two successive days. Patient will be randomized 1:1 to receive inhaled salbutamol by performing either a single breath holding maneuver or by five tidal breaths on the first day of evaluation. Each patient will undergo spirometry using the other alternative procedure on the next day. The randomization sequence will be computer generated. The sequence generated will be kept in a sealed opaque envelope and will be opened at the time of procedure|t|t|t|t
34082261|NCT00461734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082262|NCT01542008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082263|NCT06019572|||COHORT||RETROSPECTIVE|||||||
34082264|NCT05843409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Controlled Trial (RCT)||||
33906437|NCT00001933||||TREATMENT||||||||
33906438|NCT04420871|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A multicenter, randomized, open-label, three-period, and reference-replicated crossover study||||
33906439|NCT06041698|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33988708|NCT01594203|||COHORT||PROSPECTIVE|||||||
33988709|NCT04280107|||COHORT||RETROSPECTIVE|||||||
33988710|NCT02561520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988711|NCT01979861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988712|NCT05519800|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||randomised counter-balanced|t|f|f|f
33988713|NCT02411903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988714|NCT01796730|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33988715|NCT05941065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988716|NCT04579770|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33988717|NCT02503527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33988718|NCT01354860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775313|NCT05445687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the outcome assessors will be blinded to the type of intervention given.|A comparative intervention study comparing the effect of narrative language intervention on narrative language skills in children with hearing impairment and children with developmental language disorder in comparison to conventional language intervention.|t|f|f|t
33775314|NCT04253704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were not told which arm received treatment versus placebo lotions.|Test materials were applied to forearm skin of each subject. The left arm was used for the test material IDL lotion. The right arm was used for the hydrating control lotion.|t|t|f|t
33775315|NCT00519246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988719|NCT00091052||||TREATMENT||NONE||||||
33988720|NCT05241691|||COHORT||RETROSPECTIVE|||||||
33988721|NCT03171545|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study is a 2X2 factorial design, such that five facilities will get the provider education only; five will get the patient activation intervention only; five will get both interventions; and five will get no interventions.||||
33988722|NCT06366581|||COHORT||RETROSPECTIVE|||||||
33988723|NCT05099198|||COHORT||RETROSPECTIVE|||||||
33988724|NCT02058862|||COHORT||PROSPECTIVE|||||||
33988725|NCT01314391|||CASE_CONTROL||RETROSPECTIVE|||||||
33988726|NCT02584439|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33988727|NCT00813787|||COHORT||PROSPECTIVE|||||||
33988728|NCT04353063|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33988729|NCT02769494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082265|NCT03367000|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label controlled trial||||
34082266|NCT02664675|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082267|NCT00300157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082268|NCT03575416|||COHORT||PROSPECTIVE|||||||
34082269|NCT01613443|||OTHER||RETROSPECTIVE|||||||
34082270|NCT04724135|||COHORT||PROSPECTIVE|||||||
34082271|NCT00846365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082272|NCT01832766|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34082273|NCT06473350|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|To examine the effect of the predetermined right lateral, supine, and prone positions on preterm infants, all infants comprising the sample group were sequentially subjected to all positions. Therefore, blinding was not performed. In this study, preterm infants who met the inclusion criteria for the sample group were selected. The composition of the sample group solely with infants naturally resulted in blinding, as the infants were not aware of the positions being applied.|Experimental study in a single group with three positions applied sequentially||||
34082274|NCT01850641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082275|NCT01079780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082276|NCT01042795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082277|NCT05959928|||COHORT||PROSPECTIVE|||||||
34082278|NCT04811196|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a phase 1/1b single centre study with two arms. Arm A is a dose escalation study assessing the safety, tolerability and preliminary antitumor activity of low dose metronomic Selinexor in adult patients with locally advanced/unresectable or metastatic MPNST, endometrial stromal cell sarcomas or angiogenic tumors. This is a dose escalation study and will consist of ascending doses of Selinexor administered metronomically as a single agent.~Up to 36 patients will be enrolled in Arm A.~Arm B of this study will enroll all soft tissue sarcoma histologies to receive flat dosing Selinexor 40mg in the morning, 20mg in the afternoon and 20mg at night orally on days 1, 8, 15, 22 of a 28-day cycle. Twenty patients will be enrolled to this arm. This pattern will continue until disease progression or unacceptable toxicity. Quality of life assessments will occur at pre-dosing, cycle 2 day 1, cycle 6 day 1 and cycle 12 day 1 for those who remain on study."||||
33775316|NCT03627988|NA|SINGLE_GROUP||OTHER||NONE||||||
33775317|NCT04763135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775318|NCT05553574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33775319|NCT03477461|||OTHER||RETROSPECTIVE|||||||
33775320|NCT01704885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33775321|NCT00180518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775322|NCT00006085||||TREATMENT||||||||
33775323|NCT00533247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775324|NCT01133093|||||CROSS_SECTIONAL|||||||
33775325|NCT03035071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775326|NCT01619787|||||CROSS_SECTIONAL|||||||
33775327|NCT00168194|||COHORT||PROSPECTIVE|||||||
33988730|NCT02294786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988731|NCT05056974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988732|NCT00476281|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988733|NCT01639534|||CASE_ONLY||OTHER|||||||
33988734|NCT01538888|NA|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33988735|NCT03649477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Three parallel groups (two different doses of carbetocin and placebo) for the first 8 weeks; two parallel groups (two different doses of carbetocin) during 56 weeks of follow-up and the optional extension period|t|t|t|t
33988736|NCT04551976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants in the control condition are told that we are interested in better understanding the behavioral habits of gamers. We ask them to complete the tasks as they normally would. Every participant will be debriefed after the final study session has concluded.|"2 x 2 study design with four groups. Half the participants will be randomized to a control condition and half will be randomized to an experimental condition (i.e., mindfulness). All participants will complete each of two study activities, but the order of the activities will be crossed over so that order effects for the activity are minimized. Thus, the groups will be as follows:~Group 1: mindfulness condition and play video game first, fold laundry second Group 2: mindfulness condition and fold laundry first, play video game second Group 3: control condition and play video game first, fold laundry second Group 4: control condition and fold laundry first, play video game second"|t|f|f|f
33988737|NCT00850174|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988738|NCT05839834|||CASE_CONTROL||PROSPECTIVE|||||||
33988739|NCT00678717|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33988740|NCT01098786|||COHORT||PROSPECTIVE|||||||
33988741|NCT04957953|||COHORT||PROSPECTIVE|||||||
33906440|NCT03268746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906441|NCT01600547|||CASE_CONTROL||PROSPECTIVE|||||||
33906442|NCT02883465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906443|NCT03124615|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide||||
33906444|NCT06350604|NA|SINGLE_GROUP||PREVENTION||NONE||All participants receive the same intervention||||
33906445|NCT00758927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906446|NCT03042611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906447|NCT05897138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906448|NCT06376604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Outcomes Assessor|||||
33906449|NCT03844633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention and control injection arms will be blinded. The no injection arm will be unblinded.||t|t|t|t
33906450|NCT06181396|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial of singleton gestations receiving oxytocin during the second stage of labor at a single tertiary medical center. Women will be randomly allocated to one of two groups - immediate initiation of oxytocin at full dilation versus delayed oxytocin initiation following one hour of full dilation.||||
33906451|NCT01222338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906452|NCT00404781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906453|NCT00776776|||COHORT||OTHER|||||||
33906454|NCT04742946|NA|SINGLE_GROUP||TREATMENT||NONE||A quasi-experimental pre-post study||||
33906455|NCT01818622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906456|NCT01166659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906457|NCT06127225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906458|NCT06693765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906459|NCT00178360|RANDOMIZED|CROSSOVER||||NONE||||||
33906460|NCT03797950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906461|NCT00653835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906462|NCT04207567|RANDOMIZED|PARALLEL||OTHER||SINGLE|The researchers assessing outcomes as well as the researcher performing statistical analysis will be blinded to participants' group assignment.|"Participants will be randomized (1:1) to an intervention or waitlist control group. The intervention group will perform one set of the bodyweight exercises (i.e., push-ups, angled-rows, bodyweight squats), with training and coaching, unsupervised every weekday for 12 weeks. The waitlist control group will refrain from resistance training for the initial 12.~After a 12-week follow-up assessment, the intervention group will continue the RT program for an additional 12 weeks, and the waitlist control group will initiate the RT program and continue for 12 weeks. A 24-week follow-up assessment will then be conducted."|f|f|f|t
33906463|NCT02481960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906464|NCT00079612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906465|NCT00815412|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906466|NCT03165981|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906467|NCT01452074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775328|NCT01055106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33775329|NCT01574911|||CASE_ONLY||PROSPECTIVE|||||||
33775330|NCT06228729|||COHORT||PROSPECTIVE|||||||
33775331|NCT06575192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775332|NCT06198660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33775333|NCT05679700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775334|NCT03251404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors (performance tests and neuromuscular function) blinded to group allocation|Two-armed cluster randomized parallel trial|f|f|f|t
33775335|NCT02026713|NON_RANDOMIZED|PARALLEL||||NONE||||||
33775336|NCT03072082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775337|NCT01386515|||||OTHER|||||||
33775338|NCT06160349|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33775339|NCT02380521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775340|NCT05124249|||COHORT||PROSPECTIVE|||||||
33775341|NCT00553020|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33775342|NCT00610675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775343|NCT05906537|NA|SEQUENTIAL||TREATMENT||NONE||||||
33988742|NCT05643911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775344|NCT02580773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775345|NCT00074763|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775346|NCT00802841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775347|NCT02546687|||COHORT||PROSPECTIVE|||||||
33775348|NCT01994720|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33775349|NCT01662427|||COHORT||PROSPECTIVE|||||||
33775350|NCT02148718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775351|NCT06378502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775352|NCT03426917|||OTHER||RETROSPECTIVE|||||||
33775353|NCT05555095|||COHORT||PROSPECTIVE|||||||
33775354|NCT00457613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775355|NCT03261544|||COHORT||PROSPECTIVE|||||||
33775356|NCT01339611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775357|NCT02763891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33775358|NCT03366883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906468|NCT05152160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906469|NCT01201538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906470|NCT03014219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906471|NCT06693323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906472|NCT04557449|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906473|NCT05139368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906474|NCT03641469|NA|SINGLE_GROUP||TREATMENT||NONE|The outcomes assessor will be blinded to brace type when measuring the out-of-brace x-ray.|Current TLSO users will crossover to use of the GSM brace.||||
33906475|NCT00544128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906476|NCT01611402|||COHORT||CROSS_SECTIONAL|||||||
33906477|NCT03357276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906478|NCT00399269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988743|NCT03593512|NA|SINGLE_GROUP||TREATMENT||NONE||"Evaluation of symptomatology before and after implantation of DBS electrodes; followed by cross-over of on and off stimulation"||||
33988744|NCT04127656|NA|SINGLE_GROUP||OTHER||NONE||||||
33988745|NCT04926480|RANDOMIZED|PARALLEL||SCREENING||NONE|low flow high flow|||||
33988746|NCT02781545|||COHORT||PROSPECTIVE|||||||
33988747|NCT04438187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This will be a pragmatic, before-and-after, cluster-randomized, protocol crossover study.||||
33988748|NCT05088577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33988749|NCT02476994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988750|NCT04983433|||OTHER||PROSPECTIVE|||||||
33988751|NCT00202722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988752|NCT00628654|||CASE_CONTROL||PROSPECTIVE|||||||
33988753|NCT03647254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33988754|NCT02360761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988755|NCT00814034|||COHORT||PROSPECTIVE|||||||
33988756|NCT05996926|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33988757|NCT05060926|||COHORT||RETROSPECTIVE|||||||
33988758|NCT00836758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants wore a PAP device and had a PSG at the same time. These participants had their PSG data compared to the PAP data.||||
33988759|NCT02957994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988760|NCT02624050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775359|NCT05620017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775360|NCT00232934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775361|NCT01615991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775362|NCT04313348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33775363|NCT05675917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33775364|NCT04530474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33906479|NCT05738096|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906480|NCT05828264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||this study is an experimental, parallel-group (intervention-control), randomized controlled design||||
33906481|NCT00059436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33906482|NCT04603677|||COHORT||PROSPECTIVE|||||||
33906483|NCT01796353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33906484|NCT01383200|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34082279|NCT04632004|NA|SINGLE_GROUP||PREVENTION||NONE||Patients, visitors, and staff members of the University Medical Center Goettingen are invited to participate within the survey study.||||
33685677|NCT04635670|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Allocation will be masked for both participants and investigators. Only after completion of all study visits by all participants and after database lock the randomization code will be opened.|Randomised, double blinded, placebo controlled, crossover, single-centre study. A total of 46 participants will be randomly assigned into two groups of 23 to a sequence of treatment (active followed by placebo or vice versa). Allocation will be masked for both participants and investigators.|t|t|t|t
33685678|NCT01331018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685679|NCT02034136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685680|NCT04421547|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two arms, prospective, open-label multi center randomized phase III study.||||
33685681|NCT03411837|||COHORT||PROSPECTIVE|||||||
33685682|NCT03234881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treating therapists will be blind to outcome data|This is a randomized RCT in which one half of participants will be assigned to MOVE! (treatment-as-usual weight management) and the other half will be assigned to MOVE! plus the experimental condition (clinician-led Cognitive Behavioral Therapy).|f|t|f|f
33906485|NCT05398003|NA|SEQUENTIAL||TREATMENT||NONE|Patients will only know the stimulation modes|Hierarchical sequential study with a fixed sequence of 3 successive hypotheses = tested with a 5% risk until one hypothesis is rejected. These three successive hypotheses are a non-inferiority test, followed by two superiority tests.||||
33906486|NCT03879668|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Convergent mixed methods design: Quantitative quasi-experimental study with retrospective and prospective control group; Qualitative interviews with patients and focus groups with professionals.||||
33906487|NCT00733356|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||||||
33906488|NCT06178133|||CASE_CONTROL||RETROSPECTIVE|||||||
33906489|NCT05545813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, placebo-controlled, double-blinded.|t|t|t|t
33906490|NCT05184296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906491|NCT02851680|NON_RANDOMIZED|PARALLEL||||NONE||||||
33906492|NCT05469932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient does not know wheater they are on treatment or placebo arm.||t|f|f|f
33906493|NCT04150640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082280|NCT00116688|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906494|NCT02889510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33906495|NCT05892783|RANDOMIZED|PARALLEL||TREATMENT||NONE|due to the nature of the study, neither the participants nor the investigator will be blinded.|two parallel arms interventional studies||||
33906496|NCT05155787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906497|NCT06404125|||COHORT||PROSPECTIVE|||||||
33906498|NCT00608335|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33906499|NCT00001262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906500|NCT03249350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906501|NCT01741194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33906502|NCT02514512|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906503|NCT03166358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Yoga instructor is blind to yoga intervention or waitlist group status of participants.|Participants are randomized to either a hatha yoga intervention or a waitlist control condition.|f|t|f|f
33906504|NCT03958617|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A pragmatic trial with brief randomized, double-blinded sham controlled sequences|t|t|t|t
34082281|NCT00315341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082282|NCT06407817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082283|NCT00158808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082284|NCT02051868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082285|NCT04264208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082286|NCT00435071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082287|NCT02981511|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685683|NCT04673123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685684|NCT00061282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685685|NCT01401959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685686|NCT02225054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685687|NCT00799773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685688|NCT00865488|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33685689|NCT02176720|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33685690|NCT06516718|||OTHER||PROSPECTIVE|||||||
33685691|NCT01240265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685692|NCT01123434|||CASE_ONLY||PROSPECTIVE|||||||
33685693|NCT00540098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33685694|NCT04288544|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33685695|NCT01129869|||||PROSPECTIVE|||||||
33685696|NCT01721980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685697|NCT01585584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685698|NCT01547780|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33685699|NCT01692821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33685700|NCT02522871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685701|NCT00438373|||COHORT||PROSPECTIVE|||||||
33685702|NCT03706651|||CASE_CONTROL||PROSPECTIVE|||||||
33685703|NCT06212687|RANDOMIZED|PARALLEL||OTHER||NONE||The intervention is a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is delivered stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos if needed.||||
33685704|NCT04066764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685705|NCT01733797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685706|NCT02562690|||COHORT||PROSPECTIVE|||||||
33685707|NCT05664854|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685708|NCT04567732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685709|NCT05443607|||COHORT||PROSPECTIVE|||||||
33685710|NCT01128036|||CASE_CONTROL||PROSPECTIVE|||||||
33685711|NCT03551262|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, prospective, randomized, controlled||||
33685712|NCT00312754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685713|NCT06138223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685714|NCT02442401|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685715|NCT03671590|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685716|NCT00701623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685717|NCT03120455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685718|NCT05764070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation and treatment will be carried out by different physiotherapists.||t|f|f|f
33685719|NCT04872270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685720|NCT06436300|RANDOMIZED|PARALLEL||SCREENING||NONE||Parallel arm randomized controlled trial||||
33685721|NCT00968032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906505|NCT06269211|NA|SINGLE_GROUP||TREATMENT||NONE||This study has only one arm, neoadjuvant Toripalimab treatment arm. Primary endpoint is MPR. We apply the optimal design of Simon's two-stage model to calculate the sample size and set both sides α= 0.05 and power=0.8, resulting in a total sample size of 29. Among them, 10 patients will be enrolled in the first stage. If the number of MPR cases in the first stage is less than or equal to 1, the study will be terminated in the early stage; On the contrary, participants in the second stage will continue to be enrolled. If the total number of MPR cases is greater than or equal to 5 after the completion of the second stage, the study is considered positive.||||
33906506|NCT01512394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906507|NCT05183958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906508|NCT05140525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906509|NCT00380354|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33906510|NCT04212494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906511|NCT02884791|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33906512|NCT04963712|NA|SINGLE_GROUP||TREATMENT||NONE||All participants eligible for study received the same open label drug||||
33906513|NCT00002466||||TREATMENT||||||||
33906514|NCT03527056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906515|NCT00130299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906516|NCT02742649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906517|NCT00109317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906518|NCT03588767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with polytrauma will be administered vitamin D3 + anabolic substance. Group of an identical size of patients who were treated in the past without administration of vitamin D3 and anabolic substance will be analyzed retrospectively.||||
33685722|NCT03487978|||CASE_CONTROL||PROSPECTIVE|||||||
33685723|NCT00636987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685724|NCT04757454|||CASE_ONLY||RETROSPECTIVE|||||||
33685725|NCT01245114|||COHORT||PROSPECTIVE|||||||
33685726|NCT01546402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685727|NCT03833518|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a pilot study to collect data to support a VA grant submission to study fMRI and neurophysiological predictors of hand function and recovery during a robotic intervention in people with hand impairments due to stroke or spinal cord injury.||||
33685728|NCT03800472|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Part 1 (SAD IR), Part 2 (SAD MR) and Part 4 (MAD MR) are randomized, double-blind, placebo-controlled; Part 3 (FE MR) is open-label.|t|t|t|t
33685729|NCT00383773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685730|NCT00000253|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33685731|NCT00393042|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33685732|NCT01596556|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33685733|NCT05608928|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|Vivomixx and placebo drug|Multi-site phase II randomised controlled trial|t|f|t|f
33685734|NCT00419809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775365|NCT04064554|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Experimental: BCG vaccination with MicronJet600~2. Comparator: BCG vaccination with conventional needle"||||
33775366|NCT01500226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33775367|NCT06008691|||COHORT||PROSPECTIVE|||||||
33775368|NCT04504084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel Assignment|t|f|f|t
33775369|NCT06563895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775370|NCT01054911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685735|NCT01377285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685736|NCT02330328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685737|NCT03102840|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33775371|NCT01286974|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33775372|NCT03985163|||OTHER||PROSPECTIVE|||||||
33906519|NCT04266860|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study will enroll practicing rheumatologists in the US, who will be randomly assigned to either an intervention or control arm.~All eligible and consented participants will complete two rounds of three patient simulations.~The intervention arm only will receive educational material about the DxTerity test in between these two rounds, and be provided simulated DxTerity test results in the second round of simulated cases."||||
33906520|NCT06397872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906521|NCT05630105|||COHORT||CROSS_SECTIONAL|||||||
33906522|NCT03550326|||COHORT||PROSPECTIVE|||||||
33906523|NCT03241797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906524|NCT02060201|RANDOMIZED|CROSSOVER||||NONE||||||
33906525|NCT01455428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906526|NCT05890963|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants are assigned to 1 to 5 arm sequentially.||||
33906527|NCT06691958|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33906528|NCT04120792|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33906529|NCT06586515|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906530|NCT04871633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685738|NCT02551627|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33685739|NCT00971620|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33685740|NCT03034291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33685741|NCT03108781|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685742|NCT02824861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685743|NCT00704522|||COHORT||PROSPECTIVE|||||||
33685744|NCT03874312|||COHORT||PROSPECTIVE|||||||
33685745|NCT05692973|RANDOMIZED|PARALLEL||TREATMENT||NONE||In year 1 , Participants will be randomized to a variable test condition; repeated test condition; or a placebo condition to determine if the retrieval of knowledge through testing leads to improved inference making. In year 2, participants in the variable and repeated test conditions will receive a short intervention to determine if direct instruction in inferencing leads to improved inferencing and comprehension.||||
33685746|NCT06097143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685747|NCT00544102|||COHORT||CROSS_SECTIONAL|||||||
33685748|NCT04920227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685749|NCT03785275|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33906531|NCT03661073|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33906532|NCT03694574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906533|NCT06674499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906534|NCT02778867|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906535|NCT05633576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906536|NCT00013403|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988761|NCT00522262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775373|NCT04051905|||COHORT||PROSPECTIVE|||||||
33775374|NCT00003175||||TREATMENT||||||||
33775375|NCT06283043|||CASE_CONTROL||PROSPECTIVE|||||||
33775376|NCT06363435|||COHORT||PROSPECTIVE|||||||
33775377|NCT00872469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775378|NCT02338713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33906537|NCT00387660|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906538|NCT02471248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33906539|NCT02880644|||COHORT||PROSPECTIVE|||||||
33906540|NCT03378258|||COHORT||PROSPECTIVE|||||||
33906541|NCT00594152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906542|NCT04163146|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906543|NCT06669676|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906544|NCT03704792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906545|NCT05153733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906546|NCT00928473|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33906547|NCT06693466|||COHORT||CROSS_SECTIONAL|||||||
33906548|NCT04499950|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||f|f|f|t
33906549|NCT02191085|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33906550|NCT05553548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33906551|NCT03100435|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants will wear a mouth guard holding 8 titanium discs for 3 days, during which time a natural bacterial biofilm will form on the disc surfaces. After 3 days, the discs will be removed from the mouthguard, and treated ex vivo with different decontamination methods.||||
33906552|NCT04272554|||CASE_ONLY||OTHER|||||||
33906553|NCT06692387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082288|NCT01792739|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33685750|NCT04535167|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||"Part 1 will have 2 planned cohorts. Each escalating cohort will be initiated for enrollment after assessment of safety, tolerability and PK data from previous cohorts by an independent IRC and is deemed acceptable.~Part 2 will have 2 planned cohort and each escalating cohort will be initiated after all safety, tolerability and PK data from previous cohort is evaluated and is deemed acceptable by a competent regulatory authority."|t|t|t|f
33685751|NCT01854541|||COHORT|||||||||
33685752|NCT04615455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685753|NCT00224653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33685754|NCT00470665|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33685755|NCT00947050|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33685756|NCT05776602|||COHORT||PROSPECTIVE|||||||
33685757|NCT06341803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685758|NCT05530629|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, the three experimental groups will conduct different intensities resistance training, and the control group take the normal P.E. course.|t|f|t|t
33685759|NCT00474656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685760|NCT06332469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group gets immediate access to the 9 week program, and the waitlist control group gets access after a 9 week waiting period.||||
33685761|NCT01879540|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33685762|NCT00734760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685763|NCT01113476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685764|NCT03585127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685765|NCT00477958|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33685766|NCT00476047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906554|NCT06421428|||OTHER||CROSS_SECTIONAL|||||||
33906555|NCT05130034|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906556|NCT04250298|NA|SINGLE_GROUP||TREATMENT||NONE||This monocentric study (single cohort study design) is classified as a food study (application of the commercially available supplement OLEOvital® EISEN FORTE) in an interventional setting (study-related measures: additional blood tests and oral intake of OLEOvital® EISEN FORTE).||||
33906557|NCT02552355|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants were assigned to either Metformin-Protein, Metformin-Carbohydrate, Placebo-Protein, and Placebo-Carbohydrate.|t|f|t|f
33906558|NCT02200458|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33906559|NCT06386653|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33906560|NCT04151017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906561|NCT01103349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906562|NCT02998437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906563|NCT06018831|NA|SINGLE_GROUP||SCREENING||NONE||||||
33906564|NCT00483288||||HEALTH_SERVICES_RESEARCH||||||||
33906565|NCT03066817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906566|NCT02234583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906567|NCT06176040|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988762|NCT01931007|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33988763|NCT00539110|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33988764|NCT05118412|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33988765|NCT02182817|||COHORT||PROSPECTIVE|||||||
33988766|NCT01149473|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988767|NCT03075761|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988768|NCT02001441|||COHORT||PROSPECTIVE|||||||
33988769|NCT01720147|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33988770|NCT04608188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988771|NCT03453476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Allocation of test and control quadrants were done randomly by asking each study participant to choose either numbers 1 or 2. Number 1 defined quadrants 1 and 3 as the test quadrants while number 2 referred to quadrants 2 and 4 as the test quadrants. The remaining quadrants served as the control quadrants."|Split-mouth design|t|t|t|f
33988772|NCT04391621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, investigators and outcome assessors will be blinded from the treatment allocation groups. The treatment groups will be recorded such that the assessors will be unaware of the treatment allocations that the participants were involved.|Parallel group single centre randomised control pilot trial with a 1:1 ratio.|t|f|t|t
33988773|NCT05402553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33988774|NCT05672264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988775|NCT03491072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988776|NCT04395586|||COHORT||PROSPECTIVE|||||||
33988777|NCT05854186|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be clients at local WIC agency sites where either the telehealth solution is offered or where only usual care is available (control).||||
33988778|NCT03974685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment drug:0.3mCi/kg||||
33988779|NCT05963035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988780|NCT05506007|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988781|NCT02827266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988782|NCT03248635|||OTHER||CROSS_SECTIONAL|||||||
33988783|NCT01494532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988784|NCT00439491|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33988785|NCT01305681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Please close this study at ct.gov as we have not further data at NCH as Dr. Vanderbrink left NCH in 2011.|It appears Dr. Vanderbrink left Nationwide Children's Hospital in 2011 and efforts to reach Dr. Vanderbrink have been unsuccessful. The study expired with the NCH IRB before it was ever approved for a 2nd year.||||
33988786|NCT02950987|NA|SINGLE_GROUP||SCREENING||NONE||||||
33988787|NCT01543217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988788|NCT00007605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33988789|NCT02857322|NA|SINGLE_GROUP||||NONE||||||
33988790|NCT05236764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988791|NCT00068991|NON_RANDOMIZED|PARALLEL||||NONE||||||
33988792|NCT01846572|||CASE_ONLY||PROSPECTIVE|||||||
33685767|NCT05047627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685768|NCT04425044|||COHORT||PROSPECTIVE|||||||
33685769|NCT03754192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Dual-energy computed tomography and perfusion computed tomography||||
33685770|NCT02386683|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33685771|NCT00753090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906568|NCT05629416|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples||||
33906569|NCT05155696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|a randomly generated 6-digit participant code will be allocated to each participant as a unique identifier for all data collection.|Randomised double-blind quantitative repeated measures design|t|t|t|t
33906570|NCT01566123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906571|NCT01737619|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906572|NCT05054933|NA|SINGLE_GROUP||OTHER||NONE||||||
33906573|NCT05755191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906574|NCT00849433|||COHORT||PROSPECTIVE|||||||
33685772|NCT04983953|||CASE_CONTROL||RETROSPECTIVE|||||||
33906575|NCT05910801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906576|NCT02793167|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33988793|NCT05261945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Our study will be double-blinded, outcome assessor-blinded and patient- blinded. The assessor will be blinded to avoid being biased during the outcome assessment. And, participants will be blinded to avoid the their incompliance during sessions.||t|f|f|t
33988794|NCT06445192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessments will be obtained by research staff blinded to treatment group assignment.||f|f|f|t
33988795|NCT00939718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988796|NCT02319590|||COHORT||PROSPECTIVE|||||||
33988797|NCT03036085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988798|NCT03387072|||CASE_CONTROL||PROSPECTIVE|||||||
33988799|NCT04036539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only one external research collaborator, with dental training, who will be responsible for the treatments (which will open the envelopes of randomization), will know which photobiomodulation treatment will be assigned to each patient. The identification of each group will be revealed by this collaborator to all involved only after statistical analysis of the data. Therefore, the researcher responsible for data collection, and the statistician will be blinded to the treatments assigned to the groups. The patient will also be blind to the type of treatment performed since the mini-implant placement treatment will be identical in both groups and the laser treatment for photobiomodulation will be simulated in the control group.|34 individuals will be randomly divided into 2 groups: G1 (control group) - verticalization by mini-implant + PBM simulation (placebo); G2 (experimental group) - verticalization by mini-implant + PBM.|t|f|t|f
33988800|NCT06017635|||COHORT||PROSPECTIVE|||||||
33988801|NCT05593991|NA|SINGLE_GROUP||OTHER||NONE||||||
33988802|NCT02045563|||OTHER||PROSPECTIVE|||||||
33988803|NCT01650350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024961|NCT06633614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Blinding The investigators will not be blinded, as they will be responsible for prescribing the intervention bundle to participants in the intervention arm. However, hospital staff, including nurses and surgeons, will be blinded to the allocation of study arms. It is acknowledged that maintaining full blinding for the treating team in the postoperative period may be challenging, as study details could potentially be disclosed by participants who are not blinded. Efforts will be made to minimise such disclosures to preserve blinding where possible.|This randomized controlled trial (RCT) will compare a prehabilitation program using wearable technology (swSEP) with standard preoperative care (uSEP) in elderly patients undergoing major abdominal surgery. Participants will be randomly assigned to either the intervention or control group, with stratification based on baseline physical function, surgical risk, and physiotherapist involvement. The intervention group will follow a personalized exercise program, remotely supervised via telemedicine, and monitored through a Fitbit Aspire 3 device. The control group will receive standard care without wearable technology. The trial will assess improvements in physical function, postoperative outcomes, and recovery at 4 weeks, aiming to determine the superiority of the prehabilitation program over standard care.||||
33685773|NCT05093790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685774|NCT05851001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized-controlled clinical trial||||
33685775|NCT05503927|||COHORT||RETROSPECTIVE|||||||
33685776|NCT01354873|||CASE_ONLY||PROSPECTIVE|||||||
33906577|NCT00914199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906578|NCT06692621|||COHORT||CROSS_SECTIONAL|||||||
33906579|NCT02758886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906580|NCT04442334|||COHORT||PROSPECTIVE|||||||
33906581|NCT03452150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906582|NCT00493948|||COHORT||PROSPECTIVE|||||||
33906583|NCT00705224|||COHORT||PROSPECTIVE|||||||
33906584|NCT01112930|||COHORT||CROSS_SECTIONAL|||||||
33906585|NCT02817555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906586|NCT05092815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906587|NCT00192335|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33906588|NCT06153693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906589|NCT04415489|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial comparing satisfaction between saline infusion sonography and office hysteroscopy for screening evaluation of the uterine cavity prior to embryo transfer.||||
33906590|NCT05055635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906591|NCT03924674|RANDOMIZED|CROSSOVER||OTHER||NONE||All sites will participate in a stepped wedge cluster randomized trial. This design is helpful when simultaneous implementation of an intervention is not feasible or practical, and allows for each site to collect baseline data for comparison with post-intervention data. There will be 3 groups (or clusters) of approximately 30-40 sites each, with randomization to intervention occurring at 2 month intervals. Randomization will be stratified by: geographic region, size and baseline rate of IVF use. By the end of the project, all sites in all groups will have received the intervention toolkit.||||
33906592|NCT04527172|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082289|NCT04592016|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34082290|NCT05368948|||OTHER||CROSS_SECTIONAL|||||||
34082291|NCT02553174|||COHORT||PROSPECTIVE|||||||
33685777|NCT00860977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685778|NCT00251004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685779|NCT01146210|||CASE_ONLY||RETROSPECTIVE|||||||
33685780|NCT05983887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind Randomised Controlled Trial|f|f|f|t
33685781|NCT00603772|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33685782|NCT00000506|RANDOMIZED|PARALLEL||TREATMENT||||||||
33685783|NCT01490398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685784|NCT01288976|||COHORT||PROSPECTIVE|||||||
33685785|NCT02742246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685786|NCT00447200|||||PROSPECTIVE|||||||
33685787|NCT02744937|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33685788|NCT02902679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685789|NCT03745820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685790|NCT02704845|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33685791|NCT02836743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685792|NCT06242444|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33685793|NCT04139200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients in the control group will receive a sham version of the smartphone application. Patients are unaware of the difference between the coaching programs.|1:1 randomization|t|f|f|f
33685794|NCT00489190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685795|NCT06123182|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Primary investigator is masked to intervention assignment. Participants are masked to the intervention - however may be able to figure out intervention based on the guided imagery content|2 (positive affect imagery vs. neutral) x 2 (episodic future thinking vs. recent thinking)|t|f|t|f
33685796|NCT03737851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685797|NCT06147375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685798|NCT02203084|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33685799|NCT05530512|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE||two by two factorial design for a 4 arm study.|t|f|t|t
33685800|NCT02050126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685801|NCT03080077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685802|NCT01039012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685803|NCT02816164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685804|NCT03609398|NA|SINGLE_GROUP||PREVENTION||NONE||vaccine to be administered in 1.0mL doses SQ in the upper outer aspect of the arm||||
33685805|NCT01501045|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33685806|NCT03199339|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Part 1 and Part 2 participants will be masked, Part 3 participants will not be masked.||t|f|f|f
33685807|NCT06422754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33685808|NCT00342121|||CASE_CONTROL||PROSPECTIVE|||||||
33906593|NCT03475888|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Single center pilot study of patients with CTO.||||
33906594|NCT02000986|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906595|NCT04503486|||COHORT||PROSPECTIVE|||||||
33906596|NCT02725892|||COHORT||PROSPECTIVE|||||||
33906597|NCT04633824|||CASE_CONTROL||RETROSPECTIVE|||||||
33906598|NCT05027646|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a single-center, randomized, 2-part, open-label, crossover study in healthy subjects to establish BE (Part 1) and evaluate adhesion (Part 2) between granisetron transdermal patches.||||
33906599|NCT03709888|||COHORT||PROSPECTIVE|||||||
33906600|NCT05416931|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33906601|NCT06159400|||CASE_ONLY||OTHER|||||||
33906602|NCT00235846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906603|NCT01358500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906604|NCT03342612|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Magnetic resonance imaging (MRI) to assess cerebral blood flow using Arteria Spin Labelling (ASL), structural changes using Diffusion Tensor Imaging (DTI), susceptibility weighted imaging (SWI), and functional changes using BOLD resting-functional MRI.||||
33906605|NCT02426983|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33906606|NCT02046343|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33906607|NCT01695980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906608|NCT06637826|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33906609|NCT04541849|||COHORT||RETROSPECTIVE|||||||
33906610|NCT02796690|||COHORT||CROSS_SECTIONAL|||||||
33906611|NCT06297460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906612|NCT05355090|RANDOMIZED|PARALLEL||TREATMENT||NONE||24 volunteers with pre-diabetes or Type 2 diabetes mellitus (n=24) will be quasi-randomized to one of the two groups matched by sex (men/women) and body weight. Participants will be enrolled in the study as a single cohort and participate in a 8-week protein supplementation regimen consisting of three daily servings of whey protein along with their typical dietary intake.||||
33906613|NCT01013948|||||CROSS_SECTIONAL|||||||
33906614|NCT05692193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906615|NCT04451434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Three-way crossover||||
33906616|NCT04990245|||COHORT||PROSPECTIVE|||||||
33906617|NCT06691997|||CASE_ONLY||CROSS_SECTIONAL|||||||
33906618|NCT00194636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906619|NCT04105543|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, dose escalation and dose expansion study||||
33906620|NCT04637659|||OTHER||CROSS_SECTIONAL|||||||
33906621|NCT05022004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906622|NCT06693349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906623|NCT00850759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906624|NCT02300077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906625|NCT02341170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906626|NCT01864642|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33906627|NCT00720239|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906628|NCT05951764|||COHORT||PROSPECTIVE|||||||
34082292|NCT06388772|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34082293|NCT00087178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082294|NCT04320498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082295|NCT02206347|NA|SINGLE_GROUP||||NONE||||||
34082296|NCT00821535|NA|SINGLE_GROUP||||NONE||||||
33775379|NCT04994574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775380|NCT04890522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775381|NCT00019890||||TREATMENT||||||||
33775382|NCT03856021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775383|NCT05719285|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Men and women 18 years of age or older with refractory overactive bladder or neurogenic bladder will be randomized in a 1:1 ratio into one of two groups until the targeted sample size is met:~* The single dose group will receive one dose of antibiotic prior to intradetrusor Botox injection.~* Individuals in the multi-dose group will receive one dose of antibiotic prior to intradetrusor Botox injection and additional antibiotics for a total of three days of antibiotic administration.~Random permuted block randomization with block sizes of 2, 4, 6, and 8 will be used to assign eligible patients to treatment groups"||||
33775384|NCT04028115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775385|NCT00579930|||CASE_ONLY||PROSPECTIVE|||||||
33775386|NCT00000719||||TREATMENT||NONE||||||
33775387|NCT02249871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775388|NCT06416618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary investigator will conduct the blinded statistical analysis through data anonymization and will be supervised by a biostatistician. After the blinded statistical analysis has been completed, two abstracts will be written based on the pre-blinding analysis results before the blinding is revealed.|The study is a two-center, parallel-group, randomized, superiority trial|f|f|f|t
33775389|NCT00554983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775390|NCT04097561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775391|NCT04491643|NA|SINGLE_GROUP||TREATMENT||NONE||Simon two-stage optimal design||||
33775392|NCT05197075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33775393|NCT06493838|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33775394|NCT01589302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775395|NCT03753971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775396|NCT04730934|||COHORT||PROSPECTIVE|||||||
33775397|NCT01932047|||||PROSPECTIVE|||||||
33775398|NCT03978754|||COHORT||PROSPECTIVE|||||||
33775399|NCT04833309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775400|NCT00994136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775401|NCT01259336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775402|NCT04052971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775403|NCT01702428|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33775404|NCT04507672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cluster-randomized, multiple-center trial||||
33775405|NCT03807492|||COHORT||PROSPECTIVE|||||||
33775406|NCT02254096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775407|NCT04946305|||COHORT||PROSPECTIVE|||||||
33775408|NCT00600743|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33775409|NCT00951561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775410|NCT00730990|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33775411|NCT05881083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775412|NCT03800160|||CASE_ONLY||PROSPECTIVE|||||||
33906629|NCT00690716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906630|NCT02979795|||CASE_ONLY||PROSPECTIVE|||||||
33906631|NCT05859880|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Waitlist control||||
33906632|NCT00554021|||COHORT||PROSPECTIVE|||||||
33906633|NCT01740622|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906634|NCT06613841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906635|NCT05805462|||COHORT||PROSPECTIVE|||||||
34082297|NCT03191799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082298|NCT01107925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33906636|NCT06692218|NA|SINGLE_GROUP||OTHER||NONE||||||
33906637|NCT06693076|||COHORT||OTHER|||||||
33906638|NCT06315088|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906639|NCT06693505|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE||A Double-blind Randomized Crossover Controlled Trial|t|t|t|t
34082299|NCT01677026|||CASE_ONLY||PROSPECTIVE|||||||
34082300|NCT04478838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082301|NCT03289078|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34082302|NCT02732639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082303|NCT05110508|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082304|NCT05342896|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|It will be a single-blind trial; only the assessors will be blinded to the treatment assignment.||f|f|f|t
34082305|NCT05228067|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Stimulation protocol is applied in a double blind fashion.|All participants receive sham stimulation, anodal stimulation and cathodal stimulation in a pseudo-randomized order on three separate measurement days.|t|f|t|f
34082306|NCT02644018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082307|NCT00206349|||||RETROSPECTIVE|||||||
34082308|NCT04268693|||COHORT||PROSPECTIVE|||||||
34082309|NCT02783638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082310|NCT02938468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775413|NCT01080196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33775414|NCT00334425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775415|NCT02909101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33775416|NCT01811563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775417|NCT06245837|||COHORT||PROSPECTIVE|||||||
33775418|NCT01615588|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33775419|NCT00014339||||TREATMENT||||||||
33906640|NCT03734107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomized in a 1:1 ratio to the intervention group or standard care comparison group|f|f|f|t
33906641|NCT00989430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906642|NCT02629523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775420|NCT00772798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775421|NCT01570179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33775422|NCT02234310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775423|NCT02117674|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33775424|NCT02378064|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33775425|NCT04668664|||COHORT||PROSPECTIVE|||||||
33775426|NCT01971320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775427|NCT00734890||||TREATMENT||||||||
33775428|NCT01358630|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33775429|NCT04477850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775430|NCT04033224|||COHORT||PROSPECTIVE|||||||
33775431|NCT01484158|||CASE_ONLY||PROSPECTIVE|||||||
33775432|NCT03841825|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33906643|NCT03778177|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will use of transcranial electrical stimulation (tES) to evaluate pain in patients with Trigeminal Neuralgia (TN).||||
33906644|NCT05399628|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Due to the characteristics of the intervention, both participants and outcome assessors cannot be masked. The statistician will be blind to the intervention arms.|Participants in AB arm will be assigned to perform the procedure with LISA catheter with marked tip, followed by the procedure with LISA catheter with unmarked tip. Participants in BA arm will be assigned to the reverse sequence. A washout period of 6 hours (one procedure in the morning and one in the afternoon) will be included to reduce any carryover effect||||
33906645|NCT04567316|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33906646|NCT06027242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988804|NCT03409367|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|"Due to the nature of the intervention, it is not possible blind dyads to the intervention. Administering a placebo emollient is impossible as there are no active ingredients in the emollient and using an emollient that has no barrier improvement properties may irritate the skin. The clinician completing the final assessment will be a blinded assessor.~Clinic staff will not be informed of participant enrollment or study arm. Parents will be instructed not to disclose their treatment group to clinic staff. Clinicians and clinic staff will direct participants to follow skin care recommendations as described by the study materials.~Blinded researchers will be responsible for health record review to collect the primary outcome. At completion of health record review, researchers will complete a form measuring whether the assessor became unblinded while reviewing the record."|"This is a pragmatic, multi-site, randomized community-based trial in which dyads of a parent or legal guardian (parent) and an infant age 0 to 2 months are enrolled. Participating dyads are randomly assigned to receive lipid-rich emollient with web-based instructions for daily use to infants plus routine skin care instructions (every day moisturizer group) or routine skin care instructions alone (natural skin group). Both groups will receive e-mail and text message reminders to follow protocol instructions based on their group allocation until the infant reaches 24 months old."|f|t|t|t
33988805|NCT03681080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988806|NCT01498172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988807|NCT04889586|NA|SINGLE_GROUP||SCREENING||NONE||Each subject is assessed with a clinical protocol and an instrumental test, consists in executing 10 hand gestures by wearing a EMG-biofeedback armband||||
33988808|NCT02810886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988809|NCT00803153|||COHORT||RETROSPECTIVE|||||||
33988810|NCT05087745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988811|NCT04530656|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33988812|NCT01504763|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33988813|NCT00652288|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988814|NCT01082926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988815|NCT06220097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988816|NCT01177020|||CASE_CONTROL||RETROSPECTIVE|||||||
33988817|NCT01933360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988818|NCT02613754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988819|NCT00002601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988820|NCT05212363|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Twelve healthy collegiate esport players will be recruited for this single-arm pilot study.||||
33988821|NCT02135263|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33988822|NCT05401734|||COHORT||PROSPECTIVE|||||||
33988823|NCT03205774|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33988824|NCT06139588|||CASE_CONTROL||RETROSPECTIVE|||||||
33988825|NCT03999684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988826|NCT06099795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988827|NCT03531021|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, attention-matched trial with 1:1 randomization at a single center. Subjects will be randomized in two strata, by age (14-16 years and 17-19 years).||||
33988828|NCT04531605|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33988829|NCT00568672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33988830|NCT05658783|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analysed by a independent researcher||f|f|f|t
33988831|NCT03600467|NA|SINGLE_GROUP||TREATMENT||NONE||START is an open-label, single-arm, multicentre Phase IIa signal-seeking trial.||||
33775433|NCT04735250|||CASE_CONTROL||PROSPECTIVE|||||||
33775434|NCT01877096|RANDOMIZED|PARALLEL||||NONE||||||
33775435|NCT01554254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775436|NCT04201522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized to training group or sham group.|The study is a randomized, controlled, parallel-group trial.|t|f|f|f
33775437|NCT01607814|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33775438|NCT00542659|||COHORT||PROSPECTIVE|||||||
33775439|NCT06313983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775440|NCT02726178|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33906647|NCT04841304|||COHORT||PROSPECTIVE|||||||
33988832|NCT04487691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988833|NCT04741893|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988834|NCT01827163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082311|NCT01298206|||CASE_CONTROL||PROSPECTIVE|||||||
34082312|NCT02035566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082313|NCT05576064|||CASE_ONLY||RETROSPECTIVE|||||||
34082314|NCT04437758|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Sealed opaque packets coded by Sponsor's Product Development||t|t|t|t
34082315|NCT00942916|||CASE_CONTROL||PROSPECTIVE|||||||
34082316|NCT01981616|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082317|NCT06207955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082318|NCT03012269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082319|NCT01212796|||||RETROSPECTIVE|||||||
34082320|NCT02349555|NA|SINGLE_GROUP||||NONE||||||
34082321|NCT01429090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34082322|NCT03830099|||OTHER||OTHER|||||||
34082323|NCT01482546|||COHORT||PROSPECTIVE|||||||
33906648|NCT02495649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906649|NCT05817773|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Breastfeeding cradle with remote control system is designed for the mother to breastfeed her baby comfortably. The mother can breastfeed her baby in any position without getting out of bed. Thanks to the remote control, it can give the cradle the desired position. She can safely breastfeed her baby in the cradle with seat belt and safety lock. Breastfeeding cradle with massage, music and light system will provide high comfort for mother and baby.||||
33906650|NCT06692114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|f|t|t
33906651|NCT03969901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906652|NCT02641119|||COHORT||RETROSPECTIVE|||||||
33906653|NCT06675513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906654|NCT03552549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906655|NCT02990637|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33988835|NCT02009163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988836|NCT06288035|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessors will be blinded to the group allocation.|This is a parallel, two-arm, randomized (1:1), controlled, single-center non-inferiority trial. Adults (≥18 years) with ASA physical status I-III scheduled for elective laparoscopic cholecystectomy will be eligible for inclusion. The participants will be randomized to receive either 8 mg of IV Dexamethasone at the time of induction of anesthesia or 8 mg of oral Dexamethasone at night before surgery. The primary outcome will be the incidence of postoperative nausea and vomiting. 814 patients are intended to be recruited for this non-inferiority trial.|f|f|f|t
33988837|NCT04660747|||COHORT||PROSPECTIVE|||||||
33988838|NCT01868945|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33988839|NCT06180460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988840|NCT05718284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988841|NCT01915186|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33988842|NCT00231829|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33685809|NCT05320744|||OTHER||PROSPECTIVE|||||||
33685810|NCT05067998|||COHORT||PROSPECTIVE|||||||
33685811|NCT04357691|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33721400|NCT05383560|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Pharmacy will be responsible for all IPs masking, using a masking sleeve on ready to use each injection.|Protocol versions 1.01-1.06:Randomized, Observer-Blinded (2:2:1 ratio) Protocol version 1.07:Randomized, Observer-Blinded (1:1 ratio)|t|f|t|f
33721401|NCT04208594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33906656|NCT06693180|||COHORT||RETROSPECTIVE|||||||
33906657|NCT02994069|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded trial|||||
34082324|NCT01474395|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34082325|NCT03011996|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34082326|NCT03499795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082327|NCT01677585|||COHORT||PROSPECTIVE|||||||
34082328|NCT02522117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082329|NCT03572712|||CASE_ONLY||PROSPECTIVE|||||||
34082330|NCT05596071|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34082331|NCT04624113|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34082332|NCT05547958|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34082333|NCT02611947|||CASE_ONLY||PROSPECTIVE|||||||
34082334|NCT04165122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Block randomisation|Randomized, Double-Blind, Double-Dummy|t|f|t|f
34082335|NCT02830568|||COHORT||PROSPECTIVE|||||||
34082336|NCT00972621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082337|NCT04191746|||OTHER||PROSPECTIVE|||||||
33906658|NCT05620836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized 1:1:1 to Povorcitinib Dose A, Povorcitinib Dose B, or Placebo once a day (QD); participants who complete the placebo-controlled (PC) 12-week period may continue to a 42-week extension (EXT) period with Povorcitinib (Dose A or Dose B) QD.|t|t|t|t
33685812|NCT05330078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Keloid treatment will be randomized. Participants will not be informed of which side will be treated with botulinum toxin type A vs vehicle control (saline).~Blinded physician evaluators will not have access to information regarding keloid treatment."|This is a single center, randomized, single-masked, prospective experimental study. Half the keloid tissue will be treated with Botulinum toxin type A while the other half will be treated with a vehicle control (saline) of matching number of injections and volume. All treated keloids will serve as their own internal control. The treatment and control sides of the keloid will clearly be documented in the patient's chart and source documents to allow the study physician to track treatment vs vehicle control portions of the keloid.|t|f|f|t
33906659|NCT01570985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906660|NCT03419026|||COHORT||PROSPECTIVE|||||||
33906661|NCT02043301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33906662|NCT05447377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33906663|NCT06190210|||COHORT||PROSPECTIVE|||||||
33906664|NCT03895775|||COHORT||CROSS_SECTIONAL|||||||
33906665|NCT00429377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906666|NCT06371872|||COHORT||PROSPECTIVE|||||||
33685813|NCT06506071|||CASE_CONTROL||OTHER|||||||
33906667|NCT06554626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906668|NCT06646692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906669|NCT03357822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906670|NCT00676273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906671|NCT05886647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906672|NCT04317482|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33685814|NCT02686281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33685815|NCT00401362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685816|NCT05242315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685817|NCT06318962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685818|NCT03042273|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33685819|NCT05166239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685820|NCT04231591|||CASE_CONTROL||PROSPECTIVE|||||||
33685821|NCT01185431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685822|NCT02541383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685823|NCT02918981|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33685824|NCT03175848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685825|NCT05413278|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685826|NCT03849027|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind|randomised, controlled, cross-over|t|f|t|t
33685827|NCT05561075|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33685828|NCT05130944|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster randomized comparative feasibility trial|t|f|f|f
33685829|NCT04500938|||COHORT||PROSPECTIVE|||||||
33685830|NCT00911378|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33685831|NCT04422795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685832|NCT03662230|||COHORT||RETROSPECTIVE|||||||
33685833|NCT00744822|||||PROSPECTIVE|||||||
33685834|NCT05384704|NA|SINGLE_GROUP||TREATMENT||NONE||The purpose of this research project is to assess the effectiveness of a novel internet-based cognitive behavioral therapy (iCBT) program called Empower@Home. The program is intended to decrease depression in participants by encouraging them to participate in meaningful and enjoyable activities while challenging problematic thinking patterns.||||
33685835|NCT03573102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685836|NCT02643069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33685837|NCT00434239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685838|NCT04292977|||COHORT||PROSPECTIVE|||||||
33685839|NCT05520242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33685840|NCT04279288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685841|NCT04089215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685842|NCT04420754|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33685843|NCT02397564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685844|NCT00358072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685845|NCT05176561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Control group will be told that their treatment might improve attention and concentration which in turn might improve communication ability.|Two randomly assigned treatment groups with each receiving a different treatment that is parallel for time.|t|f|t|t
33775441|NCT06480643|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||two-arm parallel-group exploratory trial including a total of 69 patients|t|t|t|f
33775442|NCT03340155|NA|SINGLE_GROUP||OTHER||NONE||Biomarker search;||||
33906673|NCT04877015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906674|NCT05147129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33906675|NCT01279538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906676|NCT02307019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33685846|NCT01525173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33906677|NCT03321552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906678|NCT02945449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906679|NCT06149403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel assignment|f|f|f|t
33906680|NCT02558738|||CASE_CROSSOVER||PROSPECTIVE|||||||
33906681|NCT06189001|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33906682|NCT05121857|||COHORT||CROSS_SECTIONAL|||||||
33685847|NCT01209832|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33685848|NCT02782078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685849|NCT04170231|||COHORT||PROSPECTIVE|||||||
33685850|NCT05543434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685851|NCT01386905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775443|NCT05800119|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants were not made aware of the condition they were assigned to.||t|f|f|f
33775444|NCT00041795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775445|NCT05697432|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33775446|NCT02391038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775447|NCT02729636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775448|NCT00134524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775449|NCT02622971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775450|NCT05760430|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33906683|NCT04207853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|group the patient will enter. The patient will be allocated among three groups. After the final evaluations, all data will be analyzed by another researcher directed solely to that purpose. Therefore, there will be a triple blinding (researcher, patient and statistician).|"6 groups: whole body vibration in diabetics (G1), the sham vibration group in diabetics (G2) and diabetic control group (G3), the whole body vibration group in non-diabetics (G4), the vibration group  sham in non-diabetics (G5) and non-diabetic control group (G6), establishing a single treatment session for G1, G2, G4 and G5."|t|t|t|f
33906684|NCT04290962|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685852|NCT04500275|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33685853|NCT03199001|||COHORT||PROSPECTIVE|||||||
33685854|NCT02970201|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33988843|NCT01110109|||CASE_ONLY||PROSPECTIVE|||||||
33988844|NCT00681798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988845|NCT01481363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685855|NCT04045509|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33685856|NCT06057740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685857|NCT02438358|NA|SINGLE_GROUP||OTHER||NONE||||||
33685858|NCT02414503|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33685859|NCT04128787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33685860|NCT04281953|||COHORT||CROSS_SECTIONAL|||||||
33685861|NCT02153710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685862|NCT06335147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685863|NCT04473573|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|Bi-directional sequencing results will not be shard with the participants, operators or Principal investigators.|All subjects receive the same number and type of test for the duration of the study.|t|f|t|f
33685864|NCT00088036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685865|NCT00762424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33685866|NCT01043042|||COHORT||RETROSPECTIVE|||||||
33685867|NCT03146936|||COHORT||PROSPECTIVE|||||||
33685868|NCT04841473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685869|NCT03540043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment were packaged in identical jars. Eligible patients will be randomized in a 1:1:1:1 ratio to receive either one of 3 concentrations of PUR 0110 cream (0.05%, 0.1% and 0.25%) or vehicle (placebo).|Randomized, Double-Blind, Parallel-Group, Placebo-controlled|t|t|t|t
33685870|NCT05459948|||COHORT||PROSPECTIVE|||||||
33685871|NCT02280083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685872|NCT06516367|||OTHER||CROSS_SECTIONAL|||||||
33685873|NCT04358601|RANDOMIZED|PARALLEL||TREATMENT||||||||
33685874|NCT06258473|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33685875|NCT04331197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685876|NCT02776020|||CASE_ONLY||PROSPECTIVE|||||||
33685877|NCT02045303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988846|NCT00060697|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33988847|NCT00059306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024962|NCT02091466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685878|NCT02702596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685879|NCT01797172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685880|NCT01655108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33685881|NCT00555139|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33685882|NCT01392521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685883|NCT01873703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988848|NCT04414891|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Consecutive patients enrolled would be randomized to either the NAVA arm or ASV arm.~NAVA NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) ASV NIV ASV will be administered using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland)"||||
33988849|NCT01551498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988850|NCT05829733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988851|NCT06083259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33988852|NCT01808794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988853|NCT00367861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988854|NCT00447577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33988855|NCT05057702|NA|SINGLE_GROUP||OTHER||NONE||||||
33988856|NCT02075463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988857|NCT02004197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988858|NCT01364493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988859|NCT06450145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988860|NCT00871247|RANDOMIZED|CROSSOVER||||NONE||||||
33988861|NCT00064090||||TREATMENT||||||||
33988862|NCT02431000|||COHORT||PROSPECTIVE|||||||
33988863|NCT02136290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988864|NCT04609917|||CASE_CONTROL||RETROSPECTIVE|||||||
33988865|NCT06023433|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Sealed envelopes|The main objective of the study is to evaluate the impact of orthodontic tooth movement on gingival crevicular fluid miRNAs related to inflammation and osteoclastogenesis.|f|f|t|t
33988866|NCT03408665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988867|NCT03194217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988868|NCT00840411|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988869|NCT00327379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33988870|NCT03498391|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33988871|NCT03018717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988872|NCT06330142|NA|SINGLE_GROUP||OTHER||NONE||||||
33988873|NCT02761512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988874|NCT00153530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988875|NCT04067635|||COHORT||PROSPECTIVE|||||||
33988876|NCT03225547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The first 10 patients will receive the same treatment. Enrollment will be paused to undergo a safety evaluation. After which, enrollment will continue and two cohorts will be preformed in parallel.||||
33988877|NCT03818581|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant, investigator, and clinical research coordinator will remain masked throughout the duration of the study. An unmasked research coordinator will be responsible for assessing mid-point outcomes on the sleep diaries and communicating with the pharmacy for re-randomization medication orders.|Sequential Parallel Comparison Design: subjects will be randomized in a 1:2 ratio to suvorexant 10-20 mg or equivalent placebo for six weeks, followed by re-randomization of placebo non-responders to either suvorexant or placebo in a 1:1 design for six weeks.|t|f|t|f
33988878|NCT00804960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988879|NCT02061917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988880|NCT02938962|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33988881|NCT02082392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988882|NCT05728541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775451|NCT04916899|||COHORT||PROSPECTIVE|||||||
33775452|NCT01253382|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33988883|NCT00208819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988884|NCT03265522|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988885|NCT03559491|||COHORT||PROSPECTIVE|||||||
33988886|NCT00002318||PARALLEL||TREATMENT||||||||
33988887|NCT01424124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33988888|NCT00204373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988889|NCT03411148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988890|NCT02078791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988891|NCT03222557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The acupuncturist is the only individual who is aware of the treatment allocation; the patients randomized to the EA/SA groups and the outcome assessor are blinded to the treatment allocation.||t|t|f|t
33988892|NCT01498120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685884|NCT04178369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized|f|t|f|f
33685885|NCT05000112|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33685886|NCT04360655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685887|NCT01445054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33685888|NCT00294281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685889|NCT06152471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind, placebo controlled|Randomization 1:1 to investigational product or placebo|t|f|t|f
33685890|NCT04179812|||COHORT||RETROSPECTIVE|||||||
33685891|NCT00507871|||||PROSPECTIVE|||||||
33685892|NCT03249688|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33685893|NCT01921088|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33685894|NCT02767544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775453|NCT00641160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906685|NCT05005156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"This is double-blinded clinical trial. The sponsor will provide investigational product and identical appearing placebo to investigators responsible for vaccine administration according to the prompts in the IWRS system.~Emergency unblinding decisions are expected to be rare and could be justified only when that information is needed for the future clinical management of that participant. The decision of emergency unblinding must be approved by the PI, the global Co-PI and the sponsor after sufficient evaluation.~Individuals will remain blinded to the first dose of the injection (First Injection Visit) until the end of the study. All individuals will receive active vaccine at Day 56 (Second Injection Visit)."|This Phase IIb study is a double-blind, randomized, multi-centre, placebo-controlled, clinical trial; approximately 876 participants 18 years of age and older, living with HIV, on stable treatment, and virologically suppressed for at least 6 months will be enrolled. All participants will receive a single dose of either the study vaccine or a placebo vaccine on First Injection Visit (2:1 allocation ratio of vaccine: placebo), and a second dose of Ad5-nCoV at Day 56 (Second Injection Visit) and will be followed to monitor vaccine candidate safety, immunogenicity (antibody response), and efficacy for a duration of 52 weeks. A subset of participants will also have cellular immunity measured after receiving the 5×1010 vp Ad5-nCoV vaccine (≥ 4 x1010 vp).|t|f|t|f
33775454|NCT03342781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775455|NCT00498420|||OTHER||PROSPECTIVE|||||||
33775456|NCT02171364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33775457|NCT01817543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775458|NCT02163447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33988893|NCT03161717|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|Parallel Assignment||||
33988894|NCT03448107|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigators responsible for analyzing the data for primary outcomes will be masked.|Two-arm, parallel, non-inferiority cluster randomized trial|f|f|f|t
33988895|NCT04343001|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2 x 2 x 2||||
33988896|NCT02404701|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33988897|NCT04862572|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross sectional case-control multimodal MRI, audio- and psychometric study||||
33988898|NCT00947076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988899|NCT00182429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33988900|NCT06326697|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33988901|NCT03026374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33685895|NCT03295565|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||randomized, open label, Phase IIB trial||||
33685896|NCT03614975|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 RCT allocation to one of two influenza vaccines: Flucelvax or Fluzone.||||
33685897|NCT03036800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685898|NCT05614167|||CASE_ONLY||CROSS_SECTIONAL|||||||
33685899|NCT01113047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33685900|NCT02873520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685901|NCT06246279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33685902|NCT02235727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33685903|NCT02708303|||CASE_ONLY||PROSPECTIVE|||||||
33685904|NCT02829944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685905|NCT01376557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685906|NCT05861180|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33685907|NCT00179244|RANDOMIZED|CROSSOVER||||NONE||||||
33721402|NCT03326973|||COHORT||PROSPECTIVE|||||||
33775459|NCT00000692||||TREATMENT||NONE||||||
33775460|NCT02505139|||COHORT||PROSPECTIVE|||||||
33775461|NCT01315743|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33775462|NCT05909787|NA|SINGLE_GROUP||OTHER||NONE||||||
33775463|NCT02425475|||COHORT||PROSPECTIVE|||||||
33775464|NCT02189863|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33775465|NCT01169259|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33775466|NCT03350477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775467|NCT00030654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775468|NCT02933463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33775469|NCT04895020|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33775470|NCT06530524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33685908|NCT03121339|RANDOMIZED|PARALLEL||OTHER||NONE||open-label with two tablet sizes labeled with different radioisotopes||||
33685909|NCT05414227|||CASE_CONTROL||PROSPECTIVE|||||||
33685910|NCT02264873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685911|NCT03221764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988902|NCT04344106|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33988903|NCT00693290|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33988904|NCT04052503|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2 groups cluster randomized controlled trial||||
33988905|NCT04351425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants: randomly selected infants, group 1 less than 1400 kg, group 2 more than 1600 kg|This was a randomized control trial with preterm neonates with birth weights \< 1400 g conducted at King Fahad Medical City, Riyadh, Saudi Arabia. We compared newborns weaned to cot at a weight of 1400 g to newborns weaned at a weight of 1600 g. The outcome was to assess the feasibility of the protocol in terms of temperature control and average weight gain.||||
33988906|NCT00276848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988907|NCT04691895|||CASE_CONTROL||PROSPECTIVE|||||||
33988908|NCT02649621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988909|NCT00312039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988910|NCT00047099|RANDOMIZED|||TREATMENT||NONE||||||
33988911|NCT05495594|||OTHER||CROSS_SECTIONAL|||||||
33988912|NCT04155294|||COHORT||PROSPECTIVE|||||||
33988913|NCT01417663|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33988914|NCT00794547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988915|NCT06452381|||OTHER||PROSPECTIVE|||||||
33988916|NCT00395694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33988917|NCT00001035||||TREATMENT||||||||
33988918|NCT06381128|||COHORT||CROSS_SECTIONAL|||||||
33988919|NCT02197780|||COHORT||PROSPECTIVE|||||||
33988920|NCT00004801||||TREATMENT||||||||
33988921|NCT03181594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988922|NCT03823924|||CASE_CONTROL||PROSPECTIVE|||||||
33988923|NCT03284476|||COHORT||PROSPECTIVE|||||||
33988924|NCT05289674|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is an observational study with a pre-, post-test design||||
33988925|NCT06161623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33988926|NCT06627725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Interventional Study Model.|f|t|f|f
33988927|NCT04666116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computerized randomization based on a single sequence based on the latest issue in the patient's medical history|Randomized, single blind clinical trial|f|f|f|t
33988928|NCT00589186|NON_RANDOMIZED|||TREATMENT||NONE||||||
33988929|NCT06000449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685912|NCT02329366|||OTHER||PROSPECTIVE|||||||
33988930|NCT03133637|||COHORT||PROSPECTIVE|||||||
33685913|NCT06061614|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||single group||||
33685914|NCT01176942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685915|NCT03328182|NA|SINGLE_GROUP||OTHER||NONE||||||
33685916|NCT03956797|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A long term safety, dose escalation study design of differing temperatures and duration to test safety and efficacy of cooling anesthesia for intravitreal injection.||||
33685917|NCT00195845|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33685918|NCT05911425|NA|SINGLE_GROUP||TREATMENT||NONE||envolizumab sovalteinib||||
33685919|NCT00377130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33685920|NCT05436340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33988931|NCT01692717|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33988932|NCT05601674|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33685921|NCT04786509|||OTHER||CROSS_SECTIONAL|||||||
33685922|NCT04112498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685923|NCT04856670|||CASE_CONTROL||PROSPECTIVE|||||||
33775471|NCT05040490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33775472|NCT06385470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775473|NCT03693599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33775474|NCT06233942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988933|NCT00082147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988934|NCT06560125|||OTHER||PROSPECTIVE|||||||
33988935|NCT02851771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988936|NCT02401607|||OTHER||PROSPECTIVE|||||||
33988937|NCT06559722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988938|NCT03378492|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33988939|NCT01010555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33988940|NCT06515054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33988941|NCT06248827|||COHORT||PROSPECTIVE|||||||
33988942|NCT05703022|NA|SINGLE_GROUP||TREATMENT||NONE||Single centre feasibility study to assess acceptability, compliance, delivery of the intervention and expected effect sizes.||||
33988943|NCT00039286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988944|NCT00787254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33988945|NCT04630431|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33988946|NCT00652977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33988947|NCT00834405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33988948|NCT03580785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||single group||||
33988949|NCT01289717|||COHORT||PROSPECTIVE|||||||
33988950|NCT04818892|||CASE_CONTROL||PROSPECTIVE|||||||
33988951|NCT02642835|||CASE_ONLY||RETROSPECTIVE|||||||
34082338|NCT03732378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Along with anti psychotics, one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group , and 500 mg corn oil one capsules daily along with anti psychotics were given to placebo group. Patients were unaware about treatment and placebo as plastic transparent same packing was used.|12 week Randomized, single blind, placebo-Controlled Trial (RCT) was conducted at King Edward medical university, psychiatry \& behavioral sciences department Lahore. one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given, or placebo (500 mg corn oil).|t|f|f|f
34082339|NCT02756702|||COHORT||PROSPECTIVE|||||||
33988952|NCT04613258|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||We aimed to determine the effect of soy, catfish, anchovy, and rice (SCAR) porridge supplementation for 14 days along with nutritional counseling on vitamin D, calcium, and biomolecular parameters on new patients diagnosed with tuberculosis and associated complications who visited two public health centers: Teladan Public Health Center and Amplas Public Health Center, located in Medan, North Sumatera, Indonesia. The sample was collected on Sumatera Island, at latitude 3.57 N and longitude 98.65 E, with enough sunlight and a temperature of ± 32 °C (90 °F). The study was performed from May to September 2019. This study was a controlled randomized clinical trial. After applying the inclusion and exclusion criteria, 43 patients participated in the study. These patients were divided into two groups: 22 patients were put into the treatment group (I) and 21 into the control group (C).||||
33988953|NCT05358405|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Experimental|Diagnostic of weaning failure due to pulmonary edema||||
33988954|NCT04548375|||COHORT||PROSPECTIVE|||||||
33988955|NCT03429712|NA|SINGLE_GROUP||OTHER||NONE||||||
33988956|NCT05180877|||COHORT||PROSPECTIVE|||||||
33988957|NCT03191474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33988958|NCT06448104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33988959|NCT03818841|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33988960|NCT02679703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685924|NCT03630276|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33685925|NCT02288377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685926|NCT00141570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33685927|NCT05238571|||COHORT||PROSPECTIVE|||||||
33906686|NCT05233631|||COHORT||CROSS_SECTIONAL|||||||
33906687|NCT06529289|NA|SINGLE_GROUP||OTHER||NONE||||||
33906688|NCT03695419|||CASE_ONLY||CROSS_SECTIONAL|||||||
33906689|NCT03198169|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Active product containers and placebo product containers will have identical labels. Product numbers to differentiate active versus placebo will be assigned and known only by the statistician.||t|t|t|t
33906690|NCT05988541|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33906691|NCT01596075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906692|NCT02490150|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906693|NCT03318640|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Comparison between treated group or not||||
33906694|NCT04893746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906695|NCT06688331|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Blinding: The following roles indicated below will not be made aware of the treatment group assignment during the trial:~* participant~* legal representatives~* site staff excluding pharmacists (applies to anti-CD20 only)"|"Trial type: Prospective randomized, placebo-controlled, parallel group, blinded trial.~Control method: placebo, active comparator, sham procedure."|t|t|t|f
33906696|NCT03107780|NA|SEQUENTIAL||TREATMENT||NONE||||||
33906697|NCT02096393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33906698|NCT05873452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906699|NCT02864745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906700|NCT03908138|RANDOMIZED|PARALLEL||TREATMENT||NONE|no mask.|The patients will be randomized either receiving RDD or receiving VDD therapy.||||
33906701|NCT05307289|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33906702|NCT03022305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906703|NCT02619253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906704|NCT04230486|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants will be given the same treatment.||||
33906705|NCT06692933|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33906706|NCT04821622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study|t|t|t|t
33906707|NCT02092740|||COHORT||RETROSPECTIVE|||||||
33906708|NCT01820689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906709|NCT02122861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988961|NCT02023177|||COHORT||PROSPECTIVE|||||||
33988962|NCT00209781|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33685928|NCT01726660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685929|NCT04932798|||COHORT||PROSPECTIVE|||||||
33685930|NCT06347679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33685931|NCT05930366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685932|NCT06515028|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33685933|NCT02830984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33685934|NCT04184258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685935|NCT00174239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775475|NCT00524238|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775476|NCT00894751|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906710|NCT03378011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906711|NCT06692634|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"Step I: VT 7 ml/kg-PBW, with constant PEEP, RR, and insufflation time (0.6 sec), without adding an EIP. I:E ratio 1:2.~Step II: VT 5 ml/kg-PBW keeping the other mechanical ventilation settings constant.~Step III: EIP will be configured to achieve an I:E ratio of 1:1, keeping the other mechanical ventilation settings constant.~Step IV: Patients will be randomized into two groups in a 1:1 ratio.~Group 1: 20% reduction in RR together with a new setting in EIP until reach I:E equal 1, without modifying the other mechanical ventilation settings.~Group 2: 20% reduction in RR without modifying the other mechanical ventilation settings. A modification of the I:E ratio will be generated concerning step III. After 60 minutes, a new EIP setting will be made until reaching an I:E ratio equal to 1.~All steps will have a 60-minute long. Both arms will have the same programming of the mechanical ventilator at the end of the study."||||
33906712|NCT02674581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988963|NCT02570009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988964|NCT04761861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33988965|NCT00409162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988966|NCT01024166|||||PROSPECTIVE|||||||
33988967|NCT05231720|||COHORT||CROSS_SECTIONAL|||||||
33988968|NCT03234179|||FAMILY_BASED||PROSPECTIVE|||||||
33685936|NCT03806660|||COHORT||PROSPECTIVE|||||||
33685937|NCT02829541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685938|NCT05245396|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A, B and C, periods 1 to 3 will be an incomplete cross-over; Part A, B and C, periods 4 and 5 are sequential. Part D, periods 1 and 2 will be 2-sequence cross-over design with 2 treatment sequences; Part D, period 3 is optional.||||
33906713|NCT06684769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, single-blinded split-mouth clinical trial|t|f|t|f
33906714|NCT02654327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906715|NCT00647777|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33906716|NCT06260176|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Machine locations were randomly assigned to 1 of 4 front-of-package message arms, stratified by baseline machine sales (high/low) and type of machine location (correctional facilities, courts/offices, large offices, police/fire, recreation centers/libraries/other) with equal probability. The investigators first randomized vending locations (e.g., floors) with beverage machines so that all machines on the same floor displayed the same label. They then randomized the remaining solo snack locations. Monthly sales data provided by the City's vending contractor indicated consumer choices. Research assistants also asked a subset of consumers (N=1,065) about their purchases. Intercepts were not allowed in the courts/offices location type and were not conducted at correctional facilities with low traffic. The aim was to collect 10 intercepts per machine visited, distributed over the entire study period, however the study was cut short in March 2020 by the Covid pandemic."||||
33906717|NCT04349254|||COHORT||RETROSPECTIVE|||||||
33685939|NCT03621345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33685940|NCT00740337|||COHORT||CROSS_SECTIONAL|||||||
33685941|NCT04581460|||CASE_ONLY||OTHER|||||||
33685942|NCT01536275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685943|NCT01403272|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685944|NCT00237510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721403|NCT06120621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721404|NCT01537510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33721405|NCT00473369|||CASE_CONTROL||OTHER|||||||
33775477|NCT02765243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775478|NCT03113760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Initial phase of 18 weeks is a single arm, open-label (SAOL) period where Tadekinig alfa is administered in addition to the standard of care treatment used for the control of flares. The SAOL period will be followed by an up to 16-week randomized withdrawal phase (RW). All patients who showed response to treatment at the end of the SAOL phase will be enrolled in the RW phase. In the RW phase patients will be randomized to either Tadekinig alfa or placebo.|t|t|t|t
33906718|NCT02956174|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906719|NCT01255397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906720|NCT02269059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988969|NCT00501488|||DEFINED_POPULATION||PROSPECTIVE|||||||
33988970|NCT01074203|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33721406|NCT02063490|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721407|NCT05217420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only research team members who will collect objective in-person data will be masked||f|f|f|t
33721408|NCT01688258|||OTHER||PROSPECTIVE|||||||
33721409|NCT05754515|||COHORT||PROSPECTIVE|||||||
33721410|NCT06099977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33721411|NCT02024867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775479|NCT02638064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775480|NCT06236581|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial, intervention vs. waitlist||||
33775481|NCT01699893|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33775482|NCT02563834|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33775483|NCT05472220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775484|NCT03988374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33906721|NCT06586320|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33906722|NCT00004895||||SUPPORTIVE_CARE||||||||
33906723|NCT06674096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906724|NCT00574158|||COHORT||PROSPECTIVE|||||||
33906725|NCT00820703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906726|NCT03959540|||COHORT||PROSPECTIVE|||||||
33906727|NCT06017063|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled trial||||
33906728|NCT02039336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906729|NCT00746577|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906730|NCT05200949|||COHORT||RETROSPECTIVE|||||||
33906731|NCT05050630|NA|SINGLE_GROUP||TREATMENT||NONE||All patients eligible for inclusion were treated with TR2-ICE：Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.||||
33906732|NCT02726750|||COHORT||PROSPECTIVE|||||||
33906733|NCT00457054|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33906734|NCT04145297|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.||||
33906735|NCT02653378|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33906736|NCT01829035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906737|NCT05490953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be stratified at randomization based on their clinical stage at diagnosis, according to the Cotswold classification system, into limited-stage (stage I or II disease without B symptoms and absence of bulky or stage IB disease without bulky disease) and advanced stage (patients with stage II disease with B symptoms or bulky disease, or stage III or IV disease). In addition, a random permutation method with blocks of size 6 will be used, thus creating 5 blocks of size 6 patients each. Each patient will be classified into a specific study group (Group A: conventional treatment plus placebo; group B: conventional treatment plus pentoxifylline).|Patients who agree to participate in this study, by signing the consent and/or informed assent, will be randomly assigned to each of the two study groups: Group A: Patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus placebo, during the first two cycles of chemotherapy. Group B: patients with conventional treatment based on the OEPA/COPDAC, ABVD or BEACOPP scheme plus pentoxifylline, during the first two cycles of chemotherapy.|t|t|t|f
33988971|NCT03265574|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33988972|NCT01727180|||CASE_ONLY||CROSS_SECTIONAL|||||||
33775485|NCT05208281|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
33775486|NCT06073028|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A biomechanics engineer leads the gait assessment, being blinded to the allocation schedule, and participants were specifically asked to not discuss the intervention.|Pilot single-blind randomized cross-over study, with the subject blind as to the hypothesis|f|f|f|t
33775487|NCT06358469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775488|NCT05902130|||COHORT||RETROSPECTIVE|||||||
33775489|NCT03260361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775490|NCT03527693|||COHORT||RETROSPECTIVE|||||||
33775491|NCT04365140|||CASE_CONTROL||PROSPECTIVE|||||||
33775492|NCT02717013|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33906738|NCT00748826|||COHORT||PROSPECTIVE|||||||
33906739|NCT05420519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906740|NCT06692283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906741|NCT02583789|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33775493|NCT00999401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775494|NCT02986737|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Medical device trial||||
33775495|NCT04776941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775496|NCT06373588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Multi-centre, pragmatic, assessor-blinded, parallel randomized controlled trial with an embedded qualitative study. In the control arm, participants will receive a standard information package and care usually provided within their clinics. In the intervention arm, participants will receive support from a trained patient navigator. The patient navigator will contact participants: 1) Within 7 days of randomization; 2) At least once every 3 months up to 12 months; 3) As needed to follow-up on tasks identified in previous visits; and 4) As initiated by the participant. The navigator will tailor the topics addressed during these interactions according to the needs of the participant and compile a care plan with input from the patient, family, and clinicians.|f|f|f|t
33775497|NCT04149262|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775498|NCT02005614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775499|NCT04686643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775500|NCT04934319|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775501|NCT04218370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775502|NCT05912530|||COHORT||CROSS_SECTIONAL|||||||
33775503|NCT06063369|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Double-Blind|Phase II - Randomized, double blind, placebo-controlled, parallel group clinical trial.|t|f|t|f
33775504|NCT06449235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775505|NCT01062906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775506|NCT04770818|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subject is randomized to one of two arms.||||
33775507|NCT01221181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775508|NCT01843452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775509|NCT06004752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775510|NCT04288362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomised controlled trial||||
33775511|NCT02011958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775512|NCT03293485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775513|NCT04104672|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose escalation design||||
33775514|NCT00003288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775515|NCT01125774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775516|NCT05159505|||OTHER||RETROSPECTIVE|||||||
33775517|NCT05970289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775518|NCT02130960|||OTHER||PROSPECTIVE|||||||
33775519|NCT02585791|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33775520|NCT06203444|NA|SINGLE_GROUP||TREATMENT||NONE||An open-label study to investigate the PK of tenapanor and AZ13792925 in breast milk of lactating female subjects||||
33775521|NCT03531463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotheraphists specialized in shoulder injuries collect all data and perform all tests / interviews of patients during FU at 3 months, 1-2-5 years. Blinded for the allocation / treatment.|Randomized controlled single-blinded trial|f|f|f|t
33775522|NCT01940653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775523|NCT00003509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906742|NCT01579539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906743|NCT05989685|||COHORT||CROSS_SECTIONAL|||||||
33906744|NCT01262261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906745|NCT01587872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906746|NCT02936505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906747|NCT03474523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|external evaluator|Randomized controlled longitudinal experimental study|t|f|f|t
33906748|NCT03274336|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33906749|NCT00399984|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33906750|NCT05005208|NA|SINGLE_GROUP||OTHER||NONE||||||
33906751|NCT06692309|||OTHER||PROSPECTIVE|||||||
33906752|NCT02665195|||COHORT||PROSPECTIVE|||||||
33906753|NCT06196476|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906754|NCT04978948|||OTHER||PROSPECTIVE|||||||
33906755|NCT02639117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906756|NCT02460588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906757|NCT00175175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33906758|NCT00781781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906759|NCT04982432|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be graded and assigned to a severity group (mild, moderate, or severe). All groups will receive the same intervention||||
33906760|NCT01452776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906761|NCT04043507|||COHORT||PROSPECTIVE|||||||
33906762|NCT04080154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906763|NCT06692920|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33906764|NCT00897520|||OTHER||RETROSPECTIVE|||||||
33906765|NCT06390982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906766|NCT03172546|||COHORT||PROSPECTIVE|||||||
34082340|NCT06235671|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm feasibility trial||||
34082341|NCT03335345|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34082342|NCT03520452|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34082343|NCT00193375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082344|NCT06519916|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082345|NCT03768713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33685945|NCT03540498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Once the patients have been selected according to the inclusion / exclusion criteria detailed below, they will be included in one of the treatment groups (control / study) in a random and random manner. The list of randomization and the labeling of the products will be carried out by independent personnel to the research team to ensure double blindness of the trial. The production of the probiotic products and control will be carried out in both cases in white boxes without any type of identification or difference between them.~The randomization will be made from an online software available at www.randomization.com. From the list of randomization generated by this software, the different products will be labeled with the patient number and the test code. The team of researchers will not have access to the randomization list. In this way, a correct randomization and double-blind trial is guaranteed."|The study will follow a randomized, double-blind, split-mouth, placebo-controlled design with two parallel prospective follow-up groups for the evaluation of two different posology models (with or without previous professional oral cleaning).|t|f|t|f
33775524|NCT03524274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
33775525|NCT05597683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients, medical staff who measure outcome variables, and nurses in the recovery room are double-blinded so that medical staff and patients do not know the patient's assigned group.|hyperthermic intra-peritoneal chemotherapy|t|t|f|f
33775526|NCT00744081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906767|NCT06687278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will employ a pretest-posttest-follow-up test experimental design with a control group.||||
33906768|NCT05379361|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33906769|NCT03832998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906770|NCT00495560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906771|NCT01958034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906772|NCT05257239|||OTHER||CROSS_SECTIONAL|||||||
33906773|NCT03020901|||CASE_ONLY||RETROSPECTIVE|||||||
33988973|NCT05332535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33988974|NCT01194648|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-Centre Prospective Single Arm Intervention Trial||||
33988975|NCT02203058|RANDOMIZED|CROSSOVER||||NONE||||||
33988976|NCT03214276|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33988977|NCT02131363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988978|NCT03987191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33988979|NCT06201650|||COHORT||PROSPECTIVE|||||||
33988980|NCT06395194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Preparation of the two drugs (to compare, valsartan and amlodipine) made identical|Investigator-designed, prospective, multi-national, double-blind, randomized, active-controlled, parallel-group design which was event driven (until accumulated 1450 primary cardiac endpoints)|t|t|t|t
33988981|NCT03992118|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be recruited to participate in a multidisciplinary feeding assessment, after which an intervention plan will be developed to address the participants feeding challenges.||||
33988982|NCT02355886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33988983|NCT01188135|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33988984|NCT01973088|||COHORT||PROSPECTIVE|||||||
33988985|NCT06126263|||COHORT||RETROSPECTIVE|||||||
33988986|NCT01393431|||COHORT||PROSPECTIVE|||||||
33988987|NCT04817904|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33988988|NCT02167620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33988989|NCT01887691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988990|NCT01010932|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33988991|NCT05460715|||COHORT||PROSPECTIVE|||||||
33988992|NCT04804605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988993|NCT01195038|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34082346|NCT02023489|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34082347|NCT06258850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo capsules will be identical to those of the active treatment. The batch of capsules for each patient will be codified and codes will be provided by the producing company to the SCReN platform who will keep them so that patients and investigators and the local pharmacy will be blind.|Multicenter clinical trial, placebo-controlled, randomized (1:1 ratio), in two parallel groups (without crossover), cuadruple blind, and add-on on existing treatments.|t|t|t|t
34082348|NCT00364065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082349|NCT02125552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082350|NCT00891280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082351|NCT06333691|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082352|NCT04489342|||COHORT||PROSPECTIVE|||||||
34082353|NCT03195439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082354|NCT01836952|||COHORT||PROSPECTIVE|||||||
34082355|NCT03844659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082356|NCT03844906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34082357|NCT02449434|||COHORT||RETROSPECTIVE|||||||
34082358|NCT04108078|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34082359|NCT03155711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082360|NCT00005338|||||RETROSPECTIVE|||||||
34082361|NCT05598970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Pregnant mothers and Community Health Workers will not know about the intervention arm they will be randomised to.|Clustered multi-arm Randomised Controlled Trial|t|t|f|f
34082362|NCT03641976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082363|NCT02150941|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34082364|NCT05360108|||COHORT||PROSPECTIVE|||||||
34082365|NCT02938780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34082366|NCT01687153|||COHORT||PROSPECTIVE|||||||
34082367|NCT01336725|||COHORT||PROSPECTIVE|||||||
34082368|NCT03229187|||OTHER||PROSPECTIVE|||||||
34082369|NCT03277937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082370|NCT00875316|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34082371|NCT01894906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082372|NCT03406520|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cohort study||||
34082373|NCT03945513|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906774|NCT03095183|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|Using a computer-generated simple randomization sequence in permuted blocks of 10, numbered study packets that include the surveys and tongue depressor will be prepared in advance. The packets, which will be prepared by a third party not participating in this research study, will include the information sheet, surveys for the investigator, participant and parent, all labeled with the sample number, and a tongue depressor within original packaging. The randomization key will be kept by the third party until the completion of data collection, at which time it will be given to the PI.|All patients registered for evaluation in the Brooke Army Medical Center Pediatric Emergency Department will be screened by evaluation of age, mental status, physical features and history of immunocompromised by the PI or AI as part of their standard triage and care procedures for their evaluation and treatment in the Emergency Department. Potential participants will be identified by the PI and AI from patients who are registered to be seen by the PI or AI. Potential participants who meet the inclusion criteria and who have none of the exclusion criteria will be approached prior to completion of the posterior oropharynx exam for permission to enroll them in this study.|t|t|t|f
33906775|NCT01318083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906776|NCT03660371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906777|NCT03931486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33906778|NCT05303571|||OTHER||PROSPECTIVE|||||||
33906779|NCT02824380|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906780|NCT06092372|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants were masked to their polygenic score group but not the diet intervention.|||||
33906781|NCT03474133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906782|NCT04212793|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||The study is a non-randomized, non-blinded, prospective, single center, pilot dose-finding study.||||
33906783|NCT02673593|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33906784|NCT02433223|||CASE_CONTROL||RETROSPECTIVE|||||||
33906785|NCT02226094|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906786|NCT06258811|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:1 to experimental or control arm. Experiment arm: neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albuminpaclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year) Control arm: standard therapy of radical surgery +adjuvant therapy (radiation/chemoradiation)||||
33906787|NCT04040088|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33906788|NCT02989636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906789|NCT02718794|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33906790|NCT02237053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33906791|NCT01707069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906792|NCT04315649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906793|NCT03473379|||OTHER||CROSS_SECTIONAL|||||||
34082374|NCT00808158|||COHORT||PROSPECTIVE|||||||
34082375|NCT00048152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082376|NCT05939908|||OTHER||OTHER|||||||
34082377|NCT03095807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082378|NCT05481710|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082379|NCT02453607|||COHORT||PROSPECTIVE|||||||
34082380|NCT01392599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082381|NCT02460016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082382|NCT03511703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082383|NCT00601055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082384|NCT02091700|||COHORT||PROSPECTIVE|||||||
34082385|NCT01226329|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34082386|NCT01404910|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082387|NCT01929447|||||PROSPECTIVE|||||||
34082388|NCT06290986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082389|NCT00284921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082390|NCT03458377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The endoscope that performs the colonoscopy and the person in charge of collecting the data of colonoscopy complications and the overall satisfaction of the procedure will be blind to the patient group.|"Reference population: all outpatient referred for the realization of a colonoscopy, regardless of the requesting Service.~Two groups. One of them will receive an complete educational telephone call 7 days before de procedure in addition to the information received from the primary care center on the day of the request for the test. The inclusion in each one of the groups will be done through a randomization sheet.~The intervention includes educational aspects:~Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test."|f|f|t|f
34082391|NCT02995993|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082392|NCT02425137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33988994|NCT04412811|||COHORT||PROSPECTIVE|||||||
33988995|NCT04760704|||CASE_CONTROL||PROSPECTIVE|||||||
33988996|NCT05265520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33988997|NCT05792072|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33988998|NCT04261894|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Hybrid Type I Cluster Randomized Effectiveness-Implementation Pragmatic Trial|f|f|f|t
33988999|NCT02023229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989000|NCT02991378|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989001|NCT01724372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989002|NCT00664014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989003|NCT01577381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989004|NCT05428943|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33989005|NCT05365932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989006|NCT03968172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study will be conducted as an investigator blinded trial and participating physicians as well as MS centres in general will not be provided with any information about the group assignment. Randomisation will take place only after baseline documentation. Blinding of the trial participants is pursued, but only possible to a limited extent. Furthermore, it cannot be prevented that patients discuss the intervention contents with their physician. Thus, participants and neurologist might realize their participation in the intervention group. While blinding in behavioural interventions is virtually not possible, the only strategy to increase similarity of groups is to have an active control group which we aim for with the optimized standard care group.||t|t|t|t
33989007|NCT02478047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989008|NCT00982397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989009|NCT03994172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All study personnel will be masked to treatment assignment and this group will include the DXA technicians, the study coordinators, and the lab technicians and lab supervisors who will analyze samples for study results.|The study design is that of a randomized double-blind, placebo (PBO)-controlled trial of the combination of teriparatide (TPTD) + the calcimimetic cinacalcet compared to monotherapy with TPTD alone in men with low bone mineral density (BMD).|t|t|t|f
33989010|NCT03572777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989011|NCT03465761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989012|NCT04360161|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33989013|NCT05951192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989014|NCT05621694|NA|SINGLE_GROUP||PREVENTION||NONE||Meditative movement practice: Tai Chi Easy||||
34082393|NCT05556655|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are blinded to TMS therapy, sham control|Mechanistic study of impact of transcranial magnetic stimulation (TMS) on cognitive function.|t|f|f|f
34082394|NCT03687632|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 2, open label trial to determine if treatment with ST266 eye drops for 28 days heals the study eye.||||
34082395|NCT01929889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082396|NCT01078493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082397|NCT05567536|||COHORT||RETROSPECTIVE|||||||
34082398|NCT04710121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled study to determine the effects of virtual reality glasses used during the colonoscopy on vital signs, pain, and anxiety levels.||||
34082399|NCT00447408|RANDOMIZED|PARALLEL||||NONE||||||
34082400|NCT05988372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906794|NCT02532634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33906795|NCT02065869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989015|NCT01644058|NA|SINGLE_GROUP||TREATMENT||NONE|Investigators were not involved in data analysis|||||
33989016|NCT03465163|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33989017|NCT04044261|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082401|NCT02431299|||COHORT||PROSPECTIVE|||||||
34082402|NCT03728569|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Both groups, young and old, will receive the same intervention; therefore, single group study model was chosen.||||
34082403|NCT00597259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082404|NCT00161213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775527|NCT00507026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906796|NCT00018122|||DEFINED_POPULATION||PROSPECTIVE|||||||
33989018|NCT04665063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906797|NCT06573073|||OTHER||PROSPECTIVE|||||||
33906798|NCT01666236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906799|NCT02431585|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33906800|NCT02474940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906801|NCT01849250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33906802|NCT06692816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906803|NCT00999128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906804|NCT00002089||||TREATMENT||NONE||||||
33989019|NCT02405481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989020|NCT00244764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989021|NCT02674880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989022|NCT06030583|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082405|NCT03560908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082406|NCT06106750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082407|NCT06450769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34082408|NCT04720443|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34082409|NCT04232839|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082410|NCT06194916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34082411|NCT03106077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082412|NCT02647138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082413|NCT05178017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082414|NCT00967122|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082415|NCT04368169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double Blind|Participants are recruited through a single health practice and randomized through block randomization to one of 2 groups: botanical extract or inert control.|t|t|f|f
34082416|NCT01195649|||COHORT||PROSPECTIVE|||||||
34082417|NCT00499811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989023|NCT01038817|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33989024|NCT01997047|||CASE_ONLY||PROSPECTIVE|||||||
33989025|NCT02625558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989026|NCT04841317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989027|NCT05099380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989028|NCT04297891|||COHORT||PROSPECTIVE|||||||
33989029|NCT02727088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989030|NCT02399917|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IB, lead-in/II to determine MTD||||
33989031|NCT02882945|||CASE_CONTROL||PROSPECTIVE|||||||
33989032|NCT00904423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989033|NCT04437706|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33989034|NCT04212234|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Scans will be evaluated by independent experts who had not performed the exams. Scans will be anonymized and ultrasound propagation velocity will not be reported on the images.||t|f|f|t
33989035|NCT02803450|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33989036|NCT02532621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989037|NCT01197248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33989038|NCT05886920|NA|SEQUENTIAL||TREATMENT||NONE||||||
33989039|NCT06102434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989040|NCT04270721|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|The patient will be blinded to their hospital's randomised sequence allocation. Analysis will be performed blind to allocation sequence (and therefore before and after status) and after data have been cleaned and locked.|"EAGLE is an international, multicentre, cluster-sequence randomised controlled study. The intervention will be delivered at hospital-level so randomisation will be by hospital, with outcomes assessed at the individual patient level.~Cluster randomisation will follow a dog-leg phased study design with 3 randomisation sequences. In the first phase, approximately 48 hospitals (clusters) are randomised between the three sequences, all three are eventually exposed to the intervention. Sequence 1 immediately receives the training intervention and data are only collected after the intervention. In sequence 2, data are collected before and after the intervention. The final sequence collects data only before the intervention. The second dogleg phase commences after the first when more clusters are ready to participate (indicatively after one month, but can be delayed as practicable). Indicatively, 7 dogleg phases with 48 hospitals each, will achieve the sample size required (333 clusters)."|t|f|f|t
33989041|NCT00828698|||COHORT||PROSPECTIVE|||||||
33989042|NCT00573417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989043|NCT03916861|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized study||||
33989044|NCT00564408|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33989045|NCT02974595|||COHORT||PROSPECTIVE|||||||
33989046|NCT00848653|||||PROSPECTIVE|||||||
33989047|NCT03128723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989048|NCT04282954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989049|NCT00313794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989050|NCT03949426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is double-blind with regard to treatment (KPG-818 or placebo) at each dose level. Any clinical staff involved in the preparation or administration of the study intervention and who are unblinded will take no further part in the study. will remain blinded during the study conduct, unless otherwise required based on study findings. The pharmacokineticist will be unblinded to perform the final PK analyses after all participants have completed the study.|Parallel and Sequential|t|t|t|f
33989051|NCT03428386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989052|NCT03605394|||OTHER||RETROSPECTIVE|||||||
33989053|NCT01090791|||CASE_CROSSOVER||PROSPECTIVE|||||||
33989054|NCT00739947|||COHORT||PROSPECTIVE|||||||
33989055|NCT03859102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential prospective cohort study||||
33989056|NCT06161350|||COHORT||RETROSPECTIVE|||||||
33989057|NCT03084250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989058|NCT02648074|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33989059|NCT04730466|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a parallel, randomized and controlled experimental study. The patients included in the sample will be randomly distributed into two groups: Cognitive rehabilitation (experimental) and No therapy (control). The randomization of the sample will be carried out through the website: http://www.randomization.com/.||||
33989060|NCT01017926|RANDOMIZED|CROSSOVER||||NONE||||||
33989061|NCT00507572|||CASE_ONLY||OTHER|||||||
33989062|NCT03957447|||COHORT||PROSPECTIVE|||||||
33989063|NCT03184389|NA|SINGLE_GROUP||PREVENTION||NONE||Each time point when participant is available (i.e., not driving, not physically active, a stress classification is possible, hasn't recently received an ecological momentary assessment (EMA) or an intervention prompt) is randomly assigned to intervention prompt or no prompt.||||
33989064|NCT01771263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685946|NCT06020638|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This study was designed as randomized, controlled, and experimental||||
33685947|NCT01403233|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906805|NCT05368428|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906806|NCT06692452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906807|NCT06316258|NA|SINGLE_GROUP||OTHER||NONE||||||
33906808|NCT03911544|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33989065|NCT04325139|||OTHER||PROSPECTIVE|||||||
33906809|NCT05916196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906810|NCT03340792|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906811|NCT02230124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906812|NCT00502606|||CASE_CONTROL||PROSPECTIVE|||||||
33906813|NCT01009996|||COHORT||PROSPECTIVE|||||||
33906814|NCT06693440|||CASE_CONTROL||RETROSPECTIVE|||||||
33906815|NCT02191917|||COHORT||PROSPECTIVE|||||||
33906816|NCT04171544|||COHORT||RETROSPECTIVE|||||||
33906817|NCT02087319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906818|NCT06429683|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906819|NCT00540969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989066|NCT06558851|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989067|NCT04258917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989068|NCT00486863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989069|NCT01997372|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989070|NCT00188539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989071|NCT03695692|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33989072|NCT02765724|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33989073|NCT06562049|||OTHER||CROSS_SECTIONAL|||||||
33989074|NCT05381220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33989075|NCT04019951|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33989076|NCT05278507|RANDOMIZED|PARALLEL||OTHER||NONE||The primary purpose of this study is to prospectively collect outcome data in order to evaluate the performance and safety of the Arrowga+rd Blue Advanced PICC with regard to first attempt insertion success and incidence of complications as compared to use of standard, unprotected PICC devices.||||
33989077|NCT01471886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989078|NCT05636020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989079|NCT04811794|||COHORT||OTHER|||||||
33989080|NCT02986386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989081|NCT03309774|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989082|NCT03965169|NA|SINGLE_GROUP||SCREENING||NONE||||||
33989083|NCT04414228|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33989084|NCT01681745|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects' abdomens treated with Myoscience device (cryoneurolysis) at various timepoints prior to an abdominoplasty. Skin examined visually and resected for histological examination.||||
33989085|NCT04685486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989086|NCT02598063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989087|NCT03916393|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33989088|NCT05119946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685948|NCT06275490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Randomized Controlled Pilot Trial|f|f|f|t
33685949|NCT03447197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33685950|NCT03723889|||CASE_CONTROL||PROSPECTIVE|||||||
33685951|NCT01302015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906820|NCT06011005|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33906821|NCT05766891|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33906822|NCT01147315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906823|NCT05782920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906824|NCT06693167|||CASE_ONLY||OTHER|||||||
33906825|NCT05609968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906826|NCT02549690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906827|NCT05110183|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33906828|NCT00003771|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33906829|NCT06578585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33906830|NCT00540722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906831|NCT01213485|||COHORT||PROSPECTIVE|||||||
33906832|NCT05468957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906833|NCT03800706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906834|NCT04379804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer generated random numbers were generated and printed on cards. These cards were placed in sealed, opaque envelopes. On the morning of operation, one envelope was opened before the operation and, depending of the parity of the number, RLN's of the patient were dissected either by cranio-caudal or lateral dissection during the operation.||t|f|f|f
33906835|NCT03736837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989089|NCT03174847|||COHORT||PROSPECTIVE|||||||
33989090|NCT02130856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989091|NCT05167981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989092|NCT00586950|||COHORT||PROSPECTIVE|||||||
33989093|NCT06136117|||CASE_CROSSOVER||PROSPECTIVE|||||||
33989094|NCT04985019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989095|NCT00461786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989096|NCT06317454|||OTHER||CROSS_SECTIONAL|||||||
33989097|NCT01839344|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33989098|NCT00088192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989099|NCT03121443|||OTHER||PROSPECTIVE|||||||
33989100|NCT02376777|||COHORT||PROSPECTIVE|||||||
33989101|NCT05439148|NA|SEQUENTIAL||TREATMENT||NONE||8 mg and 16 mg.||||
33989102|NCT05572723|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33989103|NCT01703975|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33989104|NCT04852393|||COHORT||PROSPECTIVE|||||||
34082418|NCT03609047|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 2:1||||
34082419|NCT03290742|||COHORT||RETROSPECTIVE|||||||
34082420|NCT03783637|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33685952|NCT02628665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685953|NCT03994562|||COHORT||PROSPECTIVE|||||||
33685954|NCT06482216|||COHORT||PROSPECTIVE|||||||
33685955|NCT01112683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685956|NCT01551420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Sequential testing in non-equivalent comparison groups||||
33685957|NCT04294745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33685958|NCT05435040|NA|SINGLE_GROUP||TREATMENT||NONE|the clinical trial is carried out in open label|This is a prospective, single-center, interventional, open-label, 1-day clinical investigation in a population of patients with proprioceptive knee deficiency. A randomization will be performed in order to know the order of passage of the 2 conditions: with and without wearing a knee brace.||||
33685959|NCT04334109|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33685960|NCT05150444|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33685961|NCT02700087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33685962|NCT00245583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33685963|NCT03313661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685964|NCT04584307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685965|NCT03597217|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33685966|NCT01981369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775528|NCT05631990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775529|NCT00268229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906836|NCT05570916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906837|NCT06373081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906838|NCT00046319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33906839|NCT02075502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33906840|NCT00073333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906841|NCT04864535|||COHORT||PROSPECTIVE|||||||
33906842|NCT00000539|RANDOMIZED|||TREATMENT||||||||
33906843|NCT06235099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906844|NCT03344601|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a 12 month observational study with a nested randomised controlled trial of a physical activity intervention||||
33906845|NCT00505700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906846|NCT01224912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906847|NCT03105440|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906848|NCT01173627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906849|NCT04506177|||COHORT||PROSPECTIVE|||||||
33906850|NCT00001604|||COHORT||PROSPECTIVE|||||||
33906851|NCT05547763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906852|NCT03638089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906853|NCT02411812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|f|f|f|t
33906854|NCT00931788|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33906855|NCT02637791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906856|NCT06692790|||COHORT||PROSPECTIVE|||||||
33906857|NCT05714020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33906858|NCT00797459|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33906859|NCT03271931|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33906860|NCT00145548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906861|NCT01673724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906862|NCT06276972|||COHORT||PROSPECTIVE|||||||
33906863|NCT01142219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906864|NCT03865017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906865|NCT03074162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906866|NCT04706182|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33989105|NCT06165367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double-blinded (blinded to patient and doctor performing transfer).|Randomization will be stratified according to the in-house embryo prognosis classification. Our internal data shows top quality embryos have 65% ongoing pregnancy rate and good quality embryos have 55% ongoing pregnancy rate. We assume a 20% relative increase over the baseline with the intervention which corresponds to 78% and 66% ongoing pregnancy rates for top and good quality euploid embryos, respectively. Total sample size requires in each group corresponds to 295 and 488 transfers of top and good quality embryos for a total of 783. Two interim analyses are planned when 35% (n=274) and 70% (n=548) of the target sample size is achieved to calculate conditional power. If conditional power is estimated to be lower than 15% at first interim analysis or lower than 30% in the second interim analysis, the trial will be stopped due to futility.|t|t|f|f
33989106|NCT04881435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989107|NCT01196572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989108|NCT01704222|||COHORT||PROSPECTIVE|||||||
33685967|NCT02591329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33906867|NCT04478292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989109|NCT06453980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Healthy controls (HC) and individuals with MCI will be randomized 1:1:1:1 to receive either sham or active stimulation (i.e., HC sham tDCS, HC active tDCS, MCI sham tDCS, MCI active tDCS) for 1 session using a blocked randomization design.|t|f|t|f
33685968|NCT03766282|||CASE_CONTROL||PROSPECTIVE|||||||
33685969|NCT01490827|||COHORT||PROSPECTIVE|||||||
33685970|NCT04193254|||COHORT||PROSPECTIVE|||||||
33685971|NCT03534453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775530|NCT01107730|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33989110|NCT06262269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775531|NCT04377022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775532|NCT03095599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33775533|NCT06504576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775534|NCT00721331|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33989111|NCT03692182|||COHORT||RETROSPECTIVE|||||||
33989112|NCT06323096|||CASE_CONTROL||OTHER|||||||
33989113|NCT00796341|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989114|NCT05377931|||COHORT||PROSPECTIVE|||||||
33989115|NCT02664961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989116|NCT04306783|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775535|NCT01622517|||COHORT||PROSPECTIVE|||||||
33775536|NCT06048731|||COHORT||PROSPECTIVE|||||||
33775537|NCT03450421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33775538|NCT02945293|||COHORT||PROSPECTIVE|||||||
33775539|NCT04173663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research personnel collecting follow-up data are masked.|After eligibility is determined and baseline data are collected, parents will be randomized, in two cohorts, to the treatment or materials-only control condition. Given the relatively small sample size in each cohort at each site (n = 30 at each of three sites), simple randomization is not recommended as it might result in unequal group sizes. The investigators will use 1:1 block randomization within each site to give equal number of subjects in each group. To ensure balance of important covariates, the investigators will block on key moderators: whether the youth has an Intellectual Disability (ID) and is in high school. Co-occurring ID and being in vs. out of high school impact service eligibility, and ID impacts the likelihood of post-secondary education (PSE) and community employment. By balancing moderators, the researchers maximize power to detect effect modification of the treatment effect.|f|f|f|t
33775540|NCT05136196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775541|NCT04592614|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study uses a parallel assignment intervention model.~Consenting participants (older adults and activity coaches) will be randomly assigned (at the level of their CTM group) to one of two CTM-NS study arms: 1) monthly virtual group meetings (high dose), or 2) quarterly virtual group meetings (low dose). Randomization is not relevant for provincial partners and coordinators."||||
33775542|NCT05617534|||CASE_CONTROL||PROSPECTIVE|||||||
33989117|NCT04354285|||COHORT||RETROSPECTIVE|||||||
33775543|NCT05574075|||CASE_CONTROL||PROSPECTIVE|||||||
33775544|NCT00320879|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33775545|NCT01567163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775546|NCT05825729|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The anatomo-pathologist who will analyze the samples obtained in each of the techniques will not know their order or which one he/she will be analyzing. The participants will also be blind to the same.|Multicentric, randomized comparative clinical trial, single-blind and crossover.|t|f|f|t
33775547|NCT02153021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775548|NCT00004189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775549|NCT02516033|||CASE_ONLY||PROSPECTIVE|||||||
33775550|NCT01349010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775551|NCT03692988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775552|NCT04133428|||CASE_ONLY||PROSPECTIVE|||||||
33775553|NCT04261361|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775554|NCT05539391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775555|NCT01296867|||COHORT||PROSPECTIVE|||||||
33775556|NCT01179542|||COHORT||PROSPECTIVE|||||||
33775557|NCT02333929|||COHORT||PROSPECTIVE|||||||
33906868|NCT06377644|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33906869|NCT00151762|NON_RANDOMIZED|||TREATMENT||NONE||||||
33906870|NCT01167595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906871|NCT02875314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906872|NCT03558893|NA|SINGLE_GROUP||OTHER||NONE||||||
33906873|NCT04126070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906874|NCT04475185|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33906875|NCT03204227|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33906876|NCT00859898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906877|NCT04209504|||OTHER||PROSPECTIVE|||||||
33906878|NCT06553755|||COHORT||RETROSPECTIVE|||||||
33906879|NCT01419249|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33906880|NCT00456963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33906881|NCT03175744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906882|NCT04733677|||COHORT||PROSPECTIVE|||||||
33685972|NCT02220998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685973|NCT03331471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||ARM group-applying alveolar recruitment maneuver Conventional goup-not applying alveolar recruitment maneuver|t|f|f|t
33685974|NCT05573815|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33685975|NCT03603067|||COHORT||PROSPECTIVE|||||||
33906883|NCT04975607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906884|NCT05858294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906885|NCT02695485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906886|NCT03555279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906887|NCT05769803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33906888|NCT06692491|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989118|NCT05710783|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Randomization of patients shall be carried out by a computerized system. Once the informed consent signed, the patient shall be allocated with a number coding with all his/her pseudonymously information during collection and completely anonymised during analysis.~The randomization of the first 400 study subjects will include, in addition to 1:1 randomization (experimental vaccine: active control), randomization to participate as a subsample subject for cellular immune response determinations.~Once the 1664 subjects have been randomised, the following study subjects shall be designated as experimental vaccine receptors until have enrolled all the study subjects."|Immuno-bridging|t|t|t|f
33989119|NCT00283608|||COHORT||PROSPECTIVE|||||||
33989120|NCT02075866|||CASE_CONTROL||PROSPECTIVE|||||||
33989121|NCT01642277|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082421|NCT03484169|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The result of the randomization will be placed in sealed and opaque envelopes and the information will be revealed to the member in charge of the training only at the moment the intervention is performed, guaranteeing the secrecy of the allocation. The study will be triple blind, since the randomization and allocation of participants will be performed by researcher A, electromyographic evaluations, data tabulation and statistical analysis (researcher B) and intervention (researcher C).|Will be part of the study 30 healthy women at menacme, eutrophic, nulliparous and aged between 18 and 35 years, recruited among students of the Department of Physical Therapy of the Federal University of Pernambuco. The initial sample will be divided into two groups: intervention group n=15 (GI) and one control group n=15 (CG), randomized through www.randomization.com by a researcher who will be blind regarding outcomes.|f|f|t|t
34082422|NCT03316586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082423|NCT01380236|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34082424|NCT03928457|NA|SINGLE_GROUP||SCREENING||NONE||||||
34082425|NCT03234465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082426|NCT00798005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082427|NCT02981979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082428|NCT02799927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082429|NCT01266616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082430|NCT00971217|RANDOMIZED|FACTORIAL||||NONE||||||
34082431|NCT00253136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082432|NCT03832556|NA|SINGLE_GROUP||OTHER||NONE||||||
34082433|NCT01550133|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34082434|NCT03656341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082435|NCT01370421|||COHORT||PROSPECTIVE|||||||
34082436|NCT02739893|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34082437|NCT02193841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082438|NCT02908139|||COHORT||PROSPECTIVE|||||||
33685976|NCT04900779|||COHORT||PROSPECTIVE|||||||
33685977|NCT04932187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685978|NCT00912379|||COHORT||PROSPECTIVE|||||||
33685979|NCT03682809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients who are randomized to Systane Complete will be masked to the brand of the artificial tears.~There will be a masked examiner who does not know the subject's study group."|One group will be randomized Systane Complete, and one group will be randomized to no treatment.|t|f|t|f
33685980|NCT05271279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685981|NCT00988767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685982|NCT06051708|||COHORT||PROSPECTIVE|||||||
33685983|NCT05793190|||COHORT||PROSPECTIVE|||||||
33685984|NCT03969966|||COHORT||PROSPECTIVE|||||||
33685985|NCT03120988|NA|SINGLE_GROUP||TREATMENT||NONE||Lavage with platelet poor plasma||||
33685986|NCT01261832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989122|NCT06561789|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33989123|NCT03232619|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrolled patients will receive CD19-CART cell immunotherapy.||||
33989124|NCT06560437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33989125|NCT06558721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989126|NCT00702091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989127|NCT01259791|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33989128|NCT01948414|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33989129|NCT01381978|||||CROSS_SECTIONAL|||||||
33989130|NCT04781517|||COHORT||PROSPECTIVE|||||||
33989131|NCT04011410|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-blinded, open label clinical trial||||
33775558|NCT03416504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators were blind to the exposure condition participants were assigned to.|Participants were randomly assigned to either gradual or variable exposure|f|f|f|t
33775559|NCT01988519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775560|NCT00102193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775561|NCT00104182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775562|NCT00131911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775563|NCT01112150|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33775564|NCT03092960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33775565|NCT06425705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775566|NCT05486208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33775567|NCT04039802|||CASE_CONTROL||PROSPECTIVE|||||||
33775568|NCT00492804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775569|NCT00585559|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33775570|NCT05551429|||COHORT||PROSPECTIVE|||||||
33775571|NCT05810948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775572|NCT00884520|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33775573|NCT03347864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775574|NCT01694992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775575|NCT03646045|||CASE_CONTROL||PROSPECTIVE|||||||
33775576|NCT04632290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775577|NCT02005003|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33775578|NCT02027363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775579|NCT02175160|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775580|NCT03629873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775581|NCT04178200|||COHORT||PROSPECTIVE|||||||
33775582|NCT00401921|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33775583|NCT05259943|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Participants will not know whether they received placebo or psilocybin in the first stage of the trial.~Care providers and investigators will not know whether participants received placebo or psilocybin."|This trial starts as a placebo-control for 4 weeks and then becomes Open Label for 4 additional weeks. Follow-up assessments will be performed weekly for the first 4 weeks following the last Open Label week.|t|t|t|f
33775584|NCT03862989|||COHORT||PROSPECTIVE|||||||
33775585|NCT02802683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33775586|NCT01238783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775587|NCT00288873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775588|NCT01645332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775589|NCT00826917|||CASE_CONTROL|||||||||
33775590|NCT04772157|||COHORT||PROSPECTIVE|||||||
33775591|NCT04395768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants not blinded as they will know whether they are receiving the comparator vitamin c (either IVC) or oral in addition to treatments in the control group; outcomes assessor / investigators conducting statistical analysis will be blinded|randomized investigator-blinded controlled|f|f|t|t
33775592|NCT02589925|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33775593|NCT03684187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775594|NCT05562843|||COHORT||RETROSPECTIVE|||||||
33775595|NCT00141687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775596|NCT05459220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR0410 injection compared with placebo|t|t|t|t
33775597|NCT02985333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775598|NCT00832143|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33775599|NCT02702258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775600|NCT03013361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775601|NCT04957940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33775602|NCT00663117|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33775603|NCT05929456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, single center phase I feasibility and dose finding study in a single cohort, i.e patients with glioblastoma||||
33775604|NCT01238796|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33775605|NCT03661229|NA|SINGLE_GROUP||PREVENTION||NONE||"Up to 50 patients will be assessed using the CVInsight Monitoring System. Patients will undergo two consecutive hemodialysis (HD) treatments where they will be monitored with the contact and non-contact devices throughout their HD session. The first visit will be on their first HD session of the week (after the weekend - 72 hour inter-dialytic period) and the second visit will be during the patient's second HD session of the week (mid-week - 48 hour inter-dialytic period). This will allow us to see if there is a difference between these two intervals of time.~Twenty of these patients will have additional monitoring including movement of left ventricle using echocardiography and continuous blood pressure monitoring using a finometer. The first echocardiogram will be done prior to the initiation of HD and the second at peak HD stress, which is 15 minutes before the end of the HD treatment. 20/50 patients will be chosen according to patient treatment schedule and staff schedule."||||
33775606|NCT06497660|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33906889|NCT04542798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will not be aware of the technique performed and the data will be collected by a physician unaware of the technique applied. Clinical report form will not contain any identifying data of the patient except for the identification number generated at the time of randomization. The follow up visit will be done identifying the patient by its identification number. After the technique performance, to ensure the blind, the patient will follow the planned out of study postprocedural visit, and a different physician, blind to the technique and to the patient identity, will make the follow up planned at 1, 3 and 6 months. The investigator will open the blind only if it is essential for the patients' management in efficacy and security, and if during the check visit there are clinical reason to do so (mostly severe complications related to the techniques applied and necessity for invasive intervention). The monitor can open the blind for intermediate statistical analysis.||t|f|t|t
33906890|NCT00909987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906891|NCT01971476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906892|NCT06625723|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two treatment arms, one standard postoperative protocol following rotator cuff repair surgery. The second arm with the same protocol, with the addition of the sleep assistive device.||||
33775607|NCT02465333|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33775608|NCT02577835|||COHORT||PROSPECTIVE|||||||
33775609|NCT00435903|RANDOMIZED|CROSSOVER||||NONE||||||
33775610|NCT02282735|||COHORT||PROSPECTIVE|||||||
33775611|NCT01728038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989132|NCT05514431|||COHORT||RETROSPECTIVE|||||||
33989133|NCT00113386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685987|NCT00320359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685988|NCT01142089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685989|NCT02762851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33685990|NCT00251160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685991|NCT02099071|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33685992|NCT03917433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to receive virtual reality exposure therapy with tactile feedback, point-based rewards, both tactile feedback and point-based rewards, or neither tactile feedback nor point-based rewards.||||
33685993|NCT02853227|||COHORT||RETROSPECTIVE|||||||
33685994|NCT05353140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33685995|NCT03558412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33685996|NCT00002455||||TREATMENT||||||||
33685997|NCT02686190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33685998|NCT04726098|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open-label trial involving hospitalized adult patients with respiratory failure needing oxygen therapy, caused by COVID-19.||||
33685999|NCT02655146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686000|NCT02586883|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686001|NCT00332371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686002|NCT03973801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686003|NCT04485429|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33686004|NCT05279404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775612|NCT04861207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775613|NCT04311242|||COHORT||PROSPECTIVE|||||||
33775614|NCT03295006|||COHORT||RETROSPECTIVE|||||||
33775615|NCT04102540|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will use a single pretest-posttest design to evaluate if using infographics for patient education can lead to improved patient outcomes.||||
33775616|NCT06047873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775617|NCT02448836|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33775618|NCT01708187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775619|NCT01862211|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33775620|NCT02266329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double blind placebo-controlled clinical trial with 2:1 chance of randomization to active drug.|t|t|t|t
33775621|NCT06054620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Double blinded (investigators and participants). A lab member external to the investigation will code items for the intervention.|Crossover to receive Collagen and Vitamin C (CVC) or Carbohydrate placebo. Unilateral leg exercise (EX) to give 4 outcomes. (1) CVC-EX; (2) CVC-REST; (3) PLACEBO-EX; (4) PLACEBO-REST||||
33686005|NCT05451927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33686006|NCT02019901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686007|NCT04043390|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This will be a phase III open randomised diagnostic trial.||||
33686008|NCT02973633|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33686009|NCT03103815|NA|SINGLE_GROUP||TREATMENT||NONE|The evaluating investigators will be blinded to treatment assignment. Patients in our center, include those participate in the trial and those receive standard therapy, will be evaluated by clinicians who do not know the trial.|This is a self-controlled trial. All participants will receive treatment.||||
33686010|NCT01778179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775622|NCT01734382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906893|NCT01315119|||COHORT||PROSPECTIVE|||||||
33906894|NCT06246058|||COHORT||CROSS_SECTIONAL|||||||
33906895|NCT02512263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906896|NCT06693622|||COHORT||PROSPECTIVE|||||||
33906897|NCT01180140|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906898|NCT02830841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906899|NCT05397613|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will receive 12 weeks of STAIR immediately or after a delay of 12 weeks for the waitlist control.||||
33906900|NCT04098952|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33906901|NCT01629485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33906902|NCT06512415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906903|NCT06693700|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906904|NCT01073956|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33906905|NCT05523362|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The device is used in blinded mode where both patient and provider are blinded to the data only during Phase 1.|||||
33906906|NCT02998008|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33906907|NCT01797107|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33906908|NCT03283163|NA|SINGLE_GROUP||TREATMENT||NONE||This study includes one group: Trauma-exposed participants suffering from both chronic musculoskeletal pain and varying degrees of PTSD severity. Those who meet diagnostic criteria for Chronic pain and have any symptoms of PTSD will be assigned to that group.||||
33686011|NCT04787081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Investigators hypothesized that caregivers would be more competent after lesson A (as compared with lesson B). Because of this participants were masked from knowing which lesson they'd received and were not informed about investigators hypothesis. The clinician's responsible for measuring participants' observed competence for positioning a person post-training were not informed of participant's assigned lesson. Participants were instructed to not discuss their lesson or lesson details with the clinicians' measuring those outcomes. The research assistant completed randomization and academic technology personnel registered participants into their lesson to ensure the principal investigator was not informed of participant's assigned lesson.|Mixed methods double-blind parallel group design, involving a consecutive sample of adults being randomly assigned to an educational intervention (Group A or B). The Principal Investigator enrolled participants, designating subject numbers and professional or non-professional labels. The research assistant completed randomization, drawing concealed numbers from an envelope to determine participant's educational intervention group (A or B). To balance the number of professionals and non-professionals across groups, the research assistant used co-variate adaptive group randomization and applied a difference threshold of 3.|t|f|t|t
33686012|NCT00976118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686013|NCT05245279|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A prospective cohort study was conducted among normal pregnant women recruited at 11 to 40 gestational weeks. Placental vascularization was evaluated using the 3-DPD-indices (vascularization-index (VI); flow-index (FI); vascularization-flow-index (VFI)) with the application of the sphere-technique or scanned from the entire placenta||||
33686014|NCT00812487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686015|NCT06273683|||COHORT||RETROSPECTIVE|||||||
33686016|NCT00558129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686017|NCT00281229|||CASE_ONLY||PROSPECTIVE|||||||
33686018|NCT01036061|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33686019|NCT06239623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686020|NCT04524338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686021|NCT04332809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686022|NCT04738929|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686023|NCT00373061|||COHORT||PROSPECTIVE|||||||
33686024|NCT04809636|||OTHER||CROSS_SECTIONAL|||||||
33686025|NCT00056498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686026|NCT03188172|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is designed as a single arm phase II trial with interim assessments for futility, using a Bayesian strategy for monitoring multiple outcomes.||||
33686027|NCT04973189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||SHR-1707 compared with placebo|t|f|t|f
33686028|NCT03504137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a single center prospective control trial. Participants in this study will use the mHealth application to manage and track their immunosuppression medical regimen post-transplant.||||
33686029|NCT00711074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33686030|NCT06468384|||COHORT||PROSPECTIVE|||||||
33686031|NCT00437970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686032|NCT03109847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33686033|NCT03671278|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33686034|NCT02904447|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33686035|NCT01933815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686036|NCT01221454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686037|NCT01343225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686038|NCT03046277|||COHORT||RETROSPECTIVE|||||||
33686039|NCT04494022|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||All participants underwent CEUS. The image reviews based on cross-section images will be performed with or without CEUS results. Two image sets (cross-sectional image with CEUS and without CEUS) will be compared.|f|f|f|t
33686040|NCT05465720|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33906909|NCT00017316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906910|NCT04964024|||COHORT||RETROSPECTIVE|||||||
33906911|NCT03836339|||COHORT||PROSPECTIVE|||||||
33906912|NCT02984826|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33906913|NCT04635696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906914|NCT01993329|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33906915|NCT02329795|||COHORT||PROSPECTIVE|||||||
33906916|NCT01458444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906917|NCT06424067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906918|NCT04879433|||COHORT||PROSPECTIVE|||||||
33989134|NCT02894593|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
34082439|NCT01494636|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33686041|NCT04268849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will wear sleep masks to blind intravenous intervention|Double blind, double dummy of oral versus intravenous iron for iron deficiency patients after bariatric surgery. All subjects will get either oral iron and intravenous saline, or oral vitamin C and intravenous iron.|t|t|t|t
33686042|NCT04253509|||COHORT||PROSPECTIVE|||||||
33686043|NCT00004229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686044|NCT00284960|||||PROSPECTIVE|||||||
33686045|NCT05469087|||COHORT||PROSPECTIVE|||||||
33686046|NCT01000038|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686047|NCT00206076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686048|NCT00873470|NA|SINGLE_GROUP||||NONE||||||
33686049|NCT06325332|||COHORT||RETROSPECTIVE|||||||
33686050|NCT04803942|||COHORT||PROSPECTIVE|||||||
33686051|NCT00695890|||COHORT||PROSPECTIVE|||||||
33686052|NCT02985970|||OTHER||PROSPECTIVE|||||||
33686053|NCT00789074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686054|NCT01165736|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686055|NCT02096848|||COHORT||PROSPECTIVE|||||||
33686056|NCT04836715|||OTHER||OTHER|||||||
33686057|NCT01192243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686058|NCT01528423|||CASE_ONLY||PROSPECTIVE|||||||
33686059|NCT02814331|||CASE_ONLY||PROSPECTIVE|||||||
33686060|NCT06553859|||CASE_CONTROL||OTHER|||||||
33686061|NCT04613401|||COHORT||PROSPECTIVE|||||||
33686062|NCT05990621|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and 3+3 design dose escalation phase followed by dose expansion phase||||
33686063|NCT01568801|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33686064|NCT06392945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686065|NCT04493840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686066|NCT04149275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686067|NCT04038632|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study will comprise an observation phase, during which there will be no interference with the routine TB childhood diagnosis processes, followed by an intervention phase in participating districts. During the last month of the observation phase, each district will be randomly assigned to implement either DH or PHC focused decentralisation. There will be no individual patient level randomisation.~The study will also include a nested cohort at both the DH and PHC during the intervention phase for a selected sub-set of children with presumptive TB and all children with a diagnosis of TB that consent to participate. This prospective cohort will enable to further document study endpoints related to follow up (TB treatment outcome) and to document TB diagnosis by assessing spontaneous resolution or resolution under TB treatment"||||
33686068|NCT00877097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33906919|NCT01056887|||COHORT||PROSPECTIVE|||||||
33906920|NCT06692413|||COHORT||OTHER|||||||
33906921|NCT00348803|||DEFINED_POPULATION||PROSPECTIVE|||||||
33906922|NCT02371759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33906923|NCT01328288|||COHORT||PROSPECTIVE|||||||
33686069|NCT00919841|||COHORT||PROSPECTIVE|||||||
33775623|NCT03242044|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot feasibility study that will assess maternal and infant tolerance to the protocols as well as the optimal method for performing an advanced resuscitation with an intact umbilical cord. The investigators have randomly chosen 10 study participant to make this assessment and determine methodologies. For this reason study participants will not be randomized. Pregnant women greater than 18 years of age that consent to the protocol will be enrolled in the study arm.||||
33775624|NCT00684983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906924|NCT06191354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906925|NCT05523401|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"6-period random order, placebo-controlled, double-blind, cross-over study with five active substance conditions and placebo:~1. 2C-B (10 mg), 2. 2C-B (20 mg), 3. 2C-B (30 mg), 4. MDMA (125 mg), 5. Psilocybin (25 mg), 6. Placebo"|t|t|t|f
33906926|NCT06689566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906927|NCT01293396|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33906928|NCT04581980|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Randomized, crossover design||||
33906929|NCT01096082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082440|NCT03228030|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33906930|NCT06184269|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33906931|NCT06334029|||COHORT||RETROSPECTIVE|||||||
33906932|NCT00415714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33906933|NCT04527016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33906934|NCT02733692|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33906935|NCT05142657|||CASE_CONTROL||PROSPECTIVE|||||||
33906936|NCT00982306|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33906937|NCT06306612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906938|NCT01247818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989135|NCT03435835|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects will not be told outright which therapy there are receiving (thermoneutral or HT) and the Cardiologist supervising the exercise test will not be told which therapy was given.||t|f|f|t
33989136|NCT05624034|||CASE_CONTROL||PROSPECTIVE|||||||
33989137|NCT05010018|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989138|NCT02043132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989139|NCT00139113|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34082441|NCT01447888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082442|NCT00896493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775625|NCT00394875|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775626|NCT02059343|||||PROSPECTIVE|||||||
33906939|NCT04752189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906940|NCT05639920|||COHORT||PROSPECTIVE|||||||
33906941|NCT05714306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906942|NCT02897973|||CASE_CONTROL||RETROSPECTIVE|||||||
33906943|NCT01230671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33906944|NCT02395887|||COHORT||PROSPECTIVE|||||||
33906945|NCT01205191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906946|NCT02994589|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33906947|NCT04940936|RANDOMIZED|PARALLEL||OTHER||NONE||"After inclusion in the study, the patients are randomized into Arm A and B as follows:~Arm A: Consultation as usual. Patients are informed about treatment and the two dose options according to current standards and routines.~Arm B: Consultation using the PtDA. Patients are informed about treatment and dose options using the PtDA to make the pros and cons clearer to the patients.~The doctors and nurses in the Radiotherapy Department will be educated in the use of the PtDA before initiation of the study."||||
33906948|NCT04099316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33906949|NCT01011920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906950|NCT04813237|||COHORT||CROSS_SECTIONAL|||||||
33906951|NCT05537415|||CASE_ONLY||PROSPECTIVE|||||||
33906952|NCT04929236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blinded||t|f|t|f
33906953|NCT03773523|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|"Participants will not be informed on their assigned protocol. During consent, they will be informed that there is a 50% chance of being assigned either to the group receiving active tDCS or the group receiving sham tDCS.~The Principal Investigator and research staff will also be blind to the condition the participant is assigned to."|This study is randomized, double-blind, and sham-controlled. Participants will be randomly assigned to either active or sham tDCS. We are testing device feasibility, safety, and circuit-based targeted engagement.|t|t|t|t
33906954|NCT01563562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906955|NCT01058174|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906956|NCT05966909|||COHORT||PROSPECTIVE|||||||
33906957|NCT05727163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906958|NCT04000672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be accomplished by computer-generated randomization sequence using serially numbered opaque, sealed envelopes with patients assigned either to intervention or control groups. All investigators, research staff, patients except the surgeon performing the HTO will be blinded to the group assignment of the subjects. Nor they will be aware of the regimen prescribed during the study and evaluation periods. A randomization code will be allocated to each included subjects to maintain blindness. Randomization code will be broken only after the database had been locked. Patient rehabilitation, post-operative assessment and Data analysis are conducted by personnel blinded to the patients' randomization assignment.|Control group: High tibial osteotomy with navigation Intervention group: High tibial osteotomy with navigation and PSI jig|t|f|f|t
33906959|NCT00387387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906960|NCT04769583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|a placebo which has the same visual characteristics as metronidazole in the boxes of the triple therapy||t|t|t|f
33906961|NCT01680406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906962|NCT04090489|||COHORT||PROSPECTIVE|||||||
33906963|NCT05278416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33906964|NCT03527446|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Individuals living with obesity (BMI ≥ 30 km/m2; n=15) as well as normal weight (BMI ≥ 18.5 \< 25.0 km/m2; n=15) adults (aged between 19 to 60 years) will be recruited to participate in the study. All participants will be asked to come in for a total of two visits and participate in a 4-week intervention.||||
33906965|NCT03125746|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906966|NCT03933917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33906967|NCT03969706|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-institution, single-arm phase II study of the efficacy and safety of abemaciclib in patients with recurrent oligodendroglioma.||||
33906968|NCT03623984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906969|NCT00543751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906970|NCT05550727|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study doesn't use any drugs or devices and is exempt from IRB approval requirements.||||
33906971|NCT04417088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906972|NCT04914637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33906973|NCT01572532|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|||||
33906974|NCT03238235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo was indistinguishable from the active product in color, appearance, smell and taste. Personnel involved in the study (Investigators, nurses, all other site personnel, clinical research associates \[CRA\], medical monitors, project managers, data managers and statisticians) were blinded at all times unless knowledge of the study treatment was necessary for the patient's safety.||t|t|t|t
33906975|NCT06693661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33906976|NCT00814073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33906977|NCT02151409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33906978|NCT05041374|||COHORT||PROSPECTIVE|||||||
33906979|NCT04174638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding was provided that included inclusion criteria and agreement to participate in the study|This study is a parallel group randomized controlled study|t|f|f|f
33686070|NCT02034344|||COHORT||PROSPECTIVE|||||||
33686071|NCT04759183|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33686072|NCT05648656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989140|NCT03621163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Single blinded (outcome assessor). Assessors supervisor and co-supervisor will be blinded to the assigned material. However the operator and patient can't be blinded due to the difference in preparation and shade of the ceramic materials and bleaching agent.~* The assessors will assess all outcomes blinded to the material assigned for each patient.~* Three spectrophotometer measurements will be recorded each time, with the active point of the instrument focused on the cervical third of each tooth, then mean color from three measurements will be calculated.~* Digital photograph measures the color of teeth based on the Adobe Photoshop software. (Version 5.5)."|split mouth randomized control, co-supervisor will write number for each member in each group (left side treatment A, right side treatment B or left side treatment B, right side treatment A) by indispensible pen on large white paper sheet. The sheet will be folded eight times and saved inside opaque well sealed envelope in which the inner content cannot be seen by naked eyes.|f|f|f|t
33686073|NCT02940002|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33686074|NCT05676593|RANDOMIZED|PARALLEL||PREVENTION||NONE||"We therefore propose a prospective randomised study in 2 arms :~* a group of people living with diabetes receiving standard TPE vs~* a group of people living with diabetes receiving standard TPE + FSL 28 days Ourmain objective is to determine the benefit of CGM on HbA1c at 3 months between 2 arms"||||
33989141|NCT05183425|||OTHER||PROSPECTIVE|||||||
33989142|NCT02100761|||CASE_ONLY||PROSPECTIVE|||||||
33989143|NCT00252967|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34082443|NCT04072874|RANDOMIZED|PARALLEL||TREATMENT||NONE||"An Open-label, Randomized, Non-comparative, Two-arm Exploratory study. After all the screening evaluations have been completed, the principal investigator or his designee will confirm the patient's eligibility on Day 1, and the randomization will be determined by IWRS where randomized identification of the patient will be provided.~The treatment allocation will be performed according to a computer-generated random code."||||
34082444|NCT02627560|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082445|NCT05849077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082446|NCT01317940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082447|NCT04827862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082448|NCT00900939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082449|NCT05706324|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33686075|NCT03865576|||COHORT||PROSPECTIVE|||||||
33686076|NCT01520831|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33686077|NCT02719873|||CASE_CONTROL||PROSPECTIVE|||||||
33686078|NCT01193751|||COHORT||PROSPECTIVE|||||||
33686079|NCT03616171|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized and unblinded||||
33686080|NCT05918081|||OTHER||PROSPECTIVE|||||||
33686081|NCT05011448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686082|NCT04705740|||OTHER||RETROSPECTIVE|||||||
33686083|NCT02318108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33906980|NCT04468958|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33906981|NCT04969016|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized controlled, open-label||||
33906982|NCT04628559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The surgeon and observers were all blinded to the patients until the end of the study.|"1. First arm received dexmedetomidine~2. Second arm received ketamine~3. Third arm received saline solution."|t|t|t|f
33906983|NCT03242278|||COHORT||RETROSPECTIVE|||||||
33906984|NCT03909763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906985|NCT04362579|||COHORT||PROSPECTIVE|||||||
33906986|NCT05346952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906987|NCT04722393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pulmonary Rehabilitation Group and Control Group||||
34082450|NCT04309331|NA|SINGLE_GROUP||OTHER||NONE||||||
34082451|NCT04831710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33906988|NCT06332625|||COHORT||PROSPECTIVE|||||||
33906989|NCT06381414|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33906990|NCT05664048|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33906991|NCT03089177|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33906992|NCT06004882|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33906993|NCT02811133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082452|NCT05074875|||COHORT||PROSPECTIVE|||||||
34082453|NCT02966704|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34082454|NCT01001429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34082455|NCT00663650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082456|NCT04890808|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082457|NCT01103323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082458|NCT01884597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082459|NCT01978457|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34082460|NCT05444283|||COHORT||PROSPECTIVE|||||||
34082461|NCT00032773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082462|NCT02771275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082463|NCT04666532|||COHORT||PROSPECTIVE|||||||
34082464|NCT04458896|NA|SINGLE_GROUP||PREVENTION||NONE||Non-randomized trial||||
34082465|NCT04012528|||OTHER||RETROSPECTIVE|||||||
34082466|NCT04621721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both the investigator, co-investigators, statistician and data collectors will be blinded to study assignment.||f|f|t|t
34082467|NCT01201642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082468|NCT02548936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34082469|NCT01506180|||COHORT||CROSS_SECTIONAL|||||||
34082470|NCT04315441|||CASE_CONTROL||PROSPECTIVE|||||||
34082471|NCT02737722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082472|NCT00055562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082473|NCT00594776|||COHORT||PROSPECTIVE|||||||
34082474|NCT02679664|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082475|NCT05025930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082476|NCT03880474|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082477|NCT01192321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082478|NCT01854814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906994|NCT04562064|||OTHER||CROSS_SECTIONAL|||||||
33906995|NCT04614545|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Single-center, Parallel-group trial comparing the use of virtual visit for prescription of phentermine versus standard face-to-face visits for weight management||||
33686084|NCT00177710|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33686085|NCT01466777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33906996|NCT04838691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33906997|NCT03232424|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, non-randomized, open label pilot||||
33906998|NCT03524677|||COHORT||PROSPECTIVE|||||||
33906999|NCT01444495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907000|NCT00450203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907001|NCT04228991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907002|NCT06233032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33907003|NCT00887718|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907004|NCT03421002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907005|NCT02949765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907006|NCT02986958|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33907007|NCT02597842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33907008|NCT06270940|||COHORT||PROSPECTIVE|||||||
33907009|NCT04209101|||COHORT||CROSS_SECTIONAL|||||||
33907010|NCT00851955|||CASE_ONLY||PROSPECTIVE|||||||
33907011|NCT01598857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907012|NCT03297853|||OTHER||RETROSPECTIVE|||||||
33907013|NCT01477892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33907014|NCT03241056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907015|NCT05178953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686086|NCT06324916|||COHORT||RETROSPECTIVE|||||||
33907016|NCT06467760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989144|NCT05545098|||OTHER||CROSS_SECTIONAL|||||||
33989145|NCT02496234|||COHORT||PROSPECTIVE|||||||
33989146|NCT01208727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989147|NCT04086186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989148|NCT04757220|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33989149|NCT03084991|||CASE_ONLY||PROSPECTIVE|||||||
33989150|NCT04119986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989151|NCT05468879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, single blind, two-period, single dose, cross-over study with one week washout period under fasted condition|t|f|t|f
33989152|NCT02054117|||CASE_ONLY||PROSPECTIVE|||||||
33989153|NCT01643135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989154|NCT04866524|||OTHER||CROSS_SECTIONAL|||||||
33989155|NCT04229121|||COHORT||PROSPECTIVE|||||||
33989156|NCT03827356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator doesn´t know the group of the patients until the study ends|Patients are assigned randomly to the 2 working groups, each patient only receives one of the two protocols.|f|f|t|f
33989157|NCT00852020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33989158|NCT00246922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989159|NCT01233622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907017|NCT06158490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907018|NCT05387720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907019|NCT04125914|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33907020|NCT01340235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907021|NCT00912158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907022|NCT00762801|||||PROSPECTIVE|||||||
33907023|NCT00957346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907024|NCT06693453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907025|NCT01609959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907026|NCT00878072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907027|NCT00096746|||COHORT||PROSPECTIVE|||||||
33907028|NCT01217658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907029|NCT05547438|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Single ascending doses with review of safety, tolerability and pk prior to next dose level|t|f|t|f
33907030|NCT05940987|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907031|NCT00322595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907032|NCT03393013|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907033|NCT06649383|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33907034|NCT03295097|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989160|NCT02984696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989161|NCT05684276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989162|NCT05381649|||COHORT||PROSPECTIVE|||||||
33989163|NCT03072433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33686087|NCT05386303|||COHORT||PROSPECTIVE|||||||
33686088|NCT04730414|||CASE_CONTROL||PROSPECTIVE|||||||
33686089|NCT04763876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient was unaware of the dosage of ketorolac they received.|Single blinded, randomized, non-inferiority|t|f|f|f
33686090|NCT01876433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686091|NCT03737071|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Low Carbohydrate Diet versus Simple Calorie Restriction Diet||||
33686092|NCT02591771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686093|NCT05447221|||OTHER||PROSPECTIVE|||||||
33686094|NCT05977478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686095|NCT01245361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686096|NCT00494598|||COHORT||PROSPECTIVE|||||||
33686097|NCT01042782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907035|NCT03651999|||COHORT||PROSPECTIVE|||||||
33989164|NCT03708991|||OTHER||PROSPECTIVE|||||||
33989165|NCT02778321|NA|SINGLE_GROUP||SCREENING||NONE||||||
33989166|NCT05667649|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33989167|NCT01319383|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|All participants eligible for study received the same open label drug||||
33989168|NCT04230330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775627|NCT05139979|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Upon enrollment and randomization, the intervention group will be followed weekly for 3 weeks as well as on week 6. The waitlisted control group will be followed for 3 weeks as controls and will then learn the intervention and be followed for additional 3 weeks (total of 6 weeks).||||
33775628|NCT04499742|||CASE_CONTROL||PROSPECTIVE|||||||
33775629|NCT01426906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989169|NCT02612298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775630|NCT06304311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33775631|NCT04929119|||CASE_CONTROL||PROSPECTIVE|||||||
33775632|NCT01103986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33775633|NCT06476587|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33775634|NCT06441019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775635|NCT01175538||||TREATMENT||||||||
33775636|NCT01144221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775637|NCT00315224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775638|NCT04691609|||COHORT||CROSS_SECTIONAL|||||||
33775639|NCT05594355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775640|NCT05802550|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686098|NCT02392832|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33686099|NCT04678206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33775641|NCT01959945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33686100|NCT05833022|||COHORT||RETROSPECTIVE|||||||
33686101|NCT03560739|RANDOMIZED|PARALLEL||TREATMENT||NONE||To address the primary objective of testing bioequivalence at dosing interval after Week 8 between Pre-filled Syringe (PFS) and Auto-Injector (AI), the primary analysis involves the two groups (PFS (abdomen) and AI (abdomen)). Further the pharmacokinetcs of ofatumumab will be compared between using the thigh or abdomen for injections.||||
33686102|NCT01153464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686103|NCT01891526|||CASE_CONTROL||PROSPECTIVE|||||||
33686104|NCT00849888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686105|NCT05185011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686106|NCT02486627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686107|NCT02873585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721412|NCT05389345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization sequence will be pre-generated by the study coordinator who will then inform the treating clinician. The assessors obtaining outcome measure data will be blind to participants' assigned treatment groups. Participants will not be told which stimulation group they belong to.|Participants will be randomized to receive either actual transcranial direct current stimulation (tDCS) or sham tDCS prior to engaging in executive function training (ET). All participants will receive ET.|f|f|f|t
33775642|NCT01284777|||||PROSPECTIVE|||||||
33775643|NCT04123860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double|it is randomized clinical trail|t|f|f|f
33775644|NCT00413608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775645|NCT00478296|||||RETROSPECTIVE|||||||
33775646|NCT00559910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775647|NCT04344834|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33721413|NCT00339937|||CASE_CONTROL||OTHER|||||||
33721414|NCT02922907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775648|NCT00680303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33775649|NCT05538299|||COHORT||CROSS_SECTIONAL|||||||
33775650|NCT00099216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775651|NCT00949962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775652|NCT01799772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33775653|NCT03587987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775654|NCT04239365|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|t|f|f
33775655|NCT02492217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775656|NCT05783674|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33775657|NCT01820468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775658|NCT04082182|NA|SINGLE_GROUP||TREATMENT||NONE||intra-patient dose escalation scheme||||
33775659|NCT05667389|||COHORT||RETROSPECTIVE|||||||
33775660|NCT00463541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775661|NCT02514564|||COHORT||PROSPECTIVE|||||||
33775662|NCT02496858|||CASE_CONTROL||PROSPECTIVE|||||||
33775663|NCT05540691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients were randomly divided into intervention group（noise blocking） and control group（No noise blocking）|t|f|f|t
33775664|NCT02415218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775665|NCT06083103|||COHORT||PROSPECTIVE|||||||
33775666|NCT00682695|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33989170|NCT00851825|||||CROSS_SECTIONAL|||||||
33907036|NCT06499259|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Stratified and block randomization method will be used in the randomization scheme of the study. In the study, maternal age, number of pregnancies, duration of intensive care unit stay and gestational age variables will be used in the stratification of newborns.|control group (routine care) and experimental group (mandala painting)|t|f|f|f
33721415|NCT04999150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each patient was randomly assigned an identification number (S1-S13) by picking a sealed envelope. The randomization of IDs to the right or left side for MOP was accomplished with a 1:1 allocation ratio, using a computer-generated research randomizer.|a split-mouth randomized clinical trial.|t|f|f|t
33907037|NCT00004568|||FAMILY_BASED||OTHER|||||||
33721416|NCT01675128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721417|NCT03401983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721418|NCT02877082|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33721419|NCT01361139|||COHORT||PROSPECTIVE|||||||
33721420|NCT03550703|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|open label, single arm study||||
33721421|NCT03753347|NA|SINGLE_GROUP||OTHER||NONE||||||
33721422|NCT00117247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721423|NCT04695925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775667|NCT04047069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775668|NCT01914367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907038|NCT02945761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907039|NCT03554538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial will be simple blinded because of the impossibility to blind patients nor physiotherapists to treatment.|There will be two randomized groups in a controlled clinical trial. The two groups will receive the same treatment based on an evidence-based exercise program taught by a physiotherapist, and one group will use the app multimedia to improve the performance and adherence. The other group won't use the app but a pamphlet, to follow exercises at home.|f|f|f|t
33907040|NCT00097526|||COHORT||PROSPECTIVE|||||||
33907041|NCT00426049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907042|NCT03534258|||COHORT||PROSPECTIVE|||||||
33907043|NCT03468283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907044|NCT05645484|||COHORT||PROSPECTIVE|||||||
33907045|NCT03119376|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33907046|NCT04598165|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to 1) Interactive two-way SMS dialogue or 2) Control (no SMS), using 1:1 allocation.||||
33989171|NCT00131391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989172|NCT00698256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33989173|NCT03004118|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33989174|NCT06543472|||COHORT||RETROSPECTIVE|||||||
33989175|NCT01042171|||||PROSPECTIVE|||||||
33989176|NCT02158572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989177|NCT00190840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989178|NCT02821260|||COHORT||PROSPECTIVE|||||||
33989179|NCT01149590|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082479|NCT02585869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721424|NCT06021015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775669|NCT04253197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pregnant women in 3rd trimester||||
33775670|NCT04478214|||COHORT||PROSPECTIVE|||||||
33775671|NCT00553111|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33775672|NCT06352515|||CASE_CONTROL||RETROSPECTIVE|||||||
33775673|NCT00000582||||TREATMENT||DOUBLE||||||
33775674|NCT00508339|||CASE_ONLY||PROSPECTIVE|||||||
33775675|NCT04427891|||OTHER||PROSPECTIVE|||||||
33907047|NCT02674997|||COHORT||PROSPECTIVE|||||||
33907048|NCT06109116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907049|NCT02424955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907050|NCT05288985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907051|NCT02927808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907052|NCT03919916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907053|NCT03430882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907054|NCT06687876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907055|NCT00530322|||DEFINED_POPULATION||OTHER|||||||
33907056|NCT03175380|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants (N=17) will receive BCG on Study Day 0 and Study Day 180 by intradermal administration.||||
33907057|NCT00942773|NON_RANDOMIZED|PARALLEL||||NONE||||||
33989180|NCT00579345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33989181|NCT05246293|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study|This is a phase 2 open-label study designed to evaluate the safety and tolerability of tofacitinib in RA-ILD patients. Patients who met the inclusion criteria of the study protocol will receive tofacitinib 5 mg BID for 12 months.||||
33989182|NCT02311686|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33989183|NCT06293196|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33989184|NCT05954598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082480|NCT00547144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082481|NCT04044105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34082482|NCT02271451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34082483|NCT01292408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082484|NCT04527588|||CASE_CONTROL||PROSPECTIVE|||||||
34082485|NCT04341935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082486|NCT02963480|||COHORT||PROSPECTIVE|||||||
34082487|NCT05591521|||COHORT||PROSPECTIVE|||||||
34082488|NCT03608826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907058|NCT01257646|||COHORT||PROSPECTIVE|||||||
33907059|NCT03762850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907060|NCT02995343|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33907061|NCT02948140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989185|NCT01891994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989186|NCT05275998|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34082489|NCT03290625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33989187|NCT00006682|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Navelbine (vinorelbine tartrate) and Taxotere (docetaxel) as First-Line Therapy for Metastatic Breast Cancer||||
33989188|NCT06219044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989189|NCT01112566|||CASE_ONLY||PROSPECTIVE|||||||
33989190|NCT05479487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989191|NCT02216006|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33989192|NCT01472263|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33775676|NCT06292624|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm, receiving IVT combined with cycling exercise||||
33775677|NCT00004928||||TREATMENT||||||||
33907062|NCT05832164|NA|SINGLE_GROUP||PREVENTION||NONE||The study design consists of two stages: a descriptive cross-sectional study to assess the prevalence of frailty in a cohort of HIV patients and, subsequently, a quasi-experimental before/after study without equivalent control group to evaluate the effectiveness of a multifactorial intervention. The intervention will be offered to all patients, regardless of their frailty, pre-frailty or robustness status.||||
33907063|NCT03415724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907064|NCT06554223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907065|NCT00003342||||TREATMENT||||||||
33907066|NCT02568826|NA|SINGLE_GROUP||OTHER||NONE||||||
33907067|NCT01191294|NA|SINGLE_GROUP||||NONE||||||
33907068|NCT06523426|||COHORT||PROSPECTIVE|||||||
33989193|NCT05436860|||CASE_CONTROL||PROSPECTIVE|||||||
33989194|NCT02711449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989195|NCT00219154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989196|NCT04717960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989197|NCT02820350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989198|NCT01032083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989199|NCT00471523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989200|NCT01816997|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989201|NCT02877433|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33989202|NCT04766697|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33989203|NCT05239832|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33989204|NCT03443115|||COHORT||RETROSPECTIVE|||||||
33989205|NCT03340376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989206|NCT01893008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33989207|NCT03266393|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Once enrolled, patients will be randomized 1:1 to immediate release tacrolimus that the patient had been maintained on prior to the study (twice daily formulation) or Envarsus XR® using a permuted block randomization sequence to improve the likelihood of balance between groups. Following randomization, and independent of the formulation of tacrolimus, each patient will have a run-in period of 14 days to optimize the dose to reach a tacrolimus trough level within their therapeutic target. Randomization will be stratified based on each patient's follow-up period post-transplant in 2 stratification groups."||||
33989208|NCT05956925|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking was done.|Intervention group vs control group||||
33989209|NCT05038293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors and the principal investigator will be blind to toothbrush device assignment. In order to maintain blinding and eliminate assessor bias, study team members instructing and observing participants in the use of the assigned toothbrushing device will not be outcomes assessors.|Single-blind, parallel group, randomized controlled clinical trial|f|f|t|t
33989210|NCT06560086|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33989211|NCT01762605|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989212|NCT00040391||||TREATMENT||||||||
33989213|NCT01392794|RANDOMIZED|CROSSOVER||||NONE||||||
33989214|NCT06073691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study was designed as a prospective, two-arms, blinded, randomized controlled clinical trial. Patients and evaluators were informed that the participants might receive an active pharmacological treatment or a matching placebo; however, all patients received only a placebo. The study was conducted at the Anxiety Disorder Program of the Institute of Psychiatry and at the Institute of Orthopaedics and Traumatology of the University of Sao Paulo Medical School, Sao Paulo, Brazil.|f|f|t|t
33989215|NCT00873639|||COHORT||PROSPECTIVE|||||||
34082490|NCT01622556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082491|NCT02631395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082492|NCT01369381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34082493|NCT05633511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082494|NCT00945217|||COHORT||CROSS_SECTIONAL|||||||
34082495|NCT05430906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082496|NCT01190917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082497|NCT06517342|||COHORT||PROSPECTIVE|||||||
34082498|NCT05837195|||COHORT||PROSPECTIVE|||||||
34082499|NCT02536872|||COHORT||PROSPECTIVE|||||||
34082500|NCT05493826|||COHORT||RETROSPECTIVE|||||||
34082501|NCT02633722|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34082502|NCT02502370|RANDOMIZED|PARALLEL||||NONE||||||
34082503|NCT00560963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082504|NCT02302274|||CASE_CONTROL||PROSPECTIVE|||||||
34082505|NCT01003106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082506|NCT03163446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082507|NCT06213987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|They were allocated the treatment via simple randomization by a third investigator who was not involved in data collection and analysis. Participants were given unlabeled jars of the topical agents. Assessments regarding clinical efficacy will be conducted by an assessor blind to treatment allocation.|Intra-individual design with a split-side axillary approach, participants were randomly assigned to apply both 0.025% tretinoin cream and the cream-based product on opposing sides of the axillary region.|t|f|t|t
34082508|NCT00805259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082509|NCT03908411|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34082510|NCT01701245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082511|NCT04137198|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized trial||||
34082512|NCT00914368|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33775678|NCT00002750||||TREATMENT||||||||
33775679|NCT00479596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775680|NCT00001084||||TREATMENT||DOUBLE||||||
33775681|NCT02739243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775682|NCT05884021|||COHORT||RETROSPECTIVE|||||||
33775683|NCT05552690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775684|NCT01314781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775685|NCT04079283|||CASE_ONLY||RETROSPECTIVE|||||||
33775686|NCT02033460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775687|NCT05742776|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907069|NCT03525587|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"Patients with a previous documented AGHD fitting the inclusion/exclusion criteria will be enrolled and grouped as follows:~* Group 1: patients on long-term r-hGH therapy;~* Group 2: patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will);~* Group 3: patients never treated for any reason (according to age, contraindications or lack of patient's consent).~The whole cohort of AGHD patients (n=100) will undergo 2 consecutive phases: in the first phase (12 months) patients will be evaluated as usual every six months according to our standard clinical practice without using the App and the wearable device (baseline visit, visit 1 and visit 2), while in the second phase (following 12 months) they will be evaluated every six months during the use of the App (visit 3 and visit 4)."||||
33907070|NCT05926986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775688|NCT06375629|||COHORT||PROSPECTIVE|||||||
33775689|NCT03740074|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot||||
33775690|NCT01835561|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33775691|NCT05700799|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33775692|NCT04015882|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33775693|NCT05398497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775694|NCT00026637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907071|NCT02078622|||COHORT||PROSPECTIVE|||||||
33907072|NCT06351345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907073|NCT05657743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989216|NCT02209285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33686108|NCT04612023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assistants not part of the study used a randomizer generating software to randomly assign a patient a dose. The randomly assigned dose was put in a sealed envelope labeled with the corresponding number and was recorded. Prior to the injection, a medical assistant not involved in the study retrieves the envelope to determine the dose, prepares the injection, then seals the syringe in black tape before giving it to the research staff who then performs the injection.|"Data will be prospectively collected on all injectable acellular amniotic membrane derived allograft knee performed at our institute. (FDA regulated - HCT/P regulation)~Inclusion criteria will be all patients age between 21 and 80 years with a diagnosis of osteoarthritis (OA) defined as Grade 1 to 3 on the Kellgren Lawrence grading scale.~Methods for collecting data will be through validated patient-reported outcome tools that the patient will complete pre-injection and at specified time intervals after injection: 30 days, 90 days, 180 days and 365 days.~Patient will receive a phone call 24 hours after the injection to monitor any immediate potential adverse events."|t|t|t|f
33686109|NCT00000187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686110|NCT04578080|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33686111|NCT06155864|||COHORT||RETROSPECTIVE|||||||
33686112|NCT01651689|||CASE_ONLY||PROSPECTIVE|||||||
33686113|NCT01041378|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33686114|NCT02048293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686115|NCT04330326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 45 overweight or obese patients with NAFLD will be randomized on a 2:1 basis to the cofactor mixture or placebo.|t|f|f|f
33686116|NCT02604121|NA|SINGLE_GROUP||SCREENING||NONE||||||
33686117|NCT05340647|||OTHER||PROSPECTIVE|||||||
33686118|NCT01974765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686119|NCT00000791||||TREATMENT||DOUBLE||||||
33686120|NCT05377073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were randomly assigned (in a 1:1 ratio) through sealed opaque envelopes to either to the yoga group or the stretching group by coin tossing sequence generation.|Parallel randomized controlled trial|f|f|t|f
33686121|NCT03291301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686122|NCT01322581|||COHORT||PROSPECTIVE|||||||
33686123|NCT00300209|||COHORT||PROSPECTIVE|||||||
33686124|NCT00600509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686125|NCT06283927|||COHORT||PROSPECTIVE|||||||
33686126|NCT01609478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686127|NCT04569071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686128|NCT05869084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686129|NCT01721785|||COHORT||PROSPECTIVE|||||||
33686130|NCT01931631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686131|NCT03808103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686132|NCT02102373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33686133|NCT06116240|NA|PARALLEL||TREATMENT||NONE||||||
33686134|NCT05440773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686135|NCT04369820|NA|SINGLE_GROUP||OTHER||NONE||||||
33686136|NCT05278637|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"1. Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks, Aspirin washout, Ticagrelor 90mg BID x 4 weeks.~2. Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks, Aspirin washout, Ticagrelor 90mg BID x 4 weeks."||||
33686137|NCT01629771|||CASE_CONTROL||PROSPECTIVE|||||||
33686138|NCT03490981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes assessor will be masked|Two arm parallel design: 1) primary care treatment as usual, or 2) primary care treatment as usual and Brief Cognitive Behavioral Therapy for Chronic Pain|f|f|f|t
33686139|NCT06408155|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33686140|NCT04604691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686141|NCT06523192|||COHORT||PROSPECTIVE|||||||
33686142|NCT00164970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686143|NCT00858819|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33686144|NCT03773445|||COHORT||CROSS_SECTIONAL|||||||
33907074|NCT06063434|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participant assignment will be masked within the data with unblinding occurring only after data cleaning has completed.|Physicians will be randomized in a 1:1 fashion to the intervention condition or to the control condition.|f|f|f|t
33907075|NCT04353622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33907076|NCT05816239|||CASE_CONTROL||PROSPECTIVE|||||||
33907077|NCT05687201|||COHORT||PROSPECTIVE|||||||
33907078|NCT04510857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator administrating assessments will be blinded to subject group assignment.|"Intervention group performs home exercise program using the computer-aided MOVE-IT system for upper extremity therapy.~Control group participants will be followed as they continue to receive their previously prescribed therapy services."|f|f|t|t
33907079|NCT01704326|||||PROSPECTIVE|||||||
33907080|NCT06693778|||CASE_CONTROL||PROSPECTIVE|||||||
33907081|NCT00676481|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33686145|NCT04461041|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33686146|NCT03211806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to the sedentary behavior intervention or the monitoring-only control group||||
33686147|NCT01171833|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33686148|NCT01074047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686149|NCT04554004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686150|NCT03112590|NA|SEQUENTIAL||TREATMENT||NONE||||||
33686151|NCT02910128|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686152|NCT06393959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686153|NCT00868179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686154|NCT04983303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686155|NCT03046914|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cases and historical controls||||
33686156|NCT00936429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686157|NCT02392715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686158|NCT06188273|||COHORT||PROSPECTIVE|||||||
33686159|NCT00082472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686160|NCT06136988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686161|NCT05860374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686162|NCT06181045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33686163|NCT00159562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686164|NCT03965273|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The trial employs a three arm Cluster Randomized Controlled Trial (CRCT) design and uses both quantitative and qualitative methods for evaluating TP. The arms are as follows:~Arm 1: Full TP intervention including emphasized social norms change Arm 2: Light TP intervention without emphasized social norms change Arm 3: Pure control~This 3-arm design will enable us to measure the effect of the light TP intervention as well as the effect of social norms change on TP outcomes. The effects will be determined by comparing the three arms as follows:~Arm 1 - Arm 3 = Effect of full TP intervention Arm 2 - Arm 3 = Effect of light TP intervention Arm 1 - Arm 2 = Effect of emphasized social norms change~TP will be implemented in one upazila (sub-district) of Rangpur district. Rangpur has been selected as the median age at marriage is 15 years among women aged 20-49, which is the lowest in the country."||||
33686165|NCT06282887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"All participants will be wearing a headphone, and they will not know if there will be music until they experience and finish the scan process.~Radiographers are blinding to avoid biases."||t|t|f|f
33686166|NCT03665857|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessors measuring childrens' weight and height will be blinded at follow-up phases.||f|f|f|t
33686167|NCT02218177|||CASE_CONTROL||PROSPECTIVE|||||||
33686168|NCT02277834|||COHORT||PROSPECTIVE|||||||
33686169|NCT00572221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33686170|NCT01176357|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33686171|NCT04898621|RANDOMIZED|PARALLEL||OTHER||NONE||60 healthy men will be recruited according to the inclusion criteria. All the participates are randomly allocated to Group A and Group B. Subjects in Group A will be instructed to drink fructose solution containing 75g fructose per day and those in Group B will be instructed to drink 150g fructose per day.||||
33686172|NCT01830777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686173|NCT04999254|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants will be assigned to one of two or more groups in parallel for the duration pot the study||||
33686174|NCT03085277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||When a preterm infant is delivered at these hospitals or transferred from other hospitals on the day of birth, responsible neonatologists/PIs/co-PIs will evaluate the infant for its eligibility. If the infant fulfills the recruitment criteria, parent(s) are informed and explained about the study and asked for permission to recruit their babies. After confirmed consent, the infant will be, per hospital, randomized to two groups in a 1:1 ratio. Infants should be recruited and randomized as soon as possible after birth and no later than 48 h. The first supplemental enteral feeding (PF or BC) can be given as soon as the infants are randomized. Randomization will be stratified by birth weight \< 1000 g, birth weight ≥ 1000 g, and randomly permuted blocks of size 4 and 6 will be used. A random sequence list will be generated by computer software for each hospital and a corresponding sequence number can only be checked to see allocation after informed consent is given and the baby is enrolled.|t|f|f|t
33686175|NCT03473457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686176|NCT00072527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686177|NCT00379002|||OTHER||PROSPECTIVE|||||||
33686178|NCT00290407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686179|NCT05969327|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33686180|NCT02592187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775695|NCT06318780|NA|SINGLE_GROUP||OTHER||NONE||||||
33775696|NCT02201446|||CASE_CONTROL||PROSPECTIVE|||||||
33775697|NCT06493500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* This study is a double blinded study, the participants as well as the assessors will be blinded. The operator will not be blinded to apply both interventions following the manufacturer's instructions.~* Double blinded study design is the recommended design for studies of DH. (Holland et al., 1997)~* Outcome assessors and analyst (M.S and D.E) will be blinded to the intervention group assigned to the patients.~* Operator (SH.G) will not be blinded."||t|f|f|t
33775698|NCT04323644|||COHORT||OTHER|||||||
33907082|NCT06332781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907083|NCT00298610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907084|NCT03640091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907085|NCT03126136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907086|NCT03884101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907087|NCT00496873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907088|NCT02639182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907089|NCT05427825|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Patients in the treatment group received the study protocolized care bundle including multimodal anesthesia and HPI-assisted hemodynamic therapy.|t|f|t|t
33907090|NCT01975935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907091|NCT01792622|||OTHER||PROSPECTIVE|||||||
33907092|NCT06693206|||OTHER||PROSPECTIVE|||||||
33907093|NCT05756673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33686181|NCT04175509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33686182|NCT03464565|||COHORT||PROSPECTIVE|||||||
33686183|NCT01267695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686184|NCT03204110|||COHORT||PROSPECTIVE|||||||
33686185|NCT00309660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33686186|NCT03584373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This will be an open label, prospective study of approximately 112 subjects undergoing either ureteroscopy or percutaneous nephrolithotomy. Patients who are eligible and choose to undergo ureteroscopy or percutaneous nephrolithotomy will then be asked if they would like to participate in the study and informed consent will be obtained. Patients will then be randomized to control (opioid analgesia) or non-opioid analgesia groups, and given this medication at discharge.||||
33686187|NCT00454831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686188|NCT04439565|||FAMILY_BASED||OTHER|||||||
33686189|NCT05116072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686190|NCT01007253|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33686191|NCT02755792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686192|NCT03914846|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33686193|NCT02176824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33686194|NCT03935399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participant, Investigator and outcomes assessor will be blinded. Research Pharmacist will prepare the study medication administration and hold the randomization.|Double blinded crossover treatment with oxytocin and placebo (saline)|t|f|t|t
33686195|NCT01722227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686196|NCT04789018|||CASE_ONLY||PROSPECTIVE|||||||
33686197|NCT04277000|||COHORT||PROSPECTIVE|||||||
33686198|NCT04817852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686199|NCT05879510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686200|NCT02112955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686201|NCT00078052|||COHORT||PROSPECTIVE|||||||
33686202|NCT01443767|||CASE_ONLY||PROSPECTIVE|||||||
33686203|NCT04696497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686204|NCT06107179|||COHORT||PROSPECTIVE|||||||
33686205|NCT05080231|||COHORT||PROSPECTIVE|||||||
33686206|NCT01874990|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33686207|NCT05767801|||CASE_CONTROL||PROSPECTIVE|||||||
33686208|NCT03473938|||CASE_ONLY||RETROSPECTIVE|||||||
33686209|NCT02632838|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686210|NCT00495079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907094|NCT05176262|||COHORT||PROSPECTIVE|||||||
33907095|NCT01879605|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907096|NCT00000404|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33907097|NCT01958736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907098|NCT02951988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907099|NCT00518453|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33907100|NCT04227249|||CASE_ONLY||PROSPECTIVE|||||||
33907101|NCT06034704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33907102|NCT05472597|||COHORT||PROSPECTIVE|||||||
33907103|NCT05313633|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33907104|NCT04180813|||COHORT||PROSPECTIVE|||||||
33907105|NCT02008929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907106|NCT00916955|||COHORT||PROSPECTIVE|||||||
33907107|NCT06692231|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907108|NCT00002677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907109|NCT01266798|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33907110|NCT05396066|||CASE_ONLY||PROSPECTIVE|||||||
33907111|NCT01180374|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33989217|NCT02255292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989218|NCT04206332|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33989219|NCT01677754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989220|NCT03166345|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33989221|NCT01093989|RANDOMIZED|PARALLEL||||NONE||||||
33989222|NCT04798144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686211|NCT02599805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686212|NCT03141645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33686213|NCT04859114|RANDOMIZED|FACTORIAL||OTHER||SINGLE||2x3 between subjects|t|f|f|f
33686214|NCT04958512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686215|NCT01434316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686216|NCT03316183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686217|NCT03631108|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33686218|NCT01398878|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33686219|NCT03528395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments will be made by blind evaluators with respect to the established study groups|"Patients will be randomly distributed to a control group or experimental group using the QuickCalcs application of GraphPad Software.~The following considerations will be taken into account:~Control group: 8 weeks of conventional rehabilitation based on a task-oriented approach. Consisting of five weekly sessions of physical therapy and of occupational therapy, lasting 45 minutes each.~Experimental group: 8 weeks of conventional rehabilitation provided identically as in the control group, plus virtual reality semi-immersive sessions. VR sessions will be applied following a protocol using commercial video games, three days a week (Monday, Wednesday and Friday) after the conventional rehabilitation sessions."|f|f|t|f
33989223|NCT01281891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686220|NCT04914039|||CASE_ONLY||PROSPECTIVE|||||||
33686221|NCT00048841|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33686222|NCT00993044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686223|NCT02012673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686224|NCT05329571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989224|NCT04053296|||COHORT||PROSPECTIVE|||||||
33989225|NCT02069158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989226|NCT03422653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989227|NCT01566721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989228|NCT04904705|RANDOMIZED|PARALLEL||PREVENTION||NONE||In consequence of the statistical power analysis, the number of individuals to participate in the study was determined as 34 children diagnosed with organic acidemia, including 17 in the intervention group and 17 in the control group. The study will be conducted in a randomized controlled method. Children will be divided into intervention and control groups by using a computer-assisted online randomization application. Participants will be randomly numbered and randomly assigned to the intervention or control group without repeating the same number with the online randomization application available at randomizer.org. Both groups will be given a home program that will be prepared and sent to the person via e-mail. The Cognitive Orientation for Daily Occupational Performance (CO-OP) Approach to the intervention group will be applied by video conferencing method in a total of 10 sessions, 2 sessions per week, through 5 weeks, and a total of 12 sessions with initial and final evaluations.||||
33989229|NCT02305732|||COHORT||PROSPECTIVE|||||||
33989230|NCT03038009|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989231|NCT03024515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989232|NCT05244798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989233|NCT06216561|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded, randomized 2:1 to CRS-HIPEC + LSTA1 vs. CRS-HIPEC alone||||
33989234|NCT04262934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989235|NCT04215510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989236|NCT03306030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33989237|NCT05500703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33989238|NCT05934825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989239|NCT05157477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989240|NCT06223763|||COHORT||RETROSPECTIVE|||||||
33989241|NCT02821728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989242|NCT05801432|||COHORT||PROSPECTIVE|||||||
33989243|NCT02294604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33989244|NCT02662933|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989245|NCT00745056|||COHORT||PROSPECTIVE|||||||
33989246|NCT00727480|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989247|NCT03450057|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm: Daratumumab and Dexamethasone||||
34082513|NCT01548404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082514|NCT04957901|||COHORT||PROSPECTIVE|||||||
34082515|NCT04697797|||CASE_ONLY||PROSPECTIVE|||||||
34082516|NCT03030521|||COHORT||PROSPECTIVE|||||||
34082517|NCT03879031|||COHORT||PROSPECTIVE|||||||
34082518|NCT01677663|||FAMILY_BASED|||||||||
34082519|NCT00044291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082520|NCT02934971|||COHORT||PROSPECTIVE|||||||
34082521|NCT02755753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082522|NCT03054428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082523|NCT03794895|NA|SINGLE_GROUP||SCREENING||NONE||||||
33686225|NCT05045378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686226|NCT03277833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33775699|NCT04968028|RANDOMIZED|PARALLEL||TREATMENT||NONE|In view of the obvious differences between the two surgery methods, this study was designed as an open-label trial. However, the results of X-ray, computed tomography (CT) and magnetic resonance imaging (MRI) will be independently reviewed by an independent radiographic review committee in a blind fashion in addition to the evaluation by site investigators.|||||
33686227|NCT06110975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Primary care clinics are randomized to the deprescribing intervention or control group. The control group is not contacted and comparison relies on register data.||||
33775700|NCT00995358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989248|NCT02788240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989249|NCT05361330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989250|NCT01748591|||COHORT||PROSPECTIVE|||||||
33989251|NCT00749294|||COHORT||PROSPECTIVE|||||||
33686228|NCT04665193|NA|SINGLE_GROUP||SCREENING||NONE||||||
33989252|NCT02543489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989253|NCT01907919|||CASE_CONTROL||PROSPECTIVE|||||||
33989254|NCT06420869|||COHORT||CROSS_SECTIONAL|||||||
33775701|NCT04916262|||COHORT||PROSPECTIVE|||||||
33775702|NCT00931203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775703|NCT05851989|||COHORT||PROSPECTIVE|||||||
33775704|NCT02899598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775705|NCT02210910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775706|NCT05561504|||COHORT||PROSPECTIVE|||||||
33775707|NCT00585702|||COHORT||PROSPECTIVE|||||||
33775708|NCT03979911|||COHORT||RETROSPECTIVE|||||||
33775709|NCT04421378|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775710|NCT01451060|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33775711|NCT00743743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775712|NCT00530192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775713|NCT05924490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775714|NCT00219141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775715|NCT06268639|NA|SINGLE_GROUP||TREATMENT||NONE|The study employs an open-label design, where no masking is applied. This means that the participants, care providers, investigators, and outcomes assessors are all aware of the intervention being administered. Given the nature of the intervention-osseodensification technique used in dental implant surgery-it is not feasible to blind the study participants or the clinical staff involved in the procedure and assessment to the intervention being studied. The open-label approach allows for direct observation of the intervention's effects on bone density without the complexity of blinding, which is often the case in surgical and procedural interventions where the treatment administered is evident.|The study employs a single-group, interventional model to examine the impact of osseodensification on bone density at dental implant sites. It involves a sequential process starting from pre-operative bone density assessment using DentaScan CT, followed by surgical intervention using osseodensification drills, and concluding with a post-operative bone density evaluation to compare changes. This approach aims to determine if osseodensification can significantly enhance bone density and stability around implant sites, thereby potentially improving the success rates of dental implants. The methodology includes detailed pre-operative and post-operative assessments, with statistical analysis conducted to evaluate the effectiveness of the intervention.||||
33775716|NCT03391713|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33775717|NCT01327937|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33775718|NCT00232843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775719|NCT01007552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775720|NCT04118985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized to one of 1 arms: 1) provided recommendations and materials without coaching for implementation 2) provided recommendations and materials with 10 coaching classes|f|f|f|t
33775721|NCT05757895|||CASE_ONLY||CROSS_SECTIONAL|||||||
33775722|NCT04531072|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two arm study namely: ATVr arm and AL (Control) arm each consisting of 10 participants in a parallel study design||||
33775723|NCT04537338|||CASE_CONTROL||OTHER|||||||
33775724|NCT03133468|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33989255|NCT03347435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989256|NCT00462228|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33989257|NCT00836056|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989258|NCT01547377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989259|NCT00969943|||CASE_CONTROL||PROSPECTIVE|||||||
33989260|NCT00840099|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989261|NCT01209793|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33989262|NCT04512430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989263|NCT02493868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989264|NCT04209764|||OTHER||CROSS_SECTIONAL|||||||
33989265|NCT05053763|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989266|NCT03298880|NA|SEQUENTIAL||OTHER||NONE|Participants will not be able see manometer when using VAD Analysis of ECG traces will be blind to intervention as traces will be marked with a code, interventions carried out in random order and analysed in batches|Four repeated measures in each participant in random order||||
33989267|NCT02922777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082524|NCT00513929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686229|NCT04449029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the study treatment.|Participants with CHB will be divided into two different cohorts; participants on stable nucleos(t)ide treatment and participants not currently on nucleos(t)ide therapy. For each cohort, participants will be randomized into one of the 4 different parallel arms to receive treatment.|t|f|f|f
33989268|NCT03507491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989269|NCT00002764|RANDOMIZED|||TREATMENT||||||||
33989270|NCT06380023|||OTHER||PROSPECTIVE|||||||
34082525|NCT00381628|||CASE_CONTROL||PROSPECTIVE|||||||
34082526|NCT06166563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082527|NCT05295381|RANDOMIZED|PARALLEL||TREATMENT||NONE||AWT group (n=12), AWT+CM group (n=14) control group (n=14).||||
33775725|NCT03439696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775726|NCT02026973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33775727|NCT01339494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775728|NCT02487446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33775729|NCT04974879|NA|SINGLE_GROUP||TREATMENT||NONE||osimertinib oral and bevazizumab intravenously||||
33775730|NCT05557383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator and outcomes Assessor has no information for use peanut ball|A two-group controlled, randomized study, the intervention groups: use peanut ball, control groups: not use peanut ball|f|f|t|t
33775731|NCT01934699|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33775732|NCT01403389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33775733|NCT05187598|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessor does not know who is in the control group and who is in the intervention group.|parallel group randomized controlled study|f|f|f|t
33775734|NCT05162807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Between groups, randomized design. Participants are randomized to either intervention or control conditions.||||
33775735|NCT01599416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|same capsule appearance and bottle without any marks for identification to participants, care providers and investigators except serial numbers|"U-relax Group: U-relax capsules Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsule of oral U-relax everyday before sleep~Control Group: Placebo capsules Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep"|t|t|t|f
33775736|NCT05266196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775737|NCT05711238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33775738|NCT01581879|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775739|NCT03048110|NA|SINGLE_GROUP||OTHER||NONE||||||
33775740|NCT03472287|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33775741|NCT05835193|||COHORT||PROSPECTIVE|||||||
33775742|NCT00725010|||COHORT||PROSPECTIVE|||||||
33775743|NCT04996069|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open label study; thus no randomization plan is necessary.There will be no blinding for this study|"* Primary aim: To see a reduction in the self-reported subjective perception of dryness in the oral cavity.~* Secondary aims: To measure self-reported sensitivity of the teeth, self-reported perception of teeth whiteness, and objective measurement of improvement of saliva production."||||
33775744|NCT01691443|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33775745|NCT05767047|NA|PARALLEL||TREATMENT||NONE||||||
33775746|NCT01648179|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775747|NCT01042405|||CASE_ONLY||PROSPECTIVE|||||||
33775748|NCT06423586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775749|NCT06188182|||OTHER||PROSPECTIVE|||||||
33775750|NCT04745858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775751|NCT02832765|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33775752|NCT00925028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775753|NCT00002708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775754|NCT02438462|||COHORT||PROSPECTIVE|||||||
33775755|NCT00918749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775756|NCT00301002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775757|NCT00003928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775758|NCT01919463|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775759|NCT03029780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775760|NCT03772743|RANDOMIZED|PARALLEL||TREATMENT||NONE||All comers, prospective, randomized, multicenter, open-label trial with blinded adjudicated evaluation of outcomes (PROBE).||||
33775761|NCT00804869|||COHORT||RETROSPECTIVE|||||||
33775762|NCT01621282|NON_RANDOMIZED|PARALLEL||||NONE||||||
33775763|NCT03506217|||OTHER||RETROSPECTIVE|||||||
33775764|NCT04814485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775765|NCT00351221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907112|NCT04495361|NA|SINGLE_GROUP||OTHER||NONE||"Students will be exposed to an online learning portal in which they will undergo planned electronic encounters with under five patients having pneumonia. For each case, students will have to identify the category of pneumonia and the appropriate treatment/ management in a timed session.~Upon clicking on the available case, the participant will be shown a typical case of either no pneumonia, pneumonia or severe pneumonia. The video will run for around thirty seconds to one minute during and after which the students will try to identify the case and select its category from the drop down menu of diagnosis. There will be tabs for history, examination, diagnosis and management. The student will select the best suited response from a range of options. Based on the selection of the response and the time taken to do so, a score will be generated. The student can take two attempts for each case. Students will be required to a login for 6 months whereby 3 cases will be assigned per month."||||
33907113|NCT06684431|NA|SINGLE_GROUP||PREVENTION||NONE||Dose-escalation: first low-dose group (n=5), then mid-dose group (n=5), last high-dose group (n=5)||||
33907114|NCT03471754|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, Open Label, single center trial||||
33907115|NCT02086565|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33775766|NCT03208400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775767|NCT06451744|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33775768|NCT04326985|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Controlled Trial||||
33907116|NCT00985855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082528|NCT05026502|||COHORT||PROSPECTIVE|||||||
34082529|NCT00572689|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33775769|NCT02786043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775770|NCT06196645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775771|NCT02262611|||COHORT||PROSPECTIVE|||||||
33775772|NCT05449574|||COHORT||RETROSPECTIVE|||||||
33775773|NCT00938119|||CASE_CONTROL||PROSPECTIVE|||||||
33775774|NCT03020095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775775|NCT01517841|||COHORT||PROSPECTIVE|||||||
33775776|NCT03290989|||CASE_ONLY||PROSPECTIVE|||||||
33775777|NCT04130906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33775778|NCT00955903|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33686230|NCT02601807|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33686231|NCT04531631|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33686232|NCT06247397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686233|NCT02254239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686234|NCT05517460|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33686235|NCT05415709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686236|NCT02970370|||COHORT|||||||||
33686237|NCT05655806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|drugs will be prepared by another person who is not giving drugs or collecting data||t|t|f|f
33989271|NCT00378547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989272|NCT01859858|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989273|NCT06111170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There was one blinded observer evaluating the results using pre and postoperative photographs.|two arms. After randomization one eyelid of each patient was applied with a compression dressing, the other eyelid not.|f|f|t|f
33989274|NCT03899077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989275|NCT04932863|||COHORT||PROSPECTIVE|||||||
33989276|NCT05362786|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33989277|NCT06422845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989278|NCT05522361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989279|NCT02603003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989280|NCT03769025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989281|NCT05755763|||CASE_CONTROL||PROSPECTIVE|||||||
33989282|NCT04388566|||COHORT||PROSPECTIVE|||||||
33989283|NCT05349695|||COHORT||PROSPECTIVE|||||||
33989284|NCT02334644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686238|NCT05268211|||COHORT||PROSPECTIVE|||||||
33686239|NCT05167110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|ABBiotics has been the producer of probiotics and who knows the masking||t|f|t|f
33686240|NCT02484625|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized crossover||||
33686241|NCT03190356|||CASE_ONLY||PROSPECTIVE|||||||
33686242|NCT00422318|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33686243|NCT02518503|||COHORT||RETROSPECTIVE|||||||
33686244|NCT00924781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686245|NCT02454231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686246|NCT04472754|||COHORT||PROSPECTIVE|||||||
33686247|NCT00868517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33686248|NCT05125185|RANDOMIZED|PARALLEL||OTHER||NONE||comparing effect of counseling to insulin adherence, FBS, HbA1c, HsCRP and VCAM-1||||
33686249|NCT00000527|RANDOMIZED|||PREVENTION||DOUBLE||||||
33686250|NCT02820714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686251|NCT04841200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686252|NCT01432210|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33686253|NCT04666077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All treatment arms will be conducted at the Louis Armstrong Center for Music and Medicine with staff at that location while screening and all outcome evaluations will be conducted at the Alzheimer's Disease Research Center at the Mount Sinai location. A single unblinded team member at each site will coordinate visits and data collection.|This is a randomized, controlled 6 months (24 week) trial to assess the benefits of Homebased MT through Supervised, Supported Singing (H3S) vs control condition receiving attention (AtCon) in persons with ADRD or its prodrome (MCI). A randomized sub group will receive both the H3S and Individualized Music therapy (IMT) during for the same interval. Randomization to H3S, IMT, AtCon will be 2 to 1 to 2, with stratification of disease severity to insure equal representation across arms.|t|t|t|f
33686254|NCT01066676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686255|NCT01902771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686256|NCT02282345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686257|NCT01191879|||CASE_CONTROL||PROSPECTIVE|||||||
33686258|NCT04388371|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Test subjects with spontaneous or tuberous sclerosis complex associated lymphangioleiomyomatosis (LAM) who have not been started on therapy with mTOR inhibitors such as sirolimus or everolimus to undergo a PET/CT scan using an novel PET tracer that may better evaluate disease activity in LAM subjects both before and after the initiation of mTOR inhibitor therapy.||||
33686259|NCT02699788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686260|NCT06100328|||COHORT||OTHER|||||||
33989285|NCT01794715|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33989286|NCT06558656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989287|NCT05801484|RANDOMIZED|PARALLEL||TREATMENT||NONE||open, prospective, randomized design, with two groups of patients (group with intermittent administration and group with continuous administration of the same daily dose of linezolid).||||
33989288|NCT03144453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989289|NCT02471820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989290|NCT05675033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775779|NCT06442813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"EXPERIMENTAL GROUP First Stage: Determining the groups by randomization method and filling out the data collection forms for the groups (pre-test).~Second Stage: Training pregnant women in the control group on the management of standard hyperemesis gravidarum (training content will be prepared and opinions will be obtained from 3 experts in the field).~For the intervention group, pregnant women were given a session with EFT (Average: 40-60 minutes) and a program was created for the pregnant woman to do affirmations in between depending on her condition (Positiveness with EFT strokes 3 times a day).~Third Stage: After 15 days, it is planned to conduct post-tests for both groups and"|t|f|f|f
33775780|NCT00778063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775781|NCT04602494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eligible participants will be randomly assigned in a 1:1:1 ratio, in blocks of 6, to double-blind varenicline, identical placebo prepared by the MGH research pharmacy or monitoring (i.e., assessment only). Randomization will be computer generated by the MGH Research Pharmacy personnel with no other interactions with study staff or participants. The full randomization code (drug, placebo, monitoring) will be held in the MGH research pharmacy and available to study PI only in the case of urgent medical need. A partial randomization code (treatment vs monitoring) will be held by the interventionist at the Center for Addiction Medicine. Participants, investigators and outcome assessor will remain fully blind to all 3 arms.|This a 3-arm, randomized, placebo-controlled, parallel-group design of (1) varenicline up to 1 mg bid for 12 weeks added to behavioral and texting support vaping cessation compared or (2) behavioral and texting support and placebo or (3) monitoring only.|t|f|t|t
33775782|NCT03654053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, placebo-controlled||t|t|t|f
33775783|NCT02544737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775784|NCT01984710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775785|NCT01844193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33775786|NCT00900627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775787|NCT04141579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|Two arms. One treatment arm. One arm with placebo.|t|t|t|f
33775788|NCT04707391|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907117|NCT02535949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907118|NCT03851380|||CASE_ONLY||CROSS_SECTIONAL|||||||
33907119|NCT05784909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907120|NCT02219555|||COHORT||PROSPECTIVE|||||||
33907121|NCT04604249|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33907122|NCT01002625|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33907123|NCT02244450|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33907124|NCT02379741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907125|NCT05622500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessor-blinded (single blind)|Superiority comparison using intention to treat analysis|f|f|t|t
33907126|NCT04297384|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907127|NCT03165357|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33907128|NCT05085158|||COHORT||CROSS_SECTIONAL|||||||
33907129|NCT05831059|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33989291|NCT05229133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686261|NCT01906879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686262|NCT03230201|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33686263|NCT01618812|||COHORT||PROSPECTIVE|||||||
33686264|NCT00388427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686265|NCT00677430|||CASE_ONLY||PROSPECTIVE|||||||
33686266|NCT06329115|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be included in an 8-week regular exercise program. Evaluations will be made before and after exercise.||||
33686267|NCT03110939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082530|NCT02667652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082531|NCT03055871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34082532|NCT02524119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082533|NCT04665908|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the design of the study, it is not possible to blind either caregivers or participants regarding group distribution|||||
34082534|NCT00514085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082535|NCT05524142|||CASE_CONTROL||PROSPECTIVE|||||||
34082536|NCT05500586|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All subjects will undergo one study designed to measure the hepatic response to glucagon. There will be 3 groups non-diabetic and non-obese, obese, people with type 2 diabetes||||
33686268|NCT01767831|||CASE_CROSSOVER||PROSPECTIVE|||||||
33686269|NCT06305871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686270|NCT04996472|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be told which condition they are participating in. Investigators will know because of familiarity with the stimuli.|"Adults will complete case history, language history, and hearing screening. Participants will be randomly assigned to a condition, reflecting each of the 3 phonological patterns (Single Feature, OR, Family Resemblance). Randomization will occur within groups and will be generated a priori.~Adults will participate in an experimental session, which includes exposure to the rule followed by a generalization test. A sub-group will participate in the Referential Study.~Parents of the toddlers will fill out the expressive language MacArthur-Bates Communicative Development Inventory and also a case history. Toddlers will be assigned randomly to one of four conditions: OR condition with a referent; OR condition without a referent; Family Resemblance condition with a referent; Family Resemblance condition without a referent."|t|f|f|f
33686271|NCT02478398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686272|NCT03872011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686273|NCT06454266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686274|NCT00569751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686275|NCT01467245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686276|NCT01275547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686277|NCT02195687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686278|NCT00224627|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686279|NCT00590837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686280|NCT04319822|NA|SINGLE_GROUP||OTHER||NONE||||||
33686281|NCT01967368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686282|NCT00184873|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33686283|NCT02121132|||COHORT||PROSPECTIVE|||||||
33686284|NCT00531687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686285|NCT05820737|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, parallel group, placebo controlled trial|t|t|t|f
33686286|NCT04173793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686287|NCT00721903|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686288|NCT01095094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686289|NCT04260243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33686290|NCT03444077|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33686291|NCT04322201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686292|NCT00800462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686293|NCT01680445|||||CROSS_SECTIONAL|||||||
33686294|NCT05729802|RANDOMIZED|PARALLEL||OTHER||NONE||It is a two stage study that will: 1) iteratively develop and usability test the HoloSIM software with acute care medicine specialties at Sunnybrook, and 2) determine if the HoloSIM platform is non-inferior to the current teaching and assessment standard of high-fidelity mannequin-based crisis simulation.||||
33686295|NCT02550769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686296|NCT05081102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686297|NCT00768469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686298|NCT02566408|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33686299|NCT02718300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775789|NCT06058871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33775790|NCT00007930||||TREATMENT||||||||
33686300|NCT03989726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686301|NCT04529187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686302|NCT00353028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686303|NCT01640093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775791|NCT00399425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082537|NCT02217956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082538|NCT05925192|||COHORT||CROSS_SECTIONAL|||||||
34082539|NCT00469131|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082540|NCT00427934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082541|NCT00178737|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
34082542|NCT00217490|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34082543|NCT05004090|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082544|NCT05496023|||CASE_CONTROL||RETROSPECTIVE|||||||
34082545|NCT05470452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082546|NCT01236924||||TREATMENT||||||||
34082547|NCT01311219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082548|NCT00963534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082549|NCT04236843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082550|NCT06542367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082551|NCT04224246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082552|NCT01350635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082553|NCT05465395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33686304|NCT00769483|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686305|NCT02065362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686306|NCT06206343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|45|Posttest and control grouped randomized controlled clinical trial.|t|f|f|t
33686307|NCT05447741|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33686308|NCT03149627|||COHORT||PROSPECTIVE|||||||
33686309|NCT03603509|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Eligible subjects who consent and enroll will be randomly assigned to receive either the Fluad Vaccine or Fluzone High-Dose vaccine.||||
33686310|NCT01499862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686311|NCT02577471|||CASE_CONTROL||PROSPECTIVE|||||||
33686312|NCT02648789|||COHORT||PROSPECTIVE|||||||
33686313|NCT00505388|||CASE_ONLY||PROSPECTIVE|||||||
34082554|NCT01031641|||CASE_ONLY||PROSPECTIVE|||||||
33686314|NCT00965328|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33686315|NCT01501084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33686316|NCT00003567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686317|NCT02477137|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33686318|NCT05934188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34082555|NCT04390165|||CASE_ONLY||CROSS_SECTIONAL|||||||
33907130|NCT03970226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 0 to open first and if outcomes are favorable showing drug penetration then the Feasibility Phase will open. Both arms will be open concurrently.||||
34082556|NCT03054142|||CASE_CONTROL||RETROSPECTIVE|||||||
33907131|NCT04793672|||CASE_CONTROL||PROSPECTIVE|||||||
33686319|NCT02103543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686320|NCT01764802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686321|NCT05549427|||COHORT||RETROSPECTIVE|||||||
33686322|NCT02153476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907132|NCT05649514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907133|NCT06693284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907134|NCT01984346|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomized (Convergent Procedure versus standalone endocardial catheter ablation) multi-center pivotal clinical study||||
33907135|NCT04250168|||COHORT||PROSPECTIVE|||||||
33907136|NCT01830153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907137|NCT00804193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907138|NCT04413240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A clinical study with medical device, multicenter, single-blind, randomized controlled trial.|f|f|f|t
33907139|NCT04241042|||CASE_CONTROL||PROSPECTIVE|||||||
33907140|NCT04117685|||COHORT||PROSPECTIVE|||||||
33907141|NCT00661752|||CASE_CONTROL||RETROSPECTIVE|||||||
33907142|NCT04527224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907143|NCT03987412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907144|NCT04430972|||COHORT||PROSPECTIVE|||||||
33907145|NCT00222729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907146|NCT02273154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907147|NCT03993691|NA|SINGLE_GROUP||OTHER||NONE||||||
33907148|NCT01963117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907149|NCT06179654|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-cohort study. Group A will start pelvic floor exercises before surgery and Group B will start exercises after surgery.||||
33907150|NCT01823822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907151|NCT04757935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907152|NCT04424433|RANDOMIZED|CROSSOVER||OTHER||SINGLE|TEE images will be coded and analysed in batches at a later date by a blinded reader||f|f|f|t
33907153|NCT01515176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907154|NCT04756635|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33907155|NCT00532948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907156|NCT01261728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907157|NCT06693128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907158|NCT00136747|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33907159|NCT03433846|||COHORT||PROSPECTIVE|||||||
33907160|NCT01104818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907161|NCT02692820|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907162|NCT02533648|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33907163|NCT06329141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907164|NCT03309332|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907165|NCT02518620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907166|NCT04286191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989292|NCT02729714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33989293|NCT03749252|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33989294|NCT01434147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989295|NCT03545828|||COHORT||PROSPECTIVE|||||||
33989296|NCT02417298|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33989297|NCT02596100|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989298|NCT01196000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989299|NCT02658318|||CASE_CONTROL||RETROSPECTIVE|||||||
33775792|NCT00069719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907167|NCT05336968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All staff working with the study subjects will be blinded. Once the subject signs consent, an unblinded study doctor will, using a special method, draw up the appropriate medication and blind the syringe so the the staff giving the medication will not know what is being given.|Subjects will receive either ketorolac 30 mg, triamcinolone 40 mg, or a combination of the two medications as a one-time injection into one or both affected knee joint/s.|t|t|t|t
33907168|NCT01084798|||COHORT||RETROSPECTIVE|||||||
33907169|NCT00002410||||TREATMENT||||||||
33907170|NCT05614739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907171|NCT00695084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907172|NCT05590195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither participants nor study team will know which product the participants have been assigned. Unblinding can be requested from the pharmacy if necessary.|Double-blinded, randomized, placebo controlled study|t|f|t|f
33907173|NCT06265532|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|All participants will be on one of the standard of care drugs (nintedanib or pirfenidone) and blindly given EGCG or placebo.|"This is an optional substudy to the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect. Up to twenty-two participants participating in the aforementioned study will be enrolled into this sub-study. This substudy will be conducted at a select number of sites with capabilities for performing \[68Ga\]CBP8 PET."|t|t|t|t
33907174|NCT00840645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907175|NCT03868228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907176|NCT01468727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775793|NCT03757169|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two randomized groups.||||
33775794|NCT05280470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775795|NCT00824174|||COHORT||RETROSPECTIVE|||||||
33775796|NCT02911337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775797|NCT00763932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775798|NCT01190033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775799|NCT06261944|NA|SINGLE_GROUP||SCREENING||NONE||Mass-screening||||
33775800|NCT01443429|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33775801|NCT04814017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33775802|NCT01591161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775803|NCT04276818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907177|NCT06577870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open-label study|Multicenter, interventional, prospective, randomized, controlled study||||
33686323|NCT06046157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33907178|NCT05067790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686324|NCT01357473|||COHORT||PROSPECTIVE|||||||
33686325|NCT02022176|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33686326|NCT02800876|||COHORT||RETROSPECTIVE|||||||
33686327|NCT00328978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686328|NCT05650554|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a parallel-group prevention study with up to 6 arms that will be blinded to participants, investigators / sub-investigators, outcomes assessors, and laboratory personnel (with the exception of the sentinel safety portion of the study, which will be open-label). The Sponsor study staff will be unblinded (except laboratory testing personnel).|"Sentinel Cohort: Open label~Main Cohort:~* Open label (Sponsor, except laboratory testing personnel)~* Blinded (Sites, except for those preparing/administering study intervention)"|t|f|t|t
33686329|NCT02162576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686330|NCT04501562|||COHORT||PROSPECTIVE|||||||
33686331|NCT01931176|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686332|NCT06043284|||OTHER||RETROSPECTIVE|||||||
33686333|NCT05479669|||COHORT||PROSPECTIVE|||||||
33686334|NCT04401527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686335|NCT03920072|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, international, multicenter||||
33686336|NCT01985854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686337|NCT05089071|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The primary outcome was the comparison of ADR between the control and AI groups according to the intervention system (SCAI vs ENAD system).|f|f|f|t
33686338|NCT00546221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686339|NCT03794960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686340|NCT03838783|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomization for the sequence of Interventions (A and B) will be done by an interactive system that will randomly assign patients to an intervention sequence.||||
33686341|NCT02296879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686342|NCT04946227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686343|NCT02218632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686344|NCT04010539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686345|NCT03657966|NA|SINGLE_GROUP||TREATMENT||NONE||open-label DCVAC/OvCa after treatment with carboplatin in combination with either gemcitabine or paclitaxel||||
33686346|NCT03857373|||COHORT||PROSPECTIVE|||||||
33686347|NCT05058495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients were blinded and the person responsible for the data analysis will be masked as to the patient grouping for analysis.|a prospective, randomized controlled study|t|f|f|t
33686348|NCT00137839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686349|NCT00197067|RANDOMIZED|PARALLEL||OTHER||||||||
33686350|NCT03841305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686351|NCT02859818|NA|SINGLE_GROUP||||NONE||||||
33686352|NCT04390555|||COHORT||OTHER|||||||
33686353|NCT01802970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686354|NCT06514651|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33686355|NCT00652691||||TREATMENT||||||||
33686356|NCT02981459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686357|NCT01432509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686358|NCT05969171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686359|NCT00025805||||TREATMENT||||||||
33686360|NCT02874768|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33907179|NCT03471091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907180|NCT04610242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907181|NCT04366986|||COHORT||PROSPECTIVE|||||||
33907182|NCT06653023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907183|NCT02464787|NA|SINGLE_GROUP||OTHER||NONE||||||
33686361|NCT00735059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686362|NCT06404346|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686363|NCT00749554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33686364|NCT03490318|||COHORT||PROSPECTIVE|||||||
33686365|NCT02145702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686366|NCT02259075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686367|NCT06290245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33686368|NCT01964456|NON_RANDOMIZED|PARALLEL||||NONE||||||
33686369|NCT04551339|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686370|NCT04879979|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33686371|NCT03203343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686372|NCT02954042|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33686373|NCT02270437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686374|NCT00155870|||DEFINED_POPULATION||PROSPECTIVE|||||||
33686375|NCT02098226|||||PROSPECTIVE|||||||
33907184|NCT00830453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907185|NCT06517186|||COHORT||PROSPECTIVE|||||||
34082557|NCT03175796|RANDOMIZED|PARALLEL||TREATMENT||NONE||"IMH-HV is a relationship-focused mental health intervention that aims to improve caregiver and child outcomes, including: improved caregiver mental health; enhanced positive parenting; decreased risk for physical/emotional neglect and/or abuse; and reduced risk for negative child outcomes including impaired development, cognitive delay and behavioral problems. In addition, IMH-HV services aim to reduce the probability of intergenerational transmission of the effects of unresolved loss and trauma in parents.~The IMH-HV Model uses a range of strategies for intervention, such as:~* attending to the health and basic material needs of the infant/toddler, parent(s), and family members;~* providing developmental guidance for positive parenting behavior;~* providing counseling/emotional support for the parents;~* developing parents' life coping skills and social support; and~* providing infant/parent psychotherapy."||||
34082558|NCT06307353|||OTHER||RETROSPECTIVE|||||||
34082559|NCT06332222|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34082560|NCT00746369|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34082561|NCT05553405|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34082562|NCT05671081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082563|NCT03642990|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects with stage IV breast cancer, platinum-resistant recurrent ovarian, peritoneal, endometrial, or fallopian tube cancer, or platinum-resistant recurrent or metastatic head and neck cancer will receive 300 mg NIAGEN®) daily for one week followed by dose escalation to 1000 mg daily for 11 weeks upon reporting the development of grade 1 sensory neuropathy. Those presenting with a residual sensory neuropathy of ≤ 2 as a result of prior chemotherapy will also be enrolled.||||
34082564|NCT01670370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082565|NCT05810402|NA|SINGLE_GROUP||OTHER||NONE||Homogenous cohort of BCLC Stage B and C hepatocellular carcinoma patients that will undergo immunotherapy +/- anti-angiogenic agent (bevacizumab)||||
34082566|NCT05571111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34082567|NCT05717998|||COHORT||PROSPECTIVE|||||||
34082568|NCT00621790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082569|NCT05247762|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082570|NCT02552927|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34082571|NCT05890079|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34082572|NCT04510272|NA|SINGLE_GROUP||OTHER||NONE||||||
34082573|NCT04539977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy in treating limited-stage small-cell lung cancer||||
34082574|NCT02392780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082575|NCT04579809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective cohort study|f|f|f|t
34082576|NCT01403662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082577|NCT05989529|||CASE_CROSSOVER||PROSPECTIVE|||||||
33775804|NCT01773538|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33775805|NCT04381702|||COHORT||RETROSPECTIVE|||||||
33775806|NCT00598481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775807|NCT04932720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Children who were treated at Mersin University Medical Faculty Hospital were determined by the simple random selection method and formed the experimental and control groups."||||
33775808|NCT03123263|||OTHER||RETROSPECTIVE|||||||
33775809|NCT01093300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082578|NCT00623532|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34082579|NCT04997304|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34082580|NCT05926609|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||Single-blind, placebo - controlled trial|t|f|f|f
34082581|NCT02948816|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33775810|NCT02206152|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33775811|NCT01323803|||CASE_ONLY||CROSS_SECTIONAL|||||||
33686376|NCT02901756|||CASE_ONLY||PROSPECTIVE|||||||
33686377|NCT02088515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775812|NCT03962452|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33775813|NCT00003639|RANDOMIZED|||TREATMENT||||||||
33775814|NCT04033211|||COHORT||PROSPECTIVE|||||||
33775815|NCT01490515|RANDOMIZED|PARALLEL||||NONE||||||
33775816|NCT00747773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775817|NCT05552729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775818|NCT05445596|NA|SINGLE_GROUP||TREATMENT||NONE||The study uses single-case experimental design to identify functional relations between independent and dependent variables.||||
33775819|NCT05064124|||COHORT||PROSPECTIVE|||||||
33775820|NCT06250166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775821|NCT06463457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775822|NCT01138319|||CASE_ONLY||RETROSPECTIVE|||||||
33775823|NCT05531903|NA|SINGLE_GROUP||TREATMENT||NONE||Single group of intervention. A control group with absence of dual AVN phisiology to check lack of abnormal fragmented/slow conduction confluent zones.||||
33775824|NCT05771194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775825|NCT00322374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775826|NCT03259971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized double blind placebo-controlled||t|t|t|t
33775827|NCT05474443|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 participants were recruited in study and divided into two groups. Group A was given intervention with Instrument Assisted Soft Tissue Mobilization and Group B with Myofascial gun||||
33775828|NCT01924403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775829|NCT02451904|||CASE_CONTROL||PROSPECTIVE|||||||
33775830|NCT04537949|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33775831|NCT00280423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33775832|NCT01615861|NA|SINGLE_GROUP||OTHER||NONE||||||
33775833|NCT03069794|NA|SINGLE_GROUP||OTHER||NONE||||||
33775834|NCT06328920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775835|NCT04899505|||COHORT||PROSPECTIVE|||||||
33775836|NCT00890643|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||||||
33775837|NCT00792428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33775838|NCT03268590|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will undergo neuroimaging (MRI) with electroencephalographic (EEG) cortical network mapping and cognitive assessments during room air breathing (placebo). Room air (21% inspired oxygen) will be delivered via non-rebreather face mask. Persons will serve as their own control and will next undergo neuroimaging (MRI) with electroencephalographic (EEG) cortical network mapping and cognitive assessments during pure oxygen breathing. Pure oxygen (100% inspired oxygen) will be delivered via non-rebreather face mask||||
33775839|NCT04071470|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will be comparing standard of care PrEP services with a storytelling intervention arm||||
33775840|NCT03732703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Eight Arms with 38 patients per arm||||
33775841|NCT00399282|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33775842|NCT03467581|||COHORT||PROSPECTIVE|||||||
33775843|NCT03682822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686378|NCT03095768|NA|SINGLE_GROUP||OTHER||NONE||||||
33686379|NCT01423604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686380|NCT01915628|||CASE_CONTROL||PROSPECTIVE|||||||
33775844|NCT01632332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775845|NCT00561873|||CASE_ONLY||PROSPECTIVE|||||||
33775846|NCT06062823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775847|NCT04054895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be explained to be randomized to either of the two branches. The type of therapy applied will not be communicated to the patient. The follow-up will be the same in the two branches. During the visits it will not be said which therapy has been applied.|Randomized, unicentric, simple blind.|t|f|f|f
33775848|NCT06615141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775849|NCT01950260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775850|NCT02936154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33775851|NCT01620359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686381|NCT03480633|||COHORT||PROSPECTIVE|||||||
33686382|NCT01634178|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686383|NCT04516837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686384|NCT04924803|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33686385|NCT03778775|||COHORT||PROSPECTIVE|||||||
33775852|NCT01560377|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33775853|NCT04641624|||CASE_CONTROL||PROSPECTIVE|||||||
33775854|NCT02718352|||CASE_ONLY||PROSPECTIVE|||||||
33775855|NCT02696226|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33775856|NCT00114153||||TREATMENT||||||||
33775857|NCT04079374|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33775858|NCT05232149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775859|NCT01828307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775860|NCT00892268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775861|NCT01670227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775862|NCT04112264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33775863|NCT03057158|||OTHER||PROSPECTIVE|||||||
33775864|NCT01668433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775865|NCT04974125|RANDOMIZED|PARALLEL||OTHER||SINGLE||Patient will be pre-selected before medical operation. During the surgery, if the surgeon performs only the laparoscopy, the patient will be randomized. Then, the allocated procedure (with or without drain) will be carried out.|t|f|f|f
33775866|NCT05471193|||COHORT||RETROSPECTIVE|||||||
33775867|NCT01555021|||COHORT||PROSPECTIVE|||||||
33775868|NCT06234137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775869|NCT02107443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33775870|NCT04622644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775871|NCT01460680|||CASE_CONTROL||PROSPECTIVE|||||||
33775872|NCT03213015||SEQUENTIAL||DIAGNOSTIC||NONE||||||
33775873|NCT06031324|||CASE_CONTROL||PROSPECTIVE|||||||
33775874|NCT03447379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907186|NCT03762525|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE|The choice for the device is not part of this study and will be made by the doctor in consultation with the patient and the patients anatomy.|"This study is designed as a multicenter prospective case series.~1. To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component.~2. Tocompare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device."||||
33907187|NCT00426985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907188|NCT01959386|||COHORT||PROSPECTIVE|||||||
33907189|NCT03587038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907190|NCT03080220|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33907191|NCT01143350|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33907192|NCT04841135|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082582|NCT03120611|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33907193|NCT03801304|NA|SINGLE_GROUP||TREATMENT||NONE||"* Atezolizumab will be administered of 1200 mg on day 1 of each 21-day cycle with IV infusions .~* Vinorelbine at the dose of 40 mg per days will be administered on days 1, 3 and 5 of each week of the 21-day cycle."||||
33907194|NCT05995717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989300|NCT03701191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two outcome assessors will be chosen: one will be a periodontist but not included within the research; and the other will be a non-periodontist. The outcome assessors will be blinded; they will not be informed by the type of intervention to be assessed.|"Included participants will be:~1. Gender: Male and Female~2. Age: \>20 years~3. Have RT1 and RT2 gingival recession~Exclusion criteria:~1. Medically compromised~2. History of certain medications~3. Pregnant females~4. Periapical involvement in selected teeth~5. History of periodontal surgery involving experimental teeth~6. If the problem was due to orthodontic treatment"|f|f|f|t
33989301|NCT05836545|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33989302|NCT00033917|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34082583|NCT04975425|||OTHER||PROSPECTIVE|||||||
33989303|NCT00573066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907195|NCT00692900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907196|NCT03914820|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase III randomized, multicenter study with two different arm:~* experimental: prophylactic surgery plus HIPEC CO2 performed with mitomycin~* comparator: standard surgery"||||
33907197|NCT03468192|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomized study of 394 patients operated with direct anterolateral approach.||||
33989304|NCT06366061|||COHORT||PROSPECTIVE|||||||
33989305|NCT03933852|||CASE_ONLY||RETROSPECTIVE|||||||
33989306|NCT00003630||||TREATMENT||||||||
34082584|NCT03620799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082585|NCT05785962|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects in each group will be matched by age and sex.|f|f|t|t
34082586|NCT04713072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082587|NCT01294423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082588|NCT01575132|||CASE_ONLY||RETROSPECTIVE|||||||
33686386|NCT04703101|NA|SINGLE_GROUP||TREATMENT||NONE|Analysts blinded to patient outcome and sample order|||||
33686387|NCT06127537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907198|NCT01234402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907199|NCT05861258|NA|SINGLE_GROUP||TREATMENT||NONE||A single group, two-period, fixed-order pharmacokinetic study||||
33907200|NCT00780468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907201|NCT05157672|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33907202|NCT02858193|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907203|NCT04014153|||COHORT||PROSPECTIVE|||||||
33907204|NCT04662710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907205|NCT01643915|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33907206|NCT00307593|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33989307|NCT06464120|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|Participant, Investigator, Outcomes Assessor|The experimental group was randomly assigned to receive strength training with increasing loads for post-activation enhancement intervention, while the control group received strength training with constant loads.||||
34082589|NCT06054386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082590|NCT03194477|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Care providers and investigators will not know which patients are randomized to intervention or control.|Mobile-enhanced engagement interventions (MEI) to support 1) HIV viral suppression among HIV-positive, not virally suppressed participants; 2) HIV-PrEP uptake among high-risk HIV-negative participants; and 3) engagement in substance abuse treatment for HIV-positive and HIV-negative participants.|f|t|f|f
34082591|NCT00049244||||TREATMENT||||||||
34082592|NCT01603680|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34082593|NCT00176735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082594|NCT05509361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082595|NCT04761003|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||"A full medical history was obtained. Medical history, clinical examination and local chest examination for signs of pleural effusion, Radiological data include chest X-ray, chest computed tomography (CT), and chest ultrasound (US) for localization of a better entry site.~Thoracoscopy procedure the procedure was performed in the lateral decubitus position with the affected side upward under conscious sedation. Local anesthesia consisting of 2% lignocaine was administered to the skin, subcutaneous tissue, muscle, and parietal pleura.~The appearance of the parietal and visceral pleural was assessed and recorded. Pleural biopsies were obtained using rigid forceps and cryoprobe during rigid medical thoracoscopy Complications during thoracoscopy were recorded as bleeding and surgical emphysema.~Samples were directly fixed in 10% formalin solution Biopsies obtained were examined pathologically with stress on size and quality of the sample."|t|t|f|f
34082596|NCT04361058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082597|NCT03526042|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open randomized clinical trial with parallel group comparing AT1R-ab blockade with losartan and enalapril as a control group.||||
34082598|NCT06041204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082599|NCT04480528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082600|NCT05951634|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, multicentre, single-arm study to investigate the safety and efficacy of the PerQseal Elite.||||
34082601|NCT02271321|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34082602|NCT01494207|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34082603|NCT02536911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082604|NCT01694524|||COHORT||RETROSPECTIVE|||||||
33907207|NCT06658873|||COHORT||PROSPECTIVE|||||||
33907208|NCT03912922|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33907209|NCT04615689|||CASE_CONTROL||PROSPECTIVE|||||||
33907210|NCT01710228|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33907211|NCT01902420|||COHORT||CROSS_SECTIONAL|||||||
34082605|NCT01873014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082606|NCT03451370|||COHORT||PROSPECTIVE|||||||
34082607|NCT01700491|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34082608|NCT02595658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082609|NCT03217292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, controlled, single-blind|f|f|f|t
34082610|NCT05398107|RANDOMIZED|PARALLEL||TREATMENT||NONE||This pilot Randomized Controlled Trial will involve two arms. Participants randomized to the BEAM program or the standard of care, MoodMission. The experimental arm will include 40 mothers in the BEAM program while the standard of care will include 40 mothers. Randomization will be stratified based on the telehealth group timeslots mothers are available for.||||
34082611|NCT04523012|||COHORT||RETROSPECTIVE|||||||
34082612|NCT04486664|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34082613|NCT06201312|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34082614|NCT03955172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082615|NCT04078620|||COHORT||RETROSPECTIVE|||||||
34082616|NCT05301439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical and radiographic evaluations of the complete removal of the carious lesion will be performed by two calibrated examiners blinded to the allocation of teeth to the different groups. Also, calibrated examiners, who will not be performing the restorations and therefore will be blind to the groups, will perform the assessment.||f|f|f|t
34082617|NCT00373503|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33907212|NCT06035432|||OTHER||CROSS_SECTIONAL|||||||
33907213|NCT05300867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33907214|NCT06278987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized prospective controlled trial. This will be single blinded trial. Randomization will be 1:1||||
33907215|NCT02487628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907216|NCT05331612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907217|NCT01427569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907218|NCT03536429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907219|NCT01752842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907220|NCT01990599|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33907221|NCT05326750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907222|NCT01386099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907223|NCT06693388|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33907224|NCT02017678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907225|NCT05387395|||COHORT||PROSPECTIVE|||||||
33907226|NCT00005655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907227|NCT06250283|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33907228|NCT04748276|||CASE_ONLY||PROSPECTIVE|||||||
33907229|NCT05511246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33686388|NCT04386915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775875|NCT02543723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants were randomized into the control or intervention group.|We conducted a randomized control trial study of 150 subjects where subjects were randomly assigned to control or intervention arm. The Information-Motivation-Behavioral Skills Model of Adherence and the results of objective 1 guided this aim. Controls received the standard-of-care . The intervention arm received the standard-of-care and the nurse coach intervention. Specifically, we assessed whether a tailored nurse coaching intervention component will significantly improve medication adherence at higher rates as compared to the control group. The nurse coach intervention component involved individualized barriers/facilitators screening tool, educational tools, and regular contact with cancer patients via telephone calls across a six-month period.|t|f|f|f
33775876|NCT02668406|||CASE_CONTROL||PROSPECTIVE|||||||
33775877|NCT02091258|||CASE_ONLY||PROSPECTIVE|||||||
33775878|NCT03619174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775879|NCT03273803|||CASE_ONLY||CROSS_SECTIONAL|||||||
33775880|NCT05812703|||COHORT||PROSPECTIVE|||||||
33775881|NCT02253524|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33775882|NCT01046747|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775883|NCT00230815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775884|NCT04633083|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33907230|NCT04174105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Up to 3 nominal dose levels of AT845 are planned to be evaluated in this study. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort received a single dose of 3×10\^13 vg/kg. The second dose cohort will receive a single dose of 6×10\^13 vg/kg. The third dose cohort will receive a single dose of 1×10\^14 vg/kg. Dose escalation between cohorts will be based on evaluations of safety and in consultation with the independent DMC.||||
33907231|NCT04246177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907232|NCT01675219|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33907233|NCT05394922|||COHORT||PROSPECTIVE|||||||
33907234|NCT06115421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||two-arm open-label non randomized active control study||||
33907235|NCT02107911|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33907236|NCT03615846|||COHORT||PROSPECTIVE|||||||
33907237|NCT00450372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989308|NCT01421277|||COHORT||PROSPECTIVE|||||||
33989309|NCT00445445|||CASE_CONTROL||OTHER|||||||
33686389|NCT02964923|||||PROSPECTIVE|||||||
33686390|NCT05404360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treatment administrator, all study personnel and patients will be blinded to the treatment being administrated.|The BrainsWay Deep TMS device is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a predetermined frequency.|t|t|t|f
33686391|NCT06109922|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Treatment will be blinded according to the randomisation schedule by a researcher who has no other involvement in the study.|Randomised, double-blind, placebo-controlled, parallel groups design.|t|f|t|t
33686392|NCT00416728|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686393|NCT01840644|||||CROSS_SECTIONAL|||||||
33775885|NCT04424290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This trial will consist of an single rising dose (SRD) part followed by an multiple dosing (MD) part. SRD part will be nonrandomized, open-label, and uncontrolled. MD part will be single-masked, randomized and sham-controlled (Ratio 2:1). Parties masked in the MD part are participant and masked site staff (including investigator). The Intervention model in the MD part is active group versus sham injection (=2 arms).||t|t|t|f
33775886|NCT01616290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907238|NCT04497558|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33907239|NCT03233776|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||3+3 design||||
33775887|NCT05355753|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775888|NCT02247999|||COHORT||CROSS_SECTIONAL|||||||
33775889|NCT03855111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, blinded, placebo-controlled clinical trial|t|f|t|t
33775890|NCT01703533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775891|NCT03979950|||COHORT||CROSS_SECTIONAL|||||||
33775892|NCT01024751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33907240|NCT03422133|||CASE_CONTROL||PROSPECTIVE|||||||
33907241|NCT00872170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907242|NCT01929044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907243|NCT02381756|||COHORT||PROSPECTIVE|||||||
33907244|NCT00228488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907245|NCT03477565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33907246|NCT06476275|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33907247|NCT04118712|||CASE_CONTROL||OTHER|||||||
33989310|NCT01608269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989311|NCT04383366|||CASE_ONLY||PROSPECTIVE|||||||
33989312|NCT03161158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, prospective, randomized, parallel-group, controlled||||
33989313|NCT03878862|||COHORT||PROSPECTIVE|||||||
34082618|NCT03843996|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is an randomized, single-blind, split-scalp study, such that subjects will know what side of the scalp the investigational and standard treatment products are applied. The PI will evaluate efficacy and safety blinded.|This Phase IV, post-marketing, single center study will be a single-blind, within subject split scalp efficacy comparison of Stratamed® and standard clinical practice, Bacitracin, post FUE. Twenty subjects desiring to undergo FUE for hair restoration will apply Stratamed® on one half of the donor area on the back of the scalp and Bacitracin on the other side at least twice a day for a week post procedure. The side of the scalp receiving each product will be randomized, and the evaluating physician will be blinded. Subjects will be evaluated, photographed, and will fill out subject reported questionnaires live at days 1 (+1) and 7 (±1) post procedure. Subjects will also fill out the subject reported questionnaires at home in between live study visits (days 2, 3, 4, 5, and 6).|f|t|t|t
34082619|NCT00245804|||CASE_CONTROL||PROSPECTIVE|||||||
34082620|NCT02081729|||COHORT||PROSPECTIVE|||||||
34082621|NCT03017859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082622|NCT01604785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082623|NCT00058253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082624|NCT02617537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686394|NCT00669760|||CASE_ONLY||PROSPECTIVE|||||||
34082625|NCT04159467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator will be blind in relation to group allocation and the outcome assessor will be blind too in relation to group allocation||f|f|t|t
34082626|NCT01531400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082627|NCT05036681|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082628|NCT00320060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082629|NCT03091153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082630|NCT02587208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34082631|NCT00563290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082632|NCT02578017|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34082633|NCT00624988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082634|NCT04960215|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33686395|NCT01099709|RANDOMIZED|CROSSOVER||||NONE||||||
33686396|NCT03227341|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686397|NCT03539224|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm opened with Intervention Type of Drug: Dolutegravir (DTG) and Lamivudina (3TC)||||
33686398|NCT00542451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686399|NCT00945854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686400|NCT01633437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686401|NCT01456910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907248|NCT01617681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907249|NCT03661060|||COHORT||PROSPECTIVE|||||||
33907250|NCT00848692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907251|NCT03695432|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33907252|NCT01846065|||OTHER||PROSPECTIVE|||||||
33907253|NCT02294721|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907254|NCT05844566|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient will be notified at the end of the study in regard to allocation.|Cluster randomised controlled trial. Study sites are randomised to intervention or no intervention.|t|f|f|f
33907255|NCT05380414|NA|SINGLE_GROUP||SCREENING||NONE||||||
33907256|NCT05998408|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907257|NCT04201769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Phase III, multicenter, randomized, open-label, parallel-group, active-comparator, three-arm, non-inferiority study||||
33907258|NCT03363048|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33907259|NCT06691269|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||"Study Design: This will be a series of three prospective, clinical studies in school-aged children requiring routine dental procedures.~Study Population: Healthy children aged 6-12 years old requiring routine dental treatment at the study sites. Separate cohorts will be recruited for each trial after obtaining parental consent."|t|f|f|f
33907260|NCT01176396|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33907261|NCT01921270|NA|SINGLE_GROUP||TREATMENT||NONE|Evaluators will review the videotaped examinations, presented in a random order, using the Global Dystonia Rating scale (GDS). The evaluators will rate the dystonia at baseline (injection visit) and 6 weeks after injection.|||||
33907262|NCT04126369|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907263|NCT05360277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907264|NCT03774693|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33907265|NCT01241838|NON_RANDOMIZED|PARALLEL||||NONE||||||
33907266|NCT06261138|||COHORT||RETROSPECTIVE|||||||
33907267|NCT00747890|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34082635|NCT06391424|||COHORT||PROSPECTIVE|||||||
34082636|NCT01953016|||COHORT||OTHER|||||||
34082637|NCT00850694|||COHORT||PROSPECTIVE|||||||
34082638|NCT05983263|||CASE_ONLY||RETROSPECTIVE|||||||
33989314|NCT06280781|RANDOMIZED|FACTORIAL||OTHER||NONE||"Current (NICE defined active surveillance):~PSA 3 monthly in year 1 and then 6 monthly with rectal exam annually. MRI will be carried out at 12 months (if not had one at diagnosis). A biopsy will be required if indicated due to changes in rectal exam or PSA.~Planned (Regular MRI based active surveillance):~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4."||||
34082639|NCT02634255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686402|NCT04063527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989315|NCT06196281|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized controlled trial|f|f|f|t
33989316|NCT01759277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989317|NCT06281847|NA|SINGLE_GROUP||TREATMENT||NONE||"The study comprises 4 periods:~* The pre-treatment period will consist of screening for eligibility, leukapheresis and a pre-treatment evaluation (prior to Lymphodepleting Chemotherapy (LDC)).~* The treatment period will start with LDC, followed by CCTx-001 infusion 2 to 7 days after completion of LDC. A first response evaluation will be performed at approximately 28 days after CCTx-001 infusion.~* The post-treatment period will consist of further clinical activity and safety follow-up visits at regular timepoints after CCTx-001 infusion, starting after the Month 3 visit up to the Month 24 visit.~* The long-term follow-up period will start after the Month 24 visit up to 15 years post CCTx-001 infusion."||||
33989318|NCT04354493|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Two-group study with same baseline and intervention. One group ceases intervention and returns to control condition.||||
34082640|NCT00192114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686403|NCT04250311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907268|NCT02823262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33686404|NCT05976984|||CASE_CONTROL||RETROSPECTIVE|||||||
33686405|NCT03016676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686406|NCT01362595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686407|NCT06165770|||COHORT||RETROSPECTIVE|||||||
33907269|NCT05085392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686408|NCT00003854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907270|NCT05704543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907271|NCT00003546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907272|NCT04385797|||COHORT||OTHER|||||||
33907273|NCT06075758|||COHORT||OTHER|||||||
33686409|NCT05057910|||COHORT||CROSS_SECTIONAL|||||||
33686410|NCT02750215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721425|NCT01593488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907274|NCT06663358|||COHORT||OTHER|||||||
33907275|NCT03817593|||CASE_CROSSOVER||PROSPECTIVE|||||||
33907276|NCT05474040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907277|NCT02196142|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33907278|NCT02512692|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33907279|NCT04842721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized blinded controlled study, whereas a number of patients (at least 20) with clinically-confirmed Covid-19 infection within 7 days prior to the start of the study, are equally divided into 2 groups, Active and Control groups, using Active and Control Mouth rinses respectively. The Active Rinse is a 25 ml of Hypertonic Saturated Saline solution made by mixing 10 grams of Sodium Chloride (Table Salt) in 25 ml of Tap water with some salt crystals deposited. The Control Rinse is a 25 ml of Plain Tap Water. Each Patient of both groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days. Patients of both groups will be tested once for Covid-19 7 days after the last treatment.|t|f|f|f
33907280|NCT02298270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33907281|NCT04717843|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33907282|NCT00366834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907283|NCT04908449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907284|NCT03950570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1: Dose escalation as a single agent (all tumor types); Dose escalation in combination with Abraxane (Breast Cancer);~Phase 2: Dose expansion as a single agent or in combination with Abraxane (breast cancer)"||||
33907285|NCT02991053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33907286|NCT06116435|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Trials participants will know their intervention condition as will the lay coach involved in delivering the intervention. Assessors measuring body composition (DXA), self-reported energy intake, and metabolic parameters will be blinded to participant condition.|2x2x2 full factorial pilot randomized trial|f|f|f|t
33907287|NCT02242890|NA|SINGLE_GROUP||||NONE||||||
33907288|NCT00960440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907289|NCT04713917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|According to the center's organization, an operator and an investigator-evaluator will be identified for each patient or for all patients.|"An open-label multicentre controlled trial randomized in 3 parallel groups (1:1:1) :~* Bio physical inductor : CO2 laser~* Standard treatment : Hyaluronic Acid gel~* Chemical bio inductor : injection of Hyaluronic Acid"|f|f|f|t
33907290|NCT04438746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907291|NCT03704597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907292|NCT03742336|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907293|NCT02835638|||COHORT||PROSPECTIVE|||||||
33907294|NCT06419920|RANDOMIZED|PARALLEL||OTHER||SINGLE||Feasibility study incorporating a single-blinded Phase I clinical trial with a parallel groups design, involving two treatment conditions: uneven terrain training (UT) and flat terrain (FT) training. Participants will be allocated randomly to UT and FT arms in a 3:1 ratio.|f|f|f|t
33907295|NCT04420481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All care providers and patients were masked with respect to the study drug during the study|A 12 month study, consisting of a 9 months' double-blind, placebo-controlled randomised growth hormone treatment phase followed by a 3 months' growth hormone treatment-free period.|t|t|t|t
33907296|NCT06692205|||OTHER||CROSS_SECTIONAL|||||||
33989319|NCT04887818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trial comparing efficacy and side effect profile of topical diltiazem + lidocaine vs. topical nifedipine + lidocaine|f|t|t|t
33989320|NCT02665715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33989321|NCT04724187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33989322|NCT02553564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989323|NCT03474757|||COHORT||RETROSPECTIVE|||||||
33989324|NCT02109263|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989325|NCT03874715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989326|NCT06290284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be provided an anonymized dataset.||f|f|f|t
33989327|NCT00032396||||TREATMENT||||||||
33989328|NCT04548141|NA|SINGLE_GROUP||PREVENTION||NONE|Anonymous completion of questionnaire|Self completion of questionnaire in the waiting room||||
33989329|NCT02527109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989330|NCT01924377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989331|NCT03693586|||OTHER||CROSS_SECTIONAL|||||||
33989332|NCT05171179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will be randomized into one of the three trial arms. Randomization process will involve 90 envelopes, 30 of which will contain assignment to the study arm with Exparel blocks, 30 which will contain assignment to bupivacaine blocks, and 30 which will contain assignment to lidocaine infusion (the control arm). The PI's attending nurse will randomly distribute an envelope to the study team between V1 and V2. V2, the day of surgery, will be the only visit where the patient would potentially have contact with the treatments. The patient will not be aware of what treatment they receive until after their 2-week follow-up.|"1. Group 1 (Control): Intravenous (IV) lidocaine infusion without Pecs block (standard of care per ERAS protocol)~2. Group 2: Use of Pecs block types I and II with bupivacaine as local anesthetic~3. Group 3: Use of Pecs block types I and II with mixture of bupivacaine and Exparel\* (\*Must include bupivacaine at lower dose to decrease intra-operative variability in pain control due to delayed onset of Exparel and in ability to use lidocaine infusion with injection of Exparel)"|t|f|f|f
33989333|NCT05818891|||COHORT||PROSPECTIVE|||||||
34082641|NCT01524315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34082642|NCT03720886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082643|NCT02227641|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34082644|NCT01682096|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33907297|NCT02085239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33907298|NCT02796924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686411|NCT03361176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Outcomes Assessors will be blinded to the treatment arms subjects are randomized to.|10 subjects will be part of a control group treated without triamcinolone and 20 subjects will be treated with triamcinolone.|t|f|f|t
33686412|NCT01871103|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33686413|NCT00216892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686414|NCT03869827|||COHORT||RETROSPECTIVE|||||||
33907299|NCT03328078|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A will evaluate escalating doses of emavusertib (CA-4948) either as monotherapy (Part A1) or in combination with ibrutinib (Part A2). Enrollment is closed for Part A1 and A2. Part B will comprise two expansion cohorts to assess efficacy and safety of emavusertib and ibrutinib in PCNSL.||||
33907300|NCT03186404|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907301|NCT04477304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33686415|NCT01867073|||COHORT||PROSPECTIVE|||||||
33686416|NCT00070733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686417|NCT05505994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1: Double-blind Part 2: Open label|Parallel assignment|t|t|t|t
33907302|NCT04472923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The present study included 100 children of both sexes that were included with an age ranged from (5-14 years) with FNRFI with normal bowel habits, normal defecation frequency, and normal stool consistency with incontinence score ranging from 6-24 according to Vaizey score 12. Exclusion criteria included; children who have traumatic sphincter injury, fecal impaction, spinal diseases causing incontinence, anorectal malformation, and children who were not cooperative. Patients included in this study were randomly divided and allocated into two groups Control group and Study group. Written informed consent was obtained from parents of all included children.~A detailed history was taken including bowel habits, duration history of trauma. Complete physical examination to exclude patients requiring surgical correction"|t|f|f|t
33907303|NCT00501033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907304|NCT06692023|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double||t|f|f|t
33907305|NCT02271243|||COHORT||PROSPECTIVE|||||||
33686418|NCT05669001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686419|NCT06134531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686420|NCT05169827|||CASE_CONTROL||PROSPECTIVE|||||||
33686421|NCT00060398|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33686422|NCT01732653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686423|NCT04148729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and anaesthesia providers will not know contain of the syringe.||t|t|f|f
33686424|NCT05977725|||OTHER||PROSPECTIVE|||||||
33686425|NCT04369924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686426|NCT00755911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686427|NCT05261451|NA|SINGLE_GROUP||OTHER||NONE||||||
33686428|NCT04540939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician will not know the group assignment until blind is broken. Statistician randomizes the groups. Principal investigator will not know group assignment until blind is broken.||f|f|t|t
33686429|NCT04244409|||COHORT||PROSPECTIVE|||||||
33686430|NCT03956355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigator, study center staff, subject, and Sponsor will be blinded to treatment assignment.|Following a 34-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily treatment with tapinarof cream, 1% or vehicle cream.|t|t|t|t
33686431|NCT03425422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686432|NCT01780896|||COHORT||PROSPECTIVE|||||||
33686433|NCT04220853|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking will be used in the study.|The patients will be divided into three parallel groups, depending on the indicated surgery - septoplasty, turbinoplasty, and septoplasty plus turbinoplasty.||||
33686434|NCT05161039|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907306|NCT01669369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907307|NCT01096771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907308|NCT02244359|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33907309|NCT01630044|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907310|NCT02448901|||COHORT||PROSPECTIVE|||||||
33907311|NCT05937854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be assigned a study code|double blind placebo-controlled|t|t|t|t
33907312|NCT03175003|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Products will look and taste similar, and will be provided in coded packaging|Double blind, controlled, 4 parallel arm design|t|f|t|f
33907313|NCT01104324|||COHORT||PROSPECTIVE|||||||
33907314|NCT00997633|||CASE_ONLY|||||||||
33907315|NCT05323786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33907316|NCT06219005|NA|SINGLE_GROUP||OTHER||NONE||prospective observational cohort study||||
33907317|NCT00039273||||TREATMENT||||||||
33907318|NCT01465178|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33686435|NCT00827580|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33686436|NCT02746003|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33686437|NCT05111275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686438|NCT02925793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686439|NCT04633408|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A qualitative study, a participatory design study and a randomized pilot study to assess acceptability of an intervention.||||
33686440|NCT01486810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686441|NCT04016584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686442|NCT05084495|||COHORT||PROSPECTIVE|||||||
33686443|NCT01724320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686444|NCT01251627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907319|NCT03293199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since patients are alert and conscious, therefore we are unable to blind the participants. However, care provider will not take part in the data acquisition and outcome analysis. The investigator and outcome assessor will be blinded to patients allocated group and treatment type provided in each patients.|Patients will be randomly and equally assigned to study groups, as follows: group (a) will undergo chest tube drainage implementation and group (b) will undergo repetitive needle aspiration till pnuemothorax resolution.|f|f|t|t
33907320|NCT02558881|||CASE_CONTROL||PROSPECTIVE|||||||
33907321|NCT05858944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907322|NCT00834002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907323|NCT05259553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907324|NCT04742257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907325|NCT01925001|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33907326|NCT05280704|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Each participant will collect two syringes with a code indicting the order and technique of injection. The contents of the syringe (lidocaine vs normal saline) will not be known by the care provider, outcomes assessor or participant.|Our study design is a two-period cross-over design with four groups defined by order of treatment, in which each subject will experience both injection techniques, one to each hand.|t|t|f|t
33686445|NCT01554631|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33686446|NCT04033523|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33686447|NCT03456609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686448|NCT00791232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686449|NCT00150644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686450|NCT06478628|||COHORT||PROSPECTIVE|||||||
33686451|NCT01799382|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33907327|NCT04473443|||COHORT||PROSPECTIVE|||||||
33907328|NCT03637868|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, national, multicenter, open-label, uncontrolled, multi-cohort phase II trial||||
33907329|NCT03732872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907330|NCT04567966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907331|NCT03493308|NA|SINGLE_GROUP||OTHER||NONE||||||
33907332|NCT02754778|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907333|NCT04386863|||CASE_ONLY||PROSPECTIVE|||||||
33686452|NCT03355443|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775893|NCT03376555|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigator and Outcomes Assessor are masked according to treatment.|All subjects participate in 4 diets in randomized order. The diets differ in the amount of sodium and dairy cheese content. Each diet is consumed for 8 days. Minimum washout of 1 week between diets. Baseline experiment is conducted prior to first dietary intervention, and the experiment is repeated after each dietary intervention.|f|f|t|t
33775894|NCT01012973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775895|NCT00231894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775896|NCT05832580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775897|NCT00743132|||COHORT||RETROSPECTIVE|||||||
33775898|NCT02601729|||COHORT||OTHER|||||||
33775899|NCT01722136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775900|NCT00006040||||TREATMENT||||||||
33775901|NCT01508143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775902|NCT04016051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775903|NCT01120171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775904|NCT05335772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775905|NCT02391285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775906|NCT00650221|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775907|NCT01050075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33775908|NCT05175482|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775909|NCT01549691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775910|NCT04695015|||CASE_CONTROL||PROSPECTIVE|||||||
33907334|NCT05415956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"7 week randomized controlled trial; intervention group and waitlist/control group.~The investigators will perform a cluster randomization (computer generated random numbers) according to cities across Denmark (when 4-12 pwMS are interested and eligible).~Waitlist/control group will be offered the same outdoor walking exercise therapy after the initial 7 weeks.~24 weeks after the walking exercise intervention, a follow-up test will be carried out as well."|f|f|f|t
33907335|NCT02166840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33907336|NCT01366222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33775911|NCT00857376|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33775912|NCT01340482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775913|NCT00136812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775914|NCT04184024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775915|NCT04394546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33775916|NCT02370290|||CASE_ONLY||PROSPECTIVE|||||||
33775917|NCT05181943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775918|NCT06052033|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775919|NCT02971891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775920|NCT05018429|||COHORT||RETROSPECTIVE|||||||
33989334|NCT01794039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989335|NCT00405145|||||OTHER|||||||
33989336|NCT04742543|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||: Parallel Assignment||||
33989337|NCT03944330|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989338|NCT01701492|||COHORT||PROSPECTIVE|||||||
33989339|NCT02814877|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33989340|NCT03367624|||CASE_ONLY||RETROSPECTIVE|||||||
33989341|NCT06458491|||COHORT||RETROSPECTIVE|||||||
33989342|NCT03505463|||COHORT||PROSPECTIVE|||||||
33989343|NCT02386618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989344|NCT00481637|||CASE_CONTROL||PROSPECTIVE|||||||
33989345|NCT00361751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989346|NCT02777372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686453|NCT04079673|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686454|NCT03536221|||CASE_ONLY||OTHER|||||||
33686455|NCT02628769|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33686456|NCT00874614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686457|NCT02526329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686458|NCT04785521|||CASE_CONTROL||PROSPECTIVE|||||||
33686459|NCT00112398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686460|NCT02220127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686461|NCT02596282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33686462|NCT00136604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33775921|NCT01629654|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33775922|NCT05794919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33775923|NCT04537104|||COHORT||PROSPECTIVE|||||||
33775924|NCT05753449|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Subjects will be programmed to both settings over the course of the visits, but the order is randomized to ensure appropriate blinding of the UPDRS assessor.~Unblinded examiner will then turn the DBS ON to the patient's baseline DBS settings continuously ON or to burst DBS mode.~A blinded examiner who did not perform the programming change will perform a UPDRS-III evaluation"|Randomized, double-blind cross-over study|t|f|t|f
33775925|NCT05872828|||CASE_ONLY||CROSS_SECTIONAL|||||||
33775926|NCT06275932|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33775927|NCT02168920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775928|NCT00201474|||CASE_CONTROL||PROSPECTIVE|||||||
33775929|NCT01383993|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33775930|NCT04128033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant doesn't know if the point punctured is the experimental or the placebo point.|Monocentric, randomized, simple blinded, controlled study|t|f|f|f
33775931|NCT02643979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33775932|NCT01037205|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33775933|NCT05747625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33775934|NCT05278923|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Two scenarios were simulated. CPR and ETI in an airway with regurgitation (oropharyngeal regurgitation scenario) and CPR and ETI in an airway without regurgitation (clean airway scenario). All EMT-Ps were assigned to participate initially in one of the scenarios. After all EMT-Ps had finished the first scenario, they switched to the other.|t|f|f|f
33775935|NCT06257264|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33775936|NCT01683994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775937|NCT00771875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775938|NCT02320721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775939|NCT03055832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Meibomian gland score will be assessed by a masked rater||f|f|f|t
33775940|NCT02564055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775941|NCT05482880|||COHORT||PROSPECTIVE|||||||
33775942|NCT01300559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33775943|NCT03868319|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigators, surgeons and patients remained unware of study-group assignments so as to preserve the double blinding.|Lung-protective ventilation(LPV) group (low tidal volume 6 ml kg-1 predicted ideal body weight (PBW)+ 7 cmH2O positive end-expiratory pressure(PEEP)) vs. nonprotective group (control group) (large tidal volume 9 ml kg-1 + zero PEEP (ZEEP)) mechanical ventilation in patients undergoing RARC|t|t|t|t
33775944|NCT04672746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33775945|NCT05737667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33775946|NCT02774343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33775947|NCT00354367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775948|NCT03325153|||COHORT||CROSS_SECTIONAL|||||||
33775949|NCT05194917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33775950|NCT06137196|||COHORT||PROSPECTIVE|||||||
33775951|NCT01866241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775952|NCT01140022|||COHORT||PROSPECTIVE|||||||
33775953|NCT01189253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775954|NCT05181813|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Selected children will be divided randomly into 2 groups:~Group 1: Ginge-Cal group: primary molars were filled with a creamy mixture of pulpectomy paste of Gingerols and Calcium Hydroxide.~Group 2: Metapex group: primary molars were filled with a ready-made injectable creamy mixture pulpectomy paste of Metapex."||||
33775955|NCT04616274|||COHORT||PROSPECTIVE|||||||
33775956|NCT01940094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775957|NCT04506580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|f|t|t
33775958|NCT04845438|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33775959|NCT00988585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775960|NCT03518164|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33775961|NCT00737984|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775962|NCT00416923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775963|NCT03717259|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"This is an analytical cross-sectional study for which patients with terminal chronic kidney disease will be taken from kidney transplanted from a related live donor in a tertiary hospital. The selection of patients will be done with a non-probabilistic sampling of consecutive cases.~Kidney transplantation from a live donor will be carried out by means of kidney graft procurement techniques using open surgery, laparoscopic hand-assisted surgery or pure laparoscopic surgery.~The statistical analysis will be performed with Student´s t-test and Chi-square test. To determine if the intervening variables affected the postoperative renal function, we will perform a multivariate analysis. We will consider a significant P value when it is \<0.05."|f|f|f|t
33775964|NCT06411288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775965|NCT00927628|||COHORT||RETROSPECTIVE|||||||
33775966|NCT02209636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775967|NCT05905471|||OTHER||OTHER|||||||
33775968|NCT03508128|||COHORT||RETROSPECTIVE|||||||
33775969|NCT06218836|RANDOMIZED|PARALLEL||OTHER||DOUBLE|An independent investigator, not involved in the assessment of patient, will assign the allocated intervention. The patient and the postoperative outcome assessor will be blinded to the intervention.|"Patients will be randomly divided into two groups:~Group I: Intubation with pre-inflated endotracheal tube Group II: Intubation with non-inflated endotracheal tube"|t|f|f|t
33775970|NCT06439290|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Assessments will be performed by an ENT specialist and SLP of the research group who is blinded to study evolution and group allocation.|"Purpose 1: prospective non-randomized controlled trial. Experimental group: persons undergoing phonosurgery Control group: age-matched PFAB/PMAB undergoing mastectomy/breast augmentation~Purpose 2: Predictors of the outcome of abovementioned surgery in the experimental group will be determined using correlational research (regression analysis).~Purpose 3: After optimization of MRI sequences and testing in healthy participants (n=5), a segmentation and measurement workflow will be completed. Objective measurement of pre- and postoperative laryngeal anatomy: Anatomical outcome measures will be obtained and compared before and one month/6 months after surgery in the experimental group."|f|t|f|f
33775971|NCT05967260|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907337|NCT06036433|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are unaware of which device they are receiving. The outcomes assessor is unaware of subject randomization and is not involved with any teaching or follow-up of the participants.|"There are two study arms; the first is a randomized, controlled, double-blind design with Real (Active) and Placebo groups. The study will evaluate the effect of light therapy (photobiomodulation - PBM) on treating the symptoms of moderate-stage PD. Regular exercise is a study prerequisite and must continue throughout the study. There are 30 per group, ages 55-80. Both groups will complete 30-minute, at-home PBM treatments, 3 days/week x 8 weeks (total of 24). Then devices are returned. Subjects have outcome measurement testing at Entry and the end of Weeks 1 \& 4 after the last PBM treatment.~The Crossover includes both the Active \& Placebo groups interested in participating in the same 8-week at-home Real PBM protocol outlined above. The same education and weekly support in the first arm is provided in the second arm of the study. Then the devices are returned. Outcome measurement testing will be conducted 1 and 4 weeks after the last PBM treatment."|t|f|f|t
33989347|NCT05815745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33989348|NCT03756441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33989349|NCT02148497|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33989350|NCT03567668|||COHORT||PROSPECTIVE|||||||
33989351|NCT00429286|||COHORT||PROSPECTIVE|||||||
33989352|NCT04825314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33989353|NCT05890261|NA|SINGLE_GROUP||PREVENTION||NONE||Repeated measures design||||
34082645|NCT06077539|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The anesthesiologist not involved in the study will open envelopes and will prepare the drug. All syringes will be prepared by the same investigator not one of the study researchers. Administration of anesthesia and study drugs will be made by other investigators blinded to the study drugs and not involved in the study. Data collection will be done by investigator who is included in the study.|(100) patients will be randomized into four equal groups using computer-generated block randomization and there will be five blocks each block contains 5 patients in each group.|t|t|t|t
34082646|NCT03613493|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33907338|NCT06692101|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Study Model Description: This study is a parallel-group randomized controlled trial (RCT) employing a superiority trial design to evaluate the efficacy of combining neuromuscular electrical stimulation (NMES) with oral care compared to oral care alone and standard care in improving swallowing function and reducing the incidence of stroke-associated pneumonia (SAP) in patients with acute ischemic stroke (AIS).~Randomization and Blinding: Participants were randomly assigned to one of the three intervention groups (Group A, Group B, or Group C) using a computer-generated randomization sequence to ensure unbiased group allocation.~Intervention Overview:~Group A (Oral Care Group): Focused on comprehensive oral hygiene practices administered twice daily for at least five days.~Group B (Oral Care + NMES Group, O-NMES): Received the same oral care regimen as Group A, followed"||||
34082647|NCT01511926|||COHORT||RETROSPECTIVE|||||||
34082648|NCT02352857|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33989354|NCT04244877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989355|NCT04097483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Primary Care specialist will be blind, but the telephonic intervention research nurses will not. For ethical and practical reasons, the trial will be unmasked, and participants will not be blind to the treatment condition once allocated.||f|t|f|t
33989356|NCT06486298|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33989357|NCT06038253|||CASE_CONTROL||RETROSPECTIVE|||||||
34082649|NCT01228006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082650|NCT04320719|||COHORT||PROSPECTIVE|||||||
34082651|NCT04249479|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"All subjects will be randomized into two different groups as listed in the study outline.~The randomization schedule will be prepared and centrally administered. A computer random number generator prepares the randomization schedule in a 1:1 fashion (balanced randomization). Stratification is performed, based on age (\< 60 and ≥ 60 years) and weight (\< 80 and ≥ 80 kg). Variable block randomization will distribute patients equally over time.~The blinding and randomization process will be conducted by Clinical Trial Centre Maastricht (CTCM, www.CTCM.nl) with a randomization program designed for usage of different techniques (minimization, block method, biased-coin, etc). The technician who administers the CM is aware of the CM temperature. Therefore, the technicians will be instructed before start of the study, not to give this information to the patient, not even when requested by the patient."|"It is a double-blinded randomised controlled non-inferiority trial conducted according to Guidelines of Good Clinical Practice. The aim of the study is to prospectively compare room temperature CM to pre-warmed CM with regard to image quality, safety, and participant comfort in portal venous abdominal imaging.~We are aiming to prospectively enrol 216 consecutive patients, who will be scheduled for contrast enhanced abdominal CT.~216 patients will be divided into 2 different groups:~* Group I: 300 mg/ml at a temperature of 20° C~* Group II: 300 mg/ml at a temperature of 37° C Iodine concentrated CM of 300 mg/ml is clinically used as a standard routine injection protocol for all CT scans in our department, including abdominal CT. The scan protocol is identical to our daily clinical practice. The only difference is that 50% of the included patients will receive CM warmed at room temperature. Both CM temperatures are saved/warmed in an incubator."|t|f|t|f
34082652|NCT03277131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082653|NCT06230263|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|"Randomization:~Generate a random list of 39 labels (A for DAILIES TOTAL1® for Astigmatism, B for Spherical Contact Lenses) using a computer.~Randomize the list order and apply matching coded stickers to lens packages. A designated unmasked examiner has exclusive access to the decoding key and does not partake in direct participant interaction or data handling.~Visit 1:~Confirm participant eligibility, then the unmasked examiner uses the random list to provide the coded lens package to the masked examiner.~The masked examiner fits the participant with the first set of lenses, unaware of the type.~Visit 3:~The unmasked examiner repeats Visit 1's procedure for the second set of lenses. Blinded study conditions are maintained as the masked examiner fits the second pair of lenses.~End of Study:~The unmasked examiner decodes the lens order for data analysis. This method ensures a double-blind crossover design, minimizing bias."|This study will follow a double-masked randomized crossover design \[10\], where participants will be fitted with DAILIES TOTAL1® for Astigmatism and DAILIES TOTAL1® Spherical Contact Lenses in a randomized order. Each participant will use both types of lenses over different periods.|t|f|f|t
34082654|NCT05582902|||COHORT||PROSPECTIVE|||||||
33989358|NCT01891461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989359|NCT05851391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989360|NCT04757792|||CASE_ONLY||RETROSPECTIVE|||||||
33989361|NCT02819947|||COHORT||PROSPECTIVE|||||||
33989362|NCT01944072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33989363|NCT04917328|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989364|NCT03396120|||COHORT||RETROSPECTIVE|||||||
34082655|NCT02656030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082656|NCT01192165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082657|NCT02666976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082658|NCT04384900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082659|NCT03413592|NA|SINGLE_GROUP||OTHER||NONE||||||
34082660|NCT02461693|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants, study personnel interacting with participants, and investigators were blinded. Only the study statistician knew treatment assignments.||t|f|t|f
34082661|NCT04000113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082662|NCT01953029|||COHORT||PROSPECTIVE|||||||
33989365|NCT05217225|||OTHER||CROSS_SECTIONAL|||||||
33989366|NCT02494479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989367|NCT04747769|||CASE_ONLY||RETROSPECTIVE|||||||
33989368|NCT02232776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989369|NCT02740647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989370|NCT06427161|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33907339|NCT03889093|NA|SINGLE_GROUP||OTHER||NONE||Single arm prospective study||||
33686463|NCT03042702|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33686464|NCT01035450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907340|NCT02060617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907341|NCT06682481|||CASE_CONTROL||PROSPECTIVE|||||||
33907342|NCT03992469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind placebo controlled safety trial with random assignment to groups.|Safety and Tolerability phase is a double blind randomized controlled trial to evaluate safety and tolerability over 8 weeks. This is followed by an open-labeled exploratory efficacy extension phase for 6 months.|t|t|t|f
33907343|NCT01821170|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989371|NCT04766450|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial||||
33989372|NCT01001403|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33989373|NCT00808418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989374|NCT04055558|||COHORT||RETROSPECTIVE|||||||
33989375|NCT05595590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989376|NCT03391284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989377|NCT05934565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Testing will be facilitated by study staff who are blinded to treatment assignment.|2-arm parallel remotely delivered randomized controlled trial|f|f|f|t
33989378|NCT06560853|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Blinding of intervention units, i.e. schools, to their own treatment (or that of others) is not feasible. After the initial scoping and baseline data collection (during which treatment was masked to all participants and assessors), due to the nature of the intervention, there will be no blinding: both the beneficiaries and assessors monitoring the outcomes will be able to infer whether the school is receiving the HL programme or not.|Clusters (schools) are randomised to one of 3 treatment arms. Non-compliance with treatment or control is possible if participants move between schools. We expect low rates of transfers and will track any transfers which do occur.||||
33989379|NCT04180709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomised parallel study design, with five points of measurements. Participants will receive either the Sleepio online intervention + treatment as usual (TAU) or TAU alone over an 8-week period. A follow-up period will be conducted for an additional 8 weeks. The original TAU group will be offered the intervention during this period.||||
33989380|NCT05514860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989381|NCT03568838|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomised (1:1) using an opaque sealed envelope methodology prior to coronary angiography.~Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.~Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI."||||
33989382|NCT00654030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989383|NCT03810118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single group of patient will receive 4 ml/kg fluid challenge in either 10 or 20 minutes||||
33989384|NCT06092450|||COHORT||RETROSPECTIVE|||||||
33686465|NCT06142227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33686466|NCT02064075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686467|NCT02326545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686468|NCT00140543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686469|NCT04230720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907344|NCT03048721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907345|NCT02739334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686470|NCT02944422|||||CROSS_SECTIONAL|||||||
33686471|NCT05683184|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721426|NCT06245590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721427|NCT02013648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907346|NCT06302205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The nature of the intervention does not allow blinding of study participants. However, outcome assessors and data investigators will be blinded to the participants' group allocation.|Two interventional groups and one control group|f|f|f|t
33907347|NCT02236546|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907348|NCT06059378|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907349|NCT05794945|||COHORT||PROSPECTIVE|||||||
33907350|NCT04263662|||COHORT||RETROSPECTIVE|||||||
33907351|NCT02145910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907352|NCT06678347|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907353|NCT05388435|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1, Phase 1 Dose Escalation and Part 2, Phase 2 Dose Expansion||||
33907354|NCT04775212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907355|NCT02203253|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33686472|NCT03721679|NA|SEQUENTIAL||TREATMENT||NONE||The study is largely a signal-finding exercise to determine if there is an immune and/or clinical response to the addition of poly-ICLC to aPD-1 or aPDL-1 therapy, as predicted by preclinical models.||||
33686473|NCT01500343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686474|NCT04174950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were allocated into two groups randomly.|f|f|f|t
33686475|NCT04809077|NA|SINGLE_GROUP||OTHER||NONE||||||
33686476|NCT06050603|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|It is a within-subjects design, which means that all subjects will receive both individualized stimulation based on their functional results and generic stimulation based on the results of a meta-analysis.|||||
33686477|NCT01990144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686478|NCT00951782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686479|NCT00790257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686480|NCT03633760|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33686481|NCT01063777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33686482|NCT01248182|||COHORT||PROSPECTIVE|||||||
33686483|NCT05999539|||CASE_CONTROL||PROSPECTIVE|||||||
33686484|NCT02577276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686485|NCT00146107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686486|NCT01440790|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33686487|NCT04652596|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33686488|NCT01018446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686489|NCT02387255|||COHORT||PROSPECTIVE|||||||
33686490|NCT05524298|||COHORT||PROSPECTIVE|||||||
33686491|NCT03230669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839786|NCT05559151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Neither the experimenters nor the participants knew whether they were getting an experimental drug or a placebo. In this way, the description of the therapeutic effects and adverse reactions of the subjects, as well as the record of the various reactions of the experimenters, can be as objective as possible.|Sixty patients undergoing radical gastrectomy for gastric cancer were selected and divided into two groups according to random number table method: control group (group P) and experimental group (group R), with 30 cases in each group. All enrolled patients signed informed consent. Control group: the control group (group P) received target controlled infusion of propofol. Experimental group: the experimental group (group R) received target controlled infusion of remimazolam benzenesulfonate. And the BIS value of the two groups was controlled at 50±5.|t|t|t|t
33907356|NCT02664636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907357|NCT01038284|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33907358|NCT06126653|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blinded|This is a blinded, placebo controlled, cross-over trial|t|f|t|f
33907359|NCT00592397|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907360|NCT02699515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907361|NCT01406665|||COHORT||CROSS_SECTIONAL|||||||
33907362|NCT06372665|||OTHER||PROSPECTIVE|||||||
33907363|NCT03369301|||CASE_ONLY||PROSPECTIVE|||||||
33907364|NCT03240198|||CASE_CONTROL||PROSPECTIVE|||||||
33907365|NCT06693232|NA|SINGLE_GROUP||OTHER||NONE||One group will receive mobile micro-learning.||||
33686492|NCT05287542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is not possible to blind participants or therapists to group allocation during the intervention. Independent Outcome Assessor(s) will be blinded to group allocation. Participants will be provided with new IDs in final database, blinding researchers to which group is the interventions group, active control group or passive control group during analysis.|Randomized Controlled Trial|f|f|t|t
33907366|NCT03422991|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907367|NCT03975868|||OTHER||RETROSPECTIVE|||||||
33907368|NCT03640364|||CASE_ONLY||PROSPECTIVE|||||||
33907369|NCT04718181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33907370|NCT02786355|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33686493|NCT00002967||||TREATMENT||||||||
33686494|NCT04720261|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental, prospective, non-comparative, multicentric national study||||
33686495|NCT02155946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686496|NCT04561999|||CASE_ONLY||CROSS_SECTIONAL|||||||
33686497|NCT04235010|RANDOMIZED|PARALLEL||OTHER||SINGLE|The examiner who performed clinical periodontal parameters was blinded to group assignment.||f|f|f|t
33686498|NCT00327470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686499|NCT05000333|||COHORT||PROSPECTIVE|||||||
33686500|NCT05930704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775972|NCT04823897|NA|SEQUENTIAL||TREATMENT||NONE||"This is an open-label, single-arm, single-center, Phase I dose-escalation study of CCI-001 in patients with recurrent and/or metastatic solid tumours.~Patients will be treated in cohorts of 3, with the starting cohort having an assigned dose of CCI-001 of 1.2 mg/m2. If safety criteria are met, subsequent cohorts will be administered escalating doses of CCI-001, using the modified accelerated dose-escalation method.~Any cohort in which a patient experiences DLT in Cycle 1 will be expanded to 6 patients. Dose escalation will continue if only 1 of 6 patients in a cohort experiences DLT. If 2 patients within a cohort experience DLT, the maximum tolerated dose will have been reached/exceeded.~The cohort at the dose below this cohort will be expanded to 6 patients to ensure tolerability. If none of the 3 additional patients at this lower dose experiences DLT, that dose will be declared as the recommended dose for the dose expansion phase."||||
33775973|NCT02642718|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33775974|NCT01011790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775975|NCT04376411|||CASE_CONTROL||PROSPECTIVE|||||||
33775976|NCT03785340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775977|NCT01716208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775978|NCT04786561|||COHORT||RETROSPECTIVE|||||||
33775979|NCT04454762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775980|NCT01874574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33775981|NCT04408001|||COHORT||PROSPECTIVE|||||||
33775982|NCT01608438|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33775983|NCT06220201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33775984|NCT00326729|||DEFINED_POPULATION||OTHER|||||||
33775985|NCT06126822|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33775986|NCT02347449|NA|SINGLE_GROUP||OTHER||NONE||||||
33775987|NCT03781011|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants identified as high-TMAO producers through the oral carnitine challenge test will be invited to participate in a two-month vegetarian diet intervention.||||
33775988|NCT00003238||||TREATMENT||||||||
33775989|NCT00337116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33775990|NCT03423459|||COHORT||PROSPECTIVE|||||||
33775991|NCT00605371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775992|NCT05948462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839787|NCT00402090|||||OTHER|||||||
33839788|NCT00623805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839789|NCT00540462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33839790|NCT02521714|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33839791|NCT01299480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33839792|NCT03051399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding was ensured by the fact that both capsules (placebo and EpiCor) were opaque and had an identical appearance and were packed in identical bottles by Embria Health Sciences and were labeled as A or B. A ProDigest staff member not participating in the study labelled all bottles and assigned them to each subject in accordance with the randomization list. All study participants, all members of ProDigest staff involved in the study and the Drug Research Unit Ghent (University Hospital Ghent) that actually performed the study, were blinded.|Pilot study performed according to a randomized, double-blind, placebo-controlled parallel design|t|t|t|t
33839793|NCT01424605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33839794|NCT03414385|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839795|NCT06305052|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33907371|NCT03464708|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind.|Double blind, placebo controlled, randomised controlled trial|t|t|t|t
33907372|NCT03568539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907373|NCT06050863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907374|NCT03140254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33907375|NCT06693245|||OTHER||PROSPECTIVE|||||||
33907376|NCT03046472|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One of the investigators has the role of examining the participants before and after the intervention. She will be blinded from the group allocation.|The study will consist of two groups: a Treatment group and a control group. Both groups will get personal meeting once a month and a program of exercising at home every day. Treatment group will have in addition group meeting once a week and control group not.|f|f|t|f
34082663|NCT02991001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082664|NCT00687908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082665|NCT00618293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082666|NCT04268160|||COHORT||PROSPECTIVE|||||||
34082667|NCT00848497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082668|NCT01347463|||COHORT||PROSPECTIVE|||||||
34082669|NCT02063672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082670|NCT03717571|||COHORT||RETROSPECTIVE|||||||
34082671|NCT02936973|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34082672|NCT05634655|||COHORT||RETROSPECTIVE|||||||
34082673|NCT00511381|||||PROSPECTIVE|||||||
34082674|NCT01302899|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34082675|NCT05449899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082676|NCT00787826|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082677|NCT06422039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study was an open, fixed-sequence clinical trial in healthy adult subjects||||
34082678|NCT01348841|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34082679|NCT03271138|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34082680|NCT02069795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082681|NCT06550531|||COHORT||PROSPECTIVE|||||||
34082682|NCT01449253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082683|NCT02281708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082684|NCT01916200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082685|NCT03964207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082686|NCT01378208|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082687|NCT03971331|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
33989385|NCT03733444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989386|NCT04924660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Which study drug arm the participant enters will be known to the research sites and the participants, but assignment to active versus placebo will be blinded. The randomized assignment, concealed from the research team, will be transmitted to the site pharmacy, who will provide study medication. The participant, treating clinicians, study personnel (other than the unblinded statistician who will prepare closed DSMB interim reports), and outcome assessors will all remain blinded to group assignment until after the database is locked and blinded analysis is completed.|Participants will be randomly allocated in a two-step process: 1) The participant will first be randomized in an m:1 ratio to receive an active study drug or placebo, where m represents the number of study drug arms for which the participant is eligible. 2) The participant will then be randomly assigned with equal probability to one of the study drug arms. Participants will receive the corresponding study drug or matching placebo.|t|t|t|t
33989387|NCT04444050|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33989388|NCT00510172|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||||||
33989389|NCT03494894|||COHORT||PROSPECTIVE|||||||
33989390|NCT02241863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989391|NCT00697476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989392|NCT04364841|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989393|NCT02897791|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33989394|NCT03147768|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Open Label Combination Product (Laser + Biologic + Drug) regulated as a device||||
33989395|NCT02286154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989396|NCT01686386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989397|NCT02319824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989398|NCT03810703|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Study will track participants in two assigned groups (participants that exhibit either High or Low Bipolar II/Hypomanic phenotypes)|t|f|t|f
33989399|NCT00118235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989400|NCT02570477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989401|NCT04786626|||CASE_ONLY||PROSPECTIVE|||||||
33989402|NCT03913065|||COHORT||PROSPECTIVE|||||||
33989403|NCT06542458|||COHORT||PROSPECTIVE|||||||
33989404|NCT06282874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989405|NCT05358860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989406|NCT00838630|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989407|NCT05570487|||CASE_ONLY||RETROSPECTIVE|||||||
33989408|NCT03142165|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33989409|NCT02142426|||||RETROSPECTIVE|||||||
33989410|NCT06558981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989411|NCT04490005|||COHORT||PROSPECTIVE|||||||
33989412|NCT05432687|NA|SINGLE_GROUP||SCREENING||NONE||||||
33989413|NCT04527107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989414|NCT06084494|RANDOMIZED|FACTORIAL||PREVENTION||NONE||A wet Bulb Globe temperature (WBGT) level of 28 °C was simulated, and the temperature within the climatic chamber was set at 40 °C and 31 °C at relative humidity levels of 20% and 70%, respectively. Four test conditions were designed and subjects ran at 8 km/h and walked at 5 km/h for up to 70 minutes.||||
33989415|NCT05066217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989416|NCT00811655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989417|NCT01499186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33989418|NCT00652418|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33989419|NCT05439057|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33775993|NCT01610973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989420|NCT02115347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989421|NCT05867862|RANDOMIZED|PARALLEL||PREVENTION||NONE||"For the control group: the instructions regarding OH given to the children and their parents will be the same than the one usually given by the maxilla-facial surgeons or the orthodontists during their annual follow-up visits. If the patients are in need of dental care, they will be encouraged to contact their dentist.~For the test group: a dental consultation of 30 to 45 minutes will be added to the annual visit with a dentist. During this consultation the children will be incited to have a better OH, oral and written explanations will be provided. The goal is to have the best understanding of the importance of a good OH and brushing technique from the children and the parents."||||
33989422|NCT06172894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989423|NCT03144050|||COHORT||PROSPECTIVE|||||||
33989424|NCT00002831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989425|NCT02649179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989426|NCT01992991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989427|NCT01931722|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989428|NCT04715893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989429|NCT01747135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989430|NCT00829673|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33775994|NCT04971616|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33775995|NCT03513198|||COHORT||PROSPECTIVE|||||||
33775996|NCT02682498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33775997|NCT02965209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33775998|NCT00165269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839796|NCT04367285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839797|NCT06078228|||COHORT||PROSPECTIVE|||||||
33989431|NCT01068821|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33989432|NCT02952456|||OTHER||PROSPECTIVE|||||||
33989433|NCT06099652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989434|NCT04206358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989435|NCT01913405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989436|NCT06158386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989437|NCT05922696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989438|NCT04102085|||OTHER||CROSS_SECTIONAL|||||||
33989439|NCT00151489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989440|NCT00034905||||TREATMENT||||||||
33989441|NCT03574558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989442|NCT02460653|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989443|NCT02181140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989444|NCT01033877|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33989445|NCT03841266|||COHORT||RETROSPECTIVE|||||||
33989446|NCT05050071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33989447|NCT05956561|||CASE_ONLY||CROSS_SECTIONAL|||||||
33989448|NCT00467363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989449|NCT05643976|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33989450|NCT06356766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989451|NCT04852978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989452|NCT06502340|||COHORT||PROSPECTIVE|||||||
33839798|NCT04477395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839799|NCT00331357|||DEFINED_POPULATION||PROSPECTIVE|||||||
33839800|NCT03879174|NA|SINGLE_GROUP||TREATMENT||NONE||Recently there has been a growing interest in using immune check point inhibitors in breast cancer especially among patients with triple negative and HER2 positive subtypes that are thought to be more immunogenic compared to the luminal subtypes. However there has been a growing interest in looking at immune check point inhibitors among patients with hormone receptor positive breast cancer as a potential method of overcoming endocrine resistance. In the current study we propose a phase II trial to evaluate the anti-tumor activity of pembrolizumab and tamoxifen among patients with hormone receptor positive, HER2 negative metastatic breast cancer who have progressed on a prior aromatase inhibitor and have acquired an ESR1 mutation.||||
33839801|NCT02205775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839802|NCT05251142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839803|NCT05616299|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33839804|NCT01110278|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839805|NCT01627262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33839806|NCT05040347|||COHORT||OTHER|||||||
33839807|NCT01081847|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
33839808|NCT04184453|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who was diagnosed as aceruloplasminiaemia||||
33839809|NCT00409526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839810|NCT06329323|||CASE_CONTROL||PROSPECTIVE|||||||
33839811|NCT04565275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839812|NCT05862428|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants were devided in two groups. The experimental group received rectal misoprostol before surgery and the control group not received the drug||||
33839813|NCT05781412|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||There will be three groups of participants: autism-diagnosed, autism-non-diagnosed and neurotypical individuals (healthy controls). On each group, participants will be randomly allocated to one of two groups: anodal stimulation in the first session or anodal stimulation in the second session (in the other session there will be sham stimulation).|t|f|f|f
33839814|NCT03094975|||CASE_ONLY||PROSPECTIVE|||||||
33839815|NCT04329377|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839816|NCT01469520|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839817|NCT02834767|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33839818|NCT05814588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839819|NCT05433649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839820|NCT00142090|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33839821|NCT02909218|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33839822|NCT05308030|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33839823|NCT03342833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33839824|NCT05461287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839825|NCT06034691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907377|NCT04786028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907378|NCT00589472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907379|NCT04384796|||OTHER||OTHER|||||||
33907380|NCT00227383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33907381|NCT04246372|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the investigational product, Tofacitinib.||||
33907382|NCT04280601|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months||||
33907383|NCT02379156|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907384|NCT06453447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907385|NCT02364193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907386|NCT04225624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will remain blind to treatment condition throughout the study for all participants. Participants and study therapists will be aware which treatment they have been assigned to.|At the baseline visit, eligible participants will be randomized (1:1 in parallel) to AR-ERT or SPT.|f|f|f|t
33907387|NCT04081844||SEQUENTIAL||TREATMENT||NONE||||||
33907388|NCT05299203|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907389|NCT04809467|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33989453|NCT02687126|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989454|NCT04638179|||COHORT||OTHER|||||||
33989455|NCT02295163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082688|NCT01868659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082689|NCT00578903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989456|NCT06559020|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study employs a quasi-experimental design with parallel assignment. Participants were self-selected into two groups: one receiving Kangaroo Mother Care (KMC) and the other receiving Conventional Care (CC). The intervention was applied without randomization, and both groups were followed for one year to assess differences in growth, developmental milestones, breastfeeding practices, vaccination status, and mortality among low birth weight and preterm infants.||||
33989457|NCT04570215|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33989458|NCT03429959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082690|NCT03673891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082691|NCT05120076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the investigators as well as the head of anasthesiology will be informed.||t|t|f|t
34082692|NCT02910908|||COHORT||PROSPECTIVE|||||||
34082693|NCT00313235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082694|NCT03008044|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||"For the first 10 subjects, all sensors will be removed after the end of the clamp measurement day.~The last 2 subjects will continue to wear the three sensors after the clamp study. The second clamp study will take place at Day 7±1. After the second clamp study, the commercial CGM sensor will be removed. The two FiberSense sensors will be worn for up to Day 14."||||
34082695|NCT01895985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082696|NCT00000867||PARALLEL||TREATMENT||||||||
34082697|NCT01715831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082698|NCT02737449|||COHORT||PROSPECTIVE|||||||
34082699|NCT05652127|NA|SINGLE_GROUP||OTHER||NONE||As a single arm study all participants' children will receive a game-based biofeedback intervention. They are encouraged to engage with the intervention in an entirely self-directed manner.||||
34082700|NCT02309021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082701|NCT02385786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082702|NCT00495053|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||sequential, dose escalation|t|f|t|t
34082703|NCT01140971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082704|NCT06519331|NA|SINGLE_GROUP||OTHER||NONE||||||
34082705|NCT01105052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082706|NCT00060970|||NATURAL_HISTORY||PROSPECTIVE|||||||
34082707|NCT02937597|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34082708|NCT01571388|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082709|NCT04763720|||COHORT||PROSPECTIVE|||||||
34082710|NCT05984719|||COHORT||CROSS_SECTIONAL|||||||
34082711|NCT02100332|||CASE_ONLY||CROSS_SECTIONAL|||||||
34082712|NCT03074500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure group concealment, randomization will be done by using opaque, sealed envelopes which the assessors will be blinded to|Parallel Assignment|t|f|f|t
34082713|NCT01863771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082714|NCT05573243|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082715|NCT02173782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082716|NCT01213238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082717|NCT00039403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082718|NCT03778671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082719|NCT00289211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082720|NCT03303222|||COHORT||PROSPECTIVE|||||||
34082721|NCT00919880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082722|NCT04942262|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|"An external prosthodontist provided with a denture adhesive and knew who continued using denture adhesive.~Meanwhile, the outcome assessor did not notice whether the participants continue using denture adhesive"|Before and after intervention, and then allow the participants to decide whether to continue receiving the intervention||||
34082723|NCT04041622|NA|SINGLE_GROUP||SCREENING||NONE||All inhabitants of Nord-Trøndelag County, Norway, above 18 years of age are invited to participate||||
34082724|NCT06207474|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34082725|NCT00480844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082726|NCT00966095|||CASE_CONTROL||PROSPECTIVE|||||||
33989459|NCT02157623|NA|SINGLE_GROUP||TREATMENT||NONE||All patients received a different treatment to each half of their body. First Levulan with red light PDT (to tumors on one side of the body), and then Levulan with blue light PDT (to tumors on the other side of the body), at six treatment visits.||||
33989460|NCT06429540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Randomized Controlled Clinical Trial|f|f|f|t
33989461|NCT03060863|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33989462|NCT02412384|||COHORT||PROSPECTIVE|||||||
33989463|NCT06008704|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||physio-pathological prospective open study||||
33686501|NCT02052856|||COHORT||RETROSPECTIVE|||||||
33686502|NCT01895361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686503|NCT04344288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686504|NCT01198171|||OTHER||RETROSPECTIVE|||||||
33686505|NCT03433027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686506|NCT01418560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686507|NCT00739271|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33686508|NCT02374047|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33686509|NCT02101814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686510|NCT04036643|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patient with rectal cancer treated by neoadjuvant chemo radiation therapy with clinical complete response||||
33686511|NCT03559426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants and treating clinicians will not be blinded because participants will start on different antipsychotic regimes, and those within the antipsychotic reduction intervention will follow an individualised reduction protocol.~Following trial extension the sample size was reduced from 402 to 218. The study is now powered to the primary outcome 'social functioning'.~Members of the research team conducting outcome assessments will be blinded to treatment allocation."|Open, parallel group, multi-centre randomised controlled trial.|f|f|f|t
33686512|NCT02408432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686513|NCT00827671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686514|NCT00142363|||CASE_CONTROL||PROSPECTIVE|||||||
33686515|NCT05688826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with normal genes and with functional variants of sucrase-isomaltase genes||||
33686516|NCT01329835|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33686517|NCT03784924|||COHORT||PROSPECTIVE|||||||
33686518|NCT05530876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686519|NCT01509690|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33686520|NCT03022162|||COHORT||PROSPECTIVE|||||||
33686521|NCT05829187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The test drug and the control drug are put into the capsule with the same weight, type and smell so that the patient cannot distinguish between the test drug and the control drug|the patient comes to the primary health care facility, is examined by a doctor, if malaria is suspected, a parasite examination is carried out in the laboratory. If positive for falciparum malaria and based on the results of the doctor's examination meet the criteria as research subjects, then the drug is given based on the random table that has been provided.|t|f|f|f
33686522|NCT04239430|||COHORT||PROSPECTIVE|||||||
33686523|NCT04173208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Number of enrolled mothers describes the number of mothers included for screening.|t|t|t|t
33686524|NCT06517108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686525|NCT05366673|RANDOMIZED|PARALLEL||OTHER||SINGLE||Massage|f|f|f|t
33686526|NCT01541202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686527|NCT03218683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is a 3 part, multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability,pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 alone or in combination with venetoclax in subjects with relapsed or refractory hematologic malignancies.||||
33989464|NCT03827707|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33686528|NCT04618887|||CASE_ONLY||RETROSPECTIVE|||||||
33686529|NCT05680259|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686530|NCT04482985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686531|NCT03374618|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686532|NCT00341601|||COHORT||PROSPECTIVE|||||||
33686533|NCT01407718|||COHORT||PROSPECTIVE|||||||
33686534|NCT02086279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989465|NCT06302114|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907390|NCT06111053|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Outcome assessor will not know the outcome of randomized assignment.|"A 2x2 factorial design comparing~* contingent incentives (CI) for smoking abstinence to noncontingent incentives (NI)~* the provision of ENDS (ENDS) to no provision of ENDS (No ENDS)~SWO (N=36) will be randomized to receive 4 weeks of monetary incentives contingent on their smoking abstinence (CI) or after completing breath samples only (NI). They will also be randomized to receive either a 6-week provision of ENDS with information communicating the comparative risk of ENDS use relative to smoking or information communicating the comparative risk of ENDS relative to smoking without ENDS provision. Conditions are as follows:~* C1: ENDS + CI~* C2: NoENDS + CI~* C3: ENDS + NI~* C4: NoENDS + NI"|f|f|f|t
33907391|NCT04470310|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A (glimepiride), Group B (alogliptin), and Group C (alogliptin-pioglitazone)||||
34082727|NCT05555498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Patients are randomised between the intervention group where VR glasses are added to standard care with conscious sedation (intervention group), and the control group where only standard care consisting of conscious sedation (opioids with benzodiazepines) is applied. When assigned to the intervention group, the patient will wear VR-glasses during the entire procedure of oocyte retrieval in IVF/ICSI treatment. Due to the nature of the intervention, double blind randomisation is not possible.|Randomised controlled trial||||
34082728|NCT00666237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082729|NCT01882569|||COHORT||PROSPECTIVE|||||||
34082730|NCT04405336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34082731|NCT06090838|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT with cross-over phase||||
34082732|NCT03248037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34082733|NCT05480059|||CASE_CONTROL||RETROSPECTIVE|||||||
34082734|NCT03074695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907392|NCT03207022|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34082735|NCT02394769|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34082736|NCT06472752|||COHORT||PROSPECTIVE|||||||
34082737|NCT04907266|||COHORT||PROSPECTIVE|||||||
34082738|NCT01968421|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082739|NCT03188575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082740|NCT04151394|||CASE_ONLY||CROSS_SECTIONAL|||||||
34082741|NCT04246463|||COHORT||PROSPECTIVE|||||||
34082742|NCT05413798|NA|SINGLE_GROUP||SCREENING||NONE||||||
34082743|NCT02715908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082744|NCT01537913|||CASE_ONLY||PROSPECTIVE|||||||
34082745|NCT00586560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082746|NCT05197439|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082747|NCT03850626|||COHORT||PROSPECTIVE|||||||
34082748|NCT01339065|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33686535|NCT03276520|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33686536|NCT00815724|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33686537|NCT05236595|||COHORT||PROSPECTIVE|||||||
33686538|NCT05441332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33686539|NCT00887744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686540|NCT02890628|||OTHER||CROSS_SECTIONAL|||||||
33907393|NCT04040712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33907394|NCT05406297|||COHORT||PROSPECTIVE|||||||
33907395|NCT01276067|RANDOMIZED|CROSSOVER||||NONE||||||
33907396|NCT06692179|NA|SINGLE_GROUP||OTHER||NONE||This Phase 1 pilot clinical trial that will evaluate the initial safety and feasibility of orally administered preparation of fecal microbiota (MTP-101P) in patients undergoing colon resection.||||
33907397|NCT04090931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding to treatment allocation was possible only for the investigator and data analyst because the clinicians could know the type of archwiers from their flexibility. All the trial documents were labeled with the study ID number, which was used for participant identification and data collection without unmasking the allocation group. This allowed the investigator to complete data collection and measurements blindly.|Orthodontic patients|t|t|t|t
33907398|NCT00895349|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33907399|NCT01896037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989466|NCT03772522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Thirty young people (aged 18 - 26 years) who have transitioned out of homelessness within the past three years will be offered scholarships to participate in a six-week intervention that focuses on building identity capital and providing career direction. The intervention will be designed and carried out by dk Leadership - an established, highly successful leadership and counseling centre in Toronto with a track record of significantly improving the life trajectories of teens and adults. Importantly, study participants will be incorporated into the centre's current programming, meaning the intervention will be held at a location not associated with homelessness. All of the participants will be invited to attend two focus groups, which will be conducted immediately post-intervention and at six months post-intervention. Each focus group will contain approximately 8 - 10 youth. Participants in the intervention and delayed intervention will be in separate focus groups.||||
33989467|NCT05088343|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||rosuvastatin alone and then in combination with hetrombopag||||
33989468|NCT03057210|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34082749|NCT00279084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082750|NCT00809796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082751|NCT04886414|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be block randomized to one of four possible home-based care strategies.||||
34082752|NCT03504917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082753|NCT01155570|||COHORT||PROSPECTIVE|||||||
34082754|NCT05030116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082755|NCT05983536|||COHORT||PROSPECTIVE|||||||
34082756|NCT05925439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Parallel assignment|t|f|f|t
34082757|NCT01506856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082758|NCT02814526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082759|NCT03994380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686541|NCT06430827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082760|NCT05878236|||COHORT||PROSPECTIVE|||||||
33686542|NCT00201578|||CASE_CONTROL||OTHER|||||||
33686543|NCT03856775|||COHORT||PROSPECTIVE|||||||
33686544|NCT06520579|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686545|NCT04046588|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686546|NCT03859830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686547|NCT01887093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686548|NCT04227054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686549|NCT06480162|||OTHER||PROSPECTIVE|||||||
33686550|NCT03088462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686551|NCT04221243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686552|NCT06332638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33775999|NCT04731103|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open label, non-placebo controlled. We propose a trial design involving an initial no-drug period of six weeks followed by three treatment arms each of six weeks, with a washout period of four weeks between treatment arms (considering documented drug half-lives).||||
33776000|NCT01396928|||COHORT||PROSPECTIVE|||||||
33776001|NCT03395938|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33776002|NCT05773040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776003|NCT01484509|||CASE_ONLY||CROSS_SECTIONAL|||||||
34082761|NCT05590338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In Part A the participants and investigators will be masked. In Part B there will be no masking.|"In Part A the participants will be randomly assigned in each arm to receive either active or placebo interventions.~In Part B the participants will be assigned to receive only active intervention."|t|f|t|f
33686553|NCT00972647|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33686554|NCT01283854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33686555|NCT06506305|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686556|NCT06157216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686557|NCT05996094|||COHORT||PROSPECTIVE|||||||
33686558|NCT03547193|||COHORT||PROSPECTIVE|||||||
33776004|NCT05321914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33776005|NCT01242943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686559|NCT02761837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|This is a pragmatic controlled trial. Participants randomized to the intervention group will know when they receive the intervention, which will consist of an automated contact by IVR call/text, or email.|Participants were randomized to either 1) usual care or 2) Interactive Voice Response (IVR) or 3) email. Those in the groups 2 or 3 will receive the intervention only if they smoke, underuse controller medication, or overuse rescue medication.||||
33686560|NCT03667300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686561|NCT01275339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686562|NCT06146998|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686563|NCT00812643|NA|SINGLE_GROUP||||NONE||||||
33686564|NCT02314143|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686565|NCT00321893|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33776006|NCT00580229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776007|NCT00338715|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33776008|NCT01210235|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33776009|NCT04227340|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776010|NCT01719146|||COHORT||PROSPECTIVE|||||||
33776011|NCT02626403|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776012|NCT04058821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776013|NCT06071975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839826|NCT05156151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839827|NCT03411759|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839828|NCT02246153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839829|NCT06331455|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-centre, phase 2 trial in patients with T2b-3N0-1M0 NSCLC evaluating the biologic efficacy of NORT-Durvalumab administered prior to surgery.||||
33839830|NCT05653063|||COHORT||PROSPECTIVE|||||||
33839831|NCT05454605|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33839832|NCT02157389|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33839833|NCT00338962|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33839834|NCT04247477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"We use a crossover sequential model, with all 3 strategies tested in both arms.~A reference strategy, based on the Express method (PEEP level adjusted to reach a plateau pressure of 28-30 cmH2O), is applied at the begining of the study and during a wash-out period (between the 2 periods of application of the 2 EIT-based strategies).~The 2 EIT-based strategies are applied in a randomized order."||||
33839835|NCT01236638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839836|NCT04143711|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33839837|NCT00245908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839838|NCT03507907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839839|NCT05223075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839840|NCT01076777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839841|NCT01445041|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839842|NCT05899803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33839843|NCT01902316|||CASE_ONLY||RETROSPECTIVE|||||||
33839844|NCT02894970|||CASE_CONTROL||PROSPECTIVE|||||||
33839845|NCT05798377|||CASE_ONLY||PROSPECTIVE|||||||
33839846|NCT02229851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686566|NCT03206957|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Interventional controlled cross-sectional study||||
33686567|NCT00521911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33686568|NCT06517797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|tablets of one of the actives and capsules of the other active matched to placebo tablets and capsules|Parallel assignment to putatively active treatment or placebo|t|t|t|f
33686569|NCT01562067|||COHORT||PROSPECTIVE|||||||
33686570|NCT00205400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989469|NCT06281340|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Randomization will be performed using a computerized randomization procedure by permuted blocks of 4 subjects in each recruitment center. The 6 possible sequence alternatives will be modified in each block. This task will be carried out by a person who is not involved in the study and who will not know the identity of the subjects.||t|t|f|f
33776014|NCT03949751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The institution has a standardized procedure for recruiting participants as participant studies are common. They will be preselected, based on the in- and exclusion criteria as mentioned above. If the match the inclusion criteria and do not meet the exclusion criteria, they will be informed, during the preoperative consultation by one of the study investigators, about the study, its nature, purpose, procedures involved, expected duration, participating investigators, potential risks and benefits and any potential discomfort the study could entail. The first 30 patients that can be selected through this procedure for the participation in the study will not get any therapy and therefore they will form the control group. The next 30 patients will get the therapy and so form the treatment group.|30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. 30 patients will be included in the control group. Those patients will not get the local therapy in the preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.|f|f|t|f
33776015|NCT05447247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776016|NCT03539016|||COHORT||PROSPECTIVE|||||||
33989470|NCT02278835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989471|NCT04342650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989472|NCT06597370|||OTHER||PROSPECTIVE|||||||
33989473|NCT00879918|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989474|NCT05350917|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, prospective, open-label clinical study||||
33989475|NCT00360763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989476|NCT02535611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989477|NCT04284319|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
33989478|NCT04180280|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Behavioral Counseling to Improve HIV Care||||
33989479|NCT02209194|||COHORT||PROSPECTIVE|||||||
33989480|NCT04774705|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33989481|NCT00448591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989482|NCT00122785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989483|NCT00023361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989484|NCT00659763|||COHORT||PROSPECTIVE|||||||
33989485|NCT04011917|||COHORT||PROSPECTIVE|||||||
33989486|NCT01507051|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33989487|NCT03290326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989488|NCT02856386|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33686571|NCT04467996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686572|NCT04638504|||COHORT||PROSPECTIVE|||||||
33686573|NCT05498701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33686574|NCT02856893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686575|NCT05244642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776017|NCT03390036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study subjects and the Outcomes Assessor are blinded to the study treatment.|In the 16-02 study, subjects were randomized in a 4:4:1 ratio into the Cingal, Monovisc (hyaluronic acid) or TH (triamcinolone hexacetonide) arm. The 17-02 study is a 39-week follow-up to the 16-02 study.|t|f|f|t
33776018|NCT06191731|NA|SINGLE_GROUP||OTHER||NONE||A single-center cohort descriptive study||||
33776019|NCT06354621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33776020|NCT05887804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The laboratory staff prepared the substances in identical syringes without informing the researchers according to randomization. Data processing was carried out by statisticians and clinicians other than researchers.|Patients were screened initially by measuring the length and thickness of the keloids using a ruler. Patients who met the study inclusion criteria were randomly divided into 3 groups. Each patient in the groups was given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure. Group 1 was given UC-MSC 2 million cells/mL/cm3, group 2 was given UC-CM 1 mL/cm3, and group 3 was given TA 40 mg/mL/cm3.|t|t|t|t
33776021|NCT05212493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776022|NCT01510613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776023|NCT04131868|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33776024|NCT00948012|||COHORT||CROSS_SECTIONAL|||||||
33776025|NCT02451813|NA|SINGLE_GROUP||||NONE||||||
33776026|NCT00086086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907400|NCT03596177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised, Double-Blind, Placebo-Controlled|t|t|t|t
33907401|NCT06048055|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33989489|NCT01107093|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33989490|NCT01705574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989491|NCT03354286|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33989492|NCT04757883|||COHORT||PROSPECTIVE|||||||
33989493|NCT05209347|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded to the different CDO designs and will only be introduced to each device as CDO-A or CDO-B.|All participants will be cast and fit with two CDOs. Each CDO will be labeled as CDO-A or CDO-B. Participants will be randomly assigned to one of two CDO testing sequences (AB, BA) to prevent testing order from influencing study results.|t|f|f|f
33989494|NCT00520988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686576|NCT05463627|||COHORT||RETROSPECTIVE|||||||
33686577|NCT04426903|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants are assigned to a group following different interventions||||
33686578|NCT04949919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686579|NCT03631797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686580|NCT02974101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686581|NCT01252303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776027|NCT01857323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776028|NCT05748782|||COHORT||PROSPECTIVE|||||||
33776029|NCT01553786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776030|NCT01628510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776031|NCT06386146|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33776032|NCT01531140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776033|NCT00047710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776034|NCT00959803|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776035|NCT00726336|NON_RANDOMIZED|||TREATMENT||||||||
33776036|NCT05107778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776037|NCT00027768|RANDOMIZED|||TREATMENT||||||||
33776038|NCT02929342|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33776039|NCT01041508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776040|NCT04420780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This is a triple-blind randomized, controlled, parallel-group clinical trial. Two groups will be compared: subjects who will receive a 100% xylitol chewing gum, and those who will receive a 22% xylitol gum.|t|f|t|t
33776041|NCT01117142|||COHORT||PROSPECTIVE|||||||
33776042|NCT03577145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Acute human bioavailability studies with a cross-over design. Subjects will be given a soup or drink in one of three combinations~1. Tomato onion and lovage soup~2. Inulin~3. Mixture of tomato onion and lovage soup with inulin"||||
33776043|NCT02444143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907402|NCT00189007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907403|NCT03537768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33907404|NCT06121947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907405|NCT05325814|||COHORT||PROSPECTIVE|||||||
33907406|NCT04301882|||COHORT||PROSPECTIVE|||||||
33907407|NCT03362346|||COHORT||RETROSPECTIVE|||||||
33907408|NCT04314167|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907409|NCT02310971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907410|NCT04946136|NA|SINGLE_GROUP||TREATMENT||NONE|This is a pilot single-arm study examining the effect of an intervention on biomechanical and symptomatic outcomes. There is no control group, therefore no masking employed.|||||
33686582|NCT04537221|||CASE_CONTROL||PROSPECTIVE|||||||
33907411|NCT00648843|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33907412|NCT01893840|NA|SINGLE_GROUP||||NONE||||||
33907413|NCT04845698|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A cluster randomized trial was conducted in two surgical intensive care units (ICUs) of the hospital. For each two-week period of the trial, participating ICUs (cluster) were assigned to multi-disciplinary rounds with i-Dashboard (intervention) or without i-Dashboard (control). In other words, the two ICUs were randomly assigned to multi-disciplinary rounds with i-Dashboard during the first two weeks, without i-Dashboard during the second two weeks, and with i-Dashboard during the third two weeks or vice versa.||||
33686583|NCT03363425|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686584|NCT04396054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776044|NCT04019561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776045|NCT03334760|||COHORT||PROSPECTIVE|||||||
33776046|NCT05323214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34082762|NCT00997334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082763|NCT01542827|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34082764|NCT00776880|||CASE_CONTROL||PROSPECTIVE|||||||
34082765|NCT03780582|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34082766|NCT03836586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be randomized to either a single session cognitive-behavioral intervention to reduce pain catastrophizing or a pain education control group|t|f|f|f
34082767|NCT04159714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082768|NCT04668677|||COHORT||PROSPECTIVE|||||||
34082769|NCT04929015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082770|NCT03534024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34082771|NCT04104971|||COHORT||PROSPECTIVE|||||||
34082772|NCT04477135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686585|NCT04150406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082773|NCT01570335|||COHORT||CROSS_SECTIONAL|||||||
34082774|NCT00000948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082775|NCT00648180|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34082776|NCT00785083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082777|NCT06303817|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34082778|NCT00889304|||COHORT||PROSPECTIVE|||||||
34082779|NCT01959100|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686586|NCT00829283|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33686587|NCT02951676|||CASE_CONTROL||PROSPECTIVE|||||||
33686588|NCT06484205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a Randomized controlled clinical trial with four evaluation times (T0 pre- treatment; T1 post treatment; T2 3 months after T1 and T2 6 months after T1; aimed at evaluating the effectiveness of the World Health Organization QualityRights training compared to a control intervention (another online training program) in improving caregivers' human rights knowledge and attitudes towards people with psychosocial disabilities as rights holders.|f|f|t|f
33686589|NCT02789579|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33686590|NCT01744145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686591|NCT04144491|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907414|NCT04712578|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|All investigators will be blinded to the caffeinated vs. non-caffeinated supplement (i.e., these were provided by the manufacturer in a blinded manner). Select study investigators who will not be involved in assessing outcomes will formulate the placebo supplement and be responsible for dispensing all supplements to participants. Supplements will be provided to participants in opaque containers to maintain blinding. All investigators involved in assessing outcomes will also remain blinded and will not be involved in handling or dispensing the supplements.|This study is a randomized, double-blind, placebo-controlled crossover trial.|t|f|t|t
33907415|NCT04363086|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907416|NCT00833235|||CASE_CONTROL||PROSPECTIVE|||||||
33907417|NCT05232942|||COHORT||PROSPECTIVE|||||||
33907418|NCT02846376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to Groups A, and B in a 1:1 fashion. If the safety endpoint is met for each of these groups, enrollment to Group C will open. Each patient will be monitored for toxicities for at least 28 days before the next patient is added to the same cohort.||||
33907419|NCT05657288|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Interventional prospective study||||
33907420|NCT04072354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|randomized, double-blind, parallel-group, placebo controlled, fixed-dose multicenter study|t|t|t|t
33907421|NCT04200170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The current study aims to recruit 45 patients with at least mild depressive and/or anxiety symptoms who will be consented and enrolled in a five-week study.The consented participants will be randomized to one of the two study arms: (1) the intervention arm or (2) the waitlist control arm in a 2:1 ratio.~During the course of the study, the participants in the intervention arm will use the mental health application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy. The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm."||||
33907422|NCT03238092|RANDOMIZED|PARALLEL||TREATMENT||NONE||As a pre-treatment for in vitro fertilization, one arm will receive transdermic testosterone , one arm will receive oral estradiol and a third arm will be the control group, without pre-treatment||||
33907423|NCT03476018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33907424|NCT06692439|||COHORT||PROSPECTIVE|||||||
33907425|NCT05628467|||COHORT||RETROSPECTIVE|||||||
33907426|NCT04249141|||COHORT||OTHER|||||||
33907427|NCT06098261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907428|NCT05984381|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, add-on, active-controlled, open-label, parallel-design clinical trial||||
33907429|NCT05454176|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, non-blinded, phase 4 clinical trial||||
33907430|NCT05889130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082780|NCT06095908|||CASE_CONTROL||PROSPECTIVE|||||||
34082781|NCT02068937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082782|NCT02879318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082783|NCT01578772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082784|NCT03651141|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34082785|NCT03904654|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the MBCT intervention, however they will be separated in 2 distinct groups over time, due to MBCT protocol limitations.||||
34082786|NCT00851487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686592|NCT03750370|||OTHER||OTHER|||||||
33686593|NCT03336710|||COHORT||PROSPECTIVE|||||||
33686594|NCT01190787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686595|NCT05160987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind|The participants in remimazolam group receive intravenous remimazolam. The participants in midazolam group receive midazolam.|t|f|f|f
33686596|NCT00998764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686597|NCT01946906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686598|NCT05204407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, parallel group, randomized clinical trial.|t|t|t|t
33686599|NCT05457894|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33989495|NCT05636319|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Phase1/2: 30 subjects will be randomized in a ratio of 2:1 to receive ABO1020 and placebo, intramuscularly injected in the lateral deltoid region of the upper arm according to the two doses immunization schedule on Day 0 and Day 28.~Phase3: 15000 subjects will be randomized in a ratio of 1:1 to receive ABO1020 and placebo, intramuscularly injected in the lateral deltoid region of the upper arm according to the two doses immunization schedule on Day 0 and Day 28."|t|f|t|t
33989496|NCT05260697|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33989497|NCT06562166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989498|NCT01388894|||CASE_CROSSOVER||PROSPECTIVE|||||||
33989499|NCT04400890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989500|NCT03961230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686600|NCT01314846|||CASE_CONTROL||RETROSPECTIVE|||||||
33686601|NCT03269552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686602|NCT01736657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686603|NCT01966692|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33686604|NCT06163820|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is a phase I/II, single arm, unblinded, multi-centre dose de-escalation trial to evaluate the safety and efficacy of the combination of bevacizumab, with ipilimumab plus nivolumab, and hypofractionated stereotactic radiotherapy (hSRT).||||
33686605|NCT02920853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686606|NCT03195842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33686607|NCT03520244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessors are masked to participant group.|Participants will be assigned to one of two groups in parallel for the duration of the study. One group is interventional (exercise + education sessions). This group will be evaluated in parallel against a wait-list control group.|f|f|f|t
33686608|NCT00204945|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33989501|NCT06373185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomisation using a closed envelope method based on computer-generated random numbers was to assign patients to two equal groups. Group 1 received midline US-guided sacral erector spinae plane block and Group 2 received caudal block. The experienced anesthetist who opened the envelope performed the block according to the group code and patients were followed postoperatively by an anesthetist blinded to which block was performed. Patients were also blinded as to which block was performed.|Randomized controlled double blind study|t|f|f|t
33989502|NCT02344732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989503|NCT06626776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989504|NCT00836667|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33686609|NCT01235871|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33686610|NCT05587465|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, prospective, multicenter study||||
33686611|NCT05262231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The women in the experimental and control groups were not informed about the group they belonged to. However, the researcher had information about the groups in which women were included. In this way, unilateral blinding was achieved in the study.||t|f|f|f
33686612|NCT00287170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686613|NCT03729362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686614|NCT05666115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33686615|NCT04080271|||OTHER||PROSPECTIVE|||||||
33686616|NCT03774095|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Cross-over study of 3 interventions; 1) no oil intake, 2)6g hydrolyzed pine nut oil and 3) combined intake of 3g hydrolyzed pine nut oil and 3g olive oil 30 minutes prior to an 6-hours oral glucose tolerance test (75g glucose).|t|f|f|f
33776047|NCT01160991|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33776048|NCT02500511|||CASE_CONTROL||RETROSPECTIVE|||||||
33776049|NCT02431728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776050|NCT03496025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776051|NCT00928460|||||PROSPECTIVE|||||||
33776052|NCT00311428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33776053|NCT01345643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776054|NCT03412981|||COHORT||PROSPECTIVE|||||||
33776055|NCT00432575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776056|NCT01043536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776057|NCT04791228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776058|NCT03864133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776059|NCT01424163|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33776060|NCT00126685|NON_RANDOMIZED|||TREATMENT||NONE||||||
33776061|NCT06093191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both investigators and participants were blinded to the treatment assignment throughout the study. To maintain this blinding, placebos were used, which were made indistinguishable in appearance from the inhaled tobramycin solution and oral ciprofloxacin. The taste of the inhaled tobramycin solution was not disclosed to the patients, and neither the patients nor most clinicians had prior knowledge of its taste. This blinding approach ensures that both participants and investigators remain unaware of the specific treatment each patient is receiving, thereby reducing potential biases in the study's results|Patients will be randomized into one of the four groups. No cross-over of the study group will be made|t|t|t|t
33776062|NCT01233635|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33776063|NCT01474408|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33776064|NCT03606096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither the expectant mothers themselves nor members of the clinical trial team assessing the safety or laboratory-based endpoints (immunogenicity and exploratory immunology) will be aware which of these groups the expectant mother has been randomized into.|Eligible pregnant women will be randomized in parallel into one of four groups: two groups will receive maternal Boostrix ® Polio (GSK) the other two groups Tetanus toxoid as per EPI schedule.|t|t|t|t
33776065|NCT00168051|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33776066|NCT03826433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839847|NCT05986045|||CASE_CONTROL||PROSPECTIVE|||||||
33839848|NCT05847049|||CASE_ONLY||RETROSPECTIVE|||||||
33907431|NCT06405490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907432|NCT06156384|||COHORT||PROSPECTIVE|||||||
33907433|NCT05643560|||COHORT||PROSPECTIVE|||||||
33907434|NCT00428987|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907435|NCT03664609|||OTHER||RETROSPECTIVE|||||||
33907436|NCT05579314|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33907437|NCT05617599|||COHORT||PROSPECTIVE|||||||
33907438|NCT06521229|||CASE_CONTROL||OTHER|||||||
33776067|NCT03867474|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Enrollment, Randomization and Blinding|Randomized Control Trial|f|f|f|t
33907439|NCT02369731|||COHORT||PROSPECTIVE|||||||
33907440|NCT04078152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|All involved know the identity of the intervention assignment.|||||
33907441|NCT05884073|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907442|NCT06525649|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The subject, investigator, staff, and EEG adjudicator will be blinded to the treatment assignment. All sponsor personnel will be unblinded except the sponsor's study monitor who will remain blinded.||t|t|t|t
33907443|NCT03897075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907444|NCT05998824|NA|SINGLE_GROUP||TREATMENT||NONE||measurement by survey before and after intervention||||
33907445|NCT06553625|||COHORT||PROSPECTIVE|||||||
33907446|NCT06054893|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907447|NCT05846334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33907448|NCT05777993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907449|NCT06077864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907450|NCT02710734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776068|NCT04351750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907451|NCT00475761|||COHORT||PROSPECTIVE|||||||
33907452|NCT06115252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907453|NCT05168423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose escalation design||||
33907454|NCT06636656|NA|SINGLE_GROUP||TREATMENT||NONE||The study consists of Part A and Part B.||||
33907455|NCT05216835|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907456|NCT05415215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907457|NCT05485779|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33907458|NCT05345171|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33907459|NCT04417062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907460|NCT04467411|||CASE_CONTROL||PROSPECTIVE|||||||
33907461|NCT06643455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907462|NCT04610788|||COHORT||PROSPECTIVE|||||||
33907463|NCT03437486|||FAMILY_BASED||PROSPECTIVE|||||||
33907464|NCT05500508|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907465|NCT05325632|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907466|NCT05849259|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A live open-pilot trial will be conducted of the HBPC Dementia Care Quality at Home intervention in two HBPC practices.||||
33907467|NCT06644560|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907468|NCT04544436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907469|NCT01434368|||COHORT||PROSPECTIVE|||||||
33907470|NCT06383403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907471|NCT06462404|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33907472|NCT06253897|||COHORT||PROSPECTIVE|||||||
33907473|NCT06176352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907474|NCT06195241|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single-arm, crossover study, in which each patient is his/her own historical control using a 2:1 conversion ratio of Daxxify to Botox units.||||
33907475|NCT05543915|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33907476|NCT04677569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907477|NCT05774756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907478|NCT06339177|||COHORT||PROSPECTIVE|||||||
33907479|NCT06533540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907480|NCT04352166|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm, randomized (1:1 allotment), open-label trial||||
33907481|NCT04928846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907482|NCT05649722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907483|NCT06045507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33907484|NCT02789228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907485|NCT05110157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907486|NCT03569176|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33907487|NCT00004850|||COHORT||PROSPECTIVE|||||||
33907488|NCT04756063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907489|NCT00001168|||COHORT||PROSPECTIVE|||||||
33907490|NCT05355311|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label study designed to assess the effects of L-carnitine supplementation on responses to in vivo alcohol cue exposure in the human laboratory setting.||||
33907491|NCT06640933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907492|NCT05046314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907493|NCT05658510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind placebo controlled.|"Part 1: Patients randomized to receive 60 mcg of BXCL501 or a matching placebo.~Part 2: Patients randomized to receive 120 mcg of BXCL501 or a matching placebo."|t|t|t|t
33907494|NCT05087875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907495|NCT05270668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907496|NCT03150914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Tablets are over-encapsulated. Both participant and care givers are blinded to treatment assignment. Dose adjustments for out of range sirolimus levels are made by a medical monitor at the Data Center. Sham dose adjustments are made in the placebo group|Intention to treat, randomized, placebo controlled, double blind|t|t|t|f
33907497|NCT06130540|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 patients per cohort (Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PRM) are planned to be enrolled||||
33989505|NCT05914857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989506|NCT02013154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989507|NCT05326386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33989508|NCT04949334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33989509|NCT03956862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989510|NCT00812786|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989511|NCT00903240|||COHORT||PROSPECTIVE|||||||
33989512|NCT05971420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33989513|NCT02451267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33989514|NCT02606708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989515|NCT04887480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989516|NCT03798262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||single-blinded, randomised controlled, cross-over study|t|f|f|f
33989517|NCT03506386|||COHORT||RETROSPECTIVE|||||||
33989518|NCT05992025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician responsible for the outcome analysis will be blinded as to what intervention each group has had.|Prospective, randomized controlled trial, parallel-group design|f|f|f|t
33989519|NCT03836560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor did not know which arm was interventional/control during the data analysis process.|One year, 2 arm, parallel, randomised controlled trial|f|f|f|t
33989520|NCT00960297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989521|NCT05251155|||CASE_ONLY||CROSS_SECTIONAL|||||||
33989522|NCT01593007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989523|NCT05111223|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33989524|NCT00699296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907498|NCT06191315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907499|NCT03172624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase II study evaluating the efficacy of nivolumab in combination with ipilimumab in patients with recurrent and/or metastatic (R/M) salivary gland cancers (SGCs). Patients will be enrolled to two cohorts: Cohort 1, patients with R/M adenoid cystic carcinoma (ACC group), and Cohort 2: patients with R/M SGC of any histology, except ACC (non-ACC group)."||||
33907500|NCT06500533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907501|NCT05943626|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Group allocation will be blinded to research staff and participants until the conclusion of the baseline segment.||f|f|t|t
33907502|NCT06472973|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33989525|NCT05107089|||OTHER||PROSPECTIVE|||||||
33989526|NCT00239382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989527|NCT01042665|||CASE_CROSSOVER||PROSPECTIVE|||||||
33989528|NCT03098394|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Participants, investigators, and care providers will be masked to the experimental or control arm prior to enrollment in the study. Once the participant has been enrolled in the study, they will be randomized to either the control arm or the experimental arm. Once randomization has occurred, participants, care providers, and the investigators will know which group the participants are in.|This is a prospective, non-blinded, randomized clinical control trial|t|t|t|f
33989529|NCT00952250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989530|NCT02200224|RANDOMIZED|PARALLEL||||NONE||||||
33989531|NCT03217539|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33989532|NCT00833937|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989533|NCT02714062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989534|NCT04733755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686617|NCT02785289|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33686618|NCT00981773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686619|NCT03063671|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686620|NCT03695874|||OTHER||PROSPECTIVE|||||||
33686621|NCT05847712|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Data will be blinded prior to analysis||f|f|f|t
33686622|NCT05089201|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686623|NCT05475782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|t|f|f
33686624|NCT05828771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686625|NCT04903379|NA|SINGLE_GROUP||OTHER||NONE||All webinar registrants will be invited to participate||||
33686626|NCT02496507|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686627|NCT03433729|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686628|NCT04798079|||COHORT||PROSPECTIVE|||||||
33776069|NCT00980109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33989535|NCT00840632|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989536|NCT03380845|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Randomized split-face clinical trial|t|f|f|t
33686629|NCT03513523|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33686630|NCT04157556|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There are 2 groups in the study: Athletes and sedentary people.They will apply the same acute exercise protocol (The Yo-Yo Intermittent Recovery Test Level 1). A blood test will conduct before and after the acute exercise protocol.||||
33686631|NCT03518671|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33776070|NCT06228664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776071|NCT02809274|||COHORT||PROSPECTIVE|||||||
33776072|NCT00588003|NON_RANDOMIZED|PARALLEL||||NONE||||||
33989537|NCT00834067|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989538|NCT03167515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989539|NCT03447353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33776073|NCT03728153|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II study of one dose||||
33776074|NCT06256068|||CASE_CONTROL||PROSPECTIVE|||||||
33776075|NCT01935960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776076|NCT00333788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776077|NCT00318825|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33776078|NCT04006366|NA|SINGLE_GROUP||TREATMENT||NONE||Non-controlled, single arm intervention study||||
33776079|NCT03085121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33776080|NCT00001955||||TREATMENT||||||||
33776081|NCT02561715|||CASE_ONLY||PROSPECTIVE|||||||
33776082|NCT03658811|NA|SINGLE_GROUP||TREATMENT||NONE||Patient were enrolled in the study if they had visible signs of upper lid meibomian gland dysfunction and persistent dry eye symptoms and pain despite treatment with conservative dry eye therapies.||||
33776083|NCT00187317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33776084|NCT04961216|RANDOMIZED|PARALLEL||OTHER||SINGLE||Individually randomised, two-arm, parallel-group randomised controlled trial|t|f|f|f
33776085|NCT01114620|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776086|NCT00339625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839849|NCT02102438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839850|NCT00477490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839851|NCT00002653|RANDOMIZED|||TREATMENT||||||||
33839852|NCT02448329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839853|NCT06306469|NA|SINGLE_GROUP||OTHER||NONE||||||
33839854|NCT03935256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839855|NCT06075186|||OTHER||CROSS_SECTIONAL|||||||
33839856|NCT01734733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989540|NCT06554717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989541|NCT00793832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989542|NCT06062277|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after intervention paired cohort study||||
33989543|NCT04962594|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Unique coding of the study products|Double-blind, randomized, controlled trial plus a non-randomized breastfed reference group|t|t|t|t
33839857|NCT02182427|||CASE_ONLY||PROSPECTIVE|||||||
33839858|NCT01626144|||CASE_ONLY||PROSPECTIVE|||||||
33839859|NCT00981877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33839860|NCT01254747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839861|NCT01883102|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33839862|NCT03129802|||COHORT||PROSPECTIVE|||||||
33776087|NCT05075655|NA|SEQUENTIAL||DIAGNOSTIC||NONE|pathologist do not know the technique of sampling used when analysing slides.|||||
33776088|NCT00157742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776089|NCT04496414|||COHORT||OTHER|||||||
33776090|NCT03709875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multi-center, prospective, parallel design, single-blind trial|f|f|t|t
33776091|NCT05251064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776092|NCT05133479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33776093|NCT00039182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776094|NCT01236027|||CASE_ONLY||CROSS_SECTIONAL|||||||
33776095|NCT03565770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776096|NCT02327910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776097|NCT00962663|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33776098|NCT01743274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776099|NCT05604287|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33776100|NCT00113698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776101|NCT04802642|||OTHER||CROSS_SECTIONAL|||||||
33776102|NCT02927821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776103|NCT05978648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776104|NCT01958177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776105|NCT01757080|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33776106|NCT05456815|NA|SINGLE_GROUP||PREVENTION||NONE|"Test products will be provided by the care provider/dietician. All others will be blinded during the trial."|Investigational products will be provided in a standardized environment.||||
33776107|NCT02767700|||COHORT||PROSPECTIVE|||||||
33776108|NCT06310590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776109|NCT04717063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcome Assessor)|Each subject will be randomized to receive one of the two possible study products|t|f|t|t
33776110|NCT05656638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776111|NCT02344303|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33776112|NCT02996708|||COHORT||RETROSPECTIVE|||||||
33776113|NCT01439711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776114|NCT00555204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776115|NCT01907412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33776116|NCT06140160|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776117|NCT02529865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776118|NCT03706911|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33776119|NCT05851222|||OTHER||RETROSPECTIVE|||||||
33776120|NCT01818700|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33776121|NCT03990077|NA|SEQUENTIAL||TREATMENT||NONE||If no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.||||
33776122|NCT05878925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|To blind the study team and the medical team, identically looking pens will be provided with and without vanilla or strawberry aroma.||t|t|t|t
33776123|NCT06307483|||OTHER||CROSS_SECTIONAL|||||||
33776124|NCT05263453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776125|NCT01976611|||COHORT||PROSPECTIVE|||||||
33776126|NCT03373474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776127|NCT00109928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776128|NCT00252928|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33776129|NCT03844516|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|"Patients and staff performing the peak oxygen uptake test (pVO2) will be blinded to device regulation. Blinding will be ensured by recruiting a secondary doctor or other staff to regulate pace-settings in relation to the paced pVO2 test while performing sham regulations (or just read pace-settings) in relation to the non-paced pVO2 test.~Thus, both patients and investigator are blinded."||t|f|t|f
33776130|NCT01406561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776131|NCT06139484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776132|NCT04025190|||COHORT||PROSPECTIVE|||||||
33776133|NCT01382381|||CASE_CONTROL||PROSPECTIVE|||||||
33776134|NCT00386308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776135|NCT01298180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989544|NCT05176600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776136|NCT01937780|||COHORT||PROSPECTIVE|||||||
33776137|NCT02256774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776138|NCT03268460|||CASE_ONLY||CROSS_SECTIONAL|||||||
33776139|NCT01859156|||CASE_ONLY||PROSPECTIVE|||||||
33776140|NCT04592536|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776141|NCT00688506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776142|NCT02688920|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33776143|NCT02593032|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33776144|NCT04636697|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind||t|t|t|t
33776145|NCT01831752|||CASE_ONLY||RETROSPECTIVE|||||||
33776146|NCT02382510|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33776147|NCT00548275|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34082787|NCT04539990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776148|NCT01801384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989545|NCT04030091|RANDOMIZED|PARALLEL||TREATMENT||NONE||1 arm of 2 hours pulsatile insulin infusion treatment vs. a second arm of 3 hours pulsatile insulin infusion treatment.||||
33989546|NCT05463822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989547|NCT02874677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33989548|NCT05664919|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989549|NCT06081569|||COHORT||PROSPECTIVE|||||||
33989550|NCT05748535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Individuals were divided into three groups as unilateral left, unilateral right and bilateral ear stimulations.|t|f|f|f
33989551|NCT01250912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989552|NCT04381130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989553|NCT00120198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989554|NCT03523039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989555|NCT04226027|RANDOMIZED|PARALLEL||OTHER||NONE|Because of the nature of the intervention (smartphone app), masking is not possible.|Two-arm RCT with 1:1 randomization at participant level, with stratified randomization to balance by clinical site, sex, and language, evaluate the efficacy of the T2.coach intervention||||
33989556|NCT00446563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989557|NCT02564965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082788|NCT01411852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34082789|NCT00454298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082790|NCT05975489|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34082791|NCT05164978|NA|SINGLE_GROUP||TREATMENT||NONE||All patients with EBV- HLH receive DEP combine with PD-1 antibody as an treatment.||||
34082792|NCT05095519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082793|NCT03311555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082794|NCT03599570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A cluster RCT study design will test the impact of performance feedback to reduce missed opportunities (MOs) and raise HPV vaccine rates||||
34082795|NCT01787552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082796|NCT04499703|||OTHER||PROSPECTIVE|||||||
34082797|NCT03908346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082798|NCT03707496|||COHORT||PROSPECTIVE|||||||
34082799|NCT03805334|NA|SINGLE_GROUP||TREATMENT||NONE||This study will use a non-concurrent multiple baseline design (MBD) where subjects will serve as their own control.||||
34082800|NCT00337883||||TREATMENT||||||||
34082801|NCT03830021|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34082802|NCT01407029|||OTHER||PROSPECTIVE|||||||
33776149|NCT06201013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776150|NCT03615625|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The randomization list was generated by an epidemiologist using a computer software. This epidemiologist did not participate in the recruitment or assignment to the experimental sessions. Participants and the research team were blinded to the randomization list until the moment of assignment.|A randomized controlled clinical trial with crossover design was performed in order to evaluate the effect of a power training session on office and 24h ambulatory blood pressure in older adults with hypertension.|t|f|t|t
33776151|NCT00577720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776152|NCT03658629|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33776153|NCT01804673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776154|NCT04783324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study consists of two groups: Experimental group and control group.|f|f|f|t
33776155|NCT04572490|||COHORT||PROSPECTIVE|||||||
33989558|NCT02523963|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989559|NCT06626529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989560|NCT04664556|||COHORT||PROSPECTIVE|||||||
34082803|NCT00338117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34082804|NCT02785939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082805|NCT05281406|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II prospective non-randomized biomarker-enriched single arm trial||||
34082806|NCT06551038|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082807|NCT01420159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34082808|NCT05374096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34082809|NCT02047916|||COHORT||PROSPECTIVE|||||||
34082810|NCT01132508|||CASE_ONLY||PROSPECTIVE|||||||
34082811|NCT00580476|||CASE_ONLY||PROSPECTIVE|||||||
34082812|NCT02391337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082813|NCT00060411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082814|NCT03292302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082815|NCT05176886|||CASE_ONLY||PROSPECTIVE|||||||
34082816|NCT03768193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082817|NCT00744939|||COHORT||PROSPECTIVE|||||||
33989561|NCT04528784|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm feasibility study||||
33989562|NCT03199872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989563|NCT03017885|||COHORT||OTHER|||||||
33989564|NCT00716690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989565|NCT03313323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989566|NCT06238791|||COHORT||CROSS_SECTIONAL|||||||
33989567|NCT04306133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989568|NCT03247933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Coded databases||f|f|f|t
34082818|NCT04145063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082819|NCT01990326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082820|NCT05067478|||COHORT||PROSPECTIVE|||||||
33686632|NCT03355664|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label randomised trial||||
33686633|NCT01572571|||CASE_ONLY||PROSPECTIVE|||||||
33686634|NCT04545203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33686635|NCT01680510|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Alga vs. placebo|t|t|t|t
33686636|NCT03239691|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33686637|NCT04211233|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686638|NCT00736177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686639|NCT04985643|||COHORT||PROSPECTIVE|||||||
33686640|NCT01768247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686641|NCT05506137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686642|NCT05321056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686643|NCT02094404|||||PROSPECTIVE|||||||
33686644|NCT00249288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907503|NCT06091332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A double-blind design means that throughout the entire study, neither the participating patients nor the investigators are aware of which treatment group the patients are assigned to, in order to minimize potential biases. The blinding level is double-blind, which means that both the patients in the treatment group and those in the control group, as well as the investigators, are unaware of the treatment the patients receive, ensuring objectivity and reliability of the study results.|According to the study protocol, patients were randomly divided into a normal-dose group, low-dose group, and control group at a ratio of 1:1:1. Additionally, to minimize potential bias, this study employed a double-blind approach.|t|t|t|t
33907504|NCT05626114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907505|NCT05988749|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients will be randomized in a 1:2 fashion to usual care versus usual care plus the American Heart Association's Digital Solution by dice roll.||||
33989569|NCT03793972|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomised with weekends servings as clusters.||||
33989570|NCT00096447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989571|NCT03253003|NA|SINGLE_GROUP||OTHER||NONE||A line extension of the Phonak Audéo B hearing aid product family will be fitted to the participants individual hearing loss.||||
33989572|NCT03402958|||CASE_ONLY||RETROSPECTIVE|||||||
33989573|NCT04549272|||CASE_ONLY||CROSS_SECTIONAL|||||||
33686645|NCT03442400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single group of patients with severe aortic stenosis and intermediate coronary stenoses will undergo coronary physiology assessment with iFR/FFR before and after transcatheter aortic valve replacement.||||
33686646|NCT01380938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33686647|NCT01261468|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33907506|NCT00243087||||TREATMENT||NONE||||||
33907507|NCT05556616|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907508|NCT05925803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind period- masking -everyone will be masked to the treatment allocation during the first 52 weeks Open label period - no masking- beginning at week 52, all participants will receive Anifrolumab for 52 weeks. During the open label period, there is no masking of study treatment, however, the treatment that participants received in the double blind period (first 52 weeks) will remain masked until the end of the study.|Subjects will be randomized in a 1:1 ratio to either anifrolumab or matching placebo for 52 weeks (double blind treatment period). At Week 52, all patients will be treated with Anifrolumab for 52 weeks (open label treatment period).|t|t|t|t
33907509|NCT05139069|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907510|NCT04903314|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort I will enroll 6 subjects. Upon review of Cohort I's PK analysis, a dose will be determined for Cohort IIa. Upon review of Cohot IIa's PK analysis, a dose will be determined for Cohort 11b and Cohort III.||||
33989574|NCT04311320|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34082821|NCT01965327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082822|NCT00156260|||||PROSPECTIVE|||||||
33686648|NCT00539097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686649|NCT03225157|||COHORT||PROSPECTIVE|||||||
33686650|NCT00025727||PARALLEL||TREATMENT||||||||
33686651|NCT02048579|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33907511|NCT00001248|||CASE_CONTROL||PROSPECTIVE|||||||
33907512|NCT04112316|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participant, Investigators and Care Providers are blinded to LT3 vs. Placebo and T3 results. There will be 1 unblinded physician in the study.||t|t|t|f
34082823|NCT02485665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082824|NCT06120725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of ticagrelor and aspirin or clopidogrel and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 580 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 580. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included clopidogrel. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|The investigators will conduct our single-blinded randomized controlled trial, which will contain 2 arms; the ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day). The Clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day).|f|f|t|t
34082825|NCT04584632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686652|NCT06024733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082826|NCT00069264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082827|NCT02091232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082828|NCT05453136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082829|NCT00962286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082830|NCT04606758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082831|NCT02453464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082832|NCT00464022|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34082833|NCT02903446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082834|NCT03995563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082835|NCT05402059|||COHORT||PROSPECTIVE|||||||
33686653|NCT04515862|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"The study was applied to mothers who gave birth at a time when they felt well after being taken to their postnatal room. First, the mothers who met the inclusion criteria were informed, after obtaining written consent, the mothers were randomized using a random number table and then assigned to the intervention and control groups.~All mothers were asked to fill in the breastfeeding self-efficacy scale form together with the questionnaire before the intervention. Later, a training program was conducted in the hospital with the mothers in the intervention group.~In the data collection phase of the study, 1180 women were evaluated in terms of sampling criteria. 1152 women (who did not meet the criteria or refused to participate) were excluded from the study. 90 randomized women were divided into two groups as intervention and control group. During the follow-up, 5 women in the intervention group and 5 women in the control group were excluded from the study."|t|f|f|f
33686654|NCT00872625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686655|NCT03607643|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participant, care provider, investigator, and outcomes assessor will be blinded to standard of care (SOC) alone vs treatment arm|Study length for randomized patients in the treatment group(s) will be 180 days. For those subjects randomized into the control group(s), after 90 days of the control group study treatment, will be given the choice to rollover into the treatment group. Crossover is also permitted if there is progression of disease before 90 days.|t|t|t|t
33686656|NCT01646294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33686657|NCT02607566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686658|NCT01987401|||COHORT||CROSS_SECTIONAL|||||||
33686659|NCT03554265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||mTBI patients will be in the growth hormone arm PASC patients will be in the growth hormone arm Control subjects will be in the control arm||||
33686660|NCT05200494|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors will be masked since he/she will be not present at the end of the procedure, when the intervention (Recruiting Maneuver) will be applied or not.|Patients will be randomized to receive or not a Recruiting Maneuver (RM) at the end of the Flexible Bronchoscopy. RM will be performed by the application to the airways of 30 cmH2O positive pressure for 30 seconds.|f|f|f|t
33686661|NCT04050917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776156|NCT03413605|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33776157|NCT04223154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33776158|NCT02308501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776159|NCT02019030|||CASE_ONLY||PROSPECTIVE|||||||
33776160|NCT05039775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907513|NCT05400213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Since the outcome of the study is the histologic healing, blinding of the surgeon is not necessary.~Blinding is performed only for histomorphometric measurements. The person doing histomorphometric analysis is blinded as to study group."|4 arm randomized controlled parallel study|f|f|f|t
33907514|NCT04817462|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907515|NCT05984784|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33907516|NCT04700124|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33907517|NCT04184050|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907518|NCT06062030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded (Investigator),||f|t|f|f
33907519|NCT05667142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907520|NCT06004050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907521|NCT02567201|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33907522|NCT05748834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082836|NCT05902065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Outcome Assessors will be blinded regarding treatment assignment, including clinicians assessing the eligibility of patients and enrolling them in the study; the evaluators (neurologist, physiatrist, psychologist, physical therapists, engineers, laboratory staff).~Blindness will be ensured by the modality and timing of assessments at T0, T1, and T2 that will be conducted at times other than treatment and by evaluators not involved in the treadmill training. Blinding will be removed if requested by the participant at the end of the study and in case of undesirable effects."|Single-center, randomized controlled, single-blind trial with no-profit purpose.|f|f|f|t
34082837|NCT03567681|RANDOMIZED|PARALLEL||TREATMENT||NONE|Outcome will be assessed by computer|Open randomization to parallel treatment groups||||
34082838|NCT01529606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907523|NCT03367572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33907524|NCT05357482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907525|NCT06637254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989575|NCT03114891|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The patients will be blinded as to whether or not their site of stimulation is based on the standard targeting method or our novel fMRI-guided targeting method. In addition, staff members administering TMS will not know if the site of stimulation was created based on the standard targeting method or novel fMRI method.|This is a randomized study. All subjects will receive active TMS, so there is no placebo or sham condition. However, the patients will be blinded as to whether or not their site of stimulation is based on the standard targeting method or our novel fMRI-guided targeting method. TMS is administered over to one of these two sites over a two week period, and then TMS will be administered to the other site over a subsequent two-week period. All subjects will receive TMS to both sites as a part of the study, but the order is randomized and counterbalanced.|t|t|f|f
34082839|NCT00004233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082840|NCT03089476|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Children at high risk of atopy will be followed up to 6 months of age. The investigator will obtain TEWL measurements, skin tape stripping, and questionnaire data each subsequent visit. During the latter 2 visits, skin prick allergy testing will be obtained for milk, egg, and peanut to determine risk of food allergy. Biologic parents will also undergo STS and TEWL measurements on the first visit.||||
34082841|NCT01724827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082842|NCT03435055|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082843|NCT05027854|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34082844|NCT02745470|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34082845|NCT05113082|||OTHER||RETROSPECTIVE|||||||
34082846|NCT05251597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|None (Open Label)|Parallel Assignment Randomized|t|f|f|f
34082847|NCT04905043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082848|NCT02847325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082849|NCT02190955|||COHORT||CROSS_SECTIONAL|||||||
34082850|NCT06114212|NA|SINGLE_GROUP||OTHER||NONE||||||
34082851|NCT03630848|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34082852|NCT01728545|||CASE_ONLY||PROSPECTIVE|||||||
34082853|NCT01551667|||CASE_CONTROL||PROSPECTIVE|||||||
34082854|NCT06492083|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34082855|NCT01107548|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34082856|NCT00266708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082857|NCT03377465|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33686662|NCT02127060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686663|NCT05974501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33686664|NCT02882074|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33686665|NCT01865071|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686666|NCT05200741|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686667|NCT02982278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33686668|NCT02325791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686669|NCT01604109|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33686670|NCT06251479|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33686671|NCT04972747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Babies meeting the criteria will be divided into two groups by randomization method. Randomization will be done by drawing lots using two red and blue cards. 31 red and 31 blue cards will be placed in an invisible purse. For the baby who meets the criteria, a card will be drawn by another nurse working in the clinic. Massage with sunflower oil will be applied for the baby with a red card, and skin care with coconut oil will be applied for the baby with a blue card.|randomized controlled clinical trial|f|f|t|f
33686672|NCT00657826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686673|NCT02096575|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33686674|NCT02573701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686675|NCT01117792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686676|NCT00814879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686677|NCT00910247|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33686678|NCT00136383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686679|NCT04397887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686680|NCT05811871|||CASE_CROSSOVER||PROSPECTIVE|||||||
33686681|NCT03178162|||OTHER||PROSPECTIVE|||||||
33686682|NCT01594437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686683|NCT05475340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686684|NCT01193959|||COHORT||RETROSPECTIVE|||||||
33686685|NCT03924466|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The trial consists of 3 different patient cohorts that are each investigated using a new diagnostic imaging radiopharmaceutical||||
33686686|NCT05661201|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907526|NCT06376669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907527|NCT04585477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907528|NCT05788848|NA|SINGLE_GROUP||TREATMENT||SINGLE|This study is a phase I, feasibility study for research and development of a product. We will use a single group, pre-post study design. Individuals with mild to moderate CI (diagnosis of mild cognitive impairment (MCI), probable Alzheimer's disease (AD), or Alzheimer's disease Related Dementias (ADRD)|This study is a phase I, feasibility study for research and development of a product. We will use a single group, pre-post study design.|t|f|f|f
33907529|NCT04437511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907530|NCT05903131|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907531|NCT05999123|||COHORT||PROSPECTIVE|||||||
33907532|NCT05711615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907533|NCT02955784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907534|NCT05622708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This phase IV, multicenter study uses a double-blind, placebo-controlled, randomized withdrawal design (Treatment Period 2) preceded by an open label lead-in period (Treatment Period 1).|t|t|t|t
33989576|NCT05405881|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||A cross-sectional observational psychometric study with repeated assessments.||||
33989577|NCT02259244|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33989578|NCT01171963|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33989579|NCT03977129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989580|NCT04816253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989581|NCT04738539|||COHORT||PROSPECTIVE|||||||
33989582|NCT06130436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized, patient-assessor blinded, sham-controlled trial|t|f|f|t
33686687|NCT00769665|||COHORT||PROSPECTIVE|||||||
33686688|NCT04024384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686689|NCT05369390|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33907535|NCT06554522|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A stepped wedge cluster randomized controlled trial||||
33907536|NCT06188286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33907537|NCT06245772|||OTHER||PROSPECTIVE|||||||
33907538|NCT04719988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989583|NCT00706186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686690|NCT03098888|||COHORT||PROSPECTIVE|||||||
33686691|NCT03829800|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants receive 4 nutritional formulas to evaluate their glycemic index, insulin, GLP-1, GIP levels and subjective appetite|t|t|f|f
33686692|NCT03742440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686693|NCT01580371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686694|NCT02394145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33686695|NCT00536861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686696|NCT02500576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907539|NCT05866211|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907540|NCT02107989|||CASE_CONTROL||PROSPECTIVE|||||||
33907541|NCT05011266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind masking|parallel arm, double-blind, placebo-controlled buprenorphine compared to placebo|t|t|t|t
33907542|NCT06138093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776161|NCT03034317|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33776162|NCT05950048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Prospective, parallel, two-arm randomized controlled clinical trial|t|f|f|t
33776163|NCT02178774|||CASE_ONLY||PROSPECTIVE|||||||
33776164|NCT03504865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776165|NCT04616118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33776166|NCT05405387|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|To preserve the blind, only the Investigational Drug Services Pharmacy personnel and Data Safety Monitoring Committee (DSMC) at Huntsman Cancer Institute will know treatment assignments.|Stage one is open-label safety run-in. Stage 2 is randomized, placebo-controlled.|t|t|t|t
33776167|NCT06395077|||CASE_ONLY||PROSPECTIVE|||||||
33776168|NCT05773898|||OTHER||PROSPECTIVE|||||||
33776169|NCT00158080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776170|NCT02666586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33776171|NCT06028971|||CASE_ONLY||OTHER|||||||
33776172|NCT02550275|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907543|NCT05364944|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907544|NCT05583526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, parallel-group, vehicle controlled.|t|t|t|t
33907545|NCT06362798|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Enrolled mothers who are assigned to the intervention group will be informed to not discuss the financial transfers with anyone on the NICU care team (i.e., physicians, nurses, etc.)|Two-arm single-blind 1:1 randomized controlled trial of financial transfers ($160 per week) versus usual care. Mothers in the intervention arm will access videos that explain the impact of the cash on their availability for benefits and social supports. They will also be able to ask questions to a benefits counselor about how the transfers affect their benefits during the trial.|f|t|f|t
33907546|NCT04955730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Participants, investigators and statisticians will be blinded to treatment randomization. Surgical oncologists will be blinded of treatment randomization until the dressing is applied to the wound.||t|t|t|t
33989584|NCT02659358|||COHORT||PROSPECTIVE|||||||
33989585|NCT02559063|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33989586|NCT01683474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989587|NCT05351892|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33989588|NCT04289870|NA|SINGLE_GROUP||TREATMENT||NONE||First In Human study||||
33989589|NCT01619891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989590|NCT00697983|||COHORT||CROSS_SECTIONAL|||||||
33989591|NCT00796653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989592|NCT02510391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989593|NCT03547453|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989594|NCT01480544|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989595|NCT00961207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989596|NCT02832063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989597|NCT01832350|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989598|NCT01767103|NON_RANDOMIZED|PARALLEL||||NONE||||||
33989599|NCT03207503|||CASE_CONTROL||PROSPECTIVE|||||||
33989600|NCT04024163|NA|SINGLE_GROUP||TREATMENT||NONE||Historical control-based comparison, single-arm assignment, multicentre study||||
33989601|NCT06601894|||COHORT||CROSS_SECTIONAL|||||||
33686697|NCT04322539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686698|NCT02141464|||COHORT||PROSPECTIVE|||||||
33686699|NCT02837484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686700|NCT00280670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686701|NCT02587247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686702|NCT04862195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686703|NCT04059367|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-sequence, cross-over drug interaction trial||||
33686704|NCT04403269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686705|NCT05920083|NA|SINGLE_GROUP||TREATMENT||NONE||one group, before-after design||||
33686706|NCT02882373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686707|NCT03160196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686708|NCT01812980|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33686709|NCT01444677|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33686710|NCT00564720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776173|NCT04995835|NA|SINGLE_GROUP||OTHER||NONE||||||
33776174|NCT06256887|||COHORT||PROSPECTIVE|||||||
33776175|NCT01167179|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776176|NCT00697021||PARALLEL||PREVENTION||NONE||||||
33776177|NCT04471883|||COHORT||PROSPECTIVE|||||||
33776178|NCT02017743|||COHORT||PROSPECTIVE|||||||
33907547|NCT06635915|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The upper part of the patients will be covered for the investigator, who will only have access to the patient's abdomen and will not know which patients have NGT or not.|Clinical trial that will include patients who have had NGT placed intraoperatively. 114 patients (57 with NGT and 57 without NGT) will be examined by ultrasound in the immediate postoperative period to diagnose the normal positioning of the NGT or its absence. In patients who have had NGT placed, the normal positioning of the NGT will be verified by chest X-ray.|f|t|t|f
33907548|NCT05359939|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907549|NCT01399385|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33907550|NCT05818423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907551|NCT06512194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"All subjects will receive a single 25 mg dose of psilocybin administered within a set and setting (SaS) framework of psychological support provided by trained clinicians. Post-dosing, subjects will be randomized to TAU (psilocybin dosing+integration sessions) vs. taVNS vs. sham taVNS."|t|t|t|t
33907552|NCT04451590|RANDOMIZED|PARALLEL||OTHER||SINGLE|An external assessor will score videos participants performing Airway Trauma Management using the Airway Injury Checklist on Core Decision Making Steps. The assessors will be blinded to intervention.||f|f|f|t
33907553|NCT01226316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686711|NCT01718912|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33686712|NCT01179997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686713|NCT02708082|||COHORT||PROSPECTIVE|||||||
33686714|NCT05680740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686715|NCT04412993|||COHORT||PROSPECTIVE|||||||
33686716|NCT04590742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907554|NCT05639751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907555|NCT04589845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907556|NCT04567238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907557|NCT06118515|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907558|NCT05926739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907559|NCT06201689|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on gender at birth, then randomized to one of the study arms|t|f|t|f
33907560|NCT04533750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907561|NCT04300920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant and site personnel will not know which study treatment the participant is receiving.|Eligible participants will be randomized in a 1:1 fashion to NAC or placebo, stratified by stable concomitant IPF therapy use (i.e., pirfenidone or nintedanib administered for at least 6 weeks prior to screening) versus no pirfenidone or nintedanib use. Participants will receive 600 mg NAC orally three times daily or matched placebo for 24 months.|t|t|t|t
33907562|NCT06094062|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33907563|NCT06064097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907564|NCT05827016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907565|NCT06269367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomly assigned to the two device interventions but will receive both interventions.||||
33907566|NCT01323322|||COHORT||PROSPECTIVE|||||||
33907567|NCT04994132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907568|NCT00006518|||COHORT||PROSPECTIVE|||||||
33907569|NCT01517100|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33989602|NCT03502395|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33989603|NCT00925860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989604|NCT00742547|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989605|NCT02288221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989606|NCT00095108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989607|NCT01612091|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33989608|NCT03601819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989609|NCT03253510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are assigned to two more groups in parallel for the duration of the study|t|f|f|t
33989610|NCT00376493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686717|NCT03882931|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants receiving ultrasound stimulation will be blinded to the type of ultrasound stimulation they are receiving.||t|f|f|f
33686718|NCT00719797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686719|NCT04049227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686720|NCT03993093|||COHORT||PROSPECTIVE|||||||
33686721|NCT02598570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686722|NCT04665882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989611|NCT01400984|||COHORT||OTHER|||||||
33989612|NCT00165685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989613|NCT06559982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989614|NCT05238181|||CASE_CONTROL||RETROSPECTIVE|||||||
33989615|NCT02440763|||COHORT||PROSPECTIVE|||||||
33989616|NCT06254781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989617|NCT02807597|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||A rolling six design will be used to enroll patients in the phase I dose escalating portion of the study.||||
33989618|NCT04960917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33989619|NCT03584919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989620|NCT01268787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989621|NCT02392195|||CASE_ONLY||PROSPECTIVE|||||||
33989622|NCT00681161|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989623|NCT03315247|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33989624|NCT05806957|||CASE_CONTROL||PROSPECTIVE|||||||
33989625|NCT03663322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes assessor will be blinded to the arm the participants have been randomly assigned||t|f|f|t
33989626|NCT04444583|||COHORT||PROSPECTIVE|||||||
33989627|NCT02775045|||OTHER||PROSPECTIVE|||||||
33989628|NCT00766701|||COHORT||RETROSPECTIVE|||||||
33989629|NCT02154672|||COHORT||PROSPECTIVE|||||||
34082858|NCT06130995|NA|SEQUENTIAL||TREATMENT||NONE||This is a single arm phase Ib study with safety lead-in cohorts to investigate the efficacy and safety of neoadjuvant and adjuvant hormonal therapy with relugolix plus enzalutamide in patients with high-risk locally advanced prostate cancer who are candidates for ADT followed by definitive radiation therapy (RT) or surgical treatment.||||
34082859|NCT02402400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082860|NCT04796727|||CASE_ONLY||PROSPECTIVE|||||||
34082861|NCT01093768|RANDOMIZED|CROSSOVER||DIAGNOSTIC||||||||
34082862|NCT02507570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686723|NCT01258270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686724|NCT00537901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686725|NCT06370078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686726|NCT03705624|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cluster randomized trial||||
33686727|NCT03615365|||CASE_ONLY||PROSPECTIVE|||||||
33776179|NCT01293526|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33776180|NCT02459509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776181|NCT05937958|||COHORT||PROSPECTIVE|||||||
33776182|NCT04230980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33907570|NCT06457503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907571|NCT06269679|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34082863|NCT02219256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082864|NCT00006077||||TREATMENT||||||||
34082865|NCT02757157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082866|NCT06011811|||COHORT||CROSS_SECTIONAL|||||||
34082867|NCT03107429|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|"Placebo and Acetazolamide tablets were placed into capsules that were the same by the Pharmacy department. A separate investigator generated a randomisation list for 11 volunteers to decide if a placebo or acetazolamide will be taken on Day 1. They then created envelopes with the corresponding medication in Day 1 and the other in Day 2 and these were marked as Volunteer 1, 2, 3 etc. The randomisation list was sealed and kept with each investigator so they could be accessed if required due to any adverse events.~The volunteers will be recruited and both the investigators and the volunteers were blinded to what was received on each study day."|A pilot blinded randomised cross-over study.|t|f|t|t
33686728|NCT03906227|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects with normalized CD5+ B cells are thought to be at lower risk and relapse, and therefore may not need maintenance immunosuppression. The subjects in that group will be randomized to either maintenance immunosuppression vs close clinical observation without maintenance immunosuppression.||||
33686729|NCT06243744|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a prospective single-arm, study of up to 10 study subjects undergoing a lower facelift surgery and treatment with the Renuvion APR System. The study will be conducted at up to three (3) investigational centers in the United States.~Two biopsy tissue samples will be taken during the facelift procedure prior to use of the Renuvion APR System and then at the Day 180 visit. Tissue samples will be assessed via microscopy, histology, and immunohistochemistry for biological markers of elasticity (collagen density, elastin, fibrillin-1) and hydration (\[aquaporin-3, acidic glycosaminoglycans (GAGs), HA\]). Additionally, DNA methylation will be measured in tissue samples to estimate the biological age of the skin.~Follow-up will occur 1 day, 2 days (optional), 7 days, 14 days, 45 days, 90 days, and 180 days post-procedure with images and skin quality measurements taken as described."||||
33686730|NCT06325930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686731|NCT06409455|RANDOMIZED|PARALLEL||TREATMENT||NONE|Assessor bias is eliminated by having the assessment instruments administered by the computer in an automated manner, without human involvement.|Randomized parallel group (treatment vs. waitlist control) design||||
33686732|NCT01784393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686733|NCT03235310|||COHORT||PROSPECTIVE|||||||
33686734|NCT05449483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686735|NCT02891616|NA|SINGLE_GROUP||SCREENING||NONE||||||
33907572|NCT03967158|||COHORT||PROSPECTIVE|||||||
33907573|NCT02511028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907574|NCT05769218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907575|NCT05948540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The overall 2-stage randomization scheme will be implemented by an unblinded statistician who is otherwise uninvolved in study operations. Participants will be assigned a study number at Screening (Subject ID). In the first stage of randomization, eligible participants who complete screening will be randomly assigned to an open platform cohort for which they are eligible (both site PIs and participants are aware of the cohort assignment) and, within that cohort, the second stage of randomization is to intervention vs placebo (double-blind) using Interactive Response Technology (IRT).~For this APT, participant assignment to a cohort will not be blinded. The tablets/capsules used in the cohorts may not be visually similar between cohorts and blinding to cohort assignment is not necessary to avoid bias. However, within each cohort, participants, site personnel, contract research personnel and the sponsor will be blind to treatment assignment (intervention vs. placebo)."|Daridorexant is one of multiple interventions that will be tested in this adaptive platform trial (NCT05422612).|t|t|t|t
33907576|NCT06553612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907577|NCT02637687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907578|NCT03869996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082868|NCT05285748|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34082869|NCT00002441||||PREVENTION||DOUBLE||||||
34082870|NCT02233530|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34082871|NCT04127617|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial. Participants in the study will be divided into two groups: the treatment group will receive five osteopathic manipulative treatment sessions in addition to the standard treatment, and the control group will only receive standard treatment.||||
34082872|NCT06251804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082873|NCT01287936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082874|NCT04014777|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34082875|NCT05346796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34082876|NCT00218907|RANDOMIZED|PARALLEL||ECT||NONE||||||
34082877|NCT06550492|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||experimental group using smoke filtering electrocautery device, experimental group using double mask and control group using single mask|f|f|t|f
34082878|NCT05287815|||CASE_CONTROL||OTHER|||||||
34082879|NCT00049816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082880|NCT04703413|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34082881|NCT06305663|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The identity of the study eye will be masked to subjects, assessors, and other masked personnel while masking is maintained..||t|f|f|t
34082882|NCT05728476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082883|NCT03350386|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776183|NCT01330043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Behavioral therapists were blinded until the end of open-label treatment (26 weeks). Investigators were blinded to treatment assignment until the end of the study.|Participants were randomized to extended or non-extended treatment and followed for 104 weeks.|f|t|t|f
33907579|NCT06563609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|There are none apart from listen above|"Investigator-initiated, randomized, single-center, 2-by-2 factorial clinical trial with co-enrolment into two different non-pharmacological interventions.~* A combined Intensive physical Therapy and individualised Nutritional Support intervention and administration of probiotic yeast Saccharomyces boulardii~* A combined Intensive physical Therapy and individualised Nutritional Support intervention and NO administration of probiotic yeast Saccharomyces boulardii~* Administration of probiotic yeast Saccharomyces boulardii and NO Intensive physical Therapy and individualised Nutritional Support.~* NO administration of probiotic yeast Saccharomyces boulardii and NO Intensive physical Therapy and individualised Nutritional Support. Patients will receive standard hospital care"|t|f|f|f
33907580|NCT01496625|||COHORT||PROSPECTIVE|||||||
33907581|NCT03478839|||COHORT||PROSPECTIVE|||||||
33907582|NCT01900132|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33907583|NCT06385275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Use of a placebo from Johnson Compounding Pharmacy (Waltham, MA) of similar appearance and taste to the vitamin K supplements will allow for masking of participants, the study PI, and other study team members to the treatment allocation.|A stratified permuted block randomization will be used to assign 55 participants in a 1:1:1:1 ratio to each intervention arm. A random allocation sequence will be generated by computer in blocks of 4 or 8, stratified by sex and race.|t|t|t|f
33907584|NCT03623321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907585|NCT06450366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907586|NCT03574727|||COHORT||RETROSPECTIVE|||||||
33907587|NCT04851964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.|t|t|t|t
33907588|NCT06091254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907589|NCT03374215|||COHORT||PROSPECTIVE|||||||
33907590|NCT05353478|||COHORT||PROSPECTIVE|||||||
33907591|NCT06012240|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33907592|NCT06153563|||COHORT||PROSPECTIVE|||||||
33907593|NCT05452239|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33907594|NCT06153251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907595|NCT04849416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907596|NCT05434078|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33907597|NCT03570892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, Open-Label|f|f|f|t
33907598|NCT05829265|||CASE_ONLY||PROSPECTIVE|||||||
33907599|NCT03496402|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34082884|NCT02643693|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33776184|NCT05952115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|lumbar motor control and cervical stabilization exercises|f|f|t|t
33776185|NCT05765435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907600|NCT06018454|RANDOMIZED|PARALLEL||OTHER||NONE||Patients randomized with computer generated block randomization of ratio 1:1:1 to randomize women to either 10 minute genetic counseling intervention with handout, handout, or no interventions. Randomization allocation will be performed prior to study initiation through the Institute for Clinical and Translational Science (ICTS) via REDCap software.||||
33907601|NCT03530774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants will be blinded to control (carbohydrate) or egg white protein supplement||t|f|t|t
33907602|NCT05381597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907603|NCT06386874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"This is a double-blind study, Sponsor, subjects and Investigators will be blinded to the device setting (Active/Sham). The study site team members receiving, storing, dispensing, preparing, and administering the study interventions will be blinded (except the unblinded randomizer). Subjects' caregivers will also be blinded. There are no differences in the active and sham device appearance. Due to the non-invasive nature of the treatment, as well as the physical characteristic of the EMF, there is no noticeable difference between sessions conducted using an active or a sham device, facilitating full blinding of both subjects and Investigators.~An independent unblinded statistician (not the study statistician) will perform the assessments described. Only the unblinded statistician and members of the DSMB will be exposed to the interim report."|subjects will be assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ3. system|t|t|t|t
33907604|NCT00055029|||COHORT||PROSPECTIVE|||||||
33907605|NCT01306019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989630|NCT03575585|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This is a 2 x 2 nested factorial design clinical trial. Counselors were randomized to 1) Standard training \[2 hours on using a BEST feedback report\] or 2) Enhanced training \[Standard + 8 hours on discussing sexual risk with patients + monthly coaching\]. Patients of participating counselors completed the BEST assessment and were randomized to receive no feedback or a personalized BEST feedback report, and were followed up at 3-, and 6-months (patients). Counselors were assessed at baseline, post-training and 3-months.||||
33989631|NCT02291250|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33989632|NCT03444090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34082885|NCT04872283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded at enrollment and first made aware to which intervention they were randomized when receiving their postoperative pain medication at outside pharmacies||t|f|f|f
34082886|NCT02188004|||COHORT||PROSPECTIVE|||||||
34082887|NCT05760599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686736|NCT04609475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686737|NCT01419821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686738|NCT03860935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686739|NCT00791180|||COHORT||PROSPECTIVE|||||||
33686740|NCT04101201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Diosmin is a naturally occurring flavonoid present in citrus fruits and other plants belonging to the Rutaceae family. It is used for the treatment of chronic venous insufficiency (CVI) for its pheblotonic and vaso-active properties, safety and tolerability as well.~µSmin® Plus is a proprietary flavonoid complex with enhanced bio-efficacy. It contains highly concentrated micronized and standardized Diosmin. Highly improved bioavailability and improved oral absorption by micronization of the particles."|t|f|t|f
33686741|NCT06265480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study will be singled blinded (assessors)|Randomised Controlled Trial|f|f|f|t
33686742|NCT02012582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686743|NCT02054481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686744|NCT03178695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A study group receives the intervention, which is compared in terms of efficacy against a matched group of control patients.||||
33686745|NCT01010139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686746|NCT02981355|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33721428|NCT04525508|||COHORT||CROSS_SECTIONAL|||||||
33721429|NCT01782859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721430|NCT00916747|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33721431|NCT00244946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721432|NCT01794806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082888|NCT02982707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082889|NCT05573230|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33989633|NCT06438224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome measurements and data analyses were performed by a trained and blinded outcome assessor who was not involved in the intervention.|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals. As in previous studies, the sham group was treated using an adapter that had the same shape but did not emit any energy|t|f|f|t
33989634|NCT03351244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082890|NCT02064556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082891|NCT00848523|NA|SINGLE_GROUP||||NONE||||||
33989635|NCT01858493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686747|NCT04152980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective dose optimizing study using a step-up and step-down model. In order to find the optimal dose, the infusion of pentoxifylline in different dosages will be studied, next to antibiotics with 3 patients per dosage. The first 3 patients will receive a dose of 5 mg/k/h for 6 h per day, comparable to the dose that has been used before in trials. Upward or downward dose adjustments for the following cohort of 3 patients will be considered. If the dose is effective, the next 3 patients will receive a lower dose, in order to find the lowest effective dose. After the dose optimization study an additional cohort of 10 patients will be treated with the determined optimal dose as a validation of this dose.||||
33989636|NCT03097107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686748|NCT00967928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989637|NCT00878020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989638|NCT04354974|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Evaluation of the specific therapeutic efficacy of Cognitive Training Therapy for Bipolar Patients on cognitive deficits in patients with bipolar disorder, treated over three months and followed up over nine months. Randomized, double-blind study.|t|t|t|t
33989639|NCT05322967|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|It is not possible to mask patients, care provider or investigators but the outcome assessors are masked for allocation of patients|Participants are randomized in the initial phase to take their ordinary anti-hypertensive medication in the morning or at bedtime for 8 weeks. Then the participants are switching to the alternative intervention during 8 weeks in the second phase of the study.|f|f|f|t
33989640|NCT03810950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082892|NCT01066572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082893|NCT00023231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686749|NCT03751306|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33686750|NCT03095547|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arm parallel group evaluation with fourth arm in series||||
33686751|NCT02155803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907606|NCT04492722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|No member of the study team at AstraZeneca, or representative, personnel at study centres, or any CRO handling data will have access to the randomization scheme prior to unblinding for the primary analysis.||t|t|t|t
33686752|NCT02023073|||COHORT||PROSPECTIVE|||||||
33686753|NCT02947594|||COHORT||PROSPECTIVE|||||||
33686754|NCT02237014|||CASE_ONLY||PROSPECTIVE|||||||
33686755|NCT04032574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686756|NCT00625573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686757|NCT05832476|||COHORT||PROSPECTIVE|||||||
33907607|NCT06032546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686758|NCT04532424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of 2 groups based on the presentation of restricted and repetitive behavior.||||
33686759|NCT06278610|||COHORT||PROSPECTIVE|||||||
33686760|NCT06516445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686761|NCT04781660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686762|NCT01284985|||COHORT||PROSPECTIVE|||||||
33686763|NCT01347580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686764|NCT01357200|||CASE_ONLY||PROSPECTIVE|||||||
33686765|NCT06298604|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single masking, the pathologist will be blinded to the needle used for sample collection.|Prospective, diagnostic,, cross-sectional study|f|t|f|f
33686766|NCT05404984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686767|NCT00182702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686768|NCT00335231|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33686769|NCT00872937|||CASE_CONTROL||RETROSPECTIVE|||||||
33686770|NCT03900962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator and outcome assessors were not blind to group allocation. It was also not possible to blind participants to the intervention, however, patients were unaware of the study hypotheses.|After baseline measures were collected, participants were randomly allocated (1:1) to the slow-speed strength training group or the high-speed power training group in block sizes of four using a randomisation sequence created by an independent researcher (GraphPad QuickCalcs, Graphad Software, La Jolla, CA).|f|t|f|f
33907608|NCT06089291|||COHORT||PROSPECTIVE|||||||
33907609|NCT06150898|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907610|NCT05064410|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907611|NCT04874116|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Office-GAP is a Patient Activation Intervention Program for Group 1 that includes: 1) Group visit 2) Provider training for patient activation, and 3) Office-GAP checklist used in the office. Patients in Groups 1 and 2 will attend one group visit and 5 follow-up visits with their provider in 1 month, 3, 6, 9 and 12 months after the group visit. For Group 1, the group visit is a shared decision making (SDM) activation session wherein patients learn self-management behaviors, medication use, communication skills, and use of decision support tools (DST). The Office-GAP Checklist is an in-consultation DST that helps engage the patient and provider in initiating and enhancing a SDM process via discussion of medication and secondary prevention/lifestyle changes. Way to Health is a text-based DM self-management program. Groups 1 and 2 receive a 15-week customized program of text messages after the group visit. For the remaining 12 months, they will receive standard diabetic education modules.||||
34082894|NCT03753035|||COHORT||PROSPECTIVE|||||||
33907612|NCT05543681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind for study site and participants|Multi-site, Randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to severe dementia from Alzheimer's and symptomatological Agitation.|t|t|t|f
34082895|NCT05334394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082896|NCT00003537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082897|NCT00449839|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082898|NCT00345124|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34082899|NCT00677898|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34082900|NCT00000755||PARALLEL||PREVENTION||||||||
34082901|NCT00956202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082902|NCT03810183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This was a subject and investigator-blinded study. Subjects, investigators and all site staff remained blinded to study treatment throughout the study.~The identity of the treatments was concealed by the use of study drugs that were all identical in packaging, labeling, schedule of administration, appearance, and odor.~The sponsor could be unblinded to the study treatment at any time, especially in case of a safety concern."||t|t|t|f
34082903|NCT04763993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082904|NCT03469544|||CASE_CONTROL||RETROSPECTIVE|||||||
34082905|NCT01207193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082906|NCT04582656|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, single-arm, open-label, 12-month follow-up clinical trial||||
34082907|NCT05433610|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Interventional, crossover, randomized.||||
34082908|NCT01035138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082909|NCT04040686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082910|NCT00968461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082911|NCT02288676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33686771|NCT01541345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686772|NCT04144465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686773|NCT02514954|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33686774|NCT03722043|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33686775|NCT05606146|NA|SINGLE_GROUP||TREATMENT||NONE||Endometrium ablation with the IUB SEAD device||||
33686776|NCT02093026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686777|NCT00045721||||TREATMENT||||||||
33686778|NCT06361992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686779|NCT00355277|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33686780|NCT06346808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907613|NCT04438213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907614|NCT03358810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33907615|NCT04316546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989641|NCT04093245|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989642|NCT05385640|||COHORT||RETROSPECTIVE|||||||
33989643|NCT03615105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will receive one of three myeloablative conditioning regimens followed by a Alpha/beta+ T-cell depleted peripheral blood stem cell product and short course tacrolimus. Donors are HLA mismatched unrelated adults or haploidentical family members.||||
33989644|NCT01738269|||COHORT||RETROSPECTIVE|||||||
33989645|NCT00940693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082912|NCT00333528|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34082913|NCT03305562|||COHORT||OTHER|||||||
34082914|NCT04795635|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a prospective, randomized, controlled, multi-center, clinical trial in which 80 participants diagnosed with PTPNP will be randomized 1:1 into one of two treatment groups:~1. CMM plus Axon Therapy (n=64)~2. CMM alone (n=64)"||||
33686781|NCT03638843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686782|NCT04385927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686783|NCT00366340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907616|NCT02417714|||CASE_ONLY||PROSPECTIVE|||||||
33907617|NCT01036685|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907618|NCT03484039|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients will be enrolled in one module of own choice. Except for Module 3 Submodule 2, every module will consist of a particular intervention, as well as, its accompanying set of assessments.||||
33907619|NCT05802056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907620|NCT06157580|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33907621|NCT03429036|||OTHER||PROSPECTIVE|||||||
33907622|NCT06449183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Prospective Cohort. Multicentric, International clinical study.||||
34082915|NCT04005040|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|It is impossible to mask since patients are examined at the hospital or in their own home using mobile X-ray|Randomized controlled trial|f|f|f|t
34082916|NCT00597272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082917|NCT06294288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082918|NCT04294212|||COHORT||RETROSPECTIVE|||||||
34082919|NCT06508255|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34082920|NCT05089214|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082921|NCT04324229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|double blind||f|f|t|f
33686784|NCT06064162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907623|NCT06171750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082922|NCT06520956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34082923|NCT02390232|||COHORT||PROSPECTIVE|||||||
34082924|NCT05605353|||COHORT||PROSPECTIVE|||||||
34082925|NCT04469439|||COHORT||PROSPECTIVE|||||||
34082926|NCT06011642|||FAMILY_BASED||PROSPECTIVE|||||||
34082927|NCT03733808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, randomized, sham-controlled with a 1:1 allocation into 2 parallel arms|t|t|t|t
34082928|NCT00614835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082929|NCT04927910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34082930|NCT01751282|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33686785|NCT03249389|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33686786|NCT03146598|||COHORT||RETROSPECTIVE|||||||
33907624|NCT06341712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907625|NCT06648668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel-group|t|t|t|t
33907626|NCT05464030|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907627|NCT06545331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907628|NCT06579105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking (blinding) applies to patients and investigators involved in AZD5004 and placebo arms, however not in active comparator arm.||t|t|t|f
33907629|NCT06400511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907630|NCT05711394|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33907631|NCT03949647|||OTHER||PROSPECTIVE|||||||
33907632|NCT04530110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907633|NCT05648500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907634|NCT04014673|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989646|NCT06560697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open-label phase 2 study in people with CaCu clinical stages IB3-IIIC1 treated with QT/RT. Subjects will be randomized to cervical boost with SBRT or 3D intracavitary brachytherapy in a 1:1 ratio and stratified by nodal status.||||
33989647|NCT01375920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989648|NCT06104163|||OTHER||RETROSPECTIVE|||||||
33989649|NCT05841628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989650|NCT01450592|||COHORT||CROSS_SECTIONAL|||||||
33989651|NCT04690101|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33989652|NCT02603055|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33989653|NCT04533594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group pretest-posttest design.||||
33989654|NCT03590782|||COHORT||PROSPECTIVE|||||||
33989655|NCT00545506|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33989656|NCT02670772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989657|NCT02221921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989658|NCT01521533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989659|NCT03081481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989660|NCT04383574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33989661|NCT03296722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33989662|NCT04643067|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33989663|NCT00931697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33989664|NCT00318578|||DEFINED_POPULATION||PROSPECTIVE|||||||
33989665|NCT01124175|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989666|NCT06413186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a parallel group, randomized controlled study conducted at the public hospital in Tarsus district of Mersin province. It will consist of primiparas (women who will give birth for the first time) who apply to the delivery room of Tarsus State Hospital. The sample of the research was calculated with the G-Power program. The sample size was calculated as 64 primiparous and 128 primiparous in each group. in total. However, assuming that there will be at least 10% data loss during the research, the study will be carried out with a total of 140 primiparas, 70 primiparas in each group. 70 primiparas who meet the inclusion criteria for the study will be assigned to the experimental group (physiological separation of the placenta using a mixed method), and 70 primiparas will be assigned to the control group (controlled cord traction will be used to deliver the placenta). ) through randomization.|t|f|f|f
33989667|NCT05231135|||COHORT||OTHER|||||||
34082931|NCT06213116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and Outcome Assessor do not know type of intervention|Prospective, randomized control study.|t|f|f|t
34082932|NCT05401175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082933|NCT00053625|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082934|NCT00906126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907635|NCT06052072|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, multi-center, early feasibility study||||
33907636|NCT06560281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907637|NCT05985395|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33907638|NCT05020678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082935|NCT02190188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082936|NCT00443443|||COHORT||PROSPECTIVE|||||||
34082937|NCT01530269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082938|NCT05123573|||COHORT||CROSS_SECTIONAL|||||||
34082939|NCT01768663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082940|NCT00843492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686787|NCT00873860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33686788|NCT02091674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686789|NCT01850602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686790|NCT02850081|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33686791|NCT05965271|||CASE_ONLY||RETROSPECTIVE|||||||
33907639|NCT03493425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989668|NCT02009774|||COHORT||PROSPECTIVE|||||||
34082941|NCT06529302|||COHORT||RETROSPECTIVE|||||||
34082942|NCT00925717|||COHORT||RETROSPECTIVE|||||||
33686792|NCT05461807|||COHORT||RETROSPECTIVE|||||||
33686793|NCT01459939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686794|NCT01490723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686795|NCT03351985|||CASE_ONLY||PROSPECTIVE|||||||
33686796|NCT04356170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686797|NCT04663919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686798|NCT00378079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686799|NCT00752596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989669|NCT01126203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989670|NCT04582019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are to be assigned a randomization number that will match their treatment. Block randomization using 10 blocks is to be performed by a central randomization organization (www.randomize.net) using a computerized algorithm.|"* group A - male patients who will undergo ureteral stent placement by conventional polyurethane DJ stent, Fr 6.5. N=30~* group B - male patients who will undergo ureteral stent placement by polyurethane DJ stent with magnet (Blackstar, Urotech ), Fr 7. N=30"|f|f|t|f
33989671|NCT04607499|||COHORT||PROSPECTIVE|||||||
33776186|NCT03758924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind, Randomized, Placebo-Controlled|31 participants: 6 PK open-label followed by 25 double-blind, randomized, placebo-controlled|t|t|t|t
33776187|NCT04192942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776188|NCT03900312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776189|NCT01980979|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989672|NCT04166630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33989673|NCT02365012|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33989674|NCT02618083|NA|SINGLE_GROUP||OTHER||NONE||||||
33989675|NCT05820360|NA|SINGLE_GROUP||TREATMENT||NONE||Model Description:||||
33989676|NCT02760732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989677|NCT02000362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989678|NCT03989648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082943|NCT05273762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776190|NCT00299689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907640|NCT06382948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blinded, independent IRC will perform a review of radiographic images and clinical information collected on study to determine the protocol-defined endpoints of disease response and progression. Further information on the independent review process will be provided in the BIRC Charter.|Double-blind, parallel group (two arms: elacestrant plus everolimus, and elacestrant plus placebo).|t|f|t|f
33907641|NCT06267911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907642|NCT05840159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907643|NCT06331598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907644|NCT05371093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907645|NCT06258902|||OTHER||PROSPECTIVE|||||||
33907646|NCT05624554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907647|NCT04221438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907648|NCT05282927|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel cluster-randomized trial (parallel-CRT): used in pragmatic evaluations of health program or policy interventions, where half the clusters (in this case, VA medical centers) are randomly assigned to two interventions: Foundational REP (active comparator) vs. Enhanced REP (experimental)||||
33907649|NCT06321302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907650|NCT06100289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907651|NCT05150990|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to one of two intervention groups (two types of technology): (1) virtual reality, or (2) video chat (active control)||||
33907652|NCT06242821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study aims to evaluate the efficacy of a yoga-based intervention compared to traditional physical therapy in treating non-operative AIS patients, focusing on those who are braced and non-braced. This clinical trial seeks to provide valuable insights into alternative non-surgical treatment options for AIS.~Inclusion Criteria:~Non-operatively treated AIS patients Johns Hopkins Hospital (JHH) with back pain who are candidates for physical therapy.~Cobb angle: \>25 degrees, Visual Analog Scale (VAS) Pain score \> 41/0 Braced and Unbraced Patients~Exclusion Criteria:~Scoliosis due to causes other than AIS. AIS patients who have undergone surgery for scoliosis or back pain Age less than 10 years of age or greater than 20 years of age Unable to access zoom on any electronic device~Aim 1: Assess Feasibility and Challenges of Implementing a Yoga Protocol for AIS Patients Aim 2: Compare Clinical Outcomes and Adherence Between Yoga and Traditional Physical Therapy"||||
33907653|NCT06280235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907654|NCT05065216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To minimize bias, the participant and PI will be blinded to treatment assignment. All Sub-Investigators and other members of the study team will also remain blinded except for a designated unblinded pharmacist or designee responsible for compounding the assigned study treatment. The study team will remain blinded until all data is collected and database lock occurs.|Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)|t|f|t|f
33907655|NCT05554380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907656|NCT04603807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907657|NCT06523595|NA|CROSSOVER||TREATMENT||NONE||||||
33907658|NCT06276335|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33907659|NCT05487599|NA|SEQUENTIAL||TREATMENT||NONE||||||
33989679|NCT05163119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34082944|NCT05115552|||CASE_CONTROL||PROSPECTIVE|||||||
34082945|NCT05588258|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33776191|NCT03478423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy will prepare study drugs in opaque vials with identical labels based on a randomization scheme provided by the trial methodologist. The opaque vials will be included in sealed, sequentially numbered study packets that will be replaced as they are used. To avoid potential patient selection and allocation bias, all physicians, nurses, RAs and patients will be blinded to the randomization schedule. Study investigators will be permitted to un-blind the study medication in the event of allergic reaction, consisting of rash and/or airway compromise.||t|t|t|t
33776192|NCT03848091|||COHORT||RETROSPECTIVE|||||||
33776193|NCT04877704|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33776194|NCT03870503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be a prospective double-blind randomized study|This study will be a prospective double-blind randomized study|t|t|t|t
33776195|NCT06279754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776196|NCT02524054|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33686800|NCT05968365|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The clinical trial was a prospective, single-group, uncontrolled design using the target value method~Three centers participated~A total of 36 patients were enrolled. It was developed and produced by Weikan Technology in subjects who agreed to be enrolled~The Vision Pro is trained, and after no less than 3 hours of training, the subject is good at it~Evaluate the safety and effectiveness of obstacle perception and recognition in the process of walking, and evaluate the test product in auxiliary sight~Safety and effectiveness of obstacle perception and recognition for disabled walkers."||||
33686801|NCT01150331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686802|NCT03566836|||COHORT||PROSPECTIVE|||||||
33686803|NCT04869020|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Each participant will be assigned to one of the study's two arms. Participants in Arm 1 will receive, in random order, an OtoBand or Sham Device A to use for two weeks each. Participants in Arm 2 will receive, in random order, a OtoBand or Sham Device B. The participants and researchers will be blinded to which arm of the study a participant is assigned and they will not know if the device in use is effective or placebo.||t|t|t|t
33686804|NCT02383225|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33686805|NCT02753244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686806|NCT00718081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686807|NCT01007682|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33686808|NCT02835352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33686809|NCT00624702|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33686810|NCT03673735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776197|NCT03133143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The sequences of allocation will be concealed until interventions will be assigned. Allocation will not be masked to the researchers, who will recruit patients. Outcome assessors (who will not participate in patient randomisation or daily clinical treatment at the same unit) will be masked. The data analyst (the trial statistician) will be kept blinded to the allocation. Allocation: Randomized The trial manager will allocate the patient to one of the three arms of the trial based on a list of computer-generated random numbers (provided by an external clinical trial randomisation service).|A controlled, single-blind clinical trial with a pragmatic, three-arm parallel-group design.|f|f|t|t
33776198|NCT04004208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989680|NCT05126485|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A single group of participants will undergo both traditional gait training and biofeedback-based gait training. Measurements will be taken before and after each training session. The order of training will be randomized.||||
33989681|NCT02618577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Phase 3b|t|f|t|f
33989682|NCT00296062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989683|NCT00366886|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33989684|NCT05978726|||COHORT||RETROSPECTIVE|||||||
33989685|NCT02110394|||CASE_ONLY||PROSPECTIVE|||||||
33989686|NCT02482090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989687|NCT01067183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989688|NCT04802694|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989689|NCT05606744|RANDOMIZED|PARALLEL||OTHER||SINGLE||Individuals will be randomly assigned to a BFR or non BFR exercise condition. The subjects will perform a single, 3-5 minute bout of eccentric exercise on the Eccentron device either with BFR (with restriction cuffs on the thigh per the procedures below) or without the BFR.|f|f|t|f
33989690|NCT01114048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989691|NCT01990391|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33989692|NCT05327491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34082946|NCT04500951|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A Randomized controlled time-series study. A Randomized controlled time-series study. Randomization to either SR or ORE for each of the 9 resting periods during a three-day recording session. A period of three days will allow collection of sufficient data. This will also allow the analysis to take the random effects of time and weekday into account.||||
34082947|NCT00001091||||TREATMENT||||||||
34082948|NCT05319548|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34082949|NCT06132971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All data was collected by trained interviewers or teachers. All data collectors were masked as to study conditions.||f|f|f|t
34082950|NCT02097732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082951|NCT00935285|||COHORT||PROSPECTIVE|||||||
34082952|NCT02343861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34082953|NCT04830735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082954|NCT00318695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34082955|NCT00937534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082956|NCT01201330|||COHORT||RETROSPECTIVE|||||||
34082957|NCT03694379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34082958|NCT02988661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082959|NCT04976127|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1: dose escalation phase, 3 patients with Parkinson's disease, (2 cohorts as in 1+2 patients, sequential inclusion between the first and 2nd patient)~Part 2: repeated dose administration phase, 9 patients with Parkinson's disease (1 cohort)~Part 3: Dose consolidation with intrapatient dosing, 10 patients with Parkinson's disease (1 cohort)"||||
34082960|NCT05363202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34082961|NCT01474486|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
33686811|NCT03049293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686812|NCT01145118|||CASE_ONLY||PROSPECTIVE|||||||
33686813|NCT04192227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686814|NCT01056380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686815|NCT03931668|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33686816|NCT04161300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686817|NCT00362128|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33686818|NCT02642939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776199|NCT03041454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33776200|NCT04780438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33776201|NCT03671720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082962|NCT06399601|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33686819|NCT03277079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686820|NCT00712062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686821|NCT02128360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686822|NCT04044443|||COHORT||PROSPECTIVE|||||||
33686823|NCT02022774|||CASE_ONLY||PROSPECTIVE|||||||
33686824|NCT05891964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686825|NCT04252833|NA|SINGLE_GROUP||TREATMENT||NONE||The dose to be utilized for the evaluation of food effect will be CT-044 600 mg single dose.||||
33686826|NCT05991921|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Based on simple randomization, women were assigned to one of three groups: TENS (n=46), placebo (n=46), or control (n=46). For randomization, researcher 1 used the random number generation method available on the random.org site. These processes are hidden from the rest of the study. While TENS application in the research was carried out by researcher 1; It was conducted by researcher 2, who evaluated the participants for inclusion and exclusion criteria and collected the data, who did not know the distribution of the participants. Because sham device TENS was not applied to the control group, the participants were able to realize that they were assigned to the control group. Therefore, this study was considered a single-blind study. To provide blinding in the placebo group, the participants were hooked up to the TENS unit in exactly the same way as the participants in the TENS group. The active indicator of the unit emitted light and sound, but did not transmit electrical stimulation|This study was designed as randomized, single-blind, placebo-controlled.|t|f|t|t
33686827|NCT02069288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686828|NCT05228457|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33989693|NCT00911235|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989694|NCT00005591||||TREATMENT||||||||
33989695|NCT03058003|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989696|NCT05654922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For individuals performing spirometry, every attempt will be made to keep them masked to treatment.||f|f|f|t
33989697|NCT01975623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989698|NCT04799314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989699|NCT06248879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33989700|NCT03538327|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot, single arm, interventional, longitudinal study||||
33989701|NCT02818218|||COHORT||PROSPECTIVE|||||||
33989702|NCT04131842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989703|NCT03129373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33989704|NCT04827394|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 using a block randomization scheme stratified by gestational age||||
33989705|NCT02350231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989706|NCT00223925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33989707|NCT00937898|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33989708|NCT04987411|||COHORT||PROSPECTIVE|||||||
33989709|NCT05149066|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989710|NCT02129894|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989711|NCT01987765|||COHORT||PROSPECTIVE|||||||
33989712|NCT04471363|||CASE_ONLY||PROSPECTIVE|||||||
33989713|NCT06208215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|t|t|f
33989714|NCT02443220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989715|NCT04082858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Quadruple|Pragmatic, randomised, controlled, parallel group, pilot clinical trial|t|t|t|t
33989716|NCT01721850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989717|NCT01073657|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33989718|NCT06035315|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control trial : comparison of two clusters||||
33989719|NCT00747097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082963|NCT04775030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||experimental and control group|t|t|f|f
34082964|NCT00492193|||CASE_ONLY||PROSPECTIVE|||||||
34082965|NCT04722562|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34082966|NCT00686972|NA|SINGLE_GROUP||OTHER||NONE||||||
34082967|NCT01387269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686829|NCT03689933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686830|NCT05718999|||COHORT||PROSPECTIVE|||||||
33686831|NCT04709939|||COHORT||PROSPECTIVE|||||||
33686832|NCT04592263|||OTHER||CROSS_SECTIONAL|||||||
33686833|NCT01106573|||COHORT||PROSPECTIVE|||||||
33686834|NCT05029973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686835|NCT06492343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||one group receiving NFB from DMN another group receiving NFB from motor cortex|t|t|t|t
33686836|NCT01382511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686837|NCT02312284|||COHORT||RETROSPECTIVE|||||||
33686838|NCT04951739|||COHORT||PROSPECTIVE|||||||
33989720|NCT01616381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989721|NCT04360447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989722|NCT04030845|||COHORT||PROSPECTIVE|||||||
33989723|NCT06215976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989724|NCT03173235|||CASE_CONTROL||PROSPECTIVE|||||||
33989725|NCT01795872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989726|NCT04131374|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking|"We will select 5 people living with dementia and their family caregiver. All participants will participate in developing their own tailored VR scenario and receive a weekly VR intervention (30 minutes) over a period of 10 weeks.~Participants (i.e. person living with dementia, family caregiver) will complete outcome measures at baseline (week 1), mid-intervention (week 5), the conclusion of intervention (week 10), and 5-weeks following the intervention (week 15)."||||
33989727|NCT06475924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989728|NCT05444166|||COHORT||PROSPECTIVE|||||||
33989729|NCT00859872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989730|NCT05177991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single Blind, randomized|t|f|f|f
33989731|NCT01137539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34082968|NCT05139342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082969|NCT04350593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082970|NCT02618746|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907660|NCT04458883|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The main aim of the study is to build and test a cardiac-specific coil purposely assembled in house to suit the FFC-MRI whole-body prototype and to test if it could be used for clinical cardiac scans in human subject populations.||||
33989732|NCT04166734|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Initial safety phase followed by an Expansion phase||||
33686839|NCT00607932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907661|NCT06566885|||OTHER||OTHER|||||||
33907662|NCT06433219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907663|NCT06379217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be assigned to a treatment arm based on their predominantly expressed target per PET images (based on central read):~* \[177Lu\]Lu-PSMA-617 will be assigned to those with predominant PSMA expression~* \[177Lu\]Lu-DOTA-TATE will be assigned to those with predominant SSTR2 expression~* \[177Lu\]Lu-NeoB will be assigned to those with predominant GRPR expression"||||
33907664|NCT06022822|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33907665|NCT05420064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907666|NCT04548999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907667|NCT04773353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907668|NCT05881408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686840|NCT00531986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907669|NCT05972135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907670|NCT06291376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989733|NCT06041945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989734|NCT04418310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989735|NCT04889014|RANDOMIZED|PARALLEL||OTHER||SINGLE|Instructors and all study personnel were blinded to participant PGET assignment, PGx results, and survey results.|We investigated the effect of PGET on student knowledge, comfort, and attitudes related to pharmacogenomics (PGx) in a non-blinded, randomized controlled trial. Consenting participants were randomized to receive PGET or no PGET (NPGET) during four subsequent years of a PGx course.|f|f|t|f
33989736|NCT03183986|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Infants are randomised to phototherapy with blue LED's with wavelength of 478 or 459 nm. The decrease of TSB between the groups is compared.||||
33989737|NCT04480762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989738|NCT05790824|NA|SINGLE_GROUP||TREATMENT||NONE||External comparison study between Larytherm cohort patients and Thermarthrose control patients||||
33989739|NCT00707408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989740|NCT05205876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989741|NCT05988983|||COHORT||PROSPECTIVE|||||||
33989742|NCT02514330|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33989743|NCT03987633|||COHORT||PROSPECTIVE|||||||
33989744|NCT03840291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989745|NCT00670761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989746|NCT02186691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989747|NCT00819754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989748|NCT00692939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989749|NCT04882163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989750|NCT01845376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989751|NCT01109966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33989752|NCT01928147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34082971|NCT06550726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking is performed during the study|||||
34082972|NCT02766543|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34082973|NCT02078817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989753|NCT04813692|||COHORT||RETROSPECTIVE|||||||
34082974|NCT01919931|||CASE_CONTROL||RETROSPECTIVE|||||||
33686841|NCT06040268|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33989754|NCT02310386|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33989755|NCT03128762|||CASE_CONTROL||PROSPECTIVE|||||||
33989756|NCT05200663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is single blinded study in which 110 patients are recruited into two groups .Randomization will be done by lottery method to divide the patients into group A \& group B. 55 patients in group A will be given tamoxifen 10 mg twice a day and 55 patients in group B will be given tamoxifen 10 mg twice a day and vit E 400mg once a day. Only researcher will be knowing that which treatment will be giving to which group.|110 patients are recruited into two groups .55 patients in group A will be given tamoxifen 10 mg twice a day and 55 patients in group B will be given tamoxifen 10 mg twice a day and vit E 400mg once a day.|t|f|f|f
33989757|NCT01519661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989758|NCT05750394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiologist blinded to closure method||f|f|f|t
33989759|NCT00633594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989760|NCT06118918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989761|NCT04788823|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study cohort will be randomized to one of 4 arms: control or 3 different drug protocols.||||
33989762|NCT00908128|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989763|NCT00179231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989764|NCT04656353|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33989765|NCT02210182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33989766|NCT02005497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989767|NCT06178120|||CASE_ONLY||PROSPECTIVE|||||||
33989768|NCT04887766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are assigned to one of two groups in parallel for the duration of the study.|t|t|t|f
33989769|NCT01160926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989770|NCT06196307|||COHORT||PROSPECTIVE|||||||
33989771|NCT01950715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989772|NCT05734677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989773|NCT00958334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989774|NCT02062489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082975|NCT03180710|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34082976|NCT01685879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34082977|NCT05578339|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776202|NCT04668989|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776203|NCT02649400|||COHORT||CROSS_SECTIONAL|||||||
33776204|NCT04049201|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33776205|NCT01868789|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33776206|NCT04126473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776207|NCT02468921|||COHORT||PROSPECTIVE|||||||
33776208|NCT06363955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This trial is designed as a prospective, randomized, placebo-controlled, triple blinded, with two parallel groups and an equal allocation ratio in all groups. In this study, the intervention consists of delivery of a hydrogen carbamide/peroxide mouthwash or placebo mouthwash, made by the same manufacturer.|t|f|t|t
33907671|NCT03616587|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Dose escalation and expansion, first-in-human study to evaluate safety and tolerability of AZD9833 alone (Parts A and B) or in combination with palbociclib (Parts C and D) or with everolimus (Parts E and F) or with abemaciclib (±anastrozole) (Parts G and H) or with capivasertib (Parts I and J) or with ribociclib (±anastrozole) (Parts K and L) or with anastrozole (Parts M and N) in women with endocrine-resistant ER+ HER2- breast cancer not amenable to curative treatment.~Parts A, C, E, G, I, K, and M allow for dose escalation and/or de-escalation of AZD9833 alone or in combination with palbociclib, everolimus, abemaciclib (± anastrozole), capivasertib, ribociclib (± anastrozole) or anastrozole.~Based on the findings in dose escalation, the expansions (Parts B, D, F, H, J, L, N) will further investigate selected doses of AZD9833, alone or in combination with palbociclib, everolimus ,abemaciclib (±anastrozole), capivasertib ,ribociclib(±anastrozole) and anastrozole."||||
33989775|NCT05236634|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into 3 groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.||||
33989776|NCT01515592|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33989777|NCT06558162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Pregnant women assigned to groups will not know which method (name) they are using. The person who will conduct the research analyses will be someone independent of the researchers.|Pregnant women included in the study were randomized into two groups. One group will have fetal movements assessed using the Sadovsky method. The other group will use the Mindfetalness method.|t|f|f|t
33989778|NCT00490594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989779|NCT05093205|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33686842|NCT04250090|||CASE_ONLY||RETROSPECTIVE|||||||
33686843|NCT04266938|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33686844|NCT04352127|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33686845|NCT05544981|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907672|NCT04646460|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33907673|NCT05345223|||COHORT||RETROSPECTIVE|||||||
33907674|NCT05011071|||COHORT||PROSPECTIVE|||||||
33907675|NCT05951166|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single arm, multi-center study designed to evaluate the safety, and feasibility of the Gradient Denervation System||||
33907676|NCT06475742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907677|NCT06320756|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized Control Trial with an intervention arm and a control arm.|f|f|t|t
33907678|NCT05611801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907679|NCT05422794|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33989780|NCT06319625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989781|NCT04908852|||COHORT||PROSPECTIVE|||||||
33989782|NCT03423485|NA|SINGLE_GROUP||OTHER||NONE||||||
33989783|NCT01904344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989784|NCT04376203|||CASE_CONTROL||PROSPECTIVE|||||||
33989785|NCT00817219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34082978|NCT03186313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082979|NCT05525260|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34082980|NCT00695227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686846|NCT05906238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33686847|NCT01017575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686848|NCT03790007|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||3 types of local anesthetic applying method will be compared||||
33686849|NCT02314390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686850|NCT01871064|||COHORT||PROSPECTIVE|||||||
33686851|NCT06132828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686852|NCT03500185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686853|NCT00300079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686854|NCT03155360|||CASE_CONTROL||PROSPECTIVE|||||||
33686855|NCT04466345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686856|NCT05904327|||COHORT||PROSPECTIVE|||||||
33686857|NCT00376714|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33686858|NCT03891667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a placebo-controlled study using matching capsules for disulfiram and placebo. Neither the participant, the care provider, nor the investigator will know the randomized assignment. The research pharmacy and a researcher not involved with this study will keep the code regarding group assignment.|"Patients will be randomly assigned to one of two groups:~Treatment Group I- patients will receive Disulfiram for 8 weeks~Treatment Group 2 - patients will receive Disulfiram for 4 weeks followed by 4 weeks of placebo.~The dosing follows a fixed-flexible schedule. Clinical judgment guides dosing increases, based on patient tolerance, side effects, and response.~Week 1: 250 mg every other day. Week 2: 250 mg daily (or continuation of lower dose based on clinical judgment).~Week 3: 250 mg alternating with 500 mg/daily (or continued lower dose based on clinical judgment) Week 4: 500 mg daily (or continued lower dose based on clinical judgment)~Week 5-8: 500 mg/daily (or continued lower dose based on clinical judgment) :~Primary outcome is at week 10. Patients will be reassessed at week 14."|t|t|t|f
33686859|NCT00034749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686860|NCT00505479|||||PROSPECTIVE|||||||
33686861|NCT02854475|NA|SINGLE_GROUP||||NONE||||||
33686862|NCT05144334|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33686863|NCT01346215|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33686864|NCT05448976|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Saliva and serum of periodontitis and smoking patients collected for analyzing arginine metabolites.||||
33686865|NCT01975987|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33686866|NCT03072771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686867|NCT01116479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686868|NCT05261776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as accessor of the study would be kept blind of the treatment group to which patient would be allocated. After the complete initial screening process, every recruited patient will be accessed by an independent assessor, expert will use outcome measuring tools. his will be recorded as baseline measurement assessment||f|f|f|t
33721433|NCT03066674|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721434|NCT03659981|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721435|NCT05025150|||COHORT||PROSPECTIVE|||||||
33721436|NCT05647473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33721437|NCT00887354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721438|NCT05726812|||CASE_ONLY||PROSPECTIVE|||||||
33721439|NCT01374087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721440|NCT02594839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907680|NCT02166463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907681|NCT06208267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be recruited in the pre-operative clinic for surgery and randomized once all paperwork is completed. This randomization will be completed by a research assistant and transmitted to pharmacy to allow for the delivery of the proper medication packet. Neither the patient nor the treating physician will be made aware of the group to which the patient has been assigned.||t|t|t|f
33907682|NCT05142618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907683|NCT01903811|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907684|NCT04922268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33907685|NCT04869436|NA|SINGLE_GROUP||TREATMENT||NONE||Single group 6 months treatment with Dupilumab.||||
33907686|NCT05921032|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33907687|NCT04934527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907688|NCT06416072|||COHORT||PROSPECTIVE|||||||
33907689|NCT06274515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907690|NCT06033196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907691|NCT06384157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized, double-blind, placebo-controlled study where the investigator, assessor, sponsor and participant are masked.||t|t|t|f
33907692|NCT06493851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||hyperbaric oxygen therapy (2ATA, 100% oxygen) vs. sham (1.2ATA, 21% oxygen)|t|t|t|t
33907693|NCT05800574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907694|NCT03850574|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"1. Part A: Tuspetinib dose escalation~2. Part B: Tuspetinib dose exploration~3. Part C: Tuspetinib monotherapy dose expansion~4. Part C: Tuspetinib in combination with venetoclax (doublet therapy) dose expansion~5. Part D: Tuspetinib in combination with venetoclax and azacitidine (triplet therapy) dose exploration"||||
33907695|NCT04913870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907696|NCT06276465|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible patients will be randomly allocated in a 1:1 ratio to either the:~* Control arm: ADT + darolutamide.~* Experimental arm: ADT + darolutamide + SBRT."||||
33907697|NCT04691323|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33907698|NCT06260228|NA|SINGLE_GROUP||OTHER||NONE||||||
33907699|NCT06561321|NA|SINGLE_GROUP||TREATMENT||NONE||"The treatment duration will span 16 weeks.~1. Following this 16-week period, participants who achieve disease clearance may discontinue the treatment. Patients who stop treatment at 16 weeks will be assessed for their sustained drug response, and their status of clearance will be followed at regularly scheduled visits up to 52 weeks.~2. For those whose condition has not cleared, they will continue with the extension period with the treatment from 16 weeks until their disease becomes clear or until the conclusion of the study (52 weeks), whichever comes first.~At the 52-week there will be a follow-up visit for all patients to monitor the response and check if they have maintained their response. As the drug already has a good safety profile and multiple assessments/outcome measures are being implemented, no additional follow-up is necessary but patients will be educated to come in for check-ups if any AEs persist."||||
33907700|NCT05629936|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33907701|NCT00453505|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
33907702|NCT06176300|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Three intervention strategies (i.e., PAR - the SEED Method and Youth Voices, Emerging Leaders hospital-based intervention, and Stakeholder Education) form the community-level approach to prevent youth violence. The interventions will be implemented in communities in randomized order to evaluate their combined influence.||||
33907703|NCT06047080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907704|NCT06470048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907705|NCT04686305|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The overall objective of DL-03 is to identify the partner of choice to be used in combination with T-DXd for first-line (treatment naïve patients with metastatic disease) HER2-overexpressing NSCLC patients.~Part 4 will consist of 2 Arms (4A and 4B) utilizing T-DXd in combination with rilvegostomig without or with carboplatin (ﬁrst 4 cycles in Arm 4B only). In addition to safety \& tolerability, the study will also assess preliminary efficacy based upon ORR, DoR, DCR, OS, PFS among treatment groups.~Part 3 will consist of 2 Arms (3A and 3B) utilizing T-DXd in combination with volrustomig without or with carboplatin (ﬁrst 4 cycles in Arm 3B only). The initial portion of Part 3 will assess two different doses of volrustomig for safety and tolerability. In addition to safety \& tolerability, the study will also assess preliminary efficacy based upon ORR, DoR, DCR, OS, PFS among treatment groups.~Part 2 was not initiated.~Part 1 is completed."||||
33989786|NCT00205686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686869|NCT03231150|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participants that do not experience at least a 50% reduction in pain following phase 1 will undergo randomization to either USGI or ATGI, both injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml. Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach, whereas execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach. The patients will be randomized into these groups by a specialized statistical computerized system that randomly selects a number to the participant. An even or an odd number represents which form of injection the patient is to receive.|This investigation will be chronologically divided into four stages that will commence after procurement of institutional review board (IRB) approval and funding, namely: 1) screening and enrollment, 2) random treatment allocation and treatment, 3) data collection and analysis, and 4) presentation and publication. We anticipate that it will take approximately 23.5 months to execute the clinical experiment and to prepare the report for publication.|f|t|t|f
33686870|NCT04659291|||COHORT||PROSPECTIVE|||||||
33686871|NCT00636701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33686872|NCT03648723|||CASE_CONTROL||PROSPECTIVE|||||||
33686873|NCT01690338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686874|NCT01574755|||COHORT||RETROSPECTIVE|||||||
33686875|NCT04333043|||COHORT||PROSPECTIVE|||||||
33686876|NCT06010875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686877|NCT00260611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686878|NCT02265601|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33686879|NCT06461429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The default position is that domains run on the PLATIPUS platform will be randomisation provided on a blinded basis. Blinding, however, may not always be feasible for some interventions and this will be specified in the related Domain-Specific protocol.|PLATIPUS is an Adaptive Platform Trial. Multiple interventions will be tested in this adaptive platform trial and each will be described in domain-specific platform appendices. Pregnant women and people at risk of preterm birth will participate in 'Pregnancy Domains'. Infants born preterm will participate in 'Neonatal Domains'.|t|t|t|t
33686880|NCT05283473|||CASE_ONLY||PROSPECTIVE|||||||
33686881|NCT01856764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686882|NCT03185117|||COHORT||PROSPECTIVE|||||||
33686883|NCT00862108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686884|NCT01967784|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33686885|NCT00019110||||TREATMENT||||||||
33686886|NCT04597372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33686887|NCT00003930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686888|NCT02632903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907706|NCT06266416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"This study will evaluate the efficacy of IMAGE with 14-18-year-old Black girls (n=300) and male caregivers (n=300) in a 2-arm individually randomized controlled trial. The researchers will compare SRH outcomes (STI incidence, self-reported sexual behavior) at 6- and 12-months among girls randomized to IMAGE or a time-matched general health promotion control program (FUEL).~The researchers will simultaneously evaluate implementation determinants (barriers, facilitators, constraints) and processes at Community Based Organizations working through the 3 steps of the implementation model (Prepare, Roll out, and Sustain)."|f|f|t|f
33907707|NCT05292404|RANDOMIZED|PARALLEL||TREATMENT||NONE||PCSK9 inhibitor||||
33907708|NCT04231760|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33907709|NCT05947058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907710|NCT05147636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907711|NCT06294925|||COHORT||PROSPECTIVE|||||||
33907712|NCT02432560|||COHORT||PROSPECTIVE|||||||
33989787|NCT00174551|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33989788|NCT02305394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33989789|NCT00541788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989790|NCT05604430|||CASE_ONLY||PROSPECTIVE|||||||
33989791|NCT02816996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989792|NCT04906772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989793|NCT05467111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989794|NCT06509568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989795|NCT00760825|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33989796|NCT04924920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cross-over design. The study has one single arm cross-over treatment design. The same patient will be assessed by means of the two tests. The sequence of application will be randomly generated and applied to the patients.||||
33989797|NCT05389722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989798|NCT03475303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33989799|NCT01978743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989800|NCT04308850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989801|NCT03476473|||COHORT||CROSS_SECTIONAL|||||||
33989802|NCT01462279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989803|NCT00280644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989804|NCT05704426|||COHORT||OTHER|||||||
33989805|NCT03251534|||COHORT||PROSPECTIVE|||||||
33989806|NCT03429582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989807|NCT02284490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989808|NCT06627764|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989809|NCT01350908|NA|SINGLE_GROUP||OTHER||NONE||||||
33989810|NCT04296435|||COHORT||RETROSPECTIVE|||||||
33989811|NCT03350828|||COHORT||PROSPECTIVE|||||||
33989812|NCT01144494|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33686889|NCT06197399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686890|NCT05009082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686891|NCT01253330|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33907713|NCT03640858|NA|SINGLE_GROUP||TREATMENT||NONE||"Study visits take place within the patients' usual hemodialysis unit consistent with their routinely scheduled dialysis sessions. Beginning week 5 and 25 participants use the Theranova dialyzer until the end of the dialysis week on week 16 and 48. Participants answer 9 questions at least at one session regarding symptoms experienced since their last session using the LEVIL application. Furthermore, participants answer a single time to recovery question at the first treatment of weeks 1, 16, 24, and 48 to get more detailed information on recovery time after dialysis in addition to completing the 5-D Pruritus and the Restless Legs Syndrome scales.~Bloodwork is drawn at 4 intervals throughout the study for laboratory evaluation.~Participants have an echo at baseline and between weeks 12 to 16, 20-24 and 44-48 while on the Theranova dialyzer.~In addition to this, participants will have non-invasive monitoring of circulatory stress using the CVInsight contact device."||||
33907714|NCT05780983|NA|SINGLE_GROUP||PREVENTION||NONE||All participants enrolled in the pilot trial will receive the intervention, all activities will be unblinded. Older adults utilizing outpatient primary care clinics belonging Atrium Wake Forest Baptist Health. All activities will take place within a clinical setting. Participants will be asked to monitor their sleep-activity behaviors while at home.||||
33907715|NCT06246799|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized open label study. There are 2 groups, with 2 sub groups, 1A, 1B and 1C included within Group 1.||||
33907716|NCT05877157|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33907717|NCT02262832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907718|NCT05973630|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33907719|NCT00804154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907720|NCT05941377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907721|NCT03639883|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Treating investigator will administer the study medication. Evaluating Investigator will perform the safety and efficacy evaluations.|Randomized, double-blind, vehicle-controlled, dose-escalation|t|f|t|t
33907722|NCT04145440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|The study is open label as all patients receive the same Investigational Medicinal Product (IMP) and same dose|2 cohorts by disease status (Cohort 1: Patients with newly diagnosed or relapsed membranous nephropathy; Cohort 2: Patients with membranous nephropathy refractory to immunosuppressive treatment)||||
33907723|NCT06111027|NA|SINGLE_GROUP||TREATMENT||NONE||Usability study||||
33907724|NCT06262477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907725|NCT06057948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907726|NCT05092386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Open label design will be adopted for children and adolescents aged 6-17 years and infants aged 3 months, and randomized, blind and positive control design was adopted for other populations||f|f|t|t
33907727|NCT04164641|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single Center, Non-Randomized, Single treatment group||||
33907728|NCT05217888|||COHORT||PROSPECTIVE|||||||
33907729|NCT01747213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907730|NCT06176664|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot trial to assess feasibility of the protocol for a three-armed, open-label randomized controlled trial||||
33907731|NCT05343572|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot, open-label, non-randomized study to investigate the use of autologous bone marrow derived stem cells (peripheral mobilization) for cell-based therapy in treating AS, AE, and RIF.||||
33907732|NCT06158724|||COHORT||PROSPECTIVE|||||||
33907733|NCT05849090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907734|NCT03710603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907735|NCT06079281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907736|NCT04196712|||COHORT||CROSS_SECTIONAL|||||||
33907737|NCT06539247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded assessor was considered to minimize bias in outcome measurements. The assessor was unaware of the intervention group assignment for each participant.|Group A: Motor Relearning Approach with EMS Group B: Proprioceptive Neuromuscular Facilitation Technique with EMS|f|f|f|t
33907738|NCT06334042|||COHORT||PROSPECTIVE|||||||
33989813|NCT03276754|||COHORT||PROSPECTIVE|||||||
33989814|NCT06563271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989815|NCT03187522|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, multi-center, post-market clinical follow-up, non-randomized registry of patients treated with the TREO stent-graft||||
33989816|NCT05319847|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label, Single Group Design|||||
33989817|NCT01723930|||COHORT||PROSPECTIVE|||||||
33907739|NCT06365385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This is a non-blind trial, since both participants and the investigator delivering the test-meal will be able to see the ingredients and the order in which they are consumed. However, outcome assessors will be blinded to the intervention sequence.|This study is a randomised controlled trial with a counterbalanced crossover design. Block randomisation will be performed by an external researcher, and allocation concealment will be ensured through the use of sequentially numbered, opaque, sealed envelopes.|f|f|f|t
33907740|NCT04921501|NA|SINGLE_GROUP||OTHER||NONE||Prospective single arm monocentric descriptive and evaluation study.||||
33989818|NCT05916131|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Adaptive randomization with minimization method will be conducted to ensure equal number of participants (n=10) will be randomized into the same number of the 4 experimental conditions (i.e., in 1:1:1:1 ratio). The randomization will be stratified based on whether the participant have severe hypoglycemia within the year or spending greater or equal to 1 percent of time in level 2 hypoglycemia on CGM, and the status of closed-loop pump use.||||
33989819|NCT06407700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding,refers to a practice where study participants are prevented from knowing certain information that may somehow influence them-thereby tainting the results.|Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial.|f|f|f|t
33989820|NCT02866357|||CASE_ONLY||PROSPECTIVE|||||||
33989821|NCT06560294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989822|NCT03400020|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907741|NCT06241456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989823|NCT02464553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989824|NCT00128791|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33686892|NCT02430376|||FAMILY_BASED||RETROSPECTIVE|||||||
33686893|NCT03642912|||COHORT||PROSPECTIVE|||||||
33686894|NCT00612729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33686895|NCT05165745|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33686896|NCT02669654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686897|NCT00783770|||COHORT||CROSS_SECTIONAL|||||||
33686898|NCT01467427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686899|NCT02189954|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33686900|NCT04249609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33686901|NCT02895009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33686902|NCT05909527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686903|NCT03642093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686904|NCT02309463|||COHORT||PROSPECTIVE|||||||
33686905|NCT00065364|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33686906|NCT03934697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686907|NCT03588780|||COHORT||RETROSPECTIVE|||||||
33686908|NCT01563146|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33686909|NCT01661985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686910|NCT03413943|RANDOMIZED|PARALLEL||OTHER||SINGLE|The gaze training subjects will be blinded to their cohort assignment, but investigators will know in order to carry out the proper training pending randomization.|After identification of the expert gaze, subjects will be randomized into explicit or implicit gaze training techniques.|t|f|f|f
33686911|NCT03291418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Encapsulated tablets||t|t|t|t
33686912|NCT02480725|||COHORT||PROSPECTIVE|||||||
33686913|NCT04293627|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33686914|NCT00805376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686915|NCT03877081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind randomized controlled trial|t|f|t|f
33686916|NCT02051816|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33686917|NCT04092855|||COHORT||PROSPECTIVE|||||||
33686918|NCT03818984|NA|SINGLE_GROUP||PREVENTION||NONE||Men will be offered 3 safer conception counseling sessions plus 2 booster sessions||||
33686919|NCT03744000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686920|NCT04006782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686921|NCT03736707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Neonates will be randomized and assigned either to selective HFOV or CMV|t|f|t|t
33686922|NCT03588247|||COHORT||PROSPECTIVE|||||||
33686923|NCT02446743|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686924|NCT04737057|RANDOMIZED|PARALLEL||TREATMENT||NONE|not possible, since interventions are different|||||
33686925|NCT00148551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33686926|NCT02953158|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686927|NCT02755038|||COHORT||CROSS_SECTIONAL|||||||
33686928|NCT01695668|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686929|NCT05342532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686930|NCT01276197|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33686931|NCT06080581|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721441|NCT01662518|NA|SINGLE_GROUP||TREATMENT||NONE||intervention group: 25-gauge biodegradable implant containing 350 μg of dexamethasone (DDS-25) for the treatment of decreased vision due to macular edema associated with central or branch retinal vein occlusion.||||
33721442|NCT06336915|||OTHER||RETROSPECTIVE|||||||
33721443|NCT02201706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776209|NCT04532151|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|This is an open-label study. The mRSS will be performed by an independent clinician||f|f|f|t
33686932|NCT01476644|NA|SINGLE_GROUP||OTHER||NONE||A prospective, longitudinal,observational cohort study to investigate how glaucoma affects patients' quality of life and visually-related function. Annual visits included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measure: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).||||
33686933|NCT04110600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686934|NCT01400438|NON_RANDOMIZED|PARALLEL||||NONE||||||
33686935|NCT05272644|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 128 women with stress urinary incontinence will be divided into two groups: urethral hypermobility and intrinsic sphincter deficiency; and they will be further randomized to 2 arms: surface electromyographic biofeedback arm, surface electromyographic biofeedback and electrical stimulation arm||||
33686936|NCT01048489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33686937|NCT01702181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33686938|NCT05596773|||COHORT||PROSPECTIVE|||||||
33686939|NCT04491097|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33686940|NCT03986762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686941|NCT03949491|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33686942|NCT06239818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33686943|NCT00856531|||||CROSS_SECTIONAL|||||||
33686944|NCT02054871|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33686945|NCT01307605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686946|NCT00306332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686947|NCT04356976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the staff responsible for the postoperative care of the patient will be masked for the allocation.|Randomised controlled trial comparing Ventralex hernia patch with Stratafix sutures for repair of primary ventral hernias|t|f|f|t
33686948|NCT02723318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907742|NCT05614063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907743|NCT04895436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907744|NCT00361829|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33907745|NCT05600088|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||up to 10 subjects with NSTEMI or unstable angina undergoing cryotherapy treatment of coronary vulnerable plaque lesions. Once This safety cohort has been enrolled, additional 20 subjects will be enrolled to further confirm feasibility and safety of the device.||||
33907746|NCT03598608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants in Part B: Randomized cHL-Monotherapy arm in the study will be randomized (1:1 ratio) to receive pembrolizumab or favezelimab.|||||
33907747|NCT06540911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907748|NCT04107857|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33907749|NCT06353386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907750|NCT03056755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907751|NCT04814667|||COHORT||RETROSPECTIVE|||||||
33907752|NCT05153226|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907753|NCT06107413|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907754|NCT06450197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907755|NCT00006150|||COHORT||PROSPECTIVE|||||||
33907756|NCT00001405|||COHORT||OTHER|||||||
33907757|NCT01661010|||COHORT||PROSPECTIVE|||||||
33907758|NCT06380751|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33907759|NCT05411081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907760|NCT06029114|||COHORT||PROSPECTIVE|||||||
33907761|NCT04443530|||COHORT||PROSPECTIVE|||||||
33907762|NCT06305247|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I is a dose escalation with backfill in participants with selected MAPKm advanced solid tumours.~Phase IIa (cohort expansion) is an open label randomised study."||||
33907763|NCT04545866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator, primary providers, primary data collectors, and participants will be masked to randomization arm assignment. Only research pharmacists and a designated respiratory therapist (or other qualified person) will be unmasked at the enrolling sites. The designated respiratory therapist (or other qualified person) must be unmasked to allow drug mixing at bedside for expeditious study drug administration; however, this person will not be the primary medical provider nor the primary data collector for that infant, and will not be otherwise involved in the research.||t|t|t|t
33907764|NCT05641948|||COHORT||PROSPECTIVE|||||||
33907765|NCT05742802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907766|NCT04905069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33907767|NCT06309719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907768|NCT05392946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907769|NCT03215030|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907770|NCT06369285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907771|NCT03538652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776210|NCT02080520|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907772|NCT03394066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907773|NCT04519619|||COHORT||PROSPECTIVE|||||||
33907774|NCT03802799|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label||||
33907775|NCT05672576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907776|NCT04533152|||COHORT||PROSPECTIVE|||||||
33907777|NCT06456463|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 (randomized) will evaluate 2 dose levels of tagraxofusp in parallel. The decision to proceed to Part 2 (non-randomized) will be based upon review of cumulative data from Part 1.||||
33907778|NCT03997968|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907779|NCT05543252|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907780|NCT06419634|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907781|NCT05537740|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907782|NCT00787423|||COHORT||PROSPECTIVE|||||||
33907783|NCT03837821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907784|NCT04252573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907785|NCT06205095|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33776211|NCT04894578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776212|NCT03305302|||CASE_ONLY||PROSPECTIVE|||||||
33776213|NCT03470285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776214|NCT03911193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776215|NCT01564082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907786|NCT04529044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907787|NCT01276470|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907788|NCT03485729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907789|NCT04359602|||CASE_ONLY||PROSPECTIVE|||||||
33907790|NCT06163482|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907791|NCT04251806|||COHORT||PROSPECTIVE|||||||
33907792|NCT00887939|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907793|NCT05614089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907794|NCT04126018|||COHORT||PROSPECTIVE|||||||
33907795|NCT05085366|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind||t|t|t|t
33989825|NCT04313855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a prospective case-control diagnostic study nestled in a cohort. The cohort is the set of patients operated on ambulatory surgery on the GHPSJ. In this cohort, pain patients according to the doctor's opinion are the cases. The controls are the patients who are not painful according to the doctor's opinion.~For reasons of available consultation time slots, it is not possible to see all of the patients. It was therefore decided to see all the painful patients and to select by lot the painless patients."||||
33989826|NCT02849457|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33989827|NCT05747950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researcher: Kırıkkale University, Institute of Health Sciences, 2nd year graduate student with thesis, physiotherapist, Zuhal Şevval Gökdere Participants: In this study, Kırıkkale University Faculty of Medicine, Physical Therapy and Physical Therapy in Rehabilitation Hospital and Tokat State Hospital Volunteer treated in the unit, between 18-75 years old, diagnosed with stroke, 45 individual will be included.|In the study, 45 individuals between the ages of 18-75 who were diagnosed with stroke and met the inclusion criteria will be recruited. Individuals will be divided into 3 groups according to different treatment methods.|t|f|t|f
33989828|NCT05391165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989829|NCT04123548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776216|NCT03393299|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33776217|NCT03215121|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Childrenwith documented obstructive sleep apnea (by sleep study or history obtained from the parent) due to enlarged tonsils and adenoid scheduled for tonsillectomy and adenoidectomy surgery will be enrolled in the study. Children will be randomly divided in two groups of 20 each based on the induction technique used:~Group --1: Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec Group - 2: Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec.~Group 3 - Induction of anesthesia started as follows while children are breathing spontaneously. Two handed mask airway + jaw thrust - 20 sec. then switch to one hand + chin lift - 20 sec."||||
33776218|NCT04439383|||COHORT||PROSPECTIVE|||||||
33776219|NCT01785641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989830|NCT00824291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989831|NCT01067833|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33989832|NCT01339247|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989833|NCT00695162|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989834|NCT02003833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989835|NCT00044135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989836|NCT06267703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989837|NCT01850173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989838|NCT06485531|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33989839|NCT00974935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989840|NCT00490204|RANDOMIZED|PARALLEL||TREATMENT||||||||
33989841|NCT02719652|||COHORT||PROSPECTIVE|||||||
33989842|NCT06187363|||COHORT||RETROSPECTIVE|||||||
33989843|NCT01157130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989844|NCT06125535|||COHORT||PROSPECTIVE|||||||
33989845|NCT04890418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The local pharmacy department is in charge of unmasking the drug.||t|t|t|f
33989846|NCT03546283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989847|NCT04045197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blind Randomised Controlled Trial|Randomised Controlled Trial|t|f|f|f
33776220|NCT03375814|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Osteoarthritis patients who have age between 40 to 75 years old will be selected; Based on radiographic images of patients the severity of joints damage will get detailed and they will be placed in between grade 2 and grade 3 in terms of gradation; these patients will be not located underwent surgery; Patients will complete WOMAC and KOOS questionnaires to obtain some information such as following items; They will be no history of injury; they will not have diabetic disorders, rheumatism and kidney disease, osteonecrosis, gout; they will not have a long history anti-inflammatory drugs consumption; They will not have individuals with insufferable jobs carrying heavy loads; Patients will not have the Body Mass Index (BMI) of 30 or more|t|f|f|f
33776221|NCT00523874|||DEFINED_POPULATION||PROSPECTIVE|||||||
33776222|NCT03076658|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776223|NCT04640571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33776224|NCT02838225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776225|NCT03406442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776226|NCT01270997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776227|NCT03824938|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Study biostatistician will derive the randomization schedule. Study pharmacy will make assignments and maintain blinding until data analysis is complete for the full sample.|This is a within-subject design double-blind RCT in which each participant receives 1 of 3 treatments at 3 timepoints (i.e., 3 separate days separated by 1-week washout periods).|f|f|f|t
33776228|NCT05244187|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 assignment||||
33776229|NCT06529562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776230|NCT03510858|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33776231|NCT04565314|NA|SINGLE_GROUP||TREATMENT||NONE||Participating mothers nursing children age 0-3 months at enrollment will receive 3 months of treatment with one packet of Plumpy'Mum.||||
33776232|NCT00972543|RANDOMIZED|PARALLEL||TREATMENT||||||||
33776233|NCT04716140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33776234|NCT04126525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776235|NCT04456738|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33776236|NCT01220141|||COHORT||PROSPECTIVE|||||||
33776237|NCT06418035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776238|NCT00451815|RANDOMIZED|PARALLEL||TREATMENT|||Double|||||
33776239|NCT05255263|RANDOMIZED|PARALLEL||OTHER||SINGLE||Pragmatic, cluster-randomized, open-labeled, multiple-crossover trial|f|f|f|t
33776240|NCT02541539|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33989848|NCT02354339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a study with two groups of patients with metabolic syndrome. One group received Irvingia Gabonensis and the other received placebo as control.|t|f|t|f
33989849|NCT04238754|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Epidiolex is flavor masked with cherry syrup.|Within subject comparison of Epidiolex to placebo. The order of study drug (active Epidiolex or placebo) is randomized across participants. Epidiolex is flavor masked with cherry syrup.||||
33989850|NCT02431221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34082981|NCT05678361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Psychotherapists and outcome assessors are blind to participants' group membership (i.e., sleep versus wake after exposure therapy)|Randomised controlled trial|f|t|f|t
34082982|NCT06098989|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multi-center, open-labeled, partly randomized study.||||
33776241|NCT04367142|||CASE_CONTROL||PROSPECTIVE|||||||
33776242|NCT00061360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776243|NCT03323151|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase I: Standard 3+3 design with the primary objective of determining the maximum tolerate dose (MTD)/recommended phase 2 dose (RP2D) of this combination in MCL. Both ibrutinib-pretreated and ibrutinib-naïve patients will be enrolled.~Phase II: Dose Level 2 is the RP2D. Patients will be enrolled to two cohorts, based on prior ibrutinib treatment: BTK-naïve and BTK-pretreated (BTK pretreated closed 8/7/2020)."||||
33776244|NCT00896454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776245|NCT05843175|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Randomised, single-centre, controlled crossover in parallel groups (pregnant and non-pregnant women with type 1 diabetes)|t|t|f|f
33776246|NCT01577030|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33776247|NCT03976310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This single arm protocol will study individual patient responses to 12 months of benralizumab treatment and early means of detecting them. The model is a prognostic study that will use information detected via baseline quantitative thoracic computed tomography for predicting improvement in exacerbation rate 52 weeks after the start of treatment.||||
33776248|NCT00649480|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33776249|NCT05476211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776250|NCT00255567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776251|NCT04436081|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776252|NCT00237562|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33776253|NCT04636203|||COHORT||CROSS_SECTIONAL|||||||
33776254|NCT05076370|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Initial safety pilot phase of 6 participants,(3 methadone and 3 on Buprenorphine) The general study is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or buprenorphine.||||
33776255|NCT01015573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776256|NCT02619708|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33776257|NCT03061669|||OTHER||PROSPECTIVE|||||||
33776258|NCT04368195|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind|Randomised controlled trial|t|f|t|t
33776259|NCT06475898|||COHORT||PROSPECTIVE|||||||
33776260|NCT00657111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776261|NCT01966536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776262|NCT01064583|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776263|NCT03174795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776264|NCT02636881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776265|NCT02358460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776266|NCT00671684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34082983|NCT04511325|RANDOMIZED|CROSSOVER||OTHER||NONE||For this randomized cross-over study, participants (45-80 y, BMI 25-35 kg/m2, fasting blood glucose \>126 g/dL, HbA1c 6.5-9%, non-frequent white potato consumption of \<2 servings per week) will be randomly assigned to receive pre-prepared baked white potato (100g cooked with skin; 100kcals) or a calorie-matched refined grain (75g cooked long-grain white rice; control) daily for each or two 12-week treatment periods, separated by a 2-week washout. Randomization of participants in the potato or the calorie-matched refined grain group will be done during the screening visit.||||
34082984|NCT00417066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082985|NCT00688441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34082986|NCT04349644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082987|NCT04256343|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and the outcomes assessors will be blinded to which dose of D2O the participant received, only the lead principal investigator and the investigators will know which condition each participant has been assigned to. The protein synthesis analysis will be carried out in a blinded fashion such that the individuals utilizing the analytical machines/interpreting the data will be unaware of who was assigned to which condition.|This study will be a double blind, randomized, parallel control trial.|t|f|f|t
33989851|NCT05026294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Pretest-posttest control group design was used. A sample of 47 male children participated in the current study. After gathering the baseline measurements, the participants were randomly assigned into three groups: experimental group I, (EGI) contained 16 participants, experimental group II (EGII) contained 16 participants, and control group, (CG) contained 15. The stratification was done using sealed envelopes. The children were not aware of their group.|f|f|f|t
33989852|NCT04574219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989853|NCT00962611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989854|NCT01831362|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33989855|NCT03590639|||OTHER||PROSPECTIVE|||||||
34082988|NCT03238417|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Dynamic waitlist control design with a group of 7 VA facilities was randomly allocated to Evidence-Based Quality Improvement (EBQI) in Year 1 (while 14 VA facilities serving as waitlist controls), the second group of 7 VA facilities was randomly allocated to EBQI in Year 2 (while the 7 remaining VA facilities and the first 7 EBQI sites serving as control), and the final group of 7 VA facilities was randomly allocated to EBQI in Year 3 (while the first 14 EBQI facilities subsequently serving as control). By the end of the three year study period, a total of 21 VA facilities received at least 1 year of EBQI.||||
33989856|NCT00006218||||TREATMENT||||||||
33989857|NCT04583657|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This monocentric study is an interventional, randomized, double-blind, controlled study.|t|f|t|f
33989858|NCT02811666|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33989859|NCT01364532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989860|NCT04543357|||OTHER||PROSPECTIVE|||||||
33989861|NCT03616730|||CASE_CONTROL||PROSPECTIVE|||||||
33989862|NCT02663960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989863|NCT04365153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989864|NCT01826058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989865|NCT00963482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989866|NCT05383794|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989867|NCT01610804|||||PROSPECTIVE|||||||
33989868|NCT01593852|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33989869|NCT04893057|||COHORT||CROSS_SECTIONAL|||||||
33989870|NCT02902211|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989871|NCT06559618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled clinical trial|Phase 1b, single-center, randomized, double-blind, placebo-controlled study in adults with spinal cord injury with neurogenic bladders and bacteriuria who use indwelling catheters, or who require intermittent catheterization for bladder drainage|t|t|t|t
33989872|NCT01867164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989873|NCT06562699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33989874|NCT02950805|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33989875|NCT01193712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989876|NCT00407147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989877|NCT05329103|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33989878|NCT03607253|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33989879|NCT02604420|||COHORT||PROSPECTIVE|||||||
33989880|NCT01794845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989881|NCT03596294|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, double-blind, two-period, cross-over Phase 1 study||||
33989882|NCT02233985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989883|NCT05948683|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33989884|NCT03569059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to one of four groups in parallel for the duration of the study.|f|f|f|t
33989885|NCT05108467|||CASE_CONTROL||PROSPECTIVE|||||||
33989886|NCT00985894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33989887|NCT03611608|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33989888|NCT02900872|||CASE_ONLY||RETROSPECTIVE|||||||
33776267|NCT01913964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776268|NCT01016990||||TREATMENT||NONE||||||
33989889|NCT03967938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989890|NCT01695538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989891|NCT03689595|||COHORT||PROSPECTIVE|||||||
33989892|NCT06558864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989893|NCT06331338|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33989894|NCT05754983|||COHORT||PROSPECTIVE|||||||
33989895|NCT00187720|NON_RANDOMIZED|PARALLEL||||NONE||||||
33989896|NCT06264960|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The nurse responsible for conducting all measurements, including pain and anxiety assessments using the Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI), was not part of the research team.~The nurse, being independent and not aware of the participants' group assignments, helps to ensure that the assessments are conducted impartially, without knowledge of which intervention each participant received."|This single-center, single-blind, randomized controlled trial was conducted in Izmir, Turkey, from July 2021 to July 2022. Participants were randomly assigned to one of three groups: intervention 1 (music), intervention 2 (breathing exercises), or control (standard care), in a 1:1:1 ratio.|f|f|f|t
33989897|NCT06405997|||COHORT||PROSPECTIVE|||||||
33989898|NCT06401265|||CASE_CONTROL||RETROSPECTIVE|||||||
33989899|NCT00335348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989900|NCT06559111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33989901|NCT01031394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989902|NCT06533345|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This research is a prospective longitudinal observational study to gather preliminary data for a future Sequential Multiple Assignment Randomized Trial (SMART).||||
33989903|NCT04437199|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33989904|NCT00186355|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33989905|NCT05315726|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33989906|NCT03016858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989907|NCT04972864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989908|NCT00305123|||COHORT||PROSPECTIVE|||||||
34082989|NCT02674516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34082990|NCT00818935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34082991|NCT05402956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|f|f|f|t
33686949|NCT05338398|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Control Group (Group 1):~Standard Therapy Hematologic malignancy Saline mouthwash (±Bocaliner™)~Intervention Group (Group 2):~Benzydamine mouthwash Hematologic malignancy Benzydamine mouthwash (±Bocaliner™)"||||
33686950|NCT00069888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33686951|NCT00842452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686952|NCT03500679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33686953|NCT06522191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33686954|NCT05791903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|randomized|Experimental, randomised controlled, single-blind study|t|f|f|t
33686955|NCT02463552|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33686956|NCT00421447|||CASE_CONTROL||PROSPECTIVE|||||||
33686957|NCT02417948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776269|NCT00131560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776270|NCT03117543|||COHORT||CROSS_SECTIONAL|||||||
33776271|NCT04488172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776272|NCT02912429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33989909|NCT05613686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33989910|NCT01528150|||COHORT||PROSPECTIVE|||||||
33989911|NCT05301881|NA|SINGLE_GROUP||TREATMENT||NONE||Lesion(s) will be treated with surgery, radiotherapy or radiofrequent ablation depending on the location. The treatment is standard of care and will be decided in the treating team of the patient.||||
33989912|NCT06333171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects in both aims will be assigned to Group A or Group B using a randomization scheme. Each study participant for each aim is randomly assigned to either treatment of placebo using permuted block randomization|This is a double-blind, randomized, placebo-controlled trial design.|t|f|t|f
33989913|NCT01888523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33989914|NCT02892747|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33989915|NCT05221034|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33989916|NCT04836598|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly allocated into 2 groups (Consort Chart) and each group categorized into 3 subgroups according to BMI, into class I: Obese Class 1 30-34.9kg/m2, Class II: Obese Class II 35-39.9kg/m2 and class III: Morbidly Obese Class III \>40kg/m2||||
33989917|NCT06183853|||CASE_ONLY||OTHER|||||||
33989918|NCT06462066|RANDOMIZED|PARALLEL||OTHER||NONE||"The study plan will include a baseline visit (V1), in which eligible patients will be randomly assigned in one of the two groups: Group 1 will apply GLUTACK/Glubran® Tiss 2 whereas Group 2 GLUTACK-Glubran® 2.~Application of surgical glue will be done by the surgeons, after a previous appropriate training, carried out by principal investigator (standardization application mode). Trial parameters will be recorded by a clinical evaluator at 24 hours (V2), 7 days (V3), 14 days (V4), 90 days (V5) and 180 days (V6). The last evaluation will be performed at V6, after 6 month."||||
33989919|NCT00927069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989920|NCT06169605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989921|NCT04197492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989922|NCT03040362|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33989923|NCT03805815|||COHORT||PROSPECTIVE|||||||
33989924|NCT02924363|||COHORT||PROSPECTIVE|||||||
33989925|NCT02197481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34082992|NCT02879292|||CASE_ONLY||RETROSPECTIVE|||||||
34082993|NCT04014530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In the phase-1 part of the study 2-4 groups of 3 patients each are treated with pembrolizumab 200mg i.v. q3w but with increasing ataluren doses (i.e. group1 25%, group2 50% and group3 100% of 10-10-20mg/kg). These can be either pMMR mCRC, dMMR mCRC or dMMR EC patients. The reported toxicity in phase-1 will be used to define the maximum tolerated dose (MTD) of the combination, that will determine the ataluren dose in phase-2.~In the phase-2 part of the study a dMMR group (cohort A, 20 patients either CRC of EC) and a pMMR group (cohort B, 15 CRC patients) will be treated with pembrolizumab 200mg i.v. q3w combined with ataluren t.i.d. at the MTD defined in phase-1.~Historic case-matched controls from the MK-3475-016 study (ClinicalTrials.gov Identifier NCT01876511) and the MK-3475-177 study (ClnicalTrials.gov Identifier NCT02563002)."||||
34082994|NCT04206306|||COHORT||PROSPECTIVE|||||||
34082995|NCT05475522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Tumor extent of resection will be assessed by radiologists blinded for the treatment arm||f|f|f|t
34082996|NCT05836480|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989926|NCT00112190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989927|NCT01527006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686958|NCT03044639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|No information on the lipid emulsion's type provided neither to the patient nor the leading physician|Randomized, double-blind, multi-centric study performed in four parallel groups|f|f|t|f
33686959|NCT02571036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686960|NCT02979327|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33686961|NCT01511393|||CASE_ONLY||PROSPECTIVE|||||||
33686962|NCT06309407|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants were randomized to wear either chest dosimeters only or chest and hand dosimeters for the duration of the study in order to measure differences in radiation readings by each dosimeter location.||||
33686963|NCT00155844|||CASE_CONTROL||OTHER|||||||
33686964|NCT02696187|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33686965|NCT02138526|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989928|NCT03100422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Lots will be drawn that assign to either robotic therapy or occupational therapy|randomized|f|f|t|t
33989929|NCT00709254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989930|NCT06366048|||CASE_CONTROL||RETROSPECTIVE|||||||
33989931|NCT00883922|||COHORT||PROSPECTIVE|||||||
33989932|NCT03853954|NA|SINGLE_GROUP||OTHER||NONE||This prospective open-label pilot study will examine the use of inhaled low dose methoxyflurane to facilitate shoulder reduction in a convenience sample of patients arriving with anterior shoulder dislocations. This study will test the feasibility of studying the addition of this analgesic agent to a reduction technique that classically eschews procedural sedation in order to increase successful reduction rates. Consenting eligible patients will be offered a first attempt at reduction using the method described by Cunningham, supported by self-administered low-dose methoxyflurane analgesia as instructed by the advanced/critical care paramedic. For unsuccessful first attempts, patients will then undergo the current standard of care for shoulder dislocations, which is reduction of the shoulder joint while under procedural sedation and analgesia.||||
33989933|NCT00875550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989934|NCT03327805|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Double-blind, placebo-controlled, crossover design|t|f|f|t
33989935|NCT03490058|||COHORT||PROSPECTIVE|||||||
33989936|NCT05262985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989937|NCT05796869|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33989938|NCT03115177|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33989939|NCT03839121|||COHORT||PROSPECTIVE|||||||
33989940|NCT03023956|||COHORT||RETROSPECTIVE|||||||
33989941|NCT01400087|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33989942|NCT00992147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989943|NCT05278325|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989944|NCT00687063|||OTHER||PROSPECTIVE|||||||
33989945|NCT01686451|RANDOMIZED|PARALLEL||||NONE||||||
33989946|NCT06560749|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33989947|NCT06053905|||OTHER||CROSS_SECTIONAL|||||||
33989948|NCT01649167|||COHORT||PROSPECTIVE|||||||
33989949|NCT06370377|||COHORT||CROSS_SECTIONAL|||||||
33989950|NCT02622737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33989951|NCT04865653|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||"Double-blind, placebo-controlled, 5-period cross-over design with five treatment conditions:~1. Oral drinking solution of 0.1 mg LSD base in 96% ethanol~2. Solid orodispersible film containing 0.1 mg LSD base~3. Oral drinking solution of 0.146 mg LSD tartrate in water (equivalent to 0.1 mg LSD base)~4. Intravenous administration of 0.146 mg LSD tartrate in water (equivalent to 0.1 mg LSD base)~5. Placebo"|t|t|t|f
33989952|NCT00915694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989953|NCT01468272|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989954|NCT06368219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33989955|NCT02297763|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33989956|NCT04012892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989957|NCT05402202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989958|NCT05705219|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33989959|NCT00804856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989960|NCT01736878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33989961|NCT04290858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989962|NCT06559514|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||In this single-blind, randomized controlled trial, adults aged years or older living with hearing impairment elderly will be randomized into either the intervention group (group-based multi-component psychoeducational inventions, GMC-PEIs intervention group) or the control group (waitlist control group).|f|f|f|t
33989963|NCT02253420|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33989964|NCT01488058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989965|NCT01354418|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33989966|NCT00349843|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33989967|NCT02944617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33989968|NCT02595762|||COHORT||PROSPECTIVE|||||||
33989969|NCT02186821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989970|NCT00637117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989971|NCT06340633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989972|NCT03772821|||COHORT||PROSPECTIVE|||||||
33989973|NCT03835715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989974|NCT05907421|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33989975|NCT02671526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989976|NCT04440592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989977|NCT03201523|NA|SINGLE_GROUP||PREVENTION||NONE||This is a quasi-experimental, pre-post study.||||
33989978|NCT04421508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989979|NCT06279338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989980|NCT04702581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33989981|NCT06156670|||COHORT||PROSPECTIVE|||||||
34082997|NCT05207865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776273|NCT04271384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776274|NCT01196104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776275|NCT01521949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776276|NCT02447679|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34082998|NCT04343183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The biostatistician and radiologist will not know which group received HBOT.|This study will utilize a single-center sequential two-parallel-group (HBOT/Standard care) randomized controlled design with 2 looks to allow for early stop due to clear benefit/harm.|f|f|f|t
34082999|NCT03519009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083000|NCT05444816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083001|NCT03103503|||CASE_ONLY||PROSPECTIVE|||||||
34083002|NCT03622567|NA|SINGLE_GROUP||OTHER||NONE||||||
34083003|NCT04412421|||COHORT||PROSPECTIVE|||||||
34083004|NCT04951141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083005|NCT00692822|||CASE_CONTROL||PROSPECTIVE|||||||
34083006|NCT00383799|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083007|NCT04710667|||COHORT||PROSPECTIVE|||||||
34083008|NCT04174066|||COHORT||PROSPECTIVE|||||||
34083009|NCT01313754|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33686966|NCT01846520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33686967|NCT01614379|||CASE_CONTROL||PROSPECTIVE|||||||
33686968|NCT05598827|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33686969|NCT05152264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) will be randomized to additional treatment with TENS or conventional analgesic treatment for 8 weeks in order to evaluate the acute effects of TENS treatment (n=40). Patients with endometriosis-related pain that is not frequent or without high pain intensity constitute an external control group. All patients in the study will receive TENS treatment for a total of 16 weeks, for evaluation of long-term effects of TENS treatment in chronic endometriosis-related pain.||||
33686970|NCT02597816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33686971|NCT02071784|||CASE_CONTROL||OTHER|||||||
33686972|NCT05649202|||COHORT||PROSPECTIVE|||||||
33686973|NCT01277081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686974|NCT05421403|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33686975|NCT05886517|NA|SINGLE_GROUP||TREATMENT||NONE|Nr. of all cause death patients at 30 days following TAVI/total patients|Evalutate all cause mortality at 30 days following TAVI||||
33686976|NCT01281527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686977|NCT01203176|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33686978|NCT00264862|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776277|NCT05040061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant were not made aware of the existence of the condition to which they were not assigned, nor the nature of that condition.|Participants screened to select-in GAD with a clinical interview are randomly assigned to either a savoring treatment intervention condition (SkillJoy) or an active treatment control condition emphasizing self-monitoring.|t|f|f|f
33776278|NCT04141111|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of clinical outcomes and patient reported outcomes||||
33776279|NCT01418092|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33989982|NCT05901870|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33989983|NCT00726674|||COHORT||PROSPECTIVE|||||||
33989984|NCT02890992|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34083010|NCT04030312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083011|NCT05854641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083012|NCT04768140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|SINGLE-BLIND TRIAL The patients were blinded to their group allocation.|A PROSPECTIVE, RANDOMIZED, CONTROLLED AND SINGLE-BLIND TRIAL|t|f|f|f
34083013|NCT05891548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant, Sponsor, Principal (non-injecting) Investigator, medical monitor, study coordinator, visual acuity technician, photographer, central reading center, and central laboratory will be masked to treatment assignment for the duration of the study.|Participants are randomly assigned to one of two treatment groups in parallel for the duration of the study.|t|t|t|t
34083014|NCT03118726|||COHORT||OTHER|||||||
34083015|NCT02940301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083016|NCT02809365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083017|NCT00226252|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34083018|NCT00794664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083019|NCT05075278|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34083020|NCT01284868|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083021|NCT04003909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083022|NCT03792646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized prospective clinical trial, double-blind, placebo-controlled intervention|t|f|t|f
34083023|NCT02119299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083024|NCT00103558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083025|NCT00010140|RANDOMIZED|||TREATMENT||||||||
34083026|NCT06019871|||COHORT||PROSPECTIVE|||||||
34083027|NCT04398836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083028|NCT00344799|||COHORT||PROSPECTIVE|||||||
33686979|NCT01283243|||COHORT||PROSPECTIVE|||||||
33686980|NCT00572143|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776280|NCT03930966|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective Study||||
33776281|NCT05084261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776282|NCT06396962|||CASE_ONLY||RETROSPECTIVE|||||||
33989985|NCT04627467|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm study in which healthcare workers were actively invited to participate. After verifying volunteer's eligibility through a survey that evaluated the presence of COVID-19 symptoms (primary efficacy outcome), 150 mg chloroquine base was dispensed in site by a pharmaceutical chemist at days 0, 15, 30, 45, 60, and 75. Questions regarding adverse drugs reactions (safety outcome) were included in the survey after the first dose was administered. Participants who discontinued chloroquine were followed up until study completion.||||
33989986|NCT00693628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083029|NCT06379243|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083030|NCT02659501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33686981|NCT05853627|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be randomly assigned to the STD vs. MM condition. The psychophysiology assessor, who will perform the data analysis, will be blind to Condition.|The efficacy of the MM intervention will be contrasted with a standard (STD) reactivation condition that does not include an intentional MM component. We will randomize ndividuals who have experienced a traumatic event and meet our entry criteria (please see research strategy) to one of the two treatment arms: STD/PPNL and MM/PPNL. Participants' psychophysiological (heart rate, skin conductance, corrugator electromyogram (EMG)) responses during script driven imagery of their traumatic event will constitute the R21 target.|t|f|f|t
33686982|NCT06455618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686983|NCT03555838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants, raters, and experimenters will be blinded to treatment allocation.|Within-subjects repeated measures design up to 40 SCI participants will be randomized to receive 6-week hand robotic training preceded by 20 min anodal 2mA tDCS or sham (3 sessions/week, 18 sessions total). Randomization will be done using a randomized block design with a block size of 2.|t|f|f|t
33686984|NCT05270161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33686985|NCT02803515|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33686986|NCT01206387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33686987|NCT00477074|||DEFINED_POPULATION||OTHER|||||||
33686988|NCT00812695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686989|NCT03143491|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 2, open-label, dose-rising trial. Subjects will enroll in three dose-rising cohorts of three subjects each. he next dose level cohort will enroll upon a finding of safety and tolerability at the previous cohort's first safety review. If a safety or tolerability issue arises in the first three subjects of a cohort, an additional three subjects will be enrolled at the same dose level. If ≥ 1 of the same safety and tolerability issue recurs in the additional 3 subjects, the prior dose-level will be determined to be the highest dose with an acceptable safety and tolerability profile. If no further safety and tolerability issues are identified in the expanded cohort, dose-escalation will continue.||||
33686990|NCT02370576|||COHORT||PROSPECTIVE|||||||
33686991|NCT02912143|||COHORT||PROSPECTIVE|||||||
33686992|NCT03954327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33686993|NCT00002779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686994|NCT03501771|NA|SINGLE_GROUP||TREATMENT||NONE||A single group, pre-post intervention study||||
33686995|NCT00805233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33686996|NCT04335201|NA|SINGLE_GROUP||TREATMENT||NONE|Italian Hospital|prospective, interventional, single-arm, multicentric, open label trial with a parallel retrospective collection of data on not treated patients from IRCCS, San Raffaele Scientific Institute institutional observational study (ClinicalTrials.gov Identifier: NCT04318366)||||
33686997|NCT00544531|||||PROSPECTIVE|||||||
33776283|NCT02359968|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33776284|NCT01513967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776285|NCT06318390|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776286|NCT01454713|||CASE_ONLY||RETROSPECTIVE|||||||
33776287|NCT01850966|||CASE_CONTROL||PROSPECTIVE|||||||
33776288|NCT06109259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33776289|NCT05608733|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33776290|NCT05023317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research assistants, blinded to condition, will collect baseline and 3-month follow-up data from participants. The investigators will also be blinded to participant group assignment.|Participants will be randomized to one of two conditions-(a) strengths based linkage to alcohol care plus usual care or (b) usual care only|f|f|t|t
33776291|NCT02263144|||CASE_ONLY||PROSPECTIVE|||||||
33776292|NCT00236821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776293|NCT01134211|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33776294|NCT04033991|||COHORT||RETROSPECTIVE|||||||
33776295|NCT05128292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776296|NCT02400307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776297|NCT05493904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776298|NCT04746430|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33776299|NCT00279994|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33776300|NCT04207684|NA|SINGLE_GROUP||OTHER||NONE||||||
33776301|NCT00145717|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33776302|NCT04288973|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33776303|NCT00977028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776304|NCT04342299|||COHORT||PROSPECTIVE|||||||
33776305|NCT06014567|||COHORT||PROSPECTIVE|||||||
33776306|NCT05153850|||CASE_ONLY||PROSPECTIVE|||||||
33776307|NCT05806424|||OTHER||OTHER|||||||
33776308|NCT02381860|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33776309|NCT03788148|||COHORT||RETROSPECTIVE|||||||
33776310|NCT03046303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776311|NCT01150851|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33776312|NCT05900453|||COHORT||PROSPECTIVE|||||||
33776313|NCT00773071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776314|NCT04012814|NA|SINGLE_GROUP||TREATMENT||NONE||Up to 200 subjects will be enrolled in the study to receive 3 Diode and 3 RF treatments.||||
33776315|NCT01818635|||CASE_CONTROL||PROSPECTIVE|||||||
33776316|NCT05465421|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Blinding of the participants and the operator is is not applicable, however outcome assessors and biostatistician will be blinded.||t|t|f|t
33776317|NCT01375894|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33776318|NCT03276923|||COHORT||PROSPECTIVE|||||||
33776319|NCT02478359|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33776320|NCT02328456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776321|NCT03406234|||COHORT||CROSS_SECTIONAL|||||||
33776322|NCT02900911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33776323|NCT01058863|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33776324|NCT06307938|||COHORT||PROSPECTIVE|||||||
33776325|NCT02839681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33776326|NCT05248464|||OTHER||CROSS_SECTIONAL|||||||
33776327|NCT01071265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776328|NCT02689856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776329|NCT00432861|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776330|NCT03094897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Open Label|||||
33776331|NCT05994599|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Laboratory Blinded||f|f|f|t
33776332|NCT03557983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776333|NCT01888562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776334|NCT04736940|||OTHER||PROSPECTIVE|||||||
33776335|NCT06117475|||CASE_ONLY||PROSPECTIVE|||||||
33776336|NCT02694614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776337|NCT05466474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989987|NCT04411966||SEQUENTIAL||DIAGNOSTIC||NONE||Participant received 18F-FLT and 18F-FDG at baseline, after 1st cycle , and after 2nd cycle of systemic chemotherapy.||||
33989988|NCT00104910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989989|NCT04904718|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33989990|NCT00647686|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33989991|NCT03744481|||COHORT||PROSPECTIVE|||||||
33989992|NCT00025818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33989993|NCT02545283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33989994|NCT03154047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989995|NCT04655261|||COHORT||PROSPECTIVE|||||||
33776338|NCT01833117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776339|NCT05711992|||CASE_ONLY||OTHER|||||||
33776340|NCT00150410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776341|NCT00388362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776342|NCT01151982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33776343|NCT01227343|||COHORT||PROSPECTIVE|||||||
33776344|NCT03351361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776345|NCT02292420|||CASE_ONLY||PROSPECTIVE|||||||
33776346|NCT05397938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776347|NCT03389893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776348|NCT04142463|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Patients will be recruited in phase 3 of the study, i.e. before the implementation of the care pathway (before-group) and in phase 6, i.e. after the implementation of the care pathway (after-group)||||
33776349|NCT03157102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776350|NCT00294996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776351|NCT01959880|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776352|NCT05993871|||CASE_CONTROL||RETROSPECTIVE|||||||
34083031|NCT01255163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study with code kept by NIA Pharmacist who did not share with Investigators and had no interaction with participants and caregivers.|Double-blind randomized placebo-controlled.|t|t|t|t
33776353|NCT00365495|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33776354|NCT03405662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blind assignment determined by a computer-generated random allocation schedule|"Participants randomized to the Active PBM group will use an active Vielight Neuro device, for 16 weeks, once every other day (e.g., Mon, Wed, Fri) for 20 minutes.~Participants randomized to the Sham PBM group will use a a sham Vielight Neuro device, for 16 weeks, once every other day (e.g., Mon, Wed, Fri) for 20 minutes.~All study participants will undergo cognitive and behavioral assessments, blood draw, and lumbar puncture at baseline (before using Vielight Neuro Gamma device) and after 16 weeks of using the Vielight Neuro Gamma device.~Upon completion of the post-16 week assessments, blood draw, and lumbar puncture, patients randomized to the Sham PBM group will be offered an opportunity to use an active Vielight Neuro Gamma device for 16 weeks. We will assess cognition and behavioral symptoms in Sham patients who opt to undergo active PBM 16 weeks after they start active PBM treatments."|t|t|t|t
33776355|NCT00347867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776356|NCT02372175|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33776357|NCT06048874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33776358|NCT03437434|||COHORT||RETROSPECTIVE|||||||
33776359|NCT00747981|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33776360|NCT04675242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-masked||t|f|t|f
33776361|NCT00403988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776362|NCT06190574|||CASE_CONTROL||RETROSPECTIVE|||||||
33776363|NCT01426620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776364|NCT03927872|||CASE_CONTROL||PROSPECTIVE|||||||
33776365|NCT00906295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776366|NCT03187561|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|All participants will be informed that they are being recruited into an intervention study targeting coparenting, but participants will not be informed about which arm of the study to which they have been assigned. Data collectors and outcome assessors will not be informed about which arm of the study to which participants have been assigned, to assure that all outcomes and evaluations of intervention are conducted blindly, to avoid experimenter bias.|In the proposed 3-arm RCT, in one arm families will experience Family Foundations (FF) intervention as originally formulated; in the second, families will receive an adapted FF (FF+) program that emphasizes coparenting in infant sleep contexts; the third arm will serve as controls.|t|f|f|t
33776367|NCT00129675|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33776368|NCT04268836|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, unmasked clinical study||||
33776369|NCT05381428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776370|NCT05353738|||COHORT||PROSPECTIVE|||||||
33776371|NCT06082128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the intervention the dyads cannot be blinded to allocation. The research nurse/officers involved in the consenting process will not be blinded as they will facilitate the second videoconference to inform the dyads about their allocated group (intervention or control). As data collection will occur electronically (via the FOCUSau platform) the research team will be blinded to which trial group the dyads were randomised to.|||||
33776372|NCT00510796|||CASE_ONLY||PROSPECTIVE|||||||
33776373|NCT05188365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33776374|NCT06314191|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33776375|NCT04669080|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||non-randomized pre-post test||||
33776376|NCT00876122|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776377|NCT05062629|||OTHER||RETROSPECTIVE|||||||
33776378|NCT04179994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study will be a single-center, longitudinal, triple-masked (for participants, operators, and statistician), equal ratio, randomized non-crossover design.|t|t|t|f
33776379|NCT06008535|||CASE_ONLY||PROSPECTIVE|||||||
33776380|NCT03890120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776381|NCT03699046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized at the time of surgery to either the control group or the intervention group.|The control group will be patients receiving knee arthroscopy alone and the intervention group will be patients receiving subchondroplasty and knee arthroscopy.|t|f|f|f
33776382|NCT05373602|||COHORT||RETROSPECTIVE|||||||
33776383|NCT02145481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33776384|NCT03386760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776385|NCT01203241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776386|NCT03688789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776387|NCT02460471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776388|NCT06479473|RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled patients with accordance to the inclusion criteria would first receive 4 to 6 cycles of chemoimmunotherapy (etoposide and cisplatin \& carboplatin with Adebrelimab). Then patients who were evaluated as partial response or stable disease would be assigned randomly to receive radiotherapy to all residual lesions followed by Adebrelimab maintenance or only Adebrelimab maintenance up to 2 years.||||
33776389|NCT04793464|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33776390|NCT04562506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33989996|NCT04137575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator and assessor is masked in terms of not knowing to which condition the participants will be randomized until after completion of the baseline assessment. The participants are masked in terms of not knowing that one intervention is hypothesized to yield larger effects than the other.|Participants are randomized in blocks of 16. Participants in each block will be randomly assigned in a 1:1 ratio to either CF-G or CC, resulting 2 x 8 groups of approx. 8 participants (min 5 and max 10 participants in each group). A computer-generated randomization list will be created by a person not directly involved in the intervention. Allocation to condition will take place after completion of the baseline questionnaire package|t|f|t|t
34083032|NCT05201092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083033|NCT04644172|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Pilot RCT with two arms: Immediate and Delayed Treatment with crossover to experimental intervention after 6-month followup. Delayed group is allowed to receive usual care while awaiting crossover. Testing is done for both groups at pre- and post-treatment and 6-month followup.|f|f|f|t
34083034|NCT00137553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776391|NCT01762163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776392|NCT00035958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776393|NCT02435511|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083035|NCT02295644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083036|NCT02501408|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083037|NCT00546403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776394|NCT05721339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776395|NCT01637493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776396|NCT04378634|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomised Controlled Trial|f|f|f|t
33776397|NCT03717675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776398|NCT03434535|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33776399|NCT02959138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907796|NCT05733598|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients will receive atezolizumab plus bevacizumab therapy combined with RP2.~Treatment Administration:~* RP2 administered intratumorally for a total of up to 8 doses as follows: Once every 2 weeks (Q2W) for the first 4 doses (Days 1, 15, 29, 43); Once every 3 weeks (Q3W) for up to 4 subsequent doses (Days 64, 85, 106, 127).~* The first 3 doses of bevacizumab will be administered intravenously (IV) at 10 mg/kg of body weight Q2W, starting with the fourth dose, bevacizumab will be given at 15 mg/kg of body weight Q3W. Starting with the second dose of RP2, atezolizumab will be administered IV at 840 mg for 2 doses Q2W. Starting with the fourth dose, atezolizumab will be administered IV at 1200 mg Q3W. When combination dosing with bevacizumab and atezolizumab starts, bevacizumab will be administered after atezolizumab on the same day, with a minimum of 10 minutes between dosing."||||
33907797|NCT04395001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The project manager, who is blinded of treatment group assignment, has the primary responsibility of collecting outcome data throughout the study.||f|f|f|t
33907798|NCT05970640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907799|NCT05882058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907800|NCT05007782|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907801|NCT06448286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, investigators and research staff will be blinded.||t|f|t|t
33907802|NCT03603600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Investigator implanting the IOL and designated site personnel will be unmasked to the assignment of IOLs. Subjects and designated postoperative evaluator(s) will be masked to the IOLs assigned.|Approximately 334 subjects will be implanted bilaterally with the enVista MX60EF trifocal MIOL, and approximately 167 control subjects will be implanted bilaterally with the enVista MX60E monofocal IOL|t|f|f|t
34083038|NCT00450957|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34083039|NCT04051541|NA|SINGLE_GROUP||OTHER||NONE|The investigator performing the ultrasound and the person timing the simulation were both blind to the method used for each push. An unblended investigator performed the pushes but did not assess the outcomes.|This is a simulation study in which all participants receive a dose of agitated saline through an IV using three different administration methods.||||
34083040|NCT00915590|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34083041|NCT02965651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083042|NCT00639119|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34083043|NCT03179241|||COHORT||PROSPECTIVE|||||||
34083044|NCT03985683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34083045|NCT04525521|||COHORT||PROSPECTIVE|||||||
34083046|NCT03356652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083047|NCT01298830|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083048|NCT02507791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083049|NCT00061581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083050|NCT03052894|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34083051|NCT05247164|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083052|NCT04961359|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34083053|NCT03588273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Monocentric, open-label, single-dose study with two treatment periods - before the surgery (Time 0 - T0) and 2 months after the bariatric surgery (Time 2 - T2).||||
34083054|NCT04752930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083055|NCT03365180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083056|NCT02266823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083057|NCT01107145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083058|NCT01037569|||||PROSPECTIVE|||||||
34083059|NCT04101292|NA|SINGLE_GROUP||OTHER||NONE||||||
34083060|NCT01973881|||CASE_ONLY||PROSPECTIVE|||||||
34083061|NCT02965924|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083062|NCT04509271|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34083063|NCT02130869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083064|NCT01725672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083065|NCT03118050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083066|NCT02273167|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34083067|NCT05372510|||COHORT||PROSPECTIVE|||||||
34083068|NCT06481787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083069|NCT04394026|||COHORT||OTHER|||||||
34083070|NCT04236037|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34083071|NCT03686592|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083072|NCT01433159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776400|NCT04997967|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776401|NCT03088137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776402|NCT02342587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776403|NCT05174650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776404|NCT04647019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776405|NCT05587387|||COHORT||RETROSPECTIVE|||||||
33776406|NCT02873299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776407|NCT03823976|||COHORT||RETROSPECTIVE|||||||
33776408|NCT00884286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776409|NCT05424861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776410|NCT02420327|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33776411|NCT03903146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To decrease the feeling of discomfort if the mother was not breastfeeding her infant, the trained research staff collecting data on infant feeding status at T-4, T-5, and T-6 remain blinded to the participant's group. To assure that the research staff remain blinded a script was created that explained the importance that the participant abstained to share with research staff if she was getting the visit of any other research personnel. The script was consistently read to participants in each encounter.|Participants were randomly assigned to intervention or control groups.|t|f|f|t
33776412|NCT01307852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776413|NCT04179461|NA|SINGLE_GROUP||TREATMENT||NONE||"The study has 3 study phases: baseline, intervention, and observation. Each participant will independently transition through these study phases.~Baseline period: Each participant will be given a treatment recommendation according to their asthma severity/control using the National Asthma Education and Prevention Program (NAEPP asthma guidelines).~Intervention period: Each participant will be given a personalized treatment plan based on their asthma severity/control during the baseline period, biologic, and environmental factors.~Observation period: All participants will be observed for at least 6 months. Investigators will track the participant's personal outcomes (comparing to baseline) for reutilization, symptom-free days, and quality of life."||||
33776414|NCT04437771|||CASE_ONLY||PROSPECTIVE|||||||
33776415|NCT00531011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776416|NCT05088161|||CASE_ONLY||RETROSPECTIVE|||||||
33776417|NCT04822636|NA|SINGLE_GROUP||TREATMENT||NONE||This is a within-person, pre-post design in which the investigators will test a theory-driven, family-based navigator treatment engagement intervention (FMHN) while also collecting data on the FMHN model's potential implementation and adoption within a public hospital and behavioral health settings.||||
33776418|NCT01667120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776419|NCT00029809|RANDOMIZED|||TREATMENT||||||||
34083073|NCT01694693|||OTHER||RETROSPECTIVE|||||||
34083074|NCT05225662|||COHORT||PROSPECTIVE|||||||
33776420|NCT00951860|||COHORT||PROSPECTIVE|||||||
33776421|NCT02781506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776422|NCT05122754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776423|NCT03169179|NA|SINGLE_GROUP||OTHER||NONE||Single group pre- and post- intervention, mixed methods exploratory trial||||
33776424|NCT01207934|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33776425|NCT05125692|NA|SINGLE_GROUP||TREATMENT||NONE||WOMEN IN CHILDBEARING PERIOD WITH SYMPTOMATIC POSTCESAREAN ISTHMOCELE||||
33776426|NCT05500027|||CASE_CONTROL||PROSPECTIVE|||||||
33776427|NCT03772106|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33776428|NCT01800344|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33776429|NCT03164733|||COHORT||PROSPECTIVE|||||||
33776430|NCT03666065|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33776431|NCT05312619|||OTHER||CROSS_SECTIONAL|||||||
33776432|NCT03427086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subjects, care givers, investigator, and coordinator will be blinded. The pharmacist, who will be responsible for the drug supply, will be unblinded. The investigational drug and the placebo will have identical pill shape and color. They will be supplied in identical boxes.|Prospective, double blind, placebo control, randomized 2:1 study|t|t|t|t
33776433|NCT00421694|RANDOMIZED|PARALLEL||||SINGLE||||||
34083075|NCT01892332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34083076|NCT05143684|||COHORT||PROSPECTIVE|||||||
34083077|NCT05463965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083078|NCT03059667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083079|NCT04042831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083080|NCT06376968|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083081|NCT00466817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083082|NCT00473655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083083|NCT02080416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083084|NCT02126280|||COHORT||CROSS_SECTIONAL|||||||
34083085|NCT00236691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083086|NCT03538041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083087|NCT02420639|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34083088|NCT03404245|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34083089|NCT03473405|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34083090|NCT02552485|||||PROSPECTIVE|||||||
34083091|NCT05074966|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with RAS/BRAF wild type left-sided mCRC will be randomized to two groups, which are mXELOX plus cetuximab and FOLFOX plus cetuximab.||||
34083092|NCT05793697|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34083093|NCT05246254|||COHORT||PROSPECTIVE|||||||
34083094|NCT03207399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083095|NCT00927199|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34083096|NCT02669849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083097|NCT00113607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083098|NCT02752139|||CASE_CONTROL||PROSPECTIVE|||||||
34083099|NCT01477801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083100|NCT05393596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083101|NCT01937988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083102|NCT04533178|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter study comparing treatment with or without soft spinal brace||||
34083103|NCT05550168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A clinical trial with experimental and control groups|f|f|f|t
34083104|NCT01007799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083105|NCT00707837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083106|NCT00843466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34083107|NCT02523352|NA|SEQUENTIAL||TREATMENT||NONE||35 patients will be enrolled in this study. The study is divided in two phases: the first phase will evaluate the PEEP in 12 consecutive obese subjects and 6 healthy volunteers using Trans-thoracic echocardiography (TTE) and Electrical Impedance Tomography (EIT). The second phase will evaluate the PEEP in the other 12 consecutive obese subjects and 5 healthy volunteers using Magnetic Resonance Imaging (MRI).||||
34083108|NCT01830517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083109|NCT00157339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907803|NCT04725006|||CASE_ONLY||PROSPECTIVE|||||||
34083110|NCT01087060|||CASE_CONTROL||RETROSPECTIVE|||||||
34083111|NCT03439137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083112|NCT03347643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients with internet gaming disorder will be randomly allocated into 1) actual real stimulation with tDCS group, and 2) sham stimulation with tDCS group.|t|f|t|f
34083113|NCT01112319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33686998|NCT01850433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33686999|NCT04044027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776434|NCT00321256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776435|NCT02774213|||CASE_ONLY||PROSPECTIVE|||||||
33776436|NCT05441358|||COHORT||PROSPECTIVE|||||||
33907804|NCT04463576|||OTHER||RETROSPECTIVE|||||||
33907805|NCT06442423|NA|SINGLE_GROUP||TREATMENT||NONE||We will employ an unblinded, open-label study where all participants will be given one dose of oral psilocybin 25mg. We will also have follow-up visits at 1, 4, and 6 weeks and an optional long-term follow-up at 3, 6, and 12 months.||||
33907806|NCT04923178|||COHORT||PROSPECTIVE|||||||
33907807|NCT04706663|||COHORT||PROSPECTIVE|||||||
33907808|NCT05603143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083114|NCT03055039|||COHORT||PROSPECTIVE|||||||
34083115|NCT04526002|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Patients with MDD and healthy controls will undergo TBS/fNIRS to investigate the direct effects of TBS of healthy and presumed neuropathological prefrontal cortex.~This is followed by a 4-week TBS treatment for MDD patients in order to evaluate the relationship between immediate excitability modulations of the DLPFC and treatment response."||||
33687000|NCT01019096|||CASE_ONLY||PROSPECTIVE|||||||
33687001|NCT06343714|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33687002|NCT00958490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687003|NCT00396448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687004|NCT01514370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687005|NCT06068920|||COHORT||CROSS_SECTIONAL|||||||
33687006|NCT04330820|NA|SEQUENTIAL||TREATMENT||NONE||"The phase I part will be conducted according to the enhanced algorithms of a 3+3H design (Ji et al. J Clin Oncol 2013).~The phase II part will be performed as single stage study adopting the A'Hern design (A'Hern Stat Med 2001)."||||
33776437|NCT05573919|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who are to undergo the VivAer procedure for nasal obstruction with Dr. Auddie Sweis or Dr. Joseph Raviv will be recruited to this study. They will be issued questionnaires and have PNIF measurements taken to assess their symptoms before and after the procedure in order to determine the objective improvement in the patients' symptoms.||||
33776438|NCT03638245|||COHORT||PROSPECTIVE|||||||
33907809|NCT03639753|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33907810|NCT01550575|||COHORT||RETROSPECTIVE|||||||
33907811|NCT05569174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33907812|NCT06654739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, sham controlled, single blind|t|f|f|f
33907813|NCT06550024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907814|NCT06654713|||COHORT||PROSPECTIVE|||||||
33907815|NCT05070403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687007|NCT04512339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2:1 randomization. Two-thirds will receive dupilumab injections (loading dose of 600mg subcutaneously followed by 300 mg subcutaneously every 2 weeks). One-third will receive placebo injections.|t|f|t|f
33687008|NCT00713570|||COHORT||RETROSPECTIVE|||||||
33687009|NCT00761150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687010|NCT05240586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687011|NCT04099771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776439|NCT01630031|||CASE_CONTROL||PROSPECTIVE|||||||
33907816|NCT04711252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33907817|NCT06590610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907818|NCT05649748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907819|NCT06655415|||COHORT||PROSPECTIVE|||||||
33907820|NCT04928287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects, investigators and study staff will be blinded to the assigned treatment.|A parallel study is a type of clinical study where two groups of treatments, A (HB-adMSCs) and B (Placebo), are given so that one group receives only A while another group receives only B.|t|t|t|t
33907821|NCT06592248|NA|SINGLE_GROUP||TREATMENT||NONE||"* Validation of the concept~* Absence of added risks after implementation~* Measurement of fibrous tissue formed by MRI examination~Inclusion will be done by sequencing in 2 steps:~* Inclusion of 2 patients with implementation of the experimental MD with a post-operative follow-up of 3 months,~* if no SAE linked to the experimental MD is detected, the inclusions will continue until the 5th patient with experimental DM,~* In the event of notification of an SAE linked to the experimental MD according to the investigator in the first 2 patients, within the first 3 months, the research will be stopped prematurely"||||
33907822|NCT06658912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33907823|NCT04991324|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Patient will be recruited by their regularly visit. Patients will be randomly assigned to be supplemented with monthly capsules (monthly group), weekly capsules (weekly group) or no supplementation (control group).||||
33907824|NCT06600711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907825|NCT06662019|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33989997|NCT05955534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to either the intervention group (TPUG) or the control group using a 1:1 randomization scheme.|All patients enrolled will receive bedside tracheostomy, but each patient will be randomly assigned a common method for gastrostomy placement. Patients in the control group will receive a bedside tracheostomy along with a common method of gastrostomy placement other than PUG, which may be performed at the same time or at a different time in relation to the tracheostomy. Patients in the intervention group will receive a bedside tracheostomy and a PUG at the same time using an FDA-cleared device.|f|f|t|f
33687012|NCT03318718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687013|NCT00804037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687014|NCT02593045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687015|NCT05945680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687016|NCT00284076|RANDOMIZED|||TREATMENT||||||||
33687017|NCT03125291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The interviewers are blind to the condition assigned to the families.||f|f|f|t
33687018|NCT02914145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687019|NCT00879879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687020|NCT01919840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33687021|NCT02931266|||COHORT||PROSPECTIVE|||||||
33687022|NCT01360775|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33687023|NCT03303703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33687024|NCT03284320|||COHORT||RETROSPECTIVE|||||||
33687025|NCT06510738|||OTHER||PROSPECTIVE|||||||
34083116|NCT02222662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687026|NCT04932070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687027|NCT05174364|||CASE_CONTROL||PROSPECTIVE|||||||
33687028|NCT00579085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776440|NCT01822028|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33776441|NCT03908281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For most outcomes, including the primary outcome, the outcome assessor will be unaware of group allocation.||f|f|f|t
33776442|NCT00002813||||TREATMENT||||||||
33776443|NCT01726972|||COHORT||RETROSPECTIVE|||||||
33776444|NCT01283217|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33776445|NCT01912820|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776446|NCT01632358||CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776447|NCT03041714|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33776448|NCT02522338|NA|SINGLE_GROUP||||NONE||||||
33989998|NCT00003659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33989999|NCT01948258|NA|SINGLE_GROUP||OTHER||NONE||||||
33990000|NCT05077059|||OTHER||CROSS_SECTIONAL|||||||
33687029|NCT00215670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687030|NCT04603820|||CASE_ONLY||OTHER|||||||
33687031|NCT00756925|||CASE_CONTROL||PROSPECTIVE|||||||
33687032|NCT00550056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687033|NCT04610697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and personnel conducting the assessments will be unaware of group assignment.|Double blind randomised controlled trial with active control condition. Given the clinically heterogeneous recruitment pool, pseudo-randomization will be employed to match groups on the main diagnosis.|t|f|t|t
33687034|NCT03490877|||CASE_ONLY||PROSPECTIVE|||||||
33687035|NCT03007069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33687036|NCT01410071|||COHORT||PROSPECTIVE|||||||
33687037|NCT00384111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687038|NCT02430506|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687039|NCT04944862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687040|NCT01163513|||COHORT||RETROSPECTIVE|||||||
33687041|NCT04240353|||COHORT||PROSPECTIVE|||||||
33687042|NCT06147973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either an acceptance-based treatment intervention or a health education comparison for the duration of the study.||||
33687043|NCT01844479|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33687044|NCT04426578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687045|NCT01633580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687046|NCT04753229|||COHORT||RETROSPECTIVE|||||||
33687047|NCT01973530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687048|NCT06084598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776449|NCT05175443|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated Measure||||
33907826|NCT05856227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687049|NCT06523751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Determining Distal Outflow Tract Function in Open Angle Glaucoma as a Predictive Test for the Success of Ab Interno Trabeculectomy||||
33687050|NCT00347841|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33687051|NCT06004453|||COHORT||OTHER|||||||
33687052|NCT04257097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The surgeon is masked until the envelope is opened at the time of the surgery.||t|t|t|t
33687053|NCT03380936|RANDOMIZED|PARALLEL||TREATMENT||NONE||Only patients meeting histologic criteria for AMR by Banff 2013 criteria will be randomized (ptc + g + c4d ≥ 2). Subjects will be randomized to either undergo optimization (conversion to Envarsus with goal trough tacrolimus level \> 8 ng/ml, mycophenolic acid at 720 mg, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol of or treatment.); or, to treat clinical AMR (antibody mediated rejection) with plasma exchange x 5 treatments, each followed by IVIG (intravenous immunoglobulin) 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.||||
33687054|NCT02519673|||COHORT||PROSPECTIVE|||||||
33687055|NCT01289782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687056|NCT04306185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687057|NCT05523687|NA|SINGLE_GROUP||OTHER||NONE||||||
33687058|NCT02830269|||OTHER||PROSPECTIVE|||||||
33687059|NCT01445886|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33687060|NCT01827358|RANDOMIZED|SINGLE_GROUP||PREVENTION||||||||
33687061|NCT05806684|||COHORT||RETROSPECTIVE|||||||
33687062|NCT06214494|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Case Control Cohort Study||||
33687063|NCT05765227|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33687064|NCT06352385|||COHORT||CROSS_SECTIONAL|||||||
33687065|NCT05292144|||COHORT||PROSPECTIVE|||||||
33687066|NCT02891005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687067|NCT05972603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687068|NCT04650854|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687069|NCT05649839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687070|NCT00236951|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33907827|NCT04889066|RANDOMIZED|PARALLEL||TREATMENT||NONE||Based on investigator's hypothesis of improved rate of intracranial clinical benefit at 6-months from historical control of 60% to 86% and 10% attrition rate, a sample size of 23 patients is needed per study arm (total N=46) using a two-sided exact binomial test with a two-sided α=0.1 and power=80%.||||
33907828|NCT05132296|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33907829|NCT04005339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907830|NCT06614192|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907831|NCT00923221|||COHORT||CROSS_SECTIONAL|||||||
33907832|NCT06667453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907833|NCT04466865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33907834|NCT06376695|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
33990001|NCT04678440|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy volunteers and patients with non-small cell lung cancer will undergo identical total-body PET scans. Lung cancer patients will undergo an additional PET scans after starting treatment.||||
33990002|NCT00834418|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990003|NCT00987740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990004|NCT03399812|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33990005|NCT03155672|||COHORT||PROSPECTIVE|||||||
33990006|NCT01452815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990007|NCT06424457|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33990008|NCT04954573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990009|NCT01212848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907835|NCT00026650|||COHORT||PROSPECTIVE|||||||
33907836|NCT02619838|||CASE_ONLY||PROSPECTIVE|||||||
33990010|NCT05880576|||COHORT||PROSPECTIVE|||||||
33990011|NCT01066598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990012|NCT03676764|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|The trial sites will be masked to outcomes, so the responsibility for monitoring interim analysis will fall on the DSMC|All eligible communities in Nouna District will be randomized in a 1:1 fashion to biannual azithromycin or placebo. Targeted treatment (vaccine visit) will be randomized 1:1 individually to azithromycin or placebo. Randomization will be conducted by T. Porco. Procedural and algorithmic details are provided in an appendix to the Statistical Analysis Plan.|t|t|t|t
34083117|NCT04688632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687071|NCT05636488|||COHORT||PROSPECTIVE|||||||
33687072|NCT02832583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990013|NCT05918835|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33990014|NCT03913559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990015|NCT01607918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990016|NCT04266405|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single||t|f|f|f
33990017|NCT00459420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990018|NCT03506763|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|RCT, blind|RCT|t|t|t|f
33990019|NCT00968812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990020|NCT03208374|||COHORT||PROSPECTIVE|||||||
33990021|NCT06392438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of their allocation in either the experimental group (IPL) or the control group (sham-IPL). Due to the nature of the treatment, it was not possible to mask the researcher that is performing the IPL treatment. Meibography score and conjunctival staining (requiring clinical judgment) will be analyzed by assessors that are masked (from images captured by a non-masked investigator).|This study is a randomized, sham controlled clinical trial. It consists of two treatments, one of which is applied to all the participants (cyclosporine). and the second one, for which participants are randomized in either the IPL group (experimental) or the IPL-sham group (control). Data collection is a pre-post model, with data being collected at baseline, during the trial (mid-study) and after the treatments. Data analysis is in intent-to-treat.|t|f|f|f
33990022|NCT00112463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990023|NCT01117220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990024|NCT00315562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990025|NCT00834964|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990026|NCT05169463|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33990027|NCT00175487|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990028|NCT02316015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33990029|NCT02745054|||CASE_ONLY||PROSPECTIVE|||||||
33990030|NCT01415986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990031|NCT01299454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083118|NCT03055884|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34083119|NCT02262780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083120|NCT00259103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990032|NCT05649280|||COHORT||RETROSPECTIVE|||||||
34083121|NCT00208364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083122|NCT04927637|||CASE_ONLY||PROSPECTIVE|||||||
34083123|NCT00892021|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33990033|NCT06559670|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33990034|NCT05252377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34083124|NCT05009355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083125|NCT03735290|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single arm phase 1b. Randomized phase 2.||||
34083126|NCT02374983|||||PROSPECTIVE|||||||
34083127|NCT01033838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083128|NCT02541344|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34083129|NCT03966625|||OTHER||PROSPECTIVE|||||||
34083130|NCT04352348|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34083131|NCT02933853|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34083132|NCT04268355|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, pre-post, non-randomized, unblinded pilot trial including up to 36 participants over 2 MTPC group cohorts||||
34083133|NCT03371914|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083134|NCT01009593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083135|NCT04610775|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34083136|NCT00664586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083137|NCT05064254|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single blind randomized controlled design. Pregnant women with anxiety symptoms will be randomly allocated 1:1 to either a control group (treatment as usual) or intervention group (treatment as usual plus MAPP intervention).|f|f|f|t
34083138|NCT03174444|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Individual randomized controlled trial with two arms.||||
34083139|NCT04919707|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34083140|NCT05079971|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34083141|NCT00933595|NA|SINGLE_GROUP||||NONE||||||
34083142|NCT01776086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990035|NCT03730363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990036|NCT03804749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind, placebo control||t|t|t|f
33990037|NCT01359696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990038|NCT03444792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The included patients will be randomized using sealed opaque envelope method into two groups|Prospective randomized controlled trial|f|f|t|t
34083143|NCT04909060|||CASE_CONTROL||PROSPECTIVE|||||||
34083144|NCT05523726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The principle investigator will be blind to the group assignment|Random assignment into experimental and control conditions at a 1:1 ratio|f|f|t|f
33776450|NCT03390361|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Groups will be randomized. Randomization information will be put in a sealed envelope on screening date and opened in operating theatre right before the surgery.|Patients' eyes will be randomized into two groups receiving either MCS or LCS. In the LCS group aqueous humour will be collected exactly five minutes after laser pretreatment. In the MCS group aqueous humour will be collected before manual manipulation of anterior chamber. Aqueous humour will be screened with Enzyme-linked Immunosorbent Assay (ELISA) Kits for Interleukin-1β; Interleukin-6 and PG.|t|t|t|f
33776451|NCT00068666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776452|NCT00248521|NON_RANDOMIZED|||TREATMENT||NONE||||||
33776453|NCT00306514|RANDOMIZED|PARALLEL||||NONE||||||
33776454|NCT06357546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care provider carrying out the heterocatheterization will be blinded to the participant's randomization group.|A randomization list by blocks of random size and stratified by center, by scarred uterus (with or without scar) and Body Mass Index (BMI) at the start of pregnancy (\<30 and ≥30), will be established by a methodologist independent of the study. Patients will be randomized into each group at a ratio of 1:1.|f|t|f|f
33776455|NCT04592133|||CASE_CONTROL||PROSPECTIVE|||||||
33776456|NCT01767129|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33990039|NCT00272779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990040|NCT00080951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990041|NCT02846363|||||PROSPECTIVE|||||||
34083145|NCT02048436|||||PROSPECTIVE|||||||
33687073|NCT02652767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687074|NCT04647890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687075|NCT02346578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687076|NCT00209651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687077|NCT01791556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907837|NCT04159610|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907838|NCT05387551|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33907839|NCT03957681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907840|NCT05836324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907841|NCT04543201|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990042|NCT03650985|NA|SINGLE_GROUP||TREATMENT||NONE||Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent.||||
33687078|NCT02732522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33687079|NCT03699384|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, phase I/II prospective clinical trial.||||
33687080|NCT02044770|||||PROSPECTIVE|||||||
33687081|NCT02923544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687082|NCT05428982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687083|NCT04052724|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated to either control or intervention group. Participants in the control group will receive the same treatment once the intervention group is finished with the treatment.||||
33687084|NCT06161077|||COHORT||PROSPECTIVE|||||||
33990043|NCT01763177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33687085|NCT00194675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687086|NCT01150474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990044|NCT02530333|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990045|NCT01747694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990046|NCT06319976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990047|NCT06053866|||OTHER||PROSPECTIVE|||||||
33990048|NCT02008097|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990049|NCT02837991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990050|NCT05985772|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomization will be structured so that surgeons at all sites are contributing an equal number of subjects to the non-operative and operative treatment arms, to mitigate the chance that differences in outcomes between the groups are confounded by variability in surgeon skill and technique. Randomization groups will be delivered by means of sealed opaque envelopes. Surgeons(Investigators) will be masked to the group assignment.|This study is a pragmatic design, parallel group, randomized clinical trial in which 140 subjects with a diagnosed medial meniscus root tear based on MRI and confirmed intra-operatively will be randomized to one of two treatment arms.|f|f|t|f
33990051|NCT05552482|||COHORT||RETROSPECTIVE|||||||
33990052|NCT01141374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687087|NCT01285947|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33687088|NCT02095431|||COHORT||PROSPECTIVE|||||||
33687089|NCT00973349|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33687090|NCT01987531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687091|NCT02496572|||COHORT||PROSPECTIVE|||||||
33687092|NCT00000523|RANDOMIZED|||PREVENTION||||||||
33687093|NCT05072327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687094|NCT03631355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687095|NCT01580748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776457|NCT06193759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776458|NCT06392516|RANDOMIZED|PARALLEL||TREATMENT||NONE||intervention and control||||
33776459|NCT03524820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776460|NCT02696720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776461|NCT02408549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907842|NCT06360094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907843|NCT03995979|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907844|NCT01251900|||CASE_ONLY||CROSS_SECTIONAL|||||||
33907845|NCT01191853|||COHORT||PROSPECTIVE|||||||
33907846|NCT05561842|||COHORT||PROSPECTIVE|||||||
33907847|NCT03298178|||COHORT||PROSPECTIVE|||||||
33907848|NCT06479135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo-controlled||t|t|t|t
33907849|NCT06453213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907850|NCT06589674|||COHORT||PROSPECTIVE|||||||
33907851|NCT01660984|||COHORT||PROSPECTIVE|||||||
33907852|NCT02520609|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33907853|NCT06307665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907854|NCT05819398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990053|NCT05422521|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33990054|NCT06602544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990055|NCT05074576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blind for allocation and outcomes measures.||t|f|f|f
33990056|NCT00840476|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34083146|NCT03758729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990057|NCT04559386|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants are asked to fill in a questionnaire and provide extensive information.||||
33990058|NCT05044364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33907855|NCT06378801|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on gender at birth, then randomized to one of the study arms|t|f|t|f
33907856|NCT04114877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33907857|NCT05624749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907858|NCT05376800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 0 part: measurement of BI 907828 (Brigimadlin) concentrations in brain tissue Phase Ia part: dose escalation||||
33907859|NCT04101851|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, single-arm||||
33907860|NCT05738148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Cluster-Crossover design|t|f|f|t
33907861|NCT03797716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33907862|NCT03105102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907863|NCT06587139|RANDOMIZED|PARALLEL||PREVENTION||NONE||transgender and/or gender minority youth (TGMY) (n=80) are randomly assigned to a treatment (n=40) or wait-list (n=40) control condition.||||
33907864|NCT06635226|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33907865|NCT04660812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907866|NCT03951194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33907867|NCT03366168|||COHORT||CROSS_SECTIONAL|||||||
33907868|NCT06337032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907869|NCT06636383|||COHORT||PROSPECTIVE|||||||
33907870|NCT06029270|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907871|NCT06293365|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33990059|NCT03789565|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33990060|NCT03696745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990061|NCT05669547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990062|NCT03986801|RANDOMIZED|PARALLEL||OTHER||NONE||Eligible patients will be randomized between a non-interventional group (standard management of patients according to the institution of origin) or intervention group (setting up a PASS pharmaceutical interview on the day of discharge from hospital and follow-up multidisciplinary until rights are obtained).||||
33990063|NCT03429361|||COHORT||PROSPECTIVE|||||||
33990064|NCT06559891|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The subjects and all study personnel taking follow-up blood pressure measurements will be blinded to the randomization up to 6 months post-randomization. Subjects will complete a blinding assessment prior to hospital discharge, at 2M and 6M FU. Study unblinding will occur at 6-months FU.~ABPM measurements will be sent to an independent core lab for data cleaning and analysis and will be blinded to the randomization assignment."|2:1 randomization will be used to assign subjects to treatment (RDN) or control (sham). Randomization will occur immediately after the renal angiogram.|t|f|t|t
33990065|NCT03267381|||CASE_CONTROL||PROSPECTIVE|||||||
33990066|NCT02437747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990067|NCT04966299|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"EryClot-Pilot:~This trial is a randomized, double-blind, crossover trial. The project set-up is single-center, national. In total, 3 volunteers will be enrolled. There will be 3 study arms.~EryClot This trial is a randomized single-blind, crossover trial. The project setup is single-center national. In total 10 volunteers will be enrolled. There will be 3 study arms."|t|f|f|t
33990068|NCT03979508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990069|NCT02762422|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990070|NCT04320420|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34083147|NCT01931384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083148|NCT04700969|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083149|NCT04071041|RANDOMIZED|PARALLEL||TREATMENT||NONE||A superiority, non-blinded, multicentre, randomized, interventional controlled clinical trial. Patients will be randomly assigned (1:1) to receive standard of care plus albumin (20g in 100ml) every 12 hours for 4 days or standard of care alone.||||
34083150|NCT03702660|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34083151|NCT01166256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907872|NCT06286033|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||There are 3 parts in this study. Part 1 and 2 follows a sequential design. Part 3 is a food effect study with a 2x2 crossover design.|t|t|t|t
33990071|NCT03733314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33990072|NCT01997983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083152|NCT01123330|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34083153|NCT00856180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083154|NCT03120871|||OTHER||CROSS_SECTIONAL|||||||
34083155|NCT03040232|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34083156|NCT03468088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083157|NCT02493959|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083158|NCT03346239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34083159|NCT05388799|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34083160|NCT04405258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083161|NCT03337516|NA|SINGLE_GROUP||OTHER||NONE||||||
34083162|NCT01004939|||COHORT||RETROSPECTIVE|||||||
34083163|NCT01288300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083164|NCT03912389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907873|NCT05653843|||COHORT||PROSPECTIVE|||||||
33907874|NCT03006172|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907875|NCT04368403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907876|NCT06490822|NA|SINGLE_GROUP||OTHER||NONE||||||
33907877|NCT06442592|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33907878|NCT06049927|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990073|NCT04859517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The investigator, participant and sponsor personnel involved in study intervention and study evaluation will remain blinded to each participant's assigned study treatment throughout the course of the study.|Randomized, double-blind, placebo-controlled|t|t|t|t
33776462|NCT06464679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776463|NCT03262337|||COHORT||PROSPECTIVE|||||||
33776464|NCT01077024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990074|NCT03545451|NA|SINGLE_GROUP||OTHER||NONE||||||
33776465|NCT01874327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33776466|NCT04318964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776467|NCT00799071|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776468|NCT05715775|||COHORT||RETROSPECTIVE|||||||
33776469|NCT01182922|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33776470|NCT01087372|||CASE_ONLY||PROSPECTIVE|||||||
33776471|NCT02403531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907879|NCT04410042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|To allow for the study team and participants to remain blinded to the treatment assignment, the study drug will be labeled as Tranexamic Acid/Placebo (TXAKIDS) followed by applicable dose and administration instructions.||t|t|t|f
33907880|NCT04886804|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33907881|NCT05126277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|This is a pivotal double-blind, randomized, placebo-controlled, multi-center three-arm study, evaluating at Week 72 efficacy and safety of ianalumab administered s.c. every 4 weeks or ianalumab administered s.c. every 12 weeks versus placebo, administered s.c. every 4 weeks, in adult participants with active LN receiving SoC. In addition, long-term efficacy, safety and tolerability will be collected up to Week 144.|t|t|t|t
33907882|NCT03885518|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33990075|NCT06269744|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990076|NCT03916263|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized||||
33990077|NCT01214135|||CASE_CONTROL||RETROSPECTIVE|||||||
33990078|NCT05206318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The packaging and labeling of the topical product were the same in both group. The subjects were randomized in by an interactive web response system that provided study kit number from the randomization list at the time of inclusion into the study. The randomization list was kept strictly confidential throughout the study and was not available to the investigator and patient or any other personnel who may influence the study data.|Randomized control trial, Double masked, double-blinded|t|f|t|f
33990079|NCT04564053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a non-confirmatory, randomized, participant- and investigator-blinded, placebo-controlled, single ascending dose study.|t|f|t|f
33990080|NCT02435043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33990081|NCT01660789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990082|NCT02317263|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33990083|NCT04489641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33990084|NCT05215535|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|It will not be possible to mask for either patients nor participating health care professionals if patients are enrolled in the control- or intervention group. Hence, the study will not be blinded. When the final data analysis is performed for the primary outcome measure the person performing the analysis will not be aware of which group each patient was a part of.|"Consenting patients with newly diagnosed rectal cancer who fulfil the inclusion criteria and no exclusion criteria will be randomized into two groups with regard to radiological investigation of the liver; Intervention: An abbreviated MRI of the liver/abdomen Control: A combined single venous and 3 min equilibrium phase CT of the abdomen/liver~Randomization will be conducted in blocks of 6, and stratified for sex and hospital."|f|f|f|t
33990085|NCT06111248|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Prospective interventional monocentric before-and-after clinical study to evaluate the impact of a quality improvement project intervention. The intervention consists in informing, training and coaching teams on how to use the surgical plethysmographic index, state entropy and train-of-four intraoperative monitors and AoA software."||||
34083165|NCT00228163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083166|NCT02477930|||OTHER||PROSPECTIVE|||||||
34083167|NCT04143659|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34083168|NCT06374303|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, parallel-groups pilot study||||
34083169|NCT05767983|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34083170|NCT01109407|||COHORT||PROSPECTIVE|||||||
34083171|NCT04072861|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34083172|NCT00000575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083173|NCT05029661|||COHORT||PROSPECTIVE|||||||
34083174|NCT03222908|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control||||
34083175|NCT00532051|||CASE_ONLY||PROSPECTIVE|||||||
34083176|NCT01092013|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34083177|NCT01851993|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34083178|NCT01028742|||COHORT||PROSPECTIVE|||||||
34083179|NCT05230017|||COHORT||PROSPECTIVE|||||||
34083180|NCT01430377|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083181|NCT05208541|||CASE_ONLY||PROSPECTIVE|||||||
33776472|NCT03263351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research staff who assess outcomes will be blinded to condition assignment.|This is a randomized controlled behavioral trial with two conditions - cognitive-behavioral therapy group or health education group - run in parallel.|f|f|f|t
33776473|NCT00059254|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33776474|NCT06157775|||OTHER||CROSS_SECTIONAL|||||||
33776475|NCT03554161|NA|SINGLE_GROUP||TREATMENT||NONE||Tocilizumab is approved for the treatment of several inflammatory disease, this study tends to evaluate the response to TCZ in refractory BDU, thus it is a self-control study.||||
33776476|NCT01907152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33776477|NCT02129569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776478|NCT04887220|||COHORT||PROSPECTIVE|||||||
33776479|NCT00191048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776480|NCT04689022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 218 patients completed the study. The Mississippi Scale for Combat-Related PTSD (M-PTSD) was used for assessment of the treatment outcome rate. The risk relation between treatment failure and factors was assessed by a univariate or multivariate logistic regression method, with the model accuracy measured by the AUC - Area under the ROC curve. The odds ratio (OR) was considered for the qualitative factor assessment.|f|f|t|f
33776481|NCT00442286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776482|NCT00780442|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33990086|NCT04360694|RANDOMIZED|PARALLEL||TREATMENT||NONE||REAL LIFE is a pragmatic, prospective, multicentre, open label RCT, investigator-initiated, comparing the intervention arm (incremental HD) with the control arm (standard 3HD/wk). It consists in starting the HD treatment adopting the new incremental approach guided by the VTM. The investigators recommend to start and keep on with once-weekly HD, which should be possible until residual renal urea clearance (KRU) falls below 2.5 - 3.0 mL/min/35 L, i.e., glomerular filtration rate (GFR) ≈ 4 mL/min/1.73 m2. Then, HD sessions will be increased to twice-weekly. When KRU falls bellow 1.5 ml/min/35L, dialysis schedule will change to thrice-weekly, as per criteria for progression. It is controlled through usual clinical practice.||||
33990087|NCT04700787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990088|NCT02875769|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33990089|NCT04813354|RANDOMIZED|CROSSOVER||OTHER||NONE||The study will be a randomized, multi-center, open label, placebo- controlled device handling study.||||
33990090|NCT06561035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990091|NCT01676194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990092|NCT05443750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All study procedures are web-based so delivery of intervention or control materials are fully automated, as are the outcomes assessments. The consent form informs participants they will be assigned to either a brief intervention focused on reducing risks of drinking and promoting healthy futures or an alcohol and health education intervention; they may be able to discern which condition they received upon implementation. Of necessity, the investigators know which condition they receive to initiate the proper web-based program.|brief web-based motivational behavioral economic alcohol intervention compared to web-based health education control materials|t|f|t|t
33990093|NCT05878626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776483|NCT01609153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776484|NCT05269511|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776485|NCT00926965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33776486|NCT05956977|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||retrospective matched pair control|f|f|t|f
33776487|NCT02100618|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990094|NCT05978986|NA|SINGLE_GROUP||SCREENING||DOUBLE|||f|t|t|f
33990095|NCT03230630|||COHORT||OTHER|||||||
33990096|NCT00840073|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33839863|NCT05889767|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Three study groups (n=10/ group):~1. Normal weight and low body fat percent (BMI 18.5-24.9 kg/m2, body fat percent \< 25% in males or \< 35% in females),~2. Normal-weight obesity (BMI 18.5-24.9 kg/m2, body fat percent \> 25% in males or \> 35% in female)~3. Overt obesity and high body fat percent (BMI \> 30 kg/m2, body fat percent \> 25% in males or \> 35% in females)"||||
33990097|NCT03125473|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839864|NCT01236378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839865|NCT01577277|||COHORT||CROSS_SECTIONAL|||||||
33839866|NCT05215964|||CASE_ONLY||PROSPECTIVE|||||||
33990098|NCT05928156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33990099|NCT04750707|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33990100|NCT05378217|||COHORT||PROSPECTIVE|||||||
33990101|NCT01554007|||COHORT||PROSPECTIVE|||||||
33990102|NCT04491721|||COHORT||PROSPECTIVE|||||||
33990103|NCT00193245|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990104|NCT06553664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990105|NCT00003015||||TREATMENT||||||||
33990106|NCT02362997|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990107|NCT01880853|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33990108|NCT04194801|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33990109|NCT06627699|||COHORT||PROSPECTIVE|||||||
33990110|NCT03853616|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33990111|NCT04378621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A. Pharmacological treatment with TNF-α inhibitor or JAK inhibitor Group B. Physical hand training 10 min twice daily while on stable treatment with TNF-α inhibitor or JAK inhibitor||||
33990112|NCT01926119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990113|NCT00477594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990114|NCT02021487|||CASE_CONTROL||PROSPECTIVE|||||||
33990115|NCT02691130|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990116|NCT01138540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33990117|NCT04437303|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33990118|NCT05277363|||COHORT||PROSPECTIVE|||||||
33990119|NCT00933530|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33687096|NCT05029570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical outcomes will be adjudicated by the investigator and reviewed by the Clinical Events Committee, that will be blind to treatment received by the patient.|Medical Device: Conduction System Pacing (pacemaker implantation)|f|f|f|t
33687097|NCT06355674|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33687098|NCT06255639|||COHORT||PROSPECTIVE|||||||
33687099|NCT03628261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687100|NCT05324176|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Patients will be examined in the supine position. diaphragmatic thickness will is measured on both sides during a deep breath in inspiration and during expiration in the 3 groups: (1) Gillian-Barre syndrome; (2) Myasthenia Gravis; (3) control||||
33687101|NCT02935374|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990120|NCT04776447|NA|SINGLE_GROUP||TREATMENT||NONE||Design: Open-label, non-randomized, phase II multi-centre controlled clinical trial.||||
33990121|NCT00829764|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990122|NCT00366925|RANDOMIZED|PARALLEL||||NONE||||||
33687102|NCT06458075|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33687103|NCT04344327|||COHORT||RETROSPECTIVE|||||||
33687104|NCT06142890|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be informed of the study interventions before providing informed consent but will be masked to the order of the arms until exposure (i.e., participants will not know the fan conditions before entering the environmental chamber). Data will be blinded prior to analysis (including during statistical analysis).|Each participant will complete 2 simulated heat wave exposures in random order: i) bed-rest; no fan cooling (control) and ii) bed-rest positioned beneath a ceiling fan providing standard air flow.|t|f|f|t
33687105|NCT04541251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687106|NCT05739864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To mask treatments to physicisans and recipients, both FMT flasks and syringes will be covered with dark-coloured paper before the infusion, and the patients will be unable to see the endoscopic display during the procedure. Super - donor capsules or placebo ones will look the same. Moreover, the physicians who will evsaluate patients at follow-up will not aware of the treatment being administered.|placebo-controlled, double blind randomized clinical trial|t|t|t|t
33839867|NCT01724034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33839868|NCT00518895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839869|NCT02460575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839870|NCT02076295|||COHORT||CROSS_SECTIONAL|||||||
33839871|NCT00785304|||CASE_CONTROL||PROSPECTIVE|||||||
33839872|NCT02628028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839873|NCT03931759|RANDOMIZED|CROSSOVER||SCREENING||NONE||prospective randomize clinical trial||||
33990123|NCT03413839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33990124|NCT04350723|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter, parallel-group randomized controlled trial||||
33990125|NCT03750903|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two group parallel design||||
33990126|NCT00139711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990127|NCT05170607|||COHORT||PROSPECTIVE|||||||
33990128|NCT04484883|||COHORT||RETROSPECTIVE|||||||
33990129|NCT04078763|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990130|NCT02605265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990131|NCT05816564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be debriefed after study but are not specifically told that they were recruited due to reported depression symptoms.|"Participants will be randomly assigned to positive attention training or sham attention training but will both receive mindfulness exercises."|t|f|f|f
33990132|NCT01255241|||CASE_ONLY||PROSPECTIVE|||||||
33990133|NCT04940312|||COHORT||PROSPECTIVE|||||||
34083182|NCT00113477|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34083183|NCT04352673|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083184|NCT03710512|||CASE_CONTROL||PROSPECTIVE|||||||
34083185|NCT02863666|||CASE_ONLY||PROSPECTIVE|||||||
34083186|NCT04294277|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm||||
34083187|NCT04753866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will be quantifiably evaluated regarding facial esthetics and compared before and after the full arch implant supported rehabilitation.||||
34083188|NCT00972270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083189|NCT05267665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors are blind to the condition of the family member/Veteran|Family members are randomly assigned to one of the following two groups: Brief Family Intervention (BFI) where they receive a 2-session intervention designed to help them better understand and support the Veteran's individual trauma-focused treatment, or no BFI where they do not receive the BFI sessions.|f|f|f|t
34083190|NCT00153426|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083191|NCT05143424|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
34083192|NCT02970084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34083193|NCT02064036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083194|NCT01652690|||COHORT||PROSPECTIVE|||||||
34083195|NCT00427908|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990134|NCT05355441|||COHORT||PROSPECTIVE|||||||
33990135|NCT03157193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990136|NCT06562517|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled pre-test-post-test design|f|f|f|t
33990137|NCT04932837|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33990138|NCT05278130|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33990139|NCT00556322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083196|NCT06249581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-dose clinical trial with healthy volunteers sequentially using a single dose of AUX-001 under fasting and thereafter under fed conditions||||
34083197|NCT06107452|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083198|NCT01103128|||COHORT||RETROSPECTIVE|||||||
34083199|NCT02461212|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34083200|NCT00000687||||TREATMENT||NONE||||||
34083201|NCT02073786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083202|NCT02431013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083203|NCT05637502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
34083204|NCT00038766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083205|NCT06069804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34083206|NCT05552196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083207|NCT03456245|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083208|NCT04809116|NA|SINGLE_GROUP||TREATMENT||NONE||open-label||||
34083209|NCT04695288|||COHORT||CROSS_SECTIONAL|||||||
34083210|NCT01774981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083211|NCT03575260|||COHORT||RETROSPECTIVE|||||||
34083212|NCT03236597|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A within-person, cross-over design will be used. Fifteen participants will take part in two conditions: 1) the treadmill desk: this intervention will ask participants to use a treadmill desk for a minimum of 30min per day for four weeks; and 2) the usual desk condition: participants will use their current workstation, as is, for four weeks. Participants will be randomly assigned to their initial intervention condition after baseline measures have been collected. In addition to the two condition months, there will be a one-week baseline period (to collected information on habitual activity level at work).||||
34083213|NCT00141817|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990140|NCT04225377|||OTHER||OTHER|||||||
33839874|NCT05951270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All samples and data will be coded so that no personal information about the participant can be inferred. Each subject will be assigned an individual code that will be visible on the biological samples. The code will include a participant number in chronological order and a test day number in chronological order. In addition, the label of each sample will indicate the date of collection.|The study conforms to a randomized, double-blinded, placebo-controlled parallel study design.|f|f|t|f
33839875|NCT03862677|||COHORT||PROSPECTIVE|||||||
33839876|NCT00561431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839877|NCT01538966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083214|NCT06001879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The study design is a basic experimental study design, randomized control trial (RCT) design, SBLST for the intervention group and standard intervention to the control group by using a brochure; the SBLST intervention among the control group was delayed until the end of data collection as an appreciation for their participation in the study, control group participants are wait-listed and exposed to the experimental treatment at a later point.~Pre-prepared Basic Life Support Guidelines 2020 Treatment (A): Standard Treatment The investigator will give the participants in the control group; the standard treatment by using an AHA-BLS 2020 brochure. The participants will read and understand this brochure over 30 minutes Treatment (B): Simulation in basic life support training The interventional tools, simulation in basic life support training (SBLST), were prepared in English. The researcher will use an already established BLS training from the American Guidelines 2020 (AHA, 2020c)"|t|f|f|f
34083215|NCT02834975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083216|NCT00496418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083217|NCT04265677|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083218|NCT01518101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083219|NCT00447083|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34083220|NCT03710330|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used.|"Eligible participants were allocated to one of three groups after induction of general anesthesia and immediately prior to the operation and just before skin incision. Groups were labeled as follows:~Group one (120) - 5 ml of distilled water in 20 ml of 5% dextrose~Group two (120) - TA in the dose of I gm in 20 ml of 5% dextrose~Group three(120) - TA in the dose of 0.5gm in 20 ml of 5% dextrose"|t|t|t|t
34083221|NCT00262119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34083222|NCT01924533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083223|NCT03241693|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083224|NCT04999241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083225|NCT05316558|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34083226|NCT01436734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083227|NCT06247150|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34083228|NCT03844841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083229|NCT05697913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, no randomized. It is a cohort study to compare MRDI(-) driven treatment adapted to the response versus fixed-duration therapy.||||
34083230|NCT03337126|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, Open-Label, Single Dose, Two Sequence, Crossover||||
34083231|NCT04991714|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34083232|NCT01450488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083233|NCT01060462|||CASE_ONLY||PROSPECTIVE|||||||
34083234|NCT02266485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083235|NCT04010279|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34083236|NCT05181150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083237|NCT06073288|||COHORT||CROSS_SECTIONAL|||||||
34083238|NCT05883514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34083239|NCT04273815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083240|NCT04670601|RANDOMIZED|CROSSOVER||OTHER||NONE||Single dose, open-label, randomised, 2-way cross-over bioequivalence study||||
34083241|NCT05220540|||COHORT||RETROSPECTIVE|||||||
34083242|NCT00129337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083243|NCT00358358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839878|NCT02568397|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083244|NCT05944939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34083245|NCT06253377|||COHORT||RETROSPECTIVE|||||||
33839879|NCT02573389|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083246|NCT02346734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34083247|NCT03046849|||CASE_ONLY||RETROSPECTIVE|||||||
34083248|NCT06506123|||OTHER||PROSPECTIVE|||||||
34083249|NCT06550778|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083250|NCT00306176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083251|NCT03098316|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34083252|NCT04365335|||COHORT||PROSPECTIVE|||||||
34083253|NCT06445933|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34083254|NCT01653275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083255|NCT04824001|||COHORT||PROSPECTIVE|||||||
34083256|NCT04289909|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083257|NCT04782284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial|f|f|f|t
34083258|NCT04420507|||COHORT||PROSPECTIVE|||||||
34083259|NCT03377439|||COHORT||PROSPECTIVE|||||||
34083260|NCT02208908|||COHORT||PROSPECTIVE|||||||
33990141|NCT00846560|||OTHER||OTHER|||||||
33990142|NCT06176534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990143|NCT02175602|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33990144|NCT06563362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990145|NCT00147498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990146|NCT00472602|||||PROSPECTIVE|||||||
33990147|NCT03612232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990148|NCT01665690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990149|NCT00910052|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33990150|NCT01255085|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33839880|NCT01408420|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839881|NCT03260478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label with blinded outcome evaluation.||f|f|f|t
33839882|NCT04371237|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33839883|NCT00056875|NON_RANDOMIZED|||PREVENTION||NONE||||||
33907883|NCT06042478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Eligible participants will be randomized to 1 of 4 treatment arms in a 2:1:1:2 ratio:~* Remibrutinib 25 mg b.i.d. arm: participants receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 52 weeks~* Placebo to remibrutinib arm: participants receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w.~* Placebo to omalizumab arm: participants receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d.~* Omalizumab 300 mg every 4 weeks arm: participants receive omalizumab 300 mg q4w and placebo for remibrutinib b.i.d. for 52 weeks.~All of the above arms are followed by an optional 52-week extension period where participants receive treatment with remibrutinib 25 mg b.i.d. for 52 weeks."|t|f|t|t
33907884|NCT04613596|RANDOMIZED|PARALLEL||TREATMENT||NONE||MRTX849 Monotherapy, MRTX849 in Combination with Pembrolizumab and Pembrolizumab alone||||
33907885|NCT06089616|||OTHER||PROSPECTIVE|||||||
33907886|NCT05578612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907887|NCT06075147|||COHORT||PROSPECTIVE|||||||
33907888|NCT05724108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907889|NCT03841617|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907890|NCT06402331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907891|NCT06495970|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
33907892|NCT05275335|||COHORT||PROSPECTIVE|||||||
33907893|NCT03606967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treating physicians and patients will be blinded to the results of randomization until the start of Part B.||t|t|f|f
33907894|NCT06447168|||COHORT||PROSPECTIVE|||||||
33907895|NCT05623007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Enumerator, Investigator, Outcomes Assessor) Participant, enumerator, investigator, and outcomes assessor do not know which one is the intervention product or placebo.|The product will be given to 440 overweight/obese adolescents, 220 adolescents as an intervention group, and 220 overweight/obese adolescents as a control group|t|t|t|t
33907896|NCT00046059|||COHORT||CROSS_SECTIONAL|||||||
33907897|NCT06603298|||COHORT||RETROSPECTIVE|||||||
33907898|NCT06659393|||COHORT||PROSPECTIVE|||||||
33907899|NCT06600074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907900|NCT05716100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907901|NCT06135870|||COHORT||PROSPECTIVE|||||||
33907902|NCT06608927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907903|NCT06660225|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Neither the participant of investigator will know which treatment group an individual is assigned to. After the completion of the blinded portion of the trial, all participants will be transitioned to open-label stimulation/treatment.|There will be two 4 month blocks in which, depending on group assignment, participants will receive either active or sham stimulation from the DBS device. Following completing of the first 4 month block, the groups will cross-over. Individuals originally receiving active stimulation will now receive sham, and individuals receiving sham stimulation originally will now receive active stimulation. Following the completing of both four month blocks, all participants will receive active open-label treatment. Continued follow-up psychiatric assessments will be preformed every two week during the double-blind portion of the trial, and then every 6 weeks during the open-label treatment phase.|t|f|t|f
33907904|NCT03332940|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33907905|NCT06331312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907906|NCT06588101|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||2x2 Design for randomization strategies 2x2 Desgin for retention strategies|f|t|f|t
33990151|NCT01855035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990152|NCT00723710|||CASE_ONLY||PROSPECTIVE|||||||
33990153|NCT03264352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990154|NCT05915091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33990155|NCT05382052|||COHORT||PROSPECTIVE|||||||
33990156|NCT04727398|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990157|NCT00152646|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33990158|NCT00836004|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33839884|NCT04794153|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33839885|NCT06026241|||OTHER||RETROSPECTIVE|||||||
33990159|NCT06561503|||OTHER||CROSS_SECTIONAL|||||||
33990160|NCT06627829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990161|NCT01655654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990162|NCT01881165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33990163|NCT04306068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33990164|NCT04704531|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative, controlled, multicenter, open, randomized clinical study.||||
33990165|NCT01038960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839886|NCT00343551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839887|NCT02958605|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839888|NCT01186705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990166|NCT05657860|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33990167|NCT02744794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990168|NCT03202459|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33687107|NCT04308798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient and outcome assessor will be blind|Comparison contamination rate of surgical glove in control group and surgical glove changing group during total knee arthroplasty procedure|t|f|f|t
33990169|NCT05213286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687108|NCT04255797|NA|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Clinical Trial||||
33990170|NCT06515405|||COHORT||RETROSPECTIVE|||||||
33990171|NCT04147845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990172|NCT00468455|||CASE_ONLY||PROSPECTIVE|||||||
33990173|NCT03803774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990174|NCT01978730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990175|NCT03383263|||COHORT||PROSPECTIVE|||||||
33990176|NCT05318690|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33990177|NCT06243796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The statistician will generate randomization list from block randomization, then concealed envelope|Single blinded randomized control trial|t|t|f|t
33990178|NCT03950362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990179|NCT04075578|||COHORT||PROSPECTIVE|||||||
33990180|NCT00498654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33990181|NCT05819918|||COHORT||RETROSPECTIVE|||||||
33990182|NCT02995720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990183|NCT06558370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33990184|NCT02774785|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33990185|NCT03394235|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study. We plan to enroll 15 participants who requires to do hair transplantation or normal participants who are eligible for the study.||||
33990186|NCT05587790|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after study design with one interventional group and no control or placebo group||||
33990187|NCT00678639|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33990188|NCT01555645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990189|NCT04518956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990190|NCT00834743|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990191|NCT00123734|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990192|NCT02738086|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33990193|NCT02560402|||COHORT||PROSPECTIVE|||||||
34083261|NCT01566110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083262|NCT00171275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083263|NCT00074893|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34083264|NCT02873975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083265|NCT02841124|NA|SINGLE_GROUP||||NONE||||||
33990194|NCT02086214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990195|NCT06400147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990196|NCT06090994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083266|NCT04626323|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be an open-label, randomized trial involving sixty (60) patients with DKD and obesity who will undergo RYGB (intervention arm) or receive BMT (control arm).||||
34083267|NCT00079976|RANDOMIZED|||TREATMENT||DOUBLE||||||
34083268|NCT04753034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083269|NCT01135342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34083270|NCT01186770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083271|NCT03233074|||CASE_CONTROL||PROSPECTIVE|||||||
34083272|NCT04316117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Systemic therapy||||
34083273|NCT03515746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083274|NCT01420536|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33990197|NCT05661097|RANDOMIZED|PARALLEL||TREATMENT||NONE||random control trail||||
33990198|NCT06471556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990199|NCT00561015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990200|NCT04510545|||COHORT||PROSPECTIVE|||||||
33990201|NCT05248750|||COHORT||PROSPECTIVE|||||||
33990202|NCT03311594|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33990203|NCT03508011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083275|NCT02696889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083276|NCT01477281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083277|NCT02024061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083278|NCT02574585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083279|NCT05126316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083280|NCT01869400|||OTHER||PROSPECTIVE|||||||
33687109|NCT03671200|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33687110|NCT04022161|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33839889|NCT00111267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33907907|NCT06001268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33907908|NCT06586541|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33907909|NCT06658496|||COHORT||PROSPECTIVE|||||||
33990204|NCT02281084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990205|NCT03702608|NA|SINGLE_GROUP||OTHER||NONE||||||
33990206|NCT05691322|||CASE_ONLY||PROSPECTIVE|||||||
33687111|NCT02404532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687112|NCT01676597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687113|NCT02875509|||COHORT||PROSPECTIVE|||||||
33687114|NCT00323869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687115|NCT00453388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687116|NCT02468011|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687117|NCT06312969|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized versus control group clinical trial.||||
33687118|NCT01101191|RANDOMIZED|CROSSOVER||||NONE||||||
33687119|NCT03477929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687120|NCT00579007|||COHORT||PROSPECTIVE|||||||
33687121|NCT01186497|RANDOMIZED|CROSSOVER||||NONE||||||
33687122|NCT01685346|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33687123|NCT05546801|NA|SINGLE_GROUP||OTHER||NONE||questionnaire on postnatal development||||
33687124|NCT04571515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687125|NCT02730897|||COHORT||OTHER|||||||
33687126|NCT04798807|||COHORT||CROSS_SECTIONAL|||||||
33687127|NCT04955860|||COHORT||RETROSPECTIVE|||||||
33687128|NCT01285687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687129|NCT01156727|||COHORT||RETROSPECTIVE|||||||
33687130|NCT05794451|||COHORT||CROSS_SECTIONAL|||||||
33687131|NCT06057155|||CASE_ONLY||PROSPECTIVE|||||||
33687132|NCT02142985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687133|NCT04149392|NA|SINGLE_GROUP||OTHER||NONE||||||
33721444|NCT06443840|RANDOMIZED|PARALLEL||OTHER||NONE||"This protocol is carried out in accordance with the European Regulation 2017/745 on Medical Devices (MDR) and concerns a Class I medical device (MD) of category 4.2 (Article 82 MDR), corresponding to the CE marked MD used for its intended purpose without the objective of establishing conformity, and with an additional non-invasive and non-burdensome procedure.~This is a comparative, prospective, multicenter study (4 centers), controlled, randomized, open-label, with 2 parallel arms."||||
33721445|NCT02785107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721446|NCT00452491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721447|NCT04599374|||OTHER||CROSS_SECTIONAL|||||||
33721448|NCT05282173|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|The staff member who conducts role-play assessments with participants will be minimally involved in the Siyakhana training.|"This study uses a stepped-wedge design. All groups of CHWs receive both treatment as usual (TAU) and the stigma reduction training (Siyakhana). Randomization will dictate the timing/order in which each group receives the Siyakhana training."||||
33721449|NCT01857349|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33721450|NCT00999583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33907910|NCT06657833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907911|NCT05955378|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||AB/BA||||
33907912|NCT04227301|||COHORT||PROSPECTIVE|||||||
33907913|NCT06585774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907914|NCT06586528|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||In the stepped-wedge cluster design, there is random and sequential crossover of clusters from control (phase 1) to intervention (phase 2) until all clusters are exposed|f|f|t|t
33907915|NCT04169568|||CASE_ONLY||PROSPECTIVE|||||||
33907916|NCT06662123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907917|NCT05620407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907918|NCT05541354|||OTHER||OTHER|||||||
33907919|NCT04159012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907920|NCT03582033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907921|NCT06581198|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The study investigator and the participant will be unblinded to the study treatment. A blinded assessor will perform the efficacy assessments to minimize bias in data collection.||f|f|f|t
33907922|NCT05630066|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"There will be up to 7 cohorts. The adolescents aged 15-17 will receive the adult dose. Dosing in Part 1 is pre-specified. Cohorts in Part 1 enroll a specific age range (15-17, 10-14, 5-9), with older cohorts being initiated prior to younger ones.~Part 2 features mixed-age cohorts, with age-adjusted doses. Within each Part 2 cohort, two different doses of alogabat may be used: one up to week 2, and the other from week 2 to week 12. Part 2 opens enrolment for ages 10-17 years following analysis of the 2-week data from the Part 1 cohorts aged 15-17 years and 10-14 years. Ages 5-9 years may enroll in Part 2 following analysis of the 2-week data from the Part 1 cohort with participants aged 5-9 years. A total of two optional cohorts may be utilized in this study, allocated to Part 1 and/or Part 2."||||
33907923|NCT06655896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study investigator and the participant will be unblinded to the study treatment. A blinded assessor will perform the efficacy assessments to minimize bias in data collection.||f|f|f|t
33907924|NCT06666439|||COHORT||PROSPECTIVE|||||||
33907925|NCT05375812|||OTHER||CROSS_SECTIONAL|||||||
33907926|NCT06156943|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patients are the only ones masked. As double blind is not possible, an adjudication committee, whose members will be unaware of the procedure assignments, will adjudicate all the clinical outcomes.|National prospective multicenter randomized simple blind controlled study comparing a standard of care (control group) to an individualized strategy of intraoperative GDFT driven by non-invasive continuous SV monitoring via chest bioreactance (optimized group).|t|f|f|f
33907927|NCT05640752|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33907928|NCT06346262|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083281|NCT05621161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Fascia iliaca compartment block (FICB) group, and Erector spinae plane block (ESPB) group|t|f|f|t
34083282|NCT00045266||||TREATMENT||NONE||||||
34083283|NCT06458114|||COHORT||PROSPECTIVE|||||||
34083284|NCT05137236|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part A of this study is designed as an observer-blind study. Part B of the study is designed as an open-label study.||t|t|t|t
34083285|NCT05691101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083286|NCT01464268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083287|NCT01660568|||COHORT||RETROSPECTIVE|||||||
34083288|NCT05724758|||COHORT||PROSPECTIVE|||||||
34083289|NCT01407016|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083290|NCT00325910|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33721451|NCT06113432|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Enrolled patients will receive all types of respiratory support (helmet CPAP 40 minutes followed by full face mask CPAP 40 minutes or full face mask CPAP 40 minutes followed by helmet CPAP 40 minutes) in a randomized crossover design.||||
34083291|NCT06202859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083292|NCT02039934|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083293|NCT00855218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083294|NCT00000352||||TREATMENT||||||||
34083295|NCT02076100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083296|NCT04421417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083297|NCT06238414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An experimental, randomized controlled trial will be conducted with patients hospitalized after a MSSA. The case group will receive an 8-session early psychological intervention while the control group will be treated as usual. The intervention consists of eight face-to-face sessions that include techniques from the narrative theory, dialectical behavioral (DBT), mentalization-based therapy orientation (MBT) and narrative approach, concretely an adaptation from the ASSIP therapy. Longitudinal assessment will be conducted at baseline and 3, 6 and 12 months after the early psychological intervention. The main outcome will be re-attempting suicide during the follow-up period. Secondary outcomes measures will be related to: biological (biomarkers), psychosocial (quality of life and reasons for living) and clinical (psychometric assessments, psychopathological status and suicidiological variables) factors.|f|f|f|t
34083298|NCT03258255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33721452|NCT03366376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083299|NCT02351921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34083300|NCT03665337|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors||t|f|t|t
34083301|NCT02102555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083302|NCT02711462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083303|NCT00587093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721453|NCT01620710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721454|NCT00159055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907929|NCT06478173|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The above-mentioned are masked with regards to exercise and control (non-exercise)~Statistical analysis of primary outcome will be blinded to the assessor."|The participants are randomized in a 60:40 ratio to 1) exercise training or 2) control, using a stratified randomization approach. Stratification will be based on gender (male/female), age (≥55 years vs. \<55 years), and GLP-1 agonist use (yes/no) to ensure that the distribution of gender, age, and GLP-1 agonist use is balanced across the two groups.|f|t|t|t
34083304|NCT02087098|||COHORT||PROSPECTIVE|||||||
34083305|NCT02936947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083306|NCT02008526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083307|NCT00004658||||TREATMENT||||||||
34083308|NCT06253936|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34083309|NCT00605020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083310|NCT02121977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083311|NCT06047405|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients from medical ICU or telemetry units will be randomized to one of the following arms:~Arm 1: AVAPS mode Arm 2: BIPAP S/T mode"||||
34083312|NCT04386447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083313|NCT05379920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned into 4-arms: (1) Concussed participants: high volume exercise, (2) Concussed participants: low volume exercise, (3) Healthy controls: high volume exercise, (4) Healthy controls: low volume exercise. Each group will consist of 50% males and 50% females. Exercise interventions for all participants are adjusted to the 90% Heart rate threshold (HRt) collected on the BCTT. The high-volume group will exercise aerobically at 90% of their HRt for 5 days a week for 30 minutes. The low volume group will exercise aerobically at 90% of their HRt for 3 days a week for 30 minutes. The intervention will last 2 weeks. Participants will return to the clinic and repeat testing on Days 7 and 14. Recovery is defined as (1) resolution of concussion symptoms (2) physical examination within normal limits; (3) ability to exercise to at least 80% of age-appropriate maximum HR without exacerbation of concussion-like symptoms on the BCTT.|f|t|f|f
34083314|NCT04960267|NA|SINGLE_GROUP||TREATMENT||NONE||The safety and efficacy of pre-peritoneal drain after TEP has been validated in our previous studies - which can effectively reduce seroma formation post-operatively and safe in clinical use. We shall extend the indication of pre-peritoneal drainage after robotic TAPP, results will be compared with our retrospective cohort from previous studies.||||
34083315|NCT02117258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083316|NCT01020123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083317|NCT00138528|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34083318|NCT01612663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083319|NCT03087058|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34083320|NCT03359434|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083321|NCT04818944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All study staff is masked to randomization except the following: nursing staff administrating drug, pharmacy staff, statistician, and independent safety assessor||t|f|t|f
34083322|NCT01717222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083323|NCT02737267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083324|NCT01665742|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34083325|NCT03084237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083326|NCT02443623|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33907930|NCT05281276|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort1: Chidamide(20mg)+Celecoxib(200mg); Cohort2: Chidamide(30mg)+Celecoxib(200mg)||||
33907931|NCT05345327|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907932|NCT02686125|||COHORT||PROSPECTIVE|||||||
34083327|NCT02160938|||COHORT||PROSPECTIVE|||||||
34083328|NCT05514366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083329|NCT02111200|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34083330|NCT06472739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083331|NCT03916588|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33907933|NCT05145127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083332|NCT05716334|||COHORT||PROSPECTIVE|||||||
34083333|NCT04668690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083334|NCT03362944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33907934|NCT05743699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083335|NCT03082508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083336|NCT05333497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In addition to the control and treatment groups (30 cases in each group), healthy subjects (30 cases) also provided sEMG and EEG data for reference.|t|f|f|t
33907935|NCT06587516|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study uses a crossover design where each participant will experience both the neuromuscular warm-up program (intervention) and the traditional warm-up (control). The order of the interventions will be randomized. After completing the first condition, participants will have a one-day washout period before switching to the other condition. This design allows each participant to serve as their own control, which enhances the comparison between the effects of the two conditions.||||
33907936|NCT06150534|||COHORT||PROSPECTIVE|||||||
33907937|NCT05435014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907938|NCT06454240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907939|NCT05771480|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study with durvalumab in combination with investigator's choice of 7 different background gemcitabine-based chemotherapy regimens in participants with aBTC.||||
33907940|NCT06655974|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The intervention will be at the ED level using a pre-post design with a matched comparison group.||||
33907941|NCT06041217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33907942|NCT06605560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33907943|NCT06654401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, randomized, single-center study with 2 groups of patients (investigating and control arms)|t|t|f|t
33907944|NCT05701228|||COHORT||PROSPECTIVE|||||||
33907945|NCT06268886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907946|NCT03480061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33907947|NCT00092222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907948|NCT03671629|RANDOMIZED|PARALLEL||OTHER||SINGLE|A group of physicians and clinical pharmacists will asses whether readmissions are drug-related or not. This group is blinded.||f|f|f|t
33907949|NCT06588686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907950|NCT05839600|NA|SEQUENTIAL||TREATMENT||NONE||||||
33907951|NCT04513054|NA|SINGLE_GROUP||OTHER||NONE||Single group observational study.||||
34083337|NCT00869414|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34083338|NCT00634517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083339|NCT02528474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990207|NCT05318898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person performing the analysis of the study results should be unaware of the assigned intervention so that such knowledge does not influence the results. Therefore, it will be a person outside the study.||f|f|f|t
34083340|NCT03194334|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|A co-worker, not involved in the study design and analysis, will perform the randomisation and will prepare the containers with supplements. Only the control group will know that they are part of the control group (continuing omnivorous diet). For the vegetarian groups, subject will not know whether they are in the supplemented group or not because placebo supplements will be used|The study was scheduled over a period of 6 months. Of the 40 subjects, 10 women will continue their omnivorous diet throughout the entire study (controls) and the other 30 subjects will switch to a lacto-ovo-vegetarian diet for 6 months. The vegetarian group will be split in 2 groups, matched for age, weight, height and baseline carnosine concentrations in soleus and gastrocnemius medialis muscles. Fifteen of them will be supplemented with beta-alanine and creatine (Veg+Suppl) and the other 15 women will receive a placebo (Veg+Pla).|t|f|t|t
34083341|NCT00569985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083342|NCT00049231||||DIAGNOSTIC||NONE||||||
34083343|NCT04844463|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34083344|NCT05802888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083345|NCT04041817|NA|SINGLE_GROUP||TREATMENT||NONE|Statistical analysis will be conducted by an independant statistician not involved in data collection|||||
34083346|NCT03326440|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083347|NCT00207168|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083348|NCT02911454|NA|SINGLE_GROUP||OTHER||NONE||||||
33907952|NCT04638647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907953|NCT05375643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33907954|NCT04417621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907955|NCT05976646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907956|NCT05102942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33907957|NCT06564207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized 1:1 to receive either fostamatinib plus standard of care or placebo plus standard of care.|t|t|t|f
33907958|NCT03318159|NA|SINGLE_GROUP||PREVENTION||NONE||"open label, single arm, phase 2, multicenter~\*historical control will be used for comparison: historical control patients are defined as those diagnosed with AA/hMDS and underwent ATG treatment with either fluconazole or itraconazole prophylaxis."||||
33907959|NCT06567925|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm open-label feasibility study||||
33907960|NCT06605885|||CASE_ONLY||PROSPECTIVE|||||||
33907961|NCT06011551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind (participants will be blinded to treatment assignment)|Prospective, dual arm, randomized, controlled pivotal study|t|f|f|f
34083349|NCT02022358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083350|NCT04147156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083351|NCT02175615|||COHORT||PROSPECTIVE|||||||
34083352|NCT01921400|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34083353|NCT02081989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083354|NCT00186199|||OTHER||PROSPECTIVE|||||||
34083355|NCT03779269|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||prospective convenience controlled study||||
34083356|NCT05931263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083357|NCT05579639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, parents/guardians, nursing staff (interventionists), oral evaluators, and investigators will be blinded to the intervention, administered in the form of twice-daily grape-flavored xylitol wipes or grape-flavored saline wipes (controls). Preformed packets will be prepared by CCHMC Investigational Pharmacy staff, which will consist of either saline wipes with natural grape flavoring or xylitol. The color, taste, and smell of the wipes will be identical. The statistician will be unblinded to treatment assignment for the analysis.|randomized, multicenter, double-blind, placebo-controlled|t|t|t|f
34083358|NCT00463736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083359|NCT04074811|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the use of active vs. sham rTMS. For the sham condition, the investigators will use a placebo figure-of-8 coil, which looks identical to the active coil, allows the same scalp placement, and produces the same auditory and tactile sensations as active stimulation without affecting cortical excitability.|This pilot study will use a single-blind, left dorsolateral prefrontal cortex (10-Hz) vs. sham, 2-session, within-subjects randomized crossover design.|t|f|f|f
34083360|NCT02804217|||COHORT||PROSPECTIVE|||||||
34083361|NCT02774317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990208|NCT01528462|||COHORT||PROSPECTIVE|||||||
33990209|NCT00905606|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990210|NCT01767363|||COHORT||RETROSPECTIVE|||||||
33990211|NCT00741858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990212|NCT01827566|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
33990213|NCT03859089|||COHORT||PROSPECTIVE|||||||
33990214|NCT06415045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990215|NCT00900094|||COHORT||PROSPECTIVE|||||||
33907962|NCT06480786|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||1:1 cross over design|t|f|t|f
33907963|NCT00006421|||COHORT||PROSPECTIVE|||||||
33907964|NCT06638996|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The research assistants who administer the protocol will be masked.||t|f|f|t
33907965|NCT04926766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907966|NCT06264180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907967|NCT03337698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907968|NCT06168019|||COHORT||PROSPECTIVE|||||||
33907969|NCT06645678|NA|SINGLE_GROUP||TREATMENT||NONE||"Elranatamab: C0D1 12mg sc, C0D4 32mg sc, C0D8 76mg sc, then 76mg sc weekly C1-C6, then 76mg sc bi-weekly from C7 for those achieving PR or better response, then 76mg sc q 4weeks from C12 for those achieving CR or better response Mezigdomide: per RP2D qd, D1-21, q 4weeks Dexamethasone: with elranatamab up until C6: 20mg/day C1-3 \> 10mg/day D4-6 (for those \>= 75 years old, with uncontrolled DM, Hx of intolerance, 10mg/day -\> 5mg/day)~28days/cycle, 24 cycles (2 years) fixed duration."||||
33907970|NCT06474377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33907971|NCT05917587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33907972|NCT04768322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907973|NCT05848011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33907974|NCT05211895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33907975|NCT05861999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907976|NCT03886766|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"The intervention consists of a single oral administration of 3 different formulations containing Efavirenz as model drug tracer in sub-therapeutic doses:~1. Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)~2. Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)~3. Efavirenz solution, 3 mg, oral administration (product 3) On the first visit, subjects will be randomized into three groups, starting with the ingestion of study product 1, 2, or 3 with subsequent collection of blood samples for 72 hours. After a wash out period of two weeks, participants will repeat the procedure in phase B with ingestion of the subsequent study product. After a second wash out the participants will receive the last study product in study phase C."||||
33907977|NCT05723055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907978|NCT03634540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Belzutifan in combination with cabozantinib administered orally once daily||||
33907979|NCT05782907|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33907980|NCT05695027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Labels on supplements are A and B only.|1:1 Randomization|t|f|f|f
33907981|NCT05576350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990216|NCT05886660|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A randomized double-blind (subjects and test operators) cross-over design.||t|f|f|t
33990217|NCT04028180|NA|SINGLE_GROUP||PREVENTION||NONE||This was a single-centre, single-arm study with all participants testing one or more products at one dose. The control for each test was an untreated arm. There was no blinding or randomisation employed, since the outcome measures were based on midge behaviour. Repellent product testing took place in a laboratory setting using 15 participants, with a minimum of 3 of either gender per repellent product. Each participant tested at least one single product at one dose.||||
33990218|NCT03527017|||OTHER||CROSS_SECTIONAL|||||||
33990219|NCT03022786|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990220|NCT04389489|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33990221|NCT03651219|RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental group: Irinotecan 80mg/m2 d1,d8 vi, apatinib mesylate tablets(250mg/d) po, 4-6 cycle（21d per cycle）; controlled group: Irinotecan 80mg/m2 d1,d8 vi, 4-6 cycle（21d per cycle）;||||
33990222|NCT02732821|||COHORT||PROSPECTIVE|||||||
33990223|NCT05615454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization sequence uses an online https://www.randomizer.org// procedure by an independent person not involved in the study. Matching is done using sequentially numbered, concealed opaque envelopes (SNOSE) for equal distribution of subjects between both therapies (Doig \& Simpson, 2005). An independent assessor will assess eligibility by following the inclusion and exclusion criteria for treatment allocation. Then he will collect primary demographic data and conduct all outcome measurements pre-and post-treatment. If the participant is eligible, he chooses a sealed envelope placed in a box and goes to the treating therapist. The treating therapist will be blind to outcome measurements. The participants will be blind to the type of treatment, and the independent assessor will be blind to the participants' group.|The intervention will be provided by a treating therapist who has a clinical experience of more than 13 years. The intervention for both groups will be for three consecutive weeks, five days per week (a total of 15 sessions)|t|f|t|t
33990224|NCT00532077|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990225|NCT02601560|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33990226|NCT04487158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721455|NCT00013429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907982|NCT06237257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33907983|NCT05982171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33907984|NCT05458011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33907985|NCT05973851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label, except for the assessors of the primary outcome|Parallel randomization to the 2 arms, treatment as usual (TAU) or early-intensified pharmacological treatment (EIPT).|f|f|f|t
33907986|NCT04350138|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33907987|NCT06431074|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on gender at birth, then randomized to one of the study arms|t|f|t|f
33907988|NCT05091112|||COHORT||CROSS_SECTIONAL|||||||
33907989|NCT04032470|||COHORT||PROSPECTIVE|||||||
33907990|NCT05616130|||COHORT||PROSPECTIVE|||||||
33907991|NCT03952559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were randomized to one of the four double-blind treatment arms. A separate group of 33 participants received open label baricitinib as part of pharmacokinetic (PK) lead-in (not randomized) period.||t|f|t|f
33907992|NCT04349436|NA|SINGLE_GROUP||TREATMENT||NONE||RP1 injection||||
33907993|NCT05877599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33907994|NCT04475939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, Investigator, study staff, and the Sponsor study team will be blinded.|Multicenter, randomized, double-blind, placebo-controlled study.|t|t|t|f
33907995|NCT05139862|NA|SINGLE_GROUP||TREATMENT||NONE||For MDD patients, the study will consist of six weeks of rTMS treatment using intermittent theta burst stimulation (iTBS) rTMS to the left DLPFC. Treatment will be administered daily, 5 days per week (i.e., 30 treatments).||||
33907996|NCT04167761|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||in vitro experimental study with treated and control tissue samples||||
33907997|NCT05616026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Intervention versus Control group; Randomized at the Individual level|f|f|f|t
33990227|NCT02574377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990228|NCT03697798|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990229|NCT04374630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990230|NCT02087553|||COHORT||PROSPECTIVE|||||||
33990231|NCT05580692|NA|SINGLE_GROUP||OTHER||NONE||||||
33990232|NCT04374773|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Standard drug-drug interaction study consisting of two arms with randomized, open-label, two period crossover design|t|f|t|f
33990233|NCT03040648|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33990234|NCT05385601|||COHORT||CROSS_SECTIONAL|||||||
33990235|NCT03100084|||COHORT||PROSPECTIVE|||||||
33990236|NCT05749887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990237|NCT05831449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990238|NCT05401786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990239|NCT01247701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990240|NCT01269086|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33990241|NCT02537093|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33990242|NCT01753375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33990243|NCT04952415|||COHORT||PROSPECTIVE|||||||
33990244|NCT00966589|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33990245|NCT01730638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990246|NCT00848146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990247|NCT01192932|||CASE_ONLY||PROSPECTIVE|||||||
33990248|NCT01502696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083362|NCT01503554|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083363|NCT02776293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083364|NCT02787980|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34083365|NCT02360046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083366|NCT00167700|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33990249|NCT01055041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083367|NCT01898403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083368|NCT04584814|NA|SEQUENTIAL||TREATMENT||NONE||10 preterms are going to be put on random measures in 2 hours blocks of, no intervention 2 hours of scare ventilator settled at 20 cycles per minute, and 2 hours of scare ventilator at 40cycles per minute||||
34083369|NCT01911247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083370|NCT02959801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083371|NCT01819675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34083372|NCT01717495|||COHORT||PROSPECTIVE|||||||
34083373|NCT00093483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990250|NCT02856347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990251|NCT01911676|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33990252|NCT03748381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990253|NCT06102850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study includes a phased open trial, first using a single group feasibility pilot (n=8) to refine the intervention manuals, then employed a randomized parallel feasibility pilot (n=26 in each group)||||
33990254|NCT05905718|||OTHER||PROSPECTIVE|||||||
33990255|NCT03687762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized, 3-group parallel design, 240-subject clinical trial to test the mechanisms of cognitive therapy, mindfulness meditation, and activation skills on individuals with chronic pain who endorse low back pain as a primary or secondary pain problem.|f|f|f|t
34083374|NCT06515561|||OTHER||CROSS_SECTIONAL|||||||
34083375|NCT06200532|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083376|NCT02861313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776488|NCT03254693|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|staff member not involved in the research protocol performed the randomization process with computer-generated tables. Details of the allocated groups were recorded on cards contained in sequentially numbered, opaque, sealed envelopes. Opening the envelope only on the day of the restorative procedure guaranteed the concealment of the random sequence. The examiners were not involved with the restoration procedures and therefore blinded to the group assignment, performed the clinical evaluation. Patient were also blinded to group assignment in a double-blind randomized clinical trial design.|This was a double-blind, equivalence superiority, split-mouth randomized clinical trial. The restoration procedures were carried out within the clinics of the Dental School of the Federal University of Rio de Janeiro in Rio de Janeiro (Rio de Janeiro, Brazil) and at the State University Oeste do Paraná in Cascavel (Paraná, Brazil) from July 2016 to August 2017.|t|f|f|t
33776489|NCT00126204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33907998|NCT06571552|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Patients being monitored for chronic therapeutic plasmapheresis with regional citrate anticoagulation will be recruited from the Nephrology Department at Nîmes University Hospital. After receiving written informed consent (inclusion visit), patients will be randomized to determine the nature of their first cycle (single plasma exchange or double filtration plasmapheresis. The next cycle will vary accordingly: DFPP if the first cycle was single plasma exchange, and single plasma exchange if the first session was DFPP.||||
33907999|NCT06159608|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33908000|NCT06570525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33908001|NCT06021600|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908002|NCT03818880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908003|NCT03992430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 is open-label, dose escalation; Part 2 is double-blind, dose finding, and dose comparison||t|t|t|t
33908004|NCT00895271|||COHORT||CROSS_SECTIONAL|||||||
33908005|NCT00025935|||COHORT||PROSPECTIVE|||||||
33908006|NCT06310967|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Part 1 is a randomized, double-blind, placebo-controlled study. For each dose cohort in Part 1, the Sponsor, subjects and other personnel involved with the conduct of the study will be blinded to the study products.~Part 2 is an open-label proof of concept study."|"Part 1 is a randomized, double-blind, placebo-controlled study where the doses of the study drug are escalated in a predesigned manner in 3 cohorts.~Initiation Dose shall be at 0.25 g tablets (Cohort A) and doses are escalated to 0.5 g (Cohort B) and then to 1.0 g (Cohort C) in a planned manner. Each cohort will have 10 eligible patients. Randomization will be performed in Part 1 and as per the randomization code, 8 subjects will receive the active study drug (IG3018) and 2 shall receive placebo in each dose cohort. A total of 30 subjects are planned to be enrolled.~Part 2 is an open-label proof of concept study involving hyperuricemia subjects with advanced predialysis CKD (Stage 3A, Stage 3B and Stage 4), and treated with two doses \[0.5 g BID IG3018 (Cohort D) and 1.0 g BID IG3018 (Cohort E)\] . At least 5 to 8 hyperuricemia subjects with advanced CKD will be enrolled in each dose and will receive the determined study dose of IG3018 twice daily (BID) for 4 weeks."|t|t|t|t
33908007|NCT04009499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908008|NCT03180034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908009|NCT00291096|||COHORT||PROSPECTIVE|||||||
33908010|NCT05842122|RANDOMIZED|PARALLEL||PREVENTION||NONE||In the cluster-randomized control trial, the intervention will be introduced in a parallel fashion (i.e., all pharmacies assigned a given intervention will receive the intervention at the start of the trial).||||
33908011|NCT00001456|||COHORT||PROSPECTIVE|||||||
33908012|NCT05835986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34083377|NCT05498389|NA|SEQUENTIAL||TREATMENT||NONE||||||
34083378|NCT01535118|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34083379|NCT06101238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083380|NCT03795506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083381|NCT03766035|||COHORT||PROSPECTIVE|||||||
33776490|NCT04573231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Phase 2, single-center, open-label study||||
33776491|NCT01780493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776492|NCT02873286|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33776493|NCT04796935|RANDOMIZED|PARALLEL||OTHER||NONE||An open-label, parallel, randomized study design||||
34083382|NCT03384199|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||VMAT dose escalation protocol with image guided fiducial markers||||
33776494|NCT06012838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776495|NCT04849728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083383|NCT01896063||CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34083384|NCT03670992|||CASE_ONLY||RETROSPECTIVE|||||||
34083385|NCT01338688|||CASE_CONTROL||PROSPECTIVE|||||||
33776496|NCT00739635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776497|NCT02093143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33776498|NCT05731375|||COHORT||PROSPECTIVE|||||||
33776499|NCT03501238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not know the specifics of each beverage they are taking home.||t|f|f|f
33776500|NCT02676063|||COHORT||PROSPECTIVE|||||||
33776501|NCT02694003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776502|NCT01033396|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776503|NCT02239653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776504|NCT04349111|NA|SINGLE_GROUP||TREATMENT||NONE||Single 20Gy dose of electronic brachytherapy (IORT)||||
33776505|NCT00173368|||DEFINED_POPULATION||OTHER|||||||
33776506|NCT03100838|RANDOMIZED|CROSSOVER||OTHER||NONE||A single-dose, randomized, open-label, drug-drug interaction (DDI), 4-way crossover, four-treatment, four-sequence, bioequivalence study||||
33776507|NCT00906880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776508|NCT01987375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776509|NCT00958529|NA|SINGLE_GROUP||OTHER||NONE||||||
33776510|NCT03693261|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33776511|NCT04619966|||OTHER||PROSPECTIVE|||||||
33776512|NCT02866760|||CASE_ONLY||CROSS_SECTIONAL|||||||
33776513|NCT05030935|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33776514|NCT03013699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776515|NCT05290103|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33776516|NCT05398354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Randomization is performed using a random selection method from the waiting list and the data will be coded and transferred to the database, depending on the intervention group and control group. Data analysis will be done statistically.~Each participant will be randomly assigned to each group after signing the informed consent and conducting the initial assessments. All laboratory samples and data collected will be identified with identification ID, safeguarding the confidentiality of the collected data.~At the end of this study, all participants of the control group will be offered the same intervention as the exercise group."||t|f|f|f
33776517|NCT04017741|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|This is a blinded, placebo controlled study, whereby the patient and the research team except for the injector are blinded.|Consented participants will be individually randomised by the Principal Investigator (PI) in a 1:1 ratio to receive either the GON block (active group) or the placebo injection (control group).|t|f|t|f
33776518|NCT05468671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776519|NCT00217100|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776520|NCT00170911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776521|NCT06270290|||CASE_CONTROL||RETROSPECTIVE|||||||
33776522|NCT01719120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083386|NCT03711890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687134|NCT03342300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A web-based central randomisation with block sizes of two and four was stratified by extent of disease,anthracycline administration method, and previous systemic therapy. Participants and investigators will not be masked to treatment assignment. The primary endpoint will be assessed in the intention-to-treat population. The outcome assessors will be masked to the two research groups.|Patients will be randomly assigned (1:1) to receive pegylated liposomal doxorubicin (50 mg/m² on day 1 of every 21-day cycle for up to six cycles) or pirarubicin (60 mg/m² on day 1 of every 21-day cycle for up to six cycles) plus ifosfamide (2 g/m²/d d2-4 of every 21-day cycle for up to six cycles) and dacarbazine (300 mg/m²/d d2-4 of every 21-day cycle for up to six cycles).|f|f|f|t
33990256|NCT05574647|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||two linked RCTs which will test whether bpMRI and image-fusion make a difference if used in clinical practice, across multiple centres, without the incorporation bias inherent in paired-cohort studies||||
33990257|NCT05600907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990258|NCT00947908|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33990259|NCT04962945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990260|NCT00599079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990261|NCT04255420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990262|NCT02107456|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33990263|NCT00834249|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990264|NCT01383291|||CASE_CONTROL||RETROSPECTIVE|||||||
33990265|NCT04187352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990266|NCT01194791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990267|NCT02288195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990268|NCT01725529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990269|NCT00101647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990270|NCT02224586|||CASE_CROSSOVER||PROSPECTIVE|||||||
33990271|NCT02392286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990272|NCT03266380|||COHORT||PROSPECTIVE|||||||
33990273|NCT01104077|||CASE_ONLY||RETROSPECTIVE|||||||
33990274|NCT05985343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patient will be blinded as to what medication they receive for reversal of neuromuscular blockade|Patients will be assigned to receive sugammadex or neostigmine/glycopyrrolate for reversal of neuromuscular blockade|t|f|f|f
33990275|NCT05332002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990276|NCT00906399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990277|NCT04330534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Part 3 is not masked; Parts 1 and 2 are participant and investigator masked.|Each cohort in Part 3 is enrolled as a single group; Parts 1 and 2 follow a parallel study model.||||
33990278|NCT02532439|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33990279|NCT03598595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990280|NCT04390256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990281|NCT01438853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33990282|NCT06027710|||CASE_CONTROL||RETROSPECTIVE|||||||
33990283|NCT06562738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990284|NCT02473718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990285|NCT01931553|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33990286|NCT04870606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990287|NCT00365365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990288|NCT01163461|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33990289|NCT00753194|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33990290|NCT05873283|||COHORT||RETROSPECTIVE|||||||
33990291|NCT03992222|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990292|NCT05430776|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups systemic versus local transcutaneous laser therapy||||
33990293|NCT02188563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990294|NCT01300676|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33990295|NCT02514382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990296|NCT04192162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687135|NCT00821327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990297|NCT04736186|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Non-secondary prevention: Explore the recovery time of oral loperamide 4mg T.I.D. for pyrrolitinib induced diarrhea of 1-2 degrees.~Secondary prevention: To explore the incidence of grade 3 and above diarrhea during c1D1-C1D22 in patients with oral loperamide 4 mg, T.I.D. (D1-7) →4 mg, B.I.D. (D8-21)."||||
33990298|NCT05539339|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, pilot, umbrella trial||||
33990299|NCT06560775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33990300|NCT06480032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double Blinded|BFR with standard post-operative rehabilitation for 8 weeks followed by the standard protocol progression for the remainder of the treatment program. The other group (Group 2) will receive standard post-operative rehabilitation without BFR for the duration of treatment program.|f|f|t|f
33990301|NCT03501147|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33990302|NCT02576522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990303|NCT03962439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990304|NCT04033276|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990305|NCT03492320|||CASE_ONLY||PROSPECTIVE|||||||
33990306|NCT05408169|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33687136|NCT05370456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687137|NCT06032897|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33687138|NCT06454175|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33687139|NCT01776385|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687140|NCT01859104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687141|NCT00208182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33687142|NCT05875103|NA|SINGLE_GROUP||OTHER||NONE||||||
33990307|NCT03876639|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990308|NCT00011960|RANDOMIZED|||TREATMENT||||||||
33990309|NCT06432595|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33990310|NCT01013077|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33990311|NCT01093963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687143|NCT04800666|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33776523|NCT00739193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776524|NCT04640480|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||1-7 cohorts, dose escalation method according to modified accelerated titration design||||
33776525|NCT05498766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776526|NCT01330121|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33776527|NCT01198925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908013|NCT06425133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687144|NCT05276648|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33687145|NCT00132106|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33687146|NCT02278432|||||PROSPECTIVE|||||||
33687147|NCT04441866|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687148|NCT04459429|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover||||
33687149|NCT02604017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687150|NCT00119873|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33687151|NCT02796014|||CASE_ONLY||PROSPECTIVE|||||||
33687152|NCT01652911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776528|NCT03302806|||OTHER||PROSPECTIVE|||||||
33776529|NCT03756402|||COHORT||PROSPECTIVE|||||||
33776530|NCT00467142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776531|NCT04155684|||CASE_CONTROL||PROSPECTIVE|||||||
33776532|NCT03403933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776533|NCT03565861|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Adaptive design of placebo and up to six escalating doses of NP10679|t|f|t|t
33776534|NCT01593735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776535|NCT00107380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776536|NCT05489029|||COHORT||PROSPECTIVE|||||||
33776537|NCT04137510|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multi-center, international, two-arm randomized controlled clinical study.||||
33776538|NCT02764775|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental, one-way repeated measures design||||
33776539|NCT01723553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776540|NCT04436003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessor will be masked for randomisation. It is not possible to mask the patient and treatment provider.|Patients are randomized into intervention or Control Group.|f|f|t|t
33776541|NCT01290094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776542|NCT05640739|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33776543|NCT05157685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776544|NCT00791622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776545|NCT02155582|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33776546|NCT01782326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776547|NCT02727868|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33776548|NCT05973890|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||parallel 3 arm randomized controlled study with equal allocation||||
33776549|NCT04544007|NA|SINGLE_GROUP||TREATMENT||NONE||Patients must be less than 22 years of age with a diagnosis of NF1 and LGG of the brain and spinal cord (WHO Grade 1 and 2)||||
33908014|NCT03650712|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|t|f|f
33908015|NCT06651281|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants in Group 1: Low Dose Unblinded and Group 2: High Dose Unblinded received open-label treatment on their parent studies, and will remain unblinded on this extension study.~Participants in Group 3: High Dose Blinded and Group 4: Low Dose Blinded were all blinded on their parent studies, and will remain blinded on this extension study until after regulatory approval or market authorization in the United States or European Medicines Agency, per sponsor discretion."|"This extension study will enroll participants who choose to enter from certain studies in which they are already receiving treatment (their parent studies). They will enter the appropriate arm in this study that will provide the same treatment they had been receiving on their parent study."|t|t|t|t
33908016|NCT06361251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind (participant and care provider)|Proof of concept study concerning 2 prototypes of cyto-selective cryotherapy devices corresponding to a modified CE marked medical device (ref: 822-v1).|t|f|t|f
33990312|NCT04945252|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||non-randomized parallel design||||
33990313|NCT05150691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990314|NCT05217108|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990315|NCT06022419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776550|NCT06115278|||COHORT||CROSS_SECTIONAL|||||||
33776551|NCT02935140|||COHORT||PROSPECTIVE|||||||
33776552|NCT04218136|||OTHER||PROSPECTIVE|||||||
33908017|NCT04499053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908018|NCT00340405|||COHORT||PROSPECTIVE|||||||
33908019|NCT00340028|||COHORT||PROSPECTIVE|||||||
33908020|NCT05581485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908021|NCT05532137|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the nature of the intervention, participants cannot be blinded. However, the person responsible for the statistical analysis remains blinded throughout the study. In addition, although the different versions of the application are available in the Apple Store or Play Store at all times, personal alphanumeric codes are assigned to the participants; so that each participant only has access to him/her version of the application depending on whether they belong to the intervention group ('feedback' e-12HR) or to the control group ('non-feedback' e-12HR).|"Participants (university students) are included by probability single-stage cluster sampling at the Faculties of Medicine and Pharmacy at the University of Seville (Spain), selecting 4 random classrooms in each school.~Of the 4 selected classrooms in each faculty (Medicine and Pharmacy), 2 are randomly assigned to the control group and 2 to the intervention group."|f|f|f|t
33908022|NCT04600544|||OTHER||PROSPECTIVE|||||||
33908023|NCT06253845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908024|NCT03888105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||5 cohorts The first 68 patients in the DLBCL cohort will be randomized; the remaining patients will not be randomized||||
33908025|NCT04600804|||OTHER||RETROSPECTIVE|||||||
33908026|NCT06486441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908027|NCT06470295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|During participation in these studies, the subject and the researchers will not know which treatment (C-peptide versus saline) was administered to the subject on what day until after that subject has completed the study.|Each subject will undergo two metabolic studies, one where they receive an IV infusion of C-peptide during insulin-induced hypoglycemia, and one where they will receive an IV infusion of saline instead.|t|f|t|f
33908028|NCT02108080|||CASE_CONTROL||OTHER|||||||
33908029|NCT03052608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908030|NCT05182476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908031|NCT02784509|||COHORT||PROSPECTIVE|||||||
33908032|NCT03804905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33908033|NCT03394079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908034|NCT04749446|||COHORT||RETROSPECTIVE|||||||
33908035|NCT05512377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908036|NCT04801771|NA|SINGLE_GROUP||TREATMENT||NONE||Hypoglossal Nerve Stimulation||||
33908037|NCT04509427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physical therapist responsible for baseline and post-intervention measurements will not know group assignments of the participants. Participants will be told not to tell this physical therapist their group assignment.|After baseline measurements, participants will be assigned to one of two groups. Both groups will receive the same intervention except one group will also receive video instruction of the program intervention. Both groups will receive intervention instruction handouts and video-conferencing with a physical therapist, who will provide initial instruction of the program, assist with program progression, and assess safety and quality of performance of the program by the participants.|f|f|t|f
33990316|NCT03414450|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In Phase 1A, an adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.||||
33990317|NCT01045018|RANDOMIZED|PARALLEL||||||||||
33990318|NCT02251886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776553|NCT02139982|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33776554|NCT02025205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776555|NCT00004225||||TREATMENT||||||||
33776556|NCT00506285|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33687153|NCT04094077|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a paucicentric, single arm Phase II trial conducted according to a single stage Fleming-A'Hern design and aiming to evaluate the efficacy of AGuIX® during FSRT of brain metastasis.||||
33687154|NCT04507854|NA|SINGLE_GROUP||OTHER||NONE||||||
33687155|NCT02764021|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
33776557|NCT00946647|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment was assigned sequentially for the initial dose escalation part (phase Ib): If a dose was safe, the next cohort started with the next dose level. Randomization applies only for the phase IIb part.|||||
33776558|NCT02555007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776559|NCT00085059||||TREATMENT||NONE||||||
33776560|NCT02102893|||CASE_ONLY||RETROSPECTIVE|||||||
33776561|NCT01759875|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33776562|NCT00280449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687156|NCT05962346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776563|NCT04896892|||COHORT||PROSPECTIVE|||||||
33776564|NCT00002087||||TREATMENT||NONE||||||
33776565|NCT00870025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776566|NCT00743522|||COHORT||PROSPECTIVE|||||||
33776567|NCT02410161|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Dietary Supplement: alpha-linolenic acid-rich supplement||||
33776568|NCT03913728|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice||||
33776569|NCT00097370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908038|NCT03543189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908039|NCT06507254|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33908040|NCT06646276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908041|NCT06132568|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33908042|NCT04784494|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label feasibility trial.||||
33908043|NCT06239116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908044|NCT05270356|||COHORT||CROSS_SECTIONAL|||||||
33908045|NCT06381258|||CASE_CONTROL||PROSPECTIVE|||||||
33908046|NCT01633021|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33908047|NCT05536141|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908048|NCT04513132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants are blind to the dTMS montage. Researchers in this study will include clinical evaluators, laboratory inspectors, dTMS operators, and statistical analysis. Before unblinding, each group of researchers will have no access to the information collected by the other groups.|Participants will be randomly assigned to different montage of stimulation, including deep transcranial magnetic stimulation (active-dTMS) and sham stimulation (sham-dTMS).|t|t|t|t
33908049|NCT05639543|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33908050|NCT06551311|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In this randomized controlled trial, participants were assigned to one of three groups: the concentric cycling exercise training group, the eccentric cycling exercise training group, or the control group with no exercise intervention. Over eight weeks, participants completed 24 exercise sessions, three times per week, with each session lasting between 20 and 30 minutes. The allocation of participants to groups was determined using a random numbers table.|t|f|f|f
33908051|NCT05031507|||CASE_ONLY||OTHER|||||||
33990319|NCT02140580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33990320|NCT05053854|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm, single centre, Phase 1 study||||
33990321|NCT04246476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33687157|NCT01779076|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33687158|NCT06438146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776570|NCT00813410|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687159|NCT04645485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908052|NCT04605965|||CASE_ONLY||PROSPECTIVE|||||||
33990322|NCT06486623|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33990323|NCT03325387|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33990324|NCT03500341|NA|SINGLE_GROUP||OTHER||NONE||||||
34083387|NCT05233735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Recruited patients will have at least 3 × 3 cm patches in greatest dimensions in symmetrical locations for example both forearms, both legs ect. one side will serve as target lesion and the other willl rec. Patients receiving topical or systemic therapy for vitiligo will be kept off treatment for 4 weeks prior to start of therapy.~each patient will have 2 different treatments. one side - topical application of Betamethasone alone other side - enhanced Transcutaneous Delivery of Topical Betamethasone for the Treatment after treatment with Tixel.~each patient will be treated with the 2 modes of treatments - 2 arms in symmetrical locations"||||
34083388|NCT02687802|||COHORT||PROSPECTIVE|||||||
34083389|NCT03962400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will not be informed of group designation|Randomized Controlled Trial of 2 groups. Subjects in the Control group will receive warfarin with dose adjustment guided by standard protocol. Subjects in the Treatment group will receive warfarin with dose adjustment guided by personalized protocol.|t|f|f|f
34083390|NCT04539275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participants, site investigators, clinical prescribers, site coordinators, and most other individuals involved in this study will be blinded to the treatment assignment.~Furthermore, the blind will not routinely be broken in order to select post-study, pharmacologic treatment for SARS-CoV-2 infection administered by clinical healthcare providers."|There are two study treatment arms: convalescent plasma versus saline. Participants will be randomized in 1:1 ratio to these two arms.|t|t|t|f
34083391|NCT03445026|||OTHER||CROSS_SECTIONAL|||||||
34083392|NCT04182919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, care provider and investigator, outcomes assessor in each site do not know what kind of medication in each package.|Participant in each arm will take medication provided by care providers who also do not know what kind of this medication|t|t|f|f
33776571|NCT05104411|||COHORT||RETROSPECTIVE|||||||
33776572|NCT03327675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776573|NCT00790829|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33908053|NCT03391466|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms, SOC and experimental treatment||||
33908054|NCT04912869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908055|NCT06409286|||COHORT||PROSPECTIVE|||||||
33908056|NCT06008301|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33908057|NCT04712097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776574|NCT05115656|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Rigorous, Double-Masked/Double-Blind|Participants (Moderate to Severe TBI patients) will be randomized into one of 2 online group interventions.|t|f|t|f
33776575|NCT02916082|||CASE_ONLY||PROSPECTIVE|||||||
33776576|NCT00939796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776577|NCT00518505|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33776578|NCT01300793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776579|NCT01370993|||COHORT||PROSPECTIVE|||||||
33776580|NCT00459511|||DEFINED_POPULATION||OTHER|||||||
33908058|NCT04759586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908059|NCT03474107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908060|NCT06472726|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990325|NCT03625115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research staff collecting study data will be unaware of study arm of participants.|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.|f|f|f|t
33990326|NCT03341156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990327|NCT05234567|||COHORT||PROSPECTIVE|||||||
33990328|NCT01334307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990329|NCT01902394|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33990330|NCT00868413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990331|NCT03305263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990332|NCT04952857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990333|NCT00520429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990334|NCT00682110|||CASE_CONTROL||PROSPECTIVE|||||||
33990335|NCT05300022|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33990336|NCT03557541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990337|NCT01293474|||CASE_CONTROL||PROSPECTIVE|||||||
33990338|NCT02601625|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33990339|NCT04740658|||COHORT||RETROSPECTIVE|||||||
33990340|NCT05422391|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study will utilize a pre-post interventional design to assess the acute effects of a 3 day caloric restriction protocol.||||
33990341|NCT06448663|NA|SEQUENTIAL||TREATMENT||NONE||||||
33990342|NCT06357494|||COHORT||PROSPECTIVE|||||||
33990343|NCT03797872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessor will perform clinical evaluations||f|f|f|t
33990344|NCT04567082|||CASE_CONTROL||PROSPECTIVE|||||||
33687160|NCT03494777|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The investigator and outcomes assessor will be blinded to treatment assignment of study participants.|"Randomized controlled trial with two intervention arms and a control group will receive an intervention for twelve months; those not showing viral suppression at month 12 will be randomized to either continue receiving the year 1 intervention for another twelve months, or receive an additional intervention component for twelve months.~The main analysis will be based on the sample of 330 treatment mature clients, from which the 70 treatment initiating clients will be excluded."|f|f|t|t
33687161|NCT02231047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33990345|NCT06427005|NA|SINGLE_GROUP||TREATMENT||NONE||Participants received Fruquintinib (5 mg daily for 14 days followed by a 7-day break), oral S-1 (80-120 mg daily for 14 days, followed by a 7-day break), and raltitrexed (3 mg/m² on day 1, with a maximum dose of 5 mg) every 3 weeks.||||
33687162|NCT02398227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33776581|NCT01442974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776582|NCT00288197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687163|NCT02739672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687164|NCT02793128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687165|NCT00686998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687166|NCT04507880|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687167|NCT01133327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687168|NCT02209129|||COHORT||PROSPECTIVE|||||||
33687169|NCT03562871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776583|NCT00309920|RANDOMIZED|||TREATMENT||NONE||||||
33776584|NCT01480635|||COHORT||PROSPECTIVE|||||||
33776585|NCT02006043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776586|NCT02353117|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776587|NCT02150044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776588|NCT02116140|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776589|NCT05351736|NA|SINGLE_GROUP||OTHER||NONE||||||
33776590|NCT01942655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776591|NCT04055506|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33776592|NCT00000783|||CASE_CONTROL||PROSPECTIVE|||||||
33776593|NCT05914428|||COHORT||RETROSPECTIVE|||||||
33776594|NCT01545362|||COHORT||PROSPECTIVE|||||||
33776595|NCT06242197|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33776596|NCT02064725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776597|NCT04463615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776598|NCT06160713|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial||||
33776599|NCT02887560|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776600|NCT04218643|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized prospective trial comparing US-guided PIVC insertion with standard PIVC insertion technique||||
33776601|NCT05677867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|(open label)|PF-07081532 80 mg will be provided in 2 different oral formulations (A and B). Formulation A will be administered as a PF-07081532 20 mg immediate release tablet and a 60 mg immediate release tablet. Formulation B will be administered as a PF-07081532 80 mg immediate release tablet. The overall design is a randomized, open-label, single dose, 2-period, 2-sequence, crossover study.||||
33776602|NCT05530954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|capping material used|"After informed consent, baseline clinical and radiographic assessment will be obtained and recorded in patient examination sheet. Participants who met the inclusion criteria were randomly allocated to two groups (n = 26/group, N = 52 in total) according to the capping martials using the envelope randomization method. All patients were recalled and their treated molars were evaluated clinically and radiographically at 3months, 6months, 9months ,12months follow up periods.~2 study groups according to capping material that will be used (Dycal or MTA) and each group will be divided to 2 subgroups according to site of exposure axial or pulpal"|t|f|f|f
33776603|NCT03044093|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776604|NCT05791461|||COHORT||OTHER|||||||
33776605|NCT03613779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33776606|NCT04777188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776607|NCT04607915|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33776608|NCT00649129|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33776609|NCT04746274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776610|NCT05127161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776611|NCT00918216|||CASE_ONLY||CROSS_SECTIONAL|||||||
33776612|NCT02359253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776613|NCT00429793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776614|NCT00590070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776615|NCT00043095||||TREATMENT||||||||
33776616|NCT04148001|||COHORT||PROSPECTIVE|||||||
33776617|NCT05158257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776618|NCT05540717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776619|NCT00179010|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33776620|NCT00917228|||COHORT||CROSS_SECTIONAL|||||||
33776621|NCT03623412|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33776622|NCT04745104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776623|NCT06483412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Employs a step-wedged design that involves delay-of-treatment for the control group. Prognostic blocks of schools will be assigned to treatment (10 schools) versus delay-in-treatment (10 schools) in Year 1 of the intervention. In Years 2 and 3, the 10 schools that served as control schools will cross over and implement the Healthy Futures: Alternative-to-Suspension intervention."|f|t|f|f
33776624|NCT03135548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776625|NCT04316767|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, repeated measures, longitudinal design with randomization to one of two parallel groups (control, intervention) will be employed. Participants will be randomized to group assignment after study enrollment is completed and baseline measurements are obtained.||||
33776626|NCT02986828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776627|NCT05079880|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33776628|NCT00130650|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33776629|NCT05556746|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in a 1:1 ratio to the experimental or standard groups.||||
33776630|NCT01611103|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33776631|NCT02268396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776632|NCT03413371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant)|Crossover Assignment|t|f|f|f
33776633|NCT03325621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, double-blind, placebo-controlled, two dose groups|t|t|t|t
33776634|NCT05183009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776635|NCT02748564|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33776636|NCT01406860|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33776637|NCT00677456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776638|NCT04882020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33776639|NCT03753880|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776640|NCT04583319|||CASE_CONTROL||PROSPECTIVE|||||||
33776641|NCT02418299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990346|NCT06028204|||COHORT||PROSPECTIVE|||||||
33990347|NCT03702322|NA|SINGLE_GROUP||TREATMENT||NONE|Participants in the perceptual studies rating audio and visual files will be masked.|All participants receive every intervention in randomized order||||
33990348|NCT05857774|||COHORT||PROSPECTIVE|||||||
33990349|NCT00365430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990350|NCT04988594|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33990351|NCT03917147|||COHORT||PROSPECTIVE|||||||
33687170|NCT04648501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A person not involved in the study (student helper #1) will randomize participants to study groups in permuted blocks through computer-generated random numbers list prepared by The student helper who is not involved in the recruitment, assessment of study variables, or intervention delivery will perform the allocation of participants into the experimental group and active control groups. One other part-time research assistant will be recruited to conduct all the other methodological procedures of the project (RA2). Assessments will be performed by a PhD student of the PI who is blind to treatment condition. Statistical analysis will be performed by the PI who will be blind to treatment condition during analyses.|An assessor and statistician blinded two-arm parallel group, RCT comparing dual-task (CIBT) to single-task (conventional balance, coordination and cognitive) training will be conducted with 44 participants with CA. Eligible participants will be randomized to study groups and allocation will be concealed. Participants will be randomized to one of the two groups: Group 1: Dual-task (CIBT) training; and Group 2: Single-task active control (conventional balance, coordination and cognition) training.|f|f|f|t
33687171|NCT03654742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are masked with numbers and patient records not shown to the outcomes assessor|prospective, single-blinded, randomised, controlled|t|f|f|t
33687172|NCT01834859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776642|NCT01667315|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33776643|NCT03358212|||COHORT||PROSPECTIVE|||||||
33776644|NCT01686594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776645|NCT06455761|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33776646|NCT04729283|||COHORT||PROSPECTIVE|||||||
33776647|NCT05121675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be randomized to one of the two groups and will not be informed of which one. If they directly ask the investigators will tell them at the end of the trial.|Participants will be randomized to one of the two arms. The participants getting the app with behavioral economics incentives only will be enrolled at the same time as the participants getting the app with behavioral economics + financial incentives.|t|f|f|f
33776648|NCT01720797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776649|NCT01270763|||COHORT||PROSPECTIVE|||||||
33776650|NCT06320275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33776651|NCT02451423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33776652|NCT05543421|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33776653|NCT05350085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776654|NCT05902403|||COHORT||PROSPECTIVE|||||||
33776655|NCT00305201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776656|NCT02958761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33776657|NCT03124680|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33776658|NCT04027335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776659|NCT05507489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776660|NCT05655481|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990352|NCT04834128|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, safety and tolerability, escalating dose, single arm study||||
33776661|NCT04728711|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776662|NCT00608361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776663|NCT00238043|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776664|NCT02013687|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990353|NCT00124618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990354|NCT04991194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990355|NCT01309672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990356|NCT04269642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687173|NCT05984849|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33687174|NCT04291378|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomised between 2 arms with different types of radiation therapy, and patients in both arms have similar follow up||||
33687175|NCT01230125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687176|NCT03395132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In order to keep the trial investigator-blind, packaging and labelling of the outer box will be identical for all investigational medicinal products (IMPs). Handling of individual tubes of IMP will therefore be handled by a designated third person. Individual tubes of IMP will be inaccessible for the (sub)investigator and other trial staff involved in evaluation of subjects and conduct of the trial. Subjects will be instructed to only reveal the IMP to the drug dispenser and not to the trial staff.||f|f|t|f
33687177|NCT04172129|||COHORT||PROSPECTIVE|||||||
33687178|NCT06400017|NA|SINGLE_GROUP||TREATMENT||NONE||By comparing the behavioral characteristics of the memory paradigm under microelectrode stimulation during DBS operation and the characteristics of the electrophysiological signals behind it, as well as the behavioral characteristics of the memory paradigm under electrical stimulation and the characteristics of brain network activity during DBS startup one month after surgery, we analyzed the regulatory effect of substantia nigra DBS on memory network||||
33687179|NCT00403078|||OTHER||PROSPECTIVE|||||||
33687180|NCT06114108|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open label, randomized, controlled, multicenter interventional clinical trial||||
33687181|NCT00999921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687182|NCT02582255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687183|NCT02255578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687184|NCT06499779|||CASE_CONTROL||RETROSPECTIVE|||||||
33687185|NCT04067583|||OTHER||PROSPECTIVE|||||||
33687186|NCT04004351|||OTHER||PROSPECTIVE|||||||
33687187|NCT03252340|||CASE_ONLY||OTHER|||||||
33687188|NCT06150144|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33687189|NCT03783702|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into one of two groups: one will receive acetaminophen and oxycodone while the other will receive acetaminophen, ibuprofen, and oxycodone.||||
33687190|NCT01680133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33687191|NCT01680237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687192|NCT04378452|||COHORT||CROSS_SECTIONAL|||||||
33687193|NCT03785743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776665|NCT01946243|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33990357|NCT04486794|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Patients in this current trial will initially be randomized to either needle or cannula injections, or no treatment (control; ratio 3:3:1, respectively). Subjects will proceed from randomization in parallel assignment. Subjects initially randomized to the control group at Baseline will be randomized to either needle or cannula treatment at Visit 3, Month 1 (crossover). Subjects in the crossover group will then be seen at weeks 2 and 4 post last treatment, as per Schedule 1.|f|f|f|t
33990358|NCT03077880|||COHORT||PROSPECTIVE|||||||
33990359|NCT02296086|||COHORT||PROSPECTIVE|||||||
33990360|NCT00712777||PARALLEL||DIAGNOSTIC||NONE||||||
33990361|NCT02380560|||CASE_CONTROL||PROSPECTIVE|||||||
33990362|NCT04509063|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Self administered questionnaire||f|f|t|f
33990363|NCT02321098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Only 12 first weeks of treatment with Loceryl NL and/or Loceryl alone were investigator masked and randomized.~15 months of treatment with Loceryl NL alone had an open study design"||f|f|t|f
33990364|NCT03082872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded|Patients with middle proximal fractures of fingers|t|t|t|t
33990365|NCT05640544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990366|NCT03598894|||CASE_CONTROL||PROSPECTIVE|||||||
33990367|NCT04834414|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Partial Blind|Adaptive Design|t|f|t|t
33990368|NCT04560738|NA|SINGLE_GROUP||OTHER||NONE||||||
33990369|NCT02470247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33990370|NCT04514757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33990371|NCT03692663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990372|NCT01526694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990373|NCT00077077||||TREATMENT||NONE||||||
33990374|NCT02004535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990375|NCT04048096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990376|NCT03091335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of their randomization group until all pre-operative measures have been acquired.|Randomization into two groups: music-listening vs headphones-only|t|f|f|f
34083393|NCT05239572|NA|SINGLE_GROUP||SCREENING||NONE||In Vietnam members from 60 Intergenerational Self Help Clubs have been screened for diabetes and cardiovascular diseases. (total 5,000 persons) In Myanmar members from 15 Intergenerational Solidarity Groups have undergone screening for diabetes and cardiovascular diseases using an internet application. (total 1850 persons) In Indonesia, visitors of 20 Posbindu programmes were offered screened for diabetes and hypertension in Central and East Java (10,000 persons)||||
34083394|NCT06026436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083395|NCT00051701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083396|NCT02951312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34083397|NCT02917746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083398|NCT00921323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687194|NCT00911443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687195|NCT01795690|||COHORT||PROSPECTIVE|||||||
33687196|NCT01649479|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33687197|NCT04609111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687198|NCT05456945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33687199|NCT05143359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687200|NCT02016547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990377|NCT04256720|||COHORT||CROSS_SECTIONAL|||||||
33990378|NCT02793245|NA|SINGLE_GROUP||OTHER||NONE||||||
33990379|NCT04726163|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990380|NCT04222790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990381|NCT04199741|||COHORT||PROSPECTIVE|||||||
33990382|NCT03279900|||COHORT||CROSS_SECTIONAL|||||||
33990383|NCT03774303|RANDOMIZED|PARALLEL||OTHER||NONE||RCT||||
33990384|NCT04801589|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
33990385|NCT01906918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33990386|NCT02816450|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990387|NCT03415828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990388|NCT00777972|RANDOMIZED|CROSSOVER||||NONE||||||
34083399|NCT01254500|||CASE_CONTROL||PROSPECTIVE|||||||
34083400|NCT02554396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083401|NCT01075048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase 1 is single group open label with one arm. Phase 2 is parallel, double-blind design with two arms.|t|f|t|f
34083402|NCT00394641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990389|NCT05694676|||COHORT||PROSPECTIVE|||||||
33990390|NCT03432182|NA|SINGLE_GROUP||OTHER||NONE||||||
33990391|NCT00752466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990392|NCT05908097|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All study participants are randomly assigned to a group prior to study enrollment. Participants will not be made aware of their group assignment.|Two groups: Experimental and Control|t|f|f|f
33990393|NCT05305092|||COHORT||PROSPECTIVE|||||||
33990394|NCT03342157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33990395|NCT05183191|NA|SINGLE_GROUP||OTHER||NONE||||||
33687201|NCT03714737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33687202|NCT06505967|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33687203|NCT00708071|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33687204|NCT01866553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687205|NCT00730028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687206|NCT00384527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687207|NCT03266198|||COHORT||RETROSPECTIVE|||||||
33687208|NCT04853303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687209|NCT03924271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687210|NCT01527266|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33687211|NCT05791578|||OTHER||CROSS_SECTIONAL|||||||
33687212|NCT01673750|||COHORT||PROSPECTIVE|||||||
33687213|NCT04542538|||COHORT||OTHER|||||||
34083403|NCT04919317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The surgeon (investigator), patient, and anesthesiologists were not aware of which arm each participant was assigned to. Furthermore, each injected analgesic was premixed and uniformly labeled to maintain blinding.|Double-blinded randomized controlled trial. Subjects were randomized 1:1 to the experimental or control groups. Each patient received the same Pecs II perineural block preoperatively with the same volume injected. Experimental group patients received 29mL 0.5% bupivacaine with 1mL of 4mg/mL dexamethasone, while control group patients received 29mL 0.5% bupivacaine with 1mL of 0.9% saline.|t|t|t|f
34083404|NCT05421637|||COHORT||PROSPECTIVE|||||||
33990396|NCT02092363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990397|NCT01036009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990398|NCT01910688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990399|NCT01149733|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990400|NCT03100344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990401|NCT01237691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33990402|NCT01414153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990403|NCT00978991|||COHORT|||||||||
33990404|NCT04327128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33990405|NCT02350621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990406|NCT00828295|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990407|NCT06033274|||COHORT||RETROSPECTIVE|||||||
33990408|NCT02181647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990409|NCT03832530|NA|SINGLE_GROUP||PREVENTION||NONE||Safer conception counseling||||
33990410|NCT01825447|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33990411|NCT02479633|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33990412|NCT05194020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990413|NCT02193971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990414|NCT01421264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990415|NCT02765880|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990416|NCT03394547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be randomly allocated to a treatment arm through telephone randomisation. If they are allocated to no treatment they will be aware of the management, however if allocated to use of a device the participant and care provider will be blinded to weather it is an active device or placebo device. The outcome assessor will be blinded to the treatment allocation."|Participants are allocated to 1 of 3 arms: either treatment with an active device, treatment with a placebo device, or no treatment.|t|t|f|t
33990417|NCT03665935|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083405|NCT01531426|||COHORT||PROSPECTIVE|||||||
34083406|NCT06174285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34083407|NCT02953730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083408|NCT03531749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A prospective double-blind, randomized clinical trial of microencapsulated of red pomegranate to treat HIV-infected patients|A prospective double-blind randomized clinical trial|t|f|t|f
34083409|NCT04006145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-Blind, Randomized, Placebo-Controlled|t|f|t|t
34083410|NCT00580320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083411|NCT05544097|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33990418|NCT04548635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990419|NCT00620893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990420|NCT02557347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990421|NCT03804593|||CASE_CONTROL||PROSPECTIVE|||||||
33990422|NCT00395980|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33990423|NCT06560008|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Acute stage: Randomized, double-blind, placebo-controlled, single-dose, 4-way, cross-over, study Sub-Acute Stage: Randomized, double-blind, placebo-controlled, 4 arms, parallel study|t|t|t|t
33990424|NCT01341730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33990425|NCT04205266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990426|NCT06356805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990427|NCT02723981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776666|NCT01198743|||COHORT||PROSPECTIVE|||||||
33776667|NCT06387498|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776668|NCT00178256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776669|NCT00023439|||||PROSPECTIVE|||||||
33776670|NCT00807222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990428|NCT01429870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990429|NCT03644888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990430|NCT00494338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990431|NCT01980771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33990432|NCT05662826|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990433|NCT03136627|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Tivozanib in Combination with Nivolumab||||
33990434|NCT03796871|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990435|NCT06485700|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083412|NCT00132626|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083413|NCT03292991|||CASE_ONLY||PROSPECTIVE|||||||
34083414|NCT06120608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33776671|NCT01356030|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33776672|NCT04554485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776673|NCT05819060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776674|NCT05275270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33776675|NCT05585047|||OTHER||PROSPECTIVE|||||||
33776676|NCT00147043|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous stem cells||||
33776677|NCT02687503|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776678|NCT05995340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776679|NCT02923219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990436|NCT01561391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990437|NCT04991610|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All measurements will be made by scanning of patients who coming to radiology department at sohag university hospital known of their birth date and sex who underwent thoracic CT scan evaluation during a pulmonary screening program . a descriptive comparative study will be conducted on total population of 100 sohag subjects (50 adult males and 50 adult females) from 25 years and above , using CT scan images to estimate the above mentioned diameters..||||
33990438|NCT03597243|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Two arms parallel cluster randomized trial|f|f|f|t
33990439|NCT03525522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Hystology and photographic assessment performed by independant investigators unaware of the assignement.|Patients assigned randomly to two groups: laser-treatment group and topical-corticosteroid group.|f|f|f|t
33990440|NCT01673685|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Portable oxygen concentrators vs oxygen cylinders||||
33990441|NCT02812121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083415|NCT04215367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Twenty one patients with Chronic lymphocytic leukemia (CLL) from the hematologic clinic of the General hospital of LaKonia (Greece), were enrolled to participate in the dietary intervention. CLL diagnosis was confirmed by standard criteria. Patients were untreated, in Rai stage 0 to II, did not met criteria to initiate chemotherapy and had no neoplasmatic comorbidity. Subjects were randomly selected from the Hematology Department of the General Hospital of Lakonia. Exclusion criteria were neoplastic comorbidities or severe metabolic diseases. Only one group participates in this study, which performed dietary intervention consuming EVOO rich in oleocanthal and oleacin. Clinical and molecular markers were registered 6 months before the intervention and 6 months during the intervention.||||
34083416|NCT05080712|||COHORT||PROSPECTIVE|||||||
34083417|NCT03879070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990442|NCT02753231|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34083418|NCT04237363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083419|NCT03650153|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34083420|NCT04415801||SEQUENTIAL||DIAGNOSTIC||NONE||||||
34083421|NCT04381065|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Subjects will remain blinded to treatment group throughout the life of the trial. Investigator and research staff will be unblinded to the treatment group as they will or will not have access to the PKG data to be incorporated into their standard of care practice.|Eligible subjects will be randomized using the Electronic Data Capture (EDC) system in a 1:1 ratio to the PKG- Group (standard of care clinical assessments without use of PKG data) or the PKG+ Group (standard of care clinical assessments plus use of PKG data).|t|f|f|f
34083422|NCT00001566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083423|NCT03598426|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single center, prospective, randomized, open-label study||||
33990443|NCT04466553|||COHORT||PROSPECTIVE|||||||
33990444|NCT05036707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990445|NCT05970484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researcher DL and GW will be unblinded to treatment allocation to enable the management of the BeAlcoholSmart and DrinksRation platforms and participant recruitment and retention; researcher EC will be unblinded to treatment allocation to prepare statistical reports. Researcher DL and EC will not be involved in participant engagement. All other members of the study team will be blind to treatment allocation.|This is a two-arm participant-blinded (single-blinded) confirmatory randomized controlled trial (RCT), comparing (intervention arm) the DrinksRation smartphone app with (control arm) a progressive web application (PWA) presenting NHS-focused drinking advice (named 'BeAlcoholSmart'). The DrinksRation app provides individualized normative advice with features designed to enhance participant motivation, interactive feedback, self-efficacy in modifying their alcohol consumption, and personalized gender-specific messaging. We hypothesize that the intervention arm will be efficacious in reducing alcohol consumption compared with the control arm.|t|f|t|f
33990446|NCT02053454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083424|NCT02905162|||COHORT||PROSPECTIVE|||||||
34083425|NCT04460053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective feasibility trial||||
34083426|NCT01925443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083427|NCT00190268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083428|NCT01979562|||COHORT||PROSPECTIVE|||||||
34083429|NCT05862961|||CASE_ONLY||RETROSPECTIVE|||||||
34083430|NCT05370170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083431|NCT03022409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083432|NCT06349876|||COHORT||PROSPECTIVE|||||||
33776680|NCT05451511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34083433|NCT06360861|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label phase 1, single-center, pre-post comparison study||||
34083434|NCT04400266|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label study of the Buspirone and Melatonin combination administered over 6 weeks.||||
34083435|NCT06403657|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"There are two periods - pre-implementation (used as control) and implementation. The enhanced model will be rolled out in the implementation phase. The change in hepatitis B testing will be evaluated for effectiveness.~The enhanced model of hepatitis testing and linkage to care includes three implementation interventions: 1) continued medical education (CME) for primary health providers, 2) electronic health records-based best practice alerts (BPA) for chronic hepatitis B testing, 3) point-of-care HBsAg testing (POC). These implementation interventions will be introduced sequentially and cumulatively every four months for 12 months. For example, during the first 4-month period, only CME is implemented. In the next 4 months, BPA will be introduced, coupled with the ongoing CME. In the last 4 months, POC will be introduced, together with the ongoing CME and BPA."||||
34083436|NCT02605330|||COHORT||PROSPECTIVE|||||||
34083437|NCT02444026|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908061|NCT06515002|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Phase I: open-label Phase II: double-blind|"The open-label dose escalation part, Phase I, will study the safety and efficacy of single doses of three different dose levels of BI 3720931 in trial participants with cystic fibrosis (CF).~Phase II will be a double-blind, placebo-controlled, dose expansion part with 3 arms: first arm investigating Phase II dose 1, second arm investigating Phase II dose 2, and third arm for placebo.~An interim analysis of the safety and efficacy data from Phase I will be used for the decision making to move to Phase II and the selection of doses in Phase II."|t|t|t|t
33908062|NCT06460506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776681|NCT06387732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control arm is stretching and relaxation. Prior research indicates that participants have similar efficacy expectations regarding mild stretching and aerobic exercise, which will help to improve masking. Due to the nature of the interventions, it is not possible for the participants to be masked as to the intervention they are undergoing, but all study information will be agnostic about which intervention we expect to be more effective, and all analysis will be performed by blinded staff. The trial will assess expectations and preferences about the intervention conditions, allowing for sensitivity analyses.|The trial will use a single-site parallel group design with depressed participants randomised to eight weeks of either 45 minutes of aerobic exercise of moderate-to-vigorous activity (experimental group: three times per week, N=125) or 45 minutes of non-aerobic stretching/guided relaxation (control group: three times per week, N=125).|t|f|f|f
33776682|NCT02430636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33776683|NCT02006303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776684|NCT05415059|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33908063|NCT03412877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990447|NCT06561724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized blind parallel three -arm randomized controlled trial (RCT). The RCT is double-blind, in which both the nutritionist and the volunteers are blinded to the actual biscuit allocated to the volunteer; i.e., neither the nutritionist in charge of distributing the biscuit nor the volunteer knows whether the volunteer has received prebiotic rich biscuit or placebo.||t|t|f|t
33990448|NCT01660594|||COHORT||RETROSPECTIVE|||||||
33990449|NCT05671965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33990450|NCT04935164|||CASE_CONTROL||PROSPECTIVE|||||||
33990451|NCT01358344|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990452|NCT05004740|||COHORT||PROSPECTIVE|||||||
33990453|NCT01124305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990454|NCT04831307|NA|SINGLE_GROUP||OTHER||NONE||||||
33990455|NCT03826745|||COHORT||PROSPECTIVE|||||||
33990456|NCT00247247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990457|NCT02061553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990458|NCT03338933|||CASE_CONTROL||PROSPECTIVE|||||||
33776685|NCT00156338|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33908064|NCT03453567|||COHORT||PROSPECTIVE|||||||
33908065|NCT05099003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908066|NCT04333576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908067|NCT05646862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908068|NCT03092453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990459|NCT02975765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990460|NCT06536257|||COHORT||PROSPECTIVE|||||||
33990461|NCT00413140|||||OTHER|||||||
33990462|NCT05166733|||OTHER||RETROSPECTIVE|||||||
33990463|NCT00838279|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990464|NCT04819009|||COHORT||RETROSPECTIVE|||||||
33990465|NCT02537457|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990466|NCT02525211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990467|NCT04599998|||COHORT||PROSPECTIVE|||||||
33990468|NCT02173834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990469|NCT01658774|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33990470|NCT00012974|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34083438|NCT05869799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This experiment adopts a block random assignment design, and the system assignment table (Block randomization, block size = 6) randomly generated by the program is given serial numbers and assigned to groups. The probability of assignment to each group is 1/2.||t|f|t|f
34083439|NCT00773617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776686|NCT04643249|NA|CROSSOVER||TREATMENT||NONE||All subjects are treated in the same arm, but in a crossover manner.||||
33776687|NCT00189176|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776688|NCT06471647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33776689|NCT05092360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776690|NCT02273505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33776691|NCT03264196|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33776692|NCT03487003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized parallel prospective non-inferiority study|t|t|t|t
33776693|NCT03786653|||CASE_ONLY||PROSPECTIVE|||||||
33776694|NCT04766502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776695|NCT01498913|||COHORT||PROSPECTIVE|||||||
33776696|NCT00000736||||TREATMENT||DOUBLE||||||
33776697|NCT03113162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776698|NCT03724461|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33776699|NCT03807505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776700|NCT02209207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083440|NCT02857868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990471|NCT00834535|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990472|NCT03563872|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33990473|NCT03644147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind randomized controlled trial|t|t|t|t
33990474|NCT05672030|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33776701|NCT02004860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776702|NCT01734837|||COHORT||PROSPECTIVE|||||||
33776703|NCT04005547|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776704|NCT01084928|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33776705|NCT02419755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776706|NCT03494374|NA|SINGLE_GROUP||TREATMENT||NONE||Annual evaluation after applying UCBL and exercise treatment. Cohort study.||||
33776707|NCT05627089|||COHORT||PROSPECTIVE|||||||
33776708|NCT00885495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33776709|NCT02746536|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33776710|NCT03385057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083441|NCT00297167|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34083442|NCT05519865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083443|NCT05508958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotherapist assessing functional tests will be blinded for treatment. Data analyst will be blinded for treatment.|Randomized Controlled Trial|f|f|f|t
34083444|NCT02378662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083445|NCT03757416|||CASE_ONLY||PROSPECTIVE|||||||
33776711|NCT06384443|||OTHER||CROSS_SECTIONAL|||||||
33776712|NCT03098043|||COHORT||PROSPECTIVE|||||||
33908069|NCT06095375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908070|NCT04400331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776713|NCT01625338|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776714|NCT06097104|||COHORT||PROSPECTIVE|||||||
33776715|NCT06096636|||OTHER||OTHER|||||||
33776716|NCT03670147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant and study staff will be blinded. The study physicians will not be blinded.||t|f|f|f
33776717|NCT00581256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776718|NCT02647047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776719|NCT03404869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776720|NCT00004767||||TREATMENT||||||||
33776721|NCT01316146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776722|NCT00000484|RANDOMIZED|||PREVENTION||DOUBLE||||||
33776723|NCT00911924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776724|NCT03007589|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33776725|NCT01013480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776726|NCT03601325|||CASE_ONLY||PROSPECTIVE|||||||
33776727|NCT03615482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33776728|NCT03073005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776729|NCT04357002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908071|NCT00339495|||COHORT||PROSPECTIVE|||||||
33908072|NCT00001987|||COHORT||PROSPECTIVE|||||||
33908073|NCT06493461|NA|SEQUENTIAL||TREATMENT||NONE||||||
33908074|NCT04950309|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33990475|NCT05829824|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33990476|NCT03553719|||COHORT||PROSPECTIVE|||||||
33990477|NCT00006376||||TREATMENT||||||||
33990478|NCT02926677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990479|NCT05785832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990480|NCT00426647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083446|NCT03720925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083447|NCT02551016|||COHORT||PROSPECTIVE|||||||
33776730|NCT05666102|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776731|NCT02278796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776732|NCT04192812|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||PROSPECTİVE RANDOMİSED CONTROLLED TRİAL|f|f|t|f
33776733|NCT02661854|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33776734|NCT02716597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33776735|NCT00366262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776736|NCT05674942|||OTHER||RETROSPECTIVE|||||||
33776737|NCT01324804|||COHORT||PROSPECTIVE|||||||
34083448|NCT05997277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083449|NCT02499588|||COHORT||PROSPECTIVE|||||||
34083450|NCT01589315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990481|NCT06318130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be blinded to the type of pacing lead received. Operators will not be blinded as they will be performing the procedure. Post-procedure, investigators and outcomes assessors will be blinded to the treatment arm during adjudication of outcomes.|"A target of 210 participants will be enrolled in this study consisting of two groups and randomised in a 1:1 fashion to either of two groups.~Group 1: Fixed helix, lumenless pacing lead (FHL) Group 2: Extendable helix, stylet driven pacing lead (EHL)"|t|f|t|t
33990482|NCT03269253|||COHORT||PROSPECTIVE|||||||
33990483|NCT01477476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990484|NCT05443386|||COHORT||RETROSPECTIVE|||||||
33990485|NCT01972386|||CASE_ONLY||PROSPECTIVE|||||||
33990486|NCT03657550|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study consists of 2 parts. Part 1 will be a randomized, open-label, single-dose, two-way crossover study to assess the relative BA of levamlodipine maleate tablets from CSPC versus Amlodipine Besylate Tablet NORVASC® from Pfizer Inc. after a single oral administration under fasted conditions in male and female healthy subjects. Part 2 will be a single-arm, open-label, single-dose phase to assess food effect on the PK profile of levamlodipine maleate tablets from CSPC. Subjects who have completed Part 1 will be rolled over to Part 2 after a wash-out period for at least 14-days since the last dosing. Subjects will receive a single oral administration of study drug under a high-fat / high-calorie meal that should derive approximately 150, 250 and 500-600 calories from protein, carbohydrate and fat, respectively.||||
33990487|NCT01294787|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33990488|NCT00304538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33990489|NCT04045925|NA|SINGLE_GROUP||SCREENING||NONE||||||
33776738|NCT05935280|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE||This study is a randomized, placebo-controlled, crossover trial. The factors determining the conditions varied within individuals are 'TRPM8 inhibitor', 'TRPA1 inhibitor', 'Nav1.7 inhibitor', 'Nav1.8 inhibitor' each with the levels 'inhibitor' or 'control'. The design allows estimating the effect size caused by each factor alone, as well as the fractional inhibition achieved when all four channels are blocked. In a separate condition, the hypothesized action of lidocaine against nerve conduction, thus including cold-induced activity, is intended as positive control.|t|t|t|t
33990490|NCT01079585|RANDOMIZED|CROSSOVER||||SINGLE||||||
33990491|NCT02701556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990492|NCT02529709|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33990493|NCT00875823|||COHORT||RETROSPECTIVE|||||||
33990494|NCT05827991|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33990495|NCT03289065|||OTHER||PROSPECTIVE|||||||
33990496|NCT05859425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990497|NCT03289884|||OTHER||CROSS_SECTIONAL|||||||
33990498|NCT00205621|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990499|NCT01289691|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33990500|NCT06560606|||COHORT||PROSPECTIVE|||||||
33990501|NCT02642653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083451|NCT00722878|||COHORT||PROSPECTIVE|||||||
34083452|NCT03744832|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized Controlled Trial.||||
34083453|NCT00573664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776739|NCT01177202|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33776740|NCT00325559|RANDOMIZED|CROSSOVER||||SINGLE||||||
33990502|NCT03838263|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In this study, there are 2 arms:~* Experimental arm with nivolumab 2 infusions (2 weeks apart) before Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7~* Control arm: Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7"||||
33990503|NCT05374876|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990504|NCT03129763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective randomized controlled trial.|f|f|f|t
34083454|NCT01865357|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34083455|NCT02758782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776741|NCT06143020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33776742|NCT01375959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776743|NCT05760729|||CASE_CONTROL||PROSPECTIVE|||||||
33776744|NCT01781611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pilot study|t|t|t|t
33776745|NCT02158650|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776746|NCT00632762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776747|NCT03116451|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Quasi-experimental study design||||
33776748|NCT02778282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776749|NCT01076088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776750|NCT01153854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776751|NCT01628874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776752|NCT06251726|||COHORT||RETROSPECTIVE|||||||
33776753|NCT05608941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data collection and analysis will be carried-out by a researcher, blinded to the group allocation. In order to maintain the participants blinded to the training load, the device will be covered with opaque material.||t|f|f|t
33776754|NCT06381635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33776755|NCT06221735|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be injected with Cy-TB and the results will be read after 48-72 hours. 10 mL of blood will be obtained from each participant and transferred to three TB-Feron tubes and four QFT-Plus tubes whereby the tubes will be incubated at 37℃ for 16 to 24 hours. The TB-Feron tubes will be analyzed with the fully automated STANDARD F2400 device, while QFT-Plus tubes will be analyzed using an ELISE microplate reader||||
33776756|NCT01050101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33776757|NCT06385912|||CASE_CONTROL||RETROSPECTIVE|||||||
33776758|NCT00063674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33776759|NCT03630081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776760|NCT02201563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776761|NCT05528887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776762|NCT04762173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776763|NCT02147860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776764|NCT04184102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were randomly assigned to a control of experimental group by flipping a coin|t|f|f|f
33776765|NCT04433793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized controlled trial with cancer patients suffering from fatigue is planned. The study investigates the efficacy in terms of fatigue, depression and quality of life of eight-week yoga therapy (intervention group) compared to an 8-week waiting period without supportive intervention (control group).|f|t|f|f
33776766|NCT00008437||||TREATMENT||||||||
33776767|NCT05768295|NA|SINGLE_GROUP||TREATMENT||NONE||according to local regulation : The study is an investigation on Medical Device CE marked used in its intended purpose without the objective of CE marking or establishing conformity and with additional procedure non-invasive or non-burdensome||||
33776768|NCT02334319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776769|NCT00209027|NON_RANDOMIZED|PARALLEL||||NONE||||||
33776770|NCT05267834|||CASE_ONLY||RETROSPECTIVE|||||||
33776771|NCT05114590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776772|NCT03896230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded study (only the pharmacist supervisor that has no other involvement with the study will know the dose)|3 arms each arm getting a different dose of ketamine|t|t|t|t
33776773|NCT06469073|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33776774|NCT02615756|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33776775|NCT02131714|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776776|NCT06500520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776777|NCT02089971|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33776778|NCT03706729|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776779|NCT03271619|||COHORT||PROSPECTIVE|||||||
33776780|NCT06285760|||COHORT||PROSPECTIVE|||||||
33776781|NCT03299374|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants are informed, so masking is not ensured Outcomes evaluator masked Physiotherapist none masked External adviser masked (randomization and data analysis)||t|f|f|t
33776782|NCT01859650|||COHORT||PROSPECTIVE|||||||
33776783|NCT03079115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776784|NCT00401817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776785|NCT02784652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776786|NCT03544528|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33776787|NCT00092170|RANDOMIZED|||TREATMENT||NONE||||||
33776788|NCT06500182|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33776789|NCT03662893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analysis of treatment response was performed by a single independent urologist blinded to the study groups.|Group I were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist, Group II were instructed to apply behavioural therapy with a written checklist for patients to fully complete and Group III received medical treatment plus behavioural therapy without checklist. Group IV received medical treatment with a written checklist to fully complete|f|f|f|t
33776790|NCT01071889|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33776791|NCT04778384|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Patients do not know which training series they belong to.|"Data analysis with statistical process control:~Data is collected in two time series. First, data of patients with sham intervention (control intervention) is collected, then data is collected from patients with a structured micro-training (study intervention)."|t|f|f|f
33776792|NCT01703442|||COHORT||PROSPECTIVE|||||||
33776793|NCT03202875|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776794|NCT04946448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776795|NCT04577365|||COHORT||CROSS_SECTIONAL|||||||
33776796|NCT04414358|||COHORT||RETROSPECTIVE|||||||
33990505|NCT02060747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33990506|NCT03352362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are divided 3 groups(caldolor, denogan, combination group) randomly. Each groups are received a medication by protocol during surgery|t|f|f|f
34083456|NCT04212429|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The qualified patients will be randomized on a 1:1 ratio into each treatment arm. Qualified eyes were further randomized into one of four subgroups, which specified the time between the last drop of study medication and the time of aqueous and vitreous humor sample collection (i.e., 1-, 2-, 4-, and 6-hour subgroups- about 32 patients per subgroup. Within each subgroups, there will be 16 of Levofloxacin group and 16 of Moxifloxacin group.|t|t|t|t
34083457|NCT03885947|NA|SEQUENTIAL||TREATMENT||NONE||Open label single arm||||
34083458|NCT02932657|||COHORT||PROSPECTIVE|||||||
34083459|NCT04813523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083460|NCT05966298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083461|NCT05620524|||COHORT||PROSPECTIVE|||||||
34083462|NCT02479841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083463|NCT03886272|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083464|NCT06523127|||COHORT||PROSPECTIVE|||||||
34083465|NCT03286764|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34083466|NCT02824107|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083467|NCT05686577|||COHORT||PROSPECTIVE|||||||
34083468|NCT06104917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083469|NCT02278653|||COHORT||PROSPECTIVE|||||||
33687214|NCT05095493|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Pharmacy prepares vials labeled A and B, and reveals code to PI after data lock|Single site randomized placebo controlled trial, cross-over|t|t|t|t
33687215|NCT01854944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687216|NCT03239028|||COHORT||PROSPECTIVE|||||||
33687217|NCT00395538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776797|NCT04298684|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, prospective open-label study evaluating the efficacy of metformin compared to sitagliptin on benign TN growth in subjects with T2DM. After written approval, subjects with T2DM who meet the eligibility criteria will have a thyroid ultrasound. Subjects with TN of at least 2 cm and 2 benign cytology results after fine-needle aspiration, will be included after a run-in period of 1 month with a daily basal insulin therapy in order to reduce glucotoxicity. If the Hb1Ac levels remain above 8%, the subjects will not be included. After inclusion, a central randomization will allow subjects to benefit from either metformin (group 1) or sitagliptin (group 2). In both cases, the standard nutritional care and physical activity recommendations (150 minutes of physical activity per week) will be recalled. If HbA1c levels \> 8% during the follow-up, treatment by gliclazide will be introduce (LP30mg). A follow-up schedule will be given to the included patient for future visits.||||
33776798|NCT06058143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33776799|NCT06022874|||CASE_ONLY||PROSPECTIVE|||||||
33776800|NCT03866057|||COHORT||PROSPECTIVE|||||||
33776801|NCT03093311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33776802|NCT02332681|||COHORT||PROSPECTIVE|||||||
33776803|NCT03881540|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled Trial||||
33776804|NCT05652764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This is a randomized controlled trial consisting of two groups: experimental and control.|t|f|f|t
33776805|NCT03590743|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Double blind, placebo controlled|Multicenter, randomized, double blind, placebo-controlled, superiority clinical trial.|t|t|t|t
33776806|NCT06478875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776807|NCT04068727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33776808|NCT05954793|||COHORT||PROSPECTIVE|||||||
33776809|NCT01639261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776810|NCT06372990|||COHORT||PROSPECTIVE|||||||
33776811|NCT03184714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-invasive positive pressure ventilation||||
33776812|NCT01653847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990507|NCT04850755|NA|SINGLE_GROUP||TREATMENT||NONE||For all patients, the phase I drug combination will be preceded by a 14-day run in period where selinexor alone will be administered and biopsies will be obtained both pre-and post selinexor dosing. Patients will be treated with all three drugs until disease progression (as defined by RECIST criteria) or intolerable drug toxicity.||||
33990508|NCT06352138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicentre, double-blind, randomised, parallel, equivalence trial|t|t|f|f
33990509|NCT03787641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083470|NCT00957281|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083471|NCT04421755|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A randomized control trial will be used to evaluate the two interventions among a cohort of OU Internal Medicine patients. Clinical and self-report measures will be collected for the intervention arms at four time points: baseline, three months, six months, and nine months and at two time points (baseline and nine months) for the control group. After baseline measures, participants will be randomly assigned to the fruits and vegetables only group, the fruit and vegetables plus cooking classes group, or the control group. This trial will use rolling enrollment, with interventions beginning after the enrollment of enough participants to conduct an effective cooking class. Participants in the intervention groups will receive nine months of free weekly deliveries of fresh fruits and vegetables. Participants in the control group will receive a gift card valued at twenty dollars for each survey completed and an OU gift valued at ten dollars following completion of both surveys.||||
34083472|NCT02644044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083473|NCT00296244|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34083474|NCT05944640|||CASE_CONTROL||PROSPECTIVE|||||||
33687218|NCT04132245|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687219|NCT00550251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33687220|NCT04969796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a wait list control design.|f|f|f|t
33687221|NCT06167174|||COHORT||PROSPECTIVE|||||||
33687222|NCT04934631|||COHORT||PROSPECTIVE|||||||
33687223|NCT01106469|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33687224|NCT03098771|RANDOMIZED|PARALLEL||TREATMENT||NONE||Inpatients of the Qingdao No. 9 People's Hospital will be recruited. Potential participants can contact the project manager via telephone. After providing informed consent, these potential participants will be screened using the inclusion and exclusion criteria.||||
33990510|NCT01776190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083475|NCT03193528|||COHORT||PROSPECTIVE|||||||
34083476|NCT00075231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908075|NCT05906589|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The study will be double blind, meaning both the investigator and the participants will not know if the participants are receiving inulin, psyllium plus inulin or the placebo. However, there is some difference in the consistency of the powders. The supplements will be labelled A, B and C by an independent party otherwise not involved in the study, and the investigator and participants will not know which supplement is which letter during the study period.|"The participants will be randomly allocated to one of the 6 different intervention combinations for the supplements ((A) placebo; (B) inulin; (C) psyllium plus inulin) with the same number of participants in each of the combinations.~There are 6 possible combinations:~* A \> B \> C~* B \> A \> C~* C \> B \> A~* A \> C \> B~* C \> A \> B~* B \> C \> A"|t|f|t|f
33908076|NCT00001505|||CASE_ONLY||PROSPECTIVE|||||||
33908077|NCT05217628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083477|NCT04217759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Participants were randomly allocated into two groups: one group with intervention (intervention group) and another group without intervention (control group).~Intervention group went through a healthy lifestyle intervention using evidence-based SCT strategies emphasising on PA and diet for 12 weeks via face-to-face sessions and social media tools, while the control group only received leaflets on healthy lifestyle with no further guidance."|f|f|f|t
34083478|NCT03366246|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|1 tube containing anesthetic and 1 tube containing placebo, both with the same aspect (same vehicle) were randomized in respect of which side each formulation should be applied. Tubes were labeled with the subject number and the indication of LEFT or RIGHT side for application. Therefore, these identical tubes, no longer possible to distinguish whether a particular tube was referring to test or control formulation. Those responsible for the separation did not participate in the conduct of activities of the study.|Double-blind, crossover study where the same participant received in one side of the forehead the active drug and in the other side of the forehead placebo.|t|t|t|t
34083479|NCT04559113|NA|SINGLE_GROUP||TREATMENT||NONE||quasi-experimental||||
34083480|NCT01005667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083481|NCT04821063|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|ITF2357 (therapeutic dose and supratherapeutic dose, and placebo) will be administered in a double-blinded fashion whereas no blinding will be needed with treatment moxifloxacin.||t|t|t|t
34083482|NCT05512117|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Neither care providers nor patients could be masked because the intravenous device is different and it's easy to identify the one we are using.~Outcomes assessor only works with anonymized data"|Intravenous access catheter in control group is conventional intravenous catheter (Braun Introcan Safety) Intravenous access catheter in intervention group is a midline catheter 12 cm length (Leader Cath 20 G. Vygon)|f|f|f|t
34083483|NCT05074329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083484|NCT03027947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083485|NCT02744716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083486|NCT00113165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083487|NCT02433769|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34083488|NCT04023201|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083489|NCT00879658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083490|NCT05461040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083491|NCT03745066|||COHORT||PROSPECTIVE|||||||
33776813|NCT05814874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||non-blinded randomized controlled trial Parallel group design (2 groups): vegan (exclusion of animal products) vs. omnivore (weekly consumption of meat and/or sausage), stable dietary habit since at least one year, 3 intervention groups (placebo, Brazil nut or selenium supplement)||||
33776814|NCT05125120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776815|NCT01457040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776816|NCT02703961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776817|NCT00605319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776818|NCT02675140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776819|NCT02173535|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33776820|NCT01807078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776821|NCT06179589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Double blind, randomized, parallel group, clinical trial|t|t|t|t
33776822|NCT05188391|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Physicians who will perform the examination will not know other physicians' decisions.||f|f|f|t
33776823|NCT05919667|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Randomized, single-blinded||t|f|f|f
33687225|NCT05943743|||OTHER||CROSS_SECTIONAL|||||||
33687226|NCT00464243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776824|NCT06220786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding of the two laser pens is in place till all patient data has been collected.|"Prospective randomized double blind study. Intervention 1: Low-level laser therapy ca. 72 Joules vs. Intervention 2: No Low-level laser therapy.~Doctors \& Patients do not kown which laser is the true laser or the fake laser"|t|t|t|f
33687227|NCT02044575|||COHORT||PROSPECTIVE|||||||
33776825|NCT05249764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the study and control group do not know the content of the exercise program. All groups are taking exercise programs individually at their home. So that individuals are not aware of the groups.||t|f|f|f
33776826|NCT04345211|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33990511|NCT01096433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990512|NCT05170594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990513|NCT04708028|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33990514|NCT04513587|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized intervention study||||
33990515|NCT01383304|||COHORT||PROSPECTIVE|||||||
33990516|NCT02914990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687228|NCT03684252|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34083492|NCT03618901|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"The early start group: 12-weeks (intervention) followed by 12-weeks of no exercise.~The delayed start group: 12-weeks (no exercise) followed by 12-weeks (intervention).~This model will be used for both RSB and PD SAFEx."|t|f|t|t
33687229|NCT04622228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687230|NCT04968639|||COHORT||PROSPECTIVE|||||||
33687231|NCT05419427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blinded. Participant, Investigator and Outcomes Assessor are masked||f|f|f|t
33687232|NCT06060821|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687233|NCT05740995|||COHORT||PROSPECTIVE|||||||
33687234|NCT00084591||||TREATMENT||||||||
33687235|NCT05304832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective, dual-arm, randomized controlled trial|f|f|f|t
33687236|NCT03021564|||COHORT||PROSPECTIVE|||||||
33687237|NCT00005031||||TREATMENT||||||||
33776827|NCT05687617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776828|NCT00372060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776829|NCT04522921|NON_RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|"At enrollment the participants have no knowledge of which group they are assigned.~The investigator has no knowledge of or influence on how participants are divided into different groups. Participants are assigned groups by the camp staff."|"1. Control group (CG): Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and regular follow-up.~2. Follow-up group (FUG): Current weight-loss diet (15E%/day protein) for the 10 weeks they attend the camp and increased follow-up (once every month within the first 6 month and once every other month until 52-weeks follow-up).~3. Intervention group (IG): A higher protein diet (25E%/day) for the 10 weeks they attend the camp and increased follow-up (once every month within the first 6 month and once every other month until 52-weeks follow-up)."|t|f|t|f
33990517|NCT05410002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Active product (N-111) and placebo will be in identical packets with the contents of identical weight, color and texture.|Randomized interventional parallel study|t|t|t|t
33990518|NCT04999501|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990519|NCT02651272|NA|SINGLE_GROUP||OTHER||NONE|Study is Open Label|||||
33990520|NCT01849003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990521|NCT03269838|||COHORT||CROSS_SECTIONAL|||||||
33990522|NCT05721586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990523|NCT06466707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083493|NCT01005238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083494|NCT05158621|||CASE_ONLY||PROSPECTIVE|||||||
34083495|NCT04896216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776830|NCT06458387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083496|NCT01316614|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34083497|NCT02845674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083498|NCT01156519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083499|NCT04517682|||COHORT||PROSPECTIVE|||||||
33687238|NCT00235001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687239|NCT05368454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33687240|NCT03608761|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33990524|NCT04968821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33990525|NCT00906477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990526|NCT05802784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33990527|NCT04816461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083500|NCT06466343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Study will be conducted on non-pregnant women with symptomatic uterine scar niche after lower segment CS at Obstetrics and Gynecology department at Sohag University Hospitals.||||
34083501|NCT06077175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908078|NCT05810870|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, single-cohort, non-comparative, open-label, phase II clinical trial.||||
33908079|NCT05639114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The trial is designed to evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).|t|t|t|t
34083502|NCT02100124|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34083503|NCT01710462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33908080|NCT00001979|||COHORT||PROSPECTIVE|||||||
34083504|NCT03897816|||COHORT||PROSPECTIVE|||||||
34083505|NCT00017641||||TREATMENT||||||||
33908081|NCT01712620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083506|NCT06083129|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083507|NCT04036604|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups Study Group and Control Group||||
33908082|NCT02677896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083508|NCT02472899|||CASE_CONTROL||OTHER|||||||
34083509|NCT06105606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908083|NCT06073093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908084|NCT01878045|||COHORT||PROSPECTIVE|||||||
33908085|NCT03053141|||COHORT||PROSPECTIVE|||||||
33908086|NCT05873517|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Eligible participants will either receive immediate NET+ or be assigned to a waitlist; all participants will be offered the opportunity to enroll in the NET+ intervention.||||
33908087|NCT02504879|||COHORT||PROSPECTIVE|||||||
33908088|NCT00047996|||COHORT||PROSPECTIVE|||||||
34083510|NCT05335616|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Intervention will be delivered in a separate, sealed envelope. Thereby, participants are blinded for the intervention when baseline data will be gathered (i.e. by filling out the first questionnaire).|Either of two potential interventions is delivered as written instruction to the participants||||
34083511|NCT02930694|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083512|NCT05889975|RANDOMIZED|PARALLEL||OTHER||SINGLE|the examiner will be blinded to type of intervention given to the participants. Each intervention will be given a code which will be concealed by a third-party who have no role in the study. The codes will be declared at the end of the study during data analysis.||f|f|t|f
34083513|NCT03597802|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34083514|NCT06321523|||CASE_ONLY||RETROSPECTIVE|||||||
33719874|NCT06346990|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Taking into consideration that this was a RCT, blinding the participants was not possible. However, data collectors and data analyzer were blinded. Directly after the intervention, each day at 3pm and 9 pm, the participants were evaluated for development of delirium by the Research assistant how do not know in which group was the participant allocated, and if the result was positive the intervention was discontinued.|There are two groups in this study. The intervention group and the control group. For the control group, patients are receiving routine care . For the intervention group, after patients were (1) extubated, (2) hemodynamically stable, and (3) negatively rated on primary CAM-ICU, they receive holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each. We choose these times based on the nurses' recommendations about the minimal interruptions from physician rounds and family visits. The selection of Surah Al-Rahman was based on the widespread belief that it is among the most melodic and calming passages in the Quran, especially when recited by the well-known reciter Qari AbdulBasit. 1,5,40 The listening was done using one-use headphones on an iPad. The intervention was discontinued if the participant developed delirium|f|f|f|t
33719875|NCT00254813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908089|NCT05170204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908090|NCT02417740|||COHORT||PROSPECTIVE|||||||
33908091|NCT06193902|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34083515|NCT04312100|||COHORT||PROSPECTIVE|||||||
34083516|NCT05452265|||COHORT||RETROSPECTIVE|||||||
34083517|NCT02217592|||CASE_ONLY||PROSPECTIVE|||||||
34083518|NCT03689517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33776831|NCT03178305|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial where patients will be randomly (2:2) assigned to the intervention vs control group.||||
34083519|NCT00092196|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34083520|NCT02669875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083521|NCT05948085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083522|NCT02830711|||CASE_CONTROL||PROSPECTIVE|||||||
34083523|NCT03826251|||COHORT||RETROSPECTIVE|||||||
34083524|NCT00830219|RANDOMIZED|CROSSOVER||||NONE||||||
34083525|NCT00417196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776832|NCT02079207|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33776833|NCT03188328|NA|SINGLE_GROUP||TREATMENT||NONE||3 + 3 dose escalation design||||
33908092|NCT05639933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33908093|NCT05878769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908094|NCT02639325|||COHORT||PROSPECTIVE|||||||
34083526|NCT04507152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083527|NCT04722406|||COHORT||RETROSPECTIVE|||||||
34083528|NCT04578665|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The purpose of this study is to develop a new paradigm to understand how humans physically interact with each other at a single and at multiple joints, with multiple contact points, so as to synthesize robot controllers that can exhibit human-like behavior when interacting with humans (e.g., exoskeleton) or other co-robots.||||
34083529|NCT03228901|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34083530|NCT01737606|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34083531|NCT02532036|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34083532|NCT00163592|||||OTHER|||||||
34083533|NCT01470716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083534|NCT04346316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083535|NCT02135952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083536|NCT00236743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083537|NCT05100563|||CASE_ONLY||RETROSPECTIVE|||||||
34083538|NCT06464627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|t|f|f|f
34083539|NCT04559984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083540|NCT05143463|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Subjects will be administered each treatment (NS101 or placebo), according to the block randomization scheme. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (NS101 or placebo).|For each dose level, the dose to be administered to each subject for a single infusion will be calculated based on subject's body weight, measured on Day 1.|t|f|t|f
33908095|NCT06336798|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34083541|NCT03052205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083542|NCT03523286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083543|NCT01217593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083544|NCT00235807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083545|NCT03273855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
33719876|NCT00044395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719877|NCT05113615|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33719878|NCT00955942|RANDOMIZED|||TREATMENT||DOUBLE||||||
33719879|NCT05821868|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33719880|NCT04181502|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33719881|NCT00810407|||CASE_ONLY||PROSPECTIVE|||||||
33719882|NCT02566083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719883|NCT01637467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33719884|NCT06276439|||CASE_ONLY||CROSS_SECTIONAL|||||||
33719885|NCT01548222|||CASE_ONLY||PROSPECTIVE|||||||
33719886|NCT03663725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719887|NCT02172742|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33719888|NCT02810392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719889|NCT05922787|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|This study was designed as a randomized controlled trial|This study was designed as a randomized controlled trial|t|f|f|f
34083546|NCT00270023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083547|NCT06551389|||COHORT||RETROSPECTIVE|||||||
34083548|NCT01173172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083549|NCT02377596|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083550|NCT05137665|||OTHER||OTHER|||||||
34083551|NCT03225963|||COHORT||PROSPECTIVE|||||||
34083552|NCT03568201|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||transcutaneous oximetry||||
34083553|NCT04031716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All participants will receive standard perioperative care, anesthetic management, and postoperative pain management per institutional standardized practices. Participants will be randomized into either the Meditation or Control Groups, as deemed appropriate.||||
34083554|NCT05181267|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study will be conducted as a randomized, controlled crossover study with 16 insulin-resistant subjects with overweight (BMI: 28-40 kg/m2) aged 55-70 years. Subjects must go through two study periods of each three weeks, where the interventions are alternate-day fasting (ADF) and Western diet (no restrictions), respectively, in random order. A washout period of one week follows the first study period before subjects cross over to the second study period. After each study period, subjects undergo a study day with PET scans and various laboratory examinations.||||
34083555|NCT05190614|||COHORT||RETROSPECTIVE|||||||
34083556|NCT02075125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083557|NCT03071601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083558|NCT02059707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083559|NCT06389617|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34083560|NCT01545336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908096|NCT06049654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908097|NCT06284954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908098|NCT04967599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908099|NCT02809443|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908100|NCT05044273|||COHORT||PROSPECTIVE|||||||
34083561|NCT00709189|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34083562|NCT01544036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083563|NCT05265117|||COHORT||PROSPECTIVE|||||||
34083564|NCT00419185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34083565|NCT02123641|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34083566|NCT06178692|||COHORT||PROSPECTIVE|||||||
34083567|NCT02709746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083568|NCT04333004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083569|NCT04956211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083570|NCT00997945|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083571|NCT04181866|||COHORT||PROSPECTIVE|||||||
34083572|NCT01535885|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083573|NCT01923519|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34083574|NCT05469594|||COHORT||RETROSPECTIVE|||||||
34083575|NCT06312917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083576|NCT01932489|NA|SINGLE_GROUP||OTHER||NONE||||||
33908101|NCT06463873|||COHORT||PROSPECTIVE|||||||
33908102|NCT05872763|||COHORT||OTHER|||||||
33908103|NCT05977998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908104|NCT03194685|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open Label|||||
33908105|NCT05608083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908106|NCT05890976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33908107|NCT06018753|||COHORT||RETROSPECTIVE|||||||
34083577|NCT05024279|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
34083578|NCT01108939||CROSSOVER||TREATMENT||NONE||||||
34083579|NCT01565863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083580|NCT02592824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34083581|NCT02099422|||CASE_CONTROL||PROSPECTIVE|||||||
34083582|NCT03558516|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study drug will prepared by the investigator in the same character and amount. So the patient and care provider will not know the study drug is magnesium or 0.9% sodium chloride.|We compare intraoperative blood loss in two group between the magnesium (study group) and 0.9% sodium chloride group (control group)|t|t|f|t
34083583|NCT05786859|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center randomized controlled trial.||||
34083584|NCT02859623|||||RETROSPECTIVE|||||||
34083585|NCT04351620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083586|NCT01330888|||||CROSS_SECTIONAL|||||||
34083587|NCT06054841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083588|NCT06284499|||CASE_CROSSOVER||PROSPECTIVE|||||||
34083589|NCT03318185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083590|NCT02700399|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083591|NCT03385733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will randomize into two groups as Group A: inspiratory muscle training, and Group B (control group)|t|f|f|t
34083592|NCT04590118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In phase I, the masking method is open-label, whereas in phase II, the masking method is double blind.||t|t|t|f
34083593|NCT05122611|||COHORT||PROSPECTIVE|||||||
34083594|NCT05348304|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34083595|NCT05159934|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Nicotine dose will be prepared by pharmacy|Twenty participants will have 2 Experimental Session on 2 separate days. Experimental Session 1 will determine if smokers can reliably discriminate 0.1mg nicotine/pulse nicotine from saline. Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.|t|f|t|f
34083596|NCT02860988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083597|NCT01980953|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34083598|NCT00193908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083599|NCT05310877|NA|SINGLE_GROUP||OTHER||NONE||||||
34083600|NCT01922934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083601|NCT00766571|||||OTHER|||||||
34083602|NCT06003361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776834|NCT04201496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Participants will be first randomized to taking empagliflozin or not taking this drug. Participants will then be randomized to using the Basal-IQ insulin pump first or the Control-IQ insulin pump first. Participants then transition to using the other pump.~With empagliflozin:~* Control-IQ x 4 weeks (CiQ-EMPA) then Basal-IQ x 2 weeks (BiQ-EMPA)~* Basal-IQ x 2 weeks (BiQ-EMPA) then Control-IQ x 4 weeks (CiQ-EMPA)~Without empagliflozin:~* Control-IQ x 4 weeks (CiQ-NO EMPA) then Basal-IQ x 2 weeks (BiQ-NO EMPA)~* Basal-IQ x 2 weeks (BiQ-NO EMPA) then Control-IQ x 4 weeks (CiQ-NO EMPA)"||||
33776835|NCT01739387|||CASE_CROSSOVER||PROSPECTIVE|||||||
33990528|NCT06275321|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A prospective ramonized clinical trial with two groups|f|f|t|f
33990529|NCT06095401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083603|NCT05252637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990530|NCT00256165|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083604|NCT02125240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990531|NCT00001135||||PREVENTION||DOUBLE||||||
34083605|NCT03659344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were blind about kind of sutures which were used to close flaps.|In group1, vicryl plus suture was used to close flaps. In group2,vicryl was used to close flaps|t|f|f|f
33990532|NCT00817440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34083606|NCT06441409|NA|SINGLE_GROUP||TREATMENT||NONE|open label|Patients were intervened with lifestyle only.||||
33719890|NCT04097093|||COHORT||CROSS_SECTIONAL|||||||
33719891|NCT03838822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776836|NCT02300779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34083607|NCT03203785|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33719892|NCT04770415|||CASE_CROSSOVER||PROSPECTIVE|||||||
33776837|NCT00809432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33776838|NCT04847479|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776839|NCT06150677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33776840|NCT04112472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776841|NCT03103425|||COHORT||PROSPECTIVE|||||||
33776842|NCT05554250|||OTHER||PROSPECTIVE|||||||
33776843|NCT00309335|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34083608|NCT05831800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-arm prospective feasibility study||||
34083609|NCT06032637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083610|NCT05658939|||OTHER||PROSPECTIVE|||||||
34083611|NCT03933488|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34083612|NCT03320356|||CASE_ONLY||PROSPECTIVE|||||||
34083613|NCT04407546|||COHORT||PROSPECTIVE|||||||
34083614|NCT05286892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083615|NCT05026554|||COHORT||PROSPECTIVE|||||||
34083616|NCT02142842||PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33776844|NCT02041364|||CASE_CONTROL||PROSPECTIVE|||||||
33776845|NCT00163631|||DEFINED_POPULATION||OTHER|||||||
33776846|NCT03529903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33776847|NCT05943483|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33776848|NCT04782310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776849|NCT01458275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776850|NCT00349102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776851|NCT02325726|||COHORT||PROSPECTIVE|||||||
33776852|NCT01923389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33776853|NCT02426385|||CASE_CONTROL||PROSPECTIVE|||||||
33776854|NCT01930643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776855|NCT00543218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776856|NCT00422396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776857|NCT01220440|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33776858|NCT02816047|||COHORT||RETROSPECTIVE|||||||
33776859|NCT06263361|||CASE_ONLY||PROSPECTIVE|||||||
33776860|NCT03037229|||CASE_ONLY||PROSPECTIVE|||||||
33776861|NCT02298543|||COHORT||PROSPECTIVE|||||||
33990533|NCT00685607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990534|NCT00835081|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990535|NCT03324178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A pilot two-armed, parallel-design, individually randomised controlled trial, using stratified randomization with blocking||||
34083617|NCT00787878|||COHORT|||||||||
34083618|NCT05730426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083619|NCT02074514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083620|NCT04577872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083621|NCT01492868|||COHORT||PROSPECTIVE|||||||
34083622|NCT05344469|||COHORT||PROSPECTIVE|||||||
34083623|NCT00914121|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33776862|NCT02364453|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33776863|NCT02682563|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33776864|NCT00678444|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33776865|NCT02514980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776866|NCT00519363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776867|NCT03403569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776868|NCT00513019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776869|NCT02196493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776870|NCT05666700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776871|NCT01018823|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33776872|NCT02337361|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33776873|NCT03400904|||COHORT||PROSPECTIVE|||||||
33776874|NCT02935855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776875|NCT01693939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776876|NCT02325232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776877|NCT00720005|||CASE_CONTROL||RETROSPECTIVE|||||||
33776878|NCT02930122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776879|NCT02216422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776880|NCT03963479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33776881|NCT04515160|||OTHER||PROSPECTIVE|||||||
33776882|NCT04710693|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Colonoscopy lists will be randomised for the use of a CAD polyp-detection system to be used as an adjunct to optical diagnosis. 50% of colonoscopy lists will be randomly assigned to use the CAD system and 50% of colonoscopy lists will not use the CAD system.||||
33776883|NCT00487422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776884|NCT02766673|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33990536|NCT01534663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776885|NCT04245046|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects are to be admitted the night before dose no. 1 administration, confining at clinical site until the 24 hours post dose no. 5 administration. 4-days off interval between last dose of treatment A and first dose of treatment B allowed. Subjects to be admitted the night before dose no. 6 administration, confining at clinical site until the 24 hours post dose no. 10 administration. 4-days off interval between last dose of treatment B and first dose of treatment C allowed. Subjects to be admitted the night before dose no. 11 administration, confining at clinical site until the 24 hours post dose no. 26 administration.||||
33990537|NCT03090568|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990538|NCT06318156|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33990539|NCT04576234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"After getting ethical clearance; patients were enrolled in the study, patients were selected based on the inclusion and exclusion criteria. Following an initial assessment, the patients were assigned to one of the two groups by block randomization.~Both groups received 3000 ml of feed per day and the same formula per day which was 30-35ml/kg of water, 0.8 g/kg of protein and 2000 kcal of calories for females and 2500 Kcal for males. The only manipulation was in the flow rate and the device which the feed was administred."||||
33990540|NCT06244043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not be informed which version of the introductory coaching session they are receiving.||t|f|f|f
34083624|NCT01670292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083625|NCT01047449|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33776886|NCT00000836||||TREATMENT||||||||
33776887|NCT02949518|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33776888|NCT02294162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33776889|NCT04679883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776890|NCT04746547|NA|SINGLE_GROUP||TREATMENT||NONE||Pharmacokinetic evaluation of DTG in children receiving Rifampicin containing TB treatment||||
33776891|NCT00183924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776892|NCT00315211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776893|NCT00203775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33776894|NCT00479674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776895|NCT05399979|||COHORT||RETROSPECTIVE|||||||
33776896|NCT01250249|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33776897|NCT04003311|||COHORT||PROSPECTIVE|||||||
33776898|NCT00264043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776899|NCT01899495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776900|NCT01456858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33776901|NCT04600401|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the researcher, who will collect the outcome assessments and assume data entry and analysis, will stay blinded to treatment allocations.|Participants will be randomly allocated to either the Mentis Plus+ program (experimental group) or the control group (stand-by group).|f|f|t|f
33776902|NCT00936013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776903|NCT02406014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776904|NCT01651559|||COHORT||PROSPECTIVE|||||||
33776905|NCT05209087|||COHORT||PROSPECTIVE|||||||
33776906|NCT00994487|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33776907|NCT04537351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776908|NCT03989713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33776909|NCT06401928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33776910|NCT02434952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776911|NCT00972946|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776912|NCT02659644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776913|NCT05331820|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the orthodontist did not know the group of their patients .||f|t|f|f
33776914|NCT03230955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and hospital clinicians will be blind|"Participants will be randomized into IG and CG with 2:1 allocation using mapping software, because it is expected a larger number of losses to follow-up in the CG. GI patients will be contacted by a nurse of the 061CatSalut Respon quit line who will have received specific training in intervening smokers with mental disorders. The call will take place within the first 48 h after discharge from the hospitals. The patients of the CG will be contacted by a team of the 061 CatSalut Respon in order to provide a brief counselling (first call) and evaluate their use of tobacco during the 1st, 6th and 12th month."|t|f|f|f
33908108|NCT05319600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adolescents (aged 13-17) diagnosed with type 1 diabetes will all complete a baseline assessment where they will be randomized to complete a 12-week physical activity and behavior-change skills training intervention, or to follow their usual diabetes care plan for 12 weeks. Both groups will receive a Garmin fitness activity tracker wrist watch to track their physical activity over the 12-week study period. Follow-up assessments for all participants will take place after 12 weeks.||||
33908109|NCT06511063|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33908110|NCT05610644|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33908111|NCT00515567|||CASE_ONLY||PROSPECTIVE|||||||
33990541|NCT04278560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990542|NCT03902548|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33990543|NCT05591118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990544|NCT04845802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990545|NCT03197415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990546|NCT00829452|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990547|NCT00164463|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990548|NCT03883412|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33990549|NCT05664763|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990550|NCT00988715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990551|NCT04678141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990552|NCT02372747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33990553|NCT05586490|RANDOMIZED|PARALLEL||TREATMENT||NONE||The feasibility study will involve a sequential stage of device feasibility testing with the initial aims 1 and 2 being a single group and the in-home feasibility testing will involve controls persons for an exploratory data collection. The same participants are asked to proceed sequentially through the three phase of the study. Participants in the third sub-study will then be asked to complete the open label extension.||||
33990554|NCT06093932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990555|NCT02956460|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33990556|NCT04882475|||COHORT||RETROSPECTIVE|||||||
33990557|NCT05547711|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE||At inclusion mentally healthy and patients with a depression are monitored for five years. After study inclusion participants will be seen after four weeks and then annually for five years.|t|t|f|f
33990558|NCT03483194|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083626|NCT06550479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of three different distal AVF types||||
34083627|NCT05136599|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The clinical trial will be conducted as two dependent studies. The first study is a dose identification study to determine the HID70-90 endpoint, which is the dose that induces pertussis mild symptomatic/clinical infection among 70%-90% of the volunteers inoculated with that dose. The second study and sub-study are HID70-90 dose confirmation studies to verify and confirm that the infectious endpoint has been reached to establish the pertussis CHIM.||||
34083628|NCT03641027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will not be aware of which group the patients are included in.|Parallel Assignment A single blind, randomized, controlled, intervention study. Evaluation of the addition of increased physical activity for patients undergoing obesity surgery compared to standard care.|f|f|f|t
34083629|NCT04644263|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083630|NCT05916222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be unaware of participant grouping (i.e., Direct Training Group, Indirect Training Group), treatment phase (i.e., baseline, treatment, follow-up), or status of words (i.e., treated, generalization words).|This proposed work is multisite parallel-group randomized control trial (RCT) that aims to investigate the impact of parent/caregiver involvement on DTTC treatment outcomes in children with CAS. Participants will be seen in two groups: 1) Direct Training Group (DTTC + Home Practice + Direct Caregiver Training); 2) Indirect Training Group (DTTC + Home Practice + Indirect Caregiver Training).|f|f|f|t
34083631|NCT02771756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083632|NCT03727165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be in the intensive care unit under sedative treatment and will not know about randomization Nurses in the intensive care unit (care providers of enteral nutrition infusion) will not know about the study Outcomes evaluation will be made by one independent clinical epidemiologist|Randomized clinical trial|t|t|f|t
33990559|NCT05315557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990560|NCT00593463|NA|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33990561|NCT00797160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33990562|NCT00897377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990563|NCT00904215|||||PROSPECTIVE|||||||
33990564|NCT02907983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33990565|NCT04363359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33990566|NCT01250080|RANDOMIZED|||||SINGLE|||f|f|f|t
33990567|NCT05655845|||CASE_ONLY||CROSS_SECTIONAL|||||||
33990568|NCT03530852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990569|NCT03868891|NA|SINGLE_GROUP||TREATMENT||NONE|Researchers conducing Eustachian tube function testing and those conducing statistical analysis will be blinded to the visit number.|experimental, open label||||
33990570|NCT03684538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990571|NCT01414322|||||PROSPECTIVE|||||||
33990572|NCT01058668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990573|NCT04279730|||COHORT||PROSPECTIVE|||||||
33990574|NCT06195579|NA|SINGLE_GROUP||TREATMENT||NONE||Single case design||||
33990575|NCT00621491|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33990576|NCT06563206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator will be masked from the allocation as well as outcome assessor|This study will be conducted using parallel design of three different rehabilitation approach with repeated measurements of outcomes, before and after intervention.|f|f|t|t
33990577|NCT05843357|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33990578|NCT05558787|||COHORT||CROSS_SECTIONAL|||||||
33990579|NCT01923753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33687241|NCT03228199|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Main outcome and masking: The daily mean weight of tea picked will be calculated for each worker for the 4 weeks baseline and for the 12 weeks evaluation period. The difference between these two means will be calculated for each worker, and the mean of this value will be calculated for each randomised group, with the main study outcome being the difference between these values for each group. It will not be practical to mask participants as to their study group assignment (the investigators do not feel that providing sham near correction of Plano power is ethical). However, the APPL staff measuring the weight and quality outcomes will be masked to a worker's group assignment by having an intermediate person receive the tea from the worker and carry it to the weighing station each day.|"Randomization, Balancing, and Intervention: Eligible workers completing baseline productivity assessment will be enrolled into the study, and assigned at random to one of the below groups:~Intervention Group: Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance by placing the vision chart on the top of a tea bush and directing the participant to stand as usual in picking tea. The gasses will not correct astigmatism. Distance refractive errors will be corrected for those with uncorrected VA \< 6/12 in the better-seeing eye.~Control Group: Will be deferred to receive free presbyopic spectacles after the 12 weeks evaluation period."|f|f|t|t
33687242|NCT01455129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687243|NCT04290390|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Two cohort, open label, randomized, two period (Cycle 1 and Cycle 2) crossover study. Subjects may only participate in one randomized sequence of one cohort. Subjects will be assigned to either Cohort 1 (itraconazole) or Cohort 2 (rifampin). Once assigned, a subject will then be randomized to a Sequence Group within the cohort. There will be at least a 4-week washout between Treatment Cycle 1 and Cycle 2.||||
33687244|NCT01092065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687245|NCT03248700|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687246|NCT04213573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687247|NCT05776797|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in the study|Patients fulfilling the enrolment criteria will be randomly (randomization with variable blocks of 4, 6, and 8 patients) allocated to intervention and control groups in a 1:1 ratio.||||
33687248|NCT03455764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687249|NCT06299423|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Single-center, interventional, case-series study with a historical cohort of comparison||||
33687250|NCT01567228|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33687251|NCT04452929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Randomized, double-blinded, placebo-controlled, parallel study followed by a 6-month open-label extension.|t|f|t|f
33687252|NCT00311480|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33687253|NCT02607644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33687254|NCT00001503|||COHORT||PROSPECTIVE|||||||
33687255|NCT00617643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687256|NCT04950114|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study extension||||
33687257|NCT03969992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking within active arms|Partially Blinded, Randomized, Parallel-Group Dose Ranging|t|t|t|t
33687258|NCT02388048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687259|NCT06465212|||OTHER||CROSS_SECTIONAL|||||||
33687260|NCT05354674|||COHORT||PROSPECTIVE|||||||
33687261|NCT00685087|||CASE_ONLY||PROSPECTIVE|||||||
33687262|NCT02985931|||COHORT||PROSPECTIVE|||||||
33687263|NCT05857423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33908112|NCT05475379|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|This is a randomized double-blind study. Study investigators along with study staff involved in safety evaluation and laboratory analysis will be blinded regarding the assigned treatment of the participant. The vaccine administration team will be un-blinded to the treatment assignment list. The vaccine administrator team members will not be involved in the evaluation of vaccine safety and laboratory analysis. The DSMB will be responsible for un-blinding the randomization number codes in the event of severe putative vaccine reactions. Otherwise, the codes will not be revealed until the end of the trial and until the computerized dataset has been frozen. If the intervention assignment is un-blinded, all study collaborators will be notified immediately. If deemed necessary, the DSMBs will recommend unblinding to the IRB and contact the study statistician responsible for providing information on the vaccine received by the individual in question.||t|t|t|t
33908113|NCT06414733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908114|NCT05638295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908115|NCT05659485|||COHORT||PROSPECTIVE|||||||
33908116|NCT03908099|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pragmatic, multicenter, two-arm, parallel randomized controlled trial comparing the Fit-for-Fertility lifestyle program to usual fertility care||||
33908117|NCT05248386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990580|NCT06562491|||COHORT||RETROSPECTIVE|||||||
34083633|NCT01603277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083634|NCT01276977|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083635|NCT01350219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687264|NCT01523665|||COHORT||PROSPECTIVE|||||||
33687265|NCT02005198|||COHORT||PROSPECTIVE|||||||
33776915|NCT03053492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded raters perform scoring of all assessments|Stroke survivors will either play a custom designed computer game for stroke rehabilitation called Duck Duck Punch or an off the shelf computer game with their weaker arm 3 times per week for 6 weeks. Evaluations will determine whether or not one computer game improved arm movement more than the other.|f|f|f|t
33776916|NCT02445885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776917|NCT01896011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33776918|NCT01287143|||OTHER||PROSPECTIVE|||||||
33776919|NCT05991050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776920|NCT03909581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776921|NCT02462785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33776922|NCT01048203|NA|SINGLE_GROUP||||NONE||||||
33776923|NCT00956540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33776924|NCT02059772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776925|NCT03505411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776926|NCT02938741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776927|NCT02552849|||COHORT||PROSPECTIVE|||||||
33776928|NCT03045120|||COHORT||PROSPECTIVE|||||||
33990581|NCT05822479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Sealed opaque envelopes containing study participation numbers will be used to assign each patient. A researcher not involved in patient follow-up will use the web-based Research Randomizer (Urbaniak and Plous 2013) tool to give each participation number to a random group with a 1:1 ratio. A nurse not an active investigator in the study will have each participant choose an envelope containing the study participation number. They will inform the anesthetist administering the block/blocks about which group the patient is in immediately before administration. Researchers, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program, 'Research Randomizer (Urbaniak and Plous, 2013)'.|f|t|t|t
33990582|NCT01541033|||CASE_CONTROL||PROSPECTIVE|||||||
33990583|NCT01208337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990584|NCT05167474|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33990585|NCT01045681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990586|NCT01956591|||COHORT||RETROSPECTIVE|||||||
33990587|NCT02968992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|•Randomized: Participants are assigned to intervention groups by chance||t|t|t|f
33990588|NCT05793086|||COHORT||PROSPECTIVE|||||||
33990589|NCT00958451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990590|NCT02324660|NA|SINGLE_GROUP||SCREENING||NONE||||||
33990591|NCT04594252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990592|NCT06199219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33990593|NCT05148273|||CASE_CONTROL||PROSPECTIVE|||||||
33990594|NCT04927663|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33990595|NCT05658601|||COHORT||PROSPECTIVE|||||||
33990596|NCT01164839|||COHORT||CROSS_SECTIONAL|||||||
33990597|NCT06559566|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33990598|NCT05462327|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33990599|NCT05502250|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm = 4 cycles of gemcitabine and cisplatin (GP) + tislelizumab followed by 13 cycles of tislelizumab||||
33990600|NCT05925010|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990601|NCT05517681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33990602|NCT04188080|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Within-patient Response Surface Pathway||||
33990603|NCT06560710|||COHORT||RETROSPECTIVE|||||||
33990604|NCT04325724|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|ultrasound evaluation will be on masking from clinical evaluation||f|f|t|f
33990605|NCT01327391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990606|NCT00573599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990607|NCT01383694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990608|NCT00857454||PARALLEL||TREATMENT||NONE||||||
33990609|NCT03699696|||COHORT||RETROSPECTIVE|||||||
33990610|NCT05982691|||COHORT||OTHER|||||||
33990611|NCT05674513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990612|NCT04167267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33776929|NCT02360774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776930|NCT00179842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776931|NCT01273649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990613|NCT03625063|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33990614|NCT06033456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990615|NCT02111694|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33990616|NCT05802485|NA|SINGLE_GROUP||OTHER||NONE||||||
33990617|NCT03890796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Assessors were blinded regarding the participants' belonging to the two study groups.|The study model is longitudinal, single-blind, parallel group experiment.|f|f|t|t
33990618|NCT01627158|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33990619|NCT05433857|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, Prospective, randomized, controlled, open-label study.||||
33990620|NCT05305248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33990621|NCT05545826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990622|NCT00245063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990623|NCT02953223|||COHORT||PROSPECTIVE|||||||
33776932|NCT02176928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33990624|NCT02213263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990625|NCT05095181|||OTHER||PROSPECTIVE|||||||
33990626|NCT03630471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomization list will be generated by an independent statistician. The randomization code will be concealed using sequentially numbered opaque sealed envelopes to maximize allocation concealment.~Baseline assessments will be carried out by field researchers prior to randomization. The six- and 12-week outcome assessments will be carried out by a team of field researchers who will be blind to allocation status."|A two-arm, individually randomized controlled trial with equal allocation of participants between arms.|f|f|t|t
33776933|NCT02522546|||COHORT||PROSPECTIVE|||||||
33908118|NCT03731234|NA|SINGLE_GROUP||TREATMENT||NONE||Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance||||
33908119|NCT02321501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908120|NCT05929430|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Members of the research team who are not involved in the assessments and implementation of the intervention will be responsible for the random sequence and data analysis.|A randomized controlled clinical trial (RCT) with three arms|f|t|t|t
33908121|NCT05475925|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908122|NCT06298396|NA|SINGLE_GROUP||TREATMENT||NONE|"There is no masking in this study as all participants receive all MAPs (single group study model). The term single-blinded in the official title refers to the fact that participants are blinded to the order in which they receive the MAPs."|||||
33908123|NCT06223516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908124|NCT06550830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple for children aged 2-5 years; open-label for children aged 6-17 years||t|t|t|t
33908125|NCT06389136|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908126|NCT06357130|||COHORT||PROSPECTIVE|||||||
33908127|NCT04442425|||COHORT||PROSPECTIVE|||||||
33908128|NCT04600323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908129|NCT06180837|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Group allocation will be blinded to research staff and participants until the conclusion of the baseline segment.||f|f|t|t
33908130|NCT03217422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, placebo-controlled||t|t|t|t
33908131|NCT05414136|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908132|NCT05109728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908133|NCT06202872|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, sham-controlled, crossover trial|t|t|t|t
33908134|NCT03922529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Key investigators and well as the outcomes assessor at each site will remain blinded to participant group placement.|There will be two intervention groups 1) MACRO-I in which the research team will work with the participant and providers to facilitate CR; 2) Usual care as determined by their clinical providers.|f|f|t|t
33908135|NCT05382286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908136|NCT05875805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908137|NCT03949387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be collected objectively by researchers who are blinded to treatment allocation. Researchers who are involved with delivery of the intervention will be aware of treatment allocation, but will not be involved with data collection, entry or analysis.|The study will use a two-arm, parallel group, single-blinded placebo-controlled RCT design that examines the efficacy and lasting effects of 24-weeks of FES cycling exercise compared to passive leg cycling in persons with MS with mobility impairment.|f|f|f|t
33908138|NCT02627443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908139|NCT00978003|||COHORT||PROSPECTIVE|||||||
33908140|NCT05139914|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33908141|NCT04925388|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908142|NCT00001506|||COHORT||PROSPECTIVE|||||||
33908143|NCT03076554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908144|NCT06262607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double|54 subjects, 2 arms, parallel|t|f|t|f
33908145|NCT04421963|NA|SEQUENTIAL||TREATMENT||NONE||||||
33908146|NCT03930199|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Upon enrollment, participants will be provided two sensors to track mobility and prosthesis use. Participants will wear the sensors continuously for 3 months and then will return to complete a set of assessments. The result of these assessments and analysis of sensor data will determine if the participant is meeting mobility goals and expected prosthesis use. Participants not meeting goals or prosthesis use will receive an intervention for 3 months. The intervention may include prosthetic care and physical therapy, or motivational interviewing, or both. During these 3 months, sensors will continue to monitor activity. After completion of intervention, participants will repeat the set of assessments and those who have improved in mobility goals and/or prosthesis use will continue to be monitored with sensors for an additional 3 months, after which the set of assessments will be completed a final time, assessing the maintenance of mobility goals and prosthesis use.||||
33990627|NCT06385236|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is significant in determining molecular disease endotypes in a large group of moderate to severe asthmatics. By evaluating within-person genomic level changes and response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions.||||
33990628|NCT03362710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990629|NCT04853563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990630|NCT03877692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principle investigator and outcomes assessor are masked to group assignment.||f|f|t|t
33990631|NCT01108029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990632|NCT03953287|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional (Clinical Trial)||||
33990633|NCT02300935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908147|NCT05041257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908148|NCT04549168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908149|NCT00098072|NA|PARALLEL||DIAGNOSTIC||NONE||||||
33908150|NCT06058741|||COHORT||PROSPECTIVE|||||||
33908151|NCT06074614|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33908152|NCT05876780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908153|NCT05903586|||COHORT||PROSPECTIVE|||||||
33908154|NCT01294332|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33908155|NCT06236438|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33908156|NCT02578875|||OTHER||PROSPECTIVE|||||||
33908157|NCT03576989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators, participants and care providers blinded as to treatment|2-group randomized, double-blind, repeated measures design|t|t|t|f
33908158|NCT03588481|||COHORT||PROSPECTIVE|||||||
33908159|NCT05603104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label, except for the assesseors of the primary outcome|Parallel randomization to the treatment as usual (TAU) or early-intensified pharmacological treatment (EIPT) group for each of the study groups (schizophrenia, major depressive disorder, bipolar depression) leading to 6 arms.|f|f|f|t
33908160|NCT05413304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908161|NCT03732898|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During follow-up, the conventional Deep Brain Stimulation (cDBS) program and one or more of these novel Deep Brain Stimulation (nDBS) programs are programmed into a subject's IPG. At the investigator's discretion, a copy of the cDBS program may also be stored in one of the investigational slots. The subject will be blinded to the slot number assignment for the cDBS program.||t|f|f|f
33908162|NCT06500975|||COHORT||PROSPECTIVE|||||||
33908163|NCT05671185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908164|NCT06086171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908165|NCT00011648|||CASE_CONTROL||PROSPECTIVE|||||||
33908166|NCT04869098|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33908167|NCT05654519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient, and the outcomes assessor who performs postoperative pain evaluation will not know the group.|Parallel Assignment|t|f|f|t
33908168|NCT03808558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990634|NCT04560335|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Methodology: The study design includes a randomized controlled trial to test the efficacy of CoachToFit and assess the hypothesized mechanisms of action. This will include enrollment of obese Veterans with SMI from the mental health clinics at one VA medical center (n=256). Individuals will be randomized to CoachToFit or usual care. Those in CoachToFit will have access to the app and coaching for 6 months. Outcomes are assessed at 6- and 12-months. Efficacy outcomes utilize objective measures. The design also includes a multi- stakeholder qualitative post-intervention evaluation guided by the RE-AIM framework to characterize factors that will inform future implementation and maintenance of CoachToFit. This will include interviews with Veterans randomized to CoachToFit (n=30); interviews with staff stakeholders (n=18); a discussion with Veterans in local Veteran groups (n=2 groups; n=11 Veterans), and interviews with national leadership (n=3).||||
33990635|NCT01975948|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33990636|NCT06133439|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Cluster-Randomized Stepped Wedge design. Clinics will be randomized to one of three clusters that include four defined phases each consisting of nine-month segments.||||
33990637|NCT05778110|||OTHER||PROSPECTIVE|||||||
33990638|NCT05115357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990639|NCT00665470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990640|NCT02338583|||COHORT||PROSPECTIVE|||||||
33990641|NCT03118557|NA|SINGLE_GROUP||OTHER||NONE||||||
33990642|NCT03517085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990643|NCT01792726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990644|NCT06253403|||CASE_CONTROL||PROSPECTIVE|||||||
33990645|NCT01380782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990646|NCT00689364|||COHORT||PROSPECTIVE|||||||
33990647|NCT06238388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990648|NCT03515694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel, Double blind Monocentric Prospective Vs placebo|t|t|f|f
33990649|NCT04559503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33990650|NCT05367986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33990651|NCT04013841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33990652|NCT05035394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990653|NCT00923377|||||PROSPECTIVE|||||||
33990654|NCT00234364|||DEFINED_POPULATION||OTHER|||||||
33990655|NCT04296994|NA|SEQUENTIAL||TREATMENT||NONE||||||
33990656|NCT00784472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990657|NCT05261802|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants in arm 1 receive 14 hours of Survival Skills for Healthy Families curricula over 7 weeks. Participants also receive employment supports and case management services.~Participants in arm 2 receive 14 hours of Survival Skills for Healthy Families in a compressed format during a 16-hour weekend retreat, followed by a 2-hour reflections workshop two weeks later. Participants also receive employment supports and case management services."||||
33990658|NCT03092466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990659|NCT05623735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083636|NCT00392106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083637|NCT02000921|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33908169|NCT00081523|||CASE_ONLY||PROSPECTIVE|||||||
33908170|NCT05660980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908171|NCT05031780|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33908172|NCT04691648|||COHORT||PROSPECTIVE|||||||
33908173|NCT05079464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, outcomes assessors, and investigators will be blinded to stimulation type.|Randomized, blinded, repeated-session, parallel-design study|t|f|t|t
33908174|NCT05678959|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908175|NCT05891860|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33908176|NCT06457919|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In the Phase 1b portion of the study, participants will be enrolled sequentially in cohorts of 3 for each studied combination. The recommended Phase II dose (RP2D) of each combination will be estimated separately based on the de-escalation rules.||||
33908177|NCT05297396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908178|NCT04353661|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, open-label, parallel group, randomized controlled trial (RCT).||||
33908179|NCT00071045|||CASE_ONLY||PROSPECTIVE|||||||
33908180|NCT00001888|||CASE_CONTROL||PROSPECTIVE|||||||
33908181|NCT06072781|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908182|NCT04845893|||COHORT||PROSPECTIVE|||||||
33908183|NCT06013969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908184|NCT06121843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908185|NCT06138795|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Placebo-controlled|t|f|f|f
33908186|NCT05896839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908187|NCT05568459|||COHORT||PROSPECTIVE|||||||
33908188|NCT05786066|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"This study will include Veterans and non-Veterans. Both Veterans and non-Veterans will be included because of the large sample size of individuals currently in a major depressive episode and experiencing suicidal ideation required. Subjects with treatment-resistant depression currently in a major depressive episode and experiencing at least passive suicidal ideation. The investigators are studying this symptom complex in individuals with Major Depressive Disorder (MDD), Bipolar Disorder, and Posttraumatic Stress Disorder (PTSD). These three groups have high rates of suicide and are sensitive to Ketamine's antidepressant effects.~The investigators will utilize a within-subject double-blinded, cross-over design with a counter-balanced, randomized order."|t|f|t|f
33908189|NCT04047641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908190|NCT00001351|||OTHER||PROSPECTIVE|||||||
33908191|NCT02911103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908192|NCT05469789|||COHORT||OTHER|||||||
33908193|NCT01175993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908194|NCT06340568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908195|NCT06531824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part 1: Run-in period, non randomized, single arm Part 2: Randomized (BI 690517 or placebo), double-blind, placebo-controlled follow-up period|t|t|t|t
33908196|NCT03111745|||COHORT||RETROSPECTIVE|||||||
33908197|NCT04829240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will be conducted by research assistants who are masked to participant condition|Randomized clinical trial with randomization to the intervention condition or control condition|f|f|f|t
33908198|NCT04314778|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908199|NCT04639830|||COHORT||PROSPECTIVE|||||||
33908200|NCT05767034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687266|NCT06281301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687267|NCT02942329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687268|NCT00527670|||CASE_CONTROL||PROSPECTIVE|||||||
33908201|NCT05051540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908202|NCT05187013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33908203|NCT06126224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908204|NCT06585449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908205|NCT01617408|||COHORT||CROSS_SECTIONAL|||||||
33908206|NCT03692052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908207|NCT00341237|||COHORT||CROSS_SECTIONAL|||||||
33908208|NCT05233605|||OTHER||OTHER|||||||
33908209|NCT06281834|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm, open-label, pharmacokinetic and safety study||||
33908210|NCT00291525|RANDOMIZED|PARALLEL||PREVENTION||NONE|Number of participants below refers to randomized in all 3 study arms|||||
33908211|NCT03871257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083638|NCT02726347|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33908212|NCT00001452|||COHORT||PROSPECTIVE|||||||
33687269|NCT02536833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687270|NCT02425527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33908213|NCT06207032|||COHORT||PROSPECTIVE|||||||
33908214|NCT02442011|||CASE_ONLY||PROSPECTIVE|||||||
33687271|NCT04200378|||COHORT||PROSPECTIVE|||||||
33687272|NCT04228575|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33687273|NCT03905109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind Treatment|Double-blind, placebo-controlled, randomized study|t|t|t|t
33687274|NCT02937974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687275|NCT04025671|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33687276|NCT04351061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687277|NCT02825407|NA|SINGLE_GROUP||||NONE||||||
33687278|NCT06136442|||OTHER||PROSPECTIVE|||||||
33687279|NCT03325751|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33687280|NCT03813823|||COHORT||PROSPECTIVE|||||||
33908215|NCT04998877|||CASE_CONTROL||PROSPECTIVE|||||||
33908216|NCT05224102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, open-label, single-arm study with two phases: the main study phase for all eligible patients (up to 56 weeks), followed by an optional long-term extension phase for eligible patients only in the U.S. (up to 100 weeks).||||
33908217|NCT06163534|||OTHER||PROSPECTIVE|||||||
33908218|NCT04867317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two arm study: active drug vs placebo|t|t|t|t
33908219|NCT06013241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908220|NCT00739362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908221|NCT05575063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908222|NCT06394180|||CASE_CONTROL||OTHER|||||||
33908223|NCT04846881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908224|NCT06745908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908225|NCT06617715|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Open-label for infants aged 3 months; Quadruple for other age groups.||t|t|t|t
33908226|NCT06741228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is double-blinded, which means that both the participants and the treating clinicians will be masked to treatment allocation, meaning neither party will know which participants are receiving the active drug and which are receiving the placebo. The placebo tablet is identical looking to the active drug||t|f|t|t
33990660|NCT03698981|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Staff conducting primary outcome measures with mothers at baseline, post-intervention, and week 56 (in person) will be blinded to treatment assignment."|To account for expected drop out (\~10%), \~220 participants will be recruited, resulting in MME and TAU groups of \~100 with complete data by the 56th week following the beginning of pregnancy. For the MME arm, we will enroll 9-10 women per group on a rolling basis to comprise \~12 intervention groups total; \~1 MME group will be initiated per month.|f|f|f|t
33990661|NCT04673201|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Retrospective comparative study||||
33990662|NCT01837810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33687281|NCT00847119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687282|NCT04562272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687283|NCT00841373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687284|NCT05466448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687285|NCT06134271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687286|NCT05363943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33687287|NCT02008578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33776934|NCT03712098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized, double-blind, placebo-controlled, parallel arm pilot study with one between-subjects factor of medication group (liraglutide vs. placebo).|t|f|t|t
33776935|NCT05852769|NA|SEQUENTIAL||TREATMENT||NONE||||||
33776936|NCT02200393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687288|NCT02443207|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687289|NCT01796496|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33687290|NCT01064245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33687291|NCT00633867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908227|NCT03438552|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908228|NCT00001481|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33908229|NCT06707688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908230|NCT05864846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908231|NCT06724718|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908232|NCT06743308|||COHORT||PROSPECTIVE|||||||
33908233|NCT06624670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908234|NCT04194216|RANDOMIZED|PARALLEL||TREATMENT||NONE||Applicable Clinical Trial||||
33908235|NCT06706336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908236|NCT02311959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908237|NCT06737627|||OTHER||PROSPECTIVE|||||||
33908238|NCT06686147|||COHORT||PROSPECTIVE|||||||
33990663|NCT02223585||CROSSOVER||BASIC_SCIENCE||NONE||||||
33990664|NCT05364853|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990665|NCT01239862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990666|NCT00833586|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990667|NCT05086003|NA|SINGLE_GROUP||PREVENTION||NONE||Combined kidney and bone marrow transplantation||||
33990668|NCT04596007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All are double-blind except the pre-trial group||t|t|t|t
33776937|NCT03591861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776938|NCT06185023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||As this is a feasibility study, participants can choose to participate in just one or both types of physical exercise interventions.||||
33776939|NCT03391349|||OTHER||OTHER|||||||
33776940|NCT02332330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776941|NCT02517333|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33776942|NCT00674947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776943|NCT01100840|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33776944|NCT00415740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908239|NCT06748053|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Click here to enter text.||t|f|t|f
33908240|NCT06747299|||OTHER||RETROSPECTIVE|||||||
33908241|NCT06732037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908242|NCT03788369|||COHORT||PROSPECTIVE|||||||
33908243|NCT06719011|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|f|t|f
33908244|NCT06694311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a multicentric, randomized, open label, controlled, superiority clinical trial. Participants will undergo permuted block randomization with a ratio 1:1.||||
33908245|NCT06715488|||CASE_CONTROL||PROSPECTIVE|||||||
33908246|NCT06746272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33908247|NCT06746909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908248|NCT04890314|||COHORT||PROSPECTIVE|||||||
33908249|NCT06726889|||COHORT||PROSPECTIVE|||||||
33908250|NCT06742047|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two cohorts of NGNs received the ProDevelop intervention in 2023 and 2024. A control group in 2022 did not receive the intervention but the previous introduction programme.||||
33908251|NCT06411860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33908252|NCT06544655|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908253|NCT05640843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a randomized, multi-center pilot study with 150 patients (50 per arm). Randomization will be stratified based on BMI and MGUS/SMM status. Randomization in the supplement and placebo arms will be blinded.|t|f|t|f
33908254|NCT02576431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908255|NCT06746337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33908256|NCT06747364|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||The alcohol administration study will occur at the Applied Physiology Laboratory (APL) at UNT. The naturalistic drinking study will occur at UNT and a 2nd cohort will undergo a naturalistic drinking study at UTHSCSA Behavioral Research Lab (BRL).||||
33908257|NCT06746103|||COHORT||PROSPECTIVE|||||||
33908258|NCT06748014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient and assessor doctor dont know what medication the patient recieved.||t|t|t|t
33908259|NCT06743074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33908260|NCT06747039|||COHORT||PROSPECTIVE|||||||
33908261|NCT06746532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908262|NCT06747793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Clinical interventional trial, randomized, monocentric in the Intensive Care Unit of Toulouse University Hospital.||||
33908263|NCT03816319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908264|NCT06747650|NA|SINGLE_GROUP||TREATMENT||NONE||A single cohort of teens with FASD will be administered DBT-A for the purpose of feasibility testing.||||
33908265|NCT03801434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908266|NCT04960579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908267|NCT06027996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908268|NCT06746142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908269|NCT06747910|||COHORT||CROSS_SECTIONAL|||||||
33908270|NCT06743529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908271|NCT06747000|||CASE_CONTROL||PROSPECTIVE|||||||
33908272|NCT06747221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster parallel trial with a baseline measurement period.||||
33908273|NCT05278104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908274|NCT05131022|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908275|NCT06689540|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Bayesian Optimal Interval (BOIN) Design||||
33908276|NCT06747702|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participants will be unaware of whether they belong to the experimental or control group. They will receive instructions on their workout regimen without information on the study's hypothesis regarding functional prevention training.~Individuals conducting pre- and post-intervention assessments (e.g., EMG analysis, ROM measurements, proprioception tests) will not be informed of the participant group allocation. This prevents bias in data collection and interpretation.~Data will be anonymized before analysis, and analysts will not have access to group identifiers during the statistical evaluation phase."||t|f|t|t
33908277|NCT04597125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908278|NCT05190341|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|Research pharmacist has provided either 800mg ibuprofen or 30mg ketorolac into oral capsules, and randomized sets of pills in packages 1-88. Research physicians and patients blinded which pill sets contain which drug. Will be revealed after data collection complete.|Randomized controlled trial- 88 sequential patients randomized to receive either ibuprofen on ketorolac 1 hr before HSG|t|t|t|f
33908279|NCT06747728|NA|SINGLE_GROUP||TREATMENT||NONE||Bevacizumab||||
33908280|NCT06747936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083639|NCT04907123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083640|NCT04127123|||COHORT||PROSPECTIVE|||||||
33908281|NCT06746129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908282|NCT06743035|||COHORT||PROSPECTIVE|||||||
33908283|NCT06737484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083641|NCT01297686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083642|NCT01285518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083643|NCT03167918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083644|NCT05937880|NA|SINGLE_GROUP||TREATMENT||NONE||Refractory skin Henoch-Schonlein Purpura||||
34083645|NCT04212117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083646|NCT02887703|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34083647|NCT04345003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083648|NCT00526617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083649|NCT01558934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083650|NCT04173091|||COHORT||PROSPECTIVE|||||||
34083651|NCT00553774|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34083652|NCT03613298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083653|NCT05314309|||COHORT||PROSPECTIVE|||||||
34083654|NCT04331106|||COHORT||PROSPECTIVE|||||||
34083655|NCT06328140|||COHORT||PROSPECTIVE|||||||
34083656|NCT05963646|||COHORT||PROSPECTIVE|||||||
34083657|NCT03452800|||COHORT||OTHER|||||||
33908284|NCT06746701|||CASE_CONTROL||OTHER|||||||
33908285|NCT06746168|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33908286|NCT04874428|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33908287|NCT06675929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908288|NCT06734325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33908289|NCT06718101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908290|NCT06733441|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908291|NCT06747468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor, Participant and Investigator are all masked to treatment assignment|Upon entering the Double-Blind period, approximately 75 participants will be randomized and assigned in a 3:2 ratio to either the avexitide treatment group or the placebo group, respectively.|t|f|t|f
33908292|NCT06625060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking Description|Model Description|t|t|t|t
33908293|NCT05016245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908294|NCT05677451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083658|NCT02695069|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083659|NCT01100385|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34083660|NCT01249131|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34083661|NCT00873158|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083662|NCT03903172|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Non-blinded, parallel group||||
34083663|NCT03444207|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study was designed as a prospective randomized trial.||||
34083664|NCT00909467|||COHORT||PROSPECTIVE|||||||
34083665|NCT02071537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083666|NCT03786107|||COHORT||PROSPECTIVE|||||||
34083667|NCT03175211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083668|NCT01268267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083669|NCT01591148|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083670|NCT03053739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083671|NCT01081197|||COHORT||OTHER|||||||
33687292|NCT05030961|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083672|NCT00977197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34083673|NCT04079504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083674|NCT06411652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental model with pretest posttest control group||||
34083675|NCT04630743|NA|SINGLE_GROUP||OTHER||NONE||single-arm therapeutic exploratory trial||||
34083676|NCT00120471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083677|NCT06284161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083678|NCT02617030|||OTHER||PROSPECTIVE|||||||
34083679|NCT00943436|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34083680|NCT04303351|||COHORT||CROSS_SECTIONAL|||||||
34083681|NCT02756910|||COHORT||PROSPECTIVE|||||||
34083682|NCT04699539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34083683|NCT00555854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083684|NCT04366245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776945|NCT01786746|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33776946|NCT04795024|||CASE_ONLY||PROSPECTIVE|||||||
33776947|NCT02770742|||COHORT||PROSPECTIVE|||||||
33990669|NCT03656367|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Due to the characteristics of the study design, blinding of project personnel and participants is not possible. However, statistical analyses of the results will be performed in a blinded fashion.||f|f|f|t
33990670|NCT01083719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990671|NCT04028440|NA|SINGLE_GROUP||TREATMENT||NONE||Biological: Autologous γδT cells Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.||||
33776948|NCT06448468|||OTHER||PROSPECTIVE|||||||
33776949|NCT04563442|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33776950|NCT05044793|||OTHER||OTHER|||||||
33776951|NCT02470624|||COHORT||PROSPECTIVE|||||||
33908295|NCT01422694|||COHORT||PROSPECTIVE|||||||
33908296|NCT01736293|||COHORT||PROSPECTIVE|||||||
33908297|NCT04147884|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33908298|NCT06687967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908299|NCT06708299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind, placebo-controlled|Double-blind, placebo-controlled, randomized|t|t|t|t
33990672|NCT06510998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33990673|NCT05421286|||COHORT||PROSPECTIVE|||||||
33990674|NCT04630795|||CASE_ONLY||CROSS_SECTIONAL|||||||
33990675|NCT00601120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990676|NCT04267276|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33990677|NCT02080663|||COHORT||RETROSPECTIVE|||||||
33990678|NCT05015114|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33990679|NCT00243425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776952|NCT02425683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776953|NCT02366208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776954|NCT05522920|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive study intervention||||
33776955|NCT01110720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776956|NCT03523871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776957|NCT00479037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776958|NCT06040463|RANDOMIZED|FACTORIAL||TREATMENT||NONE|No masking|Sequential Multiple Assignment Randomized Trial (SMART)||||
33776959|NCT06325943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a phase 3, multicenter, randomized, placebo-controlled, parallel-group, double-blind study|t|t|t|t
33776960|NCT03119571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776961|NCT05797311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|t|f|f|f
33776962|NCT00262743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908300|NCT05410860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients who pass the test dose of the Etripamil NS dosing regimen will be randomized in a 1:1 ratio to Etripamil NS 70mg or placebo using an Interactive Response Technology (IRT) system.|t|t|t|f
33908301|NCT06723821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908302|NCT03117972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990680|NCT01686477|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990681|NCT04533269|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Treatment kits will be coded. An unblinded statistician will provide the treatment codes after the study database is locked.||t|t|t|t
33990682|NCT01425086|||CASE_CONTROL||PROSPECTIVE|||||||
33990683|NCT04876157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990684|NCT00128167|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33990685|NCT03948022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33990686|NCT04913974|||COHORT||PROSPECTIVE|||||||
33990687|NCT05867017|||OTHER||OTHER|||||||
33990688|NCT03973658|||COHORT||PROSPECTIVE|||||||
33990689|NCT06314841|||COHORT||PROSPECTIVE|||||||
33990690|NCT02305225|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33990691|NCT00057538|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33990692|NCT06268665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990693|NCT04244097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly allocated to one of two groups with the help of computer generated random number tables in opaque sealed envelopes prepared by an anaesthesiologist not part of the study. The envelops will be opened by the staff nurse, and peritoneal solution will be prepared according to group allocation by anaesthesiologist who is not involved in the study.|"* Group 1 (Bupivacaine group= B group) will receive a 50 mL solution of bupivacaine 0.25% intraperitoneal instilled solution.~* Group 2 (Bupivacaine neostigmine group=BN group) will receive 500 μg neostigmine mixed with bupivacaine 0.25% with a total volume of 50 mL intraperitoneal instilled solution."|f|t|f|f
34083685|NCT05485753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083686|NCT00605683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083687|NCT00021788||||TREATMENT||NONE||||||
34083688|NCT05635903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083689|NCT01417169|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083690|NCT01948245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34083691|NCT00855348|||COHORT||PROSPECTIVE|||||||
34083692|NCT03057886|||CASE_CONTROL||PROSPECTIVE|||||||
34083693|NCT03381872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All end points will be independently adjudicated by Clinical Event Adjudication Committee (CEAC).|Prospective, open label, two-arm, randomized controlled trial|f|f|t|t
34083694|NCT06399042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|masking : only blind investigator||t|f|t|f
34083695|NCT02873234|||COHORT||PROSPECTIVE|||||||
34083696|NCT02811770|||COHORT||RETROSPECTIVE|||||||
34083697|NCT05232227|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|A randomized open-label superiority trial|||||
33776963|NCT00646867|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33776964|NCT02981784|||COHORT||RETROSPECTIVE|||||||
33908303|NCT06695754|||OTHER||RETROSPECTIVE|||||||
33908304|NCT06746714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908305|NCT05395351|||COHORT||RETROSPECTIVE|||||||
33908306|NCT05902663|||COHORT||OTHER|||||||
33908307|NCT06669091|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33908308|NCT06523166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908309|NCT05681351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908310|NCT06619509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908311|NCT06693921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded only the outcome assessor is masked||f|f|f|t
33990694|NCT00274651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990695|NCT05435196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking of the outcome variables|An initial evaluation, a final one, will be carried out 3 months and 6 months after the end of the study.|f|f|t|f
33990696|NCT04300946|||OTHER||OTHER|||||||
33990697|NCT03417960|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot||||
33990698|NCT01959568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33990699|NCT06115291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083698|NCT05423977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083699|NCT06467695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told whether they are receiving tDCS or SHAM tDCS in order to reduce subject expectancy bias.|Participants (n = 40) will be either in the Parkinson's Group (n = 20) or the No Parkinson's Control (N = 20). All patients will be randomly assigned to receive either tDCS or SHAM tDCS.|t|f|f|f
34083700|NCT04963699|||OTHER||RETROSPECTIVE|||||||
33776965|NCT00280293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776966|NCT02839135|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33776967|NCT03024242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33776968|NCT04962893|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded||t|f|t|f
33776969|NCT00001450||||TREATMENT||||||||
33776970|NCT00933062|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33776971|NCT01773668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776972|NCT03110328|NA|SINGLE_GROUP||TREATMENT||NONE||Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)||||
33776973|NCT03891459|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33908312|NCT01897441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908313|NCT05147662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908314|NCT06682572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908315|NCT04575883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908316|NCT06690489|||COHORT||CROSS_SECTIONAL|||||||
33908317|NCT01909453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908318|NCT05987332|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908319|NCT06719089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators that will place the stent will not be the same that will perform the follow-up visits.||f|f|f|t
33990700|NCT05122156|||OTHER||CROSS_SECTIONAL|||||||
33990701|NCT04913285|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33990702|NCT05494203|||COHORT||PROSPECTIVE|||||||
33990703|NCT06030752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990704|NCT02647944|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33990705|NCT03253315|||OTHER||OTHER|||||||
33990706|NCT04084197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990707|NCT00271115|NA|SINGLE_GROUP||||NONE||||||
34083701|NCT03019484|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34083702|NCT04534309|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083703|NCT06326736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083704|NCT00526474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34083705|NCT03876925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687293|NCT03191578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33687294|NCT03203278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687295|NCT06331845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687296|NCT05275660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687297|NCT06450951|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33687298|NCT03400982|NA|SINGLE_GROUP||OTHER||NONE||||||
33687299|NCT00588952|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33687300|NCT01484938|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33908320|NCT04880031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part C - Open Label; Part D - Open Label||t|f|t|f
33687301|NCT06233760|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33908321|NCT05440656|||COHORT||PROSPECTIVE|||||||
33908322|NCT06603844|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Three part study comprised of dose-escalation (Part A), Safety lead-in and signal seeking (Part B) and Dose Optimization (Part C).||||
33908323|NCT06718491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blind to the condition.|Participants will be randomized to receive one of two possible interventions.|t|f|f|f
33908324|NCT06709521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687302|NCT05648071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687303|NCT04983212|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687304|NCT00085228|RANDOMIZED|||TREATMENT||||||||
33776974|NCT00802737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776975|NCT04280471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776976|NCT01840761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908325|NCT06730061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908326|NCT06740409|||COHORT||PROSPECTIVE|||||||
33908327|NCT06731647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33908328|NCT06695845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908329|NCT06746402|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blind study, with an open-label positive control in Part B.|Part A, a parallel model, will be followed by Part B, a 4-way crossover model.|t|t|t|t
33908330|NCT06743360|||CASE_ONLY||PROSPECTIVE|||||||
33908331|NCT06739122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908332|NCT06746623|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants will complete screening for the condition by completing bedside Esocheck test and upper endoscopy. Providers performing endoscopy will not have result of Esocheck test available to them when performing upper endoscopy. Lab analysis team will not have endoscopy and histology results available to them to interpret methylation status results or Esoguard assay.|||||
33908333|NCT06536504|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33908334|NCT06667596|||OTHER||CROSS_SECTIONAL|||||||
33908335|NCT04106830|||COHORT||PROSPECTIVE|||||||
33908336|NCT06679114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908337|NCT06746610|NA|SINGLE_GROUP||SCREENING||NONE||||||
33908338|NCT06715371|||COHORT||PROSPECTIVE|||||||
33990708|NCT03972683|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be studied before and after a handgrip exercise training intervention.||||
33990709|NCT02982161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990710|NCT00781794|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33990711|NCT03700723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind|Subjects will be randomized in a 1:1 ratio to receive Resusix or FP24|t|f|f|t
33990712|NCT00043394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990713|NCT01998295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687305|NCT04831788|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33687306|NCT04174014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687307|NCT00000203||||TREATMENT||||||||
33687308|NCT00247533|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33687309|NCT04496934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687310|NCT03535571|NA|SINGLE_GROUP||OTHER||NONE||||||
33687311|NCT03233269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687312|NCT02336932|||COHORT||PROSPECTIVE|||||||
33687313|NCT02810353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687314|NCT00240474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990714|NCT04158245|NA|SINGLE_GROUP||OTHER||NONE||Describe the changes in the 18F-fluciclovine Positron Emission Tomography (PET) in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate-prednisone, enzalutamide or docetaxel.||||
33990715|NCT05865769|||OTHER||CROSS_SECTIONAL|||||||
33990716|NCT04916548|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33990717|NCT05523986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990718|NCT00460733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990719|NCT02897414|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33990720|NCT01398163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33990721|NCT03153540|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33687315|NCT02779387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687316|NCT00075439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687317|NCT01070797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687318|NCT01475071|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33687319|NCT05588804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687320|NCT02482207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776977|NCT05027750|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33776978|NCT04435730|||CASE_CONTROL||PROSPECTIVE|||||||
33776979|NCT03722212|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The METAglut1 test is performed blindly of the reference strategy. METAglut1's result masking is maintained for the investigator on the one hand, and the glycorrhachia value masking is maintained for the centralized testing laboratory in charge of METAglut1 on the other hand.|The METAglut1 test is performed on each patient, in parallel and blindly of the reference diagnostic strategy which is performed through the current practice (lumbar puncture (LP) performed in the fasting state with glycemia measured right before LP, followed by genetic analyses (targeted slc2a1 analysis or gene panels or whole exome sequencing).||||
33776980|NCT04467840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776981|NCT06018597|||CASE_CONTROL||PROSPECTIVE|||||||
33776982|NCT05926856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33776983|NCT05701943|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was a randomized controlled trial, where a convenience group of 17 were randomized in a 1:1 ratio to an SIT or CAET regime by using a random-block randomization scheme. Participants in both aerobic regimes received a 16-week supervised exercise program performed 3 times a week for 60 min each session. The intervention started with 8 weeks of online training via Google Meets at their homes followed by 1 month of detraining with no exercise sessions besides those made available by the SPORTS4ALL program, and another 8 weeks of on-site training at the gym. During the intervention, adherence to the protocols were assessed with an exercise diary. Schedule of enrolment, intervention, and assessments for the duration of the study are displayed in Supplement 1. Assessments were conducted on 4 occasions over a 20-week period: before (M1; 0 weeks) and after (M2; 8 weeks) the home-based intervention; and before (M3, 12 weeks) and after (M4; 20 weeks) the gym-based intervention.|f|f|t|f
33776984|NCT04859049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33776985|NCT02355405|||CASE_ONLY||PROSPECTIVE|||||||
33776986|NCT02136485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33776987|NCT02818608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776988|NCT05305937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33776989|NCT01766583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33776990|NCT00081029|RANDOMIZED|||TREATMENT||||||||
33776991|NCT02696278|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33776992|NCT03089372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776993|NCT05034510|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33776994|NCT06169436|||COHORT||OTHER|||||||
33776995|NCT05565222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33776996|NCT05655065|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33776997|NCT01613820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33776998|NCT02503462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908339|NCT06708156|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Masking aims to achieve the unpredictability of randomized treatment groups by all parties involved in a clinical trial. To reduce the influence of evaluation bias or other factors, a double-blind experimental design was adopted in this study. Placebo is the auxiliary ingredient of atropine sulfate eye drops, and its specification, color, smell, etc. are consistent with the test drug and do not contain the active ingredient of the test drug. The drug in the experimental group was packaged in the same packaging as the placebo, and blinded according to random numbers to ensure that both the investigator and the subject were masked.||t|t|t|t
33908340|NCT06715436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908341|NCT06718010|||COHORT||OTHER|||||||
33908342|NCT06740305|||OTHER||PROSPECTIVE|||||||
33908343|NCT06516965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908344|NCT06740929|||COHORT||PROSPECTIVE|||||||
33908345|NCT06738914|||COHORT||RETROSPECTIVE|||||||
33990722|NCT01218867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990723|NCT04044521|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The intervention will assess outcomes at the clinic and prescriber level. Prescribers are the population of interest.||||
33990724|NCT00440167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990725|NCT00772603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990726|NCT00893685|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33990727|NCT06133920|||COHORT||PROSPECTIVE|||||||
33990728|NCT03590808|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Double center prospective case-control clinical trial||||
33990729|NCT05770648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33990730|NCT03047343|||COHORT||RETROSPECTIVE|||||||
33990731|NCT05960747|||CASE_CONTROL||PROSPECTIVE|||||||
34083706|NCT04597567|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34083707|NCT00839124|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34083708|NCT06289179|||COHORT||PROSPECTIVE|||||||
33687321|NCT00644644|||COHORT||PROSPECTIVE|||||||
33687322|NCT04341753|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33687323|NCT02021656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687324|NCT03475875|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33687325|NCT05202470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908346|NCT06746064|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"Part 1 - SAD (single ascending dose): Randomised, double-blind, placebo-controlled, single-dose escalation, parallel-group design in HVs.~Part 2 - MAD (multiple ascending dose): Randomised, double-blind, placebo-controlled, repeated-dose escalation, parallel-group design in HVs; Part 3: Non-randomised, open-label, single dose design in HVs"|t|t|t|t
33908347|NCT06746844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908348|NCT06745986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eighty-four cases were scheduled for femoral thrombectomy and classified into tw0 equal groups (n=42 each), spinal group received spinal anesthesia with 0.5% hyperbaric bupivacaine in a total volume in a total volume 2.5ml and fascia iliaca group received ultrasound guided fascia iliaca block with 40ml of 0.25% bupivacaine for each block. Data collected for each block were onset and duration of sensory and motor block, visual analogue scale, analgesic duration and analgesic consumption, hemodynamics and complications.|t|t|t|t
33908349|NCT06747117|||COHORT||PROSPECTIVE|||||||
34083709|NCT02868515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34083710|NCT06316492|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34083711|NCT06312709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083712|NCT00492492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083713|NCT03386526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083714|NCT00442624|||CASE_CONTROL||PROSPECTIVE|||||||
34083715|NCT03964948|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34083716|NCT03951519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687326|NCT03905447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects in the surveillance phase with detectable Aspergillus fumigatus lung infections WITHOUT clinical symptoms will be eligible to receive PC945 for 28 days. Following 28 days on PC945, subjects with ongoing A. fumigatus lung infections may receive a further 56 days of PC945.~Subjects in the surveillance phase with EITHER detectable Aspergillus fumigatus lung infections WITH clinical symptoms, OR other fungal lung infection, will be eligible to be followed up for 16 weeks on Standard of Care."||||
33687327|NCT02402842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990732|NCT06456073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990733|NCT01694212|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990734|NCT03370263|||CASE_ONLY||PROSPECTIVE|||||||
33990735|NCT06062498|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990736|NCT01673672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990737|NCT04625153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990738|NCT01110122|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33990739|NCT04350359|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Subjects will be randomized to either Variable or fixed-dose (2:1) using a block size of 6 and stratified based on complete/incomplete SCI to ensure the equal allocation of the most severely injured in the two groups. The PI and investigators will be blinded to randomization and treatment allocation, managed by the research assistant.|A prospective, double-blinded, randomized trial.|f|f|t|f
33990740|NCT02184260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33990741|NCT06239350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990742|NCT00045422||||TREATMENT||NONE||||||
33990743|NCT02403947|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33990744|NCT05079425|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33990745|NCT05609643|||COHORT||PROSPECTIVE|||||||
33990746|NCT01621945|||COHORT||PROSPECTIVE|||||||
33990747|NCT01030133|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33990748|NCT06560827|NA|SINGLE_GROUP||TREATMENT||NONE||"It is planned to enroll approximately 30 participants to receive CT011 infusion.~During the trial, the sample size may be appropriately adjusted as assessed by the sponsor and the investigator."||||
33990749|NCT04537481|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33990750|NCT04452786|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33990751|NCT01367145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33990752|NCT05883215|||CASE_ONLY||PROSPECTIVE|||||||
33990753|NCT06561009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990754|NCT00000885||||TREATMENT||DOUBLE||||||
33990755|NCT03588923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083717|NCT05639517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083718|NCT02233127|||COHORT||PROSPECTIVE|||||||
34083719|NCT02819713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34083720|NCT00676117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083721|NCT04273321|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083722|NCT00001078||||TREATMENT||||||||
34083723|NCT04124133|||COHORT||RETROSPECTIVE|||||||
34083724|NCT02090296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687328|NCT01369485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687329|NCT03127800|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990756|NCT06187441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990757|NCT00849576|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990758|NCT05130762|||COHORT||PROSPECTIVE|||||||
33990759|NCT06558994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990760|NCT00002939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990761|NCT02645500|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34083725|NCT03720119|||COHORT||PROSPECTIVE|||||||
34083726|NCT01164761|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083727|NCT06293833|NA|SINGLE_GROUP||SCREENING||NONE||||||
34083728|NCT03149536|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083729|NCT04151264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized two arm study with two groups.|t|f|f|f
34083730|NCT04326257|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this open-label, 2 parallel arms trial, RNA seq analysis via the Omniseq immune report card will be used to determine which drug (Relatlimab or Ipilimumab) will be added to Nivolumab for treatment.||||
34083731|NCT03821038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Open-label pharmacist will prepare masked syringes for the ICU|International, multicenter, randomized, double-blinded placebo- controlled|t|t|t|t
34083732|NCT02060357|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34083733|NCT00609817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083734|NCT03279042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908350|NCT06745999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908351|NCT06747715|NA|SINGLE_GROUP||TREATMENT||NONE||"The therapeutic intervention is a two stage surgical procedure (with a third stage biopsy for research purposes in this trial) in which a primary traumatic or post-surgical craniofacial deformity is treated first with autologous fat grafting using freshly harvested adipose tissue. A second fat grafting procedure is performed at 3.0 months after the first procedure using autologous adipose tissue that had been cryopreserved during the first procedure.~Facial volume and appearance will be scored by 4 blinded observers (2 physicians and 2 lay-observers) from standardized photographs."||||
33908352|NCT06746311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908353|NCT06746077|||COHORT||RETROSPECTIVE|||||||
33687330|NCT03008564|||CASE_ONLY||PROSPECTIVE|||||||
33687331|NCT00214500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687332|NCT01527357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908354|NCT06747351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908355|NCT06681207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908356|NCT06718244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908357|NCT04161755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908358|NCT05102006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908359|NCT04843371|||OTHER||CROSS_SECTIONAL|||||||
33908360|NCT06051864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908361|NCT05696821|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Due to the nature of the study the intervention cannot be blinded to the participants, but for statistical assessment, data will be blinded as regard to time of collection and location.|stepped-wedge cluster randomized trial|f|f|f|t
33908362|NCT03205527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908363|NCT06747611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908364|NCT06746259|||COHORT||PROSPECTIVE|||||||
33908365|NCT06748027|||OTHER||OTHER|||||||
33908366|NCT06748066|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33908367|NCT06747104|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33908368|NCT06746584|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||randomized controlled trial single blinded|t|f|f|f
33908369|NCT06747429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Masking will be maintained for data analysts.||f|f|f|t
33908370|NCT06746220|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Open label for physical activity or no-physical activity (A versus T groups). Double-blind for placebo/probiotic supplementation (+ versus - groups)|This is a prospective, comparative, double-blind, randomized, monocentric study to explore effects of PA and/or PS on healthy women.|t|f|t|f
33908371|NCT06747884|||COHORT||PROSPECTIVE|||||||
33908372|NCT03436485|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908373|NCT06706908|||COHORT||PROSPECTIVE|||||||
33908374|NCT04768777|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33990762|NCT01445691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990763|NCT05248308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990764|NCT01862783|||||PROSPECTIVE|||||||
33990765|NCT04368520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Two treatment arms of vitamin D3: low dose (800IU) vs. high dose (3,200IU) given daily, for 3 months|t|f|f|f
33990766|NCT04439552|||COHORT||PROSPECTIVE|||||||
33990767|NCT01316055|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33990768|NCT00830349|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990769|NCT00000925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33990770|NCT04304066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990771|NCT03537482|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation and dose expansion after MTD||||
33990772|NCT04946864|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 cohort||||
33990773|NCT06318117|||OTHER||OTHER|||||||
33990774|NCT00426621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990775|NCT05790772|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||20 Male and Female Athletes Aged 18-65||||
33990776|NCT02134379|||CASE_ONLY||PROSPECTIVE|||||||
33990777|NCT06562933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33990778|NCT02485977|||OTHER||CROSS_SECTIONAL|||||||
33990779|NCT06356103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Randomized Controlled Study||||
33990780|NCT00431041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990781|NCT01845272|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33990782|NCT06106490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33990783|NCT04862767|NA|SEQUENTIAL||TREATMENT||NONE||3+3 design||||
33990784|NCT06210984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33990785|NCT01699191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990786|NCT04205123|||COHORT||PROSPECTIVE|||||||
33990787|NCT01011400|||CASE_ONLY||PROSPECTIVE|||||||
33687333|NCT02017171|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33687334|NCT01860573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687335|NCT03463876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687336|NCT02934529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687337|NCT05110001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687338|NCT01611454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33990788|NCT00575159|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33990789|NCT05870332|||CASE_CONTROL||PROSPECTIVE|||||||
33990790|NCT06562322|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Crossover|t|f|f|t
33990791|NCT02284867|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33990792|NCT03227991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33990793|NCT02702882|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||open level||||
33990794|NCT04887415|NA|SINGLE_GROUP||PREVENTION||NONE||Longitudinal pilot cohort study||||
33990795|NCT00152451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990796|NCT06133933|||COHORT||PROSPECTIVE|||||||
33990797|NCT01138163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083735|NCT03779646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator, care providers and participants will know whether the participants use the trial drug（bisoprolol） or not. But the outcome assessor who will analysis the results of the cardiac MR and echocardiography images from the participants will be blinded to the grouping situation.|This is a randomized, controlled trial.Enrolled participants should receive a kind of ACEI drug for more than 1 month and the dose should be fixed. Then the participants were randomly assigned (1:1) to receive either bisoprolol or not any beta blocker.|f|f|f|t
34083736|NCT01975402|||CASE_ONLY||PROSPECTIVE|||||||
34083737|NCT02950701|||COHORT||PROSPECTIVE|||||||
34083738|NCT05885217|||OTHER||CROSS_SECTIONAL|||||||
34083739|NCT04617821|RANDOMIZED|PARALLEL||TREATMENT||NONE|open-label|Three hundred patients with borderline resectable and locally advanced pancreatic cancer are randomized 1:1 to the AG and mFOLFIRINOX chemotherapy groups and to observe the total survival.||||
34083740|NCT06270108|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a basic science study the purpose of which is to to explore the responsivity of glutamate in treatment-resistant schizophrenia to a given challenge (riluzole).||||
34083741|NCT01621009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34083742|NCT00003686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34083743|NCT05218694|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients (n=120) are randomized 1:1||||
34083744|NCT00005925||||TREATMENT||||||||
34083745|NCT00313872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083746|NCT03312816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34083747|NCT04493346|||COHORT||PROSPECTIVE|||||||
34083748|NCT04175717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990798|NCT04173247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083749|NCT00505297|||CASE_CONTROL||OTHER|||||||
34083750|NCT04625036|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083751|NCT00550199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990799|NCT00570609|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083752|NCT03713463|||COHORT||PROSPECTIVE|||||||
34083753|NCT05115799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The randomization of the sample is done through the Excel program, where the randomization function distributes the numbers from 1 to 46 (number of research members) in the control group or intervention group.~As patients with this health problem arrive, they are distributed in order of arrival in both groups as determined by randomization"|Randomized Clinical Trial|f|f|t|f
34083754|NCT05208645|||CASE_ONLY||RETROSPECTIVE|||||||
34083755|NCT05376501|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double blind|Randomization at 1:1 ratio for active or placebo|t|t|t|t
33990800|NCT06628102|NA|SINGLE_GROUP||SCREENING||NONE||||||
33990801|NCT01318551|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33990802|NCT01109420|||COHORT||PROSPECTIVE|||||||
33990803|NCT00858754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083756|NCT02171403|||CASE_CONTROL||PROSPECTIVE|||||||
34083757|NCT01068236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083758|NCT03501251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will receive placebos. Outcome assessors and caregivers will not have access to the list of children allocated to each treatment arm.||t|t|f|t
34083759|NCT04328987|||COHORT||PROSPECTIVE|||||||
34083760|NCT01614652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990804|NCT04927013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33990805|NCT04937062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a pilot, single treatment, multiple-dose, open label, study to be conducted in up to 10 children with STXBP1-E, and 10 with SLC6A1-NDD, and 30 children with monogenetic developmental and epileptic encephalopathy.||||
33990806|NCT00684697|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990807|NCT05846022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the physiotherapist administering the intervention of dry needling is aware of the group allocation|Clinical trial|t|f|f|t
33990808|NCT00194454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990809|NCT01111045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990810|NCT01051635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990811|NCT01076023|||COHORT||PROSPECTIVE|||||||
34083761|NCT02431598|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34083762|NCT02327234|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34083763|NCT02284100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083764|NCT02118623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34083765|NCT05218278|||CASE_CONTROL||PROSPECTIVE|||||||
33908375|NCT05536076|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants (SCI N=10, SD N=10 and Able bodied N=10) will be undergo the intervention arm (acute intermittent hypercapnia)|Controlled pilot trial to assess the feasibility of using daily chemical stimuli (acute intermittent hypercapnia) in patients with chronic SCI/D in comparison to able-bodied patients with OSA.|t|f|f|f
33908376|NCT06477419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908377|NCT06717425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized, double-blind (investigator and participant), sponsor-open, placebo-controlled study.|t|f|t|f
33908378|NCT06747143|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Sequential intervention||||
33908379|NCT06746558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908380|NCT06747052|||OTHER||CROSS_SECTIONAL|||||||
33908381|NCT06716879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33908382|NCT06747195|||COHORT||PROSPECTIVE|||||||
33908383|NCT06746545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908384|NCT06746805|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Color and flavor matched placebo|Double-blind, randomized, placebo-controlled, cross-over trial|t|f|t|t
33908385|NCT06747507|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase 3b, multi-country, open-label, two-arm, active-controlled randomized clinical trial over 12 months describing the efficacy and safety of switching from DTG to DRV/r among PLWH age ≥ 3 years who are failing DTG-based ART with HIV-1 RNA ≥ 200 copies/mL and ≥ 1 major DTG-associated DRM (substitution at codon 66K, 92Q, 118R, 138K/A/T, 140S/A/C, 148H/R/K, 155H or 263K ), and most recent prior HIV-1 RNA ≥1,000 copies/mL after at least 6 months on DTG-based ART.||||
33908386|NCT06747988|||COHORT||PROSPECTIVE|||||||
33908387|NCT06746506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33908388|NCT06746896|||CASE_CONTROL||RETROSPECTIVE|||||||
33908389|NCT06747091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the ablation strategy they are randomized to||t|f|f|f
33908390|NCT06747780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33908391|NCT06746155|||COHORT||PROSPECTIVE|||||||
33908392|NCT06742957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908393|NCT05466838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908394|NCT06745336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908395|NCT06691698|NA|SINGLE_GROUP||TREATMENT||NONE|One of the outcomes will be assessed using video from baseline, post and 6 months post intervention, and the assessor of those videos will be blinded to the order and have no knowledge about the participant.|||||
33908396|NCT06726018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908397|NCT06747663|||COHORT||PROSPECTIVE|||||||
33908398|NCT06747234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33908399|NCT06746857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908400|NCT06747559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908401|NCT06608212|||COHORT||RETROSPECTIVE|||||||
33908402|NCT03350516|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33908403|NCT06747156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908404|NCT06746870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908405|NCT06747676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Statistician|Phase I/II randomized sham-controlled double-blind parallel clinical trial design|t|t|f|t
33908406|NCT06746753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908407|NCT06747533|||CASE_CONTROL||PROSPECTIVE|||||||
33908408|NCT06746961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908409|NCT06747390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized and blinded to intratumoral injection of 1% lidocaine (intervention arm) or no injection (control arm) at the time of direct laryngoscopy.|t|f|f|f
33908410|NCT05253976|||COHORT||OTHER|||||||
33908411|NCT03378856|||COHORT||PROSPECTIVE|||||||
33990812|NCT04009434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990813|NCT03755050|||CASE_ONLY||RETROSPECTIVE|||||||
33990814|NCT03923660|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33990815|NCT05957003|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33990816|NCT06481475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990817|NCT05697211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990818|NCT02226432|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990819|NCT00014768|||NATURAL_HISTORY|||||||||
33990820|NCT05039463|||CASE_ONLY||RETROSPECTIVE|||||||
33990821|NCT05519150|||COHORT||PROSPECTIVE|||||||
33990822|NCT03875521|||OTHER||PROSPECTIVE|||||||
33990823|NCT03692650|||COHORT||PROSPECTIVE|||||||
33990824|NCT02697747|||COHORT||PROSPECTIVE|||||||
33990825|NCT04843995|||COHORT||PROSPECTIVE|||||||
33990826|NCT05754203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990827|NCT00127153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33990828|NCT03306394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990829|NCT04274374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990830|NCT05943665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990831|NCT00041392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990832|NCT04605783|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomized, placebo-controlled, double-blind clinical trial||t|t|t|f
33990833|NCT05048667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990834|NCT05070663|||COHORT||OTHER|||||||
33990835|NCT00841698|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33990836|NCT02158494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990837|NCT05878964|||COHORT||PROSPECTIVE|||||||
33990838|NCT02299453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990839|NCT04965454|NA|SINGLE_GROUP||OTHER||NONE||prospective open-label single-arm diagnostic clinical trial||||
33990840|NCT03548363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the investigators with any involvement in the study or data analysis prior to database locking and subjects are blinded to what treatment they receive.|Double-blind, placebo-controlled, 4-week parallel intervention in subjects with mild to moderate Dyspepsia (as defined by the Leeds Dyspepsia Questionnaire) in 3-treatment arms: 1.) 100 mg/d Gingest; 2.) 200 mg/d Gingest; 3.) Placebo (maltodextrin)|t|f|t|f
33990841|NCT05138003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990842|NCT04398381|||COHORT||RETROSPECTIVE|||||||
33990843|NCT04742686|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33990844|NCT04642820|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33990845|NCT01519258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687339|NCT02117414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687340|NCT01396330|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33687341|NCT03740503|||COHORT||RETROSPECTIVE|||||||
33687342|NCT01712321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687343|NCT02352584|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33687344|NCT00810927|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33687345|NCT03843242|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33687346|NCT04695587|||COHORT||PROSPECTIVE|||||||
33687347|NCT02749123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687348|NCT02005328|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33687349|NCT00124397|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33687350|NCT06391801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687351|NCT01066507|||CASE_CONTROL||RETROSPECTIVE|||||||
33687352|NCT00140361|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687353|NCT06516341|||COHORT||PROSPECTIVE|||||||
33687354|NCT02477423|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33687355|NCT01097876|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33687356|NCT00121407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687357|NCT02996643|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33687358|NCT05846477|||COHORT||PROSPECTIVE|||||||
33990846|NCT03034694|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Routine Care vs The use of teledermatology|t|f|t|f
33990847|NCT05527561|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group conducted the Latin dance training content intervention designed in this study. In contrast, the control group will exercise basketball training content intended.|t|f|t|t
33990848|NCT03034798|||CASE_CROSSOVER||PROSPECTIVE|||||||
33990849|NCT04169633|||COHORT||PROSPECTIVE|||||||
33990850|NCT05172947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A prospective triple blind randomized clinical trial|Eligible patients assigned to either conventional hypoglycemic drugs without pharmaceutical care, or conventional hypoglycemic drugs accompanied with pharmacist interventions or patients will receive resveratrol 500 mg capsules orally once daily with their regular hypoglycemic drugs or resveratrol 500 mg capsule orally along with their regular hypoglycemic drugs for a period of three months, accompanied with pharmacist interventions.|t|f|t|t
33990851|NCT05336643|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Open label, single arm, feasibility study for a medical device||||
33990852|NCT06452251|||CASE_CONTROL||PROSPECTIVE|||||||
33990853|NCT01718704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990854|NCT06018285|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped Wedge Design||||
33990855|NCT02022254||CROSSOVER||TREATMENT||NONE||||||
33990856|NCT02095054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990857|NCT00802763|||CASE_ONLY||RETROSPECTIVE|||||||
33990858|NCT00996684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990859|NCT02704585|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33990860|NCT05283850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, being intrinsically unconscious from PEA, will be blinded to the intervention. EMS Supervisors, in the pre-hospital setting, will administer an opaque bag of fluids with only a bag number on it, ensuring that they are blinded to the intervention. Hospital providers/outcomes assessors will know that patients were enrolled in a study and they will only know which bag number was used. The investigator will have the capacity to unblind bag numbers, but the investigator will not be the provider or outcomes assessor for patients due to the emergent nature of PEA.||t|t|t|t
33990861|NCT04480983|||OTHER||CROSS_SECTIONAL|||||||
33990862|NCT03612960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Double-blind|Randomized|t|f|t|f
34083766|NCT05898516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of this trial, it will not be possible to blind participants to their allocation. As measures are self-report, blinding of outcome measures is also not possible. Protect against bias will occur by blinding investigators to condition (i.e., only staff directly managing participants will be unblinded).|A pragmatic, parallel arm randomized controlled superiority trial will be used. Participants will be randomly allocated in a 1:1 ratio to the control (usual practice; UP) or intervention (UP + JoyPop) condition. Stratified block randomization (block size of 10) will be used to randomly assign participants to each condition.|f|f|t|f
34083767|NCT05605821|||COHORT||RETROSPECTIVE|||||||
34083768|NCT04625283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will be performed as a pragmatic controlled clinical trial with parallel group assignment. Randomization will be in a cluster format.|t|t|t|t
34083769|NCT02465450|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34083770|NCT04198935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083771|NCT01178788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083772|NCT05327452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083773|NCT05553834|NA|SINGLE_GROUP||TREATMENT||NONE||Combination therapy involving anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab.||||
34083774|NCT03922685|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"The same eight subjects participated in counterbalanced order in:~(1) sedentary morning trial, (2) exercise morning trial, (3) sedentary evening trial, (4) exercise evening trial."||||
34083775|NCT03261206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083776|NCT00641563|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34083777|NCT06492629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083778|NCT00745888|||||PROSPECTIVE|||||||
34083779|NCT04611919|||COHORT||PROSPECTIVE|||||||
34083780|NCT02049216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34083781|NCT05304806|||COHORT||PROSPECTIVE|||||||
34083782|NCT05739916|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083783|NCT06386406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687359|NCT03988959|NA|SINGLE_GROUP||TREATMENT||NONE|No masking was done since its a case series|a case series was performed on 7 patients having mucoepidermoid carcinoma||||
33687360|NCT05635058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was conducted as the randomized controlled experimental trial.||||
33687361|NCT05753397|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33776999|NCT04794621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|to avoid bias, the personnel performing the biofilm analysis (Primary outcome) will be blinded towards the study groups.|Participants are assigned to one of two groups in parallel for the duration of the study|f|f|f|t
33777000|NCT05814861|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33908412|NCT06746090|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects will be assigned to one of the three study groups using a computer generated randomization list. There will be no blinding in the study. The recruitment of the patients will be performed by the investigator who will explain the objective, the three arms of the study and the allocation to the participants. Allocation concealment will be carried out using opaque concealed envelopes which will be opened until the use of intervention is to be explained to the patient.|||||
33908413|NCT06747897|||COHORT||RETROSPECTIVE|||||||
33908414|NCT06746194|||OTHER||PROSPECTIVE|||||||
34083784|NCT02317653|||COHORT||PROSPECTIVE|||||||
34083785|NCT06375382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34083786|NCT05049005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083787|NCT00183339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083788|NCT00682877|||CASE_CONTROL||PROSPECTIVE|||||||
34083789|NCT00282217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083790|NCT04891172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083791|NCT02597608|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34083792|NCT05261906|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be in the treatment group. This is a multisite intervention; the intervention will be first delivered at the Primary Care for Diabetes Support Program in London, Ontario with 92 participants. Following intervention completion in London, ON, the Boris Clinic in Diabetes Care and Research Program (DCRP) in Hamilton, ON will deliver the intervention as a fidelity check, with another 92 participants.||||
34083793|NCT03581214|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34083794|NCT02089477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34083795|NCT01940822|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34083796|NCT05278468|||CASE_CONTROL||PROSPECTIVE|||||||
34083797|NCT01699750|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34083798|NCT00910949|||COHORT|||||||||
34083799|NCT00611806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908415|NCT06687343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33908416|NCT06746597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908417|NCT06218914|NA|SEQUENTIAL||TREATMENT||NONE||||||
33908418|NCT05465941|NA|SINGLE_GROUP||TREATMENT||NONE|Staining will be read independently by two individuals blinded to treatment, who will score each sample for the percentage of cells that are positive for \>8 nucleoplasmic TOP1ccs.|||||
33908419|NCT06618755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908420|NCT05473637|||COHORT||PROSPECTIVE|||||||
33908421|NCT06661746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908422|NCT06685718|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908423|NCT05419388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908424|NCT06688435|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, two-phase (dose-escalation and dose-expansion), multicenter, phase I clinical study. The dose-escalation phase adopts a sequential design model, including 5 arms for 5 dose level. The arms of dose-expansion phase depends on the number of recommended dose, which may be 1-2 recommended dose.||||
33908425|NCT06704672|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33908426|NCT06738472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33908427|NCT01719055|||COHORT||PROSPECTIVE|||||||
33908428|NCT06351592|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|No masking during Open-Label Treatment Period after 4-week Double-Blind Treatment Period. This part of the study consists of a crossover design.||t|t|t|t
33908429|NCT06747481|||COHORT||RETROSPECTIVE|||||||
33908430|NCT06746350|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908431|NCT06746038|NA|SINGLE_GROUP||TREATMENT||NONE||A single group of participants will be fit with the extended wear hearing devices and will be tested in both the aided and unaided conditions in various tasks. Conditions will be counterbalanced and all participants will experience the same conditions. Conditions will include unaided, aided with pre-calculation A, and aided with pre-calculation B.||||
33990863|NCT00218257|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"Participants will be randomized to receive either progesterone or placebo during month 1, then crossover in month 2.~During each month, participants will be randomized to receive either an active or inactive dose of cocaine during a 4-day in-hospital testing visit for a total of 4 testing days with self-administered cocaine."|t|t|t|f
33990864|NCT04278261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33990865|NCT00309101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990866|NCT05535062|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The study will be randomized to avoid any bias in treatment arm assignment. Subjects will be blinded to the actual treatment arm throughout the study to allow patient to provide an honest assessment of the treatment they are receiving daily. Subjects will not be informed of the treatment at the end of their study participation.|Patients will be switched between different treatment arms and asked to complete questionnaires.|t|f|f|f
33990867|NCT06420687|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||The GaMA metric will utilize motion capture and eye tracking hardware and software during the administration of functional tasks while research participants are using commercially available prosthetic devices and investigational prosthetic devices currently in development.||||
33687362|NCT03368573|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).~Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person."||||
33687363|NCT01603238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687364|NCT03883568|||COHORT||PROSPECTIVE|||||||
33687365|NCT00193193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777001|NCT04945343|NA|SINGLE_GROUP||TREATMENT||NONE||Use of growing Rods for correction of early onset scoliosis deformity of the spine||||
33777002|NCT05722171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777003|NCT02677103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777004|NCT02095600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777005|NCT04676828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers and outcome assessors are blinded|Randomized double-blinded phase 2|t|t|f|t
33777006|NCT01917734|||COHORT||RETROSPECTIVE|||||||
33777007|NCT00750893|||COHORT||PROSPECTIVE|||||||
33777008|NCT00777803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908432|NCT06742151|||COHORT||CROSS_SECTIONAL|||||||
33908433|NCT06747377|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908434|NCT06748079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33990868|NCT00229021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083800|NCT06054997|||COHORT||RETROSPECTIVE|||||||
34083801|NCT05637983|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized trial||||
33687366|NCT01931670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083802|NCT03991871|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison between two groups||||
34083803|NCT05615077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34083804|NCT01235988|||OTHER||RETROSPECTIVE|||||||
34083805|NCT00196599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083806|NCT00453908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083807|NCT02484677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083808|NCT02678468|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33687367|NCT00453960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687368|NCT01456273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33687369|NCT05779436|||COHORT||PROSPECTIVE|||||||
33687370|NCT02355977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687371|NCT03682575|||COHORT||PROSPECTIVE|||||||
33687372|NCT05684432|||CASE_ONLY||PROSPECTIVE|||||||
33687373|NCT00946400|||COHORT||PROSPECTIVE|||||||
33687374|NCT00583479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687375|NCT02182648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687376|NCT01422967|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33777009|NCT01639274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777010|NCT04212481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777011|NCT04701437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33777012|NCT03676036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777013|NCT02117544|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33777014|NCT06273189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blind|t|f|f|t
33777015|NCT05050487|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trail||||
33908435|NCT06746571|NA|CROSSOVER||DIAGNOSTIC||NONE||||||
33908436|NCT06746207|||COHORT||CROSS_SECTIONAL|||||||
33908437|NCT06747637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908438|NCT06747975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908439|NCT06747949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908440|NCT06746519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908441|NCT06746116|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IIIb, interventional, single arm, multicentre study.||||
33908442|NCT06746025|||CASE_ONLY||PROSPECTIVE|||||||
33777016|NCT01187303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777017|NCT02385721|||COHORT||PROSPECTIVE|||||||
34083809|NCT04584788|NA|SINGLE_GROUP||OTHER||NONE||||||
34083810|NCT04208893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687377|NCT05843773|NA|SINGLE_GROUP||TREATMENT||NONE||The present study is a feasibility study. The study is based on the Consort Checklist for pilot and feasibility trials. This will be a monocentric study; the patients will be recruited at the Leukerbad Clinic.||||
33687378|NCT02160483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687379|NCT00226629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687380|NCT05478954|NA|SINGLE_GROUP||PREVENTION||NONE||Cohort||||
33687381|NCT03348787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687382|NCT06387433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33687383|NCT01465191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687384|NCT05072470|NA|SINGLE_GROUP||OTHER||NONE||||||
33687385|NCT02943902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687386|NCT02959164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687387|NCT00056056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687388|NCT05513131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687389|NCT03055858|NA|SINGLE_GROUP||TREATMENT||NONE||ADO II AS device||||
33687390|NCT03272789|NA|SINGLE_GROUP||OTHER||NONE||||||
33687391|NCT01951859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687392|NCT03551340|||CASE_ONLY||RETROSPECTIVE|||||||
33687393|NCT03206905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687394|NCT02503345|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33687395|NCT00719264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687396|NCT05646472|||COHORT||PROSPECTIVE|||||||
33687397|NCT05260281|||COHORT||PROSPECTIVE|||||||
33687398|NCT03926546|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33687399|NCT01525121|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33687400|NCT01172275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687401|NCT01227148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687402|NCT05882721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687403|NCT05526209|||COHORT||PROSPECTIVE|||||||
33839890|NCT05422690|NA|SINGLE_GROUP||TREATMENT||NONE||"Treatments are repeated every 21 days. Chemotherapy will be administered on days 1 and 8 of the 21 day cycle. For the first two cycles, treatment will consist of three drugs, gemcitabine, cisplatin and Durvalumab.~After these two cycles, the Durvalumab will be removed from the treatment plan and participants will continue on trial with gemcitabine and cisplatin alone for 6 additional cycles (8 total cycles, or 6 months total of treatment). During the 3rd and possibly the 4th cycle, these drugs will be given at a reduced dose as y-90 treatment to the tumors in your liver will also be given. The interventional team will administer y-90 during these cycles as either one dose during cycle 3, or two doses, one during cycle 3 and one during cycle 4 if there is too much cancer to treat all at once.~The remaining cycles of treatment will be with gemcitabine and cisplatin by themselves."||||
33908443|NCT06746792|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33908444|NCT06746740|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot open trial||||
34083811|NCT04583982|||COHORT||PROSPECTIVE|||||||
34083812|NCT03085303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients are blinded by wearing tinted glasses for eye protection which disenable distinction of different wave lengths of light. Medical doctors will examine patients in other rooms than those equipped with the investigational medical devices. These examiners are blinded and are therefore not involved in the preparation and process of the irradiation.||t|f|t|t
34083813|NCT05800678|||COHORT||PROSPECTIVE|||||||
33687404|NCT03790631|||COHORT||PROSPECTIVE|||||||
33687405|NCT03872414|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33687406|NCT05563480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687407|NCT00931346|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687408|NCT06278233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One researcher not involved in any aspect of the study will randomize participants to the sham and tDCS study arms using blocked randomization. To ensure blinding, one researcher will record the administration of the tDCS and assessments, while independent speech-language pathologists will monitor the assessment recordings and score the test items.|In this study, a double-blind, randomized controlled research design from experimental research methods will be applied.|t|f|f|t
33687409|NCT01040078|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33687410|NCT02480907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687411|NCT02483052|NA|SINGLE_GROUP||OTHER||NONE||RejuvenAir||||
33687412|NCT00107926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687413|NCT04043780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33687414|NCT02273609|||COHORT||RETROSPECTIVE|||||||
33687415|NCT01936402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34083814|NCT06545305|||CASE_ONLY||RETROSPECTIVE|||||||
34083815|NCT06071416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|using automated sequence generation ( randomizer. org) patients will be divided into the two groups ,In sequentially numbered , opaque, sealed envelopes, participants will be enrolled and evaluated while the allocation sequence will be kept a secret from the researchers.|"Group I, patients undergo sinus lifting using bone substitute BCP alone.~-Group II, patients who undergo sinus lifting using BCP with I-PRF."|t|f|f|t
33990869|NCT02138539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33990870|NCT02441621|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990871|NCT06525389|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Liposomal amphotericin B vs deoxycholate amphotericin B arm is an open label comparison~Flucytosine vs no flucytosine is a placebo controlled comparison"||t|t|t|t
33990872|NCT02256683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990873|NCT01932177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990874|NCT02962752|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33990875|NCT00819312|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33990876|NCT05734157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083816|NCT00792181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083817|NCT05782517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33687416|NCT00008827|RANDOMIZED|||TREATMENT||||||||
33687417|NCT05799690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Physiotherapist, neurologists, neuropsychologists and radiologist assessing the patients are blinded to group allocation.|Single-blind randomized controlled trial. Fifty PD patients are randomly divided into two groups: 25 in DUAL-TASK+AOT-MI (experimental) and 25 in the DUAL-TASK (active comparator). Half of the patients are further randomized to repeat the treatment (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE). The assessors are blinded to the group allocation. In addition, a group of 20 healthy age- and sex-matched control is included at baseline|f|f|f|t
33687418|NCT04623008|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33687419|NCT02687659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687420|NCT04988633|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, single-centre, randomized clinical trial||||
33687421|NCT04676360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687422|NCT03004248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687423|NCT02002585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687424|NCT05158647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33687425|NCT01325155|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687426|NCT04622631|||COHORT||PROSPECTIVE|||||||
33687427|NCT02305043|||COHORT||PROSPECTIVE|||||||
33687428|NCT02900001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687429|NCT02306733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687430|NCT04319679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687431|NCT02457273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687432|NCT01551940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687433|NCT04095533|||COHORT||PROSPECTIVE|||||||
33687434|NCT00088998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687435|NCT03407300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687436|NCT02048189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687437|NCT05602311|||COHORT||PROSPECTIVE|||||||
33687438|NCT01466140|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33908445|NCT06747455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908446|NCT06747208|||COHORT||PROSPECTIVE|||||||
33687439|NCT01631019|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908447|NCT06747403|||COHORT||PROSPECTIVE|||||||
33687440|NCT05929820|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33687441|NCT03346798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908448|NCT04386746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687442|NCT02577783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687443|NCT00982696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687444|NCT04031183|||OTHER||PROSPECTIVE|||||||
33687445|NCT00786851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687446|NCT03495544|||CASE_CONTROL||PROSPECTIVE|||||||
33687447|NCT01988480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687448|NCT02159274|||OTHER||PROSPECTIVE|||||||
33687449|NCT02425072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687450|NCT03377088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687451|NCT05983783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908449|NCT03215706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908450|NCT06746441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized (Random allocation will be performed using a simple lottery method.)|Parallel Assignment (The study has four distinct intervention groups: Control, Psilocybin Therapy, CBT, and Psilocybin-assisted CBT.)|t|f|f|f
33908451|NCT06747312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908452|NCT06747026|||COHORT||RETROSPECTIVE|||||||
33908453|NCT06746415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial|t|f|f|f
33908454|NCT06746298|||COHORT||PROSPECTIVE|||||||
33908455|NCT04483115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908456|NCT00378742|||COHORT||CROSS_SECTIONAL|||||||
33908457|NCT06260878|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33990877|NCT01621893|||CASE_ONLY||PROSPECTIVE|||||||
33990878|NCT05163743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990879|NCT02739503|||COHORT||PROSPECTIVE|||||||
33990880|NCT01025973|||COHORT||PROSPECTIVE|||||||
33990881|NCT01844050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990882|NCT05019261|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33990883|NCT03527485|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33990884|NCT03964662|NA|SINGLE_GROUP||TREATMENT||NONE||The goal of this study is to assess the acceptance and validity of a new technology such as WeReha for home rehabilitation of patients following a stroke episode either in sub-acute or chronic phase. The investigation will be conducted in two different countries: two sites in Northern Ireland and one in Italy.||||
33990885|NCT02354560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083818|NCT00183079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687452|NCT03402048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687453|NCT00350454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687454|NCT00413478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687455|NCT02318576|RANDOMIZED|PARALLEL||||NONE||||||
33687456|NCT02326311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687457|NCT02853630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083819|NCT02215902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777018|NCT03681821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Potential eligible participants were identified by researchers according to medical records at the colorectal surgery unit in each hospital. They were recruited with informed consent, and researchers explained the study purposes, procedures, benefits, and risks involved orally. The participants were then randomly allocated to the intervention or the control group according to a computer-generated block randomization list. The generated random numbers were put into consecutively numbered and opaque sealed envelopes. When enrolling and randomising a new participant, the enrolling investigators opened the sealed envelope after participant's name was written on next available envelopes. A sequentially numbered and opaque , sealed envelope system was used by a non-investigator. Additionally, all data collection was conducted by another research assistant who was blind to the study design and allocation of participants.|"Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. The researcher was regarded as primary leader of the intervention sessions. The leader informed patients of the schedule for each session using the educational manual 'we all can do the same: a pro-change program for self-management of an ostomy' (developed by psychologists, nursing managers, experienced ET nurses, and researchers).~No interventions were performed for the control group participants during the study. However, these patients received conventional care in the colorectal surgery units according to the three hospitals' similar nursing guidelines."|t|f|f|t
33777019|NCT01469793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777020|NCT06403241|||COHORT||RETROSPECTIVE|||||||
33777021|NCT02920593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777022|NCT06476340|||OTHER||CROSS_SECTIONAL|||||||
33777023|NCT03832725|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Subjects or investigators will not know which macronutrient diet (high protein or high carbohydrate) which they are given for the study.|Subjects will be randomized to a macronutrient high protein or high carbohydrate diet provided by the study for weight loss and remission of Type 2 Diabetes|t|f|t|f
33777024|NCT02921022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777025|NCT00021398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777026|NCT03148080|||COHORT||CROSS_SECTIONAL|||||||
33777027|NCT00444717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777028|NCT01305057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33777029|NCT06432699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be randomly assigned to receive Micro-osteoperforation and the other side will be control.|This is a single-blind, randomized parallel-arm study with two arms. Participants will be randomly assigned to either MOPS or no Mops||||
33687458|NCT03932097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33777030|NCT03507829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908458|NCT06472310|||OTHER||OTHER|||||||
33908459|NCT06746987|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|A single blind technique will be used in the research. Thus, it will not be known to the subjects whether the research participants are in the study or control groups. When the research is completed, the data of the study and control groups will be transferred to the computer environment by a researcher independent of the research, and the data will be analyzed by a statisitcian and the findings will ve reported.|Randomized controlled experimental clinical trial with pre- test and post- test measurements consisting of a study and control group.||||
33908460|NCT06747819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33908461|NCT06748040|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate versus delayed return of pharmacogenetics (PGx) testing results to provider and participant.||||
33908462|NCT06746480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908463|NCT06747260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908464|NCT06746324|||COHORT||OTHER|||||||
33990886|NCT03526757|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Outcomes assessors are masked for subject allocation.|The subjects will be allocated to one of two groups: intervention protocol (high volume of standing Pilates exercises) or control protocol (standard sequence of Pilates exercises).|f|f|f|t
33990887|NCT05458583|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator who performed the assessment of the periodontal status was blinded to study groups. Moreover, the person performing data entry and the statistician was blinded to the study groups.||f|f|t|t
33990888|NCT03105947|RANDOMIZED|PARALLEL||OTHER||SINGLE|The primary outcome will be blood LDL-cholesterol, secondary outcomes, lipid profile which will be measured in a biochemistry lab by individuals who have no knowledge of the allocation to intervention arms.|Randomized trial of different dietary fats|f|f|f|t
33990889|NCT03814993|||COHORT||PROSPECTIVE|||||||
33990890|NCT05619068|||COHORT||PROSPECTIVE|||||||
33990891|NCT04252001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33990892|NCT01499602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687459|NCT06520540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687460|NCT05762770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687461|NCT04572516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687462|NCT05942209|||CASE_CONTROL||PROSPECTIVE|||||||
33990893|NCT04503603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990894|NCT00345696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990895|NCT00281749|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33990896|NCT06562478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33990897|NCT04721834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"During treatment for the placebo arm, a sham probe will be used which will produce a noise mimicking active treatment.~Subjects would be blinded from randomization, treatment, until the end of follow-up."||t|f|f|f
33990898|NCT06411847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33990899|NCT01094054|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33990900|NCT01466166|||CASE_ONLY||PROSPECTIVE|||||||
33990901|NCT06524219|||COHORT||PROSPECTIVE|||||||
33990902|NCT04793607|||COHORT||PROSPECTIVE|||||||
33687463|NCT05769127|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33687464|NCT06148389|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33687465|NCT00277641|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33687466|NCT06012643|||OTHER||RETROSPECTIVE|||||||
33687467|NCT00844168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990903|NCT00640562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990904|NCT06242028|||CASE_CONTROL||PROSPECTIVE|||||||
33990905|NCT01470560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083820|NCT00096213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083821|NCT02452047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083822|NCT04960787|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34083823|NCT04758455|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34083824|NCT02133508|||CASE_ONLY||OTHER|||||||
34083825|NCT02896348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908465|NCT06746818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The Heart Math Institute has been researching the relationship between the heart, brain, and body and its association to personal well-being and optimal functioning. Based on extensive research, the institute has developed a program that teaches participants the science behind and techniques designed to reduce the negative effects of stress and increase resilience (HeartMath Institute, 2020). The HeartMath intervention was conducted after the researcher successfully completed 13 hours (over two months) training of professional development in The Resilience Heart TM: Trauma- Sensitive HeartMath Course from HeartMath Institute."|f|f|t|f
34083826|NCT01525797|||CASE_ONLY||PROSPECTIVE|||||||
34083827|NCT03555552|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083828|NCT00150696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34083829|NCT06390098|NA|SEQUENTIAL||TREATMENT||NONE||||||
33687468|NCT02300727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908466|NCT05781360|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908467|NCT04656340|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33908468|NCT05208814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908469|NCT06747754|||COHORT||PROSPECTIVE|||||||
34083830|NCT06502548|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083831|NCT01244867|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687469|NCT00876603|||COHORT||PROSPECTIVE|||||||
33687470|NCT01856283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908470|NCT04917809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990906|NCT03787758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990907|NCT00096291|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33990908|NCT02554890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33990909|NCT02656186|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990910|NCT01777711|RANDOMIZED|PARALLEL||TREATMENT||||||||
33990911|NCT03532035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990912|NCT04932447|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a randomized double-blinded clinical trial.|Participants will be randomly allocated using a 1:1 ratio to A) High-Intensity Training Group (75 % maximal inspiratory pressure) or B)Low-Intensity Training Group (15% maximal inspiratory pressure)|t|f|t|f
34083832|NCT01880606|||CASE_ONLY||PROSPECTIVE|||||||
34083833|NCT04513795|||COHORT||PROSPECTIVE|||||||
34083834|NCT05673395|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|double blind (participants, investigator)|The participants were randomly divided into two groups (n = 12) according to the sequence of random numbers obtained through an online number generator. After the first clinical trial, A wash-out period of one week was applied to prevent carry-over before crossing over, and the second clinical trial was performed.|t|f|t|f
33687471|NCT01631955|||CASE_ONLY||PROSPECTIVE|||||||
33687472|NCT06345664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33687473|NCT00459979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687474|NCT03007108|NA|SINGLE_GROUP||OTHER||NONE||||||
33687475|NCT01251146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687476|NCT05783882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687477|NCT05489588|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, multicenter, non-randomized, single-arm study.||||
33687478|NCT03891160|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687479|NCT04761627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators, study personnel (with the exception of the Data Monitoring Committee (DMC), and unblinded Parexel staff supporting DMC activities and randomization list activities) and the study participants will remain blinded to treatment allocation. ABP 654 and ustekinumab will be coded and labeled in a manner that protects blinding.||t|f|t|f
33687480|NCT04432220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687481|NCT00846170|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33687482|NCT05583669|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33687483|NCT05685628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687484|NCT02933203|||COHORT||PROSPECTIVE|||||||
33687485|NCT05451342|||CASE_CONTROL||PROSPECTIVE|||||||
33687486|NCT03238846|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A prospective, parallel, cluster randomized noninferiority trial with three study arms will be conducted. In this study, a health facility is a cluster or site. Study sites were purposively selected from Chitungwiza Municipality, Masvingo Provincial districts, Matebeleland South Provincial districts, and Mberengwa district where USAID partners are currently implementing CARGs. Thirty clusters were selected and randomized in two strata per geographic location (urban and rural) to the three study arms. Outcomes will be assessed after 12 and 24 months,||||
33687487|NCT01772095|||||PROSPECTIVE|||||||
33687488|NCT01897376|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33687489|NCT06288789|NA|SINGLE_GROUP||OTHER||NONE||||||
33687490|NCT04447872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687491|NCT00005934||||TREATMENT||||||||
33687492|NCT01909531|||CASE_ONLY||PROSPECTIVE|||||||
33687493|NCT06516601|||COHORT||RETROSPECTIVE|||||||
33687494|NCT05405127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687495|NCT06322290|||COHORT||PROSPECTIVE|||||||
33777031|NCT03897166|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687496|NCT05242861|||COHORT||RETROSPECTIVE|||||||
33777032|NCT00658697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777033|NCT01861782|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33777034|NCT03937050|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777035|NCT01305356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777036|NCT00305760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777037|NCT03062150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||randomized double-blind placebo-controlled parallel group design|t|t|t|t
33777038|NCT05520190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777039|NCT03268486|||CASE_ONLY||PROSPECTIVE|||||||
33687497|NCT06202651|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A single interventional group of Granular Corneal Dystrophy participants over the age of 18 years that undergo a single Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser treatment.||||
33687498|NCT05172076|||COHORT||PROSPECTIVE|||||||
33687499|NCT00847171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687500|NCT05214378|NA|SINGLE_GROUP||TREATMENT||NONE||Testing alternative stimulation patter in a set of individuals who are already implanted with device. Study participants will act as their own controls comparing outcomes with and without the intervention.||||
33687501|NCT02885168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687502|NCT00482352|||COHORT||PROSPECTIVE|||||||
33687503|NCT03828370|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The B-SMART mobile web app will be evaluated in a randomized pretest-posttest controlled design. First-time DWI offenders and their CFMs will be randomized together to the intervention (B-SMART) or a usual and customary (UC) IID information condition comparison group (n=150) following baseline assessment.|t|t|f|f
33687504|NCT06066801|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687505|NCT04179890|||COHORT||RETROSPECTIVE|||||||
33687506|NCT03625271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Subject will be blinded as to study arm assignment and will provide the primary outcome measure.|Blinded participants will be randomized into a control or experimental group and receive a quantitative electroencephalogram (QEEG). Experimental group clinicians will use the PEER Interactive Report in the medication prescription process. Control group clinicians will not receive an Outcome Report. For the experimental group the clinician is expected to incorporate the guidance of the subject's PEER Outcome Report. Study staff will note the basis for all medication decisions in the subject's treatment/study file. Two evaluations are being made in this study. 1. Clinical utility of PEER Interactive where the health outcome of the experimental group will be compared to the outcomes of the control group. 2. Validation of the PEER Interactive outcomes database which is intended to measure post-hoc the health outcomes of participants where the research staff's pharmacotherapy decisions agreed with the output of PEER Interactive.|t|f|f|t
33687507|NCT02663687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687508|NCT00337350|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33687509|NCT02097927|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33687510|NCT05179551|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Cohort Study||||
33687511|NCT03465423|||CASE_CONTROL||PROSPECTIVE|||||||
33777040|NCT05313685|||COHORT||PROSPECTIVE|||||||
33777041|NCT01651403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777042|NCT01170975|RANDOMIZED|CROSSOVER||||NONE||||||
33777043|NCT05485974|NA|SEQUENTIAL||TREATMENT||NONE||3+3 Dose Escalation Design with Expansion||||
33777044|NCT02471508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908471|NCT06746467|||OTHER||CROSS_SECTIONAL|||||||
33908472|NCT04170062|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Order of treatments tested will be randomized and only known to the person administering the study.||t|f|t|t
33908473|NCT01224691|||COHORT||CROSS_SECTIONAL|||||||
33908474|NCT04599569|||COHORT||PROSPECTIVE|||||||
33908475|NCT03759379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908476|NCT03687359|||COHORT||PROSPECTIVE|||||||
33908477|NCT06746246|||COHORT||PROSPECTIVE|||||||
33908478|NCT05142345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083835|NCT04163874|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This study will be a double-blinded study, where the participants and researchers will be blinded to the study drugs. Participants will wear two pumps for all interventions, one for insulin and the other for pramlintide/placebo (saline solution).|"This is a three-way, randomized, blinded, crossover trial to compare the following strategies:~(i) Fiasp-plus-Pramlintide closed-loop delivery with a simple meal announcement (pressing a button, no carbohydrate counting) (ii) Fiasp-plus-placebo closed-loop delivery with conventional carbohydrate counting (iii) Fiasp-plus-placebo closed-loop delivery with a simple meal announcement"|t|t|t|f
34083836|NCT05406323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34083837|NCT05670444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||multicenter, randomized , placebo-controlled trial|t|t|t|t
33687512|NCT02987660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777045|NCT01394328|||COHORT||PROSPECTIVE|||||||
33777046|NCT05810675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded for the group of participants|"The intervention group (the telehealth group) will also receive a 16-week telehealth intervention with guidance, digital learning platform, teaching parents to learn intervention skills to improve children's attention and play ability, social communication, cognition, perceptual movement, and improve parents' management of children's behavior problems.~The comparison group (telephone group) will receive 16-weeks of care and child development counseling through phone calls."|f|f|f|t
33777047|NCT05205993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777048|NCT00959504|||CASE_ONLY||RETROSPECTIVE|||||||
33777049|NCT04814342|||CASE_ONLY||PROSPECTIVE|||||||
33777050|NCT00563992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777051|NCT05746520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777052|NCT00923039|||COHORT||RETROSPECTIVE|||||||
33777053|NCT05090982|||CASE_ONLY||PROSPECTIVE|||||||
33777054|NCT02230579|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33777055|NCT03795805|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Clinical Trial|t|f|f|t
33777056|NCT00311155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908479|NCT06746233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990913|NCT01105039|||COHORT||PROSPECTIVE|||||||
33990914|NCT05146336|||COHORT||PROSPECTIVE|||||||
33990915|NCT02505347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083838|NCT01764412|||COHORT||PROSPECTIVE|||||||
33687513|NCT03804034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Human dental pulp was obtained from 40 freshly extracted maxillary and mandibular premolars with orthodontic indication from 20 healthy patients, both male and female, aged between 18 and 30 yearsThe premolars were randomly distributed into four groups, namely a group without occlusal trauma and orthodontic force chosen as the control group and three experimental groups, i.e., one occlusal trauma group experimentally induced by occlusal interferences, one moderate orthodontic force group, and one occlusal trauma plus moderate orthodontic force group.||||
33687514|NCT00058539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687515|NCT01810965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687516|NCT05244980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia|t|t|t|t
33687517|NCT03709329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcome assessors were blinded to types of treatment the patients received until the end of the study.|"Single blinded Randomized controlled study design is divided into two groups: robot-assisted walking group and conventional walking group. The random assignment is performed by Stratified Permuted Block Randomization to match Sex and Age between the two groups, and the subject is assigned using a randomly generated table before the start of the study so that the evaluator can not know what kind of treatment the subject is receiving.~Both groups undergo unassisted overground walking condition before and after treatment and after 6 weeks of treatment.~Plain gait condition at the time of evaluation: When walking, several 8-meter-long plazas are walked several times to induce a natural walk, and three natural gait cycles are selected."|f|f|t|t
33687518|NCT03825471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908480|NCT06746649|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the time-specificity of the training design there is no possibility to mask the subject distribution.|"In total, 34 previously untrained elderly subjects of both sexes, age range 65 - 80-year-old, will be recruited according to inclusion and exclusion criteria and will undergo the intervention.~The subject will be randomly assigned to the three groups:~a morning training group (n=14, 5 men, 9 women) an afternoon training group (n=14, 5 men, 9women) a control group (n=6, 6 women) Both men and women will be included to address the potential differences between sexes and to increase the clinical and practical relevance, since women make up more than 50 percent of clients visiting the Centre of Active Aging.~The duration of the training intervention is 12 weeks with the frequency 2 times per week.~The relative volume and intensity of the training for both training groups will be identical, except for timing of the training. The morning group and afternoon group will exercise exclusively between 08:00 - 09:00 h and 16:00 - 17:00 h, respectively."||||
33908481|NCT05377489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908482|NCT06747858|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple ascending dose||||
33908483|NCT06747806|||COHORT||PROSPECTIVE|||||||
33908484|NCT05041309|||COHORT||PROSPECTIVE|||||||
33908485|NCT05349838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990916|NCT06025279|||CASE_ONLY||PROSPECTIVE|||||||
33990917|NCT06464315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a prospective, single-blinded, randomized controlled trial comparing an experimental strategy of functional substrate mapping/ablation only without VT induction compared to standard VT mapping/ablation. The study subjects will be blinded to the randomization. The care providers doing the procedure (and/or investigators doing the procedure) cannot be blinded by nature of the intervention (either perform experimental mapping protocol or not).|Randomized controlled trial|t|f|t|t
33990918|NCT02963259|||COHORT||PROSPECTIVE|||||||
33990919|NCT01631331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990920|NCT06027528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083839|NCT06518252|||COHORT||PROSPECTIVE|||||||
34083840|NCT04344717|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Interventional, non-randomized, open label, monocentric controlled study||||
34083841|NCT06227169|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33908486|NCT06747832|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, single-arm clinical study.||||
33990921|NCT03642808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33990922|NCT03158467|||COHORT||PROSPECTIVE|||||||
33990923|NCT03597256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990924|NCT03341182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"1. The subjects were randomly assigned to normal method group (group A) and mirror use group (group B), and the assigned results are unknown.~2. The Outcomes Assessor is not related to the study, and does not know its contents."|normal method group (group A) mirror use group (group B)|t|f|t|f
33990925|NCT03437265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990926|NCT01442753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990927|NCT01069536|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33990928|NCT06279039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990929|NCT02838160|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34083842|NCT02404571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083843|NCT05771467|||CASE_CONTROL||PROSPECTIVE|||||||
34083844|NCT01207843|||||RETROSPECTIVE|||||||
34083845|NCT03980067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34083846|NCT01917643|||COHORT||RETROSPECTIVE|||||||
34083847|NCT04873726|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34083848|NCT00834041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083849|NCT04306523|||OTHER||PROSPECTIVE|||||||
34083850|NCT01465672|||COHORT||PROSPECTIVE|||||||
34083851|NCT04032132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083852|NCT00288912|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34083853|NCT04574518|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|Participants will not be informed that the intervention is being implemented in a randomized fashion, but they cannot be blinded to the interventions (letter and IVR) they will receive.|The investigators will use a stepped wedge cluster design to randomize at the clinic level (including both community-based outpatient clinics and the main medical center) at each of the 3 sites. The investigators will first institute Enhanced Usual Care for 6 months at each CBOC/medical center. Using a random number generator, the investigators will divide the CBOCs/medical center in the 3 facilities in 4 steps. The investigators will randomize one CBOC at each site to the intervention (interactive voice response quit line) in the first step. For steps 2-4, the investigators will randomize one third of the remaining CBOCs at each facility per step every 6 months.||||
33990930|NCT06283147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All data collection will be performed by trained research assistants blinded to the allocation status of the patients, and statistician will analyse data without referring to allocation information.|The study is a 52-week, two-arm, parallel, doubled-blinded randomized clinical trial, evaluating the clinical efficacy of RAMP-Knee OA (N=114) versus usual care (N=114) on self-reported knee pain and other secondary outcomes.|f|f|f|t
34083854|NCT03587233|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33990931|NCT03776058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990932|NCT03853005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990933|NCT04550702|||COHORT||RETROSPECTIVE|||||||
33990934|NCT02969616|||COHORT||PROSPECTIVE|||||||
33990935|NCT01686438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990936|NCT02184845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990937|NCT01972490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990938|NCT01863745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990939|NCT01526174|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990940|NCT04201353|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Facility staff will not be blinded to intervention assignment. However, all other research staff will be blinded to intervention assignment. In addition, participants will not be told during the consent process that as part of the study there are intervention and control clinics. The rationale for this is to prevent patients transferring from intervention to control clinics if they find out that there are some clinics offering cash transfers to new ART clients. Large numbers of transferring patients will compromise the integrity of the study and will create an undue burden for facility staff at intervention clinics.|2-arm cluster randomized control trial, with HIV primary care clinic as the unit of randomization|t|f|t|t
33990941|NCT04294303|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33990942|NCT01138891|||COHORT||RETROSPECTIVE|||||||
33990943|NCT06380816|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33990944|NCT03256695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990945|NCT04226248|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|A Phase III Randomised Controlled Trial of Rivastigmine versus Placebo|t|t|t|t
33990946|NCT04454229|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Direct oral challenge in patients with PEN-Fast less than 3~Eligible patients referred to the outpatient clinic reporting a penicillin allergy will be identified and assessed with a standard clinical history and the calculation of the PEN-FAST score. PEN-FAST is a three-point clinical assessment tool recently externally validated in a multicenter study, with a PEN-FAST score of \< 3 associated with 96.7% negative predictive value.~Intervention:~The patient will receive a single dose of oral penicillin, following baseline vital signs (i.e. temperature, heart rate, blood pressure, respiratory rate, skin check).~Nursing staff will repeat vital signs as needed and after oral challenge while observing for signs of an immune mediated adverse reaction.~If at any stage an antibiotic associated adverse event is noted, standard of care treatment is offered by the attending clinicians (ex. adrenalin for immediate hypersensitivity reaction)."||||
33990947|NCT05287763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990948|NCT03463226|||COHORT||PROSPECTIVE|||||||
33990949|NCT01109290|||COHORT||PROSPECTIVE|||||||
33990950|NCT00003470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990951|NCT03887910|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Principal Investigator, Co-Investigator and Outcomes Assessors are Masked||f|f|t|t
33990952|NCT00004796||||TREATMENT||||||||
34083855|NCT03946423|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083856|NCT03496389|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33908487|NCT04164472|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33990953|NCT03372187|NA|SINGLE_GROUP||OTHER||NONE||All 20 participants will be placed into the intervention group.||||
33990954|NCT02364713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908488|NCT06284408|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Systems-level intervention which using a mixed study design including stepped-wedge with a cluster randomized arm within the stepped-wedge. The implementation and evaluation of the CSU will be accomplished using cluster randomization to select 24 sites to be phased-into the CSU intervention according to a stepped-wedge design. Randomization will take place at the clinic level. The clinic clusters will be brought 'online' in a graded manner over the study period. 24 of the 35 NYC RING sites will be selected to enter the experimental (CSU) condition in three waves: Month 6, Month 12, or Month 18 after the start of the study. The remaining 11 sites will receive CSU support after completion of the third randomized group of clinics||||
33908489|NCT05360329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908490|NCT05964413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908491|NCT06276023|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||MASC is an intervention that includes evidence-based skills of: 1) mindfulness; 2) compassion toward others and self; 3) behavioral management skills. MASC comprises 6 sessions delivered in a group format over secure live video with Zoom. Each session includes psychoeducation on program skills, skill practice, strategies to incorporate the skill into the caregiver experience, and strategies for sustained practice.|t|f|f|f
33908492|NCT06746727|NA|SINGLE_GROUP||TREATMENT||NONE||This single-arm intervention will pilot a new, manualized intervention adapted from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use. ACT for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) aims to assist Veterans in developing skills central to psychological flexibility (e.g., acceptance, mindfulness, commitment to values-based action) to improve their relationship functioning and decrease IPV use in the presence of PTSD symptoms (e.g., anger, irritability, detachment from others) and alcohol use issues (e.g., cravings, triggers, disconnection from valued roles).||||
33908493|NCT06746389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double Blind RCT|t|f|t|t
33687519|NCT05628961|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908494|NCT04789044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will enroll 40 patients receiving autograft reconstruction within 24 hours of injury. Patients within each group will be randomized to either PEG mediated reconstruction (n=20); or conventional nerve reconstruction (n=20).|t|f|f|f
33908495|NCT06747585|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908496|NCT06746883|||CASE_ONLY||PROSPECTIVE|||||||
33908497|NCT06745973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687520|NCT06110520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized into one of three study groups. The patient, their caregiver, and the investigator will be masked to their treatment group. The study coordinator will organize the patients study treatment and assist in any issues that arise to keep both the patient and investigator masked at all times.|"Three single groups:~1. Violet + / Lens + Lamp emits violet light and subjects are either wearing no refractive correction or wearing CR-39 lenses that completely transmit violet light.~2. Violet + / Lens - Lamp emits violet light and subjects are wearing violet-filtering glasses that block out violet light from reaching their eyes.~3. Violet - / Lens - Lamp does not violet light and subjects are wearing CR-39 lenses that completely transmit violet light."|t|t|t|f
33687521|NCT03931343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
33687522|NCT01574079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33687523|NCT03009370|||COHORT||CROSS_SECTIONAL|||||||
33687524|NCT05695664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33687525|NCT04725929|||CASE_CONTROL||PROSPECTIVE|||||||
33687526|NCT04187079|||COHORT||PROSPECTIVE|||||||
33687527|NCT02865343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators and technicians helping for performing the test and encouraging the patient will be blind. Only one investigator will monitor the ventilation during the test and won't be blind but won't be participating to any encouragement or data acquisition.||t|t|t|t
33687528|NCT06349070|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study is a hybrid type III implementation-effectiveness trial using a longitudinal cluster-randomized trial with a modified stepped wedge design. In Year 1, all 10 clinics start with the low touch strategy, followed by randomization of clinics in Year 2 to either low touch (5 clinics) or high touch (5 clinics), and finally in Year 3, all 10 clinics will transition to the high touch strategy. Starting in Year 2, we will enroll a subsample of subjects into the a prospective cohort of pregnant persons who will participate in surveys at baseline and postpartum.||||
33687529|NCT02863601|||COHORT||PROSPECTIVE|||||||
33687530|NCT01687036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687531|NCT00814801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33908498|NCT06747065|||COHORT||RETROSPECTIVE|||||||
33990955|NCT03987984|||CASE_ONLY||CROSS_SECTIONAL|||||||
34083857|NCT04692987|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Investigators will designate participants to which arm using random sampling. Participants and care providers are masked to which arm they receive.|Parallel randomized controlled trial will be conducted in 3 months duration, with intention-to-treat.|t|t|f|f
33990956|NCT04343196|RANDOMIZED|PARALLEL||OTHER||NONE||All enrolled participants will undergo a diagnostic lower limb angiography, but the image acquisition protocol will be different. In the active comparator group a normal radiation dose will be used and the DSA images will be used for diagnosis whereas in the experimental group a low dose radiation will be applied (70% decrease compared tot he DSA protocol) and the DVA images will be used for diagnosis.||||
33990957|NCT06555913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990958|NCT01019421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990959|NCT03998150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33990960|NCT06103058|||OTHER||CROSS_SECTIONAL|||||||
34083858|NCT00549393|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34083859|NCT00572832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083860|NCT05185804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, prospective, open-label clinical trial||||
34083861|NCT00656526|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33687532|NCT06171490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a partially blinded study. The Investigator and subjects will be blinded to the randomized sequence and to the variants of the investigational product (IP). In contrast, the pharmacy staff will not be blinded to the randomized sequence and to the variants of the IP.|The study will be conducted with 4 periods and 4 sequences in a Williams design (crossover).|t|f|t|f
33687533|NCT00170924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687534|NCT05925218|||COHORT||PROSPECTIVE|||||||
33687535|NCT05155462|||COHORT||PROSPECTIVE|||||||
33687536|NCT01949285|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33687537|NCT00796354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687538|NCT01631656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687539|NCT00006487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687540|NCT04025281|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||To provide a sound basis for the statistical comparison of outcome measures for treatment assignments, participants will be randomized to 1 of 2 sequence permutations of extra virgin olive oil enriched meal and refined olive oil enriched meal. Each permutation will include a first treatment assignment, followed by a 1-week washout phase, and followed by a second treatment assignment.|t|f|t|t
33777057|NCT04598880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assignment of each treatment will be displayed at the time of patient enrollment and will be open to the participant and the physician. The investigator who performs the colonoscopy and assesses the primary outcome (digestive endoscopist) is blinded.|Subjects will be randomly assigned to 1 of 2 treatment groups with a 1:1 allocation using block sizes of 6 cases in each center.|f|f|f|t
33777058|NCT04252703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33777059|NCT02075983|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777060|NCT01470378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777061|NCT03548311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blinded randomized controlled|t|t|t|t
33802098|NCT03315481|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|"The volunteers are randomized using sealed opaque envelopes with a 1:1 ratio. The randomization defines which leg to be used for insertion of a catheter in the long-axis plane and which leg to be used for insertion in the short-axis plane of the adductor canal. Furthermore the randomization defines whether dislocation is executed in the direction of the entry or exit site. The envelopes are prepared by health personnel with no relation to the study and are based on a computer-generated randomization list.~Investigator 2, evaluating loss of sensation to cold, will be blinded to insertion technique and direction of dislocation as well as assessments of spread within the adductor canal. Investigators 3+4 are blinded with regard to direction of dislocation, each other's assessment of spread and to assessments from investigator 1+2. They will be unblinded with regard to insertion technique when they perform US scans"|This is a randomized clinical trial in healthy volunteers. 12 volunteers will have suture-method catheters placed in the adductor canal of each leg using the long-axis plane and short-axis plane technique|t|f|t|t
33908499|NCT06746376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will be blinded to the patient's allocation||f|f|f|t
33908500|NCT06747624|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33908501|NCT06746831|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blind crossover study design.|t|f|f|t
33908502|NCT06747494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908503|NCT06747845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908504|NCT06747273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908505|NCT06747325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908506|NCT06747247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Part A (SAD Study): 5 dose levels are selected for SAD study, placebo-controlled Part B (MAD Study): 3 dose levels are selected for MAD study, placebo-controlled, treatment duration is 2w, 4w and 4w respectively.~Part C (Single-arm Study): 1 dose level (with strating dose and titration period) is selected for the single arm study, the treatment duration is 52w."|t|t|t|t
33908507|NCT06126276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908508|NCT06746012|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33908509|NCT06746454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization was gender specific. Female participants were randomized to the verbal training group with combined attentional focus instruction (VFIT) and the visual training group with video instruction (VGE) by asking them to draw a paper from a black bag filled with papers with the names of both groups. For male participants, randomization was performed with a different black bag with the same characteristics.|Rrandomized, single-blind, prospective study|f|f|f|t
33908510|NCT01445288|||COHORT||PROSPECTIVE|||||||
33908511|NCT04006613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908512|NCT06226571|NA|SEQUENTIAL||TREATMENT||NONE||||||
33908513|NCT06237452|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33908514|NCT03723551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908515|NCT06214819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908516|NCT06132256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908517|NCT06746428|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will either be randomized to the Immediate Start Group or to the Delayed Start Group.~Participants in the:~* Immediate Start Group: Sessions with the exercise coach will start during the first week of participants' radiation therapy, concurrently with radiation treatment and continue post-radiation.~* Delayed Start Group: Sessions with the exercise coach will start 6-8 weeks after participants have completed radiation and continue 16-19 weeks post-radiation."||||
33908518|NCT06746688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||open-label, dose-escalating||||
34083862|NCT00597818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083863|NCT00853294|RANDOMIZED|CROSSOVER||||NONE||||||
33990961|NCT06561568|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. KInesio taping along with conventional physical therapy will be applied in one group and the second will receive conventional physical therapy only. Both groups will be recruited concurrently.||||
33990962|NCT03911258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777062|NCT03787290|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|The randomization list maintained by the Research Pharmacy will contain the treatment assignment, along with a letter code (A or B) corresponding to the two treatment groups. During the study period and continuing until the major hypotheses have been tested and reported, the correspondence of letter-coded treatment assignment to actual treatment (tocilizumab or placebo) will be known only by pharmacy staff. The study principal investigator (PI), study coordinators, clinicians conducting outcome assessments, and study statistician, as well as research assistants interacting with patients or entering study data and laboratory technicians performing/reporting biomarker assays, will have no access to any subject's treatment assignment. Only after the study statistician has completed and reported analyses by coded treatment assignment for the study aims articulated in this protocol will the correspondence between letter codes and actual treatment be revealed to study personnel.|Randomization will be conducted by randomly permuted blocks of 4. The randomization schedule will be created by a statistician who has no other role in the study data collection or analysis. The randomization schedule will be sent directly from the statistician to the Research Pharmacy which will maintain the list. Qualifying study subjects will be assigned the next sequential treatment assignment on the randomization schedule, in the order they are randomized. Participants will be randomized on a 1-to-1 allocation to one of two study arms: 1) tocilizumab followed by whole body hyperthermia (WBH); or 2) placebo followed by whole body hyperthermia (WBH). At the time of randomization, the study coordinator will contact the Research Pharmacy to complete the coded treatment assignment described below.|t|t|t|t
33777063|NCT03847636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized pilot study of highly selected patients||||
33777064|NCT01096732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777065|NCT05822297|NA|SINGLE_GROUP||TREATMENT||NONE||A single case experimental design (SCED) with sequential multiple baseline time series and a single-armed prospective study design, with a random duration of the baseline phase ranging from 3 to 6 weeks, an intervention phase of 12 weeks, and a 12 week period without measurements, followed by a follow-up phase of 3 weeks; in addition to a single-armed prospective study design.||||
33990963|NCT03070119|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34083864|NCT03265795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083865|NCT03738930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777066|NCT03374345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777067|NCT03840837|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All participants perform a baseline assessment (arm 1 - cross-sectional). A subgroup of participants (based on physician and participant choice) proceed to a 12-week treatment phase with the study drug (transdermal rivastigmine) and subsequent follow-up assessment (arm 2 - longitudinal).||||
33777068|NCT02617420|||CASE_CONTROL||PROSPECTIVE|||||||
33777069|NCT04468243|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33777070|NCT06480669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777071|NCT02718417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777072|NCT05205486|NA|SINGLE_GROUP||PREVENTION||NONE|This is an open-label, non-randomized pharmacokinetic study. All subjects will be receiving the same study treatment, thus masking is unnecessary.|This is an open-label, non-randomized pharmacokinetic study. All subjects will be receiving the same study treatment, thus blinding is unnecessary.||||
33777073|NCT03886675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to treatment allocation. Assessment of TCD embolic data, DW-MRI scan reporting and neurological and neurocognitive assessment will be carried out by blinded trained assessors.|1:1 randomisation|t|f|f|t
33777074|NCT01705470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777075|NCT03127592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777076|NCT01458249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777077|NCT00525694|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33990964|NCT01185392|||COHORT||CROSS_SECTIONAL|||||||
33990965|NCT00272519|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33990966|NCT02836821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990967|NCT03353896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990968|NCT02895373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990969|NCT04644653|||OTHER||PROSPECTIVE|||||||
34083866|NCT00595361|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33990970|NCT05264363|NA|SINGLE_GROUP||OTHER||NONE||A prospective, interventional, single-arm, monocentric, investigation in a cohort of adult healthy subjects comprising a screening visit and a single study visit.||||
33908519|NCT05374395|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Primary outcomes will come from the clinics' chart data. Individuals pulling data from charts will be blind to study condition.|A stepped-wedge cluster randomized design will include five blocks of two clinics randomized to the timing of the Peer recovery support-delivered Dropout Prevention enhancement, with each clinic having two phases: a longitudinal Usual Services (US) Phase and a longitudinal Usual Services + Peer recovery support-delivered Dropout Prevention (PDP) enhancement Phase. All clusters will have a baseline phase and will be randomized to the timing of the PDP phase. Once randomized to begin, all clusters will have a 24-month US+PDP Phase.|f|f|f|t
33908520|NCT06746181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908521|NCT06747416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908522|NCT06747962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33990971|NCT06039735|||COHORT||PROSPECTIVE|||||||
33990972|NCT04820309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687541|NCT00042692|||NATURAL_HISTORY||OTHER|||||||
33990973|NCT02477787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990974|NCT06524921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"PICO:~Population:~Children with vital deeply carious primary molars with irreversible pulpitis~Intervention:~Pulpotomy using Biodentine in carious primary molars with irreversible pulpitis.~Comparator/Control:~Parial pulpectomy using Calcium Hydroxide with Iodoform ( Metapex ) in carious primary molars with irreversible pulpitis.~Outcomes:~Primary outcome, The presence of any adverse radiographic findings (Periodontal membrane space widening, periapical radiolucency, bone resorption, or other pathological changes)"|t|f|f|f
33990975|NCT06124638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990976|NCT01015625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33990977|NCT05674734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990978|NCT01142635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687542|NCT00848003|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687543|NCT00609362|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33687544|NCT04270903|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33687545|NCT02963961|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33687546|NCT00621803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687547|NCT02911207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33687548|NCT02748603|||COHORT||RETROSPECTIVE|||||||
33687549|NCT01145911|||COHORT||PROSPECTIVE|||||||
33687550|NCT05262959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687551|NCT04562753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687552|NCT00016900||||TREATMENT||||||||
33687553|NCT03312751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687554|NCT04632914|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|trunk stabilizing exercises and cardiac rehabilitation program||||
33687555|NCT05160610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687556|NCT02388282|||CASE_ONLY||PROSPECTIVE|||||||
33687557|NCT04620707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687558|NCT00706069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33990979|NCT06561607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990980|NCT04435067|||COHORT||RETROSPECTIVE|||||||
33990981|NCT01384591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687559|NCT02345746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687560|NCT02414139|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687561|NCT01992159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687562|NCT06108986|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33687563|NCT02906488|||COHORT||PROSPECTIVE|||||||
33687564|NCT04417426|||COHORT||PROSPECTIVE|||||||
33990982|NCT01798719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990983|NCT01810419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33990984|NCT02120677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33990985|NCT04328935|NA|SINGLE_GROUP||TREATMENT||NONE||Within-group design. Repeated measurements||||
33990986|NCT00309881||||TREATMENT||||||||
33990987|NCT02921893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990988|NCT03682601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded|Randomized, Double Blinded, Placebo Controlled|t|t|t|t
33990989|NCT05976815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33990990|NCT02374385|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33990991|NCT00543205||PARALLEL||TREATMENT||NONE||||||
33990992|NCT02622386|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33687565|NCT03963375|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All patients will receive cladribine treatment per standard of care. Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures (LP) according to 1 of the 4 following schedules: Group 1: Baseline and end of Week 5; Group 2: Baseline and end of Week 10; Group 3: Baseline and end of Year 1; Group 4: Baseline and end of Year 2 . Patients in Groups 1-3 will have the option to undergo a third LP at the end of Year 2.||||
33687566|NCT02378025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687567|NCT04692740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687568|NCT01823510|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33687569|NCT05352776|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33687570|NCT00973570|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687571|NCT05181930|||COHORT||PROSPECTIVE|||||||
33687572|NCT01721577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687573|NCT06313021|||COHORT||CROSS_SECTIONAL|||||||
33777078|NCT02622139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777079|NCT00821379|||COHORT||PROSPECTIVE|||||||
33777080|NCT05226845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33777081|NCT01148043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33990993|NCT04421716|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Cohort 1 and 2 will receive either UA or CURC and Cohort 3 will receive a combination of UA and CURC. Subjects initially enrolled in Cohorts 1 and 2 may have the option to continue in Cohort 3.||||
33687574|NCT05509946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization performed by simple random sampling, the result is latern given to investigator in an envelope containing codes made by third party outside the research. Investigator and the patient do not know the allocation code|"There are 3 separate groups defined by randomization:~1. single dose of combined celecoxib 400 mg and pregabalin 150 mg an hour before surgery~2. repeated dose of combined celexocib 200 mg twice a day and pregabalin 75 mg twice a day, administered 3 days before surgery~3. placebo administered an hour before surgery"|t|t|t|f
33687575|NCT03523000|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The drugs will be delivered by the pharmacy to a blinded physician and labeled as Intrathecal solution 1 and Intrathecal solution 2 to be administered sequentially, separated by a 4-6-hr infusion of preservative-free saline. The content of Intrathecal solution 1 and 2 will be unknown to all investigators and participants in the study with the exception of the investigational pharmacy. The order of the Intrathecal solution (1 or 2) will be determined by pharmacy using a computer generated random sequence allocation.|"Patients who are considered candidates for intrathecal pump implant fulfilling the inclusion/exclusion criteria and who elect to participate in the study will be randomly assigned to two groups:~Group A tested with continuous infusion of intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml for 14-18 hours followed by a trial with normal saline for another 14-18 hours; separated by a 4-6-hr infusion of preservative-free saline.~Group B tested with intrathecal normal saline for 14-18 hours followed by intrathecal Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml for another 14-18 hours; separated by a 4-6-hr infusion of preservative-free saline."|t|t|t|f
33687576|NCT00907062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687577|NCT01888887|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33687578|NCT05978466|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687579|NCT02609997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687580|NCT03409042|||COHORT||PROSPECTIVE|||||||
33687581|NCT01818960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687582|NCT04140136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687583|NCT03489421|||CASE_CONTROL||OTHER|||||||
33687584|NCT00006157|RANDOMIZED|||TREATMENT||DOUBLE||||||
33687585|NCT05380999|||COHORT||PROSPECTIVE|||||||
33687586|NCT02037152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33687587|NCT04375475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33687588|NCT01639508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687589|NCT00266851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||2 arms are randomized, placebo-controlled, double-blinded, 1 arm was added as an open-label observational cohort|t|t|t|t
33687590|NCT01843478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687591|NCT04767308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687592|NCT01214174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687593|NCT00121797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687594|NCT01110070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687595|NCT01997385|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687596|NCT02415855|||COHORT||PROSPECTIVE|||||||
33687597|NCT00470184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908523|NCT06746662|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||"Hypno-breastfeeding Education Group~A counseling program based on hypno-breastfeeding philosophy, where 4-week education content will be presented to pregnant adolescents in their 28-30th week of pregnancy and applications will be made, will be implemented with 4 sessions and 6 follow-ups. A breastfeeding education booklet (Appendix 6) will be prepared in the implementation of the counseling service. Each session will last an average of 1 hour. The training sessions will be conducted face-to-face. The average number of pregnant women in each follow-up will consist of 3-5 people. During and after the training processes, pregnant women will be provided with regular information based on hypno-breastfeeding philosophy, affirmation, relaxation techniques and meditation materials (Appendix 6) and counseling based on hypno-breastfeeding philosophy.~First follow-up (28-30th week of pregnancy - first encounter): This midwifery intervention will be performed on pregnant women in a suitable roo"|f|f|t|f
33908524|NCT06747013|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm clinical pilot study; all patients will undergo a standard ablation protocol using the study catheter (Farapoint).||||
33908525|NCT06747741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908526|NCT06746974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908527|NCT06745960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908528|NCT06747442|||COHORT||PROSPECTIVE|||||||
33908529|NCT06746766|||OTHER||PROSPECTIVE|||||||
33908530|NCT06747572|||COHORT||PROSPECTIVE|||||||
33687598|NCT03345342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687599|NCT03831685|||COHORT||PROSPECTIVE|||||||
33687600|NCT01121094|||COHORT||PROSPECTIVE|||||||
33687601|NCT02573038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687602|NCT02238171|||COHORT||PROSPECTIVE|||||||
33687603|NCT01043900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33687604|NCT03680469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687605|NCT05211687|||COHORT||CROSS_SECTIONAL|||||||
33687606|NCT01407042|||CASE_ONLY||PROSPECTIVE|||||||
33687607|NCT02923258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687608|NCT04198818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687609|NCT01594151|NA|SINGLE_GROUP||||NONE||||||
33687610|NCT01487577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687611|NCT00817284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687612|NCT04807140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687613|NCT04256889|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective case matched controlled study (not a cohort). Enrolled infants will be matched with infants in the National Medical Index based on gestational age, gender, weight and comorbidities. A two cohort, mixed regression model would be used to correlate nfant® metrics to clinical outcomes.||||
33687614|NCT01439347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687615|NCT01906047|||COHORT||PROSPECTIVE|||||||
33687616|NCT06073990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687617|NCT02798614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687618|NCT00595777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33687619|NCT00371761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908531|NCT05463003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This Study will be an open label study. Participants will be selected from an existing database of our Institute and are specifically invited according to genotype.|"This study should investigate the differences of berberine pharmacokinetic parameters in three cohorts of healthy volunteers:~Cohort 1a) OCT1 and CYP2D6 wildtype genotypes n = 10 Cohort 1b) OCT1 and CYP2D6 wildtype genotypes n = 10 Cohort 2) OCT1 deficient/CYP2D6 wildtype genotypes n = 10 Cohort 3) OCT1 wildtype/CYP2D6 deficient genotypes n = 10"||||
33908532|NCT05109234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908533|NCT06747871|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33908534|NCT06747182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908535|NCT03575013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908536|NCT05165485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908537|NCT05411484|NA|SINGLE_GROUP||TREATMENT||NONE||Self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel||||
33908538|NCT06748001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908539|NCT05663034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and outcome assessment technicians will remain blinded to treatment assignment.|Prospective two-arm, single blind randomized controlled trial|f|f|t|t
33990994|NCT01625715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990995|NCT06025110|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33990996|NCT00571935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33990997|NCT06628336|||COHORT||PROSPECTIVE|||||||
33990998|NCT06295666|||CASE_CONTROL||PROSPECTIVE|||||||
33990999|NCT03238183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991000|NCT01639911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083867|NCT02507076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083868|NCT00571675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083869|NCT06432387|||COHORT||PROSPECTIVE|||||||
34083870|NCT03139500|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34083871|NCT01958905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083872|NCT01627548|RANDOMIZED|||TREATMENT||NONE||||||
34083873|NCT06023693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083874|NCT03245749|||COHORT||CROSS_SECTIONAL|||||||
34083875|NCT05619133|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34083876|NCT06160271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991001|NCT05418647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a single blinded study as participants will be unaware about the dialysate Na each patient receives|This research is a single-blinded randomized clinical trial in which 40 haemodialysis patients will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1.|t|f|f|f
33991002|NCT06394973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33991003|NCT00759317|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33991004|NCT02489461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908540|NCT05601505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908541|NCT01931462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908542|NCT00206999|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33908543|NCT03680794|NA|SINGLE_GROUP||OTHER||NONE||||||
33908544|NCT04009174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908545|NCT03276936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908546|NCT04068558|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover trial in the Neonatal Intensive Care Unit||||
33908547|NCT03499951|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908548|NCT03097328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908549|NCT03009331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908550|NCT03502252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908551|NCT05247632|||COHORT||PROSPECTIVE|||||||
33908552|NCT03175393|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908553|NCT03762122|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a single-arm, multicenter phase II clinical trial. The trial uses a single-stage design based on a time-to-event rate to a specific time-point using Kaplan-Meier estimators.~Rogaratinib is given at a dose of 800 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.~In order to include 24 patients into the trial, it is expected that 52 patients with advanced SQCLC have to be screened for tumor FGFR mRNA overexpression. Taking into account patients who are FGFR mRNA positive but cannot be enrolled (attrition rate of 20%), it is estimated that 68 patients will have to be screened in total."||||
33908554|NCT03934593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Using cluster randomized trial design; nine churches will be randomly assigned to the FB intervention (BHT DSMS), and nine to the FP intervention (Stanford DSMP).|We will conduct a cluster randomized trial with repeated measures to compare the effectiveness of BHT DSMS intervention strategies among 360 adult diabetic congregants from 18 predominantly Hispanic churches in San Antonio, Texas (20 participants/church).|t|f|f|f
33908555|NCT03702790|||COHORT||PROSPECTIVE|||||||
33991005|NCT06574620|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33991006|NCT01717339|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991007|NCT01796171|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908556|NCT03971461|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm, multicenter, two-stage phase 2 clinical study.||||
33991008|NCT05146492|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991009|NCT02414711|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33991010|NCT01249651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687620|NCT05210764|||COHORT||PROSPECTIVE|||||||
33991011|NCT04948905|||CASE_CONTROL||RETROSPECTIVE|||||||
33991012|NCT04204395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33991013|NCT04235595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991014|NCT04234334|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Egg or Egg substitutes (whites only) will be provided to subjects and since they are similar in appearance and color, they will not know when they are consuming them|Randomized Crossover design|t|f|f|f
33687621|NCT03579654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687622|NCT04923828|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687623|NCT01249118|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34083877|NCT03183908|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Subject, study coordinators, and investigators will be blinded to the type of flu vaccine administered. Only the vaccinator will be unblinded.||t|f|t|t
33687624|NCT03583242|||CASE_ONLY||PROSPECTIVE|||||||
33687625|NCT05521529|||COHORT||PROSPECTIVE|||||||
33991015|NCT06545890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||double blinded|t|t|t|t
33687626|NCT03221075|||CASE_ONLY||PROSPECTIVE|||||||
33687627|NCT04199598|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33991016|NCT01882686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991017|NCT00682500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991018|NCT06223932|||COHORT||PROSPECTIVE|||||||
33687628|NCT03407339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991019|NCT02822235|||COHORT||PROSPECTIVE|||||||
33991020|NCT05294783|||COHORT||PROSPECTIVE|||||||
33991021|NCT01919112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators and subjects will be masked to the trail arm assignments at randomization. The investigator reviewing outcome data will also be masked to the trial assignments.|The trial will randomize subjects to anodal transcranial direct current stimulation (tDCS) versus sham stimulation, both of them carried out in combination with standardized swallowing exercises|t|t|t|t
34083878|NCT01663623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687629|NCT00719433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33687630|NCT01022723|||COHORT||PROSPECTIVE|||||||
33687631|NCT05411354|||CASE_CROSSOVER||PROSPECTIVE|||||||
33687632|NCT00955383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33687633|NCT02457585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687634|NCT03194490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687635|NCT04686487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908557|NCT03100942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908558|NCT03862079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991022|NCT04451746|NA|SINGLE_GROUP||SCREENING||NONE||||||
33991023|NCT05537129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991024|NCT03521973|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33991025|NCT00849823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991026|NCT00682461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908559|NCT05725057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Prospective, randomized, multicenter, double-blind, placebo-controlled study||t|t|t|f
33991027|NCT01462708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991028|NCT03509194|||COHORT||PROSPECTIVE|||||||
33991029|NCT05506956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991030|NCT05472311|NA|SINGLE_GROUP||TREATMENT||NONE||Using implementation science methods to evaluate the implementation of thermal ablation for treatment of pre-cancer lesions of the cervix in reproductive health clinics||||
33991031|NCT06559124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"After giving the necessary verbal and written information about the study, patients with informed consent will be randomized and divided into 3 groups of 20 people each. The randomization and treatment of the cases will be done by the same researchers. The evaluation will be carried out before and after the treatment by another researcher who is blind to which group the participants are in.~After the initial evaluations are completed, Group 1 will receive 15 sessions of traditional physiotherapy + placebo kinesiotape every day for 3 weeks. In the 2nd group, kinesiotape will be applied with traditional physiotherapy + facilitation method. In the third group, kinesiotape will be applied with traditional physiotherapy + inhibition method."|t|t|t|t
34083879|NCT00002551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083880|NCT04889040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34083881|NCT00948545|||CASE_ONLY||PROSPECTIVE|||||||
34083882|NCT03056521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the healthcare providers do not know which patient belongs to which arm||t|t|f|f
34083883|NCT05952284|||COHORT||PROSPECTIVE|||||||
34083884|NCT05063253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083885|NCT01227369|||OTHER||CROSS_SECTIONAL|||||||
33908560|NCT03025048|||COHORT||PROSPECTIVE|||||||
33908561|NCT01199263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908562|NCT01051375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908563|NCT03259334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908564|NCT03220048|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908565|NCT00210015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33908566|NCT02610556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908567|NCT00137774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908568|NCT05470036|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33908569|NCT04426123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908570|NCT00767156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33908571|NCT05636579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908572|NCT01619384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908573|NCT06368739|RANDOMIZED|PARALLEL||PREVENTION||NONE||"From the eligible population, DHP randomly selected a subset of approximately 500 women during the pilot period, from which approximately 200 were in the program, the exposed group. The women who were covered during the same period but were not selected were not exposed to the program and will compose the comparison group."||||
33908574|NCT05888935|||COHORT||RETROSPECTIVE|||||||
33908575|NCT00909142|||COHORT||PROSPECTIVE|||||||
33908576|NCT06693609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|A Phase 2a, Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Efficacy of EMP-01 in Adult Participants with Social Anxiety Disorder|t|t|t|t
33908577|NCT02344628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908578|NCT02432001|||COHORT||PROSPECTIVE|||||||
33908579|NCT03484923|RANDOMIZED|PARALLEL||TREATMENT||NONE|After approval of protocol amendment 5 (26Jun2020), a non-randomized single arm was added|||||
33908580|NCT01996774|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33908581|NCT02042404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908582|NCT05742464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908583|NCT01830361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908584|NCT03293095|||COHORT||CROSS_SECTIONAL|||||||
33991032|NCT06558734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatments and evaluations were conducted by different researchers. As a result, masking could be performed for both the investigators and the participants.||t|f|f|f
33991033|NCT01143311|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991034|NCT01343303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991035|NCT00235352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991036|NCT02833181|||OTHER||CROSS_SECTIONAL|||||||
33687636|NCT05391971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908585|NCT04723524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial|t|t|f|f
33908586|NCT04307147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908587|NCT02151006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908588|NCT02558153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908589|NCT02614872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908590|NCT01665417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908591|NCT06681623|||COHORT||PROSPECTIVE|||||||
33908592|NCT03013777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083886|NCT04112732|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34083887|NCT01912976|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34083888|NCT05325359|||CASE_ONLY||PROSPECTIVE|||||||
33991037|NCT05841654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In the study, the selected patients would be randomly divided into the Azilsartan treatment group and the conventional treatment group, and all the selected patients would be regularly followed up for 12 months. In the Azilsartan group, Azilsartan will be added in or switched to the original antihypertensive treatment plan, starting as 20 mg Qd, and gradually increased to 40 mg Qd according to the blood pressure. If the blood pressure is still not be controlled, antihypertensive drugs other than angiotensin-converting enzyme inhibitor (ACEI), ARB or angiotensin receptor blocker and neprilysin inhibitor (ARNI) will be added until the blood pressure is controlled. In the routine treatment group, antihypertensive treatment programs other than ACEI, ARB or ARNI will be adopted, and the use of antihypertensive drugs will be adjusted until the blood pressure control is controlled.|f|f|f|t
33991038|NCT05665205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Main investigators will be masked based on a randomization program. Outcomes Assessors will be not aware of the enrollment of participants and the study design to guaranty blinding of themselves.~Participants will be randomized by a program and they will not be aware about which groups could be more beneficial to guarantee blinding."||t|f|t|t
33991039|NCT00880802|||COHORT||PROSPECTIVE|||||||
33991040|NCT02842632|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991041|NCT01891773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33991042|NCT05572281|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083889|NCT04134039|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Each condom will be individually wrapped in its primary packet then be put in an identical box. All branding will be masked.|The condom types will be tested in a 2-way cross-over design where couples will be randomised to use each of the 2 condom types in a defined order, according to the randomisation schedule.|f|f|t|t
34083890|NCT06281561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083891|NCT05731115|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33777082|NCT02355015|||COHORT||PROSPECTIVE|||||||
33777083|NCT04084743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777084|NCT00498836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777085|NCT03883685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|both drugs pills and placebo pills are provided in identical pharmaceutical shape and packing, and provided by the same manufacturer. Participants is blinded.||t|t|f|f
33777086|NCT02271282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33777087|NCT04279028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are told they will receive one of two forms of CBT. They will not receive details about the other group.~The outcomes assessor will have no information about group assignment."||t|f|f|t
33777088|NCT00096876|||||PROSPECTIVE|||||||
33777089|NCT06130943|||COHORT||PROSPECTIVE|||||||
33777090|NCT04896658|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I~1. Arm A (cycles repeated every 3 weeks)~   1. Dose level 1: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.~  2. Dose level 2: The subject will take 1.9 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 3 weeks cycles.~2. Arm B (cycles repeated every 6 weeks)~   1. Dose level 1: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 300 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.~  2. Dose level 2: The subject will take 2.5 mg/kg of Belantamab Mafodotin, 500 mg of Cyclophosphamide, and 40 mg of Dexamethasone on day 1 of each 6 weeks cycles.~Phase II~Once tolerability of the highest planned dose is established, patients will be assessed for response rate. The arm with acceptable toxicity and best response will be further assessed in the expansion cohort."||||
33777091|NCT03912480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777092|NCT00389974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777093|NCT04860700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777094|NCT00793143|||COHORT||PROSPECTIVE|||||||
33777095|NCT01561690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777096|NCT00555295|||CASE_ONLY||RETROSPECTIVE|||||||
33777097|NCT06167382|NA|SINGLE_GROUP||SCREENING||NONE||||||
33777098|NCT03810079|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized double-blind sham-controlled crossover|t|t|t|t
33777099|NCT04447781|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Part A: Open Label Part B: Double-blind||t|f|t|t
33777100|NCT00280475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777101|NCT02106221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33777102|NCT01489020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777103|NCT01531192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33777104|NCT04458389|NA|SINGLE_GROUP||TREATMENT||NONE||TY101 injection||||
33777105|NCT01754779|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33777106|NCT02595229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777107|NCT05370339|||COHORT||PROSPECTIVE|||||||
33777108|NCT02478086|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33777109|NCT01177813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33777110|NCT00402883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777111|NCT02409875|||COHORT||PROSPECTIVE|||||||
33777112|NCT01015261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777113|NCT01349829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777114|NCT06269549|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|Placebo blinding / masked for dietary supplement|The differences between groups will be tested using a two-way analysis of variance for repeated measures (factor 1 = group, factor 2 = time)|t|t|t|f
33777115|NCT00583180|||COHORT||PROSPECTIVE|||||||
33777116|NCT03259698|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33777117|NCT00060021|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33777118|NCT04925921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991043|NCT01307124|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33991044|NCT06624267|||OTHER||PROSPECTIVE|||||||
33991045|NCT00003291|||CASE_ONLY||RETROSPECTIVE|||||||
33991046|NCT04020952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor is not informed about the gauge of the wire used for patients|Three groups of patients each receives different wire gauge during canine retraction phase during space closure.|f|f|f|t
33991047|NCT05510908|||COHORT||PROSPECTIVE|||||||
33991048|NCT04873063|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Single-centre, randomized, double-blind, two-period, two-sequence, cross-over 7-day study.|t|f|t|f
33908593|NCT04506827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The envelope with the group assignment will be opened by the surgeon at the time of surgery and the patient won't be informed.~The clinician who registers clinical parameters won't be informed of the group allocation. The histologist will receive biopsies with a numeric code but without informations of the graft material used."|Three groups of patients will be treated with 3 different graft materials|t|f|f|t
33991049|NCT02492425|||COHORT||PROSPECTIVE|||||||
33991050|NCT05083715|||COHORT||CROSS_SECTIONAL|||||||
34083892|NCT04744298|NA|SINGLE_GROUP||TREATMENT||NONE||"The study uses an effectiveness-implementation hybrid design (type 1). Phase 1 will evaluate effectiveness and Phase 2 will assess the implementation of the pathway. Implementation will occur via a pragmatic registry-based stepped wedge cluster randomization of ICUs. The unit of randomization will be a cluster of 2 ICUs. The intervention will be implemented into 1 cluster every 2 months. Once implemented, the cluster will continue to receive it for the remainder of the study.~Effectiveness: There will be a 10-month baseline data collection period at the beginning of the study. The total study duration will be 29 months (Estimated18816 mechanically ventilated patients including 2688 in the ARDS subgroup). The comparison (control) therapy will be usual management assessed in the baseline period.~Implementation: A process evaluation of pathway implementation will be conducted to 1) quantitatively evaluate fidelity, 2) qualitatively assess acceptability (Estimate 1100 clinicians)."||||
34083893|NCT05618223|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pre and post-test design||||
34083894|NCT02292576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34083895|NCT01780766|||CASE_ONLY||PROSPECTIVE|||||||
34083896|NCT01607164|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083897|NCT04275336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33908594|NCT00398541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908595|NCT05536713|||COHORT||PROSPECTIVE|||||||
33908596|NCT00000748||PARALLEL||TREATMENT||||||||
33908597|NCT00149656|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34083898|NCT01518816|||CASE_CONTROL||PROSPECTIVE|||||||
34083899|NCT00559260|||||PROSPECTIVE|||||||
34083900|NCT02417025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34083901|NCT03541993|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34083902|NCT02193100|||COHORT||PROSPECTIVE|||||||
34083903|NCT05827848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083904|NCT02719977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083905|NCT00003837||||TREATMENT||||||||
34083906|NCT00709085|||CASE_CONTROL||RETROSPECTIVE|||||||
34083907|NCT04435496|NA|SINGLE_GROUP||OTHER||NONE||The study will be conducted in 20 healthy women between 18 and 48 years scheduled for elective Caesarean section.||||
34083908|NCT00251758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34083909|NCT02944175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34083910|NCT01670864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083911|NCT06188117|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083912|NCT01501240|||CASE_ONLY||PROSPECTIVE|||||||
34083913|NCT00853762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083914|NCT00117390|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34083915|NCT04801095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083916|NCT06330415|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34083917|NCT03532737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083918|NCT01547481|||CASE_CONTROL||PROSPECTIVE|||||||
34083919|NCT01149941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083920|NCT02955875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34083921|NCT02924935|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are given L-Histidine supplements and were prescribed to take 50mg/kg twice daily.||||
34083922|NCT00829270|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908598|NCT03702582|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians performing comparative analyses of primary outcomes will be blinded as to the allocation designations of patients. Otherwise there will be no masking in the study.|Cardiac surgery patients who meet study criteria and develop recurrent or persistent atrial fibrillation post-operatively will be randomized 1:1 to receive Warfarin or Rivaroxaban for prophylaxis against stroke or other systemic arterial embolism||||
34083923|NCT01505920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083924|NCT06551896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908599|NCT03282201|||OTHER||PROSPECTIVE|||||||
33908600|NCT01840176|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33908601|NCT00151060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991051|NCT01385163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|405+||f|f|f|t
33908602|NCT00965705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083925|NCT02377453|||COHORT||PROSPECTIVE|||||||
34083926|NCT01244464|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34083927|NCT00623610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083928|NCT02247622|||COHORT||PROSPECTIVE|||||||
34083929|NCT02989974|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083930|NCT01078038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083931|NCT02430558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083932|NCT05482802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991052|NCT06242613|||COHORT||PROSPECTIVE|||||||
33991053|NCT04308785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991054|NCT04362085|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants, clinical research staff, and clinicians is not possible due to the nature of the intervention. However, the biostatisticians will be blinded at the data analysis phase.|This study is a 2-arm, parallel, pragmatic, multi-centre, open-label randomized controlled trial to determine the effect of therapeutic anticoagulation on the composite outcome of ICU admission, mechanical ventilation and/or death in hospitalized patients with COVID-19.||||
33991055|NCT06223191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34083933|NCT01718483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991056|NCT00760331|||COHORT||PROSPECTIVE|||||||
33991057|NCT06488911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991058|NCT02771353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991059|NCT00469521|NON_RANDOMIZED|PARALLEL||||NONE||||||
33991060|NCT05840133|||COHORT||OTHER|||||||
34083934|NCT03261999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083935|NCT04818099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083936|NCT06200012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Providers in the experimental and control arms are are not masked. Providers in the experimental arm have a policy at their clinic change, and they are aware of the policy change. The control arm does not implement the policy change, but may be aware of the policy change in the other arm. Both arms receive an educational intervention.|||||
34083937|NCT06515288|RANDOMIZED|PARALLEL||PREVENTION||NONE||Five intervention schools and five control schools will be selected from five different municipalities in Jakarta, with each school having a minimum of 100 students (grade 10-11; 15-17 years old). First, recruitment will be based on the discussion with the local education office at the provincial level and ask for a list of schools considering eligibility criteria. Two schools in each municipality with comparable characteristics will be selected, and then each pair will be randomized to become either the intervention or the control group. Second, selected schools will be invited to participate in the study. The intervention group will receive baseline educational intervention (Nutrition Education Capacity Building for Teachers and Management) and all components of the NGTS program. While the control group will receive only the baseline educational intervention. The baseline educational intervention will be conducted in 5 days through face-to-face delivery training mode.||||
34083938|NCT00047762|RANDOMIZED|||TREATMENT||NONE||||||
34083939|NCT01840397|||COHORT||PROSPECTIVE|||||||
33687637|NCT02063971|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33687638|NCT06326970|||COHORT||PROSPECTIVE|||||||
34083940|NCT00622765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687639|NCT02656212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991061|NCT05660655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991062|NCT04435847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33991063|NCT03781102|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants (60 children and their biological mothers (n=120)) will be assigned to a clinic location nearest to their home address, which will determine the order in which they will complete the 16-week intervention. Two clinics were selected to participate in this pilot study. Randomization to the intervention and wait-list control conditions will be performed \*by site\* (flip of a coin). Randomization by site is proposed as it has the least potential for contamination during the initial delivery period. Group A participants (n=30) will begin the 16-week face-to-face group program immediately, whereas the Group B participants (n=30) will receive normal standard of care. After 16 weeks, the Group A participants will transition to follow-up while the Group B participants begin the intervention. This design is responsive to standards of care for T2D prevention by primary care providers and will provide the opportunity to investigate all the outcome questions.||||
33991064|NCT02517294|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33991065|NCT01501786|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34083941|NCT06000644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687640|NCT04644783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777119|NCT00000316||||TREATMENT||||||||
33777120|NCT00252785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34083942|NCT04291040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083943|NCT01499485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34083944|NCT05573152|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34083945|NCT05945095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The sample size in similar studies was examined and it was determined that at least 30 mothers should be included in the experimental and control groups.~Assignment of pregnant women to the experimental and control groups will be made using a simple random numbers table."|t|f|f|f
34083946|NCT00173186|||CASE_CONTROL||RETROSPECTIVE|||||||
33991066|NCT00571064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991067|NCT01793558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991068|NCT01706094|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33991069|NCT05201339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991070|NCT04508790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991071|NCT03740230|||COHORT||PROSPECTIVE|||||||
33991072|NCT05571462|||COHORT||PROSPECTIVE|||||||
33991073|NCT05984303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991074|NCT06389669|||COHORT||PROSPECTIVE|||||||
33991075|NCT06177418|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33991076|NCT03004703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991077|NCT04888039|||COHORT||RETROSPECTIVE|||||||
33991078|NCT03003091|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33991079|NCT01547286|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991080|NCT03936101|||CASE_CONTROL||PROSPECTIVE|||||||
33991081|NCT03807180|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients with Ankylosing spondylitis receiving anti-tnf alpha therapy|Randomized controlled|t|f|f|f
33991082|NCT06060145|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33991083|NCT05039112|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33991084|NCT00004148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991085|NCT03910231|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Blinding to investigator, participant and study staff. Randomization assignment and blinding provided by Investigational Drug Services|Randomized, placebo-controlled, double-blinded, parallel arm clinical trial|t|t|t|f
33991086|NCT05507580|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33991087|NCT02486081|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33991088|NCT01727947|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
33991089|NCT00224718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991090|NCT01626287|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33777121|NCT05725187|||COHORT||PROSPECTIVE|||||||
33777122|NCT02440906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777123|NCT00447330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777124|NCT05873257|NA|SINGLE_GROUP||TREATMENT||NONE||non-comparative, one-armed, open-labelled, multi-centre study||||
33777125|NCT03867708|||COHORT||PROSPECTIVE|||||||
33777126|NCT00803140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777127|NCT05829941|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33777128|NCT02319447|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33777129|NCT00050414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777130|NCT05909293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777131|NCT02036996|||COHORT||RETROSPECTIVE|||||||
33777132|NCT01602952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991091|NCT00840216|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991092|NCT00418145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991093|NCT04510597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991094|NCT03825328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991095|NCT02300103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991096|NCT01855750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991097|NCT04994847|||COHORT||PROSPECTIVE|||||||
33991098|NCT06562348|RANDOMIZED|PARALLEL||OTHER||NONE||An open label 1:1 randomized phase II trial||||
33991099|NCT05618587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777133|NCT04864496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777134|NCT03790930|||CASE_ONLY||RETROSPECTIVE|||||||
33777135|NCT02181894|||COHORT||PROSPECTIVE|||||||
33777136|NCT00591357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777137|NCT00927381|||COHORT||RETROSPECTIVE|||||||
33777138|NCT02810561|||COHORT||RETROSPECTIVE|||||||
33777139|NCT05724524|||COHORT||PROSPECTIVE|||||||
33777140|NCT03964025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991100|NCT02724605|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33991101|NCT02576938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991102|NCT00954590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991103|NCT04482465|NA|SINGLE_GROUP||PREVENTION||NONE|blood results were communicated to each participant|epidemiological intervention pilot study||||
33991104|NCT03031184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991105|NCT06544200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991106|NCT04814095|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33991107|NCT05253443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991108|NCT04710758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083947|NCT03109483|NA|SINGLE_GROUP||TREATMENT||NONE||explorative study||||
34083948|NCT00320086|||OTHER||PROSPECTIVE|||||||
34083949|NCT03492203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083950|NCT03665870|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm pre-post study.||||
34083951|NCT04194164|NA|SINGLE_GROUP||PREVENTION||NONE||Comparison of interdialytic weight gain with fluid intake as recorded by fluid app||||
34083952|NCT01244477|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34083953|NCT00105430||||TREATMENT||||||||
34083954|NCT03650634|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34083955|NCT05677399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were assessed before treatment, after treatment, 1 month after treatment and 3 month after treatment by the investigator (İ.T.) who was blinded to the study. İ.T. is medical doctor who didn't know the patients' groups.|A Randomized, single blind, prospective, parallel 1:1 group study.|f|f|f|t
34083956|NCT00906243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083957|NCT00058669|||COHORT||CROSS_SECTIONAL|||||||
34083958|NCT05068843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34083959|NCT05046808|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34083960|NCT02144909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34083961|NCT06401291|NA|SINGLE_GROUP||TREATMENT||NONE||All patients who meet the inclusion criteria will receive TENS treatment for a period of 1 month. At baseline and at 1 month evaluation will take place.||||
34083962|NCT05691543|||CASE_ONLY||PROSPECTIVE|||||||
33908603|NCT06451380|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a randomized, open-label study.|This is an interventional, prospective, randomized, open-label, controlled, single-center study.||||
33908604|NCT00006222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908605|NCT03581773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The master randomization list will be created, maintained and kept in a locked, secure location at Hospitalsapoteket Region Midtjylland, Afdeling Herning. The randomization list will not be available to any person directly involved in the study, including the study centre personnel or the project team.~Randomization will be performed via a central randomization service available in business hours on working days by fax 7843 5165. A block design randomization procedure will be used."|Randomized, double-blind, placebo-controlled phase II trial of the effectiveness of folic acid supplement for 12 weeks on mucositis. Both arms will receive best supportive care. No crossover is allowed.|t|t|t|t
33908606|NCT01103817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908607|NCT01823627|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991109|NCT06167694|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open clinical study of HRS-8080 in conjunction with Dalpiciclib||||
33991110|NCT01566617|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33991111|NCT02111239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991112|NCT05950035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908608|NCT05942339|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site, single-arm, non-blinded, non-randomized, interventional||||
33908609|NCT00442247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908610|NCT04188665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908611|NCT05348265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908612|NCT03580577|||CASE_CONTROL||PROSPECTIVE|||||||
33908613|NCT03782740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two parallel studies (dysmenorrhea and endometriosis) with 40 participants in each.|t|t|t|f
33908614|NCT00258089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33908615|NCT04077970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908616|NCT06305104|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33908617|NCT02980770|||COHORT||PROSPECTIVE|||||||
33908618|NCT01518608|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908619|NCT02415296|||OTHER||OTHER|||||||
33908620|NCT02738437|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33908621|NCT01684501|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908622|NCT00121355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908623|NCT06560632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908624|NCT00697047|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33908625|NCT05994014|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908626|NCT02709434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908627|NCT01328158|||COHORT||PROSPECTIVE|||||||
33908628|NCT04421989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908629|NCT06142253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blinded to study allocation.|Eligible participants will be randomly assigned to one of two groups: 1) Usual Care or 2) WATER+CT|f|f|f|t
33908630|NCT01008254|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33908631|NCT01623817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908632|NCT01355068|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33908633|NCT06401512|RANDOMIZED|PARALLEL||TREATMENT||NONE|The intervention is designed to evaluate a change in health service provision; therefore blinding of the intervention is not possible. The health care professionals, patients, and researchers were not blinded to the patients' group allocation. The statistician performing the analysis will be blinded.|||||
33991113|NCT00745420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991114|NCT06180980|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991115|NCT03113708|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Closed envelope||f|t|f|f
33991116|NCT04477213|||COHORT||PROSPECTIVE|||||||
33991117|NCT01568762|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33991118|NCT04306952|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to receive one of there different MBI treatments: 1) Brief MBI, 4 weeks, 2) Standard MBI, 8 weeks, 3) Extended MBI, 12 weeks||||
33991119|NCT02949635|||COHORT||PROSPECTIVE|||||||
33991120|NCT03877939|||COHORT||PROSPECTIVE|||||||
33991121|NCT05967286|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991122|NCT06153485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991123|NCT05929352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991124|NCT02787876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991125|NCT03975075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991126|NCT04704323|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991127|NCT00870662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991128|NCT00944294|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33991129|NCT03679598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|randomized (1:1), placebo-controlled|t|f|t|t
33991130|NCT06055764|||OTHER||CROSS_SECTIONAL|||||||
33991131|NCT04926818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The core part of the study and the first 12 weeks of the extension period (transition) will be double-blinded and the remainder of the extension period will be open label.||t|t|t|t
33991132|NCT04198363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991133|NCT05215483|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||In an online randomised multi-factorial survey (vignette study) participants are randomised to assess four scenario's. Between subject testing advise is randomised (IV1; 2 levels) and the availability of LFT (IV2; 2 levels). Within subject we asked participants to assess their most likely behaviour on day 1 of symptoms and day 3 of unchanged symptoms (IV3; 2 levels). Corona-related symptoms are randomly presented (IV4; 4 levels) and new incidences of symptoms are presented in additional vignettes describing new months (IV5; 4 levels).|t|f|t|f
33991134|NCT02757105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991135|NCT03107091|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Open label prospective study in a cohort of 6 patients||||
33991136|NCT04715295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991137|NCT00222625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33991138|NCT04737863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991139|NCT04596670|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Single Group Assignment||||
33908634|NCT03601416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908635|NCT02519075|||OTHER||PROSPECTIVE|||||||
33908636|NCT00713401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908637|NCT06548022|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, pre/post-test design.||||
33908638|NCT06215898|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Controlled study||||
33908639|NCT00138710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33908640|NCT02963727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908641|NCT05871125|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33908642|NCT00047281||||TREATMENT||NONE||||||
33908643|NCT01526018|||COHORT||PROSPECTIVE|||||||
33908644|NCT02423824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908645|NCT06462586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908646|NCT00398710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908647|NCT04951648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908648|NCT06692842|NA|SINGLE_GROUP||TREATMENT||NONE||Individuals with anxiety, depression or insomnia will receive the CONEMO intervention, consisting of 7 self-applied modules of strategies based on cognitive-behavioral therapy techniques. The intervention will be comparet to the treatment as usual.||||
33908649|NCT06350552|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33908650|NCT01916122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908651|NCT01064453|||COHORT||PROSPECTIVE|||||||
33908652|NCT01270581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908653|NCT03408496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be allocated in 3 groups. The myofascial release group, muscle stretching group and control group.|f|f|f|t
33908654|NCT06531382|||OTHER||CROSS_SECTIONAL|||||||
33908655|NCT00003019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908656|NCT04962542|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33908657|NCT03763643|RANDOMIZED|PARALLEL||PREVENTION||NONE||Control group and treatment/intervention group. Pilot/feasibility study.||||
33908658|NCT05164861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908659|NCT00253617||||TREATMENT||||||||
33908660|NCT02927093|||CASE_CONTROL||RETROSPECTIVE|||||||
33908661|NCT04405804|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's two-stage design||||
33908662|NCT02409784|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Ten participants received a very high fat ketogenic diet (KD) (4.5:1; lipid:protein plus carbohydrates) for four days.||||
33908663|NCT06116461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908664|NCT03169738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908665|NCT05824845|||COHORT||PROSPECTIVE|||||||
33908666|NCT02214186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908667|NCT05460871|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label interventional trial||||
33908668|NCT05702684|||OTHER||OTHER|||||||
33908669|NCT03641989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be told which toothpaste they have been given.|Participants will be randomized to brush twice daily for 30 days with the plaque disclosing agent toothpaste or a reference, non-plaque disclosing toothpaste. Toothpastes are comparable based on equivalent content of the active ingredient: fluoride.|t|f|f|f
33908670|NCT01518582|||COHORT||PROSPECTIVE|||||||
33908671|NCT00885235|||COHORT||PROSPECTIVE|||||||
33908672|NCT01543490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908673|NCT03418402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908674|NCT03575091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Randomisation is carried out with sealed envelopes that are only opened just before intervention starts.~There are different care givers who carry out the observations and who perform the interventions."|Comparison of tree parallel groups, 1 control and 2 intervention groups.|f|f|t|f
33908675|NCT01497314|NA|SINGLE_GROUP||||NONE||||||
33908676|NCT04652063|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The individual performing the developmental assessment will be unaware of study arm assignment|Randomization 1:1 to control and intervention group|f|t|f|t
33908677|NCT00395252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908678|NCT02996539|||CASE_ONLY|||||||||
33908679|NCT03362645|||CASE_CONTROL||RETROSPECTIVE|||||||
33908680|NCT06287736|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908681|NCT05034484|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33908682|NCT05431413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908683|NCT00836680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908684|NCT04867135|||COHORT||PROSPECTIVE|||||||
33991140|NCT04031001|||CASE_ONLY||PROSPECTIVE|||||||
34083963|NCT04893161|NA|SINGLE_GROUP||TREATMENT||NONE||All patients with SLE will be enrolled in one year and administrated belimumab 10mg/kg intravenous infusion over 1 hour on days 0, 14, and 28, and every 28 days through week 48.||||
33991141|NCT01115647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991142|NCT04116463|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized at the individual level into intervention or attention-control group.||||
34083964|NCT05457699|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34083965|NCT03405311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34083966|NCT00323063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083967|NCT02397746|||COHORT||PROSPECTIVE|||||||
34083968|NCT00000347||PARALLEL||TREATMENT||DOUBLE||||||
34083969|NCT02580656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083970|NCT05507138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants and clinicians conducting the metacognitive strategy coaching will be instructed not to reveal the group assignment to the member of the research team conducting assessments. Following the completion of recruitment, data will be labelled as Group A and Group B to avoid bias."|Participants will be randomized to the AKL-T01 intervention plus weekly metacognitive strategy coaching (intervention arm) or to weekly metacognitive strategy coaching plus general cognitive stimulation games such as word searches and other puzzles (control arm).|f|f|t|t
34083971|NCT02517840|||COHORT||PROSPECTIVE|||||||
34083972|NCT04211584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor is blinded regarding used access site (traditional radial or Snuffbox approach)||f|f|f|t
33687641|NCT04132375|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|A Double-blind, Placebo-controlled, IWRS based. access to unblinded interim results will be limited to the DMC and unblinded statistician|"This study will be an adaptive seamless design (ASD) phase 2/3 investigation using an inferentially seamless platform.~Stage 1 In Stage 1, subjects will be randomly assigned to receive 1 of the 3 treatment regimens (high treatment regimen, low treatment regimen, or placebo) in a 1:1:1 ratio.~Review for Dose Selection The Data Monitoring Committee will conduct a blinded safety review at the end of Stage 1 to determine the best active dose based on safety.~Stage 2 Stage 2 is considered the efficacy portion of the study. The randomization ratio for subjects in Stage 2 will be 1:1 (active treatment regimen of INM004: placebo).~Interim Analysis The intent of the unblinded interim analysis is to demonstrate superiority of INM004 versus the placebo, based on 80% reduction in the incidence of HUS in the treated cohort to stop study due to overwhelming efficacy, or declare futility, or re-estimate sample."|t|t|t|t
33687642|NCT02402478|||COHORT||PROSPECTIVE|||||||
33687643|NCT00393640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687644|NCT02596750|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Each subject will serve as his or her own control. The right forearm and the left forearm will be randomized through a binary randomization to determine whether the right arm will receive microneedle treatment or sham microneedle treatment (roller with no microneedles). This randomization is developed through code in Excel that will result in binary result of either the value 0 or 1 for each subject. For those subjects assigned a binary code of 0, the right forearm will receive microneedle treatment and the left forearm will receive sham microneedle treatment. For those subjects assigned a binary code of 1, the left forearm will receive microneedle treatment and the right forearm will receive sham microneedle treatment.|t|f|f|f
33687645|NCT00412490|||COHORT||PROSPECTIVE|||||||
33687646|NCT02117427|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687647|NCT02376283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687648|NCT04070976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687649|NCT01856023|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||assess the sequenced use of HD IL2 and IPI in metastatic melanoma patients||||
33687650|NCT06111547|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33687651|NCT02721186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687652|NCT05037188|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|"Stage 1 will be open label. The participants will receive the assigned dose of BCD-250 according to the allocation.~Stage 2 will be double blind, placebo-controlled. Investigators and subjects will be unaware of the assigned treatment (BCD-250 or placebo)."|"Stage 1. Subjects without history of COVID-19 infection will be randomized in two treatment groups to receive different doses of BCD-250. After the last subject completes the 28 days of the main study period the safety and immunogenicity analysis will be performed. Based on these results the optimal BCD-250 dose will be selected by the Sponsor considering the Independent Data Monitoring Committee recommendations.~Stage 2. Subjects without history of COVID-19 infection (Cohort 1) and with history of COVID-19 infection (Cohort 2) will be randomized to receive either selected dose of BCD-250 or placebo."|t|f|t|f
33687653|NCT01084447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687654|NCT04667143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687655|NCT00013195|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33777141|NCT00929305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908685|NCT04381819|||COHORT||PROSPECTIVE|||||||
33908686|NCT00748540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908687|NCT04224740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908688|NCT03253406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Every attempt will be made to ensure participants do not know the group with which they have been randomized, accomplished by advertising to potential college student participants that two novel, technology-based interventions will be employed in the study, with no more detail provided. After screening and randomization, participants will be informed of study intervention procedures in an identical manner regardless of group allocation via the use of a study script repeated to each participant by the study's primary investigator. The only difference between the scripts will be a discussion with experimental group participants regarding how to use the Polar M400 smartwatch during the study intervention period. Importantly, college students will be brought into the Lab for screening and baseline testing on an individual basis ensuring the individuals from different groups have no idea of the differing intervention procedures utilized between the experimental and comparison groups.|A two-arm randomized pilot trial design will be used, with one Experimental Group and one Comparison Group. A random numbers table will be used to randomize participants with a 1:1 allocation ratio.|t|f|f|f
33908689|NCT02425267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908690|NCT04146272|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participants are masked during the lab testing. They will not know which device they are testing because the Investigator will place it on their ear without letting them see it.|The participants will wear hearing aids with the current feedback system and the new feedback system each for 10 +/- 5 days. Some will wear the current hearing aids first and some will wear the new Hearing aids first.|t|f|f|f
33908691|NCT06376916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908692|NCT04723108|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33908693|NCT02620332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908694|NCT04897503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908695|NCT05293132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial||||
33908696|NCT02899416|||COHORT||CROSS_SECTIONAL|||||||
33908697|NCT00326105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33908698|NCT01719471|||CASE_CONTROL||PROSPECTIVE|||||||
33908699|NCT04583566|||CASE_CONTROL||PROSPECTIVE|||||||
33908700|NCT05303519|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908701|NCT03493685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908702|NCT05226598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908703|NCT04350658|||COHORT||PROSPECTIVE|||||||
33908704|NCT00003750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908705|NCT01296919|||COHORT||PROSPECTIVE|||||||
33908706|NCT03924024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908707|NCT00506051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908708|NCT02102282|||COHORT||PROSPECTIVE|||||||
33687656|NCT04073303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687657|NCT05235503|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blinding via pharmacy|Double blind, randomized cross-over, placebo-controlled design.|t|f|t|f
33687658|NCT04733612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33687659|NCT02577432|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687660|NCT05440071|||COHORT||PROSPECTIVE|||||||
33687661|NCT01383668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687662|NCT04447612|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking.|Randomized-controlled trial||||
33687663|NCT00474682|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||||||
33687664|NCT05386628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33687665|NCT01415739|||CASE_ONLY||RETROSPECTIVE|||||||
33687666|NCT03800303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687667|NCT01888003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687668|NCT06178705|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial design would be used in this study which is two arm study having two groups, an experimental \& wait-list control group. Experimental group will receive intervention while other group will be placed in wait-list. In this study, parallel group design would be used. The treatment will be given to all participants in a parallel way. Allocation ratio and framework would be equivalence i.e., equal number of participants in treatment and control group.||||
33687669|NCT00507468|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33687670|NCT04255927|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||randomized-controlled|t|t|f|t
33687671|NCT04999774|||COHORT||CROSS_SECTIONAL|||||||
33687672|NCT01833468|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33687673|NCT02240147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687674|NCT01733927|NA|SINGLE_GROUP||||NONE||||||
33687675|NCT04475809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) double-blinded ( patient and outcome assessors)|The patients will be divided randomly by a computer-generated randomization table into two equal groups|t|f|f|t
33687676|NCT03783247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To achieve double blinding, patients will receive the block by the anesthetist. Another doctor not involved in the block procedure will evaluate the patients postoperatively.|randomized double-blinded|t|f|f|t
33687677|NCT00307879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687678|NCT01589627|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687679|NCT04327479|||COHORT||PROSPECTIVE|||||||
33687680|NCT06286371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687681|NCT04964284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687682|NCT05937074|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687683|NCT04646772|||OTHER||RETROSPECTIVE|||||||
33687684|NCT00812344|RANDOMIZED|CROSSOVER||||NONE||||||
33687685|NCT00473746|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687686|NCT04131218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687687|NCT04621357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687688|NCT03923985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908709|NCT06285474|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33908710|NCT00903903|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908711|NCT03011840|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33908712|NCT00944606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33908713|NCT01349504|||COHORT||PROSPECTIVE|||||||
33908714|NCT04341194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Opaque sealed envelopes. which are randomly picked out before the meeting with each participant.||f|f|f|t
33908715|NCT02294149|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33908716|NCT01476176|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33908717|NCT02222012|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33908718|NCT00712114|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908719|NCT06042699|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo tablets will be indistinguishable from iron tablets. Group allocation will not be accessible to participants, care providers, investigators, or outcomes assessors.|Double blind placebo-controlled randomized controlled trial|t|t|t|t
33908720|NCT04500171|RANDOMIZED|PARALLEL||SCREENING||NONE||"The health belief model and social cognitive theory were used as foundational principles to develop an intervention that builds awareness to initiate a CRC screening behavior modification.~This research project will be the first to test the efficacy of the ColoCare FOBT home kit as a CRC screening intervention using a classical experimental (randomized clinical trial) in American Samoa. Second, the ColoCare kits can be identified as a cost-effective and culturally appropriate alternative to traditional FOBT home test kits. Lastly, results will be used to develop recommendations in healthcare delivery systems to improve information, communication, informed decision-making, and access to care in American Samoa."||||
33908721|NCT04093739|||COHORT||PROSPECTIVE|||||||
33908722|NCT05844800|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The experimental group of pectus excavatum patients (n=21) pre- and post intervention examination and control group of healthy subjects (n=22) examined twice.||||
33908723|NCT05087602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991143|NCT03562962|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|An independent blind Research Assistant (RA) will score and record the data from questionnaires administered before and after therapeutic sessions.|A concurrent experimental multiple baseline design (MBL) across participants with a follow-up phase will be conducted (A/B/Follow-up). Concurrent MBL controls historical factors and other threats to internal validity by sequentially introducing the treatment phase. The latter requires that the length of the baselines varies between participants. Additionally, the MBL allows comparing behavioral data among individuals across different or similar conditions, showing whether extraneous variables affect the participants in the same manner or not. The between-series comparisons control for threats to external and internal validity that might affect individuals in the same study.||||
33991144|NCT03192163|||CASE_ONLY||CROSS_SECTIONAL|||||||
33991145|NCT00910221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991146|NCT05422963|||COHORT||RETROSPECTIVE|||||||
33991147|NCT05248711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33991148|NCT03950336|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single-blind placebo controlled|placebo-controlled parallel study with two simultaneous interventions|t|f|f|t
33991149|NCT05080894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991150|NCT05897684|||COHORT||PROSPECTIVE|||||||
33991151|NCT02211924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33991152|NCT00031395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991153|NCT03402906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991154|NCT02992366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991155|NCT02885285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991156|NCT00109265||||TREATMENT||NONE||||||
33687689|NCT01958112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991157|NCT03896126|||COHORT||OTHER|||||||
33991158|NCT04443790|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, two arm parallel randomized controlled clinical trial||||
33991159|NCT04176835|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33991160|NCT04215718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the patients don't know which procedure they underwent|2 groups of patients with simple anal fistula each one 46 patients the1st underwent fistulotomy with marsupialization of wound edges the second underwent fistulectomy and wound closure|t|f|f|f
33991161|NCT01977521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991162|NCT02378935|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991163|NCT03876054|||OTHER||PROSPECTIVE|||||||
33991164|NCT00464581|||CASE_ONLY||RETROSPECTIVE|||||||
33991165|NCT00465621|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33687690|NCT04697381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687691|NCT02312427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687692|NCT01608854|||COHORT||PROSPECTIVE|||||||
33777142|NCT02580682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Since the treatments in this study are visualized, it is not feasible to blind the patients and therapists.Therefore, the outcome assessors will be blinded, they will not participate in the recruitment, study design and the treatment||f|f|f|t
33777143|NCT02236923|||COHORT||RETROSPECTIVE|||||||
33777144|NCT05089110|||COHORT||PROSPECTIVE|||||||
33777145|NCT03870087|||COHORT||PROSPECTIVE|||||||
33777146|NCT00455468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991166|NCT03057730|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991167|NCT00835991|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991168|NCT00852163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991169|NCT01838681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991170|NCT04402151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991171|NCT06150963|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991172|NCT02440711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991173|NCT01948167|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33991174|NCT02037763|||COHORT||PROSPECTIVE|||||||
33991175|NCT02561845|||CASE_ONLY||RETROSPECTIVE|||||||
33991176|NCT01533779|||COHORT||PROSPECTIVE|||||||
33991177|NCT00714935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991178|NCT00856167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991179|NCT03867838|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991180|NCT02525458|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33991181|NCT04478435|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34083973|NCT01317641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083974|NCT00325637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687693|NCT04167371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687694|NCT04144023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687695|NCT03341247|||OTHER||PROSPECTIVE|||||||
33687696|NCT01752712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687697|NCT01466595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687698|NCT05022875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Blinding strategies include the following: (1) the statistician will not be allowed to disclose the randomization results to others; (2) after physician referral, the participant will be immediately ushered to a separate room to ensure that the caregiver does not receive information regarding the intervention content; and (3) participants of both the experimental and control groups will download the app, but app content will be different between the two groups. (4) research assistants will specially emphasize for all participants that app usage is beneficial for disease management.|"Experimental group: The complete Healthcare chief executive officer app will be used for intervention in the experimental group.~Control Group: Participants in the control group will only install the CEO's Profile and Health Tracking interfaces of the Healthcare chief executive officer app."|t|t|f|f
33687699|NCT01415193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33687700|NCT01546480|||CASE_CONTROL||PROSPECTIVE|||||||
33687701|NCT01273285|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687702|NCT03304496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33687703|NCT03504930|||COHORT||PROSPECTIVE|||||||
33777147|NCT00862511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777148|NCT03584685|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participants are blind as to whether they are in the control or experimental groups. The investigators and outcomes assessors are blind to which patients received the intervention.|All participants will initially be treated without the surgical mask. Then, half will be treated with the mask and the other half will be treated without the mask.|t|f|t|t
33777149|NCT03432039|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33777150|NCT02322775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777151|NCT01680120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777152|NCT02460900|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33991182|NCT00085293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991183|NCT00005785||||TREATMENT||||||||
33991184|NCT03707587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083975|NCT01586195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083976|NCT04325880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34083977|NCT03042546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are blinded||t|f|f|f
34083978|NCT02391831|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33908724|NCT00333268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908725|NCT01595737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908726|NCT03649100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A blinded collaborator opened the opaque envelope after implant site development, giving the implant to the investigator that remain blinded. Both the test and control implants are perfectly the same.|To randomly compare implant stability quotient (ISQ) of Hiossen ET III implants with its new hydrophilic surface (NH) and Hiossen ET III implants with the conventional SA surface, in a split-mouth randomized study.|t|f|t|t
33908727|NCT01608789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908728|NCT01253681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908729|NCT00856271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908730|NCT00556361|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33908731|NCT03133871|||OTHER||CROSS_SECTIONAL|||||||
33908732|NCT00689377|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908733|NCT06486636|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinding to allocation will be maintained for all parties, excluding the operating surgeon and necessary operating room personnel.|Each patient will be assigned in a blinded fashion to one of two groups (left posterior pericardiotomy or no posterior pericardiotomy) in a 1:1 ratio.|t|t|t|t
33908734|NCT03613415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Each patient will be given a code by the researcher (T.A.) and the observers will be blind to which group this case belong.~* Patients, evaluators and statistician will be blinded."||t|f|f|t
33908735|NCT04041388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908736|NCT06127173|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|An attending anesthesiologist will unfold the envelopes 10min before starting the procedure. The children and the sonographer will be blinded to patient group allocation. The attending anesthesiologist will not be blinded; however, he will not participate in the ultrasonography or data analysis.|"Patients will be randomized into three groups:~* Group (ZEEP) with PEEP level 0 cmH2O.~* Group (PEEP 3) with PEEP level 3 cmH2O.~* Group (PEEP 5) with PEEP level 5 cmH2O."|t|f|f|t
33908737|NCT04423926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908738|NCT03934164|||OTHER||PROSPECTIVE|||||||
33908739|NCT06503536|||COHORT||RETROSPECTIVE|||||||
33687704|NCT00263276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687705|NCT04197687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33687706|NCT00238511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687707|NCT01683773|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687708|NCT01469117|||CASE_ONLY||PROSPECTIVE|||||||
33687709|NCT01381146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33687710|NCT05065775|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687711|NCT04519957|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33687712|NCT02142010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687713|NCT00117065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687714|NCT00127621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687715|NCT04218123|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33687716|NCT02106039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687717|NCT03420027|||COHORT||PROSPECTIVE|||||||
33687718|NCT04812678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687719|NCT01251471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687720|NCT03464695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687721|NCT01151098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687722|NCT00696475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687723|NCT04652180|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentre randomized controlled parallel-group, phase IV, superiority trial. The main purpose is to demonstrate the superiority of robot-assisted thoracic approach over thoracotomy (conventional surgery) in decreasing respiratory and overall complications in Ivor Lewis-type esophagectomy.||||
33687724|NCT06314620|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33687725|NCT03499301|||COHORT||PROSPECTIVE|||||||
33687726|NCT04230018|||CASE_ONLY||PROSPECTIVE|||||||
33687727|NCT03826576|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel randomized controlled trial||||
33687728|NCT00004382|RANDOMIZED|||TREATMENT||||||||
33687729|NCT01389362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687730|NCT04219462|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||40 patients assigned to two groups|f|f|t|f
33687731|NCT02875574|||COHORT||RETROSPECTIVE|||||||
33687732|NCT05779735|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33687733|NCT02113839|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33991185|NCT04820829|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||The Investigator will use a randomized, cross-over (balanced incomplete block) experimental design, with separate randomizations for males and females. All participants will consume a U.S. HEP - all foods provided - during 5-week controlled feeding periods. Each participant will complete two of the three controlled feeding periods, separated by four weeks when they will consume their usual unrestricted diet (washout). The three HEP interventions will be: high RM, low NSS; moderate RM, moderate NSS; and low RM, high NSS. Measurements will be made before (usual unrestricted diet) and during the last week of each HEP intervention.|f|f|t|f
33991186|NCT02577458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991187|NCT04552990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991188|NCT04543682|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized interventional study with parallel groups. Open labeled, add-on controlled study.~In this study, patients will be randomized on a 1:1:1 basis to one of the three arms (two treatment arms and one control arm)."||||
33991189|NCT02057835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33991190|NCT05281861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded (Patient and outcome assessors)||t|f|f|t
33991191|NCT03843190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991192|NCT05459571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991193|NCT04178850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991194|NCT06492876|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991195|NCT05637333|||COHORT||PROSPECTIVE|||||||
33991196|NCT05439252|NA|SINGLE_GROUP||OTHER||NONE||Single group, pre-test-post-test pilot study of acceptability||||
33991197|NCT01631552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991198|NCT03502148|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1/2, Open-Label, Single-Arm||||
33991199|NCT03730272|||COHORT||PROSPECTIVE|||||||
33991200|NCT06202755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of ticagrelor and aspirin or clopidogrel and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 580 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 580. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included cilostazol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|The investigators will conduct our single-blinded randomized controlled trial, which will contain 2 arms; the ticagrelor arm will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day). The cilostazol arm will receive (a 200mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day).|f|f|t|t
33991201|NCT06152458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991202|NCT06433388|||OTHER||CROSS_SECTIONAL|||||||
33991203|NCT02565160|||CASE_ONLY||PROSPECTIVE|||||||
33687734|NCT02233946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991204|NCT02794584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991205|NCT06102213|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|3 cohorts: Cohort A and B receive combination study drug in difference doses (Cohort A receives HMO 9.0 g and B. infantis; Cohort B received HMO 4.5 g and B. infantis) Cohort C does not receive study drug||||
33991206|NCT03407677|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|During the baseline period patients will be blinded to the feature of the ROTO track®, which registers site of insulin injection and the features (vibration and light) that can assist the patient in rotation of injections. Patients will in the first week of the study be informed, that the ROTO track® is being developed as a new automatic device to register data on insulin injections including day, time and dose of insulin.|||||
33991207|NCT01104025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991208|NCT05238168|||COHORT||PROSPECTIVE|||||||
33991209|NCT04450069|NA|SEQUENTIAL||TREATMENT||NONE||||||
33991210|NCT03969693|||COHORT||PROSPECTIVE|||||||
33991211|NCT00270634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991212|NCT00789386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33991213|NCT00275366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991214|NCT01674491|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33991215|NCT03137251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33991216|NCT06439745|||COHORT||RETROSPECTIVE|||||||
33991217|NCT01632839|||COHORT||PROSPECTIVE|||||||
33991218|NCT03720691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33991219|NCT04776798|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33991220|NCT02896010|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991221|NCT02169063|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991222|NCT00440934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991223|NCT00711386|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33991224|NCT05295550|NA|SINGLE_GROUP||OTHER||NONE||||||
33991225|NCT06227858|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|Randomisation will be processed by computer-generated random sequence number and will be performed by an independent member of the medical support team which will not be involved in the study|2 x 2 factorial design|t|t|t|t
33991226|NCT00836576|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33687735|NCT05796336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777153|NCT04858789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083979|NCT04245774|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This study was a double blind research.|Participants were divided into two groups.|t|t|t|t
34083980|NCT05363228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33777154|NCT05188079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|it will be double blinded|randomized, cross-over, placebo-controlled trial|t|f|t|t
33908740|NCT05819138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908741|NCT06331923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908742|NCT00086840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908743|NCT03542071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33908744|NCT01477697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908745|NCT03653702|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908746|NCT00307060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33908747|NCT06684626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908748|NCT00159029|||OTHER||OTHER|||||||
33908749|NCT03112213|||COHORT||PROSPECTIVE|||||||
33908750|NCT04755296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33908751|NCT06412744|||COHORT||CROSS_SECTIONAL|||||||
33908752|NCT05635552|||CASE_CONTROL||PROSPECTIVE|||||||
33908753|NCT06515652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908754|NCT03223324|||COHORT||PROSPECTIVE|||||||
33908755|NCT04585945|||CASE_CONTROL||PROSPECTIVE|||||||
33908756|NCT00092586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908757|NCT06693791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908758|NCT02041546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908759|NCT06397729|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33908760|NCT01003028|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33908761|NCT05682664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908762|NCT06346028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908763|NCT04929262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991227|NCT05895383|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive nitrous oxide at levels of mild sedation during vasectomy. Participants will hold a remote control to adjust the level of gas administered according to their comfort level.||||
33991228|NCT00629122|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33991229|NCT05178927|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991230|NCT05952544|||COHORT||RETROSPECTIVE|||||||
33991231|NCT06617260|||FAMILY_BASED||PROSPECTIVE|||||||
33991232|NCT04875117|||COHORT||PROSPECTIVE|||||||
33991233|NCT05625412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991234|NCT03536091|||COHORT||PROSPECTIVE|||||||
33991235|NCT05194059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991236|NCT04725747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This is a double masked study in which the doctor/nurse anesthetist evaluating the subject with the Ramsey scale will be masked to the treatment given. The subject will also be masked to the treatment group and the study/control drug.~To keep the doctor/nurse anesthetist masked, the unmasked nurse will prepare the study/control drug and then administer it to the subject without unmasking the doctor/nurse anesthetist or the subject. The unmasked nurse will administer one 3/50mg MK melt, or one 3mg Midazolam melt, or one 50mg Ketamine melt sublingually based on the subject's randomization assignment."|1:1:1 treatment arms. Arm 1 Ketamine/Midazolam melt. Arm 2 Ketamine melt. Arm 3 Midazolam melt.|t|t|t|t
33991237|NCT05457920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991238|NCT04164589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized, single blind placebo controlled clinical trial.|f|f|f|t
33991239|NCT05628311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991240|NCT03545022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients who met the study criteria were randomized to the type of acupuncture (active acupuncture or placebo acupuncture) and to the side of the first surgery (right or left). The randomization was performed by a researcher not involved in the study by lottery. Four papers in two opaque envelopes were used, one with the side of the teeth and another with the protocol of acupuncture treatment to be received, protocol 1 or 2.~The patients, the surgeon, the acupuncturist and the investigator were unaware of which acupuncture treatment was used at each surgery (active or placebo). In order to conceal the randomization, the needles for the active and placebo protocol were identical and were delivered to the acupuncturist in two boxes labeled protocol 1 and 2 and the codes were revealed only after completion of the study."||t|f|t|t
33991241|NCT05907733|||CASE_CONTROL||PROSPECTIVE|||||||
33991242|NCT02828033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991243|NCT03069183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991244|NCT05315063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991245|NCT05405075|||COHORT||PROSPECTIVE|||||||
33991246|NCT05105633|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will receive either intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) or standard of care (alteplase 0.9mg/kg or no lysis) +/- mechanical thrombectomy||||
33991247|NCT00316277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991248|NCT06266533|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to a conventional nutrition education or an arts-based education group.||||
33991249|NCT00557050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083981|NCT03713918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessor will be blinded to avoid performance, detection and analysis bias. Only main investigator will be aware of the allocated patients in each group and the specific type of intervention given to every patient|Patients requiring posterior single crowns or endocrowns|t|f|f|t
34083982|NCT00748202|RANDOMIZED|CROSSOVER||||NONE||||||
34083983|NCT02147301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083984|NCT02462265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083985|NCT00947544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083986|NCT06238739|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34083987|NCT04076917|||COHORT||PROSPECTIVE|||||||
33908764|NCT05820100|||COHORT||PROSPECTIVE|||||||
33908765|NCT03376425|||COHORT||PROSPECTIVE|||||||
33908766|NCT00428506|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687736|NCT04327960|||OTHER||PROSPECTIVE|||||||
33687737|NCT05384145|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33687738|NCT00336180|RANDOMIZED|PARALLEL||||NONE||||||
33687739|NCT04080687|||COHORT||PROSPECTIVE|||||||
33687740|NCT04123028|||COHORT||PROSPECTIVE|||||||
33687741|NCT02164149|||CASE_ONLY||PROSPECTIVE|||||||
33687742|NCT03954652|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Cohort 1: IQ \< 70 with and without malformations, syndromic and non-syndromic Cohort 2: Retinitis pigmentosa, achromatopsy, Bardet-Biedl syndrome, Usher syndrome, congenital stationary night blindness, LCA, macula degeneration, rod/ cone dystrophies, opticus atrophy Cohort 3: Rare paediatric solid cancers as melanoma, carcinoma of the gastrointestinal tract, tumours of the salivary gland and pancreatic tumors in children.~Plus: their respective parents"||||
33687743|NCT03291171|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with two groups: intervention group and waiting-list control group||||
33687744|NCT04706117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687745|NCT01915927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687746|NCT04589715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, investigator and outcome assessor will be masked. The care provider cannot be masked, but will be different person from investigator and outcome assessor.|Patients who sign the informed consent form and are eligible for the study entry at week 0 will be randomized to one of the two groups: electroacupuncture group and sham electroacupuncture group. The two groups will be assessed in a paralleled manner, and patients in both groups will be treated for 24 times in 3 months(3 times weekly for 4 weeks, 2 times weekly for 4 weeks and once every week for 4 weeks) and followed up for 6 months after treatment.|t|f|t|t
33687747|NCT02625883|||CASE_ONLY||RETROSPECTIVE|||||||
33687748|NCT03303482|RANDOMIZED|PARALLEL||OTHER||SINGLE||The investigators will randomly assign consenting teachers by classroom (lead teacher and/or assistant teacher) to either the fall or spring course (intervention and waitlist control groups, respectively). The course will be taught to groups of 16 teachers, with four groups in the fall course (64 teachers) and four in the spring course (64 teachers). To determine the impacts of the training intervention on those assigned to the fall course (intervention groups), those assigned to the spring course (control groups) will serve as concurrent controls during the fall.|f|f|f|t
33687749|NCT04483687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687750|NCT04394182|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||an experimental group will receive ultra low-dose lung radiotherapy||||
33777155|NCT04650347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patients, data collector, and the statistician were blinded to the type of intervention. the assessment was done to group A and B|the investigators planned to conduct a controlled trial with randomization in which eighty participants will be included with symptoms of outflow obstruction secondary to urethral stricture. this is between March 2017 and December 2019. those patients attended the outpatient clinic of our tertiary hospital of Ain Shams University. patients were allocated into 2 equal groups randomly. each group involved 40 patients. Group 1 will represent the holmium laser internal urethrotomy group while group 2 will represent the cold knife internal urethrotomy group.|t|f|t|t
33777156|NCT02999971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777157|NCT06359145|||COHORT||OTHER|||||||
33777158|NCT02662361|||COHORT||RETROSPECTIVE|||||||
33777159|NCT04388670|||COHORT||OTHER|||||||
33777160|NCT06113120|||COHORT||PROSPECTIVE|||||||
33777161|NCT00971516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777162|NCT00831246|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33777163|NCT06148714|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This study will be triple-blinded in that the study participants, the study coordinators, and the data analysis team will be blinded to the intervention or product allocation. Only the sponsor will know which product contains the active ingredients. After the study analysis is complete, the allocation will be unblinded.|Randomized-Controlled Trial|t|t|t|t
33777164|NCT03379233|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33777165|NCT00749619||||PREVENTION||||||||
33777166|NCT01235325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33777167|NCT02346487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777168|NCT01184768|||COHORT||CROSS_SECTIONAL|||||||
33777169|NCT06429371|||COHORT||CROSS_SECTIONAL|||||||
33777170|NCT01052662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908767|NCT02626819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Blinded to intervention arm|Randomized Controlled Trial|t|f|f|t
33908768|NCT06397391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908769|NCT06555367|||OTHER||RETROSPECTIVE|||||||
33908770|NCT01531127|||COHORT||PROSPECTIVE|||||||
33908771|NCT02998749|||CASE_CONTROL||PROSPECTIVE|||||||
33908772|NCT06692647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908773|NCT03408574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|This is a double blind study. The PI and all study personnel are blinded. Only the pharmacist dispensing the medication and the biostatistician who created the counterbalancing order are unblended.|Healthy older adults aged 65-75 and healthy younger adults aged 18-30 will be recruited. Each participant will take part in 3 nicotinic drug challenge days. The three drugs are counterbalanced across study days within each group and balanced by sex.|t|f|t|t
33908774|NCT05405296|||COHORT||PROSPECTIVE|||||||
33908775|NCT03827473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908776|NCT00678275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908777|NCT00675974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908778|NCT01883323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908779|NCT04937478|||COHORT||PROSPECTIVE|||||||
33908780|NCT00257387|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33908781|NCT06473623|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33908782|NCT00934557|RANDOMIZED|||PREVENTION||NONE||||||
33908783|NCT00876512|||CASE_CONTROL||PROSPECTIVE|||||||
33908784|NCT00139854|RANDOMIZED|CROSSOVER||||NONE||||||
33991250|NCT06544941|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33991251|NCT02132663|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33991252|NCT00990535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991253|NCT01112254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991254|NCT01960920|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|f|t
33777171|NCT03739385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is designed as a five-armed, cluster-randomized controlled trial with a 25-week (distributed over a school year) physical exercise training intervention. After preliminary assessment (written consent, questionnaires, personal data) the institutions with their participants will be randomly assigned to either the intergenerational group (INT), the two peer-groups PGS (peer group seniors) and PGC (peer group children) or the two control groups CONS (control group seniors) or CONC (control group children). Measurements of psychological wellbeing and physical health will occur on two occasions in all five groups: before intervention start (M1) and after the intervention period (M2).||||
34083988|NCT03297632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33777172|NCT06242496|||COHORT||RETROSPECTIVE|||||||
33777173|NCT02297503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687751|NCT04308811|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients who are diagnosed previously with severe AS will choose an envelope which determines the treatment method. There will be 60 envelops assigning for the groups mixed together in one box. This will ensure a randomized allocation of patients to either group of this study. Hysteroscopy adhesiolysis will be done to all participants in the study. in the first group, Adhesiolysis will be followed by intrauterine use of PRP then insertion of Foley balloon catheter. in the second group, adhesiolysis will be followed by insertion of Foley balloon catheter covered by freeze-dried amniotic graft. In the third group, Adhesiolysis will be followed by insertion of Foley balloon catheter. All foley ballon removed 2 weeks postoperative. All patients will be given antibiotics and hormonal treatment. Also, they will be given low dose aspirin and sildenafil 50mg daily.||||
33777174|NCT04719013|NA|SINGLE_GROUP||OTHER||NONE||||||
33777175|NCT04289987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777176|NCT06180252|||COHORT||PROSPECTIVE|||||||
33777177|NCT01177345|||COHORT||CROSS_SECTIONAL|||||||
33777178|NCT04305236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777179|NCT02662595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33777180|NCT02162693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777181|NCT03634891|||OTHER||PROSPECTIVE|||||||
33777182|NCT02395705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777183|NCT02412761|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33777184|NCT03750773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized 1:1 drug:placebo in blocks of 6 stratified by the hospital, double blind study||t|t|t|f
33777185|NCT01140659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777186|NCT05315219|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33777187|NCT01676220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777188|NCT03252678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33777189|NCT02686970|||OTHER||PROSPECTIVE|||||||
33777190|NCT05215262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083989|NCT03097601|||COHORT||RETROSPECTIVE|||||||
34083990|NCT02265965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34083991|NCT03277040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34083992|NCT01640977|||COHORT||PROSPECTIVE|||||||
34083993|NCT02158897|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33687752|NCT02551250|||CASE_ONLY||PROSPECTIVE|||||||
33687753|NCT05765981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687754|NCT00125684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687755|NCT05950139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687756|NCT00442884|RANDOMIZED|PARALLEL||ECT||NONE||||||
33777191|NCT05942404|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33777192|NCT05441475|NA|SINGLE_GROUP||TREATMENT||NONE||Absk-011 combined with atelizumab in the treatment of patients with advanced or unresectable HCC||||
33908785|NCT06470100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908786|NCT02680847||||TREATMENT||NONE||||||
33908787|NCT02027298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908788|NCT00860340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908789|NCT02633995|||CASE_CONTROL||PROSPECTIVE|||||||
33908790|NCT05578651|||COHORT||PROSPECTIVE|||||||
33908791|NCT05557890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908792|NCT02930655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908793|NCT01596842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33908794|NCT00678509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908795|NCT06290830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33908796|NCT05670964|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centered open labelled two-arm randomized (1:1) superiority trial. One arm will have standard dialysis, the other arm will have dialysis using the UPLUG device||||
33908797|NCT02954003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908798|NCT00102505|NON_RANDOMIZED|||TREATMENT||NONE||||||
33908799|NCT05965739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants assigned to control will be considered part of pooled analyses if the intervention was active at the time of their enrollment and the participants were eligible to receive that intervention. This will result in approximately a 1:1 allocation ratio for any intervention to pooled control.~Sites will be informed to which intervention appendix participants are randomized, but, when applicable, not whether the participants are allocated to the active intervention arm or control arm within that appendix. The participants and investigators will be blinded throughout the study, when possible.~If open intervention appendices do not have the ability to pool controls but have independent controls, at the second stage participants will be randomized in a 1:1 ratio to intervention vs control inside the specific intervention appendix the participants were randomized to at the first stage of the randomization procedure."|"To achieve blinding and an equitable randomization probability, a two-step randomization process will be used. The study will employ a simple (unstratified) randomization scheme.~At the first stage, each participant will be assigned with equal probability to one of the intervention appendices for which the participant is eligible, after applying any intervention-specific safety exclusions. At the second stage, each participant will be assigned according to the specific appendix's randomization procedure. Participants will have an equal chance of being randomized into any of the intervention groups."|t|t|t|f
33908800|NCT04498533|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcome-assessing investigator (O. Celik) was blinded to the randomization. All study participants were assessed by the blinded investigator (O.Celik). Follow-up measurements were performed immediately after and one month later after treatment. All treatment sessions were applied by the same investigator (S. Sencan), who was not blinded to the study groups.|A prospective, randomized and assessor-blinded study|f|f|f|t
33908801|NCT06163794|||OTHER||OTHER|||||||
33908802|NCT00899743|||||RETROSPECTIVE|||||||
33908803|NCT06130696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908804|NCT02531035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908805|NCT05529706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908806|NCT02549911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908807|NCT03885726|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908808|NCT04152525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single Blinded|t|f|f|f
33908809|NCT01864759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908810|NCT01537770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908811|NCT00484250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33908812|NCT02759146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33908813|NCT03488472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908814|NCT01593683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33908815|NCT05522335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908816|NCT05921006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908817|NCT02072317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908818|NCT01028651|||COHORT||PROSPECTIVE|||||||
33908819|NCT05723549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908820|NCT01177280|||CASE_CONTROL||RETROSPECTIVE|||||||
33908821|NCT01507610|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687757|NCT03254368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687758|NCT00225043|RANDOMIZED|PARALLEL||||DOUBLE||||||
33687759|NCT00739596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687760|NCT03119207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687761|NCT05572554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The sample size was calculated as 36 (18 for each group) elderly in total for the two groups (foot bath group, control group) with an effect size of 1,000 and the power of the targeted test was 0.90 (90%) in the G\*Power 3.1.9.6 program with the error of α=0.05 and a reference to a previous study on the subject (14). Considering the cases such as withdrawal from the study or death during the research, each group was increased and a total of 50 elderly individuals, 25 elderly people for each group, were recruited for the study||||
33777193|NCT00003241||||TREATMENT||||||||
33777194|NCT01476579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777195|NCT03018106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908822|NCT04933305|||COHORT||PROSPECTIVE|||||||
33908823|NCT01401816|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34083994|NCT04805333|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991255|NCT02504333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991256|NCT00545792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991257|NCT04737707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991258|NCT00617396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991259|NCT04196335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34083995|NCT03953742|NA|SEQUENTIAL||TREATMENT||NONE||Accelerated titration method followed by a conventional 3 + 3 study design||||
34083996|NCT03310840|||CASE_ONLY||PROSPECTIVE|||||||
34083997|NCT03618875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34083998|NCT02017002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34083999|NCT04135547|RANDOMIZED|PARALLEL||TREATMENT||NONE|The intervention (IO vs IV route) on the patients with out-of-hospital cardiac arrest can not be masked.|randomized clinical trial||||
34084000|NCT00296517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084001|NCT05220423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|patient reported outcome||t|f|f|f
34084002|NCT03096535|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34084003|NCT03164057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084004|NCT02581020|||COHORT||OTHER|||||||
34084005|NCT04206865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084006|NCT06377423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084007|NCT06039163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084008|NCT04833374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084009|NCT02139397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084010|NCT04390347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo.|Double-blind randomised controlled trial|t|t|t|t
34084011|NCT01482559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084012|NCT05625243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084013|NCT05418829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084014|NCT00287430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991260|NCT01890057|NON_RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33991261|NCT05351957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991262|NCT06562686|||COHORT||PROSPECTIVE|||||||
33991263|NCT05852392|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"We will use a stepped wedge design, in which each of 12 clinical practice site starts in the control group, and then sequentially (by random assignment) moves to become intervention. Under enrollment below, we list the number of clinics to be randomized, as individual participants are not randomized or enrolled."||||
33991264|NCT02436005|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33991265|NCT04515095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991266|NCT01503957|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33991267|NCT05469997|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This safety study consists of two 8-week interventions (MeDi-MCT and MeDi-KD) in randomized order using a cross-over design, separated by an 8-week washout period. Participants will be randomized into either the MeDi-MCT or the MeDi-KD group for the first phase of the study. After 8-weeks of intervention, they will undergo an 8-week washout period where no interventions will be applied. Subsequently, the participants will commence the second phase of the study by receiving the other study intervention for 8 weeks.||||
34084015|NCT02005874|||CASE_CONTROL||PROSPECTIVE|||||||
34084016|NCT01441869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34084017|NCT01883206|||COHORT||OTHER|||||||
34084018|NCT00437463|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084019|NCT04119687|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open Label|Part 1 - Open-Label, Single Ascending Dose Phase Part 2 - Open-Label, Expansion Phase to enroll additional patients in DMC-cleared dose levels by sequential assignment against a pre-defined randomized list||||
34084020|NCT01953991|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084021|NCT04355624|||COHORT||PROSPECTIVE|||||||
34084022|NCT05110664|||OTHER||PROSPECTIVE|||||||
34084023|NCT01104961|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34084024|NCT04659005|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34084025|NCT01189097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084026|NCT03580018|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084027|NCT05171907|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pragmatic multicentre randomised controlled trial, open-label, allocation at 1 : 1||||
34084028|NCT04451018|||COHORT||PROSPECTIVE|||||||
34084029|NCT03150459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|As the trial is blinded neither the participants or the researchers will know which group the participants has been allocated to. In order to maintain the blind participants will take two tablets once daily for simvastatin. Group one will receive one 20mg tablet of simvastatin and one placebo table, group two will receive two 20 mg tablets of simvastatin and group three will receive two placebo tablets.|Phase II, multicenter, double-blind placebo controlled, randomized clinical trial|t|t|t|f
34084030|NCT03159143|NA|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized Phase II trial in metastatic transitional cell cancer (TCC) of the urothelial tract.||||
34084031|NCT04937790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is 3 armed randomized controlled trial. Two groups will be participated exercise training, any intervention will not be applied to one group|t|f|t|f
34084032|NCT00947206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084033|NCT06094816|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double blind randomized cross-over|t|f|t|f
34084034|NCT04779177|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991268|NCT02339558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991269|NCT03948100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research staff blinded to group assignment will collect the assessments||f|f|f|t
33991270|NCT01535222|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33991271|NCT02230605|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34084035|NCT02240667|||COHORT||PROSPECTIVE|||||||
34084036|NCT00774085|||CASE_ONLY|||||||||
34084037|NCT02151721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084038|NCT01224379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084039|NCT03736967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084040|NCT01367197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084041|NCT05939687|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 electronic randomisation||||
33908824|NCT05960344|||COHORT||PROSPECTIVE|||||||
33908825|NCT05920187|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908826|NCT00002572||||TREATMENT||||||||
33908827|NCT05891249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908828|NCT02938065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33908829|NCT02332356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33908830|NCT03158688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908831|NCT00199264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908832|NCT05083156|||COHORT||PROSPECTIVE|||||||
33908833|NCT03615755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33908834|NCT00235339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908835|NCT05566678|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A three-group ambulatory preference design, multi-center study||||
33908836|NCT02211404|||COHORT||PROSPECTIVE|||||||
33908837|NCT03984318|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991272|NCT00545805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084042|NCT01878799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084043|NCT01254812|||CASE_CONTROL||RETROSPECTIVE|||||||
34084044|NCT06400901|||OTHER||PROSPECTIVE|||||||
33908838|NCT05913908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908839|NCT01998581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908840|NCT02659111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908841|NCT05511753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908842|NCT04626518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908843|NCT04703660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908844|NCT06195384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908845|NCT00392171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908846|NCT01426711|||OTHER||OTHER|||||||
33908847|NCT05471297|||COHORT||PROSPECTIVE|||||||
33908848|NCT03637842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Encapsulated medication|Double Blind Randomized Controlled Trial|t|t|t|t
33908849|NCT06342804|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33908850|NCT05160649|||COHORT||PROSPECTIVE|||||||
33991273|NCT01531894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084045|NCT00012116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084046|NCT05461066|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34084047|NCT04700865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908851|NCT03940651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908852|NCT01045772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991274|NCT05329025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991275|NCT03151876|NA|SINGLE_GROUP||TREATMENT||NONE||ChiCGB||||
33991276|NCT05119725|||COHORT||PROSPECTIVE|||||||
33991277|NCT03612440|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33991278|NCT02088931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991279|NCT04354363|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A randomized controlled trial|f|f|t|t
33991280|NCT05637125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991281|NCT05649683|NA|SINGLE_GROUP||OTHER||NONE||||||
33991282|NCT04266340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33991283|NCT00748072|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33991284|NCT02237820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991285|NCT05013463|NA|SINGLE_GROUP||TREATMENT||NONE||Simon-2-stage MinMax design||||
33991286|NCT05320146|||COHORT||PROSPECTIVE|||||||
33991287|NCT01101022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991288|NCT00835432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991289|NCT01065740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991290|NCT00706277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991291|NCT00636545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991292|NCT00181805|||CASE_CONTROL||RETROSPECTIVE|||||||
33991293|NCT00529464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084048|NCT00236626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687762|NCT03690323|RANDOMIZED|PARALLEL||TREATMENT||NONE||Radiofrequency ablation (RFA) plus chemotherapy versus chemotherapy monotherapy||||
33687763|NCT04727281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687764|NCT02361580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687765|NCT02895997|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33908853|NCT03965988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908854|NCT02960932|NA|SINGLE_GROUP||OTHER||NONE||||||
33687766|NCT02881333|||COHORT||PROSPECTIVE|||||||
33687767|NCT01362868|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687768|NCT01306877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687769|NCT04508764|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33687770|NCT04817527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687771|NCT03901703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33687772|NCT04604847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective study to analyze perioperative blood samples in patient after knee replacement surgery. Patients will be included in the study at the pre-anesthetic consultation. Serum BDNF levels will be measured preoperatively, 48h postoperatively, 3 and 6 months after surgery.||||
33687773|NCT05503121|||OTHER||PROSPECTIVE|||||||
33802099|NCT03561519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization was done by personnel not treating the patient. The participant or FMT providing personnel did not know the result of randomization. The doctors assessing the outcome have been blinded of the result of randomization.|Placebo controlled trial. 50% of patients received autologous FMT as placebo and 50% received FMT from a healthy donor.|t|t|t|t
33802100|NCT05156736|||COHORT||PROSPECTIVE|||||||
33802101|NCT05704920|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802102|NCT04132934|||COHORT||PROSPECTIVE|||||||
33802103|NCT04592393|NA|SINGLE_GROUP||SCREENING||NONE||||||
33802104|NCT03133234|||COHORT||RETROSPECTIVE|||||||
33802105|NCT03433690|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled trial||||
33802106|NCT02379715|NA|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33802107|NCT04863261|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized trial. The clinics will be randomized to either start using the Cabenuva Scheduling Alerts in the Retention \& Huddle modules of the CHORUS App (Intervention Arm) or to standard of care (Control Arm).||||
33802108|NCT02721901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802109|NCT04498624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802110|NCT01460667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802111|NCT06135246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33802112|NCT03448510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data will be analyzed in a blinded manner.|Irreversible electroporation (IRE) is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.|f|f|f|t
33802113|NCT02888860|||COHORT||PROSPECTIVE|||||||
33802114|NCT02496377|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33802115|NCT01263613|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33802116|NCT06130228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Following medical screening and consent, all patients accepted into the study will be assigned a unique identifier number (1-28), which will be provided to an outside party not associated with Dr. Tarnopolsky or co-investigators that will randomize each subject to one of two experimental conditions. Dr. Tarnopolsky, co-investigators, and the subjects will be blinded to the treatment allocations for the duration of the 4-month trial.|The present study is a 4-month randomized double-blind, placebo controlled, clinical trial with two treatments arms and groups (PDT-MIS and PLA).|t|t|t|f
33802117|NCT04763707|||CASE_CONTROL||PROSPECTIVE|||||||
33802118|NCT03818893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802119|NCT05810194|||COHORT||RETROSPECTIVE|||||||
33802120|NCT01178034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802121|NCT05957731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802122|NCT02001818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802123|NCT00756067|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33802124|NCT00806169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802125|NCT03478917|||COHORT||RETROSPECTIVE|||||||
34084049|NCT03460041|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33802126|NCT06403020|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"In this randomized double blinded study, patients will be allocated randomly into two groups by a computer generated sequence using closed envelope method. Group Q (n=23) will have qadratus lumboroum (QL) block.~Group R (n=23) will have rectus sheath (RS) block."|t|t|t|t
33802127|NCT01747070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802128|NCT05915546|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802129|NCT01337622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802130|NCT03792620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802131|NCT01382849|||CASE_CONTROL||PROSPECTIVE|||||||
33802132|NCT00632203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084050|NCT03328988|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients are randomized and allocated in blocks of ten to either epidural of QLB group|Prospective randomized controlled study||||
34084051|NCT03113734|||OTHER||PROSPECTIVE|||||||
33802133|NCT01989741|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33802134|NCT00364702|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33802135|NCT04843475|||COHORT||CROSS_SECTIONAL|||||||
33802136|NCT04121936|||OTHER||CROSS_SECTIONAL|||||||
33802137|NCT03305536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802138|NCT00243503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802139|NCT00199082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802140|NCT01582100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802141|NCT00533546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802142|NCT00771160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802143|NCT02813369|||COHORT||RETROSPECTIVE|||||||
33802144|NCT00127049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802145|NCT01714492|||COHORT||CROSS_SECTIONAL|||||||
33802146|NCT03647956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802147|NCT04362930|||COHORT||RETROSPECTIVE|||||||
33802148|NCT02283749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802149|NCT03786068|||COHORT||OTHER|||||||
33802150|NCT00962234|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802151|NCT04460807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802152|NCT01627652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802153|NCT01784575|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33802154|NCT06261710|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802155|NCT00055705||||TREATMENT||NONE||||||
33802156|NCT03791905|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized parallel study|t|f|t|t
33802157|NCT04444804|||COHORT||RETROSPECTIVE|||||||
33802158|NCT01279668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802159|NCT04629625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802160|NCT06322043|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802161|NCT03791593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will be blinded for the biomarkers results.||f|f|f|t
33802162|NCT02080754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33802163|NCT05097001|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33802164|NCT03941067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802165|NCT00864552|||COHORT||PROSPECTIVE|||||||
33802166|NCT00350792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802167|NCT05374889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33802168|NCT05493969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802169|NCT05758012|||CASE_CONTROL||PROSPECTIVE|||||||
33802170|NCT06435819|RANDOMIZED|PARALLEL||OTHER||SINGLE||3-treatment between-subjects randomized experiment|t|f|f|f
33802171|NCT05136157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802172|NCT04613700|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||randomised, double-blinded, placebo-controlled, cross-over study|t|t|t|f
33802173|NCT04412317|||COHORT||PROSPECTIVE|||||||
33802174|NCT05286489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802175|NCT01464034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802176|NCT02395913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802177|NCT05722158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33802178|NCT00531596|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33802179|NCT00087139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802180|NCT03003624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802181|NCT03209778|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33802182|NCT04833179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"110 patients with alopecia areata.~Prior the beginning of the study all subjects will undergo:~Complete physical examination Clinical image of involved locations will be taken Estimating the severity of the disease Microbiome samples Blood sample~The patients with AA will undergo randomization into two groups. Group 1 - the subjects will receive a complete fecal transplant course. Group 2 - the subjects will receive placebo."|t|t|t|f
33802183|NCT01704196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802184|NCT02407249|||CASE_ONLY||OTHER|||||||
33802185|NCT06396598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33802186|NCT04414826|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of three groups: (a) Mindfulness alone; (b) Mindfulness + Compassion; and (c) Wait-list control.||||
33802187|NCT02639091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802188|NCT05175898|||COHORT||RETROSPECTIVE|||||||
33802189|NCT02520349|||COHORT||PROSPECTIVE|||||||
33802190|NCT03643900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802191|NCT01620203|||CASE_CONTROL||PROSPECTIVE|||||||
33802192|NCT02949375|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33802193|NCT01264289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34103011|NCT06686563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A double-blind randomized controlled clinical trial will be conducted with 48 elderly volunteers from a daycare center in Famalicão. After an initial cognitive screening (MoCA), assessment of depressive symptoms (GDS-15), agility and functional balance (TUG), and chronic inflammatory conditions (blood analysis), participants will be randomly assigned to a group (IG: intervention group; CG: control group). Participants in the CG will be stimulated with theta frequency (4-7 Hz), while participants in the IG will be stimulated with gamma frequency (39-42 Hz). For both groups, the frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation at the appropriate frequency (GC: theta, GI: gamma). After this period, all participants will be re-evaluated.|t|f|f|t
33777196|NCT05683041|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|None of the participants will be informed of the allocated treatment by the surgeon or the personnel present in the OR. The medical record will not reveal any information whether antiadhesion gel was applied at the end of the procedure. In the case that the surgeon is the same person as the gynaecologist doing the second-look hysteroscopy, blinding is assured by notification of treatment allocation if the surgeon has left the operating room.|This study investigates whether the use of an intrauterine gel can prevent the development of these adhesions. The application of antiadhesion gel is compared to no gel.|t|t|t|f
33687774|NCT02590302|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33687775|NCT06274905|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Single blinding (for participants) only for patients receiving EMLA or EMLA placebo.||t|f|f|f
33687776|NCT04111952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777197|NCT02967211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777198|NCT02628847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777199|NCT06380595|||COHORT||RETROSPECTIVE|||||||
33908855|NCT04208867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777200|NCT01607411|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33777201|NCT05390892|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777202|NCT01888718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908856|NCT04684485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908857|NCT02711761|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33908858|NCT00830661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908859|NCT04702893|||COHORT||PROSPECTIVE|||||||
33908860|NCT05009823|||OTHER||RETROSPECTIVE|||||||
33908861|NCT02003651|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33777203|NCT03023332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33777204|NCT06526208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777205|NCT05599880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777206|NCT06016374|NA|SINGLE_GROUP||OTHER||NONE||||||
33777207|NCT04838093|||COHORT||PROSPECTIVE|||||||
33777208|NCT02710006|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777209|NCT04342962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777210|NCT03093363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33777211|NCT03701425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random assignment, through software, to 4 treatment groups: one, first consume the Mediterranean and exercise plan, second group will be given only nutritional plan with Mediterranean diet, the third group only exercise plan, and the fourth control group which will give a low standard low fat.||t|f|f|f
33777212|NCT03415490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33777213|NCT01587729|||||RETROSPECTIVE|||||||
33777214|NCT03887741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777215|NCT00948259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777216|NCT01327547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777217|NCT00801593|||COHORT||PROSPECTIVE|||||||
33777218|NCT03883958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33777219|NCT01034111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908862|NCT04253301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908863|NCT01058369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908864|NCT03886727|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33908865|NCT04964219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33908866|NCT05821257|||COHORT||PROSPECTIVE|||||||
33908867|NCT03493529|||CASE_CONTROL||PROSPECTIVE|||||||
33908868|NCT01670513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33908869|NCT03236350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908870|NCT05418062|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Not possible die to study design|||||
33908871|NCT04623190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33908872|NCT01223976||PARALLEL||DIAGNOSTIC||NONE||||||
33908873|NCT01324583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908874|NCT05645029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777220|NCT05898737|||COHORT||PROSPECTIVE|||||||
33777221|NCT02653274|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34084052|NCT05707221|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Sequence Generation: A computer random generator will be used to develop a simple randomization Allocation Concealment: This will be achieved using sequentially numbered, opaque and sealed envelopes which will be numbered according to the study numbers. Each envelope includes the treatment allocation card (group 1, 2 or 3) and the related cleaning method with instruction card.~Blinding: An independent person will be responsible for giving the patient the envelope, all data collection and counting will be completed by a microbiologist who would not know about the study."|"The removable appliance will be assigned randomly and blindly and fitted into the oral cavity of the patient for one week. Each individual will be given a pack containing the cleansing pack and an instruction sheet describing the cleaning regimen for his/ her appliance. The packs are similar in shape and color and will be prepared by a third person who does not know the purpose of the study. The volunteer will be grouped into three groups:~Group 1: patients will be instructed to brush both sides of the removable appliance once a day for 1 minute before bedtime using the denture brush and the CHX toothpaste (lacalut active, Germany) provided and water. Group 2: patients will be instructed to immerse the appliance in 150 ml cup with tap water and dissolve one cleansing (lacalut DENT cleaning tablet, Germany) tablet for 20 minutes according to the manufacture instructions. Group 3: Combination of brushing with CHX and cleaning tablets."|f|f|t|t
34084053|NCT03363906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33991294|NCT01469351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777222|NCT00373295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33777223|NCT00897611|NA|SINGLE_GROUP||||NONE||||||
33777224|NCT03265379|||COHORT||PROSPECTIVE|||||||
33777225|NCT02044198|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33777226|NCT01090037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777227|NCT04147260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777228|NCT06169761|||OTHER||OTHER|||||||
33777229|NCT00905060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777230|NCT04963062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized (ratio 1:1) at the time of enrollment to be treated with either the holmium laser with Moses or the thulium laser. Investigators will use Permuted Block Randomization (stratified by stone size 3 - 10 mm or 11-20 mm) (block size 4).|t|f|f|f
33991295|NCT06349863|||COHORT||PROSPECTIVE|||||||
33991296|NCT03525639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991297|NCT00836849|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991298|NCT06057727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||We will randomize primary care clinics 2:1 to the intervention arm or control arm using covariate-constrained randomization. Patients identified as at high-risk for non-completion of the flu vaccine will be additionally randomized 1:1 at the individual level to receive an additional intensification nudge compared with the multi-component nudge intervention alone.|f|f|t|t
33991299|NCT04468126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991300|NCT02257892|||FAMILY_BASED||PROSPECTIVE|||||||
33991301|NCT02177422||PARALLEL||TREATMENT||NONE||||||
33991302|NCT04874454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991303|NCT00304733|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33991304|NCT02355418|||CASE_CONTROL||PROSPECTIVE|||||||
33991305|NCT06561373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The secondary researchers will be blinded to which students are in the control and intervention groups until after they have run the statistical analyses.||f|f|f|t
33991306|NCT06488846|||CASE_CONTROL||PROSPECTIVE|||||||
33991307|NCT05594420|||OTHER||RETROSPECTIVE|||||||
33991308|NCT02478983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991309|NCT05760144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991310|NCT06249360|||CASE_CONTROL||RETROSPECTIVE|||||||
33991311|NCT06563024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687777|NCT03137576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Partecipant masking:~Both blocks are performed on the area between the scapula and the vertebral column, employing the same materials, so that the patient is masked about which block is going to be performed.~Care providers: once the block has been performed, a different anesthesiologist will take care of the patient during the procedure, eventually providing dose escalation in systemic analgesic drugs (primary end point). Surgeons performing the procedure are unaware of the type of block. Staff nurses managing post operative pain in terms of both recording (Numeric Rating Scale) and soothing (rescue analgesia distribution) are unaware of the type of block (secondary end points)."|"Eligible patients will be randomized between two groups according to loco regional pain management:~Paravertebral block Erector Spinae Plane Block Allocation to one treatment group or another will be randomized with the aim of create two unbiased groups formed out of the same group of patients. Randomization will be provided by a software."|t|t|f|f
33687778|NCT03722290|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label trial||||
34084054|NCT01758952|||COHORT||PROSPECTIVE|||||||
33687779|NCT05796778|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33687780|NCT01178996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687781|NCT00922701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687782|NCT01057901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687783|NCT00244842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687784|NCT00201331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687785|NCT03787563|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Double blinded study|all the subjects will receive sequence of different study treatments.|t|t|t|f
33687786|NCT00352716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687787|NCT04381338|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Clustered, due to catchment area of Hospital with no chance of contamination because of lock down in the area.||||
33908875|NCT03974828|RANDOMIZED|PARALLEL||OTHER||DOUBLE||1:1:1 randomization between standard of care (no contact), postoperative contact (brief), postoperative contact (long).|t|f|f|t
33908876|NCT02916498|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33908877|NCT06175650|||COHORT||RETROSPECTIVE|||||||
33908878|NCT04240067|||COHORT||PROSPECTIVE|||||||
34084055|NCT06414863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908879|NCT01229488|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33908880|NCT06409052|||OTHER||CROSS_SECTIONAL|||||||
33908881|NCT03000309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908882|NCT06569147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908883|NCT05298033|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33908884|NCT03737968|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908885|NCT03698604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908886|NCT01031758|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33908887|NCT00269074|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33908888|NCT05933577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|f|t|t
33908889|NCT02834052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084056|NCT05403645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||this study will help to Compare the effect of Exercise Therapy and Movement With Mobilization among patients with knee osteoarthritis in household females||||
34084057|NCT04933318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34084058|NCT00435383|||COHORT||PROSPECTIVE|||||||
34084059|NCT00767858|||CASE_ONLY||PROSPECTIVE|||||||
33687788|NCT00821067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33908890|NCT05442918|||OTHER||PROSPECTIVE|||||||
33908891|NCT00589888|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33908892|NCT02482363|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33908893|NCT02715960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908894|NCT06516796|||COHORT||RETROSPECTIVE|||||||
33908895|NCT03240211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, multi-arm, phase Ib, model-based dose-escalation study. There will be 3 treatment arms in this study.||||
33908896|NCT01629342|||COHORT||PROSPECTIVE|||||||
33908897|NCT04769960|||COHORT||PROSPECTIVE|||||||
34084060|NCT06005649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084061|NCT05775380|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084062|NCT01628536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084063|NCT04447859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084064|NCT00942786|||COHORT||PROSPECTIVE|||||||
34084065|NCT03424148|NA|SINGLE_GROUP||OTHER||NONE||||||
34084066|NCT01616589|||COHORT||PROSPECTIVE|||||||
34084067|NCT05598567|||COHORT||PROSPECTIVE|||||||
34084068|NCT03805841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084069|NCT00359879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084070|NCT05285111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084071|NCT01788761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34084072|NCT05571410|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34084073|NCT00906321|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084074|NCT02581592|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34084075|NCT04039724|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084076|NCT03181308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084077|NCT02009943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084078|NCT04753632|||CASE_CONTROL||PROSPECTIVE|||||||
34084079|NCT05912556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084080|NCT05144763|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Masking is not possible|"The study involves two arms: intervention and control. Health facilities will serve as clusters, with half of the facilities (20) receiving the intervention and the other half serving as controls (20). Health facilities will be randomized to their respective study arm. A parallel design (all health facilities start at the same time) will be used.~At the end of the cluster randomized controlled study, the control facilities will also receive the intervention, along with additional facilities for up to 100."||||
34084081|NCT01987856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084082|NCT00386334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084083|NCT02590458|NA|SINGLE_GROUP||SCREENING||NONE||||||
34084084|NCT00477009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084085|NCT02354768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084086|NCT03684746|||COHORT||OTHER|||||||
34084087|NCT03922880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084088|NCT03847571|||CASE_CROSSOVER||PROSPECTIVE|||||||
34084089|NCT04585919|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||"This trial uses a randomized stepped wedge study design. This pragmatic design involves a sequential, randomized roll-out of the intervention across the four participating clinical sites or clusters over 8 week intervals or steps. The intervention is the paired outreach to patients in need of CRC screening to offer FIT screening and screening for SDOH. The participants who will be enrolled are CHC staff who will provide input on the implementation processes and outcomes."||||
34084090|NCT02858401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084091|NCT06157450|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34084092|NCT05348252|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084093|NCT04213443|||COHORT||RETROSPECTIVE|||||||
33908898|NCT03414840|||COHORT||PROSPECTIVE|||||||
33908899|NCT04645017|NA|SINGLE_GROUP||OTHER||NONE||||||
33908900|NCT03450603|||COHORT||PROSPECTIVE|||||||
33908901|NCT01150994|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
33908902|NCT01814800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908903|NCT04254289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|An independent statistician will develop the randomization schedule and an unblinded study team member will document and maintain the treatment assignment log. The investigators will be adjusting the exercise regimens of those randomized to the exercise program and are unable to be blinded. All patients will receive weekly telephone calls to review activity logs. Outcomes included in the primary and secondary analysis will be blinded as possible. The staff performing the 6-minute walk test (6MWT) and interpreting echocardiograms will be blinded to the group assignment.||f|t|f|t
33908904|NCT01967667|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33908905|NCT05774912|||COHORT||PROSPECTIVE|||||||
33908906|NCT04357353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33908907|NCT03277950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34084094|NCT02084524|NA|SINGLE_GROUP||SCREENING||NONE||||||
34084095|NCT00533338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084096|NCT02184208|||COHORT||RETROSPECTIVE|||||||
34084097|NCT01472055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084098|NCT05294952|RANDOMIZED|PARALLEL||PREVENTION||NONE||preeclasmpsia pregnant women and normal pregnant women||||
34084099|NCT03510065|||COHORT||PROSPECTIVE|||||||
34084100|NCT05402709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Individuals were randomly divided into 3 different groups as posterior mobilisation, posterior capsule stretching and control group|t|f|f|f
34084101|NCT04539418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients are assigned to groups through computer-generated randomization. The investigator will know about the randomization and he will give the care provider the saline or vitamin K2|Prospective, randomized, double-blind study|t|t|f|f
34084102|NCT04616443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084103|NCT01537172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084104|NCT05332223|||COHORT||CROSS_SECTIONAL|||||||
33687789|NCT00457964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687790|NCT01483586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084105|NCT00626639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34084106|NCT06208501|||COHORT||PROSPECTIVE|||||||
33777231|NCT03550729|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33777232|NCT00649974|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33777233|NCT06305273|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study is a prospective randomized cross-over trial to be conducted at Mount Sinai Hospital (Toronto, Ontario, Canada).||||
33777234|NCT00541957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777235|NCT04322487|||CASE_ONLY||PROSPECTIVE|||||||
33777236|NCT01373853|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34084107|NCT04552197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084108|NCT06317974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled, experimental research design in pre-test, post-test design Made with|t|f|f|t
34084109|NCT04005768|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34084110|NCT05812248|||COHORT||PROSPECTIVE|||||||
34084111|NCT02459626|||CASE_CONTROL||PROSPECTIVE|||||||
34084112|NCT01225549|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33777237|NCT00123513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777238|NCT00914017|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33777239|NCT00058903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777240|NCT04481516|||COHORT||PROSPECTIVE|||||||
33777241|NCT05475769|||COHORT||OTHER|||||||
33777242|NCT03166592|||OTHER||CROSS_SECTIONAL|||||||
33777243|NCT00671593|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33777244|NCT03312803|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33777245|NCT01620411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777246|NCT06530901|||COHORT||PROSPECTIVE|||||||
33777247|NCT03413683|||COHORT||PROSPECTIVE|||||||
33777248|NCT00860561|||||PROSPECTIVE|||||||
33777249|NCT02809638|||COHORT||PROSPECTIVE|||||||
33777250|NCT04329052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777251|NCT03606135|||CASE_CONTROL||PROSPECTIVE|||||||
33777252|NCT01463774|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777253|NCT01111591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777254|NCT04129632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No demographic linking to survey participants|Cross sectional study design with intra cohort voluntary intervention participation||||
33777255|NCT00807027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777256|NCT01473420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777257|NCT05793762|||COHORT||PROSPECTIVE|||||||
33777258|NCT04166695|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777259|NCT05180747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded study. Participants were randomly assigned (1:1) to either burst or spaced groups using a computer random generated sequence. Group allocation could not be hidden from the study participant and thus once baseline measurements were recorded, a disclosure of assignment was made by the study PI. Patients Outcomes measures were be performed at baseline and 6 months by a blinded rater.||f|f|f|t
33777260|NCT00574678|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777261|NCT06077825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777262|NCT00530179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777263|NCT01827410|||COHORT||RETROSPECTIVE|||||||
33777264|NCT03833700|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33777265|NCT01359098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777266|NCT00202826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777267|NCT01047943|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33777268|NCT03896269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777269|NCT01222832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777270|NCT03247062||SEQUENTIAL||OTHER||NONE||Quality improvement project - before after design||||
33777271|NCT02246374|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33777272|NCT06308393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777273|NCT05515679|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the intervention||||
33777274|NCT06304844|||OTHER||PROSPECTIVE|||||||
33777275|NCT02998528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777276|NCT00002915||||TREATMENT||||||||
33777277|NCT01113463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777278|NCT04319003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777279|NCT04378504|||CASE_ONLY||PROSPECTIVE|||||||
33777280|NCT01364961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33777281|NCT01477749|NA|SINGLE_GROUP||||NONE||||||
33777282|NCT01381744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33777283|NCT04288466|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33777284|NCT05665764|||COHORT||PROSPECTIVE|||||||
34084113|NCT02845583|||COHORT|||||||||
34084114|NCT05624853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084115|NCT03807635|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084116|NCT01963871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084117|NCT06473584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084118|NCT01041170|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34084119|NCT01533532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084120|NCT05164211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The nurse performing the rhinopharyngometry measurements does not perform the compliance calculation (primary objective). The measurements from the acoustic pharyngometry are analysed (compliance calculation) by a doctor who does not know the child's randomisation arm. Thus, if the subjects have knowledge of their randomisation group, the assessment of the primary endpoint is blinded.|Randomised controlled trial, with minimisation criteria, single blind, bicentric|f|f|f|t
34084121|NCT01716273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084122|NCT06140290|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33777285|NCT05981729|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility study with convenience sample. All in patients with diagnosis of stroke and who fit criteria will be offered intervention.||||
33777286|NCT03841344|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33777287|NCT03254069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777288|NCT05609019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777289|NCT00000811||PARALLEL||TREATMENT||||||||
33777290|NCT00908856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777291|NCT03971695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777292|NCT03175991|||OTHER||CROSS_SECTIONAL|||||||
33777293|NCT05951699|||CASE_ONLY||PROSPECTIVE|||||||
33777294|NCT05349396|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33777295|NCT02019433|||COHORT||PROSPECTIVE|||||||
33777296|NCT00164177|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33777297|NCT04807829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777298|NCT06127160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33777299|NCT01579578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33777300|NCT00989170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33777301|NCT01272596|||COHORT||PROSPECTIVE|||||||
33777302|NCT03754738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33777303|NCT03101592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will be a cluster randomized trial comparing three different antiretroviral therapy (ART) dispensing strategies. Clusters will be comprised of individual clinics in Malawi and Zambia. Enrolled individuals will receive standard of care at their site with the exception of the ART dispensing interval based on the assigned randomization. Outcomes will be assessed after 12 months.||||
33777304|NCT04129411|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single interventional series||||
33777305|NCT00724334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777306|NCT03891680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777307|NCT04592328|||COHORT||PROSPECTIVE|||||||
33777308|NCT03640689|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33777309|NCT02311192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777310|NCT03250598|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33777311|NCT02886728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777312|NCT02594696|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33777313|NCT05348824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777314|NCT03655496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled parallel trial||||
33908908|NCT06168721|||COHORT||CROSS_SECTIONAL|||||||
33908909|NCT01513798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33908910|NCT02409706|||COHORT||PROSPECTIVE|||||||
33991312|NCT01349218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777315|NCT06010485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, single blinded, controlled study|t|f|f|t
33777316|NCT01537354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777317|NCT04404257|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will be blinded to the arm assigned to; but the investigators, cath lab operators and staff will be informed of the randomized assignment.|Randomized 1:1 like a flip of a coin, to receive either cardiac catheterization and or electrophysiology implant procedures without ControlRad system or cardiac catheterization and or electrophysiology (EP) implant procedures with the ControlRad system.|t|f|f|f
33991313|NCT02777580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991314|NCT04050254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991315|NCT04857762|||COHORT||PROSPECTIVE|||||||
33991316|NCT04074603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991317|NCT06225921|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991318|NCT01964053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991319|NCT05108779|NA|SEQUENTIAL||TREATMENT||NONE||||||
33991320|NCT04741217|||COHORT||PROSPECTIVE|||||||
33991321|NCT05155683|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Neither the participants involved in the study, nor the outcomes assessor will be aware of the groups formed, as well as the treatments received.|The abdomen of the participants will be cleaned by using a neutral cleansing soap. Each participant will receive safety glasses for eye protection, which will also contribute to blindness of the study. PBM will be applied when using abdominal straps as developed by Cosmedical (Mauá, São Paulo, Brazil). The abdomen strap will be covered with a sheet and that will also help with the blindness of the study. After randomization, the study population will be divided into four groups (n= 10 per group), which are: (1) Group A - PBM with infrared LED application + sham ultrasound + muscle electrostimulation; (2) Group B - LED sham PBM + ultrasound + muscle electrostimulation; (3) Group C - combined treatment (PBM + ultrasound) + muscle electrostimulation; (4) Group D - sham combined treatment + muscle electrostimulation.|t|f|t|t
33991322|NCT03725969|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|Double-blind||t|f|t|f
33991323|NCT05505747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The study pharmacist that prepared the randomization schedule will meet with the pre-specified unblinded study personnel prior to the site initiation visit. The unblinded personnel will then prepare sealed envelopes that contain each subject's group assignment.~The investigators will designate, a priori, study personnel that will be unblinded. These unblinded personnel will be directly involved with maintaining the drug log and communicating with participants to schedule physical therapy sessions. The unblinded pharmacist/coordinator will access the actual treatment assignment but both blinded study personnel and the patient will not know the patient's treatment assignment. The Investigator, participant, patient assessors, laboratory personnel, and statistician will remain blinded throughout the study."||t|f|t|t
33991324|NCT06157905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991325|NCT01391273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687791|NCT01369654|RANDOMIZED|PARALLEL||||NONE||||||
33687792|NCT04951232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687793|NCT00997542|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33687794|NCT04025476|||CASE_CONTROL||PROSPECTIVE|||||||
33687795|NCT00265928||||TREATMENT||NONE||||||
33687796|NCT04384588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, non-randomized, 4 arms||||
33687797|NCT05857228|||CASE_ONLY||PROSPECTIVE|||||||
33687798|NCT03410264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are prevented from having knowledge of the interventions assigned to individual participants.|Randomized controlled trial with three treatment conditions.|f|f|f|t
33687799|NCT02234856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687800|NCT04564118|||OTHER||OTHER|||||||
33687801|NCT00511212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687802|NCT02497976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687803|NCT00751439|||CASE_CONTROL||PROSPECTIVE|||||||
33687804|NCT02933346|||COHORT||RETROSPECTIVE|||||||
33687805|NCT02960997|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33687806|NCT06142526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908911|NCT03544671|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The Moses Oakford method was used by an independent researcher to randomly assign each child to 1 of 3 groups to receive the administration of the three supplments. A computer was used to generate the random numbers (STATA v.13). Groups were stratified by age from 12- 18 months, from 19- 24 months and form 25- 30 months of age. Each block group was assigned 73 children.|"Double blind, randomized, parallel, controlled trial was conducted in children from 12 to 30 months of age who received four supplements. Four treatments groups were assign randomly to children: One group received 400 IU/d, the second group received 800IU/d of vitamin D2 and the third one 1,000IU/d of colecalciferol D3. The fourth group-control-group- received a multy vitamin supplementation containing: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12.Children were enrolled from 14-day-care centers which are part of a national government program Secretaria de Desarrollo Social SEDESOL , which main objective is to support working mothers and those who intend to work and do not have access to a health service."|t|t|t|t
33908912|NCT02621268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908913|NCT03689283|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants will be blinded to group allocation. Participants in the control group will receive sham needling.|Prospective randomized controlled trial|t|f|f|t
33908914|NCT05249543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators are blinded to treatment condition in the analysis phase. Outcome assessors conducting diagnostic interviews and clinical severity ratings are blinded to treatment condition at post assessment.|Participants are consecutively included in the study and randomly allocated to treatment condition using a 1:1 ratio.|f|f|t|t
33908915|NCT03139955|||COHORT||PROSPECTIVE|||||||
33908916|NCT01563484|||CASE_CONTROL||PROSPECTIVE|||||||
33908917|NCT03023982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33908918|NCT00003943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908919|NCT05239897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908920|NCT05599126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991326|NCT06299319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991327|NCT02846285|||COHORT||PROSPECTIVE|||||||
33991328|NCT06119763|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33991329|NCT00834431|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991330|NCT05110963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study condition masking|Behavioral skills training to improve medication adherence|t|t|t|t
33991331|NCT03785301|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33991332|NCT06164860|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991333|NCT05190068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991334|NCT06321835|||OTHER||PROSPECTIVE|||||||
33991335|NCT00350753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991336|NCT04512586|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients are randomized to either~1. Conduction system pacing via His-pacing electrode, in combination with AV node ablation~2. Pulmonary vein isolation ablation"||||
33991337|NCT05765708|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33991338|NCT00980915|||COHORT||PROSPECTIVE|||||||
33991339|NCT02096185|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33991340|NCT03680053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991341|NCT01125163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33991342|NCT03600805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991343|NCT04603482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991344|NCT00604474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991345|NCT01191996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991346|NCT05829421|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study, non-randomised. An adaptive approach will be used to optimise the intervention content and study conduct as feasibility data are cumulated||||
33991347|NCT01823263|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33991348|NCT06332170|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991349|NCT03242213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991350|NCT00070148|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33991351|NCT03407287|||COHORT||PROSPECTIVE|||||||
33991352|NCT04499664|||COHORT||PROSPECTIVE|||||||
33991353|NCT01966484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991354|NCT05383807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The datasets given to the statistician will be masked to the condition.||f|f|f|t
33991355|NCT06253533|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33991356|NCT02412085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991357|NCT06626698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991358|NCT03110874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33991359|NCT01628835|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33991360|NCT06627010|||COHORT||RETROSPECTIVE|||||||
33991361|NCT00907907|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34084123|NCT00667264|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34084124|NCT00823654|||COHORT||PROSPECTIVE|||||||
34084125|NCT03448848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34084126|NCT00898755|||CASE_ONLY||CROSS_SECTIONAL|||||||
34084127|NCT01571843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084128|NCT03413514||SEQUENTIAL||TREATMENT||NONE||||||
34084129|NCT03556306|||COHORT||RETROSPECTIVE|||||||
34084130|NCT00565864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084131|NCT05387642|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34084132|NCT05090254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084133|NCT01737736|||COHORT||PROSPECTIVE|||||||
33687807|NCT05272085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687808|NCT00407290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991362|NCT06626763|||COHORT||CROSS_SECTIONAL|||||||
33991363|NCT01213797|||||PROSPECTIVE|||||||
33991364|NCT05510830|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991365|NCT02072577|NA|SINGLE_GROUP||||NONE||||||
33991366|NCT03716466|||COHORT||PROSPECTIVE|||||||
33991367|NCT05131113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991368|NCT00178802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991369|NCT04629963|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Investigators will enroll participants from human rights centers and compare the diagnostic ability of the United Nations Istanbul Protocol (UNIP) alone to the UNIP plus a validated pain screen (BPISF), both against the gold standard for pain assessment (pain specialist exam). Participants will complete individual interviews during which we will present our somatic pain treatment model and receive feedback on challenges, limitations, and acceptability of the interventions. A feasibility sub-study will be conducted with the primary outcome being recruitment and retention of participants over a 6-month period. Secondary outcomes include analysis of study visit data (i.e. migration stress, pain, cardiovascular) collected at enrollment and again after 6 months. Digital and biometric data will be collected continuously from a study-provided smartphone application and wearable fitness device for up to 6 months.||||
33991370|NCT04665596|NA|SINGLE_GROUP||TREATMENT||NONE||Ultrasound treatment of calcific aortic stenosis||||
33687809|NCT06259500|||CASE_CONTROL||OTHER|||||||
33687810|NCT03792984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991371|NCT00466401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991372|NCT06628115|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series||||
33991373|NCT04196764|||CASE_ONLY||PROSPECTIVE|||||||
34084134|NCT01930539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084135|NCT01688713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084136|NCT01466361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084137|NCT05241301|NA|SINGLE_GROUP||OTHER||NONE||one to one interviews||||
34084138|NCT01061372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084139|NCT01613924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084140|NCT01846949|||COHORT||PROSPECTIVE|||||||
34084141|NCT03316846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084142|NCT02783898|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084143|NCT00284856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084144|NCT01235377|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084145|NCT02632617|||COHORT||PROSPECTIVE|||||||
34084146|NCT06401876|||CASE_ONLY||PROSPECTIVE|||||||
33687811|NCT05607836|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33687812|NCT04729946|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No Masking is planned|Single-Center Pilot Study||||
33687813|NCT04781777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687814|NCT00790361|||COHORT||PROSPECTIVE|||||||
33687815|NCT06219551|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled, paralel arm, prospective cohort||||
33777318|NCT02086799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777319|NCT05931705|||CASE_ONLY||PROSPECTIVE|||||||
33777320|NCT01880515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33777321|NCT01953510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33777322|NCT02213419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908921|NCT06478758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization of the participants was performed according to computer-generated random number tables, and allocation to a treatment group was performed using the envelope technique. For each participant taken the operating theater for laparoscopic cholecystectomy, an envelope was randomly selected and the code was recorded. The participants were unaware of which drug was being administered. The researcher who recorded the participants' demographic and follow-up data was also unaware of the type of drug being administered.|The present study included ASA grade I-II participants aged 18-65 years scheduled for laparoscopic cholecystectomy. Participants with a history of allergies or hypersensitivity to the aforementioned agents, renal, hepatic or gastrointestinal disease, significant cognitive impairment, recent use of long-term nonsteroid anti-inflammatory and opioids, oral anticoagulant use or known bleeding disorders, diabetes or any other neuropathic diseases and those who were pregnant or breastfeeding were excluded from the study.|f|f|t|f
33908922|NCT04089605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908923|NCT02379234|RANDOMIZED|PARALLEL||TREATMENT||NONE||We performed a 2-phase (training and evaluation), randomized, single-center, open study: During the training phase, intensive care unit nurses underwent a 6-hour training pro- gram and were randomized to receive (intervention) or not (control) an additional high-fidelity simulation training (6 hours). During the evaluation phase, management of CRRT sessions was randomized to either intervention or control nurses.||||
33908924|NCT03075397|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33908925|NCT00983450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33908926|NCT03077178|NA|SINGLE_GROUP||OTHER||NONE||||||
33908927|NCT02659683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33908928|NCT04833985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33908929|NCT02915861|||CASE_CONTROL||PROSPECTIVE|||||||
33908930|NCT03631862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908931|NCT04691752|||OTHER||RETROSPECTIVE|||||||
33908932|NCT02929563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908933|NCT00711399|||CASE_CONTROL||PROSPECTIVE|||||||
33908934|NCT04852588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908935|NCT01061515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908936|NCT04018963|||COHORT||PROSPECTIVE|||||||
33908937|NCT06689059|||COHORT||RETROSPECTIVE|||||||
33908938|NCT01832714|||CASE_CONTROL||PROSPECTIVE|||||||
33687816|NCT00511264|||||PROSPECTIVE|||||||
33687817|NCT02017600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687818|NCT03340428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Intervention arm will be masked to the field researchers and the investigators until unblinding during final analysis.|Individually randomized trial with 2:1 allocation to the intervention compared to care as usual|f|f|t|t
33687819|NCT02399618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687820|NCT01622127|||COHORT||PROSPECTIVE|||||||
33687821|NCT03052543|||CASE_CONTROL||PROSPECTIVE|||||||
33687822|NCT03810404|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33687823|NCT02978131|||CASE_ONLY||RETROSPECTIVE|||||||
33687824|NCT00456807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33687825|NCT02283177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687826|NCT05771168|||COHORT||PROSPECTIVE|||||||
33687827|NCT06363864|||CASE_CONTROL||PROSPECTIVE|||||||
33687828|NCT04517760|||OTHER||CROSS_SECTIONAL|||||||
33687829|NCT05004454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Bacillus subtilis BS50 and placebo powders will be manufactured in to capsules and provided to the clinic in blindly coded containers. The code was generated by parties not responsible for data collection, analysis, or interpretation.||t|f|t|t
33687830|NCT05684731|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a multicenter, open label, non-controlled, exploratory study. The 3+3 dose escalation design will be implemented to evaluate the safety and tolerability of KM1 in the treatment of subjects with recurrent or refractory ovarian cancer."||||
33908939|NCT02688842|NA|SINGLE_GROUP||TREATMENT||NONE||all patients implanted Firehawk stent of new specification (38mm long)||||
33908940|NCT02510235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908941|NCT00921856|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908942|NCT05070273|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908943|NCT03356158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908944|NCT03782818|NA|SINGLE_GROUP||TREATMENT||NONE||The design is open-label. A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given progressive doses of olaparib up to 300mg BID for 24 weeks.||||
33991374|NCT01270594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33991375|NCT00835536|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991376|NCT06485323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patients will have a CT scan (classic follow-up) and an MRI (for the study)||||
33991377|NCT06558760|||COHORT||RETROSPECTIVE|||||||
33991378|NCT00573443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991379|NCT05124366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991380|NCT00084526||||DIAGNOSTIC||||||||
33991381|NCT02399423|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084147|NCT01514916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084148|NCT06288568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33991382|NCT06470906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase 2 participants will be randomized at a 1:1 ratio (intervention: placebo) using a permuted block design. Concealment of random assignment will be accomplished by creation of randomized treatment assignment list, based on permuted block size, by a statistician/data manager at Columbia University who is not part of the investigative team. This statistician/data manager will hold the key to the treatment assignment and will also 1) communicate with the manufacturer on the labeling of sachets, 2) provide the random assignment list to the study site (which will lack information on treatment assignment or block size). In addition, the intervention and placebo will use identical packaging and labeling, and the placebo will have the same amount and similar taste/appearance as the intervention.|30 TGM on TT will be recruited and randomized them to take the intervention (n=15) or placebo (n=15).|t|t|t|t
33991383|NCT05499897|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"Participants will be randomized into 2 groups using the closed envelope method:~Group GA (Patients who will be operated under general anesthesia): Standard ASA monitoring, induction with 2 mg/kg propofol, 0.6mg/kg rocuronium bromide, 1µcg/kg fentanyl. Maintenance with 2MAC sevoflurane + 40% air mixture. Flow 2L/min. Before extubation, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals.~Group IS (Patients who will undergo surgery with interscalen block): 20 ml of 0.25% bupivacaine for anesthesia. Before being taken to the postoperative unit, 1 mg/kg tramadol and 15 mg/kg paracetamol will be administered iv. Paracetamol will be repeated at 8 hour intervals."|This is a randomized,single blind|t|f|f|f
33991384|NCT00130377|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34084149|NCT03037632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinded until intervention is assigned to subject.||t|f|t|f
34084150|NCT05761600|||OTHER||OTHER|||||||
34084151|NCT06300502|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991385|NCT00641134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084152|NCT04678284|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an in-person, phone, or video based behavioral intervention. It will involve a diabetes wellness coach assisting participants to set goals related to diabetes self-care and co-morbidities or social conditions that get in the way of diabetes self-care. There will be encouragement to work on diabetes medication adherence and to address any un/under-treated behavioral health conditions.||||
34084153|NCT00401999|||||PROSPECTIVE|||||||
34084154|NCT01254370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34084155|NCT02442219|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084156|NCT00889239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084157|NCT01181167|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084158|NCT03332537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Using a stratified and blocked randomization scheme.||t|f|f|f
34084159|NCT04630548|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized clinical trial||||
34084160|NCT02600117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777323|NCT02907697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777324|NCT06098807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777325|NCT00507910|||COHORT||PROSPECTIVE|||||||
33777326|NCT05373290|||COHORT||PROSPECTIVE|||||||
33777327|NCT05530967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777328|NCT05879640|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Before-after||||
33777329|NCT04555629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind. Assessor will be blinded to the study. Due to the nature of the intervention, the facilitator and participants cannot be blinded||f|f|f|t
33777330|NCT00615602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777331|NCT01351610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777332|NCT00681187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777333|NCT02034084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777334|NCT04223921|||COHORT||PROSPECTIVE|||||||
33777335|NCT06697743|||COHORT||PROSPECTIVE|||||||
33777336|NCT05818813|||COHORT||PROSPECTIVE|||||||
33777337|NCT04326751|||COHORT||PROSPECTIVE|||||||
33777338|NCT00463151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777339|NCT03498755|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two communities in each of two study regions will be assigned to one of the three treatments (i.e., six communities in total per region). Assigning two communities to the same treatment in each region will allow us to assess differential intervention design and implementation needs for communities in similar geographic areas. Ten women in each community will be purposefully selected for participation to ensure intra-community variation on participant age, socioeconomic status, years of experience with fish smoking, and the scale of fish smoking enterprises. Across both regions, 120 women will be recruited from a total of 12 communities. While the interventions will be delivered to individual women, treatment assignment will be carried out at the community-level given the risk of sharing information and inputs within communities that could contaminate intervention exposure and bias observed treatment effects.||||
33802194|NCT03556085|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single arm, open label clinical study||||
33802195|NCT06281912|||COHORT||RETROSPECTIVE|||||||
33802196|NCT03953001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084161|NCT01356095|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084162|NCT05312996|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34084163|NCT02709317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084164|NCT05138146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084165|NCT01089036|||COHORT||PROSPECTIVE|||||||
34084166|NCT04656990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084167|NCT06088641|||COHORT||RETROSPECTIVE|||||||
33991386|NCT04535388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991387|NCT06623591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991388|NCT04435197|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 1 and 22. Surgery will be performed within 4-6 weeks after completion of preoperative therapy.||||
33991389|NCT04776226|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|There is no masking|Three-site, prospective, nonrandomized controlled trial.|f|f|f|t
33991390|NCT02660996|||COHORT||PROSPECTIVE|||||||
33991391|NCT02695472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991392|NCT04145427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991393|NCT03905980|||COHORT||PROSPECTIVE|||||||
33991394|NCT05086835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991395|NCT00030186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991396|NCT05686694|RANDOMIZED|PARALLEL||OTHER||SINGLE|The research was planned as a single-blind randomized controlled experimental study. The homogeneity of the pregnant women in the education and control groups will be ensured according to age, education level and Instagram usage time. Considering the inclusion and exclusion criteria of the study, pregnant women will be divided into education and control groups by stratified randomization method. For this purpose, pregnant women who meet the criteria of the study will be assigned to the education and control group using a computer-assisted randomization program (https://www.random.org/). Pregnant women will not be informed about the groups they are in, and only the researcher will know which group they will be in, and single-blindness will be provided.|single-blind, randomized controlled, experimental design|t|f|f|f
33991397|NCT01370369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084168|NCT00694772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34084169|NCT00244439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084170|NCT05029492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|an independent researcher assigned the participants to one of the two study groups, by opening sealed envelopes containing serially ordered numbers. An independent assessor analyzed the patients' blood samples for hormonal profile and another assessor blinded to patients' allocation interviewed the patients for the questionnaire and assessed the weight.|Polycystic ovarian women were assigned to either group (A), receiving a low-calorie diet for three months, or group (B), receiving the same diet as group (A) together with visceral manipulation of the pelvic organs and their related structures for the same study period (three months).|f|f|f|t
34084171|NCT00492011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084172|NCT03613831|||CASE_ONLY||PROSPECTIVE|||||||
34084173|NCT02938663|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34084174|NCT02014272|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34084175|NCT02644746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34084176|NCT03528421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084177|NCT01396603|||COHORT||CROSS_SECTIONAL|||||||
33687831|NCT04463511|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In the delivery room, the infant is randomised to application of a polyethylene bag before or after cord clamping. Neither the delivery room care provider nor the investigator are blinded to the group assignment. When the infant is stable, they are be transferred from the delivery room to the neonatal unit. The outcome assessor is the admitting nurse in the neonatal unit who will be blinded to the group assignment.|Single-centre randomised controlled trail|t|f|f|t
33687832|NCT04010188|||COHORT||PROSPECTIVE|||||||
34084178|NCT04197193|||COHORT||PROSPECTIVE|||||||
34084179|NCT03263013|||CASE_ONLY||PROSPECTIVE|||||||
33687833|NCT00133731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687834|NCT04028661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study, the operator and patients can't be blinded. Blinding of the outcome assessors can be done by sealing the name of the patient and the of the pre and post treatment radiographs used for analysis.|The design of this randomized controlled trial is a parallel group, two arm, superiority trial with 1:1 allocation ratio.|f|f|f|t
33687835|NCT03549351|||COHORT||PROSPECTIVE|||||||
33687836|NCT03295526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687837|NCT02958384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687838|NCT05811650|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|School Children in the control group will be in control and will not receive any intervention|The intervention will target school teachers and school children for counseling and oral health promotion education|t|f|f|f
33991398|NCT03031847|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, controlled trial of CRT-P vs. CRT-D in HF patients (age ≥ 75 years)||||
33991399|NCT06627959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991400|NCT03927300|||COHORT||OTHER|||||||
33991401|NCT02158741|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33991402|NCT02586844|||COHORT||PROSPECTIVE|||||||
33991403|NCT04898647|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33991404|NCT06559813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991405|NCT01891877|||CASE_CONTROL||RETROSPECTIVE|||||||
33991406|NCT03867721|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33991407|NCT06429592|||CASE_CONTROL||PROSPECTIVE|||||||
33991408|NCT00865163|||COHORT||PROSPECTIVE|||||||
33991409|NCT05947734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991410|NCT03589313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991411|NCT05519787|||COHORT||RETROSPECTIVE|||||||
33991412|NCT04835363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33687839|NCT04746742|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33687840|NCT02744001|NA|SINGLE_GROUP||OTHER||NONE||||||
33687841|NCT00119600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687842|NCT02436655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687843|NCT05307939|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687844|NCT04195126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors are unaware of the patient groups. Treated patients are not informed regarding randomisation results.|Patients included in our study are randomised into treatment or control groups.|t|f|f|t
33687845|NCT00938964|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687846|NCT02166372|||CASE_ONLY||PROSPECTIVE|||||||
33687847|NCT05430256|||COHORT||CROSS_SECTIONAL|||||||
33802197|NCT01669005|||COHORT||PROSPECTIVE|||||||
33802198|NCT02460393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991413|NCT05049746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991414|NCT01020474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991415|NCT00805779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991416|NCT01106794|||COHORT||PROSPECTIVE|||||||
33991417|NCT01024985|||COHORT||PROSPECTIVE|||||||
33991418|NCT06561672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33991419|NCT03113877|||CASE_ONLY||PROSPECTIVE|||||||
33991420|NCT06619093|||COHORT||OTHER|||||||
33991421|NCT04247243|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084180|NCT01988207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084181|NCT03804281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084182|NCT00676949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084183|NCT02153918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084184|NCT04150315|||COHORT||RETROSPECTIVE|||||||
34084185|NCT04976725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"75 individuals will be included in our study, including 3 groups: control group (N= 25), osteopathic manipulative technique (n= 25), myofascial relaxation group (n=25). Which group of individuals will be determined by randomizing them with closed envelope method.~Osteopathic Manipulative Therapy and myofascial relaxation treatment applications will be applied 2 days a week, for periods of 30 min for 4 weeks."|t|t|t|t
34084186|NCT04454424|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34084187|NCT02688790|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34084188|NCT01563939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33991422|NCT01575457|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33991423|NCT04427358|||CASE_ONLY||OTHER|||||||
33991424|NCT06448221|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33687848|NCT05897944|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33991425|NCT01855685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084189|NCT06516432|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients will be classified into a case group with parasternal block and a control group without parasternal block, with a ratio of cases to controls of 1:1.~In the case-control groups, patients with elevated serum lactate levels above 2 mmol/L and those who remained below this limit will be identified."||||
33687849|NCT00760084|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084190|NCT01901185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084191|NCT00857506|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34084192|NCT05777655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34084193|NCT02758418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084194|NCT05906368|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants will wear both a conventional blood pressure cuff and the ClearSight finger cuff throughout the duration of the 4-hours post-epidural placement.|Participants are randomized to receive standard clinical care (SCC) blood pressure measurement or blood pressure monitoring of HPI via ClearSight with SCC.|t|f|f|f
34084195|NCT00562406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084196|NCT05722691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084197|NCT02191826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084198|NCT00945737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084199|NCT00002844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084200|NCT02691715|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687850|NCT03174496|||OTHER||PROSPECTIVE|||||||
33687851|NCT06338332|||COHORT||PROSPECTIVE|||||||
33777340|NCT06085560|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|Participants will be unaware of their assignment to usual care vs. intervention conditions|Design is factorial. After watching a brief didactic video, participants who opt to partake in colorectal cancer screening self select one of three screening modalities (colonoscopy vs. FIT Kit vs. sDNA Kit). Participants are then randomly assigned to one of three study arms (usual care vs. implementation intentions intervention vs. culturally targeted implementation intentions intervention). Screening selection and study arms are fully crossed.|t|f|f|f
33991426|NCT02566850|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991427|NCT05571449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687852|NCT04690205|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33687853|NCT00003395||||TREATMENT||||||||
33687854|NCT03551080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33687855|NCT03224780|||COHORT||PROSPECTIVE|||||||
33687856|NCT01656174|||COHORT||PROSPECTIVE|||||||
33687857|NCT03767803|||COHORT||PROSPECTIVE|||||||
33687858|NCT00121888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33687859|NCT01124630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687860|NCT04086875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687861|NCT00469261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687862|NCT05018936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991428|NCT02844660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991429|NCT02703194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991430|NCT03923374|||OTHER||PROSPECTIVE|||||||
33991431|NCT00777023|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33991432|NCT05039996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The participants in the intervention group will receive the education and training program in addition to the routine pharmacological treatment whereas the participants in the control group will receive only the routine pharmacological treatment.|t|f|f|f
34084201|NCT06294561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084202|NCT02601755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084203|NCT04675892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were randomized in two groups according to a computer-generated list ranging from 01 to 60 (www.randomization.com). Surgery was then performed according to the method chosen by randomization.||t|t|t|f
33687863|NCT02042105|||COHORT||PROSPECTIVE|||||||
33687864|NCT03384797|||COHORT||CROSS_SECTIONAL|||||||
33991433|NCT06426290|||COHORT||OTHER|||||||
33991434|NCT03463850|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33991435|NCT06627166|||COHORT||PROSPECTIVE|||||||
33991436|NCT00825331|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34084204|NCT00003819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084205|NCT02991079|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084206|NCT00472420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084207|NCT05676554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084208|NCT02901223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084209|NCT02838745|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33687865|NCT00623584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687866|NCT01358071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777341|NCT03670797|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33777342|NCT01013220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33687867|NCT02704910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33777343|NCT06019897|||COHORT||PROSPECTIVE|||||||
33777344|NCT02761629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777345|NCT05143242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be randomly assigned to the control group (GBR) or test group (CTG). Simple randomization was performed using sealed envelopes with an equal number of envelopes for every treatment group. Group allocation was revealed just prior to surgery by the surgeon.~The measuring clinician will not be involved in the treatment of any of the patients and will be blinded to allow unbiased registrations."|randomized clinical trial|f|f|f|t
33687868|NCT05719727|||CASE_ONLY||PROSPECTIVE|||||||
33777346|NCT03317210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.||||
33777347|NCT02011243|||COHORT||PROSPECTIVE|||||||
33777348|NCT05293366|||CASE_ONLY||CROSS_SECTIONAL|||||||
33777349|NCT01091285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34084210|NCT05053581|||COHORT||PROSPECTIVE|||||||
33777350|NCT00364728|||CASE_CONTROL||RETROSPECTIVE|||||||
33777351|NCT00862875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777352|NCT05674084|||CASE_ONLY||PROSPECTIVE|||||||
33777353|NCT03374111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Parallel Assignment|t|t|t|t
33777354|NCT03677375|NA|SINGLE_GROUP||OTHER||NONE||||||
33777355|NCT05608720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33777356|NCT00285090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33777357|NCT01491529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777358|NCT01461993|RANDOMIZED|||PREVENTION||TRIPLE|||t|t|t|f
33777359|NCT05380739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in the MCI group will be assigned to receive either in-person (Arm1) or online WM training (Arm2), based on their preference and availability of equipment ensuring a stable internet connection, for 10 training sessions. Participants in the HC group will receive online training (Arm3). Data for HC who received in-person training was already collected (HUM00033133). WM performance in conjunction with brain imaging will be assessed within-subject, twice pre-training (Time1 and Time2) and once post-training (Time3), as well as \~1 month after training (Follow-up). The Time1 vs. Time2 comparison will reveal task-exposure effects, whereas the Time2 vs. Time3 comparison will reveal training effects.||||
33991437|NCT03421717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Maintenance treatment (test/control) was performed after the investigator left the room. Investigator did not have access to the registration forms where information regarding assignment (test/control) was noted|6 month after surgical intervention, the population is randomly assigned to two parallel groups, receiving one of two maintenance programs - use of titanium curettes or chitosan brushes. Randomization was performed by pulling notes test/control.|f|f|t|t
33991438|NCT00966485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991439|NCT05163847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Syringes wrapped to obscure color of contents|Subjects assigned randomly to one of four cohorts concurrently|t|t|t|t
33991440|NCT05569629|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|All bronchial washing samples will be examined independently by two senior pathologists, who will be blinded to the sequence of bronchial washing and results of the other samples.||t|f|f|t
33991441|NCT06172283|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal||||
34084211|NCT04836377|||COHORT||PROSPECTIVE|||||||
33687869|NCT03117088|RANDOMIZED|CROSSOVER||OTHER||NONE||two armed cluster randomized crossover three periods prospective single centre pilot study||||
33777360|NCT00159510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777361|NCT00655070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991442|NCT06491706|||COHORT||RETROSPECTIVE|||||||
33991443|NCT01422291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33991444|NCT04605211|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991445|NCT04313751|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|After enrollment and baseline assessment, participants will be randomized to a community site receiving either the intervention or waitlist control.||t|f|t|t
33991446|NCT04715646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084212|NCT02265003|||COHORT||PROSPECTIVE|||||||
34084213|NCT06395467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Staff conducting assessments are blinded to participant condition.||f|f|f|t
34084214|NCT03173274|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34084215|NCT02183363|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084216|NCT00926523|||CASE_CONTROL||PROSPECTIVE|||||||
34084217|NCT04952259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687870|NCT01739855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687871|NCT03674931|RANDOMIZED|PARALLEL||PREVENTION||NONE||Longitudinal RCT (clinical trial) with an experimental group and an active control group||||
33687872|NCT01933789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777362|NCT05716646|||OTHER||PROSPECTIVE|||||||
33777363|NCT00253903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777364|NCT03548636|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33777365|NCT02877953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777366|NCT02165124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777367|NCT04548154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777368|NCT02854306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777369|NCT02333396|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777370|NCT05646485|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33777371|NCT05461560|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33777372|NCT05915871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777373|NCT00619151|RANDOMIZED|PARALLEL||||NONE||||||
34084218|NCT01248416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084219|NCT00689065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084220|NCT01982864|NA|SINGLE_GROUP||OTHER||NONE||||||
33991447|NCT06402799|NA|SINGLE_GROUP||PREVENTION||NONE||Feasibility of home-based e-biking among individuals with cerebral palsy. The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised.||||
33991448|NCT00170547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33991449|NCT06146374|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33991450|NCT01811758|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33991451|NCT02208128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991452|NCT03991273|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33991453|NCT01370083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991454|NCT04870320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33991455|NCT03114748|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33991456|NCT04653363|||CASE_CONTROL||PROSPECTIVE|||||||
33991457|NCT04984902|RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary objective is to demonstrate the reduction of BK viremia by treating kidney transplant patients with the Seraph 100 Microbind® Affinity Blood Filter from ExThera Medical.||||
33991458|NCT00959153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991459|NCT02736721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991460|NCT03214952|||COHORT||PROSPECTIVE|||||||
33991461|NCT04500015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized controlled study|double blind randomized controlled study|t|t|t|t
33991462|NCT03831139|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33991463|NCT03076593|||COHORT||CROSS_SECTIONAL|||||||
34084221|NCT04031495|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34084222|NCT05302011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084223|NCT03335046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will be a randomized wait-list control trial. Participants will be randomized to the intervention or control arm for the study observation period. At the conclusion of the observation period, the control group will receive the intervention.||||
33687873|NCT04350398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data will be collected on the Montpellier Institut du Sein site by relying on the CRA who will follow up and check the information in due time of the self-questionnaires. The data will be duly anonymized and handled blindly. Data will be centralized on a secure server at the Equiphoria Institute. Their processing and analysis will be carried out blindly by the PI or by a private service provider (Biostatem France)|A randomized simple-blind controlled trial on efficacy of the hippotherapy treatment against conventional one will be conducted. Patients selected will be randomly divided into 2 groups: hippotherapy treated group versus control group. To ensure that patients in the 2 groups are similar in all respects, except for the planned intervention, the randomization will be stratified by age representing respectively two stages: 1) Pre-menopause; 2) Post-menopause; and by type of treatment: A) Single treatment: surgery or chemotherapy or hormone therapy or radiotherapy; B) Two or more treatments.|f|f|t|f
33687874|NCT04304157|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33687875|NCT01394172|||COHORT||PROSPECTIVE|||||||
33687876|NCT00146588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687877|NCT03204786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687878|NCT01414452|||COHORT||PROSPECTIVE|||||||
33687879|NCT04443751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687880|NCT06477328|RANDOMIZED|PARALLEL||SCREENING||NONE||It is a prospective, randomized controlled, method clinical research study. Patients who were hospitalized with COPD exacerbation in the last year were included in the study and were divided into 2 groups.||||
33687881|NCT02325856|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687882|NCT01215864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687883|NCT01525901|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33687884|NCT02486562|||COHORT||OTHER|||||||
33687885|NCT02663583|||COHORT||PROSPECTIVE|||||||
33687886|NCT02043379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687887|NCT01477203|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687888|NCT02503995|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33777374|NCT01506492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777375|NCT05204784|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33777376|NCT06337539|||COHORT||PROSPECTIVE|||||||
33777377|NCT03199716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777378|NCT00178243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991464|NCT02526121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991465|NCT00787553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777379|NCT00680056|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33991466|NCT06216756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991467|NCT02016274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991468|NCT03086460|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33991469|NCT03251807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991470|NCT03774680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991471|NCT00680277|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084224|NCT03477162|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084225|NCT05283746|NA|SINGLE_GROUP||OTHER||NONE||||||
33777380|NCT06104865|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single arm clinical trial||||
33777381|NCT04042662|||COHORT||RETROSPECTIVE|||||||
33777382|NCT05754021|||COHORT||PROSPECTIVE|||||||
33991472|NCT05491187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will be randomly distributed in the two groups using computed generated numbers that will be concealed in sequentially numbered, opaque sealed envelopes.~The envelopes will be opened by an attending nurse not involved in the study just before the procedure. The study drug will be prepared by the attending anesthesiologist/ resident who will perform the subarachnoid block. The assessment of pain and data collection, data analysis will be done by principle investigator who is blinded to procedure.~Thus, the patients and investigating and analyzing personal will be blinded to the procedure."|Participants are assigned to study where two groups of treatments B and BF are given so that one group receives only B while another group receives only BF for the duration of study.|t|f|t|f
33991473|NCT03874143|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084226|NCT00388245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084227|NCT06523179|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34084228|NCT03738735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34084229|NCT05912868|||COHORT||RETROSPECTIVE|||||||
34084230|NCT06039202|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Up to 100 subjects will be enrolled in this study (including drop-out subjects), with 50 subjects assigned to each treatment arm.~For arm 1, subjects will receive the assigned dose level of CA102N in combination with trifluridine/tipiracil (TAS-102). For Arm 2, subjects will receive bevacizumab in combination with trifluridine/tipiracil (TAS-102)"||||
34084231|NCT03638323|||CASE_ONLY||PROSPECTIVE|||||||
34084232|NCT00465179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084233|NCT05695703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084234|NCT00624091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084235|NCT01836237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34084236|NCT03513952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777383|NCT02799160|||COHORT||PROSPECTIVE|||||||
33777384|NCT01326585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33777385|NCT03460106|||CASE_ONLY||CROSS_SECTIONAL|||||||
33777386|NCT02025348|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33908945|NCT06257238|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Control group: (34 patients with shoulder dysfunction) receive traditional PT for shoulder dysfunction post neck dissection surgeries.~Study group: (34 patients with shoulder dysfunction) receive fully immersive Head-Mounted Display virtual reality exercise plus traditional PT for shoulder dysfunction post neck dissection surgeries."||||
33908946|NCT03417284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908947|NCT04758273|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33687889|NCT01593722|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33687890|NCT05894122|||COHORT||PROSPECTIVE|||||||
33687891|NCT00603421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33687892|NCT04271280|||COHORT||OTHER|||||||
33777387|NCT03757611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33777388|NCT00461565|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33777389|NCT04958187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908948|NCT03411746|||CASE_ONLY||PROSPECTIVE|||||||
33908949|NCT03792776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908950|NCT06693830|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
33908951|NCT06350227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33908952|NCT03160404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908953|NCT02344069|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33908954|NCT05361980|||COHORT||PROSPECTIVE|||||||
33908955|NCT05994794|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33908956|NCT01797198|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33908957|NCT02254668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084237|NCT06201104|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The data of the research will be collected by a statistics expert who has no knowledge of the research process. Patients will not know which group they are in.|Two pulmonology services will be selected by lottery among a total of 9 pulmonology services. Among two chest diseases services, patients will be randomly assigned, one in the experimental group and the other in the control group.|t|f|f|t
34084238|NCT00309517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084239|NCT01933594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084240|NCT04801212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34084241|NCT05148728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991474|NCT05526183|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Vaccines will be provided to the study pharmacist and the randomization to dose levels will be prepared by the pharmacist. The vaccines will be provided to the investigators with volunteer numbers|Parallel arm, double blind study with no control arm. Two doses of vaccine will be administered and the randomization will be performed for dose levels.|t|t|t|t
33687893|NCT04188171|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal prospective study including adult patients, with or without bleeding disorders, with hemorrhoidal disease grades I to III submitted to polidocanol foam sclerotherapy in three health institutions during an inclusion period of 1.5 years. Efficacy and safety outcomes will be compared between two groups of patients: with bleeding disorders (Group A) and without bleeding disorders (Group B).||||
33687894|NCT04934943|||COHORT||PROSPECTIVE|||||||
33687895|NCT01247181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33687896|NCT01046760|||COHORT||RETROSPECTIVE|||||||
33687897|NCT02393586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687898|NCT03867409|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|The study design will be a fractional factorial design for delivering a CRC intervention. Patients will either see a racially concordant virtual human message, a racially discordant virtual human message, a racially concordant text-based message, a racially discordant text-based message, or an attention control message.||t|f|f|f
33687899|NCT02914587|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33777390|NCT01306708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777391|NCT06388070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777392|NCT03564054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777393|NCT03220737|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|The study will be conducted as a double-blind study through 181, where neither the sponsor, the statistical team, study volunteer subjects, nor clinical site personnel (except for the unblinded administration staff) will know subjects' treatment assignment. Once each subject has reached their Day 181 visit they will be individually unblinded.|"This is a randomized, placebo-controlled, double-blind, single-crossover study with three age cohorts and two treatment groups within each cohort.~The main study consists of a screening period of 30 days, a treatment period from Day 1 to Day 29, and a follow-up period through Day 181. Cohort 1 has an optional sub-study consisting of a long-term follow-up period through Day 730."|t|t|t|t
33777394|NCT02472314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777395|NCT01628328|||CASE_CONTROL||PROSPECTIVE|||||||
33777396|NCT02344836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777397|NCT03685279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777398|NCT01547793|||||PROSPECTIVE|||||||
33991475|NCT00027664|RANDOMIZED|||TREATMENT||||||||
33991476|NCT05713058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991477|NCT06559358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991478|NCT05041855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Family participants (children and their caregivers) will be randomized to the Healthy Living Program group intervention or the Recommended Treatment of Obesity in Primary Care individual intervention for an observation period of 18 months from baseline.||||
33991479|NCT06558357|||COHORT||RETROSPECTIVE|||||||
33991480|NCT01034358|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33991481|NCT01652092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991482|NCT06321263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33687900|NCT05630300|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777399|NCT06581536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802199|NCT02411084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991483|NCT00620074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991484|NCT01787565|||COHORT||PROSPECTIVE|||||||
33991485|NCT01439451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991486|NCT03847688|||COHORT||PROSPECTIVE|||||||
33991487|NCT01293591|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33991488|NCT05493735|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33991489|NCT05651191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991490|NCT00041847|||||RETROSPECTIVE|||||||
33991491|NCT06560060|||COHORT||PROSPECTIVE|||||||
33991492|NCT01203267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991493|NCT02163382|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991494|NCT00100464|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33991495|NCT03009955|||COHORT||PROSPECTIVE|||||||
33777400|NCT04850144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Bioanalytical laboratory will be blinded with regard to the sequence of the product administration.|The study is a 2-part 4-period crossover study where the study subjects participate either in part 1 (20 subjects) or in part 2 (20 subjects). Parts can run in sequence or parallel. All study subjects receive single dose of Tiotropium Easyhaler on 3 periods and Spiriva HandiHaler on 1 period.||||
33777401|NCT00203138|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777402|NCT03175575|||CASE_ONLY||CROSS_SECTIONAL|||||||
33908958|NCT04904653|RANDOMIZED|PARALLEL||OTHER||SINGLE||"After axillary node dissection, patients will be randomised to:~* Hemopatch Group: Hemopatch (hemostatic device and surgical sealant) + suction drainage~* Control group: no sealant (liquid, gel or patch) + suction drain"|t|f|f|f
33908959|NCT05006534|||CASE_ONLY||RETROSPECTIVE|||||||
33908960|NCT00112099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908961|NCT01574222|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
33908962|NCT04065022|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33991496|NCT05472350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991497|NCT01137591|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33991498|NCT00027053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33991499|NCT03348553|RANDOMIZED|PARALLEL||PREVENTION||NONE||subjects are randomised into one of 4 intervention groups (control group (CG; consumption of 2 capsules of JP+® Omega Blend/d (Ω2); consumption of 4 capsules JP+® Omega Blend/d (Ω4); consumption of 2 capsules JP+® Omega Blend + Juice Plus+® fruit, vegetable and berry juice concentrate with 2 capsules each /d (Ω2+OGV)). Subjects allocated to Ω2 and Ω4 will receive the herbal fatty acid nutraceutical in the 4-month long study period (intervention phase), subjects allocated to Ω2+OGV will additionally receive the fruit, vegetable and berry juice concentrate. The control group will refrain from using any supplements over the course of this period and will maintain their usual eating habits.||||
33991500|NCT06323239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991501|NCT05726669|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both participants and researchers will not be blinded to condition. This is necessary as participants will know before they consent to the study that they may be randomised to a wait list condition or the intervention, and the lead researcher will contact participants during the intervention (at two weeks) to gather acceptability and adherence feedback. Therefore the researcher needs to know who is in the intervention group to contact them.|A randomised controlled trial (RCT) design will be used, with participants randomised on a 1:1 basis to either a CBT informed self-help intervention to help manage depression in pulmonary hypertension or a controlled wait list condition.||||
33991502|NCT06196515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991503|NCT01200810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991504|NCT01804244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991505|NCT03676946|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908963|NCT03590262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908964|NCT02899793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908965|NCT03092258|||COHORT||PROSPECTIVE|||||||
33908966|NCT00177541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908967|NCT03393364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908968|NCT03041116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33908969|NCT01648608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908970|NCT01841658|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33908971|NCT04346628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908972|NCT01379534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33908973|NCT06681077|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33908974|NCT02015598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908975|NCT02839967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33908976|NCT05208424|||COHORT||PROSPECTIVE|||||||
33908977|NCT02918188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908978|NCT00252902|RANDOMIZED|PARALLEL||||SINGLE||||||
33908979|NCT02293954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33908980|NCT02702908|||COHORT||RETROSPECTIVE|||||||
33908981|NCT00740779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33908982|NCT04290650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908983|NCT05994157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908984|NCT06002282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33908985|NCT01892033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908986|NCT02032537|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33908987|NCT05698771|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33908988|NCT02472548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33908989|NCT02969343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33908990|NCT01977053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33991506|NCT01043952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991507|NCT00926887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991508|NCT01220635|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33991509|NCT00256230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991510|NCT05344053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991511|NCT00298961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33908991|NCT03697967|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomised two arms study|f|f|t|t
33908992|NCT06625112|||CASE_ONLY||OTHER|||||||
33908993|NCT00462696|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33991512|NCT02948335|||COHORT||PROSPECTIVE|||||||
33991513|NCT06012435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991514|NCT05795751|||COHORT||RETROSPECTIVE|||||||
33991515|NCT01055795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991516|NCT04247945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991517|NCT04823169|NA|SINGLE_GROUP||OTHER||NONE||||||
33991518|NCT03016650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991519|NCT06163989|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants will be randomized to receive either the active treatment (TheaLoz Duo) or control condition (no eyedrops) at the first visit. The cross-over will occur one month following the first phase, followed by another month when the participant will be assessed again at the final visit.|f|f|t|t
33991520|NCT04723134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991521|NCT05840796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084242|NCT04739228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084243|NCT05046600|||COHORT||PROSPECTIVE|||||||
33777403|NCT04868474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The smoking cessation experts administering the trainings will not be blinded. GPs will be not be blinded. GPs in the control group will likely realize their training is shorter, and GPs in the intervention group will realize their training is different from traditional teachings. Patients will be told that the study compares two training programs. To the extent possible, outcome assessors will be blinded to study arm when performing follow-up. The statistician performing the primary outcome analyses will be blinded to group assignments.|Cluster randomized trial|t|f|f|f
33777404|NCT00081471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777405|NCT01581047|||COHORT||PROSPECTIVE|||||||
33777406|NCT05203939|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33777407|NCT03943303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor is unaware of the treatment that the patients received.|The study will be carried out on the beaches of Areia Preta de Guarapari (source of monazitic sands) and on the beach of Itapoã in Vila Velha (sand without radiation). Selected patients will have their knees fully covered with beach sand, properly analyzed for radioactivity and temperature, for 30 minutes on 2 mornings a week for a period of 1 (one) year.|f|f|f|t
33777408|NCT00279279|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33777409|NCT02475044|RANDOMIZED|PARALLEL||||NONE||||||
33777410|NCT00906490|||COHORT||PROSPECTIVE|||||||
33777411|NCT02229903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777412|NCT05490069|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33777413|NCT05360758|||COHORT||PROSPECTIVE|||||||
33802200|NCT00412308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839891|NCT04332055|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Patients are blinded from the randomisation, and blinding of the consulting surgeon is not possible since the intervention is an interface add-on to the conventional treatment.|Patients will be randomised to the two intervention arms using a randomised block design stratified by age, Oxford Hip- or Knee Score at baseline and location of disability. Age and Oxford scores are subdivided into suitable categories20. Randomization will be done using REDCap electronic data capture21. Block sizes will be random with possible volumes of four and eight patients. Patients will be randomised after completion of the survey questions at the ePRO kiosk. Information regarding randomisation will be typed in separate REDCap module by the designated helper, after which a randomisation key is automatically generated, which can then be extracted by the designated helper, but blinded from the patient.|t|f|f|f
33839892|NCT03680547|||OTHER||CROSS_SECTIONAL|||||||
33908994|NCT04095286|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a three-period crossover study||||
33908995|NCT06517953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908996|NCT04090281|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, single arm, pragmatic study to determine feasibility of intervention||||
33908997|NCT01850849|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33908998|NCT04070313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33908999|NCT04053179|NA|SINGLE_GROUP||OTHER||NONE||||||
33909000|NCT05480787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33909001|NCT04947683|||OTHER||RETROSPECTIVE|||||||
33909002|NCT06467435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909003|NCT01942213|||COHORT||PROSPECTIVE|||||||
33909004|NCT04065880|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded participants and unblinded investigators and evaluators||t|f|f|f
33909005|NCT05332067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study site's research pharmacy will dispense the study drug as per the randomization schedule provided by REDCap. Prior to injection, an unblinded site pharmacist will confirm the expiration date, the dose, and randomization assignment. The injections will be administered in the Clinical Research Center at the study site by unblinded and trained nursing staff. The product will remain blinded to the investigators, other site staff, the participant, and legal guardians.|Single site, prospective, parallel-group, double-blinded, randomized clinical trial conducted over three consecutive fall seasons.|t|t|t|t
33909006|NCT05239286|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33909007|NCT00190203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909008|NCT04746612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909009|NCT04615962|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33909010|NCT02252874|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33909011|NCT01688752|||COHORT||PROSPECTIVE|||||||
33909012|NCT02028364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991522|NCT00247195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991523|NCT02149420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment was unblinded at an individual patient level at Week 24 to determine their progress in the study (follow-up, open-label VAY736 or End of Study Visit).||t|t|t|t
33991524|NCT05630586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777414|NCT04575805|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The participants will know that they will receive a treatment, but they will be blinded to randomization, i.e. will not know which groups they can be randomized to.|"Factor 1: Cognitive Bias Modification-Interpretation (yes or no)~Factor 2: Cognitive Bias Modification-Attention (yes or no)~Each participant will be randomized to one of four conditions:~Condition 1: Cognitive Bias Modification-Interpretation and Cognitive Bias Modification-Attention~Condition 2: Cognitive Bias Modification-Interpretation and No Cognitive Bias Modification-Attention~Condition 3: No Cognitive Bias Modification-Interpretation and Cognitive Bias Modification-Attention~Condition 4: No Cognitive Bias Modification-Interpretation and No Attention Bias Modification-Attention"|t|f|f|f
33991525|NCT06350955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991526|NCT00200187|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33991527|NCT02903407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991528|NCT02572713|||COHORT||PROSPECTIVE|||||||
33991529|NCT05400694|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Treatments are blinded.||t|f|f|f
33991530|NCT00333645|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33991531|NCT04275479|||COHORT||PROSPECTIVE|||||||
33991532|NCT05452785|RANDOMIZED|CROSSOVER||OTHER||NONE|Laboratory personnel conducting the PK sample assessments are blinded to the treatments.|Single-center, randomized, open-label, laboratory-blinded, 3-treatment, 3-period, 6-sequence, single-dose, crossover study. Eligible subjects will be randomized to a treatment sequence as follows: ABC; BCA; CAB; ACB; BAC; CBA.||||
33991533|NCT01319162|||COHORT||PROSPECTIVE|||||||
33991534|NCT02283463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33991535|NCT06449053|RANDOMIZED|PARALLEL||OTHER||NONE|soins usuels|"* Use of a dedicated e-health application. In order to promote the implementation of DILH prevention measures, we will use an e-health application developed specifically for the study by PRESAGE in the areas where the intervention will take place. This innovative application will be used on admission for all patients included in the acute geriatric sectors in which the intervention will be deployed. It will first assess the risk of DILH individually for each of the 6 risk factors, and then scale the risk for the patient. Once the risk assessment has been carried out, the system will immediately produce a document setting out the personalized care plan for each patient, and disseminate knowledge through documents aimed at patients and caregivers.~* The use of portable, connected treadmills (Ezygain, CE marked)~* The installation of motion detector lighting in hospital rooms"||||
33991536|NCT01527890|||COHORT||RETROSPECTIVE|||||||
33777415|NCT01225042|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33991537|NCT05235386|||COHORT||RETROSPECTIVE|||||||
33991538|NCT00211653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991539|NCT06447948|NA|SINGLE_GROUP||PREVENTION||NONE||Phase 1- Acceptability Study \& Phase 2-Feasibility Study||||
34084244|NCT06221709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants will be blinded to which group they will be allocated, as well as data assessors, who will not have contact with participants on the day of the procedure. In order to avoid differentiating the number of perforations needed to perform each procedure, all patients will receive the same bandage (Opsite®) in the anterior region of the hip, with instruction to remove it only the day after the procedure.||t|f|f|t
33777416|NCT00848211|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34084245|NCT04066374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084246|NCT03895801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084247|NCT01330082|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34084248|NCT00927407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777417|NCT00628069|||CASE_CONTROL||PROSPECTIVE|||||||
33777418|NCT01316497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33991540|NCT00104481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991541|NCT01937143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991542|NCT03616405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084249|NCT05143697|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The proposed study is a pragmatic cluster-randomized trial to test the impact of a modified version of the BMI2 intervention, which we have named mBMI2Kids. Target population are children aged 2-8 years with a BMI-for-age ≥85 percentile from 49 Kaiser Permanente pediatric clinics in Southern California. All children and their parent/guardian reached will be included according to the clinic in which they receive care (Intervention-to-treat approach).||||
34084250|NCT05003674|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084251|NCT05122481|NA|SINGLE_GROUP||OTHER||NONE|Randomized number allocation|This is a pilot dose-finding study comprising 20 older people ENRICH listed care home residents (aged 65+) with capacity.||||
34084252|NCT01470534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084253|NCT00611052|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34084254|NCT05297357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687901|NCT06518694|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only outcomes assessor will be blinded to the study arm (Blinded endpoints prospective trial)|National, Multicenter, Randomised, Open-label, Non-inferiority, Blinded endpoints prospective trial|f|f|f|t
33687902|NCT02757950|||COHORT||PROSPECTIVE|||||||
33687903|NCT01860846|||COHORT||PROSPECTIVE|||||||
33687904|NCT06192589|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Part 1 of the study will be double-blind, and the blind will be maintained through a randomization schedule held by the dispensing pharmacist. The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.~Part 2 is an open label study."|"This is a two-part study. Part 1 is a randomized, double-blind, placebo-controlled, parallel study in 200 subjects (150 subjects receiving cannabidiol and 50 subjects receiving placebo).~Part 2 is an open-label, sequential study in 40 subjects (two separate cohorts of 20 subjects)."|t|t|t|t
33687905|NCT04403490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33687906|NCT00782327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687907|NCT00797342|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33687908|NCT02272387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33687909|NCT02099812|||COHORT||CROSS_SECTIONAL|||||||
33687910|NCT06032481|||COHORT||RETROSPECTIVE|||||||
33687911|NCT00156702|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33687912|NCT01705782|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33687913|NCT02633618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777419|NCT04119245|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777420|NCT00117754|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33777421|NCT05805540|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the participants and the investigators who performed the intervention were didn't know whether they were drinking the protein-carbohydrate supplementation or the placebo.|A crossover design was used to examine the effects of four different recovery interventions on muscle damage and fatigue and physical performance after a maximal exercise test in elite male basketball players. Thus each athlete performed all the recovery methods that were included in the study, one week apart; including CWI, carbohydrate-protein supplementation, active recovery, and placebo-control condition.|t|f|t|f
33777422|NCT01336062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777423|NCT00642928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777424|NCT00283309|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33777425|NCT04351490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777426|NCT03819569|NON_RANDOMIZED|PARALLEL||OTHER||NONE||non-randomized, comparative||||
33777427|NCT04506671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777428|NCT03070314|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study participants take 5 tablets Echinaforce junior at once one after another per os. registered in Switzerland for children from age of 4 -12 years Six capillary blood draws are taken at the following time points: Start (0), after 15, 30, 60, 90, 270 minutes and then analyzed on the amount of tetraen. Bioavailability parameters will thereafter be calculated.||||
33777429|NCT03696979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33777430|NCT06160921|||COHORT||RETROSPECTIVE|||||||
33777431|NCT03055845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Following treatment of 2 patients in each dose group (injections with active drug and placebo, respectively), safety data will be reviewed. If no safety or tolerability concerns are identified, the next 3 patients in each dose group will be treated (active treatment or placebo \[2:1\]).|t|t|t|t
33777432|NCT06200038|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants did not know the difference between sham and true mobilisation.||t|f|f|f
33777433|NCT04529538|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||It will be an 8-arm, randomized, observer-blind, controlled trial|t|f|t|t
33777434|NCT02420275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777435|NCT02059161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777436|NCT02914106|||CASE_CONTROL||PROSPECTIVE|||||||
33777437|NCT06213012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777438|NCT03198260|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33777439|NCT05054829|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33909013|NCT02908958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909014|NCT02026908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909015|NCT06472258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909016|NCT02256865|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33909017|NCT03852810|||OTHER||PROSPECTIVE|||||||
33909018|NCT06692517|||COHORT||OTHER|||||||
33909019|NCT02535520|||CASE_ONLY||PROSPECTIVE|||||||
33909020|NCT02226042|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909021|NCT06099600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909022|NCT05599685|||COHORT||PROSPECTIVE|||||||
33909023|NCT04686006|||CASE_ONLY||RETROSPECTIVE|||||||
33909024|NCT04124523|||OTHER||PROSPECTIVE|||||||
33909025|NCT01713335|||OTHER||PROSPECTIVE|||||||
33909026|NCT01724736|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33909027|NCT03002389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084255|NCT04084496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084256|NCT06124508|RANDOMIZED|PARALLEL||SCREENING||SINGLE|All participants will be randomized in a 1:1 ratio to the intervention or control arm via a blinded systematic randomization.||t|f|f|f
34084257|NCT04611880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687914|NCT04782960|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33687915|NCT00911742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687916|NCT01285960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687917|NCT02581540|||COHORT||PROSPECTIVE|||||||
33687918|NCT02530567|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33687919|NCT03961074|||COHORT||PROSPECTIVE|||||||
33687920|NCT03064581|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33687921|NCT02274701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33687922|NCT00479583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909028|NCT04329611|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|A randomized, double-blind, placebo-controlled trial - trial staff and patients will all be blinded to the treatment allocation.|Randomization will be conducted using an online tool. The use of an online tool will allow for dynamic randomization which ensures concealment of allocation. We will use a minimal sufficient balance randomization tool to ensure balance on age, sex, risk status (binary variable based on immune competence and other identified risks), days from symptom onset to randomization and provincial health zone (5 categories). These variables will be identified at telephone screening by a study coordinator, clarified with a physician when necessary, and entered into the online randomization tool. It is predicted that many patients will want treatment. Further, immunosuppressed patients may be at the highest risk of fatal outcomes. Therefore, we will use 2:1 randomization (HCQ: placebo).|t|t|t|f
33909029|NCT06158854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909030|NCT01734187|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33909031|NCT04514237|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||Part 1 was a two-way crossover design, followed by two sequential ascending dose periods. Part 2 was designed to be a multiple ascending dose design.|t|f|t|t
33909032|NCT02476981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909033|NCT03712163|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33909034|NCT01087528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909035|NCT03011372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909036|NCT01815710|||OTHER||OTHER|||||||
33909037|NCT01554956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909038|NCT02520804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084258|NCT03176771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084259|NCT02029417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909039|NCT06691906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33909040|NCT00883558|RANDOMIZED|CROSSOVER||||NONE||||||
33909041|NCT01233401|||CASE_ONLY||CROSS_SECTIONAL|||||||
33909042|NCT03666117|||COHORT||PROSPECTIVE|||||||
33909043|NCT03382899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909044|NCT05903300|||OTHER||CROSS_SECTIONAL|||||||
33909045|NCT04158024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33909046|NCT05313711|||COHORT||PROSPECTIVE|||||||
33909047|NCT00019513||||TREATMENT||||||||
33909048|NCT06239909|||CASE_CONTROL||PROSPECTIVE|||||||
33909049|NCT01583322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909050|NCT04332029|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to each of the two treatment conditions in accordance with a computer-generated randomization list. The treatment conditions will be actively running in parallel.||||
33909051|NCT01105416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33909052|NCT04552535|||COHORT||RETROSPECTIVE|||||||
33909053|NCT04229550|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909054|NCT04044391|||COHORT||PROSPECTIVE|||||||
33909055|NCT04796662|||OTHER||OTHER|||||||
33909056|NCT03705962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909057|NCT02709135|||COHORT||PROSPECTIVE|||||||
33909058|NCT00170248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909059|NCT04140708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909060|NCT01244542|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33909061|NCT01313104|NA|SINGLE_GROUP||SCREENING||NONE||||||
33909062|NCT05516901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group allocation was done by sealed opaque envelope technique. All blocks were performed by the same anesthesiologist while the measurements were taken by another anesthesiologist who is blinded to the study groups and had no subsequent involvement in the study.|Fifty obese patient BMI (30-40), aged (21-65) years ASA (ІΙ and ΙΙІ) and scheduled for elective Epigastric hernia repair were enrolled in the study.|t|f|f|t
33909063|NCT00584220|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33909064|NCT03587675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||adolescents from different athletic disciplines and recreational adolescents will be tested for atopy, exercise-induced bronchospasm measured by EVH and biomarkers for EIB will be studied in blood and induced sputum||||
33909065|NCT06175611|||OTHER||PROSPECTIVE|||||||
33909066|NCT01888705|||||CROSS_SECTIONAL|||||||
33909067|NCT01507584|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33909068|NCT02255851|||COHORT||PROSPECTIVE|||||||
33909069|NCT01850563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909070|NCT06692855|||CASE_ONLY||RETROSPECTIVE|||||||
33687923|NCT06115837|||CASE_ONLY||RETROSPECTIVE|||||||
33687924|NCT04552262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33687925|NCT06206070|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to treatment group and waitlist group in parallel for the duration of the study|f|f|f|t
33687926|NCT00048087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687927|NCT01784627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687928|NCT00461331|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33687929|NCT03608423|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We will include 40 patients in the surgical arm (inclusion in three hospitals) and aim for 120 matched controls in the other arm (in 7 other hospitals).|f|f|f|t
33909071|NCT01689207|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33909072|NCT00166179|||COHORT||PROSPECTIVE|||||||
33909073|NCT00086957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909074|NCT03653611|||OTHER||PROSPECTIVE|||||||
34084260|NCT02330341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a study with two groups of patients with prediabetes. One group received the investigational product (Artemisia Dracunculus) and the other received placebo as control.|t|f|t|f
34084261|NCT00523211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084262|NCT02650375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084263|NCT01893606|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33991543|NCT05912127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will be classified into 2 groups according to the implant treatment concept they received:~* Group 1 (control group); included 3 patients who received All on 4 implant-supported fixed restoration. The patients received 2 inclined implants anterior to the mental foramina and 2 vertical implants in the lateral incisor/canine areas.~* Group 2 (test group); included 3 patients who received All on 3 implant-supported fixed restoration. The patients received 2 inclined implants anterior to the mental foramina and 1 vertical implant in the midline of the mandible."|t|f|f|f
34084264|NCT03351803|||COHORT||PROSPECTIVE|||||||
34084265|NCT01102634|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34084266|NCT05158569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084267|NCT05017844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084268|NCT01077219|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084269|NCT03928366|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Volunteers receiving propofol and then remifentanil.||||
34084270|NCT04236284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084271|NCT03881683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084272|NCT05647187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084273|NCT06419491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084274|NCT03456661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34084275|NCT06082479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A) Sequence generation;was done using a random sequence number generated by computer software.~B) Allocation Concealment Mechanism: Folded, numbered papers were placed in tightly sealed envelopes containing the patient's coding"|This study was designed to be a randomized, controlled, single-blinded, single-center clinical trial.|f|f|t|t
33687930|NCT03960021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687931|NCT05156476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33687932|NCT00877474|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084276|NCT03281044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084277|NCT04442711|||COHORT||PROSPECTIVE|||||||
34084278|NCT02969785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084279|NCT01077336|||COHORT||RETROSPECTIVE|||||||
34084280|NCT02169882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084281|NCT03444558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double-blind study|placebo-controlled study|t|f|t|f
33687933|NCT04307745|||COHORT||OTHER|||||||
33687934|NCT03309046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33687935|NCT02249962|||COHORT||PROSPECTIVE|||||||
33687936|NCT04258137|RANDOMIZED|PARALLEL||OTHER||NONE||"For each distinct population of patients with Advanced solid tumor (colorectal cancer and non-small-cell lung cancer), patients will be randomized between two arms:~Experimental procedure: initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up combining standard imaging and ctDNA analysis (subsequent MTBs at each radiological assessment).~Standard procedure: initial MTB providing therapeutic recommendation based on tumor sequencing and then follow-up based on standard imaging."||||
33687937|NCT00400114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687938|NCT06374251|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33687939|NCT00333892|||COHORT||PROSPECTIVE|||||||
33991544|NCT04757298|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||SMART Design||||
33991545|NCT05150041|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084282|NCT02196584|||CASE_CONTROL||PROSPECTIVE|||||||
34084283|NCT06104397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There are 3 treatment groups: 1) standard care, 2) written exercise guidance by neurologists, and 3) physical therapy.||||
34084284|NCT02147626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084285|NCT04506736|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participant, Care Provider||t|t|f|f
34084286|NCT02111083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084287|NCT03795415|||CASE_CONTROL||PROSPECTIVE|||||||
34084288|NCT02333253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777440|NCT03162809|||CASE_ONLY||PROSPECTIVE|||||||
33991546|NCT03851354|NA|SINGLE_GROUP||OTHER||NONE||"The measurement will be carried out by experienced intensive care physicians who have completed a 4-hour training (12 patients). Patients will be placed with elevation of the head at 30 ° (except in patients with hip or spinal cord injury). For gastric scanning, a 2 to 5 Hz curved transducer for ultrasound will be used, in a parasagittal plane in the epigastric area. The right lobe of the liver and the abdominal aorta will be used as posterior and internal reference points. Once the visualization is achieved, it will rotate to achieve the transverse view of the gastric antrum.~Measurements will be made at 2, 5, 10, 20, 30 and 60 minutes for gastric tolerance and the difference between the initial and final measurement will be measured to see the tolerance of it. At the end of the test, a gastric residue measurement will be performed to compare results."||||
33991547|NCT05235581|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Prospective, multicenter, controlled, randomized study on healthy volunteers.||||
33991548|NCT01322880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991549|NCT05852405|||COHORT||PROSPECTIVE|||||||
33991550|NCT06469671|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33991551|NCT03931460|||CASE_ONLY||PROSPECTIVE|||||||
33991552|NCT05748990|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||In a single-blind crossover design, participants will undergo an \[18F\]-FDG PET scan on 2 separate occasions separated by 4-7 days. One of the PET scans will be following intranasal placebo (saline) and the other will follow an intranasal insulin challenge (160 IU). The scans will be conducted in a randomized counterbalanced order across participants to account for exposure to antipsychotics between the two scans.|t|f|f|f
33991553|NCT01152827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991554|NCT00002880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991555|NCT04371081|||COHORT||PROSPECTIVE|||||||
33991556|NCT01471353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991557|NCT00078039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33991558|NCT03935880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991559|NCT06523842|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33991560|NCT04584294|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research assistants (RAs) who assess outcomes will remain blinded to provider study arm assignment throughout the trial. RAs will be blinded to patient study arm assignment during patient enrollment and baseline surveys but will become unblinded to individual patient study arm assignment during the course of outcome assessment.|Provider participants are randomized to one of two groups - usual care or intervention group - at the start of the study, prior to any Veteran enrollment. Subsequently, Veterans scheduled to see these providers will be enrolled as patient participants and automatically allocated to the study group of their scheduled provider.|f|f|f|t
33991561|NCT05597982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33687940|NCT03858465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33687941|NCT01285440|||CASE_ONLY||PROSPECTIVE|||||||
33687942|NCT02050971|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33687943|NCT03977428|||COHORT||PROSPECTIVE|||||||
33687944|NCT01355029|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33687945|NCT05915559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687946|NCT01542177|||COHORT||PROSPECTIVE|||||||
33687947|NCT06282367|||COHORT||PROSPECTIVE|||||||
33687948|NCT06104046|||OTHER||PROSPECTIVE|||||||
33687949|NCT00468767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687950|NCT05151627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991562|NCT01724294|||COHORT||PROSPECTIVE|||||||
33991563|NCT00172679|||DEFINED_POPULATION||OTHER|||||||
33687951|NCT01203254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687952|NCT00333203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33687953|NCT00880165|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33687954|NCT02741388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777441|NCT05275517|||CASE_CONTROL||PROSPECTIVE|||||||
33777442|NCT01062815|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33777443|NCT00830986|||CASE_CONTROL||PROSPECTIVE|||||||
33777444|NCT04724174|||CASE_CONTROL||RETROSPECTIVE|||||||
33777445|NCT04106687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All Children will be randomly assigned to one of 2 groups of 20 patients each using a computer-generated number table.|t|f|f|t
33777446|NCT02501811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777447|NCT02915380|||COHORT||PROSPECTIVE|||||||
33909075|NCT06499545|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33909076|NCT05218499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909077|NCT05124054|||CASE_CROSSOVER||PROSPECTIVE|||||||
33909078|NCT04060173|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33909079|NCT00343304|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909080|NCT00878540|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909081|NCT04419064|||COHORT||RETROSPECTIVE|||||||
33909082|NCT03532945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084289|NCT01719653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34084290|NCT00076570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687955|NCT04387760|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel, prospective, interventional and randomized open label pilot trial involving 150 patients with COVID-19 disease. On confirmation of SARS-CoV-2 infection subjects will be randomised to hydroxychloroquine or favipiravir or standard clinical care.||||
33687956|NCT02240173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33687957|NCT04357847|||COHORT||PROSPECTIVE|||||||
33687958|NCT05551637|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Control Group (300 participants): Children eat usual dietary(not using Oral Nutritional Supplementation) for 3 months. After that, they will use the product for 3 months.~Specific Intervention Group (300 participants): Children eat usual dietary, with 2 glasses of Oral Nutritional Supplementation as the side meals. The product provides GOS, Calcium, Probiotics, HMO, DHA, and Taurine within 3 months of use."|"Step 1: Investigate the nutrition status of all children aged 24 - 71 months in 10 preschools in 10 selected communes. Expecting 3500 targets in 10 examined preschools~Step 2: After the investigative selection, participants that meet the standard will be invited to the study ( the communes selected can be narrowed if the targets are hit). As soon as parents sign the consent paper, the study will move to the next step.~Step 3: Groups will be divided to investigate activities. Creating a list for all participants that meet the criteria, with WHZ/BAZ \<-0,5. Randomly selection based on age to ensure that there is no significant difference in the nutritional index or related indicators in the group to assess the effectiveness of the intervention (divided by class/age). Then, randomly divided the target by class into three large groups (300 targets per group)"|t|f|t|f
33687959|NCT02382250|||COHORT||PROSPECTIVE|||||||
33687960|NCT00676221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687961|NCT03624530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687962|NCT06154200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double|Subjects randomized to either placebo or drug|t|f|t|t
33687963|NCT03844477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33687964|NCT01646060|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33687965|NCT00882492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687966|NCT05505773|||COHORT||PROSPECTIVE|||||||
33687967|NCT00401141|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33687968|NCT01209962|||COHORT||PROSPECTIVE|||||||
33687969|NCT05652829|||COHORT||CROSS_SECTIONAL|||||||
33687970|NCT02653261|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33687971|NCT05606718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687972|NCT05809739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687973|NCT04029532|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33777448|NCT00165620|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33777449|NCT02775747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777450|NCT01277237|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33777451|NCT01889160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33777452|NCT00816140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777453|NCT01269398|NA|SINGLE_GROUP||||||||||
33777454|NCT04466332|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777455|NCT06229470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777456|NCT06492941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized in a 2:1 ratio to Docetaxel for Injection (Albumin Bound ) in combination with best supportive care or placebo in combination with best supportive care|t|t|t|t
33839893|NCT01365936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839894|NCT01708343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839895|NCT04968431|||COHORT||PROSPECTIVE|||||||
33839896|NCT02793271|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33839897|NCT01157286|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33687974|NCT01095471|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33687975|NCT00840814|||COHORT||CROSS_SECTIONAL|||||||
33687976|NCT06053008|NA|SINGLE_GROUP||OTHER||NONE||||||
33687977|NCT00908011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687978|NCT02403388|||OTHER||PROSPECTIVE|||||||
33687979|NCT06268145|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33687980|NCT04113811|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-centre prospective phase 2 trial to investigate the efficacy of Microwave needle thermoablation of prostate cancer using the Biomedical TATO3® (Thermal Ablation Treatments for Oncology 3) ablation system in patients with localized prostate cancer.||||
33687981|NCT00762593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33687982|NCT06415851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839898|NCT06337604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839899|NCT00633880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839900|NCT01680081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839901|NCT03186001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|f|t
33839902|NCT03684564|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants enrolled in RISAPS will be randomly allocated 1:1 to receive either oral rivaroxaban 15mg twice daily or oral warfarin (standard of care in the RISAPS trial) to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months.||||
33839903|NCT01364337|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33909083|NCT00500786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909084|NCT00002118||||TREATMENT||NONE||||||
33909085|NCT03311607|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33909086|NCT04735367|||COHORT||RETROSPECTIVE|||||||
33909087|NCT04951336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Mix model involving two groups and multiple measurements across study time-points|t|t|t|f
33909088|NCT06551077|||COHORT||PROSPECTIVE|||||||
33687983|NCT02516735|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33687984|NCT03228290|||COHORT||PROSPECTIVE|||||||
33687985|NCT04169347|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter open-label||||
33909089|NCT06255561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909090|NCT05856799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Partly patient and accessor blinded and partly open label.|Combined parallel and crossover randomized trial|f|f|t|t
33909091|NCT00488033|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33909092|NCT00454064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909093|NCT00543829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909094|NCT05356624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909095|NCT01833273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909096|NCT00538876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909097|NCT03839147|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This randomized controlled study was conducted at Gulhane Training and Research Hospital, Obstetrics and Gynecology clinic between May 2016 and January 2017. The CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting randomised controlled trials (RCTs) has been used to describe the methods.|t|f|t|f
33909098|NCT01003561|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33909099|NCT02674737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909100|NCT03002116|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33909101|NCT02493309|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33909102|NCT00257192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909103|NCT01989546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909104|NCT01100307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909105|NCT00386893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909106|NCT05039580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909107|NCT02003196|||COHORT||PROSPECTIVE|||||||
33687986|NCT05963893|||COHORT||PROSPECTIVE|||||||
33909108|NCT01878851|||CASE_ONLY||PROSPECTIVE|||||||
33687987|NCT00455910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33687988|NCT00613197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909109|NCT05894278|||COHORT||PROSPECTIVE|||||||
33991564|NCT05806853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991565|NCT04505085|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A non-randomized quasi-experimental design will be used to evaluate the feasibility of the Active Dads Healthy Families intervention, and provide preliminary data of changes over time and between two forms of the intervention. The investigators will recruit two cohorts totaling 30 father-child dyads (15 per cohort) to take part in the 8-week program delivered by Parks and Recreation. The primary outcome is program feasibility.||||
33991566|NCT00859105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991567|NCT05955417|||CASE_ONLY||CROSS_SECTIONAL|||||||
33991568|NCT02375386|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33991569|NCT02269657|||COHORT||PROSPECTIVE|||||||
33991570|NCT03556813|||COHORT||PROSPECTIVE|||||||
33991571|NCT06627140|||COHORT||PROSPECTIVE|||||||
33991572|NCT06324825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084291|NCT00485355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34084292|NCT04222491|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label observational single center study of clinical food oral immunotherapy outcomes with biomarker samples and participant and/or caregiver-completed questionnaires in participants between 6 months and 65 years of age with IgE-mediated peanut allergy undergoing food oral immunotherapy.||||
34084293|NCT03370952|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991573|NCT04968405|NA|SINGLE_GROUP||TREATMENT||NONE||Catalyst CSR Shoulder System||||
33991574|NCT05204979|||COHORT||PROSPECTIVE|||||||
33991575|NCT01355133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084294|NCT03945630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"* Procedure: Quadratus Lumborum Block (QLB) Ultrasound guided Quadratus Lumborum block using an anterior approach. (QLB3; TQL-Transmuscular Quadratus Lumborum)~* Procedure: Standard of Care (no QLB)"|f|t|f|t
34084295|NCT05516303|||CASE_CONTROL||RETROSPECTIVE|||||||
34084296|NCT02519725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the psychologist is blind for the study for assessing outcome measures||f|f|f|t
34084297|NCT00321763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34084298|NCT04547400|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084299|NCT05485311|||COHORT||CROSS_SECTIONAL|||||||
33991576|NCT04514939|||CASE_CONTROL||PROSPECTIVE|||||||
34084300|NCT00599560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687989|NCT04687618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Control Trial||||
34084301|NCT00880217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33687990|NCT04291274|||COHORT||RETROSPECTIVE|||||||
33687991|NCT03504579|RANDOMIZED|PARALLEL||OTHER||DOUBLE||In the R61 phase of the study,changes in a target brain region(s) will be demonstrated after the rt-fMRI based neurofeedback session.|t|t|f|f
33687992|NCT02094495|||CASE_ONLY||CROSS_SECTIONAL|||||||
33687993|NCT02201511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33687994|NCT04016740|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||2 roll-in patients followed by 20 patients in the interventional model.||||
33687995|NCT05675605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33687996|NCT05841121|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants are women with singleton pregnancy, from 18 to 45 years old, at 34+0/7 to 36+6/7 weeks of gestation and at high risk for delivery during the late preterm period in the next 7 days.|f|t|t|t
33687997|NCT03723603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33687998|NCT02370446|||CASE_CONTROL||PROSPECTIVE|||||||
33687999|NCT06234384|||OTHER||PROSPECTIVE|||||||
33688000|NCT04153071|NA|SINGLE_GROUP||OTHER||NONE||||||
33688001|NCT04163731|||COHORT||PROSPECTIVE|||||||
33688002|NCT03735173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688003|NCT06278974|||COHORT||PROSPECTIVE|||||||
33777457|NCT04123873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study medication will be masked by the pharmacy. The experimental medicine will be packed and labelled by Skanderborg Pharmacy in accordance with the Good Manufacturing Practice regulations. The sponsor has a set of sealed, opaque envelopes with the participants' allocation, and these will only be revealed for the investigators when the data has been analysed and abstracts and conclusions covering the different possibilities for interpreting the trial results, have been agreed upon by the steering committee||t|t|t|t
33991577|NCT06382636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33688004|NCT00320723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688005|NCT00316550|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33688006|NCT04934280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777458|NCT02156882|||CASE_ONLY||PROSPECTIVE|||||||
33777459|NCT00083564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777460|NCT02880449|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33777461|NCT02800811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777462|NCT01575782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777463|NCT03195582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study will be single blinded. The examiners of the clinical measurements, ELISA samples and the radiographs will be blinded to the patient's group.|"patients will be divided randomly in to 2 groups:~1. Control: following uncovering of the implant a 4 mm height healing abutment will be screwed to the implant (the standard treatment modality) without using CHX gel or any other gel.~2. Test group: following implant exposure this group will receive CHX 1% gel (Corsodyl®) the gel will be applied on the abutment as well as on the implant internal hex and then a 4 mm healing abutment will be connected."|f|f|t|t
33777464|NCT03082209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991578|NCT00216242|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33991579|NCT00650871|RANDOMIZED|CROSSOVER||DIAGNOSTIC||||||||
33991580|NCT03956784|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991581|NCT05240989|||COHORT||PROSPECTIVE|||||||
33991582|NCT01625858|||COHORT||PROSPECTIVE|||||||
33991583|NCT02767791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991584|NCT03719040|||COHORT||PROSPECTIVE|||||||
34084302|NCT04117854|||OTHER||CROSS_SECTIONAL|||||||
34084303|NCT04998708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084304|NCT00005793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084305|NCT01782339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688007|NCT03923478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, placebo-controlled trial involving two sequential non-overlapping cohorts, with intervening interim analysis|t|t|t|t
33688008|NCT04650646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33688009|NCT05351398|||CASE_CONTROL||PROSPECTIVE|||||||
34084306|NCT01217996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688010|NCT03097354|||COHORT||CROSS_SECTIONAL|||||||
33688011|NCT02381457|||COHORT||PROSPECTIVE|||||||
33777465|NCT00355823|||CASE_ONLY||PROSPECTIVE|||||||
33777466|NCT05854940|||COHORT||PROSPECTIVE|||||||
33777467|NCT04716595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909110|NCT06693154|||CASE_CONTROL||PROSPECTIVE|||||||
33909111|NCT01215734|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33909112|NCT02614144|||COHORT||PROSPECTIVE|||||||
33909113|NCT03968861|||COHORT||PROSPECTIVE|||||||
33909114|NCT04527354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blind will be performed by using Placebo equivalent to Treamid tablets without active substance and the corresponding labeling of the study drug.||t|f|t|f
33909115|NCT03864263|||CASE_CONTROL||PROSPECTIVE|||||||
33909116|NCT06302309|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Randomization will be performed in CastorEDC, a web-based data management system for academic studies (www.castoredc.com). Breaking of the randomization code is not applicable, since researchers and trainers cannot be blinded.|||||
33909117|NCT03165513|NA|SINGLE_GROUP||TREATMENT||NONE||Descriptive study||||
33909118|NCT02540252|||COHORT||PROSPECTIVE|||||||
33909119|NCT04005209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909120|NCT02241746|||||CROSS_SECTIONAL|||||||
33909121|NCT01234012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909122|NCT01269957|||||CROSS_SECTIONAL|||||||
33909123|NCT04836143|||CASE_ONLY||RETROSPECTIVE|||||||
33909124|NCT05862324|NA|SINGLE_GROUP||TREATMENT||NONE||In Phase 1, escalating doses of TAC01-CLDN18.2 will be evaluated to identify the RP2D using the classic 3+3 dose escalation study design. In Phase 2, dose expansion groups will further evaluate the safety, efficacy, and PK of the MTD or RP2D for TAC01-CLDN18.2 in subjects with gastric and esophageal AC (Group A), PDAC (Group B), and ovarian and NSCLC cancers (Group C). In Phase 2, definitions of eligible CLDN18.2+ IHC expression levels will be based on retrospective analysis of data from Phase 1 in association with clinical efficacy because there are no formal CAP/ASCO definitions for CLDN18.2+ IHC expression levels. In Phase 2, a Simon 2-stage design will be used to enroll up to 57 subjects in Group A and 22 subjects in Group C. Group B will enroll up to 10 subjects without a Simon 2-stage design due to its historically low ORRs. The 10 treated subjects in Group B are designed to seek evidence of potential efficacy in this difficult to treat CLDN18.2+ subpopulation of PDAC.||||
33909125|NCT04357379|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909126|NCT05320458|NA|SINGLE_GROUP||TREATMENT||NONE||Single group 30 individuals were included in the study. Surgery, adjuvant chemotherapy and radiotherapy processes of all patients included in the study were completed. Patients between the ages of 18-65 and in remission period were included in the study. Patients with suspected pregnancy, diabetes mellitus, metastatic patients, and patients with acute and chronic infections were excluded from the study.||||
33909127|NCT04352322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909128|NCT06692543|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||2x20 people aged \>55 yo, 1 group physically active, the other is physically inactive|t|f|f|f
33909129|NCT01743586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909130|NCT01585961|||CASE_ONLY||PROSPECTIVE|||||||
33909131|NCT04378309|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909132|NCT04158908|||OTHER||OTHER|||||||
33909133|NCT00002058||||TREATMENT||||||||
33909134|NCT04169334|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention study with one controlgroup and one intervention group||||
33909135|NCT03064776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909136|NCT00348634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688012|NCT01948310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688013|NCT00246688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688014|NCT01795378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688015|NCT02125773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688016|NCT00600860|||COHORT||PROSPECTIVE|||||||
33688017|NCT03578770||SEQUENTIAL||OTHER||NONE||Feasibility device||||
33688018|NCT05198778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel study between groups (crossover study within healthy patients)||||
33688019|NCT01894815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909137|NCT06693063|||COHORT||PROSPECTIVE|||||||
33909138|NCT04987983|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33909139|NCT06034834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The surgeons will be blinded as to the results of the intraoperative perfusion assessment in order to prevent bias.|The study is a prospective observational multicentre pilot study. All included patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion assessment will not affect the treatment of patients.||||
33909140|NCT02844101|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33909141|NCT05987293|||COHORT||PROSPECTIVE|||||||
33909142|NCT02446054|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33909143|NCT01473251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33909144|NCT01574313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909145|NCT03703921|||CASE_ONLY||PROSPECTIVE|||||||
33909146|NCT02142179|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33909147|NCT04775797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single blind only (Participant) in Part 2b||t|t|t|f
33909148|NCT01666275|||CASE_ONLY||PROSPECTIVE|||||||
34084307|NCT02904746|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33688020|NCT01887743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688021|NCT00349271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688022|NCT05577468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688023|NCT00392821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777468|NCT04974320|||OTHER||RETROSPECTIVE|||||||
33777469|NCT01233102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777470|NCT00008502|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33909149|NCT06141213|||COHORT||PROSPECTIVE|||||||
33909150|NCT03415919|||CASE_ONLY||CROSS_SECTIONAL|||||||
33909151|NCT00110656|||||RETROSPECTIVE|||||||
33909152|NCT05916833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909153|NCT03987620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, placebo-controlled, double-blind study|t|f|t|f
33909154|NCT02947295|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33909155|NCT02272322|||CASE_ONLY||PROSPECTIVE|||||||
33909156|NCT02269111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909157|NCT00465153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909158|NCT00849979|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33909159|NCT03212404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991585|NCT05347719|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||To achieve our study aims, we designed a randomized, controlled trial with a treatment as usual (TAU) control group. A total of 240 eligible participants will be randomized to either an MBCT intervention group (Group 1) or an TAU control (Group 2). In Phase I, Group 1 will complete the intervention and Group 2 will remain in TAU. In Phase II , Group 2 will complete the intervention and Group 1 will continue TAU. Depending on the recruitment site, TAU may consist of receiving psychotherapy, pharmacotherapy, or combined treatment within an academic medical center. Data collection will be completed at baseline, post-intervention for Group 1 and pre-intervention for Group 2, and after follow-up for Group 1 and post-intervention for Group 2. This design allows us to provide fair treatment for both trial arms as well as allowing for follow-up assessment of Group 1.|f|f|t|t
33991586|NCT04722458|||CASE_ONLY||PROSPECTIVE|||||||
33991587|NCT04367766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991588|NCT03872128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Randomized Double-blind, placebo-controlled, parallel design|t|t|t|t
33991589|NCT04712045|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33991590|NCT04260217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||APG2575 400 mg ramp up arm||||
33991591|NCT01521715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991592|NCT05286047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991593|NCT04292873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991594|NCT01273350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991595|NCT00830258|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991596|NCT05547737|||CASE_ONLY||PROSPECTIVE|||||||
33991597|NCT05679024|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic Prospective Open Label Parallel-Group Multicenter Phase 3b Randomized Controlled Clinical Trial||||
33991598|NCT06563115|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double: participant, investigator|Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study|t|f|t|f
33991599|NCT00755339|||||PROSPECTIVE|||||||
33991600|NCT01015300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991601|NCT06407206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991602|NCT00620711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991603|NCT03158727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991604|NCT03110848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Ophthalmologist blinded to treatment||f|f|t|f
33991605|NCT05193461|NA|SINGLE_GROUP||SCREENING||NONE||||||
33991606|NCT05388266|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33991607|NCT05384769|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33991608|NCT05646251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991609|NCT06181422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991610|NCT04594577|NA|SINGLE_GROUP||OTHER||NONE||||||
33777471|NCT01004419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777472|NCT02830789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777473|NCT03391167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Controlled randomised blinded preospective study|f|t|f|f
33777474|NCT01154803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33991611|NCT01083264|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777475|NCT01020565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777476|NCT00235495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909160|NCT03811223|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33909161|NCT01920620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909162|NCT03666260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991612|NCT04989491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991613|NCT05234463|||COHORT||PROSPECTIVE|||||||
33777477|NCT02264392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777478|NCT03492996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909163|NCT01647594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33909164|NCT03398018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909165|NCT05320770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909166|NCT04670965|||COHORT||PROSPECTIVE|||||||
33909167|NCT02159963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909168|NCT04076722|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|Study condition (weight stigma vs. not stigma) was contained in a blinded envelope that only the confederate had access to. The PI does not know which condition the participant got. And the outcomes assessors did not know the condition.||t|f|t|t
33909169|NCT00397969|RANDOMIZED|||||||||||
33909170|NCT01194557|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33909171|NCT00237796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909172|NCT05170893|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33909173|NCT05528783|||COHORT||PROSPECTIVE|||||||
33909174|NCT06320665|||OTHER||RETROSPECTIVE|||||||
33909175|NCT04889313|||OTHER||PROSPECTIVE|||||||
33909176|NCT06416059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909177|NCT04941378|NA|SINGLE_GROUP||OTHER||NONE||||||
33909178|NCT00977327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909179|NCT01452126|NA|SINGLE_GROUP||||TRIPLE|||t|t|f|t
33991614|NCT01312844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991615|NCT00354835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991616|NCT02220647|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084308|NCT00339417||||TREATMENT||||||||
33688024|NCT06356701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688025|NCT00293488|NON_RANDOMIZED|||TREATMENT||NONE||||||
33688026|NCT00733889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688027|NCT01562873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688028|NCT00210171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909180|NCT05079191|||CASE_CONTROL||RETROSPECTIVE|||||||
33909181|NCT01461954|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33909182|NCT05690412|||COHORT||RETROSPECTIVE|||||||
33909183|NCT05769608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33909184|NCT02882399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909185|NCT05513703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909186|NCT01911624|RANDOMIZED|PARALLEL||||NONE||||||
33909187|NCT03977285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909188|NCT01321996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909189|NCT04649528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The exercise physiologist performing the maximal oxygen uptake pre and posttests was blinded with reguards to which intervention group the participants had been assigned.|Randomized trial|f|f|t|f
33909190|NCT05679687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909191|NCT01543464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909192|NCT02110810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909193|NCT05896761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909194|NCT02372292|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33909195|NCT05049512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909196|NCT01727635|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33909197|NCT01571037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909198|NCT01655264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909199|NCT00483249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909200|NCT00279552|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909201|NCT01305330|||CASE_ONLY||PROSPECTIVE|||||||
33909202|NCT05873101|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33909203|NCT00668434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909204|NCT01123278|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33909205|NCT03088293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909206|NCT02433288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909207|NCT03557398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909208|NCT00906607|||COHORT|||||||||
33909209|NCT01231633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909210|NCT04516486|||COHORT||RETROSPECTIVE|||||||
33909211|NCT03914287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909212|NCT02634879|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909213|NCT02588274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909214|NCT01992445|||CASE_CONTROL||PROSPECTIVE|||||||
33909215|NCT04152005|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909216|NCT01641835|||CASE_ONLY||PROSPECTIVE|||||||
33909217|NCT05429723|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33909218|NCT02756715|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33909219|NCT05874401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909220|NCT03796156|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Adjudication of outcomes blinded||f|f|f|t
33909221|NCT04109625|NON_RANDOMIZED|PARALLEL||OTHER||NONE||3 parallel groups of 10 volunteers||||
33909222|NCT01576016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909223|NCT00398151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909224|NCT05515601|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33909225|NCT05483816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33909226|NCT03849040|||COHORT||PROSPECTIVE|||||||
33909227|NCT01343134|||COHORT||RETROSPECTIVE|||||||
33909228|NCT04409795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084309|NCT05808985|NA|SINGLE_GROUP||PREVENTION||NONE||Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭)||||
33688029|NCT06041776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688030|NCT03673410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Once consent has been signed, the patient will be assigned to any of the two groups, using a computer-based randomization on REDCap and the patient will be assigned to the corresponding study arm.|We will randomise 60 patients between robotic (30 patients) and laparoscopic revisional bariatric surgery (30 patients) to evaluate those procedures in terms of perioperative safety, weight loss and comorbidity resolution.|t|f|t|t
33688031|NCT03645018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocenter prospective no-profit single group interventional study.||||
33909229|NCT05158205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A sham control condition will be implemented if randomized to the control group.||t|f|f|f
33909230|NCT01366911|||OTHER||PROSPECTIVE|||||||
33909231|NCT03156556|NA|SINGLE_GROUP||TREATMENT||NONE||8-week pretest/post-test open trial including a 3-month follow-up.||||
33909232|NCT01963520|||COHORT||PROSPECTIVE|||||||
33909233|NCT03165136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active drug and placebo will be exactly the same|Double Blind Randomized clinical trial|t|t|t|t
33909234|NCT02801097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909235|NCT02151123|||CASE_ONLY||CROSS_SECTIONAL|||||||
33909236|NCT00108849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909237|NCT01955343|||OTHER||PROSPECTIVE|||||||
33909238|NCT05236673|||COHORT||PROSPECTIVE|||||||
33909239|NCT04446936|||COHORT||RETROSPECTIVE|||||||
33909240|NCT05103319|||COHORT||RETROSPECTIVE|||||||
33909241|NCT04420455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909242|NCT00003982||||TREATMENT||||||||
33909243|NCT00431847|||COHORT||PROSPECTIVE|||||||
33909244|NCT03523832|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33909245|NCT02177851|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33909246|NCT02267863|NA|SEQUENTIAL||TREATMENT||NONE||||||
33909247|NCT00870948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33909248|NCT01434472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909249|NCT02223221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33991617|NCT04347018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups will receive treatment and be observed over the course of the alignment phase of their orthodontic treatment. Regular photographic records will be taken during appointments and the data will be analysed after the 18 week period is completed for all patients involved in the study|f|f|f|t
33991618|NCT00530647|||DEFINED_POPULATION||PROSPECTIVE|||||||
33991619|NCT00089011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991620|NCT00489177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33991621|NCT05221021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigational Pharmacy will randomize all participants via random allocation rule fixed blocking in a 1:1 ratio into either vaginal estrogen treatment group or oral Mirabegron treatment group. Medication doses will be 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week or 50 milligrams oral Mirabegron once daily for twelve weeks which are standard doses. The investigators, patients and clinical staff will be blinded to patient allocation. The patients will receive either a placebo vaginal cream or placebo oral medication depending on their treatment allocation. Medications will be dispensed once for their 12 weeks of therapy. The oral placebo and active medication will be encapsulated in gel capsules with filler to give identical weight and appearance. The vaginal cream placebo (Medisca's VersaPro Cream Base) and active medication will be placed in jars and have similar color, smell, and consistency.|Single site, double blinded, randomized controlled trial of Mirabegron vs Vaginal Estradiol for overactive bladder syndrome|t|t|t|t
33688032|NCT05504720|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients will receive pembrolizumab at a dosage of 200 mg flat dose in combination with trastuzumab (6 mg/kg after loading dose of 8 mg/kg) every 3 weeks and 5-FU 2600 mg/m2 for 24 h, folinic acid 200 mg/m2, oxaliplatin 85 mg/m2 and docetaxel 50 mg/m2 (FLOT regimen) every 2 weeks for 8 weeks, followed by surgical resection 4 weeks after last preoperative treatment at the earliest, followed (within 4-10 weeks) by further 8 weeks of the same regime, followed by pembrolizumab 200 mg and trastuzumab 6 mg/kg alone for up to 11 cycles. In total 1 year of systemic treatment (17 pembrolizumab/ trastuzumab administrations max. per patient incl. pre- and postoperative chemo-immunotherapy).||||
33777479|NCT02556723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777480|NCT00980707|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909250|NCT02920684|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33909251|NCT00746031|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33909252|NCT03739307|||COHORT||CROSS_SECTIONAL|||||||
33909253|NCT03851276|NA|SINGLE_GROUP||OTHER||NONE||||||
33909254|NCT01158495|||COHORT||PROSPECTIVE|||||||
33909255|NCT00088634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909256|NCT05368285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909257|NCT02065947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909258|NCT05869851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909259|NCT06514820|||COHORT||CROSS_SECTIONAL|||||||
33909260|NCT01073696|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909261|NCT02013024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909262|NCT06338553|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|For applicable participants, a placebo will be given prior to a pre-TZIELD® meal test. For participants who have already received Teplizumab (TZIELD®) or those who are progressing to the 2 remaining study visits, a GLP-1Ra or placebo will be given in random orders at these two visits. The GLP-1Ra will only be given one time.|In this study, participants with stage 2 T1DM undergoing Teplizumab (TZIELD®) treatment will be randomly assigned to receive single doses of either a GLP-1Ra or a placebo. Three separate MMTT tests will be conducted to assess the effects on blood sugar levels, insulin function, and vascular health. The first test will occur before TZIELD® treatment and participants will receive a placebo at this MMTT. The other two tests will take place 3-5 months after TZIELD® treatment. In these post-treatment tests, the study team will 'cross over', or switch, the order in which participants receive the GLP-1Ra or placebo, with a minimum one-week gap to avoid overlap of effects. For example, a participant may take the GLP-1Ra then placebo or the placebo then the GLP-1Ra. In some cases, the investigator may allow participants who have already received TZIELD® treatment prior to joining the study to skip the pre-treatment test and proceed directly to the post-treatment tests.|t|t|t|t
33909263|NCT02592603|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33909264|NCT01967420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33909265|NCT04182659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blinded study where only the statistician is aware of the randomization.|There are two groups: one will receive active rTMS and the other group will receive sham rTMS.|t|t|t|f
33909266|NCT01319591|||COHORT||RETROSPECTIVE|||||||
33909267|NCT06693687|||COHORT||PROSPECTIVE|||||||
33909268|NCT02597023|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33909269|NCT03744676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909270|NCT04065230|||COHORT||PROSPECTIVE|||||||
33909271|NCT05549063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluation and treatment will be carried out by different physiotherapists. In this way, it is aimed to provide an objective evaluation.|"It is planned to randomly divide 40 individuals diagnosed with pes planus by the physician into two.~In these groups, there should be a pes planus problem on both sides. The first group will be given stretching exercises, while the second group will be given mobility and stability exercises."|t|f|t|f
33909272|NCT02041715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909273|NCT00595699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909274|NCT06269341|||COHORT||RETROSPECTIVE|||||||
33909275|NCT01597622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909276|NCT05863689|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909277|NCT00549237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909278|NCT02551133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33909279|NCT03445013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909280|NCT06130657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909281|NCT04039685|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33909282|NCT01958606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909283|NCT03218293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991622|NCT06505343|||OTHER||PROSPECTIVE|||||||
33991623|NCT00222118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991624|NCT05967390|||CASE_CONTROL||RETROSPECTIVE|||||||
33777481|NCT06696794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a double-blind, parallel-group, placebo-controlled, multicenter, prospective, randomized controlled Phase III clinical trial|t|f|t|f
33777482|NCT05987150|||COHORT||PROSPECTIVE|||||||
33991625|NCT05035056|||OTHER||PROSPECTIVE|||||||
33991626|NCT02348463|||COHORT||PROSPECTIVE|||||||
33688033|NCT02869984|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991627|NCT01502176|||COHORT||RETROSPECTIVE|||||||
33991628|NCT06560528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991629|NCT02163837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991630|NCT01168856|||COHORT||PROSPECTIVE|||||||
33991631|NCT06191094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33991632|NCT02221141|||COHORT||OTHER|||||||
33688034|NCT01488968|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688035|NCT03894592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sequentially Numbered opaque sealed envelopes ( SNOSE) and an online randomization tool|"This is a Randomized control study. The pre and post VAS scores will be rated by the patient. Randomization will be achieved using Sequentially Numbered opaque sealed envelopes ( SNOSE) and an online randomization tool. All the patients will choose one of three virtual reality experiences.~1. Passive VR Movie~2. Interactive relaxation/exploration~3. Active/Adventure experience"|f|f|t|t
33777483|NCT03302533|||CASE_CONTROL||RETROSPECTIVE|||||||
33777484|NCT05299489|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Split mouth design|t|t|f|t
33777485|NCT00182663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777486|NCT02182882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33991633|NCT05909085|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33991634|NCT05011695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not know which treatment group they are in.|Patients will be divided into 3 groups. The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness.|t|f|f|f
33991635|NCT05025085|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
33991636|NCT06627465|||COHORT||PROSPECTIVE|||||||
33777487|NCT00701311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777488|NCT03994575|||COHORT||PROSPECTIVE|||||||
33777489|NCT00309816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777490|NCT05164536|NA|SINGLE_GROUP||OTHER||NONE||||||
33777491|NCT05963425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33777492|NCT00996086|||CASE_ONLY||PROSPECTIVE|||||||
33777493|NCT00236028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33991637|NCT04632550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777494|NCT04295174|||CASE_ONLY||PROSPECTIVE|||||||
33777495|NCT00238199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777496|NCT01871285|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33777497|NCT04012320|||COHORT||RETROSPECTIVE|||||||
33777498|NCT05847790|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33777499|NCT02490384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777500|NCT05525208|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Vaccine candidate and active comparator are masking.||t|f|t|f
33777501|NCT04349761|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Placebo is identical in appearance to IP|Double-blind, placebo-controlled, single ascending dose study.|t|f|t|f
33777502|NCT00647348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|over-encapsulation of IMP|RCT|t|t|t|t
33777503|NCT06120062|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33777504|NCT00329719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777505|NCT00636584|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33777506|NCT01635894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33777507|NCT04625855|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open-Label)|Single-Center, Open-Label, Non-Randomized, Phase 1 Study||||
33777508|NCT01410006|||OTHER||OTHER|||||||
33777509|NCT03672864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessing therapists are masked to the child's group assignment.|Randomized, controlled trial|f|f|f|t
33777510|NCT04843319|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm||||
33777511|NCT01852955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33991638|NCT02427763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33991639|NCT01895335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991640|NCT04207437|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Subjects will be instructed to perform 3-minutes of vibration therapy per hand each day using a hand held vibration device for 4 weeks. The amount of time that subjects perform vibration therapy will be recorded on their Daily Compliance form and subjects will complete questionnaires daily and weekly.||||
33991641|NCT01613872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991642|NCT05404815|||COHORT||PROSPECTIVE|||||||
33991643|NCT05959512|||COHORT||CROSS_SECTIONAL|||||||
33991644|NCT03563274|||COHORT||PROSPECTIVE|||||||
33991645|NCT00526188|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991646|NCT01527578|||COHORT||PROSPECTIVE|||||||
33991647|NCT04537663|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo consists of intradermal injection of sterile 0.9% NaCl.||t|t|t|t
33991648|NCT05900713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|parallel study is a type of clinical study in which two or more groups of participants receive different interventions.|t|f|f|t
33991649|NCT00572637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991650|NCT00838539|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33688036|NCT03792425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33688037|NCT05939011|NA|SINGLE_GROUP||PREVENTION||NONE||Single-arm, pilot clinical trial||||
33688038|NCT00357032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084310|NCT06367543|||COHORT||RETROSPECTIVE|||||||
33777512|NCT01668979|||COHORT||CROSS_SECTIONAL|||||||
33777513|NCT05162118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991651|NCT06272266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991652|NCT05041075|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33991653|NCT01610245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991654|NCT00418561|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33991655|NCT05357235|||COHORT||PROSPECTIVE|||||||
33991656|NCT06560099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33991657|NCT02984098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33991658|NCT01701063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991659|NCT03745963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two research assistants (RA1, RA2) who are blinded to the intervention condition will be hired to complete facial coding and calculation of infant PIPP-R scores. Each research assistant will only code data for preterm infants in the skin to skin condition (RA1) or the sucrose condition (RA2) and will not be aware of whether they are watching preterm infant responses to noxious or non-noxious stimulation. To minimize observer bias, research assistants will not be informed of the study design, will not be permitted to attend data collection sessions, and will not share datasets or communicate with the other research assistant regarding the study. During data collection, up close video recording of only the preterm infants face will be completed to attempt to keep coders blind to the nature of the intervention.||f|f|f|t
33991660|NCT03919435|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33991661|NCT02785887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33991662|NCT02917525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991663|NCT06560814|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, Parallel design randomized clinical trial||||
33991664|NCT05464394|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33991665|NCT06166277|||CASE_CROSSOVER||PROSPECTIVE|||||||
33991666|NCT00942968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991667|NCT03469843|||CASE_ONLY||PROSPECTIVE|||||||
33991668|NCT01090687|||COHORT||PROSPECTIVE|||||||
33991669|NCT03734718|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The peptides/placebo is prepared, in a randomized fashion, by a laboratory assistant.|placebo-controlled, double-blinded, cross-over study|t|t|t|f
33991670|NCT02056691|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33991671|NCT01842750|NA|SINGLE_GROUP||||NONE||||||
34084311|NCT03236454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham Stimulation: Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end||t|f|f|f
34084312|NCT06007976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will self-select one of four treatment options: 1 week (2 treatment), 2 weeks (4 treatments), 3 weeks (6 treatments) and 4 weeks (8 treatments).||||
34084313|NCT04376281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084314|NCT00971113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34084315|NCT05285839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084316|NCT00000732||||TREATMENT||NONE||||||
34084317|NCT01905696|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084318|NCT03415516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084319|NCT04710732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084320|NCT01218308|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34084321|NCT00381212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084322|NCT04286971|||CASE_ONLY||RETROSPECTIVE|||||||
34084323|NCT03288038|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34084324|NCT04538508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will not be aware about the treatment any participants will/had received|Randomized controlled trial|f|f|f|t
34084325|NCT03273062|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"The participant, respective care provider, as well as the investigator and research coordinator (outcomes assessor) will all be blind to the order of placebo or medication (Tolcapone) administration in this two-arm, crossover study."|Interventional clinical trial with a double-blind, randomized placebo-controlled crossover design|t|t|t|t
34084326|NCT01989039|||COHORT||RETROSPECTIVE|||||||
34084327|NCT00388921|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34084328|NCT02701634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084329|NCT03543163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* Blinding of the participants is not applicable.~* Blinding of the operator is not applicable.~* Outcome assessor (primary and secondary outcomes) \& biostatistician will be blinded."||f|f|f|t
34084330|NCT06359899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084331|NCT04377295|||COHORT||RETROSPECTIVE|||||||
34084332|NCT04228224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084333|NCT02415972|||COHORT||PROSPECTIVE|||||||
34084334|NCT04341090|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33688039|NCT04330196|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be masked to the type of beverage ingested at each visit (200ml of water containing glucose or aspartame). Furthermore, participants will be masked to glucose levels throughout the study|Participants will undergo two experiments in random order. In the experiments, driving performance will be assessed after administration of glucose (intervention arm) or aspartame (control arm).|t|f|f|f
33688040|NCT06097780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial will be two-armed double-blind (participant and investigator's team responsible for outcome assessments).|"The trial will evaluate 120 adult patients (male and female) aged 18 to 55 years with Huntington's disease:CAG repeats from 40 to 50; HD diagnostic confidence level (DCL) score of 4;UHDRS Total Functional Capacity (TFC) from 7 to 12, suggesting mild-moderate functional impairment.~Each patient participates in the trial for approximately 14 months, two months for screening, and twelve months for investigational product administration and follow-up."|f|f|f|t
33688041|NCT01205581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688042|NCT04264052|||COHORT||PROSPECTIVE|||||||
33688043|NCT03319966|||CASE_CONTROL||PROSPECTIVE|||||||
33688044|NCT00674167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688045|NCT03359343|||COHORT||PROSPECTIVE|||||||
33688046|NCT04373668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688047|NCT04661020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084335|NCT00320047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084336|NCT01491516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084337|NCT03348449|||COHORT||RETROSPECTIVE|||||||
34084338|NCT02399332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084339|NCT00706316|NA|SINGLE_GROUP||||NONE||||||
33909284|NCT02772354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909285|NCT03830008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All instruments and questions will be administered using tablets by trained research staff blind to the allocation status of the participants.|"The exploratory RCT will inform us about the feasibility, safety, and delivery of the intervention; this will identify issues around its training, supervision and outcome measures.~After the baseline assessment, sixty participants (N = 60) will be involved in the exploratory RCT (assigned to either the PM+ intervention (n=30) or the ETAU control condition (n=30)). The investigators intend to deliver the intervention to 30 participants, allowing us to test the feasibility and acceptability of the intervention in the proposed setting and inform the sample size for a future definitive trial."|f|f|f|t
33909286|NCT01066078|||COHORT||PROSPECTIVE|||||||
33909287|NCT04993586|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909288|NCT04463329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"After completion of the block, a blinded observer recorded demographic data and questioned the patients for felt pain related to the block procedure using a 10-cm visual analog scale (0 cm = no pain, 10 cm = worst imaginable pain). Patients were also questioned for symptoms related to the local anesthetic toxicity.~Subsequently, measurements of brachial plexus blockade were carried out every 5 mins until 30 mins by the same blinded observer."|the patients were randomly allocated to one of the two groups as Group C (conventional two-operator axillary brachial plexus blockage) and Group J (axillary brachial plexus block with single operator using Jedi grip)|f|f|f|t
33909289|NCT05344079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909290|NCT03785717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909291|NCT00461955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909292|NCT04446234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909293|NCT06242236|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomized control trial two arms by 1:1 ratio after the participants were recruited.||||
33909294|NCT04747548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909295|NCT00005051||||TREATMENT||||||||
33909296|NCT01125176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909297|NCT04429503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084340|NCT06281509|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking will be done in this study|Two groups: Patients with Dupuytren Disease and healthy control group. They will be age matched (50 years of age or higher) with the objective to have a proportionate division (50/50) between the genders.||||
33688048|NCT01915966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688049|NCT03052933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688050|NCT02898116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688051|NCT03405636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688052|NCT02599948|||OTHER||PROSPECTIVE|||||||
33688053|NCT03332550|||COHORT||RETROSPECTIVE|||||||
33688054|NCT05651568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688055|NCT05606653|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33688056|NCT02263131|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33688057|NCT00322153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688058|NCT03096145|NA|SINGLE_GROUP||OTHER||NONE||||||
33688059|NCT04349293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688060|NCT00818675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688061|NCT05313100|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33688062|NCT01872234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688063|NCT03582228|NA|SINGLE_GROUP||OTHER||NONE||||||
33688064|NCT06523374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688065|NCT04961970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688066|NCT06179368|||COHORT||PROSPECTIVE|||||||
33688067|NCT03129256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688068|NCT01076296|||CASE_ONLY||PROSPECTIVE|||||||
33688069|NCT04387825|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adipose Derived Stromal Vascular Fraction (ADSVF) was obtained in a laboratory by enzymatic digestion of fat graft harvested by liposuction. This ADSVF and micro fat grafts were applied into the hands with fibrosis and digital ulcers caused by Systemic Sclerosis in the experimental group. The control group was treated with medical treatment only||||
33688070|NCT03053765|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33688071|NCT00673270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33688072|NCT02797054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33688073|NCT03325660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study group included 30 patients participated in pelvic floor muscle training and whole-body vibrations, 3 times weekly for 4 consecutive weeks; the frequency and peak-to-peak displacement of vibration were 2 mm/20 Hz for the first week for 5 minutes, 3mm/25 Hz, 10 minutes for the second week and 4 mm/30 Hz, 15 minutes for the last two weeks. The control group included 31 patients received only pelvic floor training only. Pelvic floor exercises: Each patient was prepared and taught a program of pelvic floor exercises to be performed in daily sessions in lying, sitting, and standing positions consisting of 10 seconds of contractions followed by 10 seconds of relaxation and repeating the exercises 15 times each session.||t|f|f|t
33688074|NCT04470921|||COHORT||PROSPECTIVE|||||||
33688075|NCT03882775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688076|NCT01840839|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33688077|NCT01280955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991672|NCT03701594|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|The people administering the self-reported outcome measures will be blinded to the condition the subject participated in.|The study will be a randomized, controlled, single-blinded, crossover design with three conditions: condition A will consist of 1 hour of yoga-based physical therapy session in a group setting; condition B will consist of 1 hour of one-on-one conventional physical therapy; condition C will consist of 1 hour of seated rest in a relaxing environment in a group setting.|f|f|f|t
33777514|NCT01992198|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777515|NCT04729738|||COHORT||RETROSPECTIVE|||||||
33777516|NCT01625910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777517|NCT00099424|RANDOMIZED|CROSSOVER||||SINGLE||||||
33777518|NCT01831492|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33777519|NCT02990221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777520|NCT01813422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777521|NCT03342911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777522|NCT02903784|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777523|NCT01686269|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777524|NCT00072163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777525|NCT01899248|||COHORT||PROSPECTIVE|||||||
33777526|NCT01171365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777527|NCT04595695|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Patients will not know that their surgeon is participating in a research study. Visits will be completed as they typically would with the surgeon wearing a mask.|Patients will be randomized into typical covered mask versus transparent mask worn by the surgeon.|t|f|f|f
33777528|NCT05676398|||COHORT||PROSPECTIVE|||||||
33777529|NCT05886075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777530|NCT02306395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777531|NCT00942240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777532|NCT02372448|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33777533|NCT01454336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777534|NCT03807193|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"A factorial design with four cells:~Cell one: Predetermined treatment program with weekly support Cell two: Predetermined treatment program with support on demand Cell three: Self-selected treatment program with weekly support Cell four: Self-selected treatment program with support on demand"||||
33777535|NCT04920461|NA|SINGLE_GROUP||OTHER||NONE||||||
33777536|NCT01925170|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33777537|NCT00921297|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777538|NCT05719636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777539|NCT00242463|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33777540|NCT03029338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991673|NCT06626555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991674|NCT00000330||||TREATMENT||DOUBLE||||||
33991675|NCT00905528|||COHORT||PROSPECTIVE|||||||
33991676|NCT00462345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991677|NCT05096663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991678|NCT05174741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991679|NCT05270135|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study of an intervention using one group comprised of three pharmacies and their enrolled staff.||||
33991680|NCT06209983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991681|NCT00881634|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991682|NCT02753179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991683|NCT02115165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991684|NCT02139215|||COHORT||PROSPECTIVE|||||||
33991685|NCT03302780|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33777541|NCT01646320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777542|NCT00537862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777543|NCT00018161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33777544|NCT03774992|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777545|NCT01656759|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33777546|NCT01988987|||COHORT||PROSPECTIVE|||||||
33777547|NCT02467959|||COHORT||PROSPECTIVE|||||||
33777548|NCT01067495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777549|NCT02018315|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33777550|NCT05573113|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33777551|NCT04696848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777552|NCT02187822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777553|NCT00625274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777554|NCT01507129|||CASE_ONLY||CROSS_SECTIONAL|||||||
33777555|NCT00218985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33777556|NCT00052559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777557|NCT04114396|||COHORT||PROSPECTIVE|||||||
33777558|NCT05080621|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991686|NCT03274492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991687|NCT03292458|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33991688|NCT01056861|||CASE_CONTROL||PROSPECTIVE|||||||
33991689|NCT02835573|||CASE_ONLY||PROSPECTIVE|||||||
33991690|NCT02599558|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991691|NCT04216329|NA|SEQUENTIAL||TREATMENT||NONE||||||
33991692|NCT05191550|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|All participants are provided a number and only the principal investigator has access to this information|Virtual Reality Simulated practice and realistic brain tumor simulation||||
33991693|NCT01756326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991694|NCT02891980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33991695|NCT06120465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991696|NCT01158274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777559|NCT02355704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777560|NCT02682017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33777561|NCT04658719|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33777562|NCT04340674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991697|NCT02157974|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33991698|NCT05276635|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|This open-label randomised controlled trial study was conducted at Elabbasia Mental Hospital and Osana family wellness elderly nursing home at Maadi, Cairo|An open-label randomized controlled trial design was utilized in this study. It was open-label because the type of intervention could not be concealed to participants or researchers.|f|f|f|t
33688078|NCT06210308|||COHORT||PROSPECTIVE|||||||
33688079|NCT04551144|||COHORT||PROSPECTIVE|||||||
33688080|NCT05697744|||COHORT||PROSPECTIVE|||||||
33688081|NCT05135312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688082|NCT02533791|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33688083|NCT02948218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777563|NCT06028256|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33777564|NCT04576871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777565|NCT05556005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33777566|NCT00955656|||COHORT||PROSPECTIVE|||||||
33777567|NCT04501458|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33688084|NCT03027479|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33777568|NCT01591395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909298|NCT06296628|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Participants are patients admitted to the acute inpatient rehabilitation unit for rehabilitation of the hand and fingers who have one paralyzed hand without pronounced spasticity.||||
33909299|NCT03569293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909300|NCT05497778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909301|NCT05399238|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909302|NCT06262555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909303|NCT02053272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909304|NCT01712386|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33909305|NCT01831934|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33909306|NCT04030052|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777569|NCT00669695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991699|NCT00161850|RANDOMIZED|PARALLEL||||DOUBLE||||||
33991700|NCT02067611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991701|NCT06562647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991702|NCT00412503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991703|NCT03777826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777570|NCT02104856|||CASE_ONLY||OTHER|||||||
33777571|NCT04531150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Fully blinded||t|t|t|t
33991704|NCT04630834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two arms will be run in parallel. One arm will be acetaminophen and ibuprofen combined. The other arm will be ibuprofen alone with a placebo.|t|t|t|t
33688085|NCT01727700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688086|NCT05354154|||COHORT||CROSS_SECTIONAL|||||||
33688087|NCT03062410|NA|SINGLE_GROUP||OTHER||NONE||||||
33688088|NCT04084678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688089|NCT01009281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688090|NCT02283151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688091|NCT02666703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688092|NCT02431247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688093|NCT02267642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777572|NCT03248440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777573|NCT05410535|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||patients who participated in PEGASUS-D clinical trial||||
33777574|NCT01492517|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33777575|NCT05830461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients are not aware that there is an experimental group and a control group, the participants are not related and do not know each other.|The study has two arms, one is the experimental group that will receive the treatment through the online platform only, and the other is the comparison group that will receive the treatment delivered through printed visual material. The program consists of three stages that are aimed at: 1) Patients who undergo screening and obtain negative results for malignancy, 2) patients with suspicion and undergo a biopsy, 3) Patients with positive results for breast cancer.|t|f|f|f
33909307|NCT05609747|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33909308|NCT05217784|||COHORT||PROSPECTIVE|||||||
33909309|NCT06554314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33991705|NCT01942122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991706|NCT02379884|||COHORT||PROSPECTIVE|||||||
33991707|NCT06547541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991708|NCT00445796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991709|NCT04194476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991710|NCT04995783|||CASE_CONTROL||OTHER|||||||
33991711|NCT01492556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991712|NCT01385930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991713|NCT06560658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991714|NCT04077723|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991715|NCT05028608|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991716|NCT02358538|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33991717|NCT04486066|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34084341|NCT04120935|||COHORT||PROSPECTIVE|||||||
34084342|NCT03306199|||COHORT||RETROSPECTIVE|||||||
33991718|NCT03151798|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||"In Phase I, liver samples derived from patients undergoing either bariatric surgery or a liver biopsy to diagnose nonalcoholic fatty liver disease, are tested one time in vitro. There is no treatment in Phase I.~In Phase II, only patients with nonalcoholic fatty liver disease (and not those who have had bariatric surgery) are eligible to go into a study in which they are randomly assigned to 1) a lifestyle treatment program or 2) a control group undergoing standard care. Allocation is 2:1 subjects in the treatment vs standard care groups.~Thus, the arms are:~Arm 1: Phase I studies with no treatment, only observational data generated in vitro from the liver samples Arm 2: Phase II lifestyle treatment Arm 3: Phase II control standard of care"|f|f|f|t
33991719|NCT06742385|RANDOMIZED|PARALLEL||OTHER||NONE||Multicenter randomized controlled trial comparing two strategies to following-up patients with active IBD; Active arm: alerts activated, Control arm: alerts disabled||||
33991720|NCT05331508|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991721|NCT04738448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991722|NCT06732674|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||international, multi-center, 2-arm, 54-week, randomized controlled trial||||
33991723|NCT05560698|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants are randomized 1:1 across treatment group|f|f|t|t
33991724|NCT06555458|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33991725|NCT05136703|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33991726|NCT00164307|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33991727|NCT06152081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991728|NCT00090662|||COHORT||OTHER|||||||
33991729|NCT01048281|||COHORT||PROSPECTIVE|||||||
33991730|NCT06094023|||COHORT||PROSPECTIVE|||||||
33991731|NCT00583453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33991732|NCT05247723|RANDOMIZED|PARALLEL||TREATMENT||NONE||On each patient, the testes were randomized to undergo testicular sperm aspiration using a standard IV cannula on one side, followed by surgical microscopic testicular sperm extraction on the contralateral testis.||||
33991733|NCT06007690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject, Assessor, and Sponsor masked trial.||t|f|f|t
33991734|NCT05377827|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two cohorts (AML and T-NHL) will enroll and be treated independently in the Dose Escalation portion of the study. Patients in each cohort will be treated following an accelerated titration 3+3 design, meaning that one patient will be treated at a dose level with continued escalation until a DLT is observed, at which point a traditional 3+3 design will be triggered in that cohort moving forward. Upon confirmation of the recommended phase 2 dose (RP2D) for either cohort, enrollment to the Dose Expansion portion of the study for that cohort will commence.||||
33991735|NCT00320034|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33991736|NCT00028951|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33991737|NCT06323408|||COHORT||PROSPECTIVE|||||||
33991738|NCT05747807|NA|SINGLE_GROUP||TREATMENT||NONE||One group pre-posttest design||||
33991739|NCT01442558|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33991740|NCT05382715|||COHORT||PROSPECTIVE|||||||
33991741|NCT00555113|||COHORT||RETROSPECTIVE|||||||
33991742|NCT06741436|||COHORT||PROSPECTIVE|||||||
33991743|NCT06562387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first moments of the stimulator being turned on, without being able to modify cortical excitability.~The applicators of the stimulation techniques will be the same as those who evaluate and will not remain blind to the maneuver, unlike the students. All the applicators will be randomized to form the two groups and the applicator of the techniques will know whether it is the experimental maneuver or the placebo maneuver."|"single-blind, comparative clinical trial (cognitive stimulation + active tDCS vs. cognitive stimulation + sham tDCS). Randomization will be carried out with a list of numbers in Excel that will be in charge of one of the members of the research who will not have contact with the participants.~The applicators of the stimulation techniques will be the same as those who evaluate and will not remain blind to the maneuver, unlike the students. All the applicators will be randomized to form the two groups and the applicator of the techniques will know whether it is the experimental maneuver or the placebo maneuver."|t|t|f|f
33991744|NCT06742905|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|t|f
33991745|NCT01098591|||CASE_ONLY||RETROSPECTIVE|||||||
33991746|NCT02488408|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991747|NCT03390322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991748|NCT04443907|NA|SINGLE_GROUP||TREATMENT||NONE|The is an open-label study.|||||
34084343|NCT01559441|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34084344|NCT00748241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688094|NCT03372889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Subjects are randomized into one of the following two groups:~Group 1: Print based PEM Group 2: Media based PEM All study outcomes are compared between the two groups."||||
33688095|NCT01680549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991749|NCT04854798|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||The participants will be randomized to two groups: ultrasound group and control group. All participants will still receive standard clinical care. The ultrasound group will receive daily ultrasound application to the spleen for up to 7 days, in addition to the standard clinical care. The control group will receive standard clinical care without ultrasound stimulation.||||
33991750|NCT04573023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991751|NCT00500994|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33991752|NCT03037671|||COHORT||PROSPECTIVE|||||||
33991753|NCT06655545|||COHORT||RETROSPECTIVE|||||||
33991754|NCT06595706|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||2 MAD cohorts. Each MAD cohort will enroll 8 participants randomized 6 active:2 placebo to receive multiple doses of Lucid-21-302.|t|t|t|f
33991755|NCT05958537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991756|NCT06511349|NA|SEQUENTIAL||TREATMENT||NONE||0.3mg/kg,0.45mg/kg,0.6mg/kg||||
33991757|NCT06598930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991758|NCT03882034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991759|NCT04061486|||CASE_CROSSOVER||PROSPECTIVE|||||||
33991760|NCT06465810|||COHORT||PROSPECTIVE|||||||
33991761|NCT06602219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991762|NCT04076059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991763|NCT06594354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The data obtained from the study will be collected using a simple randomization method and a computerized randomization program will be used (www.randomizer.org). The groups determined in the program will be the intervention group and the control group; Group 1 and Group 2 will be written on two different papers and will be determined by the chemotherapy unit nurse by drawing lots. Patients who meet the sampling criteria will be divided into two randomized groups as patients who will be applied intraoral ice (intervention group) and patients who will not be applied (control group). Patients who meet the study inclusion criteria will be numbered and delivered to the researcher by the chemotherapy unit nurse on each application day. The patient will be included in the group according to the number given to the patient.|Oral cryotherapy is a safe, cost-effective and easily applicable important nursing intervention used in addition to oral care in patients receiving chemotherapy, especially to prevent or reduce the severity of oral mucositis. The effectiveness of oral cryotherapy, known as the application of ice or cold water to the oral cavity, in the management of taste alteration is emphasized.|f|t|f|f
33991764|NCT06511245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991765|NCT06669338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|results evaluator|experimental study with three groups.|f|f|t|t
33991766|NCT05802615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991767|NCT02906540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991768|NCT02287961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991769|NCT01528696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33991770|NCT06558890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991771|NCT02286050|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991772|NCT01500447|||CASE_ONLY||CROSS_SECTIONAL|||||||
33991773|NCT05388305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991774|NCT05879107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991775|NCT06558942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991776|NCT05363059|||COHORT||CROSS_SECTIONAL|||||||
34084345|NCT01033136|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Post-treatment and follow-up assessments are conducted by an assessor masked to treatment condition.|Multiple Channel Exposure Therapy is a behavioral treatment that simultaneously targets panic disorder and PTSD.|f|f|f|t
34084346|NCT05955482|||COHORT||PROSPECTIVE|||||||
34084347|NCT00835718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084348|NCT06258252|||COHORT||PROSPECTIVE|||||||
34084349|NCT02844478|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34084350|NCT05151185|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084351|NCT04764045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084352|NCT05504057|||CASE_CONTROL||RETROSPECTIVE|||||||
34084353|NCT02891512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084354|NCT01862770|||||PROSPECTIVE|||||||
34084355|NCT05681988|RANDOMIZED|PARALLEL||TREATMENT||NONE||National multi-centre, two-arm, open labelled randomised controlled trial within the stroke units and stroke centres of the swiss stroke registry in a superiority fashion.||||
34084356|NCT02936999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084357|NCT02410759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084358|NCT02347618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084359|NCT04576000|||COHORT||PROSPECTIVE|||||||
33777576|NCT02435238|||OTHER||PROSPECTIVE|||||||
33991777|NCT04410263|||COHORT||PROSPECTIVE|||||||
33991778|NCT05947591|||COHORT||PROSPECTIVE|||||||
33991779|NCT06587217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991780|NCT05983445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991781|NCT02101788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991782|NCT05415501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991783|NCT06636370|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33991784|NCT05365308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Stratified physician-randomized controlled quality improvement intervention study.||||
33991785|NCT02861300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084360|NCT01776957|||COHORT||RETROSPECTIVE|||||||
33777577|NCT05551962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084361|NCT00505921|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777578|NCT00372528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991786|NCT05159388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991787|NCT00303940||||TREATMENT||||||||
33991788|NCT00829530|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991789|NCT06476977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991790|NCT01112761|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33991791|NCT04476160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991792|NCT01718873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991793|NCT04740632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991794|NCT05919810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991795|NCT06721351|RANDOMIZED|PARALLEL||SCREENING||NONE||"The DRES-POCAI study uses a randomized controlled, open-label, parallel superiority trial.~Randomization: Participants will be randomized into two groups: usual care (receive a retinal screening by an optometrist) or intervention group (receive a retinal screening using a special camera and FDA-cleared EyeArt® system, an autonomous AI-based DR screening).~Open-label Design: Blinding participants and providers to the autonomous DR screening is logistically difficult. The intervention's immediate results and potential impact on the workflow necessitate an open-label approach.~Parallel Design: The parallel design allows for a clear, side-by-side comparison of outcomes between the intervention and usual care groups over time.~Superiority Evaluation: The primary objective is to determine if the multi-component DRES-POCAI intervention is superior to usual care in increasing DR screenings, early detection, referrals, and patient knowledge/self-efficacy."||||
33991796|NCT06741761|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33688096|NCT00882401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688097|NCT01957891|||COHORT||PROSPECTIVE|||||||
33688098|NCT05299788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33688099|NCT03076229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688100|NCT03329781|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33688101|NCT03843710|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Research participants and site personnel are not masked to study drug, but will be blinded to study dose for each cohort (single-blinded).|Open Label, Investigator Blinded, Sequential Cohort (max of 2 cohorts amongst the possible 4 interventions)||||
33688102|NCT05265871|||CASE_CONTROL||PROSPECTIVE|||||||
33688103|NCT05589090|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Study participants who met the inclusion criteria were randomly assigned to the experimental and control groups. The control group did not receive any intervention during the eight-week duration of the program. However, both groups underwent pretest and posttest assessments. Children assigned to the control group will receive the intervention after the 12-month follow-up assessment.|f|f|f|t
33688104|NCT04385407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688105|NCT05965648|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33777579|NCT01332240|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777580|NCT00965484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777581|NCT02819479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777582|NCT03479060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777583|NCT01448174|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33777584|NCT03548545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the Participant, the outcome assessor and the Psychologist providing the CBT will be blinded to the type of the stimulation that the subject is receiving. Unblinding will occur at the end of the participation in the study and subjects that received sham tDCS will have the chance to receive the active tDCS.|This is a parallel randomized, double blinded, sham controlled clinical trial in which a total of 72 MDD subjects(36 per arm) will be randomized to one of two groups: CBT combined with either active or sham tDCS.|t|t|f|t
33777585|NCT03174093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991797|NCT03575910|||COHORT||PROSPECTIVE|||||||
33991798|NCT06055725|||COHORT||PROSPECTIVE|||||||
33991799|NCT06560645|NA|SEQUENTIAL||TREATMENT||NONE||||||
33991800|NCT00909753|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991801|NCT04396873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991802|NCT03635164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991803|NCT02226289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991804|NCT04042233|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33777586|NCT05293535|||COHORT||RETROSPECTIVE|||||||
33777587|NCT04635787|||COHORT||PROSPECTIVE|||||||
33777588|NCT03508102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33777589|NCT00122161|RANDOMIZED|PARALLEL||||NONE||||||
33777590|NCT05734365|||COHORT||PROSPECTIVE|||||||
33777591|NCT03383185|||COHORT||RETROSPECTIVE|||||||
33777592|NCT00056641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777593|NCT05484258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777594|NCT04127305|||COHORT||PROSPECTIVE|||||||
33777595|NCT03625011|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33777596|NCT04525274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blinded (patient, surgeon and outcomes assessor)|The patients will be divided randomly by a computer-generated randomization table into three equal groups|t|t|f|t
33777597|NCT01102842|||||CROSS_SECTIONAL|||||||
33777598|NCT04576195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33777599|NCT01448837|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33777600|NCT02342314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33777601|NCT06277128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777602|NCT06494423|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single arm proof-of-concept trial with up to 35 HSCT survivors reporting employment concerns.||||
33777603|NCT00632528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777604|NCT03285711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777605|NCT06386224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants are not informed of their condition assignment and both receive online programs for chronic pancreatitis. Investigators are blinded \& masked to study condition, and all outcomes are assessed via self-reported REDCap surveys. Care providers are not involved in the study (N/A).|Participants randomized to the active intervention arm will receive access to the Pancreatitis Pain Course to learn cognitive-behavioral (CBT) pain self-management skills (e.g., changing negative thoughts, relaxation, activity pacing, goal setting). Participants randomized to the control arm will receive access to an education website.|t|f|t|t
33777606|NCT05836662|RANDOMIZED|PARALLEL||OTHER||NONE||"In this randomized study, all participants will receive two types of concussion education (CrashCourse and Brain Fly-Through). Participants will be randomized to the 2D or 3D (Virtual Reality) group, and will experience both concussion educations in that modality (either 2D or 3D).~During their in person study visit, participants will complete a brief ( \~5 minute) pre-survey before viewing the CrashCourse and Brain Fly-Through concussion educations. Participants will then be asked to complete a brief ( \~2 minute) survey to assess their knowledge, self-efficacy, and empathy surrounding concussions.~Two months later, participants will receive a brief ( \~5 minute) follow-up survey via email, assessing the same constructs."||||
33777607|NCT04473859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777608|NCT01158378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777609|NCT02269618|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33777610|NCT05732675|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33777611|NCT00915070|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33777612|NCT01625039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777613|NCT00651469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777614|NCT04044079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777615|NCT04519775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777616|NCT02590133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777617|NCT04496167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777618|NCT02599220|||COHORT||PROSPECTIVE|||||||
33777619|NCT05031936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777620|NCT05211830|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Active and placebo will be provided in a blinded fashion.|Patients will act as their own controls as they will all be treating different contralateral areas of the skin with active and placebo creams in a blinded fashion.|t|t|t|t
33777621|NCT00795418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777622|NCT01152554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991805|NCT03465839|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33991806|NCT02982577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33991807|NCT05221229|||CASE_CONTROL||PROSPECTIVE|||||||
33991808|NCT05074472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991809|NCT06052917|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trial with waiting list||||
33991810|NCT06559735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991811|NCT04988464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will complete at least five daily sleep diaries over one week, complete a pre-treatment survey assessment, be randomized in a 1:1 manner into either Sleep Scholar or Building Healthy Habits, complete a post-treatment survey assessment, then complete at least five daily sleep diaries each week for four weeks, and complete a survey assessment both one-week and one-month post-treatment. In total, participants will complete daily sleep diaries for five weeks (35 days) and survey assessments pre-treatment, post-treatment, one-week post-treatment, and one-month post-treatment.|t|f|f|t
33991812|NCT06025578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777623|NCT02283099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777624|NCT03244592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
33777625|NCT02332317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33777626|NCT02114281|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777627|NCT03272958|||COHORT||PROSPECTIVE|||||||
33777628|NCT01804543|||COHORT||PROSPECTIVE|||||||
33777629|NCT01244763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777630|NCT01477645|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33777631|NCT05015777|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Those conducting the measurements were unaware of the purpose of this study and the fact that the participants were divided into groups|A study model based on randomized controlled trial - parallel group design was used.|f|t|t|t
33777632|NCT01949675|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777633|NCT03847168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839904|NCT02443753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991813|NCT01130545|||OTHER||PROSPECTIVE|||||||
33991814|NCT05034094|||CASE_CONTROL||RETROSPECTIVE|||||||
33991815|NCT06527742|||COHORT||PROSPECTIVE|||||||
33991816|NCT06358950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991817|NCT04779918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991818|NCT04675372|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33991819|NCT03353194|||OTHER||PROSPECTIVE|||||||
33991820|NCT01601158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991821|NCT01937234|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33991822|NCT01778504|||COHORT||PROSPECTIVE|||||||
33991823|NCT02554877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084362|NCT03500978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization occurs after the baseline assessment, so the assessor is blinded to study condition. Follow-up assessments of outcome are completed by study personnel who are blinded to intervention (i.e., they had no part in the intervention and no access to the randomization schedule). An electronic research management system (RedCAP) is used to deliver the random assignments to the interventionist digitally after baseline is completed. None of the data collection or intervention staff have access to the database underlying the random assignment in RedCAP. The randomization schedule was established by the biostatistician, who has no role in the data collection or intervention delivery.|Two group (behavioral intervention vs. no treatment) randomized trial with a pre-intervention and 10- and 14-week post-intervention assessment phases.|f|f|f|t
34084363|NCT05313308|||COHORT||PROSPECTIVE|||||||
34084364|NCT01482611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688106|NCT05523518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The intervention and measurements were carried out by the researcher||f|f|t|f
33688107|NCT00939952|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33688108|NCT04088604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None，Open Label|Parallel||||
33688109|NCT01569464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688110|NCT01255787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688111|NCT06536231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688112|NCT04637828|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, controlled, randomized phase 2 study||||
33688113|NCT04048785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Trial participants and individuals assessing the outcomes are blinded to the participant's condition|Infants are randomly assigned to one of two groups: Behavioral Sleep Intervention or Control.|t|f|f|t
33688114|NCT00282542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688115|NCT05696860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33688116|NCT06200194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688117|NCT01577810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688118|NCT03073161|||COHORT||PROSPECTIVE|||||||
33688119|NCT01383512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33688120|NCT05038904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688121|NCT00745615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding performed by interactive voice response system (IVRS) and relevant only to the first period of the extension. General medical evaluations will be assessed separately from neurological assessment evaluations by two different neurologists/ physicians. Magnetic resonance imaging (MRI) scan evaluation will be performed at a central reading center by staff that does not have access to the clinical data.||t|f|t|f
33688122|NCT01452009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688123|NCT01198379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33688124|NCT03950037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688125|NCT02789332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688126|NCT03517488|NA|SEQUENTIAL||TREATMENT||NONE||||||
33688127|NCT00636220|||CASE_ONLY||CROSS_SECTIONAL|||||||
33688128|NCT02607839|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33688129|NCT02025556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688130|NCT04080076|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"ACTHar gel alone- patients will receive 80units SQ 2X/week for 52 weeks~ACTH gel 80 units 2X per week plus oral Tacrolimus (1.0 mg BID) titrating to a trough level of 4-6 ng/ml for 52 weeks"||||
33688131|NCT03251664|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33688132|NCT05829200|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33688133|NCT02622360|||CASE_CONTROL||RETROSPECTIVE|||||||
33688134|NCT02866487|||OTHER||PROSPECTIVE|||||||
33688135|NCT05811533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688136|NCT05770531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688137|NCT06438627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688138|NCT03020290|||CASE_ONLY||PROSPECTIVE|||||||
33688139|NCT03425019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688140|NCT05208307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688141|NCT03209453|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33688142|NCT03804073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688143|NCT03816670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688144|NCT06522347|||COHORT||PROSPECTIVE|||||||
33688145|NCT03914508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839905|NCT00099749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839906|NCT01971151|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839907|NCT01530581|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839908|NCT02118649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839909|NCT04150159|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized, open-label, 7-month trial in eighty (80) adult subjects. Forty (40) subjects will be randomized to the intervention FMD arm with a 5 day meal program every month for four (4) months. Forty subjects will be randomized to a follow a Mediterranean diet plan for four months.||||
33839910|NCT01074684|||COHORT||PROSPECTIVE|||||||
33839911|NCT00769262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839912|NCT04647838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: Arm 1_NSCLC Patients with non-small cell lung cancer (NSCLC) harboring MET alteration Experimental: Arm 2_Other solid tumors Solid tumors excluding NSCLC harboring MET alteration||||
33839913|NCT01623193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839914|NCT00286806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839915|NCT01852461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839916|NCT03064152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839917|NCT04920643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839918|NCT03405090|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33839919|NCT02370264|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33839920|NCT01145989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839921|NCT00969683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839922|NCT03987828|||COHORT||RETROSPECTIVE|||||||
33839923|NCT00339664|||CASE_ONLY||RETROSPECTIVE|||||||
33839924|NCT04220398|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 2:2:1||||
33688146|NCT06477224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be Randomized control trial in which Purposive sampling technique will be used. Two groups of 6-10 age will be formed in which participants will be randomly divided. Group A will only receives the experimental treatment, which in this case involves scooter board activities designed to improve neck control and potentially alleviate dysphagia symptoms and group B will receives conventional care, which typically involves standard physical therapy practices, serving as a baseline to evaluate the effects of the experimental treatment.|t|f|f|f
33991824|NCT06651099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding the therapists will not be possible due to the nature of the interventions. Because outcomes are self-reported, blinding participants to the intervention will also not be possible. However, an assessor who will be unaware of the group allocation will perform the data collection. The researcher responsible for the statistical analysis will also be blinded to the group allocation (i.e. they will receive the data sheet with the groups/individuals coded numerically).|Multicenter trial-based economic evaluation comparing mhealth intervention versus a conventional exercise therapy intervention alone. All participants will be randomly assigned to one of two groups: 1) blended mhealth intervention (mhG) or 2) conventional exercise therapy delivered by a booklet (beG).|f|f|f|t
33991825|NCT01101620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991826|NCT04739475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688147|NCT00952627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33688148|NCT00081965|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33688149|NCT00050687|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688150|NCT04325984|||COHORT||RETROSPECTIVE|||||||
33688151|NCT00610584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688152|NCT05249777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding is performed by the same appearance of TD0069 and placebo. The request for unblinding is done in accordance with the study protocol in cases of SAEs with the request of the investigators.|Study subjects are randomized in a 2:1 ratio to 14 days treatment with TD0069 (3 capsules x 3 times/day) or Placebo (3 capsules x 3 times/day) based on a randomization block size of 6.|t|f|t|f
33688153|NCT03596632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688154|NCT00936091|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33688155|NCT03518749|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33688156|NCT00652639|RANDOMIZED|CROSSOVER||||NONE||||||
33688157|NCT05205967|||COHORT||PROSPECTIVE|||||||
33688158|NCT00375869|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33688159|NCT04810572|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33688160|NCT00134537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688161|NCT03823833|||COHORT||PROSPECTIVE|||||||
33688162|NCT02583243|||COHORT||PROSPECTIVE|||||||
33688163|NCT01687621|||COHORT||PROSPECTIVE|||||||
33688164|NCT06400771|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33688165|NCT00510952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688166|NCT06521840|||COHORT||PROSPECTIVE|||||||
33688167|NCT04348084|||COHORT||RETROSPECTIVE|||||||
33688168|NCT00806507|||CASE_ONLY||PROSPECTIVE|||||||
33991827|NCT05407935|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33991828|NCT04645160|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991829|NCT02334722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991830|NCT06430177|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991831|NCT01552317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991832|NCT05074745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, Prospective, 3 components Nasopharyngeal swab by PCR Buccal swab by PCR Buccal by ELISA POCT||||
33991833|NCT06597396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991834|NCT06627569|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator and outcomes assessors will not know the group assignment of participants.|Participants will be asked to complete 2 study days before and again after a 12-week intervention period, during which they will either continue with usual activities or be asked to complete exercise sessions four times per week. They will be randomly assigned to one of these conditions (exercise or not) and will not be able to choose their group assignment.|f|f|t|t
33991835|NCT05044338|||COHORT||PROSPECTIVE|||||||
33688169|NCT01698281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688170|NCT02653404|||CASE_ONLY||OTHER|||||||
33688171|NCT02276573|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688172|NCT06422273|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The investigational pharmacist will be responsible for randomizing on the day of bronchoscopy to placebo or Tranexamic acid in a 1:1 fashion using REDCap software. The pharmacist will be the only individual aware of the randomization assignment. All other study personnel will be blinded to the randomization assignment.|The study design will be a single-center, randomized, double-blinded, placebo-controlled study. The control group will receive topical saline (placebo) and the experimental treatment group will receive topical Tranexamic acid (TXA active drug).|t|t|t|f
33688173|NCT03809793|RANDOMIZED|PARALLEL||PREVENTION||NONE|both participants and investigators will know if they are ingesting Acipimox or nothing.|34 pre-diabetics will be split into 2 groups; one will ingest Acipimox for 12-weeks and the other will ingest nothing.||||
33688174|NCT06165224|||COHORT||OTHER|||||||
33688175|NCT05185336|||COHORT||PROSPECTIVE|||||||
33688176|NCT05016284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688177|NCT02515032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688178|NCT02129218|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688179|NCT05163873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33688180|NCT00957385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688181|NCT02997267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688182|NCT05152914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688183|NCT02206243|||CASE_ONLY||PROSPECTIVE|||||||
33688184|NCT05818111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688185|NCT02330809|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33688186|NCT00686387|||CASE_ONLY||PROSPECTIVE|||||||
33688187|NCT01658865|||CASE_ONLY||PROSPECTIVE|||||||
33688188|NCT03462290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a randomized, double-blind, cross-over, placebo-controlled pilot study|t|f|t|f
33688189|NCT05088655|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688190|NCT05866627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688191|NCT03784287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688192|NCT01837706|||COHORT||PROSPECTIVE|||||||
33688193|NCT04969003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33688194|NCT00576212|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688195|NCT06195761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||treatment plan includes harvesting and fixing the bone graft in posterior mandibular area using a computer-modified surgical guide|t|f|f|t
33688196|NCT01277042|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33688197|NCT06551103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688198|NCT04856475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, non-randomised, phase II study to evaluate the efficacy of neratinib in combination with SOC systemic therapy on CNS metastasis both as for secondary prevention (cohort 1), primary treatment (cohort 2) and for the treatment of LM disease (cohort 3) in subjects with HER2 positive metastatic BC.||||
33777634|NCT03862482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For the initial study, a statistician had prepared a sampling design that included three configuration diagrams. Each diagram identified five implants of the three types, and showed how one of each type was to be placed in a cyclical, side-by-side, rotating fashion at five sites between mental foramena. Allocation concealment by the project coordinator then allowed 20 participants to receive Configuration 1, 19 had Configuration 2, and 19 had Configuration 3. Configuration diagram (but not number) was stored inside each chart, and only shown to the operating team at the time of surgery.~The present study is a continuation of this clinical trial, including data collected at the 25-year (24.6 ± 0.19 years, mean ± SE) follow-up. Twenty-two of the original participants (41.5%, age 71.1 ± 1.2 years, 11 women, 110 implants) were enrolled in this study. Eight participants (40 implants) received Configuration 1, 8 (40 implants) had Configuration 2, and 6 (30 implants) had Configuration 3."||t|t|t|f
33777635|NCT05761093|||CASE_CROSSOVER||PROSPECTIVE|||||||
33777636|NCT00864565|RANDOMIZED|CROSSOVER||||NONE||||||
33777637|NCT02687386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777638|NCT04937959|||CASE_CONTROL||RETROSPECTIVE|||||||
33777639|NCT03348826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777640|NCT05279027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777641|NCT00163215|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777642|NCT05443399|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33777643|NCT03748537|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"Eligible patients for aim#3 will be randomly assigned in a 1:1 ratio of hydrocortisone and no hydrocortisone administration (control group), in a block of four patterns. Serum cortisol will be collected before administration.~Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped. In control group, patient will not receive any corticosteroids for seven day after inclusion."|f|f|t|f
33777644|NCT02728921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777645|NCT03580720|NA|SINGLE_GROUP||OTHER||NONE||||||
33777646|NCT06458660|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33688199|NCT04421807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688200|NCT05341388|||CASE_CONTROL||PROSPECTIVE|||||||
33688201|NCT01066442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688202|NCT01662414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33688203|NCT00494845|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33688204|NCT00937781|||OTHER||RETROSPECTIVE|||||||
33688205|NCT03878186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688206|NCT02116218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777647|NCT01594658|||CASE_CONTROL||PROSPECTIVE|||||||
33777648|NCT01040780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777649|NCT02986724|||COHORT||PROSPECTIVE|||||||
33777650|NCT00504348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777651|NCT00281944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777652|NCT00180674|NA|SINGLE_GROUP||TREATMENT||NONE||The study employed a single centred, prospective, open labelled design. Practical as well as safety concerns dictated that the study could not be conducted in a blinded fashion, since patients taking anticoagulation require monitoring. The study consisted of two 8 week phases: Phase 1 and Phase 2.||||
33777653|NCT03354988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777654|NCT03560141|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||In this contralateral study, subjects will be randomized to wear the investigational lens in 1 eye and the control lens in the other eye.|t|f|t|f
33777655|NCT01603940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777656|NCT00184613|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777657|NCT03928561|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Randomized, cross-over, double-blind placebo-controlled study including 24 cat-asthmatic patients with GINA 1 asthma.|t|f|t|f
33777658|NCT03327506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777659|NCT02031744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777660|NCT00604929|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33777661|NCT00620165|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33777662|NCT04558099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33777663|NCT02789163|||CASE_ONLY||PROSPECTIVE|||||||
33777664|NCT06026787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777665|NCT04242875|||COHORT||PROSPECTIVE|||||||
33777666|NCT04487028|||COHORT||PROSPECTIVE|||||||
33777667|NCT05767138|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33991836|NCT00875524|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The first and second vaccinations were administered in a blind-observer manner. The third vaccination was planned to be administered in a single-blind manner; however, due to the cancellation of the statistical analysis after the second vaccination, the third vaccination was also administered in a blind- observer manner. To ensure the blind-observer design of the 3 vaccinations, the product was prepared in a separate room whether neither the Investigator nor participant had access.||t|f|t|t
33688207|NCT04337385|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33688208|NCT03431103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688209|NCT00924417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33688210|NCT04610164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688211|NCT02316873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688212|NCT03260439|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, controlled and double blind assignment|t|f|t|t
33688213|NCT03149393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688214|NCT02313454|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33688215|NCT04064567|RANDOMIZED|PARALLEL||PREVENTION||NONE||There will be two groups that participants can be assigned to if they choose to participate in the study. Each person will be randomly assigned to one of these groups. One group will provide information about PrEP and HIV prevention and referral to PrEP clinics in the community. The second group will the same as the first group but will also provide access to a CHW who will assist them with getting to a PrEP clinic and also helping them with other needs they may have.||||
33688216|NCT06072027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688217|NCT06489379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688218|NCT03412071|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open label with 5 arms||||
33688219|NCT01486485|RANDOMIZED|PARALLEL||||NONE||||||
33688220|NCT05969418|||COHORT||PROSPECTIVE|||||||
33688221|NCT00596362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688222|NCT04204785|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE|Participants are not randomly assigned to a group.|Pre-Post Education Survey study||||
33688223|NCT02481427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688224|NCT04201301|||OTHER||CROSS_SECTIONAL|||||||
33688225|NCT05888012|||COHORT||RETROSPECTIVE|||||||
33688226|NCT06336759|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688227|NCT04285580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688228|NCT03114059|||COHORT||PROSPECTIVE|||||||
33688229|NCT05993975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Group BUPPURE will receive 1.5 ml of hyperbaric 0.5% bupivacaine (1.5 ml/7.5 mg) whereas the BUPIDEX group will receive Dexmedetomidine 3 micrograms (0.3mL)with hyperbaric 0.5% bupivacaine (1.2 ml/6 mg) to be given to one group.|t|f|f|t
33688230|NCT04503291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assigned groups are secreted to the participant and outcome assessors|"1. supra-papillary metal stent group~2. trans-papillary metal stent group"|t|f|f|t
33688231|NCT03360786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An assessor who is blinded to group allocation will perform the pre and post assessment measures.||f|f|f|t
33688232|NCT06477809|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Inter-rater reliability checks will be undertaken during the study to compare sensor-based and manual methods of recording trial times and travel distances The control arm will be the participant's ordinary/preferred practice undertaking each task, referred to as non-ARIA.|||||
33688233|NCT03378180|||COHORT||RETROSPECTIVE|||||||
33688234|NCT04151342|||COHORT||OTHER|||||||
33688235|NCT02421003|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688236|NCT05719987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple Masking: Patients, Investigators and Statistician|Randomized controlled trial.|t|f|t|t
33688237|NCT03729687|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with short-course radiotherapy (scRT) followed by 4 cycles of CAPOX chemotherapy and surgery in locally advanced rectal cancer while waiting for the results of the randomized phase III RAPIDO trial||||
33688238|NCT00421291|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE||||||
33688239|NCT01992978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777668|NCT03430128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The investigators and the clinical team which manages the patient, will be blinded.||t|t|t|t
33777669|NCT03749382|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will receive a brief description of both the appearance-based intervention and general stop smoking intervention. Participants will not know prior to taking part which condition they will be randomised into, on completion of the intervention it will become apparent whether they received the appearance-based intervention or general intervention. For participants randomised to the appearance intervention the instruction type will remain concealed. The investigator will not be blind throughout.|Parallel assignment|t|f|f|f
33777670|NCT04664335|||COHORT||RETROSPECTIVE|||||||
33839925|NCT00988299|RANDOMIZED|CROSSOVER||||NONE||||||
33839926|NCT05727189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part 1: Open Label Part 2: Double-blind Placebo Controlled Part 3: Double-blind Placebo Controlled Part 4: Open Label|"Part 1: Parallel group comparison, single dose level of 5 forms of the investigational study drug.~Part 2: Parallel group comparison, single dose escalation (3 dose levels) of 4 forms investigational study drug and placebo.~Part 3: Placebo controlled, multiple dose cross-over within 4 parallel group comparison.~Part 4: Single-dose food effect cross-over."|t|f|t|f
33839927|NCT03551691|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33839928|NCT02734498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839929|NCT05821556|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized electronically 1:1 to one of the two arms:~A. Standard: Nab-paclitaxel 125 mg/m2 followed by gemcitabine 1000 mg/m2 on days 1, 8, and 15 (AG); or nab-paclitaxel 150 mg/m2, followed by gemcitabine 800 mg/m2, followed by cisplatin 30 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 on days 1-28 (PAXG). B. Experimental: Chemotherapy (AG or PAXG) + simvastatin oral daily at a fixed dosage of 20 mg in combination with increasing doses of valproic acid administered oral daily from day -7 with an intra-patient titration for a final target serum level of 50-100µg/ml."||||
33688240|NCT00329940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688241|NCT05730816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688242|NCT03924531|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33688243|NCT01055496|NON_RANDOMIZED|||TREATMENT||NONE||||||
33991837|NCT00051233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991838|NCT05162222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991839|NCT06648850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909310|NCT03463694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The team in the virology lab carrying out the analysis of the nasal swabs will be blinded to the allocation of the participant.|ELVIS Kids is a parallel, open label, randomised controlled trial (RCT) of HS nose drops (\~2.6% NaCl) vs. standard care in children \<7 years of age with symptoms of an URTI.|f|f|f|t
34084365|NCT05941806|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients randomized to the intervention group will receive 0.4 mg tamsulosin capsules, administered orally, once a day for 5 days before surgery, the morning of surgery and the day after surgery. Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec|"Our study will be a phase III double-blind randomized clinical trial. A period of 12 to 24 months is planned for recruitment. The primary outcomes are the incidence of postoperative urinary retention in men undergoing rectal resection and the efficacy of prophylactic tamsulosin to prevent this type of complication.~The secondary outcomes are the length of stay between experimental and placebo groups, the number of urinary catheterizations, the number of urine catheter reinsertions and total duration of urinary catheter being in-situ."|t|t|f|f
34084366|NCT04172740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084367|NCT01328015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34084368|NCT03678077|||COHORT||RETROSPECTIVE|||||||
33909311|NCT02857907|||COHORT||PROSPECTIVE|||||||
33909312|NCT00843310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909313|NCT01096446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909314|NCT00683358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909315|NCT03535701|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909316|NCT00120445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991840|NCT04699630|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991841|NCT04561492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991842|NCT00883233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33991843|NCT06121973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33991844|NCT02393885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991845|NCT05705180|||COHORT||RETROSPECTIVE|||||||
33991846|NCT06310252|||COHORT||PROSPECTIVE|||||||
33991847|NCT04185493|||COHORT||PROSPECTIVE|||||||
33991848|NCT03767374|||COHORT||CROSS_SECTIONAL|||||||
33991849|NCT02365363|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33991850|NCT04407403|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084369|NCT02198196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084370|NCT04151511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34084371|NCT03424135|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909317|NCT00148460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909318|NCT02618850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991851|NCT00004738|||FAMILY_BASED||PROSPECTIVE|||||||
34084372|NCT01627665|RANDOMIZED|CROSSOVER||||NONE||||||
34084373|NCT02329717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084374|NCT01900444|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34084375|NCT03851575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991852|NCT06741527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991853|NCT06524479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991854|NCT03861247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991855|NCT06627868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991856|NCT04596891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688244|NCT00463073|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33688245|NCT00894374|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33688246|NCT01497145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688247|NCT01692873|NA|SINGLE_GROUP||OTHER||NONE||||||
34084376|NCT01622322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33688248|NCT03425227|NA|SINGLE_GROUP||TREATMENT||NONE||"Screening was arranged for 65 subjects in total in accordance with the following criteria.~Of the 65 individuals who showed interest in taking part in the study, 46 met the inclusion criteria, and these subjects were again asked to carry out some specific tests in order to evidence their degree of frailty.~Frailty screening was undertaken using the short physical performance battery (SPPB).~Of the 46 subjects, 40 obtained scores below 10, i.e. 40 subjects may be considered frail.~In addition to the Barthel scale, the 40 subjects filled in the following questionnaire: EuroQol 5D-5L™. Medical records related to risk of heart failure were also gathered.~To undertake randomisation, these 40 subjects were classified according to range of age, gender and Barthel score, obtaining a study group and a control group of subjects respectively."||||
33688249|NCT02810678|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688250|NCT05737771|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688251|NCT04444427|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 employs a dose-escalation design to determine the recommended phase 2 dose. This is followed by Part 2, which involves parallel dosing of 3 different cohorts at the dose determined in Part 1.||||
33688252|NCT00414427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688253|NCT01840995|||||PROSPECTIVE|||||||
33688254|NCT04890743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants of all 4 groups will benefit from a unified kinesiotherapeutic program. Then, after the randomization, participants will undergo treatments, but they will not know what type of therapy they will undergo.|The study will include healthy volunteers, students of the university in the area of Rzeszów with cervical spine pain syndrome caused by distance learning.|t|f|f|t
34084377|NCT03563222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33688255|NCT03091972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688256|NCT06289621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a Type 1 hybrid-effectiveness implementation trial. Study participants are randomized into the brief transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD) or an enhanced standard care control group.|f|f|f|t
33688257|NCT01815203|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33688258|NCT00248885|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33688259|NCT06491667|||COHORT||PROSPECTIVE|||||||
33688260|NCT05868889|||CASE_ONLY||RETROSPECTIVE|||||||
33688261|NCT01555957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The care taker team provided daily weight to the research pharmacist for calculating the dose of the lipid according to the assignment and then calculated the rate of administration over 18 to 24 hours depending on the volume. The rate and dose was masked to the investigators and participants.||t|f|t|f
33688262|NCT03383705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688263|NCT06028100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The patient did not know what was done to him/her because the block was performed before the patient woke up.~The investigator who questioned postoperative pain and opioid consumption did not know to whom the block was performed."|54 patients were included in the study, divided into two groups of 27 patients as esp block (group 1) and control group (group 2), both groups underwent standard general anaesthesia. The blocks were performed in the operating theatre at the end of the operation, before the patient woke up.A patient-controlled analgesia (PCA) device was given to both groups by another doctor blinded to the group, and Visual Analogue Scale (VAS) scores assessed for 24 hours.And total consumption of analgesic and rescue analgesics were recorded.|t|f|f|t
33688264|NCT01669707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688265|NCT02184351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33777671|NCT06176456|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"The design of the study involves following stages:~* diagnostic stage and randomization;~* 10 sessions of placebo-controlled stimulation protocols (high- and low-frequency magnetic pulses)~* primary analysis of the effectiveness of protocols after 10 sessions of stimulation, followed by the transfer of all patients, including the placebo group to the most effective stimulation regiment (20 sessions of active neuromodulation)~* final analysis of the effectiveness after 20 sessions of TMS and follow-up period (visits after 1 month and 6 months)"|t|t|f|t
34084378|NCT03886909|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839930|NCT04158804|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33839931|NCT06068764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Due to the difference in the physical appearance of etomidate and propofol medications, the anesthesiologist administering any of these medications will not be blinded. Only study patients will be blinded to the anesthesia induction agent they receive. Therefore, this study is considered single-blinded.~Since this is a clinical trial, blinding is an important method to reduce bias and ensure the validity of study results. Unblinding is unnecessary in this study unless the situation when a participant experiences a serious adverse event that is unexpected and related to the anesthesia induction agent (study intervention) and the course of treatment needs to be adjusted. Unblinding in this situation will be the decision of the principal investigator (PI). The PI will unblind the patient (i.e., tell the patient about the assigned group), and take any additional necessary course of treatment."|Single-center, prospective, single-blinded, randomized controlled clinical trial|t|f|f|f
33839932|NCT02271360|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33991857|NCT06570655|NA|SEQUENTIAL||TREATMENT||NONE||||||
33991858|NCT06486454|||COHORT||PROSPECTIVE|||||||
33991859|NCT06655324|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33991860|NCT05946031|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete two Experimental Marketplace conditions, representing one with real and one with hypothetical purchasing outcomes. Within each condition, taxes will be increased proportionally across 6 trials to examine how cigarette purchasing, substitution, and poly-tobacco purchasing (i.e., diversity in products purchased) are affected.||||
33991861|NCT06397560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991862|NCT02927639|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34084379|NCT03146676|||OTHER||PROSPECTIVE|||||||
34084380|NCT03750721|||COHORT||RETROSPECTIVE|||||||
33991863|NCT06632600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The benznidazole arm is open-label.~For the LXE and placebo arms:~Participants, investigator, staff, and persons performing the assessments will remain blinded to the identity of the treatment from the time of randomization until final (12 month) database lock for blinded arms. The sponsor clinical trial team (CTT) will be blinded until the primary endpoint analysis (when all participants complete 6 month visit) and may become unblinded as needed at any other interim analysis."||t|t|t|t
34084381|NCT05966103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluations were done by a different physical therapist. The physiotherapist who administered the treatment was different. In addition, the participants did not know which group they were in.|Randomized Comparative Double-Blind Study|t|f|f|t
33688266|NCT02474225|||COHORT||PROSPECTIVE|||||||
33688267|NCT00267618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688268|NCT03333733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Treatment allocation will be withheld from research staff collecting the data. Screening forms will not indicate whether they have been recruited from active or control Centres The chief investigator, trial coordinator and statistician will not be provided details of treatment allocation.||f|f|t|t
33688269|NCT05728775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33688270|NCT05578157|||COHORT||CROSS_SECTIONAL|||||||
33777672|NCT03985722|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a phase I, non-randomised, one-armed, multicenter trial, open-label.~The dose escalation rules include patients in blocks of 3 o 6 patient. Treatment is a combination of unlimited cycles of oralatumab and trabectedin."||||
33909319|NCT06342726|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The study will use a crossover design on where research participants will undergo repetitions of the same scenario with different interventions in order to serve as their own control. The research participants will be healthy volunteers providing both oral and written consent.~Before the start of experiment, the research participant will be cooled in an ice cave wearing wet clothing and with 2-3 m/s wind to a core temperature of 35.0 °C using the established protocol for inhibition of shivering. The maximum cooling time will be 2 hours (120 minutes). The order of interventions will be randomized.~When the research subjects reach the target temperature of 35.0°C or the maximum cooling time of 2 hours, they will be subjected to one of the two scenarios listed below, with a rewarming phase of maximum 60 minutes."|t|f|t|t
33909320|NCT05794516|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33909321|NCT03403504|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33909322|NCT05091190|NA|SINGLE_GROUP||OTHER||NONE||||||
33909323|NCT03901612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Solution infused prepared by a different team with a rescue envelop to open in case of incident|Randomized Controlled double blind|t|t|t|t
33909324|NCT00107770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909325|NCT05940844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A total of up to 36 patients will be screened and 18 enrolled. At least 3 patients at each of the 4 dose levels (0.25, 0.5, 1.0, and 1.5 mg/kg planned) and up to 6 patients at the highest dose(s) if no MTD. An additional 3 patients may be recruited at any of the dose levels to define the dose(s) for further development. Each patient will be enrolled for at least one 28-day cycle of treatment with a FU period of up to 12 months.||||
33909326|NCT02329522|||COHORT||PROSPECTIVE|||||||
33909327|NCT01242020|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33909328|NCT05118958|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Initial open-label crossover (Part 1) followed by double-blind, randomised, placebo-controlled part (Part 3).||t|t|t|t
33909329|NCT04702555|||CASE_ONLY||PROSPECTIVE|||||||
33909330|NCT05663996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients diagnosed with osteoarthritis by a physical therapy and rehabilitation specialist according to ACR criteria were randomized into the study by the University Biostatistics Unit.|The study was conducted using a pre-test and post-test, randomized controlled trial pattern and semi-structured in-depth interview method of qualitative research.|t|f|f|f
33909331|NCT03132792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909332|NCT04374825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients participating in the online pilot will be randomized to 1 of 3 study arms: 1) a usual care control, 2) CBSM, and 3) ACT. Women taking part in the intervention trial (i.e. women living with Stage IV \[M1\] breast cancer) will complete self-report psychosocial measures online at four assessments. Change across time will be assessed from baseline to mid-intervention (Week 4 of 8), immediately post-intervention (Week 8), and a one month follow-up.||||
33909333|NCT00041717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909334|NCT06463769|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1: Patients with prodromal PD receiving nutritional intervention Arm 2: Patients with clinical PD receiving nutritional intervention Arm 3: Patients with clinical PD receiving standard of care (control)||||
33909335|NCT00757562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909336|NCT05090917|||CASE_CONTROL||RETROSPECTIVE|||||||
33909337|NCT04856436|||COHORT||RETROSPECTIVE|||||||
33909338|NCT06561685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909339|NCT00012337||||TREATMENT||||||||
33991864|NCT01961947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33991865|NCT06741852|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The participant, investigator, and outcomes accessor was blinded to the intervention.||t|f|t|t
33991866|NCT03319108|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991867|NCT01663233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084382|NCT00459017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084383|NCT03432832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||per protocol analysis versus intent to treat analytic approach due to the pandemic|f|f|f|t
34084384|NCT00129831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084385|NCT05963399|NA|SINGLE_GROUP||OTHER||NONE||||||
34084386|NCT00002557||||TREATMENT||||||||
34084387|NCT02765035|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34084388|NCT02303665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084389|NCT00827567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084390|NCT03758469|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084391|NCT03274817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34084392|NCT02879058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084393|NCT02727712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688271|NCT03742908|RANDOMIZED|PARALLEL||PREVENTION||NONE|Treatment allocation is revealed to the surgical team intraoperatively. Treatment allocation is revealed to the patient post-op in their first followup visit in the clinics.|Block randomization is generated by one investigator that is not involved in surgery and the block size is kept hidden from other investigators and patients.||||
33688272|NCT06271499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688273|NCT03280927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688274|NCT00728767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688275|NCT03918668|||COHORT||PROSPECTIVE|||||||
33688276|NCT01337687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688277|NCT01997710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688278|NCT04143529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688279|NCT00741962|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33688280|NCT00621400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688281|NCT00003950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688282|NCT00625482||||PREVENTION||||||||
33688283|NCT02836600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688284|NCT00597844|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33688285|NCT05125887|||COHORT||PROSPECTIVE|||||||
33688286|NCT00626054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688287|NCT02894008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688288|NCT01163032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688289|NCT02786524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688290|NCT01076894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688291|NCT03103061|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Stress and rest perfusion imaging using Lexiscan as the coronary vasodilator (pharmacological stressor).||||
33688292|NCT01165567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688293|NCT04700033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, PI and Outcome Assessor remain blinded for the entirety of the study.|The study is a single center, prospective randomized controlled clinical trial. The purpose of the study is to provide critical information about the efficacy of Immersive Virtual Reality (IVR) to decrease the experience of neuropathic pain in the upper and lower extremities of people with a spinal cord injury.|t|f|t|t
33688294|NCT01280045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||We woudl be comparing aromatase inhibitors versus GnRH analogs|f|f|t|t
33688295|NCT02102971|||COHORT||PROSPECTIVE|||||||
33909340|NCT03754283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1|f|f|f|t
33909341|NCT02330627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909342|NCT02573532|||COHORT||PROSPECTIVE|||||||
33909343|NCT00251407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909344|NCT00571363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33991868|NCT06664502|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participant, Investigator, Outcomes Assessor|"Part 1 is a multiple ascending dose (MAD) study, and patients will be enrolled sequentially in ascending order through the dose levels until the highest level is reached or until a maximum tolerated dose is reached, whichever comes first.~Part 2 is a randomized double-masked study where patients on all arms may be enrolled in parallel."|t|f|t|t
33991869|NCT03032107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688296|NCT06265779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688297|NCT03158714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688298|NCT05144594|||OTHER||RETROSPECTIVE|||||||
33688299|NCT01693302|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688300|NCT05694000|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33688301|NCT01554969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688302|NCT04585139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study consists of two phases. Phase I is a single-arm, prospective, multicenter, interventional design. Phase II is a randomized controlled arm study during which participants will be randomized 1:1 to Commercial CGM or Updated CGM||||
33688303|NCT03442764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777673|NCT02156791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777674|NCT00188396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777675|NCT04055285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839933|NCT03512964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839934|NCT04562740|NA|SINGLE_GROUP||TREATMENT||NONE||During the index angioplasty revascularisation procedure of the limb salvage programme, the ABLUMINUS DES drug eluting stent will be deployed after successful conventional balloon angioplasty.||||
33839935|NCT00652769|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839936|NCT03655886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839937|NCT04329637|RANDOMIZED|PARALLEL||OTHER||NONE||Patients were prospectively randomized to either the integrative health care model (IHC model) or usual care (UC)/control group after signing informed consent. Demographics, clinical characteristics and outcomes of interest were measured at baseline before the intervention, and at 3 and 6 months. Global psychological distress ,depression, catastrophizing, anxiety/pain-related fear, and social support were assessed using validated tools. Coping skills were measured with the validated short version of the COPE questionnaire. Quality of sleep was assessed using Pittsburgh Sleep Quality Index (PSQI). HRQoL was measured with the NIH PROMIS Short Forms. Health care utilization was recorded.||||
33909345|NCT06692803|||COHORT||RETROSPECTIVE|||||||
33909346|NCT00276237|||||PROSPECTIVE|||||||
33909347|NCT04066816|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909348|NCT04481425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909349|NCT02411227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839938|NCT04685837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839939|NCT02926222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839940|NCT00253357|||||PROSPECTIVE|||||||
33839941|NCT00585858|||COHORT||PROSPECTIVE|||||||
33909350|NCT02734602|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33909351|NCT02544971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909352|NCT04776356|||CASE_ONLY||PROSPECTIVE|||||||
33909353|NCT00102453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909354|NCT02526927|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33909355|NCT02462005|||OTHER||PROSPECTIVE|||||||
33991870|NCT04029415|||OTHER||PROSPECTIVE|||||||
33991871|NCT02069535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991872|NCT01419561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991873|NCT06742255|||COHORT||PROSPECTIVE|||||||
33991874|NCT03523377|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The OnFACT study is a pilot randomized controlled trial of prolonged overnight fasting among adult survivors of childhood cancer.||||
33991875|NCT05966753|||COHORT||RETROSPECTIVE|||||||
33991876|NCT06169124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991877|NCT06544902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991878|NCT06337552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Clinical response will be determined in clinic when patients undergo blinded tumor assessments by standard digital rectal exam, endoscopy, and rectal MRI at baseline and at the end of the intervention.|Participants will be randomized to either the FEED-FF Arm or the Standard of Care (SUC) Arm|f|t|f|f
33688304|NCT01473927|||CASE_ONLY||CROSS_SECTIONAL|||||||
33688305|NCT06035055|NA|SINGLE_GROUP||TREATMENT||NONE||30 patients will be recruited and will receive the study intervention.||||
33688306|NCT05742178|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33688307|NCT01244360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33688308|NCT02599675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688309|NCT03174899|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33991879|NCT01531985|||CASE_ONLY||PROSPECTIVE|||||||
33991880|NCT00834561|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991881|NCT03647293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33991882|NCT06742164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991883|NCT06588153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991884|NCT06616532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991885|NCT01915511|||COHORT||PROSPECTIVE|||||||
33991886|NCT05755282|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All participants will try all products. Participants are randomized to the order of study product application.||t|f|f|f
33991887|NCT05703360|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Interventional, pragmatic, cross-over, single-blind, multi-centre study|f|f|f|t
33991888|NCT06551090|||COHORT||PROSPECTIVE|||||||
33688310|NCT05861531|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Parents, registered nurses, therapists, and providers will be visually separated by a curtain while the oromotor stimulation or no oromotor stimulation is occurring with the participant||t|t|f|t
33688311|NCT03954522|NA|SINGLE_GROUP||OTHER||NONE||||||
33688312|NCT03824067|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The design of this study is a cluster-randomized stepped wedge trial. This is whereby an intervention is rolled out sequentially to the study facilities over a number of time periods. The order in which the different clusters receive the intervention is determined at random and by the end of random allocation, all facilities will have received the intervention. Testing sites (determined from the list of all project facilities excluding pilot sites) will be randomized regarding timing of POC implementation; sites that serve as hub sites and their associated spoke sites will be given the same designation. The study will use a mixed method approach in data collection, and a qualitative component will also be conducted, including interviews and focus groups."||||
33688313|NCT03920384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study.|Randomised case series|t|f|f|t
33688314|NCT03207334|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive midostaurin and cytarabine.||||
33688315|NCT00594451|||COHORT||CROSS_SECTIONAL|||||||
33777676|NCT04361630|NA|SINGLE_GROUP||PREVENTION||NONE|Single Blinded trial.|This study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the treatment of Miller's class I and class II gingival recessions.||||
33777677|NCT02874846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777678|NCT03862443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|An independent outcomes assessor and PIs will be blinded to participants' group assignment, and participants will be told that the examiner and PIs cannot answer any incentive questions and they should not mention the incentive program to them. (Due to the nature of the intervention, the staff explaining the study arms after randomization and providing the incentive gift cards at follow-up visits cannot be blinded.)|Eligible consenting parent-child participant dyads, within strata and permuted blocks, will be randomized in equal allocation to one of three arms. Strata will be based on smartphone operating system (iOS or Android).|f|f|t|t
33777679|NCT05542017|||CASE_ONLY||RETROSPECTIVE|||||||
33991889|NCT06558708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991890|NCT00781339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991891|NCT03221543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991892|NCT03631628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991893|NCT00308152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991894|NCT02070458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777680|NCT03064893|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777681|NCT01423903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991895|NCT05349513|NA|SINGLE_GROUP||OTHER||NONE||||||
33991896|NCT02361905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991897|NCT05022381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991898|NCT05954650|||COHORT||RETROSPECTIVE|||||||
33991899|NCT06742307|NA|SINGLE_GROUP||TREATMENT||NONE||Patients included, once diagnosed with neovascular macular dengeration, will embark on a planned quarterly (every 12-16 weeks) aflibercept injection schedule for one year, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. If disease inactivity is not achieved during the maintenance phase, patient's injection interval may be shortened.||||
33991900|NCT02817867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33991901|NCT00627016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991902|NCT06540716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777682|NCT01223859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777683|NCT03024320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized Controlled Trial with three arms.|f|f|t|t
33777684|NCT01995942|||COHORT||PROSPECTIVE|||||||
33777685|NCT01515956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991903|NCT03964935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688316|NCT00349427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688317|NCT03598634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688318|NCT01512290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688319|NCT01513369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688320|NCT04853381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688321|NCT00896636|||COHORT||PROSPECTIVE|||||||
33688322|NCT03119701|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Multicentre, randomised, double-blinded, Phase II, parallel group comparison study of the efficacy and safety of FP-1201-lyo compared to placebo in patients surviving emergency open surgery for an infra-renal ruptured abdominal aortic aneurysm.|t|t|t|t
33688323|NCT00766961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688324|NCT01695200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688325|NCT04211805|||COHORT||PROSPECTIVE|||||||
33688326|NCT03813797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study will be carried out:~* Blind patient: The patient will not know the group he belongs to, in order to minimize the bias related to the self-evaluation of postoperative pain~* Blind for the outpatient evaluator: the surgeon will blindly evaluate the primary endpoint: patient's discharge criteria. This evaluator surgeon will be different from the operator surgeon The blind will minimize the measurement bias."||t|f|f|t
33688327|NCT03930160|||COHORT||RETROSPECTIVE|||||||
33688328|NCT04820127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33991904|NCT00829790|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33991905|NCT05885971|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33991906|NCT01778010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33991907|NCT06138821|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized, controlled, open-label clinical trial.||||
33991908|NCT03973268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34084394|NCT01530542|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33909356|NCT06388590|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patient sample will be both control and treatment groups. Individuals will not be divided into distinct groups. Patients will serve as their own controls. Control patients will be participating in standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention. The same patients will then be re-evaluated and will be offered Acupuncture with Dragon technique (see attachment Protocol for Needle Insertion) as a means of pain control once per week for 4 weeks.||||
33909357|NCT05826197|||CASE_CONTROL||PROSPECTIVE|||||||
33909358|NCT02021058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909359|NCT02600026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991909|NCT02580279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991910|NCT06560372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients hospitalized at Martinique University Hospital for treatment or monitoring of a moderate or severe TBI (Glasgow Score less than or equal to 13 at initial treatment) presenting with SAH on initial cerebral CT scan||||
33991911|NCT05884190|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study population will include adult postpartum women at least 18 yrs old that are at-risk for hypertension and/or poor mental health outcomes. This is a multi-site intervention study that follows a sequential stepped-wedge design with the 3 hospitals randomized to their start time for the first arm followed by the second and third arms.||||
33991912|NCT03397251|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, non-blinded, single-arm study evaluating the feasibility and safety of the AMDS||||
33991913|NCT04673721|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33991914|NCT02882282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991915|NCT03011476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991916|NCT00443651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991917|NCT04132518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991918|NCT04099823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33991919|NCT04456881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991920|NCT03710928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled trial, 12-week feeding study||||
33991921|NCT03689257|||COHORT||PROSPECTIVE|||||||
33991922|NCT02510118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33991923|NCT05014958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33991924|NCT04070547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The sham stimulation experience is very similar to the tVNS stimulation experience. Participants will be provided a detailed instructions and manual how to use the tVNS device and at what part of the ear they will place the electrode on.|Participants will be randomly assigned to one of 4 groups - receiving either transcutaneous vagal nerve stimulation or sham in first 2 weeks (Early group), or being first 2 weeks on the waiting list and receiving either transcutaneous vagal nerve stimulation or sham in the second 2 weeks of the study participation (Late group). The randomization will have two steps: 1.) Prior to the first laboratory session all participants will be assigned into either Early or Late group; 2.) At the end of the pre-intervention laboratory session participants will be randomized between tVNS or sham stimulation.|t|f|f|f
33991925|NCT03713086|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33991926|NCT05954728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991927|NCT02493283|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33991928|NCT02220985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991929|NCT03714594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991930|NCT00723047|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33991931|NCT05554406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991932|NCT04542577|||CASE_ONLY||PROSPECTIVE|||||||
33991933|NCT06521021|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33991934|NCT02199873|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33991935|NCT04019015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991936|NCT01744587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34084395|NCT00199173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084396|NCT05919628|||COHORT||RETROSPECTIVE|||||||
34084397|NCT02137655|||COHORT||PROSPECTIVE|||||||
33688329|NCT05193357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688330|NCT01385228|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084398|NCT04920435|||COHORT||RETROSPECTIVE|||||||
34084399|NCT03304236|||COHORT||PROSPECTIVE|||||||
34084400|NCT04755010|||COHORT||PROSPECTIVE|||||||
34084401|NCT06440928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomised controlled and experimental study||||
33688331|NCT03252184|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study will be separated in phases in according to photobiomodulation device employed. Initially, we will use the laser with 658nm, power output of 10mW per point and fluence of 18J, 36J e 54J per area. The individuals will be randomly assigned to: group 1 (energy dose of 18J), group 2 (energy dose of 36J), group 3 (energy dose of 54J), and group 4 (placebo). In the second phase, we will use the laser with 810nm, power density of 714 mW/cm2 and fluence of 30 J per spot. The individuals will be randomly assigned to: group 1 (energy dose of 30J), group 2 (energy dose of 60J) and group 3 (placebo). Finally, we will measure the time of blood vessel dilation after photobiomodulation with 30J and 60J.|t|f|f|t
33688332|NCT04499547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33688333|NCT04733391|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33688334|NCT06278909|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a traditional feasibility study, which evaluates preliminary safety and effectiveness information. It does not meet the definition of a device feasibility study."||||
33688335|NCT02531334|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33688336|NCT06479395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688337|NCT00005851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688338|NCT00983788|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33688339|NCT02886065|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688340|NCT02569827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688341|NCT03371771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to receive either Volunteer or MSW-delivered Behavioral Activation|f|f|f|t
33688342|NCT02815488|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33688343|NCT03010761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688344|NCT01250639|||CASE_CONTROL||PROSPECTIVE|||||||
33688345|NCT05596123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants, the outcome assessors, and the statistician will be unaware of the group assignment.|This is a prospective, two-arm, double-blinded, randomized controlled trial. A one-to-one ratio will be used to randomly assign participants to the TCFM group or the placebo massage group. Six weekly 25-minute TCFM sessions will be delivered to participants in the TCFM group. Six weekly 25-minute sessions of placebo massage will be delivered to participants in the placebo massage group.|t|f|t|f
33688346|NCT03249220|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33688347|NCT03906188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33688348|NCT05998928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688349|NCT02655393|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
33688350|NCT02914821|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33688351|NCT00876798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688352|NCT00655135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688353|NCT00188331|||||PROSPECTIVE|||||||
33777686|NCT01882062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777687|NCT03553940|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33777688|NCT00220103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777689|NCT02127684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777690|NCT00179608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777691|NCT02900781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33777692|NCT00440674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777693|NCT06091566|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group assignment||||
33777694|NCT00623415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33777695|NCT01603121|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33777696|NCT03289546|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33777697|NCT05705050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777698|NCT04538807|||CASE_ONLY||CROSS_SECTIONAL|||||||
33777699|NCT06031662|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33777700|NCT04039880|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33777701|NCT01264263|||COHORT||CROSS_SECTIONAL|||||||
33777702|NCT06529211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777703|NCT01481935|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33777704|NCT06440382|||CASE_CONTROL||RETROSPECTIVE|||||||
33777705|NCT00426374|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909360|NCT06257706|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Study participants and investigators will be unblinded to the treatment target group assignment.~Central readers performing the assessment of IUS, endoscopy, and histology assessments will be blinded to treatment target randomization, participant, treatment received, and timepoint which will be used to determine treatment escalation."|This is an interventional, randomized, parallel-group, multicenter, controlled study. A total of approximately 304 participants with moderately-to-severely active CD from multiple international sites will be enrolled into this study. All qualified participants will be randomly assigned in a 1:1 ratio to one of 2 different treatment target groups: Group 1 will be treated over 48 weeks to achieve a target of corticosteroid-free IUS-based outcomes + clinical remission + biomarker remission. Group 2 will be treated over 48 weeks to achieve a target of corticosteroid-free clinical remission + biomarker remission. Randomization will be stratified by the following baseline factors: prior exposure to an approved biologic/small molecule advanced therapy for CD (yes or no), disease location (ileal-predominant or colonic), and disease duration (≤ 2 years or \>2 years, based on the date of diagnosis).||||
33909361|NCT01822470|||CASE_CONTROL||PROSPECTIVE|||||||
33909362|NCT05952856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909363|NCT01062451|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33909364|NCT04792853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study uses an experimental pre- and post-test repeated measures design. Those satisfying the inclusion and exclusion criteria are randomly assigned to the intervention (Tab-G, n=20) or comparison group (n=20).||||
33909365|NCT02179515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909366|NCT06518109|||COHORT||PROSPECTIVE|||||||
33909367|NCT06227390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688354|NCT06002022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Control arm: Patients will be treated as usual after the first-line breast cancer treatment. Specifically, this process entails biannual medical evaluation control visits for the first port-treatment year at the Oncology Department, including standardised blood examinations.~Experimental arm: Additionally, patients will be trained in the use of the REBECCA mobile and online monitoring platform, which will be used longitudinally, with the collection of real-world data within the REBECCA framework. Their supervising health personnel will be given access to the REBECCA patient dashboard, which provides in-depth information about their lifestyle, as well as continuous REBECCA measurements for their online behaviour and self- or companion-reported measures of emotional state and quality of life."||||
33688355|NCT01314911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688356|NCT05920915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization will be done by closed envelope method||f|f|t|f
33688357|NCT04428437|||COHORT||PROSPECTIVE|||||||
33688358|NCT00116792|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33688359|NCT05527132|||CASE_ONLY||RETROSPECTIVE|||||||
33688360|NCT04457219|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 arms of randomisation (1:1:1 ratio), parallel treatments||||
33688361|NCT02280473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777706|NCT03654586|RANDOMIZED|FACTORIAL||PREVENTION||NONE||"There was no answer option for our study design, but factorial is most similar. Participants will be randomly assigned to one of four conditions described below.~1. Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels.~2. Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay~3. Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage~4. Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."||||
33777707|NCT02521519|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33777708|NCT04535739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777709|NCT05466708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777710|NCT02038283|||COHORT||PROSPECTIVE|||||||
33777711|NCT04850365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777712|NCT03839563|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A pragmatic, single-blinded, randomized controlled trial with three arms will be conducted to investigate the effectiveness of conventional exercise and tai chi chuan, compared to health education/usual physical activity.|t|f|f|f
33777713|NCT00181779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777714|NCT02726555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777715|NCT02351895|||COHORT||PROSPECTIVE|||||||
33777716|NCT00635843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777717|NCT02157415|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33777718|NCT03572829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777719|NCT05653180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777720|NCT03499600|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Coders assessing therapist fidelity to the CFI are kept unaware of the condition to which each participant is assigned. Participants will also be unaware of the condition to which they have been assigned.|Randomized control trial in which participants are randomly assigned to either receive a diagnostic and clinical assessment plus the cultural formulation interview (CA and CFI) or the diagnostic and clinical assessment (CA).|t|f|f|t
33777721|NCT02875678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33991937|NCT04145622|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33991938|NCT06421337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Outcome will be evaluated by an independent assessor blinded to the monitoring results at the acute phase|||||
33991939|NCT00764712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991940|NCT03938246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be randomly assigned to experimental or placebo arms.|t|f|f|f
33991941|NCT06005610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991942|NCT02648997|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||After completion of accrual to Cohort 1, we opened accrual to Cohort 2.||||
33991943|NCT00001254|||COHORT||PROSPECTIVE|||||||
33991944|NCT04708431|||COHORT||PROSPECTIVE|||||||
33991945|NCT03730168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991946|NCT05201469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991947|NCT01818024|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33688362|NCT05034666|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|the participants are not informed about the visit, and the investigator is measuring the ETT cuff pressure in the absence of the participant.|anaesthetists of anaesthesia department on Suez canal university|t|f|f|f
33688363|NCT04178083|||COHORT||PROSPECTIVE|||||||
33688364|NCT01043315|||CASE_ONLY||PROSPECTIVE|||||||
33991948|NCT05718700|||COHORT||OTHER|||||||
33991949|NCT06463587|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33991950|NCT05677321|||CASE_CONTROL||PROSPECTIVE|||||||
33991951|NCT06576037|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991952|NCT02257658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777722|NCT03311854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909368|NCT02647762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909369|NCT05437224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909370|NCT03455478|NON_RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE|||f|f|f|t
33909371|NCT02075762|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909372|NCT02372825|||||CROSS_SECTIONAL|||||||
33909373|NCT05520996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909374|NCT01757639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909375|NCT03709810|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33909376|NCT04729088|NA|SINGLE_GROUP||OTHER||NONE||Phase I, single-center, single-dose clinical trial (test drug), in which participants will receive the test drug intra-anal||||
33909377|NCT02973464|||COHORT||PROSPECTIVE|||||||
33991953|NCT05184894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33991954|NCT06251180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33991955|NCT03199963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double blind, placebo controlled|t|t|t|t
33991956|NCT00114647|||COHORT||PROSPECTIVE|||||||
33991957|NCT01885572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991958|NCT03579303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991959|NCT06447922|||COHORT||PROSPECTIVE|||||||
33991960|NCT06218394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991961|NCT06489223|NA|SINGLE_GROUP||OTHER||NONE||||||
33777723|NCT02448719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777724|NCT00125775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777725|NCT04629144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33777726|NCT05270382|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33777727|NCT04643730|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33777728|NCT05516628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777729|NCT05661760|||COHORT||PROSPECTIVE|||||||
33777730|NCT01241578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777731|NCT05641077|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909378|NCT04371172|||COHORT||PROSPECTIVE|||||||
33909379|NCT03568149|||CASE_CONTROL||PROSPECTIVE|||||||
33909380|NCT06596629|||CASE_ONLY||RETROSPECTIVE|||||||
33909381|NCT05740436|||CASE_ONLY||PROSPECTIVE|||||||
33909382|NCT05437172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909383|NCT04081649|||COHORT||PROSPECTIVE|||||||
33909384|NCT04413448|||OTHER||RETROSPECTIVE|||||||
33909385|NCT03225781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909386|NCT03341897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909387|NCT02026622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909388|NCT03166436|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
33909389|NCT04761094|||COHORT||CROSS_SECTIONAL|||||||
33909390|NCT06295081|||COHORT||PROSPECTIVE|||||||
33909391|NCT00466128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909392|NCT02260167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909393|NCT05508776|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33909394|NCT03003143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909395|NCT05655390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental randomized clinical study. Rater-blinded. Sample: Suicidal attempters.|f|f|t|f
33909396|NCT01848964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909397|NCT05122663|||COHORT||PROSPECTIVE|||||||
33909398|NCT00296959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33909399|NCT02891031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909400|NCT01540188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909401|NCT00659919|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33909402|NCT02739594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688365|NCT05246904|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will be randomly assigned and will not know which fit is first.|Participants will be randomly assigned to arm 1 (audiologist fit) or arm 2 (self fit) first. After 2-3 weeks they will be tested and then assigned to the opposite arm.|t|f|f|f
33688366|NCT01284933|||COHORT||PROSPECTIVE|||||||
33688367|NCT01171170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688368|NCT04399174|||COHORT||PROSPECTIVE|||||||
33688369|NCT04896021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Allocation is concealed from all people involved in eligibility screening and recruitment.~Pathology services reception and blood collection staff members may be employed across different collection centers that could include both intervention and control sites. Thus, concealment at the cluster level (as per this study design) is critical and all procedures undertaken by staff members interacting with participants (reception and blood collection staff) will be identical. At the participant level, there will be no indication provided regarding allocation (all participants will have the same information and undergo the same protocol at baseline assessment). Investigators will be blinded to participant allocation. Outcomes assessment is via linkage to health outcomes data."|Participants attending pathology services for blood cholesterol assessment will be randomized to intervention or control arms. Randomization is clustered at the level of general practice clinics (n=60 target) referring patients to pathology services for blood cholesterol assessment.|t|f|t|t
33909403|NCT03415477|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Patients with recurrent and/or refractory aneurysmal bone cysts treated with denosumab perioperatively.||||
33991962|NCT04830462|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study consists of two arms with different patient populations. Both arms will receive identical treatment. Arm A will have type 2 diabetes and latent tuberculosis infection (LTBI). Group B will not have any form of diabetes, but LTBI.||||
33991963|NCT06675331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991964|NCT00827463|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33688370|NCT01165580|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33688371|NCT00354588|||COHORT||PROSPECTIVE|||||||
33688372|NCT04672681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention is a parallel model where the participants are randomized to either the intervention group or standard care.||||
33688373|NCT04679545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized at a 1:1 ratio.|There are 2 groups in this trial: interventional group (active drug) and control group (placebo).|t|f|t|f
33688374|NCT06302738|||COHORT||CROSS_SECTIONAL|||||||
33688375|NCT05949944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688376|NCT00809029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33688377|NCT00002083||||TREATMENT||||||||
33688378|NCT04923165|||COHORT||PROSPECTIVE|||||||
33688379|NCT01469104|RANDOMIZED|CROSSOVER||||NONE||||||
33688380|NCT06151184|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The intervention for this proof-of-concept trial is chiropractic manual adjustments. Participants will undergo chiropractic care from a state licensed chiropractor. Each individual's care plan will be determined by that individual and their specific field doctor for frequency of visits and type of chiropractic technique used. Participants will undergo 6 weeks of chiropractic for this study.||||
33688381|NCT00480974|||CASE_ONLY||RETROSPECTIVE|||||||
33688382|NCT00522964|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33688383|NCT01315236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688384|NCT01165190|||COHORT||PROSPECTIVE|||||||
33688385|NCT06516159|||COHORT||PROSPECTIVE|||||||
33688386|NCT03293511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind within-subject design|t|f|t|t
33688387|NCT02011893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688388|NCT05896579|NA|SINGLE_GROUP||OTHER||NONE||Study participants will undergo testing to identify patterns of right ventricular dysfunction. If a study participant decides to participate in exercise training, the participant will complete an exercise training intervention followed by repeat testing to determine impact of exercise training on right ventricular dysfunction.||||
33688389|NCT03762915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688390|NCT01299701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688391|NCT03734484|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33688392|NCT03249493|||COHORT||PROSPECTIVE|||||||
33688393|NCT05346367|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33688394|NCT05483881|||CASE_ONLY||RETROSPECTIVE|||||||
33777732|NCT00179283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33909404|NCT03026543|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33909405|NCT05828238|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909406|NCT00200525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33909407|NCT01532323|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909408|NCT05880368|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge with a parallel control arm||||
33909409|NCT03288272|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization Best Supportive Care, Two Radiotherapy Dosing Regimens||||
33909410|NCT02288767|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909411|NCT06691945|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33909412|NCT02929095|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33909413|NCT00817986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909414|NCT03108755|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33909415|NCT00972244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991965|NCT04175977|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33991966|NCT05944510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991967|NCT04456842|||COHORT||PROSPECTIVE|||||||
33991968|NCT04184167|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33991969|NCT05078970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to treatment assignment. It is not possible for clinicians or families to be blind to treatment procedures in psychotherapy since orientation to the model of care is part of psychotherapy.|"Participants will be randomized in a 1:1:1 ratio to~1. Safety Planning Intervention plus follow up,~2. Collaborative Assessment and Management of Suicidality, or~3. usual care"|f|f|f|t
33991970|NCT06045546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33991971|NCT05487989|||COHORT||PROSPECTIVE|||||||
33991972|NCT03549754|||OTHER||PROSPECTIVE|||||||
33688395|NCT02776371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688396|NCT00926068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991973|NCT03316963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688397|NCT01142128|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33688398|NCT04315935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688399|NCT06256627|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33991974|NCT06731803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All eligible patients in cohort NeoART-001 will receive: Trastuzumab-deruxtecan 5.4 mg/kg i.v., on day 1, Q3W plus 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W All eligible patients in cohort NeoART-002 will receive: Trastuzumab-deruxtecan 5.4 mg/kg i.v., on day 1, Q3W plus FLO: oxaliplatin 85 mg/m2 \& leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W followed by surgery determined by the location of the primary tumor and post-operative care according to the guidelines and to local standards outside of this trial.||||
33991975|NCT01340495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991976|NCT00597805|||CASE_ONLY||PROSPECTIVE|||||||
33991977|NCT06495684|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will receive 5 sessions of active tDCS in one block and 5 sessions of sham tDCS in another block. The tDCS device allows for researchers and participants to remain blind to the condition until the end of the study by randomly assigning participants to either the active or the sham block and providing the study team members a unique code to enter into the tDCS device at the start of each session.|Within-subject, cross-over, double-blind, randomized controlled trial|t|f|t|f
33991978|NCT06558617|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33991979|NCT05315999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33991980|NCT03083574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991981|NCT03771469|NA|SINGLE_GROUP||SCREENING||NONE||This will be a prospective validation study of a sample of consecutive pediatric Down syndrome patients who are seen through the weekly Down syndrome clinic at OHSU/Doernbecher's.||||
33991982|NCT05143801|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||non-blinded randomized repeated measures crossover||||
33991983|NCT03958396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group study comparing patients with obstructive sleep apnea undergoing tonsillectomy or tonsillectomy and adenoidectomy to controls with no history of obstructive sleep apnea undergoing general anesthesia for any procedure. The study will be conducted in the patient's preoperative holding area room. Two intravenous catheters will be placed, one for a remifentanil infusion and one for blood draws to measure the blood concentration of remifentanil. Patients will have standard ASA monitors placed with vital signs monitored on a portable monitor, and a remifentanil infusion will be started. Blood draws will be taken at seven time points: zero, one, two, four, six, ten and fifteen minutes. Concomitantly, recordings of end tidal CO2, respiratory rate, and pupil diameter will be made at the seven time points.||||
33991984|NCT04084080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33991985|NCT02378857|||COHORT||CROSS_SECTIONAL|||||||
33991986|NCT05081934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991987|NCT00984022|RANDOMIZED|PARALLEL||TREATMENT||NONE||Aquacel vs. Iodoform Gauze||||
33991988|NCT01857934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991989|NCT05456360|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33991990|NCT03606174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There are 9 cohorts (having 9-55 maximum patients enrolled in each; based upon response rate). Patients are assigned to cohorts based upon their prior treatments for urothelial carcinoma.||||
33991991|NCT06603077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33991992|NCT01447017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33991993|NCT06571747|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33991994|NCT06680869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33991995|NCT05516667|||COHORT||PROSPECTIVE|||||||
33991996|NCT05377242|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The participant, the study PI, and the main research team will be blinded.|The study uses a prospective, pseudo-randomized, placebo-controlled, blinded, within-person clinical trial design. Individuals will be randomized in a double-blind fashion to either the curcumin, resveratrol, or stinging nettle treatment.|t|f|t|t
34084402|NCT03549026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34084403|NCT00921024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688400|NCT03654430|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688401|NCT05043285|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"This is a randomized, double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety, tolerability and immunogenicity of SCTV01C (A Bivalent Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Variants) in healthy population aged ≥18 years previously vaccinated with inactivated vaccine against COVID-19.~In the study, participants receive 20 µg dose or placebo, 40 µg dose or placebo."|t|t|t|f
33688402|NCT00964080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688403|NCT00375947|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33688404|NCT04834765|RANDOMIZED|FACTORIAL||TREATMENT||NONE||3 intervention groups- Mindfulness only, Art Therapy only and combined Mindfulness based Art Therapy. 1 control group.||||
33688405|NCT05060484|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33688406|NCT04867434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777733|NCT05118087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688407|NCT03421327|||COHORT||RETROSPECTIVE|||||||
33688408|NCT04768985|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33688409|NCT04186091|||CASE_CONTROL||PROSPECTIVE|||||||
33688410|NCT04215133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688411|NCT01346280|||||OTHER|||||||
33688412|NCT04589312|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|"Study nursing staff and participants will be blinded to the vaccine given and vaccine syringes will be covered with an opaque label, obscuring the vaccine. Only the preparing pharmacist will be aware of the vaccine used. A study nurse who is blinded to the vaccine given will observe for immediate reactions to the vaccine in a separate room from where the woman will receive her vaccination. This room will have an emergency trolley with appropriate drugs available should these be required.~The laboratory-based research team conducting the assays will be blinded to subject allocation."|"The study will take a 2x2 formation, with four groups:~1. HIV-uninfected women, standard of care vaccines in pregnancy;~2. HIV-uninfected women, Tdap vaccine in pregnancy;~3. HIV-infected women, standard of care vaccines in pregnancy;~4. HIV-infected women, Tdap vaccine in pregnancy."|t|t|t|t
33688413|NCT05637593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688414|NCT00300118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688415|NCT01962922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688416|NCT00231374|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688417|NCT00210860|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33688418|NCT04872530|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Subjects who volunteer for this study will undertake SIX controlled feeding trials, each trial separated by 7 days.Subjects will be assigned to a randomised sequence of six protein isolates including: (1) pea-protein concentrate; (2) fava-bean protein concentrate; (3) chickpea protein concentrate; (4) red lentil protein concentrate; (5) non-essential amino acid blend (negative control);( 6) whey protein concentrate. Protein is dosed at 0.33 g/kg body mass in 500 ml of water.|t|f|f|f
33777734|NCT03700606|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33777735|NCT02427646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777736|NCT06351267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909416|NCT01668563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909417|NCT00050349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909418|NCT03985072|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33909419|NCT02805868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909420|NCT06692569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688419|NCT00712556|||COHORT||RETROSPECTIVE|||||||
33688420|NCT04757740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688421|NCT02631356|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33688422|NCT00003184||||TREATMENT||||||||
33688423|NCT04019418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators will be masked to the contents of the beverage. They will not be masked to whether it is a resting or exercise condition as this is not possible.|Participants perform all four trials in a randomized order|t|f|t|f
33777737|NCT01880554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777738|NCT03929302|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777739|NCT04769882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure confidentiality of the data, each subject will be assigned a serial number so that only one of the experimenters will be able to link a number to the corresponding person. In addition, a dedicated computer will be used for data collection and analysis, which will be set up to allow limited access with a password known only to one of the experimenters.|The patients will be randomly assigned with a software (Excel 2007) to two groups: group A, control group, which includes treatment with traditional therapy; group B, intervention group, which includes treatment with Er:YAG laser therapy.|f|t|f|t
33777740|NCT04243161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33777741|NCT00105885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777742|NCT06166511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909421|NCT04285346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909422|NCT03329937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991997|NCT03781622|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, non-randomized, multi-center, feasibility clinical investigation to evaluate the safety and device technical performance of the WOLF Thrombectomy Device in removing thrombus from an occluded large intracranial vessel(s) in patients with acute ischemic stroke. The device may be used alone or as an adjunct to intravenous tissue plasminogen activator (tPA) and/or to other traditional, thrombectomy modalities.||||
33991998|NCT01315990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33991999|NCT00574847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992000|NCT02006212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992001|NCT05686395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992002|NCT01734369|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33777743|NCT00565682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777744|NCT06164353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777745|NCT02838004|NA|SINGLE_GROUP||OTHER||NONE||||||
33909423|NCT04898829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33909424|NCT02191423|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33909425|NCT02126904|||COHORT||RETROSPECTIVE|||||||
33909426|NCT03091062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909427|NCT06512818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There wiil be two arms. One group will undergo the intervention with the bioactive compound psiguavin, and the other will follow a placebo-based treatment. Both groups will start and finish the project at the same time.|t|t|t|t
33992003|NCT00841542|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992004|NCT03572868|||COHORT||PROSPECTIVE|||||||
33992005|NCT06485804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33909428|NCT04458727|||OTHER||OTHER|||||||
33909429|NCT03442335|||COHORT||PROSPECTIVE|||||||
33909430|NCT02795351|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33909431|NCT06498739|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33909432|NCT03890887|NA|SEQUENTIAL||TREATMENT||NONE||||||
33909433|NCT05275153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909434|NCT03569111|||COHORT||PROSPECTIVE|||||||
33909435|NCT02401555|||CASE_CONTROL||PROSPECTIVE|||||||
33909436|NCT05205434|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Study||||
33909437|NCT05473624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909438|NCT05769842|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Pediatric patients were randomly assigned to either the propofol group or the control group. In the propofol group, after the child regained spontaneous breathing before extubation, propofol was administered in small repeated doses, each dose being 0.5mg/kg, with a total amount of 1\~2mg/kg. The control group received an equivalent volume of normal saline. The occurrence of respiratory adverse events (such as laryngospasm, bronchospasm, breath-holding, coughing, decreased oxygen saturation, and airway obstruction) was observed in both groups post-extubation, with the presence of any one or more events considered indicative of respiratory adverse events.|t|t|f|t
33909439|NCT05681741|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||parallel affectation|t|f|f|t
33909440|NCT04188340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients with insomnia divided into two groups, each group is 20 patients as follows: 1) control group, using sweet al mond o il apply to GV20, GV24 SP6 , HT7 and PC6 acupoints, and massage for 10 times before sleep continuously 28 days; 2) treatment group, using Su Man formula m assage oil apply to GV20, GV24 , SP6 , HT7 and PC6 acupoints, and massage for 10 times before sleep cont inu ously 28 days.|t|t|t|t
33909441|NCT04492956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909442|NCT01248624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909443|NCT04368806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909444|NCT00619411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909445|NCT06688084|||COHORT||OTHER|||||||
33909446|NCT06556056|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33909447|NCT03803904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909448|NCT06242665|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blinded to their condition.|Multi-method, mixed-design|t|f|f|f
33909449|NCT03167580|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Parallel Assignment||||
33909450|NCT01793051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909451|NCT05647811|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will enroll a planned number of 18 patients as subjects for the trial with the potential for more enrollment. Each cohort will consist of 6 subjects in a total of three cohorts at doses of 5, 10, or 20 mg/kg NM8074. No more than two to three subjects will be dosed in a single day. Safety data will be assessed and reviewed by the Sponsor and Study Investigators for dosed subjects prior to dose escalation or dosing of the rest of the study subjects within the Cohort. Dose escalation will occur only after four (4) subjects have been dosed and safety data has been evaluated.||||
33992006|NCT01163435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992007|NCT05569512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909452|NCT06275971|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment group: glycemic control using CGM Control group: glycemic control using arterial/venous blood sampling and POCT glucose||||
33909453|NCT05687994|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33909454|NCT05260931|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33909455|NCT01728584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909456|NCT02323672|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909457|NCT04932525|NA|SINGLE_GROUP||OTHER||NONE||"The proportion of patients presenting at least one genomic alteration will be estimated in the eligible NGS population and reported using frequency and proportion. The 95% two-sided confidence limits (95%CI) will be provided for the estimated proportion (binomial law). In addition, counts, proportions and 95%CI will be reported for each individual genomic alteration.~Survival data will be analysed by standard time-to-event survival techniques."||||
33909458|NCT01035606|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The design for Arms 1 and 2 was a cross-over design. Half the participants completed Arm 1 first and then crossed-over to Arm 2; the remaining half completed Arm 2 first and then crossed-over to Arm 1. Thus, all participants completed both Arm 1 and 2.~Arm 3 represented a parallel study. Participants enrolled in this arm did not cross-over to any other condition."||||
33909459|NCT04297670|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33909460|NCT05858736|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three dose levels will be tested sequentially.||||
33909461|NCT01615224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909462|NCT00694876|||COHORT||PROSPECTIVE|||||||
33909463|NCT05951738|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33909464|NCT01675531|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33909465|NCT06499506|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparison between Skew flap and long posterior flap for below knee amputation||||
33909466|NCT02951611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909467|NCT06107283|||CASE_ONLY||RETROSPECTIVE|||||||
33909468|NCT06336577|||COHORT||RETROSPECTIVE|||||||
33909469|NCT00745485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909470|NCT04352634|||COHORT||PROSPECTIVE|||||||
33909471|NCT05562726|||COHORT||PROSPECTIVE|||||||
33909472|NCT05111496|||COHORT||PROSPECTIVE|||||||
33909473|NCT02773719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909474|NCT05420272|||COHORT||PROSPECTIVE|||||||
33909475|NCT06113185|||COHORT||PROSPECTIVE|||||||
33909476|NCT06265987|||COHORT||RETROSPECTIVE|||||||
33909477|NCT03548597|||COHORT||PROSPECTIVE|||||||
33909478|NCT03190720|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two different single-arm study||||
33909479|NCT03179306|||COHORT||PROSPECTIVE|||||||
33909480|NCT04160468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909481|NCT04436822|NA|SINGLE_GROUP||OTHER||NONE||||||
33909482|NCT03985605|||COHORT||PROSPECTIVE|||||||
33909483|NCT05185570|||CASE_ONLY||PROSPECTIVE|||||||
33909484|NCT01107977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909485|NCT06235463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who will be responsible for carrying out the measurements of lower limb volume via water displacement will be blinded to the condition each participant is randomized to. Withholding this information from the investigator conducing the measurements will prevent this information from influencing how the measurements are conducted and therefore removing bias that could skew the results in support of the study's hypotheses (i.e., that the pedal pump does reduce lower limb volume in older adults with lower extremity lymphedema).|Fifty two participants will be randomized to one of two conditions: to receive the osteopathic pedal pump (treatment group) or to receive a light tough treatment (control group).|f|f|t|f
33909486|NCT04165083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909487|NCT01370278|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33909488|NCT04356144|||COHORT||PROSPECTIVE|||||||
33909489|NCT02196194|||COHORT||RETROSPECTIVE|||||||
33909490|NCT02918487|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33909491|NCT05465603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients do not know which dose they are reciving compared to the other group||t|f|t|t
33909492|NCT02191202|||COHORT||PROSPECTIVE|||||||
33909493|NCT01333982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33909494|NCT01798134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992008|NCT03122535|RANDOMIZED|PARALLEL||OTHER||SINGLE|Each participant will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye||t|f|f|f
33992009|NCT06562621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992010|NCT03872713|||CASE_ONLY||PROSPECTIVE|||||||
33992011|NCT06034483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992012|NCT06272942|||COHORT||RETROSPECTIVE|||||||
33992013|NCT03324646|||COHORT||OTHER|||||||
33992014|NCT06499519|||OTHER||PROSPECTIVE|||||||
33992015|NCT03138863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992016|NCT03367702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992017|NCT06690333|RANDOMIZED|PARALLEL||OTHER||SINGLE|Clinical Events Committee is masked||f|f|f|t
34084404|NCT04653311|RANDOMIZED|PARALLEL||TREATMENT||NONE|The primary outcome will be blindly assessed at one year|Arm 1: Endomina procedure + lifestyle intervention Arm 2: Lifestyle intervention||||
33909495|NCT00000271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909496|NCT04313335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome of the study will be assessed by a third-party organization who will be blinded to the study allocation.||f|f|f|t
33909497|NCT03062904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909498|NCT00511589||PARALLEL||||NONE||||||
33909499|NCT03233490|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33909500|NCT05029596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909501|NCT00002452||||TREATMENT||||||||
33909502|NCT03161678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Ninety healthy Amish subjects (30 CES1 G143E allele carriers, 30 carriers of a risk variant to be determined, and 30 age/sex-matched controls) will be enrolled. We will prospectively evaluate the effect of CES1 genotype on clopidogrel and ticagrelor response, as assessed by agonist-stimulated platelet aggregation, through the completion of a randomized crossover study of clopidogrel (75 mg per day for 7 d) and ticagrelor (90 mg twice daily for 7 d) in 90 healthy Amish individuals stratified by CES1 genotype as described above, with at least a 14-day washout period between drug interventions.||||
33688424|NCT03845465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33688425|NCT02764125|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33688426|NCT02722096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688427|NCT02116478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688428|NCT04062318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be unaware of the order in which they receive TMS interventions.|"All participants will complete an initial MRI. MRIs are subsequently used for TMS neuronavigation (region of interest targeting). There is no intervention applied during the MRI session.~In two subsequent concurrent TMS-EEG sessions, all participants will receive active TMS while carrying out a tactile detection task. During one of the two TMS-EEG sessions, TMS will be applied over primary somatosensory cortex. During the other TMS-EEG session, TMS will be applied over a control brain region.~The order of somatosensory vs. non-somatosensory TMS targeting will be counterbalanced across participants."|t|f|f|f
33688429|NCT00618839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688430|NCT05486741|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33688431|NCT02787070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688432|NCT02550431|||OTHER||CROSS_SECTIONAL|||||||
33909503|NCT01267097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909504|NCT03807739|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909505|NCT03389126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909506|NCT04062422|||COHORT||CROSS_SECTIONAL|||||||
33909507|NCT06095245|||OTHER||RETROSPECTIVE|||||||
33909508|NCT04820452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909509|NCT00006360||||TREATMENT||||||||
33909510|NCT02363036|||COHORT||PROSPECTIVE|||||||
33909511|NCT05145504|||OTHER||PROSPECTIVE|||||||
33909512|NCT03055104|||COHORT||OTHER|||||||
33909513|NCT02667990|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909514|NCT02811458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33909515|NCT00694512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33909516|NCT00809172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909517|NCT06222372|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As an additional feature of this sub-study, we will test two SDR regimens. One regimen will be the until now standard SDR regimen of 600 mg rifampicin for adults weighing 35 kg and over, 450 mg for adults weighing less than 35 kg and for children older than 9 years, and 300 mg for children aged 5 to 9 years. The other regimen will be double this dose (1200 mg rifampicin for adults weighing 35 kg and over, 900 mg for adults weighing less than 35 kg and for children older than 9 years, and 600 mg for children aged 5 to 9 years). The patients and their contact group will be equally allocated through randomization to one of the two SDR regimen groups.|Contacts of new MB leprosy patients with a bacterial index (BI) of 2 or more will be included. To determine the effect of SDR on M. leprae infection rate using UCP-LFA prospectively, SDR will be administered to 10 contacts of the new leprosy patients (n=100). M. leprae infection will be determined for each patient and contact by finger stick UCP-LFA for multiplex detection of anti-M. leprae antibodies and cytokines at time points 0 (intake), 2 weeks, 4 weeks, and 6 months after SDR (n=4,400). Contacts will include both household and neighbor contacts.|t|f|f|f
33909518|NCT05339438|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33909519|NCT02322320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909520|NCT02519751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909521|NCT06691100|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909522|NCT05673005|NA|SINGLE_GROUP||TREATMENT||NONE||Medical device (MED3000)||||
33909523|NCT00435032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909524|NCT00473161|||COHORT||PROSPECTIVE|||||||
33909525|NCT00928616|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34084405|NCT03871374|||OTHER||CROSS_SECTIONAL|||||||
34084406|NCT01813266|||COHORT||PROSPECTIVE|||||||
34084407|NCT03826615|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34084408|NCT01576848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33992018|NCT05187481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992019|NCT03036748|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|open label|"Experimental: Kidney transplant recipients with ACR \> 300mg/g receiving standardized sodium diet (150 mmol NaCl/day) for 5 days and amiloride tablet 10 mg two times daily (morning and afternoon) on the last day.~Interventions:◦Dietary Supplement: Standardized salt diet~◦Drug: Amiloride~•Experimental: Kidney transplant recipient with ACR\< 30mg/g (Control) receiving a standardized salt diet (150 mmol NaCl/day) for 5 days, then amiloride tablet 10 mg two times daily (morning and afternoon) for 1 day.~Interventions:◦Dietary Supplement: Standardized salt diet~◦Drug: Amiloride"||||
33777746|NCT02856919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777747|NCT01845636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777748|NCT06021119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777749|NCT02977975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909526|NCT02274324|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33909527|NCT05160077|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"A comparison is made between 3 study arms:~A: Fasting,~B: Standardised breakfast,~C: Standardised breakfast with added ICG (250mg in 50ml aqua).~As part of the crossover design, each participant will be assigned to all three study arms on three different days. There is a period of at least 48 hours between two consecutive study days for each subject."||||
33909528|NCT06552585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The physiotherapist who carried out the swimmer's interventions was external to the study. The participants were unaware of the existence of other sample groups.|Care provider and participants blinded, parallel, randomized controlled trial|t|t|f|f
33909529|NCT04111276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909530|NCT06555250|||COHORT||PROSPECTIVE|||||||
33909531|NCT06693271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33909532|NCT06302933|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Study type: a study nested in the ANRS 12225 - Pediacam III cohort, comprising two phases~* A retrospective phase: case-control study The analyzed data are those collected previously or measured from the already available bio bank, within the framework of the Pediacam III cohort during the primary infection phase before the initiation of HAART, at 6 months after the end of the first series of EPI vaccines, and at 2 years.~* A prospective phase: cross-sectional study Based on an ad hoc bio bank created for parameters we couldn't measure on the existing bio bank"||||
33909533|NCT03833674|NA|SINGLE_GROUP||TREATMENT||NONE|Participants and the clinical evaluator will be informed of possible interventions but will be blinded to the gas mixture (hypoxic vs normoxic air) used during each AIH intervention.|Participants will complete a battery of clinical assessments and 4 randomly ordered intervention and testing blocks. Blocks 1, 2 and 3 include a 5 day intervention (e.g., dAIH and/or respiratory training) or sham protocol, followed by a 3-week washout period, with follow up measurements at 1 day, 3 days and 1 week post-intervention. The final block includes a 5-day protocol followed by 1-day, 3-day and 1-week post-tests.||||
33909534|NCT03636776|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33909535|NCT03986346|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909536|NCT02069223|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33909537|NCT00074100||||TREATMENT||NONE||||||
33909538|NCT03516292|||CASE_CONTROL||PROSPECTIVE|||||||
33909539|NCT02973529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909540|NCT05553756|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33909541|NCT06258577|||CASE_CONTROL||RETROSPECTIVE|||||||
33992020|NCT05156983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Adaptive parallel-group sequential design.|t|f|t|t
33992021|NCT04165252|||COHORT||PROSPECTIVE|||||||
33992022|NCT06044090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33992023|NCT01678222|||COHORT||CROSS_SECTIONAL|||||||
33992024|NCT01180322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992025|NCT05636735|||CASE_ONLY||CROSS_SECTIONAL|||||||
33992026|NCT02311361|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992027|NCT03948503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992028|NCT06167122|||COHORT||RETROSPECTIVE|||||||
33992029|NCT06660368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992030|NCT00649987|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992031|NCT03757845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized trial of dietary intervention|f|f|t|t
33777750|NCT05797753|NA|CROSSOVER||TREATMENT||NONE||||||
33777751|NCT05866380|||COHORT||PROSPECTIVE|||||||
33777752|NCT00489073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33777753|NCT03044496|||COHORT||PROSPECTIVE|||||||
33777754|NCT01153256|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33777755|NCT00563654|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992032|NCT00976781|||OTHER||RETROSPECTIVE|||||||
33992033|NCT06224959|||OTHER||CROSS_SECTIONAL|||||||
33992034|NCT02588339|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33992035|NCT06052267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084409|NCT01579214|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This is a quasi-experimental design study with two periods of study. The pre-intervention period serves as the control group. During the intervention period, participants received one of three message types to be informed of their test results: 1) a standard message informing their abnormal result, 2) the standard message protected by a PIN number code, and 3) a coded texted message ABCDEFG.~For our a priori hypotheses about the effect of receiving an SMS message on outcomes, we compared results for participants in the pre-intervention period with all those in the post-intervention period. This was a non-randomized intervention.~For our primary outcome (time to ART initiation) we assessed all participants with abnormal CD4 count results who were ART-naive at study enrollment. For our secondary outcome (time to clinic return) we looked at all study participants with abnormal CD4 counts."||||
34084410|NCT04791176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084411|NCT06018012|||COHORT||RETROSPECTIVE|||||||
34084412|NCT04292236|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double blinded, randomised, crossover, placebo controlled.|t|f|t|t
34084413|NCT05058963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084414|NCT05496790|||COHORT||PROSPECTIVE|||||||
34084415|NCT06429241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688433|NCT01216007|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33688434|NCT01082640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992036|NCT05801315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33992037|NCT05337540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992038|NCT06155721|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking was involved in this study as all participants received the same intervention (the cognitive stimulation program using virtual reality created in collaboration with Reality Telling SL), and the open-label nature of the intervention made it impractical to blind participants or researchers to the treatment being provided.|This is a single-arm interventional study where all participants receive the same intervention- a cognitive stimulation program administered through virtual reality (VR). Participants with mild to moderate cognitive impairment will engage in structured VR sessions aimed at stimulating cognitive functions, particularly attention and memory. The study will monitor participants' cognitive performance through standardized cognitive scales pre- and post-intervention, as well as gather subjective feedback on their experience to evaluate acceptability and motivation. Additionally, healthcare professionals' perceptions of the VR intervention's applicability to clinical practice will be assessed through structured interviews or questionnaires.||||
33992039|NCT06561841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992040|NCT05453422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Self-Acupressure and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33992041|NCT03346902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992042|NCT05889546|||CASE_ONLY||PROSPECTIVE|||||||
33992043|NCT00001276|||COHORT||PROSPECTIVE|||||||
33992044|NCT04763733|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33992045|NCT06378099|RANDOMIZED|PARALLEL||OTHER||NONE|Blinding of the participants and the pharmacists involved in the care is not possible due to the nature of the intervention.|An exploratory clinical trial with a baseline reference period of parallel groups will be conducted. The study will take place over a period of 10 months, during which 5 MA will be analyzed, and for each of them, patients will be followed up on days 3, 5, 7, and 10 post-care (intervention). Drugstores and drugstores/pharmacies (groups) will be randomized in a 1:1 ratio to enroll in the intervention group or the control group.||||
33992046|NCT04150913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992047|NCT06269952|||COHORT||CROSS_SECTIONAL|||||||
33992048|NCT06663813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33688435|NCT06254222|||OTHER||CROSS_SECTIONAL|||||||
33688436|NCT03094039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33688437|NCT01142518|||CASE_ONLY||PROSPECTIVE|||||||
33688438|NCT04075370|||COHORT||PROSPECTIVE|||||||
33688439|NCT06497036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|patients will not have access to the treatment assignment code and, therefore, will not know which study drug they are receiving|Multicenter, single-blind, randomized controlled trial of efficacy and safety in two parallel groups|t|f|f|f
33688440|NCT00230477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688441|NCT06163469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688442|NCT04109898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33992049|NCT00353158|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33992050|NCT01444053|||CASE_CONTROL||RETROSPECTIVE|||||||
33992051|NCT04244968|||OTHER||PROSPECTIVE|||||||
33688443|NCT05743517|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The researchers will use a MOST full factorial study design to optimize the Fit4Treatment physical activity intervention by testing the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity: 1) symptom-burden tailored goal setting app, 2) exercise partner, 3) oncology provider engagement, and 4) coaching calls. Patients will be randomized to 16 groups formed by all possible combinations of these four components in a full factorial design.||||
33992052|NCT05466942|NA|SINGLE_GROUP||OTHER||NONE||||||
33992053|NCT00702377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992054|NCT06421636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992055|NCT00675142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688444|NCT00746447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688445|NCT01825954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992056|NCT02937948|NA|SINGLE_GROUP||OTHER||NONE||||||
33688446|NCT00899509|||CASE_ONLY||RETROSPECTIVE|||||||
33688447|NCT05806671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688448|NCT01115803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33688449|NCT04163822|||COHORT||RETROSPECTIVE|||||||
33777756|NCT00899002|||CASE_ONLY||RETROSPECTIVE|||||||
33777757|NCT04159116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777758|NCT01421043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33777759|NCT06488729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"To prevent interaction between groups, the data collection process of the control group was completed first.~The researchers were not blinded to the groups, but the statistician was."|The patients were separated into two groups with the randomisation method. These groups were named the foot massage group and the control group|t|f|f|t
33777760|NCT01973465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777761|NCT05625841|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|f|t
33909542|NCT03988829|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"If a volunteer meets the inclusion and exclusion criteria, he or she will be randomized into one of the three training arms. This assignment will be based on a random computerized allocation plan, where the average cognitive frailty, age, education and gender distribution will be maintained to be equivalent across the three arms. To maintain the balance between the arms, we will randomize between blocks of 15 participants. By randomly assigning participants in the training arms and by assessing outcomes by blinded experimenters, we will avoid selection bias and outcome assessment bias.~No masking is required for the younger adults, as they will not be undergoing any training.~The PI will be blinded to training assignment of any subject, and will only analyze de-identified data."|"We will conduct a randomized control trial on healthy older adults, where attentional control demands in cognitive training will be systematically increased using engaging game-based simulations. There are three parallel arms: predictable low attentional control (Arm 1: Low-C), unpredictable high attentional control (Arm 2: High-C), and a commercially-available strategy video game (Arm 3: High-C+). In all three training arms, neural and cognitive changes in both near and far tasks will be examined immediately after the 8-week long intervention. Long-term cognitive changes will also be assessed at 6 months after completion of training. The far and near cognitive outcomes that will be examined are episodic memory (the primary cognitive outcome) and executive control (the secondary cognitive outcome).~Additionally, a single-session functional neuroimaging dataset will be collected in a functional control group of younger adults; they will not undergo any intervention."|t|f|t|t
33909543|NCT02778516|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33992057|NCT04303884|NA|SINGLE_GROUP||TREATMENT||NONE||Chemo-Resistant Gestational Trophoblastic neoplasias||||
33992058|NCT06239064|||COHORT||PROSPECTIVE|||||||
33992059|NCT00463684|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33992060|NCT00398983|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33992061|NCT01788800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992062|NCT06588283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992063|NCT06482658|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33992064|NCT00912769|||COHORT||RETROSPECTIVE|||||||
33992065|NCT05007470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized placebo controlled trial|t|f|t|t
33992066|NCT03347487|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive bilateral surgical implantation of DBS system.||||
33992067|NCT00001205|||COHORT||PROSPECTIVE|||||||
33992068|NCT06533553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992069|NCT04547192|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic randomized clinical trial with introduction of the TIF at 8 hospitals sequentially, with start times randomized by stepped-wedge design.||||
33992070|NCT00429416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992071|NCT06580197|||COHORT||PROSPECTIVE|||||||
33777762|NCT06343961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 80 patients with vitreous hemorrhage diagnosed in Sichuan Provincial People's Hospital from January 2024 to December 2025 were selected. The number of included cases was calculated according to the minimum sample size of 200 patients with vitreous hemorrhage in our hospital, 95% confidence level and 5% confidence interval, and the calculated result was 79. The included cases were equally divided by random number method. 40 patients in the control group were given vitrectomy and other conventional operations such as retinal laser photocoagulation. In contrast group, 40 patients were given vitrectomy combined with intraoperative fluorescein angiography and other conventional operations such as retinal laser photocoagulation. The diagnosis rate of primary disease cause, observation rate of neovascularization and non-perfusion area, visual acuity, visual field, thickness of macular fovea and postoperative complications (ciliary detachment, secondary vitreous hemorrhage, neovascu|t|f|f|f
33777763|NCT02726243|||CASE_CONTROL||PROSPECTIVE|||||||
33777764|NCT05836155|NA|SINGLE_GROUP||TREATMENT||NONE||unblinded longitudinal study will be performed||||
33777765|NCT01712789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777766|NCT02940769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33777767|NCT01561079|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33777768|NCT00179829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777769|NCT03162965|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants randomized to (1) Choice - they get to choose (1a) self-test vs (1b) HCT (HIV testing and counseling at clinic) or (2) they are randomized to HCT.||||
33777770|NCT06410911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777771|NCT02071095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777772|NCT04860154|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33777773|NCT02303340|||||PROSPECTIVE|||||||
33777774|NCT01367587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777775|NCT04329143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992072|NCT06667700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777776|NCT04969744|NA|SINGLE_GROUP||OTHER||NONE||"ICE BAT study will be performed in two stages. In stage 1, we will recruit 12 to 24 healthy volunteers aged between 16-26 years.~In stage 2, we will recruit 12 children aged between 8-16 years with NAFLD and 12 age- and sex-matched controls (healthy volunteers)."||||
33777777|NCT03208309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777778|NCT06227325|NA|SINGLE_GROUP||TREATMENT||NONE||RC48+PD-1+chemotherapy||||
33777779|NCT01968161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909544|NCT06689839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Participants will be randomized in 1:1 ratio to:~* Transcatheter Aortic Valve Replacement (TF TAVR) with the F2 Cerebral Protection System (CPS) (treatment group) or~* Transcatheter Aortic Valve Replacement (TF TAVR) with Standard of Care treatment (no embolic protection or use of the commercially available protection device, Sentinel System; control group)"|f|f|f|t
33909545|NCT04026438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909546|NCT02261870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909547|NCT03384290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization is assigned by the pharmacist according to predetermined randomization code.|Single Group Assignment This is a phase 1, dose escalating study to assess safety, tolerability, and PK of a single dose of PRS-060 administered by oral inhalation or IV infusion to healthy male and female subjects. This study will be conducted utilizing a single-blind, randomized, dose-escalating design.|t|f|f|f
33909548|NCT04593940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study Drug and Matching Placebo|"ACTIV-1 IM builds upon findings and the model used for other network COVID studies. Including multiple therapeutic agents under a single protocol avoids duplication of effort in terms of infrastructure, trial governance, information systems (EDC, web-based randomization, etc.) and other aspects of study management. Implementation of the master protocol facilitates discontinuation of less promising agents and addition of possibly newly emergent agents that become available after the study begins, without stopping and starting the study itself for extended pauses.~All test agents are evaluated as add-on therapies to the local SoC at each clinic. The master protocol design allows for the efficacy and safety of each agent to be determined based on comparisons with a pooled control group, consisting of patients receiving SoC plus placebo. Sharing control patients across all test agents substantially reduces the sample size requirements for the study."|t|f|t|t
33909549|NCT01463826|||||CROSS_SECTIONAL|||||||
33992073|NCT06243913|||COHORT||PROSPECTIVE|||||||
33992074|NCT06733025|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992075|NCT03891784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992076|NCT04879719|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants do not know that there exists more than one condition.|Participants are randomly assigned to either a ego-depletion- or a control group.|t|f|f|f
33992077|NCT06506903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992078|NCT01791751|RANDOMIZED|PARALLEL||||NONE||||||
33777780|NCT00317538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777781|NCT06104774|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33777782|NCT04644497|||COHORT||PROSPECTIVE|||||||
33777783|NCT02472561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992079|NCT02339571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992080|NCT03512925|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Eligible participants are randomly assigned either to the intervention arm (standardized post-coercion review session session) or to the Treatment-as-usual (TAU) arm.||||
33992081|NCT06228066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992082|NCT05935605|||COHORT||CROSS_SECTIONAL|||||||
33992083|NCT06472167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33992084|NCT05746455|NA|SINGLE_GROUP||TREATMENT||NONE||Open Trial||||
33992085|NCT05617872|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992086|NCT06441682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992087|NCT06623409|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34084416|NCT00535470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084417|NCT01727921|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34084418|NCT06285500|||COHORT||OTHER|||||||
34084419|NCT01857752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084420|NCT00002438|RANDOMIZED|||TREATMENT||||||||
34084421|NCT02051166|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33777784|NCT00447915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777785|NCT06478771|RANDOMIZED|PARALLEL||SCREENING||NONE|In this study, masking (blinding) is not possible due to the nature of the intervention. Both the participants and care providers, as well as the outcome assessors, will be aware of the type of retainer being used.|Study group: Patients choose the type of retainer (Subgroup: fixed or removable) Control group: The clinician selects the retainer type (Subgroup: fixed or removable)||||
33777786|NCT00866710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777787|NCT02050789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33777788|NCT03660722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777789|NCT03038074|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33777790|NCT00972985|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33777791|NCT03190863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777792|NCT01867853|||CASE_ONLY||PROSPECTIVE|||||||
33777793|NCT05804864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777794|NCT04315038|||COHORT||PROSPECTIVE|||||||
33777795|NCT02065921|||COHORT||CROSS_SECTIONAL|||||||
33777796|NCT02011308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777797|NCT00258713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777798|NCT01579617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777799|NCT01318811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777800|NCT01195064|||COHORT||PROSPECTIVE|||||||
33777801|NCT00739583|RANDOMIZED|PARALLEL||||NONE||||||
33777802|NCT06614335|||COHORT||OTHER|||||||
33777803|NCT01349907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777804|NCT00652574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777805|NCT04018781|||COHORT||PROSPECTIVE|||||||
33777806|NCT06505850|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33992088|NCT06116617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33992089|NCT06127095|||COHORT||CROSS_SECTIONAL|||||||
33992090|NCT02435160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992091|NCT02561611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33992092|NCT02517554|||OTHER||OTHER|||||||
33992093|NCT02010463|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33777807|NCT03132714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992094|NCT02100917|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33992095|NCT00835666|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992096|NCT02956525|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992097|NCT05824481|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: Cadonilimab Drug: Lenvatinib||||
33992098|NCT05266313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992099|NCT01564238|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33992100|NCT06366113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992101|NCT03566017|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label extension study||||
33992102|NCT06656338|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Statisticians Laboratory personnel|Randomized cross-over|f|f|t|t
33992103|NCT02973867|||COHORT||RETROSPECTIVE|||||||
33992104|NCT06395324|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects will be enrolled and will consume study provided high arabinose foods during the intervention period.||||
33992105|NCT01564394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33992106|NCT02257528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992107|NCT05093153|||COHORT||OTHER|||||||
33992108|NCT06531421|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a pragmatic single-arm trial using an interrupted time-series design.||||
33992109|NCT06479096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner-blind||f|f|t|f
33992110|NCT06523634|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority randomized controlled trial||||
33992111|NCT01087346|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33992112|NCT00663481|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992113|NCT01180361|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084422|NCT04627636|RANDOMIZED|PARALLEL||TREATMENT||NONE||study group: which treated with MTrPs release combined with shockwave therapy and conventional program, while control group: treated with a conventional selected exercise program||||
34084423|NCT02178514|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084424|NCT02844595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084425|NCT00607217|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34084426|NCT00881166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084427|NCT05426785|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 ratio||||
33777808|NCT02169830|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777809|NCT03575442|NA|SINGLE_GROUP||SCREENING||NONE||||||
33777810|NCT04563052|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33777811|NCT01429714|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33777812|NCT03756649|||CASE_ONLY||PROSPECTIVE|||||||
33777813|NCT06478823|NA|SINGLE_GROUP||OTHER||NONE||||||
33777814|NCT02848495|||FAMILY_BASED||PROSPECTIVE|||||||
33777815|NCT06614452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777816|NCT00832260|||CASE_ONLY||PROSPECTIVE|||||||
33777817|NCT02059317|||CASE_CONTROL||PROSPECTIVE|||||||
33992114|NCT04728828|||COHORT||PROSPECTIVE|||||||
33992115|NCT03651739|||CASE_ONLY||PROSPECTIVE|||||||
34084428|NCT03880513|||COHORT||OTHER|||||||
34084429|NCT00243243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084430|NCT01679743|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084431|NCT03721354|NA|SINGLE_GROUP||TREATMENT||NONE|the ultrasonography examiner is blind on the ventilatory mode|pilot interventional study||||
34084432|NCT01611519|||||PROSPECTIVE|||||||
34084433|NCT02026349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777818|NCT04928989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization will take place from a computer-based generated randomization list developed by a statistician. Randomization will be handled by a person not involved in intervention or evaluation. Investigators/ asessors will be blinded for randomization.||f|f|t|t
33777819|NCT00414869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33777820|NCT06373692|||COHORT||PROSPECTIVE|||||||
33777821|NCT01529762|||COHORT||PROSPECTIVE|||||||
33777822|NCT00471575|||DEFINED_POPULATION||OTHER|||||||
33777823|NCT00534911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777824|NCT03464643|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777825|NCT02521259|||CASE_ONLY||PROSPECTIVE|||||||
33777826|NCT04846205|||COHORT||RETROSPECTIVE|||||||
34084434|NCT01375543|||OTHER||PROSPECTIVE|||||||
34084435|NCT01712178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084436|NCT00764634|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34084437|NCT02860052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084438|NCT03980119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777827|NCT00835874|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33777828|NCT01800409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777829|NCT00610883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777830|NCT05898061|||CASE_CROSSOVER||PROSPECTIVE|||||||
33777831|NCT01854333|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33777832|NCT04473300|||COHORT||PROSPECTIVE|||||||
33777833|NCT01110564|||||CROSS_SECTIONAL|||||||
33777834|NCT02034721|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33777835|NCT01300429|||COHORT||PROSPECTIVE|||||||
33777836|NCT04271592|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33777837|NCT00738530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777838|NCT04100161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777839|NCT01656603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777840|NCT06010121|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33777841|NCT01166087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777842|NCT06246994|||COHORT||PROSPECTIVE|||||||
33777843|NCT06697938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777844|NCT01446029|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33777845|NCT04182607|||COHORT||RETROSPECTIVE|||||||
33777846|NCT04827017|||COHORT||PROSPECTIVE|||||||
33777847|NCT04313387|||CASE_CONTROL||RETROSPECTIVE|||||||
33777848|NCT03354403|||COHORT||CROSS_SECTIONAL|||||||
33777849|NCT02341534|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|An independent Endpoint Committee was installed to evaluate all reported cardiovascular and serious AEs. The information provided to the Committee did not contain information about the group assigment of the patients.||f|f|f|t
33777850|NCT05728983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33909550|NCT03665350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Insulin-HF is a randomized, open-label, controlled, multicenter (PROBE design, prospective Randomized Open Trial with Blinded Evaluation of Outcomes), and central adjudication of adverse events.~All study events, clinical and laboratory, will be independently validated by an Event Committee"|"The primary endpoint, glucose variability, will be computed from 3 daily glucose profiles performed before the baseline, 1, 6, 12 mo follow-up and at end study visit and calculated as the average of the three daily standard deviations. Blood glucose values will be reported by the patient in an ad hoc form and the responsible physician will input this data in the e-CRF.~An intensive ambulatory self-monitoring of weekly body weight and possible changes in diuretic treatment is required.~At 1, 6, 12 mo of follow up and/or at end of study visit:~1. patients will be examined,~2. the information about clinical events will be collected.~3. natriuretic peptide plasma concentration, HbA1c and urinary albumin excretion will be measured Echocardiographic evaluation will be done at baseline, 1 and 12 mo after randomization.~Central randomization in a 1:1 ratio will be performed by a web-based system."|f|f|f|t
33909551|NCT05387382|||COHORT||PROSPECTIVE|||||||
33909552|NCT05292729|||COHORT||PROSPECTIVE|||||||
33909553|NCT03431675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909554|NCT03123354|NA|SINGLE_GROUP||OTHER||NONE||||||
33909555|NCT05399706|||COHORT||RETROSPECTIVE|||||||
33909556|NCT01975766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909557|NCT03311776|||COHORT||PROSPECTIVE|||||||
33909558|NCT06330272|NA|SINGLE_GROUP||TREATMENT||NONE||"MIH lesions will receive prophylaxis with pumice stone before application of CPP-ACPF-based dental foam (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse Plus to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute. The application will be carried out once a week, for four consecutive weeks."||||
33777851|NCT01214564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777852|NCT04066855|||CASE_CONTROL||PROSPECTIVE|||||||
33909559|NCT04045613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909560|NCT04841382|||COHORT||PROSPECTIVE|||||||
33992116|NCT01767974|||COHORT||PROSPECTIVE|||||||
33992117|NCT03744585|||COHORT||RETROSPECTIVE|||||||
33777853|NCT03688542|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33992118|NCT03090789|||CASE_CONTROL||PROSPECTIVE|||||||
34084439|NCT03675217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients evaluator and Outcomes Assessor are masked|Parallel Assignment|f|f|f|t
33909561|NCT04575857|||COHORT||PROSPECTIVE|||||||
33909562|NCT03065504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33909563|NCT06093022|||CASE_CONTROL||OTHER|||||||
33909564|NCT01204840|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909565|NCT01996735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34084440|NCT02683343|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33777854|NCT03386695|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33909566|NCT05201859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909567|NCT02256332|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33909568|NCT00174616|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909569|NCT03919253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909570|NCT03296124|||COHORT||RETROSPECTIVE|||||||
33909571|NCT05238467|||COHORT||PROSPECTIVE|||||||
33992119|NCT02151981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992120|NCT02143245|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992121|NCT06575686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992122|NCT04979910|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a phase II, open-label trial where n=20 patients with treatment resistant depression will be treated with ixekizumab for 4 weeks and will undergo brain scans before and after the treatment period.||||
33992123|NCT06562283|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992124|NCT06133972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The trial is designed to evaluate long-term safety, tolerability and efficacy of two regimen of ianalumab versus placebo, given as monthly or quarterly subcutaneous (s.c.) injection|t|t|t|t
33992125|NCT05996185|NA|SINGLE_GROUP||TREATMENT||NONE||"All subjects are scheduled to receive six cycles of DA-EPOCH + Mogamulizumab~Cycle 1: Mogamulizumab on days 1,8,15, of a 21-day cycle with DA-EPOCH on day 1.~Cycle 2 onwards: Mogamulizumab on day 1 with DA-EPOCH"||||
33992126|NCT01131637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992127|NCT06561646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992128|NCT06061562|||COHORT||PROSPECTIVE|||||||
33992129|NCT04003272|||COHORT||PROSPECTIVE|||||||
33992130|NCT03304704|||COHORT||PROSPECTIVE|||||||
33992131|NCT01899755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992132|NCT05143177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992133|NCT06265727|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A three part study||||
33992134|NCT04364581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33992135|NCT05262530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992136|NCT02102815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084441|NCT03311906|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind|A split mouth study design is used where all participants receive both interventions|t|f|f|t
33992137|NCT03264339|NA|SINGLE_GROUP||TREATMENT||NONE||Single-subject research design (SSRD) will be used with each participant serving as his/her own control.||||
33992138|NCT00471133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992139|NCT05281744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992140|NCT03973372|||COHORT||PROSPECTIVE|||||||
34084442|NCT00336544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777855|NCT01017120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909572|NCT01552928|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33909573|NCT05024123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33909574|NCT06434103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992141|NCT00167063|||DEFINED_POPULATION||PROSPECTIVE|||||||
33992142|NCT05826327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992143|NCT06355752|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33992144|NCT02231840|||CASE_CONTROL||PROSPECTIVE|||||||
34084443|NCT01240746|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084444|NCT06456385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084445|NCT04058496|||COHORT||PROSPECTIVE|||||||
34084446|NCT01938326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084447|NCT01064544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909575|NCT00166010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909576|NCT03008746|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33909577|NCT00868244|||CASE_ONLY|||||||||
33909578|NCT03972592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, parents, nurses and investigators will be blinded for the treatment allocated to each area of the CMLM, during the first step of the study (until week 12, where primary endpoint will be assessed). To ensure the double blinding, both areas will be randomized, and the topical treatments (sirolimus and vehicle) to be applied will have similar packaging. Their appearance is similar, thus the active drug (topical sirolimus) and vehicle cannot be distinguished at drug allocation. Furthermore, the consistency of the creams is similar.|Split-body randomised, double-blind, vehicle-controlled clinical trial|t|t|t|t
33909579|NCT06331065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33909580|NCT02469831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33909581|NCT03681652|||CASE_CONTROL||PROSPECTIVE|||||||
33909582|NCT06198621|||OTHER||CROSS_SECTIONAL|||||||
33909583|NCT05784948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33909584|NCT01542411|||CASE_CONTROL||RETROSPECTIVE|||||||
33909585|NCT03777579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909586|NCT03900559|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33909587|NCT02909673|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909588|NCT04802252|||COHORT||PROSPECTIVE|||||||
33909589|NCT06092242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909590|NCT03440216|NON_RANDOMIZED|PARALLEL||OTHER||NONE||2 groups of patients studied in parallel||||
33909591|NCT05475262|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33909592|NCT06018584|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33909593|NCT04286412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909594|NCT03856086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized between screening with the CSS-CG + consultation (S+C, and enhanced usual care.||||
33909595|NCT00008294||||TREATMENT||||||||
33909596|NCT04585399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will only told if they are assigned to the contingency management group because there are different procedures for those individuals. The care providers will not know which participants are in the control group but they may know when people are in the CM group because extra urine screens will be collected and they will be scheduled for rides.|Two group, randomized controlled trial.|f|t|f|t
33909597|NCT03887559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909598|NCT00771407|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33909599|NCT06099509|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33909600|NCT02223143|||CASE_ONLY||PROSPECTIVE|||||||
33909601|NCT05822895|||CASE_CONTROL||OTHER|||||||
33909602|NCT02764632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909603|NCT00993603|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909604|NCT00828087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909605|NCT01626183|||CASE_ONLY||RETROSPECTIVE|||||||
34084448|NCT01072591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084449|NCT04487223|||COHORT||OTHER|||||||
34084450|NCT00848016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084451|NCT02033798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084452|NCT02378272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084453|NCT03434288|||CASE_ONLY||PROSPECTIVE|||||||
34084454|NCT02318199|||COHORT||PROSPECTIVE|||||||
34084455|NCT03225430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors will receive no information on participant history and psychopathology. All evaluation sessions will be audio-recorded for reliability and to ensure that treatment status is not divulged. The Assessors will be separated from the therapists by geographical location site and will sign agreements not to discuss cases in the study with any other team member. Child and adult participants will agree not to discuss treatment or therapy during evaluation. Management of assessors will be delegated to a separate clinical coordinator who will assume overall responsibility for evaluations and preempting any direct contact between the principal investigator and Co-investigators and the assessors.||f|f|t|t
34084456|NCT00641056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084457|NCT02460510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084458|NCT01939912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909606|NCT02334332|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909607|NCT02819648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909608|NCT01701583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909609|NCT02631135|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33909610|NCT04653909|NA|SINGLE_GROUP||TREATMENT||NONE||Case study||||
33909611|NCT00943293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909612|NCT06692478|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The physical therapist doing the evaluations, the data analyst, and primary investigator will all be masked.||f|t|t|t
33909613|NCT05474508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992145|NCT03249454|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Crossover design with 9 arms: Anodal tsDCS, Cathodal tsDCS, Sham tsDCS|t|f|t|t
33992146|NCT03285594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688450|NCT03790423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777856|NCT00056368|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33777857|NCT00004074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777858|NCT05063643|||COHORT||PROSPECTIVE|||||||
33777859|NCT04294979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777860|NCT02208323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909614|NCT05785117|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33992147|NCT02642042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992148|NCT00350389|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33688451|NCT01702051|||COHORT||RETROSPECTIVE|||||||
33688452|NCT02070471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688453|NCT02197455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688454|NCT01328171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688455|NCT03033446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688456|NCT06542263|||COHORT||PROSPECTIVE|||||||
33688457|NCT03691324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33688458|NCT01030367|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33688459|NCT03639532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33688460|NCT02514473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688461|NCT02165176|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33688462|NCT05523440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688463|NCT01993784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688464|NCT01744912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688465|NCT02605837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688466|NCT06217185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688467|NCT05468853|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33909615|NCT03227848|||COHORT||CROSS_SECTIONAL|||||||
33909616|NCT03564171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 arms: Intervention and Control (chosen by closed envelope, 1:1 randomization)||||
33909617|NCT00904163|||CASE_ONLY||PROSPECTIVE|||||||
33909618|NCT00722553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909619|NCT02338076|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909620|NCT00293774|||COHORT||PROSPECTIVE|||||||
33909621|NCT03555903|||COHORT||PROSPECTIVE|||||||
33909622|NCT05092971|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909623|NCT01785433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909624|NCT02512003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909625|NCT05589116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to treatment allocation|Participants will be randomly allocated to either a treatment or wait-list control group. The study will use a repeated measures, randomised controlled trial design.|f|f|f|t
33909626|NCT01102153|||COHORT||PROSPECTIVE|||||||
33909627|NCT01975272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909628|NCT01987986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992149|NCT06517719|||COHORT||PROSPECTIVE|||||||
33992150|NCT00840866|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992151|NCT00380679|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33992152|NCT06307431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33992153|NCT02632864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992154|NCT05239585|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33777861|NCT03330119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777862|NCT04587531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment device will deliver subsensory treatment while the sham device will deliver no treatment.|A 6-week, randomized, double-blind, placebo controlled evaluation of efficacy and tolerability of cranial electrotherapy stimulation (CES) for the treatment of adults with depression. EEG readings will evaluate changes in neural signals following CES treatment.|t|t|t|f
33777863|NCT03956576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33777864|NCT02318225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777865|NCT01154036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777866|NCT03645486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777867|NCT00110682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33777868|NCT04153513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Participants will be randomly assigned to two study groups. An envelope containing a note, mother's milk group or lanolin group will be randomly distributed among women by a midwife who is not a part of the study. The participants will know which group they belong to. A single blind masking will be used during telephone data collection on day three and seven of treatment."||f|f|t|f
33777869|NCT06498674|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909629|NCT05703802|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909630|NCT03659747|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||Crossover Assignment Randomized, double-blind, placebo-controlled, parallel-group study|t|t|t|t
33909631|NCT03828006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909632|NCT06031480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777870|NCT00003009||||TREATMENT||||||||
33909633|NCT01984541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909634|NCT01053546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33777871|NCT03943186|||OTHER||PROSPECTIVE|||||||
33777872|NCT00780611|||CASE_ONLY||PROSPECTIVE|||||||
33777873|NCT03282175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777874|NCT01052740|||||PROSPECTIVE|||||||
33777875|NCT05190549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777876|NCT03664167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909635|NCT01598727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909636|NCT00610935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909637|NCT04151537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992155|NCT03909607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992156|NCT01505933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33992157|NCT02540603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084459|NCT02980016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084460|NCT01849614|||COHORT||PROSPECTIVE|||||||
34084461|NCT05141032|||COHORT||PROSPECTIVE|||||||
34084462|NCT01935115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084463|NCT02016846|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34084464|NCT01196780|||COHORT||PROSPECTIVE|||||||
34084465|NCT04327778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084466|NCT01004614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084467|NCT01994200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992158|NCT06330584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All study personnel except the personnel at the facility preparing the investigational medicinal product (IMP) (Hospital Pharmacy, University Hospital Basel), and all patients will be blinded to the assigned treatment. Allocation will be concealed using sequentially coded drug packs (using consecutive patient identification numbers from 1 to 36) containing the IMP that are otherwise identical. Each drug pack will contain two nasal sprays of identical appearance. Patients and all trial personnel involved in recruitment and care of patients, trial assessment, monitoring, and analyses will be blinded to the assigned trial arm. Blinding will be upheld until the last patient (36 patients, i.e., 12 per study arm) has completed the pilot study and data entry into the trial database has been completed.~To safeguard blinding, placebo formulation will be produced with the same pH as the active study drug formulations to mimic nasal irritation induced by verum sprays."|Double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study with three study arms|t|t|t|t
33992159|NCT06034392|||COHORT||OTHER|||||||
33992160|NCT05926362|||CASE_ONLY||CROSS_SECTIONAL|||||||
33992161|NCT04075864|NA|SINGLE_GROUP||OTHER||NONE||||||
33992162|NCT03135301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992163|NCT03343535|NA|SINGLE_GROUP||TREATMENT||NONE||OCS Lung System||||
33992164|NCT02889380|||OTHER||RETROSPECTIVE|||||||
33992165|NCT04523168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992166|NCT04811235|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33992167|NCT04842123|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33992168|NCT03221972|||OTHER||CROSS_SECTIONAL|||||||
33992169|NCT01444378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992170|NCT04277403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Observer-blinding||f|t|f|f
33992171|NCT05640115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084468|NCT05262374|||COHORT||PROSPECTIVE|||||||
34084469|NCT02055586|||COHORT||PROSPECTIVE|||||||
33992172|NCT03110627|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||DX AF is a prospective, randomized-controlled, open-label trial. Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).||||
33992173|NCT00834275|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33777877|NCT03635138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Bottles with a label remarked with 2 letters A and B , same aspect|Split mouth, 2 premolars restored with 2 dental adhesives , 1 experimental and 1 control|t|t|t|t
33777878|NCT01935661|||CASE_CONTROL||PROSPECTIVE|||||||
33992174|NCT06485089|||COHORT||PROSPECTIVE|||||||
33992175|NCT02825160|||COHORT||PROSPECTIVE|||||||
33992176|NCT05974267|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Label||||
33777879|NCT02810808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777880|NCT04754061|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a multi-site, open-label, single-arm phase 1/2 proof-of-concept dose-finding, feasibility and preliminary efficacy clinical trial.||||
33992177|NCT03089515|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"* Healthy Controls who were not in the WTC program (n = 20)~* Uncontrolled Lower Respiratory Symptoms in WTC Surivivors; ULRS study) with persistent LRS (n = 40)"||||
33777881|NCT01837758|||COHORT||PROSPECTIVE|||||||
33777882|NCT00192283|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33777883|NCT05123131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777884|NCT00655395|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777885|NCT05153278|||CASE_CONTROL||RETROSPECTIVE|||||||
33992178|NCT00598052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33992179|NCT00346385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992180|NCT00388531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992181|NCT05842135|||CASE_CROSSOVER||OTHER|||||||
33992182|NCT05477589|RANDOMIZED|FACTORIAL||TREATMENT||NONE||AML patient eligible for stem cells transplantation will be randomized either get conditioning regimens CloFluBu or BuCyMel.||||
33992183|NCT03677141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992184|NCT06689956|||COHORT||PROSPECTIVE|||||||
34084470|NCT05737511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084471|NCT01777841|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084472|NCT02865863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34084473|NCT00172874|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084474|NCT00636727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084475|NCT03189082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084476|NCT02334761|||OTHER||PROSPECTIVE|||||||
34084477|NCT04069117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded clinical trial|randomized controlled trial|t|f|t|t
34084478|NCT03913234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084479|NCT04780321|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34084480|NCT02084823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34084481|NCT04503044|||COHORT||RETROSPECTIVE|||||||
34084482|NCT04716244|||COHORT||CROSS_SECTIONAL|||||||
34084483|NCT03807024|||CASE_ONLY||RETROSPECTIVE|||||||
34084484|NCT01192178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084485|NCT01578265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084486|NCT03767712|||COHORT||PROSPECTIVE|||||||
34084487|NCT02810782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084488|NCT01182025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909638|NCT06317272|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The participating patients will undergo weekly (during radiotherapy treatment) 2 CTs in DIBH; one using ABC and one using voluntary coaching (VC).||||
33909639|NCT05676528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909640|NCT03184909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Concealment of allocation and blinding of active versus placebo and blinded assessment||t|t|t|t
33909641|NCT04137276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909642|NCT00398619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33909643|NCT02648035|||COHORT||PROSPECTIVE|||||||
33909644|NCT02522962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909645|NCT02883582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909646|NCT06554392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992185|NCT05672186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Following site enrollment, sites will be randomized by wave to receive the full-service market intervention or serve as a waitlist control by the study statistician, who will be blinded to study site names. After randomization, the study statistician will be unblinded to site names by being given the key that matches sites with their assigned numbers. The study statistician will use this key to inform the mobile market co-investigator of site allocation to allow time for the mobile market to plan for market routes and schedules while baseline data collection is ongoing. Participants, site locations, the PI, university non-statistician trial investigators, and research staff will be blinded to site randomization results until baseline data collection is complete. Only the project manager and study statistician will be aware of the key (the link between the site names and the assigned site numbers linked to the data to be used in analysis) until analysis is complete.|||||
33992186|NCT05615974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992187|NCT00429962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992188|NCT01344863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992189|NCT02718326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992190|NCT05910164|||CASE_CROSSOVER||PROSPECTIVE|||||||
33992191|NCT02534233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992192|NCT04258735|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33992193|NCT04016415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI, study coordinator, and all study personnel collecting outcomes, will be blinded from the treatment assignments. Only the MBSR and SME instructors and the study personnel who schedule the classes, videorecord the classes, and code the videos will have knowledge of the assignments, and these individuals will not be involved in the collection of outcomes. Subjects will be asked to keep their treatment assignment concealed from study personnel collecting outcomes. However, complete blinding may not be possible given the nature of this study.|This is a randomized, parallel group two-arm trial that will determine the effects of an online 6-month Mindfulness-based stress reduction (MBSR) intervention compared to Stress Management Education (SME) (active control) on glucose control in at least 290 patients with uncontrolled diabetes. Both MBSR and SME will be delivered online by experienced instructors in a live interactive virtual classroom using videoconferencing.|f|f|t|t
33992194|NCT06193200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992195|NCT06510504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992196|NCT06107634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization process is initiated after general anesthesia is induced and the group affiliation will be determined by opening of a sealed envelope specifying the group assignment. The information of group allocation is stored in a closed envelope kept in a locked archive until the study is completed.|Conventional paraesophageal hernia repair with the addition of gastropexy|t|f|t|t
33992197|NCT04677075|||CASE_ONLY||PROSPECTIVE|||||||
33992198|NCT00003885||||TREATMENT||||||||
33992199|NCT00001392|||COHORT||PROSPECTIVE|||||||
33909647|NCT06340152|||COHORT||PROSPECTIVE|||||||
33909648|NCT06692660|||CASE_ONLY||PROSPECTIVE|||||||
33909649|NCT02689219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909650|NCT03450590|||CASE_CONTROL||PROSPECTIVE|||||||
33909651|NCT03783650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909652|NCT01399801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909653|NCT03879148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Postoperative pain assessment was performed by a anesthetists blinded to the procedure.|randomized prospective study|f|f|f|t
33909654|NCT02856581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33909655|NCT04991506|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33909656|NCT03400696|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants are randomized to either a RCT or 'Participant choice' block, with 3 parallel interventions within each block|f|f|t|t
33777886|NCT03572010|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34084489|NCT01064011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084490|NCT00915317|||COHORT||PROSPECTIVE|||||||
33777887|NCT00377741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777888|NCT02717598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33777889|NCT00290082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33909657|NCT06177054|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||First two weeks observational, then instruction to avoid areas with hyperechogenicity for better absorption of insulin||||
33909658|NCT05517525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084491|NCT00720499|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34084492|NCT03984357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084493|NCT01565577|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34084494|NCT00737178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084495|NCT03615963|||COHORT||PROSPECTIVE|||||||
34084496|NCT04429958|||COHORT||PROSPECTIVE|||||||
33777890|NCT00443469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33777891|NCT02635061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777892|NCT04816994|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
33777893|NCT00360555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777894|NCT00360893|||COHORT||PROSPECTIVE|||||||
33777895|NCT02507219|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33909659|NCT02487849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909660|NCT01502657|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33909661|NCT03040388|||COHORT||PROSPECTIVE|||||||
33909662|NCT01855542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33909663|NCT04759638|||COHORT||RETROSPECTIVE|||||||
33909664|NCT04443127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33909665|NCT02361203|RANDOMIZED|PARALLEL||||NONE||||||
33909666|NCT01726322|||COHORT||PROSPECTIVE|||||||
33909667|NCT00409422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909668|NCT03605810|||COHORT||RETROSPECTIVE|||||||
33909669|NCT00146393|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909670|NCT02500199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909671|NCT01675804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909672|NCT05962996|||OTHER||PROSPECTIVE|||||||
33909673|NCT04355091|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In order to determine the risk of depression, the Edinburgh Postpartum Depression Scale (EPDS) will be administered to the pregnant women. Pregnant women who receive 12 ≥ points from the EPDS will be included in the randomization process.~Subsequently, the tests will be applied to experimental and control groups. EFT will be applied to women in the experimental group. One or two weeks after the application, it will be discussed again and questioned how she feels, whether that problem still disturbs her. The number of EFT sessions can be increased or decreased depending on the condition of the woman (the average number of sessions reported in the studies ranges from 2-10). After all EFT sessions are completed, three months and six months after the last application, post-tests will be done. the control group will receive routine midwifery care. The post-tests will be done by the control group after three months and six months"||||
33909674|NCT00011765||||TREATMENT||||||||
33909675|NCT01532700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909676|NCT03901287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909677|NCT04170205|||OTHER||RETROSPECTIVE|||||||
33909678|NCT01279772|||COHORT||PROSPECTIVE|||||||
33909679|NCT06100471|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909680|NCT00092040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909681|NCT03273738|||CASE_CONTROL||RETROSPECTIVE|||||||
33909682|NCT05438680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Masking controlled clinical trial will be used to assess the effect of prophylactic bovine colostrum in preventing retinopathy of prematurity.|t|f|f|f
33909683|NCT03108014|||COHORT||PROSPECTIVE|||||||
33909684|NCT02099916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909685|NCT04200105|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||1:1 randomisation||||
33909686|NCT02474030|||CASE_ONLY||PROSPECTIVE|||||||
33909687|NCT06093763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"A web based randomisation tool will used for randomization according to the GCP-guidelines. Prestratification per hospital will be performed. Patients and the treating surgeon cannot be blinded for the treatment because a part of these patients will undergo bone grafting derived from the iliac crest. The statistician will be blinded for the treatment.~6.3 Study"|All included patients will undergo an open wedge osteotomy and plate fixation according to the standard surgical techniques. In one group, the bone defect will be filled with bone graft of the iliac crest after open wedge osteotomy according the standard procedure. The other group includes patients who will not receive any bone grafts. The participating hospitals have extensive experience with both treatments.|t|f|f|f
33909688|NCT03047993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909689|NCT02353637|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33909690|NCT01420705|||COHORT||RETROSPECTIVE|||||||
33909691|NCT00601523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909692|NCT04511637|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34084497|NCT02053103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084498|NCT04909944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084499|NCT03168373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084500|NCT02244632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084501|NCT01281696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084502|NCT01649219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084503|NCT04059718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084504|NCT02442609|||CASE_ONLY||PROSPECTIVE|||||||
34084505|NCT03885557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single blind randomized control trial in which study participants were randomly allocated in 2 groups by sealed envelope methods||t|f|f|f
34084506|NCT02251353|||COHORT||PROSPECTIVE|||||||
34084507|NCT01926158|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084508|NCT03353220|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34084509|NCT01737801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909693|NCT04072146|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33909694|NCT02782663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909695|NCT05553431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909696|NCT00367640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909697|NCT00738504|||CASE_CONTROL||RETROSPECTIVE|||||||
33909698|NCT03879317|||COHORT||PROSPECTIVE|||||||
33909699|NCT06683209|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||In each group, patient receive two different types of scleral depressor, one in each eye.||||
33909700|NCT04559152|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The subjects were divided into two groups (zinc supplementation and a placebo (control) group). Researchers and the subjects did not know the type of zinc supplementation or placebo given. The blinding process is carried out by the research assistant to the subject in the field at the time of retrieval of the research data. The selection of samples for each group uses the blocked randomization technique.|An experimental study with pre-test/post-test control groups, double-blind with randomization block technique|t|f|t|f
33909701|NCT00875017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33909702|NCT03229759|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33909703|NCT02100748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909704|NCT01032512|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909705|NCT04032496|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33909706|NCT01425190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909707|NCT02276157|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33909708|NCT02318914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909709|NCT04009096|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909710|NCT01840020|||CASE_ONLY||PROSPECTIVE|||||||
33909711|NCT00932139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The care provider or acupuncturist does not know the outcome of the treatment. The investigator does not know the participants and the outcome of the study. The outcome assessor does not know the participants.|Two different formulated sets of acupoints will be used as EA intervention in the treatment of hypertension.|f|t|t|t
33909712|NCT04709991|||COHORT||RETROSPECTIVE|||||||
33909713|NCT03285217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909714|NCT03495687|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909715|NCT04082364|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort A is a single-arm cohort to evaluate safety and efficacy of margetuximab plus retifanlimab. Cohort B Part 1 is a randomized, 4-arm segment to evaluate margetuximab plus retifanlimab plus chemotherapy, margetuximab plus tebotelimab plus chemotherapy, margetuximab plus chemotherapy, vs trastuzumab plus chemotherapy.||||
33909716|NCT05913427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909717|NCT03736746|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33909718|NCT03648476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33909719|NCT04397393|||CASE_CONTROL||PROSPECTIVE|||||||
33909720|NCT01295112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909721|NCT00444886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909722|NCT00004284|RANDOMIZED|||TREATMENT||DOUBLE||||||
33909723|NCT04322630|||OTHER||OTHER|||||||
33992200|NCT05456191|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992201|NCT05454683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992202|NCT06623643|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992203|NCT04987554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33992204|NCT06377605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer-generated sequence will be used for randomization and opaque envelopes will be used for concealment.|randomized controlled trial- single blinded|t|f|f|f
33992205|NCT05609617|RANDOMIZED|PARALLEL||TREATMENT||NONE||"145 subjects divided into 2 groups (Randomization 3:1 for the face):~• 107 subjects in treatment group on the face. Among these patients, N=55 were injected on the neck and N=49 on the décolleté.~38 patients were included in the control group. Among these patients, all were studied on the neck and N=34 were studied on the décolleté"||||
34084510|NCT00880126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084511|NCT04052828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084512|NCT03208803|||CASE_ONLY||OTHER|||||||
34084513|NCT03111290|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34084514|NCT04938791|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084515|NCT03556033|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34084516|NCT00643175|||CASE_ONLY||PROSPECTIVE|||||||
34084517|NCT00501631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084518|NCT02212964|||CASE_ONLY||CROSS_SECTIONAL|||||||
34084519|NCT04751617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084520|NCT00374634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084521|NCT05246449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084522|NCT03468621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients are randomised to intradermal and transdermal wound closure techniques. Randomisation is 1:1 and block randomisation is used|f|f|t|f
34084523|NCT04496232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34084524|NCT02177500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084525|NCT03957616|||COHORT||RETROSPECTIVE|||||||
34084526|NCT00149097|||COHORT||CROSS_SECTIONAL|||||||
34084527|NCT02108301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909724|NCT05270538|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Control group (G1) and study group (G2) were defined from the use of random sampling software that gave numbers to each participant, distributing them between the two groups - participants who removed odd numbers were assigned to G1 while participants who removed even numbers to G2.|Of the 57 participants, 26 are allocated as G1 (46.5%) and 31 as G2 (53.5%) After the collection of blood gases and cardiovascular parameters- Systolic Blood Pressure, Diastolic Blood Pressure, Heart Rate and O2 Saturation - before and after physical exercise, all participants answered a socio-demographic questionnaire informing their weight, height and gender, in addition to completing the Informed Consent Form on the experiment||||
33909725|NCT06381648|||CASE_CONTROL||RETROSPECTIVE|||||||
33909726|NCT01397071|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33909727|NCT00559052|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33909728|NCT00532883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909729|NCT04398017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909730|NCT01958671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909731|NCT01469013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909732|NCT00266721|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33909733|NCT02555644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909734|NCT00807846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909735|NCT00633438|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33909736|NCT04719169|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909737|NCT01786616|||COHORT||PROSPECTIVE|||||||
33909738|NCT00252486|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33909739|NCT04015947|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is an open label, single-institution pilot study to evaluate local response to split-thickness skin grafts from a matched bone marrow donor to chronic GVHD-affected skin in a hematopoietic stem cell transplant patient.||||
33909740|NCT02275689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909741|NCT01428063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909742|NCT00255684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909743|NCT01884454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909744|NCT04801537|||COHORT||PROSPECTIVE|||||||
33909745|NCT02976584|||CASE_ONLY||PROSPECTIVE|||||||
33909746|NCT01259752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909747|NCT04032743|||COHORT||RETROSPECTIVE|||||||
33909748|NCT01374815|NA|SINGLE_GROUP||SCREENING||NONE||||||
33909749|NCT05161351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Adaptive, ascending-dose, parallel groups design.|t|f|f|f
33909750|NCT04755543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909751|NCT01145027|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33909752|NCT04680286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation and study medication will be handled by the hospital pharmacy. All research team members, caregiving clinicians and enrolled patients will be blinded to the study allocation arms and the randomisation list will be concealed until all statistical analyses are made.|Randomized controlled trial.|t|t|t|t
33909753|NCT03443726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* The participant is not told which technique will be used on him/her.~* Surgeon does not know the anesthetic technique used to numb the third molar.~* When the statistician and primary investigator receive the collected data to be analyzed, the techniques are labeled 1 and 2."|"* Control group: inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve block.~* Test group: infiltration anesthesia buccaly between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc ligually to the third molar using the same anesthetic."|t|t|f|t
33909754|NCT05952869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909755|NCT00527111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084528|NCT00888654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084529|NCT01741415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084530|NCT01549158|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084531|NCT01426581|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34084532|NCT04740307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084533|NCT02526238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909756|NCT05813327|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33909757|NCT02036593|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33909758|NCT03546387|||COHORT||PROSPECTIVE|||||||
33909759|NCT00845923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909760|NCT01350037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909761|NCT00083239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909762|NCT04556084|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33909763|NCT05464758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084534|NCT06140186|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label trial, and no one will be masked|40 Adult patients aged 18 or above who received EGFR-TKI for the treatment of NSCLC, who develop paronychia (affecting fingernails, toenails or both), will be included in this study. Patients will be randomized in 1:1 ratio using computer-generated randomization list.||||
33909764|NCT00541892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909765|NCT02580487|||COHORT|||||||||
33909766|NCT01879618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909767|NCT04413435|||OTHER||RETROSPECTIVE|||||||
33909768|NCT03481881|||COHORT||PROSPECTIVE|||||||
33909769|NCT03816306|||COHORT||PROSPECTIVE|||||||
33909770|NCT03342469|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigators and the participants will be masked as to contents of the chocolate cookies provided during the challenge periods. One research assistant will be unblinded and will not have contact with the participants.|All ADHD participants and a subgroup of control participants will be exposed to all challenge mixtures (artificial food coloring/placebo, placebo/artificial food coloring) with adequate washout periods between exposures.|t|f|t|f
33909771|NCT04591912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909772|NCT00766259|||CASE_CONTROL||PROSPECTIVE|||||||
33909773|NCT04863573|||COHORT||PROSPECTIVE|||||||
33909774|NCT01528800|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33909775|NCT02840058|NA|SINGLE_GROUP||OTHER||NONE||||||
33909776|NCT05187806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Without knowing that participants are in the experimental or control group||t|f|f|f
33909777|NCT02467803|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33909778|NCT04993950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909779|NCT04310163|||COHORT||OTHER|||||||
33909780|NCT00664092|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|t|f|f
33909781|NCT04145830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909782|NCT01351077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33909783|NCT02713230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33909784|NCT02776696|RANDOMIZED|CROSSOVER||TREATMENT||NONE||segment 1 part 1 is a single arm study, segment 1 part 2 is a is a crossover study, segment 2 is a randomized crossover study , segment 3 is a parallel study and segment 4 is a single arm study||||
33909785|NCT02353351|||COHORT||PROSPECTIVE|||||||
33909786|NCT02050633|||COHORT||PROSPECTIVE|||||||
33909787|NCT01240122|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
33909788|NCT05239949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|our study will be single-blinded, outcome assessor will be blinded to avoid being biased during outcome assessment.||f|f|f|t
33909789|NCT02460926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33909790|NCT01926041|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909791|NCT03930680|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Each subject will receive one dose of dexrazoxane.||||
33909792|NCT05950412|||COHORT||PROSPECTIVE|||||||
33909793|NCT00658372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909794|NCT01839188|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909795|NCT03342391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909796|NCT00390000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909797|NCT06103695|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33909798|NCT02588248|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33909799|NCT04645459|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33909800|NCT01893190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909801|NCT03766750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909802|NCT01060735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909803|NCT05946135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909804|NCT06624085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909805|NCT05641818|||COHORT||CROSS_SECTIONAL|||||||
33909806|NCT01532271|||COHORT||PROSPECTIVE|||||||
33909807|NCT04156750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Part A - Double-blind. Part B - Open label.|Part A - Parallel design. Part B - Open label design.|t|f|t|f
33909808|NCT05701969|RANDOMIZED|PARALLEL||TREATMENT||NONE|The research pharmacy will randomize the study.|a prospective double-blinded randomized control trial to investigate the effect of melatonin on sleep quantity and quality in resident physicians assigned to a night float system.||||
33909809|NCT04787159|||CASE_ONLY||RETROSPECTIVE|||||||
33909810|NCT06459531|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33909811|NCT03196505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909812|NCT05526170|||COHORT||PROSPECTIVE|||||||
33909813|NCT00718419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909814|NCT03832062|||OTHER||OTHER|||||||
33909815|NCT00342342|||COHORT||OTHER|||||||
33909816|NCT00601588|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909817|NCT01135953|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33909818|NCT04006899|||OTHER||PROSPECTIVE|||||||
33992206|NCT03839719|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|"This single-center, double-masked, placebo-controlled study was conducted over a period of 02 months. The participants and investigator are blinded about mouthrinse use and assigned quadrant.~Then Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse and Ultrasonic scaling is done in the 2nd and 3rd quadrant by giving either OC/CHX/Placebo mouth rinse"|Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity. After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient. Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria After ultrasonic scaling of the 1st and 4th quadrant and after 2nd and 3rd quadrant.|t|f|t|t
33992207|NCT05687552|||COHORT||PROSPECTIVE|||||||
33992208|NCT03480230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992209|NCT03556618|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084535|NCT04149080|RANDOMIZED|PARALLEL||OTHER||TRIPLE||30 subjects will be divided randomly in two groups. The study is triple masked.|t|t|f|t
34084536|NCT03773874|||COHORT||PROSPECTIVE|||||||
33909819|NCT03657680|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33909820|NCT03347331|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33909821|NCT03781882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were not allowed to know allocations|All cases with disrupted surgical wounds admitted at Obstetrics and Gynecology departments|t|f|f|f
33909822|NCT01544777|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33909823|NCT06552520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909824|NCT01572883|||COHORT||PROSPECTIVE|||||||
33909825|NCT04022174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909826|NCT02150369|||CASE_ONLY||PROSPECTIVE|||||||
33909827|NCT04875039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A research assistant (licensed anesthesiologist) will prepare the local anesthetic solutions and will add the study drug following the randomization order. The operator, patient and investigator assessing the block will be blinded to group allocation.|blinded-randomized controlled trial|t|t|t|t
33909828|NCT04165343|||OTHER||PROSPECTIVE|||||||
33909829|NCT00673998|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909830|NCT04142047|||COHORT||PROSPECTIVE|||||||
33909831|NCT05117229|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will have the MetaWear Sensors used on them||||
33992210|NCT05843864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992211|NCT00956579|||OTHER||OTHER|||||||
33777896|NCT05762393|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|The PI, study staff, and participants will be blinded as to receipt of study vaccine or placebo. The unblinded pharmacy staff preparing the study product syringes and the unblinded study nurse who is administering the product will not be involved in the safety assessment of participants and will be instructed not to comment on the experimental agent to study staff.||t|f|t|t
33777897|NCT05170035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded photo assesment of wound healing by two independent trained clinical doctors.|A randomized controlled clinical trial|f|f|f|t
33688468|NCT00730262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688469|NCT02983643|||COHORT||RETROSPECTIVE|||||||
33688470|NCT04581447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33777898|NCT01200719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777899|NCT00136916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777900|NCT03791528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled study|t|f|t|t
33777901|NCT01853254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777902|NCT04725409|||COHORT||CROSS_SECTIONAL|||||||
33777903|NCT02861495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777904|NCT02722941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777905|NCT01325987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33777906|NCT00305890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777907|NCT00323167|||COHORT||OTHER|||||||
33777908|NCT01642134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777909|NCT00238862|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777910|NCT00005543|||||PROSPECTIVE|||||||
33777911|NCT06405321|||COHORT||RETROSPECTIVE|||||||
33777912|NCT00636714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33777913|NCT00255814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909832|NCT00035425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909833|NCT03286088|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909834|NCT04708392|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33909835|NCT05663359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909836|NCT05556239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909837|NCT01137331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909838|NCT00041223|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33909839|NCT00787696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909840|NCT00052169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909841|NCT01247220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909842|NCT00048594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909843|NCT03490799|||CASE_ONLY||PROSPECTIVE|||||||
33909844|NCT03649958|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Study I - Single-blind (participants and outcomes assessors blinded, but technologists are not), up to 126 enrolled (target of 106 being randomized)~Study II - Controlled (participants randomly assigned to one of two interventional arms, no blinding due to 5 or 10 sessions), up to 110 enrolled (target of 86 being randomized)"|randomized controlled trial||||
33909845|NCT04594239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909846|NCT01386580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688471|NCT01082380|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688472|NCT05547971|||COHORT||PROSPECTIVE|||||||
33909847|NCT01441440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688473|NCT00879931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688474|NCT04862858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33688475|NCT01412918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33688476|NCT00708201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688477|NCT05254054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized control trial. Participants will be randomly allocated into either intervention group(vibration training+ conventional rehabilitation program) or control group(conventional rehabilitation program).||||
33688478|NCT06311552|||COHORT||CROSS_SECTIONAL|||||||
33688479|NCT00623116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688480|NCT03449238|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients with metastatic breast cancer with at least 2 brain metastases, eligible to receive SRS. Patients will complete radiation therapy within 1 week and Pembrolizumab may be continued every 3 weeks until evidence of brain progression or serious adverse toxicity. Patients will be followed until death.~Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity."||||
33688481|NCT02405936|||COHORT||PROSPECTIVE|||||||
33688482|NCT01954420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688483|NCT03338309|||CASE_ONLY||PROSPECTIVE|||||||
33688484|NCT05784961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||tDCS versus sham tDCS|t|t|t|t
33688485|NCT00004727|RANDOMIZED|||PREVENTION||DOUBLE||||||
33688486|NCT00151853|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688487|NCT04783142|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Principal investigator and analysts will be blinded. The participant will not be told to which diet they are randomized.|Participants are randomly assigned to either the high-fiber, low protein diet or the low-fiber, high-protein diet.|t|f|t|t
33688488|NCT04291261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688489|NCT06210672|||COHORT||PROSPECTIVE|||||||
33688490|NCT04176887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688491|NCT00099645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688492|NCT01178827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688493|NCT03230305|||COHORT||PROSPECTIVE|||||||
33688494|NCT05999942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688495|NCT00439465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688496|NCT03445182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Intervention Model: Split-mouth assignment||||
33688497|NCT06488105|RANDOMIZED|PARALLEL||PREVENTION||NONE||130 Emergency Department patients will be randomized with chest pain 1:1 to Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) or usual care.||||
33688498|NCT00702572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084537|NCT02495389|NA|SINGLE_GROUP||TREATMENT||NONE|There is no masking scheme|All patients receive mirabegron daily for 12 weeks||||
34084538|NCT01427140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084539|NCT06233708|||COHORT||RETROSPECTIVE|||||||
34084540|NCT02890862|||COHORT||PROSPECTIVE|||||||
34084541|NCT04020536|||COHORT||PROSPECTIVE|||||||
34084542|NCT04221529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084543|NCT03447834|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized in a 1:1 fashion to either routine PPCI (control arm) or intracoronary hypothermia in addition to PPCI (hypothermia arm). For the patients randomized to intracoronary hypothermia will follow the steps below.~For the routine PPCI a regular guidewire will be advanced across the occlusion followed by pre-dilatation and/or (direct) stenting according to the operator's preference."||||
34084544|NCT03703895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084545|NCT03713099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084546|NCT03468504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Experimental Group saw mirror image of non-affected limb in mirror while walking on treadmill.~Placebo Group saw no refection of the non-affected limb due to positioning of mirror while walking on treadmill.~Outcome assessor was blinded to treatment allocation. They evaluated participants in separate lab and was asked not to discuss the treatment given to patients. Even if the patient mentioned the trials they would discuss the fact that they were using Mirrors and Treadmill."|Pilot Randomised Placebo Controlled Trial|t|f|f|t
34084547|NCT02903979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909848|NCT00830037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909849|NCT05992519|||COHORT||PROSPECTIVE|||||||
33909850|NCT03572270|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking|||||
33909851|NCT05058664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||There are 3 arms: control and 2 intervention arms. One of the intervention arms includes further twice daily (within-person) randomizations.|f|f|f|t
33909852|NCT02742077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909853|NCT03063775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909854|NCT00389896|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33909855|NCT02564159|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909856|NCT04032639|||OTHER||CROSS_SECTIONAL|||||||
33909857|NCT02917187|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33909858|NCT02801630|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33909859|NCT00046605|||COHORT||PROSPECTIVE|||||||
33909860|NCT05498961|||COHORT||RETROSPECTIVE|||||||
33909861|NCT03536312|RANDOMIZED|PARALLEL||OTHER||NONE||Patients between the age of 18 and 79 with an asymptomatic ascending aortic aneurysm between 5.0 cm and 5.4 cm in maximal diameter are entered into the randomization study.||||
33909862|NCT05126368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909863|NCT06234735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator and the professional who will do the statistical analyses, will be blinded to the group allocation.||f|f|t|f
33909864|NCT04247022|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial, single-arm||||
33909865|NCT01081223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909866|NCT00942045|||COHORT||PROSPECTIVE|||||||
33909867|NCT06324747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the differences in techniques, the operating surgeon can not be blinded to the procedure|Two equal parallel groups with a 1:1 allocation ratio to receive either vestibular socket therapy (test group) or to be treated with conventional mucoperiosteal flap (control group).|t|f|f|t
33909868|NCT04162886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909869|NCT04687202|||CASE_ONLY||RETROSPECTIVE|||||||
33909870|NCT03871140|||COHORT||PROSPECTIVE|||||||
33909871|NCT04664920|||COHORT||RETROSPECTIVE|||||||
33909872|NCT05910294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909873|NCT03436446|||COHORT||PROSPECTIVE|||||||
33909874|NCT05118386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and all study personnel were blinded to the randomization. Authorized study site personnel would administer doses.|Randomized, double-blind, placebo-controlled study of RSM01. The study was conducted in 2 parts: A Dose Escalation Phase (28 participants) with 4 dosing cohorts, followed by an Expansion Phase (28 participants) with a single cohort.|t|f|t|f
33909875|NCT05058131|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33909876|NCT06224894|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33909877|NCT05818293|RANDOMIZED|PARALLEL||TREATMENT||NONE|will be blind|"1) Radiofrequency (RF):~* Twenty six post-menopausal women in group (A) will receive RF, is a healthy and effective method for reducing the abdominal obesity regulation of insulin secretion, and enhance quality of life of post-menopausal women. It will be directed to group (A) only .~* Group (A) will receive 30 minutes on the abdominal area, twice per week, as recommended in the standard treatment protocol by the manufacturer. Group (B) (control group) will receive regular diet habits only."||||
33909878|NCT02689336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909879|NCT04031378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909880|NCT02195791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909881|NCT03375112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patients will be randomized to receive fascia iliaca blocks post-operatively or to receive a touch with a blunt needle and a bandaid post-operatively by the regional anesthesia team. Neither the patient nor the investigators will have knowledge of which group the patients belong to until the completion of the data collection.||t|f|t|t
33909882|NCT04045249|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study involved 3 arms; 1st arm was treated as per standard protocol. 2nd arm was provided half calories from RUTF and half from home based food, 3rd arm was provided home based food along with MMS||||
33909883|NCT03930212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909884|NCT02666092|||CASE_CONTROL||RETROSPECTIVE|||||||
33992212|NCT06550076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992213|NCT04639219|NA|SINGLE_GROUP||TREATMENT||NONE|None (open-label)|||||
34084548|NCT05840445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Simple randomization was performed in two groups: the Onabotulinum group and the Prabotulinum group. Each group would receive an intramuscular application of onabotulinum toxin-A and prabotulinum toxin-A in the upper facial third, respectively.||||
33688499|NCT02392845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992214|NCT05761652|||OTHER||CROSS_SECTIONAL|||||||
33992215|NCT06552780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"participants will be divided into three groups of equal number group A , group B ,and group C~,the randomization will be performed by computerized randomization."|Treatment|t|f|f|f
33992216|NCT05877261|||COHORT||CROSS_SECTIONAL|||||||
33992217|NCT06491420|NA|SINGLE_GROUP||TREATMENT||NONE||A single limb interventional study where all cases presenting with pipkin 1 fractures are treated with arthroscopy||||
33992218|NCT03659994|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33992219|NCT06465927|||OTHER||RETROSPECTIVE|||||||
33992220|NCT00702533|||CASE_CONTROL||PROSPECTIVE|||||||
33992221|NCT05232786|||COHORT||CROSS_SECTIONAL|||||||
33992222|NCT06559410|||OTHER||PROSPECTIVE|||||||
33992223|NCT03142568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992224|NCT05521984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992225|NCT01354626|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33992226|NCT04521218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assignment|f|f|f|t
34084549|NCT02388451|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34084550|NCT04620499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group A receives treatment as usual (TAU); Group B receives access to the PEER Report (technology under investigation)|t|f|f|f
34084551|NCT03812419|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084552|NCT06211023|RANDOMIZED|PARALLEL||TREATMENT||NONE||SHR-A1921 with or without Carboplatin compared with Investigator's Choice of Platinum-based Doublet Chemotherapy||||
34084553|NCT03736252|||COHORT||PROSPECTIVE|||||||
34084554|NCT01879293|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34084555|NCT04971603|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm prospective study. A total of 500 eligible patients will be recruited for 24-week treatment and 12-week follow up.||||
34084556|NCT05399797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The participating pharmacists, the mystery patient and the investigator will not know who is in the control or the intervention group|The pharmacists in the interventional group will receive educational training after baseline assessment while those in the control group will receive the same training at the end of the study|t|f|t|t
33688500|NCT01905111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688501|NCT06365034|||OTHER||RETROSPECTIVE|||||||
33688502|NCT01376531|||||PROSPECTIVE|||||||
33688503|NCT02873403|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33688504|NCT01911637|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33688505|NCT00792831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688506|NCT03494348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688507|NCT04300543|||CASE_CONTROL||RETROSPECTIVE|||||||
33777914|NCT03528135|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study includes a randomized controlled trial with one intervention condition and one wait-list control condition. All participants will complete the pre-test and be randomized to receive Project PRIDE immediately or to wait approximately 5 months before receiving it. Randomization will occur as follows: for each recruitment wave (n = 41 per wave), 41 sealed envelopes, each containing a card with the condition (14 cards labeled wait-list for the wait-list control group; 27 labeled group to start shortly for the intervention group), will be pinned to a foam board. Each participant will choose one card and open it. Those in the intervention group will be assigned to one of two groups of 13-14 participants. After completing the 8 sessions, those in the intervention and those in the matched control will complete the post-test. Approximately 3 months later, these participants will complete the follow-up; those in the control will then receive Project PRIDE."||||
33909885|NCT01597557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909886|NCT06424873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||PET/CT||||
33909887|NCT06387888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33909888|NCT02955654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909889|NCT01252797|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33909890|NCT01048190|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33909891|NCT01951014|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34084557|NCT04850989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084558|NCT05409365|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33688508|NCT05002153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777915|NCT01222247|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33777916|NCT02537353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33777917|NCT03157011|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Global symptom score (GSS) questionary . This questionnaire has the advantage of grading the severity of These digestive symptoms.||||
33777918|NCT05126758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Cohort A: placebo-controlled, double-blind, randomized 1:1 (active:placebo); Cohort B: placebo-controlled, double-blind, randomized 1:1 (active:placebo)|t|t|t|t
33992227|NCT04636034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992228|NCT05323916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All patients meeting the above criteria will be invited to participate and asked to provide a written informed consent. They will be randomly assigned (1:1:1:1) as soon as possible, but always within 48 hours of admission, into one of the four interventions (represented by Group 1, 2, 3 or 4) using offsite-independent randomization protocols (www.randomization.com). Concealed allocation will be performed using sequentially numbered opaque sealed envelopes only accessible by research personnel with no involvement in the trial.|Randomised Double Blinded Controlled Trial with a longitudinal design|t|f|t|t
33992229|NCT06588296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992230|NCT04161885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777919|NCT06208124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777920|NCT06613516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777921|NCT02668432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909892|NCT03367130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|This study will be a double blinded RCT. HIV-positive individuals will be blinded to allocation group. Further, those who deliver the intervention will be blinded to the allocation. Intervention and control groups will receive similar intervention strategies. Only the content of the interventions will be different. Therefore, it is difficult for HIV-positive individuals to tell if they are receiving intervention or control. The outcome assessor will be masked to the allocation of each HIV-positive individual by using trial identity numbers. Only the principal researcher will have complete access to all the information.||t|f|f|t
33909893|NCT02898025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33909894|NCT04867655|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33909895|NCT03883022|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33909896|NCT00331825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33909897|NCT04802876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909898|NCT03127215|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|randomized||||
33992231|NCT06594926|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm phase 2 prospective, interventional study to assess the efficacy and safety of cyclical testosterone and darolutamide in non-metastatic castration-resistant prostate cancer.||||
33777922|NCT04499040|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33777923|NCT01539434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33777924|NCT03100695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777925|NCT06252389|||CASE_ONLY||RETROSPECTIVE|||||||
33777926|NCT06359795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777927|NCT04025372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992232|NCT01180634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992233|NCT06602674|||OTHER||RETROSPECTIVE|||||||
33777928|NCT06697626|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Twice daily intervention for 12 weeks with one of the following treatments (in powder form):~1. An enriched functional drink containing chicory inulin (10g), folic acid (100µg), vitamin B12 (5µg), vitamin B6 (5mg), riboflavin (2.5mg) and vitamin D (5µg).~2. A control/placebo drink with similar energy content but without the additional nutrient provision."|t|f|t|f
33992234|NCT06320171|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33992235|NCT04363554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A case control, randomized crossover study||||
33777929|NCT03597893|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The study utilized a randomized, double-blind, PBO controlled, between-subject design.|t|f|t|f
34084559|NCT04035616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both investigators and patients were unaware of the assignment and were blinded to the labelling process performed by the sample supplier. The patients were randomly allocated to one of two groups; those who received sample labelled A or B. Emergency code break were kept at the manufacturing factory and no code break was needed throughout the trial duration. Both the MCP and placebo were manufactured and supplied by B-Crobes Laboratory Sdn. Bhd. as powder in identical sachets and labelled as A and B. Investigators have no contact with the manufacturing staffs at any point during the trial process. Following data analysis, unblinding was performed to complete the study process.|The subjects received either the probiotics or a placebo.|t|f|t|f
34084560|NCT03918317|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34084561|NCT05782153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Cross-over within-subjects design. Forty participants will randomly be assigned to do a hearing aid self-fitting with direct adjustment (Intervention A) or a hearing aid self-fitting with in-situ audiometry (Intervention B) using the Lexie Powered by Bose hearing aids and will be asked to wear the hearing aids for four weeks. After four weeks, they will be crossed over to be fitted with the alternative fitting strategy, and they will be asked to wear the hearing aids again for four weeks.|t|f|t|f
33777930|NCT05258396|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084562|NCT02818504|NON_RANDOMIZED|PARALLEL||||NONE||||||
34084563|NCT03117504|||COHORT||CROSS_SECTIONAL|||||||
34084564|NCT00864110|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33777931|NCT03980405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physicians will be blinded to the randomization and dietary advice received||f|f|t|f
33777932|NCT02061761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33777933|NCT03279705|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|These codes were contained in pre-arranged opaque envelopes, which were opened immediately before insertion of the colonoscope.|A total of 120 patients were allocated into one of two groups by computerized randomization. In group A (Two-channel group), clear water was infused through the water jet channel and dirty water was sucked form the accessy channel. In group B (One-channel group), water exchange was done by using the accessory channel for both infusing and suctioning of water.||||
33777934|NCT01339325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777935|NCT01034761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33777936|NCT06078683|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized, double-blinded, placebo-controlled, crossover study|t|f|t|t
33777937|NCT01349751|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33777938|NCT04321200|||OTHER||PROSPECTIVE|||||||
33777939|NCT02647918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777940|NCT06134245|||CASE_ONLY||CROSS_SECTIONAL|||||||
33777941|NCT00419003|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33777942|NCT03047603|||COHORT||PROSPECTIVE|||||||
33777943|NCT00486161|||CASE_CONTROL||OTHER|||||||
33777944|NCT05934097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned to one of 2 treatment regimens corresponding to different schedules (standard or alternate) of R-CHOP||||
33777945|NCT04908436|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33777946|NCT04159961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33992236|NCT01442155|||COHORT||PROSPECTIVE|||||||
33992237|NCT02915198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992238|NCT03289923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992239|NCT04360252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992240|NCT01449383|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33909899|NCT03546725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes will be self-reported, and the author that assesses the outcomes and performs data analyses will be blinded.|Participants will be randomised to wear a compression stocking on either the left or the right leg during a 3 - 3.5 hour flight. All participants will act as their own control, and as a result all data will be paired.|f|f|f|t
33909900|NCT02747277|||OTHER||CROSS_SECTIONAL|||||||
33909901|NCT01703286|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33909902|NCT01474330|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33909903|NCT01600183|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909904|NCT01124058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909905|NCT02245568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909906|NCT04611711|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33909907|NCT06203496|||COHORT||PROSPECTIVE|||||||
33909908|NCT02131051|||CASE_ONLY||PROSPECTIVE|||||||
33909909|NCT01139385|||CASE_CONTROL||PROSPECTIVE|||||||
33909910|NCT02690233|||COHORT||PROSPECTIVE|||||||
33909911|NCT06155266|||COHORT||PROSPECTIVE|||||||
33909912|NCT03602352|||COHORT||RETROSPECTIVE|||||||
33909913|NCT05999474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33909914|NCT01470573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909915|NCT05195736|||COHORT||RETROSPECTIVE|||||||
33909916|NCT01301742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909917|NCT00455247|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33909918|NCT02532595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992241|NCT05598047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Testers will be unaware of which training condition participants are assigned.|A pre-post two-group experimental design will be used. One group will receive the experimental executive functioning training and the other group will not receive anything (no-contact control group)|t|f|f|f
33992242|NCT01788423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33992243|NCT04609878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992244|NCT01528163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992245|NCT02558491|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33688509|NCT06421818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|For groups receiving Baitouweng Decoction by oral administration and rectal edema，the interventions are single-blind to investigators and outcomes assessor. For groups receiving Baitouweng Decoction or placebo by colonic TET, the interventions are double-blind to participants, care provider, investigators and outcomes assessor.||t|t|t|t
33688510|NCT01429038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688511|NCT03751774|RANDOMIZED|PARALLEL||PREVENTION||NONE||Clusters (maternity wards) are randomized to either intervention or control (standard ANC). Intervention coverage 27000. Data collection for the primary and secondary trial outcomes includes 1.921 interviewed participants in the pre-intervention survey and 2.232 interviewed participants in the post-intervention survey.||||
33688512|NCT05953714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The inclusion criteria included the absence of systemic and chronic disease (thyroid disease, gestational diabetes, gestational hypertension or allergy), no history of previous abdominal surgery, a newborn baby follow-up with no health problems that would hinder the breastfeeding process, 37 gestational weeks of pregnancy and above, pregnant women with a low-risk pregnancy, those with a body mass index between 20 and 30 who were at least a primary school graduate, and who were between 19 to 40 years of age.|They were randomly divided into povidone iodine (PI) group (A) clorhexidine gluconate (CG) group (B) and CG shower (C) operated by two Gynecology and Obstetrics physician. Data from the in house blinding study to avoid bias and follow-up of the women was done for 7 day duration following postnatal to assess postoperative for comfort, pain, wound complications.|t|f|f|f
33688513|NCT02105818|||COHORT||CROSS_SECTIONAL|||||||
33688514|NCT01214148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688515|NCT01372982|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688516|NCT05408468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688517|NCT02942576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688518|NCT03905070|||COHORT||CROSS_SECTIONAL|||||||
33688519|NCT01565499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688520|NCT00171678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688521|NCT05271708|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes (VSS score) assessors do not know which side is applied with the therapeutic ointment.|The patient's wound was treated with a placebo or therapeutic ointment on the right side and a placebo or therapeutic ointmenton the left side.|t|f|f|t
33777947|NCT04289285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777948|NCT04387890|||COHORT||PROSPECTIVE|||||||
33777949|NCT02449044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777950|NCT03210883|||COHORT||RETROSPECTIVE|||||||
33777951|NCT01866917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33777952|NCT05420987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33777953|NCT02633319|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33777954|NCT01779921|||COHORT||PROSPECTIVE|||||||
33777955|NCT03230929|NA|SINGLE_GROUP||SCREENING||NONE||||||
33777956|NCT04612114|||CASE_ONLY||PROSPECTIVE|||||||
33777957|NCT01023308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777958|NCT02965144|||COHORT||PROSPECTIVE|||||||
33909919|NCT01463072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909920|NCT01577160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909921|NCT02253706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909922|NCT00501566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33909923|NCT00905879|||COHORT||PROSPECTIVE|||||||
33909924|NCT04348487|NA|SINGLE_GROUP||TREATMENT||NONE||Introducing new approach of chemoport insertion||||
33777959|NCT04032808|||COHORT||PROSPECTIVE|||||||
33777960|NCT03142217|NA|SINGLE_GROUP||OTHER||NONE||||||
33909925|NCT01054677||||HEALTH_SERVICES_RESEARCH||||||||
33909926|NCT05868993|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33909927|NCT06555692|||CASE_CONTROL||PROSPECTIVE|||||||
33909928|NCT01225640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909929|NCT01168713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909930|NCT03651193|||COHORT||CROSS_SECTIONAL|||||||
33909931|NCT06554938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomized trial by lots|The study comprised 18-35-year-old girls and boys planning orthodontic treatment. Participants had upper right tooth to lower left molar braces, a pocket depth of 3 mm, and had not flossed in 24 hours. Smoking, periodontal disease, missing teeth, voids between teeth in the arch, and systemic disorders disqualified participants.|t|t|t|f
33909932|NCT01778387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33909933|NCT05029544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the investigator who performed the acromiohumeral distance measurements was blinded.||f|f|t|f
33909934|NCT03257072|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|double-blind|double-blind, placebo-controlled, dose-escalation trial|t|t|t|f
33992246|NCT01160666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992247|NCT06510361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992248|NCT04948658|||COHORT||PROSPECTIVE|||||||
33992249|NCT06394089|||COHORT||PROSPECTIVE|||||||
33992250|NCT00001991||||TREATMENT||NONE||||||
33909935|NCT04176432|||COHORT||RETROSPECTIVE|||||||
33909936|NCT04181567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909937|NCT01420588|||COHORT||PROSPECTIVE|||||||
33909938|NCT01029288|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33992251|NCT04936581|||COHORT||PROSPECTIVE|||||||
33992252|NCT02388971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992253|NCT02243579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992254|NCT06743438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992255|NCT06206291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992256|NCT01534819|||COHORT||PROSPECTIVE|||||||
33992257|NCT02307994|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084565|NCT03863353|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|"Group assignment will be coded for subjects and data collectors. Subjects will be blinded to whether the information they receive is the Intervention vs. Control.~Group assignment will coded on data entry and unblinded after analyses."|randomized, controlled, factorial design|t|f|t|t
34084566|NCT03627104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the person who will perform the statistical analysis will be blinded from the intervention group by assigning each patient|The groups will receive the treatment simultaneously|f|f|f|t
34084567|NCT01324102|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084568|NCT00742950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084569|NCT00493675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084570|NCT01548365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33688522|NCT03830177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688523|NCT06143605|||COHORT||RETROSPECTIVE|||||||
33688524|NCT03201627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688525|NCT05637658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|parallel assignment|t|f|f|f
33688526|NCT05644847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a another person who will be unaware of the group the participant belongs to.|Single Blinded Parallel Randomised controlled Trial|f|f|f|t
33688527|NCT01489371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909939|NCT06413173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The tDCS unit software has a double-blind selection, blinding all study members, care providers, and participants until blinds are broken.|This is a double-blind, randomized, placebo (sham) controlled pilot study.|t|t|t|f
33909940|NCT06055881|||COHORT||PROSPECTIVE|||||||
33909941|NCT03332108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33909942|NCT02150824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33909943|NCT01166412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909944|NCT02342561|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33909945|NCT03714113|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33909946|NCT06504173|||COHORT||RETROSPECTIVE|||||||
33909947|NCT01081873|||CASE_ONLY||PROSPECTIVE|||||||
33909948|NCT03648840|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects are not informed which session will include aversive cues.|2 session crossover, random order, single blind|t|f|f|f
33909949|NCT01860053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33909950|NCT03434964|||COHORT||PROSPECTIVE|||||||
33909951|NCT01052168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33909952|NCT03306615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33909953|NCT01245426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33909954|NCT03633227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909955|NCT02855346|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33909956|NCT02411201|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33909957|NCT01120093|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33909958|NCT00337467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909959|NCT04864912|||COHORT||OTHER|||||||
33909960|NCT02205827|NA|SINGLE_GROUP||OTHER||NONE||||||
33909961|NCT00541086|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33909962|NCT00850460|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33909963|NCT00038701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909964|NCT02194400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909965|NCT03212131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor staff involved in the clinical trial is masked according to company standard procedures|||||
33909966|NCT05264571|||COHORT||RETROSPECTIVE|||||||
33909967|NCT02898220|||COHORT||PROSPECTIVE|||||||
33909968|NCT04111887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33909969|NCT02763904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777961|NCT06126419|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1 will consist of participants scheduled for liver resection and will undergo high-dose insulin therapy preoperatively to determine if baseline liver function can be optimized/improved, as measured by 99mTc-Mebrofenin HBS. Cytokine profiling will also be collected and analyzed pre- and post-insulin infusion.~Group 2 will consist of participants scheduled for liver resection that require LVD. They will then be randomized to two different arms -- control vs high-dose insulin therapy."||||
33777962|NCT00058851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33777963|NCT03110679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|cover the syringe to mask the contents|autologous bone marrow concentrate vs. hyaluronic acid.|t|f|t|f
33777964|NCT02790762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33777965|NCT06312631|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33777966|NCT02015663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777967|NCT05564182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33777968|NCT06696742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33777969|NCT05665309|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33777970|NCT06133127|NA|SINGLE_GROUP||OTHER||NONE||||||
33777971|NCT04004793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33777972|NCT00674492|||||RETROSPECTIVE|||||||
33777973|NCT06140667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33777974|NCT05419674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777975|NCT01290016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777976|NCT01807819|||COHORT||PROSPECTIVE|||||||
33777977|NCT01826903|||COHORT||CROSS_SECTIONAL|||||||
33777978|NCT00271843|||||PROSPECTIVE|||||||
33777979|NCT02099032|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33777980|NCT00014950|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||||||||
33777981|NCT03670745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This project will utilize a sequential explanatory research design, with an embedded randomized controlled trial (RCT) intervention .|t|f|f|f
33777982|NCT00494923|||COHORT||PROSPECTIVE|||||||
33777983|NCT01046019|||COHORT||PROSPECTIVE|||||||
33777984|NCT05248360|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33777985|NCT00000242||||TREATMENT||||||||
33777986|NCT01593878|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33777987|NCT01036711|||||OTHER|||||||
33777988|NCT01648218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777989|NCT01241136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33777990|NCT06171048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33777991|NCT01793246|||COHORT||PROSPECTIVE|||||||
33777992|NCT03047369|||COHORT||PROSPECTIVE|||||||
33777993|NCT00124800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33777994|NCT06492538|||COHORT||PROSPECTIVE|||||||
33777995|NCT04807660|||COHORT||PROSPECTIVE|||||||
33777996|NCT06102785|||COHORT||PROSPECTIVE|||||||
33777997|NCT05647369|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All patients will be allocated at a 1:1 ratio between group A (mastic group) and group B (placebo group), for each sex separately using stratified randomization. Two random sequences of 15 letters (A or B) will be obtained from www.random.org (List Randomizer service), one for males and one for females. Those letters were written on paper and then sealed in opaque envelopes, sequentially numbered from M1 to M15 for males and from F1 to F15 for females respectively. All envelopes were sealed, numbered and stored in a drawer by a person not involved in the study. Every patient enrolled in the study will receive an envelope in a numerical order and their name was written on the envelope. Informed consent will be obtained from parents / legal guardians and written consent upon information and prior to the randomization or application of any procedure obtained from the patients.|This trial is designed as a prospective, randomized, placebo-controlled, double (investigator and patient) blinded, with two parallel groups and an equal allocation ratio in all groups. In this study, the intervention consists of delivery of mastic mouthwash or placebo lozenges.|t|f|t|f
33777998|NCT00330213|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33777999|NCT01015183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778000|NCT01249742|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33778001|NCT03805490|||OTHER||PROSPECTIVE|||||||
33778002|NCT04800835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be studied in a randomized open label single center study that will run 52 weeks. Subjects will be randomized to two treatment groups: Group 1- Spatz3 adjustable balloon 12-month implantation; and Group 2 - 6-month non adjustable balloon implantation with additional 6 months of dietician follow-up after balloon extraction|t|f|f|f
33778003|NCT01682707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778004|NCT04610424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33778005|NCT04517903|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||eye rubbing questionnaire at baseline and 15 days later for exploratory phase; at baseline and at 6 month follow-up for confirmatory phase and at home||||
33778006|NCT02015195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33778007|NCT01473511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778008|NCT03135132|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33778009|NCT01899560|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33778010|NCT01253915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778011|NCT03031028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778012|NCT05280535|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will receive all components of this study. Participants receive laboratory sessions in a within-person randomized order. Randomization will determine whether participants receive a cigarette OR e-cigarette cue during the in-vivo cue reactivity task. Participants who receive a given cue during the first laboratory session will receive the other cue during the second session. Within each laboratory session, the presentation order of the trials within the computerized visual dot probe task will also be randomized such that participants will either receive the cigarette vs. neutral OR e-cigarette vs. neutral block first (all participants receive both blocks of trials in both sessions).||||
33778013|NCT00146640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909970|NCT02422953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909971|NCT01542476|||COHORT||PROSPECTIVE|||||||
33909972|NCT05490628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly divided into intervention and control groups. Both groups will be treated for 6 weeks. Each participant will be treated for a total of thirty hours, one hour a day, five days a week.|t|t|f|f
33909973|NCT02353260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909974|NCT02404155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992258|NCT05388214|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive behavioral therapy-based cognitive rehab intervention developed to address CRCD in older adults with cancer and is delivered over the course of 10 individual workshops with a trained health professional. MAAT-G focuses on an individual's psychological response to injury as compared to the biological events triggering cognitive dysfunction, and provides education and training in adaptive behavioral coping skills, stress management techniques, and compensation strategies. Geriatric Oncology-Exercise for Cancer Patients (GO-EXCAP) leverages a mobile app to deliver an individually tailored, low-to-moderate intensity, home-based walking and progressive resistance exercise program designed for patients with cancer, tailored to their physical capacity. The E-Co intervention will integrate components of GO-EXCAP into MAAT-G.||||
33992259|NCT05345509|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992260|NCT04022954|||OTHER||PROSPECTIVE|||||||
33992261|NCT06603103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992262|NCT01286545|||COHORT||PROSPECTIVE|||||||
33992263|NCT03322267|NA|SINGLE_GROUP||TREATMENT||NONE||Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab||||
33992264|NCT00830414|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992265|NCT06102044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992266|NCT03873272|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The preferred intervention can be selected during the ongoing enrollment as soon as the pre-specified selection criteria are met, and further enrollment will cease.||||
33992267|NCT00841191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992268|NCT01660945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992269|NCT05289648|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33992270|NCT02842853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33992271|NCT06072768|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|None (open label)|Participants will be allocated to the 15-day strategy preferentially until enrollment goals have been met; once completing the 15-day strategy, many participants will also be eligible to complete the 150-day strategy, and may subsequently enroll in it if they wish.||||
33909975|NCT04211610|||COHORT||CROSS_SECTIONAL|||||||
33909976|NCT00756587|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33909977|NCT01133210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909978|NCT05646303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909979|NCT05901714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33909980|NCT05956249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will occur for the scientific initiation scholarship holder responsible for reassessing the scales.||f|f|f|t
33909981|NCT00004013||||TREATMENT||||||||
33909982|NCT01977209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992272|NCT01498939|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33909983|NCT04439630|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants knew which test products that were included in the study, but not the consumption order|randomised crossover study in healthy young adults with normal BMI|t|f|f|f
33909984|NCT03847155|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participant, care provider and investigator will be masked as far as the treatment provided is concerned.|The patients will be randomized into two study groups, with the active substance and placebo.|t|t|t|f
33909985|NCT03154723|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33688528|NCT03665415|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants cannot be blinded to assignment. Objective outcomes (physical activity, height, weight, blood pressure) will be collected by masked assessors. The primary investigator and all data analysts will be blinded to participant assignment.|The project will be carried out in three phases: 1) Formative research to implement the intervention with n=6 youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase; 2) The pilot intervention comprised of a randomized wait-list controlled pilot intervention at two sites (school and clinic) during the school year; 3) an unsupported follow up period where participants in the school-based intervention will be offered the intervention during the summer months without school staff support. Wait-listed school site participants will also receive the unsupported intervention in this phase.|f|f|t|t
33688529|NCT04729478|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|NSE and DISE will be performed by two separate researchers, blinding the ENT surgeon who performs the NSE or DISE for the outcome of the other procedure. This is a blinded study and the researchers will have no knowledge of the patient's characteristics / demographic variables and their history.|Blinded, prospective, single-center, comparative cohort study.|f|f|f|t
33688530|NCT03319290|||OTHER||CROSS_SECTIONAL|||||||
33688531|NCT01653782|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33688532|NCT04996147|||COHORT||PROSPECTIVE|||||||
33688533|NCT00079014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688534|NCT01616134|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33688535|NCT05973396|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33688536|NCT05648253|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective single-arm pre/post repeated-measures pilot study||||
33688537|NCT05025540|||CASE_CONTROL||RETROSPECTIVE|||||||
33688538|NCT05497700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Drug will be prepared by an anesthesia nurse not involved in the care of the patient and labeled as VASO-IRC-inclusion number."||t|t|t|t
33688539|NCT04975529|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Two-group quasi-experimental|t|f|f|f
33688540|NCT00806364|||CASE_ONLY||CROSS_SECTIONAL|||||||
33688541|NCT04722653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The non-Asian part is run in parallel to the Japanese part in an open design. The Japanese part is double-blinded. Sponsor staff involved in the clinical trial is masked according to company standard procedures.|The present trial is split into two parts reflecting the two trial populations: Japanese subjects and non-Asian subjects. For the Japanese part, it is designed as a randomised, placebo-controlled, double-blinded within cohorts, parallel group, single-dose trial. The non-Asian part is run in parallel to the Japanese part in an open design|t|t|t|t
33688542|NCT00510874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33688543|NCT05860231|RANDOMIZED|PARALLEL||OTHER||NONE|Data analysis will be blinded to the intervention arm as well as the laboratories that will carry out the analysis of the urine and catheter samples.|||||
33688544|NCT03242824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688545|NCT04077476|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a randomized control trial with baseline and post-intervention (8 wks from baseline) assessments. Participants are randomized into either an online yoga group or an online yoga plus Facebook group.||||
33688546|NCT01593462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688547|NCT02037581|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33688548|NCT03538574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor is blind to treatment condition|Randomized, non-inferiority design|f|t|f|t
33688549|NCT05354804|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33688550|NCT04850898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Exploratory randomised, Phase 2a, double blind, placebo-controlled study.|t|t|t|f
33688551|NCT04954170|||COHORT||PROSPECTIVE|||||||
33688552|NCT04389970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688553|NCT03927599|||OTHER||OTHER|||||||
33778014|NCT02496494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778015|NCT03911375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778016|NCT05826717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This study is an open-label, randomized, single meal, cross-over study in healthy individuals.||||
33778017|NCT04313530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909986|NCT05362851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|The purpose of this study is to investigate the efficacy and safety after administration of YYC301(Experimental) or Celecoxib(Comparator) in subjects with knee osteoarthritis in a state of uncontrolled pain who took Celecoxib(Cox-2 inhibitor).|t|f|t|f
33778018|NCT03355911|||COHORT||RETROSPECTIVE|||||||
33778019|NCT04443920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33909987|NCT03182205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33909988|NCT05436613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33909989|NCT00193440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33909990|NCT04388280|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||multi-center prospective, randomized, open label, parallel group comparison of 2 diagnostic strategies||||
33909991|NCT04655950|||COHORT||PROSPECTIVE|||||||
33909992|NCT00907881|||COHORT||PROSPECTIVE|||||||
33909993|NCT01913210|||||PROSPECTIVE|||||||
33909994|NCT02607969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33909995|NCT01798784|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33909996|NCT01519245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33909997|NCT00631488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33909998|NCT05542771|||COHORT||PROSPECTIVE|||||||
33909999|NCT01766830|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910000|NCT05267353|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|Blindness is difficult to perform, all patients are treated at the same hospital, and contamination of the control group is easy. Hence, a pre- and post- study would be conducted and patients in exercise group were recruited based on gender and type of neck dissection in control group.|A pre- and post- study design was used to recruit patients. Data collection for usual care (control) group was completed before recruitment of exercise (intervention) group.||||
33910001|NCT05811494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be three groups of robotic treatment. One of them will receive the walking training with an End-effector Device (LEXO), another with a fixed exoskeleton (Lokomat), and the last one with a Body-Weight Support Treadmill system with Augmented Reality (C-Mill). Theree will be an experimental group which will receive the walking rehabilitation by using a Treadmill with Body-Weight Support|f|f|t|f
33992273|NCT00325663|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33910002|NCT03793816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be informed which side was operated with the BiZact™ device. Surgeons however inevitably know side. The side will also be documented in the surgical report. Follow-up specialists must refrain from reading through surgical reports, thus not know which technique was used for which side. Discharging letters will not include technique information.|Cross-over block design with block sizes of 12, such that after 12 patients every group was chosen three times. 48 patients in 4 groups (BiZactTM first / BiZactTM second, BiZactTM right / BiZactTM left side).|t|f|f|t
33910003|NCT00290576|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33910004|NCT06317857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910005|NCT00002663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910006|NCT02401750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910007|NCT05379426|||OTHER||CROSS_SECTIONAL|||||||
33910008|NCT05881551|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33910009|NCT02073981|||COHORT||PROSPECTIVE|||||||
33910010|NCT01524445|||CASE_ONLY||RETROSPECTIVE|||||||
33910011|NCT03606252|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33910012|NCT02148458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910013|NCT02575079|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Arm 1 is comprised of study participants receiving parafilm applied over the CVC hub or around the CVC hub connection. Arm 2 is a retrospective historical cohort of pediatric patients receiving HCT for the purpose of comparing CLABSI rates.||||
33910014|NCT01742468|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33910015|NCT02187094|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33910016|NCT04960345|||COHORT||PROSPECTIVE|||||||
33992274|NCT05842473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33992275|NCT02193724|||COHORT||PROSPECTIVE|||||||
33992276|NCT03893487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992277|NCT05686122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992278|NCT06644300|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992279|NCT02617966|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992280|NCT06443151|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992281|NCT06470425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33992282|NCT02724696|||COHORT||PROSPECTIVE|||||||
33992283|NCT04571021|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped-Wedge cluster randomized design||||
33992284|NCT06561997|||CASE_CONTROL||RETROSPECTIVE|||||||
33992285|NCT04974684|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992286|NCT03587493|NA|SINGLE_GROUP||OTHER||NONE||||||
33992287|NCT05675423|||COHORT||PROSPECTIVE|||||||
33992288|NCT03612271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33992289|NCT02465060|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992290|NCT05659381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992291|NCT06087289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992292|NCT02137330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084571|NCT02322736|||COHORT||PROSPECTIVE|||||||
33688554|NCT05155137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|investigator and patient will be blinded for polypill or placebo and the outcomes evaluator will be blinded for the treatment|Phase III Randomized Clinical Trial, prospective, placebo controlled. 60 Primary Care Health Units will be randomized (clusters) to use or not the approach of community health workers with the Stroke Riskometer. After the patients will be randomized for polypill (valsartan 80 mg, amlodipine 5 mg e rosuvastatin 10 mg) or placebo|t|t|t|t
33688555|NCT00833079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688556|NCT02074371|||CASE_CROSSOVER||PROSPECTIVE|||||||
33688557|NCT00906997|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33688558|NCT03857152|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33688559|NCT05419479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688560|NCT05994495|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an operational, randomized, open-label trial to assess appropriateness of therapy, diagnostic accuracy, clinical and microbiological outcomes, and acceptability of an etiology approach using a molecular test (NAAT) versus a clinical syndromic approach for the management of STDs in patients followed by a STD clinic of a National Referral Hospital in Kampala, Uganda.||||
33688561|NCT05445934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688562|NCT02586402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688563|NCT02369562|||COHORT||RETROSPECTIVE|||||||
33688564|NCT03832244|||COHORT||CROSS_SECTIONAL|||||||
33688565|NCT01221103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688566|NCT00901680|||||PROSPECTIVE|||||||
33688567|NCT00647218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688568|NCT04628832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33688569|NCT02374762|||CASE_ONLY||PROSPECTIVE|||||||
33688570|NCT05068895|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33688571|NCT02851862|||COHORT||PROSPECTIVE|||||||
33688572|NCT03002376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688573|NCT02734433|NA|SEQUENTIAL||TREATMENT||NONE||||||
33688574|NCT05320627|NA|SINGLE_GROUP||OTHER||NONE||||||
33688575|NCT06007703|||COHORT||PROSPECTIVE|||||||
33688576|NCT02717377|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33688577|NCT06070571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688578|NCT01983150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33688579|NCT06517524|||CASE_ONLY||PROSPECTIVE|||||||
33688580|NCT02140476|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|f|t
33688581|NCT03695276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Investigators and the Data Safety Monitoring Board will receive data summaries that mask identification of groups.|Randomized controlled trial, with randomization at the individual level|f|f|t|f
33688582|NCT02440412|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33688583|NCT04118582|||OTHER||PROSPECTIVE|||||||
33688584|NCT04265768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Due to the nature of the intervention, both participants and clinicians performing the surgical intervention will be un-blinded.~Conversely, outcome examiners will be blinded to treatment allocation throughout the whole study duration."|The study will includes 3 groups randomised in parallel.|f|f|f|t
33910017|NCT06473155|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized clinical trial comparing two psychosocial interventions with a control group (waiting list).||||
33910018|NCT03514303|||COHORT||PROSPECTIVE|||||||
33910019|NCT03016442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910020|NCT01696734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910021|NCT00006708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910022|NCT00065780|||COHORT||PROSPECTIVE|||||||
33910023|NCT05841134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910024|NCT03611933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized-controlled quasi experimental study|t|f|f|f
33910025|NCT04996862|||COHORT||PROSPECTIVE|||||||
33910026|NCT03758378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910027|NCT00968253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910028|NCT05169645|||CASE_ONLY||PROSPECTIVE|||||||
33910029|NCT02928406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910030|NCT02572830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33910031|NCT01912768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33910032|NCT00443339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084572|NCT00560729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084573|NCT02359240|||CASE_CONTROL||PROSPECTIVE|||||||
34084574|NCT05553327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084575|NCT00385840|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34084576|NCT04093856|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084577|NCT01168388|||||PROSPECTIVE|||||||
33778020|NCT00283738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33778021|NCT03822624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33778022|NCT05439265|||COHORT||RETROSPECTIVE|||||||
33778023|NCT00185367|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33778024|NCT02459990|||CASE_CONTROL||RETROSPECTIVE|||||||
33778025|NCT03664323|||COHORT||RETROSPECTIVE|||||||
33778026|NCT00394511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778027|NCT03637595|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33778028|NCT05696418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33778029|NCT01365520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778030|NCT00107874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33778031|NCT00401466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778032|NCT00798395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33778033|NCT04374617|||COHORT||PROSPECTIVE|||||||
33778034|NCT05535686|||OTHER||CROSS_SECTIONAL|||||||
33778035|NCT00911963|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33778036|NCT06071884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778037|NCT02782429|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33778038|NCT03591965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778039|NCT06029361|RANDOMIZED|PARALLEL||TREATMENT||NONE|an assessment will be made by questionnaires and an objective assessment by physiotherapists who will not be involved in the treatment of the SELFIT system in the interventional group|||||
33778040|NCT06305507|||COHORT||PROSPECTIVE|||||||
33778041|NCT02748239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778042|NCT00056290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778043|NCT00699543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778044|NCT05023720|||COHORT||RETROSPECTIVE|||||||
33778045|NCT01798082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33778046|NCT02724072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778047|NCT05547802|||CASE_CONTROL||PROSPECTIVE|||||||
33778048|NCT00503828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33910033|NCT01680094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910034|NCT04720508|||CASE_CONTROL||RETROSPECTIVE|||||||
33910035|NCT00918476||CROSSOVER||||NONE||||||
33910036|NCT03132805|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Outcome assessors are blind to intervention status.|Schools are randomly assigned to 1 of 3 conditions, control, universal classroom-based preventive intervention, and universal classroom-based intervention plus an indicated preventive intervention. Data on student outcomes to be collected at pre- post- and 6 month follow-up. \*Enrollment numbers reflect both students and teachers who agreed to participate in the study.|f|f|f|t
33910037|NCT04676750|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33910038|NCT05300100|NA|SINGLE_GROUP||OTHER||NONE||||||
33910039|NCT06517615|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|as a quasi-experimental research|The study was planned as a quasi-experimental research.||||
33910040|NCT06437561|||CASE_ONLY||RETROSPECTIVE|||||||
33910041|NCT01966562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33778049|NCT05953961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778050|NCT03417973|||COHORT||PROSPECTIVE|||||||
33992293|NCT00611364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778051|NCT00415493|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33778052|NCT04596527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778053|NCT00112112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778054|NCT01440049|||COHORT||PROSPECTIVE|||||||
33778055|NCT01403675|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33778056|NCT05775796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778057|NCT04124991|NA|SINGLE_GROUP||TREATMENT||NONE||Transarterial radioembolization (TARE) with yttrium-90 microspheres will be employed in combination with an intravenous (IV) dose of 1500 mg durvalumab every 4 weeks (Q4W) until PD. TARE will be performed 1-2 weeks (7 to 14 days) before the first dose of durvalumab and a maximum of 2 more times during the treatment period, per Investigator discretion. If additional TARE is performed, the interval between additional TARE treatments and administration of durvalumab should be at least 1 week.||||
33778058|NCT03086122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910042|NCT02566330|||COHORT||PROSPECTIVE|||||||
33910043|NCT04125797|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33910044|NCT00313807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33910045|NCT01123369|||CASE_CONTROL||PROSPECTIVE|||||||
33778059|NCT03310229|||OTHER||CROSS_SECTIONAL|||||||
33778060|NCT00618670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778061|NCT03760315|||COHORT||PROSPECTIVE|||||||
33778062|NCT03659487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Laparoscopic total (Nissen) vs posterior 270 degrees (Toupét) partial fundoplication for the treatment of gastroesophageal reflux disease.|t|f|f|t
33778063|NCT03671538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778064|NCT00178022|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33778065|NCT00248443|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33992294|NCT05111574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992295|NCT00001467|||OTHER||CROSS_SECTIONAL|||||||
33992296|NCT03161808|||COHORT||PROSPECTIVE|||||||
33778066|NCT04802863|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33778067|NCT03907605|||COHORT||RETROSPECTIVE|||||||
33778068|NCT05218122|||CASE_ONLY||PROSPECTIVE|||||||
33778069|NCT03100682|||COHORT||PROSPECTIVE|||||||
33778070|NCT03137316|||COHORT||RETROSPECTIVE|||||||
33778071|NCT02733107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778072|NCT04838821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||156 participants will be allocated randomly to either one of three treatment groups or to placebo through an internet based randomizer (Studyrandomizer.com). Participants can withdraw from the study at any time.|t|t|t|t
33778073|NCT04850742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910046|NCT03977727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910047|NCT03121872|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this randomized controlled clinical trial, multiple gingival recessions were treated by T-PRF in 16 patients and by CTG in 18 patients selected by the coin-toss method. All surgical procedures, measurements and follow-up were performed by the same clinician||||
33910048|NCT04806932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomized to the conventional Approach (CA) or modified Approach (MA) group in a 1:1 ratio using a computerized system. The allocation process was intensively managed by an allocation group using sequentially numbered containers and the allocation result was concealed until it was implemented. When a patient was eligible, the investigator informed the allocation group to get intervention group allocated to the patient: CA orMA group. Because of feasibility issues, operators were not blinded to the assignment.||t|f|f|f
33910049|NCT00941616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910050|NCT03492463|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33910051|NCT04831216|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will be assigned to a single intervention arm.||||
33910052|NCT02934412|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33910053|NCT01924910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910054|NCT02029404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910055|NCT06692829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910056|NCT02963714|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778074|NCT04121221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"During the placebo controlled period subjects will receive either 40mg of GA Depot or matching placebo, IM, once every 4 weeks, for a total of 13 times.~Subjects who complete the PC period of the study will be offered to continue into the open label period for an additional 52 weeks, in which all subjects will receive 40mg of GA Depot IM once every 4 weeks."|t|t|t|t
33778075|NCT06358742|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Toothpaste packaged in white tubes with a study label which only differentiates products with a alphanumeric code.||t|f|t|t
33778076|NCT02703038|||COHORT||PROSPECTIVE|||||||
33778077|NCT00691028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778078|NCT03801772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind: one party, either the investigator or participant, is unaware of the intervention assignment; also called single-masked study.|participants are assigned to one of two or more groups in parallel for the duration of the study|f|f|f|t
33778079|NCT02942147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778080|NCT02202590|NA|SINGLE_GROUP||OTHER||NONE||||||
33778081|NCT01548443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778082|NCT06021210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778083|NCT05711329|||COHORT||PROSPECTIVE|||||||
33778084|NCT06463262|||COHORT||PROSPECTIVE|||||||
33778085|NCT05070650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778086|NCT05503420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33778087|NCT05051787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778088|NCT04887961|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective multicenter phase II study||||
33910057|NCT02327286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910058|NCT05833893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910059|NCT00421343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910060|NCT03241758|||CASE_CROSSOVER||PROSPECTIVE|||||||
33910061|NCT00894413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910062|NCT02076555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910063|NCT00003636|RANDOMIZED|||TREATMENT||||||||
33910064|NCT06018467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910065|NCT04308512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33910066|NCT01196169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778089|NCT06242457|||CASE_ONLY||PROSPECTIVE|||||||
33778090|NCT04038099|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33778091|NCT02711722|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33778092|NCT04086173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Neither the participant nor the Care provider administrating treatment will know the type of treatment.|Double-blinded randomized placebo-controlled clinical assay|t|t|f|f
33778093|NCT01975350|||COHORT||PROSPECTIVE|||||||
33778094|NCT00654238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778095|NCT02389426|NON_RANDOMIZED|PARALLEL||||NONE||||||
33778096|NCT05250479|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33778097|NCT06175663|||COHORT||PROSPECTIVE|||||||
33778098|NCT02198456|||COHORT||PROSPECTIVE|||||||
33778099|NCT01759992|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33778100|NCT01759433|||COHORT||PROSPECTIVE|||||||
33778101|NCT02007083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778102|NCT05498311|NA|SINGLE_GROUP||TREATMENT||NONE||Intraoperative Radiotherapy (IORT)||||
33778103|NCT03713645|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778104|NCT06242509|||COHORT||PROSPECTIVE|||||||
33778105|NCT05986669|||OTHER||PROSPECTIVE|||||||
33778106|NCT05270824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778107|NCT03076359|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778108|NCT02064621|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778109|NCT03839472|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm where each patient will act as his/her own internal control (cell count before and after CBI).||||
33778110|NCT05420662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33778111|NCT02992015|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910067|NCT02358330|||OTHER||PROSPECTIVE|||||||
33910068|NCT04284982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910069|NCT04360187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910070|NCT01186211|||COHORT||PROSPECTIVE|||||||
33910071|NCT03786146|||CASE_CROSSOVER||PROSPECTIVE|||||||
33910072|NCT05596968|||COHORT||PROSPECTIVE|||||||
33910073|NCT06241599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910074|NCT03950245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33910075|NCT05282264|||COHORT||PROSPECTIVE|||||||
33910076|NCT05066997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910077|NCT03537820|||CASE_ONLY||PROSPECTIVE|||||||
33910078|NCT01529476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33778112|NCT04238221|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Randomization, drug administration and patient training will be performed by an operator not involved in patients' recruitment and in the data collection and analysis.|Phase 4, single center, prospective, interventional, randomized, single blind, crossover|f|t|t|t
33778113|NCT03428061|||COHORT||PROSPECTIVE|||||||
33778114|NCT01316692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778115|NCT01079455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778116|NCT00590980|||COHORT||PROSPECTIVE|||||||
33778117|NCT03564275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Matched pair analysis. Each prospective patient will be matched with two historical patients based on the inclusion, exclusion and match criteria.||||
33778118|NCT05375565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778119|NCT01077674|||CASE_ONLY||PROSPECTIVE|||||||
33910079|NCT04339075|||COHORT||PROSPECTIVE|||||||
33910080|NCT06363045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910081|NCT05523713|NA|SINGLE_GROUP||OTHER||NONE||||||
33910082|NCT03013322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688585|NCT04847089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910083|NCT01580592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910084|NCT05012319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the list of the members of the resrach team who will be blinided have been identiifed and a full procedure has been identified|This is a randomized, double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in healthy adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection.|t|t|t|f
33910085|NCT00169494|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910086|NCT03727321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910087|NCT01889199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910088|NCT00553059|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33910089|NCT05112458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Half of the participants will receive the intervention and half will receive standard care. All will be assessed at enrollment, 1 month, 3 month, and 6 month time points.||||
33910090|NCT03121183|||OTHER||RETROSPECTIVE|||||||
33910091|NCT02869750|||COHORT||PROSPECTIVE|||||||
33910092|NCT02639793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910093|NCT05121727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910094|NCT06457984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double(Participant, Investigator)|Parallel Assignment|t|f|t|f
33910095|NCT03451864|||COHORT||PROSPECTIVE|||||||
33910096|NCT05647876|||COHORT||PROSPECTIVE|||||||
33910097|NCT05796453|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33910098|NCT05217680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Clinical study, phase III, multi-centric, randomized, double-blind, with active parallel control to show non-inferiority.|f|f|t|t
33910099|NCT04641364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910100|NCT04980846|NA|SINGLE_GROUP||OTHER||NONE||||||
33910101|NCT02671890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910102|NCT05789264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910103|NCT06693414|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33910104|NCT06512441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind randomized controlled trial involving patients and healthcare providers||t|f|t|f
33992297|NCT04684186|||COHORT||PROSPECTIVE|||||||
33688586|NCT00468039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688587|NCT01028378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688588|NCT02879240|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33688589|NCT04079569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688590|NCT03686644|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33688591|NCT03574324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910105|NCT02731508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688592|NCT01036230|||||OTHER|||||||
33688593|NCT02252276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33688594|NCT01727778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688595|NCT00184574|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688596|NCT03549403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688597|NCT06276985|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33688598|NCT03895762|||CASE_ONLY||PROSPECTIVE|||||||
33688599|NCT02127398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688600|NCT03833947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33688601|NCT05836779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688602|NCT02102360|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33910106|NCT03897920|||COHORT||PROSPECTIVE|||||||
33910107|NCT00174707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910108|NCT00363805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910109|NCT03963245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33910110|NCT01448291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992298|NCT04739800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992299|NCT02322593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992300|NCT00191815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992301|NCT05642923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992302|NCT06591598|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992303|NCT00473863|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33992304|NCT05996198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688603|NCT01206673|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688604|NCT00976573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688605|NCT02992132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992305|NCT03934281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910111|NCT02868216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding occurs only in relation to the evaluator of endothelial function|One group receives training for anger management, with guidance on infarction and physiology of anger and another group, does not receive.|f|f|f|t
33688606|NCT02379845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688607|NCT03091777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33688608|NCT02670213|||COHORT||PROSPECTIVE|||||||
33688609|NCT01364675|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688610|NCT05038176|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33688611|NCT03074942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778120|NCT01019356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33778121|NCT02821520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778122|NCT02567474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33910112|NCT01227538|||COHORT||PROSPECTIVE|||||||
33910113|NCT02686697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910114|NCT05803837|||OTHER||PROSPECTIVE|||||||
33910115|NCT01121159|||COHORT||PROSPECTIVE|||||||
33910116|NCT04355312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910117|NCT05935904|||COHORT||PROSPECTIVE|||||||
33910118|NCT03650348|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Drug PRS-343 Combination Therapy||||
33910119|NCT01380002|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33910120|NCT00002157||||TREATMENT||NONE||||||
33910121|NCT02255812|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33910122|NCT02656992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910123|NCT05883592|||CASE_ONLY||PROSPECTIVE|||||||
33910124|NCT01109004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910125|NCT03472378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910126|NCT05906641|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910127|NCT06085352|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33910128|NCT02779192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910129|NCT02179021|||CASE_ONLY||PROSPECTIVE|||||||
33910130|NCT05445622|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33910131|NCT06377800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910132|NCT03308084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33992306|NCT06558825|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33992307|NCT01725958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992308|NCT05776277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992309|NCT04496349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of Part 1 APG-115 as monotherapy. Part 2 APG-2575 in combination with APG-115 dose escalation and APG-2575 in combination with APG-115 dose expansion phase. APG-115 and APG-2575 will be orally administrated on 21-day cycles. Patients will receive APG-115 QOD, 2 weeks on, 1 week off, and APG-2575 QD, in repeated 21-day cycles.||||
34084578|NCT01170585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084579|NCT03952819|||CASE_CONTROL||PROSPECTIVE|||||||
34084580|NCT02247388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688612|NCT04993222|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33688613|NCT04510571|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33688614|NCT03488823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778123|NCT04365413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778124|NCT01920776|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778125|NCT02419547|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778126|NCT02298075|||OTHER||RETROSPECTIVE|||||||
33910133|NCT03392155|NA|SINGLE_GROUP||OTHER||NONE||||||
33910134|NCT01146067|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910135|NCT04669678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Different groups receive different interventions at same time during study.||||
33910136|NCT00520195|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910137|NCT05238948|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||One arm and 1-sequence crossover||||
33688615|NCT02038374|NON_RANDOMIZED|PARALLEL||||NONE||||||
33688616|NCT05366205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910138|NCT00038688|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34084581|NCT06051513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084582|NCT00822848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084583|NCT00699868||PARALLEL||||NONE||||||
34084584|NCT01500980|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33688617|NCT02658097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688618|NCT00691353|||CASE_ONLY||CROSS_SECTIONAL|||||||
33688619|NCT02862600|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, 2 period, dose escalation study of perhexiline in symptomatic patients with hypertrophic cardiomyopathy||||
33688620|NCT04136756|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33688621|NCT00569907|||CASE_CROSSOVER||PROSPECTIVE|||||||
33688622|NCT01994499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688623|NCT00930982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688624|NCT03448081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688625|NCT04186689|||COHORT||CROSS_SECTIONAL|||||||
33778127|NCT03396419|||COHORT||OTHER|||||||
33910139|NCT03840668|NA|SINGLE_GROUP||OTHER||NONE||||||
33910140|NCT02661607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910141|NCT01057199|||CASE_ONLY||RETROSPECTIVE|||||||
33910142|NCT01589068|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33910143|NCT02388516|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910144|NCT00375882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910145|NCT04719338|NA|SINGLE_GROUP||SCREENING||NONE||This research is a cross sectional study. Target population: thirty patients with end-stage renal disease (ESRD) receiving hemodialysis treatment from different dialysis centers in Alexandria will be enrolled in the study after achieving sustained virological response 24 weeks after the end of treatment with directly acting antiviral drugs (DAADs).will be screened for the presence of occult HCV infection.||||
33910146|NCT04857073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients will be randomized into one of two arms~1. daily, 4 times a day glucose monitoring (fasting, 2 hours post prandial x 3)~2. every other day, 4 times daily glucose monitoring (fasting, 2 hours post prandial x 3)"||||
33910147|NCT02053389|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33910148|NCT05610462|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910149|NCT05431140|||COHORT||PROSPECTIVE|||||||
33910150|NCT05465733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910151|NCT06519214|||OTHER||CROSS_SECTIONAL|||||||
33910152|NCT00344149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910153|NCT01245478|||CASE_ONLY||RETROSPECTIVE|||||||
33910154|NCT03570281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910155|NCT00861484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910156|NCT06247059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910157|NCT01379638|||CASE_CONTROL||PROSPECTIVE|||||||
33910158|NCT03174717|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33910159|NCT02058927|||COHORT||PROSPECTIVE|||||||
33910160|NCT00433732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33910161|NCT03235544|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33910162|NCT01380106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910163|NCT04289129|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33910164|NCT01153763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084585|NCT06516770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34084586|NCT05076734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084587|NCT03933059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084588|NCT03628443|||COHORT||PROSPECTIVE|||||||
33688626|NCT03702296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded assessors will review the patients for 3 days post-operatively and assess sleep quality using the Richard-Campbell sleep questionnaire.||f|f|f|t
33688627|NCT01751802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33688628|NCT00112697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688629|NCT03959228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688630|NCT01729247|||CASE_ONLY||PROSPECTIVE|||||||
33688631|NCT01178255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688632|NCT00375375|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688633|NCT05064839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910165|NCT00488618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910166|NCT00005117|RANDOMIZED|||TREATMENT||DOUBLE||||||
33910167|NCT05787834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084589|NCT00089219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084590|NCT03211065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084591|NCT01831843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33688634|NCT04676555|||COHORT||CROSS_SECTIONAL|||||||
33688635|NCT03285776|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084592|NCT06076785|||CASE_ONLY||RETROSPECTIVE|||||||
34084593|NCT06137079|||COHORT||PROSPECTIVE|||||||
34084594|NCT04664218|NA|SINGLE_GROUP||OTHER||NONE||||||
34084595|NCT04409613|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084596|NCT05116553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Pre-intervention test will be administered to the participants (T1) to assess their psychological well-being, motivation, awareness of change, self-confidence and self-efficacy.~Participants will be randomly divided into two group: the experimental group will receive the standard 2 Self Determination Theory (SDT) psychological interviews with the support of the APP with the Conversational Agent (CA), while the control group will receive the 2 SDT (Self Determination Theory) psychological interviews.~At the end of the pathway post-intervention test (T2) will be administered to the participants with the same questionnaire of the beginning."|t|f|f|f
33910168|NCT02193269|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34084597|NCT05512663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084598|NCT05720403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were evaluated at the beginning of the study and 8 weeks later by an experienced physical therapist blind to randomization. The group participants belonged to was not disclosed to the participants from the initial assessment to the end.|Using a computer program, the investigators randomly placed individuals who completed the initial assessment into the pilates group (PG) or control group (CG).|t|f|f|t
34084599|NCT00591877|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34084600|NCT00002419||||TREATMENT||||||||
34084601|NCT01556217|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34084602|NCT01655875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084603|NCT03694704|NA|SINGLE_GROUP||OTHER||NONE||||||
33910169|NCT02687594|||COHORT||PROSPECTIVE|||||||
33910170|NCT03084575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|assessment will be done by junior stuff who is blind to the technique of intervention|randomization was done using a computer-generated random numbers with proper concealment in opaque sealed envelopes .|f|f|f|t
33910171|NCT03794141|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910172|NCT00365716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33910173|NCT02704728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910174|NCT04374305|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a platform-basket trial that includes a Master Protocol with embedded Drug Sub-studies. Currently, there are two drug sub-studies: sub-study A (brigatinib) and sub-study B (neratinib). The overall number of arms is not fixed by design because the investigators include arm-dropping rules for futility and allow for the possibility of arm addition by amendment.||||
33910175|NCT03072719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910176|NCT02654704|||OTHER||PROSPECTIVE|||||||
33910177|NCT03277170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug (montelukast granules) and identical control will be prepared by the Vanderbilt Investigational Drug service. Participants will be randomized by computerized program by study biostatistician.|Two-arm, parallel randomized controlled trial|t|t|t|t
33910178|NCT01734941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910179|NCT05740449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910180|NCT00539630|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910181|NCT04183842|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Randomization chart Code number for Product / Placebo distribution|Randomized, double blind, placebo controlled, crossover study.|t|t|t|t
33910182|NCT01803763|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33910183|NCT01881035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992310|NCT06601933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will know their treatment condition. Study investigators and clinicians and blinded research coordinator who administers outcomes assessments remain blind to treatment condition.|Comparison of 3 treatment arms|f|t|t|t
33992311|NCT05449743|NA|SINGLE_GROUP||TREATMENT||NONE||before / after study||||
33992312|NCT06004895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||One eye of the participant is randomised to receiving IPL and LLLT, while the other eye of the same participant will receive sham intense pulsed light therapy and low-level light therapy.|t|f|t|t
33992313|NCT06674577|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33992314|NCT04625205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992315|NCT03292484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992316|NCT00943215|||CASE_ONLY|||||||||
33992317|NCT05461768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992318|NCT03878121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992319|NCT00644137|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33992320|NCT02082808|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992321|NCT06332430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992322|NCT05942066|||COHORT||CROSS_SECTIONAL|||||||
33992323|NCT06438315|||CASE_CONTROL||PROSPECTIVE|||||||
33992324|NCT04705935|||COHORT||CROSS_SECTIONAL|||||||
33992325|NCT06662786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992326|NCT06488716|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992327|NCT01171898|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992328|NCT01805869|||COHORT||PROSPECTIVE|||||||
33992329|NCT05192720|RANDOMIZED|PARALLEL||OTHER||SINGLE|the patients do not know if they get Andosan or placebo.|25-30 patients in each arm receiving Andosan or placebo.|t|f|f|f
33992330|NCT03037554|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Treatment and sham-control sleepwear will be allocated to subjects in a counterbalanced manner by a study administrator who will not otherwise interact with subjects.|Hierarchical linear model evaluating repeated measures nested within subjects|t|t|t|f
33992331|NCT03832361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992332|NCT06679309|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33992333|NCT03587311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992334|NCT00651131|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992335|NCT05911321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992336|NCT03520647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688636|NCT03490279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688637|NCT01561027|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33688638|NCT03706898|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33688639|NCT02809261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688640|NCT01455376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992337|NCT06587464|||COHORT||RETROSPECTIVE|||||||
33992338|NCT04455841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992339|NCT05043038|||COHORT||PROSPECTIVE|||||||
33992340|NCT04789655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992341|NCT06660173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992342|NCT05824897|||COHORT||PROSPECTIVE|||||||
33992343|NCT04410796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A phase 2 randomized study of osimertinib versus osimertinib plus chemotherapy for patients with metastatic EGFR-mutant lung cancers that have detectable EGFR mutant cfDNA in plasma after initiation of osimertinib treatment.||||
33992344|NCT00302146|||COHORT||PROSPECTIVE|||||||
33992345|NCT04408586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688641|NCT03810820|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective cohort of consecutive patients booked for outpatient TAVI.||||
33688642|NCT00752544|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33688643|NCT01205178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33688644|NCT03302520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688645|NCT01661816|||COHORT||PROSPECTIVE|||||||
33688646|NCT01695655|||COHORT||PROSPECTIVE|||||||
33688647|NCT02992561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688648|NCT03998813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688649|NCT00579436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33688650|NCT05330169|||COHORT||PROSPECTIVE|||||||
33688651|NCT03397654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688652|NCT05344638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688653|NCT04048811|RANDOMIZED|PARALLEL||TREATMENT||NONE|Upon enrollment of the 40 subjects, 6 more subjects will be enrolled by West China Hospital of Sichuan University. These 6 subjects will not be randomized, but will directly enter into propofol induction + HSK3486 maintenance group for study.|||||
33688654|NCT05697120|||COHORT||PROSPECTIVE|||||||
33992346|NCT04013802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992347|NCT04931342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992348|NCT06046430|||COHORT||PROSPECTIVE|||||||
33992349|NCT05685498|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33992350|NCT04086108|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||For the study, research subjects will visit the university on four test days separated by a wash out period of one week.||||
33992351|NCT05479643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33992352|NCT00835692|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992353|NCT01553214|NA|SINGLE_GROUP||OTHER||NONE||||||
33992354|NCT02207894|||COHORT||PROSPECTIVE|||||||
33992355|NCT03869892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992356|NCT05159700|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1, open label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024.||||
33992357|NCT05194982|NA|SEQUENTIAL||TREATMENT||NONE||||||
33992358|NCT05945290|||COHORT||PROSPECTIVE|||||||
33992359|NCT06685445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Continous Erector Spinae Block (Group ESPB) group, and Serratus Anterior Plane Block + Continous Erector Spinae Block (Group ESPB+SAPB) group|t|f|f|t
34084604|NCT00488397|||COHORT||PROSPECTIVE|||||||
33688655|NCT04577352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910184|NCT02434627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688656|NCT02385188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688657|NCT02609698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688658|NCT01408329|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33688659|NCT00710437|||CASE_CONTROL||RETROSPECTIVE|||||||
33910185|NCT01395095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910186|NCT02241395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910187|NCT01868178|||CASE_ONLY||PROSPECTIVE|||||||
33910188|NCT05414708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910189|NCT05556733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will receive FMT while the control group will not receive FMT.||||
33910190|NCT06199440|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33910191|NCT03192982|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective study||||
33910192|NCT05304182|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"There are two identical arms in this study: pre-operative and post-operative. Every participant starts in the pre-operative arm and crosses over to the post-operative arm. During both arms, each study subject undergoes the experimental intervention and the control intervention.~The study objective is to assess the clinical performance of the investigational device. This assessment is performed by a statistical analysis of the measurement results from the experimental intervention and the control intervention. The surgery is not a study intervention."||||
33910193|NCT02335216|||COHORT||PROSPECTIVE|||||||
33910194|NCT00551824|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34024963|NCT03443271|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients will be randomly allocated in equal groups of 25 each to undergo TAP block (T group) with 20ml of 0.25% bupivacaine per side or TAP block with 20 ml of normal saline on both sides, which will be the control group (C group). The allocation sequence will be generated by a random number table, and group allocation will be concealed in sealed, opaque envelopes, which will not be opened until patient consent will be obtained. The process of randomization and blinding will be done by the clinical trial unit and according to the group allocation; pre-formed sterile syringes will be dispensed by the clinical trial unit to anesthesiologist performing the TAP block. The anesthesiologist performing the TAP block, patients and staff providing postoperative care will be blinded to group assignment.|Prospective double blind randomized control trial|t|f|t|t
34024964|NCT00763061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024965|NCT03558061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084605|NCT04434508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Enrolled patients in the study were randomized to either laparoscopic or open right hemicolectomy with CME and central vascular ligation. The randomization process was performed using a closed envelope method which was withdrawn in the outpatient clinic by a nurse.|Enrolled patients in the study were randomized to either laparoscopic or open right hemicolectomy with CME and central vascular ligation. The randomization process was performed using a closed envelope method which was withdrawn in the outpatient clinic by a nurse.|t|f|f|f
33688660|NCT02410733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688661|NCT04549974|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688662|NCT05538819|||COHORT||PROSPECTIVE|||||||
33688663|NCT05765656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Non applicable|Pragmatic cluster-randomized controlled trial||||
33688664|NCT01575288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688665|NCT03231982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688666|NCT03152422|||COHORT||RETROSPECTIVE|||||||
33688667|NCT02759978|||COHORT||PROSPECTIVE|||||||
33688668|NCT01739400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688669|NCT05967897|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33688670|NCT00254774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688671|NCT01725412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688672|NCT04539587|||OTHER||PROSPECTIVE|||||||
33688673|NCT06287567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688674|NCT01624870|||COHORT||PROSPECTIVE|||||||
33688675|NCT03612856|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688676|NCT05263947|NA|SINGLE_GROUP||TREATMENT||NONE||This is a treatment group. Patients with EGFR L858R mutation will be assigned to treatment group.The study includes the following stratification factors : sex (female/male), disease stage (stage IIIb vs. stage IV), and brain metastasis (yes vs. no).||||
33688677|NCT05742347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33688678|NCT04414332|||COHORT||PROSPECTIVE|||||||
33688679|NCT01706679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688680|NCT04895540|||CASE_CONTROL||PROSPECTIVE|||||||
34084606|NCT04369417|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33688681|NCT05436366|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm||||
33688682|NCT05982431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688683|NCT03487679|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084607|NCT02239211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688684|NCT00660283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688685|NCT05908318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this study, different researchers will be responsible for randomization, olfactory training, anesthesia and visit. Due to the peroperative olfactory training in the olfactory training group, it is impossible to blind the participant and researchers implementing olfactory training.A researcher is responsible for assigning random numbers to ensure the randomness of the study groups. In order to ensure that the whole study is not affected by subjective factors, the researchers implementing and visiting are blinded, who do not know the anesthesia grouping, and are responsible for anesthsia, case enrollment screening, signing informed consent, preoperative and postoperative delirium evaluation, postoperative pain evaluation, complications and safety evaluation.|Recruited patients will be randomly divided into control group and olfactory training group.The olfactory training group was performed 24-48h before surgery used phenylethyl alcohol (rose), phytol (press tree), citronella (lemon), eugenol (clove) 4 kinds of smell，twice a day for three days.|f|f|f|t
34084608|NCT05773742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084609|NCT00004921|RANDOMIZED|||TREATMENT||||||||
34084610|NCT01459926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084611|NCT06032728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910195|NCT04548089|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"Upon referrals made by the collaborating institutions and other community dementia-care organizations, consenting caregivers will be allocated to either the immediate treatment group or wait-list control group. Baseline assessment \[T1\] is conducted through face-to-face interviews, or self-administered questionnaires, facilitated by the research team.~Participants assigned to the treatment group will then attend a 4-week MCAT-DC programme conducted jointly by an experienced mindfulness practitioner and a credentialed art therapist or artist. Thereafter, immediate post intervention assessment \[T2\] will be carried out, with follow-up assessments at 4 weeks \[T3\], 3-months \[T4\] and 6-month \[T5\]. Participants assigned to the wait-list control group will be assessed at second baseline \[T2\], thereafter, attend a 4-week MCAT-DC programme, followed by an immediate post intervention assessment \[T3\], as well as follow-up assessments at 3-months \[T4\] and 6-months \[T5\]."||||
33992360|NCT03605342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To fully assess and appreciate complex symptomatology in this patient population, assessments were selected to have both relevance to the investigators' study of PTSD and comorbid OUD. Assessments will be done by an Independent Evaluator (IE) blind to treatment group.|This study is a 14-week, open-label randomization: 1) buprenorphine (BUP) + CPT-C vs (2) BUP + IDC. Phase I: buprenorphine induction and stabilization for all participants. Participants starting dose 2mg/0.5 mg BUP/NLX this will increase as needed up to 24 mg per day. Phase II: randomization to CPT vs. IDC (x12 weeks). Phase III: Subjects will be referred to one of the buprenorphine clinics and will be referred for ongoing treatment for PTSD if they choose, including the option for CPT-C for those who did not receive this during the study. Participants will be seen on a daily basis (excluding weekends) for the initial 5-7 day induction. Once subjects are on maintenance dose of BUP/NLX, they will be seen weekly by study Registered Nurse (RN) for the first 4 weeks, biweekly for a month then monthly for symptom evaluation, and medication refill.|f|f|f|t
33992361|NCT02077894|||CASE_CONTROL||OTHER|||||||
33992362|NCT04334941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992363|NCT06217822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992364|NCT06563336|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Outcome measurements were performed at baseline and immediately after 12 weeks rehabilitation. The outcome measurements and data analyses were performed by a trained and blinded outcome assessor who was not involved in the intervention.||f|f|f|t
33992365|NCT02422875|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992366|NCT00001355|||COHORT||PROSPECTIVE|||||||
33992367|NCT05260957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992368|NCT02760927|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33992369|NCT04717349|||COHORT||PROSPECTIVE|||||||
33992370|NCT06462196|||COHORT||PROSPECTIVE|||||||
33992371|NCT06429007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992372|NCT06042738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||two groups with full (simple) randomization|t|f|t|f
33910196|NCT01333267|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33910197|NCT05022771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910198|NCT03359005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910199|NCT03352414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910200|NCT04341597|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33910201|NCT06428643|NA|SINGLE_GROUP||SCREENING||NONE|None (Open Label)|Community based screening of young men for chlamydia, gonorrhea, HIV, and syphilis. Expedited treatment for positive subjects and their sexual partners.||||
33910202|NCT03834129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910203|NCT04118686|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A prospective, double-blind, randomized, parallel, controlled study|t|f|t|f
33910204|NCT02488551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33910205|NCT05927727|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33910206|NCT03779425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910207|NCT00366730|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33910208|NCT01921257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33910209|NCT03027804|||OTHER||OTHER|||||||
33910210|NCT03797040||SEQUENTIAL||TREATMENT||NONE||||||
33992373|NCT06508710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992374|NCT06211244|||COHORT||CROSS_SECTIONAL|||||||
33992375|NCT02993159|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33992376|NCT00455312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992377|NCT05286229|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992378|NCT06321016|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33992379|NCT01010503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992380|NCT05138250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992381|NCT02595944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992382|NCT01815320|NA|SINGLE_GROUP||||NONE||||||
33992383|NCT05292365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||eligible caregiver/child dyads are randomized to intervention or active control||||
33992384|NCT06335082|||COHORT||PROSPECTIVE|||||||
33910211|NCT00043875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33910212|NCT00536978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910213|NCT04972032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910214|NCT04129684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910215|NCT01536977|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33910216|NCT00580177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910217|NCT04477824|||COHORT||PROSPECTIVE|||||||
33778128|NCT04619680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* Patients will be assigned to nintedanib or placebo by random chance in a 1:1 allocation. There is 50% chance to receive the study drug and a 50% chance to receive the placebo.~* Randomization will be stratified by site and subgroup (fibrotic and non-fibrotic) to ensure treatment balance. I.e., within the fibrotic subgroup, the randomization will ensure 50% are assigned to the nintedanib arm and 50% are assigned to the placebo arm. Similarly, treatment balance within the non-fibrotic subgroup will be ensured.~* The study will be double blinded. No one (including the patient or the study team) will know who is receiving the study drug or the placebo. If it becomes urgently necessary for a patient's care, the study doctor will be able to find out whether the patient is taking the placebo or the study drug, nintedanib.~* Patients will be told whether they received the study drug, nintedanib, or the placebo once the study is finished."||t|t|t|f
33778129|NCT05357807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778130|NCT00004108||||TREATMENT||||||||
33778131|NCT05470062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778132|NCT04463953|NA|SINGLE_GROUP||TREATMENT||NONE||Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15.||||
33778133|NCT03172117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778134|NCT03477942|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, single-center phase I pilot study to evaluate the safety and tolerability of a single intra-articular injection of autologous bone marrow-derived MSCs in 16 subjects, 8 who have knee osteoarthritis and 8 who have a focal chondral defect in the knee.|t|f|f|f
33778135|NCT02203097|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33778136|NCT00037999|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33778137|NCT05821413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778138|NCT04108689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778139|NCT01755689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778140|NCT00590993|||COHORT||PROSPECTIVE|||||||
33778141|NCT05414721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Sixty patients were included in the study. The patients were randomly divided into two groups as low flow anesthesia and normal flow anesthesia. All patients were preoxygenated. Midazolam, fentanyl, propofol and rocuronium were administered iv for induction of anesthesia. After intubation all patients were mechanically ventilated with 50%O2+50% air+7% desflurane in a 4L/min fresh gas flow until the MAC value reached to 1.~When the MAC value of desflurane was 1, the fresh gas flow was reduced to 0.5L/min (60%O2+40%air) in GroupD.~In GroupN, the fresh gas flow was reduced to 2L/min (40%O2+60% air). The anesthesia was maintained in these fresh gas flows. HR, SBP, DBP, MBP, SpO2 and BIS values were recorded preanesthesia and during surgery. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route."|f|f|t|f
33778142|NCT01246648|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33778143|NCT01461616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778144|NCT01398761|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33778145|NCT02366585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778146|NCT04789200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778147|NCT05969106|||CASE_CONTROL||PROSPECTIVE|||||||
33778148|NCT03407040|||COHORT||RETROSPECTIVE|||||||
33778149|NCT03219437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910218|NCT00540436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910219|NCT02708043|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33910220|NCT02088684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910221|NCT01936285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910222|NCT01599754|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910223|NCT02683915|||CASE_CONTROL||PROSPECTIVE|||||||
33910224|NCT01550718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910225|NCT01876732|NA|SINGLE_GROUP||||NONE||||||
33910226|NCT06086639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910227|NCT03591679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910228|NCT02280967|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|||||
33992385|NCT05187923|||COHORT||OTHER|||||||
33992386|NCT04189926|||COHORT||PROSPECTIVE|||||||
33992387|NCT01619241|||CASE_ONLY||PROSPECTIVE|||||||
33992388|NCT05373615|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33992389|NCT05706909|||CASE_ONLY||PROSPECTIVE|||||||
33910229|NCT04574284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992390|NCT01030328|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33992391|NCT03649633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, Care Provider, Investigator, Outcomes Assessor|Single-center, prospective, randomized, doubleblind, placebo-controlled, parallel-group clinical trial.|t|t|t|t
33992392|NCT00342654|||COHORT||OTHER|||||||
33688686|NCT05715879|||CASE_CONTROL||PROSPECTIVE|||||||
33688687|NCT04308473|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Group 1 = Ultra-Processed Food Meal + Antibiotics to suppress gut flora; Group 2 = Ultra-Processed Food Meal with No Antibiotics; Group 3 = Whole Food Meal + Antibiotics to suppress gut flora; Group 4 = Whole Food Meal with No Antibiotics||||
33688688|NCT00192686|||||RETROSPECTIVE|||||||
33688689|NCT00586326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688690|NCT04173364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688691|NCT05034445|||COHORT||PROSPECTIVE|||||||
33688692|NCT05196178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688693|NCT04564885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will not be told their treatment group prior to surgery||t|f|f|f
33992393|NCT04747535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33992394|NCT00051857|||COHORT||PROSPECTIVE|||||||
33992395|NCT04902352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sealed envelope system for allocation of intervention Master list held by third party, researcher and surgical team aware of intervention Intervention NOT documented in notes making clinical follow up team, investigator and outcomes assessor blind to arm allocated|Randomised Control Trial|t|f|t|t
33992396|NCT06661044|||OTHER||OTHER|||||||
33992397|NCT01272037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992398|NCT00287131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992399|NCT06074328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33688694|NCT00390234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688695|NCT01507454|||COHORT||PROSPECTIVE|||||||
33688696|NCT03490162|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33688697|NCT00521001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778150|NCT00157586|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33910230|NCT02910180|||OTHER||PROSPECTIVE|||||||
33910231|NCT03929588|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||All enrolled subjects will have measurements with the phoropter, autorefractor and handheld device plus mobile app.|t|f|f|t
33910232|NCT06182072|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study includes a dose escalation arm, followed by an expansion arm at the ideal dose for participants with previously untreated advanced Pancreatic ductal adenocarcinoma (PDAC).||||
33910233|NCT02026843|||CASE_CONTROL||PROSPECTIVE|||||||
33910234|NCT04332640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910235|NCT03566693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992400|NCT03410784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992401|NCT00024804|||CASE_ONLY||PROSPECTIVE|||||||
33992402|NCT04170894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084612|NCT03865823|||COHORT||PROSPECTIVE|||||||
33778151|NCT06334536|||OTHER||CROSS_SECTIONAL|||||||
33778152|NCT00997243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910236|NCT02266901|||COHORT||RETROSPECTIVE|||||||
33910237|NCT04632095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910238|NCT04095988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910239|NCT03165591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910240|NCT05276713|||COHORT||RETROSPECTIVE|||||||
33910241|NCT00748059|NA|SINGLE_GROUP||SCREENING||NONE||||||
33992403|NCT02476045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992404|NCT03668041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688698|NCT02771587|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33688699|NCT02301988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688700|NCT01424202|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33778153|NCT06042985|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"All the patients will be used in a cross-over study design. The same patient will be using study drugs A or B and switching in the study to the other drug.~7 days period will be applied for any wash-out or possible carry-over effect."|In a double-blind-randomization procedure, surgeons, the research team, the laboratory, and the statistical analysis team will be blinded; the patient has no influence and not necessary to be blind.|t|f|f|f
33778154|NCT02207361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778155|NCT03112122|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, controlled, three-arm, double-blind study||||
33778156|NCT04420689|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This is a Phase 1/Phase 2 study in patients undergoing Head \& Neck Surgery.||||
33778157|NCT01454856|||COHORT||PROSPECTIVE|||||||
33778158|NCT02259920|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778159|NCT01725997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778160|NCT03914339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778161|NCT04055896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The study will be an adaptive trial design with two phase.~* Phase 1 will be an internal pilot to allow for refinement.~* Phase 2 will be a larger randomized controlled trial after Phase 1 refinement"|f|t|f|t
33910242|NCT00369668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910243|NCT02618928|||COHORT||PROSPECTIVE|||||||
33910244|NCT01614769|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33910245|NCT02567344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33910246|NCT06294652|||OTHER||OTHER|||||||
33910247|NCT01912729|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910248|NCT00025532||||TREATMENT||||||||
33910249|NCT01721408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910250|NCT03136757|||COHORT||RETROSPECTIVE|||||||
33910251|NCT03121222|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Double blind crossover design||t|f|f|f
33910252|NCT05397886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910253|NCT02311855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910254|NCT06110793|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ib/II open label study||||
33910255|NCT01742624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910256|NCT05747131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910257|NCT03152916|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33910258|NCT02165657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910259|NCT03071224|NA|SINGLE_GROUP||OTHER||NONE||||||
33910260|NCT04261387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910261|NCT00277316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910262|NCT04659226|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910263|NCT00122005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910264|NCT04148924|||OTHER||PROSPECTIVE|||||||
33910265|NCT05158595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910266|NCT01662297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910267|NCT05128253|||COHORT||CROSS_SECTIONAL|||||||
33910268|NCT04051021|RANDOMIZED|PARALLEL||TREATMENT||NONE|Research assistants consenting patients and collecting and analyzing data will be blinded to the allocation.|||||
33910269|NCT05127096|||CASE_CONTROL||PROSPECTIVE|||||||
33910270|NCT01009801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910271|NCT03899194|RANDOMIZED|PARALLEL||TREATMENT||NONE||group 1: escitalopram group 2: escitalopram + Omega-3 PUFAs||||
33910272|NCT02477085|||COHORT||PROSPECTIVE|||||||
33910273|NCT06355336|||COHORT||PROSPECTIVE|||||||
33910274|NCT02577250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910275|NCT04629989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33910276|NCT03213626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910277|NCT03566524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33910278|NCT06515327|||COHORT||PROSPECTIVE|||||||
33910279|NCT05195333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which group to belong to.||t|f|f|f
33992405|NCT00444353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33992406|NCT04049760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688701|NCT04814901|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arms parallel group of patients will be assigned to this trial: The trial will be in superiority in an allocation of 1:1 ratio.||||
33778162|NCT04857450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All participants including care provider and outcome assessors will unaware of group allocation.|"Sixty adult cardiac patients, older than 18 with ASA II or III physical status who underwent upper endoscopy together with colonoscopy for management of acute anemia in the cardiac intensive care units from November 2020 - October 2021. They were randomly divided into two groups. All patients received 0.05 mg/kg midazolam and 1µg/kg fentanyl slow IV as basal sedation and analgesia, then :~Group (E): Received Etomidate 0.1 mg/kg IV over 20-30 seconds, followed by 0.05 mg/kg IV and repeated when needed, and Group (KE): Received Ketamine 0.5 mg/kg IV over 20-30 seconds followed by Etomidate 0.05 mg/kg IV over 20-30 seconds and repeated when needed."|t|t|f|t
33688702|NCT01108471|||COHORT||PROSPECTIVE|||||||
33688703|NCT04779931|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34084613|NCT01231217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688704|NCT06329089|||COHORT||PROSPECTIVE|||||||
33688705|NCT04490031|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Both the patients and surgeon will be blinded from knowing the sedative agent||t|t|f|f
33688706|NCT00008554||PARALLEL||TREATMENT||||||||
33688707|NCT01304784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688708|NCT04526990|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688709|NCT04910373|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33688710|NCT02916238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688711|NCT03000127|NA|SINGLE_GROUP||TREATMENT||NONE|All patients will receive either testosterone or placebo at some phase of treatment, but which phase will be testosterone and which will be placebo will be unknown (blinded) to participant, care provider, and outcomes assessor.|Single arm, testosterone or placebo will be administered to all patients at some period of study, but which period of study the they will recieve placebo or testosterone gel will be blinded (unknown) to participant, care provider, and outcomes assessor.||||
33688712|NCT00291733|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33688713|NCT06184308|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33778163|NCT00345462|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33778164|NCT03952065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778165|NCT05843630|||COHORT||RETROSPECTIVE|||||||
33778166|NCT03497182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778167|NCT00906503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688714|NCT00238537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688715|NCT02728778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688716|NCT05982210|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33688717|NCT04870736|||CASE_CROSSOVER||PROSPECTIVE|||||||
33688718|NCT04914416|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33688719|NCT01858584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688720|NCT04741178|||COHORT||OTHER|||||||
33688721|NCT04529473|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688722|NCT00083096||||TREATMENT||NONE||||||
33688723|NCT02355600|||COHORT||PROSPECTIVE|||||||
33778168|NCT01293162|||CASE_CONTROL||PROSPECTIVE|||||||
33778169|NCT05790239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized study. Participants will be 1:1 randomized to receive either MDMA or d-amphetamine. Stratified randomization will be used, with gender as the stratification variable. Within each of the two strata, the investigators use permuted randomized blocks with a block size of 4.|t|t|t|f
33778170|NCT02885532|||COHORT||PROSPECTIVE|||||||
33910280|NCT06355557|RANDOMIZED|PARALLEL||OTHER||DOUBLE||3-arm prospective randomised controlled trial.|f|f|t|t
33910281|NCT00819624|RANDOMIZED|CROSSOVER||||NONE||||||
33910282|NCT06363448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910283|NCT01835496|NA|SINGLE_GROUP||||NONE||||||
33910284|NCT06693752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910285|NCT01180413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910286|NCT00940342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910287|NCT02767141|||CASE_ONLY||CROSS_SECTIONAL|||||||
33910288|NCT02858609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910289|NCT04137133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910290|NCT04341675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randmized, double blind, placebo controlled|t|t|t|t
33910291|NCT00506077|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33910292|NCT02946775|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33910293|NCT01815333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910294|NCT01661400|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33910295|NCT01957826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910296|NCT03575520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910297|NCT04023513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33910298|NCT02426658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910299|NCT02516800|||OTHER||CROSS_SECTIONAL|||||||
34084614|NCT02631941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084615|NCT02789371|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34084616|NCT02433990|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34084617|NCT06228404|NA|SEQUENTIAL||TREATMENT||NONE||A：0.25×106/kgBW B: 0.75×106/kgBW C: 2×106/kgBW||||
34084618|NCT02808988|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34084619|NCT01872962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084620|NCT00681200|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34084621|NCT06378177|NA|SEQUENTIAL||TREATMENT||NONE||This is a multicenter, open-labeled, single-arm Phase 2 clinical study.This study comprises two parts. Part 1 (Safety Run-in Phase) is designed to confirm the dose of combination therapy in Part 2.||||
33688724|NCT03373799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688725|NCT05395273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688726|NCT06400927|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33688727|NCT04308005|||OTHER||CROSS_SECTIONAL|||||||
33688728|NCT04608994|||COHORT||PROSPECTIVE|||||||
33910300|NCT01515982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33910301|NCT05322863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33910302|NCT00988559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910303|NCT01252043|||CASE_CONTROL||RETROSPECTIVE|||||||
33910304|NCT04798885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910305|NCT01655823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910306|NCT01402284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910307|NCT05380297|NA|PARALLEL||DIAGNOSTIC||NONE||||||
33910308|NCT02932475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910309|NCT03302793|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33910310|NCT03541512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33910311|NCT03215264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Standard 3+3 design to determine the maximum tolerated dose||||
33910312|NCT00186745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910313|NCT02848690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084622|NCT02825823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34084623|NCT01592214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084624|NCT00356018|||OTHER||PROSPECTIVE|||||||
33688729|NCT01076075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688730|NCT01187719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688731|NCT00442468|||||PROSPECTIVE|||||||
33688732|NCT06387160|||COHORT||PROSPECTIVE|||||||
33688733|NCT02312882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688734|NCT00423696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910314|NCT04153006|||COHORT||RETROSPECTIVE|||||||
33910315|NCT03502213|||CASE_ONLY||PROSPECTIVE|||||||
33910316|NCT00347711|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33688735|NCT05868720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33688736|NCT04431427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688737|NCT02448680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688738|NCT02847468|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688739|NCT02151136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688740|NCT00412269|||COHORT||PROSPECTIVE|||||||
33688741|NCT03730454|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multisite randomized control trial.||||
33688742|NCT03565471|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084625|NCT02126176|||CASE_ONLY||PROSPECTIVE|||||||
34084626|NCT02643277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34084627|NCT01414179|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33688743|NCT06523517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688744|NCT05644249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688745|NCT03157323|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33688746|NCT00761748|RANDOMIZED|CROSSOVER||||NONE||||||
33688747|NCT02474888|||COHORT||PROSPECTIVE|||||||
33688748|NCT03484260|||CASE_CONTROL||RETROSPECTIVE|||||||
33688749|NCT00912665|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688750|NCT03986632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33688751|NCT03335917|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized,Counter Balanced, Repeated Measures, Crossover||||
33688752|NCT00004017||||TREATMENT||||||||
33688753|NCT03013127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688754|NCT01392482|||COHORT||RETROSPECTIVE|||||||
33778171|NCT02143674|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084628|NCT05928923|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778172|NCT03255941|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Women who are new users of injectable contraception will be randomly assigned to receive services from an LHW or an FWW and will be randomly assigned to receive either intramuscular DMPA or the subcutaneous formulation, Sayana Press.||||
33778173|NCT03083743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778174|NCT00922844|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33778175|NCT04374929|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33778176|NCT04075981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is a double-blind multicenter randomized trial comparing treatment with botulinum toxin to normal saline (placebo) on top of usual treatment to prevent atrial fibrillation in patients undergoing cardiac surgery (coronary artery bypass graft surgery (CABG), aortic valve surgery, or ascending aorta surgery).|t|t|t|f
33778177|NCT04267653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778178|NCT00002735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778179|NCT06347471|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778180|NCT01672983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778181|NCT05108727|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33778182|NCT01289704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778183|NCT03693820|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|the infiltration cocktail of local anesthetic will be replaced by saline in the same volume.||t|t|t|t
33778184|NCT05504174|||CASE_CONTROL||PROSPECTIVE|||||||
33778185|NCT02887950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778186|NCT05651880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778187|NCT02945774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778188|NCT03433092|||OTHER||RETROSPECTIVE|||||||
33778189|NCT01719861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778190|NCT00341640||||TREATMENT||||||||
33778191|NCT01536353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778192|NCT03985852|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33778193|NCT03084952|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33778194|NCT02492061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778195|NCT02720887|||COHORT||PROSPECTIVE|||||||
33778196|NCT01049750|||COHORT||CROSS_SECTIONAL|||||||
33778197|NCT04710355|||COHORT||PROSPECTIVE|||||||
33778198|NCT01023737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778199|NCT04124822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is a double blinded study in which investigator /caregiver and participant will be blinded and 3rd person not in the study will be dispatching drugs from the coded bottles .|subjects are randomly placed into one of the three groups: Placebo, Piroxicam (20 mg), Prednisolone (20 mg). The drugs will be given thirty minutes before procedure starts,followed by one visit root canal procedure. Postoperative pain will be evaluated up to 96 hours interval using a visual analog scale.|t|t|t|f
33778200|NCT06283082|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33839942|NCT03840005|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"This is a double-blind trial. The investigators, clinical study team, participants and analysing statistician will be blind to treatment allocation. The active treatment will be over-encapsulated and a matched placebo manufactured to maintain the blind.~The Independent Data Monitoring Committee (IDMC) is the only oversight body that has access to unblinded accumulating comparative data."|A randomised double-blind, placebo controlled 48 week trial of UDCA at a daily dose of 30 mg/kg in patients with early Parkinson's disease \<3 years post diagnosis.|t|f|t|t
33839943|NCT05756712|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33839944|NCT05504850|NA|SINGLE_GROUP||OTHER||NONE||||||
33910317|NCT00719576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910318|NCT00606762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34084629|NCT04693403|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stepped wedge cluster randomised trial (8 Clusters).||||
34084630|NCT01868646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34084631|NCT05429840|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Part 1: Open Label Part 2: Blinded||t|f|t|t
34084632|NCT05748899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839945|NCT04278027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Study Procedure. 60 patients with schizophrenia disorder (according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classification, determined by The Structured Clinical Interview for DSM-5 (SCID-5) interview will be recruited and randomly allocated in one of the two groups: CRT or treatment as usual control group. All participants will undergo neurocognitive testing over a 2-week period, followed by a blood draw. After random allocation, 40 participants will follow a computerized cognitive remediation program and 20 will be followed a similar period of time without any cognitive intervention. Subjects will have another blood sample drawn after completion of the cognitive therapy or the TAU. All subjects should remain on stable doses of medications while in the study (no dose change \> 10%). Finally, subjects will be reassessed on PANSS and cognitive measures and social functioning by personnel blind to group assignment.|f|f|t|t
33839946|NCT05946720|RANDOMIZED|PARALLEL||OTHER||DOUBLE||pre- post test, training and control group, randomise controlled trial|t|f|f|t
33839947|NCT02345590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839948|NCT05232747|||OTHER||CROSS_SECTIONAL|||||||
33839949|NCT00455221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839950|NCT05774288|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority randomized controlled clinical trial||||
33839951|NCT00567567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839952|NCT01606670|||COHORT||PROSPECTIVE|||||||
33839953|NCT03219957|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33839954|NCT06236633|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the type of intervention and the design of the study, the patient and the referring caregivers cannot be blinded.|Pilot exploratory descriptive prospective bicentric study to evaluate the safety and efficacy of an innovative procedure: inferior mesenteric artery embolization prior to rectal cancer surgery involving 2 groups: one with standard treatment and the other with inferior mesenteric artery embolization.||||
33839955|NCT04221672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839956|NCT03873168|||COHORT||PROSPECTIVE|||||||
33910319|NCT05337813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Only one arm for each disease (LiESWT group)||||
33910320|NCT01986569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910321|NCT05839431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910322|NCT03229915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: PTSD patients Group 2: trauma-exposed control Group 3: no trauma healthy control Group 1 and 2 will undergo CPT.||||
33910323|NCT06693583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be blindly randomly allocation to the control or intervention arm, however due to the nature of the study it will not be possible to blind the participant or assessor.|||||
33688755|NCT05521776|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33910324|NCT01769690|NA|SINGLE_GROUP||OTHER||DOUBLE|Participant was blinded to the DBS settings during the sleep study but investigator was not; however, the investigator was blinded to the DBS setting during the interpretation of the sleep study.||t|f|t|f
33910325|NCT05387915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910326|NCT05502263|||COHORT||RETROSPECTIVE|||||||
33910327|NCT00243230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There were Double-blind and an Open Label extension period.||t|f|t|t
33910328|NCT05853562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33910329|NCT01516164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688756|NCT05108922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688757|NCT04969367|||OTHER||PROSPECTIVE|||||||
33688758|NCT01361451|||COHORT||PROSPECTIVE|||||||
33688759|NCT05547152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688760|NCT05867342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688761|NCT05337930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839957|NCT00917800|||CASE_ONLY||PROSPECTIVE|||||||
33839958|NCT04127981|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC) or pancreatic cancer without cachexia, and 20 patients with advanced/metastatic colorectal, non-small cell lung cancer (NSCLC), or pancreatic cancer with documented cachexia||||
33910330|NCT05391984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910331|NCT03510832|||COHORT||PROSPECTIVE|||||||
33910332|NCT03808623|||CASE_ONLY||RETROSPECTIVE|||||||
33910333|NCT02619019|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910334|NCT05336526|NA|SINGLE_GROUP||OTHER||NONE||||||
33910335|NCT03699852|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910336|NCT00634244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910337|NCT01661361|||COHORT||PROSPECTIVE|||||||
33910338|NCT02145299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084633|NCT04555603|||COHORT||RETROSPECTIVE|||||||
33910339|NCT00410501|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910340|NCT05392127|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-center, single arm, open-label, fixed sequence, self-control||||
33910341|NCT00466999|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910342|NCT03152136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The first two weeks of the study are double-blinded for the treatment and sham arms. The subjects and rating movement disorder neurologists will be blinded to the therapy allocation for the treatment and sham arms. The subjects in the 'no intervention' arm and their rating neurologists will not be blinded to their therapy allocation.~The last two weeks are open-label, and all subjects will be given the option to use the Cala ONE device."|The first two weeks are a 3-arm parallel design (treatment, sham, and 'no intervention'). The second two weeks are open-label (all subjects cross-over to treatment arm).|t|f|f|t
33910343|NCT03707652|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910344|NCT03965663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910345|NCT05079282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910346|NCT04516018|NA|SINGLE_GROUP||TREATMENT||NONE||a single arm, longitudinal study (10-day intermittent shivering exposure) in a pre-post design||||
33910347|NCT02432287|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33910348|NCT03073655|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33910349|NCT04258111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910350|NCT05131451|RANDOMIZED|PARALLEL||SCREENING||NONE|Participants are masked to the study arms until after randomization|"1. Control Arm - Standard of care referral to an eye care provider + Educational Reinforcement~2. Intervention Arm - Point of Care Diabetic Retinopathy screening using Autonomous artificial intelligence on a non-mydriatic fundus camera"||||
33910351|NCT04150874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910352|NCT05974735|||COHORT||PROSPECTIVE|||||||
33910353|NCT03144141|NA|SINGLE_GROUP||OTHER||NONE||||||
33910354|NCT01825590|||COHORT||RETROSPECTIVE|||||||
33910355|NCT05302739|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33910356|NCT02077075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910357|NCT05569304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910358|NCT03200457|NA|SINGLE_GROUP||OTHER||NONE||||||
33910359|NCT04398719|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33910360|NCT02462304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910361|NCT05433389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910362|NCT04655495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910363|NCT00736710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910364|NCT00926055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910365|NCT01743339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910366|NCT05129813|||CASE_ONLY||PROSPECTIVE|||||||
33910367|NCT04019093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||People with and without jaw pain, including temporomandibular joint and muscle disorder (TMD) will receive an active oral dose of alcohol or placebo in a counterbalanced manner.|t|f|t|f
33910368|NCT00837512|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910369|NCT05047640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33910370|NCT02774226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910371|NCT02351245|||COHORT||RETROSPECTIVE|||||||
33910372|NCT03387904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910373|NCT04420416|||COHORT||CROSS_SECTIONAL|||||||
33910374|NCT06471465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910375|NCT01741272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910376|NCT02636348|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910377|NCT04035135|NA|SINGLE_GROUP||TREATMENT||NONE||Open label combination treatment||||
33910378|NCT00682799|||||PROSPECTIVE|||||||
33910379|NCT00300300|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33910380|NCT04883580|RANDOMIZED|PARALLEL||TREATMENT||NONE||NS100||||
33910381|NCT01327040|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34084634|NCT03508024|||COHORT||RETROSPECTIVE|||||||
34084635|NCT00850876|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34084636|NCT05084391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084637|NCT02899520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084638|NCT06517381|NA|SINGLE_GROUP||OTHER||NONE||||||
33992407|NCT01386437|||COHORT||PROSPECTIVE|||||||
33992408|NCT05071963|||COHORT||PROSPECTIVE|||||||
33992409|NCT06439836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992410|NCT06690411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher who makes the evaluations will not know which treatment the individuals received, in other words, will be blind to the groups.|This study will be a single blind-randomized clinical trial. The researcher who makes the evaluations will not know which treatment the individuals received, in other words, will be blind to the groups.|f|f|f|t
33992411|NCT06615752|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This study includes a dose-escalation study and an expanded phase II study. For the dose-escalation study, patients will be assigned to different dose levels in the order of recruiting. For the expanded phase II study, patients will be randomly assigned to the green tea plus quercetin group receiving green tea + quercetin + docetaxel, or the placebo group receiving placebo + docetaxel.|t|t|t|t
33992412|NCT06067438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992413|NCT00835575|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992414|NCT06308861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992415|NCT05450107|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical intervention trial||||
33992416|NCT01791686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992417|NCT05479448|||COHORT||PROSPECTIVE|||||||
33992418|NCT06376331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992419|NCT06119464|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge cluster randomized trial, randomizing the sequence of entry into intervention at a cluster level.||||
33992420|NCT05640765|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084639|NCT06551402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, a specially trained and qualified nurse randomly assigned participants to receive Dabigatran or rivaroxaban. We prepared Sequentially numbered opaque sealed envelopes and 580 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 580. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included dabigatran, and Drug B included rivaroxaban. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We compared the efficacy and safety of a Dabigatran 150 mg Bid administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban once daily were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications|f|f|t|t
34084640|NCT04422067|||CASE_CONTROL||RETROSPECTIVE|||||||
34084641|NCT03553147|NA|SINGLE_GROUP||SCREENING||NONE|No masking|||||
34084642|NCT03210740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084643|NCT05263193|||CASE_CONTROL||RETROSPECTIVE|||||||
34084644|NCT04881643|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility and pilot study using within-group design. 20 patients will be included and 4 therapists. Semi-structured interviews will be conducted after treatment with a selection of therapists and patients with questions regarding the helpfulness and feasibility of the treatment. Effects of treatment patients estimate forms regarding PTSD, depression, anxiety, sleep, quality of life, function and patient satisfaction / acceptance. Measurements are performed before, during, immediately after and 6 months after treatment.||||
34084645|NCT02411643|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084646|NCT00587067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084647|NCT01860859|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34084648|NCT05802433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are not informed of their genetic variations until completion of the trial|Participants are grouped based on their genetic risk of vitamin D deficiency, all participants are given 10µg vitamin D supplements for 90 days|t|f|f|f
34084649|NCT06249230|||COHORT||RETROSPECTIVE|||||||
34084650|NCT03748329|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|The transducer will remain in place during the performance of the block but the monitor will be above the head of the patient in the 12 o'clock position so as to not be in direct view.|Split mouth study|t|f|f|f
34084651|NCT05675163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||3 way crossover trial for evaluating the effect on oxidative stress markers. The first study period, is also used as a parallel study for studying the effect on immune markers.|t|f|t|t
34084652|NCT02256098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910382|NCT01918098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910383|NCT01406210|||CASE_ONLY|||||||||
33910384|NCT00284895|||||PROSPECTIVE|||||||
33910385|NCT05745896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Adequate masking will be tentatively done by ensuring the allocation concealment, mitigating possibilities of masking violations by outcomes assessors. In addition, an electronic case report form system will be used in a de-identified manner. Only study's chairs will have access to codes. Finally, interim and final analysis will be done in the same manner after dataset locking.|A superiority randomized clinical trial (RCT), comparing usual care against telemedicine prenatal care. The allocation ratio is a proportion of 1:1 and the maximum follow-up will last 41 weeks (6 weeks pregnancy to 6 week postpartum).|f|f|f|t
33910386|NCT04115033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, sham placebo-controlled|Cranial electrical stimulation (CES) using a FDA-approved device that uses earclip electrodes to deliver current through the earlobe. The stimulator is meant to stimulate branches of the cranial nerves via the external ear.|t|t|t|t
33910387|NCT02532361|||COHORT||RETROSPECTIVE|||||||
33910388|NCT00441558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910389|NCT02754934|||||CROSS_SECTIONAL|||||||
33910390|NCT05951998|||CASE_CONTROL||PROSPECTIVE|||||||
33992421|NCT06136546|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All treatment teams, outcome assessors, and data analysts will be blind to randomization assignment until the primary study results have been analyzed.|A permuted block design (n=4) on a 1:1 allocation will be used to assign participants to each intervention group.|t|f|t|t
33992422|NCT02849496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992423|NCT05470348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688762|NCT03247803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each study subject will be blinded to the study device they receive; however, the anesthesia provider will not be blinded to the study device and will have access to all monitors deemed appropriate by the primary anesthesia team caring for the subject.|Adult patients presenting for a surgical or interventional procedure requiring general anesthesia and tracheal intubation, who do not meet any of the study exclusion criteria, and who give their informed consent, will be randomly allocated to receive either an air-Q SP or Williams Intubating Airway as a conduit to aid flexible bronchoscopic intubation.|t|f|f|t
33910391|NCT05678413|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.||||
33910392|NCT04126967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688763|NCT02360605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910393|NCT01300611|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33688764|NCT00076024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688765|NCT02225392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33688766|NCT00476801|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33688767|NCT05314491|||COHORT||PROSPECTIVE|||||||
33688768|NCT00246415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688769|NCT04756674|||COHORT||PROSPECTIVE|||||||
33688770|NCT02710500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33910394|NCT05918874|||CASE_CONTROL||PROSPECTIVE|||||||
33910395|NCT03771508|||CASE_ONLY||PROSPECTIVE|||||||
33910396|NCT04523844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who will measure the IOP will be masked to group assignment.||f|f|t|f
33910397|NCT04263337|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33910398|NCT02380430|||||PROSPECTIVE|||||||
33992424|NCT01434953|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33992425|NCT06346483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992426|NCT04387552|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33992427|NCT06685835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992428|NCT04229225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688771|NCT02216825|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33688772|NCT00640835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688773|NCT00814125|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33688774|NCT04195737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups were made one test and control. The test group will be treated with coronally advanced flap with ossix volumax™ collagen matrix and control group will be treated with coronally advanced flap with Sub epitheial Connective Tissue Graft.|f|f|f|t
33688775|NCT02552615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688776|NCT02889276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33688777|NCT06011031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|all selected patients were restored with a complete denture prosthesis and then wer devided using random allocation software into 2 groups|This is a Randomized Clinical Trial (phase IV) as it will compare two types of attachment systems (a new one with an old one), assess the effects of both types, and state which one is better.|f|f|t|f
33688778|NCT00095680|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688779|NCT05983146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688780|NCT01757691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688781|NCT02085915|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688782|NCT03189771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688783|NCT05012787|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33688784|NCT01736332|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33688785|NCT04600310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33688786|NCT02555241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688787|NCT02069418|NA|SINGLE_GROUP||||NONE||||||
33688788|NCT01375478|||COHORT||RETROSPECTIVE|||||||
33688789|NCT00095927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688790|NCT01973738|||CASE_CONTROL||PROSPECTIVE|||||||
33688791|NCT00972855|RANDOMIZED|PARALLEL||||NONE||||||
33688792|NCT04335422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Prospective randomized single blind controlled study|f|f|f|t
33688793|NCT05074173|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33688794|NCT03159702|NA|SINGLE_GROUP||TREATMENT||NONE||Study subjects will receive different doses of Melphalan during the trial. This is done for safety per FDA recommendations. Subjects younger than 60 years or have will receive doses at 140 mg/m\^2/day while subject 60 years or old or have a Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of \>3 will receive 70 mg/m\^2/day. The populations will be combined for analysis and reporting.||||
33688795|NCT02818491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688796|NCT02564432|||COHORT||PROSPECTIVE|||||||
33688797|NCT05222490|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33688798|NCT02766842|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33688799|NCT01797939|||CASE_CONTROL||RETROSPECTIVE|||||||
33992429|NCT04923763|||COHORT||PROSPECTIVE|||||||
33992430|NCT01246258|||CASE_ONLY||CROSS_SECTIONAL|||||||
33992431|NCT02081105|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33992432|NCT04243538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992433|NCT05594693|||COHORT||PROSPECTIVE|||||||
33992434|NCT03656757|||COHORT||PROSPECTIVE|||||||
33992435|NCT01811953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992436|NCT05434364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33992437|NCT06361407|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The group will be masked at the stage of data analysis. It cannot be masked at the prior stages|Individuals with schizophrenia will be tested in parallel with neurotypicals||||
33688800|NCT00272753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33778201|NCT05274776|RANDOMIZED|PARALLEL||TREATMENT||NONE|Hospitals nor physicians are blinded for the assigned study protocol. Since the assigned protocol is considered standard care for newborns with suspected EOS within 0-24 hours after birth during the study period in that hospital, independent of study participation, parents of participants are not blinded as well.|A prospective, cluster-randomized trial will be conducted; five hospitals will be randomized to NVK guidelines use, five hospitals will be randomized to EOS calculator use. After randomization, the assigned protocol is considered standard care for newborns with suspected EOS within 0-24 hours after birth during the study period in that hospital. This means that the NVK guidelines or the EOS calculator (depending on randomization) will be used for all newborns at risk for EOS (within 0-24 hours after birth) in the assigned hospital, independent of study participation. It is noteworthy that attending physicians have the option to choose for clinical management according to another protocol instead of the assigned protocol.||||
33688801|NCT04039035|||CASE_ONLY||PROSPECTIVE|||||||
33688802|NCT04309747|NA|SINGLE_GROUP||TREATMENT||NONE||To evaluate whether the nanosecond knife can achieve the effectiveness and safety of liver cancer ablation treatment.||||
33778202|NCT05574374|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778203|NCT04262154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688803|NCT02910375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778204|NCT01336335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778205|NCT02083640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33778206|NCT05461963|||CASE_CONTROL||PROSPECTIVE|||||||
33778207|NCT02628522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778208|NCT05944367|||COHORT||PROSPECTIVE|||||||
33778209|NCT03799705|||FAMILY_BASED||OTHER|||||||
33778210|NCT04053283|NA|SEQUENTIAL||TREATMENT||NONE||||||
33778211|NCT04328376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778212|NCT01528709|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778213|NCT00526305|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778214|NCT04751513|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will conduct a randomized controlled trial by randomly assigning all participants to either the experimental group receiving auricular acupressure and usual care or the control group only receiving usual care. This study provides an auricular acupressure for eight weeks, and assesses the immediate and carry-over effects. These assessments happen biweekly during the intervention period, two weeks after the intervention period, as well as one month after the end of the chemotherapy course.||||
33778215|NCT03750279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Two laser devices of the same appearance are used, i.e. one with 3x60 mW output power and one with 0 mW output power (sham). Participants in one group is treated with the sham laser device and the other group is treated with laser. The laser beam is invisible for the eye (wavelength 904 nm) and of such low power that heat is not detected. Thus, the participants, therapists and assessors are unaware of which laser device is active/inactive. The laser devices were randomly coded by a secretary who is not otherwise involved in the study.||t|t|t|t
33778216|NCT06529783|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33778217|NCT01804634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778218|NCT05883579|||COHORT||RETROSPECTIVE|||||||
33778219|NCT00372307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778220|NCT05690022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Before/after study design||||
33778221|NCT01700504|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33778222|NCT02772250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33778223|NCT04889781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778224|NCT00787943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778225|NCT02834715|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33778226|NCT06425978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778227|NCT01296529|||COHORT||CROSS_SECTIONAL|||||||
33778228|NCT00260156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778229|NCT02009917|||COHORT||PROSPECTIVE|||||||
33910399|NCT04486443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Participants individually randomised to one of two parallel groups (Özdemir O 2009). It was considered sufficient to select the participants in the intervention and control groups with the similar 3-4 variables including age and gender (Büyüköztürk Ş 2016). Therefore, patients in the intervention and control groups were randomized according to age, gender and disease stage. The coin tossing method was used to determine which group the patients would involve in. All patients continued to use all medications prescribed before, during and after the research, and no interventions and changes were performed to the patients in this regard. Pain scores of all patients were at 3 and above and they received narcotic analgesics. Researcher generated the allocation sequence, enrolled participants, and assigned participants to interventions."|t|f|f|f
33910400|NCT06133647|||COHORT||RETROSPECTIVE|||||||
33910401|NCT04736706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910402|NCT02306187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33688804|NCT02684318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688805|NCT00902161|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33688806|NCT04642183|||COHORT||PROSPECTIVE|||||||
33688807|NCT02284178|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33688808|NCT02237833|||COHORT||PROSPECTIVE|||||||
33910403|NCT02580916|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910404|NCT01766336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910405|NCT00340626|||FAMILY_BASED||PROSPECTIVE|||||||
33910406|NCT04356755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910407|NCT01754922|||||CROSS_SECTIONAL|||||||
33910408|NCT05307822|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910409|NCT02307344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33910410|NCT04645472|||CASE_ONLY||PROSPECTIVE|||||||
33910411|NCT04056364|||CASE_CONTROL||PROSPECTIVE|||||||
33910412|NCT00586924|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33910413|NCT03065712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910414|NCT03960138|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33778230|NCT03136250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, investigator and outcome assessor are not aware of which treatment group the participant/patient is placed in.|A randomized Controlled trial will be conducted in order to find and compare the effectiveness of conventional stretching and MET stretching (autogenic inhibition and reciprocal inhibition). One Control group (conventional group) and two Experimental groups (Experimental Group A - Autogenic Inhibition \& Experimental Group B - Reciprocal Inhibition) will be formed. The participants will be recruited in the study if they meet the inclusion criteria using consecutive sampling from Fauji Foundation Hospital and randomized into the three respective groups. All the groups will receive the gold standard treatment for chronic neck pain including mobilization and modalities. In addition to the gold standard treatment the participants will receive specific stretching protocol based on their interventional group.|t|f|t|t
33688809|NCT00920829|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33688810|NCT06156475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study consisted of patients with subacromial impingement syndrome evaluated by an orthopedist. Patients who met the inclusion criteria were divided into two groups.|t|f|f|f
33778231|NCT02029703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33778232|NCT06698211|||COHORT||PROSPECTIVE|||||||
33778233|NCT01612364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33778234|NCT03966287|||COHORT||RETROSPECTIVE|||||||
33778235|NCT02912195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778236|NCT02153294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778237|NCT04479098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778238|NCT03773055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778239|NCT03674840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment. For each patient one eye was randomly selected as design group and receive a SBL-3 implantation based on angle kappa, while the other eye was included in control group and receive a SBL-3implantation of 0 to 180 degree|t|f|f|f
33688811|NCT00167466|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33688812|NCT05110547|||COHORT||PROSPECTIVE|||||||
33688813|NCT05993182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688814|NCT00054171|RANDOMIZED|||TREATMENT||||||||
33688815|NCT06379425|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33688816|NCT04568343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule will be used. The Endocapsule is 26mm x 11mm in size and 3.3g in weight. It has 160° angle of view with 12 hours of battery life, 2 frame per second sampling rate. One antenna unit will be packed on the patient's waist during examination adjacent to a recorder. \[17\] The CapsoCam Plus capsule is 31mm x 11mm in size and 4g in weight. It has a field of view of 360° with at least 15 hours of battery life, takes 20 images per second maximum, (4 frames per second from each of the four cameras). No other accessories are needed during the procedure.||||
33688817|NCT00500305|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778240|NCT01710293|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33778241|NCT04910906|||CASE_ONLY||PROSPECTIVE|||||||
33778242|NCT04571762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778243|NCT06460012|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Care partners will be randomized into one of two groups. Care partners will be blinded to which group they are in.|Care partners will participate in a self-directed, 8-week online course via the STELLA-R website, followed by 8-weeks of unrestricted access to the website, with 8 weeks of restricted access. One group will receive the 8-week online course followed by the 8-week unrestricted access immediately after enrolling. The other group will receive the 8-week online course and 8-week unrestricted access 2 months after enrolling.|t|f|f|f
33778244|NCT03325335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778245|NCT05218564|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|It is foreseen that the professional (Psychologist other than the one involved in the administration of the tests inherent to the assessment), once the patient has been identified, proposed the study and the readiness to manage the eventual episode of acute respiratory infection, and obtained his consent, will use the results of the above-mentioned system to assign the participant to one of the two groups and therefore to the order of conditions. In this way, the physiotherapist performing the planned treatment, the psychologist involved in administering the psychological assessment and the physician performing the respiratory function tests will be excluded from the randomisation process and blinded to the treatment.||t|t|f|f
33778246|NCT04457479|||COHORT||PROSPECTIVE|||||||
33778247|NCT03567083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778248|NCT03790293|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients included and treated in the RITUXIMAB 3 study (NCT00784589):~* Rituximab in combination with reduced corticosteroids~* Standard corticosteroid"||||
33778249|NCT06418295|||COHORT||PROSPECTIVE|||||||
33778250|NCT06443671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778251|NCT04122053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||eligible volunteers will be randomly assigned to one of the study groups which receive either dietary advice or dietary advice and genotype information|t|f|f|f
33910415|NCT06458140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910416|NCT06052735|NA|SINGLE_GROUP||OTHER||NONE||||||
33910417|NCT00362063|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33910418|NCT06336031|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33910419|NCT04460378|NA|SINGLE_GROUP||TREATMENT||NONE||repeated measure of a single group||||
33910420|NCT03201198|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33910421|NCT04053543|NA|SINGLE_GROUP||TREATMENT||NONE||CXA-10||||
33910422|NCT00403858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910423|NCT05517603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910424|NCT02417870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688818|NCT06159101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688819|NCT05251428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688820|NCT06038474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688821|NCT02818647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688822|NCT02920073|||CASE_CONTROL||PROSPECTIVE|||||||
33688823|NCT01227564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778252|NCT04319094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33778253|NCT05987579|||COHORT||RETROSPECTIVE|||||||
33778254|NCT00519987|NA|SINGLE_GROUP||||NONE||||||
33778255|NCT03808441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992438|NCT00919113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992439|NCT03547271|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Modified double blind for Groups 1 and 2 and open label for Groups 3 and 4 for meningococcal vaccines. Open-label for all concomitant routine vaccines.~Modified double-blind: the participants parent / legally acceptable representative, the Investigator, and other study personnel remain unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator will administer the appropriate vaccines but will not be involved in safety data collection."||t|t|t|t
33992440|NCT05634369|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, unblinded, phase I/II study||||
33992441|NCT04290546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992442|NCT05722184|||OTHER||PROSPECTIVE|||||||
33688824|NCT00000832||||PREVENTION||DOUBLE||||||
33688825|NCT06240507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688826|NCT03865628|||COHORT||PROSPECTIVE|||||||
33688827|NCT00020332||||TREATMENT||||||||
33688828|NCT02217540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688829|NCT03156361|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This is a single center, double blind, active comparator controlled 2-Way crossover multiple dose safety, tolerability and efficacy study.|t|t|t|t
33688830|NCT02631564|||COHORT||PROSPECTIVE|||||||
33688831|NCT03531073|||COHORT||PROSPECTIVE|||||||
33688832|NCT04124718|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33688833|NCT03210987|RANDOMIZED|PARALLEL||OTHER||SINGLE||On the day before the ward round, patients will be randomized 1:1 into one of both study arms. In one study arm, patient case presentation will be performed at bedside. In the other study arm, patient case presentation will be performed outside the room.|f|f|f|t
33688834|NCT04884776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33778256|NCT01720017|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33778257|NCT04422821|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33778258|NCT06581640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778259|NCT04910321|||COHORT||PROSPECTIVE|||||||
33778260|NCT05353569|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778261|NCT05926661|NA|SINGLE_GROUP||OTHER||NONE||||||
33778262|NCT00903773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778263|NCT02078310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33778264|NCT04545619|NA|SINGLE_GROUP||OTHER||NONE||||||
33778265|NCT00147979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778266|NCT02166086|||CASE_ONLY||PROSPECTIVE|||||||
33778267|NCT03729206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778268|NCT02055911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778269|NCT04967248|||COHORT||PROSPECTIVE|||||||
33992443|NCT05628545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992444|NCT05108948|||COHORT||PROSPECTIVE|||||||
33992445|NCT01463423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992446|NCT05450692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992447|NCT06561659|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and investigators will not know the condition assignment until the intervention is about to begin. So the informed consent process, the study eligibility interview, and the self-report measures will be completed prior to condition assignment.|||||
33992448|NCT06730919|||COHORT||RETROSPECTIVE|||||||
33992449|NCT06273124|NA|SINGLE_GROUP||TREATMENT||NONE||Device Extended Wear Infusion Set Each participant will wear each extended wear infusion set for up to 168 hours for 12 sequential wear periods.||||
34024966|NCT05806294|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024967|NCT02933255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024968|NCT05998512|||COHORT||PROSPECTIVE|||||||
34024969|NCT02642848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024970|NCT00096837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024971|NCT04697095|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024972|NCT06338124|||CASE_CONTROL||PROSPECTIVE|||||||
33688835|NCT02060448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688836|NCT02824172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688837|NCT00531674|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33688838|NCT03862040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688839|NCT02091687|||COHORT||OTHER|||||||
33688840|NCT01630785|||CASE_CONTROL||PROSPECTIVE|||||||
33688841|NCT04997590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688842|NCT01954147|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33688843|NCT04708665|||COHORT||PROSPECTIVE|||||||
33688844|NCT00259675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778270|NCT01062984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778271|NCT00436787|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33778272|NCT00524147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33778273|NCT06268353|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Non-pregnant controls and pregnant women||||
33778274|NCT04266743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33778275|NCT02184897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778276|NCT02821390|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33778277|NCT00999661|||COHORT|||||||||
33778278|NCT06129825|||COHORT||PROSPECTIVE|||||||
33778279|NCT05149079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The groups will be randomly labelled A or B. Neither participants, care providers or statistician will know the treatments of the groups before the statistical analyses for the primary outcome have been completed.|Randomized, double blind, placebo controlled clinical study|t|t|f|t
33778280|NCT02092987|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33778281|NCT02414828|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778282|NCT01244009|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778283|NCT03002987|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024973|NCT06588842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910425|NCT00909766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910426|NCT00002789|RANDOMIZED|||TREATMENT||||||||
33910427|NCT01762540|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33910428|NCT05142332|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parent Cluster Randomized Trial: Intervention arm is delivery of Covid vaccine messaging Non-intervention arm is usual care. (2 arms)|f|f|f|t
33688845|NCT03310320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study is double-blind; patients, study site personnel and AZ personnel involved in the evaluation of the data must be kept blinded.~Packaging and labelling of study drug will be performed in a way that ensures blinding."|This is a randomised, double-blind, placebo-controlled, multi-centre, parallel group Phase 1b study in patients with moderate to severe plaque psoriasis. The study is designed to evaluate the pharmacodynamic effects, clinical efficacy and safety of AZD0284 compared with placebo as measured by the relative change from baseline in Psoriasis Area and Severity Index score and biomarkers associated with the mechanism of disease and AZD0284. It comprises 8 clinic visits over approximately 10 weeks including screening visit.|t|t|t|t
33688846|NCT02859506|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33688847|NCT02715778|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33688848|NCT02906462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688849|NCT05808283|||OTHER||PROSPECTIVE|||||||
33688850|NCT01639586|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33688851|NCT03092804|||COHORT||PROSPECTIVE|||||||
33688852|NCT01847911|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33688853|NCT00955227|RANDOMIZED|PARALLEL||||NONE||||||
33688854|NCT03074370|||COHORT||RETROSPECTIVE|||||||
33688855|NCT03712254|||COHORT||PROSPECTIVE|||||||
33688856|NCT05023876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688857|NCT03772860|||CASE_CONTROL||PROSPECTIVE|||||||
33688858|NCT04297657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pre evaluation-final evaluation, control group work||||
33688859|NCT01191307|||||PROSPECTIVE|||||||
33688860|NCT00218101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688861|NCT04030455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778284|NCT03230487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778285|NCT02817490|||COHORT||PROSPECTIVE|||||||
33778286|NCT04222647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778287|NCT04032457|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Clinician masking achieved by clinic coordinator dispensing lenses. Open label to participants.|Randomized cross-over after 1 week of wear of two lens brands.|f|t|f|f
33778288|NCT05552053|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the participants nor the investigators will know which group women have been randomized to. The care provider must know, in order to properly assist with use of the mobile health application.|"This RCT will examine the clinical effectiveness of the Candlelit Care mobile health intervention at reducing mental and physical health risk compared to the standard Maternal Wellness Self-Help (MWSH) mobile health application.~Hypothesis 1a: Compared to a standard of care control group (N=75), Black pregnant women (N=75) randomized to MWSH + Candlelit Care and structured postpartum follow up will have reduced rates of APOs and PMADs.~Hypothesis 1b: Among women diagnosed with PMADs, participants in the intervention group will have an increase in adherence to recommended postpartum mental health treatment. They will also report increased self-advocacy skills, increased communication with providers, and reduced levels of perceived medical discrimination."|t|f|t|f
33778289|NCT05352529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Statistical analyses of all data were carried out independently of investigators by a biostatistical resource department of an academic health center for validation.|This randomized controlled trial assigned participants to two conditions: the experimental condition that implemented the assistive technology intervention and the control condition that implemented educational videos|t|f|f|t
33778290|NCT00376480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778291|NCT06345209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33778292|NCT00333138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778293|NCT01109303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33778294|NCT00671541|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778295|NCT02763540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778296|NCT03116763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33910429|NCT01739777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33910430|NCT00218036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910431|NCT05228444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910432|NCT00524316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910433|NCT00002333||||TREATMENT||DOUBLE||||||
33910434|NCT03904446|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688862|NCT01552473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688863|NCT01108289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688864|NCT00801671|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33688865|NCT03901456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Phase I of the study will include enrollment of 20 participants to test and refine the online tool \[non-randomized\]; in Phase II, we aim to enroll 100 participants to generate preliminary evaluation data \[randomized\].|f|f|f|t
33688866|NCT02644200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688867|NCT01782703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33688868|NCT02520128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910435|NCT06156111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessment and the measurements will be performed by a separate person, not the operator. The patient will not know in which quadrant the abutments will be placed or not.|Prospective double-blinded, randomized, paired sample (split-mouth).|t|f|t|f
33910436|NCT04808154|NA|SINGLE_GROUP||TREATMENT||NONE||SNP-630||||
33910437|NCT04921345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910438|NCT03899129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study will be participant-blind where the participants will not know the intervention done. The applications could not be blinded; however, the statistician will be blinded.|Type: Two arm, parallel, randomized clinical trial. Allocation ratio: 1:1 Framework: Superiority.|t|f|f|t
33910439|NCT05021536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688869|NCT06353230|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomly allocated groupA,B or C by computer generated lottery method.and participants ,care provider and outcome assessor were kept blind by removing the drug name from injection vial|Comparison of 5% phenol in almond oil, 15% hypertonic saline and 50% dextrose water for sclerotherapy treatment of rectal prolapse in children.||||
33688870|NCT01596543|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910440|NCT05687695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688871|NCT03763227|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1: Patients with best corrected visual acuity (BCVA) \< 0.5 will receive carbonic anhydrase inhibitors (CAI) \[oral acetazolamide 500mg/day or topical brinzolamide twice daily\] and followed up for three months. Phase 2: Patients who do not show an adequate response with CAI will receive three 0.5mg IVR injection at monthly intervals.||||
33688872|NCT00700076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33688873|NCT04183517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910441|NCT03087825|RANDOMIZED|CROSSOVER||PREVENTION||NONE||2 groups : spontaneous breathing and non invasive pressure support ventilation 2 conditions : without inward air leak and with inward air leak||||
33910442|NCT00264992|||||PROSPECTIVE|||||||
33910443|NCT05323968|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The two imaging examinations will be done by different radiologists blinded for the previous results.|Cohort study with comparison of two different diagnostic tools||||
33910444|NCT00303108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910445|NCT01601054|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33910446|NCT05108909|||COHORT||PROSPECTIVE|||||||
33688874|NCT03800082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It is not possible to blind the participants to group allocation due to the specific nature of the intervention; however, a data analyst at the University of Toronto's Faculty of Nursing who is blinded to treatment allocation will conduct the analysis ensuring neutrality of the outcome assessment.|A two group parallel single blind pilot RCT.|f|f|f|t
33688875|NCT01362751|||COHORT|||||||||
33910447|NCT05115500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910448|NCT06462417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910449|NCT03757481|NA|SINGLE_GROUP||OTHER||NONE||||||
33910450|NCT02002442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992450|NCT03490864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The study is designed as a randomized controlled trial where each participant will receive one of four intervention types. Subjects will be randomized at baseline visit to one of four arms using a randomized block design to achieve balanced groups. Randomization will be stratified by sex. The allocation will be created using an online randomization tool. This study will include a 6 week four arm field intervention to evaluate the independent effect of meal of timing or melatonin as well as their combined effects.|t|t|t|t
33992451|NCT00005917|||COHORT||PROSPECTIVE|||||||
33992452|NCT06532877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research staff will be blind to study condition when administering assessments to participants via phone.|Advanced gastrointestinal cancer patient-family caregiver dyads (N = 244) will be randomly assigned in equal numbers to Acceptance and Commitment Therapy (ACT) or education/support using a stratified block randomization scheme to balance the groups by patient age (\<65 vs. \>=65 years) and performance status (patient-reported Eastern Cooperative Oncology Group \[ECOG\] scores 0 or 1 vs. 2).|f|f|f|t
33992453|NCT02468518|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992454|NCT05119296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992455|NCT01887522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992456|NCT04678856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024974|NCT02940132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084653|NCT05362201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"A randomised clinical trial was conducted with 20 patients diagnosed with ADDWR through RDC/TMD and they were randomly allocated into the group 1(traditional group):the therapeutic position of the ARS were determinded by the minimum protrusive position;group2(digitial group): the therapeutic position of the ARS were determinded by the VTO analyse."|f|t|f|t
33688876|NCT05340907|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33688877|NCT06000176|||CASE_CONTROL||PROSPECTIVE|||||||
33688878|NCT06321588|||COHORT||OTHER|||||||
33688879|NCT05731531|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33688880|NCT05669248|||COHORT||PROSPECTIVE|||||||
33688881|NCT00273507|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688882|NCT03792243|||COHORT||RETROSPECTIVE|||||||
33688883|NCT01196039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33688884|NCT04967612|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33778297|NCT04001114|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants compare different research cigarettes. Neither the participant nor the investigators know which cigarette is of which type.|We will compare participants with and without a diagnosis of schizophrenia. Study procedures are identical for the two groups.|t|f|t|f
33910451|NCT03866863|||COHORT||RETROSPECTIVE|||||||
33910452|NCT00245193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910453|NCT04917835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910454|NCT02184143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33910455|NCT00768833|||COHORT||PROSPECTIVE|||||||
33910456|NCT04950582|||COHORT||PROSPECTIVE|||||||
33910457|NCT05279833|||OTHER||RETROSPECTIVE|||||||
33910458|NCT05390450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910459|NCT05545267|||COHORT||RETROSPECTIVE|||||||
33910460|NCT02692339|||COHORT||PROSPECTIVE|||||||
33910461|NCT02123160|RANDOMIZED|PARALLEL||TREATMENT||NONE||Psychotherapy-behavioral intervention||||
33910462|NCT01395589|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33688885|NCT05120843|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33688886|NCT02927067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778298|NCT00176865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778299|NCT04919681|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants are blinded to the results of the pressure pain threshold measurements. Participants and examiner are blinded to the results of the range of motion and passive resistive torque measurements.|Single-blind longitudinal repeated measures study||||
33778300|NCT03951376|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster, randomized, controlled (two parallel groups) trial. The intervention is conducted in two phases (intensive phase and follow-up phase). The intervention is repeated 2 times during 3 years (2 waves)||||
33778301|NCT00379249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778302|NCT06161649|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778303|NCT02195674|||COHORT||PROSPECTIVE|||||||
33778304|NCT05837975|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778305|NCT02407509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910463|NCT04604236|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33910464|NCT05493865|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of intervention, blinding participants to the allocation is impossible. But Before the intervention starts, participants have no knowledge on which group they are belonging to.||f|f|f|t
33910465|NCT06484530|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with tuberculosis who meet the research criteria will be randomly assigned into 2 groups using a block of four method with a 1:1 ratio. Patients in group 1 will undergo NAT2 gene testing before starting anti-tuberculosis medication. If the NAT2 gene phenotype is identified as slow acetylator, the patient will receive NAC medication at a dose of 600 mg twice daily for 8 weeks in addition to anti-tuberculosis medication. If the NAT2 gene phenotype is identified as rapid or intermediate acetylator, the patient will receive only anti-tuberculosis medication. Patients in group 2 will receive standard anti-tuberculosis medication without NAT2 gene testing.All patients will undergo blood tests to monitor liver function, kidney function, and blood count at 2, 8 weeks, and 6 months after starting medication.||||
34084654|NCT02657330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910466|NCT04462718|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients diagnosed with unilateral or bilateral PFPS will be divided into two groups, randomly selected (experimental group and control group), of 45 subjects each.~Allocation was concealed and it was done by central randomisation by computer (EPIDARcomputer program).~The subjects of the experimental group will undergo a program of supervised physical therapeutic exercise. And the subjects of the control group will follow the medical-pharmacological treatment and the ergonomic recommendations according to the established protocol.~The target population will be all patients diagnosed with patellofemoral pain syndrome (PFPS) unilaterally or bilaterally, from the health area of La Rinconada while the eligible population will be composed of all those patients residing in or around Seville who can and wish to be part of it. of the study and that they meet the inclusion and exclusion criteria"||||
34084655|NCT06209918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084656|NCT06474533|||COHORT||PROSPECTIVE|||||||
34084657|NCT04726553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no masking.|Parallel Groups will include ten SLE patients who receive anifrolumab added to standard of care and ten patients who receive only standard of care||||
34084658|NCT03804658|||COHORT||PROSPECTIVE|||||||
34084659|NCT06190340|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34084660|NCT04270188|||CASE_ONLY||PROSPECTIVE|||||||
34084661|NCT05016596|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34084662|NCT02070510|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084663|NCT02579629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33910467|NCT03539458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910468|NCT06252311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the study, the researcher will not be blinded during the intervention implementation and data collection via telephone interviews. However, the control group will receive general breastfeeding education, allowing for participant blinding. Randomisation will be performed by an independent statistician using randomly generated numbers. Additionally, blinding of statisticians will be implemented during data entry and analysis by labelling primiparas in the experimental group as Xa and multiparas as Xb, and primiparas in the control group as Ya and multiparas as Yb|Participants are assigned to one of two groups with a Mindfulness-Based Breastfeeding Programme and control group||||
33910469|NCT01640587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084664|NCT02555592|||COHORT||PROSPECTIVE|||||||
33910470|NCT00952289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084665|NCT02651389|||CASE_CONTROL||PROSPECTIVE|||||||
34084666|NCT05540119|||COHORT||RETROSPECTIVE|||||||
34084667|NCT05169086|||COHORT||PROSPECTIVE|||||||
34084668|NCT01256515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084669|NCT00627692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084670|NCT03546465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084671|NCT01548599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084672|NCT00494663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910471|NCT05794932|NA|SINGLE_GROUP||OTHER||NONE||||||
33910472|NCT05889520|||COHORT||PROSPECTIVE|||||||
33910473|NCT05073458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study will be a 24 week double-blind period followed by a 24 week open-label period, followed by a long term extension period.||t|t|t|f
33910474|NCT01264250|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33910475|NCT06210191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910476|NCT02742922|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910477|NCT00786838|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33910478|NCT00443378|RANDOMIZED|PARALLEL||||NONE||||||
33910479|NCT01560546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084673|NCT05297682|||COHORT||PROSPECTIVE|||||||
34084674|NCT04802200|||COHORT||OTHER|||||||
34084675|NCT01683461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084676|NCT05012267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084677|NCT00151944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084678|NCT00216255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084679|NCT05131763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084680|NCT06381245|||COHORT||PROSPECTIVE|||||||
34084681|NCT05052580|NA|SINGLE_GROUP||OTHER||NONE||||||
34084682|NCT01349595|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084683|NCT05550324|||FAMILY_BASED||PROSPECTIVE|||||||
34084684|NCT03307421|RANDOMIZED|PARALLEL||OTHER||SINGLE||2 parallel groups, stratified by center, randomized by center|t|f|f|f
34084685|NCT05366855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992457|NCT06203938|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||The investigators propose to study the effects of non-invasive transcranial infrared light stimulation (TILS) on individuals with ASD using cognitive testing, questionnaires, and non-invasive near-infrared spectroscopy (NIRS). Participants will have the brain activity monitored by NIRS before and after TILS. Cognitive testing and questionnaires before and after TILS will measure beneficial effects of TILS on cognition and ASD symptoms. TILS will be administered with light-emitting diodes (LEDs), which have general FDA clearance as safe for use in humans.|t|t|t|t
33992458|NCT00741780|||||PROSPECTIVE|||||||
33992459|NCT06743139|||OTHER||OTHER|||||||
33992460|NCT06742138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992461|NCT01421901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084686|NCT05543304|||COHORT||PROSPECTIVE|||||||
34084687|NCT03540862|||COHORT||PROSPECTIVE|||||||
34084688|NCT01448733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778306|NCT04501328|RANDOMIZED|PARALLEL||TREATMENT||NONE||Coaching Into Care plus VA-CRAFT consists of four 45-min. telephone coaching calls over 8-12 weeks, delivered by a coach following a manual. Calls focus on supporting and holding the participant accountable for using the VA-CRAFT for PTSD web-based course. This course is based on Community Reinforcement and Family Training (CRAFT) which is intended to help family members of Veterans with PTSD who are resistant to seek treatment for PTSD to initiate care as well as promote the family member's wellbeing and improve their relationship with the Veteran. Calls are designed to: 1) help participants maintain motivation to complete VA-CRAFT lessons in a timely fashion by using reinforcement and motivational techniques; 2) consolidate information and implement skills that they are learning in the course through lesson review, role plays, and problem solving; and, 3) normalize and validate the challenges of having a loved one with PTSD who is reluctant to seek care (i.e., supportive caring).||||
33778307|NCT02303574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33778308|NCT05727995|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|The statistician generates the random list and the outcome assessors guarantee the blinding procedure.|After checking the patients' eligibility they will be blindly randomized in the arm allocation (allocation 1:1).|f|f|f|t
33910480|NCT05959772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be conducted by the main researcher, responsible for the evaluation and application of the questionnaires, who will not be aware of which group will be the experimental and/or placebo. The study will have a collaborator trained in the application of phototherapy, also without prior knowledge of both groups||f|f|f|t
33910481|NCT01429987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910482|NCT01071746|||COHORT||PROSPECTIVE|||||||
33910483|NCT02336594|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33910484|NCT01488825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992462|NCT05146076|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992463|NCT04855279|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33992464|NCT06423339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33992465|NCT06604026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||At each participating site, one medical or surgical unit will conduct the treatment arm and one unit will conduct the control arm randomizing which unit will perform the treatment or control arm at the study site.||||
33992466|NCT06310668|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized clinical trial||||
33992467|NCT03734705|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be randomly assigned to imaginal exposure writing intervention or neutral control writing.||t|f|f|f
33992468|NCT06354894|||COHORT||PROSPECTIVE|||||||
33992469|NCT02348281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992470|NCT03528187|||CASE_CONTROL||PROSPECTIVE|||||||
33910485|NCT04517617|||COHORT||PROSPECTIVE|||||||
33910486|NCT01193348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910487|NCT06187987|||COHORT||RETROSPECTIVE|||||||
33910488|NCT01831973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910489|NCT02566525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910490|NCT05275738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both patients, care givers and investigators are masked to the treatment||t|t|t|t
33910491|NCT05878808|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33910492|NCT02734589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind||f|f|t|f
33992471|NCT05486156|RANDOMIZED|PARALLEL||PREVENTION||NONE|In this study data analysts were blinded.|Participants will be separated into two groups during the study, the intervention group (IG) and the control group (CG).||||
33992472|NCT00924547|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34084689|NCT00505635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084690|NCT00737022|||COHORT||RETROSPECTIVE|||||||
34084691|NCT03974464|||OTHER||PROSPECTIVE|||||||
34084692|NCT03423069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, single blind clinical trial|t|f|f|f
34084693|NCT05047744|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective non randomized Clinical Trial||||
34084694|NCT01019993|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084695|NCT03776279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910493|NCT05872971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluations of the participants and the analysis of the data will be carried out by a researcher blind to the allocation of the subjects in each group.|This is a randomized blind clinical trial, with a longitudinal characteristic in the area of physiotherapy and orthopedics. The intervention will consist of 6 weeks, 2 times a week, and the variables of interest will be measured in the pre-treatment period, after the first week, after the third week of treatment, after the end of treatment and after that, there will be a follow up of eight and twelve weeks after treatment.|f|f|t|t
33992473|NCT03934476|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking will be used in this study.|The study subjects will be randomized into four study groups, one of which will be the control group.||||
33992474|NCT02622867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992475|NCT06560762|NA|SEQUENTIAL||TREATMENT||NONE||This is a Phase 1, open-label, multi-center, dose-ranging study evaluating the safety and tolerability of STM-01 administered by intravenous infusion in participants with HFpEF. Up to 18 participants will be enrolled (Up to 6 participants, for 5 completers per cohort). Each successive cohort of participants will receive STM-01 at the following doses: 50.0 x 106 neonatal mesenchymal stem cells (nMSCs), 100.0 x 106 nMSCs, and 200.0 x 106 nMSCs.||||
33992476|NCT01222234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910494|NCT02020096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33910495|NCT00649467|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33910496|NCT05954832|||COHORT||PROSPECTIVE|||||||
33910497|NCT01249872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33910498|NCT01880255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910499|NCT01556516|||COHORT||PROSPECTIVE|||||||
33910500|NCT05616767|NA|SINGLE_GROUP||SCREENING||NONE||||||
33910501|NCT01603316|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910502|NCT04345991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910503|NCT06492785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910504|NCT04511234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible subjects will be randomised via a secure online system to a labelled device and to receive either Magic Touch sirolimus drug coated balloon in addition to standard balloon angioplasty or standard balloon angioplasty and placebo balloon.|t|t|t|t
33910505|NCT01079962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910506|NCT06185218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910507|NCT03272854|||COHORT||PROSPECTIVE|||||||
33910508|NCT00981383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910509|NCT01368341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33910510|NCT01850784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33910511|NCT00868959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910512|NCT01119274|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33910513|NCT03551301|||COHORT||PROSPECTIVE|||||||
33910514|NCT01836575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910515|NCT04302610|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Heat Exchange Mask SHAM Mask|randomised cross-over design|t|f|f|f
33910516|NCT06430047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910517|NCT04801342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910518|NCT01186146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910519|NCT03323229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33910520|NCT02028429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910521|NCT03270696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33910522|NCT02857855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33910523|NCT00882726|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33910524|NCT04437017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910525|NCT05868876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910526|NCT04115046|||COHORT||PROSPECTIVE|||||||
33910527|NCT03003416|||COHORT||PROSPECTIVE|||||||
33910528|NCT00704743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910529|NCT01613287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910530|NCT03803540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910531|NCT04829383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910532|NCT00603980|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|In order to reduce discrimination between placebo and active Staccato Alprazolam, taste blinding will be accomplished using a rapidly dissolving, intensely flavored product (candy, strip or breath spray). The product will be administered immediately after each oral capsule dosing (at the -60-min and 0- min time points).|The crossover schedule is planned according to a 7-treatment, 7-period Latin Square design due to E.J. Williams (1949), which is balanced for first-order carryover effects (Fleiss, 1986). Each subject will receive all treatments in this 7-treatment, 7- period Williams Square crossover design as suggested by Chen \& Tsong (2007). This Williams Square will include one replication by 1 subject of each of the 14 sequences|t|t|t|t
33910533|NCT01869829|||COHORT||PROSPECTIVE|||||||
33910534|NCT04186000|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants receive a heterologous vaccine regimen with Ad26.ZEBOV as first vaccine followed by second dose with MVA-BN-Filo administered 56 days later (Day 57). After randomization (1:1), a booster vaccination with Ad26.ZEBOV will be executed at 1 year post first dose or 2 years post first dose.||||
33910535|NCT06553339|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33910536|NCT02586636|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33910537|NCT01762293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910538|NCT02242994|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910539|NCT02217319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33910540|NCT00660036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910541|NCT01290081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910542|NCT00958308|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33992477|NCT03816345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992478|NCT06562764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|An open-label trial, or open trial, is a type of clinical trial in which information is not withheld from trial participants.|A parallel study is a type of clinical study in which two or more groups of participants receive different interventions. Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial.||||
33688887|NCT04254042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The double-blind model is applied to the study. Only the adjudicator, responsible for the distribution of medication knew the different regimes. Perindopril and Zofenopril were packaged in boxes of identical appearance and labeled for each participant by name and number of the randomization program. The randomization and packaging of the drugs was done by an investigator who had no clinical involvement.|PEZO-HP trial is a double blind, randomized, controlled parallel clinical trial conducted at the Yaounde central hospital, Cameroon|t|f|t|f
33688888|NCT01765803|NA|SINGLE_GROUP||||NONE||||||
33688889|NCT00553865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688890|NCT04956523|||CASE_ONLY||PROSPECTIVE|||||||
33688891|NCT04608942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33688892|NCT02935543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688893|NCT02669277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688894|NCT04841915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be randomized to one of 3 treatment arms. Protein interventions (MCI and WPI) will be blinded to participants and investigators, but controls with regular diet will not be blinded.||t|f|t|f
33688895|NCT05805358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33688896|NCT03762538|||CASE_ONLY||PROSPECTIVE|||||||
33688897|NCT04884932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688898|NCT00396747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33688899|NCT05592834|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Evaluators, Participants, and caregivers facilitating the PFT and PD training sessions will be blinded on group allocations. A group of independent outcome assessors (evaluators), not involved in the intervention, will administer the outcome measures after the interventions. These evaluators will also be blinded to group allocation to avoid reporting bias.|This will be a 2x2 factorial quasi-randomised controlled trial assessing the effects of the Positive deviance (PD) (Yes/No) and Parent facilitator training (PFT) (Yes/No) strategies within four experimental conditions: i) Both PD and PFT, ii) Only PD, iii)Only PFT, iv) Neither PD and nor PFT(controls).|t|t|f|t
33688900|NCT03127748|||OTHER||PROSPECTIVE|||||||
33688901|NCT06178328|||COHORT||PROSPECTIVE|||||||
33688902|NCT05141825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688903|NCT03474315|||COHORT||PROSPECTIVE|||||||
33688904|NCT01629706|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33688905|NCT02689687|NA|SINGLE_GROUP||||NONE||||||
33688906|NCT03067831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778309|NCT06051539|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The study will follow a withdrawal with randomized re-treatment design. The study will consist of two steps. In Step 1, all participants will receive the MR-001 intervention for 12 weeks, followed by a 12-week washout period. At Step 2, participants will be randomized to receive either another 12 weeks of intervention followed by another 12-week washout or continue their first washout for an additional 24 weeks.||||
33778310|NCT01714089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33778311|NCT01010893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33778312|NCT00001230|||COHORT||PROSPECTIVE|||||||
33778313|NCT02847065|||OTHER||RETROSPECTIVE|||||||
33778314|NCT03194776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, patient and investigator-blinded, placebo controlled, parallel group study|t|f|t|f
33778315|NCT03073629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778316|NCT02379117|||COHORT||PROSPECTIVE|||||||
33778317|NCT01839825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778318|NCT03985098|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778319|NCT04936490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778320|NCT05899556|||CASE_CROSSOVER||PROSPECTIVE|||||||
33778321|NCT01861301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778322|NCT02816333|||COHORT||PROSPECTIVE|||||||
33910543|NCT02381106|||CASE_ONLY||PROSPECTIVE|||||||
33910544|NCT05132816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910545|NCT03894527|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33910546|NCT01952834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910547|NCT05629533|||COHORT||RETROSPECTIVE|||||||
33910548|NCT01372111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910549|NCT03253991|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective multi-site, single-arm study||||
33910550|NCT05179031|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33910551|NCT04834882|||COHORT||CROSS_SECTIONAL|||||||
33910552|NCT06505057|NA|SINGLE_GROUP||OTHER||NONE||||||
33910553|NCT02427477|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33910554|NCT02724774|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910555|NCT04382859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910556|NCT00137852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910557|NCT00267280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992479|NCT05782946|||CASE_CONTROL||PROSPECTIVE|||||||
33992480|NCT04914351|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I, first-in-human, single-arm and multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of HY-0102 in adult patients with locally advanced/metastatic malignant solid tumors.||||
33992481|NCT05015751|||COHORT||PROSPECTIVE|||||||
33992482|NCT03769896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo-controlled, double-blind, parallel-group with 1 : 1 randomization|randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study|t|t|t|t
34084696|NCT04901624|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084697|NCT04808583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910558|NCT04276220|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910559|NCT01806077|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33910560|NCT01596959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910561|NCT04175704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910562|NCT05233696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910563|NCT04292405|||COHORT||PROSPECTIVE|||||||
33910564|NCT03903393|||CASE_CONTROL||PROSPECTIVE|||||||
33910565|NCT03218423|||OTHER||PROSPECTIVE|||||||
33910566|NCT04436627|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992483|NCT03221530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992484|NCT00679081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992485|NCT05990907|NA|SINGLE_GROUP||PREVENTION||NONE|Due to the study design, randomization and blinding are not possible.|"The research project is a controlled, single-arm, monocentric clinical study. Due to the study design, randomization and blinding are not possible.~Unfortunately, there is no scientific data on how long the effects of ischemic preconditioning last. Thus, in a cross-over design study with protocols 1 and 2 in a different order, there would be a risk or bias that subjects who received ischemic preconditioning in the first measurement would have this effect in the second measurement. For this reason, we decided on a standardized procedure for measurement 1 (without ischemic preconditioning) and measurement 2 (with ischemic preconditioning). In this case, the study design would be one-armed."||||
33992486|NCT03664063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992487|NCT04236596|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33992488|NCT06741683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Cohort 1 is randomized and double-blinded. Cohort 2 is non-randomized and open label.||t|f|t|f
33992489|NCT04831580|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992490|NCT06421935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992491|NCT05365451|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33688907|NCT03348384|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||\[C-11\]NOP-1A||||
33688908|NCT01976078|||COHORT||PROSPECTIVE|||||||
33688909|NCT04746872|||CASE_ONLY||PROSPECTIVE|||||||
33688910|NCT03498001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688911|NCT02157207|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33688912|NCT04694456|NA|SINGLE_GROUP||OTHER||NONE||Interventional pilot study||||
33688913|NCT04570267|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33688914|NCT03457233|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33688915|NCT05170568|NA|SINGLE_GROUP||TREATMENT||NONE||PA3-17 injection||||
33688916|NCT03636711|||COHORT||PROSPECTIVE|||||||
33688917|NCT02359162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688918|NCT02718950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778323|NCT04990440|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33778324|NCT03505359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A blinded randomized clinical trial will be conducted to evaluate the effects of two protocols for the rehabilitation of patients undergoing combined re-construction of ACL and ALL.|f|f|t|f
33778325|NCT04288193|||COHORT||PROSPECTIVE|||||||
33778326|NCT01306565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33778327|NCT00671463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33778328|NCT01839643|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33778329|NCT01333943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33778330|NCT05247879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778331|NCT05594563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Care provider and Investigator blinded|Subject are randomized to either treatment or placebo arm.|t|t|t|f
33992492|NCT04410731|NA|SINGLE_GROUP||TREATMENT||NONE||Staggered enrollment for subjects 1 to 3, followed by conditioned open enrollment for subjects 4 to 10.||||
33992493|NCT05747469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992494|NCT03379883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind (investigator) study||f|f|t|f
33992495|NCT04380181|||COHORT||RETROSPECTIVE|||||||
33992496|NCT05187208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084698|NCT06519227|||OTHER||CROSS_SECTIONAL|||||||
33688919|NCT05455762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688920|NCT06336083|NA|SINGLE_GROUP||SCREENING||NONE||||||
33688921|NCT01728714|||CASE_CONTROL||PROSPECTIVE|||||||
33688922|NCT01384643|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33688923|NCT06245187|||COHORT||OTHER|||||||
33688924|NCT04895800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double Blind|A Randomized Double-Blind Placebo-Controlled Study|t|f|t|f
33688925|NCT04643171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688926|NCT02104973|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33688927|NCT03346707|||CASE_CONTROL||PROSPECTIVE|||||||
33688928|NCT02710643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688929|NCT04945642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084699|NCT01850316|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34084700|NCT03597438|||COHORT||PROSPECTIVE|||||||
34084701|NCT01496456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34084702|NCT02897349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084703|NCT04941872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects with various types of cancer undergo contemporaneous 68Ga-DOTA-2P(FAPI)2 and 68Ga-DOTA-FAPI-46 PET/CT either for an initial assessment or for recurrence detection.||||
34084704|NCT04513509||SEQUENTIAL||TREATMENT||NONE||||||
34084705|NCT05352646|NA|SEQUENTIAL||TREATMENT||NONE||||||
34084706|NCT00328705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084707|NCT03751813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084708|NCT06369064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084709|NCT06522425|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084710|NCT03105011||SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34084711|NCT01918228|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34084712|NCT00033280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084713|NCT00972764|||CASE_CONTROL||PROSPECTIVE|||||||
34084714|NCT00173485|||DEFINED_POPULATION||OTHER|||||||
34084715|NCT06307262|||OTHER||OTHER|||||||
33688930|NCT00475475|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33688931|NCT03986515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688932|NCT04864080|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Feasibility study||||
33688933|NCT00890188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688934|NCT05302661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688935|NCT00207571|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33688936|NCT00840502|||COHORT||PROSPECTIVE|||||||
33778332|NCT05013164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778333|NCT02703285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778334|NCT03344614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778335|NCT04469842|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled pilot study.||||
33910567|NCT00086710|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910568|NCT02434341|||COHORT||PROSPECTIVE|||||||
33910569|NCT04316689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910570|NCT03417180|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33910571|NCT01258348||SEQUENTIAL||TREATMENT||NONE||||||
33910572|NCT02079883|||CASE_ONLY||PROSPECTIVE|||||||
33910573|NCT01503645|||||CROSS_SECTIONAL|||||||
33910574|NCT00685620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910575|NCT01073345|||COHORT||PROSPECTIVE|||||||
33910576|NCT03435991|||COHORT||PROSPECTIVE|||||||
34084716|NCT01252368|||CASE_CONTROL||PROSPECTIVE|||||||
34084717|NCT00932932|||CASE_CONTROL||PROSPECTIVE|||||||
34084718|NCT05811481|||COHORT||PROSPECTIVE|||||||
34084719|NCT04382534|||COHORT||PROSPECTIVE|||||||
34084720|NCT01641042|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084721|NCT05219383|||CASE_ONLY||CROSS_SECTIONAL|||||||
33688937|NCT02391896|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33688938|NCT00665301|||CASE_ONLY||PROSPECTIVE|||||||
33688939|NCT02029599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688940|NCT03492775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688941|NCT04309071|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688942|NCT04776044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|matching placebo tablets|Randomized, double-blind, placebo-controlled, multi-centre|t|f|t|f
33688943|NCT03498664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33688944|NCT03442283|||OTHER||PROSPECTIVE|||||||
33688945|NCT02034422|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33688946|NCT02819661|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33688947|NCT01858636|||COHORT||PROSPECTIVE|||||||
33688948|NCT06020547|||COHORT||CROSS_SECTIONAL|||||||
33688949|NCT04534465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688950|NCT05312047|||COHORT||PROSPECTIVE|||||||
33688951|NCT06522412|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33688952|NCT03226873|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33910577|NCT00002887||||TREATMENT||||||||
33910578|NCT03928834|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Two-arm, cluster-randomized trial~1) clinics that provide the Standard of care (SOC)VL testing and management to adolescents and 2) clinics that provide an enhanced adherence package consisting of VL testing using Dried Blood Spots(DBS), including the Nzira Itsva ( NI) intervention and low-cost genotyping and drug resistance monitoring."||||
33910579|NCT04427787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910580|NCT02083510|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910581|NCT05580172|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33910582|NCT03825601|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084722|NCT05981924|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned into two groups, the experimental group will receive music therapy and oxycodone for the pain management after thoracic surgery. The control group will only use oxycodone to relief the pain.||||
34084723|NCT03564990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34084724|NCT02523209|||COHORT||PROSPECTIVE|||||||
34084725|NCT01055990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084726|NCT01534793|||COHORT||PROSPECTIVE|||||||
34084727|NCT00978952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688953|NCT05871983|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, non-randomized, single-arm, international, multicenter, clinical study designed to evaluate the safety and performance of the P\&F MUNICH TMVR System in a population of patients with moderate to severe symptomatic mitral regurgitation, who are not suitable for surgical or approved percutaneous treatments. All patients will be followed closely up to 12 months after the intervention and long-term safety and effectiveness will be collected annually up to 5 years.||||
33688954|NCT03705078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688955|NCT02517970|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33688956|NCT00279370|||COHORT||PROSPECTIVE|||||||
33688957|NCT06338761|||COHORT||RETROSPECTIVE|||||||
33688958|NCT05012436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688959|NCT06231836|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688960|NCT00970736|||COHORT||PROSPECTIVE|||||||
33688961|NCT02775903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688962|NCT02352922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33688963|NCT05814601|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33688964|NCT02884843|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34084728|NCT00158353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688965|NCT05086068|NA|SINGLE_GROUP||TREATMENT||NONE||Single site, single group of patients identified as requiring treatment for early Osteoarthritis of the knee.||||
34084729|NCT00499122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688966|NCT00000977||||TREATMENT||||||||
34084730|NCT03361046|||COHORT||PROSPECTIVE|||||||
33688967|NCT00448968|||DEFINED_POPULATION||OTHER|||||||
33688968|NCT00573196|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688969|NCT06111391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33688970|NCT04835467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group patient enrollment and scheduled 6-month follow-up assessment||||
33688971|NCT00597337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778336|NCT05729815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778337|NCT05835492|||COHORT||PROSPECTIVE|||||||
33778338|NCT06053593|||COHORT||PROSPECTIVE|||||||
33778339|NCT00830947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778340|NCT01435408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910583|NCT01831557|||CASE_ONLY||PROSPECTIVE|||||||
33910584|NCT04898907|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Partially blinded study. Patients are blinded as to treatment assignment. Care Provider, Investigator, and Outcomes Assessor will be blinded to ANG-3777 IV or saline IV, but Moxifloxacin Hydrochloride pill will be provided open label.||t|t|t|t
34084731|NCT03506477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind, vehicle-controlled from week 0 to 4|4:1 Enstilar(R): placebo from baseline to week 4, then open-label Enstilar from weeks 4 to 8.|t|t|t|t
34084732|NCT06454786|RANDOMIZED|PARALLEL||OTHER||SINGLE|In order to prevent selection bias in the study, the assignment to the experimental and control groups will be made on a computer by a person who is unfamiliar with the research process. The analysis of the data will be done by a statistics expert who is outside the research process.|Two groups with experimental and control groups|f|f|f|t
34084733|NCT05252858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Single-center prospective, randomized, open label trial involving patients undergoing unilateral hip replacement and patients undergoing unilateral knee replacement that score \<19 on the PROMIS Emotional Distress - Anxiety - Short Form 8a|t|t|t|f
33688972|NCT02945787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688973|NCT00391261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688974|NCT01135576|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33688975|NCT02986880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688976|NCT01511224|||COHORT||PROSPECTIVE|||||||
33688977|NCT03571477|||COHORT||PROSPECTIVE|||||||
33688978|NCT06169631|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Each experiment arm will have its own group(s).|t|f|f|f
33688979|NCT01208831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33688980|NCT01274494|||||PROSPECTIVE|||||||
33688981|NCT03614767|||COHORT||PROSPECTIVE|||||||
33688982|NCT05216601|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33688983|NCT05825261|||CASE_ONLY||CROSS_SECTIONAL|||||||
33688984|NCT04276454|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive a single intervention.||||
33688985|NCT02716896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688986|NCT03173534|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized in a 1:1 allocation ratio to the following treatment arms TAVR + Medical Therapy (n=175) or simultaneous TAVR + WATCHMAN (n=175)||||
33688987|NCT04985188|||COHORT||PROSPECTIVE|||||||
33688988|NCT00731432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33688989|NCT00667420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084734|NCT05224830|||COHORT||RETROSPECTIVE|||||||
34084735|NCT01943617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084736|NCT00861081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33910585|NCT04434053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084737|NCT05129696|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigators that are analyzing the data are blinded to treatment assignment during analysis.||f|f|t|f
34084738|NCT02530775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084739|NCT04741048|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34084740|NCT00453687|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34084741|NCT03794739|||COHORT||RETROSPECTIVE|||||||
34084742|NCT04725669|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34084743|NCT04865809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084744|NCT06032806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34084745|NCT03147326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084746|NCT05968105|||COHORT||PROSPECTIVE|||||||
34084747|NCT02432599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084748|NCT02105324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084749|NCT06115655|||COHORT||PROSPECTIVE|||||||
34084750|NCT03206125|||CASE_CONTROL||OTHER|||||||
33910586|NCT00219765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910587|NCT02166021|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients were randomised into three groups and treated intrathecally (IT) or intravenously (IV) with autologous MSCs or placebo. At 6-months, treatment groups were crossed over and patients re-treated with either MSC or placebo|t|f|t|f
33910588|NCT05754190|||COHORT||PROSPECTIVE|||||||
33910589|NCT02446730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910590|NCT02738827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910591|NCT02417233|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910592|NCT02541838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910593|NCT01519622|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34084751|NCT03884010|||OTHER||CROSS_SECTIONAL|||||||
34084752|NCT05063994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084753|NCT02979704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084754|NCT05307393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084755|NCT01719432|||CASE_CONTROL||PROSPECTIVE|||||||
34084756|NCT05598697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084757|NCT06134063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910594|NCT01834144|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33910595|NCT02000570|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910596|NCT01158833|||COHORT||RETROSPECTIVE|||||||
33910597|NCT02840487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910598|NCT01433458|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910599|NCT03823417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Patients who choose to participate will be randomized to receive either:~1. placebo i.e. saline 0.9% (intravenous injection) (Control Group) or~2. intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery"|t|t|f|t
33910600|NCT05618457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910601|NCT00916123|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33910602|NCT06217458|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33910603|NCT00555828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910604|NCT00188877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910605|NCT06092138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910606|NCT03599141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910607|NCT03860311|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910608|NCT02427594|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33910609|NCT02439281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910610|NCT02396823|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910611|NCT05768620|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Proof-of-concept trial||||
33910612|NCT00013624||||TREATMENT||||||||
34084758|NCT03938571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084759|NCT00496561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084760|NCT06550908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34084761|NCT00671268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084762|NCT00930618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084763|NCT02830139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084764|NCT02365883|||CASE_ONLY||CROSS_SECTIONAL|||||||
34084765|NCT05493631|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34084766|NCT00366496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084767|NCT02328508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084768|NCT01201863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084769|NCT01515124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All participants asked at the start of each measurement encounter not to inform measurement staff of their randomization group status. All measurement staff asked to guess group status at end of each measurement encounter. Patterns of responses beyond chance result in corrective action to improve masking (e.g.; requests from PI for participants to mask group status)||f|f|f|t
34084770|NCT00311051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084771|NCT00922636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084772|NCT05791617|||COHORT||PROSPECTIVE|||||||
34084773|NCT03355144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084774|NCT00000552|RANDOMIZED|||TREATMENT||||||||
34084775|NCT05414188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34084776|NCT01911832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084777|NCT00338780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688990|NCT00331253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33688991|NCT01264627|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33688992|NCT04455243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33688993|NCT05761938|||COHORT||PROSPECTIVE|||||||
33910613|NCT01101568|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33910614|NCT01350349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084778|NCT06195085|||COHORT||RETROSPECTIVE|||||||
33688994|NCT00757107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33688995|NCT01027078|||COHORT||PROSPECTIVE|||||||
33688996|NCT06130306|||CASE_CONTROL||RETROSPECTIVE|||||||
33688997|NCT02039440|NA|SINGLE_GROUP||||NONE||||||
33688998|NCT00193388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33688999|NCT05053542|||COHORT||RETROSPECTIVE|||||||
33778341|NCT04004858|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The prospective pilot study will consist of two cohorts of patients: one cohort planned with the current standard PTV margin and the second cohort planned with the reduced margin validated from the retrospective study. The first cohort will be recruited while the retrospective study is being carried out and the second cohort will be accrued once the retrospective validation is completed.||||
33778342|NCT03816527|||CASE_CONTROL||PROSPECTIVE|||||||
33910615|NCT01449357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910616|NCT02149654|||OTHER||PROSPECTIVE|||||||
33910617|NCT04054778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The therapists, the study coordinator and the participants will be aware of the interventions after the allocation randomization. The principal investigators and independent evaluators will be blind to the random allocation conditions. The evaluators will be separated from the therapists by working at a separate location on the hospital grounds and will sign agreements not to discuss cases with any other team member. Management of the evaluations will be delegated to a coordinator preventing any direct contact between the investigators and the independent evaluators.|Each participant will be randomized to receive either TA or CBTp.|f|f|f|t
33910618|NCT05373706|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two conditions (Personalized feedback and assessment-only control group).||||
33910619|NCT01468909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910620|NCT06555666|||COHORT||OTHER|||||||
33910621|NCT01187901|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33910622|NCT01236612|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33910623|NCT05560841|NA|SINGLE_GROUP||TREATMENT||NONE||Topical application of Nailner brush 2in1 (medical device) for the treatment of toenail onychomycosis||||
33910624|NCT02941107|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910625|NCT04757779|NA|SINGLE_GROUP||TREATMENT||NONE||From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach. Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle). On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.||||
33910626|NCT00175084|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33910627|NCT02739022|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34084779|NCT06082440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084780|NCT06330714|||COHORT||PROSPECTIVE|||||||
34084781|NCT03916666|||COHORT||RETROSPECTIVE|||||||
34084782|NCT02111018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084783|NCT03571035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084784|NCT06472479|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment \& Two-cohort; LCAR-M61S and LCAR-M61D cells preparation intravenous infusion; Pretreatment of cyclophosphamide and fludarabine.||||
34084785|NCT02770703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084786|NCT04673929|||COHORT||RETROSPECTIVE|||||||
33778343|NCT06285916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778344|NCT00813488|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33778345|NCT02046538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778346|NCT01468415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084787|NCT00175227|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084788|NCT05267704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084789|NCT03477656|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084790|NCT06366789|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation and dose optimization study||||
33778347|NCT01192490|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34084791|NCT00197678|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689000|NCT00260078|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689001|NCT03289364|NA|SINGLE_GROUP||PREVENTION||NONE||Patients will use the Penguin Cold Caps during prior to, during, and after chemotherapy administration. Cold-cap therapy will commence at least 50 minutes prior to infusion, and will continue for 4 hours following completion of chemotherapy.||||
33689002|NCT06007859|||COHORT||RETROSPECTIVE|||||||
33689003|NCT00558571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689004|NCT00209508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992497|NCT06627270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992498|NCT05579535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992499|NCT00004847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992500|NCT00570635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992501|NCT06572111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Part A: open-label, single arm, single-dose Part B: non-randomized, open-label, single-arm, single period, fixed sequence, crossover||||
33778348|NCT01971307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33992502|NCT00326482|||COHORT||PROSPECTIVE|||||||
33992503|NCT05574270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084792|NCT02104440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084793|NCT04887363|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084794|NCT01120262|||COHORT||RETROSPECTIVE|||||||
33992504|NCT02635750|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992505|NCT01426633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084795|NCT03095235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084796|NCT03498677|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084797|NCT01242982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084798|NCT00306254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34084799|NCT04913831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778349|NCT03431805|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind||t|f|t|f
33778350|NCT05584657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778351|NCT05616182|||OTHER||PROSPECTIVE|||||||
33778352|NCT04861922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33778353|NCT04883346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778354|NCT06696937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910628|NCT04610034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910629|NCT00780897|||||CROSS_SECTIONAL|||||||
33910630|NCT01165021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910631|NCT00332514|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910632|NCT02126605|||COHORT||PROSPECTIVE|||||||
33910633|NCT01094717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Excimer laser active and comparator were delivered the same way by a non-blinded person who applies a cap to the laser head to block UV rays for a sham administration. The masking was done by blindfolding the patients so they could not see which side was treated with active or sham laser. The outcomes assessor did their assessment in a separate room and access restricted to the randomization assignments.||t|f|f|t
33910634|NCT00490373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910635|NCT02911545|||COHORT||PROSPECTIVE|||||||
33910636|NCT02142192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910637|NCT02523326|||||PROSPECTIVE|||||||
33910638|NCT00791713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084800|NCT04678817|||COHORT||PROSPECTIVE|||||||
34084801|NCT04879368|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34084802|NCT04867759|||COHORT||PROSPECTIVE|||||||
34084803|NCT02384447|||CASE_ONLY||PROSPECTIVE|||||||
34084804|NCT05423951|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33778355|NCT05414929|NA|SINGLE_GROUP||SCREENING||NONE||||||
33778356|NCT04804085|||CASE_ONLY||RETROSPECTIVE|||||||
33910639|NCT03393052|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33910640|NCT00935142|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910641|NCT04004624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This prospective, multi-center controlled study enrolles patients with infarct-related VT refractory to anti-arrhythmic drugs. The outcome of the study group will be compared to historical control group of patients matched for age, LVEF and VT burden.||||
33910642|NCT02557971|||COHORT||RETROSPECTIVE|||||||
33910643|NCT00210080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910644|NCT05491057|||CASE_ONLY||PROSPECTIVE|||||||
33910645|NCT05281601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910646|NCT02519244|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33910647|NCT01323257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992506|NCT05970913|||COHORT||PROSPECTIVE|||||||
33992507|NCT05393193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992508|NCT01966666|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33992509|NCT06560346|||CASE_CONTROL||PROSPECTIVE|||||||
33992510|NCT05305690|||CASE_ONLY||RETROSPECTIVE|||||||
33992511|NCT01253772|||||PROSPECTIVE|||||||
33992512|NCT01414933|||COHORT||PROSPECTIVE|||||||
33992513|NCT02476838|NA|SINGLE_GROUP||OTHER||NONE||||||
33992514|NCT05362344|||COHORT||CROSS_SECTIONAL|||||||
33992515|NCT05517473|||COHORT||RETROSPECTIVE|||||||
33992516|NCT04709081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Part 1 and Part 2 could be conducted concurrently or separately.||||
33992517|NCT04521426|||CASE_CONTROL||PROSPECTIVE|||||||
33992518|NCT06331910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084805|NCT03125174|||COHORT||PROSPECTIVE|||||||
34084806|NCT02426099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084807|NCT04077762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084808|NCT00275652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084809|NCT05198141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084810|NCT00062166|||COHORT||PROSPECTIVE|||||||
34084811|NCT00257790|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084812|NCT02859883|||COHORT||PROSPECTIVE|||||||
34084813|NCT04979871|||COHORT||PROSPECTIVE|||||||
34084814|NCT04290104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients discharged after laparoscopic cholecystectomy for acute Calculous Cholecystitis constitutes the study population. The patients discharged are randomized into two groups by the clinical secretary with the help of a computer program.~Antibiotics are included in the prescription given to group 1 on the way home. The patient receives 1 gram of Ampicillin/sulbactam twice daily for 5-7 days at home.~The patient, who was randomized to the second group, does not have antibiotics on his prescription.~After the patients are discharged, they are called for weekly control for a month, and they are examined in terms of surgical site infection.~The study reaches the result by making statistical analysis in terms of the rate of surgical site infection between both groups."|t|f|t|f
34084815|NCT04482634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be two groups. The first group will perform the exercises at their home under remote supervision (tele-rehabilitation group) and the second group will perform the exercises at their home on their own (home exercise group)|f|f|f|t
34084816|NCT05719168|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective, cross-sectional||||
34084817|NCT01813747|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Even though this study has recruited slightly more than 10 participants, it is a feasibility study, designed to test the prototype rather than measuring health outcomes. It is to confirm the operating specifications before beginning a full clinical trial.||||
34084818|NCT06493916|||CASE_CONTROL||PROSPECTIVE|||||||
34084819|NCT04392310|||OTHER||PROSPECTIVE|||||||
34084820|NCT02426684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084821|NCT04897620|||CASE_CONTROL||RETROSPECTIVE|||||||
34084822|NCT03495518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084823|NCT03797859|||CASE_ONLY||PROSPECTIVE|||||||
33910648|NCT00187837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910649|NCT01364571|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33910650|NCT02714673|||COHORT||PROSPECTIVE|||||||
33910651|NCT04276311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910652|NCT03766087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910653|NCT00430521|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910654|NCT05462769|||COHORT||PROSPECTIVE|||||||
33910655|NCT03661268|NA|SINGLE_GROUP||TREATMENT||NONE||A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.||||
33910656|NCT06316791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910657|NCT02426372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910658|NCT04042610|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two groups: intervention or control after informed consent is obtained. The intervention will be conducted for 8-weeks and consist of two components: education and electronic prompt to interrupt sitting time. Upon receiving the electronic prompt, the intervention group is encouraged to participate in 2 minutes of physical activity. Both groups will be provided an Amazfit BIP device to record and submit their step count during weeks: 1,2,4, 6 and 8.||||
33910659|NCT00862966|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33910660|NCT06121557|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, dose-escalation and dose-expansion study||||
33910661|NCT06358417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910662|NCT02261168|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910663|NCT05554159|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33910664|NCT04547738|||COHORT||PROSPECTIVE|||||||
33910665|NCT03116399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33910666|NCT01605565||PARALLEL||BASIC_SCIENCE||NONE||||||
33910667|NCT00086658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33910668|NCT05076851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Proxalutamide: androgen deprivation therapy（ADT）=2:1|t|f|f|f
33910669|NCT03657914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910670|NCT01327287|||CASE_CONTROL||RETROSPECTIVE|||||||
33910671|NCT01680419|RANDOMIZED|PARALLEL||||NONE||||||
33910672|NCT01457118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910673|NCT03645408|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Nursing staff at the general Clinical Research unit were not blinded to the study medication. These nurses' only role in the study was providing injections of the study drug. All other staff were blinded to medication assignments. The sham injection was a needlestick using the exenatide multi-dose syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose was only .08ml. It is not expected that subjects would sense this volume of fluid (or lack thereof) during the injection. Subjects were shielded from seeing the injection to maintain the blind. The individual who administered medication did not participate in subject evaluation to maintain the study blind.|This is a double-blind, randomized, placebo-controlled, crossover design trial that tested the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol.|t|t|t|t
33778357|NCT03449459|RANDOMIZED|PARALLEL||PREVENTION||NONE|Although this study is unblinded, we will adopt method of allocation concealment to reduce selection bias.|Participants are equally assigned to four groups in parallel to accept oral probiotics, aerosol inhaled amikacin, combined vaccination or blank control for the duration of the study.||||
33910674|NCT04293042|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This open-label, single-arm clinical trial||||
33910675|NCT00159744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910676|NCT00915005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910677|NCT03101397|||COHORT||PROSPECTIVE|||||||
33910678|NCT01470885|||COHORT||PROSPECTIVE|||||||
33910679|NCT05888428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33910680|NCT01498965|||COHORT||PROSPECTIVE|||||||
33910681|NCT03260205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910682|NCT04954222|||COHORT||PROSPECTIVE|||||||
33910683|NCT04288804|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33910684|NCT02624401|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33910685|NCT03161769|||COHORT||PROSPECTIVE|||||||
33910686|NCT01280890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33910687|NCT00118482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910688|NCT01856595|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33910689|NCT04182997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded to which arm they were assigned. This will be accomplished by the research coordinator determining the randomization status and passing this information along to a surgical nursing staff. The nurse will the procure either the placebo or treatment drug and give it to the treating physician and announce which treatment drug the patient is receiving.|Patients will be randomly assigned to either the treatment group or the placebo group. At the end of surgery patients in the treatment group will have the surgical site lavaged with dexamethasone while patients in the placebo group will have the surgical site lavaged by sterile saline.|t|f|f|f
33910690|NCT06131346|||COHORT||RETROSPECTIVE|||||||
33910691|NCT00001458|||COHORT||PROSPECTIVE|||||||
33910692|NCT05932511|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot study||||
33910693|NCT02916030|||CASE_CONTROL||PROSPECTIVE|||||||
33910694|NCT01726920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910695|NCT02496637|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910696|NCT06391073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910697|NCT01300468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910698|NCT06105944|||COHORT||RETROSPECTIVE|||||||
33910699|NCT04265586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689005|NCT06423417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The present study is a two-arm randomized controlled superiority trial. This trial will be conducted in a university setting. A guided web-based resilience and mental wellbeing programme (LifeHack) will be compared to a waiting list condition. Participants in the waiting list condition will start with the programme 4 weeks after randomization.||||
34084824|NCT01913301|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33689006|NCT01616082|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689007|NCT02691962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689008|NCT06127251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33689009|NCT03740802|||COHORT||RETROSPECTIVE|||||||
33689010|NCT05202132|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689011|NCT04732897|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized trial||||
33689012|NCT01522586|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33689013|NCT02145507|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33689014|NCT00988325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910700|NCT04212338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33910701|NCT03264508|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Investigators collecting and analyzing data will be blinded to subject treatment arms. It is not possible to blind subjects.|Randomized, controlled (parallel design), single-blind|f|f|t|f
33910702|NCT01828268|||COHORT||PROSPECTIVE|||||||
33689015|NCT02479061|||OTHER||CROSS_SECTIONAL|||||||
33689016|NCT03593434|||COHORT||PROSPECTIVE|||||||
33689017|NCT01269788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689018|NCT06071936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689019|NCT02914015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33689020|NCT06164210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689021|NCT03706222|||CASE_ONLY||RETROSPECTIVE|||||||
33689022|NCT00989573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689023|NCT03280043|||CASE_CONTROL||RETROSPECTIVE|||||||
33689024|NCT04282798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689025|NCT00479895|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33689026|NCT04788784|||COHORT||PROSPECTIVE|||||||
33689027|NCT00366015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778358|NCT04081545|RANDOMIZED|PARALLEL||OTHER||SINGLE||The investigators plan to enroll 196 subjects at Virginia Mason Medical Center that are undergoing laparoscopic bariatric surgery. Subjects who volunteer to be involved in the study will be randomized to either the opioid free or traditional anesthetic arm, with a computer generated arm assignment. Subjects will be blinded to the assigned arm. Group A will receive a traditional opioid restrictive general anesthetic and group B will receive an opioid-free anesthetic technique.|t|f|f|f
33910703|NCT05990660|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||BIPASS-AKI is a single-arm, unblinded interventional study designed to assess the safety of the JuxtaFlow System.||||
33910704|NCT02196038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910705|NCT00264316|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33910706|NCT05681195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910707|NCT02046031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910708|NCT01652248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910709|NCT00150371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910710|NCT02037802|RANDOMIZED|PARALLEL||||NONE||||||
33910711|NCT00819208|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34084825|NCT00913601|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33689028|NCT06385990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689029|NCT04518202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blinded randomized controlled trial|double blinded randomized controlled trial|t|t|t|t
33689030|NCT00132561|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33689031|NCT04138888|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department. Study participants will be aware they will receive different formulations of the same drug, without being informed which product (Test or Reference) is being administered.||f|f|f|t
33689032|NCT01799577|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689033|NCT06025929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689034|NCT03362307|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects were aligned based on computer randomization in two groups: In group 1(intervention), subjects received LLL and LED after implant placement and in group 2 (control) the same device was used while device was off.||||
33689035|NCT04674579|||COHORT||PROSPECTIVE|||||||
33778359|NCT04101864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Postoperative computed tomography measurements of acetabular component position will be done by independent technician.|Sample size will be calculated. The Consolidated Standards of Reporting Trials statement guidelines will be followed to perform this prospective, randomized, controlled, trial and to present the results. Included patients will be randomly allocated in a 1:1 ratio into the study and the control group. Randomization will be conducted using computer-generated numbers.|f|f|f|t
33778360|NCT01863966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778361|NCT03511989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778362|NCT03673098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention: 10 weekly sessions of the adapted Relaxation Response Resiliency Program (3RP) Control: 10 weekly sessions of a supportive psychotherapy program||||
33910712|NCT03255291|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The research staff will be blinded to participants' risk display format conditions, but they will be unblinded to mental imagery behavior condition|Participants were randomly assigned by a computer algorithm to one of six intervention arms according to a 3 (risk display format: text, table, ladder) x 2 (imagery behavior: exercise, sleep) between-subjects factorial design. Although randomization was done at the same time and at the beginning of the study, participants received the risk display intervention first, then answered a survey containing two of the primary outcomes, then received the mental imagery intervention followed by another survey.|f|f|t|f
33910713|NCT01982708|||CASE_ONLY||PROSPECTIVE|||||||
33910714|NCT03662503|||COHORT||RETROSPECTIVE|||||||
33992519|NCT06742489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This trial will include patients with storage symptoms as the main manifestation and undergo surgical treatment for benign prostatic hyperplasia. There is still a lack of similar products on the market to be used as a control, and thus the sham group will use the same device without therapeutic effect as a blank control.|t|t|f|f
33992520|NCT00707330|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33992521|NCT06736691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor staff, Site staff,||t|f|t|t
33992522|NCT06742411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992523|NCT06319495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992524|NCT05686707|||COHORT||PROSPECTIVE|||||||
33992525|NCT06146972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992526|NCT05382858|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33992527|NCT05012254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992528|NCT04889716|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort 1 subjects will receive mosunetuzumab. Pending demonstrated safety of cohort 1, the trial will progress to cohort 2, in which subjects will receive glofitamab with obinutuzumab.||||
33778363|NCT05560516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33778364|NCT02613897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778365|NCT02058342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910715|NCT02912000|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910716|NCT00313599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910717|NCT06491953|||COHORT||PROSPECTIVE|||||||
33910718|NCT02668120|||CASE_CONTROL||PROSPECTIVE|||||||
33910719|NCT03071835|||CASE_CONTROL||OTHER|||||||
33910720|NCT00184106|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33910721|NCT05866835|NA|SINGLE_GROUP||OTHER||NONE||Prospective, multi-center experimental study||||
33910722|NCT03153215|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients will randomly be allocated to two groups with 23 patients in each group|"A total of 46 patients with severe early onset intrauterine growth retardation will be enrolled in a randomized placebo control controlled study .~Patients will randomly be allocated to two groups with 23 patients in each group"|t|f|t|f
33910723|NCT04296500|||CASE_ONLY||RETROSPECTIVE|||||||
33910724|NCT01322295|||CASE_ONLY||PROSPECTIVE|||||||
33910725|NCT05075096|||CASE_CONTROL||RETROSPECTIVE|||||||
33910726|NCT04406246|NA|SINGLE_GROUP||TREATMENT||NONE||"In this cohort study, all health workers of the Maternal-Perinatal Hospital Mónica Pretelini Sáenz, with symptoms of SARS-CoV-2 will be treated promptly with nitazoxanide."||||
33992529|NCT03320252|||COHORT||PROSPECTIVE|||||||
33992530|NCT03919071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910727|NCT03233100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910728|NCT01952197|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
33910729|NCT01073527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910730|NCT01876914|||CASE_ONLY||PROSPECTIVE|||||||
33992531|NCT05037461|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33992532|NCT05862545|||CASE_ONLY||PROSPECTIVE|||||||
33689036|NCT05599919|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization|t|t|t|t
33992533|NCT05647005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant, outcomes assessor)|It is a parallel, three-group randomized controlled trial with a prospective, pretest, posttest experimental design.|t|f|f|f
33992534|NCT06351488|||COHORT||PROSPECTIVE|||||||
33910731|NCT04855123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910732|NCT03462446|||COHORT||RETROSPECTIVE|||||||
33910733|NCT02202031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910734|NCT02005848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910735|NCT05807724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910736|NCT01429103|||COHORT||CROSS_SECTIONAL|||||||
33910737|NCT06271200|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a randomized, parallel-group, observer-masked clinical trial. A total of 120 obese participants with MetS will be enrolled. Eligible subjects will be randomly assigned to the ILI group or ULI group with an allocation ratio of 2:1.||||
33910738|NCT03386812|||OTHER||PROSPECTIVE|||||||
33910739|NCT05800444|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33910740|NCT00003243||||TREATMENT||||||||
33910741|NCT06293625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910742|NCT03025737|||CASE_CONTROL||PROSPECTIVE|||||||
33910743|NCT03920982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910744|NCT04425421|||COHORT||PROSPECTIVE|||||||
33910745|NCT04640324|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The 92 enrolled patients were divided in three groups: NAFLD wild type control group (n. 30), NAFLD treated wild type group (n. 30), NAFLD treated mutated group (n. 32). The block randomization method was used to randomize the 60 not mutated patients in the NAFLD wild-type control group and NAFLD treated wild type one.~The patients inserted in the NAFLD treated wild type and NAFLD treated mutated groups were undergone to an oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months. At the baseline and end of treatment, the assessment of WHtR, blood pressure measurement, BMI, Blood glucose and insulin, HOMA-IR, AST, ALT, GGT, blood count, CRP, TBARS, liver stiffness and CAP was performed. During the experimental observation, patients were on free diet on the basis of dietary habits before the enrollment and any type of physical exercise was recommended during the study period."||||
33910746|NCT06390579|||COHORT||RETROSPECTIVE|||||||
33910747|NCT02081339|||COHORT||PROSPECTIVE|||||||
33910748|NCT02849990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910749|NCT02810106|||CASE_ONLY||PROSPECTIVE|||||||
33910750|NCT02496728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33910751|NCT06555003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910752|NCT05794152|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33910753|NCT00069576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910754|NCT03217578|||COHORT||PROSPECTIVE|||||||
33992535|NCT04629014|||COHORT||PROSPECTIVE|||||||
33992536|NCT00616863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992537|NCT06648655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084826|NCT05920005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The experimental/comparator drug has different characteristics. To allow blinding, the Double-Dummy method will be performed, where study sites will receive two drug presentations (active and placebo), thus preventing any violation of blinding.|A multicenter, double-blind, phase III, parallel, controlled and randomized clinical trial.|t|t|t|t
34084827|NCT01835106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33689037|NCT04626310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689038|NCT05612100|||COHORT||PROSPECTIVE|||||||
33689039|NCT01117051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084828|NCT05440032|||COHORT||PROSPECTIVE|||||||
34084829|NCT02879214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084830|NCT02686996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084831|NCT05216484|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34084832|NCT03045172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Dermatopathologist||t|t|f|f
34084833|NCT04474483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||placebo-controlled randomized double-blind pilot trial|t|t|t|t
34084834|NCT06088693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigator blind the participant allocation||t|f|f|t
33689040|NCT05947643|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Double-blinded, meaning neither the subjects nor the investigators will be aware of the intervention received by any subject.|Single-site, double-blinded, placebo-controlled randomized clinical trial performed at a tertiary academic medical center.|t|f|t|f
33689041|NCT05837143|NA|SEQUENTIAL||TREATMENT||NONE||||||
33689042|NCT00548106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689043|NCT03330574|||COHORT||PROSPECTIVE|||||||
33689044|NCT05082532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689045|NCT03406923|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33689046|NCT01657929|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33689047|NCT01772511|||COHORT||PROSPECTIVE|||||||
33689048|NCT03115580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689049|NCT03080974|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will undergo irreversible electroporation and treatment with Nivolumab||||
33689050|NCT02581839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689051|NCT05014412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689052|NCT04114032|||COHORT||PROSPECTIVE|||||||
33689053|NCT02982785|||COHORT||PROSPECTIVE|||||||
33689054|NCT00970866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33689055|NCT00589784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910755|NCT05630404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, investigators and the pain nurse who performs postoperative pain evaluation will not know the group.|There are three models for this study. The first group is ultrasound guided erector spinae plane block group. The second one is surgical injection erector spinae plane block group. The third one is the no intervention control group.|t|f|t|t
33910756|NCT02801162|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910757|NCT01276665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33910758|NCT01160055|||COHORT||PROSPECTIVE|||||||
33910759|NCT01542840|||COHORT||PROSPECTIVE|||||||
33910760|NCT01452958|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33910761|NCT02833649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910762|NCT00377143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33910763|NCT01165723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689056|NCT06260527|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Single ascending dose (SAD) following by multiple ascending dose (MAD) and food effect study|t|f|t|f
33689057|NCT03251677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689058|NCT00417482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910764|NCT03122028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910765|NCT00947570|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33910766|NCT04870112|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910767|NCT04875975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910768|NCT06373913|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084835|NCT00961701|||CASE_ONLY||CROSS_SECTIONAL|||||||
34084836|NCT01950962|NON_RANDOMIZED|PARALLEL||||NONE||||||
33689059|NCT03593941|||CASE_CONTROL||PROSPECTIVE|||||||
33689060|NCT02187770|||CASE_ONLY||PROSPECTIVE|||||||
34084837|NCT04958967|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689061|NCT04778072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Subjects will be randomized into one of three arms (20 subjects per arm) but will be blinded as to which group they are in. The three arms are as follows:~Group 1: ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily (and matching placebo) Group 2: ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily (and matching placebo) Group 3: ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron twice daily (and matching placebo)"|Three groups in parallel|t|t|t|t
33689062|NCT06420128|||COHORT||RETROSPECTIVE|||||||
33689063|NCT00284622|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33689064|NCT03231020|||FAMILY_BASED||PROSPECTIVE|||||||
33689065|NCT02828527|||COHORT||PROSPECTIVE|||||||
33689066|NCT05888571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689067|NCT02455141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689068|NCT05319093|||CASE_CONTROL||PROSPECTIVE|||||||
33689069|NCT00785967|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689070|NCT04877223|||COHORT||PROSPECTIVE|||||||
33689071|NCT00543855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689072|NCT04626466|||COHORT||PROSPECTIVE|||||||
33689073|NCT03416374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689074|NCT05500066|||COHORT||PROSPECTIVE|||||||
33689075|NCT03703570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||An interventional, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial|t|f|t|f
33689076|NCT05581875|NA|SEQUENTIAL||TREATMENT||NONE||||||
33689077|NCT02851186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33689078|NCT02554188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33689079|NCT04916782|||COHORT||PROSPECTIVE|||||||
33689080|NCT02138370|||COHORT||RETROSPECTIVE|||||||
33689081|NCT04451642|||CASE_ONLY||RETROSPECTIVE|||||||
34084838|NCT04614506|||COHORT||PROSPECTIVE|||||||
33689082|NCT05883371|||OTHER||PROSPECTIVE|||||||
33689083|NCT02123628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689084|NCT05226949|||CASE_CONTROL||RETROSPECTIVE|||||||
33689085|NCT06001229|||OTHER||OTHER|||||||
33689086|NCT03701737|||COHORT||PROSPECTIVE|||||||
33689087|NCT02139800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689088|NCT03639571|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33689089|NCT04134351|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33689090|NCT03095274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study includes a combined treatment of Durvalumab plus Tremelimumab||||
33689091|NCT05265377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689092|NCT03663738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Researchers who recruited participants and applied the baseline and 3-month questionnaires were not blinded to the allocation sequence. Given the nature of the intervention patients could not be blinded|||||
33778366|NCT04360226|||COHORT||PROSPECTIVE|||||||
33778367|NCT04239287|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33910769|NCT01412645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33910770|NCT02405052|||COHORT||CROSS_SECTIONAL|||||||
33910771|NCT05495074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910772|NCT00316303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910773|NCT01881594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910774|NCT05087628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910775|NCT00088803|||CASE_CONTROL||PROSPECTIVE|||||||
33992538|NCT06434753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase III, randomized, double-blind clinical trial with two parallel groups, controlled with placebo. This is a low-level intervention clinical trial since the experimental drug is an authorized medication. This is a multicenter national study with fifteen Spanish centers recruiting patients|t|t|f|f
33992539|NCT02161783|||COHORT||PROSPECTIVE|||||||
34084839|NCT01408823|||CASE_CONTROL||PROSPECTIVE|||||||
34084840|NCT01218802|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34084841|NCT00076388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084842|NCT06015100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084843|NCT00194376|NA|SINGLE_GROUP||OTHER||NONE||||||
33689093|NCT02755688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689094|NCT02808572|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33778368|NCT03466840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|According to the allocation sequence obtained from the computer software the numbers will be written in small folded opaque papers and put in opaque sealed envelopes. All those papers will be ready before conducting any procedure. The patients will be allowed to pick his/her number from the pile of envelopes and will be assigned accordingly. The number of papers will decrease as each patient picks his number and so on.||t|f|f|f
33992540|NCT06609343|NA|SINGLE_GROUP||TREATMENT||NONE||A phase 2, open-label, single-arm, single-center, prospective, fixed-dose, 8-week intervention study.||||
33992541|NCT01169558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689095|NCT01609101|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33689096|NCT03007901|NA|SINGLE_GROUP||OTHER||NONE||||||
33689097|NCT00941382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33689098|NCT00515710|||CASE_ONLY||PROSPECTIVE|||||||
33689099|NCT05409820|||CASE_CROSSOVER||PROSPECTIVE|||||||
33689100|NCT04539145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization per envelope|120 patients (60 per group) Special balloon (chocolate balloon with a special nitiol cage around the balloon - not drug coated) versus standard uncoated balloon|t|f|f|f
33689101|NCT02889562|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689102|NCT04863209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33689103|NCT03470233|||CASE_ONLY||OTHER|||||||
33689104|NCT01504061|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33992542|NCT01013649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910776|NCT04119726|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Research personnel, investigators, study coordinators and research assistants conducting the assessments and statisticians will not be informed of the allocation.|400 patients with AMI on admission will be continuously enrolled and randomly allocated to either the control or intervention group. The intervention group will receive internet-based counseling, individual drug reminders, recommendations for healthy lifestyles, cardiovascular education about AMI, and follow-up reminders four times a week, while the control group will only receive cardiology knowledge and follow-up reminders four times a week. Mobile health tools (WeChat applet) were developed through cooperation with a technology company to establish appropriately. Trained research nurses will conduct the follow up in the 4th, 8th, 12th months by telephone or face-to-face visit. All the adverse events will be collected through a self-reported section in the mobile health tools. The study will evaluate the acceptability, utility of the intervention based on Internet consulting management.|f|f|t|t
33910777|NCT04421196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33910778|NCT01758393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910779|NCT04626024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910780|NCT01290484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910781|NCT05990764|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33910782|NCT00287326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33910783|NCT01029002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910784|NCT02756390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910785|NCT06128005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910786|NCT06555926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910787|NCT05729217|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33689105|NCT05458726|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33689106|NCT01273376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689107|NCT01807832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689108|NCT01854931|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33689109|NCT00023192||||TREATMENT||||||||
33689110|NCT02721979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689111|NCT00057122|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689112|NCT04389814|||COHORT||PROSPECTIVE|||||||
33689113|NCT05791370|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All data collected were blinded to the investigators by an independent third party until the completion of the analysis. The efficacy of the blinding procedure was assessed by evaluating the compliance of participants using the visual analogue scale to the experimental diets.|We recruited a total of 156 overweight individuals, aged 25-45 years, with waist circumference ≥ 90 cm for men and ≥ 80 cm for women in a single-blind 3-arm randomised controlled trial. The participants consumed isocaloric diets (\~ 2400 kcal) enriched with red palm olein (RPOO), extra virgin coconut oil (EVCO) and extra virgin olive oil (EVOO, as a control) for a 12-week duration|f|t|t|t
33689114|NCT03049527|NA|SINGLE_GROUP||SCREENING||NONE||The single group will receive an intervention of enhanced education and incentives aimed at increasing hydration and reducing heat stress.||||
33910788|NCT03572439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910789|NCT04068467|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33910790|NCT05197595|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33910791|NCT00439673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689115|NCT04807478|||COHORT||PROSPECTIVE|||||||
33689116|NCT01322308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689117|NCT01268371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689118|NCT00745576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689119|NCT00622076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689120|NCT00773383|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910792|NCT04104100|||COHORT||RETROSPECTIVE|||||||
33910793|NCT03326219|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910794|NCT06440161|||COHORT||RETROSPECTIVE|||||||
33910795|NCT03173820|RANDOMIZED|PARALLEL||TREATMENT||NONE||genotype guided vs conventional tacrolimus dosage regimen||||
33910796|NCT02034357|NA|SINGLE_GROUP||||NONE||||||
33910797|NCT01181518|||CASE_ONLY||RETROSPECTIVE|||||||
33910798|NCT02361762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910799|NCT02391506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992543|NCT05501886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992544|NCT05670262|||COHORT||PROSPECTIVE|||||||
33992545|NCT02005419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992546|NCT02942563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992547|NCT06330896|||CASE_ONLY||PROSPECTIVE|||||||
33689121|NCT06271655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992548|NCT05181969|||OTHER||OTHER|||||||
33992549|NCT03660826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689122|NCT02895633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689123|NCT03739840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689124|NCT03127787|||COHORT||PROSPECTIVE|||||||
33910800|NCT05954377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study concerns patients who ended the 6 months obesity treatment program proposed by the center. At the end of this 6 months care phase, patients will be randomized in 2 groups (ratio 1:1).~The intervention will be and addition of telemedicine quarterly follow up (remote motivational interviews) to the standard multidisciplinary follow-up post care management program"||||
33910801|NCT01419665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A subset of patients is switched from GP2013 to MabThera or continued with MabThera during the maintenance phase, for these patients the treatment is finished as an open labeled parallel arm study. The original treatment assignment is kept blinded.|t|t|t|t
33992550|NCT04821375|RANDOMIZED|PARALLEL||PREVENTION||NONE|Only a designated biostatistician and investigational pharmacy personnel will be aware randomization until after a subject is enrolled, and then all involved in the study will be aware of assignment.|Randomized at enrollment to either immediate study agent or study agent after a 6-months wait.||||
33992551|NCT01585792||||TREATMENT||||||||
33992552|NCT04657289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* The BCVA examiner will only conduct refraction and BCVA assessments and will be masked to participant study eye assignment and study visit type.~* The BCVA examiner will have no access to a participant's BCVA scores from previous visits and will be aware only of the participant's refraction data from previous visits.~* The BCVA examiner may provide no other direct or indirect participant care."|Phase 3b|f|f|f|t
33992553|NCT06732284|||CASE_CONTROL||PROSPECTIVE|||||||
33992554|NCT02510417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992555|NCT03567447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind masking|Phase II single center, double-blind, randomized, placebo-controlled, efficacy study|t|f|t|t
33689125|NCT06427915|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33910802|NCT05902507|||COHORT||PROSPECTIVE|||||||
33910803|NCT04721236|NA|SINGLE_GROUP||TREATMENT||NONE||a multiple center, one arm clinical trial||||
33910804|NCT02778750|||COHORT||PROSPECTIVE|||||||
33992556|NCT05921227|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The children and their caregivers will not be told which condition they are assigned to. However, the Augmentative and Alternative Communication device is quite obvious, so although caregivers will not be explicitly told, it is likely they will be aware their child is in that arm.|All participants will start in the traditional Vocabulary Acquisition and Usage for Late Talkers (VAULT) model. Those who do not respond to treatment early on will be moved to the Augmentative and Alternative Communication Device arm of the treatment.|t|t|f|f
33992557|NCT04071652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992558|NCT05598320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992559|NCT01799811|||COHORT||PROSPECTIVE|||||||
33992560|NCT05364424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689126|NCT05390190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689127|NCT02548468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689128|NCT05715801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910805|NCT03640806|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992561|NCT00006256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689129|NCT02633852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992562|NCT03307317|||CASE_CONTROL||PROSPECTIVE|||||||
33992563|NCT01056484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992564|NCT06031883|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33992565|NCT05421858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689130|NCT00582283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992566|NCT03374176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33992567|NCT00840879|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33689131|NCT04896775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910806|NCT04898426|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The patient cannot be blinded to the allocation. The colonoscopist (care provider) is blinded to the allocation. The investigator and statistician will remain blinded to the allocation until analysis has been conducted.||f|t|t|t
33910807|NCT00638326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910808|NCT05505968|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33910809|NCT03765801|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910810|NCT01487668|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33910811|NCT03634358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparing Outcomes of two different surgical techniques between two groups|t|f|f|f
33910812|NCT02820727|||CASE_ONLY||PROSPECTIVE|||||||
33910813|NCT01004783|||COHORT||PROSPECTIVE|||||||
33992568|NCT06547177|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910814|NCT02814357|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33689132|NCT03850288|||OTHER||PROSPECTIVE|||||||
33689133|NCT06452082|||CASE_CONTROL||RETROSPECTIVE|||||||
33689134|NCT02428985|||COHORT||PROSPECTIVE|||||||
33689135|NCT01568307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689136|NCT02049671|||COHORT||PROSPECTIVE|||||||
33778369|NCT00387192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910815|NCT00248313|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910816|NCT04661930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||An interventional single-arm non-randomized pilot study in 15 patients, followed by an Interventional double-blinded randomized quadruple masked study in 40 patients.|t|t|t|t
33910817|NCT02853734|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33992569|NCT03354858|||COHORT||PROSPECTIVE|||||||
33992570|NCT01851135|NON_RANDOMIZED|PARALLEL||||NONE||||||
33689137|NCT03081221|||COHORT||CROSS_SECTIONAL|||||||
33689138|NCT04251156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33689139|NCT03481660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689140|NCT01613196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689141|NCT02677727|||COHORT||PROSPECTIVE|||||||
33778370|NCT06325397|||COHORT||PROSPECTIVE|||||||
33778371|NCT03012880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992571|NCT06422507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study will be conducted in double-masked fashion. Study participants and masked study site personnel will remain masked to all randomization assignments throughout the study. The Sponsor personnel who are in regular contact with the study site will remain masked to all participant randomization assignments. The operational conduct of the study after the primary analysis at Week 48 will be maintained by a masked team. No decisions on data will be taken by any of the unmasked study personnel.~To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56."|The study duration for a participant is approx 63 weeks. EOS is defined as the last visit of the last participant. HD aflibercept is the sponsor's study intervention under investigation. 322 participants will be randomized into 2 treatment groups in a ratio of 1:1 to receive either 2 mg aflibercept every 8 weeks following 5 initial monthly doses (2q8) or HD aflibercept (8mg) every 16 weeks following 3 initial monthly doses (HDq16). Randomization will be stratified according to baseline Central subfield thickness (CST \<400µm, ≥400µm), baseline BCVA (\<60 vs ≥60 ETDRS letters) and prior treatment for DME. Only 1 eye per participant is identified as the study eye. If a participant's fellow (non-study) eye has DME or Neovascular age-related macular degeneration (nAMD) that requires anti-Vascular endothelial growth factor (VEGF) treatment during the participant's involvement in the study, this eye should be treated with EYLEA (2mg aflibercept) and won't be considered an additional study eye.|t|f|t|f
33910818|NCT05369117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33992572|NCT06007664|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33992573|NCT03674619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33992574|NCT05599711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992575|NCT05124405|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33992576|NCT06161961|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33992577|NCT03763435|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992578|NCT01563874|||CASE_ONLY||RETROSPECTIVE|||||||
33992579|NCT03686007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992580|NCT05063201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992581|NCT06741696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33992582|NCT04896008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Each eligible participant will be randomized in a 1:1 ratio to 1 of the following 2 treatment arms during the double-blind placebo-controlled (DBPC) Treatment Period:~* Arm 1: Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy~* Arm 2: Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy"|t|t|t|f
33992583|NCT02267187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992584|NCT06136728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992585|NCT06743412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34084844|NCT06022913|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to blind the assessor to phase or baseline duration of participants in the case-series, as the length of time between assessments will reveal this. Nevertheless, the assessor and clients will be asked not to disclose which therapist is treating them. Use of self-report measures as the primary outcome measure is intended to minimize potential biases on the side of the researcher.|This is a case series using a multiple baseline design whereby participants are randomly allocated to one of 6 durations of wait at baseline before commencing treatment.||||
34084845|NCT00123344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084846|NCT06525467|||CASE_ONLY||RETROSPECTIVE|||||||
34084847|NCT01882452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084848|NCT03040726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34084849|NCT04923425|||COHORT||RETROSPECTIVE|||||||
34084850|NCT02466399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084851|NCT02287077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34084852|NCT01418469|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34084853|NCT04244136|||COHORT||PROSPECTIVE|||||||
34084854|NCT01396564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084855|NCT00199953|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34084856|NCT00454870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33992586|NCT04369937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992587|NCT04311853|||COHORT||CROSS_SECTIONAL|||||||
34084857|NCT06328088|||CASE_ONLY||PROSPECTIVE|||||||
34084858|NCT05632614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084859|NCT05613348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084860|NCT06017271|||COHORT||RETROSPECTIVE|||||||
34084861|NCT02230215|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34084862|NCT04158765|||COHORT||PROSPECTIVE|||||||
34084863|NCT01677286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084864|NCT03758508|RANDOMIZED|PARALLEL||TREATMENT||NONE||Efficacy of alternating NIV and HFO compared to HFO alone in the determination of an improvement of PaO2/FiO2 at 21 hours compared to baseline PaO2/FiO2||||
34084865|NCT05881811|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34084866|NCT03809390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084867|NCT00938938|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34084868|NCT00004558|RANDOMIZED|||PREVENTION||DOUBLE||||||
34084869|NCT05277207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084870|NCT01514565|||COHORT||PROSPECTIVE|||||||
34084871|NCT02518334|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084872|NCT04081688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689142|NCT04041791|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34084873|NCT06122558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084874|NCT03186755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, Monocentric, Randomized Controlled Trial, Parallel-group, Single-masked for assessors|f|t|f|t
34084875|NCT01547715|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34084876|NCT01203696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084877|NCT05105256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The primary and secondary outcomes will be evaluated by a doctor who does not know in which group the patient is randomized.~This doctor is different from the interventional rheumatologist. Furthermore, the patient is completely unable to determine the group in which he was included. In fact, the infiltrations of the posterior inter-apophyseal joints are carried out in prone position. This technical aspect leads to the patient's ignorance of the treatment received."||t|f|t|f
34084878|NCT02426697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084879|NCT01381497|||COHORT||PROSPECTIVE|||||||
34084880|NCT01780623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34084881|NCT06050681|NA|SINGLE_GROUP||OTHER||NONE||Single group intervention feasibility||||
34084882|NCT05339958|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind, placebo-controlled|This is a 6-month, multi-center, randomized, double-blind, placebo-controlled study in adult male subjects with self-perceived hair thinning. Subjects will be randomly assigned to either Nutrafol® Men hair growth supplement or placebo.|t|t|t|f
34084883|NCT01607658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689143|NCT00401895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084884|NCT05475145|NA|SINGLE_GROUP||TREATMENT||NONE|We consider it not possible to mask för participant or care provider.|Non-blinded randomized split-mouth longitudinal 3 year follow up study.||||
34084885|NCT04333693|||COHORT||PROSPECTIVE|||||||
34084886|NCT00781950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34084887|NCT00551369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084888|NCT04989673|||CASE_CONTROL||PROSPECTIVE|||||||
34084889|NCT00957359|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34084890|NCT04918823|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive study drug to be used in their device.||||
33689144|NCT00398489||||TREATMENT||NONE||||||
33689145|NCT03590418|||CASE_CONTROL||PROSPECTIVE|||||||
33689146|NCT01367119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689147|NCT02606695|||COHORT||PROSPECTIVE|||||||
33689148|NCT02284672|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33689149|NCT01623986|||COHORT||PROSPECTIVE|||||||
33689150|NCT01216267|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689151|NCT03758326|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689152|NCT00556231|||CASE_CONTROL||PROSPECTIVE|||||||
33778372|NCT02490930|NA|SINGLE_GROUP||OTHER||NONE||||||
33910819|NCT05055115|NA|SINGLE_GROUP||TREATMENT||NONE||"50 patients will fill out the ETDQ-7 questionnaire before and after tympanostomy. Results will be compared to 50 age- and gender matched controls with no history of ETD or ear-surgery.~Both MRI and Cone Beam-CT scans are performed in order to obtain a complete overview of ET. Twelve patients with ETD and 12 healthy controls are examined with both MRI and CBCT. The dimensions and angulations of the ET in the two groups are compared to identify significant differences.~Tubomanometry is a tool to measures the dynamic function of the eustachian tube. 50 patients are examinated and compared to 50 controls to investigate tubomanometry's ability to distinguish the two groups.~A REDCap-database is established in order to create a national cohort where all patients undergoing first time Balloon Eustachian Tuboplasty in Denmark, are registered. All patients are followed for 12 months. The patients, who benefit from the procedure, will be compared to those without effect."||||
33689153|NCT00728078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910820|NCT03633786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910821|NCT04013282|||CASE_ONLY||PROSPECTIVE|||||||
33910822|NCT06071494|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33689154|NCT00989690|RANDOMIZED|||TREATMENT||NONE||||||
33689155|NCT02756065|||CASE_CONTROL||PROSPECTIVE|||||||
33689156|NCT03718299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689157|NCT05783986|||OTHER||RETROSPECTIVE|||||||
33689158|NCT02750228|||COHORT||PROSPECTIVE|||||||
33778373|NCT00445692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778374|NCT00752570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778375|NCT02846662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33778376|NCT06697210|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33778377|NCT05761080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778378|NCT06039891|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33992588|NCT01537887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33910823|NCT03281291|||COHORT||PROSPECTIVE|||||||
33910824|NCT04422665|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly allocated to one of two intervention groups. Due to the single-legged typed of resistance exercise, each subject will be its own control.||||
33910825|NCT00875784|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910826|NCT06555055|||COHORT||PROSPECTIVE|||||||
33910827|NCT00788515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778379|NCT00226200|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33910828|NCT00003648|||CASE_ONLY||PROSPECTIVE|||||||
33778380|NCT06436547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910829|NCT04234815|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants are not informed of their condition, but may reasonably deduce it.|||||
33910830|NCT02422927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910831|NCT01592890|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33910832|NCT03571620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778381|NCT04428086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms Assignment||||
33910833|NCT00943319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910834|NCT04956822|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992589|NCT06563401|||COHORT||PROSPECTIVE|||||||
33992590|NCT04170283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992591|NCT06561893|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomised Double-blind Placebo-controlled Crossover Study|t|t|t|t
33992592|NCT04777994|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992593|NCT05719493|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33992594|NCT06514612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a double -masked study with subjects, Investigators, Site Staff, Reading Centre personnel, and Santen personnel involved in the conduct of the study all masked to the study treatment.~Each eligible subject will receive a numbered study treatment kit assigned by central randomisation via IWRS at Baseline."|Subjects diagnosed with acquired blepharoptosis who meet eligibility criteria at Visit 1 (Screening) will return within 8 days for Visit 2 (Baseline, Day 1). At Visit 2 (Baseline, Day 1) they will be randomised to receive double-masked treatment for 6 weeks, with study visits completed at Week 2 (Day 14) and Week 6 (Day 42), and a post-treatment visit completed 2 weeks (± 3 days) after last study drug administration. This study will consist of a screening period of up to 8 days, a 6-week double-masked treatment period, and a post-treatment visit 2 weeks after the last administration of the study drug.|t|t|t|f
33992595|NCT03219853|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33992596|NCT01368991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33992597|NCT03646292|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|This study will evaluate the efficacy in lowering liver fat and the safety of empagliflozin 10mg, pioglitazone 15mg, alone or in combination (empagliflozin 10mg/pioglitazone 15mg), over a 24-week period.||||
33992598|NCT03182075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33992599|NCT05460676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33910835|NCT03696758|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at a separate visit. These visits can occur in either order. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out.|f|f|f|t
33910836|NCT00436969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33910837|NCT05784415|||COHORT||RETROSPECTIVE|||||||
33992600|NCT05650775|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a sequential partial-crossover design. All participants will complete the Baseline visit, the methylphenidate trial, and a follow-up lab visit. Participants with \< 30% symptom improvement on methylphenidate will then complete a 1-2 week washout, followed by a trial of mixed amphetamine salts and a second follow-up lab visit.||||
34084891|NCT01363635|||COHORT||PROSPECTIVE|||||||
34084892|NCT00102323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084893|NCT01868568|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34084894|NCT05094427|||COHORT||RETROSPECTIVE|||||||
34084895|NCT03270306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34084896|NCT00976339|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910838|NCT02046265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33910839|NCT01687738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910840|NCT00701818|||COHORT||PROSPECTIVE|||||||
33778382|NCT04549077|||CASE_CONTROL||OTHER|||||||
33778383|NCT06084429|NA|SINGLE_GROUP||OTHER||NONE||||||
33778384|NCT00628693|||COHORT||PROSPECTIVE|||||||
33778385|NCT00871611|||COHORT||PROSPECTIVE|||||||
33992601|NCT06400563|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"The study team will collect MRI-derived region of interest (ROI) data with T1, T2 and DCE-MRI sequences from 20 women with breast abnormalities and NIRS data concurrently. The study team will test whether the breast interface can provide optical measurements with positional data sensitivity \>1%.~The study team will conduct two interim analyses of optical sensitivity after completion of 5-10 patient exams to decide whether the breast interface should be modified.~The breast interface is a non-significant risk device."||||
33778386|NCT06103474|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Interpreting radiologists will be blinded to survey data. The PI will be blinded to the intervention type during the review.|Survey, cross-sectional study of sixty (n=60) participants undergoing MRI for lower back pain will be randomized to receive an anatomic report (standard of care) versus a Clinical Report (CR). Ordering physicians receiving the Clinical Reports will be instructed to avoid terms that may result in cyberchondria or fear (e.g. disc bulge or nerve impingement) when discussing MRI results.|f|f|t|f
33992602|NCT06206226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992603|NCT04626050|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The outcomes assessor will not be aware of the condition for Phase 1 or Phase 2 of the study.||f|f|f|t
33992604|NCT06625463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Masking could not be done for researchers and research subjects, but was done for enumerators and assessors of research outcomes. During the data collection and measurement process, enumerators and cardiologists did not know the allocation of research subjects. Likewise, the statistician who will process the data does not know the allocation for each research data.||f|f|f|t
33992605|NCT06058663|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992606|NCT04986982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992607|NCT05353647|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-randomized, multi-center, phase 2, single arm study||||
33992608|NCT01242098|||COHORT||RETROSPECTIVE|||||||
33992609|NCT06501924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992610|NCT00840281|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992611|NCT05168735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33992612|NCT00489307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33992613|NCT00418938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084897|NCT06062992|||COHORT||PROSPECTIVE|||||||
34084898|NCT03002896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34084899|NCT01198405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34084900|NCT01478659|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34084901|NCT04315402|||COHORT||PROSPECTIVE|||||||
33778387|NCT01760681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778388|NCT04534855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778389|NCT05752578|||COHORT||PROSPECTIVE|||||||
33778390|NCT00688961|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33778391|NCT05281393|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Control Trial||||
33778392|NCT05151133|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33778393|NCT05300880|||OTHER||PROSPECTIVE|||||||
33910841|NCT06198049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get a separate protocols and possible efforts will be put to mask the both groups about their treatment.|This will be Randomized Clinical Trial to see the effect of Pilates Training versus Balance Proprioception exercises on lower extremity function in children with hearing impairment|t|f|f|f
33910842|NCT04906889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33910843|NCT03517683|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33910844|NCT04369430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910845|NCT01241851|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||||||||
33910846|NCT00045682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910847|NCT02676076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689159|NCT03981302|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study has a quasi-experimental design and will conduct baseline and post-test in two comparable groups of patients and their selected family members: An intervention group and a historical control group. The data from the historical control group will be collected initially in the study to prevent pollution of the data when the intervention nurses are educated in Family nursing.~The study is a part of a superior explanatory sequential mixed methods design consisting of a total of three substudies. The two other substudies have qualitative designs."||||
33689160|NCT06104371|||OTHER||PROSPECTIVE|||||||
33689161|NCT00381953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689162|NCT00772070|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689163|NCT02662218|||COHORT||PROSPECTIVE|||||||
33689164|NCT02469038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33689165|NCT06459141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910848|NCT02232672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910849|NCT00880672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910850|NCT00285298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910851|NCT00511407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910852|NCT06555835|||OTHER||CROSS_SECTIONAL|||||||
33910853|NCT03333057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910854|NCT02167568|||COHORT||PROSPECTIVE|||||||
33910855|NCT01474746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910856|NCT00913978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910857|NCT05504148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Inclusion criteria:~1. Age 25-80 years old, female;~2. Patients diagnosed with breast cancer by histopathology;~3. Patients who plan to receive adjuvant radiotherapy/chemotherapy or combined adjuvant trastuzumab or pertuzumab targeted therapy;~4. Patients who completed at least 6 cycles of treatment after enrollment;~Exclusion criteria:~1. pregnant or breastfeeding women;~2. Patients with poor echocardiographic image quality;~3. Persistent atrial fibrillation and severe arrhythmia affect the collection and analysis of ultrasound data;~4. Patients who are participating in other clinical studies.~Eligible patients were randomly divided into 1:1 group and divided into crocin group and placebo control group. Both groups of subjects received crocin or placebo on the basis of standard anti-tumor treatment."|t|t|t|t
33910858|NCT02678741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910859|NCT00372190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910860|NCT02143362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910861|NCT06520176|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, two-arm, multicenter, exploratory study||||
33910862|NCT01735747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910863|NCT02421328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910864|NCT04255550|||CASE_CONTROL||PROSPECTIVE|||||||
33910865|NCT00470353|RANDOMIZED|||TREATMENT||||||||
33910866|NCT02998554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910867|NCT03090620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910868|NCT04969640|||OTHER||PROSPECTIVE|||||||
33910869|NCT01662700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910870|NCT02728128|||COHORT||PROSPECTIVE|||||||
33910871|NCT02467387|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33910872|NCT05478044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910873|NCT01930799|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33910874|NCT02772965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33910875|NCT04353960|||COHORT||PROSPECTIVE|||||||
33910876|NCT06131554|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33910877|NCT05458063|||COHORT||PROSPECTIVE|||||||
33910878|NCT04279561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992614|NCT06043037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither participant nor the outcome assessor know the group districution|The present study included 50 participants, aged 20 to 45, with teeth that needed to be extracted. After Kafrelsheikh University research ethics committee approval, participants were randomized into 2 groups: the control group patients underwent immediate implantation using SS protocol, while the study group patients underwent the same procedure, but ADDG was created using the extracted palatal portion of the tooth; and then placed in the peri-implant gap defect. Clinically, pink aesthetic score (PES), midfacial mucosal alterations (MFMA), implant stability quotient (ISQ) were observed at baseline, six and twelve months after implantation. Moreover, baseline, 6- and 12-months alterations of radiographic horizontal bone dimension (HBD), buccal marginal bone level (BMBL), peri-implant Bone Density (PIBD) and peri-implant vertical bone defect (PIVBD) changes were assessed using cone beam computed tomography (CBCT).|t|f|f|t
33992615|NCT04358874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992616|NCT06271070|||OTHER||CROSS_SECTIONAL|||||||
33992617|NCT03939897|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992618|NCT05180422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992619|NCT05620511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992620|NCT04499677|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Double-blind|Randomised, double-blind, 2x2 factorial placebo-controlled|t|t|t|f
33992621|NCT06559345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689166|NCT01234818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910879|NCT02114333|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33910880|NCT01467908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910881|NCT01228071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910882|NCT04697472|NA|SEQUENTIAL||TREATMENT||NONE||||||
33910883|NCT00584337|||COHORT||PROSPECTIVE|||||||
33910884|NCT04894786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910885|NCT02343536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33910886|NCT03516019|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|eFHS researchers, statistician, research assistant, and clinic staff are masked to intervention assignment.|The research design includes a cohort eFHS Study and an embedded randomized factorial trial on a subset of the cohort.|f|f|t|f
34084902|NCT04698811|NA|SINGLE_GROUP||SCREENING||NONE|Masking will not occur.|Participants will be invited to the activities through the publication of registration on social networks. After reading and accepting the informed consent form, the initial information for the design of the group will be filled out. The activities will be applied to a minimum group of 135 people. If the number of registrants qualified for the study does not reach 135 individuals, the registration period will be extended by 15 days in order to complete the sample. Still being insufficient, the test will be carried out with the sample found.||||
34084903|NCT02243657|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34084904|NCT00744341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689167|NCT05280379|||OTHER||CROSS_SECTIONAL|||||||
33689168|NCT05536505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689169|NCT00179127|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33689170|NCT04416425|||COHORT||PROSPECTIVE|||||||
33689171|NCT04758845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33689172|NCT00312637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689173|NCT00602745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689174|NCT04533477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689175|NCT05022264|||OTHER||PROSPECTIVE|||||||
33689176|NCT03565965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33689177|NCT00336583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084905|NCT01052948|||COHORT||RETROSPECTIVE|||||||
33689178|NCT00176722|||||PROSPECTIVE|||||||
33910887|NCT03560193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910888|NCT05736588|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910889|NCT04182620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded until the 6 month visit, at which time they will be un-blinded prior to the follow up CT/MRI. The Clinical Events Committee and Echo Core Lab will remain blinded throughout the trial. In general, the CEC will be blinded to the treatment arms. However, once the nature of the event has been adjudicated, the blind will be broken for that individual patient as necessary to enable the CEC to determine relatedness to the study device.||t|f|f|t
33910890|NCT03099369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910891|NCT01213433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910892|NCT04989192|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|no masking required|Randomization of patients referred for a staging CT scan one of three CT scanners routinely used for this purpose in our department||||
33910893|NCT00587821|||CASE_ONLY||PROSPECTIVE|||||||
33910894|NCT03218254|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Identical placebo tablets are produced. Study pharmacy produces study medication containers and randomizes patients, and keeps track of unique study IDs. Unblinding is only done after completion or in emergency situations|Methylphenidate or Placebo titrated according to effect and toxicity week 1-6 followed by 1 week of washout and then crossover followed by repeated procedures with the other treatment for week 8-13.|t|t|t|t
33910895|NCT03269292|||COHORT||PROSPECTIVE|||||||
33910896|NCT00851734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33910897|NCT00813280|||COHORT||RETROSPECTIVE|||||||
33910898|NCT02843334|||COHORT||CROSS_SECTIONAL|||||||
33910899|NCT02238028|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33992622|NCT06313034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|While it is known by the researcher whether the mothers are in the experimental or control group, it is not known by the mother.|The sample of the research will consist of mothers who gave primary vaginal birth (40 experimental group and 40 control group)|t|f|f|f
33689179|NCT01453192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689180|NCT04478331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33689181|NCT02272543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689182|NCT02257450|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33689183|NCT03128151|||CASE_CONTROL||PROSPECTIVE|||||||
33689184|NCT03116347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689185|NCT05438641|||COHORT||RETROSPECTIVE|||||||
33689186|NCT00491426|||||RETROSPECTIVE|||||||
33689187|NCT04325399|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33689188|NCT05078918|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a non-randomized controlled trial. Control groups will be enrolled first considering contamination of educational intervention.||||
33689189|NCT00404703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689190|NCT03059446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689191|NCT01689909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689192|NCT01234727|||COHORT||PROSPECTIVE|||||||
33689193|NCT00504036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689194|NCT02857595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33689195|NCT01417182|NA|SINGLE_GROUP||SCREENING||NONE||||||
33689196|NCT01110655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689197|NCT01411930|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33689198|NCT05072886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992623|NCT05949684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992624|NCT06035250|||COHORT||PROSPECTIVE|||||||
33992625|NCT03106415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992626|NCT06485908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992627|NCT00001174|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33992628|NCT04512781|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33992629|NCT05642780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689199|NCT01753739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689200|NCT01179035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
33910900|NCT03764215||SEQUENTIAL||TREATMENT||NONE|We propose to perform an open label, Phase Ib, proof of concept study to evaluate the impact of low doses of Nilotinib treatment on safety, tolerability and biomarkers in participants with HD. We propose an adaptive design based on safety and tolerability of 150mg Nilotinib treatment for 3 months. We will first enroll 10 participants who will receive an oral dose of 150mg Nilotinib once daily (group 1) for 3 months. If these participants tolerate 150mg dose of Nilotinib, an additional 10 new HD participants (group 2) will be enrolled to evaluate the effects of 300 mg dose of Nilotinib for 3 months. We will then compare baseline with the effects of 3-months Nilotinib treatment within each group and between groups (1 and 2). Participants (group 1 and 2) will return for a follow up visit one month after the termination of 3-months treatment with Nilotinib and results will compared to baseline visits and end of study visits.|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.||||
33910901|NCT05651139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33910902|NCT04905381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910903|NCT05863494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be assigned a random unique number which will be randomly correlated with either treatment group or sham group. The participant will not have access to see in the redcap system which arm they are in. The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current but mimics treatment with an initial small tingle. The investigator who is not involved in assigning groups will receive data with de-identification.|"The proposed study employs a randomized, double-blind, sham-controlled design to evaluate the effects of the tDCS using the tKIWI device on chronic pain. The participant will be randomly assigned to the treatment (tx) or sham/placebo group.~Up to 40 participants will be recruited and randomly placed in either the treatment or the sham group. The randomization ratio is 1:1. Each participant has an equal chance of being assigned to each condition and each participant will be assigned to a condition independently of the other participants. The sample is small (20 each group), so in order to ensure random assignment, we will assign a unique number to every participant of the study's sample. Then, we will use a lottery method to randomly assign each number to the control or experimental group."|t|f|t|f
33910904|NCT04331873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910905|NCT03994926|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33910906|NCT00207103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910907|NCT02632708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910908|NCT04387058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33910909|NCT05549141|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33910910|NCT05996731|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778394|NCT05950906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study; treatment assignment will not be known to the subjects, the Sponsor and staff involved in the clinical evaluation of the subjects and the analysis of data. The randomization schedule and disclosure envelopes will be generated by an unblinded statistician. The unblinded statistician will not be involved in decisions relating to populations for analysis prior to unblinding. Prior to database lock and unblinding, all original randomization materials including the original final signed and dated randomization schedule will be held by the Quality Assurance department at the study site. The Data Sciences department will not have access to the randomization schedule before database lock/unblinding. There may be instances where interim data has the potential to reveal treatment. In these cases, every effort will be made by the unblinded pharmacokinetic scientist to maintain blinding by appropriate presentation of data to the study team.|Part 1 Cohorts 1-5 will assess single ascending doses (SAD) of subcutaneous administration PDM608. Part 2 will assess multiple ascending doses (MAD) administrations given once weekly for 4 weeks in up to 4 cohorts of participants. The parts of the study are not required to be conducted entirely sequentially, provided that this is justified by PK and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from SAD Cohort 3 and dosing for each MAD cohort will not exceed the a dose level previously deemed safe in a SAD cohort.|t|t|t|t
33778395|NCT04871373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Two dentists were in charge of the study logistic. They enrolled and allocated the participants according to the order of arrival and following the list of random numbers. A coding system was used as a concealment mechanism, which consisted of colored labels attached to the participants' file. This system was only known by the logistics managers and the interviewer (the periodontist who provided the OHI and the MI). Thus, the participant and the evaluator (the periodontist who recorded the data) were masked.|Orthodontic patients were recruited to be divided into a control group (that received oral hygiene instructions) and an experimental group (that received oral hygiene instructions and motivational interviewing sessions).|t|f|f|t
33778396|NCT03604861|||COHORT||PROSPECTIVE|||||||
33778397|NCT06432543|||COHORT||PROSPECTIVE|||||||
33910911|NCT04890574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|This is a prospective, single arm, open label non-randomized safety and device feasibility study.|This is a prospective, single arm, open label non-randomized safety and device feasibility study.||||
33910912|NCT01635751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33778398|NCT01984125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778399|NCT02240680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778400|NCT00887731|||CASE_CROSSOVER||PROSPECTIVE|||||||
33778401|NCT02954718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778402|NCT05058586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778403|NCT02110927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33910913|NCT06534424|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33910914|NCT00901537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910915|NCT03657368|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33910916|NCT04815590|||COHORT||PROSPECTIVE|||||||
33910917|NCT04749979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33910918|NCT03248622|||CASE_ONLY||RETROSPECTIVE|||||||
33910919|NCT02435277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910920|NCT02898090|||COHORT||RETROSPECTIVE|||||||
33910921|NCT02560688|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34084906|NCT03023995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084907|NCT01977846|||CASE_ONLY||OTHER|||||||
34084908|NCT00581217|||COHORT||PROSPECTIVE|||||||
34084909|NCT06044987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084910|NCT05093868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084911|NCT00106002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778404|NCT00000556|RANDOMIZED|||TREATMENT||||||||
33778405|NCT05095155|||OTHER||PROSPECTIVE|||||||
33778406|NCT05564299|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33910922|NCT06144528|||CASE_ONLY||CROSS_SECTIONAL|||||||
33910923|NCT03487380|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study will compare three groups of 100 patients, corresponding to 200 patients with Alzheimer disease (whom 100 patients in the rapid cognitive decline group and 100 patients without rapid cognitive decline) and 100 patients in the control group.||||
33910924|NCT00623454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910925|NCT04603196|||COHORT||PROSPECTIVE|||||||
33910926|NCT00654511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33910927|NCT01815892|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34084912|NCT03019380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084913|NCT03242785|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34084914|NCT00714701|||COHORT||PROSPECTIVE|||||||
34084915|NCT02317380|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34084916|NCT01162343|||COHORT||PROSPECTIVE|||||||
33689201|NCT03911310|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|"The assigned scan order will be blind to the recruiting physicians and the nuclear medicine physicians interpreting the images.~Next to the clinical trial coordinators, also the staff members responsible for the preparation of the individual \[18F\]PSMA-11 and \[68Ga\]PSMA-11 dose and the IV injection of this dose are aware of the scan order which means that they are NOT blinded. However, these staff members do not carry out any further study specific handlings."|The trial encompasses a double-blind randomized cross-over design whereby each patient will be subjected to a \[18F\]PSMA-11 scan and a \[68Ga\]PSMA-11 scan, with an interscan period of four days to maximum three weeks. Half of the patients will be first scanned with \[18F\]PSMA-11 and subsequently (maximum three weeks later) with \[68Ga\]PSMA-11. The scan order in the remaining group of patients will be reversed. Randomization of patients to one of these groups will be performed using a block randomization design with block sizes of six.|t|f|t|t
33910928|NCT05185752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The type of masking applied was:~First part of study (until 24 hours after surgery): single-blind, the patient did not know what type of treatment he had received, but the anaesthesiologist in the operating room, and the main intraoperative and immediate postoperative period evaluator were aware of all this.~Second part of study (3 months and 1 year after surgery): double-blind, the patient did not know what type os treatment he had received, and the anesthesiologist who was the responsible of collecting data through the telephone interview or her medical history, did not know the treatment taken by the patient."|Patients undergoing breast tumour surgery were randomised to undergo one of three locoregional techniques in three study groups (Erector Spinae Plane block -ESP block-, Pectoral Nerve Block type II -PECS II block-, or Serratus-Intercostal fascial Plane Block-SIFP block). Locoregional techniques were performed under light sedation and then, general anaesthesia was used for the breast tumour surgery.|t|f|f|f
33910929|NCT04762108|||COHORT||PROSPECTIVE|||||||
33910930|NCT00358618|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33910931|NCT00158548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33910932|NCT06417931|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Quasi-randomised control trial|t|f|f|f
33992630|NCT04275895|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||"Attention performance of a group of prematurely born children will be compared on a classical school chair and a mobile school chair. The same comparison will be made for a group of term born children.~The perception of the Vertical gravity of the two groups will be evaluated in sitting position, lying to the right side and lying the left side.~The postural control of the two groups will be evaluated standing on a force plate in three conditions : eyes opened watching a cartoon, eyes opened gazing a fixation cross on the wall and eyes closed.~The postural control of the two groups will be measured during the execution of three different attentional tasks. For each task, two levels of difficulty will be tested.~Finally, growth trajectory from birth will be analysed as a confounding factor."||||
33992631|NCT01120340|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33992632|NCT03746795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"During the experiment, six measurements will be performed for each examined individual to calculate the spirometric parameters of FVC, FEV1 and Tiffenea's index (TI) FEV1/FVC. Spirometry measurements will be performed in a randomized order: two standard spirometric examinations, two spirometric examinations using EIT and two simultaneous measurements using both methods.~Each subject will undergo all six measurements."||||
33992633|NCT01602939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992634|NCT01039363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992635|NCT05905640|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomized trial of twelve public health clinics assigned 1:1 to implement either the intervention of One stop PrEP care pathway or usual clinic flow as control.||||
33992636|NCT05821647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patient and the researcher performing the analysis are blinded. Because of the nature of the interventions, the investigators and treating anesthesiologist, anaesthesia nurse, intensivist and critical care nurse will not be masked to group allocation.|The study has two arms in which patients are allocated in a 1:1 randomization ratio.|t|f|f|f
33992637|NCT04784338|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34084917|NCT01785381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34084918|NCT04018066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Longitudinal study||||
34084919|NCT04321889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized double-blind placebo clinical trial for parallel groups to evaluate the clinical efficacy of defurocumarinized bergamot loaded in a nanotechnological system of essential oil release in the pharmaceutical form of a cream in the treatment of agitation, in patients of both sexes with severe dementia diagnosis. Subjects will be eligible if they meet all inclusion criteria. A total of 134 patients will be enrolled, randomized, in a 1:1 ratio, to treatment with defurocumarinized bergamot loaded in a nanotechnological release system or placebo.|t|f|f|t
33689202|NCT01568788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689203|NCT05590221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689204|NCT01411072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689205|NCT00285467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689206|NCT03550651|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||5x5 latin cross over study|t|f|t|t
33689207|NCT01393015|RANDOMIZED|PARALLEL||||NONE||||||
33689208|NCT05078502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Immediately after randomization, random numbers of the two sets were assigned as patient code number. One set was designated as intervention group and another set was placebo group. Then the set of code numbers that belong to the intervention group were written as patient ID numbers on the packages contained vitamin D3 capsules. On the other hand, the set belongs to the placebo group were designated as patient ID numbers on the packages containing placebo capsules. This total procedure was conducted by the persons unrelated to this research. Thus the participants, caregiver, outcome assessor and the analyst, who require being blind for such study, were effectively blinded.|Randomized, double-blind, placebo controlled study|t|f|t|f
33689209|NCT04563676|NA|SINGLE_GROUP||SCREENING||NONE||||||
33689210|NCT05481788|||COHORT||RETROSPECTIVE|||||||
33689211|NCT05956210|||COHORT||PROSPECTIVE|||||||
33778407|NCT00399178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778408|NCT04021056|||COHORT||OTHER|||||||
33778409|NCT02413788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33778410|NCT04171726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910933|NCT06536153|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The trial subjects, bread distributors, and outcome assessors (data collectors) will be all unaware of the study groups assignment and bread content. The bread distributers for the maize and amaranth groups will be distinct, and there will be 12 bread-distributers, one for each kebele. Twelve boxes, one for each kebele, will be packed and tagged with the name of the pregnant women. Every day, each bread-distributer fed the pregnant women at their home, under their close supervision. Unopened bread will be returned and recorded by the coordinator each day in the event of absences or refusals.|Both bi-variable and multivariable analyses using multilevel mixed effects modified Poisson models with random effects will be carried out if the outcome variable prevalence is greater than 20%. If the prevalence is less than 20%, a multilevel mixed effects binary logistic regression model will be utilized to adjust for between- and within-cluster variation for adjusted analysis.|t|t|f|t
33910934|NCT05304871|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo and antibiotic packaged similarly, code identified by Investigational Pharmacy. Patients and providers will not know which had been administered.||t|t|t|t
33910935|NCT03869957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A team researcher will use Stata 12, to perform randomization with a 1:1 allocation using random block sizes of 4. Once the treatment group is determined, the PN will be prescribed accordingly and the preparation will be carried out in the pharmacy and it will have the same appearance in both arms. Patients and researchers who will evaluate the outcomes and perform the statistical analysis will be blinded to the assigned group.|Randomized, double-blind, controlled clinical trial|t|f|t|f
34084920|NCT05043740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084921|NCT00395577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084922|NCT05495178|||COHORT||PROSPECTIVE|||||||
34084923|NCT06432348|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34084924|NCT03099525|||COHORT||PROSPECTIVE|||||||
34084925|NCT03279458|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084926|NCT03635918|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084927|NCT03159403|||CASE_ONLY||RETROSPECTIVE|||||||
34084928|NCT03409744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084929|NCT02944292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084930|NCT05646914|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessor was kept blinded to allocation of participants.|A randomized control study with a pretest-posttest design.|f|f|f|t
34084931|NCT01646437|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34084932|NCT05966233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084933|NCT03542578|||COHORT||PROSPECTIVE|||||||
34084934|NCT03708146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084935|NCT02889419|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34084936|NCT05074901|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Open populational trial|t|f|f|f
34084937|NCT04793945|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with three patches of Alopecia Areata the first patch will be treated by topical steroid and Excimer light the second patch will be treated by topical steroid only the third patch will be left as a control||||
34084938|NCT01036802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084939|NCT04789122|||OTHER||PROSPECTIVE|||||||
33689212|NCT03504670|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to early amniotomy (\<4cm cervical dilation) or late amniotomy (≥4cm dilated). Participants may crossover due due to clinical conditions that are not preventable. These conditions may include: unengaged vertex at time of attempted amniotomy, need for internal monitors, or cervical dilation that does not reach 4cm.||||
33689213|NCT06063707|||COHORT||PROSPECTIVE|||||||
33689214|NCT02331875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689215|NCT03131453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778411|NCT01246843|||CASE_ONLY||PROSPECTIVE|||||||
33778412|NCT00149721|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910936|NCT02491437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910937|NCT01729013|||COHORT||PROSPECTIVE|||||||
33910938|NCT03278080|NA|SINGLE_GROUP||OTHER||NONE||||||
33910939|NCT01433627|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33910940|NCT03770364|||COHORT||PROSPECTIVE|||||||
33910941|NCT05078333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084940|NCT06426745|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084941|NCT03767127|||COHORT||PROSPECTIVE|||||||
34084942|NCT03250273|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084943|NCT02737358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084944|NCT01824667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34084945|NCT04324749|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group A: Habitual diet + 25 g/day of whole skin roasted peanuts (RP) Group B: Habitual diet+ 2 tbsp/day (32 g/day) of peanut butter (PB) Group C: Habitual diet + control supplement (containing the same proportion of macronutrients as in the intervention)||||
34084946|NCT01715051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34084947|NCT04330599|||COHORT||PROSPECTIVE|||||||
34084948|NCT06394258|NA|SINGLE_GROUP||TREATMENT||NONE||Endometrial Cancer adjuvant treatment: Exclusive fractionated radiosurgery 21 Gy/3 fractions (BED10 35,7 Gy) prescribed to 100% isodose at 5 mm from the mucosa surface and 150% isodose to the mucosa surface (BED10 64,675 Gy)||||
34084949|NCT01466868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992638|NCT06742918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"It is a randomized clinical trial. Participants are the patients who came randomly into the settings and enrolled based on inclusion and exclusion criteria. They are divided into three groups. Group I received Tablet HBR (Aqueous Extract Berberis), Group II received Syrup SBM (a Unani formulation) and Group III received a combination of both.~Investigator is the researcher of the study."|Group I was given the Tablet HBR (Aqueous extract Berberis), Group II received Syrup SBM (A Unani Formulation), and Group III was given a combination of both. The groups were divided based on the treatment findings to evaluate the efficacy of the medicines, i.e. whether these medicines are effective individually against Uropathogens of in combination.|t|f|t|f
33992639|NCT06729385|||COHORT||PROSPECTIVE|||||||
33992640|NCT05489289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992641|NCT05884320|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689216|NCT06447493|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Two by Two cross-over trial. Measurements will be taken on both shoulders with only the dominant shoulder receiving osteopathic manipulative treatment (OMT). The order in which the measurements and OMT treatment is performed will be randomized. The cross-over design allows for the opportunity to estimate 3 components, the possible effect of ultrasound measurement on the outcomes even when OMT is not performed, the combined effect of OMT and ultrasound measurements on outcomes, and an adjusted estimate OMT treatment effect removing any ultrasound effects if those effects exist. Change scores for all outcomes will be calculated per shoulder and then a comparison between change scores will be conducted using a paired design.||||
33689217|NCT01549912|||CASE_CONTROL||RETROSPECTIVE|||||||
33910942|NCT04358094|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33689218|NCT05540080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910943|NCT01477190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910944|NCT00162396|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33992642|NCT04841096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992643|NCT06350500|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33992644|NCT00835588|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992645|NCT03474965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992646|NCT06742853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992647|NCT02203903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992648|NCT00905658|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33992649|NCT05763537|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33992650|NCT06541145|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33992651|NCT00750243|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33992652|NCT03280862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients are unaware of treatment arm. All patients undergo the same pre-implant program and follow-up. Healthcare personel performing follow-up are blinded for treatment arm. Outcome events are evaluated by a committee blinded for treatment arm.|"Double-blind randomised controlled trial. Patients are included and randomised 1:1 into two groups for implantation of either~1. a CRT-D/P device with the LV lead positioned according to the latest electrical activation in the CS (intervention group) or~2. a CRT-D/P device with the LV lead positioned preferentially in a posterolateral, non-apical position (control group)"|t|t|t|t
33992653|NCT04173104|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689219|NCT03518931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689220|NCT02781519|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33689221|NCT01231230|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33689222|NCT01339026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689223|NCT00002988||||TREATMENT||||||||
33689224|NCT01594385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689225|NCT00488878|||COHORT||OTHER|||||||
33689226|NCT05369260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689227|NCT04900168|||COHORT||PROSPECTIVE|||||||
33778413|NCT03735810|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33778414|NCT06615648|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33910945|NCT04683198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910946|NCT03154632|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33910947|NCT06441812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910948|NCT05722236|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778415|NCT02702934|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33778416|NCT03413774|||CASE_CONTROL||PROSPECTIVE|||||||
33778417|NCT05876936|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778418|NCT00257816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778419|NCT03354299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The patients were divided into 2 groups, groups I received 25 g of sugar plus 50 cc of coconut milk (200 kkal) as late night snacks (LNS); and group II received 50 g of sugar alone (200 kkal) as LNS||||
33910949|NCT05888467|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, monocentric, interventional, randomized-controlled trial||||
33910950|NCT05956886|NA|SINGLE_GROUP||TREATMENT||NONE|This is a feasibility study aimed at developing a new intervention strategy.|Using the pretest-posttest design, the investigators will test the efficacy of the 4-week sleep chatbot intervention on improving sleep health (primary) and metabolic syndrome factors (exploratory).||||
33910951|NCT05295368|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33910952|NCT01124084|||COHORT||PROSPECTIVE|||||||
33910953|NCT04989829|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study is a single-center, open, single-dose, Fixed-sequence clinical trial.||||
33910954|NCT04691063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1316 in combination with chemo-radiotherapy.|t|t|t|t
33910955|NCT01201096|||CASE_CONTROL||PROSPECTIVE|||||||
33910956|NCT06165484|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910957|NCT05149937|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33910958|NCT00089843|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33992654|NCT03749187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689228|NCT00147420|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33689229|NCT01293500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689230|NCT06281275|||COHORT||PROSPECTIVE|||||||
33689231|NCT01795820|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33778420|NCT03055585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33910959|NCT06255470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910960|NCT01880268|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33910961|NCT02610400|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33910962|NCT04964063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910963|NCT03001037|||CASE_CONTROL||PROSPECTIVE|||||||
33910964|NCT04480892|||COHORT||PROSPECTIVE|||||||
33910965|NCT01570712|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910966|NCT00853333|RANDOMIZED|PARALLEL||||NONE||||||
33910967|NCT05158309|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants experienced both experimental (capsaicin) condition and placebo conditions. Due to the long-lasting effects of capsaicin after 24 hours of application, placebo condition always preceded the capsaicin condition.|t|f|f|f
33910968|NCT04192448|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant will only be blind to emotion condition. Participants will be informed of their alcohol condition. Investigator and experimenter will be aware of participants' assigned condition.|The study utilizes a 2x2 (Alcohol and Emotion) design in which participants will be randomly assigned to one of four groups: AlcoholxAnger, AlcoholxControl, SoberxAnger, SoberxControl|t|f|f|f
33910969|NCT01883440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910970|NCT04591509|||COHORT||PROSPECTIVE|||||||
33910971|NCT02800564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study design and communities' status as active or passive are not discussed with the field staff.||f|f|f|t
33910972|NCT05204199|||COHORT||PROSPECTIVE|||||||
33910973|NCT03974347|||COHORT||PROSPECTIVE|||||||
33910974|NCT05425238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33910975|NCT04397406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients will be randomly allocated into three equal groups by computer generated sequence through sealed opaque envelopes. Each group will include 30 patients.~Group C (Control group): Epidural analgesia with levobupivacaine alone Group D (Dexmedetomidine group): Epidural analgesia with levobupivacaine and dexmedetomidine Group F (Fentanyl group): Epidural analgesia with levobupivacaine and fentanyl"|t|f|t|f
33910976|NCT06105879|||CASE_ONLY||PROSPECTIVE|||||||
33910977|NCT05311280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||intervention group: Myotherapy+High intensity interval training Control group: Myotherapy + general home exercise|f|f|f|t
33910978|NCT02763878|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33910979|NCT01673464|||COHORT||PROSPECTIVE|||||||
33910980|NCT02787434|NA|SINGLE_GROUP||SCREENING||NONE||||||
33910981|NCT04544709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33910982|NCT00279968|||||PROSPECTIVE|||||||
33910983|NCT00374153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33910984|NCT02936219|||COHORT||PROSPECTIVE|||||||
33910985|NCT02531373|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33910986|NCT03738566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects who agreed to participate in the randomized trial were randomized to standard clinical care consisting of endoscopic dilation as needed versus esophageal self-dilation therapy in a 1:1 ratio using a block randomization approach. Subjects randomized to the standard clinical care group were offered cross-over to the esophageal self-dilation therapy if they failed stand of care. Subjects who agreed to take part in in the observational prospective study either commenced ESDT or continued standard clinical care based on shared decision making with their esophageal provider.||||
33910987|NCT05602259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33910988|NCT03563703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Because of the physical nature of the interventions, it will not be possible to conceal the group allocation from the nurses or trial participants.|Once eligibility, informed consent and assent are confirmed, participants will be randomly assigned, in the appropriate age stratum, to 1 of 2 groups: peripheral intravenous catheterization with the standard approach or with the help of either ultrasound or near-infrared vascular imaging. Randomization will be achieved with the use of an online, computer-generated program.|f|f|t|t
33910989|NCT05804305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|This is a double blind randomised control trial to see the effect of Misoprostol in treating patients with NASH|t|t|t|t
33910990|NCT01253421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There were two groups of subjects: currently experiencing a major depressive episode, or normal health controls. The groups were matched for age, gender, and race. Within each group, half of the subjects were assigned to receive the study drug (amisulpride) and half to receive a placebo.|t|f|t|f
33910991|NCT06250530|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study is a single centre, pilot randomised controlled, patient blinded study that will randomly assign 40 participants with medial knee osteoarthritis undergoing medial opening wedge proximal tibial osteotomy (MOWHTO) to either current standard of care, with TOMOFIX plating system, or utilise patient specific instrumentation and custom-made plate development, with BodyCAD Fine Osteotomy.||||
33910992|NCT05790811|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33910993|NCT05831670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33910994|NCT00368134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33910995|NCT01241669|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33910996|NCT02813798|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33910997|NCT05977517|||COHORT||PROSPECTIVE|||||||
33910998|NCT01005732|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33910999|NCT06084390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911000|NCT00626912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911001|NCT01620385|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911002|NCT01636024|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33911003|NCT01240811|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911004|NCT00414310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911005|NCT04387370|||CASE_CONTROL||PROSPECTIVE|||||||
33911006|NCT04716192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911007|NCT06553417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The moisturizer codes will be blinded (double-blind) until all study phases are completed. This ensures that the participants, investigators, and outcomes assessors are unaware of which intervention each participant is receiving during the study. This helps to minimize potential bias in the evaluation of the treatment outcomes.||t|f|t|t
33911008|NCT03897582|||COHORT||PROSPECTIVE|||||||
33911009|NCT00103194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911010|NCT02020031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992655|NCT02045667|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33992656|NCT06532565|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992657|NCT06339645|||COHORT||RETROSPECTIVE|||||||
33992658|NCT03325881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992659|NCT00268879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992660|NCT06614725|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Click here to enter text.||t|t|t|t
33689232|NCT03435640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689233|NCT00905775|||CASE_CONTROL||PROSPECTIVE|||||||
33689234|NCT03858439|NA|SINGLE_GROUP||TREATMENT||NONE||Single group before / after dietary intervention.||||
33689235|NCT05532787|||COHORT||PROSPECTIVE|||||||
33689236|NCT00367770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689237|NCT03551483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689238|NCT00137865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689239|NCT02973607|||COHORT||OTHER|||||||
33689240|NCT04190303|||OTHER||PROSPECTIVE|||||||
33689241|NCT00381381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689242|NCT00177476|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689243|NCT00470912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33689244|NCT01627171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33689245|NCT01409759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689246|NCT03895242|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The priority of the positions to be given to preterm infants was randomly determined.The positions of preterm infants was identified using the closed envelope method.The positions of infants were written in envelopes and closed.The clinical nurse, who was not in the research, pulled the envelope and identified the infant position.First group was first supine position,then prone position (n = 19), second group was first prone position, then supine position (n = 19).||||
33689247|NCT05673460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689248|NCT04537260|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The research member enrolling the patient in the study, the participant, and the person collecting the questionnaires were all blind to what arm of the study the participant would be placed into (control vs intervention with video group). A computer-generated allocation sequence to determine randomization. Randomization assignments were placed in sealed, opaque envelopes that were opened sequentially after verbal and signed consent was obtained for the study. The research team members who collected the outcome data (example, parity, delivery method, etc) was also blind to which arm the participant was assigned too.|Participants were either enrolled in the control arm (no intervention) or the intervention group (3-minute educational video intervention)|t|t|t|t
33689249|NCT06079528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689250|NCT02648321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689251|NCT01037270|||COHORT||PROSPECTIVE|||||||
33689252|NCT02259790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33689253|NCT03262402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689254|NCT01487473|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33689255|NCT04949971|||COHORT||PROSPECTIVE|||||||
33689256|NCT03463031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778421|NCT05575843|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The HCPs and neurologists performing the examinations are blinded to each others' assessment scores and to the results of previous clinical EDSS examinations. The evaluating experts are blinded to the raters' identity until watching an examination video.|Multicentre randomized cross-over study: Randomization 1:1 to group A and group B. Group A undergoes first the Neurostatus-EDSS® and afterwards the Neurostatus-SMARTCARE. Group B starts with the Neurostatus-SMARTCARE and finishes with the Neurostatus-EDSS®. At the next visit the reverse order is applied, by the same neurologist and HCP.|f|f|f|t
33778422|NCT04750408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778423|NCT05435183|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients were randomized to receive one hour each of the two non-invasive ventilation modes before and after, and one hour of washout after receiving the first mode of ventilation before receiving the second intervention.||||
33778424|NCT02662738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33778425|NCT02788136|NON_RANDOMIZED|PARALLEL||||NONE||||||
33778426|NCT02081365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778427|NCT01066156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778428|NCT01870817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778429|NCT04079036|||CASE_CROSSOVER||PROSPECTIVE|||||||
33778430|NCT02842879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778431|NCT06585020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778432|NCT03444675|||COHORT||PROSPECTIVE|||||||
33778433|NCT00518375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778434|NCT05678595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911011|NCT02118610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911012|NCT05892133|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33911013|NCT04973033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911014|NCT03957109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992661|NCT06613906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992662|NCT06741800|||COHORT||PROSPECTIVE|||||||
33992663|NCT06321731|||COHORT||RETROSPECTIVE|||||||
33992664|NCT06589726|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33911015|NCT00000309|RANDOMIZED|||TREATMENT||DOUBLE||||||
33911016|NCT05718154|||COHORT||CROSS_SECTIONAL|||||||
33911017|NCT02437097|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33911018|NCT04505696|NA|SINGLE_GROUP||OTHER||NONE||Single group pre-post||||
33911019|NCT01094002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33911020|NCT02572518|||CASE_CONTROL||PROSPECTIVE|||||||
33911021|NCT00236639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911022|NCT02028546|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33992665|NCT05757453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992666|NCT05955508|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992667|NCT04610866|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992668|NCT05452902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778435|NCT03019458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778436|NCT02518932|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33778437|NCT05159882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Dapagliflozin tablets, 10mg; Double Blind; Each subject will receive Dapagliflozin (active tablet) once daily for the duration of the study.|THR-1442 tablets, 20 mg; Double-Blind; Each subject will receive THR-1442, 20 mg once daily for the duration of the study.|t|t|t|f
33778438|NCT02278575|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33778439|NCT00901056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778440|NCT06367062|||COHORT||RETROSPECTIVE|||||||
33778441|NCT01034475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778442|NCT03950401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There is no way to mask the two techniques from the provider or patient since they will see the final result of the technique. The data analysis can be performed in a blinded manner.|Randomization to Monocryl versus subcuticular Nylon type of skin closure.|f|f|f|t
33992669|NCT06634797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33992670|NCT01933620|||COHORT||PROSPECTIVE|||||||
33992671|NCT06471660|||OTHER||CROSS_SECTIONAL|||||||
33992672|NCT02960295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992673|NCT02308059|||||CROSS_SECTIONAL|||||||
33992674|NCT02709018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992675|NCT00298415|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34084950|NCT02823119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34084951|NCT02650817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084952|NCT05412134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only person who will know the arm of each participant will be the study team member in charge of randomization (the clinical research coordinator)||t|t|t|t
34084953|NCT05349305|||CASE_ONLY||RETROSPECTIVE|||||||
34084954|NCT06157229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084955|NCT04820907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084956|NCT04894708|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084957|NCT04093271|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34084958|NCT03072186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34084959|NCT03817528|NA|SINGLE_GROUP||TREATMENT||NONE|None (open label)|open-label||||
34084960|NCT06094465|||COHORT||RETROSPECTIVE|||||||
34084961|NCT00697320|||||PROSPECTIVE|||||||
34084962|NCT04301973|NA|SINGLE_GROUP||OTHER||NONE||||||
34084963|NCT01376219|||COHORT||RETROSPECTIVE|||||||
34084964|NCT02333643|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34084965|NCT01451372|||COHORT||OTHER|||||||
34084966|NCT00109096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34084967|NCT05087589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084968|NCT02020941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084969|NCT02548871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084970|NCT00302900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34084971|NCT05531877|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The P.I.M.P Chart will be hung on the operative room wall and penile measurements pre and post operatively recorded as the surgery progresses together with the Penile Implant size.||||
34084972|NCT02593500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34084973|NCT02439164|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34084974|NCT00801944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34084975|NCT00920062|||||PROSPECTIVE|||||||
34084976|NCT03397017|||COHORT||PROSPECTIVE|||||||
34084977|NCT02787499|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34084978|NCT01769547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084979|NCT01940848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778443|NCT04755868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778444|NCT05799924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33778445|NCT04708184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778446|NCT02719197|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33778447|NCT00799461|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||||||
33992676|NCT02247791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34084980|NCT04596319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled|t|t|t|f
34084981|NCT01806181|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33778448|NCT00070629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778449|NCT02554175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778450|NCT03033121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778451|NCT05830695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992677|NCT03646175|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33778452|NCT05101109|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: ABL501||||
33778453|NCT04813146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778454|NCT04302090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Each participant will experience successives periods A period of 4 consecutive contractions without using the expiration mouthpiece and a second period of 4 consecutive contractions using the the expiration mouthpiece .~pain levels measured in each period will be compared for the same participant"||||
33778455|NCT00595283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778456|NCT00107185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778457|NCT00811889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778458|NCT06200155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33778459|NCT03415087|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33778460|NCT03964480|||COHORT||PROSPECTIVE|||||||
33778461|NCT03871881|||COHORT||CROSS_SECTIONAL|||||||
33778462|NCT01661881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778463|NCT01932996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778464|NCT02543593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778465|NCT06474117|||CASE_CONTROL||PROSPECTIVE|||||||
33778466|NCT06619912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778467|NCT00675961|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33778468|NCT04164160|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33778469|NCT04774185|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33778470|NCT01924143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911023|NCT02074579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911024|NCT05796427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911025|NCT04106427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Assessments will be conducted by blind assessors. Participants will be blind to the type of psychotherapy and the type of rTMS administered||t|t|t|t
33911026|NCT00455260|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911027|NCT01540461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33911028|NCT02164513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911029|NCT04177056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911030|NCT01935687||CROSSOVER||TREATMENT||NONE||||||
33911031|NCT01996137|NA|SINGLE_GROUP||TREATMENT||NONE||1 hour of VASST II training, total 15 sessions over 5 weeks continuously||||
33911032|NCT03201172|||COHORT||RETROSPECTIVE|||||||
33911033|NCT01746732|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33911034|NCT05126524|||COHORT||PROSPECTIVE|||||||
33992678|NCT05981040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992679|NCT01983969||SEQUENTIAL||TREATMENT||NONE||||||
33992680|NCT04504617|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33992681|NCT06154135|||COHORT||PROSPECTIVE|||||||
33992682|NCT02404870|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33992683|NCT06293586|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33992684|NCT06393387|||COHORT||RETROSPECTIVE|||||||
33992685|NCT00295477|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992686|NCT03012529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992687|NCT06626204|||OTHER||PROSPECTIVE|||||||
33992688|NCT06601140|NA|SINGLE_GROUP||OTHER||NONE|Patient health questionnaire - 9 (PHQ-9) and (Montgomery Asberg Depression Rating Scale) MADRS assessments will be performed by an investigator who doesn't know the score obtained with EMOCARE|The participant will continuously use the EMOCARE software during the 6 weeks of follow-up and will answer the questionnaires usually used on a regular basis over the same period.||||
33992689|NCT05276219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching and identical placebo (saline)|"Inter-regional collaborative, randomized, placebo-controlled trial with 1:1:1 allocation~* Boluses of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician.~* Boluses of 3 mg IV isosorbide dinitrate given as soon as possible and repeated up to 10 times by the discretion of the treating physician.~* Boluses of both 3 mg IV isosorbide dinitrate + of 40 mg furosemide given as soon as possible and repeated up to 10 times by the discretion of the treating physician."|t|t|t|t
33992690|NCT05047536|NA|SINGLE_GROUP||TREATMENT||NONE||"All subjects will receive 30 to 60-minute intravenous infusion of KZR-261 via a central line on Days 1, 8, and 15 of a 4-week (28-day) treatment cycle.~Up to approximately 50 subjects will be enrolled and treated with KZR-261 in Part 1 (Dose Escalation). In Part 2 (Dose Expansion), up to 175 subjects (15-35 per tumor cohort \[melanoma, uveal melanoma, colorectal cancer, prostate cancer, mesothelioma, and All-Tumor\]) will be enrolled."||||
33992691|NCT05844605|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot single-cohort feasibility open-label trial||||
33992692|NCT05333471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992693|NCT06741735|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992694|NCT06699433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33992695|NCT02007733|||COHORT||PROSPECTIVE|||||||
33992696|NCT06742762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Up to three groups (two renal impairment groups and controls with normal renal function) will be enrolled into this study.~All subjects will receive the study intervention:~Group 1 will enroll 7 participants with severe renal impairment Group 2 will enroll \~7 participants with normal renal function matched by sex, age, and body weight Group 3 (optional) will enroll 7 participants with moderate renal impairment"||||
33992697|NCT06450041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992698|NCT00663663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992699|NCT06742567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Eligible patients will be enrolled after informed consent. Randomization will be undertaken once post primary PCI echocardiography is done and LV function is recorded. Patients with anterior wall myocardial infarction with severe left ventricular dysfunction defined by an EF\<35% without evidence of LV thrombus will be screened. Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT for two weeks in addition to other guideline directed medical therapy (GDMT). After two weeks of triple therapy (DOAC+DAPT), aspirin will be dropped in the study arm. The control arm will be standard DAPT and GDMT without apixiban.~Primary endpoint will be the incidence of left ventricular thrombus in the study arm vs the control group at one month echocardiographic follow up. While an open label trial, end point adjudication will be blinded where the echocardiographer will not know treatment allocation of the two groups."|f|f|f|t
33911035|NCT02249234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911036|NCT03314519|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||Compare lung collapse of lung ultrasonography to fiberoptic bronchoscopy.|t|t|f|t
33911037|NCT01341431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33911038|NCT00002533|RANDOMIZED|||TREATMENT||||||||
33911039|NCT04997070|||OTHER||PROSPECTIVE|||||||
33911040|NCT05020652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911041|NCT01685632|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911042|NCT06203730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911043|NCT02669797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Like most behavioral interventions, it is not possible to double blind this RCT because interventionists will be delivering the in-home visiting components to participants. However, the proposed study incorporates participant, study staff, physician, and investigator blinding as much as possible. The intervention will be administered by trained staff assigned to the intervention team, who will not be involved with evaluation team responsibilities/meetings. Evaluation team members will carry out all measurement home visits and will be blinded to participant study arm assignment. They will not be involved with intervention team responsibilities/meetings. Specific co-investigators are responsible for training and supervising staff within the intervention team versus the evaluation team in to order to blind as many co-investigators as possible.|Three-arm, individual randomized controlled trial.|t|t|t|t
33911044|NCT03554005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911045|NCT06198959|RANDOMIZED|CROSSOVER||OTHER||NONE||The investigators propose a single-center multiple crossover randomized trial to determine cutaneous heat transfer with four warming devices and five blankets. Cutaneous heat loss/ gain will be measured with thermal flux transducers in unanesthetized volunteers.||||
33911046|NCT02427256|||COHORT||PROSPECTIVE|||||||
33911047|NCT05130333|||OTHER||PROSPECTIVE|||||||
33911048|NCT01446198|||CASE_CONTROL||RETROSPECTIVE|||||||
33911049|NCT00292474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911050|NCT06291103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911051|NCT05478343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911052|NCT01449591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911053|NCT04386044|||OTHER||OTHER|||||||
33911054|NCT01934192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911055|NCT02518984|||COHORT||PROSPECTIVE|||||||
33911056|NCT00921999|||||PROSPECTIVE|||||||
33992700|NCT03643250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33992701|NCT00377260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992702|NCT04913233|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33992703|NCT00304187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992704|NCT00237016|RANDOMIZED|PARALLEL||||DOUBLE||||||
33992705|NCT06725069|||OTHER||PROSPECTIVE|||||||
33992706|NCT02272803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992707|NCT00809250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992708|NCT03957226|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33992709|NCT04089917|||COHORT||RETROSPECTIVE|||||||
33992710|NCT05850416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992711|NCT05064891|||COHORT||PROSPECTIVE|||||||
33992712|NCT06742775|||COHORT||PROSPECTIVE|||||||
33992713|NCT06496568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992714|NCT01862731|||COHORT||PROSPECTIVE|||||||
33992715|NCT01165450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33992716|NCT06213649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34084982|NCT00722020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34084983|NCT00606008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084984|NCT03387293|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33778471|NCT05059574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Since there is no placebo group, masking will not be done.|While crawling to the breast is tried in the experimental group, biological breastfeeding will be applied in the control group.||||
33778472|NCT02194218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778473|NCT05761925|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778474|NCT02800928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33778475|NCT02453230|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33778476|NCT05992155|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33778477|NCT03503994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911057|NCT03445897|NA|SINGLE_GROUP||TREATMENT||NONE||Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).||||
33911058|NCT03505567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Eligible participants assigned two interventions under random sequence assignments.||||
33911059|NCT03979105|||COHORT||RETROSPECTIVE|||||||
33992717|NCT06497127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911060|NCT01795222|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33778478|NCT05010382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will recieve an implant with either hybrid surface (test group) or moderately rough surface (control implants|t|f|t|t
33778479|NCT06696495|||COHORT||PROSPECTIVE|||||||
33992718|NCT03904329|||COHORT||PROSPECTIVE|||||||
33992719|NCT06054555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is double-blinded; therefore, the investigators, study personnel (with the exception of the data monitoring committee, authorized unblinded sponsor and contract research organization staff, and unblinded site pharmacy staff) and the study subjects will remain blinded to treatment allocation. ABP 206 and nivolumab will be coded and labeled to protect blinding.||t|f|t|f
33992720|NCT06741397|RANDOMIZED|SINGLE_GROUP||OTHER||NONE|This is an open label study.|||||
33992721|NCT02581553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992722|NCT06741839|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34084985|NCT00460967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778480|NCT03068923|||COHORT||PROSPECTIVE|||||||
33778481|NCT04266990|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33778482|NCT00963703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911061|NCT05179460|||COHORT||RETROSPECTIVE|||||||
33911062|NCT00846079|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911063|NCT04905537|||CASE_ONLY||PROSPECTIVE|||||||
33992723|NCT05746806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992724|NCT06741826|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33992725|NCT06741553|||COHORT||PROSPECTIVE|||||||
33992726|NCT06743399|||CASE_CONTROL||PROSPECTIVE|||||||
33992727|NCT04548596|||CASE_ONLY||PROSPECTIVE|||||||
33689257|NCT03216031|NA|SINGLE_GROUP||PREVENTION||NONE||In the implementation phase, a falls prevention gardening group will be implemented. Staff members of the Integrated Falls and Bone Health Service will offer their patients who decline to take part in the standard prevention exercise programme or who have completed the other prevention classes to participate in a gardening programme. The goal is to recruit 30 patients as participants of the gardening programme and to engage them in weekly gardening activities for 8 weeks (either 8 weeks in a row or 8 attendances over 3 months to allow for sickness / other reasons for non-attendance). 3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the new growing site. Only participants who have passed the risk screening of the Integrated Falls and Bone Health Service and who meet all inclusion criteria will be invited to join the gardening programme.||||
33689258|NCT04450459|||COHORT||PROSPECTIVE|||||||
33689259|NCT05825612|||COHORT||PROSPECTIVE|||||||
33778483|NCT02713997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778484|NCT00124605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778485|NCT05053308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778486|NCT01375712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778487|NCT03660605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778488|NCT04934553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778489|NCT01577732|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778490|NCT06697509|||COHORT||PROSPECTIVE|||||||
33778491|NCT02949674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33778492|NCT02555371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778493|NCT00742885|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33778494|NCT00865475|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778495|NCT02953548|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
33778496|NCT00380887|||DEFINED_POPULATION||OTHER|||||||
33778497|NCT02037061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778498|NCT05567666|NA|SINGLE_GROUP||TREATMENT||NONE||Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter.||||
33778499|NCT00166634|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
33778500|NCT04752657|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Each participant will be randomized to one of the 2 groups. A statistician will generate randomization lists with the use of randomly permuted blocks of varying sizes, with stratification according to participant's age (≤75 years vs. \>75 years) and type of phone (android vs. iphone). Randomization will be implemented centrally through the app.|f|t|t|t
33778501|NCT04880915|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778502|NCT00604721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778503|NCT06613555|||COHORT||PROSPECTIVE|||||||
33778504|NCT00538408|||||PROSPECTIVE|||||||
33778505|NCT01419301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33778506|NCT05468567|||CASE_CONTROL||PROSPECTIVE|||||||
33778507|NCT00940134|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33778508|NCT01258387|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33778509|NCT01194505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patient, the orphopaedic surgeon and the anesthesiologist in the OR did not know at which group the patient belonged to.||t|t|f|t
33778510|NCT01894958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911064|NCT01884129|||COHORT||PROSPECTIVE|||||||
33911065|NCT00417976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911066|NCT05807334|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized, crossover design, controlled trial||||
33911067|NCT05296850|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial: Two parallel treatment groups; participants were randomly allocated to Group 1 \[Manual release (MR)\] and Group 2 \[Kinesio taping (KT)\]||||
33911068|NCT02794051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911069|NCT01044381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778511|NCT00044590|||CASE_CONTROL||OTHER|||||||
33778512|NCT05347537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778513|NCT03753321|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33911070|NCT03233412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients between 25 and 50 years old with histological diagnosis of high-grade intraepithelial lesion, obtained through satisfactory colposcopy and without previous treatment, who will be selected in the preventive clinic of the Hospital de Cancer de Barretos-SP (HCB ). Eligible patients will be identified at the return visit, when they will come to the hospital to check the result of the examination. In this study the patients will be randomized into two groups: Group 1: Control, where standard treatment will be offered, which is the conization of the uterine cervix with loop electrosurgical excision procedure(LEEP); Group 2: experimental group, which will receive topical treatment in the uterine cervix with immunomodulator (Imiquimod), for a period of 12 weeks, with weekly applications (1x / week). 30 to 60 days after immunomodulatory treatment the patient will be submitted to standard treatment with cervical conization with LEEP.|f|f|f|t
33992728|NCT00472589|||||PROSPECTIVE|||||||
33778514|NCT05407363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33778515|NCT05402579|||CASE_CONTROL||OTHER|||||||
33778516|NCT02747264|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33778517|NCT02096081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911071|NCT05605379|||COHORT||RETROSPECTIVE|||||||
33911072|NCT01218412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33911073|NCT00107068|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33992729|NCT06743191|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33992730|NCT03937557|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33992731|NCT06720584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Pilot randomized wait-list controlled trial||||
33992732|NCT06733597|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689260|NCT03083860|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||2 groups of 15-45 patients will be recruited in parallel and monitored for 4-6 weeks, than they will be followed for 4-6 weeks. They will receive feedback based on diary information and EEG.||||
33689261|NCT02990156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689262|NCT03583203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689263|NCT03002727|||COHORT||PROSPECTIVE|||||||
33689264|NCT05840029|||COHORT||PROSPECTIVE|||||||
33689265|NCT04766372|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the study, it will not be possible to blind participants to their study condition (as they will know whether they are engaging the physical activity programme or not). As the researchers will be doing the data collection and conducting the behaviour change support calls, it will also not be possible to blind the researcher to the study.|Using block randomisation on Microsoft Excel, participants will be assigned to one of the four groups following baseline measures||||
33689266|NCT01936077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689267|NCT00434395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33689268|NCT03439527|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Open-label, monocentric, first-in-man trial to assess safety and tolerability of a new therapeutic strategy for stress urinary incontinence based on the implantation of muscle precursor cells (MPCs) 40 female patients suffering from urinary incontinence since at least 6 months (predominant clinical diagnosis of SUI) and who are candidate for a surgical treatment will be included .~All patients are treated by the same product: Autologous MPCs. After treatment, the patients will be randomized 1:1 in the MPC-group or NMES+MPC-group to investigate the benefits of an additional physiotherapy."||||
33689269|NCT01390220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911074|NCT06376474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911075|NCT03716232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911076|NCT00807833|||COHORT||PROSPECTIVE|||||||
33911077|NCT04393636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911078|NCT02533518|NA|SINGLE_GROUP||SCREENING||NONE||||||
33911079|NCT03661827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|yES|||||
33911080|NCT01770873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084986|NCT02458066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911081|NCT03252704|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Study products were concealed in opaque foil envelopes. The treatments were identified by alphanumeric code. The subjects and investigators did not know the identity of the treatments.||t|f|t|f
33911082|NCT05328921|||CASE_ONLY||CROSS_SECTIONAL|||||||
33911083|NCT02884817|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34084987|NCT01059331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911084|NCT05740852|||CASE_CONTROL||RETROSPECTIVE|||||||
33911085|NCT02504476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911086|NCT04753203|NA|SINGLE_GROUP||TREATMENT||NONE||A phase lb/ll, open label, single arm study||||
33911087|NCT00340314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911088|NCT04561635|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911089|NCT03104335|NA|SINGLE_GROUP||TREATMENT||NONE||participants will be advised to recieve 750 mg daily once apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.||||
34084988|NCT06467721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34084989|NCT02675166|||COHORT||PROSPECTIVE|||||||
33911090|NCT03593967|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Based on availability of schedule, participants will sign up for one of the 4 groups available (ie. 2 intervention groups and 2 wait-list control group). Wellbeing and self-concept assessments will be conducted for all groups at baseline (T1), thereafter the intervention groups will undergo a 5-weeks 15-hour ARTISAN intergenerational arts programme that integrates curated museum visits, facilitated storytelling, creative art-making, and reflective writing for exploring and sharing life narratives on heritage, adversity, strengths and unity, with the aim to foster aspirations, resilience, wellbeing and social cohesion. Upon completion of programme among the intervention group, all 4 groups will be assessed again (T2), and thereafter, the wait-listed controlled group will received the same 5-week 15-hour programme. At the end of all intervention components, a final exit assessment will be conducted on all groups (T3).||||
33992733|NCT04570748|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33992734|NCT06299280|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double-blind|randomised controlled|t|f|f|t
33911091|NCT05851508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Trial subjects, treating physicians and outcome assessors will be blinded throughout the entire study. Pharmacy staff will be unblinded for randomization and treatment allocation.~Emergency unblinding may occur in the following situations: in case of a medical emergency where knowledge of the blinded treatment is necessary, for the treatment of (serious) adverse event, in the event of a SUSAR (Suspected Unexpected Serious Adverse Reaction) needing expedited reporting or if requested by the Safety Committee."|A multicenter, double-blinded, randomized, placebo-controlled trial|t|t|t|t
33911092|NCT03559244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor blinded to participants' allocated group|Parallel group randomized controlled study|f|f|f|t
33911093|NCT01172587|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33992735|NCT02908776|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34084990|NCT02254642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911094|NCT06245018|NA|SEQUENTIAL||TREATMENT||NONE||||||
34084991|NCT03608605|||CASE_CONTROL||PROSPECTIVE|||||||
33992736|NCT04966104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|An independent statistician logged on to a secure program (managed by the UHN THETA institute) that used randomly permuted blocks to assign subjects to ODYSSEE-vCHAT or the control group. To reduce the chance of patient allocation being predictable, we followed the convention whereby the block sizes and the fraction of each block size were known only by an independent statistician. We tested this algorithm with staff at THETA prior to subject recruitment. Our team of investigators remained blinded to ensure impartiality in decisions about procedures and analyses.|Double arm, parallel group, single-blind randomized trial|f|f|t|f
33992737|NCT03502889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689270|NCT05348135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33992738|NCT05660798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33992739|NCT06435429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992740|NCT01788735|||COHORT||PROSPECTIVE|||||||
33992741|NCT06742008|||COHORT||PROSPECTIVE|||||||
33992742|NCT06203119|||COHORT||PROSPECTIVE|||||||
33992743|NCT06742372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34084992|NCT02366871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33689271|NCT06424418|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33689272|NCT02140775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689273|NCT02972762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33689274|NCT05032430|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33689275|NCT04567654|||OTHER||RETROSPECTIVE|||||||
33689276|NCT00879944|||||PROSPECTIVE|||||||
33689277|NCT05427955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689278|NCT05494762|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689279|NCT02394002|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689280|NCT03709732|||COHORT||OTHER|||||||
33689281|NCT05439642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Validation and reliability study||||
33689282|NCT04231318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689283|NCT01108978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689284|NCT03023046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689285|NCT06156124|||CASE_CONTROL||RETROSPECTIVE|||||||
33689286|NCT01464983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33689287|NCT04481009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689288|NCT03198039|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33689289|NCT03978715|||OTHER||RETROSPECTIVE|||||||
33689290|NCT00937391|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689291|NCT02480712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689292|NCT03461510|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689293|NCT03894137|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33689294|NCT05920928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689295|NCT03455049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double Blind|Clinical Trials with Randomization, Double Blind, Crossover|t|f|t|f
33689296|NCT04499599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|For comparison between the placebo breakfast bar and the Fast Bar groups, the participants are masked.||t|f|f|t
33689297|NCT05616715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689298|NCT04618770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689299|NCT03636737|||COHORT||RETROSPECTIVE|||||||
33689300|NCT04369170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant and care provider are blinded, the outcomes assessor is also masked but the investigator knows if the participant belongs to group A or B when the data is recorded|Parallel blinded clinical trial|t|t|f|t
33689301|NCT02499458|||COHORT||PROSPECTIVE|||||||
33689302|NCT03403270|NA|SINGLE_GROUP||PREVENTION||NONE|Outcome Assessors will not be aware of previous research data collected. As this is a single group study, all participants will receive the intervention as described.|Time Series Quasi-Experiment||||
33689303|NCT01384071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689304|NCT00586196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33689305|NCT05411133|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689306|NCT00033072|RANDOMIZED|||TREATMENT||SINGLE||||||
33911095|NCT03312777|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Overencapsulation||t|t|t|t
33911096|NCT00339183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992744|NCT05786573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689307|NCT02852772|||CASE_CONTROL||PROSPECTIVE|||||||
33689308|NCT05027893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients were randomly and equally assigned to treatment groups. The study was planned as a double-blind. Thus, neither the patients nor the researchers knew whether the patients were prescribed antibiotics or placebo tablets, because the tablets were marked with a label that was in the formed codebook. All the film-coated tablets used were of the same appearance (both the antibiotics and the placebo). There was 157 participants, patients and the same oral surgeon.|A RANDOMIZED CONTROLLED TRIAL|t|t|t|t
33689309|NCT02640040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689310|NCT02581943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689311|NCT00002398||||TREATMENT||NONE||||||
33778518|NCT03941938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33778519|NCT02093585|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33778520|NCT06613711|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label multicenter study enrolling up to 60 participants at up to 5 sites in Italy.||||
34084993|NCT04845230|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Blinding of participants or Operation Food Search staff is infeasible in this study. Operation Food Search will need to know participants' treatment assignment in order to provide the appropriate services, and the participants will also be aware of the services they receive from Operation Food Search. However, the administrative health care claims data used to assess outcomes in this study will not be subject to any bias, as the entities responsible for entering those claims will be blind to the treatment assignment of participants.|This is a three-arm experiment where each arm iteratively adds additional program components (see study description for more detail).|f|f|f|t
34084994|NCT04796701|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Intervention group: living in three predefined municipality Control group: living in one predefined municipality|Non-randomized controlled trial||||
34084995|NCT04676373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34084996|NCT00573924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34084997|NCT06078618|||COHORT||RETROSPECTIVE|||||||
34084998|NCT05002803|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34084999|NCT05906849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To attain this project's aims a longitudinal research will take place. Adolescents presenting SAD or GAD will be randomly allocated to a Control Group (no intervention group), or an Experimental Group (individual intervention group). Adolescents with SAD will be randomly allocated to the control group (n≥13), and to the SAD Experimental Group (n=29). Similarly, adolescents with GAD will be randomly allocated to the control group (n≥13), the to the GAD Experimental Group (n=29). Therefore, the Randomized and Parallel Controlled Trial will include a Control Group (N=29), a SAD (n=29) and a GAD (n=29) Experimental Group.|f|f|f|t
34085000|NCT01042626||PARALLEL||BASIC_SCIENCE||NONE||||||
34085001|NCT05238623|||COHORT||PROSPECTIVE|||||||
34085002|NCT02246933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689312|NCT02875925|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33689313|NCT05266274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689314|NCT02175875|||CASE_ONLY||PROSPECTIVE|||||||
33689315|NCT00021944|||||RETROSPECTIVE|||||||
33689316|NCT05561179|RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-blinded, single center, randomized prospective trial||||
33689317|NCT00965510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33689318|NCT01684020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689319|NCT06008626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689320|NCT05500547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689321|NCT01785095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689322|NCT03142061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689323|NCT01449227|||COHORT||PROSPECTIVE|||||||
33689324|NCT05641727|||OTHER||OTHER|||||||
33689325|NCT01168960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689326|NCT04378985|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33689327|NCT06086691|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized Crossover Trial||||
33689328|NCT00218127|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33689329|NCT00066144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689330|NCT03169751|||COHORT||PROSPECTIVE|||||||
33689331|NCT00559936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689332|NCT03396393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be received DHA 40mg or DHA 80mg or DHA 120mg or placebo continuously for 24 weeks.|t|t|t|t
33689333|NCT00630474|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33689334|NCT05152316|||COHORT||PROSPECTIVE|||||||
33689335|NCT03468543|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33778521|NCT04254679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient-reported outcomes and treatment adherence data will be collected via self-administered electronic questionnaires distributed using REDCap (http://project-redcap.org/) and completed by patients via smartphone, tablet or personal computer. Electronic outcome data will be transmitted directly to the REDCap database and verified by a blinded assessor. Adherence data will be verified by unblinded study staff. Patients who are not computer savvy, have limited access or prefer non-electronic assessment will complete the questionnaires via telephone interviews with a blinded assessor; in this case, data will be recorded in paper forms and subsequently transferred to the REDCap database. Outcome data that are not patient-reported (e.g. postoperative complications, unplanned healthcare utilization, chronic opioid use), will be obtained from medical records by a blinded assessor.|This study will be a parallel, two-group, assessor-blind, pilot randomized trial.|f|f|f|t
33911097|NCT05818124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911098|NCT02146079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911099|NCT06480097|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33911100|NCT02731703|||COHORT||PROSPECTIVE|||||||
33911101|NCT04598581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Information on group allocation will not be disclosed to either the patient or the ICU-staff.||t|t|f|f
33911102|NCT01938794|||OTHER||CROSS_SECTIONAL|||||||
33911103|NCT05256277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911104|NCT04355156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911105|NCT06448312|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a 1:1 ratio to one of two intervention groups.||||
33911106|NCT02248935|||COHORT||PROSPECTIVE|||||||
33911107|NCT03873467|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes Assessor will be masked to group allocation.|Randomized Controlled Trial (RCT). Participants will be randomized into one of two groups: (1) the GLB Intervention Group and (2) the wait-list controlled group.|f|f|f|t
33911108|NCT00604058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911109|NCT01240044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911110|NCT02630082|NA|SINGLE_GROUP||||NONE||||||
33911111|NCT03637192|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low altitude and High altitude||||
33911112|NCT00411788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778522|NCT06168656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single|Single blind pre-post test randomized controlled design|t|f|f|f
33778523|NCT06109532|||COHORT||PROSPECTIVE|||||||
33778524|NCT05700721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778525|NCT01907399|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33778526|NCT03432221|||CASE_CONTROL||PROSPECTIVE|||||||
33778527|NCT05646069|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Assignment||||
33778528|NCT06140420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778529|NCT04027790|||CASE_CONTROL||PROSPECTIVE|||||||
33778530|NCT00527085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778531|NCT01693146|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33778532|NCT02269436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778533|NCT03931005|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33778534|NCT00481754|||CASE_ONLY||CROSS_SECTIONAL|||||||
33778535|NCT05911074|||OTHER||CROSS_SECTIONAL|||||||
33778536|NCT03314337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778537|NCT04610203|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|single-blind|randomised, repeat measure, crossover design trial|t|f|f|f
33778538|NCT06065007|||CASE_ONLY||CROSS_SECTIONAL|||||||
33778539|NCT01951365|||COHORT||RETROSPECTIVE|||||||
33778540|NCT00813111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33778541|NCT06265649|||COHORT||RETROSPECTIVE|||||||
33778542|NCT01387646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33778543|NCT06040892|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778544|NCT00184028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778545|NCT06497634|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33778546|NCT04355676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778547|NCT00147433|||CASE_CONTROL||OTHER|||||||
33778548|NCT04209127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT with inteventional cohort continuation|f|f|f|t
33778549|NCT06391034|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778550|NCT03904628|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33778551|NCT04846062|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|buffer zone will be set between control and intervention will masked with|nutrition Behavior intervention will be given for intervention arm (0) the control arm will not receive(1)|t|f|f|f
33778552|NCT04832477|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778553|NCT06615271|||COHORT||PROSPECTIVE|||||||
33778554|NCT01725867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778555|NCT03640013|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled randomized clinical trial||||
33778556|NCT00791531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778557|NCT04284891|||OTHER||PROSPECTIVE|||||||
33778558|NCT03050281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778559|NCT00742274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778560|NCT04125511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778561|NCT06352190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778562|NCT06309303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33778563|NCT05329389|RANDOMIZED|PARALLEL||PREVENTION||NONE||In case of presence/absence of inclusion/exclusion criteria and written informed consent will be obtained, patients will be randomized in a 1:1:1 ratio according to the list of randomized blocks using a computer generator. Patients will be randomized at the last available moment in order to minimize bias.||||
33778564|NCT04170660|||CASE_ONLY||PROSPECTIVE|||||||
33778565|NCT05650294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The clinical study will be performed unblinded. However, analysis of blood samples at analysis partner will be performed blinded. After closure of data base, data will be unblinded and evaluated according to product affiliation.|randomized, two-way cross-over study||||
33778566|NCT05539404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911113|NCT04043338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
33911114|NCT02939144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911115|NCT05607290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911116|NCT04811313|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33911117|NCT01808118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778567|NCT05481034|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778568|NCT03377075|||COHORT||PROSPECTIVE|||||||
33778569|NCT01627847|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778570|NCT03356743|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778571|NCT00792129|||COHORT||PROSPECTIVE|||||||
33778572|NCT04542447|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|An open label proof of concept study|Immunomodulator in COVID 19, Intervention - Sequentially numbered IP kits||||
33778573|NCT06143761|||COHORT||RETROSPECTIVE|||||||
33778574|NCT01506921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33911118|NCT06231199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|foam roller combined with gastrocnemius release and conventional treatment|f|f|t|t
33911119|NCT01481636|||CASE_ONLY||CROSS_SECTIONAL|||||||
33911120|NCT05342129|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33911121|NCT01763905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911122|NCT03945045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911123|NCT02626104|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911124|NCT01863849|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||parallel-group, in two age groups||||
33911125|NCT00076219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911126|NCT01387295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992745|NCT03427463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded|This study will be conducted as a randomized controlled single-blinded clinical trial with patients being randomized to receive either 0.1 or 0.05 mg of IT morphine.|t|f|f|f
33992746|NCT06163625|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33992747|NCT05624450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992748|NCT00470704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992749|NCT05672836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992750|NCT05869955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992751|NCT02544022|||COHORT||PROSPECTIVE|||||||
33992752|NCT05231187|||CASE_ONLY||PROSPECTIVE|||||||
33992753|NCT00001223|||COHORT||PROSPECTIVE|||||||
33689336|NCT02038829|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33689337|NCT02528266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689338|NCT03136731|||COHORT||PROSPECTIVE|||||||
33992754|NCT06552091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Standard group: standard care.~* Hypnosis group: experimental care with 3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily."||||
33992755|NCT04855188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992756|NCT04222413|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992757|NCT05934019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study participants cannot be blinded regarding the intervention condition as they realize whether they are in the condition using an online-program or not. Members of the study team guiding the participants as e-coaches during the online-program cannot be blinded as it is obvious for them that this is the condition receiving the online-program. Members of the study team who are conducting the diagnostic interviews do not have any other contact with the participants and will thus be blinded regarding the participants' assignment to the group conditions (EMPATIA vs. CAU).|The present study is a monocentric, two-arm, single-blinded, randomized controlled trial with CAU as control condition.|f|f|f|t
33992758|NCT04632238|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Trial (SW-RCT)||||
34085003|NCT05596799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085004|NCT03927443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34085005|NCT05776667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085006|NCT01664091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689339|NCT01566760|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33689340|NCT04243421|NA|SINGLE_GROUP||TREATMENT||NONE||case series||||
33689341|NCT01816841|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689342|NCT01546064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689343|NCT03901118|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689344|NCT01542671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33689345|NCT02186366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992759|NCT05822414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33992760|NCT06590532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992761|NCT06635629|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33992762|NCT06743165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992763|NCT03451799|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, prospective cohort||||
33992764|NCT04772079|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33992765|NCT04145141|||COHORT||PROSPECTIVE|||||||
33992766|NCT02218996|||CASE_CONTROL||PROSPECTIVE|||||||
33992767|NCT06177743|||COHORT||PROSPECTIVE|||||||
33992768|NCT06279247|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992769|NCT06596018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992770|NCT02815566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085007|NCT02812784|||COHORT||PROSPECTIVE|||||||
34085008|NCT04533256|||COHORT||PROSPECTIVE|||||||
34085009|NCT03108482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085010|NCT02364557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689346|NCT03176758|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The participant will be non-randomly enrolled into two groups. The default treatment, which was found as the preferred method by numerous investigators will be offered to all participants. Those who will ask for the second option (general anesthesia) or those who will not be aligble for spinlal block will be enrolled in the second group.||||
33689347|NCT00400530|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33689348|NCT01931202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085011|NCT00114556|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33689349|NCT01759485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689350|NCT03220529|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689351|NCT02149615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689352|NCT00002178||||TREATMENT||||||||
33689353|NCT04105829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33689354|NCT00745225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind randomized placebo-controlled trial, all parties are masked|Double-blind randomized placebo-controlled trial|t|t|t|t
33992771|NCT03904147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992772|NCT06014866|||COHORT||RETROSPECTIVE|||||||
34085012|NCT03971760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085013|NCT01389739|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34085014|NCT04235946|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, non-randomized, monocentric study, which aims to show that physical activity carried out within a high-level structure and coached by elite trainers contributes to psychological and social recovery and to the reduction of fatigue in patients in remission breast cancer.||||
34085015|NCT00966368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33689355|NCT03687970|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689356|NCT00590460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689357|NCT03237871|NA|SINGLE_GROUP||OTHER||NONE||||||
33689358|NCT00715169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689359|NCT00138411|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34085016|NCT03265561|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bone allograft group will receive bone structural allograft; Auto and allograft group will receive bone structural allograft plus spongy autograft.||||
34085017|NCT04609137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34085018|NCT02817139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085019|NCT00576511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085020|NCT05630196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085021|NCT00619827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689360|NCT02547285|||COHORT||PROSPECTIVE|||||||
33689361|NCT05240287|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33689362|NCT02827565|NA|SINGLE_GROUP||OTHER||NONE||||||
33689363|NCT04728672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two parallel groups pretest-posttest design.|t|f|f|t
33689364|NCT01723462|||COHORT||PROSPECTIVE|||||||
33689365|NCT02565927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689366|NCT03925168|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster-randomized clinical trial||||
33689367|NCT02110823|||COHORT||PROSPECTIVE|||||||
33689368|NCT02169193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689369|NCT01488162|||COHORT||PROSPECTIVE|||||||
33992773|NCT05494801|||CASE_CONTROL||PROSPECTIVE|||||||
33992774|NCT06050122|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33992775|NCT06345339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992776|NCT03712618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992777|NCT06483789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An unblinded pharmacist will be utilized to assign bottles to each patient using an interactive voice response system (IVRS) central randomization system. Study treatment or placebo will be dispensed to patients in blinded bottles.|A sample size of 240 patients (up to a maximum of 600) is planned for the study to be randomized in a 3:1:1:1 ratio of active to monotherapy to monotherapy to placebo control.|t|t|t|f
34085022|NCT03659630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085023|NCT04796415|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34085024|NCT05355155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778575|NCT03398356|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|At the beginning of the study, patients are assigned a number by a nurse and are assigned to group A or B according to ID. When analyzing the results, the researchers only knows the numbers of blood samples.|"The group of patients taking the drug at the target dose of 3 x 1000 after 4 weeks returned to the dose of 3 x 500 mg. The group of patients taking the drug at the target dose 3 x 500 mg consequently had this dose during the whole study period.~The basic parameters and biochemical parameters from healthy individuals at the beginning of the study were assessed to compare with patients with pre-diabetes. This group did not take the metformin and thus did not have further examination and lab-tests during the study."|f|f|t|f
33778576|NCT03806049|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, open-label, three arm study||||
33778577|NCT01106976|||COHORT||PROSPECTIVE|||||||
33778578|NCT00386711|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33911127|NCT03445052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Group Allocation will be concealed from the statisticians conducting the analysis until the analysis relevant to the primary study objective has been completed.~Care providers: Group allocation will be concealed from the XP clinical team who are not part of the research team. This is to avoid change in the standard care of these participants during the trial (i.e., greater/less discussion of adherence to photoprotection during the routine clinical appointment). Randomisation will be broken if the intervention facilitator is concerned about the participant's emotional wellbeing at any point during delivering the intervention. In this case the clinical team will be alerted and the participant will be referred to the clinical psychologist at the XP service for assessment."|"The study will test the efficacy of the intervention using a randomised controlled trial design. It is a delayed RCT, one group will receive the intervention in year 1 and be compared to the other control group in year 2. The control group will receive the intervention in year 2. The UVR dose to the face will be measured at baseline (21 days in March -April 2018) and will then be assessed at two follow-up periods in 2018 (June to July; August to September); two periods in 2019 (delayed intervention group). Psychosocial constructs will be measured by self report questionnaires at baseline and at the start of each UVR measurement period, as well as daily during these episodes. 9 months after baseline self-report questionnaires will be completed. A qualitative process evaluation will be conducted after the intervention is complete. A health economic evaluation of the intervention will be assessed by completion of HRQOL and service use questionnaires in December 2018, 2019."|f|f|f|t
33911128|NCT01933191|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33911129|NCT02349334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911130|NCT02996695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33911131|NCT03747835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911132|NCT06162260|||COHORT||RETROSPECTIVE|||||||
33911133|NCT00142519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911134|NCT04209296|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33911135|NCT02473133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911136|NCT02380352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911137|NCT06440369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Control group (CG): Patients will continue their lifestyle. Physical activity orientation group (G0-AP): Patients will be encouraged to practice physical activity and will benefit from telephone calls for instructions regarding this practice. They will be contacted by telephone each week, for a total of 6 calls, each lasting approximately 10 minutes.~Training group (GE): Patients will begin the individualized PA program during the inclusion visit and will continue it for 6 weeks, at a rate of 3 sessions per week (for a total of 18 sessions). At the end, patients will be able to resume their usual activities and will be evaluated again 6 weeks after stopping the program. The training program will be supervised by a physical activity instructor adapted and carried out at the CHRU, in the Nephrology or Rheumatology Department depending on the patient's pathology."|t|f|f|t
33911138|NCT03372278|||COHORT||PROSPECTIVE|||||||
33911139|NCT06186882|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33911140|NCT02892461|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33911141|NCT03184298|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33911142|NCT04226859|||COHORT||PROSPECTIVE|||||||
33911143|NCT02672319|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparison of clinical outcomes of a prospective study cohort to those in a historical control group||||
33911144|NCT02162485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911145|NCT02819310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911146|NCT04379934|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911147|NCT01834924|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33911148|NCT06263426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911149|NCT02128620|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33911150|NCT03181165|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will know group assignments|Pragmatic effectiveness trial of diet intervention led by community pharmacists versus treatment-as-usual waitlist control.||||
33911151|NCT03243513|||OTHER||RETROSPECTIVE|||||||
33911152|NCT00040833||||SUPPORTIVE_CARE||||||||
34085025|NCT01524835|||COHORT||CROSS_SECTIONAL|||||||
34085026|NCT02835716|||CASE_ONLY||PROSPECTIVE|||||||
33911153|NCT03381924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911154|NCT04439838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911155|NCT05528497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911156|NCT04603404|||COHORT||PROSPECTIVE|||||||
33911157|NCT04491786|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will treated postoperative analgesia with 600 mg of gabapentin plus 65 mcg/kg/hour during 24 hours of nefopam||||
34085027|NCT00590499|||COHORT||PROSPECTIVE|||||||
33689370|NCT05629104|||COHORT||PROSPECTIVE|||||||
33689371|NCT02557438|||COHORT||PROSPECTIVE|||||||
33689372|NCT03124238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||repeated measures crossover||||
33689373|NCT03512015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Consenting patients will be assigned in a 1:1 randomized way to receiving either standard care or LuCApp in addition to standard care. During the treatment period, LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met.||||
33992778|NCT05474027|NA|SINGLE_GROUP||OTHER||NONE||Our goal is to enroll 50 patients. Patients will be recruited from Dr. Kinard's regularly scheduled orthognathic cases at UAB Highlands Hospital. The patient will be informed of the study in advance and have consent signed pre-operatively. 1g of tranexamic acid will be given perioperatively as already routinely performed. The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to patient baseline.||||
33689374|NCT03317132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33689375|NCT02235259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689376|NCT04703179|||COHORT||PROSPECTIVE|||||||
33689377|NCT01395615|||COHORT||PROSPECTIVE|||||||
33689378|NCT03671473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689379|NCT03268473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||It's an assessor blinded, parallel group, randomized controlled trial aimed at investigate whether non-surgical periodontal treatment on serum and saliva oxidative stress parameters in patients with periodontitis and obstructive sleep apnea syndrome (OSAS) and in patients with periodontitis only.|f|f|t|t
33689380|NCT00425633|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33689381|NCT01011023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689382|NCT04449471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy adults with predetermined CYP2C9 genotype will receive the probe drug, naproxen.||||
33689383|NCT05748041|||COHORT||PROSPECTIVE|||||||
33689384|NCT00057681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689385|NCT04082039|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33689386|NCT05402020|||COHORT||RETROSPECTIVE|||||||
34085028|NCT01562899|NON_RANDOMIZED|||TREATMENT||NONE||||||
33689387|NCT04167956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689388|NCT00252629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689389|NCT04041700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992779|NCT04336228|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33689390|NCT02419274|||COHORT||PROSPECTIVE|||||||
33911158|NCT00696865|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33689391|NCT03462069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911159|NCT02116660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992780|NCT00156767|||COHORT||PROSPECTIVE|||||||
33992781|NCT02203526|NA|SEQUENTIAL||TREATMENT||NONE||||||
33992782|NCT05171647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992783|NCT05027958|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33992784|NCT06183931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992785|NCT02890355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992786|NCT01218854|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689392|NCT04410770|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The clinical coordinator screens, consents, and completes baseline assessments with the participants. The clinical coordinator passes on the participants to the counselor who completes the support calls. The clinical coordinator and the counselor are unmasked. The participant is unmasked as he/she is aware of when he/she is receiving the support calls and when he/she is not. The 6 and 12 week outcomes are collected by a separate research assistant who is masked. The investigators are not exposed to the randomization process and are unaware of which arm the participant is assigned to.|Randomized, parallel group, single masked, controlled trial with cross-over|f|f|t|t
33689393|NCT03017781|||CASE_CONTROL||PROSPECTIVE|||||||
33689394|NCT04459767|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33689395|NCT01919762|||CASE_CONTROL||PROSPECTIVE|||||||
33911160|NCT05224401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911161|NCT05137509|||CASE_CONTROL||RETROSPECTIVE|||||||
33911162|NCT03204721|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients admitted for allogeneic stamcelltransplantation who consent participation in the study are randomized 1:1, either to receive ECP or no-ECP||||
33911163|NCT03428412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911164|NCT05177952|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and Investigators will be aware of treatment groups|Randomized between group parallel||||
33911165|NCT04355975|||COHORT||PROSPECTIVE|||||||
33911166|NCT06373614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||foot massage (intervention group) bed bath (intervention group) control (control group)||||
33911167|NCT02874690|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33911168|NCT04319562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911169|NCT01762657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911170|NCT01345123|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33911171|NCT03583762|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33911172|NCT02367170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33911173|NCT04802850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911174|NCT02145156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33911175|NCT03546413|||COHORT||CROSS_SECTIONAL|||||||
33911176|NCT00825955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911177|NCT03660813|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33911178|NCT01631279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911179|NCT03051334|||CASE_CONTROL||RETROSPECTIVE|||||||
33992787|NCT04613453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992788|NCT00001971|||COHORT||PROSPECTIVE|||||||
34085029|NCT03559816|||COHORT||PROSPECTIVE|||||||
34085030|NCT02352194|||COHORT|||||||||
34085031|NCT05614271|||COHORT||PROSPECTIVE|||||||
34085032|NCT05604898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085033|NCT03862638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778579|NCT06505265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778580|NCT06483984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778581|NCT01698671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778582|NCT02621567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778583|NCT02008266|||CASE_ONLY||CROSS_SECTIONAL|||||||
33778584|NCT03059836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33778585|NCT06058689|RANDOMIZED|CROSSOVER||OTHER||NONE||An open label, balanced, randomized, two treatments, two sequences, two periods, single dose, crossover, bioequivalence study.||||
33778586|NCT02696252|||COHORT||PROSPECTIVE|||||||
33778587|NCT05612529|||COHORT||PROSPECTIVE|||||||
33778588|NCT01303185|||CASE_CONTROL||PROSPECTIVE|||||||
33778589|NCT04035759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33911180|NCT04020484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Blinding of participants and program facilitators (i.e. the staff delivering the M3 program) will be difficult to completely achieve given the nature of the intervention. The investigators will attempt to ameliorate bias by explaining to participants and program facilitators that the study is interested in evaluating the intervention to be given to all participants, however, in planning the logistics of the intervention, some participants will receive the intervention in the very near future, whereas others will receive the intervention in approximately 12 weeks. In so doing, the investigators hope to eliminate any biases associated with the participants' and program facilitators' perception or biases of being assigned to the treatment or control group.|This is a parallel, partially nested randomized controlled trial (RCT) comparing two arms: intervention (M3) and treatment-as-usual (i.e. wait-list control). Participants will be randomized 1:1 into the intervention or control arm. This study will not interfere with patients' clinical care. The intervention will be delivered online to groups of 4-8 on a rolling basis to minimize wait-times and allow for timely access to the intervention for the waitlist controls. We believe this strategy is very important to increase the odds that families will decide to participate in the study. Sample size calculations showed that 76 child-parent dyads will be required (38 intervention, 38 control), and to account for a liberal 24% attrition rate, 100 child-parent dyads will be recruited.|t|t|f|f
33911181|NCT03072017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911182|NCT02592629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911183|NCT05903196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911184|NCT01801137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911185|NCT00818324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992789|NCT02108028|||COHORT||PROSPECTIVE|||||||
33992790|NCT05234983|RANDOMIZED|PARALLEL||SCREENING||NONE||The intervention will consist of training for practitioners (2 half-days), supportive material via a mobile app, peer networking via social media, and technical assistance to deliver the intervention. The practitioners will then deliver brief advice to patients in the practice setting. Interested patients will then receive follow- up counseling by an NSF-Mumbai counselor via phone. For those who do not receive the intervention, the patients will be provided educational pamphlets. The control arm will have the opportunity to receive the intervention later on (delayed start).||||
33992791|NCT03828994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33992792|NCT06447376|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort study.||||
33992793|NCT06457854|||COHORT||CROSS_SECTIONAL|||||||
33992794|NCT04660201|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33992795|NCT06511830|||OTHER||PROSPECTIVE|||||||
34085034|NCT04562974|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085035|NCT06032663|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085036|NCT00017251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085037|NCT03927170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085038|NCT05654038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085039|NCT04271215|||COHORT||OTHER|||||||
34085040|NCT04322136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085041|NCT00490035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778590|NCT06115122|||COHORT||PROSPECTIVE|||||||
33778591|NCT06491381|||COHORT||PROSPECTIVE|||||||
33778592|NCT04308174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778593|NCT06233955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778594|NCT05891613|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778595|NCT04448795|||COHORT||RETROSPECTIVE|||||||
33778596|NCT05168865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992796|NCT05293041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation will be handled by a nurse not involved in the study, and both the patient, treating physician and nurse, the study nurse and the investigators will be blinded to the study treatment.|Singel center double-blinded, randomized, placebo-controlled trial.|t|t|t|t
33992797|NCT05164367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992798|NCT05517421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor Staff is also masked, so the study is Quadruple-blind.||t|f|t|t
33992799|NCT05982314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33992800|NCT04521712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992801|NCT02476916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992802|NCT05623982|NA|SEQUENTIAL||TREATMENT||NONE||||||
33992803|NCT03191058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized into the study using a permuted block method with a random number generator. The study statistician will prepare the randomization scheme. The block size will be varying and study personnel will be blinded to the randomization block size.|The study is a randomized, double blind, parallel--group clinical trial with two treatment arms conducted both at the University of Texas Southwestern in Dallas, Texas and at the Temerty Centre for Therapeutic Brain Intervention based at CAMH in Toronto, Canada. Both sites aim to recruit 130 participants each.|t|t|f|t
33992804|NCT00007150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992805|NCT06058949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992806|NCT05524571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor Staff is also masked, so the study is Quadruple-blind.||t|f|t|t
33911186|NCT02934776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911187|NCT02538588|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33911188|NCT01041690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911189|NCT04586894|||COHORT||PROSPECTIVE|||||||
33911190|NCT04935060|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911191|NCT05924906|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||BOIN design dose escalation scheme for phase Ia||||
33911192|NCT03036332|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911193|NCT01257282|||COHORT||PROSPECTIVE|||||||
33911194|NCT05923489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911195|NCT03476785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to subject randomization.|Parallel Assignment|f|f|f|t
33911196|NCT02216253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911197|NCT05754619|||COHORT||OTHER|||||||
33911198|NCT04673526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective case-control study||||
33911199|NCT05795218|||COHORT||PROSPECTIVE|||||||
33911200|NCT03219749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911201|NCT06060275|||CASE_CONTROL||PROSPECTIVE|||||||
33911202|NCT00752609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689396|NCT05357053|||CASE_CONTROL||PROSPECTIVE|||||||
33689397|NCT02770261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689398|NCT05852600|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Study team members who conduct and code the condom skills demonstrations will be blind to participant condition.||f|f|f|t
33689399|NCT01742247|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33911203|NCT03524833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||20 participants receive intraluminal eradication of H. pylori. Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics (amoxicillin, and metronidazole) for 14 days.||||
33911204|NCT03463616|||COHORT||RETROSPECTIVE|||||||
33911205|NCT03750032|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in the study.|The patients will be randomized into three groups of various appendicular stump closure.||||
33911206|NCT02260908|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33911207|NCT04208763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911208|NCT00347555|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33992807|NCT00001853|||COHORT||CROSS_SECTIONAL|||||||
33992808|NCT04855227|||COHORT||PROSPECTIVE|||||||
33992809|NCT05796154|NA|SINGLE_GROUP||OTHER||NONE||||||
33992810|NCT05133531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992811|NCT06453616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The methodologists will be blind of the study group and not aware on whether group A and B are control or intervention groups|cluster randomized controlled trial|f|f|f|t
33689400|NCT05919927|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33689401|NCT00996723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992812|NCT06376045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992813|NCT05600894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992814|NCT05184335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a parallel group efficacy and safety study with 3 treatment arms (2 active, one placebo, randomized 1:1:1) that is blinded for participants and involved study staff except dedicated unblinded individuals in statistics and drug safety. The OLE part will provide RP5063 15 mg, 30mg or 50mg OD open label to all participants.|t|t|t|f
33689402|NCT00517803|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33689403|NCT00062673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689404|NCT04146298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689405|NCT02545231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689406|NCT04661969|||CASE_ONLY||RETROSPECTIVE|||||||
33689407|NCT01097798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689408|NCT06519110|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with advanced solid tumors (non-small cell lung cancer, cholangiocarcinoma, cervical cancer, salivary gland cancer) with HER2 mutations.||||
33778597|NCT05010772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778598|NCT04615858|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|"Active Comparator: Genepro Gen2 Protein 11g Serving of Genepro Gen3 Protein daily will be used in each subject. Intervention: Bi-Weekly blood draws will determine the effect on blood protein levels.~Active Comparator: Whey Protein Isolate 30g Serving of Whey Protein will be used daily in each subject. Intervention:Bi-Weekly blood draws will determine the effect on blood protein levels."||t|f|f|f
33778599|NCT05454137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778600|NCT02375763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33778601|NCT04367194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33778602|NCT05808647|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33778603|NCT02654067|||COHORT||PROSPECTIVE|||||||
33778604|NCT01443143|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778605|NCT05491005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778606|NCT02479529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778607|NCT05657067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778608|NCT01093261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778609|NCT01273090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778610|NCT00958009|NA|SINGLE_GROUP||||NONE||||||
33778611|NCT00239629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778612|NCT02667691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33778613|NCT03888885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992815|NCT05979116|NA|SINGLE_GROUP||TREATMENT||NONE||a single group study as a study that consists of only a single group of subjects included in the study design, in which all subjects received a single intervention and the outcomes are assessed over time .||||
33992816|NCT05925491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992817|NCT04100135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992818|NCT05368974|||OTHER||RETROSPECTIVE|||||||
33992819|NCT02834013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992820|NCT04609904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992821|NCT06186765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992822|NCT03410875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778614|NCT01008722|||COHORT||PROSPECTIVE|||||||
33778615|NCT01026779|||CASE_CONTROL||RETROSPECTIVE|||||||
33911209|NCT04008433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33911210|NCT03696264|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants blinded to the protein dose consumed in a given metabolic trial|||||
33911211|NCT04017533|NA|SINGLE_GROUP||TREATMENT||NONE||Single group study||||
33911212|NCT03892785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911213|NCT04738500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911214|NCT01031524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911215|NCT00385567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911216|NCT04576637|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33911217|NCT02831075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911218|NCT02244723|||COHORT||PROSPECTIVE|||||||
33911219|NCT05745402|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33911220|NCT04950881|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33911221|NCT04664413|||CASE_ONLY||RETROSPECTIVE|||||||
33911222|NCT03082495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor will be blinded to group assignment for the clinical outcomes including treatment toxicity, treatment completion, treatment response, and surgical complications.||f|f|f|t
33911223|NCT03350152|||OTHER||RETROSPECTIVE|||||||
33911224|NCT04346069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911225|NCT03506698|||CASE_ONLY||PROSPECTIVE|||||||
33911226|NCT00924976|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33911227|NCT04408859|||COHORT||PROSPECTIVE|||||||
33911228|NCT05509205|||OTHER||CROSS_SECTIONAL|||||||
33911229|NCT01999413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911230|NCT04202861|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The investigators plan to conduct a randomised controlled trial to evaluate a new treatment strategy for CRGNB infections, termed guided antibiotic combination therapy, using the most effective (synergistic and bactericidal) antibiotic combination indicated by iACT. It is an investigator-initiated, two-site, two-arm, open-label, RCT.~The randomisation will be stratified for the 2 hospitals. At each site, treatments will be randomly assigned to study subjects in a 1:1 ratio using a computer-generated, permuted-block randomisation schedule with a random block size known only to the study biostatistician. Randomisation of participants can be done through a web portal, or through backup randomisation envelopes if internet service is disrupted."||||
33992823|NCT06246357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992824|NCT04460937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992825|NCT02359825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992826|NCT04671485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992827|NCT06592144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"All assistant team members (physicians, pharmacists, nurses, etc.) and statisticians responsible for the analyses will remain blind to the identity of the treatments throughout the study.~The placebo (sesame oil) will be prepared in a similar packaging and with a volume identical to that of testosterone cypionate.~If a patient experiences an adverse effect potentially related to the medication, the attending physician may request to break the study blinding."|"Intervention Group: Participants will receive 200 mg of testosterone cypionate intramuscularly every 5 days, up to a maximum of 3 doses.~Control Group: Participants will receive sesame oil (placebo) intramuscularly every 5 days, up to a maximum of 3 doses."|t|t|t|t
33992828|NCT05211115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992829|NCT02141919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085042|NCT02152007|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34085043|NCT00329108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34085044|NCT02629783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34085045|NCT00448799|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085046|NCT01308619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085047|NCT02693067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085048|NCT00003261||||TREATMENT||||||||
34085049|NCT05774314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085050|NCT01712711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34085051|NCT04297020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085052|NCT03380286|||COHORT||PROSPECTIVE|||||||
33689409|NCT03901898|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Four practices will be randomly assigned to the intervention group, while the other four practices will be assigned to the wait list control group. The wait list control group will deliver care as usual, and deliver the intervention after six months.||||
33689410|NCT05469204|NA|SINGLE_GROUP||OTHER||NONE||||||
33689411|NCT01539668|||||PROSPECTIVE|||||||
33689412|NCT01049477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33689413|NCT02763761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689414|NCT01654796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689415|NCT06309537|||COHORT||PROSPECTIVE|||||||
33689416|NCT04070638|||OTHER||CROSS_SECTIONAL|||||||
33689417|NCT04991428|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Single-blind cross over experimental trial|t|f|f|f
33689418|NCT05585788|NA|SINGLE_GROUP||PREVENTION||NONE||To assess the impact of a password-protected pill-dispensing system, Addinex, on unused opioid disposal, opioid use, and opioid refills rates after cancer-related surgery.||||
33689419|NCT03300648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators assessing outcome will be blinded to the arm to which the participant was randomly assigned|Participants will be randomly assigned to one of three study arms.|f|f|f|t
33689420|NCT05274659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689421|NCT04061473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The study is designed as a randomised, double-blinded, crossover study.|t|f|t|f
33689422|NCT06222359|||COHORT||PROSPECTIVE|||||||
33689423|NCT01952470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689424|NCT06423729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689425|NCT02958189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689426|NCT00837629|||||PROSPECTIVE|||||||
33689427|NCT03544476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33689428|NCT06432881|NA|SEQUENTIAL||OTHER||NONE||||||
33689429|NCT05060523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778616|NCT05185700|||COHORT||PROSPECTIVE|||||||
33778617|NCT00737308||PARALLEL||TREATMENT||NONE||||||
33778618|NCT06696885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911231|NCT05512130|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, placebo-controlled, double-blinded, crossover trial|t|t|t|t
33911232|NCT05942950|||OTHER||CROSS_SECTIONAL|||||||
33911233|NCT00905021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911234|NCT02304783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33911235|NCT03517748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Because the comparator will be in commercial packaging, the blinding of the subject is not possible.~However, the study will be blinded for the investigator: evaluations will be done by an independent investigator, different than the person who will distribute the product. Subjects will be identified by a patient number. Each patient number will be associated to a treatment number, according to a randomization list provided before the beginning of the clinical investigation, and randomized either in one of both treatment groups (DM05 or Optive®)."|f|f|t|f
33911236|NCT05345834|RANDOMIZED|PARALLEL||OTHER||NONE|None (Open Label)|Women in the patient navigator arm (Group 2a) can choose to participate in group-based preventive interventions based on: (1) a culturally adapted CBT (in person within prenatal care site or virtual given COVID); (2) peer support group (virtual); or (3) both. Women in the threshold risk group (Group 2b) at baseline warrant treatment interventions and will be invited to participate in: (1) culturally adapted CBT (individual, in person or virtual given COVID); (2) peer support (virtual); or (3) both. Women in this more severe risk group may be referred for psychiatric treatment if warranted. Randomization lists will be generated by the study statistician using a permuted block design and uploaded to a HIPAA-compliant, password-protected website (REDCap) allowing for patient randomization at the time of registration in the data collection system.||||
33911237|NCT04372576|||COHORT||PROSPECTIVE|||||||
33911238|NCT03584854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911239|NCT00537550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911240|NCT04698590|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34085053|NCT01309334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085054|NCT04773132|NA|SINGLE_GROUP||OTHER||NONE||||||
34085055|NCT04295252|||COHORT||PROSPECTIVE|||||||
34085056|NCT00963508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911241|NCT02159391|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911242|NCT03992768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911243|NCT01771718|||CASE_ONLY||RETROSPECTIVE|||||||
33689430|NCT04387383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects of both groups will be randomly assigned to receive either electro-acupuncture or control (sham) treatment. For randomization, simple, complete non-sequential random numbers will be generated in advance by a computer program in a block of four, and kept by the principal investigator. After a patient's eligibility is confirmed, a randomization number which corresponds to the group allocation will be provided to the acupuncturist by the PI. This arrangement will ensure that the clinical assessor and participants are blinded to the allocation.|single-blinded, randomized, sham-controlled clinical trial|t|f|f|f
33911244|NCT02287012|||COHORT||RETROSPECTIVE|||||||
33911245|NCT02787993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33992830|NCT02535702|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33689431|NCT03213353|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33689432|NCT00580567|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689433|NCT03694171|||COHORT||RETROSPECTIVE|||||||
33689434|NCT04561674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a randomized controlled experimental research with a pre-test post-test control group design||||
33689435|NCT04352231|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This study involves recruitment of healthy volunteers to participate in a 2x2 crossover design controlled-diet study.||||
33689436|NCT02050542|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33689437|NCT02168426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689438|NCT02848053|||CASE_CONTROL||PROSPECTIVE|||||||
33689439|NCT03953118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33689440|NCT03718325|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|There will be two research teams. One team will be unblinded (e.g. clinical care provider/company representative, study coordinator) and will perform stimulator programming/adjustment, and the other team will be blinded (e.g. research personnel) and will perform clinical testing and collect study outcome measures.||t|f|t|t
33689441|NCT03548090|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33689442|NCT03799172|||COHORT||RETROSPECTIVE|||||||
33778619|NCT04562779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778620|NCT02223182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778621|NCT05392985|||COHORT||RETROSPECTIVE|||||||
33778622|NCT05463211|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33778623|NCT01155999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33778624|NCT05468593|||COHORT||PROSPECTIVE|||||||
33778625|NCT02276547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778626|NCT06569290|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Principal investigators and data analysts will be masked to group assignment when analyzing data to determine the effectiveness of the recruitment strategy.||f|f|t|t
33778627|NCT05391828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778628|NCT04438551|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single-center prospective randomized controlled trial||||
33911246|NCT05722899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911247|NCT02020993|||CASE_CONTROL||PROSPECTIVE|||||||
33911248|NCT06312267|RANDOMIZED|PARALLEL||PREVENTION||NONE||Total of 20 patients will be identified and divided in two groups (control and experimental group). 10 of the patients undergo surgery using current ERAS protocol standard of care skin cleaning preparation. The other 10 patients skin prep will be substituted with the Bioelectrical dressing preoperatively and post-operative.||||
33911249|NCT06187844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911250|NCT02486510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911251|NCT06354296|||OTHER||RETROSPECTIVE|||||||
33911252|NCT02843867|||COHORT||PROSPECTIVE|||||||
33911253|NCT04604106|||CASE_CONTROL||PROSPECTIVE|||||||
33911254|NCT03439748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992831|NCT06161532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992832|NCT03569631|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double||t|f|t|f
33992833|NCT02744677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992834|NCT06693518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33992835|NCT06430866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992836|NCT03793179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992837|NCT06389084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized control trial|f|f|f|t
33689443|NCT06133738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible patients will be randomly allocated to either the study group or the control group (1:1). Participants will be blinded to their group assignment.|This will be a 2-arm quasi-randomized controlled trial of eight weeks of intervention involving eight sessions of standardized exercise program and either concomitant iCBT and educational sessions or educational sessions only. Measurements will be taken at baseline and eight weeks immediately following the intervention. Primary outcome measures are a numerical pain rating scale, 40-m Fast-Paced Walk Test, Step Test, and 30 seconds Chair Stand Test. Secondary outcome measures are Patient Health Questionnaire, Psychological Distress, Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form, Health-Related Quality of Life-Short Form-12, and Quadriceps Maximum Isometric Muscle Strength.|t|f|f|f
33689444|NCT01019811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689445|NCT00990275|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33689446|NCT02359851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689447|NCT05527873|||COHORT||RETROSPECTIVE|||||||
33689448|NCT02856321|||COHORT||RETROSPECTIVE|||||||
33689449|NCT04085367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689450|NCT02943252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778629|NCT01803932|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33778630|NCT03709784|||COHORT||PROSPECTIVE|||||||
33778631|NCT03190083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram||||
33778632|NCT02787538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33778633|NCT02803840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778634|NCT06685107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778635|NCT06080217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778636|NCT04512742|NA|SINGLE_GROUP||OTHER||NONE||Controlled human infection study, with an adaptive design. The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only \< 6 subjects develop PCCL lesions, then an adaptive design will be followed as described elsewhere.||||
33778637|NCT04921995|NA|SINGLE_GROUP||TREATMENT||NONE||Main group: Patients with unresectable, recurrent NPC who were treated with tislelizumab plus investigator's choice chemotherapy, with re-irradiation postponed or omitted. But there are two subgroups, one subgroup was ICI naive patients and were given first line tislelizumab plus investigator's choice chemotherapy. The other subgroup included patients who displayed no response to or progressed after previous PD-1 blockade, and were treated with tislelizumab rechallenge plus either chemotherapy or low dose SBRT.||||
33778638|NCT04435886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|12-week randomized, double-blind, parallel-group, placebo-controlled study|t|f|t|f
33778639|NCT05761444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778640|NCT02253238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778641|NCT03795779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778642|NCT00514072|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33778643|NCT01379235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778644|NCT02130492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778645|NCT01837043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778646|NCT00514007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778647|NCT03190174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778648|NCT06037252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778649|NCT04636086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778650|NCT03801720|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33778651|NCT06398457|NA|SINGLE_GROUP||TREATMENT||NONE||Daratumumab-SC (days -42, -35, -28, -21) followed by standard of care DSA desensitization and alloBMT||||
33778652|NCT02015533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33778653|NCT03256266|||COHORT||PROSPECTIVE|||||||
33992838|NCT03307343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the participant group assignment.||f|f|f|t
33992839|NCT06480825|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992840|NCT04713449|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992841|NCT04376190|RANDOMIZED|PARALLEL||TREATMENT||NONE||laser group and control group||||
33992842|NCT06730815|||OTHER||CROSS_SECTIONAL|||||||
33992843|NCT06449066|||COHORT||RETROSPECTIVE|||||||
33992844|NCT06742229|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two groups- Group 1 Pregnant and Group 2 Non Pregnant. From Group 1-Pregnant group we will obtain their standard of care scans along with the research scan whereas Non pregnant group will have only research scans||||
33992845|NCT06737445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992846|NCT05954741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992847|NCT02102191|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33992848|NCT05864807|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33689451|NCT01736384|||OTHER||PROSPECTIVE|||||||
33689452|NCT01807702|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33689453|NCT02571400|||COHORT||PROSPECTIVE|||||||
33689454|NCT02732743|NA|SINGLE_GROUP||SCREENING||NONE||||||
33689455|NCT05702853|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689456|NCT00354900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689457|NCT00249158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689458|NCT05054244|||COHORT||PROSPECTIVE|||||||
33689459|NCT00035373|||COHORT||PROSPECTIVE|||||||
33689460|NCT04661553|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689461|NCT02433158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689462|NCT05272215|||COHORT||PROSPECTIVE|||||||
33689463|NCT05235464|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomized cross-over study|t|f|f|t
33689464|NCT00566644|RANDOMIZED|||PREVENTION||NONE||||||
33689465|NCT01747018|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085057|NCT05346029|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the intervention (physical therapy and nutritional optimization) there is no masking in this study|Participants are randomly assigned to standard medical care or to intervention group for the duration of the study||||
34085058|NCT03220503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085059|NCT05557864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085060|NCT05563558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085061|NCT04896671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants would not know there are two groups. Each participant would assume to participate in physical exercise at some point.|A total of 30 participants with BAP were randomly assigned to either groups: 1) intervention group (12 treadmill running sessions, two sessions per week and each session 30 minutes) and 2) control group: waitlist control group.|t|f|f|f
34085062|NCT02327845|||COHORT||PROSPECTIVE|||||||
34085063|NCT04496297|||COHORT||PROSPECTIVE|||||||
33689466|NCT04008043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689467|NCT04873271|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33689468|NCT02054468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689469|NCT06168227|||COHORT||RETROSPECTIVE|||||||
33689470|NCT03506867|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The research staff analyzing the data and members of the Data and Safety Monitoring Committee will be blinded to the allotment and reported outcomes.|Randomized Controlled Cross-Over Trial comparing access to improvement in 'social capital' vs. usual care in low income People Who Use Drugs at-risk for or living with HIV/AIDS and/or HCV. The usual care group will be offered the intervention after six months.|f|f|t|t
33689471|NCT02125643|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33689472|NCT03223636|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689473|NCT00120354||||TREATMENT||||||||
33689474|NCT06515067|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33689475|NCT06329843|||COHORT||CROSS_SECTIONAL|||||||
33689476|NCT00470132|||COHORT||RETROSPECTIVE|||||||
33689477|NCT04985370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers involved in recording outcome measures will not be aware of treatment allocation. Patients will be encouraged to not tell the evaluators about the received treatment.||f|f|f|t
33689478|NCT03150667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689479|NCT03784365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689480|NCT04698265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33689481|NCT02730208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689482|NCT06398795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689483|NCT00541463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689484|NCT04705038|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33689485|NCT02524977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778654|NCT05960279|||COHORT||PROSPECTIVE|||||||
33778655|NCT01744496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911255|NCT03910933|||COHORT||PROSPECTIVE|||||||
33911256|NCT04304755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085064|NCT04424979|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33689486|NCT06520202|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33689487|NCT00458497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085065|NCT00825240|||CASE_CROSSOVER||PROSPECTIVE|||||||
34085066|NCT04776603|||CASE_ONLY||RETROSPECTIVE|||||||
34085067|NCT02283398|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34085068|NCT06237270|||COHORT||RETROSPECTIVE|||||||
34085069|NCT00630916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085070|NCT05720819|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is a randomized, pilot study comparing the intervention of combined biofeedback-VR plus standard medical care as treatment for chronic migraine versus a wait-list control group receiving standard medical care alone as treatment for chronic migraine.||||
34085071|NCT00005649||||TREATMENT||||||||
34085072|NCT01231269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689488|NCT05988697|||COHORT||PROSPECTIVE|||||||
33689489|NCT01091727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689490|NCT00205829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085073|NCT02650739|||CASE_CONTROL||RETROSPECTIVE|||||||
33689491|NCT06295978|||COHORT||PROSPECTIVE|||||||
33689492|NCT02172170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689493|NCT02903212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689494|NCT02398409|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33689495|NCT06130007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689496|NCT00920907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689497|NCT03918681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be blind to treatment group.|pre-test, post-test, single-blind randomized controlled trial study design|f|f|f|t
33689498|NCT02942589|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33992849|NCT02165007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689499|NCT02306499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689500|NCT06197425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689501|NCT05611177|||COHORT||PROSPECTIVE|||||||
33992850|NCT06741514|||OTHER||PROSPECTIVE|||||||
33992851|NCT05256147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992852|NCT06742645|NON_RANDOMIZED|PARALLEL||OTHER||NONE||INTERVENTION The health workers of the Borgo Reno Community House perform the outpatient visit and after having identified the health problems they propose a possible treatment. Subsequently, the citizen included in the study is subjected to the intervention, short motivational interview (BMI). By putting the relationship, listening, assertive communication, motivation and direct involvement of the patient in the treatment path in the foreground, the trained workers conduct the BMI to motivate the users of the various services to improve their lifestyles. Objectives to be achieved within six months will be agreed upon. The short motivational interview lasts approximately 15 minutes COMPARISON The health workers of the Navile Community House perform the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire||||
33992853|NCT03168126|||COHORT||PROSPECTIVE|||||||
33992854|NCT06736626|||COHORT||PROSPECTIVE|||||||
33992855|NCT06517680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992856|NCT06741943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689502|NCT05904990|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||High intensity laser|t|f|t|f
33689503|NCT01653028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689504|NCT06004687|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33689505|NCT04838392|NA|SINGLE_GROUP||TREATMENT||NONE|All information as provided by CGM system will be masked from subjects and study team during the study.|||||
34085074|NCT02785263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689506|NCT06115031|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33689507|NCT05843487|||COHORT||PROSPECTIVE|||||||
33689508|NCT01612728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689509|NCT00003046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085075|NCT00952198|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33689510|NCT06521099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689511|NCT03932968|||COHORT||PROSPECTIVE|||||||
33689512|NCT05656989|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689513|NCT01336569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778656|NCT03423264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants receiving radiation therapy as part of the OPTIMA II trial (NCT03107182) will be randomized to receive prophylactic gabapentin plus best supportive care versus best supportive care alone.||||
33778657|NCT01004263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778658|NCT00983619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778659|NCT06611722|||CASE_CONTROL||RETROSPECTIVE|||||||
33778660|NCT04878172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There are 4 different arms, each with different time frames based on thei subjects' availability. Each group uses the same device and treatment parameters, with the only difference being when follow up measures are taken.||||
33911257|NCT02684019|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"Group M: the Drug consisted of 2 ampoules each one containing 2500 mg magnesium sulphate (Egypt Otsuka pharma.Co)in 50 ml syringe .(i.e. 100 mg/ml). Loading dose was 40mg/kg, given over 10min and maintenance dose was 10mg/kg/h.~Group D: the Drug consisted of 2ml containing 200μg Dexmedetomidine (precedex®; united pharmaceutical group company, USA) diluted up to 50ml with normal saline (4μg/ml). Loading dose was 1μg/kg; given over 10min. The maintenance dose was 0.5 μg / kg / h."|t|t|f|t
33911258|NCT02259036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911259|NCT01667575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911260|NCT04985799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911261|NCT03293277|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33911262|NCT03859986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911263|NCT03191656|||CASE_ONLY||PROSPECTIVE|||||||
33911264|NCT02876055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911265|NCT00789477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085076|NCT04451278|||CASE_ONLY||PROSPECTIVE|||||||
34085077|NCT06170710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085078|NCT01145482|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34085079|NCT00379106|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992857|NCT06741813|RANDOMIZED|PARALLEL||TREATMENT||NONE||For the adult patients (≥ 18 years) with Ann-Arbor stage III or IV T-LBL and achieving CR after 3 courses of induction chemotherapy, all the patients who fulfilled inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive ASCT (ASCT group) or receive allo-HSCT (Allo-HSCT group). Patients would receive additional 1 course of chemotherapy after randomization and then received HSCT. Then we compared the clinical outcomes between the two groups.||||
33992858|NCT06741579|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33992859|NCT04447313|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33992860|NCT06741709|||COHORT||PROSPECTIVE|||||||
33992861|NCT06741904|||COHORT||PROSPECTIVE|||||||
33689514|NCT02122731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689515|NCT02666521|||OTHER||OTHER|||||||
33689516|NCT03961373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689517|NCT05587673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689518|NCT05214846|RANDOMIZED|PARALLEL||PREVENTION||NONE||This randomized controlled study was conducted at state hospital of nothern Turkey Obstetrics and Gynecology polyclinic between January 2021 and January 2022. The CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting randomised controlled trials (RCTs) has been used to describe the methods.||||
33689519|NCT02909803|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33689520|NCT06330844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups assignment - One group will complete the original ME-CCT training program. The other group will complete the newly developed RBSE-CCT-MCI.||||
33689521|NCT03845049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33689522|NCT02028871|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33689523|NCT05640102|||COHORT||OTHER|||||||
33689524|NCT03037268|||COHORT||CROSS_SECTIONAL|||||||
33689525|NCT04816201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33992862|NCT03476603|||CASE_ONLY||PROSPECTIVE|||||||
33992863|NCT06514807|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm, multicentre, descriptive study of ropeginterferon alfa-2b in essential thrombocythaemia patients||||
33992864|NCT01441297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689526|NCT04797897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689527|NCT01607840|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33689528|NCT01943708|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33689529|NCT00097851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689530|NCT00325975|||COHORT||CROSS_SECTIONAL|||||||
33689531|NCT01981876|||COHORT||PROSPECTIVE|||||||
33689532|NCT03350984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689533|NCT03192878|||CASE_ONLY||PROSPECTIVE|||||||
33689534|NCT06325475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992865|NCT03990662|||COHORT||PROSPECTIVE|||||||
33992866|NCT00151229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992867|NCT03671213|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Study Design||||
33992868|NCT06742827|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689535|NCT01242397|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33689536|NCT06086626|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689537|NCT03069118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689538|NCT05610085|RANDOMIZED|PARALLEL||TREATMENT||NONE||If seizures persist or recur after 60 mg/kg LEV patients will be randomized to receive either dose escalation of levetiracetam or phenobarbital. Randomization will occur in a 3:1 ratio LEv: PHB stratified by site.||||
33911266|NCT03571334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911267|NCT00900380|||OTHER||RETROSPECTIVE|||||||
33911268|NCT06208982|||COHORT||RETROSPECTIVE|||||||
33911269|NCT04279912|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-centre, prospective, single-arm, open-label pilot trial assessing the feasibility and safety of MRgFUS thalamotomy for refractory hand tremor in up to 6 patients with multiple sclerosis||||
33911270|NCT02745158|||COHORT||PROSPECTIVE|||||||
33911271|NCT01014637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911272|NCT00377624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689539|NCT03264170|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||All participating women will be randomised to one of two groups at the time of recruitment. The intervention group will receive the prediction score. The control group will not receive the prediction score.||||
33778661|NCT04279964|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33911273|NCT01002534|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33911274|NCT01716533|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911275|NCT06150690|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911276|NCT05434247|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized trial with retrospective comparator group||||
33911277|NCT00321984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911278|NCT03209544|RANDOMIZED|PARALLEL||TREATMENT||||||||
34085080|NCT02751229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911279|NCT05241015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911280|NCT01482741|||COHORT||PROSPECTIVE|||||||
33911281|NCT05346601|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911282|NCT02632110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085081|NCT05318664|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34085082|NCT04127370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992869|NCT02807987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992870|NCT01501955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992871|NCT05278221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The evaluator of the outcomes will be blinded|The study has 2 parts; part I that includes healthy volunteers and part II that includes patients with focal epilepsy. Each healthy volunteer will participate in three sessions every 2 weeks and will receive a single per os dose of Lacosamide (200 mg), Brivaracetam (50 mg) or placebo. Patients in part II will receive either Lacosamide, 300 mg p.o. or Brivaracetam, 100 mg p.o. All participants will perform a test using the tested software that combines a Transcranial Magnetic Stimulation with EEG/EMG|f|f|f|t
33778662|NCT06379893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992872|NCT06130345|||COHORT||RETROSPECTIVE|||||||
33992873|NCT02015013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33992874|NCT03279978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992875|NCT04858412|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33992876|NCT06743009|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33992877|NCT05094128|||COHORT||PROSPECTIVE|||||||
33992878|NCT06626581|||CASE_ONLY||CROSS_SECTIONAL|||||||
33992879|NCT00243347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992880|NCT00110604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33911283|NCT03161639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|At the end of the canal access, the first operator will leave the surroundings and a second operator will continue. A length measurement will be determined in order to define the working length. After the working measurement length performed by the second operator, the first operator will be informed about the working length of each canal without the knowledge of which method was used for the length measurement . From then on, the first operator will continue the endodontic treatment. A third operator will evaluate the outcomes.|Patients between 6 and 9 years old who search for endodontic treatment in primary teeth. The allocation of subjects to groups will be achieved by randomization. These patients will be randomly divided into 2 groups: G1 - pulpectomy with length measurement performed through radiography and G2 - pulpectomy with length measurement performed with the aid of an apex locator.|t|t|t|t
33911284|NCT05909566|RANDOMIZED|PARALLEL||TREATMENT||NONE||"We will be providing clinical decision support tools for children receiving HHFNC for bronchiolitis, testing the impact of decision support compared to usual care in a pragmatic randomized trial. All subjects will receive standard of care.~Decisions regarding management will be at the discretion of the treating provider and will not be restricted or altered in any way."||||
33911285|NCT00861367|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33911286|NCT02596711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911287|NCT02593747|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911288|NCT01251172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911289|NCT05277155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||patient will be randomized 1:1 to placebo with SOC and BEJO Red Ginger with standard of care (SOC).|t|f|t|f
33911290|NCT06482554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Compare lumateperone treatment with existing medication|t|f|t|f
33911291|NCT05048823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Volunteers will be randomly distributed into two groups called intervention protocol and placebo protocol. Only the participant and the outcome assessor will be blinded to the protocols.||t|f|f|t
33911292|NCT02028104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911293|NCT06553144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911294|NCT05682820|||CASE_CONTROL||RETROSPECTIVE|||||||
33911295|NCT06316622|NA|SINGLE_GROUP||OTHER||NONE|relationship between body mass index and the skin epidural space distance|relationship between body mass index and the skin epidural space distance||||
33911296|NCT03433287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open cohort study||||
33911297|NCT05128435|||COHORT||PROSPECTIVE|||||||
33911298|NCT02325635|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33911299|NCT01833767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911300|NCT06342050|||OTHER||CROSS_SECTIONAL|||||||
33911301|NCT04906655|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study is open label, and treatment groups are assigned by Cohorts starting with A, then B, then C, then D. The method of treatment will be filled on a first come, first served basis. Movement from one cohort to the next will be determined by the medical monitor after evaluation of the safety and efficacy data that is available after each cohort is filled. There may be a very brief enrollment (baseline) pause for this to occur.||||
33911302|NCT00734773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992881|NCT03690960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992882|NCT00003035||||TREATMENT||||||||
33992883|NCT06705465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT||||
33992884|NCT06135051|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33992885|NCT02511535|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33992886|NCT01044537|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33992887|NCT05167487|||CASE_ONLY||RETROSPECTIVE|||||||
33911303|NCT02403193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911304|NCT02529761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911305|NCT00100633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911306|NCT00408421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911307|NCT05505578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34085083|NCT04194112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085084|NCT00458237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085085|NCT00461058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085086|NCT01452620|||COHORT||RETROSPECTIVE|||||||
34085087|NCT06479902|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi Interventional Study||||
34085088|NCT03248297|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized Controlled Trial|t|t|t|t
33911308|NCT06463158|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A phase I clinical trial using a 2-stage sequential cohort design to test the impact of the Family Room on family caregiver well-being, engagement, and satisfaction||||
33911309|NCT05943327|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33911310|NCT06290895|||COHORT||RETROSPECTIVE|||||||
33911311|NCT02697461|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33992888|NCT04512235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, randomized, multicenter international Phase 3 study.|This is a double-blind, randomized, multicenter, international Phase 3 study of CAEL-101 combined with SoC PCD treatment versus placebo combined with SoC PCD treatment in Mayo stage IIIa PCD treatment-naïve AL amyloidosis patients. Approximately 267 patients will be enrolled using a 2:1 randomization ratio and stratification will be based on geographic region across investigator sites. The primary evaluation treatment period (PETP) part of the study will stop when the last patient is randomized in the PETP plus 18 months. Patients in both study intervention groups will be followed from randomization until death from any cause, heart transplant, left valve assist device (LVAD) implantation or until end of study.|t|t|t|t
33992889|NCT06619184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992890|NCT05117489|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33992891|NCT03834077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be allocated to intervention (flossing) or control group (conventional physiotherapy) using a randomized list of allocated numbers generated by a computer program. Opaque envelope will contain the patients allocation while outcome assessors, care provider and principal investigator will be blinded to the allocation process.|Randomized controlled trial|f|t|t|t
33992892|NCT02490072|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33992893|NCT02125435|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33992894|NCT00376285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33992895|NCT00798603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689540|NCT05769543|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33992896|NCT05005026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomly assigned to one of two intervention arms. Both groups receive the same number of sessions, duration of sessions, and measures procured.|t|t|t|f
33992897|NCT01877317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689541|NCT02537574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689542|NCT06166030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689543|NCT04584697|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Initially, 2 subjects will be enrolled at the 40 mg dose level. If no safety concerns arise, 48 subjects will then be randomized 1:1:1:1 to receive 40 mg COVI-AMG, 100 mg COVI-AMG, 200 mg COVI-AMG, or placebo.|t|t|t|t
33689544|NCT03745430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689545|NCT02711345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689546|NCT06059118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689547|NCT00075673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689548|NCT04639115|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689549|NCT01222403|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33689550|NCT04936464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911312|NCT02066025|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911313|NCT02210637|||COHORT||RETROSPECTIVE|||||||
33911314|NCT05808998|||COHORT||PROSPECTIVE|||||||
33911315|NCT00312884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911316|NCT02322892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911317|NCT05676320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689551|NCT05922969|||CASE_ONLY||RETROSPECTIVE|||||||
33992898|NCT02291796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33992899|NCT06070922|||COHORT||PROSPECTIVE|||||||
33992900|NCT00938509|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689552|NCT05321160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689553|NCT04127812|NA|SINGLE_GROUP||PREVENTION||NONE||Selected classrooms will receive the Savor the Flavor intervention. Data will be collected prior to and after the intervention. Children, their parent/guardian, and classroom teachers will participate in the research.||||
33689554|NCT05049733|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind (Participant, Outcomes Assessor), placebo controlled|All participants will complete all dose conditions (study arms) in a randomized order|t|f|f|t
33689555|NCT03663153|||OTHER||PROSPECTIVE|||||||
33689556|NCT04590079|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"First intervention group: patients with peripheral osteoarthritis who will have: 3 months of conventional pain treatment and daily sessions with the medical device followed by 1 month of wash out and then 3 months of conventional pain treatment.~Second intervention group: patients with peripheral osteoarthritis who will have: 3 months of conventional pain treatment followed by 1 month of wash out followed by 3 months of conventional pain treatment and daily sessions with the medical device."||||
33689557|NCT04733443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689558|NCT01157156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689559|NCT01451268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689560|NCT00436930|RANDOMIZED|||TREATMENT||||||||
33689561|NCT00505882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689562|NCT01709578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689563|NCT05198700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, double-blind, placebo-controlled|t|t|t|t
33689564|NCT01397318|||CASE_CONTROL||PROSPECTIVE|||||||
33689565|NCT01221038|||CASE_CONTROL|||||||||
33689566|NCT04415060|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre open-label, pragmatic, randomized controlled trial and a parallel prospective (non-randomized) cohort study||||
33689567|NCT04735718|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation||||
33689568|NCT06017544|||CASE_CONTROL||PROSPECTIVE|||||||
33689569|NCT03577405|||COHORT||PROSPECTIVE|||||||
33689570|NCT02821910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33689571|NCT04205097|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689572|NCT01530347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33689573|NCT00498056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33689574|NCT04988828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33689575|NCT05897970|||COHORT||RETROSPECTIVE|||||||
33689576|NCT04096222|||CASE_CONTROL||OTHER|||||||
33778663|NCT06487650|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33778664|NCT04722224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778665|NCT05324982|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo controlled, double blind drug administration|A within-subjects design.|t|t|f|f
33911318|NCT05159596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are randomly assigned to treatment arms by People Power. Identical systems are self-installed by caregivers in all homes regardless of treatment arm. Initiating the features of the system appropriate to the assigned treatment arm is done remotely by a member of the People Power staff following the installation. All participants complete the same questionnaires at the same intervals.||f|f|t|f
33911319|NCT00138151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911320|NCT05841602|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33911321|NCT02634918|||COHORT||PROSPECTIVE|||||||
33911322|NCT06297694|||CASE_ONLY||CROSS_SECTIONAL|||||||
33911323|NCT02292303|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33911324|NCT01230658|||COHORT||PROSPECTIVE|||||||
33689577|NCT01199900|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33689578|NCT00738192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689579|NCT04448782|||COHORT||PROSPECTIVE|||||||
33689580|NCT03256630|||CASE_ONLY||PROSPECTIVE|||||||
33689581|NCT01087866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689582|NCT01298193|NA|SINGLE_GROUP||TREATMENT||NONE||Patients that experiment emesis within the first cycle in spite of the administration of antiemetics, may opt to participate in a subsequent efficacy phase||||
33911325|NCT04022811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911326|NCT00789100|||COHORT||PROSPECTIVE|||||||
33911327|NCT00587418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911328|NCT03411213|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911329|NCT01115569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911330|NCT01044173|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911331|NCT04573452|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33911332|NCT04123756|||COHORT||PROSPECTIVE|||||||
33911333|NCT04336397|RANDOMIZED|PARALLEL||SCREENING||SINGLE||3-arm cluster-randomized controlled trial|t|f|f|f
33911334|NCT00920608|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33911335|NCT04478682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Study||||
33992901|NCT06637423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992902|NCT04958915|||COHORT||PROSPECTIVE|||||||
34085089|NCT00653874|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34085090|NCT04020562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085091|NCT03485625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085092|NCT02673749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085093|NCT02870491|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34085094|NCT01220570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085095|NCT03513120|||COHORT||PROSPECTIVE|||||||
34085096|NCT05981846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34085097|NCT01704365|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085098|NCT03342066|||COHORT||PROSPECTIVE|||||||
34085099|NCT04087512|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors are blinded during baseline-assessment.||f|f|f|t
34085100|NCT04113135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers and participants will not be blinded due to the nature of the intervention. Participants will know whether or not they are performing yoga or just receiving the control group intervention. Additionally, the PI is leading the intervention and will therefore know who is in the control vs the experimental. Investigators will attempt to blind clinicians and students completing pre and post intervention testing to who was in the control vs experimental, however, this may not be possible.||f|f|f|t
34085101|NCT04063839|||COHORT||PROSPECTIVE|||||||
34085102|NCT05446103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using sham blood flow restriction (A cuff will be placed on the arm with minimum pressure \<20% of arterial occlusive pressure)||t|f|f|t
34085103|NCT06551740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||healthy volunteers||||
34085104|NCT05054634|||COHORT||PROSPECTIVE|||||||
34085105|NCT00720135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085106|NCT05445089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The assigned treatment will not be known to the study subjects, the participating researchers and the evaluators of the criteria of study assessment. The placebo should contain the same technical specifications and physical appearance of modified Isothymol.~To ensure individual opening of the randomization code, sealed envelopes will be prepared for each subject, which will contain the specific treatment received by each. These envelopes can be controlled by the Clinical Researcher, the Nursing Staff or Pharmacy available 24 hours.~After obtaining informed consent, the treatment strategy uses centralized randomization, using a phone system. Eligible patients will be randomized to one of the following therapeutic strategies:~* Modified Isothymol Treatment Group: Immediately after randomization a dose of 6 mg/ml of modified isothymol.~* Placebo Treatment Group: Immediately after the randomization a placebo dose will be administered."|"Randomized, double-blind, multicenter study with blind evaluation of events, designed to compare the efficacy and safety of Isothymol modified with placebo in patients ≥18 years of age who meet the inclusion criteria.~* Drug administration scheme: Randomized and parallel (modified isothymol and placebo).~* Statistical design: Superiority. It will allow to detect difference between drug and placebo after parallel administration."|t|f|f|f
34085107|NCT00512525|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34085108|NCT03006432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085109|NCT04412889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992903|NCT06557785|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33992904|NCT06165354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo X-secret and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo X-secret suspension is unrecognizable to investigators except the PI and analyzer due to opaque plastic container.|Parallel Assignment Parallel Assignment Blind, randomized, and controlled clinical trial|t|t|t|f
33992905|NCT01532635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992906|NCT05057039|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33992907|NCT03932058|||CASE_CONTROL||RETROSPECTIVE|||||||
33992908|NCT01726933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778666|NCT06330831|NA|SINGLE_GROUP||TREATMENT||NONE|No masking occurred for the participants or care providers since all parents/caregivers consented to have their children participate in the intensive group based CIMT intervention. The parents/ care providers knew who the interventionists were. The principal investigator was aware of all participants' assignment to the study. The principal investigator also delivered the intervention to the 2-3-year-old group and also served as the assessor of outcomes along with trained student investigators. The principal investigator attempted to limit bias by having all students achieve an inter-rater reliability level of 90% or above (intra-class correlation coefficient ICC\>.90) on the QUEST and by not allowing the student investigators or herself to consult the pre-intervention assessment outcome scores until after post-intervention outcome assessment scoring was completed.|Study 1 is a single group pre-post study of children who received 1 episode of the intensive, group based CIMT intervention (2 data points- pre CIMT 1 and post CIMT1). Study 2 is a repeated measures design to evaluate the long-term effects of the first episode and the effects of the second episode of intensive group based CIMT (4 data points- pre CIMT1; post CIMT1 (at the end of 1 month intervention); pre CIMT 2- 11 months after post of CIMT1; post CIMT 2- 12 months post CIMT 1)||||
33778667|NCT04212169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigation product only will be prepared and administered by unmasked personnel. All subjects will receive the same number of injections at each dose.|Participants will be randomised to receive MEDI3506 dose 1, MEDI3506 Dose 2 or MEDI3506 dose 3 or placebo.|t|t|t|t
33778668|NCT06693037|||COHORT||OTHER|||||||
33778669|NCT05925270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778670|NCT03174964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778671|NCT01235273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911336|NCT01956409|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911337|NCT05263102|NA|SINGLE_GROUP||TREATMENT||NONE||before and after treatment||||
33911338|NCT04699604|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Identity of the study article will be known only by the investigational pharmacist charged with dispensing the product and the research coordinator responsible for administering the study articles and obtaining timed blood specimens associated with pharmacokinetic and pharmacodynamic study objectives. Blinding of the principal investigator and co-investigators will be safeguarded by blinding the identity of the study articles (LTZ 0.5 mg/ml oral solution or placebo solution similar in color, flavoring and consistency) and preventing access to specific source documents that will be used for recording of collected blood samples until the time of data analysis.|Randomized, double-blind, placebo-controlled, crossover study|t|t|t|t
33911339|NCT02773069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911340|NCT05056467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911341|NCT02693483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911342|NCT03587558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911343|NCT02027116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085110|NCT04615936|NA|SINGLE_GROUP||TREATMENT||NONE|N/A- masking not required|There is only a single group of patients in the study who will undergo treatment. There is a small sub group/'nil' group of 3 healthcare workers that will not be undergoing the treatment but will instead be doing multiple nasal swabbing in the course of 5 days.||||
34085111|NCT00747214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085112|NCT02696798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085113|NCT06372535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689583|NCT02964403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33689584|NCT02772484|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689585|NCT02806193|||||RETROSPECTIVE|||||||
33689586|NCT00312403|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689587|NCT02044328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689588|NCT05779670|||COHORT||PROSPECTIVE|||||||
33689589|NCT03418467|||CASE_CONTROL||PROSPECTIVE|||||||
33689590|NCT06023524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689591|NCT02284971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778672|NCT03059030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778673|NCT02284464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778674|NCT04520958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33778675|NCT04521205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689592|NCT06424665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778676|NCT01790945|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33689593|NCT02207660|||COHORT||RETROSPECTIVE|||||||
33689594|NCT02758977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689595|NCT04908020|||COHORT||CROSS_SECTIONAL|||||||
33689596|NCT00566501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085114|NCT03799861|||COHORT||PROSPECTIVE|||||||
33689597|NCT03899688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the surgeon will be blinded until the maxillary sinus augmentation is filled with the biomaterial.|test and control group|f|f|t|t
33689598|NCT02278471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689599|NCT02297282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992909|NCT06732102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants can choose whether they wish to participate in the DECIDE group sessions or engage in traditional CHW services, yet they will be randomized to receive either one or two calls per month from their designated community health worker. A 1:1 randomization process will be employed, whereby each individual is assigned a random number generated by a computer algorithm. Participants with an even number will be allocated to receive one call per month (the current standard of care), while those assigned an odd number will receive two calls per month. This random assignment ensures an equal probability of assignment to each group, minimizing selection bias and supporting balanced distribution across the study conditions participation in the DECIDE intervention vs no DECIDE sessions. Participants will be blinded to their assigned call schedule and will be notified at the end of the trial as part of the dissemination of study results.|t|f|f|f
33689600|NCT00867477|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33911344|NCT04644289|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be treated in two consecutive cohorts (A, B) of 30 patients each, with A) olaparib alone or B) olaparib in combination with durvalumab. Treatment allocation will take please in two consecutive cohorts rather than by randomization. This will allow to evaluate the safety and feasibility in a step-wise approach. A trial steering committee (TSC) meeting will take place between the cohorts to review safety and feasibility prior to starting the second cohort. The safety follow-up of the first cohort will take 90 days as of the first dose of therapy.||||
33911345|NCT01922427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085115|NCT05976945|NA|SINGLE_GROUP||TREATMENT||NONE|The investigator will not have access to assignment of participants to waitlist length and the data until data collection is complete.|Multiple baseline case series design: by randomizing participants to different lengths of waitlist (baseline) and comparing means and slopes of weekly reported depression severity and core beliefs, the effectiveness of the treatment is tested.||||
33992910|NCT03273153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992911|NCT06562114|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33992912|NCT00960414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992913|NCT00360607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992914|NCT03776396|||COHORT||PROSPECTIVE|||||||
33992915|NCT02480660|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34085116|NCT00841984|||||PROSPECTIVE|||||||
34085117|NCT04155801|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085118|NCT02678117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34085119|NCT03146390|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34085120|NCT06001671|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34085121|NCT04451096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded|placebo controlled|t|t|t|t
33992916|NCT04168398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Block randomization: Two elements A for CAT, B for AAT A A B B A B A B A B B A B B A A B A B A B A A B|Randomized controlled Prospective study: It will include all patients presented to our department fulfilling the inclusion criteria. We revascularize about 5-10 limbs per week and the study will be carried over 30 months; sample size will be 600-1200 patients|t|t|t|t
33689601|NCT02774733|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689602|NCT02845518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689603|NCT02749669|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33689604|NCT00123968|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33992917|NCT04485767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participants, Investigators and Research Staff will remain blinded.~Only exercise personnel and study statistician will be unblinded."|Structured Resistance Exercise vs Control Exercise|t|f|t|f
33992918|NCT02812420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992919|NCT02525445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33992920|NCT02110277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992921|NCT03418753|||COHORT||PROSPECTIVE|||||||
33992922|NCT03183609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double blind trial|t|t|t|t
33992923|NCT05543135|||CASE_ONLY||RETROSPECTIVE|||||||
34085122|NCT03786835|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33689605|NCT03268148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two independent assessors blinded to intervention read the video, and then record vital signs and pain score. The videos are cut from heel-lancing to the end so that the assessors do not know whether the neonate receive low level laser or breast milk.|low level laser group and breast milk group|f|f|f|t
33689606|NCT00477581|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33689607|NCT00221312|||CASE_CONTROL||PROSPECTIVE|||||||
33689608|NCT03960554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and clinical research coordinators will be blinded to treatment assignment for the duration of the study.||t|f|t|f
33689609|NCT01237964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689610|NCT02717845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689611|NCT04516044|||COHORT||RETROSPECTIVE|||||||
33689612|NCT03641885|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33689613|NCT01231308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33689614|NCT06091787|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomised controlled trial with 2 groups. One group receiving Tablet Ursodeoxycholic acid and the other group not receiving standard medical therapy||||
33689615|NCT03526731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33778677|NCT05400720|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"We aim to conduct the study over 6 to 12 months to obtain enough experience to enable feasibility evaluation.~Mentor pool sample size: We anticipate having about 10 patients in the mentors' pool during the study period.~Mentee sample size: We anticipate approaching between 20 to 30 dialysis patients over the study period.~Supporting team: All members of the supporting staff will be invited to participate."||||
33778678|NCT05282342|||OTHER||CROSS_SECTIONAL|||||||
33911346|NCT05834803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the operator and his team will know whether the patient receives active treatment or sham treatment. The patient will wear a sleep mask and earplugs during the procedure to ensure blinding. Pressure gradient measurements will be performed in both groups.|A Danish Nationwide (3-center) Randomized and Sham-Controlled Study.|t|t|t|f
33911347|NCT02548104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33911348|NCT03355287|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911349|NCT00528346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911350|NCT02536170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911351|NCT00000461|RANDOMIZED|||TREATMENT||||||||
33911352|NCT02773238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911353|NCT00115349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911354|NCT02258009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911355|NCT02399813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911356|NCT05169307|||COHORT||RETROSPECTIVE|||||||
33911357|NCT06326775|||OTHER||RETROSPECTIVE|||||||
33911358|NCT05308225|NA|SEQUENTIAL||TREATMENT||NONE||To determine DLT and MTD, the design uses a 3+3 design for the dose-escalation stage.||||
33911359|NCT03732391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911360|NCT00856076|||CASE_CONTROL||RETROSPECTIVE|||||||
33911361|NCT00313534||||TREATMENT||||||||
33911362|NCT00093080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911363|NCT05280431|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33911364|NCT01601275|||CASE_ONLY||PROSPECTIVE|||||||
33911365|NCT05135130|||CASE_CONTROL||RETROSPECTIVE|||||||
33911366|NCT03399175|NA|SINGLE_GROUP||OTHER||NONE||Early systemic high-dose corticosteroid and immunosuppressive therapy||||
33911367|NCT05728671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33911368|NCT05745324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigators, care providers and outcome assessors would be blinded to the smoking status of the participants||f|t|t|t
33992924|NCT05162105|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be provided information regarding hypotheses or expected results from the different conditions.|Participants are randomly assigned to the QR-condition (evening shift followed by a day shift) or a day shift followed by another day shift. After a four week wash-out, participants return to work in the opposite condition.|t|f|f|f
33992925|NCT04654182|NA|SINGLE_GROUP||OTHER||NONE||||||
33992926|NCT06366750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992927|NCT00665925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992928|NCT02390518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689616|NCT01395862|||||PROSPECTIVE|||||||
33992929|NCT06426225|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33992930|NCT01995227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689617|NCT04163679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689618|NCT01030627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689619|NCT04246255|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33689620|NCT01645722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689621|NCT01522729|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33689622|NCT01148797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689623|NCT00470158|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689624|NCT04440371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689625|NCT04040868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689626|NCT03535376|||CASE_ONLY||PROSPECTIVE|||||||
33689627|NCT01426997|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689628|NCT03574480|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33689629|NCT06087315|||OTHER||OTHER|||||||
33689630|NCT03621618|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33689631|NCT01511185|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33689632|NCT03385083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33689633|NCT04323605|NA|SINGLE_GROUP||OTHER||NONE||||||
33689634|NCT05997472|||OTHER||CROSS_SECTIONAL|||||||
33689635|NCT05931588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689636|NCT02363569|||COHORT||PROSPECTIVE|||||||
33689637|NCT04148677|||CASE_CONTROL||PROSPECTIVE|||||||
33689638|NCT00817583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689639|NCT05314985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33689640|NCT02416310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33689641|NCT00173043|||CASE_CONTROL||PROSPECTIVE|||||||
33689642|NCT00417573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689643|NCT01957527|||CASE_ONLY||PROSPECTIVE|||||||
33689644|NCT05802875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33689645|NCT04538196|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33689646|NCT00920231|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689647|NCT04654884|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomisation into two groups. Group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy)Group 2, the control group, will receive TaU.||||
33689648|NCT01824212|||CASE_ONLY||PROSPECTIVE|||||||
33689649|NCT01578564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689650|NCT05899010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689651|NCT00006367||||TREATMENT||||||||
33689652|NCT01178073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689653|NCT02016339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689654|NCT02186132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911369|NCT03638947|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|After the patient has signed consent, they will receive a pre-surgical kit that will include swabs to be used in the nares, arm pit and groin area (standard of care). In a 1:1 randomization scheme, one half of the patients will receive povidone-iodine swab in addition to the kit (treatment).||t|f|f|f
33911370|NCT01008995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689655|NCT05705414|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The intervention will be administered to the subjects by appropriately trained delegates.|The study design will consist of a crossover schema, with one arm starting on amino acid Valine and the other on EAA for a period of 8 weeks, followed by a washout period of 1 week, and then assignment to the nutritional supplement that they have not already taken for the remaining 8 week period that they are participating in this study.||||
33911371|NCT01388582|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911372|NCT04752579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked assessor conducted the measurements.|Parallel Assignment|f|f|f|t
33911373|NCT05909254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911374|NCT00149851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911375|NCT03644940|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33911376|NCT01106196|||||RETROSPECTIVE|||||||
33911377|NCT03419767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911378|NCT00120120|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33911379|NCT02814968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992931|NCT00271492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992932|NCT01269840|||COHORT||RETROSPECTIVE|||||||
33992933|NCT01321450|||COHORT||PROSPECTIVE|||||||
33992934|NCT05828511|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Note: Phase 1 part B will be randomized 1:1. All other participants will be non-randomized.||||
33992935|NCT05835349|||COHORT||OTHER|||||||
33992936|NCT02795663|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689656|NCT05368077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33689657|NCT00155103|||CASE_CONTROL||RETROSPECTIVE|||||||
33689658|NCT05443061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689659|NCT00315068|||DEFINED_POPULATION||PROSPECTIVE|||||||
33689660|NCT00652197|||COHORT||CROSS_SECTIONAL|||||||
33689661|NCT05645250|||OTHER||PROSPECTIVE|||||||
33689662|NCT00188799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689663|NCT03962309|||COHORT||CROSS_SECTIONAL|||||||
33689664|NCT01182779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689665|NCT03505671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33992937|NCT05517447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992938|NCT00860938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992939|NCT05571592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33992940|NCT00721435|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992941|NCT05811247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992942|NCT05387603|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized, open-label, controlled trial in which patients are assigned to either non-personalized treatment with 4 cycles of 7.5 gigabequerel (GBq) 177Lu-DOTATOC (TOC), or personalized treatment based on dual imaging. In the personalized arm patients are treated according to the results of the dual imaging at screening:~A. Patients with 68Ga-1,4,7,10-tetra-azacyclododecane-N.n,N,N-tetraacetic acid (DOTA)-positron emission tomography (PET)-positive but 18F-2-fluoro-2-deoxy-D-glucosefluorodeoxyglucose (FDG)-PET-negative NET will receive dosimetry-based PRRT only (dTOC) B. Patients with 68Ga-DOTA- and 18F-FDG-PET-positive NET will receive a combination of capecitabine and dosimetry-based PRRT (CAP-dTOC)."||||
33992943|NCT04489719|||COHORT||PROSPECTIVE|||||||
33992944|NCT00911274|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33992945|NCT04026815|||COHORT||CROSS_SECTIONAL|||||||
33992946|NCT04925791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33992947|NCT05404490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-Blind||t|f|f|f
33992948|NCT05572437|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|El investigador responsable de la recogida de los datos a partir del informe clínico de los anestesiólogos responsables del manejo clínico intra y postoperatorio de los pacientes no sabrá qué pacientes han sido incluidos en el grupo Intervención.|The randomization of the patients will be carried out by a collaborating researcher through a computer program (Excel 2016) at the time of inclusion in the study. This collaborating researcher will not be able to be present at the surgical intervention and will contact the nursing staff by telephone, indicating which patient should be given music therapy upon arrival in the pre-surgery room.|f|t|t|t
33689666|NCT04145479|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||all women with diet and lifestyle controlled gestational diabetes. each will serve as their own control||||
33689667|NCT01231152|||CASE_ONLY||PROSPECTIVE|||||||
33689668|NCT03593161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689669|NCT00411931|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689670|NCT04216914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689671|NCT01907438|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689672|NCT04673084|||COHORT||PROSPECTIVE|||||||
33689673|NCT01380210|||CASE_ONLY||RETROSPECTIVE|||||||
33689674|NCT02645604|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689675|NCT00992303|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689676|NCT02854410|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33778679|NCT06110143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778680|NCT03849872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911380|NCT01514188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911381|NCT00782665||PARALLEL||TREATMENT||NONE||||||
33911382|NCT05016947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911383|NCT00041613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911384|NCT00926796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911385|NCT01986634|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33911386|NCT03108144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Organizations will be randomly allocated in a 1:1 allocation ratio to Group A (Test) or Group B (Control) accounting for rurality, organization type, practice size and academic affiliation.|f|f|t|f
33992949|NCT06350747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pretest-posttest with control group||||
33992950|NCT05842629|||COHORT||PROSPECTIVE|||||||
33992951|NCT01369368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992952|NCT05464186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomly assigned for 1 year to receive home delivery of: 1) Whole milk, 3 cups a day or 2) Nonfat milk, 3 cups a day.|f|f|f|t
33689677|NCT05596396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent researcher who is not involved in the study will generate the random sequence using a computer random sequence generator. Randomisation will take place at an individual level, stratified by gender and the university where students study. Participants will be randomised into two groups (LifeHack vs LifeHack-C) with an allocation ratio of 1:1. Block randomisation with randomly varied block sizes (6 to 12 allocations per block) will be conducted to prevent foreknowledge of intervention assignment. Allocation will be concealed from the study's researchers. It is not possible to mask personnel and participants to the treatment allocation because of the nature of the intervention|The present study is a two-armed randomized controlled trial. This trial will be conducted in a university setting. A guided web-based intervention to improve positive mental health and well-being (LifeHack) will be compared to an unstructured version of the same intervention (LifeHack-C)|f|f|t|t
33689678|NCT00116662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33689679|NCT05240508|||COHORT||PROSPECTIVE|||||||
33689680|NCT03206073|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689681|NCT03177343|||COHORT||RETROSPECTIVE|||||||
33689682|NCT04743518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689683|NCT01733849|||COHORT||PROSPECTIVE|||||||
33689684|NCT01244698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911387|NCT02934048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911388|NCT03126539|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33911389|NCT00300469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911390|NCT00562757|||CASE_CONTROL||PROSPECTIVE|||||||
33911391|NCT04829955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911392|NCT02128763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911393|NCT05365620|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was designed as a randomized, open-label, parallel, non-inferiority, controlled trial.||||
33911394|NCT01656681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33911395|NCT03934892|||COHORT||RETROSPECTIVE|||||||
33911396|NCT04360616|||COHORT||PROSPECTIVE|||||||
33911397|NCT06224985|||COHORT||PROSPECTIVE|||||||
33911398|NCT03343431|NA|SINGLE_GROUP||PREVENTION||NONE||All participants receive the intervention||||
33911399|NCT02718586|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33911400|NCT00632463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911401|NCT03855137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992953|NCT06743113|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Each enrolled patient will be randomized to treatment with either hypoxic RBCs or conventional RBCs after successful completion of the screening period. After 6 months in the randomized treatment arm, two Wash Out transfusions of conventional RBCs will be scheduled. The patient will then cross-over into the other treatment arm to complete another 6 months of treatment."|t|f|f|f
33992954|NCT03385421|||COHORT||PROSPECTIVE|||||||
33992955|NCT05136001|||COHORT||RETROSPECTIVE|||||||
33992956|NCT04468763|||COHORT||PROSPECTIVE|||||||
33992957|NCT02896985|||COHORT||PROSPECTIVE|||||||
33992958|NCT00672984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33911402|NCT06365814|||COHORT||RETROSPECTIVE|||||||
33911403|NCT02786732|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33992959|NCT03984565|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33689685|NCT02274441|||COHORT||RETROSPECTIVE|||||||
33911404|NCT02642887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911405|NCT00173004|||CASE_CONTROL||OTHER|||||||
33911406|NCT01134692||PARALLEL||PREVENTION||DOUBLE||||||
33911407|NCT05836818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|outcomes assessor will not know arm assignment|A three-arm cluster randomized control trial to determine the effect of vaccine messaging and a question about acceptance, a question about acceptance without messaging, and standard care affect vaccine uptake in the ED.|f|f|f|t
33992960|NCT05710510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992961|NCT05433090|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The intervention used in this study is an inpatient advance care planning intervention. We will adapt the Serious Illness Care Program, an evidence-based intervention that promotes serious illness conversation between patients and clinicians, to be used by advance practice providers and hematology/oncology fellow physicians in the inpatient setting.||||
33992962|NCT04620603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992963|NCT05100095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992964|NCT00042783||||TREATMENT||NONE||||||
33992965|NCT05665608|RANDOMIZED|PARALLEL||PREVENTION||NONE|The PROFID EHRA trial is an open-label, blinded outcome assessment study. Thus, unblinding procedures for investigators are not applicable.|An investigator-driven, prospective, parallel-group, randomised, open, blinded outcome assessment (PROBE), multi-centre, non-inferiority trial without investigational medical products (Proof of Strategy Trial)||||
33992966|NCT05667532|||COHORT||PROSPECTIVE|||||||
33689686|NCT01575886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33689687|NCT00046891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33778681|NCT00322868|NA|SINGLE_GROUP||TREATMENT||NONE|This was open-label and no one was masked.|||||
33778682|NCT02510066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778683|NCT04280328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778684|NCT06428253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|subject/evaluator blinding||t|f|t|f
33911408|NCT06101394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689688|NCT04534803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and investigators and designated staff whose responsibility will be to administer the BCG vaccine or placebo will be blinded.|Participants will be randomized in a 1:1 allocation to receive intradermal administration of BCG vaccination or placebo.|t|f|t|t
33689689|NCT05236153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911409|NCT02097095|||COHORT||OTHER|||||||
33911410|NCT00562796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911411|NCT05949099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911412|NCT04997889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33911413|NCT03266484|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Will be a double blinded randomized controlled trial. Masking will be done by the provider of the probiotics/placebo||t|t|t|f
33911414|NCT04684550|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* The first group of health personnel who work in places of greater risk (hospitals and primary level consultation) with conventional protection elements added to the application of 2 nasal puff every 8 hours of a nasal spray containing 0.9% SSN (placebo) and gargles (SSN 0.9%).~* A second group of health personnel who work in higher risk places (hospitals and primary level consultation) with conventional protection elements added to the application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm)."|A randomized, double-masked, placebo-controlled clinical experiment is proposed.|t|t|t|f
33911415|NCT04688346|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a, single-blinded, placebo-controlled, split-mouth randomized trial. A sample size of 20 pediatric patients will be used for this pilot study.||||
33911416|NCT03677687|NA|SINGLE_GROUP||OTHER||NONE||||||
33911417|NCT02150187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911418|NCT02385825|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911419|NCT02993224|NA|SINGLE_GROUP||OTHER||NONE||||||
33911420|NCT02329873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911421|NCT01046448|||COHORT||PROSPECTIVE|||||||
33689690|NCT05507827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911422|NCT00055822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911423|NCT00702052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911424|NCT01784406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689691|NCT05956184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participants will not know which method would be applied to them.|Two groups as conventional method and direct method|t|f|f|f
33689692|NCT04572802|||CASE_CONTROL||RETROSPECTIVE|||||||
33689693|NCT00925171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689694|NCT02125474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689695|NCT01903525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778685|NCT02362113|||||CROSS_SECTIONAL|||||||
33778686|NCT03459820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778687|NCT03300089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor and statistician are blinded.||f|f|f|t
33778688|NCT03927365|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Randomization of a salt particle inhaler devices with (active) or without (placebo) content|Participants cross over from active to placebo or vice versa in random order|t|t|t|t
33689696|NCT01949454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689697|NCT00450112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689698|NCT05041530|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, single-arm, feasibility study||||
33689699|NCT06636266|||CASE_ONLY||RETROSPECTIVE|||||||
33689700|NCT01515540|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33689701|NCT03224546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33689702|NCT06622889|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911425|NCT04953949|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, multi-center study||||
33689703|NCT03577171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33689704|NCT03723200|||OTHER||RETROSPECTIVE|||||||
33689705|NCT05453266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33689706|NCT05024318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689707|NCT01617148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778689|NCT01861756|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778690|NCT02501733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778691|NCT00950053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778692|NCT02424331|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33778693|NCT01723826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778694|NCT05976594|||CASE_CONTROL||RETROSPECTIVE|||||||
33778695|NCT06085196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33778696|NCT01636440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778697|NCT02377765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778698|NCT00503048|||COHORT||RETROSPECTIVE|||||||
33778699|NCT00935792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911426|NCT04283994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33911427|NCT02426411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911428|NCT05223621|||COHORT||PROSPECTIVE|||||||
33911429|NCT03531437|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33911430|NCT02876939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911431|NCT01810198|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33911432|NCT05006898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While in office the care provider took a number out of a closed container. Number 1 was designated for the placebo; Number 2 was designated for the compound|Pilocarpine, brimonidine, oxymetazoline (PBO) compound was instilled in the non-dominant eye of presbyopic patients, while in the dominant eye pilocarpine or brimonidine were instilled.|t|t|f|f
33911433|NCT03430687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911434|NCT03917719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911435|NCT01273688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911436|NCT00331370|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33911437|NCT04005820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911438|NCT00597935|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33689708|NCT06321627|||COHORT||PROSPECTIVE|||||||
33911439|NCT05288634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
33911440|NCT00678106|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33911441|NCT00121303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689709|NCT02814032|||COHORT||PROSPECTIVE|||||||
33689710|NCT02859272|||COHORT||RETROSPECTIVE|||||||
33689711|NCT04066465|||OTHER||PROSPECTIVE|||||||
33689712|NCT00107367||||TREATMENT||NONE||||||
33689713|NCT00127595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689714|NCT00003171||||TREATMENT||||||||
33689715|NCT00802607|||||OTHER|||||||
33689716|NCT00450775|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33689717|NCT05893901|||COHORT||CROSS_SECTIONAL|||||||
33689718|NCT01778777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689719|NCT02515812|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33689720|NCT02187874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689721|NCT00926588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689722|NCT05588557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The subjects of each cohort will be randomly arranged to receive ND-340 or control drug (Marcaine® Injection 0.5%, equal to bupivacaine base 5 mg/mL) in the ratio of 3:1.|t|f|t|f
33689723|NCT04232306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to treatment arm to which patients are assigned.|randomized, single-blind, active-controlled trial|t|f|f|f
33778700|NCT04058314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be masked to the eye that receives the study device||t|f|f|f
33778701|NCT03746444|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33911442|NCT02290535|||CASE_CONTROL||PROSPECTIVE|||||||
33911443|NCT04472364|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will receive the HemoPill Acute ® capsule. In case of blood detection in the upper gi-tract (capsule positive), the endoscopy will be performed within 12 hours. If no blood is found in the upper GI tract (capsule negative), endoscopy will be performed after 48 to 96 hours.||||
33911444|NCT00562003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911445|NCT05428072|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33911446|NCT02274584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911447|NCT05257720|||COHORT||PROSPECTIVE|||||||
33992967|NCT02854800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants in all 3 study arms were given the same intervention treatment. Arms differed only by the number of days they had been enrolled in an outpatient opioid dependence program.||||
33992968|NCT03522142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33992969|NCT05216315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||sham versus stimulation|t|f|f|f
33992970|NCT02977221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33992971|NCT02722239|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992972|NCT05220098|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation Phase is non-randomized and Cohort-expansion Phase will include randomized and non-randomized cohorts.||||
33992973|NCT05612204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33992974|NCT04786496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were blinded to the intervention condition. Moreover, both the speech and math tasks of the Trier Social Stress Test were done in front of two confederates (one woman and one man) who were blind to the intervention condition and who had not had previous contact with the participant|"Participants were randomized (balanced for sex and levels of depression and social anxiety) to one of three groups (i.e., ITP+SA, ITP, and CC) in parallel for the duration of the study.~Given the relevance of depression and social anxiety during stress tasks such as the TSST, these measures were used to balance participants within intervention and control groups. Specifically, a cluster analysis using mean scores on depression and social anxiety was conducted, resulting in a four-cluster solution according to the participants' level of depression and social anxiety. One-third of the males of each cluster and one-third of the females of each cluster were randomly assigned to each of the experimental conditions (i.e., ITP+SA, ITP, and CC). This allowed the three conditions to be balanced in gender and social anxiety and depression scores"|t|f|f|f
33992975|NCT06705998|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Double-blind: Active or placebo|"The Part A of the study follows a randomised, double-blind, placebo-controlled, parallel group design. The participants are enrolled in 4 consecutive cohorts of 8 healthy subjects each. In each cohort, the first 2 groups include 2 subjects each, while the 3rd group in each cohort includes 4 subjects. Each group of subjects is exposed to the treatment under investigation only if the Investigator's evaluation of the previous group's safety data up to 72 h post-dose is satisfactory and if the competent Ethics Committee gives written authorisation to continue with the next group. At the end of each cohort, before proceeding to the next dose level, safety and tolerability results up to 168 h post-dose (Day 8) are evaluated by a Data Safety Monitoring Board.~Part B of the study: Two ascending doses of IMP identified in study Part A, are subsequentially administered as daily multiple doses for 2 consecutive weeks (14 days) in two cohorts of 10 healthy subjects each."|t|f|t|t
33992976|NCT06660069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33992977|NCT05354544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992978|NCT06297863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded central imaging core lab, whose members will be unaware of the procedure assignments, will assess all imaging outcomes, including the primary efficacy outcome (collateral status, assessed during the pretreatment diagnostic angiographic series of mechanical thrombectomy)|The DOWN-SUITE trial is a prospective, multicenter, proof of concept, randomised, controlled, open label, phase 2a/b clinical trial with blinded outcome assessment, comparing cerebral collateral status in patients with acute ischemic stroke due to middle cerebral artery occlusion (M1 segment) treated with in-hospital application of HDT15 (-10° to -15°) versus usual positioning (0° to +30°), before and during mechanical thrombectomy.|f|f|f|t
33992979|NCT05862012|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689724|NCT02177578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689725|NCT06049680|NA|SINGLE_GROUP||OTHER||NONE||||||
33689726|NCT05892861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33689727|NCT00102492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689728|NCT04561427|||COHORT||RETROSPECTIVE|||||||
33689729|NCT04522908|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm, all eligible patients will receive Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks, followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards||||
33689730|NCT04707352|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, open-label and single-arm||||
33689731|NCT05039827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689732|NCT04172662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled trial||||
33689733|NCT05346432|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33689734|NCT04213521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689735|NCT05471700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689736|NCT03727373|||OTHER||PROSPECTIVE|||||||
33689737|NCT05189457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689738|NCT04885231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single center randomized control trial consisting of two groups - one control and one experimental.||||
33689739|NCT00571376|||COHORT||PROSPECTIVE|||||||
33689740|NCT05162040|||COHORT||OTHER|||||||
33689741|NCT04314310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|care provider and participant were masked|treatment: Tenoxicam; control: placebo|t|t|f|f
33778702|NCT04596761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Assessors will not be exposed to the type of brush the subject is using or to the group they are assigned to (treatment or control).|Single blind prospective study|f|f|f|t
33778703|NCT02754609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Re-identifiable IP containers|Placebo, 20 hookworm L3 or 40 hookworm L3|t|t|t|t
33778704|NCT05737758|||CASE_CROSSOVER||PROSPECTIVE|||||||
33778705|NCT06669871|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Two interventions; shirt A with customized design and another shirt B with simple design will be provided to the participants. Half of the participants will use shirt A, while remaining half will use Shirt B and their motion will be captured by hi speed cameras by trained engineers under the supervision of Co-PI. After one week of initial recording, they will be invited for second recording with the other design of the shirt.||||
33778706|NCT06614738|||COHORT||PROSPECTIVE|||||||
33778707|NCT02821598|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33778708|NCT01403987|RANDOMIZED|PARALLEL||||NONE||||||
33778709|NCT02433093|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33911448|NCT05686473|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Assessments with the evaluation measures will be performed at referral to Regional competence centre/inclusion to study (baseline), at admission to the centre 4-5 months later (pre-intervention), and 4-5 months after finishing program (post-intervention). The period between baseline and pre-intervention will be regarded as a control period, in contrast to the intervention period.||||
33911449|NCT05427071|NA|SINGLE_GROUP||TREATMENT||NONE||All patients received magnetic seeds guided localization of axillary lymph node and breast tumor and superparamagnetic iron oxide-guided sentinel lymph node biopsy||||
33911450|NCT05329181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911451|NCT05008913|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33778710|NCT02431533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778711|NCT04105985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778712|NCT04227925|||CASE_ONLY||PROSPECTIVE|||||||
33778713|NCT05879211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Several interventions will be tested, at the patient and provider levels||||
33911452|NCT06553274|NA|SINGLE_GROUP||TREATMENT||NONE||Based on the nutritional factor prediction model, the individualized nutritional management of patients with umbilical cord blood transplantation (UCBT) was carried out to observe the impact on the survival efficacy of patients.||||
33911453|NCT06046495|NA|SEQUENTIAL||TREATMENT||NONE||||||
33911454|NCT05272072|||COHORT||PROSPECTIVE|||||||
33911455|NCT05120622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911456|NCT01720615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911457|NCT03778983|||COHORT||RETROSPECTIVE|||||||
33911458|NCT04087343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911459|NCT02024893|||COHORT||CROSS_SECTIONAL|||||||
33911460|NCT00337376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911461|NCT04221906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911462|NCT04258332|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33911463|NCT00392262|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911464|NCT03422406|||CASE_ONLY||PROSPECTIVE|||||||
33992980|NCT05114460|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33992981|NCT02826694|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33992982|NCT04417660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992983|NCT06302335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know what kind of substance will be used during the surgery.|This a randomized clinical trial involving patients undergoing colorectal surgeries who will submitted to the application of povidone-iodine versus saline solution in their surgical sites.|t|f|f|f
33992984|NCT00068731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992985|NCT05666791|||CASE_ONLY||CROSS_SECTIONAL|||||||
33992986|NCT02030223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33992987|NCT04955470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33992988|NCT05192486|NA|SEQUENTIAL||TREATMENT||NONE||||||
33992989|NCT02311933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33992990|NCT06446713|NA|SINGLE_GROUP||TREATMENT||NONE|All participants receive the experimental treatment|Single arm Bayesian Phase I intervention study||||
33992991|NCT05266001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, randomized, double-blind, placebo-controlled clinical trial of the drug GM-CSF vs placebo|t|t|t|t
33992992|NCT06742515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33992993|NCT06042166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911465|NCT05255055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911466|NCT02040194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911467|NCT03766334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911468|NCT05565300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911469|NCT05808348|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911470|NCT00816907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911471|NCT03670641|NA|SINGLE_GROUP||TREATMENT||NONE||10 participants will be recruited soon after diagnosis of type 2 diabetes and started on short term insulin therapy to achieve euglycemia with insulin doses guided by continuous glucose monitor algorithm||||
33911472|NCT03011034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911473|NCT03679663|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The outcomes will be assessed by an observer who was not in the room when the puncture site was identified and was blinded to the study group. The room set up will be identical with the handheld ultrasound placed visible in all cases, including those randomized to the palpation group.|RCT|f|f|f|t
33992994|NCT04403672|||CASE_CONTROL||PROSPECTIVE|||||||
33992995|NCT06185088|NA|SINGLE_GROUP||OTHER||NONE||||||
33992996|NCT06073223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group will be blinded to the intervention and receive usual care, which involves providing no disease or treatment specific information outside the surgeon visit.||t|f|f|f
33689742|NCT04496310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33689743|NCT04862286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689744|NCT06709274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689745|NCT03480867|NA|SINGLE_GROUP||TREATMENT||NONE||RT 28Gy in 7 fractions with a concomitant boost of 42Gy in 7 fractions+ Temozolomide (75mg/m2) followed by surgery then Temozolomide (150-200mg/m2) q 5 days every 28 days.||||
33689746|NCT02130726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689747|NCT01203527|||COHORT|||||||||
33689748|NCT02285283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689749|NCT06074601|||COHORT||PROSPECTIVE|||||||
33689750|NCT03676985|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689751|NCT01490788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33689752|NCT03193125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689753|NCT00419679|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33689754|NCT03460600|||CASE_ONLY||RETROSPECTIVE|||||||
33689755|NCT05760118|||CASE_ONLY||PROSPECTIVE|||||||
33689756|NCT05682248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33689757|NCT04724876|||COHORT||PROSPECTIVE|||||||
33689758|NCT02310321|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33689759|NCT02582762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689760|NCT02794740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689761|NCT03590197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The recruited patients will be randomized by simple randomization into two treatment groups using computer-generated random codes. The random allocation code of the participants will be generated by PI who will not be involved in the patient recruitment. The codes will be assigned to a sequence of numbers and the numbered stickers will be pasted on the similar looking drug containers. The drug containers will be given to another investigator who will be responsible for patient recruitment. This process ensured allocation concealment.||t|t|t|f
33689762|NCT02637128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689763|NCT00744458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33689764|NCT01232218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689765|NCT03952754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689766|NCT03418571|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33689767|NCT06335290|||CASE_ONLY||PROSPECTIVE|||||||
33689768|NCT02452697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911474|NCT00564954|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33911475|NCT01716468|NA|SINGLE_GROUP||||NONE||||||
33911476|NCT00896987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911477|NCT03135587|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33911478|NCT03543384|||COHORT||RETROSPECTIVE|||||||
33911479|NCT05579756|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33911480|NCT00021697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911481|NCT05550948|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||TRIPLE|The proposed study is a double-blind, randomized placebo-controlled pilot study of remotely delivered tPBM paired with cognitive training.||t|t|f|t
33911482|NCT03288519|||OTHER||PROSPECTIVE|||||||
33911483|NCT00547599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911484|NCT01477151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911485|NCT03169829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33911486|NCT02325323|||COHORT||PROSPECTIVE|||||||
33911487|NCT06555315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A statistician who is blinded to the study allocation will analyze the data.||f|f|f|t
33911488|NCT00200499|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33911489|NCT01996202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911490|NCT02657668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911491|NCT04631120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911492|NCT02340819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911493|NCT05080179|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants were unaware they were participating in a study, and were thus blinded to their treatment assignment.|This is a 2 (Self-Benefit vs. Other-Benefit) x 2 (Social Norm vs. No Social Norm) design. There are thus four conditions total.|t|f|f|f
33911494|NCT02668107|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33911495|NCT00002340||||TREATMENT||||||||
33911496|NCT01633905|||CASE_CONTROL||PROSPECTIVE|||||||
33992997|NCT05438550|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized, controlled study||||
33911497|NCT03480282|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33911498|NCT03514758|NA|SINGLE_GROUP||OTHER||NONE||a group of normal-hearing volunteers||||
33911499|NCT02389816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911500|NCT02108600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911501|NCT05535127|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33911502|NCT05054673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes assessor)|parallel assignment|t|f|t|t
33689769|NCT00003301||||TREATMENT||||||||
33689770|NCT00768937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689771|NCT05956379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689772|NCT01689961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33689773|NCT06572228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689774|NCT00711724|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689775|NCT05831631|||COHORT||PROSPECTIVE|||||||
33992998|NCT05822089|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor will be masked to the intraocular lens implanted|Intra-individual comparison of 7 groups receiving predefined monofocal and enhanced monofocal intraocular lenses (EMO IOLs). Investigated IOLs will be implanted subsequently according to the study protocol with one IOL type in the dominant eye and the other IOL type in the non- dominant eye.|f|f|f|t
33992999|NCT03945773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085123|NCT05126693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We will include patients who receive BoNT injections at the lower limb in the intervention group. Patient with no indication for treatment in the next three months (besides the routine physical therapy and orthotic management) will be asked to participate in the control group. Justification for the non-randomized design is stated above.||||
34085124|NCT04188054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085125|NCT02071498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34085126|NCT01001741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085127|NCT06517992|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi experiment||||
34085128|NCT05786313|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34085129|NCT06208813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911503|NCT06354270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911504|NCT00198445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33911505|NCT04967508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911506|NCT00986258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085130|NCT06269835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34085131|NCT03573297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911507|NCT00657631|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33911508|NCT05913960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911509|NCT05897346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research assistant undertaking recruitment will be responsible for data collection and be blinded to the group assignment.|14 clusters will be randomized to the intervention or control group using a 1:1 ratio by a research assistant using an independent computerized randomization sequence process.|t|f|f|f
33911510|NCT02539082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911511|NCT01218932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911512|NCT03346655|||COHORT||PROSPECTIVE|||||||
33911513|NCT00462098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911514|NCT06346288|NA|SINGLE_GROUP||OTHER||NONE||||||
33911515|NCT00050999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911516|NCT00922194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911517|NCT01239186|||CASE_ONLY||PROSPECTIVE|||||||
33911518|NCT02249286|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911519|NCT03916250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911520|NCT05252884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It will be randomized by the block method and will be stratified by institution, type of disease (benign vs. malignant) and presence or absence of central voiding. This will be done centrally.|Randomized, parallel, multicenter stratified clinical trial with 1:1 allocation.|t|t|f|f
33911521|NCT05556824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911522|NCT00516269|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911523|NCT01053845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33911524|NCT01914705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911525|NCT01000701|||COHORT||PROSPECTIVE|||||||
33911526|NCT06197945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911527|NCT02242825|||COHORT||PROSPECTIVE|||||||
33911528|NCT02568033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911529|NCT02419183|||CASE_CROSSOVER||PROSPECTIVE|||||||
33911530|NCT00735124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911531|NCT03744780|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be assigned to the same intervention.||||
33911532|NCT05818527|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33911533|NCT05464446|||OTHER||CROSS_SECTIONAL|||||||
33911534|NCT05281783|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, prospective non-randomized, controlled clinical trial||||
33911535|NCT04939077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911536|NCT01426425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911537|NCT00429065|||DEFINED_POPULATION||PROSPECTIVE|||||||
33911538|NCT02241044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911539|NCT00443911|||CASE_ONLY||PROSPECTIVE|||||||
33911540|NCT03459131|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911541|NCT03306134|||COHORT||PROSPECTIVE|||||||
34085132|NCT01554124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085133|NCT03136393|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34085134|NCT06313645|||COHORT||PROSPECTIVE|||||||
34085135|NCT03054623|||COHORT||PROSPECTIVE|||||||
34085136|NCT04483765|||COHORT||PROSPECTIVE|||||||
34085137|NCT04021433|NA|SINGLE_GROUP||TREATMENT||NONE||open||||
33911542|NCT03350750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The primary intervention will be the initiation of the randomized initial shunt valve opening pressure setting to create a delayed treatment group in half of the study patients.~Randomization will be to active or placebo (closed) shunt settings. At the time of the standard four-month evaluation, all subjects will be similarly non-invasively adjusted to bring all subjects in both groups to the active setting while maintaining blinding of the subjects. All settings will be verified by the adjusting neurosurgeon."|t|f|f|t
33911543|NCT00540553|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33911544|NCT03374514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, controlled and double-blind experimental study.|t|t|t|f
33911545|NCT00773760|||COHORT||PROSPECTIVE|||||||
33911546|NCT05673863|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Children who met the criteria of the study and agreed to be included in the study were first divided according to age groups (11-13 years and 14-16 years) by block randomization and the sample group was formed. These individuals were then randomly assigned to the intervention and control groups by double-blinding method.|The sample consisted of girls who agreed to participate in the study and one of their family members (mother, father, aunt, etc.).|t|f|t|f
33911547|NCT03637699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911548|NCT06033339|NA|SINGLE_GROUP||OTHER||NONE||Among the 40 subjects to be enrolled: 10 are MEFV homozygous patients, 10 are symptomatic MEFV heterozygous patients, 10 are asymptomatic MEFV heterozygous patients and 10 are control subjects. All enrolled patients receive the same intervention (biological sample collection).||||
33911549|NCT02197052|||COHORT||CROSS_SECTIONAL|||||||
33911550|NCT00704509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911551|NCT02469181|||CASE_ONLY||PROSPECTIVE|||||||
33911552|NCT03691610|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study has a modified double blind design for each group at enrollment, and thus, with the exception of the personnel administering the vaccine, everyone involved in study is blinded to avoid any bias.||t|t|t|t
33993000|NCT06741865|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The INSPIRE Study employs a single-blind design, where participants are unaware of their group assignment (intervention or control) to minimize bias in reporting and behavior. However, the investigators and study staff administering the interventions and conducting assessments are not blinded due to the nature of the intervention, which requires direct interaction and coaching. To further reduce potential bias, outcome assessors involved in data analysis will remain blinded to the group assignments until after the primary data analysis is completed.|The INSPIRE Study is a randomized controlled trial (RCT) with 2,000 participants aged 55 and older. Participants will be randomly assigned to either an intervention group, receiving a personalized, lifestyle-based program with health coaching, or a control group, receiving standard health education materials. Both groups will undergo baseline and follow-up assessments, including cognitive tests and lifestyle evaluations. The study emphasizes community engagement and culturally relevant interventions, aiming to provide insights into the impact of lifestyle changes on cognitive health and to inform public health strategies for dementia prevention in at-risk populations.|t|t|f|f
33993001|NCT03637764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778714|NCT04578028|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind study. A sentinel dosing approach will be used in the study at each new ascending dose level in Part A, B, and C. To maintain the blinded nature of the study, the sentinel participants will be randomised to drug or placebo in a 1:1 ratio.|This is a single centre, three-part study conducted at a specialised Phase I centre to evaluate the safety, tolerability and pharmacokinetics of ONO-2808. This study consists of: Part A single ascending dose (including an assessment of potential food effects), Part B an assessment of age, and Part C multiple ascending dose. All parts of the study are conducted in healthy male and female (women of non-child bearing potential) participants. All parts of the study will have a 28-day screening period followed by admission to the clinical unit at least one day prior to dosing (Day -1) for baseline assessments. For all Parts of the study, a sentinel dosing approach is used to mitigate the overall safety risk with at least 1 day stagger to the rest of the cohort.|t|f|t|f
33778715|NCT06051942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778716|NCT03100474|||OTHER||PROSPECTIVE|||||||
33778717|NCT04677465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel group design randomizing patients in a 2:1 ratio to the treatment vs. sham group. Randomization will be blocked and stratified by site and FEV1 (\<50% vs. \>/= 50%)|t|f|t|t
33778718|NCT03026569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993002|NCT03986697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993003|NCT06242145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of clopidogrel or cilostazol by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 580 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 580. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included clopidogrel, and Drug B included cilostazol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|The investigators will conduct our single-blinded randomized controlled trial, which will contain 2 arms; the clopidogrel arm will receive (a 300 mg loading dose during the first 24 hours of stroke onset, followed by 75 mg daily from the 2nd to the 90th day). The cilostazol arm will receive (a 200mg loading dose during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd to the 90th day).|f|f|t|t
33993004|NCT05635812|||COHORT||PROSPECTIVE|||||||
33778719|NCT04632966|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose-escalation||||
33778720|NCT05140174|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled psychotherapy trial (longitudinal study with no control group)||||
33993005|NCT05603741|NA|SINGLE_GROUP||OTHER||NONE||||||
33993006|NCT05447312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in two arms (traditional music intervention and adaptive music intevention groups) will not know which arm of the intervention they will be receiving until after the intervention period has been completed. This is to control for potential response bias in participants on the psychosocial outcome measures and/or the placebo effect.|Three-arm, randomized control trial for psychosocial and cognitive intervention. Participants will be in one of three groups: those receiving music enhanced with frequencies, those receiving music without enhancement, and a waitlist control receiving no intervention.|t|f|f|f
33993007|NCT04031209|||OTHER||OTHER|||||||
33993008|NCT02891863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993009|NCT05431699|NA|SINGLE_GROUP||SCREENING||NONE||||||
33993010|NCT04521764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993011|NCT06741371|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33993012|NCT06567314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993013|NCT03315806|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double blind||t|f|t|f
33778721|NCT00558324|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33778722|NCT04061161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|This will be a multicenter parallel design randomized placebo controlled double-blinded study.|t|t|t|t
33778723|NCT01474512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778724|NCT03490890|NA|SINGLE_GROUP||TREATMENT||NONE|All patient with GGO were treated with microwave ablation|All patient with GGO were treated with microwave ablation||||
33778725|NCT05039203|||CASE_CONTROL||PROSPECTIVE|||||||
33778726|NCT04150835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778727|NCT00712855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778728|NCT01998282|||COHORT||PROSPECTIVE|||||||
33778729|NCT04761419|||COHORT||PROSPECTIVE|||||||
33778730|NCT04132284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778731|NCT05748795|||OTHER||CROSS_SECTIONAL|||||||
33778732|NCT04575675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778733|NCT03272646|||COHORT||PROSPECTIVE|||||||
33778734|NCT05112874|||COHORT||PROSPECTIVE|||||||
33778735|NCT01373047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778736|NCT00576602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778737|NCT06204523|||CASE_ONLY||PROSPECTIVE|||||||
33778738|NCT01615627|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33778739|NCT06137755|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33778740|NCT04924582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33778741|NCT06697067|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised control trials||||
33778742|NCT00664521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778743|NCT04638699|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33778744|NCT06614153|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33778745|NCT03835520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking and allocation tbc|"The trial will include patients with any type of cancer treated with one of the following regimens after signing of the patient's informed consent:~* I: Molecular targeted agent~* II: Immunotherapy"||||
33778746|NCT02184884|||CASE_CONTROL||PROSPECTIVE|||||||
33993014|NCT04023981|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessment of the primary study outcome was by independent blinded assessment of digital photographic images, by assessors who did not undertake study visits and who were unaware of the participant's allocated treatment.||f|f|f|t
33993015|NCT06742190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993016|NCT02756663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993017|NCT03663933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993018|NCT06485791|||CASE_ONLY||PROSPECTIVE|||||||
33993019|NCT02434926|||CASE_ONLY||RETROSPECTIVE|||||||
33778747|NCT06267274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind study|Subjects will be randomized in such way that ratio of treatment distribution will be nearer to 1:1 between the treatment arms, and within the combined stratification criteria.|t|f|t|t
33911553|NCT03817255|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Participants: Although they cannot be masked to the content of the intervention (questionnaire), they are only informed that the study is about health behaviours in general. Thus, they are masked as to whether they are in the intervention or control group.~Care provider: As they cannot have access to the participants' questionnaires, they are masked."|Participants are assigned to either the intervention or the control condition.|t|t|t|t
33911554|NCT03477526|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33911555|NCT00997048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911556|NCT00683956|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33911557|NCT04065477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study staff conducting baseline and follow-up assessments will be blind as to which group participants are placed. Study staff conducting intervention sessions will be blind to participants' baseline and follow-up assessment performance.||f|t|t|f
33689776|NCT00272727|RANDOMIZED|CROSSOVER||||NONE||||||
33689777|NCT00773916|NA|SINGLE_GROUP||||NONE||||||
33911558|NCT00161980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33911559|NCT06554925|||COHORT||RETROSPECTIVE|||||||
33911560|NCT05520814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911561|NCT05686616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911562|NCT04243135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911563|NCT02260102|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33911564|NCT03898336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind placebo controlled following open label phase|t|t|t|t
33911565|NCT00672529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911566|NCT01839292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911567|NCT04041076|||COHORT||RETROSPECTIVE|||||||
33911568|NCT02755844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911569|NCT00146705|||DEFINED_POPULATION||PROSPECTIVE|||||||
33911570|NCT01093924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911571|NCT00615290|||CASE_ONLY||PROSPECTIVE|||||||
33911572|NCT06060223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33911573|NCT04486924|NA|SINGLE_GROUP||OTHER||NONE||||||
33911574|NCT00330655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911575|NCT02387541|||CASE_CONTROL||PROSPECTIVE|||||||
33911576|NCT03665376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were randomly allocated into two arms: intervention arm (ERAS) and control arm|f|f|f|t
33911577|NCT03885739|NA|SINGLE_GROUP||TREATMENT||NONE||interventional study.||||
33911578|NCT04176055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911579|NCT05256056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized using the closed envelope method. While the practitioner knows the interventions to be made, the data collector will collect the data without learning the patient's group.|Group A patients will be injected with 20 cc of 0.25% Bupivacaine, and Group B patients will be injected with 30 cc of 0.25% Bupivacaine|t|f|f|t
33911580|NCT04971395|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33911581|NCT01688167|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33911582|NCT04770987|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33778748|NCT05531825|||CASE_CONTROL||PROSPECTIVE|||||||
33778749|NCT04069910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911583|NCT05366699|RANDOMIZED|PARALLEL||PREVENTION||NONE||After informed consent is obtained, all subjects will undergo an initial study evaluation to establish the pre-operative baseline and to determine eligibility for randomization. Group A will under axillary lymphadenectomy alone and Group B will undergo axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) using reverse mapping using the SPY System. Each of the baseline measures will be repeated at 3-month intervals over the 12 months of enrollment in the study. These include lymphography, limb volume measurements, skin thickness measurements, bioimpedance spectrosocpy, and quality-of-life assessment.||||
33911584|NCT03294681|||COHORT||PROSPECTIVE|||||||
33911585|NCT00419354|||COHORT||PROSPECTIVE|||||||
33911586|NCT00028366||PARALLEL||TREATMENT||NONE||||||
33911587|NCT00127062|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911588|NCT04392102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911589|NCT02856269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and the research nurse are unblinded. The research assistant and the principle investigator are blinded.|This is a pilot open labeled randomized double arm trial, studying zinc supplementation to prevent HIV comorbidities that are linked to inflammation. Patients will be given zinc gluconate 45 mg capsule once daily in one arm, and 90 mg zinc gluconate in the other arm for 16 weeks.|f|f|t|t
33911590|NCT00961337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911591|NCT05702125|||COHORT||PROSPECTIVE|||||||
33911592|NCT00003117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911593|NCT05381376|||COHORT||PROSPECTIVE|||||||
33911594|NCT03747224|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33911595|NCT02231255|||COHORT||PROSPECTIVE|||||||
33911596|NCT02437448|||CASE_CONTROL||PROSPECTIVE|||||||
33911597|NCT04026152|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be aware of the three study conditions in order to provide informed consent for participation; however, they will not receive detailed information or materials about any condition until they have been assigned to it. The personal trainers who will be administering the resistance training sessions do not know about the presence of the waitlist or resistance training + Unified Protocol conditions. The therapist who is administering the Unified Protocol will be aware of all conditions. The Outcomes Assessor and Investigator will also be aware of all conditions.|Participants will be randomly assigned to one of three conditions: resistance training plus Unified Protocol, resistance training, or waitlist. Participants will then complete their assigned condition. Participants who receive the waitlist condition will have the option to be re-randomized into one of the resistance training conditions after they have completed their last waitlist measure.||||
33911598|NCT05590663|||COHORT||PROSPECTIVE|||||||
33911599|NCT03765541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993020|NCT05558501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study participants will be blinded to the composition of the gas mixture. In addition, the research staff that do not administer the treatment (gas mixture) will complete a blind analysis of all the outcome measures.|"The present study utilizes a double blind parallel randomized design using an equal allocation ratio for each arm. Block randomization will be conducted to reduce the probability that a disproportionate number of participants are randomized to one group. Mild intermittent hypoxia and sham MIH will be administered during wakefulness each day for 15 days over a 3-week period."|t|f|f|t
33993021|NCT06514261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993022|NCT03516539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993023|NCT02087423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993024|NCT06055686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993025|NCT03835689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician conducting analysis will be blinded to group assignment||f|f|f|t
33993026|NCT05817357|NA|SINGLE_GROUP||OTHER||NONE||||||
33993027|NCT05668013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993028|NCT05457452|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients at Cipto Mangunkusumo Hospital and Gatot Soebroto Hospital, who underwent ACL reconstruction in the period January 2022 - January 2022 who met the inclusion and exclusion criteria.||||
33993029|NCT06742710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993030|NCT06437691|||CASE_CONTROL||RETROSPECTIVE|||||||
33911600|NCT04837534|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Primary Purpose: Our primary objectives are a) to determine if parental counseling has an impact on adherence to follow-up, b) To determine if reminders through phone calls and SMS increase the follow-up rate in pediatric patients.~Assessing the cost-effectiveness of counseling and reminder SMS and phone calls, and determining the role of counselors and their sustainability are our secondary objectives. We hypothesize that counseling will increase the follow-up rate from 22% to 50% and reminders through phone calls and SMS from 22% to 25% of pediatric patients attending Bharatpur Eye Hospital"||||
33911601|NCT00914836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911602|NCT01188382|||CASE_ONLY||PROSPECTIVE|||||||
33911603|NCT03179514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911604|NCT01524172|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911605|NCT06007482|NA|SEQUENTIAL||TREATMENT||NONE||||||
33911606|NCT00029848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911607|NCT02426554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33911608|NCT01963299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911609|NCT03836976|NA|SINGLE_GROUP||OTHER||NONE||Single arm. All participants will receive auditory gamma-frequency sensory stimulation.||||
33993031|NCT05059028|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33993032|NCT06726850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993033|NCT05695209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33993034|NCT06336200|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33993035|NCT06098755|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33993036|NCT03683589|||COHORT||PROSPECTIVE|||||||
33993037|NCT00121901|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33993038|NCT05756634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993039|NCT02222818|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993040|NCT01022983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689778|NCT03570879|||CASE_CONTROL||RETROSPECTIVE|||||||
33689779|NCT04073329|||COHORT||PROSPECTIVE|||||||
33689780|NCT03206255|||COHORT||PROSPECTIVE|||||||
33689781|NCT05580510|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized clinical trial||||
33689782|NCT01863810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689783|NCT03280095|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33689784|NCT02651714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689785|NCT02068339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33689786|NCT01020539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689787|NCT00156572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689788|NCT02728791|||COHORT||PROSPECTIVE|||||||
33689789|NCT00397410|RANDOMIZED|||||NONE||||||
33911610|NCT05624684|||COHORT||PROSPECTIVE|||||||
33911611|NCT05913934|||CASE_CONTROL||OTHER|||||||
33911612|NCT03442413|NA|SINGLE_GROUP||OTHER||NONE||||||
33911613|NCT03167086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Principal Investigators and Statisticians performing analyses will be blinded.|The design is a randomized 3-arm study comprised of 2 active psychological treatments (ER \& CBT) and a health education (HE) arm that controls for time and attention.|f|f|t|t
33911614|NCT01076842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911615|NCT05655156|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with multiligament knee injuries will be evenly distributed across potential ligament reconstruction treatment options: PCL, ACL, MCL, LCL.||||
33911616|NCT02988466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911617|NCT03239756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911618|NCT04846751|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Study composed of 4 trials, full-crossover, administered in a randomized order with the inclusion of a control trial.|f|f|f|t
33911619|NCT04005898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911620|NCT02112994||SEQUENTIAL||TREATMENT||NONE||||||
33911621|NCT02191241|NA|SINGLE_GROUP||||NONE||||||
33993041|NCT05003232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33993042|NCT06558695|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants were randomly assigned to one of two groups using a computer-generated list: the Sevoflurane group (Sevo group) and the Total Intravenous Anesthesia group (TIVA group), each comprising 26 patients. The assignment and subsequent anesthesia management were conducted in a double-blinded manner, ensuring that neither the patients nor the clinicians administering the treatments or assessing the outcomes were aware of the group allocations|This randomized controlled trial involved 52 patients scheduled for lumbar spine surgery under general anesthesia. Participants were randomly allocated to either the TIVA group (n=26) or the sevoflurane group (n=26). Measurements of respiratory mechanics, including peak airway pressure (Ppeak), mean airway pressure (Pmean), positive end-expiratory pressure (PEEP), end-tidal CO2 (ETCO2), tidal volume (VT), respiratory rate (RR), and minute ventilation (MV), were taken at various intervals. Hemodynamic parameters such as systolic and diastolic blood pressures and heart rate were continuously monitored.|t|f|f|t
33993043|NCT06201234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993044|NCT00080392||||TREATMENT||||||||
33993045|NCT04160013|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking.|Randomized controlled trial||||
33689790|NCT00959335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689791|NCT03367806|||COHORT||PROSPECTIVE|||||||
33689792|NCT00427960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689793|NCT01025765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689794|NCT05129891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689795|NCT02653885|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33689796|NCT01711879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689797|NCT01240343|||OTHER||PROSPECTIVE|||||||
33689798|NCT00306202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689799|NCT00321724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911622|NCT05072548|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be made aware what group they are randomized to (i.e., control or treatment group).|||||
33911623|NCT05662137|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33689800|NCT00803218|||CASE_ONLY||PROSPECTIVE|||||||
33689801|NCT01555437|||||PROSPECTIVE|||||||
33689802|NCT05917509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689803|NCT03964844|||OTHER||OTHER|||||||
33689804|NCT06482762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689805|NCT02723253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689806|NCT05442775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689807|NCT02285556|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33689808|NCT05990998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689809|NCT00953459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689810|NCT03785288|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will compare two standard of care treatments: HDR vaginal brachytherapy 3 fractions of 7Gy to HDR vaginal brachytherapy 6 fractions of 4Gy for early stage endometrial cancer.||||
33689811|NCT04710277|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned prospectively to one of two interventions according to protocol to evaluate the effect of the intervention on their postoperative pain, quality of recovery, patient satisfaction, and overall analgesic use.||||
33689812|NCT01181648|||OTHER||PROSPECTIVE|||||||
33689813|NCT06483451|||COHORT||PROSPECTIVE|||||||
33689814|NCT01094639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689815|NCT04804501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689816|NCT00813033|NA|SINGLE_GROUP||||NONE||||||
33689817|NCT01212133|||COHORT||PROSPECTIVE|||||||
33689818|NCT00587977|||COHORT||PROSPECTIVE|||||||
33689819|NCT03665831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689820|NCT01384279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689821|NCT01791010|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33689822|NCT00679055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33689823|NCT02445391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689824|NCT06338605|||COHORT||RETROSPECTIVE|||||||
33689825|NCT03187327|||CASE_ONLY||PROSPECTIVE|||||||
33689826|NCT05464329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689827|NCT05090462|||COHORT||PROSPECTIVE|||||||
33689828|NCT05458427|||COHORT||PROSPECTIVE|||||||
33911624|NCT05357352|||CASE_ONLY||RETROSPECTIVE|||||||
33911625|NCT02018952|NA|SINGLE_GROUP||||NONE||||||
33689829|NCT01545843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689830|NCT00756327|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689831|NCT06155643|NA|SINGLE_GROUP||SCREENING||NONE||Use of the Eko device||||
33689832|NCT05023798|||COHORT||OTHER|||||||
33689833|NCT03642743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33689834|NCT03580304|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33689835|NCT03778944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Using computer \& sealed envelope randomization, patients are assigned to receive either Mannitol \[M group; n=20\], Dopamine \[D group; n=20\] or adequate hydration \[C group; n=20\]|f|f|f|t
33689836|NCT04246736|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomised into intervention group and control group. The intervention group received the intervention and were followed-up until 6 months after the intervention. After that, the control group received the intervention.||||
33689837|NCT02561910|||COHORT||PROSPECTIVE|||||||
33689838|NCT02026726|||COHORT||PROSPECTIVE|||||||
33689839|NCT05812079|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689840|NCT00234260|||||PROSPECTIVE|||||||
33911626|NCT00119301||||TREATMENT||||||||
33911627|NCT04207957|RANDOMIZED|CROSSOVER||OTHER||NONE||3 Treatment Periods for Cohorts A and B 2 Treatment Periods for Cohort C||||
33911628|NCT03537339|||COHORT||PROSPECTIVE|||||||
33911629|NCT04146467|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33911630|NCT06552312|||OTHER||PROSPECTIVE|||||||
33911631|NCT04435262|||COHORT||PROSPECTIVE|||||||
33911632|NCT03055403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911633|NCT05475821|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33911634|NCT04625569|||CASE_ONLY||CROSS_SECTIONAL|||||||
33911635|NCT00620321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911636|NCT00129805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911637|NCT05415540|||CASE_ONLY||PROSPECTIVE|||||||
33911638|NCT03706534|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|"The study consisted of 10 readers with varying levels of training and experience providing analysis on a randomized set of 300 patients' breast ultrasound data with and without S-Detect for Breast. Two reading periods separated by at least 3-week washout, totaling 600 cases analyzed per reader. PI and her associate have knowledge about patients diagnosis and other information. So, they are exclueded in readers for reviewing. And all breast US images are de-indentified."|This clinical study performed by multiple reader multiple case (MRMC) study design, where as set of clinical readers evaulate under multiple reading condition. All Interpreting physician(reader) independently read all of the cases. (fully-crossed design).|f|f|f|t
33911639|NCT03165721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911640|NCT02156869|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33911641|NCT02641236|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911642|NCT05930392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993046|NCT03420482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be performed by the lab producing the FMT and placebo capsules. Participants, providers, investigators and research assistants will be blinded.|This is a two part study. The first part is a 10-patient pilot study, used to find 2 stool donors who precipitate the largest improvement in recipient neurological function and microbiome composition. The second part is a 20-patient RCT, where patients will be randomized to FMT or placebo.|t|t|t|t
33993047|NCT05806593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993048|NCT06548789|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993049|NCT03969628|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33993050|NCT02748707|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33911643|NCT01606592|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33993051|NCT06742502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911644|NCT00995345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911645|NCT03920826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911646|NCT04708652|||COHORT||PROSPECTIVE|||||||
33911647|NCT03119116|||COHORT||RETROSPECTIVE|||||||
33911648|NCT05602441|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot intervention study with pre- and post assessment of effects||||
33911649|NCT01201798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911650|NCT00260637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911651|NCT01383395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911652|NCT02153450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911653|NCT03075462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993052|NCT06171386|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be invited to participate in the study through the clinic setting - aim to have around 30 patient volunteers. Of the 30 patients, 15 will be randomized to receive microneedling, and 15 will receive dermabrasion.||||
33993053|NCT06733701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This will be a randomized, single-blinded, two-arm pilot study. Due to the nature of the intervention, participants cannot be blinded to allocation, but the physician performing the oocyte retrieval will be blinded to minimize the risk of bias.|f|t|f|f
33689841|NCT02194608|RANDOMIZED|PARALLEL||||NONE||||||
33689842|NCT02448342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689843|NCT00043121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689844|NCT04805827|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized single oral dose, open-label, two-way, two-periods, UN-replicated crossover design.||||
33689845|NCT06495866|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689846|NCT02815774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689847|NCT00170963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33689848|NCT04841746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689849|NCT03210181|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33689850|NCT05819684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects. Include three stages: dose escalation, PK expansion, and efficacy expansion.||||
33689851|NCT02438306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33689852|NCT00575250|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33911654|NCT03803852|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study involves 5 different groups. All groups will be investigated seperately.~Alcon Clareon toric group: 130 eyes Rayner RayOne group: 130 eyes Hoya Nanex group: 130 eyes Hoya Vivinex Impress: 120 eyes Rayner RayOne EMV toric group: 120 eyes"||||
33911655|NCT04767256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911656|NCT01152008|||CASE_ONLY||PROSPECTIVE|||||||
33911657|NCT04018469|||COHORT||PROSPECTIVE|||||||
33911658|NCT02198287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911659|NCT02745223|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33911660|NCT04652336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911661|NCT04343521|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911662|NCT01913249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911663|NCT05412719|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled two groups (control group and intervention group)||||
33911664|NCT01588145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911665|NCT01790893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911666|NCT00900250|||CASE_ONLY||PROSPECTIVE|||||||
33911667|NCT06420765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33911668|NCT00344617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911669|NCT05036265|||OTHER||RETROSPECTIVE|||||||
33911670|NCT05760209|||COHORT||PROSPECTIVE|||||||
33778750|NCT05634057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The SEPSIS patients will be randomly assigned to four groups in a ratio of 1:1. The groups will consist of the conventional treatment group and the anisodamine hydrobromide combined with heparin treatment group.|t|t|f|f
33778751|NCT05353530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778752|NCT06393322|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33778753|NCT04217070|||CASE_ONLY||PROSPECTIVE|||||||
33911671|NCT04649203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33911672|NCT00321100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911673|NCT02227017|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993054|NCT06741748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this trial, participants and outcomes assessors will be masked to ensure unbiased results. The embryologists performing the thawing procedures will not be masked, as they are directly involved in applying the assigned thawing method (either the direct warming method or the conventional multi-step method). Additionally, the research staff responsible for enrolling participants will also remain blinded to group assignments to maintain allocation concealment. However, participants who are determined not to be pregnant after embryo transfer may be informed of their group assignment at that time. However, if a pregnancy is confirmed, participants will not be informed of their group assignment until after delivery or in the event of pregnancy loss.|This study uses a parallel assignment model where participants are randomized into two groups: one group will receive the novel direct warming method, and the other group will undergo the conventional multi-step thawing method. Both groups will be followed to compare clinical outcomes such as pregnancy rates, live birth rates, and cost-effectiveness.|t|f|f|t
33993055|NCT06741722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993056|NCT06145308|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993057|NCT05312879|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33993058|NCT04777084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993059|NCT05332756|||COHORT||PROSPECTIVE|||||||
33993060|NCT04576117|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993061|NCT05655078|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control arm (standard of care) vs experimental arm (proton beam therapy) in 1:1 randomisation||||
34024975|NCT05062889|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a prospective, open-label, multicentre study, including two phase II randomized trials (Part 1 and Part 2) and a non-randomized cohort (Part 1 target-driven)~In Part 1 resected stage III and high-risk stage II colon cancer patients with positive ct- DNA after surgery will be randomized to receive FOLFOX for 12 cycles or CAPOX for 8 cycles (at investigator choice) versus FOLFOXIRI for 12 cycles;~In Part 1 target-driven resected stage III and high-risk stage II HER2+ RAS wild-type colon cancer patients with positive ct-DNA after surgery will receive Trastuzumab and Tucatinib plus FOLFOX for 12 cycles.~In Part 2 resected stage III and high-risk stage II colon cancer patients with positive ct- DNA after the end of a fluoropyrimidine and oxaliplatin-based adjuvant therapy - either in the frame or outside of Part 1 - will be randomized to receive observation or Trifluridine/Tipiracil for 6 cycles."||||
34024976|NCT04769414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085138|NCT06514339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This study will adopt the block randomization method to randomly assign qualified subjects to the test group or the control group in a ratio of 1:1. A central randomization system was used for randomization and drug distribution management. From randomization until the database is locked, subjects, investigators, data analysts, sponsors, and all medical personnel involved in the treatment or clinical evaluation will remain blind to the reality of the treatment.~The random number table (blind bottom) used in this study will be generated by the randomization specialist and imported into the system. The random number is reproducible. The relationship between the experimental group drug or the control group simulated drug and the subjects was represented by random number and drug number. The blind bottom is kept by the randomisation Specialist and remains unknown to both subjects and investigators throughout the trial."|"The researchers were randomly assigned to either a trial or a control group. Experimental group: sepsis cluster therapy + Shenhuang granules, course of 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Shenhuang Granules (Tianjin Hongri Pharmaceutical Co., LTD.) : 2 times a day, 1 pack each time, 100ml of warm water (temperature about 40°C) after dissolution, oral or nasal feeding (stomach tube or intestinal tube).~Control group: sepsis cluster therapy + placebo for 5 days. For the treatment of sepsis cluster, refer to the 2021 International Guidelines for Severe Sepsis and Septic Shock. Placebo (Tianjin Hongri Pharmaceutical Co., LTD.) : After dissolution of 100ml warm water (temperature about 40°C) in 1 pack twice a day, oral or nasal feeding (gastric tube or intestinal tube)."|t|t|t|t
34085139|NCT01855022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085140|NCT00042211|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34085141|NCT01997125|NA|SINGLE_GROUP||OTHER||NONE||||||
33778754|NCT02402764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778755|NCT04958031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|• Double Blind: two or more parties are unaware of the intervention assignment (Blinded: Participant, Caregiver, Investigator)|Participants are assigned to one of two or more groups in parallel for the duration of the study|t|t|t|f
33778756|NCT01256476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778757|NCT02890056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778758|NCT02219828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778759|NCT04307602|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33911674|NCT01592279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911675|NCT03460834|||COHORT||PROSPECTIVE|||||||
33911676|NCT04346134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Double-arm, prospective, Randomized, intervention study|f|f|f|t
33911677|NCT02315937|||CASE_ONLY||PROSPECTIVE|||||||
33911678|NCT02433379|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33911679|NCT05059652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33911680|NCT05340257|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study|This is a single arm study||||
33911681|NCT00533637|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33911682|NCT04194658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993062|NCT06558916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The physician who evaluated the patient ordered the analgesic X. Before the evaluation, the patients were informed about the pain scales to be used in the study, namely the visual analog scale (VAS) and verbal rating scale (VRS). The patients then made VAS and VRS markings on the evaluation forms without looking at the previous marking location. Neither the patients nor the physicians knew which study group they were in during the clinical practice phase, as the study was double-blind.~The study drugs were administered to patients suspected of having renal colic in random order with the same appearance. The nurse who prepared the solution was informed about the study, but the nurse who administered the drug did not know which group the patient was in."|The patients were randomized and numbered using a computer. Ninety eligible patients diagnosed with renal colic and who agreed to participate in the study were included. Thirty patients were assigned to each of the three groups-dexketoprofen trometamol, meperidine and paracetamol.The study drugs were administered to patients suspected of having renal colic in random order: dexketoprofen trometamol IV 50 mg (ampoule containing Dexalgin 50 mg injectable solution), meperidine IV 50 mg (Aldolan 100 mg ampoule) and paracetamol IV 1000 mg (Perfalgan 10 mg/mL infusion solution) was prepared as a 250 mL solution in standard saline, with the same appearance. The drugs were given as a single dose over 15 minutes.|t|t|f|f
33993063|NCT06377566|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, investigator-initiated, single-arm phase II trial.||||
33993064|NCT03913377|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993065|NCT06073951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993066|NCT02710370|||COHORT||PROSPECTIVE|||||||
33689853|NCT03235427|||CASE_CONTROL||PROSPECTIVE|||||||
33993067|NCT01728181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689854|NCT00002585||||TREATMENT||||||||
33689855|NCT05574166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Dose escalation|t|f|t|f
33689856|NCT05547022|||COHORT||RETROSPECTIVE|||||||
33689857|NCT03931954|||CASE_ONLY||CROSS_SECTIONAL|||||||
33689858|NCT04424524|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33689859|NCT02790905|||OTHER||CROSS_SECTIONAL|||||||
33778760|NCT04921605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778761|NCT05583747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33778762|NCT02521064|||CASE_CONTROL||PROSPECTIVE|||||||
33778763|NCT05481749|||CASE_ONLY||CROSS_SECTIONAL|||||||
33778764|NCT05857137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33778765|NCT00465712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778766|NCT04479293|||COHORT||PROSPECTIVE|||||||
33778767|NCT01028703|||CASE_CONTROL||PROSPECTIVE|||||||
33778768|NCT05401422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689860|NCT06331676|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants enrolled in this study will be given an eutopic and ectopic endometrium biopsies, blood and peritoneal fluid sampling and should answer to a questionnaire on menstrual health and history of hormone treatments for the research purpose..||||
33689861|NCT00135070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689862|NCT01879527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33689863|NCT03508531|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Controlled randomized study|t|t|f|t
33689864|NCT04756180|RANDOMIZED|PARALLEL||TREATMENT||NONE|Double Blinded|||||
33689865|NCT00901927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689866|NCT05817071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778769|NCT05871242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778770|NCT02841722|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778771|NCT04924101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911683|NCT03314051|||COHORT||RETROSPECTIVE|||||||
33778772|NCT05087732|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|"Treating investigators (Injectors) , subjects, blinded live evaluator and Independant Photographic reviewer are blinded.~The product name will not be printed on the labels of investigational device (outside boxes, blisters and syringes )"|Within-subject study with treatment of one nasolabial fold with STYLAGE® M and STYLAGE® M Lidocaïne of the other nasolabial fold|t|f|t|t
33911684|NCT03397277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All women will be shown a video (also women not screening positive for IPV). Unless staff ask women about the content of the video or the women discloses this, care providers will not know which film participants have viewed. As we include a group of women who screened negative for IPV in the assessment three months after birth care providers will not know who who screened positive and who screened negative. In the file the variable for control og intervention video will be blinded. Women will be selected for the post-partum questionnaire based on the screening for abuse. All abused women and for each abused woman two without abuse will be selected.|Pregnant women will be screened for IPV using a modified version of the Abuse Assessment Screening. Women who screen positive are randomized into either the intervention video or a control video. Women screening negative for violence will be shown the control video. All women receive standard care and a card with high quality websites about safe pregnancy. Hidden among these is a webside that informs women about IPV (rights, safety etc..). Three months after birth all the women screening positive for violence will receive another questionnaire to fill out. In addition will a random sample of women who screened negative for IPV be asked to fill out a questionnaire at the same time. This group will be double the size of the women screening positive.|f|t|t|t
33778773|NCT02585310|||COHORT||PROSPECTIVE|||||||
33911685|NCT01972880|RANDOMIZED|CROSSOVER||||NONE||||||
33911686|NCT01774344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778774|NCT01536782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778775|NCT03766828|||COHORT||RETROSPECTIVE|||||||
33778776|NCT00654940|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33778777|NCT03193892|||COHORT||PROSPECTIVE|||||||
33778778|NCT01212263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778779|NCT05513040|||COHORT||PROSPECTIVE|||||||
33778780|NCT04840953|||CASE_ONLY||PROSPECTIVE|||||||
33778781|NCT01663675|||COHORT||PROSPECTIVE|||||||
33778782|NCT03068286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778783|NCT04349579|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33778784|NCT01924234|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33778785|NCT00451997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778786|NCT06696898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778787|NCT02696785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778788|NCT02694679|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33778789|NCT05343481|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants are randomised to the three treatment groups. Allocation to the groups is 1:1:1 allocation.||||
33778790|NCT02781064|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double Blinded IMP||t|t|t|t
33778791|NCT03420235|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized clinical multi-center study to evaluate the effect of home monitoring on disease-specific HRQOL, (appropriate) medication use and other patient-relevant outcomes in patients with IPF treated with anti-fibrotic drugs. Patients with IPF about to start on anti-fibrotic medication will be randomly assigned to receive either the home monitoring program integrated with standard care or standard care alone after informed consent. Patient will be stratified for study center and medication.||||
33778792|NCT04286282|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911687|NCT01515995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993068|NCT06741657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993069|NCT05866588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Experimental Design|f|f|f|t
33993070|NCT06012812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993071|NCT04456972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993072|NCT05457413|||COHORT||PROSPECTIVE|||||||
33993073|NCT06742541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993074|NCT04230681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993075|NCT04250545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993076|NCT06527404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993077|NCT05932563|||COHORT||OTHER|||||||
33993078|NCT01310998|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778793|NCT00083174|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778794|NCT05220124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778795|NCT05547659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778796|NCT04770597|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Each sensor will be randomized to Sham-Intervention or Intervention-Sham cross-over. Additionally, each sensor will measure CO2 during a baseline and post-intervention phase.||||
33911688|NCT00262418|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33911689|NCT00065741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689867|NCT06242483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be instructed not to mention their allocated group to the outcome assessor until the end of the follow-up visit.||f|f|f|t
33911690|NCT01152333|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33911691|NCT04349306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993079|NCT01208935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33993080|NCT04972565|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hypermobile EDS and HSD participants will be randomized to an inspiratory muscle training group versus usual care. Baseline measures will be compared to 17 age and sex-matched healthy controls.||||
33993081|NCT06742684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993082|NCT06743022|NA|SINGLE_GROUP||OTHER||NONE||||||
33993083|NCT00106223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993084|NCT03710629|||COHORT||PROSPECTIVE|||||||
33689868|NCT02519387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689869|NCT00434343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689870|NCT01642654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689871|NCT05166889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|unblinded administrator/pharmacist||t|t|t|f
33689872|NCT00568685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689873|NCT04005989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|DOUBLE BLIND|"It is a randomized, prospective, double-blind, placebo-controlled clinical study.~Eligible patients will be randomly divided into 4 groups (one control group and 3 active treatment groups): 10 PATIENTS EACH ARM Control Group - saline injection Low dose group (BD) - hASC injection (1x106 / kg body weight) Intermediate dose group (DI) - injection of hASC (2x106 / kg body weight) High dose group (AD) - hASC injection (4x106 / kg body weight)"|t|t|t|t
33689874|NCT03491189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689875|NCT00413166|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689876|NCT02894632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689877|NCT03401853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689878|NCT05087849|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm study in which all participants will receive intralesional Gardasil 9 vaccine to their condyloma.||||
33689879|NCT04198506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689880|NCT03431311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689881|NCT01246531|||CASE_CONTROL||PROSPECTIVE|||||||
33689882|NCT02337348|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689883|NCT02037607|||COHORT||PROSPECTIVE|||||||
33689884|NCT03704324|||COHORT||PROSPECTIVE|||||||
33689885|NCT00415571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689886|NCT00301821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911692|NCT02049255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911693|NCT05158452|||CASE_ONLY||PROSPECTIVE|||||||
33911694|NCT05264090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Monocenter, non-randomized, controlled study||||
33911695|NCT04987060|NA|SINGLE_GROUP||TREATMENT||NONE|irregullar astigmatism group|Irregular astigmatism group||||
33911696|NCT00975702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911697|NCT03628430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||participants were assigned to one of two groups in parallel for the duration of the study|t|t|f|t
33911698|NCT04397237|||COHORT||CROSS_SECTIONAL|||||||
33911699|NCT02902172|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33911700|NCT03545724|NA|SINGLE_GROUP||TREATMENT||NONE||Assignment||||
33993085|NCT06741774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993086|NCT06670963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993087|NCT06742073|||COHORT||RETROSPECTIVE|||||||
33993088|NCT04814160|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33993089|NCT06159673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993090|NCT06743204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778797|NCT05012423|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33778798|NCT03429452|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33778799|NCT01339221|||CASE_ONLY|||||||||
33778800|NCT00765362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911701|NCT06555705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911702|NCT02370849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911703|NCT03867669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911704|NCT03163199|||CASE_ONLY||PROSPECTIVE|||||||
33911705|NCT03955887|||CASE_CONTROL||PROSPECTIVE|||||||
33911706|NCT01068041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911707|NCT05528003|||COHORT||RETROSPECTIVE|||||||
33993091|NCT06046053|RANDOMIZED|PARALLEL||OTHER||NONE|Since the two films will differ by shape, masking is not possible once the product is removed from packaging for the participant and clinicians assessing the clinical outcomes. However, the assessors of the vaginal microenvironment endpoints will be masked as to product assignment.|"Participants will be randomized (1:1) to insert either placebo vaginal film A or placebo vaginal film B once monthly for two months. Films A and B are 2 x 2 in size and differ only by shape (square versus rounded corners)."||||
33993092|NCT02998229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993093|NCT05254002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993094|NCT06440343|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33993095|NCT06255171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will know that they are allocated to one of 3 arms, but will not know if the arm is a control group or experimental. After the main part of the study, all groups of participants will be involved in a group debriefing conversation, providing an opportunity for feedback from both the study's facilitators and participants. It will facilitate clarification of conditions (experimental or control group) and provide a platform for discussing participants' feelings, potential dilemmas, questions, etc.|Participants will be allocated to one of 3 arms, one of which will be an experimental group and 2 will be control groups.|t|f|f|f
33993096|NCT04092283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993097|NCT04713774|||COHORT||PROSPECTIVE|||||||
33993098|NCT03017755|||COHORT||PROSPECTIVE|||||||
33993099|NCT03686540|||COHORT||RETROSPECTIVE|||||||
33778801|NCT01881438|||||RETROSPECTIVE|||||||
33778802|NCT03540979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778803|NCT06029751|||OTHER||RETROSPECTIVE|||||||
33778804|NCT03457194|||COHORT||PROSPECTIVE|||||||
33778805|NCT03500705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor only was masked.|Pilot Randomised Controlled Trial|f|f|f|t
33778806|NCT04648891|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33778807|NCT00000286||||TREATMENT||DOUBLE||||||
33778808|NCT04125017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||effect of using LASER pulse versus micro-needle use in the artificial shrinkage of blastocysts .|t|t|t|t
33778809|NCT01347645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689887|NCT04071587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments will be done by assessors blinded to treatment allocation.|Patients are randomized to one of two treatment options, intervention or standard rehabilitation|f|f|f|t
33689888|NCT05368532|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33689889|NCT05515666|||COHORT||PROSPECTIVE|||||||
33689890|NCT02354482|||COHORT||PROSPECTIVE|||||||
33689891|NCT05633225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689892|NCT06003400|NA|SINGLE_GROUP||TREATMENT||NONE||Administration of Tri.O FITT for upto 12 weeks or until wound closure.||||
33689893|NCT00916214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689894|NCT05143554|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Each subject will be randomized to receive active vs sham therapy, then cross over to the other during the following cycle of chemotherapy|t|t|t|f
33689895|NCT05541068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689896|NCT02024438|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33689897|NCT05541731|||OTHER||PROSPECTIVE|||||||
33689898|NCT04437849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689899|NCT02492581|||COHORT||PROSPECTIVE|||||||
33689900|NCT00558376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33689901|NCT06087003|||COHORT||RETROSPECTIVE|||||||
33689902|NCT00228137|||DEFINED_POPULATION||PROSPECTIVE|||||||
33689903|NCT04054154|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33689904|NCT01049399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689905|NCT00195871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689906|NCT01159977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33689907|NCT05048797|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study consists of two open-label treatment arms:~Arm 1: Trastuzumab Deruxtecan Arm 2: Standard of Care treatment (platinum, pemetrexed and pembrolizumab)"||||
33689908|NCT06709313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"2 groups:~Experimental Group:~Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.~Control Group: Participants will not receive chromium after sacroiliac joint injection."|f|f|f|t
33689909|NCT06418152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Up to 5 individuals with previously implanted deep brain stimulation and Parkinson's disease||||
33778810|NCT05382455|||COHORT||PROSPECTIVE|||||||
33778811|NCT02578420|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33778812|NCT03257488|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33778813|NCT04651231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants were masked during study time through permuted variable block randomization scheme.|Eighty Patients inclusive, randomly distributed for tight flap technique group (forty patients-group A) and for loose flap technique (securing sutures) group (forty patients-group B).|t|f|f|f
33778814|NCT01994733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778815|NCT06108141|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33993100|NCT06016738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993101|NCT02968212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993102|NCT06742060|||COHORT||PROSPECTIVE|||||||
33993103|NCT04481958|NA|SINGLE_GROUP||PREVENTION||NONE||Single case study, purposeful sampling||||
33689910|NCT06491914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689911|NCT05472454|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-post design||||
33689912|NCT00440778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689913|NCT01698632|||COHORT||PROSPECTIVE|||||||
33689914|NCT00597701|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33689915|NCT04746716|||CASE_CONTROL||PROSPECTIVE|||||||
33689916|NCT04720157|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient randomized to SOC arm have an option to crossover to 177Lu-PSMA-617 treatment after rPFS||||
33689917|NCT01596673|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33689918|NCT04946149|||COHORT||PROSPECTIVE|||||||
33689919|NCT03486717|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33689920|NCT03175432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689921|NCT03626571|||COHORT||PROSPECTIVE|||||||
33689922|NCT01397812|||CASE_ONLY||PROSPECTIVE|||||||
33689923|NCT05868668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911708|NCT04786873|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|"This study is open label. Masking is performed with regard to the GHST results (i.e. growth hormone (GH) values).~GH values from all GHSTs will be assessed centrally by a central lab: GH values following the two standard GHSTs at V3 and V4 will not be disclosed to the trial site prior to the end of V5 (i.e., the second macimorelin GHST). To avoid bias in the final diagnostic assessments by the investigators, macimorelin pharmacodynamic (PD) data will remain blinded to the trial sites, clinical research associates (CRAs), and trial management at contract research organization (CRO) and Sponsor until trial closure.~An Independent Adjudication Committee (IAC) is established to perform ongoing blinded adjudication of subjects' growth hormone deficiency status. The IAC will adjudicate in a consistent manner by use of pre-defined definitions and guidelines."|This is an open label, single-dose trial to determine the diagnostic efficacy and safety of macimorelin in pediatric subjects aged 2 to less than 18 years of age in whom, based on auxological and clinical criteria, growth hormone stimulation test (GHST) is indicated due to suspected growth hormone deficiency. Four GHSTs will be conducted during the trial: the macimorelin GHST will be performed twice, and arginine and clonidine standard GHSTs will be performed once each. The macimorelin GHST will be administered at the beginning of the trial and after serial performance of the two different standard GHSTs. The macimorelin GHSTs will be performed twice to show repeatability of the macimorelin GHST. All subjects will be randomized 1:1 to the order of the arginine and clonidine GHSTs, and in a crossover manner all subjects will receive both these GHSTs.|f|f|f|t
33911709|NCT04497662|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
33911710|NCT01679080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911711|NCT01506778|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33993104|NCT05224531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Endpoint||f|f|f|t
33993105|NCT05262491|NA|SEQUENTIAL||TREATMENT||NONE||||||
33993106|NCT06072339|RANDOMIZED|PARALLEL||OTHER||NONE||open-labeled, controlled, randomized study||||
33689924|NCT06282848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|Randomized clinical trial|t|f|t|f
33689925|NCT02610959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689926|NCT01031121|||||OTHER|||||||
33689927|NCT00644748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33689928|NCT02250027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33689929|NCT04510974|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33689930|NCT00144027|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33689931|NCT03408002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33689932|NCT06184399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant) Treatment allocation will be masked using appearance-matched placebos.||t|f|f|f
33689933|NCT05191979|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Non-blinded, non-randomized intervention design||||
33689934|NCT04000230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33689935|NCT05789108|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33689936|NCT05260970|||CASE_CONTROL||PROSPECTIVE|||||||
33689937|NCT00397566|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33689938|NCT00687232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689939|NCT02013401|||COHORT||CROSS_SECTIONAL|||||||
33689940|NCT03548571|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomized||||
33689941|NCT04397627|||COHORT||PROSPECTIVE|||||||
33689942|NCT02266043|||COHORT||PROSPECTIVE|||||||
33689943|NCT03347708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|f|t
33689944|NCT00891111|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33911712|NCT06262750|||OTHER||PROSPECTIVE|||||||
33911713|NCT02007785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911714|NCT01986218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911715|NCT00978861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911716|NCT01869114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911717|NCT01886131|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33689945|NCT06437990|NA|SINGLE_GROUP||TREATMENT||NONE||Late-onset brachial plexus injury patient with concomitant subclavian or axillary artery injury||||
33689946|NCT03809923|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33689947|NCT01464723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689948|NCT02665676|||COHORT||RETROSPECTIVE|||||||
33911718|NCT01252134|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33911719|NCT01651052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911720|NCT01212172|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33911721|NCT00002288||||TREATMENT||||||||
33911722|NCT05941949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Softgels with similar appearance|Randomized, Prospective, Double Blind, Placebo-Controlled design|t|f|t|t
33911723|NCT02481726||PARALLEL||DIAGNOSTIC||NONE||||||
33911724|NCT04289415|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic, two-arm, parallel, superiority, randomised controlled trial||||
33911725|NCT02227329|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33911726|NCT02805556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993107|NCT06216964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993108|NCT03886129|||CASE_CONTROL||PROSPECTIVE|||||||
33993109|NCT02593773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993110|NCT04060108|||CASE_CROSSOVER||PROSPECTIVE|||||||
33993111|NCT06075264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind, placebo controlled|Double-blind, placebo-controlled randomized trial|t|f|t|f
33993112|NCT05877339|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33993113|NCT05600322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a prospective, comparative, within patient controlled, multi-center study of Hexvix Blue light cystoscopy and standard White light cystoscopy in the detection of bladder cancer. Patients with suspicious or confirmed bladder cancer will be enrolled and there will be a maximum of three regular study visits for each patient. Visit 1 is a screening visit, Visit 2 is the cystoscopic examinations and Visit 3 is the safety follow-up.~At Visit 2, enrolled patients will be instilled with 50 mL Hexvix solution in the bladder for one hour. After bladder evacuation, the inspection of the bladder and mapping of lesions seen under White light will be done. Secondly, inspection of the bladder and mapping of lesions seen under Blue light will be done. The Richard Wold PDD system (System Blue) will be used. Lesions detected will be resected or biopsied and sent to the local and central pathologists for analysis."||||
33993114|NCT05496348|||COHORT||PROSPECTIVE|||||||
33993115|NCT06364891|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomised control study||||
33993116|NCT06628128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993117|NCT06742801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993118|NCT05666726|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33993119|NCT06741475|RANDOMIZED|PARALLEL||OTHER||DOUBLE|A researcher is responsible for the randomization process and the results are coded with predefined IDs that investigators and outcomes assessors are unaware of the meaning.||f|f|t|t
33911727|NCT05369416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|"We are using a crossover design of low-sodium and high-sodium diets of 2 week duration each.~Both diets consecutively given to each subject recruited in the study."|||||
33911728|NCT06276608|||COHORT||RETROSPECTIVE|||||||
33911729|NCT00808691|||COHORT||PROSPECTIVE|||||||
33911730|NCT04236479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911731|NCT02968043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993120|NCT06742983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993121|NCT03843294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993122|NCT06434064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993123|NCT05727891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-masked, placebo-controlled clinical trial|t|t|t|t
33993124|NCT03302039|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33993125|NCT03146156|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993126|NCT04013217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993127|NCT00414180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33993128|NCT01852487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993129|NCT05279742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33993130|NCT00636129|||CASE_ONLY||PROSPECTIVE|||||||
33993131|NCT05508217|||COHORT||PROSPECTIVE|||||||
33993132|NCT01260389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993133|NCT06562257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both patients and the principal investigator will remain blinded throughout the completed treatment period. Treatment allocations will only be disclosed after the final database lock. The patients are primarily handled by a principal investigator and resident doctor who is in charge of the evaluation of inclusion or exclusion criteria, adverse events, relapses, and side effects||t|f|t|t
33993134|NCT01090635|||CASE_ONLY||PROSPECTIVE|||||||
33993135|NCT01683045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993136|NCT04322292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911732|NCT03437772|||COHORT||PROSPECTIVE|||||||
33911733|NCT04482491|||COHORT||PROSPECTIVE|||||||
33911734|NCT05699746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911735|NCT02016092|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911736|NCT05256069|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33911737|NCT02114567|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33911738|NCT05542303|NA|SEQUENTIAL||TREATMENT||NONE||||||
33911739|NCT00219336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993137|NCT05311085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993138|NCT00761813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024977|NCT06115915|||COHORT||PROSPECTIVE|||||||
34024978|NCT06558149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34024979|NCT00083603|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34024980|NCT02542605|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34024981|NCT03423017|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34024982|NCT05850806|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participants and the assessors will be masked to the study arm||t|f|f|t
34024983|NCT05053334|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34024984|NCT06548815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024985|NCT02069431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024986|NCT01025115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024987|NCT06632899|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single||t|f|f|f
34024988|NCT01621477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024989|NCT06157736|||CASE_CONTROL||PROSPECTIVE|||||||
34024990|NCT05651789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024991|NCT06355791|NA|SINGLE_GROUP||OTHER||NONE||||||
34024992|NCT02183181|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34024993|NCT05021718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024994|NCT06050343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double-blinded|Crossover Assignment two-way crossover|t|f|t|f
34024995|NCT04962152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024996|NCT02730026|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34024997|NCT01231386|||COHORT||OTHER|||||||
33689949|NCT06515249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33689950|NCT02029339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689951|NCT04688879|||COHORT||RETROSPECTIVE|||||||
33689952|NCT01005043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689953|NCT06278220|||OTHER||PROSPECTIVE|||||||
33689954|NCT01176344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689955|NCT03860883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778816|NCT05495451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomisation will be effectuated with the participant number only for the Intermittent Fasting Intervention.|36 participants will be taught to follow the Mediterranean diet (40% carbohydrates) and training 3 times a week (HIIT and weight training) for 3 months. At 3 months, there will be a randomization: 12 participants will continue the same interventions while 24 will add Intermittent Fasting Intervention for 3 months.|f|f|f|t
33911740|NCT04178681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each research subject will visit the university on three separate occasions with a wash-out period of at least one week. At each visit the research subject will undergo one of the three dietary lipid challenge tests (a shake) in a randomized order. All research subjects have consumed all three dietary lipid challenge tests at the end of the study.|t|f|t|t
33911741|NCT00590018|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33911742|NCT04766203|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||This study will be comprised of: 1) screening of athletes for symptoms of REDS; and 2) treating athletes diagnosed with REDS with a nutritional intervention||||
33911743|NCT02222038|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33911744|NCT02316691|||COHORT||PROSPECTIVE|||||||
33689956|NCT03101267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33689957|NCT01361854|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33911745|NCT04017988|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33911746|NCT04739657|||COHORT||PROSPECTIVE|||||||
33911747|NCT00281151|||COHORT|||||||||
33911748|NCT01594632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33911749|NCT02566941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33911750|NCT03257930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911751|NCT00493103|||||OTHER|||||||
33911752|NCT04655105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911753|NCT02844023|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33911754|NCT04041778|||CASE_ONLY||PROSPECTIVE|||||||
33911755|NCT04430049|||CASE_CONTROL||PROSPECTIVE|||||||
33911756|NCT00088582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911757|NCT00376597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911758|NCT05610995|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective, multicenter, randomized, two-arm, parallel, open-label, interventional controlled trial with masked outcome assessment (PROBE design)|f|f|f|t
33911759|NCT05915754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33911760|NCT02215993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911761|NCT03057834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be determined based on the score on the SPPB.||||
33911762|NCT00137436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911763|NCT03491722|||CASE_ONLY||CROSS_SECTIONAL|||||||
33911764|NCT02481037|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33911765|NCT06425783|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind|randomized controlled, parallel group. A single center|t|f|t|f
33911766|NCT04987853|||COHORT||PROSPECTIVE|||||||
33911767|NCT01611233|||COHORT||PROSPECTIVE|||||||
33911768|NCT05579093|||COHORT||PROSPECTIVE|||||||
33911769|NCT02155296|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33911770|NCT00708604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911771|NCT04657016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911772|NCT06369675|NA|SINGLE_GROUP||OTHER||NONE||||||
33911773|NCT02109094|||CASE_CONTROL||PROSPECTIVE|||||||
33911774|NCT00180596|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34024998|NCT03499210|NA|SINGLE_GROUP||OTHER||NONE||||||
34024999|NCT00316095|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34025000|NCT01145508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025001|NCT00952731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025002|NCT06012461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911775|NCT03726671|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|Participant dietary arm assignment is randomized by a randomization plan created by the study coordinator at www.randomization.com. Each of the 3 hormonal related demographic groups (male, premenopausal females, and postmenopausal females) will have a list of the same order of diets created by the randomizer. Each participant will be assigned upon entry into the study into the next open diet for their group as ordered by the randomizer. No one collecting or processing data will be informed of the choline levels the participant is experiencing in their dietary arms at any given time to attempt to eliminate bias and ensure appropriate data collection. All staff who interact with participants or who are handling samples/data, will not be informed of the code linking dietary choline levels to diet order.|Healthy volunteers will consume meals, provided by the investigator, in two week intervals with 3 different levels of choline (Cho). Participants will receive 100% of the recommended daily intake (RDI) of Cho (550 mg Cho/day); 50% of the RDI of Cho (275mg/day); and 25% of the RDI of Cho (137.5 mg/day). The meal order will be randomly assigned and all participants will receive all diets at some point in the study. There will be a minimum of a two week washout between diet intervals where participants return to their regular diets. Both participants and researchers will be blinded to the diet order.|t|f|t|t
33689958|NCT04968054|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33911776|NCT02831634|NA|SINGLE_GROUP||OTHER||NONE||||||
33911777|NCT01435239|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33911778|NCT02837692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911779|NCT00019500||||PREVENTION||||||||
33911780|NCT03810690|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33911781|NCT01727232|||COHORT||RETROSPECTIVE|||||||
33689959|NCT03099070|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||2 x 2 randomized crossover design||||
33911782|NCT00908206|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911783|NCT01281683|||COHORT||PROSPECTIVE|||||||
33911784|NCT05906134|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomization method will be sealed opaque envelopes with computer generated numbers inside that will have been created at the start of the study. The envelopes will be kept in the Thoracic Surgery clinic by the research coordinator. At the time of randomization, the envelope will be picked from random for each patient designating which group they will be assigned to. The anesthesia team, the thoracic surgeon performing the surgery, and the thoracic surgery clinical fellows for the study will be made aware of what arm the subject is part of for preoperative planning.||||
33911785|NCT05426707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911786|NCT01151995|||COHORT||RETROSPECTIVE|||||||
33911787|NCT04288726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911788|NCT01750398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993139|NCT06160804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial. Subgroups will be determined using equal block randomization. Block randomization will be used for this study. Blocks will be set to groups of 4 with each block of 4 comprising 2 traction and 2 splint opaque envelopes in random order. The envelope will be stored in the office of the principle investigator and opened following subject enrollment. This ensures subjects are blinded to their initial treatment modality. Standard of care will be followed for all clinical decisions beyond the type of stabilization procedure to be used.||||
33993140|NCT01633268|||COHORT||PROSPECTIVE|||||||
33993141|NCT00007423||||PREVENTION||DOUBLE||||||
33993142|NCT01304823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33993143|NCT01993810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993144|NCT06117579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993145|NCT01299662|NA|SINGLE_GROUP||||NONE||||||
33993146|NCT06626971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993147|NCT05970172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993148|NCT02698579|||CASE_ONLY||PROSPECTIVE|||||||
33993149|NCT01701323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993150|NCT02905435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993151|NCT06112379|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a 1:1 ratio to one of two intervention groups.||||
33689960|NCT02732080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689961|NCT05751616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911789|NCT05901038|||COHORT||PROSPECTIVE|||||||
33911790|NCT00904826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911791|NCT03868007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The RIC and sham procedure were performed by using identical devices with different cuff pressures (200mmHg versus 60 mmHg). Patients, investigators, and raters were all blinded to the treatment assignment.||t|t|t|t
33911792|NCT00793676|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33911793|NCT01380158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33911794|NCT02915367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33911795|NCT02583945|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993152|NCT02396459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993153|NCT00747305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993154|NCT04529772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant Care provider Investigator Outcomes assessor|Double-blind Randomised Placebo-controlled Study|t|t|t|t
33993155|NCT00394485|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33993156|NCT06741423|||OTHER||RETROSPECTIVE|||||||
33993157|NCT03461445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993158|NCT06729268|||COHORT||PROSPECTIVE|||||||
33993159|NCT03227835|||COHORT||PROSPECTIVE|||||||
33993160|NCT04509167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993161|NCT03617198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993162|NCT06741488|||CASE_ONLY||CROSS_SECTIONAL|||||||
34025003|NCT00752765|||CASE_ONLY||PROSPECTIVE|||||||
33689962|NCT05121493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689963|NCT03503851|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multi-center, randomized, parallel-arm trial||||
33689964|NCT05821101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689965|NCT02506569|||CASE_ONLY||PROSPECTIVE|||||||
33689966|NCT04335799|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33689967|NCT03000270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689968|NCT04774120|||COHORT||CROSS_SECTIONAL|||||||
33993163|NCT06371300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Each participant is randomised to either of 3 groups: Red light only group, red plus blue light group, or sham treatment group.|t|f|t|t
33993164|NCT06742281|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33993165|NCT03458520|||COHORT||PROSPECTIVE|||||||
33993166|NCT02651948|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993167|NCT04501003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993168|NCT06741449|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993169|NCT05091437|||COHORT||OTHER|||||||
33993170|NCT05487248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689969|NCT05905796|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33689970|NCT02041442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33689971|NCT04812080|NA|SINGLE_GROUP||OTHER||NONE||||||
33689972|NCT04376892|||COHORT||RETROSPECTIVE|||||||
33689973|NCT03386851|||CASE_ONLY||PROSPECTIVE|||||||
33689974|NCT01120834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689975|NCT00997438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689976|NCT04541160|||COHORT||PROSPECTIVE|||||||
33689977|NCT02992210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689978|NCT06518889|||COHORT||PROSPECTIVE|||||||
33689979|NCT00560885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689980|NCT04552730|||COHORT||PROSPECTIVE|||||||
33689981|NCT01740843|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33689982|NCT05266027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33911796|NCT02410707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911797|NCT01026701|||CASE_ONLY||PROSPECTIVE|||||||
33911798|NCT01294735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911799|NCT04094350|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Project coordinators and residents in the selected operational districts will not be masked to the intervention. However, all case finding activities will be done without reference to the intervention group. The data analysts will be masked to intervention allocation and will only analyse de-identified data.|A 12-moth pragmatic cluster randomized controlled trial will be conducted to evaluate different TB case-finding strategies. Eights operational districts consisting a total of 70 health centers will be randomized into one of the four groups (2 operational district per group): 1) Active case finding (ACF) with the seed-and-recruit model by KHANA, 2) ACF targeting household and neighborhood contacts by the National Center for Tuberculosis and Leprosy Control (CENAT), 3) ACF targeting the older population using mobile screening units by Cambodia Anti-Tuberculosis Association (CATA) and 4) Passive case finding (PCF).|f|f|f|t
33911800|NCT02231658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911801|NCT06445101|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Due to the PA intervention and associated activities, it is not possible to blind the researchers and department managers to the condition they are assigned to. However, employees in the departments randomized to the intervention or control group are not aware of the research design. Only department managers are informed about the research design and the outcome of randomization, and they are asked not to communicate the research design to the employees.|"Cluster randomized controlled trial comparing intervention group with care as usual group.~Randomization is carried out at the cluster (team or department) level to prevent contamination between employees assigned to the intervention group and those in the control group."|t|f|f|f
33911802|NCT00912015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911803|NCT02781467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911804|NCT00841503|||COHORT||PROSPECTIVE|||||||
33911805|NCT06447025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911806|NCT02810262|||COHORT||PROSPECTIVE|||||||
33911807|NCT05516108|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33911808|NCT00335946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911809|NCT01503073|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33689983|NCT00910468|||CASE_CONTROL||RETROSPECTIVE|||||||
33689984|NCT01371370|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33689985|NCT01418027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689986|NCT06381973|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33689987|NCT02602977|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33689988|NCT01936727|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33689989|NCT02351986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33689990|NCT05913531|||COHORT||RETROSPECTIVE|||||||
33689991|NCT02753218|NA|SINGLE_GROUP||OTHER||NONE||||||
33689992|NCT00881478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33689993|NCT06186544|||COHORT||PROSPECTIVE|||||||
33689994|NCT03301974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33689995|NCT02992080|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33689996|NCT01225536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33689997|NCT04598789|||OTHER||RETROSPECTIVE|||||||
33689998|NCT02208700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993171|NCT06149429|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group open pilot, pre- post-intervention study||||
33993172|NCT06732414|||COHORT||PROSPECTIVE|||||||
33993173|NCT01448590|||||RETROSPECTIVE|||||||
33993174|NCT06439485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993175|NCT05934981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993176|NCT06003387|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993177|NCT06425536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993178|NCT06732960|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33993179|NCT06743425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a multi-center, parallel, unblinded, randomized controlled clinical trial.||||
33993180|NCT06597695|NA|SINGLE_GROUP||OTHER||NONE||||||
33993181|NCT06627127|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Multicenter, proof- of-concept (POC) study. Electrode arrays percutaneously placed under ultrasound adjacent to nerves, connected to an external pulse generator will be used to evaluate the combined effect of short-term stimulation on airflow and/or AHI.||||
33993182|NCT06503250|||COHORT||RETROSPECTIVE|||||||
33993183|NCT04028479|||COHORT||PROSPECTIVE|||||||
34025004|NCT04920500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025005|NCT01128608|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34025006|NCT05653284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025007|NCT02394704|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34025008|NCT03349086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will undergo one of two study conditions immediately following a standard of care Botox injections. One condition is a 45 minute voice rest condition and the other condition is a 45 minute voice exercise condition.||||
34025009|NCT06604884|||COHORT||PROSPECTIVE|||||||
34025010|NCT01723618|RANDOMIZED|PARALLEL||||NONE||||||
34025011|NCT00000591|RANDOMIZED|||TREATMENT||||||||
34025012|NCT04688905|||COHORT||PROSPECTIVE|||||||
34025013|NCT05720065|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34025014|NCT02292173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025015|NCT06019598|NA|SINGLE_GROUP||OTHER||NONE||||||
34025016|NCT02288910|||CASE_ONLY||PROSPECTIVE|||||||
34025017|NCT02942641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025018|NCT03421795|RANDOMIZED|PARALLEL||OTHER||NONE|"Organizations will not be made explicitly aware of whether they have been allocated as part of the control or experimental conditions. Organizations will be told, however, that if they are not assigned to the experimental group, they will be given the option to also have an additional training about pain in children with DD at the end of the study. They will also know about the topics of both training programs and the purpose of the study. Participants will only be told that the purpose of the study is to learn about the impact that training programs can have on respite workers' knowledge about caring for children with DD. However, given some of the information in the consent form (e.g., study title is Let's Talk about Pain), it is likely that the treatment condition is clear to participants."|This is a multi-centre clustered parallel RCT with an intervention group (pain training) and control group (control training about family centered care, with an option to receive pain training after follow-up).||||
34025019|NCT02618135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025020|NCT04717557|RANDOMIZED|PARALLEL||PREVENTION||NONE||Permuted block||||
34025021|NCT06624644|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 1:1:1 between LNS8801 + pembrolizumab, LNS8801 monotherapy, and PC arms. In the LNS8801 + pembrolizumab arm, LNS8801 will be administered every day per week and pembrolizumab will be administered 200 mg Q3W for up to 35 cycles (approximately 2 years; Note: Physicians may modify the pembrolizumab regimen to 400 mg Q6W pembrolizumab after 6 months of treatment, if appropriate). In the monotherapy arm, LNS8801 will be administered every day per week. In the PC arm, patients may receive chemotherapy (dacarbazine, temozolomide) or immunotherapy (pembrolizumab, nivolumab/relatlimab, nivolumab/ipilimumab). Patients' randomization will be stratified by normal or elevated baseline LDH, number of disease sites (\<3 or ≧3), and physician's determination of primary vs secondary resistance to prior anti-PD-1 therapy per SITC guidance. Patients who are on LNS8801 + pembrolizumab combination therapy may drop one of the study medications for safety reasons.||||
34025022|NCT03190902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single center, double blind, randomized clinical trial (RCT).|t|f|f|t
34025023|NCT05649930|||COHORT||PROSPECTIVE|||||||
34025024|NCT02347826|||||RETROSPECTIVE|||||||
34025025|NCT06536140|||COHORT||CROSS_SECTIONAL|||||||
34025026|NCT04608435|||COHORT||PROSPECTIVE|||||||
34025027|NCT03207737|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34025028|NCT03177213|||COHORT||PROSPECTIVE|||||||
34025029|NCT01833819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025030|NCT04328961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025031|NCT00025012||||PREVENTION||||||||
34025032|NCT04020289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Treatment as usual (TAU); and Psychoeducational Program BalancingMySwing"|f|f|f|t
34025033|NCT04184505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025034|NCT03351465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be recruited and randomized to the CALM intervention delivered in their homes or to treatment as usual.|f|f|f|t
34025035|NCT02573844|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33778817|NCT03250312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The investigators who determine the expression profile of the 60 immune cell biomarkers would not know which group does each sample belong to|Participants will be randomly assigned into two groups, control or OMT using a random number generator. Males and females will be randomized separately to ensure equal distribution into the two study groups.|f|f|t|f
33778818|NCT00184119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778819|NCT04982965|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants and outcome assessor will not be made aware if they are receiving active or placebo marijuana.||t|f|t|t
33778820|NCT03066024|||COHORT||RETROSPECTIVE|||||||
33778821|NCT03464396|||COHORT||PROSPECTIVE|||||||
33778822|NCT05108389|||COHORT||PROSPECTIVE|||||||
33778823|NCT02705326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778824|NCT02865434|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778825|NCT06146738|||COHORT||PROSPECTIVE|||||||
33778826|NCT02040792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778827|NCT06006130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Experiment 1: Outcomes assessor will be blinded to the groups (fibromyalgia vs controls) the data is obtained from Experiment 2: Outcomes assessor and participants will be blinded to the intervention group that participants are allocated to (sham vs real treatment)|Experiment 1: Response to real intervention compared between fibromyalgia and healthy control group Experiment 2: Fibromyalgia participants allocated to real or sham intervention|t|f|f|t
33778828|NCT02057380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778829|NCT02773251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778830|NCT06258239|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Nursing staff who will administer the treatment will not be blinded, given that they will receive instructions regarding text to be communicated with participants while administrating the treatment. The participants and the outcomes assessors will not know which study arm they entered (both will be blinded).|Parallel design - subjects are allocated into one of two study arms|t|f|f|t
33778831|NCT06323538|||COHORT||PROSPECTIVE|||||||
33778832|NCT03779451|RANDOMIZED|PARALLEL||PREVENTION||NONE|An open-label randomized controlled study|A randomized controlled study||||
33911810|NCT01476150|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33911811|NCT02283606|||COHORT||PROSPECTIVE|||||||
33911812|NCT04520516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33911813|NCT00635947|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33911814|NCT01248234|RANDOMIZED|PARALLEL||||NONE||||||
33911815|NCT02160379|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911816|NCT04268368|||COHORT||PROSPECTIVE|||||||
33911817|NCT04495452|||COHORT||PROSPECTIVE|||||||
33911818|NCT02918266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33911819|NCT00543569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911820|NCT03141086|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33911821|NCT05009459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911822|NCT05641792|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33911823|NCT01326052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33911824|NCT01175967|||CASE_ONLY||PROSPECTIVE|||||||
33911825|NCT02477722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911826|NCT06381518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single centre, open-label cohort study, conducted in Zuyderland Medical Centre in which adult IBD patients in remission on stable IV IFX therapy are switched to SC CT-P13 and is designed to compare the pharmacokinetics of SC CT-P13 to IV IFX and relate this to the pharmacodynamics.||||
33911827|NCT03407196|||COHORT||RETROSPECTIVE|||||||
33911828|NCT00997295|||CASE_CONTROL||PROSPECTIVE|||||||
33911829|NCT05284578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant did not know prior to their study participation that there are three different study conditions, and they did not find out which condition they were randomized to until the end of their study participation.|1/3 of the study participants (43 from UWaterloo, 98 from Prolific) were placed into the self-compassionate writing intervention group, 1/3 of the study participants (42 from UWaterloo, 100 from Prolific) were placed into the expressive writing intervention group, and 1/3 of the study participants (41 from UWaterloo, 100 from Prolific) were placed into the control group.|t|f|f|f
34025036|NCT05893810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34025037|NCT05744141|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Controlled Trial||||
34025038|NCT04942743|||OTHER||RETROSPECTIVE|||||||
34025039|NCT05719792|||CASE_CONTROL||PROSPECTIVE|||||||
34025040|NCT05183659|||COHORT||CROSS_SECTIONAL|||||||
33778833|NCT00547261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778834|NCT01132911|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778835|NCT05743764|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33911830|NCT04620824|||OTHER||PROSPECTIVE|||||||
33911831|NCT02082314|||COHORT||PROSPECTIVE|||||||
34025041|NCT02826538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911832|NCT06280261|||FAMILY_BASED||PROSPECTIVE|||||||
33911833|NCT05594680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911834|NCT06284018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||intervention The design of the study was randomized controlled study. The patients were divided randomly into two equal groups (A\&B). Group A consisted of thirty postnatal women. They were treated by progressive muscle relaxation exercises three times per week for 4 weeks. Group B consisted of thirty postnatal women. They were treated by pilates exercises three times per week for 4 weeks.|t|t|f|t
33911835|NCT02458079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911836|NCT00214851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911837|NCT00083070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911838|NCT03268070|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects will be blinded to the type of TMS that they receive on each day.||t|f|f|t
33911839|NCT05162950|||CASE_CONTROL||PROSPECTIVE|||||||
33911840|NCT02044159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911841|NCT00771030|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33911842|NCT02519049|||OTHER||PROSPECTIVE|||||||
33911843|NCT00143221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911844|NCT00932529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911845|NCT04075201|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Open-labelled in the adults participants, and double-blinded in the children ans neonates participants.|Single group in the adults participants, and parallel groups in the children and neonates participants.|t|f|t|t
33911846|NCT00226681|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33911847|NCT02302794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911848|NCT02880579|||CASE_ONLY||PROSPECTIVE|||||||
33911849|NCT00004285|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33911850|NCT03700476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911851|NCT02651194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911852|NCT00444223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911853|NCT01745393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33911854|NCT05430451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33911855|NCT00210340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911856|NCT02932722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33911857|NCT05803889|||COHORT||PROSPECTIVE|||||||
33911858|NCT02053220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911859|NCT05220228|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33911860|NCT04817085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Subjects will be masked to their assignment to either the treatment or control group. Clinical personnel who perform clinical assessments will also be masked to the subjects' assignment to either the treatment or control group (masked evaluators). The eye care professional who inserts the test and control devices will not be masked and will not be eligible to perform follow-up evaluations."|All study subjects will receive treatment. Study subjects will be randomized (2:1 ratio) with 2 subjects randomized to receive the Visant Medical Canalicular Plug for every 1 subject randomized to receive the commercially available canalicular plug.|t|f|f|t
33911861|NCT01847833|||OTHER||PROSPECTIVE|||||||
33689999|NCT03155412|||COHORT||CROSS_SECTIONAL|||||||
33911862|NCT00108927|||||PROSPECTIVE|||||||
33911863|NCT02388529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911864|NCT05884411|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either receive the new pacing lead in the left bundle branch area or continue current cardiac therapy (CRT) with biventricular CRT||||
33911865|NCT03000816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911866|NCT01871896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911867|NCT05905211|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911868|NCT04070768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911869|NCT05781815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911870|NCT01294891|||CASE_CONTROL||PROSPECTIVE|||||||
33911871|NCT00138034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911872|NCT01152164|||COHORT||PROSPECTIVE|||||||
33690000|NCT05561010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33690001|NCT02567552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked samples for histological evaluation and assessment of gene expression|Parallel Assignment|f|f|f|t
33690002|NCT01857310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690003|NCT03551353|||OTHER||OTHER|||||||
33690004|NCT04399031|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33690005|NCT04208581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690006|NCT01323842|||COHORT||PROSPECTIVE|||||||
33690007|NCT03333954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690008|NCT02707809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33911873|NCT04069793|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Study Design includes using the subjects to complete both aims in a balanced randomized cross-over study.~Using blocked randomization, which will be achieve using a simple randomization script written in~Matlab. The two study conditions that will be analyzed are:~Condition A-a single DOF terminal device with a 1-DOF (rotation) wrist Condition B-a single DOF terminal device with a 2-DOF (rotation + flexion/extension) wrist~Condition A is the control condition in this project as it represents the state-of-the-art in clinical care. Condition B is the experimental arm."||||
33911874|NCT02284958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690009|NCT02525315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690010|NCT02745067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690011|NCT04639037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Active comparator (manual adjustment of vasopressor infusion) and Experimental (automated management of vasopressor infusion)|t|f|f|f
33690012|NCT01806727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911875|NCT03927937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911876|NCT00682916|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33911877|NCT05685641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911878|NCT06224699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes|The study was designed as a double-blind randomized controlled trial (RCT) with 2 parallel groups of individuals with gingivitis|t|f|t|f
33911879|NCT02973841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911880|NCT03176940|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|The dietary supplement will be delivered to the Clinical Research Center by the Investigational Pharmacy at Vanderbilt University Medical Center. Staff nurses and participants will be blinded to the capsule dosage content.|The 3+3 design will be employed for this trial. At least 3 volunteers will be studied at each dose level and evaluated for adverse effects. If 0 of 3 volunteers experiences adverse events (AE), the dose is escalated. If 1 of 3 volunteers experiences an AE, 3 additional volunteers are treated. If none of the additional volunteers develop an AE, the dose is escalated, otherwise escalation ceases. If 2 of 3 or 2 of 6 volunteers experience an AE, the maximum tolerated dose (MTD) has been exceeded.|t|t|f|f
33911881|NCT03740841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33911882|NCT05092737|||COHORT||RETROSPECTIVE|||||||
33911883|NCT04544384|||OTHER||RETROSPECTIVE|||||||
33911884|NCT04087421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911885|NCT03032185|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911886|NCT03076047|||COHORT||PROSPECTIVE|||||||
33911887|NCT00905307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911888|NCT02902016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33911889|NCT02388061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911890|NCT06093035|||COHORT||PROSPECTIVE|||||||
33911891|NCT02577406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690013|NCT04672330|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) prior to surgery（radical nephroureterectomy, segmental ureteral resection, endoscopic ablation）||||
33690014|NCT04640181|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Open-label Multicenter Prospective Randomized Trial in hospitalized patients with severe acute respiratory syndrome (SARS)-CoV-2 infection. Patients will be randomized 1:1 to subcutaneous enoxaparin (Lovenox) versus rivaroxaban after hospitalization, with the exact dosing is based on an adaptive strategy.||||
33690015|NCT00882973|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33690016|NCT02697097|||CASE_CONTROL||PROSPECTIVE|||||||
33690017|NCT02670343|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690018|NCT06033508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33690019|NCT00773266|||CASE_ONLY||RETROSPECTIVE|||||||
33690020|NCT01129570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690021|NCT06271174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911892|NCT06549023|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated to either the single-session (SS-PRP) or multiple-sessions (MS-PRP) panretinal photocoagulation groups using a computer-generated sequence. Block randomization will be utilized to ensure balanced group sizes and comparable participant characteristics.||||
33993184|NCT06741956|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The WEAPOM project is a single-blind, randomized-controlled trial where only the outcome assessors are blinded. Eligible participants are randomly allocated in a 1:1 ratio to one of two groups. The masking ensures that assessors evaluating outcomes are unaware of participant group assignments, reducing bias in the assessment of results.|The WEAPOM project is a single-blind (assessor), randomized-controlled trial. Eligible participants will be randomly assigned (1:1) to two groups: (i) a lifestyle modification program increasing impacts and physical activity level with a duration of 9 months (EV), or (ii) an unsupervised control group (CON) that will continue with their usual treatment.|t|f|f|t
33690022|NCT03841838|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33690023|NCT02812303|||COHORT||PROSPECTIVE|||||||
33690024|NCT04827121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33690025|NCT00744471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690026|NCT02179775|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690027|NCT03181373|||CASE_ONLY||PROSPECTIVE|||||||
33690028|NCT02563132|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33911893|NCT03136549|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33911894|NCT03504774|NA|SINGLE_GROUP||TREATMENT||NONE||Food allergy OIT in a single group design||||
33911895|NCT06253286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized controlled clinical trial of 2 parallel groups with an allocation ratio of 1:1|f|f|t|t
33911896|NCT03696069|||COHORT||RETROSPECTIVE|||||||
34085142|NCT05903352|RANDOMIZED|PARALLEL||TREATMENT||NONE||All eligible patients with confirmed CAP and willing to participate will be included and randomly assigned (1:1 ratio) by the investigator, to either continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 3 days of treatment in total), or to stop the antibiotic treatment.||||
34085143|NCT03020368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690029|NCT04801316|RANDOMIZED|PARALLEL||PREVENTION||NONE||Part 1 of the study is a pre-post non-randomised study with qualitative methods. Part 2 is an open-label, parallel randomized controlled trial.||||
33690030|NCT01165333|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690031|NCT03005938|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33690032|NCT03734744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690033|NCT01726231|||CASE_ONLY||CROSS_SECTIONAL|||||||
33690034|NCT04165811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
33690035|NCT05310903|||CASE_ONLY||CROSS_SECTIONAL|||||||
33690036|NCT03660631|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patient subjects will participate in their office's randomization group (intervention or control) for the 1st 12 months of their participation. After 12 months, each patient subject in the control group will receive the study intervention for months 13-24. Patient subjects in the intervention will be followed by study pharmacists during months 13-24.||||
33911897|NCT06368687|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study. Ten consecutive patients with anorexia nervosa (AN) plus autism will be admitted to the autism care location at an inpatient ward for eating disorders. The planned period of care for each patient is 12 weeks. The patient will be assessed (including weight, height, self-report questionnaires and interviews) before admission, at discharge and 6 months later.||||
33911898|NCT01926054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085144|NCT05723926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, randomized, open-label, blinded endpoint evaluation|f|f|f|t
34085145|NCT04499885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085146|NCT03534674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085147|NCT04015362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085148|NCT04823234|||COHORT||RETROSPECTIVE|||||||
33690037|NCT02195284|RANDOMIZED|CROSSOVER||||NONE||||||
33690038|NCT05658666|||CASE_ONLY||CROSS_SECTIONAL|||||||
33690039|NCT01425775|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33690040|NCT01350518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690041|NCT04843852|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33690042|NCT00589485|||COHORT||PROSPECTIVE|||||||
33911899|NCT05916677|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33911900|NCT05428748|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33911901|NCT03162783|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33911902|NCT02484196|||COHORT||PROSPECTIVE|||||||
33911903|NCT05279612|||OTHER||PROSPECTIVE|||||||
33911904|NCT02680223|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911905|NCT02836990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911906|NCT03577093|||COHORT||PROSPECTIVE|||||||
33911907|NCT04730986|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33911908|NCT02669004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33911909|NCT04866537|||CASE_ONLY||RETROSPECTIVE|||||||
33911910|NCT04800419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911911|NCT02949115|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33911912|NCT04582734|RANDOMIZED|PARALLEL||SCREENING||NONE|Because of the conditions required for psycho-educational interventions, it is not possible to blind the intervention staff and patients. All baseline information and clinical interviews are collected and performed before randomization. Physical tests, data collection, data management and administration will be done by blinded staff. Statistical analysis of outcomes and conclusions from these will be blinded. Results of the trial are analysed by an independent statistician, and the results will be interpreted by the research group. The conclusion will be prepared in two versions, before the allocation code is broken, with the two arms alternately assumed as intervention (one that assumes that arm A is the intervention, and second, that assumes that the arm B intervention).|||||
33911913|NCT03958682|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33911914|NCT04367116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911915|NCT02942095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911916|NCT01506752|RANDOMIZED|CROSSOVER||||NONE||||||
33911917|NCT01281852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911918|NCT06356246|||CASE_ONLY||CROSS_SECTIONAL|||||||
33911919|NCT02797704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993185|NCT06415058|||COHORT||PROSPECTIVE|||||||
33993186|NCT04519515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33911920|NCT00578864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911921|NCT04404595|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation and expansion||||
33911922|NCT04183205|NON_RANDOMIZED|SEQUENTIAL||SCREENING||DOUBLE|Participants will be unaware of whether or not they are on placebo or sertraline at any given moment and the placebo and sertraline capsules look identical. The outcomes assessor is unaware of the study design, study hypotheses, and whether a participant is on placebo or sertraline.|All eligible participants will first undergo a 2 week placebo lead in. Following this 2 week period, placebo responders will remain on placebo. All other participants will begin a 12 week sertraline trial.|t|f|f|t
33911923|NCT03699787|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33911924|NCT00884182|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911925|NCT06108427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911926|NCT03703375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911927|NCT01131221|||||RETROSPECTIVE|||||||
33911928|NCT04527562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33911929|NCT00308425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911930|NCT00323505|RANDOMIZED|CROSSOVER||||NONE||||||
33993187|NCT03277807|||COHORT||PROSPECTIVE|||||||
33993188|NCT06563297|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993189|NCT05311046|||CASE_CONTROL||OTHER|||||||
33993190|NCT06395246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|triple-blind: participants, intervention researchers - except for the nutritionist in charge of diet and lifestyle counseling - and data analysts will be blinded.|Randomized parallel-arm design (n=40) with consecutive 1:1 allocation to either a continuous calorie restriction diet (n=20) for a healthy Mediterranean diet or an early time-restricted eating protocol + continuous caloric restriction (n=20) over 12 weeks.|f|f|t|t
33993191|NCT06558929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993192|NCT00070915|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33993193|NCT05893290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085149|NCT04347772|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a pragmatic randomized clinical trial involving patients undergoing major elective surgery.~Baseline will be commenced before operation, when the decision to operate electively was made in the outpatient setting, and ended 6 hours before surgery. Next visit will be commenced on the first day that the patient was able to take free fluids or a light diet after operation, and ended 4 weeks after discharge from hospital."||||
33993194|NCT02949739|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34085150|NCT04025424|||COHORT||OTHER|||||||
34085151|NCT00059540|||COHORT||PROSPECTIVE|||||||
34085152|NCT05589974|||COHORT||PROSPECTIVE|||||||
34085153|NCT05608057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085154|NCT03077217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690043|NCT00542971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690044|NCT04926727|||OTHER||OTHER|||||||
33690045|NCT03707184|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085155|NCT01393535|||COHORT||PROSPECTIVE|||||||
34085156|NCT01026493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085157|NCT00001132||||TREATMENT||DOUBLE||||||
34085158|NCT03448198|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33690046|NCT02097537|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690047|NCT02861989|||||CROSS_SECTIONAL|||||||
33690048|NCT05157503|||COHORT||PROSPECTIVE|||||||
34085159|NCT06369636|||CASE_CONTROL||PROSPECTIVE|||||||
34085160|NCT05209919|||COHORT||PROSPECTIVE|||||||
34085161|NCT05965414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the investigator nor the subject will know who has received the study drug or the placebo, The injections will be prepared by an unblinded pharmacist according to the randomization list.|"SAD:~5 cohorts 8 of healthy volunteers each will receive single ascending doses of either study drug or placebo (6 active:2 placebo).~MAD:~2 or more cohorts 8 of healthy male and female volunteers each will receive single ascending doses of either study drug or placebo (6 active:2 placebo). The subjects will be stratified on their APOE4 status. Each cohort needs to have at least 4 APOE4 carriers."|t|f|t|f
34085162|NCT02703766|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34085163|NCT03647592|||COHORT||RETROSPECTIVE|||||||
34085164|NCT03429413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The statistical team is blinded to the clinic assignment.|Clinics are randomly assigned to use the intervention app or not. A 5th clinic, will use the app, but has not been involved in the app development.|f|f|f|t
34085165|NCT04487990|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical trial of treatment, randomized-controlled, parallel, open, with two arms||||
34085166|NCT02426801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085167|NCT01837745|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085168|NCT04152590|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085169|NCT05063240|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085170|NCT02457975|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085171|NCT05811364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Every effort will be made to blind subjects to the treatment device up to the 1 year follow up visit. The independent Core Lab and Clinical Events Committee (CEC) members will also be blinded.|Subject randomized to a VBX device group and BMS control group|t|f|f|t
34085172|NCT01712282|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34085173|NCT03521310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085174|NCT04662333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085175|NCT01553929|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085176|NCT02559167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085177|NCT02577029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085178|NCT01220791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34085179|NCT00826839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085180|NCT01947361|||COHORT||RETROSPECTIVE|||||||
34085181|NCT01399307|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690049|NCT06518902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690050|NCT04627662|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Care partners will participate in 2, 8-week sessions to learn about distressing behavioral symptoms in dementia.||||
33690051|NCT04356365|||OTHER||CROSS_SECTIONAL|||||||
34085182|NCT00423046|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34085183|NCT00000965||||TREATMENT||||||||
34085184|NCT06050213|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34085185|NCT02596048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778836|NCT05313009|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||(1) Safety lead-in: A minimum of 6 patients and as many as 18 patients will be enrolled in a safety lead-in cohort to evaluate the safety of the combination of tarloxotinib and sotorasib. (2) Dose expansion: Once the tarloxotinib RP2Dc is reached, an expansion cohort of up to 12 patients will be enrolled to evaluate the safety of the combination of tarloxotinib and sotorasib.||||
33778837|NCT02033993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778838|NCT02451280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993195|NCT03579615|RANDOMIZED|CROSSOVER||OTHER||NONE|FIASP vs standard of care insulin|An open-label, single-centre, randomised, two-period, cross-over study||||
33993196|NCT03680313|||CASE_CONTROL||PROSPECTIVE|||||||
33993197|NCT06230783|||COHORT||PROSPECTIVE|||||||
33993198|NCT04362293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690052|NCT05562947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690053|NCT01600742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690054|NCT03368963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690055|NCT06168760|||CASE_CONTROL||PROSPECTIVE|||||||
33690056|NCT04115540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690057|NCT02443779|||CASE_ONLY||PROSPECTIVE|||||||
33690058|NCT05631288|||CASE_CONTROL||RETROSPECTIVE|||||||
33690059|NCT05550610|RANDOMIZED|PARALLEL||PREVENTION||NONE|All participants were aware whether they were assigned to receive mindfulness and yoga or training as usual.|group randomized trial||||
33778839|NCT04069390|NA|SINGLE_GROUP||OTHER||NONE||||||
33778840|NCT01355783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778841|NCT04218760|NA|SINGLE_GROUP||OTHER||NONE||Case-control study.||||
33778842|NCT00683449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778843|NCT05568485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778844|NCT02891590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778845|NCT05284721|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778846|NCT06303778|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Following completion of informed consent and baseline assessments, participants will be randomized in a 1:1 ratio to MAUD+SD-App or MAUD only conditions.||||
33778847|NCT03909165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A will be open-label, while Part B will be double-blinded.||t|t|t|t
33778848|NCT02602457|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33778849|NCT05010694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993199|NCT06742268|||OTHER||PROSPECTIVE|||||||
33993200|NCT00979147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993201|NCT06328738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1a will be a dose escalation of ELVN-002 in combination with fixed doses of trastuzumab or trastuzumab + chemotherapy according to the Bayesian Optimal Interval Design model. Phase 1b will be a dose expansion at one or more doses of ELVN-002.||||
33993202|NCT00029965|||COHORT||PROSPECTIVE|||||||
33993203|NCT06743152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993204|NCT04930874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993205|NCT06742099|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"2.4.1- Type of the study: Retrospective and Prospective 2.4. 2- Study Setting: All patients with malignant pleural effusion and either underwent intercostal tube insertion or had pleurodesis done in 2 to 3 years' timeframe.~2.4. 3- Study subjects:~1. Inclusion criteria:~   All patients presented with malignant pleural effusion to Assiut University Hospital regardless of sex And age~2. Exclusion criteria:~   All patients presented with pleural effusion other than malignant pleural effusion, including patients with debilitating diseases and terminal patients.~3. Sample Size Calculation:~Sample size calculation was carried out using G\* Power 3 software. To detect significant differences between both groups as regard post-operative complications with expected frequency of 14.5-16.7% and based on the following parameters: an error probability of 0.05 and 80% power on a two-tailed test, a calculated minimum required sample of 110 patients will be required."||||
33690060|NCT05718050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690061|NCT02931591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690062|NCT00570479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33690063|NCT03486704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33690064|NCT03680430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690065|NCT04877106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690066|NCT03361579|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigator is blinded about the source of education a participant recieved prior to Placebo application. Investigator is blinded about during which Intervention the Placebo is applicated|investigator blinded, cross over design|f|f|t|t
33690067|NCT04020575|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33778850|NCT05374083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778851|NCT06697990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778852|NCT00048854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778853|NCT00805636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778854|NCT01134809|||COHORT||PROSPECTIVE|||||||
33690068|NCT01323738|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33690069|NCT01386112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690070|NCT02376829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690071|NCT01504568|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690072|NCT04411524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778855|NCT04889885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33778856|NCT00170235|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33778857|NCT04201951|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All providers and delivered women will be blinded for the content of the bags which will be applied for women randomly|Two infusion bags will be prepared and labeled as bag A (experimental group) containing 1 g/10mL Tranexamic acid diluted with 20mL of 5% glucose water, and bag B (placebo group) containing 30 mL of 5% glucose water. Providers and patients will be blinded to the contents of the bags until the end of the study. TA or placebo will be administered intravenously immediately after the delivery of the fetus.|t|t|t|f
33778858|NCT05828784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993206|NCT06185491|NA|SINGLE_GROUP||OTHER||NONE||||||
33993207|NCT06414889|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33993208|NCT03712605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993209|NCT06742697|NA|SINGLE_GROUP||TREATMENT||NONE||Single-cohort feasibility trial.||||
33993210|NCT05291286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|randomized, placebo controlled, double blind|Participants will be assigned to 1 of 2 treatment arms (BXQ-350 or placebo) in a 1:1 ratio for the first two treatment cycles. At the end of the second treatment cycle, participants will be unblinded to their individual treatment assignment. Participants who received placebo will be offered 2 cycles of open-label BXQ-350. Participants who received BXQ-350 in Cycles 1 and 2 will continue to the Post-Treatment Follow-Up. If placebo participants elect to forego BXQ-350 at the time of unblinding, their participation in the study will end following an end of study visit.|t|t|t|t
33993211|NCT01000961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993212|NCT04086485|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993213|NCT06356129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993214|NCT06742021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690073|NCT06366022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690074|NCT00565903|||FAMILY_BASED||PROSPECTIVE|||||||
33690075|NCT00048763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690076|NCT03531034|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690077|NCT03052764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690078|NCT04028245|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study||||
33690079|NCT01728948|||COHORT||PROSPECTIVE|||||||
33690080|NCT02886156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993215|NCT06559657|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993216|NCT00369421|||OTHER||PROSPECTIVE|||||||
33993217|NCT06113705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993218|NCT05187065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33993219|NCT06289738|NA|SINGLE_GROUP||OTHER||NONE||||||
33993220|NCT04931810|NA|SINGLE_GROUP||TREATMENT||NONE||All community sites will implement the program as most appropriate for their communities.||||
33993221|NCT02010918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993222|NCT03616886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993223|NCT06725186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993224|NCT05720949|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The patient, research assistants, and biostatisticians are blinded to whether the patient was randomized to the control or intervention group.|Double blind randomized control trail|t|f|f|t
33993225|NCT06628258|NA|SINGLE_GROUP||OTHER||NONE||||||
33993226|NCT06742996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690081|NCT04957095|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Basic science study of effects of therapeutic interventions on intracranial physiology||||
33690082|NCT00674778|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690083|NCT05832827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690084|NCT05293509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690085|NCT02247947|||COHORT||PROSPECTIVE|||||||
34085186|NCT05584098|NA|SINGLE_GROUP||SCREENING||NONE|Mask all identified labels in all raw data|In a cross-sectional study, the investigator measures the outcome and the exposures in the study participants at the same time.||||
33690086|NCT03839927|||OTHER||OTHER|||||||
33690087|NCT01950910|||OTHER||PROSPECTIVE|||||||
33690088|NCT05035641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690089|NCT00882700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690090|NCT05223335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690091|NCT06144151|||COHORT||PROSPECTIVE|||||||
33690092|NCT02783846|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33690093|NCT02129660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690094|NCT00296803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690095|NCT00495131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690096|NCT01889940|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33690097|NCT04143061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This trial is a modified double-blind trial (except for toddlers in India), which means that the participant's parent / legally acceptable representative, the Investigator, and other study personnel remain unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator administer the appropriate vaccine but is not involved in safety data collection. The Sponsor and laboratory personnel performing the serology testing are also blinded to treatment assignments throughout the trial until database lock.~It will be open-label for toddlers population in India."|Toddlers (open-label), children, adolescents and adults aged 12 months and above are enrolled in India, and children and adolescents aged 2 to 17 years are included in RSA. The older populations (adults) are recruited before initiating the study in children and adolescents younger than 17 years of age in India.|t|t|t|t
33690098|NCT05086939|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open-label, Clinical Trial comparing 3 active treatments.||||
33690099|NCT05788796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Since there is no placebo group, masking will not be done.|"Pregnant women in the application group will be asked to take a hazelnut-sized cotton ball before going to bed, put it in the middle of the navel and close it diagonally with a band-aid.~Pregnant women in the control group will be asked not to make any lifestyle changes and to continue their routine daily lives."||||
33690100|NCT04211571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690101|NCT03791827|||CASE_ONLY||PROSPECTIVE|||||||
33690102|NCT03026088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690103|NCT04455984|||COHORT||RETROSPECTIVE|||||||
33690104|NCT06371508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33690105|NCT00084838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690106|NCT05568706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690107|NCT05708027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690108|NCT04996823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690109|NCT06640569|||OTHER||PROSPECTIVE|||||||
33690110|NCT00190515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690111|NCT05091502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690112|NCT06655870|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33690113|NCT00276913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690114|NCT00586729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690115|NCT06589687|||COHORT||PROSPECTIVE|||||||
33690116|NCT06466486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690117|NCT00344240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690118|NCT06138288|||CASE_CONTROL||OTHER|||||||
33690119|NCT04702854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690120|NCT00815516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993227|NCT04654143|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33993228|NCT04477447|||COHORT||PROSPECTIVE|||||||
33993229|NCT04461964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690121|NCT01536288|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33993230|NCT06626724|||COHORT||RETROSPECTIVE|||||||
33993231|NCT06407505|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|The process will not know the group to which the patient belongs.|Our study was designed as a randomized, controlled, single-blind, placebo-designed experimental study.|t|f|f|f
34025042|NCT06160193|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will conduct a two-armed randomized controlled trial. Children and their parents will be randomly assigned (simple and parallel randomization) to (a) the intervention condition in which parents receive the brief parent training and may receive care as usual, or (b) the control condition in which parents may receive care as usual only.||||
34025043|NCT02457663|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34025044|NCT03845803|||CASE_ONLY||PROSPECTIVE|||||||
33690122|NCT06182709|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33778859|NCT03649789|||COHORT||RETROSPECTIVE|||||||
33778860|NCT05711628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778861|NCT03394664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors conducting analyses of biospecimens, laboratory personnel, DXA technologists, and research nurses were blinded to random group assignment. They were not involved in the randomization process or any aspects of the intervention. The statistical team worked with masked labels for the diet arms.||f|f|t|t
33993232|NCT06737913|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 78 patients (anticipated) will be randomized (1:1) to two arms to receive Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W) and intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W) plus HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W) or intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W) and intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W) plus HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery, Q3W). The Two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity.||||
33993233|NCT06728293|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be randomized on a 1:1 basis, stratified by race and SES. NIH randomization tool will be used to randomize patients into status of care and intervention arms.|20 patients will then be randomized to SOC and 20 to the Liver-Link Intervention. Randomization will be stratified by race and SES.||||
33993234|NCT06742788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993235|NCT03500081|||COHORT||PROSPECTIVE|||||||
33993236|NCT06743048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993237|NCT06622239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993238|NCT06289517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085187|NCT04079790|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind study.|Part 1 is a 3-period, fixed-sequence study of a single 1500-mg dose (Period 1) and two 3000-mg doses of gepotidacin at Hours 0 and 12 (Period 2) and Hours 0 and 6 (Period 3) in healthy adult subjects. Part 2 is a 2-period, fixed sequence study of a single 1500 mg dose (Period 1) of gepotidacin and two 3000 mg doses (Period 2) of gepotidacin in healthy adolescent subjects. .|t|f|t|f
34085188|NCT01217346|||CASE_ONLY||CROSS_SECTIONAL|||||||
34085189|NCT06002100|||COHORT||PROSPECTIVE|||||||
34085190|NCT06238180|||COHORT||PROSPECTIVE|||||||
34085191|NCT04596904|RANDOMIZED|PARALLEL||PREVENTION||NONE||Clinical research with herbal products||||
34085192|NCT06150261|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomised, double-blind placebocontrolled, paralell-group trial|t|f|t|f
34085193|NCT03453294|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085194|NCT05279872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085195|NCT02491762|||COHORT||PROSPECTIVE|||||||
34085196|NCT03336125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Double blind|Pre and post-test design|t|f|f|f
34085197|NCT02164916|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085198|NCT00635505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085199|NCT05790590|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34085200|NCT03528941|||OTHER||RETROSPECTIVE|||||||
33690123|NCT04050371|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will receive Truvada for study duration and will take pills using daily observed therapy.||||
33690124|NCT02912988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690125|NCT05684523|RANDOMIZED|PARALLEL||OTHER||DOUBLE|matching placebo|randomized, double blind, placebo-controlled|t|f|t|f
33690126|NCT05961644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33690127|NCT05894239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690128|NCT01982058|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33690129|NCT03902106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33690130|NCT04128332|NA|SINGLE_GROUP||OTHER||NONE||||||
33690131|NCT03176875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690132|NCT00014027||||TREATMENT||||||||
33690133|NCT02236481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690134|NCT02467335|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690135|NCT03600688|||COHORT||PROSPECTIVE|||||||
33690136|NCT00462371|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690137|NCT06468969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690138|NCT05468385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33690139|NCT03509467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690140|NCT04549324|||COHORT||CROSS_SECTIONAL|||||||
33690141|NCT00215579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690142|NCT02808091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690143|NCT05965297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Noninferiority trial|t|f|f|f
33690144|NCT02424214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33690145|NCT04087928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690146|NCT06084728|||COHORT||PROSPECTIVE|||||||
33690147|NCT06404424|||COHORT||PROSPECTIVE|||||||
33778862|NCT02225275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690148|NCT04587180|||COHORT||PROSPECTIVE|||||||
33690149|NCT00377000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690150|NCT00723203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690151|NCT04630639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690152|NCT03750422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects are provided with de-identified tubes of both study product and vehicle then instructed on which de-identified product is to be used for aftercare on which side of the abdomen.|double-blinded, randomized split-body study|t|f|t|f
33690153|NCT04682873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Capsule formulations of the placebo Amizon® Max (IMP-2) is identical in appearance (size, shape, and color), taste, and smell as the active drug capsule.||t|t|t|t
33690154|NCT00198796|NA|SINGLE_GROUP||SCREENING||NONE||We will initially study the effects of a 1x109 dose of H10407 (in 5 subjects) and then proceed to the dose-finding portion of the trial to study the effects of low (5x108) or higher doses (5x109) of the CS17 expressing strains (total of 20 subjects)||||
33778863|NCT06067529|||COHORT||PROSPECTIVE|||||||
33778864|NCT05335174|||COHORT||PROSPECTIVE|||||||
33778865|NCT00180947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778866|NCT01985698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993239|NCT04241757|||OTHER||PROSPECTIVE|||||||
33993240|NCT01087307|||OTHER||OTHER|||||||
33993241|NCT03399500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911931|NCT02615535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911932|NCT03682757|||COHORT||PROSPECTIVE|||||||
33911933|NCT00305006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911934|NCT06287502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33911935|NCT01712087|||CASE_CONTROL||PROSPECTIVE|||||||
33911936|NCT04417777|||COHORT||PROSPECTIVE|||||||
33911937|NCT00016874||||TREATMENT||||||||
33911938|NCT05362643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33911939|NCT01905319|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33911940|NCT00101192||||TREATMENT||NONE||||||
33911941|NCT02197429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911942|NCT03956953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There will be two dose groups. Once the safety and tolerability up to discharge (Day 24) of Group 1, has been assessed and deemed safe; dosing for Group 2 will begin.|t|f|t|f
33911943|NCT01623297|||CASE_CONTROL||PROSPECTIVE|||||||
33911944|NCT03064295|||OTHER||PROSPECTIVE|||||||
33911945|NCT01985009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33911946|NCT06553456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911947|NCT03798912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy men and women volunteers||||
33911948|NCT02547831|||CASE_ONLY||PROSPECTIVE|||||||
33911949|NCT03553433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33911950|NCT05078697|||COHORT||PROSPECTIVE|||||||
33911951|NCT05404204|||COHORT||PROSPECTIVE|||||||
33911952|NCT03751995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||pilot pragmatic cluster randomized trial|f|f|t|t
33911953|NCT06163456|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33690155|NCT00869843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911954|NCT01423617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33911955|NCT02561260|||CASE_CONTROL||PROSPECTIVE|||||||
33911956|NCT04438889|||COHORT||PROSPECTIVE|||||||
33911957|NCT03086317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Pre- and post-treatment computed tomography angiography (CTA) will be compared by independent radiologists who are blinded to the type treatment received.~Pre- and post-treatment echocardiograms will be interpreted by independent cardiologists who are blinded to the type of treatment received."|Participants will be randomized to receive one of two treatments for acute, submassive pulmonary embolism.|f|f|f|t
33911958|NCT06323915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911959|NCT00486538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911960|NCT01005719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911961|NCT01351766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911962|NCT02225041|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911963|NCT06330948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33911964|NCT00793702|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33911965|NCT01743963|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33911966|NCT02841787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911967|NCT03798145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911968|NCT01337531|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33911969|NCT01463904|||COHORT||PROSPECTIVE|||||||
33911970|NCT03760848|NA|SINGLE_GROUP||OTHER||NONE||||||
33690156|NCT02876640|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690157|NCT01557894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690158|NCT03977454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690159|NCT06417073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690160|NCT04163718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690161|NCT03741127|NA|SINGLE_GROUP||OTHER||NONE||||||
33690162|NCT00883584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690163|NCT03217981|||COHORT||RETROSPECTIVE|||||||
33690164|NCT00399672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690165|NCT01828515|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33690166|NCT06115148|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The randomization scheme will be blinded to the PI and biostatistician. Due to the intervention (feeding vs fasting), the participant and other study staff cannot be blinded.||f|f|t|t
33690167|NCT05704296|RANDOMIZED|PARALLEL||TREATMENT||NONE||Saphenous vein as Y-composite graft based on the left internal thoracic artery versus aortocoronary conduit||||
33911971|NCT03073681|||COHORT||PROSPECTIVE|||||||
33911972|NCT02218658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33911973|NCT01520480|||CASE_CONTROL||RETROSPECTIVE|||||||
33911974|NCT01515306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993242|NCT05426265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research design is randomized and double-blinded. Subject randomization in study arms as well as treatment is automatized.|The effectiveness of MEL-T01 and comparator MEL-S01 are studied. Their effectiveness is compared to a treatment-as-usual (TAU) group who also receive the intervention after a 12 week waiting period.|t|t|t|t
33993243|NCT06359587|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Intervention Arm (Intervention Bundle Implementation):~This arm involves the time periods where hospital units are actively receiving the intervention bundle, including healthcare provider (HCP) and patient engagement tools.~Control Arm (No Intervention Bundle Implementation):~This arm represents the time periods when the hospital units do not receive the intervention bundle. This time period is the control period. Each hospital will contribute to intervention and control period data."||||
33993244|NCT06649435|||COHORT||PROSPECTIVE|||||||
33993245|NCT01794403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993246|NCT06104618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993247|NCT03233711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993248|NCT01164241|||COHORT||PROSPECTIVE|||||||
33993249|NCT06537622|RANDOMIZED|PARALLEL||SCREENING||NONE||CNFUN sites are the unit of randomization to the order in which they receive the implementation strategy||||
33993250|NCT06236451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993251|NCT05303532|NA|SEQUENTIAL||TREATMENT||NONE||||||
33993252|NCT06088303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993253|NCT06742892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993254|NCT06045689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993255|NCT05335369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The UR-GOAL 1) conducts assessments of fitness, 2) elicits patient values via Best-Worst Scaling, and 3) elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.||||
33993256|NCT06741631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33993257|NCT04799288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993258|NCT05177107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Double-blind:~Patient will be randomized to receive either active phage or placebo treatment."|2:1, phage: placebo|t|t|t|f
33993259|NCT05554198|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed study uses a single group, pre/post-test, mixed method study design with quantitative data collection at baseline and post-intervention and qualitative data collection once at post-intervention. Participants will have access to the Attend Behavior program for a full year, but intervention usage monitoring and study outcomes will be assessed until post-intervention (12-weeks post-baseline).||||
33993260|NCT06349980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993261|NCT06700109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||MULTI-CENTER, RANDOMIZED, CONTROLLED STUDY|f|f|f|t
33993262|NCT00540995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993263|NCT05047172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|1:1:1 treatment allocation||t|t|t|t
33993264|NCT05554328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993265|NCT06466733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993266|NCT03235271|||COHORT||PROSPECTIVE|||||||
33993267|NCT06742359|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993268|NCT06516354|NA|SINGLE_GROUP||SCREENING||NONE||||||
33993269|NCT05049967|||OTHER||PROSPECTIVE|||||||
33993270|NCT06546202|||COHORT||RETROSPECTIVE|||||||
33993271|NCT05183126|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993272|NCT05592574|||COHORT||PROSPECTIVE|||||||
33993273|NCT06722521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993274|NCT05025618|||COHORT||RETROSPECTIVE|||||||
33993275|NCT06732986|||OTHER||CROSS_SECTIONAL|||||||
33690168|NCT04805944|||COHORT||PROSPECTIVE|||||||
33690169|NCT05641675|||COHORT||PROSPECTIVE|||||||
33690170|NCT05151601|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be recruited into a two-phase project. Phase 1A: an 8-week double-blinded, placebo-controlled, randomised trial. Participants child will be randomised to one of groups 1) treatment (HMOs/Probiotic group) or 2) control group (placebo product).~Phase 1B: is an 8-week open-label trial. All children who successfully complete phase 1A will be recruited into phase 1B. All participants in phase 1B will receive the treatment product (HMOs/probiotics).~Follow up will occur at week 8 and week 17."||||
33690171|NCT02052570|||||RETROSPECTIVE|||||||
33993276|NCT06084416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993277|NCT01409499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993278|NCT02266095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993279|NCT05770388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993280|NCT06502379|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33993281|NCT05592678|||COHORT||PROSPECTIVE|||||||
33993282|NCT04081701|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993283|NCT06743061|||CASE_CONTROL||RETROSPECTIVE|||||||
33993284|NCT00164684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993285|NCT02912559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993286|NCT01449981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993287|NCT00452920|NON_RANDOMIZED|||TREATMENT||NONE||||||
33993288|NCT06667674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Active control group, waitlist control group and intervention group.|t|f|f|f
33993289|NCT06742216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993290|NCT00006453|RANDOMIZED|||TREATMENT||||||||
33993291|NCT06742632|||COHORT||PROSPECTIVE|||||||
33993292|NCT00540787|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33993293|NCT06743178|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33993294|NCT04258605|||COHORT||PROSPECTIVE|||||||
33993295|NCT06742242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993296|NCT03831256|RANDOMIZED|PARALLEL||SCREENING||NONE||Open-label prospective comparative-effectiveness (utility) randomised trial between first-tier NIPS and the standard of care (2nd-tier NIPS).||||
33993297|NCT05143931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||single-site, prospective, four-parallel-arm, randomized controlled trial|f|f|t|t
33993298|NCT03017794|||COHORT||PROSPECTIVE|||||||
33993299|NCT00872729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993300|NCT01016613|||COHORT||PROSPECTIVE|||||||
33993301|NCT05032807|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33993302|NCT05931458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993303|NCT04979663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993304|NCT05385757|||COHORT||PROSPECTIVE|||||||
33993305|NCT04349475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993306|NCT03609203|||CASE_CONTROL||PROSPECTIVE|||||||
33993307|NCT06561594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|recombinant human follicle-stimulating hormone-CTP Fusion protein injection or placebo combined with chorionic gonadotropin for injection|t|t|t|t
33993308|NCT00264966|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33993309|NCT06015984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33993310|NCT06626997|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The study will be masked by using identical packaging for both the study group and the control group (placebo), which participants will consume at home or at their mealtimes during the 6 weeks of the intervention.~The researchers themselves will administer the product (with identical external appearance for both groups) individually to each participant."|Prospective, parallel, randomized 6-week nutritional intervention study.|t|f|t|f
33993311|NCT01988376|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33993312|NCT03806257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled prospective design involving two study groups: 1) standard-of-care for cardiac physical therapy, and 2) enhanced protocol for cardiac physical therapy. Primary aim is to assess difference, if any, between groups for ICU and hospital length of stay.||||
33993313|NCT02281994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993314|NCT01154712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993315|NCT06366815|||COHORT||PROSPECTIVE|||||||
33993316|NCT00000915||||TREATMENT||||||||
33993317|NCT06714565|||COHORT||PROSPECTIVE|||||||
33993318|NCT01770223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993319|NCT00211263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993320|NCT03399214|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33993321|NCT02552758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33993322|NCT00217113|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33993323|NCT02281253|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33993324|NCT05019560|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Randomization was performed using a computer-generated random number table in opaque sealed envelopes with 1:1 allocation ratio by an anesthesiologist not directly involved in the trial or patient care.|"Interventions: Patients were randomized into either Group A (who received inhalational induction) and Group B (who received total intravenous induction followed by maintenance infusion).~Main outcome measure: IFT response was recorded at laryngoscopy and intubation to identify awareness at this stressful timepoint."|t|f|t|t
33993325|NCT05594095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993326|NCT02882776|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33993327|NCT04939051|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study statistician will be blinded towards the group's identity while analyzing the data. Further, neither the participants, nor the investigators will have any knowledge of the individual arm assignment.||t|f|t|t
34085201|NCT05580016|||COHORT||PROSPECTIVE|||||||
33690172|NCT05303272|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33993328|NCT04847466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993329|NCT00262392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993330|NCT04509453|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33993331|NCT01294020|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993332|NCT06741605|||OTHER||CROSS_SECTIONAL|||||||
33993333|NCT06742034|||OTHER||OTHER|||||||
33993334|NCT06742333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993335|NCT05502835|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993336|NCT02919540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34085202|NCT04568655|||COHORT||RETROSPECTIVE|||||||
34085203|NCT00934375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085204|NCT05468320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085205|NCT03470922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993337|NCT06742398|RANDOMIZED|CROSSOVER||OTHER||NONE||For the three testing visits (V2-V4), subjects will perform a 12.8 km running TT on a motorized treadmill, with the only difference between visits being the form of treatment. Either a carbohydrate MR solution (called CMR), water MR solution as a control (called WMR), or carbohydrate DS (called DS) will be administered at each visit in a randomized order. Study visits will be separated by at least 5 days, and all visits will take place in the Human Nutrition Lab (HNL) at the University of Georgia in Athens.||||
33690173|NCT06336161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690174|NCT03320603|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33993338|NCT03030664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993339|NCT00178607|||CASE_ONLY||PROSPECTIVE|||||||
33993340|NCT06742866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993341|NCT06446479|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33993342|NCT06559904|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||First, the intervention group was created in the study and the study was completed, then the control group was studied. 5 interviews were conducted with the women in the intervention group and the average time between the first and last interviews was 15.03±1.59 weeks. 2 interviews were conducted with the women included in the control group and the time between these interviews was 1.41±0.53 weeks.||||
33993343|NCT06489262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993344|NCT06741982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993345|NCT04884841|||COHORT||OTHER|||||||
33993346|NCT00001184|||COHORT||PROSPECTIVE|||||||
33993347|NCT04878263|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33993348|NCT06564311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Care Providers, Investigator, Outcomes Assessor|This is a Phase 2, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of obexelimab in patients with RMS. The study consists of a Screening Period (Day 28 to Day -1), followed by a 24-week Treatment Period (Part A or RCP consists of 12 doses of obexelimab or placebo; Part B or OLP consists of 12 doses of open-label obexelimab), and an expected 12-week Follow-up Period.|t|t|t|t
33993349|NCT06026488|||COHORT||OTHER|||||||
33993350|NCT02475681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993351|NCT06741462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Intervention group: Participants in the intervention group were patients with proven care level who had been provided ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were gathered using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1). Control group: Participants in the control group were patients with proven care level who were not provided with ADELE for the duration of the study. The observation period per participant was 3 months on average. Data on the primary, secondary and exploratory endpoints were collected using questionnaires at study inclusion (t0) and an average of 3 months after randomization (t1).~In addition, after the end of the observation period (from t0 to t1), the participants in the control group were offered an extension of a further 3 months on average using ADELE (from t1 to t2)."|t|f|f|f
33993352|NCT01571700|||CASE_CONTROL||OTHER|||||||
33993353|NCT03776552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor was masked|Randomized controlled study|f|f|f|t
33993354|NCT06741566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993355|NCT06580054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993356|NCT06742736|||COHORT||RETROSPECTIVE|||||||
33993357|NCT06145282|NA|SEQUENTIAL||TREATMENT||NONE||||||
33993358|NCT06619483|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blind||t|f|f|f
33993359|NCT02243852|||CASE_CONTROL||PROSPECTIVE|||||||
33993360|NCT04198207|||COHORT||PROSPECTIVE|||||||
33993361|NCT03914300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993362|NCT06737367|||COHORT||RETROSPECTIVE|||||||
33993363|NCT01689077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993364|NCT06741501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33993365|NCT01126762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33993366|NCT05226533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993367|NCT02157051|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993368|NCT06741592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993369|NCT03307577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study, which means that neither the patient nor the investigator will know which cream the patient is using.||t|t|t|t
33993370|NCT06670053|||COHORT||PROSPECTIVE|||||||
33993371|NCT02224781|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993372|NCT06703333|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085206|NCT03891225|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study||||
33690175|NCT01960387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690176|NCT01727908|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33690177|NCT01099800|||FAMILY_BASED||PROSPECTIVE|||||||
33690178|NCT00129818|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33690179|NCT04099251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690180|NCT06156540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33690181|NCT02845830|||CASE_CONTROL||PROSPECTIVE|||||||
33690182|NCT00320164|||CASE_CONTROL||PROSPECTIVE|||||||
33993373|NCT06729632|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Aim 1 studies will use a crossover study design. Aim 2 studies will use a parallel model.|t|f|f|t
33993374|NCT01438203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993375|NCT06742931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical outcome assessment will be performed under blinded assessment about the allocated treatment group.|A prospective, multi-center, open-label, randomized controlled, and superiority trial.|f|f|t|t
33993376|NCT04440436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993377|NCT06743373|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33993378|NCT04484012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993379|NCT05387954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The clinical event adjudication committee will blind to the treatment allocated by randomization.|PFO closure + antiplatelet therapy versus antiplatelet therapy alone Oral anticoagulants versus antiplatelet therapy|f|f|f|t
33993380|NCT00172822|||NATURAL_HISTORY||PROSPECTIVE|||||||
33993381|NCT05355545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study uses a parallel group delayed intervention design. In the first half of the study (Weeks 0 to 12), the intervention arm will receive the virtually supervised exercise intervention, while the active comparator arm will receive the health education program. In the second half of the study (Weeks 13 to 24), the intervention arm will continue the virtually supervised exercise intervention, while the active comparator group will start the virtually supervised exercise intervention. The primary timepoint of interest will be at 12 weeks.|f|f|f|t
33690183|NCT04041739|||COHORT||PROSPECTIVE|||||||
33778867|NCT01433653|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33778868|NCT02796443|||COHORT||RETROSPECTIVE|||||||
33778869|NCT02309528|NA|SINGLE_GROUP||||NONE||||||
33690184|NCT04092569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"All patients who are 'newly referred for advanced diabetes management' from general practitioners or general out-patient clinic to specialist out-patient clinic of Alice Ho Miu Ling Nethersole Hospital from 1/8/2019 to 31/12/2019 will be recruited.~After signing written informed consent on day of diabetes complication screening, they will be randomized into CG (n=10 for pilot study; n=60 for main study) or IG (n=10 for pilot study; n=60 for main study) groups, using sealed envelope, opened by an independent staff, containing randomly generated computer codes for group assignment. All patients will undergo diabetes complication screening including examination of eye and feet, collection of blood and urine samples and filling in DM questionnaires at baseline, and HbA1c with diabetes self-care questionnaires at 24 weeks (for IG only) and 36 weeks."||||
33690185|NCT05333783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690186|NCT02906969|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33690187|NCT01058265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690188|NCT04488107|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This study plans to start dose escalating from 50 mg, followed by 100, 200, 300, 450, and 600 mg as tentatively designated escalating dose groups. After the initial dose group, it is allowed to adjust the subsequent dose level according to the test data, but it will not exceed 100% dose increment. After the completion of DLT observation in each group, the next dose group and the number of cases were determined according to the safety, efficacy and PK data of the dose group. The traditional 3+3 method was used in the design of dose escalating stage, and the improved Fibonacci series was used for the dose increasing stage."||||
33690189|NCT01400685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778870|NCT00003650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778871|NCT04346303|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33778872|NCT00930189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33778873|NCT01521143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778874|NCT06450535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This trial is considered a randomized single blind clinical trial due to the following:~* The participants will be blinded to the technique that will be used during the surgical procedure.~* The operator will not be blinded for both techniques during the surgical procedure as the two techniques are different.~* The outcome assessor cannot be blinded. C) Data collection, management, and analysis:"|"Randomzed cinical trial~A trial will be caried out in hosptal of Oral and Maxllolacial surgery department- Faculy of Oral and Dental Medicine Cairo Univerity.~Equal randomizaion: participants wih equal probabilites for intervenion~Postive controlled :Both groups receiving treatment~Parallel group study: Each group of patients receives a single treatment simutaneously"|t|f|f|f
33778875|NCT02460744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778876|NCT04055480|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blinded||t|t|t|t
33778877|NCT06697795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911975|NCT00024076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33911976|NCT00087737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33911977|NCT00511524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33911978|NCT02528097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911979|NCT04442958|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33911980|NCT02638805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33911981|NCT02982304|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33911982|NCT01912430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33911983|NCT02405234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33911984|NCT02871180|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33911985|NCT05740293|||COHORT||PROSPECTIVE|||||||
33911986|NCT03455309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Sponsor, principal investigator and study site are all blinded but can access key if safety issues require unblinding|double-blind, placebo-controlled, randomized study|t|t|t|t
33911987|NCT05836532|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993382|NCT06626841|||COHORT||PROSPECTIVE|||||||
33911988|NCT02430662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33911989|NCT01216592|||COHORT||PROSPECTIVE|||||||
33911990|NCT04654000|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33911991|NCT03221322|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33911992|NCT01249183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911993|NCT03969797|||COHORT||PROSPECTIVE|||||||
33911994|NCT04523441|||COHORT||PROSPECTIVE|||||||
33911995|NCT02775552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33911996|NCT03860545|||COHORT||PROSPECTIVE|||||||
33911997|NCT05929144|NA|SINGLE_GROUP||OTHER||NONE||||||
33911998|NCT03978819|||COHORT||PROSPECTIVE|||||||
33911999|NCT01341652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912000|NCT03703830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912001|NCT04889534|||COHORT||PROSPECTIVE|||||||
33912002|NCT01141634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912003|NCT05948657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.||||
33912004|NCT01318473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912005|NCT01520415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912006|NCT04591470|||COHORT||RETROSPECTIVE|||||||
33912007|NCT03437538|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912008|NCT00810719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912009|NCT00695591|||CASE_ONLY||PROSPECTIVE|||||||
33912010|NCT00575952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912011|NCT04081883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912012|NCT03292679|||COHORT||PROSPECTIVE|||||||
33912013|NCT03491553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912014|NCT05728970|||CASE_ONLY||PROSPECTIVE|||||||
33912015|NCT04705558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double|"two intervention:combination of continuous aerobic exercise in form of treadmill 5 sessions per week and ketogenic diet.~ketogenic diet alone."|t|f|t|f
33912016|NCT05523063|||COHORT||PROSPECTIVE|||||||
33912017|NCT04344405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912018|NCT02734719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912019|NCT05226819|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778878|NCT02714985|||COHORT||PROSPECTIVE|||||||
33912020|NCT02546674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912021|NCT00422838|||COHORT||PROSPECTIVE|||||||
33912022|NCT02342821|||OTHER||CROSS_SECTIONAL|||||||
33912023|NCT03702530|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participant, clinical trial physicians and laboratory personnel are blinded for treatment allocation. Blinding is maintained by exposing the volunteers in the placebo group to a mock infection with water. During the trial clinical trial physicians are blinded to the outcome measures (i.e. Kato-Katz outcomes), laboratory staff are blinded for the study code of samples delivered.|Volunteers are randomized into either the intervention or the placebo group (2:1 allocation). The two groups run parallel in the trial. At the moments of immunization in the intervention group volunteers in the placebo group receive a mock infection with water to maintain blinding.|t|f|t|t
33778879|NCT01311089|||||PROSPECTIVE|||||||
33912024|NCT00986492|||||PROSPECTIVE|||||||
33912025|NCT01912937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912026|NCT06347276|||COHORT||PROSPECTIVE|||||||
33912027|NCT02432248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912028|NCT04848337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912029|NCT00798213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912030|NCT04836455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912031|NCT00256048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912032|NCT00964548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912033|NCT06004349|||COHORT||PROSPECTIVE|||||||
33912034|NCT05459389|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly allocated to antibiotic regimen guided by conventional culture technique (n=24) or targeted antibiotics therapy guided by resistance genotyping (n=24)||||
33993383|NCT05429476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33993384|NCT05742217|||OTHER||OTHER|||||||
33993385|NCT04527315|||CASE_CONTROL||PROSPECTIVE|||||||
33993386|NCT06609889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778880|NCT04752540|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33778881|NCT06229886|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33778882|NCT06285526|||CASE_CONTROL||PROSPECTIVE|||||||
33778883|NCT02373293|||COHORT||PROSPECTIVE|||||||
33778884|NCT06407479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778885|NCT05883319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33778886|NCT06697964|||CASE_ONLY||PROSPECTIVE|||||||
33778887|NCT06477354|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label, post-marketing surveillance||||
34085207|NCT00481663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085208|NCT04866576|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participants, study personnel and the data analysts will not be aware of which powder is the active powder and which one is the placebo. Only Principle Investigator will be made aware.|This is a free-living prospective, randomized, double-blind, parallel study design with 31 subjects in free-living conditions. subjects will be randomized to receive either Q CAN powder or placebo powder for 12 weeks.|t|t|f|t
34085209|NCT01660035|||COHORT||PROSPECTIVE|||||||
34085210|NCT06115460|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085211|NCT02262117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085212|NCT03183817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085213|NCT04694469|||COHORT||PROSPECTIVE|||||||
33690190|NCT05122676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Usual care arm participants are not informed of the study; their secondary data are used for study analyses. Investigators are masked to all individuals in usual care arm and to the safety monitoring reports shared with the Data and Safety Monitoring Board (DSMB); study arms are masked in safety monitoring reports provided to the Data Safety and Monitoring Board unless the DSMB requests that they be unmasked; and statistical analysts conducting main outcomes are blinded to arm by masking and omission of any data in main analytic datasets that would indicate intervention arm (e.g., any measures related to nurse care managers).||f|f|t|t
33690191|NCT02433327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912035|NCT03226080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigators, surgeons, intraoperative anesthesiology providers, and patients will be blinded.|84 patient under GA with spinal anesthesia will be block randomized to either neuromuscular blockade or placebo. Randomization will be tracked by the research pharmacist at Loyola University|t|f|t|t
33690192|NCT02380820|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33690193|NCT00281073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690194|NCT04633460|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Overview: The overall study design will be a randomized, double-blind crossover comparison of ketone ester (KE) therapy vs. KE-free vehicle in 20 patients with established HF with preserved ejection fraction (HFpEF). The main outcomes will be measures of exercise performance (peak and submaximal exercise).|t|f|t|t
33690195|NCT04022343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690196|NCT04336644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690197|NCT02641483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690198|NCT01732003|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33690199|NCT00775385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690200|NCT02435069|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33690201|NCT05805202|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33912036|NCT03017924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912037|NCT01457287|||CASE_CONTROL||PROSPECTIVE|||||||
33912038|NCT01993511|||COHORT||PROSPECTIVE|||||||
33912039|NCT00334932||||TREATMENT||||||||
33912040|NCT03685799|||COHORT||RETROSPECTIVE|||||||
33912041|NCT05263440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912042|NCT01150955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33912043|NCT00314756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912044|NCT06376214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912045|NCT01862510|||COHORT||PROSPECTIVE|||||||
33912046|NCT02278289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912047|NCT00256867|RANDOMIZED|PARALLEL||TREATMENT||||||||
33912048|NCT02665234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912049|NCT05864443|||COHORT||RETROSPECTIVE|||||||
34085214|NCT05291507|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single arm, single center, non-randomized feasibility study of the Muse MRgFUS System in subjects with breast cancer.||||
34085215|NCT05354297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085216|NCT03261193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085217|NCT04896463|||OTHER||PROSPECTIVE|||||||
34085218|NCT02410629|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34085219|NCT05763225|||COHORT||PROSPECTIVE|||||||
34085220|NCT00944554|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34085221|NCT03966066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085222|NCT00764114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690202|NCT05373940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Three experts in cardiac electrophysiology and ICD will be in charge of uniformly approving, while blinded to the study group, ICD tracings, cardiovascular events, including specific causes of death, in order to validate the primary and secondary endpoints.|This is a 2-arm parallel non-inferiority, randomized, open label, multicenter trial.|f|f|f|t
33690203|NCT03258177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33690204|NCT01916967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33690205|NCT03764488|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33690206|NCT04914507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690207|NCT03889171|||CASE_ONLY||PROSPECTIVE|||||||
33690208|NCT04260490|||CASE_CONTROL||PROSPECTIVE|||||||
33690209|NCT03858231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690210|NCT05143190|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|Phase 2 open-label||||
33690211|NCT03671993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690212|NCT04461249|||CASE_ONLY||PROSPECTIVE|||||||
33690213|NCT02793466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690214|NCT03277521|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33690215|NCT02622750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690216|NCT04533958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690217|NCT02843308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33690218|NCT06476964|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33690219|NCT00605527|||COHORT||PROSPECTIVE|||||||
33690220|NCT01834482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778888|NCT05799053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Peppermint oil capsules and placebo are double blinded, peppermint sweets are open-label|Patients are randomized in three groups: 1) peppermint oil capsules, 2) placebo), peppermint sweets|t|t|t|t
33778889|NCT04078100|||COHORT||RETROSPECTIVE|||||||
33778890|NCT03703206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a prospective, randomized, blinded study with a parallel design and an allocation ratio of 1 to 1 for the treatment groups|t|t|f|t
33778891|NCT05084300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778892|NCT04890132|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33778893|NCT00030875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778894|NCT02554513|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single|Each participant received each arm of treatment|f|f|f|t
33778895|NCT06004063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33778896|NCT02221479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778897|NCT03337347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778898|NCT04100954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778899|NCT00877851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778900|NCT04121273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778901|NCT02128503|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912050|NCT02746393|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33912051|NCT04213287|RANDOMIZED|PARALLEL||TREATMENT||NONE||Power analysis will be done after a pilot study. Number of patient may vary.||||
33912052|NCT04282226|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and outcomes assessors will be masked.|Randomised, cross-over design with placebo control|t|f|f|t
33912053|NCT05453513|||COHORT||PROSPECTIVE|||||||
33912054|NCT02514460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912055|NCT04648423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The control medication (placebo) was identically-looking and identically tasting as active.|double-blind, placebo-controlled study with parallel group|t|t|t|t
33912056|NCT01512641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912057|NCT03834571|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will receive standard chemotherapy and radiation for the first 8 weeks of the trial. Four (4) to 8 weeks after finishing standard therapy, participants meeting eligibility criteria for randomization will be assigned to 1 of 2 arms. Arm 1 will receive up to 4 cycles of adjuvant IV chemotherapy (carboplatin and paclitaxel, 21-day cycle length), and arm 2 will undergo active monitoring for cancer recurrence or progression. All participants will be monitored every 3 months for recurrence or progression through 2 years after study enrollment.||||
33912058|NCT02408796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912059|NCT01375504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993387|NCT01908556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993388|NCT06737887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33993389|NCT06741618|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33993390|NCT06641310|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993391|NCT05605535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993392|NCT04939038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690221|NCT00823342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690222|NCT04586361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690223|NCT02878824|||OTHER||CROSS_SECTIONAL|||||||
33690224|NCT01637987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690225|NCT00398333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690226|NCT05838235|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690227|NCT05616806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993393|NCT06529744|||CASE_ONLY||PROSPECTIVE|||||||
33690228|NCT03977909|||COHORT||PROSPECTIVE|||||||
33690229|NCT06446102|||COHORT||RETROSPECTIVE|||||||
33690230|NCT02233062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993394|NCT06128629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized in a 2:1 ratio to NTLA-2001 or placebo|t|t|t|t
33993395|NCT03089983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33993396|NCT02977403|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Assignment to intervention or control made by a person who has no contact with study subjects to place the appropriate program on the phone used by the subject. Blind was maintained until all subjects had completed all assessments for the randomized phase.|Overweight youth with loss of control over eating randomized to intervention or control groups Overweight youth without loss of control over eating randomized to intervention or control groups|t|t|t|t
33993397|NCT05373173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993398|NCT04196907|NA|SINGLE_GROUP||OTHER||NONE||||||
33993399|NCT06731023|||OTHER||PROSPECTIVE|||||||
33993400|NCT06742437|||COHORT||PROSPECTIVE|||||||
33993401|NCT06743243|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33993402|NCT04373096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research coordinator documenting all outcome data will be blinded to the group allocation.||f|f|f|t
33993403|NCT03059979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690231|NCT05320302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690232|NCT00318227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690233|NCT01023451|||COHORT||CROSS_SECTIONAL|||||||
33690234|NCT05334511|NA|SINGLE_GROUP||OTHER||NONE||||||
33912060|NCT01496430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912061|NCT01432652|||COHORT||PROSPECTIVE|||||||
33912062|NCT02896907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912063|NCT04671914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant will not be informed about usage of hyalobarier gel or not. Care provider - at the time of RCUI the surgeon will know from randomisation if apply the gel or not. The investigator performing evaluation of adhesions by hysteroscopy will be blinded to the arm which the participants belong to.|Multicenter prospective controlled study|t|f|t|f
33912064|NCT05277870|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|single|crossover assignment|f|f|t|f
33912065|NCT01627067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912066|NCT06064786|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690235|NCT01606254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690236|NCT01912963|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Of note, this is not a parallel assignment rather one Phase I arm and two Phase II arms all independently evaluated.||||
33690237|NCT01543373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690238|NCT05768958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690239|NCT01278303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690240|NCT01479985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33690241|NCT06688851|||COHORT||PROSPECTIVE|||||||
33690242|NCT04365062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690243|NCT05183893|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33690244|NCT05075057|NA|SINGLE_GROUP||PREVENTION||NONE||subjects aged ≥60 with chronic bronchitis and COPD receive three doses of inactivated COVID-19 vaccine||||
33690245|NCT02568982|||COHORT||PROSPECTIVE|||||||
33690246|NCT04595240|||OTHER||PROSPECTIVE|||||||
33690247|NCT04631302|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Outcomes assessor will be blind to participant allocation||f|f|f|t
33690248|NCT00234910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912067|NCT02191709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912068|NCT01438567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912069|NCT04088851|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912070|NCT03297099|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912071|NCT02297334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912072|NCT01928108|||COHORT||PROSPECTIVE|||||||
33993404|NCT05432557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993405|NCT06203951|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993406|NCT06741917|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33993407|NCT06419205|NA|SINGLE_GROUP||OTHER||NONE||||||
33993408|NCT04901169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identically-labeled infusion bags of either angiotensin II or saline placebo will be prepared by a research pharmacist.|Randomized, double-blind, placebo-controlled.|t|t|t|t
33993409|NCT03988595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Exercise therapy will consist of individualized walking delivered 3 to 5 times weekly for 24 weeks. This trial will evaluate four escalated doses of exercise (90 mins/wk, 150 mins/wk, 225 mins/wk, 300 mins/week, or 375 mins/week).||||
33993410|NCT06480552|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34085223|NCT00266318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085224|NCT01299584|||COHORT||PROSPECTIVE|||||||
33690249|NCT01435317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690250|NCT00072176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690251|NCT04910282|||COHORT||CROSS_SECTIONAL|||||||
33690252|NCT02477267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33690253|NCT04348890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690254|NCT03668366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690255|NCT04744038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993411|NCT05238740|RANDOMIZED|PARALLEL||OTHER||SINGLE|The CT Reviewer and data analysts, will be blinded as to which bone graft treatment the patient received. Blinding is ensured by coding the electronic case report forms (eCRFs)/ database and images.|The study is a prospective randomized assessor blind monocentric trial. It aims for non-inferiority.|f|f|f|t
33993412|NCT06581939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993413|NCT04992390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993414|NCT05873699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690256|NCT05242523|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33690257|NCT00636883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690258|NCT03795610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690259|NCT01565837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690260|NCT02034071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690261|NCT02747173|||COHORT||PROSPECTIVE|||||||
33690262|NCT02597634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690263|NCT06638268|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open label trial||||
33690264|NCT04414514|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33778902|NCT04729140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Data analysis will be carried out using statistical package for the social sciences software (SPSS). Interim data analysis will be performed at three different levels of the number of participants starting at sample size 20, 30 and 50. If no significant findings are obtained from the data at N=50, then it will add more participants to the study to achieve statistical significance. Sponsor and Principal Investigator will defer data analysis to a statistician. A Data Monitoring Committee (DMC) is going to be established in order to review accumulating trial data by treatment group in order to monitor patient safety and efficacy, ensure validity and integrity of the trial and make benefit-risk assessment. This is going to be conducted by a third party external DMC.|Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.|t|t|t|f
33690265|NCT01272284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690266|NCT06248411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778903|NCT06297564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778904|NCT02244593|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778905|NCT02062190|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778906|NCT03259347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778907|NCT06306430|||COHORT||PROSPECTIVE|||||||
33778908|NCT06235164|||COHORT||RETROSPECTIVE|||||||
33778909|NCT02362633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778910|NCT06148259|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778911|NCT03902340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778912|NCT01808443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778913|NCT03975803|||COHORT||PROSPECTIVE|||||||
33778914|NCT04784273|||COHORT||PROSPECTIVE|||||||
33778915|NCT06484764|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33778916|NCT04018443|||OTHER||PROSPECTIVE|||||||
33778917|NCT02509884|||||RETROSPECTIVE|||||||
33778918|NCT03443596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation of the BP control arm was not disclosed to the study participants|Randomized controlled study|t|f|f|f
33778919|NCT03005288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778920|NCT01219504|||||PROSPECTIVE|||||||
33778921|NCT02569229|||COHORT||PROSPECTIVE|||||||
33778922|NCT01164163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778923|NCT02461511|||COHORT||PROSPECTIVE|||||||
33778924|NCT00372567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778925|NCT05051098|||COHORT||PROSPECTIVE|||||||
33778926|NCT01397487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778927|NCT02687919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993415|NCT06092671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993416|NCT05238857|||CASE_ONLY||CROSS_SECTIONAL|||||||
33690267|NCT05671328|||COHORT||PROSPECTIVE|||||||
34085225|NCT00880841|||OTHER||PROSPECTIVE|||||||
33690268|NCT00010127||||TREATMENT||||||||
33690269|NCT01144871|||COHORT||CROSS_SECTIONAL|||||||
33690270|NCT04005170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690271|NCT03609151|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33690272|NCT02890290|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33778928|NCT01537653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778929|NCT02303743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33778930|NCT00670982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778931|NCT02706626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778932|NCT02729792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33690273|NCT04849325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690274|NCT03968705|||COHORT||PROSPECTIVE|||||||
34085226|NCT03797352|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34085227|NCT03695081|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"An intervention group is compared to a cross-sectional retrospective group.~A group of 60 patients with hip fracture will get an intervention by a clinical pharmacist who performs medication reconciliation and medication review during hospitalisation, they will receive a discharge summary where the medication part is optimised. After six weeks the patients will be get a follow-up with a second medication reconciliation and - review. This group will be compared with the last 50 patients with hip fracture who did not get the intervention."||||
33778933|NCT04049721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085228|NCT00972751|||COHORT||RETROSPECTIVE|||||||
34085229|NCT04210934|||COHORT||CROSS_SECTIONAL|||||||
34085230|NCT02117518|||COHORT||PROSPECTIVE|||||||
33690275|NCT02374086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690276|NCT05807633|||COHORT||RETROSPECTIVE|||||||
33778934|NCT00619476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085231|NCT00112749|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085232|NCT00128128|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690277|NCT02942420|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The study is unmasked, i.e., is open label.|Dosing will occur sequentially from low to high dose: The 600 mg bucillamine dose group (Arm A) will enroll first, then after safety is assured, the 900 mg bucillamine dose group will enroll.||||
33778935|NCT01795352|||||RETROSPECTIVE|||||||
34085233|NCT02033512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690278|NCT04061382|||OTHER||PROSPECTIVE|||||||
33778936|NCT02178462|||CASE_CONTROL||PROSPECTIVE|||||||
33778937|NCT05124899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes (erythema) assessor is blinded to treatment allocation||f|f|f|t
33778938|NCT04824443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778939|NCT04884698|NA|SINGLE_GROUP||OTHER||NONE||Open-label, sponsor-initiated feasibility study. 2 groups of patients treated - healthy subjects and elective surgery patient||||
33778940|NCT05349318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Eligible candidates will be randomized with equal probability to the HBOT and sham interventions. Randomization will be performed using a computer software based on patients' code.~Since the HBOT chamber can hold six subjects, the randomization will be done in clusters of six patients. After randomization, when a cluster of six subjects from one of the arms will be filled, the intervention for that cluster will begin.~Three study technicians will be the only unblinded staff who have the key for the group assignment of each subject. They will exclusively activate the HBOT/sham protocol during session times. All subjects and other clinic staff will remain blinded to the group assignments."|Upon consent and evaluation, eligible participants will be randomized with equal probability into one of two arms: HBOT or SHAM. The evaluation procedure will be performed at baseline, after the treatment and after a maintenance period.|t|t|t|t
33778941|NCT05414565|||CASE_CONTROL||PROSPECTIVE|||||||
33778942|NCT00482105|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778943|NCT04560907|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, non-inferiority clinical trial||||
33778944|NCT04821999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients with SARS-CoV2 infection confirmed with PCR with loss of taste sensation|t|f|f|t
34085234|NCT02653820|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690279|NCT00558779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33778945|NCT03122964|||CASE_ONLY||PROSPECTIVE|||||||
33778946|NCT05399888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778947|NCT00696293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778948|NCT04547803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33778949|NCT05202236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778950|NCT06051760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778951|NCT02955433|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33778952|NCT03569917|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33912073|NCT01996904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912074|NCT03364426|||OTHER||CROSS_SECTIONAL|||||||
33912075|NCT00675558|||CASE_CONTROL||PROSPECTIVE|||||||
33690280|NCT02822391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690281|NCT04063098|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690282|NCT04689815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690283|NCT02065115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690284|NCT04653532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690285|NCT00560378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690286|NCT04223648|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690287|NCT02829983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690288|NCT04307732|||OTHER||RETROSPECTIVE|||||||
33690289|NCT03945292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690290|NCT04481464|||COHORT||RETROSPECTIVE|||||||
33690291|NCT01043328|||CASE_CONTROL||RETROSPECTIVE|||||||
33690292|NCT03024437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778953|NCT04975789|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33778954|NCT03297775|||COHORT||PROSPECTIVE|||||||
33778955|NCT01992419|||||PROSPECTIVE|||||||
33778956|NCT03752736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33778957|NCT01427387|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33778958|NCT02496988|NON_RANDOMIZED|PARALLEL||||NONE||||||
33778959|NCT04884984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085235|NCT01781897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085236|NCT00322322|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34085237|NCT01277029|||COHORT||PROSPECTIVE|||||||
34085238|NCT05971589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690293|NCT03294473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33912076|NCT04202562|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group received combined surgery, while the other cataract surgery alone||||
33912077|NCT03623139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912078|NCT05051865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912079|NCT06552611|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a prospective, open-label, two-intervention arm cross-over clinical trial of transcutaneous spinal cord stimulation combined with therapy compared to therapy alone in four adults with MS and upper extremity impairment.|f|f|f|t
33912080|NCT05607940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33912081|NCT01361009|||CASE_ONLY||CROSS_SECTIONAL|||||||
33912082|NCT03724630|||COHORT||PROSPECTIVE|||||||
33912083|NCT02421497|||COHORT||PROSPECTIVE|||||||
33912084|NCT05867316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912085|NCT00426335|||||PROSPECTIVE|||||||
33993417|NCT06562452|RANDOMIZED|PARALLEL||OTHER||NONE||This study was a split-mouth randomized clinical trial was conducted on 31 patients (9 male, 22 females age ranging 14-31 years) who were treated for Class I malocclusion with the extraction of the maxillary first premolar. After the leveling and alignment phase, the canines were retracted with 150gm forces. The i-PRF was prepared from the blood of each patient then injected immediately before canine retraction on the buccal and palatal aspects of the extraction sites. Digital model were obtained at five time points: before tooth extraction (T0) and in the fourth week (T1), eighth week (T2), twelfth week (T3), sixteenth week (T4) from the beginning of distalization.||||
33912086|NCT00109187||||TREATMENT||NONE||||||
33912087|NCT01597427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912088|NCT02270892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993418|NCT01410227|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993419|NCT03848377|||COHORT||PROSPECTIVE|||||||
33912089|NCT03010995|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|All the outcome measurements will be performed by staff that will be blinded to the participant and their exposure.||f|f|f|t
33912090|NCT06288672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The true or sham avoidance diet for each participant is randomly assigned by the study administrator. Assignments will not be made available to participants until after their study completion or to investigators until all 250 participants have completed the study and the results have been analyzed.|Participants with IBS are patch tested to 80 type 4 food allergens. Those with questionable or positive patch test reactions are randomized to follow a patch test-directed avoidance diet or a sham diet (avoidance of foods to which the patch tests showed no reaction) for 16 weeks. Upon conclusion of the avoidance diet, participants complete a brief questionnaire to assess their response to the avoidance diet.|t|t|t|t
33912091|NCT01263691|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33912092|NCT03005977|NA|SINGLE_GROUP||SCREENING||NONE||||||
33912093|NCT02742272|||COHORT||PROSPECTIVE|||||||
33912094|NCT05422352|RANDOMIZED|PARALLEL||PREVENTION||NONE|intervention clinical trial|intervention study clinical trial||||
33912095|NCT06241755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778960|NCT03356067|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized sham-procedure controlled trial with crossover after 6 months after procedure|t|f|f|t
33778961|NCT03650738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912096|NCT02413125|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912097|NCT01660087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912098|NCT03664193|NA|SINGLE_GROUP||TREATMENT||NONE||Male patients with a histologically confirmed diagnosis of non-metastatic prostate adenocarcinoma, meeting the inclusion and exclusion criteria below, and electing to undergo definitive radiation treatment with SBRT, will be eligible for participation in this study. Patients will receive 35 Gy in five fractions, also, patients will receive a simultaneous integrated boost from 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy. Gastrointestinal/genitourinary toxicities will be assessed at every visit, including quality of life questionnaires and EPIC scores will be assessed at the one month follow up visits.||||
33912099|NCT01202708||CROSSOVER||TREATMENT||NONE||||||
33778962|NCT06479993|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33778963|NCT03147092|NA|SINGLE_GROUP||TREATMENT||NONE||A single group of hypertensive individuals will be submitted to same treatment.||||
33778964|NCT02658292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778965|NCT00005594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778966|NCT00968838|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33778967|NCT03638856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33778968|NCT02708641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778969|NCT00709891|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
33778970|NCT01237678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33778971|NCT01025661|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33778972|NCT04560582|||COHORT||PROSPECTIVE|||||||
33778973|NCT01617083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778974|NCT05387005|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33778975|NCT05733923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33778976|NCT04159896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33778977|NCT05498974|||OTHER||OTHER|||||||
33778978|NCT04037111|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33778979|NCT06283602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33778980|NCT01877603|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33778981|NCT02117336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778982|NCT01285219|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33778983|NCT02681822|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33778984|NCT06197880|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm clinical trial||||
33778985|NCT02479867|RANDOMIZED|CROSSOVER||||NONE||||||
33778986|NCT03229889|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Both patients and treating surgeons (who are also on the study team) will be blinded. None physician researchers will be unblinded to tract and randomize patients.|Patients will be randomized into 1 of 4 groups: Flomax + Placebo, Cialis + Placebo, Cialis + Flomax, Placebo + Placebo.|t|t|t|f
33778987|NCT03369288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective PET-MRI follow-up||||
33778988|NCT03708380|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33778989|NCT03410485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33778990|NCT06089876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912100|NCT04609345|||CASE_ONLY||CROSS_SECTIONAL|||||||
33912101|NCT00764400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33912102|NCT01472172|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912103|NCT06179550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers respectively responsible for intervention, assessment, and data collection maintained an isolated status from the patients enrolled beyond the necessary contact, strictly adhering to the principle of not disclosing group information. Furthermore, the trained professionals who were not involved in the intervention were selected to conduct all assessments, data collection, and analysis to ensure the objectivity and independence of result evaluation. All medical personnel involved in interventions received detailed training to ensure their understanding and proper implementation of the interventions.||f|f|t|t
33912104|NCT02375633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912105|NCT05803720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be blind to the study condition assignment.||f|f|f|t
33690294|NCT02800954|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33690295|NCT00079534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690296|NCT04965558|||COHORT||RETROSPECTIVE|||||||
33690297|NCT06386731|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a single-center, with block randomisation \[1:1\], open-label, parallel group study.||||
33690298|NCT03949907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690299|NCT06706726|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690300|NCT04926298|||COHORT||RETROSPECTIVE|||||||
33778991|NCT00333515|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33778992|NCT04550754|||COHORT||RETROSPECTIVE|||||||
33778993|NCT01345461|||COHORT||PROSPECTIVE|||||||
33993420|NCT01036971|||OTHER||PROSPECTIVE|||||||
33993421|NCT05402358|||CASE_ONLY||PROSPECTIVE|||||||
33993422|NCT05942469|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993423|NCT00835263|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993424|NCT00115063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993425|NCT02421822|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993426|NCT00955448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993427|NCT00518258|||CASE_CONTROL||PROSPECTIVE|||||||
33993428|NCT03933592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993429|NCT05921188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The children in the study and their caregivers will not be told which treatment group their child is in.|The investigators will use treatment effect sizes to compare children to themselves (treatment v. control) and across groups (More Familiar Sounds v. Less Familiar Sounds).|t|t|f|f
33993430|NCT05387408|NA|SINGLE_GROUP||OTHER||NONE||||||
33993431|NCT00294047|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993432|NCT06120803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993433|NCT04150133|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigator will be ignorant of how preparation was taken|single blind trial of FDA approved preparation with per labeling clear liquid diet versus a single day low residue diet|f|f|t|f
33993434|NCT00953823|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993435|NCT05402137|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33993436|NCT06689098|||CASE_CONTROL||PROSPECTIVE|||||||
33993437|NCT03246763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will conduct a mixed-methods study using focus groups and interviews to explore the facilitators and barriers to program implementation, and a time-series analysis to examine program engagement and individual health outcomes. This study design will be repeated at each of the four sites. Aim 1 will consent and enroll program providers to obtain qualitative feedback on program design and implementation; Aim 2 will collect de-identified program-level data on attendance and program components; Aim 3 will consent patients for individual-level baseline and outcomes data.Subjects will be enrolled at our community sites. A research assistant will conduct all the enrollment, consent, and data collection. Where needed, the investigators will report or obtain required IRB authorization agreements for each site, including Federal Wide Assurances, Data Transfer Agreements, or other documents as required by federal regulation.||||
33993438|NCT05911308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993439|NCT04118335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993440|NCT03629054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993441|NCT01619904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993442|NCT04479527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993443|NCT04803487|RANDOMIZED|PARALLEL||OTHER||SINGLE|single-blind|random controlled trial|t|f|f|f
33993444|NCT05065281|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized stepped wedge cluster trial (incomplete design)||||
33993445|NCT02744287|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993446|NCT06733675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993447|NCT02415127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993448|NCT05432817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are assigned to one of two therapy-intervention groups: CPT or active waitlit control group|t|f|t|t
33993449|NCT06742177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993450|NCT01783366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993451|NCT05947084|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Study infant formulas have been blinded|Randomization and exclusive feeding of study formulas by 14 days of age. Breastfed Cohort will be evaluated over the 16 weeks.|t|t|t|t
33993452|NCT06743386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085239|NCT05816941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Test and Control group. All patients received oral hygiene instructions followed by complete oral disinfection (removal of hard and soft deposits, scaling and root planing, mouth rinse with 0.2% chlorhexidine twice in one minute, pocket rinse with 0.2% chlorhexidine three times in ten minutes). Ultrasonic (Piezoled, KaVo) and hand instruments (Gracey curettes, Hu-Friedy, USA) were used for this purpose. Afterwards, the patients were randomly divided into test and control groups. The patients in the test group received aPDT as adjuvant treatment in pockets with PPD ≥ 5 mm.|f|f|f|t
34085240|NCT01014234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085241|NCT01356420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690301|NCT00446589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33778994|NCT01719640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912106|NCT05764356|||COHORT||PROSPECTIVE|||||||
33912107|NCT01924546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912108|NCT03047863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912109|NCT04507438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912110|NCT00305643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33912111|NCT01887249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912112|NCT04704999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor) This is a double-blind randomized superiority trial. The laboratory staff responsible for reading the malaria blood smear slides will be blinded to treatment allocation.||f|f|f|t
33912113|NCT01523808|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912114|NCT04592432|RANDOMIZED|CROSSOVER||OTHER||NONE|Due to the nature of the interventions evaluated, participants cannot be blinded to group allocation. Furthermore, since the primary investigator is a PhD candidate and that this is his doctoral project, he will also not be blinded to group allocation as he will be responsible for assigning participants to one of the two intervention sequences and provide technical support, if needed.|The quantitative component is a two-group randomized crossover trial with 1:1 group allocation. Each participant will be randomly allocated to one of the two intervention sequences (i.e., the serious game SIGN@L-A followed by the serious game SIGN@L-B or vice versa). The randomization sequence list will be generated by an individual independent to quantitative data collection using an online program (randomizer.org). The primary investigator will not have access to this list. This individual will inform the primary investigator of participants' allocation after they have consented to be randomized, their randomization order based on the exact time they have completed the online consent form. Block randomization will be used with block sizes of six to avoid imbalances in group sizes.||||
33912115|NCT03301766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912116|NCT06553534|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Adaptive Hybrid Stepped-wedge||||
33912117|NCT01151592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993453|NCT01050556|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993454|NCT06743269|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33993455|NCT06743087|||OTHER||PROSPECTIVE|||||||
34085242|NCT02308046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085243|NCT03130413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085244|NCT06283017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690302|NCT00346944|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34085245|NCT03874611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690303|NCT02896374|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33690304|NCT05751096|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|LIFU vs SHAM application study visit will appear identical to study participants.|Participants will act as their own control with a cross over study design. LIFU application vs Sham will be applied on separate study days for both pain cohorts (FM and CRPS).|t|f|f|f
34085246|NCT04186156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085247|NCT01384656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34085248|NCT00367926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34085249|NCT03143959|||CASE_ONLY||PROSPECTIVE|||||||
34085250|NCT00434486|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690305|NCT05844709|||COHORT||RETROSPECTIVE|||||||
33912118|NCT01687413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085251|NCT03228082|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Participants will be randomized at the end of the baseline visit to self-measurement of bloodpressure at home (intervention group) or usual care (control group).||||
34085252|NCT03359746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085253|NCT03847402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912119|NCT06072872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective interventional, with first period without use of study device, followed with second period using study device||||
33993456|NCT05963568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993457|NCT02294487|||CASE_CONTROL||PROSPECTIVE|||||||
33993458|NCT06510309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993459|NCT02156102|||CASE_ONLY||CROSS_SECTIONAL|||||||
34085254|NCT03882632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085255|NCT04744623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||10 patients suffering from MMP were selected after complete diagnosis based on their clinical diagnosis and immunopathologic findings of IgG, IgA, and/or C3 targeting skin basement membranes with a linear deposition pattern referred from dermatology department. These patient were treated using large dose of prednisone 60mg daily plus intrational injection of Triamcinolone Acetonide every week until no further improvement of the lesion occurred (stage I) then the prednisolone is withdrawn gradually and substituted with using 1 g of MMF plus 50 mg dapsone till the lowest dose of prednisone could be reached (stage II). The lesion size and pain score will be assessed before treatment and during treatment in stage I and stage II. These data will be tabulated and statistically analyzed||||
34085256|NCT03451071|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34085257|NCT06320392|||CASE_CONTROL||RETROSPECTIVE|||||||
34085258|NCT04556747|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085259|NCT00776256|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33690306|NCT00246779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690307|NCT00371007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690308|NCT01041729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33690309|NCT04544969|||CASE_ONLY||PROSPECTIVE|||||||
33690310|NCT06290973|||COHORT||PROSPECTIVE|||||||
33690311|NCT02009007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690312|NCT04777838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993460|NCT06559085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993461|NCT05879055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993462|NCT03489278|||COHORT||PROSPECTIVE|||||||
33993463|NCT03606408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993464|NCT06046820|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study INZ701-106 (ENERGY 3) is a multicenter, randomized in a 2:1 ratio, controlled, open-label Phase 3 study to evaluate the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.||||
33993465|NCT06742840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33778995|NCT03887104|||COHORT||PROSPECTIVE|||||||
33778996|NCT04628416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled multicentered trial with blinded evaluation of the primary outcome, comparing 2 management techniques applied on the skin graft done on the donor sites of fibula free flaps.|f|f|f|t
33778997|NCT03853590|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Eligible patients were consecutively recruited and treatment allocation was decided after clinical evaluation.||||
33912120|NCT05560815|||COHORT||RETROSPECTIVE|||||||
33912121|NCT00403559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33912122|NCT03982771|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single center, single arm, phase-II pilot study.||||
33912123|NCT04917744|||CASE_ONLY||PROSPECTIVE|||||||
33912124|NCT04804722|||COHORT||RETROSPECTIVE|||||||
33912125|NCT06442852|||CASE_CONTROL||PROSPECTIVE|||||||
33912126|NCT02795195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912127|NCT06514846|||OTHER||CROSS_SECTIONAL|||||||
33912128|NCT02410902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912129|NCT00688168|||CASE_ONLY||PROSPECTIVE|||||||
33993466|NCT02498600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993467|NCT06338085|RANDOMIZED|PARALLEL||TREATMENT||NONE||the groups with a conventional therapy control group||||
33993468|NCT06406621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization to intervention or control group||||
33912130|NCT02397993|||COHORT||PROSPECTIVE|||||||
33993469|NCT06738277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912131|NCT04229589|||COHORT||PROSPECTIVE|||||||
33912132|NCT03734081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912133|NCT00962039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912134|NCT05752851|||CASE_CONTROL||PROSPECTIVE|||||||
33912135|NCT01155648|RANDOMIZED|PARALLEL||||NONE||||||
33778998|NCT06427538|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33912136|NCT02421367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33912137|NCT02750800|||CASE_ONLY||PROSPECTIVE|||||||
33912138|NCT00200252|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912139|NCT04705324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912140|NCT04284956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912141|NCT02530606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912142|NCT01819545|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912143|NCT01175278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912144|NCT01675011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912145|NCT00921817|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33912146|NCT06206668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33912147|NCT04758429|||COHORT||PROSPECTIVE|||||||
33912148|NCT01555112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912149|NCT00307515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912150|NCT04286542|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Visit 1: screening, baseline sample collection. Visit 2: sample collection, provocation with cold dry air, sample collection||||
33912151|NCT00538980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912152|NCT02251054|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33912153|NCT02627131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912154|NCT00004735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912155|NCT05116540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blinded Randomized Study|Randomized, Double-Blind|t|t|t|t
33912156|NCT01919333|||COHORT||PROSPECTIVE|||||||
33912157|NCT05689658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33912158|NCT06053827|||COHORT||RETROSPECTIVE|||||||
33993470|NCT06742606|NA|SINGLE_GROUP||TREATMENT||NONE||"patients diagnosed as IBD~Inclusion Criteria:~1. Age: patients diagnosed as IBD aged from 1 month to 16 years~2. Patients fulfilling modified Porto criteria for diagnosis of IBD including clinical features, laboratory, radiological and pathological findings (Levine et al, 2014).~3. Patients initially severely diseased or in relapse and planned to start or change biological therapy.~Exclusion Criteria:~1. Patients already on biological therapy and controlled.~2. Patients with known humeral or cell mediated immunodeficiency."||||
33993471|NCT05729438|||COHORT||PROSPECTIVE|||||||
33993472|NCT02264977|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33993473|NCT04947553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993474|NCT00128960|||COHORT||PROSPECTIVE|||||||
33912159|NCT03456713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912160|NCT03951857|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33912161|NCT03739463|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33912162|NCT03172611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912163|NCT01614236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912164|NCT04799405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912165|NCT06085846|||CASE_ONLY||PROSPECTIVE|||||||
33912166|NCT02137590|NA|SINGLE_GROUP||||NONE||||||
33912167|NCT01255046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912168|NCT02125006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33912169|NCT06194279|||CASE_ONLY||RETROSPECTIVE|||||||
33912170|NCT03059810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912171|NCT04037670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912172|NCT05253313|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33912173|NCT01369316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993475|NCT06743347|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33912174|NCT04680663|||COHORT||PROSPECTIVE|||||||
33912175|NCT04913714|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Data analyst did not know which group received the intervention||f|f|f|t
33912176|NCT04598347|||CASE_ONLY||PROSPECTIVE|||||||
33912177|NCT06494878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912178|NCT01787812|||CASE_ONLY||PROSPECTIVE|||||||
33912179|NCT01911572|||FAMILY_BASED||OTHER|||||||
33993476|NCT06351332|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993477|NCT00923442|||COHORT||PROSPECTIVE|||||||
33993478|NCT05649956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993479|NCT06025721|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an in-person, phone, or video based behavioral intervention. It will involve a wellness coach assisting participants to set goals related to diabetes self-care and co-morbitities or social conditions that get in the way of health and wellness. There will be encouragement to work on medication adherence and to address getting healthy sleep, quitting tobacco, being more active, and eating better.||||
33993480|NCT03545906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33993481|NCT06328777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025045|NCT05576883|NA|SINGLE_GROUP||PREVENTION||NONE||This study utilizes a Micro Randomized Trial \[MRT\] method to evaluate the effects of the intervention. Compared to a multi-arm trial, in which participants are randomized to an intervention or control group, in an MRT individuals are randomized repeatedly to different interventions during the trial which allows for a large number of observations of the targeted proximal outcome(s) per participant (in this case, emotional states). This design also allows us to investigate contextual moderators of proximal effects such as time of intervention delivery and emotional state.||||
34025046|NCT06629831|||COHORT||CROSS_SECTIONAL|||||||
34025047|NCT05149859|||CASE_CONTROL||PROSPECTIVE|||||||
34025048|NCT04038983|||OTHER||PROSPECTIVE|||||||
33912180|NCT04698213|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a phase II trial with a partial treatment discontinuation design in patients who achieved tumor decrease greater than 30% compared to baseline during the first 36 weeks of therapy.~All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.~Treatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner."||||
33912181|NCT03007953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912182|NCT04502810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Baseline evaluation - Randomization to real laser or sham laser (12 sessions in 6 consecutive weeks) - Post-treatment evaluation|t|t|t|t
33912183|NCT03650452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912184|NCT02826733|||CASE_ONLY||PROSPECTIVE|||||||
33912185|NCT01557608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33912186|NCT00440427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912187|NCT03060603|||COHORT||PROSPECTIVE|||||||
33993482|NCT02595905|RANDOMIZED|PARALLEL||TREATMENT||NONE|The remaining patient on treatment has been unblinded to reveal their usage and dosage of ABT-888 (veliparib). The unblinding was prompted by the pharmaceutical collaborator's (AbbVie) notification of the discontinuation of the ABT-888 (veliparib) development program. Any investigators with patients currently on treatment with ABT-888 or placebo must unblind their patients to determine if their patients are receiving ABT-888 (veliparib) or placebo. If a patient is found to be receiving ABT-888 (veliparib), the treating investigator should discuss alternative treatment options, as well as a suitable transition date prior to the expiration of the blinded supplies. Treating investigators may request that the patient be allowed to continue open-label ABT- 888 (veliparib), noting the agent will no longer be available after December 31, 2024.|||||
33993483|NCT06278779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome raters will be blinded to treatment allocation.|Randomized, prospective, parallel group, comparative effectiveness trial.|f|f|f|t
33993484|NCT06396286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993485|NCT01836380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993486|NCT04986748|||CASE_ONLY||PROSPECTIVE|||||||
33993487|NCT04793971|||COHORT||CROSS_SECTIONAL|||||||
33993488|NCT05350072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators, investigator staff, persons performing the assessments and Novartis Clinical Trial Team will remain blinded to the identity of the treatment from the time of randomization until the final database lock.||t|t|t|t
33993489|NCT06743256|NA|SINGLE_GROUP||OTHER||NONE||||||
33993490|NCT03703154|||COHORT||PROSPECTIVE|||||||
33993491|NCT05757960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085260|NCT02645890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912188|NCT04415567|||CASE_CONTROL||RETROSPECTIVE|||||||
33912189|NCT03871517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912190|NCT03466489|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized||||
33912191|NCT02210871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993492|NCT04563520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993493|NCT06041971|RANDOMIZED|CROSSOVER||OTHER||NONE||Treatment Groups Randomized Crossover: Participants will be randomized 1:1 within each age cohort to either conduct the two-week control period before use of the AIDANET system (group A) or after use of the AIDANET system (group B).||||
33993494|NCT03125447|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||Attention capacity will be compared in three situations of posture/mobility in a group of prematurely born children, and compared to the same situations in a group of term born children||||
33993495|NCT05239195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025049|NCT03107221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34025050|NCT02101593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025051|NCT05469555|||COHORT||PROSPECTIVE|||||||
34025052|NCT02505087|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34025053|NCT06486805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|quadrible blinded|Randomized controlled study|t|t|t|t
34025054|NCT04278716|||COHORT||PROSPECTIVE|||||||
34025055|NCT06246214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025056|NCT02527538|||COHORT||PROSPECTIVE|||||||
34025057|NCT00151346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025058|NCT05657119|RANDOMIZED|PARALLEL||PREVENTION||NONE||Using a parallel group design trial, our design considers the acceptability, feasibility and signals of impact of two different interventions: (1) the Family Safety Net for those whose household may benefit from lethal means reduction counseling due to having someone in their home who is struggling; and (2) a General Firearm Safety intervention for households with firearms who did not endorse an item on the family-focused mental health screening.||||
34025059|NCT04939376|||COHORT||PROSPECTIVE|||||||
34025060|NCT05551871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34025061|NCT05819710|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34025062|NCT02876107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025063|NCT06374758|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34025064|NCT01864395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34025065|NCT03452878|||CASE_ONLY||PROSPECTIVE|||||||
34025066|NCT00602368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085261|NCT03310567|NA|SINGLE_GROUP||TREATMENT||NONE||Women with recurrent/ metastatic endometrial carcinoma would be treated with Epacadostat and pembroluzimab||||
33690313|NCT03676335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690314|NCT02135939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690315|NCT02909179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33912192|NCT02514928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912193|NCT00813514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912194|NCT04217577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912195|NCT06468982|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups for patients with AMI scheduled for CABG: Group A with IABP support, and Group B (the control group) without IABP||||
33912196|NCT01994226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912197|NCT00125658|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33912198|NCT04760353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912199|NCT02874404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912200|NCT03252496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912201|NCT05149794|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33912202|NCT00077805|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912203|NCT03741894|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled trial|t|f|f|t
33912204|NCT06004141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912205|NCT05093413|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33912206|NCT01023399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912207|NCT03021798|||COHORT||PROSPECTIVE|||||||
33912208|NCT04536740|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912209|NCT01386710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912210|NCT05171231|||OTHER||PROSPECTIVE|||||||
33912211|NCT04068064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|the grouping is blind to both participants and the investigator|a randomized, between-subject design, including an intervention group and a control group|t|f|t|f
33912212|NCT05261672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33912213|NCT03311490|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33912214|NCT04569552|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33912215|NCT04321252|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33912216|NCT01753076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912217|NCT00347854|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33912218|NCT02042729|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912219|NCT01331239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912220|NCT03825276|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912221|NCT00008138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912222|NCT02207699|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912223|NCT02392039|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33912224|NCT03268668|||CASE_ONLY||CROSS_SECTIONAL|||||||
34085262|NCT01233765|||CASE_CONTROL||PROSPECTIVE|||||||
34085263|NCT01924598|NA|SINGLE_GROUP||OTHER||NONE||||||
34085264|NCT00114985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690316|NCT03582644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690317|NCT00289718|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690318|NCT00963677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690319|NCT01918722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690320|NCT04671173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||multi-center, non-randomized, historically controlled, prospective pilot trial of the MY01 device.||||
33690321|NCT03601000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double-blind, placebo-controlled study.|t|t|t|f
33690322|NCT01704898|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33690323|NCT00787995|||CASE_ONLY|||||||||
33690324|NCT03516981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690325|NCT01571297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690326|NCT04581135|||COHORT||PROSPECTIVE|||||||
33690327|NCT03912896|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33690328|NCT05152875|||COHORT||RETROSPECTIVE|||||||
33690329|NCT01216995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690330|NCT04263454|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE||Healthy controls and fibromyalgia patients will have an MRI scan both before and 3 hours post endotoxin injection.|f|t|t|t
33690331|NCT03972475|||COHORT||OTHER|||||||
33690332|NCT05696080|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33690333|NCT02770469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33690334|NCT02366598|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33690335|NCT02901639|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33690336|NCT03415100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690337|NCT01864122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690338|NCT01861171|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33690339|NCT04941781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690340|NCT02301585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690341|NCT00229918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33690342|NCT01402895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33690343|NCT06260761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The data collector, an orthopedic resident unaware of the surgical technique used, obtained information after operation.|prospective, parallel group, assessor-blinded, randomized controlled trial. randomized with computer generator number and use block-of-four.|f|f|t|t
33690344|NCT04658173|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33690345|NCT05959603|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33690346|NCT00218725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690347|NCT00355901|||||PROSPECTIVE|||||||
33690348|NCT04623385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690349|NCT01898494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690350|NCT00430651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690351|NCT01455467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690352|NCT06298045|||COHORT||PROSPECTIVE|||||||
33912225|NCT05912959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Concealed allocation will be performed by a researcher who will not be involved in the treatment or assessment. Permuted blocks will be used to assure an equal 1:1 allocation ratio. Due to the nature of the study, the assessor and the patients will be blindfolded (double-blinded). During the first treatment session, the therapist will be allowed to uncover the allocation code to be able to conduct the appropriate treatment.|parallel model study where 2 groups (experimental and control) will receive specific interventions. then the outcome measures will be assessed at baseline, after treatment (at 4 weeks) then at 3 month follow up|t|f|f|t
33912226|NCT00366548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33912227|NCT06472700|||COHORT||RETROSPECTIVE|||||||
33690353|NCT01991106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33690354|NCT02906371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690355|NCT03903653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33690356|NCT00186329|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33690357|NCT01920555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912228|NCT05787912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912229|NCT00611897|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33912230|NCT04002154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912231|NCT02729558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912232|NCT02930798|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912233|NCT05153941|||COHORT||PROSPECTIVE|||||||
33912234|NCT04999826|||COHORT||PROSPECTIVE|||||||
33912235|NCT02390336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912236|NCT02520622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912237|NCT05700175|||CASE_CONTROL||PROSPECTIVE|||||||
33912238|NCT03533998|||COHORT||RETROSPECTIVE|||||||
33912239|NCT06318663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912240|NCT05931523|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33912241|NCT02935634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912242|NCT02391090|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912243|NCT05431517|||CASE_CONTROL||RETROSPECTIVE|||||||
33912244|NCT01540916|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912245|NCT06502756|NA|SINGLE_GROUP||PREVENTION||NONE||uncontrolled, single-arm, pilot study||||
33912246|NCT05130164|||OTHER||CROSS_SECTIONAL|||||||
33912247|NCT02473159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912248|NCT02931695|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33912249|NCT06164444|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Patients will not specifically be blinded to the treatment allocation and those operated under non-general anaesthesia are likely to see the drapes and gowns used. However, most patients are unlikely to be able to recognise and differentiate between the different types of reusable and single use gowns and drapes, meaning unblinded patients are a low risk of bias.~As this is a cluster randomised trial, outcome assessors are likely to know the hospital allocation and are therefore unlikely to be blinded. Assessors will receive formal training to undertake patient record review, in-person wound assessment, or telephone follow-up, as appropriate for their site. Assessors will collect detailed wound-related variables. The primary outcome of SSI will be determined by a computer-based algorithm based on the CDC criteria, using this data."|Pragmatic 1:1 international multi-centre non-inferiority cluster randomised controlled trial, with an internal pilot. Clusters are individual hospitals.|f|f|f|t
33912250|NCT02528500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912251|NCT01406847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33912252|NCT05955586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912253|NCT03114982|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33912254|NCT01290172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912255|NCT05632458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912256|NCT00409604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912257|NCT02600325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912258|NCT00228254|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33912259|NCT00751530|||COHORT||RETROSPECTIVE|||||||
33912260|NCT02047513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912261|NCT02576964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912262|NCT01542359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912263|NCT00579124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993496|NCT06561516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participating physicians in the study are kept unaware of which group each patient belongs to. However, patients are randomly divided into the Red ginseng and Control groups by research nurses, and they become aware of their group assignment (whether they will take red ginseng tablets or not) in a single-blind study format.|We randomly assign enrolled patients in two groups, Red ginseng group and Control group. The Red ginseng group will consume red ginseng (ginsenoside 500mg/T) for three months starting one month after surgery. Microbiome analysis will be conducted before surgery and at four months after surgery to investigate the prebiotic effects of red ginseng on gut microbiota distribution. The control group will not recieve any intervention during the experimental periods.|f|f|t|f
33993497|NCT00137254|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993498|NCT06087640|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993499|NCT06709222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690358|NCT03200665|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33690359|NCT06235242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690360|NCT03144024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690361|NCT04733378|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690362|NCT03777735|||COHORT||PROSPECTIVE|||||||
33690363|NCT02025517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33690364|NCT03557554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690365|NCT01859585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33690366|NCT00002664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690367|NCT00494065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690368|NCT04405427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33690369|NCT00162721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690370|NCT01460576|||COHORT||PROSPECTIVE|||||||
33690371|NCT01374711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690372|NCT02602847|||OTHER||PROSPECTIVE|||||||
33690373|NCT02142114|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33690374|NCT04564781|||COHORT||PROSPECTIVE|||||||
33690375|NCT01701427|||COHORT||PROSPECTIVE|||||||
33690376|NCT03211962|||COHORT||PROSPECTIVE|||||||
33690377|NCT00883844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912264|NCT05072769|RANDOMIZED|PARALLEL||PREVENTION||NONE|There is no need for masking as placebo will not be applied.|There will be an experimental and a control group. Dates will be given to the experimental group after the birth, while the control group will be treated in line with the hospital routines.||||
33912265|NCT04086563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33912266|NCT02108951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912267|NCT06503289|||COHORT||PROSPECTIVE|||||||
33912268|NCT04783532|NA|SINGLE_GROUP||OTHER||NONE||||||
33912269|NCT04371731|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two arms, one using the platform to help manage their heart failure and one standard of care.||||
33912270|NCT03725995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant was blinded, the first assistant who explained the pain scale to the participants and asked him\\her to record the score of pain associated with the drug administration was also blinded.|blinded, randomized placebo-controlled trial, comparing three groups.|t|f|t|f
33912271|NCT00920595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912272|NCT00149604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912273|NCT03346369|NA|SINGLE_GROUP||TREATMENT||NONE||This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis. Patients will be treated during 2 consecutive 14-day treatment periods with a low and a high dose of Lanthanum Carbonate respectively.||||
33912274|NCT04058119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912275|NCT03084393|||COHORT||PROSPECTIVE|||||||
33912276|NCT01117688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912277|NCT04008589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, controlled|t|f|t|t
33912278|NCT03448718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912279|NCT02850887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912280|NCT04414657|||COHORT||PROSPECTIVE|||||||
33912281|NCT03632681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912282|NCT00071201|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912283|NCT02077634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912284|NCT01072097|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33912285|NCT04236206|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Quasi-experimental; non-randomized, pre-test, post-test control group design.||||
33912286|NCT04709263|||CASE_CONTROL||PROSPECTIVE|||||||
33912287|NCT05313932|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33912288|NCT02924506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912289|NCT00002057||||TREATMENT||||||||
33912290|NCT05449613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912291|NCT02180503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690378|NCT06423989|NA|SINGLE_GROUP||OTHER||NONE||||||
33690379|NCT00949286|||COHORT||PROSPECTIVE|||||||
33690380|NCT04699253|||COHORT||PROSPECTIVE|||||||
33690381|NCT01755273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690382|NCT01771575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912292|NCT05323903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912293|NCT04666324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912294|NCT01649739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912295|NCT06263634|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33912296|NCT04129749|||COHORT||PROSPECTIVE|||||||
33912297|NCT01443455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912298|NCT03007745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912299|NCT00932152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912300|NCT05009316|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912301|NCT05631015|||OTHER||RETROSPECTIVE|||||||
33912302|NCT01274442|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34085265|NCT03779555|||COHORT||PROSPECTIVE|||||||
34085266|NCT03347591|||CASE_ONLY||CROSS_SECTIONAL|||||||
34085267|NCT03332342|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34085268|NCT03332615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085269|NCT03424278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An assessor who don't now in which groups the participants has been allocated.|Parallel randomized controlled trial.|f|f|f|t
34085270|NCT01294813|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085271|NCT02236221|||COHORT||PROSPECTIVE|||||||
33690383|NCT00182871|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33690384|NCT03385161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the surgeon during injection knows the active material||t|f|t|t
33690385|NCT04428775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two doses of ALZT-OP1a (cromolyn) are being evaluated in this study. Each dose of ALZT-OP1a (cromolyn) will be co-administered with a stable dose of ALS standard-of-care treatment as prescribed by their physician.||||
33993500|NCT04975880|NA|SINGLE_GROUP||TREATMENT||NONE||"Following enrollment participants will begin hemodialysis treatments on the SC+ machine on a prescription of four-hour treatments, three times per week or per facility standard for training within a hemodialysis facility for a minimum of 4 weeks.~During this time, both patients and caregivers will undergo extensive training and competency sign off on all aspects of safely administering hemodialysis treatment in the home. This 4 week period can be extended week by week to a maximum of 8 weeks until competency sign off is achieved.~Upon completion of training, a 1 week transition period will occur followed by the home hemodialysis phase (test phase) which consists of 8 weeks of treatments performed 4 times per week, 3.5 hours each treatment in the participant's home setting by the participant or their care partner."||||
33993501|NCT05631964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993502|NCT06743230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessments will be performed by an investigator who was blinded to group allocation.|Two groups with a neuro athletic training group and a control group.|f|f|f|t
33993503|NCT03972306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993504|NCT05660707|||OTHER||OTHER|||||||
34085272|NCT03276208|RANDOMIZED|PARALLEL||OTHER||SINGLE|During initial telephone screening participants will be randomized to either intervention or control group||t|f|f|f
34085273|NCT04367805|||CASE_ONLY||PROSPECTIVE|||||||
33690386|NCT00107952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085274|NCT02060409|||CASE_ONLY||RETROSPECTIVE|||||||
34085275|NCT03622450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34085276|NCT01067391|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34085277|NCT04366674|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085278|NCT00523432|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34085279|NCT05088356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085280|NCT06222801|||COHORT||PROSPECTIVE|||||||
34085281|NCT03979066|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized phase 2 trial for a total of 20 patients per cohort||||
33690387|NCT02803762|NA|SINGLE_GROUP||||NONE||||||
33690388|NCT00692133|||||PROSPECTIVE|||||||
33690389|NCT02922491|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33690390|NCT02925325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690391|NCT01643603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690392|NCT02641977|||COHORT||PROSPECTIVE|||||||
33690393|NCT01759888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690394|NCT01180530|||OTHER||PROSPECTIVE|||||||
33690395|NCT04956770|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, non-randomized, interventional study||||
33690396|NCT02923427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33690397|NCT03722173|NA|CROSSOVER||TREATMENT||NONE||Open-label, one-way crossover design||||
33690398|NCT04656275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690399|NCT02675101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912303|NCT00407264|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33912304|NCT03914443|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912305|NCT02666755|||CASE_ONLY||PROSPECTIVE|||||||
34085282|NCT00667511|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690400|NCT00939757|RANDOMIZED|CROSSOVER||||NONE||||||
33690401|NCT03555773|NA|SINGLE_GROUP||TREATMENT||NONE||15 patients with complex fistulizing perianal Crohn's disease refractory to biological therapy||||
33690402|NCT03824028|||COHORT||PROSPECTIVE|||||||
33690403|NCT03967678|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind|Double blind randomised controlled trial|t|f|t|t
33690404|NCT01683227|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33912306|NCT01980121|||CASE_ONLY||PROSPECTIVE|||||||
33912307|NCT04628013|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators propose a single arm/pre-post trial to examine the effects of NxES on resting pain (BPI, ICOAP), pain sensitivity (PPT, HTS, CPM), movement-related pain (5xSTS), and physical function (5xSTS, KOOS) for people with knee OA. The investigators plan to examine the potential time-course effects after a single intervention (immediate, 1-hr, 24-, and 72-hours) and due to repeated treatment (3x/week for 2-weeks) at the end of treatment (post 72-hours and 4-weeks).||||
33912308|NCT03951961|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, multicenter phase II, non-randomized||||
33912309|NCT02616627|||CASE_ONLY||OTHER|||||||
34085283|NCT03798236|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Single center, randomized, double-blind, placebo-controlled clinical study.|t|f|t|f
34085284|NCT00933153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085285|NCT04968704|||CASE_ONLY||PROSPECTIVE|||||||
34085286|NCT02576470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34085287|NCT05994742|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adaptive, multi-arm randomised controlled trial||||
34085288|NCT03356093|||COHORT||PROSPECTIVE|||||||
33912310|NCT06312449|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33912311|NCT03647371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33912312|NCT00002250||||TREATMENT||||||||
34085289|NCT01799889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912313|NCT01740037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912314|NCT02205437|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912315|NCT01201070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33912316|NCT02510729|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33912317|NCT03471767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomized to either take AXS-05 or BUP SR in parallel for the duration of the study.|t|t|f|f
33912318|NCT03450369|NA|SINGLE_GROUP||TREATMENT||NONE||Open label.||||
34085290|NCT01005381|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34085291|NCT01841203|||COHORT||PROSPECTIVE|||||||
34085292|NCT04894058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085293|NCT03139539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085294|NCT04975139|||COHORT||PROSPECTIVE|||||||
34085295|NCT06522113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085296|NCT04103840|||COHORT||PROSPECTIVE|||||||
34085297|NCT00443859|||COHORT||PROSPECTIVE|||||||
34085298|NCT01851746|||CASE_CONTROL||PROSPECTIVE|||||||
34085299|NCT03039075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912319|NCT06371898|||CASE_CONTROL||RETROSPECTIVE|||||||
34085300|NCT01734720|||COHORT||RETROSPECTIVE|||||||
34085301|NCT05227248|NA|SEQUENTIAL||OTHER||NONE||||||
34085302|NCT02425553|||CASE_CROSSOVER||PROSPECTIVE|||||||
34085303|NCT04968496|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled trial|f|f|f|t
34085304|NCT02931461||PARALLEL||OTHER||NONE||||||
34085305|NCT06389461|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34085306|NCT00941343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912320|NCT00320736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912321|NCT01070719|||COHORT||CROSS_SECTIONAL|||||||
33912322|NCT03420131|||COHORT||PROSPECTIVE|||||||
34085307|NCT01271959|||||RETROSPECTIVE|||||||
34085308|NCT06436768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The doctors making the follow-up assessment were unaware of the treatment received, and none of the doctors who administered the injections carried out the follow- up evaluations. Thus, both the patients and the assessing doctors were remained unaware of the treatment received throughout the trial|Randomized parallel controlled trial|t|f|t|t
34085309|NCT05572086|||CASE_ONLY||CROSS_SECTIONAL|||||||
34085310|NCT01274468|||CASE_ONLY||PROSPECTIVE|||||||
34085311|NCT04168242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085312|NCT00644059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34085313|NCT06351176|||COHORT||PROSPECTIVE|||||||
34085314|NCT01865019|||CASE_CONTROL||PROSPECTIVE|||||||
34085315|NCT02347709|||COHORT||PROSPECTIVE|||||||
33993505|NCT06639451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993506|NCT06422520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993507|NCT06737354|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993508|NCT06297122|||CASE_ONLY||RETROSPECTIVE|||||||
33993509|NCT02991300|||CASE_ONLY||OTHER|||||||
33993510|NCT04711057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993511|NCT04442646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993512|NCT04581304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993513|NCT05977686|||COHORT||PROSPECTIVE|||||||
33690405|NCT05158387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|unblinded administrator/pharmacist||t|t|t|f
33690406|NCT01070862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690407|NCT02307786|||COHORT||RETROSPECTIVE|||||||
33690408|NCT04108676|NA|SINGLE_GROUP||OTHER||NONE||repeated oral doses of Omeprazole on the pharmacokinetic profile of a single dose of Fluzoparib||||
33690409|NCT03310827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||a phase I randomized controlled trial of 42 adults (19 to 50 years) with depressive disorders using a 2:1 ratio of group selection (28 in the intervention {I} group and 14 in the control {C} group) is proposed.|t|f|f|f
33690410|NCT05503316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085316|NCT00619840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690411|NCT03649867|NA|SINGLE_GROUP||OTHER||NONE||Qualitative Study - semi-structured interviews||||
33690412|NCT04596553|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||- Double-blinded, randomized controlled, parallel design study, with 3 treatment groups (placebo, collagen peptide, and essential amino acid)|t|f|t|t
33690413|NCT04570722|NA|SINGLE_GROUP||OTHER||NONE||||||
33690414|NCT02780609|NA|SEQUENTIAL||TREATMENT||NONE||||||
33690415|NCT05938179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690416|NCT04119154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking, open label.|Cancer suspects will undergo standard diagnostic evaluation and novel diagnostic. Single arm.||||
33690417|NCT04955964|||COHORT||PROSPECTIVE|||||||
33690418|NCT00769574|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33690419|NCT00000574|RANDOMIZED|||TREATMENT||DOUBLE||||||
33690420|NCT01732731|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690421|NCT00462527|||COHORT||PROSPECTIVE|||||||
33690422|NCT01247038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690423|NCT05674552|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible children will be randomized into two equal-sized groups. Study group: will receive exogenous ketone esters plus standard of care. Control group: will receive only standard of care.||||
33690424|NCT01754909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33690425|NCT00145678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690426|NCT02495103|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690427|NCT03005171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085317|NCT01077492|||CASE_ONLY||PROSPECTIVE|||||||
33690428|NCT03261180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690429|NCT06008834|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Interventional Pilot Study.||||
33690430|NCT05562271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690431|NCT00015938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690432|NCT00023244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993514|NCT06743334|||COHORT||RETROSPECTIVE|||||||
33993515|NCT05450393|||CASE_ONLY||PROSPECTIVE|||||||
33993516|NCT06741878|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33690433|NCT06169397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912323|NCT02305901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912324|NCT01641549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912325|NCT01055808|||||PROSPECTIVE|||||||
33912326|NCT03614091|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double Blind (caregiver,outcome Assessor)||f|t|f|t
33912327|NCT02255123|||CASE_ONLY||RETROSPECTIVE|||||||
33912328|NCT00406952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912329|NCT05056454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912330|NCT04091282|||COHORT||PROSPECTIVE|||||||
33912331|NCT03092869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33912332|NCT02197039|||CASE_CONTROL||PROSPECTIVE|||||||
33912333|NCT04097756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33912334|NCT06014554|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33912335|NCT03298412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912336|NCT06116877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912337|NCT01806246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912338|NCT05640713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912339|NCT03452553|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33993517|NCT06722235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993518|NCT06742723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled|International, multi-centre, randomised, double-blind, parallel-group, active-controlled, event-driven, outcome|t|t|t|t
33912340|NCT05066828|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33912341|NCT04716166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912342|NCT00760227|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33993519|NCT06742749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients, their parents/guardians, and the person who assessed the primary outcome were blinded to the type of intervention and the randomization sequence. The primary outcome assessor was a physiotherapist already trained in rehabilitating children with orthopedic disorders and the manual muscle strength testing scale. The assessment of the primary outcome was done in the physiotherapy department of the EDCD center.|The study was a randomized clinical trial. It was done to check the equivalence between two parallel groups of patients with DDH who underwent open reduction operation for their hips. In the first group, the psoas tendon was sectioned at the pelvic brim (proximal level), while in the second group, the section of the tendon was done just above the lesser trochanter (distal level). The allocation ratio was 1:1.|t|f|f|t
33993520|NCT01956084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993521|NCT06742671|||COHORT||PROSPECTIVE|||||||
34085318|NCT01553851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993522|NCT06459258|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Study group allocation is performed in a randomized and examiner-blinded fashion.~All study authors and examiners are blinded to the group allocation until completion of data analysis."||f|f|t|t
33993523|NCT06451614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993524|NCT02532244|||CASE_ONLY||PROSPECTIVE|||||||
33993525|NCT06742450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993526|NCT06311214|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993527|NCT06743451|NA|SINGLE_GROUP||SCREENING||NONE||||||
33993528|NCT03532282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors||f|f|t|t
34085319|NCT05442008|||COHORT||PROSPECTIVE|||||||
34085320|NCT03044418|||CASE_ONLY||PROSPECTIVE|||||||
34085321|NCT04547816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After randomization eligible subjects are to receive one of the treatment option described in the Model Description according to the order placed in a closed envelope which is to be opened by person who perform biofeedback (BFT) and tibial neuromodulation (TNM). The investigator responsible for the study conduction, clinical assessment and high-resolution anorectal manometry measurements is not supposed to get the information about the number of procedures (BFT+TNM; or BFT+TNM + pelvic floor muscles training (PFMT); or BFT+TNM + PFMT + diet modification (DM)) that a certain subject receives|"Random assignment to one of the groups depending on the treatment options:~1. biofeedback and tibial neuromodulation~2. biofeedback and tibial neuromodulation + pelvic floor muscles training~3. biofeedback and tibial neuromodulation + pelvic floor muscles training + diet modification"|f|f|t|t
34085322|NCT02997163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690434|NCT02579928|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Midazolam was chosen as an active placebo in keeping with its similar pharmacokinetic profile and precedent as a reasonable comparator for nonspecific behavioral effects of ketamine|Participants were randomly assigned the treatment order, with participants receiving a single infusion of either ketamine hydrochloride (0.5 mg/kg) or midazolam (0.045 mg/kg) on Day 1, and the alternate compound 2 weeks later.|t|t|t|t
33690435|NCT01337271|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|t|f|f
33690436|NCT04328350|||COHORT||PROSPECTIVE|||||||
33690437|NCT01164384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690438|NCT00633620|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33690439|NCT05469685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690440|NCT05611125|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690441|NCT06240780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Double blinded stratified randomization of subjects from two arms into one of three groups per arm.|. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type.|t|t|t|f
33912343|NCT02300415|||CASE_ONLY||PROSPECTIVE|||||||
33690442|NCT01875003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690443|NCT03859206|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33912344|NCT01419483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912345|NCT00051558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690444|NCT04867031|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33690445|NCT01616511|||COHORT||PROSPECTIVE|||||||
33690446|NCT04386629|||COHORT||PROSPECTIVE|||||||
33690447|NCT02775201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912346|NCT06360874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33912347|NCT03617133|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, observational, validation study to EMBRACE I||||
33912348|NCT03969043|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912349|NCT03093493|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912350|NCT02115815|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33912351|NCT01419275|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33912352|NCT01082718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912353|NCT02368340|||COHORT||PROSPECTIVE|||||||
33993529|NCT03087981|||CASE_ONLY||RETROSPECTIVE|||||||
33993530|NCT06067828|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34085323|NCT05943951|||CASE_ONLY||PROSPECTIVE|||||||
33912354|NCT05151328|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33912355|NCT04901065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research assistant enrolling the patients was blinded to treatment assignment because he did not know to which bottle the patient was randomized (A or B) and he did not know what was contained in the bottle||t|t|t|t
33912356|NCT04480697|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part 1 SAD: 6 cohorts Part 2 MAD: 3 cohorts|t|f|t|f
33912357|NCT00130806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912358|NCT03282903|||COHORT||PROSPECTIVE|||||||
33912359|NCT05978830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is double-blinded, meaning both participant and Investigator are unaware of the treatment received by the patients.|Cognitive assessment was performed by neuropsychological professionals before and after each treatment, and treatment was performed with real and fake stimuli Multimodal MRI was performed again 2 days later. (1) Subjects in one group received Active Transcranial ultrasound stimulation for 2 weeks ; The other group received Sham Transcranial ultrasound stimulation for 2 weeks.|t|f|t|f
33912360|NCT01579981|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33912361|NCT05148585|RANDOMIZED|PARALLEL||TREATMENT||NONE||"randomised-controlled trial group 1 (get only physiotherapy) After flexor tendon repair patients start getting physiotherapy. They use static dorsal splint.~exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. then follow-up sixth months.~group 2 (get both physiotherapy and activity-based therapy) After flexor tendon repair patients start getting physiotherapy. They use static dorsal splint.~exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. then follow-up sixth months. Additionally group 2 gets activity-based therapy once a week about an hour. activities are also progressive according to the patients needs."||||
33912362|NCT02215421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993531|NCT06606262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085324|NCT04343144|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallels arms randomized open-label multi center clinical trial||||
34085325|NCT00384631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085326|NCT05412277|NA|SINGLE_GROUP||TREATMENT||NONE||Up to 35 patients at up to 15 sites will receive treatment.||||
34085327|NCT00639184|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33778999|NCT04446975|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||"This trial will be designed using a stepped wedge design with randomization occurring based on timing and location of enrollment according to PRECIS-2 (PRagmatic Explanatory Continuum Indicator Summary) to maximize applicability. The BPA will be turned OFF vs. ON in the participating hospitals according to each 8-week study interval. OFF and ON periods will be separated by 4-week washout intervals. An 8-week period prior to study start will provide baseline trends in prescription patterns. The investigation will commence with two OFF periods to assess if reduction in prescribing patterns occurs over time regardless of the intervention. Two ON periods at the end of the study will determine if any observed changes in prescribing patterns stabilize or continued changes take place."|t|f|f|f
33779000|NCT06239402|||COHORT||PROSPECTIVE|||||||
33779001|NCT02809027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779002|NCT06475235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779003|NCT06094933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33912363|NCT02730507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912364|NCT03355599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993532|NCT06445049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Deferred consent model||||
33912365|NCT03284619|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of concept including accuracy and safety aspects according to R-IDEAL stage 1 criteria||||
33993533|NCT06736743|||COHORT||RETROSPECTIVE|||||||
33993534|NCT06742593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993535|NCT06741787|||COHORT||PROSPECTIVE|||||||
33993536|NCT06149286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912366|NCT02686606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690448|NCT01063712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912367|NCT04242017|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33912368|NCT02307721|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912369|NCT03397927|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912370|NCT04136561|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Prospective with historical case matched controls, Non-randomized, Single site||||
33912371|NCT05509231|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will consist of individuals diagnosed with autism spectrum disorder and neurotypical children. The intervention includes high-intensity whole-body exercise (Group 1), intervention using wearable technology (arm and sleeve sensor) (Group 2), and no-intervention control (waitlist control) (Group 3). Experienmental Group 1 will participate in a traditional physical fitness program combined with exergaming, Group 2 will train using wearable technology, and Group 3 will be waitlisted for the intervention.||||
33912372|NCT04261634|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33912373|NCT05980832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking could not be done in the study because training was to be provided. The identification and randomization of groups will be performed by the center staff using the blinding technique without the knowledge of the researcher to avoid bias.|||||
33993537|NCT04949256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993538|NCT00001823|||COHORT||PROSPECTIVE|||||||
33993539|NCT06576791|||CASE_ONLY||OTHER|||||||
33993540|NCT02648542|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33993541|NCT06254807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993542|NCT05615688|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject.~Activity monitors will be provided and participants instructed to wear 24/7 unless showering or swimming to measure and collect level of physical activity~Baseline data will be collected via questionnaires that include: Medical History, Demographics, and Perceived Stress Scale.~Subjects will also complete a Recurrent Questionnaire at 2-4 hrs post placement and every evening for days 2-7 to report Pain Intensity using a Visual Analog Scale"||||
33993543|NCT06741969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomly assigned to one of the 2 identical studies (conducted under this single protocol) to make a total of 300 participants in each study. Participants in each study will be randomly assigned to one of the arms nipocalimab or placebo respectively.|t|t|t|t
33993544|NCT06124339|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33993545|NCT06742346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The primary intervention study model is parallel (no messages, non-tailored messages and linguitically tailored messages. However, we added one additional crossover arm, that will receive tailored messages followed by non-tailored messages (and vice versa)|t|f|f|f
34085328|NCT05623527|||COHORT||RETROSPECTIVE|||||||
33690449|NCT03915522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All patients included in the study are transferred the day after the total knee arthroplasty surgery to the postoperative resuscitation unit.~A sterile dressing of the lower extremity is performed and after the adductor canal is identified with ultrasound image, a medial leg puncture is done with or without doing the canal adductor block. At the end all patients have a sterile apposite on the puncture site.~All variables and outcomes are collected and registered by people not involved in the realization of the intervention."|A simple randomization is made to distribute the included patients in two groups: Standard Group and Intervention Group. A table of random numbers is used, first selecting the starting point and later the movement direction remains constant throughout the whole table. The even numbers are allocated in the standard group and the odd ones in the intervention group.|t|f|f|t
33690450|NCT05333081|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690451|NCT02547714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690452|NCT04601337|||COHORT||CROSS_SECTIONAL|||||||
33912374|NCT01187108|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33912375|NCT02191787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690453|NCT01852357|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33993546|NCT04652856|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"All participants will undergo both electrical brain stimulation (EBS) and sham electrical brain stimulation (SEBS) at brain locations where alteration of visual attention behavior is expected to occur, as well as at control locations.~The participants will be informed that they will receive both EBS and SEBS, but blinded to the location of each trial and whether the trial is EBS or SEBS. Participants will also be blinded to the objectives of stimulation.~The order of stimulation locations and whether the trial is EBS or SEBS will be randomized."||||
33993547|NCT06742463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993548|NCT05115110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085329|NCT05069467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The principal investigator, study investigators, patients, study staff, and the statistician will be blinded to the treatment assignments among interventions. The acupuncturists cannot be blinded to verum acupuncture or the sham owing to the characteristics of acupuncture procedure. Patients allocated to both verum acupuncture and sham acupuncture groups will be asked to guess which type of acupuncture (verum acupuncture, sham acupuncture, or unclear) they had received after the end of last treatment.|Patients will be randomly 2:1:1 allocated to the verum acupuncture (n=60), sham acupuncture (n=30), or usual care (n=30) group.|t|f|t|t
33993549|NCT01514045|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33993550|NCT06742879|||COHORT||PROSPECTIVE|||||||
33993551|NCT03196258|RANDOMIZED|PARALLEL||PREVENTION||NONE|Eligible participants will be randomized to 1 of 2 groups: 1) CBT intervention or 2) standard of care. Due to the nature of the intervention, it will not be feasible to blind participants, treating surgeons, or CBT therapists to treatment allocation. The data analyst and Steering Committee will be blinded to treatment allocation|Participants with operatively managed extremity fractures who screen positive for unhelpful illness beliefs (SPOC scores ≥78) 6-weeks post-fracture fixation will be randomized to receive either 6 weekly one-on-one, 1-hour sessions of cognitive behavioral therapy (CBT) or standard of care (control). Outcomes will be assessed at 3 months, 6 months, 9 months, and 12 months' post-fracture||||
33993552|NCT06742944|||COHORT||PROSPECTIVE|||||||
33993553|NCT02684747|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33993554|NCT05329961|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993555|NCT00830024|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993556|NCT03162315|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993557|NCT03168763|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33993558|NCT06352645|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled clinical trial||||
33993559|NCT06130553|NA|SEQUENTIAL||TREATMENT||NONE||This is a FTiH (first time in human), modular Phase I/IIa, open-label, multi-centre study of AZD3470, in participants with MTAP deficient advanced/metastatic solid tumors. The study consists of individual modules, each evaluating safety and tolerability of AZD3470 dosed as a monotherapy and in combination with specific treatments. Module 1 describes AZD3470 monotherapy, and will have at least two parts. Part A will include the dose escalation cohorts. Part B will include the dose optimization and expansion cohorts.||||
33993560|NCT01004835|||FAMILY_BASED|||||||||
33993561|NCT02193282|RANDOMIZED|PARALLEL||TREATMENT||NONE|As of June 15, 2017, sites will sign into RAVE to unblind any patients that had previously enrolled|||||
33993562|NCT06475846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993563|NCT06743295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993564|NCT06398314|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority, multicenter||||
33993565|NCT00746421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993566|NCT06742814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993567|NCT01470976|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33993568|NCT06296537|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is designed as a prospective, randomized, controlled study.||||
33993569|NCT02875392|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33993570|NCT06694259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993571|NCT06463860|||CASE_CONTROL||RETROSPECTIVE|||||||
33993572|NCT05502679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The first patient from each type of Schatzker classification 1-4 tibial plateau fractures will be randomly assigned to either WBG or TG. Then each patient will be alternatively assigned to WBG or TG as a stratification method to ensure that each group has equal distribution from each type of Schatzker classification 1-4 tibial plateau fractures. The randomization file will be generated by an investigator (TH) not involved in the data collection process, with the results stored in a spreadsheet accessible only to the investigator responsible for the subjects' group assignment (MI). This investigator will not participate in any data collection or subject treatment. Due to the nature of the study, participants will not be blinded to the group assignment and treatment they will receive. However, the investigators measuring the dependent variables will be blinded to the group assignment.|Randomized Clinical Trial|f|t|f|t
33993573|NCT04534205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993574|NCT05240417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel three-arm randomized clinical study|t|f|f|t
33993575|NCT00127985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993576|NCT05188508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, non-randomized phase II trial of combination pembrolizumab with olaparib and temozolomide in patients with gliomas divided into two cohorts.||||
33993577|NCT01274338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993578|NCT06742125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993579|NCT01730092|||CASE_CONTROL||PROSPECTIVE|||||||
34085330|NCT04903301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085331|NCT01903226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34085332|NCT03566953|||OTHER||CROSS_SECTIONAL|||||||
34085333|NCT00236717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34085334|NCT03470467|||COHORT||PROSPECTIVE|||||||
34085335|NCT06135038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085336|NCT03848663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085337|NCT02870868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085338|NCT00109343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085339|NCT06399159|||COHORT||RETROSPECTIVE|||||||
33779004|NCT05700708|||COHORT||PROSPECTIVE|||||||
33779005|NCT03704298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34085340|NCT02935920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085341|NCT06057064|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in adult participants. Approximately 116 participants in Russia will be randomized at up to 10 study sites in a ratio of 3:1 to either AZD3152 or placebo administered IM.|t|t|t|t
34085342|NCT00081003||||SCREENING||||||||
34085343|NCT00945243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085344|NCT02254746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085345|NCT05423418|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
34085346|NCT03869099|||CASE_ONLY||PROSPECTIVE|||||||
34085347|NCT05645198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085348|NCT02371616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085349|NCT06027515|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085350|NCT05808179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085351|NCT02192788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085352|NCT01094288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690454|NCT04528771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigational product will be prepared and dispensed by designated unblinded site personnel at the pharmacy; the investigational product label will indicate the study number but will not indicate the treatment assignment. Any site personnel involved in the administration and assessment of the investigational product will be blinded to subject treatment assignments throughout the study.|Single-site, double-blinded, randomized, placebo controlled trial with a superiority design. The study will randomize 24 patients 1:1 (12 treatment vs 12 control) to either S-nitrosylation therapy or placebo arms.|t|t|t|t
33690455|NCT03247478|||COHORT||PROSPECTIVE|||||||
33690456|NCT00005665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690457|NCT01600508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690458|NCT03051646|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinding will be overseen by the CUMC pharmacy; randomization schedule will be submitted to the pharmacy by a third party who is not involved in the study (i.e., non-study personnel). Study investigators will remain blinded until data collection is complete and data have been analyzed.|Design is a within-subject crossover placebo-controlled experiment. Each participant will be seen for two exercise sessions (stationary cycling) on two days separated by one week, and will receive either ASA or placebo (treatment) at each session prior to commencing exercise. Order of treatment will be randomized and counter-balanced. As such, each participant will serve as his/her own control.|t|f|t|f
33690459|NCT05473182|NA|SINGLE_GROUP||TREATMENT||NONE||One group pretest-posttest design with a single session retention trial 4 weeks after the end of the intervention period.||||
33690460|NCT04927000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690461|NCT00898378|||CASE_CONTROL||PROSPECTIVE|||||||
33690462|NCT02914847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690463|NCT00286611|||||PROSPECTIVE|||||||
33690464|NCT04026581|||CASE_ONLY||PROSPECTIVE|||||||
33690465|NCT03658707|||CASE_ONLY||PROSPECTIVE|||||||
33690466|NCT05803980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The collected data will be analyzed in blind, as only one person not involved in the activities related to all the procedures of the study will know if faeces will be infused from a healthy donor or if an autologous FMT will be performed|Recruited subjects will be randomized with 1:1 ratio to receive FMT from healthy donors or autologous FMT (placebo). Patients will be evaluated before FMT and after 30, 60, 90 and 365 days|t|f|t|f
33690467|NCT03364907|||COHORT||PROSPECTIVE|||||||
33690468|NCT04107259|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690469|NCT03823378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690470|NCT03351595|||COHORT||PROSPECTIVE|||||||
33690471|NCT03679585|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690472|NCT00315354|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33690473|NCT00851760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690474|NCT04300374|||COHORT||RETROSPECTIVE|||||||
33690475|NCT00894127|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33690476|NCT05929755|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33690477|NCT06503965|||COHORT||OTHER|||||||
33690478|NCT03951311|||COHORT||PROSPECTIVE|||||||
33690479|NCT04224883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690480|NCT04171427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three parallel groups testing different dosages / combinations of treatments|t|f|t|f
33690481|NCT04840576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Once it is confirmed that the patient meets the inclusion criteria, exclusion criteria have been ruled out and after signing the corresponding informed consent, randomization will be carried out. The randomization will be carried out by the research center, and the assignment will be made through opaque envelopes.~The assignment of the intervention group will be made by the nursing staff of the surgical area.~In cases where a bilateral inguinal approach coexists in the same surgical procedure, the right side will be randomized; the contralateral incision will receive alternative therapy by default."|2 parallel groups receiving different interventions|t|f|f|f
33779006|NCT04917380|||CASE_CONTROL||RETROSPECTIVE|||||||
33779007|NCT06696807|||COHORT||PROSPECTIVE|||||||
33779008|NCT01632865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912376|NCT04190784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treating therapist, for both the control and intervention groups, was unblinded to the treatment method but the subjects and assessor who conducted the measurements were blinded. Assessor blinding was obtained through an independent research assist; not knowing the study design and not specifically involved in any aspect of the trial|A prospective, double blinded, parallel-group, randomized clinical trial was conducted at one of our university's research departments,|t|f|t|f
33912377|NCT01633996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912378|NCT00162838|||DEFINED_POPULATION||OTHER|||||||
33912379|NCT04500314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912380|NCT03037658|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33912381|NCT05120960|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085353|NCT01822444|||COHORT||PROSPECTIVE|||||||
34085354|NCT01673386|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34085355|NCT02957201|NA|SINGLE_GROUP||OTHER||NONE||||||
33993580|NCT06035224|NA|SINGLE_GROUP||TREATMENT||NONE||A Single Arm, Phase II Trial of Cadonilimab (AK104) Plus lenvatinib in Previous immunotherapy treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)||||
33993581|NCT06742086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993582|NCT05490888|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993583|NCT04862039|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993584|NCT06741995|||COHORT||PROSPECTIVE|||||||
33993585|NCT04173858|||COHORT||PROSPECTIVE|||||||
33690482|NCT04907461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are under narcosis during randomisation and intervention. The surgical staff are aware of randomisation and intervention.|Randomized controlled trial. The participants are during surgery randomized to either Laparoscopic guided TAP block or Ultrasound guided TAP block.|t|f|f|f
33690483|NCT00046111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690484|NCT00006389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690485|NCT01880047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690486|NCT03316534|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||HIV subjects (all on ABC therapy) who fulfilled thee admission criteria will be randomized to either of 2 groups (A or B) with 20 subjects each that received placebo or aspirin (100 mg/daily) for two weeks. At the end of the two week period (T15), patients of group A will be switched to placebo, while group B will be switched to aspirin for another 2 weeks (T30). Adherence will be confirmed by pill count at the end of each study period.|t|f|t|f
33690487|NCT04350346|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33690488|NCT00340288|||CASE_ONLY||PROSPECTIVE|||||||
33690489|NCT01083927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690490|NCT04551391|||CASE_CONTROL||PROSPECTIVE|||||||
33690491|NCT06632769|||OTHER||PROSPECTIVE|||||||
33690492|NCT05323565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690493|NCT04935437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Before and after trial matched cohort trial.||||
33690494|NCT04735575|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation followed by Cohort Expansion Phase at the RP2D.||||
33690495|NCT05396703|||CASE_ONLY||OTHER|||||||
33690496|NCT04472091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690497|NCT00135915|||CASE_CROSSOVER||PROSPECTIVE|||||||
33690498|NCT01111409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690499|NCT04830644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690500|NCT02059005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690501|NCT01016561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690502|NCT01410552|NA|SINGLE_GROUP||TREATMENT||NONE||ICD device||||
33690503|NCT06550635|||COHORT||RETROSPECTIVE|||||||
33690504|NCT00526877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690505|NCT01278160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690506|NCT03012022|||OTHER||PROSPECTIVE|||||||
33690507|NCT04445116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690508|NCT06077708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085356|NCT02332603|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33690509|NCT00433654|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33912382|NCT01551758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912383|NCT01228266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33912384|NCT01395368|||COHORT||PROSPECTIVE|||||||
33912385|NCT06072001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912386|NCT04970771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912387|NCT02423434|||COHORT||PROSPECTIVE|||||||
33912388|NCT02524860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912389|NCT04056013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients meeting eligibility criteria will be randomized to treatment with either Vicryl Rapide or nonabsorbable suture. To ensure comparable numbers patients with buried sutures, there will also be 1 block of 8 patients that is randomized for absorbable or nonabsorbable closure in patients who are receiving buried sutures.|t|t|t|f
33912390|NCT01826292|||OTHER||RETROSPECTIVE|||||||
33912391|NCT01613014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912392|NCT05868941|NA|SINGLE_GROUP||PREVENTION||NONE||This study is a multicenter, prospective local medical device clinical trial.||||
33912393|NCT02648958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33993586|NCT06743321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The independent statistician conducting the interim analysis will be masking. The statistician analyzing the primary and secondary outcome data will also be masking.|||||
33993587|NCT06743217|||CASE_CONTROL||RETROSPECTIVE|||||||
33993588|NCT06726135|||OTHER||PROSPECTIVE|||||||
33993589|NCT06742203|NA|SINGLE_GROUP||TREATMENT||NONE||Tolerability: Identification of dose ranges that do not cause discomfort or adverse symptoms over the study period.||||
33779009|NCT02114008|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33993590|NCT06177457|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33690510|NCT04714359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690511|NCT01210287|NA|SINGLE_GROUP||||NONE||||||
33779010|NCT03250325|NA|SEQUENTIAL||TREATMENT||NONE||||||
33779011|NCT04019821|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33779012|NCT01005771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779013|NCT04403061|||COHORT||PROSPECTIVE|||||||
33779014|NCT02956967|||COHORT||PROSPECTIVE|||||||
33779015|NCT03745755|||COHORT||PROSPECTIVE|||||||
33779016|NCT01668147|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33912394|NCT01262300|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912395|NCT05212168|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33912396|NCT04062851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Unblinded Single center Randomized controlled trial||||
33912397|NCT00263302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912398|NCT02352051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912399|NCT01300897|||CASE_CONTROL||PROSPECTIVE|||||||
33993591|NCT04266197|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993592|NCT06742476|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33993593|NCT05752721|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993594|NCT06736990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993595|NCT03954808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993596|NCT01103843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993597|NCT03110991|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34085357|NCT04117022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each site will evaluate 15 diabetics after comprehensive ophthalmic examination and with a confirmed diagnosis at least greater than 5 years without retinopathy or mild-moderate retinopathy..Flicker and chromatic ERG, macular pigment optical density, and ultrawide-field undus photography will be conducted at baseline and after 6-months supplementation with a novel multi-component nutritional supplement (DVS)||||
34085358|NCT03668106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|zeta technique|swim up technique|t|t|f|t
34085359|NCT05643235|NA|SINGLE_GROUP||OTHER||NONE||Single arm, prospective study of implanted loop recorders (ILR) for the detection of arrhythmia in patients initiating treatment with BTK inhibitors.||||
34085360|NCT00346866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690512|NCT05403333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690513|NCT01571024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690514|NCT02531243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690515|NCT05716503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients will randomly be divided into two groups - study group and control group. Study group (A): Will Receive negative pressure wound therapy dressings before skin grafting to prepare the wound bed and after skin grafting.~Control group (B): Will Receive once daily dressing with antibiotic ointment and gauze before and after skin grafting."||||
33690516|NCT02240290|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690517|NCT05551572|||COHORT||PROSPECTIVE|||||||
33690518|NCT00882219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690519|NCT02615925|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690520|NCT05946265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Immediately after periodontal treatment, the researcher responsible for applying the FBM will remove and open 1 envelope and perform the indicated procedure (FBM or simulation). Only this researcher will know the intervention applied to each patient. All other investigators will be blinded to the intervention.|Forty-four patients with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) (660nm, 100W, area 0,5cm2, 200w/cm2, 30 seconds, 3 J, 6J/cm2. The primary outcome of the study will be the assessment of dentinal sensitivity after 7 days of RAR measured with the visual analog scale (VAS). The cutoff of VAS is 3. Also, it will be assessed the impact of oral health on the participant's quality of life, with the OHIP-14 questionnaire. The use of analgesics (paracetamol) will be prescribed as needed and the amount of medication will be calculated. These outcomes will be evaluated after 7 days and 1 month of application.|t|f|t|t
33690521|NCT03719768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690522|NCT00244166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690523|NCT04129502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690524|NCT05328115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The arm with ALZ-101 400 μg will be open-labelled treatment||t|t|t|t
33690525|NCT06481176|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two conditions that will be occurring simultaneously.||||
33690526|NCT05440708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779017|NCT00747929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779018|NCT03328559|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779019|NCT05897736|||CASE_ONLY||PROSPECTIVE|||||||
33690527|NCT00364130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690528|NCT01604759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779020|NCT04357249|||COHORT||PROSPECTIVE|||||||
33690529|NCT01668927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690530|NCT03130595|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33690531|NCT05279053|||OTHER||PROSPECTIVE|||||||
33779021|NCT03511183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779022|NCT00225420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779023|NCT06474416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779024|NCT03291795|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779025|NCT02723877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779026|NCT00282321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33779027|NCT06528782|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Since the application will be performed by the researcher, patients will be blinded in this study. The statistician will be blinded in the evaluation of the data.|Two groups with pecha kucha group and control group|t|f|f|t
33779028|NCT06187181|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33779029|NCT05455658|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779030|NCT05525975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33779031|NCT04145336|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33779032|NCT04612309|||COHORT||RETROSPECTIVE|||||||
33779033|NCT04415593|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomly assigned to two groups. During the maintenance phase, the first group will receive low dose of peanut protein, which amounts 150mg, the second will get high dose, which is 300 mg of peanut protein. Oral immunotherapy with low (150mg) and high (300mg) dose of peanut protein in children randomly assigned to two groups (1:1).~Patients will receive ground peanuts mixed with apple mousse (supposing apple tolerance). For the transparency of the study all patients will receive the same commercially prepared apple muss product."||||
33779034|NCT03574701|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients will be randomized into 3 groups using the sealed envelope method. Each patient will be his or her own control. There will be two possible scenarios resulting from randomization:~* Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.~* Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.~* Group C: This study group will receive only standard of care ."||||
33690532|NCT00688727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690533|NCT06463678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779035|NCT02685293|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33779036|NCT01686295|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33912400|NCT02662517|||COHORT||PROSPECTIVE|||||||
33912401|NCT06502470|NA|SINGLE_GROUP||OTHER||NONE||Abdominoplasty model||||
33912402|NCT06382974|NA|SINGLE_GROUP||TREATMENT||NONE||A case series study.||||
33690534|NCT06109285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690535|NCT04891731|||COHORT||PROSPECTIVE|||||||
33690536|NCT05508724|||CASE_ONLY||CROSS_SECTIONAL|||||||
33912403|NCT02488759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912404|NCT03838770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912405|NCT03913624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912406|NCT02273752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912407|NCT01052987|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33690537|NCT05331027|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33690538|NCT02793193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912408|NCT04220489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, Randomized, Double-Blind, Placebo Controlled trial involving opiate-dependent patients undergoing lumbar spine surgery|t|t|t|f
33912409|NCT02594475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912410|NCT01755494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33912411|NCT00080366||||TREATMENT||||||||
33912412|NCT04058262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33912413|NCT03071536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912414|NCT04362904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||a randomized, controlled trial in pre-test post-test design||||
33912415|NCT05110716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Data collection and randomization to groups was performed online without the investigators' direct involvement|Participants are randomly assigned to either a gains or losses group and subsequently complete conditions at bundle-sizes 1, 3, and 9 (within-subjects, order counterbalanced).|f|f|t|t
33912416|NCT02796534|||CASE_ONLY||PROSPECTIVE|||||||
33912417|NCT00000728||||TREATMENT||NONE||||||
33912418|NCT04619121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912419|NCT00121069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912420|NCT05304910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912421|NCT06242067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912422|NCT01437670|||||PROSPECTIVE|||||||
33912423|NCT06450691|NA|SINGLE_GROUP||OTHER||NONE||||||
33912424|NCT02757066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912425|NCT02029508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912426|NCT06020274|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to either the iCF-PWR group or the standard care group. The investigators will follow CONSORT guidelines for non-pharmacological trials with 1:1 random assignment to iCF-PWR or standard care. As such, 30 children with CF/30 child siblings will be randomly assigned to the iCF-PWR group and 30 children with CF/30 child siblings will be randomly assigned to the standard care group.||||
33993598|NCT06742528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be divided randomly in two groups using blocked randomization generated by computer software.|Brief history and demographic data including age, gender, duration of pallor, residence, weight, educational level of mother, socioeconomic status of father will be noted. Under aseptic techniques 5cc venous sample will be drawn and send to hospital laboratory for baseline hemoglobin and serum ferritin level. All patients will be dewormed before starting therapy by giving oral albendazole l0 ml stat dose. Patients will be divided randomly in two groups using blocked randomization generated by computer software. Group A will be given ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form. Group B will be given Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks. Both the groups will be called for follow up. Hemoglobin level will be assessed after 8 week of therapy.|t|f|f|f
33993599|NCT06741891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Auricular stimulation|f|f|f|t
33993600|NCT06742424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993601|NCT06742294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085361|NCT05016960|NA|SINGLE_GROUP||OTHER||NONE||The investigators will develop and pilot test a modified CBT-I treatment that incorporates technology, user-centered design principles, and CogSMART strategies to improve sleep and rehabilitation outcomes for Veterans with co-occurring insomnia and MCI. The investigators will assess the feasibility and acceptability of Sleep-SMART (Sleep Symptom Management and Rehabilitation Therapy), which will seamlessly incorporate select CogSMART cognitive strategies within a standard 6-session 50-minute CBT-I treatment protocol. Sleep-SMART will focus on enhancing CBT-I by providing supportive cognitive strategies designed to boost treatment learning and adherence.||||
34085362|NCT04457856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double-blind|Randomized, Double-blind, Placebo-controlled|t|f|f|f
34085363|NCT05001620|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33779037|NCT04374565|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase II trial to assess preliminary efficacy and confirm safety of infusions of antiSARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms with or without confirmed interstitial COVID-19 pneumonia by CXR or chest CT. A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.||||
33779038|NCT06349486|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. bismuth-amoxicillin-vonoprazan triple therapy~2. vonoprazan-amoxicillin dual therapy~3. proton pump inhibitor-based standard triple therapy"||||
34085364|NCT05124015|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085365|NCT00133796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085366|NCT06243302|||COHORT||PROSPECTIVE|||||||
34085367|NCT06517199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993602|NCT06717269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a 2-cohort, fixed-sequence, 3-period, relative bioavailability, food-effect, and drug-drug interaction study, which will enroll 18 volunteers. A total of 48 healthy, adult male and female (of non-childbearing potential) volunteers are planned to be enrolled.||||
33993603|NCT05405231|RANDOMIZED|PARALLEL||PREVENTION||NONE||In Phase 1, we will utilize a cluster randomized control trial (RCT) design to recruit from approximately 12 National Guard (NG) units within the Michigan NG. Soldiers from the selected NG units will be approached for study recruitment during their drill weekends. Only units with \>25 Soldiers (out of \~110 units in Michigan) will be eligible to be selected for study recruitment.||||
34085368|NCT02294266|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34085369|NCT00235261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33993604|NCT03734861|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomized to one of two arms:~1. BreathSmart system~2. Standard of Care"||||
34085370|NCT00122057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085371|NCT02424825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085372|NCT05947331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients with infantilenystagmus related head turn are divided randomly in two groups according to the surgical procedure to be performed Group I (Graded Anderson procedure);Group II (Kestenbaum procedure)|t|t|f|f
34085373|NCT05662969|||COHORT||RETROSPECTIVE|||||||
34085374|NCT01977833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085375|NCT03034967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085376|NCT02652793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993605|NCT02648438|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34085377|NCT01803438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085378|NCT03927092|||CASE_ONLY||CROSS_SECTIONAL|||||||
34085379|NCT05295407|||COHORT||PROSPECTIVE|||||||
34085380|NCT01803386|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085381|NCT04140448|||COHORT||PROSPECTIVE|||||||
34085382|NCT02016326|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34085383|NCT04197440|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34085384|NCT05048888|||COHORT||PROSPECTIVE|||||||
34085385|NCT01627132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779039|NCT04457271|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||This study is an effectiveness trial investigating GMT as an intervention for both PTSD-related cognitive impairment/dysfunction, and PTSD symptoms themselves. Participants will be randomized to one of two conditions: GMT or wait list.|f|f|f|t
33779040|NCT03270579|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33779041|NCT06121791|||CASE_ONLY||RETROSPECTIVE|||||||
33779042|NCT06049693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779043|NCT02909361|||CASE_ONLY||PROSPECTIVE|||||||
33779044|NCT01897857|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33779045|NCT02150850|||CASE_CONTROL||PROSPECTIVE|||||||
33779046|NCT05777590|||COHORT||PROSPECTIVE|||||||
33779047|NCT05899764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779048|NCT03530020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patient will receive a restoration with superior function, esthetics, and excellent clinical performance.|t|f|f|t
33779049|NCT04798105|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33779050|NCT00768599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779051|NCT05416437|RANDOMIZED|PARALLEL||TREATMENT||NONE|The is an open label study. There is no masking|Randomized Control Trial||||
33779052|NCT02174198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779053|NCT01853163|NA|SINGLE_GROUP||SCREENING||NONE||||||
33779054|NCT01317017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33779055|NCT05694507|RANDOMIZED|PARALLEL||OTHER||NONE||Experimental and waitlist control groups||||
33779056|NCT03605017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779057|NCT02391220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779058|NCT04253821|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33779059|NCT06613659|||COHORT||PROSPECTIVE|||||||
33779060|NCT04943835|||COHORT||PROSPECTIVE|||||||
33779061|NCT04947124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Masked investigational product labeling.|Patients take 2 different doses of investigational product at distinct treatment periods. Dose is masked.|t|f|t|f
33779062|NCT06330818|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779063|NCT01115998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779064|NCT02462083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779065|NCT00197912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779066|NCT03660072|||COHORT||OTHER|||||||
33779067|NCT02580825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779068|NCT00924664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779069|NCT05571800|RANDOMIZED|PARALLEL||OTHER||NONE|None (Open Label)|Randomized, calorie-match controlled||||
33779070|NCT02711072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779071|NCT05029856|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779072|NCT00169741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779073|NCT05142228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779074|NCT02393664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779075|NCT03739879|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients underwent an interview about their medical history, tested spirometry using Carefusion®, and the inspiratory muscle strength was assessed using Micro RPM Carefusion®. The St George Respiratory Questionnaire (SGRQ) was used to assess the health status and the 6-minute Walking Test (6MWT) was conducted to assess functional capacity. Subject exercised using inspiratory muscle trainer (Philips Respironic®) for eight weeks.||||
33779076|NCT02854891|||COHORT||PROSPECTIVE|||||||
33779077|NCT06013488|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|In this trial, the Outcome Assessors administering study assessments at baseline and at 1-, 3- and 6-month follow-up will be masked to the intervention arm that participants are allocated to receive. Masking outcome assessors will minimize potential bias due to knowledge of which arm the participant is allocated to, and can ensure unbiased ascertainment of study outcomes. For allocation concealment, the intervention allocation for each participant will not be revealed to the participant until they have been enrolled into the trial, to avoid selection bias.|This study employs a 2-arm parallel randomized controlled trial design. Participants will be randomly allocated to 1) a character-strengths based coaching intervention consisting of a five-day residential workshop and supplemental 8- to 10-week remote telephonic coaching support in addition to 'routine (health system) supervision' (face-to-face by a supervisor in groups of 1 supervisor for \~20 health workers), or 2) 'routine supervision' alone.|f|f|f|t
33912427|NCT05505565|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, non-blinded, parallel, intervention vs control group||||
33912428|NCT04510194|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Only the investigational pharmacy and unblinded statistician have access to patient treatment allocation.||t|t|t|t
33912429|NCT01204658|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33912430|NCT03230344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912431|NCT01853111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779078|NCT04742244|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779079|NCT04502667|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open controlled clinical trial||||
33779080|NCT02681276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779081|NCT03250780|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779082|NCT03065790|||COHORT||PROSPECTIVE|||||||
33779083|NCT04136028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779084|NCT00144794|||COHORT||OTHER|||||||
33779085|NCT06043804|||COHORT||PROSPECTIVE|||||||
33779086|NCT01029249|||COHORT||PROSPECTIVE|||||||
33912432|NCT02711215|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912433|NCT00827996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912434|NCT06291181|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33912435|NCT03157154|||CASE_ONLY||PROSPECTIVE|||||||
33912436|NCT04807543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33912437|NCT03041194|||COHORT||PROSPECTIVE|||||||
33912438|NCT01999634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912439|NCT01554540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912440|NCT04053088|||COHORT||PROSPECTIVE|||||||
33912441|NCT01345877|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33912442|NCT02825264|||COHORT||OTHER|||||||
33993606|NCT03364192|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive peer-delivered Whole Health Coaching but the start date will be randomized between 4 and 13 weeks from initiation of the study.||||
33993607|NCT03505905|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A double-blind, placebo-controlled, Sequential Parallel Comparison Design (SPCD) trial of pregnenolone. SPCD is a clinical trial design that may reduce the effect of placebo response on signal detection and maximize the ability to assess efficacy by dividing the trial into two phases, and then re-randomizing placebo non-responders.|t|t|t|t
33993608|NCT06082102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993609|NCT03824691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993610|NCT01801501|||COHORT||PROSPECTIVE|||||||
33993611|NCT00111397||||TREATMENT||||||||
33993612|NCT05172180|||COHORT||PROSPECTIVE|||||||
34085386|NCT06294470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085387|NCT02431429|||CASE_ONLY||PROSPECTIVE|||||||
34085388|NCT02387086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085389|NCT02597413|||CASE_CONTROL||PROSPECTIVE|||||||
34085390|NCT02149134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085391|NCT03028441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34085392|NCT03164642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085393|NCT06447636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085394|NCT02678819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085395|NCT06045117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There is a study group that uses the device \& the data is monitored and sent to the physician. The second group is a control group that will not use the device and will continue with normal standard of care.|f|f|f|t
34085396|NCT00068185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085397|NCT02005796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34085398|NCT03496740|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34085399|NCT06326957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A statistician blind||f|f|t|f
34085400|NCT03953716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|One fourth of participants will receive Ding Kun Dan Pills, one fourth of participants will receive Simulated drug of DING KUN DAN Pills, one fourth of participants will receive MARVELON ,and the another fourth will receive low level light therapy|t|f|t|f
34085401|NCT03893786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34085402|NCT01795443|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34085403|NCT01580631|||CASE_CONTROL||PROSPECTIVE|||||||
34085404|NCT01099644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085405|NCT03012646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993613|NCT06730113|||COHORT||PROSPECTIVE|||||||
33993614|NCT06742658|||COHORT||RETROSPECTIVE|||||||
33690539|NCT02001025|||COHORT||PROSPECTIVE|||||||
34085406|NCT01118299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993615|NCT05234788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690540|NCT04432337|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Type 2 diabetics patients||||
33779087|NCT06186505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|By the nature of the study treatments used within this study, blinding of the participants and clinicians is not possible.|All cohorts of study will receive heat therapy from AirGlove device. Patient cohorts will undergo 12 weeks of heat therapy. Healthy control cohort will only receive a single session of heat therapy.||||
33690541|NCT01171664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690542|NCT05678049|||COHORT||PROSPECTIVE|||||||
33690543|NCT05325437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690544|NCT06134609|RANDOMIZED|PARALLEL||OTHER||SINGLE||A prospective, randomized, clinical trial. Patients will be randomized into two groups (by concealed envelopes). The study group is subjected to have intercourse without using a condom at the evening/night after the embryo transfer, while the control group is subjected to abstain for the next 48 hours after the transfer.|f|t|f|f
33690545|NCT00739492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690546|NCT01232205|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33779088|NCT06615414|||OTHER||CROSS_SECTIONAL|||||||
33779089|NCT05168644|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|The investigators, study coordinators, study subjects and the Sponsor will be blinded to treatment assignment.|"Part A: Eight (8) subjects will participate in each of the 3 dose escalations. Subjects will be randomized to receive either Niclosamide Inhalation Powder or placebo by inhalation (6 active, 2 placebo per group of 8).~Part B: Eight (8) subjects will participate in each of the 2 dose escalations. Subjects will be randomized to receive either Niclosamide Inhalation Powder or placebo by inhalation (6 active, 2 placebo per group of 8)."|t|f|t|f
33779090|NCT00416091|||CASE_CONTROL|||||||||
33779091|NCT05674968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||60 families will be enrolled in the study. The researchers will use block randomization to assign half to the treatment group and half to a wait-list control group. Participants will be blocked by gender and condition.|t|f|f|t
33779092|NCT06215729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33779093|NCT02991287|||COHORT||PROSPECTIVE|||||||
33779094|NCT03789903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912443|NCT02979886|NA|SINGLE_GROUP||SCREENING||NONE||||||
33912444|NCT05621824|||COHORT||PROSPECTIVE|||||||
34085407|NCT05024448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085408|NCT05321537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will not know to which treatment group each belongs.|A single center, parallel, randomized, blinded rater, controlled clinical trial will be conducted. The 25 requirements proposed by the CONSORT declaration will be followed.|f|f|f|t
34085409|NCT03746496|||CASE_ONLY||PROSPECTIVE|||||||
33779095|NCT06113029|||CASE_CONTROL||RETROSPECTIVE|||||||
33779096|NCT00630539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912445|NCT04489225|||COHORT||PROSPECTIVE|||||||
33912446|NCT03300700|||COHORT||PROSPECTIVE|||||||
33912447|NCT03830996|||COHORT||PROSPECTIVE|||||||
33912448|NCT00520559|||COHORT||PROSPECTIVE|||||||
33912449|NCT01753258|||CASE_CONTROL||PROSPECTIVE|||||||
33912450|NCT04398849|||COHORT||PROSPECTIVE|||||||
33912451|NCT02145091|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912452|NCT01966575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690547|NCT06326489|NA|SINGLE_GROUP||TREATMENT||NONE||The study will include 30 children with type 1 diabetes aged seven years and older who use a predictive low glucose suspend insulin pump (740G). Patients eligible for the study will receive a 780G insulin pump for three months.||||
33993616|NCT06475053|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and the examiner tasked with obtaining study outcome data will be masked to the design or brand of lenses. An unmasked examiner will be available to address any issues of lens wear or other adverse events.|This will be a prospective, double-masked, crossover trial.|t|f|f|t
33993617|NCT06627322|RANDOMIZED|PARALLEL||PREVENTION||NONE||RRCT (Registry-based randomized controlled trial)||||
33993618|NCT05255601|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993619|NCT06558500|||CASE_CONTROL||PROSPECTIVE|||||||
33993620|NCT06741644|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993621|NCT06699134|||COHORT||RETROSPECTIVE|||||||
34085410|NCT05600959|||OTHER||PROSPECTIVE|||||||
33690548|NCT02015702|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33690549|NCT00599781|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690550|NCT02686528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690551|NCT04856865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690552|NCT06255210|NA|SINGLE_GROUP||TREATMENT||NONE||umbrella design||||
34085411|NCT04529694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779097|NCT01258218|||COHORT||PROSPECTIVE|||||||
33779098|NCT02621788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779099|NCT01538446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779100|NCT01511536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779101|NCT06067425|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779102|NCT03697460|NA|SINGLE_GROUP||TREATMENT||NONE||Topical INCB018424||||
33779103|NCT01178398|||||CROSS_SECTIONAL|||||||
33779104|NCT03724474|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Pretest-Posttest Control Group Design||||
33779105|NCT05885945|||CASE_CONTROL||PROSPECTIVE|||||||
33779106|NCT00840320|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33993622|NCT06680271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform.||||
33993623|NCT06402201|NA|SEQUENTIAL||TREATMENT||NONE||IV dose escalation||||
33993624|NCT06742580|||CASE_CONTROL||PROSPECTIVE|||||||
33993625|NCT02641444|||COHORT||CROSS_SECTIONAL|||||||
33993626|NCT06742112|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993627|NCT06743126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993628|NCT05061719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993629|NCT03854318|||COHORT||PROSPECTIVE|||||||
34085412|NCT00390715|||CASE_ONLY||PROSPECTIVE|||||||
34085413|NCT01481493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085414|NCT00144313|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34085415|NCT02915835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690553|NCT05882071|||COHORT||RETROSPECTIVE|||||||
33779107|NCT04647136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data analysis will be blinded to the treatment assignment.||f|f|f|t
33779108|NCT00512720|||CASE_CONTROL||RETROSPECTIVE|||||||
33779109|NCT04705974|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33779110|NCT01873677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779111|NCT00542945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779112|NCT06698224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779113|NCT05990920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779114|NCT01228383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779115|NCT01102296|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779116|NCT01781702|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33779117|NCT05535036|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33779118|NCT05035264|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Under general anaesthesia|Paediatric patients (between 2-18 years) undergoing elective airway management without predicted/confirmed difficult airway with the laryngeal mask airway after anaesthesia induction|t|f|f|f
33779119|NCT02886936|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||single-group pre-post intervention study||||
33779120|NCT05126446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779121|NCT00425542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33779122|NCT00178620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779123|NCT05645913|||COHORT||OTHER|||||||
33779124|NCT01910558|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33779125|NCT00847093|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33779126|NCT06697704|||OTHER||CROSS_SECTIONAL|||||||
33779127|NCT02817503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779128|NCT04166461|||COHORT||PROSPECTIVE|||||||
33779129|NCT06696911|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993630|NCT05301608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double-blind, placebo-controlled, full cross-over masking|All participants will receive all interventions, in counter-balanced order.|t|t|t|t
33993631|NCT05139836|||COHORT||PROSPECTIVE|||||||
33993632|NCT05148299|NA|SINGLE_GROUP||TREATMENT||NONE||open label, single arm, multicenter||||
34085416|NCT05859698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085417|NCT05893238|||COHORT||PROSPECTIVE|||||||
34085418|NCT02663700|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34085419|NCT03774108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085420|NCT03599960|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive 3 cycles of a combination of chemotherapy (Met/Ida/L-Asp/Dex)||||
34085421|NCT05788263|RANDOMIZED|PARALLEL||TREATMENT||NONE||basic randomization via spss 24.00 program||||
34085422|NCT05313139|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085423|NCT04270877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A parallel randomized (1:1) double blind, placebo-controlled superior trial|t|t|t|t
34085424|NCT06227195|||OTHER||PROSPECTIVE|||||||
34085425|NCT04209608|||CASE_ONLY||PROSPECTIVE|||||||
33912453|NCT00937768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912454|NCT01599468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33912455|NCT05667727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"the clinical pharmacist will label the medications according to coding system. 2 boxes will be available, one for weight less than 20kg and other box for patient weight more than or equal of 20 kg. Both boxes will contain both medications (epinephrine and salbutamol) in identical syringe with the same volume.~The patient, physician and the nurse will be blinded to the 4th nebulization (experimental intervention)~Once patient get enrolled in the study and received the standard of care (back to back nebulization), the nurse with take the experimental intervention according to the weight and the coding which been done the pharmacist."|both groups will receive salbutamol and ipratropium as back to back nebulization for 3 times. Then the candidate will be randomized into experimental group (epinephrine nebulization) and the control group (salbutamol nebulization as 4th nebulization)|t|t|t|f
33912456|NCT04523064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912457|NCT06370936|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Treatment order (PBMA intervention - Meat intervention versus Meat intervention - PBMA intervention) is masked for the researchers. The order is not masked for participants.|Participants will follow both an 8-week completely controlled dietary intervention followed by a 10-week washout period followed by another 8-week completely controlled dietary intervention.|f|f|t|f
33912458|NCT03176797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912459|NCT05050721|||OTHER||RETROSPECTIVE|||||||
33912460|NCT02509598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912461|NCT00375115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912462|NCT02876770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912463|NCT05781971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33912464|NCT01975779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912465|NCT04961372|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33912466|NCT01204619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912467|NCT06503861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912468|NCT01897961|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33912469|NCT00525148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912470|NCT00246467|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33993633|NCT04374864|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Good health of the human subjects was confirmed with a complete medical history and physical examination. Fasting of all volunteers eliminated the possible interaction from high fat meals. The evaluation of safety of the study was based on monitoring of blood glucose level, vital signs, pulse rate, monitoring of adverse events, and physical examination. Samples from 6 healthy, adult, male, Egyptian volunteers (age: 25-39 years, average weight: 89.8 kg, average body mass index (BMI): 34.2) were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 8, 24, 48, 72, 96, 120, 144 and 168 hrs, transferred to heparinized centrifuge tubes and analyzed with the proposed method after single oral dose administration of one Zafatek® tablet nominally containing 50 mg TLN. Blood samples (1 mL of each sample) were centrifuged at 3000 rpm for 5 min.||||
33993634|NCT06737055|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is an implementation science project to develop and test an educational program for teaching home visitors and expectant and new parents about sleep. The study uses the RE-AIM framework.||||
33993635|NCT04733183|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Safety Run in: Six (6) Patients will be treated with 1000 or 850 mg/m2 dacarbazine (DTIC) on Day 1 every three weeks plus 13 µg/kg L19TNF on Days 1, 3 and 5 every three weeks to test for safety of the combination as evaluated by an independent Data Safety Monitoring Board (DSMB).~Tumor Activity Evaluation Part Arm 1: Patients will receive DTIC on Day 1 and L19TNF on Days 1, 3 and 5 every 3 weeks.~Arm 2: Patients will receive DTIC on Day 1 every 3 weeks."||||
33993636|NCT06742970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993637|NCT06732349|||COHORT||PROSPECTIVE|||||||
33993638|NCT01653951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33993639|NCT06742619|||CASE_CONTROL||PROSPECTIVE|||||||
33993640|NCT05479552|||COHORT||CROSS_SECTIONAL|||||||
33993641|NCT00884637|||COHORT||PROSPECTIVE|||||||
33993642|NCT04897256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators involved in measuring outcomes and analyzing the data, will remain blinded to the group that participants are assigned to.||f|f|f|t
33993643|NCT04109131|NA|SINGLE_GROUP||OTHER||NONE||||||
33993644|NCT06245408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993645|NCT05487625|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be provided with study cigarettes (commercially available) however the brand will not be provided to them.|Participants will complete five ETM conditions, which include six trials assessing different cigarette prices: a) high-ventilated cigarette alone, b) low-ventilated cigarette alone, c) high- and low-ventilated cigarette with high-ventilated cigarettes increasing in price, d) high- and low-ventilated cigarette with low-ventilated cigarettes increasing in price, and e) usual, high- and low-ventilated cigarette with usual cigarettes increasing in price.|t|f|f|f
33779130|NCT01400893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912471|NCT04611685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, investigator and outcome assessors are all prevented from having knowledge of the interventions assigned to individual participants. Only the care provider knows individual specified intervention.|Participants are assigned to one of two groups in parallel during the study, using the method of randomization. The ratio is 1:1.|t|f|t|t
33779131|NCT05148767|NA|SEQUENTIAL||TREATMENT||NONE||||||
33779132|NCT02659995|||COHORT||PROSPECTIVE|||||||
33779133|NCT03004599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779134|NCT03660943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779135|NCT02471846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779136|NCT00884819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779137|NCT05685680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779138|NCT05440799|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33779139|NCT06163716|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The GOIZ ZAINDU pilot trial is a one-year controlled, randomized, multidomain intervention trial, for prevention of cognitive decline, carried out in the municipality of Beasain in the Basque Country (Spain).|t|t|t|t
33912472|NCT00878917|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33912473|NCT01683071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912474|NCT01727310|||CASE_ONLY|||||||||
33912475|NCT01251276|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912476|NCT05960188|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|At the end of the study, the participant is debriefed about their performance.|We are asking the opinions of a group of clinicians.|t|f|f|f
33912477|NCT02266186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912478|NCT01625598|||CASE_ONLY||PROSPECTIVE|||||||
33912479|NCT01157416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912480|NCT06554470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912481|NCT01001455|||||PROSPECTIVE|||||||
33912482|NCT02347111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912483|NCT02007330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33912484|NCT00207766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912485|NCT01013909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33912486|NCT04761887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912487|NCT00572806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993646|NCT05896995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993647|NCT03922724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993648|NCT05719558|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993649|NCT00027274|||FAMILY_BASED||OTHER|||||||
33993650|NCT05513677|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"1. Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised)~   Selection follows documented hospital protocols for routine catheterisation~2. Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)~   * 20 who receive the M4D coated catheter.~  * 10 who receive the standard uncoated catheters used in routine patient care."||||
33993651|NCT06741540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33993652|NCT06726993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993653|NCT01714895|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33993654|NCT05816785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993655|NCT06743282|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993656|NCT05745493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993657|NCT05025527|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33993658|NCT06626932|||COHORT||CROSS_SECTIONAL|||||||
33993659|NCT06741410|||CASE_CONTROL||RETROSPECTIVE|||||||
33993660|NCT06493019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993661|NCT06114095|||COHORT||PROSPECTIVE|||||||
33993662|NCT06250881|||COHORT||RETROSPECTIVE|||||||
33993663|NCT01747668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993664|NCT04633564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Multicenter, Double-Blind, Randomized, Parallel-Group|t|t|t|t
33993665|NCT01018862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993666|NCT03053362|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Determining the effectiveness of a new tool used to detect changes in cognition among individuals with MDD.||||
33993667|NCT00491192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993668|NCT04884308|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33993669|NCT02070783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33993670|NCT00421304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993671|NCT05437068|NA|SINGLE_GROUP||OTHER||NONE||||||
33993672|NCT04432636|NA|SINGLE_GROUP||OTHER||NONE||||||
33779140|NCT05039424|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||A comparative effectiveness, single center (with two surgical units), randomized (1:1) study of POP vs. sham endoscopic surveillance in patients with medically refractory gastroparesis. This study will also include a crossover approach, offering POP to patients randomized to the sham arm, if they remain symptomatic at 12 weeks post randomization.|t|t|t|f
33779141|NCT05742724|NA|SINGLE_GROUP||OTHER||NONE||||||
33779142|NCT00293462|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33779143|NCT01133262|||||PROSPECTIVE|||||||
33839959|NCT05445947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The centers will be randomized by the research team to the intervention group (five to six centers) or control group (five to six centers) using a random number generator.|The EASEL trial will employ a Type 2 hybrid implementation-effectiveness design using a cluster randomized controlled trial. A hybrid design approach involves the simultaneous evaluation of both a programme's outcomes as well as the effectiveness of the implementation of the programme. A Type 2 hybrid design also enables the assessment of the feasibility of the programme. As part of the trial, 12 childcare centres will be randomized to receive training in the EASEL Approach (six sites, referred to as the intervention sites) or continue with business-as-usual (BAU) (six sites). Educators in the BAU group will be provided the option to be trained in the EASEL Approach following completion of the study.|f|f|f|t
33912488|NCT04315376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912489|NCT01959737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690554|NCT02417844|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690555|NCT01125501|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33690556|NCT06081517|||COHORT||PROSPECTIVE|||||||
33690557|NCT00920205|NA|SINGLE_GROUP||||NONE||||||
33690558|NCT03733340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690559|NCT02799979|||CASE_CONTROL||PROSPECTIVE|||||||
33690560|NCT05305027|||COHORT||RETROSPECTIVE|||||||
33690561|NCT03325699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690562|NCT06364774|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot, phase I/II study of 12 subjects.||||
33690563|NCT05541224|||CASE_ONLY||RETROSPECTIVE|||||||
33690564|NCT05592522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690565|NCT00637871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690566|NCT05350176|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33690567|NCT03194503|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690568|NCT01764035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690569|NCT04113031|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33690570|NCT06390137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33690571|NCT06183190|||COHORT||PROSPECTIVE|||||||
33690572|NCT03354975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33690573|NCT05028738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-masked (i.e. raters)|Two-arm, randomized feasibility trial|f|f|t|t
33690574|NCT05192122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Discontinue maintenance therapy after 3 years for Bone marrow MRD-negative VGPR or CR (on 2 separate occasions 12 months apart)~Continue maintenance therapy per standard of care (SOC) for Bone marrow MRD-positive VGPR or CR"||||
33690575|NCT00082927|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33690576|NCT06425159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690577|NCT03508427|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One-arm study||||
33779144|NCT06263257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Blinding In this study, blinding of participants and the statistician is planned. Blinding of the researcher implementing the intervention will not be possible. Since participants will not know to which group they are assigned, participant blinding is considered feasible. Data related to the scales (post-test) will be coded as 'A' and 'B' without indicating whether they belong to the intervention or control group. The coded data will be analyzed by a statistician, without knowledge of group allocation. After the statistical analyses are completed, the coding for the intervention and control groups will be revealed. This blinding technique is intended to minimize statistical bias.|For the intervention group, the first measurement (afternoon of the day before surgery) will include State-Trait Anxiety Inventory and General Comfort Questionaire, the second measurement (Postoperative Day 5 - discharge day) will include State Anxiety Inventory and General Comfort Questionaire. The sessions of the Mandala Art Therapy training program for the intervention group will be conducted as follows: Session 1 on Postoperative Day 5 - discharge day (after the scales), Session 2 on 1st Control (1 week after surgery), Session 3 on 2nd Control (2 weeks after surgery), and the third measurement at 3rd Control (1 month after surgery). For the Control Group, the third measurement (1 month after surgery) will be collected through self-reporting for State Anxiety Inventory and General Comfort Questionaire. This stage aims to conduct a randomized controlled study.|t|t|f|t
33779145|NCT05123274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779146|NCT05518123|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779147|NCT04581239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779148|NCT04311073|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized Double Blind Placebo clinical trial|t|t|t|f
33838830|NCT04074057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization and group allocation are done by the research coordinator. Final assessment is also arranged by research coordinator. Blinded assessor will conduct the final assessment|All patients who are referred for Cardiac Rehabilitation post discharge from hospital will be assessed by the Physiotherapist during the first follow-up appointment to determine eligibility for inclusion. During this session, exercise testing and a body composition analysis will be done for every patient. The Physiotherapist will then stratify all patients into low, moderate and high-risk groups only those with low and moderate risk will be included into the study after informed consent is attained. A research assistant randomise the patients into two groups, namely the intervention group or the control group. Block randomisation method will be used by using the randomisation function in Red Cap created by independent aata manager who is not part of the study team.|f|f|t|t
33839960|NCT00709267|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33839961|NCT00590655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993673|NCT01302548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33993674|NCT01609257|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993675|NCT00402103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993676|NCT01367054|RANDOMIZED|CROSSOVER||||NONE||||||
33993677|NCT04056585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33690578|NCT02594332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690579|NCT01900639|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33690580|NCT04383899|||CASE_CONTROL||PROSPECTIVE|||||||
33690581|NCT03473249|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690582|NCT06088381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690583|NCT02779465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690584|NCT05350735|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which arm they belong to.||t|f|f|f
33690585|NCT02521103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690586|NCT04713657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double-blinded, placebo-controlled (1:1) randomized, single-center trial|t|t|t|f
33690587|NCT04493879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690588|NCT05773157|NA|SINGLE_GROUP||PREVENTION||NONE||A single pilot group of participants will complete the online modules and evaluate their effectiveness using pre and post surveys.||||
33690589|NCT00002311||||TREATMENT||||||||
33690590|NCT06744634|||OTHER||PROSPECTIVE|||||||
33690591|NCT04557748|||COHORT||PROSPECTIVE|||||||
33690592|NCT02801344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33690593|NCT06699056|||COHORT||PROSPECTIVE|||||||
33912490|NCT01865435|NA|SINGLE_GROUP||||NONE||||||
33912491|NCT05674344|NA|SINGLE_GROUP||OTHER||NONE||||||
33912492|NCT02946879|||COHORT||PROSPECTIVE|||||||
33912493|NCT01680588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912494|NCT06260644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double ( participants, outcomes assessor) participants and both assessors will be blind to the type of material used|parallel assignment|t|f|f|t
33912495|NCT01790737|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993678|NCT06559280|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993679|NCT01645007|||COHORT||PROSPECTIVE|||||||
33993680|NCT06242717|||COHORT||PROSPECTIVE|||||||
33993681|NCT02332863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993682|NCT00787124|||COHORT||PROSPECTIVE|||||||
33993683|NCT06208358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085426|NCT02996383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085427|NCT04329260|||FAMILY_BASED||PROSPECTIVE|||||||
34085428|NCT01086488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085429|NCT01685437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085430|NCT03023501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085431|NCT01341704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34085432|NCT02759458|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34085433|NCT02265523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085434|NCT02658539|||COHORT||CROSS_SECTIONAL|||||||
34085435|NCT02978469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085436|NCT06099535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085437|NCT01667588|||COHORT||PROSPECTIVE|||||||
34085438|NCT06181149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34085439|NCT04273490|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085440|NCT02790177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085441|NCT02530541|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912496|NCT06156358|||OTHER||RETROSPECTIVE|||||||
33912497|NCT03246217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33912498|NCT04861961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized study comparing three bariatric surgical techniques|t|f|f|f
33912499|NCT00757939|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33912500|NCT03096223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912501|NCT05835752|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33912502|NCT01636752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912503|NCT05929417|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33912504|NCT00586391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912505|NCT04541212|||COHORT||OTHER|||||||
33912506|NCT00521092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993684|NCT04387786|||CASE_ONLY||RETROSPECTIVE|||||||
34085442|NCT05972707|||OTHER||CROSS_SECTIONAL|||||||
34085443|NCT03426345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912507|NCT01189435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912508|NCT02500238|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33912509|NCT02069496|||||PROSPECTIVE|||||||
33912510|NCT03140930|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33912511|NCT02130427|NA|SINGLE_GROUP||OTHER||NONE||Pilot study||||
33912512|NCT00882102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912513|NCT03923283|||CASE_CONTROL||RETROSPECTIVE|||||||
34085444|NCT01621061|||CASE_CONTROL||PROSPECTIVE|||||||
34085445|NCT03532763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, double blind, placebo-controlled, parallel|t|f|t|f
34085446|NCT01469871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085447|NCT06418048|||COHORT||PROSPECTIVE|||||||
34085448|NCT03043053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085449|NCT00729742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085450|NCT01183923|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34085451|NCT02251847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085452|NCT03444584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, Placebo-controlled, Double-blind Study|Efficacy and Safety of MEDI0382 versus Placebo in Overweight/Obese Participants with Type 2 Diabetes Mellitus Treated with Dapagliflozin and Metformin|t|t|t|t
34085453|NCT05259631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085454|NCT04116333|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be aware of the general nature of the study, but they will be blinded to specific objectives of the study|Participants will be randomized to perform either Macintosh laryngoscope or Macintosh laryngoscope with endotracheal tube introducer first, using the envelope method. After completing these initial interventions, they will use the second method.|t|f|f|f
34085455|NCT05805449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085456|NCT03667521|||CASE_CONTROL||PROSPECTIVE|||||||
34085457|NCT01973751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085458|NCT00322036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085459|NCT04192149|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Within subjects design of focused ultrasound and control|t|f|f|f
34085460|NCT00930020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085461|NCT02226770|NA|SINGLE_GROUP||SCREENING||NONE||||||
33912514|NCT05647902|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912515|NCT00437606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912516|NCT04451655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912517|NCT06141434|||COHORT||PROSPECTIVE|||||||
33912518|NCT06117800|NA|SINGLE_GROUP||OTHER||NONE||||||
33912519|NCT06152250|NA|SINGLE_GROUP||OTHER||NONE||Liver Fine-Needle Aspiration, blood sampling and clinical evaluation||||
33779149|NCT06517758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This is a participant, investigator, and sponsor-blinded study. Participants, investigator staff, persons performing the assessments and the Clinical Trial Team will remain blinded to the identity of treatment from the time of randomization until database lock after all participants have completed the double-blind treatment period. The following methods will be used to ensure that blinding is properly maintained:~1. Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by anyone involved in the study~2. The identity of the treatment will be concealed by the use of study treatments that are all identical in packaging, labeling, schedule of administration, appearance, taste, and odor"|The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.|t|t|t|t
33779150|NCT03904082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779151|NCT02900027|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33779152|NCT02213679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33779153|NCT02152436|||OTHER||PROSPECTIVE|||||||
33779154|NCT03213041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779155|NCT00714233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779156|NCT03772314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779157|NCT00651170|||COHORT||PROSPECTIVE|||||||
33779158|NCT01092624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779159|NCT04116320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779160|NCT00801242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779161|NCT03471468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33779162|NCT02055859|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779163|NCT00528190|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33912520|NCT04185480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A prospective cohort will be compared to a historical control group.||||
33912521|NCT04362462|||COHORT||OTHER|||||||
33912522|NCT00374374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33912523|NCT00916500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912524|NCT03147144|||COHORT||PROSPECTIVE|||||||
33912525|NCT05742672|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33912526|NCT03526003|||COHORT||PROSPECTIVE|||||||
33912527|NCT01176097|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33912528|NCT02782871|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33912529|NCT01784601|||CASE_CONTROL||PROSPECTIVE|||||||
33912530|NCT05265741|||CASE_CROSSOVER||PROSPECTIVE|||||||
33912531|NCT03979521|||COHORT||RETROSPECTIVE|||||||
33912532|NCT06519006|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33912533|NCT06121700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912534|NCT01788306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779164|NCT03109106|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Will identify eligible patients and controls prospectively in 2 week alternating blocks. Study candidates enrolled during the intervention blocks will receive PCT-guided therapy. Study candidates enrolled during the control periods will receive standard care.||||
33779165|NCT05297123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779166|NCT00165139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085462|NCT03093727|||CASE_ONLY||PROSPECTIVE|||||||
33779167|NCT01968005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085463|NCT05884593|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will undergoing posterior thoracolumbar arthrodesis procedures utilizing pedicle screw instrumentation.||||
34085464|NCT00110708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34085465|NCT03601676|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pragmatic clinical trial of a multidimensional technology and educational intervention undertaken over 16 months with an 8-month pre-intervention and an 8-month post-intervention period, conducted across 21 emergency departments with 10 serving as intervention and 11 as control sites.||||
34085466|NCT01383278|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34085467|NCT05187221|||COHORT||CROSS_SECTIONAL|||||||
34085468|NCT00909870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085469|NCT02337764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085470|NCT03369782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The syringes are prepared by the research assistant who was not involved in patient management. The anesthetist and surgeon are blinded for patient allocation.|Group A receives rocuronium, followed by sugammadex. Group B receives placebo|t|t|t|t
34085471|NCT06380569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Kessler Foundation Strength Identification and Expression (KF-STRIDE®)|f|f|f|t
34085472|NCT04364516|||COHORT||RETROSPECTIVE|||||||
34085473|NCT01130844|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085474|NCT04280549|||CASE_CONTROL||PROSPECTIVE|||||||
33690594|NCT06674018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Randomization is performed by external party. Each capsule bottle is named with a unique number (1-96) and no other identifier. Capsule bottles have already been randomized by the external party using block randomization with random block sizes of 4 or 8. Study participants recieve the next available capsule bottle based on their order of recruitment. This way, everyone involved in the study is fully blinded and it is also impossible to guess which participants belong to the same group. When all study participants have been recruited and the collected data have been cleaned, the researchers performing the statistical analyses are informed about which participants belong to the same group. The identity of the groups will only be revealed after statistical analyses have been completed.||t|t|t|t
34085475|NCT00650962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34085476|NCT01032928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085477|NCT02850835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34085478|NCT02225418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085479|NCT05216575|||COHORT||RETROSPECTIVE|||||||
33690595|NCT06703190|||CASE_CONTROL||RETROSPECTIVE|||||||
33690596|NCT06728228|NA|PARALLEL||TREATMENT||NONE||||||
33690597|NCT05201924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||An bedtime routine interventional group and a healthy lifestyle control group|t|t|f|f
34085480|NCT05188105|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33690598|NCT02929251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690599|NCT03624296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690600|NCT02666534|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33690601|NCT04468321|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33690602|NCT06238817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085481|NCT02676804|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690603|NCT06274801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690604|NCT06322537|||COHORT||RETROSPECTIVE|||||||
33690605|NCT02301611|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33690606|NCT00253500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690607|NCT06507722|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Randomization will be done via a computer-generated random number list prepared by the statistician who will have no clinical involvement in the study. The list will then be provided to the study coordinator. The investigator will not be masked to assignment for Aim 1 as the investigator will be available during OGTT testing as needed. In Aim 2, the investigator will be blinded to randomization.|For randomization in Aim 1, participants will be assigned to Early or Late OGTT for the first visit with crossover to the alternate for the second visit. In Aim 2, participants will be assigned to Early or Late standardized first meal for Day 1 with crossover to the alternate for Day 8.|f|f|t|t
33690608|NCT04325373|||CASE_ONLY||RETROSPECTIVE|||||||
33779168|NCT01085461|||CASE_ONLY||CROSS_SECTIONAL|||||||
33779169|NCT05861089|||COHORT||PROSPECTIVE|||||||
34085482|NCT01096940|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34085483|NCT03257267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085484|NCT03592628|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085485|NCT01631942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085486|NCT04793568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085487|NCT05453812|||COHORT||PROSPECTIVE|||||||
33779170|NCT05282199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779171|NCT01449929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779172|NCT06324955|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33779173|NCT04317170|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085488|NCT01715246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34085489|NCT05426174|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This study will be blinded to participants, investigators/sub-investigators, outcomes assessors, laboratory personnel, and the sponsor study staff (with the exception noted for study staff involved in the ESDRs). Study staff involved in the ESDRs will be unblinded to group assignment of participants in the sentinel safety cohorts. After the ESDRs are performed for the sentinel safety cohorts, the SMT will continue monitoring the safety aspects of the study as part of blinded periodic safety reviews. Those preparing/administering the study interventions will be unblinded.||t|f|t|t
33690609|NCT05250752|NA|SINGLE_GROUP||TREATMENT||NONE||Cross-over. Off-On-Off treatment. Dose response||||
33690610|NCT06694701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779174|NCT00486915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33779175|NCT01261195|||COHORT||CROSS_SECTIONAL|||||||
33779176|NCT04925700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779177|NCT03359681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085490|NCT03881436|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34085491|NCT01597986|NA|SINGLE_GROUP||||NONE||||||
34085492|NCT03662412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993685|NCT05826119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The patients were randomly divided into two groups according to a 1:1 randomization ratio using opaque sealed envelopes before surgery. Study randomization was performed using computer generated randomization codes by SPSS v23.0 (IBM, New York, USA). Each patient was asked to choose an envelope and the patients were assigned to the study according to the group specified in the envelope. The drugs to be used were prepared 30 minutes before the surgery by the nurse who did not participate in the study in the drug preparation room. Everyone involved in this study, including patients, researchers, the anesthesiologist responsible for anesthesia management, and the surgeon, remained blind to group distribution during the study.|t|f|f|t
33993686|NCT02589301|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33993687|NCT03510923|||COHORT||PROSPECTIVE|||||||
33993688|NCT00216736|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33993689|NCT05943613|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33993690|NCT04640129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993691|NCT00746395|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33993692|NCT06556849|||CASE_CONTROL||RETROSPECTIVE|||||||
33993693|NCT01058213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993694|NCT00975754|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33993695|NCT05832658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993696|NCT03904381|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33993697|NCT05564091|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34085493|NCT02266524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085494|NCT04980404|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34085495|NCT01308515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085496|NCT00310544|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34085497|NCT02339688|NA|SINGLE_GROUP||||NONE||||||
34085498|NCT02078544|||CASE_ONLY||PROSPECTIVE|||||||
34085499|NCT03278899|||COHORT||PROSPECTIVE|||||||
34085500|NCT02890017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34085501|NCT05513547|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|Blinding of participants and researchers is not possible in this design|"Sequential Bayes Factor approach: spectral characteristics of daytime LE varied in a within-subject manner in three sequential 7-hour LE protocols (P1, P2, P3).~Physical activity varied between subjects in two subgroups: one 'resting' group and one 'hiking' group. The latter will hike (P2/3) or walk on a treadmill (P1) for 4 hours during LE."||||
34085502|NCT02737137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34085503|NCT01612195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085504|NCT01242436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085505|NCT05442658|||CASE_CONTROL||PROSPECTIVE|||||||
34085506|NCT01060371|||COHORT||PROSPECTIVE|||||||
34085507|NCT03311191|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085508|NCT04166214|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34085509|NCT00601081|||COHORT||PROSPECTIVE|||||||
34085510|NCT04009616|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34085511|NCT02730962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085512|NCT04939467|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34085513|NCT02160626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690611|NCT05718544|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690612|NCT04059185|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33690613|NCT00216554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690614|NCT03508271|||COHORT||RETROSPECTIVE|||||||
33690615|NCT02732717|||COHORT||PROSPECTIVE|||||||
33690616|NCT05988515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"All perceptual ratings will be obtained from trained listeners who are blinded to treatment group and to timepoint. Binary rating of accuracy of the r sound (i.e., judgments of correct or incorrect) will be obtained from three listeners per token."|"Participants will be randomized across two conditions, CONCURRENT and SEQUENTIAL~Participants randomized to receive CONCURRENT treatment will receive speech lessons with a human clinician once per week for five weeks, along with 3 sessions per week of parent-supervised Chaining-AI (15 Chaining-AI sessions). Therefore, clinician-led and Chaining-AI are completed concurrently.~Participants randomized to receive SEQUENTIAL treatment will receive speech lessons with a human clinician once per week for five weeks, followed by three sessions per week of parent-supervised Chaining-AI for the NEXT five weeks. Therefore, clinician-led and Chaining-AI are completed sequentially."|f|f|f|t
33690617|NCT05315856|||COHORT||PROSPECTIVE|||||||
33690618|NCT00002567||||TREATMENT||||||||
33690619|NCT00400946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690620|NCT06743763|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental group: receives 8-week functional near-infrared spectroscopy (fNIRS) neurofeedback training (coupled with virtual reality), twice per week, each lasting 1 hour.~Comparative group 1: receives 8-week functional near-infrared spectroscopy (fNIRS) neurofeedback training without virtual reality(VR) technology, twice per week, each lasting 1 hour.~Comparative group 2: receives 8-week training using VR technology (without neurofeedback) twice per week, each lasting 1 hour."||||
33779178|NCT04088994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|"Randomized controlled experimental study, with 1:1 allocation ratio and two-armed blind assessment. Randomization will be stratified by age and level of HFC system to obtain two groups balanced with respect to the level of functional impairment of the upper limbs to be subjected to treatment in the two groups. Clinical evaluations will be performed before treatment (T0), at the end of treatment (T1), from 8 to 12 weeks after the end of treatment (T2) and finally, from 24 to 28 weeks after the end of treatment (T3).~Evaluation by fMRI will be performed at T0 and T1."|f|f|f|t
33779179|NCT01462201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779180|NCT05104931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33779181|NCT02829424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779182|NCT01770860|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33779183|NCT02404246|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779184|NCT06697353|||COHORT||RETROSPECTIVE|||||||
33993698|NCT03405688|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993699|NCT02278757|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33993700|NCT00371839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993701|NCT05264597|||CASE_CONTROL||PROSPECTIVE|||||||
33690621|NCT06568783|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center, single-arm study enrolling 21 adult participants to evaluate \[18F\]-FAPI-74 PET/ MRI for assessment of muscle and soft tissue involvement in Dermatomyositis.||||
33690622|NCT04494815|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33690623|NCT05868382|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690624|NCT04995796|NA|SINGLE_GROUP||OTHER||NONE||Prospective, single arm pre/post pilot study. This non-therapeutic study will provide no direct medical benefit to the research participants but will help the researchers learn more so that future generations may benefit.||||
33779185|NCT05323721|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779186|NCT05611619|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants will be aware that in any given study night they can be exposed to traffic noise. They will not be informed what noise condition will occur in any given night, but they can become unblinded to the exposure if they are awake, as they will hear the noise.~Study investigators responsible for analysing cognitive performance variables and physiological sleep data will be be blind to which noise interventions were introduced on which study nights."|"There will be two separate study periods, each one affording the opportunity to investigate different acoustical characteristics of tyre noise and their physiological effects. Each of these study arms has a prospective within-subjects cross-over design. The order of the noise exposure conditions will be be randomly assigned across participants using a Latin square design to avoid first-order carryover effects. Each subject will be exposed to one night of each of the following:~One quiet night: No noise will be played, serving as a control night to assess individual baseline sleep, cardiometabolic profile, and cognitive performance;~Four traffic noise nights: Tyre noise from road traffic noise be played into the rooms to determine the effects of noise on sleep, cardiometabolic function and cognitive performance. These noise nights will be in a 2×2 factorial design so that we can examine each combination of two specific noise characteristics."|t|f|f|t
33779187|NCT04668144|RANDOMIZED|PARALLEL||TREATMENT||NONE|Laboratory personnel will be blinded to treatment assignments|||||
33779188|NCT05377710|NA|SINGLE_GROUP||TREATMENT||NONE||human||||
33779189|NCT01321073|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study is observational and intended to provide ongoing support for the approximately 20 remaining subjects enrolled in the DelIVery for PAH Study including support of pump refills and system replacements. The study is expected to continue at the eight (8) remaining centers located in the United States that have current DelIVery for PAH study subjects enrolled.||||
33779190|NCT05734456|||OTHER||CROSS_SECTIONAL|||||||
33779191|NCT06696183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779192|NCT02663258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779193|NCT05986019|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single-blind|Active or Sham tFUS|t|f|f|f
33779194|NCT04648306|||COHORT||PROSPECTIVE|||||||
33779195|NCT00125983|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33779196|NCT05827419|||CASE_ONLY||PROSPECTIVE|||||||
33779197|NCT01039090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779198|NCT06433466|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33779199|NCT00890474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33779200|NCT06431022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33838831|NCT06189859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation of patients will be in sealed envelopes to be opened on day of the procedure. The investigator and care provider (same) will thus be unmasked. Participant and outcomes assessor will remain masked until the end of the study.||t|f|f|t
33838832|NCT00200291|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33838833|NCT00958542|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993702|NCT03786172|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993703|NCT03260686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993704|NCT03590795|||OTHER||PROSPECTIVE|||||||
33993705|NCT06056414|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993706|NCT00310271|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33993707|NCT01969123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993708|NCT01789463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690625|NCT03353389|||COHORT||RETROSPECTIVE|||||||
33690626|NCT06571409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690627|NCT01614860|||COHORT||PROSPECTIVE|||||||
33838834|NCT05923099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838835|NCT02908763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838836|NCT06165757|NA|SINGLE_GROUP||OTHER||NONE||||||
33838837|NCT01055704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838838|NCT00455806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839962|NCT04700553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839963|NCT00919191|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33839964|NCT03470259|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993709|NCT06015958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A staff member not part of the study group will be assigned to distribute blinded samples. The participant or the investigators will not be aware of the dose groups.|Participants will be randomly assigned to one of the 2 groups for brushing teeth with a probiotic toothpaste containing different doses of Streptococcus salivarius M18 Study Group A: BLIS M18 Toothpaste (10 million Cfu/dose) (n = 10) Study Group B: BLIS M18 Toothpaste (1 Million Cfu/dose) (n = 10)|t|f|f|f
33912535|NCT04894006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Community health worker (CHW) delivered home visit, culturally and language-appropriate intervention for ethnic and underserved dementia family caregivers of persons with dementia (PWD). The CHW delivered home visit intervention includes stress reduction techniques by mindful deep breathing and compassionate support/listening and caregiving education to improve caregiver's health, wellbeing, and positive interactions with the PWD.||||
33993710|NCT05962476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993711|NCT04116957|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33993712|NCT05744232|RANDOMIZED|PARALLEL||TREATMENT||NONE|"An independent member of the research team, who will not be delivering the intervention or conducting baseline or follow-up assessments, will do the randomisation by inputting the data onto the software. The research team will then notify the participant of their allocation group and further steps.~Due to the nature of the intervention and the control group, blinding of the participants and the researchers to the intervention is not possible. However, the assessment of the primary outcome will be blinded, as questionnaires will be self-administered online. The PIS will present the study to participants in a more general context, focusing on the impact of total diet replacement on well-being, without mentioning disordered eating, as this could predispose participants in their questionnaire answers and heavily affect the outcomes of this study, introducing measurement bias and weakening the conclusions drawn."|||||
33912536|NCT05271084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993713|NCT05619692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993714|NCT02709057|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33993715|NCT02679729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33993716|NCT02965859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993717|NCT02615249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912537|NCT05625386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993718|NCT00650377|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993719|NCT02518945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993720|NCT02462681|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33912538|NCT00518219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912539|NCT02912806|||COHORT||PROSPECTIVE|||||||
33912540|NCT02629601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33912541|NCT00548080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993721|NCT06320067|RANDOMIZED|PARALLEL||TREATMENT||NONE||Platform trial testing three research comparisons where patients are randomised either to experimental treatments in Arms S, P and N or their corresponding SoC control Arms A and A(N).||||
33993722|NCT03810586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Recruitment will be via printed advertisements distributed throughout the medical center. Volunteers will arrive on the morning of the test and fill a questionnaire about their demographics and every day activities. After completing the questionnaire, the participants will be connected to both devices, one on each arm and undergo a briefing about both devices. A first calibration measurement will take place followed by BP measurement every 20 minutes, and up to a 24 hour period. After 24 hours of measurements, the participants will return to Hadassah Medical Center and fill in another questionnaire, which will include feedback on the use of both devices.||||
33993723|NCT03442530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912542|NCT00360243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912543|NCT01763476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912544|NCT01943734|NA|SINGLE_GROUP||SCREENING||NONE||||||
33779201|NCT05881785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|A total of 465 patients were randomly assigned to 100mg GR1501 injection, 200mg GR1501 injection, and placebo group at 1:1:1. Randomized stratification factors included history of biologic therapy and weight. After the completion of 16-week ,subjects in the GR1501 injection group continued to be administered GR1501 injection, and those in the placebo group were randomly assigned 1:1 to the 100mg GR1501 injection and 200mg GR1501 injection.|t|t|t|t
33779202|NCT03059992|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, non-comparator, single arm||||
33690628|NCT05967416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Enrollment will begin with Cohort 1, Group 1 (SIRPant-M monotherapy, low dose). Upon approval from the SRC after Cohort 1, Group 1 review, enrollment in Cohort 1, Group 2 (SIRPant-M coupled with XRT, low dose) and Cohort 2, Group 3 (SIRPant-M monotherapy, intermediate dose) will open. Upon approval from the SRC after Cohort 1, Group 2 and Cohort 2, Group 3 review, enrollment in Cohort 2, Group 4 (SIRPant-M + XRT, intermediate cell dose) will open. Upon further approval from the SRC, Cohort 3, Groups 5 and 6 (high cell dose + XRT, alternate day- versus weekly IT-dosing) will enroll.||||
33690629|NCT06701578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690630|NCT01669564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33690631|NCT03599401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed Envelopes|A total of 42 subjects participated in the study. All the subjects underwent scaling and root planning and were divided into 3 groups Group 1 - low dose aspirin ( 75 mg) once daily Group 2 - omega 3 fatty acids (500 mg) twice daily Group 3 - placebo once daily|t|f|f|t
33690632|NCT04679298|||COHORT||PROSPECTIVE|||||||
33690633|NCT01373307|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33690634|NCT05533476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690635|NCT04476823|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33690636|NCT06042881|||COHORT||RETROSPECTIVE|||||||
33690637|NCT06704295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690638|NCT05372536|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33690639|NCT05006794|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779203|NCT04216225|||OTHER||PROSPECTIVE|||||||
33779204|NCT01697137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33779205|NCT00061100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779206|NCT02357758|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33779207|NCT00004287||||TREATMENT||||||||
33779208|NCT03393260|||OTHER||CROSS_SECTIONAL|||||||
33779209|NCT02128646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779210|NCT06697665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779211|NCT00000926||||PREVENTION||DOUBLE||||||
33779212|NCT01656941|||COHORT||PROSPECTIVE|||||||
33779213|NCT00972712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690640|NCT02829918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690641|NCT01257802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690642|NCT06411561|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33690643|NCT03512990|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"We suggest an injection more distally, where superior trunk is in costoclavicular space below omohyoid muscle, proximal to the suprascapular outlet. The needle is advanced below the prevertebral layer of deep cervical fascia, avoiding that the tip of the needle lies in the fascial plane between investing layer of deep vertebral fascia and prevertebral layer.~Patients scheduled for rotator cuff surgery will receive 6 mL of 0,5% bupivacaine. Successful block is defined as motor score of ≤ 2 on modified Bromage scale in the deltoid and bíceps; absent sensation to cold and pinprick sensation in C5 and C6 dermatomes within 30 minutes of injection.~To evaluate phrenic nerve, diaphragmatic excursion will be assessed by ultrasonography of ipsilateral hemidiaphragm and with impedance tomography.~Moreover, 6 mL of methylene blue will be injected into cadavers to evaluate if dispersion was restricted to fibers of the superior trunk and don't reach phrenic nerve."||||
33690644|NCT01742871|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690645|NCT05045157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779214|NCT03503838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention group with a wait-list control group||||
33779215|NCT04671290|||CASE_CONTROL||RETROSPECTIVE|||||||
33779216|NCT06634459|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in a 1:1 ratio to receive either (1) the Reia System (RS) or (2) standard pessary care (SPC).||||
33779217|NCT02485795|||COHORT||PROSPECTIVE|||||||
33779218|NCT03082885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33779219|NCT02859597|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779220|NCT02354248|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779221|NCT06184477|||CASE_CONTROL||RETROSPECTIVE|||||||
33779222|NCT05785845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779223|NCT02187211|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33779224|NCT04822753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Single blinded, assessor blinded||t|f|f|t
33779225|NCT05818397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912545|NCT03327753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Given that this is an exercise study blinding of participants and those delivering the exercise program will not be possible. Outcome measures will be collected by an investigator not aware of treatment allocation, but most outcome measures will be self-reported and thus, true assessor blinding will no be possible. All statistical analysis will be conducted by a blinded investigator.|Participants will be randomized into one of two groups, both of which are exercises considered part of standard care.|f|f|t|t
33912546|NCT05631327|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779226|NCT04099953|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized Controlled Study||||
33779227|NCT06417255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779228|NCT03628924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779229|NCT06303830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779230|NCT05811208|||COHORT||PROSPECTIVE|||||||
33779231|NCT04570085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779232|NCT01342653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779233|NCT00616161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779234|NCT05103254|||COHORT||OTHER|||||||
33779235|NCT03232177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779236|NCT03605875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||1:1 allocation||||
33779237|NCT06697613|||COHORT||RETROSPECTIVE|||||||
33779238|NCT06696976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated.||f|f|f|t
33779239|NCT06563531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779240|NCT01333761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779241|NCT05046483|||CASE_CONTROL||PROSPECTIVE|||||||
33912547|NCT06530602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993724|NCT06626607|||COHORT||RETROSPECTIVE|||||||
33912548|NCT03628508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912549|NCT05550194|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Achalasia (phenotypes II and III) with VZV DNA in saliva||||
33912550|NCT06552559|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1/2 study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with secondary central nervous system involving relapsed or refractory B-cell non-Hodgkin lymphoma: a single arm, open label, multicentre study||||
33912551|NCT00665288|||COHORT||PROSPECTIVE|||||||
33912552|NCT03616665|NA|SINGLE_GROUP||TREATMENT||NONE||In the proposed prospective, mono-site, evaluator-blinded study, 100 PDD patients will be included. The study addresses the primary research question: Is the six-week inpatient CBASPersonalized-treatment effective in PDD? It is hypothesized that six weeks after randomization, CBASPersonalized will evoke significant reduction in depressive symptomatology. In addition, feasibility will be examined and differential indication by moderator, process and long-term analyses will be investigated. A follow-up survey six months after end of treatment will provide important results on long-term treatment outcome.||||
33912553|NCT01390116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33912554|NCT02362087|||COHORT||PROSPECTIVE|||||||
33912555|NCT02985450|||COHORT||PROSPECTIVE|||||||
33912556|NCT03430245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912557|NCT04538885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33912558|NCT03622593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33993725|NCT00242554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993726|NCT01576705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993727|NCT06366386|||COHORT||PROSPECTIVE|||||||
33993728|NCT00834717|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993729|NCT03797703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33993730|NCT01229800|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33993731|NCT06627218|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33993732|NCT05199064|||OTHER||RETROSPECTIVE|||||||
33993733|NCT02257554|||COHORT||PROSPECTIVE|||||||
33690646|NCT06483074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690647|NCT03470974|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33690648|NCT06458959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|cluster randomization at the service coordinator level||f|t|f|f
33690649|NCT04028414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690650|NCT06614712|||COHORT||RETROSPECTIVE|||||||
33690651|NCT03935620|NA|SINGLE_GROUP||TREATMENT||NONE||A single case multiple-baseline across behaviors (i.e., EMT strategies) design-replicated across ten caregiver-child dyads will be used to evaluate the effect of implementing EMT via telepractice on parent's EMT strategy usage and concomitant increases in child communication. Within each design there will be three potential demonstrations of effect and three potential replications across participants||||
33690652|NCT04685590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690653|NCT06730334|||COHORT||PROSPECTIVE|||||||
33690654|NCT06552364|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Blinding of exposures will be performed by the air pollution exposure laboratory (APEL) engineer. Visually indistinguishable inhalers will be coded by research pharmacy staff. All assays will be performed by personnel who do not know the exposure conditions of individual samples.|Participants will become their own control as they experience all four combinations of exposures at four different time intervals, each separated by at least a month for washout: 1) Filtered Air-Inhaled Corticosteroid (FA-ICS), 2) Filtered Air- No Inhaled Corticosteroid (FA-no ICS), 3) Diesel Exhaust-Inhaled Corticosteroid (DE-ICS), and 4) Diesel Exhaust- No Inhaled Corticosteroid (DE-no ICS).|t|f|t|t
33690655|NCT00371501|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33690656|NCT03163810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912559|NCT06422351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912560|NCT05111899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912561|NCT03664973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912562|NCT06177782|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912563|NCT03682510|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants who fulfilled the eligibility criteria were explained about the study with the beneficial and possible adverse effects of lidocaine. Informed consent was obtained from them after that participant were randomized into 3 groups: group 1 \[N\&H technique\], group 2 \[N\&H technique\] and group 3 stepwise devascularization||||
33912564|NCT00240630|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33912565|NCT04543474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912566|NCT04983329|NA|SINGLE_GROUP||OTHER||NONE||||||
33912567|NCT00772993|||||PROSPECTIVE|||||||
33912568|NCT04699903|||COHORT||PROSPECTIVE|||||||
33912569|NCT05436899|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33912570|NCT00059722|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33912571|NCT02928549|||COHORT||PROSPECTIVE|||||||
33912572|NCT03169452|||OTHER||CROSS_SECTIONAL|||||||
33912573|NCT05477342|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Transtheoretical Model||||
33912574|NCT02953392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33912575|NCT03798444|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912576|NCT03625362|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33912577|NCT00931671|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33912578|NCT03106194|NA|SINGLE_GROUP||SCREENING||NONE||||||
33912579|NCT06419868|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is an experimental study, with a randomized controlled trial design, with a control group.|f|f|t|t
33912580|NCT06323772|||COHORT||PROSPECTIVE|||||||
33912581|NCT01325480|||CASE_ONLY||CROSS_SECTIONAL|||||||
33912582|NCT04424355|||CASE_CONTROL||PROSPECTIVE|||||||
33912583|NCT02358252|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912584|NCT04030104|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Readers will not be provided with information regarding the initial patient diagnosis|This will be a controlled, blinded, multi-reader, multi-case (MRMC) study using a sequential design. The study will include 15 readers with an additional 5 as back-up readers depending on qualifications and availability. Readers that participated in the Seno PIONEER Study or the Reader-01 Feasibility Study are not eligible to participate as readers in this Pivotal Study.|f|f|f|t
33912585|NCT02857335|NA|SINGLE_GROUP||||NONE||||||
33690657|NCT04852289|||COHORT||PROSPECTIVE|||||||
33690658|NCT02103049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690659|NCT06663631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690660|NCT05421728|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
33690661|NCT03939637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690662|NCT05437835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690663|NCT01674634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690664|NCT04095156|||COHORT||OTHER|||||||
33690665|NCT06165627|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33690666|NCT00766441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690667|NCT00190944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690668|NCT06734689|||CASE_CONTROL||PROSPECTIVE|||||||
33690669|NCT02729675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33912586|NCT00896753|||COHORT||RETROSPECTIVE|||||||
33912587|NCT03857763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912588|NCT02458950|||COHORT||RETROSPECTIVE|||||||
33912589|NCT04860661|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"1. Assign a researcher to determine the order of patients and coordinate the relationship between researchers;~2. For each patient, an anesthesiologist was assigned to manage anesthesia and collect intraoperative data;~3. A researcher who was not aware of the protocol was assigned to conduct preoperative evaluation and postoperative follow-up, and received training on evaluation methods before the study."|The incidence of PPD: the EPDS scale was assessed by face-to-face or telephone interview of the Puerpera 7 d, 30 d, 60 d and 90 d after delivery. EPDS score ≥ 10 was defined as antenatal depression or postpartum emotional disorder.|t|t|t|t
33912590|NCT00551720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912591|NCT04836767|||CASE_CONTROL||PROSPECTIVE|||||||
33690670|NCT02855515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690671|NCT01053949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690672|NCT06082271|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients scheduled for hip arthroscopy for treatment of FAI and/or labral pathology were enrolled. The two treatments, cortisone (gold standard) or collagen Pepetids, were administrated to patients intraoperatively with random sampling||||
33690673|NCT01236118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690674|NCT05928871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33690675|NCT01002482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690676|NCT06042907|||OTHER||CROSS_SECTIONAL|||||||
33690677|NCT03146884|||COHORT||PROSPECTIVE|||||||
33690678|NCT00002898|RANDOMIZED|||TREATMENT||||||||
33690679|NCT05317416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690680|NCT03300518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912592|NCT03188679|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with seroconversion for CMV undergo amniocentesis. RNA markers for neurological outcome in amniotic fluid CMV PCR negative foetuses are compared with those with amniotic fluid CMV positive PCR.||||
33912593|NCT00755430|||COHORT||OTHER|||||||
33912594|NCT02683525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912595|NCT05242549|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33912596|NCT05029115|||CASE_CONTROL||PROSPECTIVE|||||||
33912597|NCT05457933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912598|NCT00649649|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33912599|NCT00736086|||||PROSPECTIVE|||||||
33912600|NCT03432910|NA|SINGLE_GROUP||TREATMENT||NONE||Assignment||||
33912601|NCT05890287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993734|NCT01501253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912602|NCT05627934|||COHORT||PROSPECTIVE|||||||
33912603|NCT02567110|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912604|NCT03219593|NA|SINGLE_GROUP||TREATMENT||NONE||Apatinib Monotherapy||||
33912605|NCT01698424|||CASE_ONLY||CROSS_SECTIONAL|||||||
33912606|NCT00624572|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33912607|NCT02364206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912608|NCT00001439||||TREATMENT||||||||
33912609|NCT00276978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993735|NCT00004933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993736|NCT05524051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993737|NCT04035187|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33993738|NCT04221958|||OTHER||PROSPECTIVE|||||||
33993739|NCT05113953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993740|NCT00859521|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993741|NCT02885909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993742|NCT01023334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993743|NCT06560801|RANDOMIZED|PARALLEL||TREATMENT||NONE||Drug: dapagliflozin, other: standard of care||||
33993744|NCT04848987|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33993745|NCT04854954|||COHORT||RETROSPECTIVE|||||||
33993746|NCT04392999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants as well as the individuals collecting and analyzing outcome data will be blinded. The Primary Investigator, who is also the physician delivering the study compound, will not be blinded but will have no role in data collection or analysis.|Eligible participants who consent to study participation will be randomized to one of two groups: PRP injections, or corticosteroid injections.|t|t|f|t
33993747|NCT04370509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993748|NCT06626815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993749|NCT02319980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993750|NCT04356729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993751|NCT04504747|||COHORT||PROSPECTIVE|||||||
34085514|NCT03705325|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective single arm study of 12-21 year olds with persistent asthma. Participants will be given the home spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app. Participants will be asked to use the spirometer at least twice daily (in the morning between 6am and 10am and in the evening between 6am and 10pm) and whenever rescue medication (albuterol) is administered or the participant feels symptoms of asthma (such as cough, wheezing, or shortness of breath) in order to document lung function. After performing the spirometry maneuver, the user will be prompted to answer questions about their asthma symptoms. Changes in lung function will be matched to subject-reported asthma symptoms and/or albuterol use.||||
33912610|NCT01811849|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33993752|NCT04667338|||COHORT||CROSS_SECTIONAL|||||||
33993753|NCT06627543|||CASE_CONTROL||PROSPECTIVE|||||||
33993754|NCT04629326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085515|NCT06403943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912611|NCT01067508|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912612|NCT06496321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will not know which group he was assigned to, and the researcher who will evaluate the patients postoperatively will not know either, only the surgeon at the time of performing block randomization prior to surgery.|"Corresponds to a single-center, open, non-inferiority, randomized controlled clinical trial.~A probability of complication of saphenectomy by conventional or control technique of 10% was assumed, based on studies from our institution, and according to preliminary studies we expect to find 50% more in the no touch technique, therefore 15%. The non-inferiority limit will be 20%. With these values, assuming a 95% confidence interval and a power (1 - beta) of 80%, and taking into account a probable 20% of lost patients, we can calculate the necessary population sample size, which was in total 52 patients; 26 people in the group with conventional technique and 26 in the no touch."|t|f|t|f
33912613|NCT02348411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912614|NCT00808327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912615|NCT03948659|||COHORT||RETROSPECTIVE|||||||
33993755|NCT01904162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993756|NCT02868463|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993757|NCT03600363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993758|NCT06235203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993759|NCT02407548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993760|NCT06243380|||COHORT||RETROSPECTIVE|||||||
33993761|NCT05309135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Within the treated groups, the sponsor, investigator, assessor, and subject will be masked to the assigned dose.||t|t|t|t
33993762|NCT06561984|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The intervention group will receive educational sessions regarding modes of delivery, while the control group will receive the routine antenatal care only in the antenatal clinics|The intervention group will receive educational sessions regarding modes of delivery, while the control group will receive the routine antenatal care only in the antenatal clinics|t|f|f|f
33993763|NCT06200363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993764|NCT03022643|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33993765|NCT00492076|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34085516|NCT01458626|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33993766|NCT04050709|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993767|NCT02557035|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993768|NCT05773300|||COHORT||PROSPECTIVE|||||||
33993769|NCT00419640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993770|NCT05635448|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Data will be de-identified prior to analysis|"This is a randomized controlled trial. All enrolled participants will complete the pretest baseline survey. After baseline data collection is completed, the participants will be randomized into either a control or intervention group. This randomized controlled trial study design will offer the BT coaching to the intervention group for the duration of 4-months (February 1st 2023- May 31st 2023) and to the control group for the duration of 4-months (September 1st 2023 - December 31st 2023).~At two different timepoints, all participants will be offered surveys containing the following validated indices: burnout, imposter syndrome, self-compassion, moral injury, discrimination, and flourishing. All participants will be offered the survey at baseline- January 2023 (T0), post intervention- May 2023 (T1)."|f|f|f|t
33993771|NCT06352775|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The quasi-experimental design will include a prospective treatment group and retrospective historical control group. The prospective treatment group will identify 50 patients who will be voluntarily consented and receive calcium carbonate (500mg every 4 hours, per standardized treatment protocol) plus standard-dose oxytocin. This group will be compared against a retrospective historical control group of 200 randomly selected patients (1:4 ratio) who presented for induction at the same institution within the previous three years and received standard-dose oxytocin alone.||||
34085517|NCT02144766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34085518|NCT04111835|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34085519|NCT05189002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Dose Dimolegin - DD217 in each group was blinded for a patient and investigator (double-blind method) using six tablets for each administration, some of them contained Dimolegin - DD217, and others were masked as Placebo of the study product|Multicenter, double blind, randomized, prospective|t|t|t|f
34085520|NCT05916547|||COHORT||PROSPECTIVE|||||||
34085521|NCT00279929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34085522|NCT01946503|||CASE_ONLY||OTHER|||||||
34085523|NCT04942704|||OTHER||OTHER|||||||
34085524|NCT06405893|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34085525|NCT06514300|||COHORT||PROSPECTIVE|||||||
34085526|NCT05098769|||COHORT||PROSPECTIVE|||||||
34085527|NCT00769418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085528|NCT02765165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085529|NCT03412214|||COHORT||PROSPECTIVE|||||||
34085530|NCT02596295|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34085531|NCT05583630|||OTHER||PROSPECTIVE|||||||
34085532|NCT04578366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085533|NCT02667639|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34085534|NCT04242849|||COHORT||PROSPECTIVE|||||||
34085535|NCT03000153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34085536|NCT04871464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study is double blind design||t|f|t|f
34085537|NCT05719961|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34085538|NCT02909062|||COHORT||PROSPECTIVE|||||||
34085539|NCT00486044|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34085540|NCT02382939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085541|NCT03998735|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34085542|NCT06524115|NA|SINGLE_GROUP||SCREENING||NONE||||||
34085543|NCT05109715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085544|NCT01464138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085545|NCT02736357|||COHORT||PROSPECTIVE|||||||
34085546|NCT01147822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085547|NCT06519058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085548|NCT05037630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085549|NCT00038285|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34085550|NCT01482832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34085551|NCT05115396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085552|NCT00717886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085553|NCT01494558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085554|NCT01709461|||CASE_ONLY||PROSPECTIVE|||||||
34085555|NCT02435134|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34085556|NCT03334175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085557|NCT04812158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34085558|NCT04239924|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34085559|NCT06464029|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085560|NCT00141609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34085561|NCT03968809|||COHORT||PROSPECTIVE|||||||
34085562|NCT03702699|||OTHER||PROSPECTIVE|||||||
34085563|NCT00000498|RANDOMIZED|||TREATMENT||||||||
34085564|NCT01749371|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085565|NCT03614000|NA|SINGLE_GROUP||SCREENING||NONE||||||
34085566|NCT05724290|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||f|t|t|t
34085567|NCT02456896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085568|NCT01154660|RANDOMIZED|PARALLEL||||NONE||||||
34085569|NCT02251275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085570|NCT06262984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085571|NCT05884216|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085572|NCT05336539|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34085573|NCT02002663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085574|NCT03988660|||COHORT||PROSPECTIVE|||||||
34085575|NCT03699748|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33912616|NCT01982604|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912617|NCT02617342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33690681|NCT03937869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085576|NCT00513214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085577|NCT05278897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085578|NCT00560716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085579|NCT03722576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912618|NCT00295698|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33912619|NCT04628403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the results assessor will not be aware of the subject allocation group||f|f|f|t
33912620|NCT05604469|||CASE_CONTROL||PROSPECTIVE|||||||
33912621|NCT02273050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912622|NCT04622787|||CASE_ONLY||PROSPECTIVE|||||||
33912623|NCT00862849||CROSSOVER||||DOUBLE|||t|f|t|f
33912624|NCT02233400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912625|NCT04369183|||CASE_ONLY||RETROSPECTIVE|||||||
33912626|NCT01490268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912627|NCT00202111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912628|NCT04520022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912629|NCT04838925|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33912630|NCT05250271|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants are blinded to sensor and plasma glucose.|3-period crossover design|t|f|f|f
33912631|NCT02481336|||COHORT||PROSPECTIVE|||||||
33912632|NCT01570400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912633|NCT00788775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912634|NCT05744076|||COHORT||OTHER|||||||
33912635|NCT02900924|||COHORT||PROSPECTIVE|||||||
33912636|NCT02752529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912637|NCT06088316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware about which group of treatment they are getting but the investigator will know about the treatment allocation.|"participants will be randomly assigned into two groups- Group A \& Group B. Group A will receive amoxicillin-esomeprazole high dose dual therapy for 14 days.~Group B will receive levofloxacin containing triple therapy for 14 days. dyspeptic symptoms,drug side effects \& H.pylori eradication rates will be compared between two groups."|t|f|f|f
33912638|NCT06480305|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33912639|NCT05196243|||CASE_CONTROL||PROSPECTIVE|||||||
33912640|NCT02569411|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33779242|NCT01954043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779243|NCT02511561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993772|NCT01711632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779244|NCT03260842|||COHORT||PROSPECTIVE|||||||
33993773|NCT02448862|||CASE_CONTROL||RETROSPECTIVE|||||||
33993774|NCT02957942|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33993775|NCT06562868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While the materials used for the restorations were known to the practitioner, neither the patients nor the specialist dentists conducting the follow-up examinations were aware of them.|Three groups with different restoration materials|t|f|f|t
33993776|NCT04964973|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The principal investigator and the patient do not know which technique will be applied. The principal investigator and the patients do not know which group they are in, intervention, placebo or control.|Randomized trial|t|f|t|t
33993777|NCT06394648|||COHORT||PROSPECTIVE|||||||
33993778|NCT05236348|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All study participants will wear the Aktiia.bracelet-us during 9 visits that will be held over the span of seven days. In order to induce blood pressure changes and to simulate ambulatory scenarios, the study participants will be asked to perform a set of activities, involving body position changes and physical exercises during these visits.||||
33993779|NCT03037463|||CASE_CONTROL||PROSPECTIVE|||||||
33993780|NCT00194363|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33779245|NCT00979173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779246|NCT00003957||||TREATMENT||||||||
33779247|NCT02613858|||COHORT||PROSPECTIVE|||||||
33779248|NCT01812876|||COHORT||PROSPECTIVE|||||||
33779249|NCT03818997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779250|NCT04296942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779251|NCT00740662|||COHORT||PROSPECTIVE|||||||
33779252|NCT03244137|||COHORT||PROSPECTIVE|||||||
33779253|NCT03691584|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33838839|NCT05214664|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"In each center, a pair of practitioners has been identified: one practitioner, Anesthesia, will be in charge of the randomization and the realization of the anesthesia by one of the two techniques (EZ-Block or conventional freehand technique). Another practitioner, Surgery, will be blinded to the anesthesia technique used. It is this practitioner who will perform the surgical procedure described below."|Multicenter, randomized, single-blind, controlled clinical trial with cross-over.|f|f|t|f
33838840|NCT04273139|NA|SEQUENTIAL||TREATMENT||NONE||||||
33838841|NCT03745677|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two group pretest-posttest analysis||||
33838842|NCT00551850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838843|NCT03003585|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33838844|NCT01061099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838845|NCT02334579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838846|NCT03371147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838847|NCT05312346|||COHORT||PROSPECTIVE|||||||
33838848|NCT04549818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838849|NCT03776708|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838850|NCT00498472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838851|NCT06238635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838852|NCT06478511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients participating in this study will sign an informed consent demonstrating the purpose of this study, treatment procedure, probable risks and benefits from this treatment procedure.~Patients will be randomly allocated to one of three groups:~1. Group 1 (control group):~   Will include 11 implants (Nucleoss T6®) , maximum two per patient, will be placed immediately after atraumatic extraction.~2. Group 2 :~   Will include 11 implants, maximum two per patient will be placed immediately after atraumatic extraction and subepithelial connective tissue graft will be harvested and placed.~3. Group 3:~Will include 11 implants, maximum two per patient will be placed immediately using Socket Shield Technique.~All osteotomy sites will receive Biogap® bone graft if there are gap between implant and labial bone/ buccal shield ≥ 2mm.~All the selected patients will receive full mouth scaling, preoperative periapical x-ray and cone beam computed tomography."|t|f|f|f
33838853|NCT06316518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two groups with a supportive care control groups|t|f|f|f
33838854|NCT04478136|||COHORT||PROSPECTIVE|||||||
33838855|NCT02883855|||CASE_ONLY||RETROSPECTIVE|||||||
33690682|NCT05447039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690683|NCT02013869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||We studied the time to reach a MAC value for two fifferent anaesthetic machines, Flow-i versus Aisys looking at the time to reach 1 MAC desflurane|f|f|t|f
33690684|NCT01496768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690685|NCT06659718|||COHORT||RETROSPECTIVE|||||||
33690686|NCT06594627|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||It is a single group, pre- and post- test/eval design.||||
33690687|NCT05220631|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||This intervention will use a closed-cohort stepped wedge design. In a stepped wedge design, the timing of the intervention is randomized by cluster, with sequential crossover of clusters from control to intervention until all clusters have received the intervention. With this design, each cluster contributes data when they are participating in the intervention and when they are not. This study will be a two-step stepped wedge design; each of the seven targeted centers will then be randomly assigned to one of two cohorts. Participants in Cohort 1 will receive the intervention first. Six months after baseline data have been collected, Cohort 1 participants will finish the intervention and crossover will occur as Cohort 2 participants begin the intervention. At the 12-month time point, the second cohort will complete the intervention. Data will be collected for both groups in each time period T0-T3.||||
33690688|NCT00797368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690689|NCT05570201|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690690|NCT02886689|||COHORT||PROSPECTIVE|||||||
33690691|NCT01197729|||CASE_ONLY||PROSPECTIVE|||||||
33690692|NCT00009061||||TREATMENT||||||||
33690693|NCT03458793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computerised randomisation will be performed by an external researcher not involved in the delivery of the intervention or outcome assessment. Participants who will be assessors of their psychosocial outcomes using self-report questionnaires will be blind to the allocation concealment at the time of completing the initial questionnaires. Intervention providers who will be responsible for outcome assessments will not be blind to the intervention assignment as this would not be possible given the study and walks will be conducted by the PhD student.|This will be a two-arm randomised controlled trial (RCT) with a wait-list control group|t|f|f|f
33690694|NCT02701920|||COHORT||PROSPECTIVE|||||||
33690695|NCT01467583|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33690696|NCT06318754|||COHORT||PROSPECTIVE|||||||
33779254|NCT05073081|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants and those delivering the intervention is not possible within rehabilitation trials and blinding of assessors is not possible when participants are not blinded, and outcomes are self-reported. Research coordinators involved in data collection and researchers involved in data analysis, however, will be blinded.|This is a mixed methods two-armed pilot RCT evaluating an 8-week virtual prehabilitation program for participants undergoing LSS surgery versus usual care. A longitudinal qualitative study will be conducted parallel to the pilot RCT.||||
33779255|NCT00350961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779256|NCT05018962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779257|NCT01884987|||COHORT||PROSPECTIVE|||||||
33779258|NCT01684488|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33779259|NCT01201564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779260|NCT00950209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33779261|NCT04245033|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is an effectiveness-implementation hybrid trial to assess feasibility and effectiveness of IPTsc using DP against standard of care (control). Wards in the three study districts (Handeni DC, Handeni TC and Kilindi DC) will be the randomisation unit (clusters). Each ward will be randomised to implement IPTsc or not (control).||||
33993781|NCT04034290|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This clinical trial on the second stage is designed as a double blind randomized placebo-controlled study||t|f|t|f
33993782|NCT06557421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993783|NCT05133804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Patients will be randomized into two groups: either treatment with medication or treatment with placebo.~In addition, within each group patients will be randomized into a group for EEG recording and a group for fNIRS recording. This is a non-interventional randomization."|t|t|t|f
33993784|NCT05738421|||COHORT||PROSPECTIVE|||||||
33993785|NCT04377087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993786|NCT06242912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993787|NCT05581329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||2-arm parallel design, randomized, controlled and single blinded trial|t|f|f|f
33993788|NCT04053153|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Will not be known if participant is getting the actual device or using the placebo||t|t|t|f
33779262|NCT03015740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779263|NCT00761254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779264|NCT02543450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085580|NCT06332482|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||digital impressions will be made for each patient,3 technique will be used to determine intermaxillary relation. Occlusal prematurties of final prosthesis will compared using occlusense device and all patients will be followed up for one year|t|f|f|f
33690697|NCT04457973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33690698|NCT06034327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and parents of participants will be masked. Investigational site staff tasked with measuring key primary variables will be masked.||t|f|f|t
33690699|NCT03071198|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This strategy is called neoadjuvant hierarchical treatment based on chemotherapy for rectal cancer. All patients with T3-4N0-2M0 middle and lower rectal caner will firstly receive neoadjuvant chemotherapy consisting of four cycles of XELOX. After four cycles, the patients achieved cCR or cPR will be perform the operation. And the patients who can not achieve cCR or cPR after the four cycles, then concurrent chemoradiotherapy will be added."||||
33690700|NCT05834673|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33690701|NCT04707326|||COHORT||PROSPECTIVE|||||||
33690702|NCT04638192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33690703|NCT00055471||||TREATMENT||||||||
33690704|NCT05940324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized with a 1:1 allocation to either IV ketamine + oral placebo or IV ketamine + oral opioid antagonist naltrexone|t|t|t|t
33690705|NCT06630247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This study is divided into three stages:~The first stage is the dose escalation stage that evaluates how much of XL495 alone patients can safely tolerate.~The second is the dose finding stage that evaluates how much of XL495 to give patients in combination with other anti-cancer medications.~The third stage is the expansion stage that evaluates how XL495 performs in patients in combination with other anti-cancer medications."||||
33779265|NCT04394624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690706|NCT01210573|||CASE_ONLY||PROSPECTIVE|||||||
33779266|NCT04075292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690707|NCT06631079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690708|NCT03920618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690709|NCT03370289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690710|NCT05404503|||COHORT||RETROSPECTIVE|||||||
33690711|NCT05120349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690712|NCT05128773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-dummy||t|t|t|t
33779267|NCT04660968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779268|NCT06043635|||CASE_ONLY||PROSPECTIVE|||||||
33779269|NCT04834024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779270|NCT03099785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779271|NCT03811561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33779272|NCT04376983|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT||||
33779273|NCT04760444|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33779274|NCT02424461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779275|NCT04453787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779276|NCT04860128|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33779277|NCT00201526|||CASE_ONLY||CROSS_SECTIONAL|||||||
33779278|NCT05562830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779279|NCT06325202|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Multiple Assignment Randomized Trial (SMART) design||||
33779280|NCT00793390|||CASE_CONTROL||RETROSPECTIVE|||||||
33779281|NCT02554435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779282|NCT02223689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779283|NCT03954067|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779284|NCT02721459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779285|NCT03050294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779286|NCT03693222|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The investigator's study is a prospective, randomized, double-blind study.|Patients included in the study were randomly divided into 2 groups. Cases were assessed as intravenous opioid with 1 mg/kg tramadol HCl (Group O, n=20) or ultrasonography-guided quadratus lumborum block (Group B, n=20).|t|f|t|t
33912641|NCT06106633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912642|NCT00404027|||COHORT||RETROSPECTIVE|||||||
33912643|NCT01852097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34085581|NCT05107375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085582|NCT03409965|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized study||||
33779287|NCT05962840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, single-blinded, placebo-controlled, pilot study|t|f|f|f
33779288|NCT04798703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779289|NCT03436121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomly assigned to either the experimental condition (ketamine + midazolam) or the active control condition (placebo + midazolam)|t|t|t|t
33779290|NCT04788017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33779291|NCT04986540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1906 compared with placebo|t|t|t|t
33779292|NCT06530654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779293|NCT01167270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779294|NCT06614179|||CASE_ONLY||RETROSPECTIVE|||||||
33779295|NCT03066388|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779296|NCT02242461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779297|NCT05823779|||COHORT||PROSPECTIVE|||||||
33779298|NCT06280560|||CASE_CONTROL||PROSPECTIVE|||||||
33779299|NCT05925959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of the patient reported outcomes will be blinded. Hernia recurrence will be assessed by blinded review of CT scans by 3 surgeons.||f|f|f|t
33779300|NCT05072990|||CASE_ONLY||RETROSPECTIVE|||||||
33779301|NCT04786886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912644|NCT03134950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912645|NCT05398276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33912646|NCT04228120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912647|NCT00882999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912648|NCT02883907|||CASE_CONTROL||PROSPECTIVE|||||||
33912649|NCT03799718|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33912650|NCT00429039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912651|NCT00791440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085583|NCT02026297|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779302|NCT05631574|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is an ascending multiple dose clinical trial followed by cohort expansion. The dose escalation part is primarily intended to identify the optimal biologic dose (OBD)(s) of BMF-219 and to obtain initial safety and tolerability information regarding the compound when administered orally to subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. This study will also evaluate the PK/PD profiles of multiple dose administration of BMF-219. Following completion of the dose escalation, cohort and arm-specific expansion cohorts will commence in order to further confirm the safety and tolerability of BMF-219 dosed at or near the OBD.||||
33779303|NCT03160911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, the investigator and the outcome assessor would be blinded.|There are two separate interventional arms. In case of treatment failure, the two groups are allowed to crossover to the other group.|t|f|t|t
33779304|NCT06483802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779305|NCT04931173|RANDOMIZED|PARALLEL||OTHER||NONE||This is a multi-centre, parallel, two-arm, non-inferiority randomized controlled trial comparing IVA+OA+MBP versus IVA+OA to reduce surgical site infection following colon surgery||||
33779306|NCT02292667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912652|NCT06527612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912653|NCT04279977|||COHORT||PROSPECTIVE|||||||
34085584|NCT01577069|||COHORT||PROSPECTIVE|||||||
34085585|NCT01626170|||COHORT||RETROSPECTIVE|||||||
34085586|NCT01620424|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34085587|NCT02282462|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34085588|NCT01118676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085589|NCT04378881|||COHORT||RETROSPECTIVE|||||||
34085590|NCT05319717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Control study arm: Locally produced Ready to use therapeutic food (RUTF)~Intervention study arm: Locally produced Ready to use therapeutic food plus rice bran (RUTF+RB)"|t|t|f|t
33779307|NCT05986435|||OTHER||OTHER|||||||
33838856|NCT02437942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838857|NCT02625064|||COHORT||PROSPECTIVE|||||||
33838858|NCT05977205|||COHORT||CROSS_SECTIONAL|||||||
33838859|NCT05821920|||COHORT||PROSPECTIVE|||||||
33838860|NCT05648643|||OTHER||PROSPECTIVE|||||||
33838861|NCT02318953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33838862|NCT06263686|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33838863|NCT00493740|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33838864|NCT00618176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838865|NCT04291053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838866|NCT03222713|RANDOMIZED|PARALLEL||OTHER||NONE||The participants were randomly assigned into three groups: Condition I followed the health school program (PSE), Condition II group followed the PSE and the Self-regulation Health - SRH program, and the control group did not enroll in either of the health promotion programs||||
33838867|NCT03733353|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The study is a double-blind dose escalation cohort study in healthy volunteers and participants with either mild to moderate psoriasis or mild to moderate atopic dermatitis. The study consists of 10 cohorts and will test doses of EDP1815 versus placebo. The safety and tolerability of EDP1815 will be tested in participants with psoriasis and atopic dermatitis alongside pharmacodynamic effects on the systemic immune system and observation of any clinical effects.|t|f|t|f
33838868|NCT06245460|||COHORT||PROSPECTIVE|||||||
33838869|NCT01384812|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33838870|NCT03064945|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33838871|NCT05925257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||unblinded, parallel-arm randomized controlled clinical trial||||
33838872|NCT02878447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838873|NCT05303389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838874|NCT05643755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33838875|NCT01457638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085591|NCT02517749|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779308|NCT05934318|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be placebo-controlled involving a maltodextrin/lactose anhydrous/citric acid/lemon flavour powder for the L-citrulline powder intervention. The placebo powder will be indistinguishable in size, quantity, taste and colour from the L-citrulline product to ensure blinding of all investigators and study staff during allocation and for the duration of the trial. All participants and the clinical and research staff will be masked to the treatment assignment of these individual women. The trial statistician will also be blinded regarding the treatment code when s/he develops the statistical analysis plan and writes the statistical programmes, which will be validated and completed using dummy randomisation codes.|"* Allocation: randomised; Intervention model: parallel assignment~* Design: Superiority trial~* Arms: two~* Allocation ratio: 1:1; stratified by site (hospital) and gravidity (pauci,- and multigravidae) Masking: placebo-controlled"|t|t|t|t
33779309|NCT06340529|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33779310|NCT05455463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who elect to take part in the exercise intervention will be assigned to the intervention group, while those who do not will be assigned to the control group.||||
33779311|NCT02442297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912654|NCT00127504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779312|NCT06696586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients will be randomly allocated to one of two groups; each group consisted of 42 patients. Randomization will be performed using a closed envelope method||t|t|t|t
33779313|NCT06086002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912655|NCT05749926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33912656|NCT01980108|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33912657|NCT03235570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912658|NCT06023173|||COHORT||RETROSPECTIVE|||||||
33912659|NCT00323180|||OTHER||PROSPECTIVE|||||||
33912660|NCT01163253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912661|NCT00420394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912662|NCT03086200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085592|NCT01366391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085593|NCT00771108|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34085594|NCT00988182|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34085595|NCT02900716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085596|NCT00980876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085597|NCT00029237|RANDOMIZED|CROSSOVER||ECT||NONE||||||
34085598|NCT01860196|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34085599|NCT01548963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085600|NCT01657617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085601|NCT03890575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912663|NCT01043185|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34085602|NCT06426030|||COHORT||PROSPECTIVE|||||||
33912664|NCT00741143|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33912665|NCT05429372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085603|NCT01922453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085604|NCT04936893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34085605|NCT02638792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085606|NCT05844540|NA|SINGLE_GROUP||TREATMENT||NONE||eleven partially edentulous patients seeking horizontal and vertical alveolar bone augmentation in the anterior maxilla or mandible were included in this study. For each patient, autogenous bone block was harvested from the symphysis, trimmed to L-shape and used to augment the anterior maxilla or mandible.||||
34085607|NCT04931615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded patient and blinded assessor|Randomised controlled trial|t|f|f|t
33779314|NCT03663712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912666|NCT05441566|||COHORT||PROSPECTIVE|||||||
33912667|NCT03695991|||COHORT||PROSPECTIVE|||||||
33912668|NCT06106321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085608|NCT02629770|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34085609|NCT04078386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912669|NCT04998045|NA|SINGLE_GROUP||PREVENTION||NONE||All eligible youth will be screened for substance use and assigned to the intervention based on level of substance use risk. Immediately after the intervention they will rate the acceptability of the intervention. After enrollment is over, peers, clinic staff and youth will be asked to give feedback (qualitative and quantitative) on the feasibility and acceptability of the intervention.||||
33912670|NCT01401010|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912671|NCT04461405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33779315|NCT01265082|||CASE_CONTROL||PROSPECTIVE|||||||
33912672|NCT03649321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912673|NCT03777371|||OTHER||RETROSPECTIVE|||||||
33912674|NCT04745793|||COHORT||PROSPECTIVE|||||||
33912675|NCT06250127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding to treatment allocation is possible only for the outcomes assessor because the clinicians know the intervention. The trial documents will be labeled with ID number, which be used for participant identification and data collection without unmasking the allocation group||f|f|f|t
33912676|NCT06373445|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||participants randomly allocated to either no, one, some or all interventions simultaneously|f|t|f|f
33993789|NCT06626984|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Investigators taking blood samples and performing ultrasound based imaging techniques will be blinded to the treatment allocation.|"The first 5 participants recruited to this study will receive intravenous fluid therapy only. This will allow us to directly elucidate the effects of intravenous fluid therapy on markers of vascular injury, markers of systemic inflammation, microcirculatory function and venous congestion in healthy volunteers.~After the first 5 participants have completed the interventions, a 2x2 factorial design will be adopted, in which participants are randomised to:~1. Intravenous fluids or no intravenous fluids, AND TO~2. Imatinib or no imatinib"|f|f|t|t
33993790|NCT00042874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993791|NCT05586945|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993792|NCT01586520|||CASE_CONTROL||PROSPECTIVE|||||||
33993793|NCT06364735|||OTHER||RETROSPECTIVE|||||||
33993794|NCT03635320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patient is masked during the study. He/she will be notified during inform consent that either treatment will be used but they will not be informed exactly which group.|"The study population will include 188 patients with proximal femur fracture undergoing internal fixation using an intramedullary nail.~Subjects will be randomized in a 1:1 ratio to receive either the investigational TFNA devices (n=94) or to the control PFNA-II devices (n=94)."|t|f|f|f
33779316|NCT03953443|||CASE_ONLY||PROSPECTIVE|||||||
33779317|NCT01515358|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33779318|NCT03826212|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33779319|NCT05078021|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33779320|NCT01583946|||COHORT|||||||||
33779321|NCT02069587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779322|NCT01155245|||COHORT||PROSPECTIVE|||||||
33779323|NCT04714216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779324|NCT00741273|NON_RANDOMIZED|PARALLEL||||NONE||||||
33779325|NCT02945202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779326|NCT01395771|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33779327|NCT03212365|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Patients will be randomized into one of two groups (enoxaparin 40mg twice daily or enoxaparin 0.5mg/kg twice daily, rounded to the nearest milligram).|t|f|t|f
33779328|NCT02535338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779329|NCT01659138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779330|NCT01764061|||||PROSPECTIVE|||||||
33779331|NCT00355667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779332|NCT01260662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779333|NCT05055375|||OTHER||PROSPECTIVE|||||||
33779334|NCT02955277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors were blind to group allocation.||f|f|f|t
33779335|NCT04201015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the technician doing the programming will know how the pacemaker has been set.||t|t|t|t
33779336|NCT04060784|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysis will be blind. Intraexaminer reliability will be performed.|There are two groups in this study, 13 patients each. Subjects who fulfill the inclusion criteria with one failing anterior tooth will be included into this study.|f|f|f|t
33779337|NCT06554808|||COHORT||OTHER|||||||
33779338|NCT03251378|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779339|NCT02008058|||COHORT||PROSPECTIVE|||||||
33779340|NCT02310490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779341|NCT01974687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779342|NCT02949310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33779343|NCT04662034|RANDOMIZED|PARALLEL||TREATMENT||NONE|Device vs Standard of Care, no masking possible|||||
33779344|NCT03317561|||CASE_CONTROL||PROSPECTIVE|||||||
33779345|NCT05173051|NA|SINGLE_GROUP||OTHER||NONE||Quasi-experimental study||||
33779346|NCT06089187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized controlled study|t|f|f|f
33779347|NCT02156115|||FAMILY_BASED||PROSPECTIVE|||||||
33779348|NCT03553862|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33779349|NCT05617235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33779350|NCT05322980|||COHORT||RETROSPECTIVE|||||||
33779351|NCT03372486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33779352|NCT03300817|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779353|NCT05284097|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779354|NCT00386594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779355|NCT06018428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779356|NCT00641953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779357|NCT05962424|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33912677|NCT05233449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In order to avoid the bias related to the order of the stimuli, the order of application of the stimuli will be randomized according to a Latin square of order 3.||||
33912678|NCT02147704|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912679|NCT05151770|||OTHER||OTHER|||||||
33912680|NCT00696657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912681|NCT02987764|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33912682|NCT06473337|||COHORT||PROSPECTIVE|||||||
33912683|NCT04770610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912684|NCT02039180|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33912685|NCT03764202|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912686|NCT01192217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912687|NCT01057719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33912688|NCT00427583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912689|NCT03754608|||CASE_CONTROL||PROSPECTIVE|||||||
33912690|NCT02006667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912691|NCT03539172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912692|NCT02848300|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33912693|NCT00871949|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33912694|NCT02829177|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33779358|NCT00136903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779359|NCT05766163|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33779360|NCT00891085|||OTHER||PROSPECTIVE|||||||
33779361|NCT04952987|||COHORT||PROSPECTIVE|||||||
33779362|NCT05306457|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779363|NCT02224014|||COHORT||PROSPECTIVE|||||||
33779364|NCT02156362|NA|SINGLE_GROUP||OTHER||NONE||||||
33779365|NCT02402179|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33779366|NCT06586216|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33779367|NCT04412564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779368|NCT05692843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Non-randomized clinical trial. The intervention consists in additional follow-up visits out of usual clinical practice. According to RD 1090/2015 of December 4, which regulates clinical trials with drugs, it is considered a low level intervention clinical.||||
33779369|NCT03641833|||CASE_CONTROL||PROSPECTIVE|||||||
33779370|NCT01101906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779371|NCT06296251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779372|NCT03431519|||OTHER||RETROSPECTIVE|||||||
33779373|NCT04560361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization scheme is generated, validated and imported into the central randomization system by a statistician who do not participate in this trial by using R software. The central randomization system has set strict personnel permissions, and no one has right to view the randomization scheme except the highest-level system administrator. Patients and study investigators (i.e., outcome assessors, data recorders, data entry clerks and statistical analysts) will be blinded to the group assignment. Due to the nature of the intervention, acupuncturists will not be blinded to the treatment.|Using the center stratification block randomization method, the center is used as the stratification factor, and subjects were randomly assigned to the electroacupuncture group and the sham electroacupuncture group at a ratio of 1:1. The central randomization system is used for randomization operations.|t|f|t|t
33779374|NCT04922021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779375|NCT03620071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779376|NCT05392582|||COHORT||PROSPECTIVE|||||||
33912695|NCT03988257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients, their caregivers, researchers, physicians, nurses, the statistician will be blinded to the intervention.|This will be a randomized, double-blind, placebo-controlled trial, with allocation 1:1.|t|t|t|t
33912696|NCT02898207|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33912697|NCT03860727|||COHORT||PROSPECTIVE|||||||
33912698|NCT00001019||||PREVENTION||DOUBLE||||||
33912699|NCT01111539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912700|NCT01893944|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33912701|NCT02147145|||COHORT||PROSPECTIVE|||||||
33912702|NCT00294008|||CASE_ONLY|||||||||
33912703|NCT03317275|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective randomised cohort study, partial blinded|t|f|f|f
33912704|NCT06273657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912705|NCT01947049|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33912706|NCT00982241|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33912707|NCT01291329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912708|NCT06049771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912709|NCT01796704|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912710|NCT02590445|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33912711|NCT04926194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993795|NCT06561906|||CASE_CONTROL||PROSPECTIVE|||||||
33779377|NCT03766594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are randomized to receive either folic acid and sildenafil citrate or folic acid and placebo. Placebo tablets were same size and appearance of the sildenafil citrate tablets.|"Patients will be randomized into two groups: Group (A) folic acid and sildenafil citrate and Group (B) folic acid and placebo.~Folic acid (0.5 mg) will be started 3 months before conception in the two groups. Sildenafil citrate (dose: 25 mg; oral tablets, 4 times/day) or placebo will be started preconception for 24 days"|t|t|f|f
33779378|NCT03180411|||COHORT||PROSPECTIVE|||||||
33779379|NCT06228703|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33779380|NCT06324500|||COHORT||PROSPECTIVE|||||||
33779381|NCT06065553|||CASE_ONLY||CROSS_SECTIONAL|||||||
33912712|NCT05522712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912713|NCT03136705|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Double blind, randomized, placebo-controlled, 2x2 factorial|t|t|t|f
33912714|NCT04422717|||COHORT||CROSS_SECTIONAL|||||||
33912715|NCT02802059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33912716|NCT05653739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912717|NCT02786589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912718|NCT01008501|||OTHER||PROSPECTIVE|||||||
33993796|NCT02749266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993797|NCT00348764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33779382|NCT01314092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993798|NCT04822259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993799|NCT02179788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993800|NCT03487081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33993801|NCT04398056|NA|SINGLE_GROUP||TREATMENT||NONE||This study used Simon's two-stage design. The main purpose of the study was to determine the objective response rates (PR+CR) of local-regional radiotherapy combined with Toripalimab followed by systemic chemotherapy for de novo metastatic nasopharyngeal carcinoma.||||
33993802|NCT02855853|RANDOMIZED|PARALLEL||||NONE||||||
33993803|NCT06237049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind (site- and sponsor-unblinded)||t|f|f|f
33993804|NCT01004562|||||RETROSPECTIVE|||||||
33993805|NCT02369822|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33993806|NCT04821349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"Each center will receive from another center anonymized patient videos that have been uploaded on an encrypted USB key. Indeed, expert gastroenterologists from each center will proceed with AI-assisted video reading without knowing which center the video comes from nor the results of the normal reading. Reading conditions are the same as for standard reading.~Results from both normal and AI-assisted reading will be compared. In the case of significant disagreement between the results from conventional capsule endoscopy reading and AI-assisted reading (e.g. missed lesions), a consensus review for each center will be done. Any lesion shall be considered."|||||
33993807|NCT02261389|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993808|NCT02951858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993809|NCT03428880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993810|NCT02125981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993811|NCT01015703|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33993812|NCT02228421|||COHORT||PROSPECTIVE|||||||
33912719|NCT01902277|||||PROSPECTIVE|||||||
33912720|NCT05122988|||COHORT||PROSPECTIVE|||||||
33912721|NCT00931580|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33912722|NCT00385268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912723|NCT02792010|NA|SINGLE_GROUP||||NONE||||||
33993813|NCT06561490|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33993814|NCT02055547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parts 1 and 2 were parallel in design and Part 3 was crossover in design.|t|f|t|f
33993815|NCT00844987|||COHORT||PROSPECTIVE|||||||
33993816|NCT06319482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33993817|NCT01343004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993818|NCT01883713|||COHORT||PROSPECTIVE|||||||
33779383|NCT06015295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779384|NCT04785287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779385|NCT04897087|||OTHER||RETROSPECTIVE|||||||
33779386|NCT03318744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779387|NCT02992665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779388|NCT02165423|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33779389|NCT04525300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779390|NCT05050370|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The experimental group will receive a face-to-face group session and a package of information on lifestyle-integrated exercise and physical activity.||||
33912724|NCT04567602|||COHORT||PROSPECTIVE|||||||
33912725|NCT06270693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912726|NCT01458509|||COHORT||PROSPECTIVE|||||||
33912727|NCT02524652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33912728|NCT00400829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912729|NCT06146712|NA|SINGLE_GROUP||OTHER||NONE||||||
33912730|NCT02356406|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33912731|NCT02969317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912732|NCT06553924|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33912733|NCT05841550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779391|NCT05708898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Pharyngeal exerciser group: In this group, the device will be placed around the neck overlying the laryngeal cartilage using the Velcro fastening in the back of neck. The externally applied pressure will be measured via the pressure gauge included in the device (see figure). Patients are asked to follow exercise regimen: to perform 30 swallows at 15 seconds interval against minimal resistance of 20 mm Hg applied by pharyngeal exerciser over larynx during the first 2 weeks. This is repeated 3 times per day and the external resistance is increased every 2 weeks from 20 to 30 mm Hg and subsequently from 30 to 40 mm Hg in another 2 weeks.~Sham exerciser group: In this group, sham device will be placed around the neck overlying the laryngeal cartilage. No external pressure will be applied during exercise. These patients will be asked to follow the exercise regimen: to perform repetitive tongue protrusion for 5 times without any pressure. This will be repeated 3 times a day for 6 weeks."|t|f|f|t
33690713|NCT06505629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690714|NCT00620789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33690715|NCT04991103|NA|SEQUENTIAL||TREATMENT||NONE||All patients with start with 6 cycles of quadruplet induction with daratumumab, lenalidomide, bortezomib and dexamethasone and then depending of their response will receive additional consolidation/maintenance therapy.||||
33690716|NCT05479773|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33690717|NCT05553067|||CASE_ONLY||RETROSPECTIVE|||||||
33690718|NCT02500407|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690719|NCT00573365|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||The enrollment goal of 40 includes 20 for each arm.|f|f|f|t
33690720|NCT04824183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single-blind multicenter randomised controlled trial|f|f|f|t
33690721|NCT06706752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33690722|NCT02761291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690723|NCT01756300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779392|NCT03557255|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33690724|NCT06668142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690725|NCT00679744|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
33690726|NCT04448873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors are blinded, neither clinicians nor patients, because they should be attentive of the risk of relapse in the discontinuation group. Also, it seems unethical if researchers were not to discover the group of patients in the maintenance group who can discontinue sirolimus without relapsing. Clinicians should be given the possibility to adjust dose and ensure the benefits of patients. Therefore, this trial only includes assessors blinding.||f|f|f|t
33690727|NCT03868124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33690728|NCT04726397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690729|NCT05553951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779393|NCT04763291|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779394|NCT06689475|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33779395|NCT04174560|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33779396|NCT00142220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33779397|NCT04834362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912734|NCT01016106|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
33912735|NCT06217016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and bedside nurses cannot be blinded, but the attending physicians and the medical ultrasound doctor will be blinded. The medical team will ensure that the patients and bedside nurses keep the group assignment confidential from the attending physicians and the medical ultrasound doctor. Unblinding will occur when the patient is discharged, and any instances of premature unblinding will be recorded. Additionally, the data analysts involved in this study will be blinded.||f|t|f|t
33912736|NCT00605410|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33912737|NCT06122428|||CASE_CONTROL||RETROSPECTIVE|||||||
33912738|NCT03168256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912739|NCT06139679|||OTHER||CROSS_SECTIONAL|||||||
33912740|NCT01672996|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33912741|NCT00334009|||||PROSPECTIVE|||||||
33912742|NCT02220348|NA|SINGLE_GROUP||OTHER||NONE||||||
33912743|NCT04929340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|yellow / blue dots on the bottles indicates different groups||t|t|t|t
33912744|NCT05415046|||CASE_ONLY||RETROSPECTIVE|||||||
33912745|NCT00632190||||DIAGNOSTIC||NONE||||||
33912746|NCT06142461|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Open-label vaccination. Serology samples for immunogenicity assessment are blinded.||f|f|f|t
33690730|NCT02494700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690731|NCT02687178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690732|NCT06538649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Random assignment (2:1) to either statin (Arm 1) or placebo (Arm 2), such that 2/3 of participants will be assigned to Arm 1, and 1/3 of participants will be assigned to Arm 2.|t|f|t|f
33690733|NCT02985203|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690734|NCT03911219|||COHORT||PROSPECTIVE|||||||
33690735|NCT04076527|||COHORT||PROSPECTIVE|||||||
33993819|NCT05763498|||COHORT||PROSPECTIVE|||||||
33993820|NCT01916239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33993821|NCT06469645|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel-group prospective randomised open-label blinded endpoint (PROBE) controlled trial||||
33779398|NCT04321876|||COHORT||PROSPECTIVE|||||||
33779399|NCT02688036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993822|NCT06561074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993823|NCT01885117|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33993824|NCT00496860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993825|NCT05831657|RANDOMIZED|PARALLEL||TREATMENT||NONE||An academically initiated randomized controlled clinical trial where Prevent It 2.0 is compared with waitlist control across three language sites (i.e., Swedish, Portuguese, and German)||||
33993826|NCT03835286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993827|NCT02028715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33993828|NCT05334875|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33993829|NCT05072535|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33993830|NCT06259630|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33993831|NCT05464563|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33993832|NCT06512909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33993833|NCT03031821|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993834|NCT02839252|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33993835|NCT01153503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993836|NCT02464254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33993837|NCT03880461|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33993838|NCT03260153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993839|NCT05356481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assignment|t|f|f|f
33993840|NCT06398262|||COHORT||PROSPECTIVE|||||||
33993841|NCT02584907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912747|NCT01465971|||COHORT||PROSPECTIVE|||||||
33912748|NCT00883480|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33912749|NCT03118531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912750|NCT01339949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912751|NCT01938781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085610|NCT00223821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085611|NCT05110235|||COHORT||RETROSPECTIVE|||||||
34085612|NCT04059952|||CASE_CONTROL||PROSPECTIVE|||||||
34085613|NCT00726245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085614|NCT05230836|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinding of participants and evaluator shall be performed using the same equipment, electrodes, cables, and placement for the actual or placebo treatments. In addition, the participants and the evaluator will not have a view of the equipment screen. Blinding of the outcome assessor will be performed using different team members for randomization of the interventions (Investigator 1), intervention (Investigator 2), evaluation (Investigator 3) and statistical analysis (Investigator 4). Randomization will be kept hidden from participants and research team members in sealed envelopes and only the researcher who will deliver the intervention (researcher 2) will know the group assignment. Successful blinding of participants and evaluator will be analyzed.|"Four interventions will be performed in randomized order: Group A: 30 kHz HFAC, group B: 40 kHz HFAC, group C: 50 kHz HFAC and group D: simulated electrical stimulation.~kHz (kilohertz)"|t|f|f|t
34085615|NCT04772443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085616|NCT02696616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085617|NCT00091078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779400|NCT05962398|||COHORT||PROSPECTIVE|||||||
33779401|NCT05571930|||COHORT||PROSPECTIVE|||||||
33779402|NCT06282549|||COHORT||PROSPECTIVE|||||||
34085618|NCT00587665|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34085619|NCT01391806|||COHORT||PROSPECTIVE|||||||
34085620|NCT03934775|||COHORT||PROSPECTIVE|||||||
33779403|NCT05398341|||COHORT||PROSPECTIVE|||||||
33912752|NCT03768531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912753|NCT00884624|||COHORT||PROSPECTIVE|||||||
33912754|NCT02555761|||COHORT||PROSPECTIVE|||||||
33912755|NCT01301560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912756|NCT03102944|||OTHER||PROSPECTIVE|||||||
33912757|NCT04323748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993842|NCT00755313|||CASE_CONTROL||PROSPECTIVE|||||||
33993843|NCT03685305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690736|NCT05570253|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||This is a single-center, placebo-controlled phase 2 randomized control trial.|t|t|t|f
33690737|NCT05132075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690738|NCT01326741|||COHORT||RETROSPECTIVE|||||||
33993844|NCT01473173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33993845|NCT02699463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993846|NCT00841659|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993847|NCT00396929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33690739|NCT03822468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993848|NCT03581097|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeon and investigators involved in subsequent data analysis were blinded to group assignment|Retrospective, single centre, case-control trial|f|f|t|f
33993849|NCT04754984|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is possible due to the nature of the study.|Participants will be randomly assigned to the intervention or control group. The intervention group will receive the perineal education workshop. The control group will receive standard care. Both groups will receive surveys at baseline, 3, 6 and 12 months postpartum to assess pelvic floor distress.||||
33690740|NCT06745011|||CASE_CONTROL||PROSPECTIVE|||||||
33690741|NCT04574427|||CASE_ONLY||PROSPECTIVE|||||||
33690742|NCT05983159|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"i) Participants with slow-flow vascular malformations with an eligible gene mutation will receive 48 weeks of treatment with open-label alpelisib.~ii) Participants with fast-flow vascular malformations with an eligible gene mutation will receive 48 weeks of treatment with open-label mirdametinib"||||
33779404|NCT02770079|||CASE_CONTROL||PROSPECTIVE|||||||
33779405|NCT06425302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779406|NCT04808869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912758|NCT05744115|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible and consenting participants (male veterans) will receive a single administration of 3-7mCi Ga-68-PSMA-11 per enrollment in addition to conventional imaging (MRI, CT, and/or molecular imaging bone scan).||||
33912759|NCT01465698|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33912760|NCT04526756|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, non-randomized, controlled, outcome-blinded study|f|f|f|t
33912761|NCT03435172|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects will have at least one deep partial or full thickness burn wound of ≥ 250 cm2 that is to be autografted with a split thickness meshed skin graft (STSG) . The Subjects will be randomized to treatment or usual care group at 2:1 ratio. Harvested tissue will be processed in the Celution® System to isolate and concentrate ADRCs. Then the subject will be followed by peripheral intravenous delivery of ADRCs within 4 hours of completion of Celution® processing.~Up to 15 subjects will be enrolled. Each subject will contribute up to three qualified wound areas for the analysis. Randomization will be stratified to ensure that the numbers of wounds treated with STSG are balanced across the treatment groups."||||
33912762|NCT01316601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993850|NCT03874052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993851|NCT03501511|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993852|NCT03442322|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Outcome assessors will be blinded to the treatment arm the facility is randomly assigned to.|This cluster pragmatic trial randomized eligible nursing homes to one of the two intervention arms according to the predetermined protocol to evaluate the effect of the facility-level intervention on resident (i.e. long term care residents living with Alzheimer's Disease or Related Dementia) and staff outcomes.|f|f|t|t
33993853|NCT04613167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993854|NCT02937259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993855|NCT05257564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective quantitative accuracy study||||
33993856|NCT05245006|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33993857|NCT02645253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33993858|NCT05398094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993859|NCT04349553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Placebo|"Cohort 1 will consist of 9 participants, who will receive 3 doses of 1x10\^9 Colony Forming Units (CFU) of ZH9PA (6 participants) or placebo (3 participants).~Cohort 2 will consist of 18 participants, who will receive 3 doses of 1x10\^10 CFU of ZH9PA (12 participants) or placebo (6 participants).~Cohort 3 will consist of 18 participants, who will receive 3 doses of 1x10\^10 CFU of ZH9PA and 1x10\^10 CFU of ZH9 (12 participants) or placebo (6 participants)."|t|f|t|f
33993860|NCT06433739|||COHORT||RETROSPECTIVE|||||||
33993861|NCT06066047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33993862|NCT03393754|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33993863|NCT03129841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993864|NCT06500858|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993865|NCT06502301|||OTHER||CROSS_SECTIONAL|||||||
33993866|NCT06112626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33993867|NCT04342663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33993868|NCT03214120|||COHORT||PROSPECTIVE|||||||
33993869|NCT01490567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993870|NCT03398486|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Experimental: Kinesiotaping Participants receive an application of active tapes (KT) Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.~Experimental: active inactivation of trigger points (TrP) Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break"||||
33993871|NCT04430725|||COHORT||PROSPECTIVE|||||||
33993872|NCT03091140|||COHORT||PROSPECTIVE|||||||
33993873|NCT04365387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085621|NCT05407883|RANDOMIZED|PARALLEL||PREVENTION||NONE|The nature of the intervention is a traffic control measure who will be present at the school crossing points|Random allocation of schools into the intervention and control group will be done parallel using proper allocation concealment when enrolling schools into the respective study arms.||||
33690743|NCT06496386|||CASE_CONTROL||RETROSPECTIVE|||||||
33912763|NCT02563288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993874|NCT06182449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The objective is to recruit 20 mothers of premature newborns. This will correspond to a total sample of 40 participants as they will be their own control. We will recruit 50% more mothers (10) to compensate for the usually high attrition or rejection rate for this population, thus a total sample of 30 mothers.~In addition, allocation to either control or intervention will be randomized at first then switched at the crossover period. However, there will be no washout period between sequences."||||
33993875|NCT05109377|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33993876|NCT06626620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993877|NCT02352727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33993878|NCT02580045|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993879|NCT03448263|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Certified endodontists trained in the procedures, devices, and systems investigated took part in the research. All experts tracked a pre-established procedure for the Balanced Force technique, WaveOne, and Reciproc instrument systems.|Random Selection of instrumentation groups. Of the sample of 216 teeth, 72 were randomly assigned to the one of the 3 instrumentation methods. Treatment was performed by 3 experienced endodontists; each prepared 72 teeth, 24 per technique.|t|f|t|f
33993880|NCT02767804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912764|NCT01968096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993881|NCT00525213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085622|NCT00519350|||COHORT||PROSPECTIVE|||||||
34085623|NCT06524258|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085624|NCT02767531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085625|NCT02057341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085626|NCT05184855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blueberry powder supplement and a carbohydrate- and fiber-matched placebo powder with flavoring, aroma, and coloring.|Randomized, parallel groups|t|f|t|f
34085627|NCT05127460|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34085628|NCT05024383|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single arm study design with group comparisons||||
34085629|NCT00448656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085630|NCT05503498|||COHORT||RETROSPECTIVE|||||||
34085631|NCT03913247|||COHORT||PROSPECTIVE|||||||
34085632|NCT06525792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085633|NCT03786640|||CASE_ONLY||PROSPECTIVE|||||||
34085634|NCT00407511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085635|NCT05413044|||COHORT||RETROSPECTIVE|||||||
34085636|NCT04394325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085637|NCT04443192|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Part A Groups 1-6 and Part B Group 1 will be double-blind; Part A Group 7 (food effect) and Part B Groups 2-4 will be open label|This is a double-blind, randomised, placebo-controlled, single ascending and repeat dose trial in healthy subjects and subjects carrying at least one Z-A1AT allele (PiXZ subjects)|t|t|t|t
34085638|NCT04447729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085639|NCT05822466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34085640|NCT05090644|||OTHER||PROSPECTIVE|||||||
34085641|NCT00164359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33690744|NCT02171702|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690745|NCT06684457|NA|SINGLE_GROUP||PREVENTION||NONE||"Study design:~A single center, cross sectional, uncontrolled, open-label, non-randomized, single arm, experimental pilot study using an LLM based prompt-engineered education chatbot, to impart a Q and A format atrial fibrillation education to patients, prior to their first appointment with a cardiologist or a cardiac electrophysiologist. The prompt-engineered chatbot is built on LLM capabilities yet tailored with the help of physician provided, vetted, open source atrial fibrillation educational material as well as empathy enhancing scripts, and simplified language to a 6th-8th grade reading level. The chatbot would be utilized to enhance the patient-provider interaction by providing empathetic education to patients regarding atrial fibrillation, and empower them with the knowledge they would need to ask informed questions during their patient visit. The chatbot will also be able to direct patients to Heart Rhythm Society's open source educational videos for atrial fibrillation (UpBeat"||||
33690746|NCT06184971|||CASE_ONLY||RETROSPECTIVE|||||||
33912765|NCT04901403|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912766|NCT00202631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912767|NCT05531058|RANDOMIZED|PARALLEL||OTHER||NONE||We aim to have two study group, including the AI-driven vaccine communicator intervention group and the self-learning of COVID-19 vaccine knowledge control group.||||
33912768|NCT04542382|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a single center, an open-label, non-randomized, fixed-sequence study.||||
33912769|NCT01803399|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34085642|NCT03133013|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34085643|NCT01853865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34085644|NCT06452342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085645|NCT01414244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085646|NCT02866643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085647|NCT04224467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085648|NCT03093181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085649|NCT05974761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34085650|NCT06185296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085651|NCT01760902|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34085652|NCT02968810|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33912770|NCT02347241|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33912771|NCT04789642|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33912772|NCT01805232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912773|NCT05924776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912774|NCT06317233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912775|NCT02855411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33912776|NCT03994263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912777|NCT03811678|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33779407|NCT03425136|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||A three-wave stepped-wedge (phased-in) cluster randomized trial, with districts as the unit of randomization (and outcomes assessed at the clinic/individual level within each district)||||
33779408|NCT03155191|NA|SINGLE_GROUP||TREATMENT||NONE||"Peripheral blood will be collected from a subject after obtaining a written informed consent. Peripheral blood mononuclear cells (PBMCs) and plasma are obtained from the blood, and T cells contained in the PBMCs are transduced with anti-CD19 CAR gene by using retroviral vector.~Cyclophosphamide will be administered after obtaining a written informed consent and completing registration.~CD19-CAR-T will be administered in the split dose. Phase 2 recommended dose will be applied for phase 1 portion. The investigator assesses efficacy of CD19-CAR-T in accordance with study-specific criteria, at 8 week after the infusion of CD19-CAR-T (or at the time of termination). The investigator also assesses the safety during the follow-up period. Long-term follow-up study is conducted at frequency of once a year for 15 years after the infusion of CD19-CAR-T in reference to guidelines of FDA."||||
33779409|NCT00771628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33779410|NCT00901485|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33779411|NCT05812755|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33779412|NCT03394963|||OTHER||OTHER|||||||
33779413|NCT02133274|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33779414|NCT00813007|||CASE_ONLY||PROSPECTIVE|||||||
33779415|NCT06231485|RANDOMIZED|PARALLEL||OTHER||SINGLE|Interviewers (outcomes assessors) are masked to the intervention arm to reduce the potential for bias during the interview process, as all surveys are interviewer-administered.|Half of the participants will be randomized to receive the socialization and sex education curriculum (STEPS2), and half to the nutrition and physical exercise curriculum (STYH)|f|f|f|t
33779416|NCT05830916|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33779417|NCT06696157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779418|NCT00212511|||CASE_ONLY||PROSPECTIVE|||||||
33912778|NCT03354819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The eligible participants will be randomized into the 2 groups (MBCT and SIRE), following the allocation concealment mechanism by an independent assistant. The research assistants who were blinded to the group assignment performed all of the outcome measurements and data entries. The procedure and treatment allocation will be blinded to the investigator and the interventionists until the baseline measurement is completed.|A prospective, single-blind, parallel-group randomized controlled trial (RCT) will be adopted to test the hypotheses and compare the immediate effects and its effects over a 3-month follow up between the MBCT program and an active control group (social interactions and routine education on dementia care) for the family caregivers of PWD in the community. The MBCT program consists of seven sessions, including different mindfulness activities (such as mindful eating and mindful walking) and peer sharing, while the parallel active control group will have the social interactions and routine education on dementia care, including seven education sessions on dementia care, caregiver skills training and group sharing, aiming to control/balance the social interaction effects that can also be found in the MBI group. The study will also follow the guideline recommended by the latest Consolidated Standards of Reporting Trials (Schulz et al., 2010) statements.|f|f|f|t
33912779|NCT05853523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split Mouth: all patients involved received both treatments randomly assigned to either the right or left halves of the dentition.|t|f|t|t
33912780|NCT02640846|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33912781|NCT03761043|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33912782|NCT00492947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912783|NCT04824196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912784|NCT04885491|NA|SINGLE_GROUP||TREATMENT||NONE||Observational period with placebo treatment, followed by treatment with PDNO.||||
33912785|NCT01127126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912786|NCT05685368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912787|NCT05219422|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants from 42 schools will be randomized to received Project ALERT, Project ALERT + Getting to Outcomes, or waitlist control|t|f|f|f
33912788|NCT01850745|||COHORT||OTHER|||||||
33912789|NCT04232891|||COHORT||PROSPECTIVE|||||||
33912790|NCT01205672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912791|NCT04740125|||OTHER||CROSS_SECTIONAL|||||||
33912792|NCT02021526|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33912793|NCT04798391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912794|NCT01794494|||CASE_CONTROL||PROSPECTIVE|||||||
33912795|NCT00510328|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912796|NCT02172521|||COHORT||PROSPECTIVE|||||||
33912797|NCT01272297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912798|NCT06254105|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Cohort design involving people with hand OA, general practitioners and occupational therapist employing a mixed-method approach||||
33912799|NCT03271385|||CASE_CONTROL||PROSPECTIVE|||||||
33912800|NCT04664595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|4 second generation of supraglottic airway device|t|f|t|f
33912801|NCT03314441|NA|SINGLE_GROUP||TREATMENT||NONE||4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.||||
33912802|NCT01122628|||COHORT||RETROSPECTIVE|||||||
33779419|NCT06198517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779420|NCT03104569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779421|NCT05860816|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993882|NCT03299829|||COHORT||RETROSPECTIVE|||||||
33779422|NCT03184428|||COHORT||RETROSPECTIVE|||||||
33779423|NCT00003840||||TREATMENT||||||||
33779424|NCT01901549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779425|NCT03461887|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33779426|NCT06666205|||CASE_ONLY||CROSS_SECTIONAL|||||||
33779427|NCT04442659|||COHORT||PROSPECTIVE|||||||
33779428|NCT03050840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779429|NCT00859417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779430|NCT03614858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779431|NCT06556030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779432|NCT04339478|||COHORT||PROSPECTIVE|||||||
33779433|NCT03152565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912803|NCT01438749||CROSSOVER||||DOUBLE|||t|f|t|f
33912804|NCT06266273|NA|SINGLE_GROUP||SCREENING||NONE||||||
33912805|NCT02310802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912806|NCT00563004|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33912807|NCT03169010|||COHORT||PROSPECTIVE|||||||
33912808|NCT06281886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912809|NCT00209599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912810|NCT06383351|||COHORT||CROSS_SECTIONAL|||||||
33779434|NCT02273011|||CASE_CONTROL||PROSPECTIVE|||||||
33779435|NCT04007003|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33912811|NCT03338751|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33912812|NCT05799443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912813|NCT03765476|RANDOMIZED|PARALLEL||TREATMENT||NONE||"one group receives add-on- intervention SALIENCE"||||
33912814|NCT02399839|||OTHER||PROSPECTIVE|||||||
33912815|NCT03057457|||COHORT||PROSPECTIVE|||||||
33912816|NCT00222378|||CASE_CONTROL||PROSPECTIVE|||||||
33912817|NCT01830543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912818|NCT02345252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912819|NCT00104494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912820|NCT04573634|||COHORT||PROSPECTIVE|||||||
33912821|NCT04612062|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open Label Study|"This is a FIH study of CEE321 in Adult Healthy Subjects (Part A) and Subjects with Atopic Dermatitis (Part B).~Enrollment started with Healthy Subjects in Feb 2020. The protocol was amended Jul 2020 to include Atopic Dermatitis (AD) Subjects (Part B)."||||
33912822|NCT01849835|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33912823|NCT05950477|||COHORT||PROSPECTIVE|||||||
33912824|NCT03862690|||COHORT||PROSPECTIVE|||||||
33912825|NCT01188915|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912826|NCT00157092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912827|NCT00258427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912828|NCT03648281|||COHORT||PROSPECTIVE|||||||
33912829|NCT01163162|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912830|NCT00308438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993883|NCT03254225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993884|NCT04836494|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34085653|NCT05969444|||COHORT||RETROSPECTIVE|||||||
34085654|NCT02923869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33779436|NCT05764317|||OTHER||OTHER|||||||
33779437|NCT06313411|||CASE_ONLY||RETROSPECTIVE|||||||
33912831|NCT00116857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912832|NCT01863407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912833|NCT02352610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912834|NCT00077337||||TREATMENT||NONE||||||
33912835|NCT02623036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912836|NCT02817152|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33912837|NCT06291116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912838|NCT01867541|||COHORT||PROSPECTIVE|||||||
33912839|NCT00665496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085655|NCT03920956|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34085656|NCT00405769|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34085657|NCT05711368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085658|NCT00000220||||TREATMENT||DOUBLE||||||
33993885|NCT06559878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study protocol includes five clinical visits. At first visit, an informed consent will be obtained, followed by assessment of inclusion/exclusion criteria. Participants fulfilling the criteria will be enrolled in the study. At second visit, magnetic resonance studies will be performed to quantify liver fat content. Visits 3-5 consist of metabolic studies using the 13C-ketoisocaproate breath test and, in a random order, infusions of either a) saline alone, b) saline, a lipid emulsion and heparin or c) saline and ethanol.||||
33993886|NCT02577653|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33993887|NCT05007067|||CASE_ONLY||RETROSPECTIVE|||||||
33993888|NCT04476511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993889|NCT01640197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33993890|NCT04754035|NA|SEQUENTIAL||TREATMENT||NONE||Venetoclax will be administered, initially as single agent, orally once daily (QD), starting with 20 mg on Day 1, followed by weekly dose escalation up to 400 mg At Cycle 12 Day 1 Minimal residual disease (MRD) in the peripheral blood will be evaluated in patients with CR or PR by flow cytometry. All MRD negative subjects (defined as those with MRD level in the PB \<10-4 in the PB and in the BM aspirate) will discontinue venetoclax at the end of Cycle 12. All MRD positive subjects (defined as those with MRD level in the PB \>10-4) and patients with stable disease will continue venetoclax and start treatment with ibrutinib at the standard dose for CLL of 420 mg QD. Venetoclax will be administered until unacceptable toxicity or disease progression or for a maximum of 2 years and ibrutinib will be continued until unacceptable toxicity, confirmed MRD negativity, or disease progression.||||
33993891|NCT04200274|||CASE_ONLY||CROSS_SECTIONAL|||||||
33993892|NCT01604941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993893|NCT03315650|||CASE_ONLY||PROSPECTIVE|||||||
33993894|NCT05456763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993895|NCT06377410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993896|NCT02623413|||COHORT||PROSPECTIVE|||||||
33993897|NCT03138967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33993898|NCT05913128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized clinical trial|f|f|t|f
33993899|NCT04571684|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Matched, cluster randomized controlled design||||
33779438|NCT00783718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33993900|NCT00447941|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33993901|NCT01746056|RANDOMIZED|PARALLEL||TREATMENT||NONE||one arm receiving intervention in daily for 12 week the other receives the intervention 2 weeks on and 2 weeks off for 12 weeks||||
33993902|NCT02630797|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||This partially randomized crossover design model will include participants assigned first to a control baseline period followed by three intervention phases with a low, medium or high daily dose of blueberry products in a randomized order.|f|f|f|t
33993903|NCT05911152|||COHORT||RETROSPECTIVE|||||||
33993904|NCT05628103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993905|NCT04281472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993906|NCT01712906|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33993907|NCT02742194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993908|NCT01463579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33993909|NCT00346190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33993910|NCT04185272|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||colon cancer patients and metastatic colon cancer patients will be included in this study. We expect that BTNL molecules expression is different depending of the aggressiveness of the illness||||
33993911|NCT03999216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085659|NCT05224323|||COHORT||PROSPECTIVE|||||||
34085660|NCT00924898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085661|NCT01047319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085662|NCT00769301|||COHORT||PROSPECTIVE|||||||
34085663|NCT04623710|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34085664|NCT03845894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33690747|NCT06692764|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"Potential participants will be screened to assess their eligibility to enter the study up to 7 days prior to first administration of study intervention. Eligible participants will be randomized to Treatment Sequence AB or BA on Period 1 Day 1. A 14-day washout period will be required between the final dose in Period 1 and start of baseline ABPM in Period 2.~In Periods 1 and 2, participants will return to the study site for an OPV on Day -1 for the start of the baseline ABPM. The ABPM device will be worn for 25 hours. Participants will return to the study site for an OPV on the following day (Day 1) for removal of the ABPM device and to begin self-administration of AZD0780 or placebo for 29 ± 2 days as per the randomization scheme. First dose of study intervention will be taken after the ABPM device is removed on Day 1 at the study site after the baseline ABPM is qualified (i.e., determined not to require repeat)."|t|f|t|t
34085665|NCT00490308|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085666|NCT01413997|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085667|NCT00010998||||TREATMENT||||||||
33690748|NCT05272839|RANDOMIZED|PARALLEL||TREATMENT||NONE||At the first visit, patients will be randomly assigned to control group or intervention group.||||
33690749|NCT03986437|||COHORT||PROSPECTIVE|||||||
33690750|NCT05407753|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34085668|NCT05902676|||CASE_CONTROL||PROSPECTIVE|||||||
34085669|NCT02033863|||CASE_ONLY||PROSPECTIVE|||||||
34085670|NCT05051917|||COHORT||PROSPECTIVE|||||||
34085671|NCT06473805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly allocated according to predetermined computer-generated randomization using www.Randomizer.org|Patients with a gummy smile caused by excessive gingival display ≥ 4 mm due to sub nasal depression will be randomly divided into 2 groups, each will perform minimally invasive vestibular incision subperiosteal tunnel access (VISTA) and place whether 3D printed PMMA or PEEK implants.|f|f|f|t
34085672|NCT00822471|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34085673|NCT03567096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, two-arm, randomized 1:1, multicenter study|f|f|f|t
34085674|NCT05576311|||COHORT||CROSS_SECTIONAL|||||||
34085675|NCT05217030|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of patients had comparison of measurements-one group received AAT; one group did not||||
34085676|NCT02783066|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085677|NCT02242617|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085678|NCT00433836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085679|NCT04898881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085680|NCT03094156|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34085681|NCT03350919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085682|NCT05105685|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085683|NCT00982345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085684|NCT02855255|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33690751|NCT05720702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690752|NCT02680899|NA|SINGLE_GROUP||OTHER||NONE||||||
34085685|NCT01502553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690753|NCT05386823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690754|NCT02273518|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33690755|NCT06744296|||COHORT||PROSPECTIVE|||||||
33690756|NCT04784299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33690757|NCT06395948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Sponsor's study staff will also be blinded in the study.||t|t|t|t
33690758|NCT01721473|||COHORT||PROSPECTIVE|||||||
33690759|NCT05394129|||CASE_CONTROL||PROSPECTIVE|||||||
33779439|NCT05395143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double-blind, placebo-controlled trial where one group consists of 46 hyperlipidemic patients under treatment with atorvastatin and zinc; and another group consists of 46 hyperlipidemic patients under treatment with atorvastatin and placebo|t|f|t|f
33779440|NCT04673175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779441|NCT00005611||||TREATMENT||||||||
33912840|NCT00711269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912841|NCT06065527|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking will not occur because it is not a blinded study.|This is a multi-site, two-arm, pragmatic randomized controlled trial (RCT) of primary family caregivers of individuals with IDD. Family caregivers will be randomized 1:1 to one of 2 treatment arms described above. This is a non-blinded study because the nature of the intervention prevents participants from being blinded to their study arm.||||
33912842|NCT00195260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912843|NCT03265509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33912844|NCT05218850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912845|NCT03509207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912846|NCT03236688|||COHORT||PROSPECTIVE|||||||
33912847|NCT00782418|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33912848|NCT00436566|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33912849|NCT03018626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912850|NCT06288776|NA|SINGLE_GROUP||TREATMENT||NONE|Single-blinded study where participant will be masked.|In this study, participants will be selected by consecutive non-random sampling technique.||||
33912851|NCT01740440|NA|SINGLE_GROUP||||NONE||||||
33912852|NCT03540134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912853|NCT01104259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912854|NCT06006858|||OTHER||RETROSPECTIVE|||||||
33912855|NCT05942937|NA|SINGLE_GROUP||OTHER||NONE||This is a single group, non-randomised, before-and-after trial of an education intervention being conducted in three to six selected prisons in Australia.||||
33912856|NCT00471445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33912857|NCT02508688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912858|NCT01810042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085686|NCT04472702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A random number table will be used for group allocation and the values recorded separately into opaque, sealed envelopes. This will be performed by a clinical coordinator who is not involved in study to ensure allocation concealment. Outcomes for the primary, secondary, and exploratory aims will be completed by research staff who are blinded to the subject treatment allocation. Data analyses will also be completed in a blinded fashion by the study statistical consultant.|Participants (N=90; 45 at each site) will be randomized with equal probability to either treatment group, restricted by equal enrollment and equal distribution at each site. Patients will be enrolled for the exploratory aim separately at the University of Florida site only. After enrollment into the main study (primary and secondary aims), subjects at the UF site will be offered enrollment into the exploratory aim (N=24) on a consecutive basis restricted by equal enrollment into each treatment arm. A random number table will be used for group allocation and the values recorded separately into opaque, sealed envelopes. This will be performed by a clinical coordinator who is not involved in study to ensure allocation concealment. Outcomes for the primary, secondary, and exploratory aims will be completed by research staff who are blinded to the subject treatment allocation. Data analyses will also be completed in a blinded fashion by the study statistical consultant.|f|f|t|f
34085687|NCT04553419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded||t|t|t|t
34085688|NCT05733910|NA|SINGLE_GROUP||OTHER||NONE||The patients will be prospectively enrolled and treated at the sponsor's premises. Only one group of subjects will enter the phase II trial.||||
34085689|NCT06523582|||COHORT||PROSPECTIVE|||||||
34085690|NCT03620162|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33690760|NCT05347446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once the subject is consented and enrolled after intraprocedural confirmation of inclusion and exclusion criteria, the randomization envelope will be opened to assign the subject to either Hybrid ESD or Non-Hybrid ESD.|This is a randomized trial where the subject will either be randomized to Hybrid Endoscopic Submucosal Dissection or Non-Hybrid Endoscopic Submucosal Dissection. The provider nor the participant will be aware of what group the subject will be randomized to.|t|t|f|f
33912859|NCT03533725|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention group having peer counseling and education and a comparative (control) group having standard of care||||
33912860|NCT05489822|||COHORT||PROSPECTIVE|||||||
33912861|NCT00472472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912862|NCT00777491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912863|NCT01226420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912864|NCT05329987|||COHORT||PROSPECTIVE|||||||
33912865|NCT02167841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912866|NCT00657852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33912867|NCT03126929|||COHORT||PROSPECTIVE|||||||
33912868|NCT01143493|||COHORT||PROSPECTIVE|||||||
33912869|NCT00869765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912870|NCT06552507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912871|NCT05603039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912872|NCT06553326|||CASE_ONLY||PROSPECTIVE|||||||
33912873|NCT04353921|||COHORT||OTHER|||||||
33912874|NCT00753935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33912875|NCT04287998|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33912876|NCT04158713|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Allocation: randomised; intervention model: parallel assignment; arms: 2; allocation ratio: 1:1; stratified by site (hospital) and HIV-status (known-positive and newly-diagnosed). Masking: Placebo controlled|t|t|t|t
33912877|NCT02328989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912878|NCT05441137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912879|NCT00660504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779442|NCT03805360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study aims to assess the systemic absorption of ropivacaine when it is administered into the erector spinae plane compartment.|t|t|t|t
33779443|NCT01649440|||CASE_CONTROL||PROSPECTIVE|||||||
33779444|NCT03049982|NA|SINGLE_GROUP||OTHER||NONE||||||
33912880|NCT01735617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912881|NCT01220648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912882|NCT04059445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33912883|NCT00234858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912884|NCT04715308|||COHORT||PROSPECTIVE|||||||
33912885|NCT04569474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33912886|NCT02955134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912887|NCT05813171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A randomized, double-blinded, placebo-controlled trial|A randomized controlled trial with two parallel groups of participants|t|t|f|f
33912888|NCT01166360|||COHORT||PROSPECTIVE|||||||
33912889|NCT04105556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Male child and care provider|Type of intervention, testing the comfort and components of children and parents of the circumcision operation plan with Nursing Care Based on Kolcaba's Comfort Theory|t|t|f|f
33912890|NCT05595785|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33912891|NCT02515864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33912892|NCT00216853|||COHORT||PROSPECTIVE|||||||
33912893|NCT02491073|||CASE_CONTROL||PROSPECTIVE|||||||
33912894|NCT00004880||||TREATMENT||||||||
33912895|NCT01899404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912896|NCT01520168|||CASE_ONLY||RETROSPECTIVE|||||||
33912897|NCT05342584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912898|NCT03826355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The ultrasonographer will be blinded to the procedure performed in each ovary after surgery. The patient will not be told which procedure has been performed in each ovary. The investigator will not know which procedure has been performed in each ovary until the end of the study. Only the surgeon will know which procedure is performed in each ovary.|Randomized prospective pairwise-data study. Patients with bilateral endometrioma with surgical indication will be selected. Ovarian reserve will be evaluated before and after surgery in both ovaries separately, using antral follicle count (AFC) and volume measurement. Type of surgery in each ovary will be randomized in the operating room (standard cystectomy vs laser vaporisation). A blinded ultrasonographer will evaluate AFC and volume measurement in both ovaries, before and three and six months after surgery. Therefore, each ovary will be compared with its contralateral in the same patient.|t|t|t|f
33912899|NCT00879814|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912900|NCT00819533|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33993912|NCT05594238|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Participants are first randomly assigned to two interventions: either Telephone Engagement or Portal Engagement. Participants who do not meet the criteria for response at the post-test will be re-randomized into either enhanced first stage or a Telehealth MI-CBT program.|f|f|f|t
33993913|NCT06557239|||OTHER||PROSPECTIVE|||||||
33993914|NCT03639077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33993915|NCT03997019|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|both patient and data collector will be unaware of the group nature|group A WILL RECEIVE OPOID analgesia group B will receive ESP block|t|f|f|t
33993916|NCT06152796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993917|NCT00467103|||COHORT||PROSPECTIVE|||||||
33993918|NCT05892081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993919|NCT05692362|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33993920|NCT03596567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33993921|NCT04211779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33993922|NCT01960296|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34085691|NCT03627676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779445|NCT01073098|NA|SINGLE_GROUP||||NONE||||||
33779446|NCT04255875|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Masking will only be applicable to Part 1 of the study where Healthy participants will be enrolled and randomized to receive either PF-07209326 or to placebo. In Part 2 of the study, all eligible SCD participants will receive PF-07209326 and no masking will be required.||t|t|t|f
33779447|NCT04120337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779448|NCT06158347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779449|NCT04548232|||CASE_ONLY||RETROSPECTIVE|||||||
33779450|NCT00665561|||COHORT||PROSPECTIVE|||||||
33690761|NCT05893797|NA|SINGLE_GROUP||TREATMENT||NONE||Baseline occurs at study period 1, week 5 and 6. During study period 1, participants will be masked to their bolus insulin delivery details in the connected insulin management platform. During study period 2, participants will not be masked to the bolus insulin delivery details.||||
33690762|NCT06734858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690763|NCT05944224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690764|NCT04177238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33690765|NCT00938223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690766|NCT06404047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Appendix A: Single (Outcomes Assessor masked) The assessor of the primary outcome, Endurance Shuttle Walk Test (ESWT), is blinded.~Appendix B: None (open label / no masking)"|This platform protocol is designed to allocate participants into an appropriate intervention appendix based on their symptoms of exercise intolerance or post-exertional malaise (PEM). Once assigned to an appendix, eligible participants are randomized in a 1:1 ratio to either the study intervention group or a control group.|f|f|f|t
33690767|NCT01902251|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33690768|NCT01915264|||COHORT||PROSPECTIVE|||||||
33690769|NCT03560830|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690770|NCT02670278|||||CROSS_SECTIONAL|||||||
33690771|NCT01041495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33690772|NCT01171508|||COHORT||PROSPECTIVE|||||||
33690773|NCT01473056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690774|NCT03243266|||COHORT||CROSS_SECTIONAL|||||||
33690775|NCT03256188|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33912901|NCT00465855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912902|NCT05137119|RANDOMIZED|FACTORIAL||TREATMENT||NONE|This is an open-label study|Participants enrolled into the study have the option of deciding whether to be randomised in one or more (if available) treatment domains concurrently, if they meet the eligibility criteria.||||
33912903|NCT00742443|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33912904|NCT01260467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912905|NCT05787353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912906|NCT04907578|||COHORT||PROSPECTIVE|||||||
33912907|NCT05501574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912908|NCT02408055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912909|NCT01560728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912910|NCT02636062|||COHORT||PROSPECTIVE|||||||
33912911|NCT01887028|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33912912|NCT00547378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912913|NCT03850327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912914|NCT03505138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33912915|NCT04321317|NA|SINGLE_GROUP||OTHER||NONE||||||
33912916|NCT04755712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33912917|NCT02662777|||COHORT||PROSPECTIVE|||||||
33912918|NCT04405505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912919|NCT02768649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912920|NCT01376713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912921|NCT00239187|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33912922|NCT04169594|||CASE_ONLY||PROSPECTIVE|||||||
33912923|NCT02742870|||CASE_ONLY||RETROSPECTIVE|||||||
33912924|NCT00423410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912925|NCT00645567|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33912926|NCT02436577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33912927|NCT00121992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912928|NCT00475462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912929|NCT03174821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Normal group (NC) and Type 2 diabetic (DM) group||||
33912930|NCT01260766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993923|NCT00196963|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33993924|NCT04676503|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label pilot study||||
33993925|NCT00792753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993926|NCT02318420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993927|NCT00836472|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33690776|NCT00002576|RANDOMIZED|||TREATMENT||||||||
33690777|NCT04240002|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690778|NCT02929784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33690779|NCT06120777|NA|SINGLE_GROUP||OTHER||NONE||||||
33690780|NCT05765812|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment applies to the arm groups within Phase 1 of the study. Sequential assignment will apply to Phases 1 and 2 of the study.||||
33690781|NCT06548074|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690782|NCT04980573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33690783|NCT05501262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779451|NCT04330846|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"A prospective multicenter randomized comparative study of the treatment of de novo stenosis due to CD, comparing endoscopic treatment (stent or EBD) vs. surgical resection (SR).~The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed."||||
33779452|NCT00514605|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33779453|NCT06100029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779454|NCT05559892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33912931|NCT05848830|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|Both the participants and the investigators are blinded to the active and placebo groups. A third party, Gruppo Nutrition (Windsor, ON) will conduct the randomization for our supplemental interventions and manage blinding procedures. Neither the participants nor the investigators will be unblinded to the supplement randomization. Lastly, researchers will only be unblinded upon finishing the data analysis.|All participants will undergo 16 weeks of home-based exercise training. Half of them are randomized in an active group with a multi-ingredient supplement, and half will be given a placebo. Both the participants and the investigators are blinded to the groups.|t|t|t|f
33912932|NCT03673241|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, non-blinded, randomized trial. This cohort will be divided into two groups: (1) The Control Group (2) The Study Group||||
33912933|NCT04129606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33912934|NCT01765049|||COHORT||PROSPECTIVE|||||||
33912935|NCT03235596|NA|SINGLE_GROUP||TREATMENT||NONE||It's an interventional, prospective and monocentric pilot study.||||
33912936|NCT01073280|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33912937|NCT00187239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690784|NCT02278341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690785|NCT05323578|||COHORT||CROSS_SECTIONAL|||||||
33690786|NCT06710106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel groups, blind, 8-week randomized nutritional intervention|t|f|f|f
33779455|NCT03169361|||COHORT||PROSPECTIVE|||||||
33779456|NCT04685343|NA|SINGLE_GROUP||OTHER||NONE||||||
33779457|NCT03610217|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779458|NCT04244175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779459|NCT05665595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779460|NCT01891032|||CASE_ONLY||PROSPECTIVE|||||||
33779461|NCT05861284|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33779462|NCT00628628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779463|NCT06180382|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization comparing 2 therapeutic strategies||||
33779464|NCT00616278|||COHORT||PROSPECTIVE|||||||
33779465|NCT02186938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779466|NCT03883646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779467|NCT06697054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"A single arm interventional study aiming at the comparison of the effectiveness of detection for sentinel lymph node biopsy using charcoal carbon dye compared to classic indocyanine (ICG) tracer in early stage cervical cancer.~Sentinel lymph node detection rates of both tracers in pelvic, obturator and inframesenteric para-aortic whteher bilateral/ unilateral) will be compared in addition to sensitivity, specificity and negative and positive predictive value."||||
33779468|NCT02669719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912938|NCT00319852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912939|NCT00431405|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33912940|NCT02893774|NA|SINGLE_GROUP||OTHER||NONE||||||
33993928|NCT05389735|||OTHER||PROSPECTIVE|||||||
33690787|NCT04982588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690788|NCT01599832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690789|NCT04245371|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-Blind|Participants will serve as their own control|t|f|t|t
33690790|NCT01624805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690791|NCT02178683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690792|NCT03957590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993929|NCT02714465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993930|NCT01510938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33993931|NCT03679091|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33993932|NCT01693523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33993933|NCT04311164|||COHORT||CROSS_SECTIONAL|||||||
33779469|NCT05386719|NA|SINGLE_GROUP||SCREENING||NONE||The screening program will refer patients to established institutional programs and resources (Cardiovascular Disease prevention program, Healthful Weight Eating Activity Program and Endocrinology).||||
33993934|NCT06534996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993935|NCT00107991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993936|NCT03648580|RANDOMIZED|PARALLEL||TREATMENT||NONE|It's an open study. The number of protocol evaluable subjects for each group that complete the study and comply well with study protocol is planned to be 30.|the subjects will be randomized into intervention group and control group.||||
33779470|NCT03328520|NA|SINGLE_GROUP||OTHER||NONE||||||
33779471|NCT01982760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779472|NCT01394991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912941|NCT05822908|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple ascending dose design||||
33912942|NCT01768598|||COHORT||PROSPECTIVE|||||||
33912943|NCT00353951|||COHORT||PROSPECTIVE|||||||
33912944|NCT00074412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33912945|NCT03215394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912946|NCT00825383|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912947|NCT01671930|||COHORT||CROSS_SECTIONAL|||||||
33912948|NCT00681967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912949|NCT06010316|||COHORT||PROSPECTIVE|||||||
33912950|NCT05623904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912951|NCT06093373|||OTHER||OTHER|||||||
33912952|NCT06409078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912953|NCT00585923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779473|NCT02147990|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912954|NCT04840992|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33912955|NCT05717452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Standard two-arm trial with a placebo arm and active intervention arm|t|f|f|t
33912956|NCT03071549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||RCT|t|t|f|t
33912957|NCT05607225|||COHORT||PROSPECTIVE|||||||
33912958|NCT01532063|NA|SINGLE_GROUP||OTHER||NONE||||||
33912959|NCT03075176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked as to which type of surgery they receive in either eye.|Each participant will receive wavefront optimized surgery in one eye and topography-guided surgery in the second eye.|t|f|f|f
33912960|NCT04079894|||COHORT||PROSPECTIVE|||||||
33912961|NCT01441921|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33912962|NCT00005986||||TREATMENT||||||||
33912963|NCT03026413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912964|NCT03129581|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, non-blinded, behavioral intervention pilot study||||
33912965|NCT05186883|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912966|NCT05557773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33912967|NCT02623634|||COHORT||PROSPECTIVE|||||||
33912968|NCT01226355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33912969|NCT06330662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization would first be generated using a computer-selected program, and then the protocol itself would be placed in opaque sealed envelopes and handed to the operator immediately before the procedure with a decision as to whether or not hyaluronic acid (HA) would be applied. In treated areas where HA will not be applied, the operative site will be treated only with saline. The patient as well as the researcher and the outcomes assesssor will not be informed which patient belongs to which group. Randomization and allocation of envelopes as well as allocation of patients to groups will be determined by a fourth party.|The control group refers to surgical intervention using a coronally advanced flap to cover multiple gingival recessions without the addition of hyaluronic acid (CAF) and the experimental group indicates the surgical intervention using a coronally advanced flap to cover multiple adjacent gingival recessions with the addition of hyaluronic acid intraoperatively (CAF + HA).|t|f|t|t
33912970|NCT06515769|||CASE_CONTROL||PROSPECTIVE|||||||
33912971|NCT05618899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33912972|NCT02458690|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33912973|NCT04391426|||CASE_CONTROL||PROSPECTIVE|||||||
33912974|NCT04056455|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33912975|NCT03420378|NA|SINGLE_GROUP||SCREENING||NONE||||||
33912976|NCT01765361|||OTHER||PROSPECTIVE|||||||
33912977|NCT04270994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912978|NCT02023164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33912979|NCT05649618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912980|NCT01657448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33912981|NCT02969434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33912982|NCT00235651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912983|NCT00133237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912984|NCT00619580|||COHORT||RETROSPECTIVE|||||||
33912985|NCT00504335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33912986|NCT00878657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33912987|NCT04848584|||CASE_CONTROL||RETROSPECTIVE|||||||
33912988|NCT00941954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33912989|NCT04721015|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33993937|NCT03692611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized controlled trial to discover whether STOMP is an efficacious Pain Self-Management (PSM) intervention, mediated by the hypothesized Social Cognitive Theory (SCT) constructs.|f|f|t|t
33993938|NCT00446966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34085692|NCT06215742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34085693|NCT02779985|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34085694|NCT03136198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A central, independent, Core Lab will review all images.||f|t|t|f
33912990|NCT03172221|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839965|NCT06056843|NA|SINGLE_GROUP||SCREENING||NONE||This is a single-arm study in which women with a positive clinical breast examination will be triaged using a portable ultrasound device by non-radiologists. The gold standard is mammography, ultrasound and histology if needed.||||
33912991|NCT06336551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912992|NCT03668691|||CASE_ONLY||PROSPECTIVE|||||||
33912993|NCT01407497|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33912994|NCT03521687|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study that will enroll 20 subjects with central centrifugal cicatricial alopecia. All subjects will receive apremilast.||||
33912995|NCT01389648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33912996|NCT01425073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33912997|NCT04313361|||COHORT||PROSPECTIVE|||||||
33912998|NCT01710111|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33912999|NCT05737173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33913000|NCT05792670|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|According to randomization, the anesthesiologist is informed about the ventilation mode but the surgeons are absolutely blind. The surgeons will perform the RIRS without knowing the type of ventilation mode.|The patients will be divided randomly by a computer-generated randomization table into two equal groups.|f|f|t|f
33913001|NCT05096871|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33913002|NCT00016198||||TREATMENT||||||||
33913003|NCT00796601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913004|NCT00084916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913005|NCT05213468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parallel study, single blinded|Parallel study, single blinded|f|t|f|f
33839966|NCT03439267|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839967|NCT00245180|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839968|NCT04211090|NA|SINGLE_GROUP||TREATMENT||NONE||patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer||||
33839969|NCT00671177|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33839970|NCT04457349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839971|NCT02349152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839972|NCT03572647|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839973|NCT01147536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839974|NCT00773799|||CASE_ONLY||RETROSPECTIVE|||||||
33839975|NCT01133834|||||PROSPECTIVE|||||||
33839976|NCT00968526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839977|NCT06345469|||COHORT||RETROSPECTIVE|||||||
33839978|NCT02868606|||COHORT||RETROSPECTIVE|||||||
33839979|NCT05101382|||COHORT||RETROSPECTIVE|||||||
33839980|NCT04878315|RANDOMIZED|CROSSOVER||TREATMENT||NONE|It is an open-label study.|This is a 3-period, 2-treatment, 3-sequence, partially replicated crossover study||||
33839981|NCT00371098|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33839982|NCT01987362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839983|NCT02519140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839984|NCT04472884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839985|NCT05548660|RANDOMIZED|PARALLEL||OTHER||NONE||Post-surgery pharmacogenetic-guided analgesic selection versus usual care analgesia||||
33839986|NCT02592876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839987|NCT04611165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839988|NCT00002775||||TREATMENT||||||||
33839989|NCT04765917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 different groups receive different interventions at the same time during the study|t|f|t|t
33839990|NCT04263038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839991|NCT00954889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839992|NCT00785811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33839993|NCT05078541|NA|SINGLE_GROUP||TREATMENT||NONE||Safety and Feasibility Study||||
33839994|NCT00448877|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33839995|NCT02765334|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Feasibility of nBETTER training (60 minutes) with conventional arm therapy (30minutes) for chronic stroke.||||
33839996|NCT02320513|||CASE_CONTROL||PROSPECTIVE|||||||
33839997|NCT01213524|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and outcomes assessor were blind to patch condition (NIC or PLA)|Within-subjects design study that investigated the separate and combined effects of sensorimotor replacement for smoking (very low nicotine content \[VLNC\] cigarettes vs. no cigarettes) and transdermal nicotine replacement (42 mg nicotine \[NIC\] vs. placebo \[PLA\] patches). Participants were smokers with schizophrenia and equally-heavy smokers without psychiatric disorders. Each participant underwent the following conditions, in counterbalanced order: VLNC + NIC, VLNC + PLA, no cigarettes + NIC, no cigarettes + PLA, usual-brand cigarettes + no patches.|t|f|f|t
33839998|NCT03025750|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33839999|NCT02797652|||COHORT||PROSPECTIVE|||||||
33840000|NCT05837377|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840001|NCT00223470|||CASE_CONTROL||PROSPECTIVE|||||||
33840002|NCT01492153|||COHORT||PROSPECTIVE|||||||
33913006|NCT01418664|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913007|NCT06225960|||COHORT||PROSPECTIVE|||||||
33913008|NCT00000741||PARALLEL||TREATMENT||||||||
33913009|NCT04393584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993939|NCT05921214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The late talkers and their caregivers will not explicitly be told what condition their child is in.|Using treatment effect sizes, children will be compared to themselves (treatment words v. control words) and across groups (familiar word group v. less-familiar word group).|t|t|f|f
33993940|NCT00029263|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33993941|NCT06412861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Patients will be randomly assigned to one of two groups (1:1 ratio, parallel randomization) by randomization using the computer program ResearchRandomizer (Urbaniak and Plous 2013), conducted by a team member not involved in surgery or patient assessment. There will be 30 patients in each group."|t|f|t|t
33993942|NCT04522258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators, and personnel involved in data analyses are blinded to the intervention. Unblinding occurs after all data has been collected AND analysed.||t|f|t|t
33993943|NCT00586989|||COHORT||PROSPECTIVE|||||||
33993944|NCT05251727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33993945|NCT02316223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33993946|NCT06103812|||COHORT||PROSPECTIVE|||||||
33993947|NCT06558968|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|articipants will be blinded to the type of intervention. Teeth treated will be assigned codes so that outcome evaluators at the follow up appointments are blinded. On the other hand, the operator/ primary investigator cannot be blinded, as she is already familiar with the nature of the materials used. For statistical analysis, codes will also assure blinding and confidentiality. For the patient, both types of space maintainers will have the same color and design.||t|t|f|f
33993948|NCT00545428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33913010|NCT03072121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913011|NCT02804880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33913012|NCT04740268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants in the Straberi microneedling trial are those who are seeking improvement for atrophic acne scaring.||||
33913013|NCT03785886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993949|NCT04584749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will be randomized in a 1: 1 ratio to one of two treatment groups: Lidocaine or Placebo.~To preserve the masking of the study, the list with the recruited patients will be sent weekly to an independent researcher from IDIBGI, who will be in charge of providing the names and numbers of the medical records to the pharmacy service.~The randomization process has been carried out using the PASS 16.0.4 program. Only the Pharmacy staff will know the randomization tables and codes. The main investigator will have the emergency codes in case of need"|a phase IV, randomized, double-blind, two-arm, parallel-group clinical research trial|t|f|t|f
33913014|NCT02087384|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913015|NCT01944969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913016|NCT06457035|||COHORT||RETROSPECTIVE|||||||
33913017|NCT00382980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33993950|NCT02951247|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33993951|NCT04251429|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993952|NCT00835484|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33993953|NCT06441591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33993954|NCT01666262|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33993955|NCT04993274|||COHORT||PROSPECTIVE|||||||
33993956|NCT05027503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33993957|NCT02022150|||COHORT||PROSPECTIVE|||||||
33993958|NCT06483646|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913018|NCT03284294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Controlled Trial|t|t|t|t
33913019|NCT03698513|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33913020|NCT01465711|||CASE_CONTROL||PROSPECTIVE|||||||
33913021|NCT04915664|||COHORT||PROSPECTIVE|||||||
33913022|NCT01725152|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33913023|NCT03535038|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33913024|NCT00446446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913025|NCT01593501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913026|NCT00633581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33913027|NCT05591898|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized controlled clinical trial||||
33913028|NCT04662242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913029|NCT05142514|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33913030|NCT00480922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913031|NCT04161586|||COHORT||RETROSPECTIVE|||||||
33913032|NCT03226223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants and study staff conducting the lab sessions will be blinded to the treatment condition (i.e., naltrexone 0 mg or 50 mg)|Participants will complete two testing sessions in which the effects of oral naltrexone (0 mg \& 50 mg) will be tested in combination with intranasal methamphetamine. Participants will complete two testing sessions (naltrexone 0 mg + Methamphetamine \& naltrexone 50 mg + methamphetamine), in randomized order.|t|f|f|f
33690793|NCT03257176|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690794|NCT02061436|||COHORT||PROSPECTIVE|||||||
33690795|NCT06182579|NA|SEQUENTIAL||TREATMENT||NONE||dose escalation in a 3+3 study design||||
33690796|NCT04059198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690797|NCT04974918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690798|NCT02133521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690799|NCT06040879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||PCA group and PENG BLOCK group|t|f|f|f
33690800|NCT00546468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690801|NCT04997265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, open-label, parallel-group, randomized pilot trial||||
33690802|NCT06199037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1707 compared with placebo|t|t|t|t
33690803|NCT01721707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690804|NCT01139840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33690805|NCT02057627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690806|NCT05625620|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Crossover Assignment|t|f|f|f
33690807|NCT03028350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690808|NCT03258138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The amount of exposure to the programs will be known to participants and providers.|Enrolled participants will be allocated to one of the two intervention groups for the duration of the study. One group will be assigned to the more intensive program (MIP= usual care plus healthy lifestyles program) and the other group will be assigned to the less intensive program (LIP= usual care plus health goal development).||||
33690809|NCT03882008|NA|SINGLE_GROUP||OTHER||NONE||||||
33690810|NCT03187756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690811|NCT05876260|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33690812|NCT04601922|||COHORT||PROSPECTIVE|||||||
33690813|NCT00808431|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33690814|NCT00321061||||TREATMENT||||||||
33690815|NCT02495012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690816|NCT06022029|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In Part 1a patients will receive ONM-501 as a single agent; in Part 1b patients will receive ONM-501 in combination with Cemiplimab; Part 2 will be an expansion of ONM-501 in combination with Cemiplimab.||||
33690817|NCT04509739|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690818|NCT05947578|NA|SEQUENTIAL||TREATMENT||NONE||Dose group A (Low dose) Dose group B (Mid dose) Dose group C (High dose)||||
33690819|NCT06703983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This study is an open-label randomized clinical trial with two arms:~Low Glycemic Index therapy (LGIT) Classic Ketogenic Diet (CKD) Each arm will include 20 participants, allocated using a block randomization process. After three months, seizure reduction outcomes will be compared between the two groups.~All 40 participants in both arms will recieve diet for 3 months.Parents will monitor and report the impact of the dietary therapy on seizure frequency, and each participant will be categorized into one of four groups based on the reported reduction:~1. Seizure free:No more seizures reported~2. More than 90% seizure reduction~3. More than 50% seizure reduction~4. Less than 50% seizure reduction Based on previous studies, a reduction of less than 50% is considered an unsuccessful therapy.~After three months, all 40 participants will be evaluated to determine the effectiveness of each diet in treating epilepsy and results will be analyzed and reported."|f|f|f|t
33690820|NCT02269826|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33690821|NCT02698059|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33690822|NCT05721755|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690823|NCT05091203|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33690824|NCT00995865|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690825|NCT00326573|RANDOMIZED|PARALLEL||ECT||NONE||||||
33690826|NCT00160966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690827|NCT02913040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690828|NCT00800748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690829|NCT05587218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33690830|NCT05344885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33690831|NCT02616432|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33690832|NCT03609580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690833|NCT05007015|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|"Allocation with be generated by a centralized computer generated randomized sequence to ensure allocation concealment.~Data analyst will be blinding to treatment group but no other masking is feasible given the treatment"|Multicenter randomized controlled crossover trial||||
33690834|NCT05218265|||CASE_ONLY||PROSPECTIVE|||||||
33690835|NCT01973543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||VY-AADC01|f|f|f|t
33690836|NCT05288699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690837|NCT05270421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using block randomization, the patients are randomly assigned to one of two groups by a statistician outside of the research group. The codes for each group remain unknown to the researchers until after statistical analysis, with only the nurse and physician in charge of delivering the therapy and monitoring the patients being made aware.|500 patients will be randomly and equally divided into the intervention and control groups.|t|f|t|f
33690838|NCT02902978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33690839|NCT03981796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant, Investigator, study staff, and the Sponsor study team and its representatives will be blinded to the assigned treatment.||t|t|t|t
33690840|NCT05879718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||About 48 eligible participants will be randomized in a 2:1 ratio to receive either PF-06823859 or placebo. Following assessments for the primary endpoint at Week 12, participants who are receiving active PF-06823859 or who are placebo non responders (responder is defined by ≥4 point reduction from the baseline in CLASI-A score) will receive PF-06823859 beginning at Week 16, while placebo responders will continue to be in the placebo group. The last dose of study intervention will be administered at Week 40 followed by last full study assessments at Week 48. The final follow up visit will be conducted at Week 60.|t|f|t|t
33690841|NCT06388434|NA|SEQUENTIAL||OTHER||NONE||The study will include two groups (older adults and people with peripheral neuropathy) which will be assessed pre- and post-intervention||||
33690842|NCT06723522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33690843|NCT02809521|NA|SINGLE_GROUP||OTHER||NONE||||||
33690844|NCT00255801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690845|NCT03606395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Randomized, placebo-controlled, single dose|t|t|t|t
33690846|NCT06515509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690847|NCT06745024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690848|NCT05161117|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33690849|NCT01158703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690850|NCT00977808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690851|NCT05838378|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690852|NCT05709249|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33690853|NCT01295931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690854|NCT03552965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690855|NCT06530615|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690856|NCT03913325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33690857|NCT04964271|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33690858|NCT05745038|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|None (Open Label)|||||
33690859|NCT05149495|||CASE_ONLY||RETROSPECTIVE|||||||
33690860|NCT04054570|||OTHER||CROSS_SECTIONAL|||||||
33690861|NCT06183216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690862|NCT06361238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690863|NCT00478374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690864|NCT01100736|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33690865|NCT06294548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690866|NCT03458663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients will be seen and the primary outcome assesed by a nurse in the out patient department who is blinded to the postoperative care the patient has recieved.|Single blinded, randomized controlled trial .|f|f|f|t
33690867|NCT01993251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690868|NCT00655460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690869|NCT01765660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690870|NCT02180074|||CASE_CONTROL||PROSPECTIVE|||||||
33690871|NCT05086952|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33690872|NCT06274567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|We will use an active/placebo TMS coil. TMS operator and participant will be blinded to active versus sham. Investigator will be blinded to participant condition assignment.|Randomized allocation|t|t|t|f
33690873|NCT06732830|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental before-after clinical trial in patients diagnosed with mild/moderate dry eye (mild moderate dry eye is defined as those that produce symptoms in the patient and may or may not have signs detectable to the slit lamp but that may disappear with appropriate treatment) and who attend the Ophthalmology consultation of the outpatient clinic building of the Araba University Hospital and who meet the following inclusion criteria and none of exclusion.||||
33690874|NCT02392871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690875|NCT03968653|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690876|NCT02800759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690877|NCT06708468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluators will be blinded to the treatment group of the participants. It is not possible to blind the participants themselves; however, they will be asked not to share their group allocation with the others, including the evaluators. A staff member may unblind the intervention assignment for any participant with a serious adverse event.|This is a multi-site randomized control trial with two study arms - interventional and control group that will be investigated pre-and-post four-month intervention, and at 10-month and 16-month for follow-up. The participants will involve three different rare-NMDs (CMT, FSHD, DM1) from the four health regions of Norway - South-Eastern, Northern, Central, and Western. The participants will be randomly allocated to either the intervention or control group. The interventional group will undergo a personalized four month exercise training program at a rehabilitation centre followed by at-home digital exercises; whereas, the control group will receive usual care. The two groups will be stratified by study site, diagnosis and sex.|f|f|f|t
33913033|NCT03641209|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Placebo, 0.45 % saline, is similar to paracetamol, both being clear liquids, so the staff will remain unaware which drug the patient receives. The study drug will be kept and prepared away from the NICU, at the separate ward 55 office, in a locked cabinet. The study drug will be prepared by the research nurse, the pharmacist of the ward, or during nighttime, by a nurse who does not participate in the study patients' treatment in any way.|Randomized, controlled, one center trial|t|t|t|f
33993959|NCT04626154|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||We aim to enroll pediatric patients admitted to the MGH Pediatric Intensive Care Unit (PICU): 10 patients with respiratory distress and 10 patients without respiratory distress. Readings from the TAA-monitoring device will be compared to clinical assessments made by nurses and physicians.||||
33993960|NCT05474079|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33993961|NCT00003766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993962|NCT06169150|||COHORT||PROSPECTIVE|||||||
33993963|NCT05412576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33993964|NCT04825847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the anesthesiologist in charge in the operating room will be aware of treatment group|Prospective monocentric randomized controlled trial|t|f|f|t
33993965|NCT01830335|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33690878|NCT05295797|RANDOMIZED|PARALLEL||PREVENTION||NONE||Thirty WLWH will be enrolled and randomized to the (1) group-based 12-week dance program (N=15) or (2) waitlist control (N=15) (participants in the waitlist control will be assigned to a waiting list and will be invited to participate in dance classes after the intervention arm 12-week dance program has ended).||||
33690879|NCT05559333|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||randomized-split mouth clinical trial|f|f|f|t
33690880|NCT00880685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690881|NCT06218459|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind|Sequential randomised assignment to intervention or control arms.|t|f|f|t
33690882|NCT06179433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690883|NCT05822635|||COHORT||PROSPECTIVE|||||||
33690884|NCT04647253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, Randomized (2:1), Multicenter Trial|t|f|f|f
33690885|NCT05774977|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Subjects, study personnel and those assessing outcomes will be unaware of order of the exposure conditions. Investigators will only learn about the condition after the start of the sleep period of participants.|We will investigate participants in 6 groups of 4 subjects each. Each participant of a group will be exposed to the same condition in each study night. In this randomization paradigm, each condition appears in each position exactly once, and is preceded by each other condition exactly once.|t|f|t|t
33690886|NCT04185246|NA|SEQUENTIAL||DIAGNOSTIC||NONE|The reviewer of echocardiograms in this trial is blinded to the treatment assignments and subject identifiers.|||||
33913034|NCT03378154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913035|NCT01860534|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33913036|NCT02471664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913037|NCT05816018|||COHORT||OTHER|||||||
33913038|NCT03251287|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|This will be a double blind study. The placebo and active treatments will appear identical and will be dispensed in identical containers. All trial patients, care providers, outcome assessors and data analysts will remain blind throughout the study.|This is a placebo-controlled, random-order mechanistic study of oral inorganic sodium nitrate versus placebo in cross-over fashion in patients with non obstructive hypertrophic cardiomyopathy and exercise limitation.|t|t|t|t
33913039|NCT03815487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913040|NCT05188534|||CASE_CROSSOVER||PROSPECTIVE|||||||
33913041|NCT04220632|NA|SEQUENTIAL||TREATMENT||NONE||||||
33913042|NCT04508673|||COHORT||RETROSPECTIVE|||||||
33913043|NCT03188588|||COHORT||PROSPECTIVE|||||||
33913044|NCT01151579|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33913045|NCT02131948|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33913046|NCT01182623|||COHORT||PROSPECTIVE|||||||
33913047|NCT03446534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a phase IV double-blind, placebo-controlled, multicenter, nationwide, randomized superiority trial of amoxicillin versus placebo in children aged 1-5 years of age with a lower respiratory infection.|t|t|t|t
33913048|NCT04251208|||COHORT||PROSPECTIVE|||||||
33913049|NCT04979832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993966|NCT00886522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993967|NCT01261039|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33993968|NCT01117623|NON_RANDOMIZED|PARALLEL||||NONE||||||
33993969|NCT06085703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993970|NCT03077451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993971|NCT01197391|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33993972|NCT03035643|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, non-blinded, single-arm study evaluating the feasibility and safety of AMDS||||
33913050|NCT05175287|||OTHER||CROSS_SECTIONAL|||||||
33913051|NCT04474899|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double (Participant, Investigator)|Randomized, double blind cross over study|t|t|t|t
33993973|NCT00633672||PARALLEL||TREATMENT||DOUBLE||||||
33993974|NCT06562179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993975|NCT03589430|||CASE_ONLY||PROSPECTIVE|||||||
33993976|NCT03216967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993977|NCT00351039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993978|NCT05723393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690887|NCT05871606|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study has been designed to follow a standard 3+3 cohort expansion design, assessing 5 doses. Specifically, 3 individuals will begin at dose 1. If none of these individuals experience a dose limiting toxicity (DLT), then the dose will be escalated to dose 2. DLT is defined as a patient experiencing sICH, our primary outcome measure, or any other listed ASE. Dose escalation will continue after each set of 3 individuals until at least one person experiences DLT. If only 1 of the 3 experience a DLT, the cohort will be expanded to 6 (an additional 3). If 2 of the 6 experience DLTs, then dose escalation is stopped and the previous dose level (one level below) is declared the maximum tolerated dose. If 2 of the initial 3 experience DLT, the previous dose level (one level below) is declared the maximum tolerated dose. However, if only 1 of 6 experience DLT, the dose will escalate.||||
33690888|NCT00295971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690889|NCT04401644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The participants and the primary care provider will be masked to the outcome of the test. The test will not be used to determine clinical care and the result of the original diagnostic test will be masked from the outcomes assessor of the novel test under investigation.|within group comparison of methods of detection of virus by two test methodologies. Post hoc validation of test performance against reference set.||||
33690890|NCT03729973|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33779474|NCT06614647|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The region of residency determines the allocation to the intervention group or standard-of-care group. Patients in the intervention group will be stage I-II colorectal cancer survivors residing in Central Denmark Region and North Denmark Region. Both regions have fully implemented 'organ-specific late-effects clinics' offering a standardized patient-centered, interdisciplinary, multiorgan approach and have implemented the digital platform that supports the smartphone care guide. Patients in the standard group will be the corresponding patients residing in the remaining Danish Regions, in which similar standardized late effects clinics and the digital care-guide framework are not yet implemented.||||
33779475|NCT06356259|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33779476|NCT01932944|||COHORT||PROSPECTIVE|||||||
33779477|NCT02359149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779478|NCT02734368|||CASE_CONTROL||PROSPECTIVE|||||||
33779479|NCT03917043|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation of APG-2449 will use standard 3+3 design. The starting dose is 150 mg and will be increased in subsequent cohorts to 300mg, 450mg, 600mg, 750mg, 900mg, 1200mg and 1500mg, accordingly.||||
33779480|NCT05693805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blinded evaluator will utilize remote videoconferencing to conduct structured interviews and assess each participant at baseline (prior to randomization), and post-treatment, and (for Phase Two only) at 3-month follow-up.|Parallel Assignment for Phase One, Random Assignment for Phase Two.|f|f|f|t
33779481|NCT01668875|RANDOMIZED|CROSSOVER||||NONE||||||
33779482|NCT00002730||||TREATMENT||||||||
33993979|NCT01798264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993980|NCT01348438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993981|NCT03060486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993982|NCT03961828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33993983|NCT01490372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33993984|NCT06541327|||COHORT||OTHER|||||||
33993985|NCT06253572|NA|SINGLE_GROUP||OTHER||NONE||Design of the research: This study is a mixed method design. The first part of the study was planned in a quantitative design with a one-group pretest-posttest quasi-experimental type. The second part of the study was planned in qualitative design and phenomenological type.||||
33993986|NCT04685291|RANDOMIZED|PARALLEL||TREATMENT||NONE|The comparator group will get systemic conventional pain management. Pain management using placebo would be harmful in patients with clavicular fractures. If these patients will have a severely dislocated fracture, they will be scheduled to have internal fixation of the fracture within the next 24 hours. They will receive oral and intravenous pain management.|Prospective randomised single centre study||||
33913052|NCT05110040|NA|SINGLE_GROUP||TREATMENT||NONE|Assessors who calculate the changes of the images are masked of the diagnosis and treatment.|participants diagnosed of TAO administrated with immunosuppressive agents||||
33913053|NCT06011746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913054|NCT03427905|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913055|NCT01480141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913056|NCT02001116|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33913057|NCT06063408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913058|NCT01737840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085695|NCT03603613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Under the supervision of Innovations for Poverty Action (IPA) Sierra Leone, local research assistants (blind to site and youth condition assignments) will conduct all screening, baseline, and follow up quantitative assessments. Ongoing data collection at all sites will include youth attendance and satisfaction with YRI content, counselor satisfaction with content and delivery via scales and qualitative exit interviews, as well as monitored audio-recording of all sessions for fidelity by an independent expert rater hired by CARITAS. The expert fidelity monitor will be a skilled YRI trainer and supervisor from our prior RCT and will not be a part of the standard CTS training condition nor the ICT Seed Team, thus allowing them to provide impartial and blinded fidelity ratings of all audio-transcripts.|A cluster randomized three-arm trial will be employed in the pilot phase in the same districts as the scale-up study. Youth (N=180, 18-26 years old, 50% female), stratified by gender, will be randomized into the three study arms. Once youth are enrolled into the study, they will be assigned to community level sites based on geographical location. Each of these community level sites will make up one cluster. The clusters will then be randomly assigned into the three study arms so that sixty youth will be randomized into the youth employment promotion program (EPP) arm, sixty youth will be randomized into the YRI+EPP arm, and sixty youth will be randomized into the control arm . The pilot study will last approximately 12 weeks and data will be collected at baseline and post-intervention. Further, we will survey 120 third-party reporters for a total pilot study sample size of 300 participants.|f|f|f|t
34085696|NCT04053582|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||ELA-exposed youth are randomly assigned to receive augmented mindfulness training with real-time neurofeedback or a sham condition.||||
34085697|NCT02265835|||CASE_CONTROL||RETROSPECTIVE|||||||
34085698|NCT05453721|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study has two parallel arms, Indocyanine green fluorescence imaging method (treatment arm) and Modified inflation-deflation method (control arm) are included in this study.||||
34085699|NCT06069388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085700|NCT03629288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A double-blind, randomized controlled trial, where patients with a Severe Periodontitis with potencial for additional tooth loss and moderate rate of progression (Stage III grade B). The intervention group received non-surgical periodontal therapy (NSPT) plus azithromycin, and the control group received NSPT plus placebo. The clinical variables were measured before the treatment, and in the first, third and sixth month of the end of the NSPT, while the microbiological variables were measured before the treatment and in the third and sixth month after treatment.|t|t|f|t
34085701|NCT03783065|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085702|NCT05250232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085703|NCT00434434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085704|NCT05150574|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34085705|NCT05265572|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are divided into two groups and one group is assigned to one household hygiene and an educational intervention which they apply and the impact of the intervention on lead exposure is assessed and the other group has no intervention.||||
34085706|NCT00815152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913059|NCT04991844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913060|NCT03940924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collected on the volunteers will be made anonymous.||t|f|f|f
33913061|NCT04855565|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Site staff treating subjects, subjects themselves and the Investigator will be blinded to the treatments being administered.|Single dose escalation study|t|t|t|t
33913062|NCT03972644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913063|NCT01987349|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33913064|NCT00527215|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913065|NCT01693458|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33913066|NCT00462020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913067|NCT01892098|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33913068|NCT04611295|NA|SINGLE_GROUP||OTHER||NONE||||||
33913069|NCT05537948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"phase 1: randomized, prospective, single-center, parallel-group study~phase 2: observational study"|f|f|t|t
33913070|NCT03790462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|It is a triple blinded study||t|f|t|t
33913071|NCT01412658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33913072|NCT03305094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blinded to group assignment|Randomized controlled prospective trial|t|f|f|f
33913073|NCT02843373|||COHORT||PROSPECTIVE|||||||
33913074|NCT03791437|RANDOMIZED|PARALLEL||TREATMENT||NONE||digital chest drainage system||||
33913075|NCT02499003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085707|NCT04597437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pilot, randomized, double-blind, placebo-controlled trial of the safety and efficacy of inhaled zanamivir (n=37) versus placebo (n=37) therapy for dengue|t|t|t|t
33913076|NCT00583323|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34085708|NCT01979432|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34085709|NCT06354608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is an experimental, parallel-group (intervention-control), randomized controlled design||||
33913077|NCT00155207|||DEFINED_POPULATION||OTHER|||||||
33913078|NCT01586156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913079|NCT00764959|||COHORT||RETROSPECTIVE|||||||
33993987|NCT05191680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The trial will occur in two stages. Following an initial 3-arm Pilot stage, a go-no go decision will be made. If successful, the trial will progress and adapt to become a 2-arm trial in the subsequent stage.|t|t|t|t
33993988|NCT05406050|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33993989|NCT02121067|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33993990|NCT00903877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993991|NCT06001463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33993992|NCT06474936|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33993993|NCT05975905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study in which treatment assignment will be blinded for the Investigators and any personnel (other than the unblinded pharmacist or designee) involved with the study conduct or evaluation at the investigational sites, the CRO, and the Sponsor.|Participants will be randomly assigned in a 2:2:2:3 ratio to 1 of 4 treatment arms.|t|t|t|t
33993994|NCT04222023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33993995|NCT00486239|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33993996|NCT01318369|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33993997|NCT04057287|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34085710|NCT01824017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085711|NCT04383522|||CASE_CROSSOVER||PROSPECTIVE|||||||
34085712|NCT02690727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085713|NCT05342571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085714|NCT05841511|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34085715|NCT00169299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34085716|NCT05987800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085717|NCT04337632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085718|NCT05569096|||CASE_CONTROL||RETROSPECTIVE|||||||
34085719|NCT05899361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085720|NCT02517281|NA|SINGLE_GROUP||OTHER||NONE||||||
34085721|NCT04529564|||COHORT||RETROSPECTIVE|||||||
34085722|NCT05462574|||COHORT||PROSPECTIVE|||||||
34085723|NCT02576899|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085724|NCT03693196|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34085725|NCT01951716|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34085726|NCT02790983|||CASE_ONLY||PROSPECTIVE|||||||
34085727|NCT04900311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690891|NCT04841226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33690892|NCT06330688|||COHORT||PROSPECTIVE|||||||
33690893|NCT04972630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33690894|NCT05220410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690895|NCT05124301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33690896|NCT06687889|||OTHER||CROSS_SECTIONAL|||||||
33690897|NCT05537025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690898|NCT03469388|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective,multidisciplinary single center study||||
33993998|NCT01357668|||COHORT||PROSPECTIVE|||||||
33993999|NCT02173886|RANDOMIZED|CROSSOVER||||NONE||||||
33994000|NCT01782053|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33994001|NCT00925964|||||PROSPECTIVE|||||||
33994002|NCT00553241|||COHORT||PROSPECTIVE|||||||
33994003|NCT01544049|||COHORT||RETROSPECTIVE|||||||
33994004|NCT01852721|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994005|NCT01671696|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33994006|NCT01843179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994007|NCT05735145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994008|NCT01009229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994009|NCT05979662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994010|NCT05450653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994011|NCT05562778|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2-arm randomized controlled trial of a chatbot for personal/family history intake vs. usual care (intake via the clinician interview). Enrolled patients will be randomized in a 1:1 ratio.||||
34085728|NCT06369480|||COHORT||RETROSPECTIVE|||||||
34085729|NCT03699592|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||time series prospective cohort and comparison group design||||
34085730|NCT03587636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085731|NCT02394756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085732|NCT03906864|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single Blind||f|f|f|t
34085733|NCT04219189|RANDOMIZED|CROSSOVER||OTHER||NONE||This study consists of a baseline assessment which is followed by two within-subject, laboratory conditions that differ by the product used: 1) JUUL e-cigarette with a 5% nicotine pod, 2) no active e-cigarette use (uncharged JUUL with empty pod). The condition orders (i.e., 1 then 2, or 2 then 1) will be randomly ordered and assigned following enrollment. During the vaping condition, participants will be asked to take 20 e-cigarette puffs over 20 minutes before consuming an ad libitum buffet meal. During the alternative control condition, participants will have access to an uncharged JUUL with an empty pod for 20 minutes (instead of vaping) before consuming an ad libitum buffet meal.||||
34085734|NCT01706328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085735|NCT04524156|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085736|NCT00922584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085737|NCT02178865|||CASE_ONLY||OTHER|||||||
34085738|NCT04287348|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, one-treatment-arm, monocentre study||||
34085739|NCT01100788|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34085740|NCT01104168|||COHORT||RETROSPECTIVE|||||||
33994012|NCT04325321|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994013|NCT04272216|||COHORT||PROSPECTIVE|||||||
33994014|NCT02067650|||OTHER||CROSS_SECTIONAL|||||||
33994015|NCT03045757|||COHORT||PROSPECTIVE|||||||
33994016|NCT04137835|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994017|NCT01748773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994018|NCT03123315|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-Center Prospective Cohort||||
33994019|NCT01862601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994020|NCT06560073|||COHORT||PROSPECTIVE|||||||
33994021|NCT03506672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33994022|NCT05068284|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33994023|NCT05259657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33994024|NCT02795572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085741|NCT05627596|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34085742|NCT04096690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085743|NCT04642222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization is performed by a researcher not involved in data management. The researcher who evaluates the outcomes of interest is masked.|This is a randomized control trial with two groups: the Treatment As Usual control group (TAU group) and the APOLO-Teens web-based intervention group (APOLO-Teens group). Adolescents attending a medical appointment scheduled for any multidisciplinary obesity appointment at a public Portuguese health facility will be invited to participate. The criteria for inclusion/exclusion will be given to the healthcare professionals conducting these medical appointments, to screen for potential participants. After completing the baseline assessment participants will be consecutively randomized to the Treatment As Usual control group (TAU group) or the APOLO-Teens web-based intervention group (APOLO-Teens group). Participants in the APOLO-Teens group received the APOLO-Teens web-based intervention in addition to their treatment as usual (TAU).|f|f|f|t
34085744|NCT01955811|NA|SINGLE_GROUP||||NONE||||||
34085745|NCT02750995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085746|NCT06055374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085747|NCT03473990|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34085748|NCT03485586|||CASE_CONTROL||PROSPECTIVE|||||||
34085749|NCT05233813|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085750|NCT02815371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34085751|NCT06101498|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34085752|NCT01455519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085753|NCT03312738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085754|NCT02258672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33690899|NCT04808284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690900|NCT04765059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, the Investigator, and the study site staff will be blinded to osimertinib or placebo allocation. Patients may participate in the open label part of trial at the discretion of the investigator to receive osimertinib and continue any ongoing chemotherapy if intracranial progression is their first progression event.||t|t|t|t
33690901|NCT05715671|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33690902|NCT03455959|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A single time point study with all information obtained at the time of bronchoscopy||||
33690903|NCT03955380|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, multiple ascending dose, multi-cohort|t|f|t|f
33690904|NCT01999101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994025|NCT03275363|||COHORT||PROSPECTIVE|||||||
33994026|NCT03333551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||each participant will be subject to the intervention which is PET/CT imaging (Positron emission tomography-computed tomography) with florbetapir F-18||||
33994027|NCT06395792|||CASE_ONLY||RETROSPECTIVE|||||||
33994028|NCT06627660|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||INTERVENTIONAL|t|f|f|t
33994029|NCT06265753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"In the study, 2 different groups (experimental and control) will be formed by using randomisation method. In addition to 45 minutes of classical physiotherapy exercises, 10 minutes of gastrocinemius function massage will be applied to the experimental group, while 10 minutes of sham massage and 45 minutes of classical physiotherapy exercises will be applied to the control group. The application will continue 2 days a week for 6 weeks. Spasticity, gait parameters and fall risks of the participants will be evaluated before and after the treatment with the help of various tests.~Translated with www.DeepL.com/Translator (free version)"|t|f|f|f
33994030|NCT05198622|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33994031|NCT06504004|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33994032|NCT05012358|||COHORT||PROSPECTIVE|||||||
33994033|NCT02825680|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33994034|NCT06628011|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are aware of which group they are assigned to.|Participants will be randomized at a 1:1 allocation ratio into an Intervention Group or Control Group.||||
33994035|NCT05885412|NA|SEQUENTIAL||TREATMENT||NONE||||||
33994036|NCT01842477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994037|NCT03798457|||COHORT||PROSPECTIVE|||||||
33994038|NCT00500201|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34085755|NCT02068014|||COHORT||PROSPECTIVE|||||||
34085756|NCT02471339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085757|NCT03816358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085758|NCT04707937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34085759|NCT06380283|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33690905|NCT01927302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994039|NCT06183125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the experiment, participants will not be blinded. However, the intervention provider and the evaluator will be blinded.|A randomized controlled trial will be conducted among 92 office workers with self-reported sitting time of 5.5 hours or longer per workday. They will be randomly assigned to intervention (TCM-based program) and wait-list control groups.|f|f|t|t
33994040|NCT04965935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each bottle of drug will be identified with a unique Composite ID in order to maintain the blind. By way of an Unblinding List, Pharmacy will provide treatment allocations of each Composite ID. The Unblinding List will be maintained within a secure location in the Pharmacy. Blinded personnel will not have access to this list.|Study participants will be allocated to receive either 10 mg daily of dapagliflozin or a matching placebo for 12 weeks in a 1:1 ratio while continuing on existing medical therapy for glycemic control as recommended by Diabetes Canada.|t|f|t|t
33994041|NCT06353139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994042|NCT01299207|||COHORT||PROSPECTIVE|||||||
33994043|NCT01970566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994044|NCT02417363|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33994045|NCT03061591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Placebo and curcumin capsules are identical in appearance, and will be marked as A or B. Study participants and staff will be blinded to the capsule content. A locked file containing the description will remain in a locked file on the study coordinators computer."|6 months of Curcumin vs. placebo treatment outcomes will be compared.|t|t|t|t
33994046|NCT04806035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085760|NCT04765787|||COHORT||PROSPECTIVE|||||||
34085761|NCT01967199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085762|NCT05300282|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The phase I part is aimed at determining the MTD of atezolizumab when combined with BEGEV schedule. Atezolizumab dosing starts at 1200 mg and decreases in the successive cohort to the dose of 840 mg and 600 mg to reach MTD which will be used in the phase II part where patients will be randomized in 2 arms: arm A will receive the BEGEV regimen followed by ASCT for patients achieving CR and arm B will receive combination treatment with Atezolizumab and BEGEV regimen followed for patients reaching CR by ASCT plus a consolidation with 6 doses of atezolizumab at 1200 mg every 4 weeks.||||
34085763|NCT00183430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085764|NCT02181595|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690906|NCT04890067|||COHORT||PROSPECTIVE|||||||
34085765|NCT02783911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085766|NCT01124253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085767|NCT05455775|||CASE_ONLY||PROSPECTIVE|||||||
34085768|NCT03272152|||CASE_CONTROL||PROSPECTIVE|||||||
34085769|NCT00247234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085770|NCT00670059|RANDOMIZED|PARALLEL||||NONE||||||
34085771|NCT02011178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085772|NCT04337788|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective cohort study (here and elsewhere)||||
33690907|NCT06395753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779483|NCT01363947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779484|NCT02062905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779485|NCT05937672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label extension study. During a clinical care visit, if a patient is eligible and agrees to participate, lesions will be selected by the dermatologist prior to procedure. All lesions selected will be treated with non-thermal atmospheric plasma (NTAP).||||
33779486|NCT02451293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779487|NCT02062411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779488|NCT03906474|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33779489|NCT03341806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838876|NCT03790696|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Subjects will be randomized to active vs. sham treatment on a 50/50 basis. The participants and the staff performing the pre- and post- treatment psychiatric interviews will remain blinded throughout the study. Study staff administering the treatment will be aware of the active vs. sham status of the participant, in order to deliver and monitor the appropriate cognitive training program.|This study is a randomized control trial.|t|t|t|t
34085773|NCT01080261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085774|NCT02188550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085775|NCT05741697|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085776|NCT03831022|||COHORT||PROSPECTIVE|||||||
34085777|NCT00844311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085778|NCT03406663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085779|NCT03889392|||COHORT||RETROSPECTIVE|||||||
34085780|NCT00006362||||TREATMENT||||||||
33690908|NCT02262052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690909|NCT03753490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690910|NCT03127956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690911|NCT04534218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690912|NCT02193425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690913|NCT04319783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690914|NCT05080309|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcome assessor (i.e. obstetrician) will be unaware of group allocation|controlled and monitored oral fruit juice intake in order to achieve an oral calory intake \> 44kCal/hour during labor|f|f|f|t
33690915|NCT01759134|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690916|NCT05045547|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33690917|NCT06480864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690918|NCT01805271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690919|NCT05291689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690920|NCT06743477|NA|SEQUENTIAL||TREATMENT||NONE||||||
33690921|NCT05909176|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33690922|NCT05093933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33690923|NCT01314612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690924|NCT00005863|RANDOMIZED|||TREATMENT||||||||
33994047|NCT05125900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant and Investigator)|Each patient received one or two restorations in a posterior tooth on any side randomly selected from the 4 tested restorative materials, all materials were used according to manufacturers' instructions|t|f|t|f
33994048|NCT05911633|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33994049|NCT00018213|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33994050|NCT05701384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994051|NCT01322633|||COHORT||PROSPECTIVE|||||||
33994052|NCT05581407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Comparison of licensed influenza vaccine with study vaccines combining 1/5 of the dose of the standard vaccine added with two different doses of LiteVax Adjuvant.|t|t|t|t
33994053|NCT01804608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994054|NCT02987153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994055|NCT03044210|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33994056|NCT03121716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994057|NCT06556017|||CASE_CONTROL||RETROSPECTIVE|||||||
33994058|NCT05676749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994059|NCT01440803|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33994060|NCT01099189|||COHORT||PROSPECTIVE|||||||
33994061|NCT01121601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994062|NCT06258746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994063|NCT03579394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994064|NCT02175095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a imaging biomarker study to evaluate feasibility of \[18F\]FLT-PET as a potential candidate for predictive imaging biomarker of regorafenib treatment in mCRC patients who progressed after prior standard therapies.~The mCRC patients who failed to all 3 active cytotoxic chemotherapy (fluoropyrimidines, oxaliplatin and irinotecan) with or without targeted agents will be accrued. Patients will be scheduled to perform \[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.~Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle.~Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional \[ 18F\]FDG-PET will be performed before treatment and at 21 days after treatment."||||
33994065|NCT01846260|||COHORT||PROSPECTIVE|||||||
33994066|NCT03577938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994067|NCT06187142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33994068|NCT00348543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994069|NCT05858333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33994070|NCT02818530|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994071|NCT00603499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994072|NCT03942770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085781|NCT01131273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085782|NCT03794596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laboratory staff and the blinded statistician will remain blinded to trial treatment arm|"Patients will be randomly assigned to one of two arms:-~* 21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)~* 21 patients into Arm B: Avelumab + Aspirin + PPI"|f|f|f|t
34085783|NCT04913922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085784|NCT01470170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34085785|NCT04761913|||CASE_ONLY||RETROSPECTIVE|||||||
33994073|NCT05107635|||COHORT||OTHER|||||||
33779490|NCT03972293|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants are randomized to two arms: 'receive notifications' or 'do not receive notifications'. The 'do not receive notifications' group will not receive any notifications for the entire study. The 'receive notifications' group will receive notifications according to a micro-randomized trial design.~For the 'receive notifications' group, each participant-week is randomized between 4 different interventions (mood notifications, activity notifications, sleep notifications or no notifications). If the participant-week is randomized to a mood notification, activity notification, or sleep notification week, the participant will receive notifications of that category during that week.~For mood notification, activity notification, and sleep notification weeks, each participant-day is also randomized between: send notification that day or do not send notification that day."||||
33779491|NCT04448327|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33779492|NCT06691971|||COHORT||PROSPECTIVE|||||||
33779493|NCT01089556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779494|NCT03268135|||CASE_CONTROL||RETROSPECTIVE|||||||
33779495|NCT03987581|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33779496|NCT03674606|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three-armed parallel, multi-center, open-label randomised control trial||||
33779497|NCT01425762|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33779498|NCT03603457|||COHORT||PROSPECTIVE|||||||
33779499|NCT05925881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779500|NCT05391204|RANDOMIZED|PARALLEL||PREVENTION||NONE||"There is therefore a lack of specific clinical tests allowing the functional evaluation of the hip. This is why it is necessary to study the possibility of deploying tests evaluating the functional capacities of the lower limb to characterize the functions of the hip.~The study will compare patients group versus healthy volunteers and reproducibility."||||
33779501|NCT04370236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo + Standard of Care vs. INB03 + Standard of Care|t|t|t|t
33779502|NCT00311792|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|f|t
33779503|NCT00209729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779504|NCT03012217|||CASE_ONLY||PROSPECTIVE|||||||
33779505|NCT02748512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779506|NCT05314283|NA|SINGLE_GROUP||OTHER||NONE||Including a pilot cohort and a main cohort||||
33913080|NCT02891798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779507|NCT00257777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779508|NCT05314010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779509|NCT02165982|||CASE_CONTROL||PROSPECTIVE|||||||
33779510|NCT00498277|||CASE_ONLY||PROSPECTIVE|||||||
33779511|NCT00740285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779512|NCT00725582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913081|NCT01003080|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33913082|NCT05341505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913083|NCT04010786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures|First human dose trial; a single-centre, placebo-controlled, double-blind (within cohorts), randomised SD and MD ascending dose trial with a sequential trial design|t|t|t|t
33913084|NCT02308345|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33913085|NCT01887899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913086|NCT05180110|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||IVD Performance Evaluation Study||||
33913087|NCT03813719|||COHORT||PROSPECTIVE|||||||
33913088|NCT05155475|||COHORT||PROSPECTIVE|||||||
33913089|NCT01130389|||CASE_CONTROL||RETROSPECTIVE|||||||
33913090|NCT06555614|||CASE_CONTROL||PROSPECTIVE|||||||
33779513|NCT06696391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913091|NCT02104804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913092|NCT01620632|||CASE_ONLY||PROSPECTIVE|||||||
33994074|NCT00896688|||OTHER||PROSPECTIVE|||||||
33994075|NCT00957021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994076|NCT05135104|||OTHER||RETROSPECTIVE|||||||
33994077|NCT05372744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994078|NCT03835780|||COHORT||RETROSPECTIVE|||||||
33913093|NCT03342482|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Subjects will be randomized to immediately start a one-month dietary intervention restricting consumption of glutamate, or will be waitlisted as a control group for the first month, and then will begin the one-month dietary intervention period (which will be completed at home). Then subjects will return to DC, will complete all measures again, and then will participate in a double-blind, placebo-controlled, crossover challenge with MSG and placebo.|t|f|t|t
33994079|NCT00000653||||TREATMENT||||||||
33994080|NCT04471922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994081|NCT00227370|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33994082|NCT05853445|||COHORT||PROSPECTIVE|||||||
33913094|NCT04093518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple|Randomized, add-on to anti-psychotics, double blind, placebo-controlled, parallel group clinical trial|t|t|t|f
33913095|NCT01882998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913096|NCT01907594|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33913097|NCT00078962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913098|NCT03907982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patient and physician - blinded randomisation to intervention (DCCV, or Pulmonary Vein Isolation plus DCCV)~Once subject participation in the trial is complete, the patient and physician will be unblinded."|Internal Pilot as part of a future study, Randomised, blinded, controlled trial with 2 arms.|t|f|t|f
33913099|NCT03806179|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33913100|NCT01670214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913101|NCT05844345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After the preterm neonates abiding by the inclusion criteria in the research are randomly allocated to the study groups, parents will provide written consent with an informed volunteer consent form without giving parents information about which group their infant will be included in. The researcher will apply the hydrocolloid barrier and facial massage themselves, so the researcher will not be blinded. However, to prevent bias, research outcome measures will be recorded by two nurses who are employed in the NICU, are university graduates and who do not know which infant is in the experiment or control groups. With the aim of preventing bias during analysis of data, the database for the study groups will be coded A, B and C by someone other than the researcher, and analysis of data will be performed by an independent statistical expert. Blinding of outcome measures, statistical analysis and reporting will be performed with the aim of preventing statistical and reporting bias.|randomized controlled experimental|t|f|f|t
33913102|NCT04554849|||COHORT||RETROSPECTIVE|||||||
33994083|NCT01116739|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33994084|NCT05866263|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||COVID-19 on an outpatient basis were completed with 40 individuals, 20 of which were in the green walking and intelligence game group and 20 were in the control group||||
33994085|NCT06356558|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This pilot study will be a pre-post trial of the intervention (VISACT - VISuAl aids, Coach providers in communication, and Train organizations in health literacy) at 2 sites. This design was selected because the intervention is an implementation strategy and it will not be possible to randomize patients to a non-intervention arm once the VISACT is delivered to a facility. All patients, providers, and organizational units will be subject to downstream effects of VISACT once implemented.||||
33994086|NCT06563505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994087|NCT01522820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994088|NCT02507128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33994089|NCT05539157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994090|NCT06627153|||OTHER||RETROSPECTIVE|||||||
33994091|NCT04906148|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33994092|NCT04112823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994093|NCT01371435|||OTHER||PROSPECTIVE|||||||
33994094|NCT00307996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994095|NCT01545193|||COHORT||PROSPECTIVE|||||||
33994096|NCT01524185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994097|NCT04423549|||COHORT||RETROSPECTIVE|||||||
33690925|NCT02660398|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085786|NCT04642989|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are not informed of the treatment group they are randomized into||t|f|f|f
34085787|NCT01175057|||CASE_CONTROL||RETROSPECTIVE|||||||
34085788|NCT04716985|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|They will be labeled study (randomization number to respect blind and legal notices labeling clinical research).|Double-blind, randomized, multicentre comparative study.|t|f|t|t
34085789|NCT06279715|||COHORT||RETROSPECTIVE|||||||
34085790|NCT00772837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085791|NCT04452864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomly assigned to one of three study arms and conduct a Computerized Cognitive Training (CCT) at home (daily) and on site (weekly) for 10 weeks. Before and after the CCT, neuropsychological assessments will be conducted.|t|f|t|t
34085792|NCT01654276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085793|NCT05029531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085794|NCT06305481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34085795|NCT00411320|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085796|NCT00000972|RANDOMIZED|||PREVENTION||||||||
34085797|NCT04092478|||CASE_CONTROL||PROSPECTIVE|||||||
34085798|NCT02764736|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study|||||
34085799|NCT00912366|||COHORT||PROSPECTIVE|||||||
33913103|NCT04756362|||COHORT||OTHER|||||||
34085800|NCT01502891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34085801|NCT01885065|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085802|NCT05793411|||COHORT||CROSS_SECTIONAL|||||||
34085803|NCT05877989|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will receive the amino acid intervention that is provided in addition to 'usual care' enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day. The physical exercise intervention will be delivered by trained nursing staff,and started as close to the time of randomisation as feasible (ie, within 24hours of randomization). The intervention group will receive exercise sessions, for up to 20 min duration.||||
34085804|NCT01788514|NA|SINGLE_GROUP||OTHER||NONE||||||
34085805|NCT01814540|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34085806|NCT04493762|||COHORT||CROSS_SECTIONAL|||||||
34085807|NCT01399996|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34085808|NCT03246178|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|Patients with SAA||||
34085809|NCT00997893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085810|NCT02313402|NA|SINGLE_GROUP||||NONE||||||
34085811|NCT02265510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085812|NCT00129636|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34085813|NCT04671199|||COHORT||PROSPECTIVE|||||||
34085814|NCT01841372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085815|NCT02980315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085816|NCT04716543|||COHORT||PROSPECTIVE|||||||
34085817|NCT02937376|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34085818|NCT00004261||||DIAGNOSTIC||||||||
34085819|NCT05441007|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participant undergoes all three phases of the experiment and the participant does not know which one is it.|Interventional single blinded randomized crossover prospective study. All participants go through all study arms, in random order.|t|f|f|f
34085820|NCT02457091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34085821|NCT01118078|||CASE_ONLY||PROSPECTIVE|||||||
34085822|NCT03150043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Since every patient will have the device placed during delivery, there will be no masking. However, the actual values obtained from the monitor will be masked.|All patients who agree to participate in the study will have the non-invasive hemoglobin monitor placed on their finger during delivery. The values obtained from the non invasive monitor will be masked to the clinicians during delivery. No medical decision making will be based on values obtained from the non-invasive monitor. After the patient leaves the recovery room, values obtained from the monitor will be compared to those obtained via blood draw. Patients will be separated into quartiles based on drop in hemoglobin (between pre-op and post-op day 1) and hemoglobin values obtained from the monitor will be compared between the quartiles.||||
34085823|NCT03174639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085824|NCT02500498|||COHORT||RETROSPECTIVE|||||||
33690926|NCT00689091|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913104|NCT06447116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913105|NCT01548898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085825|NCT00116181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085826|NCT03427411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085827|NCT04495621|NA|SEQUENTIAL||TREATMENT||NONE||Step 1: Confirmation of Dose for Cohort Expansion / Step 2: Cohort Expansion||||
34085828|NCT05340699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085829|NCT03834350|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34085830|NCT05257070|||CASE_ONLY||PROSPECTIVE|||||||
34085831|NCT01858961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085832|NCT06094036|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34085833|NCT00964782|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34085834|NCT05475639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque sealed envelope|this trial has three group; two experimental and one control|t|f|f|f
34085835|NCT05222867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085836|NCT05655871|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|When creating groups in the study, the participants learned which group they belonged to, and blinding was done when the data was sent to the statistician for analysis.|There are two groups in the study, these are control and intervention groups.|t|f|f|t
34085837|NCT01211171|||COHORT||PROSPECTIVE|||||||
34085838|NCT01726166|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34085839|NCT02742207|||COHORT||PROSPECTIVE|||||||
34085840|NCT00276302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085841|NCT00581191|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33690927|NCT01926665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690928|NCT02480985|NA|SINGLE_GROUP||OTHER||NONE||||||
33690929|NCT03381274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690930|NCT06575452|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33690931|NCT06664853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690932|NCT06659679|||COHORT||RETROSPECTIVE|||||||
33690933|NCT06667687|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690934|NCT06367972|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690935|NCT01863550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690936|NCT04942353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690937|NCT04597918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690938|NCT05120271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690939|NCT03295461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690940|NCT02902796|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34085842|NCT05598736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085843|NCT00355927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085844|NCT02977351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085845|NCT01131936|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085846|NCT04330872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085847|NCT02422758|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34085848|NCT03754920|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33690941|NCT05585164|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33690942|NCT01601964|||CASE_ONLY||PROSPECTIVE|||||||
33690943|NCT06243627|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33690944|NCT06305468|||OTHER||RETROSPECTIVE|||||||
33690945|NCT06659744|||COHORT||RETROSPECTIVE|||||||
33690946|NCT06181279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33690947|NCT00775944|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33690948|NCT04446442|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33690949|NCT05618431|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Demonstrating non-inferiority means ensuring that the product tested does not have an efficacy that would be too inferior to the reference product.||||
33690950|NCT01812590|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33690951|NCT02474680|||COHORT||OTHER|||||||
33690952|NCT01459848|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33690953|NCT01272661|NON_RANDOMIZED|PARALLEL||||NONE||||||
33690954|NCT04767282|NA|SINGLE_GROUP||PREVENTION||NONE||A fruit and vegetable prescription is written by pediatricians to exchange for $15 of fresh produce. Prescriptions are redeemable at a local farmers' market and mobile market.||||
33690955|NCT00929812|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33690956|NCT06743997|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33690957|NCT06469398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690958|NCT00069966||||TREATMENT||NONE||||||
33690959|NCT03622528|||COHORT||CROSS_SECTIONAL|||||||
33690960|NCT06731608|RANDOMIZED|PARALLEL||PREVENTION||NONE|The OsteoPorotic fracTure preventION System (OPTIONS) intervention is a facility-level initiative for Skilled Nursing Facilities (SNFs) and16 SNF sites will receive the OPTIONS intervention, while 16 SNF sites will serve as a comparator group, receiving enhanced usual care with the Stopping Elderly Accidents, Deaths, and Injuries (STEADI) Toolkit.|A matched-pair cluster randomized controlled trial (RCT) design||||
33690961|NCT06468215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690962|NCT05493618|NA|SEQUENTIAL||TREATMENT||NONE||"Safety lead-in Cohort: After the first 10 patients are enrolled, an independent safety review committee will meet to review adverse events and toxicity and determine whether the trial will continue to enroll.~Phase 2 portion: The remainder of patients will be enrolled using a Simon's - 2 stage design."||||
33690963|NCT00048711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33690964|NCT05014490|RANDOMIZED|CROSSOVER||OTHER||NONE||Two-period, two-sequence, two-way crossover single dose study||||
33690965|NCT02090868|||COHORT||PROSPECTIVE|||||||
33690966|NCT03008408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690967|NCT05558917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838877|NCT02078362|||||PROSPECTIVE|||||||
34085849|NCT04720391|||COHORT||OTHER|||||||
34085850|NCT05347628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085851|NCT02598674|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085852|NCT04641806|||CASE_CONTROL||PROSPECTIVE|||||||
34085853|NCT05644496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085854|NCT00761098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085855|NCT03798314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085856|NCT00299520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34085857|NCT04061785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34085858|NCT06079294|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085859|NCT03353077|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34085860|NCT01568463|||OTHER||PROSPECTIVE|||||||
34085861|NCT04211376|||CASE_ONLY||PROSPECTIVE|||||||
34085862|NCT03502824|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34085863|NCT00374868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085864|NCT05234021|||CASE_CONTROL||PROSPECTIVE|||||||
33690968|NCT03640767|RANDOMIZED|PARALLEL||PREVENTION||NONE||This pilot randomised controlled trial aimed at examining the effectiveness of message-based lifestyle intervention. Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160.||||
33690969|NCT03175276|||COHORT||PROSPECTIVE|||||||
33690970|NCT06004908|||CASE_CROSSOVER||PROSPECTIVE|||||||
33690971|NCT05998785|||CASE_ONLY||PROSPECTIVE|||||||
33690972|NCT04734106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33690973|NCT06218069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1: n=10 patients, who will receive a single subcutaneous injection with sasanlimab at 4-5 weeks prior to surgery.~Arm 2: n=10 patients, who will receive a single subcutaneous injection with sasanlimab at 4-5 weeks prior to surgery, and a single dose radiation therapy in the week following sasanlimab injection."||||
33690974|NCT05053230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33690975|NCT06259201|NA|SINGLE_GROUP||TREATMENT||NONE||"Each participant will begin the study with the first baseline phase (1 month).~Each participant will receive 1 month of VNS administered twice per day (AM \& PM).~During the study, the participant (or legal guardian) and the study team can decide whether to:~1. Complete 1 month of VNS and go to Baseline 2 (ABA design); or~2. Continue with 2 months of VNS and go to Baseline 2 (ABBA design); or~3. Continue with 3 months of VNS and go to Baseline 2 (ABBBA design)~Each participant will have 1-month, 3-month, and 6-month follow-ups with the study team."||||
33690976|NCT06629259|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind|randomized double blind, placebo controlled|t|t|t|t
33690977|NCT00669968|||CASE_ONLY||PROSPECTIVE|||||||
33690978|NCT05594043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690979|NCT01351246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690980|NCT03354559|||COHORT||RETROSPECTIVE|||||||
33779514|NCT02945020|NA|SINGLE_GROUP||OTHER||NONE||||||
33779515|NCT00614744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779516|NCT05117034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind randomized controlled trial. Participating adults having craniotomy surgery will be randomized in a 1:1 ratio to intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure, or a matching placebo.|t|t|t|t
33779517|NCT06343779|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33779518|NCT04888923|||OTHER||PROSPECTIVE|||||||
33779519|NCT01257165|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33779520|NCT05337969|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33779521|NCT03114995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33779522|NCT03290469|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All investigators are masked to the study arm until Day 15 to ensure SOC throughout first 15 days on study.|Multi-cohort, time delay study receiving Clinical Whole Genome Sequencing (cWGS) at either 15 days or 60 days in an acutely ill newborn population|t|t|t|f
33779523|NCT03313089|||COHORT||PROSPECTIVE|||||||
33779524|NCT03352050|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33779525|NCT03405181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor won't have any knowledge about the study purposes and will be unaware of the group allocation.||f|f|f|t
33779526|NCT05215756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Open Label|Cross-sectional study||||
33779527|NCT06696664|||CASE_CONTROL||PROSPECTIVE|||||||
33779528|NCT05160025|NA|SINGLE_GROUP||OTHER||NONE||Repeated measures design||||
33779529|NCT01421771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779530|NCT02243072|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33779531|NCT04121208|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blind with participants blinded to treatment.|Phase 1b, randomised, single-blind, placebo-controlled parallel-group trial with JNJ-40346527 in adults with Mild Cognitive Impairment (MCI)|t|f|f|f
33779532|NCT02193633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779533|NCT04238455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a two-arm randomized study of chest wall nerve blocks for postoperative analgesia after elective minimally invasive lung resection. The two study groups are: (1) usual care plus serratus anterior plane block (treatment arm), and (2) usual care plus sham serratus anterior plane block (control arm).|t|t|t|f
33779534|NCT00772928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779535|NCT01859195|||OTHER||CROSS_SECTIONAL|||||||
33779536|NCT02932111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779537|NCT05939622|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33779538|NCT06220500|||CASE_CONTROL||PROSPECTIVE|||||||
34085865|NCT00610415|||COHORT||PROSPECTIVE|||||||
34085866|NCT00166699|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085867|NCT04905992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors in charge of the measures will be blind to the group assignment of participants until the study has been completed|A non-inferiority randomized clinical trial (single-blinded assessor).|f|f|f|t
33779539|NCT04517448|||CASE_ONLY||PROSPECTIVE|||||||
33779540|NCT05401682|||COHORT||PROSPECTIVE|||||||
33779541|NCT00471263|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33779542|NCT01186861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779543|NCT02677246|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779544|NCT03294265|RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-probabilistic sampling, by convenience (for the leaders). Randomization was performed by random stratified sampling, for which we considered age, sex and metabolic parameters (HbA1c, tryglycerides, blood pressure and body-mass index) of every patient in its fourth visit||||
33779545|NCT05786586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779546|NCT00337415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33779547|NCT04511130|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33779548|NCT06697535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690981|NCT04229004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779549|NCT05221398|||COHORT||PROSPECTIVE|||||||
33779550|NCT06697574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Original care providers who are preforming the follow up would be blinded to the intervention. The provider of the intervention is not aware of the state of the lichen planus of each patient.|60 randomised patients as well as 30 retrospective|f|t|f|f
33690982|NCT06605378|||CASE_ONLY||CROSS_SECTIONAL|||||||
33690983|NCT01327911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085868|NCT02375503|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34085869|NCT03483428|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085870|NCT05841420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085871|NCT00336908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34085872|NCT02406820|||COHORT||PROSPECTIVE|||||||
34085873|NCT04546841|NA|SEQUENTIAL||PREVENTION||NONE||Part I: Adults aged 18-55 years, n=12 Part II: Adults aged 56-74, n=12 Part III: Adults aged ≥ 75, n=12||||
34085874|NCT01105325|||COHORT||PROSPECTIVE|||||||
34085875|NCT06550323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33690984|NCT05571579|||COHORT||PROSPECTIVE|||||||
33690985|NCT06149273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779551|NCT06339983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779552|NCT02851199|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779553|NCT06696547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085876|NCT05968378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085877|NCT00473083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779554|NCT06615687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085878|NCT02974504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085879|NCT03028246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085880|NCT01860209|RANDOMIZED|PARALLEL||||NONE||||||
34085881|NCT01220284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085882|NCT03789721|||COHORT||PROSPECTIVE|||||||
34085883|NCT05232721|||OTHER||PROSPECTIVE|||||||
34085884|NCT05161390|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34085885|NCT03314480|||CASE_ONLY||PROSPECTIVE|||||||
33913106|NCT00695968|||COHORT||PROSPECTIVE|||||||
34085886|NCT03002402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085887|NCT01512888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085888|NCT03243396|RANDOMIZED|CROSSOVER||TREATMENT||NONE|No masking--Child/Adolescent participants and their participating guardian will be able to tell to which arm they were allocated or randomized, given that they know from whom they receive treatment (from teachers, indicating Education or from Community Health Volunteers, indicating Health). There are other participant types in addition to children/adolescents and guardians who are enrolled in BASIC (per above description) to answer implementation questions (Aims 1 and 2 of BASIC). As noted above, these other participants include the lay counselors (teachers and Community Health Volunteers, their site leaders \[Education: Head Teachers and Deputy Teachers; Health: Community Health Extension Workers\]).|Child mental health outcomes are assessed using an incomplete stepped wedge, cluster randomized controlled trial with 7 sequences. Child participants \& one guardian each are randomized to receive the treatment (therapy sessions) from lay counselors in the Health (Community Health Volunteer) or Education (teacher) sector, with timing based on the sequence to which their village cluster was randomly assigned. These participants are the focus of the Interventional Study Design in Aim 3. Also included are lay counselors \& site leaders (Head Teachers, Deputy Teachers, \& Community Health Extension Workers), given that it is a hybrid effectiveness-implementation trial. These participants, the focus of implementation questions in Aims 1 \& 2, provide TF-CBT \& do not receive therapy sessions themselves. The village clusters are randomized to sequences in the SW-CRT, \& if randomized to sequences 2-7, they receive coaching support informed by sequence 1 on how to effectively implement TF-CBT.||||
34085889|NCT02081807|||COHORT||RETROSPECTIVE|||||||
33779555|NCT00003802||||TREATMENT||||||||
33913107|NCT04935125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913108|NCT03020758|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33913109|NCT01979796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913110|NCT04476355|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||In the same ICU, the patients in the study period were the experimental group and the former patients were the control group.||||
33913111|NCT00745368|NA|SINGLE_GROUP||||NONE||||||
33913112|NCT00986427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33913113|NCT04818814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913114|NCT05463874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913115|NCT04043182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913116|NCT00133900|||COHORT||PROSPECTIVE|||||||
33913117|NCT01504854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913118|NCT00208312|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33913119|NCT02375958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913120|NCT00115804|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33913121|NCT04513938|||COHORT||RETROSPECTIVE|||||||
33913122|NCT04769635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913123|NCT01085305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913124|NCT05667155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913125|NCT02493816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913126|NCT03182400|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33913127|NCT02529241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913128|NCT04100798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913129|NCT04228692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33690986|NCT01292785|||CASE_CONTROL||PROSPECTIVE|||||||
33690987|NCT04462419|||CASE_ONLY||PROSPECTIVE|||||||
33690988|NCT05373771|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33690989|NCT04793061|||COHORT||PROSPECTIVE|||||||
33690990|NCT06729645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690991|NCT01626638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33690992|NCT03015883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690993|NCT02128828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690994|NCT01955980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913130|NCT01824316|||COHORT||PROSPECTIVE|||||||
33913131|NCT04899791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913132|NCT01104584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913133|NCT00679757|||||CROSS_SECTIONAL|||||||
33913134|NCT06530589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be comparison between two groups, experimental and control|f|f|f|t
33913135|NCT00242385|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33913136|NCT02577328|||CASE_ONLY||PROSPECTIVE|||||||
33779556|NCT02181959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33779557|NCT05764603|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||mri and ct arthrography||||
33779558|NCT03293420|||OTHER||RETROSPECTIVE|||||||
33779559|NCT06698185|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779560|NCT02980679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779561|NCT02134275|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779562|NCT06477406|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33779563|NCT06349785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|using sealed envelopes,|randomized controlled trial|t|f|f|f
33779564|NCT03623711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779565|NCT05041647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study participants will be randomly assigned in a 1:1:1 manner to one of the three treatment arms using a computer-generated, permuted-block randomization schedule. Randomization will be stratified by sex. All of the treating physicians who will be also administering the clinical questionnaires, the trained graduate student conducting cognitive testing, as well as any other trial staff, will be blinded to the subjects' status until the end of the study.|The study will be a pilot, three-arm, randomized, double-blind, placebo-controlled trial.|t|t|t|t
33779566|NCT05789355|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, prospective, open-label pilot study.||||
33779567|NCT03888703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treatment and control areas were randomized in advanced such that the investigator did not choose which sections to treat. Control areas were covered during the treatment so the investigator/provider could only see areas to be treated. Outcomes assessors evaluated photographs without knowledge of the identity of each area. The participant could not be masked due the experience of receiving treatment.|Each subject possessed extensive burn wounds. Wounds on each subject were divided into treatment arms of intervention with fractional ablative CO2 laser and control.|f|t|t|t
33779568|NCT02007447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779569|NCT06475677|NA|SINGLE_GROUP||TREATMENT||NONE||As osteoarthritis is a chronic condition, outcomes will be compared to baseline measurements for the same participant.||||
33779570|NCT04007887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779571|NCT05049525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779572|NCT06614868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779573|NCT02559817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779574|NCT02916472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779575|NCT04637035|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33779576|NCT05737030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779577|NCT06692725|||COHORT||OTHER|||||||
33779578|NCT01692262|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33779579|NCT05929846|||COHORT||PROSPECTIVE|||||||
33779580|NCT05781529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779581|NCT01511627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779582|NCT02988375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779583|NCT04304105|||COHORT||PROSPECTIVE|||||||
33779584|NCT01455740|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study used a randomized trial design for two treatment arms: (i) Participants in the provider visit incentive (PVI) arm were told that they would receive $30 after attending each scheduled provider visit (a CCT). (ii) Participants in the incentive choice (IC) were given a choice between the above CCT and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit and meeting an ART adherence threshold. A block randomization scheme, stratified on whether or no the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm and 19 to the IC arm.||||
33779585|NCT06445920|||CASE_CONTROL||RETROSPECTIVE|||||||
33779586|NCT00414414|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33779587|NCT05768555|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33779588|NCT01821924|||COHORT||RETROSPECTIVE|||||||
33779589|NCT02358590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779590|NCT03835117|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Prospective Randomized 12-week Double-Blind Placebo-Controlled Cross-over|t|t|t|t
33779591|NCT00681811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779592|NCT05735015|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33779593|NCT02109887|||COHORT||PROSPECTIVE|||||||
33779594|NCT02181205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33779595|NCT04974502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33779596|NCT03442920|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779597|NCT05548127|NA|SEQUENTIAL||TREATMENT||NONE||"Phase 1b will use an escalation/de-escalation approach to determine the RP2D of ARV-471 when administered in combination with abemaciclib. The decision to de-escalate the starting dose levels of ARV 471 will be using mTPI-2 decision criteria based on the number of DLT-evaluable participants and the number of DLTs in those participants during the DLT observation period (Cycle 1 \[first 28 days\]).~Phase 2 will further evaluate the preliminary antitumor activity and safety of the combination RP2D."||||
33779598|NCT02349113|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33779599|NCT02781155|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33779600|NCT04312828|||COHORT||OTHER|||||||
33779601|NCT05121870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, multicenter study|t|t|t|t
33779602|NCT06409585|||COHORT||PROSPECTIVE|||||||
33779603|NCT02046642|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779604|NCT03487874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779605|NCT01515319|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Part A: Treatments were administered single-blind; subjects were blinded with regard to treatment and clinical staff remained blinded with regard to treatment until the Safety Committee meeting. Part B was double blind.|"Part A was a single blind, randomised, placebo controlled, single ascending dose (SAD) study.~Part B was a double blind, randomised, placebo controlled, multiple ascending dose (MAD) study"|t|f|t|f
33779606|NCT04003974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be performed in a double-blind fashion. The investigator, study staff, subjects, sponsor and monitor will remain blinded to the treatment until study closure.|This study is a randomized, double-blind, placebo-controlled, 48-week parallel-group study.|t|t|t|t
33838878|NCT01870947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085890|NCT02943213|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085891|NCT00264212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085892|NCT05815966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34085893|NCT04056169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085894|NCT01569022|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized trial||||
34085895|NCT01230528|||CASE_ONLY||RETROSPECTIVE|||||||
34085896|NCT01740232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085897|NCT02667899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34085898|NCT04664205|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34085899|NCT03415178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085900|NCT05223127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34085901|NCT02218463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085902|NCT02629302|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34085903|NCT02404142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34085904|NCT01130272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085905|NCT04223947|||COHORT||PROSPECTIVE|||||||
34085906|NCT04156698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085907|NCT00393315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085908|NCT01584934|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34085909|NCT03568435|||COHORT||RETROSPECTIVE|||||||
34085910|NCT04260165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085911|NCT01116557|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34085912|NCT05507450|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34085913|NCT03504553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085914|NCT05308914|||OTHER||OTHER|||||||
34085915|NCT04808102|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigator and trial participants will be blinded throughout the study due to the automised randomization process via the online server SosciSurvey. Statistical analysis will be executed by generating a number for each group, with its affiliation unknown to the analyst.|"This trial is a RCT with an experimental and a control group, with participants being individually allocated to either of the groups. The allocation ratio is 50:50. This RCT adopts a pre-post-test strategy with the between-participant factor group and the within-participant factor time."|t|f|t|t
34085916|NCT02279953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085917|NCT03243149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of whether the thermometer ratings they see while in the scanner are false feedback consisting of noise or true activation.|The investigators will test (1) the efficacy of neurofeedback in subjects with PTSD attempting to upregulate ventral medial PFC and simultaneously downregulate amygdala, and (2) determine the number of neurofeedback sessions (dose) needed for target engagement and transfer. Prior to the neurofeedback training, participants' baseline ability to regulate in the absence of neurofeedback from real-time fMRI will be ascertained. Then during session, participants will receive veridical real-time feedback in the scanner indicating the activation level of ventromedial PFC minus amygdala. Participants will attempt to regulate to achieve a predetermined target level known to the participant.|t|f|f|f
34085918|NCT06551545|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34085919|NCT04786769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two-arm trial of intravenous iron supplementation vs placebo, randomized 1:1.|t|t|t|t
34085920|NCT04996030|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The characterization of single-dose PK will be conducted in an open-label, randomized crossover 3-period, 3-treatment, 2-sequence design, separated by ≥1 week of washout.||||
34085921|NCT05627687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant is advised that they are entering a study in which they will be randomized to one of two conditions designed to potentially reduce stress and caregiver burden. Neither condition is presented as the control, thus participants are blinded to the expectations of the assigned condition.|This is a two-arm parallel randomized controlled trial comparing heart rate variability biofeedback to a music listening control condition, both practiced 4-5 days per week for 8 weeks.|t|f|f|f
34085922|NCT01840852|||CASE_CROSSOVER||PROSPECTIVE|||||||
34085923|NCT02934594|||CASE_ONLY|||||||||
34085924|NCT05761847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Hybrid Type 2 Randomized Controlled Trial (RCT)|f|f|f|t
34085925|NCT02437292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085926|NCT05899998|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34085927|NCT04092413|||OTHER||PROSPECTIVE|||||||
34085928|NCT02582489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33838879|NCT01644864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33838880|NCT06541769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838881|NCT00607724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838882|NCT05065047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838883|NCT05446753|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33838884|NCT06170177|||COHORT||PROSPECTIVE|||||||
33913137|NCT06170372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33913138|NCT05364879|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690995|NCT03410823|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33690996|NCT02616471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33690997|NCT01982331|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33690998|NCT02779855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33690999|NCT01184131|RANDOMIZED|PARALLEL||||NONE||||||
33691000|NCT03495180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691001|NCT06745128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691002|NCT02524964|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33691003|NCT06128824|||COHORT||PROSPECTIVE|||||||
33691004|NCT01483690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691005|NCT05520398|||COHORT||CROSS_SECTIONAL|||||||
33779607|NCT04675411|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients and families will not be aware of their group enrollment and will be masked to the care model they receive. Research nurses who collect data will be independent of those who deliver the interventions.|Participants in this trial will receive two care models: usual care and the Smart Care Model (SCM). The SCM will have two components: fall risk monitoring with an alarm, and activity-level monitoring with feedback. These SCM components are designed to enhance caregiver competence, decrease patient risk for subsequent falls, and improve postoperative recovery for hip-fractured patients with cognitive impairment (Table 2). We have integrated the technology of remote monitoring with smart clothing into continuous rehabilitation and discharge planning, along with geriatric consultation. We will compare the effects of the SCM and usual care in this trial.|t|f|f|t
33779608|NCT02893540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779609|NCT03946657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients were randomly assigned using opaque sealed envelopes to two groups; the Inhalation group including those who received sevoflurane-remifentanil for the maintenance of anesthesia (n = 30) and the TIVA (total intravenous anesthesia) group including those who had propofol-remifentanil infusion for the maintenance of anesthesia (n = 30). Randomization was performed according to a computer-generated randomization code, and a statement showing the patients' group was placed in sealed, numbered enveloped according to the results. Each patient drew an envelope and was enrolled in the study depending on the group written in the envelope. Randomization was performed by a physician who was not involved in the monitorization of the patients.|For the investigation, the patients were randomly assigned to two groups; the Inhalation group including those who received sevoflurane-remifentanil for the maintenance of anesthesia (n = 30) and the TIVA (total intravenous anesthesia) group including those who had propofol-remifentanil infusion for the maintenance of anesthesia (n = 30). The anesthesiologist caring for the patient was aware of the group assignments. The patients were blinded to the group assignments.|t|f|f|f
33779610|NCT03477682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The plastic surgeon who performs the sartorius flap does not know which group the patient will be randomized to (early ambulation versus standard 5 days bedrest) until after the surgery is completed.||f|t|f|f
33838885|NCT06050642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pragmatic, randomized, prospective, multisite (national), real-life study comparing home support service models||||
33838886|NCT00089960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838887|NCT00489801|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33838888|NCT05392647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838889|NCT00890578|||COHORT||PROSPECTIVE|||||||
33838890|NCT04777110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838891|NCT03281161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were not aware of the condition in which their organization was enrolled.||t|f|f|f
33838892|NCT04848818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838893|NCT00681148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838894|NCT01562639|||COHORT||PROSPECTIVE|||||||
33838895|NCT03516305|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects receive a single dose of Staccato Alprazolam 1 mg||||
33840003|NCT04255472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Outcome assessors will be blind to the allocations status of participants. To ensure blinding, participants will be instructed to not disclose their allocation during assessment.~Fidelity of masking will be ensured by having assessors guess the allocation status of participants at the end of assessments."|Two arm, single blind individual randomized controlled trial (RCT)|f|f|t|t
33840004|NCT00381927|||DEFINED_POPULATION||PROSPECTIVE|||||||
33840005|NCT05417295|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691006|NCT06238947|||COHORT||PROSPECTIVE|||||||
33691007|NCT03923322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blinded randomized, placebo-controlled trial|t|t|t|t
33691008|NCT06135168|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33691009|NCT03580148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691010|NCT04805320|||COHORT||PROSPECTIVE|||||||
33691011|NCT02561624|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33691012|NCT03913442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33691013|NCT00749580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691014|NCT06617429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691015|NCT06411353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691016|NCT05732831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation (sequential) followed by phase 2 dose expansion in 5 arms (parallel)||||
33691017|NCT02487823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691018|NCT03150810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691019|NCT06561971|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 90 systemically healthy non-smoker individuals with heavy smokers (H, n=30), light smokers(L, n=30) and non-smokers (N, n=30).||||
33691020|NCT00290979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691021|NCT03312400|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691022|NCT03875573|RANDOMIZED|PARALLEL||TREATMENT||NONE||Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms.||||
34085929|NCT00431418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34085930|NCT03829176|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participant, care provider, and study genetic counselor will be blinded to the arm in which the participant was assigned until 3-4 months post-enrollment when the laboratory notifies if a WGS report is generated or not.||t|t|f|f
33779611|NCT06696404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician is blinded to group assignment.|"1. Nerve block anesthesia group (NA group): Combined Lumbar Plexus(0.33% ropivacaine 30ml)and Sacral Plexus Block(0.33% ropivacaine 20ml) + sedation or laryngeal mask anesthesia~2. General anesthesia group (GA group): General anesthesia (Endotracheal intubation) + iliac fascial block(0.33% ropivacaine 30ml)~3. Spinal anesthesia group (SA group): Spinal anesthesia with ropivacaine 8-20 mg or an equivalent dose of Bupivacaine."|f|f|f|t
33779612|NCT02794961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779613|NCT02691065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779614|NCT04170426|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients who failed disease-modifying antirheumatic drug (DMARDs).|t|t|t|t
33779615|NCT01047072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779616|NCT03605186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779617|NCT01232556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779618|NCT05228509|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33779619|NCT03194061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779620|NCT04803084|||COHORT||PROSPECTIVE|||||||
33779621|NCT00557505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779622|NCT03078387|||CASE_ONLY||RETROSPECTIVE|||||||
33779623|NCT02199990|||CASE_CONTROL||PROSPECTIVE|||||||
33779624|NCT05621629|||COHORT||PROSPECTIVE|||||||
33779625|NCT02482909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779626|NCT02453646|NA|SINGLE_GROUP||OTHER||NONE||||||
33779627|NCT01630499|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779628|NCT03215225|||COHORT||PROSPECTIVE|||||||
33779629|NCT02649790|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779630|NCT04066543|RANDOMIZED|PARALLEL||TREATMENT||NONE||TACE vs.TACE+Anlotinib||||
33779631|NCT06005103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither patients nor the research team knows which headbands apply treatment A or B. The firm MoodHeadBand Aps was in charge of the randomization procedure. The headbands, control boxes and powerbanks are identifical. No difference can be seen or felt when the headbands are plugged into the control boxes and powerbanks. A small bulb will be lit when the controlbox is connected to a charged powerbank.|Patients will receive either active (A) or placebo (B) treatment with the T-PEMF technology using af headband designed for this. The headbands will be chosen randomly from a bag containing a mix of headbands applying either treatment A or B. There will be two bags to choose from, one bag is designated for patients who use antidepressant drugs, the other is designated for patients who do not use antidepressant drugs at the time of inclusion in the study. The firm MoodHeadBand Aps was in control of the randomization procedure, making sure that each bag contained the same amount of headbands applying treatment A and B.|t|t|t|t
33779632|NCT02451930|NA|SEQUENTIAL||TREATMENT||NONE||||||
33779633|NCT00115180|||COHORT||PROSPECTIVE|||||||
33913139|NCT06254352|||COHORT||PROSPECTIVE|||||||
33913140|NCT04548687|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1: patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities.~Group 2: patients with planned minimally invasive or repeated cardiac surgery using standard methods of deaeration of cardiac cavities, supplemented with carbon dioxide insufflation during surgery"||||
33913141|NCT01332812|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33913142|NCT04579679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913143|NCT04004533|||CASE_ONLY||PROSPECTIVE|||||||
33913144|NCT00058734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913145|NCT01184404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913146|NCT02030145|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34085931|NCT03151369|NA|SINGLE_GROUP||SCREENING||NONE||||||
34085932|NCT00976365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085933|NCT01391611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085934|NCT04518696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085935|NCT05244200|RANDOMIZED|PARALLEL||TREATMENT||NONE||In these selective control trial, 100 patients with type 2 diabetes mellitus, those that they are on the end stage management protocol are going to be randomly allocated into two different groups, namely intervention and non-intervention groups. In the intervention group, a strict protocol developed by IDC for insulin prescription is going to be implement and patients will be assessed for the therapeutic outcomes along with the detection and resolution of drug therapy problems throughout the course of 6 months study. On the side, patients in the non-intervention group will be followed for the therapeutic outcomes and detection of DTPs without tempting to resolve them.||||
34085936|NCT02636621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34085937|NCT02438579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34085938|NCT04768348|||COHORT||PROSPECTIVE|||||||
34085939|NCT01366716|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33691023|NCT05559879|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ib/II, single-arm, combination therapy of the safety and efficacy of therapy involving a tyrosine kinase inhibitor along with immunotherapy in the setting of recurrent carcinosarcoma.||||
33691024|NCT05014802|||COHORT||PROSPECTIVE|||||||
33691025|NCT03845296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085940|NCT03329885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691026|NCT01197742|||COHORT||PROSPECTIVE|||||||
33691027|NCT05736406|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 model.The dose of light will be escalated in successive cohorts of patients. The starting dose is at 200 J/cm2. Enroll 3 patients at the first dose level and proceed to the next higher dose level with a cohort of 3 patients until at least 1 patient experiences a dose-limiting toxicity (DLT).||||
34085941|NCT05551416|||COHORT||PROSPECTIVE|||||||
33691028|NCT05878561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691029|NCT05391451|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33691030|NCT03645681|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients will be implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. There are two model versions of the InnAVasc Graft. The looped model and the straight model. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."||||
33994098|NCT04797663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994099|NCT00735540|||CASE_ONLY||RETROSPECTIVE|||||||
33994100|NCT05140759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994101|NCT06628063|||OTHER||CROSS_SECTIONAL|||||||
33994102|NCT05905276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994103|NCT03796611|||CASE_CONTROL||PROSPECTIVE|||||||
33994104|NCT00028587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994105|NCT06455514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33994106|NCT05441670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33994107|NCT01175135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994108|NCT04937439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33994109|NCT00000458|RANDOMIZED|||TREATMENT||DOUBLE||||||
33994110|NCT04865003|||OTHER||RETROSPECTIVE|||||||
33994111|NCT06562309|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994112|NCT02095379|||CASE_ONLY||RETROSPECTIVE|||||||
33994113|NCT02421653|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33994114|NCT03013413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994115|NCT00507117|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33994116|NCT03283358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994117|NCT02606032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994118|NCT02856308|NA|SINGLE_GROUP||OTHER||NONE||||||
34085942|NCT04260633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study will be a prospective, randomized, controlled, single-blind, parallel group clinical trial.|t|f|f|t
34085943|NCT02245711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085944|NCT00504400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085945|NCT02574091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085946|NCT02497469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085947|NCT01516216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085948|NCT00434629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085949|NCT02841696|||COHORT||OTHER|||||||
34085950|NCT01477567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34085951|NCT00193635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085952|NCT01323556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085953|NCT05227716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Triple blind: Participants and researchers will be unaware of the type of intervention used (administration of MgSO4 or Placebo).|"* Clinical trial: An intervention will be carried out in the population to be studied for the purpose of the research and there will be a control group.~* Triple blind: Participants and researchers will be unaware of the type of intervention used (administration of MgSO4 or Placebo).~* Randomized: A list of random numbers will be used to assign patients to study groups."|t|t|t|t
34085954|NCT05152121|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34085955|NCT00723827|||COHORT||PROSPECTIVE|||||||
34085956|NCT01926691|||COHORT||PROSPECTIVE|||||||
34085957|NCT01416038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085958|NCT00400244|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085959|NCT02613130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994119|NCT03785730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994120|NCT01395628|||CASE_ONLY||RETROSPECTIVE|||||||
33994121|NCT01732224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994122|NCT01783184|||COHORT||PROSPECTIVE|||||||
33994123|NCT02990286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994124|NCT02254005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994125|NCT05235854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will not know whether he has been randomized to the meniscal wall infiltration group or the intra-articular filtration group. The investigator following up the patients after infiltration will not know whether his:her patient has had an intra-articular infiltration or a meniscal wall infiltration.|Single-center, randomized, double-blind, controlled study comparing two management strategies.|t|t|f|f
33994126|NCT03494127|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Repeated measures crossover clinical study design||||
33994127|NCT06182722|||COHORT||PROSPECTIVE|||||||
33994128|NCT00461721|||CASE_CONTROL|||||||||
33994129|NCT02625974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994130|NCT01601405|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994131|NCT04150029|NA|SEQUENTIAL||TREATMENT||NONE||safety -run -in with escalating dose of MBG453 followed by expansion||||
34085960|NCT00299858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085961|NCT04732793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085962|NCT05047900|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34085963|NCT00112164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34085964|NCT00006180||||TREATMENT||||||||
34085965|NCT01038765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691031|NCT01152450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33994132|NCT04660864|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment.||||
33994133|NCT02922569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691032|NCT05468736|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33994134|NCT02991196|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994135|NCT02853643|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33691033|NCT06547840|NA|SINGLE_GROUP||TREATMENT||NONE||Bayesian logistic regression model with overdose control||||
33691034|NCT05654883|||COHORT||PROSPECTIVE|||||||
33994136|NCT05900648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691035|NCT05912504|||OTHER||CROSS_SECTIONAL|||||||
33691036|NCT04418232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33691037|NCT05831540|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33994137|NCT05572398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691038|NCT05441579|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33779634|NCT05230082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779635|NCT03141164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Computerized training for all groups. This is a pilot study.|||||
33779636|NCT06258993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779637|NCT01224561|||||PROSPECTIVE|||||||
33779638|NCT04683497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779639|NCT01255605|||||CROSS_SECTIONAL|||||||
33779640|NCT06128863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779641|NCT05717075|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33779642|NCT02763098|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33779643|NCT02024243|||COHORT||PROSPECTIVE|||||||
33779644|NCT06447974|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|Participants undergo personal exposure monitoring before and after the introduction of mitigation strategies.||||
33779645|NCT06093529|||CASE_ONLY||CROSS_SECTIONAL|||||||
33913147|NCT03347604|||CASE_ONLY||CROSS_SECTIONAL|||||||
33913148|NCT04895943|||CASE_ONLY||PROSPECTIVE|||||||
33913149|NCT02583802|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33913150|NCT06405022|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The study is constructed as a cross-over design (Fig. 1), where participants function as their own control condition. The control condition (the first period) and the intervention (the latter period) consists of a 6 week training period, both leading up to a prioritized international competition||||
33913151|NCT06282497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994138|NCT00740103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994139|NCT01902719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994140|NCT04940494|||COHORT||RETROSPECTIVE|||||||
33994141|NCT06133101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective parallel arm randomized controlled study|f|f|t|f
33779646|NCT06291077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779647|NCT01051011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994142|NCT05297227|||COHORT||PROSPECTIVE|||||||
33994143|NCT01221129|||||PROSPECTIVE|||||||
33994144|NCT00387933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994145|NCT05043103|||COHORT||OTHER|||||||
33994146|NCT04223791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779648|NCT06697522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913152|NCT01773135|||CASE_ONLY||CROSS_SECTIONAL|||||||
33913153|NCT03297892|||COHORT||PROSPECTIVE|||||||
33913154|NCT02273440|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33913155|NCT01525849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913156|NCT05485272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The operator will not be blinded due to differences between both materials.|A 3-arm randomized clinical trial. Randomization will be done according to a check list including the number of participants divided into 3 groups of 14 patients (42 total) according to interventions/Control assessment methods.|t|f|f|t
33913157|NCT04619875|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33994147|NCT06627946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994148|NCT05001958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994149|NCT00728039|||COHORT||PROSPECTIVE|||||||
33994150|NCT00023881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994151|NCT03423654|RANDOMIZED|PARALLEL||OTHER||NONE||Spatial Training group and Control group||||
33691039|NCT05508867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691040|NCT06039267|||COHORT||PROSPECTIVE|||||||
33691041|NCT05497635|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33691042|NCT04771897|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691043|NCT05870579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691044|NCT06488807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33779649|NCT02237079|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33779650|NCT04818879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33779651|NCT04871087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single arm assesment||||
33779652|NCT04415892|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33779653|NCT01133509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779654|NCT03151421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779655|NCT03715374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779656|NCT04524182|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled||||
33779657|NCT01938417|||COHORT||PROSPECTIVE|||||||
33779658|NCT05420532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913158|NCT02833116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994152|NCT03340623|||COHORT||RETROSPECTIVE|||||||
33994153|NCT02901379|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994154|NCT05315713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994155|NCT03698357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994156|NCT00881751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994157|NCT00932477|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33994158|NCT01665495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779659|NCT00324532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779660|NCT06284109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All participants will receive nerve blocks with Local anesthetic. Participants will be Randomized on a 1:1 fashion to cryoanalgesia or sham cryoanalgesia, based on computer-generated codes and use random-sized blocks. Patients will not be told which group they are in.|Pre-Operative Patients will receive cryoanalgesia or sham cryoanalgesia before amputation.|t|f|t|t
33779661|NCT05034575|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33779662|NCT06615388|||CASE_ONLY||CROSS_SECTIONAL|||||||
33779663|NCT03878082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779664|NCT04770090|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779665|NCT05716633|||COHORT||PROSPECTIVE|||||||
33779666|NCT00861978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779667|NCT04231110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779668|NCT00231179|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779669|NCT06426407|||COHORT||PROSPECTIVE|||||||
33779670|NCT04987710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779671|NCT05593575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779672|NCT01803126|||CASE_ONLY||PROSPECTIVE|||||||
33779673|NCT05334381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33913159|NCT00848549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913160|NCT05181319|||COHORT||PROSPECTIVE|||||||
33913161|NCT01152567|||COHORT||RETROSPECTIVE|||||||
33913162|NCT05145075|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33913163|NCT03242083|||COHORT||PROSPECTIVE|||||||
33913164|NCT02364947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913165|NCT02822443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913166|NCT02653105|NA|SINGLE_GROUP||SCREENING||NONE||||||
33913167|NCT02776657|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33913168|NCT03998475|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913169|NCT00004986||||TREATMENT||||||||
33913170|NCT02683616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913171|NCT00454155|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33913172|NCT00094341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913173|NCT04196361|||COHORT||PROSPECTIVE|||||||
33913174|NCT02620462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33913175|NCT05140005|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||30 subjects split evenly into two sections: 15 participants testing themselves and 15 participants testing another person (child).||||
33913176|NCT05582811|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33913177|NCT01002859|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913178|NCT03740607|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||randomized prospective cohort|t|f|f|t
33913179|NCT00396708|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691045|NCT05926804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Gastroenterologist or trained physician who performs the surveillance after eradication treatment. No other parties will be masked in the clinical trial.|"Screening phase: 14-18-year-old students (up to 1000) from three cities will be invited. After obtaining informed consent, eligible participants without exclusion criteria will undergo an H. pylori screening test (Urea Breath Test; UBT). Those negative will exit, except for a subset to be followed as a non-infected controls. Subjects with a positive test will undergo two confirmatory tests 30 days apart to confirm infection persistence. Approximately 20-25% are expected to be positive.~Intervention phase: those with persistent H. pylori infection will undergo gastroenterological evaluation 1 month before randomization (2:1) to receive antimicrobial treatment or no treatment. Non-infected controls will be followed at matched intervals. If untreated, subjects with persistent infection will be offered the eradication regimen after completing the initial 6-month follow-up with blood and stool samples taken."|f|f|f|t
33691046|NCT04623775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691047|NCT03953183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Neither the site staff nor the subject will be informed about the product variant the subjects have been randomized to.|A randomized, double-blinded, 2-arm parallel groups, single center study|t|f|t|f
33691048|NCT02245204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691049|NCT06146179|||CASE_ONLY||RETROSPECTIVE|||||||
33913180|NCT02280291|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913181|NCT01455038|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691050|NCT05893979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691051|NCT05022446|||CASE_ONLY||CROSS_SECTIONAL|||||||
33691052|NCT05646277|||CASE_CONTROL||PROSPECTIVE|||||||
33691053|NCT03704701|||COHORT||PROSPECTIVE|||||||
33691054|NCT04732156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913182|NCT01469494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913183|NCT04131517|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33913184|NCT03578848|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Each patient will be randomly assigned, using a standard computer protocol at the General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan, to intervention in a 1:1:1 ratio to home BP, uAOBP, or central BP using sealed opaque envelopes (sequentially numbered). The study coordinator will oversee the enrollment and intervention assignment and keep allocation concealment. The caring physicians will remain blinded to the allocation by providing them with the measured BP values through a standardized report form without the knowledge of the used BP monitoring devices.|BP will be taken simultaneously from both upper arms by an oscillometric BP monitor. Subjects with SBP Differences between both arms more than 5 mmHg will be excluded. For the unattended automated BP (uAOBP) and central BP (CBP), the measurements will be conducted in a quiet room without the presence of clinical personnel. Simultaneously, the central BP will be measured in the other upper arm. The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment. As for the home BP measurements, a validated device will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP will be generated and provided for clinicians to guide their treatment.|t|t|f|f
33913185|NCT05315232|||COHORT||PROSPECTIVE|||||||
33913186|NCT03262597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Repeated-measures design with generalized latin square arrangement. Each participant will complete 4 separate trials.||||
33913187|NCT00863837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913188|NCT03416738|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33913189|NCT03506399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33913190|NCT01622920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913191|NCT03108118|||COHORT||PROSPECTIVE|||||||
33913192|NCT02140359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913193|NCT03029416|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 Gy single fraction SBRT 18 Gy x three fractions||||
33913194|NCT01510808|||CASE_CONTROL||RETROSPECTIVE|||||||
33913195|NCT04551573|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33913196|NCT05291949|NA|SINGLE_GROUP||OTHER||NONE|No masking|Each patient receives monitoring by all standard intraoperative monitors in addition to monitoring by the ATLASense RAPHAEL PolyMonitor during their surgery.||||
33913197|NCT05198752|NA|SEQUENTIAL||TREATMENT||NONE||30 participants in Cohort (C)1:50 mcg of SW1115C3 ; C2: 100 mcg of SW1115C3; C3: 150 mcg of SW1115C3.||||
33913198|NCT03223857|||OTHER||PROSPECTIVE|||||||
33913199|NCT04142307|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective randomized controlled parallel group study ratio 1:1.||||
33913200|NCT05763160|NA|SINGLE_GROUP||TREATMENT||NONE||Second injection session of RZL-012 will be administered to subjects who previously treated with RZL-012 in submental fat||||
33913201|NCT02581319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779674|NCT06099743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Stakeholder interviews in up to 15 participants and an open pilot in up to 10 participants to refine the intervention followed by a pilot randomized control trial (n=100) in which participants will be randomized 1:1 to the intervention versus usual care||||
33779675|NCT06075888|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33779676|NCT05846087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers responsible for randomization and data-analysis will be blinded to the study arms.|open labelled, randomized controlled trial|f|f|f|t
33779677|NCT05795790|||OTHER||CROSS_SECTIONAL|||||||
33779678|NCT05200390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779679|NCT04323735|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Design: Prospective, randomized pilot intervention clinical trial. Target Enrollment: 182 subjects with NLUTD at least 6 months and who use IDC for bladder management. Setting: National sample (N=114 intervention only, no urine collection) and local Washington, DC metropolitan area (N=68 intervention + urine collection).~Controls: This is a 2-arm dose-finding pilot clinical trial, as such there is no control group"||||
33691055|NCT02207985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691056|NCT05916950|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, multicenter, and open-label study||||
33691057|NCT05219123|||COHORT||PROSPECTIVE|||||||
33691058|NCT06139692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691059|NCT03972930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691060|NCT02436642|||CASE_ONLY||PROSPECTIVE|||||||
33691061|NCT03643744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33691062|NCT00737464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691063|NCT01819376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33691064|NCT02531100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33691065|NCT02369406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691066|NCT01871857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691067|NCT06143111|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33691068|NCT00649415|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33691069|NCT06526195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691070|NCT02309866|||CASE_ONLY||CROSS_SECTIONAL|||||||
33691071|NCT06556563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The participants in the study will be randomized in a ratio of 2:1 in favor of the treatment group to one of the following groups:~Treatment Group - Optune concomitant with maintenance TMZ and pembrolizumab.~Control Group - Optune concomitant with maintenance TMZ and placebo."|t|t|t|t
33691072|NCT03522025|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691073|NCT05603663|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33691074|NCT03282851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33691075|NCT04509765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691076|NCT03265327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691077|NCT03583515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be assigned to and receive feedback via the computer. Once they have received feedback a research assistant will print this feedback for them to take home. At this time, research assistants will become unblinded to condition, but will not administer any new procedures other than answering participant questions.|Half of participants will be randomly assigned to receive personalized normative feedback about their drinking. The other half will be randomly assigned to receive control feedback about social media use.|t|f|t|f
33691078|NCT02826135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691079|NCT02658058|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691080|NCT04147572|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691081|NCT03371719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691082|NCT04622735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind. Participants, investigators, and all persons involved in the conduct, data management, and analysis of the study will be fully blinded to the participant's treatment.||t|f|t|f
33691083|NCT01338142|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33691084|NCT05171049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691085|NCT05302908|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691086|NCT01145612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691087|NCT05977361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691088|NCT04811573|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Five-period, ten-sequence crossover trial.~Periods:~(A): EU-sourced Otezla - fasted condition (B): US-sourced Otezla - fasted condition (C): EU-sourced Otezla - fed condition (C): US-sourced Otezla - fed condition (E): Japan-sourced Otezla - fasted condition~Sequences: see Arms"||||
33691089|NCT06299150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a randomized clinical trial (RCT) where 2 arm parallel groups with a 1:1 allocation ratio were compared. The child participants and the legal guardian of each participating child and the statistician were blinded.|t|f|f|f
33691090|NCT06504862|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||fixed-sequence crossover||||
33691091|NCT03283878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691092|NCT04312113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691093|NCT02442115|||COHORT||PROSPECTIVE|||||||
33691094|NCT06107231|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33691095|NCT02123043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691096|NCT04179851|||COHORT||PROSPECTIVE|||||||
33691097|NCT06045169|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi Experimental Pre-test Post-test design||||
33691098|NCT02449720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691099|NCT06354829|||COHORT||PROSPECTIVE|||||||
33779680|NCT02372331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation and judgement for morbidity (primary endpoint) / mortality (secondary endpoint) was made by Morbidity and Mortality Committee in our division. Committee members were blinded about knowledge of the interventions assigned to individual participants.|Two study groups (Control (conventional) group and study (intervention) group) were randomly allocated and assigned to one of two groups in parallel for the whole duration of this study.|f|f|f|t
33994159|NCT06136039|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study has prospective cohort design. Prior to surgery, a sarcopenia assessment was conducted to categorize patients into sarcopenia and normal groups. Sarcopenia was reassessed at 6 and 12 months post-surgery for comparison with the preoperative state. Additionally, clinical outcomes of patients were evaluated at 3, 6, and 12 months post-surgery for comparison between the normal and sarcopenia groups.||||
34085966|NCT05622006|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"This study will be conducted as randomized controlled crossover trials involving 4 different trial conditions in each of the studies. Randomization will be stratified based on sex. The order of trials will be assigned randomly by a third party using a computer software.~After pre-testing and familiarization (visit 1), the participants will undergo 4 different trial conditions of 7 hours. The trials are all iso-caloric, but with different intervals of sitting and executing moderate physical activity by treadmill walking corresponding to 60-65% of their individual VO2max values, estimated from the individual's pre-test. The volume of sedentary- and physical activity time will be identical in each trial condition. Blood samples will be taken and blood pressure measured every 30 minutes. The visits for main testing will be separated by a washout period of minimum 5 days, and women will be tested in the follicular phase."||||
33779681|NCT01361815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779682|NCT01786343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779683|NCT06551246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is single-blinded, and the study subject will receive medication delivered from the study site. The investigator does not know which treatment the individual participant receives. Participants will be informed that they are not allowed to reveal the blinded investigator the study medication, and an unblinded nurse will guide and answer questions to participants in case of dose titration.|Children aged 5-14 years diagnosed with daytime urinary incontinence refractory to standard urotherapy will be randomized to four treatment groups, randomization 1:1:1:1.|f|f|t|f
33779684|NCT02536690|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33779685|NCT06042998|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A (experimental group): Performing robot radical gastrectomy Group B (control group): Performing laparoscopic radical gastrectomy||||
33779686|NCT06272955|||CASE_ONLY||PROSPECTIVE|||||||
33779687|NCT00062868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779688|NCT02300311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33779689|NCT01627340|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779690|NCT04690283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Subject diagnosed with colorectal cancer stages IIa-IIIc, suitable for receiving FOLFOX4 or mFOLFOX6 as adjuvant chemotherapy after radical resection of colorectal cancer, receiving each dose and cumulative dose of oxaliplatin are 85mg/m2 and ≥540 mg/m2 respectively, with Karnofsky performance status scale (Schag et al.1984) index ≥60 points and an expected survival time ≥6 months, over 18 years of age, men or women, without severe damage of the heart, liver, kidney or hematopoietic system.|t|f|t|f
33779691|NCT01941914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779692|NCT05514470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33779693|NCT05968521|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinding of allocation will be maintained for the principal investigator's, statistician, and quantitative research assistant.|The study is a single blind parallel randomised feasibility trial comparing a CR programme against usual care with 100 CYP (50 per arm) aged 11-16 diagnosed with a heart condition.|f|f|f|t
33779694|NCT04807179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779695|NCT01447355|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33994160|NCT00313937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994161|NCT04313764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994162|NCT04285814|||CASE_CONTROL||PROSPECTIVE|||||||
33994163|NCT05100212|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Interventional, randomized, controlled, double-blind, with an adaptive design to evaluate safety and efficacy of allogeneic CB-RBC transfusions.|f|t|f|f
33994164|NCT02647463|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994165|NCT00935012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994166|NCT05413096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|caregiver and participants and investigator are masked|A randomized clinical, double-blind, placebo-controlled study|t|t|t|f
33994167|NCT06201390|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will complete a 6-week study that will involve five study visits. The first visit will include informed consent, collection of demographic data, sleep- and health-related surveys, and familiarization with study procedures. Participants will then be block randomized to either habitual sleep followed by stable sleep, or stable sleep followed by habitual sleep - each sleep condition will lasts two weeks. In the habitual sleep condition, participants will be asked to follow their normal routine without concern about their sleep duration. In the stable sleep condition, participants will be asked to keep the same bedtime and wake-time schedule without deviation. Blood pressure, blood vessel vasodilatory function, and cardiovascular responses to exercise will be our main outcome variables. These variables will be measured before (on day #13) and after (on day #14) one night of sleep deprivation.||||
33994168|NCT05608642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994169|NCT05582915|||OTHER||PROSPECTIVE|||||||
33994170|NCT05143047|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomized to control or intervention group.||||
33994171|NCT02220049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994172|NCT00205777|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34085967|NCT04492943|||COHORT||RETROSPECTIVE|||||||
34085968|NCT02130999|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34085969|NCT02706574|||COHORT||PROSPECTIVE|||||||
34085970|NCT04050033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085971|NCT01576614|||COHORT||PROSPECTIVE|||||||
34085972|NCT02983123|||COHORT||PROSPECTIVE|||||||
34085973|NCT02585440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779696|NCT06605677|||OTHER||CROSS_SECTIONAL|||||||
33779697|NCT04973618|NA|SINGLE_GROUP||TREATMENT||NONE||APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.||||
33779698|NCT03633903|RANDOMIZED|PARALLEL||PREVENTION||NONE||Adolescents are randomly assigned to either a mindfulness intervention or no intervention.||||
33691100|NCT04916210|||COHORT||PROSPECTIVE|||||||
33691101|NCT05162170|||COHORT||RETROSPECTIVE|||||||
33691102|NCT00728052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33691103|NCT04376177|||COHORT||CROSS_SECTIONAL|||||||
33691104|NCT06067009|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Statistician||t|f|t|t
33691105|NCT06475339|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33691106|NCT06400979|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||To collect a sample of one hundred adult patients admitted to an acute care medical surgical unit. A quasi-experimental study with a single-arm pre-/post-test design evaluated one-time use of inhaled aromatherapy on hospitalized adults on an acute care unit. Pre-test tools included a numeric pain rating scale, facial anxiety scale and 0-5 nausea scale by Halpin et al. Aromatherapy (Elequil aromatabs) was administered for 8 hours. Sleep, satisfaction, well-being, and concurrent medication use were assessed post-aromatherapy.||||
33691107|NCT02861131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33691108|NCT02140632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691109|NCT06643026|||COHORT||PROSPECTIVE|||||||
33691110|NCT05307731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691111|NCT05422612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The overall 2-stage randomization scheme will be implemented by an unblinded statistician who is otherwise uninvolved in study operations. Participants will be assigned a study number at Screening (Subject ID). In the first stage of randomization, eligible participants who complete screening will be randomly assigned to an open platform cohort for which they are eligible (both site PIs and participants are aware of the cohort assignment) and, within that cohort, the second stage of randomization is to intervention vs placebo (double-blind) using Interactive Response Technology (IRT).~For this APT, participant assignment to a cohort will not be blinded. The tablets/capsules used in the cohorts may not be visually similar between cohorts and blinding to cohort assignment is not necessary to avoid bias. However, within each cohort, participants, site personnel, contract research personnel and the sponsor will be blind to treatment assignment (intervention vs. placebo)."|Multiple interventions will be tested in this adaptive platform trial and each will be described in Master Protocol cohort-specific platform appendices.|t|t|t|t
33691112|NCT04455360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Patient reported outcomes at 6-months post-hospital discharge|||||
33691113|NCT00004637|RANDOMIZED|||TREATMENT||DOUBLE||||||
33691114|NCT05927324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779699|NCT03859700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779700|NCT05963867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779701|NCT00680693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779702|NCT01477788|||COHORT||RETROSPECTIVE|||||||
33779703|NCT04270513|||COHORT||PROSPECTIVE|||||||
33779704|NCT04044794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779705|NCT03725943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Dreem||||
33779706|NCT01472627|||CASE_ONLY||PROSPECTIVE|||||||
33779707|NCT02173353|||CASE_ONLY||PROSPECTIVE|||||||
33779708|NCT02014610|||COHORT||PROSPECTIVE|||||||
33779709|NCT05927961|||CASE_CONTROL||PROSPECTIVE|||||||
33779710|NCT05703347|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Investigators will be blinded, except the psychologist on the team who needs to train and direct the virtual study visit delivery for one of the intervention components.|A computerized random number generated by the Way to Health platform will assign children to 1 of 16 study conditions for a 6-month intervention period. The study conditions differ with respect to: sleep goal (fixed or modifiable), digital sleep guidance (active or active with virtual study visit), parent-directed incentive (inactive or active), and personalized feedback (inactive or active). Our design includes one constant: all participants need to self-monitor their sleep duration by wearing the sleep tracker to allow for daily capture of sleep duration and goal achievement status. The intervention period is therefore designed to test the effectiveness of 4 components, each with two levels, using a factorial design.|f|f|t|f
33779711|NCT05634889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994173|NCT05814783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994174|NCT03572335|||COHORT||PROSPECTIVE|||||||
33994175|NCT03498235|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33691115|NCT02427620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691116|NCT02852213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691117|NCT05838625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691118|NCT03470571|||COHORT||RETROSPECTIVE|||||||
33691119|NCT05109975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691120|NCT00124488|||CASE_ONLY||RETROSPECTIVE|||||||
33691121|NCT06709300|||COHORT||PROSPECTIVE|||||||
33691122|NCT04690582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691123|NCT06745297|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"Part 1a of this trial is a randomized, single-blind, and placebo-controlled. Part 1b of the trial is randomized, open-label, and with a two-way crossover design.~Part 2 of the trial is single-blind, randomized, and placebo-controlled."|"This trial will be conducted in 2 parts: Part 1 (single doses) and Part 2 (multiple doses). Part 1 comprises of 2 subparts: Parts 1a and 1b.~Part 1b starts only after the dose has been tested in part 1a and was safe and of acceptable tolerability.~Part 2 of the study will only commence after the successful administration of the planned dose to the last subject in part 1a."|t|f|f|f
33691124|NCT05633004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective||||
33691125|NCT06745271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691126|NCT04018183|||CASE_ONLY||RETROSPECTIVE|||||||
33691127|NCT06638294|||COHORT||PROSPECTIVE|||||||
33691128|NCT06712628|||COHORT||PROSPECTIVE|||||||
33691129|NCT00457366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691130|NCT04704336|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33691131|NCT06409403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994176|NCT03783897|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33779712|NCT02455479|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33691132|NCT06480981|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33691133|NCT05367336|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691134|NCT00729599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691135|NCT05189639|||COHORT||PROSPECTIVE|||||||
33691136|NCT01314157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Os pacientes selecionados foram alocados de forma aleatória através da lista de randomização gerada por computador, foram confeccionados envelopes lacrados e opacos utilizados para manter o segredo de alocação. Todos foram submetidos à avaliação inicial (T0), com 20 dias (T20) e com 45 dias (T45), por um avaliador cego.|Alocados de forma cega para o grupo de intervenção: 27 pacientes com diagnóstico de lombalgia crônica realizaram o Isostretching e uso de diclofenaco em caso de dor e grupo controle:27 pacientes com lombalgia crônica sem atividade física com uso apenas de diclofenaco em caso dedor Todos foram submetidos à avaliação inicial (T0), com 20 dias (T20) e com 45 dias (T45), por um avaliador cego. Os pacientes foram instruídos nos dois grupos, pelo médico, a utilizar o diclofenaco de sódio 50mg, a cada oito horas de acordo com a dor.|f|t|f|t
33691137|NCT06594068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691138|NCT00765024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691139|NCT02872571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691140|NCT05922553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691141|NCT00403403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691142|NCT00843726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779713|NCT05014620|||COHORT||PROSPECTIVE|||||||
33779714|NCT01712685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779715|NCT01982071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779716|NCT03972423|||COHORT||PROSPECTIVE|||||||
33779717|NCT03699124|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33779718|NCT04261920|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with colorectal cancer diagnosed by histopathological examination; patients after radical resection of colorectal cancer confirmed by histopathological examination, staged as high-risk II stage||||
33779719|NCT00250419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779720|NCT04435080|||COHORT||RETROSPECTIVE|||||||
33779721|NCT03522428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized clinical trial|f|t|f|f
33779722|NCT06697587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779723|NCT06301399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779724|NCT03087721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779725|NCT02548195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913202|NCT06128590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researcher responsible for administering FBM will be aware of the assigned interventions for each participant. Participants will remain unaware of the specific treatment they receive, as the treatment is standardized across both groups, with FBM being simulated in the control group. The outcome assessor will also be blinded to the interventions. Group identifications will be revealed only after the statistical analysis|To randomly allocate participants into the experimental groups, a draw was conducted with 50 numbers using the Sealed Envelope website: https://www.sealedenvelope.com. The distribution was identical (1:1) for both groups, using a blocked design.|t|f|t|t
33913203|NCT00458406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913204|NCT01552382|||COHORT||RETROSPECTIVE|||||||
33691143|NCT05696769|||CASE_ONLY||PROSPECTIVE|||||||
33691144|NCT06087614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691145|NCT04007432|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691146|NCT05952492|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33691147|NCT04759027|||OTHER||PROSPECTIVE|||||||
33691148|NCT03893331|||CASE_ONLY||PROSPECTIVE|||||||
33691149|NCT01514500|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33691150|NCT05274139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691151|NCT06743724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691152|NCT04525443|||CASE_CONTROL||PROSPECTIVE|||||||
33691153|NCT04597008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691154|NCT01682668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691155|NCT05638477|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691156|NCT00844818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691157|NCT04391413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779726|NCT04652895|||COHORT||PROSPECTIVE|||||||
33913205|NCT04343079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913206|NCT02557386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913207|NCT02390115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913208|NCT06454604|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group randomized trial||||
33994177|NCT06308484|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33779727|NCT05879874|||COHORT||PROSPECTIVE|||||||
33779728|NCT04979390|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||SHR-1316 administrated intravenously (IV) at protocol defined dose levels||||
33779729|NCT01031043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779730|NCT04019522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779731|NCT06137313|||COHORT||PROSPECTIVE|||||||
33779732|NCT05144815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779733|NCT00717119|||COHORT||RETROSPECTIVE|||||||
33779734|NCT03282019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779735|NCT01029600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779736|NCT04440969|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33779737|NCT01745874|||COHORT||PROSPECTIVE|||||||
33779738|NCT04089176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33779739|NCT06339112|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled experimental study||||
33779740|NCT00410384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779741|NCT00298935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33779742|NCT02365896|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779743|NCT01272011|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779744|NCT06085092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779745|NCT02393261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691158|NCT02425644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691159|NCT05933070|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|Participants will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 in addition to supportive care. Three cohorts, comprised of at least 3 participants, are planned. Each participant will be screened up to 28 days prior to treatment. After participants have received all doses, they will be reviewed at Day 29 and Day 43 and then followed up with monthly clinic appointments for the following 3 months (Days 73 and 119) for clinical assessment and blood tests. Once Day 119 visit is completed this classifies end of study for the participant. The trial will end after data collection has been completed for each trial participant.||||
33779746|NCT01359410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant's were blinded to the results of the randomization for 6 weeks.||t|f|f|f
33779747|NCT03968991|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779748|NCT04822298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779749|NCT03738579|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study model is modified psuedo-factorial design with a parallel base. The Next Science treatment arm (using TorrentX Wound Wash and BlastX Wound Gel) is compared against 2 controls, one using a standard dressing and another using a standard dressing with an antimicrobial component.||||
33691160|NCT03904615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Parallel randomized double blind phase 1 trial of 3 interventions|t|t|t|t
33691161|NCT01375426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691162|NCT04354727|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779750|NCT06116643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779751|NCT03232190|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779752|NCT02162732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913209|NCT00556218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913210|NCT00319228|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913211|NCT01085058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913212|NCT04698616|||COHORT||PROSPECTIVE|||||||
33913213|NCT04387136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913214|NCT03272945|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33913215|NCT01503476|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33913216|NCT03191006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33913217|NCT01473810|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33913218|NCT01822041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913219|NCT03531177|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised model, two arms. Intervention assessed against control.||||
33913220|NCT01838967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913221|NCT04222439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913222|NCT02669550|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
33913223|NCT03498417|||COHORT||CROSS_SECTIONAL|||||||
33913224|NCT06378294|||COHORT||PROSPECTIVE|||||||
33913225|NCT06553378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|f|f|f|t
33913226|NCT01025817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913227|NCT05998954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913228|NCT00632541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913229|NCT02731391|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913230|NCT04772599|||OTHER||PROSPECTIVE|||||||
33913231|NCT01794819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913232|NCT01316991|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33913233|NCT02511951|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33913234|NCT04907006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994178|NCT06561477|||COHORT||PROSPECTIVE|||||||
33779753|NCT02401399|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779754|NCT00902382|||COHORT||PROSPECTIVE|||||||
33779755|NCT04243447|||COHORT||PROSPECTIVE|||||||
33779756|NCT00050401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779757|NCT05759806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779758|NCT00082290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779759|NCT04094909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913235|NCT01694576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913236|NCT03699631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913237|NCT04339569|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33913238|NCT04070352|||CASE_ONLY||PROSPECTIVE|||||||
33913239|NCT06043206|||CASE_CONTROL||RETROSPECTIVE|||||||
33913240|NCT00002833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913241|NCT06100640|||COHORT||RETROSPECTIVE|||||||
33913242|NCT01413984|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33913243|NCT00169988|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33913244|NCT01154972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913245|NCT04940871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded||t|t|t|t
33913246|NCT06552442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The main study group receives intracoronary methylprednisolone for the no-reflow phenomenon. The control group does not receive any pharmacological intervention. Considering that this complication is very rare, the control group was selected retrospectively.|f|f|t|f
33913247|NCT02123563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913248|NCT01405846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913249|NCT02691650|||CASE_CONTROL||PROSPECTIVE|||||||
33913250|NCT04729582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized placebo-controlled clinical trial|t|t|t|t
33913251|NCT02040883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913252|NCT02132234|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33913253|NCT04863014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913254|NCT05209932|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators were not aware of whether the participants were assigned to eNBP or the wait-list control condition.|Participants were randomized to receive an online parenting program for divorced and separated parents (N=81) or a wait list control condition (N=50)|f|f|t|f
33994179|NCT01484912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994180|NCT02466451|||CASE_ONLY||PROSPECTIVE|||||||
33994181|NCT05173350|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33691163|NCT06698536|NA|SINGLE_GROUP||OTHER||NONE||Study subjects are asked to stay seated while 3 successive measurements are taken with the device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).||||
33691164|NCT06659263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691165|NCT04473625|||COHORT||PROSPECTIVE|||||||
33691166|NCT04526301|||COHORT||PROSPECTIVE|||||||
33691167|NCT02780219|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994182|NCT02072096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994183|NCT02380976|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994184|NCT01066858|||COHORT||PROSPECTIVE|||||||
33994185|NCT04790526|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33691168|NCT02469376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994186|NCT03641079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994187|NCT00838136|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33994188|NCT02125461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994189|NCT03186651|RANDOMIZED|PARALLEL||OTHER||NONE|Open Lable|||||
33994190|NCT06628232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The same neonatal nurse with at least 5 years of experience will perform the interventions.~Salivary cortisol sample will be taken by the same investigator with 5 years of experience.~Salivary cortisol analysis will be performed in the laboratory by biochemistry specialists who have not seen the interventions performed on the newborn.~Babies will be video recorded before, during and after the procedure.~Video recordings will be monitored and recorded by 2 independent investigators.~Data will be analyzed by an independent statistician other than the researchers."|"Application of 3 different interventions to reduce pain during heel prick blood collection in newborns and comparison with the control group.~Control Group 1 (swaddling from mother\&amp;amp;amp;amp;amp;#39;s lap) Experiment Group 2 (swaddling from mother\&amp;amp;amp;amp;amp;#39;s lap + pacifier) Experiment Group 3 (swaddling from mother\&amp;amp;amp;amp;amp;#39;s lap + heel warming) Experiment Group 4 (swaddling from mother\&amp;amp;amp;amp;amp;#39;s lap + pacifier + heel warming)"|f|f|t|f
33994191|NCT02183311|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33994192|NCT04906538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33994193|NCT05235568|NA|SINGLE_GROUP||OTHER||NONE||||||
33994194|NCT02832921|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33994195|NCT06603675|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994196|NCT05803187|||CASE_ONLY||PROSPECTIVE|||||||
33691169|NCT01710618|||COHORT||PROSPECTIVE|||||||
33691170|NCT04353414|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33994197|NCT02193022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994198|NCT04398147|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691171|NCT02091219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691172|NCT04638673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691173|NCT04024878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691174|NCT04616027|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33691175|NCT01665612|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33691176|NCT04612790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691177|NCT05828719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical outcome assessment will be performed under blinded assessment about the allocated treatment group.|Prospective, multi-center, open-label, randomized controlled, superiority trial|f|f|f|t
33691178|NCT03315182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a dose escalation trial that will begin with the minimal efficacious dose as determined by preclinical studies and approved by the FDA. During the course of the trial, if safety is shown the dose will be escalated according to the clinical protocol.||||
33691179|NCT05366075|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33691180|NCT01190618|||CASE_ONLY||RETROSPECTIVE|||||||
33994199|NCT03889639|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33994200|NCT05512650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691181|NCT04491253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779760|NCT03824236|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779761|NCT02970747|||CASE_ONLY||PROSPECTIVE|||||||
33779762|NCT01376583|||CASE_ONLY||PROSPECTIVE|||||||
33779763|NCT05225454|||OTHER||OTHER|||||||
33779764|NCT01607970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33779765|NCT04428970|||COHORT||RETROSPECTIVE|||||||
33779766|NCT00094250|RANDOMIZED|PARALLEL||||||||||
33691182|NCT03981822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|"The aim of Part A is to determine the two best treatment regimens for evaluation of safety and efficacy in Part B. Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups (n=6/group) that will enroll progressively.~Part B of the study will begin enrollment only after the Sponsor has selected the two dose regimens in Part A, which will be called VP-102 Regimen 1 and Regimen 2.Approximately 90 subjects will be enrolled and randomized to one of four treatment arms (two treatment regimens, each with VP-102 and Placebo). Randomization will be stratified by sex so that neither gender exceeds \~60% of any treatment arm. Two of the treatment arms will be VP-102 Regimen 1 and VP-102 Regimen 2. The other two treatment arms will be placebo (Placebo Regimen 1 and Placebo Regimen 2), with corresponding durations of skin exposure matching those selected for VP-102 Regimen 1 and Regimen 2."|t|t|t|t
33691183|NCT04374968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant and investigator will be aware of treatment arm allocation. Outcomes will be assessed in a masked fashion|Parallel randomized controlled trial with a treatment and control group|f|f|f|t
33691184|NCT04417543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||100 patients divided into two groups each group 50patients|t|t|f|f
33691185|NCT06207799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691186|NCT03022227|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33691187|NCT01713387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691188|NCT06674109|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33691189|NCT02636842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913255|NCT02280928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913256|NCT06290947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|None (Open Label)|This study employs a randomized controlled trial model with a parallel assignment to evaluate the efficacy of Blood-Flow Restriction Walk Training compared to a control condition. Participants are randomly allocated into two groups: one receiving the intervention (BFR walk training) and the other serving as a control (usual walk training). This design allows for the direct comparison of outcomes between the intervention and control groups over the study period.||||
33913257|NCT01336179|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33994201|NCT02974621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994202|NCT06093984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994203|NCT02479763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994204|NCT03264521|||COHORT||CROSS_SECTIONAL|||||||
33994205|NCT06374134|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33994206|NCT01876992|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33994207|NCT01326494|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994208|NCT01127971|||OTHER||PROSPECTIVE|||||||
33994209|NCT02275143|||COHORT||PROSPECTIVE|||||||
33994210|NCT06386094|||COHORT||PROSPECTIVE|||||||
33994211|NCT02993562|||CASE_CONTROL||PROSPECTIVE|||||||
33994212|NCT01310257|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994213|NCT06115317|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Double blind cross over.|t|f|t|t
33994214|NCT01746472|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
33994215|NCT03675633|||COHORT||PROSPECTIVE|||||||
33994216|NCT00003003||||TREATMENT||||||||
33994217|NCT03115957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994218|NCT03261297|||COHORT||PROSPECTIVE|||||||
33994219|NCT06503900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994220|NCT05370807|NA|PARALLEL||TREATMENT||NONE||3 cohorts||||
33994221|NCT05249257|||CASE_ONLY||PROSPECTIVE|||||||
33994222|NCT00932841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994223|NCT03407963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994224|NCT05226702|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994225|NCT05316454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33994226|NCT05024682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994227|NCT01945307|||COHORT||PROSPECTIVE|||||||
33994228|NCT01366963|||CASE_CONTROL||PROSPECTIVE|||||||
33994229|NCT02611440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994230|NCT06324864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994231|NCT03286439|||COHORT||PROSPECTIVE|||||||
34085974|NCT05053906|||CASE_CONTROL||PROSPECTIVE|||||||
34085975|NCT05231356|||COHORT||PROSPECTIVE|||||||
34085976|NCT00647478|||COHORT||PROSPECTIVE|||||||
34085977|NCT01248455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913258|NCT02004587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913259|NCT04310150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The agent was selected using the sealed envelope system. The selected agent was prepared immediately prior to use after randomization, and was delivered to the site of bleeding via a single-barrel syringe.|In cardiac surgery, patients were randomized to receive Floseal® or Collastat® (n=40), respectively. The selected agent was applied in the operating room.|t|f|f|f
33994232|NCT05374057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants are blinded. The two chiropractor groups are single-blinded, while the two pharmacological groups are double-blinded. Chiropractor investigators are un-blinded in relation to the manual therapy they apply. Outcome assessors are blinded to group allocation of participants during the study and data analysis.|A 4-arm parallel clinical placebo randomized controlled Trial.|t|t|t|t
33994233|NCT04739358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase I - Two arms (Monotherapy and Combination therapy) with a primary endpoint of Dose Limiting Toxicity Phase II - Two arms Monotherapy Cohort: Primary endpoint is Intracranial Objective Response Rate; Combination Cohort: Primary endpoint is overall and extracranial ORR among patients treated with the combination of tepotinib and concurrent TKI.||||
33994234|NCT05746104|NA|SINGLE_GROUP||OTHER||NONE||||||
34085978|NCT06270134|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pragmatic, two-arm, parallel-group, open-label, individual-randomized, superiority trial that will be conducted in hemodialysis units across Ontario. Patients at each dialysis unit will be randomly allocated into one of two study arms in a 1:1 ratio to receive a dialysate bicarbonate concentration of either 32 or 38 mmol/L.||||
34085979|NCT03517904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085980|NCT00806377|||COHORT||PROSPECTIVE|||||||
34085981|NCT03294915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085982|NCT00911911|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34085983|NCT05005598|||CASE_ONLY||RETROSPECTIVE|||||||
33691190|NCT03442387|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33691191|NCT00083512|||COHORT||PROSPECTIVE|||||||
33691192|NCT00213408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691193|NCT04244110|||COHORT||PROSPECTIVE|||||||
33691194|NCT02163122|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691195|NCT00117286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691196|NCT01173861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691197|NCT05921318|||COHORT||PROSPECTIVE|||||||
33691198|NCT06120504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691199|NCT06744816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691200|NCT05569811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691201|NCT00166569|||CASE_CONTROL||PROSPECTIVE|||||||
33691202|NCT01155219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691203|NCT05539716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691204|NCT00928798|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33691205|NCT04205994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33691206|NCT05369403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691207|NCT03230253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691208|NCT05522387|NA|SINGLE_GROUP||TREATMENT||NONE||An Open-Label Extension of XPro1595 in Patients with Alzheimer's Disease (AD) That Have Completed a Phase 2 Study with XPro1595||||
33691209|NCT04860089|||COHORT||PROSPECTIVE|||||||
33691210|NCT00062322||||TREATMENT||||||||
33691211|NCT03239964|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33913260|NCT04915677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33913261|NCT05276050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913262|NCT00006054||||TREATMENT||||||||
33913263|NCT01928121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33913264|NCT05224869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913265|NCT00563836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913266|NCT03203889|RANDOMIZED|PARALLEL||TREATMENT||NONE||Native American participants will be randomly assigned to one of the two arms: (1) culturally adapted CRAFT or (2) twelve-step facilitation for concerned significant others (TSF-CSO). Follow ups will be conducted at 3- and 6-months.||||
33913267|NCT03194152|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel design with two intervention arms||||
33913268|NCT04912037|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33913269|NCT05147558|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single institution, phase II study||||
33913270|NCT04263142|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open label study.|Eligible participants will be randomly assigned to 1 of 2 treatment sequences (AB or BA) in Part 1 and 1 of 3 treatment sequences (CDE, DEC, or ECD) in Part 2.||||
33913271|NCT03518099|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33913272|NCT05041959|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This is a smoking abstinence manipulation. No masking is possible.|Participants will abstain from smoking for 24 hours before one MRI scan and continue smoking as usual before the other||||
33691212|NCT00568490|||COHORT||PROSPECTIVE|||||||
33691213|NCT02495233|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913273|NCT03718052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913274|NCT05909215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913275|NCT02142894|||CASE_ONLY||PROSPECTIVE|||||||
34085984|NCT02517619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34085985|NCT01897116|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33691214|NCT03376438|||COHORT||PROSPECTIVE|||||||
33691215|NCT05031598|NA|SINGLE_GROUP||OTHER||NONE||single-arm interventional study||||
33691216|NCT04327310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691217|NCT05745285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691218|NCT06112743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913276|NCT03077126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913277|NCT02754830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33913278|NCT03608553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913279|NCT01818050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691219|NCT05576129|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33779767|NCT02968940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779768|NCT05117840|||COHORT||PROSPECTIVE|||||||
33779769|NCT04603521|||COHORT||RETROSPECTIVE|||||||
33779770|NCT06405074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The Sham condition will be conducted using an interface which does not allow ultrasound energy to pass from the transducer to the target. The administration of LIFU/sham will be conducted in a double-blind fashion.|within subject, randomized, double-blind, sham-controlled trial|t|f|t|f
33994235|NCT00404963|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33779771|NCT01146808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779772|NCT04317768|RANDOMIZED|PARALLEL||OTHER||SINGLE|The statistician is blinded to groups.|"This is a cross-sectional study on a randomly selected group of children from randomly selected social homes in Jordan. Children and/or the care giver (n=500) will answer a questionnaire in an interview about his/her demographics, oral health related habits, the child general health status, the child oral health related quality of life, barriers to getting dental care, treatment needs for those children.~A thorough clinical examination will be done to these children by a mouth mirror and explorer at a suitable room in the social home. The investigators will record the baseline oral health status parameters (Caries, gingival health and presence of plaque).~For the interventions; A representative sample (25%) will be divided to two subgroups; group one (Study) and group two (Control) which will be matched for age and gender."|f|f|f|t
33994236|NCT04920279|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994237|NCT06627530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994238|NCT03721471|||COHORT||PROSPECTIVE|||||||
33994239|NCT02045849|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994240|NCT05986188|||COHORT||RETROSPECTIVE|||||||
33994241|NCT02649647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994242|NCT00367133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994243|NCT05069688|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm, open-label, pharmacokinetic and safety study||||
33994244|NCT02153203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994245|NCT04722198|NA|SINGLE_GROUP||OTHER||NONE||||||
33994246|NCT02394860|||COHORT||PROSPECTIVE|||||||
33994247|NCT06210880|||COHORT||PROSPECTIVE|||||||
33994248|NCT00197353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33994249|NCT03614039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.||t|f|t|t
33994250|NCT04651335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994251|NCT05133180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-masked study||t|t|t|f
33994252|NCT01075282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994253|NCT00167453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33994254|NCT01161420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34085986|NCT00660452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34085987|NCT06068959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34085988|NCT00959257|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085989|NCT02008656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34085990|NCT04265482|||COHORT||PROSPECTIVE|||||||
34085991|NCT05661032|||COHORT||CROSS_SECTIONAL|||||||
34085992|NCT04318197|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33779773|NCT02731404|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33779774|NCT02605499|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. Total of 83 rooms.||||
33691220|NCT05552157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Stage 1: Interventional/matching placebo; Stage 2: Open Label Potential for future interventions to be added|t|t|t|t
33691221|NCT06651970|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691222|NCT04423939|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691223|NCT06462716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691224|NCT01149811|||COHORT||PROSPECTIVE|||||||
33691225|NCT00423748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691226|NCT05695534|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691227|NCT03703596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691228|NCT04120493|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33691229|NCT04456010|||OTHER||PROSPECTIVE|||||||
33840006|NCT04000984|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Research Assistants who perform the pre- and post-assessments will not be privy to the group assignment of the participants and will not be involved in the data collection process during the duration of the intervention weeks.|Participants will be randomly assigned to receive either the treatment intervention, Mindfulness-Based Intervention, compared against an active control, the Cognitive Rehabilitation Training in parallel and both groups will also be compared against a passive control group, the Treatment as Usual, where no intervention takes place.|f|f|t|t
33840007|NCT02056626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840008|NCT05276089|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33840009|NCT01619189|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Phase II Interventional Clinical Trial (Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders)||||
33840010|NCT02917772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840011|NCT05973123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840012|NCT00513877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840013|NCT01346072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840014|NCT06227546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840015|NCT04397211|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33840016|NCT04724447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840017|NCT02984007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840018|NCT03822429|||COHORT||RETROSPECTIVE|||||||
33840019|NCT00230750|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33840020|NCT02278484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994255|NCT03155503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|subjects randomized to drug or placebo|t|t|t|t
33994256|NCT04353362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33994257|NCT04828122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34085993|NCT04600349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|During the study an endocrinologist who will be blinded to randomization groups will evaluate the biological markers of the participants at baseline, posttreatment and follow-up.||f|f|f|t
33994258|NCT03024086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994259|NCT04728542|||COHORT||PROSPECTIVE|||||||
33994260|NCT04467151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34085994|NCT03621956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34085995|NCT04174742|||COHORT||PROSPECTIVE|||||||
34085996|NCT02240329|NA|SINGLE_GROUP||||NONE||||||
34085997|NCT00177697|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34085998|NCT05572580|||COHORT||PROSPECTIVE|||||||
34085999|NCT03440905|||COHORT||OTHER|||||||
33691230|NCT03786614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person performing the data collection (rater) will be blind to the randomization of the patient for the entire duration of the study||f|f|f|t
33691231|NCT01082731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691232|NCT03454321|||OTHER||PROSPECTIVE|||||||
33691233|NCT03622749|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33691234|NCT06010836|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33691235|NCT01638819|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33691236|NCT06047301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691237|NCT03111069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691238|NCT05045573|||COHORT||RETROSPECTIVE|||||||
33691239|NCT06199726|||CASE_ONLY||PROSPECTIVE|||||||
33691240|NCT03771547|||CASE_CONTROL||PROSPECTIVE|||||||
33691241|NCT04134260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691242|NCT06313879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups: comparative experiment and control||||
33840021|NCT03731897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840022|NCT01114880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994261|NCT05393050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994262|NCT04492540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33994263|NCT04890353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086000|NCT04283318|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086001|NCT02066571|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34086002|NCT03588117|||COHORT||PROSPECTIVE|||||||
34086003|NCT01357772|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34086004|NCT02542527|NA|SINGLE_GROUP||OTHER||NONE||||||
34086005|NCT02837588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33840023|NCT05854407|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single (participant)||t|f|f|f
33840024|NCT01979705|||COHORT||PROSPECTIVE|||||||
33840025|NCT00307762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840026|NCT01478451|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33840027|NCT04283539|||COHORT||PROSPECTIVE|||||||
33840028|NCT04408053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840029|NCT00088933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840030|NCT03079297|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33840031|NCT05035147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840032|NCT03339739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086006|NCT05482334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||IP vs Placebo|t|t|t|t
34086007|NCT01262586|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994264|NCT05231603|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a randomized, double blind, placebo controlled clinical trial evaluating the effect of Ivermectin for post exposure prophylaxis among close contacts of COVID-19 positive case patient as an index case.|Randomized, double blind, placebo controlled clinical trial|t|f|t|f
34086008|NCT02606812|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33691243|NCT03961854|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A randomized, double-blinded, placebo-controlled clinical trial will be carried out with children and adolescents (8-less than 18 years old) with T1D|t|t|t|t
34086009|NCT04210518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An independent assessor blinded to the data collection was responsible for the allocation process. A list of the computer-generated number was employed to assign participants to balance training group, balance training with stroboscopic glasses group or control group.|This study was a single-blinded randomized controlled trial with two intervention groups consisted in multimodal balance training, multimodal balance training in addition to stroboscopic glasses and control group.|f|t|t|t
34086010|NCT03594006|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086011|NCT01279746|||CASE_ONLY||PROSPECTIVE|||||||
34086012|NCT06265311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086013|NCT03885973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34086014|NCT02170714|||COHORT||PROSPECTIVE|||||||
34086015|NCT01044524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086016|NCT02698293|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691244|NCT01450111|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33691245|NCT06632951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691246|NCT04643457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33691247|NCT04784104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study covers 2 groups. Supraclavicular block will be applied to the first group and infraclavicular block will be applied to the second group.|f|f|f|t
33691248|NCT04425824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691249|NCT00000434|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33691250|NCT01195077|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33691251|NCT03751228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691252|NCT05673564|||COHORT||RETROSPECTIVE|||||||
33691253|NCT03492411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor will be blinded to group allocation. Follow up data will be collected via online survey or telephone interview with survey questions. Mode of data collection will depend on participant preference|150 couples will be randomized to group allocation, intervention group or control group with use sequentially numbered opaque envelopes|f|f|f|t
33691254|NCT01515007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691255|NCT00095628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691256|NCT06256120|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Patients and those evaluating blood samples will not know which group they are in the study.|"Patients will be randomly divided into two groups: restrictive and liberal fluid replacement groups. 3 ml/kg/hour Ringer's lactate (RL) solution will be given to the group that will receive restrictive fluid replacement (Group R), and 7 ml/kg/hour RL solution will be given to the group that will receive liberal fluid regimen (Group L). Patients in both groups will receive 1.5 ml/kg/hour crystalloid fluid replacement on postoperative day 1, and oral intake will be increased on day 2.~Serum creatinine, GFR and blood urea nitrogen (BUN) values will be measured in all patients before surgery and 48 hours after removal of the renal pedicle clamp. Patients' blood and blood product replacement, vasopressor and inotrope needs will be recorded. Serum cystatin C level will be measured by taking serum samples before the surgery and at the 48th hour postoperatively."|t|f|f|t
33691257|NCT01056328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691258|NCT03491683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691259|NCT05988073|||COHORT||PROSPECTIVE|||||||
33691260|NCT02003339|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691261|NCT03624829|||OTHER||OTHER|||||||
33691262|NCT02723578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691263|NCT03905473|||COHORT||CROSS_SECTIONAL|||||||
33691264|NCT01830075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691265|NCT05512364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691266|NCT02962765|||COHORT||PROSPECTIVE|||||||
33691267|NCT04838197|||COHORT||PROSPECTIVE|||||||
33691268|NCT06455358|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33691269|NCT04268446|||OTHER||CROSS_SECTIONAL|||||||
33691270|NCT06441955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.|"A parallel study is a type of clinical study in which two or more groups of participants receive different interventions. Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial. Assignment to a group usually is randomized. Study participants are only exposed to the treatment that is assigned to the particular study arm they are enrolled in.~For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A in parallel to participants in the other group, who receive drug B."||||
33840033|NCT00819143|||||PROSPECTIVE|||||||
33840034|NCT00213200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840035|NCT05223010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33840036|NCT02209090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840037|NCT03615560|||COHORT||CROSS_SECTIONAL|||||||
33994265|NCT02408367|||CASE_CROSSOVER||PROSPECTIVE|||||||
33994266|NCT02286362|||COHORT||PROSPECTIVE|||||||
33994267|NCT01870453|||COHORT||PROSPECTIVE|||||||
33994268|NCT04193241|RANDOMIZED|PARALLEL||TREATMENT||NONE|WinPepi software will be used to randomly assign the participants into either of the two arms of intervention|142 patients will be randomly assigned into two parallel groups of 71 each for each arm of the intervention||||
33994269|NCT04286074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33994270|NCT05091151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33994271|NCT03488147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study (12 week follow-up).~Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.~Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study (12 week follow-up)."|After consent has been obtained, eligible subjects will be randomized into 1 of 3 different treatment groups designated A, B, and C, using a random number generator.|t|t|t|f
33994272|NCT04159285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994273|NCT03681470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994274|NCT01147939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086017|NCT05424341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group A: Muscle energy technique along with routine physical therapy, Group B: Counterstrain technique along with routine physical therapy|t|f|f|t
33779775|NCT05156801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Primary objective will be analyzed using nasal video endoscopy and a CT scan, by an external experts in a blinded fashion. Secondary objective will be analyzed using side-specific SNOT-22 questioner, subjects will be blinded to the treatment type.|50 chronic rhinosinusitis patients, that met the inclusion criteria will undergo randomization into ArchSinus / Propel or ArchSinus / NasoPore implantation group. Comparative treatment sides will be randomly assigned; 13 subjects will be assigned to ArchSinus (right)/ Propel (left); 12 subjects will be assigned to ArchSinus (left)/ Propel (right); 12 subjects will be assigned to ArchSinus (right)/ NasoPore (left); 13 subjects will be assigned to ArchSinus (left)/ NasoPore (right) groups.|t|f|f|t
33779776|NCT01041547|||COHORT||CROSS_SECTIONAL|||||||
33779777|NCT05943587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to the group allocation.|Randomized Controlled Trial, Modified Delphi Study|f|f|f|t
33779778|NCT00375128|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779779|NCT04848896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779780|NCT05395572|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33779781|NCT04145687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779782|NCT02081391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial was double-blinded to prevent bias. The blind was broken for the participants aged 2 years to \<18 years (Pediatric Committee of the European Medicines Agency \[EU PDCO\] set) before recruitment of the \<6 month-old subjects for the United Sates Food and Drug Administration (US FDA) set (which comprised participants from birth to \<18 years) was completed. Participants not belonging to the EU PDCO set (\<2 years old) remained blinded (as independent randomization lists were used for participants aged \<2 years old) and were unblinded only after the data base was locked for all participants from birth to \<2 years old who were included in the US FDA \<2 years population.||t|t|t|t
33779783|NCT05886738|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Participants will be fasting for 48 hours so it will not be possible to mask the intervention|||||
33779784|NCT00985075|||CASE_ONLY||PROSPECTIVE|||||||
33779785|NCT01551589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779786|NCT00735800|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33779787|NCT04265547|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33779788|NCT05450263|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33779789|NCT02942901|||COHORT||PROSPECTIVE|||||||
33779790|NCT05698355|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33779791|NCT05350995|||CASE_ONLY||RETROSPECTIVE|||||||
33779792|NCT04187911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Phase 2 Months 10-26 (17 months) To examine the research questions, and minimise bias, we propose to use a single-blind randomised controlled design, with two-groups. The aim of this phase will be to respond to what recruitment and retention rates are over 6 months and trial assessments and intervention acceptability. We will aim to recruit around 60 families.~Consenting families will be individually randomised 1:1 to DDP or SAU, stratified by site. Individuals who consent to take part will have an equal chance of being randomised to either group.~Phase 3 (27 months RCT) The third phase will continue as a single-blind individually randomised control superiority definitive trial and will examine clinical and cost-effectiveness of DDP for improving child mental health, compared to SAU. We will aim to recruit additional 180 families. All the procedures will be same as during Phase 2 as explained in details above."|f|f|f|t
33779793|NCT03780205|||COHORT||PROSPECTIVE|||||||
33779794|NCT01018043|||COHORT||PROSPECTIVE|||||||
33779795|NCT06615167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|In this study, there will be two data analysts involved. Analyst 1 will be responsible for analyzing the results generated by the ALZGUARD application, which are based on the ALZGUARD AI model. This analyst will assess whether each subject has dementia and the likelihood or probability of the diagnosis. Analyst 1 will be blinded to any clinical assessments or dianoses made by the neurologists.|"This is a single-arm, interventional clinical trial designed to evlauate the efficacy and safety of ALZGAURD, a smartphone-based digital therapeutic, in detecting dementia.~Study type: interentional (clinical trial) Masking: Single-blind (Outcomes assessor) Intervention description: The ALZGUARD application will be used by participants to assess cognitive function. Results will be compared to clinical diagnoses made by neurologists.~Primary Outcome: the accuracy of the ALZGUARD diagnosis, measured by Area Under the Curve."||||
33840038|NCT04737876|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33840039|NCT04690153|||CASE_CONTROL||RETROSPECTIVE|||||||
33840040|NCT01508949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779796|NCT04597411|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study-eligible participants with PSMA-positive, metastatic, castration resistant (mCRPC) prostate cancer will be assigned to one of three groups, A, B, and C based on their prior prostate cancer treatment history:~1. Group A: Men that have received prior cytotoxic chemotherapy and an ARPI, who Have Not been previously treated with prior 177Lu-PSMA-617 radioligand therapy or 177Lu-PSMA I\&T.~2. Group B: Men that Have Not received cytotoxic chemotherapies, ARPIs, and 177Lu-PSMA radioligand therapy or 177Lu-PSMA I\&T. Due to geographical differences in disease presentation/aggressiveness and access to treatment of mCRPC, group B participants will be enrolled only in South Africa, after medical review determines the need for therapy as part of a clinical study.~3. Group C: Men who HAVE been previously treated with 177Lu-PSMA-617 radioligand therapy or 177Lu-PSMA I\&T. Prior chemotherapy or ARPI is not required."||||
33691271|NCT06048614|RANDOMIZED|PARALLEL||TREATMENT||NONE||The treatment group will receive SE with normal saline (20-40 ml/kg/per SE) 2 times a day at 48 to 72 hrs of age at the earliest. The infant with medical instability procedure will be deferred until the infant is medically fit and intervention is continued until the infant reaches full feeds, defined as 110 ml/kg/day or yellow stools whichever is earlier. SE will be recommenced if the infant does not open bowel for 2 days before reaching full feeds. In ≤ 750 grams infant, paediatric surgeons would perform the first catheterisation with 6F catheter, insertion length will be limited to 8 cm, and saline is infused with the aid of gravity. Syringe flushing is allowed if gravity force fail to drive saline to the intestine.Two ultrasound abdominal examination will be performed and first scan will coincide with first SE in 500-750 grams infants.Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons.||||
33779797|NCT05140993|RANDOMIZED|CROSSOVER||PREVENTION||NONE||suggest a single-center, open-label, multiple-crossover trial in which all eligible patients will be enrolled, and the intervention (providing extended emotional and orientation support) will be altered every two weeks against the control, which is the current clinical practice.||||
33779798|NCT04646447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779799|NCT01084421|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33691272|NCT01043510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33779800|NCT01600950|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33779801|NCT01996644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691273|NCT02812355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33691274|NCT03845374|RANDOMIZED|PARALLEL||TREATMENT||NONE||"40 patients will be randomized to one of the following 2 groups:~* Treatment Group 1: Conventional treatment of topical Antibiotics+ Hyper-CL lens~* Treatment Group 2: Conventional treatment with topical Antibiotics"||||
33691275|NCT05675982|NA|SINGLE_GROUP||OTHER||NONE||||||
33779802|NCT02689271|||COHORT||PROSPECTIVE|||||||
33779803|NCT03875495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779804|NCT04391075|||COHORT||PROSPECTIVE|||||||
33779805|NCT06564831|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will evaluate the efficacy of a single layer amniotic membrane (SLAM) and standard of care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).||||
33779806|NCT06478719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33779807|NCT02022514|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779808|NCT03016013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779809|NCT04002479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779810|NCT03138083|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A modular, multi-arm, multi-part, first time in patient study||||
33779811|NCT06697470|||COHORT||PROSPECTIVE|||||||
33779812|NCT06697912|||OTHER||OTHER|||||||
33779813|NCT03362619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779814|NCT00328185|||||RETROSPECTIVE|||||||
33779815|NCT05874999|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33779816|NCT04427722|||COHORT||CROSS_SECTIONAL|||||||
33779817|NCT05553561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779818|NCT06119087|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single-center, single-arm feasibility pilot study of in 20 patients with ALS.||||
33779819|NCT04627883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel Assignment|t|f|f|f
33779820|NCT06176612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779821|NCT03697226|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779822|NCT05128279|||CASE_CONTROL||RETROSPECTIVE|||||||
33779823|NCT00365417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779824|NCT00826423|||CASE_ONLY||PROSPECTIVE|||||||
33779825|NCT06339047|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled experimental study||||
33779826|NCT03205020|||CASE_CONTROL||PROSPECTIVE|||||||
33779827|NCT01120574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779828|NCT05256303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779829|NCT04482855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, wait-list control||||
33840041|NCT02604823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840042|NCT02279212|||OTHER||PROSPECTIVE|||||||
33840043|NCT04168983|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single centre, comparative, controlled randomized study||||
33840044|NCT04938570|||COHORT||PROSPECTIVE|||||||
33840045|NCT03085823|||COHORT||PROSPECTIVE|||||||
33840046|NCT04055090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Long term, prospective, non-interventional, safety extension study of phase 3 trial. Double blind, randomized, placebo-controlled, multicenter study/|t|t|t|t
33840047|NCT03843697|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study will assess the effect of adding an app which reminds to take an approved therapy in patients who are already on the drug without a change of the physician's predetermined regimen||||
33913280|NCT04897555|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33913281|NCT01062594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913282|NCT05705570|NA|SINGLE_GROUP||TREATMENT||NONE||"A phase I study, with a 3+3 dose escalation design"||||
33913283|NCT06083246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913284|NCT05027529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"masking by using a black-box; the control group only receives a regular ECMO tube"|prospective, randomized, controlled, blinded, monocenter trial|t|t|t|t
33913285|NCT02194101|||COHORT||PROSPECTIVE|||||||
33994275|NCT03311061|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Students are masked through|Two groups of participants. group A will receive the DREAMS Curriculum intervention. Group B (Control group) will receive curriculum already in place at school.|t|f|f|f
33779830|NCT06614322|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|This study will be double-blinded, that is, the participants, study staff, and statisticians will be blinded to the treatment assignments until the study data are locked and primary analyses have been performed. Unblinding of individual treatment sequence during the study is discouraged. However, the PI at a site may break the blind for a subject in the event of a medical emergency, where knowledge of the subject's treatment sequence must be known in order to facilitate appropriate emergency medical treatment.||t|t|t|t
33840048|NCT00002687||||TREATMENT||||||||
33994276|NCT03711760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single center, blinded assessor, controlled, randomized, intention to treat.|f|f|f|t
33994277|NCT05909358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blinding to be done|A phase I/II double blind randomized clinical trial|t|t|t|f
33994278|NCT03135236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994279|NCT02336087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994280|NCT04356508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994281|NCT04099758|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will be randomised and complete the study, including outcome measures, through an automated online programme, without involvement of the researcher.|Randomized controlled study.|f|f|t|t
33994282|NCT02673762|||OTHER||PROSPECTIVE|||||||
33994283|NCT05550064|NA|SINGLE_GROUP||PREVENTION||NONE||Pregnant women will receive an intervention for structured contraceptive counseling from participating clinics. Follow-up will be through e-surveys at 6, 12, 18, and 24 months postpartum||||
33994284|NCT05219864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will receive ruxolitinib cream (1.5%) or vehicle cream for 16 weeks, after which they will be offered the opportunity to receive ruxilitinib cream (1.5%) in the open-label treatment extension period for another 16 weeks.|t|t|f|t
33994285|NCT06331715|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33994286|NCT00066391||||TREATMENT||NONE||||||
33994287|NCT03575650|||COHORT||PROSPECTIVE|||||||
33994288|NCT00705003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994289|NCT01464450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994290|NCT01111448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994291|NCT04466111|||OTHER||PROSPECTIVE|||||||
33994292|NCT03914365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Five regional anesthesia experienced anesthesiologists not involved in the subsequent intraoperative or postoperative care of the patient will perform blocks. Pain scores using the FLACC score(16) will be recorded in the PACU and ambulatory step down unit at 5, 30, 60 and 120 minutes postoperatively by trained and blinded nurses.|Randomized blinded parallel assignment|t|t|t|t
33994293|NCT05698589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994294|NCT03810963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The hypothesis for our research aim is that combining RG-HIIT-FES cycling with nutritional counseling will be more effective than nutritional counseling alone for reducing obesity and enhancing cardiometabolic health markers in persons with chronic SCI. This will be tested using a subject-matched controlled pre-post design. The experimental group receives 30 minutes of RG-HIIT-FES cycling three times per week for eight weeks and nutritional counseling over the telephone for 30 minutes one time per week for eight weeks. The control group receives the nutritional counseling only.||||
33994295|NCT05504902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994296|NCT02193763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994297|NCT06525259|||COHORT||PROSPECTIVE|||||||
33994298|NCT05457985|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The primary outcome, the Clinician-Administered PTSD Scale (CAP-5), will be administered by a blinded, study team member.|"All eligible participants will initially be randomized to one of the two first-stage options, either PE-PC or PTSD coach with clinician support. Participants that have experienced less than a 15-point reduction, have a PCL score of greater than 60 (very severe), or cannot be reached for assessment will be classified as slow responders and will be re-randomized to one of two second-stage tactics, either (a) continue in their first-stage treatment strategy, or (b) step up to full PE. Participants who have experienced at least a 15-point symptom reduction or have a PCL score of less than 29 will be classified as early responders and will step down to a lower intensity of their current treatment strategy (i.e., early responders will not be re-randomized)."|f|f|f|t
33994299|NCT06249139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994300|NCT00233415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994301|NCT00729976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994302|NCT02172781|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33994303|NCT00919737|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994304|NCT05119504|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"Individuals conducting study assessments will remain masked to treatment condition.~Interventions have been matched for time, so that masked assessors are unable to note a discrepancy in treatment condition throughout study procedures. Intervention staff will be responsible for preparing the room with materials and for relocating participant from intervention room back to the assessment room so that the masked assessor is not able to view any materials left behind from the treatment condition. Participants will be reminded by study staff throughout study procedures that they should not disclose their treatment condition or information about their intervention meeting that could inform masked staff of randomization."||f|f|f|t
33994305|NCT00829309|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33994306|NCT05609981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33994307|NCT05125315|||COHORT||PROSPECTIVE|||||||
33994308|NCT01366781|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33994309|NCT06558955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33994310|NCT03420053|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913286|NCT03282357|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Split-face|t|f|f|t
33913287|NCT04549597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913288|NCT05347069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913289|NCT03742401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a multicentrer, crossover study with cluster randomization. In the cross over design, 1/2 of the centers are randomized to start the trial with HIFU and the other 1/2 with surgery. In the cluster randomized crossover (CXRO), all participating cluster receive both the intervention and control in a sequence determined at random||||
33913290|NCT03562585|||CASE_ONLY||PROSPECTIVE|||||||
33913291|NCT04013438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913292|NCT04778267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomization table created by a researcher who is not involved in the study. The researcher will assign the random ID to each patient and a blinded anesthesiologist will use this ID while collecting the postoperative data in the surgical ward. The block interventions of this study will be done by the same anesthesiologist (well trained to use US-guided regional techniques) while pre-operative and postoperative data collection will be done by another anesthesiologist blinded to the study.|The effectiveness of combined ultrasound guided erector spinae and pectointercostal fascial plane blocks versus ultrasound guided thoracic paravertebral block in controlling perioperative pain in modified radical mastectomy, a blinded randomized controlled trial|t|f|f|t
33994311|NCT01726491|||COHORT||PROSPECTIVE|||||||
33913293|NCT03136185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913294|NCT03503149|||COHORT||PROSPECTIVE|||||||
33913295|NCT01754220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913296|NCT00731393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913297|NCT03392753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An internet-based randomisation service will be used Outcome assessors will be blinded as to treatment offered||t|f|f|t
33913298|NCT00004993|RANDOMIZED|||TREATMENT||DOUBLE||||||
33913299|NCT05966766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913300|NCT01847664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913301|NCT03796091|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled clinical trial with 3 treatment interventions||||
33913302|NCT05526794|||COHORT||CROSS_SECTIONAL|||||||
33913303|NCT02061722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913304|NCT00139334|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33913305|NCT05420688|||COHORT||PROSPECTIVE|||||||
33913306|NCT06420648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 arm randomized controlled trial|t|f|t|t
33913307|NCT04638140|||OTHER||RETROSPECTIVE|||||||
33913308|NCT01035255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913309|NCT03185455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will be a randomized, two arm trial. Patient will be randomized to usual one time office visit based blood pressure check or to text-message based remote surveillance for two weeks. Randomization will be performed using a computer generated sequence using REDCAP. Demographic information will be collected from those who decline randomization or are ineligible in order to assess patient characteristics of those willing to be randomized and who meet eligibility.||||
33994312|NCT00443391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994313|NCT01923909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994314|NCT02442687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994315|NCT06627062|||COHORT||RETROSPECTIVE|||||||
33994316|NCT06183788|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086018|NCT00833755|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34086019|NCT00221780|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34086020|NCT02654678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086021|NCT06515990|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34086022|NCT01859039|||COHORT||PROSPECTIVE|||||||
34086023|NCT02230163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086024|NCT04551508|||COHORT||PROSPECTIVE|||||||
34086025|NCT03057574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086026|NCT04550299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086027|NCT06317012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779831|NCT03172793|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This pharmacokinetic study uses a sequential, adaptive design to determine the pharmacokinetics and safety/tolerability of increasing weight based doses of telavancin. During Arm 1, participants will receive 7.5 mg/kg daily. Upon completion of data collection and assessment of safety/tolerability, Arm 2 participants will receiving 10 mg/kg daily. After completion of Arms 1 and 2, a preliminary pharmacokinetic and pharmacodynamic analysis will be conducted. These results, combined with the safety/tolerability of the 10mg/kg dose, will provide decision support to select a PK/PD optimized dose for Arm 3.||||
33779832|NCT00855192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779833|NCT01161160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33779834|NCT03727360|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants and outcomes assessors are masked to APOE genotype. We do not share any data with care providers.||t|t|f|t
33779835|NCT05172999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779836|NCT02376933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994317|NCT00918645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994318|NCT02332967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994319|NCT01776138|||OTHER||PROSPECTIVE|||||||
34086028|NCT01721798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086029|NCT00064311||||SUPPORTIVE_CARE||NONE||||||
34086030|NCT03229499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086031|NCT02832713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086032|NCT06169722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34086033|NCT03365570|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34086034|NCT04970940|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086035|NCT01517217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086036|NCT04942067|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation and dose expansion after MTD||||
34086037|NCT01939678|||CASE_CONTROL||PROSPECTIVE|||||||
34086038|NCT00637013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086039|NCT05863442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34086040|NCT01637168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086041|NCT06532305|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33691276|NCT01482351|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Persons collecting and analyzing neurocognitive data were blinded to participants' CPAP adherence.|Memories 1 was originally designed as a 6-month double-blind randomized controlled pilot trial of active versus placebo CPAP followed by a 6-month open label trial. However, after 1 year of recruitment of 371 individuals, no one consented to be randomized. Both older adults with MCI and their physicians perceived the placebo arm as an unnecessary risk. Although CPAP eliminates OSA, it must be consistently used for at least 4 hours per night for a therapeutic response, and only 30-60% of individuals prescribed CPAP adhere to it. The investigators, the study Data Safety Monitoring Board, and the NIH approved a change to a quasi-experimental study with 2 comparison groups: 1) an MCI, OSA, and CPAP adherent group (MCI+CPAP, ≥4 hr mean CPAP use per night for 1 year); and (2) an MCI, OSA, CPAP non-adherent group (MCI-CPAP, \<4 hr mean CPAP use per night for 1 year). The final sample at 1 year consisted of 54 older adults with MCI: (1) MCI+CPAP, n = 29; and (2) MCI-CPAP, n = 25.|f|f|f|t
33691277|NCT06553027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691278|NCT06701721|NA|SEQUENTIAL||TREATMENT||NONE||Multiple Ascending Dose||||
33691279|NCT01763671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691280|NCT04490824|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The participant will not be informed as to whether the item that is first received is KELEA emitting or inactive. If requested an active item will be sent following receipt of the post inhalation results.|Participants will be sequentially assigned to receive KELEA activated or KELEA depleted water|t|f|f|f
33691281|NCT06628908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691282|NCT06604715|NA|SEQUENTIAL||TREATMENT||NONE||||||
33691283|NCT06247683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691284|NCT04856202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized pilot study||||
33691285|NCT01175837|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33691286|NCT02105766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691287|NCT06532591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691288|NCT02772679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691289|NCT00630695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913310|NCT00469755|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33913311|NCT03412318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913312|NCT04811521|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33913313|NCT02822339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913314|NCT01763281|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33913315|NCT03737006|||COHORT||CROSS_SECTIONAL|||||||
33913316|NCT02076256|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33913317|NCT03153735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subject blind||t|f|f|f
33913318|NCT02986893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913319|NCT04264455|||COHORT||PROSPECTIVE|||||||
33913320|NCT02445924|||CASE_CONTROL||PROSPECTIVE|||||||
33691290|NCT04503694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913321|NCT02942849|||COHORT||PROSPECTIVE|||||||
33913322|NCT01962714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913323|NCT01223872|||COHORT||OTHER|||||||
33913324|NCT05271019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the professionals in charge of measuring the pre- and post-intervention outcomes nor the statistician are aware of the assignment.|Parallel assignment|f|f|t|t
33913325|NCT06411119|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The researcher who completed the data analysis (JR) was blinded to the participants and specifics of the intervention.|This study employed a pre- and post-cohort model, where participants' heart rate, perceived exertion, and technology acceptance were assessed before and after a 20-minute session of Virtual Reality exergaming.||||
33913326|NCT02645058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913327|NCT01672021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913328|NCT00205725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913329|NCT02537314|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33913330|NCT01325831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913331|NCT01545908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913332|NCT05722145|||COHORT||RETROSPECTIVE|||||||
33913333|NCT04436224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086042|NCT00299039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086043|NCT05220488|||CASE_CONTROL||RETROSPECTIVE|||||||
33691291|NCT03224052|||COHORT||PROSPECTIVE|||||||
33691292|NCT05222243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913334|NCT05194293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913335|NCT05112016|||COHORT||PROSPECTIVE|||||||
33913336|NCT04861480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913337|NCT01749007|||COHORT||OTHER|||||||
33913338|NCT00978809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33913339|NCT05525767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913340|NCT00267332|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33913341|NCT03302416|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Baseline \[C-11\]NOP-1A scan Post-hydrocortisone \[C-11\]NOP-1A scan||||
33913342|NCT00924352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086044|NCT03349853|||OTHER||PROSPECTIVE|||||||
33913343|NCT05052775|RANDOMIZED|PARALLEL||PREVENTION||NONE|Total number of groups = 3 Group 1 has been given chlorhexidine mouthwash and group 2nd and 3rd have been given 20% and 30% aqueous extract of morus alba fruit respectively.|||||
33913344|NCT05209412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913345|NCT00678587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913346|NCT04386564|||COHORT||PROSPECTIVE|||||||
33913347|NCT03136081|||CASE_ONLY||PROSPECTIVE|||||||
33913348|NCT03555851|||COHORT||PROSPECTIVE|||||||
33913349|NCT03730883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913350|NCT02454218|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33913351|NCT04426825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913352|NCT05081648|RANDOMIZED|PARALLEL||TREATMENT||NONE||multiple-center, prospective, non-blind, parallel-group, randomized controlled||||
33913353|NCT02820376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913354|NCT04229498|||COHORT||PROSPECTIVE|||||||
33913355|NCT03161938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913356|NCT01308320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33913357|NCT00127556|RANDOMIZED|FACTORIAL||||NONE||||||
33691293|NCT06187675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|data analysis will be analysed blinded to group|pseudo randomized yoked design|f|f|f|t
34086045|NCT02785211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913358|NCT00502307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913359|NCT05286073|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE||Samples were randomly divided in 4 groups. Random sampling was done with computer generated method. There were 3 working groups comprising of 22 canals and 1 negative control group having 22 canals.|f|f|f|t
34086046|NCT00806065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086047|NCT00937339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913360|NCT04597034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group allocation for the AN-69 Oxiris membrane or the standard AN-69 membrane will be done by randomization before starting each CRRT treatment. This process will be performed through Epidat 4.2 software by one of the researchers from the Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán.|Randomized,open-label, controlled trial in critically ill patients with suspected or confirmed COVID-19 disease, AKI, and criteria for continuous renal replacement therapy initiation admitted in any of the two participating institutions. Patients meeting inclusion criteria will be randomized to receive CRRT with AN69-Oxiris membrane or standard AN69 membrane during a 72h period.|t|f|f|f
33691294|NCT05617794|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33691295|NCT05916495|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33691296|NCT06468605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913361|NCT06536335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator does not know to which group the patient who sent in the questionnaire belongs|Single-blind randomized controlled clinical trial|f|f|f|t
33913362|NCT05954416|||COHORT||OTHER|||||||
33913363|NCT01628744|||CASE_ONLY||RETROSPECTIVE|||||||
33691297|NCT00554112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691298|NCT05468151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691299|NCT00746044|||COHORT||PROSPECTIVE|||||||
33691300|NCT01720212|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33691301|NCT06344143|||CASE_ONLY||PROSPECTIVE|||||||
33691302|NCT04186481|||CASE_ONLY||RETROSPECTIVE|||||||
33691303|NCT03834272|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Dose Escalation||||
33691304|NCT05799183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study is divided into two parts: pre-test and formal test. Each experiment will have two independent cohorts of subjects who will receive the treatment(SHR-1210 before process changes and SHR-1210 after process changes，respectively), and each cohort will be followed by 192 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability.||||
33691305|NCT06733129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691306|NCT05104554|RANDOMIZED|PARALLEL||PREVENTION||NONE||Schools will be randomly assigned to weekly iron and folic acid (IFA) supplementation, daily multiple micronutrient supplements (MMS), or control. Supplementation will be conducted continuously over the course of the first year. Baseline and end-line surveys will be conducted to collect demographic information and assess outcomes. In the second year of the study, the more effective supplementation strategy (IFA or MMS) will be scaled up to all study schools and the outcomes will be re-assessed.||||
33691307|NCT04123665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33691308|NCT06693531|||COHORT||PROSPECTIVE|||||||
33691309|NCT05693844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691310|NCT04339166|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33691311|NCT03303248|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691312|NCT05692180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691313|NCT03789084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691314|NCT04310020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691315|NCT02701842|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33691316|NCT06659627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers are blinded. After 32 weeks of the last patient the researchers will be unblinded and the study will proceed as an open-label extension study.|Three intervention groups|f|f|t|t
33691317|NCT06593522|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691318|NCT06743958|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Bicentric feasibility trial||||
33691319|NCT03269461|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840049|NCT01541800|||CASE_ONLY||PROSPECTIVE|||||||
33840050|NCT02922023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913364|NCT06367868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913365|NCT03979963|||COHORT||PROSPECTIVE|||||||
33913366|NCT01442740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913367|NCT02062528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913368|NCT00005023||||TREATMENT||||||||
33913369|NCT06523452|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33913370|NCT01914419|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913371|NCT00162305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913372|NCT04336592|||COHORT||PROSPECTIVE|||||||
33913373|NCT00152815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913374|NCT03397693|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33913375|NCT05544422|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913376|NCT05628584|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33913377|NCT03369106|||COHORT||PROSPECTIVE|||||||
33913378|NCT03054077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinding occurs through the randomization. Once the assignment to either group 1 (control) or group 2 (intervention) occurs all participants, care providers and investigators will be aware of which group is which.|RCT with a control arm equivalent to current standard of care and an intervention arm that includes standard of care plus the addition of an iPad with downloaded games.|f|f|t|f
33913379|NCT04669314|||COHORT||RETROSPECTIVE|||||||
33913380|NCT05248087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913381|NCT00966758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913382|NCT04460690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913383|NCT05290142|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double (Investigator, Outcomes Assessor). Participants will not be blinded.|Interventional Study Model: Digital training intervention: delivered to all participants (pre-and-post comparison) Additional coaching intervention: two-arm, individually randomized controlled trial with parallel assignment|t|f|t|f
33913384|NCT03478319|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33913385|NCT04431154|RANDOMIZED|PARALLEL||SCREENING||NONE||Individuals who report results of a positive HIV test will be randomized 1:1 to the intervention (incentives) or control (no incentives) arm.||||
33913386|NCT04453696|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691320|NCT00806871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691321|NCT03937700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691322|NCT03485469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691323|NCT04791254|||OTHER||PROSPECTIVE|||||||
33691324|NCT03324672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33691325|NCT06419179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691326|NCT04258189|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33691327|NCT03625206|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants are told that they will be allocated to one of two intervention conditions, one which may be more effective than the other in challenging negative thought patterns. Outcome assessors are blind to the status of the participant.||t|f|f|t
33691328|NCT05227703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo-controlled|t|f|t|f
33691329|NCT06713642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691330|NCT05153473|||COHORT||OTHER|||||||
33691331|NCT04482478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Subjects are randomly assigned to either the test group or the control group according to the registered order. Subjects take investigational product or placebo for 12 weeks.~Investigational product (EDL): once a day, 2 tablets orally intake (Extract of Dolichos lablab Linne 715 mg/day) Placebo: consumed in the same way as the investigational product"|t|t|t|t
33691332|NCT02944071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691333|NCT01850264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691334|NCT05026645|||OTHER||RETROSPECTIVE|||||||
33691335|NCT05023928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691336|NCT04490109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, randomized, vehicle-controlled, randomized in a 1:1:1 ratio||t|t|t|t
33691337|NCT06168409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691338|NCT05388760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This trial will be assessor blinded (efficacy and safety assessments) to ensure an objective evaluation of efficacy and safety of the Investigational Medicinal Product (IMP). Due to differences in number of injections of IMP, blinding will only be maintained for the assessor. For the initial treatment period (Week 0-Week 16), the assessor will be a different person than the person administering the IMP. Subjects and the caregivers will be instructed that it is important for the trial results that they refrain from revealing their treatment allocation to the assessor.||f|f|f|t
33691339|NCT04409080|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691340|NCT06514443|||COHORT||CROSS_SECTIONAL|||||||
33691341|NCT05588648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691342|NCT01266941|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691343|NCT01331941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691344|NCT06735573|||OTHER||CROSS_SECTIONAL|||||||
33691345|NCT06745661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691346|NCT03534934|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||All subjects will participate in both baseline and three year follow-up visits and undergo identical interventions.||||
33691347|NCT05875467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691348|NCT00225303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691349|NCT04243109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691350|NCT02961218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691351|NCT03367741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840051|NCT03663062|||COHORT||PROSPECTIVE|||||||
33840052|NCT06530004|||CASE_CONTROL||RETROSPECTIVE|||||||
33840053|NCT05496153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840054|NCT02473289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840055|NCT02140853|||CASE_CONTROL||PROSPECTIVE|||||||
33840056|NCT03652441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840057|NCT00295815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840058|NCT05036980|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33840059|NCT05057871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691352|NCT04113382|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33691353|NCT06390059|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, single arm, multi-center, historical control pilot study.||||
33691354|NCT06066710|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33691355|NCT04798768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691356|NCT02025062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779837|NCT06697951|NA|SINGLE_GROUP||OTHER||NONE|Not possible to mask and not required for this study|This is a study to test the usability of a low-cost way to do Non-invasive Positive Pressure Ventilation using the Neovent a device in lower resourced nurseries, Neovent has already be shown to be feasible in a higher resourced setting outside the United States in newborn infants with mild to moderate respiratory distress. The study plans to use the Neovent in lower-resourced nurseries who have respiratory distress in Nigeria and Nepal whose mothers give consent. The Neovent has been approved by regulatory bodies in India where the device is being manufactured for low-resource settings and will only be used for this study in Nigeria and Nepal and thus does not fall under FDA regulation. No patients will be enrolled from the United States therefore this study will not collect data for the purpose of approval for use in the United States.||||
33691357|NCT05186428|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779838|NCT02602249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691358|NCT04581759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691359|NCT06724029|||OTHER||PROSPECTIVE|||||||
33691360|NCT06636734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691361|NCT05572190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33691362|NCT05992324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779839|NCT04237480|||COHORT||RETROSPECTIVE|||||||
33779840|NCT03356873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33779841|NCT05441020|||OTHER||CROSS_SECTIONAL|||||||
33779842|NCT02851043|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33779843|NCT03997942|||CASE_CONTROL||PROSPECTIVE|||||||
33779844|NCT01095718|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
33779845|NCT03869242|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomly controlled pivotal study will be conducted on 60 patients (randomized at a 1:1 ratio). Patients with histologically confirmed GBM will be randomized after debulking surgery or biopsy to either RT with concomitant TMZ and TTFields (200 kHz) for 6 weeks followed by up to 24 months of maintenance TMZ in combination with TTFields (experimental arm), or RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with TTFields (control).||||
33779846|NCT02341781|||CASE_ONLY||RETROSPECTIVE|||||||
33779847|NCT06614842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779848|NCT03054974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779849|NCT03483077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779850|NCT03656016|||CASE_CONTROL||PROSPECTIVE|||||||
33779851|NCT01809210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691363|NCT03355118|||OTHER||PROSPECTIVE|||||||
33779852|NCT04171804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779853|NCT03998462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Assessor are blinded to group assignment.||f|f|t|t
33779854|NCT00549497|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33840060|NCT03812029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)|Parallel assignment|t|t|t|f
33840061|NCT02303600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840062|NCT00214019|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33913387|NCT04937582|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33913388|NCT02508675|||COHORT||PROSPECTIVE|||||||
33913389|NCT04891991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33913390|NCT05474690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691364|NCT04017247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691365|NCT02012699|||COHORT||PROSPECTIVE|||||||
33691366|NCT01296243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691367|NCT04824859|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Electronic geriatric assessment platform to collect data (e.g., functional status, comorbidity, psychological health) that may better reflect health status of older adults with cancer||||
33691368|NCT02715479|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33691369|NCT06517940|||CASE_ONLY||PROSPECTIVE|||||||
33691370|NCT00611039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691371|NCT00625742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691372|NCT02464917|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691373|NCT06229782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691374|NCT06361797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and research assistants collecting data will be unaware of assigned treatment until study completion.|This study is designed as a parallel group 1:1:1 randomized controlled trial.|t|f|f|t
33691375|NCT05338151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691376|NCT03089866|||COHORT||PROSPECTIVE|||||||
33691377|NCT04248803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691378|NCT02112526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691379|NCT02675231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691380|NCT00842764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691381|NCT02606890|||COHORT||RETROSPECTIVE|||||||
33691382|NCT00533923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691383|NCT06623721|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33913391|NCT05342363|||COHORT||RETROSPECTIVE|||||||
33913392|NCT01000194|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33913393|NCT03550261|||COHORT||PROSPECTIVE|||||||
33913394|NCT01483313|||COHORT||PROSPECTIVE|||||||
34086048|NCT02072200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913395|NCT05201586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33913396|NCT02769845|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913397|NCT00306917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994320|NCT03257956|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||The RHEA device and Patient Monitor are used to monitor the heart rate (HR) and respiratory rate (RR) of participants at the same time in Test 1. The reference device and patient monitor are used to monitor the hear rate and respiratory rate of the same participant at the same time at Test 2. The two tests results will be compared and evaluated the accuracy of the two devices. And the RHEA device is used alone to evaluate the accuracy of motion and no motion.||||
33994321|NCT02258074|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33994322|NCT02653664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994323|NCT04418297|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33691384|NCT06744205|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind (participants; sites, except for those preparing/administering study intervention; and Sponsor will be blinded. Sponsor's internal safety monitoring team could be unblinded if necessary)|Dose escalation with sequential enrollment of sentinel cohorts followed by parallel enrollment of the main cohort.|t|t|t|t
33913398|NCT04415216|||COHORT||CROSS_SECTIONAL|||||||
33913399|NCT03200873|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|using a shall coil to mimic the active stimulation|crossover (real and sham stimulation) design with randomised allocation of outcome examination|t|f|f|f
33913400|NCT02679248|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33913401|NCT02279433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913402|NCT03205917|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913403|NCT04389749|RANDOMIZED|PARALLEL||OTHER||NONE||prospective comparative cohort study||||
33994324|NCT06133816|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||We will use a randomized factorial design to test the effects of different types of messaging with or without incentives on response rates to an eligibility survey.|f|f|f|t
33994325|NCT05073380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994326|NCT03169062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086049|NCT06353061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086050|NCT00314145|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691385|NCT05062044|||COHORT||PROSPECTIVE|||||||
33691386|NCT06317649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691387|NCT05350501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691388|NCT05336045|||COHORT||PROSPECTIVE|||||||
33691389|NCT04809454|||OTHER||CROSS_SECTIONAL|||||||
33691390|NCT04730167|||COHORT||CROSS_SECTIONAL|||||||
33913404|NCT01370096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913405|NCT03179592|||CASE_CONTROL||OTHER|||||||
33913406|NCT03323918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators who are involved in the testing sessions and data analysis are blind to group assignment. An investigator which is not directly involved in participant testing or data analysis takes care of the randomisation, and coordinates it with the home guidance centers that administer the intervention.|"Group 1 will receive the intervention specifically targeting social-communicative abilities (Project ImPACT).~Group 2 will receive a generic intervention, that will not focus on social-communicative skills."|f|f|t|t
33913407|NCT02808312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913408|NCT02656758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34086051|NCT03430739|||COHORT||PROSPECTIVE|||||||
34086052|NCT05545150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691391|NCT06652737|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|parasitology teams laboratory teams clinical teams|"The first study groups will assess 2 doses of vaccine, the target dose (2x10e5 PfSPZ) and a maximize-the-chances-of-breakthrough 2-fold higher dose (4x10e5 PfSPZ). These 2 doses will be assessed in adults (cohort 1). After SMC review of safety data from these two groups, the trial will proceed to older children (cohort 2) and then younger children (cohort 3).~Each age strata will receive a single immunization, except for group 1 (adults), which will receive three immunizations on days 1, 29 and 57. The reason for a single immunization is that the chance of breakthrough will diminish after the first dose due to the induction of immunity - thus, repeat doses are not expected to contribute more information. However, with group 1, second and third immunizations will be administered to be sure that there is no increase in reactogenicity with repeated dosing and also to address the hypothetical concern that the attenuation of second and third doses is different from what we expect"|t|t|t|f
33691392|NCT04509648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779855|NCT06614387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation to therapeutic subgroups will be in a 1:1 ratio.|"This is a multicenter, double-blind, randomized study to compare the safety, effectiveness and immunogenicity (antibodies against drug) of two biological drugs administered intravenously - vedolizumab (a drug not registered in pediatric patients) and infliximab (used as standard therapy), in pediatric patients with UC aged 6-18 years.~Before enrollment to the study, informed consent must be obtained from the participant's legal guardian and, additionally, from the participant aged \> 16 years before any procedures are performed."|f|f|t|f
33779856|NCT02476630|||CASE_ONLY||PROSPECTIVE|||||||
33779857|NCT05362526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779858|NCT03069469|NA|SEQUENTIAL||TREATMENT||NONE||||||
33779859|NCT02584790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779860|NCT02798094|||CASE_CONTROL||PROSPECTIVE|||||||
33779861|NCT05638230|||COHORT||CROSS_SECTIONAL|||||||
33779862|NCT05188963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779863|NCT02950545|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33779864|NCT06181877|||OTHER||CROSS_SECTIONAL|||||||
33779865|NCT03738241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913409|NCT01695057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913410|NCT03463941|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913411|NCT03111134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913412|NCT04860284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913413|NCT02393118|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913414|NCT00701727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913415|NCT05138185|NA|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33913416|NCT03697928|||COHORT||CROSS_SECTIONAL|||||||
33913417|NCT00666133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913418|NCT01881802|||COHORT||CROSS_SECTIONAL|||||||
33913419|NCT02218814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913420|NCT04396743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691393|NCT00001115||||TREATMENT||DOUBLE||||||
33691394|NCT05050682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691395|NCT06537596|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Proof-of-concept tumour targeting of 89Zr-TLX300-CDx (Part A), assessment of 89Zr-TLX300-CDx biodistribution and tumour uptake (Part B) and radiation dosimetry (Part C).||||
33691396|NCT05785104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double masking|Two groups, one group will be treated by muscle energy technique and other will be treated by myofascial release|t|f|t|t
33691397|NCT05912452|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33691398|NCT05758493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691399|NCT00174291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779866|NCT00145262|||DEFINED_POPULATION||PROSPECTIVE|||||||
33779867|NCT02728518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779868|NCT02903628|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33779869|NCT05146011|||COHORT||RETROSPECTIVE|||||||
33779870|NCT03261635|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a prospective, randomized, pilot study in 58 patients with naï ve CNV. Patients were randomized 1:1 into 2 groups: ranibizumab monotherapy (RM group) and ranibizumab plus indomethacin (RI group). All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. RI patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.||||
33779871|NCT03114046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913421|NCT00757770|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33913422|NCT00636376|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33913423|NCT02042495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086053|NCT04325997|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34086054|NCT06232096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086055|NCT02360332|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086056|NCT02815761|||COHORT||PROSPECTIVE|||||||
33913424|NCT02149836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691400|NCT06709924|||OTHER||PROSPECTIVE|||||||
33691401|NCT06161506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691402|NCT00063375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691403|NCT00400790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086057|NCT01631214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691404|NCT03122301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33913425|NCT01123122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913426|NCT06054022|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|there will be no masking except for the radiologist who compares the postoperative chest x-ray with the baseline||f|f|f|t
33913427|NCT04546386|||COHORT||PROSPECTIVE|||||||
33913428|NCT04335266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33913429|NCT03262532|||COHORT||PROSPECTIVE|||||||
33913430|NCT03330899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086058|NCT00352183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086059|NCT02721784|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086060|NCT05338463|NA|SINGLE_GROUP||OTHER||NONE||The study consists of 3 periods, a Screening/Run-in period, a treatment period, and a follow-up period.||||
33691405|NCT00270829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779872|NCT02408419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691406|NCT05551936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691407|NCT02372890|||CASE_ONLY||PROSPECTIVE|||||||
33691408|NCT04890444|||COHORT||PROSPECTIVE|||||||
33691409|NCT01520454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33691410|NCT05817279|||CASE_CONTROL||RETROSPECTIVE|||||||
33691411|NCT06340178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33691412|NCT06211049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, double-blind, multicenter, placebo-controlled|t|f|t|f
33691413|NCT06744686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691414|NCT02260674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33691415|NCT01218633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691416|NCT05744687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691417|NCT06723041|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients are blinded during intervention only and unblinded following intervention completion||t|f|f|f
33691418|NCT04322214|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||"Participants will undergo two 5-day treatment periods (COBI and placebo) separated by a 7-day washout period:~* COBI period: volunteers will receive once daily cobicistat (150 mg QD) for 5 days.~* Placebo period: volunteers will receive once-daily placebo (lactose) for 5 days. On day 5 of each treatment period, participants will receive a single oral dose of GHB (25 mg/kg)."|t|f|t|f
33691419|NCT04687774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691420|NCT05542134|||COHORT||PROSPECTIVE|||||||
33691421|NCT06684327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691422|NCT00797095|||||RETROSPECTIVE|||||||
33691423|NCT06745063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded|placebo-controlled trial|t|f|t|t
33779873|NCT05687942|NA|SINGLE_GROUP||PREVENTION||NONE||The scientific rationale for a single-arm study is based on existing data and experience associated with current approaches for managing abdominal closure. Suture techniques and mesh have been extensively studied (Deerenberg EB, 2015) (Jairam, 2017) and several clinical publications serve as historical precedents for the 1-month endpoint (Table 2). The results of this REBUILD Study will thus exist in a broad context of outcomes, allowing significant comparisons in the absence of a concomitant control group.||||
33779874|NCT06302790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The statistician in the study and the physiotherapist performing the evaluation will be blinded.||t|t|f|t
33779875|NCT00039208|RANDOMIZED|||TREATMENT||||||||
33779876|NCT01356238|RANDOMIZED|PARALLEL||||NONE||||||
33779877|NCT06042920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779878|NCT00412867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779879|NCT04223596|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial.||||
33779880|NCT01823120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779881|NCT04896905|||CASE_CONTROL||OTHER|||||||
33779882|NCT06683768|||COHORT||RETROSPECTIVE|||||||
33994327|NCT06531122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, a specially trained and qualified nurse randomly assigned participants to receive either rivaroxaban or apixaban. We prepared Sequentially numbered opaque sealed envelopes and 580 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 580. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included rivaroxaban, and Drug B included apixaban. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|we compared the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications.|f|f|t|t
33994328|NCT01897207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994329|NCT06360887|||COHORT||PROSPECTIVE|||||||
33994330|NCT03740295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994331|NCT03557203|||CASE_ONLY||RETROSPECTIVE|||||||
33994332|NCT06560567|||OTHER||CROSS_SECTIONAL|||||||
33779883|NCT04477200|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 0 will include 8 participants; eligible participants from phase 0 may continue on to phase 1.||||
33994333|NCT05054777|||COHORT||PROSPECTIVE|||||||
33779884|NCT05900999|NA|SINGLE_GROUP||OTHER||NONE||Survivors of stroke in early stages of recovery||||
33779885|NCT03793335|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33994334|NCT05646823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994335|NCT06627712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33994336|NCT06559202|||CASE_ONLY||RETROSPECTIVE|||||||
33691424|NCT00048061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691425|NCT04854642|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label trial. No masking procedure will be applied since an open-label design was considered adequate for evaluating objective measures such as pharmacokinetic parameters.|||||
33994337|NCT00669721|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33994338|NCT01634139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33994339|NCT01488435|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994340|NCT04621851|||COHORT||OTHER|||||||
33994341|NCT04547309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994342|NCT04188392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994343|NCT01168258|||||PROSPECTIVE|||||||
33994344|NCT02191059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994345|NCT02169323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994346|NCT02535923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691426|NCT03219879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691427|NCT00200733|||||PROSPECTIVE|||||||
33691428|NCT06691984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691429|NCT02524210|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
33994347|NCT06396858|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Matching placebos will be produced for rivaroxaban and colchicine.|they will be randomized, simultaneously, in a 1:1 ratio, to rivaroxaban 2.5 mg BID or placebo, and colchicine 0.5 mg QD versus placebo, in a 2x2 factorial design. Therefore, the study will have four possible groups: rivaroxaban 2.5 mg BID + colchicine 0.5 mg QD; rivaroxaban 2.5 mg BID + colchicine placebo QD; rivaroxaban placebo BID + colchicine 0.5 mg QD; or rivaroxaban placebo BID + colchicine placebo QD|t|t|t|t
33994348|NCT01901263|||COHORT||PROSPECTIVE|||||||
33994349|NCT05445180|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Research Assistant||f|f|f|t
33994350|NCT06627257|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|This is a double-blind study. Participants, investigators, study personnel performing any study-related assessments following study injection, and laboratory personnel performing immunology assays will be blinded to treatment assignment.||t|t|t|t
33691430|NCT04472260|RANDOMIZED|CROSSOVER||OTHER||NONE||"In order to compare the effect of prone position (PP) and verticalization (V) on the PaO2/FiO2 ratio (secondary objective of the study), a randomized cross-over experimental design was chosen.~Patients will be randomly assigned to one of the following 4 sequences. They will each include 4 treatment periods:~Sequence 1: PP-\>PP-\>V-\>V, Sequence 2: PP-\>V-\>V-\>PP, Sequence 3: V-\>PP-\>PP-\>V Sequence 4: V-\>V-\>PP-\>PP"||||
33994351|NCT01167829|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33994352|NCT01803594|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994353|NCT01826838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994354|NCT03552484|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994355|NCT06130215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994356|NCT04056338|||OTHER||PROSPECTIVE|||||||
33994357|NCT06194877|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34086061|NCT06516224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Subjects will be randomized in three groups and will be treated differently taking into account only the original Melasma Area Severity Index (MASI) score at baseline:~• An adaptive randomization scheme (minimization method) will be used to determine the treatment group (among the 3 available) to which eligible subjects will be enrolled in. This strategy will ensure a balance between treatment groups for one important prognostic factor, identified as 'baseline MASI'. When a new subject is eligible for randomization, the algorithm verifies the average MASI of the subjects in each group. The new subject will be allocated to a group in such a way that the imbalance is minimized among the groups."|single-center, randomised, 3 group study|t|f|t|f
34086062|NCT01757132|NA|SINGLE_GROUP||OTHER||NONE||||||
33994358|NCT03123094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779886|NCT02623556|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33779887|NCT02606669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994359|NCT00767260|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34086063|NCT02030600|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34086064|NCT01299909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086065|NCT03024567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34086066|NCT00770406|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086067|NCT02659735|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086068|NCT01075776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33779888|NCT05744869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779889|NCT04609150|||COHORT||OTHER|||||||
33779890|NCT02338258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33779891|NCT01893528|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34086069|NCT01327768|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33779892|NCT05167526|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33779893|NCT04561414|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|In this trial, single-blind method will be used, which means that the investigators know about the device used for treatment of the subjects while the subjects know nothing about it.|The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved.|t|f|f|f
33779894|NCT05361746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments will be performed by two dental examiners that are independent of the dentist that placed the restorations and are blinded to the treatment arms.|Each subject will have either two restorations (two teeth) or four restorations (four teeth) performed at the beginning of the study, with each tooth restoration using only one type of adhesive. Study teeth will be paired according to lesion depth and randomized to treatment in a 1:1 ratio with at least half of the teeth (ie, 1 tooth for Subjects with 2 eligible teeth or 2 teeth for Subjects with 4 eligible teeth) randomized to undergo restoration(s) using Scotchbond Universal Plus Adhesive (SBU+ Treatment group) and the other half of the teeth undergoing restoration(s) using Scotchbond Universal Adhesive (SBU Control group).|f|f|f|t
33779895|NCT05170542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779896|NCT04895787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher(s) who will conduct the outcome assessments will be masked from the group allocation.||f|f|f|t
33779897|NCT04831164|||CASE_CONTROL||OTHER|||||||
33779898|NCT05946876|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33779899|NCT00057811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779900|NCT03668782|||CASE_CONTROL||PROSPECTIVE|||||||
33779901|NCT04183192|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.~Subjects and staff will be blinded to treatment assignment during confinement, but route of administration will not be blinded. The blind will be maintained through a randomization schedule held by the dispensing pharmacist. Subjects and staff will be informed of a subject's end of study day when discharged from confinement. Subjects and staff will not be informed of the specific treatment arm assignment. The clinical research nurse will administer the study drugs in unit dose containers that are not transparent."|Subjects will be randomized to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (mepolizumab or reslizumab) or placebo|t|f|t|f
33779902|NCT06697249|||CASE_CONTROL||RETROSPECTIVE|||||||
33779903|NCT03860077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33779904|NCT02938728|||COHORT||PROSPECTIVE|||||||
33779905|NCT04287751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Recruiting participants undergoing overnight oximetry on a single night to have additional 4 nights of recording with a prolonged recording oximeter device||||
33779906|NCT01192087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779907|NCT05880693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality.|56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality.|f|f|t|f
33779908|NCT04535375|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Extra ultrasound images will be exported anonymized and analyses offline by two investigators independently|"All stable preterm infants born before a gestational age of 32 weeks are eligible for inclusion.~Since standard ultrasound protocol is different for preterm infants born below or after 28 weeks, two subgroups will be created."|f|f|f|t
33779909|NCT06206044|||COHORT||PROSPECTIVE|||||||
33779910|NCT02818816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779911|NCT04577820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913431|NCT03880240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913432|NCT05966974|||COHORT||RETROSPECTIVE|||||||
33913433|NCT00103805|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33913434|NCT05430581|||COHORT||PROSPECTIVE|||||||
34086070|NCT00908934|RANDOMIZED|CROSSOVER||||NONE||||||
34086071|NCT02786303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913435|NCT03340181|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33913436|NCT02069457|||COHORT||PROSPECTIVE|||||||
33913437|NCT00004879||||TREATMENT||NONE||||||
33913438|NCT05726019|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Single-center, prospective, open-label, randomized study. Patients with acute coronary syndrome, who meet criteria for surgical myocardial revascularization, will be selected and randomize, with drug addition, in the intervention group, within a maximum of 24 hours after randomization and maintained for up to 30 days after coronary artery bypass grafting.~Inclusion criteria: Individuals with acute coronary syndrome, with indication for myocardial revascularization surgery, of both genders, aged over 18 years.~Exclusion criteria: Inability to sign the informed consent form; Current use of colchicine; Current use of long-term corticosteroid therapy; Inflammatory bowel disease or chronic diarrhea; Clinically significant non-transient haematological abnormalities; Renal dysfunction, with creatinine greater than 2 times the upper limit of normality; Severe liver disease; Drug addiction or alcoholism; History of clinically significant sensitivity to colchicine."||||
33913439|NCT02843295|NA|SINGLE_GROUP||||NONE||||||
33913440|NCT01914887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913441|NCT00000513|RANDOMIZED|||TREATMENT||||||||
33913442|NCT05115279|NA|SINGLE_GROUP||TREATMENT||NONE||Type of the study: prospective descriptive study||||
33913443|NCT03591146|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||QUADRUPLE|To maintain objectiveness, the study drug will be managed and administered by an independent unblinded team. Subjects, investigators, and all other site staff who directly interact with subjects, evaluate safety and efficacy, and collect subject data, will remain blinded and must not communicate or discuss any study information with the unblinded team.|Subjects will be enrolled to each cohort in a 3:1 ratio. Each cohort will comprise subjects receiving a dose of TLC590 and active comparator drug (Naropin® 150 mg) in accordance with the randomization schedule and dose-escalation scheme.|t|t|t|t
33913444|NCT02537301|||||RETROSPECTIVE|||||||
33913445|NCT00403312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913446|NCT04317352|||CASE_ONLY||RETROSPECTIVE|||||||
33913447|NCT04886999|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Exploratory, double-blind, randomised, multicenter, 2x2 cross-over study|Exploratory, double-blind, randomised, multicenter, 2x2 cross-over study|t|t|t|t
33913448|NCT05249088|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The clinical team caring for participants will not be blinded due to nature of the intervention. The participants, their family and health personnel responsible for outcome assessment at follow-up will be blinded to the allocation of the intervention. The steering group, author group, trial statistician, outcome assessors, prognosticators, statisticians, and the trial coordinating team will be blinded to group allocation.||t|f|t|t
33913449|NCT05518734|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33913450|NCT00731263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913451|NCT03534063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913452|NCT06146296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33913453|NCT03237988|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33913454|NCT01104558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913455|NCT04136080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913456|NCT00042354|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913457|NCT05655637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913458|NCT05973994|||COHORT||PROSPECTIVE|||||||
33913459|NCT04284904|||COHORT||PROSPECTIVE|||||||
33913460|NCT00538824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913461|NCT05366972|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33913462|NCT01232894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913463|NCT04538092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913464|NCT04357041|||CASE_ONLY||OTHER|||||||
33913465|NCT03927508|NA|SINGLE_GROUP||TREATMENT||NONE||Pulse Spray and Infusion of r-tPA||||
33913466|NCT00824187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913467|NCT01237106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913468|NCT02860637|||||CROSS_SECTIONAL|||||||
33913469|NCT05249231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913470|NCT01037504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33913471|NCT01214746|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33913472|NCT03935087|||COHORT||PROSPECTIVE|||||||
33913473|NCT06395428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment allocations will be revealed only after study completion, unless there is concern for a serious adverse event in which case treatment team and patient will be unblinded. Interim analysis will be performed at 34 participants to evaluate for effectiveness and power|This is a single-center prospective randomized double-blinded non-inferiority trial with potential assessment of superiority comparing haloperidol to ketorolac for the treatment of back pain.|t|t|t|f
33913474|NCT03918603|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33913475|NCT00703755|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33913476|NCT01434888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33913477|NCT02351258|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33913478|NCT02645656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913479|NCT05397899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor will be kept blind about the group of patients and treatment received.|This will be a Pretest-Postest Control group Design with parallel assignment of patients into two groups.|f|f|f|t
33913480|NCT05468944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913481|NCT02704221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33913482|NCT00153894|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913483|NCT04949841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913484|NCT00835887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913485|NCT05005741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913486|NCT05804006|NA|SINGLE_GROUP||TREATMENT||NONE||Conventional physiotherapy followed by High-Intensity Interval training on the semi-recumbent bike||||
33913487|NCT01266655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913488|NCT02702427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913489|NCT00011713|||COHORT||PROSPECTIVE|||||||
33779912|NCT04176614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Overweight/obese non diabetic subjects will follow an energy-restricted diet and supplemented with a cereal-based snack fortified with legumes (intervention group) or a common cereal snack (control group) for 12 weeks. Body weight, anthropometric, clinical and biochemical characteristics will be evaluated at the beginning and at the end of the study.|t|f|f|t
33779913|NCT02522520|RANDOMIZED|PARALLEL||OTHER||SINGLE|Primary outcome (VO2 peak) Physiological tests assessors blinded||f|f|f|t
33779914|NCT04216433|||CASE_ONLY||CROSS_SECTIONAL|||||||
33779915|NCT06499207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779916|NCT02937844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779917|NCT05293496|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33779918|NCT03644134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779919|NCT06532552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840063|NCT03258723|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patient Recruitment:~The investigators are targeting the highest risk pre-diabetic patients for this study. Patient recruitment will occur through the involved health clinics.~Control Participants Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited from the ECHORN Cohort Study (ECS).~ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups. These participants will be offered a delayed intervention at the end of 2.5years, given the evidence supporting behavioral modification for diabetes prevention."||||
33913490|NCT03710941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913491|NCT04501679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913492|NCT00946946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913493|NCT01259856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994360|NCT03923192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||screening of the Patients who join the Conservative Dentistry Department clinic will be done until the target population is achieved. The Patients' teeth will be subjected to visual examination and diagnosis using dental charts. once the patient is eligible to be included in this study, they will be contacted by the research investigator who will explain the study and identify the patient interests .If the patient show interest ,further clarification and discussing wil be held .||||
33994361|NCT04221113|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This study will be single blinded means that patient will be unaware of protocol written inside the envolupe.|Healthy patients with only extensor tendon injuries will be recruited in this study and will randomly divided in two groups. An intervention in the form of rehabilitation will be given to patients in two different protocols than outcomes will be assessed.|t|f|f|f
34086072|NCT06477978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is cohort prospective study of end stage kidney disease patients on hemodialysis||||
34086073|NCT00722696|NA|SINGLE_GROUP||||NONE||||||
34086074|NCT06034496|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Coded devices with master key kept outside of research team.||t|t|t|f
34086075|NCT00902863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913494|NCT00646971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913495|NCT01604304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913496|NCT00715611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913497|NCT03841240|||COHORT||PROSPECTIVE|||||||
33913498|NCT00300651|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33913499|NCT05948410|||CASE_ONLY||PROSPECTIVE|||||||
33913500|NCT03820037|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913501|NCT02602938|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33913502|NCT01795898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913503|NCT05403749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913504|NCT01124201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33913505|NCT04068324|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33913506|NCT02262039|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33913507|NCT01968720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33913508|NCT04524286|||CASE_ONLY||OTHER|||||||
33913509|NCT06467643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913510|NCT05060666|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33913511|NCT01446952|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913512|NCT02605447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913513|NCT04748406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was designed as prospective, case-control and hospital-based.||||
33913514|NCT04357119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913515|NCT00039442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913516|NCT02731118|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33913517|NCT02875821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840064|NCT00953277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086076|NCT05066477|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34086077|NCT03340883|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
33840065|NCT00688129|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34086078|NCT03143023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34086079|NCT03966989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086080|NCT00383526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086081|NCT00327158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086082|NCT01277861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34086083|NCT03537833|||COHORT||PROSPECTIVE|||||||
34086084|NCT00181025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086085|NCT05662813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086086|NCT04980729|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This study is a Retrospective Cohort Study through retrospectively collecting patients undergoing acetabulum reconstruction after pelvic tumor resection. The patients were interfered with or without the acetabular navigation template during the hip reconstruction process."|f|f|f|t
34086087|NCT01125930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086088|NCT02532400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086089|NCT05237141|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086090|NCT01070680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086091|NCT03711721|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086092|NCT06180057|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34086093|NCT01089712|||CASE_ONLY||PROSPECTIVE|||||||
34086094|NCT05019677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086095|NCT04705090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691431|NCT04509102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the biostatistician conducting the randomization will know each participant's treatment condition (Adderall XR versus placebo) for the duration of the trial. Participants, psychiatrists, and technicians delivering rTMS and collecting assessments will be blinded to treatment condition (Adderall XR versus placebo). Active medication will be over-encapsulated by the UCLA Research Pharmacy to appear identical to placebo capsules. At the conclusion of all treatments, participants will be asked whether they believe they received Adderall XR release versus placebo. The blind will then be broken and participants may elect to continue medication management at the discretion of their personal psychiatrist.|i. Prior to initiation of any study activities, participants will be randomly assigned to one of two treatment conditions: Adderall XR (n=15) versus placebo (n=15). Randomization will be completed by a biostatistician from the UCLA Clinical and translational science institute (CTSI) statistics core, who will generate the randomization list with stratification and provide this list to the UCLA pharmacy.|t|t|t|f
33691432|NCT03241069|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33691433|NCT05008055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691434|NCT01887301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691435|NCT06135415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691436|NCT05832021|||COHORT||PROSPECTIVE|||||||
33691437|NCT03381573|||COHORT||RETROSPECTIVE|||||||
33691438|NCT00001431||||TREATMENT||||||||
33691439|NCT06743698|||CASE_ONLY||CROSS_SECTIONAL|||||||
33691440|NCT00234234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691441|NCT06706817|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, single-arm treatment study. Participants will be treated with tezepelumab Q4W from Week 0, with the last dose administered at Week 20||||
33691442|NCT00164229|RANDOMIZED|PARALLEL||||SINGLE||||||
33691443|NCT04351776|RANDOMIZED|PARALLEL||OTHER||NONE||90 participants assigned to one of three groups (30 participants for each group). VR- Biofeedback, VR-Distraction, 360 Video||||
33691444|NCT04476550|||CASE_ONLY||PROSPECTIVE|||||||
33691445|NCT03395054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086096|NCT02914327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086097|NCT06002204|||COHORT||PROSPECTIVE|||||||
34086098|NCT04468711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086099|NCT02679976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086100|NCT04663516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33691446|NCT01316328|||COHORT||PROSPECTIVE|||||||
33840066|NCT01022905|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840067|NCT02206061|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33840068|NCT00494520|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840069|NCT01011868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840070|NCT00737698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34086101|NCT05919134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment double-blind, randomized, two-arm parallel-group study|t|t|t|t
34086102|NCT00261521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086103|NCT03087240|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34086104|NCT03475238|||COHORT||PROSPECTIVE|||||||
34086105|NCT04603755|||COHORT||PROSPECTIVE|||||||
34086106|NCT04272229|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34086107|NCT00330889|||||PROSPECTIVE|||||||
34086108|NCT06370793|||COHORT||PROSPECTIVE|||||||
33913518|NCT04279379|NA|SINGLE_GROUP||TREATMENT||NONE||treatment with sintilimab and decitabine.||||
33913519|NCT03483506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913520|NCT05100316|NA|SINGLE_GROUP||OTHER||NONE||||||
33913521|NCT02694120|||COHORT||PROSPECTIVE|||||||
33913522|NCT01182948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913523|NCT04825236|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33913524|NCT01087411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913525|NCT00230529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33913526|NCT03614442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the design of the dental implant||t|t|t|t
33913527|NCT00032019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913528|NCT00430313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913529|NCT04827836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33913530|NCT01326169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913531|NCT03282695|||COHORT||PROSPECTIVE|||||||
33913532|NCT03515434|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33913533|NCT01591226|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33913534|NCT01502540|||COHORT||PROSPECTIVE|||||||
33913535|NCT00960934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913536|NCT05833321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"Inclusion criteria:~* Patients at least 18 years old~* Patient presenting with a diagnosis of cancer of ovarian origin with an indication for chemotherapy~* Patient with a diagnosis of endometrial cancer with an indication for chemotherapy~* Patient with no diagnosis of other types of cancer in the previous five years~* Collection of consent~* Patient affiliated to a Social Security scheme Non-inclusion criteria~* Patient with cancer of ovarian origin not requiring chemotherapy treatment~* Patient with endometrial cancer not requiring chemotherapy treatment~* Discovery of an intercurrent cancer other than skin or cervix cancers.~* Patient wearing a Pace maker"|prospective non-randomized interventional study||||
33913537|NCT04689750|||COHORT||PROSPECTIVE|||||||
33913538|NCT03440437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913539|NCT03238586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913540|NCT02080689|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913541|NCT01253044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913542|NCT00204997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913543|NCT06324994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913544|NCT03924791|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since masking is not possible for treatment with injections and oral pain medication, this is an open-label study. Outcomes are assessed by patients through online questionnaires and therefore the outcome assessor is not masked as well.|Patients will be randomized to either treatment with transforaminal epidural injection or standard oral pain medication.||||
33913545|NCT00005050||||TREATMENT||||||||
33913546|NCT02045212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691447|NCT00438438|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33913547|NCT00258102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913548|NCT02671695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33913549|NCT03664622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||ketamine versus morphine|t|f|t|t
33691448|NCT05540639|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Pregnant women born in Somalia with singleton pregnancy|f|f|f|t
33691449|NCT03923270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691450|NCT05882643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33691451|NCT03245229|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33840071|NCT03513926|||COHORT||CROSS_SECTIONAL|||||||
33840072|NCT03890003|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33840073|NCT02883595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840074|NCT06508294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|a random list was taken from randomised.org|8 week artifical intelligence based posture exercises|t|f|f|f
33840075|NCT05067153|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking due to ethical considerations. Primary outcome is biochemical.|Randomized, controlled trial with one intervention group and one control group.||||
33691452|NCT06729073|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691453|NCT06743893|||CASE_ONLY||PROSPECTIVE|||||||
33691454|NCT06394804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691455|NCT01564771|||CASE_ONLY||PROSPECTIVE|||||||
33840076|NCT03415633|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33913550|NCT01337011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Comparison of the effect of CD133pos. bone marrow derived stem cells using the intra-myocardial vs. the intra-coronary route of administration for improving left ventricular function in patients with chronic ischemic cardiomopathy.|t|f|f|t
33913551|NCT06553066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|in the assessment of the surgical field quality surgeons are blind respect the level of neuromuscular block received by patients||f|t|f|f
33913552|NCT05437341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913553|NCT03671824|||COHORT||PROSPECTIVE|||||||
33913554|NCT04496596|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33994362|NCT02376114|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33994363|NCT01354886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994364|NCT00776763|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994365|NCT06258421|||CASE_ONLY||PROSPECTIVE|||||||
33994366|NCT00869193|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33994367|NCT06562127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994368|NCT00833209|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33994369|NCT00585286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994370|NCT06560866|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single group intensive longitudinal observational study. This is not a randomized trial. All participants will receive Just Care for Families treatment.||||
33994371|NCT02284035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994372|NCT00202462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994373|NCT06626867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33994374|NCT04018768|||COHORT||PROSPECTIVE|||||||
33994375|NCT06284941|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33994376|NCT06150807|||COHORT||PROSPECTIVE|||||||
33994377|NCT04939571|||CASE_ONLY||OTHER|||||||
33691456|NCT04652232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"A randomisation list will be established. At the randomisation visit (Baseline visit 1), the Investigator will allocate a randomisation number to each subject according to the chronological order of inclusion. According to the list, the subject will be either randomized in one group of intervention.~The investigator will only dispense the study product to the subjects included and randomized."||||
33691457|NCT04437953|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase II single arm study will be an open label study examining the use of Avatrombopag.||||
33691458|NCT06706765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691459|NCT03901534|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|None (Open Label)|||||
33691460|NCT01967758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779920|NCT05436054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This is a single-blinded trial. The colonoscopist who performs the procedure and evaluates the quality of cleansing is blinded to which preparation was used. This is achieved during randomisation of the patient where they receive a paper form prescription, thus the colonoscopist cannot check that in the electronic system.~Blinding is not done to the patients as the bias is considered small. Cleansing agents are not normally used in the general population and the effect of previous experience to evaluate the tolerability in the present time is not considered to be large.~Subjects will be well informed in the participation information and in the meeting not to reveal the type of cleansing they received to the colonoscopist."|This is a single-center, single-blinded, randomised equivalence trial to compare the efficacy and tolerability of Picoprep® and Plenvu® as cleansing agents before colonoscopy. The trial is to be performed on patients referred to Frederikshan endoscopy center for a colonoscopy, most of these patients are referred to exclude/diagnose colon cancer. Colonoscopies are performed in Frederikshavn local hospital/North Jutland/Denmark by different colonoscopists.|f|f|f|t
33779921|NCT04918108|||COHORT||RETROSPECTIVE|||||||
33779922|NCT01378897|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33779923|NCT03905382|NA|SINGLE_GROUP||OTHER||NONE||Single group||||
33779924|NCT03923673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779925|NCT02897284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33779926|NCT03393520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33779927|NCT02927769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779928|NCT00649662|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33779929|NCT05398653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779930|NCT06615596|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention in this study involves two arms: patients either continue or discontinue anticoagulation therapy after successful catheter ablation for atrial fibrillation (AF). Participants in the continuation arm will receive non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, etc or warfarin tailored to their specific risk profiles. The discontinuation arm will cease anticoagulation therapy following randomization. Smart wearable devices will monitor for AF recurrence, and patients will be followed for 24 months, with primary endpoints including thromboembolic and bleeding events.||||
33779931|NCT06165107|||COHORT||RETROSPECTIVE|||||||
33779932|NCT03369951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779933|NCT01438229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779934|NCT04117061|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Open, randomized, parallel groups prospective study||||
33779935|NCT01800955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33779936|NCT05527470|RANDOMIZED|PARALLEL||TREATMENT||NONE||Induced Chemotherapy Combined With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma||||
33779937|NCT06697236|||COHORT||PROSPECTIVE|||||||
33779938|NCT01539941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779939|NCT03179540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779940|NCT04430374|||COHORT||OTHER|||||||
33779941|NCT00114959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691461|NCT06736405|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33691462|NCT06729190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691463|NCT06352424|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33779942|NCT06621329|RANDOMIZED|PARALLEL||TREATMENT||NONE||Both arms will receive standard of care medications for headache management. The intervention group will receive an SPG block at a specific threshold defined in the study protocol.||||
33779943|NCT06617962|||OTHER||CROSS_SECTIONAL|||||||
33779944|NCT00407940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779945|NCT01289184|||COHORT||CROSS_SECTIONAL|||||||
33779946|NCT00173212|||DEFINED_POPULATION||OTHER|||||||
33779947|NCT05326373|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33779948|NCT06270511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Part A will be open label; Part B will be double blind|||||
33779949|NCT06073964|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33779950|NCT02929290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779951|NCT05806099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779952|NCT03667235|||COHORT||PROSPECTIVE|||||||
33779953|NCT01697787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779954|NCT01484444|||COHORT||PROSPECTIVE|||||||
33779955|NCT05004480|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participant|Subjects had randomly divided into two groups. All will do aerobic exercise in form of treadmill but Group (A) will do while wearing surgical mask and Group (B) without surgical mask. To detect the Influence of surgical mask on functional capacity and quality of life during controlled endurance exercise in sedentary adults|t|f|f|f
33779956|NCT06614218|||COHORT||PROSPECTIVE|||||||
33994378|NCT03446768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33994379|NCT06410638|||CASE_CONTROL||PROSPECTIVE|||||||
34086109|NCT01253161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086110|NCT03630393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086111|NCT03651804|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33779957|NCT06613581|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients included in the study will be followed-up according to the home-based follow-up protocol. The PROMISE study is an implementation study, to further develop and improve home-based follow-up.||||
33779958|NCT04494321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086112|NCT06248606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994380|NCT05629728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the assessor will be blinded for the group assignment. trained research assistant will conduct the pretest and posttest measures, not involved in providing the intervention|the frail older adults recruited from the community, randomly assigned to either the experimental group or the wait-list control group.|f|f|f|t
33994381|NCT05770076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
33994382|NCT06464549|||COHORT||CROSS_SECTIONAL|||||||
33994383|NCT04626245|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized to a mindfulness training condition or treatment as usual.|f|f|f|t
33994384|NCT05444647|||COHORT||PROSPECTIVE|||||||
33994385|NCT02464657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994386|NCT01771016|||CASE_ONLY||RETROSPECTIVE|||||||
33994387|NCT05164354|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||NAfter the pre-test is applied to the experimental group, music therapy and aromatherapy will be given to the experimental groups by the researcher.|f|t|f|f
33994388|NCT03262103|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994389|NCT03033810|||COHORT||PROSPECTIVE|||||||
33994390|NCT04200586|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, observational||||
33994391|NCT02376881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33994392|NCT02579733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994393|NCT05638490|||CASE_ONLY||PROSPECTIVE|||||||
33994394|NCT00974558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994395|NCT05643677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994396|NCT01267162|||COHORT||PROSPECTIVE|||||||
33994397|NCT05418374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33994398|NCT03591458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo control|t|t|t|t
33994399|NCT06402695|||COHORT||OTHER|||||||
33994400|NCT04345653|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33994401|NCT04153877|||COHORT||PROSPECTIVE|||||||
33994402|NCT04101396|RANDOMIZED|PARALLEL||OTHER||NONE||All women with gestational diabetes are randomised to 4 or 7 points of self monitoring blood glucose.||||
33994403|NCT04118192|||COHORT||PROSPECTIVE|||||||
33994404|NCT06210620|||OTHER||PROSPECTIVE|||||||
33994405|NCT03195595|||CASE_CONTROL||RETROSPECTIVE|||||||
33994406|NCT05512104|||COHORT||PROSPECTIVE|||||||
33994407|NCT03641222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994408|NCT06258681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor will be blind to the group allocation and participants will be blind to the intervention.|This is a two-arm controlled single blind trial.|t|f|f|t
34086113|NCT01704261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994409|NCT00949143|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33994410|NCT01837914|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33994411|NCT05602766|||COHORT||PROSPECTIVE|||||||
34086114|NCT00004817||||TREATMENT||||||||
34086115|NCT01259245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086116|NCT05733338|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34086117|NCT04111302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086118|NCT02472353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994412|NCT05411913|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Everything is masked by QR code - participant and intervention|Individuals are provided with a sample of topical substance to apply to a localized region of pain.|t|t|t|t
33994413|NCT03811418|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086119|NCT02450643|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34086120|NCT00836732|NA|SINGLE_GROUP||||NONE||||||
34086121|NCT06550063|||COHORT||RETROSPECTIVE|||||||
34086122|NCT01687439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086123|NCT02943122|||COHORT||PROSPECTIVE|||||||
34086124|NCT06472921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group and a late initiation group.~Early initiation group: Treatment with Butylphthalide Sodium Chloride Injection begins within 3 hours, administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days.~Late initiation group: Treatment with Butylphthalide Sodium Chloride Injection begins between 3-6 hours, also administered at 100ml per dose, infused twice daily for a continuous period of 10-14 days."|f|f|f|t
34086125|NCT01402232|||COHORT||PROSPECTIVE|||||||
34086126|NCT02146183|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33994414|NCT05724784|NA|SINGLE_GROUP||PREVENTION||NONE||The study design is an open trial.||||
33994415|NCT02343926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994416|NCT02933658|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994417|NCT03541538|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Examiner 1 will receive the blinding outcome will be asked: Which intervention does the patienth as received: global manipulation or especific manipulation Their responses to these questions will be recorded and used to measure the adequacy of participants and examiners."|Participants received two interventions randomly at two times: global manipulation (GM) and specific manipulation (MS)|t|f|f|t
33994418|NCT05800262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913555|NCT03768830|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be randomly selected into 4 groups: MS individuals that will exercise - group (MSE), with related control group of individuals who will not exercise) (MSC).~In addition, a group of healthy control subjects without MS (HE) will also exercise and be evaluated after the study with related control individuals who will not exercise (HC).~Group of MS and healthy individuals will exercise under the guidance of a physiotherapist."||||
33913556|NCT05882890|NA|SINGLE_GROUP||TREATMENT||NONE|The person who does the statistic will not have participated in the treatments and will not have met the participants.|Pilot project - single group intervention with before-after comparisons.||||
33913557|NCT01640925|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913558|NCT03503682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913559|NCT05846997|||OTHER||PROSPECTIVE|||||||
33913560|NCT01328249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913561|NCT04169724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913562|NCT03264482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913563|NCT06226506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913564|NCT02415439|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33913565|NCT02568917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913566|NCT03704441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913567|NCT01389622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086127|NCT03764605|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Trial will enroll 150 subjects affected by Type I-truncating ADPKD. Their eligibility will be confirmed by the mean of eGFR calculated from the 2 pre-treatment serum creatinine assessments. Once eligibility is assessed, patients will undergo kidneys CTscan. Randomization visit will occur on Day -29. During this visit patients will be randomized (1:1) to each arm of treatment and will start IMP titration. Subjects not tolerating the minimum IMP dose will be considered Titration failures and will complete End of Treatment (EoTx) visit and will be followed up after 7 days by phone call. Subjects tolerating the minimum IMP dose enter the unblind run-in period during which, subjects will continue on a stable IMP dose to confirm tolerability over a longer period. At the end of the run-in period subjects not tolerating the minimum IMP dose will be considered Run-in failures and will complete EoTx visit. Subjects completing the run-in will start the open-label 24 months treatment period."||||
33691464|NCT05753033|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33691465|NCT02312271|||COHORT||PROSPECTIVE|||||||
33691466|NCT06736366|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33691467|NCT05948956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691468|NCT01716325|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33691469|NCT05899608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691470|NCT00504582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691471|NCT05225337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691472|NCT03793218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691473|NCT06388564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691474|NCT02696993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691475|NCT02999386|||COHORT||PROSPECTIVE|||||||
33691476|NCT00569829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691477|NCT00289484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691478|NCT02908893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33691479|NCT06701812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691480|NCT03718182|RANDOMIZED|PARALLEL||TREATMENT||NONE||"D-CODE is a two part trial entailing two vitamin D screening studies (winter and summer) and an interventional feasibility study.~The vitamin D screening studies will take place during the winter and summer months to determine the prevalence of vitamin D deficiency in patients with CD throughout the seasons.~In the intervention/feasibility stage D-CODE is an exploratory study for an open label, multi-site, superiority randomised controlled trial. Participants will be randomised to one of two parallel arms (A or B)"||||
33691481|NCT05670353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Volunteers, administrative staff, laboratory technicians, doctors who will carry out the assessments, and statisticians will be blind to the treatment group and will not know about the group treatment information.||t|t|t|t
33913568|NCT02531789|||COHORT||PROSPECTIVE|||||||
33913569|NCT02597673|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913570|NCT06137950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33913571|NCT00003662||||TREATMENT||||||||
33913572|NCT01971489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913573|NCT04748224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|All participants, investigators, care providers and outcome assessors will be blinded to the study group allocation.||t|t|t|t
33913574|NCT03241472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913575|NCT02406547|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33913576|NCT02125487|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33913577|NCT03691402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|f|t
33913578|NCT02728258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913579|NCT00114283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913580|NCT06245512|||CASE_CONTROL||PROSPECTIVE|||||||
33913581|NCT04378920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913582|NCT04792437|||OTHER||OTHER|||||||
33913583|NCT00952237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913584|NCT04851717|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A Phase 2/3 prospective, open-label trial||||
33913585|NCT02849912|||COHORT||PROSPECTIVE|||||||
33691482|NCT04884815|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33691483|NCT02839278|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691484|NCT02514317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691485|NCT03232411|||CASE_ONLY||RETROSPECTIVE|||||||
33691486|NCT04948567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33691487|NCT05837117|||COHORT||PROSPECTIVE|||||||
33691488|NCT00688142|||||PROSPECTIVE|||||||
33691489|NCT05871892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691490|NCT01780532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691491|NCT05650190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691492|NCT00684580|||COHORT||PROSPECTIVE|||||||
33691493|NCT06200116|||CASE_ONLY||CROSS_SECTIONAL|||||||
33779959|NCT06614803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33779960|NCT03303274|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33779961|NCT04494373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33779962|NCT06685276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779963|NCT03563638|||CASE_CONTROL||RETROSPECTIVE|||||||
33779964|NCT03498261|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|Once the randomization group has been defined, the pharmacist will prepare both medications and will place them inside a bag for further handling. Medications will be identified following institutional standard of procedures.|Adult patients scheduled to undergo rhinoplasty at the Ohio State University Wexner Medical Center|t|f|t|f
33779965|NCT04680936|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-Blind Study||t|t|t|f
33779966|NCT06252623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled|t|t|t|t
33779967|NCT02839083|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33913586|NCT01206010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691494|NCT06125054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo-controlled, double blind, parallel group, single center study|t|t|t|t
33691495|NCT06052891|||CASE_CONTROL||OTHER|||||||
33691496|NCT06571383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691497|NCT05633615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691498|NCT04547413|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized, controlled trial of a behavioral intervention designed to increase the use of safer sexual practices and to reduce incident STi rates. The intervention is a 2-hour class based program and therefore is not blinded. Outcome measures of sexual behavior and incident STIs will be measured at 6 and 12 months after the intervention.||||
33691499|NCT04559334|NA|SINGLE_GROUP||PREVENTION||NONE||Assessment of the effect of treatment will be based on a compassionate use study of parenterally administered 4% T-EDTA lock solution (KiteLock™ 4% Sterile Catheter Lock Solution) to determine safety and preliminary efficacy in the prevention of (1) thrombolytic occlusions, (2) catheter breakage and (3) CLABSI events. Each patient will serves as their own control with the catheter history 12 months' prior for each patient pre KiteLock ™ use (i.e., breakages, occlusions, CLABSIs) being compared with KiteLock ™ experience.||||
33691500|NCT06618287|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691501|NCT00230308|||OTHER||PROSPECTIVE|||||||
33691502|NCT04457154|||COHORT||PROSPECTIVE|||||||
33691503|NCT04073225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33691504|NCT05247255|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691505|NCT06744712|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33691506|NCT06744439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691507|NCT06744790|||CASE_CONTROL||PROSPECTIVE|||||||
33691508|NCT06744218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691509|NCT06745505|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33691510|NCT04779229|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33779968|NCT01819090|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33779969|NCT04907487|||CASE_CONTROL||PROSPECTIVE|||||||
33779970|NCT04399564|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial||||
33779971|NCT03909464|||COHORT||PROSPECTIVE|||||||
33779972|NCT03656900|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33779973|NCT04142125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessment of endpoint|investigator-initiated, open-label, blinded endpoint assessment, controlled, randomized pilot trial (PROBE design)|f|f|f|t
33779974|NCT02836977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779975|NCT05037370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient will be blinded as to which eye receives which treatment, but the surgical team will not be blinded as to which procedure is performed. Post-operatively, the ophthalmic technicians and optometrists responsible for postoperative examinations will be blinded as to which eye underwent Contoura vs WFO.|Randomized contralateral double-masked study|t|t|t|f
33779976|NCT02612662|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33779977|NCT05456685|NA|SEQUENTIAL||TREATMENT||NONE||Open-label study with treatment cycles every three weeks. All participants will receive 6 cycles of carboplatin (area under the concentration curve \[AUC\] 5) + MIRV (6 milligrams per kilogram \[mg/kg\] of adjusted ideal body weight \[AIBW\]). If participants have no progressive disease (PD) at the end of the combination treatment, they will continue to maintenance MIRV (6 mg/kg of AIBW) as a single agent.||||
33779978|NCT06615544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33779979|NCT05675774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33779980|NCT03092544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779981|NCT04237454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Thermal Imaging||||
33779982|NCT02217995|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33779983|NCT01882894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33779984|NCT05096390|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, prospective, phase II study||||
33779985|NCT00409240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779986|NCT03635788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779987|NCT06548412|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33779988|NCT06696573|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is not applicable as this study is open-label, meaning both participants and care providers are aware of the intervention assignments.|Participants will be randomly assigned to one of two arms: one group receiving prophylactic NSAIDs before the onset of pain during medical abortion and another group receiving NSAIDs on-demand. The study aims to compare the efficacy, safety, and overall pain management outcomes of the two strategies.||||
33779989|NCT06668480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be aware of which group the participant belongs to.|This is a randomized controlled trial having two groups. One group will receive conventional physical therapy along with SNAGS and the second will receive SNAGS and strengthening of lower fibers of trapezius with conventional physical therapy. Both groups will be recruited concurrently.|f|f|f|t
33779990|NCT05656313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33779991|NCT04511312|||CASE_ONLY||PROSPECTIVE|||||||
33779992|NCT05229510|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33779993|NCT06697262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33779994|NCT01559090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779995|NCT05716165|NA|SINGLE_GROUP||OTHER||NONE|the clinical trial is carried out in open label|This is a prospective, monocentric, randomized clinical investigation (order of tests with and without knee braces), carried out in open, over a period of 2 weeks (cohort 1) or 12 weeks (cohort 2), in a population of people aged 60 to 80 years practicing recreational soccer.||||
33779996|NCT01982344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33779997|NCT02392455|||COHORT||PROSPECTIVE|||||||
33779998|NCT02403674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691511|NCT04644068|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study consists of individual modules each evaluating the safety and tolerability of AZD5305 dosed as monotherapy, or with a specific combination partner:~* Module 1 (AZD5305 monotherapy)~* Module 2 (AZD5305 in combination with paclitaxel)~* Module 3 (AZD5305 in combination with carboplatin, with or without paclitaxel)~* Module 4 (AZD5305 in combination with T DXd)~* Module 5 (AZD5305 in combination with Dato-DXd).~* Module 6 (AZD5305 in combination with Camizestrant)~Modules 1 and 4 has 2 study parts: Part A consisting of dose-escalation cohorts and Part B, consisting of expansion cohorts. Modules 2, 3, 5 and 6 have only PART A."||||
33691512|NCT05409183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691513|NCT06106022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691514|NCT03502785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33779999|NCT05765032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801363|NCT02872675|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Only the company providing the nutritional supplements (HOST Therabiomics) will be aware of the supplement blinding protocol.~Upon trial completion (e.g. the final visit of the final participant), the chief investigator will contact HOST Therabiomics to obtain information on the supplement blinding protocol. Should any participants, care providers, investigators, or outcome assessors become aware of the blinding protocol during the trial they will be informed not to disclose this information to any other relevant personnel. Participants who become aware of the blinding protocol during participation would be withdrawn from the trial."|"Participants will be administered a prebiotic (galactooligosaccharide; HOST-DM059), and a taste/appearance matched placebo (Maltodextrin) in a, double-blind, placebo-controlled, crossover design.~The nutritional intervention will be completed over a twelve week period, consisting of two, four-week supplementation phases separated by a four-week wash out period. Participants will be randomly allocated one of the nutritional supplements during phase one (labelled as either 'L', or 'X'), and asked to consume one powdered sachet every morning (3.6g). Participants will then complete a four week wash out period, before being assigned the remaining nutritional supplement during phase two. Sachets can be reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc."|t|t|t|t
33801364|NCT01574859|||COHORT||RETROSPECTIVE|||||||
33801365|NCT06160518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"virtual reality intervention which will take place using a cell phone coupled with the three-dimensional image glasses. The cell phone will play three-dimensional games which will be downloaded for free. The options for images and games involved which children could choose freely, all games will be suitable for the age group of the study.~• The intervention will be applied for three days when hydrotherapy session done"||||
33801366|NCT00510302|||FAMILY_BASED||PROSPECTIVE|||||||
33801367|NCT02245555|||COHORT||PROSPECTIVE|||||||
33913587|NCT05912413|||COHORT||PROSPECTIVE|||||||
33913588|NCT00617318|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33913589|NCT06291571|||CASE_CONTROL||PROSPECTIVE|||||||
33913590|NCT00028002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913591|NCT04404582|||OTHER||RETROSPECTIVE|||||||
33913592|NCT04233359|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33913593|NCT05337527|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34086128|NCT04105608|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086129|NCT01276834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086130|NCT01141608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913594|NCT04596280|||CASE_CONTROL||RETROSPECTIVE|||||||
33913595|NCT05590741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913596|NCT03015922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913597|NCT01626911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913598|NCT03870711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913599|NCT01116219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913600|NCT04539249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33913601|NCT01858155|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913602|NCT01044238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913603|NCT05339724|||OTHER||RETROSPECTIVE|||||||
33913604|NCT06121336|||COHORT||PROSPECTIVE|||||||
33913605|NCT01276457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913606|NCT00121511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913607|NCT03468699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691515|NCT06744920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913608|NCT01787643|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913609|NCT04069013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913610|NCT01064024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913611|NCT01293032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913612|NCT03855748|||COHORT||CROSS_SECTIONAL|||||||
33913613|NCT03776643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|Safety/Efficacy|t|f|t|f
33913614|NCT05974085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913615|NCT00783341|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33913616|NCT02681380|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33913617|NCT06552598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913618|NCT05900011|||COHORT||PROSPECTIVE|||||||
33913619|NCT02426060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086131|NCT00487188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691516|NCT06242691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691517|NCT05005442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691518|NCT06325683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913620|NCT06400836|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double (Participant, Investigator)|Crossover Assignment Randomised double-blind cross-over study|t|f|t|f
34086132|NCT05368649|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|PPT measurements and data analysis will be conducted by assessors blind to group allocation.|This is a case-control study in which the control (healthy volunteers) will receive an intervention (SWD).|f|f|f|t
34086133|NCT06443008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086134|NCT00600522|||COHORT||PROSPECTIVE|||||||
34086135|NCT02224417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086136|NCT02043977|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34086137|NCT00350545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691519|NCT06744855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086138|NCT02005107|RANDOMIZED|CROSSOVER||||NONE||||||
34086139|NCT01092767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691520|NCT06745817|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33780000|NCT05619887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant will not know whether they are receiving placebo or fentanyl. The primary investigator will also no know if the participant is receiving placebo or fentanyl.|Participants will complete all interventions (control and experimental) following drug washout.|t|f|t|f
33780001|NCT00165152|RANDOMIZED|PARALLEL||||NONE||||||
33780002|NCT06023550|||COHORT||PROSPECTIVE|||||||
33780003|NCT01573143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086140|NCT05563324|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086141|NCT04227834|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33691521|NCT06492174|NA|SINGLE_GROUP||TREATMENT||NONE||A non-randomized, single arm cohort of subjects||||
33691522|NCT06615479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780004|NCT02016872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780005|NCT06698081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780006|NCT00104611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780007|NCT05252988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780008|NCT02695043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913621|NCT01096849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780009|NCT02306824|||COHORT||PROSPECTIVE|||||||
33780010|NCT04510337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780011|NCT04165369|||COHORT||PROSPECTIVE|||||||
33780012|NCT06424912|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized first-in-man study||||
33780013|NCT06654700|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33780014|NCT05592652|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||patients and volunteers will undergo a series of psychometric scales||||
33780015|NCT03918135|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33780016|NCT01553162|||CASE_ONLY||RETROSPECTIVE|||||||
33780017|NCT05823727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Placebo controlled clinical trial.|t|f|t|f
33780018|NCT00408161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913622|NCT04970524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913623|NCT04330755|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33913624|NCT02127944|||CASE_CONTROL||PROSPECTIVE|||||||
33913625|NCT05347498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HR091506 tablets compared with febuxostat tablets|t|t|t|t
33913626|NCT05940142|||CASE_ONLY||PROSPECTIVE|||||||
34086142|NCT05856968|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Doctors at the Victoria Jubilee hospital will perform continuous or interrupted subcutaneous tissue closure resulting in the reduction of the occurrence of surgical site infection on overweight and obese women|t|f|t|f
34086143|NCT01300403|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34086144|NCT02323074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086145|NCT05689437|||COHORT||PROSPECTIVE|||||||
34086146|NCT01985178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086147|NCT04259333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The surgeon (Care provider) performing all of the septorhinoplasty procedures will be blinded as to which pain medication the patients will receive postoperatively.~The outcomes assessor evaluating the severity of bruising (using postoperative photographs taken on day of cast removal) will be blinded as to which pain medication the patient received"||f|t|f|t
34086148|NCT01398241|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34086149|NCT03427892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086150|NCT03200223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086151|NCT01653691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086152|NCT01543165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691523|NCT05175352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691524|NCT06413498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691525|NCT05342883|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention is the addition of GammaTile radiation therapy to the standard of care Stupp Protocol treatment of newly diagnosed GBM patients.||||
33691526|NCT06649838|||COHORT||PROSPECTIVE|||||||
34086153|NCT05029284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086154|NCT00003858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086155|NCT00726453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086156|NCT00005676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33994419|NCT00241020|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33994420|NCT00373256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086157|NCT04541121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||3D ultrasound and picture of ultrasound or 3D ultrasound and printed model of fetal face||||
33691527|NCT06745349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691528|NCT06744478|||CASE_CONTROL||PROSPECTIVE|||||||
33691529|NCT05681169|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-randomized implementation study, ratio between intervention and control group will be 1:4.||||
33994421|NCT04674072|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention group will be instructed to include the reverse Nordic curl exercise into their warm up 15 to 20 mins before training session (3 times per week) during one season (6 months).||||
33994422|NCT03600883|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994423|NCT06558786|||COHORT||PROSPECTIVE|||||||
34086158|NCT04280666|||CASE_ONLY||PROSPECTIVE|||||||
34086159|NCT03401957|||COHORT||PROSPECTIVE|||||||
34086160|NCT01273363|||CASE_ONLY||RETROSPECTIVE|||||||
34086161|NCT02164617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34086162|NCT00489463|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33691530|NCT06082284|||CASE_ONLY||CROSS_SECTIONAL|||||||
34086163|NCT00526175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086164|NCT05853263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind, randomized|prospective, double blind, randomized controlled trial.|t|t|t|t
34086165|NCT00730184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086166|NCT02141932|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086167|NCT03170310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086168|NCT00075075||||TREATMENT||||||||
34086169|NCT02171455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086170|NCT00283179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086171|NCT06491498|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086172|NCT06314269|||OTHER||PROSPECTIVE|||||||
34086173|NCT00942643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34086174|NCT03229603|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34086175|NCT00012909|RANDOMIZED|PARALLEL||||NONE||||||
34086176|NCT04653324|||COHORT||PROSPECTIVE|||||||
34086177|NCT00424242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086178|NCT02349386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086179|NCT00339053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086180|NCT05354791|||CASE_CONTROL||RETROSPECTIVE|||||||
34086181|NCT03101020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will be blind as he will not be present during the intervention. As well as the care provider will not be present during the assessor activities.|Both experimental and control groups will receive standard care physiotherapy for low back pain according to the evidence presented in the study of Delitto et al. The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform exercise regularly. The therapist will treat the participants once a week for a 5-week period, each session will last 40 minutes. Besides the standard care, the therapist will perform cardia mobilization, pylori mobilization, Oddi's sphincter mobilization,duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.The placebo intervention involves light touch at the same regions of the techniques as above, and no intention on the part of the therapist to impart any therapeutic technique.|f|f|f|t
34086182|NCT05993104|||CASE_ONLY||OTHER|||||||
34086183|NCT00001891||||TREATMENT||||||||
34086184|NCT02500251|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086185|NCT02552940|||CASE_CONTROL||PROSPECTIVE|||||||
34086186|NCT04490408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086187|NCT05807282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||80 farmworkers identifying as Hispanic/Latinx will be randomized to one of two treatment arms: 1) individual- and workplace-level interventions to decrease the health impacts of occupational heat stress, or 2) control.||||
34086188|NCT05652777|||CASE_ONLY||CROSS_SECTIONAL|||||||
34086189|NCT05067855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086190|NCT06144372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34086191|NCT01729195|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34086192|NCT05359484|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Usage of Uroflowmetry to distinguish between bladder outlet obstruction and detrusor hypo-contractility||||
34086193|NCT00300729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691531|NCT03043599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691532|NCT06465108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691533|NCT06625333|||CASE_ONLY||PROSPECTIVE|||||||
33691534|NCT03530306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691535|NCT03901521|||OTHER||PROSPECTIVE|||||||
33691536|NCT00027326|||COHORT||PROSPECTIVE|||||||
33691537|NCT06259227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994424|NCT02164435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994425|NCT01118598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994426|NCT05244720|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Pilot study to determine feasibility|f|t|f|t
33994427|NCT02104479|||COHORT||PROSPECTIVE|||||||
33994428|NCT06603532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, single-center, double-blinded, quasi-randomized controlled clinical trial|t|f|f|t
33994429|NCT00048334||||TREATMENT||||||||
33994430|NCT03151577|NA|SINGLE_GROUP||TREATMENT||NONE||"Intraocular pressure, adverse events, complications, number of medications in mild to moderate glaucoma patients who underwent XEN® Gel Stent implantation were recorded.~Data were collected in a 2 years follow-up."||||
33994431|NCT01429363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994432|NCT05127057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33994433|NCT06562088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994434|NCT06558240|||COHORT||PROSPECTIVE|||||||
33994435|NCT00385320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33994436|NCT03425344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A case-control study without intervention||||
33994437|NCT01309763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913627|NCT06237010|||COHORT||RETROSPECTIVE|||||||
34086194|NCT03980678|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All parties directly involved in recruitment, data collection and analysis will be blinded to the supplement identities until after the data analysis.|One week (7 day) supplementation, followed by a 4 week washout, then crossover (another 7 day supplementation period).|t|t|t|t
34086195|NCT06173284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086196|NCT05545917|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Neither participants nor providers (PTs and physicians) will be blinded in this study in the context of this pragmatic RCT. An independent statistician not involved in any other parts of this trial and blinded to the participants' allocation, will conduct the statistical analyses.|Step wedge RCT|f|f|t|f
33913628|NCT00915447|||COHORT||PROSPECTIVE|||||||
34086197|NCT03980912|||CASE_ONLY||PROSPECTIVE|||||||
34086198|NCT03055936|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994438|NCT06146595|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34086199|NCT03607318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913629|NCT05524441|||COHORT||PROSPECTIVE|||||||
33994439|NCT04767347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"The participant will not be directly informed of the experimental conditions and will be blinded to the hypotheses.~The outcomes assessor will be blinded to the experimental conditions when analyzing the data."|This study will systematically examine the NIOSH recommendations for prescribing work-to-rest ratios during occupational heat stress on kidney function.|t|f|f|t
33994440|NCT05569291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994441|NCT05745363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086200|NCT04934358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Investigator)|Parallel Assignment|f|f|t|f
34086201|NCT00419705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086202|NCT01540617|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086203|NCT05817123|||OTHER||CROSS_SECTIONAL|||||||
34086204|NCT06513299|||COHORT||RETROSPECTIVE|||||||
34086205|NCT00080262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086206|NCT00217451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086207|NCT01077557|||CASE_CONTROL||RETROSPECTIVE|||||||
34086208|NCT05923996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994442|NCT03658954|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment to one of three groups in 2:1:1 ratio, each group receiving some variation on 2-week intervention. Measurements taken at baseline, 4 weeks, 8 weeks, 12 weeks.||||
33994443|NCT02597374|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994444|NCT00938795|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33994445|NCT01824940|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Given the nature of the intervention, masking to treatment group is not possible.|||||
34086209|NCT06067815|||COHORT||PROSPECTIVE|||||||
34086210|NCT05500937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34086211|NCT01922999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086212|NCT00435344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34086213|NCT00357942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086214|NCT02537496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active placebo coil will be used as a Sham condition. This coil effectively mimics the real stimulation producing somatic sensation and sound (contraction of scalp muscles) with minimal direct brain effects. Same stimulation parameters and site as active condition will be used.|Participants will be assigned randomly to a 4-week repetitive course of either rTMS or control intervention (Sham rTMS) that is similar to rTMS but does not produce the same amount of brain stimulation.|t|t|t|t
34086215|NCT01533259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086216|NCT05213780|||COHORT||PROSPECTIVE|||||||
34086217|NCT03658980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34086218|NCT05127720|||COHORT||PROSPECTIVE|||||||
34086219|NCT05094375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|a double-blinded randomized trial|a double-blinded randomized trial|t|t|t|t
34086220|NCT02254655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34086221|NCT00981617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086222|NCT03505346|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086223|NCT03408899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34086224|NCT01587313|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34086225|NCT02542969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086226|NCT01828658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33913630|NCT02320695|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33913631|NCT02960048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913632|NCT06516666|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33913633|NCT02681952|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33913634|NCT04813848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, slit-mouth, double blind clinical trial|t|f|f|t
33913635|NCT05506592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||To evaluate the impact of an anti-dandruff shampoo compared to vehicle (placebo) on scalp microflora composition after 4 weeks of treatment and 4 weeks of relapse, on healthy volunteers with moderate to severe dandruff status|t|t|t|t
33913636|NCT00625365|NA|SINGLE_GROUP||OTHER||NONE||||||
33913637|NCT02710266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33994446|NCT06193213|||COHORT||PROSPECTIVE|||||||
33691538|NCT06113445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994447|NCT05370417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The application of low-intensity laser will be simulated in one of the groups, to maintain the study blind.||t|f|f|f
33994448|NCT00573313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994449|NCT00031434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994450|NCT04964440|||CASE_CONTROL||PROSPECTIVE|||||||
33994451|NCT02949167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994452|NCT04403347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994453|NCT04532684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcome Assesor)|Randomized prospective clinical trial|t|f|f|t
33994454|NCT01262001|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|FG-3019 administered at dose of 30 mg/kg (Cohort 2 ) by IV infusion every 3 weeks for 45 weeks in the target population.(first treatment year and first extended treatment year) and every 3 weeks thereafter for three additional extended treatment years.|FG-3019 administered at dose of 15 mg/kg (Cohort 1 ) by IV infusion every 3 weeks for 45 weeks in the target population.(first treatment year and first extended treatment year) and every 3 weeks thereafter for three additional extended treatment years.||||
33994455|NCT01108445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994456|NCT03717805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial (1/1)|f|f|t|f
33691539|NCT06744556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780019|NCT02861261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780020|NCT05654636|||COHORT||PROSPECTIVE|||||||
33994457|NCT01730846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780021|NCT01543685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780022|NCT01657682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780023|NCT03853798|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780024|NCT02084082|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780025|NCT05787379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The Concordant Care approach involves engaging in processes that: 1) validate the patient's experience, 2) develop a shared understanding of the condition, and 3) create a patient-centered, whole health-oriented action plan to manage the condition. The training involves four components: completion of approx. 3 hours of online, asynchronous training; attendance to at least two tele-mentoring sessions to review specific cases, didactics, role-play exercises, and session recordings; obtaining a clinician pocket care with reminders of Concordant Care process; and being prompted by a Veteran patient to talk about their concerns with Long-COVID.||||
33780026|NCT02741011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994458|NCT06561061|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blinded placebo-controlled trial|A randomized double-blinded placebo-controlled trial|t|t|t|f
33994459|NCT04855058|||OTHER||RETROSPECTIVE|||||||
33994460|NCT01861535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994461|NCT03214588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994462|NCT06562231|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994463|NCT04410380|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33994464|NCT05189106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086227|NCT03048786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34086228|NCT06261723|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086229|NCT01899391|||COHORT||PROSPECTIVE|||||||
34086230|NCT02695407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086231|NCT03036267|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34086232|NCT00187408|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34086233|NCT05989425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086234|NCT06437756|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086235|NCT05553717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086236|NCT05806970|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34086237|NCT00522834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086238|NCT02136693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34086239|NCT00877968|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34086240|NCT06269783|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691540|NCT05610774|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34086241|NCT02220790|||COHORT||PROSPECTIVE|||||||
33780027|NCT02394886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780028|NCT02786979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780029|NCT06256302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33780030|NCT06278389|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33691541|NCT06745206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691542|NCT05985915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691543|NCT04892017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691544|NCT05232916|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind|HLA-A\*02 subjects will be randomized to GLSI-100 or placebo. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A\*02 positive and HER2/neu positive subjects.|t|t|t|t
33780031|NCT03749356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086242|NCT03513419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086243|NCT06243445|||COHORT||PROSPECTIVE|||||||
34086244|NCT05916209|||COHORT||RETROSPECTIVE|||||||
34086245|NCT04297592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086246|NCT03442452|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||For this study, we will test the feasibility and preliminary efficacy of utilizing a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.||||
34086247|NCT02243748|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086248|NCT05449665|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086249|NCT04425317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086250|NCT04040439|||CASE_ONLY||PROSPECTIVE|||||||
34086251|NCT04689542|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33780032|NCT04509284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor) The statistician, who will conduct the statistical analysis, will be blinded.||f|f|f|t
34086252|NCT05721391|||OTHER||PROSPECTIVE|||||||
34086253|NCT00524498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086254|NCT06436716|||COHORT||RETROSPECTIVE|||||||
34086255|NCT02427867|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086256|NCT00255892|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086257|NCT00701363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086258|NCT05157373|||COHORT||PROSPECTIVE|||||||
34086259|NCT05541705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086260|NCT02414061|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34086261|NCT03336346|||OTHER||CROSS_SECTIONAL|||||||
34086262|NCT05716464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086263|NCT00478959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086264|NCT03208153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086265|NCT01774526|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086266|NCT03251417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086267|NCT02550795|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086268|NCT05259917|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34086269|NCT01675609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086270|NCT00774475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086271|NCT06402019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086272|NCT01092377|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34086273|NCT06155435|RANDOMIZED|PARALLEL||OTHER||SINGLE|There was one-way blinding in the randomization of this study. While it is known to the experimental or control class researcher of pregnant women, it can be done by the pregnant woman|The experimental group was given solution-oriented training|t|f|f|f
34086274|NCT03159637|||COHORT||PROSPECTIVE|||||||
34086275|NCT03632824|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Tranexamic acid was prescribed for pregnant women with vaginal bleeding of unknown etiology in second and third trimester (13-34 weeks) gestation||||
34086276|NCT02745106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086277|NCT06342232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086278|NCT03937778|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086279|NCT03256578|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The waveform data and videos captured during the study intervention will be centralized to Leiden University Medical Center. The team at Leiden University Medical Center assessing the outcomes will be will be blinded to the randomization allocation of the infant.|Eligible infants are either randomized to the intervention, where the clinical team will be able to directly observe the monitor or randomized to the RFM-masked display arm, where they will only see a black screen.|f|f|f|t
34086280|NCT06192732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086281|NCT02528032|NA|SINGLE_GROUP||OTHER||NONE||||||
34086282|NCT05672719|||COHORT||PROSPECTIVE|||||||
34086283|NCT00170443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34086284|NCT03184740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086285|NCT00512434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086286|NCT02961842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086287|NCT05462600|||COHORT||PROSPECTIVE|||||||
34086288|NCT05394948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086289|NCT03715062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Statistical analysis is masked.|Cluster randomized controlled study, where each Long-term care facility is one cluster.||||
34086290|NCT00361985|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086291|NCT05298241|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34086292|NCT05554835|||COHORT||PROSPECTIVE|||||||
34086293|NCT01943604||CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33691545|NCT03208868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691546|NCT03993873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691547|NCT06439004|NA|SINGLE_GROUP||OTHER||NONE||||||
33691548|NCT06581146|||COHORT||PROSPECTIVE|||||||
33691549|NCT06744179|||COHORT||PROSPECTIVE|||||||
33691550|NCT06252649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691551|NCT06190509|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33691552|NCT06743971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33691553|NCT06547216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691554|NCT05768139|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33780033|NCT02158065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780034|NCT01188122|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086294|NCT00193453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086295|NCT01541306|||CASE_ONLY||PROSPECTIVE|||||||
34086296|NCT05149339|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086297|NCT04638062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086298|NCT06054711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohorte study||||
34086299|NCT01911741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34086300|NCT01739335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded Placebo-controlled||t|f|t|f
34086301|NCT06147271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086302|NCT02750631|NA|SINGLE_GROUP||TREATMENT||NONE|All patients and staff know what the treatment is.|"All patients receive Chronotherapy, which consists of a night of no sleep (Wake Therapy) followed by bright lights at their desired sleep time and two nights of Sleep Phase Advance (i.e., sleeping 6 hours earlier than desired for 1 night and 3 hours earlier for the next night, then desired sleep time)."||||
33780035|NCT01244828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086303|NCT01528371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33780036|NCT05421845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33780037|NCT03848312|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33780038|NCT04460079|||CASE_ONLY||PROSPECTIVE|||||||
33780039|NCT04505124|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Participants are blinded. Investigators are also blinded. The intervention is delivered through a mobile phone application (care provider) and automatically and objectively assessed (through sensor and purchasing data).~Some constructs are assessed via self-reported questionnaire at baseline, 12 weeks and during the 6 month voluntary follow-up (Treatment Self-Regulation Questionnaire (TSRQ); International Physical Activity Questionnaire (IPAQ short-form); Perceived competence maintaining a healthy diet (Williams, Deci \& Ryan); Perceived behavior-related control (Renner \& Schwarzer))."||t|t|t|t
33913638|NCT00297362|||||PROSPECTIVE|||||||
33913639|NCT00200694|RANDOMIZED|CROSSOVER||||NONE||||||
33913640|NCT05307757|||COHORT||PROSPECTIVE|||||||
33913641|NCT00233259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913642|NCT03453151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913643|NCT03259997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913644|NCT03759457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913645|NCT04116814|||COHORT||PROSPECTIVE|||||||
33913646|NCT00064467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33913647|NCT04657952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913648|NCT06017947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33913649|NCT06407908|||OTHER||CROSS_SECTIONAL|||||||
33913650|NCT04982120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913651|NCT06065267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33913652|NCT03535324|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33913653|NCT00364845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913654|NCT02324179|||CASE_CONTROL||PROSPECTIVE|||||||
33913655|NCT05088616|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913656|NCT06364618|||COHORT||PROSPECTIVE|||||||
33913657|NCT00002358||||TREATMENT||NONE||||||
34086304|NCT00205309|||COHORT||PROSPECTIVE|||||||
34086305|NCT03588338|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33780040|NCT03982420|||CASE_ONLY||PROSPECTIVE|||||||
33780041|NCT05980221|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Investigating the metabolome of patients with PEI in the fasted and fed state. Prospective, single centre, observational study||||
33780042|NCT03880383|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|In the context of the provided intervention (coaching vs. usual and locally available care) and outcome measures used (self-reported),blinding of participants, care providers, investigators nor that of the assessor is possible.|This is a prospective, two-arm pragmatic randomized controlled trial (RCT) comparing a developmental coaching and e-health services intervention plus usual and locally available care to the control state in which children and their families receive usual and locally available care over an 18-month time frame. The control group will be provided with partial intervention at the end of the 18 month study. The target population for this novel service delivery model is families with children aged 1.5 to 4.5 years old with developmental concerns, who are beginning to manifest impairments in developmental domains (e.g. motor, cognitive, speech, social and/or behavioural).||||
33780043|NCT06659887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Due to the clinically obvious oxygen administration modalities, study personnel in theatres cannot be blinded, but patients and parents will be blinded to group allocation.||t|f|f|t
33780044|NCT02235610|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780045|NCT06695169|||OTHER||OTHER|||||||
33780046|NCT06502015|||COHORT||PROSPECTIVE|||||||
33780047|NCT04908761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, medical staff who measure outcome variables, and nurses in the recovery room are double-blinded so that medical staff and patients do not know the patient's assigned group.|Single center, double-blind, randomized controlled trial|t|t|t|t
33913658|NCT04361643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913659|NCT04264767|||CASE_CONTROL||PROSPECTIVE|||||||
33913660|NCT02653976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913661|NCT05728086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Waitlist randomized controlled trial (RCT) design comprising an intervention group and a waitlist-control group|f|f|f|t
33913662|NCT00088868||||TREATMENT||||||||
33913663|NCT02948049|||OTHER||PROSPECTIVE|||||||
33913664|NCT03047148|||COHORT||RETROSPECTIVE|||||||
33913665|NCT02548273|||CASE_CONTROL||PROSPECTIVE|||||||
33913666|NCT00530426|||||RETROSPECTIVE|||||||
33913667|NCT05580055|||COHORT||CROSS_SECTIONAL|||||||
33913668|NCT02960867|||CASE_ONLY||PROSPECTIVE|||||||
33913669|NCT06048237|||OTHER||PROSPECTIVE|||||||
33913670|NCT02940626|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913671|NCT01976819|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913672|NCT05648227|||OTHER||RETROSPECTIVE|||||||
33913673|NCT04942938|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a pilot study using a series of 4-6 case studies for 4-6 participants. All studies will be completed entirely from the subject's home with CSHRI IRB oversight.||||
33913674|NCT01671969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913675|NCT05642013|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913676|NCT03773341|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33913677|NCT06032299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913678|NCT01960699|||COHORT||PROSPECTIVE|||||||
33913679|NCT02938585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913680|NCT01523119|RANDOMIZED|CROSSOVER||||NONE||||||
33913681|NCT00184249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913682|NCT04302103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913683|NCT02330549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913684|NCT01185145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913685|NCT03976531|||COHORT||PROSPECTIVE|||||||
33913686|NCT06296433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780048|NCT01688102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780049|NCT05455944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780050|NCT06394661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780051|NCT02703532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33780052|NCT01219465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780053|NCT00698152|||COHORT||PROSPECTIVE|||||||
33780054|NCT06658600|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33780055|NCT00550108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780056|NCT05264246|||COHORT||RETROSPECTIVE|||||||
33780057|NCT05183555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Single-center, early feasibility clinical trial (RIPH1 type) using a radiopharmaceutical (drug) off-label.~This study is based on the evaluation of an off-label radiopharmaceutical, 68Ga-DOTATOC in PET/CT, to detect infective endocarditis. The marketing authorization of 68Ga-DOTATOC is for the neuroendocrine tumors assessment (NET). Currently, a clinical study using 68Ga-DOTATOC PET/CT to detect myocarditis in the inflammatory phase is conducted by a team of the CHRU of Nancy Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours."||||
33780058|NCT03349190|||COHORT||RETROSPECTIVE|||||||
33780059|NCT00227747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780060|NCT03717194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780061|NCT01760655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780062|NCT04991389|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33994465|NCT04946708|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups pre-post assessment (pilot/feasibility study)||||
33994466|NCT05336422|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33994467|NCT06003335|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33994468|NCT02342535|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33994469|NCT04405102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994470|NCT03091205|||COHORT||PROSPECTIVE|||||||
33994471|NCT02375477|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33994472|NCT03979768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Eight community pharmacies offered a diabetes risk assessment including a diabetes risk assessment test only, while 11 community pharmacies||||
33994473|NCT06455137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994474|NCT01344590|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33994475|NCT03759717|||COHORT||PROSPECTIVE|||||||
33691555|NCT04451863|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.|t|f|t|f
33691556|NCT06745700|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Behavioral: Brief Behavioral Activation~A five-session telephone-based brief behavioral activation treatment.~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log.~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week.~Session 3-4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned. with life goals and values; creating a a maintenance plan.~Other group: care as usual."||||
33691557|NCT06745765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33691558|NCT06325709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691559|NCT06745583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691560|NCT06745557|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Intra-patient randomisation||||
33994476|NCT06234423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994477|NCT06626659|||COHORT||CROSS_SECTIONAL|||||||
33994478|NCT02651506|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33691561|NCT06744192|||CASE_CONTROL||PROSPECTIVE|||||||
33691562|NCT06745531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780063|NCT04316455|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780064|NCT02213900|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780065|NCT05454189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is a prospective, randomized study to determine the non-inferiority of every 12 week IPD flushes compared to every 4 week flushes in participants on an IPD maintenance flush schedule.||||
33780066|NCT05284188|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization was achieved using the opaque sealed envelopes, and each eligible patient was allocated to open or arthroscopic MBP in a 1:1 ratio with a random block assignment of 4 or 6. The envelopes were thoroughly shuffled and sequentially numbered and then opened before surgery. Patients were allowed to withdraw from this experiment.|||||
33780067|NCT04510519|||COHORT||PROSPECTIVE|||||||
33780068|NCT03589482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780069|NCT03341026|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33994479|NCT06253260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33994480|NCT01910753|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33994481|NCT04802057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780070|NCT02103920|||COHORT||RETROSPECTIVE|||||||
33780071|NCT02643771|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33994482|NCT06592222|||COHORT||RETROSPECTIVE|||||||
33994483|NCT01028183|||COHORT||PROSPECTIVE|||||||
33994484|NCT00404183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691563|NCT04864106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We are adding a direct laryngoscopy based airway examination to the routine patient examination. Investigators will have two (complementary) methods of a preoperative airway examination; (a) the traditional Malampati airway examination and (b) the new laryngoscopy based examination. Both airway examination methods will be correlated with the airway grading during the induction of anesthesia (Cormack airway grading). The correlation strength of these two preoperative airway assessment methods and the intraoperative Cormack airway grading will be compared.||||
33691564|NCT06737497|||COHORT||PROSPECTIVE|||||||
33691565|NCT06745492|||COHORT||PROSPECTIVE|||||||
33691566|NCT06736522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors will be masked to study condition.|Individually Randomized Group Treatment Trial Design|f|f|f|t
33691567|NCT05557409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691568|NCT06745648|NA|SINGLE_GROUP||TREATMENT||NONE||INTERVENTIONAL STUDY MODEL||||
33691569|NCT02945072|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33691570|NCT06743555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691571|NCT06735911|NA|SINGLE_GROUP||TREATMENT||NONE||before / after study||||
33691572|NCT05519878|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33691573|NCT06744595|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33691574|NCT06742320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Children will be randomly assigned to the training and control groups via a computer program.This process was carried out by a person other than the researchers.|The study is an experimental type with a pre-test, post-test and follow-up test control group.|t|f|f|t
33691575|NCT06737016|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled clinical trial||||
33691576|NCT06364696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691577|NCT06743490|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691578|NCT06739785|||COHORT||CROSS_SECTIONAL|||||||
33691579|NCT05880862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will be blinded to ensure unbiased outcome findings.|This is a pilot, multi-arm, mixed methods, randomized clinical study.|f|f|f|t
33691580|NCT06744660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691581|NCT05686551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691582|NCT06739096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691583|NCT06744010|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33780072|NCT05895656|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780073|NCT06250439|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994485|NCT06626893|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994486|NCT04474405|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33994487|NCT05439707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994488|NCT04170452|||COHORT||PROSPECTIVE|||||||
33994489|NCT03058614|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The surgical team will be blinded to the randomization outcome of the patient until the day after surgery so as to minimize any bias introduced into their preoperative counseling. After that point, treatment teams will no longer be blinded to randomization.|Randomized control study|f|t|t|f
33994490|NCT05633862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994491|NCT00120887|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33994492|NCT00951457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780074|NCT05265988|NA|SINGLE_GROUP||TREATMENT||NONE|The patients are treated in one arm.|Monocentrici Study. The patients are treated in one arm||||
33780075|NCT02733133|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780076|NCT06125262|||COHORT||CROSS_SECTIONAL|||||||
33801368|NCT05546710|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, open-label, multicenter study||||
33801369|NCT02216552|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Resveratrol as ResVida (TM) compared to a placebo|t|t|t|t
33801370|NCT05413629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Solomon four-group, randomized controlled study||||
33801371|NCT00258297||||TREATMENT||NONE||||||
33801372|NCT03108703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994493|NCT01955200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994494|NCT02380794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994495|NCT05859984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, randomized, double-blind, double-simulated, placebo parallel-controlled, multicenter design|t|t|t|t
33994496|NCT00023166|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994497|NCT05973513|||CASE_ONLY||PROSPECTIVE|||||||
33691584|NCT03882229|||COHORT||PROSPECTIVE|||||||
33691585|NCT04185532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The knee laxity measurement with KT-1000 will be performed by an assessor without knowledge of type of intervention. Other outcome measures will not be masked.||f|f|f|t
33691586|NCT06242470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691587|NCT06329401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691588|NCT06105684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691589|NCT05875545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691590|NCT05660512|||COHORT||PROSPECTIVE|||||||
33691591|NCT06744517|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33691592|NCT06293079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|f|t|t
33691593|NCT06193486|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691594|NCT00752115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691595|NCT05273749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801373|NCT03989024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801374|NCT04014439|||COHORT||PROSPECTIVE|||||||
33994498|NCT04538677|||COHORT||PROSPECTIVE|||||||
33994499|NCT02197741|||CASE_CROSSOVER||PROSPECTIVE|||||||
33994500|NCT02047305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994501|NCT05329922|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to either the training group or the control group.||||
33994502|NCT00838188|||CASE_CROSSOVER||PROSPECTIVE|||||||
33994503|NCT00106886|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33994504|NCT04331262|||OTHER||PROSPECTIVE|||||||
33994505|NCT04618900|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Healthy patients in need of dental implant in the posterior part of the maxilla|Randomized controlled trial|t|f|f|f
33994506|NCT03935815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994507|NCT03259139|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Participants did not know which condition they were in. Participants' parents were aware of the deception (hidden guns) and what condition their children were in. Research personnel knew conditions as well. Research assistants who transcribed recorded laboratory sessions did not know what condition they were coding (eg. what type of game they played)|Participants are randomly assigned to play a non-violent video game, a violent video game containing swords, or a violent video game containing guns.|t|f|f|f
33994508|NCT01203891|||COHORT||RETROSPECTIVE|||||||
33994509|NCT05615909|||COHORT||PROSPECTIVE|||||||
33994510|NCT06501222|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized Controlled Trial|t|t|t|t
33994511|NCT06627673|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study is a single arm, multi-center, prospective IDE trial. Two hundred (200) patients recruited and consented will receive the PEEK-OPTIMA™ Femoral Component and results will be compared to matched historic controls from the Maxx Orthopedics Freedom Total Knee System product registry (PK-00002 REV-01, WCG IRB# 20241890). Male and female patients 18 years of age or older with Knee Society Score (KSS) of \>25 and \<75 will be eligible for enrollment.||||
33994512|NCT01198964|||CASE_ONLY||PROSPECTIVE|||||||
33994513|NCT04702685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Bandage with tape will be placed over the presumed site of anesthetic injection||t|f|f|t
33994514|NCT02441686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994515|NCT04336605|||COHORT||PROSPECTIVE|||||||
33994516|NCT01857947|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33994517|NCT01301794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994518|NCT05911711|||COHORT||PROSPECTIVE|||||||
33994519|NCT02776774|||COHORT||PROSPECTIVE|||||||
33994520|NCT03072030|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This clinical trial is designed as a double blind randomized placebo-controlled study|t|f|t|f
33994521|NCT06559592|||COHORT||RETROSPECTIVE|||||||
33994522|NCT05452707|||OTHER||PROSPECTIVE|||||||
33780077|NCT03599115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are told there is only one intervention for the study and are not aware if they have been assigned to the intervention group or the active control. Research assistants collecting data are blind to what arm the participant was assigned to. During data preprocessing steps, individuals will be blind to what group a participant belongs too (and all data will be preprocessed together). Only when conducting statistical analyses will the principle investigator be aware of what participant belongs to what group, in order to conduct group analyses.|There are two arms of this study: food-specific inhibitory control training (condition of interest) and a generic inhibitory control training (active control). Given baseline levels of inhibitory control (assessed at baseline visit), participants are randomly assigned to the generic or food-specific month long inhibitory control training. All other protocols, including baseline and follow-up visits and assessment of food intake and weight, are identical and follow the same time line across the two arms.|t|f|f|t
33780078|NCT03899155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780079|NCT06336434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780080|NCT04007809|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994523|NCT02286479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994524|NCT01133535|||COHORT||PROSPECTIVE|||||||
33994525|NCT04935554|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994526|NCT03747276|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33994527|NCT04155450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is unaware of the treatment group he is in.||t|f|f|f
33994528|NCT01016782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994529|NCT03432663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||60 emergency adult patients who were candidates for drug cardioversion after first symptomatic episodes of Atrial fibrillation to either (1)24 hour continuous infusion or (2)72 hours continuous intravenous Amiodarone or until sinus rhythms was reached.|t|f|f|f
33994530|NCT02412553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994531|NCT03133260|||COHORT||PROSPECTIVE|||||||
33994532|NCT02450539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994533|NCT01437761|||COHORT||PROSPECTIVE|||||||
33994534|NCT06350240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33994535|NCT05312554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994536|NCT00147563|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33994537|NCT05815394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994538|NCT05329311|||COHORT||RETROSPECTIVE|||||||
33994539|NCT02915445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994540|NCT05786118|||COHORT||CROSS_SECTIONAL|||||||
33994541|NCT05460520|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The group assignment will be based on a random drawing of numbers prepared by Dr. Maruta, to the outcome of which he will be blinded. Dr. Cho (NYU) will interview each participant over the phone prior and at the completion of the final 6-month follow-up to independently record symptom severity scores as reported by the participants. Dr. Cho will be blinded to the type of the treatment that the participants received. Dr. Maruta will perform analyses of objective (posture, rotational test, VNG) and subjective (DHI, SVQ, VVAS, HADS, STAI etc.) data obtained during the treatment and at follow-ups. Dr. Maruta will be blinded to the participants' identity and the type of treatment received.|Qualified applicants with dominant oscillatory motion sensations will be randomly assigned to Groups 1 (n=50), 2 (n=50), 3 (n=30), or 4 (n=30), and those with dominant gravitational pull sensation will be randomly assigned to groups 5 (n=20) or 6 (n=20).|t|f|f|t
33994542|NCT03190239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994543|NCT06627374|||CASE_ONLY||PROSPECTIVE|||||||
33691596|NCT06347159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994544|NCT06218524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994545|NCT00878930|||COHORT||PROSPECTIVE|||||||
33691597|NCT06743568|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study is a multi-center, open-label, two-arm randomized control trial.||||
33691598|NCT06745622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691599|NCT06579040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All possible steps will be taken to maintain blinding of the patient's treating physician (i.e., gynecologist) and assessors. The gynecologist will be blinded to the patient's randomization and patients will be instructed not to disclose their allocated group to their gynecologist and/or research assistants.|Prospective, parallel, randomized controlled trial|f|t|f|t
33691600|NCT05843578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo-controlled, double-blind, parallel, multicenter, phase 2a study|t|t|t|t
33691601|NCT05657054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691602|NCT05465174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691603|NCT05975047|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33691604|NCT06740773|||COHORT||RETROSPECTIVE|||||||
33691605|NCT06744400|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The number of patients included at each dose is determined according to Bayesian optimal interval (BOIN) design.||||
33691606|NCT06740552|||COHORT||PROSPECTIVE|||||||
33691607|NCT02956291|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33691608|NCT06737601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of the therapy, it is not possible to blind the operators or patients. The medical staff responsible for collecting the disease scores, however, will be blind regarding the assignment of patients to one or the other group.|PROSPECTIVE RANDOMIZED CLINICAL TRIAL|f|f|t|f
33994546|NCT03560843|RANDOMIZED|PARALLEL||TREATMENT||NONE||MBSR is an 8 week standardized protocol that includes gentle yoga, meditation, and mindfulness practices that were originally developed by Jon Kabat-Zinn from the University of Massachusetts. A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures.||||
33994547|NCT04259476|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|double blind|randomized control trial|f|f|t|f
33691609|NCT02802969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691610|NCT06745895|NA|SINGLE_GROUP||SCREENING||NONE||Eligible and enrolled patient participants enrolled in the intervention will receive a theory-informed educational booklet about both Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) screening in English or Spanish, access to free stool-based CRC screening, and access to HCV screening. Implementation outcomes, facilitators, and barriers will be examined.||||
33691611|NCT05119985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are divided by block randomization into two arms. Arm A peripheral vein cannulation with ultrasound guidance and Arm B conventional cannulation.||||
33691612|NCT04786262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691613|NCT06737653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Split-mouth design|t|t|t|t
33691614|NCT06428019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691615|NCT06745466|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994548|NCT05616728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994549|NCT05730920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33994550|NCT05651958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994551|NCT02287844|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33994552|NCT05812118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be aware of whether or not they received the intervention.|A classroom-based randomised controlled trial|t|f|f|f
33994553|NCT06627452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994554|NCT01349257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994555|NCT00533767|||CASE_ONLY||PROSPECTIVE|||||||
33994556|NCT03873363|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Randomization to one of two surgical techniques.||||
33994557|NCT04694963|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994558|NCT05795621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994559|NCT04917419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994560|NCT01889407|||CASE_CONTROL||PROSPECTIVE|||||||
33994561|NCT06623162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994562|NCT01735994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33994563|NCT02083328|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33994564|NCT05740098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994565|NCT00501735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994566|NCT03140631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994567|NCT06080451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994568|NCT02012335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994569|NCT02327559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994570|NCT03320863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Devices are assigned per the randomization schedule, with the sham device identical to the active device in every way except that no neuromodulation is delivered. The neuromodulation that the active device delivers can be done in a way that causes no sensation, so subjects are not unmasked.|Double-blind, randomized, sham controlled study|t|t|t|t
33994571|NCT03913676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994572|NCT01608360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994573|NCT02518360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994574|NCT00844922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994575|NCT03261167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will contain a double blind treatment period (Part 1) followed by open-label treatment period (Part 2/Part3/Part4).|Subjects will receive either 400 units of botulinum toxin A injection or 240 units of botulinum toxin A injection plus placebo in double blind phase. Eligible subjects for open-label treatment period will receive 400 units of botulinum toxin A injection.|t|f|t|f
33994576|NCT04942535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33994577|NCT00815087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994578|NCT03170219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994579|NCT03419403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994580|NCT06626802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994581|NCT05271890|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33994582|NCT03822754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33994583|NCT00343681|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691616|NCT06581068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691617|NCT06743880|||CASE_ONLY||CROSS_SECTIONAL|||||||
33691618|NCT03900793|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation for Phase 1 with dose levels described in Arms and interventions.||||
33994584|NCT02727725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086306|NCT03747471|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This will be a 2 arms individual randomized controlled trial. Intervention arm will receive teaching from the nurses using diabetic conversation map with visual images and control arm will receive teaching from the nurses using the traditional diabetic counselling.||||
34086307|NCT01147796|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086308|NCT01610518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34086309|NCT04113603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086310|NCT04357795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086311|NCT04240873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086312|NCT00969774|||COHORT||CROSS_SECTIONAL|||||||
34086313|NCT02349412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086314|NCT04115813|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The laboratory staff testing the HIV blood for viral load levels were masked to the participants randomized allocation to the intervention or comparison arms.|After about 6 months and the completion of the initial intervention the intervention arm went into a less intensive maintenance phase and the comparison arm started to receive the intervention.|f|f|f|t
34086315|NCT05766241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomized to a program group or a waitlist control group. Individuals in the waitlist control group will be offered the opportunity to participate in the program once they have completed the study.||||
34086316|NCT00177411|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34086317|NCT00314405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086318|NCT04413045|||OTHER||RETROSPECTIVE|||||||
34086319|NCT05883982|NA|SINGLE_GROUP||TREATMENT||NONE||We do not choose to create a placebo group or treatment groups other than intra-articular injections. In qualified patients, the administration of the substance into the temporomandibular joint cavity will be the treatment of choice or the generally accepted continuation of therapy in which the first-line treatment (pharmacotherapy, physiotherapy, splint therapy) turned out to be ineffective.||||
34086320|NCT05378503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086321|NCT06033469|||OTHER||PROSPECTIVE|||||||
34086322|NCT00005240|||CASE_CONTROL||PROSPECTIVE|||||||
34086323|NCT02530385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086324|NCT04596293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086325|NCT05989581|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with stage 1 HTN in pregnancy will be randomized to BP goals of \<130/80mmHg or usual care to treatment only if BPs ≥140/90mmHg. For this pilot, the investigator will randomize a total of 74 eligible participants, 37 to active treatment to BP\<130/80mmHg and 37 to usual care.||||
33691619|NCT01843413|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation for radiotherapy||||
33994585|NCT00720395|||COHORT||PROSPECTIVE|||||||
33994586|NCT05360394|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33994587|NCT03049215|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to either: LAMS alone and undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter or LAMS plus double pigtail stent and undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter||||
34086326|NCT04830280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086327|NCT05375916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994588|NCT01745679|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33994589|NCT03302832|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33994590|NCT01269658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994591|NCT01406353|RANDOMIZED|PARALLEL||TREATMENT||NONE||early percutaneous mitral commissurotomy||||
33994592|NCT00551863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994593|NCT06627777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All children will experience brief standardized laboratory tasks according to the same protocol.||||
34086328|NCT05623800|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691620|NCT05093335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This protocol is a pilot protocol.||||
33780081|NCT04423406|||COHORT||PROSPECTIVE|||||||
33691621|NCT05665361|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691622|NCT02257736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691623|NCT05041426|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, open-label, single center, pilot study with historical controls||||
33691624|NCT06534671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691625|NCT05267873|||CASE_ONLY||RETROSPECTIVE|||||||
33691626|NCT04947735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691627|NCT06121297|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment in two parallel cohorts||||
33691628|NCT06744582|||COHORT||PROSPECTIVE|||||||
33691629|NCT06486948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34086329|NCT02239289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691630|NCT04325282|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Children will receive active repetitive TMS (rTMS) on one day and sham stimulation on a second day. The order of stimulation will be randomized on a per-participant basis.~Children and parents/guardians will not be told if they are receiving sham or inhibitory rTMS on a given day. The research team will know at the time of stimulation, however, as they will have to choose which coil to use. The TMS-EEG files will be coded and the team member analyzing the files for change in IED (spike) frequency and change in connectivity will be blinded to condition."||||
33691631|NCT06743503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691632|NCT05423730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33691633|NCT04273555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691634|NCT03366272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691635|NCT06346886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691636|NCT06745843|NA|SINGLE_GROUP||OTHER||NONE||||||
33691637|NCT06328608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691638|NCT05328908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691639|NCT06744608|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Structured myofascial release group~2. Tens (transcutaneous electrical nerve stimulation) group~3. group that includes lifestyle changes"||||
33691640|NCT04703166|||COHORT||PROSPECTIVE|||||||
33691641|NCT06744270|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33691642|NCT06736327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691643|NCT06744764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Clinical trial coordinators||t|f|t|f
33691644|NCT06744426|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691645|NCT03394612|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691646|NCT05322590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stage 1 (open label)/Stage 2 (Randomized, Placebo controlled, Double Blind)|"Enrollment will proceed in 2 stages. In the Stage 1 (open label) safety run-in phase, participants are enrolled and treated in cohorts of 3 in order to reach a maximum tolerated dose (MTD) or recommended Phase 2 Dose (RP2D). After the MTD/RP2D is established, a cohort expansion of up to 30 participants will be conducted at the RP2D. Stage 1 enrollment was completed in November 2024.~In Stage 2, eligible participants will be randomized in a 1:1 ratio to receive either BXQ-350 at the RP2D or placebo (0.9% normal saline) intravenously (IV) administered in combination with mFOLFOX7 and bevacizumab."|t|t|t|t
33780082|NCT06252662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be able to see overhear from the block team the type of drugs used in the block.|single blinded randomized control trial.|t|f|f|f
33780083|NCT06417645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||healthy patients proposed for elective surgery longer than 60 min, received a standard protocol TCI iv anesthesia with EEG BIS index monitoring||||
33780084|NCT06697561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33780085|NCT06341517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subjects, care providers, investigators and outcome assessors will all be blinded as to the randomization sequence, and thus will be blinded as to sham vs active TMS status.||t|t|t|t
33780086|NCT06452706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780087|NCT00200421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33780088|NCT00453089|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33780089|NCT05550337|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33780090|NCT04751864|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Participants randomized into Sham and Active device arms for four weeks. At the week 5 crossover, participants in sham arm receive active device.|t|t|t|f
33780091|NCT02272465|||COHORT||PROSPECTIVE|||||||
33780092|NCT05709548|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780093|NCT04795427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780094|NCT06189508|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33780095|NCT02609555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994594|NCT01497587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994595|NCT02939703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33994596|NCT03965598|||COHORT||PROSPECTIVE|||||||
33994597|NCT05314257|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994598|NCT01032863|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780096|NCT02153385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780097|NCT01620827|RANDOMIZED|PARALLEL||||NONE||||||
33994599|NCT00274781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994600|NCT00840398|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33994601|NCT06562504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086330|NCT00004497|RANDOMIZED|||TREATMENT||DOUBLE||||||
34086331|NCT06352606|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086332|NCT06525168|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34086333|NCT03179384|NA|SINGLE_GROUP||OTHER||NONE||||||
33780098|NCT02056119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33780099|NCT05714670|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group I: patients will receive the studied drug orally in addition to their standard treatment for three months.~Group II: patients will receive only their standard treatment for three months."||||
33801375|NCT01553058|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33801376|NCT06150508|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33801377|NCT05664204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086334|NCT01669239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086335|NCT02748772|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34086336|NCT00002703|RANDOMIZED|||TREATMENT||||||||
34086337|NCT00021242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086338|NCT03915743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT||||
34086339|NCT00623181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086340|NCT05916170|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The design of the study is a cluster randomized crossover trial, where the hookah café is the cluster and randomization is at the cluster level. Each hookah café will serve as its own control and will be used for data collection for both arms of the study. Cafes will start in the no-warning control arm and then will cross over to the intervention arm, where they will display one of four text-only warning signs. Participants will only participate in one of the arms.||||
34086341|NCT00006022|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33913687|NCT01457859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086342|NCT05458778|||COHORT||PROSPECTIVE|||||||
34086343|NCT02372461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086344|NCT03153657|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Triple Blind (Participant, Investigator, Outcomes Assessor)||t|f|t|t
34086345|NCT00300599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086346|NCT04164238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086347|NCT04635839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086348|NCT03206359|||CASE_CONTROL||PROSPECTIVE|||||||
34086349|NCT04762186|NA|SEQUENTIAL||TREATMENT||NONE|During the dose-escalation phase, the study participants and the study team are aware of the treatment as this is an open label trial.|This trial consist of an open-label dose escalation phase in SARS-CoV-2 infected participants.||||
34086350|NCT01294046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086351|NCT06072638|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086352|NCT03976908|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Clinical intervention study (double blind, randomized cross-over design). Two different stimulation paradigms will be investigated: ON and OFF stimulation.|t|f|t|f
34086353|NCT05408637|NA|SINGLE_GROUP||TREATMENT||SINGLE|During the first treatment visit, participants will receive one active tPBM treatment and one sham tPBM treatment. Participants will be blinded as to the order in which they receive these treatments.|All participants will receive five active tPBM treatments and one sham tPBM treatment.|t|f|f|f
34086354|NCT00115388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34086355|NCT03740464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086356|NCT01988324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086357|NCT00120978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086358|NCT02623192|||COHORT||CROSS_SECTIONAL|||||||
34086359|NCT04556266|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34086360|NCT05197738|||COHORT||PROSPECTIVE|||||||
34086361|NCT02774889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086362|NCT05314972|||COHORT||PROSPECTIVE|||||||
34086363|NCT04577508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1:1 randomization|f|f|t|t
33801378|NCT02076659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801379|NCT06520137|||COHORT||PROSPECTIVE|||||||
33801380|NCT04770649|||COHORT||PROSPECTIVE|||||||
33801381|NCT00392249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33801382|NCT03837886|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33801383|NCT05796323|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33801384|NCT01902784|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33801385|NCT02697877|||COHORT||PROSPECTIVE|||||||
33801386|NCT00678912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913688|NCT00786032|||COHORT||PROSPECTIVE|||||||
33913689|NCT02460757|||COHORT||PROSPECTIVE|||||||
34086364|NCT01142336|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34086365|NCT04630353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086366|NCT04877600|||OTHER||CROSS_SECTIONAL|||||||
33801387|NCT03750214|NA|SINGLE_GROUP||SCREENING||NONE||||||
33913690|NCT02730845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33913691|NCT01848054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913692|NCT03209180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||PROBE and NON-INFERIORITY DESIGN for Slow Release CarVeDilol-SR to Rapid Release Carvedilol-IR|t|t|t|f
33913693|NCT01144078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780100|NCT04813042|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Treatment allocation will be concealed prior to randomisation by the use of a web-based randomisation system. A statistician not directly involved in the analysis of the trial results will prepare the randomisation schedule using permuted block randomisation, stratified by LGA, using a random number generator on a computer. The schedule will be held by the independent statistician and embedded within the web-based data management system.~Treatment allocation will only be revealed after it has been confirmed that the participant is eligible and enrolled and has completed the baseline questionnaire. REDCap will display the father's assignment for the Project Coordinator, who will notify the father of his treatment assignment and intervention/usual care information by telephone. The treatment allocation in the database will only be visible to the Project Coordinator."|This is a parallel group randomised controlled trial. The treatment (Working Out Dads 6-week group intervention) will be compared to usual care (brief consultation + resources + referral). Randomisation and analyses will be at the level of the individual participant and adjusted for clustering at the level of the WOD group and Local Government Area (LGA) as a stratification variable. For the primary analysis, the model based mean K10 score in each trial arm will be compared at post-intervention and at the 6-month follow-up (primary outcome).||||
34086367|NCT02547740|||CASE_CONTROL||PROSPECTIVE|||||||
34086368|NCT05348434|||COHORT||PROSPECTIVE|||||||
34086369|NCT05675670|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34086370|NCT05395442|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple (Participant, İnvestigator,Outcomes Assessor)|A total of 142 people, 71 people in the experimental group and 71 people in the control group, were included in the study.|t|f|t|t
34086371|NCT01344135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086372|NCT00651209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086373|NCT00626145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780101|NCT04649359|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086374|NCT03143452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34086375|NCT04215835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086376|NCT06494657|||CASE_ONLY||PROSPECTIVE|||||||
34086377|NCT02832037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086378|NCT06472648|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34086379|NCT05669937|||OTHER||PROSPECTIVE|||||||
34086380|NCT00823706|||COHORT||PROSPECTIVE|||||||
33913694|NCT03383718|||COHORT||PROSPECTIVE|||||||
34086381|NCT04329065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086382|NCT00477685|||CASE_ONLY||PROSPECTIVE|||||||
34086383|NCT02474186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086384|NCT01838876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086385|NCT01104649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086386|NCT01138735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086387|NCT03282864|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The real air filtration device and the placebo air filtration device looked identical, however the placebo air filtration device lacked the HEPA and active carbon filters which functioned to remove airborne pollutants.|Every study subject had the air in their bedroom processed by an air filtration device (with a pre-filter, a HEPA filter and an active carbon filter) for two weeks (active comparator arm), processed by a placebo air filtration device (which did not possess the HEPA filter and active carbon filters) for two weeks (placebo arm), and underwent a two-week washout period (no use of air filtration device) between the two intervention periods.|t|t|f|t
34086388|NCT01963611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780102|NCT04060680|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33780103|NCT05101330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"We will recruit 40 patients who have just been given a new oral medication for a chronic disease. They will then be randomized (1:1) to either Pilot Trial A or Pilot Trial B.~There will be 2 pilot versions of a 2-arm parallel-group RCT."|f|f|f|t
33780104|NCT03185429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780105|NCT05660369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780106|NCT04793100|NA|SINGLE_GROUP||OTHER||NONE||||||
33780107|NCT04183829|||COHORT||PROSPECTIVE|||||||
33780108|NCT02552511|||CASE_CONTROL||RETROSPECTIVE|||||||
33780109|NCT03405415|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780110|NCT03356860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780111|NCT06036979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780112|NCT02925871|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33780113|NCT05515536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913695|NCT03095924|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis|Two arms, parallel group, randomized controlled trial|t|f|f|f
33994602|NCT03546738|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|During the 12 months following implantation of a spinal cord stimulation (SCS) system, the patients will undergo four three-month long periods with either burst SCS or no stimulation (sham) in a randomized order. All patients will undergo two periods of SCS and sham stimulation.||t|t|t|t
33994603|NCT00789308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994604|NCT05241639|||CASE_CONTROL||PROSPECTIVE|||||||
33994605|NCT00624286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994606|NCT02440607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994607|NCT06624735|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33994608|NCT03649763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994609|NCT05277896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086389|NCT00775879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086390|NCT01258374|||COHORT||PROSPECTIVE|||||||
34086391|NCT05186480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34086392|NCT05968235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086393|NCT00995878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780114|NCT06310122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups : group (A) , group (B) One of them will receive traditional treatment ( ultra sound , exercises) Other one will recieve extracorporeal shockwave therapy and traditional treatment also|t|f|f|f
33780115|NCT04002089|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33780116|NCT06117683|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|The care provider will not know the recorded lung function recordings.|Study Design A non-inferiority trial; a pre-post study design (single group, within-group comparison)|f|t|f|f
33780117|NCT00795132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780118|NCT05703542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780119|NCT03491124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33780120|NCT04484688|||CASE_ONLY||PROSPECTIVE|||||||
33913696|NCT05939596|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913697|NCT05658354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913698|NCT03758430|||COHORT||PROSPECTIVE|||||||
33780121|NCT06059313|||CASE_ONLY||PROSPECTIVE|||||||
33913699|NCT05191823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34086394|NCT01117870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086395|NCT05471505|||OTHER||RETROSPECTIVE|||||||
34086396|NCT04587713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086397|NCT03678740|||CASE_ONLY||OTHER|||||||
34086398|NCT04264741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34086399|NCT01508520|||CASE_ONLY||PROSPECTIVE|||||||
33780122|NCT06495411|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33780123|NCT01000870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801388|NCT04458454|||COHORT||PROSPECTIVE|||||||
33801389|NCT03268213|NA|SINGLE_GROUP||TREATMENT||NONE||FMT is offered as a treatment to eligible patients||||
33913700|NCT05466266|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33913701|NCT01658696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33913702|NCT02220075|||OTHER||PROSPECTIVE|||||||
34086400|NCT06284473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and study personnel are blinded except for the clinical pharmacist who prepares the intervention.|Patients presenting to the emergency department at Loyola University Medical Center for a minor medical procedure requiring local anesthesia will be randomly assigned to receive either standard local anesthesia with 0.7 mg/kg intranasal ketamine before the procedure or to standard local anesthesia with volume-based dose saline before the procedure using a 1:1 random block allocation.|t|t|t|t
34086401|NCT01307514|||CASE_CROSSOVER||PROSPECTIVE|||||||
34086402|NCT01789268|||COHORT||PROSPECTIVE|||||||
33913703|NCT05049837|||COHORT||RETROSPECTIVE|||||||
33913704|NCT04593693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913705|NCT04820543|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant and the outcomes assessor will be prevented from having knowledge of the interventions assigned to individual participants.||t|f|f|t
34086403|NCT00623675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086404|NCT00838851|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086405|NCT04194632|NA|SINGLE_GROUP||TREATMENT||NONE||As described previously, patients will undergo measurements at baseline, with pacing, and post pacing and will thus function as their own control.||||
34086406|NCT05861908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Multi-arm parallel design was followed in this study. There were four group according to placement techniques of bulk-fill resin composite restorations. Each group received 20 restored class II cavities.~All the restorations will be clinically evaluated after 1 week(baseline), 12, 24 and 36 months. Restoration will be evaluated using FDI criteria"|t|f|t|f
34086407|NCT02130609|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Even though this study has recruited more than 10 participants, it is a feasibility study, designed to test the prototype rather than measuring health outcomes. It is to confirm the operating specifications before beginning a full clinical trial. The objective of this study is to improve the treatment guidelines for the Elite+ by determining the maximum safe settings for skin and correlate them to measurement of Melanin Index (MI).||||
34086408|NCT02807922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086409|NCT00808340|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34086410|NCT03356717|RANDOMIZED|PARALLEL||OTHER||NONE||randomized study||||
34086411|NCT01794468|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33913706|NCT01554306|||CASE_ONLY||PROSPECTIVE|||||||
34086412|NCT02939352|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34086413|NCT03470519|||COHORT||PROSPECTIVE|||||||
34086414|NCT04009837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34086415|NCT02156258|||CASE_CONTROL||PROSPECTIVE|||||||
34086416|NCT02926014|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34086417|NCT02655874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34086418|NCT03315260|||COHORT||PROSPECTIVE|||||||
34086419|NCT03271697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086420|NCT03423771|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086421|NCT01022606|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34086422|NCT05201937|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34086423|NCT02849028|||CASE_CONTROL|||||||||
34086424|NCT04694092|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 1:1 to intensive rate control with landiolol vs. standard therapy||||
33801390|NCT03373708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913707|NCT05414617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, Multi-center, Open Clinical Investigation.~Two facilities are participating ; each facility will be in charge and perform a type of viscosupplementation procedure : single injection or three injections.~Subjects will received one or the other viscosupplementation depending of the facility in which they will be included."||||
33913708|NCT05923476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913709|NCT02720016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study assessors are kept blind to the couple's randomly assigned treatment condition.||f|f|f|t
33913710|NCT03959449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913711|NCT00568958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913712|NCT03532672|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33913713|NCT04190953|RANDOMIZED|PARALLEL||OTHER||SINGLE|When data will be analyzed, data will be coded to keep confidentiality for time and type of treatment.|Twin block and Hyrax appliances will be installed in 1/3 of the patients, while hyrax and twin block devices will be applied to the other 1/3 of the patients. Another 1/3 of patients will be the control group with no treatment|f|f|f|t
33913714|NCT02697084|||COHORT||PROSPECTIVE|||||||
33913715|NCT01769417|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33913716|NCT06244940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913717|NCT03085706|NA|SINGLE_GROUP||TREATMENT||NONE||14 patients conducted at the First Affiliated Hospital of Dalian Medical University, China were eligible if they had definite or probable sporadic amyotrophic lateral sclerosis (ALS).||||
33913718|NCT06219616|NA|SINGLE_GROUP||SCREENING||NONE||Every kidney transplant recipient will be tested for BKV-specific immune response after transplantation to identify the potential immune predicting tool for developing BKV reactivation.||||
33913719|NCT04910724|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized, parallel study comparing the effects of 3 magnitudes of energy deficit.||||
33913720|NCT04710524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913721|NCT00064597|||DEFINED_POPULATION||OTHER|||||||
33913722|NCT06009718|||CASE_CONTROL||PROSPECTIVE|||||||
33913723|NCT00418834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913724|NCT02165800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913725|NCT03928431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Mothers who give birth by CS will be randomized to expose their neonate to samples of their vaginal and fecal microbiome after birth or to placebo.|In this RCT, 330 infants of healthy mothers (age 18 to 40 years) with uncomplicated pregnancies will be included and the infants followed primarily for two years. The number has been increased to cover for potential drop-outs.|t|f|t|t
34086425|NCT05964062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780124|NCT06285773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for open heart surgery (coronary artery bypass) with median sternotomy will be included in the study. Patients will be randomly divided into two groups (Group PR = PIFPB + RIFPB group, Group C = Control group) including 30 patients each, before entering the operating room.|t|f|f|t
33913726|NCT01151046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086426|NCT01324297|||COHORT||PROSPECTIVE|||||||
34086427|NCT02106507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086428|NCT00570947|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913727|NCT03877120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Clinical Trials To compare Diazepam 5-20 mg IV or Dexmedetomidine 0.2-0.7 mcg / Kg / min., In monotherapy until the CIWA-Ar decreases to \<10.|t|f|f|f
33994610|NCT05668689|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|"Participants Participants will complete the test online or face-face and questions for each participant will be presented in a random order - no test is the same. Participants will not know the result of the test.~Investigators Each participant will be identified by a unique sequential number identifier allocated to them and this will ensure all participants will have pseudo-anonymised data. Investigators can only veiw the pseudo-anonymised results."|"Phase 1 Nerve block identification~Phase 2 Content and question generation~Phase 3 Preliminary testing~Phase 4 Testing for content validity~Phase 5 Psychometric main study testing"|t|f|t|f
33994611|NCT06223139|||COHORT||CROSS_SECTIONAL|||||||
33994612|NCT05429463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994613|NCT02225782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994614|NCT04159103|NA|SEQUENTIAL||TREATMENT||NONE||||||
33994615|NCT00081653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994616|NCT04994535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994617|NCT03893123|||COHORT||RETROSPECTIVE|||||||
33994618|NCT04982523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994619|NCT03774862|||COHORT||RETROSPECTIVE|||||||
33994620|NCT04505163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994621|NCT00907387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994622|NCT01521780|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33994623|NCT04084613|||COHORT||PROSPECTIVE|||||||
33994624|NCT01703754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994625|NCT06561763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086429|NCT06018090|||COHORT||PROSPECTIVE|||||||
34086430|NCT04410393|||COHORT||PROSPECTIVE|||||||
34086431|NCT00325416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086432|NCT04585997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|People assessing outcomes and analyzing results are blinded||f|f|f|t
34086433|NCT03076463|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||GRAPOM: dried and milled grape pomaces. CTR: control period. All the subjects will pass the two periods: one half will do the CTRL period followed by the GRAPOM period, and the other half will do it inversely. The assignment to each order will be done randomly. Both period will be separated by a four weeks washing period.|f|f|t|f
34086434|NCT01962675|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34086435|NCT03051711|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34086436|NCT05828342|||COHORT||PROSPECTIVE|||||||
34086437|NCT05441189|||COHORT||RETROSPECTIVE|||||||
34086438|NCT03069989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086439|NCT02445469|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086440|NCT04260113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086441|NCT01434511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086442|NCT01855269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33994626|NCT06328829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086443|NCT00677222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086444|NCT05555680|||COHORT||PROSPECTIVE|||||||
34086445|NCT04301050|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086446|NCT05203315|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open Label Study||||
33780125|NCT05446662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33913728|NCT04887103|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||pretest-posttest randomized controlled study|t|f|f|f
33913729|NCT04790994|||COHORT||PROSPECTIVE|||||||
33913730|NCT00125190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913731|NCT05445011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913732|NCT00285974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913733|NCT00906074|||CASE_CONTROL||PROSPECTIVE|||||||
33913734|NCT05201274|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33913735|NCT02352792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913736|NCT05962814|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A single group of infants without hearing impairment will be recruited so that safety and preliminary efficacy can be determined.||||
33913737|NCT02013466|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33913738|NCT01208038|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913739|NCT05201183|NA|SEQUENTIAL||TREATMENT||NONE||"A standard 3+3 phase I design of dose escalation using 3 patients per dose level cohort with an expansion to 6 patients at the MTD will be used in Phase I. We will treat 3 patients at the initial dose level of TMI. If no dose-limiting toxicity (DLT) is observed, the next cohort of three patients is treated at the next higher dose level. If 1 of the 3 patients demonstrates DLT, an additional 3 patients are treated at that dose level. If only 1 of the 6 shows DLT, the next cohort of three patients is entered at the next dose level. If 2 or more of the 6 demonstrate DLT, the MTD is defined as the previous dose level. If no DLT is observed in the final dose level, the number of patients treated will be expanded to 6. In phase II, we will enroll additional patients at the defined MTD level."||||
33913740|NCT04695106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33913741|NCT01533935|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33913742|NCT05393817|||CASE_CONTROL||PROSPECTIVE|||||||
33994627|NCT06345053|NA|SINGLE_GROUP||TREATMENT||NONE||This is a repeated measures follow-up feasibility study without control group.||||
33994628|NCT01099007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994629|NCT04716582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33994630|NCT05381727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086447|NCT01029756|RANDOMIZED|PARALLEL||||NONE||||||
34086448|NCT06372561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780126|NCT01738711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780127|NCT01125202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780128|NCT01302782|||||PROSPECTIVE|||||||
33780129|NCT01643395|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780130|NCT04027920|||CASE_ONLY||RETROSPECTIVE|||||||
33780131|NCT00508976|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33780132|NCT06647303|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33780133|NCT04734041|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study||||
33780134|NCT05012930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33780135|NCT04911686|||COHORT||PROSPECTIVE|||||||
33780136|NCT03456063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33780137|NCT03020355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780138|NCT06422026|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33780139|NCT06451510|||COHORT||CROSS_SECTIONAL|||||||
33780140|NCT02205879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780141|NCT01091181|RANDOMIZED|PARALLEL||OTHER||DOUBLE|the surgeon who performed the operation knew what technique to use. Participant were not informed in what group they were. Six months postpartum patients came to ultrasound department and underwent ultrasound examination of uterus and uterine cesarean scar. Sonographer was blinded to the surgery technique.|women aimed for emergency cesarean section were randomized into two groups according to surgery technique of opening the uterus: 1 Group - high level of hysterotomy incision; 2 Group - low level of hysterotomy incision. Opening and closing of abdomen performed in the same manner in both groups|t|f|t|f
33780142|NCT06528132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in the intervention group will receive mindfulness-based intervention from social workers either with or without peer supporters involved. The care as usual group will receive usual service provided in District Elderly Community Centres (DECC) and Integrated Community Centre for Mental Wellness (ICCMW).||||
33780143|NCT04068597|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The RP2D/MTD dose will be determined in Parts A and B. Parts C, D, E and F of the study may recruit patients concurrently.||||
33780144|NCT03941301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780145|NCT06032949|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Patients from 2 populations will be included: high-risk patients (any of the following: redo groin incision, active smoker, A1c \>/= 9.0, BMI \>/= 30) and non-high-risk patients.||||
33780146|NCT02656043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780147|NCT04714411|||COHORT||PROSPECTIVE|||||||
33780148|NCT05468203|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded|Prospective, international, multi-centre, double blinded, randomised controlled trial|t|t|t|t
33913743|NCT03213613|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33913744|NCT01954303|||||RETROSPECTIVE|||||||
33913745|NCT02692794|||COHORT||PROSPECTIVE|||||||
33913746|NCT03396250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913747|NCT02238496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|||||
33913748|NCT02457182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913749|NCT02304536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33913750|NCT00551538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913751|NCT01444794|||COHORT||PROSPECTIVE|||||||
33913752|NCT03487900|NA|SINGLE_GROUP||OTHER||NONE||||||
33913753|NCT03765619|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33913754|NCT02370498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913755|NCT02038296|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33913756|NCT03105700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913757|NCT03357809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913758|NCT02520518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33913759|NCT02366663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913760|NCT01702363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913761|NCT04048525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Pilot randomized controlled trial|f|f|f|t
33913762|NCT04747483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913763|NCT06350344|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913764|NCT04949880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913765|NCT04777643|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33913766|NCT06257498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913767|NCT04367025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913768|NCT00782015|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33913769|NCT02306707|||COHORT||PROSPECTIVE|||||||
33913770|NCT01090089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913771|NCT06280157|||COHORT||PROSPECTIVE|||||||
33913772|NCT04179968|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Unblinded, single arm imaging study||||
33913773|NCT03910998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomization into group D for Deep muscle relaxation (high doses of intraoperative rocuronium and antagonization at the end with 4mg/kg of suggamadex) vs group M for Moderate muscle relaxation (moderate doses of intraoperative rocuronium and antagonization at the end with suggamadex 2mg/kg) will be done prior to the entrance in the OR, the day of the surgery"|"Tow groups of patients. Randomization into group D for Deep muscle relaxation vs group M for Moderate muscle relaxation according to a randomization list for a total number of 100 patients"|t|t|t|t
33913774|NCT03483324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913775|NCT01782456|NA|SINGLE_GROUP||||NONE||||||
33913776|NCT05632575|NA|SINGLE_GROUP||PREVENTION||NONE||Observational, single group, pre-post test design.||||
33913777|NCT03926559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33913778|NCT05199350|||COHORT||CROSS_SECTIONAL|||||||
33913779|NCT02124616|||CASE_ONLY||PROSPECTIVE|||||||
33913780|NCT03943758|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33913781|NCT02969447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913782|NCT02052843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913783|NCT04715230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913784|NCT04478149|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Waitlist control|t|t|f|f
33994631|NCT06397339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Group Randomized Trial with 28 urban and rural clinics that serve AI/ANs in 11 states. INTACT will be randomized at the clinic level and delivered to PCPs in clinics. Most outcome data will be derived from EHRs and PCP surveys. The study will use an immediate intervention and waitlist control randomization pattern with clinics randomized to the immediate intervention group receiving the INTACT program after the baseline data collection and the waitlist control group after the 12-month follow-up data collection is complete.||||
33994632|NCT03342846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994633|NCT01169753|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33994634|NCT06128967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The production of medication bottles is carried out by a pharmaceutical company, which does not have access to members of the research centers. The pills are similar in shape, color, size and weight and are packaged in identical bottles and coded according to each medication arm, this code being inaccessible to the investigator, the sponsor, the medical care provider and the research participant.~The allocation process follows a random sequential distribution into blocks. The posology of the medications is identical for all arms."|Multicenter, adaptive, randomized, double-blind, placebo-controlled, prospective, pharmacological intervention trial|t|t|t|t
33994635|NCT04522063|||COHORT||CROSS_SECTIONAL|||||||
33994636|NCT01098903|||COHORT||PROSPECTIVE|||||||
33994637|NCT03724890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994638|NCT02336074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994639|NCT04577651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994640|NCT00101439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33994641|NCT06560502|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a prospective modified dual platform (matriarch) multicenter randomized controlled clinical trial.||||
33994642|NCT00955838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994643|NCT05921981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33994644|NCT06547294|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm with historical controls||||
33994645|NCT01661803|||CASE_CONTROL||PROSPECTIVE|||||||
33994646|NCT01148186|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33994647|NCT00876967|RANDOMIZED|PARALLEL||||NONE||||||
33994648|NCT03921879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study OT-82-001 is a Phase 1, non-randomized, controlled, first-in-human, two stage (dose escalation and dose expansion) study evaluating multiple doses and schedules of orally administered OT-82 in patients with R/R lymphoma||||
33994649|NCT00594035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691647|NCT05471479|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|"Data Analysts: These individuals are responsible for processing and analyzing the collected data. They are blinded to the group allocations to ensure that their analyses are unbiased.~Research Assistants: Those involved in collecting trial data from participants, including demographics, medical history, and treatment outcomes, are also blinded to the allocation groups."|The CHARPP pilot trial employs a Prospective Randomized Open Blinded End-point (PROBE) interventional study model. The study is designed to follow participants forward in time after their enrollment, with interventions and outcomes measured as they occur. Participants are randomly assigned to either the intervention group, which receives activated charcoal, or the control group, which does not receive activated charcoal. This randomization helps to minimize selection bias and balance known and unknown confounding factors across the study groups. The nature of the intervention (activated charcoal) makes it impractical to blind the participants or the clinicians administering the treatment, as the substance visibly changes the color of the oral mucosa to black. While the immediate caregivers and participants know the treatment allocation due to the visible nature of activated charcoal, the outcome assessors and data analysts are blinded to the group assignment.|f|f|t|t
33994650|NCT04295486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994651|NCT00352989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33994652|NCT01103713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994653|NCT06391450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994654|NCT05946486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994655|NCT06628076|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33994656|NCT02247362|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33691648|NCT06737289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blind|Split Mouth Design|t|f|f|t
33691649|NCT05276570|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33691650|NCT06735625|NON_RANDOMIZED|PARALLEL||OTHER||NONE||30 sickle cell patients over 15 and a half years old with SS or Sβ0 phenotype 30 control patients over 15 and a half years old without hemoglobin abnormalities, recruited at the hospital 20 pediatric sickle cell patients (aged between 3 and 15 and a half years) with SS or Sβ0 phenotype 20 pediatric control patients (aged between 3 and 15 and a half years) without hemoglobin abnormalities, recruited at the hospital||||
33691651|NCT05058651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780149|NCT06576193|RANDOMIZED|PARALLEL||OTHER||SINGLE|Field Data Collectors (FDCs) will be masked to the participant group assignments until after the baseline data collection is completed.|Individual AYA will be block-randomized to the SDYP intervention with standard prenatal and post-partum services (intervention condition) or standard services only (control condition) using a 1:1 allocation within each site (stratified randomization) to ensure balanced assignment, using permuted blocks sizes of 4 and 6.|f|f|f|t
33691652|NCT00330798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691653|NCT06672666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691654|NCT05955261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691655|NCT06418711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During Part A of the study, the identity of the treatments will be concealed by the use of a placebo, and treatment unblinding will only occur in the case of participant emergencies or if requested by the Data and Safety Monitoring Board (DSMB).~Sputum Test Results: Results of post-baseline testing for the presence of NTM in sputum will remain concealed until the participant has completed Part A of the study and the participant's result for the sample taken at the end of Month 6 becomes available."|At least 234 eligible participants will be randomized in a 2:1 ratio of 1 of 2 possible treatment assignments in order to ensure that a minimum of 180 participants are evaluable for efficacy: Clofazimine Inhalation Suspension (N=120) and placebo (n=60). Randomization will be stratified by type of nontuberculous mycobacteria (NTM) infection (Mycobacterium avium complex \[MAC\] infection only vs MAC co-infection with Mycobacterium abscessus complex \[MABSC\] or other NTM species) based on historical samples used to establish eligibility during screening. Enrollment of participants with MAC coinfection with MABSC or other NTM species will be capped at 20% of all participants to limit heterogeneity in the participant population.|t|t|t|t
33691656|NCT06740838|||COHORT||OTHER|||||||
33691657|NCT05851443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691658|NCT03595293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691659|NCT06395103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691660|NCT06571045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel enrollment into 1 of 3 arms|t|t|t|t
33691661|NCT06671262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691662|NCT04855136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691663|NCT06628362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691664|NCT06739057|||CASE_CONTROL||RETROSPECTIVE|||||||
33691665|NCT04541706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691666|NCT06744673|||CASE_CONTROL||RETROSPECTIVE|||||||
33691667|NCT04216719|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge design||||
33691668|NCT06745414|||OTHER||PROSPECTIVE|||||||
33691669|NCT06344780|||COHORT||RETROSPECTIVE|||||||
33691670|NCT03965468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691671|NCT06744894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691672|NCT06744569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691673|NCT06485687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691674|NCT06139211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691675|NCT06744127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691676|NCT06741670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Outcomes Assessor)|Parallel Assignment Prospective, randomized controlled trial|f|f|f|t
33691677|NCT06744114|||CASE_ONLY||RETROSPECTIVE|||||||
33691678|NCT05370885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691679|NCT06120075|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691680|NCT06432764|NA|SEQUENTIAL||TREATMENT||NONE|Open label study|||||
33691681|NCT06738316|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33780150|NCT03808922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780151|NCT02091037|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780152|NCT00000989||PARALLEL||TREATMENT||||||||
33780153|NCT03548922|||COHORT||PROSPECTIVE|||||||
33913785|NCT02391844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913786|NCT01511419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913787|NCT06254027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded evaluation is done by digital analysis of photographs of the infected toenail or fingernail.||f|f|f|t
33913788|NCT02121756|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33913789|NCT03828084|RANDOMIZED|CROSSOVER||OTHER||NONE||Four-way crossover, single dose with a 7 days washout period in between periods||||
33913790|NCT02444819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913791|NCT00625521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691682|NCT06199492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691683|NCT06079671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33691684|NCT05030766|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33691685|NCT04671797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691686|NCT05677139|||COHORT||PROSPECTIVE|||||||
33780154|NCT01730417|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780155|NCT02931162|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33780156|NCT01870609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780157|NCT00003377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780158|NCT03082300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913792|NCT04364698|||COHORT||PROSPECTIVE|||||||
33913793|NCT03014167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Mass drug administration intervention is not blinded to study participants but investigators and outcome assessors remain blind to link between allocation and outcome data||f|f|t|t
33913794|NCT03689725|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994657|NCT05854784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994658|NCT04343794|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33994659|NCT03911037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994660|NCT00052377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994661|NCT00870558|RANDOMIZED|||TREATMENT||||||||
33994662|NCT03227315|||CASE_ONLY||PROSPECTIVE|||||||
33994663|NCT02770222|RANDOMIZED|CROSSOVER||||NONE||||||
33994664|NCT03317444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994665|NCT02531620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994666|NCT01443195|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33913795|NCT01730144|||OTHER||PROSPECTIVE|||||||
33913796|NCT00712322|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33913797|NCT04325594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913798|NCT00147732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994667|NCT02563379|||COHORT||CROSS_SECTIONAL|||||||
33994668|NCT03099915|||COHORT||PROSPECTIVE|||||||
33994669|NCT00135850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691687|NCT06742554|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized, parallel-assignment study where participants are allocated to one of two intervention groups. Group A will receive a Buprenorphine 10 mg transdermal patch applied 4 hours prior to surgery, providing sustained analgesia for up to 72 hours postoperatively. Group B will receive Tramadol at a standard dosage (100 mg every 8 hours as needed for pain) starting postoperatively. Both groups will receive interscalene brachial plexus block (ISBPB) as part of their intraoperative anesthesia.|t|t|f|t
33994670|NCT01651845|||COHORT||PROSPECTIVE|||||||
33691688|NCT04519814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691689|NCT06743620|||COHORT||PROSPECTIVE|||||||
33994671|NCT06000085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33691690|NCT06439407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691691|NCT03946358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691692|NCT03524092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691693|NCT06740851|||COHORT||PROSPECTIVE|||||||
33691694|NCT03900949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691695|NCT06226818|||COHORT||PROSPECTIVE|||||||
33691696|NCT02122107|||COHORT||PROSPECTIVE|||||||
33691697|NCT06744803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized control trial (prospective follow up study)||||
33691698|NCT06735534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691699|NCT06745869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The researcher who evaluated the analysis, and the participants are blind to the study|A randomized-controlled trial|t|f|f|t
33691700|NCT06263231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691701|NCT05354947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691702|NCT06744491|||COHORT||CROSS_SECTIONAL|||||||
33691703|NCT06007651|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33691704|NCT05485831|||COHORT||PROSPECTIVE|||||||
33780159|NCT04872712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator do not know the respondents. There will be 3 Outcomes Assessors who will randomly assess the respondents. The laboratory assistant will not be informed of the treatments provided to the respondents.||f|f|t|t
33780160|NCT01085487|||CASE_CONTROL||PROSPECTIVE|||||||
33780161|NCT05000190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33780162|NCT02442544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780163|NCT04559399|NA|PARALLEL||TREATMENT||NONE||"all patients confirmed diagnosis and including criteria of intervention divided randomly in to 2 groups,control group include patients treat by transpedical screw and rod fixation and experimental group include patients treats smiley face rod technique and then clinical and radiological follow up for 6 month.~the varibals that will be measure are:~1. intraoperative variables :length of wound,blood loss and time of operation.~2. clinical outcome:pain and disability~3. radiological variables :fusion and degenerative of the adjacent level"||||
33913799|NCT04725370|||COHORT||OTHER|||||||
33913800|NCT00999856|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913801|NCT03700008|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The outcome-assessor or rater did not know which diagnosis the participant has and the participant is informed about the diagnosis after the diagnostic procedure from a physician/ psychotherapist not involved in the study.|Two randomized groups of participants, blinded to rater in relation of the diagnosis of the individual proband.|f|f|f|t
33913802|NCT05272527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant)|Randomized controlled experimental design|t|f|f|f
33913803|NCT02200367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913804|NCT06053216|RANDOMIZED|PARALLEL||OTHER||NONE|Open-label trial. However, clinicians will be blinded to indirect calorimetry measurements in the control arm.|A multi-centre, prospective, two arm parallel feasibility pilot randomised controlled trial||||
33913805|NCT05322018|||COHORT||CROSS_SECTIONAL|||||||
33913806|NCT03696303|||CASE_CONTROL||PROSPECTIVE|||||||
33994672|NCT06254014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study uses a double-blind technique, which means that neither the investigator nor the subject knows what drug is being used. The sponsor will provide the study drug and the control drug, ensuring that the placebo shape, color, and weight are identical to the study drug.|Randomized in a 1:1:1 ratio to the 1.2 mg JY09 injection group (n=90 cases), the 2.4 mg JY09 injection group (n=90 cases), and the placebo group (n=90 cases).|t|t|t|t
33994673|NCT05813847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994674|NCT06262295|||COHORT||PROSPECTIVE|||||||
33994675|NCT03542669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994676|NCT05606458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994677|NCT05026138|||COHORT||PROSPECTIVE|||||||
33994678|NCT01207479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994679|NCT02911025|||COHORT||PROSPECTIVE|||||||
33994680|NCT05755113|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
33994681|NCT00848536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994682|NCT02566122|||COHORT||OTHER|||||||
33691705|NCT06744543|RANDOMIZED|PARALLEL||SCREENING||NONE|There will be no blinding of participants or physicians as patients and providers will follow standard of care. Providers may dismiss the SIGHT - prompted provider message and not act on its recommendations at any time. No other intervention is planned. Patients would be unaware of the providers' decisions in that case unless the provider chooses independently to discuss the SIGHT score with them. A sample size re-estimation will be conducted after 250 patients have been randomized to account for uncertainty in the initial test-referral rate used in the sample size calculation. An independent analyst, who will be blinded to the randomization assignment, will calculate the observed test-referral rate across all patients.|1:1 allocation by predicted probability to either the intervention group, receiving a SIGHT-prompted provider message, or the control group, receiving standard care without the SIGHT-prompted message. The randomization process will be integrated into the routine clinical workflow, with SIGHT scores generated before regularly scheduled patient visits in pediatric primary care at VUMC.||||
33691706|NCT06745479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33691707|NCT05140369|||COHORT||PROSPECTIVE|||||||
33691708|NCT06096337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691709|NCT06738342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33691710|NCT05550532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691711|NCT04808843|||COHORT||PROSPECTIVE|||||||
33691712|NCT04850118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|For groups 1 and 2 (AGTC-501 dosing groups), both the participants and the Investigators are masked to dose assignment, and only the unmasked staff who prepare the dose are unmasked to the participants dose assignment. Due to the need to perform the subretinal injection to administer the study drug, both participants and Investigators will know whether the participant was assigned to a treatment group or to the control group. To minimize bias of the treated and control study eye evaluations, starting at Month 3, microperimetry, and BCVA/LLVA assessments will be conducted by appropriately qualified masked evaluators who do not know whether the participant underwent surgery. Participants will be instructed not to disclose whether they had surgery to the examiner administering the test.|Participants are randomized in a 1:1:1 ratio to 1 of 3 groups (high dose, low dose, untreated) control. After 12 months, participants in the untreated group will be evaluated to determine eligibility to receive the high dose of AGTC-501.|t|t|t|t
33691713|NCT06625177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691714|NCT06520215|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33780164|NCT03909139|||COHORT||PROSPECTIVE|||||||
33780165|NCT06648096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780166|NCT06696989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780167|NCT04040582|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780168|NCT06298032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780169|NCT04569708|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780170|NCT06340126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780171|NCT01492855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33780172|NCT00547664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780173|NCT03708068|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780174|NCT01427907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780175|NCT05866445|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Study team and participants will be blinded to whether they are receiving the magnetic device or sham device. Delegated unblinded team member will assign study device to recruited participants.|Participants from 2 different groups (Hypertensive and Normotensive groups) will be randomized into 2:1:1 to receive the original strength magnetic device vs half strength magnetic device (half the strength of the original magnetic device) vs the sham device respectively.|t|t|t|f
33913807|NCT02854137|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33913808|NCT04008277|||CASE_ONLY||PROSPECTIVE|||||||
33913809|NCT02771249|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33913810|NCT06519552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913811|NCT04064320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913812|NCT03085641|NA|SINGLE_GROUP||TREATMENT||NONE||prospective one armed uncontrolled intervention pilot study||||
33913813|NCT04719065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913814|NCT02976376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913815|NCT04892758|||COHORT||RETROSPECTIVE|||||||
33913816|NCT03081286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During general anesthesia, patients are randomized to either fat grafting or sham grafting with only saline. All patients undergo the same liposuction. Participants are blinded, care providers postoperatively are blinded. The surgeon performing the procedure is not blinded. The outcome assessors 3 and 6 months postoperatively are blinded.||t|t|f|t
33913817|NCT03314220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913818|NCT00259220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913819|NCT00526149|NON_RANDOMIZED|||TREATMENT||NONE||||||
33913820|NCT01521234|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33913821|NCT03233841|||COHORT||OTHER|||||||
33913822|NCT04757727|||CASE_ONLY||PROSPECTIVE|||||||
33913823|NCT00131040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33913824|NCT01171404|||COHORT||PROSPECTIVE|||||||
33913825|NCT01076634|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33913826|NCT05894473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913827|NCT06335368|||CASE_ONLY||RETROSPECTIVE|||||||
33913828|NCT04157985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913829|NCT01642524|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33780176|NCT04890665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are not aware that there is an experimental group and a control group, the participants are not related and do not know each other. The conditions of the study are only known by the researcher, the therapists, and the Research Ethics Committee of the Universidad Autónoma de Ciudad Juárez.|The study has two arms, one is the experimental group that receives the treatment solely through the online platform, and the other is the comparison group that will receive treatment delivered through a therapist through video calls. The patients in both groups will be evaluated pre and post/treatment. The participants are assigned randomly to the intervention or comparison group.|t|f|f|f
33913830|NCT01869062|RANDOMIZED|PARALLEL||OTHER||DOUBLE||CRT-D device|t|f|f|t
33913831|NCT06105424|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33780177|NCT04626921|NA|SINGLE_GROUP||TREATMENT||NONE|None, open-label.|Open-Label, Long-Term Extension.||||
33994683|NCT05795504|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33994684|NCT04332445|NA|SINGLE_GROUP||OTHER||NONE||Clinical trial, single-arm||||
33994685|NCT01910038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994686|NCT04863560|||COHORT||CROSS_SECTIONAL|||||||
33780178|NCT00205894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691715|NCT04769310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All patients will undergo a CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner. CMR protocol will include Cine MRI, contrast-enhanced (CE) MR Angiography (MRA), time-resolved 2D phase-contrast (PC) MRI, and 3D late gadolinium enhancement (LGE) involving gadolinium injection. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~Brain MRI will be used for the detection of embolic infarcts assessed on high-resolution brain MRI acquisitions. The high-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE), 3D fluid attenuated inversion recovery (FLAIR), diffusion weighted imaging (DWI), apparent diffusion coefficient maps (ADC), and susceptibility weighted imaging (SWI)."||||
33691716|NCT05986721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomized 2:1, 3:1, or 4:1, following an escalating randomization scheme. A total of 60 subjects will be randomized (approximately 44 subjects will be randomized to AGB101 and 16 to placebo)|t|t|t|t
33691717|NCT05691309|||COHORT||PROSPECTIVE|||||||
33691718|NCT06744933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691719|NCT06744348|||CASE_CONTROL||RETROSPECTIVE|||||||
33691720|NCT04073563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780179|NCT03826563|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Only the pharmacy will know the randomization arms.||t|t|t|t
33780180|NCT05727683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780181|NCT00430677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780182|NCT05362916|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre, open-label, randomized, controlled clinical trial||||
33780183|NCT03938974|||COHORT||PROSPECTIVE|||||||
33780184|NCT01253200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subject was not told by investigator if device used was Investigational or Control. The subject could ask the investigator at end of study at 3 months if they wanted to know which device was used.||t|f|f|f
33780185|NCT01939938|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33780186|NCT02783482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780187|NCT02477826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780188|NCT03437798|||COHORT||RETROSPECTIVE|||||||
33780189|NCT02925429|||COHORT||PROSPECTIVE|||||||
33780190|NCT01314495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780191|NCT00710723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780192|NCT05506345|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33780193|NCT00998816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780194|NCT03347045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blinding; due to the nature of the study, participant, care provider \& investigator cannot be blinded.|Single-center pragmatic randomized-control trial.|f|f|f|t
33780195|NCT01220674|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33780196|NCT00205530|||COHORT||PROSPECTIVE|||||||
33780197|NCT03906487|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780198|NCT01488110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780199|NCT06459986|||COHORT||PROSPECTIVE|||||||
33780200|NCT06268860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780201|NCT01245777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780202|NCT02338609|NA|SINGLE_GROUP||OTHER||NONE||||||
33780203|NCT00230685|||COHORT||PROSPECTIVE|||||||
33780204|NCT06141668|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33801391|NCT04364139|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants and investigators were masked to randomized drug but not BP goal||t|f|t|f
33913832|NCT03247660|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||3 groups: 2 experimental groups and 1 control group|f|f|t|t
33994687|NCT05488158|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994688|NCT04631562|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33913833|NCT04671316|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment single-dose, 6-sequence, 3-period Bioequivalence Study||||
33913834|NCT04115696|||COHORT||PROSPECTIVE|||||||
33913835|NCT03009539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913836|NCT01609803|||COHORT||RETROSPECTIVE|||||||
33913837|NCT05394584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a cluster randomized wait-list control study.|f|f|f|t
33913838|NCT01591772|||CASE_CROSSOVER||PROSPECTIVE|||||||
33913839|NCT02002338|||CASE_ONLY||CROSS_SECTIONAL|||||||
33913840|NCT02811536|||COHORT||PROSPECTIVE|||||||
33913841|NCT03892330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913842|NCT04774042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913843|NCT03533140|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994689|NCT00343213|NON_RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33994690|NCT02343796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086449|NCT01898416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719893|NCT03978585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"After baseline data and outcome assessment participants will consecutively be randomly assigned to intervention or control group. Thus, neither patients nor the responsible physician will know about the allocation to the HTEMS or TENS group at the time of recruitment.~Physicians responsible for the clinical examinations and outcome assessment will be blinded. Due to the technical design of the intervention patients cannot be blinded. The analyst and outcome assessors will be kept blind to patient allocation."|The random allocation sequence will be generated using the random number generator available online (www.randomization.com). The unit of randomization will be the individual participant, such that each patient will be randomised to either have use of the HTEMS device (intervention), or TENS device (control intervention). To ensure balance in the sample size across groups, we will perform a stratified block randomisation (ratio 1:1, block size 4). Subjects will be stratified by treatment delivery, taxan and oxaliplatin. To assure concealment of allocation, physicians of the Institute of Physical Medicine and Rehabilitation will report to the Institute of General Practice, Family Medicine and Preventive Medicine as soon as patient recruitment has been completed and then randomisation by computerised sequence generation will be performed.|f|f|t|t
33780205|NCT05906628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will receive ruxolitinib cream (1.5%) or vehicle cream for 16 weeks, after which they will be offered the opportunity to receive ruxilitinib cream (1.5%) in the open-label treatment extension period for another 16 weeks.|t|f|t|t
33780206|NCT00605878|||COHORT||PROSPECTIVE|||||||
33780207|NCT03818308|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, single-arm multicenter, phase II pilot trial||||
33780208|NCT06438393|||OTHER||RETROSPECTIVE|||||||
33780209|NCT04866342|RANDOMIZED|CROSSOVER||TREATMENT||NONE|"commence on either Masimo oximetry or Nellcor oximetry using the Oxygen Assist Module (OAM), IntellO2 Vapotherm device. SpO2 (range 90-95%) will be continuously monitored on a second pulse oximetry probe connected to a bedside multiparameter monitor as per normal standard of care.~To remove selection bias the 20 infants will be randomised using sealed, windowless, envelopes. Half will instruct to commence on automated control (Precision Flow technology IntellO2, Vapotherm, USA) using Masimo oximetry technology to target SpO2 to 90-95%. Half will have instructions to commence on automated control (Precision Flow technology IntellO2, Vapotherm, USA) using Nellcor oximetry technology to target SpO2 to 90-95%."|This study is a prospective, single centre, randomised crossover trial of two different internal oximeter monitoring systems in an automated (servo) control device - IntellO2 (Vapotherm, USA) - delivering nasal high flow employing automated oxygen titration. Each infant will act as their own control.||||
33780210|NCT02243007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780211|NCT05775289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780212|NCT05182177|||OTHER||RETROSPECTIVE|||||||
33780213|NCT04361747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The 62 women who met the inclusion criteria were assigned systematically from a random starting point using a week as the unit (Yang \& Chen, 2018) to either the experimental group (n = 31) or the control group (n = 31). To avoid contaminating data by allowing participants to communicate with one another during the prenatal genetic testing evaluation, data were collected on the first week from experimental-group participants, who were selected by a research assistant who draw lots (E for experimental group and C for control group) from a sack. Subsequently, the group allotment for the following week was systematically assigned in sequence to either the control group or the experimental group.|During the 12-week prenatal genetic testing evaluation period, experimental-group participants received three nursing consultation sessions plus regular care, while their control-group peers received regular care only.|t|f|f|f
33780214|NCT03093090|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A four-way randomized crossover PK study||||
33780215|NCT01275053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780216|NCT00279422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780217|NCT04082455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780218|NCT04129580|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single site, randomized controlled trial research study.||||
33780219|NCT06340789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The design and instrument are identical for two years. This add-on sodium benzoate randomized, double-blinded, placebo-controlled trial which is a two-arm, 6-week follow-up trial. The 90 patients will be 2:1 (SB: placebo) randomly assigned to 1. Treatment with sodium benzoate (A); or 2. placebo (P). The group of sodium benzoate treatment will be divided into two subgroups: 1. Responder (AR), and nonresponder (AN), as illustrated in Figure 4. The response criteria is defined the improvement of 20% total PANSS score after 6-week SB treatment. The participants with TRS will be enrolled in this trail from 3 hospitals(National Cheng Kung University Hospital, Tainan Hospital, Ministry of Health and Welfare, Chia-Yi branch, Taichung Veteran General Hospital).|t|t|t|t
33780220|NCT00480441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780221|NCT05102903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780222|NCT06438757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780223|NCT05388006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780224|NCT03566589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780225|NCT05513235|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized single group feasibility study design||||
33780226|NCT02728219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780227|NCT01253980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780228|NCT02848235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33801392|NCT03490045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086450|NCT03408067|||CASE_ONLY||CROSS_SECTIONAL|||||||
34086451|NCT01258049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086452|NCT03255187|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants are randomly assigned to two parallel groups at enrollment using a random-number table. And the investigators randomly assign the two groups in a double-blind fashion receive either ﬁsh oil or sunflower seed oil for 4 months.|t|t|t|t
34086453|NCT00575315|||COHORT||PROSPECTIVE|||||||
34086454|NCT04012463|||CASE_CONTROL||OTHER|||||||
34086455|NCT04794907|||COHORT||OTHER|||||||
34086456|NCT06048224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086457|NCT01503879|||||PROSPECTIVE|||||||
33780229|NCT01824082|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"The investigators originally planned to unmask the treatment groups following the completion of the statistical analysis (triple masked); but following the analysis using treatment A and treatment B labels, opted to wait to unmask the groups until the manuscript was drafted (quadruple masking)."||t|t|t|t
33780230|NCT03923608|||OTHER||PROSPECTIVE|||||||
33780231|NCT06611514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780232|NCT01386216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780233|NCT01374490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801393|NCT02424318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801394|NCT05058950|||COHORT||PROSPECTIVE|||||||
33801395|NCT03262831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913844|NCT06261099|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sealed envelopes will be prepared in advance for randomization and will be marked with numbers 1 and 2, indicating whether they are a study group or a control group. Randomization will be done by a third party unaware of the study content. Randomization order tracking will be done with sequentially numbered containers. Patients participating in the study will be blinded to which treatment group they will be included in.|prospective double-blind, randomized controlled trial|t|t|t|t
33913845|NCT05804409|||CASE_ONLY||OTHER|||||||
33913846|NCT03878017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913847|NCT04586868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913848|NCT05252676|||COHORT||PROSPECTIVE|||||||
33913849|NCT02125331|||COHORT||PROSPECTIVE|||||||
33913850|NCT00745394|||COHORT||PROSPECTIVE|||||||
33913851|NCT00219843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913852|NCT02594397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913853|NCT02953782|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33913854|NCT02410850|||COHORT||PROSPECTIVE|||||||
33913855|NCT03151148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913856|NCT00003539||||TREATMENT||||||||
33913857|NCT00093093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33913858|NCT04358042|||COHORT||PROSPECTIVE|||||||
33913859|NCT00738543|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33913860|NCT01842308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913861|NCT01483898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913862|NCT00471536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913863|NCT01100996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913864|NCT02416362|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33913865|NCT06064708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research assistant who did not participate in the other study phases collected the data, including blood sampling.|the participants were randomly distributed into the experimental and control groups according to a straightforward 1:1 computer-generated sequence, giving them an equal chance of being in either of the two groups.|f|f|t|f
33913866|NCT02233205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913867|NCT04961814|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33913868|NCT04768946|||COHORT||CROSS_SECTIONAL|||||||
33913869|NCT04850703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|12 patients will be receive tRNS sham 10 sessions. 12 patients will take Dapoxetine, sham 10.|Allocation: Randomized Intervention Model: Parallel Assignment|f|t|t|f
33913870|NCT06348017|||CASE_CONTROL||PROSPECTIVE|||||||
33913871|NCT00000567|RANDOMIZED|||TREATMENT||||||||
33913872|NCT02136121|NA|SINGLE_GROUP||||NONE||||||
33780234|NCT04721509|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open label|Inclusion criteria: patients with type 1 diabetes with A1c\>8.0% Exclusion criteria: chronic disease, psychological disease, children aged under 12 with parents with psychological disease, athletics Method: We divide subjects as an experimental group and a control group by randomization, and they visit outpatient clinic every 12 weeks. We perform telemedicine and education with smartphone application to the experimental group every 2 weeks. We evaluate the effect of smartphone based telemedicine and education in patients with type 1 diabetes mellitus with checking A1c and checklist at baseline, 12 weeks and 24 weeks after starting of the research.||||
33691721|NCT06734104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"In the study, the researchers will be aware of the groups to which the students are assigned in order to plan the study. Since the students in the experimental group will receive an interactive video and those in the active control group will receive a non-interactive video, the students will not know their group assignment, ensuring participant blinding. Therefore, the study is single-blinded. During the process of obtaining informed consent, students will be informed that both groups will receive education on the subject through video. Additionally, students' skills will be assessed by three experts in the field of nursing, independent of the researchers. The evaluators will not be informed about the students' group assignments, ensuring blinding for the evaluators. Blinding will also be maintained during data analysis and reporting. Data entries will be coded as A and B without specifying whether they belong to the experimental or control group. The data analysis and the prepara"|This study protocol describes a single-center, randomized controlled parallel-group single-blind experimental study (1:1) to be conducted with nursing students at a public university in a province of Turkey. The protocol has been prepared in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. The sample will include 60 students, with 30 in the experimental group and 30 in the active control group. Data will be collected using the Student Demographic Characteristics Form, the Perioperative Anti-Embolism Stockings Care Knowledge Assessment Form, the Perioperative Anti-Embolism Stockings Application Skills Assessment Form, and the Interactive Video Evaluation Form, all of which were developed by the researchers based on the literature. The study will evaluate the impact of the interactive video developed for the care of surgical patients wearing anti-embolism stockings on the knowledge and skill levels of nursing students.|t|f|f|t
33691722|NCT06744504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691723|NCT06567769|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691724|NCT05154487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691725|NCT06739330|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691726|NCT04946825|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33691727|NCT04775082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33691728|NCT05899452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Cannot blind participants due to the nature of the intervention|One group will receive bubble distraction while another group will receive video distraction.||||
33691729|NCT06739239|||COHORT||PROSPECTIVE|||||||
33691730|NCT06745401|||COHORT||PROSPECTIVE|||||||
33691731|NCT05179824|||COHORT||OTHER|||||||
33691732|NCT04436640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691733|NCT06745453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691734|NCT06743750|||OTHER||PROSPECTIVE|||||||
33691735|NCT05487235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691736|NCT00959140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691737|NCT06745167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33691738|NCT03963583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33691739|NCT06745921|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Syringe will be masked||t|t|t|f
33691740|NCT06391918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691741|NCT06745726|||COHORT||PROSPECTIVE|||||||
33691742|NCT05453578|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|A double-blind/masking technique will be used in Stage 2 of the study. The three intravenous (IV) bacteriophage doses and placebo will be packaged identically for administration so that treatment blind/masking is maintained. The study investigational pharmacist will remain unblinded throughout the study and will be informed of the appropriate dose for subjects according to procedures detailed in the Manual of Procedure (MOP)||t|t|t|f
33691743|NCT05668338|||OTHER||PROSPECTIVE|||||||
33691744|NCT06732856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780235|NCT03464253|||COHORT||PROSPECTIVE|||||||
33780236|NCT06693024|||COHORT||OTHER|||||||
33780237|NCT04880343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780238|NCT04094844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Active comparator arm: Adult caregivers (n=166) with adult patients \>/= 18 years of age (n=83) and pediatric patient \<18 years of age (n=83)~* Experimental arm: Adult caregivers (n=166) with adult patients \>/= 18 years of age (n=83) and pediatric patient \<18 years of age (n=83)"||||
33780239|NCT00994279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780240|NCT06616636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780241|NCT05185440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780242|NCT04308616|||COHORT||PROSPECTIVE|||||||
33780243|NCT04580654|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33801396|NCT01727375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913873|NCT02474667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913874|NCT05650073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33913875|NCT05072496|||COHORT||PROSPECTIVE|||||||
33913876|NCT02515617|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33691745|NCT06588738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913877|NCT00642655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913878|NCT00696462|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33913879|NCT04494633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913880|NCT05236881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913881|NCT05622383|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|aromatherapy, music concert|aromatherapy, music concert|t|f|f|f
33913882|NCT02555566|NA|SINGLE_GROUP||||NONE||||||
33913883|NCT04374110|||CASE_CONTROL||PROSPECTIVE|||||||
33691746|NCT06745050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913884|NCT03355937|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33913885|NCT01424826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913886|NCT00424112|||DEFINED_POPULATION||OTHER|||||||
33913887|NCT02317406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913888|NCT05753280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913889|NCT00004038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913890|NCT05091294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994691|NCT01160796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33994692|NCT00247923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994693|NCT03168659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994694|NCT05279599|||COHORT||PROSPECTIVE|||||||
33994695|NCT04762966|||CASE_CONTROL||RETROSPECTIVE|||||||
33994696|NCT04872075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994697|NCT03887884|RANDOMIZED|CROSSOVER||OTHER||NONE||It is a 2-way crossover Pharmacokinetic (PK) evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of Carbidopa/levodopa (CD/LD) 25 mg/100 mg (Sinemet®) under fed conditions in Parkinson's Disease patients who regularly take CD/LD.||||
33691747|NCT06731504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691748|NCT05777603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691749|NCT06745076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691750|NCT05617677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691751|NCT03652545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691752|NCT05071859|||FAMILY_BASED||PROSPECTIVE|||||||
33691753|NCT06619561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691754|NCT05873439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691755|NCT06745310|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691756|NCT05040386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33691757|NCT06550141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691758|NCT06453642|NA|SINGLE_GROUP||TREATMENT||NONE||The investigation is a single-arm, open-label, non-randomized, prospective, multicenter, multinational pivotal study.||||
33691759|NCT05259709|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691760|NCT05092373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691761|NCT06744907|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33691762|NCT06548490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691763|NCT06745934|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691764|NCT04305548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691765|NCT06132945|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-institution, single cohort, phase 1b trial of cabozantinib in combination with nivolumab in patients with metastatic RCC who are planning to undergo radiation therapy for brain metastases.||||
33719894|NCT04345263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient unaware of the material to be used, care provider will be given the material after performing full pulpotomy . Tooth crown will be masked during assessment of radiographs||t|t|f|t
33719895|NCT00453544|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33719896|NCT00670865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33780244|NCT03347838|NA|SINGLE_GROUP||TREATMENT||NONE||The goal of this clinical research study is to determine whether the Programmed cell death protein 1 (PD-1) inhibitor nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the development of lung cancer, including those with a prior smoking history, or history of lung cancer or head and neck cancer. The safety and tolerability of nivolumab will also be studied.||||
33780245|NCT05243797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913891|NCT02472925|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913892|NCT03016299|||COHORT|||||||||
33913893|NCT05157451|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33913894|NCT01078701|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33913895|NCT06361329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913896|NCT04377594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization 1:1|t|f|f|f
33913897|NCT03370991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913898|NCT06337292|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization into study treatment arms (incisional NPWT or non-suction standard of care) will occur in variable permuted blocks, stratified by clinical center, in a 1:1 ratio. Patients will be randomized electronically by an online Data Management System maintained by the Coordinating Center at Johns Hopkins School of Public Health.||||
33913899|NCT00608530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913900|NCT02449954|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
33913901|NCT05300243|||CASE_ONLY||PROSPECTIVE|||||||
33913902|NCT01872741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913903|NCT06280976|RANDOMIZED|PARALLEL||TREATMENT||NONE||PROBE design: Prospective Randomized Open Label Blinded End-point||||
33994698|NCT03243786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994699|NCT00725322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994700|NCT06287281|||CASE_ONLY||CROSS_SECTIONAL|||||||
33994701|NCT01853722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691766|NCT06533423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the NISMA intervention blinding of participants is impossible. However, the outcome assessor will be blinded, and participants will be asked not to disclose their group to the assessor.|"Randomization, allocation, and blinding Randomization 1:1 will be performed after baseline assessments and conducted using a computerized random number generator algorithm by the project manager. Randomization will be stratified by site. Therefore, a customized randomization table will be uploaded for each site to REDCap (Research Electronic Data Capture).~The project manager will enroll participants and inform them whether they have been allocated to the intervention group or the control group (see Fig. 2 for participants flow through the trial). For participants randomized to the intervention group, the first individual session will be scheduled as soon as possible after allocation.~Due to the character of the intervention, it is not possible neither to blind participants to their allocated intervention nor to blind the HP delivering the intervention. Analysis of data will be performed blinded to group allocation."|f|f|f|t
33691767|NCT06624228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691768|NCT06744465|||COHORT||PROSPECTIVE|||||||
33994702|NCT00418158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086458|NCT05280990|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Hypothesis: Using Future Liver Remnant Function (FLRF) through 99mTc-mebrofenin hepatobiliary scintigraphy (mHBS) to select patients for major hepatectomy will reduce the rate of Post-hepatectomy liver failure (PHLF), compared to our standard-of-care Future Liver Remnant Volume (FLRV) calculations for patient selection.~Methods: This is a prospective pilot study designed to evaluate feasibility and safety in the Canadian settings and will include patients undergoing major liver resection at the Queen Elizabeth II Health Sciences Centre (QEII) in Halifax, Canada, and at McGill University Health Centre in Montreal, Canada (McGill). Recruited patients, irrespective of their underlying liver quality will be randomly assigned via block randomization to have either preoperative FLRV assessment by CT/MRI volumetry or preoperative FLRF risk assessment via mHBS."||||
34086459|NCT03171090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33691769|NCT06743919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691770|NCT06229457|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33780246|NCT06696131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780247|NCT05058391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780248|NCT05064514|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, prospective single-centre interventional study to test safety and efficacy of the Tricento Transcatheter Tricuspid Valved Stent Graft||||
33780249|NCT01201083|||COHORT||PROSPECTIVE|||||||
33780250|NCT03803917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780251|NCT06692556|RANDOMIZED|PARALLEL||OTHER||NONE||"Eligible patients will be randomized (ratio 1:1) using an online platform into one of the two study arms:~* Adjuvant radiotherapy arm (=133),~* Surveillance arm (n=133)"||||
33780252|NCT05232136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780253|NCT04415840|||OTHER||PROSPECTIVE|||||||
33780254|NCT03829059|||COHORT||RETROSPECTIVE|||||||
33780255|NCT02851511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780256|NCT04811651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment and placebo solutions have identical appearance. Protocols will be designed to ensure that the physician evaluating patient safety and efficacy outcome as well as laboratory analysis, will not have access to the randomisation codes.|Two different treatment groups; intravenous umbilical cord-derived mesenchymal stem cells or intravenous placebo solution|t|t|t|t
33780257|NCT00378872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33780258|NCT00705640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780259|NCT06686875|||COHORT||CROSS_SECTIONAL|||||||
33780260|NCT06696118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994703|NCT05272813|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Stage 1 3+3 dose escalation study with expansion to Stage 2|f|f|f|t
33994704|NCT03734263|NA|SINGLE_GROUP||TREATMENT||NONE||An open-label, uncontrolled, multicentric clinical trial will be performed on pediatric patients with PDC deficiency. Enrolled subjects will receive a four-week period of treatment with NaPB; primary and secondary endpoints will be evaluated at defined time points. Before NaPB treatment, all patients will undergo a four-week period of observation during which the same parameters will be analyzed at different time points, with the aim of evaluating basal conditions in the absence of treatment.||||
33994705|NCT00178178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994706|NCT06628141|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994707|NCT01096329|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33994708|NCT06015035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994709|NCT00091871|||FAMILY_BASED||PROSPECTIVE|||||||
33994710|NCT02112123|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34086460|NCT01114724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086461|NCT04636047|||COHORT||PROSPECTIVE|||||||
33780261|NCT06029218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780262|NCT06696963|||COHORT||RETROSPECTIVE|||||||
33994711|NCT02685215|||CASE_CONTROL||RETROSPECTIVE|||||||
33994712|NCT06380777|||COHORT||PROSPECTIVE|||||||
33994713|NCT03972163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization to the educational intervention targeting hospice clinicians is at the level of the hospice. Within each of the 2 hospice agencies, The Investigators will randomize 1 office to intervention and 1 to control status. Outcomes assessment is at the level of the patient and family caregiver who will be masked to randomization status.|The Investigators will compare outcomes within and across 2 large hospice agencies using a cluster randomized trial study design.|t|f|f|f
33994714|NCT00952939|||CASE_ONLY||PROSPECTIVE|||||||
33994715|NCT04511039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994716|NCT03978442|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, two-arm clinical trial||||
33994717|NCT06415903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994718|NCT03785262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33994719|NCT03653299|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34086462|NCT01513655|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34086463|NCT00732914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086464|NCT05540431|RANDOMIZED|PARALLEL||PREVENTION||NONE|None (Open Label)|Interventional (clinical trial)||||
33913904|NCT06347991|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33913905|NCT02024204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913906|NCT02163304|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33913907|NCT04641312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33913908|NCT06128798|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33913909|NCT00849264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913910|NCT05412394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913911|NCT05094999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913912|NCT05356845|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33913913|NCT00780169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913914|NCT03744884|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Research team members administering clinical assessments will be blinded from participant allocation. Participant's allocation will not be revealed during the course of the study.|A group of children with dystonic or spastic/dystonic cerebral palsy and a group of typical developing children will be randomly assigned to an intervention or control group. The control group will only attend assessment sessions whereas the intervention group will attend both the assessment and intervention sessions.|f|f|f|t
33994720|NCT01934205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994721|NCT06603597|||COHORT||PROSPECTIVE|||||||
33994722|NCT03442491|||CASE_ONLY||RETROSPECTIVE|||||||
33994723|NCT02728999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994724|NCT04287764|||OTHER||CROSS_SECTIONAL|||||||
33994725|NCT05766150|||CASE_CONTROL||PROSPECTIVE|||||||
33994726|NCT05216562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994727|NCT01203215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086465|NCT00139529|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34086466|NCT03211507|||CASE_CONTROL||PROSPECTIVE|||||||
34086467|NCT00300053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086468|NCT03706846|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33691771|NCT01752491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691772|NCT06129539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913915|NCT04737031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33913916|NCT03912025|||OTHER||CROSS_SECTIONAL|||||||
33913917|NCT04720586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33913918|NCT06491628|||COHORT||PROSPECTIVE|||||||
33913919|NCT06346457|||CASE_CONTROL||OTHER|||||||
33913920|NCT00689819|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086469|NCT00413517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086470|NCT01654887|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086471|NCT00668616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086472|NCT02173613|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913921|NCT02098083|||||PROSPECTIVE|||||||
33994728|NCT03218787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994729|NCT02792816|||COHORT||PROSPECTIVE|||||||
34086473|NCT05664516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study staff and patients are blinded. The pharmacist is unblinded.||t|t|t|t
34086474|NCT03257579|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086475|NCT01160302|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086476|NCT04056468|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086477|NCT04100213|NA|SINGLE_GROUP||SCREENING||NONE||||||
34086478|NCT02728336|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086479|NCT00067080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913922|NCT06234618|||CASE_ONLY||CROSS_SECTIONAL|||||||
33913923|NCT04829019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913924|NCT03029650|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33913925|NCT00588250|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33780263|NCT01190670|RANDOMIZED|CROSSOVER||||NONE||||||
33780264|NCT04737174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780265|NCT06276413|||COHORT||PROSPECTIVE|||||||
33780266|NCT02856529|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780267|NCT03862521|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized to either low or very low carbohydrate diet||||
33780268|NCT03460717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|the person performing the intervention and the assessment are different|intervention offered and those who decline are followed as a waiting list control|f|f|t|t
33780269|NCT04911114|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm feasibility study||||
33780270|NCT05482919|||CASE_ONLY||PROSPECTIVE|||||||
33780271|NCT05791721|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33780272|NCT02301234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780273|NCT03302910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33780274|NCT04635878|||OTHER||PROSPECTIVE|||||||
33780275|NCT05842343|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33780276|NCT05877248|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34086480|NCT06069102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once randomization is complete, there will be no blinding of participants, care providers or investigators. Outcomes assessors will be masked to intervention arm.|The investigators will conduct a prospective single site, single-blinded, parallel randomized control trial in which individuals diagnosed with HDP will be randomized to usual care or tight blood pressure control for therapeutic intent. Subjects will undergo 3 study visits (1 in-person and 2 remote) involving BP measurements, blood draws, and/or questionnaires.|f|f|f|t
34086481|NCT04583501|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780277|NCT00168181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780278|NCT05328440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780279|NCT00151008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33780280|NCT05482568|NA|SINGLE_GROUP||TREATMENT||NONE||An open, multicenter, dose-increasing/investigational Phase IB/II clinical trial||||
33913926|NCT01156038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913927|NCT02085876|||CASE_ONLY||PROSPECTIVE|||||||
33913928|NCT03957655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to the randomization results of the participants.||f|f|f|t
33913929|NCT02783794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33913930|NCT05390814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913931|NCT00870831|||COHORT|||||||||
33913932|NCT01453569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086482|NCT05229913|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34086483|NCT00301834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086484|NCT05064163|||OTHER||PROSPECTIVE|||||||
33691773|NCT05710107|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Subjects, surgeons, and data collectors will all be blinded to the allocated group. Unblinded personnel will be the Anesthesia Attending placing the block and clinical staff assisting.||t|t|f|t
33691774|NCT06393608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a triple-blind study. Parturients will be instructed to apply soaked pads (SSE25 or sterile water) for 15 minutes, as needed, four times a day to the perineum, regardless of which group they are in. They will not know the compound in their bottle, they will only know the number of their bottle. The nurses who distribute the bottles to the patients on their shifts will not know which bottle is sterile water and which is SES.25 In addition, each container will be identical and each liquid will have the same texture and color, making it impossible to identify the contents. As described above, the hospital pharmacy will be responsible for preparing bottles and the pharmacy employees will be the only ones who know the contents. Finally, during data analysis, there will be denominationalization of patients and remittance of data that will not be associated with specific intervention groups, so that data analysis will also be blinded.|The formation of 2 groups will be done randomly. To do this, the Honoré-Mercier Hospital pharmacy will determine the identification of the A and B bottles (containing either the SSE25 or the sterile water) and will communicate it to the other 2 pharmacies. As a result, the pharmacists will be the only ones in the entire study to know the actual contents of each of the A and B bottles. The bottles will be prepared and identified by the pharmacy and given to the mother-child unit of each of the 3 hospitals. Randomization into the two groups will be done in blocks of 6 patients to limit imbalances between the groups. Participants will receive their assigned A or B bottle and the paperwork for postpartum data collection.The randomization group will be recorded on the consent form and data collection documents. Finally, data will be collected to compare the characteristics of the two groups of study participants.|t|t|t|t
33691775|NCT00596180|||OTHER||RETROSPECTIVE|||||||
33691776|NCT03678389|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33780281|NCT03328052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients undergo EEG, but results are not released to physician or patient in the control group.||t|f|f|f
33780282|NCT00177879|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33780283|NCT06615622|||CASE_CONTROL||PROSPECTIVE|||||||
33780284|NCT01174992|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780285|NCT00747786|||CASE_CONTROL||PROSPECTIVE|||||||
33780286|NCT05099887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780287|NCT02123966|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780288|NCT05298384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780289|NCT00759200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780290|NCT06175390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase II trial preceded by a safety run-in with two parallel cohorts||||
33780291|NCT03074981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780292|NCT02914067|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780293|NCT01750996|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33780294|NCT05224687|||COHORT||RETROSPECTIVE|||||||
33913933|NCT00129350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913934|NCT01626352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913935|NCT01667068|||COHORT||PROSPECTIVE|||||||
33913936|NCT02011126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913937|NCT02919488|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33913938|NCT01449682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913939|NCT03614169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33913940|NCT06514599|||CASE_ONLY||PROSPECTIVE|||||||
33913941|NCT03407924|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention will consist of aerobic exercise sessions at predetermined heart rate range.||||
33913942|NCT01921933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913943|NCT03848221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator will be masked to the subject's treatment. The subjects cannot be fully masked because there is a no treatment control group.|Investigator Masked, Randomized, Clinical Trial|f|t|t|t
33913944|NCT04599205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33913945|NCT04838106|||COHORT||RETROSPECTIVE|||||||
33913946|NCT06042621|||COHORT||PROSPECTIVE|||||||
33913947|NCT01583998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913948|NCT06553196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691777|NCT06424769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After completing their baseline survey, consented participants will be randomized to usual care and intervention groups in a 2:1 allocation ratio. A computer-generated, centralized randomization with permuted block randomization within sites to ensure allocation concealment will be utilized.||||
33913949|NCT01131598|||||PROSPECTIVE|||||||
33913950|NCT05388162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913951|NCT06115161|NA|SINGLE_GROUP||TREATMENT||NONE||Trial with condition crossover||||
33913952|NCT02696915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33913953|NCT03375359|||CASE_ONLY||PROSPECTIVE|||||||
33913954|NCT00252122|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913955|NCT02078713|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913956|NCT03046628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33913957|NCT02804412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33913958|NCT03689504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913959|NCT01488318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913960|NCT05102708|||COHORT||RETROSPECTIVE|||||||
33913961|NCT00696111|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33913962|NCT02855684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913963|NCT06154031|NA|SINGLE_GROUP||TREATMENT||NONE||Cross-sectional single arm pilot-feasibility study. Assessments and training will be performed at two laboratory visits. Participants will spend approximately 125-145 minutes at the laboratory on Day 1, and approximately 80 minutes on Day 2.||||
33913964|NCT02562248|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33913965|NCT02159326|RANDOMIZED|CROSSOVER||||NONE||||||
33913966|NCT00498108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913967|NCT04762147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913968|NCT05012852|RANDOMIZED|PARALLEL||TREATMENT||NONE||An single group pilot sub-study followed by a randomized, parallel, controlled sub-study. In the randomized part, the non cured patients in the control goup are given an option to change to active treatment after 7 days.||||
33913969|NCT00239317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33913970|NCT05583006|||COHORT||PROSPECTIVE|||||||
33913971|NCT02175173|||OTHER||RETROSPECTIVE|||||||
33913972|NCT03973684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant ,investigator) Double Blind(Subject,Caregiver,Investigator,Outcomes Assessor)|bio-equivalence study enrollment: 80|t|f|t|f
33691778|NCT03073967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780295|NCT01866475|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33913973|NCT01791114|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33913974|NCT02913222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33913975|NCT04053452|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The EMG lab physician or technician performing the ultrasound will be blinded to the EMG/NCS results.||f|f|t|f
33913976|NCT00266019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913977|NCT01517945|||COHORT||RETROSPECTIVE|||||||
33780296|NCT04123366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994730|NCT03683667|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Participants, care providers, investigators and outcomes assessors will be blinded to the azithromycin or placebo interventions. Neither participants nor outcomes assessors will be masked to the nutrition interventions. Investigators will be masked to the nutrition interventions.|For this 2 x 4 factorial, cluster-randomized trial, 566 previously defined clusters will be assigned independently to 8 different combinations of interventions: 1) azithromycin and protein supplementation; 2) azithromycin and isocaloric supplementation; 3) azithromycin and egg; 4) azithromycin and control (nutrition education); 5) placebo and protein supplementation; 6) placebo and isocaloric supplementation; 7) placebo and egg; 8) placebo and control (nutrition education).|t|t|t|t
33691779|NCT05355402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691780|NCT06743633|||COHORT||CROSS_SECTIONAL|||||||
33691781|NCT05439772|RANDOMIZED|PARALLEL||OTHER||NONE||non-blinded randomized control trial||||
33691782|NCT05160584|||COHORT||PROSPECTIVE|||||||
33691783|NCT04852783|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a prospective, multicenter single-arm study.||||
33780297|NCT05002543|||COHORT||PROSPECTIVE|||||||
33780298|NCT06691893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780299|NCT06334497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780300|NCT06459362|||OTHER||CROSS_SECTIONAL|||||||
33780301|NCT01411280|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33913978|NCT02641366|||CASE_CONTROL||PROSPECTIVE|||||||
33913979|NCT05078463|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A Sham PVA-PET Patch that has the same size and structure as the maltose microneedle will be used. The participants, care providers and outcome assessors will not be able to distinguish between the maltose and sham patch due to their similar size and structure. One of the study investigators (Ooi Kai Shen) will not be masked since the person will be instituting the interventions. However, the study investigator (Ooi Kai Shen) is not one of the outcome assessors or care providers for the study participants.||t|t|f|f
33913980|NCT06371651|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33913981|NCT04195269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913982|NCT03389061|RANDOMIZED|CROSSOVER||OTHER||NONE||Bio-equivalence Study||||
33913983|NCT00937560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33913984|NCT02074774|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33780302|NCT01204970|||CASE_CONTROL||PROSPECTIVE|||||||
33780303|NCT04577248|||COHORT||PROSPECTIVE|||||||
33780304|NCT04922099|||CASE_CROSSOVER||PROSPECTIVE|||||||
33780305|NCT04043611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780306|NCT01235585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780307|NCT00746928|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780308|NCT05455996|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label study to treat symptoms of Post-Traumatic Stress in 30 Health Care Workers using a 3-dosing model of MDMA-assisted therapy.||||
33780309|NCT05030376|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33780310|NCT05349084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780311|NCT05487469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780312|NCT02314455|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780313|NCT00767715|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780314|NCT03672539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780315|NCT05105152|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I open-label, dose-finding study employing the Bayesian optimal interval (BOIN) design||||
33994731|NCT04366544|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Potential participants will be sent email invitations approximately 2 months prior to the program. Participants will have the options to take part in online surveys, blood samples, and/or stool samples. Up to 1000 participants (attendees and spouses/significant others) may take the online surveys twice before the samyama program, 2 weeks after and 3 months after. Up to \*200 may volunteer to have 4 blood draws. 150 volunteers may also send in 3 stool samples - 1. prior to starting the Samyama pre-prep diet 2. within one week of the Samyama program 3. After returning home from the program.~Up to 50 spouses/significant others living with Samyama attendees will also be offered the opportunity to complete a shortened version of the online surveys, provide blood and/or stool samples.~\*Up to 200 volunteers at Isha can participate in blood draws. Upto 25 subjects will also be enrolled in the (2)EEG and (2)fMRI Study before and after Samyama."||||
33994732|NCT00587730|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994733|NCT03076437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994734|NCT02928185|||COHORT||PROSPECTIVE|||||||
33994735|NCT05113043|||CASE_CONTROL||PROSPECTIVE|||||||
33780316|NCT02948946|||COHORT||PROSPECTIVE|||||||
33780317|NCT05002361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780318|NCT02662244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780319|NCT01077661|||OTHER||PROSPECTIVE|||||||
33780320|NCT00986089|||||PROSPECTIVE|||||||
33780321|NCT03152604|||COHORT||PROSPECTIVE|||||||
33780322|NCT01615809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780323|NCT04900883|||OTHER||PROSPECTIVE|||||||
33780324|NCT06672900|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open-label, fixed sequence, crossover study.||||
33780325|NCT06480058|||COHORT||CROSS_SECTIONAL|||||||
33780326|NCT00864058|RANDOMIZED|CROSSOVER||||NONE||||||
33780327|NCT03782727|||CASE_ONLY||PROSPECTIVE|||||||
33780328|NCT02724761|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33780329|NCT01239615|||COHORT|||||||||
33780330|NCT06297096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780331|NCT01218685|||COHORT||PROSPECTIVE|||||||
33780332|NCT06553742|||CASE_ONLY||PROSPECTIVE|||||||
33780333|NCT00322816|||||PROSPECTIVE|||||||
33780334|NCT05040243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780335|NCT04010175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780336|NCT04372511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33780337|NCT02460029|||COHORT||PROSPECTIVE|||||||
33780338|NCT00162539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33780339|NCT02679768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780340|NCT06696339|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780341|NCT03042442|||CASE_CONTROL||PROSPECTIVE|||||||
33780342|NCT00770211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780343|NCT04590144|NA|SINGLE_GROUP||TREATMENT||NONE||INVICTA lead||||
33780344|NCT06698315|||OTHER||PROSPECTIVE|||||||
33780345|NCT01214447|||COHORT||PROSPECTIVE|||||||
33780346|NCT06696456|||CASE_ONLY||PROSPECTIVE|||||||
33780347|NCT06214143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780348|NCT04949399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780349|NCT00002179||||TREATMENT||||||||
33780350|NCT06308978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780351|NCT04576780|||COHORT||PROSPECTIVE|||||||
33780352|NCT06697340|||COHORT||RETROSPECTIVE|||||||
33780353|NCT00743405|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33780354|NCT01761422|||COHORT||PROSPECTIVE|||||||
33780355|NCT01972087|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33780356|NCT06405334|||COHORT||PROSPECTIVE|||||||
33780357|NCT06698107|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33780358|NCT04285229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780359|NCT05464784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780360|NCT05980052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Four arm randomized mechanistic proof-of-concept trial|f|f|f|t
33780361|NCT04861064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780362|NCT05905055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780363|NCT04450433|||CASE_CONTROL||PROSPECTIVE|||||||
33780364|NCT00252681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913985|NCT03598738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913986|NCT02560831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33913987|NCT01269372|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||DOUBLE|||f|t|t|f
33913988|NCT01493986|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33913989|NCT01827059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913990|NCT00195689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913991|NCT04385914|||COHORT||PROSPECTIVE|||||||
33913992|NCT03054467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33913993|NCT02310828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33913994|NCT05331950|||COHORT||CROSS_SECTIONAL|||||||
33913995|NCT01886417|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33913996|NCT01202227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33913997|NCT00554892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33913998|NCT05154409|||CASE_CONTROL||PROSPECTIVE|||||||
33913999|NCT00294502|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33994736|NCT03723044|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994737|NCT02052895|||COHORT||PROSPECTIVE|||||||
33994738|NCT04996316|||OTHER||PROSPECTIVE|||||||
33780365|NCT02637505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780366|NCT05335135|||COHORT||OTHER|||||||
33780367|NCT03513211|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I intra-patient dose escalation study Phase II Simon 2-stage cohort expansion||||
33780368|NCT01677039|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33780369|NCT03537014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Use of separate databases for outcome measures and safety data. Assessment made by pool of independent raters. Randomization will be managed via an Interactive Web Randomization System (IWRS) based on a centralized randomization schedule developed by an independent third-party vendor to maintain blinding.|Randomized, double-blind, between-group comparison of change in PTSD symptoms|t|f|t|t
33780370|NCT03976362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780371|NCT06447272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780372|NCT03606460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780373|NCT03670602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research personnel who will be conducting assessment sessions, including weight measurements, will not be informed of participant's group assignment|Participants will engage in EFT or control while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.|f|f|f|t
33914000|NCT02117167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914001|NCT01891760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914002|NCT04975971|||CASE_CONTROL||RETROSPECTIVE|||||||
33914003|NCT00173394|||DEFINED_POPULATION||OTHER|||||||
33914004|NCT01336556||PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33914005|NCT03838172|||COHORT||PROSPECTIVE|||||||
33914006|NCT00582062|||CASE_CROSSOVER||PROSPECTIVE|||||||
33914007|NCT00099359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914008|NCT04513834|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33914009|NCT00295087|||COHORT||CROSS_SECTIONAL|||||||
33914010|NCT01294124|||CASE_CONTROL||PROSPECTIVE|||||||
33914011|NCT02202096|RANDOMIZED|PARALLEL||||||||||
33914012|NCT02263482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994739|NCT00004786|RANDOMIZED|||TREATMENT||DOUBLE||||||
33780374|NCT04166968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and experimenters will be prevented from having knowledge of the assigned stimulation protocol. To do so, the investigator will create a series of numbers paired with real and sham interventions while the outcome assessor will be aware of the patient-number association only.|The present study will be conducted in over 15 recruiting centers with a randomized double-blind design. Post-stroke patients will be randomly assigned to 3 parallel groups: Control Group (neuromotor training and sham stimulation), Experimental Group 1 (neuromotor training and cathodal tDCS over the unaffected hemisphere), Group 2 (neuromotor training and anodal tDCS over the affected hemisphere). Participants will be further partitioned on the basis of the acute/subacute and subacute/chronic stages (7-90 and 91 days from lesion onset, respectively).|t|f|f|t
33780375|NCT05515874|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086485|NCT01445340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780376|NCT05103774|||OTHER||RETROSPECTIVE|||||||
33780377|NCT06085833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The sponsor is blinded toward the pathological diagnosis of the participants.|||||
34086486|NCT00216372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780378|NCT01164787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086487|NCT00433355|||CASE_CONTROL||PROSPECTIVE|||||||
34086488|NCT02924155|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34086489|NCT06216496|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086490|NCT03118180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086491|NCT03116230|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be told only that we are comparing two types of treatment for their knee pain.||t|f|f|f
34086492|NCT01408472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780379|NCT00278564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780380|NCT01590069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780381|NCT03661970|||COHORT||PROSPECTIVE|||||||
33780382|NCT05630469|||COHORT||PROSPECTIVE|||||||
33780383|NCT05589727|||COHORT||PROSPECTIVE|||||||
33780384|NCT04990882|||COHORT||PROSPECTIVE|||||||
33914013|NCT00603434|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33914014|NCT03044015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914015|NCT00808730|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33914016|NCT03039127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914017|NCT06283784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"YOVIS, the Investigational Food Supplement (IFS), is an oral formulation (capsules) containing definite mix of live probiotics. Placebo is an oral formulation of inert capsules. Placebo and YOVIS are identical in shape, size, colour and taste. Product test and placebo capsules will be indistinguishable.~Investigational food supplement products will be packed in an individual way for each subject included in the investigation."|This is a double blind, randomized, placebo-controlled study.|t|f|t|f
33914018|NCT00617006|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33914019|NCT00717262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914020|NCT01606761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914021|NCT05580861|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I dose-finding design unsing the continueal reassessment method, followed by a dose expansion cohort using a Simon's phase II design.||||
33914022|NCT03006094|||COHORT||PROSPECTIVE|||||||
33914023|NCT03442829|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Intervention allocation will be undertaken by a researcher not directly involved with participants following randomization by drawing lots.||f|f|t|t
33914024|NCT03132480|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33914025|NCT03375905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914026|NCT02119884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914027|NCT01397305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914028|NCT00394290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914029|NCT03683706|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Researchers doing outcome assessments will be kept blind to treatment allocations||f|f|f|t
33914030|NCT02697513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914031|NCT03734367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33914032|NCT01132989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914033|NCT03496363|||CASE_CONTROL||PROSPECTIVE|||||||
33914034|NCT01889966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914035|NCT05514522|||COHORT||PROSPECTIVE|||||||
33914036|NCT02529293|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33914037|NCT00354263|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914038|NCT04200677|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33914039|NCT00950079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914040|NCT02559154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914041|NCT04868591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914042|NCT03922360|RANDOMIZED|PARALLEL||TREATMENT||NONE||We are proposing a two condition, parallel groups, randomized controlled trial (RCT) of a mobile-phone-based financial incentives intervention targeting economically disadvantaged pregnant cigarette smokers. The experimental group will receive electronic vouchers contingent on the remote submission of breath carbon monoxide (CO) samples indicating smoking abstinence whereas the control group will receive best practices for promoting smoking cessation. The use of a best practices control group reflects a real-world comparison condition in that all women will receive the treatment that practitioners in the community are instructed to provide (i.e., the 5As plus quit-line referral) thereby enhancing the ecological validity of the study, while also minimizing between-subject variability in the extent of participants' exposure to these practices by implementing these treatment components ourselves.||||
34086493|NCT01189448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086494|NCT05627804|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34086495|NCT04560842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086496|NCT04480879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33914043|NCT01672606|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33914044|NCT01321502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914045|NCT04759963|||COHORT||RETROSPECTIVE|||||||
33914046|NCT03446937|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double blind|Randomised controlled trial|t|t|t|f
33914047|NCT04099732|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914048|NCT04520763|RANDOMIZED|CROSSOVER||OTHER||NONE||This study consists of four visits to the laboratory, each separated by at least 24 hours and each lasting approximately 2.5h. Total duration for each participant is approximately 2 weeks. The study is conducted in 40 healthy adults (≥ 18 years). The study is a randomized, controlled cross-over trial. We chose a cross-over design in order to test the effects of different respiratory exercises compared to a control intervention in order to minimize variability since each subject serves as his/her own control. Due to the nature of the intervention (respiratory muscle exercises), it is not possible to blind participants to the interventions.||||
33914049|NCT02096146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914050|NCT05844124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Principal Investigator will be masked to the patient treatment group assignment.||f|f|t|f
33914051|NCT03609528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914052|NCT01051986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914053|NCT03854643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blind researcher will be responsible for evaluating the volunteers. It is worth mentioning that this researcher will not have access to the research group that the participants will be allocated.||f|f|f|t
33914054|NCT04365439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914055|NCT03154398|||COHORT||PROSPECTIVE|||||||
33914056|NCT05216406|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All subjects and investigators were blinded.|This study followed a placebo (PLA)-controlled, double-blind and parallel-group design.|t|f|t|f
33914057|NCT01360944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914058|NCT04937816|||OTHER||RETROSPECTIVE|||||||
33914059|NCT05509335|||CASE_ONLY||PROSPECTIVE|||||||
33914060|NCT01485926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914061|NCT00865293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33914062|NCT03756740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not know the intervention in other groups or the research aim in details. they will only know that it is a research for low back pain treatment.~The physical therapists performing the examination pre and post intervention will be blinded to the participants group."|"Sixty patients diagnosed with chronic LBP referred for physical therapy to one of the 5 outpatient clinics of Maccabi Health Services in the Haifa metropolitan area, Israel, will be recruited for this study. each subject will undergo a baseline examination including answering several questionnaires/self-reported outcome measures, a history of present or any past LBP and a physical examination routinely conducted during physical therapy assessment and treatments.~Following the physical examination, the physical therapist will decide on the appropriate physical therapy modalities for the specific patients. These techniques will include only manual therapy (soft tissue mobilization and vertebrae segmental mobilization) and interferential electrotherapy. Furthermore, the subject will receive an appropriate exercise program which will performed at home.~Each subject will be randomly referred to one of the research groups."|t|f|f|t
33994740|NCT00730691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994741|NCT02278809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994742|NCT00959790|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33691784|NCT05042388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor collecting information from the participants during each post-discharge follow-up phase will be blind to which treatment condition the participant was assigned to.|Participants will be randomly assigned to 1 of 2 conditions: MBRP+TAU or TAU.|f|f|f|t
33691785|NCT06046014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691786|NCT06743711|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691787|NCT02435810|||COHORT||PROSPECTIVE|||||||
33691788|NCT04728451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691789|NCT06744751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691790|NCT04313712|||COHORT||PROSPECTIVE|||||||
33691791|NCT06744998|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective monocentric controlled randomized surgical trial||||
33691792|NCT06739083|NA|SINGLE_GROUP||OTHER||NONE||This study is designed as a single-group study consisting of both mentors and mentees.||||
33691793|NCT00764504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691794|NCT06551142|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691795|NCT02386969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33691796|NCT04521608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691797|NCT04984603|||COHORT||PROSPECTIVE|||||||
33691798|NCT05314504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691799|NCT04902326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All investigators, data analysts, and the project manager will be blinded to arm assignment until primary outcome data are collected||f|f|t|t
33691800|NCT00650234|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33691801|NCT03381105|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33691802|NCT03654027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691803|NCT06076564|||COHORT||RETROSPECTIVE|||||||
33691804|NCT06710509|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33691805|NCT06327542|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2x2 factorial trial|f|f|t|f
33691806|NCT05973214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel two-armed randomized controlled study with a waitlist control group.|f|f|f|t
33691807|NCT05300633|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study recruiting family member/concerned significant other participants to receive the intervention and complete outcome measures and identified patients to complete outcome measures only||||
33691808|NCT05319769|||CASE_CONTROL||RETROSPECTIVE|||||||
33691809|NCT00945867|||CASE_ONLY||PROSPECTIVE|||||||
33691810|NCT01577654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691811|NCT03300531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780385|NCT03434743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor, responsible for data collection and follow up interview post hospitalization, is blind to group assignment.||f|f|f|t
33780386|NCT01056211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33780387|NCT02459340|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33780388|NCT04873817|||COHORT||PROSPECTIVE|||||||
33780389|NCT04639206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780390|NCT01391156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780391|NCT06614075|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780392|NCT06582147|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|None (Open Label)|Hybrid effectiveness- implementation stepped wedge cluster randomized trial (SW-CRT) using the Proctor Conceptual Model of Implementation Research.||||
33780393|NCT02338921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780394|NCT04415268|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group non-randomized, prospective. Within-subject multitreatment||||
33780395|NCT03423901|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33780396|NCT05676073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780397|NCT06501300|RANDOMIZED|PARALLEL||OTHER||SINGLE|Observers do not know whether the schools they visit are intervention or control schools.|10 schools are assigned to a wait-list control group, while 10 are assigned to the intervention group.|f|f|f|t
33780398|NCT05906329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780399|NCT05756842|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780400|NCT01911221|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33780401|NCT05381038|NA|SEQUENTIAL||TREATMENT||NONE||10 participants diagnosed with breast or gastric cancer undergoing or planned for treatment will be enrolled. The participants will undergo QPOP drug selection optimisation, and those participants who are identified via QPOP to potentially benefit from azacitidine in combination with docetaxel, paclitaxel or irinotecan will transition to the CURATE.AI dose modulation phase of the trial. Only azacitidine dose in the selected azacitidine combination will be modulated by CURATE.AI||||
33780402|NCT04548609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34086497|NCT05453383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086498|NCT04748978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086499|NCT05692440|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34086500|NCT04096131|||CASE_CONTROL||PROSPECTIVE|||||||
33780403|NCT02941185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780404|NCT06036030|RANDOMIZED|PARALLEL||TREATMENT||NONE|The test drug and the control drug are put into the capsule with the same weight, type and smell so that the patient cannot distinguish between the test drug and the control drug|the patient comes to the primary health care facility, is examined by a doctor, if malaria is suspected, a parasite examination is carried out in the laboratory. If positive for falciparum malaria and based on the results of the doctor's examination meet the criteria as research subjects, then the drug is given based on the random table that has been provided.||||
33780405|NCT03781960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780406|NCT06484751|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780407|NCT01582243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780408|NCT03645603|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780409|NCT03459729|NA|SINGLE_GROUP||OTHER||NONE||||||
33780410|NCT05674903|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33780411|NCT00374621|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780412|NCT01547104|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33780413|NCT05390580|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Patients enrolled in the trial will be randomized to treatment with electrical stimulation to the auricular branch of the vagus nerve (intervention) or stimulation to the great auricular nerve (cervical nerve branch)(Sham) via an auricular, transcutaneous vagus nerve stimulator.. All patients will be fitted with the device, the investigators will attach adhesive contacts to the left ear. Patients are blinded to the intervention and study personnel will be unblinded.|This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.|t|f|f|f
33780414|NCT06131073|RANDOMIZED|PARALLEL||OTHER||SINGLE|assessor who will take the readings is blind|Randomized Clinical trial|f|f|f|t
33780415|NCT01233037|||CASE_CONTROL||PROSPECTIVE|||||||
33780416|NCT05391841|||COHORT||PROSPECTIVE|||||||
33801397|NCT05806476|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|the researchers prepared the caffeine and placebo capsules and someone outside the research team blinded them so that both the investigators and the participants were blinded. Identical opaque capsules were used for both caffeine and placebo||t|f|t|f
33801398|NCT01073358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33914063|NCT03147274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This is a 12-month randomized controlled trial evaluating the impact of a health care delivery intervention (SMART T1D - a 3-session group educational curriculum), compared to standard care, on self-care adherence and transition readiness in adolescents with type 1 diabetes. Intervention (group sessions) and control (standard care) subjects will complete the study on a parallel timeline."||||
33914064|NCT04182256|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914065|NCT03555084|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33914066|NCT00637364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914067|NCT04247750|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, pilot, open-label phase II study with sirolimus in patients with transfusion-dependent beta-thalassemia||||
33914068|NCT05591599|||CASE_CONTROL||PROSPECTIVE|||||||
34086501|NCT03736018|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086502|NCT06550921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086503|NCT02764398|||CASE_ONLY||PROSPECTIVE|||||||
34086504|NCT03410316|||COHORT||PROSPECTIVE|||||||
34086505|NCT05687539|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086506|NCT04582188|||COHORT||PROSPECTIVE|||||||
34086507|NCT02576496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086508|NCT04501900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086509|NCT03357757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780417|NCT05764512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The blood samples are numbered by writing the names of the puerperant women. Nurses who care, the biochemist who analyzes the blood samples and the specialist who does the statistical analysis will not know the groups to which the puerperal puerperants are assigned. In the hospital where the research will be conducted, one of the two parts of the postpartum service is used for the intervention group and the other for the control group in order to prevent encounters between the intervention and control group.|Two gruops with intervention gruop and control grup.|t|t|f|t
33780418|NCT05470660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780419|NCT01691989||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780420|NCT06697652|||COHORT||PROSPECTIVE|||||||
33780421|NCT02023203|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33780422|NCT06697158|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental design||||
33780423|NCT04461223|||COHORT||PROSPECTIVE|||||||
33780424|NCT02991885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780425|NCT03504605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33780426|NCT01827280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780427|NCT03753087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780428|NCT00343798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780429|NCT00378521|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33780430|NCT02018861|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33780431|NCT06217718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In order to prevent selection bias in the study, the assignment to the experimental and control groups will be made on a computer by a person who is unfamiliar with the research process. Individuals included in the study will not be told whether they are in the experimental or control group. The analysis of the data will be done by a statistics expert who is outside the research process.|Two groups with experimental and control groups|t|f|f|t
33780432|NCT05359159|||COHORT||PROSPECTIVE|||||||
33780433|NCT01459822|||CASE_CONTROL||PROSPECTIVE|||||||
33780434|NCT00723320|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33780435|NCT01551836|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33780436|NCT02711995|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780437|NCT03675724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780438|NCT06519370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780439|NCT03454243|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation, conventional 3+3 scheme||||
33780440|NCT03884231|||OTHER||PROSPECTIVE|||||||
33994743|NCT01876667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994744|NCT03426657|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Prospective, Open-Label, Non-Randomized||||
33994745|NCT05285735|||OTHER||PROSPECTIVE|||||||
33780441|NCT04219293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33780442|NCT03306186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780443|NCT00515164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780444|NCT05824221|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|With regard to the treatment, to ensure that both participants and investigators are blind to the condition (active or sham), the selection of the operation mode (15 Hz, sham) will be pre-programmed by member of the that will not be involved in data collection and analysis. Study personnel will not know which mode is being activated. Sham stimulation will use the same coil placement as that used for active stimulation. Outcomes Assessors will not be present during the rTMS sessions.|randomized, sham-controlled with a 1:1 allocation into 2 parallel arms. A third arm constituted by healthy patients.|t|f|t|t
33780445|NCT05036694|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|We are not blinding the two arms|GROUP 1_ TB SYMPTOMS GROUP2_ ADVANCED HIV WITH NO TB SYMPTOMS||||
33780446|NCT05763459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780447|NCT06696144|NA|SINGLE_GROUP||SCREENING||NONE||||||
33780448|NCT06610929|||COHORT||PROSPECTIVE|||||||
33780449|NCT05493371|NA|SINGLE_GROUP||TREATMENT||NONE||prospective single-center, phase IIa, single arm, open label, interventional proof-of-concept study||||
33780450|NCT05238597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780451|NCT03908242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780452|NCT03149211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780453|NCT01852162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780454|NCT06263985|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects undergoing the treatment for pelvic organ prolapse with Axis Dermis biologic mesh.||||
33780455|NCT06613958|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The investigators will perform a randomized two-armed cross-over study. Both groups will start with the sedentary period. Depending on the intervention arm, participants will then undergo the active morning intervention or active evening intervention first, followed by the other intervention. There will be a total of two washout periods both lasting 7 days, one between the sedentary period and first intervention and one between the first and second intervention to prevent or minimize 'carry over' of previous intervention effect. The two interventions and the sedentary period will last 14 days each and contain a 'calibration period' (7 days) and a 'measurement week' (7 days). The total study duration will be 8 weeks and the study will largely take place at the participants' home except for the training sessions (Vitality Clubs) that will take place at an outdoor sports facility in the municipality of Leiden and the study site visits which will take place in the LUMC.||||
33780456|NCT03541135|||COHORT||PROSPECTIVE|||||||
33780457|NCT00080002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780458|NCT03783533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801399|NCT00002287||||TREATMENT||||||||
33994746|NCT05657587|||CASE_ONLY||PROSPECTIVE|||||||
33994747|NCT00540423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994748|NCT01983501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994749|NCT00973388|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33994750|NCT04942496|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33994751|NCT03693014|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label Phase 2 screening trial in subjects.||||
33780459|NCT04364945|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33780460|NCT05240859|||COHORT||PROSPECTIVE|||||||
33780461|NCT06522737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780462|NCT01447797|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780463|NCT06347107|NA|SINGLE_GROUP||TREATMENT||NONE||Investigator-initiated, academic, mono-center, prospective, interventional case study||||
33780464|NCT03526445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34086510|NCT03252158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"An adapted multiple treatment reversal design will be used, in which the number of slots containing (i) less healthy items and (ii) healthier items are altered over eight 4-week periods.~Vending machines will be randomly allocated to one of two groups: (1) decreasing less healthy foods first or (2) decreasing healthier foods first."||||
33780465|NCT06576596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The parents and the child are completely blinded to the study (Child is under anaesthesia, parents are not in the operating theatre). The study is also analysed by a blinded employee of Heidelberg University Hospital, Germany.|prospective, monocentric, single-blinded clinical trial. Intervention group: receive apnoeic oxygenation via the nose Control group: Does not receive apnoeic oxygenation (standard care)|t|f|f|t
33780466|NCT06049134|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780467|NCT06614114|||COHORT||RETROSPECTIVE|||||||
33780468|NCT00839982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780469|NCT00938561|||COHORT|||||||||
33780470|NCT04985383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780471|NCT06522932|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33780472|NCT01037543|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33780473|NCT00684502|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34086511|NCT00440843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33691812|NCT04605263|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Patients will be randomly assigned (1:1) to receive either traditional STN stimulation or STN+PPN patients. Once implanted, all patients will receive stimulation of all implanted devices for the first three months to allow for stimulation parameters to be adjusted. During this time, STN+PPN subjects will have their PPN stimulation parameters mapped (all DBS contacts in the PPN will be tested to determine which stimulation pattern achieves best results). Once patients have been tested at the 3-month post-op visit, STN+PPN patients will be double-blindly randomized (1:1) to either receive or not receive PPN stimulation for the following six months before further testing. Following the 9-month testing visit, STN+PPN patients will be crossed over so that those receiving PPN stimulation before will have their device turned off, and vice versa. After further testing at 15 months, all patients will have their devices turned back on. There will be one final test at 27 months.|t|t|f|t
33780474|NCT06696651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691813|NCT05115942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780475|NCT00970411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780476|NCT06394336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental study with random allocation of patients with similar characteristics to the control and intervention groups.|t|f|f|f
33780477|NCT04682574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914069|NCT04507867|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|blinding was planned for patients and evaluators (treating physicians , care provider and laboratory personnel)|exploratory study, it is a controlled, blinded, randomized clinical trial design.|t|t|f|t
33914070|NCT04136353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691814|NCT02411760|||CASE_ONLY||PROSPECTIVE|||||||
33691815|NCT04564547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914071|NCT04664855|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33914072|NCT02736292|NA|SINGLE_GROUP||OTHER||NONE||||||
33914073|NCT04419285|NA|SINGLE_GROUP||OTHER||NONE||The exploratory study will focus on 50 subjects with Retinitis Pigmentosa at very advanced stages||||
33914074|NCT03329651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33914075|NCT05280795|||COHORT||PROSPECTIVE|||||||
33914076|NCT04574297|||COHORT||PROSPECTIVE|||||||
33914077|NCT00123851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914078|NCT02768194|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33914079|NCT02726932|||COHORT||PROSPECTIVE|||||||
33914080|NCT00355212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914081|NCT03623126|||COHORT||RETROSPECTIVE|||||||
33914082|NCT02617732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33914083|NCT03363711|||COHORT||PROSPECTIVE|||||||
33914084|NCT01288898|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33914085|NCT03586882|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33914086|NCT02692014|||CASE_CONTROL||RETROSPECTIVE|||||||
33691816|NCT05832177|||COHORT||PROSPECTIVE|||||||
33691817|NCT06334692|||CASE_CONTROL||RETROSPECTIVE|||||||
33691818|NCT01352468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33691819|NCT06628869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33780478|NCT06426771|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780479|NCT00196742|||COHORT||OTHER|||||||
33914087|NCT03989219|||CASE_ONLY||PROSPECTIVE|||||||
33914088|NCT03712566|||COHORT||PROSPECTIVE|||||||
33914089|NCT00748553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914090|NCT03573232|||OTHER||CROSS_SECTIONAL|||||||
33914091|NCT00066625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086512|NCT00297401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086513|NCT06132802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086514|NCT05041686|NA|SINGLE_GROUP||OTHER||NONE||||||
34086515|NCT06014645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086516|NCT01770964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34086517|NCT03932708|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a before/after study design. Its an implementation science project.||||
34086518|NCT03912272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914092|NCT04081935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33914093|NCT04633473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994752|NCT04866979|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|We will implement a randomized, non-pharmacological study, with a double-blind certified medical device (neither the patient nor the clinician / researcher who will carry out the evaluations will be aware of the group to which the patient has been assigned).|"200 total patients:100 AD patients,100 MCI patients. Random assignment to 1 of 5 protocols (20 AD patients and 20 MCI patients per protocol). Patients will be balanced using MMSE and age matching to create homogeneous groups.~Protocols:~1. Combination of continuous TBS plus cognitive training (cTBS + CT);~2. Combination of intermittent TBS plus cognitive training (iTBS + CT);~3. Continuous TBS only (cTBS);~4. intermittent TBS only (iTBS);~5. Cognitive training only (with placebo TBS) (CT). 2 main treatment phases; 1) intensive phase (2 weeks, applied daily 5 times a week, 10 sessions); 2) maintenance phase, (5 weeks, 2 times a week, 10 sessions).~Patients will undergo a clinical, neuropsychological, and neurophysiological evaluation before the start of treatment (baseline, t0=Week1), at the end of the intensive phase (t1= Week 4), at the end of the maintenance phase (t2 = Week 8), and after 3 (t3 = Week 12) and 5 months (t4 = Week 20) from the start of treatment."|t|t|f|t
33914094|NCT03285074|||COHORT||PROSPECTIVE|||||||
33914095|NCT06240299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914096|NCT03061370|||COHORT||RETROSPECTIVE|||||||
33914097|NCT00651976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994753|NCT00893919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994754|NCT00370539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33994755|NCT01215279|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33914098|NCT01901731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914099|NCT05387304|||COHORT||PROSPECTIVE|||||||
33914100|NCT02750657|||COHORT||PROSPECTIVE|||||||
33914101|NCT03609658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are two groups. All participants are randomized prior to informed consent, and then only patients randomized to the interventional arm are approached for consent and subsequently enrolled in the intervention group. Note that patients that do not consent to the intervention are still counted as part of control group under an intent-to-treat paradigm, which necessitates passive ascertainment mechanisms for outcomes (i.e. administrative claims or the EHR).||||
33914102|NCT01727713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994756|NCT03961204|NA|SINGLE_GROUP||OTHER||NONE||||||
33994757|NCT05999253|||COHORT||PROSPECTIVE|||||||
33994758|NCT02942823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994759|NCT00131417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994760|NCT00582179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994761|NCT04940481|||COHORT||PROSPECTIVE|||||||
33994762|NCT00611676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33994763|NCT06545474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994764|NCT05203081|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33994765|NCT05009212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994766|NCT06627998|||CASE_CONTROL||RETROSPECTIVE|||||||
33994767|NCT02374710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994768|NCT06406257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Enrolled participants were randomly assigned to a control group (Group C) or a body temperature protection group (Group W) in a 1:1 ratio.|t|f|f|t
33994769|NCT03388905|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33994770|NCT03480763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33994771|NCT06559605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking of the outcome assessor and patients||t|f|f|t
33994772|NCT03069963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33994773|NCT02742558|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33994774|NCT02269592|||COHORT||PROSPECTIVE|||||||
33994775|NCT05917821|||COHORT||PROSPECTIVE|||||||
33994776|NCT03828708|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomized to one of the two groups with different amount of iron consumed.||||
33994777|NCT04732325|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|There will be two research teams. One team will be unblinded (e.g., clinical care provider/company representative, study coordinator) and will perform stimulator programming/adjustment, and the other team will be blinded (e.g., research personnel) and will perform clinical testing and collect study outcome measures.|Subjects will receive each treatment for seven days following one of six randomly-allocated sequences|t|f|t|t
33994778|NCT03807037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33994779|NCT01065857|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33994780|NCT02863822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33994781|NCT02331823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994782|NCT02248051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994783|NCT06438640|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Trial||||
33994784|NCT06149767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994785|NCT05620862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994786|NCT00761163|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33994787|NCT03668015|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33994788|NCT03349567|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33994789|NCT03592420|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33994790|NCT05476588|RANDOMIZED|PARALLEL||SCREENING||NONE||randomized, two-group design.||||
33994791|NCT06596226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994792|NCT03757195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994793|NCT05456594|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||This study involves use of a cross-sectional observation and analysis of behavior using a cross-over approach in assessing 2 sports bra models.|f|f|f|t
33994794|NCT05497063|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33994795|NCT03406156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914103|NCT02582580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33994796|NCT04005638|||CASE_ONLY||PROSPECTIVE|||||||
33994797|NCT00967135|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33994798|NCT06043388|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914104|NCT05941572|||COHORT||RETROSPECTIVE|||||||
33914105|NCT00674830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914106|NCT02862821|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33780480|NCT03424239|NA|SINGLE_GROUP||PREVENTION||NONE||All of the participants will receive zoledronic acid, as well as supplementation with calcium and vitamin D.||||
33780481|NCT00043940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780482|NCT04269200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind, placebo-controlled|t|t|t|t
33780483|NCT04595123|||COHORT||PROSPECTIVE|||||||
33780484|NCT02922543|||CASE_ONLY||PROSPECTIVE|||||||
33780485|NCT06697873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double participant/investigator|Assignment randomized control design|t|f|f|f
33780486|NCT02343614|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33780487|NCT06216028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994799|NCT03049631|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33994800|NCT02061280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33994801|NCT03911583|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33994802|NCT04198090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm, open-label trial||||
34086519|NCT04202835|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized pilot trial||||
34086520|NCT00864318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780488|NCT06696677|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|the investigator- the surgeon- will not be aware of the pre-operative measurements found in the CT scan, not to be biased in measuring.||f|f|t|f
33780489|NCT00013026|RANDOMIZED|PARALLEL||||SINGLE||||||
33780490|NCT02870621|||COHORT||PROSPECTIVE|||||||
33780491|NCT06698159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The operators will not be blinded and will be aware of patient randomisation, which is necessary for the performance of the ablation procedure. The patient participant and the recurrence evaluation committee will be blinded.|The distribution of patients to each arm will be in a 1:1 ratio.|t|f|f|t
33780492|NCT00913679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780493|NCT06640751|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33994803|NCT00582387|||COHORT||PROSPECTIVE|||||||
33994804|NCT03578939|||COHORT||PROSPECTIVE|||||||
33994805|NCT00633022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086521|NCT01697579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086522|NCT01290328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780494|NCT02926534|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780495|NCT03608020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780496|NCT02877537|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33780497|NCT05859724|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33780498|NCT06248476|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780499|NCT04323319|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|There is blind assessor who has 20 year experienced PhD PT. Participants are also blinded.||f|f|f|t
33780500|NCT05725343|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.|Eligible subjects will be randomized in a 3:2 ratio to receive either canakinumab s.c. at 200 mg or placebo every two months.|t|f|t|f
33780501|NCT00101725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780502|NCT04929132|||COHORT||RETROSPECTIVE|||||||
33780503|NCT00353054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33780504|NCT01822821|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33780505|NCT06501872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780506|NCT03589924|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will undergo Skin Sparing Mastectomy(SSM)/Nipple Sparing Mastectomy(NSM) with one-stage or two stage IBBR with TiLoop® Bra.||||
33780507|NCT06377683|NA|SINGLE_GROUP||TREATMENT||NONE||classic 3+3 dose escalation||||
33780508|NCT02646553|||CASE_ONLY||PROSPECTIVE|||||||
33780509|NCT05098470|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780510|NCT05194007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients and investigators, excluding the study coordinator, will be blinded to treatment allocation.|This is a parallel group, randomized, double-blind, placebo-controlled pilot trial where participants will be randomized to receive either Frondanol 1000mg twice daily or placebo twice daily for 6 months.|t|t|t|t
33914107|NCT02022696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914108|NCT02175771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914109|NCT01809418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914110|NCT02073435|||OTHER||OTHER|||||||
33914111|NCT02040337|||CASE_CONTROL||PROSPECTIVE|||||||
33914112|NCT02689232|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33914113|NCT06102252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914114|NCT01415037|||CASE_ONLY||PROSPECTIVE|||||||
33914115|NCT04103255|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914116|NCT04105205|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|Double blind||t|t|t|t
34086523|NCT02049996|||COHORT||PROSPECTIVE|||||||
33914117|NCT01879956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914118|NCT04949906|||COHORT||RETROSPECTIVE|||||||
33914119|NCT00121030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914120|NCT03510611|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994806|NCT04981704|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33994807|NCT03598933|||CASE_ONLY||RETROSPECTIVE|||||||
33994808|NCT05124444|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"1. Exome-wide association study~2. Transcriptomic analyses"||||
33994809|NCT01664767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994810|NCT04542746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994811|NCT03896594|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33994812|NCT03388658|||COHORT||RETROSPECTIVE|||||||
33780511|NCT05914324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention the group who will be blinded are those conducting the analysis. PHC staff, caregivers/patients and study staff in facilities cannot be blinded to the allocation status. Researchers who are responsible for collecting data will be aware of the PHCs allocation. However, for other members of the research team, the investigators will separate those who have access to allocation and those who do not. The key of which PHCs are in which arm will be held by Stellenbosch, and the researcher who will conduct the primary analysis will not have access to this information until after the primary analysis has been completed and also approved by the Study Steering Committee (SSC). This is to ensure internal study integrity and validity.|Pragmatic 3-arm cluster randomised controlled trial (cRCT), conducted over a 18-month period. Clusters are defined as outpatient facilities (PHC, CDC, CHC), and the primary and secondary child-level outcomes will be assessed through a prospective cohort study. An embedded mixed-methods concurrent process evaluation will be conducted.|f|f|f|t
33801400|NCT03041064|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33801401|NCT05741645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801402|NCT00300131|||CASE_ONLY||PROSPECTIVE|||||||
33801403|NCT04115423|||COHORT||RETROSPECTIVE|||||||
33801404|NCT00226889|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801405|NCT03569072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801406|NCT01839331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914121|NCT03150095|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914122|NCT03364608|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33914123|NCT01097473|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914124|NCT02293018|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33914125|NCT06289166|NA|SEQUENTIAL||TREATMENT||NONE||||||
33914126|NCT01838174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914127|NCT05985122|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The samples (healthy volunteers and HUS or MPGN patients) for the study will be identified between those of patients and healthy controls who provided consent to store their samples in the certified biobank of Centro Daccò (Centro di Risorse Biologiche Mario Negri - Biobanca Malattie Rare e Renali) for two previousely approved studies."||||
33914128|NCT01628250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914129|NCT04258059|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33801407|NCT04377308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients who enter the study will be monitored daily for symptoms of COVID-19. Patients may choose to take fluoxetine or to have treatment as usual. Patients may also choose to have blood drawn and stored for a future analysis of cytokines.||||
33914130|NCT02103790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914131|NCT04852406|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914132|NCT05618496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914133|NCT04962737|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914134|NCT02324842|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914135|NCT03972358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086524|NCT06406504|RANDOMIZED|PARALLEL||OTHER||NONE||The participants were randomly assigned to in-laboratory simulation group, in-situ simulation group, and control groups.||||
33914136|NCT00434863|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33914137|NCT05040958|||COHORT||RETROSPECTIVE|||||||
33914138|NCT03288493|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1: open label, 3 + 3 design of dose-escalating cohorts Phase 2: open label, administered as a total dose||||
33914139|NCT06205758|||OTHER||OTHER|||||||
33914140|NCT02021448|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33914141|NCT01188395|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33914142|NCT02304315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914143|NCT02279524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914144|NCT02608437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914145|NCT02340988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914146|NCT02457000|||COHORT||OTHER|||||||
33914147|NCT01758666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914148|NCT04246580|||CASE_CONTROL||RETROSPECTIVE|||||||
33914149|NCT00946777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914150|NCT04898374|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled non-blinded||||
33914151|NCT03284242|NA|SINGLE_GROUP||TREATMENT||NONE||Single intravenous infusion of autologous, ex vivo, expanded Treg cells in renal transplant recipients who are on Everolimus-based immunosupressive therapy.||||
33914152|NCT00277121|||CASE_CONTROL||OTHER|||||||
33914153|NCT03888391|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label active treatment||||
33914154|NCT00683241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086525|NCT03710954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086526|NCT03540459|||COHORT||PROSPECTIVE|||||||
34086527|NCT01582347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086528|NCT01031082|||COHORT||PROSPECTIVE|||||||
33914155|NCT03196271|NA|SINGLE_GROUP||OTHER||NONE||||||
33914156|NCT02144454|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33914157|NCT04076150|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33914158|NCT05668260|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33914159|NCT00101803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914160|NCT04260334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33914161|NCT03361319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 2 only of the study is double-blinded. 2 arms|Part I: A dose-escalation - standard 3+3 design. Part 2: A placebo-controlled, randomised, double-blind, 2-arms.|t|t|t|t
34086529|NCT03539510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||will be conducted using a single center, double-blind randomized controlled trial with 2 groups; an intervention group using the HF-ACP website and control group receiving usual care.|t|f|t|f
34086530|NCT01399957|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34086531|NCT06518213|||COHORT||RETROSPECTIVE|||||||
34086532|NCT04937868|||COHORT||PROSPECTIVE|||||||
34086533|NCT05489042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not be aware of if they are receiving TMS treatment or sham TMS treatment.|The administration of rTMS will adhere to a double-blinded, randomized, controlled design with 50% of the opioid users or opioid-related patients (e.g., suicidal or depressive patients) recruited to the study receiving placebo stimulation (sham) instead of active rTMS. The placebo stimulation will use a TMS coil of identical appearance that is designed to mimic the sensations associated with the active TMS coil.|t|f|f|f
34086534|NCT04581915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacists|Participants are assigned to an interventional group or a placebo group after randomisation in parallel for the duration of the study.|t|t|t|t
34086535|NCT05033132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086536|NCT02902926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086537|NCT03555799|||OTHER||CROSS_SECTIONAL|||||||
34086538|NCT03527264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086539|NCT03752892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|assessor of the primary outcomes will be blind to the participant's group allocation|prospective, randomized controlled trial|f|f|f|t
34086540|NCT00128063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086541|NCT05793658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34086542|NCT00576082|||CASE_ONLY||PROSPECTIVE|||||||
34086543|NCT02253264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086544|NCT06393231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34086545|NCT01879267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691820|NCT02966639|||COHORT||PROSPECTIVE|||||||
33691821|NCT05735834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691822|NCT04998682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691823|NCT06200714|||COHORT||PROSPECTIVE|||||||
33691824|NCT02896933|||||CROSS_SECTIONAL|||||||
33691825|NCT00071266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691826|NCT05118178|||COHORT||PROSPECTIVE|||||||
33914162|NCT03546179|||CASE_ONLY||PROSPECTIVE|||||||
33914163|NCT05837078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914164|NCT02902744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914165|NCT05539586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914166|NCT06285929|||COHORT||PROSPECTIVE|||||||
33914167|NCT04534439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914168|NCT01132677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33914169|NCT02632890|||CASE_ONLY||CROSS_SECTIONAL|||||||
33914170|NCT02632695|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914171|NCT04765826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086546|NCT05081687|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study|Patients will be randomized 1:1 to one of two arms: TNT and conventional therapy (control). Randomization will be stratified by study site and tumor stage (II vs III)||||
34086547|NCT02982759|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086548|NCT02991807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086549|NCT03168945|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34086550|NCT05474001|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34086551|NCT00797758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086552|NCT06296511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691827|NCT05969431|||COHORT||PROSPECTIVE|||||||
33914172|NCT06339736|||CASE_CONTROL||PROSPECTIVE|||||||
33914173|NCT05931016|||CASE_ONLY||PROSPECTIVE|||||||
33914174|NCT04423900|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||One hundred twenty patients aged 18-75 years, diagnosed as Plantar fasciitis and Achilles Tendinopathy by an Orthopedic surgeon, will be included. Patients will be randomly divided into three groups according to inclusion criteria.||||
33914175|NCT02775760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914176|NCT03177330|||CASE_ONLY||RETROSPECTIVE|||||||
33914177|NCT03050359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914178|NCT01432197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914179|NCT03701360|||CASE_CONTROL||PROSPECTIVE|||||||
33691828|NCT05325424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691829|NCT01867411|||CASE_CONTROL||PROSPECTIVE|||||||
33691830|NCT06482918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33691831|NCT05885815|||CASE_ONLY||PROSPECTIVE|||||||
33691832|NCT02917993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914180|NCT00414960|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33801408|NCT06519292|||COHORT||PROSPECTIVE|||||||
33801409|NCT05278533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|t|t|t|t
33801410|NCT01538368|||COHORT||PROSPECTIVE|||||||
33994813|NCT05835804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994814|NCT00567463|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33994815|NCT05312983|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"2 groups :~* 500 participants with early onset presbycusis~* 200 participants with normal hearing for their age"||||
33994816|NCT05613972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801411|NCT05801198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994817|NCT03373968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994818|NCT00235027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33994819|NCT00521586|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33994820|NCT01751854|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33994821|NCT05825716|||COHORT||PROSPECTIVE|||||||
33994822|NCT04140071|||COHORT||PROSPECTIVE|||||||
33994823|NCT05928247|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994824|NCT00835614|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33994825|NCT06563258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Prospective parallel group single-blind randomized control trial|t|f|f|f
33994826|NCT01322321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994827|NCT00503789|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33691833|NCT06227455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33691834|NCT04643821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|unaware of dose or timing of Magnetic resonance spectroscopy|Open-label, escalating dose design|f|f|f|t
33691835|NCT03478852|||COHORT||PROSPECTIVE|||||||
33691836|NCT06323889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691837|NCT03544775|||COHORT||RETROSPECTIVE|||||||
33691838|NCT05855070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691839|NCT05950958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33691840|NCT06089473|RANDOMIZED|PARALLEL||OTHER||SINGLE|outcomes will be assessed without knowledge of group allocation.|RCT with 2 arms|f|f|f|t
33691841|NCT05036720|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33691842|NCT06598033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691843|NCT00267189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691844|NCT05851105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691845|NCT00845780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691846|NCT04806789|||COHORT||PROSPECTIVE|||||||
33691847|NCT05247424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interventional cardiologists evaluating coronary angiography will be blinded to assigned group|randomization in 1:1 ratio|f|f|f|t
33691848|NCT00276081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33691849|NCT04019587|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33691850|NCT04487522|||CASE_ONLY||PROSPECTIVE|||||||
33691851|NCT06631170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691852|NCT00707694|||CASE_CONTROL||PROSPECTIVE|||||||
33691853|NCT06281678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691854|NCT01809691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691855|NCT02421939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691856|NCT04913220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691857|NCT05882292|NA|SINGLE_GROUP||TREATMENT||NONE||ABN401||||
33691858|NCT06743867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691859|NCT03610815|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Effectiveness-Implementation Hybrid 2 Trial|f|f|t|f
33691860|NCT06745323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691861|NCT06245044|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33691862|NCT06744231|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators plan a multisite step-wedge cluster randomized trial to test the extent to which the a Local Health Department led population health program reduces rates of hypertensive disorders of pregnancy (HDP, primary outcome), patient experience measures (secondary outcomes) and maternity health worker quality of life (secondary outcome). The Thriving Hearts program will be implemented in a stepped-wedge design with six nine-month time periods, 3 sequences, and 3 or 4 counties in each sequence, with 10 counties in total.||||
33994828|NCT01978886|||COHORT||CROSS_SECTIONAL|||||||
33691863|NCT06501040|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33691864|NCT04259580|||OTHER||PROSPECTIVE|||||||
33691865|NCT01236014|||OTHER||RETROSPECTIVE|||||||
33691866|NCT04975152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691867|NCT06726577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691868|NCT06476808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691869|NCT05858060|||COHORT||PROSPECTIVE|||||||
33914181|NCT00335504|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33914182|NCT03046745|||COHORT||PROSPECTIVE|||||||
33914183|NCT01911000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914184|NCT03106506|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A sample of 40 individuals with esthetic need implants will be used for the study, where the test group (n = 20) will receive tec graft. (N = 20) will receive only the dental implant without the placement of a sub-epithelial-conjunctive tissue graft.|t|t|t|f
33994829|NCT05724394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the treatment allocation.|Feasibility Randomized Controlled Trial with participants randomized into two trial arms|f|f|f|t
33691870|NCT00484718|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33691871|NCT06745882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691872|NCT04753385|||COHORT||PROSPECTIVE|||||||
33801412|NCT02808767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801413|NCT04577924|||COHORT||PROSPECTIVE|||||||
33801414|NCT03217240|||COHORT||PROSPECTIVE|||||||
33801415|NCT05618132|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801416|NCT04244500|||COHORT||PROSPECTIVE|||||||
33801417|NCT02574442|||CASE_ONLY||PROSPECTIVE|||||||
33801418|NCT06073418|||COHORT||PROSPECTIVE|||||||
33914185|NCT04989010|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914186|NCT04431661|||OTHER||PROSPECTIVE|||||||
33914187|NCT04953650|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This trial will have two groups; the intervention and the control group. Both groups will receive health education. Hence, the Intervention group will undergo two fasting days within the week from dusk to dawn, while the control group is doing the regular diet. No exercise control for both groups.||||
33914188|NCT06554834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will employ a single-blind design, where participants will be unaware of the specific intervention they receive. However, the investigators and care providers will be informed about the group assignments to ensure proper administration of the interventions. Blinding will be maintained throughout the study to prevent participant bias.|n this study, 109 healthy subjects will be randomly assigned to one of three groups. The first experimental group will receive three 30-minute sessions of osteopathic therapy using both CV4 and RR techniques. The second group will undergo three 30-minute sessions of the CV4 technique alone. The placebo group will undergo a sham procedure using an ultrasound transducer. To assess the impact of these interventions on autonomic nervous system (ANS) function, Heart Rate Variability (HRV) will be measured using specialized equipment in a seated position over a 5-minute duration.|t|f|f|f
33914189|NCT05433194|NA|SINGLE_GROUP||PREVENTION||NONE|Phase I: Open-label|Phase I: single-arm Phase I: 48 subjects are planned to be enrolled to receive ABO1009-DP in the test group.||||
33914190|NCT00304265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914191|NCT04147832|||COHORT||PROSPECTIVE|||||||
33914192|NCT00006248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914193|NCT04363489|||COHORT||PROSPECTIVE|||||||
33914194|NCT04680078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914195|NCT05870644|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Fifteen patients with allergic rhinitis aged between 18 and 35 years who had a positive skin prick test to house dust mite (D. pteronyssinus). The experiment was a crossover design in which each participant was given aerobic exercise by ergometer in two difference temperatures room : 25 degree celsius and 34 degree celsius. Rhinitis symptoms, nasal blood flow, heart rate, and oxygen saturation were measured before, during exercise at 15, 30, and 45 minutes, and after exercise at 0, 15 and 30 minutes in each temperature. Moreover, blood pressure, peak nasal inspiratory flow, pulmonary functions, respiratory muscle strength, and fractional exhaled nitric oxide were measured before and after exercise at 0, 15 and 30 minutes in each temperature.||||
33994830|NCT00715442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994831|NCT04896580|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994832|NCT05553444|NA|SINGLE_GROUP||TREATMENT||NONE||Single subject experimental design||||
33994833|NCT02943343|||OTHER||PROSPECTIVE|||||||
33994834|NCT03639181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994835|NCT06212479|||CASE_ONLY||PROSPECTIVE|||||||
33994836|NCT03534076|||COHORT||PROSPECTIVE|||||||
33994837|NCT01438593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994838|NCT00704639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994839|NCT05658393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be divided into groups according to the randomization list created to assign each patient to a group. Two independent researchers will conduct the assignment of participants to the ReLiver-N App and active control groups and the evaluation of outcome measurement data. Researchers will not be blinded as they make these interventions. However, participants will be blinded because they do not know which group, they are in.||t|f|f|f
33994840|NCT05589753|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33994841|NCT05917522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994842|NCT03849651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994843|NCT04736303|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33994844|NCT03300011|NON_RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|masking for Ultrasonic Cardiogram investigator||f|f|t|t
33801419|NCT05859152|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33994845|NCT00378963|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33994846|NCT01899989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994847|NCT01240850|RANDOMIZED|||TREATMENT||NONE||||||
33994848|NCT01591564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801420|NCT02586597|RANDOMIZED|FACTORIAL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
33801421|NCT06075524|||COHORT||PROSPECTIVE|||||||
33914196|NCT01196624|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33914197|NCT06555237|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33914198|NCT03480607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33914199|NCT04864652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914200|NCT01043354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914201|NCT05632627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914202|NCT03149666|||OTHER||CROSS_SECTIONAL|||||||
33914203|NCT02002806|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33914204|NCT04191577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Planned dose levels are placebo, low dose, and high dose of CVN424. Study drug dispensed as CVN424 suspension (or matching placebo) in amber glass bottles suitable for self-administered dosing.|t|t|t|t
33914205|NCT01744509|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33914206|NCT06063252|RANDOMIZED|PARALLEL||OTHER||NONE||This feasibility study is designed as a randomized controlled feasibility trial (allocation ratio 1:1)||||
33914207|NCT02493426|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33994849|NCT00606281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994850|NCT03499353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||THIS IS AN OPEN LABEL SINGLE ARM STUDY||||
33914208|NCT03277014|||COHORT||RETROSPECTIVE|||||||
33914209|NCT01428518|||CASE_ONLY||PROSPECTIVE|||||||
33914210|NCT02096861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914211|NCT03736538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914212|NCT00463658|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33914213|NCT01763268|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33914214|NCT00032968|RANDOMIZED|||TREATMENT||NONE||||||
33994851|NCT03850938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33994852|NCT00486187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994853|NCT04583423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994854|NCT05766553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994855|NCT00538239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994856|NCT01860638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994857|NCT01293097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994858|NCT05294276|||CASE_ONLY||PROSPECTIVE|||||||
33994859|NCT02225405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914215|NCT01915004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914216|NCT03338517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group (I) who received medical treatment with Helium-Neon Laser therapy (HNLT), (ASA Medical laser device (manufactured by ASA Terza- Via Alessandro, Italy) and Group (II) who received medical treatment with Infrared Laser therapy (ILT), (PHYACTION 792/796 manufactured in The Netherlands by Uniphy BV). The nature of the therapy was described and explained to the patient.||t|f|f|t
33914217|NCT04685070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914218|NCT05688579|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914219|NCT04972344|||COHORT||PROSPECTIVE|||||||
33914220|NCT05520268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33914221|NCT03134508|||COHORT||RETROSPECTIVE|||||||
33914222|NCT05297422|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914223|NCT04830800|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||In Phase 1 is dose escalation design, eligible participants will be randomized to received study vaccine or placebo from low dose to higher dose and later to the formulation with CpG adjuvant. In phase 2, eligible participants will received 2 selected doses (from phase 1) or placebo.|t|t|t|t
33914224|NCT05670717|||OTHER||RETROSPECTIVE|||||||
33914225|NCT01781429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914226|NCT00859781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914227|NCT00798694|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Doctors assessing patients were masked to treatment. Patients used open label Xalantan in the right eye and Travatan Z in the left eye.||f|f|t|f
33914228|NCT04281745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914229|NCT00943163|||COHORT||RETROSPECTIVE|||||||
33914230|NCT01807715|||COHORT||PROSPECTIVE|||||||
33914231|NCT02782013|||COHORT||PROSPECTIVE|||||||
33914232|NCT04274166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914233|NCT01107756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914234|NCT03772938|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914235|NCT03596359|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33914236|NCT01302262|||||PROSPECTIVE|||||||
33914237|NCT02939924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914238|NCT04743700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914239|NCT03391687|||COHORT||PROSPECTIVE|||||||
33914240|NCT02011984|||COHORT||PROSPECTIVE|||||||
33914241|NCT04200716|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33914242|NCT03192527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33914243|NCT02678234|RANDOMIZED|PARALLEL||TREATMENT||NONE|This was an open label study.|||||
33914244|NCT04989907|||COHORT||PROSPECTIVE|||||||
33914245|NCT03861546|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33914246|NCT00182117|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33914247|NCT01287533|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914248|NCT06376266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33914249|NCT03240393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914250|NCT03017248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914251|NCT02834546|||COHORT||PROSPECTIVE|||||||
33914252|NCT05312710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914253|NCT02852148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914254|NCT05946889|||CASE_CONTROL||RETROSPECTIVE|||||||
33914255|NCT02635737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914256|NCT01984034|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914257|NCT01603641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914258|NCT03909191|||COHORT||PROSPECTIVE|||||||
33914259|NCT04743245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914260|NCT03128216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33914261|NCT01908621|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914262|NCT02756650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914263|NCT00487084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914264|NCT05763173|||CASE_ONLY||PROSPECTIVE|||||||
33914265|NCT00646841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914266|NCT06174181|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33914267|NCT04897841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914268|NCT06520319|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994860|NCT05275699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994861|NCT05603351|NA|SINGLE_GROUP||PREVENTION||NONE||A prospective cross-sectional (with a longitudinal component, 2nd screening round) study evaluating the possibility of using the abbreviated bpMRI protocol technique for screening clinically significant prostate cancer in men from the general population.||||
33994862|NCT00087932|||DEFINED_POPULATION||PROSPECTIVE|||||||
33994863|NCT03424915|||COHORT||PROSPECTIVE|||||||
33994864|NCT02873845|||||PROSPECTIVE|||||||
33994865|NCT00041015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994866|NCT00908999|||CASE_CONTROL||PROSPECTIVE|||||||
33994867|NCT01945450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994868|NCT03811158|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All data will be decoded before biostatics analysis|Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover. The primary outcome measure is the diaphragm electrical activity. The secondary outcome measures include the cardiopulmonary function, length of hospital stay, and re-intubation rate.|f|f|t|f
33994869|NCT00822744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994870|NCT06059625|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33994871|NCT05806177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A single-center, randomized, placebo-controlled, double-blind, dose-increasing study design|t|t|t|t
33994872|NCT02609568|||CASE_CONTROL||PROSPECTIVE|||||||
33994873|NCT04303221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994874|NCT02091713|||COHORT||PROSPECTIVE|||||||
33994875|NCT06508905|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33994876|NCT01895764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994877|NCT05005728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994878|NCT03197818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994879|NCT05173792|NA|SEQUENTIAL||TREATMENT||NONE||||||
33994880|NCT05315297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994881|NCT03808376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914269|NCT06452628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding refers to a practice where study participants are prevented from knowing certain information that may somehow influence them-thereby tainting the results.|Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial.|f|f|f|t
33914270|NCT04218916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914271|NCT03377010|||CASE_CONTROL||PROSPECTIVE|||||||
33914272|NCT04550793|||CASE_CONTROL||PROSPECTIVE|||||||
33914273|NCT05345886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914274|NCT03594487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914275|NCT06522581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914276|NCT05763342|NA|SINGLE_GROUP||OTHER||NONE||||||
33914277|NCT03779035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914278|NCT04958863|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33914279|NCT03144583|NA|SINGLE_GROUP||OTHER||NONE|Open label|||||
33914280|NCT02570776|||COHORT||PROSPECTIVE|||||||
33914281|NCT06061887|||COHORT||PROSPECTIVE|||||||
33914282|NCT05136248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33914283|NCT02235116|||OTHER||CROSS_SECTIONAL|||||||
33914284|NCT01778088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914285|NCT04098679|||COHORT||PROSPECTIVE|||||||
33914286|NCT03108651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Researchers do not disclose about App and messages to control group|Intervention study with two parallel arms.|t|f|f|f
33994882|NCT03649581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994883|NCT00221299|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33994884|NCT01706757|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33994885|NCT04723693|||FAMILY_BASED||PROSPECTIVE|||||||
33994886|NCT02036788|||COHORT||PROSPECTIVE|||||||
33994887|NCT05957549|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086553|NCT04084015|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective, single-arm trial will include all consecutive patients undergoing cannulation of peripheral VA ECMO at the Massachusetts General Hospital from April 2019 to March 2020. Approximately 20 subjects are anticipated to be enrolled during this time.||||
34086554|NCT01990365|||CASE_ONLY||PROSPECTIVE|||||||
34086555|NCT01369433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086556|NCT02888054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086557|NCT03000972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914287|NCT00607438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914288|NCT02221180|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914289|NCT03965832|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33914290|NCT05007249|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33914291|NCT00007904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914292|NCT01919918|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33914293|NCT05600192|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914294|NCT02733614|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33914295|NCT02648412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914296|NCT00755690|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914297|NCT05407090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33914298|NCT02084836|||COHORT||PROSPECTIVE|||||||
33914299|NCT00372034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914300|NCT03535233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914301|NCT00163150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914302|NCT02309164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914303|NCT03106493|||COHORT||PROSPECTIVE|||||||
34086558|NCT05508139|||COHORT||PROSPECTIVE|||||||
33914304|NCT01874652|NA|SINGLE_GROUP||||NONE||||||
33914305|NCT05192174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914306|NCT05481203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This was an RCT with parallel groups conducted between March, 2022 and August, 2022 at the pediatric emergency unit of a hospital in Black Sea Region Turkey||||
34086559|NCT03555162|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086560|NCT00942136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086561|NCT02990000|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34086562|NCT04113694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086563|NCT00658853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086564|NCT04132765|||CASE_ONLY||PROSPECTIVE|||||||
34086565|NCT04456686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086566|NCT05759572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086567|NCT00363740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086568|NCT01732952|||CASE_ONLY||CROSS_SECTIONAL|||||||
34086569|NCT02857504|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086570|NCT03389165|NA|SINGLE_GROUP||OTHER||NONE||||||
34086571|NCT02854462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34086572|NCT03287544|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|After the allocation in the groups, rehabilitation is not done blindly since the speech therapist knows what activities he offers to patients. However, the evaluations carried out by a speech therapist, are done without the knowledge of the rehabilitation group.|"There are two arms in the protocol: one experimental arm corresponding to the combined rehabilitation (linguistic/communication) compared with another arm corresponding to the linguistic rehabilitation.~All included patients, after allocation based on aphasia severity to the  combined  and  linguistic  groups, will have a first evaluation (E1: language, neurologic and neuropsychological exams) within 7 days after the onset. Then after a 3 months rehabilitation period they will be assessed (E2: language, neurologic and neuropsychological exams). At 6 months after the onset they will finally have the last assessment (E3: language, neurologic and neuropsychological exams)."|f|f|f|t
34086573|NCT02301455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086574|NCT04152499|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34086575|NCT01331564|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34086576|NCT05106907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086577|NCT03803826|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients not responding to Cardiac Resynchronization Therapy-Defibrillators (CRT-D) after 3 months from implementation are randomly divided into control and intervention groups. Atrioventricular interval is adjusted so that E and A waves do not overlap, the interventricular interval iss subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains. The left ventricular ejection fraction (LVEF) and NYHA (New York Heart Association Classification improvement 3 months after optimization are evaluated and the use of other strain combinations assessed.||||
34086578|NCT04432480|||CASE_ONLY||PROSPECTIVE|||||||
34086579|NCT05155319|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34086580|NCT02723240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086581|NCT05457959|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34086582|NCT01515839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086583|NCT06351046|RANDOMIZED|FACTORIAL||PREVENTION||NONE|The statistical analysis of the data will be blinded|This is an open label randomized controlled trial (RCT), which will be conducted with patients of the Copenhagen Wound Healing Center at Bispebjerg Hospital in Copenhagen (DK). The trial has three arms (1:1:1): MBSR group, VRPS group, and a control group (usual care). Participants will be randomly assigned to one of the groups. Assessments will occur at baseline and 2, 6, 9, and 12 months after intervention.||||
34086584|NCT06422533|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open, non-inferiority clinical trial comparing 1:1 two antibiotics, piperacillin/tazobactam vs. ceftolozane/tazobactam||||
34086585|NCT00345306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086586|NCT04418960|||COHORT||PROSPECTIVE|||||||
34086587|NCT04519424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086588|NCT06192316|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086589|NCT02757196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086590|NCT00058591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086591|NCT02525068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086592|NCT01351636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086593|NCT00719901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086594|NCT01641536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086595|NCT01963234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086596|NCT05205356|||FAMILY_BASED||PROSPECTIVE|||||||
34086597|NCT01786291|||CASE_CONTROL||PROSPECTIVE|||||||
34086598|NCT01981252|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34086599|NCT05203185|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086600|NCT03652896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34086601|NCT02988141|||OTHER||PROSPECTIVE|||||||
34086602|NCT00388999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914307|NCT05444972|||COHORT||RETROSPECTIVE|||||||
33914308|NCT03398369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914309|NCT06216015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33914310|NCT05280041|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a single-centered randomized control trial with three arms: Two active arms correspond to the two intervention conditions in which the content is presented in a fixed standardised order (SOLENA-F) and a self-tailored order in which the participants select the modules and their sequence (SOLENA-ST) as well as the waiting list control group.||||
33914311|NCT03775018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The analgesic treatment applied will be blinded to the treatment and to the epidemiology nurse who will assess the postoperative pain||t|f|f|t
33914312|NCT06398366|||COHORT||RETROSPECTIVE|||||||
33914313|NCT00492856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914314|NCT00064129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914315|NCT00598195|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33994888|NCT04820322|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The product was re-packaged by a GI Labs staff member not involved in the clinical trial. Product label displayed the subject number, subject initials, product ID, ingredients statement, GIL repacked date, expiration date, researcher name and telephone number, investigational use statement, and allergy warnings. After the data had been entered, checked for errors and the database locked, the code was broken, #149 corresponded to the control cookie while 394 corresponded to the Fibersym cookie..|double blind, controlled, cross-over clinical trial|t|t|t|t
33994889|NCT02538627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994890|NCT04892953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994891|NCT00064831|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33994892|NCT00620880|||||PROSPECTIVE|||||||
33994893|NCT05997108|||CASE_CONTROL||RETROSPECTIVE|||||||
33994894|NCT03884894|||COHORT||PROSPECTIVE|||||||
33994895|NCT02353936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994896|NCT06467344|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994897|NCT00996697|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33994898|NCT02036086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994899|NCT02107560|||CASE_CONTROL||PROSPECTIVE|||||||
33994900|NCT00064038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994901|NCT04206267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One investigator assigned the patients to study or control group and conducted the linear measurements with 3D Trios System, other investigator treated the samples|Subjects were randomly allocated to either the AcceleDent group or the control group. The randomization was achieved by coin-tossing by one investigator. This method is equivalent to tossing a coin for each subject that enters a trial, such as Heads = control group, Tails = AcceleDent group.|f|f|t|f
33994902|NCT01548586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33994903|NCT03218813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will adopt a non-randomised prospective intervention cohort design (i.e. controlled before-and-after (CBA) study). Two cohorts of patients will be recruited from a single NHS site over two recruitment periods. Pharmacists will be trained between these recruitment periods to deliver an intervention, thus creating two comparable groups (control/'before' group vs. intervention/'after' group).||||
33994904|NCT01159145|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33994905|NCT03502811|||COHORT||PROSPECTIVE|||||||
33994906|NCT05163691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This study will include separate single- and multiple-dose parts.~Single-dose Part:~A double-blind, placebo-controlled, randomized, parallel-group design with single, inhaled doses of GH001 in 3 groups of 10 subjects (randomized as 8 active and 2 placebo subjects per group):~* Group A: single inhaled dose of 6 mg GH001~* Group B: single inhaled dose of 12 mg GH001~* Group C: single inhaled dose of 18 mg GH001~Multiple-Dose Part:~An open-label, non-randomized administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with two different dose intervals (8 subjects per group):~* Group D: 1-hour interval~* Group E: 2-hour interval"|t|f|t|t
33994907|NCT06348329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33994908|NCT06446869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blind|Study treatment vs Placebo|t|t|f|f
33994909|NCT06626750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994910|NCT00002890||||TREATMENT||||||||
33994911|NCT00151593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994912|NCT01814904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994913|NCT03922555|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994914|NCT01674907|||COHORT||PROSPECTIVE|||||||
33994915|NCT01002963|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33994916|NCT04972578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994917|NCT00978536|NON_RANDOMIZED|PARALLEL||||NONE||||||
33994918|NCT01934816|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33994919|NCT04703504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33994920|NCT00833300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33994921|NCT01506622|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
33994922|NCT03632031|||COHORT||PROSPECTIVE|||||||
33994923|NCT04548258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994924|NCT05972759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and completed a single bout of both FE and VE.||||
33994925|NCT01080703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994926|NCT00457067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994927|NCT04379739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994928|NCT00433719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994929|NCT03185208|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, investigators (who will also be prescribers/care providers), and both clinical and cognitive raters will be blind to treatment. A non-blind physician not providing care or ratings will receive real and generate false blood levels to communicate to other investigators for the purpose of titration of the lithium/placebo. Measures for emergency unblinding will be available as well for safety.|Longitudinal, randomized, double-blind, placebo-controlled experimental trial|t|t|t|t
33994930|NCT06237322|||COHORT||PROSPECTIVE|||||||
33994931|NCT01412827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994932|NCT06245928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33801422|NCT04018924|NA|SINGLE_GROUP||TREATMENT||NONE||Patient used as control of himself: If a patient carries a wound with a diameter larger than 5 cm the wound is divided in two parts on treated with the Device the other covered and used as control, if the patient has two or more separate wounds each smaller than 5 cm in diameter the worst of them is treated the others used as control.||||
33801423|NCT06277531|||COHORT||PROSPECTIVE|||||||
33914316|NCT04037436|RANDOMIZED|SINGLE_GROUP||OTHER||NONE|Single (Outcomes Assessor)|We will use a closed cohort stepped wedge design at 4 sites (1 in Northern Ontario and 3 in Southern Ontario). In a stepped wedge, sites are cluster-randomized to implement MoveSTroNg at one of four start times, each three weeks apart.||||
33914317|NCT01525927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914318|NCT04601142|||COHORT||PROSPECTIVE|||||||
33914319|NCT00521651|||COHORT||PROSPECTIVE|||||||
33914320|NCT01413048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914321|NCT04400409|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914322|NCT02817815|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33914323|NCT05211011|NA|SINGLE_GROUP||TREATMENT||NONE||In this open prospective interventional clinical study patients with hip, knee or shoulder PJI (as defined below) caused by fosfomycin-susceptible staphylococci, streptococci, enterococci or gram-negative bacilli will be included. After inclusion and PJI-surgery, intravenous fosfomycin will be given 5 g every 8 hours for 1, 2, 3-or -4 weeks according to the pathogen and surgery procedure and generally as a part of the antibiotic combination therapy of the treatment algorithm. This Treatment is followed by oral antibiotics for a total of 3 months.||||
33914324|NCT03785496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914325|NCT00634959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914326|NCT03508388|||COHORT||PROSPECTIVE|||||||
33914327|NCT05277649|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study consists of an experimental group, which will receive an intervention, and a control group, which will neither receive nor receive any intervention.||||
33914328|NCT03056495|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33994933|NCT06179173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33994934|NCT05794685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Comparative Randomized Study between 2 groups|t|f|f|f
33994935|NCT01299935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33994936|NCT05884957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33994937|NCT05709496|NA|SINGLE_GROUP||TREATMENT||NONE||"An R-IDEAL stage 2a study aiming to demonstrate technical feasibility and establish likely toxicity rates for powering the subsequent study.~Men will receive de-escalated radiotherapy to the prostate with a boost to the dominant lesion."||||
33994938|NCT04341337|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33994939|NCT01665508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994940|NCT00006153||||TREATMENT||DOUBLE||||||
33994941|NCT01822119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994942|NCT05291819|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two-arm, parallel-group, single-blind, treatment strategy study where patients are randomized 1:1 to a conventional treat-to-target follow-up strategy with structured clinical assessment of disease activity or an imaging informed treat-to-target follow-up strategy with both structured clinical assessment of disease activity and structured imaging assessment of disease activity.||||
33994943|NCT04039451|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33994944|NCT05281120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780512|NCT05310773|RANDOMIZED|PARALLEL||OTHER||NONE||24 communities in clinic catchment areas (clinics selected and approved by City Health) that provide antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) will be randomly assigned to the four arms of the study (6 communities per arm). Arm 1 will receive the stigma awareness and education workshop and HIV testing services (HTS)/pre-exposure prophylaxis (PrEP)/anti-retroviral therapy (ART) but no Couples Health CoOp Plus (CHC+); Arm 2 will receive the stigma awareness and education workshop with HTS/PrEP/ART and CHC+; Arm 3 will receive neither the stigma awareness and education workshop nor CHC+ but will receive HTS/PrEP/ART; and Arm 4 will receive HTS/PrEP/ART and CHC+ but not the stigma awareness and education workshop. All communities will receive the community stigma assessments at baseline, 4 months, and 8 months follow-up.||||
33780513|NCT02548793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780514|NCT05899049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780515|NCT01013675|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780516|NCT05049629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|All study-related measurements will be performed by a masked observer.|After enrolment into the study three study visits will be scheduled. The selection of the study eye will be randomized using www.randomizer.org. The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.||||
33780517|NCT05376579|||COHORT||PROSPECTIVE|||||||
33780518|NCT06500949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780519|NCT01679769|||||PROSPECTIVE|||||||
33780520|NCT04087096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780521|NCT03513861|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33780522|NCT04127565|||OTHER||RETROSPECTIVE|||||||
33801424|NCT01796236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801425|NCT05370794|||COHORT||PROSPECTIVE|||||||
33801426|NCT00002383||||TREATMENT||||||||
33801427|NCT02247817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801428|NCT00709423|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33914329|NCT03577912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patients, and all data collectors were blinded regarding which group the patients were in. Surgeons who performed the case were aware of the method used but were not involved with the data collection|prospective, randomized, patient and observer blinded non-inferiority trial|t|f|t|t
33914330|NCT02464397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914331|NCT00850018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914332|NCT01841424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914333|NCT06444243|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blinded with an additional optional dosing session for open label dosing|Multi-centre, Double-blinded, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder|t|t|f|f
33914334|NCT00305851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914335|NCT04626843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914336|NCT05968976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because both patient and neurosurgeon are aware of receiving general or local anesthesia, it is not possible to blind them for treatment assignment. Patients will be instructed not to reveal the received treatment with the physician performing the 6-month assessments and neuropsychological evaluation in order to secure a blinded end-point.|The study will be a multicentre prospective randomized open label blinded (PROBE) endpoint trial comparing thalamic DBS under general versus local anesthesia|f|f|f|t
33914337|NCT01513226|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33914338|NCT06174363|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Control group: 0.9% saline solution/ Study group: Maxigesic|t|t|f|t
33914339|NCT05167500|||CASE_ONLY||RETROSPECTIVE|||||||
33914340|NCT03214692|NA|SINGLE_GROUP||TREATMENT||NONE||Daily ingestion of Gum Arabic for 12 weeks||||
33914341|NCT06423287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914342|NCT05700071|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914343|NCT05528224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914344|NCT01665755|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914345|NCT03813745|||CASE_CONTROL||PROSPECTIVE|||||||
33914346|NCT02315287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914347|NCT00679679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914348|NCT04898738|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective cohort study that aims to prospectively monitor 2,000 community-based study participants with serial serological screening for SARS-CoV-2 and enhanced molecular surveillance for active infection. Nested within this cohort is a randomized trial that will allocate study participants into two arms: thoe that receive versus do not receive alcohol-based hand sanitizer (ABHS) through the course of the study.||||
33914349|NCT02792322|NA|SINGLE_GROUP||OTHER||NONE||||||
33914350|NCT02947516|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33914351|NCT00815230|||CASE_ONLY||PROSPECTIVE|||||||
33914352|NCT04817072|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914353|NCT02290054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33914354|NCT02975440|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914355|NCT00122356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914356|NCT04767633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914357|NCT00142012|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33914358|NCT02887833|||COHORT||PROSPECTIVE|||||||
33914359|NCT04873024|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be informed what treatment will be used during the studies. The device that will be delivering therapy to them will be concealed from view throughout the study.|"This study has been designed as a single-blind, randomised crossover study, in which recruited patients who suffer from Obstructive Sleep Apnea (OSA) will undergo at least two sleep studies and receive two treatments.~The intervention arm will be stratified into two groups based on their Obstructive Apnea Index (OAI):~Group 1 (n=11): Low OAI, 0.8 \< OAI \< 2.99 and AHI \< 5.0 Group 2 (n=11): High OAI, OAI \> 3.0, and AHI \> 5.0"|t|f|f|f
33914360|NCT04815304|||COHORT||RETROSPECTIVE|||||||
33914361|NCT02004912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086603|NCT03636256|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Open-label, dose rising trial consisting of a dose escalation phase and a dose confirmation phase for direct injection doses. In the dose escalation phase, subjects will be enrolled in sequential cohorts of three subjects starting at the lowest concentration. The dose determined to be most suitable for further evaluation will enroll additional subjects to total up to 12 subjects at that dose level.~The study will also dose escalate Groups 1 and 2 for the intravesical instillation of NanoDoce concentrations (2.0 and 3.0 mg/mL)."||||
33994945|NCT04066088|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33994946|NCT00240032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086604|NCT03823144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is an open-label, non-randomized, single center, study of IVM observation in conjunction with fluorescein in subjects with solid tumors undergoing surgical resection.|||||
34086605|NCT03963440|NA|SINGLE_GROUP||SCREENING||NONE||Cross-cultural validation study of a questionnaire, interventional research involving the human person chronic low back pain, prospective, with cross-sectional cohort follow-up, multi-centric||||
34086606|NCT01457794|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33994947|NCT01808651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994948|NCT04096664|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adaptive prospective, randomized, controlled, multicenter trial, with hierarchical sequential analysis.||||
33994949|NCT01710748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994950|NCT02184936|||COHORT||PROSPECTIVE|||||||
33994951|NCT05848115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33994952|NCT02658487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994953|NCT04183335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33994954|NCT04373863|||COHORT||PROSPECTIVE|||||||
33994955|NCT04459351|||COHORT||OTHER|||||||
33994956|NCT04922827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994957|NCT04892615|||COHORT||PROSPECTIVE|||||||
33994958|NCT00259896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994959|NCT04428307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Interviewers assessing outcomes and statisticians will be blinded to arm assignment|three-arm parallel cluster randomized trial|f|f|f|t
33994960|NCT04322344|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33994961|NCT05777005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994962|NCT03115697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086607|NCT02524938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086608|NCT05299749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086609|NCT00467766|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34086610|NCT01243281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34086611|NCT05848804|||COHORT||CROSS_SECTIONAL|||||||
34086612|NCT02805023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the study will be double-blind for treatment allocation. Both BGC101 and placebo are supplied fresh in 5 mL ready-to use-syringes. Both BGC101 and placebo will be prepared by an unblinded trained personnel (external to the study staff members) who will not take part in the treatment and / or assessment of the patient. The patient will also be blinded and the investigator will delegate the unblinded and blinded staff in order to perform study procedures in a double-blind manner||t|f|f|t
34086613|NCT01426529|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34086614|NCT01963468|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086615|NCT02941640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study included 120 patients randomly divided into four groups with 30 patients in each. The study was not blinded. The nurse designated for participation in this study allocated the patients randomly into four groups by selecting a sealed opaque envelope from a box and opening it in the operating theatre. A card inside the envelope contained name of the treatment. All the envelopes were prepared in advance in a ratio of 1:4, shuffled well, and placed in the box by the same nurse.||t|f|f|f
34086616|NCT04796857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086617|NCT02603900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34086618|NCT04730011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086619|NCT06530810|NA|SEQUENTIAL||TREATMENT||NONE||||||
34086620|NCT01578291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34086621|NCT03409380|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||double - blind randomized, crossover design trial|t|t|t|t
34086622|NCT02529436|||||PROSPECTIVE|||||||
34086623|NCT05639036|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34086624|NCT05042492|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study was designed as a single centre, prospective, randomised (1:1), dual arm, single treatment, unblinded, interventional study that will be performed on patients undergoing unilateral TKA for primary OsteoArthritis.||||
33780523|NCT05315804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patients will be unaware of the type of treatment performed, with prior written informed consent. So, they will be divided in the two groups of study after a process of randomization|The study will be designed as a double-arm randomized controlled clinical trial. The intraosseous defects of subjects allocated in A group will be treated with MINSD and application of amelogenins in gel, while in B Group only MINSD will be performed. The null hypothesis of no statistically significant differences between the two modalities for the treatment of intraosseous defects will be tested.|t|f|f|f
33914362|NCT05212155|NA|SINGLE_GROUP||TREATMENT||NONE||The program is open-label.||||
33914363|NCT01602926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914364|NCT00216099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994963|NCT04635007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A double-blind study is one in which neither the participants nor the experimenters know who is receiving a particular treatment. This procedure is utilized to prevent bias in research results. Double-blind studies are particularly useful for preventing bias due to demand characteristics or the placebo effect. In a double-blind study, the investigators who interact with the participants would not know who will receive the actual drug and who will receive a placebo.|"The patients will be divided into 2 groups~Group no. (1) 100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.~Group no. (2) 100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes)."|t|f|t|f
33914365|NCT02864537|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33994964|NCT00161785|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33994965|NCT00452738|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33994966|NCT03979664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Without the subject knowing, one patch will be turned on whereas the other patch will be turned off. The patch will be turned on pulling a tab found in the middle of the butterfly-shaped patch. The other patch will be turned off by not pulling the tab found in the middle of the butterfly-shaped patch.|Subjects who meet the selection criteria will be offered an opportunity to take part in this study. This will be a prospective controlled study. After written informed consent, 20 subjects with symmetric thick plaque psoriasis lesions on the extremities and/or trunk will be enrolled and randomized to receive one activated iontophoresis patch containing dexamethasone sodium phosphate and another inactive control iontophoresis patch containing dexamethasone sodium phosphate on each limb containing a thick psoriatic plaque. Members of the research team will apply the patches. After application of the patch, subjects will be asked to return to the clinic in 1 week and 2 weeks. Efficacy will be measured at the 1-week and 2-week follow-up visit using a scale for erythema, scale, and thickness called the static Physician Global Assessment (sPGA) and subject satisfaction to treatment will be measured at the 2 week-follow-up using the PsoSat Questionnaire.|t|f|f|f
33994967|NCT01515891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994968|NCT02571686|||||PROSPECTIVE|||||||
33994969|NCT05395052|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33994970|NCT05288686|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible due to the different color of the injected tracer.|||||
33994971|NCT05312216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994972|NCT01177462|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33994973|NCT04089553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994974|NCT04422457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994975|NCT06108700|||CASE_ONLY||PROSPECTIVE|||||||
34086625|NCT01214122||||BASIC_SCIENCE||NONE||||||
34086626|NCT00566826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34086627|NCT03057418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086628|NCT04491799|||COHORT||PROSPECTIVE|||||||
34086629|NCT02106481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086630|NCT04445168|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33780524|NCT06290232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914366|NCT06268392|||COHORT||RETROSPECTIVE|||||||
33914367|NCT02812433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914368|NCT05428800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No Masking|Randomized controlled study||||
34086631|NCT05513911|NA|SINGLE_GROUP||TREATMENT||NONE||Every participant in this study will receive the intervention||||
33780525|NCT04590235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914369|NCT00903032|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914370|NCT04489485|||CASE_CONTROL||PROSPECTIVE|||||||
33780526|NCT03610633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780527|NCT06696352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33780528|NCT06566261|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Escalating Dose Cohorts||||
33780529|NCT04947969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|After random assignment to 2 groups, patients in the RS and SR groups will receive real and shame laser acupuncture (single blinding), six consecutive times every day.|Randomized controlled, double blind, cross-over study.|t|f|f|t
33780530|NCT00067145|RANDOMIZED|||TREATMENT||||||||
33780531|NCT04818320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780532|NCT01576237|||OTHER||PROSPECTIVE|||||||
33914371|NCT00673478||CROSSOVER||TREATMENT||||||||
33914372|NCT04425772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914373|NCT02456870|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914374|NCT00204425|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
33691873|NCT05906095|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a mixed-methods, hybrid (Type 2) effectiveness-implementation study with primary and administrative data collection. Our design is an incomplete stepped-wedge cohort design, where each SVH (n = 8) serves as its own control and residents and staff within SVHs are followed longitudinally from pre-intervention through sustainment measurement periods. This design is effective for evaluating interventions implemented at the site level, with strategies that target groups rather than individuals. The investigators designed an initial 3-month pre-intervention period in which each SVH builds its frontline staff huddle practice across all units. After this, each SVH will begin the 3-month LOCK intervention on all its units. A 12-month sustainment period follows. To ensure feasibility with a relatively small team, the investigators have 2 waves in the stepped-wedge design so no more than 2 site visits occur in the same month and travel remains manageable.||||
33780533|NCT06698016|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33780534|NCT00415155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780535|NCT04569461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780536|NCT03316443|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Eligible 90 adult patients will be randomly allocated by a computer-generated randomization sequence into 2 equal groups:~Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).~Glidescope group: 45 patients will be intubated by Glidescope (Group G)."|t|f|f|f
33780537|NCT01868867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780538|NCT04692181|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Double-blinding by randomization schedule||t|t|t|f
33780539|NCT06162819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients with migraine with even No. Medical Record will be assigned Amitriptyline whereas subjects with Odd Medical record No. will be treated with Flunarizine|Single blind, Randomized Parallel study design, All the consented participants will be randomized into two equal groups|t|f|f|f
33780540|NCT02616354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780541|NCT02271594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780542|NCT06278961|||COHORT||PROSPECTIVE|||||||
33780543|NCT06021990|RANDOMIZED|PARALLEL||TREATMENT||NONE||After assessing eligibility and consent patients will be randomly assigned to either the intervention arm or control arm. The control arm would be standard of care treatment according to GOLD guidelines and approved by the Pakistan Chest Society. The intervention arm will take Clopidogrel 75mg dail according the study prototcol||||
33994976|NCT03890237|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study participants will not be masked to their assignment, but will not know the full set of treatment and comparison groups, or what those other groups receive. Given cluster level randomization, contamination will be minimized. Enumerators who collect the survey data that forms the basis of the evaluation will not be explicitly told the treatment status of a given Kebele, however, given the community level nature of the intervention it may be possible for them to ascertain whether it is a treatment or control Kebele. Statistical analyses will be done by the investigators who will not be masked to the treatment status of the participants|The impact evaluation study is a cluster-randomized controlled trial among 175 communities with five study arms: control (no intervention), AWH-E, Her Spaces, AWH- E + asset transfer, and AWH-E without community engagement and systems strengthening.||||
33780544|NCT03748264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33780545|NCT04515784|NA|SINGLE_GROUP||TREATMENT||NONE||One-arm trial||||
33780546|NCT04761393|||COHORT||CROSS_SECTIONAL|||||||
33780547|NCT03267147|||COHORT||PROSPECTIVE|||||||
33780548|NCT05457842|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33780549|NCT05465694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780550|NCT04491617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780551|NCT01767909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780552|NCT04096157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33780553|NCT00522184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780554|NCT03571568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase 1/2a, dose escalation, consecutive-cohort, open-label study trial of BI-1206 in combination with rituximab||||
33780555|NCT00602901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780556|NCT00733460|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780557|NCT05841160|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33780558|NCT04011982|||COHORT||OTHER|||||||
33780559|NCT06695728|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33780560|NCT04569214|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33780561|NCT04989439|||COHORT||PROSPECTIVE|||||||
33780562|NCT03101696|||OTHER||PROSPECTIVE|||||||
33994977|NCT06212492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780563|NCT06697769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized study with a control and intervention group||||
33780564|NCT00670995|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33691874|NCT04970056|||COHORT||OTHER|||||||
33691875|NCT05335070|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective single-arm pilot study||||
33691876|NCT06496581|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, international, multicenter, randomized||||
33691877|NCT05396833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691878|NCT06744959|||COHORT||PROSPECTIVE|||||||
33691879|NCT02071147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33691880|NCT03225144|||COHORT||PROSPECTIVE|||||||
33691881|NCT06651502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691882|NCT06744985|||COHORT||PROSPECTIVE|||||||
33691883|NCT06744699|||OTHER||RETROSPECTIVE|||||||
33780565|NCT01077245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780566|NCT00457080|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33780567|NCT03163992|NA|SINGLE_GROUP||TREATMENT||NONE||Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)||||
33780568|NCT01072929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780569|NCT05256043|||CASE_CONTROL||RETROSPECTIVE|||||||
33780570|NCT05688371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780571|NCT01664234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33780572|NCT06697184|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33780573|NCT01806415|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33914375|NCT01002261|||COHORT||PROSPECTIVE|||||||
33914376|NCT03902743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914377|NCT03545698|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914378|NCT02867345|||OTHER||PROSPECTIVE|||||||
33914379|NCT00710034|RANDOMIZED|PARALLEL||TREATMENT||NONE|This was an open label trial.|||||
33914380|NCT01404026|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33914381|NCT00001165||||TREATMENT||||||||
33994978|NCT05163886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Double-blind, placebo-controlled|t|t|t|t
33994979|NCT03703258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691884|NCT05641831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33994980|NCT04423835|||COHORT||RETROSPECTIVE|||||||
33914382|NCT02470052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994981|NCT04215705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33994982|NCT02681939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994983|NCT03815903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994984|NCT03334058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994985|NCT05888311|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33994986|NCT00973219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33994987|NCT05444296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blind to the type of intervention the participant receives.|Single blinded, randomized, active control|f|f|f|t
33994988|NCT02243982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33994989|NCT06114836|RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants will be randomized to one of three arms: Natural maturation, Proton Pump Inhibitor (PPI) treatment, or Added rice (AR) formula. Subjects will be stratified and allocated 1:1:1 based on tube feeds (yes or no) and ARI (3-7% or \>7%).||||
33994990|NCT06559553|NA|SINGLE_GROUP||TREATMENT||NONE||Climbing stage, and the following two stages of research||||
33994991|NCT03889860|||CASE_CONTROL||RETROSPECTIVE|||||||
33691885|NCT05407714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691886|NCT06470672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691887|NCT03315754|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial||||
33691888|NCT06174805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691889|NCT05755620|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33691890|NCT05230914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33691891|NCT06288477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914383|NCT02446353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914384|NCT02239770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33914385|NCT00136773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914386|NCT03282708|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"1 group of caretakers (9 volunteers). For this group: one sample collection of spontaneously produced fresh stools (of the approximate size of 3 green beans);~1 group of caretakers (8 volunteers). For this group: no intervention (participant-observation only)"||||
33914387|NCT01848899|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33914388|NCT04430660|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914389|NCT01673503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914390|NCT00062634|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33914391|NCT04402268|||COHORT||RETROSPECTIVE|||||||
33914392|NCT05448560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33914393|NCT01981967|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914394|NCT01463865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914395|NCT02939937|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participant , investigator||t|t|t|t
33914396|NCT02952326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914397|NCT02296996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914398|NCT00002903||||TREATMENT||||||||
33994992|NCT04791813|||OTHER||CROSS_SECTIONAL|||||||
33994993|NCT05104723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994994|NCT06562400|||CASE_CONTROL||PROSPECTIVE|||||||
33994995|NCT04888338|||COHORT||PROSPECTIVE|||||||
33994996|NCT01262235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33994997|NCT02135757|||COHORT||PROSPECTIVE|||||||
33691892|NCT06743607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33691893|NCT04791709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691894|NCT04386967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691895|NCT05895344|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter prospective comparative phase 3 randomized 1:1 trial||||
33691896|NCT05171075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33994998|NCT01834183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33994999|NCT05799677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparing the extent of bronchiolitis between reflexology additive treatment to no reflexology treatment.||||
33995000|NCT00245882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995001|NCT04794816|||CASE_ONLY||CROSS_SECTIONAL|||||||
33691897|NCT06745687|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm multi-center trial||||
33691898|NCT06307652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven|t|t|t|t
33691899|NCT04029688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691900|NCT05462613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691901|NCT06744777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind methodology, with randomization and treatment assignment concealed.|The study employs a parallel group design, where participants are randomly assigned to one of two arms: an intervention group receiving standard treatment plus Ribavirin and a control group receiving standard treatment alone. This approach ensures that each participant is exposed to only one of the two interventions being compared. The study is designed to assess the comparative efficacy of Ribavirin in preventing clinically significant hemorrhage among dengue fever patients while minimizing confounding factors through randomization and blinding.|t|t|t|f
33691902|NCT01834001|||COHORT||PROSPECTIVE|||||||
33995002|NCT03345043|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind||t|t|t|f
33995003|NCT02965261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995004|NCT00573976|||CASE_CONTROL||PROSPECTIVE|||||||
33995005|NCT05034874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995006|NCT00531180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995007|NCT03257735|||CASE_ONLY||PROSPECTIVE|||||||
33691903|NCT05796167|NA|SINGLE_GROUP||OTHER||NONE||self-control, pilot study||||
33995008|NCT05693623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691904|NCT04420884|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691905|NCT04605055|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691906|NCT05831891|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Before surgery, patients will receive Fruquintinib 5mg, qd, 2w on/1w off, combined with Serplulimab 4.5mg/kg, IV drip, d1, q3w.||||
33691907|NCT06418425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research coordinator who assesses the outcomes will be blinded. This clinical research coordinator is different from the one taking the informed consent and performing the randomisation.|"Participants meeting the eligibility criteria, will be approached by the care coordinator. If interested in participating, they will be referred to the research team member for recruitment and consent will be taken. Participants will then be randomly assigned to intervention or usual care parallel arms. Randomisation of participants will be done on 1:1 allocation to intervention or usual care using block randomisation. Allocation will be concealed using opaque envelopes."|f|f|f|t
33691908|NCT06745180|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE||2x2 Factorial Design|f|f|t|t
33691909|NCT06745102|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33691910|NCT06744972|||COHORT||RETROSPECTIVE|||||||
33691911|NCT04846517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691912|NCT04472429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
33691913|NCT04528173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The unblinded members are the treating anesthesiologist for the case, staff who randomize, and collect and enter intra-op medications into electronic data capture (EDC).~Blinded members include the subject/family members, the surgeon, staff who perform post-op assessment, physician investigator who perform any adverse event/serious adverse event (AE/SAE) assessments, statistician and data safety monitoring board (DSMB)."|Subject will be randomized to 1:1 intra-operative opioid-free (OFG) vs traditional care anesthetic with opioids (TCG) group.|t|f|t|t
33691914|NCT06046287|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33691915|NCT06745388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995009|NCT01565447|||OTHER||CROSS_SECTIONAL|||||||
33691916|NCT06350409|||COHORT||PROSPECTIVE|||||||
33691917|NCT06410885|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691918|NCT01946204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33691919|NCT06745193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691920|NCT05856890|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|In Groups 1-4, eligible participants will be randomized at a 3:1 ratio to receive a single intravenous infusion of HepB mAb19 or placebo (normal saline) at one of four increasing dose levels (1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg). In Group 5 participants will receive HepB mAb19 at the maximum tolerated dose (MTD)||t|t|t|f
33780574|NCT06007313|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780575|NCT03756779|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780576|NCT02442414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780577|NCT01238575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780578|NCT00286910|||CASE_CONTROL||RETROSPECTIVE|||||||
33780579|NCT00800371|||COHORT||PROSPECTIVE|||||||
33780580|NCT06234397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780581|NCT03213795|||OTHER||RETROSPECTIVE|||||||
33995010|NCT02105272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33995011|NCT02601963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995012|NCT00341458|||CASE_CONTROL||RETROSPECTIVE|||||||
33995013|NCT03676634|NA|SINGLE_GROUP||OTHER||NONE||||||
33995014|NCT01946477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995015|NCT03867760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33995016|NCT05764096|||COHORT||CROSS_SECTIONAL|||||||
33995017|NCT00922896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086632|NCT04628624|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Nutritional supplements will be provided in a randomised, double-blinded manner. Both the participants and research testers will be masked from knowing the specifics of the supplement intervention.|Participants randomly assigned to either placebo, green tea extract (GTE) or GTE with antioxidants in a parallel, double blind manner|t|f|t|f
34086633|NCT01088087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086634|NCT05869474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomly assigned(1:1) to the two treatment groups by an independent staff who is not involved in the treatment. The endoscopist and patient are not masked because they exactly know whether EUS-guided implantation is performed or not. Survival will be assessed by blinded researchers during follow-up.||f|t|f|t
33691921|NCT06546826|||CASE_CONTROL||PROSPECTIVE|||||||
33691922|NCT01711190|||COHORT||PROSPECTIVE|||||||
33780582|NCT05235113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be randomized to intervention (IG) or control group (CG) with ratio of 1:1. The entire cohort will perform leg and foot exercises twice a week. The IG will use the Tele-exergaming platform, and the CG will do the exercises without the platform.|t|f|f|f
33780583|NCT02180711|NA|PARALLEL||TREATMENT||NONE||||||
33995018|NCT06626139|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Research staff will be masked in reference to the Drug condition but not the Context condition. Participants will be briefed only on the Context condition they are randomized to, and masked in reference to Drug condition.|2 x 2 Factorial Design Factor 1: Drug (Psilocybin vs Placebo) Factor 2: Context (Context 1 vs Context 2)|t|f|t|f
33995019|NCT04681391|||OTHER||OTHER|||||||
33995020|NCT04880616|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33995021|NCT04180969|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|sham (inactive) figure of 8 coil for rTMS, and placebo for pharmacological stressor|Double-blind, 1Hz mPFC (vs. sham) rTMS X stressor (vs. placebo), 4-session, within-subjects, randomized crossover design|t|f|t|t
33995022|NCT04624360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995023|NCT02035163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914399|NCT05120934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the initial 8- week period, this will be a double-blind study. Both subjects and all study personnel (except for the research pharmacist) will be blind to the treatment assignment. Unblinding for both subjects and study investigators will occur at the end of the 8-week blinded treatment period.~The subjects and all personnel involved with the conduct and the interpretation of the study, including the Investigators and other study personnel (except the research pharmacist) will be blinded to the treatment codes. Randomization data will be kept strictly confidential by the study statistician, and accessible only to authorized persons until the time of unblinding.~Only in the case of an emergency, when knowledge of the investigational product is essential for the welfare of a subject, the principal investigator may unblind a subject's treatment assignment during the 8-week blinded treatment period."||t|t|t|t
34086635|NCT01870596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780584|NCT05674526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In dose expansion patients will be enrolled in 2 parallel, disease specific cohorts to further characterize the safety, tolerability and preliminary anti- tumor activity of WU-NK-101 in combination with cetuximab||||
33780585|NCT06696625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34086636|NCT04832035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086637|NCT05545735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086638|NCT02641834|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33780586|NCT03944434|NA|SINGLE_GROUP||OTHER||NONE||||||
33780587|NCT02785601|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914400|NCT01767194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914401|NCT02586233|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33914402|NCT03653403|RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 48 subjects who meet the study criteria will be enrolled and will receive treatment with one of the 2 study drugs. Approximately 20 subjects will be enrolled in the Control Gel treatment arm and approximately 28 subjects in the IDP-126 Gel treatment arm will be enrolled||||
33914403|NCT04913961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914404|NCT02628249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914405|NCT02276235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914406|NCT03289780|||COHORT||PROSPECTIVE|||||||
33914407|NCT01648543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780588|NCT00059449|||||PROSPECTIVE|||||||
33780589|NCT01094743|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33780590|NCT04573140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995024|NCT03684928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Prospective, double-masked, bilateral, randomized, one month cross-over dispensing study.|t|f|t|f
33995025|NCT06123689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086639|NCT03583281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blinded|Obese females|t|f|t|f
33995026|NCT03459235|NA|SINGLE_GROUP||SCREENING||NONE||||||
33995027|NCT05797207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The patients will be blinded to the microbiome results for the study period. The gastroenterologists will be blinded to microbiome results. The microbiome researchers will be blinded to colonoscopy results The statisticians will be blinded to both intervention results until the end of patient enrollment|Fecal samples will be obtained from patients who are enrolled for colonoscopy for the clinical suspicion of inflammatory bowel disease||||
33995028|NCT01943695|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995029|NCT00537095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995030|NCT03837587|||CASE_ONLY||PROSPECTIVE|||||||
33995031|NCT06467513|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|The randomized personnel of the study enrolled suitable patients according to the random number table method before surgery, and then extracted drugs for anesthesia (anesthesia and patients did not know the group). The group status was not known to the post-operative follow-up personnel or the data analysts.|This study was divided into 3 groups, one group was placebo group, the other group was low-dose esketamine group (continuous injection of esketamine until the end of surgery), the dose was 0.2mg/kg; The other group was the Esketamine high-dose group (the continuous injection of esketamine during the operation until the end of the operation) with a dose of 0.4mg/kg.|t|f|t|t
33995032|NCT04125186|||OTHER||CROSS_SECTIONAL|||||||
33995033|NCT05839262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator: Statistical data analyst.|Randomized clinical trial (RCT).|f|f|t|t
33995034|NCT02189226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995035|NCT01620957|||COHORT||PROSPECTIVE|||||||
33995036|NCT04525027|||COHORT||PROSPECTIVE|||||||
34086640|NCT05043935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086641|NCT05109247|||COHORT||PROSPECTIVE|||||||
34086642|NCT02759640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086643|NCT05303714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086644|NCT05594082|||COHORT||RETROSPECTIVE|||||||
34086645|NCT05498727|||OTHER||OTHER|||||||
34086646|NCT06275269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086647|NCT03226587|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34086648|NCT01260909|||COHORT||PROSPECTIVE|||||||
34086649|NCT01715298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086650|NCT03502798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086651|NCT01508000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086652|NCT03479905|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086653|NCT03238131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086654|NCT01029210|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34086655|NCT00088426|||CASE_CONTROL||PROSPECTIVE|||||||
34086656|NCT02354326|||COHORT||PROSPECTIVE|||||||
34086657|NCT04754295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|f|t
34086658|NCT00769561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086659|NCT06551753|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Given the nature of the intervention, the investigator and patients were not blinded to the intervention. Since the patients in the intervention group were fitted with virtual reality glasses, blinding could not be performed due to the nature of the study. However, patients were blind to randomization until administration began. After the patient was pre-tested, he was informed by the researcher that he was in the intervention or control group. The investigator was also blind to randomization. Patients were assigned to intervention and control groups by an independent selection from a simple bag of random numbers prepared for randomization. Analysis of the study data was also performed by an independent statistician who was unaware of the intervention and control groups. In this study, blinding was ensured in the implementation of randomization and analysis and reporting of data.|a randomized controlled experimental study||||
34086660|NCT03470077|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The trial will be planned that neither the doctors (investigators) nor the patients' guardians or even children themselves will be aware of the group allocation and timing of drug received|"Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia. Group B: will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia."|t|f|t|f
34086661|NCT04243278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34086662|NCT04130841|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33995037|NCT06557551|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, open-label, parallel group group study||||
33995038|NCT00548522|||CASE_ONLY||CROSS_SECTIONAL|||||||
34086663|NCT02171624|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086664|NCT06147674|||COHORT||PROSPECTIVE|||||||
34086665|NCT00819039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086666|NCT05225740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086667|NCT01082419|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34086668|NCT02687672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995039|NCT04483921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Within-subjects crossover design. The order of conditions is counterbalanced within each subgroup of participants.||||
33995040|NCT00187928|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33995041|NCT03865563|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single institution, single-arm pilot study, designed to assess the feasibility, safety and efficacy of retrograde venous infusion of gemcitabine/Lipiodol® administered in a neoadjuvant setting for the treatment of patients with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma.||||
34086669|NCT06237179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691923|NCT06560021|RANDOMIZED|PARALLEL||PREVENTION||NONE|The endoscopist will not be informed of the biopsy strategy until he/she is ready to insert the scope. Participants will not be informed of the randomization until the colonoscopy is completed.|multicenter parallel group clinical trial||||
33691924|NCT06042751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"One study arm will receive exercise therapy with 6 treatments over three months.~One study arm receives psychotherapy with 6 treatments over three months. One study arm receives combined exercise and psychotherapy over three months."|f|f|f|t
33995042|NCT06409377|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|74 Adults were enrolled in the study and randomized using computer generated random numbers and divided into two groups. For the purpose of double blinding, two investigators participated in this study; an anesthesiologist who was not participating in the study prepared the study drug infusions and was responsible for drug administration. Another anesthesiologist who was unaware of group's allocation was responsible for the intubation and data collection.|Patients was allocated according to the randomly generated numbers into 2 groups; 37 patients in each group. The Dexmedetomidine Group (D): Patients received dexmedetomidine (1.5 μg/kg), propofol (2mg/kg), and fentanyl (1 μg/kg). The Control Group (C): Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).|t|t|t|t
33995043|NCT06560593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
33995044|NCT05590039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995045|NCT02939573|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995046|NCT04598763|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691925|NCT05727904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691926|NCT04556890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All stimulation procedures will be double-blinded, with clinicians, raters and patients blinded to the type of administered treatment using a designated sham coil.|"The study design includes two different stimulation protocols consisting each of 30 sessions:~A) Active rTMS treatment for depression (1800 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1; B) Active rTMS treatment for both, depression and pain (1800 pulses of iTBS to left DLPFC followed by 1500 pulses of 10 Hz to M1)"|t|f|f|t
34086670|NCT02020642|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691927|NCT05126862|NA|SINGLE_GROUP||TREATMENT||NONE||Two single groups will be recruited: one including participants with Huntington's disease and the other including participants with Parkinson's disease.||||
33691928|NCT06744322|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33691929|NCT06745141|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study employs a simulated randomized controlled trial (RCT) design to evaluate the effects of periodontal health interventions on patients with myocardial infarction (MI) complicated by periodontitis.~The study mimics the framework of a traditional randomized controlled trial but does not involve formal randomization of participants.~Participants are allocated into intervention and control groups in a structured manner to minimize bias, ensuring comparability."||||
34086671|NCT02167672|||OTHER||OTHER|||||||
33691930|NCT01999361|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33691931|NCT02252172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780591|NCT00429702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33780592|NCT04861051|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780593|NCT02758678|||COHORT||PROSPECTIVE|||||||
33780594|NCT06439953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33801429|NCT00034528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086672|NCT02873689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086673|NCT04987073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086674|NCT00070434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086675|NCT06158581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A rater blind to condition assignment will assign CGI ratings.||f|f|f|t
33995047|NCT05435638|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients with type I punctate palmoplantar keratoderma or pachyonychia congenita will be recruited to be treated, with 1% topical KM-001.~Arm 1: up to 10 eligible patients will be treated twice daily for 12 weeks. Treatment safety and efficacy will be assessed in the clinic visits up to day 84. In between, safety will also be assessed by phone. PK blood samples will be collected. 1 week after the end of treatment visit, patients will return to the clinic for final safety, efficacy and PK evaluations.~Arm 2: up to 8 eligible patients, will be treated twice daily, for 16 weeks, with 1% topical KM-001. Treatment safety and efficacy will be assessed in the clinic visits up to day 112. PK blood samples will be collected. In between visits, safety will also be assessed by phone. 2 weeks after the end of treatment visit, patients will return to the clinic for final safety, efficacy, and PK evaluations."||||
34086676|NCT03462680|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Only Pharmacists keep the log of the drug dispensed. Everyone else is blinded.|There are two arms, niacin and placebo. They are double blind and randomized.|t|t|t|t
33995048|NCT04005222|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33995049|NCT00197938|||COHORT||PROSPECTIVE|||||||
34086677|NCT01326975|||CASE_CROSSOVER||PROSPECTIVE|||||||
34086678|NCT01030900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086679|NCT00988780|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34086680|NCT02340949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086681|NCT05052840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086682|NCT04530071|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"Double-blinding will be used to prevent subjective biases of the subjects and the investigator from affecting the study results.~Subject assignment group will be disclosed only to the unblinded sub-investigator or unblinded study coordinator and unblinded investigator designated as a person responsible for IP management and procedures."|t|f|t|t
34086683|NCT03720561|||COHORT||PROSPECTIVE|||||||
34086684|NCT04399681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086685|NCT02225587|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34086686|NCT01380366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086687|NCT01922583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086688|NCT03413735|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34086689|NCT02576600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086690|NCT02120235|||OTHER||OTHER|||||||
34086691|NCT06314815|||CASE_CONTROL||RETROSPECTIVE|||||||
33691932|NCT06741930|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|In this double-blind study, participants were randomly assigned to one of the three treatment groups (Ketamine, Midazolam, or Propofol) using a sealed envelope randomization. Both the physicians who assessed the results and the patients were blinded to the assigned group. Each participant was assigned an identification number indicating the treatment group. An emergency nurse prepared the treatment solutions immediately before administration, based on the assigned identification number, and stored them in labeled containers with no indication of their contents. A clinician with 32 years of experience, who was blinded to the study's null hypothesis and did not participate in the evaluation of results, administered the treatments and recorded patient data onto a predesigned case data form. Another physician with 27 years of experience, who was not present during the treatment, assessed the EEG recordings.|Single center|t|f|f|t
33691933|NCT04467021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691934|NCT06744829|NA|SINGLE_GROUP||OTHER||NONE||||||
33691935|NCT05227690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo-controlled|t|f|t|f
33691936|NCT05365581|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691937|NCT05587842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation will be concealed to the patient and the investigators/research team until the online enrollment is completed and confirmed.|Subjects will be enrolled and randomized into one of the two postoperative weightbearing groups: either the Non-weightbearing group, or the Early weightbearing.|t|f|t|f
33691938|NCT05853575|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691939|NCT03984201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Blinded, randomized control|t|t|t|t
33691940|NCT06745258|||OTHER||OTHER|||||||
33691941|NCT03821935|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691942|NCT02307617|||CASE_CONTROL||OTHER|||||||
33780595|NCT04358471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be assigned to low dose AAVCAGsCD59, high dose AAVCAGsCD59, or sham arm.|t|f|f|t
33780596|NCT04272151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086692|NCT02699164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086693|NCT05668273|RANDOMIZED|PARALLEL||OTHER||NONE|The analysis of the tests data will be done by the statistician. No information will be given to the statistician about which group the participants are in.|This research is a randomized controlled experimental design.||||
34086694|NCT03287765|||OTHER||PROSPECTIVE|||||||
33691943|NCT06507878|||COHORT||PROSPECTIVE|||||||
33691944|NCT03538678|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995050|NCT04823832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995051|NCT01447511|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995052|NCT03806400|||COHORT||RETROSPECTIVE|||||||
33995053|NCT01268007|||COHORT||PROSPECTIVE|||||||
33995054|NCT03599362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995055|NCT02587663|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33995056|NCT02551640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33995057|NCT04367519|||COHORT||PROSPECTIVE|||||||
33995058|NCT04029545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Injections of the study device are performed by the unblinded Treating Investigator. The blinded Evaluating Investigator is not allowed to retrieve study supplies or to be present during opening of the study supplies or during the injections. The Treating Investigator is not to have any discussion with the Evaluating Investigator or subjects regarding the treatments.~Subjects are blinded to treatment assignment. Subjects are physically masked (blindfolded) just prior to and during all injection procedures to prevent observation of the syringes containing study device.~Subjects, investigators, the Sponsor's staff conducting the study, and members of the administrative team will not have access to individual subjects' treatment assignments. In the event of an emergency that requires breaking of the study blind, the randomization code will be maintained by each investigator that can be opened to reveal the study device."|This is a multicenter, double-blind, randomized, controlled, roll-over retreatment clinical study of retreatment of subjects seeking lip augmentation who received treatment with either PN40082 or Restylane Silk in prior Protocol PRO 2018-02 (NCT04032977), and PN40082 in prior Protocol PRO 2018-03 (NCT04029519). Subjects meeting the inclusion/exclusion criteria will receive a single additional treatment with either RV001, RV001 with a topical anesthetic, or PN40082. The Evaluating Investigator will be blinded to the treatment. Injections of the study device will be performed by an unblinded Treating Investigator.|t|f|f|t
33995059|NCT01051349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995060|NCT02458664|||COHORT|||||||||
33995061|NCT01724515|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995062|NCT05356091|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33995063|NCT02890069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995064|NCT04225715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995065|NCT06559371|||CASE_ONLY||CROSS_SECTIONAL|||||||
33995066|NCT05811793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995067|NCT06077786|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33995068|NCT01468623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995069|NCT06003933|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients were randomly allocated into either of the two groups using computer generated sequence and concealed in sealed opaque envelopes.|t|t|f|t
33995070|NCT06535932|RANDOMIZED|CROSSOVER||TREATMENT||NONE|N/A - No masking will be performed.|Randomized crossover||||
33995071|NCT01053585|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33995072|NCT05981794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized in a 1:1 manner to the treatment group (those receiving a heating pad with heat during the procedure) or control group (those who receive a heating pad without heat). The study is prospective, and randomization will be performed by a random allocation table. Randomization will be stratified by sex, procedure, and provider.||||
33995073|NCT03949296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A placebo-controlled, randomized, single-blinded clinical study involving a projected 90 participants with multiple sclerosis in a 50:50 randomization scheme.|f|t|t|t
33995074|NCT06376500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995075|NCT04210947|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will use a foam roller at three different paces in a randomized sequence with a week between,||||
33995076|NCT03574805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995077|NCT00253305|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33995078|NCT03168503|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double Blind (Participant, Investigator,Outcomes Assessor)|Crossover assignment|t|f|t|t
33995079|NCT01958294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995080|NCT03475251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995081|NCT04207528|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995082|NCT04383587|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34086695|NCT00758888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086696|NCT02130440|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34086697|NCT01969526|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33691945|NCT06091020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691946|NCT02234934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691947|NCT05240534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33691948|NCT06745609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691949|NCT05752266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Masked personnel will be unaware of which arm each participant is allocated to, and what type of probiotics have been assigned to each participant.|Randomized, placebo-controlled, crossover trial|t|t|f|f
33691950|NCT01177332|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691951|NCT04082559|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33691952|NCT02957565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33914408|NCT00661401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914409|NCT04423614|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized into one of two arms. In Arm 1, subjects will perform pre-operative inspiratory muscle training. In Arm 2, subjects will perform pre-operative relaxation breathing. A diaphragm biopsy will be taken during surgery for both arms and the tissue will be compared. In addition, a biopsy of the pectoralis major will be obtained from each subject and serve as a non-exercised control which will compared to the subject's diaphragm muscle biopsy (which participated in the intervention).||||
33914410|NCT00218855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914411|NCT06145685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33914412|NCT05734326|||CASE_CONTROL||PROSPECTIVE|||||||
33914413|NCT03921255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are randomized to one of three training conditions. The randomized training assignment is unknown to the participant and assessor by using code names for the training conditions.|Three training groups, assessed at pre-training, post-training, and follow-up.|t|f|f|t
33914414|NCT00970528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086698|NCT02646085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33691953|NCT04620759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the first phase of the study, participants will receive either placebo or treatment and all parties will be blinded. During the second phase of the study, all participants will receive treatment (open label).||t|t|t|t
33691954|NCT04826003|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691955|NCT05997680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The intervention team including the research coordinator will not be blinded to intervention allocation. The primary and secondary outcomes of the full trial will be assessed by a research assistant who is not part of the intervention and who will be blinded to intervention allocation. Data will be anonymised, and data quality control will be conducted by staff blinded to the intervention group. The intervention team will be blinded to the initial level of attention functioning. There will be no interference with standard clinical care. All clinical follow-up, therapies and learning-support services received as part of the standard clinical care will be documented in the electronic case report form. Due to the nature of the intervention, participants and their parents will not be blinded.||f|f|t|t
34086699|NCT01113099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086700|NCT06163859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33691956|NCT06744842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33691957|NCT06743581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691958|NCT05605093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33691959|NCT06744062|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33691960|NCT03571321|NA|SEQUENTIAL||TREATMENT||NONE||||||
33691961|NCT06736899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691962|NCT02829437|||COHORT||OTHER|||||||
33691963|NCT04214392|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691964|NCT02566473|||COHORT||PROSPECTIVE|||||||
33691965|NCT06744361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691966|NCT02643498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691967|NCT06425198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691968|NCT06521567|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691969|NCT06373263|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Assignment||||
33691970|NCT06628687|||COHORT||PROSPECTIVE|||||||
33691971|NCT05845931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This Study will be an open label study. Participants will be selected from an existing database of our Institute.|This is an unblinded, non-randomized, prospective Kinetic study comparing age-matched women and men (parallel). In women, an additional cross-over approach is applied||||
33691972|NCT04551066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind||t|f|t|t
33691973|NCT03030404|||CASE_ONLY||PROSPECTIVE|||||||
33691974|NCT02990520|||COHORT||PROSPECTIVE|||||||
33691975|NCT06745713|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|In order to blind the students, the information about which group they were in was not shared with the students, and the students were informed that training on chest tube care management would be given and tests would be applied through the e-learning application. In addition, the students were informed that the contents of the 'Chest Tube Care Management Training Programme' would be opened to everyone at different times, and that the time of opening the tests and training content was determined by the e-learning application itself. The training content was opened to the control group after the post-test data were collected. Thus, blinding of the participant students was ensured. The researcher who recorded all the data obtained as a result of the study in the statistics programme and the person who made the statistical analyses of the data did not know which groups were the experimental or control groups. While analysing the statistical data, the statistician and the researcher knew.||t|f|t|t
33691976|NCT06569095|||COHORT||PROSPECTIVE|||||||
33691977|NCT04845685|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33801430|NCT00051571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801431|NCT05293808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801432|NCT00002381||||TREATMENT||NONE||||||
33801433|NCT05212961|||CASE_ONLY||RETROSPECTIVE|||||||
33914415|NCT02065622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914416|NCT05439694|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33914417|NCT03273205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914418|NCT01769079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914419|NCT01410266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914420|NCT01260376|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33914421|NCT00570752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914422|NCT01389141|||CASE_CONTROL||PROSPECTIVE|||||||
33914423|NCT03227562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All subjects are under 0.5mg risperidone (one group). Accordin to their response to treatment (responder vs. non responder) the 2 experimental groups will be created.||||
34086701|NCT05232617|||CASE_ONLY||PROSPECTIVE|||||||
34086702|NCT02313051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086703|NCT00992888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34086704|NCT01700582|||COHORT||PROSPECTIVE|||||||
34086705|NCT01508312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086706|NCT00599001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086707|NCT03612219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086708|NCT06515275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them. The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects.|Parallel Assignment Randomized Controlled Experimental Design|t|f|f|f
34086709|NCT00712504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801434|NCT02040831|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914424|NCT01709786|||COHORT||PROSPECTIVE|||||||
33914425|NCT02307669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33914426|NCT01290133|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914427|NCT00832546|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33914428|NCT03933423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914429|NCT04759014|||COHORT||CROSS_SECTIONAL|||||||
34086710|NCT01041911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086711|NCT04582799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086712|NCT04121143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914430|NCT05479409|NA|SINGLE_GROUP||TREATMENT||NONE||Preoperative radiotherapy and concurrent chemotherapy||||
33914431|NCT05314218|||OTHER||PROSPECTIVE|||||||
33914432|NCT01691872|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086713|NCT00984867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086714|NCT00065871|NON_RANDOMIZED|||PREVENTION||NONE||||||
33914433|NCT05838833|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33914434|NCT02497872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086715|NCT01200641|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914435|NCT01160952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086716|NCT00754741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914436|NCT02268006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086717|NCT01512654|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34086718|NCT05668559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086719|NCT04031170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34086720|NCT05363774|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34086721|NCT01066234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086722|NCT01694680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914437|NCT01558518|||COHORT||PROSPECTIVE|||||||
34086723|NCT02232867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914438|NCT00217867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914439|NCT04499066|||COHORT||PROSPECTIVE|||||||
33914440|NCT03939806|||COHORT||PROSPECTIVE|||||||
33914441|NCT02010216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914442|NCT01982773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914443|NCT04667806|||CASE_ONLY||PROSPECTIVE|||||||
33914444|NCT04752098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Children (Newborns born full term (males and females), and infants born preterm (males and females)||||
33914445|NCT04705727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914446|NCT05312424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914447|NCT05508438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914448|NCT05413005|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomly allocated (1:1) in a parallel assignment involving two groups of participants: Group A (Regular-intensity arm): ECP on a regular-intensity regimen described in the Protocol as add-on T1DM standard of care, or Group B (Accelerated-intensity arm): ECP on an accelerated regimen plus T1DM standard of care.||||
33914449|NCT05633147|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33914450|NCT03136367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data analysts will be blinded to the clinician randomization.|Three-arm randomized controlled superiority trial with stratification by SES and randomization at the clinician level. Patient enrollment will occur at five cancer centers in the United States. Patients will be enrolled in one of the three arms based on the clinician they are seeing as a part of their care.|f|f|f|t
33914451|NCT03639012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised control trial into 1 of 2 groups||||
33914452|NCT04310215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A multicenter, Single-blinded, Stratified randomized|t|f|f|t
33914453|NCT02572128|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914454|NCT04556617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914455|NCT06316882|NA|SINGLE_GROUP||SCREENING||NONE||||||
33914456|NCT01156610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086724|NCT02820662|NA|SINGLE_GROUP||OTHER||NONE||||||
33914457|NCT04445493|||COHORT||PROSPECTIVE|||||||
33914458|NCT05208203|||COHORT||PROSPECTIVE|||||||
34086725|NCT03188822|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086726|NCT03316105|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34086727|NCT01346098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086728|NCT01978756|||CASE_ONLY||CROSS_SECTIONAL|||||||
34086729|NCT03163628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086730|NCT04553718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized control trial||||
33691978|NCT06076642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33691979|NCT06745752|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33691980|NCT06734923|||CASE_ONLY||CROSS_SECTIONAL|||||||
33691981|NCT06616194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33691982|NCT05710640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780597|NCT05434442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Caregivers will be assigned to control, simulation and mobile application groups by block randomization method, and communication between groups will be controlled. Caregivers assigned to groups by block randomization method will be numbered. Skill evaluation videos will be taken by a researcher. Skill assessments will also be made by another blinded researcher to the groups.|Caregivers will be assigned to control, simulation and mobile application groups by block randomization method. An equal number of caregivers from each clinic will be assigned to each group.|f|f|t|t
33780598|NCT02143531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995083|NCT06078748|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|"Outcome assessors will be masked to intervention group.~Careful wording will be used to describe the intervention groups to participants as to not disclose whether they are in experimental or control groups. For instance, all participants will be told that they will be receiving different combinations of exercise (stretching/toning is the control for aerobic/resistance exercise) and healthy lifestyle interventions (lifestyle education is control for dietary intervention)."|Factorial randomized controlled trial|t|f|f|t
33995084|NCT01739647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33995085|NCT05509023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995086|NCT01749553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995087|NCT00595348|||COHORT||PROSPECTIVE|||||||
33995088|NCT00803660|||||CROSS_SECTIONAL|||||||
33995089|NCT05567003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995090|NCT04692558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995091|NCT04375943|||OTHER||RETROSPECTIVE|||||||
33995092|NCT01717352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995093|NCT03420092|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995094|NCT06561191|NA|SEQUENTIAL||TREATMENT||NONE||||||
33995095|NCT01257633|||COHORT||PROSPECTIVE|||||||
33995096|NCT04254133|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780599|NCT05590871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780600|NCT05972083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesiologist who performs postoperative pain evaluation and the patient will not know the group.|There are two models for this study. The first group is the SPSIPB group. The second one is the control group.|t|f|f|t
33780601|NCT02264574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780602|NCT06320366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant and all study personnel are blinded.|Sham vs. real Transcranial Magnetic Stimulation (TMS)|t|f|t|t
33780603|NCT01657032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780604|NCT01700530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780605|NCT06488066|||COHORT||PROSPECTIVE|||||||
33780606|NCT05976490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open pilot to refine the intervention in up to 10 participants, followed by a pilot randomized controlled trial (n=40) in which participants will be randomized 1:1 to the intervention versus usual care||||
33780607|NCT04914312|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Experimental capsules matched to placebo capsules|randomized, controlled trial|t|f|t|f
33780608|NCT02016924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780609|NCT05919108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780610|NCT06508749|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780611|NCT05569005|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A multiregional (Europe, U.S. and Asia) multi-center, open-label study with 3-group, parallel preference design (Cigarette, THS use and Smoking Abstinence).||||
33780612|NCT04209686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780613|NCT04592510|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33780614|NCT06615037|||CASE_CONTROL||PROSPECTIVE|||||||
33780615|NCT04900389|||CASE_CONTROL||PROSPECTIVE|||||||
33780616|NCT04892303|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|This is a Phase 1, prospective, open-label treatment study.||||
33780617|NCT05437250|||COHORT||RETROSPECTIVE|||||||
33780618|NCT02721758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780619|NCT01023178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780620|NCT05572151|||COHORT||RETROSPECTIVE|||||||
33780621|NCT01445639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780622|NCT01694875|||COHORT||RETROSPECTIVE|||||||
33780623|NCT01190384|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33780624|NCT03291275|||COHORT||PROSPECTIVE|||||||
33995097|NCT06617468|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33995098|NCT01660243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995099|NCT02222064|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995100|NCT06188663|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is open-label. Blinding of participants is not possible for practical reasons. However, there is blinded assessment of change in formula derived 24-hour urinary sodium, cardiovascular biomarkers and mean 24-hour ambulatory blood pressure.|||||
33995101|NCT01924247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995102|NCT02278302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33995103|NCT05212350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995104|NCT03476226|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995105|NCT03124511|||COHORT||PROSPECTIVE|||||||
33995106|NCT05442034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which biologic agent (rh-PDGF or EMD) is being used.|Test group will receive rh-PDGF in combination with bone allograft Control group will receive EMD in combination with bone allograft.|t|f|f|f
33995107|NCT01515163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691983|NCT06531512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33691984|NCT03801876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691985|NCT06295809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In the Phase 2 of the study design, approximately 600 participants will be randomly assigned into 3 arms in an approximate 5:5:2 ratio (250 to V940 plus pembrolizumab with SOC, 250 participants to SOC only, and 100 participants to pembrolizumab monotherapy with SOC). If the decision is made to expand the study to Phase 3, the 600 participants enrolled in Phase 2 will keep their originally assigned study intervention arms in the Phase 3 Expansion, and 412 new participants will be enrolled and randomly assigned in a 1:1 ratio to receive treatment with either V940 plus pembrolizumab with SOC or SOC only. New participants will not be randomized into the pembrolizumab monotherapy with SOC arm during the Phase 3 Expansion.|f|f|f|t
33691986|NCT06743737|||OTHER||PROSPECTIVE|||||||
33691987|NCT06745245|NA|SINGLE_GROUP||TREATMENT||NONE||In the intervention, the specialized oral supplement plus very general nutritional advice is provided, to the participants in the different stages of kidney disease, as well as in the presence of replacement therapy, laboratory studies (blood and urine) are indicated to all groups.||||
33691988|NCT03866525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691989|NCT06745570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691990|NCT06743685|NA|SINGLE_GROUP||OTHER||NONE||All eligible participants will be invited to enroll in the HEALthy Beginnings intervention, a trauma-informed, chronic disease self-care intervention for middle-aged, and older homeless women. Participants will attend nine group sessions and six individual sessions over approximately 12 weeks. A subset of participants will be invited to participate in post-intervention focus groups as well as to complete a questionnaire evaluating the HEALthy Beginnings intervention.||||
33691991|NCT04883957|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691992|NCT05081583|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33691993|NCT06745375|NA|SINGLE_GROUP||OTHER||NONE||"This is a crossover study comparing patients' actual prescription contact lenses with +/- 2.00Ds contact lens fit. Given contact lens movement (\<1.00mm), coverage and push up tests are used to assess the difference, the calculated sample size is 38.~Calculation: using G\*Power (v3.1.9.4). This study aims to evaluate soft contact lens fitting, which include testing of lens movement in eye where continuous variables being obtained from paired assessments (both lenses worn by same participant) examining the ability to detect lens movement in mm. Literature review suggested mean and standard deviation of two groups can be around 0.352 ± 0.355 mm and 0.269 ± 0.179 mm with high correlation (r-0.95) (Belda-Salmerón et al). Where minimally clinical significant blink movement for optimum lens fit is set as 0.25mm. For statistical power 0.80 for rejecting null hypothesis with Type-I error probability of 0.05, 10% drop to rate, 38 participants are required."||||
33691994|NCT06265233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33691995|NCT06744101|||CASE_CONTROL||PROSPECTIVE|||||||
33691996|NCT02972372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691997|NCT06743464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33691998|NCT06225596|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33691999|NCT06745856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692000|NCT05154825|||COHORT||PROSPECTIVE|||||||
33692001|NCT06551987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692002|NCT06745115|||CASE_CONTROL||PROSPECTIVE|||||||
33692003|NCT06745778|||CASE_ONLY||PROSPECTIVE|||||||
33692004|NCT06744738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692005|NCT06744621|||COHORT||PROSPECTIVE|||||||
33692006|NCT06745089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692007|NCT05242367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692008|NCT06745154|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33692009|NCT05319587|NA|SEQUENTIAL||TREATMENT||NONE||||||
33692010|NCT06743594|||COHORT||PROSPECTIVE|||||||
33692011|NCT05672524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692012|NCT05041387|||OTHER||OTHER|||||||
33692013|NCT06744335|||COHORT||PROSPECTIVE|||||||
33692014|NCT06744725|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33780625|NCT06068153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780626|NCT00910884|||CASE_ONLY||RETROSPECTIVE|||||||
33780627|NCT00539045|||COHORT||PROSPECTIVE|||||||
33780628|NCT05791877|NA|SINGLE_GROUP||SCREENING||NONE||Prospective observational study with a single group||||
33780629|NCT06329648|||COHORT||RETROSPECTIVE|||||||
33780630|NCT00430378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780631|NCT06363383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded using matching placebo capsules containing matching pellets|two-stage, single-center, double-blinded, randomized, placebo-controlled|t|t|t|t
33780632|NCT01248221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33780633|NCT06532279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Double Blind. Fully blinded team members- Refers to individuals that have no access to view preparation of study drug. Study team members who are administering study drug (not preparing) will be included, however individuals that administer study drug should not perform efficacy assessments.~Any investigator or sub-investigator involved in performing efficacy and safety assessments- These individuals should not be involved in preparation of the study drug and should avoid visual access during study drug administration when possible. Where possible, any other site staff member who does not have specific responsibilities that require access to IP (e.g., data entry assistant) should remain fully blinded."||t|t|t|t
33780634|NCT05111093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780635|NCT00582790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780636|NCT03685747|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780637|NCT04248075|||CASE_CONTROL||PROSPECTIVE|||||||
33780638|NCT04145102|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33801435|NCT03373448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Examiners blinded to treatment allocation since treatment is performed by a dental hygienist.|Patients will be allocated either to test (Labrida BioClean® or control (titanium curettes) treatment by computer-generated block randomization to ensure equal sample sizes. The examiners will be blinded to the treatment allocation.|f|f|t|t
33801436|NCT01275534|||CASE_ONLY||CROSS_SECTIONAL|||||||
33914459|NCT00893048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995108|NCT04819386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995109|NCT02189811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995110|NCT00408018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995111|NCT02013882|||COHORT||PROSPECTIVE|||||||
33995112|NCT06416241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995113|NCT06056115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995114|NCT03187925|||COHORT||PROSPECTIVE|||||||
33995115|NCT00819169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995116|NCT02075333|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33995117|NCT01943877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780639|NCT05162768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trial personnel and subjects will be blinded to treatment until the database is locked. The Investigator will contact the Sponsor prior to unblinding any subject's treatment sequence unless in the instance of a medical emergency.|"In this 48-week trial, subjects will be randomized (in a ratio of 1:1) to one of two groups: single daily subcutaneous doses of 60mg elamipretide, or, matching placebo, using a central randomization stratified by whether or not subjects have nPMD associated with replisome-related mutations.~130 subjects, consisting of 90 subjects with nPMD associated mutations of the mitochondrial replisome for primary analysis and an additional subset of up to 40 subjects who have nPMD associated with other non-replisome-related pathogenic mutations specific to nuclear DNA. Three periods: Screening (up to 28 days), Treatment (48 Weeks) and Follow-Up Period (4 weeks)."|t|t|t|t
34086731|NCT04010305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study. Due to the nature of the drug, the pharmacist and the drug administrator will both be aware of the treatment. They have no other responsibility in the trial|This is a two-stage adaptive Phase Ib trial design. It is a randomized, double-blind, placebo-controlled, multiple ascending dose study.|t|t|t|t
34086732|NCT06550648|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780640|NCT05750511|||COHORT||PROSPECTIVE|||||||
34086733|NCT01592955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086734|NCT01206764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086735|NCT00072553||||TREATMENT||NONE||||||
34086736|NCT02662699|||OTHER||RETROSPECTIVE|||||||
34086737|NCT00295802|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086738|NCT00410163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086739|NCT00003297||||TREATMENT||||||||
34086740|NCT03657732|||COHORT||PROSPECTIVE|||||||
34086741|NCT04400994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995118|NCT02435264|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086742|NCT01409473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086743|NCT01092468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086744|NCT00426270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086745|NCT00879190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086746|NCT00835926|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086747|NCT04992247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086748|NCT01464567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086749|NCT02354118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086750|NCT05248789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086751|NCT02327455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086752|NCT06264713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind randomisation. The patients and their families/caregivers are blinded with respect to the group allocation. The assessors are not informed about the group allocation for the entire period of the study.|Randomised Clinical Trial|t|f|t|f
34086753|NCT01525953|||COHORT||RETROSPECTIVE|||||||
34086754|NCT00547339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086755|NCT01526980|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086756|NCT03259893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086757|NCT04938050|||OTHER||CROSS_SECTIONAL|||||||
34086758|NCT02057770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086759|NCT03907345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780641|NCT06085729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780642|NCT01606189|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33780643|NCT03033914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Cohort B will include patients 60 years of age and older with HL (any stage). AVD (adriamycin,vinblastine, dacarbazine)|"Cohort A will include patients less than 60 years of age with advanced stage (Stage III or IV) classical Hodgkin lymphoma (HL) who are at higer risk for relapse due to baseline international prognostic score (IPS) of 3-7 or positive PET scan after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) (PET-2 positive)."||||
33995119|NCT05887934|||CASE_ONLY||PROSPECTIVE|||||||
33995120|NCT05772702|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label||||
33995121|NCT04963270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995122|NCT04838353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995123|NCT05637762|||COHORT||PROSPECTIVE|||||||
34086760|NCT01180062|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34086761|NCT01327794|||COHORT||PROSPECTIVE|||||||
34086762|NCT03394937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||• Drug: ECI-006 mRNA Cohort 1: 5 intranodal injections of either 600 µg or 1800 µg mRNA Cohort 2: 9 intranodal injections of either 1800 µg or 3600 µg mRNA||||
34086763|NCT00380900|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34086764|NCT01800253|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34086765|NCT05466058|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|radiologist will not know if the participant has trigger finger or not.|case control clinical trial|f|f|t|f
34086766|NCT01204242|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086767|NCT01790399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995124|NCT01146223|||CASE_ONLY||PROSPECTIVE|||||||
34086768|NCT00447681|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34086769|NCT03343314|||COHORT||PROSPECTIVE|||||||
34086770|NCT01738958|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086771|NCT00703534|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34086772|NCT00408499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086773|NCT01375101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086774|NCT03962361|||COHORT||OTHER|||||||
33995125|NCT03045458|RANDOMIZED|PARALLEL||OTHER||NONE|Only the surgeon knows detail about the groups of participants. Participant, care provider,outcomes assessor have no knowledge of groups|In the surgical operations, 20 tissue-level and 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted in Group I and Group II, respectively.||||
34086775|NCT01409668|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34086776|NCT01141101|||COHORT||PROSPECTIVE|||||||
33780644|NCT06442189|||COHORT||PROSPECTIVE|||||||
33780645|NCT00279162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33780646|NCT06696612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780647|NCT06696755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780648|NCT06450184|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33780649|NCT01600846|||COHORT||PROSPECTIVE|||||||
33780650|NCT04286555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigators and the outcomes assessors will not know which order of diets the participant has been assigned. The participant will not be explicitly told which diet he or she is receiving during each period, but by the nature of higher sodium vs. lower sodium or the differences between the DASH4D and comparison diet, the participant would likely be able to guess based on the menus and taste.|The study design is a four-period crossover feeding study, in which participants will be randomly assigned to an order of four isocaloric diets for a 5-week period each.|f|f|t|t
33780651|NCT04917692|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label intervention study||||
33780652|NCT00615082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33780653|NCT05898932|||COHORT||PROSPECTIVE|||||||
33780654|NCT00556543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780655|NCT00597870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780656|NCT02438917|||CASE_CONTROL||PROSPECTIVE|||||||
33780657|NCT05764720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780658|NCT06613386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study employs a prospective, double-arm, randomized controlled trial (RCT) design, conducted in the Neonatal Intensive Care Units (NICU) of a tertiary first-class hospital in Jiangsu Province, China.|f|f|f|t
33995126|NCT00018460|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33995127|NCT04764175|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bayesian Adaptive Design||||
33995128|NCT06475651|||OTHER||CROSS_SECTIONAL|||||||
33995129|NCT00948792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995130|NCT02412358|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34086777|NCT03883386|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34086778|NCT05298657|||COHORT||PROSPECTIVE|||||||
34086779|NCT05264116|NA|SINGLE_GROUP||OTHER||NONE||||||
34086780|NCT04049461|||COHORT||PROSPECTIVE|||||||
33780659|NCT04794062|||COHORT||PROSPECTIVE|||||||
33780660|NCT03459495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective,randomized,placebo- controlled, double blind|t|f|f|t
33780661|NCT04692337|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780662|NCT06552416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation||||
33780663|NCT03930979|||COHORT||PROSPECTIVE|||||||
33780664|NCT05258617|||CASE_ONLY||PROSPECTIVE|||||||
33780665|NCT02888795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780666|NCT05357196|NA|SINGLE_GROUP||TREATMENT||NONE||One-armed test，An Open-Label Phase I/ II Clinical Study of PT-112 in Combination with Gemcitabine Injection for the Treatment of Patients with Advanced Solid Tumors||||
33780667|NCT06696430|||COHORT||PROSPECTIVE|||||||
33780668|NCT06289660|||COHORT||PROSPECTIVE|||||||
33780669|NCT01276535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780670|NCT01650311|||COHORT||PROSPECTIVE|||||||
33780671|NCT04976036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780672|NCT05533697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780673|NCT05548530|||CASE_CONTROL||RETROSPECTIVE|||||||
33780674|NCT06462833|||COHORT||PROSPECTIVE|||||||
33780675|NCT05626452|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study will use a cluster randomized, cross-sectional stepped wedge study with 12 clusters (8 CHCs from the South and 4 CHCs from the Midwest) to evaluate the effect of the intervention package as compared to the control condition (usual care) on the proportion of PrEP prescriptions among eligible participants. Cross-sectional data from participants who are eligible for PrEP will be collected at 6 different calendar intervals of 6 months (steps). Although all clusters will begin the study in the control condition (usual care), beginning in step 3 at each six-month interval three randomly chosen CHCs (containing a mix of Southern and Midwestern CHCs) will switch from the control condition to the intervention condition. Beginning at step 2, the step prior to 3 CHCs switching from control to intervention condition will be spent in a six-month transition period. This design will allow for data collection at all CHCs to contain observations from both intervention and control periods."||||
33780676|NCT01989715|NA|SINGLE_GROUP||||NONE||||||
33780677|NCT06247098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical examiners, study surgeons, and subjects will not be blinded. Analysis of histomorphometric, histologic, and volumetric data will be completed by an external lab and will not be aware of what group the subjects were in.||f|f|f|t
33780678|NCT02688621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780679|NCT04868396|||OTHER||PROSPECTIVE|||||||
33780680|NCT04600622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780681|NCT01334437|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780682|NCT05267015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780683|NCT05932329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All researchers in contact with participants will be blinded, and all analysts.|randomized intervention design|f|f|t|t
33914460|NCT01107275|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914461|NCT03071705|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33914462|NCT01731301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914463|NCT04128579|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Type A and Type B are open-label.|cohort based escalation of 6 subjects (Type A) single dose cohort of 20 subjects (Type B)||||
33914464|NCT01503060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33914465|NCT00532961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914466|NCT02078882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914467|NCT03430817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914468|NCT01405443|||CASE_CONTROL||PROSPECTIVE|||||||
33914469|NCT01114958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914470|NCT02909842|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33914471|NCT00793819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914472|NCT02808533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33914473|NCT04868006|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914474|NCT02106455|||COHORT||PROSPECTIVE|||||||
33914475|NCT05232422|RANDOMIZED|PARALLEL||OTHER||NONE||A pretest-posttest design is planned, with the pre- as well as the posttests each split into two sessions. Pretests are scheduled in the weeks before the intervention, posttests relatively soon after the intervention. At both data collection times, stress as well as cognitive performance (namely of attention) will be recorded in both groups (experimental group, waiting control group). While the experimental group participates in a 60-minute hatha yoga intervention at least three times a week for 8 weeks, the wait-list control group does not receive the yoga intervention until after the end of data collection.||||
33914476|NCT02367534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914477|NCT03605719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914478|NCT04564209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study team members who are recruiting will not be aware of which group study participants are being assigned to.|There is a treatment and a control group at each site.|f|f|t|f
33914479|NCT01947244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914480|NCT02635152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33914481|NCT05126706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914482|NCT03003780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914483|NCT05008588|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33914484|NCT00211588|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33914485|NCT03886701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914486|NCT06273306|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914487|NCT05889507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Administration of cooling therapy cannot be masked. The 24 (±2) months of age assessments will be performed by a central team of 2 to 3 examiners, masked to the allocation.||f|f|t|t
33914488|NCT02141646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33914489|NCT04027569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914490|NCT00396240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780684|NCT03177564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780685|NCT02973126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780686|NCT05469360|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Phase 1b|t|f|t|f
33780687|NCT05389358|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants at routine antenatal care will not know whether their clinic is the intervention or enhanced usual care arm, since both will offer support that is over-and-above standard care. Outcomes will be assessed using self-completed tablet computers, so there is no outcomes assessor.|2 primary health clinics offering antenatal care services in inner-city Johannesburg, South Africa will be randomized to receive intervention or enhanced standard of care. Within each clinic n=40 participants will take part in baseline, midline, and endline assessments.|t|f|f|t
33780688|NCT00895479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780689|NCT06696222|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective non-randomized intevention study where everyone serves as their own control||||
33780690|NCT03626493|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33780691|NCT06211257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized 1:1||||
33780692|NCT05417997|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The interventions were assigned to participants based on results of in vitro and in vivo studies on H1N1 virus and efficacy for interventions that were used in the study. Kunamin is a botanical drug containing no toxicity. The intervention contain KH good healthy cells (proteins). The intervention not only treat and cure but also can prevent COVID-19 for those who are infected with COVID-19 only by producing antibodies against COVID-19. Therefore, it can be used as a combined drug and oral vaccine to treat, cure and prevent COVID-19. Just like COVID-19 vaccine, the more interventions patients take, the longer period of protection. The strategy is determined by the principal investigator depending on the severity of the illness. The interventions can help prevent COVID-19.||||
33780693|NCT03486197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914491|NCT00264602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|There is no masking in this study. All study subjects will receive the same intervention.|||||
33914492|NCT00230100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914493|NCT03712501|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33914494|NCT04889573|NA|SINGLE_GROUP||OTHER||NONE||||||
33914495|NCT02316756|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33914496|NCT01502982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914497|NCT04301921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914498|NCT01554839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914499|NCT02985502|||CASE_ONLY||CROSS_SECTIONAL|||||||
33914500|NCT01672437|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914501|NCT01258972|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33914502|NCT00062699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914503|NCT06361264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914504|NCT05881772|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33914505|NCT00242580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914506|NCT05100654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914507|NCT00003353||||TREATMENT||||||||
33914508|NCT02683226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914509|NCT00176670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914510|NCT05123651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||A total of 60 volunteers were recruited and randomly divided into three groups with 20 people in each group. Among them, 17 volunteers terminated the experiment due to taking antibiotics and hormone drugs during the experiment. The remaining 43 volunteers belonged to three different groups: Control group (n=16), Viable group (n=13), Inactivated group (n=14).|t|t|t|t
33914511|NCT01167465|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33914512|NCT02909998|||CASE_CONTROL||PROSPECTIVE|||||||
33914513|NCT04504032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914514|NCT02728440|||CASE_CONTROL||PROSPECTIVE|||||||
33995131|NCT06354023|NA|SINGLE_GROUP||TREATMENT||NONE|None, each participant will receive the same treatment|The proposed clinical trial is a single-arm intervention model. Once per week for six weeks, each participant will receive an intra-articular injection of recombinant human growth hormone (rGH) 15 IU in their affected knee. During the treatment course, the participants will use the same knee brace and crutches (as needed) and be given the same exercises to complete at home. They will all be evaluated 8 weeks, 6 months, and 12 months after their initial injection.||||
33914515|NCT04895163|||COHORT||RETROSPECTIVE|||||||
33914516|NCT00407914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914517|NCT03105206|||CASE_ONLY||PROSPECTIVE|||||||
33914518|NCT01432262|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914519|NCT02776410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33914520|NCT01012505|||COHORT||PROSPECTIVE|||||||
33914521|NCT02618980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914522|NCT06332703|||COHORT||RETROSPECTIVE|||||||
33914523|NCT02058134|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914524|NCT03775096|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment: carvedilol titration; Experimental treatment with carvedilol will be offered at stabilized medical treatment. The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125mg twice daily and will be doubled every week according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 25mg twice daily (50 mg/day). Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.||||
33914525|NCT00389740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914526|NCT01821820|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33995132|NCT05419739|||CASE_ONLY||PROSPECTIVE|||||||
33995133|NCT02553863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995134|NCT04463108|||COHORT||PROSPECTIVE|||||||
33995135|NCT05906251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995136|NCT02083939|||COHORT||PROSPECTIVE|||||||
33995137|NCT01906372|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33995138|NCT04334863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995139|NCT03548194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995140|NCT04690985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995141|NCT05411276|||OTHER||PROSPECTIVE|||||||
33914527|NCT00398385|RANDOMIZED|||TREATMENT||||||||
33995142|NCT06562062|||CASE_ONLY||PROSPECTIVE|||||||
33995143|NCT02374112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Creatine|t|t|f|f
33914528|NCT04597255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33914529|NCT03996434|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33914530|NCT05437757|NA|SINGLE_GROUP||OTHER||NONE||||||
33914531|NCT00975195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914532|NCT01628016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914533|NCT01778127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33914534|NCT01348022|||COHORT||PROSPECTIVE|||||||
33914535|NCT02134327|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33914536|NCT02365493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914537|NCT03656120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914538|NCT04574609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914539|NCT00536042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914540|NCT05576948|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33914541|NCT01066195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914542|NCT06200987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995144|NCT01957059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995145|NCT01496495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995146|NCT02120872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995147|NCT03049748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995148|NCT06230094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33914543|NCT03195855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33995149|NCT01602328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995150|NCT05921864|||COHORT||PROSPECTIVE|||||||
33914544|NCT03589352|||COHORT||OTHER|||||||
33995151|NCT05661591|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, open-label, single-dose, self-control||||
33995152|NCT06219031|||COHORT||RETROSPECTIVE|||||||
33995153|NCT06389448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants undergo pCLE after pre-ESD assessment and before ESD resection.||||
33995154|NCT04957979|||COHORT||PROSPECTIVE|||||||
34086781|NCT00318396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086782|NCT02346864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914545|NCT02518152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914546|NCT00330720|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34086783|NCT03707002|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Identical sachets containing 5g of scFOS or placebo (maltodextrins)||t|t|t|t
33914547|NCT05678075|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914548|NCT02878733|||COHORT||RETROSPECTIVE|||||||
33914549|NCT03297307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a prospective intervention study of female bariatric surgical patients and their children. The dyads, consisting of one female bariatric patients and one child living in the home, will be enrolled in the study. Half of the children will attend the dietary, physical activity, and psychological counseling with the mother prior to her surgery, and the other half of the children will not receive the behavioral intervention. Outcomes from each mother-child dyad will be measured at baseline, and 3 and 6 months postoperatively||||
33914550|NCT03858062|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914551|NCT03259490|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914552|NCT01205555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914553|NCT02492997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914554|NCT01070524|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33914555|NCT06238245|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33914556|NCT01795287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914557|NCT02260245|NA|SINGLE_GROUP||OTHER||NONE||||||
33914558|NCT00913718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995155|NCT04215328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33995156|NCT00319696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995157|NCT03220958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995158|NCT00557726|||OTHER||OTHER|||||||
33692015|NCT00154726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995159|NCT03210038|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pain assessment 4 randomly assigned groups of women divided by type of cystoscope and type of local anesthesia.||||
33995160|NCT02134821|||COHORT||PROSPECTIVE|||||||
33995161|NCT04006808|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33995162|NCT03073538|||COHORT||RETROSPECTIVE|||||||
33995163|NCT04602754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995164|NCT03480880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. Anaesthetic care provider in one arm of first part of study was blinded to intraoperative changes in Bispectral index.~2. Anaesthetic care provider was blinded to Bispectral Index changes in second part of study."|"1. Inj. Thiopentone dose requirement for induction of anaesthesia with and without the use of Bispectral Index guidance.~2. Observation of Bispectral Index change in intraoperative period."|t|t|f|f
33995165|NCT02312154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34086784|NCT06381232|||CASE_CONTROL||PROSPECTIVE|||||||
33692016|NCT06743646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692017|NCT03800693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692018|NCT04218708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692019|NCT06256367|||COHORT||PROSPECTIVE|||||||
33692020|NCT05212090|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33692021|NCT06744244|||CASE_CONTROL||PROSPECTIVE|||||||
33692022|NCT06745791|||OTHER||PROSPECTIVE|||||||
33692023|NCT05718583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692024|NCT06568081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692025|NCT04063267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780694|NCT04435795|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33780695|NCT03509012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914559|NCT00091143|RANDOMIZED|||TREATMENT||||||||
33914560|NCT03808038|||COHORT||CROSS_SECTIONAL|||||||
33780696|NCT04668937|||COHORT||RETROSPECTIVE|||||||
33780697|NCT05990881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be informed of which group they are assigned. A small bandage will be placed over the injection site after the injection is performed since corticosteroid injections may cause mild, benign skin discoloration.|There will be two groups to which patients will be randomized: the control group, in which patients will receive the standard treatment for carpometacarpal joint arthritis (i.e., corticosteroid injection), and the experimental group, in which patients receive Botulinum toxin injection.|t|f|f|f
33780698|NCT05965362|||COHORT||OTHER|||||||
33780699|NCT05956834|||COHORT||PROSPECTIVE|||||||
33914561|NCT02984852|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914562|NCT05176431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914563|NCT00947752|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914564|NCT00488579|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914565|NCT06354946|||COHORT||RETROSPECTIVE|||||||
33914566|NCT05075148|||CASE_ONLY||RETROSPECTIVE|||||||
33914567|NCT03329040|||CASE_CONTROL||RETROSPECTIVE|||||||
33914568|NCT02991157|||COHORT||PROSPECTIVE|||||||
33914569|NCT05171582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single Blind|Parallel Assignment|t|f|t|f
33914570|NCT01143168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914571|NCT04433455|||COHORT||PROSPECTIVE|||||||
33914572|NCT03638661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The ready-to-use soybean used formula and n3EN formula had identical packaging with no differences in appearance, texture, or smell.||t|f|f|f
33914573|NCT04676464|||CASE_ONLY||PROSPECTIVE|||||||
33914574|NCT03859531|||CASE_ONLY||PROSPECTIVE|||||||
33914575|NCT00412698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914576|NCT00718757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914577|NCT00677690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914578|NCT01072539|||CASE_ONLY||PROSPECTIVE|||||||
33914579|NCT04496895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914580|NCT00448253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914581|NCT03404596|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33914582|NCT06170086|||COHORT||RETROSPECTIVE|||||||
33914583|NCT02625324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914584|NCT01790971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914585|NCT04839770|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33914586|NCT06286436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914587|NCT02003560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914588|NCT02199106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914589|NCT02179528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914590|NCT02569619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914591|NCT05081024|||COHORT||PROSPECTIVE|||||||
33914592|NCT04471064|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33914593|NCT01035632|||||PROSPECTIVE|||||||
33914594|NCT05385042|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|This is a prospective open-label study in which both participants and investigators know the identity of the treatment and its dosage.|||||
33914595|NCT05625529|||COHORT||PROSPECTIVE|||||||
33914596|NCT05917366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914597|NCT00736580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914598|NCT03470649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled trial|t|f|f|t
33914599|NCT00022035||||SUPPORTIVE_CARE||||||||
33914600|NCT02204241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914601|NCT06342102|||COHORT||RETROSPECTIVE|||||||
33914602|NCT00132821|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33914603|NCT01759329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33995166|NCT03559907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors who are rating intervention fidelity will be blinded to intervention assignment.|"Quasi-Experimental: Three community sites will be randomized to receive on of three prevention interventions:~1. Cooking Matters for Parents~2. Promoting Routines of Exploration and Play during Mealtime (Mealtime PREP)~3. Combined (Cooking Matters + Mealtime PREP)"|f|f|f|t
33995167|NCT02491099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995168|NCT01554410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995169|NCT00513253|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995170|NCT04784663|RANDOMIZED|CROSSOVER||PREVENTION||NONE||All participants will complete the consent process and baseline assessment by telephone with an RA and are randomized to receive the intervention at either baseline (T1), 1-month (T2) or 2-month follow up (T3). Exposure to intervention occurs over a 1-month period.||||
33995171|NCT00493805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995172|NCT00755677|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995173|NCT03166267|||CASE_ONLY||PROSPECTIVE|||||||
33995174|NCT06338826|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"Interventional, sequential, Phase IIA equivalent, multicenter, open-label, randomized, non-comparative study evaluating, for 96 weeks, the safety in terms of HBV virological control of 2 antiviral therapy relief strategies, in HIV-1 and HBV co-infected patients with prolonged virological success (undetectable HIV-1 and HBV viral loads for ≥ 2 years) and on unmodified antiviral therapy for ≥ 1 year.~Participants will be randomized 1:2:2 into 3 parallel arms:~* Arm 1 (reference arm): Continuation of continuous (7 days/week) triple antiviral therapy including TDF or TAF~* Arm 2 (T4): Relief from previous triple antiviral therapy (containing TDF or TAF) on 4 out of 7 consecutive days~* Arm 3 (B7): Switch from prior triple antiviral therapy (containing TDF or TAF) to continuous dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR). The choice of dual therapy is left to the discretion of the investigator."|t|f|f|f
33995175|NCT02718963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995176|NCT05247567|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780700|NCT00385905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780701|NCT06070597|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||A double-blind, randomised, placebo-controlled, multiple-dose, parallel group with nested crossover design trial, with moxifloxacin as positive control|t|f|t|f
33780702|NCT03245164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780703|NCT05601843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780704|NCT06698029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the primary endpoint will be assessed at one year, in a blinded,manner||f|f|f|t
33780705|NCT03894943|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780706|NCT06696235|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label Trial|Accelerated initiation of CRRT and Standard initiation of CRRT||||
34086785|NCT04861792|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Originally the SPARC trial was a stepped-wedge cluster-randomized design to evaluate the Michigan SPARC quality improvement intervention compared to usual care. We converted the trial into a program evaluation due to COVID making randomization impossible (e.g., a randomly assigned, unpredictable time to implement was unacceptable in a pandemic, COVID markedly limited primary care practices interest in the trial, and some practices that enrolled closed during the project). The originally planned random assignment to receive the AUD decision aid was not possible due to the small number of participating practices during the pandemic and the need to provide all sites the decision aid to maximize engagement in the study.||||
34086786|NCT04673773|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33780707|NCT03617874|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780708|NCT01728389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780709|NCT01536262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33780710|NCT06696248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780711|NCT05474846|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33780712|NCT02018913|||COHORT||PROSPECTIVE|||||||
33780713|NCT05508516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780714|NCT02705911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780715|NCT06081101|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33914604|NCT01826422|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914605|NCT01558024|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33914606|NCT01027208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914607|NCT04141787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective, randomized, unblinded non-inferiority trial being led by infectious diseases clinicians. We have chosen a pragmatic trial design which represents the most efficient use of available resources to test the study hypothesis and is the designed to determine effectiveness as opposed to efficacy.|f|f|f|t
34086787|NCT03913039|||CASE_CONTROL||PROSPECTIVE|||||||
34086788|NCT01381120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086789|NCT00155987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086790|NCT00398229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914608|NCT05842070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914609|NCT01932008|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33914610|NCT00126178|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33914611|NCT05886634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914612|NCT00555048||||TREATMENT||||||||
33914613|NCT06302270|||COHORT||PROSPECTIVE|||||||
33914614|NCT06406686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blinded. Investigator will know study arm, patients/participants will not. The outcomes assessor will be blinded.||t|f|f|t
33914615|NCT02681497|||COHORT||RETROSPECTIVE|||||||
33914616|NCT02836535|||CASE_CONTROL||PROSPECTIVE|||||||
33914617|NCT04452604|||COHORT||RETROSPECTIVE|||||||
33914618|NCT01113398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914619|NCT03513965|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914620|NCT01333839|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34086791|NCT05246995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34086792|NCT06514235|||COHORT||PROSPECTIVE|||||||
34086793|NCT03931564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086794|NCT00142415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995177|NCT03922490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995178|NCT00374231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995179|NCT05169710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group|t|t|t|t
33780716|NCT06515184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Design (primary) is followed by active treatment phase (still blind to dose).|t|t|t|t
33780717|NCT01799954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995180|NCT06563193|||CASE_CONTROL||PROSPECTIVE|||||||
33995181|NCT01649921|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34086795|NCT02188160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780718|NCT04900363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780719|NCT00219401|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086796|NCT04440488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780720|NCT00005864||||TREATMENT||||||||
33780721|NCT03150368|NA|SINGLE_GROUP||TREATMENT||NONE||After completion of a phase 1 trial with ModraDoc006/r, patients are able to continue weekly treatment with oral docetaxel (ModraDoc006) in combination with ritonavir, for as long as safe clinical benefit from the treatment is experienced, as judged by the treating oncologist.||||
33780722|NCT05306444|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation (Part 1) followed by Dose expansion (Part 2)||||
33780723|NCT06226870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Computer will be used to generate a sequence of random numbers for the allocation of participants into the groups. Once the computer-generated randomization number will be obtained, it will be sealed in an opaque envelope by one of the investigators. After the clinical and radiographic findings, the envelope will be opened by a clinical assistant and treatment will be allocated to the patient based on the sequence generated. The patients will be blinded about the procedure, and a single operator will perform all the endodontic procedures after the informed written consent.||t|f|f|t
33780724|NCT04651348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995182|NCT01616823|||COHORT||RETROSPECTIVE|||||||
33995183|NCT03768635|||COHORT||RETROSPECTIVE|||||||
33995184|NCT03932045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Randomized, Subject \& Evaluator-blind, Matched pairs, Prospective Study|t|f|f|t
34086797|NCT02745288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34086798|NCT06058819|||COHORT||PROSPECTIVE|||||||
34086799|NCT05338632|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open-label, randomized (IM versus IN naloxone), crossover study in a mixed population.||||
33780725|NCT04996875|NA|SINGLE_GROUP||TREATMENT||NONE||There are two parts to this study, including Part I, Dose Optimization, and Part II Expansion. Part II is separated into two stages.||||
33914621|NCT01940016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914622|NCT03817567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914623|NCT03870126|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double-blind||t|t|t|t
33914624|NCT00409201|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33914625|NCT03320291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914626|NCT04873284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33914627|NCT04141852|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33914628|NCT02964117|||COHORT||PROSPECTIVE|||||||
33914629|NCT05106452|||COHORT||PROSPECTIVE|||||||
33914630|NCT02852993|||COHORT||RETROSPECTIVE|||||||
33914631|NCT02176395|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33914632|NCT03721185|RANDOMIZED|PARALLEL||TREATMENT||NONE|Researchers assessed the efficacy of a lipolytic cream with hypocaloric diet and physical activity in the treatment of overweight and obesity. The control treatment was lypolitic cream with hypocaloric diet and physicial activity and hypocaloric diet and physicial activity alone. In total, 102 patients were recruited and allocated to treatment (51: lypolitic cream with hypocaloric diet and physicial activity and, 51: hypocaloric diet and physicial activity alone.|open-label, randomized, parallel-group||||
33914633|NCT03021291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914634|NCT05795114|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914635|NCT06153082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914636|NCT05016869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914637|NCT01133431|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33914638|NCT00444327|||COHORT||PROSPECTIVE|||||||
33914639|NCT00568880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914640|NCT01987167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914641|NCT01422811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33914642|NCT04281160|||COHORT||PROSPECTIVE|||||||
33914643|NCT03334162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All investigators dealing with the assessments (neurological and sport scientific) and data are blinded, solely the patient as well as the training staff can't be blinded due to the nature of an exercise interventional study.|This pilot study will follow a prospective, two-armed, randomized controlled design (RCT with follow-up)|f|f|t|t
33914644|NCT00444626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914645|NCT02389673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914646|NCT00022789|||COHORT|||||||||
33914647|NCT01700517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33914648|NCT04376606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers will participate in the operation to record operative parameters such as LA pressure. Other researchers including follow-up personnel and the ultrasonic data analyst are uninformed about the random situation of the patients (patient information is recorded according to the random number. Random numbers corresponding to the random allocation list are stored in the research center. After follow-up of the last patient is completed, the random allocation list is published by the random number designer; and the designer does not participate in the data collection and statistics.)|A total of 105 patients with persistent atrial fibrillation(AF), who are persistented more than one year and planned to undergo surgical treatment, will be allocated into two groups. These patients will receive left atrial appendage closure, radiofrequency ablation under the guidance of 3D mapping and left atrial appendage closure combined with radiofrequency ablation, respectively (allocation ratio, 1:1:1)|t|f|f|t
33995185|NCT06241222|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33995186|NCT03272685|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Phase III randomized, open label, multi-center study that will examine the impact of very low nicotine content (VLNC) cigarettes using an experimental marketplace that contains tobacco and nicotine products, simulating a real world environment. There are three phases: Phase 1 is smoking usual brand cigarettes. Phase 2 is access to a marketplace with usual brand cigarettes and other non-combusted nicotine and tobacco products. Phase 3 involves access to a marketplace with study cigarettes and other non-combusted nicotine and tobacco products.||||
33995187|NCT05465863|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995188|NCT02584608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995189|NCT02889107|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995190|NCT06371807|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized||||
33995191|NCT05327777|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Control group, opioid sparing arm, and zero opioid arm||||
33995192|NCT02393014|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914649|NCT00069420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995193|NCT03864380|||COHORT||PROSPECTIVE|||||||
33995194|NCT03336580|NA|SINGLE_GROUP||TREATMENT||NONE||Dose Escalation Study||||
33995195|NCT01347749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995196|NCT06093919|||COHORT||OTHER|||||||
33995197|NCT02185144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995198|NCT00834132|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995199|NCT03036228|NA|SEQUENTIAL||TREATMENT||NONE||First part of the study - different dose cohorts with escalating doses. Extension part - Characterization of the Phase 2 Recommended Dose (P2RD) in specific patient groups and correlation with clinical outcome and other PD markers is currently examined.||||
33995200|NCT05952739|||COHORT||PROSPECTIVE|||||||
33995201|NCT02469363|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33995202|NCT04614155|NA|SINGLE_GROUP||SCREENING||NONE||||||
33995203|NCT03324139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double-blind, two-parallel, placebo-controlled, phase III multicenter clinical trial.|t|f|t|f
33995204|NCT00154739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995205|NCT04879537|RANDOMIZED|PARALLEL||OTHER||NONE||Stepped-Wedge-Design||||
33995206|NCT01326663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914650|NCT04931316|||COHORT||RETROSPECTIVE|||||||
33995207|NCT06368154|||COHORT||PROSPECTIVE|||||||
33995208|NCT00625560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086800|NCT04546646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34086801|NCT00965939|||COHORT||PROSPECTIVE|||||||
33780726|NCT06336044|NA|SINGLE_GROUP||TREATMENT||NONE||20 patients will undergo skin characterists measurments at time 0 at +4weeks and at +16 weeks||||
33995209|NCT05324033|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33995210|NCT01637376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995211|NCT04692155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995212|NCT05780463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995213|NCT06219941|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is an open-label, multi-centre study of AZD0901 administered via IV, either as monotherapy or in combination with other anti-cancer agents in participants with advanced solid malignancies expressing CLDN18.2. The substudy design allows for a targeted approach to the different tumour types as monotherapy or in combination with other anti-cancer agents. These substudies include:~Substudy 1: AZD0901 monotherapy in gastric and gastric esophageal junction cancer patients Substudy 2: AZD0901 in combination with anti-cancer agents in pancreatic cancer patients."||||
33995214|NCT02570958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995215|NCT00372086|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33995216|NCT04921696|||COHORT||PROSPECTIVE|||||||
33995217|NCT06267625|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086802|NCT03720587|||OTHER||PROSPECTIVE|||||||
34086803|NCT00613795|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34086804|NCT03884764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780727|NCT03939221|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780728|NCT05212948|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33780729|NCT05946746|RANDOMIZED|PARALLEL||OTHER||SINGLE|Double blind||f|f|t|f
33780730|NCT06382545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780731|NCT00409708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780732|NCT03308058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33914651|NCT03346447|||OTHER||PROSPECTIVE|||||||
33914652|NCT03224975|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two groups: 20 patients and 20 healthy volunteers||||
33914653|NCT01165151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914654|NCT04167306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Appointed manufacturer produces, packs and labels the IMPs in two separate IMP kits and uses a blinding procedure accordance with internal standard operating procedure. IMP 1 and IMP 2, will have an unique Randomization Number generated randomly. For each randomization number, a sealed emergency code envelope will follow the shipment.||t|t|t|t
33914655|NCT00893672|||CASE_CROSSOVER||PROSPECTIVE|||||||
33995218|NCT00700739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914656|NCT05502471|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33914657|NCT06013995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995219|NCT04292548|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995220|NCT02235922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995221|NCT02716311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995222|NCT02401906|||COHORT||PROSPECTIVE|||||||
33995223|NCT04304209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995224|NCT02315963|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995225|NCT03505151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995226|NCT05323981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995227|NCT01321567|||COHORT||PROSPECTIVE|||||||
33995228|NCT05988840|||COHORT||PROSPECTIVE|||||||
33995229|NCT03251755|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-labelled, randomized, study||||
33995230|NCT03844334|||CASE_ONLY||PROSPECTIVE|||||||
33995231|NCT05748561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants won't be aware to which group they were assigned. Investigator in charge of assessing outcomes and analyzing data won't be aware to which group participants were assigned.|"Randomized groups (2)~1. Standard treatment (Intravenous methylprednisolone)~2. Intervention (Intravenous erythropoietin)"|t|f|f|t
33995232|NCT05280288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995233|NCT00894855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33995234|NCT06406725|||COHORT||PROSPECTIVE|||||||
33995235|NCT06559046|||COHORT||RETROSPECTIVE|||||||
33995236|NCT00051779||||TREATMENT||||||||
33995237|NCT04965688|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, interventional||||
33995238|NCT05498662|||COHORT||PROSPECTIVE|||||||
33995239|NCT04134910|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995240|NCT02959879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995241|NCT01736007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995242|NCT04905082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995243|NCT02393144|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33995244|NCT04293653|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A care-bundle developed for patients above 75 years undergoing emergency abdominal surgery will be investigated, and the results will be compared to a group of historical controls operated at Haukeland University Hospital in 2016-2017, using 30-day mortality as the primary outcome.||||
33995245|NCT05196334|||COHORT||PROSPECTIVE|||||||
33995246|NCT03808519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33995247|NCT05351567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995248|NCT05244876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person analysing the data does not know which group he or she belongs to.||f|f|f|t
33995249|NCT04425941|||COHORT||PROSPECTIVE|||||||
34086805|NCT03897335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Cohort 1 will consist of all children undergoing open heart surgery for congenital heart defects with or without circulatory arrest, and Cohort 2 will consist of Orthotopic heart transplantation patients. All subjects will be randomized 1:1 to aminophylline or saline placebo. Cohort 1 will be randomized using block-stratification with stratification factors age (neonate vs infant) and circulatory arrest (yes vs no). Age will be categorized as neonates (0 to \<28 days) and infants (28 days to \<1 year).~A total of 80 (60 in Cohort 1 and 20 in Cohort 2) participants are expected to be enrolled on this study."|"1 Patient randomization groups~A) Group 1: Aminophylline pre CPB \& immediately post cardiopulmonary bypass (CPB)~B) Group 2: No aminophylline prophylaxis"|t|t|t|f
34086806|NCT01693952|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086807|NCT04151459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995250|NCT01538459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995251|NCT06562998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995252|NCT05815667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995253|NCT03034096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995254|NCT06491797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Intervention group will see immediate reactivation of the program where control intervention will be the program as it is usually applied before the application of the booster measure (applied delayed by three months).|t|f|f|t
33995255|NCT02043522|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995256|NCT01930903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33995257|NCT05464836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995258|NCT03461380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995259|NCT04264221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|None (Open Label)|Parallel Assignment||||
33995260|NCT05204368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995261|NCT05105607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995262|NCT03559569|||COHORT||PROSPECTIVE|||||||
33995263|NCT03751137|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33914658|NCT03334669|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The stepped wedge design is a pragmatic design that is well suited for interventions that use a service delivery protocol and do not rely on individual recruitment of participants. The intervention is integrated into Head Start service delivery and data compiled for all enrolled children are used to evaluate the intervention. NOTE: Due to COVID-19 shutdown the final group of Head Start programs did receive the full intervention. The investigators elected to assess intervention impact with one year less data than expected. Due to low power, sensitivity analyses will examine the roles of dose, fidelity, baseline child overweight/obesity.||||
33914659|NCT05390671|||COHORT||OTHER|||||||
33914660|NCT04484779|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33914661|NCT02040818|RANDOMIZED|||||NONE||||||
33914662|NCT03349541|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33914663|NCT06124547|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33914664|NCT04912570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914665|NCT03445858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914666|NCT04713566|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33914667|NCT01217255|||COHORT||PROSPECTIVE|||||||
33914668|NCT00103545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914669|NCT00991380|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914670|NCT05067062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914671|NCT02701686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914672|NCT01091935|||COHORT||PROSPECTIVE|||||||
33914673|NCT00244894|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995264|NCT02402660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995265|NCT02116595|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33995266|NCT03198923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995267|NCT06626165|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995268|NCT02282722|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995269|NCT02063139|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33995270|NCT01075516|||COHORT||PROSPECTIVE|||||||
33995271|NCT06157268|||COHORT||PROSPECTIVE|||||||
33995272|NCT05937451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33995273|NCT04775004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995274|NCT03793803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single Blind Control - Outcomes assessor is blind to randomization arms|Patients and caregivers are randomized to receive care from the home-based palliative care team or will receive usual care from their primary physician|f|f|f|t
33995275|NCT05876819|||CASE_ONLY||CROSS_SECTIONAL|||||||
33995276|NCT01171768|||CASE_CONTROL||PROSPECTIVE|||||||
33995277|NCT06559293|||CASE_ONLY||PROSPECTIVE|||||||
33995278|NCT03850457|||COHORT||PROSPECTIVE|||||||
33995279|NCT05533411|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33995280|NCT04593160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995281|NCT04340063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study personnel performing the clinical assessments will be blinded to the intervention.|The investigators will conduct a two-arm parallel assignment intervention. Participants will be randomized into a high intensity locomotor training intervention that will be conducted in either a normal treadmill environment or in a movement amplification environment.|f|f|f|t
33995282|NCT01079845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995283|NCT01312064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995284|NCT03192007|||COHORT||PROSPECTIVE|||||||
33995285|NCT01172158|||CASE_CONTROL||PROSPECTIVE|||||||
33995286|NCT03587545|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33995287|NCT04928027|||OTHER||OTHER|||||||
33995288|NCT00625222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995289|NCT01861080|||COHORT||PROSPECTIVE|||||||
33995290|NCT05133440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995291|NCT02471027|||CASE_CONTROL|||||||||
33914674|NCT01994811|||COHORT||PROSPECTIVE|||||||
33914675|NCT00138268|||||PROSPECTIVE|||||||
33914676|NCT01322685|||CASE_CONTROL||PROSPECTIVE|||||||
33914677|NCT03114306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and treating physicians are different in this trial, that means, the assessor of primary study endpoint will be blinded regarding group allocation. Patients receive either regional-anaesthesiological catheters preoperatively or are treatet with local infiltration technique perioperatively. For the purpose of this trial is would not be feasable to perform sham regional-anaesthesiological procedures and blinding of the treating physisican will not be possible.||f|f|t|t
33914678|NCT00449111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914679|NCT03025334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33914680|NCT03180359|NA|SINGLE_GROUP||OTHER||NONE||||||
33914681|NCT02983630|||COHORT||PROSPECTIVE|||||||
33914682|NCT04189497|||CASE_ONLY||RETROSPECTIVE|||||||
33914683|NCT00074841|RANDOMIZED|||TREATMENT||||||||
33914684|NCT04811469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914685|NCT02170805|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914686|NCT02406768|||CASE_CONTROL||PROSPECTIVE|||||||
33914687|NCT00286390|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33914688|NCT00318903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914689|NCT00296725||SEQUENTIAL||TREATMENT||NONE||||||
33780733|NCT04463043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is a single-blinded trial. Participants and health personnel at the clinic will not be blinded to group allocation, whereas researchers performing the analysis and the interpretation of the results will be blinded to group allocation. Once the study is completed, the data will be extracted from the database in anonymized form for statistical analyses, i.e. all personal information that may identify specific participants or group allocation will be removed and the intervention and control groups will be randomly labelled as A, B and C.||f|f|f|t
33780734|NCT01890161|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33780735|NCT06696872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780736|NCT06086808|RANDOMIZED|PARALLEL||TREATMENT||NONE||Concurrent Parallel Randomized Clinical Trial||||
33780737|NCT04712565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995292|NCT01275235|||CASE_ONLY||RETROSPECTIVE|||||||
33995293|NCT03287154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995294|NCT04670107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780738|NCT02474615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780739|NCT05741411|NA|SINGLE_GROUP||OTHER||NONE||Single group intervention arm compared to historical controls||||
33780740|NCT01737268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780741|NCT03802877|RANDOMIZED|FACTORIAL||TREATMENT||NONE|This is a behavioural intervention study. The participant, care provider, and investigator cannot be masked. Outcomes being assessed are objective (weight, steps, etc.) or are participant perspectives that preclude masking. Allocation is concealed.|This is a feasibility (pilot) interventional study with a factorial design||||
33780742|NCT00465361|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33780743|NCT06696859|||COHORT||CROSS_SECTIONAL|||||||
33780744|NCT01999660|||CASE_CONTROL||PROSPECTIVE|||||||
33780745|NCT00670540|||COHORT||PROSPECTIVE|||||||
33780746|NCT02374502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780747|NCT06128317|||COHORT||PROSPECTIVE|||||||
33780748|NCT02453529|NA|SINGLE_GROUP||||NONE||||||
33780749|NCT06104150|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780750|NCT01438437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780751|NCT02402972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780752|NCT00004136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780753|NCT00973947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780754|NCT06009783|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33780755|NCT06697275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, controlled, open-label, three arms parallel, multicenter therapeutic trial||||
33780756|NCT04971694|||CASE_ONLY||RETROSPECTIVE|||||||
33914690|NCT01996306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914691|NCT05092399|||COHORT||PROSPECTIVE|||||||
33914692|NCT05214898|||CASE_ONLY||PROSPECTIVE|||||||
33914693|NCT05960019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914694|NCT05876858|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will undergo two PET/CT scans with two different radiotracers. In addition, participants will complete questionnaires to establish the association of quantitative TB-PET/CT measures with the NIH Helping to End Addiction Long-term (HEAL) outcome measures||||
33914695|NCT02537379|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33914696|NCT04496440|||CASE_CONTROL||RETROSPECTIVE|||||||
33914697|NCT06279130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Basket, open-label||||
33914698|NCT01797510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914699|NCT04140552|||COHORT||CROSS_SECTIONAL|||||||
33914700|NCT04084938|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized study 1:1||||
33914701|NCT04110418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914702|NCT00180141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914703|NCT05087641|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label (unblinded), multicenter, prospective trial of the Implantable Artificial Bronchus (IAB) in adults suffering from COPD/emphysema. There is no control group or comparator.||||
33914704|NCT00173251|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33914705|NCT04155710|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33914706|NCT04982510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33914707|NCT01188564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914708|NCT00856479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995295|NCT01487057|||COHORT||PROSPECTIVE|||||||
33995296|NCT03156816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914709|NCT02917551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914710|NCT03019770|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33914711|NCT06553677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|It's randomized clinical trial|f|f|f|t
33914712|NCT01184716|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33914713|NCT05742087|||COHORT||RETROSPECTIVE|||||||
33914714|NCT01630096|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33914715|NCT05529186|||CASE_ONLY||RETROSPECTIVE|||||||
33914716|NCT05255588|||COHORT||PROSPECTIVE|||||||
33914717|NCT02276716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914718|NCT02700100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914719|NCT05097053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914720|NCT05312931|||COHORT||PROSPECTIVE|||||||
33914721|NCT02236728|||COHORT||PROSPECTIVE|||||||
33914722|NCT01091987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914723|NCT01879670|||CASE_CONTROL||PROSPECTIVE|||||||
33914724|NCT04986449|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33995297|NCT01360333||CROSSOVER||PREVENTION||NONE||||||
33995298|NCT04922554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914725|NCT04586114|||COHORT||RETROSPECTIVE|||||||
33995299|NCT03319394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study statistician did not know which condition participants were assigned to.||f|f|f|t
33995300|NCT00391365|||COHORT||PROSPECTIVE|||||||
33995301|NCT03073798|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33995302|NCT05104710|||CASE_CONTROL||PROSPECTIVE|||||||
33995303|NCT00004398|RANDOMIZED|||TREATMENT||NONE||||||
33914726|NCT05178056|RANDOMIZED|PARALLEL||OTHER||SINGLE||Our goal is to evaluate the effects of the individually optimized spinal cord Epidural Stimulation (scES) (Aim 1) and to define the efficacy of scES combined with Respiratory Training (RT) (Aim 2) in individuals with Spinal Cord Injury (SCI). Thirty participants with SCI will be recruited, twenty of them will have scES implanted. After screening and recruitment, primary and secondary outcome measurements will be obtained in the Lab at the following time points: 1) Pre intervention, after 30-days without any stimulation and/or intervention, 2) Post mapping, (participants with scES, n=20), 3) Post Session #40 (after 8 weeks of intervention) and 4) Post Session #80 (after 16 weeks of intervention), and 5) Post 16-weeks Follow-up Period. In total, it is anticipated that 5 measurements will be obtained for each participant with implanted scES and 4 measurements for participants without scES.|f|f|f|t
33692026|NCT04246112|NA|SINGLE_GROUP||TREATMENT||NONE|Participant will practice 5 days p/week, 15-20 minutes p.day for 12 weeks. They will receive only feedback from the software program as they practice handwriting.|A handwriting skills training software program MovAlyzeR® will be given and downloaded to the children's laptop computer. Participants will be requested to use the software program to practice handwriting 15-20 minutes per day, 5 days a week for 12 weeks. The MovAlyzeR® keeps track (records) all the participants' practice. MovAlyzeR is HIPPA compliant. We use the MovAlyzeR as a training device for handwriting, not for data collection. Since MovAlyzeR provides instant feedback to the user on their handwriting movement, it is a fun way for the children to practice handwriting.||||
33914727|NCT02144363|||COHORT||PROSPECTIVE|||||||
33914728|NCT00005096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914729|NCT01952730|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33914730|NCT06431243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914731|NCT04144452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914732|NCT03458832|||COHORT||PROSPECTIVE|||||||
33914733|NCT03365427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914734|NCT03009201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914735|NCT00895518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914736|NCT05966532|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33914737|NCT05532098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914738|NCT03771417|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914739|NCT06259279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Testers of physical tests (Handgrip strength test and chair-stand-test) and the the statistician will be blinded for allocation.|RCT|f|f|f|t
33914740|NCT01724125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33914741|NCT02213302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914742|NCT04191421|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Arm 1- (Phase I dose level 1)- Siltuximab 6 mg/Kg every 3 weeks and Spartalizumab 300mg every 3 weeks Arm 2- (Phase I dose level 2)- Siltuximab 11 mg/Kg every 3 weeks and spartalizumab 300 mg every 3weeks Arm 3 - (Phase I doe level 2a)- Siltuximab 9 mg/Kg every 3 weeks and spartalizumab 300 mg every 3weeks Arm 4- (Phase II)- Siltuximab RP2D determined in Arms 1 to 3 and spartalizumab 300 mg every 3weeks||||
33914743|NCT04202718|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995304|NCT03783663|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||parallel arm superiority, pilot feasibility randomized controlled trial|f|f|t|f
33995305|NCT04666636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33995306|NCT06561269|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33995307|NCT00270582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995308|NCT03621995|||CASE_ONLY||RETROSPECTIVE|||||||
33995309|NCT03097445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995310|NCT06040658|||COHORT||PROSPECTIVE|||||||
33995311|NCT00983099|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33995312|NCT04796480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were divided in 2 groups.||||
33995313|NCT06126939|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33995314|NCT06362356|||COHORT||PROSPECTIVE|||||||
33995315|NCT05722496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|block randomization and envelopes|"Patients will be assigned randomly by computerized block randomization into two groups:Group (A): 30 patients aged between 45 - 55 years old will participate in 8 weeks of aerobic exercise in the form of high intensity interval training (HIIT) intradialytic pedaling exercise plus hemodialysis (3 sessions per week).~Group (B): 30 patients aged between 45- 55 years old will participate in 8 weeks of aerobic exercise in the form of moderate intensity continous training (MICT) intradialytic pedaling exercise plus hemodialysis (3 sessions per week)."|t|t|t|t
33995316|NCT06620939|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Statistician||f|f|t|t
33995317|NCT02565836|||COHORT||RETROSPECTIVE|||||||
33995318|NCT06627803|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995319|NCT06618339|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33995320|NCT04953520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995321|NCT05617391|||COHORT||PROSPECTIVE|||||||
33995322|NCT03134664|RANDOMIZED|PARALLEL||TREATMENT||NONE||Forty patients with femoral neck fractures admitted at Pudong Hospital of Fudan University, China are randomly divided into two groups.||||
33995323|NCT01885819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995324|NCT02749604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995325|NCT05982860|RANDOMIZED|PARALLEL||SCREENING||NONE||This study was planned as a randomized controlled trial.||||
33995326|NCT04161898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995327|NCT02167659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995328|NCT01225523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33692027|NCT05696392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692028|NCT06241118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692029|NCT03310957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692030|NCT04297085|NA|SINGLE_GROUP||OTHER||NONE||||||
33692031|NCT05358353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692032|NCT06677970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The mRS scores and adverse events were determined in participants at 1 month and 3 months via telephone or in person by local certified medical staff who were blinded to the treatment allocation.|a multicenter, randomized, open Lable, blinded end-point clinical trial.|f|f|f|t
33692033|NCT04793776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and outcome assessors will be masked to treatment assessment. Therapist will be masked to outcome data.|This randomized clinical trial (RCT) is designed to examine if a brief emotion regulation treatment, MERA, is efficacious at reducing aggression compared to present centered therapy (PCT) in Veterans with full or subthreshold PTSD. The investigators will use a parallel group RCT design, a 1:1 allocation ratio, and a superiority (MERA \> PCT) framework. The study will follow the SPIRIT 2013 Checklist that is recommended for RCT protocols.|t|f|t|t
33692034|NCT03837444|||COHORT||PROSPECTIVE|||||||
33692035|NCT05629585|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel||||
33692036|NCT05121545|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase I study design, evaluating the feasibility (primary endpoint), toxicity (secondary endpoint), and degree of response (exploratory endpoint) after proton GRID therapy in patients with bulky tumors.||||
33692037|NCT04901195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692038|NCT06679400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized 1:1 to receive massage where communication with the massage therapist is permitted or restricted.|t|f|f|t
33692039|NCT06634420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692040|NCT06323044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692041|NCT03674424|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized study. 2 cohorts possible depending on cisplatin-eligibility. Afterwards randomization between 2 arms into the cohort.||||
33692042|NCT05850273|||COHORT||PROSPECTIVE|||||||
33914744|NCT05383729|RANDOMIZED|PARALLEL||OTHER||SINGLE|The group assignments will be concealed from the collectors who will record the intubation data in patients. Anonymized recordings will be sent to an independent assessor who assesses the performance of FOB intubation in patients.|This is a multiple-center, randomized, single-blind, noninferiority study.|f|f|f|t
33914745|NCT06512623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914746|NCT00189241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914747|NCT02667860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914748|NCT02393573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914749|NCT03819764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914750|NCT04060264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"During the main period (first 27 weeks), test product BCD-148 and reference product Soliris®.~After Week 27, patients of both study arms will be switched to BCD-148 900 mg biweekly as maintenance therapy. Duration of this maintenance therapy will be 25 weeks."|t|t|t|t
33914751|NCT06027476|||COHORT||RETROSPECTIVE|||||||
33914752|NCT02701803|||CASE_ONLY||PROSPECTIVE|||||||
33995329|NCT02958176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995330|NCT06559631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single-blind randomized controlled trial (RCT)|Research design of the study shall consists two-arms, single-blind randomized controlled trial (RCT). While Randomized Control Trial (RCT) shall consists of two groups: Active Treatment (AT) group and Control group|t|f|f|t
33995331|NCT05458687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995332|NCT02623647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995333|NCT02456285|||COHORT||PROSPECTIVE|||||||
33995334|NCT03073850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995335|NCT01875562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995336|NCT00768963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995337|NCT04268615|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995338|NCT06408168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914753|NCT01790217|||COHORT||PROSPECTIVE|||||||
33914754|NCT00953043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914755|NCT01747278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914756|NCT01009788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995339|NCT01932021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995340|NCT03332732|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||Part 1: Cross-over Part 2: Parallel|t|f|t|f
33995341|NCT04022122|||COHORT||PROSPECTIVE|||||||
33995342|NCT01461785|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33995343|NCT05668650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This study will be double-blind during the whole study period. The double-blind design reduces the potential for bias, particularly in the assessment of AEs. Most of the other assessments in the current study are objective in nature and, therefore, less prone to bias.~The blinding for a specific subject can be broken by the investigator (emergency code breaking) only if the investigator considers the information indispensable to the safety of the subject. All subjects whose treatment are unblinded by the investigator (break blind option, emergency code breaking) while on the study will be withdrawn at the moment of unblinding, with the reason for unblinding given as the reason for discontinuation from the study."|This is a randomized, multicenter, multinational, double-blind, and parallel-group study.|t|t|t|t
33995344|NCT04309773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995345|NCT06618092|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33995346|NCT03273049|||OTHER||PROSPECTIVE|||||||
33995347|NCT06415760|||COHORT||PROSPECTIVE|||||||
33995348|NCT03665194|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Thirty-two volunteers will be enrolled and evaluated (i.e. complete the study). Subjects will be dosed in four groups of eight (purely for logistical reasons relating to the procedure times expected with dosing and ECG). Volunteers will receive either the active drug or matching placebo in a 3:1 ratio. Therefore within each cohort, six volunteers will receive the active drug and two will receive matching placebo.|t|f|t|f
33995349|NCT05850676|||COHORT||PROSPECTIVE|||||||
33995350|NCT01933282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995351|NCT04352062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995352|NCT02028221|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33995353|NCT04515719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995354|NCT01398085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995355|NCT02180321|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33914757|NCT04091230|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patient and pathologist are unaware of which needle/device is used. TRUSbx are taken from behind the back of the patient enabling masking from the patient.|20 patients eligible for prostate biopsy are randomized into 2 arms (10+10 patients) using either the novel needle and actuator device or standard tru cut needle and actuator device used in the clinic today. On average 12 biopsies are taken from each patient. Biopsy quality is evaluated by the pathologist blinded to device used.|t|f|f|t
33914758|NCT01800006|||COHORT||PROSPECTIVE|||||||
33914759|NCT00244699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33914760|NCT00358917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914761|NCT05000814|||COHORT||PROSPECTIVE|||||||
33914762|NCT05957497|||COHORT||PROSPECTIVE|||||||
33914763|NCT01553916|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33914764|NCT04933721|NA|SINGLE_GROUP||PREVENTION||NONE|No masking as this is open-label.|Open-label berotralstat (BCX7353) 150 mg orally administered QD.||||
33914765|NCT04359355|||COHORT||PROSPECTIVE|||||||
33914766|NCT02176590|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914767|NCT05835388|||OTHER||PROSPECTIVE|||||||
33914768|NCT05782036|||COHORT||PROSPECTIVE|||||||
33914769|NCT04108013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914770|NCT02506296|NA|SINGLE_GROUP||||NONE||||||
33914771|NCT02149056|||COHORT||PROSPECTIVE|||||||
33914772|NCT02575573|||COHORT||RETROSPECTIVE|||||||
33914773|NCT05397223|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914774|NCT01490749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914775|NCT06271447|||COHORT||PROSPECTIVE|||||||
33914776|NCT02364167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33914777|NCT01596452|||COHORT||PROSPECTIVE|||||||
33914778|NCT01441115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914779|NCT05259969|||COHORT||PROSPECTIVE|||||||
33914780|NCT02290886|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33914781|NCT01329523|||COHORT||PROSPECTIVE|||||||
33914782|NCT04073940|NA|SINGLE_GROUP||OTHER||NONE||||||
33914783|NCT03895944|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33914784|NCT02318524|||COHORT||PROSPECTIVE|||||||
33914785|NCT03772561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914786|NCT04729920|||CASE_ONLY||CROSS_SECTIONAL|||||||
33914787|NCT00840944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914788|NCT03896789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel cluster RCT following a baseline data collection period when all sites are in the 'control/usual care state'.||||
33914789|NCT05278650|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33914790|NCT06034717|||COHORT||PROSPECTIVE|||||||
33914791|NCT01718509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914792|NCT01760941|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33914793|NCT04095806|||COHORT||PROSPECTIVE|||||||
33914794|NCT00663728|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33914795|NCT02985814|||OTHER||PROSPECTIVE|||||||
33914796|NCT00849121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914797|NCT01237808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995356|NCT05196347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995357|NCT02640235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33995358|NCT02099227|||COHORT||PROSPECTIVE|||||||
33995359|NCT06627621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995360|NCT05705869|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33995361|NCT03007563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995362|NCT03431961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33995363|NCT00549484|||||PROSPECTIVE|||||||
33692043|NCT05948579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The overall 2-stage randomization scheme will be implemented by an unblinded statistician who is otherwise uninvolved in study operations. Participants will be assigned a study number at Screening (Subject ID). In the first stage of randomization, eligible participants who complete screening will be randomly assigned to an open platform cohort for which they are eligible (both site PIs and participants are aware of the cohort assignment) and, within that cohort, the second stage of randomization is to intervention vs placebo (double-blind) using Interactive Response Technology (IRT).~For this APT, participant assignment to a cohort will not be blinded. The tablets/capsules used in the cohorts may not be visually similar between cohorts and blinding to cohort assignment is not necessary to avoid bias. However, within each cohort, participants, site personnel, contract research personnel and the sponsor will be blind to treatment assignment (intervention vs. placebo)."|Vilazodone is one of multiple interventions that will be tested in this adaptive platform trial (NCT05422612).|t|t|t|t
33692044|NCT06008353|||COHORT||OTHER|||||||
33692045|NCT06745674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33692046|NCT06047171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086808|NCT05545501|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be randomized to a condition order. A single lab member, not involved in data collection or analysis, will know condition order and contents and distribute them to participants.|Placebo-controlled, double-blinded, randomized|t|f|t|f
33692047|NCT06745440|||COHORT||PROSPECTIVE|||||||
33692048|NCT05682560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692049|NCT05890677|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, randomized, international, multicenter superiority trial||||
33692050|NCT06200779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Intervention group: Patients will receive a prescription for oriented H. pylori eradication treatment according to the following rules: a) clarithromycin-sensitive strain (independently of levofloxacin resistance test result) - PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days; b) clarithromycin-resistant and levofloxacin-sensitive strain - PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days; c) clarithromycin-resistant and levofloxacin-resistant strain - bismuth quadruple therapy (Pylera®) for 10 days.~Control Group: Patients will receive a prescription for empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®) for 10 days."|f|f|t|f
33692051|NCT06744166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692052|NCT05706116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692053|NCT06344793|||COHORT||RETROSPECTIVE|||||||
33692054|NCT06216483|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33692055|NCT04947657|||COHORT||PROSPECTIVE|||||||
33692056|NCT06137118|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The trial will assess AZD0486 IV infusion in monotherapy. Part A will evaluate ascending dose levels of AZD0486 in participants 16-80 years with B-ALL. Part B will evaluate up to 2 safe-declared dose levels in participants with Ph(-) B-ALL aged 12-80 years to select the RP2D. Part C will expand the RP2D dose level cohort to assess efficacy in a large number of subjects.||||
34086809|NCT02209064|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692057|NCT06738407|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized 1:1:1 to (1) on-demand doxyPEP (doxycycline 200 mg as soon as possible and within 72 hours after any condomless oral, vaginal/front hole, and/or anal sex), (2) weekly doxycycline (doxycycline 200 mg weekly regardless of sexual activity), or (3) SOC (quarterly STI testing/treatment and sexual health counseling). Participants will complete quarterly study visits over the course of 1 year during which they will receive STI testing (GC, CT, and syphilis), complete surveys, undergo safety monitoring, provide specimens for objective markers of doxycycline adherence and other laboratory assessments, and provide specimens (vaginal/front hole and rectal swabs \[participant self-collected or staff-collected if the participant prefers\]) for future testing, such as microbiome analysis.||||
33692058|NCT00526045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33995364|NCT05845723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995365|NCT02313558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995366|NCT03849547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995367|NCT00796562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995368|NCT02179294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995369|NCT02483195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995370|NCT03034356|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33995371|NCT05364177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||68Ga-pentixather PET/CT, 68Ga-pentixafor PET/CT||||
33995372|NCT04418219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995373|NCT01954277|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33780757|NCT06615063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"The description of the study does not explicitly mention any masking (blinding).~In the context provided, the primary investigator collects and analyzes the data using self-designed questionnaires. Typically, in such studies, the intervention (splinting) would be known to the participants and the healthcare providers administering the IV cannulation. Therefore, masking of the participants and providers might not be feasible."|"The interventional study model of the above article is a Parallel Assignment model.~In this study, neonates are randomly assigned to one of two groups: one group receives the intervention (limb splinting) while the other group does not (non-splinted). The outcomes (e.g., lifespan of the IV cannula, incidence of complications) are then compared between these two parallel groups to determine the effectiveness of the intervention."||||
33995374|NCT01206803|||COHORT||PROSPECTIVE|||||||
33995375|NCT00766389|||CASE_CONTROL||RETROSPECTIVE|||||||
33780758|NCT06443697|||CASE_CONTROL||RETROSPECTIVE|||||||
33780759|NCT04259970|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33780760|NCT00961493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780761|NCT03829969|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33780762|NCT05838183|||COHORT||PROSPECTIVE|||||||
33780763|NCT00739453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780764|NCT04893564|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780765|NCT02381899|||COHORT||PROSPECTIVE|||||||
33780766|NCT02883543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780767|NCT00166660|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33780768|NCT05339906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Audio intervention with the same stimulus for participants with and without stuttering||||
33780769|NCT04027361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780770|NCT06615583|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, single-center, interventional, prospective, single-arm study||||
33780771|NCT04536025|||OTHER||PROSPECTIVE|||||||
33780772|NCT00839202|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780773|NCT00924989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780774|NCT06533332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780775|NCT04376476|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33780776|NCT04582045|||COHORT||PROSPECTIVE|||||||
33780777|NCT05878353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780778|NCT05975320|||CASE_ONLY||PROSPECTIVE|||||||
33780779|NCT01697761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33780780|NCT04242394|||COHORT||PROSPECTIVE|||||||
33780781|NCT01686932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780782|NCT00943423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780783|NCT05578924|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780784|NCT06321159|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be determined blindly by being assigned by a site.|Our study has two groups of 78 participants each. Our study is an experimental study with pretest-posttest control group.|t|f|f|f
33780785|NCT05099666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780786|NCT03088540|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33780787|NCT06090435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780788|NCT03356483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In the study, half of the participants will be randomized to receive psilocybin (n=15) or the active-placebo-control, niacin (n=15). Following the first treatment session of either the active agent or active-placebo-control, participants who were randomized to receive active-placebo-control will be offered the option to receive open-label psilocybin. The blind will be broken at 48-hours to make this determination.|t|t|t|t
33780789|NCT03957980|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The occupational therapist at the remote clinics assessing outcomes did not know what point in time the subjects were receiving the intervention.|This pilot study will utilize a randomized two group crossover design with assessment at 4 time periods.|f|f|f|t
33780790|NCT02467153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33780791|NCT00031447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780792|NCT00857844|||COHORT||CROSS_SECTIONAL|||||||
33780793|NCT03067467|||CASE_CONTROL||PROSPECTIVE|||||||
33780794|NCT03128203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33780795|NCT03480971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914798|NCT04729491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914799|NCT00621855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914800|NCT05762445|||COHORT||PROSPECTIVE|||||||
33914801|NCT00239772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33914802|NCT03279783|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE||Participants scheduled for colonoscopy for the assessment of symptoms or for colorectal cancer screening/surveillance receive the examination of the right colon twice, in a back-to-back fashion, with standard white light (WL) and with LCI (Linked Color Imaging). Patients are randomly assigned (1:1), via computer-generated randomisation with block size of 20, to which procedure is done first.|t|f|f|f
33914803|NCT05607017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914804|NCT02049749|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33914805|NCT05344144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914806|NCT01156597|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995376|NCT05915858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995377|NCT01165047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995378|NCT06408519|RANDOMIZED|PARALLEL||OTHER||NONE||mixed-method randomised control feasibility study||||
33995379|NCT00363077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33995380|NCT02730650|NA|SINGLE_GROUP||OTHER||NONE||||||
33995381|NCT05625178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995382|NCT03303781|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33995383|NCT00673010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995384|NCT01215760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995385|NCT02127463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995386|NCT04063631|||OTHER||OTHER|||||||
33995387|NCT00473954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995388|NCT05455671|||COHORT||PROSPECTIVE|||||||
33914807|NCT00093860||||TREATMENT||||||||
33914808|NCT03319615|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The baseline non-intervention control arm only used in the present secondary data analysis|t|f|f|f
33914809|NCT00864422|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33914810|NCT02547636|||CASE_ONLY||PROSPECTIVE|||||||
33914811|NCT06081036|||OTHER||RETROSPECTIVE|||||||
33914812|NCT03666858|||COHORT||PROSPECTIVE|||||||
33914813|NCT02860533|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914814|NCT03187912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33914815|NCT02712372|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914816|NCT02513368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33914817|NCT03021434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914818|NCT05665621|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33914819|NCT05370313|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will complete two Experimental Marketplace conditions, representing one control condition and one of the four tax proposals. Within each condition, taxes will be increased proportionally across 6 trials to examine how cigarette purchasing, substitution, and poly-tobacco purchasing (i.e., diversity in products purchased) are affected.||||
33914820|NCT05094921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914821|NCT00726817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33995389|NCT01212276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995390|NCT03380247|||CASE_ONLY||PROSPECTIVE|||||||
33995391|NCT00694187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995392|NCT06439238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is an open label, between-subject, randomized pilot study||||
33995393|NCT00091377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995394|NCT03173872|NA|SINGLE_GROUP||TREATMENT||NONE||A short prospective, exploratory one group study to assess the acceptance of Reiki in 30 military healthcare beneficiaries, by comparing pre and post Reiki intervention measures.||||
33995395|NCT01350986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995396|NCT01368380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995397|NCT04042415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995398|NCT00688571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995399|NCT03393780|||COHORT||PROSPECTIVE|||||||
33995400|NCT04366960|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Open-label Multicentre Prospective Controlled Randomized Trial in patients with SARS-CoV-2 infection. Patients will be randomized 1:1 to 40 mg subcutaneous enoxaparin o.d. versus 40 mg enoxaparin b.i.d within 12 hours after hospitalization.||||
33995401|NCT06563141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995402|NCT02680444|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33995403|NCT06627088|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995404|NCT00774189|RANDOMIZED|CROSSOVER||||NONE||||||
33995405|NCT05513196|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995406|NCT03196284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995407|NCT02293928|||COHORT||PROSPECTIVE|||||||
33995408|NCT02462837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995409|NCT02066038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995410|NCT05411653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995411|NCT03856580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995412|NCT04332198|NA|SINGLE_GROUP||OTHER||NONE||||||
33995413|NCT00831103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995414|NCT00018616|RANDOMIZED|PARALLEL||||NONE||||||
33995415|NCT00538031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995416|NCT04277793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995417|NCT03447535|||CASE_CONTROL||RETROSPECTIVE|||||||
33995418|NCT03705117|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995419|NCT04350697|||CASE_CONTROL||PROSPECTIVE|||||||
33995420|NCT05144451|NA|SINGLE_GROUP||SCREENING||NONE||A single-arm trial involving 100 patients undergoing living donor liver transplantation; all will be examined using transcranial doppler to find out its predictive value on post-transplant neurological deficits.||||
33995421|NCT02828449|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995422|NCT04807426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995423|NCT04741776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995424|NCT02385708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995425|NCT06435793|NA|SINGLE_GROUP||OTHER||NONE||||||
33995426|NCT05058430|RANDOMIZED|PARALLEL||OTHER||NONE||Single-center, prospective, open-label study.||||
33995427|NCT02280707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914822|NCT03549481|||COHORT||PROSPECTIVE|||||||
33914823|NCT03331666|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33995428|NCT05471596|||COHORT||PROSPECTIVE|||||||
33995429|NCT05948163|||OTHER||CROSS_SECTIONAL|||||||
33995430|NCT05213663|||FAMILY_BASED||PROSPECTIVE|||||||
33780796|NCT04606888|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Patient don't konw which group they are in because we all told them that they will feel nothing during the intervention.~The outcomes assessor just to evaluate indicators, they don't know the specific content of the patient's experiment"|Transcutaneous electrical acupoint stimulation group and control group|t|f|f|t
33780797|NCT06696950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914824|NCT03164512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|placebo controlled, double-blind||t|f|f|t
33914825|NCT03612180|||COHORT||PROSPECTIVE|||||||
33914826|NCT02014935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914827|NCT04872816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914828|NCT04121429|||COHORT||RETROSPECTIVE|||||||
33914829|NCT02919124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914830|NCT02649543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914831|NCT02942316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914832|NCT00948662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914833|NCT02517827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914834|NCT05582265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692059|NCT06578949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692060|NCT03935295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692061|NCT06745219|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33692062|NCT06272461|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Intravenous Lidocaine vs intravenous ketamine|t|t|f|f
33692063|NCT06073132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692064|NCT05536895|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Single center, randomized controlled trial||||
33692065|NCT03022656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692066|NCT05452564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692067|NCT05685602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692068|NCT05776810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33692069|NCT06456190|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33692070|NCT06398808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomly assigned in a 1:1 ratio|t|f|t|f
33692071|NCT06743542|||COHORT||CROSS_SECTIONAL|||||||
33780798|NCT05233085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||For each cohort, 9 participants will be randomly assigned to receive AZD4041 and 3 participants will be assigned to receive placebo. Within each cohort, 2 participants will be randomized initially to AZD4041 or placebo (1:1 ratio) to allow a sentinel dosing approach. Providing no clinically significant issues have been noted after the first 3 doses of the initial 2 (sentinel) participants in a cohort and provided the Day 3 safety laboratory tests for the 2 participants have been reviewed, the remaining 10 participants will be randomized to AZD4041 or placebo in an 8:2 ratio. All participants will receive either AZD4041 or placebo administered once daily for 14 days.|t|t|t|t
33780799|NCT00839228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780800|NCT02745769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780801|NCT04462913|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780802|NCT04668781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780803|NCT03688295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780804|NCT04400656|||OTHER||PROSPECTIVE|||||||
33780805|NCT05712811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780806|NCT03007342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780807|NCT05406986|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Experimental and control groups will be selected using the randomized control method.|t|f|f|f
33780808|NCT06396390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780809|NCT00516581|||CASE_CONTROL||RETROSPECTIVE|||||||
33780810|NCT02439255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780811|NCT01540435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780812|NCT03934905|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||We plan to include 70 DOX-naïve women with breast cancer undergoing neoadjuvant chemotherapy, with no prior cardiac disease and who will receive DOX without Her-2 receptor antagonists as part of their clinical care. Potential subjects will be recruited in a randomized, controlled; double blinded pilot study comparing SFN to placebo. Study will be conducted at the TTUHSC and UMC. The trial is approved by the institutional IRB and will be registered at clinicaltrials.gov. UMC cancer center pharmacist Ajoke A. Tijani, RPh. will receive placebo and test compound from supplier and will dispense them to test subjects. Randomization will be done with assignment of a subject ID to the study subject. The list of subject IDs will be subsequently assigned to either study drug or placebo using a randomizer software.|t|f|t|f
33780813|NCT06203262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm safety and feasibility study. There are two populations that will be enrolled and analyzed separately: patients being treated for ventricular tachycardia (VCAS-I) and patients with frequent premature ventricular contractions (VCAS-II). The intervention in both cases is similar.||||
33780814|NCT06665113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780815|NCT04161222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assesor|A specialist physician will be diagnosed the process.|t|f|f|f
33780816|NCT02068885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780817|NCT05588882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants contribute one eye to each study arm|t|f|f|f
33780818|NCT04103047|||OTHER||RETROSPECTIVE|||||||
33780819|NCT03880110|||COHORT||PROSPECTIVE|||||||
33780820|NCT06615193|NA|SEQUENTIAL||TREATMENT||NONE||||||
33780821|NCT00593164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780822|NCT02174133|||COHORT||PROSPECTIVE|||||||
33780823|NCT06400654|||CASE_ONLY||OTHER|||||||
33780824|NCT02719951|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33780825|NCT03016897|||CASE_CONTROL||PROSPECTIVE|||||||
33995431|NCT01834157|||COHORT||PROSPECTIVE|||||||
33995432|NCT03328026|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995433|NCT03512483|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995434|NCT03018925|||CASE_ONLY||PROSPECTIVE|||||||
33995435|NCT03459339|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A hundred patients are enrolled in year 1 in each of five participating centers.||||
33995436|NCT05400239|||COHORT||PROSPECTIVE|||||||
33995437|NCT03253354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient blinding|4 arm randomised single dose study|t|f|f|f
33995438|NCT02611687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995439|NCT06144996|||COHORT||PROSPECTIVE|||||||
33995440|NCT05437848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Total 16 Chinese subjects will be randomized to cotadutide or placebo in a 3:1 ratio (cotadutide \[n=12\] and placebo \[n=4\]) at multicenter in China mainland.|t|t|t|f
33780826|NCT06452394|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single arm, open label||||
33780827|NCT04485780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33780828|NCT04715178|||COHORT||PROSPECTIVE|||||||
33780829|NCT01788020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780830|NCT04497311|||COHORT||PROSPECTIVE|||||||
33780831|NCT04528355|||COHORT||PROSPECTIVE|||||||
33995441|NCT02206893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995442|NCT04129177|||COHORT||PROSPECTIVE|||||||
33995443|NCT00250263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995444|NCT02937935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086810|NCT04663113|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A total of 30 patients, 10 patients for each group, were planned to be included in the study.~The individuals participating in the study will be divided into 3 groups: Standard therapy (1st Group), Standard therapy + bicycle ergometer (2nd Group) and Standard therapy + exercise protocol to be developed (3rd Group)"||||
34086811|NCT04168957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780832|NCT04172987|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780833|NCT02214381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780834|NCT06464341|||COHORT||RETROSPECTIVE|||||||
33780835|NCT03210428|||OTHER||PROSPECTIVE|||||||
33780836|NCT06692985|||COHORT||PROSPECTIVE|||||||
33780837|NCT06518473|||CASE_CROSSOVER||PROSPECTIVE|||||||
33780838|NCT05873803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33780839|NCT06696365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780840|NCT01144117|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33780841|NCT06559228|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33780842|NCT02100722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780843|NCT05063916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780844|NCT01036087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780845|NCT02486705|RANDOMIZED|PARALLEL||||NONE||||||
33780846|NCT04155424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780847|NCT00707863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780848|NCT01580527|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780849|NCT05621655|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780850|NCT02350361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780851|NCT00593554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780852|NCT02993497|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780853|NCT04285502|RANDOMIZED|PARALLEL||TREATMENT||NONE||PROSPECTIVE RANDOMISED CONTROLLED TRIAL||||
33780854|NCT03025256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780855|NCT05051397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780856|NCT00432159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant was masked to which treatment they would receive until AFTER the surgery/treatment procedure. At that point, they were unmasked.||t|f|f|f
33780857|NCT05336552|||OTHER||CROSS_SECTIONAL|||||||
33780858|NCT04425148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780859|NCT06046872|NA|SINGLE_GROUP||OTHER||NONE||||||
33780860|NCT04232670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In addition to the participant and the investigator assessing outcomes, study coordinators involved in collecting outcomes data will be masked to the treatment assignment.||t|f|f|t
33914835|NCT03791645|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"SKY program includes gentle stretches, SK breathing, and cognitive coping and stressor evaluation strategies. SK breathing, the cornerstone of SKY program contains the following breathing components 1) Three-stage Ujjayi, 2) Bhastrika and 3) Rhythmic Breathing.~Three-Stage Ujjayi is an advanced form, with each respiratory cycle lasting approximately twenty seconds. Bhastrika, involves vigorous and faster breathing, at about 20 to 30 respiratory cycles lasting 60 seconds. Three 1-minute rounds of Bhastrika are each followed by 20 seconds of normal breathing. Rhythmic breathing are slow, medium, and fast breathing cycles in succession. Respiratory rates range from about 8-12 respiratory cycles lasting approximately 10 minutes. The participant rotates through these breathing patterns.~Upon completion of SKY program, participants will be given a home SK practice which takes approximately 25 minutes daily. Once a week, a 60-90 minutes group follow up SKY session will be held"||||
33914836|NCT00001261||||TREATMENT||||||||
33914837|NCT01890070|RANDOMIZED|CROSSOVER||||NONE||||||
33914838|NCT01426607|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33914839|NCT00946530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33914840|NCT00003444|RANDOMIZED|||TREATMENT||||||||
33914841|NCT01633034|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33914842|NCT02032745|||OTHER||PROSPECTIVE|||||||
33914843|NCT03498781|RANDOMIZED|FACTORIAL||OTHER||NONE||This study will be a between group factorial design. The between subjects variable will be group assignment. The within subjects variable will be time.||||
33914844|NCT02231450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914845|NCT03650686|||OTHER||PROSPECTIVE|||||||
33914846|NCT00617409|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33914847|NCT03678922|||COHORT||PROSPECTIVE|||||||
34086812|NCT04994964|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34086813|NCT03777241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086814|NCT01632319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086815|NCT06082739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086816|NCT01093508|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33780861|NCT05550766|||OTHER||RETROSPECTIVE|||||||
33780862|NCT01097980|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34086817|NCT05107115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086818|NCT04636723|||COHORT||CROSS_SECTIONAL|||||||
34086819|NCT00851149|||CASE_CONTROL||PROSPECTIVE|||||||
33780863|NCT06506240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients meeting the eligibility criteria for SP will be randomly assigned to either the acupuncture or sham acupuncture groups in a 1:1 ratio. The randomization sequence was generated using the blockrand package in R software (version 4.1.1) and is detailed in the supplementary materials. The sequence will be enclosed in sealed, opaque, sequentially numbered envelopes, which will be opened after participants complete all baseline assessments. Allocation to the assigned group will be conducted by a research assistant who is not involved in treatment or outcome assessments. Participants, outcome assessors, and the statistician will be blinded to group assignments, ensuring unbiased evaluation. However, the practitioner administering the intervention will not be blinded.|This trial is a single-center, parallel-arm, randomized, sham-controlled clinical trial. Eligible participants are randomized and allocated to either the acupuncture or sham acupuncture groups at a 1:1 ratio.|t|f|f|t
34086820|NCT03416101|||COHORT||RETROSPECTIVE|||||||
34086821|NCT05085145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086822|NCT03327974|NA|SINGLE_GROUP||OTHER||NONE||||||
33692072|NCT03408340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants in the study will be randomized to the control arm or experimental arm using computer-generated random assignment, which will be prepared at the start of the study and the assignments held in sealed envelopes. Once the participant is enrolled in the study and consent has been obtained the investigator will open the next consecutive sealed envelope which contains the patient's group assignment (experimental or control).||||
33692073|NCT06743672|||COHORT||PROSPECTIVE|||||||
33692074|NCT06122662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Care providers, Investigators, and study staff will be blinded to participant group assignment during the double-blind phase and extension phase|A35-009 (ORION) is a blinded, randomized, placebo-controlled, two-part Phase 2b/3 study, each part consisting of a 52-week double-blind, placebo-controlled phase followed by an optional 52-week open-label extension phase.|t|t|t|t
33692075|NCT04300855|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants participating in the study will be randomized 2:1 (2 study agent: 1 placebo) to receive Sunphenon® 90D (405 mg EGCG BID) or placebo.|t|f|t|f
33692076|NCT04364048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692077|NCT06745544|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study follows a randomized controlled trial design. Participants are randomly allocated to either the 26 weeks RYMA/ADL exercise intervention group or the control group (usual care). Baseline measures are performed at day 0. Then, follow-up regardless of group is after 26, 52 and 104 weeks and a final visit after 5 years from baseline.||||
33692078|NCT06743802|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33692079|NCT06744387|||COHORT||PROSPECTIVE|||||||
33692080|NCT04750954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692081|NCT06744049|NA|SINGLE_GROUP||OTHER||NONE||Clinical research with medical device.||||
33780864|NCT04187534|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Registry-based, stepped-wedge, implementation trial||||
33780865|NCT04524104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33780866|NCT02990728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780867|NCT04314661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780868|NCT01273558||PARALLEL||TREATMENT||NONE||||||
33780869|NCT05421273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780870|NCT00761774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780871|NCT02802020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780872|NCT03291600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Behavioral: Virtual Psychiatric Care for Perinatal Depression||||
33780873|NCT00812630|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33780874|NCT02539758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692082|NCT05741034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692083|NCT04610853|||COHORT||PROSPECTIVE|||||||
33692084|NCT06484062|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33780875|NCT06396195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780876|NCT02906683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914848|NCT00256087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33914849|NCT02892565|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33914850|NCT02208817|||CASE_CONTROL||PROSPECTIVE|||||||
33914851|NCT04757909|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33914852|NCT01743014|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914853|NCT02512068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914854|NCT01933165|NA|SINGLE_GROUP||||NONE||||||
33914855|NCT05522673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914856|NCT01317667|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914857|NCT01536002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914858|NCT00904540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914859|NCT01219517|NA|SINGLE_GROUP||||NONE||||||
33914860|NCT02586753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914861|NCT00874367|||COHORT||PROSPECTIVE|||||||
33914862|NCT06256783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914863|NCT03487640|||COHORT||PROSPECTIVE|||||||
33914864|NCT02687230|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914865|NCT04585529|||COHORT||PROSPECTIVE|||||||
33914866|NCT05674838|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914867|NCT05578235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|There is no blinding to the treatment allocation for the treating surgeon. The treatment will be blinded for the treating gastroenterologist, the endoscopist and the participants.|Randomised controlled trial. Patients with Crohn's disease will be randomised in a 1:2 ratio for stapled side-to-side anastomose versus handsewn anastomosis (either end-to-end or Kono-S) when performing an ileocolic resection for Crohn's disease.|t|f|f|t
33914868|NCT02312817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33914869|NCT03745196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study.||t|t|t|t
33914870|NCT02038218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086823|NCT06157476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective, two-arm, randomized controlled trial|f|f|f|t
33780877|NCT05895630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed about the comparison arms, or about the specific aims of the study at comparing outcomes from two different types of online interventions. They will also not be made aware of the fact that the waitlist group will be compared to the intervention groups. However, it is not possible to mask completely participants.|Three-arm parallel randomized controlled trial|t|f|f|f
33780878|NCT05740280|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33780879|NCT04478747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780880|NCT04066998|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995445|NCT03786341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients who fulfilled the inclusion and exclusion criteria were randomized (1:1) into two groups, using sequentially numbered, opaque, sealed envelopes (SNOSE) method containing a group assignment number by a person who was not clinically involved in and, therefore, was blinded to this study.|This was a randomized-prospective study and participants were recruited to each the experimental and the control group equally. Patients in the experimental group (EG) received 30-minutes rehabilitation, consisting of 15 minutes of walking training with laser quad-cane and 15 minutes of traditional physical therapy (such as strengthening and balance training). Patients in the control group (CG) received the same rehabilitation except that the walking training was by conventional strategy without lase quad-cane. The rehabilitation lasted for 4 weeks, twice per week. Gait parameters were measured by Rehab watch as primary outcomes and Berg's balance scale (BBS), timed-up-and-go test (TUG), and Barthel index were used as secondary outcomes. Both the primary and secondary outcomes were measured before the rehabilitation (baseline), 4 weeks (week 4), and 8 weeks (week 8) after the rehabilitation.|f|f|f|t
33780881|NCT05945511|||COHORT||RETROSPECTIVE|||||||
33780882|NCT06684223|||COHORT||RETROSPECTIVE|||||||
33995446|NCT02588144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995447|NCT02482922|NA|SINGLE_GROUP||OTHER||NONE||||||
33995448|NCT03741777|RANDOMIZED|PARALLEL||TREATMENT||NONE||The children included in this study will be randomly assigned into one of four groups by using randomization.org: Group 1 will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time, Group 2 will consume 5 ml/kg, Group 3 will consume 7 ml/kg, and Group 4 will consume 10 ml/kg.||||
33995449|NCT00002562||||TREATMENT||||||||
33995450|NCT03172286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind study|t|f|t|f
33780883|NCT06614439|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33995451|NCT00461435|RANDOMIZED|PARALLEL||||SINGLE||||||
33995452|NCT00464763|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33995453|NCT03162159|||COHORT||RETROSPECTIVE|||||||
33780884|NCT05565755|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Comparison of vaccine hesitancy in parents of adolescents during consultations by 2 different groups of interns:~* a group of interns trained in MI~* a group of interns not trained in IM The randomization will be done by random draw from the 3rd year list of general medicine interns."||||
33780885|NCT06199401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780886|NCT05257837|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants did not know which condition they were in. Participants' parents were aware of the deception (hidden gun) and what condition their children were in (gun safety or seatbelt safety; movie with or without guns). Research personnel knew conditions as well. Research assistants who transcribed recorded laboratory sessions did not know what condition they were coding (eg. what type of movie participants watched)~Research assistants coding the recorded observational data will be blind to the conditions of the participants they are coding, as well as the experimental hypotheses of the study."|"Participants are randomly assigned to watch a safety video about guns or a safety video about seatbelts.~Participants are then randomly assigned to watch a movie containing guns, or a movie not containing guns.~Outlier data will be excluded in analysis."|t|f|f|t
33780887|NCT01118962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780888|NCT02912039|||CASE_ONLY||PROSPECTIVE|||||||
33780889|NCT04700319|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33780890|NCT05147987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33780891|NCT05041634|NA|SINGLE_GROUP||TREATMENT||NONE||pilot study of single group pre/post design||||
33780892|NCT05360966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the randomized treatment period, the investigator and site staff performing eligibility / efficacy and safety assessments and the subjects will be masked.|Qualified subjects will be enrolled in the study and randomized in a 1:1 ratio within each site to receive 0.003% AR 15512 or AR-15512 vehicle to be administered twice daily (BID) as 1 drop in each eye for 90 days.|t|t|t|t
33780893|NCT03248570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"After determination of DNA damage repair status, subjects will be assigned to one of two treatment groups:~* Group 1 (DNA damage repair proficient group): Twenty-five subjects~* Group 2 (DNA damage repair deficient group): Twenty-five subjects~All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity."||||
33780894|NCT02947763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780895|NCT01960361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780896|NCT03081208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
33780897|NCT02328014|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33780898|NCT05503680|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this study, we will blind the data collector|||||
33780899|NCT06292702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33780900|NCT04941716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780901|NCT05382572|||COHORT||PROSPECTIVE|||||||
33780902|NCT02578602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33780903|NCT00513903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780904|NCT01351038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780905|NCT02053311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995454|NCT02913924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995455|NCT03025087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995456|NCT01844843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914871|NCT05059418|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|One clinical examinator for all examinations (baseline examination, outcome assessments), randomization, allocation and drug management by another person,|N-of-1 design. Three two-week treatment arms with a one-week wash-out period in between. After that, the patient will chose their preferred treatment and continue with that treatment for 6 months (i.e. this part is not randomized or controlled).|t|f|t|t
33914872|NCT00834704|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33995457|NCT02426918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995458|NCT03986294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33995459|NCT03187821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995460|NCT01403363|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995461|NCT01884701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995462|NCT03578497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995463|NCT01741545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995464|NCT02286466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33995465|NCT03603990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although both the patient and the investigating physician will be aware of group assignment, the evaluation of the primary endpoint (visual acuity) will be performed by independent evaluators, unaware of the randomization group for each eye. The evaluation of the CSF thickness will be automatically recorded by the OCT and therefore will not be influenced by the group.|Prospective randomized open blinded end-point (PROBE) pragmatic study|f|f|f|t
34086824|NCT06060470|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participant will be masked for the intervention group they will be assigned to. There will be masking of the outcome assessor also.|Randomized controlled trial.|t|f|f|t
33692085|NCT00106925|||CASE_CONTROL||PROSPECTIVE|||||||
33692086|NCT03319667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel and crossover|f|f|f|t
33692087|NCT01630850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692088|NCT06640959|||COHORT||PROSPECTIVE|||||||
33692089|NCT06744257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Prinicipal Investigator of the study will be blinded to all individual participant information and only have access to unique pseudonymised study numbers/ data and which group they are assigned too.||f|f|t|f
33692090|NCT06745518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692091|NCT06744088|||CASE_CONTROL||RETROSPECTIVE|||||||
33692092|NCT04228172|||CASE_CONTROL||PROSPECTIVE|||||||
33692093|NCT06132893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692094|NCT06735950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692095|NCT06741163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, placebo-controlled, two-arm parallel group study conducted in one center.|t|f|t|f
33692096|NCT05764863|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||One group of young healthy adults. Participants need to complete three experimental conditions associated with fMRI recording of brain activity. In condition A (Visual Spatial), participants will see the sequences presented from left to right; in condition B (Visual No Spatial), participants will see sequences of items presented in the middle of the screen; and in condition C (Auditory), the sequences will be presented in an auditory format.||||
33692097|NCT03986034|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33692098|NCT01158508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692099|NCT06286644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33692100|NCT06740474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692101|NCT06744140|||CASE_CONTROL||RETROSPECTIVE|||||||
33692102|NCT04586959|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A prospective multi-center non-inferiority randomized study||||
33692103|NCT05198583|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33914873|NCT00209521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914874|NCT04558788|||COHORT||RETROSPECTIVE|||||||
33914875|NCT01390090|||CASE_ONLY||PROSPECTIVE|||||||
33914876|NCT05557955|||COHORT||PROSPECTIVE|||||||
33914877|NCT03001310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33914878|NCT01605591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33914879|NCT02913352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086825|NCT02856958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086826|NCT01107210|||COHORT||PROSPECTIVE|||||||
34086827|NCT05502029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34086828|NCT00186719|||COHORT||PROSPECTIVE|||||||
34086829|NCT03885063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34086830|NCT01635088|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914880|NCT00194272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914881|NCT01021072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914882|NCT02281903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914883|NCT03629041|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33914884|NCT00000524|RANDOMIZED|PARALLEL||TREATMENT||||||||
33914885|NCT05154149|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33914886|NCT04820556|||CASE_CONTROL||OTHER|||||||
33914887|NCT00208741|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33914888|NCT00314652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33914889|NCT01560897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914890|NCT02871115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914891|NCT05633134|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33914892|NCT04061681|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two conditions that will be occurring simultaneously.||||
33914893|NCT00278772|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33914894|NCT02458157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33914895|NCT02704676|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33914896|NCT00708955|||||OTHER|||||||
33914897|NCT04065087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Phase 1: sequential dose escalation Phase 2: randomized, placebo controlled, parallel arm|t|t|t|t
33914898|NCT01623531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914899|NCT06473285|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914900|NCT01968954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086831|NCT06140134|||COHORT||PROSPECTIVE|||||||
33780906|NCT06475703|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Randomisation: Mixed-block 1:1 randomisation stratified by site and sex managed by Derby CTSU.~Intervention: The intervention group will use the AI enabled platform with the new AI module for 30 days after surgery in addition to standard post-operative wound follow-up care for 60 days after surgery. Participants will be asked to submit images and information every 7 days post operatively, up until 30 days. Participants can also submit an image during the 30 days whenever they have a concern.~Control: The control group will receive standard post-operative wound follow-up care for 60 days after surgery."||||
33780907|NCT03506269|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33780908|NCT06696638|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33780909|NCT02028910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780910|NCT02107274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780911|NCT06066424|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780912|NCT00329303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780913|NCT05714839|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Click here to enter text.|||||
33780914|NCT02528955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780915|NCT04429880|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participant will receive the same dose of oxytocin 17 micrograms via a 10 minute intravenous infusion||||
33780916|NCT03937271|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33780917|NCT02651402|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914901|NCT02796391|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33780918|NCT00591747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34086832|NCT04019639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780919|NCT03639675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086833|NCT05767385|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional Research Design||||
33780920|NCT04535882|||COHORT||PROSPECTIVE|||||||
34086834|NCT01353534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086835|NCT00329316|RANDOMIZED|PARALLEL||||NONE||||||
33780921|NCT06570785|||COHORT||PROSPECTIVE|||||||
33780922|NCT05002478|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center randomized controlled study||||
33780923|NCT04727710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33780924|NCT05408650|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914902|NCT02388022|||CASE_ONLY||RETROSPECTIVE|||||||
33914903|NCT05149248|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a mixed methods study combining public health interventions offering primary and secondary prevention of HPV to populations highly vulnerable to these health problems with evaluation of the interventions in a 12-month follow-up. In addition, the study includes qualitative interviews that will undergo systematic analysis on the perceptions, meanings, and individual experiences of the intervention, within the study groups.||||
33914904|NCT02964286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34086836|NCT05901220|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086837|NCT01799941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086838|NCT05998967|RANDOMIZED|PARALLEL||OTHER||NONE||Internet-based instruction in MRP in a self-directed or supported manner||||
34086839|NCT03163732|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"* Arm A: Tumor-based genomics according to the 324 cancer-related genes Next Generation Sequencing (NGS) panel from Foundation One (FOne panel).~* Arm B: Tumor-based genomics according to the 87 cancer-related genes NGS panel performed at Centre Leon Berard Unité de Caractérisation Tumorale (CONTROL panel).~Both panels will be performed concomitantly for all patients using the same patient tumor specimen."||||
33780925|NCT02106767|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33780926|NCT05590910|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled approach will explore the effects music has on stress and anxiety levels and academic performance among undergraduate nursing students.||||
33780927|NCT02034435|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34086840|NCT03299985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blinded randomized clinical trial|t|f|t|f
33780928|NCT06691932|||COHORT||PROSPECTIVE|||||||
33780929|NCT04205032|NA|SINGLE_GROUP||OTHER||NONE||||||
33780930|NCT02668835|||COHORT||RETROSPECTIVE|||||||
33780931|NCT00393627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780932|NCT06132919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel-group, Randomized, Double-blind|t|f|t|t
33914905|NCT05674045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914906|NCT00683475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914907|NCT05125536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33914908|NCT06249256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914909|NCT04880538|||COHORT||PROSPECTIVE|||||||
33914910|NCT04823208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33780933|NCT04181775|||CASE_ONLY||RETROSPECTIVE|||||||
33780934|NCT00987792|||COHORT||PROSPECTIVE|||||||
33914911|NCT02299063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914912|NCT02084784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914913|NCT06430112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914914|NCT02521961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33914915|NCT04467177|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33914916|NCT05294211|NA|SINGLE_GROUP||OTHER||NONE||||||
33995466|NCT04773600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995467|NCT04893408|||OTHER||RETROSPECTIVE|||||||
33995468|NCT06543303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked investigational product.|Double-masked, randomized, parallel|t|t|t|t
33995469|NCT00881569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995470|NCT06261294|||CASE_CONTROL||PROSPECTIVE|||||||
33995471|NCT04620057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995472|NCT04394806|||COHORT||PROSPECTIVE|||||||
33995473|NCT02241577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995474|NCT05138094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995475|NCT06134453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham reiki will be applied by a nurse who has not received reiki training. He will hold his hands in accordance with the Reiki protocol in the specified chakra areas of the patient for the specified time.|Reiki, Sham Reiki, Control Group|t|f|f|f
33995476|NCT05865652|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33995477|NCT03018990|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995478|NCT01032213|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995479|NCT03026153|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33995480|NCT06596889|||COHORT||PROSPECTIVE|||||||
33780935|NCT03923387|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized parallel controlled trial, in which treatment is conducted simultaneously for both the test group and the control group, so that potential differences influencing the outcome measures between both groups can be minimized.||||
33780936|NCT04467957|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33780937|NCT05365074|||CASE_ONLY||RETROSPECTIVE|||||||
33780938|NCT05518825|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33780939|NCT04430517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33780940|NCT05636436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33780941|NCT06688708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation concealment Participants and Investigators were blinded.|Intervention 1: Use vibrating foot orthosis with tactile stimulation Intervention 2: Use vibrating foot orthosis without tactile stimulation|t|f|t|f
33780942|NCT06698198|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33780943|NCT04217785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33780944|NCT04207255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780945|NCT05147805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780946|NCT02001090|||CASE_ONLY||PROSPECTIVE|||||||
33780947|NCT05965128|||CASE_ONLY||PROSPECTIVE|||||||
33780948|NCT05161715|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label||||
33780949|NCT04381897|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33780950|NCT01056562|||CASE_ONLY||PROSPECTIVE|||||||
33780951|NCT00027612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780952|NCT04679285|||COHORT||CROSS_SECTIONAL|||||||
33780953|NCT02793882|||CASE_ONLY||PROSPECTIVE|||||||
33780954|NCT06682624|||COHORT||PROSPECTIVE|||||||
33780955|NCT04805645|||COHORT||RETROSPECTIVE|||||||
33780956|NCT05585242|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding will not be implemented as condition assignment through randomization will be obvious to both the participants and the primary investigator. Participants will be provided with an introduction and rationale for the respective condition they are assigned to. Participants in the waitlist control condition will be given the opportunity to enroll in the intervention after completing the follow-up measures.|Eligible participants will be randomized either to the ACT conditions or to the waitlist control condition. Randomization will occur using a 1:1 allocation ratio and random block sizes to ensure comparable condition sizes while minimizing the ability to predict condition assignment.||||
33780957|NCT02390297|||OTHER||PROSPECTIVE|||||||
33780958|NCT05873842|||COHORT||PROSPECTIVE|||||||
33780959|NCT01033643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33780960|NCT06410443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780961|NCT06334744|||COHORT||PROSPECTIVE|||||||
33780962|NCT06667856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33780963|NCT00821236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780964|NCT00672152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780965|NCT02928939|||OTHER||RETROSPECTIVE|||||||
33780966|NCT06528496|NA|SEQUENTIAL||TREATMENT||NONE||||||
33780967|NCT01733134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780968|NCT03695289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780969|NCT01902901|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33995481|NCT05451264|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The treatment having been received previously in the PREMILOC trial, no one knows which treatment the patients received.|Descriptive cross-sectional study of the subjects included in the double-blind, monocentric randomized controlled trial (children included and followed up at the Robert Debré hospital in the PREMILOC trial): follow-up of these children approximately 10 years later on vascular parameters|t|t|t|f
33995482|NCT06299995|||CASE_ONLY||CROSS_SECTIONAL|||||||
33780970|NCT05929937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be assigned to receive 5 tablets of Oxycodone (5mg) or none||||
33780971|NCT03541811|||COHORT||CROSS_SECTIONAL|||||||
33780972|NCT03382821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each subject will be randomized into a group assignment in a 1:1 manner, #1 or #2, as outlined in the Methods section|Prospective, randomized, comparative trial|t|f|f|f
33780973|NCT03679130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||FitMum RCT is designed as an open-labeled single-site three-arm randomized controlled trial, including 220 pregnant women no later than gestational age week 15+0 days. Included women will be randomized in a 2:2:1 ratio to receive a structured supervised exercise training (EXE) intervention, receive a motivational counseling intervention supported by health technology (MOT), or a control group receiving standard treatment (CON), respectively. The participants in the EXE and MOT groups continue in the physical activity intervention as long as their pregnancy allows and ideally until delivery, in total approximately six months. Collection of data for assessment of the primary outcome will take place from randomization (one week after inclusion) to GA week 28+0-6 and will be measured by a commercial activity tracker. Secondary outcomes will be examined at Nordsjaellands Hospital six times during the study period. Time frames and methods for assessment of outcomes are specified below.||||
33780974|NCT06003101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33780975|NCT05118932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All students will be receiving the same single intervention.||||
33780976|NCT04833140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780977|NCT02519296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33780978|NCT06252675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995483|NCT04802655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33995484|NCT02273492|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995485|NCT02763345|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33995486|NCT05016986|||COHORT||RETROSPECTIVE|||||||
33995487|NCT06006273|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995488|NCT04061746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995489|NCT06026163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Preparation of caffeine and placebo will be performed by a designated pharmacist who is not part of the study. Parents and investigators will be remained blinded to the administered medications throughout the study period.||t|t|t|t
33995490|NCT00260897|||DEFINED_POPULATION||OTHER|||||||
34086841|NCT01292902||PARALLEL||||NONE||||||
34086842|NCT05397418|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two-arm parallel unblinded randomised design||||
33780979|NCT03661554|NA|SINGLE_GROUP||TREATMENT||NONE|Clinical study of BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma (single center, single arm, open clinical study)|In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5 x 106 / kg, 1 x 107 / kg and 1.5 x 107 / kg, were divided into three groups.||||
33780980|NCT00098943||||TREATMENT||NONE||||||
33780981|NCT06200571|||CASE_CONTROL||PROSPECTIVE|||||||
33780982|NCT01562743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780983|NCT04872959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33780984|NCT00221130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33780985|NCT04269070|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Flow-mediated dilation outcome: Images that are obtained will be analyzed by a blinded researcher using a previously validated, edge-detection software|This is a crossover trial where study participants will experience two conditions following a baseline usua behavior conditions. All study participants will experience each of the conditions: a standing condition, and a light intensity physical activity (LPA) intervention.|f|f|f|t
33780986|NCT06528769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780987|NCT04581590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind|This is a sham-controlled, double-blind randomized multicentric clinical trial will analyze patients with a confirmed diagnosis of Parkinson disease who were subjected to tDCS associated with dual-task motor training and cognitive tranining|t|t|t|f
33780988|NCT04354311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Patients under general anesthesia during the procedure|Prospective, interventional, analytical, monocentric, piloted study||||
33995491|NCT05337241|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.||||
33995492|NCT05017935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995493|NCT06627400|||OTHER||CROSS_SECTIONAL|||||||
33995494|NCT03954483|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33995495|NCT04672044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Feasibility of a double-blind sham-controlled intervention|t|t|t|t
33995496|NCT00249197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995497|NCT04403035|||COHORT||PROSPECTIVE|||||||
33692104|NCT06744309|RANDOMIZED|FACTORIAL||PREVENTION||NONE|No, the study does not involve masking (blinding). Due to the nature of the interventions-cool roof installation and heat literacy education-it is not possible to blind the participants or the field team members (including researchers). However, the random selection and assignment of participants to intervention and control groups will be conducted by a statistician who is not part of the research team, ensuring an unbiased allocation process.|The study uses a 2 x 2 factorial design to evaluate the effectiveness of cool roofs and heat literacy education in mitigating extreme heat impacts in rural Malaysian communities. Participants, randomly selected from the SEACO database, will be divided into four groups: both interventions, cool roof only, heat literacy only, and control. Cool roofs involve painting roofs with UV-resistant white paint to reduce heat absorption, while heat literacy includes 8-12 weeks of education on heat awareness and personal cooling strategies. Data will be collected at baseline, 3, 6, and 12 months through surveys, physical measurements, and Garmin Vivosmart 5 wearable sensor and SwitchBot meter. The primary endpoints are indoor temperature, physical activity (step count), glycemic control (HbA1c) and sleep duration. The study aims to develop an evidence-based, culturally sensitive community heat adaptation program to improve heat resilience in rural Malaysia.||||
33995498|NCT01076491|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33995499|NCT00506831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995500|NCT03922763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995501|NCT03701945||SEQUENTIAL||TREATMENT||NONE||156 patients with COPD will be followed monthly for a year and their lung microbiota and clinical data will be analysed. Community-based PR will be delivered to 56 patients. Data will be collected before, at 3 weeks, after PR and at 6 months to assess the feasibility and effects of PR.||||
33995502|NCT06485557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Prospective Cohort Study|t|t|t|f
33995503|NCT00109512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995504|NCT04565587|NA|SINGLE_GROUP||TREATMENT||NONE|Analyisis of the therapeutic effect of the viscosities will be performed in a codified manner by a researcher.|All the participants will be assigned to the same intervention.||||
33692105|NCT04333771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995505|NCT05098743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995506|NCT02528279|NA|SINGLE_GROUP||OTHER||NONE||||||
33692106|NCT03427060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692107|NCT05683392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692108|NCT04732117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780989|NCT06696703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33780990|NCT05080920|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants receive Rosmalip® capsule or Placebo tablet matching Rosmalip® orally once daily for 16 weeks.|t|t|t|f
33780991|NCT03905811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780992|NCT06698055|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled resistance exercise intervention study|f|f|f|t
33780993|NCT02040233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33780994|NCT00568347|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33780995|NCT02809911|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33780996|NCT04599452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33780997|NCT06366893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33780998|NCT01287338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33780999|NCT06414902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781000|NCT05604235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trial|t|f|t|t
33781001|NCT03112278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both patient and the evaluators that will asses the performance of the restorations are unaware about the type of material used to fabricate the occlusal veneers||t|t|f|t
33781002|NCT01641003|||||PROSPECTIVE|||||||
33781003|NCT06688136|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33781004|NCT05890911|||COHORT||PROSPECTIVE|||||||
33781005|NCT03393910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995507|NCT03373643|NA|SINGLE_GROUP||SCREENING||NONE||||||
33995508|NCT05082805|||COHORT||PROSPECTIVE|||||||
33995509|NCT04032418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086843|NCT04523376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086844|NCT04969289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessments will be electronic. If assessed via phone call, outcome assessors will be blinded to study arm.|Intervention participants receive the Dr. Eric program. Control participants will receive the standard of care.|f|f|f|t
33692109|NCT04482309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is Open-Label Study.|This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer), B) any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer), C) HER2 IHC 2+ or 1+ endometrial cancer, D) HER2 IHC 2+ or 1+ ovarian cancer, and E) HER2 IHC 2+ or 1+ cervical cancer.||||
33692110|NCT04383119|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Not applicable (open label study)|"multicenter, randomized, open-label, two arms with crossover. Patients will be randomized to receive Trabectedin (arm A) or Gemcitabine (arm B).~In case of progressive disease (PD) or unacceptable toxicity during the assigned treatment, the patient will switched to the other arm"||||
33692111|NCT06163651|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692112|NCT05316129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692113|NCT02669069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692114|NCT06582589|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized open label pre-market clinical investigation||||
33692115|NCT06419582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692116|NCT06377852|RANDOMIZED|PARALLEL||TREATMENT||NONE||500 patients will be enrolled, 250 per arm (Arm 1 being indicated dose, Arm 2 being titrated dose).||||
33692117|NCT03898960|||COHORT||PROSPECTIVE|||||||
33692118|NCT04572763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692119|NCT06683482|||COHORT||PROSPECTIVE|||||||
33692120|NCT05533216|||COHORT||OTHER|||||||
33692121|NCT04654650|||COHORT||PROSPECTIVE|||||||
33692122|NCT05665374|||COHORT||PROSPECTIVE|||||||
33692123|NCT05061550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692124|NCT02933970|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33692125|NCT06403111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692126|NCT03621592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study and products, investigator blinding is unrealistic and subject blinding is unlikely. Research staff will avoid naming the dressing or suggesting the assignment to the subjects. However, an independent monitor with experience in treating wounds will be blinded to the treatment assignment and will confirm healing outcomes based on images.||f|f|f|t
33692127|NCT05756621|||COHORT||RETROSPECTIVE|||||||
33692128|NCT05501912|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will be conducted in two stages:~Dose escalation stage: To determine MTD/RP2D and evaluate the safety and tolerability of ABM-1310 monotherapy.~Dose expansion stage: To further determine RP2D and evaluate the preliminary efficacy of ABM-1310 monotherapy."||||
33692129|NCT04549246|||COHORT||PROSPECTIVE|||||||
33692130|NCT05868213|||COHORT||PROSPECTIVE|||||||
33692131|NCT06743841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, parallel, double-blind, 8-week nutritional intervention trial|t|f|t|f
33692132|NCT05587036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators, and personnel involved in data analyses are blinded to the intervention. Unblinding occurs after all data has been collected and analysed.||t|f|t|t
33692133|NCT06213545|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086845|NCT01493622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692134|NCT06040086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995510|NCT02331563|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33995511|NCT02145273|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are 3 conditions that will be followed for up to 2 years: control, intervention and comparison. Randomization is by site. Half the sites are control half are intervention. all possible subjects are screened for depression. if the subject is depressed they are invited in to control or intervention based on site, all non depressed subjects are invited into the comparison.||||
33995512|NCT06032741|||COHORT||RETROSPECTIVE|||||||
33995513|NCT00705666|||COHORT||PROSPECTIVE|||||||
33995514|NCT01783535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995515|NCT03829670|||CASE_CONTROL||PROSPECTIVE|||||||
33995516|NCT06559917|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33995517|NCT00261391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995518|NCT02042859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692135|NCT06744946|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||comparing between two groups of thirty patients each,the first group will include talc poudrage pleurodesis and the second include chest tube injection of a mixture of bleomycin and tranxemic acid||||
33692136|NCT06710132|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692137|NCT06271018|||COHORT||PROSPECTIVE|||||||
33995519|NCT05651243|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33995520|NCT03552003|||COHORT||PROSPECTIVE|||||||
33995521|NCT02624297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995522|NCT00942838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995523|NCT02873832|||||RETROSPECTIVE|||||||
33995524|NCT06561451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995525|NCT00193960|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33995526|NCT06628050|||COHORT||OTHER|||||||
33995527|NCT00940563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086846|NCT05096715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086847|NCT04393727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086848|NCT00900562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086849|NCT05812404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086850|NCT03625128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086851|NCT01793506|||COHORT||PROSPECTIVE|||||||
34086852|NCT04704050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086853|NCT04753515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995528|NCT02726360|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995529|NCT00425308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995530|NCT04503447|||OTHER||CROSS_SECTIONAL|||||||
33995531|NCT00989950|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33995532|NCT00087529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995533|NCT03821974|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33995534|NCT06039306|RANDOMIZED|PARALLEL||TREATMENT||NONE||After consented, participants will be randomized into two groups: the intervention group and conventional group during consultation in multidisciplinary clinic.||||
33995535|NCT06154083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995536|NCT04876001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During the trial, the data collector will be blinded to the random assignment.||f|f|f|t
33995537|NCT03412058|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995538|NCT03553979|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stress management program (SM) Stress management and Buddy program (SM-B)||||
33692138|NCT06005168|RANDOMIZED|PARALLEL||OTHER||NONE|This is open label|The current model for dosing the drug cefazolin includes the selection of 2 grams if the individual weighs less than 120 kg and 3 grams if they weigh 120 kg or more. The morphomic-based model defined the choice of 2 grams versus 3 grams of cefazolin based on kidney function and body depth.||||
33995539|NCT01602575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995540|NCT03131895|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995541|NCT06626737|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33995542|NCT05025137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33692139|NCT06379932|||COHORT||PROSPECTIVE|||||||
33692140|NCT02969707|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind sham vs. real rTMS; data analysts blind to group assignment; subjects debriefed on their guess about sham vs. real - no better than chance||t|t|t|t
33692141|NCT05649137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692142|NCT05655520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692143|NCT05359328|NA|SINGLE_GROUP||OTHER||NONE||||||
33692144|NCT05664113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692145|NCT05644665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781006|NCT03831438|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, uncontrolled, non-randomized study, escalating doses of study drug in sequential patient cohorts||||
33781007|NCT05196737|NA|SEQUENTIAL||TREATMENT||NONE||||||
33781008|NCT02141581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995543|NCT05496920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Scan reviewers will be masked to dose and scan reconstruction method.|Patients will receive first a standard of care PET/CT and then an additional low dose PET/CT. The low dose PET/CT will be reconstructed using a standard CT for attenuation correction (LD-PET/CT) and with a novel CT-less method using transmission data (ultra low dose ULD-PET/CT).||||
33995544|NCT01685762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995545|NCT01501448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995546|NCT02654145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995547|NCT05255393|||COHORT||PROSPECTIVE|||||||
33995548|NCT06476093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995549|NCT04693533|NA|SINGLE_GROUP||OTHER||NONE||||||
33995550|NCT02404753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086854|NCT00515996|||CASE_CONTROL||PROSPECTIVE|||||||
33995551|NCT01978925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995552|NCT06468254|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995553|NCT03930732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995554|NCT04443998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995555|NCT04178122|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995556|NCT00828321|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995557|NCT05069571|||CASE_CROSSOVER||PROSPECTIVE|||||||
33995558|NCT03563833|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995559|NCT05244213|NA|SINGLE_GROUP||TREATMENT||NONE||A Simon two-stage design was applied. Primary endpoint for this study was MPR. The unacceptable response rate for MPR was less than 10% and desirable response rate was 30%. The error rate for alpha was set as 0.05 and 0.1 for beta. The Optimal assay was chosen and at least 35 patients should be enrolled to meet adequate statical power. 18 patients would be enrolled in stage I and at least 2 patient achieved MPR were required to proceed stage II enrollment. Overall, if 6 achieved MPR out of 35 patients, the study would be determined as positive.||||
33995560|NCT04154592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized|f|t|f|f
34086855|NCT05778565|NA|SINGLE_GROUP||TREATMENT||NONE||Extraocular muscle procedure||||
33995561|NCT06154408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33995562|NCT00873587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086856|NCT03962829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The research will be double blind; both placebo and mCPP will be presented in an identical capsule, therefore the participants and researchers do not know which treatment the participants will receive. A qualified pharmacist will follow standard operating procedures to encase the pharmacy prepared medications in a gelatine capsule in order to match the size and the appearance of the placebo. An independent researcher will prepare counterbalanced randomisation in advance.|counter-balanced, double-blind, placebo-controlled, crossover, within-subject design|t|t|t|f
34086857|NCT00695019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086858|NCT03451045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multicenter, double-blind, randomized, placebo-controlled, parallel group study.|t|f|t|f
33995563|NCT05361252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This trial had a randomised study design with simple randomisation and a fixed allocation ratio (1:1 to the low-SVV group or high-SVV group). The patients were blinded to the randomisation and allocation.|t|f|f|f
33995564|NCT01576458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33995565|NCT00834873|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995566|NCT06623227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, all care providers, investigators and outcome assessors are blind to treatment status, as well as patients and family. Three investigators, who have no direct contact with patients and families, are responsible for managing the study procedures or treatments. Another investigator, who is not involved in assessing the outcomes, interacts with families to answer any questions regarding the trial or medical issues. This investigator also ensures that the outcome assessors are not influenced by any contact with families between the assessment periods (0, 6, and 12 weeks). Families are asked to refrain from discussing their experiences and the trial outcomes on social media.|Each patients treated with Risperidone and Behavior Therapy as maintanence therapy will divided into a controled group which receive plasebo and the other as intervention group which received Vitamin E (150-200 IU/d) and C (100-200 mg/d) for 3 months. Patients are assessed at T0, T6 and T12 wk. Administration of active compound and placebo is in double-blind.|t|t|t|t
33995567|NCT04569773|||COHORT||PROSPECTIVE|||||||
33692146|NCT04799275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995568|NCT01698645|||COHORT||PROSPECTIVE|||||||
33995569|NCT02736123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086859|NCT03371550|NA|SINGLE_GROUP||TREATMENT||NONE||This was a prospective, open-label, multicentric, phase II study.||||
34086860|NCT00706563|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33692147|NCT06150183|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692148|NCT02211859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692149|NCT06113016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This is a double-blind study with respect to study agent. Because participants cannot be blinded to exercise training, the outcomes assessor (but not the physicians or participants) will be blinded to the training status of participants.||t|f|t|t
33692150|NCT06309966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692151|NCT06445062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086861|NCT04349215|||CASE_ONLY||PROSPECTIVE|||||||
33692152|NCT04318548|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blinded study. Recipients \& study evaluators will be unaware of vaccine administered.||t|t|t|t
33692153|NCT03940950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781009|NCT02138513|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33781010|NCT01857453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781011|NCT03931603|||COHORT||RETROSPECTIVE|||||||
33781012|NCT06102902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781013|NCT01068054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781014|NCT06380166|||CASE_ONLY||PROSPECTIVE|||||||
33781015|NCT05640128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781016|NCT04428164|||OTHER||PROSPECTIVE|||||||
33781017|NCT02209961|||COHORT||PROSPECTIVE|||||||
33781018|NCT04123509|||COHORT||CROSS_SECTIONAL|||||||
34086862|NCT03578042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086863|NCT05408364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Individuals and doctor were blinded to the study groups allocation. Before statistical analysis, the blind study coordinator broke the code to allocate the indivuals to the groups.||t|t|f|f
34086864|NCT04641650|||COHORT||PROSPECTIVE|||||||
34086865|NCT05518721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086866|NCT04941989|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33692154|NCT05984368|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Single-dose and multi-dose, dose escalation, placebo-controlled study|t|t|t|t
33692155|NCT01016704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33692156|NCT04700111|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33781019|NCT02481882|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33781020|NCT06546696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is cluster-randomized trial, where we anticipate randomizing 50 community centers and enrolling 750 children (15/center).|f|f|f|t
33781021|NCT04572542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781022|NCT01446003|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33781023|NCT02335021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33781024|NCT05468489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781025|NCT05796791|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
33781026|NCT01783457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781027|NCT00146211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33781028|NCT05209399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33781029|NCT00483912|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33781030|NCT01883765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781031|NCT06658522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781032|NCT06249711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33781033|NCT04058392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781034|NCT06614478|||COHORT||PROSPECTIVE|||||||
33781035|NCT01026415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781036|NCT06262334|NA|SINGLE_GROUP||OTHER||NONE||||||
33781037|NCT00449423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33781038|NCT05046834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781039|NCT05587712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781040|NCT06282770|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants in this study will not be told which belt is the sham diode brace or which is the functional diode brace. The assessor of the study will also be blinded to which belt each subject has, and data will be analyzed blindly based on patient ID alone.|Patients will come into clinic for consultation and enrollment in the study. They will have their first study visit where they will be given either and laser diode brace or a placebo brace. They will follow up with the physician after 2 weeks and then at 3, 6, 9 months and at 1 year to evaluate function and symptoms .|t|f|t|t
33781041|NCT01682538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781042|NCT03330158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781043|NCT06588205|||COHORT||OTHER|||||||
33781044|NCT04612595|||COHORT||RETROSPECTIVE|||||||
33781045|NCT06647485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781046|NCT00716573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781047|NCT05429255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Person performing outcome assessments will not know which group the patient is assigned. Participant cannot be blinded given nature of intervention.|Two parallel groups.|f|f|f|t
33781048|NCT06201065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781049|NCT00661908|||COHORT||CROSS_SECTIONAL|||||||
33781050|NCT06536751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33781051|NCT06566482|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33781052|NCT04569279|RANDOMIZED|PARALLEL||TREATMENT||NONE||"all patients will receive a weight-adjusted dose of low molecular weight heparins (LMWH) immediately after the diagnosis of (CVT) for several days as needed. Subjects will be randomly assigned to one of the two oral anticoagulation treatment groups (Rivaroxaban (R) group and Warfarin (W) group) when they can take oral medications.~Subjects will be followed up monthly for 6 months to evaluate primary and secondary outcomes."||||
33781053|NCT06610370|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33781054|NCT05193942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants (and their relationship partner) will not know in advance which arm (intervention, control) assigned to in the trial from randomization.|4-month randomized controlled trial with an informational control condition|t|f|f|f
33781055|NCT05317689|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33781056|NCT05613036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781057|NCT03711838|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33781058|NCT02369523|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781059|NCT04388852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781060|NCT06522867|NA|SINGLE_GROUP||OTHER||NONE||||||
33781061|NCT04455724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Given the physical differences in the negative pressure wound therapy systems compared to standard sterile dressings, patient participants and care providers will not be able to be blinded. Ultrasound evaluators and statisticians, however, will be.||f|f|t|t
33781062|NCT06365047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|t|f
33781063|NCT02580266|||COHORT||PROSPECTIVE|||||||
33781064|NCT05731141|||COHORT||PROSPECTIVE|||||||
33781065|NCT03135353|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|t|f
33781066|NCT00124982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781067|NCT05119855|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781068|NCT05769374|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||In this experiment, experiment group 1 is AVG with parents' participation, that is, the experiment object is accompanied by parents to complete the experiment, and experiment group 2 is to complete the experiment task by themselves under the supervision of parents. The control group did not undergo any AVG intervention and maintained the same physical activity as usual.|t|t|t|t
33781069|NCT02721199|||COHORT||PROSPECTIVE|||||||
33781070|NCT06254599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781071|NCT01644123|||COHORT||PROSPECTIVE|||||||
33781072|NCT05416749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781073|NCT03461042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781074|NCT04096365|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781075|NCT04042467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"All Greenlight Plus personnel that are in a position to change the study protocol or its implementation in study participants should be blinded to information that may allow them to do so, from when the study starts until the study ends, with specific exceptions. This means that all investigators and study staff should be blinded to study data aggregated by study arm that have the potential to impact the study's outcome.~The study statistician and programmers s/he designates will be unblinded to post-randomization outcome, mediator, moderator and process data for the purposes of generating DSMB reports.~The study statistician will remain objective when carrying out the activities of conducting the trials - preparing randomization schemes, processing of the data, cleaning and editing the data, preparation of analyses/reports of outcome, mediator, moderator and blinded process data, and transmitting those data to the DSMB."||f|f|t|t
33781076|NCT01641861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33781077|NCT05926791|||COHORT||PROSPECTIVE|||||||
33781078|NCT03519802|||COHORT||PROSPECTIVE|||||||
33781079|NCT04688021|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33781080|NCT00915850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995570|NCT03396939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Assessments of the study population are performed at baseline, at the end of week 3, at week 12 upon completion of the intervention. A blinded therapist, not involved in the project, will perform all the testing."|"The study is a two-step trial: first with the feasibility trial in a cohort of stroke patients regardless of location and temporal evolution then followed by a pilot randomized controlled study (RCT).~The feasibility study will include 30 stroke patients with reduced arm and hand functions to explore and establish a target group for whom the intervention may be best suitable in terms of compliance and improvement of perceived use.~The pilot RCT will include 30 first-time stroke patients with reduced arm and hand functions. The experimental group (15 patients) will receive an orthotic device for use during the exercises, while the control group (15 patients) will not. Both groups will receive the same amount of a study-specific training program."|f|f|f|t
33995571|NCT00994058|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33995572|NCT03222921|||COHORT||PROSPECTIVE|||||||
33995573|NCT04404439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be assigned to a study group by chance (like a coin flip) rather than by a medical decision made by the researchers. There are three arms in the study (treatment group 1 which consists of nortriptyline + topiramate, treatment group 2 which consist of verapamil + paroxetine, and a placebo group), and participants enrolling in the trial will be randomly assigned in a 1:1:1 fashion to one of the arms. The participant will remain in the same arm for the duration of the study (8 weeks). There may be multiple participants in each arm who are undergoing the study at the same time (parallel model).|t|f|t|t
33995574|NCT03359863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086867|NCT05776992|RANDOMIZED|PARALLEL||OTHER||SINGLE|Treatment and assessment in the study was performed by different physiotherapists.|Prior to and following the eight-week application, evaluation was conducted|f|f|t|f
34086868|NCT04643886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086869|NCT00931424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086870|NCT02035124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086871|NCT06274827|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will complete each stage in a randomized order.||||
34086872|NCT04400318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086873|NCT01668797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086874|NCT05494528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086875|NCT03153670|NA|SINGLE_GROUP||OTHER||NONE||||||
34086876|NCT05915468|||COHORT||PROSPECTIVE|||||||
34086877|NCT01162200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086878|NCT00990886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086879|NCT01613833|||COHORT||PROSPECTIVE|||||||
33692157|NCT04669574|||COHORT||PROSPECTIVE|||||||
33692158|NCT02910583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants with confirmed undetectable minimal residual disease (uMRD) in the MRD cohort are triple masked.~Allocation was not randomized for the Fixed Duration (FD) cohort."||t|f|t|t
33692159|NCT05897125|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators will remain masked to treatment group and data|1:1 randomization|f|f|t|f
33692160|NCT06470451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781081|NCT04873713|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33914917|NCT04552379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A prospective, cluster randomised trial of interferon versus standard of care. Index cases will be identified from databases of positive COVID-19 PCR patients from the virology lab,('Fever') clinics, outpatient clinics and hospital emergency room visits for possible COVID-19. Household contacts will be identified via the index cases and will be approached with the consent of the index case.~Randomisation: Households will be randomised to receive IFN or standard of care (as recommended by the Public Health Department).~Trial population: Index cases positively infected with SARS-CoV-2 and their exposed household contacts. Index cases will be recruited from databases of individuals with confirmed COVID-19 identified from COVID-19 ('Fever') clinics and emergency room visits in Santiago, Chile.~Eligibility criteria: Households will be randomised only if cases and at least one treatment-eligible household contact meets all the inclusion criteria and none of the exclusion criteria."|f|f|f|t
33914918|NCT03277300|||COHORT||PROSPECTIVE|||||||
33914919|NCT06555211|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will undergo intervention, which is PET/CT, and control, which is MRI. Each participant will have both intervention and control performed the same day in randomized order.||||
33995575|NCT00217763|RANDOMIZED|PARALLEL||||DOUBLE||||||
33995576|NCT03227276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995577|NCT04562935|||COHORT||RETROSPECTIVE|||||||
33995578|NCT00835705|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995579|NCT00852696|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33995580|NCT00669162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995581|NCT05718687|NA|SINGLE_GROUP||OTHER||NONE||||||
33995582|NCT03489629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995583|NCT06081634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental, multicentre, randomised, test-retest and control group clinical study to evaluate the efficacy of a cognitive reserve enhancement programme in patients with a diagnosis of bipolar disorder or schizoaffective disorder whose first episode has occurred within the last five years. Patients will be randomised into two groups: one group of patients will receive a psychological intervention for cognitive enhancement and another group of patients will receive only the usual pharmacological treatment (TAU).|f|f|f|t
33995584|NCT03856320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor will be blinded to the patient's allocation.|An educational video describing obesity treatment options available in the VA.|f|f|f|t
33995585|NCT01916915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995586|NCT04031690|||COHORT||PROSPECTIVE|||||||
33995587|NCT05800457|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33995588|NCT05154890|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33995589|NCT04037722|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Interventions (saline/LPS) or whey/3-OHB+whey will be given by the investigator, and the echocardiography will be performed by another blinded investigator.|"In a randomized crossover design, eight healthy lean young men will undergo either:~i) Healthy conditions (overnight fast) + whey protein~ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + whey protein~iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + 3-OHB/whey protein"|t|f|f|t
33995590|NCT00712959|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995591|NCT06235723|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33995592|NCT00847535|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995593|NCT01994980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995594|NCT04405479|||COHORT||PROSPECTIVE|||||||
33995595|NCT04574960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995596|NCT05583162|NA|SINGLE_GROUP||PREVENTION||NONE|Masking is not performed in a one-arm study|A cohort of athletes receive intervention in this pilot study, and changes from pre to post intervention are evaluated||||
33995597|NCT02945618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995598|NCT00499759|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995599|NCT00503477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995600|NCT01688011|||COHORT||OTHER|||||||
33995601|NCT03867890|||COHORT||PROSPECTIVE|||||||
33995602|NCT06627686|||COHORT||CROSS_SECTIONAL|||||||
33995603|NCT00292929|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33995604|NCT05169931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995605|NCT04849390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The placebo will be identical to the test product in terms of appearance, constitution of inactive ingredients, packaging, labeling and administration.||t|f|t|t
33995606|NCT00372983|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33995607|NCT03881943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Ticagrelor or Aspirin|t|f|t|f
33995608|NCT01991548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995609|NCT04395729|||OTHER||RETROSPECTIVE|||||||
33995610|NCT01968551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995611|NCT05586880|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Sequentially numbered, sealed, opaque envelopes|Randomized, Crossover Trial|t|t|t|f
33995612|NCT02495207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995613|NCT06449534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995614|NCT02263703|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33995615|NCT05560087|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995616|NCT03789110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995617|NCT01899352|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33995618|NCT00842062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995619|NCT06430632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to either the experimental group receiving robotic gait training or the control group receiving usual care gait training.|f|f|f|t
33995620|NCT04627857|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33995621|NCT05877274|||COHORT||CROSS_SECTIONAL|||||||
33995622|NCT00749762|||COHORT||RETROSPECTIVE|||||||
33995623|NCT00818558|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995624|NCT04426851|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Part 1: non-randomized, fixed-sequence design Part 2: randomized, two-period, two-sequence, crossover design||||
33995625|NCT01243983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995626|NCT05228639|||OTHER||PROSPECTIVE|||||||
33781082|NCT01278537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781083|NCT03682536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914920|NCT02648724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Arms 1-4 comprises part 1 (dose-escalation), which is an as evaluation of 4 different dose levels (DL), 6, 12, 18, and 24 mg/kg. DL data from part 1 is presented as merged in the other sections. This is due to that there were no dose level toxicities reported during the study.~Arms 5-7 comprises part 2 (dose-expansion)."||||
33914921|NCT06129318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914922|NCT04790552|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33914923|NCT01160341|NA|SINGLE_GROUP||SCREENING||NONE||||||
33914924|NCT05265130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33914925|NCT03477617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Parallel Assignment Participants are randomized to two groups; both groups will have an intraoperative minimally invasive cardiac output monitor connected.~In the intervention arm, the anesthesiologist will treat episodes of hypotension using a hemodynamic algorithm based on the information for the cardiac output monitor.~In the control arm, the anesthesiologist will treat episodes of hypotension using standard of care management and will be blinded to the information from the cardiac output monitor. Data from the monitor will be stored for comparison between the arms.~This is a pilot study; therefore, the main objective is to assess feasibility of a future multicenter RCT, based on the following domains: (i) participation rate among eligible patients; (ii) practicality of implementing the study intervention in a clinical setting; (iii) collect descriptive data for differences between the 2 arms; (iv) collect safety data to ensure no harm has resulted from the study protocol"|t|f|f|t
33914926|NCT03840083|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33914927|NCT05542329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914928|NCT00786136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33914929|NCT05099146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914930|NCT04788108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914931|NCT03041909|NA|SINGLE_GROUP||OTHER||NONE||||||
33914932|NCT02572258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995627|NCT01134549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995628|NCT01534845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995629|NCT06627361|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33995630|NCT01874535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995631|NCT03608228|||OTHER||PROSPECTIVE|||||||
33995632|NCT02512900|NA|SINGLE_GROUP||OTHER||NONE||||||
33995633|NCT05237635|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
33995634|NCT02671630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33995635|NCT04955990|NA|SINGLE_GROUP||OTHER||NONE||||||
33995636|NCT04263506|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34086880|NCT06179459|||COHORT||PROSPECTIVE|||||||
34086881|NCT02346747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086882|NCT01612013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086883|NCT03768375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086884|NCT05986110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692161|NCT05267106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study consists of 2 cohorts and participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule.||||
33692162|NCT06745427|||CASE_ONLY||PROSPECTIVE|||||||
33692163|NCT05641155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692164|NCT06286657|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33692165|NCT05846451|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33692166|NCT03391531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Person who prepares the study solution is involved neither in any step of the care of the patient neither in the collection of the study parameters|two groups : treatment group (TAP block with local anesthestic) compared to control group (TAP block with saline)|t|t|t|t
33692167|NCT04544956|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, multi-center, open label exploratory study.||||
33692168|NCT06267430|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The psychologist testing all participants, will be blinded for the allocation of the participants.||f|f|t|f
33692169|NCT05351294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33692170|NCT05930275|||COHORT||PROSPECTIVE|||||||
33692171|NCT04427384|||COHORT||PROSPECTIVE|||||||
33692172|NCT06401330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692173|NCT05070728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692174|NCT04006106|||COHORT||PROSPECTIVE|||||||
33692175|NCT05635643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692176|NCT06175234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692177|NCT06074003|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33692178|NCT05436418|NA|SEQUENTIAL||TREATMENT||NONE||||||
33692179|NCT06684639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692180|NCT05423249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33692181|NCT03213457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781084|NCT04634877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781085|NCT05240040|||COHORT||RETROSPECTIVE|||||||
33781086|NCT03667326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Preeclampsia patients will be recruited and randomized to receive either Aspirin or Placebo (n = 90). Additionally, there will be healthy patients (n = 10) recruited to collect the same set of data for comparison with no intervention.|t|t|f|f
33781087|NCT04170023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781088|NCT02039700|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781089|NCT06616779|||COHORT||PROSPECTIVE|||||||
33781090|NCT02444442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692182|NCT06743789|RANDOMIZED|PARALLEL||TREATMENT||NONE||If participants are randomized to either Arm 1 or Arm 2, participants will be in one of the three groups. Each group will enroll 3 participants, based on a criteria of consecutive enrollment over time. After 6 weeks from the last treated participant in Group 1, there will be a review of safety and efficacy of the study intervention in the treated participants before enrolling participants in the next group. This review will continue until the 3rd participant in Group 3 is enrolled and treated. Subsequently the protocol will then move into the follow up phase.||||
33781091|NCT06465576|RANDOMIZED|PARALLEL||TREATMENT||NONE||Within each pharmaceutical group, the participant will be randomized 1:1 to the intervention being compared; either abrupt withdrawal or gradual withdrawal.||||
33781092|NCT06183047|||CASE_ONLY||PROSPECTIVE|||||||
33781093|NCT05475223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Retrospective review of subjects for Standard of Care for Neonatal jaundice diagnosis and management (SOC) will be compared with a prospective group of subjects with Standard of care for Neonatal jaundice for diagnosis and management + End Tidal Carbon Monoxide management (ETCO)||||
33781094|NCT04752696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781095|NCT04524442|NA|SINGLE_GROUP||OTHER||NONE||||||
33914933|NCT05700747|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33914934|NCT03953261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914935|NCT05248971|||OTHER||RETROSPECTIVE|||||||
33914936|NCT02257164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914937|NCT05006924|||COHORT||CROSS_SECTIONAL|||||||
33914938|NCT00790738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33914939|NCT03360539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Nurse-Family Partnership (NFP) was launched by pediatrician David Olds in the early 1970s in response to the observation that low-income mothers are less likely to engage in positive health and parenting behaviors that are associated with better child development outcomes (Olds et al. 1986). NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.||||
33914940|NCT01518712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33914941|NCT05221099|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33914942|NCT04510350|||COHORT||RETROSPECTIVE|||||||
33914943|NCT04786041|||COHORT||RETROSPECTIVE|||||||
33692183|NCT02185560|||COHORT||OTHER|||||||
33914944|NCT01643759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914945|NCT00361127|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33914946|NCT01801579|||COHORT||PROSPECTIVE|||||||
33692184|NCT04214184|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants with habitual insufficient sleep schedules will complete a 4-week increased sleep duration intervention targeting the recommended 7 hours of sleep per night.||||
33692185|NCT06744413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33692186|NCT05652283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781096|NCT02862054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781097|NCT00483821|||CASE_CONTROL||RETROSPECTIVE|||||||
33781098|NCT05771662|||COHORT||PROSPECTIVE|||||||
33781099|NCT05321628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The therapists and patients will know that they are randomized, but will be informed that the randomization concerns two different types of clinical routines and supervision, and will thus be blind to the true purpose of randomization. Outcome assessors will not be informed that any randomization has occurred.||t|t|f|t
33781100|NCT02724020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781101|NCT05706025|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The EnteroTracker® is a capsule device that includes an absorbent string.||||
33781102|NCT06614816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33781103|NCT06314061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be alerted of dysglycaemia by the Dexcom G7 application, which will be muted. Thus, the alerts on deviating glucose levels will only be given to the care provider (the nursing staff at the ward)|Parallel, 2-group randomised trial blinded for participants|t|f|f|f
33692187|NCT05662397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781104|NCT06477939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914947|NCT02438995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914948|NCT04673617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33914949|NCT04019275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914950|NCT05062941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914951|NCT01661218|||COHORT||PROSPECTIVE|||||||
33914952|NCT00310570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33914953|NCT00651404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34086885|NCT00002791||||TREATMENT||||||||
34086886|NCT00122603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692188|NCT06160908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692189|NCT06256198|||COHORT||PROSPECTIVE|||||||
33692190|NCT03099681|||COHORT||PROSPECTIVE|||||||
33692191|NCT06744452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33914954|NCT03007017|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33914955|NCT01975233|||CASE_ONLY||PROSPECTIVE|||||||
33914956|NCT02352805|||OTHER||PROSPECTIVE|||||||
33914957|NCT04199208|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized two-armed clinical trial|t|t|t|t
33914958|NCT03489616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914959|NCT04649073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33914960|NCT05290649|||CASE_ONLY||PROSPECTIVE|||||||
33914961|NCT03335852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914962|NCT02428530|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33914963|NCT02815241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914964|NCT06441136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914965|NCT03378726|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33914966|NCT03293134|||OTHER||OTHER|||||||
33914967|NCT06365515|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Neither participants nor investigators will know at which time point the participant will receive Levodopa and placebo tablets. The tablets will be prepared by independent members of the university hospital.|The investigators will assess the effects of Levodopa administration on reward-learning using a double-blind randomized cross-over design. In a within-subject design, participants will get both conditions (Levodopa/placebo) at different time points (a few days apart). After drug/placebo administration we will assess cerebral blood flow and functional connectivity at rest (via functional MR imaging) during effort-based decision making task.|t|f|t|t
33914968|NCT03007485|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33914969|NCT02819895|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33914970|NCT04017442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only individual that will know to which group the patient was assigned is the individual on the study team who is drawing up the medication. This individual will have no other role in the assessment or evaluation of the patient.|Double blind, prospective, randomized|t|t|t|t
33914971|NCT02524912|||COHORT|||||||||
33914972|NCT01908959|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33914973|NCT03481127|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33914974|NCT01192750|||OTHER||RETROSPECTIVE|||||||
33914975|NCT01911845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914976|NCT00077610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914977|NCT04093817|||COHORT||PROSPECTIVE|||||||
33914978|NCT05788341|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33914979|NCT04980924|||COHORT||PROSPECTIVE|||||||
33914980|NCT00474162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33914981|NCT00128700|RANDOMIZED|||TREATMENT||NONE||||||
33914982|NCT03990519|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33914983|NCT02074306|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33914984|NCT00094887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33914985|NCT02145741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692192|NCT06047886|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study of CD34 selection for graft versus host disease (GVHD) Prophylaxis using the automated CliniMACS Prodigy Device.||||
33914986|NCT01955850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33914987|NCT06166914|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized clinical trial of patients enrolled sequentially into group A (treatment) and group B (control)||||
33914988|NCT05745116|||CASE_ONLY||PROSPECTIVE|||||||
33914989|NCT05915338|||OTHER||OTHER|||||||
33914990|NCT03052842|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Three dose groups will be enrolled in an ascending dose escalation manner|t|f|f|f
33914991|NCT04183699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33914992|NCT06364982|||COHORT||CROSS_SECTIONAL|||||||
33914993|NCT03474406|||COHORT||PROSPECTIVE|||||||
33914994|NCT05970744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33914995|NCT02858154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33914996|NCT05583981|||COHORT||PROSPECTIVE|||||||
33914997|NCT00437333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33995637|NCT04698473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086887|NCT06550596|RANDOMIZED|PARALLEL||TREATMENT||NONE||"AXOLCAMP is a multi-center, open label, randomized controlled trial to determine the efficacy of dhAM plus SOC versus SOC alone in achieving complete closure of nonhealing diabetic foot ulcers.~over 12 weeks."||||
34086888|NCT02819453|||COHORT||PROSPECTIVE|||||||
33995638|NCT01252953|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995639|NCT06423014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33995640|NCT02730533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33995641|NCT04021511|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33995642|NCT01277276|||CASE_ONLY||PROSPECTIVE|||||||
33995643|NCT00744679|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995644|NCT04938635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995645|NCT06443385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Clinicians will be assigned at random to one of three arms: PDMP legal mandate e-mails, PDMP clinical benefit emails, or a control group.||||
33995646|NCT04422262|||COHORT||RETROSPECTIVE|||||||
33995647|NCT04018404|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995648|NCT02772822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781105|NCT01905865|||COHORT||CROSS_SECTIONAL|||||||
33781106|NCT06697015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are blind.|Randomized Clinical Trial|t|f|f|f
33781107|NCT05543096|||COHORT||RETROSPECTIVE|||||||
33781108|NCT05995171|||CASE_ONLY||PROSPECTIVE|||||||
33781109|NCT05842824|||COHORT||OTHER|||||||
33781110|NCT05168371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995649|NCT00627744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995650|NCT05869721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the baseline assessment, all eligible participants will be allocated randomly in a 1:1 ratio to either (1) experimental group which received yoga programme over a period of eight weeks, or (2) wait-list control group. The research assistant, who is responsible for allocation, is independent from the data collection and analysis, and the intervention. The participants will be reminded not to disclose information related to group allocation to the assessors to prevent possible bias during measurement. All assessments will be performed by an assessor who is blinded to the group allocation and not involved in the delivery of the intervention.|This pilot randomized controlled trial will conduct at a university-affiliated rehabilitation laboratory staring from May 2023 in Hong Kong.|f|f|f|t
33995651|NCT01572662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995652|NCT04584138|||CASE_ONLY||PROSPECTIVE|||||||
33995653|NCT02504450|||CASE_ONLY||RETROSPECTIVE|||||||
33995654|NCT06066749|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33995655|NCT00673842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995656|NCT03599193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Tazarotene and tazarotenic acid plasma concentrations will be determined at a designated laboratory from the blinded samples using a validated bioanalytical method.||f|f|f|t
33995657|NCT03051945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33995658|NCT01379313|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34086889|NCT00300196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086890|NCT01458587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086891|NCT00077818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086892|NCT01867775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086893|NCT05031767|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086894|NCT00003723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692193|NCT05877430|NA|SEQUENTIAL||TREATMENT||NONE||||||
33692194|NCT03834493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study became unblinded in February 2023.||t|f|t|t
33692195|NCT06745362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33692196|NCT04064060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692197|NCT03019679|||CASE_CONTROL||PROSPECTIVE|||||||
33692198|NCT06706947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692199|NCT04262856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692200|NCT05720039|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects undergo nipple-sparing mastectomy (NSM) procedures using the da Vinci SP Surgical System or open NSM||||
33692201|NCT05717907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33914998|NCT04813159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, treating clinician, study investigator and research team analysing the data will be blinded to the treatment allocation. Study intervention will be applied by the research nurse who will not have any further contact with the participant or trial.|Consented participants presenting with STEMI within 24 hours and who fulfil the study's eligibility criteria will be assigned a participant identification number and randomised to receive either RIC or sham control in a 1:1 ratio to ensure equal distribution amongst experimental arm. Randomisation will be conducted via a secure website and will be stratified by recruiting centre and patient stratum to ensure that a minimum of 2 participants in stratum 1 (eligible for thrombolysis and within \<12 hours of MI onset) are recruited for every participant in stratum 2 (ineligible for thrombolysis because they present outside of guideline-recommended time (\<12 hours) but presenting within 24 hours of most severe chest pain onset). The patient, treating clinician, study investigator and research team analysing the data will be blinded to the treatment allocation. Study intervention will be applied by the research nurse who will not have any further contact with the participant or trial.|t|t|t|t
33914999|NCT05273008|||COHORT||CROSS_SECTIONAL|||||||
33915000|NCT04650958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization will be conducted by the Coordination Center of Clinical Trials (CenTrial) in order to keep the researchers managing the data and the statistician blind to group assignment and the study conditions. All the clinical assessments done during the trial period will be double-blind, e.g., neither the patient not the clinician or study personnel involved in the scoring will not be aware of the condition of stimulation. All personnel, except the physician-programmer responsible for the DBS setting, will be blinded to the identity of the parameters. While programming the programmer will not sit face-to-face with the patient, but in another room adjusting the parameter wirelessly with the help of the attending doctor who will inform the programmer of the patient's reaction. The electrical parameters will be tested in all patients which means they all will perceive similar stimulation related sensations during each follow-up.|In this study after having DBS leads implanted successfully, 38 patients will be randomly assigned to either the control or experimental group with a 1:1 allocation. The experimental group will receive continuous DBS stimulation for 3 months, while controls will have sham stimulation for 3 months.|t|t|t|t
33915001|NCT03420716|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Type of yogurt fed is blind for participants and investigators|3 weeks on symbiotic yogurt or control yogurt, with a 3 week wash out period in between. Type of yougurt consumed first is randomized.|t|t|t|t
33915002|NCT03209635|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33915003|NCT05075291|||CASE_ONLY||RETROSPECTIVE|||||||
33915004|NCT02790671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915005|NCT05608317|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The model is a prospective, open, multi-center, interventional, non-comparative investigation with the aim to follow exuding chronic venous leg ulcers over time for 6 weeks according to local standard of care.||||
33915006|NCT00670397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915007|NCT05971004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915008|NCT00000944||||PREVENTION||||||||
33915009|NCT00579501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915010|NCT03746964|||COHORT||PROSPECTIVE|||||||
33995659|NCT03810937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Analysis of the recorded videolaryngoscopic attempts will be performed later by a blinded researcher who was not involved with airway management.|"Participants will be randomized in 2 groups:~* Group sniffing (S): we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.~* Group flat (F): same procedure will be done but starting from sniffing position and the patient will be intubated in flat position."|t|f|f|t
33995660|NCT06560983|||COHORT||PROSPECTIVE|||||||
33995661|NCT02241551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995662|NCT06209749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Control Trial|t|t|f|t
33995663|NCT05031260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995664|NCT02992964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995665|NCT04889898|||COHORT||PROSPECTIVE|||||||
33995666|NCT04310345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995667|NCT06557954|||COHORT||RETROSPECTIVE|||||||
33995668|NCT04084639|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind crossover design||t|f|t|f
33915011|NCT05989490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants were blinded to the results of all measurements and naïve to research hypotheses.~The investigator was blinded to the results of all measurements."|This was a randomized, repeated-measures cross-over study. The interventions consist of two different stretching protocols (e.g., stretching to the point of discomfort and stretching to the point of pain). Subjects were randomized to one of two groups (pain first or discomfort first). Both groups underwent a static stretch protocol consisting of four bouts of thirty-second constant-angle static stretching of the knee flexors with a 20-second rest period between bouts. Subjects were instructed to keep the limb relaxed as the lower leg was passively moved towards extension to the point of discomfort and the point of pain.|t|f|t|f
33781111|NCT04950543|||COHORT||PROSPECTIVE|||||||
33692202|NCT05903495|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|After completion of surgery, participants will be randomly assigned to one of two groups: Group A or Group B. Group A (DBS-ON) will have their stimulator turned on after recovering from surgery. Group B (DBS-OFF) will receive sham stimulation, meaning the stimulator will remain off until Study Week 12 of the outpatient phase, at which time the stimulator will be turned on and left on for the remainder of the study. Group A will continue to receive stimulation and not have the stimulator turned off. participant and assessor will not know which group are assigned to until Study Week 12.||t|f|f|t
33692203|NCT06743659|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"During the first 6 months, the BPA will run in silent mode and will not provide notification to the clinician of record about the potential diagnosis of FH. For the following 18 months, the BPA will run in alert mode during which an on-screen alert will notify the ambulatory care clinician of record that the patient has a definite, probable, or possible diagnosis of FH but has not been recognized as such."||||
33692204|NCT05054010|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33692205|NCT05706129|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692206|NCT03143374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781112|NCT04539041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915012|NCT00357526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915013|NCT05443672|||OTHER||PROSPECTIVE|||||||
33915014|NCT00663455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915015|NCT00740883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915016|NCT02526758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915017|NCT01374776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915018|NCT04435145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915019|NCT02723604|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915020|NCT03231085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33995669|NCT05878080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33995670|NCT06625021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"48 individuals diagnosed with mechanical neck pain were included in the study. The 48 individuals were randomly divided into 4 groups via the Randomizer.org website.~* The first group is the control group(n=12); transcutaneous electrical nerve stimulation, ultrasound and appropriate neck exercises are planned to be applied every day for 4 weeks.~* The second group is the chiropractic group(n=12) and will be applied twice a week for 3 weeks by me, a Bahcesehir University Chiropractic Masters graduate, targeting the lower cervicals.~* Classic hand-wrist exercises group(n=12) such as range of motion, stretching and strengthening were applied to the third group in all directions of the wrist.~* In the fourth group, proprioceptive exercises group(n=12) such as joint approximation, traction and mobilization, similar to the classic hand-wrist exercise group, will be performed every day for 4 weeks."|t|f|f|f
33995671|NCT03280953|||CASE_ONLY||PROSPECTIVE|||||||
33692207|NCT04380129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692208|NCT05703672|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33692209|NCT06483932|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33692210|NCT06282159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692211|NCT05608369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692212|NCT02747303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692213|NCT05621460|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The investigator determining the end of the test (the time to presyncope) will be blinded to the condition.|Each participant will complete the test for every condition (3 tests per participant, order of treatment randomized).|f|f|t|f
33692214|NCT05506904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Statisticians will be blinded to treatment assignment.|Multicentre pragmatic vanguard pilot RCT of the EA tool in invasive ventilated critically ill patients, with and without COVID-19. Individual patients will be randomized (1:1) to intervention (EA tool) or control (standard care).|f|f|f|t
33692215|NCT04653454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692216|NCT04329975|||COHORT||PROSPECTIVE|||||||
33692217|NCT04081896|||COHORT||PROSPECTIVE|||||||
33692218|NCT04318717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692219|NCT06745596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||24 eyes were operated on and divided into two groups. Twelve eyes underwent combined approach and the other 12 eyes have undergone phacoemulsification only|t|f|f|f
33692220|NCT03702686|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33692221|NCT02759744|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33692222|NCT03768063|NA|PARALLEL||TREATMENT||NONE||||||
33692223|NCT06484621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781113|NCT06099821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781114|NCT06453187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781115|NCT03486743|RANDOMIZED|PARALLEL||OTHER||NONE||different sites of participant recruitment will be randomized between the use of an informational video during the survey process and no video. The primary focus of the study is the survey that is designed to collect information about cultural perspectives on LARC in the participants.||||
33995672|NCT05479058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study was double-blinded to treatment assignment until the last subject has reached the primary analysis time point.||t|t|t|t
33995673|NCT04990648|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915021|NCT03412474|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be planned that neither the doctors (investigators) nor the patients' guardians or even children themselves will be aware of the group allocation and drug received. The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection.|comparison of the analgesic effect of adding dexmedetomidine to bupivacaine with the analgesic effect of using bupivacaine alone in bilateral SMB for children undergoing CP repair under general anesthesia.|t|t|t|t
33915022|NCT04669041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915023|NCT04058054|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33915024|NCT02370355|||COHORT||OTHER|||||||
33915025|NCT05834764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915026|NCT03179280|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915027|NCT02144558|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915028|NCT06295016|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|"Prior to the commencement of the experiment and during the experimental period, both the participants and the investigator will be unaware of whether the participants exhibit a good response to compensatory training effects. After the participants complete the entire experimental procedure, they will be grouped post hoc based on their outcomes following the intervention, according to predetermined criteria.~The criteria for determining whether there is a good response to compensatory training effects:~1. Non-response group: Exercise performance during the tapering period (week 7) shows a significant increase compared to post-intervention (week 6) and is higher than pre-intervention (week 3) exercise performance.~2. Response group: Exercise performance during the tapering period (week 7) shows a significant increase compared to post-intervention (week 6) and is higher than the change in exercise performance during normal training (= week 3 - week 1)."|The present study is designed as a prospective intervention and prognostic prediction study, employing a single-subject design with a reversal (ABA) design. This design involves a self-controlled intervention experiment with three phases: baseline training period (A), high-intensity, high-volume training period (B), and reduced training period (A). Subsequently, the study aims to explore predictive factors influencing the presence or absence of favorable compensatory training effects following the intervention.|t|f|t|f
33915029|NCT04081597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind||t|t|f|f
33915030|NCT00783211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915031|NCT01895816|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33915032|NCT03989154|||COHORT||PROSPECTIVE|||||||
33915033|NCT04143620|NA|SINGLE_GROUP||TREATMENT||NONE||Manegment of uncontrolled NVG patients with dense cataract||||
33915034|NCT02694211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915035|NCT00363246|||COHORT||PROSPECTIVE|||||||
33915036|NCT03443843|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33915037|NCT04051151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915038|NCT00465491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995674|NCT03946995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blinded randomized controlled trial in which patients will be randomized into groups by sealed envelope method.|There will be two treatment groups of participants, One group will receive Dry Needling whereas other will receive Graston technique for treatment of Myofascial Trigger points.|t|f|f|f
33995675|NCT01586039|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE||Stratified randomized crossover trial. Participants randomized between CFL and LED conditions stratified by light intensity (50 lux and 90 lux).|t|f|f|f
33995676|NCT02667951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33995677|NCT02947945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995678|NCT03413423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995679|NCT01793584|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995680|NCT01325909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33995681|NCT06122805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomized assignment of study ID number|Randomized|f|f|t|f
33995682|NCT00694408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995683|NCT04065607|||CASE_ONLY||RETROSPECTIVE|||||||
33915039|NCT04434820|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Basic information included age, ethnicity, weight, height, body mass index (BMI).~Full obstetric, medical and surgical history. Informed written consent will be obtained Patients will receive standard preoperative antibiotic prophylaxis Wound dressing will be applied in a sterile fashion after primary closure of the Pfannenstiel incision closure by interrupted PROLENE Polypropylene Sutures The intervention group: placement of a sterile multilayer dressing (wicking fabric, reticulated foam, and occlusive adhesive). The dressing's tubing will then be attached to a (Yuwell 7E-A portable suction unit) that will deliver 125 mm Hg of continuous pressure to the dressing for 4 days.~The comparison group: traditional sterile wound dressing of gauze and tape for 4 days.~Post-operative data including: type of dressing used, postoperative hemoglobin, degree of pain, length of hospital stay, readmission for surgical site infection and the type of the surgical site infection."||||
33915040|NCT02504268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915041|NCT03670316|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either the Algorithm Treatment plus referral to a quitline (AT) or the quitline alone condition (eTAU).||||
33915042|NCT02148822|||COHORT||PROSPECTIVE|||||||
33915043|NCT00628953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33915044|NCT01260363|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33915045|NCT00000585|RANDOMIZED|||PREVENTION||DOUBLE||||||
33995684|NCT01923740|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995685|NCT02722421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995686|NCT04081558|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995687|NCT05509309|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995688|NCT04682951|||COHORT||RETROSPECTIVE|||||||
33995689|NCT00691782|||CASE_ONLY||RETROSPECTIVE|||||||
33995690|NCT05997797|||OTHER||PROSPECTIVE|||||||
33995691|NCT00654186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995692|NCT03145623|||COHORT||RETROSPECTIVE|||||||
33995693|NCT04697173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995694|NCT05289440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915046|NCT05524870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915047|NCT05045924|||CASE_CONTROL||PROSPECTIVE|||||||
33915048|NCT02223455|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33915049|NCT01621152|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33915050|NCT05821621|||COHORT||RETROSPECTIVE|||||||
33915051|NCT01734486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915052|NCT00092066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915053|NCT04881292|||CASE_ONLY||PROSPECTIVE|||||||
33915054|NCT04300062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915055|NCT05782179|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33915056|NCT04772664|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33915057|NCT03195062|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33915058|NCT05380674|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33995695|NCT01674387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995696|NCT03711539|||COHORT||PROSPECTIVE|||||||
33995697|NCT02321943|||COHORT||PROSPECTIVE|||||||
33995698|NCT00829712|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995699|NCT05751447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995700|NCT01942239|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33915059|NCT01382043|||CASE_CROSSOVER||PROSPECTIVE|||||||
33915060|NCT04209777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915061|NCT02019394|NA|SINGLE_GROUP||||NONE||||||
33995701|NCT01264523|NA|SINGLE_GROUP||||NONE||||||
33995702|NCT05853653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind|Randomized controlled quasi-experimental design|t|f|f|f
33995703|NCT01034215|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33995704|NCT06559644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915062|NCT01699620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915063|NCT01610648|||CASE_ONLY||PROSPECTIVE|||||||
33915064|NCT03294928|NA|SINGLE_GROUP||OTHER||NONE||||||
33915065|NCT03365804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995705|NCT00724607|||CASE_CONTROL||PROSPECTIVE|||||||
33692224|NCT06735872|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The study is experimental, descriptive, prospective and monocentric. The design is with two parallel groups where each patient is his own control. That's why there is no control group. There are two groups: one receiving ten minutes of non invasive ventilation and the other one receiving ten minutes of high flow oxygen therapy. After the treatment, each participant will have an additional chest CT to determine lung volumes.~To determine which group the participant is in, we use a randomisation without stratification."||||
33692225|NCT05995002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33692226|NCT05827614|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||BBI-355 single agent dose escalation and expansion, and BBI-355 dose escalation in combination with select targeted therapies.||||
33995706|NCT02901028|RANDOMIZED|CROSSOVER||||NONE||||||
33692227|NCT02332746|||COHORT||PROSPECTIVE|||||||
33692228|NCT06201884|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995707|NCT05168787|||CASE_CONTROL||RETROSPECTIVE|||||||
33995708|NCT01539239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995709|NCT01559363|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33995710|NCT00264108|||||PROSPECTIVE|||||||
33692229|NCT05304936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781116|NCT06556004|NA|SINGLE_GROUP||TREATMENT||NONE||"In this trial, 20 patients will be enrolled and treated with TRIMELVax (subcutaneous). The patients will be recruited from a hospital in the Metropolitan Region: The oncology section of Hospital del Salvador. This center currently treats patients diagnosed with unresectable or metastatic melanoma with checkpoint inhibitors immunotherapy (mainly with Nivolumab).~If a patient withdraws consent to participate in the study (including the use of data and samples already collected) or does not start treatment due to absence or death, he or she will be replaced by another participant until the number of 20 treated participants is completed."||||
33781117|NCT06417905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781118|NCT02994706|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33781119|NCT05452629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In a counterbalanced order, participants completed three conditions that incorporated two 30-minute experimental conditions (i.e., MI or RI) and a control condition (i.e., opened thinking)||||
33781120|NCT01060566|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781121|NCT06697600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized 1:1 to either the UR-GOAL arm or the attention control arm. If the patient has a caregiver that agrees and consents to participate in the study, the caregiver will be enrolled onto the same arm as the patient.||||
33781122|NCT00258479|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33781123|NCT02783105|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33781124|NCT00724061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781125|NCT02981134|||COHORT||PROSPECTIVE|||||||
33692230|NCT04764357|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33692231|NCT05923385|||CASE_ONLY||PROSPECTIVE|||||||
33781126|NCT00137956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781127|NCT02474511|||COHORT||PROSPECTIVE|||||||
33781128|NCT06059053|||CASE_ONLY||PROSPECTIVE|||||||
33781129|NCT05603806|||COHORT||PROSPECTIVE|||||||
33781130|NCT01364220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781131|NCT02109679|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781132|NCT06696820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781133|NCT04643353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781134|NCT03677024|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781135|NCT03992638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth design allowing to assess two types of treatment in the same patient.|f|t|f|t
33781136|NCT00006480||||TREATMENT||||||||
33781137|NCT06614361|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33915066|NCT03408951|||COHORT||PROSPECTIVE|||||||
33915067|NCT04634773|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915068|NCT03635398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33915069|NCT05514652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915070|NCT01941524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915071|NCT01970514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915072|NCT00803010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915073|NCT01930812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915074|NCT01743872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995711|NCT06621784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995712|NCT05548465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995713|NCT03946462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|subjects, caregivers and research team members are blinded while respiratory therapists are unblinded||t|f|t|f
33995714|NCT06043349|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a controlled clinical trial on male androgenetic alopecia. Research subjects will be randomly divided into two groups. The first group will receive a combination therapy of PRP injection and topical 5% minoxidil, while the second group will receive topical 5% minoxidil as monotherapy.||||
33995715|NCT03173651|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||prospective randomized trial||||
33995716|NCT03158077|||CASE_ONLY||RETROSPECTIVE|||||||
33995717|NCT02975856||CROSSOVER||BASIC_SCIENCE||NONE||||||
33995718|NCT01129986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995719|NCT05733585|||COHORT||PROSPECTIVE|||||||
33995720|NCT02451358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995721|NCT04566497|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915075|NCT05874453|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915076|NCT01264094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915077|NCT01912716|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915078|NCT06553950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915079|NCT02607358|||COHORT|||||||||
33915080|NCT04724382|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be unaware of the which educational messages are considered intervention or control. Investigators will not be in contact with participants and will only receive coded data. Outcome assessor will be unaware of treatment allocation of participant.||t|f|t|t
33915081|NCT03775772|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33915082|NCT02367482|||CASE_CONTROL||PROSPECTIVE|||||||
33915083|NCT01290120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915084|NCT06206278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915085|NCT04398199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915086|NCT00620971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915087|NCT06366828|||OTHER||RETROSPECTIVE|||||||
33915088|NCT01012193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33915089|NCT05619562|||COHORT||PROSPECTIVE|||||||
33915090|NCT01547910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915091|NCT02338791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915092|NCT04253977|RANDOMIZED|PARALLEL||PREVENTION||NONE||Healthy Eating \& Active Living Taught at Home during Pregnancy and Postpartum (HEALTH-P2) embeds content related to healthy eating and activity within Parents as Teachers (PAT)'s existing home visits.||||
33915093|NCT00228306|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33915094|NCT02634099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915095|NCT05298696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34086895|NCT04424602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be carried on40 patients with systemic lupus erythematous with lupus nephritis.the age group of patients will be between 20 to50 years.All lupus nephritis patients will be divided randomly into two groups. First group will be 20female patients on lupus nephritis .They will be given oral corticosteroid( 1mg/kg per day) and intra venous cyclophosphamide 500mg once every two weeks for 6months. Second group will be 20female patients on lupus nephritis they will be given oral corticosteroid(1mg/kg per day) and oral mycophenolat 2 to 3mg/kg for 6 months|t|f|f|f
33781138|NCT06696209|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33781139|NCT05877404|||OTHER||PROSPECTIVE|||||||
34086896|NCT02908334|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086897|NCT03998072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will utilise two conditions - intervention and waiting list. Participants on the waiting list will then proceed to the intervention condition.||||
34086898|NCT05385406|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"Allocation to the study arm will be concealed until primary HPV screening by the GeneXpert machine has been performed, in order to ensure that the health care provider enrolling the participant into the study and the participant herself have no a priori knowledge of group assignment.~Detected HPV genotypes will only be revealed to the midwife executing the pelvic examination and treatment if the participant is randomized in the intervention arm (triage by genotyping), in order to know whether to treat the participant or not. If the participant is randomized in the control arm (triage by VIA), the midwife will be blinded to the exact HPV genotype channel(s) in order to avoid influence of treatment.~The pathologist performing histological analysis (gold standard) will be blinded to the study arm and the on-site diagnosis."|National multicentric open-label two-arm randomized controlled trial|f|f|f|t
33781140|NCT05013190|||COHORT||PROSPECTIVE|||||||
33781141|NCT05177081|RANDOMIZED|PARALLEL||PREVENTION||NONE||multi-center, open label, randomized trial||||
33781142|NCT02323997|||OTHER||CROSS_SECTIONAL|||||||
33781143|NCT00562965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34086899|NCT05684770|NA|SINGLE_GROUP||OTHER||NONE||||||
33781144|NCT03076801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator will be blind to participant allocation during chart review at 12 months.||f|f|t|f
33781145|NCT01837563|||COHORT||PROSPECTIVE|||||||
33781146|NCT02926742|||COHORT||PROSPECTIVE|||||||
33781147|NCT02323880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781148|NCT01147770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781149|NCT06103422|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33915096|NCT00316381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915097|NCT03800862|||COHORT||PROSPECTIVE|||||||
33915098|NCT05249816|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33915099|NCT04050098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915100|NCT06186752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research assistant in charge of sending out electronic surveys for data collection will be masked to participants' group allocation.|Subjects will be randomized 1:1 overall to intervention and control using permuted blocks (four) designed according to each alphabetic cluster's assigned nurse coordinator.|f|f|f|t
33915101|NCT01173796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915102|NCT03072641|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33915103|NCT01647659|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33915104|NCT05752773|||COHORT||OTHER|||||||
33915105|NCT04821973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915106|NCT01344837|||COHORT||RETROSPECTIVE|||||||
33915107|NCT06049290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781150|NCT05798728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915108|NCT00001345|||COHORT||PROSPECTIVE|||||||
33781151|NCT05706662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781152|NCT00001061||||TREATMENT||||||||
33915109|NCT05258994|||OTHER||CROSS_SECTIONAL|||||||
33995722|NCT05492032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a one-year parallel design (triple-arm), double-blind RCT. Participants will be randomly assigned to receive either (1) active daily tDCS with computerized executive function training in weeks 0-2, followed by active bimonthly booster tDCS sessions in weeks 3-14, and active monthly booster tDCS sessions in weeks 15-52; (2) active daily tDCS with computerized executive function training in weeks 0-2, followed by sham bimonthly booster tDCS sessions in weeks 3-14, and sham monthly booster tDCS sessions in weeks 15-52, or sham daily tDCS with computerized executive function training in weeks 0-2, followed by sham bimonthly booster tDCS sessions in weeks 3-14, and sham monthly booster tDCS sessions in weeks 15-52.|t|t|f|t
34086900|NCT03727282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086901|NCT05967481|||CASE_CROSSOVER||PROSPECTIVE|||||||
34086902|NCT01574963|||COHORT||PROSPECTIVE|||||||
34086903|NCT04562376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A person with no further involvement in the study will manage the randomization. A research assistant will assign participants with an identification number which will be used during baseline and follow-up assessments to ensure blinding of the assessors. Thus, outcome assessors are blinded for group allocation. Data entry will be executed by a person blinded for group allocation.|This is a two-armed single-blinded randomized controlled trial of high-intensity resistance training in PwMS with fatigue where one group receive training twice a week (group A) and the other group once a week (group B). The randomization procedure will be performed after baseline assessments and will be concealed and based on computer-generated block randomization with block sizes of ten. No stratification will be used. Implementation of the random allocation will be done by means of sequentially numbered sealed opaque envelops.|f|f|f|t
34086904|NCT00293592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086905|NCT05784675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Balanced and randomized controlled cross-over within-subjects design||||
34086906|NCT00348257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692232|NCT05832307|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|Sites will be randomized 2:1 by the study statistician to intervention A vs. usual care. The randomization will be stratified by academic or academic plus community setting. This will ensure that the groups are balanced for site variables that may be correlated with the outcomes of interest. After the first intervention season, the 4 usual care sites and 6 lowest performing intervention sites (lowest change in vaccination rates from their baseline data) will be randomized 1:1 to intervention A vs. intervention B.|The investigators will conduct a cluster SMART to evaluate the effectiveness of an inpatient influenza vaccination program on influenza vaccination rates during hospitalization at 12 U.S. pediatric health systems over 3 influenza vaccination seasons (Study Years 3-5). Sites will be randomized to the standardized influenza vaccination program or usual care in the first intervention season (traditional cluster RCT). Usual care and low performing sites will be re-randomized to the standardized program (intervention A) or the standardized program with an intensified implementation strategy (intervention B) in the second season. Sites will continue their programs in the third season to assess sustainability. The unit of intervention (randomization) is the site (i.e., health system).||||
33692233|NCT06440317|||COHORT||PROSPECTIVE|||||||
33692234|NCT06220604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086907|NCT04698434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||children who underwent day surgery of pediatric circumcision were randomly divided into 3 groups according to the random number table method:0.5mg/kg esketamine group (Group A), 0.75mg/kg esketamine group (Group B) and 1.0mg/kg of esketamine group (Group C), with 30 people in each group.|t|f|f|t
33692235|NCT06410287|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33692236|NCT02008045|||COHORT||PROSPECTIVE|||||||
33781153|NCT04314128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group, prospective cohort study with healthy controls.||||
33781154|NCT01340833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086908|NCT01082471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781155|NCT05691803|NA|SINGLE_GROUP||TREATMENT||NONE||A one arm intervention study with allocation to usual care (Physical activty on Prescription) + an exercise intervention.||||
33781156|NCT01141179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781157|NCT05607966|||COHORT||PROSPECTIVE|||||||
33781158|NCT03320109|||COHORT||PROSPECTIVE|||||||
33781159|NCT02274246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692237|NCT04302493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized to an 8 week Mindfulness Based Stress Reduction (MBSR) course versus a traditional Stroke Support Group (SSG)|f|f|f|t
33692238|NCT06504446|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33692239|NCT04540536|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692240|NCT04567615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692241|NCT03388437|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomised controlled trial~* A web generated a block randomisation list.~* A block of 4, stratification based on GA, gender \& antenatal steriods~* Sequentially numbered, opaque and sealed envelopes~* Restricted access to envelopes"||||
33692242|NCT05902793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692243|NCT06710366|||COHORT||RETROSPECTIVE|||||||
33781160|NCT00189280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781161|NCT00318513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781162|NCT06287073|||COHORT||PROSPECTIVE|||||||
33995723|NCT05412485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measure assessor will be blinded to the allocation. The child performance will be recorded and the score will be obtained by another assessor who is not aware about the date of the recorded video and not knowing of the allocation.|A prospective single blinded parallet-group, randomized clinical trial would be conducted.|f|f|f|t
33995724|NCT04580784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995725|NCT01963663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995726|NCT05288972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33995727|NCT06452030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study model is parallel. Participants with recurrent low back pain in remission will be randomly allocated to receive either (1) specific sensorimotor control training, (2) general extension training or (3) fascia therapy (i.e. parallel study model).|t|f|f|t
34086909|NCT06551857|||CASE_CONTROL||PROSPECTIVE|||||||
34086910|NCT06208397|||COHORT||PROSPECTIVE|||||||
34086911|NCT00187551|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34086912|NCT05604417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086913|NCT02937441|||COHORT||PROSPECTIVE|||||||
34086914|NCT02255747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086915|NCT03173339|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34086916|NCT00737048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34086917|NCT04156659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086918|NCT05530005|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34103555|NCT06308965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be blinded and randomized into two cohorts. The selection and randomization protocol is as follows: participants eligible for the study are requested to participate and informed by the study nurse. If the patient agreed to participate, informed consent is obtained, and the patient is included in the study. At that time, the study nurse uses a mobile randomization application (Random, Dublin, Ireland) to allocate them either to the 'standard' (sacrificing the vessels) or 'vessel sparing' DAA.~Weighted randomization (1:2) is applied to compensate for a dropout of patients planned for vessel sparing surgery, but in whom the vessels were damaged unintendedly. In case a bilateral procedure will be performed, each side is randomized individually.~Surgery will be performed by the surgeon. Data collection before and after surgery is collected by personal assistant who is unaware of group assignment."|This is a monocentric prospective randomized blinded clinical trial during a period of minimal 3 years or until 150% of sample size is included (100 patients).|t|t|t|f
33692244|NCT05523167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692245|NCT06704646|||COHORT||RETROSPECTIVE|||||||
33692246|NCT05938465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692247|NCT06744374|||CASE_CONTROL||RETROSPECTIVE|||||||
33692248|NCT04184895|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33692249|NCT01168271|||COHORT||PROSPECTIVE|||||||
33781163|NCT05736770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781164|NCT04893798|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781165|NCT05299086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blinded placebo controlled randomized controlled trial|t|t|t|t
33781166|NCT05697640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind.|Two-arm parallel-group, randomized, placebo-controlled, double-blind, single-centre clinical trial in participants with post-COVID syndrome with and without ME/CFS.|t|t|t|t
33781167|NCT05753709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two groups in parallel: EE and SS, and another comparison with three arms: EE versus SS divided into two separate arms: SSSA and HSSA|t|f|f|f
33781168|NCT02488772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33781169|NCT02783183|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781170|NCT06490094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781171|NCT06088901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"All patients presenting with first occurrence of a PSP who meet criteria for chest tube placement, between the ages of 13-18, will be offered inclusion in Arm 1.~All patients presenting with recurrent PSP who meet criteria for blebectomy with a pleural procedure, between the ages of 13-18, will be offered inclusion in Arm 2."||||
33840077|NCT03439813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participant receives one of the two TASK interventions. Both are considered active interventions for anxiety.~Once started on the intervention participant may realise the type of intervention he has received, thus unblinding treatment allocation. Participants remain unaware of the contents of intervention given to the other group. Outcomes are self-completed by participants electronically to achieve assessor blinding."||f|f|f|t
33995728|NCT00031707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33995729|NCT06063213|||COHORT||OTHER|||||||
33995730|NCT00472212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995731|NCT04606550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995732|NCT01558635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995733|NCT05787678|||OTHER||PROSPECTIVE|||||||
33995734|NCT00159458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995735|NCT03192397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995736|NCT06033417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995737|NCT03469401|||COHORT||PROSPECTIVE|||||||
33995738|NCT06562374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995739|NCT00656786|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33995740|NCT03669250|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind, placebo controlled.|Male and female subjects with schizophrenia, age 18 to 50 years old, inclusive, will be randomized to 1 of 6 treatment sequences to receive 1 of 3 dose regimens in each period; a single oral administration of CVN058, or a matching placebo.|t|t|t|t
33995741|NCT06414200|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multicentre study. It will be executed in an academic and five non-academic hospitals throughout The Netherlands. Due to the nature of the intervention, which involves changes to the provision of care and interaction between participants, there is a risk of cross-contamination within centers. Therefore, to avoid contamination of current practice, the stepped wedge cluster randomized controlled trial design was selected. This implies that all participating centers ('clusters') start with standard care (usual care). Subsequently, randomization will determine in which order the centers will begin with the NutriCAD intervention. In the end, all centers will have crossed over to be exposed to the NutriCAD intervention||||
34103556|NCT03555994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692250|NCT05778266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The selection of which group each adolescent will belong to, will be made by randomization by computer numbers by a researcher from the department of medical sciences of the University of Guanajuato, who is not involved in treatment and follow-up. The researcher will designated into a placebo or L-cit group. The investigator and the participants will not know the group which they belong.|"An intervention with exercise in modality of High-Intensity Interval Training (HIIT) and Oral administration of L-citrulline (L-cit) or placebo (Pl) as follows:~Group L-cit + HIIT: capsules of 6 g of citrulline will be supplemented per day, distributed as 3 g (4 capsules) in the morning before the first meal and 3 g in the evening before sleep for a period of 12 weeks. The sessions of HIIT will be made 3 days per week in a stationary bicycle Group Pl + HIIT: Carboxymethyl cellulose will be used as placebo. 4 capsules will be taken in the morning before the first meal and 4 capsules at night before going to sleep for a period of 12 weeks. The sessions of HIIT will be made 3 days per week in a stationary bicycle.~Group L-cit without HIIT: capsules of citrulline will be supplemented per day, distributed as 3 g (4 capsules) in the morning before the first meal and 3 g (4 capsules) in the evening before sleep for a period of 12 weeks. This group will not made exercise."|t|f|t|f
33692251|NCT06417814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692252|NCT06036914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692253|NCT06679348|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33692254|NCT05583227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Subjects will be randomized in a 1:1:1 ratio to receive either low dose of tezepelumab, high dose of tezepelumab, or placebo.|t|t|t|t
33692255|NCT05750173|||CASE_ONLY||PROSPECTIVE|||||||
33692256|NCT06497075|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33692257|NCT00923026|||COHORT||PROSPECTIVE|||||||
33781172|NCT04186169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neither the patients nor the operators are NOT blinded as to whether the patients receive the ultra-high resolution CT or the standard CT. For patients with paroxysmal AF, there is no blinding because there is only one group. The patients with persistent AF will be blinded as to whether they are assigned to the PVI group or the PVI + Fat ablation group. The operators are not blinded (single-blinded design).|Arm 1: Paroxysmal AF (n=100). Observational. Arm 2: Persistent AF (n=50). PVI arm Arm 3: Persistent AF (n=50). PVI + fat-targeted ablation arm|t|f|f|f
33781173|NCT03675204|||COHORT||OTHER|||||||
33781174|NCT04653051|||COHORT||RETROSPECTIVE|||||||
33781175|NCT02193516|||CASE_ONLY||CROSS_SECTIONAL|||||||
33781176|NCT04696471|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33781177|NCT03275103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781178|NCT06335758|||CASE_ONLY||PROSPECTIVE|||||||
33781179|NCT01429961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781180|NCT04506190|||OTHER||PROSPECTIVE|||||||
33781181|NCT06575400|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33781182|NCT03090217|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33781183|NCT06562725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781184|NCT02113111|||COHORT||PROSPECTIVE|||||||
33781185|NCT01702038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781186|NCT00655434|||CASE_ONLY||PROSPECTIVE|||||||
33781187|NCT02939404|||COHORT||CROSS_SECTIONAL|||||||
33781188|NCT04906382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781189|NCT00689104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995742|NCT05159921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blinded. Participants will be aware of which arm they are randomised too (standard consent vs standard consent with automated conversational agent access), while those performing the endoscopy procedure (care providers) will not.|A single blinded parallel study with 1:1 randomisation.|f|t|f|f
33995743|NCT02226250|NA|SINGLE_GROUP||OTHER||NONE||||||
33995744|NCT05600699|||COHORT||PROSPECTIVE|||||||
33995745|NCT03659565|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33995746|NCT05490563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995747|NCT00200785|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33995748|NCT05968638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single-blind|Participants will be assigned to receive either a ketogenic diet or regular diet|f|f|t|t
34103557|NCT00600704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34103558|NCT01994005|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33781190|NCT06682117|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, single center, open label study designed as \&#34;3+3\&#34; model to explore the MTD and DLT of personalized self-DC vaccine targeting neoantigen in treatment of advanced solid tumor.||||
33781191|NCT02089451|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915110|NCT04987541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915111|NCT01917110|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915112|NCT01364350|||COHORT||PROSPECTIVE|||||||
33915113|NCT04646980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Care Provider)|Randomized double-blind placebo-controlled|t|t|f|f
33915114|NCT00804258|||CASE_ONLY||PROSPECTIVE|||||||
33915115|NCT03280641|||COHORT||PROSPECTIVE|||||||
33915116|NCT04018196|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103559|NCT03150641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103560|NCT00892450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34103561|NCT03849235|||COHORT||PROSPECTIVE|||||||
34103562|NCT02481141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915117|NCT00143260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33915118|NCT00135837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915119|NCT03993964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915120|NCT02426593|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33995749|NCT04125407|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34103563|NCT02970812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103564|NCT06552130|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34103565|NCT04892433|||COHORT||PROSPECTIVE|||||||
34103566|NCT05715281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103567|NCT06687070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103568|NCT01807741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103569|NCT06537180|||COHORT||RETROSPECTIVE|||||||
33915121|NCT03134651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915122|NCT04054349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915123|NCT05116514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915124|NCT01766882|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33915125|NCT03893773|||COHORT||PROSPECTIVE|||||||
33915126|NCT02921919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915127|NCT00014664|RANDOMIZED|||TREATMENT||||||||
33915128|NCT04761029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||retrospective||||
34103570|NCT02365688|NA|SINGLE_GROUP||OTHER||NONE||||||
34103571|NCT04634136|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Placebo product will be of the same quantity and apperance (same packaging) as the active substance. All partricipants will be blinded to relevant patient data.|"Active substance: Full-spectrum medical cannabis product of CBD/THC ratio 10:1.~Arm 1: Active substance. The starting dose will be 0,08 mg THC per kilo body weight daily in 2 divided doses which will gradually be increased (escalating dose of 0,08 mg THC kg/d) until maximal dose of 1 mg/kg/d.~Arm 2: Placebo~Crossover: After 6 weeks Arm 2 will also receive the active substance and patients in both arms will continue receiving the active substance for the next 6 weeks."|t|t|t|t
33915129|NCT04719676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692258|NCT06743932|||COHORT||PROSPECTIVE|||||||
33692259|NCT05371054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692260|NCT04365374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915130|NCT02076321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915131|NCT05601024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
33915132|NCT02643186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33692261|NCT05102916|||COHORT||OTHER|||||||
33915133|NCT01952457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915134|NCT06330597|||COHORT||PROSPECTIVE|||||||
33915135|NCT03348852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915136|NCT03395275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study will be a non-randomized prospective trial. Participants will be selected for microdose intrathecal pump therapy by their pain physicians. Eligible participants will undergo an opioid taper by their physicians, and sensory tests will be carried out in the various stages of the intrathecal microdose treatment process (pre-taper, mid-taper, post-taper and post-implant phase).||||
33915137|NCT03102177|NA|SINGLE_GROUP||OTHER||NONE||Open label prospective study||||
33915138|NCT02067091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915139|NCT00668655|||CASE_ONLY||PROSPECTIVE|||||||
33915140|NCT05610852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692262|NCT06526546|||COHORT||PROSPECTIVE|||||||
33692263|NCT03628677|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation Design||||
33692264|NCT05146973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692265|NCT05562622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator/Investigational site staff tasked with measuring key primary variables (i.e., axial length and SER) will be masked.||f|f|f|t
33692266|NCT04925752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692267|NCT06740435|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33692268|NCT06744023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||A randomised controlled trial. Upon admission to the ward from the postoperative intensive care unit, the experimental group underwent environmental remediation for three days. The environmental arrangements ensured that the patient room maintained an appropriate temperature range of 18-26 °C and humidity values of 30-60%. Monitoring took place at 21:00, 22:00, and 23:00 on Days 1, 2, and 3. On Days 1, 2, and 3, the patient room's light brightness gradually decreased at 21:00, 22:00, and 23:00. On the morning of the fourth day, the patients were interviewed face-to-face, and the research questionnaires were filled out.|t|t|t|t
33692269|NCT06469151|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33692270|NCT04915248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781192|NCT06650150|||CASE_ONLY||CROSS_SECTIONAL|||||||
33781193|NCT05663892|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781194|NCT02698462|NA|SINGLE_GROUP||SCREENING||NONE||||||
33781195|NCT06611761|||COHORT||PROSPECTIVE|||||||
33781196|NCT04840147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781197|NCT05859997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915141|NCT05346913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915142|NCT02225873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33915143|NCT04153617|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33781198|NCT04833556|||CASE_ONLY||RETROSPECTIVE|||||||
33692271|NCT06107504|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be recruited from the volunteers with choledocholithiasis at National Cheng Kung University Hospital and Siriraj Hospital. Eligible participants include patients aged ≥ 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction. Patient consent forms will be given and explained to all patients before the ERCP. Exclusion criteria include patients with no schedules for sphincterotomy, unsuccessful CBD cannulation, and allergy to sucralfate.||||
33692272|NCT05349682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692273|NCT02787369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692274|NCT04790370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded adjudication of primary composite outcome|1:1 randomization|f|f|f|t
33692275|NCT06496139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomisation will be performed externally by a person independent from the study. After group allocation, participants in the TG will be randomly assigned to one of the therapists involved in the trial. A statistician blinded to group allocation will conduct all statistical analyses.|The study is a parallel two-group randomised controlled trial with 1:1 allocation to 8 weeks of therapist-guided self-help ICBT (TG) or a waitlist control group (WL)|f|f|f|t
33692276|NCT05815160|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692277|NCT05155059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692278|NCT04024462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692279|NCT05601752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692280|NCT06745830|||COHORT||RETROSPECTIVE|||||||
33692281|NCT05259085|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781199|NCT00224133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781200|NCT00892229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781201|NCT05145556|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Starting with 100 tracheal intubations with conventional tracheal intubation and videolaryngoscopy and after 100 intubations change the device for the next 100 intubations|t|f|f|f
33781202|NCT02059915|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33781203|NCT03086694|||CASE_CONTROL||PROSPECTIVE|||||||
33781204|NCT02459587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33781205|NCT06697288|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33781206|NCT06413615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781207|NCT00525057|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33781208|NCT02327572|||COHORT||PROSPECTIVE|||||||
33781209|NCT05091372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781210|NCT06571656|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33781211|NCT01739517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781212|NCT04273685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A randomisation procedure for group allocation will be compiled with an independent statistician. A research assistant, blinded to allocation, will complete outcome assessments at the three time points (Prior to the study commencing, 2 weeks post study completion and follow up at 3 months).|This is a feasibility study with a randomised, controlled, outcome-assessor-blind, parallel- group design.|f|f|f|t
33915144|NCT01711684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915145|NCT01321931|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33915146|NCT01592409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33915147|NCT03589105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915148|NCT03611322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915149|NCT00819585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33915150|NCT01029886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915151|NCT03590522|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33915152|NCT04875338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||propective randomize|t|f|f|f
33915153|NCT05940727|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33915154|NCT01893658|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33915155|NCT02431468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915156|NCT02094872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692282|NCT06335173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692283|NCT06745635|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33692284|NCT03206099|||FAMILY_BASED||PROSPECTIVE|||||||
33692285|NCT06431815|||COHORT||PROSPECTIVE|||||||
33692286|NCT06451250|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33692287|NCT06499805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692288|NCT02613299|||CASE_ONLY||PROSPECTIVE|||||||
33692289|NCT03937830|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692290|NCT06137144|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781213|NCT04910542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study employs a mixed-methods design for intervention trials. This method is appropriate for epidemiological interventions framed under community engagement practices.||||
33781214|NCT04483544|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1 inhibitor pembrolizumab, in combination with the PARP inhibitor olaparib||||
33781215|NCT02401529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33781216|NCT00318656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781217|NCT02783950|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33781218|NCT01938664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33781219|NCT02396030|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33781220|NCT05429021|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double blind|Randomized, Double Blind, Dose Escalation|t|t|t|f
33781221|NCT00940017|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33781222|NCT06337643|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Cohort 1 is open-label. Cohorts 2-5 include two open-label sentinel participants each and the remainder of the participants are randomized and double-blind to either MVX01 or MVX01 Placebo (Participant \& Site).||t|t|t|f
33781223|NCT03887962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data collected by unblended participant and research assistant. Outcomes analysed by blinded team and statistician Objective machine outcomes are blinded|Randomised single-blind controlled trial|f|f|f|t
33781224|NCT04776213|NA|SINGLE_GROUP||OTHER||NONE||||||
33781225|NCT02335268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915157|NCT06518512|||COHORT||PROSPECTIVE|||||||
33692291|NCT06502561|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"All subjects will receive a single dose of 400 mg Aramchol meglumine granules for oral suspension (Test 1) in Period 1.~In Periods 2 and 3, subjects will be randomized to a crossover of treatments in a 1:1 ratio to receive a single dose of Aramchol meglumine granules for oral suspension (Test 2) in one period and a 300 mg Aramchol free acid tablet (Reference) in the other period. The washout interval between dosing periods will be at least 14 days."||||
33692292|NCT06567119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692293|NCT05692960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a two-arm, randomized clinical trial.||||
33692294|NCT06317285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double-blind study with respect to allocation of GSK3915393 or placebo to participants.||t|t|t|t
33692295|NCT06312553|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33692296|NCT06449287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33692297|NCT03328455|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|50 elderly participants will be randomly assigned to one of the two training groups but will not be told whether they are in the inhibitory control (experiment) or knowledge-based (control) training group.|50 elderly participants will be randomly assigned to one of the two training groups and will be asked to undergo 20 days of training (\~30 mins/day).|t|f|f|f
33781226|NCT03064503|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781227|NCT00233129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781228|NCT00626600|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781229|NCT06650930|NA|SINGLE_GROUP||OTHER||NONE||This is a single arm pharmacokinetic trial. No efficacy outcomes are analyzed. The aim of the study is to determine the pharmacokinetics of a single dose of oral calcium carbonate in parturients. The outcome of interest is serial measurement of the ionized calcium in the blood.||||
33781230|NCT05211531|||COHORT||PROSPECTIVE|||||||
33781231|NCT02708459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33781232|NCT02972138|||COHORT||RETROSPECTIVE|||||||
33781233|NCT03140293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781234|NCT00913432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781235|NCT00162942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781236|NCT03940261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The collection of study outcomes will be completed by individuals blinded to group allocation.|Participants will be randomized to 10 weeks of either high intensity interval training or continuous moderate intensity training. Training will be conducted in parallel.|f|f|f|t
33781237|NCT00991744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781238|NCT04222387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781239|NCT03031639|||COHORT||PROSPECTIVE|||||||
33915158|NCT03034759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915159|NCT02294409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915160|NCT01879176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915161|NCT02034604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915162|NCT03488121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33915163|NCT01368393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33781240|NCT03003962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781241|NCT05064280|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781242|NCT06613750|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel-group, randomized, controlled, non-inferiority study comparing the efficacy and safety of Sitagliptin Phosphate combined with Gliclazide sustained-release tablets versus Metformin in treatment-naïve patients with Type 2 Diabetes Mellitus and glucotoxicity. Participants will be randomly assigned to one of two treatment arms and followed for 12 months to evaluate glycemic control and safety outcomes.||||
33781243|NCT04038047|||COHORT||PROSPECTIVE|||||||
33781244|NCT03782038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781245|NCT02561455|NA|PARALLEL||TREATMENT||NONE||||||
33781246|NCT00461448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33781247|NCT03282123|NA|SINGLE_GROUP||TREATMENT||NONE|This study will be open label|Three sessions of MDMA-assisted therapy with flexible dose of MDMA (80 to 120 mg with optional supplemental half-dose)||||
33840078|NCT06149897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840079|NCT05134987|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33840080|NCT03269487|||OTHER||OTHER|||||||
33840081|NCT05153928|||CASE_ONLY||OTHER|||||||
33840082|NCT05367700|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840083|NCT03680352|NA|SEQUENTIAL||OTHER||NONE||||||
33840084|NCT01914770|||||RETROSPECTIVE|||||||
33840085|NCT01815086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840086|NCT03064399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840087|NCT02807272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840088|NCT04152057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840089|NCT00000219||||TREATMENT||DOUBLE||||||
33840090|NCT01968993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840091|NCT00927134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840092|NCT00384397|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33840093|NCT01375413|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33840094|NCT02963012|||CASE_ONLY||PROSPECTIVE|||||||
33840095|NCT01472224|||||PROSPECTIVE|||||||
33840096|NCT01173432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692298|NCT05574114|NA|SEQUENTIAL||TREATMENT||NONE||This is a single arm, Phase I trial designed to describe the feasibility and safety of a standardized, stage-adapted, split-course BRT regimen prior to standard of care, commercial anti-CD19 CAR T-cell therapy. This design incorporates a small early safety cohort with the option for a potential patient expansion cohort.||||
33781248|NCT04157764|NA|SINGLE_GROUP||TREATMENT||NONE||use automated peritoneal dialysis machine without SHARESOURCE for 12 weeks, then use automated peritoneal dialysis machine with SHARESOURCE for 12 weeks||||
33781249|NCT01169519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781250|NCT01924481|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33692299|NCT06745739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915164|NCT04348591|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All participants will undergo different types of neurostimulation to probe different areas of the emotion regulation and misophonic networks while being exposed to sounds. One of these neurostimulation blocks will involve sham (inactive) neurostimulation. The investigator and the participants will be blind to which block has active and which block has sham neurostimulation|The investigators plan to compare adults who report misophonia with adults who report clinical emotional dysregulation in their neurobiological response to misophonic, aversive, and neutral sounds|t|f|t|f
33915165|NCT04958616|||CASE_CONTROL||PROSPECTIVE|||||||
33692300|NCT06745947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Although it is not possible to fully blind participants due to the nature of the EFT intervention, research staff responsible for outcome assessments (e.g., PrEP adherence, methamphetamine use, and sexual risk behaviors) will be blinded to the participants' group assignment to minimize assessment bias.|A two-arm pilot randomized controlled trial|f|f|t|f
33692301|NCT06149520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781251|NCT00866216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781252|NCT05930899|||CASE_CONTROL||PROSPECTIVE|||||||
33781253|NCT05292131|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781254|NCT03805958|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33781255|NCT06581874|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33781256|NCT02634645|||COHORT||PROSPECTIVE|||||||
33781257|NCT00708097|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33915166|NCT05899387|||COHORT||PROSPECTIVE|||||||
33915167|NCT05384158|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33915168|NCT04217889|||COHORT||PROSPECTIVE|||||||
33915169|NCT02173496|||CASE_ONLY||PROSPECTIVE|||||||
33915170|NCT05465031|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blinded||t|t|t|f
33915171|NCT06483516|||COHORT||PROSPECTIVE|||||||
33915172|NCT03192072|||COHORT||OTHER|||||||
33915173|NCT03574935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915174|NCT00884468|||COHORT||CROSS_SECTIONAL|||||||
33915175|NCT04703348|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||3 groups with different healthcare conditions are compared in motor imagery capacities||||
33915176|NCT02509494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33915177|NCT00254527|||||OTHER|||||||
33915178|NCT03212664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915179|NCT06429878|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients were randomized to either MRI or no-MRI before radical prostactomy||||
33915180|NCT04693442|||COHORT||PROSPECTIVE|||||||
33915181|NCT06554002|RANDOMIZED|PARALLEL||OTHER||NONE|Single-blinded|Crossover assignment. Single-blinded, randomized, controlled, parallel arm trial with each participant block-randomized into either control or treatment group||||
33915182|NCT00622869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915183|NCT01262755|||CASE_ONLY||CROSS_SECTIONAL|||||||
33915184|NCT05944991|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33692302|NCT06741384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692303|NCT02986516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692304|NCT05861427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915185|NCT06250894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915186|NCT00945633|||COHORT||PROSPECTIVE|||||||
33915187|NCT00649376|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33915188|NCT02173210|||COHORT||PROSPECTIVE|||||||
33915189|NCT00733382|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33692305|NCT01519154|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33692306|NCT05093478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692307|NCT04404569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781258|NCT04655313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781259|NCT04006860|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781260|NCT05186090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33781261|NCT04359056|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33781262|NCT04155853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33781263|NCT01044641|||COHORT||PROSPECTIVE|||||||
33781264|NCT01084122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33781265|NCT05750030|NA|SINGLE_GROUP||TREATMENT||NONE||12 Patients with HCC who failed to achieve a complete or partial response (according to mRECIST) to atezolizumab plus bevacizumab||||
33781266|NCT01637558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915190|NCT01047761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915191|NCT03051087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915192|NCT00694954|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915193|NCT05986097|NA|SINGLE_GROUP||TREATMENT||NONE|Blood tests and continuous glucose monitoring are masked.|All participants will be provided the same intervention.||||
33915194|NCT05606224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33915195|NCT02341118|||CASE_ONLY||PROSPECTIVE|||||||
33915196|NCT03991364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915197|NCT03627910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915198|NCT04694547|||CASE_ONLY||CROSS_SECTIONAL|||||||
33915199|NCT05202093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915200|NCT05519046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915201|NCT02456545|||COHORT||PROSPECTIVE|||||||
33915202|NCT05364905|||COHORT||RETROSPECTIVE|||||||
33915203|NCT06175962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Double (Participant, Investigator)|Parallel Assignment|t|f|f|f
33915204|NCT06373042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915205|NCT02154126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915206|NCT04702217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915207|NCT01647464|||CASE_ONLY||PROSPECTIVE|||||||
33915208|NCT02730936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915209|NCT02998060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915210|NCT00138424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915211|NCT00501215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915212|NCT03611517|RANDOMIZED|PARALLEL||TREATMENT||NONE||After signed informed consent, women complete the baseline questionnaire. After completion of the baseline questionnaire and before the end of RT, patients will be randomized to either the intervention group or the control group. The control group receives care as usual. The intervention group receives the nurse-led sexual rehabilitation intervention. All patients have follow-up appointments with their radiation-oncologist (or gynecologic oncologist) at 1, 3, 6 and 12 months post RT. For the intervention group, the sexual rehabilitation intervention sessions with the nurse will be planned immediately following the appointment with the radiation-oncologist. Women in the intervention group who are treated with RTBT receive an extra session 2 months after the end of radiotherapy. All patients are asked to complete questionnaires at baseline, and 1, 3, 6, and 12 months after completion of RT.||||
33915213|NCT00165646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33915214|NCT05047159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915215|NCT01732185|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33915216|NCT00988741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915217|NCT02095236|NA|SINGLE_GROUP||OTHER||NONE||||||
33915218|NCT03936816|||COHORT||PROSPECTIVE|||||||
33915219|NCT00987233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915220|NCT02519088|||||RETROSPECTIVE|||||||
33915221|NCT02857114|NA|SINGLE_GROUP||||NONE||||||
33915222|NCT03208725|||COHORT||PROSPECTIVE|||||||
33915223|NCT02860806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915224|NCT06447324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two groups|t|f|f|f
33915225|NCT05574335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915226|NCT05109013|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33915227|NCT00132236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33995750|NCT05238428|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will read and evaluate 4 versions of the vaccination invitation. The condition will be selected randomly by the Qualtrics algorithm (with an even selection rate). The four invitations will be presented to each participant in a random order based on the Qualtrics randomisation algorithm.|In a 4 x 4 experimental design, the investigators will manipulate the content of the vaccination invitation message in within-subject and the message source in between-subjects. Each participant will hence read four versions of the COVID-19 booster vaccination invitation message sent by one of the four possible sources.|t|t|t|t
33995751|NCT04858126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995752|NCT03644550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915228|NCT00489840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915229|NCT06108869|RANDOMIZED|PARALLEL||OTHER||NONE||Single groups will be taken through the ABT programme, or the delayed control intervention||||
33995753|NCT04371224|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized phase 2 study||||
33995754|NCT01929486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692308|NCT05698459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692309|NCT06003426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781267|NCT05938868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781268|NCT06458972|||COHORT||RETROSPECTIVE|||||||
33781269|NCT01235429|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33915230|NCT01155297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33915231|NCT05105438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded randomized controlled study: participants and investigators are blinded||t|f|t|f
33995755|NCT06627114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995756|NCT04663776|||COHORT||PROSPECTIVE|||||||
33995757|NCT03873805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995758|NCT02325180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995759|NCT03503435|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a pre and post design quasi-experimental study looking at changes before and after a supportive care art therapy intervention.||||
33995760|NCT04132115|||COHORT||PROSPECTIVE|||||||
33995761|NCT06274762|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||There is an experimental group of 45 visually impaired women aged 20-69 and a control group of 45. Randomization was not possible. Blinding could not be done.||||
33995762|NCT00635648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995763|NCT06507176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995764|NCT05972590|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995765|NCT01062490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995766|NCT05643638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995767|NCT01266902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995768|NCT04976179|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized using Sealed Envelope software and assigned into 2 parallel study arrms as they are recruited. Those in the FCM group will receive Intravenous Ferric Carboxymaltose (Interventional drug) and those in the FS group will receive Oral Ferrous Sulphate (Standard drug).||||
33995769|NCT04002024|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Split face study. Half face is ramdomly applied moisturizer containing the active ingredients of licochalcone A, decanediol, L-carnitine, and salicylic acid. Another half face is assigned to use placebo which is moisturizer without those active ingredients.|t|t|t|t
33995770|NCT05789641|||CASE_ONLY||RETROSPECTIVE|||||||
33995771|NCT04184947|||COHORT||RETROSPECTIVE|||||||
33995772|NCT05664243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Arm A subjects with newly diagnosed disease will receive autologously derived, genetically modified gamma-delta T cells administered with maintenance temozolomide.~Phase 1b and Arm B subjects with relapsed disease will have allogeneic derived, genetically modified gamma-delta T cells administered with temozolomide~Arm C subjects with newly diagnosed disease will receive allogeneic derived, genetically modified gamma-delta T cells administered with maintenance temozolomide."||||
33995773|NCT04418349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995774|NCT02786433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995775|NCT01909024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995776|NCT01430533|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33995777|NCT01572051|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995778|NCT06425757|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995779|NCT05890547|||CASE_CONTROL||PROSPECTIVE|||||||
33781270|NCT01403844|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33995780|NCT03106545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995781|NCT04237415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995782|NCT06556043|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33781271|NCT04568096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995783|NCT03545880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781272|NCT03176134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded||f|f|f|t
33781273|NCT04304469|||COHORT||PROSPECTIVE|||||||
33781274|NCT01260974|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33781275|NCT00716664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33781276|NCT02675855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781277|NCT06148753|NA|SINGLE_GROUP||OTHER||NONE||||||
33781278|NCT00185484|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33781279|NCT05406492|||COHORT||PROSPECTIVE|||||||
33781280|NCT02522052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33781281|NCT05675371|||COHORT||PROSPECTIVE|||||||
33781282|NCT04339218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781283|NCT04488874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not known which of Sodium lactate or Mannitol will they receive. The drug will be hidden by an opaque drape during its administration and as soon as the administration is over it will be taken out of the operating room, so the neurosurgeon won't know which drug was given.||t|f|f|t
33781284|NCT04230161|||COHORT||PROSPECTIVE|||||||
33781285|NCT04837950|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Volume of saline in pleural cavity and surgical field overview before and after pulling traction suture|During video-assisted thoracoscopic surgery a diaphragmatic traction-suture is placed posteriorly at the border between the central tendinous part and the peripheral muscular part. Body temperate saline solution is then poured into the pleural cavity until the cavity is filled up to the soft-tissue retractor in the utility port. The volume of saline in the pleural cavity is then measured and registered before and after distal contraction of the diaphragmatic traction suture through the camera port. Subsequently the surgeon will be asked to evaluate and rate the surgical field visual overview, before and after contraction of the suture. Furthermore, anonymized video recordings focusing on the pleural cavity visual overview before and after distal contraction of the suture, will be presented to specialist thoracic surgeons for a blinded evaluation.|t|f|f|f
33781286|NCT02833454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33995784|NCT05966922|NA|SINGLE_GROUP||PREVENTION||NONE||This study will be conducted in an experimental study design.||||
33781287|NCT06542432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33995785|NCT02436200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995786|NCT02108535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995787|NCT04020458|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995788|NCT00807495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995789|NCT01152645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781288|NCT06490523|||COHORT||PROSPECTIVE|||||||
33781289|NCT04744662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this study patients will be enrolled and followed for 24 weeks (natural history phase) at which point they will be randomized to 1 of 2 doses of ONL1204 Ophthalmic Solution or sham. Weeks 24 to 48 make up the Treatment Phase. Patients will be on study for a total of 48 weeks.|t|t|f|f
33781290|NCT06615440|||COHORT||PROSPECTIVE|||||||
33781291|NCT00487721|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33781292|NCT06555432|||COHORT||PROSPECTIVE|||||||
33781293|NCT05979194|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33781294|NCT06487026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781295|NCT06549036|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
33781296|NCT03445481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781297|NCT06614894|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A Non-randomized (single arm) clinical trial where all participants will receive the same experimental therapy and undergo the same dose escalation plan. All participants will be followed over time to observe their response related to safety and effectiveness.||||
33781298|NCT03796689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781299|NCT03789253|||COHORT||PROSPECTIVE|||||||
33781300|NCT00730418|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33781301|NCT01205282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33781302|NCT00859014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781303|NCT00308061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33781304|NCT06613789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part A will be open label.|Part A is dose escalating. Part B is parallel.|t|t|t|t
33781305|NCT00333580|||||PROSPECTIVE|||||||
33781306|NCT06348186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomly assigned to one of two or groups, typically an intervention group (fascia-focused manual therapy) and a control group. Participants are randomly allocated. Participants and outcomes assessor are blinded.|t|f|f|t
33781307|NCT03730298|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind, placebo-controlled|Randomized, double-blind, placebo-controlled|t|t|t|t
33781308|NCT04827225|||COHORT||PROSPECTIVE|||||||
33781309|NCT03324685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781310|NCT01941823|||COHORT||PROSPECTIVE|||||||
33781311|NCT06685289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781312|NCT06086431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33781313|NCT05758688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781314|NCT06698302|||OTHER||PROSPECTIVE|||||||
33781315|NCT06697171|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33995790|NCT05062564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995791|NCT04738019|||COHORT||PROSPECTIVE|||||||
33995792|NCT06140082|||COHORT||CROSS_SECTIONAL|||||||
33995793|NCT06139133|RANDOMIZED|PARALLEL||OTHER||SINGLE||RCT|t|f|f|f
33995794|NCT06196554|||CASE_ONLY||PROSPECTIVE|||||||
33995795|NCT03720444|||CASE_ONLY||PROSPECTIVE|||||||
33995796|NCT01174849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995797|NCT06393530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995798|NCT05442086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995799|NCT03904095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant care provider|Patients randomly allocated to three treatment groups: , The psoas compartment block (Group I) the ESP block group (Group II) and the control group (Group III). Blocks performed after general anesthesia induction with the Ultrasound while patients lying on surgical type at the top.|t|f|t|f
33995800|NCT01548053|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33692310|NCT03623074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and parents of participants will be masked. Investigational site staff tasked with measuring key primary variables (i.e., axial length and SER) will be masked.||t|f|f|t
33692311|NCT05595499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692312|NCT05067634|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692313|NCT05109351|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33692314|NCT05708352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692315|NCT05325034|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study.~Patients will be recruited during hospitalisation and be randomised to a multifaceted intervention to be delivered either 'early' (baseline) or 'late' (6 months), in a 1:1 fashion."||||
33692316|NCT03592693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Investigators performing the follow-up, and care providers will be blinded|Randomized, multicenter, parallel group, placebo-controlled \[Vitamin c plus hydrocortisone or placebo plus placebo|t|t|t|t
33692317|NCT05690269|||COHORT||PROSPECTIVE|||||||
33781316|NCT05948098|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33781317|NCT03946202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781318|NCT05922436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781319|NCT00377598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781320|NCT04970238|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33781321|NCT01766518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781322|NCT06609902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a treatment development study that begins with an open non-randomized pilot trial (N = 10) in which we will test the manual developed for Future Self-BD by assessing the acceptability and feasibility of Future Self-BD. After completion of the non-randomized pilot trial and subsequent revisions to the Future Self-BD manual, we will conduct a parallel randomized controlled trial comparing Future Self-BD (N = 30) to a control treatment, Daily Check-Ins (N = 30). Future Self-BD and Daily Check-Ins involve six, weekly, one-hour sessions and one follow-up session one month after completion of the sixth session|t|f|f|f
33781323|NCT03337750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781324|NCT02368886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781325|NCT06374264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915232|NCT04635072|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients with mild AD will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, one time per day.~Patients with moderate disease will be instructed to use SWRB as a cleanser as above. In addition, they will also use SWRB as an emollient after constituting it into a paste as in instructions, apply at night and leave it overnight.~The patients will be followed up for four to six weeks and the clinical features tabulated. Where appropriate, photographs of the lesion/s will be taken for evaluation of progression / regression at the end of the study, while protecting the identity of the patient.~A questionnaire using the Likert scale, will be prepared for the patient's parent/s to complete. This will be to assess:~* Parents' opinion of the product~* Ease of application~* Convenience (cleaning the bed of the powder, etc.)~* Parents' perception regarding improvement seen/not seen"||||
33915233|NCT02607254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915234|NCT04045158|||COHORT||RETROSPECTIVE|||||||
33915235|NCT00648193|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33915236|NCT02012608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915237|NCT04455451|||COHORT||OTHER|||||||
33915238|NCT02065310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995801|NCT04571294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995802|NCT04273971|NA|SINGLE_GROUP||TREATMENT||NONE|The statistical analyzer will be masking for the time factor.|Single-arm design where all participants receive treatment.||||
33995803|NCT03375957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995804|NCT03005366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995805|NCT06270745|||COHORT||PROSPECTIVE|||||||
33692318|NCT06422806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692319|NCT01480206|||COHORT||PROSPECTIVE|||||||
33692320|NCT06744075|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692321|NCT05848284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692322|NCT06057038|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692323|NCT05527964|||COHORT||PROSPECTIVE|||||||
33692324|NCT05981300|||COHORT||PROSPECTIVE|||||||
33781326|NCT01169805|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33781327|NCT04704960|||COHORT||PROSPECTIVE|||||||
33781328|NCT04901975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781329|NCT03496961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will use simple randomization ways. Sofware20.0 will used to generate a random unique number for each integral number from 1 to 90 and divide the 90 numbers (1 to 90) into three groups with a ratio of 1:1:1 based on the random numbers group. The number grouping is unknown. This will be a double blind trial.|"Clinically evaluated, medically unexplained fatigue of at least 6 months duration:~Of new onset. Not a result of ongoing exertion. Not substantially alleviated rest and associated with a substantial reduction in previous levels of activity"|t|f|f|t
33781330|NCT01209676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781331|NCT06390553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781332|NCT06362941|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment 6-month, single-center, prospective interventional study||||
33781333|NCT06432998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33781334|NCT01505075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781335|NCT06614010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995806|NCT04085861|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|By using id-numbers for each respondent in this trial, the outcome assessor will not be able to identify the group of responders.|Professional dancers at the Norwegian University of Dance (NDH) (n=200) and a group of control persons (Oslo National Academy of the Arts) (n=100) are asked to take part in this study. NDH students receive an intervention after pre-tests and are re-evaluated post-intervention and 6 months post-intervention. The art students responds to similar questionnaires at the three evaluation times. Additionally, the dance teachers (n=50) are evaluated pre, post and 6-months post-intervention, receiving a specific intervention designed for teachers on mental health literacy and which actions to take if findings dancers with mental health issues.|f|f|f|t
33995807|NCT05448209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Prospective randomized controlled clinical trial|t|f|f|t
33995808|NCT04637139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995809|NCT06022107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692325|NCT06743984|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692326|NCT06743815|||COHORT||PROSPECTIVE|||||||
33692327|NCT06737562|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692328|NCT05939427|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33692329|NCT06743906|||CASE_ONLY||CROSS_SECTIONAL|||||||
33692330|NCT05567406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692331|NCT02466737|RANDOMIZED|PARALLEL||TREATMENT||||||||
33692332|NCT04148833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995810|NCT04210557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participant, the physician administering TMS, and the research psychologist will be blind to the condition. One research assistant will be unblinded to the condition. This unblinded research assistant is responsible for setting up the active TMS coils or the sham TMS coils and determining the protocol used, to maintain the blindness of other study staff and the participant.||t|f|t|f
33995811|NCT01342939|||COHORT|||||||||
33995812|NCT01140438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995813|NCT00383916|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995814|NCT01261949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995815|NCT00735176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995816|NCT02556216|||COHORT||CROSS_SECTIONAL|||||||
33995817|NCT03499873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995818|NCT03802968|||COHORT||PROSPECTIVE|||||||
33995819|NCT06146673|||OTHER||CROSS_SECTIONAL|||||||
33995820|NCT06561815|||COHORT||PROSPECTIVE|||||||
33995821|NCT03723733|||COHORT||CROSS_SECTIONAL|||||||
33915239|NCT03925818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995822|NCT00860886|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34086919|NCT03733964|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|None of the physicians were personally involved in the preparation and the manner of performing the test. Before commencing the tests, each patient was familiarised with their course, expressed their informed written consent for participation and random assignment to a specified tested group. The author of this paper had no influence on the categorisation of patients into individual treatment groups. During the studies, the physicians performing the categorisation were not informed about the results of the used treatment. However, on request they could acquire information about the result of using the procedures for a single patient. They were also informed about the occurrence of any undesired events.|"The patients were randomly divided into four groups of 50 people: the manual therapy group (A), the PNF method group (B), the manual therapy and the PNF method group (C), as well as the traditional kinesiotherapy group (D).~Therapy in all groups proceeded for ten days during a period of two weeks. Measurements of pain intensity using visual analogue pain scale (VAS) and a modified Laitinen's pain questionnaire were carried out four times (before the start of the therapy, in the middle of it, immediately after its completion and two weeks after the end of the treatment). The clinical examination (goniometric measurements of range of motion of the spine) and the evaluation of nerve root irritation (Laseque's and Mackiewicz's signs) was done twice - before and immediately after the treatment."|t|t|t|f
34086920|NCT03413696|||COHORT||CROSS_SECTIONAL|||||||
33781336|NCT05638854|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33781337|NCT03049111|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33915240|NCT01948284|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33915241|NCT06282900|||OTHER||PROSPECTIVE|||||||
33915242|NCT05948371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915243|NCT03927248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915244|NCT00916370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915245|NCT00283998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915246|NCT06148896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blinded by informing them that they will participate in one of the two treatment groups that is known to be helpful to their chronic nonspecific back pain but not known which one is better. An independent assessor who is responsible for carrying out the physical test and assist the elderly in filling of the questionnaires will be blinded for the group allocation. The research personnel who is responsible for data entry and statistical analysis will also be blinded for the group allocation.|This two-armed randomised controlled trial (RCT) aims to investigate the effectiveness of Group Exercise with PACT (GrExPACT experimental intervention) as compared to Group Exercise (GrEx) alone led by physiotherapist (control intervention) for elderly with chronic LBP|t|f|f|t
33915247|NCT00511251|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33915248|NCT02660333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study participants and researchers were masked over consumption and distribution of supplementation, respectively. Laboratory technicians who performed the blood collection were also masked as to the distribution of supplementation. Supplements and placebo were pre-packaged by the supplier in opaque and closed sachets with randomization codes, being identical in physical appearance, taste and color. Supplement identification codes were only disclosed by the supplier after statistical analysis of study data.||t|t|t|t
33915249|NCT06396780|||OTHER||CROSS_SECTIONAL|||||||
33995823|NCT01624272|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33995824|NCT00375284||PARALLEL||TREATMENT||||||||
33995825|NCT02974907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915250|NCT02124031|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33915251|NCT01927133|||COHORT||PROSPECTIVE|||||||
33915252|NCT06081998|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participant will be blinded about application of pruritogens.|The participants will be instructed to stay awake for 24 hours following the baseline session of this subproject.||||
33915253|NCT00213928|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33915254|NCT04738825|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Aims 1 and 2: Randomized controlled trial to evaluate the effectiveness of contingency management with stepped care to PrEP adherence and support services (Compass) compared to treatment as usual.~Aim 3: Implementation-focused process evaluation to gain information on implementation of the intervention from perspectives of participants as well as front-line providers and staff"||||
33915255|NCT01346371|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915256|NCT02225444|||COHORT||PROSPECTIVE|||||||
33915257|NCT02554253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915258|NCT00751114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995826|NCT00172406|||DEFINED_POPULATION||OTHER|||||||
34086921|NCT02014623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086922|NCT00522665|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34086923|NCT03184246|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Interventional group will be intubated by videolaryngoscopy, control group by direct laryngoscopy|t|f|f|t
34086924|NCT02600260|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34086925|NCT01122173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781338|NCT04681417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781339|NCT05675306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The proposed work is multisite Phase III parallel-group RCT that aims to investigate the outcomes of DTTC in children with CAS and determine whether dose frequency impacts response to treatment.|f|f|f|t
34086926|NCT05055765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinding will be adopted where the investigator analysing the results will be unaware to which group the patient belongs.||f|f|t|f
34086927|NCT00941551|||CASE_CONTROL||PROSPECTIVE|||||||
34086928|NCT00207740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781340|NCT03224338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781341|NCT03096119|||COHORT||PROSPECTIVE|||||||
33781342|NCT05649579|||COHORT||RETROSPECTIVE|||||||
33781343|NCT05641467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Sample size G-power 3.1.9.7. program (Faul et al 2007, Faul et al 2009). Shourab et al. anxiety score average in the study; It was found to be 24.9±1.9 in the intervention group and 21.2±1.1 in the control group. In the light of this study, 0.897 effect size, 0.95 power, 0.05 alpha level and bidirectional hypothesis options were selected in the program, and the number of participants for each group was 34 (Shourab et al 2016). The pregnant women who came to the hospital will evaluate in terms of sample criteria and randomized sampling will divide into two groups. In order to ensure randomization in the study, a random numbers table was created by dividing them into two groups over the number determined on the site https://www.random.org/. Pregnant women will be assigned to groups according to the randomization scheme. Considering that there may be data loss, 20% more was determined and it was planned to study with 82 (41 intervention, 41 control) pregnant women.|t|f|f|t
33915259|NCT05339243|RANDOMIZED|PARALLEL||OTHER||TRIPLE||A randomised, double-blind, placebo-controlled, parallel-group multicentre study|t|t|t|f
33915260|NCT01842607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915261|NCT05062616|||COHORT||RETROSPECTIVE|||||||
33915262|NCT05768841|||COHORT||PROSPECTIVE|||||||
33915263|NCT04240288|RANDOMIZED|PARALLEL||OTHER||NONE|Not applicable. The study is unblinded.|||||
34086929|NCT06430489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086930|NCT04611815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant will not be informed whether theis surgery was performed with robotics assist.~Outcomes Assessor, Care provider, Investigator will not be informed which type of prosthesis was used in particular patient."||t|t|t|t
34086931|NCT02610010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086932|NCT06069089|||OTHER||CROSS_SECTIONAL|||||||
34086933|NCT00248053|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33915264|NCT04161274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995827|NCT06070480|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study included 75 patients with lumbar disc herniation between the ages of 18-75, with the American Society of Anesthesiologists (ASA) 1-2. The patients were randomly divided into 3 groups: propofol, desflurane, spinal. Intraocular pressure was measured at 5 time points throughout surgery, including baseline (T1), 10 minutes after anesthesia (T2), 10 minutes after prone positioning (T3: early prone), 30 minutes after prone positioning (T4: late prone), and 10 minutes after returning to the supine position (T5). Hemodynamic parameters were measured at these time points. Hemoglobin and hematocrit values were measured preoperatively and on the first postoperative day.||||
33915265|NCT00523614|||CASE_CONTROL|||||||||
33995828|NCT03223779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995829|NCT06457308|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Non-randomized, quasi-experimental design.|f|f|f|t
33995830|NCT06255145|RANDOMIZED|FACTORIAL||OTHER||NONE||Based on the results of the power analysis, it was calculated that 80% power could be obtained at 95% confidence level when at least 42 people (21 people for each group) were included in the study all participants, body composition evaluation was carried out with the Beurer BF 1000 Super Precision device using the Bioelectrical Impedance Analysis principle, fatigue evaluation was carried out with the Fatigue Severity Scale, mobility evaluation was carried out with the Rivermead Mobility Index, and functional status evaluation was carried out with the Functional Independence Scale.||||
33995831|NCT06462027|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33995832|NCT04356313|||COHORT||PROSPECTIVE|||||||
33915266|NCT04569331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a randomized clinical trial on the efficacy of efferent loop stimulation prior to ileostomy closure together with pelvic floor rehabilitation after closure of the ileostomy, in the quality of life of patients undergoing anterior rectal resection|f|f|f|t
33915267|NCT02694094|||COHORT||PROSPECTIVE|||||||
33915268|NCT01422278|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33915269|NCT02548572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995833|NCT04573569|||CASE_ONLY||PROSPECTIVE|||||||
33995834|NCT04067739|||COHORT||RETROSPECTIVE|||||||
33915270|NCT06460077|||COHORT||PROSPECTIVE|||||||
33995835|NCT05802563|||COHORT||PROSPECTIVE|||||||
33995836|NCT05444803|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33995837|NCT00527163|||||PROSPECTIVE|||||||
33995838|NCT00604162|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33995839|NCT01022879|NA|SINGLE_GROUP||TREATMENT||||||||
33995840|NCT05059262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995841|NCT04005690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086934|NCT04225975|NA|SINGLE_GROUP||SCREENING||NONE||||||
33915271|NCT04585217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915272|NCT04092244|||CASE_CONTROL||RETROSPECTIVE|||||||
33915273|NCT02779452|||CASE_CONTROL||RETROSPECTIVE|||||||
33915274|NCT01928043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915275|NCT01860001|||COHORT||PROSPECTIVE|||||||
33915276|NCT00724724|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915277|NCT03731364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915278|NCT00592852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995842|NCT01515605|||COHORT||PROSPECTIVE|||||||
33995843|NCT03129685|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective and non-randomized clinical trial||||
33995844|NCT04143516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single institution prospective study.||||
33995845|NCT01237444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995846|NCT05517304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|sham stimulation comparison|tcVNS versus sham stimulation|t|t|t|t
33995847|NCT04212845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995848|NCT00880139|||COHORT||CROSS_SECTIONAL|||||||
33915279|NCT06187116|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33915280|NCT00148733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915281|NCT05779332|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33915282|NCT01902082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915283|NCT02008838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915284|NCT04021394|||COHORT||PROSPECTIVE|||||||
33915285|NCT02357849|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33915286|NCT06310096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995849|NCT05570539|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995850|NCT03283982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995851|NCT04821232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research data had blinded the statistician.|single blind randomized controlled trial|f|f|f|t
33995852|NCT05426395|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized Clinical Trial|t|t|t|t
33995853|NCT05471947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995854|NCT05020444|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33995855|NCT04877145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995856|NCT05723250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995857|NCT00120783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692333|NCT03480906|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33692334|NCT04318327|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692335|NCT04536831|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33915287|NCT00849251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915288|NCT01836887|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33915289|NCT04980976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After TEE insertion, the pharyngeal mucosa will be evaluated with de C-MAC videolaryngoscope by an anesthesiologist who were blinded to the study||t|f|f|t
33915290|NCT00513097|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915291|NCT04209647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915292|NCT05251454|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33915293|NCT05782335|||COHORT||PROSPECTIVE|||||||
33915294|NCT01149642|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915295|NCT04102878|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915296|NCT05845918|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915297|NCT04403984|||COHORT||RETROSPECTIVE|||||||
33915298|NCT05912855|||CASE_CONTROL||PROSPECTIVE|||||||
33915299|NCT04580394|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33915300|NCT01897181|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915301|NCT01922284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915302|NCT02854904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915303|NCT03270150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915304|NCT05723783|||COHORT||PROSPECTIVE|||||||
33915305|NCT03972124|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33915306|NCT01261806|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33915307|NCT02985905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692336|NCT03045978|||CASE_CONTROL||PROSPECTIVE|||||||
33692337|NCT03989167|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cluster randomized in the primary care setting||||
33692338|NCT05062278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with newly diagnose AML will be allocated 1:1 to recieve single dose vinblastine or daily oral hydroxiurea||||
33915308|NCT01366066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915309|NCT03482323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All baseline and follow-up assessments will be carried out by research staff who are blinded to allocation. The statistician and laboratory staff for the measurement of biomarkers remains still blinded until the end of the whole study.|The participants will be randomised into equally sized arms; tai-chi classes, exercise classes, or control.|f|f|f|t
33915310|NCT00127530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915311|NCT04637945|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33915312|NCT05896618|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33915313|NCT05637723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915314|NCT05830513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915315|NCT02725827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915316|NCT02197936|||CASE_CONTROL||PROSPECTIVE|||||||
33915317|NCT05334680|||COHORT||PROSPECTIVE|||||||
33915318|NCT01869751|||CASE_ONLY||PROSPECTIVE|||||||
33915319|NCT04459702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915320|NCT03215654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33915321|NCT00459485|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915322|NCT02498561|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33915323|NCT02727270|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33915324|NCT06012045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915325|NCT03791359|||COHORT||PROSPECTIVE|||||||
33915326|NCT02222454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915327|NCT05279989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915328|NCT03201146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915329|NCT04347317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915330|NCT03157973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The nature of the intervention rules out masking.|||||
33915331|NCT04116476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915332|NCT03105596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915333|NCT00311181|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33915334|NCT05172193|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2, non-randomized, open-label, clinical trial to evaluate the safety and immunogenicity of SARS-COV-2 Vaccine (Vero Cell) Inactivated up to 6 months post booster dose and a sub cohort study among vaccine arm to evaluate immunogenicity up to 12 months post booster dose in adults aged 18 years old and above who have received the 2 prime doses of one of SARSCOV-2 Vaccines (Vero Cell inactivated-Sinopharm SARS-COV-2 Vaccine, CoronaVac SARSCOV-2 Vaccine, or AstraZeneca SARS-COV-2 Vaccine) authorized for emergency use (EUA) in Indonesia.||||
33915335|NCT03629418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33915336|NCT00037635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915337|NCT02938052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915338|NCT03258346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Pomegranate juice will be administered in double blind placebo controlled method. Coding will be established by POM Wonderful, LLC.||t|f|t|f
33915339|NCT04414176|||CASE_CONTROL||PROSPECTIVE|||||||
33915340|NCT00000150|RANDOMIZED|||TREATMENT||||||||
33915341|NCT04825145|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33915342|NCT04673136|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33692339|NCT05463367|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|All data analysis personnel are masked regarding groupings|"There will be 2 arms of participants, those who have back pain with opioid exposure, and those who have back pain with opioid exposure and opioid misuse disorder. Each participant, regardless of the arm that they are in, will receive each of the possible study interventions. The only difference will be the order of which they receive each interventions.~Recruitment is completed. Of the collected subjects with opioid exposure none exhibited opioid misuse."|t|f|t|f
33915343|NCT04606654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915344|NCT01035242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915345|NCT03103906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915346|NCT00743600|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915347|NCT06521957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692340|NCT06352333|RANDOMIZED|PARALLEL||SCREENING||NONE||"Inclusion criteria:~* 18to60 yearsold~* ASA grade I to II~* Elective upper limb surgery"||||
33995858|NCT06556329|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention arm will have a socially assistive, artificially enhanced robot presence during an intravenous insertion procedure; the standard of care arm will follow standard procedures that are practiced clinically.||||
33995859|NCT00097734|RANDOMIZED|PARALLEL||ECT||NONE||||||
33995860|NCT03915600|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open clinical trial with randomization plus control group||||
33995861|NCT06026215|||COHORT||PROSPECTIVE|||||||
34103572|NCT05891782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study was planned as a randomized controlled clinical trial; by clustered randomization method, cases will be divided into two groups. There are 100 older adults in the nursing home to be studied. Study was planned as group 1 and group 2. The subjects will be assessed by blinded evaluators for primary and secondary outcomes at study baseline (T0), 4 weeks for the intention intervention (T1), 12 weeks for the action intervention (T2), and 8 weeks for the follow-up (T3).|f|f|f|t
33692341|NCT04643470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692342|NCT04582708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692343|NCT01600118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692344|NCT06685640|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33692345|NCT03359239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692346|NCT03759288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692347|NCT03727399|||COHORT||PROSPECTIVE|||||||
33915348|NCT01089582|||||PROSPECTIVE|||||||
33915349|NCT01367301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915350|NCT06342388|||CASE_ONLY||PROSPECTIVE|||||||
33915351|NCT04629612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33915352|NCT01717664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915353|NCT05041452|||CASE_CONTROL||PROSPECTIVE|||||||
33915354|NCT02467647|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33915355|NCT02056535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915356|NCT03684291|||OTHER||PROSPECTIVE|||||||
33915357|NCT02413619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915358|NCT05509218|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomized to one of three conditions: (1) daily surveys plus personalized feedback about yesterday's drinking, with a monetary incentive for survey completion, (2) daily surveys plus personalized feedback about yesterday's drinking, with no monetary incentive, or (3) survey assessment (baseline and follow-up) only||||
33915359|NCT02997449|||COHORT||PROSPECTIVE|||||||
33915360|NCT06281782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Topical retinoids versus topical retinoids wit PRP in acne vulgaris treatment|f|f|f|t
33915361|NCT03147339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915362|NCT02865096|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33915363|NCT04765137|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study with atorvastatin 40 mg||||
33915364|NCT06281145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study consists of two cohorts (breasts cancer and colorectal cancer) with two arms SOC + intervention vs SOC alone.||||
33915365|NCT03177980|||CASE_ONLY||PROSPECTIVE|||||||
33915366|NCT03166865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915367|NCT05509153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomly allocated to either the NAC arm or the placebo arm using Block Randomisation, stratified by site, through a centralised process, with allocation concealment.|t|t|t|t
33915368|NCT04501198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33915369|NCT02159469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915370|NCT00914602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915371|NCT00516633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103573|NCT02922712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086935|NCT05673122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patients were assigned in two allocated groups using computer randomization random allocation software into one of the 2 groups"|"Twenty patients were randomly assigned by specific computer software into two groups either in group (I) or group (II).~Group I: Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, the implant is in contact with the shield.~Group II: Ten patients undergo flapless single immediate implant placement surgery with socket shield technique, there was a jumping gap more than 2mm between the shield and the implant, in which the gap was grafted with Xenograft."|t|f|f|f
34086936|NCT04011852|||COHORT||PROSPECTIVE|||||||
34086937|NCT04632485|||COHORT||PROSPECTIVE|||||||
34086938|NCT03889288|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086939|NCT04397978|||COHORT||PROSPECTIVE|||||||
34086940|NCT05111717|||OTHER||PROSPECTIVE|||||||
34086941|NCT00255580|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34086942|NCT04657913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34086943|NCT01767337|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33915372|NCT03587480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915373|NCT01761721|||COHORT||PROSPECTIVE|||||||
33915374|NCT06525545|RANDOMIZED|PARALLEL||TREATMENT||NONE||interventional randomized case control||||
33915375|NCT06495307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915376|NCT01998269|||COHORT||CROSS_SECTIONAL|||||||
33915377|NCT03529136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with decompensated liver cirrhosis are going to be assigned to receive standard medical care plus UC-MSC treatment with two different protocol (group 1 and group 2) or standard medical care (control). Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1（once every 4 days), and two times of MSC infusion once every 7 days to group 2.||||
33915378|NCT02958397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915379|NCT00302718|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33915380|NCT01665521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915381|NCT00539253|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915382|NCT03247205|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive the intervention||||
34086944|NCT03160950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086945|NCT05650502|||CASE_CONTROL||OTHER|||||||
34086946|NCT03658525|NA|SINGLE_GROUP||TREATMENT||NONE||To assess delivery of prostate IMRT on the MR linac||||
33915383|NCT03363412|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34086947|NCT00478621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086948|NCT01989832|||COHORT||PROSPECTIVE|||||||
34086949|NCT01496742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34086950|NCT04749199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A blinded assessor and statistician will evaluate a two-arm, parallel-group, RCT that compares enhanced mirror therapy, comprised of increased task complexity and mirror image blurriness, with standard mirror therapy training among 30 participants with chronic stroke.|t|f|f|t
34086951|NCT01389778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086952|NCT04131972|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086953|NCT05284175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086954|NCT03986099|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Single blind|Patients assigned to either point of care (POC) or standard of care (SOC)|t|f|f|f
34086955|NCT04487548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding of study participants is not possible. Blinding of staff may not always be possible, although staff will not be informed which group the participant has been randomized to.|"Study Design This pilot randomized controlled trial with two parallel arms will be undertaken with current smokers who are scheduled for elective surgery at RCH. Participants will be randomized to a smoking cessation bundle (video, electronic or mailed brochure, referral to QuitNow.ca Smokers' Helpline and pharmacological smoking cessation therapy) or standard care (advice to quit and inconsistent recommendation of resources).~All current adult smokers being scheduled for elective surgery at RCH will be invited to participate. The investigators plan on recruiting 30 participants with 15 participants per group. Every eligible patient will be invited to participate."|f|t|f|t
34086956|NCT03575169|||COHORT||PROSPECTIVE|||||||
34086957|NCT06514859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086958|NCT06466239|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34086959|NCT03857256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086960|NCT01756703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915384|NCT03625427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Administration of the POA supplements and placebo (olive oil capsules) will be via a simple randomized double-blinded allocation. The study sponsor will provide the Principal Investigator with bags, or boxes, of single serve packets containing two capsules for each daily dose per participant in accordance with the proper dosage for each of the three arms of the study. The study sponsor will hold the code for the subjects and will randomize the capsules. No site personnel will have access to the randomization allocation; only the study sponsor will have the code. The identity of the capsules will be revealed once all analyses are complete.|12-week randomized, double blinded study in volunteers consuming either the test agent, 500 mg or 1,000 mg POA per day, or an olive oil containing fatty acid (placebo). There are three arms to study and 41 individuals per arm, thus, a total of 123 subjects.|t|t|t|t
33915385|NCT03873402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915386|NCT03615469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The PI will collect baseline data before the participant is randomized. The intervention/sham will be set-up by the RA and will be collected after the PI leaves the department so those collecting data will not know which group the participant has been/will be participating in. The RA who is trained in both NMES and Sham intervention will then look at the randomization schedule, and set up and train the participants on equipment use. Once trained, participants will be contacted via phone weekly by the RA who initially trained them (in order to maintain blinding). The RA applying the intervention will not have any part in the data collection of the rest of the measurements (other than adherence, tolerance and problems with equipment).|This is a double blinded, randomized controlled longitudinal study design to determine if NMES will increase muscle mass and strength, decrease sitting and lying time, and improve HF symptoms and exercise capacity thus improving likelihood of engagement with a structured exercise program. Patients will be randomized to either intervention that includes NMES or to a sham(TENS)/wait list control group. In order to ensure that the two groups are comparable between treatment and sham interventions, the participants will be randomized according to gender. Randomization via minimization will be used in order to avoid an unbalanced number of women in the two comparison groups due to chance. A file of the computer-generated random assignments will be kept by the research assistant so the PI/data collector remains blinded in a protected Box Health account.|t|t|t|t
33915387|NCT01042613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33915388|NCT04486963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915389|NCT01469806|||CASE_ONLY||PROSPECTIVE|||||||
33915390|NCT03802838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33915391|NCT03777722|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Crossover placebo controlled design|t|t|f|t
33915392|NCT01429792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915393|NCT01794481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915394|NCT03864718|||COHORT||PROSPECTIVE|||||||
33915395|NCT01575405|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33915396|NCT05152472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086961|NCT02305264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692348|NCT03632343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This will be a multi-centre, waitlist group controlled, data analyst blinded, 3-arm parallel-group superiority randomized controlled trial (RCT) with 1:1:1 allocation. Randomization will be stratified by recruitment site to account for differences in care across sites49 with block sizes of 6 and 9 within each stratum. This trial has been designed along the pragmatic end of the pragmatic-explanatory continuum. Our approach to study eligibility criteria, intervention intensity, and participant adherence will determine intervention effect under real-world conditions.|t|t|f|f
33692349|NCT00727831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086962|NCT01266343|||CASE_CONTROL||RETROSPECTIVE|||||||
33692350|NCT01389518|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33692351|NCT06710639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692352|NCT05598385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692353|NCT05822544|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This study consists of six parts: Part A (single-ascending dose), Part B (multiple-ascending dose), Part C (adaptive single- and/or multiple-ascending dose), Part D (relative bioavailability of a tablet formulation of TLC-6740), Part E (drug-drug interaction study to determine the effect of TLC-6740 on drug metabolizing enzymes), and Part F (phase 1b).|t|f|t|f
33692354|NCT03441243|||CASE_CONTROL||PROSPECTIVE|||||||
33692355|NCT02730338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692356|NCT06675812|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692357|NCT05205954|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33692358|NCT03395925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692359|NCT06710548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692360|NCT03613610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33692361|NCT04160728|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33692362|NCT01270061|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33692363|NCT05113394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|double blinded|Randomized (1:1), double blinded, placebo controlled, parallel arms, multi-site, Phase II study; 3 year treatment phase with further 1.5 year follow-up phase.|f|f|f|t
33692364|NCT06001385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915397|NCT03670914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective single cohort study that will evaluate the efficacy of the WatchPAT200 device by comparing it to an in-lab polysomnography.||||
33915398|NCT01563640|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33915399|NCT04445402|||OTHER||PROSPECTIVE|||||||
33915400|NCT00578799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915401|NCT04365985|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|No other parties blinded|Prospective, single center, randomized, double blinded study of naltrexone with an open label extension using ketamine as a rescue drug for patients who progress in their disease|t|t|t|f
33915402|NCT04651725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|a blind physiotherapist will assess the study in outcomes in all patients.|randomized pretest-posttest control group design|f|f|f|t
33915403|NCT00352755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915404|NCT05941351|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915405|NCT01449201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915406|NCT06140069|||COHORT||PROSPECTIVE|||||||
33915407|NCT06310785|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the patients who participated in the trial nor the analysis of the results of the study were aware of the experimental group||t|f|f|t
33915408|NCT01409031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915409|NCT00923819|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915410|NCT06554028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915411|NCT04709302|||COHORT||PROSPECTIVE|||||||
33915412|NCT02526719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915413|NCT06553508|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33915414|NCT01397552|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33915415|NCT05796505|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Rapid cycle cluster randomized controlled trial (RCT). Randomization will occur at different levels, depending on the intervention that is being tested. Interviews: 14 key informant interviews will be conducted within each state correctional system that is identified as high performing (high vaccination rates for staff and incarcerated individuals). For rapid RCT: Pennsylvania Department Of Corrections operates 23 prisons which incarcerate approximately 35000 men and 1800 women. Every incarcerated individual in a PA prison is a potential candidate for the rapid RCT.||||
33915416|NCT00948818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915417|NCT02565771|||COHORT||PROSPECTIVE|||||||
33915418|NCT02172079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915419|NCT04914832|NA|SINGLE_GROUP||PREVENTION||NONE||"1. Open-label, single-arm implementation study.~2. Prospective hospital and mortuary-based case-control study with test-negative controls (test-negative case-control study) and other hospital controls (standard case-control study)."||||
33915420|NCT01870024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915421|NCT02428452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915422|NCT00100412||||DIAGNOSTIC||||||||
33915423|NCT06115434|||OTHER||OTHER|||||||
33915424|NCT06350058|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915425|NCT00652431|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915426|NCT03893058|||COHORT||PROSPECTIVE|||||||
33915427|NCT03159377|||COHORT||PROSPECTIVE|||||||
33915428|NCT04791683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant) In the single-blind method,subjects do not know which of the experimental or control goups they were selected and therefore which method was applied to them. The researcher konows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects.|Parallel assignment Randomized controlled experimental study|t|f|f|f
33915429|NCT02527551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915430|NCT06080776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915431|NCT02082145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915432|NCT02523664|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33915433|NCT02295735|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33915434|NCT04144855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781344|NCT06104540|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A preliminary study will be conducted with 24 patients, 8 in the control group and 8 in the experimental group I olive oil and the experimental group II 8 with liquid vaseline. Patients will be divided into control and experimental groups by simple stratified randomization method.~In order to prevent the choice of treatment from being at the discretion of the investigator, it is necessary to ensure that the patients are randomly assigned to the study groups. The easiest method for this is simple randomization. The envelope drawing method will be used for randomization and patients who meet the research criteria will be stratified according to gender. To ensure gender stratification in the control and experimental groups, male patients will be assigned to control and experimental groups and female patients will be assigned to control and experimental groups."||||
33781345|NCT05368103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781346|NCT05632484|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781347|NCT06615128|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781348|NCT04688411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781349|NCT01221077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781350|NCT01140347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781351|NCT05640921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915435|NCT05086289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915436|NCT02099942|||CASE_ONLY||PROSPECTIVE|||||||
33915437|NCT05855928|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33915438|NCT03542045|||COHORT||PROSPECTIVE|||||||
33915439|NCT00093678|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33915440|NCT00498238|NA|SINGLE_GROUP||||NONE||||||
33915441|NCT05696171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915442|NCT06013605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors were not involved during the intervention process. Respondents were also asked not to inform the outcome assessor of the measures they received.|This study used a parallel Randomized Controlled Trial (RCT) with a 1:1 ratio.|f|f|f|t
33915443|NCT04812418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915444|NCT01319643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915445|NCT02277899|||COHORT||PROSPECTIVE|||||||
33915446|NCT01692353|||COHORT||CROSS_SECTIONAL|||||||
33915447|NCT05689138|||CASE_CONTROL||PROSPECTIVE|||||||
33915448|NCT01989234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915449|NCT05268315|NA|SINGLE_GROUP||OTHER||NONE||||||
33915450|NCT02709993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915451|NCT01518426|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915452|NCT04134585|||COHORT||PROSPECTIVE|||||||
33915453|NCT04003077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||observational case-controlled study||||
33915454|NCT00434122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33915455|NCT02260856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33915456|NCT05411640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915457|NCT02979730|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33995862|NCT05822375|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Data will be de-identified prior to analysis|"This is a randomized controlled trial. All enrolled participants will complete the pretest baseline survey. After baseline data collection is completed, the participants will be randomized into either a control or intervention group. This randomized controlled trial study design will offer the BT coaching to the intervention group for the duration of 4-months (February 1st 2023- May 31st 2023) and to the control group for the duration of 4-months (September 1st 2023 - December 31st 2023).~At two different timepoints, all participants will be offered surveys containing the following validated indices: burnout, imposter syndrome, self-compassion, moral injury, loneliness, and flourishing. All participants will be offered the survey at baseline- September 2023 (T0), post intervention- January 2024 (T1)."|f|f|f|t
33995863|NCT03784534|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Pathophysiological and longitudinal study with no therapeutic intervention||||
33995864|NCT03090880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33995865|NCT01641302|||||PROSPECTIVE|||||||
33995866|NCT06488157|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33995867|NCT03641001|RANDOMIZED|PARALLEL||PREVENTION||NONE||Community based Randomized Controlled Trial||||
33995868|NCT05608239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995869|NCT06562920|NA|SINGLE_GROUP||TREATMENT||NONE||This study plans to enroll 20 patients with previously untreated T1-3N0-1M0 resectable limited-stage small cell lung cancer. They will receive 3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment. After surgery, adjuvant therapy will be considered based on the results of MDT discussion.||||
33995870|NCT02287480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995871|NCT04948476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781352|NCT05793892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||test drug：Lidocaine tetracaine cream（CU-30101） control drug：Lidocaine tetracaine cream（Pliaglis®）|t|t|t|t
33781353|NCT06270173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781354|NCT06649552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781355|NCT00875147|||COHORT||RETROSPECTIVE|||||||
33781356|NCT04155099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blinded study meaning both Ochsner study staff and participating individuals will not know to which group they are assigned/randomized. A third party will be responsible for providing study participant randomization and recording the exact treatment to which all study participants are assigned.|Study individuals will be placed into one of four study treatment groups: High dose investigational microbiota restoration therapeutic RBX7455 group, Low dose investigational microbiota restoration therapeutic RBX7455 group, or a pill quantity-matched Placebo group. Individuals will be randomized in a 1:1:1/2:1/2 manner. It is anticipated of the 75 potentially enrolled individuals, 50 will receive active treatment (high or low dose investigational microbiota restoration therapeutic) and 25 will receive placebo.|t|t|t|f
33781357|NCT03582137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781358|NCT01541319|||||PROSPECTIVE|||||||
33781359|NCT06576284|||COHORT||PROSPECTIVE|||||||
33781360|NCT06110117|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be evaluated for symptom severity before and during use of the nasal spray product.||||
33781361|NCT06493279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781362|NCT01341080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781363|NCT03032835|||COHORT||PROSPECTIVE|||||||
33781364|NCT06460467|||COHORT||RETROSPECTIVE|||||||
33692365|NCT03832075|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692366|NCT06637332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692367|NCT06180694|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692368|NCT03306862|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized, controlled, cross-over study||||
33692369|NCT00109174|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33692370|NCT05870293|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33692371|NCT05090566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692372|NCT01164540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692373|NCT01843088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692374|NCT05053113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781365|NCT06697639|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33781366|NCT00110201|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33781367|NCT05732948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781368|NCT03276364|||COHORT||PROSPECTIVE|||||||
33781369|NCT02395185|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33781370|NCT02512146|||CASE_CONTROL||PROSPECTIVE|||||||
33781371|NCT03739411|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33781372|NCT06148766|NA|SINGLE_GROUP||OTHER||NONE||||||
33781373|NCT05388916|||COHORT||PROSPECTIVE|||||||
33781374|NCT05406934|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781375|NCT05506644|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781376|NCT06009380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781377|NCT03312985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analysist do not know the group assignment.||f|f|f|t
33781378|NCT03574909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33781379|NCT05138536|||COHORT||RETROSPECTIVE|||||||
33781380|NCT00287638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781381|NCT01772056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33781382|NCT01658488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781383|NCT01581853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781384|NCT06697860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781385|NCT03392532|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33781386|NCT03310463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781387|NCT01304524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781388|NCT05750745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781389|NCT06697366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781390|NCT01522339|NA|SINGLE_GROUP||||NONE||||||
33781391|NCT02821312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915458|NCT03866252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915459|NCT06553443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All are blinded except procedurist and protocol administrator.||t|t|f|t
33915460|NCT02712606|||COHORT||PROSPECTIVE|||||||
33915461|NCT01398033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915462|NCT04428684|RANDOMIZED|PARALLEL||OTHER||SINGLE|Sponsor, independant statistician, radiologists and bioanalytical lab are all blinded to treatment regimen|Comparative parallel design aimed at showing non-inferiority|f|f|f|t
33915463|NCT05175937|||CASE_CONTROL||PROSPECTIVE|||||||
33915464|NCT05691634|NA|SINGLE_GROUP||OTHER||NONE||||||
33915465|NCT06516939|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33915466|NCT03148431|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33915467|NCT04949178|||COHORT||PROSPECTIVE|||||||
33915468|NCT01682499|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915469|NCT00610376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915470|NCT05525338|RANDOMIZED|PARALLEL||TREATMENT||NONE|The alectinib Cmin for patients treated in arm B (standard dose arm) will be blinded to participants and care providers|Both study-arms will receive oral alectinib (Alecensa®, Roche). In arm A (TDM arm), the alectinib dose will be increased if Cmin \<435 ng/mL and manageable toxicity. In both arms, alectinib dose can be reduced based on toxicity.||||
33915471|NCT02403830|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33915472|NCT00002207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33915473|NCT03001154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915474|NCT05672966|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33915475|NCT04387994|||COHORT||PROSPECTIVE|||||||
33915476|NCT00679731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915477|NCT05862038|||COHORT||RETROSPECTIVE|||||||
33915478|NCT03814018|||CASE_ONLY||RETROSPECTIVE|||||||
33781392|NCT04758507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To mask treatments to physicisans and recipients, both FMT bottles and syringes will be covered with dark-coloured paper before the infusion, and the patients will be unable to see the endoscopic display during the procedure. Moreover, the physicians who will evsaluate patients at follow-up will not aware of the treatment being administered.|randomized controlled trial|t|t|t|t
33781393|NCT00230451|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781394|NCT04660084|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||A pragmatic, parallel-arm, single-blinded, single-centre, randomised controlled superiority trial|t|f|f|f
33781395|NCT04842968|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Outcome assessor was blinded|Five to six years ago specimens from a total fo 200 consecutive colorectal cancer resection cases were randomized into two groups: 1. main supplying artery was cannulated and injected with methylene blue solution, 2. no intervention, routine specimen handling.|t|f|f|t
33781396|NCT06373848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study was carried out utilizing a double-blind approach. In order to guarantee objectivity, all three groups - the Vitamin E group, the Coq10 group, and the control group - received medications that were indistinguishable in terms of appearance, packaging, and color. Additionally, to minimize any potential bias, a clinician who had no association with the research labeled the medications as A, B, and C (empty) based on their content, and then distributed them among the patients.|Parallel Assignment, Randomized, Double-blind, Controlled design.|t|t|t|t
33781397|NCT05087238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781398|NCT01419847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781399|NCT00484146|||COHORT||PROSPECTIVE|||||||
33781400|NCT06376994|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33781401|NCT06696196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781402|NCT01321229|||COHORT||PROSPECTIVE|||||||
33781403|NCT00201253|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781404|NCT06206681|||COHORT||RETROSPECTIVE|||||||
33781405|NCT06116110|||COHORT||PROSPECTIVE|||||||
33781406|NCT02723357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33995872|NCT05270499|||COHORT||PROSPECTIVE|||||||
33995873|NCT03931616|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
33995874|NCT05578443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995875|NCT04823091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995876|NCT04260373|NA|SINGLE_GROUP||OTHER||NONE||||||
33995877|NCT02319655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995878|NCT04935905|||COHORT||PROSPECTIVE|||||||
33995879|NCT06356636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|to be updated|The participants are divided into two or more groups, with each group receiving a different intervention or a control condition. The outcomes of each group are compared at the end of the study to assess the effectiveness of the intervention.|t|t|t|t
33995880|NCT01710722|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33995881|NCT01524874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33995882|NCT01662960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33995883|NCT00767481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995884|NCT03050021|||COHORT||RETROSPECTIVE|||||||
33995885|NCT02818790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33995886|NCT00712816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995887|NCT05653986|||COHORT||PROSPECTIVE|||||||
33995888|NCT00155220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33995889|NCT00945490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995890|NCT03125408|||COHORT||PROSPECTIVE|||||||
33995891|NCT02586350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995892|NCT00102349||||PREVENTION||||||||
33995893|NCT06311929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995894|NCT03638063|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995895|NCT06113991|||CASE_CONTROL||RETROSPECTIVE|||||||
33995896|NCT00583999|||COHORT||RETROSPECTIVE|||||||
33995897|NCT01283503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915479|NCT05078099|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single-arm prospective||||
33915480|NCT06553183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915481|NCT02047630|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33915482|NCT02211976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915483|NCT02626572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915484|NCT02214316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781407|NCT03168438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781408|NCT00451698|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33781409|NCT06593327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781410|NCT05910931|||CASE_ONLY||PROSPECTIVE|||||||
33781411|NCT02813499|||CASE_ONLY||PROSPECTIVE|||||||
33781412|NCT02810743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915485|NCT06349733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915486|NCT04640207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915487|NCT03053596|||CASE_ONLY||PROSPECTIVE|||||||
33915488|NCT06017583|RANDOMIZED|PARALLEL||TREATMENT||NONE||The random number table method.||||
33915489|NCT04872335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915490|NCT01023412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915491|NCT02382341|||CASE_ONLY||PROSPECTIVE|||||||
33915492|NCT02445144|||CASE_CONTROL||PROSPECTIVE|||||||
33915493|NCT00809458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915494|NCT02678663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915495|NCT06085261|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915496|NCT06062407|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33915497|NCT04195659|||COHORT||PROSPECTIVE|||||||
33915498|NCT02622100|||COHORT||PROSPECTIVE|||||||
33915499|NCT01902953|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915500|NCT04773899|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915501|NCT04995328|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915502|NCT01822691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915503|NCT01691352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33915504|NCT04109235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One of the investigators, Justine Horne, will be blinded to group allocations.||f|f|t|f
33915505|NCT04007055|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized controlled trial||||
33915506|NCT04904926|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995898|NCT04830540|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33692375|NCT05780710|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||"Study participants are asked to wear the Aktiia bracelet continuously every day for 4 to 19 weeks in total, depending on the study group, and initialize their Aktiia bracelet with the Aktiia cuff at different timepoints.~In parallel, GROUP 1 and 2 participants are asked to take 3 successive Blood Pressure lowering medications during 2 weeks per treatment. Treatment periods are followed by 2 weeks of washout. The order of drug intake is randomly assigned for every participant. GROUP 3 participants will receive and individualized antihypertensive medication assigned by the investigator."|f|f|t|f
33995899|NCT06560034|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33995900|NCT05256992|RANDOMIZED|PARALLEL||TREATMENT||NONE||Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.||||
33692376|NCT06701006|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This trial will use a pre- post- sequential design in which each clinic has a control period (usual care), followed by provider training, and then an intervention period (usual care plus Jaspr app).||||
33692377|NCT05210231|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33692378|NCT03271229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692379|NCT00295828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33692380|NCT04483661|||CASE_ONLY||CROSS_SECTIONAL|||||||
33692381|NCT05516953|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blind||t|f|f|t
33692382|NCT05514717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692383|NCT02744469|||COHORT||PROSPECTIVE|||||||
33692384|NCT03686826|||COHORT||PROSPECTIVE|||||||
33692385|NCT03986151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33692386|NCT04351555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The two arms with SoC chemotherapy (placebo plus chemotherapy versus osimertinib plus chemotherapy) will be double-blinded and placebo-controlled.~Osimertinib monotherapy arm will be open label, sponsor-blind."||t|f|t|f
33692387|NCT02725853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692388|NCT06448013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692389|NCT06710197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study will examine changes in the tumor microenvironment (TME) induced by 14 days of pre-operative IL-1-inhibiting therapy among patients with early breast cancer (including TNBC and ER-low positive \[1-9%\]). Key immune biomarkers (TILs, TAMs, NK cells, IL-1β and inflammasome component expression) will be evaluated at baseline and following 14 days of IL-1 antagonist therapy (Anakinra) using paired tissue specimens. A total of 50 patients will be recruited across 2-5 institutions, randomized 4:1 to treatment (n=40) versus control (n=10).||||
33692390|NCT01858311|||COHORT||PROSPECTIVE|||||||
33692391|NCT00978432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692392|NCT05290545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781413|NCT05159908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781414|NCT01930617|||CASE_ONLY||RETROSPECTIVE|||||||
33781415|NCT03031704|||CASE_ONLY||PROSPECTIVE|||||||
33781416|NCT06065774|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be assigned into four treatment groups Group I comprises of patient undergoing The Laterally Closed Tunnel Technique with SCTG , Group II comprises of patients undergoing The Laterally Closed Tunnel Technique with collagen matrix mucograft , Group III comprises of patients undergoing Modified Coronally Advanced Tunnel Technique with SCTG and Group IV comprises of patients undergoing Modified Coronally Advanced Tunnel Technique with collagen matrix mucograft||||
33781417|NCT00183573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781418|NCT05862233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915507|NCT04158089|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Due to the behavioral design of the intervention, it is impossible to mask participants (who are asked to do tasks) or investigators (who train participants and contact them about tasks). However, care providers are not involved in the study, and the statistical analyses will be conducted with a de-identified data set.|This intervention examines whether the use of texted attachment exercises to effectively increase maternal prenatal bonding.|f|t|f|t
33915508|NCT03628417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This randomized double blinded phase II study is comparing the effect of calcium electroporation with ECT with bleomycin on patients with cutaneous metastases of any histology where the metastases are randomized by block randomization and are done separately in each patient.|t|t|t|t
33915509|NCT04397718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915510|NCT00001940||||TREATMENT||||||||
33915511|NCT02237157|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Subjects receive a gradual increase of drug dose, until the full systemic dose is administered. Cycle 1: 250mg/m2. Cycle 2: 500mg/m2. Cycle 3: 750mg/m2. Cycle 4: 1000mg/m2.||||
33915512|NCT06473493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995901|NCT05319054|RANDOMIZED|PARALLEL||OTHER||NONE||Trials within Cohorts||||
33995902|NCT00576654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995903|NCT01167335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995904|NCT04143880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995905|NCT06628297|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995906|NCT03252613|||COHORT||PROSPECTIVE|||||||
33995907|NCT01539096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33995908|NCT00663234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915513|NCT04570657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915514|NCT00618449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33915515|NCT02669862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995909|NCT03586219|RANDOMIZED|PARALLEL||OTHER||NONE||This is a randomized, non-blinded, controlled trial that will be performed at two sites. Study subjects will be randomized to either the control arm (standard perioperative instructions) or intervention arm (standard perioperative instructions with additional perioperative opioid-specific education) using a randomization program in a 1:1 ratio.||||
33995910|NCT06626880|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995911|NCT04341883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995912|NCT01540422|||CASE_ONLY||PROSPECTIVE|||||||
33995913|NCT05899192|||COHORT||CROSS_SECTIONAL|||||||
33995914|NCT02419339|||COHORT||PROSPECTIVE|||||||
33995915|NCT00975494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995916|NCT04423380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995917|NCT05624788|||CASE_CONTROL||PROSPECTIVE|||||||
34086963|NCT01164436|||COHORT||PROSPECTIVE|||||||
34086964|NCT06552468|||COHORT||PROSPECTIVE|||||||
34086965|NCT06206486|||CASE_CONTROL||PROSPECTIVE|||||||
34086966|NCT01555775|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34086967|NCT03668210|||CASE_CONTROL||RETROSPECTIVE|||||||
34086968|NCT05645991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34086969|NCT02105090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34086970|NCT02992717|||COHORT||PROSPECTIVE|||||||
33915516|NCT06179615|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33915517|NCT01111201|||COHORT||RETROSPECTIVE|||||||
33915518|NCT03670394|||COHORT||PROSPECTIVE|||||||
33692393|NCT06287918|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915519|NCT05390424|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915520|NCT01350960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915521|NCT01193192|||CASE_CONTROL||RETROSPECTIVE|||||||
33915522|NCT02551198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33915523|NCT04004559|||COHORT||RETROSPECTIVE|||||||
33915524|NCT05380934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915525|NCT00654784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915526|NCT00234572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33915527|NCT06014710|NA|SINGLE_GROUP||OTHER||NONE||||||
33915528|NCT00723073|||COHORT||RETROSPECTIVE|||||||
33995918|NCT00550329|||||PROSPECTIVE|||||||
33995919|NCT05579548|||COHORT||PROSPECTIVE|||||||
33995920|NCT03992183|||CASE_ONLY||PROSPECTIVE|||||||
33995921|NCT00774540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995922|NCT06622330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|t|f
34086971|NCT04262219|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34086972|NCT04605081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34086973|NCT03540238|||OTHER||PROSPECTIVE|||||||
34086974|NCT04748718|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34086975|NCT00872742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086976|NCT02054780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915529|NCT05958095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware of whether they are receiving the MamaLift Plus interventional device or the digital placebo device. The applications have the same user interface and require a similar amount of time to complete activities. Participants in both arms will receive treatment as usual in addition.|The data of 200 participants will be collected and analyzed for this study. Participants will be selected from a pool of patients who have given birth in the last three months prior to the study start date and been diagnosed with postpartum depression or have experienced depressive symptoms. The study aims to recruit a diverse study cohort across age, race, and SES to reflect the intended user population in the United States.|t|f|f|f
33915530|NCT04729556|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915531|NCT05766839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915532|NCT00706667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915533|NCT04469374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to group allocation.|The project will be a randomised controlled trial, investigating between and within group differences pre- and post-intervention. There will be two trial arms: an intervention group and sham control group.|t|f|f|t
34086977|NCT02933814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086978|NCT05167071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086979|NCT01390506|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34086980|NCT05192642|||COHORT||RETROSPECTIVE|||||||
34086981|NCT05853900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34103574|NCT06483217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692394|NCT02779712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915534|NCT01591213|||CASE_ONLY||PROSPECTIVE|||||||
33692395|NCT00586846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692396|NCT02962947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692397|NCT06161480|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study that will be conducted in a convenience sample of adult medicine ICU||||
33692398|NCT03522753|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The resident/fellow performing closure will know what has been done for their patient, but blinded to other participants. Splints or other dressings will cover the closure. Patients will be physically blinded (i.e. eye cover) during the removal procedure. Patients and observers will assess scar appearance. Observers are the blinded surgeon or other blinded medical personnel (nurse, research assistant, CRNP, or resident/fellow who was not involved)."||t|t|t|t
33692399|NCT05440149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692400|NCT05428098|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34086982|NCT04738383|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||control group and 3 different forms of medical supervision||||
33915535|NCT00541138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915536|NCT04032171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915537|NCT02034474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915538|NCT05500924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915539|NCT03497026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915540|NCT06282471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915541|NCT04973774|||COHORT||PROSPECTIVE|||||||
33915542|NCT02466321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915543|NCT00698789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915544|NCT05872594|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33915545|NCT01317615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915546|NCT04204655|||COHORT||PROSPECTIVE|||||||
33915547|NCT04853524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915548|NCT03550131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants receiving intervention will not be informed whether it is the standard or personalized treatment.|This study will utilize a 2-group randomized controlled trial design including 2 pre-intervention and 4 post-intervention assessments. The comparator group (standard intervention) will have 112 caregiver-care receiver dyads, and the experimental group (personalized intervention) will have 113 caregiver-care receiver dyads.|t|f|f|f
33915549|NCT03971084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Same sugar free gum appearance, labelling differ with a letter (A or B)|Monocentric, randomised, double-blind, cross-over controlled study with two arms|t|t|t|t
33915550|NCT04178252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915551|NCT00306774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915552|NCT03371160|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915553|NCT03629392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Participant: The diets are similar except for methionine and cysteine, and it is thought that the participants will not be able to identify their treatment allocation by taste.~Investigator: Randomization will be carried out by an investigator that is not related to the study. All foods will be pre-packaged and delivered to the participants by an unrelated company."||t|f|t|f
33915554|NCT01353937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915555|NCT01711320|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33915556|NCT05444478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915557|NCT00702585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915558|NCT02168673|||COHORT||PROSPECTIVE|||||||
33915559|NCT05274113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915560|NCT04399512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cross-sectional and Interventional study|f|f|f|t
33915561|NCT02864940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915562|NCT01752582|RANDOMIZED|PARALLEL||||NONE||||||
33915563|NCT00495495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33915564|NCT01676142|||CASE_CONTROL||PROSPECTIVE|||||||
33915565|NCT03145194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind until the point of primary endpoint.||t|t|t|f
33915566|NCT00364494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33915567|NCT05982925|||COHORT||PROSPECTIVE|||||||
33995923|NCT05129176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33995924|NCT00052221|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33995925|NCT01193972|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33995926|NCT05325268|||COHORT||RETROSPECTIVE|||||||
33995927|NCT02114788|||COHORT||PROSPECTIVE|||||||
33995928|NCT01787695|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33995929|NCT01002287|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086983|NCT05411237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086984|NCT01675778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692401|NCT03711266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915568|NCT01255826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915569|NCT04614116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Non blinded, randomised, open label||||
33915570|NCT06200740|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33915571|NCT03898869|||CASE_ONLY||PROSPECTIVE|||||||
33915572|NCT01040208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915573|NCT05692648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single (participant, outcomes assessor)|single-centered, single-blind, 3-arm, pretest-posttest parallel-group randomized controlled trial|t|f|f|f
33915574|NCT05019040|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915575|NCT06011330|||COHORT||RETROSPECTIVE|||||||
33915576|NCT02847728|||OTHER||PROSPECTIVE|||||||
33995930|NCT05213052|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||An open-label study design where all study participants will receive the active test product and no placebo is used.||||
33995931|NCT02007863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995932|NCT05834751|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995933|NCT02637141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995934|NCT00000159|RANDOMIZED|||TREATMENT||DOUBLE||||||
34103575|NCT05965479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915577|NCT04496791|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33915578|NCT03523221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33915579|NCT03172520|NA|SINGLE_GROUP||OTHER||NONE||||||
33915580|NCT05255913|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33915581|NCT02848339|||COHORT||PROSPECTIVE|||||||
33915582|NCT00059215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915583|NCT03025217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915584|NCT03645772|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915585|NCT01870219|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33915586|NCT01218789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915587|NCT00756496|NA|SINGLE_GROUP||SCREENING||NONE||||||
33915588|NCT02851433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915589|NCT05528874|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Subject and investigators cannot know which of the last 2 formulations are given and the unmasking will be made by the coordinator group of Nutracore project|This study is composed by 2 parts. The same participants are enrolled in a single arm study (5 days), followed by a cross-over part (2 days)|t|t|t|f
33915590|NCT00456729|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915591|NCT05564286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33915592|NCT05341674|||CASE_CONTROL||RETROSPECTIVE|||||||
33915593|NCT04627298|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|On enrollment, participants randomly assigned to condition.|Random assignment to intervention or comparison|t|f|f|f
33995935|NCT03928405|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consisted of 32 subjects, which were diagnosed as mild or moderate AD by the neurologist. The balance, fall risks and gait speed were assessed. Training group was trained with games selected from different categories such as balance and aerobic exercises with Nintendo Wii virtual reality device for 6 weeks, 1 session 30 min, 2 times a week.||||
33995936|NCT03342339|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995937|NCT02244190|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33995938|NCT01196390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995939|NCT05941390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995940|NCT05104996|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33995941|NCT03827395|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33995942|NCT00680498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33995943|NCT05495763|||COHORT||PROSPECTIVE|||||||
33995944|NCT03921801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Thirty older adults will be recruited and randomized into two groups. The other groups receive an intervention including strength training and gait retraining lasting 8 weeks while the other group receives only the gait retraining. Outcome measures are obtained before and after the intervention period.||||
33995945|NCT02316054|||COHORT||PROSPECTIVE|||||||
33995946|NCT00887419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692402|NCT03970213|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Only the CRNA who is administering the medications is unmasked until completion of the data collection period.|Randomized, double-blind|t|t|t|t
33692403|NCT04665739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692404|NCT00145600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692405|NCT05365412|||COHORT||RETROSPECTIVE|||||||
33692406|NCT06403436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692407|NCT02288143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692408|NCT01388920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692409|NCT05128929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692410|NCT02752971|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33692411|NCT04944940|||COHORT||PROSPECTIVE|||||||
33692412|NCT01872260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692413|NCT03777384|||CASE_ONLY||PROSPECTIVE|||||||
33692414|NCT06707285|||CASE_CONTROL||RETROSPECTIVE|||||||
33692415|NCT01739673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692416|NCT05293015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692417|NCT01836224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692418|NCT01812772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692419|NCT03276819|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Cohort A : Patients with OPML Cohort B : Patients with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC Cohort C : Patients with resectable HNSCC wich are not eligible to cohort B||||
33692420|NCT06275412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33692421|NCT02038452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692422|NCT05152862|||COHORT||RETROSPECTIVE|||||||
33692423|NCT05939388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692424|NCT04768673|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692425|NCT02386800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692426|NCT05490238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692427|NCT06422208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915594|NCT03206242|||COHORT||PROSPECTIVE|||||||
33915595|NCT01019486|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915596|NCT02879123|||OTHER||PROSPECTIVE|||||||
34086985|NCT05072288|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive an adapted remote physical program. Half of the participants will do a 12 weeks control prior to intervention.||||
33692428|NCT00003173||||TREATMENT||||||||
33692429|NCT01076816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692430|NCT05689697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomized asignment to placebo or IP group, double-blind design||t|f|t|f
33692431|NCT03524079|||COHORT||PROSPECTIVE|||||||
33692432|NCT04565184|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible children for whom parent/guardian informed consent are obtained will be randomized to receive either artesunate-amodiaquine (group A) or artemether-lumefantrine (group B) in the ratio 1:1.||||
33692433|NCT05252065|||COHORT||PROSPECTIVE|||||||
33692434|NCT05529069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692435|NCT02675686|||COHORT||PROSPECTIVE|||||||
33692436|NCT01254903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692437|NCT02201017|||COHORT||PROSPECTIVE|||||||
33781419|NCT03935997|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There is no need to mask participants, clinicians or research staff.|Within each of the three provinces, six LTC homes will be randomly selected, and then randomly allocated using a 1:1 ratio, stratified according to province, to either the intervention or control group using a computer-generated list. For each province, three LTC homes will receive the intervention and three will receive usual care. A biostatistician not involved in recruitment will generate group assignments.||||
33781420|NCT04135924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized clinical trial|f|f|f|t
33781421|NCT06466421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781422|NCT02673008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33781423|NCT03635177|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The patients will undergo two weeks of the intervention and two weeks of controlperiod, separated by three weeks. The intervention consists of inflating a cuff on the upperarm to 200 mmHg for 4 x 5 minutes, performed every day. The control period includes no specific intervention.||||
33781424|NCT06118710|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|This is a prospective, multicenter, randomized, non-inferiority trial.||||
33781425|NCT06632262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781426|NCT00502281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781427|NCT04983888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781428|NCT00798265|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781429|NCT03578562|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33781430|NCT06441162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781431|NCT02694575|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781432|NCT05177848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete seven Experimental Tobacco Marketplace conditions. Conventional cigarette price will be parametrically increased, and the purchasing of alternative products measured. Alternative products (i.e. nicotine vaping products, heated tobacco products and nicotine pouches) will be available at different prices in separate conditions (i.e., ½ market price, market price, and 2x market price).||||
33781433|NCT04907448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective pre-test post-test randomized controlled trial|f|f|f|t
33781434|NCT04731714|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The stimulation pulses will be triggered by a computer program which will provide either rhythmic or arrhythmic MNS at the same mean rate throughout a given study session. A programmer who does not interact with the participants uses a stimulation order table created by a true random number generator to select the day 1 and day 2 program for each participant in advance. Participants and the investigator are blind to stimulation order and stimulation type. Audiovisual recordings of tics will be rated by a reviewer who will additionally be blind to time (first vs. second stimulation session)."|"After screening and characterizing symptoms and other demographic and clinical features, all participants will complete two stimulation sessions, at least a week apart. These are identical except that one session uses rhythmic and one uses arrhythmic MNS with the same number of total pulses per minute. Session order is randomized and participants are blinded to order. Biological carryover effects are very unlikely. Tics before, during and after stimulation epochs are video recorded for later analysis blind to time, stimulation (on vs. off), and stimulation type (rhythmic vs. arrhythmic).~NOTE: This study is not intended to evaluate a specific device for future use. Rather it is a study to determine the action of pulsed electrical stimulation on tic symptoms and to gain early evidence of effectiveness. This is a non-significant risk device study."|t|f|t|t
33781435|NCT00501241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781436|NCT03717311|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781437|NCT05678153|||COHORT||RETROSPECTIVE|||||||
33781438|NCT01613118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781439|NCT01995370|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781440|NCT05186844|||OTHER||OTHER|||||||
33915597|NCT06379802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915598|NCT05055167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915599|NCT00424333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915600|NCT00734786|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33915601|NCT06009224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation and judgment for morbidity (primary endpoint) / mortality (secondary endpoint) was made by Morbidity and Mortality Committee in our division. Committee members were blinded about knowledge of the interventions assigned to individual participants.|Two study groups (Control (conventional) group and study (intervention) group) were randomly allocated and assigned to one of two groups in parallel for the whole duration of this study.|f|f|f|t
33995947|NCT05029427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Treatments will be provided to participants' homes via delivery. The treatments will be in similar looking breakfast cookies that will be prepared and delivered people outside of the clinical trial team.||t|f|t|t
33995948|NCT00918684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995949|NCT06040723|||CASE_ONLY||PROSPECTIVE|||||||
33995950|NCT04068818|||CASE_CONTROL||PROSPECTIVE|||||||
33995951|NCT00299871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995952|NCT04317417|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33995953|NCT00868660|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33995954|NCT00137644|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33995955|NCT01867658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995956|NCT02610647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33995957|NCT01393951|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33995958|NCT05614453|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, open-label, multi-centre study, based on Simon's two-stage design||||
33995959|NCT02555137|||COHORT||PROSPECTIVE|||||||
33995960|NCT00736658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995961|NCT05891522|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33995962|NCT04107064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995963|NCT00789516|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33995964|NCT02438488|||COHORT||PROSPECTIVE|||||||
33995965|NCT02986555|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33995966|NCT01274143|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33995967|NCT05790863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915602|NCT05947747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The administrated dose will be unknown to the patients|This is a two arms study; one arm will receive 10\^10 dose of exosomes overexpressing CD24, and the second arm will receive Placebo dose|t|f|f|f
33915603|NCT02417909|||||CROSS_SECTIONAL|||||||
33692438|NCT06701656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The overall 2-step randomization scheme will be implemented.~* Randomization Level 1 will be open-label, assigning an eligible patient to one of the available treatment cohorts.~* Randomization Level 2 will be double-blinded and will randomize participants at a 1:1 ratio to receive either IP or placebo within a specific cohort. Thus, the PPD blinded team, site blinded staff members, and participants/legal authorized representative will be considered blinded to study treatment assignment (either IP or placebo) throughout the course of the study.~To preserve the integrity of the study blind, an unblinded pharmacist at each site will be responsible for the reconstitution and dispensation of all study drugs and placebos and will endeavor to ensure that there are no observable differences between the treatment groups (IP or placebo) when dispensing the study materials."||t|t|t|f
33692439|NCT06709131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692440|NCT06198764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692441|NCT06235281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692442|NCT05268107|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A total of 10 Caucasian, 10 Asian (Eastern and Southeastern Asian), and 10 African American patients with moderate-to severe AD (5 males and 5 females in each group) will be enrolled.||||
33692443|NCT06536439|RANDOMIZED|PARALLEL||TREATMENT||NONE||Confirmatory, multicentric, unblinded, randomized, controlled, pivotal trial using parallel group assignment and stratified randomization.||||
33692444|NCT06473987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind randomized clinical trial||f|f|f|t
33692445|NCT02881099|||COHORT||PROSPECTIVE|||||||
33692446|NCT06437353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692447|NCT06147453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692448|NCT03156491|||CASE_CONTROL||PROSPECTIVE|||||||
33692449|NCT06455839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692450|NCT05868018|||COHORT||PROSPECTIVE|||||||
33915604|NCT04753242|||COHORT||CROSS_SECTIONAL|||||||
33915605|NCT02338492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915606|NCT03661489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915607|NCT02321137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33915608|NCT05065996|||COHORT||PROSPECTIVE|||||||
33915609|NCT06156514|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase III clinical trial, open, randomized 1: 1, controlled, noninferiority, in a single hospital center. This study will include 140 patients with the diagnosis of malignant tumors of epithelial origin of the cervix.~Patients will be randomized 1: 1 to receive in arm A (experimental) to receive concomitant chemotherapy based on gemcitabine at 300 mg / m2 weekly and Arm B (control) cisplatin 40 mg / m2 weekly, both arms with RT 50.4 Gy in 5 weeks plus 30Gy brachytherapy at the end of the concomitance."||||
33915610|NCT06067412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915611|NCT02266082|||COHORT||PROSPECTIVE|||||||
33915612|NCT02490319|||COHORT||PROSPECTIVE|||||||
33915613|NCT02621879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915614|NCT05900193|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Plasma levels of glucose and hormones were analyzed without knowledge of condition participant was tested. Participants did not know their condition.|Participants were given oral glucose tolerance tests alone or with lactisole or sucralose in admixture with the glucose. All controls were within subjects in counterbalanced crossover design.|t|f|f|t
33915615|NCT05834907|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33915616|NCT06365671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915617|NCT04296526|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33915618|NCT01273415|||COHORT||RETROSPECTIVE|||||||
33915619|NCT00207922|||DEFINED_POPULATION||OTHER|||||||
33915620|NCT04305886|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33915621|NCT05597059|||COHORT||PROSPECTIVE|||||||
33915622|NCT03348111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915623|NCT03573128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915624|NCT05755334|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, single blinded, randomized non-superiority study.||||
33915625|NCT04136613|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group: Clinical trials with a single arm||||
33915626|NCT02303951|NA|SINGLE_GROUP||TREATMENT||NONE||Single armed, two-cohort Cohort I: Treatment with cobimetinib + vemurafenib; 45 patients enrolled; recruitment closed Cohort II: Treatment with cobimetinib + vemurafenib + atezolizumab; 45 patients planned; recruitment open||||
33915627|NCT00074724|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915628|NCT00028561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915629|NCT01453309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915630|NCT04448808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled study (double-blind)|t|t|t|t
33915631|NCT01021852|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33915632|NCT02145923|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915633|NCT03241563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915634|NCT02619318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915635|NCT00395408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33915636|NCT00001735||||TREATMENT||||||||
33915637|NCT02344407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33915638|NCT00186056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915639|NCT04969133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33915640|NCT03360136|NA|SINGLE_GROUP||TREATMENT||NONE||Open Clinical Trial||||
33915641|NCT04668001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915642|NCT04677621|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915643|NCT06151366|||COHORT||PROSPECTIVE|||||||
33915644|NCT05353166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915645|NCT01820078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915646|NCT06207422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33995968|NCT05759715|||COHORT||CROSS_SECTIONAL|||||||
33995969|NCT02955901|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34086986|NCT01740206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692451|NCT05454267|||OTHER||CROSS_SECTIONAL|||||||
33995970|NCT00052286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33692452|NCT01539317|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33692453|NCT05193825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692454|NCT06513728|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a pilot implementation and preliminary effectiveness study of MPACT.||||
33692455|NCT04638478|||COHORT||PROSPECTIVE|||||||
33692456|NCT06005974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are allocated to two groups, AXIN1 mutation or APC mutation, in parallel for the duration of the study.||||
33995971|NCT06623084|||COHORT||CROSS_SECTIONAL|||||||
33692457|NCT04235803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization to telemedicine follow-up versus routine in-person follow-up for the 1 week assessment after low-risk oculoplastic surgery.||||
33915647|NCT03509272|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915648|NCT04452227|||CASE_ONLY||CROSS_SECTIONAL|||||||
33915649|NCT06380361|NA|SINGLE_GROUP||OTHER||NONE|No masking|Patient with suspected lung cancer coming to the hospital for bronchoscopic biopsy will be selected for this trial.||||
33915650|NCT05790785|||COHORT||PROSPECTIVE|||||||
33915651|NCT01200615|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33915652|NCT06484439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be randomly assigned to one of two groups. Each group will be given one of two post-operative medication regimens consisting of a combination of either (1) Acetaminophen (Tylenol), Oxycodone, and Ibuprofen (Motrin), or (2) Acetaminophen (Tylenol), Oxycodone, and Ketorolac (Toradol).~This research study is a double blind study."||t|t|t|f
33915653|NCT02498756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915654|NCT01658579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915655|NCT05851339|||COHORT||PROSPECTIVE|||||||
33915656|NCT02941913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915657|NCT01862445|||CASE_ONLY||RETROSPECTIVE|||||||
33915658|NCT03619603|||CASE_ONLY||PROSPECTIVE|||||||
33915659|NCT00204334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915660|NCT00608439|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33915661|NCT05124795|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915662|NCT01861288|||OTHER||PROSPECTIVE|||||||
33915663|NCT06008249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Participants will be randomised in a 2:1 ratio to receive either lithium carbonate or placebo|t|f|t|f
33692458|NCT04735536|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.|t|t|t|t
33915664|NCT05291598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915665|NCT01015482|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33915666|NCT02843646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915667|NCT00910429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915668|NCT05120999|||CASE_CONTROL||PROSPECTIVE|||||||
33915669|NCT03176277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Part A: ONO-7475 open-label, dose escalation in R/R AML or R/R MDS Part D: ONO-7475 plus venetoclax open-label, dose escalation in R/R AML||||
33995972|NCT00840203|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33995973|NCT05346172|||CASE_ONLY||PROSPECTIVE|||||||
33995974|NCT04589286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33995975|NCT06370104|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are not blind to the treatment condition, but are unaware which is the experimental condition and which the control condition.|Parallel randomized controlled trial with a 1:1 allocation ratio.|f|f|f|t
33995976|NCT04182126|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|This study partially masking participants, because by design some participants will receive PBO treated long-lasting insecticidal nets (LLINs) and others will not receive such bed nets, therefore, those who receives the PBO LLINs can not be masked.|This study will use a longitudinal sequential multiple assignment randomized trial design. It will include multiple stages, at each stage, clusters are assigned to different arms (interventions) using an adaptive strategy. Therefore, number of arms vary from stage to stage.|f|t|t|t
33995977|NCT03078608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692459|NCT06544330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692460|NCT03978988|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692461|NCT00846742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692462|NCT03700879|||COHORT||PROSPECTIVE|||||||
33692463|NCT03707431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized and double-blinded controlled trial of web-based CBT (WebMAP) vs pain education (WebED).|t|t|t|t
33995978|NCT06626945|||COHORT||RETROSPECTIVE|||||||
33995979|NCT03492138|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label, standard 3+3 phase 1 with a Simon 2-stage design followed by stage 2||||
33995980|NCT05492162|NA|SINGLE_GROUP||OTHER||NONE||before/after study using a quasi-experimental design||||
33995981|NCT03413202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33995982|NCT00799162|||COHORT||PROSPECTIVE|||||||
33995983|NCT02888756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692464|NCT06382805|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are three groups in the study. The groups consist of the control group, kinesio tape group and high intensity laser group||||
33692465|NCT06026410|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692466|NCT05742958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995984|NCT03276559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open trial pilot and manual refinement phase followed by randomized controlled trial. Due to the COVID-19 pandemic, we included the open-trial COVID-19 phase to adjust to new circumstances. We resumed the randomized controlled trial once it was safe to do so.|f|f|f|t
33995985|NCT04051307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086987|NCT03991533|||CASE_CONTROL||RETROSPECTIVE|||||||
33915670|NCT05400005|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE||"This is a 16-week factorial study design with subjects randomly assigned to consume normal-protein diet, higher-protein diet with micellar casein protein isolates or higher-protein diet with soy protein isolates. Subjects' sleep quality will also be evaluated and screened using the PSQI questionnaire (GSS ≤5 \[good sleepers\] vs. GSS \>5 \[poor sleepers\]).~Sixty-eight older men and women (aged 60-85y, approximately half men and half women) will be recruited with the expectation that ≥ 54 subjects (≥ 18 subjects per group) will complete the study (≤ 20% dropout rate). The 18 subjects recruited for each of the intervention group were further classified into poor (n=9) and good sleepers (n=9)."|f|f|t|t
34086988|NCT01840111|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34086989|NCT06142019|||COHORT||PROSPECTIVE|||||||
33692467|NCT06636227|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled, randomized, cross-over study in which individuals with AUD (n=24) complete four sessions where they receive diclofenac (50 mg, 75 mg, or 100 mg) or placebo. Eligible participants will be randomized to receive the three doses of diclofenac and placebo in a randomized, double-blind fashion. Because the study is completely within subject, there are no groups or group assignment. There are no control subjects.|t|t|t|t
33692468|NCT06441864|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multiple baseline single case experimental design||||
33692469|NCT05053152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781441|NCT04551157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be made aware at the time of informed consent that they will be randomised to either view the videos or receive treatment-as-usual|Participants randomised to intervention group (video-viewing) or treatment-as-usual (control) group.||||
33781442|NCT02638298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781443|NCT01293461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915671|NCT05016648|||COHORT||PROSPECTIVE|||||||
33915672|NCT03508635|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33915673|NCT00062114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33995986|NCT05365698|||OTHER||CROSS_SECTIONAL|||||||
33995987|NCT01470430|||CASE_CONTROL||PROSPECTIVE|||||||
33995988|NCT04436198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33995989|NCT00015691||||TREATMENT||DOUBLE||||||
33995990|NCT04169815|||OTHER||PROSPECTIVE|||||||
33995991|NCT06559995|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blinded|Randomized, double-blind, placebo-controlled, parallel-groups design clinical trial|t|t|t|f
33995992|NCT06301386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34086990|NCT00795340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692470|NCT01387373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692471|NCT05627661|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33692472|NCT06274528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Pharmacist||t|t|t|f
33692473|NCT04037254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692474|NCT05959746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692475|NCT02883647|||COHORT||PROSPECTIVE|||||||
33692476|NCT05859555|RANDOMIZED|PARALLEL||OTHER||SINGLE||Cluster randomised controlled trial|t|f|f|f
33692477|NCT06690814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The study we propose is an evaluator-blinded, randomized clinical trial to compare the effects of topical application of three traditional medicine plant saps compared to Savlon cream or no treatment:~(A) Ficus septica plant sap (50μl) applied topically at baseline, day 3 and day 7.~(B) Pterocarpus indicus plant sap (50μl) applied topically at baseline, day 3 and day 7.~(C) Curcuma longa plant sap (50μl) applied topically at baseline, day 3 and day 7.~(D) Savlon cream (200mg) applied topically at baseline, day 3 and day 7. (E) No treatment."|f|f|t|t
33692478|NCT06112327|||CASE_ONLY||PROSPECTIVE|||||||
34086991|NCT04802434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34086992|NCT02837159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086993|NCT05676658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34086994|NCT00720759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34086995|NCT01267032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34086996|NCT03003117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34086997|NCT03530293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|open-label study drug treatment period followed by blinded randomization into treatment arm or placebo arm||t|t|t|f
33692479|NCT03739671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781444|NCT05288543|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33781445|NCT04514042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781446|NCT05008224|NA|SEQUENTIAL||TREATMENT||NONE||||||
33781447|NCT03888911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781448|NCT02060253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781449|NCT01614756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781450|NCT06345872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781451|NCT04757558|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33781452|NCT06287229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781453|NCT01556243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915674|NCT04395352|||OTHER||OTHER|||||||
33915675|NCT01277341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915676|NCT05098548|||COHORT||PROSPECTIVE|||||||
33995993|NCT01600963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33995994|NCT03561766|||COHORT||PROSPECTIVE|||||||
34086998|NCT02597270|||COHORT||RETROSPECTIVE|||||||
34086999|NCT03201666|||OTHER||PROSPECTIVE|||||||
34087000|NCT01923558|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087001|NCT02049632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087002|NCT00544414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087003|NCT00386061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33995995|NCT03389113|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients were randomly assigned to one of the two groups in a 1:1 ratio using an odd or even random numbers table. Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm. The control group performed the same sessions without vibration.||||
33915677|NCT05164406|||CASE_CONTROL||RETROSPECTIVE|||||||
33692480|NCT02180269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692481|NCT02080858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692482|NCT02629484|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33781454|NCT04794179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915678|NCT04121312|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33915679|NCT04969497|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects are randomized to receive one of six treatment sequences of three open-label treatments 48 hours apart.||||
33915680|NCT00448916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915681|NCT02391350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33915682|NCT01136421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087004|NCT01484340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915683|NCT00264849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915684|NCT05408312|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33915685|NCT05181020|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915686|NCT01665248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33995996|NCT03797248|||COHORT||PROSPECTIVE|||||||
33995997|NCT03875547|||COHORT||PROSPECTIVE|||||||
33995998|NCT00000956||||PREVENTION||DOUBLE||||||
34087005|NCT03133676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087006|NCT03095287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087007|NCT04200300|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087008|NCT06062056|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A pragmatic multiple-period, cluster-randomized crossover design will be used.||||
34087009|NCT04816344|||COHORT||PROSPECTIVE|||||||
34087010|NCT01655901|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34087011|NCT04926168|||COHORT||PROSPECTIVE|||||||
34087012|NCT05232890|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The study product and the comparator product are provided in identical packaging, the labeling shows the randomization number which, however, only the Outcomes Assessor is able to refer to the type of treatment assigned. The organoleptic characteristics of the two products are as similar as possible. The instructions given to patients regarding the preparation and consumption of the products are the same for both products.|"At enrollment, patients are randomized to one of the following study groups: Group A and Group B:~* Treatment arm A: daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from hydroponic technology (soilless), contained in a 720ml bottle.~* Treatment arm B: daily intake of minimum 100ml - maximum 200ml of 100% Italian datterino tomato puree deriving from conventional cultivation, contained in a 720ml bottle.~After this initial treatment phase, both study groups follow a 2-week wash-out period, following a low-nickel diet.~At the end of the wash-out phase, the two groups cross-over. Therefore, Group A is assigned to treatment arm B, and vice versa, for a period of 12 weeks."|t|t|t|f
34087013|NCT00843349|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33915687|NCT03783052|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33692483|NCT06427876|||COHORT||PROSPECTIVE|||||||
33692484|NCT05745532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692485|NCT03039972|||COHORT||PROSPECTIVE|||||||
33692486|NCT03436654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692487|NCT03137771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915688|NCT06303947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33915689|NCT03548038|||COHORT||PROSPECTIVE|||||||
34087014|NCT01498302|||COHORT||RETROSPECTIVE|||||||
33915690|NCT00288860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33915691|NCT04105244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data collectors and participants will be blinded to group assignment.|The proposed study is a longitudinal (9-month) randomized controlled trial (RCT) in which primary caregiver parents of technology-dependent children will be randomly assigned to one of two study arms: (1) The Attention Control arm and (2) The Resourcefulness Training(c) arm.|t|f|f|t
33692488|NCT04981860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915692|NCT02815293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915693|NCT00002344||PARALLEL||TREATMENT||||||||
34087015|NCT04711005|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers followed by a 2-cohort multiple ascending dose (MAD) study in healthy volunteers, followed by a 1-cohort single ascending dose study with collection of cerebrospinal fluid (CSF) and plasma for pharmacokinetics.|t|f|t|f
34087016|NCT01490411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087017|NCT03571789|NA|SINGLE_GROUP||PREVENTION||NONE||Multicenter, prospective, non-randomized, open-label, first-in-human (FIH) study||||
34087018|NCT03761316|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087019|NCT03984929|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087020|NCT00265434|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34087021|NCT02506920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34087022|NCT02078258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087023|NCT02515474|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087024|NCT00743392|||COHORT||PROSPECTIVE|||||||
34087025|NCT04804137|||COHORT||PROSPECTIVE|||||||
34087026|NCT01467752|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34087027|NCT02297126|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087028|NCT00632294|||CASE_ONLY||RETROSPECTIVE|||||||
34087029|NCT00666770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087030|NCT05595226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087031|NCT04198168|||COHORT||PROSPECTIVE|||||||
33692489|NCT05529940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692490|NCT03778957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692491|NCT06682650|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Prospective parallel cluster randomized trial, in which clinics are units of randomization (10 in active intervention, 10 in active comparator), and nested within clinics individual patient enrollees (whose CRC screening outcomes are Aim 1 outcomes of the study), and implementation team participants (whose survey and qualitative interview data are Aim 2 outcomes of the study).|f|f|f|t
33692492|NCT06466382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692493|NCT05295680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692494|NCT05862727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned to one of two interventions, and will not be told which intervention they are assigned to. Outcomes assessor will also be blinded to intervention assignment.|Behavioral Telehealth Intervention|t|f|f|t
33692495|NCT00242073|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692496|NCT02546115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33692497|NCT06105554|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692498|NCT02557295|||COHORT||PROSPECTIVE|||||||
33692499|NCT05309590|||COHORT||PROSPECTIVE|||||||
33692500|NCT06624449|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33915694|NCT05381012|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915695|NCT03736954|NA|SINGLE_GROUP||PREVENTION||NONE||pilot study||||
33915696|NCT01728883|||CASE_ONLY||PROSPECTIVE|||||||
34087032|NCT06366308|||COHORT||RETROSPECTIVE|||||||
34087033|NCT01946867|NA|SINGLE_GROUP||TREATMENT||NONE||This study consists of two parts: Dose Escalation and Dose Expansion. This phase I is an open-label non-randomized, dose-escalation/dose expansion study of safety and tolerability evaluation of NBTXR3, administered as an intratumoral implantation by injection, activated by intensity modulated radiation therapy (IMRT), in patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx.||||
34087034|NCT02497066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087035|NCT03742596|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087036|NCT04676204|||OTHER||PROSPECTIVE|||||||
34087037|NCT03227588|||CASE_ONLY||PROSPECTIVE|||||||
34087038|NCT05601336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087039|NCT01866254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915697|NCT02289482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915698|NCT04774679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915699|NCT04897282|||COHORT||PROSPECTIVE|||||||
33915700|NCT02840890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915701|NCT04982159|||CASE_ONLY||RETROSPECTIVE|||||||
34087040|NCT04054297|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34087041|NCT02314546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33995999|NCT05302128|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who were hospitalized for laparoscopic cholecystectomy and met the sample selection criteria will be included in the experimental and control groups by block randomization method using the random numbers table on the computer.||||
33996000|NCT06627634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996001|NCT00728351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087042|NCT05991375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087043|NCT05023980|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized 1:1 into Arm A and Arm B. Patients randomized to Arm B who have disease progression (PD) confirmed by independent review committee (IRC) may be eligible to crossover into Arm A.||||
34087044|NCT02378311|||CASE_CONTROL||PROSPECTIVE|||||||
33996002|NCT02827682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34087045|NCT01520753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33915702|NCT05338957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087046|NCT00290225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087047|NCT01949545|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087048|NCT04734613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|blood sample will be analyzed by the lab technician without identity of the group assignment. self-reported questionnaire is also used|randomized trial to assign the participants either to intervention group 1 (Tai Chi exercise) or to intervention group 2 (self management)|f|f|f|t
33915703|NCT03266978|||COHORT||PROSPECTIVE|||||||
33915704|NCT00444509|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33915705|NCT03403543|||COHORT||PROSPECTIVE|||||||
33915706|NCT05349058|||CASE_ONLY||PROSPECTIVE|||||||
33915707|NCT04636008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915708|NCT01434381|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915709|NCT04622085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915710|NCT05243394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome measuring assessors will not know from which group any of the participants comes from, and will have no interaction with any of the interventions applied.|3 groups of 22 participants will each follow a different treatment option.|f|f|f|t
33915711|NCT04941352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and caregivers were not informed about intervention content and measurements.|Randomized controlled pre-post test design|t|t|f|f
33915712|NCT06490419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915713|NCT01238315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915714|NCT05883553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority parallel cohort study||||
33915715|NCT05667792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33915716|NCT00675103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915717|NCT05178251|||COHORT||RETROSPECTIVE|||||||
33915718|NCT05068193|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915719|NCT01945333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915720|NCT06056466|||COHORT||PROSPECTIVE|||||||
33915721|NCT02090192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915722|NCT00163072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996003|NCT03227939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996004|NCT01670890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996005|NCT03098901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Patients that suffer of one of the following conditions will be included in the study~1. Patients suffering of HFpEF not explained by either hypertension or any other clinical condition.~2. Patients with systolic dysfunction and non-significant coronary artery disease.~3. Patients with diabetic cardiomyopathy~4. Patients with otherwise unexplained left ventricular hypertrophy (LVH).~5. Patients under age of 65 with idiopathic ventricular fibrillation (VF) or multiple ventricular premature beats (VPB) or ventricular tachycardia (VT) with a structurally normal heart.~6. Patients under age of 65, with unexplained sinus node disease, sinoatrial block, complete or high-degree atrio-ventricular block or significant intraventricular conduction defect, with structurally normal heart whether having or not having received permanent implanted pacemaker."||||
34087049|NCT00484016|||CASE_ONLY||RETROSPECTIVE|||||||
33996006|NCT02988258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996007|NCT01373515|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33996008|NCT05521360|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|De-identified and masked data will be analyzed by an independent outcomes assessor|Participants are randomized to either the experimental or matched wait-list control group.|f|f|f|t
33996009|NCT06058845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and the study team will be blinded to the intervention materials. The two juice prototypes will be blinded by assigning a secret code to each of the intervention products. As such, blinding of the investigators and participants will be undertaken to ensure a double-blind intervention. Moreover, the statistical analyses of the main endpoints will be done before breaking the intervention product concealment.|This is a single centre, 2-arm, 4 weeks randomised, double-blinded parallel trial with equal allocation ratios (1:1)|t|f|t|f
33692501|NCT04526418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||open-label, prospective study with a paired comparative design for pivotal evaluation of the safety and effectiveness of the 24/7 EEC SubQ system in subjects with epilepsy involving the temporal lobe region.||||
33996010|NCT02916862|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||we are testing a fiber and calcium supplement so it is not a drug|t|f|f|t
33996011|NCT05744492|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Physical therapists in charge of the intervention will not be endpoint's evaluators. Participants will be informed and encouraged not to disclose their assignment to the endpoints' evaluators, which will remain blinded to individual's membership. Investigators responsible for the statistical analysis will be blinded.|Three-branch multi-center randomized clinical trial with 1:1:1 allocation to a center-based supervised Vivifrail MCE, a home-based non-supervised Vivifrail MCE program, or to a control group.|f|f|t|t
34087050|NCT05141773|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34087051|NCT04222049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087052|NCT04938336|||COHORT||PROSPECTIVE|||||||
33692502|NCT02572193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692503|NCT03979430|NA|SINGLE_GROUP||PREVENTION||NONE||Intervention group on 5 different sites without a control group||||
34087053|NCT00093522|RANDOMIZED|||TREATMENT||||||||
34087054|NCT03103958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|Parallel Assignment|t|f|t|f
34087055|NCT00319124|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087056|NCT05282784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087057|NCT03482024|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087058|NCT05397652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087059|NCT00025402|RANDOMIZED|||TREATMENT||||||||
34087060|NCT04777513|||CASE_ONLY||PROSPECTIVE|||||||
34087061|NCT00355719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087062|NCT06036095|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This single-center, 1:1 randomized, double-blind (patient \& outcome assessor) clinical trial will compare inhalational (sevoflurane) vs. intravenous (propofol) anesthesia on POD, POCD, functional status, PROs, and biomarkers in patients ≥ 70 years undergoing elective, inpatient, non-cardiac surgery at Oregon Health \& Science University.|t|f|t|t
34087063|NCT01707524|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34087064|NCT03052686|||COHORT||PROSPECTIVE|||||||
34087065|NCT00691275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087066|NCT05258552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33692504|NCT05925075|||COHORT||PROSPECTIVE|||||||
33692505|NCT06455995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Meetings will be 60 minutes and led by an interventionist with training at the M.S.- or Ph.D.-level in nutrition, exercise physiology, or behavioral psychology blinded to study hypotheses. Dependent measures will be assessed by a trained researcher blinded to treatment assignment at 0, 3, 6, and 12 months, unless otherwise indicated. The research assistant (blinded to treatment condition) will review all assessment data for accuracy and completion.||f|f|f|t
33692506|NCT00378105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692507|NCT02136108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33692508|NCT04924205|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692509|NCT01490554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087067|NCT00863122|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087068|NCT03222726|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||corhort study||||
34087069|NCT03366753|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Acute normovolemic hemodilution consists of phlebotomy and intravascular volume resuscitation by using crystalloid/colloid in a same amount of phlebotomy||||
34087070|NCT03323762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087071|NCT06255743|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087072|NCT01134666|||COHORT||PROSPECTIVE|||||||
34087073|NCT01114555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087074|NCT00120939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087075|NCT00834184|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34087076|NCT02875457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087077|NCT00656617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692510|NCT02172066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33692511|NCT04723654|||COHORT||PROSPECTIVE|||||||
33692512|NCT01071473|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34087078|NCT04377867|||COHORT||PROSPECTIVE|||||||
34087079|NCT04909723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692513|NCT02966041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33692514|NCT05289531|||COHORT||CROSS_SECTIONAL|||||||
33692515|NCT06343350|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087080|NCT00321503|||||PROSPECTIVE|||||||
33692516|NCT00219167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33692517|NCT05607797|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"3 groups of participants :~* Patients with gout~* Patients with CKD~* Controls"||||
34087081|NCT00658528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087082|NCT01366807|||COHORT||PROSPECTIVE|||||||
34087083|NCT05883111|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087084|NCT04502277|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34087085|NCT04023578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087086|NCT05499286|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34087087|NCT01812187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087088|NCT02258581|||COHORT||PROSPECTIVE|||||||
34087089|NCT05322785|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Study sample will consist of individuals aged 4-110 with a diagnosis of acute or chronic respiratory disorders, or metabolic or systemic conditions involving diffuse inflammation, or normal subjects with no pulmonary disease.||||
34087090|NCT04139135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087091|NCT04213261|NA|SINGLE_GROUP||TREATMENT||NONE||Intra-patient Randomized, Controlled, Open-label, Multi-center||||
34087092|NCT05414604|||CASE_ONLY||RETROSPECTIVE|||||||
34087093|NCT00443300|||CASE_CONTROL||PROSPECTIVE|||||||
34087094|NCT05902624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087095|NCT01443884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34087096|NCT06232876|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients will not be told whether their monitoring system. Outcomes will be evaluated from the electronic recorded by blinded investigators.|Parallel group randomized trial.|t|f|t|t
34087097|NCT06112145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087098|NCT06091514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This clinical investigation is a comparative, one group, controlled study.~Each patient represents its own control. Patients with an ILR already implanted for the detection of AF will receive a CS Medical Watch for a period corresponding to the period at risk of AF, up to 1 year maximum.~For each patient, results obtained with the ILR device will be compared to results obtained with the CS Medical Watch device.~During the conduct of the study, all medical decisions will be taken according to the ILR already implanted. No medical decision will be taken on CardiacSense System information collected during the study."||||
34087099|NCT00410358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087100|NCT03509441|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087101|NCT02746861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087102|NCT04925401|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34087103|NCT04128553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"No researcher and participant blindness were performed.~The data were collected and recorded by an independent researcher who was trained by the researcher and did not know the groups. The statistics were performed by an independent statistician."||f|f|f|t
34087104|NCT02619201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087105|NCT03329989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087106|NCT02598908|||COHORT||OTHER|||||||
34087107|NCT02100787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915723|NCT05806047|NA|SINGLE_GROUP||TREATMENT||NONE||chidamide combined with fulvestrant||||
33915724|NCT03379610|||CASE_ONLY||PROSPECTIVE|||||||
33915725|NCT04342182|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP versus the standard of care.||||
33915726|NCT01679093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915727|NCT06426199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33915728|NCT00134225|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33915729|NCT03164226|NA|SINGLE_GROUP||OTHER||NONE||Prospective||||
33915730|NCT00808249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915731|NCT05085028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915732|NCT04382898|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915733|NCT03296865|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Children and the person that performed the evaluation were blind only to KT and placebo conditions, since they did not know if KT was tensioned were not. The person that performed data analysis was blind to all conditions.|We used a blinded and repeated-measure design, with the application of a placebo condition|t|f|t|t
33915734|NCT01911234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915735|NCT00002545|RANDOMIZED|||TREATMENT||||||||
33915736|NCT01211964|RANDOMIZED|CROSSOVER||||NONE||||||
33915737|NCT04771052|||CASE_CONTROL||RETROSPECTIVE|||||||
33915738|NCT00370695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915739|NCT00042250|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915740|NCT04903119|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915741|NCT04813939|||COHORT||PROSPECTIVE|||||||
34103012|NCT04315961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"Please note: This is a double-blind study. As part of instructions during the informed consent process, volunteers will be given a list of drugs volunteers may receive rather than informing volunteers only of the specific drugs being administered. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Researchers will be blind to the drug conditions on any given session because a pharmacy member with no participant interaction will assign the randomized dose sequence and prepare the study drugs. Masking:Triple (Participant, Investigator, Outcomes Assessor)"|"This is a within-subjects design. This study involves administration of drug conditions in different dose sequence orders. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Participants will be randomly assigned to one of several different dose sequences. As part of instructions during the informed consent process, volunteers will be given a list of drugs volunteers may receive rather than informing volunteers only of the specific drugs being administered. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Researchers will be blind to the drug conditions on any given session because a pharmacy member with no participant interaction will assign the randomized dose sequence and prepare the study drugs."|t|f|t|t
33915742|NCT02905942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915743|NCT01569425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915744|NCT00935519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692518|NCT06703242|NA|SINGLE_GROUP||TREATMENT||NONE||Mothers in the control group will receive the intervention right after the completion of the intervention group.||||
33692519|NCT04295655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692520|NCT06050395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692521|NCT06699732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Double||t|f|t|f
33692522|NCT01385176|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients were randomized in a 2:1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The primary endpoint was the change in LVend systolic diameter (LVESD) at 6 months for control vs. therapy, with secondary endpoints of other echocardiography measurements, exercise capacity, quality-of-life assessments, 24-h Holter, and circulating biomarkers.|t|f|f|t
33692523|NCT01699932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692524|NCT04632303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915745|NCT05902546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915746|NCT05235217|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, partial replicate crossover, three-phase, three-sequence, two treatments bioequivalence study.||||
33915747|NCT04078672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915748|NCT03359694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915749|NCT01417065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915750|NCT03144323|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33915751|NCT00139425|RANDOMIZED|PARALLEL||||NONE||||||
33915752|NCT03624517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915753|NCT04628728|||CASE_CONTROL||PROSPECTIVE|||||||
33915754|NCT00135486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915755|NCT02981277|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33915756|NCT04980352|||COHORT||PROSPECTIVE|||||||
33915757|NCT06389188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33915758|NCT04575272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither the patient or the investigator included in data collection will be aware of the type of block performed or the group allocation||t|f|f|t
33915759|NCT00426517|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33915760|NCT02612389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915761|NCT03050671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||There are two different intervension devices planned to be used in each research subject.||||
33915762|NCT04959552|||COHORT||PROSPECTIVE|||||||
33915763|NCT03508141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915764|NCT03998020|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Intervention = Blood withdrawal||||
33915765|NCT05638906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915766|NCT00572325|||COHORT||PROSPECTIVE|||||||
33915767|NCT03321214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915768|NCT02471001|||COHORT||CROSS_SECTIONAL|||||||
33915769|NCT03277144|RANDOMIZED|PARALLEL||PREVENTION||NONE||All gastric cancer patients who meet the inclusion/exclusion criteria and give the informed consent to participate are registered into the central trial database and centrally permuted-block randomized to one of the two arms (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ).||||
33915770|NCT04359082|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Randomized, double-blind, cross-over controlled trial|t|f|t|f
33915771|NCT02397694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915772|NCT00061126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781455|NCT06617455|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|All study drug will be blinded to the patients, the study investigators, and the study coordinators to ensure masking of the treatments. The statistician and the study investigators will remain blinded until the study database is locked. The only study personnel that will not be blinded are the research pharmacy staff in order to facilitate randomization codes and treatment delivery, and in case emergency unblinding is required.||t|t|t|t
33781456|NCT00836069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781457|NCT02295982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915773|NCT00740168|||COHORT||PROSPECTIVE|||||||
33781458|NCT06696560|NA|SINGLE_GROUP||OTHER||NONE||||||
33781459|NCT04690816|||CASE_CONTROL||PROSPECTIVE|||||||
33781460|NCT04774926|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a one-year, open-label, single arm, multicenter, phase IV study in patients with wAMD.||||
33915774|NCT05483621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||to evaluate the effect of hormonal stimulation for patients with non-obstructive azoospermia|t|f|f|f
33781461|NCT06613763|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33915775|NCT02307071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915776|NCT04143672|NA|SINGLE_GROUP||SCREENING||NONE||Prospective observational study||||
33915777|NCT00330863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781462|NCT03017456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33781463|NCT00536666|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781464|NCT06628661|||COHORT||RETROSPECTIVE|||||||
33781465|NCT04545502|||COHORT||OTHER|||||||
33781466|NCT05018585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial.|t|t|t|t
33781467|NCT00239161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915778|NCT05673473|||COHORT||OTHER|||||||
33915779|NCT00100724|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33915780|NCT03966105|||COHORT||PROSPECTIVE|||||||
33915781|NCT03096002|||COHORT||PROSPECTIVE|||||||
33915782|NCT02864966|NA|SINGLE_GROUP||||NONE||||||
33996012|NCT05448235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patients , care provider and investigator do not know the groups receive treatment|comparison between two groups one receive conventional treatment and other receives conventional treatment and thoracic mobilization|t|f|f|t
33996013|NCT02423161|||OTHER||PROSPECTIVE|||||||
34103013|NCT00555373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34103014|NCT05804227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103015|NCT00949065|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103016|NCT03292029|NA|SINGLE_GROUP||OTHER||NONE||Exploratory, interventional, open, multi-center, prospective||||
34103017|NCT04194619|||COHORT||PROSPECTIVE|||||||
33781468|NCT01764386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781469|NCT03871933|||COHORT||PROSPECTIVE|||||||
33781470|NCT04689165|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33781471|NCT00565318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781472|NCT02117115|NA|SINGLE_GROUP||SCREENING||NONE||||||
33781473|NCT06613490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781474|NCT00980278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781475|NCT00005982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781476|NCT00190346|RANDOMIZED|PARALLEL||||NONE||||||
33781477|NCT06544642|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33781478|NCT06693934|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781479|NCT01791426|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33781480|NCT04172610|||COHORT||PROSPECTIVE|||||||
33781481|NCT03042793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781482|NCT06323668|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|Randomized open label trial||||
33781483|NCT05565482|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33915783|NCT06015802|||COHORT||PROSPECTIVE|||||||
33915784|NCT05869487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective single-center evaluation of a diagnostic method||||
33915785|NCT03328585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915786|NCT01032993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33915787|NCT03496467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915788|NCT04254783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915789|NCT00509496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915790|NCT00432952|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
33915791|NCT02969850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33692525|NCT05868577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A nurse or staff member will open a previously prepared and sealed opaque envelope (prepared beforehand by the clinical coordinator) labeled with the participant identification (ID) of the patient, which will be unique to the individual and different from their Medical Record Number (MRN). In this envelope, they will discover the patient's assigned treatment arm. The nurse or staff member will then prepare the syringe with the assigned treatment arm. Once the syringe is filled with the designated substance, the syringe will be wrapped with opaque tape or dark Coban wrap to conceal the contents in the syringe for both the PI and study participant.|All patients ages 18 years and up with a diagnosis of plantar heel pain will be screened for inclusion into the study.|t|f|t|f
33692526|NCT06654258|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692527|NCT02580435|||COHORT||PROSPECTIVE|||||||
33692528|NCT06705894|||COHORT||PROSPECTIVE|||||||
33692529|NCT05746975|||COHORT||PROSPECTIVE|||||||
33692530|NCT05851326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692531|NCT04872218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692532|NCT06348134|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781484|NCT04252937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781485|NCT06697002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants are blind|randomized control design|t|f|f|f
33781486|NCT02700685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781487|NCT05488379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33781488|NCT06685185|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1 SAD and Part 3 MAD are double-blind study parts. Sponsor staff involved in the clinical trial is masked according to company standard procedures. Part 2 is open-label study part.||t|t|t|t
33781489|NCT06520657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistant doing the study measurement will not be told which group the families are in. The questions about the CHW intervention will be asked by a separate staff member or automated on the tablet as part of a battery of tests.|60 Families (2 participants in each- parent and child) will be randomized to community health worker intervention or standard social risk factor (SRF) referral for the first 3 months and then 3-6 months both groups will do the same child obesity intervention then 6-12 months both will receive no intervention.|f|f|f|t
33915792|NCT04958421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analysis of the secondary efficacy endpoint, changes in left and right ventricular function, will be analyzed by an independent Corelab, blinded to the allocated treatment arm.|Prospective, multicenter, randomized, controlled, parallel-groups, pilot stage study|f|f|f|t
33915793|NCT01123577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915794|NCT01934894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915795|NCT00983840|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33915796|NCT01684475|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33692533|NCT05184478|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Eligible participants will be randomized 1:1 to initially receive either THC:CBD 10:15 oil or placebo in Treatment Period 1, before crossing over and receiving the other study drug (THC:CBD 10:15 oil or placebo) in Treatment Period 2.|t|t|t|t
33692534|NCT00743782|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692535|NCT06710054|||CASE_ONLY||PROSPECTIVE|||||||
33915797|NCT02622724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915798|NCT02856685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087108|NCT03955549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Assessors will be blind to treatment allocation, and specific measures will be undertaken to preserve blinding and prevent a Rosenthal effect (e.g., assessors will not be employees of the same hospital, and before each assessment participants will be explicitly instructed not to disclose their group assignment to the assessor).~Randomization will be according to a randomization plan using stratified permuted block randomization with each block containing four participants. This method will be used to achieve balance among groups in terms of subjects' baseline characteristics. Stratified randomization is achieved by generating a separate block for each covariate such as age \& gender."|"This will be a three-armed parallel group, assessor-blind, randomized controlled trial comparing Insight Enhancement Program (IEP) and Metacognitive Training for Psychosis (MCT) with Treatment As Usual (TAU). Once the participant gives his/her consent, he/she will be randomized either to (IEP+TAU), or (MCT+TAU), or (TAU). Both interventions consist of eight session administered over 4 weeks. The total study duration will be 2 months as participants must be on a fixed dose of the antipsychotic medication for 4 weeks prior to starting the interventions. Participants will be assessed twice during the study period; the first assessment will be after 4 weeks of receiving the antipsychotic medication prior to starting the interventions, and the final assessment will be at the end of the study after finishing the interventions. A total of 120 participants will be recruited in the study and randomized across the three groups in a 1:1:1 proportion."|f|f|f|t
34087109|NCT01101178|RANDOMIZED|CROSSOVER||||NONE||||||
34087110|NCT05764499|||COHORT||RETROSPECTIVE|||||||
34087111|NCT04772976|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087112|NCT02396667|||COHORT||PROSPECTIVE|||||||
34087113|NCT05658068|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34087114|NCT02768987|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34087115|NCT05413772|||CASE_ONLY||RETROSPECTIVE|||||||
34087116|NCT04763512|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087117|NCT02312843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33692536|NCT06660238|||COHORT||PROSPECTIVE|||||||
33692537|NCT00666796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33692538|NCT03052907|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33781490|NCT00003431||||TREATMENT||||||||
33915799|NCT05392894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915800|NCT02276521|||COHORT||RETROSPECTIVE|||||||
33915801|NCT02366754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915802|NCT04343313|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33915803|NCT04742270|NA|SINGLE_GROUP||TREATMENT||NONE|Non applicable|There is no comparison procedure included in this feasibility trial. Patients will be their own control.||||
33915804|NCT04676945|||COHORT||RETROSPECTIVE|||||||
33915805|NCT01201421|||||CROSS_SECTIONAL|||||||
33915806|NCT00118027|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33915807|NCT00717366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915808|NCT02550314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915809|NCT03709134|||COHORT||PROSPECTIVE|||||||
33915810|NCT04257955|||COHORT||RETROSPECTIVE|||||||
33915811|NCT00668304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915812|NCT03754062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind|Placebo x Haloperidol x LDOPA|t|f|t|f
33781491|NCT02723656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915813|NCT00247182|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33915814|NCT00815906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915815|NCT00240188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915816|NCT02059213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915817|NCT01666691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915818|NCT00154141|RANDOMIZED|PARALLEL||||SINGLE||||||
33915819|NCT01746888|||CASE_ONLY||PROSPECTIVE|||||||
33915820|NCT03488914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization to YMHP or enhanced Treatment as Usual (eTAU)||t|f|f|f
33915821|NCT06324279|||COHORT||PROSPECTIVE|||||||
33915822|NCT02236949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33915823|NCT05864183|||CASE_CONTROL||PROSPECTIVE|||||||
33915824|NCT01325324|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33915825|NCT03225716|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915826|NCT04086069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915827|NCT01238133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915828|NCT04429685|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||We plan to implement a crossover design. A parallel design is an alternative approach we may consider as the primary outcome is the effect of low dose ketamine on muscle sympathetic nervous system, for which a placebo administration may not be fully necessary.|t|f|t|t
33915829|NCT05328856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087118|NCT04057092|NA|SINGLE_GROUP||PREVENTION||NONE||Eligible and consenting gynecologic oncology and general surgery patients will receive EMN's nutritional supplement INergy-FLD® both before and after elective surgery.||||
34087119|NCT02934685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087120|NCT02882971|||OTHER||PROSPECTIVE|||||||
34087121|NCT00362232|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34087122|NCT02348333|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33781492|NCT05692518|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-center, open-label, single-arm, feasibility device study.||||
33996014|NCT04658225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participant will receiver mouthwash solution with labeled number, they will not know which solution will inside.~Care provider - The research that will collect clinical parameter wil be different for researcher that will do the treatment.~Investigator will not have contact with treatment."|Thirty patients with gingivitis ages18 to 30 year with a probing depth of at most 3 mm and at least 20 teeth will select and evaluate at baseline and after 4 weeks. The periodontal clinical parameters will verify: plaque index (PI), gingival index (GI) and Simplified Oral Hygiene Index (OHIS). After evaluation of the clinical parameters, the patients will randomly allocated into two groups of 15 individuals to rinse with antimicrobials twice a day for a period of four weeks. Group A, received 0.12% chlorhexidine antimicrobian in a vial previously identified as solution 1 and group B, received saline solution identified as solution 2.|t|t|t|f
33996015|NCT06449690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996016|NCT06382896|||COHORT||RETROSPECTIVE|||||||
33996017|NCT02282124|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996018|NCT02887781|||COHORT||PROSPECTIVE|||||||
33996019|NCT00580541|RANDOMIZED|CROSSOVER||||NONE||||||
33996020|NCT03911635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996021|NCT05542056|||COHORT||PROSPECTIVE|||||||
34087123|NCT00802971|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087124|NCT01932385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087125|NCT00567632|||COHORT||PROSPECTIVE|||||||
34087126|NCT04753801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087127|NCT05406661|||COHORT||PROSPECTIVE|||||||
34087128|NCT03349307|NA|SINGLE_GROUP||OTHER||NONE||||||
34087129|NCT05236530|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34087130|NCT03176485|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087131|NCT00402935|||COHORT||PROSPECTIVE|||||||
34087132|NCT01687660|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087133|NCT01012050|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34087134|NCT00067340|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34087135|NCT01997580|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34087136|NCT04925635|||COHORT||CROSS_SECTIONAL|||||||
34087137|NCT02470741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781493|NCT00431509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33781494|NCT05042063|||COHORT||PROSPECTIVE|||||||
34087138|NCT02145390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781495|NCT04562948|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34087139|NCT03631641|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33781496|NCT04107649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigators, care providers, and outcomes assessors will not be appraised of treatment arm.|Three arm parallel randomized control trial.|f|t|t|t
33996022|NCT05597631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33996023|NCT03520972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996024|NCT06433258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996025|NCT01669460|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34087140|NCT01192815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781497|NCT06695858|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"An experienced anesthetist will open the envelopes, prepare the local anesthetics, and perform the assigned technique with no further involvement in the study.~A blinded investigator (an anesthesia and pain therapy specialist) will be responsible for perioperative data collection, pain assessment during the first 24 postoperative hours, and providing analgesia. All patients were blinded to the assigned technique."||t|t|f|t
33781498|NCT04768686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781499|NCT01167023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781500|NCT06697899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781501|NCT06631443|||OTHER||PROSPECTIVE|||||||
33781502|NCT00715286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781503|NCT04283123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781504|NCT03114943|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087141|NCT06469086|||COHORT||RETROSPECTIVE|||||||
34087142|NCT03957993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The therapist who assesses the outcomes is a different therapist than the treating (intervention) therapist.|Participants are randomized to the Telehealth arm of the study or the Standard Care arm of the study.|f|f|f|t
34087143|NCT04224116|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double blind investigation|"It's a randomized, double-blind, prospective study including patients over the age of 18 years old, programmed for potentially hemorrhagic thoracic surgery, such as pulmonary resection for aspergilloma, pulmonary tuberculosis, pleural decortication, lobectomy with parietectomy or redux. Demographic, clinical, biological data as well as transfusion requirements, blood loss and perioperative complications were identified.~Two groups of patients:~* TA group: receiving tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.~* Serum saline isotonic (SSI) group: placebo with isotonic saline serum."|t|t|t|f
34087144|NCT03950882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087145|NCT01919853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087146|NCT00719667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087147|NCT00989300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087148|NCT04956809|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34087149|NCT04910464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34087150|NCT00557232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087151|NCT03320811|||CASE_CONTROL||RETROSPECTIVE|||||||
33996026|NCT01888276|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087152|NCT01141816|NA|SINGLE_GROUP||SCREENING||NONE|The radiologist is blinded to either CEUS or CT/MRI.|||||
34087153|NCT05088265|||CASE_ONLY||PROSPECTIVE|||||||
34087154|NCT05096377|||CASE_ONLY||PROSPECTIVE|||||||
34087155|NCT04868032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research assistant blinded to study condition will conduct follow-up assessment visits.||f|f|f|t
34087156|NCT04616534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087157|NCT00774917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087158|NCT02423408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087159|NCT01946490|||COHORT||RETROSPECTIVE|||||||
34087160|NCT00537277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915830|NCT02261012|||CASE_CONTROL||PROSPECTIVE|||||||
33915831|NCT05825209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915832|NCT04835558|||CASE_CONTROL||PROSPECTIVE|||||||
33915833|NCT02507193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915834|NCT05210205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33915835|NCT06461611|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A qualified examiner blinded to individual subject treatment assignments performed the oral hygiene status index （SBI and PLI）on subjects.||f|f|t|f
33915836|NCT02738996|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915837|NCT00702156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915838|NCT04400539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915839|NCT02757781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33915840|NCT00639548|||CASE_ONLY||PROSPECTIVE|||||||
33915841|NCT00885417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915842|NCT04726293|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33915843|NCT02477228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915844|NCT05926258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33915845|NCT03365479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33915846|NCT03585322|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation study||||
33915847|NCT02985268|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33915848|NCT00103467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33996027|NCT03914664|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33996028|NCT04980105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 150 participants fulfilling the inclusion criteria, patients were randomly assigned into three groups by a computer-based protocol. The patients were separated into three groups according to the type of treatment administered.|t|f|f|t
33996029|NCT02187796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33996030|NCT06626789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Clinical Research Organizatzion (sub-contractor) responsible for interim analysis||t|f|t|t
33996031|NCT06563037|||CASE_ONLY||CROSS_SECTIONAL|||||||
33996032|NCT02649335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996033|NCT05243251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"We will prepare 82 jars containing the oral olanzapine tablets and similar 82 jars containing the placebo tablets. Each jar will have a unique number from 1 to 164. The jars will be prepared by Dr. Noha Abdel Razek, The Oncology Pharmacy Director at the department.~The codes of the jars will be safeguarded till the end of the study at a closed cupboard at our clinic. The jars will be uncoded only at the end of the study by only one investigator."|"This is a placebo-controlled double-blinded phase III randomized clinical trial. One hundred and sixty-four adult incurable cancer patients under treatment at Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) - Kasr Al-Ainy School of Medicine - Cairo University during the period from December 2021 to September 2022.~A written informed consent is to be obtained from all patients before entering the study. Then the investigators will give them dietary advice at baseline. Routine labs as complete blood count, liver, kidney function tests and CRP will be obtained to assess safety to start the drug and to assess its dose adjustment.~Participants will be 1:1 randomized to the intervention (olanzapine) arm or the control (placebo) arm. Olanzapine will be given as oral 5 mg tablets (Zyprexa) and the placebo will be given in the form of tablets containing 300 mg of microcrystalline cellulose."|t|f|t|f
33996034|NCT04934098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the characteristics of the study, it will be blind only to the researcher responsible for analyzing the collected data.|Randomization will be by lot when the patient enters the study. Envelopes will be made available that will contain a code that determines the allocation of patients in the intervention group experimental or standard.|f|f|f|t
33996035|NCT03911115|||CASE_ONLY||CROSS_SECTIONAL|||||||
33996036|NCT01975116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087161|NCT05991817|||COHORT||PROSPECTIVE|||||||
34087162|NCT03199690||SEQUENTIAL||TREATMENT||NONE||open label, single centre, sequential pharmacokinetic study||||
34087163|NCT05203653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087164|NCT04269616|RANDOMIZED|FACTORIAL||OTHER||SINGLE||2x2 between subjects|t|f|f|f
34087165|NCT02668003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103018|NCT04942327|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34103019|NCT01292265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915849|NCT02385877|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996037|NCT03448094|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants will recieve either Resveratrol or Placebo for a period of 3 months.|t|f|t|f
33996038|NCT00314834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996039|NCT01943045|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33915850|NCT04281342|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Placebo-controlled.|Each subject will be randomized immediately prior to first study treatment administration on Day 1 Period 1 to one of 12 treatment sequences following a 3 × 4 × 4 Williams square design. Moxifloxacin will be open-label on Day 10 in one period.|t|t|t|t
33781505|NCT03432533|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study; blinding procedures are not applicable.|"After signing the informed consent form (ICF), subjects will undergo the following periods:~* Screening period (35 days) to complete eligibility assessments~* Open-label treatment period (6 months)~* Follow-up period (3 months) During the open-label treatment period, subjects will be randomized to receive romosozumab either via HCP administration with PFS or via self-administration withAI/Pen.~During the follow-up period, subjects will be followed for an additional 3 months to ensure appropriate follow-up for anti-romosozumab antibody formation and adverse events.~The primary analysis will be performed after all subjects have had the opportunity to complete the Month 6 visit. The final analysis will be performed after all subjects have had the opportunity to complete the Month 9 visit."||||
33781506|NCT04086758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781507|NCT01094171|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915851|NCT04253041|RANDOMIZED|PARALLEL||OTHER||SINGLE|To mask the true purpose of the current research and avoid biased answers related to sensitive topic such as body image and satisfaction, we will present this research as a study exploring social media's impact on lifestyle satisfaction. Visual Analogue Scales will be used to test measures of body satisfaction and appreciation, but will also include scales related to financial, social, home, and school satisfaction. At the end of this study, participants will be debriefed on the true purpose using the statement: The true purpose of this study was to examine the impacts of exposure to different Instagram images on women's body satisfaction, body appreciation, and mood. In order to understand the true effects of such without giving away the intervention, these questions were masked within a lifestyle satisfaction intervention. All of your answers will remain anonymous and will not be linked to your personal information in any way. Do you have any questions?||t|f|f|f
33915852|NCT02922634|||OTHER||PROSPECTIVE|||||||
33915853|NCT02155764|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33996040|NCT01983735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996041|NCT01885897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996042|NCT04778501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996043|NCT02719665|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33996044|NCT02451163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103020|NCT06691854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34103021|NCT01523431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103022|NCT04775758|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33781508|NCT00252993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33692539|NCT06370273|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Open-label study. Trial Statistician and Health Economist to be blinded for analysis|A pragmatic, open-label, linked pair of randomised controlled trials with common outcomes and parallel economic analysis each with internal pilot phases, conducted across 30 NHS sites|f|f|f|t
33781509|NCT05338983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The observer and the recipients will be blinded to the study group to avoid bias (double blind randomized controlled trial)|"Children will be divided into 4 equal groups, 20 children each. Three experimental groups, and a(control group) . The 4 groups will be randomly allocated for each technique using block technique of simple random sampling. Randomized block designs are constructed to reduce noise or variance in the data.~Every block will include the equal number of the four groups (three experimental and one control)."|t|f|t|f
33692540|NCT01061632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692541|NCT00704808|||COHORT||PROSPECTIVE|||||||
33692542|NCT01741012|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33692543|NCT03771053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692544|NCT02343133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692545|NCT06507553|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind (observer-blind; blinded for participants and sites, except for those preparing/administering study intervention, and for the Sponsor, except for dedicated Sponsor staff who will be unblinded for interim analysis||t|t|t|t
33692546|NCT01064427|||COHORT||PROSPECTIVE|||||||
33781510|NCT05545774|||COHORT||PROSPECTIVE|||||||
33781511|NCT03206294|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33781512|NCT06697457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors and patients were not informed about group allocation|Four groups, parallel, randomized controlled|t|f|f|t
33781513|NCT00002956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692547|NCT05881460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This study is a double-blinded, crossover trial, where participants are their own control and receive both active stimulation and sham.|t|t|t|t
33781514|NCT02121938|||COHORT||PROSPECTIVE|||||||
33781515|NCT02114827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33781516|NCT06608888|||OTHER||PROSPECTIVE|||||||
33781517|NCT02629445|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33781518|NCT06250855|||COHORT||PROSPECTIVE|||||||
33781519|NCT06208462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692548|NCT06334276|||COHORT||RETROSPECTIVE|||||||
33781520|NCT02847585|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781521|NCT06549894|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33781522|NCT01126021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781523|NCT04953156|||COHORT||PROSPECTIVE|||||||
33781524|NCT02553941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692549|NCT03098628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a single-blind, open-label, randomised trial, with laboratory staff blinded to study group allocation as all the outcome measures that address the study objectives are laboratory based. Laboratory samples will be labelled with a unique trial identification number that does not identify the study group. Given the different timing of the vaccine schedules in the different study arms, the study nurses, vaccine administrators and participants will not be blinded to the study group allocation of each infant.|single-blind, open-label, randomised controlled trial|f|f|f|t
33781525|NCT05592431|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33781526|NCT00541645|||||PROSPECTIVE|||||||
33781527|NCT05585762|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Study products will be allocated a code and labelled by an external team. The coding of the study products will be recorded and sealed in 'unblinding envelopes' that will only be opened in unblinding becomes necessary for subject safety. No one on the study team (including outcome assessor and statisticians) will be aware of the study product identity. The study products are matched for appearance, taste and calories and will not be visibly distinguishable.|Parallel group, randomized, double-blind.|t|t|t|t
33692550|NCT02208375|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781528|NCT04305678|NA|SINGLE_GROUP||TREATMENT||NONE||Mepolizumab for the treatment of eosinophilic faciitis.||||
33781529|NCT01987882|||COHORT||PROSPECTIVE|||||||
33781530|NCT05404113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33781531|NCT02948543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781532|NCT01781338|NA|SINGLE_GROUP||OTHER||NONE||||||
33781533|NCT06467955|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, multi-center study enrolling up to 60 participants at up to 3 sites in Canada.||||
33781534|NCT02162940|||CASE_CONTROL||PROSPECTIVE|||||||
33801437|NCT04512482|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Investigators were blinded during the clinical phase of the study and were unaware of the agents the subjects received. The investigators were also blinded during the visual plaque score analysis of the project and were unaware of what photograph corresponded to what phase or intervention.|Enrolled subjects undergoing orthodontic treatment with fixed appliances will be randomized to receive either the Bromelain rinse or Placebo first and then will be crossed over to receive the opposite intervention. The study will consist of two treatment period (1 day) separated by a washout period of 1 week.|t|t|f|t
33915854|NCT03824925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Each patient was asked to pick one of the sealed envelopes from a box. The sealed envelopes contained either alphabets A or B. The sealed envelopes were blinded to both the investigator and the patient. The generation of random allocation sequence and assignment of participants to intervention were done by the principal investigator.~Both the investigator and the patient were blinded (double-blinded) about the groups and intervention."||t|t|t|f
33915855|NCT00292448|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33915856|NCT02675153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915857|NCT04955002|||COHORT||CROSS_SECTIONAL|||||||
33915858|NCT01951235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996045|NCT03671954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participant, outcome assessor|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone. Subjects will be assigned to one of two groups by block randomization, such that patients receiving each different implant design comprise each block.||||
33692551|NCT06080425|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Monthly in-home MNT will be conducted by the RD for members of the household but will be tailored for the participant with diabetes for 6 months. Dietary counseling will be focused on living with diabetes, appropriate food choices, glycemic control, and importance of weight management. To enhance participant buy-in and sustainability, the RD will utilize Motivational Interviewing (MI) principles to work with participants to improve self-efficacy of behavior change and set Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals each month.~Also, participants will enroll in the group facilitated Dining with Diabetes program with the option to bring one member of their social to their local Cooperative Extension offices. Dining with Diabetes is an interactive 4-session program that includes direct education on healthy eating, food preparation strategies, physical activity, emotional health, identifying complications of diabetes, and problem-solving skills."||||
33996046|NCT05049291|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33996047|NCT01073735|||COHORT||PROSPECTIVE|||||||
33996048|NCT02406235|||COHORT||PROSPECTIVE|||||||
33692552|NCT02978560|||CASE_CONTROL||PROSPECTIVE|||||||
33996049|NCT01079858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692553|NCT04957355|NA|SINGLE_GROUP||TREATMENT||NONE||Single group design to compare the effects of neuromuscular electrical stimulation on reactive balance control, gait, and fall risk in individuals with chronic stroke||||
33692554|NCT00832390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996050|NCT03983616|||COHORT||PROSPECTIVE|||||||
33915859|NCT05764018|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The participant will be blinded to both the supplement (placebo vs. caffeine) and the condition (normoxia vs. hypoxia). The investigator and the outcomes assessor will also be blinded to the supplement (placebo vs. caffeine), but both will be aware of condition (normoxia vs. hypoxia). Blinding success from the participants' perspectives will be assessed with an exit questionnaire.|Participants will perform four trials, to cover both levels of two factors; normoxia vs. hypoxia, and placebo vs. caffeine|t|f|t|t
33915860|NCT02323321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915861|NCT03245723|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Young adults born premature (some of them are registered on the National Lung Project) and Healthy Controls will undergo pulmonary function testing, cardiac positron emission tomography, and cardiac magnetic resonance imaging.||||
33915862|NCT05502653|||COHORT||PROSPECTIVE|||||||
33915863|NCT02486887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33915864|NCT00406783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915865|NCT05653297|||COHORT||PROSPECTIVE|||||||
33915866|NCT03230474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915867|NCT05598294|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33915868|NCT04412382|||CASE_CONTROL||PROSPECTIVE|||||||
33915869|NCT04515043|NA|SINGLE_GROUP||OTHER||NONE||||||
33915870|NCT02601066|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915871|NCT06371014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915872|NCT02503631|||CASE_ONLY||PROSPECTIVE|||||||
33915873|NCT03368131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915874|NCT04534569|||OTHER||PROSPECTIVE|||||||
33996051|NCT05001698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996052|NCT00529191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996053|NCT02143258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996054|NCT00835146|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996055|NCT05936645|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33996056|NCT04358237|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer||||
33996057|NCT03372876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996058|NCT00002033||||TREATMENT||DOUBLE||||||
33996059|NCT01566435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996060|NCT00873990|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33996061|NCT01637480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996062|NCT06143202|||COHORT||PROSPECTIVE|||||||
33996063|NCT00731939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996064|NCT00408616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996065|NCT04518072|||CASE_CONTROL||PROSPECTIVE|||||||
33996066|NCT00837564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996067|NCT01490190|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996068|NCT04468880|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||monocentric, double-blind, randomized, controlled, cross-over and ambulatory study|t|f|t|f
33996069|NCT03067324|||COHORT||PROSPECTIVE|||||||
33996070|NCT01949805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996071|NCT00069758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996072|NCT05232825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996073|NCT03882762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996074|NCT00736827|||COHORT||PROSPECTIVE|||||||
33996075|NCT06371703|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33996076|NCT04179058|||COHORT||RETROSPECTIVE|||||||
33996077|NCT05139563|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996078|NCT02849951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996079|NCT03462342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996080|NCT05920447|||OTHER||PROSPECTIVE|||||||
33996081|NCT01046084|RANDOMIZED|CROSSOVER||||NONE||||||
33996082|NCT04494607|NA|SINGLE_GROUP||OTHER||NONE||||||
33996083|NCT04299087|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996084|NCT03575351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996085|NCT05860777|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This is a pragmatic clinical trial-a stepped wedge cluster randomized control trial||||
33996086|NCT04842435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Stage 1 study will enroll 156 subjects with moderate COVID-19 who will be randomized into the four groups.~Stage 2 will include 220 subjects who will be divided into two groups."|t|f|t|f
33996087|NCT02216981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996088|NCT03007524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996089|NCT04854460|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996090|NCT03862573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996091|NCT03622996|||CASE_ONLY||PROSPECTIVE|||||||
33996092|NCT06555939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996093|NCT01418573|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33996094|NCT04882241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study||t|t|t|t
33996095|NCT01572415|||COHORT||PROSPECTIVE|||||||
33996096|NCT01341951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996097|NCT00035139|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33996098|NCT05343676|||COHORT||PROSPECTIVE|||||||
33915875|NCT02819115|||COHORT||PROSPECTIVE|||||||
33915876|NCT05359406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915877|NCT04263948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33996099|NCT06336993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996100|NCT06449703|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996101|NCT01802112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996102|NCT03508596|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33996103|NCT03332082|NA|SINGLE_GROUP||TREATMENT||NONE||20 patients will be recruited and treated with a commercially available tooth positioner. The results will be compared with the other group from previously treated patients who were in the alignment phase of Orthodontics.||||
33996104|NCT03921918|NA|SINGLE_GROUP||OTHER||NONE||Pilot study||||
33996105|NCT03259841|||COHORT||PROSPECTIVE|||||||
33996106|NCT02702895|||COHORT||RETROSPECTIVE|||||||
33996107|NCT01113853|||CASE_ONLY||CROSS_SECTIONAL|||||||
33996108|NCT05025163|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33996109|NCT00898508|||CASE_CONTROL||PROSPECTIVE|||||||
33996110|NCT06560450|NA|SINGLE_GROUP||TREATMENT||NONE||Ten patients were offered therapy using Stride One for one week. Several measurements are performed before the start of the therapy, immediately after the end of the intervention period and 2 days after the end of the therapy.||||
33915878|NCT01666418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915879|NCT04118114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915880|NCT03769935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915881|NCT00002434||||TREATMENT||NONE||||||
33915882|NCT00104078|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33915883|NCT01093755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915884|NCT02561299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915885|NCT05869539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915886|NCT05394740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915887|NCT04346264|||COHORT||PROSPECTIVE|||||||
33915888|NCT04068311|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Pre and post cohort study with an intervention|t|f|f|f
33915889|NCT04123717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915890|NCT00005612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915891|NCT04273399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Case control model||||
33915892|NCT03838068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and their parents, the assessor and the statistician will be blinded.|Access cavity in traumatized central incisors will be assigned into experimental or control group using simple randomization 1:1 by the help of the computer software(random.org).|t|t|f|t
33996111|NCT01125072|||COHORT||RETROSPECTIVE|||||||
33996112|NCT03605641|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33996113|NCT03769428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|t|t|f
33996114|NCT04322513|||CASE_CONTROL||PROSPECTIVE|||||||
33996115|NCT03016806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996116|NCT00197249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996117|NCT00284518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996118|NCT01791062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996119|NCT04516460|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996120|NCT02136862|||COHORT||PROSPECTIVE|||||||
33996121|NCT00961376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996122|NCT00364559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33996123|NCT01174186|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996124|NCT01582464|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33781535|NCT02427737|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The original model was to have parallel randomized MRI sites. This was possible at one participating institution, The Ohio State Universty Medical Center (OSU). For the second institution (Duke University) staff cuts resulted in personnel cross-over between test and control sites making randomization impossible. Therefore a sequential model was used compared data from the pre- to post training period for the Duke sites. In total 12 MRI entities contributed, six at OSU, and six at Duke. Also, Duke and OSU turned out to have different modes of data collection. OSU had fully automated capture of patients scheduled, showing, and completing their examination as well as a priori numbers of available imaging slots per time unit. Duke did not collect these data electronically so that personnel could only gather the pertinent measures by daily manual diary entry. Thus the mode of result presentation is not concordant in some aspects among sites.||||
33781536|NCT05931562|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE||Randomized-controlled, parallel, single-blinded design|t|f|f|f
33781537|NCT06003231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781538|NCT04402671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients are blind to the allocation. The radiographic volumetric changes and the histomorphometrical analysis are assessed by blind examiners.~Random allocation was done by the sequentially sealed envelope method. At the time of membrane placement during the surgery, the envelope corresponding to the case sequence number is opened specifying the group allocation."|This study is a pilot randomized clinical trial with parallel groups, with an observation period of 6 - 9 months. It is set to identify the equivalence between the test and the control procedures. An equal randomization is set for the 2 groups|t|f|f|t
33781539|NCT06698120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781540|NCT05154344|||COHORT||RETROSPECTIVE|||||||
33781541|NCT00272285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781542|NCT03568461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781543|NCT06613451|RANDOMIZED|PARALLEL||OTHER||SINGLE|Nursing Student|Randomized Controlled Study|f|t|f|f
33781544|NCT05149144|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33915893|NCT03911336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants, Surgeon and Assessors collecting the data and conducting the appropriate statistical analyses for all outcomes in the study will be blinded.~All surgical procedures will be scheduled between 8 and 10 AM and performed by the same blinded clinician to maintain a consistent therapeutic approach for all subjects."|This study is designed as a parallel-arm, double-blinded pilot randomized controlled trial (RCT).|t|t|f|t
33915894|NCT06422546|||CASE_ONLY||PROSPECTIVE|||||||
33915895|NCT00157937|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915896|NCT04357652|||COHORT||PROSPECTIVE|||||||
33915897|NCT02200471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33915898|NCT01522040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33915899|NCT02043223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33915900|NCT01341379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915901|NCT04288479|NA|SINGLE_GROUP||TREATMENT||NONE||before-after intervention effect measurement||||
33915902|NCT01161082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33915903|NCT03146052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded endoscopists performed endoscopic procedure and evaluated colon cleansing.||f|f|f|t
33915904|NCT05439460|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33915905|NCT04507620|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33915906|NCT04914078|||CASE_ONLY||PROSPECTIVE|||||||
33915907|NCT02361658|||COHORT||PROSPECTIVE|||||||
33915908|NCT01953536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915909|NCT01015664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915910|NCT00119730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915911|NCT01562704|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33996125|NCT03921762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996126|NCT06485284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996127|NCT05750849|||COHORT||PROSPECTIVE|||||||
33996128|NCT02265679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996129|NCT04003363|||COHORT||PROSPECTIVE|||||||
33996130|NCT02898987|||COHORT||PROSPECTIVE|||||||
33996131|NCT02550535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996132|NCT02827045|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33996133|NCT02924545|||CASE_ONLY||CROSS_SECTIONAL|||||||
33996134|NCT06559787|||COHORT||RETROSPECTIVE|||||||
33996135|NCT02781883|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996136|NCT05170087|||COHORT||RETROSPECTIVE|||||||
33996137|NCT02323256|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33996138|NCT00005923|||NATURAL_HISTORY|||||||||
33996139|NCT04544618|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study will employ a single-blind randomized design (1:1 randomization; stratified according to surgery type \[with vs. without reconstruction\] and whether or not neoadjuvant chemotherapy was received; stratification will designate equal proportions of participants with these characteristics across each of the two study groups).|t|f|f|f
33996140|NCT02463786|||COHORT||OTHER|||||||
33996141|NCT05399446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessor completing the interview at each follow-up assessment following completion of the intervention will be blinded to the condition the participant was in.||f|f|t|f
33996142|NCT02853019|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996143|NCT03103360|||CASE_ONLY||PROSPECTIVE|||||||
33996144|NCT03209505|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Subjects will be masked to the contact lens brand fit in each eye. The subject's Lid Wiper Epitheliopathy will be graded using photographs of the eyelid, where the grader is masked to the lens type in each eye.|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. One eye will be fit in a contact lens with a low coefficient of friction while the contralateral eye will be fit in a contact lens with a high coefficient of friction.|t|f|f|t
33996145|NCT05762705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33996146|NCT01386853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996147|NCT02722187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996148|NCT01083693|||COHORT||PROSPECTIVE|||||||
33996149|NCT01261663|||CASE_CROSSOVER||PROSPECTIVE|||||||
33996150|NCT03850522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781545|NCT06697496|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Random assignments will be concealed from participants and researchers throughout the trial. Follow-up data will be collected by survey research unit that will be blind to random assignment.||t|f|t|t
33781546|NCT01663337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781547|NCT02272023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781548|NCT06249867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to either a treatment (darifenacin) or placebo group in parallel for the duration of the study. Treatment will include a two-week titration period with a 7.5 mg dose of darifenacin, which will be increased to 15 mg dose for the following 22 weeks. Dosing regimen of the placebo group will be administered to match the treatment dosing regimen.|t|t|t|t
33781549|NCT05970731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781550|NCT04259762|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33781551|NCT01289405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781552|NCT04875260|||COHORT||RETROSPECTIVE|||||||
33781553|NCT05312814|||COHORT||PROSPECTIVE|||||||
33781554|NCT00550472|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33781555|NCT01724203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33781556|NCT05812794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781557|NCT01687270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781558|NCT01329120|||COHORT||RETROSPECTIVE|||||||
33781559|NCT04965493|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized 1:1 into Arm A and Arm B.||||
33781560|NCT03756389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|In Part A, all subjects will receive study drug and this is Open Label. When Part A is complete, Part B will start and this will be double blind to participant and investigators.|||||
33781561|NCT06697925|||CASE_ONLY||PROSPECTIVE|||||||
33781562|NCT05262556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781563|NCT05170854|||CASE_CONTROL||RETROSPECTIVE|||||||
33781564|NCT05851378|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33781565|NCT01701765|||COHORT||PROSPECTIVE|||||||
33781566|NCT01575860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781567|NCT05531370|NA|SINGLE_GROUP||OTHER||NONE||||||
33781568|NCT03967561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial with two interventions in parallel.|f|f|f|t
33781569|NCT02613780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781570|NCT05201989|||CASE_CONTROL||PROSPECTIVE|||||||
33781571|NCT05472649|||OTHER||PROSPECTIVE|||||||
33781572|NCT06697782|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781573|NCT06613971|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781574|NCT04945408|||COHORT||PROSPECTIVE|||||||
33781575|NCT06397885|||CASE_ONLY||PROSPECTIVE|||||||
33781576|NCT01890967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781577|NCT06689826|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781578|NCT04113837|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The foods are offered in neutral packaging and are provided regularly by the study team. All personal (participants, care provider) are blinded.|The controlled, randomized, double-blind crossover study consists of a 4-week investigation periods with a 11-week wash-out period in between. At the beginning, participants are randomly allocated into the verum or the control/placebo group. After the wash-out phase the interventions are crossed between the groups and the respective food range is consumed also for four weeks.|t|t|f|f
33781579|NCT05973669|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781580|NCT01562665|||CASE_ONLY||PROSPECTIVE|||||||
33781581|NCT02646046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781582|NCT06168604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blind allocation. The outcomes assessors will be masked to group allocation. Other research personnel (investigator, project manager, interventionist) may become aware of group allocation. Participants will be asked not to disclose to outcomes assessors the group to which they are assigned.||f|f|f|t
33781583|NCT06479915|||OTHER||RETROSPECTIVE|||||||
33781584|NCT06462261|||COHORT||CROSS_SECTIONAL|||||||
33781585|NCT00693030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781586|NCT04541186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781587|NCT03581643|||COHORT||RETROSPECTIVE|||||||
33781588|NCT05466669|||COHORT||PROSPECTIVE|||||||
33781589|NCT02641210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781590|NCT05219045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33781591|NCT06697327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781592|NCT01974232|||CASE_ONLY||RETROSPECTIVE|||||||
33781593|NCT06191536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33781594|NCT04995562|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study includes 2 cohorts: 6 infants on oxygen with nasal cannula, and 6 infants currently requiring respiratory support with high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) or RAM cannula.||||
33781595|NCT01570777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781596|NCT04727775|||COHORT||RETROSPECTIVE|||||||
33915912|NCT03796182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a Phase 1, randomized, 2 way crossover, open label study of the effect of PF 04965842 on metformin PK in healthy adult participants. The effect of PF 04965842 on N1 methylnicotinamide (NMN) PK and its correlation to the effect on metformin PK will also be assessed.~A total of approximately 12 healthy male and/or female participants will be enrolled in the study so that approximately 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods. Participants who discontinue from the study may be replaced at the sponsor's discretion. The replacement participant will receive the same treatment sequence as the participant who discontinued.~Participants will be screened within 28 days of the first dose of investigational product. Participants will report to the clinical research unit (CRU) the day prior to Day 1 (ie Day -1) dosing in Period 1 for both treatment sequences. In both sequences, participants will remain in the CRU for"||||
33915913|NCT06317077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915914|NCT04764409|||COHORT||PROSPECTIVE|||||||
33915915|NCT01592669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915916|NCT03579953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781597|NCT06091930|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|All trial parts will be conducted open label.|The trial is divided in four parts. Part I and Part III will have a sequential assignment while Part II and Part IV will have a parallel assignment.||||
33781598|NCT04106440|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Use of applications to share data||||
33781599|NCT05207540|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33781600|NCT04982380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781601|NCT05260840|||COHORT||PROSPECTIVE|||||||
33781602|NCT04545593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research staff conducting follow up assessments will be blinded to participant condition in the trial.||f|f|f|t
33781603|NCT06483022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators plan a multisite step-wedge cluster randomized trial to test the extent to which interprofessional collaboration training (IPC training) reduces racial disparities in postpartum pain (primary outcome) and pain assessment and treatment (secondary, health team processes), improves birthing people's experience of respectful care (secondary outcomes), and fostering a positive shift in health team interprofessional collaboration attitudes and teamwork (secondary process outcomes).||||
33781604|NCT06494072|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of short duration (5 days) versus a standard of care duration of antibiotics on the effective treatment of children hospitalized for uncomplicated community acquired pneumonia.||||
33996151|NCT05645120|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33996152|NCT04652622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|data will be blinded for analysis but the study is open label due to the nature of the intervention|participants will be randomized to either exposure to the intervention arm in conjunction with standard care or the control arm and will receive standard care alone|f|f|f|t
33996153|NCT06146959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33996154|NCT02956096|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33781605|NCT01245413|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33781606|NCT01423357|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781607|NCT03571594|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind (Parts A, B \&C). Open-label (Part D only)||t|t|t|t
33781608|NCT03676556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33915917|NCT05554471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915918|NCT01356836|||COHORT||PROSPECTIVE|||||||
33915919|NCT04448093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention group and control group.||||
33915920|NCT03065634|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33915921|NCT01693133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915922|NCT01450046|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915923|NCT00006604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915924|NCT02156492|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33915925|NCT03204435|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients of intracranial aneurysms with coexistence of cerebrovascular stenosis, coincident with inclusion and exclusion criterion, will be distributed into traditional therapy group(control group) and hybrid operating group(test group), and conduct with traditional neurosurgical management or one-stage hybrid operating management separately.~Traditional therapy group: intervene the aneurysms and vascular stenosis unsimultaneously. Clipping procedure is preferred to aneurysms, while endovascular intervention is preferred to stenosis.~Hybrid operation group: one-stage hybrid operating technique is conducted. The aneurysms and vascular stenosis will be executed via the cooperation of microsurgical procedure and endovascular interventional techniques."|f|f|f|t
33915926|NCT03115476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915927|NCT01265420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915928|NCT06527456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915929|NCT03446430|NA|SINGLE_GROUP||OTHER||NONE||||||
33915930|NCT03509337|||COHORT||PROSPECTIVE|||||||
33915931|NCT05142540|||COHORT||PROSPECTIVE|||||||
33996155|NCT05168163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996156|NCT01181635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996157|NCT04008563|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intervention Group: Bariatric Surgery and Progestin Intrauterine Device (pIUD) Non-Intervention Group: Progestin Intrauterine Device (pIUD) alone~Participants who consent will be randomized in a 1:1 allocation."||||
33996158|NCT02922829|||COHORT||PROSPECTIVE|||||||
33996159|NCT02569138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33996160|NCT01442376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33996161|NCT00000666||PARALLEL||PREVENTION||||||||
33915932|NCT05682586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915933|NCT02998424|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33915934|NCT05323292|||COHORT||CROSS_SECTIONAL|||||||
33915935|NCT03414762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915936|NCT01634321|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692555|NCT04471597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded ( patient and outcome assessors)|The patients will be divided randomly by a computer-generated randomization table into two equal groups|t|f|f|t
33781609|NCT00301379|||CASE_ONLY||PROSPECTIVE|||||||
33915937|NCT03570034|||CASE_ONLY||PROSPECTIVE|||||||
33781610|NCT03035240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915938|NCT00343291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781611|NCT01388543|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33915939|NCT02518308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33915940|NCT02437058|||COHORT||PROSPECTIVE|||||||
33915941|NCT04224285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||wait list control||||
33915942|NCT04108585|||COHORT||PROSPECTIVE|||||||
33915943|NCT00375817|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33996162|NCT05277402|NA|SEQUENTIAL||TREATMENT||NONE||||||
33996163|NCT01562613|||||PROSPECTIVE|||||||
33996164|NCT05347459|||COHORT||PROSPECTIVE|||||||
33996165|NCT00318188|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996166|NCT04270383|||COHORT||PROSPECTIVE|||||||
33996167|NCT00754455|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33996168|NCT04808362|NA|SINGLE_GROUP||TREATMENT||NONE||accelerated titration design||||
33996169|NCT00746850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33996170|NCT00045786|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996171|NCT04950426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996172|NCT06095180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be evaluated by an independent physiatrist, blinded for the assigned treatment.||f|f|f|t
33996173|NCT00070291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996174|NCT02930577|||||RETROSPECTIVE|||||||
33996175|NCT00964613|||CASE_ONLY||PROSPECTIVE|||||||
33996176|NCT04987216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996177|NCT06271005|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33996178|NCT05633186|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Study participants cannot be blinded to the allocation scheme as the participants will know what components are added to their intervention.|All participants receive access to the Moodbuster Life intervention with no or a maximum of 3 additional components. The investigators will use a full-factorial design to study the additional effect of each component either alone or in interaction. Participants are randomized to one of all possible combinations of the 3 components. In our study, with 3 additional components, this means that there are 8 conditions (2x2x2).|f|f|f|t
33996179|NCT01678339|||COHORT||RETROSPECTIVE|||||||
33996180|NCT02463981|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33692556|NCT05199727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996181|NCT05166109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996182|NCT05480943|||OTHER||PROSPECTIVE|||||||
33692557|NCT00777205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33692558|NCT03186898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692559|NCT01309308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692560|NCT04466228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692561|NCT01336673|||COHORT||PROSPECTIVE|||||||
33692562|NCT00825851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33692563|NCT00515047|||||CROSS_SECTIONAL|||||||
33692564|NCT03728985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study contains two single arm substudies. A primary study arm and a secondary study arm.||||
33781612|NCT06476899|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781613|NCT06615024|||OTHER||CROSS_SECTIONAL|||||||
33781614|NCT05489861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33781615|NCT03271892|||COHORT||PROSPECTIVE|||||||
33781616|NCT00889382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781617|NCT02391909|||COHORT||PROSPECTIVE|||||||
33781618|NCT00498537|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33781619|NCT02636413|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996183|NCT01597791|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33996184|NCT01616329|||OTHER||RETROSPECTIVE|||||||
33996185|NCT02121028|||COHORT||PROSPECTIVE|||||||
33781620|NCT06696378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Participants)|Parallel group placebo-controlled randomized clinical trial|t|f|t|f
33781621|NCT01560910|||COHORT||PROSPECTIVE|||||||
33781622|NCT02179645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33781623|NCT04404140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781624|NCT06187974|||CASE_CONTROL||PROSPECTIVE|||||||
33781625|NCT00341276|||OTHER||OTHER|||||||
33915944|NCT03030911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33915945|NCT03076190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915946|NCT01337063|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33915947|NCT04173442|||COHORT||PROSPECTIVE|||||||
33996186|NCT00834444|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996187|NCT02294305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996188|NCT03363555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996189|NCT02705573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33996190|NCT06627387|NA|SINGLE_GROUP||TREATMENT||NONE||usability study||||
33996191|NCT01751087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781626|NCT02862418|||CASE_CONTROL||PROSPECTIVE|||||||
33915948|NCT04245527|NA|SINGLE_GROUP||PREVENTION||NONE||Enrolled individuals will receive a Joovv solo for the 8 week study.||||
33915949|NCT04116450|NA|SINGLE_GROUP||TREATMENT||NONE||25 patient underwent Glaucolight illuminated microcatheter for primary congenital glaucoma||||
33915950|NCT06022978|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33996192|NCT01188863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996193|NCT06321653|||COHORT||PROSPECTIVE|||||||
33996194|NCT05803135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective, randomized, controlled, multicenter study|t|t|t|f
33692565|NCT06708182|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781627|NCT01952171|||COHORT||CROSS_SECTIONAL|||||||
33781628|NCT01349855|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33915951|NCT02652507|NA|SINGLE_GROUP||OTHER||NONE||||||
33915952|NCT00667251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915953|NCT03685669|||COHORT||CROSS_SECTIONAL|||||||
33915954|NCT05270850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692566|NCT06343389|||CASE_CONTROL||PROSPECTIVE|||||||
33915955|NCT01948388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915956|NCT02753036|||COHORT||PROSPECTIVE|||||||
33915957|NCT01511679|||COHORT||PROSPECTIVE|||||||
33915958|NCT00661245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33915959|NCT02951390|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33692567|NCT06707402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33692568|NCT06621914|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention, it is not possible to blind participants or outcome assessors to the treatment allocation. There is also no effective sham condition available. This is a common limitation within all blood flow restriction training research.|The overall study is a two phase RCT. Phase one will investigate two different BFR-RT protocols (high- vs low-pressure) for 1-week (7x BFR-RT sessions in 5 days). Phase two will take the BFR-RT protocol that elicited the greatest improvement in symptoms (high- or low-pressure) and compare that to conventional Uk Defence Rehabilitation practices over a 3 week period (21x BFR-RT sessions over 15 days).||||
33692569|NCT06687681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692570|NCT05049655|||CASE_CONTROL||OTHER|||||||
33692571|NCT05617209|||OTHER||PROSPECTIVE|||||||
33692572|NCT05725096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33692573|NCT04045301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692574|NCT03828318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33692575|NCT05623345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781629|NCT06087692|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Randomized-Controlled||||
33781630|NCT06339918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781631|NCT00335153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781632|NCT03675711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||supportive care||||
33781633|NCT06698237|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized crossover design, 12 participants (6 male and 6 female)||||
33781634|NCT03289455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781635|NCT06420167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781636|NCT06693999|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33781637|NCT06157892|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781638|NCT00002784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781639|NCT06678789|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781640|NCT00827944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781641|NCT03093285|||CASE_ONLY||PROSPECTIVE|||||||
33781642|NCT01542580|||COHORT||PROSPECTIVE|||||||
33915960|NCT00139685|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33915961|NCT02680886|||COHORT||PROSPECTIVE|||||||
33915962|NCT00799344|||COHORT||PROSPECTIVE|||||||
33915963|NCT05266794|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33915964|NCT01098838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33915965|NCT04170582|||COHORT||PROSPECTIVE|||||||
33915966|NCT01029431|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996195|NCT01927744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996196|NCT02438735|||COHORT||PROSPECTIVE|||||||
33996197|NCT00506376|||CASE_ONLY||PROSPECTIVE|||||||
33996198|NCT03007706|||CASE_ONLY||PROSPECTIVE|||||||
33996199|NCT03965429|||COHORT||PROSPECTIVE|||||||
33996200|NCT04335162|||COHORT||PROSPECTIVE|||||||
33996201|NCT00170729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996202|NCT00728754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996203|NCT03611335|||OTHER||PROSPECTIVE|||||||
33996204|NCT00174421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996205|NCT03510208|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996206|NCT05801822|||OTHER||CROSS_SECTIONAL|||||||
33996207|NCT01573663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996208|NCT03544216|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33781643|NCT01805323|||CASE_ONLY||RETROSPECTIVE|||||||
33781644|NCT04882462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781645|NCT04607252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33781646|NCT05981677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781647|NCT01587833|||||RETROSPECTIVE|||||||
33781648|NCT05269680|||COHORT||PROSPECTIVE|||||||
33781649|NCT06263829|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33781650|NCT00244257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781651|NCT01161017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781652|NCT05935267|||COHORT||PROSPECTIVE|||||||
33781653|NCT03521921|||COHORT||PROSPECTIVE|||||||
33781654|NCT00900289|||CASE_ONLY||PROSPECTIVE|||||||
33781655|NCT00953160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781656|NCT02977156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781657|NCT05477862|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||15 individuals with Alzheimer Disease (AD) and 15 cognitively healthy individuals.||||
33781658|NCT02644538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781659|NCT05249998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781660|NCT06693739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781661|NCT05061862|||OTHER||PROSPECTIVE|||||||
33915967|NCT01173341|||COHORT||PROSPECTIVE|||||||
33915968|NCT01722487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915969|NCT03926767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33996209|NCT04231643|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33996210|NCT04604938|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33996211|NCT00013390|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996212|NCT02277093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781662|NCT02420587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781663|NCT05349136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781664|NCT03946111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781665|NCT04768790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|f|f|t|t
33781666|NCT01312506|||CASE_CONTROL||PROSPECTIVE|||||||
33781667|NCT03892850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33781668|NCT03882515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915970|NCT01858610|RANDOMIZED|CROSSOVER||||NONE||||||
33915971|NCT02742350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33915972|NCT05044260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915973|NCT01897922|RANDOMIZED|PARALLEL||||DOUBLE||||||
33915974|NCT02875847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915975|NCT06233734|||CASE_CONTROL||PROSPECTIVE|||||||
33915976|NCT01783717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915977|NCT01069523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33915978|NCT01782794|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33915979|NCT05425875|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Investigator will be blinded to the group allotment|Three arm parallel group study|f|f|t|f
33915980|NCT06197932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor) the assessor who will take the readings is blind||f|f|f|t
33996213|NCT06595342|||COHORT||PROSPECTIVE|||||||
33996214|NCT05920486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blinded||t|t|f|t
33996215|NCT02729987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33781669|NCT00814489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33781670|NCT01819415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781671|NCT05769582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Parallel assignment Randomized|t|t|t|t
33781672|NCT03587194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781673|NCT06614062|||COHORT||PROSPECTIVE|||||||
33781674|NCT05635266|||COHORT||PROSPECTIVE|||||||
33781675|NCT06698068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915981|NCT00759980|||||PROSPECTIVE|||||||
33915982|NCT02760017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996216|NCT02878148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996217|NCT00795821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996218|NCT06432751|||COHORT||RETROSPECTIVE|||||||
33996219|NCT01007994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781676|NCT03845764|||COHORT||PROSPECTIVE|||||||
33781677|NCT01642186|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781678|NCT06696482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781679|NCT05929651|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915983|NCT05640674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781680|NCT00540605|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33781681|NCT06615102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781682|NCT04941417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781683|NCT06485297|||OTHER||PROSPECTIVE|||||||
33781684|NCT06431256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781685|NCT03613584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The vWFC or placebo will be prepared by the local hospital pharmacy or independent nurses from another ward (on holidays and weekends). To keep the blinding for the treating physicians and the study team syringes and lines with light protection (orange color) will be used. So the color of the medication (colorless to slightly yellowish) cannot be distinguished.||t|f|t|f
33781686|NCT03318913|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind||t|f|t|f
33781687|NCT03990025|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|f|t
33781688|NCT05803824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781689|NCT05243056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781690|NCT06630819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781691|NCT04960280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781692|NCT00000568|RANDOMIZED|||PREVENTION||DOUBLE||||||
33781693|NCT01460992|||CASE_ONLY||PROSPECTIVE|||||||
33801438|NCT03476811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This trial is a comparative trial investigating outcomes in 3 parallel groups. The control group will receive standard of care pain control following surgery, the Marcaine group will receive infusion of FDA approved Marcaine around the operative site following surgery through an FDA approved surgical device. The Placebo group will have the drug delivery device implanted with delivery of saline.|t|f|t|t
33801439|NCT03112135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801440|NCT04739137|||COHORT||PROSPECTIVE|||||||
33801441|NCT06374004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly divided into two groups and participants will not know which group participants are in.|One group received exercise therapy and the other group received manual therapy (thoracic mobilization) in addition to exercise therapy|t|f|f|f
33801442|NCT05660941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33915984|NCT01492283|||COHORT||PROSPECTIVE|||||||
33996220|NCT02152046|||CASE_CROSSOVER||PROSPECTIVE|||||||
33996221|NCT01412281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33996222|NCT04800718|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The intervention will include door-to-door screening and awareness generation in 8-12 villages surrounding VC and control VC will follow existing practices of awareness generation through community activities and health talks.||||
33996223|NCT03028545|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996224|NCT03405363|||COHORT||OTHER|||||||
33996225|NCT02775994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996226|NCT04817722|||COHORT||RETROSPECTIVE|||||||
33996227|NCT02799992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996228|NCT03780608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996229|NCT04631393|||COHORT||PROSPECTIVE|||||||
33996230|NCT05645081|||CASE_CONTROL||PROSPECTIVE|||||||
33915985|NCT05725382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and their relatives, outcome assessors, data analysts and PACU nurses will be blinded. However, the anesthesiologists and anesthesia nurses anesthetizing the child according to the NOL monitor/standard care cannot be blinded. The anesthesiologist and anesthesia nurses anesthetizing the child will not be involved in patient care after the patient leaves the theatre, nor in any clinical assessments, data collection or interpretation of adverse events.|Blinded, randomized, controlled multicenter trial with two parallel groups and a superiority design.|t|f|f|t
33781694|NCT03654989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Double blind (for the two groups treated with iontophoresis of treprostinil or placebo); open for the standard of care group.~The preparation of syringes of gel containing treprostinil or placebo will be centralized. Both gels will be physically identical, and investigators will not have access to the randomization list or to preparation records. This ensures proper blinding at treatment initiation. Treatment kits will subsequently be given to research nurses to continue the treatment at home. Nurses will not have access to the randomization list or preparation records either, which guarantees proper blinding throughout the 10-day treatment.~Unblinding will be done in case of any suspicion of an unexpected serious adverse reaction, prior to the declaration of the event to the competent authorities. Unblinding may be done 24/24h by the Pharmacy department."|"2 sub-studies:~* Preliminary safety study, Phase I: single ascending dose study that aims at establishing the safety, tolerability, and PK of the procedure in patients with active ulcers; we propose an accelerated titration design with 7 doses of gel. The accelerated phase (first four doses) uses single-patient cohorts per dose. After these doses, a standard 3+3 design will be performed. Any occurrence of dose-limiting toxicity (DLT) during the accelerated phase halts the accelerated titration and the cohort is expended to the standard 3+3 design. Two instances of DLT at a dose level halt escalation, and D-1 is the maximum tolerated dose.~* Proof-of-concept study, Phase II: Thirty-six patients with DFU associated with microvascular dysfunction will be randomized into three groups: Treprostinil iontophoresis; Placebo iontophoresis; Standard care. Drug administration, but not standard care, will be double-blind. After a 10-day treatment, follow-up includes 6 visits over 10 weeks."|t|t|f|t
33781695|NCT03276702|||COHORT||PROSPECTIVE|||||||
33781696|NCT02882503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915986|NCT03078036|||COHORT||OTHER|||||||
33915987|NCT04156932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33915988|NCT01694420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915989|NCT04182698|NA|SINGLE_GROUP||TREATMENT||NONE||"Experimental group: anlotinib (D1-14, d22-36, followed by 21 days cycle, taking medicine for 2 weeks, stopping for 1 week).~Group 1: 8mg po qd, Group 2: 10mg po qd, Group 3: 12mg po qd;~Combined chemotherapy:~Cisplatin + etoposide or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + pemetrexed (non-squamous cell carcinoma). Simultaneous radiotherapy: 3D-CRT or IMRT external radiotherapy (60-66 Gy, 2.0 Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."||||
33915990|NCT00844649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33915991|NCT02517593|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33915992|NCT01881685|||COHORT||PROSPECTIVE|||||||
33915993|NCT04268576|||CASE_CONTROL||PROSPECTIVE|||||||
33915994|NCT01930994|||COHORT||RETROSPECTIVE|||||||
33915995|NCT01062074|||OTHER||PROSPECTIVE|||||||
33915996|NCT05127421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|4 week double-blind treatment|This is 2:1 assignment to rux and vehicle creams.|t|f|t|f
33915997|NCT06191120|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"FoCus is a prospective monocenter, proof-of-concept, observational clinical study with a cross-sectional design to address the primary objective, and a longitudinal part to address secondary and exploratory objectives.~Participant will receive up to three \[18\]F-ALF-FAPI-74 PET/CT scans, dependent on standard-of-care procedures."||||
33781697|NCT02220283|||COHORT||RETROSPECTIVE|||||||
33996231|NCT00851305|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996232|NCT03601403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33996233|NCT02485951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996234|NCT03001596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996235|NCT02330939|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33996236|NCT02940444|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33996237|NCT05022979|||OTHER||CROSS_SECTIONAL|||||||
33996238|NCT04144998|||COHORT||PROSPECTIVE|||||||
33996239|NCT05215197|NA|SINGLE_GROUP||PREVENTION||NONE||open uncontrolled||||
33996240|NCT03835767|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33996241|NCT06013163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|"Part I: EMP22 and Xenical® have different strengths of orlistat, 60 mg and 120 mg, respectively. In order to maintain the blind, the IMP will be administered as follows:~* EMP22 60 mg orlistat, 2 capsules TID.~* Xenical® 120 mg orlistat 1 capsule + placebo 1 capsule TID. EMP22, Xenical® and placebo will be identical in appearance.~Part II will be open-label, i.e., the Investigator, trial staff and trial participants will know which treatment, EMP16 or Xenical®, that is given at each visit."|"In Part I (single-blind), EMP22 (120 mg orlistat) and orlistat in its conventional form (Xenical®, 120 mg orlistat) will be taken 3 times daily (ter in die \[TID\]) together with the 3 main daily meals for two 9-day treatment periods in a cross-over manner.~In Part II (open-label), single doses of EMP16 (120 mg orlistat/40 mg acarbose) and Xenical® (120 mg orlistat) will be taken together with breakfast on 2 separate days."|t|f|f|f
33996242|NCT01285713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996243|NCT04298086|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-center, phase 2 randomized control trial of structured exercise treatment and plant-based diet versus physical activity and nutrition counseling for 24 weeks.||||
33781698|NCT00662909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781699|NCT03728517|||COHORT||PROSPECTIVE|||||||
33781700|NCT06697834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33915998|NCT04127734|||COHORT||RETROSPECTIVE|||||||
33915999|NCT05018117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Nicotine (6 mg, polacrilex gum) and placebo will be administered to each participant in separate sessions in a within-subject double-blind randomized crossover design. Subjects will be in either a young (18-28 years) or old (60-85 years) group.|t|f|t|t
33916000|NCT04389580|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33996244|NCT01647828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996245|NCT02275962|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33996246|NCT06448689|||COHORT||PROSPECTIVE|||||||
33996247|NCT05046340|||COHORT||PROSPECTIVE|||||||
33996248|NCT04762576|||COHORT||PROSPECTIVE|||||||
33996249|NCT02256943|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33996250|NCT02559843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996251|NCT00673660|||COHORT||PROSPECTIVE|||||||
33996252|NCT03586622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996253|NCT00171015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996254|NCT00000245||||TREATMENT||||||||
33996255|NCT04196062|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single-Arm Study||||
33996256|NCT06120153|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Non-blinded cluster randomized cross-over trial||||
33996257|NCT03811145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916001|NCT03935165|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In the selected patients, after a first white light visual inspection, 0.25 mg/(kg BW) ICG were injected intravenously. After 15 to 30 minutes a second inspection of the abdomen and pelvis in Near Infrared vision was made. All the visualized lesions were carefully described pre and post the Indocyanine Green injection, removed and listed||||
33916002|NCT02557360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916003|NCT00313950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33916004|NCT01096043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916005|NCT06460636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916006|NCT03284008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916007|NCT03294408|NA|SINGLE_GROUP||PREVENTION||NONE||Interventional study among patients suffering from knee osteoarthritis for at least six months. All the patients will benefit from a multimodal imaging and clinical assessment.||||
33916008|NCT00077376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916009|NCT05963295|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33916010|NCT03766802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Group 1: Wearable watch training group. 3 orientation session Watch notifies 3/week for exercise~Benefits of watch:~BP and movement sensors allow to validate if the patient has exercised. Videos for exercises. Trackable and notifiable if patients don't exercise. Group 2: Mobile application training group. 3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise. Group 3: Supervised exercise training in a fitness center for people with DM."|t|t|f|t
33916011|NCT03874624|||COHORT||RETROSPECTIVE|||||||
33916012|NCT06411249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study.|||||
33996258|NCT00015665||||TREATMENT||||||||
33916013|NCT03180489|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33996259|NCT01456962|||COHORT||PROSPECTIVE|||||||
33996260|NCT06068491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data Collection Coordinator who conducts telephone surveys and chart reviews will be blinded to group assignment.|This is a hybrid type 1 effectiveness-implementation study utilizing formative implementation assessment prior to an effectiveness trial and assessment of implementation outcomes following the trial.|f|f|f|t
33996261|NCT04603703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know which treatment techniques are given in the specified groups.|Both groups were treated simultaneously with their specified treatment techniques within given duration.|t|f|f|f
33996262|NCT02280863|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33996263|NCT01467973|||COHORT||PROSPECTIVE|||||||
33781701|NCT04057833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781702|NCT01755286|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33801443|NCT00798642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916014|NCT03499821|NA|SINGLE_GROUP||TREATMENT||NONE||Device: Open label, all subjects receive same treatment||||
33996264|NCT05862805|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996265|NCT04511208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996266|NCT04998526|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study, which is planned as a randomized controlled and experimental study, will be conducted with type 2 (systolic blood pressure between 160 and 179 mmHg, diastolic blood pressure between 100 and 109 mmHg) essential hypertension patients who refer to Van Yüzüncü Yıl University Dursun Odabaş Medical Centre Emergency Service. The patients will be distributed as 24 in experimental group, 24 in placebo group and 24 in control group based on block randomization (gender and age) method and a total of 72 patients will be included.||||
33996267|NCT06403033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781703|NCT06623292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be assigned to experimental and control groups using block randomization method. Randomization of mothers will be done according to maternal age and number of births. Maternal age (19-25 years and 26 years and older) and number of births (primiparous and multiparous) variables will be used for block randomization. In order to reach the sample size calculated in the study, strata will be repeated six times (2X2X6) and 24 mothers will be included in each group.|t|f|f|t
33781704|NCT04029480|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33781705|NCT04107506|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants collecting the data during lab visits will not know the condition of the participant and will therefore not be biased during data collection.|Two groups. Half of the participants will be randomized into the experimental condition (FIND) while the other half will be randomized into the active control condition.|t|f|f|f
33781706|NCT03040219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781707|NCT02500927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781708|NCT04400708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781709|NCT06259981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781710|NCT05355922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781711|NCT06671483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781712|NCT04619368|||COHORT||PROSPECTIVE|||||||
33781713|NCT05397015|||COHORT||CROSS_SECTIONAL|||||||
33781714|NCT03106961|||COHORT||PROSPECTIVE|||||||
33781715|NCT00423644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781716|NCT04051619|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33781717|NCT01833975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916015|NCT01755195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916016|NCT01324622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916017|NCT04536337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916018|NCT04946799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916019|NCT00193219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916020|NCT01171196|||COHORT||PROSPECTIVE|||||||
33916021|NCT04930783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916022|NCT02055469|||COHORT||PROSPECTIVE|||||||
33916023|NCT01086150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916024|NCT00929734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916025|NCT02311699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916026|NCT06215222|||COHORT||PROSPECTIVE|||||||
33916027|NCT03976115|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33916028|NCT00289562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916029|NCT01062568|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916030|NCT04502550|||CASE_CONTROL||PROSPECTIVE|||||||
33916031|NCT03191669|||COHORT||PROSPECTIVE|||||||
33916032|NCT04620915|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33916033|NCT05414305|NA|SINGLE_GROUP||OTHER||NONE||||||
33916034|NCT01459224|||COHORT||PROSPECTIVE|||||||
33916035|NCT00930605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916036|NCT02787642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916037|NCT06214572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916038|NCT04287101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916039|NCT00484536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916040|NCT00377611|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33916041|NCT03327181|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996268|NCT04981262|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention with prebiotics to all participants for 4 weeks. Then randomisation to continue with prebiotics for 6 months or no intervention.||||
33996269|NCT00773149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996270|NCT00169364|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996271|NCT02985060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996272|NCT01323491|||COHORT||PROSPECTIVE|||||||
33916042|NCT00091845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916043|NCT02571751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996273|NCT03356691|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigators did not know which group the patients were allocated.||t|f|t|f
33996274|NCT02465125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916044|NCT04822857|||COHORT||PROSPECTIVE|||||||
33916045|NCT05108220|||COHORT||RETROSPECTIVE|||||||
33916046|NCT04910763|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are randomly assigned to one of the two intervention groups.||||
33916047|NCT03386656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103023|NCT06269107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103024|NCT05930444|||OTHER||CROSS_SECTIONAL|||||||
33781718|NCT05915130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781719|NCT01305824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781720|NCT06697080|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33916048|NCT04124536|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916049|NCT00101491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33916050|NCT03501745|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33916051|NCT01115738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916052|NCT02117596|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33916053|NCT00422409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916054|NCT01973452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916055|NCT04973592|||CASE_ONLY||RETROSPECTIVE|||||||
33916056|NCT00261326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916057|NCT05025735|NA|SINGLE_GROUP||TREATMENT||NONE||open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC.||||
33916058|NCT00022971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996275|NCT04007796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical interviewer conducting outcome-related interviews will be masked.|Randomized controlled trial with participants assigned to one of two treatment groups in parallel for the duration of the study|f|f|f|t
33781721|NCT03848195|||COHORT||PROSPECTIVE|||||||
33781722|NCT05586217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781723|NCT01426815|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33781724|NCT01899209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781725|NCT05169021|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996276|NCT06627075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33996277|NCT05208892|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|All three groups will receive a small circular band-aid on their temples (site of suprazygomatic maxillary nerve block placement).|Patients in the two intervention groups will receive bilateral suprazygomatic maxillary nerve block such that 5 mL of local anesthetic is deposited on each side. Patients in the SZMN+Dexmedetomidine group will receive Dexmedetomidine in addition to the local anesthetic with placement of the suprazygomatic maxillary nerve block (0.25 mcg/kg on each side for a total dose of 5 mcg/kg, max 20 mcg total).|t|t|f|f
33781726|NCT02883322|||||CROSS_SECTIONAL|||||||
33781727|NCT04011384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research team will create the randomization list and a research assistant will assign the participant to the correct online platform condition, but the investigators and data analysts will remain blind to group assignment. This study will contain two parallel groups. Although participants will not initially be aware of the other study condition, they will not be blinded to study condition because those in the intervention condition will be viewing the altered ordering platform as they shop.|The researchers will recruit 500 regular food pantry clients to participate in a randomized-controlled trial that involves visiting the food pantry and selecting food using the web-based ordering system, having physical measurements collected by study staff, completing food frequency questionnaires, completing a health survey, and getting a blood draw to measure fruit and vegetable intake and health outcomes from biomarkers. Participants will be randomized to 1 of 2 conditions: 1) control group (usual care); or 2) behavioral economic intervention group.|f|f|t|f
33781728|NCT03888365|||COHORT||PROSPECTIVE|||||||
33781729|NCT00310713|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33781730|NCT05806216|||COHORT||PROSPECTIVE|||||||
33781731|NCT04464941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessment of dental plaque was carried out by a single dentist, who was blind to group assignment.|Cluster Randomized Controlled Study|f|f|f|t
33781732|NCT02036060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781733|NCT06697119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781734|NCT05254730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33996278|NCT01201031|||CASE_ONLY|||||||||
33996279|NCT05446519|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33996280|NCT02367872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996281|NCT04124315|||COHORT||CROSS_SECTIONAL|||||||
33996282|NCT02129140|||COHORT||PROSPECTIVE|||||||
34087166|NCT05803460|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|"Stage 1:The data collection was carried out by a researcher who was blind to the intervention allocation, according to standard research guideline.~Stage 2 and 3:Same as Stage 1"|This study has two stages. In stage 1, investigators will conduct a single-blinded, randomized controlled study for community elderly. One hundred and twenty participants will be randomly assigned to the two experimental group and the control group. In stage 2, investigators will conduct a crossover, single-blinded, randomized controlled study for institutionalized elderly. Forty participants will be randomly assigned to the two experimental group and the control group. In stage 3, investigators will conduct a single-blinded, randomized controlled study for institutionalized elderly. Eighty participants will be randomly assigned to the experimental group and the control group.|f|f|f|t
34087167|NCT01521741|||COHORT||PROSPECTIVE|||||||
33781735|NCT02542514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781736|NCT01631708|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33781737|NCT05518513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33781738|NCT05035212|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a double-blinded, placebo-controlled study.||t|t|t|f
33781739|NCT02506387|||COHORT||PROSPECTIVE|||||||
33781740|NCT06021340|||OTHER||PROSPECTIVE|||||||
33781741|NCT05509400|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33781742|NCT02752152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781743|NCT04649138|||OTHER||PROSPECTIVE|||||||
33781744|NCT06317025|||OTHER||PROSPECTIVE|||||||
34087168|NCT03962699|||CASE_CONTROL||RETROSPECTIVE|||||||
34087169|NCT05662995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087170|NCT02023827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087171|NCT00862589|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33781745|NCT02860923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087172|NCT02650752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087173|NCT06522204|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Pediatric patients will be divided into two groups as underweight and normal weight. Children under the % percentile will be considered as underweight.||||
34087174|NCT00000840|||NATURAL_HISTORY|||||||||
34087175|NCT05031351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087176|NCT05664906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized controlled pilot study will be employed, participants will receive either CM Oral Rinse granules (CMORF-I) or placebo while they will receive standard care too. Since the duration of RT and recruitment time may vary, the intervention period starts from baseline (14 days within RT starts) to 2 weeks after the end of RT, while the post-intervention period will be 10 weeks starting from 2 weeks after the end of RT with 3 post-intervention follow-up visits (4 weeks, 8 weeks and 12 weeks after the end of RT).|t|t|t|t
34087177|NCT03309618|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087178|NCT05672563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study in a tertiary referral center. Investigators evaluated the procedure on a group of 40 participants that are invited to our unit for evaluation of cesarean scar by using a saline-infused sonography examination. Secondly, the medical records of all identified cases are retrospectively reviewed and the CSPs are classified into three subgroups according to the level of CSP sac herniation proposed by the Delphi criteria.||||
34087179|NCT02214654|||CASE_CONTROL||PROSPECTIVE|||||||
34087180|NCT00742352|||COHORT||PROSPECTIVE|||||||
34087181|NCT05666024|||COHORT||PROSPECTIVE|||||||
34087182|NCT06129214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33781746|NCT06434649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind technique will be used in this study. The blinding process will be done by a statistician unrelated to this clinical trial. Treatment group assignment will not be known to the subject or to the study followers or to the investigator who clinically evaluates the subject for the entire duration of the trial. Allocation concealment was achieved in this study through an interactive response system. In the absence of serious complications or other emergencies in the subjects during the study period, normal procedures were followed for revealing blinding, this study provides for the use of secondary blinding.||t|t|t|t
34087183|NCT01692574|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33781747|NCT06232525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients who are decided to have surgery due to stress urinary incontinence will undergo TOT surgery and urethral plication surgery, without being told which surgery they will have (both surgeries will be performed with the mid-urethral approach and the patient will not be told whether mesh is used or not), with a draw system in which the computer program will decide on the surgeon who will perform the surgery. The surgeon will always be the same person (Esercan A), and on the morning of the surgery, he will be told about the surgery he will perform and will be asked not to share it with the patient.~At the end of the 5th day, 2.5 months, 6 months and 1 year after the surgery, patients will be called for a check-up and examined by the same doctor, different from the doctors who performed the surgery and wrote the publication."|In the double-blind study, one group of patients with stress urinary incontinence will undergo transobturator tape surgery and the other group of patients will undergo urethral ligament plication surgery.|t|t|t|t
33781748|NCT06444529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781749|NCT01747161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781750|NCT06481930|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33781751|NCT02900456|||COHORT||PROSPECTIVE|||||||
33781752|NCT03422978|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Assessor of sedation scores post-procedure will be blinded to group allocation.||f|f|f|t
33916059|NCT00848250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916060|NCT03677895|NA|SINGLE_GROUP||TREATMENT||NONE|outcome assessor does not know the rotator cuff condition of patients|patients with rotator cuff disorders receving subacromial hyaluronic acid injection||||
33916061|NCT06298461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916062|NCT00979446|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33916063|NCT02163993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916064|NCT04802980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916065|NCT00301782|RANDOMIZED|||TREATMENT||NONE||||||
33916066|NCT00205296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916067|NCT01044680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33916068|NCT06163365|||CASE_ONLY||PROSPECTIVE|||||||
33692576|NCT06123650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients participated will be masked about the type of intervention, where (GA) patients will receive PT program + sham repetitive transcranial magnetic stimulation, while patients in (GB) will receive low frequency (1 Hz) rTMS to the contralesional cerebral hemisphere in addition to the same Oropharyngeal physical therapy program for dysphagia as in group A.|Randomized Controlled Clinical trial, where the recruited patients will be randomly assigned into 2 equal groups ( GA \& GB) using sealed envelopes, control group (GA) and study group (GB). Patients in (GA) will be treated by a designed physiotherapy program consists of: ice massage, oromotor exercises, Masako maneuver, resisted jaw opening exercise, modified chin tuck against resistance, Mandelson maneuver, effortful swallow and chin tuck in addition to sham repetitive transcranial magnetic stimulation. Patients in (GB) will be treated by low frequency (1 Hz) rTMS to the contralesional cerebral hemisphere in addition to the same Oropharyngeal physical therapy program for dysphagia as in group A.|t|f|f|f
33692577|NCT06333340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692578|NCT06164197|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692579|NCT02145988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692580|NCT06448585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Multicenter, prospective, controlled group, longitudinal, and randomized study|Multicenter, prospective, controlled group, longitudinal, and randomized study|t|f|t|f
33781753|NCT06207318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Surgeons, nurses, and other hospital staff involved in patient care will remain blind to psychological treatment condition to avoid potential biases. Laboratory staff processing blood samples for measuring inflammatory biomarkers will be blinded to treatment condition.|The intervention study model will be a two-group, randomized controlled trial. The randomization scheme will follow a 4:1 ratio, with the majority of participants being randomized to the intervention group.|f|t|f|f
33781754|NCT03176745|||COHORT||CROSS_SECTIONAL|||||||
33781755|NCT00554164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781756|NCT05373719|||COHORT||PROSPECTIVE|||||||
33781757|NCT03364816|||COHORT||RETROSPECTIVE|||||||
33781758|NCT02519556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781759|NCT06276595|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781760|NCT04948073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the blinded assessor|Randomized|f|f|f|t
33781761|NCT06697886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781762|NCT01627236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781763|NCT01598987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781764|NCT02742909|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33781765|NCT06024499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A Randomized, Double-blind, Placebo-controlled Study||t|t|t|t
33781766|NCT04484064|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781767|NCT05585112|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|as neither the child/parent, the investigator who performed the anesthesia/treatment, nor the assessors were aware of the type of anesthetic solution in order to avoid bias towards one of the solutions|A randomized, controlled, crossover, Triple-blinding clinical study, Comparison of articaine 4% and lidocaine 2%|t|f|t|t
33781768|NCT03545386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781769|NCT06396845|||CASE_CONTROL||RETROSPECTIVE|||||||
33916069|NCT05829616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916070|NCT02559713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916071|NCT02673892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33916072|NCT01899859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692581|NCT04913766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not be given information on what intervention services the participants are receiving.|Cluster randomized controlled trial|f|f|f|t
33692582|NCT00701376|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692583|NCT00562744|RANDOMIZED|PARALLEL||||NONE||||||
33692584|NCT02841527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692585|NCT05722522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator, site personnel, persons performing the assessments and participants will remain blinded through the Week 24 final database lock. The Novartis clinical trial and submission teams will remain blinded to the identity of the treatment from the time of randomization until the Week 16 database lock (for the primary endpoint analysis). The following methods are utilized for blinding: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by anyone else involved in the study with the following exceptions: bioanalyst; (2) the identity of the treatments will be concealed by the use of study treatments that are all identical in packaging, labeling, schedule of administration, and appearance.||t|t|t|t
33692586|NCT05250128|||COHORT||PROSPECTIVE|||||||
33781770|NCT02963597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||CPAP Device|t|f|f|f
33801444|NCT03284567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Personnel assessing the primary outcome is blinded for study participants group allocation.|1/3 of participants will be randomly allocated to the control group and 2/3 of participants will be randomly allocated to the Football fitness intervention group.|f|f|f|t
33916073|NCT02150473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916074|NCT03054948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916075|NCT04370717|||COHORT||PROSPECTIVE|||||||
33916076|NCT02915952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916077|NCT00383721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996283|NCT02153645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996284|NCT00109954|RANDOMIZED|||TREATMENT||||||||
33996285|NCT03453554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33996286|NCT02089282|||CASE_ONLY||PROSPECTIVE|||||||
33996287|NCT04556045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916078|NCT00364325|||COHORT||PROSPECTIVE|||||||
33916079|NCT04417725|||COHORT||RETROSPECTIVE|||||||
33996288|NCT01773408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996289|NCT06300216|||COHORT||PROSPECTIVE|||||||
33996290|NCT04185363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996291|NCT03830450|||COHORT||PROSPECTIVE|||||||
33996292|NCT05463601|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996293|NCT06422286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692587|NCT05384587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692588|NCT06236243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Randomized, Double-Blind, Parallel, Placebo-Controlled|t|t|t|t
33692589|NCT06709053|||COHORT||PROSPECTIVE|||||||
33692590|NCT06419231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692591|NCT02821806|||COHORT||PROSPECTIVE|||||||
33692592|NCT03717142|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Dose Escalation||||
33692593|NCT01801072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692594|NCT06708871|||COHORT||PROSPECTIVE|||||||
33692595|NCT06497569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To reduce risk of bias, only assessors unaware of randomization status will be used to assess study outcomes.||f|f|f|t
33692596|NCT02812407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692597|NCT03657862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participants (children) did not know their group allocation because a placebo was applied if SDF was not applied.~The care providers (operator) and the examiners (outcome assessor) were not informed of the children's group allocation."|"There are 2 groups of study participants in this study.~Children with decayed teeth were randomly allocated into either Group 1 (receive topical application of a SDF solution) or Group 2 (placebo) using random numbers, around 10 weeks before receiving dental restoration."|t|t|f|t
33692598|NCT03767595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692599|NCT06458595|NA|SEQUENTIAL||TREATMENT||NONE||||||
33692600|NCT06709105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33692601|NCT03544970|||COHORT||RETROSPECTIVE|||||||
33692602|NCT06707012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be double blind study in which participant and investigator who prescribe the drug will be blind|"Study Design This is a comparative clinical study with randomized groups. Participants will be allocated to either the metformin group or the placebo group in conjunction with standard antidepressant therapy. Randomization will be achieved using computer generated numbers in 1:1 ratio.~Metformin Group: Starting dose of 500 mg metformin once daily, titrated up to 2000 mg/day based on tolerance along with standard treatment of depression according to Maudsley guidelines.~Placebo Group: Identical placebo tablets, following the same titration schedule as the metformin group along with standard treatment of depression~Setting:~At psychiatric Out Patient Department of Fazaia Ruth Pfau Medical College and Hospital Karachi Pakistan~Study Duration:~18 months"|t|f|t|f
33692603|NCT03287583|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|participants will be randomized to receive either the Gambling Specific SBIRT Intervention or enhanced control.||||
33692604|NCT03828773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The investigational medicinal products will be known by all roles but the arm allocation based on a genetic analysis will be blinded.|prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial|t|t|t|t
33781771|NCT03969602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and research assistants assessing outcomes will be blinded to group assignment. The psychologist/s delivering the CBT and the clinicians delivering the educational intervention in the control group cannot be blinded. Nevertheless, patients will be blinded to study hypotheses and will be informed that the study is examining the comparative benefits of two treatments that are given in addition to usual care and that may potentially improve outcomes. The patients will not be aware of the study hypotheses and will not be informed about the likely association between a high PCS score and lower outcomes after lumbar spinal surgery, neither about the fact that the control intervention (i.e. an educational \& exercise intervention that is expected to minimize/cancel any expectation bias) will not address catastrophizing.||t|f|f|t
33781772|NCT03229798|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781773|NCT04774406|||CASE_ONLY||CROSS_SECTIONAL|||||||
33781774|NCT03570255|NA|SINGLE_GROUP||OTHER||NONE||||||
33781775|NCT04471987|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, open-label, non-randomized, multiple ascending dose, phase I dose escalation trial in patients with advanced solid carcinomas after previous immune-checkpoint blockade therapy conducted in sequential cohorts of patients followed by a dose expansion part.||||
33781776|NCT00231400|||COHORT||OTHER|||||||
33781777|NCT01517022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33781778|NCT03160209|||CASE_CONTROL||PROSPECTIVE|||||||
33781779|NCT06454344|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33781780|NCT05009485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781781|NCT06404762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical study|f|f|t|f
33781782|NCT06435299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33781783|NCT04984356|NA|SEQUENTIAL||TREATMENT||NONE||"There are two parts to this study. Phase 1 will comprise of Dose Escalation, and Phase 2 Cohort Expansion.~Phase 1 will determine the safety and tolerability of a single dose of WU-CART-007 and define the RP2D.~The Cohort Expansion Phase, will further define the safety and evaluate the initial efficacy of WU-CART-007 at the dose established from the Phase 1 Dose Escalation segment."||||
33781784|NCT00908674|||COHORT||PROSPECTIVE|||||||
33916080|NCT04936724|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be informed that they will be viewing cigarette warning labels during the eye-tracking task, but will be unaware of their randomization condition (lesser-known vs well-known harms)|It is a randomized, parallel design experimental study using objective measures and self-report survey. We will recruit 120 daily smokers (60 young adults and 60 adults) to participate in a single-session laboratory-based study. The participants will be assigned to either the lesser-known or well-known PWL group. After completing a baseline questionnaire, the participants will view 4 warning labels in a randomized order from their assigned group followed by a follow-up questionnaire. Primary outcomes will be eye-tracking measures, label recall and recognition, and knowledge of tobacco harms.|t|f|f|f
33916081|NCT03748225|||COHORT||PROSPECTIVE|||||||
33916082|NCT05902013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916083|NCT04836819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Drugs to be used will be prepared 30 minutes before the surgery in the drug preparation room by a nurse who is not involved in the study. Investigators and patients will be blinded to the group assignments.|The patients will be randomly classified into three groups.|t|f|t|f
33916084|NCT05929924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33996294|NCT06560671|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33996295|NCT05887427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996296|NCT04801654|||COHORT||PROSPECTIVE|||||||
33996297|NCT04026243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996298|NCT05721794|||CASE_CONTROL||PROSPECTIVE|||||||
33996299|NCT00387530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996300|NCT00603967|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33996301|NCT01251068|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33996302|NCT03762954|||CASE_ONLY||PROSPECTIVE|||||||
33996303|NCT04590027|||COHORT||PROSPECTIVE|||||||
33996304|NCT06206148|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The three different methods are very apparent and masking wouldn't provide any benefit|Post-operative orthopedic surgery patients will be randomly assigned to one of three pain collection methods and instructed to record their pain level as often as they like. The three methods of pain collection are: a hand-written pain journal, a smartphone app, and a novel electronic pain recorder device.||||
33996305|NCT03939364|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33996306|NCT01894802|NA|SINGLE_GROUP||OTHER||NONE||||||
33996307|NCT00592579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996308|NCT01949324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996309|NCT02895802|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33996310|NCT01608646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996311|NCT05535868|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996312|NCT00615667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996313|NCT02729090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33996314|NCT01859598|||CASE_ONLY||PROSPECTIVE|||||||
33996315|NCT00377117|||||OTHER|||||||
33996316|NCT04816396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|In the first week of the study, Life Satisfaction Scale, Adaptation Scale, Diagnostic Form and Happiness Scale will be filled in. After 8 weeks of recall therapy, the scales will be re-evaluated|"Data Collection Process of Phase 1 of the Study In the 1st stage of this research; It is aimed to reveal the experiences of elderly people who have moved from their homes to nursing homes for the first time, regarding their adaptation to nursing homes. The results to be obtained will form the basis for the second phase of the research.~The data will be collected by face-to-face interview method in depth in accordance with the qualitative research design. The interviews will be recorded with a tape recorder after the written and verbal consent of the participants. The talks will be held in a quiet and comfortable environment. The research will cease when the same information is started to be repeated by family members. Audio recordings will be destroyed after the data are analyzed.~The research was planned to be conducted in an experimental type with pre-test and post-test control group."||||
33996317|NCT01011413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087184|NCT06013566|||CASE_CONTROL||PROSPECTIVE|||||||
34087185|NCT02475369|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33996318|NCT01427062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087186|NCT00747604|||CASE_ONLY||OTHER|||||||
34087187|NCT00091429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996319|NCT01488448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996320|NCT04862806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All enrolled CLL patients have received 2 shots of BNT162b2 mRNA vaccine, and the investigators will check the efficacy and safety of this vaccine in the enrolled population- the intervention is the diagnostic test of COVID-19 serology||||
34087188|NCT05755126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996321|NCT03817151|||CASE_ONLY||RETROSPECTIVE|||||||
33996322|NCT01926145|||||PROSPECTIVE|||||||
33996323|NCT01028586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996324|NCT00450632|||||PROSPECTIVE|||||||
33996325|NCT04084795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant and the care provider will be blind to the MtCS condition, whereas the investigator (the rater) will be blind to both conditions.||t|t|t|f
33996326|NCT06263842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither participant nor the outcome assessor know the group distribution|The present study included 63 participants, aged 20 to 45, with teeth that needed to be extracted. After Kafrelsheikh University research ethics committee approval, patients were randomized into 3 groups: group I patients underwent immediate implantation using SSA protocol without grafting, while group II was grafted by xenograft, but group II was grafted with AWTG was created using the decoronated crown and the extracted palatal portion of the tooth; and then placed in the peri-implant gap defect. Clinically, pink aesthetic score (PES), midfacial mucosal alterations (MFMA), stability quotient of dental implants (SQDI) were observed at baseline, six and twelve months after implantation. Moreover, baseline, 6- and 12-months alterations of radiographic horizontal buccolingual ridge width (HBLRW), facial marginal bone level (FMBL), peri-implant Density of bone (PIDB) and peri-implant vertical bone defect depth (PIVBDD) changes were assessed using cone beam computed tomography (CBCT).|t|f|f|t
33996327|NCT03068780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087189|NCT02663986|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34087190|NCT00056147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087191|NCT02415946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087192|NCT05603247|||COHORT||RETROSPECTIVE|||||||
34087193|NCT03185000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087194|NCT01559168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087195|NCT02631057|||COHORT||RETROSPECTIVE|||||||
34087196|NCT02316925|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34087197|NCT05115929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087198|NCT01607788|||COHORT||PROSPECTIVE|||||||
34087199|NCT00084630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087200|NCT01550926|RANDOMIZED|CROSSOVER||||NONE||||||
34087201|NCT06492213|||COHORT||PROSPECTIVE|||||||
34087202|NCT00888836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087203|NCT02324153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087204|NCT05170113|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34087205|NCT00358254|||COHORT||CROSS_SECTIONAL|||||||
34087206|NCT00671060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087207|NCT03847493|||COHORT||PROSPECTIVE|||||||
34087208|NCT04571489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087209|NCT01902667|||COHORT||PROSPECTIVE|||||||
34087210|NCT01152671|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34087211|NCT04992533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34087212|NCT03073707|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34087213|NCT03679793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087214|NCT01395719|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34087215|NCT02608619|||COHORT||PROSPECTIVE|||||||
34087216|NCT01510639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087217|NCT03708224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34087218|NCT00375752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Open-label, multicenter, randomized||t|t|t|t
34087219|NCT05729958|||COHORT||OTHER|||||||
34087220|NCT00914069|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087221|NCT01010763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087222|NCT04735224|||COHORT||RETROSPECTIVE|||||||
34087223|NCT03871556|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087224|NCT01065012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692605|NCT03660488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692606|NCT02343081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692607|NCT03332771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692608|NCT03150485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||While this study utilizes two contact lenses, the purpose was to evaluate the JJVC fitting guide. This was a non-randomized study in which eye care practitioners used the JJVC fitting guide to fit subjects with a study contact lens. Subjects may fit either in a bilateral or a contralateral fashion.||||
33692609|NCT06710522|||CASE_CONTROL||PROSPECTIVE|||||||
33692610|NCT05579847|||CASE_ONLY||PROSPECTIVE|||||||
33692611|NCT06157398|NA|SINGLE_GROUP||OTHER||NONE||"1. To inform feasibility and acceptability of the intervention for deployment in a future randomized control trial.~2. Optimization of the design and implementation of a dietary intervention aimed at increasing intake of fruits, vegetables, and Omega-3 fatty acids in fish."||||
33692612|NCT04199936|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|ultrasound images, DXA scans and EMG results will be given coded labeling by a separate researcher so that investigator analysing results will be blinded to whether scans / EMG results are from intervention or control leg, or start of finish.|Single centre pilot study (randomised internal control trial)|f|f|f|t
33692613|NCT02974309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33692614|NCT05930951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781785|NCT05244421|NA|SINGLE_GROUP||TREATMENT||NONE||Primary services: Participants receive 16 hours of 24/7 Dads curricula, 4 hours of Healthy Relationships workshops, and 4 hours of Economic Stability workshops over the course of 8 weeks. Participants also receive ongoing job readiness support and post-employment support.||||
33781786|NCT05569655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781787|NCT01268059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781788|NCT05365867|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The biostatistician is masked to who is in the intervention or usual care group.|Participants are randomized to the iCAN group or usual care control group in parallel for the duration of the study.|f|f|f|t
33781789|NCT04931095|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind (Participant, Outcomes Assessor), placebo controlled, and double-dummy|All participants will complete all dose conditions (study arms) in a randomized order|t|f|f|t
33996328|NCT00634205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996329|NCT06561425|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33996330|NCT05559736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996331|NCT04309968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33996332|NCT02046863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996333|NCT04442503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996334|NCT02174926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996335|NCT03721718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996336|NCT04170335|||COHORT||PROSPECTIVE|||||||
33996337|NCT04745234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996338|NCT04534621|||OTHER||CROSS_SECTIONAL|||||||
33996339|NCT04388358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996340|NCT02878018|||COHORT||PROSPECTIVE|||||||
33996341|NCT05971056|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33996342|NCT04386577|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||VITAL is a 2 x 2 factorial randomized, double-blind, placebo-controlled trial.|t|f|t|t
33996343|NCT05893563|||COHORT||CROSS_SECTIONAL|||||||
33996344|NCT02750878|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996345|NCT00198835|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33996346|NCT01987128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33996347|NCT03224143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To ensure blinding, the psychologist who will administer the NPI-NH will not be aware of the arm to which the subjects belong.|"Each participant will undergo daily sessions of DTI or SI, lasting an hour at most, led by a trained professional caregiver. The DTI involves the presentation of a doll produced by a Swedish brand conceived for Doll Therapy use. The SI group will attend similar daily sessions, but in place of the doll, it will be presented with a non-anthropomorphic object, i.e., a soft foam rubber cube covered with a coloured and velvety textile. The 1st and 30th session of all participants will be videotaped by a trained psychologist as described below. The experimental protocol is described in detail in Pezzati et al. (2014) and it is structured with the goal of recreating a situation of (1) separation from a known figure and (2) interaction with the environment in order to partially recreate the prototypical phases of the Strange situation (Ainsworth et al., 1978)."|f|f|f|t
33996348|NCT01390415|||COHORT||RETROSPECTIVE|||||||
33996349|NCT05436028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996350|NCT00849797|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996351|NCT05269238|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996352|NCT01746550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996353|NCT01585844|||CASE_CONTROL||PROSPECTIVE|||||||
33996354|NCT04884022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33996355|NCT02128308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996356|NCT06342830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996357|NCT02786576|||COHORT||PROSPECTIVE|||||||
33996358|NCT06556602|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Hybrid Type 1, 18-month simultaneous cluster randomized controlled trial in 30 clinics||||
34087225|NCT01951300|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087226|NCT03307135|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34087227|NCT03767478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087228|NCT01045278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996359|NCT06559930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be divided into 2 groups of 20 people each. The random division of the cases into groups and their treatments will be done by the same researchers. The evaluation will be carried out by another researcher to determine which groups will be divided into before and after the treatment. After the initial evaluations are made, a traditional recording program of 30 sessions will be applied to Group 1, every day for 6 weeks. The 2nd group is traditionally equalized and a dual-task-focused training program is applied twice a week for a total of 12 sessions.|t|t|t|t
34087229|NCT00436761||||TREATMENT||NONE||||||
34087230|NCT04686032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|Both experimental and control groups will be treated at the same time following their respective protocols|t|f|f|f
34087231|NCT03069664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087232|NCT06252792|||COHORT||PROSPECTIVE|||||||
34087233|NCT02110251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087234|NCT01621074|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
34087235|NCT00482885|||COHORT||PROSPECTIVE|||||||
34087236|NCT00080340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087237|NCT05985759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087238|NCT00998192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087239|NCT06252480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996360|NCT04632641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996361|NCT06563232|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33996362|NCT04114890|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996363|NCT01592240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996364|NCT03029364|||COHORT||CROSS_SECTIONAL|||||||
33996365|NCT02871076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996366|NCT00168558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996367|NCT00857779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996368|NCT04511845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996369|NCT03497130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33996370|NCT00598780|||COHORT||PROSPECTIVE|||||||
33996371|NCT03613038|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Two groups of participants i.e., participants with ALS or PD and healthy controls will be asked to repeat sentences that have target words with varying phonetic complexity.||||
33996372|NCT05644106|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33996373|NCT00840840|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34087240|NCT05624541|||CASE_ONLY||PROSPECTIVE|||||||
34087241|NCT02136381|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34087242|NCT05286346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087243|NCT03791320|||COHORT||PROSPECTIVE|||||||
34087244|NCT04159376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087245|NCT04521296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692615|NCT03888924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"In order to guarantee a double blind design, participants, assessing neurologists and neuroradiologists will be masked to treatment allocation. A two-physician-treating and assessing-model will be used"|This is a phase II, double blind, randomized, controlled, multicenter study with two parallel groups of subjects.|t|t|t|f
33692616|NCT00092690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692617|NCT04036331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692618|NCT03448653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692619|NCT04711135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692620|NCT06158100|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation/de-escalation and dose expansion design.||||
33692621|NCT05185115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692622|NCT03415854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692623|NCT04300621|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33781790|NCT04041310|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I. Part 1. Main Study of 26 weeks. Cohort A - Dose escalation. Cohort B - Expansion Cohort at RP2D Phase I. Part 2. Extended Follow-up week 27 to 110 in Cohorts A and B. Phase II: Expansion at RP2D of Nous-209 vaccine plus pembrolizumab combination therapy in adult subjects.~* Cohort C (Phase II) - Subjects will be randomized with an allocation ratio 2:1 to Nous-209 vaccine plus pembrolizumab combination therapy versus pembrolizumab monotherapy.~* Cohort D (Phase II) - Subjects who have had radiographic progression (PD) after having a best response of stable disease (SD) or better on/after anti-PD1 treatment.~* In Phase I: 21 to 34 subjects will be enrolled across Cohorts A and B.~* In Phase II: Cohort C: up to approximately 63 subjects, Cohort D: up to approximately 18 subjects"||||
33781791|NCT02537444|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781792|NCT06614764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33781793|NCT05894759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781794|NCT03533855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781795|NCT00550732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781796|NCT00164593|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33781797|NCT02923895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33781798|NCT00374387|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33781799|NCT00427973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781800|NCT04858620|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Masking to care providers||f|t|f|f
33781801|NCT05428579|||CASE_ONLY||RETROSPECTIVE|||||||
33781802|NCT04107103|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, interventional study combining nivolumab with pemetrexed||||
33781803|NCT04746820|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"fNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.~1. Experimental group: All included patients will be examined with fNIRS, sSEP and AEP examination within 7 days after admission. fNIRS, SSEP and AEP examination.~2. Control group: The control group will be recruited among employees of the University Hospital Zurich, which are not subordinate to the PI and will have the same examinations as the experimental group."||||
33781804|NCT01851109|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33781805|NCT03130036|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|No masking is used||f|f|t|f
33996374|NCT00269386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996375|NCT00473772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996376|NCT04560725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996377|NCT04277507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781806|NCT01763736|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781807|NCT06192706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781808|NCT04609540|||COHORT||RETROSPECTIVE|||||||
33781809|NCT01594060|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781810|NCT00371774|||CASE_ONLY||PROSPECTIVE|||||||
33781811|NCT01962064|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33996378|NCT05870215|||COHORT||PROSPECTIVE|||||||
34087246|NCT01642381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087247|NCT05395585|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34087248|NCT05751551|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be conducted as an international, pragmatic pilot randomized controlled trial with two treatment arms, an intervention group (IG) and a control group (CG). It comprises a two-week intervention period in a rehabilitation clinic (for familiarization purpose) followed by a 10-week training period at home. It involves three trial partners: ETH Zürich, Don Carlo Gnocchi Foundation (Fondazione Don Carlo Gnocchi (FDG), Milan, Italy), and Materia Agecare ((MAT), Nicosia, Cyprus). The study conduction will take place at all three trial sites.||||
34103025|NCT05751811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103026|NCT02853084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103027|NCT03093246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692624|NCT06710912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in the ACT group attended four sessions of Acceptance and Commitment Therapy over a four-week period with each session lasting around 90-120 minutes. The participants were divided into three subgroups, each of which included approximately 6 to 8 participants. Prior to the intervention, participants in the ACT group received a workbook which consists of information about ACT in summary. Participants in the ACT group had accessibility to the same care similar to the TAU group. Four sessions were held for each subgroup respectively which was conducted by at least two therapists trained in ACT. The ACT module was adapted from Hayes and Harris and were conducted in the Malay language. The same workbook with guided exercise and homework were used by all the therapists to assure standardization of the intervention to ensure that each group received similar contents in each session.||||
33692625|NCT04220827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692626|NCT06405620|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33692627|NCT03613597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692628|NCT05777980|||CASE_ONLY||PROSPECTIVE|||||||
33996379|NCT05096286|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33692629|NCT03458754|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087249|NCT04732234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope.|"Group S (SHPB group 18 ultrasound guided SHPB ) using 20 ml Bupivacaine 0.5% before skin incision.~Group C (Control group 18 patients) in which same technique will be done but using normal saline 0.9%"|t|f|t|f
33996380|NCT02651987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996381|NCT01195233|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33996382|NCT03101813|||COHORT||OTHER|||||||
33996383|NCT00258687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996384|NCT00891787|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33996385|NCT02926040|||COHORT||PROSPECTIVE|||||||
33996386|NCT03515707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996387|NCT05008380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996388|NCT00820885|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
33996389|NCT03633721|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Neither participant nor care provider will be informed when cannabis/placebo are administered.|Participants will receive either cannabis or placebo on 1st visit and the opposite on the 2nd visit.|t|t|f|f
33996390|NCT06561542|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33996391|NCT01287351|||COHORT||RETROSPECTIVE|||||||
33996392|NCT02964663|||COHORT||PROSPECTIVE|||||||
33996393|NCT03807440|||OTHER||RETROSPECTIVE|||||||
34087250|NCT06520163|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, two-arm, multicenter, exploratory study||||
34087251|NCT06307379|||COHORT||PROSPECTIVE|||||||
34103028|NCT04126174|RANDOMIZED|PARALLEL||TREATMENT||NONE||Contralateral eye study||||
34103029|NCT05571696|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34103030|NCT05217446|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, multicenter study of encorafenib and cetuximab plus pembrolizumab (Triplet Arm \[Arm A\]) versus pembrolizumab alone (Control Arm \[Arm B\]) as first-line treatment in participants with BRAF inhibitor (BRAF) V600E-mutant and microsatellite instability-high/ deficient mismatch repair (MSI-H/dMMR) mCRC. Randomization will be stratified by ECOG (0 vs 1)||||
34103031|NCT04635033|||COHORT||PROSPECTIVE|||||||
33692630|NCT05591742|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All (participants, clinical staff, analyzers) are masked until all data have been analyzed.|double blinded prospective, randomized cross-over study. Taking place over 6 months with 5 clinical visits.|t|t|t|t
33692631|NCT05558124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692632|NCT04158791|||COHORT||PROSPECTIVE|||||||
33692633|NCT05344833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692634|NCT06642935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692635|NCT02131532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692636|NCT04513717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692637|NCT00923936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692638|NCT06707909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692639|NCT05298878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692640|NCT05408845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781812|NCT01027871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781813|NCT01348854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781814|NCT04890145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781815|NCT03498040|||COHORT||PROSPECTIVE|||||||
33781816|NCT03748771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781817|NCT00099918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33781818|NCT06466668|||CASE_CONTROL||PROSPECTIVE|||||||
33781819|NCT05628662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996394|NCT06430294|||COHORT||CROSS_SECTIONAL|||||||
33996395|NCT06491342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||probiotic vs placebo|t|f|t|f
33996396|NCT00003223|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996397|NCT01297504|||COHORT||PROSPECTIVE|||||||
33996398|NCT01173835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996399|NCT05250323|||COHORT||CROSS_SECTIONAL|||||||
33996400|NCT05943522|||CASE_ONLY||PROSPECTIVE|||||||
33996401|NCT03711253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996402|NCT04540094|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label two-arm, multicentre, pragmatic, parallel group randomised trial||||
33996403|NCT01756807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781820|NCT02078830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33996404|NCT01487720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996405|NCT01852799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996406|NCT04815239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masked assessors with no information about treatment group assignment will conduct all follow-up interviews.|Randomized controlled trial|f|f|f|t
33996407|NCT03706508|||CASE_ONLY||PROSPECTIVE|||||||
33996408|NCT00512811|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33996409|NCT02643407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996410|NCT04432558|||COHORT||PROSPECTIVE|||||||
33996411|NCT00177580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33692641|NCT03070886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692642|NCT02826850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33692643|NCT05090124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|This is a single-blind study, participants will be blinded to their study arm throughout.|Participants will be randomised 1:1 to receive adalimumab or placebo. Upon exiting the study, those in the treatment arm will continue to receive adalimumab without delay and those in the placebo arm will begin adalimumab therapy under NHS standard of care.|t|f|f|f
33692644|NCT00002065||||TREATMENT||NONE||||||
33692645|NCT02933580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692646|NCT06511895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692647|NCT06709716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded parties = subject, surgical team, intraoperative anesthesia team, postoperative anesthesia team, study investigators Unblinded parties = preoperative anesthesia team (providers that perform the quadratus lumborum block)||t|t|t|t
33692648|NCT00846287|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33781821|NCT02293707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781822|NCT03885037|||CASE_ONLY||PROSPECTIVE|||||||
33781823|NCT01824446|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781824|NCT02202356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781825|NCT05837026|RANDOMIZED|PARALLEL||PREVENTION||NONE||Effectiveness-implementation Hybrid Type 1 randomized trial. Participants will be randomized to EOI plus care as usual (CAU) or CAU alone using an equal (1:1) allocation ratio.||||
33781826|NCT00372970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781827|NCT05612776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33781828|NCT06378762|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33781829|NCT06044948|NA|SINGLE_GROUP||TREATMENT||NONE|In this single arm study, the subject will be masked to the lens type.|||||
33781830|NCT00024635|||COHORT||OTHER|||||||
33781831|NCT06076499|||COHORT||PROSPECTIVE|||||||
33781832|NCT03717545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781833|NCT01555762|||COHORT||PROSPECTIVE|||||||
33781834|NCT06603402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781835|NCT04530344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33781836|NCT06121115|||COHORT||RETROSPECTIVE|||||||
33781837|NCT04484909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781838|NCT00515138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781839|NCT01210053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781840|NCT06565715|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33916085|NCT06068322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessors and data analysts will be masked to group allocation. The participants will be given repeated instructions not to reveal their group allocation to the outcome assessors. The dataset will be blinded regarding group allocation when performing analyses.|In Phase 1, participants will be randomised to either interventional arm or control arm with a 1:1 allocation ratio, using a computer-generated block randomisation schedule stratified for sex (male, female), age and centre with equal allocation to all study arms. For Phase 2 only the participants with COPD will continue the maintenance program in their allocated group. A usual of care group consisting of patients with COPD will also be recruited to serve as control in the maintenance part.|f|f|t|t
33916086|NCT04922515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916087|NCT01405313|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916088|NCT05519371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33916089|NCT00239486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33916090|NCT00434512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916091|NCT05098158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group studied over 6 weeks time||||
33916092|NCT01938963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916093|NCT02719470|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916094|NCT01000727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916095|NCT05246176|NA|SINGLE_GROUP||OTHER||NONE||||||
33916096|NCT00800449|||COHORT||PROSPECTIVE|||||||
33916097|NCT00004816||||TREATMENT||NONE||||||
34103032|NCT00101400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781841|NCT06646926|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33781842|NCT05945082|NA|SINGLE_GROUP||SCREENING||NONE||||||
33781843|NCT00551213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781844|NCT06433193|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33781845|NCT02179918||||TREATMENT||NONE||||||
33781846|NCT02334943|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33781847|NCT06401577|||COHORT||PROSPECTIVE|||||||
33781848|NCT06492486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed Phase II prospective study will be split into two strata: IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) needing radiotherapy (stratum B).||||
33781849|NCT01161823|||COHORT||PROSPECTIVE|||||||
33781850|NCT06054737|||COHORT||PROSPECTIVE|||||||
33916098|NCT00601796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916099|NCT00752167|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087252|NCT05226429|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In this clinical trial, the experimental vaccine and the control vaccine will have different packages. In order to maintain the blinding process, the unblinded team will be appointed to place the vaccine in the syringe. The injection team (other team members) will later inject the vaccines according to the random group that has been selected. The unblinded team consists mostly of pharmacists and they will also have responsibilities to taking care of the vaccines and all of related documents. The injection team does not know what kind of vaccine is in the syringe. The injection team is also different from the observer team (those who will observe the subjects after the injection). This observer team does not know what kind of vaccine that already be given to the subjects.|There will be 3 groups in phase I. Two adult groups (18 year old and above) with two different doses (3 and 5 μg) and 1 control group using Coronavac-BioFarma vaccine. There will be the same 3 groups in phase II. Two treatment groups of adult will use 2 kind of doses as in phase I. The other group is for control (Coronavac-BioFarma vaccine). The vaccines will be administered with 2-dose schedule, intramuscularly. All cohorts will be followed for 12 months.|t|f|t|f
34087253|NCT02934646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781851|NCT04308551|RANDOMIZED|PARALLEL||OTHER||SINGLE|The treatment in this study was open. Optical density turbidimetric platelet aggregation (LTA) and thromboelastography (TEG) were used to detect the platelet aggregation rate induced by AA and ADP, and the metabolites were measured by ELISA. All were done by the laboratory personnel, and they were unaware of the setting of treatment medication (blind method).||f|f|f|t
34087254|NCT04320667|||CASE_CONTROL||PROSPECTIVE|||||||
34087255|NCT04377568|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to receive either standard of care (SoC) products (control) or COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19 (ratio 1:2). The intervention will consist of a single transfusion of convalescent plasma.||||
34087256|NCT00117416|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087257|NCT05974332|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34087258|NCT02456311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087259|NCT03979417|||OTHER||PROSPECTIVE|||||||
34087260|NCT05777551|||COHORT||PROSPECTIVE|||||||
34087261|NCT03184272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||evaluate direct impacts of preventive measurement||||
34103033|NCT06670677|||COHORT||PROSPECTIVE|||||||
34103576|NCT03622515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34103577|NCT04473937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103578|NCT04717739|||OTHER||PROSPECTIVE|||||||
34103579|NCT05795660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33916100|NCT06130852|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Non-pharmacological treatments focusing on parenting skills are found in many recommendations.~Programs for families of children with behavioral problems (attention deficit hyperactivity disorder, oppositional defiant disorder or conduct disorder) have been developed in several countries and adapted to ADHD. These programs take a similar approach: providing information about the disorder, changing in parents' view of their child's disorders, and didactic techniques that are known to be effective. These treatments enable parents to regain confidence in their parenting role, thanks to means of analysis (ABC model) and action (behavioral tools, such as reinforcement practice, token economy, time-out)."||||
33916101|NCT00808782|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33916102|NCT06167499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916103|NCT00669916|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33916104|NCT04914741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916105|NCT06110299|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916106|NCT03829865|||COHORT||PROSPECTIVE|||||||
33916107|NCT05801809|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33916108|NCT01600768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916109|NCT06211530|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33916110|NCT04832919|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33916111|NCT01523314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916112|NCT04345926|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33692649|NCT03091660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781852|NCT01496196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781853|NCT06696924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781854|NCT04129424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781855|NCT06698172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781856|NCT02759003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916113|NCT05204511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916114|NCT06065358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996412|NCT03747107|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33996413|NCT06559527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996414|NCT03739502|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Phase II Study Evaluating the Efficacy of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplantation||||
33996415|NCT01695239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996416|NCT01724463|||COHORT||PROSPECTIVE|||||||
33996417|NCT00276536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996418|NCT05652257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996419|NCT00645853|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996420|NCT06123195|RANDOMIZED|PARALLEL||OTHER||NONE||A single-center, open-label, randomized, controlled, parallel-group, pilot feasibility trial||||
33996421|NCT05929781|||OTHER||CROSS_SECTIONAL|||||||
33996422|NCT00284791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087262|NCT06214884|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible participants were invited to participate in the interventional study. Their participation must be voluntarily. Those who agreed to participate will be randomized either to the intervention and wait-list control group. The participants will remain unaware of their group assignment, as the randomization sequence will be generated using computer-based randomization. This is known as single-blind study. Allocation will follow a 1:1 ratio, overseen by a researcher with no other involvement in this trial. The participants' names will be matched with the random number sequence. Clusters of participants were in the same workplace to avoid contamination of the intervention and enhance compliance within the intervention group|A single blind, parallel cluster randomized controlled trial will be conducted on 86 academic staff working in the tertiary education in Northern Region, West Coast of Peninsular Malaysia. At baseline, all participants must undergo the screening criteria for inclusion which are academic staff with moderate to severe symptom of anxiety with cut-off score of 16, mild to severe symptoms of depression with cut-off score of 16, and pain intensity of LBP should be at least \>35mm using Visual analogue scale (VAS). Participants will be randomized at cluster level to receive either mindfulness intervention or control group. The intervention will be given for 5 sessions weekly for 60 minute/session. Outcome measures such as LBP, depression and anxiety symptoms, and work productivity will be measured at baseline and after 5-weeks. The control group will be given delayed treatment for 2 weeks after the trial ended.|t|f|f|f
34087263|NCT00063453|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34087264|NCT06042517|RANDOMIZED|PARALLEL||OTHER||SINGLE||"For Cohort 4: T2DM subjects, age-, BMI- and HbA1c-matched to cohorts 1 and 2 will be recruited from the same pool of volunteers and selected according to the same inclusion and exclusion criteria outlined in the human subject protection plan.~5 additional subjects will be recruited to participate in cohort 3."|t|f|f|f
33692650|NCT02179086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692651|NCT06296381|||COHORT||PROSPECTIVE|||||||
33692652|NCT01462786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692653|NCT02981810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692654|NCT05871996|||OTHER||CROSS_SECTIONAL|||||||
33692655|NCT02316912|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33692656|NCT05953376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692657|NCT02730520|||CASE_ONLY||RETROSPECTIVE|||||||
33692658|NCT02692885|||OTHER||CROSS_SECTIONAL|||||||
33692659|NCT06132399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692660|NCT06497231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33692661|NCT03453411|||COHORT||PROSPECTIVE|||||||
33692662|NCT06708754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33692663|NCT05935722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692664|NCT03035409|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692665|NCT05057715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3+3||||
33692666|NCT05425589|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional study||||
33692667|NCT06708507|||COHORT||PROSPECTIVE|||||||
33996423|NCT03585556|NA|SINGLE_GROUP||TREATMENT||NONE||All patients with treatment naive, new onset wet AMD will be treated with an intravitreal anti-VEGF at Day 0 followed by intravitreal AAVCAGsCD59 at Day 7. Patients will be followed for 12 months and treated with additional anti-VEGF monthly as needed if recurrent disease is identified.||||
33996424|NCT00217503||||TREATMENT||||||||
33996425|NCT01126463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996426|NCT01448096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996427|NCT04756921|||COHORT||RETROSPECTIVE|||||||
33692668|NCT05511519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded placebo drug is packaged to match the active study drug and will be stored under the same conditions.||t|t|t|t
33692669|NCT06557174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996428|NCT05625490|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with known or suspected disease and normal controls (no known disease) will both undergo \[68Ga\]Galmydar PET/CT MPI. Normal controls will also undergo \[13N\]ammonia PET/CT MPI.||||
33996429|NCT00239005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996430|NCT05269069|||CASE_CONTROL||PROSPECTIVE|||||||
33692670|NCT00519298|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33692671|NCT03811535|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will receive either somapacitan once weekly or Norditropin® once daily for 52 weeks (main trial period). All participants completing the main trial period will receive somapacitan weekly for 3 years (extension trial period).||||
33781857|NCT03940469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both the patients and the observer were blind to the treatment groups|three groups 20 each, Group C received 35ml levobupivacaine+2ml normal saline under ultrasound guided interscalene block. Group H received 35ml levobupivacaine+8mg dexamethasone under ultrasound guided interscalene block. Group D received 35ml levobupivacaine+100umg dexmedetomidine+1ml normal saline.|t|f|f|t
33996431|NCT05846282|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomly assigned to either the control condition (Study skills) or the experimental condition (STRVE).||||
33996432|NCT05303649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33996433|NCT03997799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996434|NCT01091480|||COHORT||OTHER|||||||
33996435|NCT00113958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087265|NCT00525356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087266|NCT03979313|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087267|NCT06486701|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33781858|NCT02304653|||COHORT||PROSPECTIVE|||||||
33781859|NCT06232499|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33781860|NCT01330355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33781861|NCT06577857|||COHORT||PROSPECTIVE|||||||
33781862|NCT03406429|NA|SINGLE_GROUP||OTHER||NONE|Through use of SHAM rTMS stimulation|Within-subject crossover design||||
33781863|NCT06340243|||COHORT||PROSPECTIVE|||||||
33781864|NCT06398626|||COHORT||PROSPECTIVE|||||||
33781865|NCT06123858|||COHORT||PROSPECTIVE|||||||
33781866|NCT06556706|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33781867|NCT02932150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781868|NCT02362035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781869|NCT02926300|||COHORT||PROSPECTIVE|||||||
33781870|NCT06103565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781871|NCT05693662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|It was not stated to the parents whether they were in the experimental or control group. It was performed in a single blind manner.The statistician is also blinded.|For randomization, parents were randomly assigned to experiment and control by using a computer program module used in randomized controlled studies (https://www.random.org/). Parents of children with ASD are numbered in the order in which they arrived at the hospital. This process was carried out until the experimental and control groups were completed. Parents of children with ASD included in the study were randomized using a single-blind randomization rule. Parents who met the sampling criteria for randomization were ranked up to 68.|t|f|f|t
33781872|NCT02788656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781873|NCT02633891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind|parallel treatments|f|f|f|t
33781874|NCT00336921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33781875|NCT05510401|NA|SINGLE_GROUP||OTHER||NONE||non-comparative clinical investigation||||
33916115|NCT01272843|||COHORT||PROSPECTIVE|||||||
33916116|NCT05685667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916117|NCT01021605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916118|NCT03733873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group1 desmopressin group2 desmopressin plus Suoquan mixture|t|f|f|f
33916119|NCT06502444|NA|SINGLE_GROUP||TREATMENT||NONE|There is only one condition. All participants know they are signing up for this one condition, an activity intervention.|The proposed design is a single condition, longitudinal pilot study examining the feasibility of using an online physical activity program to increase physical activity and improve emotion regulation in women who have experienced trauma due to experiencing an abusive or harmful relationship.||||
33916120|NCT02193815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916121|NCT00747396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33916122|NCT00469404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916123|NCT02822404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916124|NCT04315610|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33916125|NCT00262080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996436|NCT03610542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sequentially numbered opaque sealed envelopes will be used to conceal allocation. Envelopes will be prepared by a member of the research team and opened by participants.|Participants will be randomly allocated to one of three conditions: Cognitive behavioural therapy with no booster sessions, Cognitive behavioural therapy with 2 booster sessions or a no intervention control arm.|t|f|f|f
33996437|NCT04411680|RANDOMIZED|PARALLEL||TREATMENT||NONE||This Phase 2, randomized, open-label study will enroll approximately 120 patients with COVID-19 associated acute hypoxemia. It is a randomized 2:1 study to evaluate sargramostim treatment plus institutional standard of care compared to institutional standard of care alone.||||
33996438|NCT05636254|||COHORT||OTHER|||||||
33996439|NCT05098223|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigators will be blinded to intervention allocation and will not be able to manipulate any study parameter following the initial study set up, as all study procedures are taking part in the online platform. The outcome assessment is blinded, as it happens automatically in the online platform. The statistician who will analyse the data will be blinded to intervention allocation. Participants will only be aware of the trial arm that they are exposed to and will be unaware of the other trial arm|This is a randomised controlled trial with a parallel design. We will use an experimental online shopping platform to mimic the experience of online grocery shopping. Each participant will be randomised 1:1 to one of two groups and will participate in an online shopping task for about 10 minutes during which they will be exposed to a selection of products including promotions or with no promotions.|t|f|t|t
34103580|NCT06034431|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33781876|NCT00335556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781877|NCT02600156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781878|NCT00918190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33781879|NCT02125513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781880|NCT01444976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781881|NCT00108784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33781882|NCT06370351|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781883|NCT02185664|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33781884|NCT00765089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33781885|NCT05787574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-stage phase 2 study.||||
33781886|NCT06011967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||In this study we compared the ease of intubation, time needed for intubation, subglottic damage, postoperaitve sore throat, hoarseness and hemodynamic response to orotracheal intubation using three different angled intubation stylets with C-MAC R videolaryngoscope D- blade.|t|f|t|t
33781887|NCT05501132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781888|NCT03283553|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
34087268|NCT05222308|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This study aims to identify the challenges that online accounts and data present at the end of life. This study will engage life-limited cancer patients through longitudinal qualitative and technology design methods (action research, contextual inquiry, and participatory design) to:~1. empirically identify challenges that death presents for users; and~2. develop and validate strategies for end-of-life planning related to online accounts and data that honor human dignity while addressing the challenges and constraints of technology design.~Investigors will engage patients and their family/loved ones in a consulting and supportive role to:~1. identify their needs and challenges,~2. develop and implement an end-of-life plan, and~3. support family/loved ones with the execution of this plan after the patient dies."||||
34087269|NCT00392223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087270|NCT01471626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087271|NCT04491058|||CASE_CONTROL||PROSPECTIVE|||||||
34087272|NCT05558371|||COHORT||PROSPECTIVE|||||||
34087273|NCT01772082|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087274|NCT00761319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087275|NCT00764218||FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34087276|NCT02642900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087277|NCT04207671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087278|NCT03989544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781889|NCT00420472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087279|NCT02684929|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34087280|NCT01774643|||COHORT||PROSPECTIVE|||||||
34087281|NCT05162456|||COHORT||PROSPECTIVE|||||||
33781890|NCT02333851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781891|NCT06326047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures. The study will be double-blinded within dose level of once weekly subcutaneously administered NNC0519-0130 and the corresponding volume-matched placebo arms. The active comparator arm with tirzepatide will be open label.||t|t|t|t
33916126|NCT03294668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Assessor is blind to the participant's allocation to the intervention and active control group.|The participants will be randomly allocated into an intervention group (KONTAKT Australia) and an active control group (Social cooking group).|f|f|t|t
33916127|NCT03449316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding for the investigator that acess outcomes, that will not be involved in the intervention process.|Two arms single blinded randomised controlled trial with a 1 year follow up|f|f|f|t
33916128|NCT03571256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916129|NCT06216938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916130|NCT03714035|||OTHER||CROSS_SECTIONAL|||||||
33916131|NCT05216848|||COHORT||PROSPECTIVE|||||||
33916132|NCT00356863|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916133|NCT01524367|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916134|NCT00490763|||COHORT||PROSPECTIVE|||||||
33916135|NCT04300634|||FAMILY_BASED||PROSPECTIVE|||||||
33916136|NCT03780556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33916137|NCT03490357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor and patient blinded to type of block that the patient receives. Outcome assessor will check dermatomal levels after surgery.|"The expected cephalad dermatomal distribution of the TAP block is T10. A positive outcome is a QL block with patient anesthesia at 2 or more dermatomes higher than the TAP block. The investigators will assume that there is a 30% difference between the two blocks, which leads to between 24 and 33 patients in each arm (ideally aiming for 30 patients in each group).~The investigators have included other sample sizes should they find that there is a higher or lower percentage difference between the QL and TAP blocks.~Outcome: A positive block is considered anesthesia at T8 or above and a negative block is considered analgesia below T8"|t|f|f|t
33916138|NCT06196957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916139|NCT04568941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916140|NCT05790473|||CASE_CONTROL||PROSPECTIVE|||||||
33916141|NCT05552534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916142|NCT06102811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33916143|NCT01953328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916144|NCT03216317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916145|NCT03349242|||OTHER||PROSPECTIVE|||||||
33916146|NCT05299814|NA|SINGLE_GROUP||TREATMENT||NONE||single group open label design||||
33916147|NCT02178176|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33916148|NCT04859179|||OTHER||PROSPECTIVE|||||||
33916149|NCT05966844|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The project will investigate the effects of a Mindfulness pathway in RV on factors that hinder the adoption of healthy eating behaviour in the elderly population. Six meetings of about 5-10 minutes each, one per week, are planned. A randomised controlled trial (RCT) is proposed with two groups:~* An experimental group of 20 elderly people who will do the trial in the RV.~* Another control group, again of the same size, which will simply fill out simply twice the same battery of tests: one at the beginning of the project and the other at the end."|t|f|f|f
33916150|NCT02060344|||COHORT||PROSPECTIVE|||||||
33916151|NCT05294822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916152|NCT06224881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916153|NCT05138783|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33916154|NCT02055430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916155|NCT05909605|||COHORT||PROSPECTIVE|||||||
33916156|NCT05494541|||COHORT||RETROSPECTIVE|||||||
33916157|NCT01320111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916158|NCT02850991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||High dose radiation plus chemotherapy of paclitaxel and carboplatin vs standard dose radiation plus chemotherapy of paclitaxel and carboplatin.|f|f|t|f
33916159|NCT00442013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916160|NCT04371952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33916161|NCT04479917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087282|NCT01027949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916162|NCT00066664||||DIAGNOSTIC||||||||
34087283|NCT00828256|||COHORT||CROSS_SECTIONAL|||||||
34087284|NCT06026397|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34087285|NCT04009382|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34087286|NCT00618501||||TREATMENT||NONE||||||
34087287|NCT03980223|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-label randomized clinical trial||||
34087288|NCT00676884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087289|NCT04781062|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Based on the results of breast lesion biopsy, patients are assigned to two different groups:~* Breast Cancer Stage T1 Group~* Benign Breast Lesion Group"||||
34087290|NCT04745351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087291|NCT04932109|||CASE_ONLY||PROSPECTIVE|||||||
34087292|NCT03955315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087293|NCT04184141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34087294|NCT05181072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087295|NCT03747003|||COHORT||PROSPECTIVE|||||||
34087296|NCT05262101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087297|NCT00712920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087298|NCT03815513|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Both patient with intracerebral hemorrhage and healthy control will receive brain MRI with Dipyridamole stimulation for cerebrovascular reactivity measurement.||||
34087299|NCT04068532|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34087300|NCT05604313|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This study is open-label, meaning that no masking occurs. The intervention could not be masked (ergonomic equipment testing).|We designed a crossover, block randomised (block sizes of 4) and within-subjects experimental design.||||
34087301|NCT03749200|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the nature of the intervention participants or researchers could not be blinded.|Randomized clustered clinical trial, with treatment on obese children in 2 arms: a control group (CG) that will follow the usual recommendations of pediatricians and nurses in the primary care centres and an intervention group (IG) that will receive a structured motivation-based interview combined with group therapy and eHealth. the treatment of the two arms will last 12 (+3) months||||
34087302|NCT01813175|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34087303|NCT05567341|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|only the study nurse who performs the intervention is aware of the study arm|group 1: intervention, remote ischemic preconditioning for 4x5 minutes at the beginning of the surgery group 2: sham-control (4x5 min without compression of the extremity)|t|t|t|t
33916163|NCT05611359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916164|NCT05372341|||OTHER||RETROSPECTIVE|||||||
33916165|NCT03531333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Gross total resection (yes/no) on post-operative T1 postcontrast MRI scans will be evaluated by a neuroradiologist who is blinded for the treatment arm.|"The US-GLIOMA study is a randomized controlled trial with blinded primary outcome measure.~The study consists of two treatment arms: non-ultrasound guided glioma resection (conventional treatment) versus ultrasound guided glioma resection (intervention) ."|f|f|f|t
33916166|NCT02893527|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916167|NCT00254293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916168|NCT00519493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916169|NCT02474524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916170|NCT02765633|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33916171|NCT04777721|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"This is a phase I dose-escalation clinical challenge study in historically BCG-vaccinated healthy adult volunteers in which BCG will be administered via the aerosol inhaled route.~There will be four study groups with three volunteers in each group. Volunteers will be sequentially enrolled into each group in turn based on their availability. The first volunteer in each group will be challenged at least 1 hour apart from any subsequent volunteers. There will be a review of safety data at least 7 days after challenge of all volunteers within each dose group. This safety review will be performed by the Safety Monitoring Committee (SMC). Dose escalation into the next group will only occur if there are no safety concerns. Safety review will include assessment of symptom diary card, safety bloods and lung function results."||||
33916172|NCT06220630|||COHORT||RETROSPECTIVE|||||||
33916173|NCT03810417|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigational pharmacy will provide active drug or placebo|Patients undergoing coronary artery bypass surgery|t|t|t|t
33916174|NCT00846261|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33916175|NCT01530438|NON_RANDOMIZED|PARALLEL||||NONE||||||
33996440|NCT02113722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33996441|NCT05084963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996442|NCT02488239|||CASE_ONLY||PROSPECTIVE|||||||
33996443|NCT05597228|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781892|NCT06613503|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Model Description: In this clinical trial, a parallel design is employed, where participants are randomly assigned to one of two groups: an experimental group and a control group. The experimental group will use the AI-supporter for excretion detection, cleaning, and drying processes, while the control group will use traditional diapers for care. The two groups will not cross over during the trial, meaning participants will remain in their assigned group throughout the study. This design allows for a direct comparison of the intervention's efficacy, with each group receiving a distinct form of care. The primary objective is to assess the effectiveness of the AI-supporter in reducing urinary tract infections and incontinence-associated dermatitis|f|f|f|t
33781893|NCT02684084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996444|NCT06154096|||CASE_CONTROL||PROSPECTIVE|||||||
33996445|NCT00387153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996446|NCT01731977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996447|NCT05878015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34087304|NCT01140906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087305|NCT06410183|||OTHER||RETROSPECTIVE|||||||
33781894|NCT03766919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781895|NCT00898274|||CASE_CONTROL||PROSPECTIVE|||||||
33781896|NCT00594932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781897|NCT06128148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781898|NCT03251144|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781899|NCT06698094|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be recruited without knowledge of differences between the two arms, and cluster randomized based on there working space (office) with allocation concealment.|A two-arm parallel cluster randomized trail|t|f|f|f
33781900|NCT06465186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781901|NCT00412516|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33781902|NCT01434979|||CASE_CONTROL||PROSPECTIVE|||||||
33781903|NCT05883800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781904|NCT00249483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781905|NCT06684743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781906|NCT01008748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781907|NCT06204666|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigators and study participants will be blind to treatment allocation, with the hemp fiber-based supplement bars and placebo supplement bar of the same texture, taste, and look.|Randomized treatment, double blinded procedures, crossover|t|f|t|f
33781908|NCT02437851|NA|SINGLE_GROUP||TREATMENT||NONE||Surgical removal of SISCCA with quarterly monitoring for recurrence and treatment of anal high-grade squamous intraepithelial lesions.||||
33781909|NCT00262444|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33781910|NCT05720000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participants involved in the study, nor the outcomes assessor will be aware of the groups formed, as well as the treatments received.|All participants will receive PDO thread at glabella. Immediately after application, the participants will receive the intervention related to their treatment group, according to the allocation given by randomization. After randomization, the study population will be divided into two groups (n=20 per group), which are: (1) Group A - PDO thread + PBM with red LED, (2) PDO thread + PBM sham. The treatment will be performed twice a week for 30 days, in total 9 sessions.|t|f|f|t
33781911|NCT01890174|||CASE_ONLY||PROSPECTIVE|||||||
33781912|NCT06693882|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective analysis||||
33781913|NCT05760755|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781914|NCT05390645|NA|SEQUENTIAL||TREATMENT||NONE||||||
33781915|NCT06497491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analitial laboratory to assess imunogenicity||t|f|f|f
33781916|NCT03949322|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33781917|NCT03864731|NA|SINGLE_GROUP||OTHER||NONE||||||
33781918|NCT04554498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781919|NCT05137951|||OTHER||RETROSPECTIVE|||||||
33781920|NCT05205460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781921|NCT00350532|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33781922|NCT01813955|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33781923|NCT06217068|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Lab processing the blood samples is blinded to participant group.|Two group pre-test post-test study where groups are determined by current activity level (sedentary versus active). The dose of exercise is being tested between groups to see if there are differential effects of this acute dose at this intensity on biomarkers.|f|f|f|t
33781924|NCT00928109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781925|NCT06548035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781926|NCT00196911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781927|NCT05391802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781928|NCT02851810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33781929|NCT04931680|||COHORT||PROSPECTIVE|||||||
33996448|NCT05384613|||COHORT||RETROSPECTIVE|||||||
33996449|NCT00985439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996450|NCT05250960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996451|NCT05037318|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Participants know the content of their intervention, however, they do not know what other interventions there are and which group they belong to.|Two interventions are used, participants either receive only a stress reappraisal, only worked examples on breaking bad news, both interventions together, or none of the interventions.|t|f|f|t
33996452|NCT02965898|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33996453|NCT03221049|||COHORT||PROSPECTIVE|||||||
34087306|NCT05884580|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicentre, single-arm clinical evaluation||||
34087307|NCT02948400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087308|NCT03879330|||COHORT||PROSPECTIVE|||||||
33996454|NCT06345235|||FAMILY_BASED||PROSPECTIVE|||||||
33996455|NCT03684330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33996456|NCT01305109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33996457|NCT01440179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087309|NCT04013464|NA|SINGLE_GROUP||TREATMENT||NONE|changed into escitalopram in open treatment and compared to health control|Major depressive disorder compared to health control||||
34087310|NCT02945930|||COHORT||PROSPECTIVE|||||||
33781930|NCT04975581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33781931|NCT03065543|||COHORT||PROSPECTIVE|||||||
33781932|NCT03737253|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients and care providers need to know the type of hormone provided in order to be able to instruct and treat the patient. However, all roles are masked regarding the genotype.|"Women undergoing in vitro fertilization are randomized to either menotropin (urin derivate) or recombinant follicle stimulating hormone.~Inclusion criteria are:~* younger than 40 years of age~* more than 12 months of unprotected intercourse~* normal ovulatory cycles 26-32 days~* first or second IVF treatment~* indication for IVF is male factor~* tubal factor or unexplained infertility.~Exclusion criteria are:~* Anti müllerian hormone less than 5pmol or FSH more than 12 cycle day 2-3~* Endometriosis~* polycystic ovarian syndrome~* pre ovarian failure~* smoking~* male age more than 56.~The succeeding treatment is according to normal procedures at respective clinic.~End points are: total hormonal dosage, number of retrieved oocytes, fertilization rate, rate of blastocyst transfer, pregnancy rate, live birth rate.~Adverse effects e.g overstimulation is recorded."|f|f|t|t
33781933|NCT01884974|||CASE_CONTROL||RETROSPECTIVE|||||||
33781934|NCT04236713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781935|NCT03670186|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33781936|NCT01444066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781937|NCT06696846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781938|NCT04602962|||COHORT||OTHER|||||||
33781939|NCT02320253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33781940|NCT06351748|||COHORT||RETROSPECTIVE|||||||
33781941|NCT05568719|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Non-investigational study||||
33781942|NCT05397106|||COHORT||PROSPECTIVE|||||||
33781943|NCT02998164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781944|NCT03833011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781945|NCT06340854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781946|NCT04302675|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-post feasibility study||||
33781947|NCT01259687|||COHORT||PROSPECTIVE|||||||
33781948|NCT06549309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781949|NCT00218829|||CASE_ONLY||PROSPECTIVE|||||||
33781950|NCT06583837|NA|SEQUENTIAL||TREATMENT||NONE||||||
33781951|NCT02782988|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33781952|NCT04122924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An assessor blinded parallel group RCT|f|f|f|t
33781953|NCT00315627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087311|NCT04800627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996458|NCT04025021|RANDOMIZED|PARALLEL||TREATMENT||NONE|After randomization, the groups will not be blinded to the investigators or caregivers.|This study will be a randomized control trial with 2 arms: control group (standard fortification) or intervention group (targeted fortification) in a 1:1 allocation ratio. Allocation group will be stratified to four groups according to birth weight: \<750g, 751-1000g, 1001-1250g, 1251-1500g. This stratification is based upon our NICU feeding guideline, and will ensure that enrolled infants will receive comparable nutrition progression (e.g. NPO (nil per os) days, days of trophic feeds) throughout the study period. The allocation will be concealed in a sequentially numbered, opaque, sealed envelope, that will be opened after consent is obtained.||||
33996459|NCT05428826|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 4 Prednisone Dose : 1mg/kg/day at inclusion Route of administration : oral Duration of treatment: 9 to 21 months.||||
33996460|NCT05106803|||CASE_CONTROL||PROSPECTIVE|||||||
33996461|NCT00056433||||TREATMENT||||||||
33996462|NCT06619704|||COHORT||RETROSPECTIVE|||||||
33996463|NCT00161551|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996464|NCT02182713|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33996465|NCT03090321|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33996466|NCT00597454|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33996467|NCT03997890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996468|NCT03736577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-armed cluster randomized trial. As the intervention is to introduce a new way to do drug chart reviews, to prevent contamination bias within the nursing home the whole nursing home will have to be treated as a cluster. The recruited nursing homes will be randomized by a statistician to either intervention or control. Before randomization, both physicians working in the recruited facilities and selected personnel, i.e. specialized nurses, will attend a three hours lecture on dementia, depression and anxiety and psychosis on the elderly.||||
33996469|NCT00182260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996470|NCT04552665|||CASE_ONLY||PROSPECTIVE|||||||
33996471|NCT02266407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996472|NCT04444063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded|it is a Randomized clinical trial|f|f|f|t
33996473|NCT04411576|||COHORT||PROSPECTIVE|||||||
34087312|NCT00227916||||TREATMENT||||||||
34087313|NCT05922332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087314|NCT02321527|NA|SINGLE_GROUP||SCREENING||NONE||||||
33996474|NCT03721653|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, open-label, multicentric phase II randomized in a 1:2 ratio||||
33996475|NCT03600753|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996476|NCT05716490|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients are enrolled chronologically at the time of surgery into a slot of a previously randomized table with the 3 interventional arms||||
33996477|NCT03419247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781954|NCT05090423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33781955|NCT01653743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781956|NCT04854486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Placebo controlled|t|f|t|t
33781957|NCT04293991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33781958|NCT00974298|||||PROSPECTIVE|||||||
33781959|NCT05578092|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33781960|NCT00688688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33781961|NCT02338037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781962|NCT01237392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33781963|NCT06256003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996478|NCT04401137|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33996479|NCT03713866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781964|NCT05457244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781965|NCT05893043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study drug (GSBR-1290 or placebo) administration in Cohort 1 is double-blind and Study drug (GSBR-1290) administration in Cohort 2 is open label.||t|t|t|f
33781966|NCT02518906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781967|NCT01096095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33781968|NCT03625258|||CASE_ONLY||RETROSPECTIVE|||||||
33781969|NCT02618538|||OTHER||CROSS_SECTIONAL|||||||
33781970|NCT01141140|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33781971|NCT02655653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33781972|NCT01879878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33781973|NCT06238466|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Single Blind||t|f|t|f
33781974|NCT04872062|||COHORT||RETROSPECTIVE|||||||
33781975|NCT05111080|||CASE_CONTROL||RETROSPECTIVE|||||||
33781976|NCT05098015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessment interviewer will be blinded to study arm allocation of the participants at baseline only.|Individual randomization to one of two parallel groups, the intervention or usual care (no intervention) control group.|f|f|f|t
33781977|NCT06697392|||OTHER||PROSPECTIVE|||||||
33916176|NCT03984331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The burn wound trial area consists of two adjacent burn wound sites. The randomization will happen on the day of debridement. The test areas will be randomized to treatment so that one side receives early cover with fish skin and the other one with SOC. Treating physician will be aware of which product is being used on each site as temporary cover before grafting, but will not give this information to the patient. Prior to grafting, a blinded burn surgeon investigator will assess the burn wound bed. He/she will only have a subject number. The same procedure is used for the secondary endpoints of local reactions. Reassessment done by treating physician before STSG cannot be blinded as it is obvious what temporary treatment the test areas have received. Photos taken of wounds during the treatment (where products are not visible) will be judged blind by additional investigators. Scar assessment at 3 and 12 months via the Vancouver Scar Sale will also be fully blinded.|Two adjacent burn sites on the body of each burn patient will be randomized to receive initial early cover treatment after debridement with either fish skin or cadaver skin for 7± 3 days. After the initial 7± 3 days the test sites will be grafted with STSG.|t|f|t|t
33916177|NCT05316090|RANDOMIZED|PARALLEL||TREATMENT||NONE||study group and control group||||
33916178|NCT04271657|||OTHER||PROSPECTIVE|||||||
33916179|NCT02472119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916180|NCT05869552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916181|NCT03904641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical evaluations of complete removal of caries lesion, microbiological and radiographic analysis will be made by two blind examiners, who will not know to which group the participants belong.||f|f|f|t
33916182|NCT01617187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916183|NCT01095575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996480|NCT01769898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996481|NCT06272617|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33996482|NCT04306601|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with unwakefulness syndrome or minimally conscious state after traumatic brain injury||||
33996483|NCT01851772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996484|NCT02768701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996485|NCT06012006|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33996486|NCT04388722|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33996487|NCT04242823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996488|NCT04955158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33996489|NCT00857038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996490|NCT00966160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33781978|NCT04517591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781979|NCT04955587|||COHORT||PROSPECTIVE|||||||
33781980|NCT04108910|||COHORT||RETROSPECTIVE|||||||
33781981|NCT05613010|NA|SINGLE_GROUP||TREATMENT||NONE||This study uses a within-subjects micro-randomized trial design. This study involves randomizing participants within person hundreds of times over to receive intervention or not at each expected dose. Each dose is a decision-point to deliver intervention or not, allowing for within-person comparisons.||||
33781982|NCT00121199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781983|NCT06697379|||OTHER||OTHER|||||||
33781984|NCT04394819|||CASE_CONTROL||PROSPECTIVE|||||||
33781985|NCT06611137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996491|NCT02539628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33996492|NCT04157335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33781986|NCT06552689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781987|NCT04707716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781988|NCT02331940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781989|NCT04778371|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, calorie-match controlled, crossover design||||
33781990|NCT03222284|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33996493|NCT00608322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996494|NCT01047150|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33996495|NCT06542237|NA|SEQUENTIAL||OTHER||NONE||In the Phase 1b part, 4 dosing cohorts and one optional 5th cohort with 4 participants each will be evaluated.||||
33996496|NCT06425562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996497|NCT05221554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996498|NCT01719770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33692672|NCT04831606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients will be randomized into the two arms of the study according to a list of random numbers generated by special IT tools and communicated by the scientific supervisor to the Care Provider via e-mail .~It is a 1: 1, single-block randomization of 40 patients distributed in the two groups (treated and control). After the two-week enrollment observation period, the Investigator at the outpatient center will ascertains the conditions for the study prosecution and will notify the Head of the Care Providers to take charge of the patient included in the study and to proceed with the assignment to one of the groups. In this way, the Investigator at the outpatient center will be blinded to the treatment performed at home by the patient.~All patients will receive a pair of blinding glasses at the enrollment and will be required to wear them during therapy."|"A double-blind pilot trial on outpatients affected by diabetic foot ulcers, followed in an integrated way by both a specialized center and the home nursing network, for a period of 24 weeks.~The specialist center will characterize the patient, set the therapy, and evaluate them monthly, the nursing service will treat them at home biweekly.~The physician in charge of the monthly evaluation is unaware of the patient's arm. During therapy, the patient will wear blinding glasses, the control arm will simulate the use of the device switching it on without aiming it at the wound.~After a two-week pre-enrollment period to evaluate the wound progression applying only the standard care (if the wound reduces 50% or more, the patient will be excluded), the patient will be randomized into one of the study arms: the control arm will continue with the standard treatment, while the EmoLED Arm will receive EmoLED's therapy in addition to the standard treatment."|t|f|t|t
33692673|NCT00291538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692674|NCT04386057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692675|NCT05718726|||COHORT||RETROSPECTIVE|||||||
33692676|NCT06187428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes are collected digitally and pseudonymised and the statistical analyses will be blinded to group allocation since the randomisation is concealed during this process.|Two-arm parallel randomised assignment to intervention (PainSMART) group or control (usual management) group|t|f|f|t
33692677|NCT02438527|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33692678|NCT05198609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692679|NCT02811601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692680|NCT05008185|||CASE_ONLY||PROSPECTIVE|||||||
33692681|NCT06574165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||6-week structured exercise intervention. The intervention will include twice weekly, center-based, aerobic exercise consisting of continuous treadmill walking.||||
33692682|NCT05069558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692683|NCT04923542|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692684|NCT01244945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692685|NCT03589547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692686|NCT00775476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will titrate to tolerance during an initial 3 month open label period and then subjects will be randomized to one of 2 arms.|t|t|t|t
33692687|NCT06449378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692688|NCT06546969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692689|NCT03012516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692690|NCT05269251|||CASE_ONLY||PROSPECTIVE|||||||
33692691|NCT04627571|||COHORT||PROSPECTIVE|||||||
33692692|NCT06028347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33692693|NCT06294535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patient select randomly from closed label||t|f|f|f
33781991|NCT06327113|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single center, prospective, comparative interventional, two-arm parallel group, randomized, clinical safety and efficacy trial comparing a group receiving standard wound care with tumescent antibiotic injection (TAI) with a control group receiving standard wound care||||
33781992|NCT04210856|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|participants do not know the hypothesis of a study, other people cannot influence the brainwave reaction|non-randomised within subjects clinical trial.||||
33781993|NCT02261415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996499|NCT06627556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996500|NCT04789434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996501|NCT03694197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996502|NCT03999645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996503|NCT01170741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33996504|NCT06322264|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33996505|NCT00096655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996506|NCT03750448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A physiotherapist will assess the outcomes at baseline after which the patients are randomized. The same physiotherapist will then deliver the allocated intervention and no longer assess outcomes for this patient. A different physiotherapist, who is blinded to treatment allocation, will assess outcomes at the follow-up visits in this patient. At all follow-up visits, patients will be asked not to disclose any information regarding group allocation, and the physiotherapists will be instructed not to ask questions regarding group allocation.~The patients are blinded to the trial hypothesis in order to prevent ascertainment bias. The principal investigator is not an outcome assessor and will not be blinded."|"Telerehabilitation.~No intervention.~Unsupervised rehabilitation."|f|t|f|t
33996507|NCT02734511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996508|NCT06249113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996509|NCT04532879|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single center, open label. Patients will serve as their own control by comparing their bowel habits using a specific diary 2 weeks after the Linzess washout period to the 2 weeks after their HygiRelief procedure.||||
33996510|NCT05248607|||OTHER||RETROSPECTIVE|||||||
33996511|NCT04382963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996512|NCT04122950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996513|NCT01449188|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33996514|NCT03812913|||CASE_CONTROL||PROSPECTIVE|||||||
33996515|NCT03304223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996516|NCT03098485|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33996517|NCT03711448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996518|NCT05291234|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33996519|NCT01616550|||COHORT||PROSPECTIVE|||||||
33916184|NCT05515822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random numbers and groups are packed in opaque envelopes. The experimenter will open an envelope according to the random number on the envelope cover in the order from small to large according to the time of inclusion of the subject, and then obtain the random grouping of the subject (1:1:1). The random number is generated by computer, sealed into an envelope, unsealed and dispensed by professionals who do not participate in test operations. Participants and postoperative visitors did not know the grouping information. In emergency situations (e.g. allergies) or after data analysis.|Control group: Dezocine +Patient-controlled intravenous analgesia (Dezocine) ; Intervention group A: Oxycodone +Patient-controlled intravenous analgesia (Oxycodone); Intervention group B: Esketamine + Oxycodone +Patient-controlled intravenous analgesia (Oxycodone) .|t|t|f|f
33916185|NCT03259321|||COHORT||PROSPECTIVE|||||||
33916186|NCT01498081|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33916187|NCT00912899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692694|NCT06094127|||COHORT||OTHER|||||||
33916188|NCT04119427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916189|NCT04762407|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916190|NCT05852678|||COHORT||PROSPECTIVE|||||||
33916191|NCT00393913|||COHORT||PROSPECTIVE|||||||
33692695|NCT03177291|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916192|NCT01357915|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916193|NCT01162161|||CASE_CROSSOVER||PROSPECTIVE|||||||
33916194|NCT00647868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916195|NCT01585935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33916196|NCT03169023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916197|NCT05722795|NA|SINGLE_GROUP||OTHER||NONE||Window-of-opportunity trial.||||
33916198|NCT05371990|||OTHER||CROSS_SECTIONAL|||||||
33996520|NCT02802852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692696|NCT06570395|||COHORT||PROSPECTIVE|||||||
33692697|NCT00767442|||CASE_CONTROL||PROSPECTIVE|||||||
33916199|NCT00358995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916200|NCT02702518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916201|NCT01666678|RANDOMIZED|CROSSOVER||||NONE||||||
33916202|NCT04507477|NA|SINGLE_GROUP||PREVENTION||NONE||At our institution, approximately 50% of donor lungs are put on ex-vivo lung perfusion (EVLP) for clinical purposes. If a patient consents to participate in this study and their donor is EBV positive, the donor lungs will first be put on EVLP. Rituximab will be administered to the donor lungs while they are on EVLP for 3 to 4 hours before the transplant is done in order to reduce the amount of EBV virus. The amount of time the donor lungs are on EVLP will not be changed as a result of participating in this study.||||
33996521|NCT03966911|NA|SINGLE_GROUP||OTHER||NONE||||||
33996522|NCT01923545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996523|NCT00107263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996524|NCT06054633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692698|NCT01490970|||COHORT||RETROSPECTIVE|||||||
33692699|NCT02370771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692700|NCT05294536|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692701|NCT02616562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33916203|NCT03150108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916204|NCT00734734|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33916205|NCT06288958|||CASE_ONLY||RETROSPECTIVE|||||||
33916206|NCT05071560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot randomized controlled study||||
33916207|NCT00587951|||CASE_ONLY||PROSPECTIVE|||||||
33916208|NCT01202721|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916209|NCT03427749|||COHORT||PROSPECTIVE|||||||
33916210|NCT05656898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916211|NCT01996748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692702|NCT03913403|||COHORT||PROSPECTIVE|||||||
33692703|NCT01782833|||OTHER||PROSPECTIVE|||||||
33781994|NCT02850627|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33916212|NCT03767296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916213|NCT02765178|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33916214|NCT03373552|||CASE_CONTROL||PROSPECTIVE|||||||
33916215|NCT05033548|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33916216|NCT04905199|||CASE_ONLY||PROSPECTIVE|||||||
33916217|NCT03754803|||COHORT||PROSPECTIVE|||||||
33916218|NCT00230412|||CASE_CONTROL||PROSPECTIVE|||||||
33996525|NCT05959187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996526|NCT05605652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996527|NCT00615823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996528|NCT06298877|NA|SINGLE_GROUP||OTHER||NONE||||||
33996529|NCT02147379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996530|NCT02496104|||COHORT||PROSPECTIVE|||||||
33692704|NCT02393690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692705|NCT06176794|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33996531|NCT06626919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692706|NCT04166227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916219|NCT05425485|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The patients are invited to participate in an observational study of adherence, as the intervention is done at the level of the care providers.|Cluster-trial|t|f|f|f
33916220|NCT00547638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916221|NCT03667612|||COHORT||RETROSPECTIVE|||||||
33916222|NCT04350190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916223|NCT02143193|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33916224|NCT05617404|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33916225|NCT04054843|||CASE_CONTROL||PROSPECTIVE|||||||
33916226|NCT06186635|RANDOMIZED|PARALLEL||PREVENTION||NONE||In the research, firstly, a pre-test (Introductory Information Form, Multidimensional Quality of Life Scale, and Mental Well-Being Scale) will be applied to two intervention and control groups. Traditional yoga will be applied to the 1st initiative group, and artificial intelligence-supported yoga will be applied to the 2nd initiative group. No intervention will be made by the control group during the data collection process. After the applications are completed, a posttest (Introductory Information Form, Multidimensional Quality of Life Scale, and Mental Well-Being Scale) will be administered to all three groups. In order to eliminate ethical problems in the control group, after the data collection process is completed, the days and hours suitable for the individuals will be determined, and an average of 2 hours of traditional yoga or 1 hour of artificial intelligence-supported yoga will be applied, preferably once a week for 12 weeks.||||
33916227|NCT04922749|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective open cohort stepped wedge cluster randomized trial||||
33916228|NCT03331094|||CASE_CONTROL||PROSPECTIVE|||||||
33916229|NCT05779579|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33916230|NCT05189158|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916231|NCT01426399|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916232|NCT01475864|||CASE_ONLY||PROSPECTIVE|||||||
33916233|NCT04049071|||COHORT||OTHER|||||||
33916234|NCT02317536|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33916235|NCT05398419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||It will be a 3-arm randomized controlled trial where participants will be randomized to one of the three following groups: music listening intervention involving instrumental slow tempo music, non-musical sounds involving nature sounds, or standard of care on the Geriatric Assessment Unit (control). The patients will be randomized in equal ratios to the 3 groups. Each intervention will take place over 7 consecutive nights. The music or non-musical sounds will be played throughout the whole night for each patient in those groups.||||
33916236|NCT01674244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916237|NCT05499702|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||caloric restriction for six weeks||||
33916238|NCT02000713|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34087315|NCT04161196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34087316|NCT04398472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33781995|NCT03677947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent evaluators will be blind to the random allocation treatment conditions.|The RCT will compare the outcome of 16 sessions of IBCT compared to 16 sessions of ERP in OCD patients. The evaluators will be blind to the random allocation treatment conditions with a randomization ratio of 1:1. Both treatments will be administered by trained therapists on a weekly one-on-one basis over a 16-week period with 6-month follow-up conforming to current thinking on relapse in OCD. Conditions of treatment delivery, duration and monitoring will be equivalent across all groups. Both treatments are manualized and therapists will receive intensive training in one therapy protocol to ensure optimal delivery of each modality. Due to COVID-19, as of April, 2020, treatment will be delivered to participants by videoconferencing only. To protect the integrity and internal validity of the trial, participants who were recruited before this date and received the majority of treatment sessions in face-to-face physical meetings will be excluded from the principal statistical analyses.|f|f|f|t
34087317|NCT01773369|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33781996|NCT01409226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33781997|NCT05975996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33781998|NCT04377997|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized 1:1||||
33781999|NCT03281265|||COHORT||RETROSPECTIVE|||||||
33916239|NCT04191967|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33916240|NCT04995471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916241|NCT01234857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916242|NCT01179087|||COHORT||PROSPECTIVE|||||||
34087318|NCT01555593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916243|NCT01354353|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33916244|NCT02695524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33916245|NCT00574496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087319|NCT01361737|||CASE_CONTROL||RETROSPECTIVE|||||||
33916246|NCT05080959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087320|NCT01820832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087321|NCT00638430|||CASE_ONLY||PROSPECTIVE|||||||
34087322|NCT04800497|||CASE_CONTROL||PROSPECTIVE|||||||
34087323|NCT06197490|||COHORT||RETROSPECTIVE|||||||
34087324|NCT00789165|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087325|NCT00193648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087326|NCT01543854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087327|NCT00191750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087328|NCT01703468|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087329|NCT03715647|||COHORT||PROSPECTIVE|||||||
34087330|NCT01311791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087331|NCT01724268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087332|NCT00977145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087333|NCT01993966|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087334|NCT00916578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087335|NCT01452256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087336|NCT00961064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087337|NCT01311388|||||RETROSPECTIVE|||||||
34087338|NCT02295059|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087339|NCT04782141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087340|NCT03981991|||COHORT||PROSPECTIVE|||||||
33692707|NCT06518642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"At the beginning of the stimulations sessions, participants receiving both the active and sham stimulation would experience a ramp-up in current from 0 to 2 mA, then the current would ramp down to 0 mA for participants receiving sham stimulation.~Participants were told that they may experience sensations such as tingling, headache, or mild burning during the first 30 - 60 seconds of the stimulation session but that they may subside afterwards as they got used to it. In other words, participants would not be able to tell if diminishing of side effects were due to habituation (active tDCS) or ramping down of current (sham tDCS).~Moreover, the stimulation mode of the tDCS device was pre-set by a the principal investigator, who was not involved in the stimulation delivery or outcome measurements, both of which were conducted by a research assistant who was blinded to the stimulation mode."||t|t|t|t
33692708|NCT06708247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study follows a parallel interventional model where participants are randomly assigned to one of two groups. The control group receives standard peri-implant reconstructive therapy involving mechanical debridement and bone grafting with autogenous tuberosity bone. The test group undergoes the same reconstructive therapy but includes an additional intervention of electrolytic cleaning for implant surface decontamination. Both groups are monitored concurrently over a 12-month period to assess clinical and radiographic outcomes, such as probing pocket depth reduction and bone regeneration. This model allows for a direct comparison of treatment efficacy between the two intervention strategies.|t|f|f|t
33692709|NCT05659056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692710|NCT00302198|||||PROSPECTIVE|||||||
34087341|NCT01757548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692711|NCT06313008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a prospective, randomized, double-dummy, blinded-endpoint, parallel-group trial that enrolled 120 CAD patients with T2DM. The patients were randomized 1: 1 for 6 months administration of empagliflozin or vildagliptin.|t|f|t|f
33692712|NCT06544057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blinding procedure aims to minimise bias by ensuring the outcome assessor, a member of our research team, remains unaware of participants' treatment allocation (Intervention or WLCG). This 'Single-Blind' design involves blinding the internal team's outcome assessor, who evaluates study endpoints without knowledge of participants' group assignments. To uphold blinding integrity, outcome assessors refrain from engaging with participants or study personnel. Participants and intervention administrators are not blinded due to the intervention nature|This was a two-arm Block randomised pilot trial with study centres using block randomisation comparing Wait-list and Active.|f|f|f|t
33692713|NCT05730634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692714|NCT06710652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33692715|NCT01678937|||CASE_CONTROL||PROSPECTIVE|||||||
33692716|NCT02669238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692717|NCT00824278|||||PROSPECTIVE|||||||
33692718|NCT01437878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692719|NCT03709641|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Study is set as a single-arm, randomized, single-masked to evaluate Restylane Defyne for canalicular occlusion in participants with mild to moderate dry eye disease. Each participant will have a screening visit, it is then participants will be provided with informed consent form to review and ask questions before written informed consent is obtained. Screening visit occurs 30 days prior to 42 days and will be seen for follow-up exams at 3 , 14 and 42 days.||||
34087342|NCT04127474|||OTHER||OTHER|||||||
33692720|NCT05050162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692721|NCT04128774|||CASE_CONTROL||PROSPECTIVE|||||||
33916247|NCT03700788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant will be unaware as to which medication is used in the treatment procedure and will also be self-reporting outcomes.||t|f|f|t
33916248|NCT05856110|||COHORT||PROSPECTIVE|||||||
33916249|NCT03069846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916250|NCT04949555|||CASE_ONLY||RETROSPECTIVE|||||||
33916251|NCT02990897|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33916252|NCT00422708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33916253|NCT05770050|||COHORT||CROSS_SECTIONAL|||||||
33916254|NCT00624728|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916255|NCT05585086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33916256|NCT05415150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916257|NCT04807036|||COHORT||PROSPECTIVE|||||||
34087343|NCT00747877|RANDOMIZED|||TREATMENT||NONE||||||
33916258|NCT01286506|||COHORT||PROSPECTIVE|||||||
34087344|NCT03854500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, controlled multicenter study|t|f|f|t
33916259|NCT00831441|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34087345|NCT05020353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cross-sectional, prospective, field trial (untrained self-tester)||||
33916260|NCT02640352|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916261|NCT02139995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916262|NCT04901741|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916263|NCT02660619|||OTHER||CROSS_SECTIONAL|||||||
33916264|NCT00087893|||COHORT||CROSS_SECTIONAL|||||||
33916265|NCT01586026|||COHORT||RETROSPECTIVE|||||||
33916266|NCT01588860|||CASE_ONLY||RETROSPECTIVE|||||||
33916267|NCT01368159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916268|NCT06169930|||COHORT||RETROSPECTIVE|||||||
33916269|NCT04677530|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33916270|NCT01064193|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34087346|NCT04658355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Chlorhexidine Gluconate vs Povidone-iodine group||||
33996532|NCT02627963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996533|NCT02097160|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33996534|NCT03351296|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative phase II trial with two randomizations||||
33996535|NCT01512628|RANDOMIZED|PARALLEL||||NONE||||||
33996536|NCT03259165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996537|NCT04225364|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with II-IVA stage with pathologically diagnosed squamous cell lung carcinoma will be enrolled in this study. Camrelizumab plus chemotherapy will be administrated intravenously per 3 weeks at the dosage of 200mg. Contrast-CT evaluation and peripheral blood collected will be performed at pre-neoadjuvant therapy and pre-operation. 6 weeks after neoadjuvant therapy, participants who meet the indication will be assigned to operation. Another peripheral blood sample will be harvested 3-4 weeks after operation.||||
33996538|NCT06382662|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a prospective, randomized, single-blind, pilot study to assess degree of drowsiness, cognition, and driving risk following a single dose of oral metaxalone 640 mg (M640) compared to tizanidine 8 mg in healthy subjects.|t|f|f|f
33996539|NCT04919005|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996540|NCT04218435|||COHORT||PROSPECTIVE|||||||
33996541|NCT02364531|||COHORT||PROSPECTIVE|||||||
33996542|NCT03708133|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996543|NCT01747174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33996544|NCT04133311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996545|NCT03071562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Cognition, motor function (balance, walking speed), and affective (mental health, quality of life, medication adherence) evaluations will be administered at baseline and post-intervention (12 weeks) by a trained physiotherapist, blinded to the group assignment. The rationale for blinding the assessing physiotherapist is to reduce bias in scoring during the outcome assessment sessions.||f|f|f|t
33996546|NCT02542254|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33996547|NCT03669861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996548|NCT03914196|||COHORT||PROSPECTIVE|||||||
34087347|NCT02320175|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34087348|NCT01765322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087349|NCT02422654|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34087350|NCT05944796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087351|NCT03816046|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|the objective assessment with iodine starch test|describe two safe and reproducible techniques for the treatment of hyperhidrosis using botulinum toxin. The same patient will receive two different injection technique in each armpit and will be evaluated subjectively and objectively.|f|f|f|t
34087352|NCT04646629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087353|NCT01759914|||COHORT||PROSPECTIVE|||||||
34087354|NCT04023708|||COHORT||OTHER|||||||
33692722|NCT06337500|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692723|NCT06135493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33692724|NCT04824729|||COHORT||RETROSPECTIVE|||||||
33692725|NCT03309150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692726|NCT01610271|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33692727|NCT06710964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33692728|NCT05573386|||COHORT||PROSPECTIVE|||||||
33692729|NCT05672199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692730|NCT06476665|||CASE_ONLY||PROSPECTIVE|||||||
33692731|NCT06708052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Ankle application in voodoo flossing and control group|t|f|t|f
33692732|NCT00006169||||PREVENTION||||||||
33692733|NCT03887403|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692734|NCT04269486|||CASE_ONLY||PROSPECTIVE|||||||
33782000|NCT06614426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34087355|NCT02030873|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33782001|NCT06578780|||COHORT||CROSS_SECTIONAL|||||||
33782002|NCT05932459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782003|NCT01537250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782004|NCT03791177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial was blinded for data manager ( a nurse collecting the control and study group data) and statistician.||f|t|f|t
33782005|NCT01601743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916271|NCT05499611|||COHORT||RETROSPECTIVE|||||||
33916272|NCT00082758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916273|NCT02473003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916274|NCT03664284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).|t|f|f|f
33916275|NCT04935047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916276|NCT00014378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916277|NCT02389712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916278|NCT05855317|||COHORT||PROSPECTIVE|||||||
33916279|NCT06531239|||OTHER||CROSS_SECTIONAL|||||||
33916280|NCT02205606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916281|NCT01669811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916282|NCT05644379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996549|NCT04784923|||CASE_ONLY||RETROSPECTIVE|||||||
33996550|NCT06314633|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Hair collection and parents questionnaires||||
33996551|NCT04771195|||COHORT||OTHER|||||||
33996552|NCT04391270|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33996553|NCT02708251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996554|NCT00796328|NA|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33996555|NCT05496868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the identity of the treatments will remain unknown to the subject, Investigator, site staff, CRO and Dompé's personnel until the study completion and formal unmasking. Only the Data Monitoring Committee (DMC) will have access to group-unblinded and/or fully unblinded DMC reports.||t|t|t|t
33996556|NCT05404789|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Comparing layperson centrifuge tolerance between diabetics, individuals with past medical history of cardiac arrhythmia, and control subjects. All subjects will participate in the same protocols.||||
33996557|NCT00675779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996558|NCT03368443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996559|NCT02761525|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33782006|NCT05803486|||OTHER||OTHER|||||||
33782007|NCT04374877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782008|NCT02179463|||COHORT||PROSPECTIVE|||||||
33782009|NCT02135783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782010|NCT03405766|||COHORT||RETROSPECTIVE|||||||
33782011|NCT02115854|||CASE_ONLY||PROSPECTIVE|||||||
33782012|NCT02994550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782013|NCT06174480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33782014|NCT00219921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782015|NCT05111379|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33782016|NCT04890756|||OTHER||CROSS_SECTIONAL|||||||
33996560|NCT06626633|NA|SINGLE_GROUP||TREATMENT||NONE||STING agonist CRD3874-SI in patients with relapsed/refractory acute myeloid leukemia||||
33782017|NCT02469844|||CASE_ONLY||PROSPECTIVE|||||||
33916283|NCT00483275|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916284|NCT02093234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33916285|NCT03198754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Neither the study participant nor the research coordinator know that study condition of the patient.||t|t|f|f
33916286|NCT01869166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916287|NCT05320692|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Randomized, Open-Label, Multi-center phase III clinical trial。||||
33782018|NCT06522672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782019|NCT06481501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782020|NCT02509403|NA|SINGLE_GROUP||OTHER||NONE||||||
33782021|NCT04896255|||COHORT||PROSPECTIVE|||||||
33916288|NCT02182141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782022|NCT06615466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916289|NCT03719326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation||||
33916290|NCT01945424|||CASE_ONLY||PROSPECTIVE|||||||
33916291|NCT03924141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessors who will assess the video data will be blinded||f|f|f|t
33916292|NCT04237740|NA|SINGLE_GROUP||TREATMENT||NONE||The cases are from patients with recurrent hepatocellular carcinoma who underwent liver transplantation in the liver surgery department of Shanghai Renji Hospital. The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).||||
33916293|NCT06357260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Test group-1 will be administered carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need and follow up done after 1 week with subsequent follow up at 2,4,6 and 8 weeks.~control group all the armamentarium and procedure will remain same except that dose titration of carbamazepine is done till patient is relieved of pain."|f|f|f|t
34087356|NCT00589719|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34087357|NCT02141555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916294|NCT01361919|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33916295|NCT00987623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916296|NCT03089216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916297|NCT01268774|||COHORT|||||||||
33916298|NCT02634931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916299|NCT05006521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916300|NCT00539916|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33916301|NCT04653818|RANDOMIZED|PARALLEL||OTHER||SINGLE|masking for radiologists who assess HCC recurrence only. Patients and physicians: not masked.||f|f|f|t
33916302|NCT06518200|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double masking until end of intervention and evaluations|Randomized controlled trial|f|f|t|t
33916303|NCT04215523|||COHORT||RETROSPECTIVE|||||||
33916304|NCT04815551|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34087358|NCT03300765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782023|NCT02237599|||CASE_ONLY||PROSPECTIVE|||||||
33782024|NCT04214860|NA|SEQUENTIAL||TREATMENT||NONE||The study will include a safety lead-in dose-finding portion followed by the expansion portion. During the safety lead-in portion of the study, two cohorts will independently enroll patients following a 3 + 3 design.||||
33782025|NCT03782948|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33782026|NCT03197311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087359|NCT00966433|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087360|NCT04660045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087361|NCT06298149|NA|SINGLE_GROUP||PREVENTION||NONE||Each participating family will receive a monthly lesson targeting a healthy behavior (increase fruit/vegetable intake, decrease added sugar intake, increase physical activity, decrease sedentary/screen time, promote healthy sleep, and promote emotional regulation) over the course of one year.||||
33782027|NCT06275880|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33782028|NCT04841044|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"All participant, the major investigator, study coordinator and the study staff are blinded for the randomizing. The capsules and capsule containers will only be identifiable by the ID (identifying) numbers on the containers.~Allocation of participants to the specific intervention group is carried out by a statistician and one person not involved in conducting the study."|"Randomized double-blinded controlled trial (Randomized 1:1, control:intervention).~Run-in period of 3 weeks where all participants receive the control capsules."|t|t|t|f
33782029|NCT03663387|||COHORT||PROSPECTIVE|||||||
33782030|NCT00577447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692735|NCT06074536|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient not informed of the randomization arm to which their general practitioner enrolled|Patient-centered face-to-face training for General Practitioners on implementation of a shared decision|t|f|f|f
33782031|NCT06087211|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33782032|NCT06423261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692736|NCT03973073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33782033|NCT04830514|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782034|NCT04236128|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33692737|NCT06619847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782035|NCT05450302|||COHORT||RETROSPECTIVE|||||||
33692738|NCT04991935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782036|NCT06309043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782037|NCT00297765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692739|NCT06413212|||CASE_ONLY||PROSPECTIVE|||||||
33692740|NCT05896748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692741|NCT06287606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33692742|NCT00695578|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33692743|NCT00415454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692744|NCT02312921|||COHORT||PROSPECTIVE|||||||
33692745|NCT02734420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33692746|NCT05820802|||COHORT||PROSPECTIVE|||||||
33692747|NCT02584933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692748|NCT06707363|||CASE_ONLY||PROSPECTIVE|||||||
33692749|NCT06299839|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose expansion||||
33692750|NCT05802173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692751|NCT06083935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33692752|NCT03449953|||COHORT||PROSPECTIVE|||||||
33692753|NCT06691672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33692754|NCT05113095|||COHORT||PROSPECTIVE|||||||
33692755|NCT02800902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782038|NCT00503074|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782039|NCT02196012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916305|NCT00039195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916306|NCT02987348|||COHORT||RETROSPECTIVE|||||||
33916307|NCT06372067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|By nature of the interventions in this study, blinding will not be possible for the surgeon or the patient post-operatively.|Randomized, open-label, pilot randomized controlled trial|f|f|f|t
33916308|NCT02698618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916309|NCT02841111|||CASE_CONTROL||RETROSPECTIVE|||||||
33916310|NCT03357146|||COHORT||CROSS_SECTIONAL|||||||
33692756|NCT03830112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692757|NCT04673149|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33692758|NCT06187662|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The primary study team will know which arm the participating site PICUs will be in, but the local study team and care teams will be blinded.|Study sites will be randomized into two arms, in which different strategies are introduced that each target distinct determinants of blood culture overuse|t|t|f|f
33692759|NCT05806879|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants undergoing delivery at the maternal and child health centre will be randomized into an intervention and control group using a random number generator. The ratio of exposed to unexposed sample will be 1:1. The participants will be followed for 42 days via bi-weekly visits by research assistants.||||
33692760|NCT04530019|||OTHER||PROSPECTIVE|||||||
33692761|NCT06245629|||COHORT||RETROSPECTIVE|||||||
33692762|NCT00590629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33782040|NCT04006795|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33782041|NCT03186937|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782042|NCT04283409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the exercise nature of the study it is not possible to blind therapists or patients, however; assessors will remain blinded||f|f|f|t
33782043|NCT00367237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916311|NCT05311293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33916312|NCT00190983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916313|NCT03739476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded.|one arm treatment. one arm placebo.|t|f|t|f
33782044|NCT01944943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782045|NCT06239974|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Cardiovascular Magnetic Resonance Level 3 radiologists will be blinded to the patient allocation.|Single-blinded Randomised Controlled Trial|f|f|f|t
33916314|NCT05844956|NA|SEQUENTIAL||TREATMENT||NONE||Dosages include 10 mg, 25 mg, 50 mg, 100 mg, and 150 mg.||||
33916315|NCT00853489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916316|NCT05059548|||COHORT||PROSPECTIVE|||||||
33692763|NCT05060887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized assignment to experimental vaccine (three dose levels) or placebo in a 1:1:1:1 ratio.|t|f|t|f
33692764|NCT06708767|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33782046|NCT03451292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782047|NCT04758403|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33782048|NCT06693986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782049|NCT04411082|RANDOMIZED|PARALLEL||TREATMENT||NONE|Double-Blind|||||
33782050|NCT05192824|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33916317|NCT00155454|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916318|NCT05299242|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The participant will be blinded along with the assessor and other site staff. The injector and pharmacy will not be blinded.|Participants will be randomised to either receive Adalimumab or Placebo.|t|f|t|t
33692765|NCT00377975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33692766|NCT05561374|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692767|NCT06484673|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33692768|NCT05685654|||OTHER||PROSPECTIVE|||||||
33692769|NCT02030054|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33692770|NCT01866722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692771|NCT02305888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916319|NCT02273557|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916320|NCT02152670|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33916321|NCT02541474|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"This is a registry based study design. The Primary outcome is extracted from routine data recorded by clinical and administrative personell who are unaware of study allocation in the electronic health care record.~The questionnaire outcome data can not be masked as the patient and study personell will be aware of treatment allocation group. To avoid preferential recording of these outcomes, study personell assist in data collection in either treatment or control groups - never both, so that they could not compare or favor one group above the other."|Treatment patients|f|f|t|t
33916322|NCT00325286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916323|NCT00441441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916324|NCT06553430|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916325|NCT06348407|||CASE_CONTROL||RETROSPECTIVE|||||||
33916326|NCT03674203|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective cohort study with therapeutic intervention for one year. We included patients older than 18 years with a diagnosis of melanoma and a history of pregnancy with a time greater than 6 months, who were not in the period of lactation, with no history of skin cancer, with a history of liver, thyroid or injury, of acne and traumatic injuries on the face, in addition, with no work history of PRP. The patients received three sessions of PRP application, at intervals of 15 days between each of them.||||
33916327|NCT03916172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33916328|NCT00421603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916329|NCT00052884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916330|NCT03569865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916331|NCT04915924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916332|NCT05945901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916333|NCT00282789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916334|NCT02144961|||COHORT||PROSPECTIVE|||||||
33916335|NCT01892319|||COHORT||PROSPECTIVE|||||||
33916336|NCT01213368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916337|NCT05145478|||COHORT||PROSPECTIVE|||||||
33916338|NCT01199250|||OTHER||RETROSPECTIVE|||||||
33916339|NCT05775744|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The investigators will study and compare two cohorts of patients. The first is a retrospective cohort, including patients delivered at Robert Wood Johnson University Hospital and Cooperman Barnabas Medical Center. The second is a prospective cohort that will enroll patients immediately postpartum who are eligible for our treatment protocol.||||
33692772|NCT05300152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33692773|NCT05651659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Specially trained nurses (data assessors) from the project's research centre who are not affiliated with the municipalities will, together with staff members in the home care services, assess patients' baseline characteristics before randomisation. These data assessors will after randomisation be blinded to the randomisation result. They will assess the effect of the intervention via telephone by interviewing the participants, the next of kin and the staff members who know the patient best, at three months and six months after baseline assessments.|Cluster randomized controlled trial (RCT) with two parallel groups: intervention municipalities and control municipalities|f|f|f|t
33996561|NCT02471807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996562|NCT00143273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996563|NCT02741687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33996564|NCT00354419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692774|NCT06658574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692775|NCT04870957|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Sequential, multiple assignment, randomized trial (SMART) design|f|f|f|t
33692776|NCT06157567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087362|NCT01384877|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Double blind performed by pharmacy. Un blinding to occur at end of study. All subjects to be injected with 1 mL of 1% lidocaine subcutaneous prior to the initiation of the study med infusion, which will act as a masking agent.|One-sided McNemar's tests will be carried out to test whether a single infusion of subcutaneous lidocaine will cause a reduction in cancer pain for both the interim and final analyses at the p-values of 0.00153 and 0.02347 respectively.|t|t|t|f
33782051|NCT05094115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All participants will receive usual training with randomized participants being assigned to psychological flexibility training||||
34087363|NCT01225302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087364|NCT02397525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087365|NCT01053832|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34087366|NCT00014014||CROSSOVER||TREATMENT||||||||
34087367|NCT03738696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782052|NCT04285086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental Drug (Biological): Ropeginterferon alfa-2b (P1101), Q2W, SC injection Control Drug: Anagrelide, capsules, daily, p.o.||||
33782053|NCT01386840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087368|NCT05684107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33782054|NCT03879473|||COHORT||PROSPECTIVE|||||||
33782055|NCT02466126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782056|NCT01142999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782057|NCT03768544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782058|NCT06697314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782059|NCT04071691|||COHORT||PROSPECTIVE|||||||
33782060|NCT01979055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782061|NCT05210140|||COHORT||PROSPECTIVE|||||||
33782062|NCT06044961|||OTHER||RETROSPECTIVE|||||||
33782063|NCT06575647|NA|SINGLE_GROUP||TREATMENT||NONE||Cross-sectional study with safety and feasibility assessment||||
23506556|NCT06051994|||COHORT||PROSPECTIVE|||||||
34087369|NCT03795948|NA|SINGLE_GROUP||OTHER||NONE||||||
34087370|NCT06443827|NA|SINGLE_GROUP||TREATMENT||NONE|Blindness about treatment|"Double-blind, placebo-controlled, crossover (within subjects) study with an A-B-A-B treatment scheme, in which placebo (A) and amantadine sulphate (B) intervention sessions alternated weekly in the same patient for a total of four weeks (A1-B1-A2-B2)."||||
33692777|NCT05760573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33692778|NCT06252285|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* Blinding for vaccine group assignment: participants, parents or legally acceptable representatives (LARs), outcome assessors, investigators, laboratory personnel, Sponsor study staff~* No blinding for study staff who prepare and administer the study interventions"||t|f|t|t
33692779|NCT00004834|RANDOMIZED|||TREATMENT||DOUBLE||||||
33692780|NCT06128200|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This is a single-blind study; participants will be blinded to the randomization assignment.|A prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial|t|f|f|f
33692781|NCT05440214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782064|NCT02468505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33782065|NCT05507008|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will complete 2-weeks daily ketone supplementation||||
33782066|NCT05453500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782067|NCT00244361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087371|NCT00700635|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087372|NCT02455193|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996565|NCT06082505|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33996566|NCT04211935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomly assigned to one of three interventional groups. Study participants and team members will be blinded on randomized group until entering the operating room, at which point the cryoablation machine and instruments will be brought into the room for INC or the anesthesiologist will place ESB. The PCA pump will be connected to the patient's intravenous line at the end of the case.||t|t|t|f
33996567|NCT00828815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996568|NCT05644392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996569|NCT00758797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996570|NCT01093833|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33996571|NCT04695041|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Cohorts will be dosed sequentially in an ascending fashion with approximately 14 days between starting dose at each dose level.|t|f|t|f
33996572|NCT02575651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996573|NCT02805764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996574|NCT05957146|||COHORT||PROSPECTIVE|||||||
33996575|NCT02197195|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34087373|NCT05880888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087374|NCT04422886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Physiotherapists providing treatment, physiotherapists conducting assessment, research coordinator, principal investigators, participants are all blinded to treatment allocation. Research assistants administered the transcranial direct current stimulation are not blinded.|2-arm parallel group feasibility randomized control trial|t|t|t|t
34087375|NCT04016974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34087376|NCT03852511|NA|SEQUENTIAL||TREATMENT||NONE||"Patients in Part A will receive a single cycle of NG-350A study treatment, with three single doses on Days 1, 3 and 5 by IV infusion.~Patients in Part B will receive a single cycle of NG-350A study treatment, with three single doses on Days 1, 3 and 5 by IV infusion, followed by up to 8 cycles of a check point inhibitor."||||
34087377|NCT01235221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087378|NCT01730313|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34087379|NCT00090532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087380|NCT02113527|||CASE_CONTROL||PROSPECTIVE|||||||
34087381|NCT02773225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087382|NCT01994031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087383|NCT01883167|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34087384|NCT04146701|||COHORT||PROSPECTIVE|||||||
34087385|NCT03913962|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|no masking|||||
34087386|NCT05849857|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, one arm, open label clinical trial of subcutaneous mosunetuzumab mono-therapy||||
34087387|NCT03290768|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34087388|NCT02314013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087389|NCT02634177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087390|NCT03920800|||COHORT||RETROSPECTIVE|||||||
33996576|NCT06428539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33996577|NCT06451653|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33996578|NCT03354338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, care provider, Investigator, Outcomes Assessor and Statistic. The treatment codes of the study were not accessible to the investigators and to the examiner until the data will be analyzed.|"A triple-blind randomized controlled trial with 90 participants will be conducted. Participants will be assigned using block randomization in two groups and will received intensive periodontal therapy under local anaesthesia.~Test group pre-medication with 2 gr of oral amoxicilline 1 hour before treatment.~Control group with 2 gr of placebo 1 hour before treatment. Samples of blood will be taken at baseline (before treatment), immediately finished the treatment, 30 minutes later, after 24 hours, after seven days and on the day 30th to asses bacteremia and inflammatory markers"|t|t|t|t
33996579|NCT05936996|||COHORT||PROSPECTIVE|||||||
33996580|NCT04738968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|It is known whether the child has a cochlear implant or not|Participants are assigned to either the test or the control group||||
33996581|NCT03965572|||CASE_CONTROL||PROSPECTIVE|||||||
33996582|NCT05768334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087391|NCT00375661|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33782068|NCT00811187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996583|NCT03063138|||OTHER||OTHER|||||||
33996584|NCT01328652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996585|NCT01995162|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996586|NCT04431505|||CASE_ONLY||PROSPECTIVE|||||||
33996587|NCT03956758|||OTHER||PROSPECTIVE|||||||
33996588|NCT01847495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782069|NCT05889611|||CASE_ONLY||RETROSPECTIVE|||||||
33782070|NCT05350436|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33996589|NCT00913627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782071|NCT05356026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782072|NCT03700255|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996590|NCT03500094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782073|NCT01141686|||COHORT||RETROSPECTIVE|||||||
33996591|NCT01247103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33996592|NCT01537718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996593|NCT01912807|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33996594|NCT03516058|NA|SINGLE_GROUP||OTHER||NONE||||||
33996595|NCT02431949|||COHORT||CROSS_SECTIONAL|||||||
33996596|NCT03084263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996597|NCT05781737|||COHORT||PROSPECTIVE|||||||
33996598|NCT04318808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants in each group will receive real (with energy output) or sham (without energy output) laser acupuncture. The feelings of participants in each group are not different. The care provider and outcomes assessor don't involve the random allocation and don't know if participants receive real laser acupuncture.||t|t|f|t
33996599|NCT06366555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The Participant will be randomized using a computerized table and the Outcome Assessor dont know which Subjects receive the manual acupuncture twirling or sham manual acupuncture on each period|"This research design used a randomized controlled single-blind crossover trial method (Crossover Single Blinded Randomized Control Trial). Reasons for choosing to use the Crossover method because apart from being able to implement it, it can also provide far more output results with a smaller number of subjects.~The research subjects will then receive two treatments spaced 1 week apart which is called a wash out period to eliminate the carry-over effect of the treatment given. Research subjects will undergo randomization . Subjects in group A will undergo manual twisting acupuncture followed by sham manual acupuncture. The subject in group B will receive a sham acupuncture manual followed by a round of manual acupuncture twirling"|t|f|f|t
33996600|NCT00827164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996601|NCT03740360|||CASE_ONLY||PROSPECTIVE|||||||
33996602|NCT03006835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33996603|NCT06627348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996604|NCT02964039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33996605|NCT04615741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996606|NCT01553396|||CASE_ONLY|||||||||
33996607|NCT02921958|||CASE_ONLY||PROSPECTIVE|||||||
33996608|NCT01067950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996609|NCT01920334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996610|NCT04738864|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33996611|NCT02893735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996612|NCT05444205|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE|The Early Childhood Collaborative is an implementation study and therefore, all participants are offered intervention and there in so masking.|The Early Childhood Collaborative is an implementation study and therefore, all participants are offered intervention. An innovative aspect of the study is supporting parent choice of intervention. Participants are given a choice of interventions based on a tiered model, and they can also decline to engage in programs and continue in follow-up.||||
33996613|NCT04149691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996614|NCT04487184|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33996615|NCT01296607|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33996616|NCT04748991|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be recruited from the CVICU 24 hours after admission to CIVCU based on inclusion and exclusion criteria. Patients identified with new presentation atrial fibrillation with a sustained duration of greater than 30 minutes will be considered for the study. Patients will be randomized to Amiodarone versus Vernakalant using a computerized process.||||
33996617|NCT00484679|NA|SINGLE_GROUP||SCREENING||NONE||||||
33996618|NCT06014424|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a double-blind study. Participants, Subsequent decision maker and investigator will be blinded to the treatment arm. Unblinding will not be allowed unless there are exceptional clinical circumstances that justify it||t|t|t|f
33996619|NCT01828203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996620|NCT02784236|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33996621|NCT01149057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996622|NCT00926835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782074|NCT00002111||||TREATMENT||NONE||||||
33782075|NCT02095704|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33782076|NCT04697784|NA|SINGLE_GROUP||TREATMENT||NONE||Abdominal Aortic Aneurysm Stent-Graft||||
33782077|NCT03177187|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open label|||||
34087392|NCT02629978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996623|NCT02827097|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087393|NCT04923451|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Depending on the randomized group, the subject will receive one of two treatments 15 days apart (A: active anode on the right DLPFC and neutral cathode on the left shoulder; B: inactive anode on the DLPFC and inactive cathode on the left shoulder). The groups are defined as follows:~The results of randomization will not be known by the evaluator."|"Quantitative data regarding the intensity of emotional response and craving to erotic images, motor inhibition task and impulsivity will be presented in the form of frequency, mean and standard deviation (SD) calculations and compared using a 2-factor repeated measures ANOVA taking into account the fact that the patient will be compared to himself (position 1 and 2 and placebo) and to other patients using 3 kinds of images (erotic, social and neutral) with 3 types of possible stimulations.~In order to analyze the fMRI data, the regions of the patient's body will be identified. in which the BOLD activity will be correlated to the attractiveness of the image. Foreach patient, the difference before and after stimulation will be calculated. There will be no intermediate analysis."|t|t|f|f
34087394|NCT06169332|||COHORT||PROSPECTIVE|||||||
34087395|NCT00624208|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34087396|NCT04326374|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible subjects will be randomized to 1 of the 2 treatment groups: either weekly TransCon hGH or daily hGH, in a 2:1 ratio||||
34087397|NCT00254085|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34087398|NCT01552486|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34087399|NCT00710658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087400|NCT00988338|||COHORT||PROSPECTIVE|||||||
34087401|NCT02484521|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34087402|NCT02199574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087403|NCT05517590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The patient, the surgeon and the assistant that will collect the data will be masked about the patient's study group.|Prospective randomized|t|t|f|t
34087404|NCT02957552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087405|NCT00091858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087406|NCT02846961|||COHORT||PROSPECTIVE|||||||
34087407|NCT03352284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087408|NCT00724776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087409|NCT04909762|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive Early Rehabilitation and Mobilisation intervention.||||
34087410|NCT06397482|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-Arm, Pilot Study||||
34087411|NCT01741870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34087412|NCT00125918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087413|NCT03170414|||COHORT||PROSPECTIVE|||||||
34087414|NCT02616705|||COHORT||PROSPECTIVE|||||||
34087415|NCT03755817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087416|NCT05634291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087417|NCT02433717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087418|NCT04451083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087419|NCT03803696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087420|NCT05300386|||CASE_CONTROL||PROSPECTIVE|||||||
34087421|NCT00464685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34087422|NCT02479490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996624|NCT00509990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996625|NCT05377164|||OTHER||CROSS_SECTIONAL|||||||
33996626|NCT02000388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996627|NCT04558450|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
33996628|NCT00779519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996629|NCT06476015|||COHORT||RETROSPECTIVE|||||||
33996630|NCT03198663|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996631|NCT00789776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996632|NCT04936529|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33996633|NCT06161428|||COHORT||PROSPECTIVE|||||||
33996634|NCT03574051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996635|NCT06322485|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants and practitioners is not possible due to the nature of the study. However, the statistician who creates the randomization schedule and performs statistical analyses is blinded to group allocation.|||||
33996636|NCT01760551|||CASE_CONTROL||RETROSPECTIVE|||||||
33996637|NCT05203835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996638|NCT01253564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996639|NCT05426876|||COHORT||PROSPECTIVE|||||||
33996640|NCT03797196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996641|NCT03714373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782078|NCT06132776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, double-blind, placebo-controlled|t|t|t|t
33782079|NCT05780736|||COHORT||PROSPECTIVE|||||||
33801445|NCT05866978|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Using a stepped-wedge design, participants at the enrolled worksites function as their own control. Thus, the effect of the intervention is evaluated as in an RCT design. All employees are asked to complete a short screening questionnaire. Those who wish to participate are invited to the data collection containing: Signing of consent, measurements of height, body weight, fat percentage and blood pressure and answering a questionnaire. No preparation is required of the participants before data collection begins. All intervention activities and health checks take place at the participants' workplace during paid working hours. Calculation, analysis and interpretation of data will take place at the Department of Occupational and Social Medicine, Holbæk Hospital.~The intervention activities are developed by a local commitee including participants and managers, acoording a participatory approach and following the Work Health Improvements Network concept."||||
33801446|NCT02530216|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33916340|NCT05476185|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned, in a three to one ratio, to the intervention group, or the control group. All participants will complete a pretest questionnaire and have access to case management services. The intervention group will receive 16 hours of Relationship Enhancement Education, then all participants will complete a posttest questionnaire. Six months after the posttest, all participants will complete a follow-up questionnaire.||||
33916341|NCT02235987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916342|NCT05454202|||CASE_ONLY||PROSPECTIVE|||||||
33916343|NCT03543306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916344|NCT04237324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The purpose of this study is to assess the safety and efficacy of FMR and NAFL for the treatment of BLEs in Asian. After being informed about the study and potential risks, all patients giving written informed consent. Patients were randomly divided into FMR side and NAFL opposite side 3 times in total at a 1-month interval. FMR side has been used by FMR device (INFINI, Lutronic Co., Goyang-si, Korea) and the NAFL side has been used by ResurFX module of M22 (Lumenis Co., Yokneam, Israel).|f|f|t|f
33916345|NCT05508672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33916346|NCT02438644|||COHORT||PROSPECTIVE|||||||
33916347|NCT00231244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916348|NCT03136952|||COHORT||PROSPECTIVE|||||||
33916349|NCT04877314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Measuring the level of IL1, IL6, TNFα, IL10 cytokines before and after the 3 weeks intermittent fasting period for 30 overweight volunteers|Cytokine levels before and after intermittent fasting period for 3 weeks||||
33916350|NCT02815176|||CASE_CONTROL||PROSPECTIVE|||||||
33916351|NCT02337595|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33916352|NCT03414008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916353|NCT03431324|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants will be blind to the hypothesis of the study and to the condition to which they are assigned. They will be informed of both of these details during a debriefing provided by the researcher upon the conclusion of data collection.|"Stage 1 will employ a between-subjects experimental design to establish the effectiveness of the mating-EFT intervention and compare its effectiveness to that of the established general-EFT intervention (Chiou \& Wu, 2017) and a yoked control condition. This study will determine whether the effectiveness of these interventions is moderated by individual differences in relationship status, fundamental social motives (including mate-seeking motivation), self-efficacy, and nicotine dependence.~Stage 2 will employ a quasi-experimental design in which participants who are either currently involved in a committed romantic relationship or single will be randomly assigned to complete either a mating-centric EFT intervention, a general-EFT intervention, or a control activity that involves no intervention."|t|f|f|f
33916354|NCT00347763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33916355|NCT00900172|||OTHER||RETROSPECTIVE|||||||
33916356|NCT05480293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916357|NCT04859335|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33916358|NCT03711006|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is an open-label pilot study treating 7 patients with Ulcerative Colitis with 25 daily multi-donor FMT Capsules for 50 days with 6 months follow up including the treatment period||||
33916359|NCT00745186|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916360|NCT02961712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916361|NCT00029991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996642|NCT00349765|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33996643|NCT05958433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33996644|NCT06227741|RANDOMIZED|PARALLEL||OTHER||SINGLE||concept mapping|t|f|f|f
33996645|NCT04934007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996646|NCT03640741|||CASE_ONLY||RETROSPECTIVE|||||||
33996647|NCT04092387|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind dosing of tobacco cigarette nicotine content levels.|Randomized parallel groups research design.|t|f|t|t
33996648|NCT05882630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692782|NCT06264310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment of all cohorts will be double-blind (all patients, study staff, investigators and Sponsor). Site pharmacist is unblinded.|Patients will be randomly assigned to one of four cohorts. Three groups will receive R2R01, and one group will receive placebo.|t|t|t|f
33996649|NCT01949922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996650|NCT03358758|||COHORT||RETROSPECTIVE|||||||
33996651|NCT03633214|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33996652|NCT03406845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As described above.|RCT|f|f|f|t
33996653|NCT01177657|||CASE_CONTROL||PROSPECTIVE|||||||
33996654|NCT00004213||||TREATMENT||||||||
33996655|NCT03616379|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study PI and data analyst will be blind to study condition. The experimenter will and participant will be aware of the study condition because this is a behavioral intervention.||f|f|t|f
33996656|NCT01679158|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692783|NCT06416670|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33692784|NCT06543043|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33692785|NCT05712252|||COHORT||PROSPECTIVE|||||||
33692786|NCT03186885|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33692787|NCT00907868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692788|NCT06707844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692789|NCT06710444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33692790|NCT05221827|||COHORT||PROSPECTIVE|||||||
33692791|NCT06321757|||CASE_ONLY||PROSPECTIVE|||||||
33782080|NCT04018092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Use of a sham-controlled approach provides stringent experimental control, enabling the investigators to control for placebo/expectations, behavioral activation (engaging in study procedures) and practice effects related to repeated administration of the same cognitive tasks.~The MedX and Vielight devices used for delivery of active and sham NIR stimulation are identical in all respects regarding design, warmth and operation, except that no stimulation is delivered by the sham devices. Because NIR light is invisible, participants will not be able to discern if receiving active or sham stimulation. The participants, interventionists, and outcome assessors will be blinded to the participants' intervention status: Active vs Sham. At completion of the study, all participants will receive a Placebo Control Questionnaire that asks questions pertaining to what group the participant had been assigned. This data will be examined to determine the effectiveness of blinding."|Participants who meet eligibility criteria will be randomized to the Active or Sham condition. The study biostatistician will randomize participants using a 1:1 allocation scheme with stratification based on age, education, and sex. When a new participant arrives, she/he will be randomized to Active or Sham groups depending on covariate characteristics (age, education, sex) and the cumulative distribution of assignments regarding these variables at that point.|t|f|t|t
33782081|NCT05550974|||COHORT||PROSPECTIVE|||||||
33782082|NCT03889899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782083|NCT04901728|||COHORT||RETROSPECTIVE|||||||
33782084|NCT05831046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782085|NCT03422302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782086|NCT03558113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Screening of patients that come to the conservative dentistry department seeking dental care will continue until the target population is achieved. The patients' restorations will be subjected to visual examination and diagnosis using dental charts. Once the patients that are potentially eligible for this study are identified, they will be contacted by the research investigator who will explain the study and ascertains the patient's interest. If interested, more detailed evaluations and preparations are made.||||
33996657|NCT05992454|||COHORT||PROSPECTIVE|||||||
33996658|NCT05782439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Three different group (40, 20 and 40 subjects respectively) are enrolled in sequence and undergo the same evaluation procedure.||||
33996659|NCT01604239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996660|NCT00470691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996661|NCT04273386|NA|SINGLE_GROUP||OTHER||NONE||||||
33996662|NCT00765635|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692792|NCT04121416|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33692793|NCT05045365|||COHORT||PROSPECTIVE|||||||
33692794|NCT01440062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692795|NCT02162849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692796|NCT06708078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic randomized controlled trial||||
33692797|NCT00780390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692798|NCT04935359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692799|NCT05834413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692800|NCT04226534|NA|SINGLE_GROUP||SCREENING||NONE||||||
33692801|NCT01852370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692802|NCT05462873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692803|NCT01008631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782087|NCT00747279|RANDOMIZED|||TREATMENT||NONE||||||
33782088|NCT05974839|||CASE_ONLY||RETROSPECTIVE|||||||
33782089|NCT01220531|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782090|NCT04422925|||CASE_ONLY||PROSPECTIVE|||||||
33782091|NCT05577962|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33782092|NCT02359058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996663|NCT04492930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996664|NCT00171145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996665|NCT05385835|||OTHER||OTHER|||||||
33996666|NCT02665780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996667|NCT04807777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996668|NCT04985149|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34087423|NCT05696600|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692804|NCT03503071|||COHORT||PROSPECTIVE|||||||
33692805|NCT06709326|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Three groups of research subjects~1. Primary metastatic prostate cancer~2. PSA relapse~3. Healthy research subjects"||||
33692806|NCT05249192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|patients and surgeons are blinded to group allocation until the end of surgical procedure|prospective, randomized, controlled, two-arm, multi-center trial|t|t|f|f
33692807|NCT06192394|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|On the day of the colonoscopy procedure, endoscopy nurses and physicians (single blind) will not know which group the patients are in. Patients will be asked not to share information about which group they will be in with the endoscopy team.|There are three groups: control, gum chewing and walking exercise.|f|t|f|f
33692808|NCT06413680|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692809|NCT03927807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692810|NCT04624438|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33692811|NCT02972840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916362|NCT03936517|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Participants will be randomised to one of two arms: A) prednisolone in the first treatment period and hydrocortisone in the second period; or B) hydrocortisone in the first treatment period and prednisolone in the second period.~Blinding will be achieved by providing participants with a tablet three times a day regardless of the treatment they are currently on. If on a hydrocortisone treatment period, the participant will receive tablets of hydrocortisone at their personally tailored dose three times a day (morning, noon and afternoon). When on prednisolone, the participant will receive a prednisolone tablet in the morning (at their personal dose), followed by a matched placebo at noon and in the afternoon. The tablets used in the study have been specifically made for the study to maintain blinding."|Two-arm, two-period, double-blind randomised crossover study|t|t|t|t
33916363|NCT03943953|NA|SINGLE_GROUP||TREATMENT||NONE||One single group will be trialling a new self-guided psychological intervention||||
33916364|NCT01278017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916365|NCT01956240|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33916366|NCT00379197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916367|NCT02343276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916368|NCT02982538|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33916369|NCT01593163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916370|NCT01764529|||COHORT||PROSPECTIVE|||||||
33916371|NCT01393171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916372|NCT05890313|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The pilot study is single blinded in the perspective of the Neurology consultation, regarding the origin and method of referral of each patient with a suspected diagnosis of MCI or early dementia from primary care.|The unit of study is the FHU. The six FHU recruited will be randomly allocated to the three study groups and each FHU will belong to the same group during the total period of the study. The study will be conducted simultaneously in all groups.|f|t|f|f
33916373|NCT03250416|||CASE_ONLY||PROSPECTIVE|||||||
33916374|NCT02745132|NA|SINGLE_GROUP||||NONE||||||
33916375|NCT06396663|NA|SINGLE_GROUP||OTHER||NONE||||||
33916376|NCT05353101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916377|NCT05355727|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33916378|NCT04751903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study was conducted at neonatal intensive care unit (NICU) of the university hospital located in eastern Turkey between May 5th, 2017 and March 19th, 2018. The preterm infants were randomly allocated to two groups, experimental group and control group, by a computer-generated number table. The sample consisted of 77 preterm infants (39 in the experimental group and 38 in the control group) who met the inclusion criteria. The gestational weeks when babies are born were grouped as follows: 29-30 weeks, 31-32 weeks, and 33-34 weeks. In this study, only one researcher (1st author) who was not included in the intensive care team administered OMS to all the infants. Thus, the families and the NICU team were double-blinded.|The study was conducted as the randomized controlled and double-blind experimental trial. This study was guided by the CONSORT checklist|t|f|f|f
33916379|NCT05630430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916380|NCT04280419|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33916381|NCT05207306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were blinded to the allocation, because that investigator performed nerve block after induction of anesthesia. The outcome assessor not involved in this study will investigate the outcomes|A prospective randomized controlled trial|t|f|f|t
33916382|NCT00642746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916383|NCT04010890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This mixed study will be conducted in 3 phases~1. Development of culturally adapted CBT for Canadian South Asians through a qualitative study~2. Testing culturally adapted CBT against standard CBT for efficacy through RCT and economic evaluation~3. Evaluation of training of therapists in culturally adapted CBT"|f|f|t|t
33916384|NCT01371487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916385|NCT06088537|||OTHER||PROSPECTIVE|||||||
33996669|NCT00736190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996670|NCT04069936|NA|SEQUENTIAL||TREATMENT||NONE||In Part 1, approximately 3-6 subjects will be treated with MILs™ - NSCLC alone. Following Part 1, approximately 20 subjects will be treated with MILs™ - NSCLC plus nivolumab with or without tadalafil.||||
33996671|NCT06144034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor was blinded to treatment intervention|Split-Mouth Design Clinical Trial|f|f|f|t
33996672|NCT04185857|||CASE_CROSSOVER||PROSPECTIVE|||||||
33996673|NCT01675115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996674|NCT01374451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996675|NCT03711591|||CASE_ONLY||PROSPECTIVE|||||||
33996676|NCT05308186|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The guardians and outcome assessor will not be made aware of the order of interventions.||f|f|f|t
33996677|NCT02764853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996678|NCT01530048|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33996679|NCT01151280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996680|NCT04143607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Triple (Participant, Investigator, Outcomes Assessor)|t|f|t|t
33996681|NCT00584116|||COHORT||CROSS_SECTIONAL|||||||
33916386|NCT03773926|NA|SINGLE_GROUP||TREATMENT||NONE||An efficiency multicentric pilot study on a targeted population for development and use of Neuro-feedback therapy for treating tinnitus.||||
33916387|NCT03248245|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|While the school owners, school leaders, teachers and collaborators are aware of whether their respective school have been randomized to experimental or control group, the pupils are masked for this information. They are aware that the schools participate in an intervention related to interprofessional team collaboration, but they do not know whether their school have been randomized to experimental or control group.|"Cluster-randomized study. After baseline, schools will be randomized to experimental and control groups schools. The LOG-model is implemented in experimental schools, while control group schools continues with their ordinary practices (treatment as usual). Effects on teachers are analyzed on the follow up areas: interprofessional team collaboration, teachers working hours, teacher's self-efficacy. Effects on pupils are analyzed on the follow up areas: learning environment- and outcome, early intervention. Effects on school level are analyzed on the follow up areas: special needs education, pupils learning outcome."|t|f|f|f
33916388|NCT02207595|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33996682|NCT04785963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33916389|NCT02297542|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33996683|NCT01439620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996684|NCT01528735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996685|NCT03625973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A social work graduate assistant from Dr. Berg-Weger's program and Dr. Anderson's program will administer the various behavioral tests that will produce the outcome measures. This will be a different individual than the graduate assistants who conduct the RT sessions with participants. Also the assistant administering the tests will be blind as to the treatment assignment of the participants.||f|f|f|t
33996686|NCT01094457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996687|NCT03407209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087424|NCT02402062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087425|NCT04832737|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a wait list control study design with pre-, within, and post-treatment measures. A rolling entry of participants will be conducted, where once individuals have been screened their entry into the study will begin. A maximum of 30 adults aged 18+ with a confirmed diagnosis of ADHD will be allocated using block randomisation to the SDT theory-based model or wait list over a 12-week period. Following the 12-week wait, the wait list group will also be enrolled in the SDT theory-based model. This ensures all participants receive the opportunity to experience the treatment.||||
34087426|NCT01352039|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087427|NCT06521242|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087428|NCT00898937|||COHORT||PROSPECTIVE|||||||
34087429|NCT01478646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087430|NCT01563783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087431|NCT01219608|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33692812|NCT04274478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692813|NCT06474663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692814|NCT05053321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692815|NCT05748665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692816|NCT00478881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33692817|NCT03964766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692818|NCT05079516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||The study includes two experiments. Experiment 1 includes Arms 1-3, and Experiment 2 includes Arms 4-7. Arm assignment will be random within each experiment.|t|f|t|f
33692819|NCT05250089|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The time frame of the simulation (post recovery or usual) will be unknown to the evaluator|single site prospective pilot study||||
33692820|NCT03149510|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692821|NCT00606827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33692822|NCT04654468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692823|NCT06708845|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692824|NCT02636374|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692825|NCT04873128|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916390|NCT05739877|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916391|NCT02675894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33916392|NCT00229164|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33916393|NCT00328965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916394|NCT03306485|||OTHER||PROSPECTIVE|||||||
33916395|NCT01142609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33916396|NCT05582785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916397|NCT02488616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916398|NCT00567541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916399|NCT02152592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916400|NCT00000993||||PREVENTION||NONE||||||
33916401|NCT06441851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916402|NCT01907984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33916403|NCT00228969||||TREATMENT||||||||
33916404|NCT02704494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916405|NCT02598518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916406|NCT04587453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the trial participant nor any of the investigator or LEO pharma staff who are involved in the treatment or clinical evaluation and monitoring of the participants will be aware of the treatment received. The packaging and labelling of the investigational medicinal product (IMP) will contain no evidence of their identity. Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded healthcare professional at the site who will not be involved in the management of trial participants and who will not perform any of the assessments.||t|f|t|f
33916407|NCT01313806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916408|NCT05512208|NA|SINGLE_GROUP||TREATMENT||NONE||A single-stage exploratory, Phase 2, multicenter, parallel cohort, open label study designed to evaluate efficacy and safety of VS-6766 + defactinib.||||
33996688|NCT05077449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996689|NCT02779400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996690|NCT03899935|||COHORT||RETROSPECTIVE|||||||
33996691|NCT00314288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996692|NCT02541227|||COHORT||PROSPECTIVE|||||||
33996693|NCT06060834|NA|SINGLE_GROUP||TREATMENT||NONE||pre-post experiment||||
33916409|NCT05606679|||OTHER||OTHER|||||||
33916410|NCT02128282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916411|NCT00734344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916412|NCT01876394|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33916413|NCT02497157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916414|NCT01266434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916415|NCT04407455|||COHORT||PROSPECTIVE|||||||
33916416|NCT02695706|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33916417|NCT05656716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33916418|NCT04359134|||COHORT||PROSPECTIVE|||||||
33996694|NCT02911701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996695|NCT00978458|RANDOMIZED|PARALLEL||TREATMENT||||||||
33996696|NCT05274763|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33996697|NCT04895553|||COHORT||PROSPECTIVE|||||||
33996698|NCT02013635|||CASE_ONLY||PROSPECTIVE|||||||
33996699|NCT03119077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33996700|NCT02623257|||CASE_ONLY||PROSPECTIVE|||||||
33996701|NCT04257292|||CASE_ONLY||PROSPECTIVE|||||||
33996702|NCT00687206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996703|NCT04444141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916419|NCT03107676|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcome assessor will only take the endurance and isokinetic measurements without knowing the participants group. Participants will be tested and assigned only to one group using the assigned arms position.|Four equal groups of physical therapy students|t|f|f|t
33916420|NCT02723110|||CASE_CONTROL||PROSPECTIVE|||||||
33916421|NCT01864798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996704|NCT00544492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996705|NCT01090505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996706|NCT00137735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996707|NCT05325515|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 study arms in which participants are allocated by randomization 1:1. Randomixation is performed in 8 blocks of 8.||||
33916422|NCT02288065|||COHORT||RETROSPECTIVE|||||||
33996708|NCT04906070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916423|NCT02713191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916424|NCT00186654|RANDOMIZED|PARALLEL||||DOUBLE||||||
33801447|NCT05384366|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with locally advanced carcinoma of the uterine cervix were recruited for assessment of clinical and pathological therapeutic response. Multivariate analysis was conducted to predict the independent predictors of response||||
34087432|NCT05832372|||OTHER||RETROSPECTIVE|||||||
33916425|NCT02365584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916426|NCT03916471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996709|NCT03835468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomly assigned into two groups. Group 1 will receive a daily dosage of GOS over 4 weeks, whereas group 2 will receive a placebo over the same period.|t|t|t|f
33801448|NCT06523205|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33996710|NCT00553124||||PREVENTION||||||||
33996711|NCT00452348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996712|NCT01723683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996713|NCT00396162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996714|NCT01306838|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996715|NCT05574036|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is randomized controlled, parallel and prospective 6-months duration study. Accepted patients will be randomized into 2 groups as the following:~* Group 1 (Febuxostat group): 35 patients will receive 80 mg/day febuxostat for 6 months.~* Group 2 (Control group): 35 patients will receive Vitamin E 400 mg twice daily for 6 months."||||
33996716|NCT05591729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|pilates exercise and postural correction group|f|f|t|t
34087433|NCT02950389|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34087434|NCT00498303|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34087435|NCT01683526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087436|NCT00390689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087437|NCT02373527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34087438|NCT00511719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087439|NCT01009567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087440|NCT05257616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant were blinded to the both treatment groups.|It include the control and experimental group.|t|f|f|f
34087441|NCT00420745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087442|NCT05240690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087443|NCT00052338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996717|NCT06562465|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Recruit at least 174 overweight and obese children from kindergartens with a population of 200 or more in Chongqing, and recruit them in the order of screening and informed consent until they are fully recruited. Divided into intervention group and blank control group based on kindergarten.||||
33996718|NCT04567303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part 1: Visual Acuity (VA) examiner; Part 2: Participant, Investigator, VA examiner and Sponsor; Part 3: Participant, Investigator, VA examiner and Sponsor|Part 1 of the study will be an open-label multiple ascending dose study, followed by subsequent assignment to 2 groups in Part 2. Part 3 will enroll new participants to compare the efficacy of zifibancimig PD implant versus ranibizumab released via the PD implant.|t|f|t|t
33996719|NCT06532513|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33996720|NCT03857828|||OTHER||PROSPECTIVE|||||||
33996721|NCT05546060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087444|NCT01586325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087445|NCT05145972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34087446|NCT02556749|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34087447|NCT02587936|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087448|NCT05686941|||COHORT||PROSPECTIVE|||||||
34087449|NCT01284543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087450|NCT00485823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087451|NCT02019355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692826|NCT04882501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|If you agree to participate in the study you will be randomized (assigned by chance) to a product group (product A or product B) and will receive either the active intervention or placebo. There is a 50% or 1 in 2 chance of you receiving either product A or product B upon your initial complaint of nausea when on the Surgical Unit. You will receive a one-time dose for your nausea using either product A or product B based on trial randomization.|Single blinded, parallel arm, placebo- controlled, randomized clinical trial.|t|f|f|f
33692827|NCT06127121|||COHORT||PROSPECTIVE|||||||
33692828|NCT05005520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded, placebo-controlled|Randomized, placebo-controlled, double-blinded, dose escalation to evaluate the safety, PK, and PD of a single dose of investigational drug or placebo|t|f|t|f
33692829|NCT02119091|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33692830|NCT03211273|||COHORT||PROSPECTIVE|||||||
34087452|NCT02661308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087453|NCT00218413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087454|NCT06412822|||CASE_CONTROL||PROSPECTIVE|||||||
34087455|NCT06156566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial is controlled with matching placebo. Unblinding after database lock.||t|t|t|t
34087456|NCT00829556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34087457|NCT05531253|||COHORT||PROSPECTIVE|||||||
34087458|NCT01899092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087459|NCT02270476|||COHORT||PROSPECTIVE|||||||
34087460|NCT03552406|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A. Part 1: Dose escalation~* Total 15 subjects: 3 subjects in each dose level~* 1mg/kg/day, 3mg/kg/day, 5mg/kg/day, 10mg/kg/day, 20mg/kg/day~B. Part 2: Dose expansion~* Group 1 (Mono-therapy: 20 mg/kg/day, Q3W): 6 subjects~* Group 2 (Combination therapy with cetuximab 400 mg/m2 followed by 250 mg/m2, Q1W): 12 subjects"||||
34087461|NCT00687700|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34087462|NCT01367691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087463|NCT02868944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087464|NCT01303484|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34087465|NCT02357459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087466|NCT03318562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087467|NCT02549118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087468|NCT03636633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34087469|NCT00753519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087470|NCT02369653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087471|NCT06516120|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087472|NCT06318585|||COHORT||PROSPECTIVE|||||||
34087473|NCT01566370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087474|NCT01787838|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34087475|NCT02646163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087476|NCT03328065|||CASE_ONLY||PROSPECTIVE|||||||
34087477|NCT05944432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087478|NCT01642368|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34087479|NCT00739232|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33692831|NCT06458426|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087480|NCT06040320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782093|NCT06362837|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a quasi-experimental design for the evaluation of an intervention that is in the community (including schools) as well as in the local health service facilities. The data collection at baseline, midline, and end-line will occur simultaneously in the intervention and comparison selected communities. Comparison communities will not be visited during midline. Participants are unique at each time point.||||
33692832|NCT04802174|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692833|NCT01706692|||COHORT||PROSPECTIVE|||||||
33692834|NCT03487549|NA|SEQUENTIAL||TREATMENT||NONE||This study has 2 cohorts. Cohort 1 of the study enrolled 21 subjects and has completed all subject related study activities. Analysis is to be conducted at Day 84. Cohort 2 will utilize 4 sites with an enrollment of approximately 35 subjects. The primary analysis will be conducted at Day 84 with an additional period of follow up out to Day 147.||||
33692835|NCT06543394|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|PIs and data analysts will be masked to group assignment when analyzing data to determine the effectiveness of the recruitment strategy.||f|f|t|t
33692836|NCT05979727|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33692837|NCT01468103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782094|NCT02286856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916427|NCT05674500|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33916428|NCT04834973|NA|SINGLE_GROUP||TREATMENT||NONE||Standard 3 + 3 Dose escalation study||||
33996722|NCT00606658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916429|NCT00423618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916430|NCT05217992|||FAMILY_BASED||PROSPECTIVE|||||||
33916431|NCT04389398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916432|NCT04858880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996723|NCT06030661|||COHORT||PROSPECTIVE|||||||
33996724|NCT03165669|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"The principal investigator will receive the results of outcome measures without any information of the group assignement.~The outcome assessors will be masked on the group assignment, because they will receive only the list of participants,without the group assignment."|"Two groups of patients will be randomized in two parallel arms. At Time zero, the first one will receive education, the second one cervical pillow. After 4 weeks, the 1st follow-up will be done (Time one), and after 4 weeks of wash-out, the 2nd follow-up will be done (Time two). At this moment, the group that received cervical pillow will receive education, and vice versa. After 4 weeks (Time three), the final follow-up will be done.~be done."|f|f|t|t
33996725|NCT05978791|||OTHER||PROSPECTIVE|||||||
33996726|NCT01370811|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33782095|NCT04437108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782096|NCT01471262|||CASE_CONTROL||RETROSPECTIVE|||||||
33916433|NCT00301028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916434|NCT02566252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916435|NCT00955292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916436|NCT06091189|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Participants will not be informed of their assigned experimental condition until the debriefing occurs. Investigators will be blind to participants assigned experimental condition.||t|f|t|f
33916437|NCT04674618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916438|NCT01180114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33916439|NCT02859493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34087481|NCT01658410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34087482|NCT00872547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782097|NCT02028975|NON_RANDOMIZED|PARALLEL||||NONE||||||
33916440|NCT00173693|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996727|NCT05779358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"Investigator and outcomes assessor know expectancy (E+ or E-) but is blinded to the actual gluten intervention (G+ or G-).~Participants are told the expectancy, but are unaware of the actual nature of the intervention: they are unaware that there is a 50% chance of receiving either G+ or G- bread, regardless of what they were told."||t|f|t|t
33916441|NCT06399731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Four consecutive phases: 1) a no-intervention baseline phase, 2) rTMS or tDCS, 3) a second no-intervention baseline phase, 4) the second NIBS intervention. All phases have a duration of 4 weeks and the order of the NIBS interventions is counterbalanced.||||
33996728|NCT00213122|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33996729|NCT04272437|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants were randomly assigned to take either TRA or placebo. Participants in the two groups orally ingested one package of granules (5 g/package) two times daily after lunch and dinner. The placebo was prepared as granules by Chuang Song Zong Pharmaceutical Co., Ltd, and the packaging of the placebo was identical to that of herbal extract granules. During the trial, neither the care providers(including family numbers and nursing-home colleagues) nor investigators ( assist doctors or nurses ) were aware of the group.|Participants were randomly assigned to receive intervention or placebo.|t|t|t|f
33996730|NCT05699538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled pilot study||||
33692838|NCT03486431|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 phase I trial design||||
33692839|NCT05826184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692840|NCT03449108|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692841|NCT06446258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916442|NCT06182813|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33916443|NCT02370017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916444|NCT03951688|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33916445|NCT05402436|||COHORT||OTHER|||||||
33916446|NCT01709136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916447|NCT01985633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916448|NCT06250517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692842|NCT02587039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692843|NCT05105022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692844|NCT02060799|||COHORT||PROSPECTIVE|||||||
33692845|NCT05981391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33692846|NCT02936102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916449|NCT00837005|||COHORT||PROSPECTIVE|||||||
33916450|NCT01364233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916451|NCT03713931|||OTHER||PROSPECTIVE|||||||
33916452|NCT00703833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916453|NCT01652755|||CASE_CONTROL||PROSPECTIVE|||||||
33916454|NCT02664532|RANDOMIZED|PARALLEL||||NONE||||||
33996731|NCT04323527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996732|NCT03218150|||COHORT||PROSPECTIVE|||||||
33996733|NCT03759704|||CASE_ONLY||PROSPECTIVE|||||||
33996734|NCT05545436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996735|NCT05416424|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33996736|NCT04779827|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33692847|NCT06582264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692848|NCT06273540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692849|NCT06710847|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692850|NCT03319225|||CASE_CONTROL||PROSPECTIVE|||||||
33782098|NCT03570749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916455|NCT05357326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Children are randomly allocated into three groups: 0.01% atropine, 0.04% atropine and orthokeratology, each group includes 62 children.|t|t|t|f
33916456|NCT01274741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916457|NCT00754728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916458|NCT00348582|RANDOMIZED|PARALLEL||||SINGLE||||||
33916459|NCT02547116|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916460|NCT02855450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916461|NCT01635634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916462|NCT05412472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916463|NCT04866303|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit delivery by community health educators vs. passive kit delivery via mail.|f|f|t|t
33916464|NCT03832920|||COHORT||PROSPECTIVE|||||||
33916465|NCT03956225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916466|NCT03279302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916467|NCT03868384|||COHORT||PROSPECTIVE|||||||
33916468|NCT01962155|||COHORT||PROSPECTIVE|||||||
33916469|NCT00681538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33916470|NCT03326830|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bi-center, open-label, parallel, randomized trial with 1:2 allocation ratio (2 patients assigned to standard oxygen therapy for 1 patient assigned to High Flow Nasal Oxygen therapy)||||
33916471|NCT06056349|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open label, randomnized, prospective clinical trial, with a 1:1:1 aleatorization of a single third level specialized neurological center.||||
33916472|NCT00707655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916473|NCT01165593|||COHORT||RETROSPECTIVE|||||||
33916474|NCT02230878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33916475|NCT00949416|||COHORT||PROSPECTIVE|||||||
33916476|NCT03831802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916477|NCT05166746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Moreover, an interim analysis will be performed by blinded outcomes assessors according to the primary outcome.||t|t|t|f
33916478|NCT01418053|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916479|NCT05641038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was designed as prospective, case-control and hospital-based.||||
33916480|NCT06270355|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33916481|NCT02476357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|unblinded|Monocentric, open, interventional, randomized with two arms 1:1|t|f|f|f
33916482|NCT01268423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33916483|NCT05363683|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33916484|NCT02035982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916485|NCT04347226|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will receive either BMS-986253 2400mg intravenous (IV) at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if continued severe respiratory disease) or standard of care treatment.||||
33996737|NCT01402050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996738|NCT02382224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996739|NCT02311894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996740|NCT01378962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996741|NCT06095596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996742|NCT06173050|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is an open label, prospective, randomized cross over (or single arm) study designed to support the development of new accessories for PAP devices.|t|f|f|f
33996743|NCT05604014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996744|NCT05206851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996745|NCT05207072|||COHORT||PROSPECTIVE|||||||
33996746|NCT00170677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996747|NCT02373462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996748|NCT04980170|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33996749|NCT03270774|||COHORT||PROSPECTIVE|||||||
33996750|NCT03167606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33996751|NCT01411462|||COHORT||PROSPECTIVE|||||||
33996752|NCT04175158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996753|NCT04207229|||COHORT||PROSPECTIVE|||||||
33996754|NCT05731687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded study. The patients are blinded for the allocated therapy|Patients will be randomized in a 1:1 ratio to either hybrid DEB approach or two-stent strategy|t|f|f|f
33996755|NCT03121898|||COHORT||PROSPECTIVE|||||||
33996756|NCT02225457|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33996757|NCT03415867|NA|SEQUENTIAL||TREATMENT||NONE||||||
33916486|NCT02289404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916487|NCT01755468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996758|NCT03580915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Approximately 10 participants will be randomly assigned to an intervention group; another 10 will be randomly assigned to a control group.||||
33996759|NCT05388071|||COHORT||PROSPECTIVE|||||||
33996760|NCT05717673|||COHORT||PROSPECTIVE|||||||
33996761|NCT00976443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996762|NCT00002253||||TREATMENT||DOUBLE||||||
33996763|NCT04026048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087483|NCT04961489|||COHORT||RETROSPECTIVE|||||||
34087484|NCT00527995|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33692851|NCT05622370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Test preparation A(T1): Brivaracetam sustained-release tablets (100mg/ tablet, developed by Taizhou Overseas Pharmaceuticals Co.,Ltd.) Test preparation B(T2): Brivaracetam sustained-release tablets (50mg/ tablet, developed by Taizhou Overseas Pharmaceuticals Co.,Ltd.) Reference preparation (R): Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB)||||
33692852|NCT03392324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692853|NCT03988543|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This trial design, in conjunction with our aims and measurement strategy, is consistent with a hybrid Type I effectiveness-implementation trial, which primarily tests the clinical effectiveness of an evidence-based intervention while secondarily documenting and evaluating its implementation. The randomized roll-out implementation trial design is in the same class as the commonly-used stepped wedge trial, but is more practical for real-world application due to lower measurement burden on clinics due to using incomplete wedges. To assess implementation at the level of the clinic, and control for patient-level outcome prior to implementation, we use a pragmatic randomized roll-out implementation trial design with an embedded patient-level randomized group-based comparison.||||
33692854|NCT06568484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An independent Endpoint Review Committee (ERC), masked to study arm, will adjudicate the incident TB endpoints (both primary and secondary) and, if there are any deaths, determine the cause of death as TB-related or not TB-related.|A Phase III, open-label, multicenter, noninferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a WHO-recommended regimen for preventing confirmed or probable tuberculosis disease (TBD) during 72 weeks of follow-up among people living with HIV (PHIV) and high-risk Close Contacts (CC) of adults with Drug-Susceptible (DS) or Rifampin-Resistant (RR) TB|f|f|f|t
33692855|NCT05127278|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33916488|NCT05868096|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33692856|NCT02399007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33692857|NCT05976438|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33692858|NCT03153410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692859|NCT04837092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692860|NCT02526836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692861|NCT02789878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692862|NCT02298985|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33692863|NCT06130527|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||Parallel Assignment Prospective Randomized, Placebo-Controlled Clinical Tria|t|t|t|t
33692864|NCT05499650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916489|NCT05738902|||COHORT||OTHER|||||||
33916490|NCT00281216|||COHORT||PROSPECTIVE|||||||
33916491|NCT00084929|NA|SINGLE_GROUP||SCREENING||NONE||||||
33916492|NCT01866878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916493|NCT02902913|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|All participants received all four interventions in a randomized, cross-over design in which both participant and caregiver were masked to the assignment (with the exception of the fourth intervention, ibuprofen, which was always administered at the final study visit).||t|f|t|f
33916494|NCT03932682|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial is designed as an observer-blind study. During the treatment period of the study designated and trained unblinded personnel will be responsible for administering the study vaccines to the subjects.||t|t|t|t
33916495|NCT00775502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916496|NCT01485419|||COHORT||PROSPECTIVE|||||||
33916497|NCT03326154|||COHORT||PROSPECTIVE|||||||
33916498|NCT04197544|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087485|NCT01470638|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087486|NCT06492915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692865|NCT06193577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-centre, prospective, randomized, placebo-controlled, single-blind clinical trial|t|f|f|f
33692866|NCT00717444|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33692867|NCT01551537|||COHORT||PROSPECTIVE|||||||
33996764|NCT02701101|NA|SINGLE_GROUP||OTHER||DOUBLE|"It was essential that both assessing teams' results were blinded to each other. Blinding between the Specialist and the Generalist teams was successfully upheld in this study. Data entry was structured in a manner restricting access based on roles and responsibilities defined in the study. The Study Investigators and Study Coordinators (gate-keeper) were also diligent about ensuring blinding between the two assessing teams. The Principal Investigator or designated Co-Investigator were unblinded to the results of each study subject at the time of eCRF approval or exit for that subject. Prior to interim analysis, BBI's management team were also restricted to access the study's database, and thus were blinded to daily results. This further assures that no bias is introduced by the study sponsor to data collection."|"Enrolled subjects were evaluated once daily throughout the observation period for a minimum of 6 days to a maximum of 21 days upon enrollment or earlier exit from the study. Daily assessments were performed at the sacrum and both heels unless anatomical location(s) were not assessable. As it was unethical to withhold standard of care preventive measures from the enrolled subjects, in addition to the daily data collection of those listed above, daily prevention/intervention measures data was also collected. Prevention/intervention measures implemented may allow the physiology of the tissue to return to normal when intervened upon early in the pressure ulcer development pathway. Daily assessments included: 1. Risk Assessment (standard of care; Braden, Waterlow, or Norton) 2. Skin Assessment (Standard of Care visual skin assessments utilizing tactile and visual cues; and, 3. SEM Scanner readings (test variable in this study)."|f|t|f|t
33996765|NCT01277835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996766|NCT01696305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33692868|NCT02594540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996767|NCT06624488|||COHORT||PROSPECTIVE|||||||
33996768|NCT01046097|||||PROSPECTIVE|||||||
33996769|NCT05323149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996770|NCT00154258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996771|NCT03715751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33996772|NCT05663255|||COHORT||RETROSPECTIVE|||||||
33996773|NCT02663921|NA|SINGLE_GROUP||OTHER||NONE||||||
33996774|NCT06065839|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33996775|NCT02177617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996776|NCT00433745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996777|NCT05137093|||OTHER||PROSPECTIVE|||||||
33996778|NCT06626672|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study uses a delayed start design with two arms. In Arm 1, participants receive the intervention immediately for 12 weeks. In Arm 2, participants initially do not receive the intervention but will start the same intervention after a 12-week delay to ensure fairness.||||
33996779|NCT02792790|||COHORT||PROSPECTIVE|||||||
33996780|NCT05837832|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33996781|NCT06627608|||COHORT||OTHER|||||||
33996782|NCT02294981|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33996783|NCT00756171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996784|NCT05714293|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33996785|NCT03086876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996786|NCT06118697|NA|SINGLE_GROUP||TREATMENT||NONE||Mechanistic study design||||
33996787|NCT00597922|||COHORT||PROSPECTIVE|||||||
33996788|NCT01654419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996789|NCT01085981|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33996790|NCT05791422|||OTHER||PROSPECTIVE|||||||
33996791|NCT03224663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996792|NCT02881541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996793|NCT01003938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996794|NCT04296123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996795|NCT06432985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind Masking|Parallel Assignment|t|f|t|f
33692869|NCT03978481|||COHORT||RETROSPECTIVE|||||||
33996796|NCT01150422|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33996797|NCT04046705|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692870|NCT03866187|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"Study will be conducted following a staggered design overseen by Internal Safety Review Committee (iSCR):~* Step A (low dose of each vaccine): Approximately 15 patients will be randomized (1:1:1). Fourteen days after the 2nd vaccination, iSRC will review all available safety data (of at least 12 patients if approved by local authorities). If considered appropriate to continue, Step B will start.~* Step B (prime-boost with ChAd155-hIi-HBV and Modified Vaccinia Ankara HBV vaccine (MVA-HBV) and sequential administration with HBc-HBs/AS01B-4): Approximately 40 patients will first be randomized (2:1:1) for vaccination. Fourteen days after the 2nd vaccination, iSRC will review all available safety data. If considered appropriate to continue, approximately 36 additional patients will be randomized for vaccination.~* Step C (prime-boost with ChAd155-hIi-HBV and MVA-HBV and co-administration with HBc-HBs/AS01B-4): Step C randomization (2:1) will start post completion of Step B enrolment."|t|f|f|f
33692871|NCT04649242|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33996798|NCT03012451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692872|NCT00807976|||||CROSS_SECTIONAL|||||||
33692873|NCT05446181|||CASE_CONTROL||PROSPECTIVE|||||||
33692874|NCT05130723|||COHORT||PROSPECTIVE|||||||
33782099|NCT00561574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996799|NCT01024855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996800|NCT02600247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996801|NCT06016582|NA|SINGLE_GROUP||OTHER||NONE||||||
33996802|NCT05387109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996803|NCT01165632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996804|NCT06196047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of ticagrelor and aspirin or cilostazol and aspirin by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 900 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor and aspirin, and Drug B included cilostazol and aspirin. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will conduct our randomized controlled trial, which will contain 2 arms; the ticagrelor arm (group A) will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day). The cilostazol arm will receive (a 200 mg loading dose during the first 24 hours of stroke onset, followed by 100mg twice daily from the 2nd day to the 90th day). All the patients in the two groups will receive aspirin at a loading dose of 75 to 300 mg, followed by 75 mg daily for 21 days.|f|f|t|t
33996805|NCT00614861|||COHORT||CROSS_SECTIONAL|||||||
33996806|NCT00218322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996807|NCT02095613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996808|NCT03067987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996809|NCT01665404|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33996810|NCT02697682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996811|NCT06229912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996812|NCT04171115|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|randomized, double-blind, placebo-controlled|dose escalation trial of four dose cohorts of 10 subjects (A: 10mg, B: 25mg, C: 50mg, D: 100 mg)|t|t|t|t
33692875|NCT06705946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692876|NCT06362759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692877|NCT06708039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The experimental group will receive the self-management and exercise programme, which will be delivered using mobile messaging application (WhatsApp), twice per week for five weeks. In addition, the experimental group will also continue their Elderly Day Care Centre routine activities. On the other hand, the control group will continue their Elderly Day Care Centre routine activities only.||||
33782100|NCT00471640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996813|NCT06174233|||COHORT||PROSPECTIVE|||||||
33996814|NCT06266741|||CASE_CONTROL||PROSPECTIVE|||||||
33996815|NCT02625298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33996816|NCT01139762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996817|NCT02588781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782101|NCT02316314|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33782102|NCT02353611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782103|NCT05793398|||CASE_CONTROL||PROSPECTIVE|||||||
33692878|NCT04109456|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The safety and tolerability of IN10018 monotherapy (Part 1) will be assessed firstly. Other dose levels may be explored if necessary.~and then the safety and tolerability of IN10018 in combination with Cobimetinib (Part 2) will be evaluated.~the safety and tolerability of IN10018 in combination with Cobimetinib and Atezolizumab (Part 3) will be evaluated ."||||
33996818|NCT06278090|||COHORT||PROSPECTIVE|||||||
33996819|NCT00330642|||COHORT||PROSPECTIVE|||||||
33692879|NCT05805488|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33692880|NCT04526327|NA|SINGLE_GROUP||TREATMENT||NONE||Female and male patients over 70 years of age followed-up from osteoporosis outpatient clinic||||
33692881|NCT05540106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized, four-armed prospective interventional study that will test the effect of nature-based coloring activities on patients' pain and anxiety scores during their ED visit. The study will consist of three intervention groups and one active control group.||||
33692882|NCT00847639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692883|NCT05165225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692884|NCT06325020|||COHORT||PROSPECTIVE|||||||
33692885|NCT04804020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692886|NCT04742387|||COHORT||RETROSPECTIVE|||||||
33782104|NCT02338622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782105|NCT00824785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782106|NCT01055782|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33782107|NCT04783935|NA|SINGLE_GROUP||OTHER||NONE||Open label, single arm, exploratory, multicenter, 2-year, Phase IV extension study.||||
33801449|NCT04797923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996820|NCT00003357||||TREATMENT||||||||
33692887|NCT02746367|||COHORT||PROSPECTIVE|||||||
33692888|NCT06707051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996821|NCT04015024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||The dose was initiated at 150 mg bid and after completion of the safety tolerance,200 mg bid was performed.300mg qd is safe and tolerant at phase 1 ,so the other participants were able to conduct the 300 mg qd test group when the safety tolerance.|f|f|f|t
33996822|NCT01101386|||CASE_ONLY||PROSPECTIVE|||||||
33996823|NCT02484807|||COHORT||PROSPECTIVE|||||||
33996824|NCT02452619|||COHORT||RETROSPECTIVE|||||||
33996825|NCT02099318|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|f|t
33996826|NCT04381871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692889|NCT01621412|||COHORT||CROSS_SECTIONAL|||||||
33692890|NCT04210323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33692891|NCT05045833|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Double-Blinded Investigational Drug (Active and Placebo)|Multiple Ascending Dose Escalation|t|t|t|f
33692892|NCT02759354|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33692893|NCT01845233|||CASE_ONLY||CROSS_SECTIONAL|||||||
33692894|NCT06021288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33692895|NCT01743950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692896|NCT01878617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692897|NCT05086744|NA|SINGLE_GROUP||TREATMENT||NONE||This is a basket study with different Cohorts.||||
33692898|NCT03489551|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33782108|NCT05004779|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|After laser treatment on hypertrophic scars, human stem cell media was applied to one side and physiological saline was applied to the other side.|After laser treatment on hypertrophic scars, human stem cell conditioned media was applied to one side and physiological saline was applied to the other side.|t|f|f|f
33782109|NCT00001538||||TREATMENT||||||||
33782110|NCT01409174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916499|NCT02860845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916500|NCT01333696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916501|NCT06082557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916502|NCT03213912|||CASE_ONLY||PROSPECTIVE|||||||
33916503|NCT00192439|||DEFINED_POPULATION||OTHER|||||||
33916504|NCT02929849|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33916505|NCT01977079|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916506|NCT05982223|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|Preference-based comparative effectiveness clinical trial||||
33916507|NCT01204255|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33916508|NCT02841319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996827|NCT01408654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33996828|NCT01758601|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996829|NCT02132910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996830|NCT02424435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996831|NCT01160549|||CASE_CONTROL||PROSPECTIVE|||||||
33996832|NCT03090022|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33996833|NCT04755335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996834|NCT04007835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087487|NCT05241951|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A parallel cluster-randomized controlled crossover trial design, with randomization occurring at the skilled nursing facility cluster level. The trial is conducted across four hospitals and 14 independent SNFs in Washington State. SNF's are stratified by patient volume before randomly assigned to either the PIT program or usual care.||||
33692899|NCT04941963|||COHORT||PROSPECTIVE|||||||
33692900|NCT05419908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692901|NCT04966741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692902|NCT06695650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single: The outcome assessor did not know which group they were assigned to.||f|f|f|t
33692903|NCT05993039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the operating room, in order to blind the surgeon to the type of anesthesia used, a surgical drape will be placed in between the subject and the anesthesia team to conceal the anesthesia machinery and equipment. A sham intravenous pole will be at the anesthesia workstation for those subjects in the control arm to contribute to the blinding of the surgeon. Patients will not be informed about which arm they are randomly assigned to and only the anesthesiologist will be aware prior to the surgery.|double-blinded randomized control|t|t|f|f
33692904|NCT04758910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will receive two treatments : high flow oxygen therapy and T-piece.||||
33692905|NCT06386393|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33916509|NCT02311309|||COHORT||PROSPECTIVE|||||||
33916510|NCT03677817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916511|NCT03768791|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33916512|NCT00798655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916513|NCT04402008|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1 will have two randomized, parallel dose groups comparing daily dosing and twice daily dosing at 3 dose levels.~Phase 2 will be a single dose group evaluating the safety and efficacy of the dose determined in Phase 1 in 2 Cohorts. Cohort 1: EGFR exon 20 insertion mutations and Cohort 2: HER2 exon 20 insertion mutations."||||
33916514|NCT04876703|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996835|NCT03994952|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087488|NCT04226157|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with hypertension who have had a stroke within the past 6 months will be randomized into two groups in a one to one ratio: Home Blood Pressure Self-Management (HBPS) or Usual Care.||||
34087489|NCT01189266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087490|NCT00219609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087491|NCT02305979|||COHORT||PROSPECTIVE|||||||
33692906|NCT01913132|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||2 study subgroups: 1) OPEN arm for open procedures 2) EVAR arm for endovascular aortic repair|f|t|f|f
33692907|NCT03775161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916515|NCT03978182|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|unblinding will be done after the first week, in this way subjects receiving sham will have the opportunity to receive active treatment in the second week|geriatric depressed patients after randomization at time T1 (on a Monday for MRI) will be divided into two groups to receive 20 sessions of real or sham adTMS treatment respectively. A given patient who first received active treatment will not receive sham, because of the carry-over effects; a patient who first received sham treatment now receives active adTMS in an open phase. This treatment will be spread over the four succeeding afternoons (5 daily sessions). In the second week, strictly the same treatment schedule will be followed but with the reverse order. A second brain imaging assessment will be performed exactly 1 week after the first week (time T2) and a third time scan exactly after 2 weeks (time T3).|t|t|f|t
33916516|NCT04179201|||COHORT||PROSPECTIVE|||||||
33916517|NCT01370057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916518|NCT01829802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916519|NCT01841957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916520|NCT02670460|NA|SINGLE_GROUP||||NONE||||||
33916521|NCT00000255|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33801450|NCT03091244|||COHORT||PROSPECTIVE|||||||
33916522|NCT03038243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916523|NCT01904240|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33916524|NCT01398072|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33916525|NCT01831180|||CASE_CONTROL||OTHER|||||||
33916526|NCT05316337|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33916527|NCT02349789|||COHORT||CROSS_SECTIONAL|||||||
33916528|NCT01147575|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33916529|NCT01757613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916530|NCT05350566|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|One box containing the product and one containing the placebo will be labeled A or B. The code will be kept in a sealed envelope which will be revealed only at the end of the study or in case of an adverse event.|The design is a placebo-controlled, double blind, cross-over two-arm study|t|t|t|t
33916531|NCT00980980|RANDOMIZED|||PREVENTION||||||||
33916532|NCT05636371|NA|SINGLE_GROUP||OTHER||NONE||||||
33916533|NCT00613418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916534|NCT05154266|RANDOMIZED|PARALLEL||OTHER||SINGLE|The experimenter was unaware of who was allocated to the treatment or control group during data collection and analysis. A researcher external to data collection and analysis was in charge of randomization.|Wait-list control|f|f|f|t
33916535|NCT03529383|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"Two interventions, each alone and in combination, are evaluated in parallel against a control group. Women assigned to the connected device arm will follow a 6-month exercise program using a connected device. Women assigned to the therapeutic education arm will follow a 6-month program of therapeutic patient education in physical activity. Women assigned to the combined arm will follow both programs. Women assigned to the control arm will receive international recommendations on physical activity."||||
33916536|NCT02999568|||CASE_CONTROL||PROSPECTIVE|||||||
33916537|NCT01757782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916538|NCT05838651|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Clinical Trial||||
33916539|NCT04243356|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33916540|NCT00426114|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33916541|NCT01303380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916542|NCT05653154|||OTHER||OTHER|||||||
33916543|NCT03461237|||COHORT||PROSPECTIVE|||||||
33916544|NCT01694550|||COHORT||PROSPECTIVE|||||||
33916545|NCT02991937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916546|NCT03032081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916547|NCT04482868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916548|NCT05582161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916549|NCT04465396|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916550|NCT03252314|||COHORT||PROSPECTIVE|||||||
33916551|NCT00923234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916552|NCT00881855|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916553|NCT04754165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors of the QOR15 recovery scale will be blinded to group assignment.|"Research participants will be randomized to one of two groups: immersive VR plus ERAS, or ERAS alone in a 1:1 allocation.~The first 6 patients enrolled will be assigned to the VR group for the purposes of a pilot phase with the objective of identifying and refining any issues with the intervention. Data for these patients will not be included in the statistical analysis."|f|f|f|t
33916554|NCT05524740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916555|NCT04482699|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33916556|NCT01414712|||CASE_ONLY||PROSPECTIVE|||||||
33692908|NCT05796557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and Outcome Assessors will be masked to the intervention, but the clinical team at the bedside will need to know the allocation to be able to prescribe platelet transfusion according to the randomized threshold.|Subjects will be randomized in a 1:1 ratio to either arm. Subjects will be stratified by type of extracorporeal membrane oxygenation (ECMO) support (Veno-Arterial vs Veno-Venous), by site, and by age (≤28 days vs \>28 days).|f|f|t|t
33692909|NCT03139097|||COHORT||PROSPECTIVE|||||||
33782111|NCT06453109|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The Sham condition will be conducted using an interface which does not allow ultrasound energy to pass from the transducer to the target. The administration of LIFU/sham will be conducted in a double-blind fashion.|within subject, randomized, double-blind, sham-controlled trial|t|f|t|f
33782112|NCT02929069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782113|NCT06566586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782114|NCT05113589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782115|NCT02065245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801451|NCT01294085|||CASE_ONLY||RETROSPECTIVE|||||||
33916557|NCT04543955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916558|NCT05405036|||COHORT||PROSPECTIVE|||||||
33916559|NCT01318772|||CASE_ONLY||PROSPECTIVE|||||||
33916560|NCT01804322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916561|NCT06460142|||CASE_CONTROL||PROSPECTIVE|||||||
33916562|NCT06020339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The sample of the study will consist of 80 pregnant women (40 Study Group: trained, 40 Control Group: not trained), who applied to the hospital between the dates of the study, who met the inclusion criteria and accepted to participate voluntarily in the study. The sample of the first 40 pregnant women to be included in the study (20 study-20 control) will be formed in the first 1st and 3rd month of the research, and the creation of the second sample of 40 pregnant women (20 study-20 control) will be done in the 12th and 13th months of the research.|This study is a randomized controlled longitudinal study. Within the framework of the prenatal continuous midwifery care model, pregnant women who will participate in four modules of training will form the study (education) group and those who do not will form the control group.|t|f|f|f
33916563|NCT05887947|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Phase 1 (P1): 2-visit human laboratory trial with double-blind, randomized crossover design. Phase 2 (P2): 6-week, randomized substitution trial. Participants in P2 will be the same participants that completed P1.|We will conduct a 2x2 crossover study and utilize linear mixed effects models to assess differences in total inhaled volume between 1.8% and 5% nicotine concentration globally and by race. This technique allows us to handle repeated measures that are inherently correlated.|t|t|t|f
33916564|NCT06290271|||CASE_CONTROL||OTHER|||||||
33916565|NCT05360420|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33916566|NCT03367065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916567|NCT01566643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916568|NCT04311177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916569|NCT05805670|NA|SINGLE_GROUP||OTHER||NONE||||||
33916570|NCT05675891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33916571|NCT05321485|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33916572|NCT02737735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916573|NCT03440255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916574|NCT01348425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916575|NCT02072720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916576|NCT01449552|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33916577|NCT03143868|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33916578|NCT05521217|||COHORT||CROSS_SECTIONAL|||||||
33916579|NCT00862316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916580|NCT06107322|||CASE_CONTROL||RETROSPECTIVE|||||||
33916581|NCT05942157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916582|NCT02671942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916583|NCT05491694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916584|NCT02791971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916585|NCT03580382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996836|NCT05846139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33996837|NCT00899951|||COHORT||PROSPECTIVE|||||||
33996838|NCT04470739|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996839|NCT03340545|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996840|NCT06212076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996841|NCT05710354|||OTHER||PROSPECTIVE|||||||
33996842|NCT02623218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996843|NCT00794794|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33996844|NCT01847235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996845|NCT05783089|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and 3+3 design dose escalation phase followed by dose expansion phase||||
33996846|NCT06020430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996847|NCT00503867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996848|NCT02664415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996849|NCT05031858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33996850|NCT04432753|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33996851|NCT01316536|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33996852|NCT01438060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996853|NCT06257199|||CASE_CONTROL||PROSPECTIVE|||||||
33996854|NCT00417677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996855|NCT03981731|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33996856|NCT03498560|||COHORT||PROSPECTIVE|||||||
33996857|NCT01717313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996858|NCT02452463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33996859|NCT03694106|||CASE_ONLY||PROSPECTIVE|||||||
33996860|NCT05947266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, quasi-experimental, single arm study||||
33916586|NCT03752606|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Allocation was communicated by telephone after informed consent had been obtained and after lymphadenectomy had been completed. Outcome assessment was performed by the independent reviewers. Outcome assessors were blinded to the treatment allocation.|A Tachosil® patch of 4.8x4.8 cm was attached to one side of the obturator fossa (study group) and the same patient constituted also control group, because no Tachosil® patch was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed. Patients had to agree to participate in the study and signed informed consent at least one day before surgery. Taking into consideration the examined group the patient was allocated to, the surgeon applied either one Tachosil® patches in the study group or no Tachosil® in the control group. After placing for 4 minutes, a uniform pressure was applied to it to provide rapid haemostasis by forming a strong, fibrin clot adjacent to the tissue surface. Tachosil was placed alternately once in the left, once in the right obturator fossa, so that each of the patients participating in the study could be their own control.|f|f|f|t
33916587|NCT04411212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916588|NCT03489135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916589|NCT02141802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916590|NCT03218982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Families will then be randomized (as a team) to either the active intervention or the control condition. Caregivers in the active intervention will then be scheduled for six weekly intervention sessions, lasting about 2 hours each. Following the completion of the sessions, primary caregivers will complete assessment measures (that they completed at baseline) immediately after the intervention (post) and at three months. This is expected to take one hour for each assessment. Primary caregivers assigned to the control condition will also complete these assessment measures around the same those in the active intervention complete them. These caregivers will also have the option of participating in the active intervention after the three-month follow up.||||
33916591|NCT00123916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916592|NCT01881971|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33916593|NCT05662306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916594|NCT04321824|||OTHER||PROSPECTIVE|||||||
33916595|NCT03097796|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33916596|NCT06134791|||OTHER||CROSS_SECTIONAL|||||||
33916597|NCT01980706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916598|NCT02911155|||COHORT||PROSPECTIVE|||||||
33916599|NCT03205826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916600|NCT02358369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916601|NCT00580944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916602|NCT06027931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33916603|NCT02740504|||CASE_ONLY||CROSS_SECTIONAL|||||||
33916604|NCT02456181|NA|SINGLE_GROUP||||NONE||||||
33916605|NCT00692510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33916606|NCT00621452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916607|NCT05658185|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916608|NCT06262893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916609|NCT05955209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916610|NCT05203276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916611|NCT01487096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916612|NCT00348842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916613|NCT01399528|||COHORT|||||||||
33916614|NCT04224896|||COHORT||PROSPECTIVE|||||||
33916615|NCT05630170|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||In the ECG repository of Yale New Haven Hospital, all patients undergoing a 12-lead screen in an outpatient setting, from whom 20 individuals, 10 each with high and low predicted probability of LVSD, will be invited for a limited echocardiogram to definitively evaluate for LVSD. The investigators will assess whether the AI-ECG model continues to have the reported discrimination and sensitivity of \>90% for LVSD diagnosis in a screening setting in outpatient routine clinical care.||||
33916616|NCT02581111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996861|NCT03095248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants with neurofibromatosis type 2 (NF2) will be stratified based upon tumor type. Vestibular schwannomas are assigned and analyzed as Stratum 1 and all other NF2 associated tumor types will be analyzed as Stratum 2. As of November, 2022 the stratum 1 arm has been closed.||||
33996862|NCT00399555|||COHORT||CROSS_SECTIONAL|||||||
33996863|NCT00503919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996864|NCT05245500|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33996865|NCT01936662|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33996866|NCT02674711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33996867|NCT00864396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996868|NCT05490095|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996869|NCT02267707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996870|NCT00402922|||COHORT||RETROSPECTIVE|||||||
33996871|NCT03574545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916617|NCT05683652|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33916618|NCT02033772|||CASE_ONLY||PROSPECTIVE|||||||
33996872|NCT03487939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996873|NCT04472039|||CASE_CONTROL||RETROSPECTIVE|||||||
33996874|NCT02994147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996875|NCT04888767|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Bicentric; prospective; opened ; randomized; controlled study~* Distribution of patients in groups according to a ratio (1:1)"||||
33996876|NCT05937126|||COHORT||PROSPECTIVE|||||||
33996877|NCT05231616|||COHORT||PROSPECTIVE|||||||
33996878|NCT00754858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996879|NCT03850158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996880|NCT01567553|||COHORT||PROSPECTIVE|||||||
34087492|NCT04005872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible consented participants will be randomly assigned to know which side of the participant (right or left) will be control or intervention group according to a sequence generated on a Microsoft Excel sheet where the intervention (I) and the control (C) are simply randomized.|This clinical trial has potential benefits to patients where indirect pulp treatment preserves pulp vitality by partial caries removal without exposing pulp. Several materials have been used for indirect pulp technique including calcium hydroxide|t|f|f|t
33692910|NCT05575141|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This is an open-label Randomized Controlled Trial (RCT) where the patient, surgeon, research coordinators and hospital staff will be aware of the treatment arm after randomization. As the open approach is performed using a large midline incision, whereas the robotic approach applies only 6 or 7 small incisions (or less if no posterior component separation is needed), blinding of patients and physicians is difficult.~Evaluation of the radiographic imaging of the abdominal wall at 24 months (MRI or CT scan) will be done by radiologists at the local participating center blinded to the randomized treatment arm. This will be a blinded evaluation for the presence or absence of hernia recurrence. Data analysis will be performed in a blinded manner by an independent statistician."|a multicenter international randomized controlled trial||||
33692911|NCT02367989|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33692912|NCT03892473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are 2 study arms- groups - both consisting of patients with SMI (severe mental illness). One group will be receiving care as usual, which in the actual setting means mostly medical treatment, without home care and assertive treatment through community based outreach teams. Another, intervention group, will be receiving assertive treatment care, with mobile assertive teams, consisting of at least three team members.||||
33692913|NCT03776487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692914|NCT06197347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33692915|NCT03798626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692916|NCT01224665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692917|NCT02296944|||COHORT||RETROSPECTIVE|||||||
33692918|NCT00414921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692919|NCT03813771|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, longitudinal cohort study with an embedded pilot randomised controlled trial. Patients with normal naive T-cell status will receive standard T2T care with methotrexate. Patients with abnormal naive T-cell status will be randomised 1:1 to T2T care vs. Benepali + T2T care with methotrexate||||
33692920|NCT05891561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692921|NCT05384275|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33692922|NCT04189835|||COHORT||PROSPECTIVE|||||||
33692923|NCT06707974|||COHORT||PROSPECTIVE|||||||
33692924|NCT06399198|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33692925|NCT04952753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782116|NCT06526728|NA|SINGLE_GROUP||TREATMENT||NONE||50 study participants will be treated with seven once-daily sessions of hyperbaric oxygen therapy following hamstring injury.||||
33782117|NCT04307979|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized double-blind crossover design.|t|f|t|t
33782118|NCT01743209|||COHORT||RETROSPECTIVE|||||||
33782119|NCT05362578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Half of subjects will be randomized to the sham arm, and half will be randomized to the treatment arm.||t|f|f|f
33782120|NCT06068738|||COHORT||PROSPECTIVE|||||||
33782121|NCT00350181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782122|NCT01876043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782123|NCT06319144|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33782124|NCT05488782|RANDOMIZED|CROSSOVER||OTHER||NONE||41 participants are assigned to receive TEAM, and 41 participants are assigned to wait list||||
33782125|NCT03193567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782126|NCT06239662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782127|NCT04795102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782128|NCT05092932|||COHORT||PROSPECTIVE|||||||
33782129|NCT03098264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692926|NCT06172465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The anesthetist who will perform the blocks will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another anesthetist blinded to the study.|two interventional group|t|t|f|t
33692927|NCT03724175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692928|NCT04924179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692929|NCT02653027|NA|SINGLE_GROUP||SCREENING||NONE||||||
33692930|NCT06707831|||OTHER||CROSS_SECTIONAL|||||||
33692931|NCT03929484|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33692932|NCT03224455|||OTHER||OTHER|||||||
33692933|NCT06202456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33692934|NCT02917473|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33692935|NCT06704464|||OTHER||CROSS_SECTIONAL|||||||
33692936|NCT04250714|||COHORT||PROSPECTIVE|||||||
33692937|NCT06707623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a parallel designed randomized controlled trial with an allocation ratio of 1 control to 1 rehabilitation patient.|f|f|f|t
33692938|NCT06707129|||COHORT||PROSPECTIVE|||||||
33782130|NCT05793099|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33782131|NCT03505645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916619|NCT01892618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916620|NCT01676402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916621|NCT02830035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916622|NCT00750555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916623|NCT03085147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open label, investigator initiated single arm phase I/II study. The concentration for imaging OSCC is defined in Phase I. Phase II will then use this concentration to obtain preliminary data on the sensivity of PARPi-FL to detect and delinate OSCC.||||
33782132|NCT04859556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and Care provider are not able to differentiate the two different cutters since the port size are the exact same for both.||t|t|f|f
33782133|NCT05419492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Part 1 is open-label with no blinding.~Part 2 will be conducted in a double-blinded manner whereby all Primary Site Staff (including clinicians, research coordinators, neuropsychologists, pharmacists, and physical therapists), study participants and caregivers, Sponsor and Sponsor-designees will be blinded through the end of Week 52 following Day 1 for each participant. The Surgical Site Staff will be unblinded to treatment assignment."||t|t|t|t
33692939|NCT04115644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782134|NCT00438971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916624|NCT06046716|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomised control waitlist n=28 active experimental group and n=24 waitlist control delayed group||||
33692940|NCT03547986|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The existing and new diagnostic method are performed on the same patients (paired data)||||
33692941|NCT05964335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692942|NCT01753804|||CASE_ONLY||PROSPECTIVE|||||||
33692943|NCT05112991|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study is an open-label, two-arm study, without randomization and blinding||||
33692944|NCT03490968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782135|NCT04488653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996881|NCT06009796|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fifty eight patients were divided into 4 groups: FCRPE group (n: 15, 15.6 ± 1,1 years of age), MMRPE group (n:14, 15.3 ± 0,9 years of age), MARPE group (n:14, 15.7 ± 1,1 years of age), Control group (n:15, 15.4 ± 1,0 years of age). Polygraphy for respiratory evaluation, rhinomanometry for nasal airway resistance, study model and posteroanterior radiographs (PA) to measure dentoalveolar and dentoskeletal effects were used. Respiratory polygraphy, rhinomanometry, study model, and posteroanterior radiographs were obtained prior to treatment and after 3 months of expansion. Paired t tests and independent-sample t tests were used to compare the expansion appliances.||||
33996882|NCT01087502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33996883|NCT05191862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996884|NCT00829894|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33996885|NCT05132426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will not be told whether they are enrolled in the OMT intervention group or the OMT Sham Group (placebo group). Investigators will be blinded to which participants are in each group and will collect data using only subject numbers provided on labels. Outcomes assessors will analyze data with coded patient data.|This is a randomized clinical trial in which there will be a sham OMT control group and an OMT intervention group with a parallel group design.|t|f|t|t
33996886|NCT06272877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Investigator and the outcomes assesor will be different persons. Statician will be different person.|Randomised controlled|f|f|t|t
33996887|NCT04435782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996888|NCT02840669||FACTORIAL||DIAGNOSTIC||NONE||||||
33996889|NCT02228486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996890|NCT03583398|||COHORT||PROSPECTIVE|||||||
33996891|NCT00471510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996892|NCT06513052|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33996893|NCT04164706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Everyone will be blinded except for one member of the theatre staff who will operate the HumiGard, and the research team member who performs the randomisation process.|Feasibility study - 40 patients to be randomised 1:1 to two groups - 50% receiving HumiGard and 50% receiving standard care alone|t|t|t|t
33996894|NCT02970188|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33996895|NCT06031844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916625|NCT01070602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996896|NCT06276153|||COHORT||RETROSPECTIVE|||||||
33996897|NCT04307680|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33996898|NCT06555640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996899|NCT02236858|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33996900|NCT05532631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor: The individual who evaluates the outcome(s) of interest|Prospective Randomized Open label, Blinded Endpoint, parallelgroup, active controlled, non-inferiority, multicenter trial|f|f|f|t
33996901|NCT04257838|||CASE_ONLY||PROSPECTIVE|||||||
33996902|NCT03331458|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34087493|NCT02637596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087494|NCT05242211|NA|SINGLE_GROUP||OTHER||NONE||Healthy volunteers (normal and overweight ) will be recruited to participants in the study. Demographics (age, sex), anthropometric (height, weight, abdominal circumference), will be measured. By using questionnaire, physical activity behavior and motivation toward engage in physical activity will be filled by the participants. Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.||||
34087495|NCT00758992|||CASE_ONLY||PROSPECTIVE|||||||
34087496|NCT02408341|||CASE_ONLY||PROSPECTIVE|||||||
34087497|NCT02715453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916626|NCT02786758|||COHORT||PROSPECTIVE|||||||
33692945|NCT00443612|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33692946|NCT02445443|||CASE_ONLY||PROSPECTIVE|||||||
33692947|NCT01218282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782136|NCT00789061|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33782137|NCT04036240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782138|NCT05870930|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33782139|NCT06497985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782140|NCT06697444|||CASE_ONLY||CROSS_SECTIONAL|||||||
33782141|NCT06668207|||CASE_ONLY||CROSS_SECTIONAL|||||||
33916627|NCT02603913|||COHORT||PROSPECTIVE|||||||
33916628|NCT04627142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Trial consists of three parts: Monotherapy safety run-in part (Part A), combination dose escalation part (Part B), combination therapy expansion part (Part C). A randomization will be included for the expansion therapy part (Part C) because the same patient population will be recruited to two different dose levels at the same time.||||
33916629|NCT02156960|NA|CROSSOVER||TREATMENT||NONE||||||
33916630|NCT06179030|||COHORT||PROSPECTIVE|||||||
33916631|NCT01604057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916632|NCT00413062|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916633|NCT05430711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916634|NCT05679973|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33916635|NCT04964492|||CASE_ONLY||RETROSPECTIVE|||||||
33916636|NCT04793386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916637|NCT04214730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916638|NCT06320938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33996903|NCT03101358|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1/2, open-label, dose-rising trial of three concentrations of SOR007 (0.15%, 1.0%, 2.0%).~During the dose escalation phase, the study will follow a standard 3+3 dose-ascending design. If a single dose limiting toxicity (DLT) is identified in one of three subjects in the cohort, a further three subjects will be enrolled at the same dose level. If one or more DLT occur in the three additional subjects enrolled in the cohort, dose escalation will stop and the prior dose level will be regarded as the Maximum Tolerated Dose (MTD) and taken forward into the dose expansion phase. If no further DLT are identified, dose escalation will continue, until either a DLT is identified at a higher dose or the top dose of 2% is reached.~In the dose expansion phase, additional subjects will be enrolled up to a maximum of 12 subjects at the dose determined to be the MTD (or the top dose, 2.0% SOR007)."||||
33692948|NCT06002685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"2 tasks will be coded by research assistants masked to assigned intervention condition.~Child Stress Regulation: Using video-recorded data collected at Times 1 and 2, blinded coders will rate the child's emotion regulation strategies in the context of mild stressors. Coders will use the Laboratory Temperament Assessment Battery (Lab-TAB) to rate the presence/absence of the following behaviors every 5 seconds: looks to mother, communicative gestures, looks to environment; and self-stimulation. In keeping with our own and others' previous data reduction in this domain, we will compute two proportion-score composites for mother-oriented regulation and self-soothing regulation. Coders will rate children's emotional re-activity every 5 seconds to analyze emotional reactivity as a covariate.~Sensitive Parenting Behaviors: At Times 1 and 2, blinded coders will collect observational assessments of sensitive parenting behaviors in 3 contexts: (a) play, (b) child distress, and (c) feeding."|A 2-group, pre-and post-test experimental design (N = 260; 130 in each group) will be employed. All eligible mother-child dyads will be randomly assigned to receive the intervention, Attachment Biobehavioral Catch- up (ABC),or the control, Home-Book-of-the- Week (HBOW). Assessments will take place in the participant's home and on the phone.|f|f|f|t
33692949|NCT01354067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33692950|NCT05621915|||CASE_CONTROL||PROSPECTIVE|||||||
33692951|NCT05116085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692952|NCT04237012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692953|NCT06424483|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized waitlist control group||||
33692954|NCT04592250|||COHORT||PROSPECTIVE|||||||
33692955|NCT01554228|||COHORT||PROSPECTIVE|||||||
33692956|NCT03599635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33692957|NCT06403631|||COHORT||PROSPECTIVE|||||||
33692958|NCT02610569|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33692959|NCT04328675|||CASE_ONLY||PROSPECTIVE|||||||
33692960|NCT06608368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33996904|NCT00001698||||TREATMENT||||||||
33996905|NCT04608448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed by the compounding pharmacy. Ointment dispensers will be color-coded for left and right arm for each subject.|Participants will be their own control, either right or left arm will be randomized to treatment or placebo.|t|f|t|f
33996906|NCT05543720|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Propensity-score matched controls||||
33692961|NCT00557401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692962|NCT06025747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692963|NCT04926454|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33692964|NCT06709248|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33782142|NCT05379686|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Two-arm open-label intervention study.||||
33782143|NCT04344990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782144|NCT01649726|RANDOMIZED|PARALLEL||||NONE||||||
33801452|NCT05048680|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind (participant and research team) study in relation to the gas being delivered (normoxic or hypoxic mixture) during intervention.||t|t|t|t
33801453|NCT05862246|||COHORT||PROSPECTIVE|||||||
33916639|NCT05464862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is an assessor- and volunteer-blinded randomized study. As different volumes are used for the nerve blocks, the anesthesiologist and an assistant performing the nerve blocks will not be blinded, and therefore have no further contact with the volunteers after the nerve block performance and will not contribute with the data collection or statistical analysis. The nerve block procedure and assessments will take place in different rooms; hence the data collecting assessors will not be present during block performance.To ensure blinding of the volunteer, a draping will hinder the volunteer from observing which volume of lidocaine that is administered during block performance.Group A, B and C are blinded until the data analysis is finished. Group FNB of SNB are unblinded and works as active comparatives for model control, in order to establish reference points for when a nerve is considered affected.|"A randomization list is computed by the REDCap administrator from Aarhus University and imported in REDCap.The anesthesiologist and the assistant performing all the nerve blocks, are the only one with access to REDCaps randomization module, where the randomization procedure is made prior to the nerve block procedure.~The randomization list will assign each volunteer to one of six combinations, deciding which type of peripheral nerve block is used for each their leg. One leg equal one observation. The combinations ensure that observations are obtained in even numbers from right and left legs and that the total dose of perineural used lidocaine does not exceed 400 mg per volunteer.~Groups name, type of peripheral nerve block, study medication dosage and number of legs in the group."|t|f|t|t
33996907|NCT02741895|||COHORT||PROSPECTIVE|||||||
33996908|NCT04533620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996909|NCT03453840|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective multi-site study accomplished through a randomized design where children will be randomized to either 3-day or 5-day AL regimen and then for subsequent episodes of malaria, should they occur..||||
33801454|NCT03419299|||OTHER||RETROSPECTIVE|||||||
33916640|NCT05798689|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33916641|NCT05311605|||COHORT||PROSPECTIVE|||||||
33916642|NCT05851586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33916643|NCT06534814|||COHORT||PROSPECTIVE|||||||
33916644|NCT04237402||SEQUENTIAL||BASIC_SCIENCE||NONE||"2 sampling timepoints:~* before delivery~* after delivery"||||
33916645|NCT02752568|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33996910|NCT03612154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692965|NCT03843112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigator, care providers and outcome assessors are all blinded until the end of inclusion af the last subject.|Randomised placebo controlled, double blinded study|t|t|t|t
33692966|NCT02699216|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33996911|NCT05913245|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33996912|NCT00981838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692967|NCT03358537|RANDOMIZED|PARALLEL||OTHER||SINGLE|This was a randomized, endoscopists' blinded comparison of bowel cleanising, tolerability and quality indicators for colonoscopy|A total of 215 subjects were randomly assigned for this study, 105 in the clear liquid diet and 100 in the low residue-diet, 5 subjects were excluded in each group|f|t|f|f
33996913|NCT05579405|||COHORT||PROSPECTIVE|||||||
33692968|NCT00625066|||COHORT||PROSPECTIVE|||||||
33692969|NCT04766827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A prospective randomized controlled clinical trail|t|t|f|t
33782145|NCT06569953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomization was performed in a 1:1 ratio with the use of block randomization.SAS software (version 9.4 or higher) was used to generate the random number and the treatment group to which the random number was assigned.Assignment of Randomization Numbers Using the Interactive Web Response System (IWRS).|t|t|t|t
33996914|NCT04682327|||CASE_CONTROL||PROSPECTIVE|||||||
33782146|NCT06224075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782147|NCT05182437|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial Observational Model : Experimental Time Perspective : Prospective||||
33782148|NCT03880656|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-stage, randomized, unblinded, multicenter (two sites), controlled phase 1 clinical trial.||||
33782149|NCT04559932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782150|NCT00907686|||COHORT||PROSPECTIVE|||||||
33782151|NCT06494774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782152|NCT04660435|||COHORT||PROSPECTIVE|||||||
33782153|NCT04348838|||COHORT||PROSPECTIVE|||||||
33782154|NCT05282459|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33782155|NCT03924245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782156|NCT06268210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782157|NCT02098031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782158|NCT05192512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782159|NCT03569813|RANDOMIZED|PARALLEL||PREVENTION||NONE||This trial will include 396 participants with 2:1 allocation for the intervention (264) and control (132) conditions. The sample of 396 will target inclusion of 50% Black and 50% younger (aged 18-34) participants.||||
33782160|NCT02814760|||||PROSPECTIVE|||||||
33782161|NCT00198874|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33782162|NCT02651558|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782163|NCT05697965|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33782164|NCT00508443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996915|NCT04833205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996916|NCT03864094|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 04Vaso). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.|Randomized, controlled, double-blind.|t|t|t|t
33996917|NCT05174390|||COHORT||PROSPECTIVE|||||||
33996918|NCT00000950||||TREATMENT||||||||
33996919|NCT00192257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996920|NCT02940457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996921|NCT03895879|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|During every study visit the joints of all patients will be examined for pain and swelling by a blinded nurse or physician. The number of painful and swollen joints will be used to calculate the DAS28 score, the primary outcome of the study.|Patients with tocilizumab trough concentrations above 15 mg/L will be randomly assigned to dose reduction by increasing their dosing interval from once every week to once every two weeks, or to continuation of the standard dose. All patients with concentrations below 15 mg/L during the first study visit will not be randomized and all continue standard treatment.|f|f|f|t
33782165|NCT03969329|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will remain on treatment for 26 weeks from day 1 or until the time of renal transplant or parathyroidectomy, whichever occurs first. Subjects will receive a starting dose of etelcalcetide 0.07 mg/kg or 5 mg, whichever is lower, 3 times a week (TIW) intravenously. The dose of etelcalcetide will be titrated every 4 weeks (weeks 5, 9, 13, and 17) based on intact parathyroid hormone (iPTH), calcium, and safety to a maximum dose of 0.21 mg/kg or 15 mg, whichever is lower. The lowest protocol specified dose (PSD) for this study is 0.035 mg/kg or 2.5 mg, whichever is lower.||||
33801455|NCT01035034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801456|NCT01251224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996922|NCT01124786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996923|NCT01360580|||COHORT||PROSPECTIVE|||||||
33996924|NCT05496192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996925|NCT05748626|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled interventional trial||||
33996926|NCT06288217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087498|NCT00677638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087499|NCT01772862|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087500|NCT00672802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34087501|NCT03680027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087502|NCT03997877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087503|NCT00379405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087504|NCT00742937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087505|NCT01278368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087506|NCT03839641|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34087507|NCT02935270|||OTHER||CROSS_SECTIONAL|||||||
33692970|NCT03001388|||COHORT||PROSPECTIVE|||||||
33692971|NCT02156531|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33692972|NCT06449222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996927|NCT04509154|RANDOMIZED|PARALLEL||OTHER||TRIPLE|In this study, a distribution by blocks of size four was used, in which the only criterion for stratification was the reference Health Center of the patient in question. Therefore, in order to randomize a patient, the existing button on the recruitment form for this study, hosted on the REDCap platform of the Maimonides Institute for Biomedical Research in Córdoba, was clicked. (IMIBIC). The data was transferred to the electronic notebook: the Data Entry Manager. The statistician, principal investigator, and study collaborators who evaluated the respondents were not involved in patient recruitment and were blinded to group allocation. Recruiters were not blinded to be available throughout the study to ask and answer participants' treatment questions.|"The design is based on a parallel group controlled randomized clinical trial experimental study (Kristjánsdóttir et al., 2011). Block randomization is used to ensure similar numbers in each group and by phase."|t|f|t|t
33782166|NCT03418779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, and all other members with clinical involvement in the trial will be blinded to the treatment assignment for the duration of the trial. Relevant personnel have clear divisions of labor and strict permission restrictions. The blinding will be removed only if a participant has severe side effects that the affected participant will be withdrawn.||t|f|t|t
33996928|NCT00660660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33996929|NCT01446770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996930|NCT00264134|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996931|NCT03591276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087508|NCT05125445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087509|NCT02633774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087510|NCT04834596|||CASE_ONLY||RETROSPECTIVE|||||||
34087511|NCT02425085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087512|NCT02442141|||COHORT||PROSPECTIVE|||||||
33996932|NCT00748722|||CASE_ONLY||PROSPECTIVE|||||||
34087513|NCT02138383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087514|NCT01937299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33692973|NCT05957055|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|ADHD symptoms assessment will be performed with teleconsultation with outcomes assessor blinded for patient's allocation. Patients and their parents/legal guardians will be asked to not share the information with the assessor.|Interventional, open, randomized (block randomization stratified by center), assessor masked, cross-over|f|f|f|t
33692974|NCT01762046|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33692975|NCT03284437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessor is not participating in patient enrollment or administration of study intervention and will not be aware of study group assignment.|Randomized controlled trial|f|f|f|t
33692976|NCT02147002|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33692977|NCT02075970|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33692978|NCT04545359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All the persons who may interact with the participants and/or implied in the analyses.|"There are two groups : one receives the real neurofeedback task and the second receives a sham neurofeedback.~This study is double-blind randomized."|t|f|t|t
33692979|NCT05881278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692980|NCT03611010|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33692981|NCT03686488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692982|NCT06643611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33692983|NCT06319352|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
33692984|NCT02948283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692985|NCT06575309|||COHORT||PROSPECTIVE|||||||
33692986|NCT04284267|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Masking will be implemented using a active-placebo TMS coil.|There will be a healthy control group and a bipolar disorder group. The bipolar disorder group will then be randomized to one of three conditions.|t|f|f|f
33782167|NCT01650337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33782168|NCT01065415|||CASE_CONTROL||PROSPECTIVE|||||||
33782169|NCT06629766|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Statistician||t|t|t|t
33782170|NCT01929993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782171|NCT04706247|||CASE_ONLY||PROSPECTIVE|||||||
33782172|NCT06498453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782173|NCT05652608|||COHORT||PROSPECTIVE|||||||
33996933|NCT03371186|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge, cluster-controlled implementation science trial||||
33996934|NCT05267444|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33996935|NCT03285438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The trial is designed as an academic, multicenter, open, with blind evaluation (PROBE), randomized, parallel arm, controlled.|f|f|f|t
33996936|NCT00533507|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33996937|NCT05086653|||CASE_ONLY||RETROSPECTIVE|||||||
33996938|NCT04352205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996939|NCT06094764|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33996940|NCT05397444|||COHORT||PROSPECTIVE|||||||
33996941|NCT00191490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996942|NCT00122239|||CASE_ONLY||RETROSPECTIVE|||||||
33996943|NCT04007939|||COHORT||CROSS_SECTIONAL|||||||
33996944|NCT04865120|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Randomized double-blind mini-zones on volunteers back|t|t|t|t
33996945|NCT05293106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692987|NCT04796337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692988|NCT01906385|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1:~• Single arm, prospective study utilizing a modified Fibonacci dose escalation scheme.~Phase 2:~• Single arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume)."||||
33996946|NCT05886803|||CASE_CONTROL||RETROSPECTIVE|||||||
33996947|NCT04303208|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33996948|NCT06562270|||COHORT||PROSPECTIVE|||||||
33996949|NCT01190800|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33692989|NCT02819518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33692990|NCT02073708|||CASE_CONTROL||PROSPECTIVE|||||||
33692991|NCT05408975|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants, assessors, and technicians interacting with participants will be blind to assigned conditions.|"Participants will be randomly assigned to 1 of 2 treatment arms: (1) 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to presupplementary motor area for 20 minutes over 10 sessions to (2) sham tDCS following the same schedule.~Additionally, after completing the initial active or sham treatment and 2-month follow-up testing sessions, all participants will be invited back for newly assigned treatment conditions, 20 minutes over 10 sessions and will be and re-evaluated at 2-months follow-up testing sessions."|t|t|f|t
33692992|NCT06051448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33692993|NCT03711227|||COHORT||PROSPECTIVE|||||||
33692994|NCT03812432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33692995|NCT04751396|||COHORT||PROSPECTIVE|||||||
33692996|NCT06000111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon will be masked to the patient's treatment allocation until after surgery is complete. At this point, the surgeon will be made aware of the patient's treatment allocation and inform the patient in the recovery room regarding their treatment allocation. The participants and the clinical teams managing the patient care will be unmasked. The outcome assessors will be masked.|This study will be a single-centered, parallel group randomized controlled feasibility trial. Patients will be randomized 1:1 between groups.|f|f|f|t
33692997|NCT05465746|||COHORT||PROSPECTIVE|||||||
33692998|NCT04834752|||COHORT||RETROSPECTIVE|||||||
33692999|NCT06166602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigator is not masked as different volumes are applied.||t|f|f|t
33693000|NCT04082832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo controlled|ANCOVA will be used to compare efficacy endpoints between CuATSM and placebo groups|t|t|t|t
33693001|NCT03598309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33693002|NCT03248843|NA|SINGLE_GROUP||TREATMENT||NONE||Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg of KN035 weekly.||||
33693003|NCT06689800|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33693004|NCT05487014|||CASE_CONTROL||PROSPECTIVE|||||||
33693005|NCT04743505|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693006|NCT04110067|||OTHER||CROSS_SECTIONAL|||||||
33693007|NCT05650528|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33693008|NCT03267732|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33693009|NCT05591846|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33693010|NCT06223737|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33693011|NCT06543355|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Acupuncture||||
33693012|NCT06708377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693013|NCT03422627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693014|NCT06424327|||COHORT||PROSPECTIVE|||||||
33693015|NCT05814497|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33693016|NCT06408259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693017|NCT03046173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693018|NCT00889174|||COHORT||OTHER|||||||
33693019|NCT06347016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782174|NCT04017884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (participant,investigator,outcomes assessor)||t|f|t|t
33996950|NCT04899934|RANDOMIZED|PARALLEL||OTHER||NONE||A total of 24 adults releasing to one of the three participating counties in Florida will be randomly assigned to participate in the mobile and technology assisted aftercare or a treatment-as-usual (TAU) control group. Participants assigned to the treatment-as-usual control group will remain eligible to participate in all agency specific services offered to persons discharging the CSU as well as, any community resources they normally would have access to.||||
33693020|NCT04585373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693021|NCT03953898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693022|NCT06491550|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33693023|NCT05922046|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693024|NCT01158664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693025|NCT05632354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693026|NCT02414672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693027|NCT03624400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33693028|NCT06515041|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33693029|NCT01775462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693030|NCT03187951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693031|NCT00974766|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693032|NCT06430346|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693033|NCT00028275||||TREATMENT||||||||
33996951|NCT02589366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996952|NCT02616380|||CASE_CONTROL||PROSPECTIVE|||||||
33996953|NCT06119685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without daratumumab or rituximab.||||
33996954|NCT04646603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-Blind Randomized Placebo-Controlled Trial|t|f|t|f
33996955|NCT03555695|NA|SINGLE_GROUP||PREVENTION||NONE||This is a non-randomized, open-label, non-blinded, 10-week pilot study of a novel intervention, namely, non-contact karate, for early to middle stage PD.||||
33693034|NCT04974047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693035|NCT06428045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation/de-escalation and dose expansion design.||||
33693036|NCT05039853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded to whether the activity they are assigned to is the experimental intervention or the placebo activity.||t|f|f|f
33693037|NCT06707753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693038|NCT04091750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693039|NCT02745210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693040|NCT05887648|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomised into 2 groups - SinDance (interventional group) or control group. A computerised randomisation programme will generate the randomization list and a person independent from the study will prepare the sealed envelopes according to the generated randomisation list. After a participant is registered, a unique participant enrolment ID will be assigned to the participant. The envelope according to the enrolment ID will be opened on site and the participant will be allocated into either one of the two groups based on the randomisation list the group indicated.||||
33693041|NCT03708627|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will evaluate clinical photos. Other measures such as Hertel's exophthalmometry values are objective outcomes which will be made available to the Principal Investigator||f|f|f|t
33693042|NCT02750943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33693043|NCT03334708|||CASE_CONTROL||PROSPECTIVE|||||||
33693044|NCT02788474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693045|NCT02188342|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693046|NCT00021671||||PREVENTION||DOUBLE||||||
33693047|NCT00796146|||COHORT||PROSPECTIVE|||||||
33693048|NCT04597164|||COHORT||PROSPECTIVE|||||||
33693049|NCT05235139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind masking; Patient will not be informed which IOL model was implanted until end of the study. Outcomes assessors will not be informed which IOL model was implanted until end of the study.||t|f|f|t
33782175|NCT02380274|||COHORT||PROSPECTIVE|||||||
33782176|NCT05287932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to group allocation, and participants will be asked to not disclose their allocation|Pilot randomised controlled trial|f|f|f|t
33782177|NCT05418010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blind, placebo-controlled efficacy trial of hyperacute disease modifying treatment using Tysabri® in people with a first manifestation of central nervous system inflammatory demyelination.|t|t|t|t
33801457|NCT05358457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will be blind to the group that ows the patients included|Parrallel Assigment. This is a randomized clinical trial in which some patients receive the MCTf intervention and others treatment as usual|f|f|f|t
33996956|NCT06468839|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33996957|NCT01632215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33996958|NCT03908736|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a one-armed cohort intervention of zinc supplementation. Data will be collected for each participant before and after zinc supplementation.||||
33996959|NCT02970123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33996960|NCT02524691|||COHORT||PROSPECTIVE|||||||
33996961|NCT03102385|RANDOMIZED|PARALLEL||OTHER||SINGLE|All participants were informed that they would complete an on-line interview regarding blood donation. They were not be told which of the two interviews they were completing.|Participants will be randomly assigned to either (1) complete an on-line motivational interview about their blood donation experience, or (2) complete an on-line knowledge interview about blood donation.|t|f|f|f
33996962|NCT05691153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996963|NCT00757419|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33996964|NCT01080053|||COHORT||PROSPECTIVE|||||||
33996965|NCT03151954|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33996966|NCT01709903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996967|NCT05561166|||COHORT||PROSPECTIVE|||||||
33801458|NCT02376244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801459|NCT02262975|||CASE_ONLY||PROSPECTIVE|||||||
33996968|NCT00174980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33996969|NCT04044573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33996970|NCT06363617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33996971|NCT05345249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"After obtaining informed consent, the coordinating researcher creates a study case.~Patients will be randomly allocated in a 1:1 ratio to either the study group (ESPB) or the control group (placebo) by the hospital's pharmacist on the day of surgery. Permuted block randomization with varying permuted block sizes will be used. This block randomization list will be created by Sealed EnvelopeTM and managed by the hospital's pharmacist. Only the hospital's pharmacist will have access to the randomization list. The staff involved (doctors, nurses, operation room personal), as well as the research team and the patient will be blinded for treatment allocation.~The hospital's pharmacist prepares the medication on the morning of surgery, delivers it at the operation complex and collects empty syringes after injection in terms of drug accountability."|"Patients scheduled for elective lumbar spinal fusion surgery will be studied. Subject of investigation is the locoregional anesthetic technique ESPB. Subjects will be randomized to receive either ESPB with a long-acting local anesthetic or normal saline (placebo). The staff involved (doctors, nurses, OR-personal), as well as the research team and the patient will be blinded for treatment allocation. The study period includes in-hospital time after surgery and follow-up 30 days after surgery. Placement of the ESPB will be performed according to the study protocol, at the end of surgery, after wound closure. The placement of the ESPB is performed according to daily clinical practice as described by Forero et al.~Postoperative treatment of patients will be according to standard hospital protocol for lumbar spinal fusion surgery."|t|t|t|t
33996972|NCT05541198|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33996973|NCT02589093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33996974|NCT05224713|||COHORT||RETROSPECTIVE|||||||
33693050|NCT03913546|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will receive either a sham procedure or the actual intervention. The researchers in charge of outcome assessment and statistical analysis will be blinded to the allocation of participants.|Randomized, parallel, pre-post study design.|t|f|t|t
33782178|NCT04903002|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a triple-blind study. In order to protect against expectation effects and biases, neither site investigators nor patients will know which nasal spray contains oxytocin or which sequence of conditions patients are assigned. The allocation sequence will be concealed from researchers using automated randomization. The bottles containing 24-IU oxytocin, 48-IU oxytocin, and placebo will be identical in appearance, smell, texture and taste, and only identifiable through a color labeling system known to the site pharmacists and study sponsor. Each site's randomization sequence will be accessed by the site pharmacist and bottles prepared accordingly. The RA assessing outcomes will be unaware of condition.||t|t|t|t
33782179|NCT00836810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996975|NCT01370863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996976|NCT01539564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996977|NCT04193150|||COHORT||PROSPECTIVE|||||||
33996978|NCT06628037|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33996979|NCT03330990|NA|SINGLE_GROUP||OTHER||NONE||All patients entering this study will receive midazolam and entrectinib.||||
33996980|NCT03987295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996981|NCT04130464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study; the surgeon and the patient will not know which study group they are a part of. Only the IDS pharmacist and IDS pharmacy technician will know which group each study patient has been assigned to.||t|t|t|t
33996982|NCT01394094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33996983|NCT02557464|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33996984|NCT05480423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled trial||||
33996985|NCT04124354|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33996986|NCT03562182|||CASE_CONTROL||PROSPECTIVE|||||||
33996987|NCT00845637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996988|NCT02997176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33996989|NCT01131260|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study is a randomized, controlled clinical trial of 11,000 women in labor at \> 36.0 weeks gestation randomized to one of two groups using the STAN S31 system:~* Fetal STAN electrode inserted and data available to caregivers (open device group)~* Fetal STAN electrode inserted, but data masked to the caregivers (masked device group)"|"The study is a randomized, controlled clinical trial of 11,000 women in labor at \> 36.0 weeks gestation randomized to one of two groups using the STAN S31 system:~* Fetal STAN electrode inserted and data available to caregivers (open device group)~* Fetal STAN electrode inserted, but data masked to the caregivers (masked device group)"|f|t|f|f
33996990|NCT04431518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Matched case-control||||
33996991|NCT01239303|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33996992|NCT03522532|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"According to Black's Classification Criteria, patients were classified into four groups (K2 - K5). The number of patients within those groups were as follows: K2 (n=58), K3 (n=10), K4 (n=6) and K5 (n=14).~Six different DMs were used in this study. The type of DM to be used for each patient was determined in relation to the dental lesion degree. DM placement was performed in one session and only one type was used per patient. Accordingly, 6 groups (arms) of dental patients (Amg, ZnPhC, ZnPoC, GIC, TEC and BF) were formed.~Parameters of OS (MDA, GSH and tSOD) were measured in the GCF of the patients both before (day 0) and after treatment (on the 7th and 30th day)."||||
33996993|NCT01354470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33996994|NCT03482180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33996995|NCT06013150|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33996996|NCT06339658|||COHORT||PROSPECTIVE|||||||
33996997|NCT05625607|||COHORT||PROSPECTIVE|||||||
33996998|NCT05836311|||CASE_ONLY||RETROSPECTIVE|||||||
33996999|NCT01370122|||COHORT||PROSPECTIVE|||||||
33997000|NCT00015925||||TREATMENT||||||||
33997001|NCT02509143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997002|NCT01798628|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997003|NCT02638428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997004|NCT00199654|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33997005|NCT03993145|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33997006|NCT02093728|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33997007|NCT00841022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997008|NCT00357461|RANDOMIZED|||TREATMENT||NONE||||||
33997009|NCT05561088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997010|NCT04615117|||COHORT||PROSPECTIVE|||||||
33997011|NCT01513239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997012|NCT01640041|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33916646|NCT03408548|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Periodontal clinical examination (pre- and post-intervention) will be conducted by a single trained and calibrated examiner, who will be blinded to the experimental groups of the study. The examiner will also be blinded to the microbiological and immunological evaluations. SRP procedures will be performed by specialist in Periodontics, trained for these purposes, who will also be blinded to the experimental groups of the study.~The coded lozenge will be given to the examiner, who will distribute them to the patients and will not have any access to information regarding the content of the lozenge. In addition, the patients will be blinded to the content of the lozenge and the treatment assignment during the study. The meaning of each code number will be revealed by the study coordinator only after conducting the statistical analysis of the experimental data."|According to a random numeric table generated by a computer software, the study coordinator will allocate each patient into one of the following groups: Control (Scaling and Root Planing - SRP) or Test (SRP + probiotic therapy). The subjects (Control group) will receive placebo lozenge. In the Test group, the lozenge will contain Bifidobacterium lactis HN019. Individuals will be instructed (immediately after the first session of mechanical instrumentation) to consume twice a day for 4 weeks by dissolving the lozenge before bedtime and when wake up. They will also be instructed not to consume other probiotic product during the study. Clinical, immunological and microbiological parameters will be assessed at baseline (pre-intervention) and after completion of non-surgical periodontal therapy 30 and 90 days.|t|t|t|t
33916647|NCT02763293|NON_RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33916648|NCT02499341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916649|NCT02909569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693051|NCT06166004|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693052|NCT05942027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693053|NCT06520670|||OTHER||CROSS_SECTIONAL|||||||
33693054|NCT06293924|||COHORT||PROSPECTIVE|||||||
33693055|NCT02804529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693056|NCT02642874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916650|NCT04223700|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916651|NCT04045717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916652|NCT03447613|||COHORT||CROSS_SECTIONAL|||||||
33916653|NCT03334864|||COHORT||OTHER|||||||
33916654|NCT00903747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916655|NCT04809389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997013|NCT00001058||||TREATMENT||||||||
33997014|NCT01406080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997015|NCT05114512|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This is a single-group study; therefore, no masking is possible.|Single cohort of 27 individuals||||
33997016|NCT03422380|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33997017|NCT00322738|||||PROSPECTIVE|||||||
33693057|NCT06619964|||COHORT||PROSPECTIVE|||||||
33693058|NCT05321927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693059|NCT06475274|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693060|NCT05916430|||COHORT||PROSPECTIVE|||||||
33693061|NCT03519386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693062|NCT00925990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693063|NCT05798611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693064|NCT05146154|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33693065|NCT04426812|||COHORT||PROSPECTIVE|||||||
33916656|NCT04069741|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33916657|NCT04212286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916658|NCT00650091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916659|NCT05836519|||COHORT||PROSPECTIVE|||||||
33916660|NCT03810209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33916661|NCT02556593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916662|NCT02853006|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916663|NCT04903964|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||The research is a randomized controlled experimental study.|f|t|t|f
33916664|NCT06191887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916665|NCT01714752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916666|NCT00067314|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916667|NCT03432052|||CASE_ONLY||RETROSPECTIVE|||||||
33916668|NCT03220711|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33916669|NCT03508765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916670|NCT03338114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916671|NCT02439944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916672|NCT00854178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33782180|NCT02491411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693066|NCT06545825|||CASE_CONTROL||PROSPECTIVE|||||||
33693067|NCT05080660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693068|NCT04180215|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693069|NCT06380829|||CASE_ONLY||CROSS_SECTIONAL|||||||
33693070|NCT05035511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782181|NCT04992442|NA|SINGLE_GROUP||OTHER||NONE||||||
33916673|NCT00228150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916674|NCT01419704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916675|NCT02612441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916676|NCT02395497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916677|NCT03464123|||COHORT||PROSPECTIVE|||||||
33916678|NCT02486952|||CASE_ONLY||PROSPECTIVE|||||||
33916679|NCT06498752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997018|NCT05372250|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33997019|NCT04911218|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33997020|NCT06287216|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33693071|NCT02204007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693072|NCT00750880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693073|NCT03174197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693074|NCT02406950|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33693075|NCT02676466|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33693076|NCT02259218|||CASE_CONTROL||RETROSPECTIVE|||||||
33693077|NCT06709417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693078|NCT06697691|||COHORT||RETROSPECTIVE|||||||
33693079|NCT06448247|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33693080|NCT05992571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||A randomized double-blind placebo-controlled crossover design will be used to test two conditions. Participants will consume 60 mL of: 1) a drink containing a ketone monoester supplement (\[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate; 0.3 g β-OHB/kg body weight); and 2) a taste-matched calorie-free inert placebo drink.|t|f|t|t
33693081|NCT05961332|NA|SINGLE_GROUP||OTHER||NONE||||||
33693082|NCT01456390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693083|NCT03472066|||CASE_CONTROL||PROSPECTIVE|||||||
33693084|NCT05668403|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33693085|NCT04014023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693086|NCT03290079|NA|SINGLE_GROUP||TREATMENT||NONE||Simon 2-stage design||||
33693087|NCT05677048|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33693088|NCT01773772|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33693089|NCT06710301|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693090|NCT06695780|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33693091|NCT03205137|||COHORT||RETROSPECTIVE|||||||
33693092|NCT02594241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693093|NCT05885555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693094|NCT03562637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693095|NCT03583164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693096|NCT03633409|||COHORT||CROSS_SECTIONAL|||||||
33693097|NCT03568084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized parallel group multicenter clinical trial. Randomization unit and Unit of analysis: Patient.|f|f|f|t
33693098|NCT05492500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"In the main cohort (Cohort A), Cohort C and Cohort D, investigators, sponsor, participants and other site staff will be blinded to participants' assigned study intervention, including the site staff assigned to prepare and administer the study intervention. Pharmacists and site personnel will be blinded to study intervention versus placebo within each study arm.~The separate PK cohort (Cohort B) will be open-label and study treatment will be prepared and administered as per treatment assignment by qualified personnel. There is no blinding in the open-label, PK cohort (Cohort B)."|"In the main cohort (Cohort A), ponsegromab will be administered at low, medium and high doses every 4 weeks by subcutaneous injections for a total of 6 doses. Participants will be randomized to 1 of the 3 doses of ponsegromab or placebo.~In optional Cohort C, ponsegromab will be administered at low doses every 4 weeks by subcutaneous injections for a total of 6 doses. Participants will be randomized to the low dose of ponsegromab or placebo.~In optional Cohort D, ponsegromab will be administered at high doses every 4 weeks by subcutaneous injections for a total of 6 doses. Participants will be randomized to the high dose of ponsegromab or placebo.~In a separate open-label, PK cohort (Cohort B), ponsegromab will be administered at low, medium and high doses every 4 weeks by subcutaneous injections for a total of 4 doses. Participants will be randomized to 1 of the 3 doses of ponsegromab. There is no placebo in the open-label, PK cohort."|t|t|t|t
33693099|NCT02415621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693100|NCT02545140|||COHORT||CROSS_SECTIONAL|||||||
33693101|NCT05789082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693102|NCT05864170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916680|NCT04550611|RANDOMIZED|PARALLEL||TREATMENT||NONE||The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our Central blood transfusions( CBTS) in Assiut University Hospital (AUH). The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.||||
33916681|NCT04103398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916682|NCT01993862|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33916683|NCT01006863|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33997021|NCT05282693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Coded bottles|Participants will be randomized to either placebo for 9-days of the intervention separated by a 3-week washout period.|t|f|t|t
33916684|NCT02025491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916685|NCT01646424|||COHORT||RETROSPECTIVE|||||||
33916686|NCT05166759|||CASE_ONLY||PROSPECTIVE|||||||
33916687|NCT04222933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33997022|NCT06557603|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33997023|NCT00870129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916688|NCT05566652|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is an interventional prospective crossover physiological study that will take place at the Intensive Care Unit E. Vecla, Department of Anesthesia, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy."||||
33916689|NCT00446485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33693103|NCT04981392|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention will be tested using a pragmatic, cluster randomized clinical trial. Randomization will occur at the clinic level. Clinics will be matched by practice setting (Academic, Community, Federally Qualified Health Center) and other characteristics as possible. Within each pair, clinics will be randomly allocated to either the intervention or usual care Arm.||||
33916690|NCT03280342|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||a crossover, randomized, double blind design in conjunction with intensive pharmacokinetic sampling and multiple administrations of a neurocognitive test battery to directly compare the effects on cognition of IR-TPM to XR-TPM in adults with migraine. The dose will begin at 25mg and titrated in 25mg increments to reach target dose of 100mg.|t|f|f|f
33916691|NCT03201952|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Each volunteering subject will participate in 2 study visits, receiving the placebo at one visit and investigation medication at the other visit. The order of these visits will be randomized.|t|f|f|f
33916692|NCT04547894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916693|NCT02077855|||CASE_CONTROL||PROSPECTIVE|||||||
33916694|NCT01727050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916695|NCT02176291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916696|NCT04717193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blind. Surgeon cannot be blinded to the intervention. Anesthesiologist, participants, parents, and nursing staff in the OR, recovery room, and ward will be blinded.||t|t|f|t
33916697|NCT02683694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916698|NCT03766724|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33997024|NCT01032590|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33997025|NCT03699930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The only person knowing about this assignment will be the Principal Investigator.|double-blind quasi-randomized controlled design|t|t|f|t
33997026|NCT04651036|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel Assignment|f|f|f|t
33693104|NCT05671757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693105|NCT01845883|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693106|NCT06324448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized controlled trial|t|t|f|t
33693107|NCT03292211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693108|NCT05800860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782182|NCT00865956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916699|NCT00644254|||COHORT||RETROSPECTIVE|||||||
33916700|NCT02326207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33916701|NCT05014048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916702|NCT04436809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916703|NCT05259267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916704|NCT03419052|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33916705|NCT02589704|||COHORT||PROSPECTIVE|||||||
33997027|NCT00104195|||CASE_CONTROL|||||||||
33997028|NCT04941638|||COHORT||RETROSPECTIVE|||||||
33997029|NCT05778630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Individual qualitative interviews. Focus group meetings.||||
33997030|NCT06520904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997031|NCT03905967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997032|NCT03678363|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33997033|NCT06627036|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33997034|NCT00063687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997035|NCT04166162|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693109|NCT05534087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693110|NCT04360863|||OTHER||CROSS_SECTIONAL|||||||
33693111|NCT06708988|||OTHER||PROSPECTIVE|||||||
33693112|NCT04240470|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be assigned to receive endovascular treatment for acute ischemic stroke (mechanical thrombectomy) alone without using IV rt-PA.||||
33693113|NCT02835560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693114|NCT06707415|NA|SINGLE_GROUP||SCREENING||NONE||||||
33782183|NCT06103461|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
33782184|NCT06204185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Evaluate the clinical parameters ( Probing Depth, Clinical Attachment Level, Gingival and Plaque Indices) before \& after the application of locally delivered metformin as an adjunctive therapy to non surgical periodontal treatment of Stage III periodontitis.|t|f|f|t
33782185|NCT02339727|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33782186|NCT00618358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782187|NCT00302679|||DEFINED_POPULATION||OTHER|||||||
33782188|NCT02219594|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33782189|NCT01878695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782190|NCT02895282|||COHORT||PROSPECTIVE|||||||
33997036|NCT04659096|NA|SEQUENTIAL||TREATMENT||NONE||||||
33997037|NCT02328677|||COHORT||PROSPECTIVE|||||||
33693115|NCT06206213|||CASE_CROSSOVER||PROSPECTIVE|||||||
33997038|NCT03858933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The eBrainFit Platform is set to randomize each entered Subject Identification Number into either the alpha/theta or limbic modulation treatment arms. Neither the participant nor researcher will know the arm, to which the participant has been assigned.||t|f|t|f
33693116|NCT05555771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997039|NCT00456898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693117|NCT06710808|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34087515|NCT03811938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693118|NCT00005110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33693119|NCT06441474|||CASE_ONLY||PROSPECTIVE|||||||
33693120|NCT02435329|||OTHER||PROSPECTIVE|||||||
33693121|NCT04920318|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The subject codes will be used for blinding of the participants, care-providers, and speech-language therapist administering the treatment.|individuals diagnosed with Alzheimer's Disease Primary Progressive Aphasia (AD-PPA) (\~50-80 years old) will be randomized to receive active tDCS+language treatment or sham (fake tDCS)+language treatment in a cross-over design.|t|t|t|f
33693122|NCT03536897|||COHORT||PROSPECTIVE|||||||
33693123|NCT00525369|||DEFINED_POPULATION||OTHER|||||||
33693124|NCT06596031|RANDOMIZED|PARALLEL||OTHER||SINGLE||Pilot study of a single-blinded, randomised controlled trial|f|f|f|t
33693125|NCT05741840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693126|NCT04602689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693127|NCT01325623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693128|NCT04647071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Each volunteer is assigned a participant number that will be associated with a pot that will have all the product for the study.~The pot number is the same as the participant number. The pot does not indicate which product it is carrying."||t|t|t|t
33782191|NCT06697145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693129|NCT05097989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking of treatment allocation will be observed at least until Week 50.||t|t|t|t
33782192|NCT02618629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782193|NCT05674643|||COHORT||PROSPECTIVE|||||||
33916706|NCT00330525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33916707|NCT02266615|||COHORT||PROSPECTIVE|||||||
33916708|NCT00467025|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33916709|NCT00574119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916710|NCT01814683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916711|NCT01717703|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33693130|NCT02360215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916712|NCT03716986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916713|NCT06552858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693131|NCT03694002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693132|NCT01394718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693133|NCT04608968|||COHORT||PROSPECTIVE|||||||
33693134|NCT06709430|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Students will be randomly assigned (using online randomization software) to standardized patients group and control groups. Students will know that they are participating in the study and the interventions that will be applied to them, but they will be blinded as they will not know which group they are in. Due to the nature of the study, standardized patient and routine laboratory practices to be applied to the experimental and control groups will be applied by the first and second researchers. The research data will be collected by the third researcher who is blinded to the groups. In the statistical analysis of the data, the groups will be labeled as group 1 and group 2, and the fourth researcher will be blinded when evaluating the results. Thus, the 3rd and 4th researchers will be blinded to the study groups. In order to avoid bias in the evaluation of the results, the first and second researchers who are not blinded will not participate in any stage of the evaluation process.|Theoretical courses, standardized patient-based pain management laboratory practice, and clinical practice processes will be applied to students in the experimental group.|t|f|f|t
33693135|NCT06707155|||COHORT||OTHER|||||||
33693136|NCT06256757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693137|NCT05753631|||CASE_CONTROL||PROSPECTIVE|||||||
33693138|NCT06707467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with internal temporomandibular derangement are divided into three groups. The first group receives only occlusal splint therapy. The second group undergoes occlusal splint therapy combined with Rocabado exercises, while the third group is treated with occlusal splint therapy combined with postural exercises. The effectiveness of the treatment protocols is evaluated.||||
33693139|NCT06286358|||CASE_CONTROL||PROSPECTIVE|||||||
33693140|NCT02402920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693141|NCT05780931|||CASE_CONTROL||PROSPECTIVE|||||||
33693142|NCT02560181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693143|NCT05591989|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single-arm, multicenter clinical study||||
33693144|NCT05583344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693145|NCT06402084|||CASE_CONTROL||PROSPECTIVE|||||||
33693146|NCT03604692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The dose-escalation phase is a sequential group (dose-escalating) treatment study that is open-label. The dose-expansion phase is a parallel group treatment study with open-label cohorts.||||
33693147|NCT04595604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and assessors will be blinded regarding preoperative preparation. Both randomization process and rehabilitation process will be carried out by a trained nurse, physiotherapist and psychotherapist, neither of them will be involved in outcome assessment.|"Patients planned for elective, curative operations for colorectal cancer will be randomized into two groups: experimental group will take part in a dedicated 4-week multimodal preparation program followed by ERAS preoperative management, while control group will just participate in the ERAS program without specific physical and mental preparation.~2:1 randomization will be performed for interventional and control arm"|f|f|t|t
33693148|NCT01658618|||COHORT||PROSPECTIVE|||||||
33693149|NCT05371678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Children will be divided into two intervention groups by randomization method. Randomization method will be made with a computer program (Random Allocation Software version 2.0) stratified according to age and gender.|comparison of therapeutic motor control interventions which include education, dietary advice, core stabilization exercises, pelvic floor muscle training with surface Electromyographic, and breathing exercises and conventional treatment which include education, dietary advice and laxative therapy|t|f|f|f
33693150|NCT03960931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693151|NCT06708195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental group Control group|t|f|f|f
33693152|NCT05578703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693153|NCT06710171|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a cluster randomized pilot trial: healthcare providers will be randomized to either of the two arms and their clients; will then answer questionnaires.||||
33693154|NCT05528952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782194|NCT02775617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782195|NCT06606613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a single-center, prospective before-after (pre-post) interventional study, in which the effectiveness and safety of intraurethral cross-linked hyaluronic acid/dextranomer injection in female stress urinary incontinence patients were compared with those undergoing mid-urethral sling procedures.|f|f|f|t
33916714|NCT05890118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916715|NCT02140905|||COHORT||RETROSPECTIVE|||||||
33916716|NCT02432040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916717|NCT03309267|||CASE_CONTROL||RETROSPECTIVE|||||||
33916718|NCT05277688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916719|NCT05122195|||COHORT||PROSPECTIVE|||||||
33916720|NCT03000387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916721|NCT01260935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916722|NCT01153191|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33916723|NCT01345344|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Study personnel collecting, entering, and analyzing data are blind to treatment allocation.||f|f|t|t
33782196|NCT04215744|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||self-control study||||
33782197|NCT02982928|||COHORT||PROSPECTIVE|||||||
33693155|NCT04797000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators, site staffs and site monitors will remain blinded to the identity of the treatment from the time of randomization until database lock for final analysis, and the clinical study team members and anyone involved in the Japan registration activities will be blinded until database lock for the primary analysis. Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by anyone else involved in the study with the following exceptions: DMC members and who will perform data analysis for DMC.||t|t|t|t
33782198|NCT04937075|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33693156|NCT01302379|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||Main effects of the factorial design were the planned primary analysis and what the study was powered on.|t|t|t|t
33916724|NCT03522350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916725|NCT03408652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916726|NCT00523094|||COHORT||PROSPECTIVE|||||||
33916727|NCT02280941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916728|NCT04511026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916729|NCT00315705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916730|NCT02570763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916731|NCT01390961|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33916732|NCT06126874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916733|NCT02780765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916734|NCT01228942|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33916735|NCT03386578|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916736|NCT04863924|||COHORT||PROSPECTIVE|||||||
33916737|NCT01642836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916738|NCT03425942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in both the experiment condition and the active control group were told that they received one of two active treatments in a comparative study.||t|f|f|f
33916739|NCT03033238|||COHORT||PROSPECTIVE|||||||
33916740|NCT02010437|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33916741|NCT03038659|||CASE_CONTROL||PROSPECTIVE|||||||
33916742|NCT06536764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be comparison between two groups, experimental and control group.|f|f|f|t
33916743|NCT05997017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916744|NCT01057069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916745|NCT06188195|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916746|NCT02054143|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33916747|NCT06082648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916748|NCT01362218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916749|NCT03364673|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33916750|NCT00535015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916751|NCT04638712|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33916752|NCT05487716|||COHORT||RETROSPECTIVE|||||||
33916753|NCT02612961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997040|NCT04828538|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||"Double-blind randomized, placebo-controlled double blinded 2x2x2 factorial trials (includes 2 trials: treatment cohort and prevention cohort) of the following oral supplementation treatments for up to 60 days per person:~Factorial 1 (F1): 4000 IU Vitamin D vs placebo Factorial 2 (F2): 1000mg Omega DHA/EPA vs. placebo Factorial 3 (F3): Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day vs. placebo~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1"|t|t|f|f
33997041|NCT00415935|||DEFINED_POPULATION||PROSPECTIVE|||||||
33997042|NCT05203692|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33997043|NCT00308906|||CASE_CONTROL||PROSPECTIVE|||||||
33997044|NCT04501848|||CASE_CONTROL||PROSPECTIVE|||||||
33693157|NCT04025710|NA|SINGLE_GROUP||OTHER||NONE||||||
33693158|NCT02801643|||COHORT||CROSS_SECTIONAL|||||||
33693159|NCT05310188|||COHORT||CROSS_SECTIONAL|||||||
33693160|NCT01917929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693161|NCT02992223|||COHORT||RETROSPECTIVE|||||||
33693162|NCT06242678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693163|NCT06674382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693164|NCT04632953|||COHORT||PROSPECTIVE|||||||
33782199|NCT06202937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782200|NCT04900870|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33782201|NCT01102478|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33782202|NCT00335543|RANDOMIZED|||TREATMENT||NONE||||||
33782203|NCT05158712|||FAMILY_BASED||PROSPECTIVE|||||||
33782204|NCT02061306|||COHORT||PROSPECTIVE|||||||
33782205|NCT01104103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33782206|NCT00180687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782207|NCT00202397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782208|NCT00079937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782209|NCT04036799|||COHORT||RETROSPECTIVE|||||||
33782210|NCT04925050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782211|NCT02987829|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782212|NCT03812289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997045|NCT02042547|||CASE_ONLY||PROSPECTIVE|||||||
33997046|NCT04935580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997047|NCT00285961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997048|NCT00177164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782213|NCT01438099|||COHORT||PROSPECTIVE|||||||
33782214|NCT01495780|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33782215|NCT00919438|||CASE_ONLY||PROSPECTIVE|||||||
33782216|NCT04217421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782217|NCT01518257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782218|NCT00764868|NA|SINGLE_GROUP||OTHER||NONE||||||
33782219|NCT01734811|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, double-blind, placebo-controlled, multi centre, parallel-group study|t|f|t|f
34087516|NCT03335176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087517|NCT05753800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087518|NCT00873652|||COHORT||OTHER|||||||
34087519|NCT03088059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087520|NCT03452787|||COHORT||RETROSPECTIVE|||||||
34087521|NCT01163617|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33782220|NCT05433948|||COHORT||PROSPECTIVE|||||||
33782221|NCT03106376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782222|NCT05714722|||COHORT||RETROSPECTIVE|||||||
33782223|NCT02831400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782224|NCT02060097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782225|NCT04436029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782226|NCT01258361|||COHORT||PROSPECTIVE|||||||
34087522|NCT05917340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782227|NCT00740519|||COHORT||PROSPECTIVE|||||||
33782228|NCT02452229|||||RETROSPECTIVE|||||||
33782229|NCT06613802|||OTHER||RETROSPECTIVE|||||||
33782230|NCT01456663|NA|PARALLEL||OTHER||NONE||||||
33782231|NCT02458846|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916754|NCT04799236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the disparate routes of administration, the study will not be blinded for the patients or clinical team. However, the ENT doctor who provides data to calculate the primary endpoint, the mucosal severity score, will be blinded.|"The primary purpose is to perform a controlled evaluation of the cure rate of miltefosine, LAMB, and Sb for L braziliensis ML in Bolivia.~A secondary purpose is to determine the tolerance of these regimens.~Patients will be randomized between:~Group 1---40 patients. Oral miltefosine. Group 2---40 patients. Intravenous pentavalent antimony (Glucantime) Group 3---40 patients. Intravenous liposomal amphotericin B (Ambisome)~Because of the disparate routes of administration, the study will not be blinded for the patients or clinical team. However, the ENT doctor who provides data to calculate the primary endpoint, the mucosal severity score, will be blinded.~After treatment, all patients will be followed for 2, 6, 9, and 12 months after the beginning of therapy. In addition, all attempts will be made to effect follow-up at 24 months."|f|f|t|f
33916755|NCT02051894|||COHORT||PROSPECTIVE|||||||
33916756|NCT00639132|||CASE_ONLY||PROSPECTIVE|||||||
33916757|NCT05378516|||CASE_CONTROL||PROSPECTIVE|||||||
33916758|NCT01714817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916759|NCT02495740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997049|NCT06406088|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single group of infants without hearing impairment will be recruited so that the performance of the two EarGenie MVP tests of speech sound detection and discrimination can be estimated.||||
33782232|NCT06474806|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The trial consist on 2 parts: Part 1 will evaluate 3 different doses of 64Cu-DOTA-AE105 in parallel (100, 150, or 200 MBq) in 27 patients (randomized 1:1:1) . Part 2 will evaluate 1 dose of 64Cu-DOTA-AE105 (200 MBq) in 141 patients||||
33782233|NCT02889042|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916760|NCT05129995|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, within subject study design||||
33916761|NCT04721041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916762|NCT00514202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916763|NCT01670409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997050|NCT01993186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997051|NCT01232660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997052|NCT05301218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087523|NCT02177994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087524|NCT03772873|||OTHER||PROSPECTIVE|||||||
33782234|NCT04392258|||CASE_ONLY||PROSPECTIVE|||||||
33997053|NCT04342936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997054|NCT01135784|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33997055|NCT00989716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997056|NCT03467360|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I study with a prospective, multicenter, non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized Small cell lung cancer||||
33997057|NCT01187823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997058|NCT01664650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997059|NCT00078923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997060|NCT04969562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33997061|NCT03417076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997062|NCT04212390|||COHORT||PROSPECTIVE|||||||
33997063|NCT03821675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Devices may be active or sham.||t|t|f|f
33997064|NCT01200186|||COHORT||PROSPECTIVE|||||||
33997065|NCT02270697|||||RETROSPECTIVE|||||||
33997066|NCT01158118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087525|NCT02428400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087526|NCT02990052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087527|NCT05448638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087528|NCT02596516|||COHORT||PROSPECTIVE|||||||
33782235|NCT02181699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782236|NCT03882463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087529|NCT00678457|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33693165|NCT01994590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693166|NCT03557827|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The investigator and outcome assessor were blinded from the arrangement of the treatment|Split-mouth design. Each quadrant receives different treatment|f|f|t|t
33693167|NCT05581030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693168|NCT03554616|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33916764|NCT03308981|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants will be randomly assigned to one of three groups: 1) REThink group, 2) Rational-Emotive-Behavioral Education (REBE) group and 3) wait-list condition.|f|f|t|t
33693169|NCT00381121|||COHORT||PROSPECTIVE|||||||
33693170|NCT02172053|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33916765|NCT00973921|||CASE_ONLY||RETROSPECTIVE|||||||
33916766|NCT04171648|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The nature of the participants eating (whole food) peanut samples roasted or boiled allows no way for the participants or the investigators to be masked from the two interventions. The care provider does not apply in this study and the outcomes assessor will be the same individual as the investigator.|Half the subjects will receive the roasted peanut treatment and the other half will receive the boiled peanut treatment for two weeks, then both will have a week wash out, and then each group will switch to the opposite treatment for two weeks.||||
33916767|NCT01469663|||OTHER||CROSS_SECTIONAL|||||||
33916768|NCT03435263|||COHORT||PROSPECTIVE|||||||
33916769|NCT03518814|||CASE_ONLY||PROSPECTIVE|||||||
33916770|NCT00384826|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916771|NCT05004142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916772|NCT00001251||||TREATMENT||||||||
33916773|NCT02889978|||COHORT||PROSPECTIVE|||||||
33916774|NCT04379219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916775|NCT04753814|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||About 100 adult patients hospitalized for HF in the Department of Cardiology will be included in the study, including: the study group with HFrEF, with HFmrEF and with HFpEF||||
33916776|NCT04406051|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33916777|NCT00797797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916778|NCT05762874|||COHORT||PROSPECTIVE|||||||
33916779|NCT00004929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087530|NCT05531955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087531|NCT02062697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087532|NCT05037279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087533|NCT00089388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087534|NCT04002986|NA|SINGLE_GROUP||SCREENING||NONE||||||
33693171|NCT05316688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693172|NCT03833167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693173|NCT04233034|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33693174|NCT06500780|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Baseline assessments are conducted prior to randomization (Baseline assessor will not know the randomization assignment).|||||
33693175|NCT06161948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782237|NCT00599677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782238|NCT02373813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782239|NCT00964717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33782240|NCT04333836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916780|NCT01379495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33916781|NCT00183950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916782|NCT01766817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33916783|NCT05605041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087535|NCT03889132|||CASE_CONTROL||PROSPECTIVE|||||||
33916784|NCT02298478|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33916785|NCT00081341|||||PROSPECTIVE|||||||
33916786|NCT05331430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked participants. Masked data analyst|Randomized clinical trial|t|f|f|t
33916787|NCT01984879|||CASE_ONLY||PROSPECTIVE|||||||
33693176|NCT04898114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each neonate will be assigned a unique identification number. Pharmacy will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, nurses, echocardiographers, and data collectors will be unaware of group assignment and drug/placebo therapy.|Two groups of neonates with PPHN on mechanical ventilation: (1) NebMag group: receive nebulized magnesium sulfate and oral sildenafil citrate; (2) Control group: receive nebulized placebo (isotonic saline) and oral sildenafil citrate.|t|t|t|t
33693177|NCT04000880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Single blinded trial in which the study participant and select individuals in the research team (i.e., interventionists) will be aware of randomization status, but the assessors and investigators will not.|"Participants will participate in one of three arms:~1. Diet followed by Exercise intervention~2. Exercise followed by Diet intervention~3. Combined Diet and Exercise intervention"|f|t|t|t
33693178|NCT06648798|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||One study group of 30 participants involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).||||
33693179|NCT06471790|||COHORT||PROSPECTIVE|||||||
33693180|NCT04406610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33916788|NCT06219434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33916789|NCT04000555|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All investigators involved will be masked|"Our primary objective is to determine the effectiveness of vancomycin in preventing recurrent Clostridium Difficile Infection (CDI) compared to placebo. Our secondary objective is to attempt to identify risk factors associated with the development of recurrent CDI.~The purpose of this study is to gain further knowledge regarding the effectiveness of vancomycin prophylaxis in preventing Clostridium difficile infections in order to guide physicians' practices. Eligible patient's will be randomized 1:1 double-blinded placebo controlled clinical trial to determine the effectiveness of vancomycin at preventing CDI. The first arm in our study would be the study drug which is oral vancomycin. The second arm would be placebo. Patient with a history of CDI admitted to Tampa General Hospital or have been seen at Infectious Disease Associates of Tampa Bay clinics are receiving systemic antibiotics and have a history of at least one episode of CDI that was diagnosed on or after 4/1/2017."|t|t|t|t
33916790|NCT03266666|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33916791|NCT02208024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916792|NCT02692170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33916793|NCT00139139|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33916794|NCT06131125|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33916795|NCT01333852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916796|NCT02399592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916797|NCT01423773|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33916798|NCT05619679|||COHORT||RETROSPECTIVE|||||||
33916799|NCT01357304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916800|NCT04793763|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087536|NCT03515408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34087537|NCT01925417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103034|NCT04803604|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Data collectors and principal investigator will be blind to participant condition; participants will be instructed NOT to discuss their assignment with data collectors. Trials participants will know their intervention condition as will the lay coach involved in delivering the intervention.|2x2x2x2 full factorial pilot randomized trial|f|f|t|t
33916801|NCT05429554|||CASE_CONTROL||PROSPECTIVE|||||||
33782241|NCT01687192|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33693181|NCT06150820|NA|SINGLE_GROUP||OTHER||NONE||||||
33693182|NCT06087835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693183|NCT06119724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693184|NCT02869061|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33782242|NCT01369355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782243|NCT01904357|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33782244|NCT06180798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be randomised to C-EMR and H-EMR by a computer generated sequence provided in turn by the research assistant. The patient, pathologist and statistician will be blinded.|This is a single center randomized controlled study with two parallel groups with a 1:1 allocation ratio.|t|f|f|f
33693185|NCT01483807|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each participant received each arm of treatment|f|f|f|t
33782245|NCT01101165|RANDOMIZED|CROSSOVER||||NONE||||||
33782246|NCT00518752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997067|NCT05715463|RANDOMIZED|PARALLEL||OTHER||NONE||This will be an adaptive intervention. After six months, Individuals who do not respond to Arm 1, as measured by no improvement in SDoH-related needs and/or an outpatient no show or same day cancellation, will increase to the Arm 2 intervention for the next 6 months (see Schema). Patients in Arm 1 who do respond will graduate and then complete a follow-up set of questionnaires at 12 months. Patients in Arm 2 or Arm 3 who adequately respond and have had their SDoH-related needs addressed will graduate and receive a follow-up set of questionnaires at 12 months. Individuals in Arm 2 who continue to have one or more no show and/or continue to have SDoH-related needs will be ramped up to Arm 3. Individuals in Arm 3 with the same scenario will remain in Arm 3 for another 6 months. Data will be collected for 12 months (at baseline, 6 and 12 months) for participants in all arms including those who graduate at 6 months, to determine if the response was sustained.||||
33782247|NCT05930756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will be sedated and positioned so that they will not know which of the two treatments they receive. The outcomes assessor will not know which treatment the patient received, as they will not be present during the procedure. The care provider (if present) will not be told. Only care providers involved in the procedure are unblinded|Randomized controlled trial|t|t|f|t
33782248|NCT01121874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33782249|NCT06233630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33782250|NCT06232161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The first 12-month follow-up were parallel of two groups: treatment group and control group with randomized and single blind; While the second 12-month follow-up were chosen to be in the treatment group or in the control group depended on the willingness of red-light therapy from both patients and their family.||||
33782251|NCT05064761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997068|NCT00809705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997069|NCT04752605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997070|NCT02350036|||CASE_CONTROL||PROSPECTIVE|||||||
33997071|NCT01780051|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997072|NCT04790643|||OTHER||OTHER|||||||
33997073|NCT00681486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997074|NCT03240991|||CASE_ONLY||PROSPECTIVE|||||||
33997075|NCT03390790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997076|NCT02809196|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33997077|NCT00185757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997078|NCT00163345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997079|NCT02044731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997080|NCT01215721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997081|NCT06307288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997082|NCT00510848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997083|NCT02761122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33997084|NCT02854826|||OTHER||PROSPECTIVE|||||||
33997085|NCT00749658|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33997086|NCT06550661|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33782252|NCT01903382|||COHORT||RETROSPECTIVE|||||||
33997087|NCT00301886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997088|NCT00685464|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33997089|NCT06205264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||After the random assignment of the groups, the coaches will be oblivious to the investigation, so there is no bias.Furthermore, the principal investigator will not know where the data of each group comes from.|f|f|t|t
33997090|NCT03692455|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997091|NCT03909633|||COHORT||PROSPECTIVE|||||||
33997092|NCT00476034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997093|NCT04777305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693186|NCT06252298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693187|NCT03895021|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33693188|NCT06709456|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of statisticians.|Investigator-initiated, pragmatic, multicentre, open-label, randomised, parallel-group clinical feasibility trial||||
33693189|NCT04936230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693190|NCT02769676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693191|NCT00815269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693192|NCT01869972|||CASE_CONTROL||PROSPECTIVE|||||||
33693193|NCT00017238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693194|NCT01563744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33693195|NCT00504985|||CASE_ONLY||PROSPECTIVE|||||||
33693196|NCT05632406|||COHORT||CROSS_SECTIONAL|||||||
33693197|NCT00964132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997094|NCT04434716|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The overall specific aim of this study is to test whether daily monitoring of fatigue and sleep using a wrist-worn device can improve self-management and aid in the early detection of the signs and symptoms of CFO indicating increasing cardiac decompensation in heart failure. A mixed methods approach will be used to study the specific aims.||||
33997095|NCT06561308|NA|SINGLE_GROUP||TREATMENT||NONE||Carboplatin AUC=4-6 q3w , paclitaxel 175 mg/m2 q3w and Pucotenlimab iv.200mg q3w||||
33997096|NCT04879381|||COHORT||PROSPECTIVE|||||||
33997097|NCT06562010|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants, care providers and outcome assessors will be blinded|It is a two-arm 1:1 randomized control trial|t|t|f|t
33997098|NCT02184715|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33782253|NCT03089619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessors will be masked during the evaluation period. Subjects will be identified through their randomization number. Patients identification log is stored at the study site and only available to the investigator who is responsible of concealment of these information.|assignment of patients to one of the two treatment arms will be carried out randomly. Randomization process will be monitored and carried out by the center of clinical studies coordination - University Medicine Greifswald. Assignment of patient will be only known to the investigator after blood and urine sample results fulfill the inclusion criteria.|f|f|f|t
33997099|NCT06623695|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were divided into three groups: Stable Ground Group (SGG), Unstable Ground Group (USGG) and Control Group (CG). SGG and USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks. SGG participants performed exercises on a stable floor surface, while USGG participants completed the exercise program on a bosuball. CG did not participate in any exercise program. CG continued their daily routine activities and maintained their current physical activity levels.||||
33997100|NCT04563481|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Study||||
34087538|NCT04226443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was a single-blinded controlled study because the sedation and analgesia were administered by anesthesiology residents who were unaware of the technique and the study protocol, however, the protocol was known by the experienced anesthesiologist who was attending the case and collecting the data during the procedure. The preparation of midazolam and remifentanil solutions and installation of the infusion devices were done by an anesthesiologist who was blinded for the study groups.|This is a prospective, randomized clinical study. The patients were divided into two groups with a 1: 1 allocation and sealed envelope randomization method. Both groups of patients received intravenous midazolam, in Group 1, intravenous midazolam was administered continuously whereas, in Group 2, intravenous midazolam was administered as intermittent bolus doses. Both groups received intravenous remifentanil bolus doses as a rescue medication.|t|t|f|f
33782254|NCT05661526|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome evaluations will be conducted by a researcher blinded to group allocation.|This study is a randomized controlled study with experimental and control groups consisting of pre-test, post-test and persistence test.|f|f|f|t
33782255|NCT06087068|NA|SINGLE_GROUP||TREATMENT||NONE||The treatment goal after lobectomy was to control TSH within the normal reference range (0.4-5 mU/L)||||
33782256|NCT02998489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782257|NCT03746275|||COHORT||PROSPECTIVE|||||||
33782258|NCT05526508|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessor will be blinded to the participant's frequency group|There will be two frequency groups, once-weekly and twice-weekly, but the group's choice depends on the participants.|f|f|f|t
33782259|NCT00276328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782260|NCT02409160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782261|NCT04934462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782262|NCT00045695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782263|NCT04602364|||COHORT||PROSPECTIVE|||||||
33782264|NCT01313598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782265|NCT03207425|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33782266|NCT02794116|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782267|NCT00340340|||CASE_CONTROL||RETROSPECTIVE|||||||
33782268|NCT03848481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782269|NCT00248287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782270|NCT00814853|||CASE_CONTROL||PROSPECTIVE|||||||
33782271|NCT06698146|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The multidisciplinary team will decide the study arm assigned to the subject||||
33782272|NCT06615492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782273|NCT04558086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33782274|NCT03672760|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Participants will not know about other arms. Outcome assessors will not know the arms participant belong.|The participants will be randomized into 3 intervention groups as follows: IMT, IMT placebo and CardioBreath®App. The intervention will long five weeks. The exercises will be performed at home for five days/ week during 10 minute|t|f|f|t
33782275|NCT01878890|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782276|NCT05397808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Using a computer program, the investigators randomly placed individuals who completed the initial assessment into the pilates group or control group.|t|f|f|t
33782277|NCT01842243|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33782278|NCT05669833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782279|NCT03681340|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33782280|NCT05550298|||COHORT||PROSPECTIVE|||||||
33782281|NCT01459315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782282|NCT01657318|||COHORT||PROSPECTIVE|||||||
33782283|NCT05696808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All the variables would be studied before and after intervention with indian hepatoprotective diet (IHPD) in 60 patients with NAFLD and 60 healthy individuals on Western diet.||||
33782284|NCT02239185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782285|NCT05336123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One of the study MPIs and all but one of the Co-Investigators will be blind to group assignment.|Participants will be randomly assigned to either a 10 week hatha yoga class or health education class.|f|f|t|f
33782286|NCT03008343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782287|NCT00748969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997101|NCT03193021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data Safety Monitoring Committee will adjudicate endpoint events, blinded to treatment assignment when possible|Subjects randomized in 1:1 fashion to either Cardiva Mid-Bore Venous Vascular Closure Device (VVCD) or manual compression for multiple venous access site hemostasis|f|f|f|t
33997102|NCT02889315|||COHORT||PROSPECTIVE|||||||
33997103|NCT02275403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997104|NCT02638922|||CASE_CONTROL||RETROSPECTIVE|||||||
33997105|NCT01756716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997106|NCT00474058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782288|NCT00006221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782289|NCT05737563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997107|NCT06102148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782290|NCT00037700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782291|NCT02288858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33782292|NCT01101542|||COHORT||PROSPECTIVE|||||||
33782293|NCT05949372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind (researchers are not blinded) randomization will be provided, as the breastfeeding position will be given to the mother and newborn by the researchers. The statistician was also blinded for the data analysis purpose|Randomized Controlled Trial|f|f|f|t
33782294|NCT04267094|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782295|NCT00237367|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33782296|NCT06629025|||CASE_CONTROL||RETROSPECTIVE|||||||
33782297|NCT06217029|||CASE_ONLY||PROSPECTIVE|||||||
33782298|NCT04093128|NA|SINGLE_GROUP||OTHER||NONE||||||
33997108|NCT00209690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997109|NCT00934323|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33997110|NCT00136448|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33997111|NCT02672267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34087539|NCT03781271|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||2 arms of patients will undergo standard routine brachytherapy treatment. A part of the treatment involves the placement of catheters. For both arms of the study the placement of these catheters will be assisted by an electromagnetic navigation system. The difference between the arms will be that the navigation system will be used at different times in the course of their brachytherapy treatment to eliminate bias. One group will undergo electromagnetic navigation assisted catheter placement during their first fraction of treatment while the second arm will undergo electromagnetic navigation assisted catheter placement during their third fraction of treatment.||||
34087540|NCT00634504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782299|NCT04077684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782300|NCT02679651|||COHORT||PROSPECTIVE|||||||
33801460|NCT03741517|||COHORT||PROSPECTIVE|||||||
33801461|NCT04124042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916802|NCT06243341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|a double blind crossover study|a double blind crossover study|f|f|t|f
33916803|NCT04377061|||CASE_CONTROL||PROSPECTIVE|||||||
33693198|NCT04514003|||CASE_CONTROL||PROSPECTIVE|||||||
33693199|NCT02316548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693200|NCT04973397|||COHORT||PROSPECTIVE|||||||
33693201|NCT01037322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33693202|NCT06405139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693203|NCT05526989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693204|NCT05743036|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693205|NCT06637215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693206|NCT06709690|||OTHER||PROSPECTIVE|||||||
33693207|NCT04741997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693208|NCT03954041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693209|NCT06705153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized controlled study will be conducted to evaluate the effect of laughter yoga in patients with IBS who come to Erzurum City Hospital gastroenterology outpatient clinic. Patient information form, IBS symptom severity score (IBS-SSS), Depression, Anxiety and Stress Scale (DASS-42), Pittsburg Sleep Quality Index (PSQI) and IBS quality of life scale (IBS-QOL) will be applied to the patients. The patients in the intervention group will have laughter yoga for 2 sessions per week (total 8 sessions) for 4 weeks and the patients in the control group will not have laughter yoga. Patients in both groups will be evaluated for IBS-SSS at baseline and at the end of weeks 1, 2, 3 and 4. Patients in both groups will be administered DASS-42, PSQI and IBS-QOL at baseline and at the end of the 4th week.||||
33693210|NCT06709560|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants were blinded to the order of the visits until arrival at the laboratory.||t|f|f|f
33693211|NCT06549218|NA|SINGLE_GROUP||SCREENING||NONE||||||
33693212|NCT01194427|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693213|NCT03436563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693214|NCT05577871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33916804|NCT01836211|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916805|NCT04438018|||COHORT||PROSPECTIVE|||||||
33916806|NCT03377244|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Our aim is to pilot test a multi-level weight-loss intervention in the Marshallese community. Changes in outcomes were examined from baseline to 6 months post-intervention (12 months post-initiation of the intervention).||||
33916807|NCT03269656|||COHORT||PROSPECTIVE|||||||
33916808|NCT00718289|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33916809|NCT03236428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916810|NCT01479959|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33997112|NCT05570955|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be told that the monitors attached to their medication is recording their usage|All participants will receive their medication with electronic monitors attached. 50% of those enrolled will receive reminders to take their medication the other 50% will not.|t|f|f|f
33997113|NCT06627790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997114|NCT02031250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997115|NCT06626646|||COHORT||CROSS_SECTIONAL|||||||
33997116|NCT00014469||||TREATMENT||||||||
33997117|NCT01878864|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997118|NCT06301269|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33997119|NCT03051776|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The statistical analysis will be supervised by staff of the Scientific Support Unit: Epidemiology and Biostatistics (i+12), Hospital Universitario 12 de Octubre with the variables coded to blind the analyst.|"Two treatmet phases, with a four week wash out period bewtween them:~* A four week phase with Kinesio Taping~* A four week phase with compression garments."|f|f|f|t
33693215|NCT05500599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|double blinded|All children will be randomized to one of two groups of thirty patients each according to a computer-generated random numbers program in a double-blinded fashion, to receive either 0.5 mg/kg midazolam (Group M) or 10 μg/kg fentanyl (Group F) approximately 30 min before the induction of anaesthesia. All observers, as well as the children and their parents, will be blind to the study drug administered.|t|t|t|t
33693216|NCT00557427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693217|NCT05736198|||CASE_CONTROL||PROSPECTIVE|||||||
33693218|NCT02775604|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33693219|NCT01024218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693220|NCT05712369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916811|NCT01063816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916812|NCT00764478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916813|NCT05127070|||OTHER||PROSPECTIVE|||||||
33916814|NCT03314181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916815|NCT02927340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916816|NCT05562024|NA|SINGLE_GROUP||TREATMENT||NONE||Single group of qualified subjects used TAA06 injection||||
33916817|NCT01456845|||CASE_CONTROL||PROSPECTIVE|||||||
33916818|NCT03448224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33916819|NCT04381429|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916820|NCT05010629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916821|NCT01734980|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916822|NCT00280241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916823|NCT04881578|||COHORT||PROSPECTIVE|||||||
33916824|NCT04741334|||COHORT||PROSPECTIVE|||||||
33916825|NCT00574431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916826|NCT03416686|NA|SINGLE_GROUP||TREATMENT||NONE||Radiofrequency with local anesthesia: 1 episode of treatment||||
33916827|NCT00070980|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33997120|NCT02798458|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997121|NCT04777552|||CASE_CONTROL||RETROSPECTIVE|||||||
33997122|NCT01756885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997123|NCT01121419|||COHORT||RETROSPECTIVE|||||||
33997124|NCT00393276|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33997125|NCT01806272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997126|NCT05266287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997127|NCT02057562|||COHORT||PROSPECTIVE|||||||
33997128|NCT02042560|||CASE_CONTROL||PROSPECTIVE|||||||
33997129|NCT00521573|RANDOMIZED|PARALLEL||||DOUBLE||||||
33693221|NCT03875820|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Non-randomised: Participants are expressly assigned by phase of study and diagnosis.|"The dose escalation phase will enrol patients with advanced RAS mutant solid tumours.~In the dose expansion phase, patients are assigned to one of the following cohorts based on their diagnosis:~* KRAS mutant NSCLC cohort~* LGSOC cohort~* RAS mutant CRC cohort~* Advanced RAS mutant solid tumour cohort - patients in this cohort must have biopsiable disease, be willing and consent to undergo biopsies at three time-points.~* KRAS G12V mutant NSCLC cohort~* RAS/RAF mutant endometrioid cohort~* Pancreatic cohort"||||
33997130|NCT05281354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997131|NCT01855880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997132|NCT04739735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researcher (operator) who will perform all the injections and extractions as well as record heart rate measurements cannot be blinded to the type of intervention; a second impartial observer (evaluator) will record the Sensory, Eye, Motor (SEM) scale independently. The statistician will be blinded to the treatment groups. Since the participants will also be blinded, therefore, the study will be triple-blind.|"The study will be a two-arm randomized controlled clinical trial. It will be setup and reported according to the CONSORT guidelines.~Participants will be randomly and equally allocated to one of the two arms (Figure 1).~* Group I: (experimental group n = 25) assigned to CC-ILA.~* Group II: (control group n = 25) assigned to conventional injection by IANB."|t|f|t|t
33693222|NCT05868044|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33693223|NCT02005432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693224|NCT06708663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693225|NCT06503471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomize double-blind||t|f|t|f
33997133|NCT05321030|||OTHER||CROSS_SECTIONAL|||||||
33997134|NCT03245658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997135|NCT03497858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997136|NCT05239169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment consists of durvalumab and tremelimumab with or without capecitabine.||||
33997137|NCT04290507|||COHORT||RETROSPECTIVE|||||||
33997138|NCT04699084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned to two groups. One group underwent a music intervention postoperatively, while the other received only usual postoperative care (control group).||||
33997139|NCT03401281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Fats will be embedded in processed cheese - extend of masking will be assessed in sensory study||t|f|t|t
33997140|NCT02033902|||COHORT||PROSPECTIVE|||||||
33997141|NCT06175364|NA|SINGLE_GROUP||OTHER||NONE||||||
33693226|NCT06710704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693227|NCT04543409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33693228|NCT06707610|NA|SEQUENTIAL||TREATMENT||NONE||||||
33801462|NCT00452270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997142|NCT03095781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997143|NCT03273751|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, care providers, investigators and outcome assessors will be blinded to group allocation.|A prospective, randomized, parallel group, controlled study|t|t|t|t
33997144|NCT00627328|||COHORT||PROSPECTIVE|||||||
33997145|NCT01601353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997146|NCT02068651|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33997147|NCT01918813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33997148|NCT06559800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997149|NCT02073890|||||CROSS_SECTIONAL|||||||
33997150|NCT01820091|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997151|NCT05299463|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Exercise study|||||
33997152|NCT03176381|||COHORT||PROSPECTIVE|||||||
33997153|NCT03225664|NA|SEQUENTIAL||TREATMENT||NONE||||||
33997154|NCT01942135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997155|NCT02959619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997156|NCT05441592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997157|NCT01185158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997158|NCT00354159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997159|NCT01959828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916828|NCT06155916|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients start with pregabalin at dose 25mg-75mg per day according to their preference and dose will be added by 25mg to 75 mg/ 4 days up to the highest dosage the patient tolerates (maximum 300mg twice daily). After having pregabalin stabile for one month with the highest tolerated dosage, post-examinations are repeated while still using pregabalin.||||
33916829|NCT00191074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916830|NCT05242445|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33916831|NCT06390189|||COHORT||PROSPECTIVE|||||||
33916832|NCT02746523|||CASE_CONTROL||OTHER|||||||
33916833|NCT02961686|||COHORT||PROSPECTIVE|||||||
33916834|NCT00838916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916835|NCT04093258|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33916836|NCT04195100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33916837|NCT03013205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916838|NCT04811248|||COHORT||PROSPECTIVE|||||||
33916839|NCT00800865|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916840|NCT00505232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916841|NCT00694694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916842|NCT06093217|||COHORT||OTHER|||||||
33916843|NCT04274140|||COHORT||PROSPECTIVE|||||||
33916844|NCT05643092|||COHORT||PROSPECTIVE|||||||
33916845|NCT04380974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997160|NCT05644184|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||A 15-arm, randomized, observer-blind, controlled, age de-escalation, dosage escalation study.|t|t|t|t
33693229|NCT06275581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded evaluation||t|f|f|t
33693230|NCT04585152|RANDOMIZED|PARALLEL||TREATMENT||NONE||The RTX-MMF trial is an open-label, two-parallel-arm, controlled and randomized clinical trial testing the superiority of RTX over MMF in maintaining steroid free disease remission in patients with SDNS||||
33693231|NCT04944095|||CASE_ONLY||PROSPECTIVE|||||||
33916846|NCT02209311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997161|NCT06562959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33997162|NCT05512923|||COHORT||PROSPECTIVE|||||||
33997163|NCT05789173|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Open-label, two period, fixed sequence clinical study||||
33997164|NCT03849846|||OTHER||CROSS_SECTIONAL|||||||
33997165|NCT04125394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997166|NCT01584882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33997167|NCT04491422|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized in a 1:1 ratio to either quarterly Integrated Next Steps Counseling (iNSC) using point-of-care (POC) urine tenofovir (TFV) levels \[intervention arm\] or standard adherence counseling without drug level feedback \[control arm\].||||
33997168|NCT00075608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997169|NCT06185244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors will be used.|Randomized controlled trial|f|f|f|t
33997170|NCT05080387|||CASE_CONTROL||PROSPECTIVE|||||||
33997171|NCT00337493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693232|NCT00667602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997172|NCT03307551|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The patient will be blinded to the type of anaesthesia intervention.The attending anaesthesiologist will however not be blinded to the technique utilized to administer GA and recovery immediately after extubation inside the OR. The postoperative patient recovery profile will be evaluated by an independent assessor blinded to the technique of GA.|"30-patients aged 18-65 years, ASA physical status I-III, of either sex, and undergoing unilateral open thoracic surgery or unilateral video-assisted thoracic surgery (VATS) will randomly allocated by computer generated numbers to one of the following two groups of 15 patients each:~Group-1 \[CLADS Group, n=15, Study group\]: Anaesthesia will be induced and maintained with propofol administered using the automated CLADS.~Group-2 \[Manual Group, n=15, Control group\]: Anaesthesia will be induced and maintained with propofol administered using manually controlled infusion pumps titrated to BIS scores."|t|f|f|t
33693233|NCT04621565|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participant, investigator, and outcome assessors are all prevented from having knowledge of the interventions assigned to individual participants. Care provider knows the individualized interventions.|Participants are assigned to one of two groups, whether using hydrocortisone or not during peri-operation, in parallel for the duration of the study.|t|f|t|t
33693234|NCT06470607|||COHORT||PROSPECTIVE|||||||
33693235|NCT06207968|||COHORT||OTHER|||||||
33693236|NCT05437263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782301|NCT06546449|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The investigators and participants will remain blinded throughout the study. At the completion of each cohort, the statistician will be unblinded to analyze data.||t|t|t|t
33782302|NCT06107621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782303|NCT06696833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916847|NCT06025123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients in the intervention group will be treated with hypothermia, which makes blinding for care provider and next of kin difficult in the intervention phase (first 36 h). Participants will be informed of which group the were assigned to if they regained consciousness. The study personnel assessing neurologic outcome at discharge and at 90 days will be blinded for which study group the participant belongs to. In addition, the physician performing the prognostication at 72 hours from cardiac arrest will be a neurologist, intensivist or other specialist experienced and will be blinded for group allocation, but not for relevant clinical data.|Patients will be randomized by EMS personnel at the scene of cardiac arrest to either a) intervention: early transnasal evaporative cooling initiated within 20 minutes from EMS arrival, and subsequent systemic hypothermia at 33°C for 24 h and fever control for 72 h in the ICU, or b) control: standard ACLS (advanced cardiac life support) and fever control (normothermia) for 72 h in the ICU.|f|f|t|t
33916848|NCT01030458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997173|NCT05150223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
33997174|NCT03564587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997175|NCT05373576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997176|NCT00295490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997177|NCT04554290|||COHORT||RETROSPECTIVE|||||||
33997178|NCT00155649|||DEFINED_POPULATION||OTHER|||||||
33997179|NCT04848090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is an observational study to understand if the use of whole genome sequencing (WGS) increases the speed to diagnosis and how clinical management is changed in an intensive care population of neonates.~Participants will include 100 neonates and their parents for trio analysis, for up to 300 individuals for whom consent is obtained testing will be completed. Participants will also include 100 matched historical controls."||||
33997180|NCT04123587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997181|NCT00252161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997182|NCT05139628|||COHORT||PROSPECTIVE|||||||
33997183|NCT05311072|||COHORT||PROSPECTIVE|||||||
33916849|NCT01760993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916850|NCT02097758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916851|NCT03579524|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33916852|NCT02662985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916853|NCT02019524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33916854|NCT00992966|||COHORT||PROSPECTIVE|||||||
33916855|NCT03938441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916856|NCT01983410|||COHORT||PROSPECTIVE|||||||
33916857|NCT01861938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997184|NCT06063460|||COHORT||PROSPECTIVE|||||||
33997185|NCT02213705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693237|NCT05620641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33693238|NCT06682169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693239|NCT00814788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693240|NCT04595344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693241|NCT05732623|||CASE_CONTROL||PROSPECTIVE|||||||
33693242|NCT06692036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693243|NCT06709989|||COHORT||PROSPECTIVE|||||||
33693244|NCT03525093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782304|NCT05685758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One hundred and ten participants will be randomly assigned into one of the groups: the intervention group or the control group, which is a delayed intervention group (waitlist intervention). Intervention group participants will be sent a link to download an FTP-based mobile application and be asked to complete weekly surveys and monthly visits with study clinicians for 8 weeks.|f|f|f|t
33782305|NCT02692235|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33782306|NCT04986215|||CASE_CONTROL||OTHER|||||||
33782307|NCT04284748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782308|NCT00797225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782309|NCT02461238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782310|NCT01084161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782311|NCT02424344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916858|NCT04039191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916859|NCT01534234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916860|NCT02822534|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33916861|NCT05784337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916862|NCT03939351|||COHORT||PROSPECTIVE|||||||
33997186|NCT02255149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693245|NCT06695299|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group which received the selected exercise program and the study group received the same exercise training program in addition to Kinesthetic and Visual Motor Imagery Training||||
33997187|NCT05863533|||OTHER||PROSPECTIVE|||||||
33693246|NCT05736835|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33693247|NCT05732987|||CASE_CONTROL||PROSPECTIVE|||||||
33693248|NCT05276180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693249|NCT06318026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|EHR and survey (latter masked)||f|f|f|t
33997188|NCT00816413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997189|NCT03955276|||COHORT||PROSPECTIVE|||||||
33997190|NCT02024048|||CASE_CONTROL||PROSPECTIVE|||||||
33997191|NCT04921631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33997192|NCT05485064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the examination, the acupuncture position was blocked to ensure that the acupuncture position was not visible; except for researcher 1, the only researcher who knew about the grouping of patients,All trial-related data were recorded by researcher 2 , and researcher 1 was responsible for patients'sedation.||t|f|t|f
33693250|NCT06707597|||OTHER||PROSPECTIVE|||||||
33997193|NCT03317067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
33997194|NCT04070807|||COHORT||RETROSPECTIVE|||||||
33693251|NCT06708624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997195|NCT04904094|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We will include patients who receive casting at the lower limb for the intervention group. Patient with no indication for treatment will be asked for participation in the control group. The children in the control group will continue their usual care or normal routine treatment, i.e. physiotherapy and orthotic devices.||||
33693252|NCT06709066|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33693253|NCT06378866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693254|NCT06438562|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"Participants will be randomized and blinded to all treatments and treatment sequence.~Care providers and investigators are blinded to experimental treatments and treatment sequence.~Outcome assessors are blinded to all treatments and treatment sequence."|Participants will receive all 3 study treatments over 3 treatment periods.|t|t|t|t
33693255|NCT06660550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||evaluate the results of Needlescopic inguinal hernia repair in comparison with traditional laparoscopic repair in children as regard operative time, cosmetic appearance, recurrence and other complications|t|f|f|f
33693256|NCT06708286|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693257|NCT05660681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-masked, single-center, interventional trial|t|f|t|f
33693258|NCT01234207|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33693259|NCT02385214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693260|NCT01137318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33916863|NCT01884857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916864|NCT03741296|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a study is a multicentre, prospective, parallel, two-arm, randomized controlled trial aiming to assess the efficacy of single stage revision peri-prosthetic joint infection of hip arthroplasty in adult's patients, compared to the current gold standard of care, two-stage revision.||||
33916865|NCT02158702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916866|NCT01929655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997196|NCT03081897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997197|NCT03296956|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|all are blinded|one arm receives Motherwell and one arm receives placebo; randomized double blind The supplement is expected to prevent depressed mood induction during postpartum blues whereas the placebo is not. The effect of depressed mood induction is strong during postpartum blues in 75% to 95% of mothers (who do not take Motherwell). The supplement is the intervention.|t|t|t|t
33997198|NCT04125862|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Individual performing data analyses will be blinded to whether dataset corresponds to FD/MAS patient or matched healthy control|2 parallel cohorts (FD/MAS patients and matched, healthy controls)|t|f|f|f
34087541|NCT04571203|NA|SINGLE_GROUP||TREATMENT||NONE||End Stage Renal Disease subjects will receive a deceased donor kidney and vertebral body stem cell infusion. These transplant recipients post kidney transplant will undergo conditioning by ATG, Total Lymphoid irradiation and 1 single dose of TBI. Subsequently, the vertebral body stem cell infusion will be administered.||||
34087542|NCT00204789|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34087543|NCT05966558|||COHORT||PROSPECTIVE|||||||
34087544|NCT05156008|RANDOMIZED|PARALLEL||OTHER||NONE||Comparison of two arms. One arm ultrasound guided vascular access (UGVA) and control group standard vein cannulation with palpation.||||
34087545|NCT00317369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33693261|NCT05537090|NA|SEQUENTIAL||TREATMENT||NONE||This is an open-label, 3 period fixed-sequence, Phase 1 clinical study to evalu-ate the effect of multiple doses of BV100 on the Pharmacokinetics on midazo-lam and its metabolite 1-hydroxymidazolam in healthy volunteers.||||
33693262|NCT00608543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693263|NCT03740867|NON_RANDOMIZED|PARALLEL||OTHER||NONE||After completion of the program, patients will be divided into two groups according to their cognitive status (Group 1: those with poor cognition; Group 2: those with good cognition). The PR gains of the groups will be compared.||||
33693264|NCT05653726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33916867|NCT04922619|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: the patient and the investigator don't know the fitting.|"Two arms A and B:~Arm A: patient's fitting with default fitting --\> 6 weeks use --\> tests and patient's fitting with tonotopy based fitting --\> 6 weeks use --\> tests~Arm B: patient's fitting with tonotopy based fitting --\> 6 weeks use --\> tests and patient's fitting with default fitting --\> 6 weeks use --\> tests"|t|f|t|f
33693265|NCT05211518|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
33693266|NCT02661451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693267|NCT04755153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693268|NCT06708351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||hybrid type 2 implementation-effectiveness cluster randomized clinical trial||||
33693269|NCT06130800|||COHORT||PROSPECTIVE|||||||
33693270|NCT01496976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916868|NCT03488251|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33916869|NCT05986032|||COHORT||RETROSPECTIVE|||||||
33916870|NCT01972009|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33916871|NCT01129180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916872|NCT02730442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916873|NCT00992784|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33916874|NCT03374748|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33916875|NCT00564434|||COHORT||PROSPECTIVE|||||||
33916876|NCT02611674|||COHORT||PROSPECTIVE|||||||
33916877|NCT00274157|||||PROSPECTIVE|||||||
33916878|NCT01519284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916879|NCT00723411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916880|NCT01970930|||OTHER||PROSPECTIVE|||||||
33916881|NCT06402812|||OTHER||PROSPECTIVE|||||||
33916882|NCT05109819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome of randomization is not reviled to the patient.|Patients with metastatic spinal cord compression in the cervical and/or thoracic spine are randomized into two groups. Group A receives standard radiotherapy, group B receives esophagus sparing therapy.|t|f|f|f
33916883|NCT01889654|||OTHER||PROSPECTIVE|||||||
33916884|NCT05553678|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33916885|NCT02381496|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33916886|NCT03263936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916887|NCT03986775|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33916888|NCT03337152|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into one of two arms. 1a will receive primaquine for 14 days, and Arm 1b will receive chloroquine for 3 days and concomitant primaquine for 14 days.||||
33916889|NCT01721031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916890|NCT01758965|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33916891|NCT04625894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916892|NCT03001843|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33916893|NCT03889600|NA|SINGLE_GROUP||SCREENING||NONE||||||
33916894|NCT05446025|||COHORT||PROSPECTIVE|||||||
33916895|NCT03714282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916896|NCT00772382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916897|NCT03886142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||patients with chronic knee osteoarthritis non res ponders to conventional medical treatment|f|f|f|t
33916898|NCT00229203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916899|NCT03809832|||COHORT||PROSPECTIVE|||||||
33916900|NCT03079349|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Subjects were randomized into a control group attending a traditional classroom and a trial group of equal numbers participating in an online synchronous Internet streaming classroom."||||
33693271|NCT03824106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693272|NCT06067204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the emergency medical service crew will know the intervention in each participant. The patient will not be aware of the type of ventilation strategy because of OHCA status. The investigator and outcomes assessor will not able to acquire the allocation results until the study ends.||t|f|t|t
33693273|NCT05281016|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693274|NCT05497518|||COHORT||PROSPECTIVE|||||||
33916901|NCT00737009|||||PROSPECTIVE|||||||
33916902|NCT06081673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916903|NCT01270243|||CASE_CONTROL||PROSPECTIVE|||||||
33916904|NCT05469477|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33916905|NCT02258867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916906|NCT03056976|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative effectiveness of thre competing strategies for the edentulous mandible using implants||||
34087546|NCT00797563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087547|NCT01450735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087548|NCT04465422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are blind during this clinical trial. They are prevented from having knowledge of the interventions.|We will recruit 70 inpatients with schizophrenia and devided into intervention group, based on MOHO theory, and control group.|t|f|f|t
34087549|NCT01782092|||CASE_ONLY||PROSPECTIVE|||||||
34087550|NCT06420739|||COHORT||PROSPECTIVE|||||||
34087551|NCT01582451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087552|NCT01207960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087553|NCT02787304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782312|NCT05753293|RANDOMIZED|PARALLEL||PREVENTION||NONE||Sixty patients of both genders with age range from 40-50 years old will be recruited from El Khankah Centeral Hospital with positive nasopharyngeal swab samples and presence of ground-glass opacification in their chest computed tomography scan (CT-scan) will be assigned randomly into two groups A \& B and take their medications.||||
33782313|NCT00041262|RANDOMIZED|||TREATMENT||||||||
33782314|NCT01773863|||COHORT||PROSPECTIVE|||||||
34087554|NCT04103008|||COHORT||PROSPECTIVE|||||||
34087555|NCT04132713|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087556|NCT04098835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087557|NCT02213783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087558|NCT06036472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087559|NCT06251947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087560|NCT05617365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The primary aim of our study is to test the combined effectiveness of osteopathic manipulative treatment (OMT) and targeted head exercise (THE) to achieve a significant decrease in headache measures of frequency, intensity, and duration in a Treatment group when compared to a Control group whose members receive only standard medical care.|t|f|f|f
34087561|NCT02239432|||COHORT||PROSPECTIVE|||||||
34087562|NCT03853486|||COHORT||PROSPECTIVE|||||||
33916907|NCT06129396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916908|NCT02849964|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34087563|NCT01762787|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34087564|NCT01273961|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34087565|NCT02339636|||CASE_CONTROL||RETROSPECTIVE|||||||
34087566|NCT00649688|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33782315|NCT05832723|||COHORT||PROSPECTIVE|||||||
33782316|NCT01416909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34087567|NCT03582683|RANDOMIZED|PARALLEL||OTHER||NONE||After a baseline assessment, participants will be randomized to the CPSMP intervention or a 6-month, wait-list control group based on an allocation sequence based on class size, that will be stratified by site and allocated via opaque envelopes.||||
34087568|NCT01710423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693275|NCT05337293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All data were collected by a research assistant blinded to study group assignment and purpose of study. A second research assist blinded to study purpose and intervention conducted all participant contacts with the attention group.|This parallel 3-arm (intervention, attention, control) randomized controlled trial (N = 90) will concurrently enroll patients with heart failure to either a 12-week intervention (COPE-HF Partnership), a 12-week attention group (contacts spaced similarly to that of the intervention group), or a control group. All data collection contacts occur at identical intervals among groups.|f|f|f|t
33693276|NCT04910256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are randomly and evenly assigned to 2 groups using block randomization.Random numbers are generated by the stratified random method using the Statistical Analysis Software （SAS） statistical software and assigned by an independent statistician at the Good Clinical Practice Institute of XiYuan Hospital.||f|f|f|t
33693277|NCT00135733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33693278|NCT05612022|||COHORT||PROSPECTIVE|||||||
33693279|NCT06238661|NA|SINGLE_GROUP||SCREENING||NONE||||||
33693280|NCT04637906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33693281|NCT04544189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693282|NCT05945745|||CASE_ONLY||PROSPECTIVE|||||||
33693283|NCT00089284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693284|NCT02328911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693285|NCT06277037|||OTHER||OTHER|||||||
33693286|NCT05531201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782317|NCT00708279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782318|NCT01095224|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33782319|NCT03770377|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A cross-sectional study design will be used to examine laryngeal adaptation across all study groups.||||
33782320|NCT06613919|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority trial||||
33782321|NCT02249481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782322|NCT06342258|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"After baseline examination, a randomized generator, will be used in order to issue which side will bonding agent cured prior to sealant placement. Randomization will be a simple randomization, and will be determined by the provider flipping a coin. Randomization will be performed to ensure graders of sealants will be blinded to which side of bond is cured prior to sealant placement.~Heads indicates the RIGHT side of mouth WILL be cured prior to sealant placement. The left side of the mouth will have bond and sealant cured together after.~Tails indicates the LEFT side of the mouth WILL be cured prior to sealant placement. The right side of the mouth will not have bond cured prior to sealant placement."|t|f|f|t
33782323|NCT03840070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916909|NCT03170479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33916910|NCT00479557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916911|NCT00835107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916912|NCT00792233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916913|NCT00530556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33916914|NCT04466501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916915|NCT05626517|||COHORT||PROSPECTIVE|||||||
33916916|NCT02476591|||COHORT||PROSPECTIVE|||||||
33916917|NCT01471704|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33916918|NCT03814590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33916919|NCT00797069|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33916920|NCT00389103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33916921|NCT06258135|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916922|NCT05400473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The principal investigator will not be part of any assessment or treatment process.~Two researchers will be solely responsible for evaluating the outcomes. These will not participate in any other process. And they did not know the allocation of participants in their respective groups."||f|f|t|t
33916923|NCT03119844|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33916924|NCT00243100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916925|NCT04839354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33916926|NCT03217773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916927|NCT02029352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916928|NCT03311399|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33916929|NCT02165033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916930|NCT03863067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916931|NCT01349686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916932|NCT00257023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916933|NCT02558556|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33782324|NCT03810885|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|"The participants will be unaware of the treatment groups and the salt content of the bread products will be blinded to the participants.~Nurses examining participants at baseline and follow-up will be unaware of which intervention group the families were randomized into. The primary outcome measures will be blinded to the outcome assessors."|"Active Comparator:~Intervention A : Salt reduced bread~Assigned Interventions: Participants will receive salt reduced bread and no dietary counselling.~Active Comparator:~Intervention A+B: Salt reduced bread + Dietary counselling~Assigned Interventions: Participants in this group will receive both salt reduced bread and dietary counselling to reduce salt and increase potassium intake.~Placebo comparator:~Control: normal bread~Assigned Interventions: Participants will receive bread with a regular content of salt and no dietary counselling."|t|f|f|f
33782325|NCT00578695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916934|NCT06160869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Information is not withheld from trial participants|"Current study is an open label, two-arm, parallel, randomized controlled trial, evaluating the efficiency of Acceptance and Commitment Therapy (ACT) added to treatment as usual (TAU) as opposed to treatment as usual (TAU) alone on patients with schizophrenia. The study adheres to the rules for writing Clinical Trials: The Consolidated Standards of Reporting Trials (CONSORT) statement"||||
34087569|NCT04342169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2, prospective, placebo-controlled, parallel group, randomized trial||||
34087570|NCT02873663|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|t|f
34087571|NCT04639882|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Heavy drinking college students (N=498) participated in a 2 (in-person vs. remote delivery) × 2 (compensation vs. no compensation) × 2 (PNF vs. control) design with follow-up assessments occurring remotely three and six months later.|t|f|f|f
34087572|NCT04649424|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34087573|NCT02747927|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087574|NCT04132219|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessors of anthropometric, physical function, patient reported outcomes and biospecimens are blinded to arm status|We anticipate enrolling 56 dyads of participants (2 per dyad). Each dyad will be randomized to either receive the intervention for 6 months or be placed on a 6-month waitlist and offered the opportunity to try the online intervention after final assessments are completed.|f|f|t|t
34087575|NCT05237375|||OTHER||PROSPECTIVE|||||||
34087576|NCT02620280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087577|NCT04547751|||CASE_ONLY||RETROSPECTIVE|||||||
34087578|NCT00254371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087579|NCT02090881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087580|NCT06034184|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34087581|NCT02204189|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34087582|NCT03789877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34087583|NCT01868672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087584|NCT05173311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087585|NCT06193135|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center, randomized, open-label, parallel-group, low-intervention, single-center clinical trial.||||
34087586|NCT01066377|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34087587|NCT02511717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087588|NCT02664688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087589|NCT03821597|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, randomized, controlled study.||||
34087590|NCT05930288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916935|NCT00285103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916936|NCT02843581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916937|NCT06468501|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study will be double-blinded, which means that both the participants and the researchers are not aware in which treatment group participants are assigned to.|The design is a randomised controlled trial, with 4 (interventions) x 2 (high vs low SEP) between-subject conditions.|t|f|t|f
33916938|NCT05027516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33916939|NCT01170117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087591|NCT04582617|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34087592|NCT01021189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34087593|NCT01801540|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34087594|NCT02137798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087595|NCT06097832|NA|SEQUENTIAL||TREATMENT||NONE||"Open label single-arm clinical study of NXC-201 CAR-T will proceed sequentially through dose cohorts as follows:~Cohort 1 - 150×10\^6 CAR-positive (CAR+) T cells (3 patients)~Cohort 2 - 450×10\^6 CAR-positive (CAR+) T cells (3 patients)~The dose expansion phase will then proceed."||||
33916940|NCT01895452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916941|NCT05912920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916942|NCT04235530|||CASE_CONTROL||PROSPECTIVE|||||||
33916943|NCT04224428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916944|NCT00004278|RANDOMIZED|||TREATMENT||||||||
33916945|NCT06358937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33916946|NCT06345755|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33916947|NCT00374855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33916948|NCT00934427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916949|NCT03386331|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33916950|NCT06483165|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized parallel 2-group design will be used to allow a rigorous assessment of the comparative efficacy of the two acronyms (BE FAST and F.A.S.T.) among English-speaking adults of diverse race and ethnicity.||||
33916951|NCT04787588|||COHORT||RETROSPECTIVE|||||||
34087596|NCT02172547|||COHORT||PROSPECTIVE|||||||
34087597|NCT06053944|||COHORT||PROSPECTIVE|||||||
34087598|NCT02475148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087599|NCT04759547|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34087600|NCT04490460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study product was provided for each arm in identical capsules.|Balanced randomization first arm, formulation WBF-0031 and placebo. Second arm all subjects formulation WBF-0031.|t|t|t|t
34087601|NCT03764124|||COHORT||PROSPECTIVE|||||||
33782326|NCT04034238|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782327|NCT04990687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782328|NCT02582203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782329|NCT03199287|||COHORT||PROSPECTIVE|||||||
33782330|NCT03409718|||COHORT||PROSPECTIVE|||||||
34087602|NCT03931070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782331|NCT04100356|RANDOMIZED|FACTORIAL||OTHER||NONE||Diet and exercise, or diet only||||
33916952|NCT03137121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will receive the study drug or placebo in a double-blind fashion.|There will be two groups for the study: Olanzapine Group will receive the study drug and Placebo Group will receive a placebo.|t|t|t|f
33916953|NCT06409091|||CASE_CONTROL||RETROSPECTIVE|||||||
34087603|NCT02721069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916954|NCT00367289|||COHORT||PROSPECTIVE|||||||
33916955|NCT04717141|NA|SINGLE_GROUP||OTHER||NONE||||||
33916956|NCT03444818|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33916957|NCT00607958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916958|NCT02522832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33916959|NCT00004418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916960|NCT05093257|||CASE_CONTROL||RETROSPECTIVE|||||||
33916961|NCT03630484|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916962|NCT02786940|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33916963|NCT05343806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916964|NCT01951690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916965|NCT04253834|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single center, prospective, randomized controlled study||||
33916966|NCT06552715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916967|NCT04012944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33916968|NCT05693090|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33916969|NCT02042339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33916970|NCT04944888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33916971|NCT02494739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33916972|NCT05594108|RANDOMIZED|PARALLEL||OTHER||NONE||Control group=non ultrasound guided IUD insertion Experimental group=ultrasound guided IUD insertion||||
33916973|NCT03060083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33916974|NCT02357797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916975|NCT05579912|||COHORT||RETROSPECTIVE|||||||
33916976|NCT05140395|NA|SINGLE_GROUP||OTHER||NONE||in situ used for near patient In vitro Medical device||||
33916977|NCT00286130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916978|NCT02935699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916979|NCT02207478|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33916980|NCT03901807|RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects will be randomized in a 2:1 ratio to the two groups (PMX cartridge plus standard of care: standard of care alone). A blocked randomization scheme will be used to provide approximately balanced ratio allocations to the two groups for each investigative site during the study.||||
33916981|NCT01597037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916982|NCT02278640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916983|NCT06020027|RANDOMIZED|PARALLEL||PREVENTION||NONE||Water is K'é is an early child education (ECE) intervention designed to promote family-centered choice using a strength-based approach. Water is K'é promotes multilevel change through strengthened cultural connections, enhanced health literacy, and increased access to drinking water, with the goal of promoting family cohesion and improving health outcomes among family members.||||
33916984|NCT03521193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: patients treated with PFO closure Group 2: Healthy subjects on Aspirin therapy||||
33916985|NCT04307836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916986|NCT05811767|||COHORT||CROSS_SECTIONAL|||||||
33916987|NCT00747838|||COHORT||PROSPECTIVE|||||||
33916988|NCT06045559|||CASE_CONTROL||PROSPECTIVE|||||||
33916989|NCT03107455|||COHORT||PROSPECTIVE|||||||
33916990|NCT01259973|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33916991|NCT04044092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33916992|NCT01969799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33916993|NCT01760824|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33916994|NCT04966884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916995|NCT00305253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916996|NCT05732844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33916997|NCT01289626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33916998|NCT04026854|||COHORT||PROSPECTIVE|||||||
33916999|NCT01887587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917000|NCT00511342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087604|NCT04108390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087605|NCT03039478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Parallel assignment|t|f|f|f
34087606|NCT02830659|||CASE_ONLY|||||||||
34087607|NCT00025779|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34087608|NCT04443465|||COHORT||PROSPECTIVE|||||||
34087609|NCT03001102|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33782332|NCT04240119|||COHORT||PROSPECTIVE|||||||
33782333|NCT04610684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782334|NCT01426945|||CASE_ONLY||RETROSPECTIVE|||||||
33782335|NCT05196594|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33782336|NCT04544540|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized open-label pragmatic controlled trial||||
33782337|NCT00362193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782338|NCT06486935|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33782339|NCT05476822|||COHORT||PROSPECTIVE|||||||
33782340|NCT02836145|||||PROSPECTIVE|||||||
33782341|NCT00004870||||TREATMENT||||||||
33782342|NCT02941146|NA|SINGLE_GROUP||OTHER||NONE||||||
33782343|NCT01799408|||CASE_CONTROL||PROSPECTIVE|||||||
33693287|NCT06709027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study employs a parallel assignment design where participants are randomly assigned to either the experimental group receiving Mobile Health Management Intervention or the control group receiving a standard treatment. The study is single-blind, meaning participants are unaware of which group they belong to, thus minimizing potential bias. Data will be collected at regular intervals to evaluate the efficacy and safety of the intervention.|t|f|f|f
33693288|NCT05820230|||COHORT||PROSPECTIVE|||||||
33693289|NCT06697847|||CASE_ONLY||CROSS_SECTIONAL|||||||
33693290|NCT06161441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693291|NCT00053365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693292|NCT04815031|||CASE_ONLY||PROSPECTIVE|||||||
33997199|NCT05697679|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The first author will use randomizer.org for randomization. Recruitment without informing the subjects of study participation and group allocation to blind the subjects. And the allocation is also concealed for researchers in charge of data collection and processing.|The present study is based on a stratified randomized controlled design with two groups. The stratification is done with four groups based on the BMI (underweight, ≤18.5; normal weight, 18.5-24.0; overweight, 24.0-28.0; obesity, BMI of 28 or greater) indicated at registration. Each participant is randomly assigned to either the different group 1 week before the study.|t|f|f|t
33997200|NCT05795959|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized controlled trial|f|f|f|t
33693293|NCT06511882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693294|NCT03967977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693295|NCT06707649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomised Controlled Trial|t|f|f|f
33693296|NCT06015789|||OTHER||PROSPECTIVE|||||||
33693297|NCT05224349|||COHORT||PROSPECTIVE|||||||
33693298|NCT02319837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomized blinded portion of the study has concluded. The study is now being conducted open label manner.||t|t|t|t
33693299|NCT02860377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33693300|NCT03213600|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||The investigators will enroll 150 subjects comprising three population groups SZ, At Risk and HS.) Immediately after inclusion, participants will be randomized into 2 equal groups via random generation of two binary integer's reflecting tDCS-treatment condition or the tDCS control (sham) resulting in random allocation into one of 2 study arms. This randomization will be stratified per population group to insure that both conditions are equally reflected across all three groups.|t|t|t|t
33693301|NCT05489211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is open label. Patients will be assigned treatment in all Substudies.|"Within each substudy, Dato-DXd will be evaluated as monotherapy (all except #2 Gastric Cancer) and in combination with approved or novel anticancer agents that may be active in the tumour type being evaluated (all except #1 Endometrial Cancer and #7 Biliary Tract Cancer). All substudies will be treatment assigned.~Substudy 1 (Endometrial): MONO: Dato-DXd~Substudy 2 (Gastric): COMBO: Dato-DXd + capecitabine, Dato-DXd + 5-FU~Substudy 3 (mCRPC): MONO: Dato-DXd; COMBO: Dato-DXd + prednisone/prednisolone~Substudy 4 (Ovarian): MONO: Dato-DXd; COMBO: Dato-DXd + carboplatin + bevacizumab --\> Dato-DXd + bevacizumab~Substudy 5 (CRC): MONO: Dato-DXd; COMBO: Dato-DXd + 5-FU + leucovorin + bevacizumab or Dato-DXd + capecitabine + bevacizumab~Substudy 6 (Urothelial): MONO: Dato-DXd; COMBO: Dato-DXd + volrustomig, Dato-DXd + rilvegostomig, Dato-DXd + carboplatin or cisplatin~Substudy 7 (BTC): MONO: Dato-DXd"||||
33693302|NCT03051854|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33693303|NCT04868058|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This clinical investigation is an interventional uni-center, prospective, open, randomized, double arm, blinded to the pain physician and the patient, clinical evaluation|t|t|f|f
33693304|NCT05437211|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693305|NCT05956821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693306|NCT03335111|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients without BAIPC are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .|BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation).|t|f|f|f
33782344|NCT00002556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782345|NCT04737590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782346|NCT04968587|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33782347|NCT03037060|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782348|NCT05744128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782349|NCT02055209|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33782350|NCT06576908|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, single-arm, single-site study designed to generate data describing the image quality and applicability/useability of a high-performance, on-couch CBCT imaging technology in patients receiving radiation treatment for cancer.||||
33782351|NCT06156007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The research was planned as a single-center, parallel randomized controlled experimental study with stratified randomization (mild-moderate, severe-very severe) and pretest-posttest control group.|f|f|f|t
33782352|NCT03281564|||CASE_ONLY||PROSPECTIVE|||||||
33782353|NCT06313723|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (Participant) Which of the participants is the control or intervention group will be selected by randomization.|Randomized controlled single-blind quasi-experimental study|t|f|f|f
33782354|NCT02724267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801463|NCT04113096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|For each condition there will be two arms of treatment. One arm will receive the investigational product and standard of care the other arm will receive placebo and standard of care|t|t|t|t
33997201|NCT03164460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997202|NCT03774537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997203|NCT00147134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997204|NCT03595462|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||tightly-controlled, randomized cross-over design|f|f|t|f
33997205|NCT03725345|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33997206|NCT02075645|NA|SINGLE_GROUP||||NONE||||||
33997207|NCT06200480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized prospetive study||||
33997208|NCT02408653|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33782355|NCT02429609|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"This in a basic science exploratory study to examine the effect of keratoconus on visual acuity as measured using pseudo-high-pass filtered optotypes. The MAC will be compared with the standard charts currently used to monitor visual acuity (logMAR chart) and contrast sensitivity (Pelli-Robson). Researcher effects and researcher bias will be controlled by setting a written protocol for all testing procedures. Each procedure will be standardised and random checks will be made by the chief investigator on all anonymous record sheets. Neither the chief investigator nor the co-researchers will act as participants for this study."||||
33782356|NCT00647413|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33782357|NCT01230034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782358|NCT05714553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782359|NCT02333773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782360|NCT01941316|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A total of 16 patients were enrolled to the Phase 1b run-in at 3 different dosing levels:~4 patients into Dosing Level 1: 20/27 mg/m\^2 Carfilzomib, 125 mg/m\^2 Irinotecan~9 patients into Dosing Level 2: 20/27 mg/m\^2 Carfilzomib, 125 mg/m\^2 Irinotecan~3 patients into Dosing Level 3: 20/27 mg/m\^2 Carfilzomib, 125 mg/m\^2 Irinotecan~A total of 62 patients were enrolled into the Phase 2 trial. The Phase 2 component is a single-arm component, with participants stratified into two groups:~37 platinum-sensitive~25 platinum-refractory~Enrollment was not sequential, as all participants in the Phase 2 component were different individuals than the participants enrolled into the Phase 1b component."||||
33997209|NCT02684786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997210|NCT01315782|||COHORT||PROSPECTIVE|||||||
33997211|NCT01846091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997212|NCT02427919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693307|NCT03337607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"A medical assistant at the Department of Pain Medicine at the First Affiliated Hospital of Zhejiang University will allocate interventions by means of opaque sealed envelopes that will be marked according to the allocation schedule. The medical assistant will be unaware of the size of the blocks.~The randomized intervention assignment as outlined above will be concealed from both patients and health care staff until recruitment will be complete and irrevocable.~Neither patients nor therapists will be blinded in the proposed study. The therapist will be the person who will administer rEWST to the patient.~The assessor will be blinded in the proposed study. The assessor is the person who will assess treatment success during follow up."||f|f|f|t
33693308|NCT05280093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997213|NCT03366792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693309|NCT03654443|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Only the two observers are aware of the study group and none of the rest of the study team||t|f|t|t
33693310|NCT04644445|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33693311|NCT00880373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782361|NCT06004167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782362|NCT04592237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782363|NCT05492474|NA|SINGLE_GROUP||SCREENING||NONE||Any patient deemed to have a stroke like presentation or possibility of brain hemorrhage in the clinical judgement of the EMS provider and a decision to transfer the patient to the nearest ED for further evaluation has been made||||
33997214|NCT02760433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693312|NCT06030063|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33782364|NCT03830775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782365|NCT05993208|||CASE_ONLY||RETROSPECTIVE|||||||
33782366|NCT06697418|||COHORT||PROSPECTIVE|||||||
33917001|NCT05759845|RANDOMIZED|PARALLEL||TREATMENT||NONE||This single center, open label clinical trial will be conducted on total 150 patients with migraine .They will be subdivided into three group,50 patients in each group, randomized in 1:1:1 format. group A Topiramate will be given to group A as 25 mg daily for first week ,then 25 mg twice daily till the end of the study. Group B will receive Amitriptyline 10mg daily for first week then 25mg daily till the end of the study. Group C will receive Topiramate 25 mg daily plus Amitrityline 10mg daily for first week then Topiramate 25 mg twice daily plus Amitrityline 25mg daily till the end of the study. Day 1 will be date of randomization and taking drug||||
33782367|NCT06170060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782368|NCT05513521|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not know intervention group membership.|Compare velocity-based interval resistance training to load-based resistance training|f|f|f|t
33782369|NCT02876146|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33782370|NCT01070056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782371|NCT03666429|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782372|NCT05037994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33782373|NCT01043731|||COHORT||PROSPECTIVE|||||||
33782374|NCT05799560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33782375|NCT04056156|RANDOMIZED|CROSSOVER||SCREENING||NONE||This mixed methods study adopts a modified stepped wedged design. The classical stepped wedged cluster design involves a random and sequential crossover of clusters from control to intervention until all clusters are exposed. It includes an initial period in which no clusters are exposed to the intervention. We adopt a modified version: the two different intervention levels are added stepwise, while a control condition is retained until the end of the study period.||||
33782376|NCT03670381|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33917002|NCT04395534|||COHORT||PROSPECTIVE|||||||
33917003|NCT01114373|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33917004|NCT01451034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917005|NCT02590523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997215|NCT01911429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997216|NCT06241976|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be randomly allocated to the order they receive the two beverages, a glucose drink (G) and pure orange juice (O). All participants will consume both beverages at separate occasions||||
33997217|NCT01904513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997218|NCT05919199|||OTHER||PROSPECTIVE|||||||
33693313|NCT06414096|RANDOMIZED|CROSSOVER||OTHER||NONE||Examine effects of pulsatile FSH administration as a new method for stimulation in IVF||||
33997219|NCT00180401|||CASE_CONTROL||PROSPECTIVE|||||||
33997220|NCT04635020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997221|NCT03850236|||COHORT||RETROSPECTIVE|||||||
33997222|NCT03056144|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study with a before and after study design||||
33997223|NCT03416673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997224|NCT05729048|||CASE_ONLY||RETROSPECTIVE|||||||
33997225|NCT04999280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997226|NCT04599751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997227|NCT05212116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind Primary Purpose: Treatment|t|t|t|t
34087610|NCT04302597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-center, prospective, randomized controlled trial|f|f|f|t
34087611|NCT03804619|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, two-site randomized trial||||
34087612|NCT00432822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087613|NCT06031285|NA|SINGLE_GROUP||TREATMENT||NONE||Two cycles of Sinitilimab plus bevacizumab biosimilar and TACE-HAIC were administrated before resection, six months adjuvant Sinitilimab plus bevacizumab biosimilar.||||
34087614|NCT04208230|||COHORT||PROSPECTIVE|||||||
34087615|NCT00214721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087616|NCT00596492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087617|NCT00962598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087618|NCT03750565|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33693314|NCT06274788|||OTHER||PROSPECTIVE|||||||
33693315|NCT04893226|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693316|NCT06707545|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693317|NCT05421923|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33693318|NCT05983198|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782377|NCT06008067|||COHORT||PROSPECTIVE|||||||
33782378|NCT04730947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782379|NCT06167252|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33782380|NCT05125861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782381|NCT05504694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782382|NCT05972616|||COHORT||RETROSPECTIVE|||||||
33782383|NCT03929731|||COHORT||PROSPECTIVE|||||||
33782384|NCT01156415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782385|NCT06128551|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
33782386|NCT02263885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782387|NCT02744274|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33782388|NCT01716832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782389|NCT06491095|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33801464|NCT00459212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801465|NCT05945108|||COHORT||RETROSPECTIVE|||||||
33693319|NCT02638090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693320|NCT02254278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693321|NCT06706661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693322|NCT05702866|||CASE_ONLY||RETROSPECTIVE|||||||
33693323|NCT06626711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693324|NCT06080295|||COHORT||PROSPECTIVE|||||||
33782390|NCT05971641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A total of 96 patients will be recruited based on the sample size calculated using G-power analysis. Through block randomization, 48 patients will be assigned to the intervention group and 48 patients to the control group|Two group with a progressive relaxation exercise intervention group|t|f|f|f
33693325|NCT06629779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This is a double-blind study. Participants will receive PF-06821497 or matching placebo in a blinded fashion, as indicated in Section 6.1. Participants, investigators and site staff, and sponsor staff will be aware that participants in both study arms are receiving enzalutamide. Enzalutamide will be provided in an open-label manner to participants in each treatment arm.~Participants and their caregivers will be blinded to their assigned study intervention.~Investigators and other site staff will be blinded to participants' assigned study intervention Sponsor staff will be blinded to participants' assigned study intervention, except for sponsor staff involved in the assignment or distribution of study intervention."||t|t|t|t
33693326|NCT04631445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ketogenic diet with standard of care chemotherapy versus non-ketogenic diet with standard of care chemotherapy||||
33693327|NCT01250288|||COHORT||RETROSPECTIVE|||||||
33693328|NCT05473884|||COHORT||PROSPECTIVE|||||||
33693329|NCT06333067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693330|NCT02549157|||COHORT||PROSPECTIVE|||||||
33693331|NCT05910814|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||6 arms will be enrolled, with 12 participants per group.||||
33693332|NCT00506610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33693333|NCT05468463|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33693334|NCT02010827|||CASE_CONTROL||PROSPECTIVE|||||||
33693335|NCT05215990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693336|NCT05605431|||CASE_ONLY||PROSPECTIVE|||||||
33782391|NCT00534755|NA|SINGLE_GROUP||||NONE||||||
33782392|NCT02849262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782393|NCT03601728|RANDOMIZED|PARALLEL||PREVENTION||NONE||Matched case-control study design||||
33782394|NCT05137912|||OTHER||PROSPECTIVE|||||||
33782395|NCT00816582|NA|SINGLE_GROUP||OTHER||NONE||||||
33782396|NCT04805151|||COHORT||RETROSPECTIVE|||||||
33782397|NCT01113515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782398|NCT00431743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917006|NCT04631458|||CASE_CONTROL||PROSPECTIVE|||||||
33917007|NCT06299215|||COHORT||PROSPECTIVE|||||||
33917008|NCT04061252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917009|NCT00907582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917010|NCT01393756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917011|NCT01954472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34087619|NCT03965364|||COHORT||PROSPECTIVE|||||||
34087620|NCT01544231|||COHORT||PROSPECTIVE|||||||
33693337|NCT01723137|||COHORT||PROSPECTIVE|||||||
33782399|NCT05018273|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782400|NCT05535582|||COHORT||OTHER|||||||
33782401|NCT06452836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917012|NCT03117062|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33917013|NCT04869904|||CASE_CONTROL||PROSPECTIVE|||||||
33917014|NCT00987012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917015|NCT03309787|||COHORT||PROSPECTIVE|||||||
33917016|NCT06386809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917017|NCT04853043|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label||||
33917018|NCT03930641|NA|SINGLE_GROUP||TREATMENT||NONE|open label study|study with a single arm: brolucizumab 6 mg PFS||||
33917019|NCT03520816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087621|NCT02515786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087622|NCT05317351|RANDOMIZED|PARALLEL||SCREENING||NONE||This is a multicenter, 3-arm, randomized, open-label study. Subjects referred to colonoscopy for screening or surveillance will be randomized in a 2:5:5 into one of the following arms: (i) Standard Colonoscopy, (ii) Artificial Intelligence Aided Colonoscopy (GI Genius™), and (iii) Combined Artificial Intelligence Aided Colonoscopy (GI Genius™) and G-EYE® Balloon Aided Colonoscopy||||
34087623|NCT05370118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be masked from the participant's treatment arm.|This pilot clinical research study is structured as a feasibility and preliminary efficacy trial to determine if the TPAB intervention is feasible and to compare daily step improvement between the TPAB intervention group and the CTL group. The trial is designed to inform a future larger-scale efficacy trial to assess longer time points for the sustainability of intervention impact.|f|f|f|t
34087624|NCT05830565|||COHORT||PROSPECTIVE|||||||
33693338|NCT03865134|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693339|NCT04418440|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693340|NCT06709495|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693341|NCT06708273|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33693342|NCT01681797|NA|SINGLE_GROUP||OTHER||NONE||||||
33693343|NCT06457269|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33693344|NCT02684487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693345|NCT04592744|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized to the intervention group receiving angiotensin 2 in addition to standard vasopressors or to the control group in which patients will receive standard vasopressors alone.||||
33693346|NCT05411614|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical study. 1:1 randomised. Convergent Hybrid Ablation Procedure versus standalone endocardial catheter ablation).||||
33693347|NCT01583543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693348|NCT03158987|||CASE_ONLY||RETROSPECTIVE|||||||
33693349|NCT05702749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693350|NCT06706869|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33693351|NCT01740739|||CASE_ONLY||PROSPECTIVE|||||||
33693352|NCT03983837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917020|NCT01124448|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33917021|NCT03765255|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The adolescents and the staff enrolling the participants will not know of study assignment until after completing recruitment, consent, and baseline. At that point, they will open an envelope stating if it is a control or treatment cohort. The researcher conducting the outcomes analysis will not know enrollment status of an individual.|Adolescents will be randomly assigned to treatment or control by cohort (groups of 5-25 adolescents). Adolescents will consent to participation and complete baseline survey prior to randomization. Enrollment will continue by cohort for approximately 2 years. Approximately 15 sites will participate with 2-4 cohorts per site per year.|f|f|f|t
33917022|NCT01011452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917023|NCT02430428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917024|NCT02836860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917025|NCT03280433|||COHORT||PROSPECTIVE|||||||
33917026|NCT05471245|NA|SEQUENTIAL||TREATMENT||NONE||prospective enrolment of long lesions||||
33917027|NCT06101524|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33917028|NCT04597281|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917029|NCT01981278|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917030|NCT04903184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917031|NCT01999855|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33917032|NCT00008762|||DEFINED_POPULATION||OTHER|||||||
33917033|NCT02899117|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33917034|NCT05534204|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33917035|NCT03312712|||CASE_CONTROL||PROSPECTIVE|||||||
34087625|NCT02993367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087626|NCT06158945|||CASE_CONTROL||PROSPECTIVE|||||||
34087627|NCT03638466|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study|t|t|t|t
33693353|NCT06660433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster Randomized Trial||||
33693354|NCT04176705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693355|NCT06283459|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917036|NCT04704895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917037|NCT04627116|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33917038|NCT01885078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693356|NCT01370668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33693357|NCT06210282|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33693358|NCT04594954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693359|NCT02464371|||CASE_CONTROL||PROSPECTIVE|||||||
33693360|NCT04060017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple masking during blinded phase, followed by unblinding during open label phase|Prospective randomized 12-week double-blind placebo-controlled study followed by 12-week open label|t|t|t|t
33693361|NCT06395688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, placebo-controlled|t|t|t|t
33693362|NCT01897480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782402|NCT04633889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33782403|NCT06614166|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33782404|NCT04517851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782405|NCT05236543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801466|NCT03593733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917039|NCT00000639||||TREATMENT||DOUBLE||||||
33917040|NCT01220934|||COHORT||PROSPECTIVE|||||||
33917041|NCT06382337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917042|NCT04883658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917043|NCT01252342|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33917044|NCT00728741|||||PROSPECTIVE|||||||
33917045|NCT01578057|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33693363|NCT06706778|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Based on the NIH toolkit and MBIs reporting guidelines, the engagement in this pilot study will be receptive by providing participants with prerecorded, preselected playlists. Participants will also receive a guided video on maximizing music's therapeutic benefits. The playlists will be purely instrumental, with a 60-80 bpm tempo, and feature melodies and harmonies designed for stress relief, including soothing, grounding, meditation, emotional release, etc. This approach is resource-efficient and easily accessible, allowing participants to integrate it into daily pain self-management strategies. Participants will be asked to engage in the MBI in the morning and at night for 30 minutes each, wearing the abdominal belt and smartwatch.||||
33693364|NCT06369623|NA|SINGLE_GROUP||OTHER||NONE||||||
33693365|NCT06230328|||COHORT||RETROSPECTIVE|||||||
33917046|NCT00432094|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is single arm study and it is non-randomized. Overall, if patients did not have enough cells to do two transplants then they only received one transplants.||||
33917047|NCT04600050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997228|NCT05226390|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087628|NCT01202591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33693366|NCT06036056|||COHORT||PROSPECTIVE|||||||
33693367|NCT01091337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917048|NCT00041834|||DEFINED_POPULATION||OTHER|||||||
33693368|NCT06622070|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33693369|NCT02466373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693370|NCT05454904|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three parallel-group randomized controlled clinical trial||||
33693371|NCT06710691|RANDOMIZED|FACTORIAL||OTHER||NONE||The study also used an explanatory sequential design.||||
33782406|NCT03163511|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||There are two Cohorts in this study design. Cohort 1 was to enroll up to 15 subjects total. After Cohort 1 enrollment was completed, Cohort 2 was to enroll up to an additional 60 subjects.||||
33782407|NCT06614673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33782408|NCT04370093|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33917049|NCT03017482|||CASE_ONLY||PROSPECTIVE|||||||
33917050|NCT03093961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917051|NCT04850716|||COHORT||PROSPECTIVE|||||||
33917052|NCT03011580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33917053|NCT06400316|RANDOMIZED|PARALLEL||PREVENTION||NONE||One control group will receive standard care following diagnosis of a flare of rheumatoid arthritis. The parallel group will receive a 4-week intervention involving two daily amino acid supplements.||||
34087629|NCT06412003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087630|NCT03493971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087631|NCT02157844|||COHORT||CROSS_SECTIONAL|||||||
33917054|NCT03786237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917055|NCT01814488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917056|NCT04284020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||two groups: 1 experimental and 1 control group|t|f|f|t
33917057|NCT04573127|||COHORT||RETROSPECTIVE|||||||
33917058|NCT01257919|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33917059|NCT01963208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997229|NCT06596148|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will use a wait-list control design; clinicians from VA facilities will be randomized to receive access to the dashboard early vs. after a 6-9 month delay. The investigators will compare Shingrix vaccination rates in the two groups of facilities.||||
33997230|NCT03040895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997231|NCT06433232|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997232|NCT04001062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997233|NCT00134485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997234|NCT04404907|||COHORT||OTHER|||||||
33997235|NCT03032536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087632|NCT04308135|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087633|NCT02254824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693372|NCT04406285|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be included sequentially by convenience (according to the inclusion and exclusion criteria) in non-probabilistic form. The included individuals will be randomized by Random Allocation System software in two separate lists: one for patients diagnosed with leukemia (subdivided into a control and experimental group) and other for patients diagnosed with lymphoma (equally divided into a control and experimental group). The allocation ratio will be 1/1 in order to maintain balance in division between control and experimental groups. On the other hand, balancing the different clinical diagnoses will depend on chance, even though the historical average of the service shows similar proportions in the number of cases treated.||||
33693373|NCT04349514|||CASE_CONTROL||PROSPECTIVE|||||||
33693374|NCT06686316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693375|NCT04429243|||CASE_ONLY||PROSPECTIVE|||||||
33693376|NCT06709365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693377|NCT05083468|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33693378|NCT06710600|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33693379|NCT00602667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693380|NCT05502341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693381|NCT00405327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693382|NCT02778971|||CASE_ONLY||PROSPECTIVE|||||||
33693383|NCT00290212|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693384|NCT02389075|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693385|NCT04890431|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33693386|NCT05467800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693387|NCT02143466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693388|NCT06598059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693389|NCT00057876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693390|NCT04333537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693391|NCT02718001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693392|NCT04804644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693393|NCT03690011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693394|NCT05088863|NA|SINGLE_GROUP||OTHER||NONE||||||
33693395|NCT00900198|||CASE_ONLY||OTHER|||||||
33693396|NCT05554523|||COHORT||CROSS_SECTIONAL|||||||
33693397|NCT02694523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693398|NCT02970318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693399|NCT04878887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33693400|NCT06709937|||CASE_ONLY||PROSPECTIVE|||||||
33917060|NCT00883220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33917061|NCT04981574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a controlled clinical trial with parallel groups||||
33917062|NCT00445822|||COHORT||PROSPECTIVE|||||||
33917063|NCT05783193|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized, placebo-controlled, crossover trial with healthy volunteers to delineate additional information on a Health Canada-approved natural health product.|t|f|f|f
33917064|NCT04881240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917065|NCT03498287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917066|NCT05543460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917067|NCT00353964|RANDOMIZED|PARALLEL||||DOUBLE||||||
33997236|NCT06628089|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33997237|NCT05406518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997238|NCT05971394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997239|NCT03270254|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The patient and Dentist will both be aware of the type of treatment, The researcher analysing the collected samples will be blind to treatment|Randomised Split mouth|f|f|f|t
33997240|NCT04807595|||COHORT||RETROSPECTIVE|||||||
33997241|NCT06391372|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|pathologist who will examine the tissue samples in the study|Patients who will be administered 1 g of intravaginal estriol via an applicator twice a week before going to bed for 4 preoperative weeks will constitute the study group. Patients who meet the same criteria as the study group and are not treated with local estriol will constitute the control group.|f|f|f|t
33997242|NCT05843994|||COHORT||PROSPECTIVE|||||||
33997243|NCT00265226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997244|NCT02804724|||||RETROSPECTIVE|||||||
33997245|NCT01441349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997246|NCT05946239|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A randomized controlled trial (RCT) using quantitative approaches will be undertaken to assess the impact of MMP on chronic pain clinic waitlist patient health outcomes prior to attending their first pain clinic appointment. This study will have 1 intervention group (access to MMP + standard care) and 1 control group (standard care). Participants will be randomly assigned to the intervention group or control group at a 2:1 ratio to account for variations in App usage.||||
33997247|NCT01714622|||COHORT||PROSPECTIVE|||||||
33997248|NCT03289260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693401|NCT06469788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33693402|NCT06560619|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693403|NCT05777018|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33693404|NCT06518564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693405|NCT05548010|||CASE_CONTROL||PROSPECTIVE|||||||
33693406|NCT06707766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693407|NCT03936322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693408|NCT06025851|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33693409|NCT04015622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693410|NCT06709859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693411|NCT02323932|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33693412|NCT02765776|||COHORT||RETROSPECTIVE|||||||
33693413|NCT03461822|||CASE_CONTROL||PROSPECTIVE|||||||
33917068|NCT00972127||CROSSOVER||TREATMENT||NONE||||||
33917069|NCT04427436|||COHORT||CROSS_SECTIONAL|||||||
33997249|NCT06563063|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33997250|NCT03234127|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33997251|NCT05474651|||OTHER||CROSS_SECTIONAL|||||||
33997252|NCT06190977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Assignment|t|f|t|f
33782409|NCT01743651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997253|NCT01112722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997254|NCT00582205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997255|NCT04173611|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Each of the cohorts will be masked as to proceed to subsequent next dose escalation cohort.|The decision to proceed to each next cohort will be made following a full review of the safety, PK, and PD data from the previous completed cohort(s).|t|t|t|t
33997256|NCT01939080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997257|NCT01896713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693414|NCT03880604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A double-blinded randomized placebo-controlled trial|A double-blinded randomized placebo-controlled trial|t|t|t|t
33693415|NCT05653024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693416|NCT00018070||||TREATMENT||||||||
33693417|NCT01242059|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33693418|NCT05343013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693419|NCT06710236|NA|SINGLE_GROUP||TREATMENT||NONE|Participants all receive the same intervention/hearing aid, but will be blinded as to which program they are being tested with.|||||
33693420|NCT03120442|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33693421|NCT02748824|||OTHER||CROSS_SECTIONAL|||||||
33693422|NCT06345846|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33693423|NCT04173234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled study|f|f|f|t
33693424|NCT03053271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693425|NCT06536608|RANDOMIZED|PARALLEL||OTHER||SINGLE|Since the application will be performed by the researcher, patients will be blinded in this study. The statistician will be blinded in the evaluation of the data.|Two groups with oketani massage group and control group|t|f|f|f
33693426|NCT06168058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693427|NCT03350620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"If subjects meet eligibility criteria at the Screening/Baseline visit (Day 0), subjects will be randomly assigned to masked study medication.~The study will be double masked. The study medication will be provided in identical-appearing laminated pouches with no labeling indicating the identity of the study group or the contents of the ampules. The laminated pouches will contain identical-appearing ampules. Study subjects and study management personnel will be masked to the identity of treatment until after the final database lock."|"This will be a 3-arm randomized, multicenter, double-masked, placebo-controlled study conducted in 2 stages. Stage 1 is to assess the primary and secondary endpoints. Stage 2 is an extension stage for exploratory endpoints.~Stage 1 is a safety and efficacy phase of 3 years in duration, during which subjects will be allocated to 1 of 3 study medications.~Stage 2 is a randomized cross-over phase of 1 year in duration, during which subjects will be re-randomized to receive 1 of the 3 study medications with subjects initially randomized to Vehicle only eligible for randomization to low or high dose NVK-002."|t|f|t|f
33693428|NCT06693960|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33693429|NCT03878342|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33693430|NCT03304821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the primary investigator will be blinded to group assignment. Blinding will be maintained by Investigational Pharmacy and blood counts will be reviewed by one of the study co-investigators who will make dose-modifications, when necessary.|"Participants will be randomized, in a 2:1 manner, to receive:~* Group A: Subcutaneous GM-CSF 500µg on Monday, Wednesday, Friday (n=117)~* Group B: Placebo on Monday, Wednesday, Friday (n=59)~Participants will be stratified on diabetes status ensuring that a proportionate number of diabetics (2:1) are randomized to each group."|t|f|t|f
33693431|NCT05014828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693432|NCT06451263|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33782410|NCT06235879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33782411|NCT00000195||CROSSOVER||TREATMENT||DOUBLE||||||
33782412|NCT02622425|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33782413|NCT02383550|||COHORT||PROSPECTIVE|||||||
33782414|NCT01442168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782415|NCT00000764|RANDOMIZED|||TREATMENT||||||||
33782416|NCT06630312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33782417|NCT02658721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782418|NCT06183164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is an exprimental study with pre-test, intermediate test and post-test control groups.|t|f|f|f
33782419|NCT06611644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be conducted in a double-blind design. Neither the patients nor the researchers assessing pain management will know which treatment has been applied. The anesthesia team, present in the operating room and responsible for administering the blocks, will be aware of the group assignments, but the research team responsible for postoperative evaluations will not have access to this information. The operating room coordinator will assign each patient to the appropriate group according to a randomization list and will only share this information with the anesthesia team. The research team evaluating postoperative pain scores and collecting data will do so without knowledge of the patients\&#39; treatment group, ensuring objectivity in the assessments through blinding.|This study consists of three groups: a Control Group receiving standard postoperative pain management, an ESP Block Group receiving an Erector Spinae Plane (ESP) block, and an SPSIP Block Group receiving a Serratus Posterior Superior Intercostal Plane (SPSIP) block, all aimed at comparing the efficacy of these methods in managing postoperative pain.|t|f|f|t
33782420|NCT03022266|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33782421|NCT04644861|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33782422|NCT04671628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782423|NCT00578227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997258|NCT00901719|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33997259|NCT01401062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997260|NCT00111696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997261|NCT05347953|||COHORT||PROSPECTIVE|||||||
34087634|NCT04966767|||COHORT||PROSPECTIVE|||||||
34087635|NCT04270955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087636|NCT00315367|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34087637|NCT00765076|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34087638|NCT02251639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087639|NCT04288401|||COHORT||RETROSPECTIVE|||||||
33693433|NCT03783091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Vitamin B12a is bright red and excreted in the urine. Due to this, patient allocation cannot be masked for patients or individuals who may care for them.||t|t|t|t
33693434|NCT06512545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693435|NCT06488547|RANDOMIZED|PARALLEL||PREVENTION||NONE||interventional group and control group||||
33693436|NCT06706973|||COHORT||PROSPECTIVE|||||||
33693437|NCT06406777|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Three populations that will all have the same interventions.||||
33693438|NCT04593849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33693439|NCT06136247|||OTHER||PROSPECTIVE|||||||
34087640|NCT04069858|NA|SINGLE_GROUP||TREATMENT||NONE||CHB patients receiving treatment with Baraclude® 1 mg alone or in combination with other nucleos(t)ide analogues for 12 months or longer after the development of antiviral resistance.||||
33693440|NCT06638307|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34087641|NCT02513875|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34087642|NCT03629301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087643|NCT03550209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple||t|t|t|t
34087644|NCT02820415|||COHORT|||||||||
34087645|NCT01184911|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087646|NCT05424120|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled, non-blinded, single-center, quality improvement study to determine which method of standard of care thoracentesis (wall suctioning, manual aspiration, or vacuum drainage) has the shortest procedural time.||||
34087647|NCT00382616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087648|NCT00903201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087649|NCT03260400|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34087650|NCT02252263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087651|NCT06472557|||COHORT||PROSPECTIVE|||||||
34087652|NCT03396562|||CASE_ONLY||PROSPECTIVE|||||||
34087653|NCT05848063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693441|NCT03088215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693442|NCT05683223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|N/A--no masking|"1. Recruit 240 participants, with 190 meeting criteria for SAD and 50 serving as non-psychiatric controls;~2. Treat 190 SAD patients with CBT for SAD, and treat nonresponders with CBT plus SSRI;"||||
33693443|NCT02983396|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693444|NCT05135663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693445|NCT01799031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693446|NCT06698601|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All participants undergo both study arms. This means that each participant is in the blueberry (intervention) group for a period of 3 months and is in the control group for 3 months. The order in which the participants receive the forms of therapy is determined randomly. Thus, half of the study participants start the supplementary blueberry intake directly after the inpatient stay, the second half three months later (crossover design).||||
33693447|NCT01954342|||COHORT||PROSPECTIVE|||||||
33693448|NCT03143322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693449|NCT03987373|||COHORT||PROSPECTIVE|||||||
33693450|NCT04729387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087654|NCT05000762|||CASE_CROSSOVER||PROSPECTIVE|||||||
33693451|NCT06661850|||COHORT||PROSPECTIVE|||||||
34087655|NCT01969253|||COHORT||PROSPECTIVE|||||||
34087656|NCT01895842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087657|NCT03056924|||CASE_ONLY||PROSPECTIVE|||||||
34087658|NCT01481467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34087659|NCT05138562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087660|NCT04817878|||COHORT||PROSPECTIVE|||||||
34087661|NCT02064062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087662|NCT05743907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087663|NCT01336270|||COHORT|||||||||
34087664|NCT03772223|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087665|NCT05486169|NA|SINGLE_GROUP||SCREENING||NONE||||||
33693452|NCT06681688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The biostatistician analyzing the data will be masked to both treatment arm and surgery center.~When the Investigators or Sponsor look at the data, they will also be masked to treatment arm and surgery center."|"This is a 2-arm non-inferiority trial with the following arms:~* Control arm: Participants undergoing cataract surgery using conventional standard of care peri-operative eyedrops.~* Study arm: Participants undergoing cataract surgery with a regimen of peri-operative topical eyedrops administered to the participant by study staff, in combination with intracameral phenylephrine 1.0%/ketorolac 0.3%, subconjunctival triamcinolone acetonide, and intracameral moxifloxacin."|f|f|t|f
33693453|NCT06709742|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693454|NCT05475613|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will undergo downstaging treatment containing an Anti-PD-1 inhibitor (tislelizumab, pembrolizumab, nivolumab et al.). The anti-PD-1 inhibitor will be given intravenously every 3-4 weeks. Other combination regimens, such as locoregional therapies and targeted therapies, will be given to patients according to the protocol decided by the multidisciplinary team of Centers.||||
33693455|NCT04365257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693456|NCT06704503|||COHORT||PROSPECTIVE|||||||
33693457|NCT05468138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693458|NCT05866237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible patients to be randomised 1:1. None of these patients would have received the vaccine prior to entry to the study. These patients who are eligible for the intervention, randomised are to receive one of two workflows on an individual basis (standard of care or the PET).|Clustered randomised control trial (as participants will be recruited from 6 GP practices)|t|f|f|f
33693459|NCT06708728|||COHORT||PROSPECTIVE|||||||
33693460|NCT04021563|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33693461|NCT00608504|||CASE_ONLY||PROSPECTIVE|||||||
33693462|NCT05659966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33693463|NCT06613893|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33693464|NCT05442190|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||This is a 2 part study. All protocol procedures, timing for schedule of events and assessments are identical for Parts A and B. In Part A, 10-15 patients will be assigned open-label SGX302 (ointment or gel). Once the tolerability and response to SGX302 has been established, Part B of the protocol will commence. In Part B, approximately 32 patients will be randomized to double-blind treatment groups at a ratio 1:1 of active drug to a placebo.|t|t|t|t
33693465|NCT05624996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693466|NCT05114538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Enrollment: 440 parent-child dyads; 160 providers (anticipated)|f|f|f|t
33693467|NCT06708260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693468|NCT00412568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782424|NCT00788424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782425|NCT03722303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33782426|NCT06391203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782427|NCT05489224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782428|NCT04642053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be blind to treatment phase/session (i.e. Pre-Treatment, Treatment (including session #) and Maintenance), group (i.e. Immediate vs. Delayed) and word status (i.e. Treated vs. Untreated). They will performed blinded ratings of Word Accuracy and Speech Intelligibility, as well as blinded scoring of Duration and Variability.|This work will employ a delayed treatment control group design across multiple behaviors. Participants will be seen in two groups: an Immediate Treatment group and a Delayed Treatment group.|f|f|f|t
33782429|NCT00087490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917070|NCT00777231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||No control group used, single group for each of four different disease groups||||
33917071|NCT04626193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33917072|NCT00005060|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33917073|NCT00926913|||COHORT||CROSS_SECTIONAL|||||||
33917074|NCT05040789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917075|NCT04004078|||CASE_CONTROL||RETROSPECTIVE|||||||
33917076|NCT05958927|||CASE_CONTROL||PROSPECTIVE|||||||
33917077|NCT05600647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment will be done by an independent assessor who will be blinded to the aim of the study and the patient's group allocation.|the control group will receive the exercise program and the experimental group will receive the same exercise training program in addition to electromagnetic field therapy, three times per week for four weeks.|f|f|f|t
33917078|NCT00165841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917079|NCT00321425|RANDOMIZED|PARALLEL||||SINGLE||||||
33917080|NCT05785390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant, Investigator will all be blinded.|Phase IIb will be a 2 parallel arms, double - blind, randomized, placebo controlled study|t|f|t|f
33917081|NCT03503214|||CASE_CONTROL||PROSPECTIVE|||||||
33997262|NCT05565690|||COHORT||PROSPECTIVE|||||||
33997263|NCT05897619|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open pilot trial designed to assess the feasibility and acceptability of the Maya Perinatal Cognitive Behavioral Therapy Skills app. All participants will receive the same intervention and provide qualitative and quantitative feedback on app use and experience to inform future iterations of the app.||||
33997264|NCT02770690|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33997265|NCT00480038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997266|NCT00909038|||COHORT||RETROSPECTIVE|||||||
33693469|NCT04447378|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33693470|NCT05758415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator, site personnel, persons performing the assessments and participants will remain blinded through the Week 24 final database lock. The Novartis clinical trial and submission teams will remain blinded to the identity of the treatment from the time of randomization until the Week 16 database lock (for the primary endpoint analysis). The following methods are utilized for blinding: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by anyone else involved in the study with the following exceptions: bioanalyst; (2) the identity of the treatments will be concealed by the use of study treatments that are all identical in packaging, labeling, schedule of administration, and appearance.||t|t|t|t
33693471|NCT02395510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693472|NCT01284530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693473|NCT05269732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator, outcome assessors and data analysts will be blinded to participant allocation.|Participants will be randomly assigned in a 1:1 ratio to the treatment group (delivered group CBT plus TAU) or the control group (treatment as usual).|f|f|t|f
33693474|NCT06708364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782430|NCT06340880|||COHORT||PROSPECTIVE|||||||
33782431|NCT02250144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33917082|NCT04039633|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|1st blinding: patients will be blinded to the actual treatment allocation during the different study periods (first blinding). 2nd: surgeons and all study personnel involved in handling the patients and collecting the study data (except those who perform the actual setting of the device) will be blinded to the actual treatment allocation. 3rd: All study personnel evaluating end point measures will be blinded to the actual treatment. 4th All the tables and figures to be presented from the study will be settled before any data from the study is evaluated in order to avoid selective presentation of findings according to statistical results. 5th The statistician performing the statistical procedures on the outcome of the study will be blinded. The data will only show treatment allocation as treatment A and treatment B. Then the tables and figures are filled in.|During 6 months following implantation of a pulse generator, all patients will undergo 4 six-week long periods with either burst spinal cord stimulation (SCS) or no stimulation (sham) in a randomized order. During this period all patients will undergo two periods of SCS and sham stimulation.|t|t|t|t
33917083|NCT03824548|||OTHER||RETROSPECTIVE|||||||
33917084|NCT00539747|||||RETROSPECTIVE|||||||
33917085|NCT04901533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917086|NCT05293652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917087|NCT03440853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient reported outcomes will be administered centrally by blinded interviewers using computer-assisted telephone interviewing (CATI).|Patients will be randomized 1:1 to TASCCI or technology-delivered health education and undergo a 12-week intervention. Psychological and clinical outcomes will be collected at baseline, post intervention, 6 and 12 months.|f|f|f|t
33917088|NCT02351843|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||TRIPLE|||t|f|t|t
33917089|NCT00794651|||||PROSPECTIVE|||||||
33917090|NCT03741920|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33997267|NCT02818751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997268|NCT02351700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33997269|NCT06626906|||COHORT||RETROSPECTIVE|||||||
33693475|NCT05294913|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not know which group they are assigned to. Each participant will receive a debriefing form at the end of the study for transparency, and control group participants will also receive the intervention kit at the completion of the study for equal opportunity.|Upon study enrollment, participants will be randomly assigned to either the placebo control group, or the intervention group. We will ask all participants to complete two waves of data collection on survey data and salivary samples (Wave 1 \[W1\] data collection will occur at the beginning of the semester; Wave 2 \[W2\] data collection will occur near the end of the semester). Between W1 and W2 data collection (circa mid-semester), each group will receive instructions on an intervention (placebo for the control group), and we will assess if there are any outcome differences between the two groups at the end of the semester.|t|f|f|f
33917091|NCT04117178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blinded, randomized study with two arms: 'standard of care' arm and 'intervention' arm. Participants in the intervention arm will have their treatment adjusted according to Serum levels of the anti-dementia drug prescribed.|f|f|t|f
33917092|NCT00199134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917093|NCT05388591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917094|NCT03901261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional prospective monocentric, national open study with single arm||||
33917095|NCT02880397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917096|NCT01759498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917097|NCT03839017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|With or without the cognitive aid|t|f|f|f
33917098|NCT00199758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917099|NCT02472691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917100|NCT02750904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917101|NCT00259740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917102|NCT02646267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917103|NCT05624775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917104|NCT02199301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917105|NCT05254314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, placebo-controlled, single-center, proof-of-concept study with 2 treatment arms.||t|t|t|t
33917106|NCT03060330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917107|NCT03309592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917108|NCT01919905|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33917109|NCT03589885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Phase IIIb 52-week multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in approximately 120 subjects with moderate to severe plaque-type psoriasis|t|t|t|t
33917110|NCT05102149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997270|NCT05601596|||COHORT||PROSPECTIVE|||||||
33997271|NCT02182596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997272|NCT01175330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997273|NCT05538338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997274|NCT03602339|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33693476|NCT00006496|||CASE_CONTROL||PROSPECTIVE|||||||
33693477|NCT06191978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693478|NCT05901792|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Single||f|f|f|t
33693479|NCT06226467|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized waitlist-controlled trial or randomized delayed intervention-controlled design||||
33693480|NCT06708676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693481|NCT01583920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693482|NCT06253546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782432|NCT06376019|RANDOMIZED|PARALLEL||TREATMENT||NONE|the statistician will be the only one to be blinded|parallel assignment of the participants in ratio 1:1:1 will take place. For allocation concealment, opaque sealed envelopes will be used.||||
33997275|NCT00863330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997276|NCT05327894|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Definition: Provide details about the Interventional Study Model. Limit: 1000 characters.||||
33997277|NCT05544123|||OTHER||PROSPECTIVE|||||||
33997278|NCT05438433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|All roles were unmasked|both groups of patients received surgical treatment parallel to each other.||||
33997279|NCT05064917|||COHORT||PROSPECTIVE|||||||
33997280|NCT06626854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997281|NCT04852133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33997282|NCT04604262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Independent outcome assessors|This will be a 56-week single blind, stratified; parallel group randomised controlled clinical trial. This will be a pseudo-longitudinal trial where observations are recorded at certain fixed intervals.|f|f|f|t
33997283|NCT02331108|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33997284|NCT03006757|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33997285|NCT03641911|||COHORT||PROSPECTIVE|||||||
33997286|NCT05422469|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33997287|NCT02341690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997288|NCT00011063||||TREATMENT||||||||
33997289|NCT00301964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997290|NCT05336097|NA|SINGLE_GROUP||OTHER||NONE||||||
33997291|NCT00430274|||CASE_ONLY||PROSPECTIVE|||||||
33997292|NCT03210363|NA|SINGLE_GROUP||OTHER||NONE||||||
33997293|NCT03801707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997294|NCT03968328|||CASE_ONLY||PROSPECTIVE|||||||
33693483|NCT06710340|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33693484|NCT02049320|||CASE_ONLY||RETROSPECTIVE|||||||
33693485|NCT06597331|||COHORT||PROSPECTIVE|||||||
33693486|NCT05625503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33693487|NCT01264016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693488|NCT00861536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693489|NCT02279238|||CASE_CROSSOVER||PROSPECTIVE|||||||
33693490|NCT04886284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693491|NCT05861310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who evaluated the outcomes assessor will be blinded to the treatment allocation until the end of data collection.|Each research subject will receive a different cream and will be given randomly according to a computer program by a statistician. The control group will receive placebo cream (without the drug substance) and the comparison group will receive metronidazole 1% cream. The cream is used for 2 months and will be evaluated every 28 days.|f|f|f|t
33782433|NCT06401850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782434|NCT00755755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782435|NCT04939428|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33997295|NCT04917991|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Following eligibility assessment, the participants will be be randomized based on a double-blind crossover design.|t|t|t|t
33997296|NCT02828631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997297|NCT03444883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A mulicenter, randomized, parallel, double blind, placebo-controlled|t|t|t|f
33997298|NCT03153605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997299|NCT03732144|RANDOMIZED|PARALLEL||PREVENTION||NONE||The prospective randomized controlled trial is a nested cohort design that compares two levels of the intervention, a staff-based social development PA program to a generalized ASP health curriculum control, over a 10-month (40 week) time period (16-week intervention, 6 month followup). A total of 30 ASPs serving underserved middle school (\~40 youth and \~5 staff per school; N=1200 youth, 150 staff) will be randomly assigned to either receive the Connect intervention or serve as the standard ASP Health curriculum control. The project will be implemented over a 5-year period with a new cohort of 6 ASPs added each year (a total of 5 cohorts, with 6 ASPs in each cohort).||||
33997300|NCT05621252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|2:1 randomization PLN-74809:placebo|t|f|t|f
33997301|NCT04966403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997302|NCT00743535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997303|NCT05049239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997304|NCT05526313|NON_RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33997305|NCT01181284|||COHORT||PROSPECTIVE|||||||
33997306|NCT05431491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997307|NCT01375309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997308|NCT03582423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects of both groups will be randomly assigned to receive either electro-acupuncture or control (sham) treatment. For randomization, simple, complete non-sequential random numbers will be generated in advance by a computer program in a block of four, and kept by the principal investigator. After a patient's eligibility is confirmed, a randomization number which corresponds to the group allocation will be provided to the acupuncturist by the PI. This arrangement will ensure that the clinical assessor and participants are blinded to the allocation.|single-blinded, randomized, sham-acupuncture controlled trial|t|f|f|f
33997309|NCT04724707|||COHORT||PROSPECTIVE|||||||
33693492|NCT06373250|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997310|NCT04808388|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693493|NCT06296212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782436|NCT04654351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782437|NCT06141564|||COHORT||PROSPECTIVE|||||||
33782438|NCT04879355|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The patients and the pathologists are blinded to the intervention, while the clinicians performing the FNAs are not.|Eligible patients are randomised at a 1:1-ratio to one of two parallel groups, and all patients are included in the analysis on an intention-to-treat basis.|t|f|f|t
33782439|NCT03604835|||OTHER||PROSPECTIVE|||||||
33782440|NCT01991717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997311|NCT05348616|||COHORT||RETROSPECTIVE|||||||
33693494|NCT04234386|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693495|NCT04944628|||COHORT||PROSPECTIVE|||||||
33782441|NCT05709002|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33782442|NCT04216160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782443|NCT01732575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782444|NCT04424485|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33997312|NCT01740934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782445|NCT03411811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups in parallel. After that the study becomes one arm as both groups are offered dextrose.||||
33782446|NCT02899637|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33782447|NCT05359900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Participant information is pseudonymised using student numbers only. As soon is data is generated data will be fully anonymised.~The outcome assessor will be blinded to group allocation."|"Multi-site, single-blind two arm, randomised control trial.~The study would be conducted an five sites in total:~Teesside University; The Welsh institute of Chiropractic - University of South Wales; The AECC University College; McTimoney College of Chiropractic; London Southbank University.~Each site will follow the same protocol. Randomisation will occur at each individual site. Data will be pooled for analysis."|t|f|f|t
33997313|NCT04677517|NA|SINGLE_GROUP||OTHER||NONE||||||
33997314|NCT01937182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997315|NCT02271035|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33997316|NCT04199494|||OTHER||OTHER|||||||
33997317|NCT02349672|||COHORT||PROSPECTIVE|||||||
33997318|NCT02570828|NA|SINGLE_GROUP||||NONE||||||
33997319|NCT00353457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997320|NCT05817734|||COHORT||PROSPECTIVE|||||||
33997321|NCT04724616|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087666|NCT04564599|||OTHER||RETROSPECTIVE|||||||
33693496|NCT03645031|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blind to the order of the AIH/sham AIH visits, but this information will be provided to the participant after completion of last visit.|Participants will complete both the AIH and the sham AIH visits. The order of these visits will be randomized, but all subjects will complete both visits in the course of the study.|t|f|f|f
33693497|NCT05579691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693498|NCT00590798|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693499|NCT05432297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33693500|NCT03851133|||CASE_ONLY||PROSPECTIVE|||||||
33693501|NCT00992329|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33693502|NCT05144204|NA|SINGLE_GROUP||OTHER||NONE||||||
33693503|NCT05578872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693504|NCT03034200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693505|NCT01743456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33693506|NCT02035475|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33693507|NCT04738851|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693508|NCT06019429|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Schools who partake in this study decide the type of program they will receive: HiRO without judo, HiRO with judo, school-as-usual||||
33693509|NCT06252636|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33782448|NCT05860881|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33782449|NCT05265598|||COHORT||RETROSPECTIVE|||||||
33782450|NCT03415022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will not be informed as to whether a participant is randomized to 4 or 8 weeks of treatment.|Computer-based task involving free viewing of faces and listening to music|f|f|f|t
33782451|NCT05032235|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single dose of oral administration of Fluzoparib||||
33782452|NCT01513356|NA|SINGLE_GROUP||||NONE||||||
33782453|NCT04493437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087667|NCT00165074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087668|NCT02896166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087669|NCT01416571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087670|NCT01986504|||COHORT||PROSPECTIVE|||||||
33693510|NCT06710392|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33693511|NCT06701682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The overall 2-step randomization scheme will be implemented.~* Randomization Level 1 will be open-label, assigning an eligible patient to one of the available treatment cohorts.~* Randomization Level 2 will be double-blinded and will randomize participants at a 1:1 ratio to receive either IP or placebo within a specific cohort. Thus, the PPD blinded team, site blinded staff members, and participants/legal authorized representative will be considered blinded to study treatment assignment (either IP or placebo) throughout the course of the study.~To preserve the integrity of the study blind, an unblinded pharmacist at each site will be responsible for the reconstitution and dispensation of all study drugs and placebos and will endeavor to ensure that there are no observable differences between the treatment groups (IP or placebo) when dispensing the study materials."||t|t|t|f
33693512|NCT02160353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693513|NCT06707090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized to either TR987 1% gel + Standard of Care and Standard of Care alone. Sponsor, participant, and Investigator/Outcomes Assessor will be masked throughout the treatment period.|This is an outpatient, randomized, parallel- group, double-blind, multicenter, 16-week study with 2 treatment arms: TR987 0.1% gel + Standard of Care and Standard of Care alone in participants who have a non-healing Venous Leg Ulcer (VLU)|t|t|t|t
33693514|NCT06598800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693515|NCT06707948|||COHORT||PROSPECTIVE|||||||
33693516|NCT00563420|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33693517|NCT05557435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33693518|NCT06709391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693519|NCT03040973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693520|NCT02783885|||COHORT||PROSPECTIVE|||||||
33693521|NCT03432520|||COHORT||PROSPECTIVE|||||||
33693522|NCT00200551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693523|NCT06283394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33693524|NCT06709352|||OTHER||CROSS_SECTIONAL|||||||
33693525|NCT03377114|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33693526|NCT05803382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693527|NCT05377229|||CASE_ONLY||PROSPECTIVE|||||||
33693528|NCT01054807|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33693529|NCT06683222|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The cohort will be a sub-group derived from the 425 healthy female volunteers who will be recruited for the MONIKA study. For the MONIKA study, we expect around 350 to be recruited at the Nîmes and Montpellier sites. Among these women recruited at the Nîmes and Montpellier sites, 280 participants will be invited to take part in the MyOs study.||||
33693530|NCT03976245|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, open-label, randomized trial||||
33693531|NCT04048200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Double blinded study Closed sealed envelops will be used to make the participants blind to their group.~The continuous infusion regimen in the syringe pump will be prepared by anesthesia resident who will not participating in the the study . It will contain normal saline in control group and actual dexmedetomidine and ketamine in the other group. This will make the investigator blind to the group."|Prospective study|t|f|t|t
33693532|NCT05889416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Open-label Cluster-randomized Effectiveness-implementation Hybrid Trial||||
33693533|NCT05050084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782454|NCT03841708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"In this monocentric placebo controlled single blind ranomized clinical trial patients will be recruited from the Emergency Department of a University Hospital.~80 patients suffering form a out of hospital cardiac attest arriving at the Emergency Department with a lactate level \> 4 mmol/L or a mean arterial pressure below 65 mmHg will be included in the study at the moment of admission to the Emergency Department and patients in the treatment arm will be monitored on top of standard monitoring with a non invasive device measuring continuously the pleth variability index(PVI). Patients in the treatment arm will be treated according to an algorithm integrating both standard non invasive measures and the PVI. Patients in the control arm will be treated according to non invasive measures only."|t|f|f|t
33782455|NCT06283238|||COHORT||OTHER|||||||
33917111|NCT03970395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Infants were randomly assigned to two groups, OMT and LTT by using a random number generator, prepared in advance by an independent biostatistician. Sequentially numbered, opaque, and sealed envelopes were used.~Clinician-Investigators, neonatology staff, the physical therapist, and the osteopath in charge of assessment were unaware of the random list.~Infants' parents, after having signed the informed consent form, chose the numbered envelope and were unaware of the random list for the whole period of study.~The two osteopaths in charge of Osteopathic manipulative therapy and Light Touch Therapy were unblinded to group assignment.~Clinical outcomes were assessed by a biostatistician who was not involved in the patients' clinical allocation and management."|A two arms randomized controlled trial. The experimental group will receive Osteopathic manipulative Therapy and the active comparator the Light Touch Therapy|t|f|t|t
33917112|NCT05585892|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants could not be masked to the intervention as it was clear to them whether they had received an email (for intervention items) or not (for control items). Investigator and Outcomes Assessor knew that each participant was exposed to both item types but they were masked to the group a student was assigned to.|This was an educational study with a cross-over design in which every undergraduate medical student served as their own control as both groups were exposed to control and intervention items in non-graded key feature examinations.|f|f|t|t
34087671|NCT03613870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087672|NCT00255177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087673|NCT04778878|||CASE_ONLY||PROSPECTIVE|||||||
34087674|NCT05486273|RANDOMIZED|PARALLEL||OTHER||NONE||They will be randomized unequally (2:1) into one of the study groups||||
33693534|NCT01387399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693535|NCT04718103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized in a 2:1 ratio to receive either GSK3511294 (Depemokimab) or placebo as an adjunct therapy.|t|f|t|f
33693536|NCT04981067|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The biased coin design up-and-down method|t|f|f|f
33693537|NCT00365144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693538|NCT05484908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782456|NCT03457922|||CASE_ONLY||PROSPECTIVE|||||||
33782457|NCT02377219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782458|NCT05876585|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized in a 1:1 allocation ratio to receive a single dose of ondansetron 8 mg injection (arm 1) or a single dose of metoclopramide 10 mg injection (arm 2).||||
33782459|NCT06099015|||COHORT||PROSPECTIVE|||||||
33782460|NCT02632916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782461|NCT03937687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Between-subjects, three condition groups|t|f|t|f
33782462|NCT06649851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782463|NCT01600703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33782464|NCT00629512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33782465|NCT01289743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782466|NCT05766670|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33782467|NCT01970943|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33782468|NCT05989737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782469|NCT02651103|||COHORT||PROSPECTIVE|||||||
33782470|NCT06615362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two arms: one arm Autogenous Dentin Derived Barrier Membrane ,second arm Collagen Membrane .|t|f|t|t
33917113|NCT03296293|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33782471|NCT05649332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782472|NCT06613568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782473|NCT02825043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782474|NCT06346145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782475|NCT05136742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782476|NCT04582175|||COHORT||RETROSPECTIVE|||||||
33782477|NCT02562014|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33782478|NCT06528977|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A controlled feeding study prepared by registered dieticians. Participants will be pre-tested, provided a 10-day WD to be tested on day 10, then post-tested.||||
33782479|NCT02985697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33782480|NCT05627765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782481|NCT02484365|||COHORT||PROSPECTIVE|||||||
33782482|NCT03737734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782483|NCT04621071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917114|NCT06362499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782484|NCT04280029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised controlled trial|t|f|f|f
33782485|NCT05464589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome accessor involved in the clinical trial will be prevented from having knowledge of the interventions to the individual participants of each group.|It is a randomized control trial. Total 60 patients will be recruited, 30 in each group. Treatment will be allocated using a random number sheet generated by SPSS software version 21. Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33782486|NCT00647140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782487|NCT06614140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782488|NCT00471211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782489|NCT00748254|||COHORT||PROSPECTIVE|||||||
33782490|NCT05213403|||OTHER||RETROSPECTIVE|||||||
33782491|NCT00082485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782492|NCT03405298|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782493|NCT04880213|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33782494|NCT00984074|||CASE_ONLY||PROSPECTIVE|||||||
33782495|NCT05623202|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33782496|NCT01540695|||COHORT||PROSPECTIVE|||||||
33782497|NCT04174807|||COHORT||PROSPECTIVE|||||||
33782498|NCT03270020|NA|SINGLE_GROUP||TREATMENT||NONE||"The investigational arm will recruit patients who will receive denosumab 120mg sc every 2 months. The estimated duration of the recruitment period is 12 months.~The treatment period would be 6 months (denosumab administration on months: 0, 2, 4, 6) and the follow-up period would be 12 months."||||
33782499|NCT03541603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782500|NCT03033732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917115|NCT00064350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917116|NCT04070170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917117|NCT04427917|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double|This is a Phase 1, randomized, double-blind, sponsor-open, placebo-controlled study in healthy adult Japanese participants.|t|f|t|f
33917118|NCT01273389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917119|NCT02288624|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33917120|NCT00789958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917121|NCT04675359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693539|NCT06369467|NA|SEQUENTIAL||TREATMENT||NONE||||||
33782501|NCT00539903|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33782502|NCT02144324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782503|NCT06343441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782504|NCT04301388|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782505|NCT05407194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Supplement and placebo will be blinded for participants and researchers working on the study.|RCT|f|f|t|f
33782506|NCT00004643||||TREATMENT||NONE||||||
33917122|NCT04550221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory testing for PrEP drug levels will be conducted in a blinded fashion|Pilot study with 10 intervention participants followed by randomized controlled trial with 60 participants assigned to the intervention or to standard care.|f|f|f|t
33693540|NCT05368090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Four EUS-RFA intervention study groups Group 1: PA with lateralisation to left adrenal and left-sided tumour for EUS-RFA Group 2: PA with suspected left-sided overweight of aldosterone overproduction but not AVS-verified left-sided lateralisation for EUS-RFA as debulking procedure Group 3: MACS with unilateral tumour in the left adrenal and unilateral cortisol overproduction verified by AVS, for EUS-RFA Group 4: MACS with bilateral adrenal tumours and AVS-verified bilateral cortisol overproduction for EUS-RFA as debulking procedure"||||
33693541|NCT05948930|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33693542|NCT02111941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693543|NCT06708884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693544|NCT05760612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693545|NCT02617784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693546|NCT06323707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33693547|NCT06581796|||CASE_CONTROL||PROSPECTIVE|||||||
33693548|NCT04648254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693549|NCT03126877|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will be a prospective, single-center open label clinical trial where a maximum of 40 (20 with optimized ocular surface and 20 without) consecutive non-dominant eyes are implanted with the Raindrop Near Vision Inlay.||||
33693550|NCT06619080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Concealed Random Assignment: Participants will be assigned to one of three treatment groups using a computer-generated sequence. Opaque, sequentially numbered envelopes with treatment assignments will be opened after patient inclusion.~Blinding of Participants: Participants will not know the specific injection content (bupivacaine with or without corticosteroids, or saline). They will only know they are receiving one of the study interventions.~Blinding of Investigators: Investigators for initial evaluation and follow-up will not administer treatments. Independent personnel will prepare and administer treatments without evaluating outcomes.~Blind Evaluations: Pain and functionality (VAS, KOOS, WOMAC, KUJALA) will be assessed by blinded investigators. Follow-up consultations will be handled by personnel unaware of treatment details.~Documentation and Verification: Secure treatment assignment records will be accessible only to the data and safety monitoring committee."|"Study Design Type of Study: Pilot randomized controlled experimental clinical trial. Number of Groups: Three parallel treatment arms.~Intervention Groups:~Group 1: Block with 0.5% bupivacaine and corticosteroid (triamcinolone). Group 2: Block with 0.5% bupivacaine. Group 3 (Control): Block with saline solution. Randomization~Technique Description:~Patient Position: Supine with knee extended. Ultrasound-Guided Localization: Use of ultrasound with Doppler to locate genicular nerves and associated arteries.~Injection Points:~Superior medial and lateral genicular nerves: Femoral condyle and junction with the femoral shaft.~Inferior medial genicular nerve: Medial tibial-femoral joint line.~Injection Doses:~Group 1: 2.5 mL of 0.5% bupivacaine + 20 mg of triamcinolone. Group 2: 2.5 mL of 0.5% bupivacaine. Group 3: 2.5 mL of saline solution."|t|f|t|f
33693551|NCT05672108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693552|NCT06710873|||COHORT||CROSS_SECTIONAL|||||||
33693553|NCT05177211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693554|NCT06236425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693555|NCT06710119|RANDOMIZED|PARALLEL||OTHER||NONE|Participants will not be blinded to which study arm they are assigned.|Participants will either receive training with or without visual feedback of foot loading during gait.||||
33693556|NCT02754544|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693557|NCT05169073|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Outcomes Assessor and analyst|The order in which the operations will be performed by each resident is random.|f|f|f|t
33693558|NCT03029325|||CASE_ONLY||PROSPECTIVE|||||||
33693559|NCT05793437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
33693560|NCT03476668|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33693561|NCT05940311|||COHORT||PROSPECTIVE|||||||
33693562|NCT01580514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782507|NCT00764179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33782508|NCT02759198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917123|NCT06472388|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral/daily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.||||
33917124|NCT01258530|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33917125|NCT01690169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917126|NCT06079775|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|matched oral placebo capsules|Randomized, Double-Blind, Controlled, Crossover, ascending single-and multipledose design|t|t|t|t
33917127|NCT00965783|RANDOMIZED|CROSSOVER||||NONE||||||
33917128|NCT04493294|NA|SINGLE_GROUP||TREATMENT||NONE||Using low dose whole lung radiotherapy to older patients who develop COVID-19 pneumonitis to improve their survival compared to historical data||||
33917129|NCT05194046|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33997322|NCT04741477|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||A total of 5 topical cannabinoid products will be examined in this study. The study will be conducted in 5 discrete stages, one for each product. In each stage, participants (N=20), will be randomized to 1 of 2 double-blind drug conditions that entail the use of: 1) a topical product that contains CBD and a low amount of THC (N=15), or 2) a placebo topical product that does not contain cannabinoids (N=5), but which contains similar non-cannabinoid ingredients to the active product.|t|f|f|t
34087675|NCT03210532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917130|NCT00235690|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917131|NCT03751592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087676|NCT04885608|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087677|NCT00370708|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||||||
33917132|NCT02604927|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33917133|NCT04408118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997323|NCT04806763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, controlled, longitudinal||||
33997324|NCT03677960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33997325|NCT01640743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997326|NCT01826760|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33997327|NCT00866580|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34087678|NCT06387017|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087679|NCT03813108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087680|NCT05534542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087681|NCT04173949|NA|SINGLE_GROUP||TREATMENT||NONE||The study will begin as a pilot study in which 10 stuttering patients will be recruited for 12 weeks on open label Ramipril 2.5mg.||||
34087682|NCT01499524|||CASE_CONTROL||PROSPECTIVE|||||||
33782509|NCT04531683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, investigator and outcome assessor will be masked. The care provider will be different from investigator and outcome assessor.|Patients who sign the informed consent form and are eligible for the study entry at week 0 will be randomised to one of the three groups: electro-acupuncture group, sham electroacupuncture group and life style consultation group. The three group will be assessed in a paralleled manner, and patients in the first two groups will be treated 3 times per week for 8 weeks and followed up for 24 weeks, while patients in the third group will be provided with life style improvement information once and followed-up for 20 weeks.|t|f|t|t
33782510|NCT03682354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782511|NCT00341900|||CASE_ONLY||CROSS_SECTIONAL|||||||
33917134|NCT03267992|||CASE_ONLY||OTHER|||||||
33917135|NCT00231712|||DEFINED_POPULATION||PROSPECTIVE|||||||
33917136|NCT02807064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917137|NCT01098461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917138|NCT03046940|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33917139|NCT04316663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917140|NCT01916993|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087683|NCT03873584|||OTHER||PROSPECTIVE|||||||
34087684|NCT04763967|||COHORT||OTHER|||||||
34087685|NCT05980546|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Once an individual enrolls, research staff will give the anesthesiologist (a co-investigator) an opaque envelope. Inside the envelope will be an index card to let them know which group the participant is assigned to (intervention or control).~Those who will be blinded as to which group the participant is assigned to are:~* Participant~* Research personnel (research assistants)~Those who will not be blinded as to which group the participant is assigned to are:~* Primary Investigator~* Co-investigator~* Biostatistician"|A randomized control trial of two groups, intervention vs. control.|t|f|f|t
34087686|NCT02908347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917141|NCT03522272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917142|NCT02077387|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33917143|NCT00729313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917144|NCT05140954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917145|NCT05990036|NA|SINGLE_GROUP||OTHER||NONE||Prospective single cohort with no control group||||
33917146|NCT00976950|||COHORT||PROSPECTIVE|||||||
33917147|NCT01284270|NA|SINGLE_GROUP||||NONE||||||
33917148|NCT01819311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917149|NCT02068131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917150|NCT04863417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917151|NCT06164145|||OTHER||PROSPECTIVE|||||||
33917152|NCT05038748|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33917153|NCT04696458|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33917154|NCT02723292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917155|NCT03771612|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33917156|NCT06155760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917157|NCT00703027|||||RETROSPECTIVE|||||||
34087687|NCT04456127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Intra-subject comparison||||
34087688|NCT01490710|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34087689|NCT06228339|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34087690|NCT00004855||||TREATMENT||||||||
15037075|NCT05710081|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33782512|NCT06094920|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Eligible participants will be assigned to a 3-week treatment period with the SGLT2 inhibitor empagliflozin 10 mg/day, in accordance with guidelines. After 2 weeks, albuminuria levels will be assessed to determine the individual albuminuria response. Depending on the response (decrease or increase), participants will be allocated to one of three treatment regimens following the 3-week empagliflozin treatment period:~A. Albuminuria reduction \>30% and the remaining albuminuria level is \<30 mg/g: continue empagliflozin for an additional four weeks.~B. Albuminuria reduction \>30% or \>0 and ≤30%, and the remaining albuminuria level is \>30 mg/g: continue empagliflozin for an additional four weeks and intensify treatment by adding finerenone for four weeks.~C. No albuminuria reduction or increase: discontinue empagliflozin and switch to finerenone for four weeks."||||
33782513|NCT00116870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782514|NCT02806895|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33782515|NCT00766857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782516|NCT02843022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782517|NCT02763553|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782518|NCT05377099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782519|NCT04038281|||OTHER||CROSS_SECTIONAL|||||||
33782520|NCT04869657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782521|NCT00558753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782522|NCT02498613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782523|NCT06613438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782524|NCT02620189|||COHORT||PROSPECTIVE|||||||
33917158|NCT03746223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917159|NCT00479024|||CASE_ONLY||RETROSPECTIVE|||||||
33917160|NCT04259385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This randomized, controlled lab-based study will capture beverage and snack purchases from a concession stand and measure how much participants consume while watching a television show. Participants will be randomized to 1 of 3 groups: 1) calorie labels (control); 2) text warning labels; or 3) graphic warning labels displaying amounts of sugar.|t|f|f|f
33917161|NCT05824637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917162|NCT02693795|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33917163|NCT06463548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917164|NCT02587624|||COHORT||PROSPECTIVE|||||||
33917165|NCT04994444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Research Assistant collecting data at assessment sessions will not be aware of the participant's study condition.|randomized clinical trial|f|f|f|t
33917166|NCT00900913|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33917167|NCT01013896|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33917168|NCT06409702|||COHORT||PROSPECTIVE|||||||
33917169|NCT05263128|||OTHER||PROSPECTIVE|||||||
33917170|NCT05590767|||CASE_ONLY||PROSPECTIVE|||||||
33917171|NCT00946881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917172|NCT04622969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997328|NCT04121533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study consists of a double-blind, placebo-controlled experimental design. Subjects will be randomly assigned to one of three groups: (#1) vitamin D (cholecalciferol, 4000 IU) with glucosamine sulfate (1000 mg) and omega-3 fatty acids (eicosapentaenoic (EPA, 580 mg) and docosahexaenoic (DHA, 470 mg) acids), (#2) vitamin D (cholecalciferol, 4000 IU) with matching glucosamine sulfate and omega-3 fatty acid placebo supplements, or (#3) matching vitamin D, glucosamine sulfate and omega-3 fatty acid placebo supplements. Supplements will be taken daily for 84 days (12 weeks). Groups will be permuted in random blocks of six.|t|t|t|t
33997329|NCT03883126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997330|NCT05652634|||COHORT||PROSPECTIVE|||||||
33997331|NCT01639365|||COHORT||PROSPECTIVE|||||||
33997332|NCT03045198|NA|SINGLE_GROUP||TREATMENT||NONE||CF patients receive for 4 weeks Azithromycin. Study measures are assessed before and after 4 weeks||||
33782525|NCT03679702|NA|SINGLE_GROUP||OTHER||NONE||||||
33782526|NCT05661942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917173|NCT02247674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917174|NCT00283530|||CASE_ONLY||PROSPECTIVE|||||||
33917175|NCT00182923|||||PROSPECTIVE|||||||
33917176|NCT01575197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917177|NCT05600166|||COHORT||PROSPECTIVE|||||||
33917178|NCT04585295|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33917179|NCT00086424|||COHORT||PROSPECTIVE|||||||
33917180|NCT04561245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917181|NCT05124340|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Observer Blind : Investigational Product and Active Comparator are masking. Lot number is masking||t|f|t|f
33917182|NCT01236313|||COHORT||PROSPECTIVE|||||||
33917183|NCT03669991|||COHORT||PROSPECTIVE|||||||
33917184|NCT00091702|RANDOMIZED|PARALLEL||PREVENTION||||||||
33997333|NCT00940433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997334|NCT05954663|||COHORT||RETROSPECTIVE|||||||
33917185|NCT00516425|RANDOMIZED|||TREATMENT||||||||
33917186|NCT01763021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917187|NCT04848454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917188|NCT05214781|||OTHER||PROSPECTIVE|||||||
33917189|NCT03816410|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||1:1 Randomization|t|f|t|t
33917190|NCT00668200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917191|NCT02935686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33917192|NCT05545579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917193|NCT00150670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997335|NCT00935805|||COHORT||PROSPECTIVE|||||||
33997336|NCT03431493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997337|NCT00858780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997338|NCT05210647|||CASE_CONTROL||RETROSPECTIVE|||||||
33997339|NCT02813811|||COHORT||PROSPECTIVE|||||||
33997340|NCT04388787|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33997341|NCT04750239|NA|SEQUENTIAL||TREATMENT||NONE|open-label|open-label, single-arm, dose-escalation and expansion consisting of up to 13 cycles||||
33997342|NCT04002648|||CASE_ONLY||RETROSPECTIVE|||||||
33997343|NCT00595153|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33997344|NCT05276986|NA|SINGLE_GROUP||SCREENING||NONE||24 healthy university students (n=11 female, n=13 male) with a mean age of 21±2 years included the study.||||
33997345|NCT00924638|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33693563|NCT06370091|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants who meet the selection criteria will be probabilistically assigned using simple random sampling through a lottery system. An urn will be used to draw colors corresponding to a type of chewing gum|"It will be an experimental study through a double-blind parallel randomized controlled trial.~All saliva samples will be collected using the spitting method. Each participant will provide a basal saliva sample for 5 minutes. Participants must meet the following inclusion criteria: having at least 20 teeth, providing written informed consent, and being willing to comply with the study procedures. The exclusion criteria will include individuals with systemic, infectious, or inflammatory diseases or those taking medications, antibiotics, or fluoride in the last month; regular consumers of products and mouthwashes containing xylitol or sorbitol, with abnormal salivary flow (\<1 ml/min), pregnant women or those on contraceptive pill treatment, or with abnormal dietary habits; subjects with periodontal disease or presence of dental caries"|t|f|t|f
33693564|NCT05156073|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33693565|NCT04866771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693566|NCT06708897|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation and dose optimization study||||
33693567|NCT05050552|||COHORT||PROSPECTIVE|||||||
33693568|NCT00420667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782527|NCT03869853|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an economic-education intervention that implements one treatment arm (economic + nutrition/health/gender equity education) for comparison to a non-intervention control. The focus is to test an intervention that is feasible within the context of permanent institutions, thus the package components must be self-sustaining by the local institutions. The components of the stimulation package will be determined jointly with local partners after the initial baseline data collection. The control is made up of random selection of residents who are not members of the farmer-based organization.||||
33997346|NCT02011945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997347|NCT01827696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33997348|NCT02667769|RANDOMIZED|CROSSOVER||||NONE||||||
33997349|NCT03774329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997350|NCT02704091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997351|NCT02578277|NA|SINGLE_GROUP||OTHER||NONE||||||
33997352|NCT03531827|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33997353|NCT05039541|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33997354|NCT00042835|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997355|NCT00099151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33997356|NCT04728776|||OTHER||PROSPECTIVE|||||||
33997357|NCT04999423|||COHORT||PROSPECTIVE|||||||
33997358|NCT00044434|RANDOMIZED|||TREATMENT||DOUBLE||||||
33997359|NCT01906190|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33997360|NCT02173964|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33997361|NCT00989053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997362|NCT05710458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are randomised and masked from the treatment||t|f|f|f
33997363|NCT00348517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997364|NCT01063244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997365|NCT01732562|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33997366|NCT03966651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997367|NCT00091195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997368|NCT01394419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33997369|NCT01448876|||COHORT||PROSPECTIVE|||||||
33997370|NCT01057368|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33997371|NCT00265681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997372|NCT05370768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33997373|NCT04737330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a two-year multi-center Phase 3 study in patients with active, moderate to severe TED, with a randomized, parallel-group, double-blind, placebo-controlled treatment period and a follow-up/retreatment period. This study consisted of the following 3 periods: Screening period (Week -6 to Baseline); Double-blind treatment period (Baseline to Week 16); and Follow-up/open-label retreatment period (Week 16 up to Week 108)|t|f|t|f
33997374|NCT03056547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33997375|NCT03354780|||COHORT||RETROSPECTIVE|||||||
33997376|NCT02694653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997377|NCT03262051|||COHORT||PROSPECTIVE|||||||
33997378|NCT03833050|||COHORT||PROSPECTIVE|||||||
33997379|NCT01690780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997380|NCT05949853|||COHORT||RETROSPECTIVE|||||||
33997381|NCT05204420|||CASE_ONLY||RETROSPECTIVE|||||||
33997382|NCT00012818|RANDOMIZED|PARALLEL||||NONE||||||
33997383|NCT03392051|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33997384|NCT01426360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997385|NCT04837456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33997386|NCT00965757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997387|NCT06372119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997388|NCT03255733|NA|SINGLE_GROUP||TREATMENT||NONE|Investigator was blinded to the Patient Reported Outcome Measure Survey details and analysis.|Patients age 18 - 85, previously diagnosed with Chronic Lateral Epicondylitis, with symptoms exceeding 90 days, and where Standard of Care treatments have failed to resolve the symptoms.||||
33997389|NCT00112437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997390|NCT05333107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997391|NCT05173298|||COHORT||OTHER|||||||
33997392|NCT02659462|||COHORT||PROSPECTIVE|||||||
33997393|NCT01870258|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33693569|NCT05270213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"A 3+3 design will be used to establish dose limiting toxicities (DLT), the maximum tolerated dose (MTD, if applicable) and the dose level of RBS2418 as monotherapy and in combination with pembrolizumab corresponding to an optimal biologically active dose to aid in the selection of the fixed expansion cohort dose. There will be three treatment groups for this study:~* Treatment Group A-1: RBS2418 Dose Escalation (Monotherapy)~* Treatment Group A-2: RBS2418 Dose Escalation plus Pembrolizumab (Combination Therapy)~* Treatment Group B: RBS2418 as Monotherapy or RBS2418 plus Pembrolizumab Expansion Phase"||||
33693570|NCT06496503|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The team of evaluators, teachers, and researchers who process the results will be completely independent. At all stages of the study (baseline until follow-up) the same outcome assessors will be recruited. None of the individuals, researchers, or evaluators involved will have knowledge as to group allocation. The professional responsible for the physical activities will be hired for this purpose and not belong to the project research team.|Randomization will be performed carefully following the recommendations proposed by the Cochrane Collaboration. The process will consist of two stages, firstly, the generation of numbers using a random number table, and secondly, allocation concealment, using opaque, sealed envelopes. After signing the consent form, an envelope will be opened for each child and they will be instructed as to which group they have been allocated, the experimental or control.|f|f|t|t
33693571|NCT02722525|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693572|NCT00562627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693573|NCT02210273|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33693574|NCT00048451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33693575|NCT01446393|||CASE_CONTROL||PROSPECTIVE|||||||
33693576|NCT03584152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33693577|NCT06201416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential escalating dose cohorts||||
33693578|NCT06115668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693579|NCT06225817|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking in the study. Both the participants and the experimenter know that the participants will be taking open-label placebos.|This is a longitudinal parallel randomized clinical trial with chronic headache participants randomly assigned to either 1) the OLP group, or 2) the wait-list group. To examine how baseline chronic pain and sleep patterns could have impacted the effects of OLP, we will deep-phenotype participants based on their sleep profiles and fluctuations in their chronic pain characteristics via a 7-day phenotyping phase. Following the 7-day phenotyping phase, participants will enter a 45-day intervention phase. The nature of the participation will be voluntary. Namely, participants can withdraw during trial from the study without any consequences.||||
33693580|NCT06706895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693581|NCT03871335|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33693582|NCT06040528|||COHORT||PROSPECTIVE|||||||
33782528|NCT01192295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782529|NCT03906747|||COHORT||PROSPECTIVE|||||||
33782530|NCT03618303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782531|NCT01941264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33917194|NCT05510778|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Charcocaps and placebo capsules are similar in appearance and provided to investigators pre-masked (A and B).|double-blind, placebo controlled, cross-over|t|f|t|f
33917195|NCT05678192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The cohort was divided into groups depending on the treatment regimen. Group 1 (n=20) received transdermal menopausal hormone therapy (MHT). Group 2 (n=20) received oral MHT.|t|f|f|f
33917196|NCT04193852|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33917197|NCT04338880|||COHORT||PROSPECTIVE|||||||
33917198|NCT06461546|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, prospective, single arm pilot study. To evaluate the ability of Imlifidase treatment to achieve a negative virtual crossmatch in patients with available live donor kidney.||||
33917199|NCT05152017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33917200|NCT00258206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917201|NCT04045236|||COHORT||PROSPECTIVE|||||||
33917202|NCT03258047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917203|NCT02974387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917204|NCT02626845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917205|NCT01800123|||COHORT||PROSPECTIVE|||||||
33917206|NCT00000875||PARALLEL||TREATMENT||||||||
33917207|NCT00643487|||CASE_ONLY||PROSPECTIVE|||||||
33917208|NCT04597619|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pragmatic Pilot Study||||
33917209|NCT05910541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917210|NCT04252612|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33917211|NCT02542917|||COHORT||PROSPECTIVE|||||||
33917212|NCT06372821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917213|NCT00376987|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33997394|NCT03541252|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective clinical, uncontrolled, open-label, explorative phase IIa trial||||
34087691|NCT05018780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study will be single and assessor blinded. Participants will be masked about other groups but they will know what treatment they will be receiving or what exercises they will be doing. Principal investigator would also not be masked or blinded because investigator would be applying the techniques on participants of both group. So participant and and principal investigator cannot be blinded. Only assessor will be blinded and he will take outcome measures without knowing the problem and treatment techniques.||f|f|f|t
34087692|NCT02925468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087693|NCT01355965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917214|NCT02753829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693583|NCT05907122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is double-blinded; therefore, the investigators, study personnel (with the exception of the data monitoring committee, authorized unblinded sponsor and contract research organization staff, and unblinded site pharmacy staff), and the study subjects will remain blinded to treatment allocation. ABP 206 and nivolumab will be coded and labeled to protect blinding.||t|f|t|f
33693584|NCT04938349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693585|NCT04756869|||COHORT||PROSPECTIVE|||||||
33693586|NCT04166149|||COHORT||PROSPECTIVE|||||||
33693587|NCT06708585|RANDOMIZED|PARALLEL||PREVENTION||NONE||The research is a two-group parallel randomized controlled experimental study.||||
33693588|NCT00756639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693589|NCT00892242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693590|NCT02072239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782532|NCT04956692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782533|NCT03486340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782534|NCT05981456|RANDOMIZED|CROSSOVER||OTHER||NONE||randomized controlled trial||||
33782535|NCT01124617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782536|NCT05504343|NA|SINGLE_GROUP||TREATMENT||NONE||single arm single center, open label study||||
33782537|NCT01023919|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33782538|NCT02467374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782539|NCT01528124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33782540|NCT02307123|||COHORT||RETROSPECTIVE|||||||
33917215|NCT02217150|||COHORT||PROSPECTIVE|||||||
33917216|NCT04703322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917217|NCT00448760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917218|NCT06466928|||COHORT||RETROSPECTIVE|||||||
33917219|NCT02049801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917220|NCT01132339|||COHORT||PROSPECTIVE|||||||
33917221|NCT00709358|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33917222|NCT02357641|||||PROSPECTIVE|||||||
33917223|NCT04044209|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a single arm phase II trial with a safety cohort||||
33917224|NCT03627858|||COHORT||PROSPECTIVE|||||||
33917225|NCT00418964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917226|NCT00933764|||CASE_ONLY||PROSPECTIVE|||||||
33997395|NCT00983996|RANDOMIZED|CROSSOVER||||NONE||||||
33997396|NCT04643535|||COHORT||PROSPECTIVE|||||||
33997397|NCT06558812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blinding will not be feasible neither for the operator nor the patient. As there are some differences in the clinical steps, the form of the appliances and number of needed visits.~Outcome assessor and Statistician will be blinded from the intervention and control not knowing which group represents which procedure."|A randomized controlled clinical trial, parallel group, allocation ratio 1:1 Framework superiority|f|f|f|t
33997398|NCT05218824|||COHORT||PROSPECTIVE|||||||
33997399|NCT04710823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997400|NCT06563219|||COHORT||RETROSPECTIVE|||||||
33997401|NCT01442051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997402|NCT01360073|||COHORT||RETROSPECTIVE|||||||
33997403|NCT00296530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997404|NCT04031235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Mothers will be blinded as to the specific aims of the study other than that it involves safe sleep and reading with your baby."||t|f|f|f
33997405|NCT02589067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997406|NCT03973671|||COHORT||PROSPECTIVE|||||||
33997407|NCT00609726|||CASE_CONTROL||PROSPECTIVE|||||||
33997408|NCT01250730||PARALLEL||||NONE||||||
33997409|NCT00322725|||COHORT||RETROSPECTIVE|||||||
33997410|NCT02333123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997411|NCT04544800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997412|NCT05701163|NA|SINGLE_GROUP||OTHER||NONE||||||
33997413|NCT01269268|||CASE_CONTROL||PROSPECTIVE|||||||
33997414|NCT01679327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997415|NCT06060353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997416|NCT01229150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997417|NCT03146143|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33997418|NCT01202435|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33997419|NCT00833534||||TREATMENT||NONE||||||
33997420|NCT01731457|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997421|NCT01216865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997422|NCT04728750|||CASE_ONLY||RETROSPECTIVE|||||||
33997423|NCT03946436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693591|NCT02653092|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33693592|NCT03402659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled|t|t|t|t
34087694|NCT00879216|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34087695|NCT01116531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087696|NCT03953547|||COHORT||RETROSPECTIVE|||||||
34087697|NCT00167791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693593|NCT04559360|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-blind randomized controlled clinical trial.||||
33693594|NCT00721266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693595|NCT04196972|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33693596|NCT04453228|||CASE_ONLY||RETROSPECTIVE|||||||
33693597|NCT04151199|RANDOMIZED|PARALLEL||OTHER||NONE||The randomized trial is conducted in accordance with an intent-to-treat (ITT) design.||||
33693598|NCT02670174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects are randomly assigned in 3 parallel intervention groups. They cannot participate in 2 or more intervention groups.|f|f|t|f
33693599|NCT04895709|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693600|NCT06404775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693601|NCT04505397|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33693602|NCT02777736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693603|NCT06690281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693604|NCT05405114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782541|NCT05687890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782542|NCT04929379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782543|NCT01452672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782544|NCT03131141|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|open label|||||
33782545|NCT06613607|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi Experimental Study||||
33782546|NCT06648824|NA|SINGLE_GROUP||TREATMENT||NONE||Single sequence crossover design||||
33782547|NCT06697548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33782548|NCT03351829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782549|NCT02030210|||OTHER||PROSPECTIVE|||||||
33782550|NCT01668485|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33782551|NCT01955382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917227|NCT05760820|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention will be evaluated using a longitudinal ranodmized controlled trial study with a wait-list control design. Parents will be invited to the study and respond on behalf of children under the age of 11, while children aged 11 and older will respond to questions without parental assistance. Prior to baseline, parents (and all children of the parent) will be randomized (1:1) to either the intervention group (with access to the intervention) or the control group. Randomization will be blinded for participants only until the completion of the baseline questionnaire. All participants will be asked to complete questionnaires at 1- and 3-months post baseline. Those in the intervention group will gain immediate access to the digital intervention, while those in the control group will gain access after the 3-month follow-up questionnaire.||||
33917228|NCT02638896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917229|NCT00574821|||COHORT||PROSPECTIVE|||||||
33997424|NCT02663349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997425|NCT00440063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782552|NCT04234243|||CASE_CONTROL||RETROSPECTIVE|||||||
33782553|NCT05843565|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33782554|NCT03605329|NA|SINGLE_GROUP||OTHER||NONE||||||
33997426|NCT02666807|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33997427|NCT00466011|||||PROSPECTIVE|||||||
33997428|NCT05702905|RANDOMIZED|PARALLEL||TREATMENT||NONE||All subjects will be randomized into three groups: metformin single, semaglutide single, both metformin and semaglutide.||||
33997429|NCT03317080|||COHORT||PROSPECTIVE|||||||
33997430|NCT02054819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997431|NCT04419935|||COHORT||PROSPECTIVE|||||||
33997432|NCT04224584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33693605|NCT02479360|||COHORT||PROSPECTIVE|||||||
33693606|NCT06426719|RANDOMIZED|PARALLEL||OTHER||NONE||a new technique used to provide sufficient alveolar ridge width and enhance bone quality at horizontally deficient maxillary alveolar ridges prior to implant placement. the new technique uses specially designed burs called Densah burs that act by causeing bone compaction rather than bone removing from the osteotomy site||||
33693607|NCT03659786|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33693608|NCT03693170|NA|SINGLE_GROUP||TREATMENT||NONE|All involved know the identity of the intervention assignment.|||||
33693609|NCT06475183|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33693610|NCT01187199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693611|NCT06298890|||CASE_CONTROL||PROSPECTIVE|||||||
33693612|NCT00004076||||TREATMENT||||||||
33782555|NCT03752320|||COHORT||PROSPECTIVE|||||||
33782556|NCT06614517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087698|NCT04155645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single-blind with regards to treatment (AZD8233 or placebo) at each dose level. AZD8233 and placebo will be matched for appearance and amount. Subjects randomized to placebo will receive the same volume of injection as subjects on active drug.||t|f|f|f
34087699|NCT02619188|||COHORT||PROSPECTIVE|||||||
33693613|NCT05379725|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33693614|NCT02659956|||COHORT||PROSPECTIVE|||||||
33693615|NCT04960410|||COHORT||PROSPECTIVE|||||||
33693616|NCT03313778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693617|NCT04418284|||OTHER||CROSS_SECTIONAL|||||||
33693618|NCT04478123|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, open-label, pilot study of romiplostim for patients undergoing HDT-AHCT.||||
33782557|NCT03109717|||OTHER||PROSPECTIVE|||||||
33917230|NCT03544554|NA|SINGLE_GROUP||TREATMENT||NONE|Investigator|"The study sample included 100women (50 for the intervention and 50 for the control group) diagnosed with OAB syndrome. The control group was not provided with training. In addition to the pharmacological treatment, the intervention group was provided with a counseling and training program that consisted of a 45minute presentation based on Pender's Health Promotion Model. They were also given A Manual for Training on HealthyLifestyleBehaviors among women with OAB. The intervention group was requested to follow a weekly-scheduled bladder training program, keep records on the Urinary Diary form for six weeks. In the first interview and in the third month, the women in the intervention and control groups were administered the Introductory Information Form, Urinary Diary (4day), 24hour Standard Pad Test, OAB-V8, King'sHealthQuestionnaire, Healthy LifestyleBehaviorScaleII, and BriefSymptomInventory. In addition, an Inspection Form was administered in the third month."||||
33917231|NCT04706429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917232|NCT04300491|||CASE_ONLY||RETROSPECTIVE|||||||
33917233|NCT01546389|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33917234|NCT00455793|||||CROSS_SECTIONAL|||||||
33917235|NCT02709473|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33917236|NCT06359743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917237|NCT00805545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917238|NCT00383422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917239|NCT05038033|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial with two treatment arms and two intervention cohorts across two sites.||||
33917240|NCT05668468|RANDOMIZED|PARALLEL||OTHER||TRIPLE|placebo of cellulose identical in size, shape and color to intervention bifidus||t|f|t|t
33917241|NCT03657667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917242|NCT00255086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917243|NCT02935114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33917244|NCT01740388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917245|NCT03420326|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33917246|NCT06432556|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917247|NCT00523406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917248|NCT05246007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917249|NCT00960128|||COHORT||PROSPECTIVE|||||||
33917250|NCT00110318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33917251|NCT00553137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917252|NCT05360355|||CASE_ONLY||RETROSPECTIVE|||||||
33917253|NCT03616327|NA|SINGLE_GROUP||OTHER||NONE||||||
33917254|NCT04940442|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33917255|NCT05576155|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33917256|NCT04050501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PROBE design||f|f|f|t
33917257|NCT05133193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917258|NCT04124692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917259|NCT00033033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917260|NCT04678011|||COHORT||PROSPECTIVE|||||||
33917261|NCT02168894|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33917262|NCT06214351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Mobile midwifery application is a mobile application based on the prenatal process, where pregnant women can get information about pregnancy, birth and postpartum processes.||||
34087700|NCT04055870|||CASE_ONLY||PROSPECTIVE|||||||
34087701|NCT02802228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087702|NCT00294658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087703|NCT01404624|||CASE_CONTROL|||||||||
34087704|NCT00026130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087705|NCT02471443|||COHORT||PROSPECTIVE|||||||
34087706|NCT04459338|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33693619|NCT06630143|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The outcomes assessors (evaluators) will be blinded to the intervention groups (virtual simulation, clinical simulation, or combined simulation) to reduce potential bias in evaluating the study's outcomes. Assessors will evaluate participants; performance on theoretical knowledge and clinical judgment without knowing which intervention the participants received.~Specifically, for the clinical judgment evaluation, the assessors will use the Lasater Clinical Judgment Rubric. The participants will be coded, and the assessors will only receive the coded evaluations to ensure they do not know the participants' group assignments. This blinding process will help ensure that the assessment of outcomes is objective and unbiased."||f|f|f|t
33997433|NCT03595800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693620|NCT06684106|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33693621|NCT03779360|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||An interventional, open-label, comparator controlled study to investigate the immunomodulatory effects of erythromycin and clindamycin in an LPS skin challenge model in healthy volunteers.||||
33693622|NCT00772083|RANDOMIZED|PARALLEL||||NONE||||||
33693623|NCT00233428|||||PROSPECTIVE|||||||
33693624|NCT06235632|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a pretest-posttest randomized control partial cross-over trial. A subsample of stores will be randomly assigned to receive the intervention while the rest will receive the control training. After the posttest assessment is conducted, the remaining control stores will receive the intervention.||||
33693625|NCT06583239|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33693626|NCT04343729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693627|NCT05941897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693628|NCT00815243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693629|NCT02513264|||COHORT||PROSPECTIVE|||||||
33693630|NCT02705027|RANDOMIZED|PARALLEL||||NONE||||||
33693631|NCT00745173|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997434|NCT00803816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997435|NCT06365086|NA|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will receive single-pulse TMS during personalized brain activity patterns reflecting either strong or weak corticospinal tract activation|t|f|t|f
33997436|NCT05320237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693632|NCT06533735|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|This is a randomized controlled experiment (RCT) with a wait-list control group||||
33997437|NCT01538160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693633|NCT04177433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33693634|NCT06070714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single urologist will evaluate all CT scans for residual stones and will be blinded to which laser was used during ureteroscopy.|Participants will be randomized (ratio 1:1) to be treated with either the holmium laser with pulse modulation or the thulium fiber laser. Each site will randomize their own participants. Block randomization in block sizes of 4 will be used to assign participants to each laser treatment group. If unable to use the specified laser for any reason, the participant will be considered a withdrawal|f|f|f|t
33917263|NCT01185249|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33917264|NCT05048706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997438|NCT00874276|RANDOMIZED|PARALLEL||||NONE||||||
33997439|NCT00416780|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33997440|NCT02260063|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997441|NCT02725580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997442|NCT00630253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917265|NCT04697433|||COHORT||CROSS_SECTIONAL|||||||
33917266|NCT01022567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917267|NCT04687605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917268|NCT03641547|NA|SINGLE_GROUP||TREATMENT||NONE||CHARIOT will use a single arm, open-label, dose escalation, Time-To-Event Continual Reassessment Method (TiTE-CRM) to find the optimal treatment schedule.||||
33917269|NCT03740412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917270|NCT02429258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997443|NCT05582967|||COHORT||PROSPECTIVE|||||||
33997444|NCT06272643|||CASE_ONLY||PROSPECTIVE|||||||
33997445|NCT06628024|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33917271|NCT03017365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917272|NCT04619264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997446|NCT00637533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33997447|NCT02105220|||CASE_ONLY||PROSPECTIVE|||||||
33997448|NCT00925223|||CASE_CONTROL|||||||||
33997449|NCT04009447|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive the Cognitive Behavioral Therapy for Insomnia||||
33997450|NCT06042231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33997451|NCT04483596|||CASE_CONTROL||PROSPECTIVE|||||||
33997452|NCT06065280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|80 patients with established heart failure reduced ejection fraction on optimal standard medical therapy, who will be consecutively randomly allocated to the SGLT2i (10 mg once a day Empagliflozin or Dapagliflozin ) with 40 patients with diabetes mellitus group and 40 patients non-diabetes mellitus group. (Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin )|t|f|t|f
33997453|NCT05915351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997454|NCT04244760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997455|NCT03837327|||COHORT||PROSPECTIVE|||||||
33997456|NCT04516915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Parallel-Group, Open-Label Study||||
33997457|NCT01007058|||CASE_ONLY||PROSPECTIVE|||||||
33997458|NCT06150196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997459|NCT02722395|||COHORT||PROSPECTIVE|||||||
33997460|NCT01633281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997461|NCT05206838|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with the option of crossover in the control group after a certain period of time.||||
33997462|NCT05994066|||OTHER||CROSS_SECTIONAL|||||||
33997463|NCT04967170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997464|NCT00672373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997465|NCT03157115|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33917273|NCT03900806|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants and professionals is not possible for this type of intervention. Blinding for assessment is not applicable since measurements are computer-based.|A multicenter, three-armed randomized controlled trial will be conducted to evaluate the effectiveness of an online cognitive rehabilitation program. Two intervention groups (i.e., an extensive and a basic cognitive rehabilitation program) and one waitlist control group will be included. An economic evaluation will be conducted to assess cost-effectiveness of the cognitive rehabilitation program.||||
33917274|NCT05836363|||COHORT||CROSS_SECTIONAL|||||||
33917275|NCT03403894|||COHORT||RETROSPECTIVE|||||||
33917276|NCT00377910|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33917277|NCT00946569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997466|NCT02025660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997467|NCT01186835|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33997468|NCT04413799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997469|NCT05121194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997470|NCT02805166|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33997471|NCT04609280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693635|NCT06259708|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The investigators will use a crossover design for this study as it requires fewer participants and removes variance between participants in the outcomes that are irrelevant to the stimulation type in comparison to other designs where each participant only receives one stimulation. All participants receive all the stimulation types (Vim-LIFU and ZI-LIFU), but the order in which they get the stimulation types is randomized.||||
33693636|NCT06439862|||CASE_ONLY||RETROSPECTIVE|||||||
33693637|NCT03622359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33693638|NCT04008823|||CASE_ONLY||RETROSPECTIVE|||||||
33693639|NCT06332248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Participants received either 375 mg nutritional supplement magnesium or placebo pill.|t|f|t|t
33782558|NCT04672460|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomly assigned to 1 of 2 sequences to receive Treatment A, B and C in different order as shown below. The first 2 periods will be for BE assessment, with the first period being 28 days and the following periods being 21 days. Period 3 will be a 21 day period to evaluate the food effect on the PK of the proposed talazoparib soft gel capsule formulation that will be included in the fixed sequence after the 2 BE assessment periods (for participants who can tolerate one high-fat/high-calorie meal). Participants must have received 21 consecutive days of continuous 1mg QD drug administration to be considered as completers of a treatment period, before moving on to the next scheduled treatment.||||
33782559|NCT01575145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782560|NCT03452111|NA|SINGLE_GROUP||OTHER||NONE||||||
33782561|NCT00696904|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33782562|NCT02457364|||COHORT||PROSPECTIVE|||||||
33782563|NCT06615284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782564|NCT00684970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782565|NCT01827228|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782566|NCT03298932|||CASE_ONLY||PROSPECTIVE|||||||
33782567|NCT02920944|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33782568|NCT00519779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782569|NCT01218828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33997472|NCT01669980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997473|NCT04762069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Response and progression outcomes are evaluated by a blinded central reviewer for each patient according to RANO criteria|Open-Label Study with a Randomized Control Arm|f|f|f|t
33997474|NCT01059058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782570|NCT04942470|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research was planned as an experimental study with a randomized control group to determine the effect of Aloe Vera and Propolis on wound healing in pressure injuries.||||
33782571|NCT06560840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33782572|NCT04296162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917278|NCT02389140|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33917279|NCT01172834|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33917280|NCT05271422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917281|NCT03755284|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized and controlled experimental study||||
33917282|NCT01632735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917283|NCT00630812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997475|NCT00019487||||TREATMENT||||||||
33997476|NCT06064435|||COHORT||PROSPECTIVE|||||||
33693640|NCT05103527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will undergo one week DRG-S trial, and for those that respond as defined by 50% or greater pain relief, proceed to DRG-S permanent device system implant||||
33693641|NCT04704219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693642|NCT03732690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782573|NCT03647319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782574|NCT05992480|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 survivor to control||||
33782575|NCT03863717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33782576|NCT00589862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917284|NCT05415852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917285|NCT04144075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917286|NCT00638924|||||PROSPECTIVE|||||||
33917287|NCT04370860|||CASE_ONLY||RETROSPECTIVE|||||||
33917288|NCT04290481|||COHORT||PROSPECTIVE|||||||
33997477|NCT03986463|||COHORT||PROSPECTIVE|||||||
33997478|NCT02821676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33997479|NCT05168722|||COHORT||OTHER|||||||
33997480|NCT00642993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997481|NCT00143364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997482|NCT03053856|NA|SINGLE_GROUP||TREATMENT||NONE||N2 positive stage IIIA non-small cell lung cancer treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection||||
33997483|NCT05757830|NA|SINGLE_GROUP||OTHER||NONE||||||
34087707|NCT04706377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The tablets containing B12 and placebo had a similar appearance and were packed in similar containers. Patients and health care providers did not know what each package contained.|Double Blind Placebo Controlled Randomized Clinical Trial|t|t|t|t
34087708|NCT00352118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087709|NCT01865851|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34087710|NCT00455871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087711|NCT00107497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087712|NCT02805738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087713|NCT01549574|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087714|NCT02856217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33693643|NCT05251311|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Social worker that follows up with each participant will be blinded to randomization arm||f|t|f|f
33693644|NCT04974528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693645|NCT06668155|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Assignment 0 represents the autograft group. If assigned the autograft group, the surgeon will choose either bone patella tendon bone (BPTB) or all soft tissue quadriceps tendon for the graft. The graft choice will be based upon surgeon preference.~* Assignment 1 represents allograft with lateral extra-articular tenodesis LET group. The allograft used will be a non-irradiated quadriceps tendon with bone plug allograft with a donor age less than 45 years."||||
33693646|NCT06415734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693647|NCT06710678|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33782577|NCT02022462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782578|NCT06588322|NA|SINGLE_GROUP||OTHER||NONE||||||
33782579|NCT00189020|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782580|NCT01244984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782581|NCT03850444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782582|NCT05027971|||COHORT||PROSPECTIVE|||||||
33782583|NCT02321540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782584|NCT00843362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782585|NCT04550039|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782586|NCT02958228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782587|NCT03301922|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33782588|NCT04341298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"In this study, the investigative Avulux® device shall consist of a pair of optical filters in the form of spectacle lenses, provided in a standard spectacle frame; the lenses contain a dye that effectively blocks light at specified wavelength ranges while minimizing distortion of the visible spectrum. The optical filters block a portion of the optical spectrum that is suspected to stimulate photophobic responses that trigger some, and exacerbate most, migraines.~The control/sham device for this study shall be a pair of plastic lenses provided in a standard spectacle frame, which will have negligible light-blocking properties at the optical wavelengths which are blocked by the Avulux® device."|A minimum of 68 subjects will be randomized in to one of two treatment groups in a one-to-one ratio.|t|t|t|f
33782589|NCT01105494|||COHORT||PROSPECTIVE|||||||
33782590|NCT06613646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782591|NCT02116387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782592|NCT03353272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33782593|NCT05683262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, Double Blind Study|t|f|t|t
33782594|NCT03246672|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive the intervention||||
33917289|NCT03659370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087715|NCT03083756|||CASE_ONLY||PROSPECTIVE|||||||
34087716|NCT04262349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||: The study was a randomized controlled training intervention study. Sample size was calculated with G \* Power 3.0.10 program with an effect size of 0.3 (medium effect level) and a power of 80%. A total of 180 pregnant women were identified as 90 in the intervention group and 90 in the control group. Considering that data will be lost due to reasons such as discontinuation and exclusion criteria during pregnancy 10% more of the determined number was included in the study and the sample size was calculated as 198 pregnant women and 252 pregnant women were reached during the study. 36 pregnant women in the intervention group and 35 pregnant women in the control group were excluded from the study for different reasons and the study was completed with 181 pregnant women (90: control: 91). The groups were determined by randomization.||||
33917290|NCT04609085|||CASE_ONLY||PROSPECTIVE|||||||
34087717|NCT00230516|RANDOMIZED|CROSSOVER||||NONE||||||
33917291|NCT05074719|||OTHER||PROSPECTIVE|||||||
34087718|NCT00674726|||CASE_CONTROL||PROSPECTIVE|||||||
34087719|NCT02564341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34087720|NCT04578938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087721|NCT04556175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Centralized, computer-based group assignment using permuted blocks.|f|f|f|t
33782595|NCT06238648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782596|NCT02939183|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917292|NCT00424528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917293|NCT00278798|||OTHER||PROSPECTIVE|||||||
33917294|NCT00032994|RANDOMIZED|||TREATMENT||||||||
33782597|NCT03519321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782598|NCT04925180|||OTHER||CROSS_SECTIONAL|||||||
33782599|NCT02926937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782600|NCT00275587|||||RETROSPECTIVE|||||||
33782601|NCT03233165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782602|NCT04305912|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33782603|NCT02863159|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33782604|NCT06395363|||COHORT||RETROSPECTIVE|||||||
33782605|NCT04071340|||COHORT||PROSPECTIVE|||||||
33917295|NCT00239837|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33917296|NCT06127706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the two groups are invited for a lecture and are exposed to training skills|two groups randomized One with previous lecture and training, one without|t|f|f|f
33917297|NCT00738374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917298|NCT02654574|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33782606|NCT00601965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917299|NCT00679718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917300|NCT00765440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33917301|NCT00469846|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33917302|NCT00877669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917303|NCT03832153|||CASE_ONLY||PROSPECTIVE|||||||
33917304|NCT01021813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917305|NCT01594138|||CASE_CONTROL||PROSPECTIVE|||||||
33997484|NCT02224144|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997485|NCT03265860|||CASE_ONLY||PROSPECTIVE|||||||
33997486|NCT03415308|||OTHER||OTHER|||||||
33997487|NCT03867071|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33997488|NCT02399462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997489|NCT04261374|||COHORT||PROSPECTIVE|||||||
33997490|NCT03503916|||COHORT||PROSPECTIVE|||||||
33997491|NCT05869136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33997492|NCT04857138|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33997493|NCT05894148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997494|NCT01360086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997495|NCT01460628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997496|NCT06563284|||COHORT||PROSPECTIVE|||||||
33997497|NCT02997345|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33997498|NCT02888964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997499|NCT03385135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997500|NCT06007729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997501|NCT04606056|||COHORT||RETROSPECTIVE|||||||
33997502|NCT03513185|||COHORT||PROSPECTIVE|||||||
33997503|NCT03046550|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33997504|NCT00408304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33997505|NCT05623592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997506|NCT05366582|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Anesthesia approach appropriate to the group of the randomized patient before the operation will be selected. The chosen intubation method will be performed by the 1st anesthetist. The patient, the surgeon and the second anesthetist who will follow up intraoperatively and postoperatively will not know the chosen method.||t|f|f|t
33997507|NCT02344550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997508|NCT03259880|||COHORT||PROSPECTIVE|||||||
33997509|NCT01963260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997510|NCT01466894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997511|NCT01049581|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997512|NCT01677338|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33997513|NCT02754089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997514|NCT06627881|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Those in charge of evaluating results and the person in charge of statistical analysis will be blinded and will not know the assignment of the intervention. The person in charge of carrying out the assigned exercise and the participant will know the assignment of the intervention.|Randomized clinical trial|t|t|t|t
33693648|NCT06662357|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The Family Connections Model consists of the delivery of intensively integrated clinical care within pediatrics, combined with community-based parent support from family support specialists. Innovations include child mental health specialists joining the pediatrics team for huddles, psychiatry notes shared with pediatricians via the Electronic Medical Records and active inclusion of pediatricians in pre-evaluation discussions with the Family Connections Team and post-evaluation recommendations for the families. In addition, the Safety-Net model includes active communication with school personnel, child welfare, and community-based resources, when needed."||||
33997515|NCT06052839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997516|NCT04333264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two groups of patients with or without closed suction drainage after primary total hip arthroplasty.|t|t|t|f
33997517|NCT01685255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917306|NCT06269289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The research was designed as a randomized controlled experimental study with a pretest-posttest design.||||
33917307|NCT00503880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693649|NCT01590992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693650|NCT06608472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917308|NCT02489006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997518|NCT04345640|||COHORT||PROSPECTIVE|||||||
33997519|NCT01717950|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782607|NCT03458897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782608|NCT00117611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782609|NCT05864768|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782610|NCT00186810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782611|NCT01354938|||CASE_ONLY||PROSPECTIVE|||||||
33782612|NCT06630195|||COHORT||PROSPECTIVE|||||||
33782613|NCT03992911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917309|NCT04900480|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33917310|NCT01536119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997520|NCT04699396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997521|NCT05326880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997522|NCT05069480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917311|NCT04613102|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Only phase 3 of the clinical trial is going to be double-blinded.|Phase 2 of the study is open label . Phase 3 study participants will be his own control: they will be treated by the active medication ( AVCN583601) and placebo simultaneously during full study treatment period, applying thestudy cream from two different jars to two different body sides ( left/right).|t|f|t|f
33917312|NCT06330285|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917313|NCT06414538|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917314|NCT02017236|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33917315|NCT00287144|||COHORT||RETROSPECTIVE|||||||
33917316|NCT03379012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917317|NCT01322646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917318|NCT05766865|||COHORT||PROSPECTIVE|||||||
33917319|NCT05432674|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917320|NCT00091923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917321|NCT00288834|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917322|NCT01378936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917323|NCT04274660|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"Participants will be invited to take part in the 12-week DWELL Programme (the intervention) based on their eligibility as per the inclusion criteria. They will all receive the psycho-social education element in addition to two motivational interviews. Each element will be evaluated alone and in combination.~The non-intervention group will be recruited in one of two ways - they will either be people with type 2 diabetes who do not wish to participate in the 12-week programme, or they are receiving routine care (which, for UK participants, is a locally commissioned 6-week programme)."||||
33997523|NCT06628349|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33997524|NCT04614857|NA|SINGLE_GROUP||OTHER||NONE||||||
33997525|NCT05990127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997526|NCT00429221|RANDOMIZED|PARALLEL||||NONE||||||
33997527|NCT04285268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997528|NCT01426854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782614|NCT03279198|RANDOMIZED|FACTORIAL||PREVENTION||NONE||We propose a prospective randomized 2x2 factorial design: 1)usual care; 2) a TIWeb; 3) a Cancer Screening Call (CSC), and 4 a TIWEB+ a Cancer Screening Call (CSC). The intervention will be tested in 2 groups of women. Group A will include women who are nonadherent to CRC but adherent to BC screening guidelines. Group B will include women who are nonadherent to both CRC and BC screening guidelines.||||
33997529|NCT04345107|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33997530|NCT06174558|||COHORT||PROSPECTIVE|||||||
33997531|NCT06251349|||CASE_CONTROL||RETROSPECTIVE|||||||
33997532|NCT01325740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997533|NCT00108043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997534|NCT02921516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33997535|NCT06428149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997536|NCT00627796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997537|NCT04469751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997538|NCT01574027|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33997539|NCT02030535|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33997540|NCT01945580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997541|NCT00577655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997542|NCT02736019|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997543|NCT04327401|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Dexamethasone. After randomization, dexamethasone 20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days + standard treatment (according to the treatment protocol for 2019-nCoV infection).~2. Standard treatment (according to the treatment protocol for 2019-nCoV infection)."||||
33997544|NCT03947658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997545|NCT01693809|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|f|t|f
33997546|NCT02527213|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33997547|NCT06248294|||COHORT||OTHER|||||||
33917324|NCT04786132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre test, intervention and Post test. Experimental group performs and eight week dual task training with proprioception and balance exercise while including unknown sung music 2 days a week. Control group do the same protocol and the same days but without the inclusion of music.||||
33997548|NCT04034277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087722|NCT03638791|||COHORT||PROSPECTIVE|||||||
33917325|NCT01833104|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33917326|NCT02075749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33917327|NCT03522701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomised, assessor-blind, parallel group controlled trial|f|f|f|t
33917328|NCT02483403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087723|NCT00630292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917329|NCT00546039|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33917330|NCT02006264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33917331|NCT01446601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087724|NCT05409391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917332|NCT00609219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917333|NCT05877651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087725|NCT00859690|||CASE_CONTROL||OTHER|||||||
34087726|NCT05955066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087727|NCT05743972|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34087728|NCT04561791|NA|SINGLE_GROUP||SCREENING||NONE||||||
34087729|NCT03079830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087730|NCT02318264|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34087731|NCT05366686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One research assistant is trained for being a outcomes assessor in this study who did not know the allocation of participants.|Patients in the intervention group will receive a 12 week exercise program including: individual consultation, nutrition consultation, teaching exercise which contain walking and resistance exercise by using elastic bands and elastic balls.|f|f|f|t
34087732|NCT05622149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087733|NCT01454752|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34087734|NCT04388423|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087735|NCT06085144|||COHORT||PROSPECTIVE|||||||
34087736|NCT00038662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34087737|NCT00864071|RANDOMIZED|CROSSOVER||||NONE||||||
34087738|NCT00002129||||TREATMENT||NONE||||||
33917334|NCT00781248|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33997549|NCT04922957|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Randomization will be in a double blinding fashion. The IP will be delivered with a cover to maintain blinding.|"152 patients will be allocated in a 1:1 ratio between the 2 cohorts:~1. Placebo~2. Single Intravenous (IV) dose of Allocetra-OTS (10x10\^9 cells)"|t|f|t|f
33997550|NCT06405815|||COHORT||RETROSPECTIVE|||||||
34087739|NCT02679846|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087740|NCT02862509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087741|NCT04920669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34087742|NCT03945890|||OTHER||RETROSPECTIVE|||||||
34087743|NCT02918344|||COHORT||PROSPECTIVE|||||||
33917335|NCT00160576|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33917336|NCT00084812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917337|NCT01635491|||CASE_ONLY||PROSPECTIVE|||||||
33997551|NCT06466213|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33997552|NCT04403620|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose/fractionation finding Phase 1 study, followed by a randomized Phase 2 study||||
33997553|NCT02761915|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33997554|NCT04359745|||COHORT||PROSPECTIVE|||||||
34087744|NCT00056771|||COHORT||PROSPECTIVE|||||||
34087745|NCT03156894|||COHORT||RETROSPECTIVE|||||||
34087746|NCT00205166|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34087747|NCT01608594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087748|NCT00409825|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087749|NCT06519630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782615|NCT06434428|||COHORT||PROSPECTIVE|||||||
33782616|NCT00508885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917338|NCT05197673|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group will receive theory-based educational intervention using the Theory of Planned Behaviours (TPB) PLUS general health information; Control group will receive only general health information.||||
34087750|NCT06055387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34087751|NCT03091439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087752|NCT03290651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Double blind randomized, placebo-controlled pilot trial.|t|t|f|f
33917339|NCT02492685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917340|NCT05807178|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluation of Specific Light Algorithms (Dynamic Light Therapy Devices, LSA-1 and LSA-2) to Maintain and Restore Circadian Melatonin Rhythmicity in Critically Ill Patients||||
33917341|NCT03482141|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997555|NCT00323258|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33997556|NCT03573544|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33997557|NCT04861363|||COHORT||RETROSPECTIVE|||||||
33997558|NCT01260805|RANDOMIZED|CROSSOVER||||NONE||||||
33997559|NCT05936554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33997560|NCT04228822|RANDOMIZED|PARALLEL||OTHER||NONE||20 participants will be randomized to the intervention group (low carbohydrate diet) and 20 participants will be randomized to the control group||||
33997561|NCT02379533|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33997562|NCT00258024|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33997563|NCT02355730|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33997564|NCT02375750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782617|NCT05151861|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33782618|NCT05542680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33782619|NCT03000712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782620|NCT02542735|||COHORT||PROSPECTIVE|||||||
33782621|NCT06400056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||More than 4 years old||||
33782622|NCT06045637|RANDOMIZED|PARALLEL||OTHER||NONE||This research was planned as a randomized controlled experimental study. In this research, pre-test, post-test and follow-up test will be performed and there will be 1 experimental and 1 control group created by randomization.||||
33997565|NCT02235870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997566|NCT05947409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997567|NCT00272441||CROSSOVER||TREATMENT||||||||
33997568|NCT03013530|||OTHER||CROSS_SECTIONAL|||||||
33997569|NCT05612958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997570|NCT02992067|||CASE_CONTROL||PROSPECTIVE|||||||
33997571|NCT01670643|||CASE_CROSSOVER||PROSPECTIVE|||||||
33997572|NCT05508490|||COHORT||PROSPECTIVE|||||||
33997573|NCT03517319|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33997574|NCT02363764|||COHORT||PROSPECTIVE|||||||
33997575|NCT03335241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997576|NCT03929016|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double Blind|Single Ascending Dose|t|t|t|t
33997577|NCT06062615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917342|NCT04413643|NA|SINGLE_GROUP||TREATMENT||NONE||This is a feasibility trial intended to inform a larger clinical trial based on outcomes data collected.||||
33917343|NCT01235286|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33917344|NCT01088438|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33997578|NCT05203458|||COHORT||RETROSPECTIVE|||||||
33782623|NCT05656365|||COHORT||PROSPECTIVE|||||||
33997579|NCT03056287|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33997580|NCT03306758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997581|NCT03315533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997582|NCT00028613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997583|NCT05934695|||OTHER||CROSS_SECTIONAL|||||||
33997584|NCT06018116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997585|NCT03010657|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33997586|NCT03506594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997587|NCT03885934|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33997588|NCT00487435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997589|NCT06022588|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782624|NCT01571089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782625|NCT00408668|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782626|NCT03788291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782627|NCT00607035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917345|NCT01490762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33917346|NCT04496947|RANDOMIZED|PARALLEL||OTHER||SINGLE||"2 groups:~1. stress reduction intervention~2. no intervention"|f|f|f|t
33917347|NCT04450056|||COHORT||PROSPECTIVE|||||||
33997590|NCT03103711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997591|NCT03643783|||CASE_ONLY||CROSS_SECTIONAL|||||||
33997592|NCT03147053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997593|NCT00516295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997594|NCT06466135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997595|NCT05435534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33997596|NCT04762251|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33997597|NCT06136962|||COHORT||PROSPECTIVE|||||||
33997598|NCT05779943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997599|NCT04302961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917348|NCT06011291|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33917349|NCT03215082|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997600|NCT06626542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997601|NCT04484740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997602|NCT04268797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997603|NCT01956318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997604|NCT06398522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997605|NCT01261767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782628|NCT02913196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782629|NCT06071104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782630|NCT04623723|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single blinded (subject)||t|f|f|f
33917350|NCT02645383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917351|NCT03623282|NA|SINGLE_GROUP||TREATMENT||NONE||"Experimental(Single arm):~The enrolled patients will be prescribed Synatura® following measurement of pre-dose pulmonary functions, quality of life and systemic inflammatory state. Pulmonary functions, quality of life and systemic inflammatory state will be repeatedly measured after taking Synatura® for 3 months, and the changes from pre-dose measurements will be observed."||||
33917352|NCT00944255|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33917353|NCT06348810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes Assessor will be blind, so they didnt know which is intervention group or control group|eksperimental group receive dual-task training, while control group receive usual care and both conduct at the same time|f|f|f|t
33917354|NCT04907591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917355|NCT01836744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Seal envelops, codification of the side and patient and independent blind assessors|"randomizes split month trial:~* one sinus autologous bone graft~* other sinus - xenograft - osteobiol Mp3"|t|f|t|t
33917356|NCT02713763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917357|NCT00973206|||COHORT||PROSPECTIVE|||||||
33917358|NCT00171314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782631|NCT00155610|||||PROSPECTIVE|||||||
33917359|NCT01403701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782632|NCT03427229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917360|NCT05738694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917361|NCT00212303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917362|NCT05487313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917363|NCT05250830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind, randomized, sham-controlled trial parallel arm study using TrueRelief as the experimental treatment and a TrueRelief device with sham capabilities as a placebo.|t|t|t|f
33917364|NCT02287701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782633|NCT06042387|||CASE_CONTROL||PROSPECTIVE|||||||
33782634|NCT03241498|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE||"A prospective, multi-centre, randomised intervention study will be conducted simultaneously in four different regions of the United Kingdom (UK), namely:~1. Northern Health and Social Care Trust (NHSCT) and Western Health and Social Care Trust (WHSCT), Northern Ireland~2. North West Coast Academic Health Science Network (AHSN), England~3. Wessex AHSN, England~4. Eastern AHSN, England~Two GP practices will participate in the research in each of these four geographical areas. The pragmatic sample size at each site will be 50 intervention patients and 50 control patients completing a six month follow-up period i.e. a total of 800 patients (400 intervention and 400 control patients) across the eight participating GP practices. An over-recruitment of 20%, i.e. 60 each of both control and interventions patients per practice, will be recruited into the study to take account of patients who drop out of the study and/or are lost to follow up."|f|f|f|t
33782635|NCT04694560|||COHORT||PROSPECTIVE|||||||
33782636|NCT03351309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782637|NCT06589414|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33782638|NCT00250224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782639|NCT02516579|||COHORT||PROSPECTIVE|||||||
33782640|NCT04795141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782641|NCT05557019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917365|NCT05436886|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33917366|NCT06308640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The purpose of this study is to evaluate and compare the treatment effects of two bone supported protocols for bilateral distalization of maxillary molars in patients exhibiting class II pattern using Fast Back appliance and modified Leaf Spring Self-Activated Expander|t|f|t|f
33997606|NCT00874822|||OTHER||RETROSPECTIVE|||||||
33997607|NCT01456949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997608|NCT05510141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997609|NCT00111787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997610|NCT00529763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997611|NCT00004985||||TREATMENT||||||||
33997612|NCT05409651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997613|NCT01698736|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997614|NCT01591720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997615|NCT02127216|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33997616|NCT01632423|||CASE_ONLY||PROSPECTIVE|||||||
33997617|NCT05069974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analysis will be blinded.|Open-label, non inferiority, randomized clinical trial. Eligible patients will be randomized to recieve Linezolid (experimental arm) or BPG (control arm).|f|f|f|t
33997618|NCT02731781|||COHORT||PROSPECTIVE|||||||
33997619|NCT02225015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33997620|NCT00002158||||TREATMENT||||||||
33997621|NCT02824510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997622|NCT03204851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997623|NCT04158128|||COHORT||OTHER|||||||
33997624|NCT00163319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997625|NCT04408833|||COHORT||PROSPECTIVE|||||||
33997626|NCT00512239|||COHORT||PROSPECTIVE|||||||
33997627|NCT01816230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997628|NCT00343720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997629|NCT01932853|||CASE_ONLY||PROSPECTIVE|||||||
33997630|NCT00691470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997631|NCT03108235|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33782642|NCT05441280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double (participant, investigator)|Pimavanserin 34mg at bedtime|t|t|t|t
33997632|NCT00592969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997633|NCT04951778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782643|NCT06441773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A two-center, randomized, open-label, parallel-group, ratio-distributed (1:1) trial comparing the impact of respiratory rehabilitation (RR) on quality of life at 2 months in patients with advanced NSCLC associated with RR versus patients with advanced NSCLC without RR.||||
33997634|NCT03266224|||CASE_ONLY||CROSS_SECTIONAL|||||||
33782644|NCT03738358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997635|NCT06492109|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33997636|NCT05128396|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33782645|NCT03326479|||COHORT||RETROSPECTIVE|||||||
33782646|NCT02922413|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Administered doses are shielded from view. The pharmacy and one nurse who administers the drug intravenously will not be blinded.|Two group parallel blinded study comparing active drug and placebo|t|t|t|t
33782647|NCT04445844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782648|NCT00479947|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33782649|NCT00660166|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782650|NCT02742051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782651|NCT03537885|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782652|NCT04227535|||CASE_CONTROL||PROSPECTIVE|||||||
33782653|NCT03145077|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33782654|NCT05541419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study.||t|f|t|f
33782655|NCT01226264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782656|NCT00710164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782657|NCT00790062|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33782658|NCT06613932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917367|NCT04777214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The procedure for localizing the site of stimulation and TMS administration will be identical to the treatment arm, except the coil will be rotated 90 degrees during the process/administration.|The study involves two arms. The study involves a sham treatment control for half of the patients; all patients randomized to the sham treatment will be enrolled in the treatment phase after completing the sham treatment. Patients will be randomly assigned to the treatment arm or the sham treatment arm of the study. There are 3 phases: a pre-treatment evaluation phase in which baseline language and imaging data are obtained and the optimal site for stimulation is determined; a treatment phase during which TMS is delivered on 10 occasions; and a post-treatment phase during which effects of the treatment will be assessed using behavioral measures as well as fMRI at 2 and 6-months. Participants in the sham arm will undergo the same behavioral testing, MRI, and fMRI that will be administered in the treatment protocol. After the 2-month follow up visit, patients in the sham arm will be told that they did not receive real TMS and will be offered the opportunity to enter the treatment arm.|t|t|f|f
33917368|NCT00747617|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33917369|NCT04163406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33917370|NCT05912309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled parallel-arm clinical trial|f|t|t|f
33917371|NCT00852189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917372|NCT01965236|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33997637|NCT03784274|||OTHER||RETROSPECTIVE|||||||
33997638|NCT01129258|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33997639|NCT01246687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997640|NCT03825562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997641|NCT01120028|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33997642|NCT01750294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997643|NCT04162899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997644|NCT02466490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997645|NCT04440150|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Retrospective Cohort Study||||
33997646|NCT01100814|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33997647|NCT04410653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997648|NCT03534531|||COHORT||PROSPECTIVE|||||||
33997649|NCT00857558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782659|NCT04438785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Results will be analysed blinded by the investigators.|Interventional prospective multicentre trial with consecutive random assignment|f|f|f|t
33782660|NCT02051439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782661|NCT05648955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33782662|NCT02843087|||COHORT||PROSPECTIVE|||||||
33782663|NCT03661190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33782664|NCT02135393|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782665|NCT02857764|||COHORT||RETROSPECTIVE|||||||
33782666|NCT02635659|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33782667|NCT03765697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997650|NCT04898998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997651|NCT04627844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive feeding beginning at two time points.||||
33782668|NCT00076141|||COHORT||PROSPECTIVE|||||||
33782669|NCT02206685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33782670|NCT04135495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782671|NCT00783692|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33782672|NCT02398838|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782673|NCT04087772|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782674|NCT06419946|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Everyone: Radiotherapy (RT) consists of 60 Gy standard RT (RT 30x2Gy)~Experimental treatment arm (TMZ/LOM):~6 cycles of LOM/TMZ Start day 1 of RT. Cycle length of 42 days. Duration 9 months.~Standard treatment arm (TMZ):~Oral TMZ 75 mg/m2 daily during RT and with start day 1 of RT. This is followed by 6 cycles of TMZ with start 4 weeks after the end of RT. Cycle length 28 days. Duration 8,5 months.~Everyone: TTFields start with radiotherapy/chemotherapy - but only in Sweden where TTF is part of standard of care (SOC). Ongoing until 2nd progression or max 2 years."||||
33782675|NCT00002569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782676|NCT01141660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782677|NCT03812666|||CASE_CONTROL||PROSPECTIVE|||||||
33782678|NCT05868499|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Sequential Assignment||||
33782679|NCT02862782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782680|NCT06527105|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33917373|NCT03586245|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All stable isotopes (FePP, ASP, FeSO4) were all individually added to test meal and mixed thoroughly by investigators. Participants were brought the meal to consume, unknowingly of which respective treatment they were receiving.|Subjects consumed two stable isotopes (57Fe and 58Fe). Study I, three consecutive days of meal A followed by crossover of three days meal B were consumed. Study II was a crossover between meal B and meal C.|t|f|f|f
33917374|NCT00396149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917375|NCT02540096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917376|NCT05671601|||OTHER||PROSPECTIVE|||||||
33917377|NCT05084794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917378|NCT03987919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917379|NCT06394401|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double blinded randomized crossover design|t|f|t|t
33997652|NCT05391594|NA|SINGLE_GROUP||TREATMENT||NONE||Single Subject Research Design||||
33997653|NCT00057941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782681|NCT05267977|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase: Part 1: Retrospective multi-center study. Part 2: Prospective multi-center study. Number of Sites: Methodist Health System and the associated center. Description of Intervention: Phase 1: No intervention. Phase 2: Patients will be randomized to receive either cephalosporin or the combination of cephalosporin and aminoglycoside.~Study Duration: Phase 1: 3 years. Phase 2: 5 years. Subject Participation Duration: Phase 2: Patients will be enrolled in the study until discharge from the hospital. Study participation is strictly voluntary and patient can withdraw at any time."||||
33997654|NCT03717701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|both participants and researchers will be blinded to the intervention given|This is a randomized double-blinded placebo-controlled intervention trial|t|t|t|t
33997655|NCT02840149|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33997656|NCT01519830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997657|NCT02011828|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33997658|NCT02573779|||COHORT||PROSPECTIVE|||||||
33997659|NCT02840162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997660|NCT00599820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997661|NCT04750590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997662|NCT01943435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997663|NCT01728636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997664|NCT03130335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997665|NCT03008005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33997666|NCT02902601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997667|NCT00178711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997668|NCT05920603|||CASE_ONLY||CROSS_SECTIONAL|||||||
33997669|NCT02291965|||CASE_ONLY||PROSPECTIVE|||||||
34087753|NCT01577914|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087754|NCT02059239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087755|NCT02169232|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34087756|NCT05706701|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The flux/form conditions will be tested by participants in two lab visits separated by three weeks to minimize carryover effects. All sessions will be double-blinded. In the first visit, participants will use the ENDS device with one nicotine form and four fluxes in random order.|The investigators will measure arterial nicotine concentrations over discrete time-periods in a within-subject study with 15 anticipated participants who will undergo 2 ENDS use sessions that differ by nicotine form (protonated, freebase). In each session, participants will draw three 3-sec puffs with four randomly ordered nicotine fluxes (9, 18, 27, 35 μg/sec).|t|f|t|f
34087757|NCT00608920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782682|NCT05079217|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33782683|NCT02099539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782684|NCT02749708|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782685|NCT06187870|||COHORT||PROSPECTIVE|||||||
33997670|NCT00207662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997671|NCT02658214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997672|NCT06306391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997673|NCT04870333|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|PROTECT-V will be a double blind placebo controlled study where neither the participant nor clinician will be aware of treatment allocation.|"The following populations will be defined for efficacy and safety analyses:~* Intent-to-treat population (ITT) The ITT population is defined as all participants randomised in the trial, regardless of whether they actually received trial treatment. The treatment group will be analysed as randomised.~* Safety population The safety population comprises all participants randomised and having received as least one dose of trial treatment. The treatment group will be analysed as treated."|t|t|t|f
33997674|NCT05214716|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33997675|NCT04733456|||COHORT||PROSPECTIVE|||||||
33997676|NCT00958724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997677|NCT03960801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled trial in 2 parallel groups assigned to tested drug in intervention group and to reference treatment for control group.|t|f|f|t
33997678|NCT05527639|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A comparative study using data from 2 separate studies. Data used for the resistance training (RT) group from a foundational single cohort that investigated impact of RT on stress urinary incontinence (SUI) in a group of women participating in a RT program who had not previously done Kegel exercises (KE). New data for the KE+RT group was from 2 consecutive studies where the women completed a program of supervised / unsupervised KE. These 19 women took part in 12 weeks of RT to compare against the KE group. The findings of two separate studies in which the effect of RT on SUI and pelvic floor muscle strength was compared between women who completed 12 weeks of RT with or without prior KE. The RT group consisted of 14 women who did not have an experience in RT or KE and completed 12 weeks of RT. Women in the KE plus RT group (n=19) completed 12 weeks of Kegel exercise under the supervision of a qualified pelvic floor specialist; then completed the identical RT program as the RT group||||
33997679|NCT04221347|||COHORT||PROSPECTIVE|||||||
33997680|NCT05290896|NA|SINGLE_GROUP||TREATMENT||NONE||Senile cataract patients||||
33997681|NCT01265238|||CASE_ONLY||PROSPECTIVE|||||||
33997682|NCT03277963|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33997683|NCT05754788|||CASE_CONTROL||RETROSPECTIVE|||||||
34087758|NCT03834090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34087759|NCT01294514|||CASE_ONLY||PROSPECTIVE|||||||
34087760|NCT00521495|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33782686|NCT05063331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to the surgical randomization prior to surgery and will be informed of their surgical assignment (unmasked) after waking up from surgery and prior to discharge.|The study is utilizing a 1:1 randomization scheme (by site) to assign patients to one of two treatment arms: 1) minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCH+SCP, N=160) or 2) total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS, N=160).|t|f|f|f
33917380|NCT03348241|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an experimental study. It was a two-arm randomized, controlled, open-label trial. The patients was categorized into two groups; study group and control group. Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed, while patients of control group was received only chemotherapy regimen.||||
33917381|NCT00484965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917382|NCT06098209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997684|NCT01004510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087761|NCT06045260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997685|NCT06123754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a randomized, controlled, double-blind, multicenter phase Ⅲ study|t|t|t|f
33997686|NCT03983135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997687|NCT02582307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997688|NCT03090282|||COHORT||PROSPECTIVE|||||||
33997689|NCT03718039|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33997690|NCT00044876||||TREATMENT||||||||
33997691|NCT01754935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997692|NCT02028039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087762|NCT04685954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087763|NCT06525519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087764|NCT03098979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087765|NCT03773588|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Device: Closed-Loop propofol TCI with Entropy and SPI Device: Open-Loop propofol by Target Controlled Infusion Drug: propofol|t|t|t|t
34087766|NCT05532878|||COHORT||PROSPECTIVE|||||||
34087767|NCT02104687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087768|NCT01115270|||CASE_CONTROL||PROSPECTIVE|||||||
34087769|NCT04452669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled|Double-blind, placebo controlled study comparing study treatment group to placebo controls who received SOC|t|t|t|t
34087770|NCT05529433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087771|NCT06080126|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study will be conducted in a 2-phase approach corresponding to the 2 successive phases of the MRC guidance:~* Phase 1: The adaptation of the intervention to our context will be based on a literature review and a qualitative study.~* Phase 2: The feasibility and acceptability of the intervention will be assessed during a quasi-experimental before and after study conducted in two short-stay geriatric units."||||
34087772|NCT05244096|||OTHER||RETROSPECTIVE|||||||
34087773|NCT01451073|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34087774|NCT04028102|||COHORT||PROSPECTIVE|||||||
34087775|NCT05762575|||CASE_CROSSOVER||PROSPECTIVE|||||||
34087776|NCT00001011||PARALLEL||TREATMENT||||||||
34087777|NCT05320042|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34087778|NCT01176656|||COHORT||CROSS_SECTIONAL|||||||
34087779|NCT02969278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087780|NCT00896064|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34087781|NCT03386227|RANDOMIZED|PARALLEL||OTHER||SINGLE|The embryologists who assess embryo outcomes (as noted in the secondary outcomes) will be blinded to randomization.|This study will have patients randomized in a 1:1 fashion to antibiotic prophylaxis or withholding antibiotic prophylaxis.|f|f|f|t
33917383|NCT02077985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917384|NCT01159626|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33997693|NCT02042599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997694|NCT05467163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997695|NCT05497986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, nor the participants, nor the treating physicians, nor the investigator can be blinded. However, the outcomes will be analyzed an independent statistician blinded to the treatment assignments.||f|f|f|t
34087782|NCT06403800|||OTHER||PROSPECTIVE|||||||
34087783|NCT01242319|||||PROSPECTIVE|||||||
34087784|NCT01560338|||COHORT||PROSPECTIVE|||||||
34087785|NCT01385644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087786|NCT06231524|||COHORT||PROSPECTIVE|||||||
34087787|NCT04092075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Assessors will not be exposed to the type of brush the subject is using or to the group they are assigned to (treatment or control).|Single blind prospective study|f|f|f|t
34087788|NCT00006039||||TREATMENT||||||||
34087789|NCT00091819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997696|NCT04920695|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Neither the participant, nor the clinical research coordinator conducting the exercise test will know which treatment is being administered. A separate, unblinded research associate will handle and administer treatment using the SoKINOX™ NO Delivery and Monitoring System|Randomized, double-blind, placebo-controlled crossover design|t|f|t|f
33997697|NCT01873391|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33997698|NCT01715922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997699|NCT04733430|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33997700|NCT00079287|RANDOMIZED|||TREATMENT||||||||
33997701|NCT04076007|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33997702|NCT02203539|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33997703|NCT02845154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997704|NCT04882254|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomised to either intervention arm (normothermic machine perfusion, NMP) or standard-of-care (hypothermic machine perfusion, HMP)||||
33997705|NCT00469898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997706|NCT02372006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087790|NCT01775098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087791|NCT05490082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34087792|NCT01492959|||COHORT||PROSPECTIVE|||||||
33917385|NCT04338516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917386|NCT05963048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participant and outcome assrssor||t|t|t|t
33917387|NCT05711199|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Open-label, cross-over trial in healthy volunteers with random sequence of the two study interventions||||
33917388|NCT05385497|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will utilize a single group, pre-post design||||
33917389|NCT00057590|RANDOMIZED|PARALLEL||TREATMENT||||||||
33917390|NCT01185587|||COHORT||RETROSPECTIVE|||||||
33917391|NCT03695640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, controlled, prospective|f|f|f|t
33917392|NCT01532713|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917393|NCT00414778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917394|NCT02266758|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33917395|NCT01182389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917396|NCT03558555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants presenting for inguinal hernia surgery are assigned to either the oral or intravenous acetaminophen group|t|t|t|t
33917397|NCT03183830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All members of the study team and volunteer participants will be blinded to treatment versus placebo arm|Double-blind randomised-control parallel two-limb study|t|f|t|t
33917398|NCT06394518|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33917399|NCT04745286|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917400|NCT04740099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Pragmatic, multi-site, 2-armed, parallel-group, best available care controlled, analyst- and outcome assessor-blinded, superiority trial with embedded qualitative study.|f|f|t|t
33917401|NCT02813759|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33917402|NCT04586244|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33917403|NCT01523561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917404|NCT03632252|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087793|NCT02290184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|statistician has been masked from any subjects' personal and confidential information||f|f|f|t
33997707|NCT00306306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997708|NCT05882526|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluation of T loop for orthodontic maxillary canine retraction Evaluation of POWER CHAIN for orthodontic maxillary canine retraction||||
34087794|NCT01686893|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087795|NCT00104689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917405|NCT06019936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double-blinded for MT2004/matching placebo. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (MT2004 or placebo).Blinding will be maintained until at least the clinical phase of the study is completed.||t|f|t|f
33917406|NCT04042675|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33917407|NCT01833325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917408|NCT02568124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997709|NCT05088551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants, care providers were left blind. At the same time in the statistical analysis and reporting phase, the researchers were left blind.||t|t|f|f
33997710|NCT05725499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997711|NCT03271125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34087796|NCT06098183|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized crossover design||||
34087797|NCT03437967|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Sham therapy will consist of treatment using an identically appearing device that delivers low level LASER POWER to simulate LASER treatment.|This is a prospective interventional study using a double-blind 4-period crossover design to assess the efficacy of LASER Photobiomodulation therapy compared to sham (LOW POWER LASER) therapy in reducing pain and improving compliance with OPM weaning. LASER photobiomodulation treatments or sham treatments will be provided three times a week using standardized protocols. Crossover will occur every 3 weeks with weekly data collection occurring at the end of each week allowing for washout and to minimize the carryover effects of active treatment. Data collection will consist of LASER and sham treatments, prescribed pain medication dosage and quantity, subjective pain questionnaires, and urine samples. Cognitive and memory screening will occur every 3 weeks at the end of each period prior to crossover.|t|f|f|t
34087798|NCT05267717|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087799|NCT02031172|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34087800|NCT02722967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087801|NCT01239589|||COHORT||RETROSPECTIVE|||||||
34087802|NCT00981123|||CASE_ONLY||PROSPECTIVE|||||||
34087803|NCT00779337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693651|NCT06710951|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Patients did not know which percentage of povidone-iodine was utilized during their injection.~Tear breaking time and bulbar redness were automized results by Keraatopgrah. Oxford scale pre and post injection was staged by an investigator that did not know the group in which the patient was."|Clinical, prospective, randomized trial. Pre anti-VEGF intravitreal injection, with OCULUS Keratopgrapph 5M topograph, non invasive tear breaking time, bulbar redness, and Oxford scale with fluorescein staining were measured. During anti-VEGF injection, tetracaíne was use as anestetic. Povidone-iodine 1% or 5% was randomized as antiseptic. After anti-VEGF intravitreal injection, patients were examined again for tear bkreaking time, bulbar redness and Oxford sacle, plus pain 15 minutes after injection. Finally, two days after the injection, patients were interviwed by telephone about their pain.|t|f|f|f
33693652|NCT02834377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693653|NCT05682235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participants will not know in which treatment group they are, and the investigator in charge of carrying out the evaluation will not know to which group the subjects he evaluates belong to.|Through a randomization program, participants will be assigned to the treatment group or the control group.|t|f|f|t
33693654|NCT06708117|||CASE_CONTROL||PROSPECTIVE|||||||
33917409|NCT02298712|||COHORT||PROSPECTIVE|||||||
33917410|NCT00218426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917411|NCT00037505|||DEFINED_POPULATION||OTHER|||||||
33917412|NCT02927873|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind||t|t|t|t
33917413|NCT00501046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917414|NCT00701155|||OTHER||PROSPECTIVE|||||||
33917415|NCT02223195|||COHORT||PROSPECTIVE|||||||
34087804|NCT04971655|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||two groups with a music therapy group and control group||||
34087805|NCT05683821|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster-randomized controlled||||
34087806|NCT02753881|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087807|NCT06325267|||COHORT||RETROSPECTIVE|||||||
34087808|NCT04778540|||OTHER||PROSPECTIVE|||||||
34087809|NCT00489242|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693655|NCT04920136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917416|NCT04790266|||COHORT||PROSPECTIVE|||||||
33917417|NCT05239559|||OTHER||PROSPECTIVE|||||||
33917418|NCT03937193|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33917419|NCT02129335|||COHORT||PROSPECTIVE|||||||
33917420|NCT00002212||||TREATMENT||||||||
33917421|NCT00332800|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33917422|NCT00999219|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33917423|NCT03405493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* Both groups will receive treatment as usual.~* Triple Chronotherapy. This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Bright Light Therapy is given on Day 2 onwards daily.~* Comparator Intervention: Participants will be given information on sleep hygiene and getting a good night's sleep in a written leaflet and given the opportunity to ask questions. They are then given Dim Amber Light Therapy daily for 1 week."|f|f|f|t
33917424|NCT00473837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917425|NCT06313177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917426|NCT00188266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997712|NCT01891357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997713|NCT06628245|||OTHER||PROSPECTIVE|||||||
33997714|NCT04967950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997715|NCT02171988|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997716|NCT03017729|||COHORT||PROSPECTIVE|||||||
33997717|NCT04046380|||OTHER||PROSPECTIVE|||||||
33997718|NCT05959915|||COHORT||PROSPECTIVE|||||||
33997719|NCT02940613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997720|NCT01653405|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33693656|NCT04990336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693657|NCT01814618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693658|NCT04095390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782687|NCT05071573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The 10 clinics will be randomly allocated to the intervention (5 clinics) and control (5 clinics) arms. Randomisation will be stratified on clinic size, defined by the number of HIV-related visits per month (2 strata). Restricted randomisation will be used to ensure balance between study arms on the following important covariates: proportion of HIV patients who are male; proportion of HIV patients who are aged \<25 years. A computer programme will be used to prepare a list of all permissible randomised combinations; community leaders will be invited to make a random selection from the list at a public ceremony. The randomisation list will be prepared by an independent statistician and will be concealed until after randomisation. It will not be possible to blind the research staff and nurses to the intervention.|An innovative effectiveness-implementation hybrid cluster-randomised trial in 10 clinics to evaluate the effectiveness of the interventions for improving VLM and virological suppression compared with current care. Clinics will be randomly allocated to either the intervention (Quality improvement package, viral load champion, and augmentation of TIER.Net) or current care.||||
33782688|NCT02948062|||COHORT||PROSPECTIVE|||||||
33782689|NCT00562393|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33782690|NCT02639962|||CASE_CONTROL||PROSPECTIVE|||||||
33782691|NCT00000816||||TREATMENT||||||||
33782692|NCT02387203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782693|NCT02911272|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34087810|NCT02538991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693659|NCT05470985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782694|NCT04892667|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33782695|NCT02081768|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|90Yttrium colloid||||
33782696|NCT05254509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917427|NCT05138874|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients are blinded to all study arms with the exception of Public Commitment where, by design, patients are exposed to physicians' commitment. Physicians cannot be blinded to interventions that, by design, impact the electronic medical record display.|"Participants are randomly assigned to one of three levels of commitment interventions and one of three levels of feedback interventions, for a total of 9 study arms (3 X 3). One level in each factor is control which entails no intervention."|f|f|t|t
34087811|NCT00053326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087812|NCT03972540|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33693660|NCT01003444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693661|NCT03366779|NA|SINGLE_GROUP||PREVENTION||NONE||Multicenter non-randomized device trial||||
33693662|NCT03827837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693663|NCT03880994|||CASE_ONLY||PROSPECTIVE|||||||
33693664|NCT05327218|||COHORT||RETROSPECTIVE|||||||
33693665|NCT03180268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693666|NCT01329484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693667|NCT05061745|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33917428|NCT06552338|||COHORT||PROSPECTIVE|||||||
33693668|NCT04290312|NA|SINGLE_GROUP||OTHER||NONE||||||
33693669|NCT04749667|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Prospective, randomized, placebo-controlled, cross-over study|t|t|f|t
33782697|NCT06610799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917429|NCT04639401|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917430|NCT02040467|||OTHER||PROSPECTIVE|||||||
33917431|NCT03878524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693670|NCT03509610|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33693671|NCT03012568|||CASE_ONLY||PROSPECTIVE|||||||
33693672|NCT04219904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997721|NCT02075905|||COHORT||PROSPECTIVE|||||||
33997722|NCT00062296||||TREATMENT||NONE||||||
33693673|NCT01369615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693674|NCT01226043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997723|NCT04968925|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33997724|NCT06024980|NON_RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33997725|NCT02342873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997726|NCT05341180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997727|NCT05583409|RANDOMIZED|PARALLEL||TREATMENT||NONE||SBRT plus Osimertinib versus Osimertinib||||
33693675|NCT06135207|||COHORT||PROSPECTIVE|||||||
33693676|NCT03387150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693677|NCT06674031|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693678|NCT00116168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917432|NCT03720821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997728|NCT01534754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997729|NCT04996953|||CASE_ONLY||CROSS_SECTIONAL|||||||
33997730|NCT00406393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997731|NCT01189747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997732|NCT06054984|NA|SINGLE_GROUP||TREATMENT||NONE||Patients were sequentially enrolled into 3 dose escalation groups(dose level 1 to 3):5×10\^8±20%,5×10\^9±20%,5×10\^10±20%. Twenty-eight days after infusion of GB3010 cells was the observation period for DLT evaluation.||||
33997733|NCT04301258|||COHORT||OTHER|||||||
33997734|NCT04200833|||CASE_ONLY||RETROSPECTIVE|||||||
34087813|NCT02335944|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087814|NCT01945671|||COHORT||PROSPECTIVE|||||||
33693679|NCT03861923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33693680|NCT03300323|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33693681|NCT03803683|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33693682|NCT00451139|RANDOMIZED|PARALLEL||||NONE||||||
33693683|NCT05355298|NA|SINGLE_GROUP||TREATMENT||NONE||"Single arm study but 2 parts;~* Part A is dose escalation~* Part B is open label single dose level"||||
33693684|NCT06707233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087815|NCT03806816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997735|NCT03216239|||OTHER||RETROSPECTIVE|||||||
33917433|NCT02247284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917434|NCT04989504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33917435|NCT02680405|||COHORT||PROSPECTIVE|||||||
33917436|NCT02346500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917437|NCT01948141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917438|NCT05511831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917439|NCT04895605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917440|NCT03555188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blinded study.|TRITON is a parallel group, randomised, double-blinded, placebo controlled trial, to determine the superiority of Ondansetron.|t|f|t|f
33917441|NCT00762372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997736|NCT00382083|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33917442|NCT02705508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917443|NCT00069368|||CASE_ONLY||RETROSPECTIVE|||||||
33917444|NCT03000374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917445|NCT03886831|NA|SEQUENTIAL||TREATMENT||NONE||||||
33917446|NCT01628094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997737|NCT06165419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997738|NCT00405262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997739|NCT01807351|||COHORT||RETROSPECTIVE|||||||
33997740|NCT04544033|||CASE_ONLY||PROSPECTIVE|||||||
33997741|NCT00195754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087816|NCT00305526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34087817|NCT02424695|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34087818|NCT04789980|||COHORT||PROSPECTIVE|||||||
34087819|NCT01720966|||COHORT||PROSPECTIVE|||||||
34087820|NCT05269329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693685|NCT06166082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693686|NCT04266223|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a hypothesis-producing feasibility study that does not involve power calculations. The number of participants (20) was chosen to enable confidence in the primary outcome calculation.||||
33693687|NCT05843760|||OTHER||OTHER|||||||
33693688|NCT04203381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917447|NCT01504386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917448|NCT00878215|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917449|NCT05668312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The forty-eight subjects undergoing prehabilitation will be randomly allocated to one of the two possible intervention arms (tele-prehabilitation or standard prehabilitation). The twenty healthy young subject will not undergo any prehabilitation and will not be allocated to one of the two prehabilitation arms.|f|t|f|t
33917450|NCT02785952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917451|NCT01500018|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33917452|NCT03064958|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33917453|NCT03431701|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33917454|NCT00144755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917455|NCT00156299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917456|NCT02568345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997742|NCT00418106|||COHORT||PROSPECTIVE|||||||
33997743|NCT01325935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997744|NCT03587129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997745|NCT03643731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997746|NCT03342196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997747|NCT03993158|||COHORT||PROSPECTIVE|||||||
33997748|NCT05232773|||COHORT||PROSPECTIVE|||||||
33997749|NCT03224624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcome (in clinic blood pressure) will be assessed without knowledge of which group participants were assigned.|Participants will be randomized to either usual care or self-management of blood pressure using a stepped approach which participants can trigger using their home blood pressure measures.|f|f|f|t
33997750|NCT02022306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33997751|NCT00999687|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33997752|NCT00197834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997753|NCT00006516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33997754|NCT01600313|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33997755|NCT06627972|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33997756|NCT02920476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997757|NCT03334734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917457|NCT05217953|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study will recruit 40 participants suffering from type-1 diabetes, split across 2 groups, with 30 needed for statistical significance (10 extra to allow for dropouts). The participant will have their average HbA1c levels measured (lab based, CONTROL-1)||||
33917458|NCT00145249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917459|NCT01319110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693689|NCT06470867|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Following recommendations for blinding in behavioral interventions, participants will be blinded by limiting details about the study hypotheses and differences between the study arms. Furthermore, research staff involved in outcome assessment and study biostatisticians involved in data analysis will be blinded to study arms.|"Participants will be randomized 1:1 to either the intervention or the control group. Participants will be randomized 1:1 to either the intervention or the control group. Computer-generated block-randomization schemes using random block sizes generated in Stata (v17) to assign the two study arms will be created before study start. The intervention, called VA S.A.V.E., is an online, video-based training tailored to veterans and their close supports. The control will watch an information video intended to control for attention received but not including elements thought to be active ingredients in the intervention. The informational video will be similar to the intervention in duration and will also contain other design features similar to the intervention (e.g., motion graphics)."|t|f|t|t
33917460|NCT05160558|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33917461|NCT00839878|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33917462|NCT03675438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917463|NCT05108519|||CASE_ONLY||OTHER|||||||
33917464|NCT02232087|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33693690|NCT04968379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693691|NCT04084327|||CASE_CONTROL||RETROSPECTIVE|||||||
33693692|NCT00140634|||CASE_ONLY||OTHER|||||||
33917465|NCT03941236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917466|NCT01093001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693693|NCT04069078|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33693694|NCT04307914|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 216 patients with painful bone metastases will be randomized in a 1:1:1 ratio to receive EBRT only, MR-HIFU only, or EBRT followed by MR-HIFU. In addition, data of around 60-90 patients will be captured within the FURTHER Registry arm.||||
33693695|NCT04147585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693696|NCT03514017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693697|NCT00118690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33693698|NCT06707506|||COHORT||RETROSPECTIVE|||||||
33693699|NCT06259084|NA|SINGLE_GROUP||OTHER||NONE||||||
33693700|NCT05994560|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||randomized clinical tria||||
33693701|NCT06710418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693702|NCT06704087|||COHORT||PROSPECTIVE|||||||
33693703|NCT02420977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693704|NCT03694912|||COHORT||PROSPECTIVE|||||||
33693705|NCT03671018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693706|NCT06709625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Group 1 patients will undergo bilateral erector spinae plane block. Heart rate (beats/min) and systolic arterial pressure (mmHg) will be measured before and after induction, after skin incision, after sternotomy, 30 minutes after weaning from CPB, and after sternum closure. VAS and BPS will be used to evaluate pain at 0, 4, 8, 12, 24 hours postoperatively.~Group 2 patients will undergo transversus thoracic plane block and the same parameters as group 1 will be saved."||t|f|f|f
33917467|NCT05902819|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blinded|Randomized, double-blind, placebo-controlled, parallel group, single center study|t|f|t|f
33917468|NCT02559206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917469|NCT05176496|||COHORT||RETROSPECTIVE|||||||
33917470|NCT02126943|||COHORT||PROSPECTIVE|||||||
33693707|NCT05942053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693708|NCT04508140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, non-comparative study.||||
33693709|NCT04953052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33693710|NCT06709001|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33693711|NCT04387721|||OTHER||PROSPECTIVE|||||||
33917471|NCT04573205|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917472|NCT05386654|||COHORT||PROSPECTIVE|||||||
33917473|NCT04198103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917474|NCT05113173|||CASE_CONTROL||PROSPECTIVE|||||||
33917475|NCT02778633|||COHORT||PROSPECTIVE|||||||
33917476|NCT06388330|NA|SINGLE_GROUP||TREATMENT||NONE|open label strict diet phase blinded participant during reintroduction|||||
33917477|NCT01011985|||COHORT||PROSPECTIVE|||||||
33917478|NCT00296660|||COHORT||PROSPECTIVE|||||||
33917479|NCT06390254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The interventional study model for this trial follows a randomized controlled design. Participants will be randomly assigned to either the intervention group or the control group. The intervention group will receive the resilience-building nursing intervention, while the control group will receive standard care. This design allows for a rigorous evaluation of the effectiveness of the intervention by comparing outcomes between the two groups. Blinding of participants and investigators may or may not be feasible depending on the nature of the intervention. The study will adhere to established protocols for randomization, allocation concealment, and blinding to minimize bias and ensure the validity of the findings.|f|f|f|t
33917480|NCT02237976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917481|NCT06112002|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33917482|NCT01467648|RANDOMIZED|PARALLEL||||NONE||||||
33917483|NCT01938690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917484|NCT02300896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33917485|NCT03337555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917486|NCT05800106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917487|NCT02136199|RANDOMIZED|PARALLEL||||NONE||||||
33917488|NCT03579550|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomised trial||||
33917489|NCT05091229|||OTHER||PROSPECTIVE|||||||
33917490|NCT00510224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917491|NCT00041769|RANDOMIZED|||TREATMENT||NONE||||||
33917492|NCT02178293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33917493|NCT03256474|||COHORT||RETROSPECTIVE|||||||
33997758|NCT00759707|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Investigators who analyzed the results of vascular function testing were blinded to the participant identity.||f|f|f|t
33997759|NCT04752527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997760|NCT05118607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997761|NCT06406010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized study|t|t|f|t
33997762|NCT05191030|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The study is a within-subjects experiment. The order in which participants undergo the experimental or control conditions/arms will be counterbalanced. 50% of participants will undergo the experimental condition first and then the control condition, one month later. The rest of the sample will undergo the control condition first then the experimental condition, one month later.|t|f|f|f
33997763|NCT04507698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33997764|NCT03086434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33997765|NCT01768260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997766|NCT03369496|||COHORT||PROSPECTIVE|||||||
33997767|NCT00065962|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33693712|NCT03646643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once patients are enrolled in the study, they will be randomized to arm A: PVI + triggers ablation, or arm B: PVI + triggers ablation + coronary sinus-left atrium connection ablation. Patients will be blinded to the randomization scheme.|The PRECAF study is designed as a randomized, single-blind, small scale pilot study. Enrolled subjects who satisfy all eligibility criteria will then undergo the ablation procedure. Study randomization will be performed in a 1:1 fashion using the Urn Randomization program (https://health.uconn.edu/community-medicine/programs/health-services-research-unit/project-match/urn-randomization/) while balancing sex and AF type (paroxysmal and non-paroxysmal). The master list of study assignments will be kept by the study coordinator in a password protected and encrypted computer. After the ablation procedure, participants will remain in the study for 6 months. A 30-day event monitor will be used for the first month after ablation. Then, regular clinic visits at 6 weeks and 6 months will be arranged after ablation with 12 lead electrocardiogram check-up. In the last month, a 30-day event monitor will again be utilized to detect atrial arrhythmia recurrence.|t|f|f|t
33917494|NCT05463042|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be informed about which condition (intermittent hypoxia or normoxia) they are experiencing.|This is a cross-over design study that requires 2 visits (a least 1-week apart). Fifteen younger adults and 15 older adults will be recruited. Participants will be pseudo-randomly assigned to receive either intermittent hypoxia or sham during the first visit, and then switch over to receive sham or intermittent hypoxia during the 2nd visit.|t|f|f|f
33917495|NCT03110146|||CASE_ONLY||PROSPECTIVE|||||||
33693713|NCT06612853|||COHORT||PROSPECTIVE|||||||
33917496|NCT04148599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33917497|NCT04202653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693714|NCT03219918|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|It is partially blinded in the way that the endoscopist knows whether the procedure is performed with or without the EndoRings but neither patient, pathologist nor investigators will have this information, which is only to be revealed to the investigators at the end of data processing.|"The study is a single-centre prospective randomised clinical trial. Patients are included if they meet the specified inclusion criteria and accept to take part in the study after proper oral and written information (see patient information below).~Specimens i.e. removed adenomas and biopsies of suspected malignancies are analysed by pathologists according to standard procedure. The pathologist will not know the nature of specimen collection (colonoscopy with or without EndoRings). The specimens are not saved for any other study related activities."|f|f|t|t
33693715|NCT05589376|||COHORT||PROSPECTIVE|||||||
33693716|NCT03457688|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693717|NCT03602729|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33693718|NCT00191646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917498|NCT04923919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917499|NCT05739812|NA|SINGLE_GROUP||OTHER||NONE||||||
33917500|NCT04504370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917501|NCT06504329|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33917502|NCT01094730|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33917503|NCT05913141|||COHORT||RETROSPECTIVE|||||||
33917504|NCT00656734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917505|NCT06335823|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33917506|NCT01794247|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33917507|NCT03882346|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel, open label study||||
33693719|NCT06190353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a parallel two arms pilot randomized controlled study|f|f|f|t
33693720|NCT00850161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33693721|NCT03306706|RANDOMIZED|CROSSOVER||PREVENTION||NONE||randomized, controlled, cross-over||||
33693722|NCT00704912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693723|NCT06500455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693724|NCT05386485|||COHORT||PROSPECTIVE|||||||
33693725|NCT06642454|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34087821|NCT03520530|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a randomized controlled trial in which patients who make it to the second stage of labor will be randomized to wear a mouth guard while pushing during the second stage of labor or continue through the second stage of labor without a mouth guard. They will be randomized in a 1:1 fashion using RedCap.||||
33693726|NCT05991349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693727|NCT05798780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917508|NCT00423085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917509|NCT00671580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917510|NCT00003225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917511|NCT00325650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917512|NCT02152488|||CASE_CROSSOVER||PROSPECTIVE|||||||
33917513|NCT04251689|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917514|NCT03448978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087822|NCT01214278|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34087823|NCT02648685|||CASE_CONTROL||PROSPECTIVE|||||||
34087824|NCT03733236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693728|NCT05471557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Application of pain or no stimulus cannot be masked from participants, nor from outcomes assessors.|||||
33693729|NCT01512056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693730|NCT05174884|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33693731|NCT03564873|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693732|NCT06704269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693733|NCT03475693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be assigned a 3 digit number given at random and treatment arm will be randomized to day of presentation with treatment determined by even or odd day of the month|Randomized, prospective, cohort study comparing two non-invasive treatments for Mild traumatic brain injury in patients ages 12-18 that present to the Lakeland Health Emergency departments in either St. Joseph, MI or Niles, MI.|t|f|f|f
33782698|NCT05992233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||hee primary outcome was postoperative pain, evaluated using the visual analogue scale (VAS) score at Baseline, for 7 days following surgery, postoperative swelling and maximum mouth opening values evaluated at 2nd and 7th days in subject treated for third molar surgery with piezoelectric surgery or rotating drills. The secondary outcomes chosen were changes in quality of life using a questionnaire form.|t|f|f|f
33782699|NCT00917189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782700|NCT04189328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33997768|NCT03306277|NA|SINGLE_GROUP||TREATMENT||NONE||One-time intravenous administration of onasemnogene abeparvovec-xioi.||||
33997769|NCT00735319|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33997770|NCT00510393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997771|NCT01531816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087825|NCT05266768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087826|NCT01813279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087827|NCT01836120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087828|NCT03348995|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort Study||||
33693734|NCT06647498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Stage 1: Interventional/matching placebo; Stage 2: Open Label|t|t|t|t
33693735|NCT06492304|NA|SEQUENTIAL||TREATMENT||NONE||||||
33693736|NCT04185883|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693737|NCT02927262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693738|NCT04444349|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33693739|NCT04310787|||OTHER||RETROSPECTIVE|||||||
33693740|NCT06709157|||CASE_CONTROL||PROSPECTIVE|||||||
33693741|NCT00708565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33693742|NCT03384693|NA|SINGLE_GROUP||PREVENTION||NONE||Defibrotide 6.25mg/kg administered intravenously for 28-35 days||||
33693743|NCT00402142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693744|NCT01946854|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33693745|NCT03819101|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This is a 2x2 factorial randomized, multicenter, international, open phase III trial||||
33782701|NCT01608893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782702|NCT05724212|||COHORT||PROSPECTIVE|||||||
33782703|NCT05078385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782704|NCT00268411|RANDOMIZED|||TREATMENT||||||||
34087829|NCT03548779|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"The study coordinator will assign the first randomization to pre-visit preparation arm and care providers will not be told of the patient's pre-visit preparatory randomization arm prior to the first usual care visit. Randomization to exome sequencing will be performed after the first usual care visit by the study coordinator.~Investigators will receive de-identified coded data and thus will not be able to link a patient name to an intervention arm. Some analyses will require individual-level randomization arm status to allow for comparison of parent questionnaire responses or health outcomes by arm - a major focus of this study.~All interviewers and medical records staff conducting telephone surveys and/or medical records abstraction for clinical data will be blinded to the participants randomization status. Access to this information will be blocked in the electronic patient tracking status by study role."||f|t|f|t
34087830|NCT05708885|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Testing the hypothesis that striated esophagus deglutitive motor function is modulated by pharyngeal phase swallowing biomechanics in health and disease.||||
34087831|NCT01528085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087832|NCT00437762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087833|NCT02094365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087834|NCT01513590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087835|NCT06099275|||COHORT||PROSPECTIVE|||||||
34087836|NCT03823157|NA|SINGLE_GROUP||OTHER||NONE||Tai Chi exercise||||
34087837|NCT06133257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34087838|NCT05926492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087839|NCT00247286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33782705|NCT05205447|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33782706|NCT00916006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782707|NCT06022809|RANDOMIZED|PARALLEL||PREVENTION||NONE||In this study, we have a two-arm parallel assignment, with each arm receiving a different intervention (individual-level vs. group-level).||||
33782708|NCT04865562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33782709|NCT01576315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782710|NCT02768805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782711|NCT06613724|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label multicenter study enrolling up to 40 participants at up to 3 sites in Chile.||||
33782712|NCT02347917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782713|NCT06298630|||CASE_ONLY||PROSPECTIVE|||||||
33782714|NCT06613594|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having three groups. One group will receive conventional physical therapy, the second will receive conventional physical therapy along with kaltenborn linear translatoric glides and third group recevied conventional therapy along with kaltenborn traction mobilization. All groups will be recruited concurrently.||||
33782715|NCT05895773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Only the pharmacist is aware of the randomization and preparing the study drugs. The pharmacist will encode the medication bottles and keep the code key confidential until the completion of follow-up of the last patient.|The patients will be randomly allocated using a computer program into two equal groups: the treatment group and the placebo group.|t|t|t|t
33782716|NCT04614077|||CASE_CONTROL||PROSPECTIVE|||||||
33782717|NCT01616719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782718|NCT02370732|NA|SINGLE_GROUP||||NONE||||||
33782719|NCT04038476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782720|NCT02112929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782721|NCT05838560|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label||||
33782722|NCT02688361|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33782723|NCT04170764|||OTHER||RETROSPECTIVE|||||||
33782724|NCT02819193|||COHORT||PROSPECTIVE|||||||
33782725|NCT01498874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782726|NCT05611606|||COHORT||CROSS_SECTIONAL|||||||
33782727|NCT05518110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782728|NCT05497869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087840|NCT01273259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087841|NCT03873064|||COHORT||PROSPECTIVE|||||||
33693746|NCT02675114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693747|NCT06602102|||COHORT||PROSPECTIVE|||||||
33693748|NCT00990938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693749|NCT06548165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693750|NCT02252887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693751|NCT06596291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This first-in-human clinical study, performed in SCI participants with UI due to NDO and an inadequate response to current therapy, will evaluate the safety and tolerability of EG110A, and explore the potential doses for further clinical development. The present clinical study will also investigate the efficacy of EG110A via data collected in a bladder diary and via urodynamic assessments.||||
33693752|NCT04867239|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33693753|NCT01289457|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693754|NCT05914116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693755|NCT01786265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693756|NCT03553836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Investigators will be blinded in Part 1 and unblinded in Part 2, if done.||t|f|t|f
33693757|NCT00730197|RANDOMIZED|CROSSOVER||||NONE||||||
33693758|NCT06708390|||COHORT||RETROSPECTIVE|||||||
33693759|NCT05940012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects are told they will be randomized into two forms of treatment for chronic neck pain and that the study team is interested in learning the mechanisms associated with that treatment||t|f|f|f
33693760|NCT06129942|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33693761|NCT06080048|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33693762|NCT05041517|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33693763|NCT04776031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693764|NCT05854199|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be clients at local WIC agency sites where either the telehealth solution is offered or where only usual care is available (control).||||
33693765|NCT06186856|||COHORT||CROSS_SECTIONAL|||||||
33693766|NCT06706830|||CASE_CONTROL||PROSPECTIVE|||||||
33693767|NCT05887245|||COHORT||PROSPECTIVE|||||||
33693768|NCT02724150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693769|NCT06048250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693770|NCT06498505|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693771|NCT05271162|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693772|NCT05517993|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33693773|NCT03583073|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||The intervention will have two phases: 1) a Standard Care (baseline control) condition, followed by, 2) an Enhanced Referral/Linkage to Care condition. Because this is a roll-out trial, the two conditions will be compared using a non-randomized open trial design.|f|f|f|t
33693774|NCT06048536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782729|NCT05576662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782730|NCT06479460|||COHORT||PROSPECTIVE|||||||
33693775|NCT06710223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693776|NCT06678620|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693777|NCT06330051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|After 3 months of baseline information collection,20 hospitals will be randomly assigned to the control and intervention groups according to hospital level and baseline DNT to reduce the imbalance between the two groups. We will not indicate to any hospital the grouping type of other hospitals. If the selected hospital is unable to complete the study for some reason during the operation, the hospital with conditions to carry out the replacement will be selected from the hospitals of the same region, the same level and the same scale.||f|f|f|t
33693778|NCT05076565|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This device feasibility enrollment number of 200 is a larger sample in order to create a machine learning algorithm||||
33693779|NCT05633797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33693780|NCT00537628|||COHORT||PROSPECTIVE|||||||
33693781|NCT00729924|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693782|NCT06492590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No-blinded participant and personnel (research team).|This study is a Randomized controlled trial with parallel arms. Participants will be randomly allocated either to an intervention group or control by the external researcher using computer-generated random numbers||||
33693783|NCT04842422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693784|NCT01409395|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693785|NCT05095376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693786|NCT04623398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693787|NCT00666874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693788|NCT05204550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693789|NCT04167722|||CASE_CONTROL||PROSPECTIVE|||||||
33693790|NCT06153316|||COHORT||CROSS_SECTIONAL|||||||
33693791|NCT06039683|||COHORT||RETROSPECTIVE|||||||
33693792|NCT06708221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693793|NCT05473897|RANDOMIZED|PARALLEL||TREATMENT||NONE||This research protocol will utilize a randomized controlled trial, with an interventional treatment arm and a control arm, and primary endpoints revolving around patients' post-concussion symptom severity scores. The treatment arm will receive symptomatic care (see Interventions section below) along with 30 minutes of head-neck cooling in the emergency department while being monitored for side effects. The control arm will receive symptomatic care.||||
33693794|NCT03137030|RANDOMIZED|CROSSOVER||TREATMENT||NONE||For Part 1, the randomization will be realized using a Williams Square with a 4x4 design. For the optional Part 2, a standard 2x2 crossover design will be applied.||||
33693795|NCT05370391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693796|NCT05136690|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33782731|NCT04765202|NA|SINGLE_GROUP||TREATMENT||NONE|While the treatment itself is open label, the outcomes assessor will not know the treatment applied to each treatment site until after assessing the outcomes.|"Within-patient controlled - treatment sites on the same patient are randomized to be test or control~This means each participant receives both study treatments and serves as their own control."||||
33782732|NCT06280729|||OTHER||RETROSPECTIVE|||||||
33782733|NCT02398825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782734|NCT04393103|RANDOMIZED|PARALLEL||TREATMENT||NONE||Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.||||
33782735|NCT00442663|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782736|NCT00005545|||COHORT||PROSPECTIVE|||||||
33782737|NCT06481774|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33782738|NCT02530151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33782739|NCT02888158|RANDOMIZED|PARALLEL||||NONE||||||
33782740|NCT02060279|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33782741|NCT03118752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be a randomized, controlled, 2-arm, single blinded trial.|f|f|f|t
33782742|NCT04096313|||COHORT||OTHER|||||||
33782743|NCT03759171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Delayed entry, randomized trial||||
33782744|NCT06479980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782745|NCT04138940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|t|f
33917515|NCT04711876|||CASE_CONTROL||RETROSPECTIVE|||||||
33693797|NCT06248515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693798|NCT06707428|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33693799|NCT06701669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The overall 2-step randomization scheme will be implemented.~* Randomization Level 1 will be open-label, assigning an eligible patient to one of the available treatment cohorts.~* Randomization Level 2 will be double-blinded and will randomize participants at a 1:1 ratio to receive either IP or placebo within a specific cohort. Thus, the PPD blinded team, site blinded staff members, and participants/legal authorized representative will be considered blinded to study treatment assignment (either IP or placebo) throughout the course of the study.~To preserve the integrity of the study blind, an unblinded pharmacist at each site will be responsible for the reconstitution and dispensation of all study drugs and placebos and will endeavor to ensure that there are no observable differences between the treatment groups (IP or placebo) when dispensing the study materials."||t|t|t|f
33693800|NCT06708013|NA|SINGLE_GROUP||SCREENING||NONE||Treatment resistant depression patient group will be evaluated before and after Transcranial Magnetic stimulation (TMS) treatment. There is a control group consist of healthy participants that will be only evaluated for ophthalmologic measurements.||||
33693801|NCT06311721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693802|NCT02314234|||CASE_ONLY||RETROSPECTIVE|||||||
33693803|NCT06708403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33693804|NCT05527184|NA|SEQUENTIAL||TREATMENT||NONE||||||
33693805|NCT01546012|RANDOMIZED|CROSSOVER||||NONE||||||
33693806|NCT02260362|||COHORT||PROSPECTIVE|||||||
33693807|NCT06347133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782746|NCT02785055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917516|NCT06102642|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series||||
33917517|NCT03120481|||COHORT||PROSPECTIVE|||||||
33917518|NCT03141372|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomized to a backfill void trial following total laparoscopic hysterectomy or an autofill void trial following total laparoscopic hysterectomy||||
33917519|NCT00275925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917520|NCT01182337|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33917521|NCT03785795|||CASE_ONLY||PROSPECTIVE|||||||
33917522|NCT01987388|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33917523|NCT02932332|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33917524|NCT03090373|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The UroShield device actuator will activate and create the hum, which is the only sign of its working even in the active device. While the active device will transmit Surface Acoustic Waves, the sham device will work but will not transmit any acoustic waves.|This is a double blinded, randomized controlled trial. All involved will be blinded as to whether the supplied UroShield device is active or a sham.|t|t|t|f
33917525|NCT03472235|RANDOMIZED|PARALLEL||TREATMENT||NONE||"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedling using microneedling device (Dermapen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedling will be done for 4session with 4 weeks interval between each session."||||
33917526|NCT01150734|||COHORT||PROSPECTIVE|||||||
33917527|NCT05807386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693808|NCT05570825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917528|NCT03284255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917529|NCT03991884|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693809|NCT05249465|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Outcomes will be analyzed in a blinded fashion such that treatment allocation is not revealed.|This study uses a full factorial experimental design testing the efficacy of three intervention components, each with two levels (i.e., a 2x2x2).||||
33917530|NCT05936034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917531|NCT04200742|||CASE_ONLY||PROSPECTIVE|||||||
33917532|NCT04859478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917533|NCT05254613|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33997772|NCT04238195|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|"A computerized randomization scheme will be created by a CRO-statistician and it shall be considered blinded (as per the following).~The randomization is available only to the pharmacy staff that is preparing the drug who will not be involved in any other aspect of the study including administration of the drug. The randomization will also be available to the bioanalytical laboratory as sample analyses will be treatment-dependent. It will not be made available to the Sponsor, subjects, or members of the staff responsible for the monitoring and evaluation of safety assessments.~On Day 1 of each period, subjects will receive a single oral therapeutic dose of TBPM-PI-HBr (Treatment A), supratherapeutic dose of TBPM-PI-HBr (Treatment B), placebo (Treatment C), or moxifloxacin (Treatment D) according to the randomization scheme."|Over 4 separate treatment periods, each separated by a 7-day washout period, all subjects will receive a single dose of 4 different study treatments.The design is constructed from three 4x4 Latin Squares balanced for carry-over effects.|t|t|t|t
33997773|NCT04693611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693810|NCT06560424|||COHORT||OTHER|||||||
33693811|NCT04594642|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Adult subjects with RR B-NHL who have received 2 or more prior lines of therapy will be enrolled into cohorts of incrementally increasing doses. Escalation is dependent upon ongoing review of emerging data by the Safety Monitoring Group (SMG).||||
33693812|NCT03824171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693813|NCT01986907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693814|NCT05034133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693815|NCT06710145|||CASE_CONTROL||OTHER|||||||
33693816|NCT01545453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693817|NCT01640626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693818|NCT03361267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693819|NCT06707805|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33693820|NCT03408314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693821|NCT05768919|NA|SEQUENTIAL||TREATMENT||NONE||This study seeks the MTD/RP2D of LC when added to TMZ during concurrent XRT and adjuvant TMZ after XRT. The study will evaluate escalating doses of LC delivered by IV infusion weekly as a gravity infusion (without infusion pump). Within each cohort, the dose will remain the same. In the first cohort, dosing will begin at Level 1 (300 mg/m2). The infusion of LC will begin at the start of CRT. Patients will be evaluable for the cohort if they have completed 80% of the planned doses of LC, 80% of RT and 60% of TMZ within the first 10 weeks of treatment. Patients who experience a dose-limiting toxicity (DLT) will be evaluable for the cohort if they have received at least 1 dose of LC. There will be a maximum of 4 dose levels assessed in this study. The Safety Review Committee (SRC) will oversee dose level decisions throughout the dose escalation phase of the study.||||
33693822|NCT06597760|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33693823|NCT01554397|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II: IMRT (standard) vs. PET-guided Bone Marrow-Sparing IMRT (experimental), non-randomized Phase III: IMRT (standard) vs. PET-guided Bone Marrow-Sparing IMRT (experimental), randomized||||
33917534|NCT01518244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917535|NCT04109872|||CASE_ONLY||RETROSPECTIVE|||||||
33917536|NCT03671382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33917537|NCT02745236|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33917538|NCT04527601|||COHORT||RETROSPECTIVE|||||||
33917539|NCT00169117|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33917540|NCT05960461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917541|NCT00213161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33917542|NCT00353496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917543|NCT01881841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917544|NCT01962519|RANDOMIZED|PARALLEL||||NONE||||||
33917545|NCT02462941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917546|NCT04151355|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, Randomized, controlled, open-label pilot study will be conducted on 100 colon cancer patients receiving 5-FU adjuvant FOLFOX -6 \& FOLFIRI-6 therapy.||||
33917547|NCT03441893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917548|NCT01056341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917549|NCT00755846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917550|NCT05735509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The caree provider takes two impressions and the investigator selects one of them for crown manufacturing.|Tooth to be restored are randomly assigned to on of two groups. In one impressions are taken before placing the rubber dam and in the second impressions are taken after placing the rubber dam.|f|f|t|f
33997774|NCT02483507|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33997775|NCT05640011|||CASE_ONLY||RETROSPECTIVE|||||||
34087842|NCT04993846|||CASE_CONTROL||PROSPECTIVE|||||||
34087843|NCT03236792|NA|SEQUENTIAL||TREATMENT||NONE||Single Group Assignment||||
33917551|NCT01222572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917552|NCT00126399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917553|NCT01757756|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33917554|NCT00677885|||||PROSPECTIVE|||||||
33917555|NCT05847491|||COHORT||PROSPECTIVE|||||||
33917556|NCT01908517|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
12612855|NCT06578130|||COHORT||PROSPECTIVE|||||||
33917557|NCT02820883|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693824|NCT04764162|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Double-blind, placebo-controlled, crossover design|t|f|f|t
33917558|NCT00622544|||OTHER||PROSPECTIVE|||||||
33917559|NCT05550818|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The participants will be blind to what diet is being provided.||t|f|f|f
33917560|NCT02299141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917561|NCT00680290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917562|NCT04377490|||CASE_ONLY||PROSPECTIVE|||||||
33917563|NCT00051545|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33917564|NCT01000779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917565|NCT04567446|||COHORT||PROSPECTIVE|||||||
33917566|NCT01478399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917567|NCT06082752|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917568|NCT02943512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33917569|NCT00057460||||TREATMENT||||||||
33917570|NCT00844064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917571|NCT02598466|||COHORT||RETROSPECTIVE|||||||
33997776|NCT02588911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33997777|NCT04516187|||COHORT||PROSPECTIVE|||||||
33917572|NCT06194175|||COHORT||PROSPECTIVE|||||||
33917573|NCT04803968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled clinical trial|t|f|f|f
33917574|NCT02749877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997778|NCT02253329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997779|NCT00680940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997780|NCT04157205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
33997781|NCT01883960|||COHORT||PROSPECTIVE|||||||
33997782|NCT01376882|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33997783|NCT00241982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33997784|NCT01817595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997785|NCT00320307|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997786|NCT00748566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997787|NCT00623077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997788|NCT00558402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997789|NCT02928744|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997790|NCT02508233|||COHORT||PROSPECTIVE|||||||
33997791|NCT04417348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||patients with melasma divided in a UV-Visible light filter with 0.05% retinoic acid group and UV-Visible light filter alone||||
33997792|NCT05650307|||COHORT||PROSPECTIVE|||||||
33997793|NCT01137864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997794|NCT02803879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997795|NCT05262322|||COHORT||RETROSPECTIVE|||||||
33997796|NCT01924286|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997797|NCT06235008|||COHORT||RETROSPECTIVE|||||||
33997798|NCT03406598|||OTHER||PROSPECTIVE|||||||
33997799|NCT02272335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33997800|NCT03673267|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33997801|NCT03866265|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||"Blood samples will be taken at day 0 from all Subjects. 10 of them will be administered for 28 days a food supplement capsule (0.125 g of FGE-Salmon-PLs) per day, while the other 10 will be administered a placebo capsule (0.125 g of glycerine) per day, in a double blind and randomized way.~After 28-days, blood samples will be collected from all Subjects. No administration of any kind of capsules will follow for 14 days for all Subjects.~After this 14-days period, blood samples will be collected from all Subjects Then, in a crossover design each participant initially on supplement will now be administered the placebo capsules, while likewise each participant initially on placebo will now be administered the supplement capsules for 28 days.~After this new 28-days period, blood samples will be collected from all Subjects.~All collected blood samples from each participant will be tested for their platelet sensitivity against both PAF and Thrombin induced platelet aggregation."|t|f|t|f
33997802|NCT04385485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The occupational therapist who do the evaluation and make all the measurements 6 and 12 months after surgery don't know if the patient was randomised to active or passive mobilisation. Likewise the hand surgeon who do all the measurements at minimum 5 years after surgery don't know which rehabilitation protocol the patient followed.|The Patients are randomised 1-3 days after surgery to either active or passive mobilisation. The randomisation was done by a statistical software program (Medstat) and the protocols are placed in numbered sealed envelopes.|f|f|f|t
33997803|NCT06089395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Stratified Block Group Randomized Controlled Study|t|f|t|f
33693825|NCT06709144|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693826|NCT04847622|||COHORT||RETROSPECTIVE|||||||
33693827|NCT04903197|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693828|NCT05065528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33693829|NCT01157468|||CASE_CONTROL||PROSPECTIVE|||||||
33693830|NCT06708455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917575|NCT01589055|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33997804|NCT02220413|||COHORT||PROSPECTIVE|||||||
33997805|NCT00969358|||COHORT||PROSPECTIVE|||||||
33997806|NCT00469885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997807|NCT04275349|||COHORT||PROSPECTIVE|||||||
33997808|NCT04112199|RANDOMIZED|PARALLEL||TREATMENT||NONE||Thirty patients will be randomized to either BIV201 continuous infusion plus SOC or SOC alone.||||
34087844|NCT01408693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087845|NCT00862992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997809|NCT02207764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997810|NCT00448825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997811|NCT04706637|RANDOMIZED|PARALLEL||TREATMENT||NONE|The subject will be randomly assigned to one of the two arms. This is an open-label trial.|"If a subject voluntarily agrees to participate and meets the inclusion and exclusion criteria for the clinical trial, the subject will be randomly assigned to one of the two arms.~1. Arm 1: evogliptin 5mg + metformin, oral administration once a day for 48 weeks~2. Arm 2: dapagliflozin 10mg + metformin, oral administration once a day for 48 weeks"||||
34087846|NCT02514863|||COHORT||PROSPECTIVE|||||||
33997812|NCT03820063|NA|SINGLE_GROUP||TREATMENT||NONE||neoadjuvant courses PTC-Ptz; adjuvant courses Ptz (pCR) or T-DM1 (non-pCR)||||
33997813|NCT00664053|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34087847|NCT02026141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087848|NCT04518085|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The intervention group vs. active control group status will be known to the participants and the health care personnel delivering the interventions. However, the investigator, outcome assessor and the additional health care personnel at the unit will be masked to the conditions.|Randomized Controlled Trial, in which participants are randomly allocated to either the intervention group or an active control group.|f|f|t|t
34087849|NCT05927688|||COHORT||PROSPECTIVE|||||||
34087850|NCT02653846|||COHORT||PROSPECTIVE|||||||
34087851|NCT04444869|NA|SINGLE_GROUP||TREATMENT||NONE||All patients are treated with the same approach.||||
34087852|NCT04719559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997814|NCT06448390|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|The care provider instructs about the training version. Other people will evaluate the participants before and after the training period|web-based prospective randomization between two groups of training for patients with Claudicatio intermittens|f|f|t|t
33997815|NCT04495543|NA|SINGLE_GROUP||PREVENTION||NONE||3 month, within subjects longitudinal study, with each participant receiving an intensive, single session of the 'Brief Skills for Safer Living' intervention designed to mitigate suicide risk. All participants recruited will have experienced suicidal ideation within the past week at time of enrolment.||||
33997816|NCT05152745|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33997817|NCT01905605|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997818|NCT05877326|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Multicenter, controlled, randomized, two parallel-arm trial:~Perioperative anesthesia with a BIS target of 35 Perioperative anesthesia with a 55% BIS target"||||
33997819|NCT02811003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997820|NCT01572857|||OTHER||PROSPECTIVE|||||||
33997821|NCT00844935|||COHORT|||||||||
33997822|NCT02923336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997823|NCT03637127|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath through a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia.|t|f|f|f
33997824|NCT05395416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997825|NCT01282086|||||PROSPECTIVE|||||||
33997826|NCT05471687|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33997827|NCT01662050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997828|NCT03914105|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33997829|NCT03379636|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The physiotherapist who applied the tape was not blinded but he did not participate in outcome assessment. The main investigator who collected the data was blind as subjects wore a long-sleeve shirt which hid the tape and the tape was administered behind a folding screen.|"All subjects were tested without tape, with kinesiotape (KT) and with a sham tape (ST). KT and ST were applied in a randomized order.~The sequence always began with the NT condition. Then the two tapes were applied in a randomized order and the subjects repeated the same procedure. Group allocation, KT vs ST group, corresponded to the last tape the subject received and had to wear for the next three days. A computer block (n=8) randomization process was performed and sealed opaque envelopes were used."|f|f|t|t
33997830|NCT06002386|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33997831|NCT06223724|||CASE_ONLY||PROSPECTIVE|||||||
33997832|NCT01092455|||COHORT||PROSPECTIVE|||||||
33693831|NCT06462547|NA|SINGLE_GROUP||TREATMENT||NONE||The ADAPT Study (INZ701-304) is an open-label study to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.||||
33693832|NCT05670847|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible children will be randomized into two equal-sized groups. Study group: will receive exogenous ketone esters plus standard of care. Control group: will receive only standard of care.||||
33693833|NCT00956956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33693834|NCT03598244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693835|NCT02892032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997833|NCT01986647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997834|NCT04391829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997835|NCT04197154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A double-blind randomization list (stratified for gender) was created by an independent researcher. Complete blinding of the researchers during the experiment is not possible due to the nature of the conditioning paradigms. However, in this study blinding is optimized: the researchers are informed of the (conditioning) group to which participants are allocated after their final inclusion to the study and after the start of the experiment.||t|f|f|f
33997836|NCT02786784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997837|NCT04205539|NA|SINGLE_GROUP||TREATMENT||NONE||Lumbar punctures will be used to determine Alzheimer's disease status. The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The scans take around 45 minutes at no charge to the patients. The dexmedetomidine will be given to the patient after the first DTI scan; this dosage will be congruent with patient height, weight, and medical history. After the subject is asleep, the second DTI scan will be done.||||
33997838|NCT04224753|NA|SINGLE_GROUP||OTHER||NONE||||||
33997839|NCT00642811|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33997840|NCT02832960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087853|NCT00833326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087854|NCT01337934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087855|NCT00888745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087856|NCT04017962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087857|NCT01987115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087858|NCT04043026|||CASE_CONTROL||PROSPECTIVE|||||||
34087859|NCT02965170|||COHORT||PROSPECTIVE|||||||
34087860|NCT02453048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087861|NCT05273359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo group: 15 subjects (\>220 eosinophils/microliter) will receive a matching benralizumab placebo subcutaneous injection every 4 weeks for 4 complete doses.|A pilot double-blind randomized and placebo-controlled trial; participants will be blinded to the drug group; investigational pharmacist will be unblinded.|t|f|f|f
33693836|NCT03703050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab, according to patient status after previous treatment (patients in progression, into the Cohort 1; patients in CR, into the Cohort 2)||||
33693837|NCT04956094|||COHORT||PROSPECTIVE|||||||
33693838|NCT04570579|||COHORT||PROSPECTIVE|||||||
33997841|NCT05341154|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||An anesthesiologist who is not involved in the study will prepare the intervention (ketamine, dexmedetomidine, or placebo) in a standardized syringe with the same volume. Patients will be given the active comparator or placebo only once right before the induction of anesthesia.|t|t|t|t
33997842|NCT04174053|NA|SINGLE_GROUP||OTHER||NONE||||||
33997843|NCT02368262|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33997844|NCT05284539|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997845|NCT02665962|NA|SINGLE_GROUP||OTHER||NONE||||||
33997846|NCT01545349|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33997847|NCT02911909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997848|NCT06138561|||COHORT||PROSPECTIVE|||||||
33997849|NCT02632253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997850|NCT01355835|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33997851|NCT00362635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33997852|NCT03170739|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33997853|NCT04949737|||COHORT||PROSPECTIVE|||||||
33997854|NCT00621660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33997855|NCT01216020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997856|NCT02202057|||CASE_CONTROL||PROSPECTIVE|||||||
33997857|NCT03694535|NA|SINGLE_GROUP||PREVENTION||NONE||single group of patients composed of intermediate and high risk non muscle invasive bladder cancer||||
33997858|NCT04010045|||CASE_ONLY||PROSPECTIVE|||||||
33997859|NCT00854126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693839|NCT06102304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients participated will be masked about the type of intervention, where (GA) patients will receive PT program + sham shock wave on upper trapezius, while patients in (GB) will receive focused extracorpeal shock wave on the trigger points of upper trapezius in addition to the same PT program as (GA).|Randomized Controlled Clinical trial, where the recruited patients will be randomly assigned into 2 equal groups ( GA \& GB) using sealed envelopes. Control group (GA) and study group (GB). Patients in (GA) will be treated by a designed physiotherapy program consisted of Myo-facial release, stretching exercise, Proprioceptive neuromuscular facilitation (PNF) techniques, Median nerve glide techniques ,Graduated strengthening exercises for the upper limb, exercises in addition to sham shock wave on the upper trapezius. Patients in (GB) will be treated by focused Extracorpeal shock wave on the trigger points of upper trapezius in addition to the same physiotherapy program as GA.|t|f|f|f
33997860|NCT00646984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693840|NCT01920009|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33693841|NCT05577858|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blinding will be implemented to the extent possible. A researcher, unaware of the study goals and not involved with downstream data analyses will use a 1:1 block randomization to allocate participants to the diets in the first arm. Food service personnel (care provider) will not be aware of study goals and allocations. Metabolomic assays will be run in a blinded manner.||f|t|f|t
33693842|NCT06709573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33997861|NCT03543735|RANDOMIZED|PARALLEL||TREATMENT||NONE||Disulfiram usage||||
34103035|NCT05895045|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"The study will start with two treatment arms. Arm 1 will receive standard behavioral modification and possible pharmacologic intervention for six weeks without other intervention. Arm 2 will receive the same therapies in addition to participating in a weekly yoga session for six weeks. At six weeks, arms 1 and 2 we will switch intervention - Arm 1 will then initiate a weekly yoga session for six weeks with emphasis on the pelvic floor relaxation while Arm 2 will continue with standard behavioral / pharmacologic therapy.~Patients will be divided into two separate yoga groups based on age. The first group will be comprised of 8-12-year-old and the second group will be comprised of 13 - 18-year-old. These will be divided within each treatment arm (i.e Arm 1.1 and 1.2) and the interventions will remain the same."|f|t|f|f
34103036|NCT06689215|||CASE_ONLY||RETROSPECTIVE|||||||
33693843|NCT04165642|||COHORT||PROSPECTIVE|||||||
33693844|NCT01669096|NA|SINGLE_GROUP||OTHER||NONE||||||
33693845|NCT04093349|NA|SEQUENTIAL||TREATMENT||NONE||||||
33693846|NCT02497300|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33693847|NCT06533397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693848|NCT05012761|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33693849|NCT05220800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Concealement by opaque infusion bags and iv. drips.|Double-blinded clinical randomized trial.|t|t|t|t
33693850|NCT01822678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693851|NCT06479876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments performed at baseline visit and final (12-week visit) will be performed by a study team member unaware of randomization group. Clinical outcomes upon completion study will be assessed by an adjudicator who is blinded to randomization group.|Participants randomized 1:1 to 2 groups.|f|f|f|t
33693852|NCT05951257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental group: 2 intervention sessions ; Control group (waiting list): 2 control sessions followed by 2 intervention sessions.||||
33693853|NCT05917769|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A will receive conventional therapy for pain management and Rocabado exercises.~Group B will receive similar basic conventional therapy for pain management and perform posture correction exercises."||||
33693854|NCT05123911|NA|SINGLE_GROUP||OTHER||NONE||||||
33693855|NCT06648681|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a single centre, randomized, double blinded, placebo-controlled pilot trial, with 1:1 allocation of study drug to placebo.|t|t|t|t
33693856|NCT06310525|||COHORT||RETROSPECTIVE|||||||
33997862|NCT00109057||||TREATMENT||NONE||||||
33997863|NCT02670551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997864|NCT05591105|||COHORT||RETROSPECTIVE|||||||
33997865|NCT04637360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997866|NCT04633863|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
33997867|NCT06627023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, the primary investigator was informed about the type of implant connection, while the second operator and the patients were not aware of the prosthetic material. No other parties are masked.|"Example:~This study uses a parallel-group design, where patients are randomly assigned to either a group with conical connection or a group with butt-joint connection. Soft tissue changes are digitally monitored over a 12-month period."|f|f|t|f
33997868|NCT00465218|||CASE_CONTROL||PROSPECTIVE|||||||
33997869|NCT04132063|||CASE_ONLY||RETROSPECTIVE|||||||
33997870|NCT05016427|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997871|NCT02768974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997872|NCT04406545|||COHORT||PROSPECTIVE|||||||
33997873|NCT05726825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997874|NCT05056519|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The design of this trail is based on random, two-blind, placebo control. The subjects and investigators will not know the masking status, unless the specific subjects who required treatment for serious adverse events .|Totally 160 in 3-59 years old healthy people will be divided into two age group, which contain 80 people in 18-59 years old and 80 people in 3-17 years old. In each age group, subjects will be randomly divided into vaccine group and placebo group in a ratio of 3:1.|t|f|t|t
33997875|NCT04672538|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Randomized cross over|The trial will be a randomized crossover design.||||
33997876|NCT01529554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997877|NCT01368354|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33693857|NCT06707376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be randomly assigned to either the Early Kangaroo Mother Care group or control group using a computer-generated randomization sequence with block sizes of varying lengths to ensure allocation concealment and they are unaware of which group they have been assigned to as well as the outcome assessor is unaware|"Early Kangaroo Mother Care Group:~* Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants.~Control Group:~* Standard neonatal nursing practices, including incubator care, intermittent holding, and feeding as per clinical guidelines.~* Respiratory support as needed based on the severity of respiratory distress."|t|f|f|t
33693858|NCT00326794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33917576|NCT05570045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Control Group (300 participants): Children eat usual dietary(not using nutrient products) for 3 months. After that, they will use the product.~Intervention Group (300 participants): Children eat usual dietary, but with 2 glasses of the nutrient product as the side meals. The product provides L-lysin, IgG 24h Colostrum, Calcium, Probiotics, HMO, DHA(Docosa Hexaenoic Acid), and Taurine within 3 months of use."|"Step 1: Investigate the nutrition status of all children aged 24 - 71 months in 10 preschools in 10 selected communes. Expecting 4500 targets in 10 examined preschools Step 2: After the investigative selection, participants that meet the standard will be invited to the study ( the communes selected can be narrowed if the target was hit). As soon as parents sign the consent paper, the study will move to the next step.~Step 3: Groups will be divided to investigate activities. Creating a list for all participants that meet the criteria, with WHZ(Weight for Height Z-score)/BAZ(Body Mass Index for Age Z-score)\<-0,5. Random selection based on age to ensure no significant difference in the nutritional index or related indicators in the group to assess the effectiveness of the intervention (divided by class/age). Then, randomly divided the participants by class into three large groups (300 targets per group)"|t|f|t|f
33917577|NCT04810299|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33997878|NCT03947905|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Open label|Single arm crossover design where all participants receive both types of visits (Virtual and Physical visits).||||
33997879|NCT03685409|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33997880|NCT06561581|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103037|NCT05127200|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34103038|NCT05367076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103039|NCT02514746|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34103040|NCT01028560|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103041|NCT03694730|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two treatment groups receiving different activity modification instructions.||||
33693859|NCT06709508|||COHORT||RETROSPECTIVE|||||||
33693860|NCT04967664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693861|NCT04815746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693862|NCT05880654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Chronic periodontitis group chronic periodontitis with diabetes control group||||
33693863|NCT03183778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693864|NCT05807763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693865|NCT06518525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693866|NCT05274685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33693867|NCT02892123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693868|NCT06710626|NA|SINGLE_GROUP||OTHER||NONE||The study is a prospective, longitudinal, non-randomized, open-label, single-arm early feasibility study (EFS).||||
33693869|NCT04147533|NA|SINGLE_GROUP||OTHER||NONE||||||
33693870|NCT06411028|||COHORT||PROSPECTIVE|||||||
33782747|NCT04185519|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Informed consent must be signed before any procedures related to the study for any participant. The subject who meets the inclusion and exclusion criteria will be enrolled and a total of 126 subjects needed to have the power to test the hypothesis. In addition to the Hb levels and EAS doses, all HD-related bio information data in 12 consecutive months before enrollment will be uploaded into the model for further ESA dose prediction. Before randomization, the study subject will continue to receive the ESA by the prescription from the physician.~Randomization period All eligible subjects will be randomized 1:1 by their age, gender, and HD vintage into control arm and intervention arm. After randomization, the study subject will enter the study after the nearest Hb measurement coming."|f|f|t|f
33782748|NCT05626283|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782749|NCT03795974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|only one of the investigators knows the type of cell therapy for intervention group and simulation of intrathecal injection for control group .|HLA typing were done for 150 cases of spastic CP with our inclusion criteria and 36 cases of class 6 matching of HLA selected for hematopoietic stem cells derived from allogenic umbilical cord and 72 cases were randomly divided to Mesenchymal cells derived from allogenic umbilical cord and control group .|t|t|f|t
33782750|NCT04612075|||COHORT||PROSPECTIVE|||||||
33782751|NCT03912103|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The evaluation of completed deprescribing and/or medication optimization are performed by two blinded assessors (senior clinical pharmacist and/or medical physicians).|"Interdisciplinary medicine intervention focused on deprescribing and medication optimization. The control group receives standard care.~Finally we investigate the number of patients who have completed at least one deprescribing and/or medication optimization in each group."|f|f|f|t
33782752|NCT06501118|NA|SINGLE_GROUP||OTHER||NONE||||||
33782753|NCT06612606|||COHORT||CROSS_SECTIONAL|||||||
33782754|NCT02797483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33997881|NCT01685008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997882|NCT03149900|||OTHER||PROSPECTIVE|||||||
33997883|NCT04190160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997884|NCT02448160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997885|NCT03879187|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||15 healthy individuals were assessed before and after consuming a high-fat, high-energy diet for 7 days.||||
33997886|NCT03185260|||CASE_ONLY||PROSPECTIVE|||||||
33997887|NCT00949819|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33693871|NCT01229397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997888|NCT06159647|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33997889|NCT06550869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997890|NCT05432115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997891|NCT00452218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997892|NCT01859637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997893|NCT05760170|||CASE_CROSSOVER||PROSPECTIVE|||||||
33997894|NCT00213590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103042|NCT02680496|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34103043|NCT04652765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693872|NCT06708065|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. 84 hemiplegic patients, diagnosed with supratentorial cerebral infarction, were treated for stable stroke at clinical departments, meeting the inclusion and exclusion criteria.~2. Dividing the intervention group and the control group according to the lottery method of sampling.~3. Intervention content:~   * Control group: 42 patients were assigned to: regular physical therapy and occupational therapy, 90 minutes/day x 5 days/week. In addition, patients were instructed to practice at home 45 minutes/day x 5 days per week (direct instruction combined with distributing leaflets of exercises).~  * Intervention group: 42 patients were assigned to: regular physical therapy and occupational therapy, 90 minutes/day x 5 days/week. In addition, patients were trained with the Armeo Power robot 45 minutes/day, 5 days per week. - The research subjects were examined and evaluated at two points in time:~  * Time 1: Before intervention~  * Time 2: After completing 3 weeks of training (15 sessions)"||||
33693873|NCT06709599|||COHORT||RETROSPECTIVE|||||||
33693874|NCT04331236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693875|NCT03162731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782755|NCT01643512|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33782756|NCT05781724|||COHORT||RETROSPECTIVE|||||||
33782757|NCT04548622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782758|NCT00955461|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33782759|NCT05780047|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33782760|NCT03950908|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33782761|NCT04785183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33782762|NCT05983692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33997895|NCT04145635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997896|NCT02144805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997897|NCT04210544|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33997898|NCT04269122|||OTHER||CROSS_SECTIONAL|||||||
33997899|NCT00903292||PARALLEL||SCREENING||NONE||||||
33997900|NCT00826241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997901|NCT05726058|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782763|NCT01358370|||COHORT||RETROSPECTIVE|||||||
33782764|NCT05545462|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33782765|NCT06126146|||COHORT||PROSPECTIVE|||||||
33782766|NCT01974921|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782767|NCT00448864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33782768|NCT03935828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Endoscopic sinus scores will be graded by blinded assessor|Randomized to oral versus topical antibiotics|f|f|f|t
33782769|NCT06504264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782770|NCT03453385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782771|NCT01616563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782772|NCT00503568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782773|NCT05892575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33782774|NCT03932617|||COHORT||PROSPECTIVE|||||||
33782775|NCT00254475|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33782776|NCT00421421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782777|NCT01188317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782778|NCT02408965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917578|NCT04624035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997902|NCT01212640|||||PROSPECTIVE|||||||
33997903|NCT03552328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomization sequence will be implemented centrally with one of the co-investigator (Ambuj Kumar) who is off site will retain the list. Once a participant is identified the primary investigator will call the off-site co-investigator for assignment. Given that the co-investigator is not on site will ensure adequate allocation concealment.~Also, since the outcome data will be collected using a questionnaire, the possibility of interpretation does not exist. Data analysts will not be informed of the subject assignment and the coding for participant will be as group 1 or 2."|Eligible and consenting participants are randomized to one of the two study groups in a 1:1 allocation ratio. A block-stratified method using the computer will be used for generation of randomization sequence. The block size will be random.|f|f|t|t
33997904|NCT06628271|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Inclusion upon suspicion of Breath Holding Spell. Thereafter, allocation to either the group that has a defined typical Breath Holding spell, or the alternative (parallel) group that is not diagnosed with a typical Breath Holding Spell. Subsequent management of study subject in the Typical Breath Holding Spell group according to the management algorithm.||||
33997905|NCT04805840|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33997906|NCT00538109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917579|NCT02992158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917580|NCT05765695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917581|NCT06512948|||OTHER||RETROSPECTIVE|||||||
33917582|NCT05835245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917583|NCT05045469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917584|NCT04158986|RANDOMIZED|PARALLEL||PREVENTION||NONE|Allocation is blinded.|||||
33917585|NCT02482441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917586|NCT00905723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917587|NCT05553626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917588|NCT00490659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917589|NCT00398957|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917590|NCT01318512|||COHORT||PROSPECTIVE|||||||
33917591|NCT05651893|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33917592|NCT05228106|||COHORT||PROSPECTIVE|||||||
33917593|NCT01194804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917594|NCT05405595|NA|SEQUENTIAL||TREATMENT||NONE||||||
33917595|NCT00115765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917596|NCT04104906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997907|NCT03510260|RANDOMIZED|PARALLEL||OTHER||NONE||Unblinded randomized clinical trial.||||
33997908|NCT05014438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087862|NCT04479072|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|"The study team and all randomized subjects will be blinded to which arm they were placed in during the main part of the study. Subjects in the observational group will not be randomized and not given an intervention.~The sub-study portion has no blinding attached to it"|"Main Study: Subjects will be randomized to two arms. One arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit. The other arm will receive daily dose of placebo pill at their baseline visit. There will be a third arm, where subjects will not receive any study drug and will be considered the observational arm.~Sub-Study: Subjects who completed the main part of the study and choose to participate will be randomized once more into one of two arms for the purposes of the sub-study. One arm will receive the GDMP, which includes the RPM program. The other arm will not receive the GDMP and will continue thier usual standard of care course per thier treating physician."|t|f|t|f
34087863|NCT01563081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087864|NCT03385538|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087865|NCT04275856|||OTHER||CROSS_SECTIONAL|||||||
34087866|NCT00970554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087867|NCT04005742|||COHORT||OTHER|||||||
33782779|NCT03815916|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Research participants and site personnel are not masked to study drug, but will be blinded to study dose for each cohort (single-blinded).|Open Label, Investigator Blinded, Sequential Cohort (max of 2 cohorts amongst the possible 4 interventions)||||
33782780|NCT01414036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33782781|NCT01154686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782782|NCT01571778|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33782783|NCT01145144|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782784|NCT06629532|||COHORT||PROSPECTIVE|||||||
33782785|NCT01401348|||COHORT||PROSPECTIVE|||||||
33782786|NCT04942054|NA|SEQUENTIAL||TREATMENT||NONE||This is a 3 X 3 Design, sequential doses of 300 mg, 600 mg, 800 mg, 1200 mg will be studied. Other dose strength will be studied based on results.||||
33917597|NCT01928485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917598|NCT05053997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917599|NCT03154151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917600|NCT04191291|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33917601|NCT02940717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917602|NCT02262234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917603|NCT00269737|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917604|NCT03095521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917605|NCT06259773|||CASE_CONTROL||PROSPECTIVE|||||||
33917606|NCT03415763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917607|NCT04785079|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental study using a single group||||
33917608|NCT02603185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917609|NCT03170583|||COHORT||PROSPECTIVE|||||||
33917610|NCT00643591|||CASE_ONLY||PROSPECTIVE|||||||
33917611|NCT02918409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917612|NCT06051981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A web based research randomizer software will be used to generate a random sequence number to allocate the participants to different groups. The allocation will be kept concealed from patients and examiners using sequentially numbered identical containers containing experimental materials (remineralizing agents) to ensure the double blindness of the study.|"Once the FV has been applied, the examiners at Riyadh Elm University will do a visual inspection and take LF measurements (T2) on all the areas that were marked as WSL on the initial photos. The LF measurement will be carried out by the same inspectors who carried out the visual inspection.~At the end of treatment for groups II, III, IV, a visual examination and LF measurements (T2) will be conducted by the same examiners. At the next inspection (after 3 months (T3)), LF measurements will be carried out on all areas that were marked as WSL on the original photos, whether they are still existing WSL areas or they will be changed to WSL free areas."|t|f|t|t
33917613|NCT01895491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917614|NCT00530530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917615|NCT00195767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917616|NCT05024877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917617|NCT03298152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917618|NCT05837052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917619|NCT05181540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33917620|NCT01621672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917621|NCT04246593|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917622|NCT02336412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917623|NCT06243822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33917624|NCT05764278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917625|NCT02240537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917626|NCT03398122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917627|NCT03083509|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087868|NCT02543840|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34087869|NCT03640819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087870|NCT06059144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34087871|NCT05252338|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34087872|NCT05264532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34087873|NCT01392781|||CASE_CONTROL||PROSPECTIVE|||||||
34087874|NCT01222299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087875|NCT01821313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087876|NCT01260129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782787|NCT01055587|||COHORT||PROSPECTIVE|||||||
33997909|NCT03135080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|At the end of the rainy season, an independent examiner (not involved in the HEAD START evaluations) will assess the first 1-2 surgeries of the season of all study participants. The assessor will not know whether surgeons had participated in the long-term HEAD START training over the rainy season.|All study participants will have their skill levels on live surgery evaluated at the end of surgical training and again at the start of the surgical season, approximately 6 months later. Fifteen trainees will participate in long-term HEAD START practice and receive feedback throughout this break during the rainy season when surgical activity is low. An additional 15 individuals will be selected for the trainer to assess their skill levels on live surgery at the end of training and again at the start of the surgical season this fall but will not receive additional surgical practice.|f|f|f|t
33997910|NCT04057105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded (participant and the investigator are blinded from knowing the HD-tDCS allocation sequence)||t|f|t|f
33997911|NCT02167594|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33997912|NCT00310115|||CASE_ONLY||PROSPECTIVE|||||||
33997913|NCT06224088|||CASE_ONLY||RETROSPECTIVE|||||||
33997914|NCT06026267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997915|NCT00535912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997916|NCT03366948|||OTHER||PROSPECTIVE|||||||
33997917|NCT04579653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study has a within-subjects design with a randomization of the order of tVNS administered parameters||||
33997918|NCT03369535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33997919|NCT01198938|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33997920|NCT02795858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997921|NCT05525923|||COHORT||PROSPECTIVE|||||||
33997922|NCT04353986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, interventional, controlled, open-label, pharmacokinetic study.||||
33997923|NCT00836862|||OTHER||PROSPECTIVE|||||||
34087877|NCT04179630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087878|NCT02478333|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34087879|NCT03769493|NA|SINGLE_GROUP||TREATMENT||NONE||An uncontrolled open trial approach will be used in which all participants receive the MACS app.||||
34087880|NCT05729321|||COHORT||PROSPECTIVE|||||||
34087881|NCT04238741|NA|SINGLE_GROUP||OTHER||NONE||||||
34087882|NCT04319224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782788|NCT06488599|||COHORT||OTHER|||||||
33782789|NCT06523725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087883|NCT05745168|||OTHER||PROSPECTIVE|||||||
34087884|NCT00966576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087885|NCT05557214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34087886|NCT00457353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103044|NCT06054815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103045|NCT04290676|||OTHER||RETROSPECTIVE|||||||
33782790|NCT03756194|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The researchers and technical staff supporting the experiments are unable to be blinded. Therefore, a single blind masking strategy will be used meaning that the participants and their carers (apart from the control arm 2) will be left unaware of what group they have been allocated to and what type of the CARESSES robot they will be interacting with.||t|f|f|f
34087887|NCT03808766|RANDOMIZED|PARALLEL||OTHER||NONE||"Tumors are categorized into 3 groups based on the longest diameter of the largest tumor:~Group 1: ≤3cm Group 2: \>3cm to 7cm Group 3: \>7cm"||||
34087888|NCT02480296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087889|NCT02190175|||COHORT||PROSPECTIVE|||||||
33693876|NCT06707532|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Before the procedure, the anaesthetist will be given a sealed envelope by a person unrelated to the project (hospital administrative staff), with a randomised method of anaesthesia based on simple randomisation. Before the procedure, each patient will have a transthoracic cardiac ultrasound (TTE). The patient will not know which study group he/she has been classified into. The operator performing the procedure will not be informed about the type of anaesthesia performed -\[randomisation by double-blinding\].|The subjects will be randomly divided into 2 groups. Group I will consist of patients undergoing general anaesthesia without the use of the muscle relaxant rocuronium during electric current application. Group II will consist of patients undergoing general anaesthesia with the muscle relaxant rocuronium. A total of 32 patients were initially planned for the study (16 patients in each of the two groups).|t|t|f|f
33693877|NCT04512287|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33693878|NCT06587308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33693879|NCT05569473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33693880|NCT03370614|||OTHER||PROSPECTIVE|||||||
33693881|NCT01070043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33693882|NCT05049369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693883|NCT04266769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693884|NCT01538264|||CASE_ONLY||CROSS_SECTIONAL|||||||
33693885|NCT05751642|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33693886|NCT06350474|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33693887|NCT06708780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782791|NCT02347943|||COHORT||PROSPECTIVE|||||||
33782792|NCT04960618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782793|NCT06120361|||COHORT||PROSPECTIVE|||||||
33782794|NCT02201030|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33782795|NCT02379364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782796|NCT00020189||||TREATMENT||||||||
33782797|NCT00592748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782798|NCT03743922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782799|NCT04021043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782800|NCT05543369|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33782801|NCT05574634|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participant will not be aware that there are two alternate versions of the attention practice program.||t|f|f|f
33782802|NCT05682261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the current trial, the outcome assessors and study subjects will both be blinded. The supplements being administered to participants, as well as who is in the intervention group and who is in the control group, will be masked from the assessors. The trial participants will be blinded to the kind of supplements being administered to them and the group to which they were assigned.|The three arms included in this trial are the multiple micronutrient supplement arm, iron-folic acid arm, and the placebo arm. This trial is a parallel-group community-based individual randomized control trial. The participants will be allocated randomly to the three arms and receive only the intervention assigned to them.|t|f|f|t
33782803|NCT00004209|RANDOMIZED|||TREATMENT||||||||
33782804|NCT00051415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33782805|NCT04394871|||COHORT||PROSPECTIVE|||||||
34087890|NCT00359476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087891|NCT00152048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34103046|NCT04945369|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34103047|NCT00089583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103048|NCT06059846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103049|NCT01248468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693888|NCT01717144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33693889|NCT03896607|||COHORT||PROSPECTIVE|||||||
33693890|NCT04110262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Throughout data collection, study data collectors and the study coordinator will remain blinded to participants' exposure group.|Dietary intervention consisting of two 25-day feeding periods separated by a 10-day washout.|f|f|f|t
33693891|NCT05007717|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33693892|NCT02045173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782806|NCT00264589|NA|SINGLE_GROUP||||NONE||||||
33693893|NCT06016907|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessors conducting follow-up assessments (referred to as POST-1 and POST-2) will be blind to treatment allocation. At each follow-up assessment, participants will be reminded by their assessor to not reveal their study allocation. To measure blinding integrity, all assessors will record whether the participants inadvertently revealed their group allocation, and subsequently guess each participant's treatment allocation at each assessment point and motivate their choice. If the treatment allocation is accidentally revealed, the revelation part will be cut out of the Pediatric Anxiety Rating Scale audio recording and a new blind assessor will listen to the audio recording and conduct the rating that will be used in the trial. Subsequent assessments for that participant will then be conducted by someone different than the unblinded assessor. The primary analysis will be performed after the study's final participant has finished his/her POST-2 assessment.|A pilot, single-blind, parallel-group (2 groups), randomized controlled trial for children and adolescents with anxiety disorders. Participants will be randomized at a 1:1 ratio to one out of two care pathways: stepped care and stratified care. Each care pathway consists of up to two courses of treatment.|f|f|f|t
33693894|NCT03128645|||OTHER||PROSPECTIVE|||||||
33693895|NCT06707064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors were blinded to minimize bias during data collection and analysis. Participants and care providers were not masked due to the nature of the intervention.|Participants were assigned to either the SFEE intervention group or a control group receiving standard dietary advice in a 1:1 allocation ratio.|f|f|f|t
33693896|NCT02353754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693897|NCT00978107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693898|NCT04263363|NA|SINGLE_GROUP||PREVENTION||NONE||Historical prospective comparative effectiveness clinical trial||||
33693899|NCT06145607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693900|NCT05407610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Three-arm, pragmatic, prospective, multicentre, double blind, randomised sham-controlled trial|t|f|f|t
33693901|NCT06546670|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33693902|NCT03805646|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||None of the interventional study model categories aptly describe the study. The step-wedge design of the study means each site has historical controls; the only thing determining whether an individual receives the intervention or not is time (that is, whether the hospital site s/he was admitted to happens to be in the pre-intervention/baseline data collection phase or the intervention phase).||||
33693903|NCT00812747|||COHORT||PROSPECTIVE|||||||
33693904|NCT04629547|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693905|NCT01954732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693906|NCT05385185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693907|NCT06710431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782807|NCT05331495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782808|NCT04812470|NA|SEQUENTIAL||TREATMENT||NONE||dose escalation||||
33782809|NCT06613828|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33782810|NCT03942419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There will be no differences in the presentation of study drug administered. All study personnel conducting ophthalmic assessments will be masked to treatment assignment.|This is a multi-center, double masked, randomized, placebo-controlled study evaluating the efficacy of microdosed atropine 0.01%, atropine 0.1% and placebo ophthalmic solutions. Subjects will administer their assigned medication daily in both eyes for 36 months, then be re-randomized to the same or an alternative treatment arm and followed for an additional 12 months.|t|t|t|t
33782811|NCT05062590|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33782812|NCT00445627|||COHORT||PROSPECTIVE|||||||
33782813|NCT03286205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782814|NCT06443047|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The goal of this study is to perform a randomized trial to compare a new through-the-scope suturing system and conventional clips for closure of defect after ESD for 30-60 mm colonic polyps. More precisely, the hypothesis posits that the new through-the-scope suturing system can achieve higher complete closure rates in a shorter time in comparison to conventional clips.~Considering an α risk set at 5%, a power set at 80%, given an expected complete resection rate of 70% in the control group and of 95% in the experimental group, 33 patients in each group are required. Thus, the investigators will enroll 66 subjects"||||
33782815|NCT01162655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103050|NCT03394378|||OTHER||CROSS_SECTIONAL|||||||
33782816|NCT05123716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33782817|NCT04136236|||COHORT||OTHER|||||||
33782818|NCT03631147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997924|NCT02143596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997925|NCT01772407|||COHORT||PROSPECTIVE|||||||
33997926|NCT03347019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103051|NCT00979615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103052|NCT05649306|||COHORT||PROSPECTIVE|||||||
33997927|NCT00876265|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33997928|NCT03229057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits. No longer term follow-up is planned.|t|t|t|f
33997929|NCT01037231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997930|NCT02957331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997931|NCT01598896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103053|NCT06684652|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34103054|NCT06679283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures are being assessed by a clinician blinded to the patient allocation.|Parallel armed, randomised, single-blinded, controlled, clinical trial|f|f|f|t
34103055|NCT06679582|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial has two parts, Part 1 will use a parallel model by assessing two luveltamab tazevibulin doses (3.5 and 4.3 mg/kg every 2 weeks). Two cohorts will be run in parallel. The transition from part 1 to part 2 is sequential, with part 2 testing the dose selected at the end of part 1.||||
34103056|NCT00001789||||TREATMENT||||||||
34103057|NCT06669767|||CASE_CONTROL||PROSPECTIVE|||||||
33782819|NCT04296240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782820|NCT01477229|||COHORT||PROSPECTIVE|||||||
33782821|NCT05838612|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Data will be blinded prior to analysis.|Each participant will complete seven consecutive experimental sessions consisting of a passive heat acclimation involving a one hour immersion in warm water (\~40°C) with core temperature clamped at 38.5°C. Prior to and following the passive heat acclimation protocol, study participants will perform an exercise-heat stress test (Days 0 and 8) to assess whole-body heat loss in a hot-dry environment (40°C, 15% relative humidity). The exercise protocol will consist of three successive 30-minute bouts of exercise performed at increasing rates of metabolic heat production (i.e., 150, 200 and 250 W/m2), each separated by a 15-minute rest break, with the final recovery 1-hour in duration.||||
33782822|NCT02228603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782823|NCT00038792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917628|NCT04488224|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|The Postdoctoral Research Associate will collect and de-identify CBCT images acquired during Nano-X rotation session and during participants' routine treatment. The software used to display the scans will incorporate a random number generator to determine the labeling of images as 'A' or 'B'. Observers assessing image quality for study outcomes will be masked to the source of either image.|All participants will undergo CBCT imaging during rotation on the Nano-X patient rotation system. For each participant, quality of CBCT images acquired during the rotation session will be compared with quality of CBCT images collected during their standard radiation therapy treatment.|f|f|f|t
33917629|NCT00176241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917630|NCT03799926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917631|NCT01940510|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33917632|NCT05856825|||COHORT||RETROSPECTIVE|||||||
33917633|NCT01140854|||CASE_CONTROL||PROSPECTIVE|||||||
33917634|NCT06373172|NA|SINGLE_GROUP||OTHER||NONE||This quasi-experimental study used a single-group pretest-posttest design to verify the effectiveness of virtual simulation-based education for undergraduate nursing students.||||
33917635|NCT01362946|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33782824|NCT05191797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782825|NCT03975387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782826|NCT01542619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782827|NCT02656940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782828|NCT01065272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782829|NCT00450502||||TREATMENT||||||||
33782830|NCT01726959|||COHORT||PROSPECTIVE|||||||
33782831|NCT06614400|||COHORT||PROSPECTIVE|||||||
33782832|NCT06408246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants in C+ and C- subgroups will be randomized to one of two treatment arms|t|t|f|f
33917636|NCT03903744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917637|NCT00383214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917638|NCT02907320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917639|NCT05334719|||COHORT||OTHER|||||||
33917640|NCT04470492|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103058|NCT01487785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103059|NCT06563791|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34103060|NCT01555424|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33782833|NCT02336893|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782834|NCT02450071|||COHORT||PROSPECTIVE|||||||
33782835|NCT02516774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782836|NCT00266097|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33782837|NCT03975660|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33782838|NCT04497584|NA|SINGLE_GROUP||TREATMENT||NONE||Afatinib 40 mg PO daily Prednisone 40 mg PO daily (starting 7 days after afatinib)||||
33782839|NCT03424928|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-way crossover||||
33782840|NCT03397914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782841|NCT05122403|||CASE_CONTROL||PROSPECTIVE|||||||
33782842|NCT00234143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917641|NCT00736866|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917642|NCT00743457|||COHORT||PROSPECTIVE|||||||
33917643|NCT01608724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917644|NCT01415856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917645|NCT02130258|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33917646|NCT02821455|||COHORT||PROSPECTIVE|||||||
33917647|NCT02252692|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917648|NCT02363270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917649|NCT01551134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917650|NCT00623493|||||PROSPECTIVE|||||||
33917651|NCT03974113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917652|NCT03963934|NA|SINGLE_GROUP||OTHER||NONE||Prospective, monocentric, open, pilot study||||
33917653|NCT02024191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33917654|NCT04621006|||COHORT||PROSPECTIVE|||||||
33917655|NCT01724983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33782843|NCT00478556|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33782844|NCT03743012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782845|NCT01112735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782846|NCT06615089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque sealed envelope|balance training and foot orthosis|f|f|f|t
33782847|NCT00825474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782848|NCT04926324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782849|NCT03836664|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33782850|NCT05708417|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study is a one-site, single-blind, clinical intervention study.|f|f|t|f
33782851|NCT06119191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917656|NCT01549743|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33917657|NCT02051725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33917658|NCT02586987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917659|NCT02769806|||CASE_ONLY||PROSPECTIVE|||||||
33917660|NCT03162497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33917661|NCT06342323|||COHORT||PROSPECTIVE|||||||
33917662|NCT00931476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917663|NCT00796094|||COHORT||PROSPECTIVE|||||||
33917664|NCT02862223|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33917665|NCT03850782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917666|NCT03268694|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33917667|NCT01310816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917668|NCT01729637|||||PROSPECTIVE|||||||
33917669|NCT04654091|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33917670|NCT02170649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917671|NCT00623467|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917672|NCT04876599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33917673|NCT02763072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917674|NCT05688501|||COHORT||PROSPECTIVE|||||||
34103061|NCT05833945|||COHORT||PROSPECTIVE|||||||
34103062|NCT04698447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double-blind study|placebo-controlled study|t|f|t|f
34103063|NCT06613984|||COHORT||PROSPECTIVE|||||||
34103064|NCT04409418|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single-site, randomized||||
34103065|NCT02980458|RANDOMIZED|CROSSOVER||||NONE||||||
34103066|NCT06471751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103067|NCT06690593|||CASE_CONTROL||RETROSPECTIVE|||||||
34103068|NCT04356378|||COHORT||PROSPECTIVE|||||||
33782852|NCT06522035|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782853|NCT04862520|||COHORT||PROSPECTIVE|||||||
33782854|NCT01639443|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782855|NCT06030089|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782856|NCT02538640|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33782857|NCT03583437|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Experimental: 1 Healthy male volunteers Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning, Experimental: 2 Healthy female volunteers Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after a PET scanning.||||
33782858|NCT02531438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782859|NCT02248454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782860|NCT06614257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782861|NCT03293862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Suture group and prophylactic mesh group|f|t|f|f
33782862|NCT00180440|||COHORT||PROSPECTIVE|||||||
33782863|NCT05675631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782864|NCT01556841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782865|NCT01268566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782866|NCT02214459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782867|NCT06040645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33782868|NCT04140058|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33782869|NCT02519179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a within-subject study; mothers are observed during both feeding conditions.||||
33782870|NCT01049139|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782871|NCT01525979|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33782872|NCT01353235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782873|NCT04968782|||CASE_ONLY||PROSPECTIVE|||||||
33782874|NCT01495507|||CASE_ONLY||PROSPECTIVE|||||||
33782875|NCT04664777|||OTHER||PROSPECTIVE|||||||
33782876|NCT05323929|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33782877|NCT02513914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782878|NCT06041997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782879|NCT01820819|||COHORT||PROSPECTIVE|||||||
33782880|NCT02725203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782881|NCT05787652|RANDOMIZED|PARALLEL||TREATMENT||NONE|It will not be possible to blind participants or trial staff to treatment allocation, as the control group receives no intervention and participants will be aware of the general nature of the study. However, all follow-up is done remotely and will therefore be unbiased.|This is a parallel group, randomised, controlled superiority trial.||||
33782882|NCT06615180|NA|SINGLE_GROUP||OTHER||NONE||"This international curriculum was developed with researchers from seven institutions and five countries (Turkey, Spain, Czech Republic, Belgium, Slovenia, and Hungary). The transcultural nursing course, which implemented 25 hours in a one-semester elective course, had 8 hours of theoretical training and 17 hours of practical training in two nursing departments in Turkiye . The course has 3 ETCSs (a 75 h workload for the students). This elective, the Transcultural Nursing Course was chosen by 5th-semester BSc nursing students.~The aim of the course was To develop/promote awareness of culture-based care; it is aimed that at the end of this course, students would be capable of evaluating individuals, families, and communities in a proper and evidence-based manner, and they would be competent to plan, implement and evaluate culture-based nursing care. Learning outputs were prepared based on culture care theory by Madeleine"||||
33782883|NCT06136806|||COHORT||PROSPECTIVE|||||||
33782884|NCT05463120|||COHORT||PROSPECTIVE|||||||
33782885|NCT05292963|NA|SINGLE_GROUP||TREATMENT||NONE||Participants receive 26 hours of Nurturing Fathers curriculum, delivered in person or virtually over Zoom. Participants also receive employment supports, case management, and financial literacy training.||||
33782886|NCT04991025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782887|NCT04730180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782888|NCT05000775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782889|NCT06182501|||CASE_ONLY||RETROSPECTIVE|||||||
33782890|NCT04198961|NA|SINGLE_GROUP||OTHER||NONE||||||
33917675|NCT03882255|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33917676|NCT03102359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33917677|NCT01217190|RANDOMIZED|CROSSOVER||OTHER||NONE||Two period study, two treatment, randomized sequence||||
33693908|NCT05794230|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Cohort I: Infants and toddlers 6 months to 16 months of age. Eligible participants are randomized in a 1:1 ratio to receive 2 injections of either MenACYW conjugate vaccine (Groups 1 and 3) or Menactra vaccine (Groups 2 and 4), co-administered with routine pediatric vaccines.~Cohort II: Infants and toddlers 6 weeks to 15 months of age. Eligible participants are randomized in a 2:1 ratio to receive either 3 injections of MenACYW conjugate vaccine co-administered with routine pediatric vaccines (Groups 5 and 7), or routine pediatric vaccines only (Groups 6 and 8)."||||
33693909|NCT01721070|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33693910|NCT01539798|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33997932|NCT05659576|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-arm randomized study. There will be two separate randomizations in this study, one vs. two-stage consent and sucralfate vs. control.||||
33997933|NCT04004039|||COHORT||RETROSPECTIVE|||||||
33997934|NCT06368076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997935|NCT01166529|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33997936|NCT01694563|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33997937|NCT05913843|||CASE_ONLY||PROSPECTIVE|||||||
33693911|NCT06311188|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm trial||||
33997938|NCT01590563|NA|SINGLE_GROUP||PREVENTION||NONE||Intrauterine device||||
33997939|NCT02109458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33997940|NCT01663662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997941|NCT05649358|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The investigators will test the device on 8 male and 8 female participants to determine if there are any sex differences in the performance of the sensor. As there is likely going to be inter-individual variability in the participants, the investigators have chosen to test 8 males and 8 females rather than 5 and 5 as suggested by the reviewer.||||
33997942|NCT02416934|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33997943|NCT04891276|||COHORT||RETROSPECTIVE|||||||
33997944|NCT00059423|||COHORT||PROSPECTIVE|||||||
33997945|NCT05694546|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Community health worker follow-up after discharge from hospital||||
33997946|NCT00584753|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33997947|NCT05149209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participants will be blinded to the technique used since the patient will attend the same number of visits and he can not differentiate between different restorative materials.~The operator cannot be blinded because of the difference in the application procedures of each restorative material.~The outcome assessor will be blinded to the material used. This will be performed by M.S. and Y.H. Therefore the assessors mustn't be included in the preclinical assessment."|Randomized Parallel Controlled Trial. Trial type: Two, Parallel arm design. Trial framework: Equivalence frame Allocation ratio: 1:1.|t|f|t|t
33997948|NCT05582343|RANDOMIZED|PARALLEL||PREVENTION||NONE||Longitudinal, randomized RCT with repeated measures||||
33997949|NCT00254280|RANDOMIZED|PARALLEL||||SINGLE||||||
33997950|NCT05715892|||CASE_CROSSOVER||PROSPECTIVE|||||||
33997951|NCT04750681|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized double-blind placebo-controlled interventional study|t|t|t|t
33997952|NCT03958812|||COHORT||PROSPECTIVE|||||||
33997953|NCT01283763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693912|NCT04912011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33693913|NCT04680676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693914|NCT06708858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693915|NCT03756480|||CASE_CONTROL||PROSPECTIVE|||||||
33693916|NCT03861611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997954|NCT04970836|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective cohort study||||
33997955|NCT02942082|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33997956|NCT05582291|||COHORT||RETROSPECTIVE|||||||
33997957|NCT00466167||PARALLEL||TREATMENT||||||||
33693917|NCT04949685|||CASE_ONLY||RETROSPECTIVE|||||||
33997958|NCT00059332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33997959|NCT00125385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997960|NCT04843254|||OTHER||CROSS_SECTIONAL|||||||
33997961|NCT03544242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33997962|NCT02981095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33997963|NCT03766360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33997964|NCT00189553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693918|NCT01994928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693919|NCT06709807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33693920|NCT05808309|||COHORT||PROSPECTIVE|||||||
34103069|NCT06375564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103070|NCT06678828|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33693921|NCT06534125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917678|NCT06377345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will not be aware of the participants' group|A two-group randomized controlled trial (RCT) design will be used. The control group will receive the usual care, and the intervention group will receive the Aevice device on top of usual care. Outcomes will be measured at baseline, week 4, and week 12. This is to evaluate the long-term impacts of the Aevice device. Clinicians who have interacted with participants using Aevice will also be invited to participate in an interview and clinician perception survey. A convenience sampling will be used for the recruitment of clinicians.|f|f|f|t
33917679|NCT03720730|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917680|NCT02417467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693922|NCT06255834|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33693923|NCT04893096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693924|NCT05578690|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Statistical analysis of the primary outcome will be blinded to the assessors.|The trial is a randomised, parallel-group, intervention study comparing a tailored, intensive, multifactorial lifestyle intervention before and during pregnancy in women with overweight or obesity with standard of care.|f|f|f|t
33693925|NCT01553032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33693926|NCT00856648|||CASE_CONTROL||PROSPECTIVE|||||||
33693927|NCT03381183|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33693928|NCT05568472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693929|NCT06709963|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33917681|NCT01875367|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible patients, from the randomization and before starting subcutaneous trastuzumab (SC-t), received an additional intravenous (IV-t) cycle. After receiving this cycle, patients started the treatment with the study medication, SC-t at a fixed dose of 600 mg every 3 weeks (+3 days) for 4 cycles (2 administered from the injection of a vial in a syringe and 2 with the single-use injection device \[SID\]), being randomized 1:1 in two arms of treatment without washout period:~* Arm A (1 cycle of IV-t followed by 2 cycles of SC-t with vial followed by 2 cycles of SC-t with SID)~* Arm B (1 cycle of IV-t followed by 2 cycles of SC-t with SID followed by 2 cycles of SC-t with vial)~This is not a cross-over study."||||
33917682|NCT01611129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917683|NCT05819736|||COHORT||PROSPECTIVE|||||||
33917684|NCT01797965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917685|NCT00823940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917686|NCT05915234|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|This study uses a single-blind masking. The 2 interventions and the comparator are contained in opaque bags, that prevents participants from having visual knowledge of the contents of the bags.|Randomized experimental model in which 2 active cryotherapy interventions and a control are applied to all participants in a crossover single-blind design.|t|f|f|f
33917687|NCT03136133|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Protein drink With matching placebo|Crossover, placebo controlled|t|f|f|f
33917688|NCT02137759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917689|NCT03714906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917690|NCT00075244||||TREATMENT||||||||
33693930|NCT00000631||||PREVENTION||NONE||||||
33693931|NCT05427032|||COHORT||PROSPECTIVE|||||||
33782891|NCT06226025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Participants that meet eligibility for the randomized trial are randomized using minimization in a 1:1 ratio to low-dose afternoon melatonin plus a behavioral sleep intervention (MEL) or placebo tablet plus behavioral sleep placebo (CTL)~After the Randomized clinical trial portion, ten participants from the control group will be recruited to receive open label melatonin."|t|f|f|t
33693932|NCT03307057|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The diagnosticians for all measures will be kept blind to group assignment.|This study uses a 2-stage sequential multiple assignment randomized trial (SMART) design to develop an adaptive intervention. Participants will be randomized into one of two study arms at Stage 1 (6 months of age) and re-randomized into one of four arms for Stage 2 at 12 months of age. Certain study arms during Stage 2 will only be available for participants who are showing early signs of ASD.|f|f|f|t
33693933|NCT04810663|||COHORT||RETROSPECTIVE|||||||
33693934|NCT06269055|||CASE_ONLY||RETROSPECTIVE|||||||
33693935|NCT06709235|||COHORT||RETROSPECTIVE|||||||
33693936|NCT06708650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693937|NCT04559919|||COHORT||PROSPECTIVE|||||||
33693938|NCT04664244|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients will undergo the same treatment.||||
34103071|NCT06058793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103072|NCT00059280|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34103073|NCT03303066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase 2 part is an open label, single arm, dose-escalation study. Phase 3 component is a randomized, double blind, placebo-controlled study.||t|t|t|t
34103074|NCT06625086|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34103075|NCT06675266|||COHORT||OTHER|||||||
34103076|NCT00079781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34103077|NCT06686342|||COHORT||PROSPECTIVE|||||||
33693939|NCT06517836|NA|SINGLE_GROUP||SCREENING||NONE||||||
33693940|NCT05320809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693941|NCT06314308|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33693942|NCT01602380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693943|NCT04844775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33693944|NCT06686238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693945|NCT05353985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693946|NCT04090723|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33693947|NCT03447184|||CASE_ONLY||PROSPECTIVE|||||||
33693948|NCT03772678|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|Pharmacist not blind||t|t|t|t
33693949|NCT05375747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782892|NCT01445756|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33917691|NCT02723136|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33917692|NCT01865461|||CASE_CONTROL||PROSPECTIVE|||||||
33917693|NCT05247619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917694|NCT02513784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917695|NCT01062620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917696|NCT01844622|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33917697|NCT03925961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33917698|NCT04357990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917699|NCT05319080|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study for participants with a diagnosis of either schizophrenia or schizoaffective disorder with persistent auditory verbal hallucinations (AVH) that are eligible to have repetitive transcranial magnetic stimulation (rTMS) targeting the left temporoparietal junction (TPJ).||||
33917700|NCT06319001|RANDOMIZED|PARALLEL||OTHER||NONE||Combined randomized controlled trial with two parallel groups||||
33782893|NCT04651738|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible patients accept DNA methylation testing in serum, cervical cytology and endometrial tissues.||||
33782894|NCT05821907|||CASE_ONLY||CROSS_SECTIONAL|||||||
33782895|NCT03031106|||CASE_ONLY||PROSPECTIVE|||||||
33782896|NCT00895024|||OTHER||PROSPECTIVE|||||||
33782897|NCT06351956|||COHORT||PROSPECTIVE|||||||
33782898|NCT03564938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782899|NCT05396495|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, Interventional, Prospective, Open label, Single Arm.||||
33782900|NCT04792983|||COHORT||PROSPECTIVE|||||||
33782901|NCT06613620|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33917701|NCT04959253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917702|NCT06552806|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Our collaborators Massimiliano Marazzato, PhD (Sapienza University of Rome) and Claudio de Simone, MD, PhD (https://www.probiotixx.info/en/about/) will provide both placebo and treatment samples codified, and their true formulation will be revealed to the investigators at UCSD after all the experiments and analysis are performed.|Repeated measurement double-blind, placebo controlled, cross-over study|f|f|f|t
33917703|NCT03921138|||CASE_ONLY||PROSPECTIVE|||||||
33917704|NCT02124707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917705|NCT01230736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917706|NCT05015205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917707|NCT04574063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917708|NCT00261170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917709|NCT01648452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917710|NCT00310388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917711|NCT02312076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917712|NCT05364983|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The subject will be masked to randomization assignment and will be unmasked at the completion of the study. Scheduled masked postoperative assessments will be performed by a masked examiner|A prospective, randomized, controlled, double-masked, phased, multicenter clinical study|t|t|f|f
33917713|NCT01391819|NA|SINGLE_GROUP||OTHER||NONE||||||
33917714|NCT03825094|||COHORT||RETROSPECTIVE|||||||
33917715|NCT04641819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917716|NCT06071299|RANDOMIZED|PARALLEL||PREVENTION||NONE||An anticipated 100 caregivers and 100-150 children of these caregivers, and 85 professionals. Participants will be randomized (1:1) child-caregiver dyads who are reported to the New Haven, Milford and Hartford child protective services (CPS) offices after identified exposure to IPV to either the FCC model or usual child-focused care.||||
33782902|NCT00874796|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782903|NCT04870164|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Part A only|Parallel (Part A) Sequential (Part B and Part C)|t|t|t|t
33782904|NCT05298670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782905|NCT06611020|||COHORT||PROSPECTIVE|||||||
33782906|NCT01913756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33782907|NCT05969561|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33782908|NCT05387928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782909|NCT00495469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782910|NCT03116282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782911|NCT01085617|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised phase III trial of standard treatment +/- rituximab for patients with precursor B-cell ALL or nelarabine for patients with T-cell ALL. A further randomisation investigated two schedules of palifermin administration in patients undergoing myeloablative transplant.||||
33782912|NCT06580951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those who agree and sign the informed consent form will be randomized in 1:1 fashion (50/50 chance) to either the RPNI group or the no RPNI (Control) group. Subjects will remain blinded to their assigned study arm until their study participation has concluded.||t|f|f|f
33782913|NCT00142064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33782914|NCT03886181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782915|NCT00354393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782916|NCT04223362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind, outcome assessor||f|f|f|t
33782917|NCT04029740|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All patients will be treated with either internet or face to face CBT according to their preference. Circulating exosomal microRNAs will be measured pretreatment and post-treatment.||||
33782918|NCT05126602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking for participants is conducted by preparing a similar chewing tablet (appearance including the color and taste). The care provider will not aware as the tablet has been unpacked. Outcome assessors are unaware of the allocation and only statistician knows the allocation|Two arms trial will be conducted with one group receiving a high dose of vitamin D3 whereas comparison group receiving a low dose of vitamin D3|t|f|t|t
33782919|NCT06217731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients who were included in Group 1 (n=20) were treated with the low power diode laser Helbo® Theralite Laser 3D Pocket Probe once a week for one month and Rivotril 0.25mg once every 24 hours for one month. Group 2 (n=19) were treated with the same laser once a week for one month, but with the tip not activated as a placebo treatment. Group 3 (n=21) were only treated with Helbo® laser once a week for one month and Group 4 (n=18) had only Rivotril 0.25mg once a day for one month. The patients were not aware of the different groups on which this study is based.||t|f|f|f
33782920|NCT06510283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782921|NCT05805059|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33782922|NCT03959709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33782923|NCT02303119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782924|NCT02710383|||COHORT||PROSPECTIVE|||||||
33782925|NCT05879120|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782926|NCT06376890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the primary investigator will know the intervention assigned to the participants.|A 3x2 model with 2 intervention groups (green and red chili) and a control group, and pre and post-intervention measures will be taken.|t|f|f|f
33782927|NCT04285996|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33782928|NCT05300464|NA|SINGLE_GROUP||SCREENING||NONE||Clinical investigation with Medical Device class IIa marked CE||||
33917717|NCT04512469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The research coordinators will identify patients diagnosed with end-stage liver disease who are candidates for liver transplantation for study eligibility (see inclusion and exclusion criteria). Participants will be randomly selected to be included in one of two groups: the control or treatment group. The control group will undergo standard running fascial closure with PDS while the treatment group will undergo this closure plus a low molecular weight mesh extending 3 cm from the fascial incision.~There will be no alteration to this standard of care schedule for this clinical trial. Data will be collected at every 12-month intervals to rule out clinical evidence of a hernia. The presence of a hernia will be assessed via clinical examination and abdominal ultrasound imaging. If findings from the abdominal ultrasound are inconclusive, a non-contrast CT scan will be performed. The study will end when either the primary or secondary outcomes are reached."|t|f|f|f
33917718|NCT00213252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917719|NCT00804739|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33917720|NCT00679068|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33917721|NCT06003257|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"Group I: comprise of 22 primary molars that will be subdivided into two subgroups:~Subgroup IA: includes 11 primary molars will be restored by stainless steel crowns.~Subgroup IB: includes 11 primary molars will be restored by zirconia crowns.~Group II: comprise of 22 primary molars that will be subdivided into two subgroups:~Subgroup IIA: includes 11 primary molars will be restored by stainless steel crowns.~Subgroup IIB: includes 11 primary molars will be restored by fiberglass crowns."|t|t|t|f
33693950|NCT05722938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All bottles will be indistinguishable.|Subjects will be randomized on a 1:1 basis to receive trimodulin or placebo, stratified by center|t|t|t|t
33693951|NCT06708910|||COHORT||PROSPECTIVE|||||||
33693952|NCT06655909|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33693953|NCT06045650|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693954|NCT03393884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693955|NCT06708975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693956|NCT06708936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693957|NCT05398926|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33693958|NCT06710015|||CASE_CONTROL||OTHER|||||||
33693959|NCT06709118|||CASE_CONTROL||PROSPECTIVE|||||||
33917722|NCT00781599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917723|NCT00249977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917724|NCT01961843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917725|NCT01434641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917726|NCT01561560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917727|NCT00523341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917728|NCT04260659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33917729|NCT03832439|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33693960|NCT06272669|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This study comprises 3 phases: Phase 1 will be a randomized controlled trial in which 90 participants will be randomly assigned to receive either active or sham-tDCS combined with computerized executive function training for 10 consecutive working days over 2 weeks period. The other 2 phases will be an open-label, crossover phase, in which for Phase 2, participants in the sham-tDCS group will receive 10-day active tDCS and assessments will be performed before and after the 10-tDCS session. Whereas bimonthly booster tDCS sessions will be provided to all tDCS responders for the first 3 months and monthly booster tDCS in the subsequent 3 months (Total 9 sessions in phase 3), and with assessments performed every month in Phase 3.|t|t|f|t
33693961|NCT04722549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators, and personnel involved in data analyses are blinded to the intervention. Unblinding occurs after all data has been collected AND analysed.||t|f|t|t
33693962|NCT03104374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693963|NCT02469207|||COHORT||PROSPECTIVE|||||||
33693964|NCT05642507|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Sequential, escalating, multiple doses|t|t|t|t
33693965|NCT04060030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple masking during blinded phase, followed by unblinding during open label phase|Prospective randomized 12-week double-blind placebo-controlled study followed by 12-week open label|t|t|t|t
33693966|NCT05672121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693967|NCT03306927|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized, controlled, cross-over study||||
33693968|NCT05929859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All perceptual ratings will be obtained from raters who are blinded to treatment group and to timepoint. Binary rating responses will be obtained from three listeners per token.|"Participants will be randomized across two conditions, Distributed and Intensive (1:1 ratio).~All participants will complete a Dynamic Assessment (DA) session consisting of 40-minutes of instruction and feedback on how to produce the /ɹ/ or /s/ sound. Following the DA session, participants will imitate 45 syllables containing the /ɹ/ or /s/ sound, and based on their performance, will be classified as High Stimulability or Low Stimulability. Participants will be stratified randomized to receive 16, 50-minute speech sessions in Intensive Treatment or Distributed Treatment."|f|f|f|t
33693969|NCT06577116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693970|NCT05442216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693971|NCT01607268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33693972|NCT01180166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693973|NCT05780606|NA|SINGLE_GROUP||OTHER||NONE||||||
33693974|NCT05055453|NA|SINGLE_GROUP||OTHER||NONE||||||
33693975|NCT06424834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693976|NCT00696683|||CASE_ONLY||RETROSPECTIVE|||||||
33693977|NCT03722199|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The different capsules are separated into 2 boxes but both sorts of capsules have the same colour and size. They just have a different number marked on the white box. During the investigation day, the participant chooses an envelope marked with number 1 or number 2 leading to the decision of the box and thus the capsules they will get.||t|t|t|t
33693978|NCT06591286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693979|NCT06310044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33782929|NCT05500833|||COHORT||PROSPECTIVE|||||||
33782930|NCT02777983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33782931|NCT05860543|||CASE_ONLY||PROSPECTIVE|||||||
33782932|NCT04127344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized clinical trial, parallel and open label.||||
33917730|NCT00005847|RANDOMIZED|||TREATMENT||||||||
33917731|NCT03948308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33917732|NCT05985434|||COHORT||PROSPECTIVE|||||||
33782933|NCT04327596|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects will undergo early RF ablation of AF using CARTO 3 and a Thermocool ST SF ablation catheter.||||
33782934|NCT00004645|RANDOMIZED|||TREATMENT||DOUBLE||||||
33917733|NCT06043141|||CASE_ONLY||CROSS_SECTIONAL|||||||
33917734|NCT05335603|||COHORT||PROSPECTIVE|||||||
33917735|NCT01999166|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33917736|NCT01887392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33917737|NCT00494871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33917738|NCT01669941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917739|NCT02681055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917740|NCT00229788|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33917741|NCT04325776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917742|NCT02491502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917743|NCT00438399|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33917744|NCT04206527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917745|NCT04991883|||CASE_ONLY||RETROSPECTIVE|||||||
33917746|NCT01005511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917747|NCT03553602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917748|NCT03550287|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33917749|NCT01756066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917750|NCT00817206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917751|NCT00455130|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33917752|NCT00368498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33917753|NCT03662633|||CASE_CONTROL||PROSPECTIVE|||||||
33917754|NCT02580994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917755|NCT00152074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33917756|NCT02085213|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33917757|NCT05138549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers, and investigators will not know which arm patients have been assigned to or if they receive placebo or astaxanthin.|Patients will be randomized to receive 6 weeks of oral supplementation of either placebo or 12 mg astaxanthin prior to total knee replacement surgery.|t|t|t|f
33917758|NCT02545842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917759|NCT02632500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917760|NCT04540302|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study comprises 2 independent cohorts:~1. Up to 244 AVF Peripheral Subjects (1:1 randomization, with approximately 122 in the study treatment and control groups)~2. Up to 113 AVG Anastomosis Subjects (no randomization, comparison to Performance Goals)"||||
33917761|NCT02781454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917762|NCT03293966|||COHORT||PROSPECTIVE|||||||
33917763|NCT05725421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917764|NCT04101487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917765|NCT05175209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917766|NCT03388996|||CASE_CONTROL||PROSPECTIVE|||||||
33917767|NCT00684125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917768|NCT00002511||||TREATMENT||||||||
33917769|NCT02063399|||COHORT||PROSPECTIVE|||||||
33917770|NCT03085355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917771|NCT04985331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917772|NCT01498237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917773|NCT01380444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087892|NCT06425016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subjects will be blinded to the intervention. An equal number of identical bandages will be applied to the abdomen in similar locations following each intervention.|Single-blind randomized controlled trial with a 1:1 allocation ratio. The study will consist of 2 interventions: laparoscopic sleeve gastrectomy (LSG) or robotic sleeve gastrectomy (RSG). All patients will be randomized during the preoperative evaluation process. An interim analysis will be performed upon completion of the primary endpoint assessment for 91 patients to determine whether a re-estimation of the total is required. Sample size re-estimation will be planned using the conditional power method proposed by Mehta and Pocock. The 91 patients data will be used to estimate the conditional power for detecting the difference in primary outcome between two groups in the final analysis. When the conditional power is between 0.36 and 0.8, the investigators will increase the sample size accordingly, up to a sample size of 360. Otherwise, the trial will continue using the planned sample size.|t|f|f|f
34087893|NCT04640116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087894|NCT02478827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33693980|NCT02532530|NA|SINGLE_GROUP||SCREENING||NONE||||||
33693981|NCT06617832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double-blinded randomized controlled cross-over design where patients receive 1) sumatriptan or 2) placebo and are told that they receive a) sumatriptan or placebo, b) sumatriptan, or c) placebo|t|f|t|f
33693982|NCT03690453|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33693983|NCT06010030|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Care provider, participant, and outcome assessor are masked for tDCS status.|Participants will maintain one of two speech therapy modalities throughout the study and be assigned to either targeted anodal-tDCS or sham-tDCS.|t|t|f|t
33693984|NCT06704971|||OTHER||OTHER|||||||
33693985|NCT03773211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33693986|NCT05307978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33693987|NCT05907096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33693988|NCT02126358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33693989|NCT06541314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693990|NCT05892653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693991|NCT04334525|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants know which kids' meals are being promoted based on the materials received in each study group -- e.g., placemats and frequent diner cards promoting two featured (healthier) meals vs. all kids' meals -- but the health focus and research questions are not stated explicitly to the participants.|A cluster-randomized design will be used. 6 locations of Anderson's, a regional quick-service restaurant in the Buffalo, New York, area will be paired based on income levels in the surrounding census tracts. A location from each pair will be randomized to each study group (intervention, control). Phased data collection will occur, with each pair of restaurants assigned to a cohort.||||
33693992|NCT02063880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33693993|NCT00266773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33693994|NCT03698552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33693995|NCT06517823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33693996|NCT04069572|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33693997|NCT03875118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33917774|NCT00483158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917775|NCT03701217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917776|NCT02995330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917777|NCT00000113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917778|NCT02066194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917779|NCT06066203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917780|NCT01780909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33917781|NCT06087042|||CASE_CONTROL||PROSPECTIVE|||||||
33917782|NCT02640144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917783|NCT02494388|||COHORT||OTHER|||||||
33917784|NCT06364865|||CASE_ONLY||PROSPECTIVE|||||||
33693998|NCT04580225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33693999|NCT06710782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694000|NCT04465214|||COHORT||PROSPECTIVE|||||||
33694001|NCT02088242|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33917785|NCT02971111|||COHORT||RETROSPECTIVE|||||||
33917786|NCT01309438||PARALLEL||TREATMENT||NONE||||||
33917787|NCT03424889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Concealed envelopes|Randomized, double blind, placebo controlled|t|t|t|t
33917788|NCT00118729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917789|NCT00073814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34087895|NCT02182804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087896|NCT00506675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087897|NCT02998853|||COHORT||PROSPECTIVE|||||||
34087898|NCT02222467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694002|NCT00542568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694003|NCT01532973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694004|NCT06136312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694005|NCT05936970|||CASE_ONLY||PROSPECTIVE|||||||
33694006|NCT04211168|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are confirmed with advanced biliary tract cancers by imaging and histological examination and meet with the inclusive criteria, including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, common bile duct cancer and gallbladder cancer.||||
33694007|NCT06645132|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33694008|NCT00488072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694009|NCT06387537|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized controlled trial having two groups. One group will receive conventional physical therapy and the second will receive conventional physical therapy along with scapular mobilization. Both groups will be recruited concurrently.||||
33694010|NCT05613803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694011|NCT03767101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694012|NCT05725668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33694013|NCT05000697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and attending phisicians will not be blinded to the treatment arm randomized for each patient. However, as a strategy to reduce investigator's expectations and reduce inherent bias, the central committee will be blinded to the treatment arm. It is expected that blinding the central committee, who will be responsible for assessing the primary endpoint, any bias related to the investigator's expectation about the treatment arm and the chances of Watch and Wait will be nulled.|Individuals will be randomized and allocated at a 1:1 ratio to the two groups using a permuted block design with a random block size of 4, 6, and 8. (1-3) A randomization list will be generated electronically using appropriate software immediately after being considered eligible.|f|f|t|f
33694014|NCT02702063|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694015|NCT02860455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694016|NCT05398263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Subjects will be randomized in a 2:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.|t|t|t|f
33694017|NCT05417243|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster Randomized Trial||||
33694018|NCT01163266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694019|NCT01266577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33694020|NCT00694395|||||RETROSPECTIVE|||||||
33694021|NCT01434485|||COHORT||PROSPECTIVE|||||||
33694022|NCT03528694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694023|NCT05647096|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either the interventional treatment arm (SOC plus NucleoCapture) or the SOC treatment arm in a 2:1||||
33694024|NCT05419531|||COHORT||PROSPECTIVE|||||||
34087899|NCT04799990|||COHORT||RETROSPECTIVE|||||||
34087900|NCT01045785|||COHORT||CROSS_SECTIONAL|||||||
34087901|NCT02313714|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34087902|NCT05679986|||COHORT||PROSPECTIVE|||||||
34087903|NCT01269294|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34087904|NCT02609490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34087905|NCT02839317|||CASE_CONTROL||PROSPECTIVE|||||||
34087906|NCT02887742|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34087907|NCT00651846|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34087908|NCT06458270|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34087909|NCT06078982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087910|NCT02991521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087911|NCT00808925|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33694025|NCT01483768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694026|NCT06707740|||CASE_ONLY||PROSPECTIVE|||||||
33694027|NCT05396157|||COHORT||RETROSPECTIVE|||||||
33694028|NCT05265052|RANDOMIZED|PARALLEL||TREATMENT||NONE||Both phase IIa and IIb are randomized, parallel controlled studies.||||
33694029|NCT05323110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694030|NCT05726591|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33694031|NCT05590624|RANDOMIZED|CROSSOVER||OTHER||NONE||"Patients will be randomized to one of two arms which only differ in the order they will receive the two dietary interventions \[Lower Carbohydrate (LC) and Low Fat (LF)\]. All dietary interventions are on a Mediterranean foundation and are opposite in carbohydrate and fat content.~Arm 1 \[n=15 with confirmed PCa diagnosis and candidate for Active Surveillance (AS) per Standard of Care (SOC)\]: Dietary Intervention #1=Low Fat (LF) Mediterranean. Dietary Intervention #2=Lower Carbohydrate (LC) Mediterranean~Arm 2 (n=15 with confirmed PCa diagnosis and candidate for AS per SOC): Dietary Intervention #1=LC Mediterranean. Dietary Intervention #2=LF Mediterranean"||||
33694032|NCT05389423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694033|NCT06451029|||CASE_CONTROL||PROSPECTIVE|||||||
33694034|NCT06707181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694035|NCT06084078|||COHORT||PROSPECTIVE|||||||
33694036|NCT06104527|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33694037|NCT02440620|||COHORT||PROSPECTIVE|||||||
33694038|NCT01678027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694039|NCT06705062|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694040|NCT04776070|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694041|NCT02016430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694042|NCT06695312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694043|NCT05691907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694044|NCT06709040|||CASE_ONLY||PROSPECTIVE|||||||
33694045|NCT06161610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The progression will be assessed by third-party blinded investigators||f|f|f|t
33694046|NCT06710730|||COHORT||PROSPECTIVE|||||||
33694047|NCT00246896|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33694048|NCT04932512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694049|NCT06680934|||CASE_ONLY||OTHER|||||||
33694050|NCT06706791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will employ a double blind masking approach to ensure unbiased results and mainbtain the integrity of data participants masking; participants will be unaware of whether they are receiving Empagliflozin or placebo investigator masking; healthcare professionals and investigators administering the treatment will not know the treatment assignment.|"This is a comparative clinical study with randomized groups. Participants will be allocated to either the Empagliflozin group or the placebo group alongside standard therapy.~Blinding will be done by assigning drug to participants according to computer generated numbers in 2 groups in 1:1 ratio.~Empagliflozin Group: taking Empagliflozin 10mg once daily per oral along with standard treatment. Their quality of life assessed by using Kansas City Cardiomyopathy questionnaire. Placebo Group: Identical placebo tablets, following the same dose and schedule as the Empagliflozin group along with standard treatment of chronic heart failure.~Duration 18 months Setting Will take place in Fazaia Ruth Pfau medical college and hospital and NICVD hospital Karachi."|t|f|t|f
33694051|NCT05182125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694052|NCT05298306|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The crossover study (Part B) is preceded by a single ascending dose study (Part A)|t|t|t|t
33694053|NCT05959200|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33694054|NCT01798680|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694055|NCT03301506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782935|NCT05510687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial will be investigator-masked, but Community Health Workers (CHW), other fieldwork personnel and the participants will not be masked to Intervention Group assignment. This is because participants in the Intervention Group will receive eyeglasses at the start of the trial and members of the Control Group will receive theirs at the end. All care will be taken to ensure that the investigators who are not involved in fieldwork will be kept masked, and they do not foresee conditions that will require emergency unmasking.|THRIFT is a randomised controlled trial (RCT) that employs an explanatory embedded mixed methods design whereby the RCT is the primary study, and the secondary or embedded approach is a mixed-methods investigation of the culture and context surrounding the trial. The basic RCT design employs individual OAA and WA beneficiary-households in digitised safety-net catchment areas as the unit of randomization. The study uses a two-arm RCT design, one treatment and one control arm. Only households with an eligible participant who does not personally own a smartphone or feature phone and .access DFS through any phone during the time of the trial. The duration of the RCT is 12 months. The trial will be investigator masked.|f|f|t|f
33782936|NCT04777071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782937|NCT01268761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782938|NCT05633771|||COHORT||PROSPECTIVE|||||||
33782939|NCT06614621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997965|NCT05863026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Allocation concealment In this study, the allocation concealment method that will be use is the sequentially numbered, opaque, sealed enveloped methods.~This study will use the single blinding method in which the respondent will not be aware of their group status."|This is a two-arm randomised, single blinded, controlled, parallel, trial. This study will recruit and randomise school children into intervention group and control group based on selected school to avoid contamination.|t|f|f|f
33997966|NCT01328782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33997967|NCT01872676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33997968|NCT04563260|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33694056|NCT05227144|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Interval 3+3 dose escalation design, followed by dose expansion||||
33694057|NCT05147428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study design will be a prospective, randomized, open-label educational intervention trial with three arms: (1) a combined patient/caregiver and provider educational intervention; (2) a provider only educational intervention; and (3) usual care."||||
33694058|NCT03730012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997969|NCT01023113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087912|NCT03197636|||COHORT||RETROSPECTIVE|||||||
33782940|NCT03716167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33782941|NCT02760862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33782942|NCT04332276|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34087913|NCT04017377||SEQUENTIAL||TREATMENT||NONE||||||
33782943|NCT00875628|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34087914|NCT05066984|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter stepped-wedge cluster randomized controlled trial||||
33782944|NCT01395264|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33782945|NCT03554187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782946|NCT03465111|RANDOMIZED|PARALLEL||TREATMENT||NONE||"ATLAS is an Investigator-initiated, open-labelled, multi-center, randomized, phase II clinical trial, to evaluate the effect of two dose regimens of subcutaneous ACTH gel in subjects with non-infectious anterior scleritis. Thirty (30) subjects with non-infectious anterior scleritis will be enrolled and randomized (1:1) at their first visit to one of the two treatment arms:~1. Mandatory 80 U twice weekly treatment with SC ACTH gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria.~2. Mandatory 80 U thrice weekly treatment with SC ACTH gel, starting at the Baseline visit (Day 0) until end of week 16. Starting at week 17, the treatment will be administered on as needed basis, based on the retreatment criteria."||||
33782947|NCT03281343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33782948|NCT01702896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782949|NCT00074685|||COHORT||RETROSPECTIVE|||||||
33782950|NCT01671475|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33782951|NCT03978117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33782952|NCT04864561|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|study participants aged 18-29 years at the time of enrolment are unblinded, study participant aged 12-18 and 30 years above at the time of enrolment are blinded (sentinel group is unblinded) until 28 days after vaccination on day 208, when all participants will be unblinded.||t|f|t|t
33782953|NCT00530777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782954|NCT06508099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782955|NCT00823589|NON_RANDOMIZED|PARALLEL||||NONE||||||
33782956|NCT04209387|||COHORT||PROSPECTIVE|||||||
33782957|NCT04764617|||COHORT||CROSS_SECTIONAL|||||||
33782958|NCT00051311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782959|NCT04391309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo consists of identical-appearing diluent|Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
33782960|NCT06052982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33782961|NCT02493790|||COHORT||PROSPECTIVE|||||||
33782962|NCT04559308|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is an open-labeled, parallel, randomized controlled trial||||
33782963|NCT02476643|||COHORT||PROSPECTIVE|||||||
33782964|NCT05435885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782965|NCT01212016|||COHORT||PROSPECTIVE|||||||
33782966|NCT05955690|||OTHER||CROSS_SECTIONAL|||||||
33782967|NCT03967743|||CASE_ONLY||PROSPECTIVE|||||||
33782968|NCT03024541|||COHORT||PROSPECTIVE|||||||
33782969|NCT06330402|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33782970|NCT01855308|||COHORT||PROSPECTIVE|||||||
33782971|NCT05835050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33782972|NCT02729324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782973|NCT01113229|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33782974|NCT05997979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"There is no mock cutaneous patch available for capsaicin 8% cutaneous patch. So we have chosen hydrocolloid dressing for placebo since it has no known effect on neuropathic pain and the tolerability is expected as excellent.~The patient should not be aware of the specific aspect of capsaicin 8% patch and the protocol of application will be exactly the same. This should keep the patient blinded for the study treatment.~The nurse who applies the patch is unblinded."|"Multicentric randomized controlled superiority trial in parallel arms:~* experimental arm : Capsaicin 8% cutaneous patch~* control arm : Hydrocolloid dressing"|t|f|f|f
33782975|NCT06359002|NA|SEQUENTIAL||TREATMENT||NONE||||||
33782976|NCT01577043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33782977|NCT01288638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33782978|NCT05047094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782979|NCT06302062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782980|NCT06403644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|To prevent possible bias between the sham and active conditions, both groups will receive light filtering glasses (to control for light perception), noise-cancelling headphones, and be in a controlled temperature room.|Participants will have two 3-week periods of treatment with a washout week in-between treatment. Participants will be randomized to either sham PBM treatment or active PBM treatment first.|t|f|f|f
33782981|NCT04543344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only cohort 1 of the study is blinded.||t|f|t|f
33782982|NCT03269396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782983|NCT04880070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33782984|NCT02955862|NA|SINGLE_GROUP||SCREENING||NONE||||||
33782985|NCT06615674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial and Double Blind (Researcher \&amp;amp;amp;amp;amp;amp;amp;amp; Patients)|t|f|t|f
33782986|NCT01217580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33782987|NCT01567059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33782988|NCT00347659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33782989|NCT06614023|||COHORT||RETROSPECTIVE|||||||
33782990|NCT01792609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33782991|NCT02425319|||COHORT||PROSPECTIVE|||||||
33917790|NCT00075153|||COHORT||RETROSPECTIVE|||||||
33782992|NCT05149014|||COHORT||OTHER|||||||
33782993|NCT06020417|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison between the use or not of neuronavigation for corrective surgery of spinal deformity||||
33782994|NCT05235061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33782995|NCT03796494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782996|NCT04423731|||COHORT||PROSPECTIVE|||||||
33782997|NCT02005666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33782998|NCT06614413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33782999|NCT04216303|||COHORT||RETROSPECTIVE|||||||
33783000|NCT00240643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33783001|NCT04848909|NA|SINGLE_GROUP||TREATMENT||NONE||men diagnosed with prostate cancer post-prostatectomy||||
33783002|NCT01939860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783003|NCT06614530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783004|NCT05153915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783005|NCT06711471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783006|NCT03361592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were initially instructed about the study procedures with therapeutic interventions. After collected data, the participants were asked about the therapeutic intervention, if they are capable to identify which intervention were performed, SMT or SHAM, as parte of study protocol.|randomized controlled single-blinded study.|f|f|f|t
33783007|NCT05490043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783008|NCT05328505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783009|NCT03332966|||COHORT||PROSPECTIVE|||||||
33783010|NCT05597098|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33783011|NCT05157334|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Sub-project 1: Randomized crossover study Sub-project 2: Randomized parallel Sub-project 3: Single groupe||||
33783012|NCT06614283|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and Investigators are blinded.|Two-arm randomized control trial|t|f|t|f
33783013|NCT06018129|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783014|NCT03342924|NA|SINGLE_GROUP||OTHER||NONE||||||
33783015|NCT05057754|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33783016|NCT00126113|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33783017|NCT05091762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33917791|NCT00592553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917792|NCT04356417|||COHORT||OTHER|||||||
33917793|NCT05294003|||COHORT||RETROSPECTIVE|||||||
33917794|NCT01773096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917795|NCT00118508|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33917796|NCT02729948|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33917797|NCT06398106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33917798|NCT03642080|||CASE_ONLY||PROSPECTIVE|||||||
33917799|NCT00693680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917800|NCT01382836|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33917801|NCT05153798|||COHORT||PROSPECTIVE|||||||
33917802|NCT01023438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33917803|NCT00575094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917804|NCT03497429|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33917805|NCT03335618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33917806|NCT03805581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917807|NCT03691753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917808|NCT04721067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study outcomes will be analyzed and compared by blinded investigators and statisticians.||f|f|f|t
33917809|NCT02685891|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33917810|NCT01827930|RANDOMIZED|PARALLEL||TREATMENT||NONE||"IM concentration \< 1000ng/mL Randomized Cohort : adapted strategy versus standard strategy / IM concentration \>= 1000ng/mL Parallel Cohort: standard strategy"||||
33917811|NCT05938777|NA|SEQUENTIAL||PREVENTION||NONE|The study participants will be masked from the proposed intervention.|||||
33917812|NCT01757405|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917813|NCT06403891|||CASE_CONTROL||PROSPECTIVE|||||||
33917814|NCT02242227|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33917815|NCT01146249|||COHORT||PROSPECTIVE|||||||
33917816|NCT04900038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The dose level of GSK3640254 in each of the treatment arms containing GSK3640254 was blinded to the research participants and all study personnel during the study through the Week 24 primary endpoint.|This is a randomized, parallel-group study.|t|f|t|f
33917817|NCT04786548|NA|SINGLE_GROUP||OTHER||NONE||||||
33917818|NCT01573013|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33917819|NCT00012012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33997970|NCT05539937|||COHORT||PROSPECTIVE|||||||
34087915|NCT02640560|||CASE_CONTROL||RETROSPECTIVE|||||||
34087916|NCT04933565|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34087917|NCT01184872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087918|NCT04103710|||OTHER||CROSS_SECTIONAL|||||||
34087919|NCT04192682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087920|NCT03320044|||CASE_ONLY||PROSPECTIVE|||||||
34087921|NCT04884568|NA|SINGLE_GROUP||TREATMENT||NONE||Single group of patients||||
34087922|NCT00942851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783018|NCT04847648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical assessments will be performed by assessors unaware of group allocation. Bone level changes over time will be assessed on radiographs and expressed in mm by examiners blinded to group allocation.|The project will be conducted as a two-armed randomized controlled clinical trial of 5-year duration in three clinical centers.|f|f|t|t
33694059|NCT04180722|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research coordinator that is consenting the patient and doing the intervention allocation will be different than the research coordinator assessing the outcomes. The outcomes assessor will remain blinded as to whether the participant has received the intervention or not|Multicenter, prospective 12 months, 7-centre, pragmatic, parallel group, randomized controlled trial with 1:1 allocation of individuals (children and adults) newly transitioning to Home Mechanical Ventilation (HMV) in Ontario that compares a virtual transition intervention to usual care provided by specialist HMV programs.|f|f|f|t
33694060|NCT05942859|||COHORT||OTHER|||||||
33783019|NCT00320866|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33783020|NCT03032159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33783021|NCT06055075|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783022|NCT00601640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783023|NCT03315221|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33783024|NCT05898139|||OTHER||PROSPECTIVE|||||||
33783025|NCT04438915|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The doctor who ask the MMS is not informed about the design of the study .||f|f|t|f
33783026|NCT00288769|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33783027|NCT00660374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783028|NCT06384053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783029|NCT03057561|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Blinded reader of scans will not know whether subject received Dotarem or Gadovist.|Evaluating the efficacy of Dotarem enhanced MRI compared to Gadovist enhanced MRI in identifying myocardial fibrosis. Patients will be randomized (in a 1:1 fashion) to receive either Dotarem or Gadovist for LGE-CMR such that there will be 60 patients in the Dotarem cohort and 60 patients in the Gadovist cohort|f|f|f|t
33783030|NCT06630416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783031|NCT02600429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783032|NCT01649427|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33917820|NCT04580030|||COHORT||PROSPECTIVE|||||||
33917821|NCT03051724|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33917822|NCT06006312|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33917823|NCT04265170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917824|NCT06483763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33917825|NCT05797454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917826|NCT03550638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917827|NCT01706549|||COHORT||PROSPECTIVE|||||||
33917828|NCT01479166|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33917829|NCT05165979|||COHORT||PROSPECTIVE|||||||
33917830|NCT01519063|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33917831|NCT05685576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917832|NCT06419517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participants, principal investigator). To improve the effect of blindness, participants were informed that the trial intended to compare the effects of two Electrical Stimulation (ES) methods for Stress Urinary Incontinence (SUI)|Multicentric Prospective Clinical Trial with two parallel arms|t|f|t|f
33917833|NCT03863236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33917834|NCT03596658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917835|NCT02453009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917836|NCT04350229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917837|NCT01733901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917838|NCT02156232|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917839|NCT03899532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087923|NCT03736720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694061|NCT05560204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694062|NCT01587352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694063|NCT04870034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694064|NCT00430430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694065|NCT02484690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694066|NCT03191240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33783033|NCT05823636|||COHORT||PROSPECTIVE|||||||
33783034|NCT04282746|NA|SEQUENTIAL||OTHER||NONE||||||
33694067|NCT03605927|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33694068|NCT01712646|RANDOMIZED|PARALLEL||TREATMENT||||||||
33694069|NCT04173377|||COHORT||OTHER|||||||
33694070|NCT05481138|||COHORT||PROSPECTIVE|||||||
33694071|NCT06190951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694072|NCT03274687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694073|NCT01843595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694074|NCT06378125|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33694075|NCT02210468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694076|NCT02774746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694077|NCT06703281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator who measures the diaphragmatic excursions and spirometric parameters would be blind to the block type performed.||f|f|f|t
33694078|NCT00040261||||TREATMENT||||||||
33694079|NCT03858478|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study, single arm, multicentric, national||||
33694080|NCT05967143|||COHORT||PROSPECTIVE|||||||
33783035|NCT04661215|||CASE_CONTROL||PROSPECTIVE|||||||
33783036|NCT03979742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783037|NCT06001684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783038|NCT03506490|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33783039|NCT02939001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783040|NCT05155397|||COHORT||PROSPECTIVE|||||||
33783041|NCT03591289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will not be informed to which NMB depth they were randomized to.|two different regimens (doses) of two drugs (Rocuronium, Sugammadex)|t|f|t|t
33783042|NCT04695080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783043|NCT06505837|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|Parallel||||
33783044|NCT05067192|||CASE_CONTROL||PROSPECTIVE|||||||
33917840|NCT04089813|||COHORT||PROSPECTIVE|||||||
33783045|NCT00917254|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33783046|NCT02669225|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33783047|NCT05913440|||COHORT||RETROSPECTIVE|||||||
33783048|NCT03985579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33783049|NCT04340115|||COHORT||PROSPECTIVE|||||||
33783050|NCT05896306|||OTHER||PROSPECTIVE|||||||
33783051|NCT05203055|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783052|NCT05654649|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33783053|NCT06444347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917841|NCT00972829|RANDOMIZED|PARALLEL||TREATMENT||||||||
33917842|NCT04198324|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Closure of the hysterotomy at the time of primary cesarean section|t|f|f|t
33917843|NCT00917306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917844|NCT03744130|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33917845|NCT01583452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33917846|NCT04248192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783054|NCT03647475|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, single arm trial enrolling eligible subjects in the United States and Japan. Subjects will remain in the study with follow-up clinical assessments through 2 years, study exit, or death, whichever comes first.||||
33783055|NCT04689503|||COHORT||PROSPECTIVE|||||||
33917847|NCT01083082|||OTHER||CROSS_SECTIONAL|||||||
33917848|NCT04065373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917849|NCT03317574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694081|NCT06475118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694082|NCT02647437|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33694083|NCT06521658|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Only the doctor and nurses performing the colonoscopy will not be masked to the intervention|1:1 randomisation|t|f|t|t
33694084|NCT05941559|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multiple-baseline single-case experimental design (SCED) across three time series. Participants will be randomized to one of the three time series. Within the time series the start of the intervention is randomly determined. Four participants will be assigned to the shortest, three to the medium and three to the longest baseline length. The SCED study consists of a baseline phase (A1), intervention phase (B), post-treatment phase (A2), follow-up phase 1 (A3), and follow-up phase 2 (A4).||||
33694085|NCT06431373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694086|NCT06623656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694087|NCT06709781|NON_RANDOMIZED|CROSSOVER||OTHER||NONE|No masking is required as each subject will be exposed to the cooling modality and the control (non-cooling) trial.|"The investigators will conduct a randomized crossover design study.~Burn survivors (20% or more burn surface area) and non-burned individuals will perform 60-min of exercise in the heat on two occasions - one being a control (no cooling trial) and one with the implementation of the cooling modality (combination of water spray and a fan)."||||
33694088|NCT02891161|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694089|NCT01413477|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33694090|NCT05554939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783056|NCT06493929|||COHORT||PROSPECTIVE|||||||
33783057|NCT02096003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783058|NCT05365386|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center, Prospective, Open Label, with Before-After Study Design.||||
33783059|NCT01262495|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783060|NCT06613945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783061|NCT01151254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33783062|NCT03984747|||OTHER||PROSPECTIVE|||||||
33783063|NCT06704217|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33783064|NCT06614244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783065|NCT03381391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33783066|NCT00083421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33917850|NCT03016026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917851|NCT03524105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33917852|NCT06090383|||COHORT||PROSPECTIVE|||||||
33694091|NCT06660888|||COHORT||PROSPECTIVE|||||||
33694092|NCT06333821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is double-blind and will blind both the investigator and the subjects. All participants in the study (including data managers and biostatisticians) will be unaware of treatment assignment (except blind statisticians).|This is a multicenter prospective, randomized, double-blind, placebo-controlled phase III trial|t|f|t|f
33694093|NCT05684939|||COHORT||CROSS_SECTIONAL|||||||
33694094|NCT02690883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694095|NCT06330129|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33694096|NCT05591131|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33694097|NCT02296918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783067|NCT03422510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783068|NCT06690398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783069|NCT01796665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694098|NCT00539669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694099|NCT03710772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694100|NCT06455085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33694101|NCT05350592|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||2x2|t|t|t|t
33694102|NCT00773929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783070|NCT02855827|||COHORT||OTHER|||||||
33783071|NCT00003372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783072|NCT05708820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33783073|NCT06298188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783074|NCT05897788|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"Patients enrolled into the Way to Health CareConnect text line as part of usual care and meeting eligibility criteria will be enrolled in this randomized control trial and randomized to: Augmented usual care, standard Way to Health CareConnect text line Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week. Augmented usual care + text-message check-ins, standard Way to Health CareConnect Text line Patients can call or text the on-call substance use navigators (SUN) from 9a-9p, 7 days a week AND (text-message check-ins) patients will receive automated text-message check-ins up to once per day for 30 days to see if the patient needs help with anything.~Augmented usual care + contingency management (standard Way to Health CareConnect Text line) and, participants will be compensated for going to their follow-up appointments."||||
33783075|NCT06458101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783076|NCT00577629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783077|NCT03433274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783078|NCT04071080|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33783079|NCT03687385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesiologist who interviews and examines patients scheduled for colonoscopy under analgo-sedation will enroll eligible participants and will offer procedure explanation and possibility to sign uniformed written consent. Unique personal hospital admission number (UPHAN) will be assigned to all eligible participants. After that, they will be randomized to control or intervention group by using random numbers generator. Anesthesiologist who implements anesthesia will receive nontransparent envelope with assigned intervention provided by independent investigator and will not decide which participant will receive LFNO or HFNO. However, attending anesthesiologist and participants will unavoidably be aware of type of oxygenation applied. Investigator who collects data after procedure will be unaware of study protocol and will enter data to formatted database. Participants' data will be noted under UPHAN. Outcome assessors will be unaware of intervention applied.|"We plan to conduct prospective, parallel group, randomized controlled clinical trial.~In total, 126 participants will be included in this trial. These participants are patients scheduled for outpatient colonoscopy in analgo-sedation.~This study includes 126 normal weight patients of anesthesia risk ASA class I, II or III divided in three groups of 42. Each group will be divided in control subgroups of 21 patients who will receive low-flow nasal oxygenation (LFNO) and intervention subgroups of 21 patients who will receive high-flow nasal oxygenation (HFNO) during standardized intravenous analgo-sedation."|f|f|t|t
33783080|NCT06231082|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33783081|NCT06169241|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Treatment with beetroot extract powder - nutritional supplementation|t|t|t|t
33783082|NCT04401722|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|OUTCOME ASESSOR|it is a multicenter study Aseer centeral hospital, saudia and from Egypt two centers mansoura university and el menia university The patients distributed into two groups group I (G1) PD underwent in the area at the level of the sea, normal altitude region, and group II (G2) PD underwent in high altitude region.|f|f|f|t
33783083|NCT04955795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33917853|NCT03215524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917854|NCT06341179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917855|NCT06509724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917856|NCT01413841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33917857|NCT02997384|||COHORT||PROSPECTIVE|||||||
33917858|NCT04309669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917859|NCT03102216|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Investigator-initiated, Prospective, Randomised, Control Trial||||
33694103|NCT04609072|||COHORT||PROSPECTIVE|||||||
33917860|NCT06084338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917861|NCT05078073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917862|NCT02379754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917863|NCT02190682|||CASE_ONLY||PROSPECTIVE|||||||
33917864|NCT02512744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694104|NCT04469426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694105|NCT06525311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694106|NCT05026008|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33694107|NCT06686056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694108|NCT01454427|||COHORT||PROSPECTIVE|||||||
33694109|NCT05919043|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33694110|NCT03152032|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants attended the vocational training program.||||
33694111|NCT04704843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694112|NCT06273631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783084|NCT06592443|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||f|f|t|t
33783085|NCT02091063|NA|SEQUENTIAL||TREATMENT||NONE||||||
33997971|NCT04416750|NA|SINGLE_GROUP||TREATMENT||NONE||The highest tolerated dose of Imatinib determined using a Bayesian continual reassessment method. In the first part, 13 patients were recruited sequentially by protocol at a minimum of 4 week intervals. Each patient was administered a dose of imatinib between 100mg and 400mg daily. The selected dose for each patient was based upon the safety and tolerability of doses administered to preceding recruits using a Bayesian continuous reassessment method. The inclusion of patients with implanted monitoring devices allowed us to collect data on an early efficacy marker alongside data on safety and tolerability. With a small extension, we gained further data on the effect of imatinib on cardiopulmonary haemodynamics and activity in PAH patients, covering the full 100mg to 400mg dose range.||||
33783086|NCT00003195||||TREATMENT||||||||
33783087|NCT05201248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694113|NCT06144697|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33694114|NCT03378375|||COHORT||RETROSPECTIVE|||||||
33694115|NCT06142383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will receive either active XXB750 injection or a placebo injection that looks identical to the active injection. Sacubitril/valsartan will be administered in an open-label fashion||t|f|t|f
33694116|NCT02534818|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33694117|NCT05338294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783088|NCT06268925|NA|SINGLE_GROUP||TREATMENT||NONE||14 people with knee osteoarthritis will be recruited and conducted group classes through zoom||||
33783089|NCT03494738|||COHORT||PROSPECTIVE|||||||
33783090|NCT03971357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783091|NCT06452407|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33783092|NCT06221774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694118|NCT05374460|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33783093|NCT04895878|||CASE_ONLY||RETROSPECTIVE|||||||
33783094|NCT06614556|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33783095|NCT00256139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33783096|NCT01338064|||||CROSS_SECTIONAL|||||||
33783097|NCT04978363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"All participants will complete all six testing conditions, including:~1. BOOT (walking boot)~2. HFC + BOOT (Hands Free Crutch with the walking boot)~3. SAC + BOOT (Standard Axillary Crutches with the walking boot)~4. NONE (no device/baseline)~5. HFC NO BOOT (Hands Free Crutch with no walking boot) and~6. SAC NO BOOT (Standard Axillary Crutches with no walking boot).~The order of the four primary conditions will be randomized using an online random number generator (1-4) with:~1=NONE, 2=BOOT only, 3=HFC+BOOT, and 4=SAC+BOOT."||||
33783098|NCT05513690|RANDOMIZED|PARALLEL||TREATMENT||NONE||Amnioinfusion for intrapartum risk factors for neurologic morbidity versus no amnioinfusion.||||
33783099|NCT03680014|||COHORT||PROSPECTIVE|||||||
33783100|NCT03917212|||CASE_CONTROL||PROSPECTIVE|||||||
33783101|NCT06193330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783102|NCT05792046|||COHORT||PROSPECTIVE|||||||
33783103|NCT03433638|||COHORT||RETROSPECTIVE|||||||
33783104|NCT04151121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research staff conducting the outcome follow-up will be blinded to the randomization.|Simple 1:1 randomization.|f|f|f|t
33783105|NCT05707182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783106|NCT02743663|||COHORT||PROSPECTIVE|||||||
33783107|NCT02697721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783108|NCT01197885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694119|NCT05395663|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The care providers are the OSU Extension Service agents serving as the navigators in the intervention arm and the Oregon Health Authority as the usual care arm. They will not know participants assigned to the other arms. Biostatistician will evaluate the effectiveness of the intervention without knowing the condition of the participants.||f|t|f|t
33694120|NCT06708806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Intra-individual comparison of the biocompatibility of two different IOLs. Investigated IOLs will be implanted subsequently according to the study protocol with one IOL type in the eye with no astigmatism and the other IOL type in the eye with astigmatism.||||
33783109|NCT05077631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783110|NCT01759121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783111|NCT01824836|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783112|NCT01218919|||COHORT||PROSPECTIVE|||||||
33783113|NCT05923658|||COHORT||PROSPECTIVE|||||||
33783114|NCT05806138|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single center, open-label, randomized controlled trial of vericiguat in adult patients with breast cancer and Cancer Therapy-Related Cardiac Dysfunction (CTRCD).||||
33783115|NCT02485964|NA|SINGLE_GROUP||OTHER||NONE||||||
33783116|NCT05039619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783117|NCT04707794|||COHORT||PROSPECTIVE|||||||
33783118|NCT06406140|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized into two groups each group includes 25 patients:~Control group: 25 patients will receive their standard therapy only. Intervention group (niacin group): 25 patients will receive niacin 500 mg per day with their standard therapy for 3 months."||||
33783119|NCT04529057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3-arm parallel trial|t|f|f|t
33783120|NCT04474600|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33783121|NCT06152783|||CASE_CROSSOVER||PROSPECTIVE|||||||
33783122|NCT04414722|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33783123|NCT02487719|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33783124|NCT06484140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33783125|NCT00920374|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783126|NCT05370989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33783127|NCT02138916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33783128|NCT02153788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783129|NCT04095923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783130|NCT05104762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind (participant and investigator, accessor) using closed envelope 2:1 was applied. 5 sessions of plasmapheresis: IVIG 0.4g IVIG/Kg /day for 5 consecutive days. The investigators didn't know what was the type of treatment that patients received and the patient didn't know that there is another line of treatment.|2 groups of patients with Guillian Barrie syndrome were subjected to plasmapheresis or IVIG by percentage 2:1 respectively according to availability of IVIG|t|f|t|t
33783131|NCT06617065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783132|NCT02942056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694121|NCT05936385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33694122|NCT06145906|||COHORT||PROSPECTIVE|||||||
33694123|NCT03989414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694124|NCT04245462|||OTHER||CROSS_SECTIONAL|||||||
33783133|NCT03968887|||COHORT||PROSPECTIVE|||||||
33783134|NCT05785247|||COHORT||PROSPECTIVE|||||||
33783135|NCT05119933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783136|NCT05736367|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33917865|NCT03761719|||COHORT||PROSPECTIVE|||||||
33917866|NCT02748941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783137|NCT05980793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysts will be masked for treatment allocation|A parallel group, two-arm, randomized, controlled trial.|f|f|f|t
33783138|NCT04382677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783139|NCT00002589||||TREATMENT||||||||
33917867|NCT03379506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917868|NCT00002386||||TREATMENT||||||||
33917869|NCT04212858|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33917870|NCT04528797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917871|NCT06041295|NA|SINGLE_GROUP||OTHER||NONE||||||
33917872|NCT02106988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917873|NCT03712345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917874|NCT06390917|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33917875|NCT04020094|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, open label, single arm phase II trial.||||
33917876|NCT02222389|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33917877|NCT04186468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Group allocation will be masked during analysis of the primary outcome. Masking and unmasking will be done by a Trust Center by coding both groups.|The treatment group will supported by activities of an ICU follow-up clinic. The control group will receive usual care.|f|f|f|t
33917878|NCT04696874|||COHORT||CROSS_SECTIONAL|||||||
33917879|NCT05766228|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A Randomized Controlled, Multicenter Study||||
33917880|NCT04846166|||CASE_CONTROL||PROSPECTIVE|||||||
33917881|NCT06007339|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, multicentre, single-arm study to investigate the safety and efficacy of the PerQseal Elite.||||
33917882|NCT06187623|||CASE_CONTROL||PROSPECTIVE|||||||
33917883|NCT05231174|NA|SINGLE_GROUP||OTHER||NONE||||||
33917884|NCT02822911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917885|NCT02387619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33917886|NCT00220766|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33917887|NCT05562284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917888|NCT05318105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917889|NCT02303171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33917890|NCT01924052|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33917891|NCT00835419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917892|NCT02231294|||COHORT||PROSPECTIVE|||||||
33917893|NCT04674839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33917894|NCT00253318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917895|NCT02405429|||COHORT||CROSS_SECTIONAL|||||||
33917896|NCT02930603|||COHORT||PROSPECTIVE|||||||
33917897|NCT05657782|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33917898|NCT01769261|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33917899|NCT00016393||||TREATMENT||NONE||||||
33917900|NCT01177267|||CASE_CONTROL||RETROSPECTIVE|||||||
33917901|NCT04314596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-Blind, parallel, randomized, placebo-controlled trial.|t|f|t|t
33917902|NCT05097248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917903|NCT02898519|||COHORT||PROSPECTIVE|||||||
33917904|NCT00011479||||TREATMENT||||||||
33917905|NCT02421744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917906|NCT01451684|||CASE_ONLY||PROSPECTIVE|||||||
33917907|NCT02123550|||COHORT||PROSPECTIVE|||||||
33917908|NCT04831515|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33917909|NCT01315847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917910|NCT03077763|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33917911|NCT01277562|||CASE_CONTROL||PROSPECTIVE|||||||
33917912|NCT00868452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33917913|NCT01295580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigational product was masked from study staff and participants with the exception of the unblinded treating investigator conducting the intra-articular injections.||t|t|t|t
33694125|NCT06044311|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a phase 2, single-arm, Simon two-stage design. 15 participants will be enrolled in the first stage, with the potential of expanding to an additional 10 participants.||||
33694126|NCT05642637|||COHORT||PROSPECTIVE|||||||
33917914|NCT04694105|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double blind both anesthetist and patient not aware about type of local anesthesia|Parallel Assignment|t|t|f|f
33917915|NCT01028833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917916|NCT01404442|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33917917|NCT02345824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917918|NCT04260828|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33917919|NCT03448861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33917920|NCT04417504|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33917921|NCT03539861|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917922|NCT01999946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917923|NCT05072717|NA|SINGLE_GROUP||OTHER||NONE||||||
33917924|NCT02445599|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33917925|NCT04865250|NA|SINGLE_GROUP||TREATMENT||NONE|open label|Exploratory, open-label, non-randomized, single treatment, phase II study||||
33997972|NCT00508651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33997973|NCT02955628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997974|NCT02032316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997975|NCT02966782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087924|NCT03136575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|patients who signed inform consent are randomized into qigong group and wait-list control (WLC)|randomized controlled trial|t|f|f|f
33694127|NCT00486551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33694128|NCT05625893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694129|NCT06080412|||OTHER||PROSPECTIVE|||||||
33694130|NCT06097299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694131|NCT05976347|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive either an Selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI), and patients who are not interested in taking medication for their symptoms will be enrolled in an observational arm.||||
33694132|NCT00000328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33694133|NCT04180085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783140|NCT04555330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The allocation of participants will be done in 8 waves at each of the participating wards. At each hospital ward, 4 of the waves will be allocated to the control group and 4 to the intervention group. The order of the conditions is randomised.~A participant will be assigned to the wave that the ward is allocated to at the time of admission.~The wave size for each ward is set to 10 patients.~Assignment of the waves at each department will be determined before any recruitment by means of Latin square randomisation in 2 blocks of 4 waves at the 4 participating wards."||||
33783141|NCT02215798|||COHORT||PROSPECTIVE|||||||
33917926|NCT00077519||||TREATMENT||||||||
33917927|NCT01286948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33917928|NCT01650818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33917929|NCT04258046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087925|NCT05107037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087926|NCT03530696|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087927|NCT05218876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person performing all analyses on muscle tissue (primary outcome) is masked for intervention applied to the individuals and timepoint. The person doing the physical test is not masked.||f|f|f|t
34087928|NCT05859230|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34087929|NCT04742218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33694134|NCT06624358|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Principal investigator and Clinical Care providers will be masked to intervention. Research Coordinator will not be masked|A computerized random number generated by the Way to Health platform will assign children to 1 of 16 study conditions for a 12-week intervention period. The study conditions differ with respect to: personalized exercise plan(on vs off), step goals (ramp-up vs fixed), financial incentive (on vs off), and personalized feedback (on vs off). Our design includes one constant: all participants need to self-monitor their physical activity by wearing the FitBit to allow for daily capture of moderate to vigourous physical activity and step counts. The intervention period is therefore designed to test the effectiveness of 4 components, each with two levels, using a factorial design.|f|t|t|f
33694135|NCT06535919|||COHORT||PROSPECTIVE|||||||
33694136|NCT04175054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to group allocation, and will not be involved in conducting the training intervention.|This is an assessor-blinded Randomized Controlled Trial.|f|f|f|t
33694137|NCT05271630|||COHORT||PROSPECTIVE|||||||
33694138|NCT04926831|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997976|NCT05429944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinded (or masked) studies are those in which the subjects, and possibly the investigators as well, are unaware of which treatment the subject is receiving, e.g., active drug or placebo. Blinding is particularly important in drug trials when the study is assessing subjective outcomes, such as relief of pain or anxiety.~It isn't always possible to mask the treatments. For example, subjects randomly assigned to follow either a specific exercise regimen or continue their usual level of activity cannot be blinded.~Single-blinded: the subjects are unaware of which group they have been assigned to.~Double-blinded: Neither the subjects nor the investigators are aware of the treatment assignment until the end of the trial."||t|f|t|f
33997977|NCT03118687|||COHORT||PROSPECTIVE|||||||
33997978|NCT04345133|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|No informaron about sequence of drilling was used to insert the implants|Comparative|t|f|f|f
33694139|NCT03708185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Doubly-blinded \& randomised using an online randomisation website.||t|f|t|f
33694140|NCT04078178|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Participants were randomized into 2 Treatment sequences, one starting with Placebo followed by Niagen; and the other sequence starting with Active Niagen and followed by Placebo.|t|t|t|t
33694141|NCT03564691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arms are parallel, except that participants who progress by either clinical or radiographic evaluation on monotherapy with MK-4830 (Dose Escalation, Part B), may switch over into the combination therapy arm of MK-4830 and pembrolizumab (Dose Escalation, Part C), provided they meet eligibility criteria. All arms are non-randomized except Dose Expansion Arms E and F, with randomization of eligible participants between those two arms.||||
33694142|NCT01225107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33694143|NCT00001443||||TREATMENT||||||||
33694144|NCT06707116|||COHORT||CROSS_SECTIONAL|||||||
33694145|NCT03282565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694146|NCT04755244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694147|NCT05396807|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients, male and female, age ≥18 years, with WT (wild type) and RAS mutated (mut) affected by mCRC.||||
33694148|NCT04401605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694149|NCT03965208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783142|NCT03783455|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, controlled, randomized and prospective study.||||
33997979|NCT03822130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997980|NCT05131516|||COHORT||PROSPECTIVE|||||||
33997981|NCT05595980|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33997982|NCT04020796|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||randomized, crossover, placebo-controlled||||
33997983|NCT05394194|||OTHER||PROSPECTIVE|||||||
33997984|NCT05303441|||OTHER||PROSPECTIVE|||||||
33997985|NCT04298216|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33997986|NCT06089330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997987|NCT03142022|||COHORT||PROSPECTIVE|||||||
33997988|NCT00845130|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33997989|NCT06004973|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34087930|NCT00557141|||COHORT||PROSPECTIVE|||||||
34087931|NCT02015078|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087932|NCT00761878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087933|NCT03861039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694150|NCT04662580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study has dose-escalation (Phase 1a) and dose-expansion (Phase 1b) stages to identify the maximum tolerated dose (MTD) and/or recommended development doses (RDDs) of ARX517. The initial treatment regimen is by weight-based infusion at an interval of every 3 weeks. In the Phase 1b dose expansion stage, the Sponsor will evaluate cohorts with alternative dose regimens to determine RDD(s). The term alternative dose regimen refers to any monotherapy treatment regimen where ARX517 is not given at a fixed interval of every 3 weeks.~In the Phase 1b dose expansion stage, the Sponsor will also evaluate the safety and preliminary anti-tumor activity of ARX517 in combination with ARPIs (apalutamide or abiraterone acetate plus prednisone). ARPIs will be administered at the approved doses per product information. The starting dose of ARX517 to be given in combination with ARPIs will be determined by data emerging from the monotherapy dose expansion stage."||||
33997990|NCT03519139|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33997991|NCT05285865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694151|NCT04191395|||COHORT||PROSPECTIVE|||||||
33694152|NCT02723994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694153|NCT06324630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694154|NCT00975520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694155|NCT06706934|||CASE_CONTROL||RETROSPECTIVE|||||||
33694156|NCT06701630|||OTHER||PROSPECTIVE|||||||
33694157|NCT06710496|||OTHER||RETROSPECTIVE|||||||
33694158|NCT01690637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694159|NCT06706804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694160|NCT06707662|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study arm will be defined by randomization immediately before the implantation. Patients randomized to RVAP group will undergo an apex ventricular lead. In patients receiving a LBBAP CSP lead, the procedure will be anatomicaly guided, aiming for a W pattern in V1 during septal maping. Operators then will screw the lead, aiming for a moderate drop in the impedance, together with the conversion of the W pattern into a qR or rSR pattern in lead V1. The current of injury (COI) will be additionally used as a guide. The cornerstone of this study will be to accept the first location as the final location, as long as unipolar and bipolar thresholds are optimal, and the RBBB pattern in lead V1 remains. To ensure a balanced distribution between LBBP and LVSP, the first operator will not have access to any criteria measurement during the implant procedure, but the morphology in V1. After the procedure investigators will fulfill the Redcap database with all the banned EPRS measurements."||||
33694161|NCT06543615|||COHORT||CROSS_SECTIONAL|||||||
33694162|NCT05452772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694163|NCT06143774|NA|SINGLE_GROUP||TREATMENT||NONE||Dose-finding Study using 3+3 design.||||
33783143|NCT03918018|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33783144|NCT03107702|||CASE_ONLY||PROSPECTIVE|||||||
33783145|NCT03161522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783146|NCT00797862|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33997992|NCT02454595|||COHORT||PROSPECTIVE|||||||
33997993|NCT05736250|||OTHER||CROSS_SECTIONAL|||||||
33997994|NCT05515458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33997995|NCT05183282|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33783147|NCT06356142|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33783148|NCT03597308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783149|NCT06711523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783150|NCT00172614|||DEFINED_POPULATION||PROSPECTIVE|||||||
33783151|NCT05008341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783152|NCT05201768|||CASE_CONTROL||PROSPECTIVE|||||||
34087934|NCT01781247|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783153|NCT05052411|NA|SINGLE_GROUP||PREVENTION||NONE||We will enroll 50 MSM for a total of 1 month.||||
33783154|NCT05392426|||COHORT||PROSPECTIVE|||||||
33997996|NCT00467805|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33997997|NCT04831242|||COHORT||PROSPECTIVE|||||||
33997998|NCT02004769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33997999|NCT01309958|||COHORT||CROSS_SECTIONAL|||||||
33998000|NCT01926353|||COHORT||RETROSPECTIVE|||||||
33998001|NCT01736839|||COHORT||PROSPECTIVE|||||||
33998002|NCT03559738|||CASE_ONLY||PROSPECTIVE|||||||
33998003|NCT01404351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998004|NCT01083329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33998005|NCT03100019|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33998006|NCT01608984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998007|NCT03599583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||RCT study design will test the impact of the prompts intervention to reduce missed opportunities and raise HPV vaccine rates.||||
33998008|NCT04763161|||CASE_CONTROL||PROSPECTIVE|||||||
33998009|NCT02043392|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33998010|NCT02244762|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33998011|NCT01085539|||CASE_ONLY||PROSPECTIVE|||||||
33998012|NCT01030796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998013|NCT01093560|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33998014|NCT00564031|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33998015|NCT02195401|||COHORT||PROSPECTIVE|||||||
33998016|NCT01246453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087935|NCT00832975|||CASE_ONLY||PROSPECTIVE|||||||
34087936|NCT02585206|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Phase I: full factorial design of four factors each with 2 levels (16 arms); Phase II: 2-arm randomized trial|t|f|f|f
34087937|NCT01563679|||||PROSPECTIVE|||||||
34087938|NCT06102551|||COHORT||RETROSPECTIVE|||||||
34087939|NCT00959751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087940|NCT04075149|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomized cross-sectional, before and after intervention||||
34087941|NCT02638532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998017|NCT03163160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998018|NCT04142996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Both participants and research team members conducting the interviews and the TBS treatment will be blinded to the TBS treatment condition. In the unilateral arm, the right-sided stimulation will be applied with the placebo side of the coil. In the bilateral arm, the right-sided stimulation will be applied with the active side of the coil. As such, all participants will receive a total of 4 minutes of daily TBS. The master randomization list was created by a scientist of the research centre that is not involved in the research project.~The patient's study identification (ID) code is entered into the device and a software-controlled switch then automatically selects the active or the sham coil for stimulation. The electronic positioning sensor built in the coil for monitoring the coil orientation checks against the entered patient's study ID and will enable the device and start the treatment procedure only if the coil orientation is matching the patient's study ID value."||t|t|t|f
33998019|NCT03015376|||COHORT||PROSPECTIVE|||||||
33998020|NCT00870116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087942|NCT02159638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998021|NCT02620137|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998022|NCT01896479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998023|NCT00496990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998024|NCT02666482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087943|NCT02859298|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34087944|NCT02738502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087945|NCT00919672|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34087946|NCT03851289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34087947|NCT01170650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087948|NCT04632121|||COHORT||PROSPECTIVE|||||||
34087949|NCT03667287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087950|NCT02362022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34087951|NCT02754453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694164|NCT06513624|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will undergo screening procedures to determine eligibility within 28 days prior to the initial administration of ETC-159 in combination with pembrolizumab. ETC-159 in combination with pembrolizumab will be administered in 21-day cycles (1 cycle: 21 days). ETC-159 will be dosed every other day. Pembrolizumab will be dosed IV Q3W. Tumor response assessments will be done every 6 weeks (2 cycles) prior to starting the cycle starting at C3D1 (- 7 days) until C9D1 (- 7 days); thereafter every 12 weeks (4 cycles) starting at C13D1 (- 7 days) and at EOT, until disease progression or start of another anti-cancer therapy according to RECIST v1.1.||||
33694165|NCT02325310|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33694166|NCT06710756|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694167|NCT06710483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783155|NCT04094012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783156|NCT01439425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783157|NCT00868205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33783158|NCT06038071|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33783159|NCT04440228|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33783160|NCT06054789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783161|NCT00462943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917930|NCT03097224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917931|NCT03861195|||CASE_CONTROL||PROSPECTIVE|||||||
33917932|NCT02383680|||COHORT||PROSPECTIVE|||||||
33917933|NCT02418533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917934|NCT04574921|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33917935|NCT04170777|||CASE_CONTROL||PROSPECTIVE|||||||
33917936|NCT06048406|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes Assessor will not know the intervention status of the participants.||f|f|f|t
33917937|NCT06502405|||COHORT||PROSPECTIVE|||||||
33917938|NCT05267912|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* ORGANOTREAT-01: advanced, pretreated colorectal cancer (CRC).~* ORGANOTREAT-02A: advanced, pretreated solid tumors of low-to-intermediate incidence and/or with a patient tumor-derived organoid (PDO) take-on rate \<50%.~* ORGANOTREAT-02B: advanced, pretreated solid tumors with a PDO take-on rate ≥50%."||||
33917939|NCT01824173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33917940|NCT01246856|||COHORT|||||||||
33917941|NCT05538117|||CASE_ONLY||RETROSPECTIVE|||||||
33917942|NCT00304317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33917943|NCT00970957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917944|NCT00494364|||COHORT||PROSPECTIVE|||||||
33694168|NCT06626243|||COHORT||RETROSPECTIVE|||||||
33694169|NCT05293964|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694170|NCT06683339|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694171|NCT06708169|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33694172|NCT06688058|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33694173|NCT04568993|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial||||
33694174|NCT03511196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694175|NCT02213926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694176|NCT05970718|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33783162|NCT06421974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783163|NCT04002362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783164|NCT03701464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783165|NCT01576510|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33783166|NCT03959098|||CASE_ONLY||PROSPECTIVE|||||||
33783167|NCT04378179|||COHORT||PROSPECTIVE|||||||
33783168|NCT06613997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"A 2-group, randomized, double-blind, parallel clinical trial:~* albendazole 400 mg daily for 21 consecutive days~* Placebo, daily for 21 consecutive days"|t|t|t|t
33783169|NCT03350321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783170|NCT00699933|||COHORT||PROSPECTIVE|||||||
33783171|NCT01947075|||COHORT||PROSPECTIVE|||||||
33783172|NCT01557556|||||PROSPECTIVE|||||||
33917945|NCT01148316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917946|NCT02496481|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33917947|NCT00300001|||DEFINED_POPULATION||PROSPECTIVE|||||||
33783173|NCT06714331|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Separate investigator mixes the caffeine or sodium bicarbonate mixture solution. Other investigators conducting the data collection are blinded to the supplement or control mixture.|randomized, double-blind, placebo-controlled, cross-over study design with 1 intervention (supplements) with 3 arms (caffeine, sodium bicarbonate, control placebo).|t|f|t|t
33783174|NCT06470204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917948|NCT03709524|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33917949|NCT03946826|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33917950|NCT02807363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998025|NCT05832957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998026|NCT04479982|||OTHER||PROSPECTIVE|||||||
33998027|NCT04985435|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized open label trial||||
33998028|NCT02050321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998029|NCT00253838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998030|NCT01782937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998031|NCT00974350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998032|NCT00757172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783175|NCT03516149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All of participants must be healthy.|There are 2 groups. Study group will receive foam rolling exercise. Control group will receive no foam rolling exercise. They will be handed a brochure about the proprioception and its role in injury prevention and foam rolling . Study group will be evaluated before foam rolling exercise . Afterwards, second evaluation will be performed after exercise at the same day. Control group will be evaluated for the first time. Afterwards, second evaluation will be performed after resting period (2 minutes) at the same day.|t|f|f|f
33783176|NCT04783415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783177|NCT01151033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783178|NCT04895306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783179|NCT05380232|||COHORT||PROSPECTIVE|||||||
33783180|NCT00147654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33783181|NCT02824289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783182|NCT06439576|||COHORT||PROSPECTIVE|||||||
33783183|NCT04018664|NON_RANDOMIZED|CROSSOVER||OTHER||TRIPLE|"For each dosing cohort, an unblinded statistician, not otherwise involved in the study, will prepare a list of subject randomization numbers. These randomization numbers will be used to prepare individual subject doses. Sealed qualification code break envelopes will be available for each subject in case of emergency.~Upon completion of each cohort of subjects, the randomization codes for the completed subjects will be unblinded by the CRU pharmacy. After unblinding, the safety data will be reviewed to determine if dosing can proceed for the next planned dosing cohort,"|"Single-dose, randomized, double-blind, active- and placebo-controlled, double-dummy, 2-part, 7-way crossover study.~Part A: Dose selection phase Part B: Treatment Periods 1-7"|t|t|t|f
33783184|NCT05696730|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the kind of intervention and the organizational structure of the study centre, neither patients nor assessors can be blinded, but data analysts will be blinded to group assignment.|Participants are randomly assigned to either the control or intervention group.|f|f|t|f
33783185|NCT03739008|||CASE_ONLY||RETROSPECTIVE|||||||
33783186|NCT00151619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33783187|NCT06649604|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Only the collaborator who will analyse the data will be masked, due to the manifest presence or absence of the vibratory device for both the clinician and the patient.|All patient are their own control, using laser in both eyes, but only one using the Vibration Anesthesia Device.|f|f|f|t
33783188|NCT05060471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783189|NCT05127395|||OTHER||RETROSPECTIVE|||||||
33917951|NCT05167461|||CASE_CROSSOVER||PROSPECTIVE|||||||
33917952|NCT00756886|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33917953|NCT04693689|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33917954|NCT03383978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917955|NCT02867449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33917956|NCT04557254|||COHORT||RETROSPECTIVE|||||||
33917957|NCT05596903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Control Group (3) vs EMDR 2.0 Group Intervention (3)|t|f|f|f
33917958|NCT01452555|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33917959|NCT01080937|||COHORT||PROSPECTIVE|||||||
33917960|NCT00913133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917961|NCT05511675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33917962|NCT05225220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917963|NCT05091892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||2 equal groups|t|f|t|f
33917964|NCT03446651|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33917965|NCT01850862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917966|NCT02764983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917967|NCT05484180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|In the data collection process, double-blindness was provided by not specifying which group the interviewer was collecting data from and which group participants were in.|Randomization was done with 68 people. Simple randomization method was used in order to assign 68 people included in the study to the experimental and control groups in an unbiased manner. For randomization, a sample pool of people included in the study was created. Randomization was done in computer environment using https://www.random.org/ website. The women in the experimental and control groups were determined according to the order obtained. In this way, 34 individuals were included in the experimental group and 34 individuals in the control group.|t|t|t|t
33917968|NCT01555905|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33917969|NCT01911013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917970|NCT00522002|||COHORT||PROSPECTIVE|||||||
33694177|NCT05482542|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694178|NCT06710821|NA|SINGLE_GROUP||TREATMENT||NONE||Irinotecan liposome combined with temozolomide and vincristine||||
33917971|NCT00066118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33694179|NCT04137237|||COHORT||OTHER|||||||
33694180|NCT03594435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two-Arm, Randomized, Double-Blind, Placebo-Controlled|t|t|t|f
33694181|NCT04317105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694182|NCT06310213|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Aim 1: Comparison of neonates and infants with hydrocephalus and without Aim 2: Using smart soft contact lens (SSCL) for pre- and post-operative measurements on neonates and/or infants managed operatively (shunt placement) Aim 3: Direct validation by comparing SSCL to external ventricular drain (EVD) intracranial pressure (ICP) monitoring Aim 4: Using SSCL for pre- and post- reservoir tap measurements on neonates and/or infants managed operatively (reservoir placement) Aim 1: 10 patients per arm, two arms Aim 2: 5-10 patients, one arm Aim 3: 5-10 patients, one arm Aim 4: 5-10 patients, one arm||||
33783190|NCT00607516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783191|NCT04953910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783192|NCT06154226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33783193|NCT05695989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783194|NCT02443792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783195|NCT00630864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783196|NCT06542250|NA|SEQUENTIAL||TREATMENT||NONE||"The study consists of individual modules each evaluating the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD5492 as monotherapy or in combination with other anticancer treatments in participants with R/R B-cell malignancies.~- Module 1: AZD9592 Monotherapy"||||
33783197|NCT03569969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33783198|NCT06120751|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33783199|NCT05617339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The groups are predetermined based on the tool randomizer.org and blinded to the researcher assigning the participants to groups.||t|t|f|f
33783200|NCT05372003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917972|NCT01568424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917973|NCT04377334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917974|NCT01448915|||COHORT||PROSPECTIVE|||||||
33917975|NCT06159348|||COHORT||PROSPECTIVE|||||||
33917976|NCT00914758|||CASE_CONTROL||PROSPECTIVE|||||||
33917977|NCT00243113||||TREATMENT||NONE||||||
33917978|NCT05646446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33998033|NCT05290519|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33998034|NCT02123823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783201|NCT06707935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783202|NCT00870350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33783203|NCT00001532|||CASE_CONTROL||PROSPECTIVE|||||||
33783204|NCT01872611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783205|NCT04318080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33917979|NCT05174130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||15 patients in stable phase and 15 patients in weaning phase||||
33917980|NCT01313520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917981|NCT00478725|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33917982|NCT04315480|NA|SINGLE_GROUP||TREATMENT||NONE|Radiologist will be blinded for sequence|Simon's Two-stages Optimal Design||||
33998035|NCT04179396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998036|NCT02342509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33998037|NCT03926650|||CASE_CONTROL||PROSPECTIVE|||||||
33998038|NCT00525746|||CASE_CONTROL||PROSPECTIVE|||||||
33998039|NCT00620958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998040|NCT02313545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998041|NCT05198505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998042|NCT05501158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a prospective cohort study involving the breast cancer patients who participated in our previous study. Patients who are recommended to adjust their tamoxifen dosage to 40 mg and remain on tamoxifen 20 mg will be all followed up for 3 years to evaluate the clinical outcomes and medication side effects||||
33783206|NCT05806554|||COHORT||PROSPECTIVE|||||||
33783207|NCT03742843|||CASE_CONTROL||PROSPECTIVE|||||||
33783208|NCT06614205|||COHORT||RETROSPECTIVE|||||||
33783209|NCT03477110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783210|NCT03123640|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Not possible to mask the intervention|Randomized controlled trial With intervention Group and Control group||||
33783211|NCT03918577|RANDOMIZED|CROSSOVER||OTHER||SINGLE||randomized, controlled crossover study|f|f|f|t
33783212|NCT06630793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783213|NCT06112704|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33917983|NCT00238303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998043|NCT00259194|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998044|NCT04544527|||COHORT||PROSPECTIVE|||||||
33783214|NCT06701825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will remain blinded to arm assigned because pharmacogenetic phenotype and tacrolimus dose-guidance will only be exclusively accesible to the attending physician|Phase IV, multicentre, controlled, randomized, parallel and single-blind adaptive clinical trial nested within the iPHARMGx master protocol study|t|f|f|f
33783215|NCT06712069|NA|SINGLE_GROUP||PREVENTION||NONE||"The interventional study in my work , titled The Usefulness of Multimodal Intraoperative Neurophysiologic Monitoring During Brain or Spine Surgeries, employs a single-group, prospective observational design to evaluate the efficacy of Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) in preventing postoperative neurological deficits. Below are the key elements of the study model:~Interventional Study Model :~Design:~Type: Interventional, Prospective Observational Single Group Assignment: All participants undergo the same intervention using MIONM during their neurosurgical procedures.~No Control Group: The outcomes of MIONM use are directly compared with expected standards of care based on existing literature"||||
33783216|NCT04452591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783217|NCT06091436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783218|NCT06058637|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Research assistants who will perform the measurements after randomisation will be masked.||f|f|t|f
33783219|NCT06614946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||There are 2 arms: ESP only and ESP with text-based program. The ESP with text-based program arm includes twice daily (within-person) randomizations.|f|f|f|t
33783220|NCT06382142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783221|NCT05452941|||CASE_CONTROL||PROSPECTIVE|||||||
33783222|NCT05318014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783223|NCT02058914|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33783224|NCT01642264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33783225|NCT06365554|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33998045|NCT03313895|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33998046|NCT01917227|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33998047|NCT01715779|||COHORT||PROSPECTIVE|||||||
33998048|NCT04792723|NA|SINGLE_GROUP||TREATMENT||NONE||single-dose, two-treatment, two-period, two-sequence, randomized, crossover design||||
33783226|NCT00006265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998049|NCT01927380|||COHORT||PROSPECTIVE|||||||
33783227|NCT01461356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783228|NCT06631573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783229|NCT00112723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783230|NCT00563277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783231|NCT03084861|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label||||
33783232|NCT06360718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783233|NCT00852475|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783234|NCT04155892|||COHORT||PROSPECTIVE|||||||
33783235|NCT04953702|||COHORT||PROSPECTIVE|||||||
33783236|NCT06500572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33783237|NCT04892810|||COHORT||PROSPECTIVE|||||||
33783238|NCT06427603|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33783239|NCT02499289|||COHORT||PROSPECTIVE|||||||
33783240|NCT00279474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783241|NCT04750629|||OTHER||PROSPECTIVE|||||||
33998050|NCT02516189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33998051|NCT04863144|||CASE_ONLY||PROSPECTIVE|||||||
33998052|NCT02395809|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33998053|NCT06454214|||CASE_ONLY||PROSPECTIVE|||||||
33998054|NCT06144398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998055|NCT05461716|||CASE_CROSSOVER||PROSPECTIVE|||||||
33998056|NCT04262245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998057|NCT03563443|||CASE_CONTROL||PROSPECTIVE|||||||
33998058|NCT02687958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998059|NCT04200872|||COHORT||RETROSPECTIVE|||||||
33998060|NCT00944190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998061|NCT01957280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998062|NCT05092035|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||3 Groups, two control Groups (smokers and non-smokers), one COPD group, one ILD group|t|f|f|f
33998063|NCT01151618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998064|NCT03082586|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|open label|||||
33998065|NCT00246792|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33783242|NCT04311203|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and researchers will not be blinded to treatment allocation due to the nature of the study.|The study is a multi-centred, two-arm clustered randomised controlled trial. Organisations will be randomly allocated to the control or intervention. The intervention is the standard MHFA intervention provided by Mental Health First Aid England (MHFAE). The control condition will be organisations having a brief consultation from MHFAE on promoting mental health and well-being in the workplace.||||
33783243|NCT05557422|||COHORT||CROSS_SECTIONAL|||||||
33783244|NCT05759221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783245|NCT03208556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783246|NCT05515367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783247|NCT03344289|RANDOMIZED|PARALLEL||PREVENTION||NONE||An international, multicenter, parallel randomized controlled trial.||||
33998066|NCT00694044|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33998067|NCT03292705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor will be blinded to the group assignment. The participants will be informed to avoid discussing their intervention activities at the post-training and follow up assessments.|A single-blinded, multi-site (4 SLCs) randomized controlled trial of PEP+CCI, vs. control + CCI is involved. For PEP+CCI group, PEP will be implemented for the first 4 weeks, and CCI for the following 6 weeks. For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks. Assessments will be conducted by our research team. Separate staff blind to group assignment will conduct post-training and follow-up assessments. All intervention and assessments will occur in private rooms in relevant SLCs.|f|f|f|t
33998068|NCT02845336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694183|NCT06708026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and the researcher who will enroll in the intervention process and conduct the qualitative interview will not be blinded. The data analyst and the baseline and outcome assessor will be blinded from the group assignment.|We aim to have two study groups. Forty-six participants will be randomized into the intervention group, receiving an 8-week AOMI intervention combined with basic wheelchair exercises, or the control group, receiving basic wheelchair exercises with the same duration, number of sessions, and frequency as the intervention group.|f|f|f|t
33694184|NCT06705907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694185|NCT06508489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694186|NCT03003611|||CASE_CONTROL||PROSPECTIVE|||||||
33694187|NCT04728867|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||prospective, randomized, blinded study|t|f|f|f
33694188|NCT02394678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694189|NCT00132353|||OTHER||OTHER|||||||
33694190|NCT06509334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694191|NCT05231668|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33694192|NCT06710717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694193|NCT01588249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694194|NCT05515471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||SHR8058 eye drops compared with placebo|t|f|t|t
33694195|NCT02212899|||CASE_ONLY||PROSPECTIVE|||||||
33694196|NCT00154492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694197|NCT06085547|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will be unaware of their assignment to a general versus rural-targeted condition.|This study will use a two-group design (Video tutorial: general versus rural-targeted). Half of White rural participants will receive general video education/messaging and half of White rural participants will be assigned to an intervention condition that includes rural-targeted information about SARS-CoV-2 antibody testing.|t|f|f|f
33694198|NCT03810339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694199|NCT05650567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694200|NCT03471065|NA|SINGLE_GROUP||TREATMENT||NONE||SAPIEN 3 Ultra System||||
33694201|NCT05736783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694202|NCT02169973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694203|NCT00606944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694204|NCT06614829|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel between group study||||
33783248|NCT04374318|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double blinded||t|t|t|t
33783249|NCT03218956|NA|SINGLE_GROUP||OTHER||NONE||||||
33801467|NCT04138394|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Allocation will be random and concealed and will be blinded to everyone except the pharmacist at each site. The vitamin C will be sourced locally and prepared in a blinded manner by local research pharmacies that will be responsible for preparing study samples and delivering them to the ICU in a blinded fashion. The randomization system, which has proven reliable in several prior RCTs, has a robust audit trail, and will maintain concealment and blinding.|Patients will be allocated to receive intravenous vitamin C at 50mg/kg, every 6 hrs for 96 hrs or placebo. We justify this proposed dosing strategy as the proposed dose of vitamin C has been shown to be safe and effective in patients with sepsis and lung injury whereas prior dosing strategies used in the burns literature (66 mg/kg/24 hours) have safety issues and are not long enough in duration. Control group: patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.|t|t|t|t
33998069|NCT00954408|||CASE_ONLY||CROSS_SECTIONAL|||||||
33998070|NCT00879164||||SUPPORTIVE_CARE||||||||
33998071|NCT00052923|RANDOMIZED|||TREATMENT||||||||
33998072|NCT05015595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998073|NCT00884390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998074|NCT05493163|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicentre, randomized, active-controlled, unblinded, parallel-group study to evaluate clinical outcomes in patients with intermediate-high risk acute PE undergoing CDT in comparison to standard anticoagulation therapy.||||
33998075|NCT03764657|||CASE_CONTROL||PROSPECTIVE|||||||
33998076|NCT05028855|||COHORT||PROSPECTIVE|||||||
33998077|NCT04207333|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be exposed to mental stress following either 20 min or 120 min sitting||||
33998078|NCT01103882|||COHORT||PROSPECTIVE|||||||
33998079|NCT04803162|||COHORT||PROSPECTIVE|||||||
33998080|NCT05812625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998081|NCT01225510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998082|NCT04871308|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33998083|NCT01714141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087952|NCT06329167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087953|NCT05112978|||OTHER||CROSS_SECTIONAL|||||||
34087954|NCT06408766|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694205|NCT06660277|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:3 or 1:1 (Expanded HD : Conventional High-Flux HD) ratio, depending on their study site.||||
33694206|NCT05581953|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blinding will be implemented to the extent possible. A researcher, unaware of the study goals and not involved with downstream data analyses will use a 1:1 block randomization to allocate participants to the diets in the first arm. Food service personnel (care provider) will not be aware of study goals and allocations. Metabolomic assays will be run in a blinded manner.||f|t|f|t
33694207|NCT04250155|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694208|NCT06099782|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694209|NCT03436810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|f|t
33694210|NCT06365060|||COHORT||PROSPECTIVE|||||||
33694211|NCT05217927|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33694212|NCT05957367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694213|NCT05628883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694214|NCT05086978|||COHORT||PROSPECTIVE|||||||
33694215|NCT03956056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694216|NCT06596005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694217|NCT04371315|||OTHER||PROSPECTIVE|||||||
33783250|NCT04028674|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|"The blinded procedures include PIF, CAPE-V, NGA, X-Tol.~* PIF: A research staff member will be unblinded and control the pacer programmer. The testing condition will be programmed prior to start of test. Both patient and staff administering the test will be blinded to testing condition.~* CAPE-V: Clinically-certified SLPs involved in perceptual ratings of voice quality will be blinded to experimental testing condition and data collection timepoint.~* NGA: NGA is analyzed from stills of the glottis collected during endoscopy. These images will be randomized and de-identified before analysis to blind the rater.~* X-Tol: A research staff member will be unblinded and control the pacer programmer. The testing condition will be programmed prior to start of test. Both patient and staff administering the test will be blinded to testing condition."|"Following implantation of the laryngeal pacing device and post-operative visit, participants will be randomized to their treatment group (Early Activation vs. Delayed Activation) and unilateral stimulation side (Right PCA vs. Left PCA) using the REDCap randomization module.~1. To treatment group at a 1:1 ratio-Either the Early Activation Group (n=4) or the Delayed Activation Group (n=4)~2. To unilateral stimulation side at a 1:1 ratio-The side for unilateral stimulation will be either the left PCA muscle (n=4), or the right PCA muscle (n=4)"|f|f|f|t
33783251|NCT04426487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33783252|NCT05425797|RANDOMIZED|PARALLEL||OTHER||SINGLE||We will study two experimental groups (telephone and video) compared to the control group of in-person BETTER intervention delivery. Mode of delivery will be randomized between patients. If it is not feasible yo offer all three (e.g. PP only has capacity to offer virtual appointments, study population lives greater than 30 minutes travel from PP location), a subset of the three will be offered.|f|f|t|f
33783253|NCT06481735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801468|NCT06334913|||COHORT||PROSPECTIVE|||||||
33801469|NCT05836116|||CASE_CONTROL||PROSPECTIVE|||||||
33694218|NCT06647849|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study will be single-blind. The patient will not know the intern's level of training (trained or untrained).||t|f|f|f
33801470|NCT05910411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801471|NCT01306786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998084|NCT06312462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This model evaluates the effectiveness of schistosomiasis health education led by community health volunteers by training the volunteers on Pemba Island and having them conduct health education for local students. It also discusses the feasibility of promoting this model in Africa.||||
33998085|NCT00609557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33998086|NCT03545334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The surgeons performing SLNB will be the blinded persons. The results of the lymphoscintigraphy will not be marked on the patient's skin as usual and no preoperative access to the images will be granted to the surgeons.|A diagnostic sensitivity study comparing intradermal indocyanine green (ICG) and near infrared fluorescence imaging (NIRFI) with intradermal technetium 99m and traditional lymphoscintigraphy (LS) for transcutaneous identification of sentinel lymph nodes (SLN) in malignant melanoma - a prospective Phase II clinical study in a single center.||||
33998087|NCT01880476|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33998088|NCT02155257|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33998089|NCT03279250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694219|NCT02459652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694220|NCT01764425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694221|NCT06709638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694222|NCT04548648|NA|SINGLE_GROUP||TREATMENT||NONE||Simon Two-stage study to a pilot study.||||
33694223|NCT06572241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694224|NCT06091579|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34087955|NCT03341520|NA|SINGLE_GROUP||TREATMENT||NONE||Open, non-controlled, national multi-center phase II trial||||
33801472|NCT05027607|||COHORT||OTHER|||||||
33801473|NCT06221436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled (experimental and control group)|t|f|f|f
33998090|NCT04599842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33998091|NCT03980522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998092|NCT00393250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998093|NCT00397735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087956|NCT01348243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087957|NCT01603160|||||PROSPECTIVE|||||||
34087958|NCT03062371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087959|NCT03456934|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Prospective, randomized, double-blind with nonrandomized breast-fed reference group|t|t|t|t
34087960|NCT02025608|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34087961|NCT01998360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087962|NCT02295137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34087963|NCT03186352|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Sample for microbiological evaluation is to be taken from each patient before and after intervention (PAD). Before-After Study Type.||||
34087964|NCT06228976|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34087965|NCT06470581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087966|NCT03998631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34087967|NCT02353780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34087968|NCT02179619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34087969|NCT04042792|||COHORT||PROSPECTIVE|||||||
34087970|NCT04265001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical outcomes were assessed by an investigator masked about the treatment modality that has been used||f|t|f|t
34087971|NCT03535181|||COHORT||RETROSPECTIVE|||||||
34087972|NCT03088397|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087973|NCT00083915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087974|NCT03526705|NA|SINGLE_GROUP||OTHER||NONE||||||
34087975|NCT02335853|||CASE_ONLY||CROSS_SECTIONAL|||||||
34087976|NCT04582526|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34087977|NCT03037242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087978|NCT00382356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087979|NCT01869374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Electroconvulsive Therapy / Magnetic Seizure Therapy|t|t|f|t
33694225|NCT00089323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694226|NCT00984373|||||PROSPECTIVE|||||||
33694227|NCT02545075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694228|NCT00573248|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33694229|NCT03448055|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Nutritional supplemetation with Immunocal 20gm daily for 6 months (180 days)||||
33694230|NCT03988413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694231|NCT04962646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective, randomized, controlled, patient- and reviewer blinded interventional study.|t|f|f|t
33694232|NCT03029273|NA|SINGLE_GROUP||TREATMENT||NONE||"One arm, open label, dose escalation, single dose phase I study of safety and tolerability.~NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.~Patients, who receive an infusion of TAEST16001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment.~Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."||||
33694233|NCT05546918|||OTHER||CROSS_SECTIONAL|||||||
33694234|NCT03491943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694235|NCT02808871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998094|NCT06465654|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The participant will wear a high flow nasal canula for oxygen treatment during both endurance shuttle walk tests, which will mask the mode of oxygen delivery and dose for both the participant and the assessor (investigator). A health care professional not involved in the data collection or outcome assessment will set up the equipment before each test to secure masking of the O2matic device and oxygen delivery mode.|In random order the participants will conduct the endurance shuttle walk test with either fixed dose oxygen treatment or automated oxygen titration treatment|t|t|t|t
33998095|NCT01783392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998096|NCT02874781|||COHORT||CROSS_SECTIONAL|||||||
34087980|NCT03246945|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Dermatologist providing remote diagnosis was blinded to whether parents were provided instructions, which phone they took and the diagnosis provided by the in-person dermatologist|Patient/parent dyads visiting a pediatric dermatology clinic were invited to participate. After consent, patient/parent dyads were randomly assigned to photography instruction versus no instruction. In both arms, parents photographed their child's skin condition (via smart phone) and provided medical history. Images were uploaded securely to the child's electronic health record for independent diagnosis by a dermatologist not involved in the patient's care.|f|t|t|f
34087981|NCT02952417|||COHORT||PROSPECTIVE|||||||
34087982|NCT03518684|RANDOMIZED|PARALLEL||PREVENTION||NONE||In this randomized controlled study, the patients will be randomly assigned to either Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel or Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous \[never delivered beyond 20 weeks of gestation in a previous pregnancy\] or primiparous or more). Based on our departmental statistics, \~90% of laboring patients receive epidural. Hence receiving an epidural will not have a major impact on the duration of the second stage of labor; yet, whether the patient received epidural or not will be adjusted for.||||
33694236|NCT01697358|RANDOMIZED|PARALLEL||TREATMENT||NONE||Period I (from randomization to 6 months) is the randomized parallel group comparative phase. Day zero for the study is the point of randomization. The randomization ratio is 1:1 (SCS+OMM to OMM). For the SCS+OMM arm, the screening test and/or implant occurred after randomization. Period II (6 to 24 months) is the long-term observational follow-up phase.||||
33694237|NCT04157621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694238|NCT06261268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled equivalence clinical trial will be performed, with two parallel groups, a 1:1 allocation ratio, and a 12-month follow-up.|f|f|f|t
33998097|NCT01336088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998098|NCT02426450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998099|NCT06110351|||COHORT||RETROSPECTIVE|||||||
34087983|NCT01570764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34087984|NCT03426904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087985|NCT01474343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087986|NCT05051163|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label parallel group randomized controlled trial||||
34087987|NCT00481039|||CASE_ONLY||RETROSPECTIVE|||||||
34087988|NCT02685930|||CASE_CONTROL||PROSPECTIVE|||||||
33694239|NCT01601431|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694240|NCT05889572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694241|NCT03052192|||COHORT||PROSPECTIVE|||||||
33694242|NCT01865084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694243|NCT00961766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694244|NCT00697073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694245|NCT03949985|||COHORT||PROSPECTIVE|||||||
33801474|NCT02814838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34087989|NCT06069362|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm clinical trial||||
34087990|NCT05635617|||COHORT||PROSPECTIVE|||||||
34087991|NCT02898467|||CASE_CONTROL||PROSPECTIVE|||||||
34087992|NCT05053867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34087993|NCT02193295|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34087994|NCT00706797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34087995|NCT02799524|||COHORT||PROSPECTIVE|||||||
33694246|NCT04460456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694247|NCT05249790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694248|NCT04098666|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|the study will be placebo controlled|randomized 1:1 placebo controlled double blinded|t|t|t|t
33694249|NCT05597670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional physical therapy treatment, but group (B) will receive additional proximal stability exercise.|t|f|t|t
33694250|NCT00890266|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33694251|NCT02526173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694252|NCT01932073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694253|NCT01133561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694254|NCT06602063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694255|NCT06482814|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33694256|NCT05633693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694257|NCT06710275|||COHORT||RETROSPECTIVE|||||||
33998100|NCT01953458|||COHORT||PROSPECTIVE|||||||
33998101|NCT04366635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998102|NCT04304417|||COHORT||CROSS_SECTIONAL|||||||
33998103|NCT01116505|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998104|NCT03024268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998105|NCT00866476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33998106|NCT02305134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998107|NCT03201003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998108|NCT04289805|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"3 groups:~* 113 patients in the standard-stimulated cohort,~* 113 patients in the letrozole-stimulated cohort,~* 339 patients in the non-stimulated cohort."||||
33998109|NCT00252564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694258|NCT06699342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694259|NCT00642473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694260|NCT03274271|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The different participants will receive different website links to the intervention website, according to their group. The link will not provide information about their group.|2x2x2 design with 3 behaviour change techiques provided or not provided|t|f|f|f
33694261|NCT02988154|||OTHER||PROSPECTIVE|||||||
33917984|NCT05005988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The outcome evaluator will be external to the intervention and will not know whether the mothers belong to the intervention or control group. This person will be trained and standardized in the handling of the instruments, will know the general elements of the study, and will ensure compliance with the ethical conditions established in the study.~Outcome evaluator will be informed at the time of applying the instruments and recording the information related to the variables of interest of the study and will verify the complete filling out of the instruments."|Single-blinded, parallel, randomized clinical trial. Mothers in the intervention group will receive a pre-discharge empowerment educational intervention, and the control group will receive the usual discharge preparation. Three 30-minute sessions will be conducted with each mother in the intervention group, the first during the first week after admission, the second session within 7 days after the second session, and the third 3 to 2 days before discharge. An induction to the out-of-hospital kangaroo program will also take place on the day of admission to the program. Mothers will receive a booklet with general care contents and empowerment information. Mothers in the control group will receive the usual preparation for discharge from the NICU. Response variables will be measured at three time points: At admission (baseline), before discharge and one week after the discharge.|f|f|f|t
33917985|NCT00607568|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33917986|NCT01650792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33917987|NCT04905875|||COHORT||OTHER|||||||
33917988|NCT02225574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694262|NCT03364790|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33694263|NCT04012918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694264|NCT02849665|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33694265|NCT01981759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33917989|NCT04970316|||COHORT||PROSPECTIVE|||||||
33917990|NCT00003026|RANDOMIZED|||TREATMENT||||||||
33694266|NCT05654441|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33694267|NCT06676488|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33694268|NCT06463574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a prospective randomized clinical trial with a follow up of 6 months. The clinical examiner and the participant will be kept unaware of the treatment being administrated.|A total of 20 patients will be selected and divided randomly into two main groups according to the type of composite used, the first group will use Surefil one self-adhesive bulk-fill composite for restoring 10 posterior class I cavities and the second group will use 3M Filtek One high viscosity bulk-fill composite for restoring 10 posterior class I cavities.|t|t|f|f
33694269|NCT02341105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801475|NCT05680389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801476|NCT02489695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917991|NCT03298191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|false preterm labour|complications ofthe drugs good response to drugs|t|f|f|f
33917992|NCT01935362|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33917993|NCT02210104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33917994|NCT05429177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33917995|NCT06278558|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33917996|NCT02719236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33917997|NCT03896880|||CASE_ONLY||PROSPECTIVE|||||||
33917998|NCT05978856|||OTHER||RETROSPECTIVE|||||||
33917999|NCT05625854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33918000|NCT04005196|||COHORT||PROSPECTIVE|||||||
33918001|NCT03544268|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Experimental: Acoustic Angiography||||
33918002|NCT00945074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918003|NCT01557218|RANDOMIZED|CROSSOVER||||NONE||||||
33918004|NCT02910544|||COHORT||PROSPECTIVE|||||||
33918005|NCT06483490|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33918006|NCT00637715|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918007|NCT04983719|||CASE_ONLY||PROSPECTIVE|||||||
33918008|NCT06079957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind study; in which only analyst will be blinded.|Both groups will be recruited concurrently. both groups will recieve treatment|f|f|f|t
33918009|NCT00393757|||||PROSPECTIVE|||||||
33918010|NCT04457414|||COHORT||PROSPECTIVE|||||||
33918011|NCT06134596|||COHORT||PROSPECTIVE|||||||
33918012|NCT01750632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918013|NCT01262612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918014|NCT00847938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918015|NCT01552824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918016|NCT01549223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694270|NCT00788398|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33694271|NCT05204732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694272|NCT04911413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694273|NCT06710093|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694274|NCT05495087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||IHT vs Sham-IHT Control|t|f|f|t
33694275|NCT00766883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694276|NCT05230459|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33694277|NCT04493333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The cytologist's reading specimens will be blinded.|Subjects are randomly assigned to the Intrarosa® or Replens™ arm by a 1:1 ratio. Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week). Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks.|f|f|f|t
33694278|NCT03549013|||COHORT||RETROSPECTIVE|||||||
33694279|NCT05794971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694280|NCT04253964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694281|NCT03079180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33694282|NCT00054717||PARALLEL||TREATMENT||||||||
33694283|NCT03024697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33694284|NCT03952637|NA|SEQUENTIAL||TREATMENT||NONE||||||
33694285|NCT03420417|NA|SINGLE_GROUP||OTHER||NONE||||||
33694286|NCT06707454|||COHORT||PROSPECTIVE|||||||
33783254|NCT03871998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research personnel responsible for conducting atopic dermatitis assessments during study follow-up visits will be blinded to the treatment allocation.|Single-centre, randomised, open-label, controlled study to evaluate whether short-term skin barrier protection using a moisturizer from birth to 2 months can prevent the onset of atopic dermatitis and food allergy at 12 months. Assessments of atopic dermatitis will be blinded.|f|f|f|t
33783255|NCT04708821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783256|NCT03625921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783257|NCT05239702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783258|NCT06329869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783259|NCT00810303|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33783260|NCT00828945|||CASE_ONLY||PROSPECTIVE|||||||
33783261|NCT00658411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33783262|NCT04865302|||COHORT||PROSPECTIVE|||||||
33783263|NCT03329833|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Participants will be aware which group they are assigned to. Study team members who will be providing assessments will be blinded to the condition the participant is in.|This study examines how a web-based application and/or motivational interviewing impact a participant's exercise routine compared to an educational control group.|f|t|f|t
33783264|NCT03677726|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive either a Mindfulness-based Therapy for Insomnia (MBTI) or a Sleep Hygiene Education Program (SHEP). The intervention is for 8 weeks. Measures will be administered prior to and on completion of the intervention.||||
33783265|NCT00248612|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33694287|NCT05417217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783266|NCT06214806|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Food delivered via Instacart versus comparator arm of food purchased in-person at Rouses Market||||
33783267|NCT05561855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918017|NCT00184782|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33918018|NCT05078606|||COHORT||PROSPECTIVE|||||||
33918019|NCT01206478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918020|NCT01479374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918021|NCT05663840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33694288|NCT05708846|||COHORT||PROSPECTIVE|||||||
33694289|NCT00381251|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33694290|NCT04620655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694291|NCT02942875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918022|NCT00250991|RANDOMIZED|||TREATMENT||DOUBLE||||||
33918023|NCT01006720|||||PROSPECTIVE|||||||
33918024|NCT04448262|||COHORT||PROSPECTIVE|||||||
33918025|NCT06553846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918026|NCT02260466|NA|SINGLE_GROUP||SCREENING||NONE||||||
33918027|NCT06152419|NA|SINGLE_GROUP||OTHER||NONE||A first video illustrating the general radiotherapy process was created with voice-over in Dutch and French. The video will be shown to 125 patients undergoing radiotherapy in 3 Flemish and 2 Walloon radiotherapy departments. Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information. Patients will be recruited at the first consultation at the radiotherapy department or at one of the first radiotherapy sessions. In addition, focus groups will be organised to assess whether this video meets the patients' needs. At least 25 patients at at UZ Gent will be invited to participate in 5 focus groups, each focus group concentrating on one of the 5 most frequent tumor groups. Based on the collected data, both a qualitative and quantitative. In a second phase, additional visual material will be created.||||
33918028|NCT02849314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918029|NCT00109304|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33918030|NCT05052541|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||One Main Arm is Crossover (Analgesia Arm) One Main Arm is Parallel (Reduction Arm)|t|f|t|t
33694292|NCT00664027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783268|NCT02190838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783269|NCT03494699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33783270|NCT04542824|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1: Sequential Assignment~Part 2: Parallel Group Assignment"||||
33783271|NCT01464294|||CASE_CONTROL||PROSPECTIVE|||||||
33783272|NCT02047786|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33783273|NCT06615336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783274|NCT06347315|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Randomized|parallel and pivotal|t|t|t|f
33783275|NCT00875641|||COHORT||OTHER|||||||
33783276|NCT05978661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801477|NCT00107159||||TREATMENT||NONE||||||
33694293|NCT05273970|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Recordings will be obtained from intracranial electrodes placed for clinical or approved research purposes during neurosurgical procedures, and/or thereafter, while patients are followed in the epilepsy monitoring unit (EMU). Electrodes approved for human use may be placed on the cortex or within subcortical structures. Recordings may be obtained during passive conditions and task-based recordings designed to study particular regions of interest will be carried out in the EMU, as well as passive without task performance.~Patients undergoing surgery for invasive functional brain mapping may also undergo electrical microstimulation in addition to neurophysiological recording. Stimulation is typically delivered in 2-5 second bursts (25-50 Hz, 0.3 ms pulse width, 1-15 mA). Recording and microstimulation may take place either intra-operatively and/or post-operatively in the EMU."||||
33694294|NCT06552247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm. Consecutive patients in a general ophthalmology consultation will be offered intervention||||
33694295|NCT00000656||||TREATMENT||NONE||||||
33918031|NCT00257491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918032|NCT01457001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918033|NCT00543907|||COHORT||RETROSPECTIVE|||||||
33998110|NCT03734354|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33998111|NCT00721162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998112|NCT01127087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998113|NCT04919785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998114|NCT01970592|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33998115|NCT03595254|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized waitlist controlled trial (first ?? participants) Open trial (following ?? participants)||||
33998116|NCT02829684|||COHORT||PROSPECTIVE|||||||
33783277|NCT05822440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Masking: None (open label)|||||
33783278|NCT04390464|RANDOMIZED|PARALLEL||TREATMENT||NONE||TACTIC-R is a randomised, parallel arm, open-label platform trial.||||
33783279|NCT03116204|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33783280|NCT01304147|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33918034|NCT04569916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918035|NCT06490198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918036|NCT05931744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918037|NCT02573376|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918038|NCT04205578|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33918039|NCT05059951|||COHORT||PROSPECTIVE|||||||
33918040|NCT00634114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918041|NCT04119817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, controlled, double blind study|t|t|f|f
33918042|NCT00000240||||TREATMENT||NONE||||||
33918043|NCT02979301|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918044|NCT03885089|||CASE_ONLY||OTHER|||||||
33918045|NCT02489565|RANDOMIZED|PARALLEL||||NONE||||||
33918046|NCT01599546|||COHORT||PROSPECTIVE|||||||
33918047|NCT05067686|||OTHER||CROSS_SECTIONAL|||||||
33918048|NCT00676936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33918049|NCT03830814|||CASE_ONLY||PROSPECTIVE|||||||
33918050|NCT04180800|||COHORT||PROSPECTIVE|||||||
33918051|NCT01604876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918052|NCT02056834|||COHORT||PROSPECTIVE|||||||
33918053|NCT03583372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918054|NCT01743599|||CASE_CONTROL||PROSPECTIVE|||||||
33918055|NCT03648307|||COHORT||RETROSPECTIVE|||||||
33918056|NCT00615251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918057|NCT01805141|||COHORT||CROSS_SECTIONAL|||||||
33918058|NCT03374384|||OTHER||CROSS_SECTIONAL|||||||
33918059|NCT01488942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918060|NCT05344625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918061|NCT02810652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918062|NCT02190747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918063|NCT01731613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33918064|NCT04689594|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918065|NCT03763903|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918066|NCT00063583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918067|NCT03986008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918068|NCT00219232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918069|NCT00236119|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918070|NCT06089668|||COHORT||PROSPECTIVE|||||||
33918071|NCT00003450||||TREATMENT||||||||
33918072|NCT03355794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998117|NCT01196949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998118|NCT04206462|||COHORT||PROSPECTIVE|||||||
33998119|NCT05965908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998120|NCT03828539|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33998121|NCT00991796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998122|NCT02044939|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998123|NCT03124758|NA|SINGLE_GROUP||OTHER||NONE||||||
33694296|NCT03029702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study team members assessing delivery outcomes will be masked to the participant's study assignment|Pilot randomized controlled study|f|f|f|t
33694297|NCT06421207|RANDOMIZED|PARALLEL||OTHER||NONE||Abdominoplasty model||||
33694298|NCT03367013|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694299|NCT03576222|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|intraoperative use of randomized dressing|PICO dressing prevents surgical site ocurrences after abdominal Wall repair|t|f|f|f
33694300|NCT00764491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694301|NCT04490811|||COHORT||RETROSPECTIVE|||||||
33694302|NCT06515522|||COHORT||RETROSPECTIVE|||||||
33694303|NCT02057393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783281|NCT05724173|NA|SINGLE_GROUP||OTHER||NONE||||||
33783282|NCT04609293|||CASE_ONLY||PROSPECTIVE|||||||
33783283|NCT05974709|||COHORT||CROSS_SECTIONAL|||||||
33801478|NCT00912600|||COHORT||PROSPECTIVE|||||||
33801479|NCT01892683|||COHORT||PROSPECTIVE|||||||
33918073|NCT01321840|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33918074|NCT02161497|||CASE_ONLY||PROSPECTIVE|||||||
33918075|NCT03737422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918076|NCT03722784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject will know the name of the lens however they will not be aware of which lens is investigational and which lens has been previously cleared. The licensed investigator has not been informed which lens is the investigational lens.||t|f|t|f
33918077|NCT04096352|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33918078|NCT05614713|RANDOMIZED|PARALLEL||TREATMENT||NONE||study group and control group||||
33918079|NCT04564430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33918080|NCT00041353||||SCREENING||||||||
33918081|NCT01477372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998124|NCT01344031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998125|NCT05812638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33998126|NCT02349763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33998127|NCT05053360|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998128|NCT04872777|RANDOMIZED|PARALLEL||TREATMENT||NONE|Forty-subjects with NASH will be randomized 1:1 to either receive Noom HW mHealth lifestyle intervention or standard clinical care.|||||
33801480|NCT03510676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998129|NCT03113227|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33998130|NCT05252195|||COHORT||PROSPECTIVE|||||||
33998131|NCT03443492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998132|NCT04828616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998133|NCT04749550|||OTHER||PROSPECTIVE|||||||
33998134|NCT00327145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998135|NCT02919462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998136|NCT02333162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998137|NCT01167439|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998138|NCT00491738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998139|NCT04600635|||COHORT||RETROSPECTIVE|||||||
33998140|NCT03485118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, single-blind, controlled, multicenter phase II study.|t|f|f|f
33998141|NCT00890864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998142|NCT01939535|||CASE_ONLY||PROSPECTIVE|||||||
33998143|NCT06486389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Supportive Care||||
34087996|NCT06190028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34087997|NCT04769297|NA|SINGLE_GROUP||TREATMENT||NONE||Retrospective, Open-label chart review||||
34087998|NCT06184282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918082|NCT06019910|NA|SEQUENTIAL||PREVENTION||NONE||At baseline, all participants use snus, and will be asked to quit their usage. They will then be followed for up to 12 weeks. If and when they relapse in snus use, another 12 weeks will commence, during which the same measurements will repeated but for a second period of up to 12 weeks.||||
33918083|NCT05123612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918084|NCT01079533|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
33918085|NCT00267397|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33918086|NCT03296787|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34087999|NCT02131688||PARALLEL||TREATMENT||NONE||||||
34088000|NCT06108921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33694304|NCT03376906|NA|SINGLE_GROUP||TREATMENT||NONE||"The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions in a random order, which were performed with a 96 h interval between them. In order to obtain the experimental session order, the researcher asked each subject to pick out random numbers that were inside an opaque envelope generated at www.randomizer.org.~Before the experimental sessions, subjects were instructed to maintain a regular sleep pattern, and to not consume alcohol, caffeine or xanthines (coffee, chocolate, soft drinks and tea), take medication or exercise in the 24 h prior to the experimental protocol sessions. In addition, they were duly instructed to fill out the food registry (food recall)."||||
33694305|NCT06626958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher performing the statistical analysis will not know which data is the experimental group and which is the control group.|randomized controlled experimental trial|f|f|f|t
33694306|NCT06084468|||COHORT||PROSPECTIVE|||||||
33694307|NCT01788176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694308|NCT06339632|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The researchers responsible for assessing diaphragm muscle through ultrasound will perform image recordings and captures during the TEPNS and TEDS intervention moments. Subsequently, the images will be analyzed by a blinded evaluator for the adopted intervention. The analyses will follow the methods described in the diaphragm muscle mobility and diaphragm muscle thickness and thickening fraction sections. Study participants will also be instructed not to disclose information regarding their experience and sensations during the intervention period, ensuring study blinding."||f|f|f|t
33694309|NCT01598168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694310|NCT02068456|||OTHER||PROSPECTIVE|||||||
33694311|NCT01086293|||COHORT|||||||||
33694312|NCT03063203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783284|NCT06712277|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||It was planned as a single-group quasi-experimental study to determine the effect of training on patient and caregiver compliance with gastrostomy and the caregiver's gastrostomy care skills.||||
33694313|NCT02922595|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33783285|NCT05874791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918087|NCT04020146|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918088|NCT02933541|||CASE_ONLY||PROSPECTIVE|||||||
33918089|NCT00817401|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33694314|NCT03538431|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33694315|NCT00596856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33998144|NCT02440997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998145|NCT06108557|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998146|NCT00584103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694316|NCT05199740|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694317|NCT00723216||PARALLEL||PREVENTION||NONE||||||
33783286|NCT04774718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694318|NCT05472324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694319|NCT06708819|||COHORT||PROSPECTIVE|||||||
33694320|NCT04568889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33694321|NCT01516671|||COHORT||PROSPECTIVE|||||||
33694322|NCT03188627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694323|NCT02155569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694324|NCT04152707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694325|NCT00884377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694326|NCT05753618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783287|NCT03614234|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label extension study||||
33783288|NCT05423080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783289|NCT04215913|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783290|NCT06211140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment; Non-Randomized; Open-label||||
33998147|NCT04892420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|using computer generated codes and opaque sealed envelopes:||t|t|t|t
33998148|NCT00937664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783291|NCT00416286|||DEFINED_POPULATION||PROSPECTIVE|||||||
33998149|NCT06447753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33998150|NCT04883996|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33998151|NCT04842019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998152|NCT03702816|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking|All participants will receive one Flutriciclamide (18F-GE180) PET scan.||||
33998153|NCT01627639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998154|NCT05283954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33998155|NCT02125760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998156|NCT00981344|NA|SINGLE_GROUP||||NONE||||||
33998157|NCT00858403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998158|NCT03900039|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The assessment of the implants was done by a secondary center that was unaware of which the bearing type was in which patient.||f|f|f|t
33998159|NCT01105299|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998160|NCT02977416|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33998161|NCT04712838|RANDOMIZED|CROSSOVER||OTHER||NONE||The relative bioavailability of SHR0302 tablets with three different formulations||||
33998162|NCT04186286|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33998163|NCT00129038||||TREATMENT||||||||
33998164|NCT03636386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998165|NCT02420353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998166|NCT02677558|||CASE_CONTROL||OTHER|||||||
33998167|NCT00471094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998168|NCT05197062|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998169|NCT05232539|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||A prospective, randomized, comparative study conducted at the SOMICH Eye Center s.r.o. in Karlovy Vary, comparing the effectiveness and safety of the use of Intraoperative Optical Coherence Tomography (iOCT)||||
34088001|NCT04249024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking for the assessors of microbial, immunological and radiographic analyses.||f|f|f|t
33694327|NCT00076973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694328|NCT00208299|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33694329|NCT01550471|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694330|NCT00273910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694331|NCT03080610|||OTHER||OTHER|||||||
33998170|NCT02045108|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|f|t
33998171|NCT03581630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998172|NCT04482816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient will be explained to be randomized to either of the two branches. The type of therapy applied will not be communicated to the patient. The follow-up will be the same in the two branches. During the visits, it will not be said which therapy has been applied.~The echocardiographer and the follow-up by the Hemodynamic Team will be blind."||t|f|f|t
33998173|NCT03220373|||COHORT||PROSPECTIVE|||||||
33998174|NCT02344953|||COHORT||OTHER|||||||
33998175|NCT02355847|NA|SINGLE_GROUP||||NONE||||||
33998176|NCT02995135|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33998177|NCT01587456|||COHORT||PROSPECTIVE|||||||
33998178|NCT01627431|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998179|NCT05010135|||CASE_CONTROL||PROSPECTIVE|||||||
33998180|NCT01743898|||CASE_CONTROL||PROSPECTIVE|||||||
33998181|NCT06318598|||COHORT||PROSPECTIVE|||||||
34088002|NCT05237427|||COHORT||CROSS_SECTIONAL|||||||
34088003|NCT01979900|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088004|NCT01658839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088005|NCT00565461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088006|NCT03746509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088007|NCT04140110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open intervention; outcome assessments undertaken by trained research staff who are kept blind to treatment allocation|Different intensities of blood pressure management using locally available intravenous antihypertensive agents|f|f|f|t
34088008|NCT05404100|||CASE_ONLY||PROSPECTIVE|||||||
34088009|NCT05694650|||COHORT||PROSPECTIVE|||||||
34088010|NCT02632318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33694332|NCT05379972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694333|NCT05512091|||COHORT||PROSPECTIVE|||||||
33694334|NCT00810381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33694335|NCT06707961|||COHORT||PROSPECTIVE|||||||
33694336|NCT04533880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783292|NCT05321069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783293|NCT00321477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33783294|NCT00846781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783295|NCT04554069|||COHORT||PROSPECTIVE|||||||
33783296|NCT04679272|||COHORT||RETROSPECTIVE|||||||
33998182|NCT00045162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998183|NCT05948072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088011|NCT04828499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088012|NCT01971177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088013|NCT00851591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34088014|NCT04615000|||COHORT||PROSPECTIVE|||||||
33694337|NCT04885946|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Patients are randomized to either vancomycin + 2 FMT or 2 placebo. An open-label arm exists for patients with fulminant CDI.|t|t|t|t
33694338|NCT06621186|||CASE_ONLY||PROSPECTIVE|||||||
33694339|NCT04473846|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694340|NCT04372797|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998184|NCT01715077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088015|NCT04683575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants, investigators were blinded to the grouping of the experiment and the intervention.|experimental group：Selenium yeast treatment group control group：Placebo control group blank control group|t|f|t|f
34088016|NCT01446705|||COHORT||RETROSPECTIVE|||||||
34088017|NCT03547128|||COHORT||PROSPECTIVE|||||||
34088018|NCT02120404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088019|NCT04116567|||COHORT||PROSPECTIVE|||||||
34088020|NCT00439621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088021|NCT00639509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694341|NCT01677637|||||PROSPECTIVE|||||||
33694342|NCT03411915|NA|SEQUENTIAL||TREATMENT||NONE||||||
33694343|NCT03036306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694344|NCT05674175|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694345|NCT03923738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783297|NCT01282099|||COHORT||PROSPECTIVE|||||||
33783298|NCT05833360|||COHORT||PROSPECTIVE|||||||
33783299|NCT04173845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33783300|NCT00800124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783301|NCT04451733|||COHORT||PROSPECTIVE|||||||
33783302|NCT03921528|RANDOMIZED|PARALLEL||TREATMENT||NONE|Active treatment, randomized, double-blind for Cohort 3|||||
33783303|NCT02013232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783304|NCT02222415|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33783305|NCT05588674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33783306|NCT04163666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33783307|NCT00626847|||COHORT||PROSPECTIVE|||||||
33783308|NCT06713512|||COHORT||PROSPECTIVE|||||||
33998185|NCT03660787|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The present study was conducted as a double blind trial. Neither a medical investigator, nor patients had access to the treatment assignment code in order to ensure the maximum objective evaluation of the primary endpoint.~Blinding was performed in such a way that disclosing a randomization code of a certain subject excluded a disclosure of the code in general (i.e. the randomization code had no indication to the treatment group). However, there were no cases of the randomization code disclosure in the study"||t|f|t|f
33998186|NCT00114504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998187|NCT05767905|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open-label Study|||||
34088022|NCT06462677|||COHORT||PROSPECTIVE|||||||
33783309|NCT04129762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918090|NCT04568317|RANDOMIZED|PARALLEL||OTHER||NONE||Upon giving consent, participants will be randomised in two arms: iCBT intervention (n=35) and iCBT intervention with smartwatch (n=35). Participants who decline consent will be excluded from the study and will receive iCBT treatment as usual. The sample size of 70 aligns with the literature around desired sample sizes for feasibility and acceptability studies (Teare et al., 2014). Participants will be recruited regardless of whether they own a smartwatch. As the smartwatch is a new addition to the iCBT intervention, this will be the first time for all participants using a smartwatch within the 'Space from Depression' program. The degree to which participants' experience/familiarity with the smartwatch technology influenced acceptance outcomes will be investigated in a secondary analysis.||||
33783310|NCT00414492|||CASE_ONLY||PROSPECTIVE|||||||
33783311|NCT03061955|||OTHER||PROSPECTIVE|||||||
33783312|NCT05583617|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783313|NCT06601907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783314|NCT03288350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783315|NCT05934773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918091|NCT05506553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised Control Trial|t|f|f|f
33918092|NCT03190226|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||split-mouth trial||||
33918093|NCT00375635|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33998188|NCT04074707|NA|SINGLE_GROUP||OTHER||NONE||each subject acts as her own control by going through all the three supplementation cycles. Women will be randomly assigned to start with the 60mg daily vs alternate day, 120mg daily vs alternate day or 120mg daily vs every third day supplementation cycle.||||
33998189|NCT01131091|NON_RANDOMIZED|PARALLEL||||NONE||||||
33998190|NCT01159873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998191|NCT05063591|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single-center, prospective pilot study||||
33998192|NCT02864836|||OTHER||PROSPECTIVE|||||||
33998193|NCT00266487|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33998194|NCT05804786|||COHORT||PROSPECTIVE|||||||
33998195|NCT06158607|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33998196|NCT00629304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998197|NCT05462080|||COHORT||PROSPECTIVE|||||||
33998198|NCT03669731|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33998199|NCT04531969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be aware of group distribution due to the nature of the study. Therefore, the only outcome assessor will be blinded|Parallel Assignment|f|f|f|t
33998200|NCT02086474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998201|NCT05026320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33998202|NCT03558295|||COHORT||PROSPECTIVE|||||||
33998203|NCT06254560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998204|NCT03570060|||COHORT||PROSPECTIVE|||||||
33998205|NCT01698554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998206|NCT00064324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998207|NCT02856594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998208|NCT01812993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998209|NCT01166464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998210|NCT02618460|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998211|NCT05816005|||OTHER||PROSPECTIVE|||||||
33998212|NCT00726830|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998213|NCT05251805|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998214|NCT06516172|||COHORT||PROSPECTIVE|||||||
33998215|NCT05643105|||COHORT||PROSPECTIVE|||||||
33998216|NCT01993940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998217|NCT04605835|||COHORT||RETROSPECTIVE|||||||
33998218|NCT05453487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998219|NCT01282736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088023|NCT02243514|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783316|NCT02487290|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a feasibility study, where initially 5 patients are to be treated.||||
33783317|NCT06170489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783318|NCT00809224|||CASE_CONTROL|||||||||
33783319|NCT04502927|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34088024|NCT04546763|||COHORT||PROSPECTIVE|||||||
34088025|NCT01018979|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088026|NCT03579667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088027|NCT00080054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088028|NCT06518226|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33783320|NCT03668067|||COHORT||PROSPECTIVE|||||||
33998220|NCT03584308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double blind. To achieve the masking of the research product, these have been labeled by a computerized randomized balanced list, which will be in the possession of the promoter and the study Biostatistician. The masking will be maintained until the analysis of the data. However, access to the code will be allowed if serious adverse events arise related to the research product.|Random assignment, through a list obtained by computer. Patients will be randomized in the consultation of the upper digestive tract, once the anatomopathological result with the presence of coilocytes is received, and they meet the established selection criteria.|t|f|t|f
33998221|NCT03008616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998222|NCT03246503|NA|SINGLE_GROUP||SCREENING||NONE||||||
33998223|NCT00108030|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33998224|NCT02339038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998225|NCT00731458|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33998226|NCT01728480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088029|NCT01026935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088030|NCT02246777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088031|NCT00323219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694346|NCT06120491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|within each cohort (HRRm and non-HRRm), participants are randomised in 1:1 ratio to one of two treatment arms|t|t|t|t
34088032|NCT06557681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088033|NCT01267578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694347|NCT00232167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33694348|NCT06551636|||OTHER||PROSPECTIVE|||||||
33694349|NCT01143207|NA|SINGLE_GROUP||||NONE||||||
33694350|NCT05383885|||CASE_ONLY||PROSPECTIVE|||||||
33694351|NCT01428362|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33783321|NCT04068194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783322|NCT04398459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783323|NCT03381430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783324|NCT01324882|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33783325|NCT00694811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783326|NCT00611065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694352|NCT02101203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088034|NCT04441125|||OTHER||OTHER|||||||
33694353|NCT00736671|||CASE_CONTROL||PROSPECTIVE|||||||
33694354|NCT06214507|||COHORT||PROSPECTIVE|||||||
33694355|NCT01454115|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33694356|NCT03459924|||COHORT||RETROSPECTIVE|||||||
33694357|NCT06238362|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be asleep during both therapies.|Patients will be treated with both the interventional therapy and standard CPAP therapy in one night to compare efficacy.|t|f|f|f
33694358|NCT00853073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694359|NCT04684290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694360|NCT02876744|||OTHER||CROSS_SECTIONAL|||||||
33694361|NCT00814151|||CASE_CONTROL||PROSPECTIVE|||||||
33694362|NCT04504773|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assessor is not involved in treatment, and will assess the severity of the participants anxiety.|||||
33694363|NCT06707493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694364|NCT06589830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694365|NCT04069299|||CASE_ONLY||PROSPECTIVE|||||||
33694366|NCT02135159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694367|NCT04400942|||COHORT||RETROSPECTIVE|||||||
33694368|NCT06076707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The data collector and the investigator will be blind for the study while the patient is not.||f|f|t|t
33694369|NCT06516484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783327|NCT05205941|NA|SEQUENTIAL||TREATMENT||NONE||||||
33783328|NCT03556826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998227|NCT06182293|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33998228|NCT02738164|||COHORT||PROSPECTIVE|||||||
33998229|NCT01772277|||CASE_CONTROL||RETROSPECTIVE|||||||
33783329|NCT05705401|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects who are receiving standard of care systemic HER2-targeted therapies are randomized to standard of care adjuvant breast radiation or no breast radiation||||
33783330|NCT04467463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|masking from the aim of the study|"The two study groups were:~* Group GPN, 20 patients received bilateral greater palatine nerve block.~* Group SMN, 20 patients received bilateral suprazygomatic maxillary nerve block."|f|t|f|f
33783331|NCT00123799|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783332|NCT04669613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783333|NCT00986271||PARALLEL||DIAGNOSTIC||NONE||||||
33783334|NCT00438906|||COHORT||PROSPECTIVE|||||||
33783335|NCT03597321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783336|NCT03318120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783337|NCT05835466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783338|NCT03487666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783339|NCT01425372|||COHORT||PROSPECTIVE|||||||
33783340|NCT02579512|||CASE_ONLY||RETROSPECTIVE|||||||
33783341|NCT03211598|NA|SINGLE_GROUP||OTHER||NONE||||||
33783342|NCT00902434|||CASE_ONLY||RETROSPECTIVE|||||||
33783343|NCT06640894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A single-blind randomized controlled parallel trial with a 24 week follow-up.|f|f|t|f
33783344|NCT04571073|NA|SINGLE_GROUP||TREATMENT||NONE|The AI taking the ultrasound images was blinded to study phase of the participant he was screening.|||||
33918094|NCT01395836|||COHORT||PROSPECTIVE|||||||
33918095|NCT03730194|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The investigators utilized a sequential, multiple assignment, randomized trial (SMART) pilot feasibility study design to inform implementation of a future full-scale SMART design that will be used to construct adaptive biobehavioral sleep intervention strategies involving melatonin, a behavioral sleep intervention (The Bedtime Bank), and their combination for the management of sleep disturbance in adolescents with neurodevelopmental (NDDs). Participants completed 1 week of baseline data collection, and than were randomly assigned to either melatonin or The Bedtime Bank. Response (\>/= 18 minute average nightly increase in total sleep time \[TST\]) was measured at Week 4 and Week 8. Participants who responded (\>/= 18 minute average nightly increase in TST) at Week 4 remained on the assigned intervention. Participants who were non-responsive at Week 4 were re-randomized to a different sleep intervention or combined interventions.||||
33998230|NCT02803827|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33998231|NCT04506918|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized to one of two arms : 1) IVR or 2) SMS. Participants in the first study arm will receive an IVR survey. Participants in the second study arm will receive a SMS survey.|f|f|f|t
33998232|NCT01771653|||COHORT||PROSPECTIVE|||||||
33998233|NCT01320722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998234|NCT03949062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783345|NCT00232011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783346|NCT06121570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783347|NCT03109288|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33783348|NCT06714435|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33783349|NCT03881254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Human Homologous Autologous Skin Construct (SkinTE™) in the Treatment of Diabetic Foot Ulcers||||
33783350|NCT05247489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783351|NCT00828620|||COHORT||PROSPECTIVE|||||||
33783352|NCT06226480|||COHORT||RETROSPECTIVE|||||||
33783353|NCT04920214|||COHORT||PROSPECTIVE|||||||
33783354|NCT06028048|RANDOMIZED|PARALLEL||OTHER||SINGLE|The analyses will be performed blinded after one researcher codes the intervention and control group to either 0 or 1.|A non-blinded RCT will be conducted with a follow-up of 12 months. The study will compare two arms: (1) an intervention group, in which participants will receive the PLACES intervention, and (2) a control group, in which participants will receive CAU. Data on primary (i.e. obtainment of paid employment) and secondary outcomes (e.g. quality of life and self-efficacy regarding RTW) will be gathered at baseline (T0) and after three (T1), six (T2) and twelve months of follow up (T3) using questionnaires .|f|f|f|t
33783355|NCT04082637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33998235|NCT03369132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998236|NCT01988636|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33998237|NCT01832922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998238|NCT01323062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088035|NCT02804893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088036|NCT06033378|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34088037|NCT04062227|||COHORT||PROSPECTIVE|||||||
34088038|NCT03634423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34088039|NCT06277375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34088040|NCT00968162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088041|NCT03860155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088042|NCT04508816|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34088043|NCT05392400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33783356|NCT02967692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 and Part 2 are open- label. Part 3 is double-blind and randomized.||t|t|t|t
33783357|NCT03549806|||COHORT||PROSPECTIVE|||||||
33783358|NCT00623246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783359|NCT02978456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783360|NCT06527768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33783361|NCT06180356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783362|NCT03174938|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783363|NCT06092710|||OTHER||PROSPECTIVE|||||||
33783364|NCT05946798|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33783365|NCT00611637|NA|SINGLE_GROUP||||NONE||||||
34088044|NCT05293795|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||3D ultrasound and picture of ultrasound or 3D ultrasound and printed model of fetal face and normal controls||||
34088045|NCT06514131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34088046|NCT03335527|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694370|NCT02758756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694371|NCT06653153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783366|NCT04940390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33694372|NCT04723758|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The patient and colonoscopist (care provider) cannot be blinded to the allocation. The investigator and statistician will remain blinded to the allocation until analysis has been conducted.||f|f|t|t
33694373|NCT06485674|||COHORT||RETROSPECTIVE|||||||
33783367|NCT00832780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783368|NCT04373135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pre-/post-intervention survey with random allocation of a brief educational intervention about scarce resource allocation policy||||
33783369|NCT03966716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783370|NCT01502865|||OTHER||RETROSPECTIVE|||||||
33783371|NCT00884611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783372|NCT02763020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33783373|NCT06466499|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||In the RCT measurements will be conducted three times; baseline, post intervention, and at six months follow-up.|f|f|t|f
33783374|NCT06310239|||OTHER||PROSPECTIVE|||||||
33783375|NCT06343155|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups: Therapeutic group and Rocabado's group.||||
33783376|NCT02400190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088047|NCT01065441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088048|NCT02101151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088049|NCT05304325|||OTHER||PROSPECTIVE|||||||
34088050|NCT02707497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088051|NCT03595397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088052|NCT05429996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34088053|NCT00374504|||CASE_CONTROL||PROSPECTIVE|||||||
34088054|NCT01314729|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33694374|NCT06281288|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|f|t
33694375|NCT00460369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694376|NCT04366973|||COHORT||PROSPECTIVE|||||||
33694377|NCT06708741|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33694378|NCT04407481|||COHORT||CROSS_SECTIONAL|||||||
33694379|NCT04340193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694380|NCT03647332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694381|NCT05584371|NA|SINGLE_GROUP||OTHER||NONE||||||
33694382|NCT03467607|RANDOMIZED|PARALLEL||PREVENTION||NONE|open label, randomisation blinded|parallel assignment||||
33694383|NCT03300310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694384|NCT02568137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33694385|NCT05516810|||COHORT||PROSPECTIVE|||||||
33694386|NCT06039384|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783377|NCT05341167|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Not aware of the study group|Prospective, Randomized, Double-Blinded clinical trial|t|t|f|t
33783378|NCT03750656|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open-blind clinical trial||||
33783379|NCT05015478|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33783380|NCT05805345|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33783381|NCT05067959|||COHORT||PROSPECTIVE|||||||
33783382|NCT01149135|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783383|NCT06083714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783384|NCT06364410|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783385|NCT00255021|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33783386|NCT01853358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783387|NCT02803294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783388|NCT04574245|||COHORT||RETROSPECTIVE|||||||
33783389|NCT05491317|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 is sequential, Part 2 is parallel (randomized)||||
34088055|NCT03749161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34088056|NCT03635216|||COHORT||RETROSPECTIVE|||||||
34088057|NCT02054156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694387|NCT05879835|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multisite, randomized, open-label, 2-arm parallel-group superiority trial||||
33694388|NCT03881410|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33694389|NCT00781508|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33694390|NCT00181623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694391|NCT02126371|NA|SINGLE_GROUP||||NONE||||||
33694392|NCT04515927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694393|NCT06709092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694394|NCT04092270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694395|NCT02378623|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33694396|NCT00096954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694397|NCT04047862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694398|NCT05174845|||COHORT||RETROSPECTIVE|||||||
33694399|NCT03579576|||COHORT||PROSPECTIVE|||||||
33694400|NCT04396496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088058|NCT02025075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34088059|NCT00557466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088060|NCT02585765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088061|NCT02668068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088062|NCT03477175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088063|NCT01518062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088064|NCT00229801|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783390|NCT03771326|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|All the individuals were told before the use of Kp-10 administration. however, to avoid psychological effect the exact time was not disclosed.|Fourteen volunteers (aged 20-45 years), including seven adult normal weight healthy men (mean body weight and BMI 75.5±4.8 kg and 23±0.7 kg/m2, respectively) and seven obese men (mean body weight and BMI 115±15 kg and 34±2 kg/m2, respectively), participated in this clinical study||||
33783391|NCT02342912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998239|NCT06089057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All research assistants and biostatistics personnel will be masked to each participant's assignment. Participants and study staff are unaware of group allocation at the time of recruitment and baseline assessments because randomization is performed after participants have completed baseline assessments. However, there is no blinding to group allocation after randomization.|Veterans will be randomized to either the intervention to an attention control. Randomization will be performed by the biostatistician. Veterans will be randomized to the intervention group (or to the attention control) using a block randomization scheme with randomly selected block sizes of 2, 4, and 6. Participants in the attention control will receive educational resources regarding the benefits of physical activity prior to intervention start (A brief document related to the importance of physical activity in kidney disease and handouts from the Center for Disease Control's recommendations for physical activity for older adults). Participants in the attention control may also receive a weekly phone call on general health.|f|f|f|t
33998240|NCT05895435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998241|NCT05306496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998242|NCT01682421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998243|NCT01904305|||COHORT||PROSPECTIVE|||||||
33998244|NCT00377039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998245|NCT06256224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998246|NCT06359015|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups: experimental and control. The control group receives expectant management. The experimental group receives expectant management and medication treatment.||||
33998247|NCT03948854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998248|NCT05403463|||OTHER||RETROSPECTIVE|||||||
33998249|NCT00130949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998250|NCT00867360|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33998251|NCT03675750|||COHORT||PROSPECTIVE|||||||
33783392|NCT04701502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998252|NCT06348888|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33998253|NCT05120388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data analysis will be masked|Dietary intervention study: GDM patients receiving a WHO diet with or without addition of extra virgin olive oil|f|f|t|f
33998254|NCT03946787|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Group A: Treatment as Usual (TAU);~2. Group B: TAU plus Eye Movement Desensitization and Reprocessing (EMDR) Therapy"||||
33783393|NCT03115346|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a cluster randomized study. Sites will be randomly assigned to the intervention group - (decision aid +survey), or control group (survey only). The randomization scheme is 9:1, for complex and intermediate VA sites.||||
33998255|NCT01694758|||COHORT||PROSPECTIVE|||||||
33998256|NCT01193387|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33998257|NCT02054715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33998258|NCT00585741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998259|NCT03284138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998260|NCT01800838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998261|NCT03578822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801481|NCT02029235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998262|NCT00438633|||COHORT||PROSPECTIVE|||||||
33998263|NCT03141853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care provider, and outcomes assessor will be masked as to which is the intervention and which is the control|Randomized Controlled Trial. One group will receive equine-assisted therapy and the second group will receive arthritis exercise education|t|t|f|t
33998264|NCT02455947|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998265|NCT03028792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998266|NCT03257228|||COHORT||PROSPECTIVE|||||||
33998267|NCT03811977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998268|NCT04560231|NA|SINGLE_GROUP||TREATMENT||NONE||Qausi-experimental||||
34088065|NCT04747340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization stratified by center.|f|f|f|t
34088066|NCT02967575|||COHORT||PROSPECTIVE|||||||
33998269|NCT05359965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study investigators and care providers will be blinded and not involved in any CPAP or no CPAP related set-up, instruction, or device troubleshooting during the course the treatment phase. Lab personnel performing biomarker analysis will only have access to subject study ID and not treatment group assignments.|Subjects will be assigned to treatment groups using a 1:1 randomized block design via the randomization module in REDCap. The PI and study coordinator will be blinded to next assignment.|f|t|t|t
33998270|NCT03069976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088067|NCT00006126||||TREATMENT||||||||
34088068|NCT03625024|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34088069|NCT06480630|NA|SINGLE_GROUP||PREVENTION||NONE||Addition of CD25 monoclonal antibody at +3 days post unrelated umbilical cord blood transplantation (UCBT)||||
34088070|NCT05052905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088071|NCT04363476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Research assistants performing testing and data entry and the investigators performing analysis will be blinded throughout the study.|Step-wedge design with two parallel arms|f|f|t|t
34088072|NCT00891813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088073|NCT03004040|||CASE_CONTROL||PROSPECTIVE|||||||
34088074|NCT01981083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088075|NCT00883727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088076|NCT04525196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34088077|NCT05374278|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34088078|NCT01587677|||COHORT||PROSPECTIVE|||||||
34088079|NCT05001048|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Due to the study design, masking is not possible. The time points and dosages of the study drug will be known to the participant. Further, due to the wash-out time of the acute hypoxia/hyperoxia interventions, these will always be completed second to the interventions breathing room air.|Participants will partake in all three arms of the study, which include: 1) low altitude, 2) early acclimatization, and 3) late acclimatization to high altitude assessments.||||
34088080|NCT00640289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088081|NCT01883674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088082|NCT00750269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088083|NCT05000827|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Intervention~PSMA PET/CT based indication for ePLND:~1. Node-negative PSMA PET/CT \[N0\] and M0: do not perform ePLND~2. Node-positive PSMA PET/CT \[N1\] and M0: perform ePLND~Comparator Nomogram-based indication for ePLND (conform current EAU guidelines)"||||
34088084|NCT06157437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088085|NCT03665324|||CASE_CONTROL||RETROSPECTIVE|||||||
33998271|NCT02691676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998272|NCT00591760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33998273|NCT04941313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998274|NCT01569854|||COHORT||PROSPECTIVE|||||||
33998275|NCT06563427|||OTHER||CROSS_SECTIONAL|||||||
33998276|NCT03891095|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34088086|NCT02702544|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34088087|NCT03035019|NA|SINGLE_GROUP||OTHER||NONE||||||
34088088|NCT00589459|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694401|NCT04309812|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Since the subject sets the stimulation settings for each day of treatment, it is not possible to employ a full placebo with this device. We will inform the subjects that we are uncertain whether short stimulation of 1 minute is less effective than is longer stimulation of 30 minutes, which is a true statement according to our current state of knowledge. We will use a balanced deck of randomized cards setting the initial treatment arm as SHORT in 15 cases and LONG in 15 cases.|Randomized to SHORT or LONG dose tDCS as first treatment|f|t|t|t
33694402|NCT01502280|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33694403|NCT01206868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694404|NCT00935051|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918096|NCT01134757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918097|NCT04727502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope.|"2 equal groups ( Group A) :receive duloxetine for 12 weeks and (Group B) control group receive pregabalin for 12 weeks .~• Dosing and administration Group A) Duloxetine 30 mg /day at bed time and (Group B) control group Pregablin 150mg /day( 75 mg /12 hours"|f|t|f|t
33918098|NCT05369026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33918099|NCT04962503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918100|NCT03334396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918101|NCT02658994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918102|NCT04494555|NA|SINGLE_GROUP||TREATMENT||NONE||This is a repeated measures prospective study.||||
33918103|NCT01705925|||COHORT||PROSPECTIVE|||||||
33918104|NCT05905341|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33918105|NCT00721422|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33918106|NCT00699101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918107|NCT05551338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to participant assignment.|"Group 1: 10 patients will be asked to perform two 30-minute sessions per week of training using serious games over a 3-month period in addition to their conventional care.~Group 2: 10 patients will only receive their conventional care."|f|f|f|t
33918108|NCT04436874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918109|NCT01605344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33918110|NCT05197478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||It was conducted prospectively on 31 January - 31 May 2021 patients over 50 years of age, who were hospitalized in the pandemic ward, had the appearance of COVID 19, and were taken into ethical examination (E-17073117-050.06). 50.06,||||
33918111|NCT00776945|||CASE_ONLY||PROSPECTIVE|||||||
33918112|NCT04939025|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The MIRACLE study is an international multicenter clinical effectiveness study, whereby the current local practice (control cohort) will be evaluated, and subsequently compared to the results after implementation of the multi-interventional program (intervention cohort).||||
33918113|NCT00362791|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33918114|NCT05442294|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Non-Randomized Control Cluster Trial|f|f|f|t
33918115|NCT05699772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918116|NCT02130479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918117|NCT03337139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918118|NCT02510170|||OTHER||CROSS_SECTIONAL|||||||
34088089|NCT04562909|||COHORT||PROSPECTIVE|||||||
33694405|NCT04081233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783394|NCT03829280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Raters assessing clinical outcome variables are centralized raters who are blind to treatment group as well as study design and aims.|Cluster Randomized clinical trial conducted at 8 community mental health outpatient treatment sites across the country|f|f|f|t
33783395|NCT05785897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783396|NCT05971381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918119|NCT03604237|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33783397|NCT05756439|||COHORT||CROSS_SECTIONAL|||||||
33783398|NCT02087033|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33918120|NCT02771652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918121|NCT01274572|||CASE_ONLY||PROSPECTIVE|||||||
33918122|NCT01527227|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783399|NCT01238029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918123|NCT02871193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918124|NCT03353753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918125|NCT04102735|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918126|NCT04899713|||COHORT||RETROSPECTIVE|||||||
33783400|NCT02862704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918127|NCT00174785|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33918128|NCT00472355|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33918129|NCT04312438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918130|NCT06195826|||CASE_CONTROL||RETROSPECTIVE|||||||
33783401|NCT05676762|||COHORT||PROSPECTIVE|||||||
34088090|NCT00607893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783402|NCT02391662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918131|NCT01843400|||COHORT||PROSPECTIVE|||||||
34088091|NCT02712853|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918132|NCT03665428|RANDOMIZED|PARALLEL||TREATMENT||NONE||PAMB group (modified quadruple therapy) vs. PBMT group (bismuth-containing quadruple therapy)||||
33918133|NCT03497234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator is blinded to results of the analyzer but all patients have samples run on analyzer|This is a multi-centered, prospective study, involving pregnant women presenting to the labor and delivery unit||||
33783403|NCT04162808|||COHORT||PROSPECTIVE|||||||
33783404|NCT05996146|||COHORT||PROSPECTIVE|||||||
33783405|NCT00273676|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783406|NCT05209542|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783407|NCT04160585|||OTHER||CROSS_SECTIONAL|||||||
33918134|NCT02466568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918135|NCT03811717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Allocation concealment, assessor blinding||f|f|t|t
33918136|NCT00289185|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33918137|NCT01293149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918138|NCT06170801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of interventions, blinding of patients/therapists concerning the treatment is impossible, but all assessments as well as data analysis will be blinded to treatment allocation.|prospective, bicenter, evaluator- and statistician-blinded, randomized clinical trial with an active control condition|f|f|f|t
33918139|NCT01883934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33918140|NCT04656444|||COHORT||PROSPECTIVE|||||||
33918141|NCT04255836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918142|NCT05908812|||CASE_CONTROL||OTHER|||||||
33918143|NCT02387372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918144|NCT05539105|||COHORT||PROSPECTIVE|||||||
33918145|NCT04979949|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-Blind|Double-Blind, Randomized, Controlled, Multi-Center Phase 2 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2 (Hybrid COV-Rapel TR)|t|t|t|f
34088092|NCT03661775|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Factorial 2-by-2 open labeled randomised controlled trial||||
34088093|NCT02826213|||CASE_CONTROL||PROSPECTIVE|||||||
34088094|NCT01763229|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34088095|NCT05848349|||COHORT||PROSPECTIVE|||||||
34088096|NCT05209698|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088097|NCT02026466|||COHORT||PROSPECTIVE|||||||
33783408|NCT02275936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783409|NCT06629623|||CASE_ONLY||PROSPECTIVE|||||||
33783410|NCT00361998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783411|NCT02256969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783412|NCT05826366|||COHORT||PROSPECTIVE|||||||
33783413|NCT00073957|NA|SINGLE_GROUP||TREATMENT||NONE||Standard Phase 2||||
33783414|NCT06696079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor masking and blinded data interpretation.||f|f|f|t
33801482|NCT03296540|RANDOMIZED|PARALLEL||TREATMENT||NONE||Crushed versus uncrushed tablets Prasugrel loading dose||||
33918146|NCT05843110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33918147|NCT03058172|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33801483|NCT04240613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918148|NCT03355235|||COHORT||PROSPECTIVE|||||||
33918149|NCT00589979|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33918150|NCT01801722|||OTHER||CROSS_SECTIONAL|||||||
33918151|NCT03522493|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33918152|NCT03287752|||COHORT||PROSPECTIVE|||||||
33918153|NCT04082468|||CASE_ONLY||PROSPECTIVE|||||||
33918154|NCT01695850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918155|NCT00358904|||COHORT||PROSPECTIVE|||||||
33918156|NCT00232440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918157|NCT02572895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918158|NCT00773565|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918159|NCT05911815|||COHORT||PROSPECTIVE|||||||
33918160|NCT03116373|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33801484|NCT00269464|||||RETROSPECTIVE|||||||
33918161|NCT04388098|||COHORT||CROSS_SECTIONAL|||||||
33918162|NCT03312296|||CASE_ONLY||PROSPECTIVE|||||||
33918163|NCT02238795|||CASE_ONLY||PROSPECTIVE|||||||
33694406|NCT06053463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694407|NCT05523206|||COHORT||PROSPECTIVE|||||||
33694408|NCT06661694|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33694409|NCT04634890|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694410|NCT05374668|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Semi-randomized controlled prospective study.||||
33694411|NCT01296360|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694412|NCT06707896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3+3 dose escalation design||||
33694413|NCT06344182|||COHORT||CROSS_SECTIONAL|||||||
33694414|NCT04285099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Because our study is a double-blinded trial within one group, participant and investigator do not know whether the frequency is 130Hz or 60Hz.||t|f|t|f
33694415|NCT06612541|||CASE_ONLY||PROSPECTIVE|||||||
33694416|NCT00438451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694417|NCT02695875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694418|NCT02245178|||COHORT||PROSPECTIVE|||||||
33694419|NCT06708689|||CASE_CONTROL||RETROSPECTIVE|||||||
33694420|NCT05712876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694421|NCT03139695|||COHORT||PROSPECTIVE|||||||
33694422|NCT06707103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Particpants will be randomized to either TR987 1% gel + Standard of Care and Standard of Care alone. Sponsor, particpant, and Investigator/Outcomes Assessor will be masked throughout the treatment period.|This is an outpatient, randomized, parallel- group, double-blind, multicenter, 16-week study with 2 treatment arms: TR987 0.1% gel + Standard of Care and Standard of Care alone in participants who have a non-healing Venous Leg Ulcer (VLU).|t|t|t|t
33694423|NCT01737450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694424|NCT00503438|||COHORT||PROSPECTIVE|||||||
33694425|NCT04733144|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33694426|NCT03866031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694427|NCT06072248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||200 patients included in our study from those who showed no improvement and still had respiratory failure and completed ventilation for 4 days and fulfilled \> 2 parameters on SOFA score \[9-10\] and \> 6 on CPIS score and randomly allocated in two groups 100 patients in each.|f|f|t|f
33694428|NCT04292392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33694429|NCT02806973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33694430|NCT05748444|||OTHER||CROSS_SECTIONAL|||||||
33694431|NCT05400122|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately 12 subjects will be enrolled in this trial and all will receive a preparative regimen consisting of lymphodepleting chemotherapy agents followed by two infusions of ex vivo-expanded NK cells in combination with vactosertib and IL-2 (Proleukin®).||||
33694432|NCT02199860|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33694433|NCT01612949|||COHORT||PROSPECTIVE|||||||
33694434|NCT03031236|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33694435|NCT01012076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694436|NCT02193451|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694437|NCT06710769|NA|SINGLE_GROUP||OTHER||NONE||This study is an investigation of the characteristics of patients who utilize ovarian tissue cryopreservation, the timing of ovarian tissue use, and pregnancy outcomes.||||
33918164|NCT01461512|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33918165|NCT04700852|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918166|NCT05258708|||COHORT||PROSPECTIVE|||||||
33694438|NCT01461278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694439|NCT01837732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801485|NCT00209742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918167|NCT00057395|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998277|NCT01888107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998278|NCT03488407|||COHORT||PROSPECTIVE|||||||
33998279|NCT02929472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998280|NCT04422730|||CASE_CONTROL||PROSPECTIVE|||||||
33998281|NCT04567329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998282|NCT04778358|NA|SINGLE_GROUP||TREATMENT||NONE||Oocyte donors||||
33998283|NCT00838838|||COHORT||PROSPECTIVE|||||||
33998284|NCT01621438|||COHORT||PROSPECTIVE|||||||
33998285|NCT03458741||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33998286|NCT02610881|RANDOMIZED|CROSSOVER||||NONE||||||
33998287|NCT04385511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33694440|NCT06708702|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be blind to the group in which they are included, as will the study team. The non-blind team will be composed of the pharmacy team, that will be responsabli for the randomization and for dispensing of the investigational product/placebo.|"This is a phase II, randomized, placebo-controlled, double-blind study in a single institution, to evaluate the effectiveness of copaiba-based mouthwash in preventing oral mucositis in the tumor area in patients with oral cancer undergoing RT alone or in combination with CT. The participant will be randomized 1:1 to the study groups in a stratified manner according to the oncological treatments to which the patient will be subjected, according to the groups: exclusive treatment with RT and treatment with RT associated with CT. Randomization will be carried out using the REDCap® program by a non-blinded pharmacist, trained for this role.~Participants\&#39; daily care (outcome assessment) will begin on the first day of RT, and continue until the end of it, regardless of whether the patient has already reached the study\&#39;s primary outcome or not."|t|t|t|t
33694441|NCT04155489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33694442|NCT05438212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694443|NCT06099236|||OTHER||PROSPECTIVE|||||||
33694444|NCT03765879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This experiment will not be blinded. Participants will be aware if they are in the verum VGAIT or sham VGAIT group by nature of the interventions.|In this study, participants will be randomly assigned to receive one of two interventions: verum video-guided acupuncture imagery treatment (VGAIT) or sham VGAIT.|f|f|t|t
33918168|NCT00873769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Single-center, single-dose, single-treatment, open label study|||||
33998288|NCT03957096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783415|NCT04863898|NA|SINGLE_GROUP||OTHER||NONE||Pilot study to test a drug-use stigma-reduction intervention with staff (study participants) who work in HIV care and treatment clinics. Participants were enrolled, not clinics. This is a single arm study (no comparison group), pre and post survey design with qualitative data collection post pilot intervention.||||
33783416|NCT02312440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783417|NCT05826548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||PD, Stroke and MCI patients will be recruited in the IRCCS San Camillo Hospital. The selection will be based on diagnosis made by an expert neurologist and on a neuropsychological evaluation. Enrolled patients will be randomized in two groups and by using a block randomization sequence (Random.org), to receive telerehabilitation treatment (TR; N=70) or conventional treatment (CT; N=70). The CT group will undergo the standard cognitive training offered by the Hospital. The TR group will perform 5 daily sessions, 1 hour each, per week: 3 online, together with a remote therapist, and 2 offline that the therapist will be able to set and control in every moment, from a PC-based workstation in the hospital. The trainings will last 4 weeks.|t|f|f|f
33783418|NCT05499585|NA|SEQUENTIAL||TREATMENT||NONE||||||
33783419|NCT06308055|||COHORT||PROSPECTIVE|||||||
33783420|NCT04751383|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783421|NCT05180240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo will match active study drug in color, odor, taste and appearance to assure proper blinding.|Multi-center, double-blind, randomized, placebo-controlled, parallel group design. 1:1 randomization|t|t|t|t
33783422|NCT04500821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998289|NCT02733211|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998290|NCT01676064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33998291|NCT03050424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, placebo-controlled, randomised trial||t|t|t|t
33998292|NCT05818345|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33998293|NCT05206162|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||three experimental sessions at randomized order, at least one week apart, in a cross-over design|t|f|f|t
33998294|NCT04715451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33998295|NCT05491499|||CASE_ONLY||PROSPECTIVE|||||||
33998296|NCT02614898|||COHORT||PROSPECTIVE|||||||
33998297|NCT03671343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998298|NCT04710290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|this trial is single-blind clinical trial|beta-glucan group; beta-glucan + glutamin; placebo|t|f|f|f
33998299|NCT01989884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998300|NCT01025141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088098|NCT04075448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants will be aware the possible contents of each treatment, however, neither the participants or investigators will be aware of which treatment the participants are receiving at the point of testing. All analysis will be performed in relation to a treatment code which will only be revealed once analysis is completed.|Participants will be assigned to both the walnut and control conditions in a randomised order.|t|f|t|t
34088099|NCT00960427||||TREATMENT||NONE||||||
34088100|NCT05088941|||COHORT||RETROSPECTIVE|||||||
34088101|NCT03517982|||COHORT||PROSPECTIVE|||||||
34088102|NCT06461754|||COHORT||PROSPECTIVE|||||||
34088103|NCT02190201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088104|NCT00757653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694445|NCT05277961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Two groups of healthy volunteers are UV radiated with two different dosage regimen.~DNA repair excreted in the urine are quantified by LC-MS"||||
33694446|NCT06706986|||OTHER||OTHER|||||||
33694447|NCT03423134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33694448|NCT01046370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694449|NCT05918458|||CASE_CROSSOVER||PROSPECTIVE|||||||
33694450|NCT03530566|||COHORT||PROSPECTIVE|||||||
33694451|NCT00894348|||OTHER||PROSPECTIVE|||||||
33694452|NCT00686179|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33694453|NCT04312230|||COHORT||PROSPECTIVE|||||||
33694454|NCT03597269|||COHORT||PROSPECTIVE|||||||
33783423|NCT03502668|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multicenter, open label||||
33783424|NCT01093534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34088105|NCT04573270|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||This study is a randomized assignment, double-blind, placebo-controlled, multi-arm, multi-site study located at Southern California Hospitals at Culver City and Hollywood.|t|t|t|f
34088106|NCT00733798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694455|NCT04259281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694456|NCT06708533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694457|NCT03656835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694458|NCT00600444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088107|NCT03157089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088108|NCT01110941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103078|NCT05612750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and research staff will know arm assignment. Co-investigators, project statisticians, and the protocol director at each study site will remain blinded until final assessment.|A pragmatic clinical trial randomizing to one of two (standard of care) online group behavioral treatments: (1) 8-session cognitive behavioral therapy for chronic pain (pain-CBT); and (2) single-session pain relief skills intervention for chronic pain (Empowered Relief).|f|f|t|t
34103079|NCT00289978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103080|NCT01796470||SEQUENTIAL||TREATMENT||NONE||||||
34103081|NCT03407833|||CASE_CONTROL||PROSPECTIVE|||||||
34103082|NCT05410795|||OTHER||CROSS_SECTIONAL|||||||
34103083|NCT05773352|||COHORT||PROSPECTIVE|||||||
33694459|NCT06706921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694460|NCT04703218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33694461|NCT01942473|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694462|NCT06576427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694463|NCT06709950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694464|NCT05109052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694465|NCT04190173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention was blinded to patients, nurse, investigators, and radiologist|Consecutive enrolment parallel group in intervention group and placebo group|t|t|t|t
33694466|NCT05494320|||COHORT||PROSPECTIVE|||||||
33694467|NCT06704477|||OTHER||PROSPECTIVE|||||||
33694468|NCT00292318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694469|NCT05213572|||CASE_ONLY||PROSPECTIVE|||||||
33694470|NCT00620464|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694471|NCT06707298|||OTHER||CROSS_SECTIONAL|||||||
33694472|NCT06587750|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
33694473|NCT03768973|||CASE_CONTROL||PROSPECTIVE|||||||
33694474|NCT02938845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694475|NCT00063193|RANDOMIZED|||TREATMENT||DOUBLE||||||
33694476|NCT06708143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694477|NCT05665179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33694478|NCT06704997|||COHORT||RETROSPECTIVE|||||||
33694479|NCT03036319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Given the nature of this study, the participant, care provider, investigator, and/or outcome assessors may or may not be blinded to the treatment condition.|||||
33694480|NCT01420653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694481|NCT06708494|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694482|NCT02929173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694483|NCT06702111|||COHORT||OTHER|||||||
33694484|NCT02195206|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694485|NCT04966052|||COHORT||PROSPECTIVE|||||||
33694486|NCT03766685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694487|NCT03821051|||COHORT||PROSPECTIVE|||||||
33694488|NCT04706260|||CASE_CONTROL||RETROSPECTIVE|||||||
33694489|NCT00410202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694490|NCT01516528|||CASE_ONLY||PROSPECTIVE|||||||
33694491|NCT06679842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694492|NCT06709768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694493|NCT01406925|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33694494|NCT04421573|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open-label crossover study comparing BHDCP with D5W versus a waiting period in which usual care is allowed.||||
33694495|NCT02313324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694496|NCT05564793|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A multicenter randomized controlled study to assess patient response to cardiac resynchronization therapy comparing ECGI map guided left ventricular lead placement with empirical lead placement.||||
33918169|NCT04621669|RANDOMIZED|PARALLEL||TREATMENT||NONE||To observe the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium, metformin hydrochloride and to evaluate the safety. The subjects will take digoxin, Rosuvastatin calcium, metformin hydrochloride at first single dose, then wash out ,and take it at second time together with SHR3680 after multiple administration of SHR3680||||
33918170|NCT03910647|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33918171|NCT04008901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Random assignment, double blind placebo human application study|This study is a single center, random assignment, double blind placebo human application study. If a subject agrees in writing to participate in the human aptitude test, the medical examination required in accordance with the human aptitude test plan were conducted and randomly assigned only to those who are suitable for the selection criteria. The randomly assigned target was given a Lonicera Flos extract (BST104) 250 mg/day or placebo for eight weeks.|t|t|t|t
33918172|NCT01588353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918173|NCT05240638|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33918174|NCT01784952|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33694497|NCT05436223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694498|NCT02869997|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694499|NCT05176509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694500|NCT00411437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33694501|NCT01969552|||||PROSPECTIVE|||||||
33694502|NCT01539642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694503|NCT06708546|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Control Group (490 participants): children eating normally (not using Oral Nutritional Supplementation) during 4 months of intervention. After the end, the product will be used for the following 4 months.~Intervention Group (491 participants): children eating normally, with 2 boxes of Oral Nutritional Supplementation (180ml each) as a snack meal. The product provides 9,5% milk powder, milk fat and 26 micronutrients and provides FOS, HMO, DHA, and Taurine within 4 months of use."|"Step 1: Investigate the nutritional status of all children aged 24 - 59 months in 6 selected communes in Yen Bai province. Expecting 2000 participants in 6 examined communes.~Step 2: After the investigative selection, participants that meet the standard will be invited to the study ( the selected communes can be narrowed if the targets are met). The study will move to the next step when parents sign the consent paper.~Step 3: Groups will be divided to investigate activities. Creating a list for all participants that meet the criteria, with Z-score height for age \<-1 and Z-score weight for height\<1. Random selection based on age ensures no significant difference in the nutritional index or related indicators in the group to assess the effectiveness of the intervention (divided by class/age). Then, randomly divided the target by class into two large groups (500 targets per group)"|t|f|t|f
33694504|NCT04679844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intra-patient control. Each patient serves as their own control.||||
33694505|NCT04538573|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Every patient (20) will be their own control (20+20 = 40). Allocation to either intervention or control will be randomized at first and then switched at the crossover period.||||
33694506|NCT03517124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled clinical study|t|f|f|t
33694507|NCT02866994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33694508|NCT00234273|RANDOMIZED|PARALLEL||||NONE||||||
33694509|NCT04953429|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33694510|NCT03497793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783425|NCT03968237|||OTHER||OTHER|||||||
33694511|NCT05283928|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant served as their own control. Each participant had at least 1 control implant and at least 1 test implant.||||
33694512|NCT03456440|||CASE_CONTROL||PROSPECTIVE|||||||
33694513|NCT03975062|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded evaluation of primary outcome by Imaging expert, who will made decision regarding achievement of primary outcome|PROBE design, multicenter, active control trial|f|f|f|t
33694514|NCT06709170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694515|NCT04576624|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||three-year project using a combined pragmatic randomized controlled clinical trial and multiple case studies mixed-method research design|t|t|f|t
33694516|NCT00895856|||||PROSPECTIVE|||||||
33694517|NCT06498960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694518|NCT04686123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm parallel groups randomized clinical trial|t|f|f|t
33694519|NCT06709703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician will be blinded to the intervention|Double-blind randomized controlled-trial|t|f|f|t
33694520|NCT04875208|||OTHER||PROSPECTIVE|||||||
33694521|NCT03304418|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase IIa, open label, single arm, prospective study||||
33694522|NCT06663852|||COHORT||RETROSPECTIVE|||||||
33694523|NCT00275964|||||PROSPECTIVE|||||||
33694524|NCT04865640|||OTHER||PROSPECTIVE|||||||
33694525|NCT00261118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694526|NCT02450188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694527|NCT05267548|||COHORT||PROSPECTIVE|||||||
33694528|NCT03631693|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The calibrated examiners will be blinded to the study treatment. Samples will be labelled anonymously with subject ID and without codes relating to treatment group; therefore, all sample analyses will be blinded.~Blinding of the statistician will also take place. Data will be coded during data entry according to treatment group with a number disallowing group identification during analyses. Code details of which each treatment group will be revealed only once analyses are complete."|Single centre, randomised, single-blind, parallel-group clinical trial.|f|f|f|t
33694529|NCT01624051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694530|NCT01129674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694531|NCT04430829|||OTHER||CROSS_SECTIONAL|||||||
33694532|NCT06679075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694533|NCT06585033|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Statistician||t|f|t|t
33694534|NCT02832843|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33694535|NCT01600807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694536|NCT04234360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigators / outcome assessors / care givers and study staff are blinded to eosinophil / basophil / monocyte results and treatment allocation.|This is a randomised (1:1), 2-parallel arm, double-blind trial comparing outcomes for a group of eosinophilic COPD patients (n=150) treated via corticotherapy versus a 2nd, similar group (n=150) treated via placebo. Secondarily, the same comparison (2x n=150) will be made for non-eosinophilic patients (totally excluding non-eosinophilic patients would potentially affect biomarker knowledge and subsequent care decisions, leading to bias).|t|f|t|t
33783426|NCT06441331|NA|SINGLE_GROUP||TREATMENT||NONE||"Three sequential age cohorts:~1. ≥ 12 to \< 18 years old~2. ≥ 6 years to \< 12 years old~3. ≥ 2 to \< 6 years old~A minimum of 20 participants with SSTR-positive tumors of which at least six participants will have gastroenteropancreatic neuroendocrine tumors (GEP-NETs).~A minimum of six participants will be required in each age cohort."||||
33783427|NCT06492603|||COHORT||PROSPECTIVE|||||||
33783428|NCT06470698|||CASE_ONLY||PROSPECTIVE|||||||
33783429|NCT06712797|NA|SINGLE_GROUP||PREVENTION||NONE||"A single-arm trial evaluating the feasibility and acceptability of a 6-month Physical Activity (PA) and Nutrition (N) intervention for Intraductal Papillary Mucinous Neoplasm (IPMN) patients who are overweight and viscerally obese (on MRI) and/or have elevated levels of SOC incretin, cytokine, or adipokine biomarkers.~Patients with IPMNs (\>15 mm) who have received or will receive care in Moffitt Cancer Center's Pancreas Interception Center (PIC) will be recruited."||||
33783430|NCT01789203|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33783431|NCT06360926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783432|NCT02911571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998301|NCT06625255|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Flyers will be distributed, and participants will be able to contact the PI via email and use the QR code to complete the screening for eligibility. Eligibility screening will be conducted online by the prospective participant answering the following questions: (1) do you have a child aged 2 to 5? (b) do you speak and read English? and (c) can you attend two online sessions via Zoom where the content be provided via PowerPoint slides? Next, eligible participants will be asked to provide their email address and will then receive a link to complete the online consent procedure and pre-test through Qualtrics along with an assigned code to connect their pre-and-post data. The intervention group will begin when there are at least five eligible parents who consented. New enrolled parents will be waitlisted for two to three weeks after they completed the pre-program questionnaires, then after a two-week wait period they will be asked to complete the post-test Qualtrics survey 3.||||
33694537|NCT01350154|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33694538|NCT00378586|||||PROSPECTIVE|||||||
33694539|NCT01516073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694540|NCT03894956|||COHORT||PROSPECTIVE|||||||
33694541|NCT04938479|||CASE_ONLY||RETROSPECTIVE|||||||
33694542|NCT03090412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694543|NCT06487078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694544|NCT00514566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694545|NCT06471062|||COHORT||PROSPECTIVE|||||||
33694546|NCT05550649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694547|NCT05127031|||CASE_ONLY||OTHER|||||||
33694548|NCT02685514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694549|NCT03747419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998302|NCT03431558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Randomization will be carried out by Data management unit and all investigators /dispensers and participants will be masked to the randomization.~Clinical Trial Unit (CTU) of the Aga khan university will dispense the randomized supplemnt/placebo"|"Group 1: bLF (150 mg) will be administered after 48 hours of age with a single daily dose mixed with milk (preferentially breast milk otherwise premature formula milk).~Group 2: bLF will be administered (300mg) after 48 hours of life with a single daily dose mixed with milk (preferentially breast milk otherwise premature formula milk).~Group 3: Placebo will be administered after 48 hours of life (Placebo will be physically identical to the bLF mixed with breast milk or premature formula milk)."|t|t|t|t
33998303|NCT05233254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998304|NCT05341453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All participants of the study will undergo a clinical examination including a questionnaire survey, led by a blinded independent examiner, who will not have access to intervention documentation. The examiner will see each patient twice, before the first intervention and 6 days later in the end last therapy. The examiner will be prohibited to talk about the therapy attended. The parents of patients will be informed about the character of the examination ant the importance of the most objectivity possible. All therapists can apply both interventions, therefore masking is more efficient.|A randomized controlled trial. 16 children will be randomized into two interventional groups, on classic physiotherapy, the second hippotherapy. Participants both groups will undergo 12 therapies, twice a day, 15 minutes long. Before and in 6 day all children will be examined by a blinded independent clinician.|f|f|f|t
33998305|NCT03621046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A placebo controlled double-blinded proof-of-concept study|t|t|t|t
33998306|NCT03508063|||OTHER||RETROSPECTIVE|||||||
33998307|NCT00211562|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33998308|NCT02956681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088109|NCT03318172|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The day of the SCS implantation (RestoreSensor Surescan MRI Neurostimulator, Medtronic ©) the patients are randomized based on a random number assigned from www.randomization.com. The random number table is sent to the MedTronic representative in charge of the SCS mode control by the operating nurse who has no information about the study protocol. At this time, implantation practitioners and other research participants don't know which group is assigned first. Subjects with SCS implantation will be assigned 1:1 to either group C (conventional stimulation) or H (High-Density stimulation) to find an effective mode of pain relief.|"V1 SCS trial for 6 days (3d conventional + 3d HD stimulation).~V2 Enrolled if positive response (≥50% pain reduction) in one of the two modes during V1 + informed consent and randomization + blinding~* Group C Conventional mode (2 weeks) + HD mode (2 weeks)~* Groups H HD mode (2 weeks) + conventional mode (2 weeks)~V3 After 2 weeks (+3d allowed) from V2. Cross-over performed by the MedTronics person in charge of adjusting the SCS mode. Mode-related information will not be shared with other researchers~V4 (unblinding) 2 weeks from V3 (+3d allowed). Patients will be questioned about the more effective mode (primary endpoint). The SCS will be programmed accordingly~V5 (follow-up 1) 4 weeks after V4 (±5d). Short-term assessment of effectiveness and safety~V6 (follow-up 2) 12 weeks after V4 (±5d). Middle-term assessment of effectiveness and safety~V7 (follow-up 3) 24 weeks after V4 (±5d). Long-term assessment of effectiveness and safety"|t|t|t|f
34088110|NCT04199520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088111|NCT00662337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34088112|NCT00963235|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34088113|NCT02731898|||COHORT||PROSPECTIVE|||||||
34088114|NCT02880423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088115|NCT05948306|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was planned as a randomized controlled trial including experimental and control groups.|t|f|f|f
34088116|NCT02034006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694550|NCT04914923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment-seeking participants at Sunnybrook Health Sciences Centre (SHSC) and St. Joseph's Healthcare Hamilton, McMaster University (McMaster) with a primary DSM-5 diagnosis of OCD will be randomly assigned to receive a: 1) 12-week MBCT group intervention, 2) a 12-week CBT intervention or 3) a 12-week waitlist condition and will complete repeated assessments at baseline, throughout treatment, at post-treatment and three-month follow-up||||
34088117|NCT06280651|||OTHER||CROSS_SECTIONAL|||||||
34088118|NCT02166112|||COHORT||CROSS_SECTIONAL|||||||
33694551|NCT01415544|||COHORT||PROSPECTIVE|||||||
33694552|NCT06490731|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33694553|NCT00294476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694554|NCT03768570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694555|NCT05430542|||COHORT||PROSPECTIVE|||||||
33694556|NCT04126551|||COHORT||PROSPECTIVE|||||||
33783433|NCT03047733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A randomized, controlled, split-body, non-inferiority trial.~Patients with stable symmetric vitiligo were enrolled. The paired symmetric vitiliginous lesions were randomized to either the continuous or the cyclic on-off excimer laser treatment.~Total duration of study was 9 months.~In cyclic on-off excimer laser treatment, the cycle was arbitrarily determined that one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off)."|f|f|f|t
33783434|NCT00932919|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33783435|NCT01021644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783436|NCT06714279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783437|NCT02283645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694557|NCT05128123|||COHORT||OTHER|||||||
33694558|NCT05352490|||CASE_ONLY||PROSPECTIVE|||||||
33694559|NCT01225796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33694560|NCT06575894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||pragmatic cluster randomized trial||||
33694561|NCT00069433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694562|NCT02603328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694563|NCT02788929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694564|NCT02891811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694565|NCT02747654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783438|NCT05763251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998309|NCT01249703|||CASE_CONTROL|||||||||
33998310|NCT05062460|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33998311|NCT01732354|||COHORT||PROSPECTIVE|||||||
33783439|NCT05322161|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigator is blinded to study allocation (yoga or control group) prior to enrollment. Once participant is randomized the investigator will know which group the participant is in.|Control group receives standard of care for parent support. Interventional group receives virtual yoga classes in addition to standard of care for parent support.|f|f|t|f
33783440|NCT05366387|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Phase 1 : Open label Phase 2 : The primary endpoint is defined by quantitative analysis of SPECT images. Analysis is done by a project Partner (Inserm UMR1101), blinded to treatment arm.|Phase 1 : Delivery of intrapulmonary percussive ventilation (IPV) to assess for discomfort and adverse effects Phase 2 : Delivery of radiolabelled aerosols with or without IPV, in a crossover design|f|f|f|t
33783441|NCT02187653|||COHORT||PROSPECTIVE|||||||
33783442|NCT01685580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783443|NCT06250075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the first stage of the research, patients eligible for cancer gastrectomies were invited at FCECON on an outpatient basis or through the surgical map on the day of admission. Randomization took place through a specific application called Randomizer for Clinical Trial Lite. Different wards were assigned to each group to avoid contact between research participants (G1 intervention and G2 non-intervention). For the G3 (control) group, they will be recruited by invitation, they must be FCECON employees, this group will specifically be matched by the socioeconomic level of the patients in the G1 group. The G4 and G5 groups will be recruited and randomized in the second stage of the research after the end of the collection of the G1 and G2 groups, for analysis of clinical outcomes in the 7-day postoperative period.|In time 1 of the research, patients will be distributed through the Randomizer Clinical Trial Lite application into 4 groups (G1, G2, G4 and G5) to receive 1 capsule a day of probiotics (groups G1 and G4) will receive a formulation containing 20 billion of microorganisms. In group G2 (no intervention), treatment with standard nutrition, without the use of probiotics. The intervention product (probiotic capsules) will be distributed and packaged according to randomization for blinding. In the case of group G3 (control), they will receive probiotic capsules after the end of groups G1 and G2. Both groups that will use probiotic capsules, 1 capsule per day, in the same shift, must continue for 7 days, without interruption in monitoring. In relation to groups G4 and G5, they constitute time 2 of the research, with G4 being the group that will use probiotics following the G1 standard and G5 will use placebo capsules with 0.5g of calcium carbonate to test the power of the intervention.|t|f|f|f
33783444|NCT02977143|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783445|NCT00897767|||CASE_ONLY||PROSPECTIVE|||||||
33783446|NCT05120869|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"* Participants \[blinding\]: participants will be randomly assigned to treatment and control groups, they will not be made aware of other participant's receipt of treatment or control materials. Participants will be asked not to discuss this project outside of the intervention; delivery of the intervention or other educational materials will be virtual, limiting the ability of participants to interact with one another during the study.~* Outcome assessor \[blinding\]: to reduce bias in the implementation and assessment of the clinical trial, participant information and pre-post survey responses will be maintained separately from the assignment and delivery of the intervention."|A parallel trial design will be used to examine the effectiveness of a tailored HPV education and professional skills intervention. Emerging and current healthcare providers will be randomly assigned to one of two conditions: 1) treatment condition in which they will receive a tailored Education and Professional Skills Intervention, and 2) control condition in which they will receive general, publicly available information about HPV and communication skills. Participants will then be followed over time and the responses will be compared between groups.|t|f|f|t
33783447|NCT01532050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783448|NCT05039736|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783449|NCT04460443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783450|NCT06336746|||CASE_CONTROL||PROSPECTIVE|||||||
33783451|NCT02728986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33783452|NCT06118619|||COHORT||PROSPECTIVE|||||||
33783453|NCT03921905|||COHORT||PROSPECTIVE|||||||
33783454|NCT06714630|||COHORT||RETROSPECTIVE|||||||
33783455|NCT05152628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783456|NCT01572077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33783457|NCT06331962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783458|NCT06614088|||CASE_CONTROL||PROSPECTIVE|||||||
33783459|NCT03127345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783460|NCT05847764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783461|NCT05536466|NA|SINGLE_GROUP||TREATMENT||NONE||Pharmacokinetics of doravirine will be investigated before as well as after bariatric surgery and will be compared for each patient||||
33783462|NCT04523181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, Placebo Controlled|A Phase 2 Randomized, Double blind, Placebo Controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients with Mild to Moderate Pneumonia due to COVID 19|t|t|t|t
33783463|NCT00889564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783464|NCT01312662|||CASE_CONTROL||PROSPECTIVE|||||||
33783465|NCT01981161|||OTHER||PROSPECTIVE|||||||
33783466|NCT00304811|RANDOMIZED|PARALLEL||||SINGLE||||||
33998312|NCT05820828|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998313|NCT02805114|||CASE_ONLY||PROSPECTIVE|||||||
33998314|NCT02195544|||COHORT||PROSPECTIVE|||||||
33998315|NCT04039022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998316|NCT04320563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the participants and Investigators were masked. Only the study staff we helped with the Rexon-eye treatment was unmasked.||t|f|t|f
33998317|NCT01503658||PARALLEL||TREATMENT||NONE||||||
33998318|NCT02143726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998319|NCT00668551|||COHORT||PROSPECTIVE|||||||
34088119|NCT03247309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088120|NCT05238662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088121|NCT00169832|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088122|NCT03245606|||CASE_ONLY||PROSPECTIVE|||||||
34088123|NCT04841889|NA|SINGLE_GROUP||SCREENING||NONE||||||
34088124|NCT03739892|NA|SINGLE_GROUP||OTHER||NONE||physiopathological study||||
33694566|NCT05650060|||COHORT||RETROSPECTIVE|||||||
33918175|NCT04662216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Periodontal examination, microbiologic sampling and professional oral cleaning will be performed by the investigator, unaware of periodontal treatment. Periodontal treatment will be performed by the investigator, unaware of clinical examination. Microbiological analysis will be performed by a third investigator, masked from clinical measurements and periodontal treatment.|"The treatment will consist of two treatment modalities: (1) Control group - full mouth scaling and root planing (SRP) (2) Test group - full mouth SRP + Perisolv +Hyadent BG gels."|f|t|t|t
33918176|NCT02997254|||COHORT||RETROSPECTIVE|||||||
33918177|NCT00760604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918178|NCT04755465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918179|NCT01429077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088125|NCT02902575|NA|SINGLE_GROUP||TREATMENT||NONE||laparoscopic-assisted gastrectomy for advanced Gastric Cancer after neoadjuvant chemotherapy||||
34088126|NCT05245162|||COHORT||PROSPECTIVE|||||||
33694567|NCT00664469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694568|NCT06643845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694569|NCT06701929|||COHORT||PROSPECTIVE|||||||
33694570|NCT00551044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694571|NCT02703623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694572|NCT01462227|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33694573|NCT06692686|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694574|NCT03086421|||CASE_CONTROL||PROSPECTIVE|||||||
33694575|NCT04542044|||COHORT||PROSPECTIVE|||||||
33694576|NCT04895748|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694577|NCT05548738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) double blinded||f|t|f|t
33694578|NCT01248481|||||PROSPECTIVE|||||||
33694579|NCT01308931|||CASE_CONTROL||PROSPECTIVE|||||||
33694580|NCT06654791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694581|NCT05946213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694582|NCT01419743|||COHORT||PROSPECTIVE|||||||
33694583|NCT01729260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694584|NCT01833546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694585|NCT00810524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694586|NCT04993495|||COHORT||PROSPECTIVE|||||||
33694587|NCT06710353|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694588|NCT03252938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694589|NCT03946488|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33694590|NCT04424550|||OTHER||RETROSPECTIVE|||||||
33694591|NCT03712631|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33694592|NCT02632643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694593|NCT00359697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694594|NCT01087697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694595|NCT06710743|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33694596|NCT01397669|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33694597|NCT01083173|||CASE_ONLY||PROSPECTIVE|||||||
33694598|NCT00736879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694599|NCT04104334|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Randomization into Monitored group M (BIS + NOL + Flotrac EV1000) vs control group C (standard of care anesthesia) will be done prior to the entrance in the OR, the day of the surgery."|"2 groups of patients. Randomization into Monitored group M (BIS + NOL + Flotrac EV1000) vs control group C (standard of care anesthesia) according to randomization list for a total number of 80 patients."|t|t|t|t
33694600|NCT01199107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694601|NCT04200859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No blinding in the study.|Prospective, parallel three armed, randomized controlled trial||||
33694602|NCT06707194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33694603|NCT03506061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694604|NCT03225274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694605|NCT03374631|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will complete active and sham simulation sessions in a randomized, counterbalanced order approximately one week apart.|t|f|f|t
33694606|NCT04918576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized on the REDCap system. Their assignment will be made available to research team member, which will be preparing syringes with either TXA or placebo.|"Randomized Controlled Trial (RCT) with 2 arms: the interventional arm (receiving topical TXA) and the control arm (receiving placebo).~Intervention: Topical application of 3 grams of tranexamic acid (30 mL of 100mg/mL) diluted in 10 mL of normal saline in the breast.~Placebo: Topical application of 40 mL of 0.9% normal saline to the breast."|t|t|f|f
33694607|NCT06279013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Interviewers will be blinded to the study arm; IVR is automated.|Cluster randomized|f|f|f|t
33694608|NCT02506946|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33694609|NCT00229151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694610|NCT00739050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694611|NCT06709885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694612|NCT05753527|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33694613|NCT03148275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694614|NCT02637622|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694615|NCT03472872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The provider will place orders in the electronic medical record for Headache study order set. This order set includes Compazine® 10 mg IV, Benadryl® 25 mg IV, and study drug. Pharmacy will receive the order for the study drug. The research pharmacist will randomly assign participants to group A (1000 mg Ofirmev®) or group B (15 mg ketorolac)."|Randomized, double-blind trial comparing two parenteral adjuvant treatments for headache among patients presenting to the Lakeland Health Emergency Department in St. Joseph, MI.|t|t|f|f
33694616|NCT06706856|||COHORT||PROSPECTIVE|||||||
33694617|NCT00572897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694618|NCT06553170|||COHORT||RETROSPECTIVE|||||||
34088127|NCT04555447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A research assistant not involved in the study was responsible for the generation of each participant's code, and for providing codified bags with ready-to-use sachets of each dietary supplement with the corresponding dose. The clinical trial coordinator enrolled participants, and investigators and participants were blinded to treatment allocation.|Healthy and obese participants randomized into agavins (prebiotic fiber) or placebo group received the corresponding dietary supplement simultaneously|t|f|t|f
33783467|NCT04500743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783468|NCT04463082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The pediatric patients will be divided into three groups, according to weight: 10-20kg, 20-30kg, 30-50kg.||||
33783469|NCT06650696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33998320|NCT04168307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physiotherapist conducting follow ups at 6, 12 and 52 weeks was masked for group affiliation||f|f|t|t
33998321|NCT03183622|||CASE_ONLY||PROSPECTIVE|||||||
34088128|NCT04319705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783470|NCT00990756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33783471|NCT05727956|||CASE_ONLY||RETROSPECTIVE|||||||
33783472|NCT01368120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33783473|NCT06651658|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33783474|NCT03683355|||COHORT||PROSPECTIVE|||||||
33783475|NCT00331162|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998322|NCT03967262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998323|NCT01953185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088129|NCT05888519|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998324|NCT04146805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998325|NCT02183727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998326|NCT03097198|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33998327|NCT02281539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998328|NCT02766257|NA|SINGLE_GROUP||||NONE||||||
33998329|NCT01377441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34088130|NCT02472405|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each participant scar was randomized to the 3 treatment arms.|f|f|f|t
34088131|NCT02641054|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34088132|NCT00002846||||TREATMENT||||||||
33694619|NCT06707311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694620|NCT01854203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783476|NCT04835584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783477|NCT00375856|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33783478|NCT00052962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783479|NCT03323840|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33783480|NCT03356015|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33694621|NCT06170203|||OTHER||PROSPECTIVE|||||||
33783481|NCT06045806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998330|NCT06363799|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33998331|NCT03708406|||COHORT||PROSPECTIVE|||||||
33694622|NCT06704776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers, outcome assessors and statisticians will be blinded to the group assignments and will not be involved in the trial operations. The patients will also be blinded to the group assignments. Due to the impossibility of blinding the surgeons, they will not be involved in any outcome assessments. Allocation results will be placed in sealed envelopes before the surgery. The envelopes will be opened prior to surgery after the administration of general anaesthesia.|"The trial employs a random allocation method. A randomization table will be generated using SPSS 26.0 software. Treatment groups will be selected based on patients' random numbers, ensuring that this clinical institution stratifies the subjects into an The medially pedicled IPFP flap group and a Complete IPFP removal group at a 1:1 ratio."|t|f|f|t
33694623|NCT06569251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both the patient and the principal investigator will know the intervention, the data analyst researcher does not know the group to which the patients have been assigned.|Experimental. Single-blind, parallel-group, non-inferiority randomized clinical trial.|f|f|f|t
33694624|NCT00001095||||TREATMENT||||||||
33694625|NCT06707779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694626|NCT06338748|NA|SINGLE_GROUP||OTHER||NONE|The study will involve using blinded Dexcom G7 continuous glucose monitoring (CGM) devices|Patients undergoing heart surgery at the Cleveland Clinic (main campus) who would normally be tested for high sugar levels by poking a finger and using a test strip.||||
33998332|NCT04436419|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33783482|NCT03825393|||CASE_CONTROL||RETROSPECTIVE|||||||
33783483|NCT00555581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998333|NCT04460716|||COHORT||RETROSPECTIVE|||||||
33918180|NCT04414696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Investigators and programmers/analysts will be blinded to the intervention assignment. The participants, project manager and research assistant will not be masked.||f|f|t|f
33918181|NCT01225471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918182|NCT03497260|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33918183|NCT04348656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918184|NCT00776932|||COHORT||CROSS_SECTIONAL|||||||
33918185|NCT04143763|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33918186|NCT03747744|NA|SINGLE_GROUP||TREATMENT||NONE||Intratumoral injection of T-VEC followed by intratumoral injection of CD1c (BDCA-1)+ myDC||||
33918187|NCT01545609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918188|NCT00895193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33918189|NCT02193256|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33918190|NCT04580823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will have to do the 3 acute interventions||||
33918191|NCT01595165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918192|NCT00994656|||COHORT||PROSPECTIVE|||||||
33918193|NCT01766570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33918194|NCT01476384|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33918195|NCT05638763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918196|NCT01140802|||CASE_CONTROL||PROSPECTIVE|||||||
33918197|NCT05444010|NA|SINGLE_GROUP||PREVENTION||NONE||This study is an experimental study with pre-test and post-test control grups||||
33918198|NCT02842112|||COHORT||RETROSPECTIVE|||||||
33918199|NCT05580471|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Use 4DryField~One group use 4DryField before wound closure. One group do not use 4DryField before wound closure."||||
33918200|NCT01562366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33918201|NCT01327872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918202|NCT02123030|||OTHER||PROSPECTIVE|||||||
33918203|NCT02930616|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33918204|NCT01680770|||COHORT||PROSPECTIVE|||||||
33998334|NCT04915339|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The study hypothesis is not given to the participants and the investigator will not be aware of the group the participants have been allocated to.|"* Group 1: physical activity (one month) then cognitive training (one month)~* Group 2: Cognitive training (one month) then physical activity (one month)~* Group 3 : resonance frequency breathing (one month) then combined physical activity and cognitive (one month) training"|t|f|t|t
33694627|NCT00674973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694628|NCT02818231|||CASE_CONTROL||PROSPECTIVE|||||||
33694629|NCT01205815|||OTHER||PROSPECTIVE|||||||
33694630|NCT02588937|RANDOMIZED|||TREATMENT||NONE||||||
33783484|NCT05843500|||COHORT||PROSPECTIVE|||||||
33783485|NCT06392360|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigators and study participants will be blind to treatment allocation, with the betaine and placebo supplements in capsules of the same color.|Randomized treatment, double blinded procedures, crossover|t|f|t|f
33783486|NCT02947711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783487|NCT03364179|||CASE_ONLY||PROSPECTIVE|||||||
33783488|NCT04399707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are randomized to one of three groups in parallel for the duration of the study|t|t|t|t
33783489|NCT03310528|||CASE_CONTROL||PROSPECTIVE|||||||
33783490|NCT01675830|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33783491|NCT05536427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783492|NCT01853917|||COHORT||PROSPECTIVE|||||||
33783493|NCT04699448|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918205|NCT05271396|||CASE_CONTROL||PROSPECTIVE|||||||
33783494|NCT00816335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783495|NCT05171933|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33783496|NCT00003543||||TREATMENT||||||||
33783497|NCT00490555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783498|NCT05551403|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33783499|NCT06197672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783500|NCT05180474|NA|SEQUENTIAL||TREATMENT||NONE||||||
33783501|NCT03063307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783502|NCT01822158|NA|SINGLE_GROUP||OTHER||NONE||||||
33783503|NCT04210024|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783504|NCT06713772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783505|NCT06454292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783506|NCT04912557|||COHORT||PROSPECTIVE|||||||
33783507|NCT05417698|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised-controlled||||
33783508|NCT06713837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783509|NCT00138450|||||PROSPECTIVE|||||||
33783510|NCT04908163|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study uses a randomized controlled trial design with one-month intervention program and six months of follow-up in order to test the effects of a culinary intervention program to improve cooking and healthy eating behaviour in overweight and obese patients.~The culinary intervention program will be given over a one-month period, two days a week for four weeks. Participants in the control group (CG) will receive dietary training based on Mediterranean diet at the baseline visit and a leaflet explaining this dietary pattern. The participants assigned to the culinary intervention program will receive the same nutritional recommendations and eight online nutritional and cooking classes."||||
33783511|NCT00253214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33783512|NCT02616263|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33783513|NCT06708832|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33783514|NCT01636362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783515|NCT06575517|||OTHER||PROSPECTIVE|||||||
33783516|NCT04550650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783517|NCT06581926|||CASE_CONTROL||PROSPECTIVE|||||||
33783518|NCT04213846|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two conditions (mobile Alcohol Expectancy Intervention and assessment-only control group).||||
33783519|NCT05536284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783520|NCT00555347|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33783521|NCT03165383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783522|NCT01394770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33783523|NCT06711666|||COHORT||PROSPECTIVE|||||||
33783524|NCT01886469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801486|NCT03459677|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a randomized controlled superiority trial (RCT) that compares a modular trans-diagnostic CBT intervention (Back2School), treating school absenteeism in youths aged 7-17 years with treatment as usual (TAU). The design will follow a two (Back2School and TAU) by four (Time: pre, post, 3-month, and 1-year assessment) mixed between-within design.||||
33801487|NCT02213744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801488|NCT05530161|||CASE_CONTROL||RETROSPECTIVE|||||||
33801489|NCT04502472|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 will be recruitment and enrollment of plasma donors. Phase 2 will be continued recruitment and enrollment of plasma donors, with the addition of recruitment and enrollment of plasma recipients.||||
33694631|NCT05262725|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, pre/post pilot trial||||
33694632|NCT06710002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694633|NCT05841901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694634|NCT03183011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694635|NCT00287079||PARALLEL||TREATMENT||NONE||||||
33694636|NCT06708208|||COHORT||RETROSPECTIVE|||||||
33694637|NCT05345054|||COHORT||PROSPECTIVE|||||||
33783525|NCT05931484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a phase 2, double-blind, multi-center, placebo-controlled clinical study to evaluate the safety, tolerability, efficacy, and PK of FHL-301 in adult patients with early-stage PD. Following screening, qualifying patients who meet all inclusion and exclusion criteria will be randomized 1:1 ratio to receive FHL-301 or Placebo. The study is comprised of two phases: the Dose Titration Phase (DTP) in which participants will be started with a dose of 200 mg BID (30 minutes before the morning and evening meals) and increased during a 3-week treatment period. Patients who complete the DTP of the study will enter the Maintenance Phase and remain on the final titrated dose for up to 48 weeks post titration. If at any stage during the titration phase the participant cannot tolerate the increased dose, the dose will be decreased by 100 mg BID weekly until the highest tolerated dose is reached.|t|t|t|t
33783526|NCT00419068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33783527|NCT03917381|NA|SEQUENTIAL||TREATMENT||NONE||||||
33783528|NCT03371108|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects who meet the study eligibility criteria will be centrally randomized 1:1 in an open-label fashion to receive either Gan \& Lee Insulin Glargine Injection or Lantus® for 26 weeks.||||
33694638|NCT03705247|||COHORT||PROSPECTIVE|||||||
33694639|NCT06706596|||OTHER||PROSPECTIVE|||||||
33694640|NCT01316354|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33694641|NCT00799110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783529|NCT00418847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783530|NCT05869838|||CASE_ONLY||PROSPECTIVE|||||||
33783531|NCT03034733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783532|NCT00589732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783533|NCT05245656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783534|NCT03905135|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783535|NCT03136276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|f|t
33783536|NCT04699799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918206|NCT03975374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"In group one, patients will be instructed to instill 2 gtt of Tobradex ophthalmic solution for 10 days.~In group two, patients will be instructed to instill 2 gtt of Tobramycin/dexamethasone solution for 10 days ."|t|f|f|f
33918207|NCT03600948|||COHORT||PROSPECTIVE|||||||
33918208|NCT04679259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918209|NCT02557412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918210|NCT00789269|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918211|NCT00748085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918212|NCT01671956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918213|NCT03771456|||COHORT||PROSPECTIVE|||||||
33918214|NCT04433624|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33918215|NCT00223691|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33918216|NCT04840706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918217|NCT05831618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918218|NCT01806376|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918219|NCT03637907|||CASE_ONLY||PROSPECTIVE|||||||
33918220|NCT05044585|NA|SINGLE_GROUP||OTHER||NONE||prospective feasibility study,||||
33918221|NCT00661349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918222|NCT00901147|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918223|NCT02863939|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918224|NCT03677310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The bags of IV solution will be masked by the pharmacists before sending to the operating room.|There is no effective treatment for post-operative dysphagia. Thus crossover is not expected.|t|f|t|f
33918225|NCT00004799|RANDOMIZED|||PREVENTION||DOUBLE||||||
33918226|NCT03536598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918227|NCT02063919|||CASE_CONTROL||PROSPECTIVE|||||||
33918228|NCT01894529|||COHORT||PROSPECTIVE|||||||
33918229|NCT04699552|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Treating surgeons will know the randomization at the time of the operation however the postoperative data analysis and results will be performed by the research team in a blinded fashion when examining clinical outcomes and adverse events||t|f|f|t
33918230|NCT01927419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998335|NCT05485662|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The study will be blinded to both the study team and the subjects.|This is a double-blind, randomized, sequential, single center, controlled clinical trial.|t|f|t|f
33998336|NCT05197491|||COHORT||RETROSPECTIVE|||||||
33998337|NCT01155531|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998338|NCT04202757|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding will be achieved by preparing both yFFP and placebo (0.1% riboflavin in normal saline) solution into identical-sized, masked bags. The riboflavin is added to the saline to achieve indistinguishable color when compared to the yFFP. Physicians who evaluate patients are masked from treatment assignment.|Placebo controlled trial|t|t|f|t
33998339|NCT02518139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998340|NCT00844974|NA|SINGLE_GROUP||||NONE||||||
33998341|NCT01750827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998342|NCT00293878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998343|NCT03995849|||COHORT||PROSPECTIVE|||||||
33694642|NCT06708442|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33694643|NCT01698112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694644|NCT00121173|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33694645|NCT02808650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694646|NCT06653036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998344|NCT00085501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998345|NCT06298162|||COHORT||CROSS_SECTIONAL|||||||
33998346|NCT03341013|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33694647|NCT01843517|||COHORT||PROSPECTIVE|||||||
33694648|NCT04520373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998347|NCT06492252|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Healthy right-handed adults with normal hearing will be recruited in equal number from both sexes. All participants will be fluent English speakers.||||
33998348|NCT02943538|RANDOMIZED|PARALLEL||||NONE||||||
33998349|NCT01300884|||CASE_CONTROL||PROSPECTIVE|||||||
33998350|NCT02766218|||COHORT||PROSPECTIVE|||||||
33998351|NCT00662272|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33998352|NCT06028477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blinded for 6 months followed by an unblinding of everyone with the exception of the clinical assessor||t|t|t|t
33998353|NCT02861560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998354|NCT00464594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998355|NCT03368209|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open, non-randomized comparison study between device and blood references with diabetic patients||||
33998356|NCT05031455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998357|NCT03790163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double(participant ,care provider)||t|t|f|f
33998358|NCT03314857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998359|NCT04737239|||COHORT||OTHER|||||||
33998360|NCT01186458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998361|NCT05264896|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33998362|NCT01704105|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Analysts and lab technicians were masked to intervention status. Outcome collectors were not informed of intervention status, but could have inferred status from observing intervention hardware during household visits.||f|f|t|f
33998363|NCT05762016|||COHORT||RETROSPECTIVE|||||||
33998364|NCT00095537|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998365|NCT02267408|RANDOMIZED|PARALLEL||TREATMENT||NONE||Dosing of warfarin according to the Fearon algorithm or routine during 6 months for patients with unstable INRs||||
33998366|NCT05475392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998367|NCT02927210|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33998368|NCT01307761|||||RETROSPECTIVE|||||||
33998369|NCT05686993|NA|SEQUENTIAL||TREATMENT||NONE||Treatment with 2 study drugs with 2 weeks of drug washout in between Study drug treatments are: cinnarizine for 2 weeks, nifedipine for 2 weeks Order randomly determined by computer program, with results released by an independent clinician as patients are recruited||||
33998370|NCT05201235|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The training will be performed at home. The investigators/evaluators will send a download link of the therapy to the patient's parents without knowing which therapy it corresponds to.|"On the first group children will be trained first with MAEVAD then with a control training that does not stimulate the VA span. On contrary, on the second group children will first perform the control training and then MAEVAD.~For each intervention the sessions will lasts 15 minutes. 5 sessions are planned per weeks for 6 weeks."|f|f|t|t
33998371|NCT05623228|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented|f|f|f|t
33998372|NCT06042296|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33998373|NCT04038866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapists who assessment gait before and after interventions (post and follow-up) did not know to which group each patient belonged.|Patients were randomized into two groups: control and experimental. Both groups performed different physical therapy programs to rehabilitate gait, in the experimental group they were included dual tasks during the walking exercises. Control and experimental group developed the rehabilitation programs at the same time.|f|f|f|t
33998374|NCT04471116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998375|NCT03431636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998376|NCT04785053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be randomized to the tACS treatment (target tACS, minimum 2 days later an active sham control).||t|f|f|f
33998377|NCT03701451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998378|NCT03505996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694649|NCT03200158|NA|SINGLE_GROUP||OTHER||NONE||||||
33694650|NCT03701321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 arms in phase I, 2 arms in phase II||||
33783537|NCT02487641|||CASE_CONTROL||PROSPECTIVE|||||||
33783538|NCT05630339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the patient nor the treating doctor will know the study group the participant was randomized.|"Study groups:~1. Intervention group that will receive 1.2 g of magnesium chloride (equivalent to 360 mg of magnesium elemental) + 4000 IU of vitamin D once a day, for four months.~2. Control group that will receive inert placebo for four months."|t|t|f|f
33783539|NCT05804396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694651|NCT03341039|||COHORT||PROSPECTIVE|||||||
33694652|NCT05095831|||CASE_CONTROL||PROSPECTIVE|||||||
33694653|NCT01410539|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694654|NCT02147912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694655|NCT00494273|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33694656|NCT01231854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783540|NCT06300398|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
33783541|NCT00188929|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801490|NCT06520449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801491|NCT00137722|||||RETROSPECTIVE|||||||
33998379|NCT05028140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998380|NCT06203080|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33998381|NCT05153304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998382|NCT02018263|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998383|NCT03284697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33998384|NCT06057558|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998385|NCT00690027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33998386|NCT06256562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998387|NCT02193945|||CASE_ONLY||RETROSPECTIVE|||||||
34088133|NCT05759910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088134|NCT00485836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694657|NCT06707857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was single blinded, as accessor of the study were kept blind to the intervention groups|In this parallel- group randomized control trial(RCT) Rotator cuff tendinopathy patients will be assigned to either tendon neuroplastic training or to traditional treatment plan. this study aims to evaluate the effects pf tendon neuroplastic training on pain, range of motion and disability.|f|f|f|t
33694658|NCT05704725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694659|NCT06440629|RANDOMIZED|PARALLEL||TREATMENT||NONE|The joint assessor will be blinded.|||||
33998388|NCT05722080|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||First arm to model the learning curve of opthalmologist residents Second arm to show the impact of sleep deprivation on the surgical performance of experienced opthalmologist residents||||
33998389|NCT05646316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998390|NCT00320684|||CASE_CONTROL||PROSPECTIVE|||||||
33998391|NCT04967469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998392|NCT01531790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694660|NCT04606914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694661|NCT02712255|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33694662|NCT06433401|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not know which group they are in. They will be assigned to groups by simple simple random randomization method. Since the researcher was the one who provided the training, researcher blinding could not be performed.|The study included two groups, an intervention group and a control group. Intervention group receiving transitional care training and control group receiving routine care.|t|f|f|f
33694663|NCT02310932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694664|NCT01177254|||CASE_CONTROL||RETROSPECTIVE|||||||
33694665|NCT01935102|||COHORT||RETROSPECTIVE|||||||
33694666|NCT02374515|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694667|NCT06433570|||CASE_ONLY||CROSS_SECTIONAL|||||||
33694668|NCT06708481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
33694669|NCT05255029|NA|SINGLE_GROUP||TREATMENT||NONE||1) Summary of investigational lens Model: POD T 49P General name: PODEYE Toric Construction Single-piece construction lens consisting of the optic and the haptic made of the same material, optic diameter: 6.0 mm, overall length: 11.4 mm (Fig.1). Cylinder power is added on the posterior optics.||||
33694670|NCT05067595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694671|NCT04575844|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33694672|NCT02544074|||OTHER||PROSPECTIVE|||||||
33694673|NCT02291536|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33694674|NCT00187759|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33694675|NCT02232191|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33694676|NCT02372240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694677|NCT03552458|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||randomized double blind prospective placebo controlled clinical study|t|f|t|t
33694678|NCT06143553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694679|NCT00949273|||CASE_CONTROL||PROSPECTIVE|||||||
33694680|NCT00638807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694681|NCT06547021|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The order of treatments is only known by the study coordinator, the PI and the supervisor. The order of treatments will be randomized.|All participants receive all 4 treatments in a randomized order with washout period of 2-5 months.|t|t|f|t
33694682|NCT06708000|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"The randomization will be conducted in a 1:1 ratio using an internet-based randomization solution.~Then, patients will be randomly assigned to either the control group or the intervention group, and regardless of study allocation and initial RF-CL assessement, all patients will then receive an initially blinded CCTA. The cardiologist conducting the CCTA is unaware of the patient's randomization status.~Patients in the intervention group with a clinical likelihood of obstructive CAD (RF-CL) ≤5% will receive a blinded CCTA.~Patients in the intervention group with RF-CL \>5% will undergo a CACS assessment to estimate a CACS-CL.~Patients in the control group, and patients in the intervention group with a CL \>5%, will receive their test results, including unblinding of the results from the CCTA.~Patients in the intervention group with CL≤5% will also receive their test results, except for the CCTA results which remain blinded.~The interviewer at follow-up is unaware of the CCTA result."|The project is a randomized, multi-centre interventional study that includes patients without prior evaluation for obstructive CAD who are referred for cardiac CT based on clinically suspected stable ischemic heart disease. Participants are 1:1 randomized into either an intervention group where patient management relies on an initial CL evaluation, or a control group that adheres to current standard diagnostic procedures. This design allows for direct comparison of outcomes between the new and existing diagnostic strategies.|f|f|t|f
33694683|NCT02294773|RANDOMIZED|PARALLEL||||NONE||||||
33694684|NCT03272230|NA|PARALLEL||DIAGNOSTIC||NONE||||||
33694685|NCT00042367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694686|NCT02218983|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694687|NCT03506932|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized, controlled, cross-over study||||
33694688|NCT00862290|||CASE_CONTROL||PROSPECTIVE|||||||
33694689|NCT03815617|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Patients entered the following program:~* A run-in period of one month when symptoms, intestinal permeability, intestinal microbiota, and dietary evaluations were performed;~* Phase 1: randomization to treatment or placebo lasting 30 days;~* Wash-out period lasting 15 days, at the end of which symptoms were assessed;~* Phase 2: switch to next treatment in a crossover fashion. Treatment lasted for 30 days and at the end symptoms, intestinal permeability, and intestinal microbiota were evaluated again."||||
33694690|NCT06003569|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33694691|NCT00493376|||COHORT||PROSPECTIVE|||||||
33694692|NCT01077232|||CASE_ONLY||PROSPECTIVE|||||||
33694693|NCT01222858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694694|NCT03161821|||OTHER||PROSPECTIVE|||||||
33694695|NCT06247800|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33694696|NCT01840618|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33694697|NCT00311662|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33694698|NCT01439568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694699|NCT00884533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33694700|NCT04524169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33694701|NCT06707727|||COHORT||PROSPECTIVE|||||||
33694702|NCT06639217|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33783542|NCT03566680|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will be fit in orthokeratology contact lenses and be monitored for three months.||||
33694703|NCT04072575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694704|NCT01407744|||||RETROSPECTIVE|||||||
33783543|NCT03861455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomized 1:1 to receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0 or placebo.|t|f|t|f
33783544|NCT05590715|||COHORT||CROSS_SECTIONAL|||||||
33783545|NCT03382743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled trial|t|f|f|f
33783546|NCT06271356|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783547|NCT05546099|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will monitor home BP and adjust meds based on a protocol and under the guidance of a clinical pharmacist.||||
33783548|NCT03794778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783549|NCT02775435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783550|NCT03040193|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33783551|NCT00854139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783552|NCT04516811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither participants nor the investigators will be aware of the participant's treatment allocation until the end of the study (double blinding). Blinding will be maintained by local blood bank preparing the appropriate IP and Placebo. Unmasking procedures are detailed by SOP|Participant identification numbers (PIN), assigned at the screening/enrolment visit, will be used throughout the study. After signing the informed consent document, eligible participants will be randomised to one of the treatment arms, stratified by study site, age group (\<=65; \>65 years old) and body mass index (BMI) (\<30; \>=30 kg/m2). An electronic randomisation application will generate the treatment allocation. The trial Program Manager (PM), who will have no direct contact with trial participants or involvement in eligibility assessment or outcome assignment, will maintain the randomisation code.|t|t|t|f
33783553|NCT06378879|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783554|NCT02871765|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33783555|NCT06311227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783556|NCT00893217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783557|NCT05939947|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Double-blind|Thirty-eight patients will receive 3 doses of ALE.F02 or matching placebo, administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses per patient at the same dose level. The 4 cohorts are enrolled in a staggered sequence and escalated upon review and approval of a Safety Review Committee: Cohort 1 (low dose) (4:2 active:placebo), Cohort 2 (intermediate dose) (8:4), Cohort 3 (intermediate dose) (8:2), Cohort 4 (high dose) (8:2).|t|f|t|t
33783558|NCT06711224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783559|NCT00423774|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33694705|NCT00857402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33783560|NCT01111890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33783561|NCT05913323|||OTHER||CROSS_SECTIONAL|||||||
33783562|NCT02386371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783563|NCT05814640|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Both the patient and the psychiatrist know which group they are allocated to, while the outcome assessor and data analyst are kept blind to the allocation. The clinicians providing the intervention do not perform the assessment and are unaware of the results.|After receiving fluoxetine and fluoxetine combined with cognitive-behavioral therapy, the next stage of treatment is determined by the patient's response (remission and non-remission) and is scheduled according to the patient's wishes and random assignment.|f|f|t|t
33783564|NCT00232076|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33783565|NCT06713148|NA|SEQUENTIAL||TREATMENT||NONE||||||
33918231|NCT03195504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Consented patients will be randomly assigned either to the interventional group (High Flow Nasal Cannula- HFNC) or to the control group (CON). The Group HFNC will be preoxygenated using HFNC and the Group CON will receive standard preoxygenation.|t|f|f|f
33918232|NCT01167582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918233|NCT03110419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33918234|NCT01935336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918235|NCT04147871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918236|NCT06362460|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918237|NCT01336166|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694706|NCT02935101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33694707|NCT05695196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694708|NCT03617354|||COHORT||PROSPECTIVE|||||||
33694709|NCT00959712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694710|NCT04196751|NA|SINGLE_GROUP||OTHER||NONE||Open-label Prospective Longitudinal Study||||
33694711|NCT00130273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33694712|NCT05141201|||COHORT||PROSPECTIVE|||||||
33694713|NCT03109054|||CASE_CONTROL||PROSPECTIVE|||||||
33694714|NCT02947412|||CASE_ONLY||RETROSPECTIVE|||||||
33783566|NCT03421444|||COHORT||PROSPECTIVE|||||||
33783567|NCT05976854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33783568|NCT01796977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783569|NCT04141163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783570|NCT05908448|||COHORT||PROSPECTIVE|||||||
33783571|NCT04729543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783572|NCT05207787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783573|NCT04467762|||CASE_CONTROL||PROSPECTIVE|||||||
33783574|NCT06371482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783575|NCT00945477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783576|NCT02938390|||CASE_ONLY||PROSPECTIVE|||||||
33783577|NCT03623646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694715|NCT06005142|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All subjects and the principal investigator will remain blinded to treatment until data analysis is complete. Eriomin (lemon flavonoids extract) and Placebo (composed of microcrystalline corn starch) were encapsulated in tablets of the same size, shape, and color, by a registered pharmacist.|"A crossover, randomized, placebo-controlled, double-blind clinical trial will be conducted for 12 weeks, with a two-week washout interval, followed by another 12 weeks, totaling 26 weeks.~All participants must be under oral biguanide (metformin) (1000 mg/day) regimen by at least two weeks before the intervention, and they will be measure for glycemia, HbA1c and OGTT, and an interview with an MD and Nutritionist in order to confirm eligibility, according to the inclusion/exclusion criteria.~The selected individuals will be randomly distributed into 2 groups, and they will receive alternately Eriomin (or placebo), followed by 2-weeks of washout, and placebo (or Eriomin) for 12 weeks.~At the beginning of the first, 12th, 14th, and 26th weeks, all subjects will be evaluated for the following: Glycemia, OGTT, HbA1c, Insulin, Lipids, TEAC, MDA, GLP-1, inflammatory, hepatic, kidney, and anthropometric parameters, and microbiota composition."|t|f|t|t
33694716|NCT06228131|||COHORT||PROSPECTIVE|||||||
33694717|NCT05255653|RANDOMIZED|PARALLEL||TREATMENT||NONE||Platform trial wherein eligible patients are assigned to one of four parallel running clinical trials. Three of four trials are randomised controlled trials and one is a prospective clinical trial with two study arms.||||
33694718|NCT02320318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694719|NCT05790057|||OTHER||CROSS_SECTIONAL|||||||
33918238|NCT00961922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918239|NCT00390416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918240|NCT03285763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918241|NCT03299855|NA|SINGLE_GROUP||OTHER||SINGLE||Passation of MMS and MoCA tests associated to passation of neuropsychological test|t|f|f|f
33918242|NCT00691262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918243|NCT01254513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918244|NCT04030780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participants, care providers, investigators and outcomes assessor are blinded during the randomized placebo-controlled phase (8 weeks) but not during the open-label extension phase (8 weeks)|randomized placebo-controlled study in 2 parallel FD cohorts|t|t|t|t
33918245|NCT05475093|||OTHER||PROSPECTIVE|||||||
33918246|NCT03600714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918247|NCT01373866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33918248|NCT04533815|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study in 3 nursing homes. The pilot phase (R61) informs the next phase (R33), a clinical trial using an incomplete, stepped, wedge cluster randomized controlled trial (RCT) design with 24 nursing homes. Each nursing home in the full clinical trial (R33) will act as its own control (4 staggered steps, with 6 nursing homes per step).||||
33918249|NCT04658381|NA|SINGLE_GROUP||SCREENING||NONE||||||
33918250|NCT01974713|||COHORT||PROSPECTIVE|||||||
33998393|NCT00412464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998394|NCT01968369|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33998395|NCT03097692|RANDOMIZED|PARALLEL||OTHER||DOUBLE||intervention group well be pretreated with cardiac preconditioning|t|f|f|t
33694720|NCT02746068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998396|NCT01866124|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998397|NCT01026402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694721|NCT04856891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694722|NCT05532475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33694723|NCT04850313|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1: This phase will establish baseline characteristics for each patient that is randomized into the treatment arm for the phase 2 part of the study.~Phase 2: This phase will test the intervention of using ProKera Plus® versus continuing conventional treatment for the corneal ulcer"||||
33694724|NCT04973696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Research assistants who assess outcomes and collect data after randomization, orthopedic surgeons, and statistician will be blinded.~The study clinicians will be unblinded. The research assistant who enrolls participants and performs activities before randomization will be unblinded."||f|f|t|t
33694725|NCT00833716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694726|NCT06051591|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will not be masked as they will be receiving twice monthly groceries if they are enrolled in the Food FARMacia program.|Participants will be randomized and assigned to enroll in the Food FARMacia program for the duration of the study period or to receive usual care.|f|t|t|t
33694727|NCT00355654|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694728|NCT05884710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|30 participants with patellofemoral pain syndrome|Participants with Patellofemoral Pain Syndrome (PFPS) will be randomly divided into 2 groups.|t|f|f|f
33918251|NCT02490917|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33694729|NCT06325904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694730|NCT04741698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694731|NCT02793011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918252|NCT05847244|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective open-label, randomized controlled study||||
33918253|NCT00141700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918254|NCT05102396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918255|NCT05564910|||CASE_CONTROL||PROSPECTIVE|||||||
33918256|NCT05946759|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918257|NCT05532995|||COHORT||RETROSPECTIVE|||||||
33998398|NCT02749305|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998399|NCT05172921|||CASE_CONTROL||PROSPECTIVE|||||||
34103084|NCT03956082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|A sample size of 20 patients should provide a sufficient sample size for comparative analysis to prior clinical data relative to Ultravision and published peer reviewed clinical data on laparoscopy and low impact laparoscopy|"This is a prospective single arm study. The study will enroll 20 patients. Comparisons to prior clinical trials and published literature will be made to assess the relative significance of the study results.~Duration of Study: The target for the overall duration of the study is four months"||||
34103085|NCT06011252|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, prospective, multi-center, non-randomized, single-arm study||||
34103086|NCT06290635|||COHORT||PROSPECTIVE|||||||
33783578|NCT05166343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Paramedic services across Ontario will participate in the study. All sites will begin with a period of baseline data collection (standard of care arm) and will cross over to the intervention arm (Intramuscular Epinephrine Dose arm) on a staggered schedule and in random order. Each site will remain in the intervention arm, once cross over happens, for the duration of the study.||||
33783579|NCT04413279|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33783580|NCT00009685||||TREATMENT||||||||
33783581|NCT05167747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783582|NCT00117377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783583|NCT00359957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783584|NCT05566405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783585|NCT04144985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783586|NCT01031693|RANDOMIZED|PARALLEL||TREATMENT||||||||
33783587|NCT06708962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783588|NCT05567159|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33783589|NCT06584513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessment is performed by research team blinded to the allocated intervention.|Participating physicians will be randomly assigned in a 1:1 ratio in clusters to either the intervention group or the control group. Patients of participating physicians will be assigned to the physician randomisation group.|t|f|f|t
33783590|NCT01203553|||CASE_CONTROL||PROSPECTIVE|||||||
33783591|NCT06714357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783592|NCT06711614|RANDOMIZED|CROSSOVER||OTHER||SINGLE|environmental engineer (administering the woodsmoke exposure) will be masked to diet assignment|Each participant will be randomized to begin the study with the control diet (their usual diet) or the intervention diet (aimed at increasing intake of fatty fish high in omega-3 fatty acids, fruits, and vegetables) x \~4 weeks. After a washout period of at least 4 weeks the participant will complete the alternate assignment. At the end of each assignment (control or intervention diet) the participant will undergo a controlled exposure to wood smoke x 2 hours, following which lung health outcomes will be assessed as described.|f|f|t|f
33998400|NCT04435574|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"the population for the study will be Scholar age Children attend family medicine clinic for treatment of iron deficiency anemia and their parents accept participation in the study.~For confirmation of the diagnosis of iron deficiency anemia the following investigations will be done:~* CBC~* Serum total iron~full medical history and examination will be performed. study participants will be assigned to either group A (lactoferrin group) or group B (ferrous sulfate group), and will receive the corresponding medication for 8 weeks.~4 weeks follow up for side effects and hemoglobin level and 8 weeks follow up for side effects, hemoglobin level and serum iron will be performed."||||
33694732|NCT05997771|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The evaluation of the usability will be done using a prospective single arm design (n=80). In addition, we will collect data regarding the efficacy of the intervention by comparing results of the study participants to results of historical controls (n=80). Historical controls are patients receiving the same usual care dietary counselling as the study participants but without assistance by the personal nutrition advisor.||||
33998401|NCT00327847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998402|NCT03488108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998403|NCT02131220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783593|NCT02758262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33783594|NCT00852228|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783595|NCT04706013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783596|NCT00174720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783597|NCT01250951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783598|NCT06551584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998404|NCT04603547|||COHORT||PROSPECTIVE|||||||
33998405|NCT03791307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One researcher will be blinded to the conduct of evaluations and revaluations. One researcher will be blinded for outcomes statistics analysis.||f|f|t|t
33998406|NCT04837469|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33998407|NCT03391505|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33998408|NCT02227238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998409|NCT01614288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33998410|NCT05089903|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|||t|f|t|f
33998411|NCT05376423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998412|NCT01275664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998413|NCT04198701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study begins with a Pilot Phase, followed sequentially by a Pivotal Phase consisting of 3 arms enrolling simultaneously: Roll-in, Paroxysmal AF, Persistent AF||||
33998414|NCT01807026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33998415|NCT02822716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998416|NCT06069037|NA|SINGLE_GROUP||TREATMENT||NONE||SALT for patients who meet the enrollment conditions and successfully match the donor liver. Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.||||
33998417|NCT01929187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998418|NCT04626440|||COHORT||PROSPECTIVE|||||||
33783599|NCT03186807|||COHORT||PROSPECTIVE|||||||
33783600|NCT01174550|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33801492|NCT00150813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801493|NCT03580369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigator staff and personnel performing the study assessments remained blinded to the identity of the treatment from the time of randomization until final database lock. The study drug was prepared by an independent unblinded pharmacist (or authorized delegate) and administered by an independent unblinded study drug administrator. Neither the unblinded pharmacist nor the unblinded study drug administrator was involved in any assessments.|This was a Phase III multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.|t|t|t|f
33998419|NCT05871463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103087|NCT04418505|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized trial||||
33801494|NCT01376700|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918258|NCT03658993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation and labelling follow guidelines defined by the Danish Medicines Agency and will be performed by the Hospital Pharmacy Region Midtjylland Clinical Trial Unit, Aarhus University Hospital and Norgine. For equal allocation to the two treatment arms computer generated block randomisation (blocks of 8) will be performed|A prospective, randomised, double-blind, placebo-controlled trial|t|t|t|t
33918259|NCT00469638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918260|NCT00845546|RANDOMIZED|CROSSOVER||||NONE||||||
33998420|NCT04454307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A randomized Double Blind Controlled Clinical Trial|A randomized Double Blind Controlled Clinical Trial|t|t|f|f
33998421|NCT04934254|||CASE_ONLY||PROSPECTIVE|||||||
33998422|NCT00467597|||CASE_CONTROL||PROSPECTIVE|||||||
33998423|NCT01961817|RANDOMIZED|CROSSOVER||||NONE||||||
33918261|NCT05899712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918262|NCT02086721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918263|NCT00000417|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918264|NCT03269890|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33918265|NCT06157047|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918266|NCT01954069|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918267|NCT00996021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33918268|NCT02731807|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33998424|NCT04672603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33998425|NCT02235558|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33998426|NCT03690063|||COHORT||PROSPECTIVE|||||||
33998427|NCT02121184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998428|NCT03249844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor don't know patient treatment||f|f|f|t
33694733|NCT06528873|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE||"The COMS One therapy system is a CE-marked medical device for treating chronic leg and foot ulcers. It uses electromagnetic fields and photons non-invasively, non-ionizingly, non-thermally, and non-medicinally.~The device transmits extremely low frequency (ELF) electromagnetic fields using a coil connected to a signal generator. It emits twenty trapezoid-shaped bursts per second, with the field's polarity switching every 2 minutes over a 16-minute session. The flux densities range from 0.4 mT to 1.6 mT in four-minute intervals.~Photons are delivered via LEDs with peak wavelengths of 660 nm and 830 nm, targeting cytochrome C Oxidase. The light pulses at 1000 Hz, providing a radiant exposure of 2-5 J/cm² at a 1 cm distance from the skin.~Technical details are in the IFU (100.0053_C_IfU)."|f|f|f|t
33694734|NCT00139061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33694735|NCT05869565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A Randomized, Blinded, Placebo-Controlled phase 2B clinical Trial|A Randomized, Blinded, Placebo-Controlled phase 2B clinical Trial|t|t|t|t
33694736|NCT04829448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694737|NCT05456919|||CASE_CONTROL||PROSPECTIVE|||||||
33694738|NCT04416308|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|For the first 30 employees a second test will be carried out a few minutes after the first test by another nurse blinded to the result of the first test in order to estimate the agreement between - observers.|"This is a multi-center cross-sectional survey at risk and minimal constraints, among GHT Haute Bretagne employees in order to know the prevalence of the presence of anti-SARS-CoV-2 antibodies.~For a sample of employees with no additional prospective follow-up will be done on D30 and D90."|f|f|f|t
33783601|NCT04844099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This will be a double-blinded study. Patients on DP will also receive SP placebo, and those on SP will in addition, receive DP placebo. All laboratory staff will be masked to the treatment assignment of individual participants. The trial statistician will also be blinded regarding the treatment code when he/she develops the statistical analysis plan and writes the statistical programmes, which will be validated and completed using dummy randomisation codes.|This will be a randomized, double-blind, parallel-group superiority trial of weekly single-day courses of DP for an average of 18 months compared to monthly single-day courses of SP in SCA patients. The study will be conducted in Uganda and Malawi, using randomisation stratified by bodyweight and study centre. Participants will be randomized using an allocation of 1:1 to DP or SP. Patients on DP will also receive an SP placebo, and those on SP will in addition, receive a DP placebo|t|t|t|t
33783602|NCT00070954|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33783603|NCT02892409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783604|NCT05777057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|2 radiologist don't know the results of diagnodent and doctor in lab also don't know the the results of diagnodent and radiograph|Extracted teeth are radiographed and examined by diagnodent and then sections are examined under light microscope||||
33783605|NCT00157053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783606|NCT00296543|||COHORT||PROSPECTIVE|||||||
33783607|NCT05917717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The study team will not be blinded to which patients receive which arm of the trial and will be aware of what each service is delivering in each phase of the study. The research team carrying out the flow up will be blinded to the arm of the trial that the participant was in when they are collecting outcome and follow up data.~It is impossible to blind the care providers.~Participants will be blinded to which arm of the trial they were in (should they regain capacity)."|Pilot study - randomised controlled trial|f|f|f|t
33783608|NCT01648283|NA|SINGLE_GROUP||OTHER||NONE||||||
33783609|NCT01496898|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33783610|NCT06711068|||COHORT||OTHER|||||||
33783611|NCT02652494|||COHORT||PROSPECTIVE|||||||
33783612|NCT03256682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Healthy individuals recruited through advertisement||||
33783613|NCT03115775|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, controlled clinical trial|t|t|t|t
33783614|NCT06711055|||COHORT||OTHER|||||||
34088135|NCT05666973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomly distributed in two groups manually by writing specific numbers that will be concealed in sequentially numbered, opaque sealed envelopes. The envelopes will be opened by an attending nurse not involved in the study just before the procedure. The incision will be given by the attending general surgery resident who will perform the inguinal hernia repair. The assessment of pain and data collection, data analysis will be done by principle investigator who is blinded to procedure. Thus, the patients and investigating and analyzing personal will be blinded to the procedure.|Participants are assigned to study where two groups of treatments Group 1 (Scalpel) and Group 2 (Electrocautery) are given so that Group 1 will receive skin incision only by Scalpel and another group will receive skin incision by Electrocautery for the duration of study.|t|f|t|f
34088136|NCT03810443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088137|NCT03169439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088138|NCT01555814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998429|NCT05759663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998430|NCT06276660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33998431|NCT00279045|RANDOMIZED|PARALLEL||TREATMENT||||||||
33998432|NCT02886676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998433|NCT05861973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized control trial with 3 parallel intervention arms. One arm will be the SMARTer active treatment group, one the active DPP treatment group, and the other an assessments-only control group. Assessors will be blinded to study condition, and intervention will be behavioral.|f|f|f|t
33998434|NCT03002935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998435|NCT04254315|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized study with~* Intervention group~* Control group with psychological distress~* Control group without psychological distress (not part of randomization)"||||
34088139|NCT00187434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088140|NCT03555929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088141|NCT02022917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088142|NCT02059109|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34088143|NCT03170713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33783615|NCT01944982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088144|NCT01997658|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34088145|NCT02910232|||COHORT||CROSS_SECTIONAL|||||||
34088146|NCT04780399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088147|NCT05948488|||CASE_ONLY||PROSPECTIVE|||||||
34088148|NCT02202252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088149|NCT05230901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088150|NCT02659618|||COHORT||PROSPECTIVE|||||||
34088151|NCT03873532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088152|NCT04221971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088153|NCT01701310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088154|NCT05581563|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|the use of general anesthesia of all participants the outcomes assessor will not be able to have any information regarding tourniquet use|Longitudinal Study Designs Cohort Study Simple randomisation with a 1:1 allocation ratio outcomes is measured after tourniquet use|t|f|f|t
34088155|NCT04814446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind clinical trial.The identity of Gardasil 9® vaccine and placebo cannot be concealed as presentation. They will be packed in boxes of identical appearance to achieve double blindness. During the study designated unblinded trained and qualified site staff will be responsible for preparing the Gardasil 9® vaccine or placebo out of view of patients and an unblinded nurse(s) or physician(s) will be responsible for administering the study products to the patients.|Multicenter national clinical trial, phase III, two parallel group randomized (in a 1:1 ratio)|t|f|t|f
34088156|NCT05636943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34088157|NCT02349438|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34088158|NCT00002302||||TREATMENT||DOUBLE||||||
33998436|NCT03993535|NA|SINGLE_GROUP||OTHER||NONE||12-month naturalistic follow-up of open treatment with evidence-based pharmacologic agents (SSRIs) or cognitive-behavioral therapy (CBT) for OCD||||
33998437|NCT00005040||||TREATMENT||||||||
33998438|NCT00009945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998439|NCT03985657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be assigned to a Baseline polysomnography and CPAP polysomnography in a randomized fashion. Participants will then be switched to the second polysomnography within 14 days of the first. The baseline polysomnography represents the exposure to sleep disordered breathing and the CPAP polysomnography represents the relief of the exposure. Markers of hemodynamic stress will be assessed in the morning after both studies.||||
33998440|NCT02734758|||COHORT||PROSPECTIVE|||||||
33998441|NCT06316336|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33998442|NCT04316962|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking: only single group pre-post|A pilot study using mixed method with a longitudinal explanatory pre-post design, whereby quantitative data are collected longitudinal and qualitative data are collected in means of focus groups at the end of the rehabilitation program (after 12 weeks). Mixed methods design are reckoned to be a new and important research paradigm because the use of both quantitative and qualitative data may provide an increased insight in both processes and outcomes and thereby provide a more nuanced and complete understanding of the topic in focus, here, cancer rehabilitation.||||
33998443|NCT02252016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998444|NCT01971554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998445|NCT01472432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998446|NCT03805633|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783616|NCT02321358|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33783617|NCT01641276|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33783618|NCT06518187|||COHORT||PROSPECTIVE|||||||
33783619|NCT04178005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783620|NCT01784380|||CASE_CONTROL|||||||||
33783621|NCT01565538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783622|NCT00362752|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33783623|NCT03079375|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|The study is double blinded. The pharmacist do not know, whether the patient is randomized to the basic or to the extended intervention before they conduct the medication review. That is why the patients in the intervention group are randomized two times.|The combination of pharmacist interventions are compared with medication review alone in comparison to non-intervention (a control group).|f|t|f|t
33783624|NCT01143077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783625|NCT02601703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783626|NCT00462553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783627|NCT05967689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||4 Cohorts based on eligibility criteria||||
33783628|NCT04221035|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783629|NCT03793855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783630|NCT04739423|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-Blind|Two 14-day periods, 2-way crossover design|t|t|t|t
33783631|NCT05360732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783632|NCT06610864|||COHORT||RETROSPECTIVE|||||||
33783633|NCT06150885|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33783634|NCT06016556|||COHORT||RETROSPECTIVE|||||||
33783635|NCT04580407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783636|NCT04836195|NA|SEQUENTIAL||TREATMENT||NONE||For Part A dose-escalation, patients will be enrolled in cohorts of 3 to 6 patients to each dose level. Six patients will be treated at the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D).||||
33783637|NCT00438425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783638|NCT00968331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783639|NCT06196710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomized in a 1:1 ratio to receive; endoscopic treatment using OTSC or standard therapies.||||
33998447|NCT03382041|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will compare intramedullary nailing( placing a rod in the tibia) of open and closed tibia shaft fractures with carbon fiber implant (tibial nail) versus titanium implant (tibial nail) in a Level I trauma setting.||||
33998448|NCT02131077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998449|NCT04766905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998450|NCT04189627|||COHORT||PROSPECTIVE|||||||
33998451|NCT01298050|||COHORT||RETROSPECTIVE|||||||
33998452|NCT00214682|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33998453|NCT01338090|||COHORT||PROSPECTIVE|||||||
33998454|NCT05305495|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional, single arm, cohort study||||
33783640|NCT02680769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783641|NCT03200743|||CASE_CONTROL||PROSPECTIVE|||||||
33783642|NCT02790606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783643|NCT04591899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783644|NCT01986244|||COHORT||PROSPECTIVE|||||||
33783645|NCT05355805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783646|NCT01810445|||CASE_ONLY||PROSPECTIVE|||||||
33783647|NCT06102343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783648|NCT06323525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783649|NCT06478654|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33783650|NCT00077883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783651|NCT04927052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Additionally, the Sponsor's staff conducting the study, and members of the administrative team will not have access to individual subjects' treatment assignments.|A split-face study in subjects seeking to correct mid-face volume deficit. Subjects will be treated with Revanesse Shape + with Lidocaine on one side of the face and Juvederm Voluma with Lidocaine on the other side of the face. The side of the face for each device will be randomly assigned.|t|t|f|t
33783652|NCT06167655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33998455|NCT02218398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998456|NCT05854563|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783653|NCT03355703|||CASE_CONTROL||PROSPECTIVE|||||||
33783654|NCT06081855|||COHORT||RETROSPECTIVE|||||||
33783655|NCT03980756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33783656|NCT05226481|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33783657|NCT04167891|||COHORT||PROSPECTIVE|||||||
33783658|NCT02860091|||COHORT||PROSPECTIVE|||||||
33783659|NCT03239210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783660|NCT06038851|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Single-center, prospective superiority study, randomized controlled, triple blind|t|t|f|t
33918269|NCT05830188|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33918270|NCT04634786|||CASE_ONLY||RETROSPECTIVE|||||||
33918271|NCT03160105|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This is a pragmatic multicentre, 2x2 factorial randomized controlled trial with 1:1:1:1 randomization. A sample size of 92 patients in each group will be required to demonstrate non-inferiority with a non-inferiority (NI) margin of 12%.||||
33783661|NCT03463811|||COHORT||PROSPECTIVE|||||||
33783662|NCT04938817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918272|NCT03888859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33918273|NCT01486784|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918274|NCT04776811|||COHORT||PROSPECTIVE|||||||
33918275|NCT04224818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918276|NCT00111917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918277|NCT03092349|||COHORT||PROSPECTIVE|||||||
33918278|NCT06289842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918279|NCT05450458|NA|SINGLE_GROUP||TREATMENT||NONE||A study group will be integrated which will be evaluated before the intervention and after 15 days, 3 and 6 subsequent months.||||
33918280|NCT00887146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918281|NCT02456376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918282|NCT05019755|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918283|NCT06171672|||COHORT||RETROSPECTIVE|||||||
33918284|NCT05518175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918285|NCT03363217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking as part of this study. Only one study treatment will be given to all treatment groups at age and weight based dose.|This trial will include 4 parallel groups. Each group will include a particular type of peripheral nerve or central nervous system tumor or mutation.||||
33918286|NCT02296437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918287|NCT04498819|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will be a 6-week single cohort prospective feasibility study. The study will involve a total of nine weeks of involvement time, one week of study set-up, one week of baseline, six weeks of intervention time, and in the eighth week a follow-up survey and fitness test. There is one condition; participants are self-selecting themselves to be a part of this intervention being offered, in addition to the usual care offered at the PCDSP clinic.||||
33918288|NCT05073965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33918289|NCT05366270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participant and clinician assessors will be blinded until study completion. The PI will only be unblinded in the event of an adverse event.|Subjects are randomized to Control/Sham and Intervention groups|t|f|t|t
33918290|NCT04727606|NA|SINGLE_GROUP||OTHER||NONE||||||
33918291|NCT05017714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918292|NCT00861861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918293|NCT04363437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918294|NCT05991674|||COHORT||PROSPECTIVE|||||||
33918295|NCT02523820|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918296|NCT00878631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918297|NCT06410079|||COHORT||PROSPECTIVE|||||||
33918298|NCT01573507|NA|SINGLE_GROUP||TREATMENT||NONE||Hypertonic lactate||||
33918299|NCT01413542|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33918300|NCT06391957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918301|NCT06275243|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||It is a longitudinal randomised clinical study, in which two study groups were used. A group of cases diagnosed with Alzheimer's disease and a control group of healthy individuals without Alzheimer's disease.||||
33918302|NCT03390712|||OTHER||RETROSPECTIVE|||||||
33918303|NCT06419647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33918304|NCT01308723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918305|NCT05750134|||COHORT||OTHER|||||||
33918306|NCT02787330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918307|NCT04822272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate||||
33918308|NCT02946541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918309|NCT04612153|||OTHER||RETROSPECTIVE|||||||
33918310|NCT01635010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918311|NCT00884052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918312|NCT05866393|RANDOMIZED|PARALLEL||PREVENTION||NONE|Using the randomization software the investigators will know who is in the CHAMPs or UC groups and will then assign the newly enrolled participant to an interventionist at each site. The randomization software will assign 0's and 1's. The 1's will indicate who is in the intervention group. For those assigned to CHAMPs, the interventionist after baseline data is collected will go in to set up the participants for the intervention which entails the CHAMPs system being placed on the bedrail and participants shown how it works and a patient return demonstration of use.|In this 4-year project, the investigators will conduct a two-group parallel-design, RCT to determine the efficacy of a novel technology-based patient hand-hygiene system (CHAMPs) as a method to improve hand-hygiene behavior and reduce patients' hand contamination (Aim 1).||||
33918313|NCT01894464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918314|NCT02168933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783663|NCT06383884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783664|NCT00846209|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33783665|NCT05638659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33783666|NCT04679584|||COHORT||PROSPECTIVE|||||||
33783667|NCT02846818|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34088159|NCT02064244|||||PROSPECTIVE|||||||
33783668|NCT03437668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783669|NCT04831775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention will be delivered by a research assistant and outcome data collection will be done by two other research assistants||f|f|t|t
33998457|NCT03169816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783670|NCT01588704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783671|NCT01746394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918315|NCT05478330|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918316|NCT00078559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918317|NCT00207259|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33918318|NCT03350178|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998458|NCT02119988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998459|NCT05219734|||CASE_ONLY||PROSPECTIVE|||||||
33998460|NCT03248128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind study. Subjects and investigator will be masked.|Subjects will be randomized to receive FDC of FF/VI inhalation powder compared to FF inhalation powder, once daily in cohort A and cohort B.|t|f|t|f
33998461|NCT05315791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998462|NCT02160613|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33783672|NCT05258760|||COHORT||PROSPECTIVE|||||||
33801495|NCT02846909|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918319|NCT03837353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918320|NCT04365998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918321|NCT02251444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918322|NCT03117166|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33918323|NCT05398133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918324|NCT02505412|||COHORT||CROSS_SECTIONAL|||||||
33918325|NCT04810234|||OTHER||CROSS_SECTIONAL|||||||
33918326|NCT04706169|||OTHER||CROSS_SECTIONAL|||||||
33918327|NCT06099691|||COHORT||CROSS_SECTIONAL|||||||
33918328|NCT02488096|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998463|NCT00785603|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33998464|NCT06026657|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33998465|NCT05772559|||COHORT||PROSPECTIVE|||||||
33998466|NCT03624751|||COHORT||PROSPECTIVE|||||||
33998467|NCT02125149|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33998468|NCT00479531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998469|NCT03690349|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33998470|NCT05990894|||COHORT||PROSPECTIVE|||||||
33998471|NCT01140672|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33998472|NCT05758753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998473|NCT05945472|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Once participants have signed the informed consent form and meet the inclusion requirements, they are randomly assigned 1/1 to the fasting or non-fasting intervention group.~The statistician does not know to which group the participants belong."|There are three arms, two of intervention and one control. Arm 1: intervention with fasting method Arm 2: Non-fasting method Arm 3: Control group|t|f|f|t
33998474|NCT01172912|NON_RANDOMIZED|||TREATMENT||NONE||||||
33998475|NCT01214590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918329|NCT03016546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918330|NCT02425007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918331|NCT00987922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918332|NCT01671722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998476|NCT04852627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998477|NCT03853187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998478|NCT00302991|||||PROSPECTIVE|||||||
33998479|NCT01675596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998480|NCT05215496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||185 MBq of \[18F\]fluoro-PEG-folate PET tracer will be intravenously administered to 15 patients with radiologically advanced stage EOC who are scheduled to undergo cytoreductive surgery, after which an FR-targeted PET/CT will be made. FR-targeted PET/Ct results will be compared to the intraoperative findings, postoperative histopathology (gold standard) and the conventional CT scan.||||
33998481|NCT06252363|||OTHER||CROSS_SECTIONAL|||||||
33998482|NCT02934334|||CASE_ONLY||PROSPECTIVE|||||||
33998483|NCT03215641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998484|NCT04448730|||COHORT||CROSS_SECTIONAL|||||||
33998485|NCT03065751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088160|NCT01160614|NA|SINGLE_GROUP||||NONE||||||
33918333|NCT04891055|||OTHER||PROSPECTIVE|||||||
33918334|NCT04872803|||CASE_ONLY||RETROSPECTIVE|||||||
33918335|NCT03227965|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918336|NCT00915044|||CASE_ONLY||CROSS_SECTIONAL|||||||
33918337|NCT02011867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918338|NCT01653158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918339|NCT00645294|RANDOMIZED|CROSSOVER||||NONE||||||
33918340|NCT05124977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33918341|NCT00523276|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34088161|NCT06478290|NA|SINGLE_GROUP||OTHER||NONE||This pilot study will have an open label pre-post design, so no randomization or blinding of treatment (COD) will occur.||||
34088162|NCT04548245|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34088163|NCT03837847|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to blind the participants or the study team as subjects will know if they are receiving a health coaching call.|Randomized Control wait design||||
34088164|NCT02346604|||CASE_CONTROL||PROSPECTIVE|||||||
34088165|NCT06057987|||CASE_ONLY||OTHER|||||||
34088166|NCT02880618|||COHORT||PROSPECTIVE|||||||
34088167|NCT05612321|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, prospective, randomized open trial||||
34088168|NCT06515782|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34088169|NCT00267540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34088170|NCT00675350|NA|SINGLE_GROUP||||NONE||||||
34088171|NCT01860989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801496|NCT03778515|||CASE_CONTROL||PROSPECTIVE|||||||
33801497|NCT01426698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33918342|NCT04353336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918343|NCT01147081|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918344|NCT03374553|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||26 patients enrolled into first arm, when enrolment completed, an additional 26 patients enrolled into second arm||||
33918345|NCT03519516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the partial and final analysis.~The masking will be done using boxes in the primary packaging identical in the two groups. Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the allocation number.~Blinding may be opened in the following cases:~1. Presence of a serious adverse event.~2. Safety alarm due to the use of the drugs under study.~3. In case the sponsor determines it for any reason of security or other reason that considers pertinent."|Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory.|t|f|t|t
33918346|NCT01951248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918347|NCT04766138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918348|NCT03026335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918349|NCT06226688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT 2 groups One of them control group And the other is study group|t|f|t|f
33918350|NCT04591795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33918351|NCT03230162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918352|NCT01930526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918353|NCT01547754|||||PROSPECTIVE|||||||
33918354|NCT04114500|||COHORT||RETROSPECTIVE|||||||
33918355|NCT03905395|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized trial where women in an experimental arm will receive 3 times a three hour work shop with introduction to meditation and mindfulness during a 7 week period. Women in the other arm will have no intervention.||||
33918356|NCT02089620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918357|NCT03411772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will sign an informed consent entailing their knowledge and acceptance of being included in the trial, however patients will not be aware to the group they will be included to. In addition, the operating surgeon will not be aware to the nature of the study.||t|t|f|f
33918358|NCT02000518|||COHORT||PROSPECTIVE|||||||
33918359|NCT02717065|NA|SINGLE_GROUP||OTHER||NONE||||||
33918360|NCT05904184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33918361|NCT01495338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33918362|NCT04046406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918363|NCT06443476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Evaluate bone gained (height and width) and the period of time of healing in the atrophic posterior mandible when using the tenting abutment technique compared to the tent pole|t|f|t|f
34088172|NCT06209242|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This prospective randomized controlled trial enrolled participants aged over 60 years with AO23-A2 or AO23-A3 distal radius fractures and no contraindications for local anesthesia. The participants were randomly assigned to either the cast immobilization or percutaneous pinning group.|f|f|f|t
34088173|NCT03384680|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088174|NCT00720278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088175|NCT03355027|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Randomisation to be performed to a 1:1 ratio.~Alirocumab treatment arm\*:~Alirocumab (150mg) \& Statin (either: Simvastatin 80mg od, Rosuvastatin 20mg/40mg od or Atorvastatin 40/80mg od)~\*May be required to complete a 4 week washout period on a statin before entering the study: Simvastatin 80mg od, Rosuvastatin 20mg/40mg od or Atorvastatin 40/80mg od.~Comparator treatment arm\*:~Ezetimibe (10mg) \& Statin (either: Simvastatin 80mg od, Rosuvastatin 20mg/40mg od or Atorvastatin 40/80mg od)~\*May be required to complete a 4 week washout period on a statin before entering the study: Simvastatin 80mg od, Rosuvastatin 20mg/40mg od or Atorvastatin 40/80mg od."||||
34088176|NCT04658589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088177|NCT05234671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised controlled trial|f|f|t|f
34088178|NCT05814796|||CASE_CROSSOVER||PROSPECTIVE|||||||
34088179|NCT03354871|||COHORT||PROSPECTIVE|||||||
34088180|NCT02875080|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088181|NCT03315637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088182|NCT00498017|||CASE_ONLY||PROSPECTIVE|||||||
34088183|NCT02889913|||COHORT||RETROSPECTIVE|||||||
34088184|NCT06024122|||CASE_CONTROL||PROSPECTIVE|||||||
33783673|NCT05646511|RANDOMIZED|PARALLEL||TREATMENT||NONE||standard arm: 5x5Gy - - 12 wks CAPOX- - restaging - - surgery or non-operative management experimental arm: 5x5Gy - - 12 wks CAPOXIRI - - restaging - - surgery or non-operative management||||
33783674|NCT05464927|||CASE_ONLY||PROSPECTIVE|||||||
34088185|NCT03024372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783675|NCT06459661|||COHORT||CROSS_SECTIONAL|||||||
33783676|NCT05180045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088186|NCT04158609|||COHORT||PROSPECTIVE|||||||
34088187|NCT03204214|||CASE_CONTROL||RETROSPECTIVE|||||||
34088188|NCT02196831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088189|NCT04034472|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34088190|NCT01842204|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34088191|NCT05029947|||COHORT||RETROSPECTIVE|||||||
34088192|NCT01731548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088193|NCT00847314|||COHORT||PROSPECTIVE|||||||
34088194|NCT00482833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088195|NCT05375318|||COHORT||PROSPECTIVE|||||||
34088196|NCT03662568|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088197|NCT06532942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This first-in-human trial will be conducted in healthy adult volunteers and will investigate the safety, tolerability, and PK of MNKD-201. MNKD-201 will be evaluated over a range of doses, first in a SAD phase (Part A) and then in a MAD phase (Part B), to inform doses for further evaluation in a subsequent trial. Approximately 40 participants will be enrolled into 1 of 3 SAD cohorts and 2 MAD cohorts, 8 participants per cohort.|t|t|t|t
34088198|NCT01694238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088199|NCT01269944|||COHORT||PROSPECTIVE|||||||
34088200|NCT03200821|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open, parallel group, active comparator||||
34088201|NCT06098040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||three-armed parallel group|f|f|f|t
34088202|NCT05780398|||CASE_ONLY||RETROSPECTIVE|||||||
34088203|NCT05398523|||CASE_ONLY||PROSPECTIVE|||||||
34088204|NCT00008424||||TREATMENT||||||||
34088205|NCT01567514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088206|NCT04309513|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control||||
34088207|NCT00537836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088208|NCT00055146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783677|NCT02967666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783678|NCT03686384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088209|NCT04724057|NA|SINGLE_GROUP||OTHER||NONE||||||
33783679|NCT05798104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783680|NCT02861573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783681|NCT02944903|||OTHER||PROSPECTIVE|||||||
33783682|NCT06615323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33783683|NCT06712303|||OTHER||CROSS_SECTIONAL|||||||
33783684|NCT01495637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783685|NCT04572295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783686|NCT06431698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783687|NCT05629156|||COHORT||PROSPECTIVE|||||||
33783688|NCT03395587|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, multicenter, open-label, randomized phase 2 study with two parallel groups||||
33783689|NCT01363479|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33783690|NCT01202864|||CASE_CONTROL||OTHER|||||||
33783691|NCT04252820|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be carried out by a collaborator investigator using a computer program (Excel 2016) when a new patient is included into the clinical trial. This collaborator investigator will tell the nurse in charge of receiving the patient in the preanesthetic room how long prewarming has to be given to the patient: 0 minutes (no prewarming), 15 minutes, 30 minutes or 45 minutes, according to the group given by the computer program. This collaborator investigator will not provide clinical care to the patient. Attending anesthesiologist will be blind to the allocation of the participants. Principal investigator will not be able to know how long prewarming will be given.|Different time periods of prewarming will be compared: 0 minutes (control group), 15 minutes, 30 minutes and 45 minutes|f|t|t|f
34088210|NCT01658163|||CASE_CONTROL||PROSPECTIVE|||||||
34088211|NCT02260271|||CASE_ONLY||RETROSPECTIVE|||||||
34088212|NCT02398344|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34088213|NCT01303419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088214|NCT04144816|||COHORT||PROSPECTIVE|||||||
33783692|NCT03813056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088215|NCT01815489|||CASE_CONTROL||PROSPECTIVE|||||||
34088216|NCT02912936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088217|NCT05228340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34088218|NCT04345224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study participants will be randomly qualified (allocated via a computer program) to the tree groups: A - dynamic tape, B - rigid tape, C - sham tape|t|f|f|t
34088219|NCT01259999|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918364|NCT02699242|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34088220|NCT03921983|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||measurements will be made with and without short term oxygen supplementation||||
33694739|NCT01360281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33783693|NCT05515796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Gastric cancer:CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative)（n=80） Gastric cancer:CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive )（n=20） Rectal cancer:Radiotherapy with CapeOx+ Terelizumab (aka Tislelizumab)（n=100）||||
33783694|NCT03768245|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention program is split into two groups of participants which receive two deferments treatments (Arms); treatment (Arm 1) is applied to all participants (n=800), while treatment 2 (Arm 2) is randomly applied just in the Mestizo group (n=117), i.e. schools and grade are randomly allocated in Arm 2||||
33783695|NCT06593314|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients with high risk of heart failure (see inclusion/exclusion) who underwent echocardiography will make up the clinical cohort. Corresponding providers will be enrolled in the clinical trial of a clinical decision support tool.||||
33783696|NCT00114881|||CASE_CONTROL||PROSPECTIVE|||||||
33783697|NCT02676297|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34088221|NCT05253508|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Repeated-measures design, order randomized||||
34088222|NCT02674659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33783698|NCT01781910|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33783699|NCT00051974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783700|NCT05091424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783701|NCT02286440|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33783702|NCT00717613|||COHORT||CROSS_SECTIONAL|||||||
33783703|NCT04159506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant who will collect study assessments will not know the randomization of participants to conditions. Randomization will be conducted by the study coordinator.|Participants will be block randomized to receive either 1) The Equus Effect (TEE) or 2) attention control (AC), both group interventions. Each week, the 4-session TEE will include 1) mindfulness activities, 2) emotion regulation and interpersonal skills education, 3) experiential activities with horses incorporating opportunities to develop emotion regulation and interpersonal skills, and 4) between-session application of lessons learned from the equine activities. AC will have similar elements without equine features.|f|f|f|t
33783704|NCT05460130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783705|NCT05717335|||COHORT||OTHER|||||||
33783706|NCT06340347|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||An open label, single dose, parallel cohort study||||
33694740|NCT05011656|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|"Patients will be randomized to receive either Arm 1: Seraph 100 treatment plus 'State of the Art' or Arm 2: 'State of the Art' care alone. State of the Art care will be defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home"||||
33783707|NCT05005169|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33783708|NCT01348321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33783709|NCT01383083|||CASE_ONLY||PROSPECTIVE|||||||
33783710|NCT04004000|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-centre, open-label pilot study with open-label extension||||
33783711|NCT00000746||||PREVENTION||||||||
33783712|NCT06615115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will do the evaluations but no info will be given about the randomization adn groups.|Participants who meet the inclusion criteria will be randomized into external focus of attention, combined focus of attention, and control groups. The same exercise program will be administered to all three groups by the same physiotherapist. The exercise program will last for 6 weeks, with sessions held three times a week. Although the exercises will be the same, the instructions given to the patients will vary by group. Assessments will be repeated at the beginning of treatment and at the end of the 6th week by a blinded evaluator.|f|f|f|t
33783713|NCT03238729|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33783714|NCT00249223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33918365|NCT03336827|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This is a two-armed, randomized, waiting-list controlled trial. Patients who agree to participate in the study will be randomly assigned to two groups: 1) the experimental group (EG) where six patients will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis; and 2) the waiting-list control group (CG) where six patients will receive the same intervention 4 months later. Patients will be assessed at three time points: 1) at baseline (T1), 2) 4 months later (T2), that means just after the intervention for the experimental group (EG) and just before the intervention for the control group (CG), and 3) 4 months later (T3), that means 4 months after the T2 for the experimental group and just after the intervention for the control group (CG).||||
33694741|NCT01419639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694742|NCT02260531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694743|NCT04176575|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This clinical trial is a descriptive, interventional, and open-label pilot study.||||
33783715|NCT05341544|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Patients will be allocated to either LLTS first and then sham-stimulation, or sham-stimulation first and then LLTS.|t|t|t|t
33918366|NCT00581906|||CASE_ONLY||PROSPECTIVE|||||||
34088223|NCT03301259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088224|NCT04912076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, placebo-controlled, single centre Phase I study with an open comparator group|t|t|t|t
34088225|NCT01242787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694744|NCT06596668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694745|NCT06708923|NA|SINGLE_GROUP||TREATMENT||NONE||"This study employs an Observational Retrospective Cohort Design to investigate the impact of acupuncture on pregnancy outcomes in patients diagnosed with recurrent implantation failure (RIF) undergoing frozen embryo transfer (FET) cycles.~Participants are categorized into two cohorts:~Acupuncture Cohort: Patients who received acupuncture treatments before and after embryo transfer during their IVF cycle.~Non-Acupuncture Cohort: Patients who did not receive acupuncture during their IVF cycle.~The study analyzes historical medical records to compare key clinical outcomes between the two cohorts, including clinical pregnancy rate (CPR), ongoing pregnancy rate (OPR), and live birth rate (LBR).~No experimental interventions are conducted during the study period, as it relies on previously collected data. Statistical methods are applied to adjust for confounding variables such as age, BMI, and number of prior failed cycles to ensure accurate comparisons and reliable conclusions."||||
33694746|NCT02547948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918367|NCT02043405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918368|NCT02462733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918369|NCT05027542|||OTHER||RETROSPECTIVE|||||||
33918370|NCT02219087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998486|NCT04060251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants assigned to one of three groups, there is no crossover. Participants remain in their assigned group until completion of study.||||
33998487|NCT04070898|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter prospective, controlled, randomized, non-inferiority study on the management of the bladder catheter in scheduled laparoscopic colon surgery||||
33998488|NCT03416049|||CASE_CONTROL||PROSPECTIVE|||||||
33694747|NCT02243475|||COHORT||PROSPECTIVE|||||||
33694748|NCT04088656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33694749|NCT00570414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694750|NCT06415318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694751|NCT06215716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998489|NCT03472196|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Open label, single arm, open label study||||
33694752|NCT06173141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (participant)|Sixty-four patients undergoing haemodialysis randomly be allocated into three groups, (A, B \& C). Group A (low- to moderate-continuous intensity cycling exercises, group B (moderate- to high-interval intensity cycling exercises), the exercises performed two sessions per week for two months and group (C) received the hemodialysis sessions only.|t|f|f|f
33694753|NCT03488927|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control intervention trial with a wait-list control condition, randomized at the individual level||||
33694754|NCT03054454|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33783716|NCT04438811|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-inferiority, randomized trial. Patients will be randomized to receive a protocolized spinal anesthetic from a consultant anesthetist or a trained medical officer. Failure rates and need for rescue will be assessed as primary outcomes.||||
33998490|NCT03207152|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998491|NCT01146080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998492|NCT00394303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998493|NCT05368753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998494|NCT05526703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998495|NCT01687335|||COHORT||PROSPECTIVE|||||||
33998496|NCT01654484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33694755|NCT05513820|||OTHER||OTHER|||||||
33694756|NCT04840069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694757|NCT03857906|||COHORT||PROSPECTIVE|||||||
33694758|NCT06596577|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33694759|NCT01347307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694760|NCT06359431|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33694761|NCT00406094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33694762|NCT04685031|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33694763|NCT04545554|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783717|NCT06607809|||CASE_ONLY||RETROSPECTIVE|||||||
33783718|NCT02949271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33783719|NCT06536036|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918371|NCT01464242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918372|NCT05874687|||COHORT||PROSPECTIVE|||||||
33918373|NCT04953117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918374|NCT05451472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918375|NCT02541006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918376|NCT01053117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998497|NCT00096460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998498|NCT00950300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998499|NCT03456544|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33998500|NCT05390255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998501|NCT03483818|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a feasibility study comparing delivery of care pathways rather than evaluating medication||||
33998502|NCT05856760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998503|NCT05210608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told to which condition they were randomized.|Participants will be randomized to the Computerized Working Memory Training or the Computerized Control Condition|t|f|f|f
33998504|NCT03062787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998505|NCT05653934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Determine if virutal reality help reduce postoperative anxiety in patients operated for colorectal cancer||||
33998506|NCT03522649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998507|NCT01628887|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998508|NCT02201316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998509|NCT00073580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088226|NCT02791698|||COHORT||PROSPECTIVE|||||||
34088227|NCT04783662|||COHORT||PROSPECTIVE|||||||
34103088|NCT03964233|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103089|NCT06189846|||COHORT||PROSPECTIVE|||||||
34103090|NCT04837196|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694764|NCT01241240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694765|NCT00455767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694766|NCT01646073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694767|NCT06082830|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of this pilot work, masking is not feasible.|||||
33783720|NCT04790344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Physiologic Sensor data will be blinded to participants and care providers. LUX-Dx ICM commercial features will be Open Label.|||||
33783721|NCT06472089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918377|NCT03165188|||COHORT||PROSPECTIVE|||||||
33783722|NCT05144217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|study medication and placebo are provided in identical blister|prospective placebo-controlled dose-finding study|t|f|f|f
33783723|NCT00933296|||CASE_CONTROL||PROSPECTIVE|||||||
33783724|NCT01597518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783725|NCT04028492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783726|NCT06714201|||OTHER||CROSS_SECTIONAL|||||||
33783727|NCT06055556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783728|NCT00984178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783729|NCT03748160|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Cluster (household) RCT with three treatment arms|t|t|t|t
33783730|NCT02232763|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33783731|NCT00597883|||CASE_CONTROL||PROSPECTIVE|||||||
33783732|NCT03237221|||CASE_ONLY||PROSPECTIVE|||||||
33783733|NCT01688973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783734|NCT02288715|||CASE_CONTROL||PROSPECTIVE|||||||
33783735|NCT03773965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783736|NCT01644773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783737|NCT05310721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33783738|NCT06440109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33783739|NCT06711081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Assignment|t|t|f|f
33783740|NCT06712160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783741|NCT03028948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783742|NCT01454362|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33783743|NCT05630495|NA|SINGLE_GROUP||SCREENING||NONE||||||
33783744|NCT00353145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783745|NCT04477798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783746|NCT05273801|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|All individuals involved in the study will be aware when HR feedback as well as monitoring occurs during the study.|Participants will be enrolled in a single arm where they may receive HR monitoring with visual feedback or HR monitoring with no visual feedback. Observed condition will alternate by session.||||
33783747|NCT05153954|||COHORT||PROSPECTIVE|||||||
33783748|NCT01665729|||CASE_ONLY||PROSPECTIVE|||||||
33783749|NCT06211075|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group A (Experimental group, Intervention Group): will receive the intervention straight away Group B: (Control, Wait List Control Group): participants are allocated to the waitlist and will receive the intervention after the end of the study.|f|f|f|t
33783750|NCT02891369|||COHORT||RETROSPECTIVE|||||||
33918378|NCT00964158|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33998510|NCT04156737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Unmasked study personnel at the site will be trained to the randomization process through the EDC system and will randomize subjects. The surgeon and the operative staff will know which lens type is implanted. There may also be site coordinators and other site study staff, such as those performing slit-lamp exams, who will be unmasked. Unmasked study site staff will be instructed not to disclose the lens type the subject received or to talk about the lens to any masked evaluators or to the study subjects. The subjects and the study technicians performing the postoperative vision tests are to be masked through study completion. To maintain subject masking, a temporary IOL implant identification card will be issued to the subject at the time of surgery. Following completion of the final study exam, each subject will be given the permanent IOL implant identification card.||t|t|f|f
33998511|NCT06273956|||OTHER||CROSS_SECTIONAL|||||||
33998512|NCT06627816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind|comparative study|t|t|t|t
33998513|NCT02027337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33998514|NCT03528486|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33998515|NCT03181386|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998516|NCT04481451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The identity of the study block type will be hidden from caregivers unless clinically mandated.|2 arm randomized controlled non-inferiority trial.|t|t|f|t
33998517|NCT04633122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998518|NCT03618615|||COHORT||PROSPECTIVE|||||||
33998519|NCT05405023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998520|NCT06000163|||COHORT||PROSPECTIVE|||||||
33998521|NCT01230229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998522|NCT00948480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783751|NCT06089629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783752|NCT03861273|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783753|NCT05924893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783754|NCT05392764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918379|NCT02591004|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998523|NCT00921674|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33998524|NCT05826093|||COHORT||PROSPECTIVE|||||||
33998525|NCT00339157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998526|NCT01337427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694768|NCT00051454|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33694769|NCT02207673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694770|NCT03263585|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomized controlled trial||||
33694771|NCT06448182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The products (experimental and placebo), will be produced by an external producer, who will save the codes. None of the researchers involved in the study development or analyses will know the association until the end of the study.|Randomised, double blinded, parallel intervention|t|t|t|t
33694772|NCT03182062|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33694773|NCT06379087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694774|NCT02173184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33694775|NCT06134167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998527|NCT00421863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998528|NCT03577535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998529|NCT05223608|NA|SINGLE_GROUP||TREATMENT||NONE||Observational study model with additional blood samples and urine collection||||
33694776|NCT05635669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33694777|NCT00426231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694778|NCT01068652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694779|NCT01715714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694780|NCT03375827|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33694781|NCT06050525|||OTHER||RETROSPECTIVE|||||||
33694782|NCT00857415|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33694783|NCT02883192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694784|NCT05184075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694785|NCT00013234|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694786|NCT05495685|||CASE_CONTROL||PROSPECTIVE|||||||
33694787|NCT06707038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will use a 1:1 allocation ratio of randomization to intervention and control. Randomization will be stratified by sex (male, female) and age (divided into 2 categories). Participants will be assigned to a randomization group upon completing the eligibility screener and consent has been obtained, which will occur after the patient has attended the Roundtable visit and completed baseline questionnaires, but before their first visit with the center.||||
33694788|NCT03718871|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a mixed methods study where Aims 1 and 2 have both qualitative and quantitative arms. Aim 3 is an unblinded intervention, with a control arm, to be delivered in cluster-randomized fashion (Sept 2019-June 2020). Healers will be treated as clusters and randomized to either intervention or control arm.||||
33694789|NCT06391385|RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding or masking is implemented in this open-label study. Both participants and healthcare providers are aware of the intervention status. This design allows for transparency in the treatment approach, and outcomes will be assessed without blinding. The lack of masking is a characteristic of the study design and does not impact the validity of the results.|The surgical procedure was performed by laparotomy, with resection of the rectum and mesorectum (TME) up to the level of the pelvic diaphragm, sparing the autonomic nerves. End-to-end anastomosis was performed either with a stapler or by hand-sewn. Patients were assigned to group I (19 patients) who had undergone temporary ileostomy, and group II (28 patients) who didn't undergo ileostomy. Patients were followed up at regular intervals and outcomes were compared between two groups.||||
33694790|NCT01267656|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33694791|NCT06019507|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33694792|NCT05607771|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33694793|NCT06275607|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33694794|NCT00315159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694795|NCT01460316|||COHORT||PROSPECTIVE|||||||
33694796|NCT02035501|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33694797|NCT06199050|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33694798|NCT01444352|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33694799|NCT00719095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694800|NCT03710876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694801|NCT05337436|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33694802|NCT04178473|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double (Participant, Investigator) closed envelop will be used for randomization. The patient and the investigator will be blinded.|Group A will have total abdominal hysterectomy Group B will have subtotal abdominal hysterectomy Sacrocolpopexy will be done using Polypropylene mesh for all women with uterovaginal prolapse|t|t|t|f
33694803|NCT01401972|||CASE_ONLY||PROSPECTIVE|||||||
33694804|NCT03075046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694805|NCT00518973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694806|NCT06699875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will not be blinded to patients because masking the use of an application is impossible. However, mobility assessment will be blinded, so the researchers involved in this task will not know the patient group.|"The allocation of patients to treatment groups will be performed randomly. IIS Biodonostia will generate the randomization list using R software and enter it into REDCap. This ensures that researchers will neither know nor be able to decide which group each study patient will be randomized to.~* Control group: The exercise protocol will be completed using printed paper sheets.~* Treatment group: The exercise protocol is to be completed using the TRAK tool."|f|f|f|t
33694807|NCT02134197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694808|NCT03543618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33694809|NCT05600738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33694810|NCT05804942|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33694811|NCT06348901|||COHORT||PROSPECTIVE|||||||
33694812|NCT00471016|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33694813|NCT00969904|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33694814|NCT06708715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694815|NCT00895427|||COHORT||CROSS_SECTIONAL|||||||
33694816|NCT05521724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled clinical trial|t|f|t|t
33694817|NCT02521571|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694818|NCT05040399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Case-Control||||
33694819|NCT02092272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33694820|NCT02671773|||||CROSS_SECTIONAL|||||||
33694821|NCT00386607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694822|NCT01131767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694823|NCT02688712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694824|NCT01057771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694825|NCT04627025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783755|NCT05305911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment will be blinded to the participant and investigator. Assignment of treatment arm will be managed by Abbott Northwestern Heart Hospital pharmacy.||t|f|t|f
33783756|NCT03669042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783757|NCT06494553|RANDOMIZED|PARALLEL||TREATMENT||NONE|Simple randomization was done as the following the name of each subject was written on a paper folding it and putting it in a box; finally papers were picked and assigned to two groups|Pre and post randomized control trial design will be used in this study||||
33783758|NCT05402293|||COHORT||PROSPECTIVE|||||||
33783759|NCT06622941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783760|NCT01408680|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33783761|NCT06176144|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33783762|NCT01756365|NA|SINGLE_GROUP||TREATMENT||NONE||The culture of corneal epithelium strives to produce a reconstructed tissue with the therapeutical aim of treatment of limbal stem cell deficiency. The study is a phase I / phase II study with the goal to evaluate safety and efficacy of the CECA graft for the treatment of human patients suffering from limbal stem cell deficiency.||||
33998530|NCT02041013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33998531|NCT06405854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants, specifically the preschool children, may not be informed of their group assignment (Exercise Group or Control Group) to prevent behavior changes based on perceived expectations.|Randomized Controlled Trial|t|f|f|f
33998532|NCT00072514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783763|NCT03897998|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The UM Pharmacy will assign de-identified study IDs to participants and provide the study drug (Naloxone or Saline) so that participants, the person conducting the experiment, and the investigator will be blind to the participant's group.|This will be a 2 (group: naloxone vs. saline) X 2 (condition: placebo vs. control) double-blind mixed experimental design with group as the between-subjects factor and condition as the within-subjects factor. Each participant will be randomly assigned to either the naloxone or the saline group.|t|f|t|t
33783764|NCT05079698|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a single-institutional pilot study of 6 total patients at MSKCC.||||
33783765|NCT06711159|||CASE_CROSSOVER||PROSPECTIVE|||||||
33783766|NCT00406809|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783767|NCT01417000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783768|NCT03383211|||CASE_CONTROL||PROSPECTIVE|||||||
33783769|NCT00602160|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33783770|NCT04533217|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33783771|NCT00740272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783772|NCT03243760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33783773|NCT01452490|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Even though this study has recruited more than 10 participants, it is a feasibility study, designed to test the prototype rather than measuring health outcomes. It is to confirm the operating specifications before beginning a full clinical trial.||||
33783774|NCT01752101|||COHORT||PROSPECTIVE|||||||
33783775|NCT03454932|||COHORT||PROSPECTIVE|||||||
33998533|NCT00483743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998534|NCT02115776|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33998535|NCT04050943|||COHORT||PROSPECTIVE|||||||
33998536|NCT01954030|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998537|NCT04323683|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33998538|NCT02174185|||COHORT||PROSPECTIVE|||||||
33998539|NCT01049464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998540|NCT02924025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998541|NCT03814850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The person performing the RIPC is not blinded.||t|t|t|t
33998542|NCT01753362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998543|NCT02364986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998544|NCT04249765|NA|SINGLE_GROUP||SCREENING||NONE||Cross sectional research design with data collected over one semester.||||
33998545|NCT06627985|||OTHER||RETROSPECTIVE|||||||
33998546|NCT05318859|||COHORT||PROSPECTIVE|||||||
33998547|NCT00902538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998548|NCT04883164|||CASE_CONTROL||PROSPECTIVE|||||||
33998549|NCT04643691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998550|NCT02169752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998551|NCT01839539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998552|NCT00772408|||CASE_CONTROL||PROSPECTIVE|||||||
33998553|NCT06529146|||COHORT||RETROSPECTIVE|||||||
33998554|NCT04418167|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A total of up to 80 subjects are anticipated in the JSI-1187 monotherapy dose-escalation phase (Part A). A total of up to 36 subjects are anticipated in the JSI-1187 plus dabrafenib dose-escalation phase (Part B). A total of 58 subjects are anticipated in the JSI-1187 plus dabrafenib expansion phase||||
33998555|NCT04433130|||OTHER||PROSPECTIVE|||||||
33998556|NCT04811729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998557|NCT00867763|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33998558|NCT00470379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998559|NCT05348928|||OTHER||PROSPECTIVE|||||||
33998560|NCT06339437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|outcomeassessor was not told about group allocation|ERAS protocols applied|f|f|f|t
33998561|NCT02997891|||CASE_CONTROL||PROSPECTIVE|||||||
33998562|NCT01947738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998563|NCT02579005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998564|NCT04153305|||COHORT||RETROSPECTIVE|||||||
33998565|NCT01662011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998566|NCT05979311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998567|NCT01949532|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103091|NCT06014723|||COHORT||PROSPECTIVE|||||||
34103092|NCT05943990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998568|NCT00796913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918380|NCT05279664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|RIC will be masked from the local team of healthcare workers and parents/caregivers. A trained research fellow/nurse not involved in the circle of care will perform, behind a portable sliding medical privacy screen, inflation/deflation of the cuff (RIC intervention) or sham inflation/deflation of the cuff connected to a dummy neonatal arm to mimic the noise of cuff inflation (control). Both limbs (receiving and not receiving RIC) will be blinded from the circle of care and parents/caregivers. During the RIC procedure, the research fellow/nurse will monitor the oxygen saturation of the limb receiving RIC via pulse oximetry. The circle of care will continue to monitor the neonate's clinical parameters on the cardiopulmonary monitor on the other side of the privacy screen.|The intervention used in this study is remote ischemic conditioning (RIC). Patients randomized to the intervention arm will receive RIC as well as the standard medical management for NEC. RIC will consist of 4 cycles of limb ischemia (5 minutes) followed by reperfusion (5 minutes), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of the same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure.|t|t|f|t
33918381|NCT00394238|||DEFINED_POPULATION||OTHER|||||||
34088228|NCT04134390|NA|SINGLE_GROUP||TREATMENT||NONE||Cabozantinib 40 mg per os (p.o.) once daily in 28-day cycles. Dose can be escalated to 60 mg to avoid suboptimal exposure to the drug if 40 mg is considered tolerated. If the dose of 40 mg is not tolerated, a de-escalation to 20 mg, temporary interruption, or stopping cabozantinib will be possible.||||
34088229|NCT01805999|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34088230|NCT06235554|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study, prospective, open-label, single center, single-arm study||||
33694826|NCT05667194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694827|NCT03706131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Spasticity evaluations will be done by blind investigator.||f|f|f|t
33694828|NCT02962362|||OTHER||PROSPECTIVE|||||||
33918382|NCT01728753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918383|NCT03638882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33918384|NCT06295432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918385|NCT05786014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subjects and investigators will not be blinded to treatment allocation. Outcome assessors will be blinded.||f|f|f|t
33918386|NCT03904524|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918387|NCT01396993|||COHORT||PROSPECTIVE|||||||
33918388|NCT01345097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918389|NCT00251563|||CASE_CONTROL||OTHER|||||||
33918390|NCT02961517|||OTHER||CROSS_SECTIONAL|||||||
33918391|NCT03608904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be exposed to music or no music (spoken words only) during their fMRI scans.|f|f|t|t
33918392|NCT02649530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918393|NCT00941889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918394|NCT04163107|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, dose escalation study in two centers. 3+3 design in five dose levels.||||
33918395|NCT04130828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918396|NCT02611063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918397|NCT05109130|||COHORT||PROSPECTIVE|||||||
33918398|NCT03247413|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The patient, care providers, and principle investigator will be blinded.|Each patient serves as his or her own control. Investigators are recruiting patients who are undergoing bilateral procedures. Each patient will receive dexamethasone at each lesion site post-ablation on one side, and placebo (saline) on the other.|t|t|t|f
33918399|NCT01029015|||CASE_CONTROL||PROSPECTIVE|||||||
33918400|NCT01154179|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33918401|NCT01681576|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33918402|NCT03075748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918403|NCT01106625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918404|NCT00261248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33918405|NCT01464463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918406|NCT03870256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study was a prospective double-blind randomized study|This study was a prospective double-blind randomized study|t|t|t|t
33918407|NCT03141268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918408|NCT02947022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918409|NCT04813536|||CASE_CONTROL||RETROSPECTIVE|||||||
33918410|NCT03304470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918411|NCT03985748|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrolled patients will be randomized to receive AeroEclipse® II BAN or SN in the Rhode Island Hospital (RIH) Emergency Department. They will have an equal chance of being placed in either group. Patients will be screened and identified in the Emergency Department. They will receive the BAN or SN for the duration of their stay in the hospital, as long as clinically indicated.||||
33918412|NCT06095752|||COHORT||PROSPECTIVE|||||||
33918413|NCT02800473|NA|SINGLE_GROUP||OTHER||NONE||||||
34088231|NCT05844462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088232|NCT00185159|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088233|NCT02101567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088234|NCT01020422|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33694829|NCT05704010|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694830|NCT03802812|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694831|NCT05080127|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* study group - 500 children with known food allergy~* control groups - A. 50 children with atopic comorbidities but no food allergy. B. 50 children without atopic comorbidities"||||
33694832|NCT01384097|||COHORT||RETROSPECTIVE|||||||
33694833|NCT04432272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No parties blinded as to receipt of study article. Participant, care provider and investigator blinded to actual antibody concentration in unit of plasma provided.|Prospective, single health system, non-randomized, open-label study.||||
33694834|NCT02597868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694835|NCT00289367|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34088235|NCT02625584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783776|NCT06473480|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"PERIOD 1: Fingerstick glucose monitoring = Standard care, 140 participants~* Substudy 1-3: all participants~* Substudy 4: 20 patients of the 140 participants~PERIOD 2\*: Fingerstick glucose monitoring = standard care + blinded sensor, 70 participants~* Substudy 5\*: all participants~* Substudy 6\*: all participants~PERIOD 3: Continuous glucose monitoring system = study Intervention 140 participants~* Substudy 1-3: all participants~* Substudy 4: 20 participants of the 140 participants~* Substudy 5\*: 70 participants of the 140 participants~* Substudy 7: 27 participants (surgical nursing staff,10 surgical nursing staff from Odense University Hospital, 10 surgical nursing staff from Zealand University Hospital Koege, and 7 specialized diabetes nurses from Odense University Hospital)~  * Only conducted at Odense University Hospital"||||
33783777|NCT02049437|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33783778|NCT05841784|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33783779|NCT05801042|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33998569|NCT00003953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998570|NCT01559727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998571|NCT05616416|||COHORT||RETROSPECTIVE|||||||
33998572|NCT02258035|||CASE_ONLY||PROSPECTIVE|||||||
34088236|NCT02971826|NA|SINGLE_GROUP||OTHER||NONE||||||
34088237|NCT05618990|||COHORT||OTHER|||||||
34088238|NCT04213911|||COHORT||PROSPECTIVE|||||||
34088239|NCT02671968|RANDOMIZED|PARALLEL||||||||||
34088240|NCT04670211|||COHORT||PROSPECTIVE|||||||
33694836|NCT02427828|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694837|NCT01887340|NON_RANDOMIZED|PARALLEL||||NONE||||||
33694838|NCT05264415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33998573|NCT04872231|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|The investigators, study coordinators, study subjects and the Sponsor will be blinded to treatment assignment.|"Part A: Eight (8) subjects will participate in each of the 4 dose escalations. Subjects will be randomized to receive either Voriconazole Inhalation Powder or placebo by inhalation (6 active, 2 placebo per group of 8).~Part B: Eight (8) subjects will participate in each of the 4 dose escalations. Subjects will be randomized to receive either Voriconazole Inhalation Powder or placebo by inhalation (6 active, 2 placebo per group of 8)."|t|f|t|f
33694839|NCT01676727|||COHORT||PROSPECTIVE|||||||
33694840|NCT03139279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33694841|NCT03754673|||CASE_ONLY||CROSS_SECTIONAL|||||||
33998574|NCT06316557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter Randomized Double-Blind Controlled Study|t|t|t|t
33694842|NCT03092271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessments will be conducted by assessors who are naive to randomization assignment. Every effort will be made to conceal all information regarding randomization and randomization assignment to staff involved in assessment, recruitment, or other study activities that could lead to bias. It is not possible to conceal randomization status from intervention staff, as they will be delivering the intervention.|Randomization to one of two conditions: 1) Zero suicide Best Practices/Quality Improvement; or 2) Zero suicide Best Practices/Quality Improvement plus stepped care for suicide prevention intervention|f|f|f|t
33694843|NCT02910869|||CASE_CONTROL||RETROSPECTIVE|||||||
33998575|NCT01208194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998576|NCT05050851|||CASE_CONTROL||PROSPECTIVE|||||||
33998577|NCT00963495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088241|NCT05907447|||COHORT||RETROSPECTIVE|||||||
33694844|NCT04490239|NA|SEQUENTIAL||PREVENTION||NONE||This study will evaluate the acute and multi-day (14 days) tolerability of intranasally administered heparin. Two doses will be tested in the acute phase: 1000 U/day, then 2000 U/day. In the multi-day phase, the highest tolerated dose from the acute phase will be tested over a 14-day period of daily self-administration.||||
33694845|NCT00723931|||COHORT||RETROSPECTIVE|||||||
33694846|NCT05455385|RANDOMIZED|PARALLEL||OTHER||SINGLE||3-arm randomized controlled trial|f|f|f|t
33694847|NCT01986140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One blinded observer assesses the patient outcome||f|t|f|f
33998578|NCT00290927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998579|NCT02632968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34088242|NCT01360307|||||CROSS_SECTIONAL|||||||
34088243|NCT04849013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34088244|NCT00068523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088245|NCT04383132|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088246|NCT04705662|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34088247|NCT03570788|||COHORT||PROSPECTIVE|||||||
34088248|NCT01471990|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33694848|NCT05666622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694849|NCT04243785|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694850|NCT04951440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694851|NCT05159856|||COHORT||PROSPECTIVE|||||||
33694852|NCT00348244|RANDOMIZED|PARALLEL||||SINGLE||||||
33694853|NCT00910988|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33694854|NCT03850665|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694855|NCT00070655|RANDOMIZED|||TREATMENT||NONE||||||
33694856|NCT00689598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998580|NCT06180395|||OTHER||PROSPECTIVE|||||||
34088249|NCT01776229|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34088250|NCT02143687|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34088251|NCT02270268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088252|NCT04381715|||COHORT||OTHER|||||||
34088253|NCT02374242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088254|NCT02429440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088255|NCT05481437|||COHORT||PROSPECTIVE|||||||
34088256|NCT01452347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088257|NCT05857072|||COHORT||PROSPECTIVE|||||||
34088258|NCT01268735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694857|NCT05076071|||COHORT||PROSPECTIVE|||||||
33694858|NCT06409351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes assessor is masked. No other parties are masked.|Participants are assigned to either treatment or control group only during the duration of the study|f|f|f|t
33783780|NCT05191901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33783781|NCT03364387|||COHORT||PROSPECTIVE|||||||
33918414|NCT02895256|||COHORT||RETROSPECTIVE|||||||
33918415|NCT05218057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The urologist performing the surgery could not be blinded due to the nature of the intervention. Patients receiving the treatment and investigators assessing for the outcomes are blinded from the allocated treatment arm.||t|f|f|f
33918416|NCT05727085|||COHORT||PROSPECTIVE|||||||
33918417|NCT01010711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918418|NCT01818388|||CASE_ONLY||PROSPECTIVE|||||||
33998581|NCT00770952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998582|NCT00210223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918419|NCT01397448|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918420|NCT04234126|||COHORT||RETROSPECTIVE|||||||
33918421|NCT04561921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918422|NCT03689413|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33918423|NCT02275767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918424|NCT02694627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918425|NCT03810001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998583|NCT04964687|||COHORT||RETROSPECTIVE|||||||
33998584|NCT05718180|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33998585|NCT01345539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998586|NCT06038760|||COHORT||PROSPECTIVE|||||||
33998587|NCT03428750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998588|NCT03704103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998589|NCT06491927|||OTHER||PROSPECTIVE|||||||
33998590|NCT01165060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998591|NCT04879927|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33998592|NCT00235963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998593|NCT03314376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33998594|NCT04424108|||COHORT||PROSPECTIVE|||||||
33998595|NCT03385863|||CASE_ONLY||RETROSPECTIVE|||||||
33998596|NCT01376596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33998597|NCT00686764|||CASE_ONLY||CROSS_SECTIONAL|||||||
33998598|NCT00232687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998599|NCT01285895|||||PROSPECTIVE|||||||
33998600|NCT04383249|||OTHER||RETROSPECTIVE|||||||
33998601|NCT03053245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998602|NCT05689541|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33998603|NCT05588063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial will be double blinded to the investigators and participants. Unblinding will occur after all participants have completed the randomization phase of each study trial (Week 26).||t|t|t|t
33998604|NCT06166862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Prospective randomized controlled study|f|f|f|t
33998605|NCT01360138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998606|NCT05475964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998607|NCT06267339|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33998608|NCT02847624|||COHORT||PROSPECTIVE|||||||
33998609|NCT04862130|||COHORT||OTHER|||||||
33998610|NCT03695354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33998611|NCT05123443|||COHORT||PROSPECTIVE|||||||
33998612|NCT06531408|||COHORT||CROSS_SECTIONAL|||||||
33998613|NCT01833702|||COHORT||PROSPECTIVE|||||||
33998614|NCT00547794|||COHORT||PROSPECTIVE|||||||
33998615|NCT00296270|RANDOMIZED|FACTORIAL||ECT||DOUBLE||||||
33998616|NCT05871437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998617|NCT02962180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998618|NCT02611362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998619|NCT03531060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998620|NCT05562011|NA|SINGLE_GROUP||SCREENING||NONE||Caretaker device placement||||
33998621|NCT02144844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998622|NCT01635582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998623|NCT00964054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33998624|NCT04468282|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study was an open label, randomized, crossover, 2 periods study in 20 healthy male/female volunteers. Subjects received 500 mg of the new formulation of soluble tablets vigabatrin or Sabril TM, as single oral administration in 2 different study periods depending on the randomization, with a 7-days wash out period between administrations.||||
33998625|NCT05086913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998626|NCT06186414|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694859|NCT00558727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694860|NCT02713204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694861|NCT03507062|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33694862|NCT01297998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694863|NCT01725607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694864|NCT06344741|||CASE_CONTROL||PROSPECTIVE|||||||
33918426|NCT03286712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998627|NCT05913115|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998628|NCT03648931|||COHORT||CROSS_SECTIONAL|||||||
33998629|NCT01205035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998630|NCT05518331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998631|NCT03911206|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998632|NCT04264169|||COHORT||PROSPECTIVE|||||||
33998633|NCT04584541|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33998634|NCT03256396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33998635|NCT06405243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088259|NCT01822743|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33783782|NCT04638387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participants will not know if they are receiving PB125 or placebo. Participants will complete pain surveys. Team members making measurements of mobility and mitochondrial energetics will not know if participants or samples are PB125 or placebo.|Primary comparisons will be between pre-test and post-test measures. We had initially planned control group comparisons as well, but the pandemic has cut this pilot study short of budget and time. Therefore, the primary comparisons will now be pre-test to post-test to maximize the number of participants enrolled to receive the experimental treatment.|t|f|f|t
33783783|NCT06613815|||COHORT||RETROSPECTIVE|||||||
33694865|NCT03048461|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33694866|NCT03589014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Treat_CCM is a Prospective Randomized Open Trial with Blinded Evaluation of outcomes (PROBE).~Clinical events CCM-related (i.e. intra-cerebral hemorrhage and focal neurological deficits excluding seizures) will be blindly adjudicated by an independent Event Committee.All MRI exams will be read in a Central Laboratory by experienced neuroradiologists, unaware of patient identification and study treatment."||f|f|f|t
33694867|NCT06710938|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Thoracoabdominal Artery Stent Graft System. The system includes the G-Branch™ thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system.||||
33694868|NCT04870281|||COHORT||PROSPECTIVE|||||||
33694869|NCT01927341|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33694870|NCT00041821|RANDOMIZED|CROSSOVER||||SINGLE||||||
33694871|NCT00678340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694872|NCT02127723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694873|NCT05132868|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783784|NCT05311475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33783785|NCT02896608|||OTHER||CROSS_SECTIONAL|||||||
33783786|NCT00288964|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33783787|NCT05453682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783788|NCT06712472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783789|NCT02919085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783790|NCT06447142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783791|NCT04018729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783792|NCT04759417|||OTHER||PROSPECTIVE|||||||
33918427|NCT05314712|NA|SINGLE_GROUP||OTHER||NONE||Pre and post test of intervention group; pilot test||||
33918428|NCT05611840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918429|NCT05154513|||COHORT||PROSPECTIVE|||||||
33918430|NCT02834234|||COHORT||RETROSPECTIVE|||||||
33918431|NCT05902429|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, phase IV, single-center, proof-of-concept clinical trial||||
33918432|NCT01221688|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Early breast cancer patients treated with neo-adjuvant chemotherapy (NAC) were included. Before NAC, patients with cytologically proven node involvement were allocated into the pN1 group, other patient were allocated into the cN0 group. After NAC, pN1 group patients underwent sentinel lymph node (SLN) and axillary lymph node dissection (ALND); cN0 group patients underwent SLN and ALND only in case of mapping failure or SLN involvement.||||
33918433|NCT02943018|||||PROSPECTIVE|||||||
33918434|NCT01363557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918435|NCT02299765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918436|NCT06347341|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||Prospective, crossover, randomized, double-blind clinical study comparing a gluten-containing diet to a gluten-free diet.|t|f|t|f
33918437|NCT03475576|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||before and after study||||
33918438|NCT02035150|RANDOMIZED|PARALLEL||||NONE||||||
33918439|NCT06092853|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918440|NCT00216177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918441|NCT03226132|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33918442|NCT01397916|||CASE_CONTROL||PROSPECTIVE|||||||
33918443|NCT00598169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918444|NCT01928836|||CASE_CONTROL||PROSPECTIVE|||||||
33918445|NCT04633057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918446|NCT02204826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918447|NCT05684653|NA|SINGLE_GROUP||OTHER||NONE||||||
33918448|NCT02791087|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918449|NCT04426838|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||40 dyads of people living with dementia (PLwD) and their caregivers will be enrolled to participate in the behavioral intervention together.||||
33918450|NCT03299738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918451|NCT01532167|||COHORT||PROSPECTIVE|||||||
33918452|NCT04028999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918453|NCT03411265|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918454|NCT01592877|||CASE_ONLY||PROSPECTIVE|||||||
33918455|NCT03179007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918456|NCT02292316|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33918457|NCT01980251|||COHORT||PROSPECTIVE|||||||
33918458|NCT00441103|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33918459|NCT04894812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918460|NCT06339333|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This quantitative study will be a two arm randomised control trial with an intervention group and waitlist group.|t|f|f|f
34088260|NCT00793975|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34088261|NCT00116142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998636|NCT03145987|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|subjects were randomly allocated to one of two groups treated as follows: Group 1, N = 57 to be treated with Cognigrape capsule (verum 250 mg/day); Group 2, N = 54 to be treated with placebo for 12 weeks. Neither subjects recruited for the study nor investigators knew the content of sachets or were able to differentiate the two different treatments.|Randomized, double-blinded, placebo controlled study.|t|t|f|t
34088262|NCT01572792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783793|NCT03377036|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomized to either Digital Breast Tomosynthesis plus synthesized 2D mammograms (DBT+s2D) or 2D Full-Field Digital Mammography (2D-FFDM)||||
33783794|NCT06095206|NA|SINGLE_GROUP||OTHER||NONE||||||
33783795|NCT06604104|||CASE_ONLY||CROSS_SECTIONAL|||||||
33783796|NCT04618016|||COHORT||PROSPECTIVE|||||||
33783797|NCT05407220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783798|NCT04776434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783799|NCT04476043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple||t|f|t|t
33783800|NCT06152198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783801|NCT06106945|NA|SEQUENTIAL||TREATMENT||NONE||This protocol has a modular design, with the potential for future treatment arms, study parts, or modules to be added via protocol amendments. Module 1 will include Phase Ia (Dose escalation), and Phase Ib (Dose expansion/optimization).||||
33783802|NCT06401993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783803|NCT05718219|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783804|NCT04721392|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33783805|NCT01016353|||CASE_CONTROL||PROSPECTIVE|||||||
33783806|NCT01838551|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|A data integrity plan prevented the Sponsor from accessing summary efficacy data prior to locking the clinical database.|Dose titration||||
33783807|NCT06555419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783808|NCT06641778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783809|NCT04717882|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Before-after study design||||
33783810|NCT06384430|||COHORT||CROSS_SECTIONAL|||||||
33783811|NCT00049114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783812|NCT00082719|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783813|NCT06323174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783814|NCT02459964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33783815|NCT05495711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomize double-blind||t|f|t|f
33783816|NCT04639947|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All subjects will first take their pressure using the EyeCheck with contact lens in and then remove their lens have pressures taken with Goldmann and Tonopen (two standard of care techniques of taking pressures of the eyes).||||
33783817|NCT04000893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33783818|NCT02341313|||COHORT||PROSPECTIVE|||||||
33783819|NCT04541225|NA|SEQUENTIAL||TREATMENT||NONE||||||
33783820|NCT06610357|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33783821|NCT05926323|||OTHER||PROSPECTIVE|||||||
33783822|NCT04267146|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open label, prospective study including successively a phase I trial and then a phase II trial||||
33783823|NCT01238497|||CASE_ONLY||PROSPECTIVE|||||||
33783824|NCT06659289|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will use a 1:1 stratified randomisation. The stratification will be based on the patient's stage of CKD at the time of enrolment (strata - stages 0-2, 3-4).||||
33783825|NCT03296579|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to use non-invasive face masks on the control patients so the study is unblinded.|||||
33998637|NCT04276064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33998638|NCT03329924|||COHORT||PROSPECTIVE|||||||
33998639|NCT02188407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998640|NCT00327587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998641|NCT03795012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998642|NCT06492369|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33998643|NCT01243151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998644|NCT05717790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783826|NCT02309840|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33783827|NCT05947513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783828|NCT02595307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33694874|NCT04731961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will not be informed of which arm they are assigned to before the procedure.|Patients will be assigned to arms with either 5 or 15 injections.|t|f|f|f
33694875|NCT06033716|||COHORT||PROSPECTIVE|||||||
33783829|NCT00002374||||TREATMENT||||||||
33694876|NCT04789681|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33694877|NCT06152731|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694878|NCT06205381|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Parts A and B of the study comparing AV078 to placebo will be a double-blind design (participant and investigator) Parts C, D and E are open label.|"Part A will study single doses of AV078 in a double-blind randomized, placebo-controlled, parallel-group and dose-escalating design (single ascending dose \[SAD\] study).~Part B will study repeated doses of AV078 (once daily for 14 days) in a double-blind, randomized, placebo-controlled, parallel-group and dose-escalating design (multiple ascending dose \[MAD\] study).~Part C will study the effect of food on the PK of AV078 in an open-label, randomized sequence 2-way crossover design.~Part D will study the effect of itraconazole on the PK of AV078 in an open-label, fixed sequence design.~Part E will study the effect of AV078 on the PK of midazolam and fexofenadine in an open-label, fixed sequence design."|t|f|t|t
33694879|NCT06560398|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33694880|NCT06070012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694881|NCT01825603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783830|NCT04108338|||COHORT||PROSPECTIVE|||||||
33783831|NCT02886988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33783832|NCT04813211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Nonrandomized Trial: participants are expressly assigned to intervention groups through a non-random method, such as physician choice|Participants are assigned to one of two or more groups in parallel for the duration of the study||||
33783833|NCT06711016|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"The control group: The goals of resuscitation include radial oxygen saturation between 92 and 98%, MAP ≥ 65 mmHg, Hb ≥ 7 g/dL, pH 7.35 to 7.45, and coagulation in accordance with ECMO management requirements. Routine fluid resuscitation, dehydration and intracranial pressure reduction, ECMO circulatory flow adjustment, temperature management, ventilator-supported ventilation, coronary angiography if coronary causes are suspected.~The experimental group：The Vm will maintained between 56-85 cm/s, Vd\>30cm/s，PI \<1.2, the cerebral oxygen saturation (rSO2) in the brain region will maintained between 60%-70%, ONSD\<5.5mm, and the pathological state will be monitored with EEG by regulating the ECMO parameters, temperature treatment, ventilation, vasoactive agent, sedative and antiepileptic drug et al. if necessary. The rest were monitored and treated with the control group."|f|f|f|t
33783834|NCT06713161|||CASE_ONLY||PROSPECTIVE|||||||
33694882|NCT04268550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783835|NCT05067283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783836|NCT04323995|||OTHER||RETROSPECTIVE|||||||
33783837|NCT06161883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The intervention trial consisted of a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial with a total duration of 16 weeks, which includes 2-weeks run-in period, 6 week intervention period (soffito or control group), 2-weeks wash-out period and 6 week intervention period (soffito or control group).||||
33783838|NCT05687123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783839|NCT03364959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33783840|NCT04486638|||COHORT||PROSPECTIVE|||||||
33783841|NCT03236233|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33918461|NCT00258388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918462|NCT04932902|||COHORT||PROSPECTIVE|||||||
33918463|NCT03317249|||COHORT||PROSPECTIVE|||||||
33918464|NCT05675111|||COHORT||RETROSPECTIVE|||||||
33918465|NCT03354702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918466|NCT03484351|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918467|NCT01625312|||COHORT||PROSPECTIVE|||||||
33918468|NCT00897325|||CASE_ONLY||PROSPECTIVE|||||||
33918469|NCT04096326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918470|NCT02525419|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33918471|NCT03615911|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918472|NCT06482580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary researcher will ensure blinding. Participants and the researcher conducting the assessments will be blinded to group information.|"This study was designed as an experimental, 3-arm parallel-group, double-blind randomized controlled trial with a 6-week intervention period.~The study will be conducted at Toros University physiotherapy and exercise laboratory."|t|f|f|t
33918473|NCT01240148|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33918474|NCT01244347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918475|NCT03121833|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 150 cases, according to 2: 1 random into the group. Among them, 100 cases of Endostar combined chemotherapy group, 50 cases of placebo + chemotherapy group.|t|f|t|f
33918476|NCT06159166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1 will test the safety of multiple dose regimens of mirdametinib, in order to identify a recommended phase 2 dose(s) for phase 2a. The phase 1 portion will enroll participants in dose regimens 1 to 3 concurrently. Enrollment of participants to dose regimen 4 will be conducted only if no DLT occurred in any of the three previous regimens within at least, the first three cycles. The study will continue until one of the following stopping conditions is met.~* The RP2D(s) have been identified with sufficient accuracy (The dose regimen(s) selected as the RP2D have been fully enrolled with at least 3 cycles of treatment completed for all participants)~* All dose regimens are deemed to have unacceptable safety"||||
33918477|NCT01906866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998645|NCT04475315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998646|NCT05754528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998647|NCT02429583|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33998648|NCT00382187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34088263|NCT03160170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088264|NCT02469857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33783842|NCT03818061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The sample size calculation will use an adaptive Simon 2-stage design based on the strategy developed by Lin and Shih (Biometrics 2004). This method allows checking the result at the first stage, adjusting the power and success rate if necessary, and adapting the decision rule accordingly. A minimum of 69 patients (up to 110) will be enrolled in 2 parallel independent cohorts depending on the HPV status of their tumors: cohort A (HPV+, N = 42 to 59) and cohort B (HPV-, N = 27 to 51).||||
33783843|NCT04478175|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33918478|NCT04653142|NA|SEQUENTIAL||TREATMENT||NONE||After the completion of dose escalation with BI 765063 in Part A, Part B will commence and successive dose groups of patients will receive escalating doses of BI 765063 in combination with a fixed dose of BI 754091.||||
33918479|NCT05143762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918480|NCT05426369|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33918481|NCT01747785|||CASE_CONTROL||PROSPECTIVE|||||||
33918482|NCT02503774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998649|NCT04968951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Antibiotics and placebo will be disguised|Participants are assigned to one of two groups. One group will be assigned to receive pre-treatment with antibiotics before Fecal Microbiota Transportation. The other group will be assigned to receive pre-treatment without antibiotics (with placebo) before Fecal Microbiota Transplantation.|t|t|t|f
33998650|NCT04106063|||COHORT||PROSPECTIVE|||||||
33998651|NCT01252758|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33998652|NCT00397657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998653|NCT01232049|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33998654|NCT02092857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33998655|NCT03898908|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort 1 will include patients with asymptomatic brain metastases and without previous local treatment in the brain (N=48), while cohort 2 will include patients with symptomatic brain metastasis and without previous local treatment in the brain (N=15).||||
33783844|NCT06291701|||CASE_ONLY||CROSS_SECTIONAL|||||||
33918483|NCT05751486|NA|PARALLEL||TREATMENT||NONE||Parallel||||
33918484|NCT03341923|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33918485|NCT02895776|||CASE_CONTROL||PROSPECTIVE|||||||
33918486|NCT04566822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The participants will be blinded as to which group is receiving the intervention being assessed|t|f|f|f
33918487|NCT00506948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918488|NCT00228670|||OTHER||PROSPECTIVE|||||||
33918489|NCT03604510|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918490|NCT00391417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998656|NCT01889758|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998657|NCT02966860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998658|NCT02484716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998659|NCT03057535|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33998660|NCT04628663|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Not aware of the study group|Prospective, Randomized, Placebo -controlled, Double-Blinded clinical trial|t|t|t|f
34088265|NCT03982537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34088266|NCT06349278|NA|SINGLE_GROUP||TREATMENT||NONE||One group will undergo intervention prospectively.||||
34088267|NCT04087447|||COHORT||PROSPECTIVE|||||||
33918491|NCT01120379|||COHORT||PROSPECTIVE|||||||
33918492|NCT06106646|||CASE_CONTROL||PROSPECTIVE|||||||
33998661|NCT04688333|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998662|NCT02083809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998663|NCT04428645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998664|NCT00221520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33998665|NCT00916786|||CASE_CONTROL||OTHER|||||||
33918493|NCT04362449|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694883|NCT05527405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Statistical analyses of all data will be carried out independently of investigators by a biostatistical resource department of an academic health center for validation.|The study will be a randomized controlled clinical trial in which two conditions will be investigated: a control and an experimental condition.|t|f|f|t
33694884|NCT04326075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694885|NCT06707558|||OTHER||PROSPECTIVE|||||||
33694886|NCT02138422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694887|NCT06123663|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33783845|NCT03504449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918494|NCT01405118|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918495|NCT04300530|||COHORT||CROSS_SECTIONAL|||||||
33918496|NCT06113497|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33918497|NCT04095754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33918498|NCT01480492|NA|SINGLE_GROUP||||NONE||||||
33918499|NCT05237180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918500|NCT02877355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918501|NCT02461836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918502|NCT05391568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918503|NCT00234416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694888|NCT06707259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694889|NCT02237911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918504|NCT00316342|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||||||
33918505|NCT02092441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33998666|NCT04162171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694890|NCT00005928||||TREATMENT||||||||
33694891|NCT04169100|NA|SINGLE_GROUP||PREVENTION||NONE||Single group, Preventative care, Proof of concept study||||
33694892|NCT03190369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694893|NCT06500273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694894|NCT05420727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918506|NCT04474119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918507|NCT05412537|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||The RCT will compare two groups: (a) a consult as usual (a regular consult with the medical advisor) and (b) an intervention based on motivational interviewing performed by a medical advisor.|t|f|t|t
33998667|NCT00504062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998668|NCT01828437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998669|NCT01164657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998670|NCT01944722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998671|NCT04027023|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, prospective, phase IV study||||
33998672|NCT05073523|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33998673|NCT02671474||||DIAGNOSTIC||||||||
33998674|NCT06466317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783846|NCT06228742|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single leg immobilization model consisting of one leg randomly assigned to immobilization with a knee brace and the other leg remaining active and non-immobilized, for 5 days.||||
33783847|NCT05237193|||COHORT||PROSPECTIVE|||||||
33783848|NCT05727059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694895|NCT03095443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33694896|NCT00135044|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33694897|NCT04448054|||CASE_ONLY||PROSPECTIVE|||||||
33694898|NCT05760105|||CASE_ONLY||PROSPECTIVE|||||||
33694899|NCT02889692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694900|NCT06656975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To the extent possible, the assessor will be blinded. The study team will track any instances where an assessor becomes unblinded to a participant's arm assignment.|Participants will be randomized into 1 of 3 arms in a 1:1:1 ratio (see Protocol for detailed descriptions).|f|f|f|t
33694901|NCT02344615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33694902|NCT06216834|||COHORT||CROSS_SECTIONAL|||||||
33694903|NCT06134375|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 portion is single group. Phase 2 portion is parallel.||||
33694904|NCT02499978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694905|NCT00234403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694906|NCT05599269|NA|SINGLE_GROUP||TREATMENT||NONE||retrospective study||||
33694907|NCT01654627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694908|NCT01606644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694909|NCT05041946|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33694910|NCT00074438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694911|NCT05907291|NA|SEQUENTIAL||TREATMENT||NONE||||||
33694912|NCT01479504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783849|NCT02883504|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783850|NCT06117176|||COHORT||PROSPECTIVE|||||||
33783851|NCT06480422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783852|NCT01492309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783853|NCT03453632|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Each subject is his own witness, receiving the 2 treatments : left foot vs. right foot|t|t|t|f
33783854|NCT05210842|||COHORT||RETROSPECTIVE|||||||
33783855|NCT02065011|NA|SINGLE_GROUP||OTHER||NONE||||||
33783856|NCT04663399|||COHORT||PROSPECTIVE|||||||
33783857|NCT06711432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33783858|NCT04045119|NA|SINGLE_GROUP||OTHER||NONE||This is a quasi-experimental (i.e., prospective, non-randomized, non-controlled), open label trial||||
33918508|NCT05261880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single blinded as assessors of the study would be kept blind of the treatment group to which patient will allocated.||f|f|f|t
33918509|NCT03043729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918510|NCT00054249||||TREATMENT||NONE||||||
33998675|NCT02117141|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33998676|NCT04727164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694913|NCT04007211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694914|NCT05432141|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33694915|NCT01093638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694916|NCT04170842|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33694917|NCT01121731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694918|NCT06701318|||OTHER||CROSS_SECTIONAL|||||||
33694919|NCT05075382|||COHORT||PROSPECTIVE|||||||
33694920|NCT04814862|||COHORT||RETROSPECTIVE|||||||
33694921|NCT03635554|||CASE_CONTROL||PROSPECTIVE|||||||
33694922|NCT01867112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33694923|NCT06709469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I, open label, prospective, single center, two-armed, non-randomized trial||||
33694924|NCT00441454|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694925|NCT00133393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694926|NCT00486174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694927|NCT05357547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33694928|NCT04149873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694929|NCT03654066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783859|NCT04990674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918511|NCT05338281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33918512|NCT01904734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918513|NCT00720421|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33918514|NCT02221271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918515|NCT03711994|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918516|NCT02932189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33918517|NCT05101460|||CASE_ONLY||PROSPECTIVE|||||||
33918518|NCT03634904|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33918519|NCT01354041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918520|NCT04602676|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33918521|NCT06010355|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33918522|NCT02101840|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33918523|NCT03265743|||OTHER||PROSPECTIVE|||||||
33694930|NCT04865575|||CASE_CONTROL||PROSPECTIVE|||||||
33694931|NCT06508944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33694932|NCT00645684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33694933|NCT05685836|||COHORT||PROSPECTIVE|||||||
33783860|NCT00990678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783861|NCT00191685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783862|NCT01618331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33918524|NCT01587573|||CASE_CONTROL||PROSPECTIVE|||||||
33918525|NCT00419913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998677|NCT04875585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998678|NCT05719467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694934|NCT06157060|||COHORT||PROSPECTIVE|||||||
33694935|NCT06384261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998679|NCT03259113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Consecutive insertable cardiac monitors in 30 patients with hypertrophic cardiomyopathy||||
33694936|NCT01672736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694937|NCT01941043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998680|NCT04783337|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998681|NCT06356077|||COHORT||PROSPECTIVE|||||||
33998682|NCT03486496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998683|NCT01951209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33998684|NCT05939102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33998685|NCT01457196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998686|NCT02545179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33998687|NCT01194908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088268|NCT03870490|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34088269|NCT01603602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088270|NCT01285544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088271|NCT02921165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33694938|NCT04368273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694939|NCT03307304|||COHORT||OTHER|||||||
33694940|NCT00841971|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33694941|NCT05909904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694942|NCT02158260|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33694943|NCT03930953|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694944|NCT02864719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33694945|NCT06278662|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The masking is dependent of the future interventions.|"The CIRCUS study has a cmRCT design to determine the effects of (eHealth) interventions in asthmatic children. Children are included in the prospective dynamic cohort during outpatient visits. Children and/or their parents are asked to sign consent for three parts of the cmRCT, of which at least consent for part 1 is needed to be eligible for participation:~1. Participating in the prospective dynamic cohort and data collection.~2. Willingness to participate in interventions.~3. Willingness to fill out additional questionnaires and/or do additional measurements if a child is randomly selected for the control group of an intervention, which uses additional outcomes."||||
33694946|NCT06708611|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Double-blind, double-dummy, two-period, two arm, randomized, crossover clinical trial.|t|t|t|t
33694947|NCT02225509|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
34088272|NCT05600478|||COHORT||CROSS_SECTIONAL|||||||
33694948|NCT05716399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to ensure the objectivity and reliability of the study, the statistical analysts are blinded, and the subjects and operators are not blind. The operator is responsible for the implementation of anesthesia, the connection and use of TEAS, and data collection; The statistical analyst is responsible for data entry, data sorting and statistical analysis.||f|f|t|t
33694949|NCT06313593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33694950|NCT05736224|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory technicians will be blinded to treatment of samples.|Within subject design where participant serves as own control.|f|f|f|t
33694951|NCT05998278|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||They were randomly divided into two groups. One group received targeted biopsy plus systematic biopsy. The other group received targeted biopsy plus plus personalized systematic biopsy.|t|f|f|f
33694952|NCT04660253|NA|SINGLE_GROUP||TREATMENT||NONE|Researchers doing outcome assessments|This integrated intervention is called LTP Plus Dads consisting of 10 group sessions delivered weekly by trained professionals who received weekly supervision by LTP Plus master trainers.||||
33694953|NCT04161066|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||open-label pilot study||||
33694954|NCT03860142|||COHORT||PROSPECTIVE|||||||
33694955|NCT00362037|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33694956|NCT00073073|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33694957|NCT02962154|||COHORT||PROSPECTIVE|||||||
34088273|NCT01034553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088274|NCT01799694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088275|NCT00121875|||CASE_CONTROL||PROSPECTIVE|||||||
34088276|NCT05306704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Its double blind trail so trail is blinded for Participants, Care Provider, Investigator and Outcome Assessor.|Parallel group trial design. Parallel arm design is the most commonly used study design. In this design, subjects are randomized to one or more study arms and each study arm will be allocated a different intervention.|t|t|t|t
33694958|NCT02905656|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33694959|NCT06558006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694960|NCT01660308|||CASE_CONTROL||PROSPECTIVE|||||||
33694961|NCT01465061|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33694962|NCT02922400|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801498|NCT03110549|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Five qualifying participants will be enrolled into each of seven dosage Arms - three escalating subcutaneous dosages (Cohort 1), and four escalating intramuscular dosages (Cohort 2). Enrolling participants will be randomized to receive active TMB-607 or placebo. Beginning with the lowest dosage group, a Data Safety Monitoring Board (DSMB) will review available data after four participants have completed two weeks of post-dose follow-up to determine whether escalation to the next dosage group may proceed|t|f|t|t
33998688|NCT01622764|NA|SINGLE_GROUP||OTHER||NONE||||||
33998689|NCT00582244|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33998690|NCT01151696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998691|NCT02777307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998692|NCT03058107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998693|NCT06298123|||COHORT||RETROSPECTIVE|||||||
33998694|NCT02331511|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998695|NCT01437735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998696|NCT05235022|||CASE_ONLY||PROSPECTIVE|||||||
33998697|NCT02086838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998698|NCT05592808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801499|NCT05351424|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||2x2||||
33918526|NCT02530671|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33918527|NCT02131012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918528|NCT03937258|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33918529|NCT03210779|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Double Blind (Participant, Care Provider, Investigator)|Cross-over pilot trial|t|t|f|f
33918530|NCT03297437|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33918531|NCT06108349|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33918532|NCT04780555|||COHORT||PROSPECTIVE|||||||
33918533|NCT06348732|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33998699|NCT01143337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998700|NCT00510861|||||RETROSPECTIVE|||||||
33998701|NCT04917393|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Subjects will be blinded during the procedure by a combination of the conscious sedation, sensory isolation and sedation and lack of familiarity of the procedural details and duration (i.e., subjects will not know the difference between the renal angiography procedure alone and the renal angiography and denervation procedure).|The study is a prospective, single-arm, multi-center, sham controlled feasibility study|t|f|f|f
33998702|NCT03141151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and data collectors will be blinded to randomization status. Because this is a behavioral intervention, the participants and interventionists will be unblinded.||f|f|t|t
33998703|NCT00835796|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33998704|NCT03283748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998705|NCT02642809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998706|NCT00235560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998707|NCT04506619|||COHORT||PROSPECTIVE|||||||
34088277|NCT02502448|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34088278|NCT01991314|NA|SINGLE_GROUP||TREATMENT||NONE|This was an open label trial|||||
34088279|NCT02967445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088280|NCT01369550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088281|NCT00845182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088282|NCT05256264|||OTHER||PROSPECTIVE|||||||
34088283|NCT02337127|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088284|NCT02124226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34088285|NCT04311957|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study.|Participants will be randomized to the B/F/TAF or continuation bPI group in a 1:1 ratio.||||
34088286|NCT00005663||||TREATMENT||DOUBLE||||||
34088287|NCT02421042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088288|NCT03396224|||COHORT||PROSPECTIVE|||||||
33801500|NCT03035396|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33801501|NCT06288607|||COHORT||PROSPECTIVE|||||||
33998708|NCT06447285|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33998709|NCT03302598|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective study of 40 patients admitted with the diagnosis of enterocutaneous fistula and prepared for definite surgical repair in the form of resection anastomosis of ECF. the investigators used preoperative serum C-reactive protein as predicting factor to recurrence and independent variable for timing of surgery.||||
34088289|NCT00520000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088290|NCT01471301|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34088291|NCT01583088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34088292|NCT01256307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088293|NCT00148798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088294|NCT00467792|||COHORT||PROSPECTIVE|||||||
34088295|NCT02544789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088296|NCT02598310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088297|NCT04519190|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33801502|NCT04717544|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33801503|NCT03773835||SEQUENTIAL||TREATMENT||NONE||||||
33801504|NCT01199133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801505|NCT05045196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801506|NCT06409299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The study comprises a multicenter, parallel-group, double-blind, randomized placebo-controlled clinical trial (RCT) with a single intervention.|t|t|t|t
33801507|NCT01449123|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801508|NCT03829852|||COHORT||RETROSPECTIVE|||||||
33801509|NCT01925365|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33801510|NCT02058108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801511|NCT04854772|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility/pilot Study||||
33801512|NCT03085394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998710|NCT05070754|RANDOMIZED|PARALLEL||TREATMENT||NONE||During a clinical care visit, if a patient is eligible and agrees to participate, lesions will be selected by the dermatologist prior to procedure.The lesions will be marked randomly for a certain treatment regimen. The number of lesions treated will not exceed standard of care (SOC) recommendations. They will be determined by provider assessment and anatomical location. Participants with one lesion will receive either non-thermal atmospheric plasma (NTAP) or SOC. SOC is cryotherapy for warts and cantharidin for molluscum. Participants with greater than 2 lesions will receive equal treatment of NTAP and SOC. The number of lesions treated will be based off the providers assessment and anatomical location. Treatment of a single lesion or an odd number of multiple lesions will be based off a randomized list. All SOC lesions will be treated first to reduce the number of patients not wanting return to the more painful modality.||||
33998711|NCT03694236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998712|NCT04595669|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998713|NCT06213792|||COHORT||PROSPECTIVE|||||||
33998714|NCT03531450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998715|NCT00326872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998716|NCT00533156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998717|NCT04010227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Advanced gastrointestinal cancer patient-family caregiver dyads (N = 40) were randomly assigned in equal numbers to Acceptance and Commitment Therapy (ACT) or education/support using a stratified block randomization scheme to balance the groups by patient performance status (patient-reported Eastern Cooperative Oncology Group \[ECOG\] scores 0 or 1 vs. 2).|f|f|f|t
33998718|NCT02439515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998719|NCT02661022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998720|NCT01380392|||CASE_ONLY||CROSS_SECTIONAL|||||||
33998721|NCT01496118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998722|NCT02119637|||||PROSPECTIVE|||||||
33998723|NCT00068042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998724|NCT03680144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998725|NCT02485938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998726|NCT03914898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998727|NCT05677243|||COHORT||CROSS_SECTIONAL|||||||
33998728|NCT00005873||||TREATMENT||||||||
33998729|NCT04443049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998730|NCT06443125|NA|SEQUENTIAL||TREATMENT||NONE||||||
33998731|NCT04090021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998732|NCT00275249|RANDOMIZED|PARALLEL||||DOUBLE||||||
33998733|NCT04909970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||waiting list||||
33998734|NCT02015832|||CASE_ONLY||PROSPECTIVE|||||||
33998735|NCT02133638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998736|NCT01424020|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998737|NCT02757287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998738|NCT02790658|NA|SINGLE_GROUP||||NONE||||||
33998739|NCT03595436|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double-blind, placebo-controlled|tightly-controlled, randomized crossover design|t|f|t|t
33998740|NCT03024801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998741|NCT03673514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|However, the decision to discharge subjects was made by physiotherapists blinded to treatment and based on objective criteria. These criteria were: 1) being autonomous for transfer from bed/chair to upright position 2) being able to walk with walking aid 3) climbing stairs in a safe way 4) having a pain level contained by painkillers. No restrictions were recommended for either group. The same rehabilitation and pain protocols were used for both approaches. In addition, statistical analyses were performed by an independent consultant who remained blinded to treatment group assignment.||f|f|f|t
33998742|NCT05040737|NA|SINGLE_GROUP||OTHER||NONE||||||
33998743|NCT05706415|||CASE_CROSSOVER||PROSPECTIVE|||||||
33998744|NCT00286533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998745|NCT03141580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998746|NCT04408924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998747|NCT03548155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998748|NCT05261191|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33998749|NCT03937206|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33998750|NCT02231957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33694963|NCT05324618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|200 opaque envelopes will be numbered serially and the corresponding letter which denotes the allocation will be put according to the electronic randomization table. Then all envelopes will be closed and put in one box. When the first patient arrives, the envelope will be opened and the patient will be allocated according to the letter inside.|prospective, double blinded, simply randomized clinical trial|t|t|f|f
33694964|NCT05436834|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33694965|NCT02097043|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33694966|NCT04422743|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33694967|NCT06680726|||COHORT||PROSPECTIVE|||||||
33694968|NCT01889524|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33694969|NCT02546635|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33694970|NCT04171284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694971|NCT04330183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998751|NCT04692363|||COHORT||RETROSPECTIVE|||||||
33998752|NCT03323450|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998753|NCT05212987|NA|SEQUENTIAL||TREATMENT||NONE||Open-Label Phase 1 Dose escalation study||||
33998754|NCT02763488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998755|NCT02621190|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998756|NCT01788644|||COHORT||PROSPECTIVE|||||||
33998757|NCT02560051|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998758|NCT06225245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998759|NCT02873260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33998760|NCT02577913|||COHORT||PROSPECTIVE|||||||
33998761|NCT01930409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33998762|NCT04878211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998763|NCT03675763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33998764|NCT06367985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Sibling oocytes||||
33998765|NCT04535986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998766|NCT04827251|RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective, open label, controlled study||||
33998767|NCT05156086|||COHORT||PROSPECTIVE|||||||
33998768|NCT02161705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998769|NCT04759989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998770|NCT01159899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998771|NCT03681938|||CASE_CONTROL||RETROSPECTIVE|||||||
33998772|NCT00268216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088298|NCT01140750|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088299|NCT00745602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33694972|NCT05361928|||COHORT||CROSS_SECTIONAL|||||||
33694973|NCT06710041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694974|NCT05413031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694975|NCT01570920|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33694976|NCT02496962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33694977|NCT01886716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33694978|NCT03805906|||COHORT||PROSPECTIVE|||||||
33694979|NCT05693727|||COHORT||PROSPECTIVE|||||||
33694980|NCT02958501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694981|NCT05136807|||COHORT||PROSPECTIVE|||||||
33694982|NCT00096083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801513|NCT00223067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801514|NCT05408572|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33801515|NCT02403297|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34088300|NCT03092232|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33694983|NCT05432362|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The randomizer (online tool of the Medical University of Graz) will be used for randomisation of group assignment. The two juices are provided in the same containers.|"This monocentric study is a food product study (comparison between in trade available polyphenol-rich juice and a placebo).~Aronia juice is a locally produced, commercially available natural source of various secondary plant nutrients. It naturally contains high amounts of polyphenols. The placebo juice is prepared according to a published recipe and contains comparable amounts of nutrients such as vitamins and minerals but is totally polyphenol-free.~Six study groups are designated:~Group VN = normal weight participants receiving polyphenol-rich juice (verum) (n=20) Group VA = adipose participants receiving polyphenol-rich juice (verum) (n=20) Group VD = depressive patients receiving polyphenol-rich juice (verum) (n=20) Group CN = normal weight participants receiving placebo (control) (n=20) Group CA = adipose participants receiving placebo (control) (n=20) Group CD = depressive patients receiving placebo (control) (n=20)"|t|f|f|f
33694984|NCT06710470|||COHORT||RETROSPECTIVE|||||||
33694985|NCT06702930|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33694986|NCT02586285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33694987|NCT00950287|||COHORT||PROSPECTIVE|||||||
33694988|NCT04265469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33694989|NCT02107352|||COHORT||PROSPECTIVE|||||||
33694990|NCT02413177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33694991|NCT05873673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694992|NCT01695512|||COHORT||PROSPECTIVE|||||||
33998773|NCT05044962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and care providers will not be masked (open label), but the principle and site-principal investigators and study statistician will be blinded to arm allocation.|The hybrid trial will be a parallel, randomized design.|f|f|t|t
33694993|NCT04741230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783863|NCT06712004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject numbers and corresponding medication numbers are permanently identified and unique for each successfully randomized patient. If any patients who have been successfully randomized do not receive the trial medication or cannot be reassigned to others, their medication and medication numbers will be invalidated by the medication administrator. To ensure blinding during the trial execution, unblinded personnel responsible for administering and configuring the trial drug must sign a confidentiality agreement.|The subject numbers and corresponding medication numbers are permanently identified and unique for each successfully randomized patient. If any patients who have been successfully randomized do not receive the trial medication or cannot be reassigned to others, their medication and medication numbers will be invalidated by the medication administrator. To ensure blinding during the trial execution, unblinded personnel responsible for administering and configuring the trial drug must sign a confidentiality agreement. Investigators, other blinded investigators, subjects, and sponsors will not have access to any information regarding group assignment or related documents pertaining to the trial drug.|t|f|t|f
33694994|NCT01952600|||||PROSPECTIVE|||||||
33694995|NCT00945555|||COHORT||PROSPECTIVE|||||||
33694996|NCT03311620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The needle size to be used first will be chosen by permuted block randomization scheme by the statistician|All abnormal lymph nodes able to be visualized by EBUS will be biopsied with sequential passes until a macroscopic specimen can be seen in the sample container. Each needle size will be used to take consecutive passes until the sample is complete and each pass will consist of 15-20 agitations. The needle size to be used first will be chosen by permuted block randomization scheme by the statistician. After all passes are done with the first needle, the alternate size needle will be used to biopsy the same lymph node. Samples will be placed in separate containers of formalin. Any subsequent lymph nodes in the same patient will be biopsied with the alternate sized needle first. Further, any lung nodules or masses that can be adequately visualized by EBUS where biopsy is clinically indicated will be sampled with both 22g and 19g TBNA needles in the same fashion. However, these lesions will be randomized separately from any lymph nodes biopsied during the case.||||
33783864|NCT03771235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|f|t
33694997|NCT04251273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not explicitly told they are in the control group, although they may deduce their assignment from presence or lack of regular text message intervention.|Arm 1: Intervention - Text message intervention Arm 2: Control - Assessment only|t|f|f|f
34088301|NCT02084342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33694998|NCT05658536|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, 2-group parallel design, 50-subject pilot clinical trial to examine the feasibility, acceptability, and initial effects of a telemedicine group-based intervention designed to improve symptom management and coping in adults with Post-COVID.||||
33694999|NCT03164577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783865|NCT00188409|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783866|NCT06554964|NA|SINGLE_GROUP||OTHER||NONE||Prospective non-randomized cohort study including patients undergoing laparoscopic salpingectomy for tubal ectopic pregnancy.||||
33783867|NCT00002563|||CASE_ONLY||PROSPECTIVE|||||||
33783868|NCT00774111|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33783869|NCT00188240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783870|NCT05047354|||COHORT||PROSPECTIVE|||||||
33783871|NCT04816526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088302|NCT04243668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088303|NCT00327535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783872|NCT05341661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33783873|NCT02008292|NA|SINGLE_GROUP||OTHER||NONE||||||
33783874|NCT01906229|||COHORT||PROSPECTIVE|||||||
33783875|NCT06525246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783876|NCT06329414|||CASE_ONLY||PROSPECTIVE|||||||
33783877|NCT06713681|||CASE_ONLY||PROSPECTIVE|||||||
33801516|NCT04728906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088304|NCT03867435|||COHORT||PROSPECTIVE|||||||
34088305|NCT00922311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801517|NCT05958836|||CASE_CONTROL||PROSPECTIVE|||||||
33801518|NCT03776500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088306|NCT04011072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088307|NCT01088386|||COHORT||PROSPECTIVE|||||||
33695000|NCT05930769|||CASE_CONTROL||RETROSPECTIVE|||||||
33918534|NCT01383967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695001|NCT06021665|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both groups and the study coordinators will be blinded to the allocation.|Two-group, randomized controlled trial|t|f|t|f
33783878|NCT03686683|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 2:1 to the sipuleucel-T arm or the control arm.Participants randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals. Participants randomized to the control arm will be followed on AS as standard of care described in the schedule of events.||||
33783879|NCT05471726|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge||||
33783880|NCT01719289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695002|NCT02862899|NA|SINGLE_GROUP||OTHER||NONE||||||
33783881|NCT04046575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783882|NCT05383963|||COHORT||RETROSPECTIVE|||||||
33918535|NCT06390631|NA|SINGLE_GROUP||TREATMENT||NONE||CPAP treatment||||
33695003|NCT03139318|NA|SEQUENTIAL||TREATMENT||NONE||||||
33918536|NCT06509711|RANDOMIZED|PARALLEL||OTHER||SINGLE|single (outcome assessor) who take the readings is blind|randomized clinical trials|f|f|f|t
33998774|NCT06315660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|When a participant is randomized to TAU+VR, the senior researcher reveals the allocation to the assigned clinician via secure e-mail. The assigned clinician then schedules the eight therapy sessions with the participant who is thus unblinded to their treatment allocation. If the participant is randomized to TAU, the assigned clinician will inform the participant as soon as possible. The researchers collecting data from the patient and the researchers performing data analysis remain blinded. There are no circumstances wherein unblinding of outcome assessors or data analysists is permissible.|The study is a parallel group, investigator initiated, pragmatic, assessor-blinded, 1:1 randomized, clinical feasibility trial.|f|f|t|t
33998775|NCT00204451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998776|NCT02000258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33998777|NCT06251206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33998778|NCT04534985|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33998779|NCT05731024|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33695004|NCT00458068|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33695005|NCT01793831|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695006|NCT02854176|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33695007|NCT04282512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Group A subjects: first 15-day period drinking a sodium bicarbonate-rich mineral water Group B subjects: first 15-day period drinking tap water Washout period of 15 days Group A subjects: last 15-day period drinking tap water Group B subjects: last 15-day period drinking a Sodium bicarbonate-rich mineral water||||
33695008|NCT05173480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695009|NCT02405754|||CASE_ONLY||RETROSPECTIVE|||||||
33695010|NCT00463203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33783883|NCT02905513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33783884|NCT00499317|||FAMILY_BASED||PROSPECTIVE|||||||
33783885|NCT01963026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783886|NCT05108051|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33783887|NCT02828930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783888|NCT05916560|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33783889|NCT06303986|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33783890|NCT03768661|||COHORT||RETROSPECTIVE|||||||
33783891|NCT02912780|||||PROSPECTIVE|||||||
33783892|NCT03834844|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2 x 2 factorial design||||
33783893|NCT05711940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783894|NCT05190185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918537|NCT04733846|||COHORT||RETROSPECTIVE|||||||
33918538|NCT03721393|||COHORT||PROSPECTIVE|||||||
33918539|NCT02608034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918540|NCT00423735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918541|NCT05584930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918542|NCT05387252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants are told that they would receive a cup of mulberry juice in which the volume is randomized, without knowing the exact dose range.|Participants are divided into three groups, namely, the low dose group (10 ml), middle dose group (50 ml), and high dose group (100 ml).|t|f|f|t
33918543|NCT04410198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918544|NCT05650931|NA|SEQUENTIAL||TREATMENT||NONE||||||
33918545|NCT02439645|||CASE_ONLY||PROSPECTIVE|||||||
33695011|NCT03084510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783895|NCT00765661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783896|NCT02547805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33783897|NCT03129035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801519|NCT02831231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918546|NCT00095368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33918547|NCT02471911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918548|NCT00731848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998780|NCT05319574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998781|NCT00538863|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783898|NCT06297980|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a parallel group randomized control trial of a personalized glucose control intervention to target changes in glycemic control related to the menstrual cycle that are identified during a 3 month observational period.||||
33783899|NCT04863105|RANDOMIZED|CROSSOVER||TREATMENT||NONE||an open, randomized, single-dose, three-cycle, three-sequence crossover study||||
33783900|NCT03983343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Cosmetic result will be assessed 4-6 weeks after the repair by a doctor who did not participate in tear suturing immediately after delivery, and is not aware to the repair method used.|"Eligible patients will be asked to participate in this trial before perineal tear repair.~The patients will be randomly assigned to one of the two groups in a 1:1 ratio:~1. Suturing the perineal skin of the perineum using fast-absorbable running sutures (Vicryl Rapide 3-0)~2. Closing the perineal skin using adhesive glue- exofin® (Octyl-2-cyanoacrylate). Other than skin closure, both groups will be treated similarly according to standard protocol used for perineal tear repair. In both groups, the walls of the vagina, the perineal muscles and the subcutaneous tissue will be repaired and approximated using the standard method, i.e. with running sutures using Vicryl Rapid Stitch 2-0."|f|f|f|t
33783901|NCT05214794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783902|NCT03297983|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33783903|NCT04887272|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The data analysis assessor will be blinded to pre and post-testing samples, as well as to the treatment group.||f|f|f|t
33783904|NCT03867864|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33783905|NCT05238779|||COHORT||PROSPECTIVE|||||||
33783906|NCT04990635|||CASE_ONLY||CROSS_SECTIONAL|||||||
33783907|NCT04816682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective open label study using historical cohort for propensity-match analysis||||
33783908|NCT05169281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will be blinded to their random assignment into the control or treatment (medication disposal packet) group||t|f|f|f
33783909|NCT04902742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33783910|NCT00819234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33783911|NCT04348370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be done centrally and computer generated with stratification per hospital in random blocks of 2, 4 and 6. The BCG vaccine will be administered by research nurses. Participants and investigators will be blinded. The research nurse that administers the BCG vaccine or placebo will not be blinded. This research nurse will not be involved in the collection of outcome data.|Participants will be randomized to BCG:placebo in a 1:1 ratio.|t|f|t|f
33783912|NCT05266261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918549|NCT04703127|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will be equally divided into 2 groups (30 patients each).Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse. Group 1 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.|All patients will be equally divided into 2 groups (30 patients each). Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse. Group 1 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.|f|f|t|f
33918550|NCT00980343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918551|NCT05435144|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918552|NCT02193828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998782|NCT05642130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||randomized controlled trial|t|f|f|f
33998783|NCT03064620|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33998784|NCT05534113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998785|NCT06149962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998786|NCT04816227|||CASE_CONTROL||PROSPECTIVE|||||||
33998787|NCT02285049|||CASE_ONLY||PROSPECTIVE|||||||
33998788|NCT03989141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998789|NCT03601845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Additional sequences during magnetic resonance elastography by intrinsic activation with or without stimuli||||
33998790|NCT04203667|NA|SINGLE_GROUP||TREATMENT||NONE||Post-market, prospective, non-randomized, multi-center study for the treatment of subjects with the need for resection of recurrent flat or sessile colorectal lesions where EndoRotor is the primary resection modality of persistent adenoma with a scarred base.||||
33998791|NCT01327976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33998792|NCT00862563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998793|NCT02108639|NA|SINGLE_GROUP||||NONE||||||
33801520|NCT04729972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801521|NCT04215172|||CASE_CONTROL||PROSPECTIVE|||||||
33801522|NCT01505712|||OTHER||RETROSPECTIVE|||||||
33801523|NCT03752034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801524|NCT00610649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695012|NCT04378946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation will be concealed from the individual assigning participants to groups until the moment of assignment. The therapist will be notified of subject group allocation via a sealed envelope prior to the first treatment session. Participants will also be blinded to group allocation. Finally, those assessing outcomes as well as those analysing data will be blinded by concealing patient group allocation.|This double-blind randomized controlled trial (RCT) complies with Consolidated Standards of Reporting Trials (CONSORT) and the Template for Intervention Description and Replication (TIDieR) checklist and guide. The trial will be prospectively registered in Clinicaltrials.gov and the protocol will be published following the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement.|t|f|f|t
33695013|NCT01365065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783913|NCT04939207|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||After coronary CT-scan, patients will be randomized in one of three possible study arms. One arm will receive additional CT-derived calculation of coronary blood flow, one arm will receive angiography-derived calculation of coronary blood flow and one arm will receive standard routine care. Standard care consists of coronary angiography and invasive coronary blood flow measurements. The results of these tests determine the need for treatment of coronary artery disease. After these tests, patients will be treated and followed according to routine care guidelines.||||
33783914|NCT00568503|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33783915|NCT01051778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783916|NCT02485353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783917|NCT00421902|NA|SINGLE_GROUP||TREATMENT||NONE||Acupuncture to pevent hot flushes||||
33783918|NCT05592613|NON_RANDOMIZED|PARALLEL||OTHER||NONE||For 30 days, the next-generation Reader and ID-Cap System will be used in an open-label, observational trial with N=30 participants (N=15 HIV-negative individuals on PrEP and N=15 PLWH on ART).||||
33783919|NCT04709731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783920|NCT00721864|||COHORT||PROSPECTIVE|||||||
33783921|NCT05247853|||COHORT||CROSS_SECTIONAL|||||||
33783922|NCT06616506|||COHORT||PROSPECTIVE|||||||
33783923|NCT03770624|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783924|NCT01334541|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783925|NCT02846415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33783926|NCT01110174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783927|NCT06416085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783928|NCT06711978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783929|NCT05168969|||COHORT||PROSPECTIVE|||||||
33783930|NCT06429410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33783931|NCT06141746|||COHORT||PROSPECTIVE|||||||
33783932|NCT03429309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998794|NCT03493633|||OTHER||PROSPECTIVE|||||||
33998795|NCT00980941|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33998796|NCT04989244|NA|SINGLE_GROUP||OTHER||NONE||||||
33998797|NCT05729854|RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental and control group||||
33998798|NCT03572582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998799|NCT02089360|||COHORT||PROSPECTIVE|||||||
33998800|NCT03749707|NA|SINGLE_GROUP||PREVENTION||NONE||Early-stage cervical cancer patients treated with radical hysterectomy and removal of SLNs.||||
33998801|NCT03166527|NA|SINGLE_GROUP||TREATMENT||NONE||Each patient with active CIDP will receive Panzyga (immune globulin) at standard and high infusion rates and will act as their own control.||||
33998802|NCT05121935|||COHORT||PROSPECTIVE|||||||
33998803|NCT00677872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998804|NCT03256149|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33998805|NCT00003808||||TREATMENT||||||||
33998806|NCT05613426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998807|NCT00486434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998808|NCT05000138|||COHORT||PROSPECTIVE|||||||
33998809|NCT00731367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998810|NCT01667822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998811|NCT06462495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998812|NCT00000595||||TREATMENT||||||||
33998813|NCT00834158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998814|NCT06192524|||COHORT||PROSPECTIVE|||||||
33998815|NCT03818464|||COHORT||PROSPECTIVE|||||||
33998816|NCT00288704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998817|NCT03890705|||OTHER||CROSS_SECTIONAL|||||||
34088308|NCT04943224|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088309|NCT05605990|NA|SINGLE_GROUP||PREVENTION||NONE||We will recruit 160 nurses in high-risk units of the hospital.||||
34088310|NCT02308878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783933|NCT03425292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783934|NCT05540990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783935|NCT06060418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The ward Manager/Head Nurse will act as an outcome assessor and blind to the intervention group and control group|"After deciding the participant of intervention group the researcher will start the protocol of intervention The intervention will start if NRS score is \> 1 for nausea and with the 1st episode of vomiting.~The researcher will soak a 4×4 cm sterile gauze pad with 0.2 ml equivalent to 2 drops of 10% Lavender essential oil and will suspended the soaked gauze at a distance of 10cm from the patient's nose with the help of forcep, and he or she will have asked to inhale its scent for 5 min. 15 and 40 minutes after the beginning of the aromatherapy treatment, the researcher will measure the nausea and vomiting scores by using the standardized tool. During this entire 40 minutes the researcher will strictly monitor the participant's condition. If the nausea score will be still higher than 1 or vomiting persists the participants will be noted as failure of treatment and move to standard care and the control group received standard care against the complain of nausea and vomiting."|f|f|f|t
33783936|NCT05035836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783937|NCT03298087|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm Phase II clinical trial||||
33783938|NCT01729871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783939|NCT06051162|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33783940|NCT06583590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783941|NCT06712394|||CASE_ONLY||PROSPECTIVE|||||||
33783942|NCT01133613|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33783943|NCT06601387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||comparative prospective study||||
33783944|NCT06100939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783945|NCT06713720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783946|NCT04657081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918553|NCT03655717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Subjects will be randomly assigned to one of the possible orders according to a randomization schedule generated by the study staff using a random number generator and computer program. The Massachusetts General Hospital (MGH) research pharmacy will generate a blinded randomization code for order of dosing and will dispense blinded drug in the dose ordered and identical placebo for use on separate study days. Ethanol or placebo drink will be prepared by a member of the research unit staff not otherwise associated with study visits.|"In Phase 2A, a double-blind placebo-controlled, random order cross-over study of single dose dronabinol, participants received dronabinol or identical placebo on two separate study visits in randomized order.~In Phase 2B, a randomized, double-blind, 4-treatment, 4-period, crossover study with THC or placebo administration and ethanol or placebo administration, participants were randomly assigned to 1 of 24 sequences of each of the following treatments: placebo dronabinol and placebo ethanol, placebo dronabinol and ethanol, dronabinol and placebo ethanol, and dronabinol and ethanol."|t|t|t|t
33918554|NCT01844830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918555|NCT05992415|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Masking will be conducted by the study biostatistician and is cluster randomization by housing development. Using a random number generator, the 5 (masked) developments were chosen for the usual care arm, and the 9 (masked) developments for the intervention."|The proposed innovative clinical trial will be a hybrid 2, masked, 2:1 cluster-randomized design (by housing development) comprised of adults age 21+ of diverse race/ethnicity (primarily African American and Hispanic/Latino) with high rates of inadequate eye care.|t|f|f|f
33918556|NCT01841918|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33918557|NCT01745991|||COHORT||PROSPECTIVE|||||||
33918558|NCT03314714|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918559|NCT03666975|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Blinding / masking of participants investigator and assessor|Vibration therapy intervention study involving children with pre-existing LLD to be assessed monthly for 4 months and then randomised to have one of 2 vibration therapies for three months and finally 6 months leg-length measurements to assess changes in extra bone length achieved in the shorter leg during the intervention.|t|f|t|t
33918560|NCT02517151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918561|NCT00154167|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33918562|NCT04392336|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33998818|NCT02835157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Serially numbered, sealed, opaque pouches containing 10 bags of 500 ml of either MES or saline each will be kept at the study site. Each of the 500 ml bags will be packed in sealed opaque covers inside the pouches as well.The research staff will pick the bag of fluids kept as per allocation sequence and start the bolus in the patient.|The enrolled children will be randomized to either balanced crystalloid (Plasma-Lyte A or multiple electrolyte solutions or MES group) or 0.9% saline (saline group).|t|t|t|t
33998819|NCT04429113|||CASE_CONTROL||RETROSPECTIVE|||||||
33998820|NCT00185120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33998821|NCT04386122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, single-dose, 2-sequence, 2-period, 2-treatment crossover study||||
33783947|NCT06456554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998822|NCT06323616|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Randomized, Single-Blind, Prospective, Interventional|t|t|f|f
33998823|NCT05874596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33783948|NCT06652763|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33783949|NCT04895345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783950|NCT03908047|||COHORT||PROSPECTIVE|||||||
33783951|NCT06465316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783952|NCT06712433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783953|NCT03820986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783954|NCT05549024|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33783955|NCT04069546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33783956|NCT01420367|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33783957|NCT04784065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The occupational therapists fabricating the orthoses used the study are the only ones not blinded in this study. The participants, principal investigator, and research assistants are all blinded to the treatment allocation.||t|f|t|t
33783958|NCT06388187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783959|NCT06212921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Sequential blood samples will be collected from study subjects||||
33783960|NCT00715806|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33783961|NCT06566664|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33783962|NCT06607965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33783963|NCT06536517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33783964|NCT04620239|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Phase III, single arm, non randomized, multicenter trial||||
33918563|NCT01107769|||COHORT||PROSPECTIVE|||||||
33918564|NCT05551598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918565|NCT03364335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double blind, placebo controlled trial||t|t|t|f
33918566|NCT00941902|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918567|NCT03736174|||CASE_CONTROL||PROSPECTIVE|||||||
33918568|NCT03687138|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918569|NCT01442532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918570|NCT02157506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918571|NCT01413334|||COHORT||CROSS_SECTIONAL|||||||
33918572|NCT00594204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918573|NCT00150059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918574|NCT03004469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918575|NCT04276129|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33918576|NCT04742426|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinding of participants and researchers involved in the experiment is not possible. Only the outcome assessor and data analyst is kept blinded to the allocation of subjects.|single-center, randomized (1:1), parallel-group, simulation study|f|f|f|t
33918577|NCT00943982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918578|NCT06041646|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label||||
33918579|NCT00246948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33918580|NCT01885858|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33918581|NCT00003817|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33918582|NCT00939224|||COHORT||PROSPECTIVE|||||||
33918583|NCT04259866|||CASE_ONLY||CROSS_SECTIONAL|||||||
33918584|NCT01351402|RANDOMIZED|||BASIC_SCIENCE||SINGLE||||||
33918585|NCT03452891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918586|NCT00004992|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918587|NCT03303092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918588|NCT01213095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918589|NCT06433518|||COHORT||PROSPECTIVE|||||||
33918590|NCT03463096|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918591|NCT03397355|||COHORT||PROSPECTIVE|||||||
33918592|NCT00349752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918593|NCT05138406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918594|NCT01427283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918595|NCT01693055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918596|NCT04314479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998824|NCT00002592||||TREATMENT||||||||
33998825|NCT04425577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who are clinically undergoing intrauterine device (IUD) placement will be consecutively studied||||
33998826|NCT04129060|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Medication will be administered double blind. The investigators, nurses working on the project, and participants will not know which drug they receive on any study day.|This study is a randomized, placebo-controlled trial of the effects of nicotinic blockade on working memory performance and brain activation in healthy postmenopausal women.|t|f|t|f
33998827|NCT03888235|RANDOMIZED|PARALLEL||TREATMENT||NONE||Of all the patients with low back pain, those with sacroiliac malrotation will be randomized to: group 1 an exercise to correct the malrotation, group 2 given a pelvic belt to stabilize the sacroiliac joints, group 3: use of usual treatment and treatment with the belt and exercise one month later. The degree of pain relief and improved function between the first visit and the second visit one month later will be assessed.||||
33998828|NCT00166751|||CASE_CONTROL||OTHER|||||||
33695014|NCT02554851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998829|NCT03252990|||COHORT||CROSS_SECTIONAL|||||||
34088311|NCT01698788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088312|NCT00340093||||TREATMENT||||||||
34088313|NCT04145817|NA|SINGLE_GROUP||PREVENTION||NONE||Women referred to genetic counselling in the participating Cancer Genetic Clinics will be included according to the selection criteria.||||
34088314|NCT04192331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088315|NCT05663970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088316|NCT04814797|||CASE_CONTROL||PROSPECTIVE|||||||
34088317|NCT03770819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a Split Mouth Double Blind Randomized Controlled Clinical Trial in which both participants and care provider are blinded.|"16 patients contributing a total of 64 sites will be selected. Recording of clinical and microbiological parameters will be done at baseline, end of 1 month, and 3 months. Oral hygiene instructions will be given. Following full mouth SRP, each quadrant will be randomly assigned by simple randomization using a computer generated randomization technique into one of the following four treatment modalities.~Group 1 (control) - Application of placebo gel followed by sham PDT (Directing the Light cure device without turning on the light beam).~Group 2 -Application of Zinc oxide gel followed by sham PDT. Group 3 - Application of placebo gel followed by PDT. Group 4 - Application of Zinc oxide gel followed by PDT. The procedure mentioned for each group will be performed on all periodontal pockets in the assigned quadrant at baseline, end of 1 week and 1 month from the first session.~Study period - 3 months"|t|t|f|f
34088318|NCT03368417|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695015|NCT02471976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33695016|NCT05110443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695017|NCT06556693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695018|NCT00168402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088319|NCT03147963|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients was divided 1:1 into docetaxel 2-weeks regimen group and docetaxel 3-weeks regimen group||||
33695019|NCT05339126|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34088320|NCT02178332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088321|NCT02022553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695020|NCT00325884|||COHORT||RETROSPECTIVE|||||||
33695021|NCT03860961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695022|NCT01484054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695023|NCT01702831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695024|NCT01880216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695025|NCT06488248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695026|NCT00003254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695027|NCT05005754|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33695028|NCT06239935|||COHORT||RETROSPECTIVE|||||||
33695029|NCT01200849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695030|NCT03548233|NA|SINGLE_GROUP||PREVENTION||NONE||bcg vaccine||||
33695031|NCT05218239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695032|NCT00976170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695033|NCT06554730|||COHORT||PROSPECTIVE|||||||
33695034|NCT00753779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695035|NCT04594148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088322|NCT02879032|||OTHER||CROSS_SECTIONAL|||||||
33695036|NCT02857179|||COHORT||PROSPECTIVE|||||||
33695037|NCT01910571|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33695038|NCT06706843|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Transtheoretical Model Based Motivational interview was conducted.||||
33695039|NCT00598702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695040|NCT04916769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A Phase 1, open-label, randomized, single dose, 3-period, 6-sequence, crossover study in healthy participants||||
33783965|NCT06251908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Owing to the nature of the intervention, neither participants nor staff can be blinded to allocation. They will be instructed not to disclose the allocation status to the researchers. Baseline data will be collected prior to randomisation and the research clinicians and research assistant that collect follow-up data will be blinded. If he or she is unblinded during the follow-up assessments, for instance if the participant accidentally reveals his or her allocation status, the participant will be invited to another follow-up session, with a blinded assessor. An employee outside the research team will extract data from REDCap on study completion and group allocation will be coded with A and B to ensure blinding of the researchers while analysing data, interpretation of data, drawing conclusions, and writing up reports.|The RCT is designed as an investigator-initiated, randomised, two-arm, single-blinded, multi-center, waiting list-controlled superiority trial, with an embedded pilot RCT.|f|f|t|t
33783966|NCT03563781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients with early ovarian cancer will receive sentinel node procedure before full lymphadenectomy, in order to assess the accuracy of sentinel node in diagnosing the presence of nodal metastases.||||
33783967|NCT03214887|RANDOMIZED|PARALLEL||TREATMENT||NONE||"RV-P1501-4: Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution~RV-P1501-5: Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution~RV-P1501-6: Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution"||||
33783968|NCT05211284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This phase 2a study is a randomized, placebo-controlled, double-blind, parallel arm trial to evaluate the safety and efficacy of Saroglitazar Magnesium 4 mg compared with placebo in biopsy-proven NAFLD in people living with HIV (PLWH). Eligible participants will be randomized in a 1:1 ratio to receive Saroglitazar Magnesium 4 mg or placebo.|t|t|t|t
33783969|NCT05626660|||OTHER||CROSS_SECTIONAL|||||||
33783970|NCT06185985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783971|NCT05283720|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34088323|NCT06343324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34088324|NCT02292251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088325|NCT04646278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who underwent coronary angiography and further hyperemic stimui||||
34088326|NCT05326516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will use a Bayesian optimal interval (BOIN) design to evaluate the doses and determine the maximum tolerated dose.||||
34088327|NCT03438266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088328|NCT02098772|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34088329|NCT05572931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34088330|NCT00903968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695041|NCT06317441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695042|NCT01047735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695043|NCT05630092|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Results from the modified walk test will not be provided to the medical team prescribing ambulatory oxygen assessment.|Perform test A followed by test B (randomised order)|f|t|f|f
33695044|NCT00423670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695045|NCT04407611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomization to 1 of 2 study arms.|t|f|f|f
33695046|NCT06708091|||COHORT||RETROSPECTIVE|||||||
33695047|NCT03114488|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33783972|NCT06423781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783973|NCT06710977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34088331|NCT02186028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088332|NCT02741934|||CASE_CONTROL||PROSPECTIVE|||||||
34088333|NCT06480708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33783974|NCT00871429|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33783975|NCT03057132|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Open label no masking required|||||
33783976|NCT03875703|||COHORT||PROSPECTIVE|||||||
33783977|NCT00354029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783978|NCT03523702|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study with 2 cohort (PembrolizumabRT cohort) part of the trial and SOC cohort (not part of the trial)||||
33783979|NCT06609876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783980|NCT04805346|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33783981|NCT06309992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33783982|NCT00731042|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33783983|NCT06711289|||CASE_CONTROL||PROSPECTIVE|||||||
33783984|NCT03332797|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33783985|NCT06203626|||COHORT||PROSPECTIVE|||||||
33783986|NCT01580943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33783987|NCT05186454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33783988|NCT02068729|||COHORT||PROSPECTIVE|||||||
33783989|NCT04209881|||CASE_CONTROL||PROSPECTIVE|||||||
33783990|NCT06713421|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33783991|NCT04670575|||COHORT||PROSPECTIVE|||||||
33783992|NCT06510517|||COHORT||PROSPECTIVE|||||||
33783993|NCT06714526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783994|NCT06713382|RANDOMIZED|PARALLEL||TREATMENT||NONE||"- Control Group (Standard Care):~Patients will receive the current standard of care, which includes antibiotics, chest tube placement, and intrapleural tPA/DNase therapy based on the criteria outlined above.~- Intervention Group (Standard Care + Saline Irrigation):~In addition to the standard care, patients in this group will receive pleural saline irrigation through the chest tube immediately after IPFT. The amount of saline will be determined by free-flow saline infusion up to 250 mL. This maneuver will be repeated every time that IPFT is administered, based on treating physician's criteria"||||
33783995|NCT06711887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33783996|NCT01979978|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33783997|NCT06054828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33783998|NCT05565521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33783999|NCT02553382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784000|NCT05198453|||CASE_CONTROL||RETROSPECTIVE|||||||
33784001|NCT05784935|||CASE_ONLY||PROSPECTIVE|||||||
33784002|NCT05415930|||COHORT||PROSPECTIVE|||||||
33784003|NCT01097655|||COHORT||PROSPECTIVE|||||||
33784004|NCT04159155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784005|NCT00657774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784006|NCT05835024|||COHORT||PROSPECTIVE|||||||
33784007|NCT05343455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multinational, multicenter, randomized, parallel-group, double-blind, controlled study.|t|t|t|t
33784008|NCT03981549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, examining ophthalmologist, visual acuity examiner, photographers and OCT, perimetry, and ERG technicians will remain masked to study treatment assignment for study duration.||t|f|t|t
33784009|NCT06589986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784010|NCT05499481|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy."||||
33784011|NCT06613399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784012|NCT03194893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784013|NCT03923101|||COHORT||OTHER|||||||
33784014|NCT02477943|||COHORT||PROSPECTIVE|||||||
33784015|NCT06714149|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A Cross-Sectional Paired Comparison Study||||
33784016|NCT02042443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784017|NCT05724550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784018|NCT00716079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784019|NCT06711029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be divided into 3 groups according to the final irrigation activation method; Group 1: Control Group, Group 2: Passive Ultrasonic Irrigation 3\*20 sec, Group 3: Passive Ultrasonic Irrigation 6\*10 sec.|t|t|f|t
33784020|NCT06613425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695048|NCT04963231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Stage 1 of the trial is open-label. Participants who were eligible to enter Stage 2 of the trial were randomized in a blinded manner at the Stage 2 Entry Visit in a 2:1 ratio to receive either setmelanotide or placebo.||t|t|t|f
33695049|NCT03264313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695050|NCT02276404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695051|NCT02675712|||CASE_ONLY||PROSPECTIVE|||||||
33695052|NCT05177133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695053|NCT05752981|||COHORT||PROSPECTIVE|||||||
33695054|NCT06301464|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695055|NCT04520893|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33695056|NCT06710158|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33695057|NCT06131320|||COHORT||RETROSPECTIVE|||||||
33695058|NCT05909735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an interventional non-comparative pilot clinical trial||||
33695059|NCT05555758|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33695060|NCT00945997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784021|NCT06713564|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The pathologist evaluating the biopsy samples will be blinded as to patient participation in the study.|"A single-dose, open-label, dose-escalation Phase 1b study in patients scheduled to undergo minimally invasive surgery (MIS) for known or suspected lung cancer via thoracoscopy (i.e., VATS). Single dose IV administration of LS301-IT, either on the day before surgery with 4 different doses in cohorts between 3 to 6 patients starting at a dose of 0.025 mg/kg with escalation or de-escalation.~The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV) in patients undergoing surgical thoracoscopy and VATS (Video-Assisted Thoracoscopic Surgery) resection of lung cancer. Safety is the primary objective of this study, followed by evaluation of the fluorescence signal as it relates to dose level and dosing time interval which will not be used for decision-making in the surgical resection in this study."|f|f|f|t
33784022|NCT03530280|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33784023|NCT05376488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients are blinded|Randomized single blind|t|f|f|t
33784024|NCT03634189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784025|NCT06705491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784026|NCT06524583|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, randomized and comparative phase II trial and prospective cohort||||
33784027|NCT05986487|||COHORT||PROSPECTIVE|||||||
33784028|NCT06329804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918597|NCT03827668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a Phase I, open label, fixed sequence study. The study will consist of 2 periods in a single fixed sequence. In Period 1, participants will receive PF-06650833 once daily on Days 1-5 and PF-06650833 PK will be assessed for 24 hours following Day 5 dosing. Participants will be discharged on Day 6 after completion of study related activities. There will be a washout period of at least 7 days between last dosing in Period 1 and first dosing in Period 2. In Period 2, participants will receive PF-06651600 once daily alone on Days 1-7, and PF-06651600 once daily together with PF-06650833 once daily on Days 8-12. PF-06651600 PK will be assessed for 24 hours following Day 7 dosing, while PK for both PF-06651600 and PF-06650833 will be assessed for 24 hours following Day 12 dosing. Across both periods few additional pre-dose (trough) PK samples will be collected. Participants will remain in the unit up to Day 13 when they will be discharged after completion of study related activities.||||
33918598|NCT05344027|||COHORT||RETROSPECTIVE|||||||
33918599|NCT03054987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918600|NCT02637726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33998830|NCT05727020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33998831|NCT04647825|||COHORT||PROSPECTIVE|||||||
33998832|NCT00225641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998833|NCT01080820|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33998834|NCT01790685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998835|NCT02627001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33998836|NCT01360437|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33998837|NCT03419260|||COHORT||PROSPECTIVE|||||||
33695061|NCT01107418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695062|NCT04516135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695063|NCT00950495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695064|NCT02943460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695065|NCT03242395|||COHORT||PROSPECTIVE|||||||
33695066|NCT02719327|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||1:1 randomization of icosapent ethyl 4 g daily vs matching placebo|t|t|t|t
33695067|NCT05979285|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective cohort study||||
33695068|NCT00185770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33695069|NCT02002611|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695070|NCT05388695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695071|NCT05830084|NA|SINGLE_GROUP||TREATMENT||NONE||Patient with Ewing Sarcoma male or female age ≥2 years and \<50 years (from second birthday to 49 years 364 days) who are assessed as medically fit to receive the Ewing sarcoma standard multimodal treatment and regorafenib. Patients will benefit from the social security coverage in force in their country and will have received free and informed information allowing the collection of their consent.||||
33695072|NCT05521568|||COHORT||PROSPECTIVE|||||||
33695073|NCT06562803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695074|NCT03957031|||CASE_CONTROL||PROSPECTIVE|||||||
33695075|NCT05937373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695076|NCT01423149|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695077|NCT00046514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695078|NCT04073368|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33695079|NCT03732677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695080|NCT01590576|||||RETROSPECTIVE|||||||
33998838|NCT06212869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998839|NCT01286805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695081|NCT05388396|||COHORT||RETROSPECTIVE|||||||
33695082|NCT05410392|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33695083|NCT06708130|||COHORT||OTHER|||||||
33695084|NCT02585622|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33695085|NCT06707246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695086|NCT02595970|NA|SINGLE_GROUP||TREATMENT||NONE|This was an open label single-arm study; therefore treatment blinding was not necessary.|||||
33695087|NCT06605456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor was blinded to the randomization of subjects into the intervention groups|"Group A, who were assigned the PNF neck pattern intervention, a rhythmic initiation technique was implemented.~Group B were assigned active neck muscle stretching as well as self-isometric strengthening exercises, targeting all cervical muscle groups."|f|f|f|t
33695088|NCT06707584|||OTHER||OTHER|||||||
33695089|NCT02715973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695090|NCT00816114|||CASE_CONTROL||RETROSPECTIVE|||||||
33695091|NCT06701591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33695092|NCT05648760|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33695093|NCT04904679|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, unmasked single center interventional study||||
33695094|NCT06688266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695095|NCT02263209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695096|NCT00462540|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695097|NCT04075279|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33784029|NCT03014687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784030|NCT01441778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784031|NCT03412838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients included in the clinical trial were randomly allocated by a blinded assistant in two groups: in the cortico-cancellous group (CC), and cancellous group (C). Allocation of participants to intervention groups in a truly unpredictable, randomized sequence was performed using a computerized random number generated by the GraphPadQuickCalc software (GraphPad Software Inc., La Jolla, CA). Blocked randomization was performed to maintain equal group size. As a result 14 patients were randomly assigned to de CC group and other 14 to the C group. All bone augmentation surgeries were performed by the same oral surgeon, with expertise on block surgeries (JT).|Twenty-eight patients referred for implant placement and with insufficient bucco-lingual (BL) alveolar bone width (\<4 mm) were included in the study. Patients received freeze dried bone allograft (FDBA) blocks of either allogeneic cancellous or cortico-cancellous bone obtained from the iliac crest. Patients included in the clinical trial were randomly allocated by a blinded assistant in two groups: in the cortico-cancellous group (CC), and cancellous group (C).|t|f|t|f
34088334|NCT05936307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants and experimenters (including tDCS operator) will not be informed about the nature (active or placebo) of the stimulation they will receive.|Double-blind, placebo-controlled, randomized crossover study including 30 healthy participants who will receive active and placebo HD-tDCS in a counterbalanced order.|t|f|t|t
34088335|NCT03391895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784032|NCT04635111|||COHORT||PROSPECTIVE|||||||
33918601|NCT04961099|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||HY01 will be administrated on D1, D4 and D7, and no other drugs or treatments will be given during the trial period (D1-30).||||
33918602|NCT00986310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33918603|NCT01705197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918604|NCT02500602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918605|NCT03663894|||COHORT||RETROSPECTIVE|||||||
33918606|NCT02793895|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33695098|NCT06383598|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695099|NCT05515172|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33695100|NCT04723901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695101|NCT06580080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695102|NCT00589290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695103|NCT02394548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695104|NCT04604158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33695105|NCT03238742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blind (Participant, Investigator, Outcomes Assessor)|Parallel Assignment|t|f|t|t
33695106|NCT05888415|||COHORT||CROSS_SECTIONAL|||||||
33918607|NCT01108497|||COHORT||PROSPECTIVE|||||||
33918608|NCT04823767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918609|NCT05964946|||COHORT||RETROSPECTIVE|||||||
33918610|NCT05821153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695107|NCT03400644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Prospective, parallel single-blinded randomized controlled trial|f|t|f|t
33695108|NCT06703385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695109|NCT06023225|||CASE_ONLY||PROSPECTIVE|||||||
33695110|NCT06308627|||COHORT||PROSPECTIVE|||||||
33695111|NCT06306053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918611|NCT03155295|||COHORT||PROSPECTIVE|||||||
33918612|NCT03018912|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33918613|NCT01461408|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33918614|NCT01892449|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33918615|NCT02359695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918616|NCT00794014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918617|NCT01288508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918618|NCT00945802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918619|NCT01785810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918620|NCT02542436|||COHORT||RETROSPECTIVE|||||||
33918621|NCT03512977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918622|NCT01925859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918623|NCT04779671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33918624|NCT01142284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918625|NCT00974051|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918626|NCT06148012|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918627|NCT02172092|NA|SINGLE_GROUP||OTHER||NONE||||||
33918628|NCT04000087|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33998840|NCT05770011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blinded|one control group and two comparator groups|t|f|t|t
33998841|NCT02647853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998842|NCT05693532|||COHORT||PROSPECTIVE|||||||
33998843|NCT04037488|||COHORT||PROSPECTIVE|||||||
33998844|NCT03410030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998845|NCT01015287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998846|NCT00619853|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998847|NCT02385760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998848|NCT04780451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33998849|NCT02873182|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33998850|NCT04485806|RANDOMIZED|PARALLEL||OTHER||NONE||Effect of two different culture dishes with two different oil overlay which used in human embryos culturing through ICSI procedures on the pre implantaion embryonic development.||||
33998851|NCT02559076|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34088336|NCT05276739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||3 condition, parallel arm randomized control trial|f|f|f|t
34088337|NCT04023968|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34088338|NCT05307107|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants (n=80) are educators working in health and social care education in secondary level education in five different educational organizations, which have similar management systems and providing time-support to implement SHINE during working hours. Organizations are randomly assigned either in intervention group (IG, n=2) receiving SHINE or in control group (CG, n=3) without the program continuing their normal daily routines receiving SHINE for their voluntary use after this study.||||
34088339|NCT03911388|NA|SINGLE_GROUP||TREATMENT||NONE||A traditional 3 + 3 design will be used with four patient cohorts.||||
34088340|NCT04970082|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34088341|NCT06179940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088342|NCT01757015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088343|NCT01099956|||CASE_CONTROL||PROSPECTIVE|||||||
34088344|NCT02229838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088345|NCT06371391|||COHORT||RETROSPECTIVE|||||||
34088346|NCT01869309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088347|NCT03428373|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34088348|NCT06369688|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|In this placebo-controlled trial, patients will be blinded to their group allocations. Additionally, WSNs, who are trained for delivering special PIP care bundles, as well as nursing staff who are responsible for measuring wounds and collecting data, and data analyst, will also be blinded.|C-RCT will be conducted with a three-arm parallel design and a 1:1:1 allocation ratio. The experimental groups will consist of two arms: the intervention group and the placebo group. The third arm will be the control group.|t|t|t|t
34088349|NCT01537367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33801525|NCT05459233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded trial|Patients will be randomized in a 1:1 fashion to valve hemodynamic optimization according to Doppler-echocardiography versus cardiac catheterization parameters.|t|f|f|f
33998852|NCT03234907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998853|NCT01859260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998854|NCT02512328|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33998855|NCT00685854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998856|NCT04768114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998857|NCT02533466|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33998858|NCT06262503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group1:conventional physiotherapy for phantom Pain Group2:conventional physiotherapy and Virtual Reality for phantom Pain|t|f|f|t
33998859|NCT00697827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998860|NCT01446445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998861|NCT04151368|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Single Arm||||
33998862|NCT05576831|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695112|NCT05278208|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I (4-12 yrs) Lutathera (maximum dose of 200 mCi) once every 8 weeks (one cycle) for 4 cycles.~Level 0: 150 mCi\*(BSA/1.73m2). Level 1#: 200 mCi\*(BSA/1.73m2). Level 2: 250 mCi\*(BSA/1.73m2).~#starting dose~Phase II (\>12 yrs) RP2D 200 mCi once every 8 weeks"||||
33695113|NCT04691401|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33695114|NCT00428129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695115|NCT06374095|||CASE_CONTROL||RETROSPECTIVE|||||||
33695116|NCT06529757|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33695117|NCT06096272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695118|NCT05535231|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomization at 1:1 ratio for test product or comparator|t|f|t|f
33784033|NCT04887285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessor will be unaware of treatment allocation but the patient and provider cannot be.|Parallel study comparing virtual reality to sedation to standard care (no sedation or virtual reality) for procedure-related pain in patients undergoing lumbar epidural steroid injections.|f|f|f|t
33784034|NCT00948844|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695119|NCT05483270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784035|NCT01919619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784036|NCT05591950|||OTHER||PROSPECTIVE|||||||
33784037|NCT06565988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784038|NCT05825417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||2x2 crossover study in which the effects of adding an oral drug targeting the prostacyclin pathway and the switching of PDE5i to sGCS will be examined following 12-weeks on treatment.||||
33784039|NCT04459832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor, who took the measurements for both the intervention and control groups, was blinded to the subject's group, while the treating therapist was not blinded to the treatment intervention.|randomized controlled trial study 100 participants will be recruited to participate in the study after assigning a conset form, participants will be divided into 4 group ,one control which will not receive stretch of hamstring and 3 experimental groups will recive different duration for hamstring stretch 15,30,60 and DSSEP will be measured as the primary outcome and knee ROM will be measured as a secondary outcomes in order to identify the optimal duration of hamstring stretch|t|f|f|f
33784040|NCT03867617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784041|NCT04308447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784042|NCT04083599|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784043|NCT06615453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784044|NCT04389255|||COHORT||PROSPECTIVE|||||||
33784045|NCT04676347|||COHORT||PROSPECTIVE|||||||
33784046|NCT06711146|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784047|NCT01365338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784048|NCT03023059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784049|NCT02718469|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33784050|NCT03378479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784051|NCT05588141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784052|NCT06713057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784053|NCT03660917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||We opted for a randomized, double-blind, placebo-controlled pilot trial with a lead-in phase. Moreover, the patients to be included in the placebo arm will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.|t|f|f|t
33784054|NCT05421533|||COHORT||PROSPECTIVE|||||||
33784055|NCT02727621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784056|NCT03530553|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||There are two arms in this study. One group will receive the HMS and the other will not and will receive standard of care.||||
33784057|NCT03266874|||COHORT||PROSPECTIVE|||||||
33784058|NCT06446674|||COHORT||PROSPECTIVE|||||||
33784059|NCT05484726|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|The mothers, medical staff involved in general care, nursing staff involved in the intervention, and doctors conducting the assessment of oral feeding skills (OFS) were all blinded to allocation. The nursing staff was informed at the time of intervention that participating infants would receive either sensory motor stimulation or sham oral stimulation depending on group allocation.|"1. Maternal involvement in perioral sensory-motor stimulation be in three stages~   1. Observer status~  2. Performing under supervision~  3. Independent~2. Intervention period: 5 days as~   1. Training phase (T): T1 and T2 (for mothers by the nurse)~  2. Direct feeding phase (D): F1, 2, and 3 (oral feed shall be offered to neonate)~3. Stimulation for 7 minutes and 15 minutes before feeding twice a day at 1100 and 1700 hrs.~4. Two groups~   1. Intervention group (GI): by mothers~  2. Control group (G II): by staff nurses"|f|t|f|f
33784060|NCT03571243|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784061|NCT05929807|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will roll over from previous TransCON CNP clinical trials||||
33784062|NCT04269850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784063|NCT06622408|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33784064|NCT02121704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784065|NCT06121544|||COHORT||PROSPECTIVE|||||||
33784066|NCT03038256|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33695120|NCT00846404|||CASE_CONTROL||PROSPECTIVE|||||||
33784067|NCT05931211|||COHORT||CROSS_SECTIONAL|||||||
33784068|NCT05199116|||OTHER||PROSPECTIVE|||||||
33784069|NCT06071468|||CASE_ONLY||PROSPECTIVE|||||||
33784070|NCT06706063|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784071|NCT04515797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784072|NCT06080958|RANDOMIZED|PARALLEL||TREATMENT||NONE||Negative pressure wound therapy (vacuum-assisted wound closure) for postoperative flap care||||
33784073|NCT03013842|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33784074|NCT05304390|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695121|NCT03838965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695122|NCT04019431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695123|NCT02999399|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695124|NCT00003307||||TREATMENT||||||||
33784075|NCT00003891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801526|NCT01467375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801527|NCT05833256|||OTHER||RETROSPECTIVE|||||||
33695125|NCT06488313|NA|SEQUENTIAL||TREATMENT||NONE||All participants will receive 5 doses of Study Drug via intravenous infusion at one of the three dose levels. Dose levels will be enrolled sequentially.||||
33695126|NCT04465162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695127|NCT02098824|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33695128|NCT03236831|NA|SINGLE_GROUP||PREVENTION||NONE||Open label single group interventional study||||
33695129|NCT04279860|||OTHER||CROSS_SECTIONAL|||||||
33695130|NCT00751621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695131|NCT01094756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695132|NCT05663268|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients of either gender suffering from Hidradenitis suppurativa resistant to conventional therapies||||
33695133|NCT01298973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695134|NCT00005093|RANDOMIZED|||TREATMENT||||||||
33998863|NCT05065346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998864|NCT01728987|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33998865|NCT00213850|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33998866|NCT05753904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and assessors will not be blinded to intervention. The primary outcome is postoperative functional internal rotation. Secondary outcome measures include VAS, ASES, SANE, PROMIS, and VR-12 scores, as well as forward elevation and external rotation at the side, and complications at any time point. Our null hypothesis is that patients who undergo conjoint tendon resection during RTSA will have significantly increased functional internal rotation and clinically significant improved above-mentioned scores compared to non-resected tendon patients.|This study will be a prospective, randomized-controlled clinical trial comparing standard of care RTSA to RTSA with conjoint tendon resection in 64 patients undergoing RTSA by a single surgeon.|t|f|f|t
33998867|NCT03748095|||OTHER||PROSPECTIVE|||||||
33998868|NCT01812239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998869|NCT06346535|||CASE_CONTROL||PROSPECTIVE|||||||
33998870|NCT05392959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33918629|NCT01965912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695135|NCT06075199|||COHORT||PROSPECTIVE|||||||
33784076|NCT04248829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Approximately 380 patients will be randomized in a 1:1 ratio to either lazertinib (n=190) or gefitinib (n= 190).~Following objective disease progression according to RECIST v1.1, as per investigator assessment, patients who were randomized to gefitinib arm may have the option to receive open-label lazertinib"|t|t|t|t
33784077|NCT05800964|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33998871|NCT04267692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998872|NCT04089462|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"An open-labelled randomized controlled crossover study will be performed. The participants will go through the following elements:~1. Screening day~2. Run-in period~3. Intervention period~4. Wash-out period~5. Intervention period"||||
33695136|NCT02413021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695137|NCT06708104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784078|NCT02687243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784079|NCT02943382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784080|NCT05926960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784081|NCT00912041|NA|SINGLE_GROUP||OTHER||NONE||||||
33784082|NCT06709677|||OTHER||CROSS_SECTIONAL|||||||
33784083|NCT06696092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784084|NCT02240875|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784085|NCT06712771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918630|NCT01689402|||COHORT||PROSPECTIVE|||||||
33918631|NCT01925638|NA|SINGLE_GROUP||||NONE||||||
33918632|NCT00918086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33918633|NCT03125876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918634|NCT00218920|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33918635|NCT04480242|||COHORT||PROSPECTIVE|||||||
33918636|NCT02325947|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33918637|NCT01136668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33918638|NCT00307424|RANDOMIZED|CROSSOVER||||NONE||||||
33918639|NCT02477293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918640|NCT05310994|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33998873|NCT06170762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695138|NCT05044091|||COHORT||RETROSPECTIVE|||||||
33695139|NCT06652256|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695140|NCT06710795|NA|SINGLE_GROUP||TREATMENT||NONE|All subjects enrolled will receive the MaxTack™ Motorized Fixation Device|||||
33784086|NCT06224426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784087|NCT06098586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data assessors and analysts will be masked for treatment allocation (covered wrist / anonymous data sheet).||f|f|f|t
33784088|NCT06713369|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking|Approximately 8 patients will be enrolled, all will be assigned to the same treatment arm with no randomization or masking. All eligible patients will begin dosing in Part A, followed by a washout period, followed by Part B.||||
33784089|NCT05513300|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784090|NCT06713759|||OTHER||CROSS_SECTIONAL|||||||
33918641|NCT00954317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918642|NCT01379352|||||PROSPECTIVE|||||||
33918643|NCT06504485|||COHORT||PROSPECTIVE|||||||
33918644|NCT01948895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918645|NCT00966810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918646|NCT04880850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918647|NCT04534036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33918648|NCT05720442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998874|NCT06402227|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The Investigator who receives the questionnaires and the Investigator who types the information remain masking.|The investigators randomly divided students' classes into the experimental group and the control group. The former received gamified instruction, while the latter received conventional lesson lecture. After a one-month delay, students in the control group were invited to participate in the board game.|f|f|t|f
33998875|NCT06083623|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088350|NCT01753063|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34088351|NCT02037087|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33695141|NCT05235477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Due to the type of intervention only the outcome assessor and the statistician will be blinded.~Single blinded:~* Blinding of the participants is not applicable.~* Blinding of the operator is not applicable.~* Outcome assessor (primary and secondary outcomes) and biostatistician will be blinded."|Group A (Intervention): Patients will receive Tube technique. Group B (Control): Patients will receive Hyaluronic acid.|f|f|f|t
33695142|NCT05213000|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"There are two arms for the initial COVID immunization. The arms are a control no exercise group, and an exercise treatment group."|f|f|f|t
33695143|NCT06265051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695144|NCT06523283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|outcome assesments will be performed by statistician who has blinded to group allocation.|One intervention group and one control group|f|f|f|t
33695145|NCT06710262|||CASE_ONLY||PROSPECTIVE|||||||
33695146|NCT04298034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician will be masked to which group the patient was randomized to.||f|f|f|t
33695147|NCT06281171|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695148|NCT02967718|||COHORT||CROSS_SECTIONAL|||||||
33695149|NCT03420859|||COHORT||OTHER|||||||
33918649|NCT02716194|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918650|NCT05663736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918651|NCT02670330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918652|NCT02303873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918653|NCT00351338|||DEFINED_POPULATION||PROSPECTIVE|||||||
33918654|NCT02863367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918655|NCT05347784|||COHORT||RETROSPECTIVE|||||||
33918656|NCT02119234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918657|NCT01522625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33918658|NCT00780052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918659|NCT01018719|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918660|NCT00360919|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33918661|NCT00507416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918662|NCT01884168|||COHORT||PROSPECTIVE|||||||
33918663|NCT02178501|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33918664|NCT00657124|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918665|NCT03132168|NA|SINGLE_GROUP||OTHER||NONE|No masking|All consented subjects will be undergoing elective, scheduled surgeries with standardized anesthesia regimen per protocol. Each participant will complete surveys and procedures as outlined per protocol.||||
33918666|NCT01958125|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33918667|NCT05326217|RANDOMIZED|PARALLEL||TREATMENT||NONE|First stage: Open Label Second stage: Single Blind for probiotics treatment|||||
33918668|NCT03126331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918669|NCT01789853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998876|NCT03530241|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33998877|NCT00353535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998878|NCT00905541||CROSSOVER||BASIC_SCIENCE||NONE||||||
33998879|NCT03892343|||COHORT||PROSPECTIVE|||||||
33998880|NCT02752854|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33998881|NCT00385736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998882|NCT05909436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998883|NCT01513941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998884|NCT00287053|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33998885|NCT03134053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998886|NCT06010823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998887|NCT05213962|||COHORT||PROSPECTIVE|||||||
33998888|NCT04685382|||OTHER||CROSS_SECTIONAL|||||||
33998889|NCT03999008|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33998890|NCT02711644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33998891|NCT04847401|||CASE_CONTROL||PROSPECTIVE|||||||
33998892|NCT04595591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998893|NCT02441985|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33998894|NCT02293486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998895|NCT02754219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998896|NCT02483416|||OTHER||PROSPECTIVE|||||||
33998897|NCT02582463|||COHORT||PROSPECTIVE|||||||
33998898|NCT00929019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998899|NCT04816773|||COHORT||RETROSPECTIVE|||||||
33998900|NCT05529576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998901|NCT00659828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998902|NCT02364869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33998903|NCT01985724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998904|NCT06346951|||COHORT||PROSPECTIVE|||||||
33998905|NCT05021276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998906|NCT01492439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998907|NCT03404921|RANDOMIZED|PARALLEL||TREATMENT||NONE|The operator only understands the operation method required by the patient and is unaware of the observation indicators|||||
33998908|NCT05536960|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998909|NCT01139216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998910|NCT05665387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33998911|NCT00498498|||CASE_ONLY||PROSPECTIVE|||||||
33998912|NCT03651336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998913|NCT02387034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998914|NCT00619281|||CASE_CONTROL||PROSPECTIVE|||||||
33998915|NCT02501863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33998916|NCT04510766|||OTHER||PROSPECTIVE|||||||
33998917|NCT00990574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33998918|NCT05278858|NA|SINGLE_GROUP||OTHER||NONE||||||
33784091|NCT05877547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33998919|NCT03504085|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will be conducting a pilot RCT with two types of yoga interventions. A total of 50 participants will be randomized to attend either active Hatha yoga or restorative yoga. Enrollment will be conducted on a rolling basis.||||
33998920|NCT05447416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trail 2 groups treatment - HBOT and IHT|f|f|f|t
33998921|NCT05450549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784092|NCT05004610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33998922|NCT04339634|||COHORT||RETROSPECTIVE|||||||
33998923|NCT00403806|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33998924|NCT01909713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784093|NCT06711757|||COHORT||RETROSPECTIVE|||||||
33998925|NCT03789630|||COHORT||PROSPECTIVE|||||||
33998926|NCT04220606|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33998927|NCT00168233|||COHORT||PROSPECTIVE|||||||
33998928|NCT05146024|||OTHER||OTHER|||||||
33998929|NCT05963841|||COHORT||OTHER|||||||
33998930|NCT03112031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998931|NCT05189938|||COHORT||PROSPECTIVE|||||||
33998932|NCT00096850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998933|NCT02911636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998934|NCT02705716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33998935|NCT01907048|||OTHER||CROSS_SECTIONAL|||||||
33998936|NCT04814628|NA|SINGLE_GROUP||OTHER||NONE||||||
33998937|NCT01050764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998938|NCT02808494|||CASE_CONTROL||PROSPECTIVE|||||||
33784094|NCT06649344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784095|NCT03575962|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|Subjects will receive GSK3640254 bis-hydrochloride salt capsule followed by mesylate salt capsule or vice versa in two treatment periods.||||
33784096|NCT01462019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784097|NCT06675357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784098|NCT00902447|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33784099|NCT06713187|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33784100|NCT01879904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784101|NCT06711731|||COHORT||PROSPECTIVE|||||||
33998939|NCT05704491|||CASE_CONTROL||OTHER|||||||
33998940|NCT06562101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998941|NCT03150901|||COHORT||PROSPECTIVE|||||||
34088352|NCT05419518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an, open label, single-institution, Phase II trial of palliative radiation dose escalation study for painful non-spine bone Metastases and painful non-bone metastases.~Dose escalation with 2D/ 3D-CRT in ten fractions in non-spine bone metastases will be evaluated. The total dose will range from 40-50 Gy depending on normal tissue constraints. This dose in ten fractions will lead to BED10 of 56 - 75 Gy which is higher than the BED10 39 Gy with 30 Gy in ten fractions."||||
34088353|NCT04179643|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784102|NCT06533254|||COHORT||PROSPECTIVE|||||||
33784103|NCT01026662|||CASE_ONLY||PROSPECTIVE|||||||
33784104|NCT06707792|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784105|NCT00910702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784106|NCT04604782|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33784107|NCT06479564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants are blind|randomized control design|t|f|f|f
33784108|NCT05435963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784109|NCT02618590|||CASE_ONLY||RETROSPECTIVE|||||||
33784110|NCT06188559|RANDOMIZED|PARALLEL||TREATMENT||NONE||For Dose Optimization (Part 1), this study is randomized and for Dose Expansion (Part 2), there will be no randomization.||||
33784111|NCT04644016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784112|NCT05603026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784113|NCT00703482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784114|NCT06360601|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33784115|NCT03665506|||CASE_ONLY||PROSPECTIVE|||||||
33784116|NCT06626074|NA|SINGLE_GROUP||OTHER||NONE||||||
33784117|NCT05820074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33784118|NCT05927480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are two treatment arms. Each undergo traction pin placement, but one arm is provided headphones with music while the other is not offered anything.||||
33784119|NCT06714604|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled two-arm open label phase 3 trial||||
33784120|NCT06270719|||COHORT||PROSPECTIVE|||||||
33784121|NCT01982019|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33784122|NCT01949584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784123|NCT03618472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784124|NCT04191551|||COHORT||PROSPECTIVE|||||||
33784125|NCT05962125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33784126|NCT04495894|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801528|NCT02462616|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33801529|NCT00441298|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33998942|NCT05922306|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and investigators will be informed of the treatment protocol. Participants will be grouped according to the random number method at initial entry and will be given the option to continue in the current cohort or withdraw from the cohort study at their own discretion after treatment assessment at each node.|||||
33998943|NCT01620840|||CASE_ONLY||PROSPECTIVE|||||||
33998944|NCT03776344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As we had two groups in which one used a device for ensuring the masking the entire procedure was conducted in a separate room.|We tested the efficacy of a VR environment in the treatment of pain after surgery.|t|t|f|f
33998945|NCT02604641|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33998946|NCT02498938|||CASE_CONTROL||RETROSPECTIVE|||||||
33998947|NCT00842127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998948|NCT03439085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998949|NCT04701216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695150|NCT06525532|||COHORT||PROSPECTIVE|||||||
33998950|NCT04146090|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Subjects will be randomised in a 1:1 ratio (www.random.org) into 2 groups: LP (low-pressure) or S (standard). Group assignments will be sealed in sequentially numbered opaque envelopes that will be opened after patient inclusion into the study. Care providers, researchers, and patients will be blinded to group assignments.Insufflation pressure will be maintained in 14 mmHg (group S) or 10 mmHg (group LP). Anesthesiologists and surgeons will not have access to insufflation pressure display (it will be covered by an opaque paper and will be set by operating room personnel).|Double blinded, randomised controlled trial|t|f|t|t
33695151|NCT05237297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomization, Open-label, Repeated administration, Crossover||||
33784127|NCT06518837|NA|SINGLE_GROUP||TREATMENT||NONE||"Tirzepatide will be administered subcutaneously in the stomach, upper arm, or thigh. Administer once weekly at any time of day, with or without meals. Start with an initial dosage of 2.5 mg. After 4 weeks, increase to 5 mg weekly. Further increases may be made in 2.5 mg increments after at least 4 weeks on the current dose, aiming for a target of 15 mg (i.e., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). Consider treatment tolerability when selecting the maintenance dose. If not tolerated, consider the next lower maintenance dose. Recommended maintenance doses are 5 mg, 10 mg, or 15 mg, with 5 mg as the lowest evaluable dose. The 2.5 mg dose is not a maintenance dose. The maximum allowed dosage is 15 mg once weekly.~20 Black and 20 Non-Black breast cancer patients will be enrolled. More black patients will be enrolled to enrich this cohort with the population that has an established significant disparity in HR+ breast cancer and obesity related outcomes."||||
33784128|NCT02725281|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784129|NCT04910022|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784130|NCT05896189|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33784131|NCT01079598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784132|NCT04826224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784133|NCT06707883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784134|NCT05284422|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A random list is generated by a computer randomizer program. Sealed numbered envelopes are prepared with study documents and the technique to be performed. Investigators take envelops in consecutive order as long as participants accept to be included in the study|Participants are assigned to the traditional or ultrasound-guided insertion group|t|t|t|f
33918670|NCT03372668|NA|SINGLE_GROUP||TREATMENT||NONE||"Repeated measures, single-subject withdrawal design with three, 4-week study phases; also referred to as an ABA withdrawal design. Study intervention consisted of twice weekly, 20-minute treatments for four weeks (8 total treatments) and is delivered during the second 4-week study phase.~All subjects who enroll in the study will receive the intervention during the second 4-week study phase. There is no randomization."||||
33918671|NCT05089344|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918672|NCT06050967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918673|NCT00004095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998951|NCT05723796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998952|NCT02870686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918674|NCT05402098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33918675|NCT01529385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33918676|NCT03835000|||OTHER||RETROSPECTIVE|||||||
33918677|NCT02327221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33998953|NCT01633619|||COHORT||PROSPECTIVE|||||||
33918678|NCT03428321|||COHORT||RETROSPECTIVE|||||||
33918679|NCT01933750|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918680|NCT01464216|||COHORT||PROSPECTIVE|||||||
33918681|NCT00497016|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33998954|NCT03044873|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33998955|NCT03580863|||COHORT||RETROSPECTIVE|||||||
33998956|NCT00005967|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998957|NCT04488380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One of the Glass ionomer restorative or Resin composite restorative materials were applied to carious mandibular 2nd molar teeth.|f|f|f|t
33998958|NCT06375915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998959|NCT06040606|||COHORT||PROSPECTIVE|||||||
33998960|NCT03264092|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33918682|NCT01243099|||CASE_CONTROL||PROSPECTIVE|||||||
33918683|NCT00695240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918684|NCT04986020|||CASE_CONTROL||RETROSPECTIVE|||||||
33918685|NCT00503360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33918686|NCT00804375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918687|NCT00078988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918688|NCT04121520|||COHORT||PROSPECTIVE|||||||
33998961|NCT05823662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918689|NCT05747755|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Interrupted time series||||
33918690|NCT02240745|||CASE_ONLY||CROSS_SECTIONAL|||||||
33918691|NCT01557309|||CASE_ONLY||PROSPECTIVE|||||||
33918692|NCT03333330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918693|NCT03173482|||COHORT||PROSPECTIVE|||||||
33998962|NCT01169038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998963|NCT01533038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695152|NCT02493387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695153|NCT04765111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695154|NCT06710665|||COHORT||RETROSPECTIVE|||||||
33695155|NCT00608972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695156|NCT04645888|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|This was a triple-blinded study in which the surgeon, the patient and the statistician who performed the data analysis did not know which anesthetic solution had been used.|Randomized, split-mouth, triple-blinded study was designed.|t|t|f|t
33695157|NCT02185846|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695158|NCT02378675|||COHORT||PROSPECTIVE|||||||
33695159|NCT04535765|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33695160|NCT04335838|||COHORT||RETROSPECTIVE|||||||
33695161|NCT00526604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695162|NCT04663373|||COHORT||PROSPECTIVE|||||||
33695163|NCT02857582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918694|NCT05984797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Owing to the nature of the intervention, it is not possible to blind participants or intervention practitioners. Individual participants are allocated on a 1:1 basis to receive either palliative rehabilitation plus usual care or usual care. Treatment allocation will not be disclosed to the CTRU KCTU trial team or to other members of the research teams involved in data analysis to maintain blinding during outcome assessment and to minimise possible bias. Individual participants are allocated on a 1:1 basis to receive either palliative rehabilitation plus usual care or usual care. A computer-generated minimisation programme that incorporates a random element will be used to ensure that treatment groups are well balanced for: trial country ,baseline FACT-G score (\<=64, 65-79, 80+), ECOG performance status (2, 3) in order to guard against chance bias in patient allocation for prognostic factors.|Multinational, parallel group, randomised, controlled, assessor blind, superiority trial|f|f|f|t
33918695|NCT03418051|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33998964|NCT00414726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33918696|NCT04540081|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998965|NCT00201396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998966|NCT02698345|||CASE_ONLY||PROSPECTIVE|||||||
33998967|NCT02637180|||COHORT||PROSPECTIVE|||||||
33998968|NCT03655977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33998969|NCT06478745|||OTHER||OTHER|||||||
33998970|NCT06468514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998971|NCT02470260|||COHORT||PROSPECTIVE|||||||
33998972|NCT00893945|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33998973|NCT02005276|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33998974|NCT03661151|||OTHER||PROSPECTIVE|||||||
33998975|NCT03045536|||COHORT||RETROSPECTIVE|||||||
33998976|NCT03031795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33998977|NCT00957762|||||PROSPECTIVE|||||||
33998978|NCT02118324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33998979|NCT02694536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998980|NCT01712633|||COHORT||PROSPECTIVE|||||||
33998981|NCT02570854|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33998982|NCT04440358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998983|NCT02847416|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33998984|NCT06098313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088354|NCT01147835|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33998985|NCT01127113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34088355|NCT06037980|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, multicenter, randomized phase II-III study||||
34088356|NCT05833815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695164|NCT05825755|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695165|NCT06707168|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695166|NCT05834322|||COHORT||CROSS_SECTIONAL|||||||
33695167|NCT06350773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695168|NCT04637113|||COHORT||PROSPECTIVE|||||||
33695169|NCT03589781|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918697|NCT01872091|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33918698|NCT04973410|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33998986|NCT00147693|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33998987|NCT00307723|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33918699|NCT05208723|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomized using computer generated randomization at one point in time by an independent researcher|Enrolled participants are randomized to intervention or control group|f|f|t|f
33918700|NCT05329779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918701|NCT02496117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|RNS guided RDN|RNS checked RDN||||
33918702|NCT02319096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918703|NCT03977350|||COHORT||PROSPECTIVE|||||||
33918704|NCT03121118|||OTHER||PROSPECTIVE|||||||
33918705|NCT03148626|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multi-center cluster randomized controlled trial||||
33918706|NCT00674518|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33918707|NCT02062463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088357|NCT03318341|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will be blinded to the conditions, since they will not perceive any vibration for both conditions. The researcher conducting the evaluations with participants will also be blinded with the following procedure: A person outside the university will generate a random condition assignment sequence and send a custom program to the researcher to use.|The study will use a 2×2 crossover design. Participants will be randomly assigned to either the treatment or control condition for the first month, followed by a 2-week washout period and then crossover to the other condition.|t|t|t|t
34088358|NCT03579888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088359|NCT05512559|||OTHER||PROSPECTIVE|||||||
34088360|NCT00474019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088361|NCT03197129|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34088362|NCT04652089|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Parallel Assignment Participants will be randomly allocated to one of two groups (simvastatin or placebo) and take the assigned medication for 7 days|t|t|t|t
34088363|NCT00657605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088364|NCT03844737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695170|NCT06604520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695171|NCT05360368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695172|NCT00284596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695173|NCT00716131|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695174|NCT04508335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695175|NCT06525571|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695176|NCT02355496|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695177|NCT04492124|||COHORT||PROSPECTIVE|||||||
33695178|NCT03170856|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to either the exercise intervention group or the usual care group.||||
33695179|NCT04150939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695180|NCT06710327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||placebo-controlled|t|t|t|f
33695181|NCT00543738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695182|NCT06529042|||COHORT||RETROSPECTIVE|||||||
33695183|NCT06710379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33695184|NCT00002121||||TREATMENT||NONE||||||
33695185|NCT04215588|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33695186|NCT03029429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695187|NCT04461288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695188|NCT05254223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33695189|NCT04753476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918708|NCT00818571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918709|NCT03798171|||CASE_ONLY||PROSPECTIVE|||||||
33918710|NCT02322268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918711|NCT01226212|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33918712|NCT05704439|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Comparison of Neurologist initiated treatment of Hypertension or Hyperlipidemia versus usual care||||
33918713|NCT03585192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918714|NCT04249505|||COHORT||RETROSPECTIVE|||||||
33918715|NCT04260919|RANDOMIZED|PARALLEL||TREATMENT||NONE|One control group and one intervention group, where chest physiotherapy is used.|Randomized trial with two groups.||||
33918716|NCT01187784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918717|NCT01586806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33918718|NCT04871685|||COHORT||PROSPECTIVE|||||||
33918719|NCT00890071|||CASE_ONLY||PROSPECTIVE|||||||
33918720|NCT05664334|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33918721|NCT04841720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918722|NCT04083898|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33918723|NCT03067129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918724|NCT05528770|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be randomized to the order that they experience the use of the Bolus Priming System (BPS) in fully automated closed loop (FCL) (for 24 hours each, with a 24-hour challenge period in between): 1) with the BPS active, 2) BPS inactive.||||
33918725|NCT02140203|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33918726|NCT01768468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918727|NCT00966394|||COHORT||CROSS_SECTIONAL|||||||
33918728|NCT05557734|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded(the surgeon and the outcome assessor)||f|t|f|t
33918729|NCT05447598|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomized 1:1 to a nurse-led remote monitoring program or to usual care||||
33918730|NCT03571841|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33918731|NCT06114394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participant: Initially, the subject will not know what technique has been received, the complete information regarding the surgical technique used, as the results obtained in his case, will be given in the last visit of the year.~Observer: Another periodoncist (R.E.), outside the intervention, would be in charge of recording the clinical parameters.~Analyst: The statistician (X.M.) does not know which treatment corresponds to each variable."|We will perform the experimental or control technique according to the randomization sequence.|t|f|t|t
33998988|NCT05081193|NA|SINGLE_GROUP||TREATMENT||NONE||Oral Testosterone Therapy-396 mg given twice per day on days 1-7 and 15-21 of a 28 day cycle until radiographic progression. After a 21 day washout period, Enzalutamide therapy given at 160 mg once daily will be taken for a maximum of 6 cycles while on study.||||
33998989|NCT03168035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998990|NCT03066544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a prospective, non-blinded, non-randomized, proof-of-concept study.||||
33998991|NCT02136251|||OTHER||PROSPECTIVE|||||||
33998992|NCT00548431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33998993|NCT01820962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33998994|NCT03526484|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33998995|NCT00459407|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33998996|NCT02708758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998997|NCT06283888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998998|NCT02003391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33998999|NCT05757609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Statiticians will be masked||t|t|t|t
33999000|NCT01104181|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33999001|NCT02941159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33999002|NCT01476969|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33999003|NCT02259439|||CASE_ONLY||PROSPECTIVE|||||||
33999004|NCT02884986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999005|NCT01979146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999006|NCT06219980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999007|NCT00617825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999008|NCT05643833|||COHORT||RETROSPECTIVE|||||||
33999009|NCT02519153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999010|NCT04218994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33999011|NCT04594434|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999012|NCT06221124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999013|NCT00420095|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999014|NCT06103097|||COHORT||RETROSPECTIVE|||||||
33999015|NCT00139594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999016|NCT04518553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999017|NCT02117830|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33999018|NCT02339363|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33999019|NCT02833428|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999020|NCT00895050|||COHORT||PROSPECTIVE|||||||
33999021|NCT01055834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999022|NCT01572623|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33999023|NCT02290262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33999024|NCT05291195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999025|NCT02391233|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33999026|NCT01016054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999027|NCT06628154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|double-blind|Parallel randomised experimental medicine trial|t|f|t|t
33999028|NCT05092464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088365|NCT03344471|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33695190|NCT02584699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918732|NCT05371067|NA|SINGLE_GROUP||OTHER||NONE||This study is a monocentric, prospective, non-randomized, comparative assay in which volontarees are enrolled in order to study the fructose effects on intestinal microbiote and their consequencies on the emotions and the neuroinflammation.||||
33695191|NCT02266914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918733|NCT05848206|||COHORT||RETROSPECTIVE|||||||
33918734|NCT02335580|||COHORT||PROSPECTIVE|||||||
33918735|NCT02733406|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33918736|NCT04780958|NA|SINGLE_GROUP||OTHER||NONE||||||
33918737|NCT00027456||||TREATMENT||||||||
33918738|NCT02581358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918739|NCT01807260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918740|NCT05092880|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized phase 2||||
33918741|NCT03780036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not know which implant was used for segmental replacement of his or hear femur.|Random assignment of patients into one of the two study arms: porous collar magaprostheses or porous collar with HA megaprostheses.|t|f|f|f
33918742|NCT00395837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918743|NCT00205699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918744|NCT01824264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918745|NCT02567617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918746|NCT01422590|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918747|NCT04460417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918748|NCT05010525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918749|NCT02305654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918750|NCT00403819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33918751|NCT03335956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33999029|NCT04707963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|PI and Co-Is will be blind to participant randomization. One study staff member will be responsible for administering the supplements to participants per randomization|Intervention group will receive the supplement during the study period and the wait-listed control group will receive the supplement after the study period. Both groups will participate in resistance training during the 10 week period|f|f|t|t
33918752|NCT00671814|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33918753|NCT00757484|||COHORT||RETROSPECTIVE|||||||
33918754|NCT01892397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918755|NCT02874183|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33999030|NCT02507063|||CASE_ONLY||PROSPECTIVE|||||||
33999031|NCT03956420|||CASE_CONTROL||PROSPECTIVE|||||||
33999032|NCT01710696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999033|NCT00220844|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999034|NCT00688844|||COHORT||PROSPECTIVE|||||||
33918756|NCT00641524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918757|NCT04913415|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to either the Low Suction or Standard Suction chest tube management group||||
33918758|NCT05875558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918759|NCT02557854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918760|NCT04565366|||CASE_CONTROL||PROSPECTIVE|||||||
33999035|NCT00657254|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999036|NCT00690495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33999037|NCT05809180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999038|NCT02831920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999039|NCT04691960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999040|NCT04823533|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind|Randomized controlled trial|t|f|t|f
33999041|NCT02195739|||COHORT||RETROSPECTIVE|||||||
33999042|NCT05651698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999043|NCT01808716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999044|NCT04476277|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999045|NCT00031954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999046|NCT02375815|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33999047|NCT01389713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695192|NCT05637671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784135|NCT06713603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be randomized into intervention or usual care.|f|f|f|t
33784136|NCT03070392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784137|NCT05098600|||COHORT||PROSPECTIVE|||||||
33784138|NCT03898687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784139|NCT04107519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784140|NCT06008678|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm trial||||
33784141|NCT03507309|||COHORT||PROSPECTIVE|||||||
33784142|NCT06713252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784143|NCT01631903|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33784144|NCT05538793|||OTHER||OTHER|||||||
33999048|NCT04364191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999049|NCT00229944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33784145|NCT05451108|NA|SINGLE_GROUP||OTHER||NONE||||||
33784146|NCT02823743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784147|NCT03134456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784148|NCT02820051|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33784149|NCT05893121|||CASE_ONLY||PROSPECTIVE|||||||
33784150|NCT05196633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784151|NCT02887651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784152|NCT01371201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784153|NCT04238715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784154|NCT04889118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784155|NCT00651677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784156|NCT02572778|||COHORT||PROSPECTIVE|||||||
33784157|NCT05759377|||COHORT||PROSPECTIVE|||||||
33784158|NCT00483262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784159|NCT06565390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will have two groups. One group will use the Owlet OSS 3.0 pulse oximeter and the other group will not.||||
33784160|NCT06711185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784161|NCT06630273|||COHORT||PROSPECTIVE|||||||
33784162|NCT05933122|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* Cohort called elsewhere = cohort without specific care by a sexologist~* Cohort called here = cohort with an intervention by a sexologist"||||
33784163|NCT02682355|||COHORT||PROSPECTIVE|||||||
33784164|NCT05492890|||CASE_CONTROL||PROSPECTIVE|||||||
33784165|NCT05469438|||CASE_ONLY||PROSPECTIVE|||||||
33918761|NCT06087952|RANDOMIZED|PARALLEL||OTHER||NONE|Blinded endpoint adjudication|"Patients with low recurrent VTE risk are advised to stop anticoagulant therapy. Patients with high recurrent VTE risk and low bleeding risk are advised to continue anticoagulant therapy.~Patients with intermediate recurrent VTE risk, or high recurrent VTE risk and high bleeding risk are randomised to stop or continue anticoagulant therapy."||||
33918762|NCT04392206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918763|NCT04994652|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, randomised clinical trial||||
33918764|NCT06072859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Feasibility quasi-experimental||||
33918765|NCT04260061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918766|NCT00067470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999050|NCT01204138|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999051|NCT00746460|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33999052|NCT02186353|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34088366|NCT00127803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34088367|NCT00025337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088368|NCT00782964|||COHORT||PROSPECTIVE|||||||
34088369|NCT01578382|||CASE_CONTROL||PROSPECTIVE|||||||
34088370|NCT00047827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088371|NCT03832478|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective observational study||||
33784166|NCT00071643|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33784167|NCT06644014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Note: Participants are blinded to the outcome measure (CVA) on their Oura App. Outcomes are analyzed by blinded researchers not actively involved in data collection.||t|f|f|t
33784168|NCT06540118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|By the nature of the dietary intervention, it is impossible to blind participants to study arm assignment. However, research staff collecting outcome data, apart from dietary adherence data, will remain blinded to participants' assigned study arm throughout data collection. Additionally, the statistician(s) analyzing data for efficacy of the intervention will use a dataset with study arm masked in order to remain blinded to the assigned intervention for the final analysis.||f|f|t|t
33784169|NCT06711341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a single-blinded randomized controlled trial. Participants are not blinded to their group assignment. However, the researcher responsible for conducting tests and data collection is blinded to the group assignments to avoid any assessment bias. The researcher who handles randomization and group allocation is not blinded.||f|f|t|t
33784170|NCT04852887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784171|NCT03230565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and participants will be masked to treatment group. Care providers will be necessarily unmasked.|Comparison of two groups: 1) Continuous infusion group 2) Bolus Infusion group|t|f|t|t
33784172|NCT06253325|||COHORT||PROSPECTIVE|||||||
33784173|NCT05904106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784174|NCT06644651|||COHORT||PROSPECTIVE|||||||
33784175|NCT02774356|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33784176|NCT06712537|||COHORT||RETROSPECTIVE|||||||
33784177|NCT06323330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the intervention|The MIT- Indian Adaptation will be tested and compared with standard speech rehabilitation in post-stroke non-fluent aphasia|f|f|f|t
33784178|NCT01061905|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33784179|NCT06712355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33784180|NCT06440174|||COHORT||PROSPECTIVE|||||||
33999053|NCT05535920|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Chronic outpatient hemodialysis patients have high rates of rapid changes in potassium and other electrolytes critical to the generation cardiac arrythmias. A growing body of data suggests that intra-dialytic K+ levels fall to level of 2.0 or lower and are a potential major contributor to the generation of atrial fibrillation, bradycardia, and other clinically significant arrhythmias. We propose that raising the dialysate bath to 3.0 K+ from current standard of care levels of 2.0 K+ will reduce levels of hypokalemia-induced arrhythmias. We further propose that the use of sodium zirconium cyclosilicate (Lokelma) will ensure that secondary hyperkalemia is controlled following the introduction of the 3.0 K+ dialysate bath.||||
33999054|NCT05762458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999055|NCT04332484|||COHORT||PROSPECTIVE|||||||
33784181|NCT05829681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999056|NCT05796843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999057|NCT03232762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999058|NCT01483820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999059|NCT01291095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999060|NCT03939117|||COHORT||PROSPECTIVE|||||||
33999061|NCT01011855|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33999062|NCT00575601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33784182|NCT06713824|||CASE_CONTROL||RETROSPECTIVE|||||||
33784183|NCT04001504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784184|NCT06611358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784185|NCT03203161|||COHORT||PROSPECTIVE|||||||
33999063|NCT05503992|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a two-arm cluster-randomized trial. The unit of randomization is the health facility catchment areas (HFCAs) which will be matched in pairs on 1) ruralness as defined by distance/time to the nearest tertiary clinic or district capital; 2) supply chain performance as defined by number of family planning commodities stockouts in the nearest preceding three to six month period for which data are available (for baseline: August to October, 2022; for endline: February to June 2023); 3) catchment area size and; 4) number of CHW affiliates. This effectiveness evaluation will be paired with a concurrent implementation evaluation, making it a Type 2 Hybrid Design.||||
34088372|NCT02494011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088373|NCT03031925|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34088374|NCT05709093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088375|NCT01604772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918767|NCT01991938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918768|NCT02923752|||OTHER||PROSPECTIVE|||||||
34088376|NCT06391411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34088377|NCT03907215|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind to the administration of ACT-541468 (participant). Single- and double-blind to the administration of ACT-541468 (Investigator, single-/double blind is dependent on treatment arm team). Single-blind study with the inclusion of two double-blind nested crossover parts, i.e., subjects will remain blinded to all administrations of ACT-541468.|Single-center, single-blind, randomized, placebo-controlled, sequential design Phase 1 study with the inclusion of two double-blind nested crossover parts|t|f|t|f
34088378|NCT02066116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34088379|NCT04179214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|Both experimental and control groups will be treated simultaneously with one treatment option common to both groups|t|f|f|f
34088380|NCT04323592|||COHORT||PROSPECTIVE|||||||
34088381|NCT01254877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34088382|NCT04571593|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34088383|NCT02305316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088384|NCT03059368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918769|NCT01344252|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33918770|NCT03271788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918771|NCT04169061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088385|NCT03654352|||CASE_CONTROL||PROSPECTIVE|||||||
33784186|NCT02518243|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918772|NCT03792451|||COHORT||CROSS_SECTIONAL|||||||
33918773|NCT05833685|||COHORT||CROSS_SECTIONAL|||||||
33918774|NCT04005950|||CASE_ONLY||PROSPECTIVE|||||||
33918775|NCT00776399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918776|NCT02321618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918777|NCT00304902|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33918778|NCT01157052|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33918779|NCT00192036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918780|NCT00466583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918781|NCT02916095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918782|NCT06082869|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators performing plaque scoring, study coordinators entering plaque scores and handling data, and the statistician performing the data analysis were all blinded to the treatment regimen|Randomized, single-center, examiner-blinded, parallel design clinical trial.|f|f|t|t
33918783|NCT03891394|||COHORT||PROSPECTIVE|||||||
33918784|NCT02500394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918785|NCT06457815|||COHORT||PROSPECTIVE|||||||
33918786|NCT02344420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918787|NCT03864809|||CASE_CONTROL||PROSPECTIVE|||||||
33918788|NCT03095716|||OTHER||CROSS_SECTIONAL|||||||
33918789|NCT05432102|||COHORT||PROSPECTIVE|||||||
33918790|NCT04724278|||COHORT||PROSPECTIVE|||||||
33918791|NCT01396902|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33918792|NCT02435641|||COHORT||PROSPECTIVE|||||||
33784187|NCT06709846|||COHORT||PROSPECTIVE|||||||
33918793|NCT02701192|||CASE_ONLY||PROSPECTIVE|||||||
33918794|NCT00312299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918795|NCT01763866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918796|NCT05467462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33918797|NCT02491697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918798|NCT00741299|||||RETROSPECTIVE|||||||
33918799|NCT03273517|||COHORT||PROSPECTIVE|||||||
33918800|NCT05931055|||CASE_CONTROL||PROSPECTIVE|||||||
33918801|NCT00599027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33918802|NCT04945824|NA|SINGLE_GROUP||OTHER||NONE||||||
33918803|NCT01861054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918804|NCT00985556|RANDOMIZED|||TREATMENT||NONE||||||
33918805|NCT03308565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918806|NCT01509872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33918807|NCT03357913|||COHORT||RETROSPECTIVE|||||||
33918808|NCT05539469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two parallel arms.|f|f|t|t
33918809|NCT05529290|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33918810|NCT03007121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918811|NCT01271387|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33918812|NCT00367198|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918813|NCT00954837|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918814|NCT02790554|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33999064|NCT05798884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All patients and the investigators including the research assessors, the statistician, and the researchers interacting with the patients except the one who conducts the acupuncture therapy will be blinded.||t|t|f|t
33999065|NCT01506349|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33999066|NCT00361049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999067|NCT02155153|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33999068|NCT00301327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999069|NCT00627731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999070|NCT01527435|||CASE_CONTROL||RETROSPECTIVE|||||||
33999071|NCT00789464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784188|NCT02858323|||COHORT||RETROSPECTIVE|||||||
33784189|NCT02122848|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33784190|NCT06508346|||CASE_ONLY||PROSPECTIVE|||||||
33784191|NCT01796093|||CASE_CROSSOVER||PROSPECTIVE|||||||
33784192|NCT04941027|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784193|NCT00507637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784194|NCT00809874|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33784195|NCT05844423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Triple (Participant, Investigator, Outcomes Assessor)||t|t|t|t
33784196|NCT05842850|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will be recruited from a nested case-control (NAFLD) screening study. Participants will be examined on two separate days at baseline (both groups) and after 4-weeks caloric restriction (LBW with NAFLD only). The caloric restriction intervention will start immediately after completion of baseline examinations. Participants will adhere to a caloric restriction protocol for 4-weeks limiting daily food intake to a window of 8 hours (8am to 4pm) and water-fasting for the remaining hours of the day. Participants will be instructed to eat a balanced diet according to the current dietary guidelines reduced by 20% calories to ensure energy deficit. A weighed food diary and accelerometers will be used for 3-days to estimate baseline dietary intake and physical activity and to monitor intervention adherence after 2 and 4 weeks.||||
33784197|NCT06712316|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784198|NCT05978609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784199|NCT01585181|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33784200|NCT04315220|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two group pre-test post-test design||||
33918815|NCT03143972|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||All volunteers will receive 2 standardized anesthesia sessions with a washout period of at least one week between sessions. During the first session volunteers will receive dexmedetomidine, during the second session they will first receive remifentanil and afterwards the combination of drugs will be administered. Anesthetic depth will be evaluated by MOAA/S scores (see table 2), testing of tolerance to electrical stimuli and laryngoscopy. Furthermore multichannel EEG-data will be collected to get insight in the drug dependent characteristics. Measured effects will be related to drug plasma concentrations.||||
33918816|NCT00231855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918817|NCT03074994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33918818|NCT03712332|NA|SINGLE_GROUP||TREATMENT||NONE||A basic two-phase AB case series design will be used. All participants will complete a seven day baseline phase, followed by the intervention phase of up to three weeks.||||
33918819|NCT03630978|||COHORT||PROSPECTIVE|||||||
33918820|NCT03434704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918821|NCT03489681|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators performed a prospective, randomized controlled study with three arms, the high-dose acupuncture, low-dose acupuncture, and healthy controlled groups.||||
33918822|NCT00206895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33918823|NCT04701905|||CASE_ONLY||RETROSPECTIVE|||||||
33918824|NCT03617367|NA|SINGLE_GROUP||TREATMENT||NONE|not applicable (open label)|This is a Phase 3, open-label, multi-center trial to evaluate the long-term safety, efficacy, and immunogenicity of up to four continuous treatment cycles of daxibotulinumtoxinA (DAXI) for injection with up to four different doses in adults with isolated cervical dystonia (CD).||||
33918825|NCT06180759|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||On 3 separate days, participants will be administered DMT, ketamine or placebo in a randomized, counter-balanced order. Their effect on experimentally induced acute pain will be evaluated and compared.|t|t|t|f
33918826|NCT04875949|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34088386|NCT06259526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784201|NCT06712511|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33784202|NCT06713018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784203|NCT06582628|RANDOMIZED|PARALLEL||TREATMENT||NONE||Exceptionally the Cross-over model will be allowed: from the control arm to the experimental arm upon progression is allowed in participants who meet certain criteria.||||
33784204|NCT05213208|||COHORT||PROSPECTIVE|||||||
33784205|NCT05173571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Minimal intervention study, pre- and post- supportive care effects on quality of life||||
33784206|NCT05945823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784207|NCT00583089|||COHORT||PROSPECTIVE|||||||
33784208|NCT06511934|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33784209|NCT05761067|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective individual patient meta-analysis of open-label, multicentre randomized trials.||||
33784210|NCT06265168|||OTHER||PROSPECTIVE|||||||
33784211|NCT02999217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784212|NCT01304706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784213|NCT05800665|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33999072|NCT04461587|NA|SINGLE_GROUP||TREATMENT||NONE||Open label interventional study observing US FDA approved Esbriet (for Interstitial Pulmonary Fibrosis) in Coal Workers' Pneumoconiosis patients with pulmonary fibrosis.||||
33999073|NCT01707316|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999074|NCT03181620|RANDOMIZED|PARALLEL||TREATMENT||NONE||Un-blinded, Prospective, Randomized Control Trial||||
33999075|NCT03773653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695193|NCT06709183|RANDOMIZED|CROSSOVER||OTHER||NONE|Assistant researcher|"The research will be conducted through simulation using a standard mannequin in room 428 in the general intensive care unit. Room 428 in the general intensive care unit is a standard intensive care room with four walls of glass, 15 m2 in size, one supply cabinet, one cloakroom, oxygen panel, mechanical ventilator, monitor and single bed, where patients can be monitored instantly with a camera system. In our study, this intensive care room will be used to evaluate the effectiveness of the oral care retractor designed for intensive care patients in order to ensure that oral care procedures to be applied by nurses are in a realistic environment and that nurses feel as if they are applying to a live patient.~Simulation method will be used for the experimental study part of this research. Laerdal brand MegaCode Kelly emergency care simulator will be used in the study."||||
33695194|NCT03169309|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre- and post- intervention trial||||
33784214|NCT02973919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784215|NCT04462120|||COHORT||PROSPECTIVE|||||||
33784216|NCT06629467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784217|NCT03673202|||COHORT||PROSPECTIVE|||||||
33918827|NCT02264899|NA|SINGLE_GROUP||OTHER||NONE||||||
33999076|NCT06389227|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999077|NCT00247013|RANDOMIZED|PARALLEL||||SINGLE||||||
33999078|NCT03118063|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33999079|NCT04233060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999080|NCT04865471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999081|NCT04948619|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695195|NCT06150755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be done by the outcomes assessor and one of the study authors will remove the prosthetic part before measuring crestal bone loss by outcome assessor through cone paralling technique. Blinding of the outcomes assessor for assessment by oral health questionnaire will be done as well|completely edentulous patients treated with overdenture retained by immediately loaded implant in the canine region|f|f|f|t
33695196|NCT04151329||SEQUENTIAL||TREATMENT||NONE||||||
33695197|NCT06039488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695198|NCT00443105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088387|NCT02058095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34088388|NCT05053490|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants of group A will perform static stretches and group B will perform dynamic stretching. After a gap of 3 days, interventions will be switched, now group A will perform dynamic stretching and group B will perform static stretching.||||
33695199|NCT05437159|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33695200|NCT06243224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695201|NCT06709833|||COHORT||PROSPECTIVE|||||||
33695202|NCT04710420|||COHORT||PROSPECTIVE|||||||
33695203|NCT05523297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Given the physical differences in the products and the emergency nature of the intervention, attending clinicians present during the infusion of the blood products/components will not be blinded to the treatment. To minimize bias, treating clinicians will be blinded to group assignments until immediately prior to IMP infusion.||t|f|f|t
33695204|NCT05476536|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33695205|NCT00771316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695206|NCT06324708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695207|NCT01556737|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33695208|NCT01904565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695209|NCT04903522|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695210|NCT02643329|RANDOMIZED|CROSSOVER||||NONE||||||
33695211|NCT04916002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695212|NCT04367883|||COHORT||PROSPECTIVE|||||||
33918828|NCT00750165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918829|NCT02755610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants in the Study Arm receive standard care and a paper check list to record product defect information Participants in the Control Arm receive standard care||||
33918830|NCT01900678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918831|NCT04874467|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918832|NCT01236742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918833|NCT04629898|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33918834|NCT05577091|NA|SINGLE_GROUP||TREATMENT||NONE||Recipients with the Ommaya reservoir implanted will be assigned to three courses. Arm A: Two patients, 1×10\^7 autologous Tris-CAR-T, at least 1 dose, maximum 6 doses. Arm B: Two patients 1×10\^8 autologous Tris-CAR-T, at least 1 dose, maximum 6 doses. Arm C: Six patients 5×10\^7 autologous Tris-CAR-T, maximum 8 doses.||||
33695213|NCT00992927|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918835|NCT03162055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918836|NCT04545788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918837|NCT00599261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918838|NCT02957149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33918839|NCT06441110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918840|NCT06033950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918841|NCT04368455|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918842|NCT03991559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999082|NCT03433404|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33999083|NCT05430815|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Information on all outpatient visits occurring between delivery discharge and 12 weeks postpartum will be abstracted and blinded for review. Two independent physicians will review the blinded information and determine whether the visit meets the criteria for a comprehensive postpartum visit.||f|f|f|t
33695214|NCT06703138|||OTHER||CROSS_SECTIONAL|||||||
33695215|NCT04214873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695216|NCT03135626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth study design was used|t|f|f|t
33695217|NCT02204280|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695218|NCT05152563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695219|NCT06551688|||COHORT||PROSPECTIVE|||||||
33695220|NCT02325661|NA|SINGLE_GROUP||||NONE||||||
33695221|NCT01443273|||COHORT||RETROSPECTIVE|||||||
33695222|NCT05935514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33695223|NCT01649609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695224|NCT05093348|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Demographics will be such that the data subject cannot be identified. It will not be possible to mask the ocularist, data manager or the trial manager. Every effort will be made to mask the patient and investigators from knowing which type of prosthesis is being worn during the trial. However, due to the differing methods of manufacture of a digital artificial eye compared to the traditional artificial eye, upon close inspection, it may be possible to denote differences in the cosmetic appearance. Should the participant ask or comment on which type of artificial eye they are wearing to the ocularist or research member then a scripted response will be provided.~The trial statistician who is analysing trial data will be masked until primary analysis is completed. Un-masking of the ocular prosthesis will occur after confirmation of primary analysis has been performed."|Pseudonymised single site investigation randomised crossover trial|t|f|t|f
33999084|NCT00000562|RANDOMIZED|||TREATMENT||||||||
33999085|NCT01799850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999086|NCT02369458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784218|NCT04793139|||OTHER||PROSPECTIVE|||||||
33784219|NCT02392156|||COHORT||PROSPECTIVE|||||||
33784220|NCT06556212|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The intervention group (feedback) will differ from the control group (non-feedback) in that they will have the FORM goggles display on and receive real-time metrics and guided workouts throughout the remainder of the study. Non-feedback will have the display turned on but will only have the workout timer visible during rest. Each group will be provided with the same twelve-week training program that differs only in the prescribed pace for each workout."||||
33784221|NCT06712667|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33695225|NCT00685555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695226|NCT03364530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695227|NCT05043558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999087|NCT04720547|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Personnel conducting assessment of outcomes and data analysis are blinded to treatment.|After an initial assessment to determine eligibility, participant complete two in-lab night studies in a randomized manner including one night with the administration of zolpidem and another without zolpidem.|f|f|f|t
33999088|NCT06348979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999089|NCT04988438|||CASE_ONLY||OTHER|||||||
33999090|NCT00198133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695228|NCT01484132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695229|NCT00351000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695230|NCT01621503||PARALLEL||DIAGNOSTIC||NONE||||||
33695231|NCT02534220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33695232|NCT04449887|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695233|NCT05120661|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33695234|NCT00679978|||COHORT||PROSPECTIVE|||||||
33695235|NCT04589325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695236|NCT05274165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which device they are wearing as these devices are placed deep in the ear canal by a licensed hearing care professional. The devices are designed to stay in the ear 24 hours a day, and can be worn for several weeks or months at a time.|In this study, new hearing aid candidates will be randomly assigned to one of two groups, but such that each group will have an equal number of participants.|t|f|f|f
33695237|NCT04326959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784222|NCT03155204|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33784223|NCT04974489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784224|NCT04893421|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||At each site, the first cohort of 25 participants will be treated with the standard of care approach (WGS or RSL) and the subsequent cohort of 25 participants will be treated with MOLLI.||||
33784225|NCT04651179|||OTHER||RETROSPECTIVE|||||||
33784226|NCT03117036|||COHORT||PROSPECTIVE|||||||
33784227|NCT06364423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784228|NCT03394248|||COHORT||PROSPECTIVE|||||||
33784229|NCT05214365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be explained to be randomized to either one of the two branches. The type of therapy applied will not be communicated to the patient. The follow-up will be the same in the two branches. During the visits it will not be said which therapy has been applied.|Randomized, unicentric, simple blind.|t|f|f|f
33784230|NCT06369129|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized clinical trial.~* Parallel group study.~* A trial will be carried out in hospital of Oral and Maxillofacial surgery department - Faculty of Oral and Dental Medicine - Cairo University .~* Equal randomization : participants with equal probabilities for intervention.~* Positive controlled : Both groups receiving treatment."||||
33784231|NCT02460887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784232|NCT03180190|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784233|NCT05310084|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is an Observer-Blind Study. The vaccines and placebo will be administered by an unblinded third-party site staff member.||t|t|t|t
33784234|NCT02840448|||COHORT||PROSPECTIVE|||||||
33784235|NCT06667414|||OTHER||OTHER|||||||
33784236|NCT05800821|||COHORT||PROSPECTIVE|||||||
33784237|NCT05367674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinical assessments for both groups (intervention and control) will be conducted by trained personnel that are blinded to participants' treatment arm assignment.|Phase 2 prospective randomized controlled trial|f|f|f|t
33784238|NCT04380844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33784239|NCT05300555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784240|NCT06393634|RANDOMIZED|PARALLEL||OTHER||NONE||Three groups in phase one and two groups in phase two, randomized by a computer.||||
33801530|NCT04788212|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open trial feasibility study|8 participants with autism and depression, anxiety or anger will participate||||
33999091|NCT05535998|||COHORT||RETROSPECTIVE|||||||
33999092|NCT04840927|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999093|NCT04392596|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33999094|NCT00032227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999095|NCT03672916|||COHORT||PROSPECTIVE|||||||
34088389|NCT01191658|||COHORT||PROSPECTIVE|||||||
34088390|NCT04507113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088391|NCT01544881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34088392|NCT03736304|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|All study investigators and participants were blinded to patients randomization status.||t|f|f|t
33695238|NCT03306810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695239|NCT06680193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695240|NCT04547790|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695241|NCT01641510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33695242|NCT02462174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33695243|NCT04370431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695244|NCT03171051|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All subjects to receive the same treatments - right flank of abdomen with the experimental LED device and the left flank of the abdomen with the active comparator diode laser device.||||
33801531|NCT01850459|||CASE_CONTROL||PROSPECTIVE|||||||
33695245|NCT01011738|||COHORT||PROSPECTIVE|||||||
33695246|NCT02525042|||FAMILY_BASED||RETROSPECTIVE|||||||
33695247|NCT02047149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695248|NCT02986971|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695249|NCT06087406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695250|NCT06087146|NA|SINGLE_GROUP||OTHER||NONE||||||
33695251|NCT05443360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33695252|NCT00150540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695253|NCT06161272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695254|NCT06685068|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||No randomization will be performed in Part A (dose escalation- sequential assignment). In Part B (tumor-specific expansion- parallel assignment), participants in each cohort will be randomized to receive one of the RP2Ds of GEN1286.||||
33695255|NCT02921360|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33695256|NCT02503007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33695257|NCT02634281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695258|NCT04388384|||COHORT||PROSPECTIVE|||||||
33695259|NCT00445978|NA|SEQUENTIAL||TREATMENT||NONE||||||
33695260|NCT06707870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695261|NCT04564495|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will attend live zoom classes with instructor feedback, and the other group will exercise using pre-recorded sessions.||||
33695262|NCT03670927|||CASE_CONTROL||PROSPECTIVE|||||||
33695263|NCT01555983|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33695264|NCT04280146|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigate cultural difference on eating behaviour|"Subjects are exposed foods for four days. 1 day Ultra processed fast food~1 day Ultra processed slow foods~1 day unprocessed fast food~1 day unprocessed slow food"|t|f|f|f
33695265|NCT05129423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695266|NCT01282203|||||PROSPECTIVE|||||||
33695267|NCT00098098|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33695268|NCT04780581|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomised clinical trial comparing 2 active treatments. Low-intervention clinical trial||||
33695269|NCT01056731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695270|NCT03345069|||COHORT||PROSPECTIVE|||||||
33695271|NCT05019794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784241|NCT03367364|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Within strata, a coin toss (ERH) will be used to randomize floors into either the Patient education bundle arm or the Nurse feedback arm. The VTE prophylaxis medication non-administration dataset provided to the biostatistical team (i.e. outcomes assessors) for analysis will be blinded by treatment arm and department.|"In the PEB arm, the intervention will include:~A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.~In the NFC arm, the intervention will include:~Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers."|t|f|f|t
33784242|NCT03910465|||COHORT||PROSPECTIVE|||||||
33784243|NCT06712888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784244|NCT05737628|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784245|NCT04077281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33784246|NCT06069232|||COHORT||PROSPECTIVE|||||||
33784247|NCT05417204|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE||Adaptive design: a sample size calculation based on the primary outcome will be performed after 30 patients complete the post-intervention evaluation.|t|t|f|f
33784248|NCT03111095|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784249|NCT06288880|||OTHER||CROSS_SECTIONAL|||||||
33918843|NCT01206452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918844|NCT04439370|||COHORT||PROSPECTIVE|||||||
33918845|NCT04369755|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33918846|NCT01148563|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33918847|NCT01077388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33918848|NCT00020566|RANDOMIZED|||TREATMENT||||||||
33918849|NCT05776914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695272|NCT06678724|||COHORT||PROSPECTIVE|||||||
33695273|NCT03049254|||FAMILY_BASED||PROSPECTIVE|||||||
33695274|NCT01272102|||CASE_ONLY||PROSPECTIVE|||||||
33918850|NCT03827590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918851|NCT03694041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel design for SAD and MAD studies Crossover design for Food and Drug interaction studies|t|f|t|f
33695275|NCT05126498|||OTHER||PROSPECTIVE|||||||
33695276|NCT04407052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695277|NCT00850707|||CASE_CONTROL||PROSPECTIVE|||||||
33695278|NCT02672280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695279|NCT05120609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695280|NCT04573998|||OTHER||RETROSPECTIVE|||||||
33695281|NCT06081400|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695282|NCT04252365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695283|NCT04033510|||COHORT||PROSPECTIVE|||||||
33695284|NCT00145171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695285|NCT02091973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695286|NCT05273307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Packaging and labeling of test and control treatments will be identical and performed by Miracle Fruit Farm to maintain blinding conditions.||t|f|t|f
33918852|NCT01481168|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33918853|NCT04149639|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label design||||
33918854|NCT00050791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695287|NCT04490161|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33695288|NCT06557109|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The evaluator does not know which group is the experimental and control group.|randomized posttest control group design|f|f|f|t
33999096|NCT05953987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Twenty-four smokers aged between 20 and 45 years were allocated into 3 groups: a sedentary control group (CON, n = 8), an aerobic exercise group (EX, n = 8), and an aerobic combined with diaphragmatic breathing exercise group (EXDB, n = 8). The general physiological characteristics, pulmonary function, and respiratory muscle strength values before and after 8 weeks were meas-ured. The Quit Smoking Questionnaire and urine cotinine were measured for either 30 days after the training.|f|f|f|t
33695289|NCT02073110|||CASE_ONLY||PROSPECTIVE|||||||
33695290|NCT03342521|||COHORT||PROSPECTIVE|||||||
33999097|NCT05452213|NA|SINGLE_GROUP||TREATMENT||NONE||One-arm, open-label||||
34088393|NCT04985162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were divided into intervention group and control group.||t|f|f|f
33695291|NCT06365541|NA|SINGLE_GROUP||TREATMENT||NONE||Exploring the efficacy and safety of dapagliflozin in improving heart failure in dialysis patients by the analysis and comparison of patients' own data before and after dapagliflozin treatment||||
33695292|NCT03148418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088394|NCT04943783|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33695293|NCT01913223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695294|NCT00766077|||COHORT||PROSPECTIVE|||||||
34088395|NCT03104413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784250|NCT05403138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088396|NCT02612857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088397|NCT00751127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999098|NCT05962164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of the participant to the condition (heat therapy or sham) is not possible. Data that needs to be analyzed (i.e. ultrasound videos for blood flow and FMD) will be coded by a team member that is not involved in data collection or analysis. The outcomes assessor will be blind to the participant, condition and time point of the file. Breaking of the code will only occur when all data analysis is complete.|Parallel 2-Arm Randomized Control Trial|f|f|f|t
34088398|NCT04695561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088399|NCT01993199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088400|NCT06224049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088401|NCT05068544|||COHORT||PROSPECTIVE|||||||
34088402|NCT01532089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088403|NCT02101294|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34088404|NCT05071924|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a pre-post study with assessments at baseline and immediate post- intervention.||||
34088405|NCT00612235|||COHORT||PROSPECTIVE|||||||
33695295|NCT05113290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695296|NCT02034032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695297|NCT05243641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695298|NCT06608225|||COHORT||PROSPECTIVE|||||||
33695299|NCT03427112|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695300|NCT04041375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This is a single-blind, parallel group, randomized trial of a 3-month peer-navigation intervention for Veterans with DM and elevated levels of diabetes-related distress. Participants will be assigned at random (see below) to the intervention (peer navigation with follow-up) or usual care (print materials and encouragement to continue follow-up with health care providers). Assessment of primary, secondary and intermediate end points will occur pre-intervention at baseline and post-intervention at 3 and 6 months.|f|f|t|t
33695301|NCT01140373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999099|NCT04349696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999100|NCT01939990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33999101|NCT05214677|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999102|NCT03971305|||COHORT||PROSPECTIVE|||||||
33999103|NCT01019525|||||CROSS_SECTIONAL|||||||
33999104|NCT01828112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999105|NCT01965093|||COHORT||PROSPECTIVE|||||||
33999106|NCT02739724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999107|NCT02751437|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695302|NCT02197793|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695303|NCT05942261|||COHORT||CROSS_SECTIONAL|||||||
33695304|NCT04798495|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33695305|NCT00625794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695306|NCT06668649|||CASE_CONTROL||PROSPECTIVE|||||||
33695307|NCT01567735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695308|NCT00410228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33695309|NCT04187677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695310|NCT06704347|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33695311|NCT02682407|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort 2 and 3 subjects are randomized in a 1:1 fashion during the first 12 weeks of treatment. Cohort 1 and 4 are non-randomized.||||
33695312|NCT01632046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695313|NCT00169884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33695314|NCT05653258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and subjects randomized to study drug/placebo will be blinded to which intervention they receive.|All participants will undergo cellular/molecular profiling and older obese participants will be randomized into 3 arms.|t|f|t|f
33695315|NCT00027937||||TREATMENT||NONE||||||
33695316|NCT00683085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695317|NCT05358015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695318|NCT02058472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695319|NCT06187337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will do measurements on study models. The study models will be masked when it comes to treatment modality. Surveys will be masked.|This is a 2-arm parallel-group, randomized controlled trial with a 1:1 allocation ratio.|f|f|f|t
33695320|NCT02857361|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695321|NCT00481208|||NATURAL_HISTORY||OTHER|||||||
33695322|NCT02831374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695323|NCT01931332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695324|NCT06680336|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Longitudinal study with 3 measurements (S1, S2, S3) and two groups of stroke patients (post-stroke-delirium (PSD) patients, non PSD patients)||||
33695325|NCT03894046|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study drugs will not be masked due to logistical reasons, every attempt will be made to maintain the blind for patients, all staff at the site, and the Sponsor or its designees, except for the treatment physician and other immediate healthcare providers.|||||
33695326|NCT01050127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695327|NCT00975637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695328|NCT00174811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695329|NCT00660621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695330|NCT03711201|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33695331|NCT02556203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695332|NCT04234451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695333|NCT03779958|||COHORT||PROSPECTIVE|||||||
33695334|NCT06253104|||COHORT||PROSPECTIVE|||||||
33999108|NCT04221048|||COHORT||RETROSPECTIVE|||||||
34088406|NCT05168904|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33695335|NCT00206310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33695336|NCT05318339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695337|NCT06557317|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33695338|NCT05850312|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
33695339|NCT01869725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695340|NCT01012167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695341|NCT06212427|NA|SINGLE_GROUP||OTHER||NONE||||||
33695342|NCT06671873|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695343|NCT00756015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695344|NCT01675427|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33695345|NCT01262209|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33695346|NCT00943696|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33695347|NCT02072902|||COHORT||OTHER|||||||
33695348|NCT04982107|||COHORT||RETROSPECTIVE|||||||
33695349|NCT04376879|||COHORT||PROSPECTIVE|||||||
33695350|NCT02071927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695351|NCT01222884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695352|NCT01291433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695353|NCT04676854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695354|NCT05102695|||CASE_CONTROL||PROSPECTIVE|||||||
33695355|NCT01135290|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33695356|NCT02761434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33999109|NCT02075385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999110|NCT02052817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999111|NCT06627413|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study includes 3 sequential study parts (Parts A, B and C). Part A consists of 4 cohorts (Cohorts 1 to 4), Part B of up to 3 cohorts (Cohorts 5 to 7), and Part C of up to 2 cohorts (Cohorts 8 and 9). Within each study part, cohorts may be enrolled in parallel.||||
33999112|NCT05032963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The neurocognitive evaluators who administer the neurocognitive battery (MCCB) will be blinded to sleep schedule.||f|f|f|t
33999113|NCT04202484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999114|NCT00936351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999115|NCT05282680|||COHORT||PROSPECTIVE|||||||
33999116|NCT06452758|||COHORT||PROSPECTIVE|||||||
33999117|NCT04835116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999118|NCT03951727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999119|NCT02352233|||CASE_ONLY||PROSPECTIVE|||||||
33999120|NCT02222272|||COHORT||PROSPECTIVE|||||||
33999121|NCT03997253|NA|SINGLE_GROUP||OTHER||NONE||various blood and urine samples will be collected from the recipient at D0, D1, D3, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection ancillary studies : stools at D0 D7 M1 and M3 will be collected for liver transplant patient||||
33999122|NCT01173705|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999123|NCT00740896|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33999124|NCT04021160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695357|NCT06065423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33999125|NCT02607826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999126|NCT00080795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999127|NCT00919711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999128|NCT05368480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Clients will be kept on a waitlist. When a companion becomes available in a particular geographic area, the agency will take the top two on the list with corresponding geographies, complete an intake interview for both and then use a computer to randomly assign one to treatment (receiving the companion) and one to control (referrals to other services).||||
33999129|NCT04892147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Wait-list control||||
33999130|NCT06059755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33999131|NCT02020850|||CASE_ONLY||CROSS_SECTIONAL|||||||
33999132|NCT05248399|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster Randomized||||
33999133|NCT04285073|NA|SINGLE_GROUP||OTHER||NONE||||||
33999134|NCT01257451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999135|NCT04756739|||CASE_ONLY||PROSPECTIVE|||||||
33999136|NCT06217432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33999137|NCT00458822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999138|NCT04869995|||OTHER||PROSPECTIVE|||||||
33999139|NCT03681977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The Participants and the researchers at the Constance Lethbridge Rehabilitation Centre responsible for collecting the kinematic and gait data (motion capture, questionnaires, performance measures) will be blinded.~For analysis purposes the Participants will be dummy coded (0 = one group, 1 = the other group). The blinded parties will know the dummy code but they will not know which group is assigned to each code."|A prospective, double-blinded, randomized control study consisting of a clinical follow-up followed by a knee kinematics assessment. Patients outcomes will be measured pre-operatively, and at 1 and 2 years post-surgery. Measures will include joint mechanics and neuromuscular activation during walking and stair stepping measured with motion capture and electromyography, and clinical/self assessment including pain in response to physical activity.|t|f|f|t
33999140|NCT05698316|||COHORT||OTHER|||||||
33999141|NCT04181736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, Care Providers, and Investigators will be blinded throughout the course of the study to avoid bias.|We will randomize participants to one of two groups, treatment or placebo. Participants will have the option to proceed to an open label phase, post-treatment.|t|t|t|f
33999142|NCT03972696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999143|NCT06179953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999144|NCT05683561|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33999145|NCT02130180|||COHORT||CROSS_SECTIONAL|||||||
33999146|NCT01196598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999147|NCT00310674|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33999148|NCT03408730|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Double-blind Randomized Controlled Trial|t|f|t|t
33999149|NCT02535468|||COHORT||PROSPECTIVE|||||||
33999150|NCT02918058|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34088407|NCT04183101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enzyme inhibitor, enalapril, in children and adults with C3 glomerulopathy||||
34088408|NCT02460731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088409|NCT05172570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088410|NCT05669157|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34088411|NCT00302471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088412|NCT04466189|||COHORT||PROSPECTIVE|||||||
34088413|NCT03052621|||COHORT||RETROSPECTIVE|||||||
33695358|NCT04058418|||OTHER||CROSS_SECTIONAL|||||||
33695359|NCT01490164|||CASE_ONLY||PROSPECTIVE|||||||
33999151|NCT00260715|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33999152|NCT03356340|||COHORT||PROSPECTIVE|||||||
33999153|NCT00785135|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33695360|NCT00509392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999154|NCT05471349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999155|NCT05711901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter prospective study with a control group to evaluate the efficacy and safety of LPS sorption using the Efferon LPS device in postpartum sepsis||||
33999156|NCT01525628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999157|NCT03769636|||COHORT||PROSPECTIVE|||||||
33999158|NCT02379624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999159|NCT02152618|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999160|NCT05848908|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33999161|NCT05128058|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33695361|NCT04943718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999162|NCT01070745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999163|NCT05316636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33999164|NCT02232945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33999165|NCT04508205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999166|NCT05140603|||CASE_ONLY||RETROSPECTIVE|||||||
33999167|NCT05179122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician involved in the statistical analyses of results will be blinded to the arm of treatment||f|f|f|t
33999168|NCT05857969|||COHORT||PROSPECTIVE|||||||
33999169|NCT01260623|||OTHER||PROSPECTIVE|||||||
33999170|NCT00629057|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999171|NCT02784262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999172|NCT06358027|||COHORT||PROSPECTIVE|||||||
33999173|NCT05078554|||CASE_ONLY||RETROSPECTIVE|||||||
33999174|NCT01218360|||COHORT||PROSPECTIVE|||||||
33999175|NCT05440968|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33999176|NCT01197937|||COHORT||RETROSPECTIVE|||||||
33999177|NCT04416438|||COHORT||RETROSPECTIVE|||||||
33999178|NCT01508065|||COHORT||PROSPECTIVE|||||||
33999179|NCT01311596|||COHORT||PROSPECTIVE|||||||
33999180|NCT04223349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999181|NCT05470153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999182|NCT00860145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999183|NCT01971645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999184|NCT02050165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999185|NCT01706601|||COHORT||RETROSPECTIVE|||||||
33999186|NCT04235660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiologist assessing response will be blinded to the treatment type||f|f|f|t
33999187|NCT02583698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999188|NCT01116791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999189|NCT04203823|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm (Cohort) assignment||||
33695362|NCT04950166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A two group interventional, open-label, single arm trial where each patient is his/her own intrapatient control. All patients will receive a single dose of pegsitacianine administered intravenously prior to standard of care surgery.||||
33695363|NCT06679790|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33695364|NCT02869438|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33695365|NCT02751788|||CASE_ONLY||PROSPECTIVE|||||||
33695366|NCT04732169|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind|We plan to administer Epidiolex (CBD) or placebo in double blind, randomized, cross-over fashion.|t|f|t|t
33695367|NCT02928120|||CASE_CONTROL||PROSPECTIVE|||||||
33695368|NCT03015545|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33695369|NCT05661357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695370|NCT00000762||||TREATMENT||DOUBLE||||||
33695371|NCT01904539|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695372|NCT06703697|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33695373|NCT04879069|||CASE_ONLY||PROSPECTIVE|||||||
33784251|NCT06351904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784252|NCT04107337|RANDOMIZED|PARALLEL||OTHER||NONE||"1. Experimental group (N=10): vocal work session based on semi-occluded vocal-tract exercises with a straw.~2. Control group (N=10): the second group acting as control group will perform a vocal work session based on open mouth exercices (vocalizations)."||||
33784253|NCT01969890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784254|NCT02588222|||CASE_CONTROL||PROSPECTIVE|||||||
33999190|NCT02835222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999191|NCT02472639|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999192|NCT05698407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All participants, attending anesthesiologists and other health-care team members, and outcome assessors are blinded to the study group assignment.|a randomized, double-blind, pilot trial with two parallel-arms|t|t|f|t
33999193|NCT06179641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|quadruple|single centered, prospective, randomized double blinded controlled trial|t|t|t|t
33999194|NCT03822949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999195|NCT06335927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999196|NCT01614262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088414|NCT05201417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695374|NCT00560274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801532|NCT04533061|||COHORT||PROSPECTIVE|||||||
33999197|NCT00419224|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999198|NCT05774522|NA|SINGLE_GROUP||SCREENING||NONE||||||
33999199|NCT03367260|||COHORT||PROSPECTIVE|||||||
34088415|NCT01113775|||COHORT||PROSPECTIVE|||||||
34088416|NCT01179516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088417|NCT00655889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088418|NCT05994183|NA|SINGLE_GROUP||OTHER||NONE||An open-label single-arm pilot study to assess feasibility of study procedures.||||
34088419|NCT05992441|||OTHER||OTHER|||||||
33999200|NCT05415891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will include two levels of randomization: clinic level and provider level. We will randomize the two clinic study sites into one of two study conditions. One clinic will be randomized to the stigma-reduction training arm, and one clinic will be randomized to the no stigma-reduction training arm (but will receive the training at the end of the study). At the provider level, we will use a multiple baseline design that is fundamental to idiographic approaches. All providers will receive the You℞ Decision prescribing platform. Providers will be randomized to one of four intervention schedules: (a) 1-week baseline + 11-week intervention, (b) 2-week baseline + 10-week intervention, (c) 3-week baseline + 9-week intervention, and (d) 4-week baseline + 8-week intervention. Randomization will be stratified by clinic. Two providers (one from each site) will be randomized to each intervention schedule (for a total of 8 providers).||||
33695375|NCT02765685|RANDOMIZED|PARALLEL||||NONE||||||
33695376|NCT06418750|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups studied: preventive and curative.||||
33695377|NCT05635071|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695378|NCT03115073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695379|NCT03242538|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33695380|NCT01304160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695381|NCT04574323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695382|NCT05771792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695383|NCT02193698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695384|NCT04945876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The complex intervention makes masking of participants and care provider impossible. An independent therapist will conduct baseline testing before randomization. The same therapist will conduct the re-testing at 12 weeks and six month, the assessor will be blinded to group allocation and not be part off providing the intervention. The person conducting the data-analyzes will be blinded to group allocation.~A computer-generated, permuted block randomization scheme will be used to allocate patients."|Pragmatic randomized, controlled trial|f|f|t|t
33695385|NCT05416151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"The study Test and Control products have similar appearance including packaging and texture, smell, and taste, in order to preserve the double-blind methodology.~The blinding of study products will be performed by assigning a study product number corresponding to the randomization list. Then blinded study product packages will be carried to the investigational site for assignment to the subjects.~Product allocation will be performed by randomized method (IWRS validated system) as it is a Randomized Controlled Trial. The participants are thus assigned to intervention groups randomly."|A proof-of-efficacy, randomized, controlled, double-blind, monocentric, parallel arms design|t|t|t|t
33784255|NCT04123002|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Study participants would be divided into 2 groups. Group A would received tooth brush and paste and Group B would receive Miswak chewing stick along with tooth brush and paste. They would be instructed to use the assigned oral hygiene aid for a week. Then the groups would cross-over and continue for 1 week. Plaque and gingival measures would be taken at baseline, end of week 1 and end of week 2.||||
33918855|NCT04350736|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||double-blind, randomized, placebo-controlled|t|t|t|f
33918856|NCT05933252|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33918857|NCT02723266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918858|NCT04511819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be performed in a double-blind fashion. The investigator, study staff, subjects, Sponsor, and monitor will remain blinded to the treatment until study closure.|This study is a randomized, double-blind, placebo-controlled study.|t|t|t|t
33918859|NCT04101760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918860|NCT03886025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to receive either combined anodal tDCS and cognitive training or combined sham tDCS and cognitive training. The participants will be blind to whether the tDCS is active or sham.|Single blind Randomized Controlled Trial|t|f|f|f
33918861|NCT02570529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918862|NCT02591342|||COHORT||PROSPECTIVE|||||||
33918863|NCT05426629|NA|SINGLE_GROUP||TREATMENT||NONE||Every participant will receive the same treatment||||
33918864|NCT00175799|||COHORT|||||||||
33918865|NCT06216587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918866|NCT01767519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918867|NCT01943929|||COHORT||CROSS_SECTIONAL|||||||
33918868|NCT04910074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and outcomes assessor will be blinded to which group participants belong to.|intervention vs placebo|t|f|f|t
33695386|NCT01021579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33999201|NCT05758623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999202|NCT05182606|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Investigators will conduct a pilot trial to investigate the feasibility, acceptability, and preliminary effectiveness of the algorithm Implementation Package. The investigators will conduct the pilot in 3 University of Pittsburgh Medical Center (UPMC) practices. the investigators will randomize by site and use a waitlist control. Feasibility and acceptability will be assessed qualitatively and via a clinician survey. Preliminary effectiveness outcomes will include reduction in concerning behaviors and increased diagnosis/treatment of Opioid Use Disorder (OUD). The investigators will also pilot Electronic Health Record-based outcomes assessment.||||
34088420|NCT03687424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesiologist who interviews and examines patients scheduled for colonoscopy under analgo-sedation will enroll eligible participants and will offer procedure explanation and possibility to sign uniformed written consent. Unique personal hospital admission number (UPHAN) will be assigned to all eligible participants. After that, they will be randomized to control or intervention group by using random numbers generator. Anesthesiologist who implements anesthesia will receive nontransparent envelope with assigned intervention provided by independent investigator and will not decide which participant will receive LFNO or HFNO. However, attending anesthesiologist and participants will unavoidably be aware of type of oxygenation applied. Investigator who collects data after procedure will be unaware of study protocol and will enter data to formatted database. Participants' data will be noted under UPHAN. Outcome assessors will be unaware of intervention applied.|"We plan to conduct prospective, parallel group, randomized controlled clinical trial.~In total, 126 participants will be included in this trial. These participants are patients scheduled for outpatient colonoscopy in analgo-sedation.~This study includes 126 patients divided in 3 groups of according to BMI: 18\<BMI\<30 kg/m2, 30\<BMI\<40 kg/m2 or BMI ≥40 kg/m2. Each group will be divided in control groups of 21 patients who will receive LFNO and intervention groups of 21 patients who will receive HFNO during standardized intravenous analgo-sedation."|f|f|t|t
33695387|NCT06680245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|There will be no blinding of the ophthalmologist to participant's study group as they will need the information to execute the correct intervention. The type of treatment received (mitomycin-C or no intervention) will be blinded for the patient, and all patients will be asked at the last follow-up visit which treatment location they felt they received. This data will be used to assess the level of treatment masking. The success of blinding will be calculated using Bang's Blinding Index. The person performing statistical analysis will be blinded to the intervention groups. The groups will be coded and the analyst will be unaware of which group receives mitomycin-C or no intervention with the Ahmed valve implant.|The study design is a parallel-armed clinical superiority randomized trial. The study participants will be blinded to the use of the mitomycin-c with the Ahmed valve implant. Participants will be randomly allocated to either the experimental group using mitomycin-c injections or the control group receiving no intervention. The trial will be conducted at the Hamilton Regional Eye Clinic at St. Joseph's Healthcare Hamilton to maintain standardization of care and follow-up.|t|f|f|t
33999203|NCT06071338|||OTHER||CROSS_SECTIONAL|||||||
33695388|NCT06155565|||CASE_CROSSOVER||PROSPECTIVE|||||||
33695389|NCT06677242|||COHORT||PROSPECTIVE|||||||
33695390|NCT04651972|||CASE_CONTROL||OTHER|||||||
33695391|NCT00614328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33695392|NCT05245253|||CASE_ONLY||PROSPECTIVE|||||||
33695393|NCT02484287|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
33695394|NCT02637336|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784256|NCT06713785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single site, open label||||
33784257|NCT05909943|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695395|NCT01526122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695396|NCT03925064|||CASE_CONTROL||PROSPECTIVE|||||||
33695397|NCT06631755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695398|NCT00138177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695399|NCT04102956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695400|NCT06260098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695401|NCT06392971|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a prospective, single-center, randomized controlled clinical study. The present study intends to continuously enroll 120 patients with esophageal cancer who are to receive radiotherapy, and randomly divide the enrolled patients into two groups. One group receive treatment of deep-sea fish oil and the other group is blank control. The differences of ARIE occurrence, ARIE degree, pain degree, and the changes of the inflammatory index were compared.|t|t|t|t
33695402|NCT01404975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695403|NCT04259554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695404|NCT04287400|||COHORT||PROSPECTIVE|||||||
33695405|NCT00491231|||CASE_ONLY||PROSPECTIVE|||||||
33695406|NCT04736342|||CASE_ONLY||PROSPECTIVE|||||||
33695407|NCT01067976|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695408|NCT06312722|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, multi-center, post market clinical trial||||
33695409|NCT02517216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695410|NCT04802070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695411|NCT05288413|||OTHER||CROSS_SECTIONAL|||||||
33695412|NCT04622982|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label study||||
33695413|NCT01013298|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33695414|NCT05354505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695415|NCT03215979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695416|NCT04342234|||COHORT||PROSPECTIVE|||||||
33695417|NCT04704284|NA|SINGLE_GROUP||OTHER||NONE||||||
33695418|NCT02455882|||COHORT||PROSPECTIVE|||||||
33695419|NCT05276947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There will be an intervention group and a control group.||||
33695420|NCT03764085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will perform the assessment of primary, secondary efficasy and safety parameters||f|f|f|t
33695421|NCT03029130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918869|NCT04992039|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Equal number of participants will be recruited simultaneously in both group of control and intervention. After certain time period of intervention participants of both groups will be evaluated and the differences of outcome will be measured.|t|f|f|f
33918870|NCT01500928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918871|NCT00744016|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33918872|NCT05605483|||CASE_CONTROL||PROSPECTIVE|||||||
33918873|NCT01174953|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918874|NCT00280319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918875|NCT00822484|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33918876|NCT01956266|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, pretest postest behavioral treatment design||||
33918877|NCT02860754|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918878|NCT00857753|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918879|NCT05239377|||COHORT||PROSPECTIVE|||||||
33918880|NCT05940597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918881|NCT02581566|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918882|NCT00680160||||TREATMENT||NONE||||||
34088421|NCT04236778|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This Phase 1a/1b, first-in-human, open-label, single-center, dose-escalation study will evaluate the safety and microbiota changes induced by ingestion of VE303 following administration of oral vancomycin and VE303 administered without vancomycin pre-treatment in healthy adult subjects. Approximately 48 subjects are anticipated for enrollment, unless intermediate cohorts are required, in which case, up to an additional 18 subjects (for a total of approximately 66 subjects) may be enrolled.||||
34088422|NCT01155765|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33695422|NCT06410404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33695423|NCT01563211|||COHORT||PROSPECTIVE|||||||
33695424|NCT02103218|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695425|NCT04160481|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized, double-blind, placebo-controlled, cross-over|t|f|t|t
33695426|NCT05610514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33695427|NCT00662220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695428|NCT04385732|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The trial is an open-label, multi-site, parallel-arm randomised controlled trial. Participants meeting the eligibility criteria will be randomised 1:1 to either standard care or the intervention arm. Randomisation will be 1:1 to either Intervention or Control group stratified by high/ultra-high risk of 2nd primary melanoma, sex, 2D/3D imaging, GP/Dermatologist.||||
33784258|NCT03526120|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two parallel groups according a block randomization stratified on habitual energy intake and initial body weight (as in http://www.consort-statement.org/checklists/view/32--consort-2010/87-randomisation-type, § 8B). Randomisation: type).||||
33784259|NCT06714110|||COHORT||RETROSPECTIVE|||||||
33784260|NCT06712927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784261|NCT06356181|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784262|NCT06714292|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33918883|NCT01702662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918884|NCT05310513|||CASE_ONLY||RETROSPECTIVE|||||||
33918885|NCT06256029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918886|NCT06485986|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"Two groups of patients will be recruited:~* Parkinson's disease patients treated with deep brain stimulation and no impulse control disorder~* Parkinson's disease patients treated with deep brain stimulation and impulse control disorder (an increase in QUIP-RS after surgery)"|t|f|t|t
33918887|NCT03978624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918888|NCT01656317|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918889|NCT02451436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918890|NCT04888351|||COHORT||RETROSPECTIVE|||||||
33784263|NCT05676996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33784264|NCT06538181|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784265|NCT03956173|||CASE_CROSSOVER||PROSPECTIVE|||||||
33784266|NCT04427098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study consists of two parts:~* a phase II single-arm interventional prospective study including all patients treated with the study drug;~* an observational prospective cohort study including all patients screened for receiving the study drug but not included in the phase II study."||||
33784267|NCT06698367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Opaque sealed envelopes||f|f|t|t
33784268|NCT06714539|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33784269|NCT05199688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918891|NCT02480179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918892|NCT01506050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33918893|NCT02732340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918894|NCT05275621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918895|NCT01594294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33918896|NCT03213262|||CASE_ONLY||PROSPECTIVE|||||||
33918897|NCT04825119|||COHORT||PROSPECTIVE|||||||
33918898|NCT02217228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918899|NCT03506022|NA|SINGLE_GROUP||OTHER||NONE||All patients over 18 years with type 1 mellitus diabetes will be included. The exclusion criteria are type-free diabetes (type 1 slow), age \<18 years, a poor compliance with the follow-up (meetings unfulfilled without justification). All patients with known sleep disorders (OSA, narcolepsy, idiopathic hypersomnia).||||
33918900|NCT02769351|||CASE_ONLY||PROSPECTIVE|||||||
33918901|NCT05184309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded in enrollment and assessment process.||t|f|f|f
33918902|NCT06484426|||COHORT||PROSPECTIVE|||||||
33918903|NCT02589795|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33918904|NCT02246023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918905|NCT03670524|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A unique pragmatic interventional trial with longitudinal follow up to assess the cardiovascular effects of increasing residential greenery.||||
33918906|NCT06329999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918907|NCT03734952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918908|NCT04793854|||CASE_CONTROL||PROSPECTIVE|||||||
33918909|NCT04908917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once a participant is recruited, an identification number in a sequence number (001, 002, 003, etc.) will be assigned to him or her. A simple randomization will be performed by the unblind study Biostatistician with random block sizes of 4 and 6 to allocate recruited participants into the intervention group (N=100, 50% allocation rate, PAC use with HEPA filter) and control group (N=100, allocation rate 50%, PAC use without HEPA filter).|This study is designed as a randomized, double-blind, sham-controlled parallel limb clinical trial. Two-hundred participants will be recruited and randomly allocated into the intervention group (N=100) to use a PAC with a HEPA filter in the bedroom and the control group (N=100) with a sham PAC (no HEPA filter inside the container).|t|f|t|f
33918910|NCT00518921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33918911|NCT00939575|||CASE_CONTROL||PROSPECTIVE|||||||
33918912|NCT00611221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918913|NCT00344955|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33918914|NCT04583111|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33918915|NCT02795546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918916|NCT05907993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33918917|NCT03528889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are masked about which group they are randomized in|"Randomization into two study arms:~1. Classic control of extension and derotation using a Moeltgen goniometer intraoperatively~2. Control of extension and derotation using an electromagnetic tracking device intraoperatively"|t|f|f|f
33918918|NCT03696706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In the placebo group, the same procedures of the LED group will be made, but the device will be turned off. Participants will not know whether they are in the active or placebo group.~The investigator will not know to which group the participants belong, only the care provider."||t|f|t|f
33918919|NCT06244173|||CASE_CONTROL||RETROSPECTIVE|||||||
33918920|NCT02578823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088423|NCT00627107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33784270|NCT04485741|||COHORT||PROSPECTIVE|||||||
33784271|NCT01106287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695429|NCT05116358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Phase II - Masked (Sham Controlled) Single (Participant)|Phase II Interventional (Clinical Trial) Determine whether use of the light therapy device (versus sham device) results in changes to self-reported sleep quality, self-reported sleep continuity, objectively-estimated sleep continuity, and objectively-estimated sleep architecture. Additionally, to determine whether use of the light therapy device (versus placebo device) results in improvements in mood and daytime functioning .and induce improvements in mood, stress, morning energy levels, perceived daytime functioning, and fatigue levels.|t|f|f|f
33695430|NCT00122278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695431|NCT04832087|||COHORT||PROSPECTIVE|||||||
33695432|NCT00003548||||TREATMENT||||||||
33695433|NCT05816096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, controlled, crossover clinical study, comparison of ART and Hall Technique.||||
33695434|NCT00114387|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33695435|NCT02119169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695436|NCT01061983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695437|NCT02171572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695438|NCT05727462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked assessor will conduct the measurements|An assessor-blind randomized controlled trial lasting five weeks, with a six-month follow-up, will be conducted on 80 adult women with chronic neck pain and at least one trigger point in the upper trapezius muscle. Participants will be randomly allocated into two groups of 40 each (intervention and control). The intervention group will receive a combined treatment of manual techniques with two TECAR anti-static electrode bracelets, while the control group will follow the same protocol without the electrode bracelets. All participants will undergo a total of 15 treatments over the five-week period.|f|f|f|t
33695439|NCT05162859|||COHORT||RETROSPECTIVE|||||||
33695440|NCT05036369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study. The subjects and the evaluators will be blinded to the treatment allocated to each subject. Each site will assign an unblinded person that will handle all issues related to capsule administration and accountability. The unblinded person will not be involved in any subject's assessments. Rest of the site staff will remain blind throughout the study.|The objectives are to assess the efficacy and safety of Vibrant capsule administered twice a week|t|f|t|f
33695441|NCT01779115|||CASE_ONLY|||||||||
33695442|NCT00013468|||||PROSPECTIVE|||||||
33695443|NCT00474838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695444|NCT06130917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be kept blinded about the intervention which the patients will be going to receive.||t|f|f|t
33695445|NCT02026960|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33695446|NCT04268589|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33695447|NCT05910177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695448|NCT01906593|||ECOLOGIC_OR_COMMUNITY|||||||||
33695449|NCT00287651|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695450|NCT00210132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695451|NCT02164773|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33695452|NCT01155505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695453|NCT06008028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695454|NCT05986760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The SPARK is an evidence based plan designed to improve health-related well-being and to maintain the positive socialization and enjoyment of physical activities or academic achievements.(4) The SPARK discipline is in line with NASPE (National Association of Sport and PE) guidelines. A standard SPARK lesson will be delivered in two parts: a health fitness activity and a skill-fitness activity. In the health fitness activity part, there will be 13 activities that include aerobic dance, running games and jump ropes. In this part, the main focus will be on developing cardiovascular endurance and promotion by modifying the intensity, duration and complexity of the activities.||||
33695455|NCT05341934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695456|NCT03208595|||COHORT||PROSPECTIVE|||||||
33695457|NCT01782911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695458|NCT03500471|||COHORT||PROSPECTIVE|||||||
33695459|NCT02898155|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33695460|NCT05770869|NA|SINGLE_GROUP||OTHER||NONE||||||
33695461|NCT06680154|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33695462|NCT06708416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695463|NCT02273531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784272|NCT03720340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784273|NCT02416635|||COHORT||RETROSPECTIVE|||||||
33784274|NCT06711991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784275|NCT06713889|||COHORT||PROSPECTIVE|||||||
33918921|NCT01832012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33918922|NCT02302885|||COHORT||PROSPECTIVE|||||||
33918923|NCT04705441|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants will be randomized to either the intervention arm or waitlist arm for a period of 6 months. Participants receiving the intervention will participate in 8 web-based group sessions over Zoom led by a Nurse Educator and Peer Educator with epilepsy. The intervention will happen over 10-12 weeks and with virtual follow-up visits in both the intervention and the wait list groups. After month 6 follow-up visits have been completed (the primary study out evaluation), then the waitlist arm will start the SMART intervention and both the original SMART group and original waitlist group will be followed for an additional year.||||
33784276|NCT03342079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784277|NCT00354094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784278|NCT05066451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784279|NCT06668740|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33784280|NCT03097211|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33801533|NCT05229835|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Intervention studies|f|f|t|f
34088424|NCT05884619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088425|NCT02997540|||CASE_ONLY||PROSPECTIVE|||||||
34088426|NCT05871476|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34088427|NCT02682758|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34088428|NCT00282932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33918924|NCT06293664|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE||The research involves a double-blinded, randomized, placebo-controlled crossover study to assess the therapeutic potential of α-MSH infusion in T2DM patients.|t|t|t|t
33918925|NCT04136795|||COHORT||RETROSPECTIVE|||||||
33918926|NCT05123898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918927|NCT01680978||CROSSOVER||||DOUBLE|||t|f|t|f
33918928|NCT00003466||||TREATMENT||||||||
33918929|NCT00197652|||COHORT||PROSPECTIVE|||||||
33918930|NCT05298644|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||"Sequential Assignment:~1. st phase: Dose-finding part participants aged ≥5 to \<12 years~2. nd phase: Dose-finding part participants aged ≥2 to \<5 years~3. rd phase: Confirmatory Part participants aged ≥5 to \<12 years~4. th phase: Confirmatory Part participants aged ≥2 to \<5 years"|t|t|t|t
33918931|NCT06352242|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695464|NCT05391542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Sequence Generation: A computer random generator will be used to develop a simple randomization with an equal allocation ratio (1:1) and without stratification.~Allocation Concealment: This will be achieved using sequentially numbered, opaque and sealed envelopes which will be numbered according to the study numbers. Each envelope includes the treatment allocation card (group 1 or 2) and the related archwires.~Blinding As the study will be conducted in different clinics, all data collection and measurement will be completed with the investigator being masked to the allocation groups, though blinding of the operator will not be possible during the archwire placement."|"The patients will be treated with straight wire appliance using MBT prescription brackets with 0.022-inch slot (Pinnacle®, Ortho Technology, USA). Initially, teeth polishing will be performed with pumice and rubber cup, followed by water rinsing and air drying~Archwire sequence for each group will be as follows:~1. Coaxial tubular superelastic nickel-titanium Group (TuNT) (Speed tubular supercable, Speed System™ Orthodontics, Ontario, Canada):~   * 0.016-inch~  * 0.018-inch~2. Copper-nickel-titanium Group (CuNT) (Damon Optimal-Force Copper Ni-Ti®, Ormco, Glendora, Calif):~   * 0.014-inch~  * 0.018-inch Allocation Concealment: This will be achieved using sequentially numbered, opaque and sealed envelopes which will be numbered according to the study numbers. Each envelope includes the treatment allocation card (group 1 or 2) and the related archwires."|t|f|t|t
33918932|NCT05291416|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695465|NCT05231681|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|This is an open-label single-group, non-randomized, non-controlled interventional treatment study.||||
33695466|NCT04185870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will receive standard photographs and a 3D scan||||
33695467|NCT00093782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784281|NCT03813407|NA|SINGLE_GROUP||TREATMENT||NONE|All phases in the study are open-label|Treatment includes 3phases:CP,MP,LTMP Eligible participants with hyperkalaemia will enter CP receiving fixed dose of SZC three times daily(TID) for up to 3days until normokalaemia.Within each cohort 2 to\<18 years,initial participants will be allocated to dose level (DL)5g TID.After recommendation of higher DLs by iDMC,subsequent participants may be allocated in the CP to 10g TID and potentially 15g TID.Participants in 0 to\<2 years cohort will be assigned to the same DL decided based on data from older cohorts.Those who achieve normokalaemia in the CP will enter a 28-day MP,which starts with once daily administration of the dose received TID in the CP.During MP,the Investigator is able to titrate the dose up or down in the range 2.5gto15g body weight equivalent to maintain normokalaemia.For participants who,at the end of MP,are normokalaemic/hyperkalaemic without being on maximum dose,the MP is followed by option to continue in an LTMP where the same titration regimen is used as in MP.||||
33784282|NCT06628401|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784283|NCT04318444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784284|NCT06704945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784285|NCT05161494|||COHORT||PROSPECTIVE|||||||
33918933|NCT01478152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088429|NCT06222567|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33695468|NCT04634838|NA|SEQUENTIAL||TREATMENT||NONE||||||
33695469|NCT02494362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695470|NCT00353639|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695471|NCT01033461|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33695472|NCT02926560|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695473|NCT05330455|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a double-blind study|Parts 1 and Part 2B are crossover and Part 2A, Part 3 and Part 4 are parallel group|t|t|t|f
33784286|NCT02744508|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33784287|NCT06534983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784288|NCT00182416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801534|NCT01622400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801535|NCT03485898|||COHORT||PROSPECTIVE|||||||
33801536|NCT01676558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918934|NCT03101059|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33918935|NCT01831206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918936|NCT03019744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918937|NCT05866653|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33918938|NCT03695393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918939|NCT04768335|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33918940|NCT00131664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918941|NCT01608490|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group received standard of care and LVRC and the control group received only standard of care.||||
33918942|NCT00847756|||COHORT||PROSPECTIVE|||||||
33918943|NCT02350933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918944|NCT00762294|||CASE_ONLY||PROSPECTIVE|||||||
33918945|NCT03213977|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Open Label|||||
33918946|NCT01290445|||COHORT||PROSPECTIVE|||||||
33918947|NCT01208701|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34088430|NCT05608863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088431|NCT00646516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088432|NCT04311632|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34088433|NCT00259831|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33695474|NCT05633654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695475|NCT04663061|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33695476|NCT01425788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695477|NCT02562833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695478|NCT02434367|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33695479|NCT06681675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33695480|NCT05932784|||COHORT||PROSPECTIVE|||||||
33695481|NCT03004222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695482|NCT05635851|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33695483|NCT03956381|||COHORT||PROSPECTIVE|||||||
33695484|NCT05805930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695485|NCT05399303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695486|NCT06681181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators will be blinded not knowing which study intervention each participant will be assigned to and this will be maintained throughout the course of the study.||t|f|t|f
33695487|NCT01634763|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695488|NCT00986479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33695489|NCT04008238|NA|SINGLE_GROUP||SCREENING||NONE||||||
33695490|NCT04322981|RANDOMIZED|PARALLEL||TREATMENT||NONE||Screening, evaluation and treatment at an outpatient pharmacy compared to referral to hepatology clinics||||
33695491|NCT02979717|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33695492|NCT04766073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33695493|NCT06709820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33695494|NCT06058078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695495|NCT01863238|||COHORT||PROSPECTIVE|||||||
33695496|NCT04360590|||CASE_CROSSOVER||PROSPECTIVE|||||||
33695497|NCT03689673|||COHORT||PROSPECTIVE|||||||
33695498|NCT02666716|||CASE_ONLY||PROSPECTIVE|||||||
33695499|NCT01884623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695500|NCT05617443|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695501|NCT01962831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695502|NCT06680323|||COHORT||RETROSPECTIVE|||||||
33695503|NCT02069132|||COHORT||PROSPECTIVE|||||||
33695504|NCT05327959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695505|NCT01199731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784289|NCT05281471|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization (2:1) is either into the Experimental Arm which is Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab or into the Active Comparator Arm which is Physician's Choice of chemotherapy and bevacizumab.||||
33784290|NCT05767073|NA|SINGLE_GROUP||TREATMENT||NONE||Un controlled cohort study||||
33784291|NCT05905458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784292|NCT06508658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784293|NCT06015646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|One of the two principal investigators and researchers who analyze the data will be blinded to the group assignment.|The investigators will randomize the participants who have consented to participate in the study to intervention or control arms at the beginning of each of the 3-week study periods. Participants will wear a Fitbit watch for one week prior and one week after 3-4 night shifts. The baseline online survey will collect data on sex, training year, current satisfaction levels with lifestyle strategies, morning-evening chronotype, Sleep-related Impairment, and Task Load. During the nightshifts, the following outcome measures: psychomotor vigilance test, Stanford Sleepiness Scale, Task Load Index, and Noordsy-Dahle Subjective Experience Scale will be assessed during the window of circadian low (2 to 6 am) and at a time that is most convenient time for each participant. A final online survey will assess satisfaction levels with lifestyle strategies, Sleep-related Impairment, Task Load, and satisfaction and feedback about the program at the end of the study.|f|f|t|t
33784294|NCT03870945|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784295|NCT05346692|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784296|NCT01779375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784297|NCT04505709|||COHORT||PROSPECTIVE|||||||
33784298|NCT02741843||||HEALTH_SERVICES_RESEARCH||||||||
33784299|NCT01214902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784300|NCT03316456|||COHORT||PROSPECTIVE|||||||
33784301|NCT01040663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33784302|NCT03343171|||COHORT||PROSPECTIVE|||||||
33784303|NCT05345821|||COHORT||PROSPECTIVE|||||||
33695506|NCT01015053|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33695507|NCT00806338|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33695508|NCT02372370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695509|NCT01176331|||||RETROSPECTIVE|||||||
33695510|NCT06681337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695511|NCT05589272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33695512|NCT02832388|||COHORT||PROSPECTIVE|||||||
33695513|NCT06707714|||COHORT||PROSPECTIVE|||||||
33784304|NCT00000772||||TREATMENT||NONE||||||
33784305|NCT05586321|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784306|NCT06463171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784307|NCT02377206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784308|NCT06461741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33784309|NCT05278988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784310|NCT04181801|||CASE_ONLY||PROSPECTIVE|||||||
33784311|NCT06245226|||CASE_CONTROL||PROSPECTIVE|||||||
33695514|NCT02646254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33695515|NCT02611037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695516|NCT04521777|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33695517|NCT03950791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33695518|NCT04946461|||COHORT||PROSPECTIVE|||||||
33695519|NCT03439943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695520|NCT05220917|||COHORT||RETROSPECTIVE|||||||
33695521|NCT04450836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695522|NCT02514707|||COHORT||PROSPECTIVE|||||||
33695523|NCT01681017|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695524|NCT03246620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695525|NCT01570868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants enrolled before July 25, 2013 were given a starting dose of 45 mg per day. The study was amended and the dose was lowered due to tolerability. Participants enrolled after this date were given a starting dose of 30 mg per day.||||
33695526|NCT06707571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomly assigned to receive spinal anesthesia using the surface landmark-guided (landmark group) or preprocedural ultrasound-assisted (ultrasound group) technique using a computer-generated table of random numbers. Group allocation will be concealed by sequentially numbered, sealed opaque envelopes, which are opened only by the attending anesthesiologist immediately before the procedure.||t|t|t|t
33999204|NCT05548335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking. All subjects have same intervention.|There are no groups. All subjects will have the same inclusion criteria and will have the same intervention.||||
33695527|NCT00063323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695528|NCT05844397|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized contralateral study.||||
33999205|NCT03819088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999206|NCT06399445|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||factorial randomised controlled trial|t|f|f|f
33999207|NCT04168580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999208|NCT01720953|||CASE_CONTROL||PROSPECTIVE|||||||
33695529|NCT00200161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695530|NCT01607671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784312|NCT06615297|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784313|NCT04531540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784314|NCT02563600|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33784315|NCT06628531|||COHORT||PROSPECTIVE|||||||
33784316|NCT06714006|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Part A will be randomized, double-blind, placebo-controlled, Single Ascending Dose study.~Part B and Part C will be open-label study."|"The study comprises of 3 parts:~Part A (SAD - Healthy) will be conducted as a randomized, double-blind, placebo-controlled, SAD study to assess the safety, tolerability, PK, PD, and immunogenicity of PYC-003 in healthy adult participants. On Day 1, each participant will receive either PYC-003 or placebo, as a single intravenous infusion.~Part B (Control MRI - Healthy) will be conducted to qualify the local imaging vendor at each CRU participating in Part C and will enrol healthy participants who have not previously received the IP. The anticipated number of participants in Part B is approximately 1 participant per CRU participating in Part C. Part B participants will not receive the IP after study enrolment.~Part C will be conducted as an open-label SAD study to assess the safety, tolerability, PK, PD, and immunogenicity of PYC-003 in adult participants with confirmed PKD1 mutation-associated ADPKD. On Day 1, each participant will receive PYC-003 as a single IV infusion."|t|f|f|f
33784317|NCT04866407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784318|NCT00507611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784319|NCT01380119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784320|NCT03519451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784321|NCT06360640|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|This is a double-blind trial.|Placebo-controlled, 6 sequential cohorts.|t|f|t|f
33784322|NCT06032234|||COHORT||PROSPECTIVE|||||||
33784323|NCT06714227|||CASE_ONLY||PROSPECTIVE|||||||
33784324|NCT06614634|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Patients with coronary artery disease who met the inclusion criteria were allocated into hospital-based and tele-cardiac rehabilitation groups.|f|f|f|t
33784325|NCT04056221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both patients and investigators who will assess the outcomes have no knowledge of the interventions assigned to individual participants.|Sjogren syndrome's patients will be randomly assigned to either acupuncture (experimental group) at the selected acupoints (R6, E6,E2, Ig4, VC24, TA23, B2) or sham acupuncture (control group), where the needles do not penetrate the skin into non acupuncture points, for 8 weeks, 20 minutes sessions with 12 weeks of follow up.|t|f|t|t
33784326|NCT06104657|||CASE_ONLY||PROSPECTIVE|||||||
33784327|NCT01287156|||CASE_ONLY||PROSPECTIVE|||||||
33801537|NCT00639860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801538|NCT02168400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33801539|NCT02189915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801540|NCT02487069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801541|NCT00436631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801542|NCT04433975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33801543|NCT01921049|||COHORT||PROSPECTIVE|||||||
33918948|NCT00061919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695531|NCT06668181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918949|NCT00790101|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33918950|NCT04094766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33918951|NCT01353144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918952|NCT01499901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918953|NCT04306055|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33918954|NCT00295217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918955|NCT01929473|||COHORT||PROSPECTIVE|||||||
33918956|NCT04292379|||COHORT||PROSPECTIVE|||||||
33918957|NCT02058485|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33918958|NCT01703299|||COHORT||PROSPECTIVE|||||||
33918959|NCT03927053|||COHORT||PROSPECTIVE|||||||
33918960|NCT04024059|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33918961|NCT02806466|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33918962|NCT05165992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33918963|NCT03822871|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33918964|NCT05260229|||CASE_CONTROL||PROSPECTIVE|||||||
33918965|NCT03548974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33918966|NCT02853955|||COHORT||RETROSPECTIVE|||||||
33918967|NCT04208334|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33918968|NCT05643157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33918969|NCT00391378|||||OTHER|||||||
33918970|NCT01079429|||COHORT||PROSPECTIVE|||||||
33918971|NCT06350565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918972|NCT05608148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918973|NCT03264794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918974|NCT04965129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Parallel Assignment|t|t|t|t
33918975|NCT02114554|||CASE_ONLY||RETROSPECTIVE|||||||
33999209|NCT01497743|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33918976|NCT02930369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33918977|NCT05260892|||COHORT||PROSPECTIVE|||||||
33918978|NCT01360762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33918979|NCT01021514|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33918980|NCT03451500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All tablets will be identical in appearance. The Director of Research will be aware of treatment assignment. Patients, their Care Providers and all other study staff will be blinded to treatment.|Randomized, prospective, placebo controlled|t|t|f|t
33918981|NCT00645918|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33918982|NCT06089161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33918983|NCT05071352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999210|NCT03667963|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33999211|NCT05521919|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete one session of each condition: stress and no-stress. Participants will be randomly assigned to one of the two conditions for their first session. Participants will then be randomly assigned to the remaining condition for the second session.||||
33999212|NCT01887795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999213|NCT00674908|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33999214|NCT00804973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999215|NCT03680001|||COHORT||CROSS_SECTIONAL|||||||
34088434|NCT04272515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||BA patients and their parents will be enrolled in this study.||||
34088435|NCT04377659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088436|NCT00689741|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088437|NCT04285411|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Testing was conducted under normal office environment conditions. The VitalDetect™ pulse oximetry was placed on the right index finger of all subjects to evaluate the SpO2 and pulse rate accuracy performance during steady state non-motion conditions. A Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws and the real time oxygen saturation status. The subject was in a reclined position and connected to a breathing circuit, for administering medical grade oxygen and nitrogen. The gas flow delivery was adjusted for subject comfort. Arterial blood samples were drawn during simultaneous data collection from the control pulse oximeter and the test oximeters. The blood was immediately analyzed by Reference CO-Oximetry providing functional SpO2 for the basis of the SpO2 accuracy comparison. The pulse rate for the VitalDetect™ was compared to Reference ECG Heart Rate collected during the study.||||
34088438|NCT00715208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088439|NCT03922373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088440|NCT05759793|NA|SINGLE_GROUP||TREATMENT||NONE||"This study sampled the 3+3 dose-escalation design, and set up three dose-increasing dose groups of 0.5×10\^6 CAR-T/Kg, 1.0×10\^6 CAR-T/Kg, 2.0×10\^6 CAR-T/Kg, and subjects will receive a single infusion of CAR-GPRC5D/ single dose. Each dose group level will include 3-6 subjects, and the total number of subjects depends on increased dose levels. The estimated number of enrollment at this stage will be 9-18 cases in total. This study is to observe the characteristics of dose-limiting toxicity (DLT), pharmacokinetics, pharmacodynamics, and immunogenicity of CAR-GPRC5D in different dose groups. And to preliminarily observe the efficacy in small samples of patients with R/R MM or Plasma cell leukemia and confirm the recommended phase II dose (RP2D)."||||
34088441|NCT04796961|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34088442|NCT00529035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088443|NCT02965482|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34088444|NCT04186065|||OTHER||CROSS_SECTIONAL|||||||
34088445|NCT00870675|||CASE_ONLY||PROSPECTIVE|||||||
34088446|NCT02640209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088447|NCT01408641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695532|NCT00751010|||CASE_CONTROL||PROSPECTIVE|||||||
33918984|NCT00240539|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33918985|NCT04799184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Patients will be randomized into two groups, this will be done through a table of computer-generated random numbers.~Group I will receive ESP block with vasoconstrictor and Group II will receive ESP block without vasoconstrictor."|t|t|t|t
33918986|NCT04184115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|study is double-blinded placebo controlled for all treatment arms. All DPI-386 Nasal Gel and placebo nasal gel vials are opaque and indistinguishable. The DPI-386 Nasal Gel and placebo nasal gels are identical in color and viscosity, and without identifiable smell. Each placebo patch is similar in color and size as the TDS patch but does not deliver any medication or contain any excipients. A designated independent (unblinded) applicator will administer all patch application and removal, including an opaque waterproof bandage cover over the patch, to further prevent unblinding.||t|f|t|t
33918987|NCT03998917|||CASE_CONTROL||PROSPECTIVE|||||||
33918988|NCT05978687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33918989|NCT03102619|||OTHER||PROSPECTIVE|||||||
33918990|NCT05950347|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999216|NCT01958476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999217|NCT04744467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999218|NCT04763031|NA|SINGLE_GROUP||TREATMENT||NONE||Single 20 Gy (gray) dose of electronic brachytherapy (IORT)||||
33999219|NCT00754507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999220|NCT00425841||||TREATMENT||NONE||||||
33999221|NCT02664792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999222|NCT02331628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33918991|NCT05820620|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the patients are routinely put to sleep, TAP block will be applied to the 1st group, QLB block will be applied to the 2nd group, and no intervention will be performed to the 3rd group as it is the control group.||||
33918992|NCT06322524|||CASE_ONLY||PROSPECTIVE|||||||
33695533|NCT03436836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The enrolled patients were randomized according to computer-generated random number into two equal groups of twenty two patients each and concealed using sequentially numbered sealed opaque envelopes.~Patients of Group N received local anesthetics received 6 ml of 0.5% bupivacaine 1 ml hyaluronidase (75 IU) , and 4mg of Nalbuphine in 1 ml of saline (total 8 ml) and patients of Group C received 6 ml of 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and1 ml saline (total 8 ml)"|Forty-four patients were enrolled in the current study and randomly allocated into two equal groups \[Group N (n=22) and Group C (n=22)\]. Two patients in Group N and three patients in Group C were excluded from the study due to failure of the block to achieve satisfactory surgical condition (inadequate akinesia OMS\>2) so, received additional supplementations 2-3 ml of LA mixture and were excluded from the study|t|t|f|f
33695534|NCT05280210|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33695535|NCT00883987|||COHORT||PROSPECTIVE|||||||
33695536|NCT00950911|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33695537|NCT03707054|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||prospective trial||||
33695538|NCT03555435|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial with three groups: 1) Use of online problem-solving program on one's own. 2) Use of online problem-solving program with peer support. 3) Wait control group.||||
33918993|NCT06239506|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695539|NCT06169852|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants will be randomly assigned each of three different stimulation paradigms for 4 month intervals. Participants and researchers will be blinded to the stimulation paradigm used at any given point in the study.|We are investigating unilateral dual-target DBS. The stimulation paradigms utilized include STN DBS alone, GPi DBS alone, and combined STN/GPi DBS.|t|f|t|t
33695540|NCT04763174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695541|NCT00538564|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33695542|NCT00753428|||COHORT||CROSS_SECTIONAL|||||||
33695543|NCT06210581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695544|NCT06002490|NA|SINGLE_GROUP||TREATMENT||NONE||Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of P1101 (ropeginterferon alfa-2b) once every 2 weeks||||
33695545|NCT02764697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695546|NCT00690222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784328|NCT03970447|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"GBM AGILE is a multi-arm, platform trial. The evaluation of each therapy in GBM AGILE proceeds in 2 possible stages. A therapy's Stage 1 is an adaptively randomized Screening stage for evaluating the therapy within patient signatures compared against a common control. A therapy in Stage 1 will stop accruing patients if it reaches its maximal sample size, drops for futility, or evinces inadequate safety. If a therapy reaches an efficacy threshold for graduation from Stage 1, it will move into Stage 2 within one of the prospectively defined signatures. The maximum sample size in Stage 1 is 150 patients.~For a therapy graduating to Stage 2 there is a fixed randomization, expansion cohort. The maximum sample size in Stage 2 is 50 experimental patients in the graduating signature. The primary analysis of a regimen's effect on OS uses all patients in both its stages and all control patients in the trial in the graduating signature, suitably adjusted for any possible time trends."||||
33784329|NCT00689156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33918994|NCT05964764|||COHORT||PROSPECTIVE|||||||
33918995|NCT06261931|||COHORT||PROSPECTIVE|||||||
33918996|NCT04201977|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Evaluators will be blind to interventions.|The four interventions will be randomized.|f|f|f|t
33999223|NCT05579262|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33999224|NCT04220736|||CASE_CONTROL||RETROSPECTIVE|||||||
33999225|NCT01216254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999226|NCT03127241|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33999227|NCT00994604|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999228|NCT01732328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33999229|NCT03332264|RANDOMIZED|PARALLEL||TREATMENT||NONE|Corelab will be masked for the bare metal and paclitaxel coated stent arm.|Vessel patency will be compared by quantitative angiography at 12 months in patients who have been treated either with paclitaxel coated balloon catheter, paclitaxel coated stent or bare metal stent in femoropopliteal arteries||||
33999230|NCT02151149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999231|NCT06310395|||COHORT||RETROSPECTIVE|||||||
33999232|NCT06404463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695547|NCT00014404||||PREVENTION||||||||
33695548|NCT01598675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695549|NCT04056351|NA|SINGLE_GROUP||SCREENING||NONE||||||
33999233|NCT01202253|||COHORT||RETROSPECTIVE|||||||
33695550|NCT00749515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784330|NCT05413928|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33784331|NCT05603962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33784332|NCT03379415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the participant is blinded to the randomization|Testing meniscus patients for several different shoes|t|f|f|f
33784333|NCT06356272|||COHORT||PROSPECTIVE|||||||
33784334|NCT06652984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A blind physiotherapist will be in charge of the assessment of the outcomes of the study in all patients.|Randomized pretest-posttest parallel group design|f|f|f|t
33918997|NCT00457470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33918998|NCT03927638|||COHORT||CROSS_SECTIONAL|||||||
33918999|NCT04584658|||COHORT||PROSPECTIVE|||||||
33999234|NCT01395017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999235|NCT01374646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999236|NCT05356169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999237|NCT03621150|||CASE_ONLY||PROSPECTIVE|||||||
33999238|NCT05692791|||COHORT||PROSPECTIVE|||||||
33999239|NCT05951088|||COHORT||PROSPECTIVE|||||||
33695551|NCT06676995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695552|NCT01805778|||COHORT||PROSPECTIVE|||||||
33695553|NCT04771884|||COHORT||PROSPECTIVE|||||||
33695554|NCT06709755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695555|NCT05080907|||COHORT||PROSPECTIVE|||||||
33695556|NCT05558644|NA|SINGLE_GROUP||OTHER||NONE||||||
33695557|NCT00476359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695558|NCT05661214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|In this study, whole participants will be masked during the study. After study, researchers will encode the data different names and send to the statistician. Therefore, statistician will not know which group is control or intervention.|This study was designed with Solomon four groups design. There will be control group one, control group two, intervention group one and intervention group two.|t|f|f|t
33784335|NCT06711770|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33784336|NCT05867121|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784337|NCT04874610|||COHORT||PROSPECTIVE|||||||
33784338|NCT04680910|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pilot Study for safety and feasibility (open label)||||
33784339|NCT03514368|NA|SINGLE_GROUP||OTHER||NONE||||||
33784340|NCT05176353|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of this pilot trial the study will obtain an exemption from informed consent.|Implementation of a VAP diagnostic stewardship bundled intervention targeting ordering, collection and reporting results of respiratory cultures among mechanically-ventilated patients. Interventions will be implemented through a custom order set within the institutional electronic medical record in 2-month sequential intervals. Safety, ICU-specific antibiotic utilization rates and adherence to study interventions will be monitored.||||
33784341|NCT05610410|||COHORT||PROSPECTIVE|||||||
33784342|NCT05178394|NA|SINGLE_GROUP||OTHER||NONE||||||
33784343|NCT05422924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784344|NCT06401005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999240|NCT05702762|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter prospective open label randomized controlled study||||
33784345|NCT01071694|||COHORT||PROSPECTIVE|||||||
33919000|NCT04475822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999241|NCT01049282|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33999242|NCT04058977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Personnel performing outcomes will be blinded to study group||f|f|f|t
33999243|NCT04333134|NA|SINGLE_GROUP||TREATMENT||NONE||This study will enroll a single cohort of healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjects||||
33999244|NCT01875055|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33999245|NCT04702789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After signing the informed consent form (ICF), every subject will receive a coded patient number. Randomization will take place through and integrated web response system (IWRS). In the first step, during the eligibility visit, all patients will be assigned the same treatment (Gaap Ofteno PF®). After one month, patients that once again comply with the inclusion criteria will be assigned randomly (1:1) to one of the two investigation products, either Krytantek Ofteno PF® or Eliptic Ofteno PF®.|Randomized, double blind, multicenter with parallel groups.|t|f|t|f
33999246|NCT05407064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999247|NCT03008655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088448|NCT06440512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Τhe study does not use the method of blind evaluation due to the nature of the interventions, which are easily identifiable by the participants|This study employs a crossover design to investigate the effects of chocolate consumption on vascular function of endurance runners. Participants will undergo multiple treatment periods where they will receive either dark chocolate or white chocolate, followed by washout periods to minimize carryover effects. The order of treatment administration will be randomized to mitigate potential sequence effects. Outcome measures will be assessed at the end of each treatment period to evaluate the impact of chocolate consumption on vascular function, athletic performance and other relevant outcomes.||||
34088449|NCT05018793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919001|NCT01491555|||CASE_CONTROL||PROSPECTIVE|||||||
33919002|NCT04402853|||CASE_CROSSOVER||PROSPECTIVE|||||||
33919003|NCT04238884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919004|NCT01926847|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33919005|NCT01204541|||CASE_CONTROL||PROSPECTIVE|||||||
33919006|NCT02567214|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33695559|NCT05806723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919007|NCT05674201|||COHORT||OTHER|||||||
33695560|NCT04644991|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33695561|NCT06223035|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695562|NCT03839082|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919008|NCT01667393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919009|NCT02767453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919010|NCT06033846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919011|NCT00565058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919012|NCT05339386|||COHORT||PROSPECTIVE|||||||
33919013|NCT02858687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919014|NCT01621724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919015|NCT05107349|NA|SINGLE_GROUP||OTHER||NONE||||||
33919016|NCT01026389|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33919017|NCT02271867|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33919018|NCT05224154|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be told how they can earn back access to their applications but they will not be told whether this is considered the active or control condition.|Aim 1 will use small focus groups and feedback sessions (n = 4-6) to gain insight into the acceptability and usability of Re-Connect. Up to 3 single-case design studies (n = 4/round) will then be conducted to get more extended use of the app in a real world context to get additional information about usability and acceptability of the app. Aim 2 will involve a 2-group (AC vs SC), pilot randomized control trial to test the feasibility, acceptability, and preliminary efficacy of Re-Connect.|t|f|f|f
33919019|NCT01029808|||COHORT||CROSS_SECTIONAL|||||||
33919020|NCT01471860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999248|NCT05539794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment staff will be blinded to participant randomisation assignment. Yet, because of the nature of the study, it will not be possible to conceal the group assignment from the staff (i.e., fitness specialists, psycho-oncologists and nutritionists) involved in the different intervention (physical exercise and health counselling) sessions. Participants will be explicitly informed on the group to which they will be assigned as well as on the study hypotheses and will be reminded not to discuss their randomisation assignments with assessment staff and/or other patient.|The investigators will apply a two-arm RCT design, following the Consolidated Standards of Reporting Trials recommendations (1:1 randomisation ratio using a computer-generated random allocation sequence with a block on gender and main tumour type \[leukaemias/solid tumours\])|f|f|f|t
33999249|NCT01371617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999250|NCT03590119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study uses a with-in subject randomization between intra-arterial treatment via the left or right hepatic artery.|f|f|f|t
34088450|NCT04955756|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34088451|NCT00470548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695563|NCT04761822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the different dosing schedules for the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine, it will become apparent to both the site staff and study participant which vaccine has been assigned, once their second injection is scheduled. Participants and the staff will be unblinded (unmasked) during the follow-up call 3 days after the second injection when a third appointment (for those who received a placebo injection first) is, or is not (active vaccinations only) scheduled.||t|f|t|t
33695564|NCT01654861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695565|NCT06434818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695566|NCT03327597|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|Investigators and participants will be blinded to what participants are in the normal group and which participants are in arm 1 in the MGUS-group.||t|t|t|t
33695567|NCT02423772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695568|NCT06664827|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695569|NCT02089854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695570|NCT00251355|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695571|NCT00202176|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33695572|NCT06710587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open label, parallel-group, superiority randomised controlled trial||||
33695573|NCT04550169|||COHORT||PROSPECTIVE|||||||
33919021|NCT00280150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919022|NCT01701219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919023|NCT01830296|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33919024|NCT05193981|||COHORT||PROSPECTIVE|||||||
33919025|NCT01995279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33919026|NCT05150834|||COHORT||PROSPECTIVE|||||||
33919027|NCT01160653|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919028|NCT02977013|||CASE_ONLY||PROSPECTIVE|||||||
33919029|NCT00390247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919030|NCT03300752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33919031|NCT02215408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919032|NCT05363709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919033|NCT02028585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919034|NCT03082989|||COHORT||PROSPECTIVE|||||||
33919035|NCT01764256|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33919036|NCT01954251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919037|NCT00951938|||CASE_ONLY||PROSPECTIVE|||||||
33919038|NCT01158729|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33919039|NCT01458314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919040|NCT05265143|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||f|f|t|f
33919041|NCT00194025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919042|NCT04972916|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33919043|NCT02590887|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33919044|NCT04785391|||COHORT||PROSPECTIVE|||||||
33919045|NCT06553638|||CASE_ONLY||PROSPECTIVE|||||||
33999251|NCT03513549|||COHORT||PROSPECTIVE|||||||
33999252|NCT05191238|NA|SINGLE_GROUP||OTHER||NONE||||||
33999253|NCT01121744|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919046|NCT04944329|||COHORT||RETROSPECTIVE|||||||
33919047|NCT01660139|||OTHER||PROSPECTIVE|||||||
33919048|NCT02665364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919049|NCT04284943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919050|NCT03179436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919051|NCT00943488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33919052|NCT04791267|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The ENCOMPASS study will evaluate the effectiveness of a community health navigator program using a two-armed, pragmatic, randomized waitlist-controlled trial. The intervention arm will receive the CHN program for six months. The waitlist control arm will have a six month waiting period followed by six months of CHN program. This study will employ patient-level block randomization. Research staff will be blinded to block size. In the case where participants live together in the same residence, they will be randomly assigned to the same study arm.||||
33919053|NCT06512025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A CONSORT-compliant parallel group randomized controlled trial will be conducted|f|f|f|t
33999254|NCT00156182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999255|NCT01659073|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999256|NCT03122522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999257|NCT03161197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Dialysis patients will receive the intervention individually while on dialysis. Dialysis is an optimal time for conducting interventions as patients are there for 3-4 hours every 3 days. For 8-10 weeks (which will begin the week after the baseline interview). Chronic Kidney Disease (CKD) patients will receive the intervention in group setting. Since CKD patients only come to see their nephrologist once a month, all CKD potential participants will be invited to attend eight consecutive weekly sessions.||||
33999258|NCT01881763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999259|NCT03867916|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33919054|NCT01305213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919055|NCT03532984|||COHORT||PROSPECTIVE|||||||
33919056|NCT02027168|||CASE_ONLY||PROSPECTIVE|||||||
33919057|NCT03400137|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33919058|NCT05696262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33919059|NCT05628025|||COHORT||PROSPECTIVE|||||||
33919060|NCT06382363|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33919061|NCT02435550|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919062|NCT02937532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33919063|NCT02475395|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919064|NCT00002392||||TREATMENT||||||||
33919065|NCT01995136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919066|NCT01016691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919067|NCT00889993|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33919068|NCT03205306|||COHORT||RETROSPECTIVE|||||||
33919069|NCT04699071|NA|SINGLE_GROUP||TREATMENT||NONE||combination therapy of continuous daily oral lenvatinib with three-weekly intravenous pembrolizumab in patients with recurrent clear cell carcinoma of gynecological origin (CCGC).||||
33919070|NCT01431144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919071|NCT04752124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695574|NCT04204122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The eyes of each enrolled participant will be randomized such that one eye is treated with Vigamox and the other eye is treated with a placebo eye drop.|t|t|t|f
33919072|NCT00796133|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33919073|NCT03385382|||OTHER||OTHER|||||||
33919074|NCT04426370|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919075|NCT03968614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919076|NCT01767870|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919077|NCT03102320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919078|NCT04603391|RANDOMIZED|CROSSOVER||OTHER||SINGLE||An open-label, randomized crossover design is proposed wherein healthy volunteer subjects (n=12) would receive a single dose of immediate-release dl-methylphenidate (Ritalin®) concomitantly with orally administered CBD (Epidiolex®) solution or an equal volume of Epidiolex® placebo solution (i.e vehicle with no CBD) which have been dosed to plasma steady-state conditions.|t|f|f|f
33695575|NCT01008150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695576|NCT04343300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33695577|NCT00443027|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33695578|NCT05724225|||COHORT||PROSPECTIVE|||||||
33695579|NCT05821426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695580|NCT02518412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695581|NCT01667692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33695582|NCT03364894|||COHORT||PROSPECTIVE|||||||
33695583|NCT01451580|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33695584|NCT01331733|||COHORT||PROSPECTIVE|||||||
33695585|NCT05263596|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33695586|NCT02787460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695587|NCT00877201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33695588|NCT04996641|NA|SINGLE_GROUP||TREATMENT||NONE||This study involves a modified, expedited tooth restoration procedure for individuals scheduled to undergo radiation therapy for head and neck cancer.||||
33919079|NCT06251219|||CASE_ONLY||PROSPECTIVE|||||||
33919080|NCT05202769|||CASE_ONLY||PROSPECTIVE|||||||
33919081|NCT04084626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919082|NCT02595047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919083|NCT01240655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919084|NCT02469792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088452|NCT01719328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088453|NCT04861298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088454|NCT02049203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33919085|NCT04172753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919086|NCT05517330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919087|NCT01193140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919088|NCT06209814|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33919089|NCT03543358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919090|NCT02679209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919091|NCT00542724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919092|NCT01795586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919093|NCT00470652|||||PROSPECTIVE|||||||
33919094|NCT00326417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695589|NCT06356090|NA|SINGLE_GROUP||TREATMENT||NONE||Single case experimental design (SCED) with multiple baselines||||
33695590|NCT00567593|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695591|NCT06143800|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33695592|NCT06665906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33695593|NCT01907100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33695594|NCT06589661|||COHORT||PROSPECTIVE|||||||
33695595|NCT04483167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||7 healthy volunteers (1+3+3) and 6 asymptomatic patients||||
33695596|NCT01088737|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33801544|NCT06545565|RANDOMIZED|PARALLEL||OTHER||NONE||"Infants who will meet the inclusion criteria and whose parents will consent to participate will be randomized to one of the two intervention groups (So-A, or the standard So-C) prior to the preparation and commencement of PN. Randomization will be performed by pharmacists at the Sterile Preparation/Parenteral Unit of AKU hospital upon enrolment of each case. The randomization process will be performed according to a computer-generated list. For multiple births, each infant will be individually randomized.~The interventional group: This group will receive sodium acetate in the neonatal PN.~Control Group: The control group will receive sodium chloride in the neonatal PN.~Intervention of the study: Use of sodium acetate in neonatal PN."||||
33801545|NCT01003405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801546|NCT00092300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919095|NCT01898364|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695597|NCT05291026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants knew neither the identity nor the group placement of other participants. The clinicians who provided care for the participants did not know the identity or the group placement of the participants. Investigators/ Outcome assessors were not among the care givers and did not interface physically with either caregivers or study participants.|All newly-diagnosed type 2 diabetes patients within the one month period following the retrospective document review, were enrolled, provided they gave their informed consent. Study participants were randomly assigned to either of two equal-sized control and intervention cohorts. The Randomizer App software was used to assign participants to the control and intervention groups. The control group received standard of care only. The intervention group received the standard of care in addition to the mobile phone-based health education and follow-up messaging at the frequency of once daily for 6 months.|t|t|f|f
33695598|NCT05985005|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33695599|NCT03585348|||COHORT||RETROSPECTIVE|||||||
33695600|NCT00530101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695601|NCT01672073|||CASE_ONLY||PROSPECTIVE|||||||
33784346|NCT05555485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The placement of either active or sham tAN device will be done by dedicated and unblinded study personnel. These study personnel will administer active tAN or sham tAN stimulation and have no additional involvement with participants or data collection. No other study staff members at UTMB who interact with participants or collect data will know which type of stimulation the participants received. Participants will additionally remain unaware (e.g., masked) of which type of tAN they are receiving until after study completion.~Active or sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal)."|All participants will be randomized to one of two arms (active tAN vs. sham tAN) in a 1:1 fashion such that each arm will have 20 participants with complete data. A block randomization procedure will be utilized to ensure that equal numbers of participants are assigned to each of the two conditions.|t|t|t|t
33784347|NCT06706505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In randomized controlled trials, it is crucial for groups to be equal and balanced in terms of baseline characteristics. To achieve this, simple stratified randomization based on gender was used to assign nurses to the intervention and control groups. To prevent bias, both researchers and participants were blinded to group assignments until after randomization. Due to the study's nature, blinding the researcher administering the intervention and participants was not feasible. However, a pre-test was administered before randomization. A blind technique was applied with the help of an independent statistician. Participants were randomly assigned using a number generator, and a third party conducted a coin flip to determine group assignments. The data will be coded by a nursing expert to ensure the statistician remains unaware during analysis. Group codes will be revealed after data analysis to minimize bias.|pre-test post-test follow-up and control group experimental study|f|f|f|t
33784348|NCT02513433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33784349|NCT06714370|||COHORT||OTHER|||||||
33784350|NCT05879926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784351|NCT05507697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784352|NCT00274989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784353|NCT06714188|||COHORT||PROSPECTIVE|||||||
33999260|NCT05562037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome measures will be obtained by a blinded research assistant over the phone within 1 week of completing the 8 week rehabilitation program|The planned research is to improve enrollment, adherence and completion of CR and PR using stepped care (SC). The proposed SC model enables a patient-centered approach by matching intensity of treatment with individual patient needs.|f|f|f|t
33784354|NCT06355817|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant and surgeon was not made aware of which intervention the participant would receive first until the time of the procedure. Randomization was made at the time of the procedure.|Each patient will receive both interventions and serve as their own comparator.|t|t|f|f
33784355|NCT06712264|||OTHER||PROSPECTIVE|||||||
33784356|NCT05468333|NA|SINGLE_GROUP||OTHER||NONE||||||
33784357|NCT04952272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784358|NCT06612554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784359|NCT03381794|||COHORT||OTHER|||||||
33784360|NCT05379868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed of chosen treatment|Randomized clinical trial|t|f|f|f
33784361|NCT06478199|||CASE_CONTROL||PROSPECTIVE|||||||
33784362|NCT03387917|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The trial uses an accelerated titration design (ATD) up to the occurrence of the first DLT, followed by a modified continual reassessment method (mCRM) for dose escalation part and randomized cross-over design for the comparative PK part||||
33784363|NCT04910347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784364|NCT04624230|NA|SEQUENTIAL||TREATMENT||NONE||Single Group||||
33784365|NCT06702839|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784366|NCT03698136|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated measurement interventional Single Subject Design||||
33784367|NCT06268301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999261|NCT00001191||||TREATMENT||||||||
33695602|NCT06412575|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was a parallel, open-label randomized trial that aimed to assess safety and efficiency of JNT and TNT to guided OGT-overlap oesophagojejunostomy. Gastric/gastroesophageal junction (G/GEJ) cancer patients who underwent LTG with OGT-overlap oesophagojejunostomy||||
33695603|NCT00792077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695604|NCT00501579|RANDOMIZED|PARALLEL||||DOUBLE||||||
33784368|NCT06624059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784369|NCT06125028|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33784370|NCT02392338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784371|NCT01546571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784372|NCT01066260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801547|NCT04914494|||COHORT||RETROSPECTIVE|||||||
33801548|NCT00273624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999262|NCT03610607|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33999263|NCT05389813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33695605|NCT05067673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind randomized clinical trial in parallel groups||t|f|t|f
33695606|NCT04449861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695607|NCT00503516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784373|NCT06316297|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Sponsor study staff involved in early safety data reviews (ESDRs) will be unblinded at the time of the ESDR|Sequential and parallel design|t|f|t|t
34088455|NCT05211700|||COHORT||CROSS_SECTIONAL|||||||
33784374|NCT06384131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)||t|t|t|f
33695608|NCT06182280|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Blinding will occur at the statistician and investigator levels, but is not possible for participants or staff in the intervention. Participants will be followed for 18 months.|The 2x2 factorial design has two actors: individualized, one-on-one peer navigation (PrEP4T vs none) and group-based behavioral intervention (LS4TM vs none). The comparator is standard-of-care information and resources on HIV prevention and linkage to care.|f|f|t|t
33695609|NCT03246984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695610|NCT01057823|||COHORT||CROSS_SECTIONAL|||||||
33695611|NCT01442038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695612|NCT05886218|||OTHER||PROSPECTIVE|||||||
33784375|NCT01709292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784376|NCT01149603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784377|NCT06435312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784378|NCT00541632|||||PROSPECTIVE|||||||
33784379|NCT04749693|||COHORT||PROSPECTIVE|||||||
33784380|NCT06712212|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33784381|NCT06707220|||COHORT||PROSPECTIVE|||||||
33784382|NCT06711965|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33784383|NCT06687460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784384|NCT06641076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784385|NCT04268264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784386|NCT06713044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant|"This is a randomized, controlled trial with a parallel assignment study design. Participants will be randomly allocated to one of three groups:~Murottal Group: Participants will listen to selected Islamic recitations (murottal) as a therapeutic intervention during their postoperative recovery.~Classical Music Group: Participants will listen to selected classical music pieces to evaluate its impact on postoperative pain and inflammation.~Standard Care Group: Participants will receive standard postoperative care without any additional therapeutic interventions.~The goal is to assess and compare the effectiveness of murottal and classical music in reducing postoperative pain intensity and inflammation (measured by interleukin 6 levels), compared to the standard care. Randomization ensures unbiased distribution among the groups, and the parallel design enables simultaneous assessment of the interventions' effects in different groups."|t|f|f|f
33919096|NCT01084642|||COHORT||PROSPECTIVE|||||||
33919097|NCT03303040|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a within subjects design. One side of each subject's diaphragm will be stimulated. The other side of the subject's diaphragm will not be stimulated and will therefore serve as the control. Biopsies will be taken from both sides and compared.||||
33919098|NCT06070740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919099|NCT04295200|NA|SINGLE_GROUP||TREATMENT||NONE||single group pre-test/post-test study design||||
33919100|NCT02616016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919101|NCT06061042|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919102|NCT05125107|||CASE_CONTROL||PROSPECTIVE|||||||
33695613|NCT06359990|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33695614|NCT04996797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919103|NCT01806636|||COHORT||PROSPECTIVE|||||||
33919104|NCT05522088|||COHORT||PROSPECTIVE|||||||
33919105|NCT01017809|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919106|NCT03130478|||COHORT||RETROSPECTIVE|||||||
33919107|NCT02065596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919108|NCT04658472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919109|NCT05486013|||COHORT||PROSPECTIVE|||||||
33919110|NCT03454412|||CASE_ONLY||PROSPECTIVE|||||||
33919111|NCT04015414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33919112|NCT06069011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33919113|NCT00178048|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33919114|NCT05723315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34088456|NCT04853485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088457|NCT00954876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088458|NCT01806129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33695615|NCT04407260|||COHORT||PROSPECTIVE|||||||
33695616|NCT04866329|||COHORT||PROSPECTIVE|||||||
33695617|NCT02024282|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33695618|NCT04648709|||COHORT||PROSPECTIVE|||||||
33695619|NCT01052844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695620|NCT06680284|||COHORT||PROSPECTIVE|||||||
33695621|NCT05010408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Same packaging for all (cans). Color and flavor matched.||t|t|t|t
33695622|NCT05868473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695623|NCT00497276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695624|NCT00275327|||||RETROSPECTIVE|||||||
33695625|NCT06709651|||COHORT||PROSPECTIVE|||||||
33695626|NCT06709586|||COHORT||PROSPECTIVE|||||||
33695627|NCT04281641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695628|NCT02908867|||||CROSS_SECTIONAL|||||||
33695629|NCT03793868|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Matching placebo|This is a pilot study for the assessment of transcranial magnetic stimulation as a biomarker for ALS and to obtain information to guide a dose selection for future biomarker driven Phase 2 studies of Perampanel in ALS.|t|t|t|t
33695630|NCT05232981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients only will be masked||t|f|f|f
33695631|NCT00993161|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695632|NCT01841307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695633|NCT05774275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695634|NCT04960800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure randomization to the two groups in the RCT, participants will, following baseline assessments, be allocated to the two groups by block randomization. Blocking will be masked and not stated in the protocol to avoid selection bias. The group allocation will be administrated by a research assistant, to ensure blinding of the assessor. This study is assessor blinded only, as participants and the physiotherapist running the intervention groups cannot be blinded.|This will be an exploratory, assessor blinded, randomized, controlled, parallel group trial|f|f|t|t
33695635|NCT05921747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants consented to participate will be assigned a unique number. The detailed list will be kept confidentially under the custody of the Principal Investigator. Unique numbered envelop will be provided to the participant. The participant will tell his number to the receptionist. The receptionist will send the participant to treatment room according to randomly allocation list. An outcome assessor will fill the form after treatment.|After selecting the desired sample size (tentative 17) the subjects will be randomly allocated to the both treatment groups|t|f|f|t
33695636|NCT00760214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695637|NCT03720834|||COHORT||PROSPECTIVE|||||||
33695638|NCT05936281|RANDOMIZED|PARALLEL||TREATMENT||NONE||Acute gout patients initiating urico-lowering therapy Group A: Genakumab 100mg single injection; Group B: Genakumab 200mg single injection;Group C: Colchicine 0.5mg qd po.for 12 weeks||||
33695639|NCT03964116|NA|SINGLE_GROUP||OTHER||NONE||||||
33695640|NCT05266716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695641|NCT00068783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695642|NCT00446342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695643|NCT06681415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695644|NCT03346044|RANDOMIZED|PARALLEL||TREATMENT||NONE||A comparative single centre study of two porcine bioprostheses indicated for the surgical treatment of heart valve diseases. The study will compare two equal sized patient groups using either the Medtronic Mosaic and Carpentier-Edwards SAV bioprostheses.||||
33784387|NCT02467582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801549|NCT02590341|||COHORT||PROSPECTIVE|||||||
33919115|NCT06027073|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The randomization procedure with random selection will rely on computer-generated numbers using a computer program (Excel, version 14.2.0, 2020 Microsoft Corporation). The patients will be randomized into four groups 1:1:1:1 as follows:~Group A: Xolair® Group B: Actair® Group C: Actair® and Xolair® Group D: Standard of Care (no interventional therapy)."||||
33919116|NCT04385615|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group will receive the FMD diet. The other group will be the control.||||
33919117|NCT04113447|||OTHER||PROSPECTIVE|||||||
33919118|NCT01196650|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33919119|NCT01644942|NON_RANDOMIZED|PARALLEL||||NONE||||||
33919120|NCT03182465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919121|NCT06098196|||COHORT||PROSPECTIVE|||||||
33919122|NCT06241287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to blind the individual participants in this trial, but the individuals who will be analysing data or overseeing trial including health economists, co- investigators and trial statistician will remain blind until the blinded analysis detailed in the Statistical Analysis Plan has been conducted and reported to the trial team. The exception will be one of the co-investigators leading the process analysis.Unblinding will be performed following procedures outlined in NWORTH SOPs.||f|f|f|t
33919123|NCT02661841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919124|NCT02322684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33919125|NCT04722484|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919126|NCT03798249|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||single-blinded, randomised - controlled, crossover|t|f|f|f
33919127|NCT02721251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33919128|NCT01967524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784388|NCT03621553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Groups separated by a) use / non-use of oral prednisone, and b) status of serum 25-hydroxy-vitamin-D level (sufficient or insufficient). Those who are vitamin-D insufficient will be randomized to receive either vitamin D2 or placebo.|Vitamin-D insufficient subjects will receive either vitamin D2 repletion or placebo Vitamin-D sufficient subjects will be observed without treatment.|t|t|t|f
33919129|NCT05429229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Clinical trial phase 2 A.|f|f|t|t
33919130|NCT04966195|NA|SINGLE_GROUP||TREATMENT||NONE||stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis||||
33784389|NCT02360345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919131|NCT01690689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919132|NCT02245451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919133|NCT06096285|||COHORT||PROSPECTIVE|||||||
33919134|NCT06097767|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919135|NCT05136378|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919136|NCT02292992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919137|NCT01479894|||COHORT||RETROSPECTIVE|||||||
33919138|NCT01949727|||COHORT||PROSPECTIVE|||||||
33919139|NCT03059719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999264|NCT03454737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999265|NCT01813864|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33999266|NCT00755235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33999267|NCT01816360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33999268|NCT04097041|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Surgery arm - patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb). Patient has routine follow up - H\&P, 2 weeks after surgery and then H\&P, Audiometry and Tympanometry over 12 months post surgery (3rd month, 6th month and 12th month). Non surgery arm - patient has audiological consult and fitting of masking device.~The Patient has a routine follow up - H\&P, 2 weeks after masking fitting and then H\&P, Audiometry, Tympanometry over 12 months (3rd month, 6th month and 12th month). Patient cross over to change arms, at 6 months, if they have no resolution of symptoms."||||
33999269|NCT03893617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33999270|NCT01499043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999271|NCT04686435|||COHORT||PROSPECTIVE|||||||
33999272|NCT04714060|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33999273|NCT02722798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999274|NCT02726841|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999275|NCT04013763|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999276|NCT03113396|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33999277|NCT02671058|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088459|NCT01420744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088460|NCT02741778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088461|NCT01694134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088462|NCT05830747|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34088463|NCT00480714|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34103093|NCT03881878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"(A, Neoadjuvant setting): TAHP (Docetaxel, Atezolizumab, Trastuzumab sc and Pertuzumab) D1 X 6 cycles q3weeks, intravenous(IV) administration~(B, Adjuvant setting) : patients with pCR: AHP(Atezolizumab, Trastuzumab sc and Pertuzumab) D1 X 11-12 cycles q3weeks~patients with non-pCR: Doxorubicin plus cyclophosphamide: D1 X 4cycles q3weeks followed by AHP (Atezolizumab, Trastuzumab sc and Pertuzumab) D1 X 11-12 cycles q3weeks"||||
34103094|NCT03228043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33695645|NCT04317976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participant will not be informed of their anatomical details. Care provider will not be informed of their accuracy of performance of the airway manoeuvre.|The study is a case-control intervention study, where all and every participant will be both the case and the control of their own.|t|t|f|f
33695646|NCT05563844|NON_RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33695647|NCT05830903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33695648|NCT00116428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695649|NCT03511118|||OTHER||PROSPECTIVE|||||||
33695650|NCT03432312|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33695651|NCT00234390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33784390|NCT06534463|||COHORT||PROSPECTIVE|||||||
33784391|NCT02741479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33695652|NCT00674076|||CASE_CONTROL||PROSPECTIVE|||||||
33784392|NCT04327037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695653|NCT02614651|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695654|NCT02606474|||CASE_CONTROL||PROSPECTIVE|||||||
33801550|NCT01370343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33919140|NCT04203563|RANDOMIZED|PARALLEL||PREVENTION||NONE|Randomization to arm follows the baseline assessment visit.|"Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks.~Group 2 participants receive twice weekly progressive strength training classes in January 2020 for 12 weeks. During the first 12 weeks of the study Group 2 participants do not receive these classes. (Delayed)"||||
33919141|NCT03565848|||COHORT||PROSPECTIVE|||||||
33999278|NCT06103383|NA|SINGLE_GROUP||OTHER||NONE||Prospective, observational, single-center, prospective cohort pilot study||||
33999279|NCT05654363|||CASE_CONTROL||RETROSPECTIVE|||||||
33999280|NCT02812381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695655|NCT04332380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801551|NCT01227265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695656|NCT00136331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33695657|NCT02939079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695658|NCT02639156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695659|NCT05646940|||CASE_CONTROL||PROSPECTIVE|||||||
33695660|NCT05650242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784393|NCT03199469|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||ASPIRO was being conducted in two parts. Part 1 was a dose escalation phase that was evaluating the preliminary safety and efficacy of resamirigene bilparvovec at doses of 1.3x10\^14 vg/kg and 3.5x10\^14 vg/kg. Part 2 of ASPIRO was a pivotal expansion cohort designed to confirm the safety and efficacy of resamirigene bilparvovec at a dose of 3.5x10\^14 vg/kg. The pivotal expansion cohort enrolled eight subjects, consisting of four age-matched pairs (within +/- 6 months of age). One subject from each pair was randomized to receive a single dose of resamirigene bilparvovec at 3.5x10\^14 vg/kg, and the other served as a delayed treatment control. Eligible delayed treatment control subjects administered resamirigene bilparvovec after that individual subject completed the Week 24 visit as a delayed treatment control.||||
34103095|NCT06686303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784394|NCT04736056|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34103096|NCT06196879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103097|NCT02062346|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33784395|NCT06712576|||COHORT||PROSPECTIVE|||||||
33784396|NCT04401436|||COHORT||PROSPECTIVE|||||||
33784397|NCT05995782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784398|NCT00358306|||COHORT||CROSS_SECTIONAL|||||||
33784399|NCT06636253|||COHORT||PROSPECTIVE|||||||
33919142|NCT03140995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At baseline assessment demographic information and outcome measures will be collected by a physiotherapist not involved in the intervention and will be blinded to which arm the participant has been allocated to. This will all take place at the Department of Clinical Therapies, University of Limerick.|Single centre, single blinded pilot randomised controlled trial, comparing an aerobic intermittent exercise training intervention (walking programme) against verbal and written instructions regarding the benefits of exercise in RA.|f|f|f|t
33919143|NCT06018610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919144|NCT02000453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919145|NCT06076200|||COHORT||PROSPECTIVE|||||||
33919146|NCT01670656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919147|NCT03013244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919148|NCT04248790|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919149|NCT00151749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919150|NCT04172909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There will be two experimental groups including the LEGO Bricks group, and the Mock MRI tube group, as well as a retrospective age matched control group.|f|f|t|f
33919151|NCT03983928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919152|NCT02483104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919153|NCT04043403|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will have either the Percept PC system, or Summit RC+S system from Medtronic PLC implanted.|t|f|f|t
33919154|NCT05685888|||CASE_CONTROL||RETROSPECTIVE|||||||
33919155|NCT01807195|||CASE_ONLY||RETROSPECTIVE|||||||
33919156|NCT01248494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919157|NCT04686019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|External assessor unknown to the participants of the intervention group and control group||f|f|f|t
33919158|NCT04223024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919159|NCT02066753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919160|NCT00757926|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33919161|NCT05949606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919162|NCT01231360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919163|NCT00274872|RANDOMIZED|||TREATMENT||NONE||||||
33919164|NCT03466021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective, randomized, placebo-controlled, double-blinded, parallel group and two-center trial.|t|f|t|f
33919165|NCT04578106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919166|NCT05342467|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison between intravaginal gemeprost and dinoprostone.||||
33919167|NCT05283863|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||All subjects underwent two weeks of conventional stimulation, followed by randomization to receive either subthreshold high-density (HD) or sham stimulation; this was followed by a crossover during which the participants who had received subthreshold HD stimulation were treated with sham and vice versa.|t|t|f|t
33919168|NCT02026206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919169|NCT02001597|||COHORT||PROSPECTIVE|||||||
33919170|NCT01595659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33919171|NCT05943067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919172|NCT03441568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919173|NCT04485091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919174|NCT01750944|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919175|NCT03255993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919176|NCT04413721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919177|NCT00824928|||CASE_ONLY||PROSPECTIVE|||||||
33919178|NCT00071422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919179|NCT02819505|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33919180|NCT03230747|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33919181|NCT05861804|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695661|NCT04996381|||COHORT||PROSPECTIVE|||||||
33999281|NCT03675815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695662|NCT02269046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784400|NCT05754333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695663|NCT06705218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33695664|NCT00121264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695665|NCT02476422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999282|NCT01045044|||COHORT||PROSPECTIVE|||||||
33695666|NCT04578678|||COHORT||PROSPECTIVE|||||||
33695667|NCT06588218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33695668|NCT03491306|RANDOMIZED|PARALLEL||OTHER||TRIPLE||2 parallel groups one group will receive RPD with PEEK denture base and the other will get Bre Flex denture base material|t|t|f|t
33999283|NCT03161236|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33999284|NCT06315387|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33999285|NCT03081624|||CASE_CONTROL||PROSPECTIVE|||||||
33999286|NCT04194333|||COHORT||PROSPECTIVE|||||||
33999287|NCT06249776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999288|NCT06383130|||OTHER||PROSPECTIVE|||||||
33999289|NCT05995054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999290|NCT00383058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999291|NCT05373043|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Aim 2 will be a double blind placebo controlled design.|"Aim 1: Participants will be either long-COVID (n=40), COVID recovered (n=40), or Controls who never had COVID (n=40) and testing will take place at baseline, months 3 and 6, and every 6 months thereafter until the end of year 4. Peripheral and cerebral vascular endothelial function, along with neurocognitive testing, pulmonary function, physical function, and quality of life, will be assessed at baseline, months 3 and 6, and then every 6 months for four years.~Aim 2: Participants will be either long-COVID (n=60), COVID-recovered (n=60), or Controls who avoided COVID (n=60) as defined in Aim 1. Participants will be assigned to the Exercise+Placebo or Exercise+Mito-Q rehabilitation interventions using block randomization (block size 10). This will provide equal sample sizes (n=30) per intervention for each group."|t|f|t|f
33999292|NCT02779933|||COHORT||RETROSPECTIVE|||||||
33999293|NCT06209255|||CASE_ONLY||RETROSPECTIVE|||||||
33999294|NCT04083326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The group allocation is masked for the surgeon and for the outcome assessors||f|t|t|t
33999295|NCT01072162|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33999296|NCT00487695|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33999297|NCT00943033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999298|NCT03103594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will not be notified of which arm they are randomized to.||t|f|f|f
33999299|NCT04467619|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33999300|NCT04983862|NA|SINGLE_GROUP||TREATMENT||NONE||This is a first-in-human, single-arm, open-label, dose-escalation phase I study to investigate the safety of Illuminare-1, a myelin-binding fluorescent small molecule in patients undergoing routine minimally invasive radical prostatectomy.||||
33999301|NCT00715676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999302|NCT04863131|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33695669|NCT01385007|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33695670|NCT06680947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695671|NCT02241993|||CASE_ONLY||PROSPECTIVE|||||||
33695672|NCT00090051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695673|NCT02824965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999303|NCT01986725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33999304|NCT05687448|RANDOMIZED|PARALLEL||TREATMENT||NONE|The Outcomes adjudication will be performed blinded of patients treatment|"This study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with mechanical aortic valve at least 7 days after cardiac surgery.~Experimental group:~Patients treated with apixaban 5 mg twice daily (BID)~Active Comparator group:~Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)"||||
33999305|NCT04431973|NA|SINGLE_GROUP||OTHER||NONE||||||
33999306|NCT06431776|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study||||
33695674|NCT03796832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This will be a mono-centre randomized controlled trial with a 1:1 allocation into the experimental treatment (exercise therapy and Flat Flexible Shoes) and comparator treatment (exercise therapy and Stable Supportive Shoes). Exercise therapy will consist of supervised facility- and home-based exercises for 3 months (primary time point) and unsupervised home-based exercises for a subsequent 6 months (secondary time point).|t|f|t|t
33695675|NCT04627337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695676|NCT04680156|||COHORT||PROSPECTIVE|||||||
33784401|NCT02929108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A pragmatic cluster randomized controlled trial will randomly assign hospice sites (cluster) to 2 of 3 groups: 1) Enhanced usual care 2) Enhanced usual care and private Facebook group 3) Enhanced usual care, private Facebook group, and ACCESS. Each hospice site (cluster) will go through 2 arms of the intervention but the family caregiver participants will only complete one arm.||||
34103098|NCT03487510|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33784402|NCT06712381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784403|NCT01244100|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33784404|NCT01634919|||COHORT||PROSPECTIVE|||||||
33784405|NCT06688214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784406|NCT02812966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784407|NCT05164666|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784408|NCT04771273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784409|NCT06711380|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33784410|NCT06711497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|global postural reeducation and deep neck flexor activation exercises|t|f|f|t
33784411|NCT01456780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784412|NCT06713525|||COHORT||PROSPECTIVE|||||||
33784413|NCT06713863|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33999307|NCT03614728|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, multicenter, multi-part study.||||
33999308|NCT00405860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999309|NCT01828294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999310|NCT01670097|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999311|NCT04425096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled single-blind experimental study.|t|f|f|f
33784414|NCT02993029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999312|NCT04348422|||COHORT||PROSPECTIVE|||||||
33999313|NCT03001934|||COHORT||PROSPECTIVE|||||||
33999314|NCT01102127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999315|NCT05294016|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33999316|NCT03917758|NA|SINGLE_GROUP||OTHER||NONE||||||
33999317|NCT03050866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784415|NCT01784289|||COHORT||CROSS_SECTIONAL|||||||
33784416|NCT01387256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801552|NCT04665960|||COHORT||PROSPECTIVE|||||||
33919182|NCT03737292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a prospective randomized controlled, double blind study.|t|t|t|f
33919183|NCT02357953|||COHORT||PROSPECTIVE|||||||
33919184|NCT00002783||||TREATMENT||||||||
33919185|NCT00894491|||COHORT||RETROSPECTIVE|||||||
33919186|NCT03047850|||COHORT||PROSPECTIVE|||||||
33919187|NCT05767710|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33919188|NCT01840228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33919189|NCT06350968|||COHORT||PROSPECTIVE|||||||
33919190|NCT04417114|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919191|NCT02624011|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33919192|NCT00165061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33919193|NCT03895112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919194|NCT03608891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919195|NCT01608399|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919196|NCT00370240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919197|NCT00363051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919198|NCT02022072|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919199|NCT04419324|NA|SINGLE_GROUP||SCREENING||NONE||This is a case-control pilot study||||
33919200|NCT05363670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919201|NCT06243315|||COHORT||PROSPECTIVE|||||||
33919202|NCT01152736|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33919203|NCT01369212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919204|NCT06402669|||COHORT||RETROSPECTIVE|||||||
33919205|NCT01794013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919206|NCT04000919|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both the participant and assessors are blinded to which drug/placebo the participant reviews because all drugs are housed in similar capsules. Only the PI and caregiver will be aware of which drug will be administered for safety purposes.||t|f|f|t
33919207|NCT04799951|||COHORT||PROSPECTIVE|||||||
33919208|NCT00972842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919209|NCT05624567|||COHORT||PROSPECTIVE|||||||
33919210|NCT03372629|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33919211|NCT03427541|||COHORT||RETROSPECTIVE|||||||
33919212|NCT04173052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919213|NCT02072772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919214|NCT03554070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919215|NCT05602610|||COHORT||PROSPECTIVE|||||||
33919216|NCT05627570|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|To minimise unnecessary unblinding, participants will not be informed of the order in which they receive their diets, but it will likely become clear which diet they are consuming, and thus the study will not be considered to be blinded.|2x2, randomised, controlled crossover trial|t|f|f|f
33919217|NCT01560442|||||CROSS_SECTIONAL|||||||
33919218|NCT00700531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999318|NCT02587143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999319|NCT05200442|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33999320|NCT04298151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919219|NCT05549648|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919220|NCT04753047|||COHORT||CROSS_SECTIONAL|||||||
33919221|NCT04151095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Allocation concealment, assessor blinding||f|f|t|t
33919222|NCT03039933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919223|NCT00126581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919224|NCT05321940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919225|NCT01842841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999321|NCT04731324|NA|SINGLE_GROUP||TREATMENT||NONE||A phase 1, prospective open label, single dose, single arm study||||
33999322|NCT06385301|RANDOMIZED|CROSSOVER||OTHER||NONE||Each participant is its own control||||
33999323|NCT01459601|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33999324|NCT04499209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Period 1: Participants and investigators were blinded Period 2: Open label|Period 1: ascending single-dose of XG005 vs Placebo; Period 2: combination of Naproxen and Pregabalin|t|f|t|f
33919226|NCT04296006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|d-Amphetamine doses will be administered under double-blind conditions.|A placebo-controlled, randomized, within-subjects design will be used to assess drug-vs-money choice in cocaine use disordered subjects as a function of alternative reinforcer value and d-amphetamine SR treatment.|t|f|f|t
33919227|NCT04810585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919228|NCT00371111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919229|NCT02130154|||CASE_CONTROL||PROSPECTIVE|||||||
33919230|NCT00729326|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33919231|NCT02808741|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919232|NCT01593579|||||PROSPECTIVE|||||||
33919233|NCT01873092|||COHORT||PROSPECTIVE|||||||
33919234|NCT01314625|||CASE_ONLY||PROSPECTIVE|||||||
33919235|NCT04123418|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919236|NCT01560221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919237|NCT03307954|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33919238|NCT01825980|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33919239|NCT03647436|||COHORT||PROSPECTIVE|||||||
33919240|NCT04394455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will not take part in the baseline symptom evaluation of subjects or the post-intervention evaluation.|The interventional models are brief cognitive behavioral therapy and crisis intervention therapy through telepsychiatry. Each arm will be divided into therapy groups with a maximum of 10 participants per group. Each therapy session will be directed by a therapist and a co-therapist using a predefined structure for each intervention, with a duration of 60-90 minutes per session.|f|f|t|f
33919241|NCT00030615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919242|NCT00338468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919243|NCT00993395|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919244|NCT02859389|||COHORT||PROSPECTIVE|||||||
33919245|NCT00531245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919246|NCT03242005|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33999325|NCT02350257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999326|NCT01125527|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33999327|NCT05004649|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999328|NCT01482117|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33999329|NCT01323127|||CASE_CONTROL||PROSPECTIVE|||||||
33999330|NCT05702255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|a randomization sequence will be generated by an independent statistician. The randomization list will be recorded and enclosed in sequentially numbered, opaque envelopes. after finishing baseline assessment, the training researcher will open the envelopes to avoid selection bias. only the training researcher will know the group allocation. Participants and other relevant researchers (the outcome evaluator, data managers, and statisticians) will be blinded to the group allocation.||t|f|f|t
33999331|NCT02699866|NA|SINGLE_GROUP||OTHER||NONE||||||
33919247|NCT03151252|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919248|NCT00780702|RANDOMIZED|PARALLEL||TREATMENT||||||||
33919249|NCT04446026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919250|NCT05496322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919251|NCT03006471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919252|NCT04779944|||COHORT||PROSPECTIVE|||||||
33919253|NCT03771599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor was kept blind about group identification of the participants before assessments at baseline, after 06 weeks and 12 weeks of intervention.|It is a RCT with two groups, control and intervention. Both groups received routine physical therapy five days a week for a period of three months. Intervention group also received traditional massage for thirty minutes before start of the routine physical therapy. Data was collected at baseline, after 06 weeks and 12 weeks of intervention|f|f|f|t
33919254|NCT02912598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919255|NCT03407508|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33999332|NCT05807958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695677|NCT04349085|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|A researcher will program the device (placebo or PMBT) and will be instructed not to inform the volunteers or other researchers as to the type of treatment (PMBT or placebo). Therefore, the researcher responsible for the treatment will be blinded to the type of treatment being administered to the volunteers. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or PBMT).|"The volunteers will be allocated to four interventions/situation:~1. Effective PBMT/sMF before WOD and placebo PBMT/sMF after WOD;~2. Placebo PBMT/sMF before WOD and effective PBMT/sMF after WOD;~3. Effective PBMT/sMF before WOD and effective PBMT/sMF after WOD;~4. Placebo PBMT/sMF before WOD and placebo PBMT/sMF after WOD. The order of the interventions will be randomized."|t|t|t|t
33695678|NCT03110731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784417|NCT06108492|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle invasive bladder cancer.||||
33695679|NCT04644536|||COHORT||RETROSPECTIVE|||||||
33695680|NCT05956873|||COHORT||RETROSPECTIVE|||||||
33695681|NCT04398862|||CASE_ONLY||PROSPECTIVE|||||||
33695682|NCT03929627|||OTHER||OTHER|||||||
33695683|NCT04522531|NA|SINGLE_GROUP||OTHER||NONE||||||
33784418|NCT00547976|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919256|NCT02284685|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33919257|NCT01313208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33919258|NCT04973215|||OTHER||OTHER|||||||
33919259|NCT02726113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33919260|NCT03172858|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33919261|NCT05719051|||COHORT||RETROSPECTIVE|||||||
33695684|NCT06586190|NA|SINGLE_GROUP||OTHER||NONE||||||
33695685|NCT01104701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695686|NCT05755737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695687|NCT06271486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695688|NCT06380179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In order to facilitate participant blinding to their randomized study group, all participants (regardless of their assigned study group) will be asked to wear blackout glasses and headphones during their treatment.|Approach: Special Operators attending THOR3 coach led training will be invited to participate. After consenting and screening for inclusion/exclusion, participants will be randomized into two groups: 1) sham PBMT and 2) PBMT (applied to quadriceps up to 3 times per week, post coach-led training, taking approximately 5-20 minutes each time). Baseline measurements will include body fat percentage, height, weight and military/demographic information. Metrics for counter movement jump and self-reported delayed muscle onset soreness will be taken at baseline and weekly for three weeks. Isokinetic dynamometer measurements for the lower extremities, and self-reported exertion and fatigue will be taken at baseline and at the 3-week follow-up (post three-week intervention). Oura rings will be assigned at baseline and will continuously measure sleep, heart rate, Sp02, and activity. Activity and pain will also be self-reported throughout the duration of the study.|t|f|f|f
33695689|NCT04223232|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695690|NCT02162472|||COHORT||PROSPECTIVE|||||||
33695691|NCT00972088|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695692|NCT04119310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Double Blind: The subjects will not know what intervention they are receiving - same generic script is provided. One Investigator is performing all pre and post-tests without knowledge of intervention, the other investigator is opening the envelope and providing the intervention behind a screen without knowledge of test results. This investigator will record the subjects assigned # and which intervention they received. Investigators will record data on spreadsheet separately.~The outcomes will be evaluated by a masked outcome assessor."|Participants will be randomly assigned to one of two interventions, thrust-mobilization or sham mobilization.|t|f|t|t
33695693|NCT02667327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695694|NCT03512899|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison between internal jugular vein versus via axillary vein with single-incision for placement of implantable ports in cancer patients. Investigators are recruiting 240 patients and randomizing 120 for each arm. Primary outcome is early complications, until 30 days and secondary outcome late complications, between 30 days and 6 months. The follow-up is 6 months.||||
33784419|NCT02552550|||COHORT||PROSPECTIVE|||||||
33784420|NCT06132321|||COHORT||PROSPECTIVE|||||||
33784421|NCT06713551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Study|f|f|t|f
33784422|NCT05202080|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33784423|NCT00081809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784424|NCT04196985|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784425|NCT01619254|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33784426|NCT05930041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784427|NCT06458738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919262|NCT01009983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919263|NCT01064076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919264|NCT02779673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919265|NCT04436679|||COHORT||RETROSPECTIVE|||||||
33919266|NCT04744636|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919267|NCT05263817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919268|NCT02492971|||OTHER||CROSS_SECTIONAL|||||||
33919269|NCT05177822|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088464|NCT04673500|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The whole arm with the intravenous catheter was covered with a green sheet, from where the mixture of propofol-lidocaine was given.|Patients were randomized into two groups, eighty each. In all patients 15 to 30 minutes before shifting to the operation room a 20 gauge intravenous catheter was inserted either in a large antecubital vein (Group-1) or in a vein on dorsum of hand (Group-2). Lactate Ringer infusion was initiated at the rate of 120 ml/h. The arm was covered with green sheet. Patients received admixture of 2% lidocaine (1ml) in 1% propofol (19ml) either through large antecubital vein (Group-1, n = 80) or (Group-2, n = 80) through a vein at dorsum of hand. In both groups initially, thirty percent of the calculated dose of propofol (2mg/kg) was injected through an intravenous catheter. All patients were informed to report the researcher about the intensity of pain they experienced in numbers. Then induction of anesthesia was continued as routine.|t|t|f|t
34088465|NCT04740853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088466|NCT00190034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34088467|NCT01278667|||CASE_CROSSOVER||PROSPECTIVE|||||||
34088468|NCT05866224|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33784428|NCT03444779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient blinded until D2 visit.||t|f|f|f
34088469|NCT02788487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088470|NCT02442128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088471|NCT02385318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088472|NCT02795143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34088473|NCT01465269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088474|NCT01260948|RANDOMIZED|CROSSOVER||||NONE||||||
34088475|NCT00208975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784429|NCT01688544|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33784430|NCT04633343|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33784431|NCT06044649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of research staff and participants until baseline assessment is completed. Masking of research staff who interact with patients for outcome assessments.|4-arm parallel randomized clinical trial comparing three therapies with each other and with a treatment as usual control|f|f|f|t
33784432|NCT06712199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784433|NCT06610526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784434|NCT05058794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784435|NCT00000106|RANDOMIZED|PARALLEL||TREATMENT||||||||
33784436|NCT02749331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784437|NCT01723774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784438|NCT05037656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784439|NCT01123161|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Randomized to normothermia or hypothermia|f|f|f|t
33999333|NCT03814122|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Pre- and post- assessments will be administered by someone blind to group assignment.|The proposed study will be a two-group randomized control cross-over trial. Participants will be randomly assigned to receive ABCR or treatment-as-usual (TAU) for a period of 8 weeks. After this time, the TAU group will receive ABCR. Evaluations of the participant's cognitive functioning, self-esteem, psychotic symptoms, and functional skills will be completed at baseline, post-treatment (approximately 8 weeks), and 16 weeks later.|f|f|f|t
33999334|NCT00905008|||CASE_CONTROL||RETROSPECTIVE|||||||
33999335|NCT03209115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intracanal medication|t|t|f|f
33999336|NCT04584073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999337|NCT01300273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999338|NCT06050239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999339|NCT03214523|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants were recruited without emphasis on study arm. All outcomes will be assessed without knowledge of the treatment arm.|Half the subjects will be followed without any attempt to improve sleep, and half will undergo a brief educational intervention to try to improve sleep.|t|f|f|t
33999340|NCT04971512|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33999341|NCT02933060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999342|NCT03066479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999343|NCT05997030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999344|NCT02867358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999345|NCT02469480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999346|NCT06559761|||COHORT||PROSPECTIVE|||||||
34088476|NCT05243706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088477|NCT04826562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088478|NCT01911091|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34088479|NCT04141605|||COHORT||CROSS_SECTIONAL|||||||
34088480|NCT01314547|||COHORT||PROSPECTIVE|||||||
33919270|NCT06264349|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Quasi-experimental - controlled, non-randomized pilot study||||
33919271|NCT06141941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort||||
33919272|NCT05753332|||COHORT||CROSS_SECTIONAL|||||||
33919273|NCT03178812|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||One arm containing patients with pancreatic lesion and one control group arm of healthy volunteers||||
33919274|NCT03605199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919275|NCT03583320|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"As stated earlier for patients assigned to Arm B i.e. the control arm (standard of care arm) who undergo CTCA, the results will not be released to the patient and their medical care givers in hospital.~CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. \>50% stenosis in the left main (LM) coronary artery, and/or \>50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."|Once patients consent to participate in the study, they will be randomised into the intervention group (i.e. with CTCA) or the control group (i.e. hs-cTn based standard of care) on a 1:1 ratio. For purposes of Study 2, the control group of patients will also be consented to undergo CTCA. However, CTCA will not form part of their in-patient clinical management as the clinical teams will be blinded from CTCA findings (except for cases of prognostically significant coronary disease e.g. 50% stenosis of the LM and/or proximal LAD coronary arteries).|t|t|f|f
33919276|NCT06474429|||COHORT||PROSPECTIVE|||||||
33919277|NCT02493114|||COHORT||PROSPECTIVE|||||||
33919278|NCT06036134|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33919279|NCT05467930|||COHORT||PROSPECTIVE|||||||
33919280|NCT04865185|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33999347|NCT02096692|||CASE_ONLY||PROSPECTIVE|||||||
33999348|NCT02967926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999349|NCT01345305|||CASE_ONLY||PROSPECTIVE|||||||
33999350|NCT00082160|||DEFINED_POPULATION||OTHER|||||||
33999351|NCT05352048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999352|NCT04361838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33999353|NCT05029726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, surgeons and anesthesiologists will all be blinded to treatment allocation. Syringes containing the fluid to be injected will be prepared by pharmacy and labeled with subject number in such a manner to blind the anesthesiologist performing the ESPB to its contents.|All patients will undergo surgery using an enhanced recovery after surgery (ERAS) multi-modal anesthesia protocol that is currently in standard use for MIS lumbar spine surgical procedures. Patients will be randomized in a 1:1 ratio to investigational and control arms.|t|t|t|t
33999354|NCT04516096|NA|SINGLE_GROUP||TREATMENT||NONE||Open label long term extension of treatment||||
33999355|NCT00870935|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34088481|NCT06164171|||OTHER||PROSPECTIVE|||||||
34088482|NCT04387968|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34088483|NCT01060501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088484|NCT03753906|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients were implanted with self-inflating hydrogel expander in subperiosteal positions using the pouch technique in the mandibular anterior region.||||
34088485|NCT01680614|||COHORT||PROSPECTIVE|||||||
34088486|NCT04945811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088487|NCT00817063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088488|NCT05528848|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34088489|NCT04516876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088490|NCT03499132|||COHORT||PROSPECTIVE|||||||
34088491|NCT02499562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088492|NCT05395507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695695|NCT02106910|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33695696|NCT06613867|||OTHER||PROSPECTIVE|||||||
33695697|NCT05005078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A: Open label, Part B: double-blinded||t|t|t|t
33695698|NCT05550844|||COHORT||CROSS_SECTIONAL|||||||
33999356|NCT00860262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999357|NCT03549897|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999358|NCT01802645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088493|NCT06125418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||patients in each group will received different types of customized healing abutment|t|t|f|f
34088494|NCT00846599|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999359|NCT01777815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999360|NCT00770458|||COHORT||CROSS_SECTIONAL|||||||
33999361|NCT03347058|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33999362|NCT05828290|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"At the end of the research, the groups will be coded as A and B. Statistical analysis will be made by the statistics expert who is blinded to the groups in the study."|pretest, posttest design, follow-up, randomized controlled trial|f|f|f|t
33999363|NCT05554887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All these evaluations will be carried out by a blind evaluator who does not know which group the participants belong to.|randomised sham controlled study involving 2 parallel groups|f|f|f|t
33999364|NCT02383836|||CASE_CONTROL||PROSPECTIVE|||||||
33999365|NCT01825694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999366|NCT03687619|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33999367|NCT02686567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33999368|NCT00307541|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33999369|NCT05456451|NA|SINGLE_GROUP||TREATMENT||NONE||The participants wit Parkinson disease, who has Hohen Yahr grade 2-3 will be included in the study.||||
33999370|NCT00714051|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34088495|NCT02420574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088496|NCT02335281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088497|NCT00778050|RANDOMIZED|CROSSOVER||||NONE||||||
34088498|NCT06067919|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||assess the impact of disseminating of a decision tree on prescribing practices, a cluster randomised, stepped-wedge, multicentre, national, interventional, pragmatic and open study will be carried out.||||
34088499|NCT00415467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088500|NCT04976374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088501|NCT04229823|||COHORT||PROSPECTIVE|||||||
34088502|NCT00001938|||COHORT||PROSPECTIVE|||||||
34088503|NCT05504525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088504|NCT01446185|NA|SINGLE_GROUP||||NONE||||||
34088505|NCT02001883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088506|NCT02238366|||COHORT||PROSPECTIVE|||||||
34088507|NCT03284099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34088508|NCT03983031|NA|SINGLE_GROUP||TREATMENT||SINGLE|Each patient will be video recorded at base line, week 12, 20 and 40 in order to enable blinded assessment by an independent rater, and for the patient's own evaluation.||f|f|f|t
34088509|NCT04055883|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34088510|NCT00132886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088511|NCT00003871|RANDOMIZED|||TREATMENT||||||||
34088512|NCT01423669|||COHORT||CROSS_SECTIONAL|||||||
34088513|NCT05522478|||OTHER||CROSS_SECTIONAL|||||||
34088514|NCT02750423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088515|NCT05357495|NA|SINGLE_GROUP||OTHER||NONE||||||
33784440|NCT06711783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784441|NCT05660850|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34088516|NCT01682031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34088517|NCT00108446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34088518|NCT02322996|||OTHER||OTHER|||||||
34088519|NCT04697849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blind to treatment condition. Statistician to create randomization table.|The Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) intervention provides compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, and then uses exposure therapy to reduce the distress associated with discarding items. CREST will be compared to case management for hoarding symptoms.|f|f|f|t
33999371|NCT05093686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked observers will complete the behavior observation of paraeducator use of RUBIES strategies (fidelity) and Behavior Observation of Students in School (BOSS; assessment of functional communication and classroom compliance) at all study points. Subject identity will be masked using numeric codes and only the principal investigator and research coordinator will have access to the password-protected master lists. Masked observers will receive identity coded videotapes to prevent unmasking of study condition or phase. Inclusion of UCT ensures that our behavior observation raters can remain masked to treatment assignment.|"Simple 1:1 random assignment will be used to assign half (n=40) of the paraeducator/teacher/child triads to remote training in RUBIES, allowing for personalized delivery and tailoring of RUBIES to the paraeducator-child dyad, and the other half (n=40 dyads) to Usual Care Training (UCT, an Autism 101 attention control condition) over a three-year period. No greater than 10% paraeducator turnover each year is expected based on prior studies."|f|f|f|t
33999372|NCT06403423|||CASE_CONTROL||PROSPECTIVE|||||||
33999373|NCT03256864|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999374|NCT04780711|||OTHER||PROSPECTIVE|||||||
33999375|NCT01546363|||COHORT||PROSPECTIVE|||||||
33999376|NCT05036005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999377|NCT04477434|||COHORT||PROSPECTIVE|||||||
34088520|NCT04600037|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34088521|NCT05604300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34088522|NCT05927974|||CASE_CONTROL||PROSPECTIVE|||||||
34088523|NCT03403049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088524|NCT02171351|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34088525|NCT03218501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088526|NCT00820378|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34088527|NCT06403371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Nor the subjects neither the investigator knew the type of varnish they received. Additionally, the outcome assessor was blinded before making the analysis|Double blinded randomized controlled clinical trial|t|t|t|t
34088528|NCT04362826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34088529|NCT00702169|||CASE_CONTROL||PROSPECTIVE|||||||
34088530|NCT04340583|||COHORT||PROSPECTIVE|||||||
34088531|NCT06464159|||CASE_CONTROL||PROSPECTIVE|||||||
34088532|NCT02744586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34088533|NCT00021164|RANDOMIZED|||TREATMENT||||||||
34088534|NCT05880719|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34088535|NCT00829153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34088536|NCT05956743|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and the researcher cannot be blinded due to the nature of the research. According to the randomized controlled research design, in this study, the groups of patients who would or would not be treated according to the simple random sampling method were determined.|The research is carried out in two groups as control and intervention groups.||||
34088537|NCT02708056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088538|NCT01148485|||CASE_ONLY||PROSPECTIVE|||||||
34088539|NCT04742699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088540|NCT05668247|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33695699|NCT00801918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919281|NCT03712800|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to one of the three groups (rhythmical massage, HRV biofeedback or control). After the three-month intervention period, the controls receive rhythmical massage for ethical and compliance reasons. Assessments are taken before and after the intervention phase. Pain intensity is once more queried three months after the end of the intervention period.||||
33919282|NCT03486210|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919283|NCT01991405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33919284|NCT01178736|||CASE_ONLY||PROSPECTIVE|||||||
33919285|NCT00453232|NON_RANDOMIZED|||TREATMENT||||||||
33919286|NCT02270684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919287|NCT03196193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|(Investigational group) or ZNN CM Asia without AS2 technique (Control group). The randomization scheme is based on equal numbers per group. The randomization will occur via a random number generator (computer) using a blocked randomization procedure. The block size will not be disclosed to the sites, and the doctor or other health care professional will not have influence on the randomization scheme. Sealed opaque envelopes, which will be prepared based on predetermined randomization assignment, will be provided to each study site before study initiation.|At surgery, intervention group using ZNN CM Asia with AS2 technique. At surgery, conventional group using ZNN CM Asia without AS2 technique.|t|t|t|t
33919288|NCT05895227|||COHORT||RETROSPECTIVE|||||||
33919289|NCT06247358|||COHORT||PROSPECTIVE|||||||
33919290|NCT00425711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919291|NCT01022346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088541|NCT00815074|||OTHER||RETROSPECTIVE|||||||
34088542|NCT04187313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study statistician will not be aware of intervention assignment|The intervention will be administered to private practitioners in the selected areas (clusters), at their place of practice. Once the study participants have received the intervention, real-time monitoring of referral practice of patients for diagnosis and notification will be undertaken through the web-link to the app.|f|f|f|t
34088543|NCT01272206|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34088544|NCT03418519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088545|NCT01071577|||OTHER||PROSPECTIVE|||||||
34088546|NCT05512975|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single blinded study. All participants will consume 2 fortified meals and 1 placebo/ control meal. All participants will be blinded to the intervention provided|"Single group, cross-over design where each participant will consume one of 3 different porridge recipes on separate testing visits.~The study will be conducted single blind as it not feasible to blind the researcher. Each participant will attend 3 study visits and all porridges will be provided in a blind manner."|t|f|f|f
34088547|NCT05188482|||CASE_CONTROL||PROSPECTIVE|||||||
34088548|NCT02332642|||CASE_ONLY||OTHER|||||||
34088549|NCT01675726|NA|SINGLE_GROUP||OTHER||NONE||||||
33919292|NCT02603354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33919293|NCT00111579|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919294|NCT05233982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088550|NCT03219580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both patients and physicians are blinded in this study. The study log is maintained by a study nurse who maintains the log of which side is randomized to placebo and active treatment arm respectively. The study nurse is also responsible for preparing the 2 arms in identical syringes, ensuring each arm is injected into its respective laterality|Patients who undergo bilateral direct brow ptosis repair will be randomized to have one brow as the placebo arm and one arm as the active treatment arm. This original randomization will be maintained throughout the study.|t|f|t|f
34088551|NCT05718596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919295|NCT05841264|||COHORT||CROSS_SECTIONAL|||||||
33919296|NCT03419221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33919297|NCT01763463|||COHORT||PROSPECTIVE|||||||
33919298|NCT04828785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Owing to the nature of the intervention, participants, providers, and many study staff will know to which group individual participants have been randomized. However, efforts will be made to keep the study statistician and outcome assessors blinded to randomization group during the course of the trial.|Participants will be assigned in 1:1 ratio to one of two intervention arms|f|f|f|t
33919299|NCT00303758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919300|NCT01839175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919301|NCT01640990|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33919302|NCT02031822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919303|NCT02260648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919304|NCT04375241|||COHORT||PROSPECTIVE|||||||
33695700|NCT03432156|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental group: immunotherapy. subjects who are treated with autologous Tcm cells immunotherapy.~No intervention group: subjects who are treated without autologous Tcm cells immunotherapy."||||
33695701|NCT00006363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695702|NCT01288027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695703|NCT05671471|||COHORT||PROSPECTIVE|||||||
33695704|NCT02593201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695705|NCT00642720|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33695706|NCT03892031|||CASE_ONLY||PROSPECTIVE|||||||
33695707|NCT05032248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695708|NCT00467610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695709|NCT02674373|||COHORT||PROSPECTIVE|||||||
33695710|NCT01241084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695711|NCT06710028|||COHORT||PROSPECTIVE|||||||
33695712|NCT01634490|||COHORT||PROSPECTIVE|||||||
33695713|NCT04645420|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open Label||||
33695714|NCT03053583|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33695715|NCT02004392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695716|NCT05345873|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784442|NCT03749291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784443|NCT06585540|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Prospective, randomized, subject blinded, placebo-controlled crossover pilot study.|t|f|f|f
33695717|NCT04210583|NA|SINGLE_GROUP||OTHER||NONE|"1. Long term safety of the Venus Fiore Fiore™ (MP)2 system in improving vaginal laxity and skin laxity of the mons pubis and labia.~   * Subject's assessment of discomfort and pain as measured by a 10 cm visual analog scale (VAS) at 12 months if treatment (optional) is provided.~  * Subjects experiencing a treatment-related adverse event (AE) at six-months and twelve-months post-treatment.~2. Long term efficacy of the Venus Fiore Fiore™ (MP)2 system in improving vaginal laxity and skin laxity of the mons pubis and labia.~   * Improvement in vaginal laxity at six-months and twelve-months post-treatment compared to baseline as defined as a score \>4 on the VLQ.~  * Improvement in FSFI mean score at six-months and twelve-months post-treatment compared to baseline."|"1. Long term safety of the Venus Fiore Fiore™ (MP)2 system in improving vaginal laxity and skin laxity of the mons pubis and labia.~   * Subject's assessment of discomfort and pain as measured by a 10 cm visual analog scale (VAS) at 12 months if treatment (optional) is provided.~  * Subjects experiencing a treatment-related adverse event (AE) at six-months and twelve-months post-treatment.~2. Long term efficacy of the Venus Fiore Fiore™ (MP)2 system in improving vaginal laxity and skin laxity of the mons pubis and labia.~   * Improvement in vaginal laxity at six-months and twelve-months post-treatment compared to baseline as defined as a score \>4 on the VLQ.~  * Improvement in FSFI mean score at six-months and twelve-months post-treatment compared to baseline."||||
34088552|NCT04138017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088553|NCT04568005|||OTHER||CROSS_SECTIONAL|||||||
33695718|NCT04857970|||OTHER||PROSPECTIVE|||||||
33695719|NCT00447317|RANDOMIZED|PARALLEL||||NONE||||||
33695720|NCT00369122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695721|NCT04429360|||COHORT||PROSPECTIVE|||||||
33695722|NCT04537455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will have an ultra-high frequency electrocardiogram done.||||
33695723|NCT02443519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695724|NCT06597916|RANDOMIZED|PARALLEL||OTHER||SINGLE|Controls will be randomized in a 1:1 ratio before study intervention at V1 to receive Arexvy / saline.|Prospective, single-center, parallel group, controlled, phase-2b|t|f|f|f
33695725|NCT03985384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind Placebo Controlled|t|t|t|t
33695726|NCT05746962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33695727|NCT00794781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695728|NCT03773367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695729|NCT00595842|||CASE_ONLY||RETROSPECTIVE|||||||
33695730|NCT01516229|||COHORT||PROSPECTIVE|||||||
33695731|NCT04282278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695732|NCT04076046|||COHORT||PROSPECTIVE|||||||
33695733|NCT02407418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33695734|NCT05748418|||OTHER||CROSS_SECTIONAL|||||||
33695735|NCT05919004|||OTHER||RETROSPECTIVE|||||||
33784444|NCT05991505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784445|NCT06595030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784446|NCT04763317|||COHORT||PROSPECTIVE|||||||
33784447|NCT06266650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects diagnosed with pelvic SD will be divided into two groups. One group will be treated with traditional one-sided MET, the second group will be treated with combination MET. Results of post-treatment exams will be collected and statistically analyzed.||||
33784448|NCT06657768|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33784449|NCT06644430|||COHORT||RETROSPECTIVE|||||||
33784450|NCT01386424|||OTHER||OTHER|||||||
33919305|NCT02410603|||CASE_ONLY||PROSPECTIVE|||||||
33919306|NCT00803543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919307|NCT01186718|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919308|NCT02098694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919309|NCT04965376|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ultrasound guided steroid injection into the glenohumeral joint versus ultrasound guided suprascapular nerve block||||
33919310|NCT04243252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919311|NCT02094053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919312|NCT04503928|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|All participants eligible for study received the same open label drug||||
33919313|NCT04564326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33919314|NCT04724733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized with equal probability to 1 of 3 study groups in blocks of 2, 4 and 5. Random assignment of the participants will be determined using a randomization software. Random group assignment and a corresponding unique study identification (ID) number will be placed in sealed envelopes that are numbered sequentially. After the consent is signed, research personnel will open the envelope to reveal the participant's group assignment. Research personnel will record the participant's name, study ID and group assignment in a password-protected spreadsheet stored on a secure server at WSU. As part of (virtual) study visit 1, intervention participants will download the app to their smartphones. A set-up macro will ask the participant to enter their study ID which can be associated with all data captured by the app.|f|f|t|f
33999378|NCT05569109|||CASE_CONTROL||RETROSPECTIVE|||||||
33999379|NCT04912609|||CASE_ONLY||PROSPECTIVE|||||||
33999380|NCT02218216|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999381|NCT05418790|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33999382|NCT03734458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999383|NCT02344849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999384|NCT00613730|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999385|NCT00972231|||COHORT||RETROSPECTIVE|||||||
33999386|NCT00498264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33999387|NCT03959150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33999388|NCT04311346|||CASE_ONLY||PROSPECTIVE|||||||
33999389|NCT03672240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999390|NCT03199196|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999391|NCT04202705|NA|SEQUENTIAL||TREATMENT||NONE||||||
33999392|NCT01664169|||COHORT||RETROSPECTIVE|||||||
33999393|NCT03046433|||COHORT||PROSPECTIVE|||||||
33999394|NCT03174158|RANDOMIZED|PARALLEL||TREATMENT||NONE||4 arm randomized controlled trial||||
33999395|NCT04485208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999396|NCT01476904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999397|NCT05907694|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial comparing transcatheter PFO closure + medical treatment vs. medical treatment alone.||||
33999398|NCT02040961|NA|SINGLE_GROUP||||NONE||||||
33999399|NCT01690260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999400|NCT03252457|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33999401|NCT00070122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999402|NCT00702507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695736|NCT03619343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Control Intervention : ETOIMS apply group|f|f|t|t
33695737|NCT04014309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||In this cluster randomized study, a cluster unit is defined as the clinic held by the individual oncologists who are treating eligible patients. The randomization schedule will allocate the cluster units (i.e. each oncologist and their clinic) in a 1:1 ratio to either the new supportive and survivorship care program or usual care arm. Therefore, all participants who received care from the same oncologist will have the same allocation.|f|f|t|t
33695738|NCT05596942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33695739|NCT06330454|||COHORT||PROSPECTIVE|||||||
33695740|NCT02922933|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695741|NCT03143881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695742|NCT00000188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999403|NCT03965065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Block randomisation 1:1 of conventional Vs sutureless aortic bioprostheses.|f|f|t|t
33999404|NCT06268457|||COHORT||PROSPECTIVE|||||||
33999405|NCT01165749|||COHORT||PROSPECTIVE|||||||
33999406|NCT02028455|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33999407|NCT02161263|||COHORT||PROSPECTIVE|||||||
33999408|NCT01426568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999409|NCT05746143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33695743|NCT06084013|||COHORT||PROSPECTIVE|||||||
33695744|NCT06709378|||CASE_CONTROL||RETROSPECTIVE|||||||
33695745|NCT01810211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695746|NCT06668194|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Split mouth design|t|f|t|t
34088554|NCT03233256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.||||
33695747|NCT00629174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33695748|NCT00341445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695749|NCT01427322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695750|NCT02009969|||COHORT||PROSPECTIVE|||||||
33695751|NCT04824365|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||15 COVID-19 infected patients will be assigned to the placebo and 15 COVID-19 infected patients assigned to the drug treatment for a total of 30 patients.|t|t|f|t
33695752|NCT05997758|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695753|NCT01231347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695754|NCT05237271|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33695755|NCT01933217|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33695756|NCT05082831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized on the treatment day (Visit 2 per Schedule of Activities below) to undergo microfracture surgery with or without HST003 injection into the interstices and defect post-microfracture procedure. Each clinical site will have a study drug dispenser who will be responsible for randomizing the patient via the IWRS and will know whether the patient will be receiving HST003 or not, maintaining the blinding until the surgeon is approaching the end of the procedure.|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery. The primary purpose of the study is to compare the two groups: microfracture surgery + HST003 as compared to the microfracture surgery only group.|t|f|f|f
33695757|NCT00543491|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33784451|NCT05866016|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The outcomes assessor and care provider will be masked to minimize the biases. Trainers will be outcomes assessors and trainees who complete modular training and provide maternal and child health services are considered as care providers.|The competencies of skilled birth attendants who receive modular training will be compared with those of skilled birth attendants who receive existing standard training.|f|t|f|t
33784452|NCT04787133|||COHORT||PROSPECTIVE|||||||
33784453|NCT03317392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919315|NCT05307445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a randomised, double blind clinical trial|t|f|t|t
34088555|NCT00929669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919316|NCT02322151|||CASE_ONLY||RETROSPECTIVE|||||||
33919317|NCT04782986|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|The capsule endoscopy reader will be independent from the physicians performing the conventional colonoscopies, and all investigators will be blinded to each other's findings and reports. Capsule endoscopy and colonoscopy findings will be compared and in case of disagreement it will be discussed until a consensus is reached, if necessary, with the intervention of an independent third reader, experienced in both techniques and not involved in the primary reading of any of the examinations.|Prospective, single-blinded, single center cohort study. All patients will undergo pan-intestinal capsule endoscopy followed by conventional colonoscopy with deep sedation in the same day, with no need for further bowel preparation.|f|t|t|f
33919318|NCT04914377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study|This is a randomized, double-blind, placebo-controlled phase II study to assess the safety and efficacy of TQ Formula versus placebo in the treatment of Covid-19 in an outpatient setting. Participants will be randomized 1:1 to receive either 3 g per day of TQ Formula or placebo (identical in appearance). The participants will receive up to 14 days of dosing.|t|f|t|f
33919319|NCT00928356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919320|NCT03430583|||COHORT||PROSPECTIVE|||||||
34088556|NCT00101959||||TREATMENT||||||||
34088557|NCT02140944|||COHORT||PROSPECTIVE|||||||
34088558|NCT00831844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695758|NCT02496065|NA|SINGLE_GROUP||OTHER||NONE||||||
33695759|NCT05921604|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33695760|NCT01270542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695761|NCT02693392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33695762|NCT05847283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695763|NCT04012125|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919321|NCT01678716|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33919322|NCT06412419|||OTHER||PROSPECTIVE|||||||
33919323|NCT03624218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919324|NCT06315205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33999410|NCT01347476|||CASE_CONTROL||RETROSPECTIVE|||||||
33999411|NCT06197867|||OTHER||PROSPECTIVE|||||||
33999412|NCT03624868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pre- and Post-intervention assessments will be conducted by an assessor who is blind to study condition.|Participants will be randomly assigned to Tai Chi or Wellness Education|f|f|f|t
33999413|NCT03366428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999414|NCT01457092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088559|NCT01244659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088560|NCT04277585|NA|SINGLE_GROUP||TREATMENT||NONE|open label|Open feasibility trial of addition of telehealth to an Early Psychosis Coordinated Specialty Service||||
34088561|NCT04492670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088562|NCT02517723|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34088563|NCT05649501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized||t|f|t|f
34088564|NCT02763618|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34088565|NCT01404481|||COHORT||PROSPECTIVE|||||||
34088566|NCT03183206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34088567|NCT06002802|||COHORT||PROSPECTIVE|||||||
34088568|NCT01289522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999415|NCT05128136|RANDOMIZED|CROSSOVER||OTHER||NONE|We propose a randomized, open-label, parallel group, 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 couples. At enrollment, each woman will be randomly assigned to 1 of 6 sequences of IVR use (A-B-C, A-C-B, etc.) and will use each of the 3 IVRs (A, B and C) for 30d per IVR (90d total).|||||
33999416|NCT01653704|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|f|t
33999417|NCT03440658|||CASE_CONTROL||RETROSPECTIVE|||||||
33999418|NCT03611387|||COHORT||PROSPECTIVE|||||||
33999419|NCT00172796|||CASE_CONTROL||OTHER|||||||
33695764|NCT02612129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695765|NCT01851915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695766|NCT00632307|||OTHER||PROSPECTIVE|||||||
33695767|NCT01885871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695768|NCT06708234|||COHORT||OTHER|||||||
33695769|NCT00000671||||TREATMENT||DOUBLE||||||
33695770|NCT01998815|||COHORT||PROSPECTIVE|||||||
33695771|NCT03265678|||OTHER||OTHER|||||||
33695772|NCT02080637|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33695773|NCT06676709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695774|NCT05077878|||CASE_CONTROL||PROSPECTIVE|||||||
33695775|NCT04482712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind clinical trial||t|f|t|f
33695776|NCT01781533|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33695777|NCT02516254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33695778|NCT04926077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695779|NCT02794012|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695780|NCT05665023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695781|NCT03434795|||COHORT||PROSPECTIVE|||||||
33695782|NCT01087242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695783|NCT05809622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695784|NCT02968511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695785|NCT00877110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695786|NCT02810340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33695787|NCT02490410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33695788|NCT00351546|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33695789|NCT00602173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695790|NCT03361033|||COHORT||PROSPECTIVE|||||||
33695791|NCT06316115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695792|NCT05467176|||COHORT||PROSPECTIVE|||||||
33695793|NCT04319731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695794|NCT04708600|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33695795|NCT02031211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088569|NCT01649765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695796|NCT03637179|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Crossover Assignment Including a baseline assessment and assessments at Low altitude and High altitude||||
33695797|NCT00739999|NA|PARALLEL||OTHER||NONE||||||
33695798|NCT04104529|NA|SINGLE_GROUP||OTHER||NONE||||||
33919325|NCT04282057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34088570|NCT02234271|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34088571|NCT03416790|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695799|NCT06327659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695800|NCT00398827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919326|NCT01791699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919327|NCT01582971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919328|NCT03034408|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33919329|NCT01374217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919330|NCT04180995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919331|NCT01054976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919332|NCT00215436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919333|NCT06379867|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33919334|NCT00411736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33919335|NCT05941858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study staff conducting data management and analyses.||f|f|f|t
33919336|NCT05640856|||COHORT||PROSPECTIVE|||||||
33919337|NCT03670069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919338|NCT00966303|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33919339|NCT05663242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33919340|NCT02570282|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33919341|NCT04059406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919342|NCT03897868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919343|NCT01552187|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33919344|NCT02626741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919345|NCT03546790|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33919346|NCT05356741|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919347|NCT04559542|||COHORT||CROSS_SECTIONAL|||||||
33919348|NCT03726619|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33919349|NCT00086944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919350|NCT02831842|||COHORT||PROSPECTIVE|||||||
33919351|NCT05862558|||COHORT||PROSPECTIVE|||||||
33919352|NCT02659605|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919353|NCT04761172|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label pilot study||||
33919354|NCT03848611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919355|NCT04084132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919356|NCT02310906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking Description: Part 1 is double-blind and randomized; Part 2 is open-label.||t|t|t|t
33919357|NCT01354431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919358|NCT05043246|||COHORT||PROSPECTIVE|||||||
33919359|NCT04185441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088572|NCT06436417|||COHORT||PROSPECTIVE|||||||
33695801|NCT02809326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695802|NCT01736020|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33695803|NCT01323946|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects were to be stratified into three age strata (6 to 11 months, 12 to 23 months and 24 to 35 months) in the ratio of 2:1:1.||||
33695804|NCT05201742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695805|NCT02580903|||COHORT||PROSPECTIVE|||||||
33695806|NCT01589328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33695807|NCT06517563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919360|NCT02411383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919361|NCT04768699|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919362|NCT06198075|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be randomized controlled trial used to evaluate the effectiveness of action observation therapy on balance in children with down syndrome. Subjects with down syndrome meeting the inclusion and exclusion criteria will be divided into two groups using non-probability sampling technique.||||
33919363|NCT05738499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33919364|NCT05780346|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed pilot study will include four treatment groups of 6 caregivers (N = 24) receiving the 12-session, 60-minute, video telehealth group intervention.||||
33919365|NCT00843843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33919366|NCT01298622|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919367|NCT01497535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919368|NCT00736788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919369|NCT01899677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919370|NCT00386490|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|double-blind|Phase 1, randomized, double-blind, placebo controlled multi-dose study|t|f|t|f
33919371|NCT02438215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919372|NCT01594333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919373|NCT06314529|||CASE_ONLY||PROSPECTIVE|||||||
33919374|NCT02539355|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33919375|NCT01374763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919376|NCT03908710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999420|NCT00672217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33999421|NCT05821608|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not know treatment status but callers and investigators will not be blinded to treatment status.||t|f|f|f
33999422|NCT00141258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999423|NCT01977456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999424|NCT00327457|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33999425|NCT00238615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999426|NCT03225443|||CASE_CONTROL||PROSPECTIVE|||||||
33999427|NCT04947761|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34088573|NCT05987384|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33695808|NCT01632137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695809|NCT06709729|NA|SEQUENTIAL||TREATMENT||NONE||||||
33695810|NCT02963831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The Phase 1 cohorts were enrolled sequentially. In Phase 2, the two expansion cohorts are enrolled in parallel.||||
33695811|NCT00960739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695812|NCT00200096|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33695813|NCT05774548|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695814|NCT00354471|||||PROSPECTIVE|||||||
33695815|NCT04439175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695816|NCT01822496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695817|NCT00004198||||TREATMENT||||||||
33695818|NCT02616419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33695819|NCT06672146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695820|NCT05401240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695821|NCT02192073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695822|NCT06517212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695823|NCT00390598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33695824|NCT03161132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multicentric||||
33695825|NCT05961878|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695826|NCT04834674|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention：Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres Drug: Apatinib 250mg once daily (QD) oral dosing. Drug: PD-1 antibody 200mg every 3 weeks Other Name: Programmed cell death 1 antibody||||
33695827|NCT03211338|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33695828|NCT05732220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695829|NCT06418893|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomised, controlled, double blind|t|f|t|t
33695830|NCT04704973|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-case experimental design, with a multiple baseline across participants.||||
33695831|NCT06576843|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695832|NCT01977950|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695833|NCT03555734|||OTHER||PROSPECTIVE|||||||
33695834|NCT01456507|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33695835|NCT03788382|||COHORT||PROSPECTIVE|||||||
33695836|NCT02147028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695837|NCT01672762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695838|NCT05268055|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33695839|NCT06599697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Using an online randomization tool (e.g. REDCap), 12 total participants will be randomized 1:1 in blocks of 4 to receive either intravenously administered pooled human immunoglobulin (IVIG) 2g/kg every 4 weeks or placebo (0.9% sodium chloride solution at equivalent volume to corresponding IVIG weight-based dose). The research pharmacy will assign treatment status using the randomization tool and will prepare IVIG or placebo for clinical research unit staff in a blinded fashion.|A randomized, placebo-controlled, double blinded phase 2 exploratory clinical trial of intravenously administered pooled human immunoglobulin (IVIG) in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune mediated necrotizing myopathy (IMNM). Planned enrollment is 12 individuals with active anti-HMGCR IMNM meeting inclusion and exclusion criteria. Enrolled participants will be randomized 1:1 to receive either IVIG 2g/kg or placebo (0.9% sodium chloride at equivalent volume) at weeks 0, 4, and 8. The 2g/kg q4 weeks regimen of IVIG was chosen based on the investigators' clinical experience and prior studies. The primary endpoints will be assessed at week 12. After the randomized phase of the trial, all participants, except those who were randomized to IVIG and met the clinical deterioration criteria, will be offered an open-label extension to receive IVIG at weeks 12, 16, and 20.|t|f|t|f
33784454|NCT06714383|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33784455|NCT06389786|NA|SINGLE_GROUP||SCREENING||NONE||||||
34088574|NCT02310308|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784456|NCT06711120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784457|NCT06395311|||COHORT||CROSS_SECTIONAL|||||||
33784458|NCT06371417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784459|NCT05036772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784460|NCT05974605|NA|SINGLE_GROUP||PREVENTION||NONE||The trail will collect data from a single group. The results will be compared to a previously collected data from two arms of an RCT.||||
33784461|NCT06174896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Sealed opaque envelopes containing study participation numbers will be used to assign each patient. A researcher not involved in patient follow-up will use the web-based Research Randomizer (Urbaniak and Plous 2013) tool to give each participation number to a random group with a 1:1:1 ratio.~A nurse not an active investigator in the study will have each participant choose an envelope containing the study participation number. They will inform the anesthetist who will administer the methods which group the patient is in immediately before administration. Researchers, patients, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program, 'Research Randomizer (Urbaniak and Plous 2013)'.|t|t|t|t
33784462|NCT06712056|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||quasi-experimental study with a pretest posttest controlgroup design||||
33784463|NCT05968508|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33784464|NCT04601857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784465|NCT05437471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All recruited women will be allocated in three groups, and endometrial tissue sampling will be obtained prior to medical intervention assigned during luteal phase depending on their menstrual cycle. All these women will be divided randomly in three groups A, B \& C equally by using the auto-randomized program in SPSS version 21.0.||||
33784466|NCT04287166|||COHORT||PROSPECTIVE|||||||
33919377|NCT04358198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The surveillance EGD in patients with GIM will be done as scheduled and then pictures at GIM lesions and normal mucosa was done and sending to AI for learning. Then AI will be used for diagnosing GIM by using pathology as a gold standard||||
33919378|NCT04997824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919379|NCT00218790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33919380|NCT05314361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the research coordinator cannot be blinded to group condition though the research assistants making reminder calls and data analysts will not be aware of group status.|A parallel-group Ontario-wide RCT with experimental (workshop) and TAU (control) groups will address our objectives. Participants will be randomly assigned in a 1:1 ratio to the treatment or control groups.|f|f|t|t
33919381|NCT04643223|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This process will only be known to the researcher responsible for the project that will apply the kinesio tape on the scars; guaranteeing the concealment of the allocation with the triple masking, since the patients, the evaluators responsible for the Vancouver evaluation, the analysis of the histological and immunohistochemical material and the statistic will not be aware of this process.|Clinical trial randomized triple blind sham controlled. An experimental group that will use the elastic bandage with seventy to ninety percent tension on the hypertrophic scar. It was a controlled sham that had used the elastic bandage without strain on the hypertrophic scar.|t|t|f|t
33919382|NCT00040014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088575|NCT00479752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088576|NCT02818673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088577|NCT01056276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784467|NCT00097474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784468|NCT02124460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784469|NCT05450783|||COHORT||PROSPECTIVE|||||||
33784470|NCT01218503|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33784471|NCT06593054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784472|NCT05825820|NA|SINGLE_GROUP||PREVENTION||NONE||Open, non-randomized single-arm design||||
33784473|NCT05767450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized in blind (by a computer) in 1:1 allocations. Participants enrolled in both arms and their parents wil be blinded to treatment as sachets provided will be identical as will be the visual aspect and taste of the Vivomixx probiotic.|Interventional, randomized (1:1), 2-arm, single-center, placebo controlled|t|f|f|f
33784474|NCT02527850|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33784475|NCT06711419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784476|NCT04274179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms (diet and drugs) with ability to cross-over at 1 or 3 months.||||
33784477|NCT06350123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentre, randomised, double-blind, dose-finding, parallel group, double-dummy|t|t|t|t
33784478|NCT06122415|||COHORT||PROSPECTIVE|||||||
33784479|NCT06293963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784480|NCT06505980|NA|SINGLE_GROUP||TREATMENT||NONE|Coders will be masked to treatment time-point when measuring observed outcomes.|||||
33784481|NCT00971009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784482|NCT06711367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34088578|NCT04060836|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34088579|NCT00998283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919383|NCT04075526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919384|NCT03110198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919385|NCT00855257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088580|NCT02834273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919386|NCT03272360|||COHORT||PROSPECTIVE|||||||
33919387|NCT04473144|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919388|NCT06043661|||COHORT||PROSPECTIVE|||||||
33919389|NCT05782166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919390|NCT05816967|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919391|NCT01913808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919392|NCT04009213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization to either Investigational or control device will occur at the surgery visit. The patients will be blinded to their randomly assigned treatment device prior to surgery and during the follow up period following surgery. While it is not possible to blind investigators/staff members to the treatment device used, Investigators and staff members will not learn of randomized device until immediately prior to use of device, so as to maintain subject blinding prior to the hernia repair. Investigators and staff members will be asked to maintain subject blinding through the course of the follow up visits so as to not bias subject feedback on applicable study assessments. Patients will receive the same standard of care prior to, during and following surgery regardless of randomized device assignment, and therefore will not be able to individually determine what device they have been randomized to.|Patients will be randomized to one of two treatment arms, LiquiBand FIX8® or Control (AbsorbaTack™) device at a 1:1 ratio. Subjects will also be randomized according to laparoscopic technique used (TEP or TAPP hernia repair procedure), so that there is appropriate distribution between the Investigational and control devices. Randomization will occur immediately prior to use of either device for mesh fixation (TEP repairs) or mesh fixation and peritoneal closure (TAPP repairs only) and only after the Investigator has laparoscopically inspected the site of repair and determined the patient to be eligible for participation in the study.|t|f|f|f
33919393|NCT04876989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088581|NCT03018327|||CASE_CONTROL||PROSPECTIVE|||||||
34088582|NCT05839977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088583|NCT01877798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088584|NCT01983631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088585|NCT01503788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919394|NCT04980313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088586|NCT01944423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088587|NCT00825006||CROSSOVER||TREATMENT||NONE||||||
33919395|NCT04536649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919396|NCT03485092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo controlled trial|Randomised, placebo controlled trial|t|t|t|t
33919397|NCT04873076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919398|NCT04366752|||CASE_ONLY||PROSPECTIVE|||||||
33919399|NCT05521100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33919400|NCT02227108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919401|NCT04611178|||COHORT||RETROSPECTIVE|||||||
33919402|NCT05385874|||COHORT||PROSPECTIVE|||||||
33919403|NCT02766322|||OTHER||OTHER|||||||
33919404|NCT06006884|||COHORT||PROSPECTIVE|||||||
33919405|NCT00773123|||||PROSPECTIVE|||||||
33695840|NCT04110587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment allocation was concealed from participants and examiner (using sealed and numbered opaque envelopes by the research coordinator), and the data analyst (by encoded data).||t|f|t|t
33695841|NCT03110744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695842|NCT04562493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695843|NCT04302818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Teacher-assessors are blinded pre-, post, and follow-up.||f|f|f|t
33695844|NCT01243671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695845|NCT01039844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695846|NCT05324332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695847|NCT06709794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33695848|NCT04338984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695849|NCT01241773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695850|NCT01842815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695851|NCT05773703|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Each Trillium Compound will first be evaluated alone, then with single doses (5, 10, 15 mg) of the cytoprotective agent, PTI-122. Trillium Compound with two doses of PTI-122 at the preferred dose level may be studied if indicated.||||
33695852|NCT05010720|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695853|NCT05426798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695854|NCT06288126|||COHORT||PROSPECTIVE|||||||
33695855|NCT03708848|NA|SINGLE_GROUP||TREATMENT||NONE||After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid and two sensitive ones of clarithromycin, metronidazole,levofloxacin and tetracycline.||||
33784483|NCT00092560||||TREATMENT||||||||
33784484|NCT00444574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695856|NCT05394714|NA|SEQUENTIAL||TREATMENT||NONE||||||
33695857|NCT03969511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695858|NCT01674283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33695859|NCT04399837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088588|NCT03365648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|A randomized, double-blinded, parallel-group, placebo-controlled clinical study|t|f|t|f
33695860|NCT04795622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784485|NCT06480968|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"FIH-CTH120-SAD and FIH-CTH120-MAD: double-blind, placebo-controlled trial preventing the knowledge of the study drug allocation. Thus, all trial stakeholders but the Pharmacy personnel will be blinded throughout the trial including the Sponsor personnel, the participating subjects, the study team at the investigational site, including the person administering the study drugs to the subject as well as the CRO personnel involved in the data management and statistical analysis.~FIH-CTH120-FI: open-label study."|"FIH-CTH120-SAD: Prospective, monocentre, double-blind, randomized, placebo-controlled, subsequent-group, Phase I investigation to assess the safety, tolerability and pharmacokinetics of CTH120 administered orally in single ascending doses.~FIH-CTH120-MAD: Prospective, monocentre, double-blind, randomized, placebo-controlled, subsequent-groups, Phase I investigation to assess the safety, tolerability and pharmacokinetics of CTH120 administered orally in multiple ascending doses.~FIH-CTH120-FI: Prospective, open-label single dose, two-condition (fed versus fasting), two sequences, crossover Phase I investigation to assess the effects of food on the bioavailability of CTH120."|t|t|t|t
33784486|NCT03593317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784487|NCT03528954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33784488|NCT06516887|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1b of the study will be conducted to establish the maximum tolerable dose, after pharmacokinetic samples from the first 10 subjects have been collected they will commence Cycle 1, Day 1 treatment. Phase 2 will then be enrolled in a single arm comparison study where some patients will be selected to undergo biopsy.||||
33784489|NCT05580146|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Triple masking|Balanced crossover|t|f|t|t
33784490|NCT06713356|||OTHER||CROSS_SECTIONAL|||||||
33919406|NCT05631054|||CASE_CONTROL||RETROSPECTIVE|||||||
33919407|NCT01833780|||COHORT||PROSPECTIVE|||||||
33919408|NCT06248905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919409|NCT05041322|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33919410|NCT05147974|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This is a clinical trial as the DOZE app intervention is being assessed for improving outcomes in the YAC patient population.~We propose a cohort of the YAC patients to be studied, pre \& post-intervention, prospectively.~All participants will be assigned to the intervention (complete DOZE app: Sleep diary and DOZE modules).~Optional Actigraphy device use for measuring physical activity, sedentary behavior, sleep health parameters."||||
34088589|NCT01939457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088590|NCT01560117|NA|SINGLE_GROUP||TREATMENT||||||||
34088591|NCT01092923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088592|NCT05920226|||COHORT||PROSPECTIVE|||||||
34088593|NCT04682301|||COHORT||PROSPECTIVE|||||||
34088594|NCT02880501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088595|NCT04355273|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34088596|NCT05732389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088597|NCT01848028|||COHORT||PROSPECTIVE|||||||
34088598|NCT00005996||||TREATMENT||||||||
34088599|NCT05255107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Simple block randomization will be used to assign subjects in a 1:1 ratio to 2 treatment arms. Subjects will be randomized consecutively (not stratified by site) to ensure balance between the treatment arms at any point in the study.|t|f|f|f
34088600|NCT03250806|||COHORT||PROSPECTIVE|||||||
33695861|NCT05678582|||COHORT||CROSS_SECTIONAL|||||||
33695862|NCT04622462|||COHORT||PROSPECTIVE|||||||
33695863|NCT03469570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695864|NCT05059587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695865|NCT01147172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695866|NCT05135247|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals were randomized into four groups: continuous aerobic training (CA), interval aerobic training (IA), resistance training (R), and control (C), which performed physical exercises three times a week for twelve weeks, with a total of 36 sessions. The tilt test was performed before and after the research protocol. Individuals in the control group were only encouraged to maintain their usual activities.||||
33695867|NCT01945112|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33695868|NCT05588271|||COHORT||RETROSPECTIVE|||||||
33695869|NCT04053634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695870|NCT01509508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695871|NCT01079507|||CASE_ONLY||RETROSPECTIVE|||||||
33695872|NCT02783677|||CASE_CONTROL||PROSPECTIVE|||||||
33695873|NCT00920101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919411|NCT00379262|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33695874|NCT00225446|NON_RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33695875|NCT00943124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695876|NCT03796533|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33695877|NCT06064604|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study includes one pre-specified group, stroke survivors, to receive intervention with two exoskeleton devices.||||
33695878|NCT03998878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695879|NCT02240225|||||PROSPECTIVE|||||||
33695880|NCT01295229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695881|NCT01225887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695882|NCT05016219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33695883|NCT00140946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695884|NCT03024814|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33695885|NCT01086423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784491|NCT03142789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Please see Model Description"|The study is performed as a blinded, randomized, controlled study. Randomization will be based on a computer-generated block randomization list in a 1:1:1 ratio, block sizes of 9. A person, not otherwise involved in the study, will prepare the randomization list and keep it, locked away in a secure place. 2 sets of consecutively numbered, sealed, opaque, code envelopes will be prepared by the same person.|t|t|f|t
33784492|NCT05044130|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33784493|NCT06712251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784494|NCT06458673|||COHORT||PROSPECTIVE|||||||
33695886|NCT03819426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695887|NCT06680115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784495|NCT05049382|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33784496|NCT06419621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784497|NCT06043700|||COHORT||PROSPECTIVE|||||||
33784498|NCT01227356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784499|NCT06625762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33784500|NCT03983161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784501|NCT03628079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784502|NCT05893966|||COHORT||PROSPECTIVE|||||||
33784503|NCT06707272|||COHORT||RETROSPECTIVE|||||||
33784504|NCT03302065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33784505|NCT06614569|||COHORT||PROSPECTIVE|||||||
33784506|NCT03681639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784507|NCT01875835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784508|NCT05447923|NA|SINGLE_GROUP||SCREENING||NONE||||||
33784509|NCT06703892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784510|NCT02887378|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784511|NCT03511248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study, with randomisation undertaken by Barts Cardiovascular Clinical Trials Unit|Randomised double-blind placebo-controlled parallel two-limb study|t|t|t|t
33784512|NCT02735252|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33784513|NCT04199156|||COHORT||PROSPECTIVE|||||||
33784514|NCT01390857|||OTHER||PROSPECTIVE|||||||
33784515|NCT06613698|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33784516|NCT05475470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784517|NCT05700123|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33784518|NCT02890693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784519|NCT02552277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919412|NCT06293677|RANDOMIZED|PARALLEL||TREATMENT||NONE||Our study is an open-label, re-randomized controlled trial in multi-episodes settings. So the care team, researchers and patients will be informed of the allocation group. Patients will be able to participate in each episode of febrile neutropenia. At each inclusion the patient may be in a different group.||||
33919413|NCT00997321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919414|NCT04453904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695888|NCT00837928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695889|NCT04579848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical placebo cannot be produced due to text, color and shape of methotrexate tablets. Thus, both placebo and methotrexate will be encapsulated to ensure blinding.|An investigator-initiated, randomized, double-blinded, placebo-controlled, parallel-group, single-center, phase IV, superiority study, exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.|t|t|t|t
33695890|NCT01104155|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695891|NCT03885440|||CASE_CONTROL||RETROSPECTIVE|||||||
33784520|NCT04230694|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Dexcom Generation 6 CGM (Dexcom Gen6) device||||
33919415|NCT04333121|||COHORT||RETROSPECTIVE|||||||
34088601|NCT00593814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088602|NCT00001038||||TREATMENT||||||||
33695892|NCT00603785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695893|NCT02041988|||CASE_CONTROL|||||||||
33695894|NCT05658003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784521|NCT02652130|NA|SINGLE_GROUP||OTHER||NONE||||||
33784522|NCT06116019|||COHORT||PROSPECTIVE|||||||
33919416|NCT04882709|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33919417|NCT06141655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33695895|NCT00336154|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33695896|NCT05715333|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33695897|NCT00979069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695898|NCT00244517|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33695899|NCT06519825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33695900|NCT02640469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33695901|NCT04034082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695902|NCT00869427|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33695903|NCT03773380|NA|SINGLE_GROUP||OTHER||NONE||||||
33695904|NCT06237647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695905|NCT06482749|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33695906|NCT04308603|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695907|NCT00932737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33695908|NCT04022434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33695909|NCT02163980|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33695910|NCT02887573|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33695911|NCT03799211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695912|NCT01923714|||CASE_ONLY||PROSPECTIVE|||||||
33695913|NCT04769856|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33695914|NCT00731016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695915|NCT00426998|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33695916|NCT01670604|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33695917|NCT02640716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695918|NCT02291744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695919|NCT01549470|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33695920|NCT00537784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784523|NCT06714175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Two long-term care centers were selected for the study. One center was randomly assigned to the experimental group through a lottery system, while the other served as the control group.|This is a randomized controlled trial with a parallel assignment model. Participants are randomly assigned to either the experimental group or the control group. The experimental group undergoes lower limb leg press power training combined with visual feedback games twice a week for 12 weeks, while the control group maintains their usual daily activities. The outcomes are assessed before and after the 12-week intervention, focusing on physical performance, cognitive function, and heart rate variability (HRV).||||
33784524|NCT06613464|||CASE_ONLY||PROSPECTIVE|||||||
33695921|NCT03092024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33695922|NCT03130491|NA|SINGLE_GROUP||OTHER||NONE||||||
33695923|NCT03642665|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter prospective randomized clinical trial||||
33695924|NCT03414671|||COHORT||OTHER|||||||
33695925|NCT06160076|||COHORT||PROSPECTIVE|||||||
33695926|NCT03449368|||COHORT||RETROSPECTIVE|||||||
33695927|NCT01742936|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695928|NCT05126953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695929|NCT00101712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33695930|NCT03004443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695931|NCT03170076|||CASE_CONTROL||PROSPECTIVE|||||||
33695932|NCT06415942|NA|SINGLE_GROUP||OTHER||NONE||||||
33784525|NCT00232193|||CASE_CONTROL||PROSPECTIVE|||||||
33784526|NCT03860246|||COHORT||PROSPECTIVE|||||||
33784527|NCT02606292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784528|NCT06711601|||CASE_CONTROL||PROSPECTIVE|||||||
33784529|NCT04074954|||COHORT||PROSPECTIVE|||||||
33784530|NCT02739568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784531|NCT04651361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Naldebain (active drug in solvent containing benzyl benzoate and sesame oil) or placebo drug (solvent containing benzyl benzoate and sesame oil) will be prepared by the clinical pharmacists in an identical injection syringe within 30 min before injection. The participants, anesthesiologists, surgeons, investigators and outcomes assessors will be blinded to the treatment groups.||t|t|t|t
33784532|NCT03547999|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-Label|||||
33695933|NCT03891836|||OTHER||CROSS_SECTIONAL|||||||
33695934|NCT03875235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Durvalumab in Combination with Gemcitabine plus Cisplatin Placebo in Combination with Gemcitabine plus Cisplatin|t|t|t|t
33695935|NCT01199328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695936|NCT03563287|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695937|NCT04768725|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33695938|NCT05860335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695939|NCT06709664|||CASE_ONLY||CROSS_SECTIONAL|||||||
33695940|NCT05726734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695941|NCT01848704|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33695942|NCT01459237|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33695943|NCT05964205|||COHORT||OTHER|||||||
33695944|NCT01631812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695945|NCT01291654|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33695946|NCT01327456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33695947|NCT04152044|||COHORT||RETROSPECTIVE|||||||
33919418|NCT01480557|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33919419|NCT03719482|NA|SINGLE_GROUP||OTHER||NONE||||||
34088603|NCT01636843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919420|NCT05475574|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33919421|NCT05677191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919422|NCT04090047|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33919423|NCT00164736|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34088604|NCT02043067|||COHORT||PROSPECTIVE|||||||
33919424|NCT05665244|||CASE_ONLY||PROSPECTIVE|||||||
34088605|NCT00855608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919425|NCT03270553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919426|NCT05915494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088606|NCT06282055|||COHORT||PROSPECTIVE|||||||
33919427|NCT02450734|||CASE_ONLY||PROSPECTIVE|||||||
34088607|NCT04525092|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot, Randomised, Open-label, Parallel Groups (co-intervention, 1:1:1) of three interventions: conventional HD, pre-dilution HDF and post-dilution HDF||||
34088608|NCT03261401|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34088609|NCT02608606|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088610|NCT01950663|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088611|NCT06436638|||COHORT||PROSPECTIVE|||||||
34088612|NCT00970580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088613|NCT02921100|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34088614|NCT05169983|||COHORT||CROSS_SECTIONAL|||||||
34088615|NCT00535184|||COHORT||PROSPECTIVE|||||||
34088616|NCT02821845|||CASE_CONTROL||PROSPECTIVE|||||||
33919428|NCT02247401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919429|NCT00245414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919430|NCT01541527|||COHORT||PROSPECTIVE|||||||
33919431|NCT03943979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The difference between the two groups is the tDCS therapy. To mask this difference, the duration time of the session will be the same under both conditions but a standard Sham tDCS protocol will be used for the Active Control group. That is, a 3-sec ramp-up and ramp-down current stimulation, so the subject perceives the current just like the real tDCS, but it is not strong nor durable enough to have any effect on the neuronal activity.|"Active Control group: Subjects will receive CT and sham tDCS during four consecutive days.~Active group: Subjects will receive CT and active tDCS during four consecutive days."|t|t|t|t
33919432|NCT01890512|||COHORT||PROSPECTIVE|||||||
33919433|NCT01214317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919434|NCT01921946|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33919435|NCT04209894|||CASE_CONTROL||PROSPECTIVE|||||||
33919436|NCT05618275|||CASE_ONLY||RETROSPECTIVE|||||||
33919437|NCT01199055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919438|NCT03219892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919439|NCT03258697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient blinded, observer blinded study|"1. PCA only~2. Peri-articular Levobupivacaine + PCA~3. Intra-articular Levobupivacaine + PCA"|t|t|f|t
33919440|NCT03480204|||COHORT||PROSPECTIVE|||||||
33999428|NCT04654429|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||All patients participating in this study will be randomised two times into 4 groups: LP, HP, LO, HO (L= low-temperature range, H= high-temperature range, P= placebo, O=Ondansetron). The OT temperature will be set to a random range on every Monday, 7am to either lower temperature range group (17.0-19.0⁰C), set at 18.0⁰C; or higher temperature range group (19.1-22.0⁰C), set at 21.0⁰C by an OT engineer who is not involved in this study. OT engineer will open a sealed opaque envelope which contains target temperature to be set for the week, which is randomised prior using computer generated sequence. The temperature setting will maintain for one week and change on the following Monday 7am.|t|t|t|t
33999429|NCT05789121|||COHORT||PROSPECTIVE|||||||
33999430|NCT05662605|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 randomization||||
33999431|NCT05274022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999432|NCT05336669|||COHORT||PROSPECTIVE|||||||
33999433|NCT02077907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784533|NCT05502380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The microbiologists culturing the pathogens of eventual surgical site infections are blinded to the prior prophylaxis during the index surgery|At enrollment (Day 1), the investigator will prescribe the preoperative antibiotic prophylaxis based on instructions provided in the protocol according to the patient's randomization. Patients will be randomized in the ratio 1:1 into the investigational group (broad-spectrum prophylaxis) and the control group (usual prophylaxis). Each patient can be included several times with one episode for each surgical interven-tion in the operating theatre. The initial consent form is valid during 1 month and will be renewed in case of another inclusion following a delay of 1 month after the initial signature of the patient.|f|t|f|f
33784534|NCT06635824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999434|NCT03515044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding will be maintained in the QD SSD cohorts by administering placebo as the second daily dose.|Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study|t|t|t|f
33784535|NCT01695343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088617|NCT03502109|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Each participant will sign an informed consent, without knowing that there is another group of patients.||t|f|f|f
34088618|NCT02970864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088619|NCT02430233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088620|NCT01737528|||COHORT||PROSPECTIVE|||||||
34088621|NCT01240694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784536|NCT02394834|||COHORT||PROSPECTIVE|||||||
34088622|NCT01126424|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34088623|NCT02730104|||COHORT||PROSPECTIVE|||||||
34088624|NCT04075175|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34088625|NCT05801692|||COHORT||PROSPECTIVE|||||||
34088626|NCT02385890|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33784537|NCT06055777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919441|NCT03894774|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Pseudonymization at first stage of the intervention. Additional anonymization for all outcomes assessors.|"The study was conducted in the following randomized waiting control design:~After being included in the study at time T0 the children stay in Treatment-As-Usual (TAU) for at least three months and are then randomly assigned to the Intensive Inpatient Psychotherapy Treatment Group (IG) or the Waiting Control Group (WCG) after this TAU time period (This period is considered necessary and sufficient in order to reliably estimate possible trends of changes in the brain). The children in the WCG stay in TAU and are assigned to the IG as soon as a treatment place is available. The waiting period will be included in the analysis as a confounder. The third group is a Healthy Control Group (HCG) of matched pairs (matched for gender, age and handedness)."|f|f|f|t
33919442|NCT05060783|||COHORT||PROSPECTIVE|||||||
33919443|NCT05108480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919444|NCT03101514|NA|SINGLE_GROUP||PREVENTION||NONE||Kanglaite injection + Radiotherapy ± Chemotherapy||||
33919445|NCT03314558|||COHORT||PROSPECTIVE|||||||
33919446|NCT04324918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919447|NCT05731843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919448|NCT01195363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999435|NCT00563394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999436|NCT00366639|||COHORT||PROSPECTIVE|||||||
34088627|NCT00988026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34088628|NCT06127732|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, crossover intervention study conducted with participants selected by the investigators, and invited to participate in the study.||||
34088629|NCT00218010|||COHORT||PROSPECTIVE|||||||
34088630|NCT02954770|||COHORT||CROSS_SECTIONAL|||||||
34088631|NCT02741284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34088632|NCT02467816|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088633|NCT01516099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088634|NCT04553094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||3 groups of physical training intervention compared with control group||||
34088635|NCT04254757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088636|NCT05505552|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33919449|NCT03497442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a split face study. All participants will follow an identical protocol with active medication applied to half of their face and placebo applied to the other half. Treatment and placebo side will be randomized.||t|t|t|t
33919450|NCT00000196||||TREATMENT||DOUBLE||||||
33919451|NCT02585726|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999437|NCT01334593|||COHORT||PROSPECTIVE|||||||
33919452|NCT00565656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919453|NCT06467123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919454|NCT02294318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919455|NCT02943005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919456|NCT00000450|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Naltrexone and placebo were identical in appearance and packaging to preserve the double blind.|Naltrexone 50 mg was provided for 3 months to all study participants, who were masked regarding the identity of study medication. At 3 months, full and partial responders were randomized to an additional 9 months of double blind treatment with naltrexone or matched placebo. Full responders were defined as complete abstinence for the last six weeks of the acute phase. Partial responders were defined as having no more than 2 heavy drinking days in any given week and/or a 50% reduction in weekly alcohol consumption from baseline over the last six weeks of the acute phase.|t|t|t|t
33919457|NCT01922778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919458|NCT03019224|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|t|f
33919459|NCT03177265|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The investigators will first randomize each Veteran, stratified by site, to: a) Text-to-Engage vs. standard Proactive Outreach (PrO). For those who enroll in counseling, the investigators will then randomize them to: b) Text-to-Enhance + Telephone Counseling vs. Telephone Counseling alone (TelC). Primary outcomes will be the rate of enrollment in counseling and cotinine-verified quit rate at 12 months.|f|f|t|t
33999438|NCT05462548|NA|SINGLE_GROUP||TREATMENT||NONE||18 years old or above||||
33999439|NCT06253117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999440|NCT01020825|||OTHER||PROSPECTIVE|||||||
34088637|NCT01915316|||COHORT||CROSS_SECTIONAL|||||||
33919460|NCT05437393|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33695948|NCT03298776|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33695949|NCT04499976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind randomized controlled study|double blind randomized controlled study|t|t|t|t
33695950|NCT02520661|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33695951|NCT05542186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695952|NCT03250871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33695953|NCT06665672|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the condition (arm) when the ApolloNeuro device is to be applied.||t|f|f|f
33695954|NCT04048551|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This is a cluster randomized trial that utilizes a 2 x 2 factorial design to assess the impact of S\&D reduction training and the YWHC intervention, resulting in four study conditions: (1) Clinic S\&D reduction training + PrEP/SRH + YWHC, (2) Clinic S\&D reduction training + PrEP/SRH only, (3) No Clinic S\&D reduction training +PrEP/SRH + YWHC, (4) No Clinic S\&D reduction training + PrEP/SRH only. The researchers will examine two primary endpoints: (1) the proportion of AGYW who are ready to uptake and initiate PrEP and SRH services; and, (2) the differences in levels of PrEP adherence between each intervention condition and the standard of care comparison at 3-, 6- and 9-month follow-up.||||
33695955|NCT02602899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695956|NCT06221917|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33695957|NCT05352399|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919461|NCT00004207||||TREATMENT||||||||
33919462|NCT00003893|RANDOMIZED|||TREATMENT||||||||
33919463|NCT03411057|||COHORT||PROSPECTIVE|||||||
33919464|NCT00507598|||||PROSPECTIVE|||||||
33919465|NCT02614287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919466|NCT04632537|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33919467|NCT02546427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919468|NCT00664209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919469|NCT03798184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919470|NCT01511107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919471|NCT00598715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919472|NCT05611099|NA|SINGLE_GROUP||OTHER||NONE||||||
33919473|NCT03795818|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open clinical trial of an psychosocial intervention for adolescents||||
33919474|NCT02368080|||COHORT||CROSS_SECTIONAL|||||||
33919475|NCT04840017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919476|NCT04641390|||OTHER||RETROSPECTIVE|||||||
33919477|NCT04157868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919478|NCT01314976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919479|NCT02201381|NA|SINGLE_GROUP||TREATMENT||NONE||Matched historical control comparison||||
33999441|NCT03862547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999442|NCT00834613|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34088638|NCT00056680|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34088639|NCT00482092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088640|NCT04399447|||CASE_CONTROL||PROSPECTIVE|||||||
34088641|NCT00169312|RANDOMIZED|||||SINGLE||||||
34088642|NCT00189930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695958|NCT00477932|||||PROSPECTIVE|||||||
33695959|NCT01902433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33695960|NCT05400915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088643|NCT03932357|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088644|NCT06003413|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33695961|NCT04107779|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized, Open-Label, Parallel-Group||||
33999443|NCT04902963|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|2 examiners used otomicroscopy to document the function of the ear tube by documenting the number of weeks the lumen remained patent and the number of weeks until the device was fully resorbed. All examiners documented results independent of the other examiner.|14 patients underwent placement of a novel absorbable ventilation tube to test utility of this prototype device and monitor resorption over a period of weeks. 14 participants were approved for this study of feasibility to allow for patients who did not follow up per the study protocol.||||
33695962|NCT03882788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|EEG, metabolic/NMRS analysis and neurodevelopment outcome is blinded.||f|f|f|t
33999444|NCT00840658|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33695963|NCT02370277|||CASE_CONTROL||PROSPECTIVE|||||||
33695964|NCT03566511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The subject will be blinded to which study drug is received first (Drug or Placebo).This protocol follows a double blinded, randomized, crossover design.||t|f|f|f
33695965|NCT04953299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not be masked to group allocation, data collection will be completed by a student apprentice blind to condition.|Two groups of participants- one acts a control group and accesses the NHS 12 week programme the other group receives the FIT intervention.|f|f|f|t
33695966|NCT06016192|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm randomized||||
33999445|NCT05344118|||COHORT||PROSPECTIVE|||||||
33999446|NCT06214832|||CASE_ONLY||PROSPECTIVE|||||||
33999447|NCT03960762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant will be blinded to the study|Fifty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for VATS under general anesthesia will be included in the study. Patients with a history of bleeding diathesis, receiving anticoagulant treatment, known local anesthetics and opioid allergy, infection of the skin at the site of the needle puncture, pregnancy or lactation, and patients who do not accept the procedure will be excluded from the study. Randomization will be achieved using a randomizing computer program. Patients will be randomly divided into two groups (Group A = ESP group, Group B = SAP group) including 25 patients each, before entering the operating room.|t|f|f|t
33999448|NCT03816449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088645|NCT00521183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088646|NCT01493817|||CASE_ONLY||RETROSPECTIVE|||||||
34088647|NCT05723770|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot, open label, single-arm, single-center study will consist of 2 study visits in subjects with dry eye disease associated with MGD. A Screening Visit will occur to verify subjects are eligible to participate followed by an Assessment Visit to evaluate tear film parameters at baseline and over approx. 4 hours following a single instillation of NOV03||||
34088648|NCT05803707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088649|NCT05576896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088650|NCT03824431|||CASE_CONTROL||PROSPECTIVE|||||||
34088651|NCT06516471|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34088652|NCT00312416|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34088653|NCT04818775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088654|NCT00265278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088655|NCT04329819|||COHORT||RETROSPECTIVE|||||||
33695967|NCT03857035|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33695968|NCT01279473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695969|NCT00001137|||COHORT||PROSPECTIVE|||||||
33695970|NCT00985816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33695971|NCT00126607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088656|NCT03407456|||COHORT||PROSPECTIVE|||||||
34088657|NCT03252626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784538|NCT05279963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the characteristics of acupuncture, acupuncture manipulators cannot be blinded. Nevertheless, to avoid the subjective bias of researchers and subjects, outcome assessment and statistical analysis will be performed by different researchers blinded to the allocation information. Patients are informed that they will receive one of two effective acupuncture interventions after enrollment, and during the treatment, patients in EA or SA groups will be in separate rooms to avoid communication. The participant' s allocated intervention will not be revealed until the statistical analysis reports are completed.||f|f|f|t
33784539|NCT03034382|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34088658|NCT05076227|||COHORT||PROSPECTIVE|||||||
34088659|NCT00474513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088660|NCT04712461|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34088661|NCT05475509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The research will be carried out by applying an experimental research design with a control group, pre-test-post-test applied, repetitive measurement.||||
33784540|NCT06599021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784541|NCT06188260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784542|NCT06582251|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784543|NCT05139056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784544|NCT06711900|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a 1:1 ratio to one of two intervention groups.||||
33784545|NCT06626685|||COHORT||PROSPECTIVE|||||||
33784546|NCT04913649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and patient will be blinded for treatment allocation. As the IVI solution is brown and the placebo solution is colourless, the infusion bags and lines will be light-protected in order to prevent identification of the investigational product.|Two center randomized controlled trial. Patients will either receive IVI (Monofer) or placebo. Via a computer generated randomization patients will be randomly assigned (1:1) to either a single dose of intravenous ferric derisomaltose (Monofer) 100 mg/mL solution for infusion (intervention group) or intravenous NaCl 0.9% (placebo group) (randomisation with block size 4). Stratification takes surgical intervention (AVR or CABG) and hospital location into account.|t|f|t|f
33784547|NCT00903045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784548|NCT06031441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919480|NCT01615796|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33919481|NCT06430710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixteen patients with anterior deep over bite participated in two groups each group contains eight patients||||
33919482|NCT03076866|||COHORT||PROSPECTIVE|||||||
33919483|NCT02759302|||CASE_ONLY||PROSPECTIVE|||||||
33919484|NCT04684914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919485|NCT00274768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025067|NCT04547842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Randomization will be done using computer-generated number table of random numbers in a 1:1 ratio in opaque and sealed envelope (SNOSE). The assigned treatment will be written on a card and sealed in opaque envelopes consecutively numbered. These envelopes will be opened just immediately before administering the medication in the patient's room.~The study drugs will be prepared by the hospital pharmacy and the patients, follow-up will be conducted by an anaesthesia resident who is not involved in any other part of the study.The patients and the investigators who collected the data will be blinded to the patient's group"|"patients will be randomly divided into 2 equal groups; The M(Mirtazapine) group:(n=45) each patient will receive an oral disintegrating tablet (ODT) of mirtazapine 30 mg with sips of water and 100 ml 0.9% sodium chloride (IVI) over 15 min as a placebo 1 h preoperatively.~The D (Dexamethasone) group: (n=45) each patient will receive a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 min, 1 h preoperatively"|t|t|t|t
34025068|NCT03764098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695972|NCT01933711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695973|NCT04790396|||CASE_ONLY||PROSPECTIVE|||||||
33695974|NCT06161571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33695975|NCT01776047|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33695976|NCT05912660|||OTHER||RETROSPECTIVE|||||||
33695977|NCT02836353|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33695978|NCT05544370|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33695979|NCT00488280|||COHORT||PROSPECTIVE|||||||
33695980|NCT04701788|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Study group is PPV23 revaccination and control group PPV23-vaccination.||||
33695981|NCT00453518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33695982|NCT03508375|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33695983|NCT06710249|NA|SEQUENTIAL||TREATMENT||NONE||||||
33695984|NCT04099342|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33695985|NCT06087458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 will enroll in a dose escalation study model, followed by a Phase 2a cohort that will be randomized among two arms.||||
33695986|NCT03727425|NA|SINGLE_GROUP||OTHER||NONE||||||
33919486|NCT01107405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33919487|NCT00425477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33695987|NCT03939156|||COHORT||PROSPECTIVE|||||||
33695988|NCT02752204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695989|NCT06244017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33695990|NCT01209728|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33695991|NCT04462510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were randomized using computer generated numbers and did not know which group did they fall in|Single blinded where the patients were blinded. They were randomly divided into local infiltration group or illioinguinal/illiohypograstric block|t|f|f|f
33695992|NCT03819673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695993|NCT03964805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33695994|NCT02366858|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33695995|NCT02521766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33695996|NCT02414451|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33695997|NCT04121988|||COHORT||PROSPECTIVE|||||||
33695998|NCT05559866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized||||
33695999|NCT01279031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696000|NCT04293731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
33696001|NCT01343927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696002|NCT00886912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33919488|NCT05879627|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33919489|NCT01309841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33919490|NCT00048399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919491|NCT01578785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919492|NCT03560635|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33919493|NCT02615795|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919494|NCT05670405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919495|NCT04875403|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized clinical trial||||
33784549|NCT05398120|NA|SINGLE_GROUP||TREATMENT||NONE|There is one condition so masking is not relevant|Participants already receiving services in the psychosis-risk clinic at the University of Pittsburgh will be asked to participate in the psychosis-risk skills group. Data collected on feasibility and outcome measures will occur pre (within 1 month) -post (up to 4-5 months) and half-way (up to 2-3 months) through the intervention.||||
33784550|NCT02915809|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33696003|NCT06142903|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Consented patients will be randomized using a computer-generated scheme in REDcap to delivery of either 7 dinner meals or 21 meals (7 breakfast, 7 lunch, 7 dinner meals) each week for 4 weeks duration. At approximately day 0, 30 and 60 relative to discharge from the hospital, patients will be contacted by telephone to assess their malnutrition risk score, diet quality relative to AHA dietary goals, and obtain their self-measured weight and calf circumference.||||
33696004|NCT05612698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sample size has been calculated to detect significant differences in FPG of at least 2 mg/dl and considering a standard destination of 2 mg/dl in any of the three modalities and a dropout rate of 10%, so 30 subjects will be needed in each group, with a sample of 90 participants. Furthermore, a control group (30 patients) will be added to evaluate the effect of any type of monitored exercise in these patients versus usual clinical practice. Randomization will be done by permuted blocks of 8 in a 1:1:1:1 ratio and participants will be stratified by gender, age and obesity using the open-source Oxford Minimization and Randomization (OxMaR) program|"The GLYCEX study (GLYcaemic Control with EXercise) is a randomised, parallel, phase II clinical trial with three active arms and a control group, with a duration of 15 weeks in each phase. Control group will receive general recommendations of PA, based on WHO recommendations, and after 15 weeks. Baseline evaluations will be repeated 15 weeks.~Study interventions were reported using the Template for Intervention Description and Replication (TIDieR) as reference. The present protocol was elaborated following the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) 2013 State-ment. Reporting of the study will follow the CONSORT statement recommendations on RCTs."|f|f|t|t
33696005|NCT01330706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696006|NCT03948607|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696007|NCT04860427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696008|NCT01690026|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33696009|NCT00452855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33696010|NCT03310710|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with Viabahn BX stents||||
33696011|NCT02700022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784551|NCT06391775|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784552|NCT00991276|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33784553|NCT04338529|||COHORT||PROSPECTIVE|||||||
33784554|NCT01750957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919496|NCT00211250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919497|NCT05239364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919498|NCT01362686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919499|NCT04659434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919500|NCT03786198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"1. Home-based walking intervention for 24 weeks + standard adjuvant AI therapy~2. Physical activity according to standard recommendations for 24 weeks + standard adjuvant AI therapy"||||
33919501|NCT00947999|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919502|NCT04354155|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919503|NCT00355849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919504|NCT02822872|||COHORT||CROSS_SECTIONAL|||||||
33919505|NCT00825019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919506|NCT05627700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919507|NCT04326023|||CASE_ONLY||CROSS_SECTIONAL|||||||
33919508|NCT00546793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919509|NCT05186766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33919510|NCT04163640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919511|NCT01372371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33919512|NCT05865873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Because of the nature of the study intervention, neither research team members nor study respondents can be masked.|Parallel-group Cluster Randomized Controlled Trial (CRCT) will be used to address the objectives of the current study. The study is a 2 arm CRCT, with every cluster being kebeles located in the Dale and Wonsho districts of Sidama region, Ethiopia. The hallmark of this design is each cluster remains in the arm it was randomly assigned to during the course of the whole study period. Thus, all study subjects are randomly assigned into a group and all the study subjects in the assigned group obtain or do not obtain an intervention.|f|f|f|t
33919513|NCT00699842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919514|NCT06134713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088662|NCT03776045|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors and data analysts were blind to treatment allocation. It was not possible to blind participants or the intervention facilitator.|After baseline measures were collected, participants were randomly allocated (1:1) to standard care or standard care plus exercise using a randomisation sequence created by an independent researcher (nQuery, Statistical Solutions, USA). Treatment allocation was concealed from the research team until after baseline measurements were collected.|f|f|f|t
34088663|NCT06520384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088664|NCT00152347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088665|NCT02771964|||COHORT||PROSPECTIVE|||||||
34088666|NCT02528227|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34088667|NCT00620906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088668|NCT02265653|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088669|NCT01367041|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33696012|NCT05778851|RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE|||t|f|f|f
33696013|NCT00641303|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33696014|NCT00270712|||COHORT||OTHER|||||||
33696015|NCT05050929|RANDOMIZED|PARALLEL||TREATMENT||NONE||Equal arms (1:1)||||
33696016|NCT03539354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696017|NCT00591344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696018|NCT05629546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrollment will occur in parallel into arms 1 and 2, but sequence of enrollment will be staggered for the first 3 patients, with sequential patients being enrolled upon the previous patient completing 30 days of observation. Approximately 11 allogeneic donors will also be enrolled for subjects in Arm 2.||||
33696019|NCT06195683|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with ⅠB(≥4cm)-ⅢA and TPS ≥ 50% non-small cell lung cancer patients, excluding EGFR and ALK gene mutations. They will receive 4 cycles of Serplulimab monotherapy at 4.5mg/kg as neoadjuvant treatment before surgery. Subsequently, they will undergo surgical resection and the effectiveness of the neoadjuvant treatment will be evaluated. After surgery, they will receive 14 cycles of Serplulimab as adjuvant treatment.||||
33696020|NCT02595996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696021|NCT00600535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696022|NCT02796742|||COHORT||PROSPECTIVE|||||||
33696023|NCT06341764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696024|NCT00612183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696025|NCT00071578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919515|NCT02793323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919516|NCT05136846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919517|NCT04819802|||COHORT||RETROSPECTIVE|||||||
33919518|NCT05431049|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33919519|NCT01313364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919520|NCT03111550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|subject/evaluator-masked||t|f|f|t
33919521|NCT04907552|||COHORT||RETROSPECTIVE|||||||
33919522|NCT05341570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919523|NCT01144234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33919524|NCT04591041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919525|NCT03011450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919526|NCT04782193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919527|NCT02812446|||CASE_CONTROL||RETROSPECTIVE|||||||
33919528|NCT04003337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once patients accept to be enrolled in the study, one of the nurses will allocate the patient to one of study groups. Neither the patient nor the doctor will know the group assigned.|Two arms interventional prospective randomized controlled trial.|t|t|f|f
33919529|NCT04984785|||COHORT||PROSPECTIVE|||||||
33919530|NCT01544803|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33696026|NCT00900601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696027|NCT00145704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696028|NCT06707350|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696029|NCT06710314|||COHORT||PROSPECTIVE|||||||
33696030|NCT00537238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696031|NCT01240876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696032|NCT06706271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study targets children diagnosed with chronic kidney disease, categorized into two groups based on their glomerular filtration rate (GFR): those with GFR \< 90 mL/min/1.73 m² and those with GFR ≥ 90 mL/min/1.73 m². Participants are selected through purposive sampling, ensuring they meet defined inclusion criteria related to age, CKD diagnosis, and baseline serum levels. Serum levels of vitamin D, hepcidin, and ferritin are measured before and after vitamin D3 supplementation. This allows for comparative analysis of changes within each group and between the two groups, providing insights into the effects of vitamin D3 on iron metabolism.||||
33696033|NCT01512030|||COHORT||PROSPECTIVE|||||||
33696034|NCT02897765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696035|NCT04526509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking|||||
33999449|NCT05264207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The type of intervention on which the project is based does not allow for the participants to be masked and they will know to which group they are allocated. However, the team that will collect data (assessors) will not know the group to which each participant is allocated. To ensure assessor masking, participants will be instructed to never reveal the group to which they have been assigned and assessors will be instructed to never ask the participants to which group they have been assigned. The assessors will not participate in the recruitment process, the supervision of nursing students' home-visits, nor the data analysis process. The group to which the participants have been allocated will be numerically coded (not labelled) in the database and the researchers in charge of data analysis will not know which numerical code refers to the intervention group and which code refers to the control group.|Older adults who meet the inclusion criteria and voluntarily accept to participate in this study will be randomly allocated to one of two arms: intervention group (arm 1) or control group (arm 2). Participants from both arms will be assessed at the same time for data collection purposes (pre-test, post-test and 6-month follow-up) and they will be exposed to the experimental condition (intervention group) or the control condition (control group) at the same time for 12-weeks.|f|f|t|t
33999450|NCT05674188|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999451|NCT03756233|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||In this study, remifentanil gradually withdrawal goup (test group) and remifentanil immediately stop group (control group) were divided into two groups. In the Remifentanil gradual reduction group (test group), 20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes. The control group stopped remifentanil 10 minutes before the end of the operation.|t|f|f|f
33999452|NCT00834353|||CASE_CONTROL||PROSPECTIVE|||||||
33999453|NCT01219140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999454|NCT04809363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999455|NCT04758208|||COHORT||RETROSPECTIVE|||||||
33999456|NCT05485051|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||The study consists in two intervention (chlorhexidine baths) periods (three months each period) and two control (usual baths) periods (three months each period) for each cluster. The clusters will crossover between intervention and control with one month of washout period between different periods.|f|f|f|t
33999457|NCT06017427|||COHORT||PROSPECTIVE|||||||
33999458|NCT01941680|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33999459|NCT05779527|NA|SINGLE_GROUP||TREATMENT||NONE||Single Case Experimental Design||||
33999460|NCT01875107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999461|NCT00400634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999462|NCT00889486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999463|NCT02013050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999464|NCT03971435|||OTHER||CROSS_SECTIONAL|||||||
33999465|NCT00913276|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696036|NCT04373174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||prospective,randomized|t|f|f|f
33999466|NCT05472415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696037|NCT04137432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants will receive either 24 IU of intranasal OT or placebo (PLC) over the four intervention sessions. All participants in one intervention group will receive the same substance.|t|t|t|f
33696038|NCT01727843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696039|NCT02645721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696040|NCT00831350||PARALLEL||TREATMENT||NONE||BRVO and CRVO will be enrolled in this trial.||||
33696041|NCT02874287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696042|NCT03141762|||COHORT||PROSPECTIVE|||||||
33696043|NCT05689944|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33696044|NCT01724411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33696045|NCT06010732|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|double blind||t|f|t|t
33696046|NCT05554575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696047|NCT00199069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696048|NCT00982124|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33696049|NCT04908657|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, Randomized Controlled||||
33696050|NCT03014492|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696051|NCT00905216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33696052|NCT04497207|||OTHER||RETROSPECTIVE|||||||
33696053|NCT03851471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696054|NCT01517061|||||RETROSPECTIVE|||||||
33919531|NCT02505542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919532|NCT03066141|||COHORT||PROSPECTIVE|||||||
33919533|NCT03915236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919534|NCT03445754|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blinding will be done so the investigator performing the FMD, LSCI and PWA testing will be blinded to the allocation of TVS||t|t|f|t
33919535|NCT00673894|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33696055|NCT04554173|||COHORT||RETROSPECTIVE|||||||
33696056|NCT04033198|||COHORT||PROSPECTIVE|||||||
33696057|NCT02583373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696058|NCT02963935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696059|NCT04256096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham endovascular procedure has been rejected due to the medical risk of the angiography and practical issues that difficult to maintain blindness of investigators. For the primary endpoint, subjects will be followed for 90 days post-randomization. Distribution of the modified Rankin Scale scores at 90 days will be evaluated by two separate assessors who are blinded to treatment. Primary Endpoint will consider central core lab readings only (video interview with RFA method) with local reading as a back-up mechanism.|The randomization employs a 1:1 ratio of mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone|f|f|f|t
33696060|NCT01813110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33696061|NCT05843162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696062|NCT03686514|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33696063|NCT06710184|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, non-inferiority, randomized controlled trial||||
33696064|NCT03438318|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696065|NCT06274307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will be unaware of their grouping allotment. The outcomes assessor will be unaware of the patient grouping allotment.|The treatment group (Group 1) will have a transversus abdominis plane (TAP) block performed with an insufflated abdomen in the operating room. The control group (Group 2) will receive the traditionally performed standard of care TAP block performed in the post-anesthesia care unit|t|f|f|t
33696066|NCT00427271|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33696067|NCT01914731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696068|NCT02378727|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33696069|NCT04177927|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33696070|NCT06704386|||COHORT||CROSS_SECTIONAL|||||||
33696071|NCT06039410|NA|SINGLE_GROUP||TREATMENT||NONE||Thus, the study is a single centre, unblinded, pre-post study. All participants will act as their own control, and all will receive the intervention.||||
33696072|NCT03828409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient will not know what technique was used for the abdominal wall closure. The medical officers that will assess patient's PCA morphine usage and VAS score post-operatively will not know which technique of suturing was used for that particular patient.|"Patients will be randomized into two arms (short stitch: SS and long stitch:LS).The LS belongs to our conventional mass closure technique for midline laparotomy. SS technique has been used to investigate other parameters such as surgical site infection and incisional hernia.~This study is carried out to evaluate if SS technique will reduce post-operative pain."|t|f|f|t
33696073|NCT04801173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919536|NCT04658420|RANDOMIZED|FACTORIAL||TREATMENT||NONE||All four groups will receive treatment as usual as defined above (potential approved hospitalization, medication, psychotherapy, outpatient referrals, suicide safety planning). A factorial design is being implemented to test four interventions. One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music will be compared to 3 other groups: One group will receive the same dose of ketamine without music, one group will one hour of music without ketamine, and one group will receive neither music nor ketamine. During the 4-week follow up interval, subjects from both groups will be contacted by phone for weekly assessment of depression, SI and quality of life.||||
33919537|NCT06103448|||COHORT||CROSS_SECTIONAL|||||||
33919538|NCT04003753|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be randomly (matched by clinical relevance of fear of heights and sex) allocated to treatment groups (experimental group, control group). The experimenter evaluating the primary outcome will be blinded (unaware of group assignment of participants, single-blind).|randomized controlled single-blind study design|t|f|f|t
33919539|NCT03587870|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, randomised controlled pilot study in critical ill patients with a protein-rich formula||||
33919540|NCT00214968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919541|NCT00041691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919542|NCT00443235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919543|NCT05631548|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33919544|NCT00423241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919545|NCT05071729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919546|NCT03051841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919547|NCT05753098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919548|NCT05257135|NA|SINGLE_GROUP||OTHER||NONE||||||
33919549|NCT06348953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33919550|NCT02120157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919551|NCT03198780|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||pilot study||||
33919552|NCT02484612|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33919553|NCT05812469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is an experimentally designed study with a randomized control group and repeated measurements (pre-test, mid-test, post-test).|t|f|f|f
33919554|NCT03988608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919555|NCT02329002|||COHORT||PROSPECTIVE|||||||
33919556|NCT03838562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999467|NCT05461157|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomized to either silicone ointment or placebo ointment prior to undergoing scheduled surgery. After surgery, all participants will use silicone ointment.|t|t|t|t
33999468|NCT01583530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999469|NCT02349854|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999470|NCT04384224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999471|NCT01055886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999472|NCT01886222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33999473|NCT04872608|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single institution pilot phase 1b study of the oral progesterone antagonist, onapristone ER (Apristor), used as triplet escalation therapy patients with ER+/PR+/HER2- MBC who do not achieve mCR after six months (+/- 4 weeks) of treatment with letrozole and palbociclib in the first line.||||
33999474|NCT00868998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696074|NCT02160782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Open-label single arm study with a randomized placebo-controlled parallel group period|t|t|t|f
33696075|NCT04192370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999475|NCT02396888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33999476|NCT05236062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999477|NCT01214980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34088670|NCT05033041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Research pharmacy to prepare the study medication blinding the participant, care providers, investigator and outcomes assessor.|Randomized controlled blinded study|t|t|t|t
33696076|NCT05392517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696077|NCT03057379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Participants will be randomized to one of four arms to receive 0,1,2,or 3 reminders for overdue HPV vaccine doses.|f|t|f|t
33696078|NCT00351988|||OTHER||PROSPECTIVE|||||||
33696079|NCT04112888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696080|NCT02620007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696081|NCT06191523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696082|NCT02385370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696083|NCT00572923|||COHORT||PROSPECTIVE|||||||
33696084|NCT06557252|||COHORT||PROSPECTIVE|||||||
33696085|NCT06384690|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33696086|NCT00521612|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33696087|NCT06313827|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participants will be randomly assigned to one of three study groups by the person conducting the intervention.~All participants receive usual physiotherapy treatment, and both intervention groups receive monitoring and follow-up of their clinical situation.~The evaluators are unaware of the assignment at all times."||t|f|t|t
33696088|NCT06680986|||COHORT||RETROSPECTIVE|||||||
33919557|NCT04339270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"CASA-Q scoring is performed by the patient and then sealed away from investigator-view. Similarly, mucus rheology results are blinded. The patient does not know what arm he/she is in, as so does not know exactly why the prescription was made or not.~Similarly, investigators/outcome assessors are blinded to both CASA-Q scores and sputum rheology. The prescription strategy is determined according to an algorithm, and investigators/outcome assessors do not know what arm the patient is in nor exactly why a prescription was made or not."|Randomized controlled trial comparing outcomes in 2 parallel arms (36 vs 36 patients).|t|f|t|t
33919558|NCT02070406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919559|NCT00545987|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919560|NCT05262582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919561|NCT04556370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33696089|NCT05621551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919562|NCT00450047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919563|NCT00131820|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33919564|NCT04497298|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"As safety precaution, the study will begin with enrollment of two successive unblinded dose groups of sentinel participants randomized into groups of three in an open-label fashion (group A and B). All site personnel, Sponsor and participants will be unblinded.~Then remaining participants will be randomized in a blinded manner to one of three cohorts (A, B, C) and between vacccine candidate and placebo. Site personnel responsible for study medication handling, preparation and Administration will be unblinded, only."|Parallel Assignment|t|t|t|t
33919565|NCT02147496|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33919566|NCT00698061|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33919567|NCT06454851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919568|NCT00583440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919569|NCT04198896|||COHORT||PROSPECTIVE|||||||
33919570|NCT01978158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919571|NCT02816125|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33919572|NCT03541655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919573|NCT00234728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919574|NCT02623595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919575|NCT04409652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33919576|NCT01835613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919577|NCT05520749|||COHORT||RETROSPECTIVE|||||||
33919578|NCT03292952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||3-week, open-label dose-optimization phase followed by a 1-week randomized, double-blind treatment phase|t|t|t|t
33919579|NCT00874679|||COHORT||PROSPECTIVE|||||||
33919580|NCT03106051|||COHORT||PROSPECTIVE|||||||
33919581|NCT01401465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919582|NCT02596152|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33696090|NCT00857428|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696091|NCT04504279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696092|NCT02386306|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33696093|NCT03275311|||COHORT||RETROSPECTIVE|||||||
33696094|NCT02589379|||COHORT||PROSPECTIVE|||||||
33696095|NCT05441761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696096|NCT00498524|||CASE_CONTROL||RETROSPECTIVE|||||||
34088671|NCT00718601|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33919583|NCT06163560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34088672|NCT05274282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919584|NCT00089453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919585|NCT00921882|||COHORT||PROSPECTIVE|||||||
33919586|NCT02466165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088673|NCT02954341|||COHORT||PROSPECTIVE|||||||
33919587|NCT03803592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All outcome measurements will be collected by assessors who are blinded to the group assignment of participants|A two-arm non-randomized study design will be adopted to test the effect of a dyadic multisensory and cognitive stimulation program (MCS) for PWD and their caregivers between the intervention and control group. The Intervention group will attend the home-based dyadic MCS group, while the control group will receive the usual care. The dyadic MCS program is a 15-week program which composes of center-based face to face sessions (FTF) and caregiver-delivered home-based sessions. In the first 4 weeks, participants will attend the center-based FTF session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers at home and was suggested to deliver 3 times/week. To address any difficulties from the caregivers, the home-based sessions will be supplemented with weekly telephone follow-up and 2 FTF sharing sessions which will be held on the 8th and 12th week over the intervention period.|f|f|f|t
33919588|NCT02692456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088674|NCT02515929|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088675|NCT06466200|RANDOMIZED|PARALLEL||OTHER||NONE||"During their management in the 3 study centers, if the diagnosis of dentin hypersensitivity (DH) is made, a patient may be offered to participate in the study. The group of patients without DH (control group) will consist of patients who meet the inclusion and non-inclusion criteria and who agree to participate.~Participants will answer the questionnaires on their first visit. A second visit will be organized for the 60 patients randomly selected for a re-test at 15 days."||||
34088676|NCT02474836|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34088677|NCT05945407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088678|NCT01458977|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34088679|NCT02127853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919589|NCT05075967|RANDOMIZED|PARALLEL||PREVENTION||NONE||"16 communities will participate in the study, each made up of one or more counties selected from the southern counties and states identified in the Ending the HIV Epidemic (EHE) plan. The communities will be matched into 8 pairs based on population, HIV prevalence and viral suppression. Within each pair, one community will be randomized by public ceremony to receive the components of the integrated strategy, and the other will serve as the standard-of-care (SOC).~A starfish sampling approach (the combination of venue-time-based and respondent-driven sampling) will be employed to recruit and enroll individual participants in both intervention and control communities for the cross-sectional assessments."||||
33919590|NCT01609179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919591|NCT00160394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33919592|NCT00456794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919593|NCT03368625|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with resectable brain mets will receive neoadjuvant stereotactic radiosurgery prior to surgical resection.||||
33919594|NCT04574388|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919595|NCT03537352|||CASE_ONLY||CROSS_SECTIONAL|||||||
33919596|NCT06118567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Room air (vs. Nitrous Oxide Inhalation)||t|f|f|t
33919597|NCT03098758|||COHORT||PROSPECTIVE|||||||
33919598|NCT01382199|RANDOMIZED|||PREVENTION||DOUBLE||||||
33919599|NCT01434264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919600|NCT02219633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919601|NCT03444194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33919602|NCT03453021|||COHORT||PROSPECTIVE|||||||
33919603|NCT05101486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33919604|NCT05999903|||COHORT||PROSPECTIVE|||||||
33999478|NCT04071613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The people assessing the outcomes The people analysing the results/data|Multicentre, prospective, randomised open-label blinded endpoint (PROBE) phase II study in stroke thrombolysis patients to compare tenecteplase and alteplase for an outcome of less disability at 3 months|f|f|f|t
33999479|NCT02392858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999480|NCT02754076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999481|NCT01781234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999482|NCT05909696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999483|NCT02491853|||COHORT||PROSPECTIVE|||||||
33999484|NCT01868243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999485|NCT00196235|||||PROSPECTIVE|||||||
33999486|NCT01964950|||COHORT||PROSPECTIVE|||||||
33999487|NCT05274724|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33999488|NCT02818894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33999489|NCT03922750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999490|NCT05963464|||CASE_ONLY||PROSPECTIVE|||||||
33999491|NCT02946424|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33999492|NCT01728116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999493|NCT01485068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999494|NCT03333863|||CASE_ONLY||RETROSPECTIVE|||||||
33999495|NCT03475433|||COHORT||PROSPECTIVE|||||||
34088680|NCT00334308|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34088681|NCT06042075|||OTHER||CROSS_SECTIONAL|||||||
34088682|NCT02253342|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34088683|NCT05324202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696097|NCT01356927|||COHORT||PROSPECTIVE|||||||
33696098|NCT04877743|||COHORT||PROSPECTIVE|||||||
33696099|NCT01859143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33999496|NCT04956848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A pilot study randomizing embryos into two study groups comparing two decision support tools in the ranking of embryos for transfer.|t|t|t|t
33999497|NCT05822726|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33999498|NCT02416180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999499|NCT03001167|||COHORT||PROSPECTIVE|||||||
33999500|NCT02510872|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999501|NCT04384289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled intervention study with a parallel group in a pretest-posttest design||||
33999502|NCT04163094|NA|SINGLE_GROUP||TREATMENT||NONE||This is a first-in-human, open label phase I study.||||
33999503|NCT02663661|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999504|NCT01509391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999505|NCT02096705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999506|NCT04129554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999507|NCT00170469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33999508|NCT03093025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999509|NCT04561115|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study model for this is Single-Sequence crossover.||||
33999510|NCT04550260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor, excluding supply chain management personnel, will remain blinded.||t|t|t|t
33999511|NCT02858037|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to be replaced each month for a total period of 12 months of use.||||
33999512|NCT02387762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999513|NCT00550147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999514|NCT03616691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999515|NCT00088608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999516|NCT03438643|||COHORT||PROSPECTIVE|||||||
33999517|NCT04554186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999518|NCT00881426|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999519|NCT04844411|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33999520|NCT06533215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33999521|NCT03191305|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Only Participants would not know about the any other choice of the Drug available.|Patients of CVT from Fauji Foundation would be be in Coumadin Arm ,and patients of CVT from Pakistan Institute of Medical Sciences Hospital would be in Rivroxaban arm.|t|f|f|f
34088684|NCT03600259|||COHORT||OTHER|||||||
34088685|NCT06436859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088686|NCT03029390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696100|NCT02022631|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33696101|NCT04571008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34088687|NCT04575870|||CASE_CONTROL||PROSPECTIVE|||||||
34088688|NCT02713672|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34088689|NCT03007875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999522|NCT03302949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999523|NCT01749085|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33999524|NCT05912335|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The participant and the applicator don't know which formulation was applied because these were named A, B, C, and D and the applicator doesn't have access to the data of which formulation was titled by each letter.|40 volunteers will receive the following formulations: hydrogels containing LAs - lidocaine, and prilocaine (both at 2.5%) encapsulated in CLN (XAN-CLN) or not (XAN-CLN ), EMLA and placebo hydrogel. The formulations will be applied for 2 minutes, bilaterally on the palatal mucosa (first premolar region), in two distinct sessions. Soon after the removal of the topical formulation, an AL will be performed at the region using 0.3 mL of anesthetic solution at an injection speed of 1 mL/min. Pain resulting from needle insertion and LA injection will be measured using two visual analog scales (VAS).|t|t|f|f
33999525|NCT04117880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999526|NCT01491464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999527|NCT02545530|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999528|NCT03386461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Two types of pills (calanus or placebo) will be prescribed to subjects, investigator will randomly assign the subjects to the arms|The exercise training intervention with or without omega-3 supplementation (Calanus oil) will be prescribed to non-trained sedentary elderly women|t|t|f|f
33999529|NCT03185741|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33999530|NCT05301855|||OTHER||CROSS_SECTIONAL|||||||
33999531|NCT05244928|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||"The stepped wedge cluster randomized controlled trial imply the framework for how the Team Strategies and Tools to Enhance Performance and Patient Safety® intervention will be introduced in the two clusters. To ease the logistics need for training and the implementation, two clusters will be formed from seven ambulance stations within the same organization. The order in which the two clusters will undergo the intervention will be randomized. The intervention will be introduced for one cluster in February 2022, and for the other cluster in September 2022."||||
33999532|NCT00084097||||TREATMENT||||||||
33999533|NCT02245503|||COHORT||PROSPECTIVE|||||||
33999534|NCT01710280|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33999535|NCT00695045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33999536|NCT00283842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999537|NCT01656876|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33999538|NCT01235260|||COHORT||RETROSPECTIVE|||||||
33999539|NCT05193734|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33999540|NCT00061776|RANDOMIZED|||TREATMENT||DOUBLE||||||
33999541|NCT02721563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999542|NCT01465113|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088690|NCT03443648|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34088691|NCT00389389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088692|NCT04686331|||COHORT||PROSPECTIVE|||||||
34088693|NCT03901300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34088694|NCT05091242|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Part A: Open-label pharmacokinetic part (n =16) Part B: Randomized placebo-controlled part (n =320)|t|t|t|t
34088695|NCT01714934|||COHORT||PROSPECTIVE|||||||
34088696|NCT04143048|||COHORT||PROSPECTIVE|||||||
34088697|NCT05556252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34088698|NCT06308783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One group receives Diaphragmatic Breathing, one group receives Global Postural Reeducation, and the other group receives no intervention.|f|f|f|t
34088699|NCT01401166|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34088700|NCT06022575|||COHORT||PROSPECTIVE|||||||
34088701|NCT01171599|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34088702|NCT03443297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34088703|NCT01138241|||COHORT||CROSS_SECTIONAL|||||||
33696102|NCT02753374|||COHORT||PROSPECTIVE|||||||
33696103|NCT00003800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919605|NCT03038802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, the investigator and outcomes assessors will be blinded as to which vaccine the subject has received||t|f|t|t
33919606|NCT03905629|||COHORT||RETROSPECTIVE|||||||
33999543|NCT02488057|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919607|NCT03134313|NA|SINGLE_GROUP||OTHER||NONE||||||
33919608|NCT02392494|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In each panel (A, B, C, and D), participants will receive a single dose of MK-1075 (100, 200, 400, and 800 mg, respectively) in a fasted state. Safety and viral load (VL) data from the previous panel will be assessed before dosing the subsequent panel.||||
33999544|NCT04671147|||COHORT||RETROSPECTIVE|||||||
33999545|NCT03985124|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomised controlled trial||||
33999546|NCT03596710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999547|NCT02582190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999548|NCT02544139|||CASE_ONLY||PROSPECTIVE|||||||
33999549|NCT05172362|||COHORT||PROSPECTIVE|||||||
33919609|NCT01025258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999550|NCT00033527|RANDOMIZED|||DIAGNOSTIC||DOUBLE||||||
33999551|NCT06154993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999552|NCT00415181|||COHORT||PROSPECTIVE|||||||
33999553|NCT03651973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696104|NCT03225599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919610|NCT00544011|NON_RANDOMIZED|||TREATMENT||||||||
33919611|NCT01403467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919612|NCT05374148|||OTHER||CROSS_SECTIONAL|||||||
33919613|NCT02667548|||CASE_ONLY||PROSPECTIVE|||||||
33919614|NCT01571648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919615|NCT03516734|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants, care provider, and investigators will be masked on the distribution of iron-fortified lentil among 3 different adolescent group.|Thick preparation of cooked Iron-fortified lentils (37.5gm raw lentil) will be provided. There will be three lentils based dietary intervention arm in this efficacy trial. Arm 1 will be intervened with iron-fortified lentils, Arm 2 will be non-iron fortified lentils, and Arm 3 arm will be the usual intake of lentil (no additional lentil). Arm 2 will be served as a comparison group and arm 3 will be served as control group.|t|t|t|f
33919616|NCT04615702|||CASE_ONLY||PROSPECTIVE|||||||
33919617|NCT01204697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999554|NCT04411654|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded assessor used in secondary outcome measures|||||
33999555|NCT06332690|||COHORT||PROSPECTIVE|||||||
33999556|NCT01372930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999557|NCT06105450|||COHORT||PROSPECTIVE|||||||
33999558|NCT04337658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999559|NCT02313662|||CASE_ONLY||PROSPECTIVE|||||||
33999560|NCT01206751|||CASE_ONLY||RETROSPECTIVE|||||||
33999561|NCT04138251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999562|NCT06127186|||CASE_ONLY||CROSS_SECTIONAL|||||||
33999563|NCT03396354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999564|NCT01859936|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33999565|NCT04908540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999566|NCT05421039|||CASE_CONTROL||RETROSPECTIVE|||||||
33999567|NCT01459380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999568|NCT02247687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999569|NCT02747680|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33999570|NCT05361057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999571|NCT00067327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999572|NCT04519255|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999573|NCT04889365|||COHORT||PROSPECTIVE|||||||
33999574|NCT04372641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999575|NCT05673707|||COHORT||PROSPECTIVE|||||||
33999576|NCT02517424|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33999577|NCT00562718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999578|NCT00197873|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33999579|NCT03531645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999580|NCT01876758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999581|NCT05369039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blinded to the patient's group||f|f|f|t
33999582|NCT00718458|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999583|NCT01292837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999584|NCT06063590|NA|SINGLE_GROUP||TREATMENT||NONE||The patients will be assigned into one group receiving allogeneic bone marrow (BM)- derived Mesenchymal Stromal Cell (MSC) formulated in infusion solution (sodium chloride supplemented with human serum albumin Pre-screening visit will be conducted within 7 days of the screening visit then eligible patient will participate in the Study for approximately 6 months and will have a total of 5 on-site visits, including a screening visit, a treatment administration visit, and 3 follow-up visits.||||
33999585|NCT02308241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999586|NCT06599619|||COHORT||PROSPECTIVE|||||||
33999587|NCT02082327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088704|NCT00894192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088705|NCT00483665|||CASE_ONLY||PROSPECTIVE|||||||
34088706|NCT00262925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999588|NCT02774018|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33999589|NCT00494013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999590|NCT02579577|||COHORT||PROSPECTIVE|||||||
33999591|NCT05936047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999592|NCT05330780|NA|SINGLE_GROUP||OTHER||NONE||||||
33999593|NCT00393705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999594|NCT03100357|||COHORT||PROSPECTIVE|||||||
33999595|NCT06149949|||COHORT||OTHER|||||||
33696105|NCT05454306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999596|NCT01624233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999597|NCT00556673|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33696106|NCT03347188|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33999598|NCT02159820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999599|NCT00704249|RANDOMIZED|PARALLEL||||NONE||||||
33999600|NCT05378958|||CASE_ONLY||CROSS_SECTIONAL|||||||
33999601|NCT01044823|||COHORT||PROSPECTIVE|||||||
33999602|NCT05029895|||COHORT||PROSPECTIVE|||||||
33999603|NCT00735696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999604|NCT06289296|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A parallel crossover design, in which a group of lean and a group of obese participants are allocated to complete two seven-day intervention periods with twice daily consumption of either medium-chain fatty acids or long-chain fatty acids.||||
33999605|NCT00624351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999606|NCT05863221|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase IV open-label, randomized, active-controlled study on subjects undergoing laparoscopic sleeve gastrectomy under general anesthesia.||||
33999607|NCT01064960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999608|NCT00333450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999609|NCT01756313|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33696107|NCT02219347|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33696108|NCT05739630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696109|NCT02161029|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919618|NCT05962918|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Since the researcher did the intervention and analysis, only the participants did not know which group they were in, so single blinding was done.|Paralel designed non randomized two armed study|t|f|f|f
33919619|NCT03128385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919620|NCT06118346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919621|NCT02326467|NA|SINGLE_GROUP||OTHER||NONE||||||
33919622|NCT02407041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919623|NCT06019923|||CASE_ONLY||PROSPECTIVE|||||||
33919624|NCT03900754|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double Blind|The study uses a combined within- and between-subject placebo-controlled study design. After screening, participants will be randomized into two study arms for the fMRI phase of the study. In each study arm, participants will complete a placebo-controlled, within-subject, pharmaco fMRI paradigm with one of two possible dosages of oxytocin (20 or 40IU) and placebo. 75 participants will be randomized to receive 20IU oxytocin and placebo and 75 will be randomized to receive 40IU oxytocin and placebo, with the order of administration randomized and separated by two weeks. Following the fMRI phase of the study, participants will be randomized to receive the same dosage of oxytocin the participant received in the fMRI phase, or placebo, twice daily for 3 weeks.|t|f|t|f
33919625|NCT03111355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33919626|NCT03231215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33919627|NCT05894044|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||This is a crossover, experimental, randomized, double-blind trial composed of apparently healthy participants.|t|f|t|f
33919628|NCT00211718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919629|NCT04180501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919630|NCT04416126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded, Placebo Controlled||t|f|t|f
33919631|NCT02396342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919632|NCT00868166|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33919633|NCT00504387|||||PROSPECTIVE|||||||
33999610|NCT01296841|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33999611|NCT06033586|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label rusfertide||||
33999612|NCT02896296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999613|NCT02146690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999614|NCT05636111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999615|NCT02107469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696110|NCT05064904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The randomization procedure was developed at the WHI Clinical Coordinating Center and implemented locally through a distributed study database, using a randomized permuted block algorithm, stratified by clinical center site, diabetics mellitus and age group.|The randomization procedure was developed at the WHI Clinical Coordinating Center and implemented locally through a distributed study database, using a randomized permuted block algorithm, stratified by clinical center site, diabetics mellitus and age group.|t|f|f|f
33696111|NCT01998139|||COHORT||RETROSPECTIVE|||||||
33696112|NCT05091671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696113|NCT04209348|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33696114|NCT06708637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696115|NCT06143098|||OTHER||PROSPECTIVE|||||||
33696116|NCT06477133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696117|NCT06146881|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33784555|NCT03990038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants won't know their group because this study will use a double placebo:~Group U: placebo for extended release hydromorphone (4 doses) Group C: sham perineurial infusion for 48h in group C (Perineurial catheter is connected to perineurial infusion pump but not infusion) Perineural infusion pumps will be covered with an opaque plastic bag to ensure blinding for patients and care providers Nurses and anesthesiologist and physiotherapist will be blinded to patient group allocation Investigator and outcome assessor will be blinded to group allocation"|"Two multimodal analgesic protocols will be compared. Patients will be randomized to one of two analgesic protocol:~C: Single-shot adductor canal block followed by a 48h perineurial continuous infusion of ropivacaine U: Single-shot adductor canal block and post operative extended release hydromorphone for 48h (4 doses)"|t|t|t|t
33784556|NCT06711328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696118|NCT06304038|||CASE_CONTROL||RETROSPECTIVE|||||||
33696119|NCT06680596|NA|SINGLE_GROUP||TREATMENT||NONE||After an initial screening phase to identify patients with blood circulating tumours persistent, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).||||
33696120|NCT02427971|||COHORT||PROSPECTIVE|||||||
33784557|NCT05799222|||CASE_ONLY||PROSPECTIVE|||||||
33784558|NCT02782182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784559|NCT06055985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor and CRO staff is blinded.||t|t|t|t
33784560|NCT05750095|RANDOMIZED|PARALLEL||TREATMENT||NONE|All measures are parent reported|||||
33784561|NCT03286725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind (outcome assessor)|Parallel assignment|f|f|f|t
33784562|NCT03049696|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Control Group: Publically funded bariatric surgery program administered through the Centre for Bariatric and Metabolic Surgery (CMBS).; Matched control group Intervention Group: CMBS Program standard of care plus the ENCOURAGING START Program (University of Manitoba Active Living Centre)|f|f|f|t
33784563|NCT06094205|NA|SINGLE_GROUP||OTHER||NONE||||||
33784564|NCT02259413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784565|NCT04220229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784566|NCT02912065|||||RETROSPECTIVE|||||||
33784567|NCT04344158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919634|NCT02388841|||CASE_CONTROL||PROSPECTIVE|||||||
33919635|NCT05352906|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33919636|NCT04816149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919637|NCT01408667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919638|NCT04133805|||OTHER||OTHER|||||||
33919639|NCT02252575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919640|NCT03828149|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33919641|NCT06168500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919642|NCT03698188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919643|NCT00697658|||||PROSPECTIVE|||||||
33919644|NCT01986153|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919645|NCT04940507|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33919646|NCT03409029|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single site, non-randomised basic science study||||
33919647|NCT02655445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919648|NCT00660569|||COHORT||PROSPECTIVE|||||||
33919649|NCT02709083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919650|NCT04532918|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Fixed-sequence||||
33919651|NCT02756975|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33919652|NCT04227392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919653|NCT05015166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919654|NCT05519618|||COHORT||PROSPECTIVE|||||||
33919655|NCT03285906|NA|SINGLE_GROUP||SCREENING||NONE||||||
33919656|NCT01705548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919657|NCT02766790|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33919658|NCT02097433|NA|SINGLE_GROUP||||NONE||||||
33784568|NCT06241664|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784569|NCT05727176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784570|NCT05033067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784571|NCT03794804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784572|NCT06713993|||COHORT||PROSPECTIVE|||||||
33784573|NCT06713291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999616|NCT05878132|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Randomization was stratified based on the participant's baseline upper limb severity according to the FTHUE-HK. Masking to treatment allocation for therapist and participants was not feasible.~Only the outcome assessor was blinded to the treatment allocation and participants were instructed not to tell the assessor their group allocation"|Single-blinded randomized crossover trial|f|f|f|t
33999617|NCT03720548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33999618|NCT03345615|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2:1 enrollment into parallel groups (intensive monitoring vs. standard care).||||
33999619|NCT01724762|NA|SINGLE_GROUP||||NONE||||||
33999620|NCT01158313|||CASE_CONTROL||PROSPECTIVE|||||||
33999621|NCT02064153|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33999622|NCT02386358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784574|NCT03066596|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Follow up assessments will be collected by blinded interviewers|enhanced Usual Care and Intervention sites||||
33784575|NCT03607565|||COHORT||RETROSPECTIVE|||||||
33784576|NCT06708793|||OTHER||RETROSPECTIVE|||||||
33784577|NCT01024179|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784578|NCT06704633|NA|SINGLE_GROUP||TREATMENT||NONE||This is an interventional single center single group pre-post study with a follow-up of 10 months.||||
33784579|NCT05262972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999623|NCT03264716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999624|NCT02218541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999625|NCT02054494|||CASE_CONTROL||PROSPECTIVE|||||||
33999626|NCT02626260|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999627|NCT04462276|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label, multicenter, phase II trial||||
33999628|NCT02614196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor is also masked.||t|f|t|f
33696121|NCT00240227|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33696122|NCT02040285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696123|NCT02787551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696124|NCT05962749|||OTHER||OTHER|||||||
33696125|NCT03173027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696126|NCT02628717|||COHORT||PROSPECTIVE|||||||
33696127|NCT05074043|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33696128|NCT03606629|||COHORT||PROSPECTIVE|||||||
33696129|NCT02271373|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33784580|NCT03683472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784581|NCT05601583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33784582|NCT05975294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784583|NCT06712966|NA|SINGLE_GROUP||OTHER||NONE||Single-arm interventional study with comparison to historical controls||||
33784584|NCT00690456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784585|NCT03460353|||CASE_ONLY||PROSPECTIVE|||||||
33784586|NCT00946192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784587|NCT01663610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919659|NCT06195501|||CASE_ONLY||PROSPECTIVE|||||||
33919660|NCT03587818|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A before and after design was performed; the control group were included from November 2012 to January 2014. This was followed by introducing the intervention to the clinicians, and the intervention group were included from March 2014 to June 2015. Patients were assigned consecutively at the three hospitals. No blinding was applied.||||
33919661|NCT05994586|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33919662|NCT00845494|RANDOMIZED|PARALLEL||||NONE||||||
33919663|NCT02404883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919664|NCT03520725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919665|NCT01205451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919666|NCT00728312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919667|NCT06168370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919668|NCT02919683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919669|NCT06159829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919670|NCT05398393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919671|NCT02207556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919672|NCT04408248|||COHORT||PROSPECTIVE|||||||
33919673|NCT00576251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919674|NCT00173563|||||PROSPECTIVE|||||||
33919675|NCT01303809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919676|NCT04717076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919677|NCT03954444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919678|NCT04273126|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919679|NCT04165941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696130|NCT00508768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33696131|NCT06033612|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Part A and B (Cohorts 1 -2) participants and care providers will remain blinded to study allocation. Part B (Cohort 3) and Part C participants will not be blinded to their study treatment.~The placebo bottle will be covered with a paper sleeve to ensure contents remain blinded. Pharmacy staff preparing investigational products will not be blinded to drug assignment. During the trial, individual randomisation codes will be kept in the site's clinical trials pharmacy, accessible to the pharmacy personnel only. Drug accountability will be reviewed by an unblinded CRA.~Sponsor staff involved in clinical decision-making (e.g. Safety Review Committee) will be blinded to drug assignment. Sponsor staff performing PK analysis will be unblinded but will deliver blinded PK data and reports to the blinded sponsor and Investigator teams. A cardiologist will examine all ECG recordings of Part B participants with readers blinded to treatment allocation."||t|t|t|t
33696132|NCT00761579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696133|NCT04887428|||OTHER||CROSS_SECTIONAL|||||||
33696134|NCT04436211|||CASE_CONTROL||PROSPECTIVE|||||||
33696135|NCT05735353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696136|NCT06516822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696137|NCT02185755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696138|NCT04879277|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||One group of healthy subject and one group of patient with phenylketonuria. Primary objective is to compare inflammation profile between the two groups through cytokine assay.||||
33696139|NCT01384006|||||PROSPECTIVE|||||||
33696140|NCT03564028|RANDOMIZED|CROSSOVER||OTHER||NONE||"Patients will perform two stair climbing sessions (each session include 108 steps) under two different conditions on the same day with at least 30 minutes of rest between the two sessions.~the order of the two conditions will be randomly assigned"||||
33696141|NCT04398992|||CASE_ONLY||PROSPECTIVE|||||||
33696142|NCT00509080|||COHORT||PROSPECTIVE|||||||
33696143|NCT02322021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999629|NCT02207582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696144|NCT05140850|||CASE_CONTROL||PROSPECTIVE|||||||
33696145|NCT00277797|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33696146|NCT06511050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696147|NCT01572259|NON_RANDOMIZED|PARALLEL||||NONE||||||
33696148|NCT00211484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696149|NCT05314478|NA|SINGLE_GROUP||OTHER||NONE||The study is an interventional clinical trial involving a single group of 30 participants undergoing a continuous laryngoscopy during exercise test with the HALOS headgear.||||
33999630|NCT00682201|||COHORT||PROSPECTIVE|||||||
33696150|NCT04552925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696151|NCT04117139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696152|NCT06061731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||low-frequency acupoint electrical stimulation|t|f|t|t
33696153|NCT01702571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696154|NCT05426096|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will assess this intervention using a sequential and repeated cross-over design at the institutional level with periods of time for wash in, wash out, control and study intervention.||||
33696155|NCT02767505|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1||||
33696156|NCT04924673|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33696157|NCT03360747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784588|NCT00819910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784589|NCT04423393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999631|NCT01304979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696158|NCT03981952|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33696159|NCT03424668|||COHORT||PROSPECTIVE|||||||
33696160|NCT02938039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696161|NCT01050049|||COHORT||RETROSPECTIVE|||||||
33696162|NCT00632073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696163|NCT03852004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|simulated osteopathic treatment||t|f|t|t
33696164|NCT02144129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696165|NCT02586051|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696166|NCT03995836|||COHORT||PROSPECTIVE|||||||
33696167|NCT03987776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The randomized controlled intervention study. A nutritional intervention will be based on an energy-restricted anti-inflammatory diet that will be compared with an isocaloric standard diet (55-60% carbohydrates, 25% fat, 15-20% protein).||||
33696168|NCT00953381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696169|NCT00512967|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784590|NCT03484182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784591|NCT05669794|||COHORT||PROSPECTIVE|||||||
33784592|NCT02755922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784593|NCT05792540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
33784594|NCT03969277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784595|NCT05350202|||COHORT||PROSPECTIVE|||||||
33784596|NCT05305040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784597|NCT03529019|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Potential subjects with potential malnutrition and critical limb ischemia.||||
33784598|NCT02708862|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784599|NCT06470776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784600|NCT06528457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This double-blinded study is designed to examine two potential uses of ISLA101, the first being prophylaxis against infection and the second being treatment of established infection.|t|f|t|f
33999632|NCT05063630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999633|NCT01353157|||CASE_ONLY||PROSPECTIVE|||||||
33999634|NCT05826301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999635|NCT06236880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999636|NCT03195387|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33999637|NCT03212651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999638|NCT02525263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696170|NCT04940208|||COHORT||CROSS_SECTIONAL|||||||
33696171|NCT04295473|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696172|NCT06374771|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696173|NCT01299987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696174|NCT02175784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696175|NCT03174249|NA|SINGLE_GROUP||TREATMENT||NONE||A series of case-studies||||
33696176|NCT00976677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696177|NCT06464471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-arm non-randomized study||||
33696178|NCT05076396|NA|SINGLE_GROUP||TREATMENT||NONE||First-in-human, open-label, dose-finding, phase I trial, using a classical 3+3 design followed by a continual reassessment method (CRM)||||
33696179|NCT02208895|||CASE_ONLY||PROSPECTIVE|||||||
33696180|NCT02497612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696181|NCT02188225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696182|NCT01072669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696183|NCT02024529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696184|NCT02209831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696185|NCT02758171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696186|NCT05983978|||COHORT||PROSPECTIVE|||||||
33696187|NCT04537039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696188|NCT05766501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696189|NCT06680505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696190|NCT06340061|||COHORT||PROSPECTIVE|||||||
33696191|NCT03805607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo (normal saline) or ketorolac in syringe prepared by the investigational pharmacy with study patient number and blinding key maintained by investigational pharmacy until time of unblinding.|Randomized Placebo-Controlled Trial|t|t|t|t
33696192|NCT03654300|||COHORT||PROSPECTIVE|||||||
33696193|NCT00004347||||TREATMENT||||||||
33696194|NCT00132639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696195|NCT01038193|||CASE_ONLY||PROSPECTIVE|||||||
33696196|NCT02321631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696197|NCT04708119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696198|NCT02127593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696199|NCT00940030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696200|NCT04965766|NA|SINGLE_GROUP||TREATMENT||NONE||One group of 99 participants treated with U3-1402||||
33696201|NCT05281952|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomization in two groups: endoscopic ligation or supra-selective embolization and real-life study for a third group||||
33696202|NCT05729230|||COHORT||PROSPECTIVE|||||||
33696203|NCT02216201|||COHORT||PROSPECTIVE|||||||
33696204|NCT01130103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696205|NCT00359931|||COHORT||OTHER|||||||
33919680|NCT05341635|||CASE_CONTROL||PROSPECTIVE|||||||
33919681|NCT03212846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Radomized controlled trial with two groups: intervention group (hippotherapy + conventional treatment) and control group (conventional treatment).|f|f|f|t
33919682|NCT01556802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919683|NCT01738737|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33919684|NCT00818285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999639|NCT02247037|||CASE_ONLY||PROSPECTIVE|||||||
33999640|NCT05646537|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants will not know they are in the experimental or control group|NLP techniques will be applied to the experimental group, and no intervention will be applied to the control group.|t|f|f|f
33919685|NCT02180217|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||It is a double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period.|t|t|t|t
33919686|NCT01464788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919687|NCT00101621|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33919688|NCT00903253|RANDOMIZED|||||DOUBLE||||||
33919689|NCT01191905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919690|NCT04580251|||CASE_ONLY||PROSPECTIVE|||||||
33919691|NCT02962219|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33919692|NCT00325338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33919693|NCT01445145|||||PROSPECTIVE|||||||
33919694|NCT06101082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999641|NCT02528019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999642|NCT04211480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696206|NCT05424523|||COHORT||RETROSPECTIVE|||||||
33696207|NCT03031535|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"This study consists of two study parts. In Study Part 1, 12 subject will be randomized into one of four study arms using a 4x4 modified latin square design.~In Study Part 2, subjects will be randomized into one of two arms using a 2x2 crossover design."|t|t|t|t
33696208|NCT06391346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Perfusion parameters from MSOT would be measured on patients with gluteal claudication in Fontain stage 2 before and after the revascularisation.||||
33696209|NCT03918889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696210|NCT04045795|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696211|NCT03003156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696212|NCT06070441|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The interventor providing the education sessions will be blinded to group allocation The outcome assessor will be blinded to the intervention|Two arms study, experimental vs control|f|t|f|t
33696213|NCT02642029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33696214|NCT01017471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696215|NCT06117358|||OTHER||PROSPECTIVE|||||||
33696216|NCT04329442|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm longitudinal pre/post study||||
33696217|NCT00775216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696218|NCT04804540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696219|NCT02297243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696220|NCT06403215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696221|NCT02611960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088707|NCT06339840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Based on the design of this clinical trial, blinding is not implement ed for participants and care providers. Blinding is only applied to outcome assessors and investigators. Outcome assessors are clinical staff members who are unaware of the group assignments, and data is collected directly from the medical records system by EDC data entry personnel for management (double-checking). Data analysts will directly extract information and data from the EDC database for statistical analysis. Blinding will be revealed upon completion of result analysis.||f|f|t|t
34088708|NCT01691664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088709|NCT04943393|||COHORT||CROSS_SECTIONAL|||||||
34088710|NCT02479282|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34088711|NCT02515227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088712|NCT05478109|NA|SINGLE_GROUP||OTHER||NONE||||||
34088713|NCT01282788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696222|NCT03848338|NA|SINGLE_GROUP||OTHER||NONE||||||
34088714|NCT00587457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088715|NCT00576537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088716|NCT04861181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34088717|NCT00442793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088718|NCT04542941|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a prospective randomized two arm open label clinical trial. Patients with confirmed COVID-19 who meet the study eligibility criteria will be randomized to receive either CCP in addition to standard of care therapy or standard of care therapy alone.||||
34088719|NCT03534219|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Since there will be no dummy devices in this trial, we will be unable to blind the patients and physicians to whom is using the EP device. The assessors/data collectors will be blinded for patient follow-up, and the statistician will be blinded. Therefore this will be a double blinded study.|All subjects will be randomized in a 1:1 ratio using permuted blocks. Subjects will be stratified by site (Lenox Hill) prior to randomization.|f|f|t|t
33696223|NCT02761928|||COHORT||PROSPECTIVE|||||||
33696224|NCT06373237|||COHORT||RETROSPECTIVE|||||||
33696225|NCT05806983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the research, it was planned to blind the participant and outcome evaluation.|Parallel Assignment|t|f|f|t
33696226|NCT03267303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696227|NCT06069648|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33696228|NCT05917210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696229|NCT04845373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696230|NCT03902860|||CASE_ONLY||PROSPECTIVE|||||||
33696231|NCT03012724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696232|NCT04637490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696233|NCT05907980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696234|NCT00706810|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33784601|NCT05391126|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33784602|NCT06712238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088720|NCT00516607|NON_RANDOMIZED|||TREATMENT||NONE||||||
34088721|NCT05622903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34088722|NCT00499213|||||PROSPECTIVE|||||||
33784603|NCT05974202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Active high-frequency stimulation vs. sham (placebo) stimulation|t|t|t|t
34088723|NCT05441904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696235|NCT04095832|||COHORT||PROSPECTIVE|||||||
33696236|NCT04676217|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33696237|NCT02515643|||COHORT||PROSPECTIVE|||||||
33696238|NCT03452228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696239|NCT00635791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696240|NCT01225770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696241|NCT02623478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33696242|NCT05235243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An RCT in a double-blind setting comparing three groups across three measurement points in time (baseline, post-intervention, and 6-month follow-up)|t|f|f|f
33696243|NCT00912678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784604|NCT02576418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784605|NCT03520075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919695|NCT00765128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919696|NCT04470713|||CASE_ONLY||OTHER|||||||
33919697|NCT05108610|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33919698|NCT03591094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919699|NCT01980212|||OTHER||PROSPECTIVE|||||||
33919700|NCT02978664|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33919701|NCT01216449|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33919702|NCT03777202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919703|NCT03922633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33919704|NCT00830570|||COHORT||PROSPECTIVE|||||||
33919705|NCT04462757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Patients will be randomly assigned to one of two arms:-~* Subcutaneous arm: 100mg anakinra SC will be administered subcutaneously at consistent times that are convenient and practical for the patients and research/nursing staff providing there is a minimum 8 hours and maximum 16 hours between administrations.~* Intravenous arm: 100mg anakinra in 100mL 0.9% NaCl will be administered intravenously four times a day every 6 hours."||||
33919706|NCT04520828|NA|SINGLE_GROUP||TREATMENT||NONE||pilot study||||
33919707|NCT04422106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919708|NCT01352676|||COHORT||PROSPECTIVE|||||||
33919709|NCT04624828|NA|SINGLE_GROUP||OTHER||NONE||||||
33919710|NCT04689672|||COHORT||OTHER|||||||
33919711|NCT05684601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment performed with sealed envelopes|Thee primary outcome was postoperative pain, evaluated using the visual analogue scale (VAS) score at Baseline, 1, 2, 5, 7, 10, 14 and 28 days following surgery in subject treated for third molar surgery with piezoelectric surgery or rotating drills. The secondary outcomes chosen were changes in postoperative swelling and maximum mouth opening values compared to preoperative ones.|t|t|f|f
33919712|NCT05085431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696244|NCT02203071|||COHORT||PROSPECTIVE|||||||
33999643|NCT03234309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999644|NCT01301937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33999645|NCT05055687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999646|NCT04816851|||COHORT||PROSPECTIVE|||||||
33999647|NCT01940445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999648|NCT06602414|||COHORT||PROSPECTIVE|||||||
33999649|NCT02600676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999650|NCT03493919|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33999651|NCT04919616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999652|NCT00271973|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33696245|NCT04993560|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33696246|NCT01336192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696247|NCT02976233|||COHORT||PROSPECTIVE|||||||
33696248|NCT02027038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696249|NCT01200862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Open-label in Part 1 and double-blind in Part 2.||t|f|t|f
33696250|NCT04208568|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33696251|NCT00140478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696252|NCT01385631|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33696253|NCT03007407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696254|NCT02801305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696255|NCT01905410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696256|NCT02133040|||CASE_ONLY||PROSPECTIVE|||||||
33919713|NCT03743233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919714|NCT02585999|NA|SINGLE_GROUP||OTHER||NONE||||||
33919715|NCT05035823|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33919716|NCT00992004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919717|NCT04683107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919718|NCT03866148|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups with the intervention the difference.||||
33919719|NCT02601183|||CASE_CONTROL||PROSPECTIVE|||||||
33919720|NCT02411526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919721|NCT02618343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919722|NCT03598569|||OTHER||PROSPECTIVE|||||||
33919723|NCT02527655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919724|NCT00937794|||COHORT||PROSPECTIVE|||||||
33919725|NCT01781767|||CASE_CONTROL||PROSPECTIVE|||||||
33919726|NCT00019721||||TREATMENT||||||||
33919727|NCT02530957|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919728|NCT03794752|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will wear a head mounted visual enhancement device.||||
33919729|NCT03591055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33919730|NCT00460681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919731|NCT04744701|||COHORT||PROSPECTIVE|||||||
33919732|NCT05009030|||COHORT||RETROSPECTIVE|||||||
33919733|NCT03160664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919734|NCT00844285|||COHORT||PROSPECTIVE|||||||
33919735|NCT00433446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919736|NCT00778986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919737|NCT04345497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Determine the effects of a diabetes-specific formula \[1-2 servings per day as a (partial) meal replacement\] in addition to standard of care on HbA1c level, in comparison with the standard of care only||||
33784606|NCT06645249|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a multicenter randomized phase IV open clinical trial. Patients with persistent AF (≥7 days duration) electively referred for CVE will be selected.~Two amiodarone regimens administered pre-CVE will be compared evaluating their cardioverter efficacy. Patients will be randomized to 2 groups:~c. Treatment impregnation with amiodarone starting one month before ECV (600 mg/day 1st week, 400 mg/day 2nd week and 200 mg/day thereafter until ECV).~d.Treatment impregnation with amiodarone 800 mg/day started 5 days before ECV."||||
33784607|NCT04759339|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||An open label, non-comparative study of the systemic exposure to articaine after topical ocular dosing of articaine sterile topical ophthalmic solution||||
33784608|NCT04954430|||OTHER||PROSPECTIVE|||||||
33784609|NCT01144949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784610|NCT05395208|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled two groups (control groups and intervention group)||||
33784611|NCT06708312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant blinding by divide into two group randomly and received true ear acupuncture or sham acupuncture randomization were done by research assistant outcome assesed by research assistant|intervention group : ear acupuncture control group : sham ear acupuncture|t|f|f|t
33784612|NCT00002620|RANDOMIZED|||TREATMENT||||||||
33784613|NCT05133167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784614|NCT06713811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999653|NCT05964049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999654|NCT03840577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The primary outcome Compare delirium and coma-free days until 14 days after the end of deep sedation will be assessed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scale. The evaluations will be conducted by blinded evaluators who are unaware of the patient's assigned sedation management group"|Patients will be assigned according to the randomization to clinical monitoring groups or Bispectral Index (BIS) monitoring group. The ranzomization will be stratified randomization by neuromuscular bloquers.|t|f|f|t
33999655|NCT05049200|||COHORT||PROSPECTIVE|||||||
33999656|NCT05810636|||CASE_CONTROL||PROSPECTIVE|||||||
33999657|NCT04039230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999658|NCT05448157|||OTHER||PROSPECTIVE|||||||
33999659|NCT05228249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999660|NCT04149301|||COHORT||CROSS_SECTIONAL|||||||
33999661|NCT01675973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999662|NCT02324452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999663|NCT04721145|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33999664|NCT02942810|NA|SINGLE_GROUP||OTHER||NONE||||||
33999665|NCT01834027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999666|NCT01310855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999667|NCT04150549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33999668|NCT03010605|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999669|NCT06380387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999670|NCT01468935|||COHORT||PROSPECTIVE|||||||
33999671|NCT05529238|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999672|NCT05563207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33999673|NCT02629640|||COHORT||PROSPECTIVE|||||||
33999674|NCT01207856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999675|NCT06322251|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Baseline measure - Number of patients that are identified fo being exposed to violence.~Intervention:~There are three settings:~1. Primary Care Health Centers~2. Youth Clinics~3. Maternity Clinics~At each type of clinic, the following interventions will be applied:~Identification of domestic violence through~1. Use of Virtual patient~2. use of screening questionnaire~3. a combination of a and b above.~The clinics will randomised to either condition a, b or c."||||
33999676|NCT03087162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999677|NCT05499728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999678|NCT03266276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Randomized Controlled Trial~After completing HNC staff interprofessional team training in PSO and PC, an RCT will be used to examine the impact of using a standardized PSOPC pathway approach, prompted follow up with patients and documentation. Participants will be recruited and randomized into (1) care as usual group and (2) intervention PSOPC pathway group."||||
33999679|NCT01448434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999680|NCT03773939|||COHORT||OTHER|||||||
33999681|NCT02737462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999682|NCT02179190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999683|NCT03449225|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33999684|NCT03086941|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33999685|NCT02223169|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33999686|NCT06338410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999687|NCT06078176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999688|NCT03708536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999689|NCT06282562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999690|NCT00341094|||COHORT||RETROSPECTIVE|||||||
33999691|NCT01196858|||COHORT||RETROSPECTIVE|||||||
33784615|NCT04577183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784616|NCT04132505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784617|NCT05861986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088724|NCT05037604|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696257|NCT03438383|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients were assigned into the following two study groups postoperatively:~1. Sham Bi-PAP (control group) group in which sham Bi-PAP was applied through nasal mask for 3 days postoperatively.~2. Bi-PAP group in which Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively.~1 patient was initially enrolled in the protocol but was excluded from the participant flow design because of recent onset of cardiovascular disease (CAD)."||||
33696258|NCT04934475|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"All patients will receive ISa-KRD treatment for induction. Depending on MRD status, patients will be randomized :~MRD Standard-risk post induction MRD \<10-5,(1:1 Randomization):~Arm A: 6 additional cycles of Isa-KRD Arm B: ASCT followed by 2 cycles of Isa-KRD MRD High-risk (post induction MRD \>10-5) (1:1 Randomization) Arm C: ASCT followed by 2 cycles of Isa-KRD Arm D: tandem ASCT~Maintenance:~In arms A/B, patients will receive commercial Lenalidomide, for 3 years. In arms C/D, patients will receive Iberdomide and Isatuximab for 3 years. Treatment allocation A/B to patients: randomization stratified per center according to LP score.~Treatment allocation C/D to patients: randomization stratified per center according to LP score.~For each randomization, primary analysis will evaluate MRD (NGS, 10-6 threshold) after all subjects have completed the post-consolidation response evaluation or have been discontinued from study treatment by this timepoint"||||
34088725|NCT00629902|||CASE_ONLY||PROSPECTIVE|||||||
34088726|NCT00104234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088727|NCT02346318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088728|NCT04521868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.||t|t|t|t
34088729|NCT05676437|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696259|NCT04036734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Intraoperative draping to obscure patient view|Parallell block randomised groups|t|f|f|f
33696260|NCT06387511|RANDOMIZED|PARALLEL||PREVENTION||NONE|No possible to mask intervention due to the specifity of the intervention tested|A two arms opened pragmatic parallel cluster-randomized controlled trial with baseline measure||||
34088730|NCT00734565|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34088731|NCT02320409|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34088732|NCT00824668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088733|NCT03884036|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088734|NCT00559000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34088735|NCT03611543|||CASE_ONLY||PROSPECTIVE|||||||
34088736|NCT00770367|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34088737|NCT04032938|||CASE_CONTROL||PROSPECTIVE|||||||
34088738|NCT00128843|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088739|NCT02355223|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33696261|NCT03481283|||COHORT||CROSS_SECTIONAL|||||||
33919738|NCT00234819|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34088740|NCT00602485|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34088741|NCT00780832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088742|NCT01748149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088743|NCT03454620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088744|NCT00434252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088745|NCT03118882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919739|NCT02787603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696262|NCT02044835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696263|NCT03686761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|The clinical assessment was not masked , however, the histological and biomarker examination were send to blind investigator not directly involved in the study|Surgical distraction was performed in 20 cleft lip and palate (CLP) subjects with class III malocclusion, gingival GCF were collected from teeth neighboring the osteotomy site and from premolars of the opposite arch as control.||||
33696264|NCT03111173|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33696265|NCT02025673|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696266|NCT04075110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696267|NCT01316471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919740|NCT00792038|||CASE_CONTROL||PROSPECTIVE|||||||
33919741|NCT05795010|||CASE_ONLY||OTHER|||||||
33919742|NCT02705118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919743|NCT01125878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33919744|NCT00672360|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33919745|NCT00369395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919746|NCT00862654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33919747|NCT06007404|||COHORT||CROSS_SECTIONAL|||||||
33919748|NCT01606293|||COHORT||PROSPECTIVE|||||||
33919749|NCT04468334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919750|NCT00511953|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33919751|NCT01409993|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33919752|NCT02188719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919753|NCT03823092|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34088746|NCT00635713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088747|NCT05502874|||COHORT||PROSPECTIVE|||||||
34088748|NCT03639415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088749|NCT06053359|||OTHER||RETROSPECTIVE|||||||
34088750|NCT02950571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34088751|NCT06084689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 single-arm phase II trials:~* Cohort A: soft-tissue sarcomas~* Cohort B: Solid tumors \[non-small cell lung cancer (NSCLC) or triple negative breast cancer (TNBC) or MMS colorectal cancer (MSS-CCR) or biliary tract cancer (BTC)\]"||||
34088752|NCT04334369|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33919754|NCT02186262|||CASE_ONLY||PROSPECTIVE|||||||
33919755|NCT03328624|NA|SINGLE_GROUP||OTHER||NONE||||||
33919756|NCT03971500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Patients will undergo 1:1 randomization (first randomization) to either IVUS-guided DES implantation which will be the treatment group or Angio-guided DES implantation which will be the control group based on an online Clinical Research Data Management Platform. The initiation of the trial is defined as the time of randomization. After study subjects' enrollment and randomization, the study intervention will take place immediately. The follow-up visits for the primary TVF endpoint are scheduled at 1, 4, 6, and 12 months after the index procedure.~Patients will undergo 1:1 randomization (second randomization) to either SAPT which will be the treatment group or DAPT which will be the control group based on an online Clinical Research Data Management Platform. The follow-up visits for the primary superiority bleeding endpoint and non-inferiority ischemic endpoint are scheduled at 3, 5, and 11 months after the second randomization."|t|f|t|t
33919757|NCT06161155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are masked regarding the protein source in the dietary intervention. Participants are not masked regarding the ingestible.|After baseline measurements for all participants without dietery intervention, participants will follow a dietary intervention for 7 days followed by a 7-day wash-out period and another 7-day dietary intervention.|t|f|f|f
33919758|NCT00625898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919759|NCT01031485|RANDOMIZED|PARALLEL||||DOUBLE||||||
33919760|NCT04794556|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919761|NCT05603507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919762|NCT00426556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919763|NCT03699449|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized, multi-center, open label, phase II study for HRD+ patients and a biomarker-driven multiple-arm phase II study for HRD- patients.~This study will consist of a number of study modules (substudies), each evaluating the antitumor activity of targeted agents in patients whose tumors express specific phenotype relevant to the molecules under investigation."||||
33919764|NCT05522894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919765|NCT03749798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919766|NCT04584853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919767|NCT04870827|||CASE_CONTROL||PROSPECTIVE|||||||
33919768|NCT06364631|RANDOMIZED|PARALLEL||TREATMENT||NONE||International, multicenter, open-label, randomized, controlled Phase 3 trial - 2 arms (A and B)||||
33919769|NCT06364956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919770|NCT05912712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33919771|NCT04074395|||OTHER||RETROSPECTIVE|||||||
33919772|NCT04150562|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919773|NCT04047758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919774|NCT04334915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999692|NCT01228539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696268|NCT02908243|||COHORT|||||||||
33696269|NCT04319991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33696270|NCT00691067|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33696271|NCT00808678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696272|NCT06681597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34088753|NCT03716960|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33696273|NCT02791399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33696274|NCT04795986|||COHORT||PROSPECTIVE|||||||
33999693|NCT04435054|NA|SINGLE_GROUP||SCREENING||NONE||||||
33696275|NCT03141073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696276|NCT06562751|||OTHER||OTHER|||||||
33696277|NCT03057509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696278|NCT02770170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919775|NCT05684952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A double-blinded, placebo-controlled, randomized clinical trial|t|f|t|t
33696279|NCT03036605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696280|NCT04896879|||OTHER||PROSPECTIVE|||||||
33784618|NCT06450210|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|"This is a double-blind study. Participants will be told they will receive a range of psilocybin doses (maximum 4.2 mg) and at least one dose of placebo. This will control for expectancy effects on cognitive testing and questionnaires."||t|f|f|f
33784619|NCT04363515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is a pilot feasibility study, but statisticians will be blinded to group assignment when assessing outcomes|A control group versus interventional group. Interventional group and their social support network will complete questionnaire.|f|f|f|t
33919776|NCT03411850|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33919777|NCT04922697|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919778|NCT04546464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33999694|NCT03257254|||COHORT||PROSPECTIVE|||||||
33999695|NCT03619330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999696|NCT06205316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999697|NCT02480634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696281|NCT02883166|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088754|NCT00157755|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34088755|NCT04181788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696282|NCT05708586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696283|NCT00797602|||COHORT||PROSPECTIVE|||||||
33696284|NCT06393478|||COHORT||PROSPECTIVE|||||||
33696285|NCT05160090|RANDOMIZED|CROSSOVER||OTHER||NONE|Open label (laboratory blind)|Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design||||
33999698|NCT04070508|||COHORT||PROSPECTIVE|||||||
33999699|NCT04659668|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33999700|NCT04965831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696286|NCT05377203|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Persons except who make masking plan and conduct medicine coding, are all masked.|2×2 crossover design|t|t|t|t
33999701|NCT02545309|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696287|NCT00261300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696288|NCT05588778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be explicitly told which condition they are randomized to, but are likely to know. All data collectors will be blinded to participants' study condition.|Conduct a 6-month RCT comparing BAILAMOS™ @home/en casa and ¡En Forma y Fuerte! @home/en casa among 100 older Latino adults with symptoms of cognitive decline.|t|f|f|f
33696289|NCT01945359|||COHORT||PROSPECTIVE|||||||
33696290|NCT05002283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784620|NCT04506086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999702|NCT02893163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999703|NCT03390244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999704|NCT02834962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33999705|NCT02473393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999706|NCT03143049|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomised phase 3 study in Asian patients with relapse multiple myeloma after prior bortezomib and lenalidomide who will be treated by PD or PCD. Randomisation will be 1:1 using a computer algorithm. There will be no blinding. The patient in the 2 arms will be stratified according to ISS stage 1 or 2 versus stage 3.~Cross-over for patients randomised to Pomalidomide and Dexamethasone at progression:~Upon progression, patients randomized to pomalidomide and dexamethasone (PD) can cross-over to the PCD arm and have cyclophosphamide added to their regimen according to the PCD regimen. Cyclophosphamide should be added at the beginning of a cycle. They can continue on PCD until further progression. However for these PD patients that cross-over to PCD, the primary endpoint for analysis will be based on response and progression on PD."||||
33919779|NCT06051136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The randomization will be done online directly from Smarty, the software that will manage the eCRF for collecting of the study data.~Furthermore, outcomes will be assessed blindly by staff involved in the research project who do not directly deliver the intervention."|Single-center, two-arm, open-label pilot RCT.|f|f|t|t
33919780|NCT03360045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33919781|NCT03453190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919782|NCT06190405|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33999707|NCT03247335|||OTHER||OTHER|||||||
34088756|NCT01541748|||COHORT||PROSPECTIVE|||||||
34088757|NCT02255864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088758|NCT02198352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088759|NCT00458835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088760|NCT06438601|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34088761|NCT04358523|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088762|NCT00055237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088763|NCT00847028|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34088764|NCT01878591|||COHORT||PROSPECTIVE|||||||
34088765|NCT06305013|||COHORT||PROSPECTIVE|||||||
34088766|NCT00275613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088767|NCT00248560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784621|NCT00735566|||COHORT||PROSPECTIVE|||||||
33784622|NCT01793740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784623|NCT06712173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784624|NCT04356066|NA|SINGLE_GROUP||OTHER||NONE||||||
33784625|NCT05462119|||COHORT||PROSPECTIVE|||||||
33696291|NCT04540575|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Mothers will be randomized into one of two groups after enrollment. Group 1, or Mother Provides Mother's Own Milk (MOM), will receive the standard of care. Group 2, or NICU Acquires MOM, will receive the intervention. Two levels based on gestational age (extremely preterm \< 28 weeks vs. very preterm 28-31 6/7 weeks, with approximately 50% expected in each group based on historical Rush University NICU births) will be crossed with three racial/ethnic categories (black, Hispanic, and white). The stratified random allocation table will be integrated into the baseline demographic questionnaire programmed in REDCap, allowing both patient and interviewer to be blind to condition until the end of the consent process and interview."||||
33696292|NCT01753102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696293|NCT02284360|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33696294|NCT05770583|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33696295|NCT03898843|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696296|NCT01338571|||CASE_CONTROL||PROSPECTIVE|||||||
33696297|NCT00160173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784626|NCT04844866|RANDOMIZED|PARALLEL||TREATMENT||NONE||unblinded 1:1 randomization into IMP or SoC||||
33784627|NCT01021930|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33919783|NCT01559064|||COHORT||PROSPECTIVE|||||||
33919784|NCT00460447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919785|NCT02058758|||COHORT||PROSPECTIVE|||||||
33919786|NCT00673517|||COHORT||PROSPECTIVE|||||||
33919787|NCT04695548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999708|NCT00748787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919788|NCT04019652|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The Investigator, participants, and all other clinical management and personnel will be blinded to treatment. CS-3150 and moxifloxacin (positive control) treatments will be blinded by matching placebos.|"This is a phase 1, single center, randomized, single-dose, double-blind, double-dummy, placebo- and positive-controlled, 4-period crossover study. Participants will be randomized to one of the following 4 treatment sequences:~1. CS-3150 (10-mg dose)/CS-3150 (40-mg dose)/moxifloxacin/placebo~2. CS-3150 (40-mg dose)/placebo/CS-3150 (10-mg dose)/moxifloxacin~3. Moxifloxacin/CS-3150 (10-mg dose)/placebo/CS-3150 (40-mg dose)~4. Placebo/moxifloxacin/CS-3150 (40-mg dose)/CS-3150 (10-mg dose)"|t|f|t|f
33919789|NCT04176445|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||at a single day: arm 1: bedside sitting posture followed by orthostatic board at 45º and 60º; arm 2: orthostatic board at 45º, 60º, and 80º followed by bedside sitting posture.||||
33919790|NCT04237818|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33919791|NCT05485259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919792|NCT04839991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label multi center non randomised study.|Initial dose escalation cohorts followed by dose expansion cohorts consisting of 2 arms, monotherapy and combination therapy cohorts .||||
33919793|NCT00870285|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919794|NCT00700895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999709|NCT03242980|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||To ensure that the effect of this intervention is measured and to avoid a long delay in adopting the intervention, a stepped wedge design was chosen. In addition the study would thus not disrupt the on-going staggered roll-out of routine viral load provision to patients on ART at the 12 health facilities. Stepped wedge designs are a form of clustered study in which the intervention is delivered to groups rather than individuals.||||
33999710|NCT05453708|||CASE_CONTROL||RETROSPECTIVE|||||||
33999711|NCT01857687|||COHORT||RETROSPECTIVE|||||||
33999712|NCT04104360|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696298|NCT05508997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patients were under general anesthesia didn't know which procedure they received \& the outcomes assessor done by my supervisors and didn't know which result related to specific group|group A receive Reverse Trendelenburg Position (RTP) + Positive End Expiratory Pressure (PEEP) titration, and group (B): receive Reverse Trendelenburg Position (RTP).|t|f|f|t
33696299|NCT03388515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696300|NCT06529965|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial with two arms: (i) online intervention in addition to treatment-as-usual versus (ii) treatment-as-usual||||
33696301|NCT05839483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696302|NCT02863757|||COHORT||RETROSPECTIVE|||||||
33696303|NCT01223638|||CASE_CONTROL||PROSPECTIVE|||||||
33696304|NCT04931212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696305|NCT03297814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33999713|NCT05666596|||CASE_ONLY||PROSPECTIVE|||||||
33999714|NCT03166904|NA|SINGLE_GROUP||TREATMENT||NONE||Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle||||
33999715|NCT03414151|||CASE_ONLY||PROSPECTIVE|||||||
33999716|NCT02472834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088768|NCT03380156|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blinding will be done so the investigator performing the FMD and PWA testing will be blinded to the allocation of TNS||t|f|t|t
33696306|NCT04542304|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33784628|NCT00138164||||TREATMENT||NONE||||||
33784629|NCT02550054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33784630|NCT05508360|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study. Patients will receive one implant if they meet all inclusion/exclusion criteria after a review by the Medical Advisory Board (MAB).||||
33784631|NCT06345443|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The pharmacy will be responsible for randomization and dispensing appropriate randomized intervention.||t|t|t|f
33784632|NCT06040476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784633|NCT06144684|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This is a double-blind study; each cohort will include matching placebo and active drug solutions.|This phase 1 study, will be conducted to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending subcutaneous doses of GUB014295|t|f|t|t
33784634|NCT06705439|||OTHER||PROSPECTIVE|||||||
33784635|NCT02979483|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33784636|NCT05403450|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784637|NCT04940546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696307|NCT03361254|NA|SINGLE_GROUP||TREATMENT||NONE||demonstrate the ability of this technique to follow high intensity regimen recommendations||||
33696308|NCT00364754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696309|NCT05885542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization allocation will be completed by statisticians in the Biostatistics Resource Core and all other investigators, study personnel, and participants will be blinded to past and future study allocation.|Participants will be randomized to receive either double-blind single-dose CBD 800 mg or matched placebo (1:1) utilizing a stratified random block design. Randomization will be stratified by biological sex (female, male) to facilitate analyses incorporating sex as a biological variable.|t|t|t|t
33696310|NCT05577403|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Allocation: Randomized|t|f|f|t
33784638|NCT06440850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784639|NCT05854992|||OTHER||RETROSPECTIVE|||||||
33784640|NCT05166174|||CASE_CONTROL||PROSPECTIVE|||||||
33784641|NCT06096129|||COHORT||RETROSPECTIVE|||||||
33784642|NCT03192085|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||Randomised crossover trial of diagnostic test with assessment of comparative accuracy - feasibility study.|t|f|t|f
33784643|NCT05878743|||CASE_ONLY||RETROSPECTIVE|||||||
33784644|NCT03374072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784645|NCT00542022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784646|NCT05218915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784647|NCT02800161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784648|NCT03939520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784649|NCT05496049|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into two groups by a randomization list provided by a computer program. The intervention group will receive a triburter device for training, the patients will have to repeat 50 ventilations (start with 20 repetitions in the first week, 30 in the second, 40 in the four week, and 50 in the last week) five days per day. For the control group (incentive spirometry) they will repeat 10 ventilations per 5 five times a day. Both interventions will be performed for 4 weeks.||||
33784650|NCT06613776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33784651|NCT06711211|||COHORT||OTHER|||||||
33784652|NCT01928940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784653|NCT04139694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784654|NCT01257503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784655|NCT05228860|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will know which group they have been randomized to. The investigator and statistician will not know to which group a participant belongs. Group identifiers will be removed prior to analysis.|Participants will be randomized 1:1 to receive household food deliveries and intensive lifestyle intervention OR to a waitlist control group who only receives the household food deliveries (after a 6 month wait). Both groups will be followed for 12 months. Both groups will continue usual primary care for their diabetes.|f|f|t|t
33784656|NCT05555264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each client will choose one of the following: self-guided Alcohol Change Course Enhanced (8 weeks), therapist-guided Alcohol Change Course Enhanced (8 weeks)||||
33784657|NCT02471365|||COHORT||CROSS_SECTIONAL|||||||
33784658|NCT01251614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784659|NCT06711744|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33784660|NCT03649555|NA|SINGLE_GROUP||OTHER||NONE||||||
33784661|NCT06489249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33784662|NCT03656133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784663|NCT03132454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784664|NCT05251259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784665|NCT06554444|NA|SINGLE_GROUP||SCREENING||NONE||Dental implant placement in the posterior mandible||||
33784666|NCT02096289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784667|NCT02583074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33784668|NCT06527027|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33784669|NCT06678516|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This study is a randomized, cross-over trial with healthy participants aged 18-65 years. Following random order, participants must go through two study periods: one month of intermittent fasting and ad libitum diet (no restrictions), respectively, with one month of washout period following the first study period before participants cross over to the second study period.~Since the intervention is performing/not performing fasting, the participants cannot be blinded. The participants are instructed and guided through the interventions and before randomization will sign the PIF."||||
33784670|NCT06707987|||COHORT||PROSPECTIVE|||||||
33784671|NCT05343559|||COHORT||PROSPECTIVE|||||||
33784672|NCT05295225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33784673|NCT06707675|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784674|NCT05783817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized with a 1:1 allocation to either MDMA-assisted CBT or methamphetamine-assisted CBT (active control).|t|t|t|t
33784675|NCT04773002|||CASE_ONLY||PROSPECTIVE|||||||
33784676|NCT03417843|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective, open- label study||||
33784677|NCT06390488|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33784678|NCT06055621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784679|NCT03875690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33784680|NCT05473520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784681|NCT05366361|||COHORT||PROSPECTIVE|||||||
33784682|NCT06562608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33784683|NCT06696300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations will be made by a single evaluator who is unaware of the groups.||f|f|f|t
33784684|NCT04753996|||CASE_CONTROL||PROSPECTIVE|||||||
33784685|NCT01021332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784686|NCT06711705|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, single arm, open label clinical trial||||
33784687|NCT05154799|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34088769|NCT03478280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomised, double-blind, placebo-controlled, trial|t|f|t|t
34088770|NCT04378478|||CASE_ONLY||RETROSPECTIVE|||||||
33784688|NCT00372216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784689|NCT00088465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696311|NCT04539873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the sample size of 120 subjects each arm of 60 subjects. Random assignment (1: 1) to either colchicine plus standard treatment or control arm (standard treatment) orally for 14 days. An initial dose of 1.5 mg orally on the first day, followed by 0.5 mg every 12 hours on days 2 to 7 and continuing with 0.5 mg a day until completing 14 days ± 1. It will be followed on days 1, 3, 7, 14, and day 28, evaluating physical examination, clinical situation, laboratories, and adverse events. The primary efficacy data correspond to the deterioration in the clinical status of the patients through the semiquantitative ordinal scale suggested by the WHO R\&D committee. Expected results: It is expected to find out how, through different pathways, colchicine could act in modulating or preventing|"This is a phase IIIa, prospective, open-label, randomized, parallel-group study designed to evaluate the efficacy and safety of oral colchicine plus standard therapy versus standard therapy in the clinical course of SARS-CoV-2 infection, in a population group with moderate COVID-19 compromise and requiring hospitalization.~Patients diagnosed with COVID-19 and meeting all eligibility criteria will be randomized for treatment in a 1: 1 ratio through a central voice response system. Randomization will be balanced in each of the 2 strata: 1) hospitalized patients with clinical stage 4 (requirement of supplemental oxygen by nasal contact lenses or mask) of the World Health Organization (WHO) classification, see ANNEX 2, who will receive in addition to the usual treatment for COVID-19 oral colchicine (exposed group); 2) hospitalized patients with clinical stage 4 of the WHO classification who will receive the usual treatment for COVID-19 (control group)."|t|f|f|f
33696312|NCT03111966|||COHORT||PROSPECTIVE|||||||
33999717|NCT04974580|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Evaluators are blinded to the study arm assignment of participants.|A 2x2 factorial design will be used where all participants receive quitline-delivered phone counseling, and components to be tested are a digital intervention (with text-based cessation and online cessation support) and nicotine replacement therapy (NRT).|f|f|f|t
33999718|NCT04082741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999719|NCT00263458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999720|NCT00413049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088771|NCT03779607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999721|NCT01282450|NA|SINGLE_GROUP||||NONE||||||
33999722|NCT00009776||||TREATMENT||||||||
34088772|NCT01705418|||COHORT||PROSPECTIVE|||||||
33999723|NCT02401139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696313|NCT05741658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696314|NCT02395783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696315|NCT02521493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088773|NCT05695287|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33696316|NCT03698331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088774|NCT06552169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696317|NCT02248415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34088775|NCT01777724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696318|NCT02129829|||COHORT||PROSPECTIVE|||||||
34088776|NCT04538105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088777|NCT05619224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088778|NCT04207138|||CASE_ONLY||PROSPECTIVE|||||||
34088779|NCT03833310|||CASE_CONTROL||PROSPECTIVE|||||||
34088780|NCT03503045|||COHORT||CROSS_SECTIONAL|||||||
34088781|NCT05037162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a double-blind study: neither the participants nor the investigators will be aware of arm allocation of each study participant.~Blindness is important to avoid bias. Monitoring and reporting of the success of blindness are important for the reader's confidence of the trial results. Groups should be marked by capital letter and blindness should maintain throughout the study."|"Multi-center multinational-controlled study in Israel, Brazil, Spain, and South-Africa.~240 adult patients who suffer from moderate COVID-19 infection. Safety will be assessed through collection and analysis of adverse events, blood and urine laboratory assessments and vital signs.~After Screening visit, the study drug will be administrated twice a day morning and evening (every 12 hours) during (day 1 and day 2) The patients will be randomized in 1:1:1 ratio to study drug (CimetrA) in two dosages in addition to Standard of Care - Arm 1, 2 or (Placebo) in addition to Standard of Care- Arm 3."|t|t|t|f
33696319|NCT00732797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696320|NCT01565174|||COHORT||CROSS_SECTIONAL|||||||
33696321|NCT03392077|||OTHER||CROSS_SECTIONAL|||||||
33696322|NCT02613949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696323|NCT05936125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696324|NCT06377306|||COHORT||PROSPECTIVE|||||||
33696325|NCT06174259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696326|NCT03409068|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33696327|NCT06680258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696328|NCT01367431|||||PROSPECTIVE|||||||
33696329|NCT01161797|||COHORT||PROSPECTIVE|||||||
33696330|NCT04109560|||COHORT||PROSPECTIVE|||||||
33696331|NCT05428293|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696332|NCT05464173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696333|NCT01922674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696334|NCT02174354|||COHORT|||||||||
33696335|NCT02643290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999724|NCT02817828|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33999725|NCT04559841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single examiner blinded to the treatment assignment was responsible for evaluating the clinical parameters|single-center, parallel group, 6 month randomized clinical trial|f|f|f|t
33999726|NCT05956717|||COHORT||PROSPECTIVE|||||||
33999727|NCT01963455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999728|NCT01897064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999729|NCT01751633|||COHORT||PROSPECTIVE|||||||
33999730|NCT00611650|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088782|NCT04443608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blinded, placebo-controlled parallel group|t|t|t|t
33696336|NCT06090591|||COHORT||PROSPECTIVE|||||||
33696337|NCT03126370|NA|SINGLE_GROUP||OTHER||NONE||||||
33696338|NCT01090973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088783|NCT00513539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088784|NCT00454077|||NATURAL_HISTORY||PROSPECTIVE|||||||
33784690|NCT02734004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088785|NCT01975441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088786|NCT03704740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088787|NCT03868371|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33784691|NCT01841840|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33784692|NCT05877560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784693|NCT04692714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784694|NCT06712030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The analysis of the echocardiogram will be performed by evaluators blinded to the treatment and the timing of the imaging.||f|f|f|t
33784695|NCT06341374|||COHORT||PROSPECTIVE|||||||
33784696|NCT06030427|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33784697|NCT05855226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784698|NCT05882032|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33919795|NCT03222076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919796|NCT02275598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919797|NCT00698035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919798|NCT01770691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919799|NCT04075773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be made aware of the purpose of the study. Research assistants, who interact with the participants, will not be made aware of which writing prompt any given participant will receive.|Participants will be randomized to either an intervention condition, where they will write about how their drinking relates to their religious identity, or to a control condition, where they will write about how their drinking relates to their age.|t|t|f|f
33919800|NCT06337682|||COHORT||RETROSPECTIVE|||||||
33919801|NCT05270642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919802|NCT01852695|RANDOMIZED|PARALLEL||||NONE||||||
33919803|NCT03489993|||COHORT||PROSPECTIVE|||||||
33919804|NCT01669642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919805|NCT03084289|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919806|NCT05556551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Different restoration inserted in the patient mouth|Two different restorations in patient mouth|t|f|f|f
33919807|NCT03676153|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic study examining the impact of a nurse-guided self-administered integrative medicine intervention on quality-of-life outcomes in cancer care.||||
33919808|NCT00740922|||COHORT||RETROSPECTIVE|||||||
33919809|NCT02441855|||CASE_CONTROL||PROSPECTIVE|||||||
33919810|NCT05828732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33919811|NCT02088229|||CASE_ONLY||PROSPECTIVE|||||||
33919812|NCT00006454|RANDOMIZED|||TREATMENT||||||||
33919813|NCT05765487|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33919814|NCT02797691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919815|NCT02892838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919816|NCT05690334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33919817|NCT06078787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919818|NCT06255054|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33919819|NCT03723005|||COHORT||PROSPECTIVE|||||||
33919820|NCT04209257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919821|NCT05496894|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919822|NCT00124241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919823|NCT02534194|||COHORT||PROSPECTIVE|||||||
33919824|NCT01478438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919825|NCT03737045|NA|SINGLE_GROUP||OTHER||NONE|Participants will have a choice of decision aids (web or paper) and will not be blinded. The study team will be aware of each prototype and decision aid that participants use.|Patients and providers will use a web-based or paper decision aid. They will not be assigned to specific arms or undergo randomized treatment.||||
33919826|NCT04740736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919827|NCT02029495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919828|NCT05424887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919829|NCT00180219|||COHORT||PROSPECTIVE|||||||
33919830|NCT03833622|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919831|NCT03031548|||COHORT||PROSPECTIVE|||||||
33999731|NCT03276767|RANDOMIZED|PARALLEL||PREVENTION||NONE|The recruitment procedure and the treatment is fully automated and delivered by web, e-mail and SMS-textmessages - i.e., the participant is not contacted by any care providers, investigators or assessors during recruitment or treatment.|Participants receive one out of two versions of a web-based smoking cessation program. The only difference between the two versions is the medium of the reminder: either SMS-textmessage or e-mail.||||
33999732|NCT05055713|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784699|NCT06308653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The following roles will be blinded to the treatment group assignment in the Double-blind Period during the trial: Participant, Investigator, Site Personnel, Facilitators, Efficacy Raters (including Site Raters, Participant Raters, and Central Raters), Contract Research Organization (CRO) Staff, and Sponsor.~All roles other than the Sponsor, CRO, and Ethics Committees will also be blinded to the randomization ratio and Patient Health Questionnaire-9 (PHQ-9) score for re-administration eligibility.~The Central MADRS Rater will also be blinded to all aspects of the protocol and trial visit for each participant.~Blinded trial site personnel will complete administration of the IP.~Full blinding of trial personnel, Sponsor, and participants will be maintained until database lock at the conclusion of the trial."|"Participants will be randomized to receive Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo under double-blind conditions. After the initial 6-week Double-blind Period, all participants will proceed into a 1-year Follow-up Period. During this 1-year Follow-up Period, eligible participants who meet pre-determined criteria may be offered open-label Psilocybin 25 mg in the context of a Set and Setting (SaS) Protocol."|t|f|t|t
33784700|NCT02266420|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784701|NCT04228276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly assigned to one of two groups to receive active or sham rTMS.|t|f|t|f
33784702|NCT03148054|||CASE_ONLY||PROSPECTIVE|||||||
33784703|NCT06191744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784704|NCT06712524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784705|NCT02560103|||CASE_ONLY||PROSPECTIVE|||||||
33784706|NCT00522847|||COHORT||PROSPECTIVE|||||||
33784707|NCT06062888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Control vs Experimental Biologic Group|t|f|f|t
33784708|NCT00315965|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33784709|NCT00410995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784710|NCT01019148|||CASE_ONLY||PROSPECTIVE|||||||
33784711|NCT06622031|NA|SINGLE_GROUP||TREATMENT||NONE||TIPS procedure||||
33919832|NCT06070116|RANDOMIZED|PARALLEL||TREATMENT||NONE|While this is an open label study and there is no placebo treatment group, all efforts will be made to ensure that that medical/technical staff assessing skin Mf, adverse events (AEs) and ophthalmological findings will be unaware of initial baseline skin and ocular Mf findings and treatment arm as best as possible.|"IVM + ALB (IA) - Dose of oral IVM (150 µg/kg) plus ALB (400 mg)~Mox + ALB (MoxA) - Dose of oral Mox (8mg tablets) plus ALB (400mg)~IVM + DEC + ALB (IDA) - Dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)~MOX + DEC + IVM (MoxDA) - Dose of oral Mox (8 mg), DEC (6 mg/kg) and ALB (400 mg)"||||
33919833|NCT00436319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919834|NCT02293356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919835|NCT02882763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33919836|NCT03315728|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33919837|NCT04888234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919838|NCT05250193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919839|NCT03532581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919840|NCT01789346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919841|NCT02229630|NA|SINGLE_GROUP||SCREENING||NONE||||||
33919842|NCT00879606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919843|NCT05058898|||CASE_CONTROL||PROSPECTIVE|||||||
33919844|NCT03146221|NA|SINGLE_GROUP||OTHER||NONE||||||
33919845|NCT01969942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919846|NCT05389059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33919847|NCT01836263|||COHORT||PROSPECTIVE|||||||
33999733|NCT06204939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized single blinded for one of two study arms/procedures. 3 years post-operative unblinding will be done for participants wishing this.|Single blinded randomized controlled trial|t|f|f|f
33999734|NCT03254732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999735|NCT01617096|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33999736|NCT00128219|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33999737|NCT04664751|||COHORT||PROSPECTIVE|||||||
34088788|NCT06441799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Three doctors set up a blind evaluation group to evaluate the photos of the subjects before and after receiving the device treatment|The method of randomized control and evaluator blindness is suitable for screening A total of 224 subjects were enrolled and randomly divided into control group and experiment according to 1:1 ratio Group)|f|f|f|t
34088789|NCT00484159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696339|NCT02556736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696340|NCT04350606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696341|NCT00990873|||CASE_ONLY||RETROSPECTIVE|||||||
33696342|NCT04925271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients undergoing closure of a mucosal or submucosal defect in the gastrointestinal tract will be randomized 1:1 to either closure with X-Tack or closure with Overstitch.|t|f|f|f
33696343|NCT05137990|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomized to complete one of two conditions: 1) 14 weeks of a home-based virtual HIIT exercise intervention or 2) 14 weeks of a stretching intervention (control group).||||
33696344|NCT03563976|||CASE_ONLY||RETROSPECTIVE|||||||
33696345|NCT06317376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696346|NCT01771380|||COHORT||CROSS_SECTIONAL|||||||
34088790|NCT02841046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696347|NCT00046748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33696348|NCT04094623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696349|NCT02239224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696350|NCT04623307|||CASE_CONTROL||PROSPECTIVE|||||||
33696351|NCT04872400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This will be a single-blind study as only the participants will be blinded to the treatment.|The management of open fractures involves an expedited administration of systemic antibiotics and while effective in reducing the rate of infection, complications from infections are still common following open fractures. This trial aims to evaluate the incidence of surgical site infections using topical vancomycin antibiotic powder or topical tobramycin antibiotic powder in combination with standard of care treatment and to evaluate the effectiveness of both topical antibiotic powders in reducing surgical site infection.|t|f|f|f
33696352|NCT01230710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784712|NCT03389581|||OTHER||PROSPECTIVE|||||||
33784713|NCT06080711|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33784714|NCT02655692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784715|NCT06554652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784716|NCT06712043|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Not possible in this situation|Single group intervention study with historical control group||||
34088791|NCT00022477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088792|NCT06374849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088793|NCT01246284|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34088794|NCT00850577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784717|NCT06714045|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33696353|NCT03302195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blinded to group assignment|Randomized control prospective trial|t|f|f|f
33784718|NCT02197234|NA|||TREATMENT||NONE||||||
33696354|NCT03266523|||COHORT||PROSPECTIVE|||||||
33784719|NCT00531479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696355|NCT02289001|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33784720|NCT06680479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized (2:1), 20 participants in Arm 1 and 10 participants in Arm 2||t|f|t|f
33696356|NCT04449510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33696357|NCT05819606|||COHORT||PROSPECTIVE|||||||
33696358|NCT04521673|||COHORT||PROSPECTIVE|||||||
33784721|NCT02286661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784722|NCT02867839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784723|NCT05174169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784724|NCT05373901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696359|NCT05154201|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696360|NCT01284582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784725|NCT06705374|||COHORT||PROSPECTIVE|||||||
34088795|NCT06060366|||COHORT||PROSPECTIVE|||||||
34088796|NCT00067834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088797|NCT01065181|||COHORT||CROSS_SECTIONAL|||||||
34088798|NCT01298258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088799|NCT02928484|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34088800|NCT04858464|||OTHER||PROSPECTIVE|||||||
34088801|NCT02472444|||COHORT||PROSPECTIVE|||||||
34088802|NCT06064448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088803|NCT05683067|||COHORT||PROSPECTIVE|||||||
34088804|NCT03820232|||COHORT||PROSPECTIVE|||||||
34088805|NCT02247544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088806|NCT02831777|||COHORT||RETROSPECTIVE|||||||
34088807|NCT03804307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088808|NCT03754543|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34088809|NCT04767451|||CASE_CONTROL||PROSPECTIVE|||||||
34088810|NCT03514953|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34088811|NCT05106478|||COHORT||PROSPECTIVE|||||||
34088812|NCT00532623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088813|NCT02300610|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34088814|NCT03315949|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34088815|NCT06212791|||COHORT||PROSPECTIVE|||||||
34088816|NCT02987881|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Open Label|||||
34088817|NCT05284253|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34088818|NCT06305845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will not be informed of which crown they will receive|a randomized clinical trial with two parallel arms|t|f|f|f
34088819|NCT05509504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088820|NCT01650428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088821|NCT02371005|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34088822|NCT00910585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088823|NCT05769101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||6 Weeks of resistance training (alternate days), with a post-workout or Maltodextrin intake.|t|t|t|t
34088824|NCT05403918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088825|NCT01777646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088826|NCT02122419|||||RETROSPECTIVE|||||||
34088827|NCT06277167|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33801553|NCT03224858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants, care providers, investigator, and initial trained research assistant will be blinded initially during consent and baseline interview survey procedures. Once, randomization has occurred, the participants, care provider, investigator, and subsequent outcomes assessor will not be blinded.|"This is a pragmatic wait-list control design. Participants will be consented and baseline survey administered after which patient will be randomized by computer generated algorithm into 2 arms: immediate or 6-month 'wait-list.' Immediate group will start intervention and be followed at 6 month intervals for 12 months. 'Wait-list' group will resume usual care for 6-months, after which they will cross-over to the intervention group for 12 months."|t|t|t|f
33801554|NCT00277914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801555|NCT05251844|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|all violators' identities are masked to Protenus.|one group received email notice while the group didn't|t|t|t|t
34088828|NCT01084304|||COHORT||PROSPECTIVE|||||||
34088829|NCT06518291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088830|NCT04926181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088831|NCT02819128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088832|NCT00452569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088833|NCT05482867|||COHORT||PROSPECTIVE|||||||
34088834|NCT03150212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34088835|NCT05672875|||COHORT||PROSPECTIVE|||||||
34088836|NCT01745510|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Intervention was blinded through assinging a code, printed and saved into opaque envelopes did it by a researcher who did not participate in the fieldwork.~Randomization was carried out through the Random Allocation Software v.1"|The intervention was the docosahexaenoic acid, a nutraceutical derived from the omega 3 fatty acids.|t|t|f|t
34088837|NCT01548235|||COHORT||PROSPECTIVE|||||||
34088838|NCT00058981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34088839|NCT02367560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088840|NCT01531634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088841|NCT04470427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part A is observer-blind. Part B is open-label; participants can request to be unblinded by scheduling a Participant Decision clinic visit. Part C offers participants the option to receive a booster dose for those participants who received at least one dose of mRNA-1273 in the study.||t|t|t|t
34088842|NCT01212510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088843|NCT05722301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088844|NCT00997529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999738|NCT06180915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Stratified block randomization will be used to prevent selection bias. In this study regarding application bias, it was ensured that the researcher and the participants had not met before and that the researcher did not play a direct role in the academic success of the participants. Researcher and participant blinding will not be possible. Because the researcher will perform the application himself and placebo will not be used in the intervention.~Pretest and posttests to prevent detection bias will be administered online via Google Forms®, independently of the researcher.~To prevent reporting bias, the data obtained from the research will be coded as A and B by an independent researcher and transferred to the SPSS program. Analysis of the data will also be done by an independent statistician.~In order to prevent attrition bias, Attrition Bias and Intention to Treat Test will be used in case of attrition/reduction in the sample group or if the final tests are not completed."|"In order to ensure similarity between groups; Stratified block randomization will be used to assign the women in the sample group to the experimental and control groups. According to the stratified block randomization method, imbalances that may arise in the experimental and control groups are limited. In this method, after stratification according to risk factors, block randomization is performed within each stratum (Akın \& Koçoğlu, 2017; Kanık, Taşdelen \& Erdoğan, 2011). 1st Layer: 1st grade students. 2nd Layer: 2nd grade students. 3rd Layer: 3rd Grade. grade students In order to determine which stratum group the woman who is found to meet the research criteria and agrees to participate in the study is in, blocks will be created with a combination of 8 and an assignment list will be determined through the website www.randomizer.org.~Mersin and Tarsus University Midwifery departments were chosen due to the similarity of their core curricula and education in similar geography."|t|f|f|t
33999739|NCT00362687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999740|NCT03151824|||COHORT||CROSS_SECTIONAL|||||||
33999741|NCT02161549|||COHORT||PROSPECTIVE|||||||
33999742|NCT03196817|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33999743|NCT01406639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999744|NCT01680601|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33999745|NCT01401296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999746|NCT02409797|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999747|NCT00579631|||CASE_ONLY||CROSS_SECTIONAL|||||||
33999748|NCT04423003|||COHORT||PROSPECTIVE|||||||
33999749|NCT04504162|||OTHER||PROSPECTIVE|||||||
33999750|NCT00938782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999751|NCT00250354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999752|NCT06088095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999753|NCT03004157|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33999754|NCT01684280|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999755|NCT03609749|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999756|NCT03241836|||CASE_ONLY||CROSS_SECTIONAL|||||||
33999757|NCT00751023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999758|NCT03926416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33999759|NCT06374654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999760|NCT00452543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088845|NCT05884450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental study|t|f|f|f
34088846|NCT02318940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088847|NCT00849056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999761|NCT00065949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33999762|NCT04546412|||COHORT||PROSPECTIVE|||||||
33999763|NCT06116396|||CASE_CONTROL||OTHER|||||||
33999764|NCT01415596|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33999765|NCT06204367|||CASE_ONLY||PROSPECTIVE|||||||
33999766|NCT05278403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized groups. Participants do not know to which group they are assigned. The other participants are unaware of the purpose of the study.|Two randomized groups. A control group and an experimental group.|t|f|t|t
33999767|NCT02538211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999768|NCT01944553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088848|NCT01722799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088849|NCT00596635|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34088850|NCT00486681|||CASE_CROSSOVER||PROSPECTIVE|||||||
34088851|NCT01206491|||CASE_CONTROL||PROSPECTIVE|||||||
34088852|NCT05579834|||CASE_ONLY||RETROSPECTIVE|||||||
34088853|NCT02363088|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34088854|NCT01093417|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34088855|NCT05309772|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||Patients will be randomised using a 4:5 allocation between standard-of-care/biomarker arms. Stratified randomisation will be adopted according to recruiting centre, using a web-based allocation system.|t|t|t|f
34088856|NCT06551844|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a phase 2 randomized, adaptive, open label trial for antiviral screening in patients with dengue presenting at the healthcare settings within 48 hours.||||
33999769|NCT06416449|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||We'll assess balance, agility, and jumping. Tests include Star Balance Test, T-Agility Test, and Vertical Jump Test. In Star Balance, lines are drawn on the ground, the individual stands on one foot, reaching out with the other to touch lines. In T-Agility, a course is set, and time is recorded. The Vertical Jump Test measures the highest point reached against a wall-mounted ruler. Kinesio tape, allowing 55-60% elongation, will be used. Tests are conducted both with and without tape, with rest intervals.||||
33999770|NCT06502951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999771|NCT01226953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33999772|NCT03451747|||CASE_CONTROL||RETROSPECTIVE|||||||
33999773|NCT04826250|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33999774|NCT03196687|||COHORT||PROSPECTIVE|||||||
33999775|NCT05642936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All investigators and clinic staff were blinded to treatment assignment, except the project manager who did not collect data from participants. Primary care physicians were blinded to the treatment assignments of their patients. Since participants were necessarily aware of their treatment status.|This was a randomized controlled community-based clinical trial|f|t|t|t
33999776|NCT02986256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33999777|NCT03192813|||CASE_CONTROL||PROSPECTIVE|||||||
33999778|NCT03201276|||CASE_ONLY||PROSPECTIVE|||||||
33999779|NCT01299779|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33999780|NCT03523650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999781|NCT03348527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blinded to whether they are receiving a treatment dose of 35% or 45% of total prostate volume in stage I or 16mL or 20mL in stage II.|"Stage I: 20 Subjects will be enrolled into one of two groups, each receiving a single dose of Liproca®Depot. The target treatment dose will be 35% (Cohort 1) or 45% (Cohort 2) of the prostate volume (mL).~Stage II: 40 subjects will be randomized to receive either 16 mL (Cohort 3) or 20mL (Cohort 4) of Liproca®Depot."|t|f|f|f
33999782|NCT04396964|||COHORT||CROSS_SECTIONAL|||||||
33999783|NCT03945916|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Crossover - dark chocolate vs. placebo|t|f|t|t
33999784|NCT00933140|||COHORT||PROSPECTIVE|||||||
33999785|NCT06439446|||COHORT||PROSPECTIVE|||||||
33999786|NCT05926245|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33999787|NCT00163124|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34088857|NCT05142735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators and research staff are blinded to the conditions. Research Pharmacy staff are unblinded and responsible for randomization and NAC or placebo dispensing.|"Participants are assigned to one of NAC or placebo groups in parallel for the duration of the study. This will be a randomized, double-blind, placebo-controlled trial.~Participants will be randomized to take either NAC 2000 mg or placebo, in the form of oral capsules, every morning for 8 weeks."|t|t|t|t
34088858|NCT00941928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999788|NCT05588505|NA|SINGLE_GROUP||TREATMENT||NONE||In the first (open trial) phase of the study, all participants will receive group cognitive-behavioral therapy (CBT) for executive self-management skills, including time-management, organization, and planning. Students will be assessed on measures of ADHD symptoms and executive self-management skills before and at the conclusion of the 12-week treatment program. Each group session lasts 2 hours.||||
33999789|NCT05646238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Those with a VAS score of 4 and above were assigned to the experimental and control groups.|randomized controlled experimental design|t|f|f|f
33999790|NCT04188964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999791|NCT00335062|||COHORT||PROSPECTIVE|||||||
33999792|NCT02727192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999793|NCT04876716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088859|NCT01643213|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34088860|NCT05372159|||CASE_CONTROL||PROSPECTIVE|||||||
34088861|NCT05994807|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34088862|NCT02865291|NA|SINGLE_GROUP||OTHER||NONE||||||
34088863|NCT05704712|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34088864|NCT06255041|||COHORT||PROSPECTIVE|||||||
34088865|NCT06063889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34088866|NCT02349880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34088867|NCT04320537|||COHORT||PROSPECTIVE|||||||
34088868|NCT00120744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34088869|NCT05149105|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34088870|NCT01113242|||CASE_CONTROL||PROSPECTIVE|||||||
33999794|NCT05033145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Randomized, double-blind, parallel, placebo-controlled trial|t|t|t|t
33999795|NCT01102660|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33999796|NCT05308316|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999797|NCT00150683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999798|NCT00273013|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33999799|NCT02975713|||CASE_CONTROL||PROSPECTIVE|||||||
33999800|NCT01835548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999801|NCT03117244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33999802|NCT04914546|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33999803|NCT02816684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33999804|NCT02985749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999805|NCT05758129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33999806|NCT00894764|||COHORT||PROSPECTIVE|||||||
33999807|NCT05815225|||OTHER||PROSPECTIVE|||||||
33999808|NCT00643305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33999809|NCT02699762|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33999810|NCT03540160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999811|NCT00000380||||TREATMENT||||||||
33999812|NCT04179539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999813|NCT04003441|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33999814|NCT02898740|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33999815|NCT00111137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999816|NCT05270044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33999817|NCT03226613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigators conducting the ultrasound study will be masked as to the characteristics/location of patient's tumor in order to determine feasibility of identifying oropharyngeal cancers as a sole imaging technique.|||||
33999818|NCT04474587|||CASE_ONLY||PROSPECTIVE|||||||
33999819|NCT03537209|||OTHER||RETROSPECTIVE|||||||
33999820|NCT03202927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As this is single blind study so study participants would be blinded in the study|This is a single blind parallel comparative immunogenicity study|t|f|f|f
33999821|NCT04965233|||CASE_CONTROL||PROSPECTIVE|||||||
33999822|NCT04736537|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999823|NCT03121937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999824|NCT00746486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999825|NCT03577561|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving PBP training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.~Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy PBP training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time.~Interventional Group:~The blood sampling error rate in those doctors in training given the improved proficiency based progression training under investigation from March 30th 2018"||||
33999826|NCT04148287|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm intervention. All patients will receive APX001. On Days 1-3, APX001 will be administered intravenously. Thereafter, if the patient is able to take oral medication, APX001 tablets will be taken orally.||||
33999827|NCT05125276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999828|NCT04459754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999829|NCT03332433|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33999830|NCT00486993|||COHORT||PROSPECTIVE|||||||
33999831|NCT00879684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999832|NCT05624424|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Care provider and investigator (anesthesiologist) cannot be blinded for different appearance of remimazolam, propofol and sevoflurane.|This is a RCTs.|t|f|f|t
33999833|NCT03294317|||COHORT||PROSPECTIVE|||||||
33999834|NCT01291862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999835|NCT00135187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999836|NCT05734716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants and researchers involved in data collection are blinded to the treatment assignment of all participants.||t|t|t|f
33999837|NCT02119936|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34088871|NCT02531685|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34088872|NCT05207501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The active-control group will receives a comparable standard treatment to the three other groups: Moderate Intensity Interval Training on a ergocycle without any additional feature.|This study is designed as a randomized parallel group active-control study.|t|f|f|f
34088873|NCT05873738|||COHORT||PROSPECTIVE|||||||
34088874|NCT03755466|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34088875|NCT00489580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34088876|NCT05746923|||COHORT||PROSPECTIVE|||||||
33801556|NCT03136042|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomized in first visits into crossover techniques: (i) hypertonic saline (3%) - HS technique; (ii) physiotherapy techniques (oscillatory positive expiratory pressure, forced expiration and acceleration of expiratory flow) - P technique; (iii) hypertonic saline + physiotherapy techniques - HSP technique. All children attended three visits and 90 samples were collected. All patients underwent induced sputum and pulmonary function before and after bronchodilator.||||
33801557|NCT02371512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999838|NCT03748251|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999839|NCT03300687|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33999840|NCT01968031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999841|NCT02931630|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33999842|NCT05771051|||CASE_CONTROL||PROSPECTIVE|||||||
33999843|NCT00144222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999844|NCT02046122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999845|NCT00526136|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33999846|NCT01742208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999847|NCT03371524|||CASE_ONLY||PROSPECTIVE|||||||
33999848|NCT00901524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999849|NCT02786160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33801558|NCT04667780|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, prospective, randomized, controlled, open-label and pragmatic trial, comparing the administration of Colchicine plus standard treatment vs. standard therapy, in hospitalized patients with COVID-19, within the first 48 hours, and no severity criteria.||||
33999850|NCT02783287|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33999851|NCT03019016|||COHORT||RETROSPECTIVE|||||||
33999852|NCT04046094|NA|SINGLE_GROUP||TREATMENT||NONE||To assess pathologic downstaging rate in MIBC cisplatinineligible patients when IVC is added to a gemcitabine/carboplatin NAC regimen.||||
33999853|NCT01256996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999854|NCT05268458|||COHORT||PROSPECTIVE|||||||
33999855|NCT01021657|||COHORT||PROSPECTIVE|||||||
33999856|NCT01842555|||COHORT||OTHER|||||||
33999857|NCT06462976|||CASE_ONLY||PROSPECTIVE|||||||
33999858|NCT06677697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801559|NCT00921154|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33801560|NCT02624141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801561|NCT04811716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919848|NCT04082702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research personnel involved in delivering interventions were not allowed to facilitate the outcome measures. Project coordinator, key personnel, and trained volunteers (which included graduate students) collected all the data elements. Statisticians and data coordinators were blinded of intervention group assignments of the participants until the end of the study.|This study uses a prospective, 2-group, randomized nested (by church) design with eleven congregations, comparing a healthy weight management program with a pastor/church leader component (Intervention) to a healthy weight management program without a pastor/church component (Control). Focus groups were conducted with a sample of 64 participants for understanding needs, perspectives and barriers to healthy weight management. A total of 221 overweight and obese female participants from about 11 churches (approximately 25-30 individuals per church) were recruited and participated in this study following the protocols. The DPP Curriculum includes an intervention phase (approximately weekly for 4 months) and maintenance phase (once or twice a month for 6 months). Faith components (handouts and mini-sermon) are only used by the treatment (intervention) group through both the intervention and maintenance phase.|f|f|f|t
33999859|NCT04967209|||COHORT||PROSPECTIVE|||||||
33999860|NCT02017873|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33801562|NCT05443737|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Fertility specialists and their support staff will be blinded to the intervention status of the cluster from which a patient is referred to minimize differences in counseling in patients whom they expect to receive financial navigation.|Stepped wedge cluster randomized controlled trial|f|t|f|f
33919849|NCT00171106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33919850|NCT04899960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919851|NCT05388019|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33919852|NCT04777578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|f|t
33919853|NCT03076125|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|data collectors conducting post-intervention and 8-week follow up are blinded to participant treatment groups|randomized controlled two-group pre-post test design|t|f|f|t
33919854|NCT04948411|||COHORT||CROSS_SECTIONAL|||||||
33919855|NCT02116816|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33919856|NCT05273840|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. life intervention group~2. nutritional supplement intervention group"||||
33919857|NCT02884830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919858|NCT01046383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999861|NCT04097444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999862|NCT02832466|||COHORT||PROSPECTIVE|||||||
33999863|NCT03005834|||COHORT||PROSPECTIVE|||||||
33999864|NCT01074827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999865|NCT05842720|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999866|NCT04039360|||CASE_ONLY||PROSPECTIVE|||||||
33999867|NCT02494505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999868|NCT05064007|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33999869|NCT05211505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999870|NCT03859050|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999871|NCT02542462|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33999872|NCT04568707|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999873|NCT00006942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999874|NCT04273295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).|First group receives senna-based laxatives . Second group managed by abdominal massage with senna-based laxatives. Evaluation of outcome of two groups as regard to continence and radiological study.|f|f|f|t
33999875|NCT05710588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will know they are allocated to one group randomly but they will not know which group is this.|There are two different intervention groups: M-DTT and C-DTT. Participants will be allocated to either M-DTT or C-DTT group.|t|f|f|f
33999876|NCT04173923|||OTHER||OTHER|||||||
33999877|NCT04987645|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant will be blinded to the intervention until after the pain score has been completed.|Each participant would be randomly assigned to either water only or water and air insufflation on insertion via a computer-generated random number.|t|f|f|f
33999878|NCT04266548|NA|SINGLE_GROUP||TREATMENT||NONE||The study was the clinical feasibility study. Only selected single HCC patients was enrolled to study the feasibility of image guide surgery for laparoscopic hepatectomy||||
33999879|NCT02233751|RANDOMIZED|PARALLEL||TREATMENT||NONE|The dose assignment was random among the enrolled participants.|||||
33999880|NCT03290807|||COHORT||PROSPECTIVE|||||||
33999881|NCT05838716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33999882|NCT03601585|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||f|f|t|t
33999883|NCT01711801|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34088877|NCT03823027|NA|SINGLE_GROUP||TREATMENT||NONE||The single-arm study is designed to collect data on changes over time, i.e. comparing the pre-treatment/baseline value with the value achieved after full treatment (12 weeks). Thus, each individual act as his/her own control. The study design has been discussed with notified bodies, and deemed appropriate as there is no state-of-the-art pharmacotherapy for treatment of prediabetes to compare with.||||
34088878|NCT04165057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind||f|f|t|f
34088879|NCT03617302|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34088880|NCT02085551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088881|NCT01631188|NA|SINGLE_GROUP||OTHER||NONE||||||
34088882|NCT02199496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088883|NCT04607096|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants wil either receive a control diet or join the intermittent fasting group stratified by glycemia (prediabetes/diabetes) as well as by subphenotype.||||
34088884|NCT01503047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088885|NCT04947891|||CASE_CONTROL||PROSPECTIVE|||||||
34088886|NCT04761250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088887|NCT01754649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088888|NCT05821829|||COHORT||PROSPECTIVE|||||||
34088889|NCT01852903|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34088890|NCT01861392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34088891|NCT02750293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088892|NCT04130087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"A randomisation code will be drawn up by a researcher not involved in the study using a randomisation tool online (https://www.sealedenvelope.com/simple-randomiser/v1/lists). The study randomisation code will be kept in a sealed envelope in a dedicated cabinet in Neurosciences Building of The Department of Psychiatry. At the end of the study, the randomisation blind will be broken by the principal investigator by opening the randomisation code envelope.~Blinding will be achieved by identical encapsulation of the selegiline and the placebo using the Departmental Standard Operating Procedure for drug encapsulation."|"Placebo controlled trial.~27 participants will be allocated to receive a single 10mg of selegiline and the same number will receive a single dose of placebo (lactose tablet.)"|t|t|t|t
34088893|NCT02038192|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34088894|NCT03445169|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088895|NCT01933724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088896|NCT02340455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999884|NCT04262180|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Stratified randomization. Assessors will be blinded to which arm the participant is in.|One control arm and two randomized arms. Every participant starts with a base intervention, non-responders will be randomized to one of the two arms.|f|f|f|t
33999885|NCT04727554|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33999886|NCT02380534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999887|NCT04292691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomization will be conducted by the Principle Investigator through RedCap. The syringe is prepared under sterile setting in a separate room by a nurse not involved in any further part of the medical treatment. The syringe with unknown content will be handed to the anaesthesiologist performing the anaesthesia. Therefore the anaesthesiologist performing the block as well as the guiding the anaesthesia throughout the surgery does not know what was injected.~The total intraoperative morphine milligram equivalent dose will be automatically drawn from our anaesthesia recording program (NarcoData) and the cumulative morphine milligram equivalent dose use between skin incision and beginning Recovery Room calculated. The patient than receives the Piritramid PCA and the total morphine milligram equivalent dose use will again be drawn automatically from the machine. The VAS Score will be entered by the patient in a tablet."|Double blinded, randomised control trial|t|t|f|f
33999888|NCT02725515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized (1:1, no stratification), Double-Blinded, Placebo-Controlled|t|t|t|t
33999889|NCT04491838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999890|NCT02582944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801563|NCT00557492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801564|NCT03323775|||CASE_ONLY||PROSPECTIVE|||||||
34088897|NCT00937950|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34088898|NCT05731765|||COHORT||RETROSPECTIVE|||||||
34088899|NCT03164681|||COHORT||PROSPECTIVE|||||||
34088900|NCT04167813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|TOPHAT is a double blind, individually randomized, placebo-controlled, parallel group, flexible dose trial|t|t|t|t
34088901|NCT02993276|||COHORT||PROSPECTIVE|||||||
33801565|NCT04654598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801566|NCT01095822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34088902|NCT06492993|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33696361|NCT00955123|||CASE_CROSSOVER||PROSPECTIVE|||||||
33696362|NCT04515446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, prospective, transversal, diagnostic measurement, blind, descriptive study||||
33696363|NCT04920682|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"For each patient, an opaque envelope will be prepared, sealed and numbered sequentially containing the group to which the patient will be allocated. A list of random numbers generated by computer (www.random.org), in blocks of 1: 1: 1: 1, will be used for this purpose. No collaborator in the operating room, surgeon or anesthesiologist involved in the control of anesthesia and data collection will be aware of the content of the solutions (neostigmine with atropine or saline). An anesthesiologist not involved in the study will be responsible for preparing the solutions:~* solution 1 (administered when TOF = 3) - neostigmine 60 mcg/kg and atropine 30 mcg/kg diluted with SF until 20 mL (group M); neostigmine 30 mcg/kg and atropine 15 mcg/kg diluted with SF to 20 mL (group N) or 0.9% SF 20 mL (group S)~* solution 2 (administered when T4 / T1\> 0.4) - neostigmine 30 mcg/kg and atropine 15 mcg/kg diluted with SF until 20 mL (group M or N) or SF 0.9% 20 mL (group S)"|Prospective, randomized, controlled and double-blind clinical trial|t|t|t|f
33696364|NCT05068024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696365|NCT01527318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696366|NCT00109200||||TREATMENT||||||||
33696367|NCT05139082|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1/PD-L1 monoclonal antibody resistance, abnormal cell cycle, digestive system tumors||||
33696368|NCT01340547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696369|NCT00917111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696370|NCT00750386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696371|NCT00619138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696372|NCT00389727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999891|NCT05066334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization will be centralized and stratified on the investigation center. Treatment allocation will be performed 24 hour-a-day online by a central randomization web-service. The patient identification must be unique within all randomizations performed. For double-blind trial the randomization result will be a treatment code. Blinding or masking will be carried out at all stages of packaging and conditioning for shipping following the treatment allocation. Injections used for all groups will be clear and indistinguishable from each other.|Patients will be randomized in 2 arms of 26 patients and followed up for 24 months.|t|t|f|t
33999892|NCT05685550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999893|NCT05705141|||COHORT||PROSPECTIVE|||||||
33999894|NCT02926755|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999895|NCT06403150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999896|NCT00028873||||TREATMENT||||||||
33999897|NCT05046951|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33999898|NCT00623896|||CASE_ONLY||PROSPECTIVE|||||||
33999899|NCT03171194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999900|NCT04483895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33999901|NCT02300168|||CASE_ONLY||PROSPECTIVE|||||||
33999902|NCT00475410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33999903|NCT03655860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999904|NCT00651651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999905|NCT00225329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999906|NCT02970149|||COHORT||PROSPECTIVE|||||||
33999907|NCT02148744|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33999908|NCT05296928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999909|NCT00595140|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999910|NCT03196557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33999911|NCT03123874|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All participants will pump their milk with two pump set-ups: own and sterile supplies. The pump set-up each woman used first was randomized according to infant feeding status (human milk only vs. human milk and complementary foods).||||
33999912|NCT02063815|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33999913|NCT03454490|||CASE_ONLY||RETROSPECTIVE|||||||
33999914|NCT03900013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the type of intervention, only the outcome assessor and the statistician will be blinded.||f|f|f|t
33999915|NCT02702635|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999916|NCT02233374|NA|SINGLE_GROUP||OTHER||NONE||||||
33999917|NCT02248012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999918|NCT00260026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999919|NCT05878899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999920|NCT03357380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33999921|NCT01881737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999922|NCT05305586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants were unaware of the group allocation. In addition, the outcome assessments were performed by a blinded investigator|The study model was a randomised control trial. The included patients were randomly allocated to either group by a lottery method.|t|f|f|t
33999923|NCT00358631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999924|NCT02599662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999925|NCT01963351|||COHORT||PROSPECTIVE|||||||
33999926|NCT04511156|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Raters of competency will watch video-taped role plays and they will be blinded as to whether the role plays were conducted pre- or post-training.|This study is a single group, multi-site, uncontrolled before- and-after trial, which will evaluate the effectiveness of a training intervention to improve foundational helping skills in non-specialists naïve to mental health and psychosocial support. We will compare change in trainees' foundational helping skills competency scores from pre-training (baseline) to post-training, as well as knowledge, attitude, and self-efficacy scores. We will also explore the feasibility, acceptability, and perceived benefit of the Foundational Helping Skills training package for remote and in-person delivery. The study will be conducted in three country settings, Nepal, Perú and Uganda. The study design will be the same in all three country sites.||||
33999927|NCT01234961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999928|NCT06223490|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33999929|NCT01897324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999930|NCT05010551|||OTHER||CROSS_SECTIONAL|||||||
33784726|NCT05534945|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The group allocation will be concealed in an opaque envelope that will be opened by a PACU nurse in order to program the epidural infusion pump according to the allocated group: f5, f6, f7, f8, f9, f10, or m5, m6, m7, m8, m9 or m10 mL. The pump will be started with the first bolus 30 min after the epidural loading dose at the end of the surgery. This nurse is otherwise not involved in the patient's care or in the research project. After programing the pump, the pump will be covered by an opaque plastic bag in order to maintain blinding. Out of concern for patient safety, health care providers involved in the management of patient care will have access to the information on pump settings through the research pharmacy, if needed. Subjects and outcome assessors will be blinded to the allocation group throughout the study.|The biaised coin up-and-down allocation method will be used and is described below for women. The same approach will be used for men. The PIEB dose for the first female patient will be set at 5 mL. Subsequent doses for the following female patients will be determined by the response of the previous female patient. The doses studied will be 5, 6, 7, 8, 9, and 10 mL. If a patient does not respond successfully to a dose, the dose for the next patient will be increased by 1 mL. If a patient responds successfully, the dose for the next patient will decrease by 1 mL with a probability of 1/9. Otherwise the dose will remain unchanged. In case of successful response in group 5 mL or a failure in group 10 mL, the dose for the subsequent patient would remain the same until the biased-coin program indicated to increase or decrease. The biaised-coin allocation after each successful response will be implemented using a computer-generated list of random responses.|t|f|t|t
33784727|NCT06085950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784728|NCT06391177|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33784729|NCT05708261|RANDOMIZED|PARALLEL||OTHER||NONE||This is a behavioral intervention designed to provide HIV communication and disclosure skill building to improve treatment adherence.||||
33784730|NCT01735929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784731|NCT03361735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784732|NCT06713980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784733|NCT04083183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784734|NCT06711107|||COHORT||RETROSPECTIVE|||||||
33784735|NCT04228770|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33999931|NCT00443885|||COHORT||PROSPECTIVE|||||||
33999932|NCT01198392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999933|NCT01519947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999934|NCT00051805|RANDOMIZED|PARALLEL||||||||||
33999935|NCT01647321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33999936|NCT01507662|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33999937|NCT06175741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999938|NCT03214237|||OTHER||CROSS_SECTIONAL|||||||
33999939|NCT00352196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999940|NCT01391650|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33999941|NCT01458886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999942|NCT03505216|||COHORT||PROSPECTIVE|||||||
33999943|NCT05285319|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase II prospective randomized trial with 2 arms:~* Prostate Only (Arm A)~  o Hypofractionated Intensity modulated radiotherapy (IMRT) to the prostate only to dose of 60Gy/20fractions (3 Gy per fraction)~* Prostate \& Pelvic Lymph Nodes (Arm B)~  * Hypofractionated Intensity modulated radiotherapy (IMRT) with elective pelvic nodes irradiation up to 44Gy/20 fractions (2.2 Gy per fraction) with a Simultaneous Integrated Boost (SIB) to the prostate to dose of 60Gy/20fractions (3 Gy per fraction)"||||
33999944|NCT02991846|||COHORT||PROSPECTIVE|||||||
34088903|NCT04818801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088904|NCT00896831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088905|NCT06066567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088906|NCT03617887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||25 subjects will be randomized into both groups: experimental and control|f|f|f|t
34088907|NCT03628300|||CASE_ONLY||PROSPECTIVE|||||||
34088908|NCT02214472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999945|NCT04815668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participants in acupuncture group and SA group, outcome evaluators and statistician in the two acupuncture groups will be blinded to the group allocation throughout the entire trial. Participants in the rescue medication group and acupuncturists will not be blinded.|Participants who agreed to randomization will be allocated to the acupuncture group, sham acupuncture group or rescue medication group in a 1:1:1 ratio|f|f|t|t
33696373|NCT05044000|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Heavy blanket and similar blanket (not heavy)||t|f|f|f
33696374|NCT03401593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696375|NCT06045104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696376|NCT06681792|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking will not be possible due to the method of application of this study. However, the data collector, statistician and reporting will be masked during the research process. In the research process, pre-test data will be collected by the teachers workin in the study school. The post-test data will be collected by another researcher (a researcher trained in the data collection form and trained in the field of nursing). The research data will be transferred to the computer by the researcher who collected the post-test data by coding the experimental and control groups as 'environment' and 'world' respectively. The transferred database will be analysed by a statistical expert. After the research report has been written, the codings made for the experimental and control groups will be explained.||f|f|f|t
33696377|NCT01310881|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33696378|NCT04160962|||COHORT||RETROSPECTIVE|||||||
33696379|NCT02475031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696380|NCT01498601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696381|NCT06393036|||COHORT||CROSS_SECTIONAL|||||||
33696382|NCT03848104|||COHORT||RETROSPECTIVE|||||||
33696383|NCT01542658|||CASE_CONTROL||RETROSPECTIVE|||||||
33696384|NCT01043146|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696385|NCT04642170|||CASE_CONTROL||RETROSPECTIVE|||||||
33696386|NCT03283111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696387|NCT02578771|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33696388|NCT04659239|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696389|NCT05272449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696390|NCT01008397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784736|NCT05776706|NA|SINGLE_GROUP||OTHER||NONE||Patients who undergo craniotomy using navigation system for cerebral disease in a single institution||||
33784737|NCT04071522|||CASE_ONLY||PROSPECTIVE|||||||
33784738|NCT06708325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and outcome assessors, the data analysts were masked to group assignment throughout the study. The data analysts were not present during the exercise sessions or assessments and did not have access to information that could potentially reveal whether data belonged to the exercise or control group.||t|f|f|f
33784739|NCT03614143|||COHORT||PROSPECTIVE|||||||
33784740|NCT05199025|||COHORT||PROSPECTIVE|||||||
33784741|NCT02654262|||COHORT||PROSPECTIVE|||||||
33801567|NCT06517459|NA|SINGLE_GROUP||OTHER||NONE||Participants will be assigned to the modified GLB-CVA program, available in Spanish or English.||||
33801568|NCT00401908|||COHORT||PROSPECTIVE|||||||
33999946|NCT01573390|||OTHER||PROSPECTIVE|||||||
33999947|NCT01931449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999948|NCT04396392|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"The study is a two-phased intervention study~Participants with PSA will be randomized into three self-guided intervention groups and one delayed waiting list group as follows:~Group 1: receiving VR intervention (3 weeks)~Group 2: receiving VR intervention (3 weeks) + text-based exposure program (T-B-Exp) (3 weeks)~Group 3: receiving text-based psychoeducation and exposure program (T-B PE + T-B Exp) (6 weeks)~Group 4: Waitlist (3 weeks) + receiving text-based psychoeducation (T-B PE) (3 weeks)"||||
33999949|NCT04775316|||COHORT||PROSPECTIVE|||||||
33999950|NCT01588743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999951|NCT04288076|NA|SINGLE_GROUP||OTHER||NONE||||||
33999952|NCT03792139|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999953|NCT00686868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33999954|NCT00131716|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33999955|NCT06371313|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33999956|NCT04133116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33999957|NCT04453969|||COHORT||PROSPECTIVE|||||||
33999958|NCT01596127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999959|NCT05650151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999960|NCT02004717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999961|NCT04837664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33999962|NCT04945096|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized after the investigator has verified that all eligibility criteria have been met. Subjects will be randomized in a 1:1 ratio to either Experimental Group (Acetylcysteine + Decitabine) or Active Comparator Group (Standard Treatment).||||
33999963|NCT04136067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|3 cohorts are planned. Each cohort will consist of 12 subjects, with 9 subjects being randomised to receive NNC0268-0965 and 3 subjects being randomised to insulin glargine.|t|t|t|t
33696391|NCT01757262|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33999964|NCT03281733|||COHORT||RETROSPECTIVE|||||||
33999965|NCT01348958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999966|NCT03937791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999967|NCT00686309|||CASE_CROSSOVER||PROSPECTIVE|||||||
33999968|NCT02973906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33999969|NCT04668820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Two phsyiatrist who will perform virtual video Pediatric Gait, Arms, Legs and Spine (V-pGALS) and the physiatrist who will perform face to face examination will be blinded to each other|Children between the ages of 7-18 who admit pediatric rehabilitation outpatient clinic||||
33999970|NCT04404725|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33999971|NCT03617419||SEQUENTIAL||DEVICE_FEASIBILITY||NONE||This study is being done to evaluate and gather feasibility data and user feedback on the use of the Vscan Access R2 device in vivo on pregnant volunteers in their 2nd and 3rd Trimester. The study will be conducted in two parts, including an initial pilot for determination of parameters (Part 1) and continued testing (Part 2).||||
33999972|NCT00674128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999973|NCT02757703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999974|NCT01559116|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33999975|NCT02926716|||CASE_ONLY||PROSPECTIVE|||||||
33999976|NCT00268762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999977|NCT02717260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33999978|NCT00728364|||COHORT||CROSS_SECTIONAL|||||||
33999979|NCT01257984|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33999980|NCT03116776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|outcome assessor and statistician will be blinded||f|f|t|t
33999981|NCT00246662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33999982|NCT00372996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088909|NCT06092151|RANDOMIZED|PARALLEL||TREATMENT||NONE||feasibility study||||
33696392|NCT01179893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33696393|NCT01502007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696394|NCT04473092|||CASE_CONTROL||PROSPECTIVE|||||||
33696395|NCT01924624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696396|NCT05695300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33696397|NCT00931736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696398|NCT01110304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696399|NCT00694707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696400|NCT00828854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696401|NCT02002390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696402|NCT05707936|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33696403|NCT03527030|||OTHER||CROSS_SECTIONAL|||||||
33999983|NCT00397696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999984|NCT02227615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33999985|NCT00970788|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33999986|NCT01677728|||CASE_CONTROL||PROSPECTIVE|||||||
33999987|NCT00594503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999988|NCT01712568|RANDOMIZED|CROSSOVER||||NONE||||||
33999989|NCT02428348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33999990|NCT04789330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||pragmatic, cluster-randomized, open-labeled, multiple-crossover trial|f|f|f|t
33999991|NCT02503618|||COHORT||PROSPECTIVE|||||||
33999992|NCT00660387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33999993|NCT05748938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33999994|NCT00414479|||COHORT||PROSPECTIVE|||||||
33999995|NCT00348296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33999996|NCT02230930|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33999997|NCT04943822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33999998|NCT00175669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33999999|NCT04092595|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000000|NCT00635687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000001|NCT00521508|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000002|NCT03337893|||COHORT||PROSPECTIVE|||||||
34000003|NCT04797936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000004|NCT01721772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000005|NCT01847950|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34000006|NCT00113061|RANDOMIZED|PARALLEL||PREVENTION||||||||
34000007|NCT00838162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000008|NCT02586324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34000009|NCT02484508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000010|NCT01790308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000011|NCT04661202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000012|NCT05951205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000013|NCT01656915|||CASE_CONTROL|||||||||
34000014|NCT01731028|||COHORT||PROSPECTIVE|||||||
34000015|NCT04049097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000016|NCT06246591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088910|NCT01416779|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34088911|NCT00975871|||CASE_ONLY||PROSPECTIVE|||||||
34088912|NCT01451658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088913|NCT00197743|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088914|NCT01951950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103099|NCT05944393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be randomized to one of two groups with a computer-generated arm assignment. The sealed envelopes will be opened immediately prior to nerve block. One group will receive a ESP block and the other will receive a placebo block. The provider performing the block will not be blinded, however all other members of the care team, the patient, and the investigator collecting data will be blinded to the randomization.|"after being informed about the study and potential risks. All patients giving written consent will be randomized in a double-blind manner into 2 groups each one containing 25 patients, ESP group (n =25 ): The patients will receive Erector Spine Plane Block (ESP Block) after induction of general anesthesia.~Control group (n =25 ): The patients will receive a placebo block after induction of general anesthesia"|t|t|f|t
33696404|NCT06680557|NA|SINGLE_GROUP||TREATMENT||NONE||"Each participant will be assigned to perform either the aerobic or the resistance exercise sessions following the lunch meal in a random sequence by the withdrawal of a sealed envelope containing a paper with a written random sequence of the two exercise sessions.~The envelope will be withdrawn randomly and opened immediately before the first exercise session.~The other type of exercise session will be performed after 48 hours."||||
33696405|NCT04072562|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study.|||||
33696406|NCT05034432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696407|NCT01413412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000017|NCT02933892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000018|NCT00685334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000019|NCT01090245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000020|NCT05525169|||OTHER||PROSPECTIVE|||||||
34000021|NCT01153438|||||PROSPECTIVE|||||||
34000022|NCT00223093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000023|NCT05109104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes (erythema) assessor is blinded to treatment allocation||f|f|f|t
34000024|NCT02162615|||COHORT||PROSPECTIVE|||||||
34000025|NCT02940652|||COHORT||PROSPECTIVE|||||||
34000026|NCT00292760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000027|NCT03910049|||COHORT||PROSPECTIVE|||||||
34000028|NCT01380613|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000029|NCT00985751|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34000030|NCT00850551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000031|NCT05886127|||COHORT||OTHER|||||||
34000032|NCT05827263|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000033|NCT03943706|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34000034|NCT03682276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103100|NCT05856461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2 parellel groups|t|f|f|t
34103101|NCT02241772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103102|NCT06222294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103103|NCT06101069|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, observational, multi-cohort, unblinded, single-center study.||||
34103104|NCT03471286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000035|NCT04715906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103105|NCT06674837|||COHORT||PROSPECTIVE|||||||
34103106|NCT05684198|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34103107|NCT02601365|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, open label dose escalation study||||
34103108|NCT04016428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103109|NCT05164172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103110|NCT06425588|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34103111|NCT03048305|||COHORT||PROSPECTIVE|||||||
34103112|NCT04569825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103113|NCT00379379|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34000036|NCT03973151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000037|NCT02299869|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34000038|NCT06045390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000039|NCT01206192|||COHORT||RETROSPECTIVE|||||||
34000040|NCT01940159|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34000041|NCT04993118|RANDOMIZED|PARALLEL||TREATMENT||NONE||Official Title: Effects of Integrated Neuromuscular Inhibition technique on upper trapezius trigger points in patients with non-specific neck pain.||||
34103114|NCT06180421|||COHORT||PROSPECTIVE|||||||
34103115|NCT06689761|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34103116|NCT04911751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000042|NCT01242124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000043|NCT01554111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34000044|NCT01273467|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33696408|NCT04839146|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||ABNCoV2 is a virus-like particle vaccine. It will be administered as two intramuscular injections in groups of up to 9 volunteers. All subjects will receive a second vaccination with the same dose and formulation 4 weeks following the first vaccination. The pre-defined escalation schedule will start with 6 μg ABNCoV2, followed by 12, 25 and 50 μg with a maximum dose of 70 μg. MF59-adjuvanted and non-adjuvanted formulations will be tested in parallel to detect superiority or futility of the MF59-adjuvanted against the non-adjuvanted formulation at the 6, 12 and 25 μg dosage. Approval for further dose escalation and choice of adjuvant use will be provided by a safety monitoring committee (SMC), supported by pre-defined analyses of safety, tolerability and immunogenicity data at day 14 post-first-vaccination. Recruitment for the two best (safe, tolerable and most immunogenic) regimens will continue until 12 volunteers per regimen have been immunized.||||
34000045|NCT00193492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000046|NCT04576936|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34000047|NCT03031951|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34000048|NCT05776901|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants enrolled in the study were asked to use the C-STRESS app daily for 6 weeks.||||
34000049|NCT06066671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000050|NCT05973331|||COHORT||PROSPECTIVE|||||||
34000051|NCT04000776|||COHORT||CROSS_SECTIONAL|||||||
34000052|NCT06209996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to intervention or active control or waitlist arms.~The participants are masked in terms of not knowing that the intervention are hypothesized to yield larger effects than the others (i.e. controls)."|This is a 3-arm feasibility trial study with one intervention group, one active control group and one waitlist control group. Computer-generated block randomization sequences will be generated by a statistician who is blinded to the identity of participants prior to the start of the trial. A block randomisation structure with randomly permuted block sizes of 3 and 6 will be used to reduce selection bias and ensure close balance of the numbers in each arm. The serially labelled opaque sealed envelope method will be used for randomisation.|t|t|t|t
34000053|NCT01751919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088915|NCT03213717|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"We will recruit healthy individuals who work at or close to the Institution of Neuroscience and Physiology at the Sahlgrenska Academy. We will ask healthy people who do not know the hypothesis of the study. Each study subject will be given a randomized code to use for the study. Only the study subject and the investigator will be able to connect each study subject with their randomized code. This will only be used under special circumstances, for example, if a study subject requests removal of his or her study data.~As this study uses a cross-over design each subject will then be its own matched control.~Subject eligibility will be established before enrolment and randomization. Subjects will be randomized strictly sequentially, as subjects are eligible for randomization. If a subject discontinues from the study, the subject number will not be reused, and the subject will not be allowed to re-enter the study."|"The study is executed with all 15 study subjects over three study days with one week between each study day. In order to decrease the variation of the measurement values and increase the power of the study we will use a cross-over study design. The study subjects will on one of the days wear a weight vest with 10 % of body weight in the standing position, on one of the days the same study subject will wear a weight vest with 1 % of body weight in the standing position and on one of the days the same study subject will wear a weight vest with 1 % of body weight in the sitting position.~Hence, three procedures are included in the study. Each of the procedure corresponds to a separate day."|f|t|t|t
34088916|NCT02522741|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34088917|NCT03965585|||COHORT||PROSPECTIVE|||||||
33696409|NCT00411112|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696410|NCT02362178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696411|NCT04469075|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2, multicenter, open-label study.||||
33696412|NCT06218602|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696413|NCT04738734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each subject will be evaluated by the blinded site investigator conducting assessment of outcomes at 7, 30, 60, and 90-days following CellFX and Cryosurgical treatments.||f|f|f|t
33696414|NCT05927701|||COHORT||PROSPECTIVE|||||||
33696415|NCT04152031|NA|SINGLE_GROUP||OTHER||NONE||||||
33696416|NCT02720237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33784742|NCT05560399|NA|SEQUENTIAL||TREATMENT||NONE||"Part 1 is a dose-finding evaluation of Iberdomide in combination with Elotuzumab and Dexamethasone at their approved doses for patients with relapsed/refractory multiple myeloma.~Part 2 of this study is an open-label, single-arm dose expansion cohort that will enroll additional patients at the recommended maximum tolerated dose of Iberdomide as determined in Part 1."||||
34000054|NCT02928627|||OTHER||PROSPECTIVE|||||||
34000055|NCT05856058|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34000056|NCT01140607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000057|NCT04943549|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|t|f
34000058|NCT05402046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a multicentre, low-intervention, prospective study. Patients scheduled for excisional biopsy of skin lesion(s) will be invited to participate in this study. Photo-documentation of the skin neoplasm(s) in the ProRodinki application will be performed, and the generated report will be sent for evaluation by artificial intelligence. Following this procedure, an excisional biopsy of the lesion(s) will be scheduled. From the moment of inclusion in the study until the excisional biopsy, an interval of no more than 2-4 weeks is allowed. After excisional biopsy of the skin neoplasm(s), a routine intravital pathological examination with hematoxylin and eosin staining will be performed, if necessary, immunohistochemical and molecular genetic tests will be performed. The selected biosamples (paraffin blocks) will then be analyzed centrally by a morphologist.||||
33784743|NCT03869710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000059|NCT01540344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784744|NCT06507969|||OTHER||OTHER|||||||
34000060|NCT02346825|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34000061|NCT04509232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Involves two groups of participants. One group receives|t|f|t|f
34000062|NCT01634685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784745|NCT01078233|||COHORT||OTHER|||||||
33784746|NCT01649102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784747|NCT04377633|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33784748|NCT05308836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784749|NCT06711653|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33784750|NCT03390556|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33784751|NCT06705023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective, randomized, controlled, multicenter, safety and efficacy study in patients with iHF comparing best available medical treatment plus a balloon-enhanced single i.cv. injection of UA-ADRCs isolated from lipoaspirate at point of care using the Transpose RT / Matrase system (InGeneron) in 24 patients, to best available medical treatment in 12 patients in the control group|f|f|f|t
33784752|NCT00662064|||||PROSPECTIVE|||||||
33784753|NCT03478579|||COHORT||PROSPECTIVE|||||||
33784754|NCT01965080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784755|NCT06614231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784756|NCT02356029|||COHORT||CROSS_SECTIONAL|||||||
33784757|NCT04257279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784758|NCT05963776|||CASE_CONTROL||PROSPECTIVE|||||||
33784759|NCT04135144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784760|NCT06713629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000063|NCT00834314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000064|NCT01135940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000065|NCT06067789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Group allocation will not be indicated in data analyzed by the outcome assessors.||f|f|f|t
34000066|NCT04506567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"In schema 1 (dose-fractionated cohort), subject enrollment will be done in a fractionated dose-escalation study design at each dose level with treatment during one cycle to be administered on Day 1 and Day 15.~In schema 2 (multiple dose cohort), subject enrollment will be done in a dose-escalation single dose study design at each dose level with treatment administered as a single dose per cycle every 6 weeks up to 4 cycles. Additional patients will be enrolled at lower doses previously shown to have efficacy (cohorts -1 and -2). The rationale for enrollment of patients at these lower dosing cohorts is to determine whether a smaller number of cycles at higher radioactivity is superior, inferior, or no different than a larger number of cycles at a lower dose."||||
34000067|NCT05869162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000068|NCT04320745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088918|NCT02630030|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33784761|NCT06339905|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33784762|NCT06712225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784763|NCT04549051|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784764|NCT01049620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784765|NCT06630962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Potential Crossover: An interim analysis will be conducted once 50% of the recruitment target (100 participants total) have completed at least 6-months of follow-up, which is estimated to occur at approximately 1 year from start of the study. If significant differences between the Financial Navigation Program (FNP) and routine care arms are observed, all enrolled participants in the control arm will be given access to the FNP. Endpoint-related data will be collected until study completion (1-year follow-up for all enrolled participants).|f|f|t|t
33784766|NCT02214251|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33784767|NCT00753987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784768|NCT01440465|||||PROSPECTIVE|||||||
34088919|NCT03469804|NA|SINGLE_GROUP||TREATMENT||NONE||2-stage phase II Simon's Optimal Design||||
34025069|NCT04112186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and the majority of study personnel, including the study statistician, will be blinded to the treatment assignment until the database is unlocked. Assessors (of endpoints) will also be blinded to treatment assignment. That is, treatment allocation will only be known by selected research associates who are not involved in assessment or treatment. The selected research associates who are unblinded will handle randomization and preparation of any unblinded reports (if required); they will not have access to the data and no involvement in data monitoring or analyses.|"Individuals with opiate use disorder (iOUD) will be randomized to one of two 8-weeks of group therapy and scanned with magnetic resonance imaging (MRI) immediately before and after treatment. Functional MRI (fMRI) scans during select tasks and at rest will assess responsiveness and connectivity of neural networks underlying impairments in Response Inhibition and Salience Attribution (iRISA). Structural MRI will assess the morphological integrity of the neural networks. A follow-up visit will take place 3 months after the second MRI scan.~Healthy controls will be scanned at similar time intervals. Data collected from healthy control subjects will be used for comparative analyses."|f|f|t|t
34025070|NCT02816008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088920|NCT02827526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088921|NCT01267279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784769|NCT06220474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is a double-masked randomized study. Assigned treatment of a specific patients would be kept confidential in both the recruited participants and investigators.|One group of patients receiving radiofrequency treatment (RF) followed by meibomian gland expression (MGX) Another group of patients receiving and MGX|t|f|t|f
34088922|NCT06128538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34088923|NCT05803317|||COHORT||RETROSPECTIVE|||||||
34088924|NCT01417416|||COHORT||PROSPECTIVE|||||||
34088925|NCT03261232|||COHORT||RETROSPECTIVE|||||||
34088926|NCT00858988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088927|NCT00741611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088928|NCT05649462|||COHORT||RETROSPECTIVE|||||||
34088929|NCT04298385|||COHORT||PROSPECTIVE|||||||
34088930|NCT03834168|NA|SINGLE_GROUP||OTHER||NONE||||||
34088931|NCT04133389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be informed that there are different versions of the educational program and thus will be blind to group allocation. Randomization will be fully automated by the online intervention administration system such that researchers will also be blind to group allocation during intervention administration as well as during pre- and post-intervention data collection. Because randomization is automated, neither researchers nor participants will be able to predict randomization assignments. Outcomes will be measured quantitatively thus no assessment of primary outcomes will take place. However, assessors of the manipulation check (which codes for participant engagement in the intervention) will not be masked and thus will be aware of allocation (experimental or control).|The current study is a two-wave randomized controlled trial that employs a 2 (group - between participants) by 2 (time - within participants) mixed measures design to assess a brief online implicit theory of personality intervention.|t|f|t|f
33784770|NCT01234194|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696417|NCT03736694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"After recruitment and assessment for inclusion and exclusion criteria, the participants are randomly assigned with numbers generated by computer and divided equally into 3 groups managed by an independent administrator.~The participants are required to fill in online questionnaires themselves to prevent possible biases during outcome assessments.~The participants will be labelled by numbers without any personal information or intervention group allocated during data analysis."|"A prospective randomized controlled trial (RCT) will be performed to compare the effectiveness of the 3 types of therapies.~After recruitment and assessment for inclusion and exclusion criteria, the participants are randomly assigned with numbers generated by computer and divided equally into 3 groups managed by an independent administrator.~The first intervention group (Group 1) will attend one half-day cognitive behavioural therapy for insomnia (CBTI) workshop in the community setting. The second intervention group (Group 2) will receive self-help CBTI. The control group (Group 3) will receive sleep hygiene education (SHE)."|f|f|t|t
33784771|NCT02257866|||COHORT||PROSPECTIVE|||||||
33784772|NCT02953275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919859|NCT04032626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Beside the clinical pharmacologist and biostatistician, all parties involved in the present study will be blinded until all data are collected, including medical staff, patients and his/her car giver, imaging staff, and scientists collecting data from biosamples. The blinding will be lifted only after all data are acquired, and before statistical analysis.|This study will take place at a single site. We will enroll 30 male and female outpatients, 50-90 years of age. Lenalidomide 10 mg/day vs. placebo will be taken daily orally (ratio 1:1). The effects of lenalidomide treatment will be assessed after 12 months of treatment and 6 months washout (month 18). Participants completing the study will be involved for up to 20 months in duration, from screening to end of study.|t|t|t|t
33919860|NCT05344976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919861|NCT05654766|||COHORT||PROSPECTIVE|||||||
33919862|NCT02306239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33696418|NCT01823354|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696419|NCT01847001|NA|SINGLE_GROUP||OTHER||NONE||||||
33696420|NCT00560469|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696421|NCT01416844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696422|NCT05789381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696423|NCT01933958|||COHORT||PROSPECTIVE|||||||
33696424|NCT05533723|||CASE_CONTROL||RETROSPECTIVE|||||||
33696425|NCT04256954|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33696426|NCT01658852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696427|NCT05573828|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33696428|NCT02608203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696429|NCT03132012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33696430|NCT00464269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696431|NCT04817735|NA|SINGLE_GROUP||OTHER||NONE||||||
33696432|NCT00316771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696433|NCT06247423|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Blinding of participants will be performed using the same equipment, electrodes, and placement for the real or sham stimulation treatments. In addition, both the participants and the outcome assessor will not have a view of the equipment screen.~Blinding of the outcome assessor will be performed using different team members for randomization of the interventions (Researcher 1), intervention (Researcher 2), evaluation (Researcher 3), and statistical analysis (Researcher 4). Randomization will be kept hidden from participants and research team members and only the researcher who will deliver the intervention (Researcher 2) will know the group assignment. Successful blinding of participants and evaluator will be analyzed."|"Two interventions will be performed:~* Intervention A: active stimulation (High-frequency current stimulation 10kHz).~* Intervention B: sham stimulation (simulated electrical stimulation)."|t|f|f|t
33696434|NCT00835159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696435|NCT03992729|||COHORT||PROSPECTIVE|||||||
33696436|NCT02714907|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33696437|NCT04743349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696438|NCT03781544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696439|NCT04564274|||OTHER||OTHER|||||||
33696440|NCT01016756|||FAMILY_BASED||PROSPECTIVE|||||||
33696441|NCT04579029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696442|NCT04284852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696443|NCT00060515|NON_RANDOMIZED|||TREATMENT||||||||
33696444|NCT06609668|||COHORT||PROSPECTIVE|||||||
33696445|NCT06273293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696446|NCT02526901|||COHORT||PROSPECTIVE|||||||
33696447|NCT00674427|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696448|NCT04620395|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33784773|NCT06687668|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking due to the visible nature of the interventions (type of plaster cast), but the outcomes assessor is blinded to treatment assignment when evaluating follow-up outcomes.|Two arms in parallel: One group receives the Short Leg Walking Plaster Cast, and the other receives the Walking Foot Plaster Cast.||||
33784774|NCT01281761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784775|NCT05606575|||OTHER||PROSPECTIVE|||||||
33784776|NCT01147549|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33696449|NCT02974582|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696450|NCT00155922|||CASE_CONTROL||PROSPECTIVE|||||||
33696451|NCT02562768|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33696452|NCT04079010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33696453|NCT02998216|||COHORT||PROSPECTIVE|||||||
33696454|NCT01960673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696455|NCT01997502|||COHORT||PROSPECTIVE|||||||
33696456|NCT06332833|||COHORT||PROSPECTIVE|||||||
33696457|NCT06681662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* The surgeon will be blinded to treatment group allocation during the induction.~* The anesthesia personnel will be blinded to treatment group allocation during induction and intubation, but after gathering the data, they will be unblinded.~* The investigator controlling the nerve stimulator will be blinded throughout the whole procedure.~* Surgical personnel will be blinded to treatment group allocation during induction."|"This is a randomized study. Patients will be allocated randomly at a ratio of 1:1 to receive either 0.15 mg/kg ephedrine or saline (placebo). Randomization will be done at the day of operation after written informed consent is obtained. An independent investigator will allocate patients by using a computerized random number generator in REDCap. In REDCap patients also receive a number, which pseudo anonymizes data.~The study drug is prepared in the medicine room before the operation. This is done under double control by the investigator who also performed the randomization. The study drug, either ephedrine or saline, will be prepared in a 1 mL syringe. The dose will be mixed with saline to a total of 1 mL to secure blinding."|t|t|f|t
33696458|NCT01359007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696459|NCT01770652|NON_RANDOMIZED|PARALLEL||||NONE||||||
33696460|NCT00849537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696461|NCT05800873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696462|NCT03439657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696463|NCT04792515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696464|NCT02577497|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33696465|NCT01465854|||CASE_ONLY||PROSPECTIVE|||||||
33696466|NCT04064177|||COHORT||PROSPECTIVE|||||||
33696467|NCT03589469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696468|NCT04625816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696469|NCT02748473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696470|NCT05961059|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Double blind|A phase Ia/b dose escalation, randomized, double-blind, placebo-controlled clinical trial|t|t|t|f
33696471|NCT00973271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696472|NCT06351865|||COHORT||PROSPECTIVE|||||||
33696473|NCT05048082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||An interventional, open-label, single arm trial where each patient is his/her own intrapatient control. All patients will receive a single dose of pegsitacianine administered intravenously prior to standard of care (SOC) surgery.||||
33784777|NCT06713902|||COHORT||CROSS_SECTIONAL|||||||
33784778|NCT06224595|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The study consists of 3 parts: single ascending dose (SAD), food effect (FE) and multiple ascending dose (MAD). Both SAD and MAD study are a randomized, double-blind, placebo-controlled dose-escalation design. The FE study is a randomized, open-label, two-period, two-crossover design.|t|t|t|t
33784779|NCT06712420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696474|NCT00604305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784780|NCT04824131|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33784781|NCT05599633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Intervention (Sago starch) and control (corn starch) will be packed in individual aluminium sachets and will not be distinguishable from each other. The included subjects and investigators will be blinded from the study arm assignment. Randomisation and dispensation of the study starch will be done by the unblinded pharmacists only, who will not be involved in the care of the patients and study endpoint assessments.||t|t|t|f
33919863|NCT00793182|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33696475|NCT04052282|||OTHER||PROSPECTIVE|||||||
33696476|NCT05642078|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696477|NCT06154538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919864|NCT06303492|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33696478|NCT01498835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696479|NCT02647840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919865|NCT04275050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919866|NCT01368666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919867|NCT05269550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919868|NCT02189590|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33919869|NCT00461578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919870|NCT05669300|||CASE_CONTROL||RETROSPECTIVE|||||||
33919871|NCT02770313|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33919872|NCT02415764|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33919873|NCT04857749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33919874|NCT05365009|||COHORT||PROSPECTIVE|||||||
33919875|NCT01682070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919876|NCT02527122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919877|NCT05651516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The analyses for the three aims will use analysis of variance to test for group differences among the three groups (OUD/OD+, OUD/OD-, HC).||||
33919878|NCT06418126|NA|SINGLE_GROUP||OTHER||NONE||||||
34000069|NCT04127292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The study will follow a double-blind procedure to minimize the effects of expectation bias. Prior to the start of the study, the Co-Investigators will assign different letters to the ESA training and control group; they will not reveal which letter corresponds to which condition to the coordinators and research assistants until the completion of the study. The Co-Investigators at each site will carry out the randomization procedure and record this information in a password-protected file. Following the baseline T0 assessments but prior to the T1 VHI, the Co-Investigators will inform the coordinators which condition each CP has been assigned to. Although the CPs will be aware that they are receiving feedback on their ESA ratings, they will not know that this is the active component of the training. To ensure PP blinding, CPs will be asked not to discuss the VHI experience with their colleagues or patients to minimize the potential that they will figure out which condition they are in.|Two experimental groups will complete the same Virtual Human Interaction (VHI) scenarios. Only the Emotional Self-Awareness (ESA) group will also receive clinician-focused, comprehensive feedback in ESA, while the Control group will assess the VH's suicide risk without receiving the ESA feedback. The study team will measure the VHI ESA training effectiveness by comparing clinician participants' (CPs) ESA towards virtual humans at post-training (T2), adjusting for pre-training (T1) levels. The study team will measure the impact of the VHI ESA on patient participants' (PPs) suicidal outcomes by assessing the primary and secondary outcome variables in both CPs and PPs three times: at baseline (T0), after the first post-training treatment session (T3) and after the final treatment session, one month post-training (T4). The study team will examine the role of therapeutic alliance as a possible mediator of the relationship between clinicians' ESA and their patients' SI and SCS.|t|t|f|f
33696480|NCT00372203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696481|NCT05462470|||COHORT||RETROSPECTIVE|||||||
33696482|NCT05631665|NA|SINGLE_GROUP||TREATMENT||NONE|"The group of patients who are in the postmenopausal period and undergo laser treatment for sexual problems.~Laser will be applied to the postmenopausal patient group with vaginal dryness and dyspareunia complaints. This group will form the study group. The same surveys will be made before and after the procedure in the 1st month, 3rd month and 6th month. According to the results of the survey, the rate of improvement in sexual problems will be studied."|Patients who are in the postmenopausal period and undergo laser treatment for sexual problems||||
33696483|NCT06030310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34000070|NCT01650155|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33696484|NCT03516617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696485|NCT02404467|||OTHER||PROSPECTIVE|||||||
33696486|NCT04670055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696487|NCT06070311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33784782|NCT06711198|RANDOMIZED|PARALLEL||OTHER||SINGLE||The control group, the calf tongue group, will have an episiotomy on the calf tongue. The virtual reality group will have an episiotomy with virtual reality glasses. The mixed group will first have an episiotomy on the calf tongue with virtual reality glasses and then have an episiotomy on the calf tongue.|f|f|f|t
34000071|NCT03786770|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000072|NCT05915923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000073|NCT05755854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000074|NCT02359864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single group pilot study of radiation treatment. The two arms are sequential dose increase.||||
34000075|NCT01896934|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000076|NCT02571257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000077|NCT01780350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025071|NCT06634173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All scans will be reviewed by two senior nuclear medicine physicians (NWZ-Alkmaar and/or NCI-AVL), separately and blinded to any clinical information. If a consensus is not reached, a third observer is included.|This is an interventional study without concurrent controls.||||
34088932|NCT01571791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088933|NCT03195556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103117|NCT05093166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103118|NCT06068075|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103119|NCT03291626|||COHORT||PROSPECTIVE|||||||
33784783|NCT06244147|||COHORT||PROSPECTIVE|||||||
33696488|NCT04949464|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33784784|NCT05209672|||COHORT||PROSPECTIVE|||||||
33784785|NCT05218603|||CASE_ONLY||PROSPECTIVE|||||||
33784786|NCT02248142|||COHORT||PROSPECTIVE|||||||
33784787|NCT06219213|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||The first eleven (11) subjects enrolled will be assigned to group A. Group B will follow with the eleven next subjets (subjects 12 to 22) and group C will complete the study with subjects 23 to 33. The pre-treatment state of subjects will serve as control for the effects observed following treatment.||||
33784788|NCT06709339|NA|SINGLE_GROUP||TREATMENT||NONE||This study will be conducted in adult Caucasian participants with symptomatic macular PCV, a subtype of nAMD, which was under-represented in the faricimab Phase III pivotal Studies TENAYA (ClinicalTrials.gov identifier: NCT03823287) and LUCERNE (ClinicalTrials.gov identifier: NCT03823300) where less than 2% of the enrolled participants with nAMD were diagnosed with PCV and no Caucasian participants with symptomatic macular PCV were identified in the mentioned pivotal Studies.||||
33696489|NCT02760576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696490|NCT01353261|||COHORT||PROSPECTIVE|||||||
33696491|NCT06218212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696492|NCT02722486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696493|NCT05995119|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33696494|NCT06680674|||COHORT||CROSS_SECTIONAL|||||||
33696495|NCT00715923|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33696496|NCT03235843|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The pacing mode set by the pacemaker technician will not be disclosed to either patients or the study physician.|Patients enter a double blind randomized cross-over pilot study and will be randomized in a 1:1 fashion to either rate responsive (MV sensor only) function on or off. After 3 months the pacing mode will be switched to the opposite mode.|t|f|t|f
33696497|NCT04718961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking in Part 2 Only|Randomized Open-label two arm study (Part 1) followed by a randomized double-blind, placebo controlled, study (Part 2)|t|f|t|f
33784789|NCT05206357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784790|NCT05458102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784791|NCT01473628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088934|NCT04877002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The purpose of this study is to validate the performance of the Sona Saliva C-19 rapid Test for rapid detection of SARS_CoV_2 infection when using saliva specimens. A prospective randomized and blinded study to evaluate a rapid point of care antigen test for the detection of viral proteins and compared against an approved RT-PCR test.~Saliva samples will be collected along with the current standard of care collection."||||
34088935|NCT05997745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34088936|NCT00272402|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34088937|NCT05483647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784792|NCT06506084|||CASE_ONLY||PROSPECTIVE|||||||
33784793|NCT05892289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784794|NCT03234829|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784795|NCT00818025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33784796|NCT00867347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784797|NCT06022848|NA|SEQUENTIAL||SCREENING||NONE||||||
33784798|NCT06552234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784799|NCT05468658|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33784800|NCT05944237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784801|NCT02298374|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784802|NCT01021878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784803|NCT06622499|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33784804|NCT04304729|||COHORT||PROSPECTIVE|||||||
33784805|NCT00196170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784806|NCT01598025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784807|NCT06711939|||CASE_CONTROL||PROSPECTIVE|||||||
33784808|NCT06712979|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcomes assessors will be blinded for intervention applied before the asessment|all participants will perform adapted Lee Silverman Method (Adapt Lee) and Lung volume recruitment technique plus Adapt Lee during 2 weeks, with washout period of 6 weeks.|f|f|f|t
33784809|NCT06555965|||COHORT||PROSPECTIVE|||||||
33784810|NCT02544282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33784811|NCT06141239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919879|NCT05239468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919880|NCT01044420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33919881|NCT01338883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919882|NCT03812523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Coded Bottles|This is a two-arm randomized controlled clinical trial in cancer patients receiving oxaliplatin treatment reporting neurotoxicity Grade 2 or higher by CTCAE guidelines to a member of their medical team. Enrollment goal is 50 patients. (25 evaluable patients per arm)|t|t|t|f
33919883|NCT03090464|||CASE_ONLY||PROSPECTIVE|||||||
33919884|NCT03001583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919885|NCT03623425|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Phase III, open, single center, prospective, controlled and randomized crossover study comparing diagnostic performance of 68GA-PSMA-11 and 18F-Fluorocholine. 68GA-PSMA-11 PET and 18F-Fluorocholine PET interpretation will be done by different nuclear physicians.||||
33919886|NCT00506571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919887|NCT01507844||CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33919888|NCT01105221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33919889|NCT04606524|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919890|NCT03180827|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33919891|NCT00178464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919892|NCT05700955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The experience with neoadjuvant immunotherapy has raised the possibility of utilizing surgical resection/immunotherapy as a combination treatment for patients with recurrent glioblastoma. There are several reasons that suggest that surgical resection will likely enhance the activity of immunotherapy in glioblastoma.This includes 1) direct impact on tumor cells; 2) impact on immune cells; and 3) impact on immune infiltration. The combination of the evidence that neoadjuvant Pembrolizumab has a positive effect on GBM survival, the evidence in lung cancer that chemotherapy and checkpoint inhibitor therapies are synergistic and the clinical utility of surgery in patients with recurrent glioblastoma has suggested that the neoadjuvant administration of Pembrolizumab and temozolomide prior to and following maximal surgical resection represents a very attractive experimental combination for the treatment of recurrent glioblastoma.||||
33696498|NCT03157960|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Interventional study. Participant will on sex different occasions receive drinks containing fructose (fructose drink, coca-cola or blueberry drink) with and without the addition of a high-fat meal||||
33696499|NCT04208464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant and investigators will not be blinded because it will be clear whether IMP is being administered from baseline or after a 12 week delayed start. However every attempt will be made to keep the muscle function and disease activity and damage outcome assessor blinded to the treatment arm.|This is a randomised, treatment-delayed trial design. Participants will be randomised into two arms: participants in one arm will receive 24 weeks of baracitinib treatment from baseline with 12 weeks of follow up; participants in the other arm will have a delayed treatment start for 12 weeks, then will receive 24 weeks of baracitinib treatment with 4 weeks of follow up for safety.|f|f|f|t
33696500|NCT03469050|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study is a phase II, multicenter, double-blind, placebo-controlled, randomized clinical trial.|t|t|t|t
33696501|NCT03696173|||COHORT||RETROSPECTIVE|||||||
33696502|NCT03755388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696503|NCT02076633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696504|NCT02027376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696505|NCT05995808|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696506|NCT03263000|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696507|NCT04964843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Arm 1: n-acetylcysteine. 25 participants randomly selected Arm 2: placebo. 25 participants randomly selected|t|t|t|f
33696508|NCT02884531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment at inclusion was done before randomization, and was also blinded at follow-ups|A blinded RCT|f|f|f|t
33696509|NCT03652376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with severe eosinophilic asthma (n=20) will be treated with benralizumab 3 times every 4 weeks, and the effect of this treatment on dendritic cell concentrations and dendritic cell characteristics will be investigated 4 weeks after the last benralizumab dose and after a follow-up of 3 months. There will be a separate control group of subjects (not a treatment or placebo arm) without asthma not treated with benralizumab (to study dendritic cell concentrations and dendritic cell characteristics in patients without asthma and without benralizumab treatment).||||
33696510|NCT04779996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696511|NCT00902733||||HEALTH_SERVICES_RESEARCH||||||||
33696512|NCT01604473|||COHORT||PROSPECTIVE|||||||
33696513|NCT00352443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696514|NCT04498312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696515|NCT05560035|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33784812|NCT06488365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All study participants will be blinded from their results.|"Healthy subjects and melanoma patients will be tested in this study. All subjects will receive the same Cytophone intervention (testing). Healthy subjects will receive one Cytophone test, and melanoma patients will receive four tests. There will be four cohorts to the study:~Cohort 1: 30 healthy subjects to address the calibration purpose. Cohort 2: 50 stage 0-I melanoma patients to link the presence of CTCs in blood circulation or increase in CTC count with metastatic disease initiation.~Cohort 3: 50 stage II melanoma patients to define the correlation between CTC count and metastatic disease initiation/progression and further recurrence.~Cohort 4: 50 stage III-IV melanoma patients to link CTC counts, metastatic disease progression and therapy efficiency."||||
33784813|NCT05424198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized to one of two standard of care procedures: trident cannula cervical medial branch radiofrequency ablation or conventional cervical medial branch radiofrequency ablation. Participants will be blinded to which group they are randomized to. Outcomes will be collected by a blinded third party.|To compare procedural characteristics, pain, and disability outcomes of cervical medial branch radiofrequency ablation (CMBRFA) using either a Trident or conventional cannula in patients with confirmed facet mediated pain (defined by ≥80% symptom reduction after dual medial branch block).|t|f|f|t
33784814|NCT06297590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33784815|NCT02295475|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784816|NCT06541041|||COHORT||OTHER|||||||
33784817|NCT06714513|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784818|NCT03356262|||COHORT||PROSPECTIVE|||||||
33784819|NCT04345523|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 ratio for CP: Control arm. Also, approximately 140-200 CP donors.||||
33784820|NCT06042725|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784821|NCT04231461|||COHORT||PROSPECTIVE|||||||
33784822|NCT03614130|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||In this contralateral study, subjects will be randomized to wear the investigational lens in 1 eye and the control lens in the other eye.|t|f|t|f
33784823|NCT03588975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784824|NCT05129800|||CASE_CONTROL||RETROSPECTIVE|||||||
33784825|NCT05988203|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33784826|NCT02292394|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33784827|NCT06714422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784828|NCT06056050|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33919893|NCT03882398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Fourteen patients were randomly assigned to the two groups|A pilot randomized controlled trial.|t|f|t|t
33919894|NCT02405585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919895|NCT00255099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919896|NCT04846894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919897|NCT01240512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919898|NCT03568110|||COHORT||PROSPECTIVE|||||||
33919899|NCT06411223|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single-arm prospective interventional pilot study. This study uses a hybrid type 3 implementation study design to evaluate an enhanced pharmacist-led collaborative drug therapy management model (CDTM+) for women with health-related social needs (HRSN), in terms of implementation (primary) and clinical (secondary) outcomes.||||
33919900|NCT01376726|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919901|NCT04319419|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group received only nutrition education and treated group received nutrition education plus a supplement with milk protein and micronutrients.||||
33696516|NCT01128751|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33696517|NCT02942927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33696518|NCT02952729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696519|NCT04060862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696520|NCT01385371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696521|NCT00093548||||TREATMENT||||||||
33696522|NCT03327454|||CASE_ONLY||CROSS_SECTIONAL|||||||
33696523|NCT05782231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696524|NCT04264689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33696525|NCT01545258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33696526|NCT05438693|||CASE_ONLY||CROSS_SECTIONAL|||||||
33696527|NCT00452478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696528|NCT00835822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696529|NCT00237887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33696530|NCT06525597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696531|NCT06206265|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be randomized either into the immediate therapy vs. waitlist control. Patients in the waitlist control will eventually be offered the same therapy at 8 weeks post enrollment. The delayed treatment arm will initiate therapy on the same schedule as the immediate treatment arm.||||
33696532|NCT02644031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33696533|NCT02563990|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33696534|NCT01816308|||CASE_CONTROL||PROSPECTIVE|||||||
33696535|NCT04447417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784829|NCT06713694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Participants will be divided into high and low groups based on the results of the Chinese Confucian coping Thinking Scale assessment. After completion of the first baseline assessment, patients will be randomly assigned to the experimental or waiting-list control condition.Randomization will be stratified by gender, disease type and will be conducted by an off-site statistician not involved in patient recruitment or assessment, using random allocation software.Participants assigned to the experimental condition will start treatment as soon as possible (maximum within 6 weeks). The second, mid-treatment assessment will take place four weeks following start of treatment and the third assessment one month following completion of treatment. Following the first baseline assessment, participants assigned to the waiting-list control condition will wait 3.5 months, then they will be asked to complete a follow-up assessment after waiting/baseline before they are treated with CBT.|t|t|f|t
33784830|NCT06713408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33784831|NCT05306418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784832|NCT03655483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784833|NCT03899805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784834|NCT06711913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784835|NCT06697041|||OTHER||CROSS_SECTIONAL|||||||
33784836|NCT06306274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784837|NCT05334082|RANDOMIZED|PARALLEL||PREVENTION||NONE||Experimental, randomized, controlled and multicenter study||||
33784838|NCT05428436|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696536|NCT03472898|||OTHER||OTHER|||||||
33696537|NCT06388382|||COHORT||PROSPECTIVE|||||||
33696538|NCT06207838|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is a two-centers, randomized controlled, parallel group study||||
33696539|NCT05515198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696540|NCT00071396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784839|NCT06268418|||OTHER||RETROSPECTIVE|||||||
33784840|NCT06015737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a parallel group treatment study in two concurrent stages (Stage 1 and Stage 2) and each stage will have two arms.|t|f|t|f
33784841|NCT00477412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784842|NCT06684314|||COHORT||OTHER|||||||
33784843|NCT01895257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784844|NCT02482493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784845|NCT06227338|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."||||
33919902|NCT00262977|RANDOMIZED|PARALLEL||||NONE||||||
33919903|NCT02279121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919904|NCT03493867|NA|SINGLE_GROUP||OTHER||NONE||Vitaliti Continuous Vital Sign Monitoring Device - Version 2.0||||
33919905|NCT00488592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919906|NCT02072512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919907|NCT04605536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33919908|NCT05157399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants with vertigo and dizziness will be asked to participate in the study. Subjects that give consent will be entered into the study and three conditions (sham, therapeutic and no device) will be tested within an hour in a randomized sequence, with the OtoBand remaining in place throughout (turned off in the no device condition). The subjects will complete a Participant Questionnaire following the testing."||t|f|f|t
33919909|NCT02912728|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33919910|NCT04352595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919911|NCT06184737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919912|NCT05708937|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33919913|NCT05249985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|As no placebo supplement is being used in this intervention, it is not possible to do any form of masking.|Participants are assigned to one of two groups in parallel for the duration of the study. This will be either (a) NMES plus protein supplementation, or (b) NMES only.||||
33919914|NCT01112423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33919915|NCT04005976|||COHORT||OTHER|||||||
33919916|NCT04359719|||CASE_ONLY||CROSS_SECTIONAL|||||||
33919917|NCT01235169|NA|SINGLE_GROUP||TREATMENT||||||||
33919918|NCT00981318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784846|NCT06713473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784847|NCT06668818|||COHORT||PROSPECTIVE|||||||
33784848|NCT05154916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34088938|NCT02418897|||CASE_CONTROL||PROSPECTIVE|||||||
33784849|NCT05487586|||OTHER||OTHER|||||||
33784850|NCT05784155|RANDOMIZED|SEQUENTIAL||OTHER||NONE||A randomized, open, single-dose, 2x2 crossover-design clinical trial||||
33784851|NCT02831153|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||f|t|t|t
33784852|NCT01873287|||COHORT||PROSPECTIVE|||||||
33784853|NCT06426082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||This study will consist of a randomized controlled trial in which forty young, lean women will be assigned to a control group (n=10; receiving a thermoneutral exposure 2 hours/day at 32ºC; 5 days/week) or a cold exposure group (n=10; receiving 2 hours/day at 18ºC; 5 days/week) or aerobic exercise group (n=10; receiving 5 days/week at 65% heart rate reserve for 60 minutes each training session) or an ADBR2 agonist ingestion (n=10; salbutamol 12 mg/day. 7 days week).|f|f|t|f
33784854|NCT06631547|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Intramuscular injection of progesterone||||
33784855|NCT06631001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single-blind, meaning that participants are unaware of whether they are in the intervention or control group, while care providers and investigators have access to this information.|Participants are randomly assigned to either the intervention group receiving abdominal massage or the control group|t|f|f|f
33784856|NCT01328587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784857|NCT05954871|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784858|NCT04746859|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33784859|NCT04960709|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel||||
33784860|NCT03529864|RANDOMIZED|PARALLEL||PREVENTION|||This study was single-blind, parallel-group, and participants were randomly assigned to either the experimental (EG) or the control group (CG). Randomization was designed after initially evaluating the participants. The EG participated in the progressive exercise therapy program. In contrast, the CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form.|"Why: The design of the intervention took into account the available evidence for the prevention and treatment of neck and low back pain.~What: Materials: mats, fit-balls, TheraBands, towels, Dyn-Air cushions, chairs, stretchers.~Procedures: 3 levels of exercises of increasing difficulty. Standing warm-up exercises. Exercises involving: body scanner and breathing pattern re-education (4 minutes), neutral lumbar-pelvic position control in all directions (6 minutes); transverse abdominis activation (4 minutes); neutral cervical position control (2 minutes); global stabilizer activation exercises for the lumbar-pelvic and cervical-scapular regions (4 minutes); low back flexibility (2 minutes); and muscular strengthening and stretching (12 minutes).~Who provided: Physiotherapist. How: Face to face, group with 8-9 participants."||||
33784861|NCT04364880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784862|NCT06599879|NA|SINGLE_GROUP||OTHER||NONE||||||
33784863|NCT01660295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784864|NCT06702761|||COHORT||CROSS_SECTIONAL|||||||
33784865|NCT06268613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784866|NCT03137914|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment The clinical study model adopted is a single experimental group. Ten participants with dentofacial deformities related to severe degenerative TMJ changes, who are candidates for orthognathic surgery to repair these deformities, will be evaluated, who will be submitted to treatment with nasal septum autologous chondrocytes transplantation. There will be no evaluation of the control group in this study, as it is a case report. Injection of the experimental treatment will be done through an ultrasound-guided arthrocentesis.||||
33784867|NCT06711679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784868|NCT02695121|||COHORT||RETROSPECTIVE|||||||
33784869|NCT06711393|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33784870|NCT05975931|||OTHER||RETROSPECTIVE|||||||
33784871|NCT06614985|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||After completing the induction treatment period, patients undergo an efficacy evaluation to determine if complete remission or partial remission has been achieved. Patients who have not achieved complete or partial remission are classified as non-responders. Patients who have achieved complete or partial remission are then randomly assigned to either Group A or Group B at a 1:1 ratio. Non-responders are also randomly assigned to either Group C or Group D at a 1:1 ratio. Treatment administration is subsequently carried out based on group assignment.||||
33784872|NCT05931835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919919|NCT01990014|||CASE_ONLY||PROSPECTIVE|||||||
33919920|NCT03943173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919921|NCT01207817|||CASE_CONTROL||PROSPECTIVE|||||||
33919922|NCT03750071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919923|NCT01381029|||CASE_ONLY||PROSPECTIVE|||||||
33919924|NCT03909932|||OTHER||CROSS_SECTIONAL|||||||
33919925|NCT03281447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919926|NCT06197542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers who evaluated the participants were not informed of how the participants were grouped. Participants were informed that they would receive one of two different interventions without indicating which group should undergo trunk stability or conventional physiotherapy program.|Participants were randomly assigned to the A group or B group after a baseline assessment with a lottery ticket and an opaque envelope containing the same number of folded papers labeled \&quot;Group A\&quot; or \&quot;Group B.\&quot; Each participant took a piece of paper that identified their group and gave it to the researchers without seeing what was written. Participants were not notified which group was assigned to.|t|f|f|t
33919927|NCT04511780|||COHORT||PROSPECTIVE|||||||
33919928|NCT01965418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919929|NCT01024478|||COHORT||PROSPECTIVE|||||||
33919930|NCT03428997|RANDOMIZED|PARALLEL||OTHER||SINGLE|The evaluator was blind to the placement of the interventions on the test sites.|The experimental lotion and negative control were both applied to test sites on each subjects back.|f|f|t|f
33919931|NCT05923450|||COHORT||RETROSPECTIVE|||||||
33919932|NCT01867814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919933|NCT01703611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696541|NCT05318482|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cardio-respiratory patients (COPD and CHF), with similar comorbidity, needing rehabilitation, will be consecutively enrolled at Istituti Clinici Scientifici Maugeri.||||
34088939|NCT00668928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33784873|NCT05667753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled trial utilizing a hybrid type III implementation-effectiveness design.||||
33784874|NCT06426654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784875|NCT05061524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784876|NCT02825654|||COHORT||CROSS_SECTIONAL|||||||
34088940|NCT00244309|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33784877|NCT02960776|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34088941|NCT05769972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind: outcomes assessor do not know where the participants are allocated.|"Two interventions or each disease:~Parkinson's disease:"|f|f|f|t
33696542|NCT06090357|NA|SINGLE_GROUP||OTHER||NONE||||||
33784878|NCT05829174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33784879|NCT06611176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33784880|NCT06042127|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33696543|NCT03451942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784881|NCT04928157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784882|NCT05799573|||COHORT||PROSPECTIVE|||||||
33784883|NCT04547543|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33784884|NCT02107001|||COHORT||PROSPECTIVE|||||||
33784885|NCT06713122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33784886|NCT06132737|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784887|NCT04143646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784888|NCT04362319|||COHORT||CROSS_SECTIONAL|||||||
33784889|NCT03398135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33784890|NCT05426291|||COHORT||PROSPECTIVE|||||||
34088942|NCT02674503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088943|NCT02566005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696544|NCT06556719|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088944|NCT02835066|||COHORT||PROSPECTIVE|||||||
33696545|NCT05111808|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33696546|NCT02649114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696547|NCT01011712|||OTHER||PROSPECTIVE|||||||
33696548|NCT03355781|||COHORT||PROSPECTIVE|||||||
33696549|NCT01042574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696550|NCT00957112|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33696551|NCT05906173|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33696552|NCT02477969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696553|NCT03699683||SEQUENTIAL||TREATMENT||NONE||two groups (experimental and control) randomly assigned||||
33696554|NCT03126903|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label clinical trial||||
33784891|NCT03986606|NA|SEQUENTIAL||TREATMENT||NONE||||||
33784892|NCT05120440|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33784893|NCT05819827|||COHORT||PROSPECTIVE|||||||
33784894|NCT01096056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784895|NCT03952481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784896|NCT06709482|||OTHER||PROSPECTIVE|||||||
33784897|NCT06042114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784898|NCT06188494|||OTHER||RETROSPECTIVE|||||||
33784899|NCT05650411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784900|NCT05628727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784901|NCT04311619|NA|SINGLE_GROUP||OTHER||NONE||||||
33784902|NCT05360654|||CASE_ONLY||PROSPECTIVE|||||||
33784903|NCT02921230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784904|NCT05913739|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomization of the patients will be carried out receiving oxygen therapy (treatment group) and those not receiving this treatment (control group): randomization will be done according to list||||
33784905|NCT01268891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33784906|NCT03744117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784907|NCT05121207|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Skin cancer group and a dry skin condition group||||
33784908|NCT06713499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784909|NCT05642000|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33919934|NCT00003810||||TREATMENT||||||||
33919935|NCT01086046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919936|NCT01547468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33919937|NCT03308162|NA|SINGLE_GROUP||TREATMENT||NONE||Within subjects repeated measures||||
33919938|NCT04851002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The group in which the patients were included was determined by pulling the closed envelope just before the surgery. Test side was determined by tossing a coin after the implant cavities were prepared but before the implants were placed. The examiners who carried out the measurements and analyzes were unaware of the study and the groups.|This is a split-mouth design study. Accordingly, our study was conducted on 40 patients, including 20 patients in the CGF(Concentrated Growth Factor) study group and 20 patients in the A-PRF(Advanced Platelet Rich Fibrin) study group. While the implant combined with any regenerative material (CGF or A-PRF) was applied to the test site randomly assigned in the mouth, dental implants were placed according to traditional methods without applying any additional material to the contralateral site. Implants were placed symmetrically in the region of incisors, premolars or molar teeth in the mandible.|t|t|t|t
33919939|NCT04579796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The performer of the hysteroscopy will not be aware of the result of the ultrasound exam|||||
33919940|NCT04218799|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33919941|NCT05181904|||COHORT||PROSPECTIVE|||||||
33919942|NCT04895098|||COHORT||RETROSPECTIVE|||||||
33919943|NCT04111172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919944|NCT00696813|||COHORT||PROSPECTIVE|||||||
33919945|NCT04101435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784910|NCT06570759|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The patients will be randomized to the current STEMI/NSTEMI versus OMI/NOMI approaches using a cluster randomized trial design. In each center, a STEMI/NSTEMI and an OMI/NOMI intervention group will be formed from intervenional cardiologists. After these two groups are formed, the patients will be block-randomized into STEMI/NSTEMI and OMI/NOMI cohorts according to the team on-duty, i.e., the approach that center will follow on a certain day will be defined by the team on duty. The interventional cardiologists in both groups will be ensured to have a similar experience level (in terms of years of training, and angiography and primary PCI counts in the past year). When an OMI/NOMI investigator is on duty, AI supported ECG application will interpret ECGs as OMI or not-OMI. When a STEMI/STEMI investigator is on duty, AI supported ECG application will not interpret the ECG and will prompt Follow standard care."||||
34000078|NCT06453837|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The investigational and comparator products are alphabetically coded, using the codes A and B, by inovapotek's personnel not involved in the clinical study in order for the study to be performed in a double blinded fashion.~Subjects and Investigators enrolled in this study will not know to what product each code corresponds. The traceability of the products during and after the clinical investigation will be achieved by assignment of a code number and a batch number to each product.~Each subject is randomly assigned to one of the groups (Group I or Group II) according to a Table of Random Numbers created on Microsoft Office Excel."|The subjects are randomly divided in two groups, the test group, taking the active ingredient (Mentha Suaveolens extract) incorporated into a food supplement and the placebo group, taking the food supplement without the active ingredient. Each subject is randomly assigned to one of the groups (Group I or Group II) according to a Table of Random Numbers created on Microsoft Office Excel.|t|t|t|t
34000079|NCT04893941|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34000080|NCT01415245|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000081|NCT06228196|||COHORT||PROSPECTIVE|||||||
34088945|NCT00423605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784911|NCT04465890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784912|NCT06548009|||COHORT||PROSPECTIVE|||||||
33784913|NCT00164489|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33784914|NCT06377228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784915|NCT02518893|||CASE_ONLY||CROSS_SECTIONAL|||||||
33784916|NCT06705530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784917|NCT06711796|||CASE_ONLY||PROSPECTIVE|||||||
33784918|NCT06706518|||COHORT||PROSPECTIVE|||||||
33784919|NCT06352294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784920|NCT05912816|NA|SINGLE_GROUP||TREATMENT||NONE||"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."||||
34088946|NCT01950702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33784921|NCT03015831|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34088947|NCT06522321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Purposive Sampling technique will be done. All the patients who meet the eligibility criteria will be screened and then 20 patients will be randomly allotted into either of the two groups. The treatment allocation to the test and control group will be assigned by means of a sealed envelope containing a code derived from a computer-generated randomized list to receive either -~1. TEST GROUP (n =10)- FDBA and PRF(i-prf) with immediate implant placement.~2. CONTROL GROUP (n = 10) - FDBA alone with immediate implant placement."|f|f|f|t
33784922|NCT05349877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, clinical trial assessing the efficacy of a brief, unsupervised, self-guided psychological intervention targeting sexual and gender minorities' mental health.|t|f|t|t
33784923|NCT06630221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000082|NCT03457402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Care Providers are told about the two possible groups during the Consent and will be aware of their child's assignment in terms of whether the child begins treatment immediately after baseline or has to wait 6 weeks prior to treatment.~Members of the research team who are designated as video coders for the Effortful Control tasks will be blind to the group assignment of the participants in the video recordings."|"Participants are randomly assigned to one of two possible groups.~Group 1: Treatment; this group begins 6-week training with the self-control shaping application immediately after baseline.~Group 2: Wait-list Control; After baseline, this group waits for 6-weeks before completing another pre-training assessment and then starts the 6-week training with the self-control application."|f|f|f|t
34000083|NCT01169896|||COHORT||PROSPECTIVE|||||||
34000084|NCT04129944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000085|NCT01344018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000086|NCT05633251|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants were not aware of the purpose of the intervention.|Number of participants below is best estimate of students exposed to the intervention based on school lunch participation rates.|t|f|f|f
34000087|NCT06465979|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000088|NCT02676973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000089|NCT01721551|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34000090|NCT00822887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000091|NCT06627855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784924|NCT05653037|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34000092|NCT06300086|RANDOMIZED|FACTORIAL||OTHER||NONE||2x2 factorial design||||
33784925|NCT06030687|||CASE_ONLY||PROSPECTIVE|||||||
34000093|NCT02337322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000094|NCT04284007|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind||t|t|f|f
34000095|NCT04090658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34000096|NCT03088007|||OTHER||CROSS_SECTIONAL|||||||
34000097|NCT03835845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000098|NCT02242734|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34000099|NCT01547728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000100|NCT04929821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000101|NCT00684801|||COHORT||RETROSPECTIVE|||||||
33784926|NCT06706882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel group randomized controlled trial|t|f|f|f
33784927|NCT05096117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000102|NCT03539926|RANDOMIZED|PARALLEL||OTHER||NONE|The process of randomization, either device use or use of strips, will be masked until the moment it is delivered to the patient. The random assignment to each product will be made through lists created by an ad hoc computer program.|"Patients will receive the product for home pH monitoring, but they will keep following the doctor's recommendations indicated in the usual clinical practice.~The proportion of patients will be 1: 1 between the study group (Lit-control®pH Meter) and the control group (test strips)."||||
34088948|NCT05345080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088949|NCT06135714|RANDOMIZED|PARALLEL||TREATMENT||NONE||If this 12-week systemic therapy does not cause any progression or complete response, patients proceed to second registration for randomization; arm A continues same systemic therapy alone, and arm B performs MDT followed by same systemic therapy. The MDT will involve either RT or surgery, and RT will involve mainly SBRT and partly conventional RT.||||
34088950|NCT00484510|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34088951|NCT03279575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We will mask the intervention status of participants when analyzing the data.|1:1:1:1 allocation|f|f|f|t
34088952|NCT06425640|||COHORT||CROSS_SECTIONAL|||||||
34088953|NCT05849805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34088954|NCT06082232|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
34088955|NCT06415630|||COHORT||RETROSPECTIVE|||||||
34088956|NCT01260506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784928|NCT04914676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784929|NCT06614686|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784930|NCT04074499|||COHORT||CROSS_SECTIONAL|||||||
33784931|NCT06028841|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34000103|NCT00216060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33784932|NCT02931396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33784933|NCT02507310|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33784934|NCT06711718|||OTHER||OTHER|||||||
33784935|NCT06572462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784936|NCT04893135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784937|NCT05565742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33784938|NCT06712147|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33784939|NCT03936062|||COHORT||RETROSPECTIVE|||||||
33784940|NCT06714240|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The study is a prospective, randomized, longitudinal, controlled interventional trial with a parallel-group design.|t|f|t|t
33784941|NCT02820857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784942|NCT04817254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784943|NCT00421915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33784944|NCT01224678|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33784945|NCT01101919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088957|NCT01499407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088958|NCT01346306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088959|NCT00089648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34088960|NCT00255385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34088961|NCT01250704|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088962|NCT04287179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088963|NCT00836108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34088964|NCT05702632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34088965|NCT04715490|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34088966|NCT04696198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded|The patients are randomized to either of the groups, intervention or delayed intervention.|f|f|f|t
34000104|NCT04414046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000105|NCT03795441|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34000106|NCT03330132|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Annual vaccination with standard influenza vaccine or enhanced influenza vaccine, including some combination strategies (alternating each year) and some strategies with the same vaccine administered each year|t|f|t|t
34000107|NCT01102907|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34000108|NCT03540433|||COHORT||PROSPECTIVE|||||||
34000109|NCT02465892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
34000110|NCT01868204|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088967|NCT02111044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34088968|NCT05151913|||COHORT||PROSPECTIVE|||||||
34088969|NCT01241929|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33784946|NCT02516176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784947|NCT00049517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784948|NCT05506930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient and their parent/guardians will be blinded.||t|f|f|f
33784949|NCT05687877|||COHORT||PROSPECTIVE|||||||
33784950|NCT03331328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All subjects will be consented for the study prior to the procedure. They will be made aware of the meaning of case control study. Subjects will be randomized to a treatment or a non-treatment group.|t|f|t|t
33784951|NCT03688854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33784952|NCT06711809|||COHORT||PROSPECTIVE|||||||
33784953|NCT06615609|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention in this study is the implementation of the \&amp;#34;Smart family doctor\&amp;#34; system, a digital health management tool designed to support secondary prevention in post-CABG patients. This system leverages knowledge from coronary artery disease (CAD) secondary prevention guidelines, expert consensus, and a knowledge base addressing common post-CABG issues. It is powered by a large-scale, medical knowledge-enhanced conversational model, enabling personalized interactions with patients to guide their recovery and lifestyle management following surgery.||||
33784954|NCT06713083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study follows a parallel assignment model, where participants are randomized into two distinct groups. One group will follow a specifically designed exercise program tailored for individuals on bed rest during high-risk pregnancy, while the other group will receive standard care without structured physical activity. The intervention group will perform daily resistance and strength exercises adapted for execution while in bed. The control group will serve as a comparison to evaluate the impact of the exercise program on physical and emotional health, quality of life, and sleep during hospitalization. Randomization ensures unbiased allocation, and both groups will be monitored simultaneously throughout the study duration.||||
33784955|NCT02019706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33784956|NCT00881335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33784957|NCT03904719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784958|NCT05931198|NA|SINGLE_GROUP||OTHER||NONE||||||
34000111|NCT02016235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000112|NCT02032927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000113|NCT00795158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000114|NCT06076109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000115|NCT04166058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000116|NCT00106106|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34000117|NCT05568849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000118|NCT01661517|NA|SINGLE_GROUP||SCREENING||NONE||||||
34000119|NCT02634736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000120|NCT03243591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Gels are in coded opaque tubes created at the manufacturer|prospective, randomized, controlled, double-blind, single center|t|f|t|t
34000121|NCT04464005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000122|NCT05778760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000123|NCT05336487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A physically active intervention group is compared to a physically inactive control group||||
34000124|NCT03350191|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34000125|NCT00840190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000126|NCT01992094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103120|NCT00678574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000127|NCT05511935|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34000128|NCT00579358|||CASE_CONTROL||PROSPECTIVE|||||||
34000129|NCT00759616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103121|NCT03470883|||COHORT||RETROSPECTIVE|||||||
34103122|NCT05996445|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignments||||
34103123|NCT01482403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103124|NCT05776381|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study is a clinical multicenter, non-randomized, interventional phase II study. Three to five departments of colorectal surgery in Danish hospitals will be invited to participate in the study.||||
34103125|NCT06113562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103126|NCT06054880|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34000130|NCT04402892|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The recruitment of healed patients will be carried out via the Mondor and Bichat hospitals.~After information and obtaining consent at D0 :~* the patients will be taken from the departments of the participating centres (35 ml of blood, 5 LITHIUM HEPARINATE tubes).~* Inpatients will be drawn from the wards of the participating centres (35 ml of blood, 5 LITHIUM HEPARINATE tubes).~Inpatients will be drawn from the departments of the participating centres (35 ml of blood, 5 LITHIUM HEPARINATE tubes) at D21, then at D90 (3 months) for both groups of patients.~Patients in both groups will be collected from the departments of the participating centres (35 ml of blood, 5 LITHIUM HEPARINATE tubes) at 6 months."||||
34000131|NCT00695110|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects were enrolled into a single group and proceeded through the four Treatment Periods 1-4 in a sequential manner.||||
34000132|NCT06593418|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000133|NCT01874041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000134|NCT02288923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000135|NCT01211951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34000136|NCT01884844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000137|NCT03567551|||COHORT||PROSPECTIVE|||||||
34000138|NCT05920395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34000139|NCT00000124|RANDOMIZED|||TREATMENT||||||||
34000140|NCT05139394|||COHORT||PROSPECTIVE|||||||
34000141|NCT06099158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to treatment allocation. Active-arm participants will be unblinded at the time of first HeartLogic alert.||t|f|f|f
34000142|NCT05228717|||CASE_ONLY||PROSPECTIVE|||||||
34000143|NCT06467032|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34000144|NCT06498986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000145|NCT03730558|||COHORT||PROSPECTIVE|||||||
34000146|NCT06339424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000147|NCT02095522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000148|NCT01567527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696555|NCT03344354|RANDOMIZED|CROSSOVER||OTHER||NONE||"This is a non-significant risk, crossover, comparative, prospective, five-armed, open-label clinical investigation in which failure rates of surgical gloves from four manufacturers will be evaluated in double-gloving fashion.~The investigation is to be conducted over the course of ten (10) periods where the Biogel® brand of NRL and synthetic latex overgloves and undergloves are compared to other brand products from three manufacturers with comparable glove materials and thickness, and used during similar types of procedures. Study clinicians will be divided into five study groups based on specialty: Cardiothoracic and plastic surgery, Neurosurgery, Orthopaedic surgery, Trauma and acute general surgery, and Colorectal surgery. Before the first period each of five study groups will be randomized to one glove brand to start with in period 1. After each period the study group will cross over to the next period and brand of gloves according to a pre-defined order of rotation."||||
34000149|NCT05397977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000150|NCT01980173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000151|NCT02885441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34000152|NCT06534645|||COHORT||PROSPECTIVE|||||||
34000153|NCT01517919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000154|NCT04808908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000155|NCT00001864||||TREATMENT||||||||
34000156|NCT02943096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088970|NCT03273972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Independent CRF research nurse to perform the drug administration. CRF nurse will be unblinded whilst the rest of the study team (including the CI/PI) are blinded. This will involve the ACRC nurse bringing the injection in a sealed box to the room, preparing a shield (so the volunteer is blinded), administering the injection (via alirocumab pen or placebo - saline in insulin syringe) and then putting the syringe back in the sealed box and removing the screen. They have to ensure none of the study team are aware of the Rx as well as the patient.~CRF nurses will also have to collect and store medication in their building. Statin can be stored in a locked cupboard (open label)."|"Randomisation to be performed to a 1:1 ratio.~Alirocumab treatment arm:~* V2: Alirocumab (150mg)~* V3: Alirocumab (150mg) \& Atorvastatin (20mg)~Comparator treatment arm~* V2: Placebo~* V3: Placebo \& Atorvastatin (20mg)"|t|f|t|f
34088971|NCT02624596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088972|NCT05675800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088973|NCT05324917|||COHORT||PROSPECTIVE|||||||
34088974|NCT00049569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088975|NCT03699423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study treatments will be labelled as A, B and C by one of the team member who does not involve in the assessment and follow-up. The masked study products will then be sent to the study coordinator to dispense||t|t|t|t
33696556|NCT05318937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088976|NCT02137811|||COHORT||PROSPECTIVE|||||||
34088977|NCT06524661|||COHORT||RETROSPECTIVE|||||||
34088978|NCT01692756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34088979|NCT04474106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stratified block randomization with a block size of four and a 1:1 allocation will be used to assign participants to one of two groups (treatment vs. placebo). Three neurological levels of injury will be used for stratification.|Two-arm three-stage adaptive, prospective, multi-center, randomized, double-blind, placebo-controlled clinical trial|t|t|t|t
34088980|NCT00078520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696557|NCT06195735|||COHORT||OTHER|||||||
33696558|NCT06394154|||CASE_ONLY||CROSS_SECTIONAL|||||||
34088981|NCT00634972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34088982|NCT00559078|||||CROSS_SECTIONAL|||||||
33696559|NCT00785018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34000157|NCT00955422|||||PROSPECTIVE|||||||
34000158|NCT01073631|||CASE_ONLY||PROSPECTIVE|||||||
34000159|NCT01638273|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34000160|NCT05284552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000161|NCT02836457|||COHORT||PROSPECTIVE|||||||
34000162|NCT01071876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000163|NCT01231737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000164|NCT05336994|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Participants will be randomly assigned to receive either supplement A or supplement B during the first visit. Five to seven days later, participants will receive the other supplement.|t|t|t|t
33696560|NCT05405933|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33696561|NCT02572609||CROSSOVER||TREATMENT||NONE||||||
33784959|NCT06435572|NA|SINGLE_GROUP||TREATMENT||NONE||Each patient will be considered as both an experimental and a control group.Two different aspiration methods will be applied in line with the patient's aspiration needs, and the effect of the methods will be evaluated on the same patient. In the study, open aspiration applied to the patient will be evaluated as control, and closed aspiration will be considered as the experimental group.||||
33784960|NCT04982926|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784961|NCT05882318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784962|NCT01619943|||COHORT||PROSPECTIVE|||||||
33784963|NCT06573762|||CASE_ONLY||PROSPECTIVE|||||||
33784964|NCT01264718|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33784965|NCT04737720|||OTHER||PROSPECTIVE|||||||
33784966|NCT06411132|||COHORT||CROSS_SECTIONAL|||||||
33784967|NCT06714409|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Single centre, parallel group, randomized controlled trail. Approximately 250 participants will be screened to achieve 90 randomly enrolled to study intervention and 90 participants to SOC arm for an estimated total of 180 evaluable participants.||||
33784968|NCT06351631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784969|NCT03446508|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33784970|NCT06526663|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33784971|NCT06460818|||CASE_CONTROL||PROSPECTIVE|||||||
33784972|NCT05440929|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33784973|NCT03278197|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33784974|NCT01032850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784975|NCT05296629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multicenter, randomized, parallel-group, double-blind, controlled study.|t|t|t|t
33784976|NCT06165679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33784977|NCT05474664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784978|NCT01821911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33784979|NCT04162509|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomly (matched by clinical relevance of fear of spiders and sex) allocated to treatment groups (experimental group, control group). The experimenter evaluating the primary outcome will be blinded (unaware of group assignment of participants, single-blind).|Randomized controlled single-blind study design|f|f|f|t
33784980|NCT03553615|NA|SINGLE_GROUP||TREATMENT||NONE||Oral Ivermectin||||
33784981|NCT03293667|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33784982|NCT03493178|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33784983|NCT05144386|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33784984|NCT05165238|NA|SINGLE_GROUP||OTHER||NONE||||||
34000165|NCT01929681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000166|NCT05076682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000167|NCT04712903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000168|NCT01927016|||COHORT||RETROSPECTIVE|||||||
34000169|NCT01172249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000170|NCT02895841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696562|NCT00886184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696563|NCT01860781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696564|NCT04727931|||CASE_CONTROL||OTHER|||||||
33696565|NCT00739557|||||PROSPECTIVE|||||||
33696566|NCT06680362|||OTHER||RETROSPECTIVE|||||||
33696567|NCT03847870|||OTHER||CROSS_SECTIONAL|||||||
33696568|NCT01485393|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Patients will receive both interventions in a randomized order.||||
33696569|NCT05718804|||OTHER||PROSPECTIVE|||||||
33696570|NCT03648827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696571|NCT06681246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784985|NCT05598528|||COHORT||PROSPECTIVE|||||||
33784986|NCT06607484|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33784987|NCT00406289|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33784988|NCT01997840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784989|NCT05668091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33784990|NCT06565481|NA|SINGLE_GROUP||OTHER||NONE||"This study, including two time points, is performed to determine validity and reliability of performance based assessments using a one-arm sample.~A test retest design is used to determine reliability and a cross-sectional design to determine validity.~For each participant, the measures will be performed on two time points with a minimal recovery break of 2 days in one single centre in the Canton of Zurich (University Hospital Zurich)."||||
33784991|NCT03531905|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33784992|NCT00723294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33784993|NCT06714123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, International|t|t|t|t
33784994|NCT03610477|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33784995|NCT02611427|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33784996|NCT04244591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33784997|NCT05263141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801569|NCT06107751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the study, patients and care providers will be blind|"There are two group;~1. Experimental Group: Group R; Ramped Group; Pillows will be placed under the patient's upper body and head, with the external auditory canal and sternal notch horizontal.~2. Sham Comparator: Group S; Sniffing Group; A 7 cm high pillow will be placed under the occiput while the patient is in the supine position."|t|t|f|f
33801570|NCT06100185|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33801571|NCT03886116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801572|NCT02306954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801573|NCT01286714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000171|NCT02489864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34088983|NCT05962697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000172|NCT05963750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"A list with numbers from 1 to 120 was produced prior to the study on Excel. Each number was assigned a random group (with and without VR).~During the first consultation, the patient was assigned a number (the practitioner followed the list on Excel) and therefore a group. Both practitioner and patient knew the patient's group for the next appointment.~When the patient filled out the questionnaires, he was referring to his assigned number and not his name. Then, the practitioner filled in the Excel file with the data collected (characteristics of the patients, STAI-YA score, VAS), which were associated with the patient's number, and which were therefore anonymous."||||
33696572|NCT06135402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Monocentric, prospective, randomized, single-blinded, active-controlled|f|f|f|t
33696573|NCT04533685|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||A 2x2x2 factorial design, nested within a parallel 2-arm trial.|t|f|f|f
34000173|NCT00427154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696574|NCT02556827|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696575|NCT05285644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the randomized treatment period, the investigator and site staff performing eligibility / efficacy and safety assessments and the subjects will be masked.|Qualified subjects will be enrolled in the study and randomized in a 1:1 ratio within each site to receive 0.003% AR 15512 or AR-15512 vehicle to be administered twice daily (BID) as 1 drop in each eye for 90 days.|t|t|t|t
33696576|NCT06392607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696577|NCT00700570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696578|NCT06677866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study is conducted by four main professionals: the neuropsychiatrist principal investigator (Dr. Paolo Alfieri) responsible for the FXS treatment group; the neuropsychiatrist (Dr. Giovanni Valeri) responsible for the ASD treatment group; the cognitive behavioral therapist performing the intervention with the FXS treatment group (Dr. Alice Federica Maria Montanaro) and the cognitive behavioral therapist performing the intervention with the ASD treatment group (Dr. Laura Casula).~The two neuropsychiatrists conducting the clinical evaluation of the severity of the disorder and the presence of changes following the intervention (using the CGI-S scale) remain blind to treatment allocation during the trial and analyses until the conclusion of the study. Furthermore, the evaluating psychologists (who are different from the two therapists performing the intervention) and a speech therapist perform blinded assessments at T0-T1-T2."||f|f|t|t
33696579|NCT06185127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696580|NCT03004196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33784998|NCT06714474|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Masking Description In this study, outcomes assessors are blinded to the group assignments to reduce bias in evaluating participants' performance, satisfaction, confidence, and comfort levels. Participants and care providers are not blinded due to the nature of the interventions, as the experimental group engages with a Virtual Simulation Game (VSG) platform that is distinguishable from the standard teaching method used in the control group.~No other parties are masked in this trial."|"Model Description~In this randomized controlled trial, participants are assigned to one of two parallel groups:~Experimental Group: Participants receive training using a Virtual Simulation Game (VSG) for venous blood sampling (VBS) skills.~Control Group: Participants receive traditional training methods for VBS skills.~The interventions are applied concurrently, and the outcomes (knowledge, skill performance, satisfaction, confidence, and comfort) are compared between the two groups."|f|f|t|t
33784999|NCT06712485|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785000|NCT03593759|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, non-inferiority, randomized controlled with blinded end-point analysis.||||
33785001|NCT06155890|||COHORT||RETROSPECTIVE|||||||
33785002|NCT06613737|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33785003|NCT04684342|NA|SINGLE_GROUP||SCREENING||NONE||||||
33785004|NCT06629753|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||PPHIV and their children identified who are clinically stable will be differentiated to a care pathway that provides simplified PMTCT services that are adapted to their needs and preferences. PPHIV and their children who are clinically unstable will be differentiated to a care pathway that provides intensified PMTCT services.||||
33785005|NCT05988489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785006|NCT05242458|||COHORT||RETROSPECTIVE|||||||
33785007|NCT05604391|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Method clinical trial Free gingival graft application has been a routine and successful treatment option since the 1960s. Positioning methods are applied on or apical gingival recession. The aim of this study is to evaluate the effect of two different free gingival graft positioning techniques on the creeping attachment.|t|f|t|t
33785008|NCT06629857|||COHORT||CROSS_SECTIONAL|||||||
33785009|NCT05610696|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized clinical trial, of the crossover type||||
33785010|NCT06209359|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33785011|NCT02817373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785012|NCT05887557|NA|SINGLE_GROUP||OTHER||NONE||Hybrid type 2 implementation-effectiveness Trial||||
33785013|NCT03547505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial|f|f|t|f
33785014|NCT00450892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785015|NCT06712368|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33785016|NCT03961256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785017|NCT06029660|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects will be blinded to the treatment arm prior to the index procedure; after the procedure, they will be unblinded prior to discharge to prevent unintentional unblinding due to imaging|A prospective, multicenter, randomized, open-label trial.||||
34000174|NCT03221205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000175|NCT01156987|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000176|NCT01083797|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34000177|NCT01577173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000178|NCT04484090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000179|NCT02024230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000180|NCT01664039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000181|NCT01878435|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696581|NCT04064788|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696582|NCT04598464|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000182|NCT01872507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000183|NCT00748696|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34000184|NCT04657315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000185|NCT01824498|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33696583|NCT03153956|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase I - A prospective, interventional, randomized, double-arm clinical evaluation of patients who have been diagnosed with OA of the knee. The active treatment arm (personally calibrated biomechanical device) will be compared to a control arm (sham-placebo device) (similar shoes without biomechanical elements).~Phase II - Open-label, cross-over study design. After the completion of phase one patients will be un-blinded to their group allocation. Patients that were allocated to the sham-placebo control group will cross to the active group and will receive the AposTherapy treatment. Patients that were allocated to the active group will continue with treatment."||||
34000186|NCT03504020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000187|NCT01361633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34000188|NCT01096745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000189|NCT03245333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696584|NCT06279520|NA|SINGLE_GROUP||SCREENING||NONE||||||
33696585|NCT01310504|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33696586|NCT01433731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696587|NCT05008614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor not involved in this study will investigate the outcomes.|A prospective randomized controlled assessor-blinded non-inferiority trial|f|f|f|t
33785018|NCT00552734|||||PROSPECTIVE|||||||
33785019|NCT00003311|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785020|NCT06392256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33785021|NCT00441675|||CASE_ONLY|||||||||
33785022|NCT05916885|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be allocated into two groups by randomization. The experimental group in which patients will be given short-intensity mCIMT along with conventional therapy. A control group, in which patients will be given conventional therapy alone. The therapy regime will be 3 hours/ day, 5 days/week, and 4 successive weeks.||||
33785023|NCT00009958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785024|NCT05478863|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33785025|NCT06268028|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33785026|NCT01065454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785027|NCT04222244|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785028|NCT06209060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785029|NCT03881631|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33785030|NCT03995810|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34000190|NCT03387462|NA|SINGLE_GROUP||OTHER||NONE||||||
34000191|NCT00651183|||||PROSPECTIVE|||||||
34000192|NCT00898664|||CASE_ONLY||PROSPECTIVE|||||||
34000193|NCT04709757|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know to which treatment they are assigned.|"Participants will be randomized to receive 1) Intermittent Dosing Therapy 30 seconds ON 90 seconds OFF or 2) Intermittent Dosing Therapy 30 seconds ON and 360 seconds OFF~Patients will be seen and evaluated prior to randomization, and thereafter at 2, 4 and 6 weeks. At the 6-week time period, patients will be crossed over to the other study arm and thereafter evaluated at 2, 4 and 6 weeks."|t|f|f|f
34000194|NCT05832424|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34000195|NCT00796796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000196|NCT01675739|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34000197|NCT00095160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785031|NCT02454543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785032|NCT05161403|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither the operator nor the patients could be blinded due to the nature of the study, but the statistician will be blinded.|Randomized Clinical Trial||||
33785033|NCT05998005|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Waitlist-control design||||
33785034|NCT03882489|||OTHER||PROSPECTIVE|||||||
34000198|NCT05006573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000199|NCT04492696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000200|NCT04981457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Randomized Clinical Trial|t|f|f|f
34000201|NCT00058435|RANDOMIZED|||TREATMENT||NONE||||||
34000202|NCT05285358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000203|NCT03119896|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||"Two groups; one active group receiving the intervention, and one control group receiving standard care without the intervention."||||
34000204|NCT01676324|||COHORT||PROSPECTIVE|||||||
34000205|NCT04175587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a prospective, non-inferiority, randomized controlled clinical trial. The non-inferiority is concluded if the lower limit of the 95% CI for the difference in proportion of patients achieving EFS is greater than the -10% non-inferiority margin. The survival curves are estimated by using the Kaplan-Meier method and will be compared by using the log-rank test.|t|t|t|f
34000206|NCT01145157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34088984|NCT02032485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785035|NCT02109393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785036|NCT03455413|||COHORT||PROSPECTIVE|||||||
33785037|NCT02205931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785038|NCT06713876|||COHORT||RETROSPECTIVE|||||||
33785039|NCT04357418|||OTHER||RETROSPECTIVE|||||||
34000207|NCT06352762|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was conducted as a randomized controlled study.The first of the cases that met the study criteria was included in the study group, and the second in the control group. Randomization continued in this way.||||
34000208|NCT01310933|||||RETROSPECTIVE|||||||
34000209|NCT00924053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000210|NCT01569113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000211|NCT01066286|||CASE_ONLY||RETROSPECTIVE|||||||
34000212|NCT04385251|||COHORT||PROSPECTIVE|||||||
34000213|NCT04345822|||COHORT||PROSPECTIVE|||||||
34000214|NCT06632054|||COHORT||PROSPECTIVE|||||||
34000215|NCT05263635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized single-blind, comparator controlled trial involving patients undergoing ambulatory breast surgery, laparoscopic cholecystectomy surgery, or laparoscopic hernia repair surgery that score ≥19 on the PROMIS Emotional Distress - Anxiety - Short Form 8a|t|f|f|f
34000216|NCT03104231|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34000217|NCT05434091|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34000218|NCT00400452|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34000219|NCT05025033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000220|NCT01316432|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34000221|NCT01110863|||COHORT||PROSPECTIVE|||||||
34000222|NCT02941939|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34000223|NCT05773222|||CASE_ONLY||PROSPECTIVE|||||||
34000224|NCT01851876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000225|NCT03368027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34000226|NCT05006560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000227|NCT00001469|||COHORT||OTHER|||||||
34000228|NCT01013818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000229|NCT03670758|||CASE_CONTROL||OTHER|||||||
34000230|NCT01507207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000231|NCT04346680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000232|NCT02650570|||CASE_CONTROL||PROSPECTIVE|||||||
34000233|NCT05559060|||CASE_ONLY||CROSS_SECTIONAL|||||||
34000234|NCT02107196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000235|NCT01742403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000236|NCT03272997|||COHORT||RETROSPECTIVE|||||||
34000237|NCT05694117|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34000238|NCT02450058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000239|NCT00640926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000240|NCT04823936|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||pre-test post-test randomized controlled trial|t|t|t|t
34000241|NCT00213551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34000242|NCT02070523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000243|NCT01821157|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000244|NCT00664196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000245|NCT02907125|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34000246|NCT00967148|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000247|NCT02821208|||COHORT||PROSPECTIVE|||||||
34000248|NCT03074799|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We propose a cluster randomized trial to be conducted in 16 decentralized care clinics with existing TB services that will measure the implementation of symptom-based, nurse-led initiation of IPT compared to the current standard of care with TST-based referral to a pediatricians at the district hospital. A baseline assessment of clinic records and procedures will inform clinic stratification prior to randomization. Clinics will be stratified by size (number of patients seen per month) and TB case notifications. The clinics will then be randomized in a 1:1 ratio to receive either the intervention or the current standard of care. Given the intervention will be carried out by a clinic in its entirety, neither the provider nor the patient will be blinded to the study procedure. No additional staff will be provided to the clinics to assist in this process as we wish to evaluate the implementation of IPT for child contacts under 5 years old in a real world, resource-limited setting.||||
34000249|NCT00504634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000250|NCT03750357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34000251|NCT04947930|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34000252|NCT00004216||||TREATMENT||||||||
34000253|NCT01755585|||CASE_CONTROL||PROSPECTIVE|||||||
34000254|NCT01444196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000255|NCT00153439|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34000256|NCT01977313|||CASE_ONLY||CROSS_SECTIONAL|||||||
34000257|NCT02597257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000258|NCT05768087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000259|NCT04368416|||COHORT||PROSPECTIVE|||||||
34000260|NCT02321839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000261|NCT01887158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34000262|NCT05136469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000263|NCT02646488|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34000264|NCT01315717|||COHORT||CROSS_SECTIONAL|||||||
34088985|NCT06141005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000265|NCT05531136|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Once a participant has accomplished the baseline measurements, the assessor requests group allocation. The project administrator then sends the allocation to the trainer, who assigns the participant to the allocated group. The nature of the intervention precludes blinding of the participants and the trainers, however staff members involved in the recruitment of participants and in the assessment of measurement variables remain blinded to the group allocation until the post-processing of data that involves any subjectivity has been completed.|The study design is an assessor-blinded RCT with two parallel groups. Participants are randomly assigned in a 1:1 ratio to either the intervention or the control group by the use of a computer-generated randomization list managed by an independent project administrator. Blocking, the size of the blocks undisclosed, is applied in order to ensure the balanced allocation at several time points in the trial.|f|f|t|t
34000266|NCT02981004|||CASE_ONLY||PROSPECTIVE|||||||
34000267|NCT05330533|||COHORT||PROSPECTIVE|||||||
34000268|NCT06626503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial|t|f|f|f
34000269|NCT01889706|||COHORT||PROSPECTIVE|||||||
34088986|NCT04478669|||OTHER||PROSPECTIVE|||||||
34088987|NCT00125944|RANDOMIZED|PARALLEL||||DOUBLE||||||
34088988|NCT03938519|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34088989|NCT05953415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34088990|NCT06103045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors in charrge of pre- and post-test assessments were blinded to randomized allocation and intervention.|Patients with unilateral stroke and the onset within one month will be recruited and then randomly allocated to one of the three groups (including unilateral mirror therapy, bilateral mirror therapy, and conventional occupational therapy).|f|f|f|t
34088991|NCT02069314|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34088992|NCT01946945|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34088993|NCT03197727|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34088994|NCT03440320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Demographic data and measures will be collected by a blinded and trained research assistant.~The assessor and participants will be blinded to the randomization. We will maintain assessor and participant blinding through established mechanisms (e.g., not discussing information or intervention)."|Online intervention|t|f|f|t
34088995|NCT05082480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34088996|NCT05076786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103127|NCT05795764|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33919946|NCT05994313|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blinded to whether they are receiving the intervention or control, but it is not possible to blind them to the food itself. The researcher conducting the statistical analysis will be blinded prior to analysis, using a second set of unique study ID codes.|12-week Randomised controlled trial|f|f|f|t
33919947|NCT01113554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919948|NCT00241306|||DEFINED_POPULATION||OTHER|||||||
33919949|NCT04578730|||COHORT||PROSPECTIVE|||||||
33696588|NCT04796571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Blinding of participants was not possible because telephone visits were only offered to participants in the intervention arm. Investigators were blinded to the randomization order, but patients, staff, and providers were not blinded to arm assignment. The investigators who validated the data and performed the data analysis remained blinded to patient group assignment.||f|f|t|t
33696589|NCT02054377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696590|NCT05426239|||COHORT||RETROSPECTIVE|||||||
33696591|NCT00892658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696592|NCT05860933|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
33696593|NCT03753269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696594|NCT06103890|||COHORT||PROSPECTIVE|||||||
33696595|NCT04183062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696596|NCT05726916|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The present proposal is a randomized, controlled, multicenter, open-labelled study.~In the experimental group, Ecu will be administered at randomization according to usual recommendations in aHUS (4 intravenous administrations, 900mg/w until W4 then 1200mg/2w starting at W5, until W13).~In both experimental and control group, BP control with systematic maximum tolerated dose of RAS blockers will be administered."||||
33696597|NCT04664959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785040|NCT06694389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33785041|NCT05788926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785042|NCT01894347|||COHORT||PROSPECTIVE|||||||
33785043|NCT05165069|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785044|NCT03869034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None in this study will be masked.|Patients enroll in this study will receive hepatic arterial infusion chemotherapy with FOLFOX regimen (FOLFOX-HAIC), or combined with Sintilimab PD-1 inhibitor.||||
33785045|NCT05913973|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33785046|NCT04654936|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This study includes 2 intervention arms and one control group||||
33785047|NCT04165798|||COHORT||PROSPECTIVE|||||||
33696598|NCT00580008|||CASE_ONLY||RETROSPECTIVE|||||||
33785048|NCT00303303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919950|NCT01995812|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34000270|NCT06428305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The statistician will be blinded in the research. Researcher blinding cannot be done because he is a practitioner. But the researcher will open the envelope created by the statistician just before the application and find out which group the mother belongs to. In order to prevent bias in the evaluation of the data, groups will be coded as A and B, and the analysis of the data will be carried out by an independent statistical expert. After the analysis and interpretation of the data are completed, the codes of the intervention and control groups of the study will be revealed.|The intervention group receiving planned education on genital hygiene using the teach-back method and the control group not receiving education|t|f|f|t
34000271|NCT01969760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34000272|NCT00053339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000273|NCT05589636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000274|NCT03828435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103128|NCT03027050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33696599|NCT03303014|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33785049|NCT04068545|||COHORT||PROSPECTIVE|||||||
33785050|NCT02858934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785051|NCT03361111|||COHORT||CROSS_SECTIONAL|||||||
33696600|NCT00001122||CROSSOVER||TREATMENT||||||||
33696601|NCT04095273|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696602|NCT05245942|||OTHER||PROSPECTIVE|||||||
33696603|NCT05601037|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||blinded randomized prospective|t|f|f|f
33696604|NCT05991219|||COHORT||CROSS_SECTIONAL|||||||
33785052|NCT06562218|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not know which group they have been assigned to, and the researchers evaluating the results will not know which group participants have been assigned to.|prospective randomized controlled double-blind clinical trial|t|f|f|t
33801574|NCT05425862|NA|SINGLE_GROUP||TREATMENT||NONE||This is phase I, open label, multicentre, dose-escalation study where both doses of talazoparib and pidnarulex will be escalated to define the MTD and RP2D for the combination.||||
33801575|NCT03553472|||COHORT||CROSS_SECTIONAL|||||||
33919951|NCT04278508|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33919952|NCT01644955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919953|NCT00005848|NA|SINGLE_GROUP||TREATMENT||||||||
33919954|NCT02682030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919955|NCT02263495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919956|NCT00111475|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part A was a sequential cohort dose escalation study. Part B was a randomized, placebo-controlled parallel group study.|t|f|t|f
33919957|NCT01809925|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33919958|NCT01241396|||CASE_ONLY|||||||||
33919959|NCT05271110|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective cohort study||||
33919960|NCT00114270|RANDOMIZED|||PREVENTION||DOUBLE||||||
33919961|NCT00797914|||CASE_ONLY||PROSPECTIVE|||||||
33919962|NCT02376894|||OTHER||CROSS_SECTIONAL|||||||
33919963|NCT01502475|||CASE_ONLY||CROSS_SECTIONAL|||||||
33919964|NCT00664755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33919965|NCT00685529|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919966|NCT03224585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919967|NCT04488848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33919968|NCT04656418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34000275|NCT00893776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000276|NCT01663896|||CASE_ONLY||PROSPECTIVE|||||||
33919969|NCT02687750|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000277|NCT00004162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000278|NCT04929730|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||alternating cluster-randomised allocation of investigation-periods alternierende Cluster-randomisierte Zuordnung der Untersuchungszeiträume|t|t|f|t
33696605|NCT05189379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"A two group study is constructed with the sole intention to balance the amount of participants who would undergo the same experiment with a different order. Half of the participants will receive odour based Cue Reactivity Task first, other half will complete the image based Cue Reactivity Task first.~Before the MRI screening participants would be asked about their preference between beer, wine and schnapps then during the odour based Cue Reactivity Task only their preferred beverage odour would be delivered."||||
34000279|NCT00532012|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33696606|NCT04945031|||CASE_ONLY||RETROSPECTIVE|||||||
34000280|NCT06020040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study takes a single-blind method. During research process, the researchers cannot avoid knowing the type of abutment used by the subjects during the clinical examination and operation, so the subjects can only be single-blinded. The clinical examination data will be measured and averaged by two independent clinicians. The data will be analyzed by a third person.|The researchers prospectively and continuously recruited subjects who underwent implant therapy with xenogeneic bone graft material in the Oral Implantation Center of the Stomatology Hospital Affiliated to Zhejiang University School of Medicine, and all subjects who signed written informed consent were divided into 2 groups (large bone particles and small bone particles) through a table of random numbers.|t|t|f|t
34000281|NCT03306238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient and the investigator will not be informed of the type of approach they had. These will be marked as A and B with only the care povide/surgeon being aware of the actual approach. The investigator of complications and assessor of the case outcomes will collect data without the knowledge of the group the patient belongs to. The surgeon or car eprovider cannot be masked in this case due to technical limitations but they will not contribute towards analysing the results.|This is a randomised single blinded prospective trial comparing two similar groups directly to check for differnces in time to approach and complication rate|t|f|t|t
34000282|NCT04192032|RANDOMIZED|CROSSOVER||OTHER||NONE||In this study, we will recruit 80 young (18-24) JUUL users. Each participant will undergo 3 JUUL smoking sessions: 1) one where they will be vaping their preferred flavor; 2) one where they will be vaping the standard classic tobacco flavor; 3) a third one in which they will be vaping their preferred flavor in a JUUL Ecigarette (JEC) device that has a health warning label (HWL) attached to it. In addition, 10 participants will be invited to come back for two additional sessions: one in which they will be vaping their preferred flavor pod with a 3% nicotine concentration, and one in which they will use their preferred flavor pod with 0% nicotine concentration. Measurement of JUUL satisfaction, dependence, harm perception, and exposure to nicotine and toxicants will be conducted in all 5 sessions.||||
34000283|NCT00804011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696607|NCT03068598|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The subject will receive a watch connected to a smartphone, wear at night and objectively evaluate sleep in ecological conditions||||
33696608|NCT05191654|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785053|NCT06277817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The randomization of this study was performed by a statistical expert independent of the study, using the computer-assisted Random Allocation Rule method, which is one of the random assignment methods (http://biostatapps.inonu.edu.tr/RAY/).78 patients to be included in the study were divided into 3 groups and assigned an equal number of patients in each group according to the results of the random assignment method. In order to assign patients to research groups impartially, the research groups determined were written on papers and group assignments were made by drawing lots. Thus, the number of individuals in the groups and the probability of each patient included in the study being in either of the experimental or control groups were equalized.|t|f|f|f
33919970|NCT04081376|NA|SINGLE_GROUP||OTHER||NONE||There is one single treatment group (HM), and no control group.||||
33919971|NCT04447703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33919972|NCT03018457|||COHORT||PROSPECTIVE|||||||
33919973|NCT04243616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919974|NCT05846295|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|The investigators will be blinded regarding which participants are randomized to which arm.|This is an educational intervention study.|f|f|t|t
34000284|NCT01788709|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34000285|NCT03261843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the person performing the statistical analysis shall be masked|single center, prospective randomized comparative trial|f|f|f|t
34000286|NCT01994915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000287|NCT00784095|RANDOMIZED|PARALLEL||||NONE||||||
34000288|NCT02277262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000289|NCT02036398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696609|NCT00050271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785054|NCT06703424|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Two-arm intervention, crossover study design|t|f|f|f
34000290|NCT00858416|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34000291|NCT03336788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000292|NCT02689817|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The investigator and outcomes assessors will be masked to the pressure data during the operating room and follow-up.|||||
34000293|NCT01479062|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34000294|NCT03610555|||OTHER||PROSPECTIVE|||||||
33785055|NCT03578185|||COHORT||RETROSPECTIVE|||||||
34000295|NCT05590676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000296|NCT06388733|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinded Independent Central Review is composed of independent radiologists and will be utilized to assess progression of disease|||||
34000297|NCT06482606|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2 groups of participants, both undergoing flickering checkerboard stimulus. Patient group (participants with recovered depression) and a healthy control group.||||
34000298|NCT01274962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000299|NCT05428696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000300|NCT04552405|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34000301|NCT04197908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000302|NCT04020445|||CASE_ONLY||PROSPECTIVE|||||||
33785056|NCT06344455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33785057|NCT03711617|||COHORT||PROSPECTIVE|||||||
34000303|NCT05737160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000304|NCT02538549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34088997|NCT05141253|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a single center, open label, non-controlled, exploratory study. The 3+3 dose escalation design will be implemented to evaluate the safety and tolerability of RD133 in the treatment of subjects with relapsed/refractory MSLN-positive solid tumors."||||
34088998|NCT00452595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785058|NCT06032923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785059|NCT04432974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000305|NCT06559956|||COHORT||PROSPECTIVE|||||||
34000306|NCT00105157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000307|NCT00003725|RANDOMIZED|||TREATMENT||||||||
34000308|NCT01577251|||OTHER||PROSPECTIVE|||||||
34000309|NCT02448563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000310|NCT00421837|||CASE_CONTROL||PROSPECTIVE|||||||
34000311|NCT06390813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000312|NCT02346435|||OTHER||PROSPECTIVE|||||||
34000313|NCT01939106|NA|SINGLE_GROUP||||NONE||||||
34000314|NCT02901730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000315|NCT03515473|||CASE_CONTROL||RETROSPECTIVE|||||||
34000316|NCT03045016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000317|NCT02745600|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000318|NCT01199653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696610|NCT03965767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696611|NCT06680297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33696612|NCT01925274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696613|NCT00754988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696614|NCT04189575|NA|SINGLE_GROUP||OTHER||NONE|All participants will be assigned to the text message intervention and therefore no masking is necessary.|||||
33696615|NCT01655680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696616|NCT00807131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33696617|NCT04197752|||CASE_CROSSOVER||PROSPECTIVE|||||||
33696618|NCT00661973|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33696619|NCT00881101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696620|NCT05627648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696621|NCT00673946|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33696622|NCT03775291|||CASE_CONTROL||PROSPECTIVE|||||||
33696623|NCT00805948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696624|NCT03600298|NA|SINGLE_GROUP||TREATMENT||NONE||Open interventional before and after study on the effect of on-site full-scale simulation with a subsequent course follow-up and a three month follow-up observation pertaining to behavioural changes in communication of the paediatric intensive care unit staff that is participating in the on-site simulation training||||
33696625|NCT06008158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Cosmetic outcome assessed by blinded medical doctor review.|||||
33696626|NCT05833334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000319|NCT06357741|||OTHER||PROSPECTIVE|||||||
33696627|NCT04483323|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34000320|NCT05032898|||CASE_ONLY||PROSPECTIVE|||||||
34000321|NCT04541264|||COHORT||OTHER|||||||
34000322|NCT03242746|||COHORT||PROSPECTIVE|||||||
33696628|NCT00717028|||||CROSS_SECTIONAL|||||||
33696629|NCT00596297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696630|NCT03508739|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double-blind|prospective randomized, double-blind, crossover study, mechanistic/ translational study (not to change labeling or marketing, not classic phase 3 or 4 study), IND exempt|t|t|t|t
33696631|NCT02667431|||COHORT||PROSPECTIVE|||||||
33696632|NCT05936268|RANDOMIZED|PARALLEL||TREATMENT||NONE||Acute gout patients with gout flare Group A: Genakumab 200mg single injection;Group B: Etoricorxib 120mg qd po.(until remission or intorlerance, no longer than 8 days)||||
33696633|NCT00437320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696634|NCT03376100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696635|NCT00482261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696636|NCT00715000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696637|NCT00537992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696638|NCT03150160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a multicenter, randomized, double-masked, two-arm, placebo-controlled, parallel group study in patients with normal tension glaucoma who were insufficiently controlled on travoprost 0.004% (Travatan) monotherapy.|t|f|t|f
33696639|NCT06038981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696640|NCT04410536|NA|SINGLE_GROUP||TREATMENT||NONE||withdrawal program will be performed at home||||
33696641|NCT02563951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696642|NCT03815708|||OTHER||PROSPECTIVE|||||||
33696643|NCT04396665|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33696644|NCT05261282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research staff who conduct the hand hygiene observations for the physician teams will not know the randomization status of the physician teams. The investigators are unable to mask the research assistants from the randomization status of the nursing units.|This is a multi-center, repeat-measures, randomized controlled mixed-methods trial. At each study site the participating physician teams and nursing units will be randomly assigned into one of two study arms (intervention/control). For physician teams, this will occur on a rolling basis for 12 months with 2 physician teams randomly selected at each site each month for participation (1 intervention, 1 control). For nurses, 2-4 hospital units at each study site will be assigned to either intervention or control for the study period.|f|f|f|t
34000323|NCT00061464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696645|NCT06283914|||COHORT||PROSPECTIVE|||||||
33696646|NCT02517866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696647|NCT06679998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696648|NCT02616848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696649|NCT04064385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696650|NCT03630367|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696651|NCT01397201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33696652|NCT00810693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696653|NCT03118973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with challenging biliary cannulation randomized to either Goff trans-pancreatic septotomy or double wire technique to facilitate biliary cannulation.||||
33696654|NCT03862716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696655|NCT03221907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696656|NCT04348110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696657|NCT00185991|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33696658|NCT00002078||||TREATMENT||||||||
33696659|NCT01141387|||COHORT||PROSPECTIVE|||||||
33696660|NCT02103010|||CASE_CONTROL||PROSPECTIVE|||||||
33696661|NCT04840173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696662|NCT06397664|||OTHER||RETROSPECTIVE|||||||
33696663|NCT03784417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000324|NCT00080613||||TREATMENT||||||||
34000325|NCT04008680|RANDOMIZED|PARALLEL||OTHER||DOUBLE||4 group randomized clinical trial|t|f|f|t
34000326|NCT03732833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000327|NCT02609191|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000328|NCT05207605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000329|NCT00048139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696664|NCT02869503|||COHORT||PROSPECTIVE|||||||
33696665|NCT05030246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785060|NCT05153174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785061|NCT06570551|||OTHER||CROSS_SECTIONAL|||||||
33785062|NCT05254197|||COHORT||PROSPECTIVE|||||||
33785063|NCT06548399|||COHORT||PROSPECTIVE|||||||
33785064|NCT04815824|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Crossover design comparing mode of endurance exercise (cycling versus treadmill).||||
34000330|NCT04358367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34000331|NCT02994836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000332|NCT01188590|||CASE_CONTROL||PROSPECTIVE|||||||
34000333|NCT05108935|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34000334|NCT00028925|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34000335|NCT00722436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000336|NCT03155893|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34000337|NCT03576040|||COHORT||PROSPECTIVE|||||||
33785065|NCT02303769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785066|NCT06637904|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pre-phase is the control arm and Post-phase is the interventional arm (uses TriVerity Test intervention)||||
34000338|NCT00193323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000339|NCT00185809|||COHORT||PROSPECTIVE|||||||
34000340|NCT02404558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000341|NCT05475548|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34088999|NCT01687933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089000|NCT03979404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000342|NCT03099590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participants nor the study personnel providing the care/assessments will know whether the treatment received is active or placebo|Half of the enrolled subjects will receive treatment with Alkontrol-herbal, kudzu extract, and half will receive a placebo control.|t|t|f|f
33785067|NCT00803426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33785068|NCT04215341|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785069|NCT02036931|||COHORT||RETROSPECTIVE|||||||
33785070|NCT06712953|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696666|NCT04398251|RANDOMIZED|PARALLEL||PREVENTION||NONE|Make a random table, and the patients are divided into the group according to the random table according to the order of enrollment.|"2020.1 -2020.12 patients with urolithiasis and hyperuricemia were enrolled in the urology department of our hospital (100 cases). The patients were informed of this study before operation and randomly divided into uric acid drug control group (n = 50) and non-drug control group (n = 50).~For non-drug control group: Patients are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly.~Uric acid drug control group:or the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 20 mg three times a week"||||
33696667|NCT03161093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696668|NCT00942955|||CASE_CONTROL||PROSPECTIVE|||||||
33696669|NCT03561350|||CASE_ONLY||PROSPECTIVE|||||||
33696670|NCT05179850|||COHORT||OTHER|||||||
33696671|NCT01453660|||COHORT||RETROSPECTIVE|||||||
33696672|NCT03844607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696673|NCT06063772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"1. Initial identification of patients will be based on measured blood pressure. No other criteria will be used to identify patients for screening.~2. Cohort assignment will be made using a block randomization table.~3. The investigator measuring hemodynamics in the OR during induction will be blind to the patient's cohort assignments."|Prospective blinded trial comparing the effect on post induction hemodynamic stability of pre-induction treatment of hypertension to placebo.|t|t|t|t
33696674|NCT02996734|||CASE_ONLY||RETROSPECTIVE|||||||
33696675|NCT05142722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablet made to resemble active|Placebo-controlled, double-blind, randomized|t|t|t|t
33785071|NCT01102361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785072|NCT03083522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785073|NCT00961805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785074|NCT03995043|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants are blinded through the study arm and the outcomes assessor and investigator are blinded to participant group assignment for the intervention.|This is an individually randomized parallel group study design.|t|f|t|t
33785075|NCT00883350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33785076|NCT04768062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785077|NCT03337503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785078|NCT06710574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785079|NCT06011200|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785080|NCT06711094|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-arm, single-center, open, exploratory clinical study||||
33785081|NCT05646836|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785082|NCT03189602|||CASE_ONLY||RETROSPECTIVE|||||||
33785083|NCT06607003|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33785084|NCT00927342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33785085|NCT03915262|||CASE_ONLY||PROSPECTIVE|||||||
33785086|NCT06278857|NA|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomised, prospective, pilot, open-label, single arm study. Participation in this trial involves seven dostarlimab sessions over 12 months, with a treatment protocol of four cycles every three weeks, followed by a three-week break, and then three cycles every six weeks.||||
33919975|NCT03707964|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Deliberate deception (by not informing of the aim of assessing for ability to challenge authority) will be used to blind the participants. However, open disclosure and explanation of the rationale for deception will be conducted during the debriefing sessions and participants will be extensively counselled.~The confederate specialist will also be blinded to the allocation of the control or intervention arm of participants.~All sessions will be video recorded and assessed in random order by two independent raters blinded to group allocation, using the modified Advocacy-Inquiry Score (mAIS)."||t|t|f|t
33919976|NCT04494464|||CASE_ONLY||CROSS_SECTIONAL|||||||
33919977|NCT01399749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919978|NCT01799018|||CASE_CONTROL||PROSPECTIVE|||||||
33919979|NCT02195934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919980|NCT04000347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Single blind controlled trial between participants, drug preparing team, doctors, investigators, and outcome assessors.||t|f|f|f
33919981|NCT01546844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34000343|NCT02032030|||OTHER||PROSPECTIVE|||||||
34000344|NCT04121507|NA|SINGLE_GROUP||SCREENING||NONE||||||
34000345|NCT01962298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34000346|NCT05511662|||COHORT||PROSPECTIVE|||||||
34000347|NCT04651816|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants will not know what intervention group they will be assigned to (motivational messaging, incentives or control group).||t|f|f|f
34000348|NCT00003906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34000349|NCT06348277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000350|NCT03370510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eighty children will be randomly assigned to receive PRT with either oxytocin (forty children) or a placebo (forty children).|t|t|t|t
34000351|NCT01954212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33919982|NCT06253013|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33919983|NCT05875376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33919984|NCT04031053|||OTHER||PROSPECTIVE|||||||
33696676|NCT03550885|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All study personnel, excluding those directly involved with meal preparation, will be blinded to the subjects' diet sequence.|"The proposed study will utilize a randomized, crossover, controlled feeding trial design composed of two experimental diets: (1) animal-based, high in taurine and saturated fat (HT-HSAT) and (2) plant-based, low in both taurine and saturated fat (LT-LSAT) (each consumed for 21 days with a minimum 3-week washout between diets).~At baseline and post-diet (day 22) for each of the two 3-week diets, subjects will undergo a flexible sigmoidoscopy, fasting and non-fasting blood draw, and provide a stool sample."|f|f|t|f
33696677|NCT00535366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33696678|NCT05748470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696679|NCT06310200|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All besides PI||t|t|t|t
33696680|NCT03802227|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||A double-blind, double-dummy, parallel-group, randomized, positive control study.|t|t|t|f
33696681|NCT00237185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696682|NCT00055224|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33696683|NCT04728165|||CASE_CONTROL||PROSPECTIVE|||||||
33696684|NCT05025254|||COHORT||CROSS_SECTIONAL|||||||
33696685|NCT00051389|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33696686|NCT05393674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696687|NCT04951804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33696688|NCT05934942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696689|NCT06681389|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33696690|NCT05895864|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: Utidelone||||
33696691|NCT03853343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696692|NCT06363357|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study compares variables before and after wearing the shoulder orthosis in patients with Duchenne muscular dystrophy.||||
33696693|NCT06302127|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The follow-up data collection, data entry, and data quality checks will be conducted by researchers unaware of the group assignments. The analysis of results will also be performed by statisticians unaware of the allocation.||f|f|f|t
33696694|NCT05863273|||COHORT||PROSPECTIVE|||||||
33696695|NCT01070758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696696|NCT01248845||CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33696697|NCT00036296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696698|NCT00612027|||COHORT||PROSPECTIVE|||||||
33696699|NCT06235307|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696700|NCT06142630|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33696701|NCT02186431|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33696702|NCT06681454|||COHORT||RETROSPECTIVE|||||||
33696703|NCT01193842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696704|NCT00209768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696705|NCT03113916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Trial participants are randomly assigned to one of two conditions: 1) Enhanced usual care control, or 2) a culturally tailored behavioral intervention.|t|f|f|t
33696706|NCT04670172|||COHORT||PROSPECTIVE|||||||
33696707|NCT06015971|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919985|NCT05061797|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Samples are coded with 3 digit, randomized codes. Active study product and placebo are not known to the administrators of the study or the participants.|Double-Blind, Randomized, Crossover Study|t|f|t|f
33919986|NCT00608452|||CASE_ONLY||PROSPECTIVE|||||||
33919987|NCT01064219|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33919988|NCT00514436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33919989|NCT00477555|||COHORT||PROSPECTIVE|||||||
33919990|NCT03123055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||B-701 (vofatamab) as monotherapy for first 2 weeks followed by B-701 (vofatamab) in combination with pembrolizumab thereafter.||||
33919991|NCT01240408|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33919992|NCT00000341|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33919993|NCT02327533|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33919994|NCT03943888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33919995|NCT04092816|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Because this is a pilot study, all participant dyads will receive the same intervention and no blinding will take place.|10 patient and co-parent dyads (20 participants in total) will participate in the pilot study to evaluate the feasibility and acceptability of the FAMILY intervention. Preliminary effects of the intervention will also be examined.||||
33696708|NCT03843827|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"50Patients are randomly divided by computer designed lists and then concealed in closed envelopes into 2 equal groups:~1. Group A (n = 25), in which classic LMA is used for ventilation.~2. Group B (n = 25), in which I gel is used for ventilation."|Investigators hypothesize that both supraglottic devices, the classic LMA and i gel are effective in ventilation of obese patient.|t|t|f|f
33785087|NCT06066970|||COHORT||PROSPECTIVE|||||||
33785088|NCT05798208|||COHORT||RETROSPECTIVE|||||||
33801576|NCT05806060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801577|NCT01094184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33919996|NCT03520192|||COHORT||PROSPECTIVE|||||||
33919997|NCT03325556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33919998|NCT05072665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33919999|NCT05003063|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The study will be double blind||t|f|t|t
33920000|NCT00738205|||COHORT||PROSPECTIVE|||||||
33920001|NCT02602171|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33920002|NCT00001449||||TREATMENT||||||||
34000352|NCT01189656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000353|NCT06331572|||CASE_CONTROL||RETROSPECTIVE|||||||
33785089|NCT05493787|RANDOMIZED|PARALLEL||PREVENTION||NONE|Although patients will not be explicitly informed of which arm they were randomized to, they will be aware of the messages they receive.|||||
33785090|NCT02844764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785091|NCT06705413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785092|NCT06628479|||CASE_CONTROL||PROSPECTIVE|||||||
33785093|NCT04582877|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785094|NCT05823987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785095|NCT01497444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785096|NCT01112072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785097|NCT05772962|||CASE_CONTROL||RETROSPECTIVE|||||||
33785098|NCT05618301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785099|NCT04298840|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Participants will be randomized to receive creatine monohydrate or placebo for daily consumption during the study period.|t|f|t|t
33785100|NCT05120596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||dose-finding, safety, and proof-of-concept study||||
33785101|NCT04659031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785102|NCT02361788|||COHORT||PROSPECTIVE|||||||
33785103|NCT04656470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients will receive dexmedetomidine anesthesia during the study visit.||||
33785104|NCT01772719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785105|NCT02256787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33785106|NCT04415112|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study design was single blind and the participants did not know what diet they had taken.|The study design was a single-blinded randomized, parallel assignment clinical trial of children with NAFLD was conducted. Participants were randomized in a 1:1 fashion to either 12-weeks of a Mediterranean diet or a low fat diet.|t|f|f|f
33785107|NCT05657912|||OTHER||PROSPECTIVE|||||||
34000354|NCT03944057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000355|NCT03292263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000356|NCT06357416|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000357|NCT02509286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000358|NCT04994431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All subjects that sign a study consent and meet inclusion and exclusion criteria will receive the the study drug.||||
34000359|NCT01091363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000360|NCT04986254|||COHORT||PROSPECTIVE|||||||
34000361|NCT01015963|||CASE_ONLY||RETROSPECTIVE|||||||
34000362|NCT01277510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000363|NCT03344120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000364|NCT01625403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000365|NCT04394130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000366|NCT04642781|||COHORT||CROSS_SECTIONAL|||||||
34000367|NCT04257695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785108|NCT04821544|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785109|NCT06370325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785110|NCT06037382|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785111|NCT04004702|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with clinical Alzheimer's disease and neuro-psychiatric symptoms will all be assessed with electroencephalogram, and all participants with epileptiform discharges will receive levetiracetam. Those without epileptiform discharges will be followed with serial inventories of symptom severity and functioning, but will not receive experimental treatment nor placebo.||||
33785112|NCT03720015|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Case study||||
33785113|NCT04376164|RANDOMIZED|PARALLEL||TREATMENT||NONE||control group laser group||||
33801578|NCT02861066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801579|NCT06337058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000368|NCT06441695|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34000369|NCT03326167|||COHORT||PROSPECTIVE|||||||
34000370|NCT00225849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000371|NCT02865824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000372|NCT05374850|||COHORT||PROSPECTIVE|||||||
34000373|NCT02511860|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34000374|NCT03820258|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000375|NCT05530811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34000376|NCT03789487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785114|NCT04589611|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"Phase I: 6 patients will be treated with single dose open label, and safety measures will be assessed.~Phase IIa: Once initial safety is confirmed, 20 amobarbital:10 control patients will be treated with the single dose at the initial operation. Patients and attending surgeons will be blinded to the identity of the dose. Assuming continued safety, an additional 20 amobarbital: 10 control patients will be treated with two doses and evaluated. The second dose of 2.5 mM amobarbital will be administered during the second operation."|t|t|f|t
33785115|NCT06505031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785116|NCT00826280|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33920003|NCT03896113|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, proof of concept phase II study. One arm, no placebo: All the patient will received the treatment and biopsies before and after the treatment will be compared regarding Indoleamine 2,3-dioxygenase 1 (IDO-1) expression and Immune T cells infiltration of the tumour||||
34000377|NCT04163588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000378|NCT05638035|||CASE_CONTROL||PROSPECTIVE|||||||
34000379|NCT04429984|||COHORT||OTHER|||||||
33920004|NCT06285110|||COHORT||PROSPECTIVE|||||||
33920005|NCT04742920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920006|NCT01825655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920007|NCT02300428|||COHORT||RETROSPECTIVE|||||||
33920008|NCT01450956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920009|NCT00600028|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920010|NCT01659333|||COHORT||CROSS_SECTIONAL|||||||
33920011|NCT02159261|||COHORT||PROSPECTIVE|||||||
33920012|NCT03272217|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
33920013|NCT02691221|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920014|NCT01736254|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920015|NCT02069236|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920016|NCT05821348|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33920017|NCT00272636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920018|NCT02581865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920019|NCT05093998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is double-blind. Clinical center staff and patients will not know what therapy and in what doses are prescribed for each individual patient. Blinding will be achieved by masking the AV5080/placebo drug (each patient will take a pill corresponding to 80 mg or placebo) and dispensing the drug using IWRS. Each patient will be given the study drug in banks. Banks will have a unique identification number, otherwise they will be identical in marking.||f|f|f|t
33920020|NCT04518982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920021|NCT03989752|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920022|NCT01959399|NA|SINGLE_GROUP||||NONE||||||
33920023|NCT06005298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920024|NCT04346693|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33920025|NCT00046176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920026|NCT00609011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920027|NCT00039741|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33920028|NCT04230798|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33920029|NCT00413335|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34000380|NCT02323555|NA|SINGLE_GROUP||OTHER||NONE||||||
34000381|NCT05488262|||COHORT||RETROSPECTIVE|||||||
34000382|NCT03521362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000383|NCT04119505|||COHORT||PROSPECTIVE|||||||
34000384|NCT02174276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000385|NCT01812603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000386|NCT06048848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33785117|NCT05692401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920030|NCT00795353|||CASE_ONLY||PROSPECTIVE|||||||
33920031|NCT05232019|||COHORT||RETROSPECTIVE|||||||
33920032|NCT01079286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920033|NCT05415345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920034|NCT02999880|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33920035|NCT03173586|||COHORT||PROSPECTIVE|||||||
33920036|NCT01610076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920037|NCT02071264|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920038|NCT00139620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920039|NCT00327548|RANDOMIZED|PARALLEL||||DOUBLE||||||
33920040|NCT02118857|||COHORT|||||||||
33920041|NCT01589510|||COHORT||PROSPECTIVE|||||||
33920042|NCT04268472|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|Crossover Assignment two-way crossover||||
33920043|NCT01481909|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33920044|NCT03402152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and Care Providers will be masked with regard to medication administered.||t|t|f|t
33920045|NCT03859492|NA|SINGLE_GROUP||SCREENING||NONE||Patients are prospectively assigned to the CEDM /screening intervention which may lead to additional screening or biopsy based on the study schema.||||
33920046|NCT03849976|||CASE_CONTROL||PROSPECTIVE|||||||
33920047|NCT06047899|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||randomized double-blind placebo-controlled cross-over counter-balanced|t|t|t|t
33920048|NCT00797524|||COHORT||PROSPECTIVE|||||||
33920049|NCT05457348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be selected and randomized into two groups after obtaining informed consent. patient will not know about the intervention|Patients will be randomized into experimental and controlled groups|t|f|f|f
33920050|NCT03263156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920051|NCT04970394|||COHORT||PROSPECTIVE|||||||
33920052|NCT01771458|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920053|NCT01224587|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33920054|NCT00259441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33920055|NCT04404010|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33920056|NCT00718107|||CASE_ONLY||CROSS_SECTIONAL|||||||
33920057|NCT02941341|||COHORT||PROSPECTIVE|||||||
33920058|NCT05126745|||COHORT||PROSPECTIVE|||||||
33920059|NCT04613505|||COHORT||PROSPECTIVE|||||||
33920060|NCT06241417|||OTHER||PROSPECTIVE|||||||
33920061|NCT06223438|||COHORT||PROSPECTIVE|||||||
33920062|NCT03533322|||COHORT||CROSS_SECTIONAL|||||||
33920063|NCT00293423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33920064|NCT02577679|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920065|NCT03741725|RANDOMIZED|PARALLEL||SCREENING||NONE||3-arm superiority randomized controlled||||
33920066|NCT01539785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33920067|NCT03689062|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920068|NCT02758223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920069|NCT06356948|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An anesthesiologist or anesthesia assistant not involved in the study will draw up TXA and labelling them based on the randomization.|"prospective, randomized, double-blind, non-inferiority trial.~Arm 1: Intravenous infusion of TXA 1g (10 mL) administered over 1 minute. Arm 2: Intravenous infusion of TXA 1g (10 mL) administered over 10 minutes"|t|t|t|f
33920070|NCT00110578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920071|NCT05308758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be blinded to treatment allocation because of the intervention nature. To avoid contamination between treatment groups, intervention deliverers will be provided with a list of students in the intervention program. Only those on the list can participate in the intervention.||f|f|f|t
33920072|NCT06045949|||COHORT||OTHER|||||||
33920073|NCT01244191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920074|NCT04595396|||COHORT||PROSPECTIVE|||||||
33920075|NCT06401057|||COHORT||PROSPECTIVE|||||||
33920076|NCT03514069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920077|NCT00268099|||||RETROSPECTIVE|||||||
33920078|NCT05796882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the intervention (type of diet) is not possible to mask either the participants or the investigator.|Prospective study, randomized pilot clinical trial.|f|f|f|t
33696709|NCT04962048|NA|SINGLE_GROUP||OTHER||NONE||"After ensuring a comfortable position, each subject will receive treatment with the pulse-synchronized negative pressure (PSNP) device on one randomly chosen lower leg for 120 minutes.The non-invasive imaging (Laser-Doppler Imaging = LD , Hyperspectral Imaging = HS, Thermal Imaging = TH) will be performed before and after the intervention.~This treatment course will be applied twice a day (with 4h +/- 2h in between) for two consecutive days. Toleration of the treatment and wellbeing of the subjects will be assessed by a Visual Analogue Scale.~Finally, another series of imaging (LD, HS, TH) will be performed on the morning of the third day without a prior intervention."||||
33696710|NCT00359918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696711|NCT04180774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Studied therapy - tag-7 gene-modified vaccine (GMV) is administered intradermally at three spots (3 cm from each other) in the paravertebral area 4-6 weeks after surgery in an adjuvant or metastatic setting in patients with melanoma or kidney cancer (4 cohorts in parallel). Treatment with GMV will be administered as described until the patient experiences either unacceptable toxicity or unequivocal disease progression (PD). Biomarkers were assessed at the end of the study.||||
33696712|NCT01737502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696713|NCT04020328|RANDOMIZED|PARALLEL||TREATMENT||NONE|it is a open label trial|the participants who met the inclusion and exclusion criteria were randomly assigned to leflunomide + low dose glucocorticoids treatment group and conservative treatment group in a 1:1 ratio||||
33696714|NCT03396198|||COHORT||PROSPECTIVE|||||||
33696715|NCT02138435|||COHORT||PROSPECTIVE|||||||
33696716|NCT02653534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696717|NCT00892918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801580|NCT06521151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A total of 300 pregnant women will be selected randomly from participants of the baseline survey, and enrolled in four arms in a 1:1:1:1 allocation ratios:|Following the baseline survey, four-arm cluster- randomized controlled trial (cRCT) will be conducted to evaluate the effectiveness of nutrition education and egg-based diet interventions on dietary intake practice, nutrient adequacy, and gestational weight gain among pregnant women and birth weight|t|f|f|f
33920079|NCT02745301|||COHORT||PROSPECTIVE|||||||
33920080|NCT06499727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920081|NCT01071096|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920082|NCT02535832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920083|NCT02990455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33920084|NCT00264446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920085|NCT00742807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920086|NCT06437145|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|HRV parameters analysis will be blinded regarding the exercise training modality.|Each patient will have a bout of HIIT during one session and a bout of MICT during another session performed in a random order.|f|f|f|t
33920087|NCT05533255|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33920088|NCT03052439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants blinded to randomization of order of reintroduction; Investigators blinded to order of reintroduction|Food items will be blindly reintroduced, and symptoms will be measured.|t|f|t|t
33920089|NCT00505895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920090|NCT02697630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920091|NCT05997186|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective case series (pilot study)||||
33920092|NCT03919968|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33920093|NCT00218140|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34000387|NCT04438434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The products will be packaged in such a way that they are not recognizable either by the operator or by the patient. Each package will be assigned a number that in turn will refer to the type of the product. The association between the number and type of the product will be collected by another operator on the basis of the association carried out by a dedicated software. The operator who will deliver the product will be informed about the type only at the end of the treatment.~The data will be collected in pseudonymised form and inserted into a dedicated database in order to carry out the statistical analysis provided."||t|f|t|f
34000388|NCT00686062|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34000389|NCT02490800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000390|NCT00772148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000391|NCT01875120|||COHORT||PROSPECTIVE|||||||
34000392|NCT04881188|||COHORT||PROSPECTIVE|||||||
34000393|NCT06209034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Single(Participant)|||||
34000394|NCT02212457|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34000395|NCT03628807|||COHORT||OTHER|||||||
34000396|NCT00960154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000397|NCT01342991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34000398|NCT05696548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089001|NCT00312442|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000399|NCT02188628|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded therapist assessor to determine clinical outcomes at pre and post treatment and follow up.|H-Man training + conventional therapy vs equal amount of conventional therapy 1:1 allocation|f|f|f|t
34000400|NCT00292227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34000401|NCT02838953|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34000402|NCT01119625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000403|NCT04237688|||COHORT||PROSPECTIVE|||||||
34000404|NCT05337202|||COHORT||PROSPECTIVE|||||||
34000405|NCT03381586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34000406|NCT03126292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34000407|NCT03511976|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785118|NCT06714669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to ensure the management of perioperative anesthesia and the safety of patients, this study is a single-blind study, that is, anesthesiologists know what kind of anesthesia they have received, and carry out anesthesia plans for patients according to groups (group P / R). Participants and postoperative evaluators will not know the grouping of patients.|participants in the experimental group used remimazolam as intravenous anesthetics while participants in the control group used propofol.|t|t|f|f
33785119|NCT03805165|||OTHER||OTHER|||||||
33785120|NCT06310993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785121|NCT02637271|RANDOMIZED|PARALLEL||||NONE||||||
34000408|NCT01476501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785122|NCT06118255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785123|NCT06061484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33785124|NCT00840047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000409|NCT03438916|||COHORT||PROSPECTIVE|||||||
34000410|NCT05172687|||COHORT||RETROSPECTIVE|||||||
34000411|NCT06485518|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34000412|NCT05616455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000413|NCT02786953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34000414|NCT04898816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000415|NCT00000623|||||PROSPECTIVE|||||||
34000416|NCT00914654|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34000417|NCT02230267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000418|NCT02979132|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000419|NCT01097109|||COHORT||CROSS_SECTIONAL|||||||
34000420|NCT04885751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000421|NCT03318133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34000422|NCT00240734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34000423|NCT02417428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696718|NCT04068610|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is designed to concurrently evaluate potential novel combinations with clinical promise using a 2-part approach.~Part 1 is a Phase 1b study of safety, and Part 2 is a Phase 2 study of efficacy and safety. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety outcomes in Part 1.~Following a screening period of up to 28 days, participants will be centrally assigned (Part 1) or randomized (Part 2) to one of the open study arms. In both study parts, study treatment may be administered until disease progression or any discontinuation criteria are met.~In Part 2, experimental arms may be closed early based on futility from results of a planned interim analysis for each study arm. In both parts, new experimental arms consisting of FOLFOX and bevacizumab plus novel agent(s) may be added based on emerging nonclinical and clinical data via protocol amendment."||||
34000424|NCT05993390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34000425|NCT00347048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696719|NCT01251744|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33696720|NCT00597974|||CASE_CONTROL||PROSPECTIVE|||||||
33785125|NCT00005106||PARALLEL||TREATMENT||||||||
33920094|NCT05576480|NA|SINGLE_GROUP||TREATMENT||NONE||This is a two staged, single arm phase II trial of short-course radiotherapy sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable locally advanced rectal cancer. Twenty-three patients will be enrolled in the first phase and if the number of pathological complete remission is ≤ 3, the trial will be terminated; if \> 3, the trial will proceed to the second phase and continue to enroll up to 48 patients. Taking into account a 15% abscission rate, the total number of patients enrolled will be 55.||||
33920095|NCT00282269|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33920096|NCT02817893|||COHORT||PROSPECTIVE|||||||
34000426|NCT00006258||||TREATMENT||||||||
34000427|NCT04784416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000428|NCT03036592|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34000429|NCT06146660|||COHORT||PROSPECTIVE|||||||
34000430|NCT05307276|NA|SINGLE_GROUP||OTHER||NONE||Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).||||
34000431|NCT02392689|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000432|NCT05904639|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|masking of participants to biostatistician.|In this study, we will implement a high quality AHA plant-based diet intervention on cardiac patients and study its effects on GE. We will use a GE-whole genome sequencing (WGS) cluster approach in which we will integrate genetic-biological technologies within pathways associated with CVD to create risk score clusters. We will develop risk scores and identify top (most significant by p value) genetic clusters in common functional pathways. We will further integrate genetic information with clinical factors and CVD risk factors and investigate association with AHA diet.|t|f|f|f
34000433|NCT03645876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000434|NCT00363857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34000435|NCT05457868|||COHORT||RETROSPECTIVE|||||||
34000436|NCT05533151|RANDOMIZED|PARALLEL||TREATMENT||NONE||All study participants will be divided into 3 groups according to their lung disease. Each group should contain 20 patients, who will be randomly split into an intervention and a control group of 10 patients each.||||
34000437|NCT03646409|||COHORT||RETROSPECTIVE|||||||
34000438|NCT02707276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The system can operate in sham mode, with identical sounds to active mode. The system can be programmed to randomize subjects automatically without the knowledge of study staff.|There are two phases. The first, pilot phase was a randomized, double-blinded crossover design. Following review of data from a different Low Field Magnetic Stimulation study (2012P002380) that showed a large order effect from the crossover design, revision of study design was prompted. The study design for this second phase was a randomized, double-blinded sham-controlled parallel design.|t|f|t|f
34000439|NCT02759380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34000440|NCT02285257|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34000441|NCT05339191|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants who are attending the NHS Lanarkshire Community Learning Disability Team and are experiencing mental health difficulties will be recruited. Participants will be asked to attend a two-session workshop through which they will be supported to develop and use their own compassionate image. The research questions will be answered by obtaining descriptive data from data recording sheets completed during the sessions and by interviewing participants about their experiences of the workshop.||||
34000442|NCT01556906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920097|NCT00502320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920098|NCT02133742|NA|||TREATMENT||NONE||||||
33920099|NCT05739760|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696721|NCT04650776|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33696722|NCT05820061|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696723|NCT01689168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696724|NCT02169284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696725|NCT03565913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To provide adequate blinding, each medication sachet will be labelled with the study name, IRB number, principal investigator's name, expiration date and identification number of the study subject. Labels will be applied to the appropriate medication sachets once the subject has been randomized and assigned to a treatment group. Labelling of the sachets will be done by non-patient care personnel.|Subjects will be randomized into two groups in a parallel design. One group will take EffCaMgCit 15 meq (300 mg) Ca, 10 meq Mg (122 mg) and 45 meq total citrate thrice daily, while the other group will take calcium acetate suspension/solution (CaAcS) 15 meq Ca thrice daily for two years.|t|t|t|t
33920100|NCT04521335|NA|SINGLE_GROUP||TREATMENT||NONE||A standard 3+3 dose escalation design will be used to determine the recommended phase 2 dose (RP2D) while ensuring the safety and tolerability of the treatment. Once the RP2D has been assigned in dose-escalation, an expansion cohort will open to the enrollment of 14 additional patients to further characterize the safety and tolerability of the study intervention.||||
33920101|NCT02833220|||COHORT||PROSPECTIVE|||||||
33920102|NCT02289274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920103|NCT05497895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"DESIGN: Double-blinded, parallel, randomized controlled clinical trial. SETTING: Faculty of Dentistry, King Abdulaziz University, and Qassim University, Saudi Arabia PARTICIPANTS AND METHODS: This trial will enroll 63 participants with age group between 18-40 years attending the outpatient clinics of Faculty of dentistry, Qassim University, Saudi Arabia with confirmed clinical diagnosis of gingivitis. The enrolled subjects will be categorized in three groups: Group I-TQ gel with SRP, Group II-Placebo with SRP, and Group III-SRP alone and clinical outcomes will be measured at baseline and two-week follow-up visit.~MAIN OUTCOME MEASURES: Plaque Index (PI), Papillary Bleeding Index (PBI) and any adverse events with TQ gel categorized as mild, moderate, and severe.~SAMPLE SIZE: 63 patients. Group I (n=21); Group II (n=21); Group III (n=21)"|t|t|t|f
33920104|NCT00517335|||CASE_CONTROL||PROSPECTIVE|||||||
33920105|NCT02486211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920106|NCT05186909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920107|NCT04242238|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Standard 3+3 design||||
33920108|NCT04644549|||COHORT||OTHER|||||||
33920109|NCT05456152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920110|NCT05304000|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective||||
33920111|NCT01330563|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920112|NCT05657704|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Phase IV trial and low intervention, multicenter study. Group 1: Tramadol, 100 mg according to clinical practice for the treatment of postoperative pain. Group 2: Dexketoprofen 25 mg according to clinical practice for the treatment of postoperative pain. Experimental group 3: patients in this group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours and Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours||||
33920113|NCT04958304|||COHORT||PROSPECTIVE|||||||
33920114|NCT06195657|||CASE_ONLY||RETROSPECTIVE|||||||
33920115|NCT05688319|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33920116|NCT05956587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920117|NCT03287245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920118|NCT02952703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920119|NCT03862742|||COHORT||PROSPECTIVE|||||||
33920120|NCT00380276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920121|NCT03563456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The assessors for blood measure are not aware of the group of experiment, since the blood samples will not carry any descriptions of the group.~The assessors for physical fitness are not aware of the group of experiment, since the medical record is not provided to the assessors."|randomized controlled trial|f|f|f|t
33920122|NCT05931913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, parents (if applicable), the ERP therapist, the independent evaluator (but not active vs. sham status).|Quadruple-masked Randomized Controlled Trial (RCT) with parallel assignment|t|t|t|t
33920123|NCT00234208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920124|NCT06371339|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33920125|NCT01705964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920126|NCT04912999|||COHORT||PROSPECTIVE|||||||
33920127|NCT05293574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920128|NCT02823678|||CASE_ONLY||PROSPECTIVE|||||||
33920129|NCT00141557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920130|NCT00225290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33920131|NCT05591794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised controlled trial|f|f|t|t
33920132|NCT05061394|||COHORT||CROSS_SECTIONAL|||||||
33920133|NCT00676793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920134|NCT03276013|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, single arm, multi-center, phase II study||||
33920135|NCT04599049|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33920136|NCT05783453|||COHORT||PROSPECTIVE|||||||
33920137|NCT03513250|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A prospective randomized clinical trial|t|t|t|t
33920138|NCT05729425|||CASE_ONLY||PROSPECTIVE|||||||
34000443|NCT01307358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34000444|NCT05472740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and the provider completing the endometrial biopsy will be blinded to what group (intervention or placebo) that the subject is in. The clinical research coordinator assisting with the study and placement of the TENS will not be blinded.||t|t|f|f
34000445|NCT00882245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000446|NCT03155867|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34000447|NCT06207253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696726|NCT03854188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696727|NCT02200783|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696728|NCT01978171|||COHORT||PROSPECTIVE|||||||
33696729|NCT05346250|||COHORT||PROSPECTIVE|||||||
33696730|NCT02215031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33696731|NCT05058352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785126|NCT02770664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785127|NCT06502977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785128|NCT04676802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696732|NCT02687373|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696733|NCT05077527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696734|NCT04163497|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The finaly analysis, by the statistician will be masking.||f|f|f|t
33696735|NCT05266534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blinded Randomized Placebo-Controlled Trial|Double Blinded Randomized Placebo-Controlled Trial|t|t|t|f
33785129|NCT00287573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785130|NCT00270114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785131|NCT05412030|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33785132|NCT01051882|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785133|NCT02157714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785134|NCT05072314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All trial participants, research coordinators, members of the anaesthesia and surgical teams, pharmacists, theatre and ward staff and all individuals performing patient follow up will be blinded to the patient's treatment allocation. All of the trial committees associated with the study will be blinded, with the exception of the Data Safety and Monitoring Committee (DSMC), who will receive unblinded (open) reports from the independent statistician. Unblinding of the patient's treatment allocation will be possible in exceptional circumstances, and a process will be in place to facilitate unblinding requests.||t|t|t|t
33785135|NCT06146101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Phase 2 (3 arms)~1. IHL-42X low dose (2.5mg dronabinol, 125mg acetazolamide)~2. IHL-42X high dose (5mg dronabinol, 250mg acetazolamide)~3. Placebo~Phase 3 (4 Arms)~1. IHL-42X (Optimal dose from phase 2)~2. Dronabinol (equivalent dose strength to that in the IHL-42X optimal dose strength)~3. Acetazolamide (equivalent dose strength to that in the IHL-42X optimal dose strength)~4. Placebo"|t|t|t|t
33785136|NCT03791229|||COHORT||CROSS_SECTIONAL|||||||
33785137|NCT05967403|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Inside the operating, the attending anaesthesiologist will not be blinded to the technique utilized to administer general anaesthesia (GA) and the recovery parameters immediately after extubation. However, the postoperative patient recovery profile will be evaluated by an independent assessor blinded to the GA technique and peri-extubation profile.|"One hundred participants (50/group) aged 18-65 years, ASA physical status I-II, of either sex, and undergoing elective non-cardiac surgery of minimum 60-minutes duration recruitment will be randomly divided into one of the two groups:~Group-1 \[Conventional CLADS (CC) group, n= 50\]: Anaesthesia will be induced and maintained with propofol administered using the automated conventional CLADS.~Group-2 \[Hermetic CLADS (HC) group, n= 50\]: Anaesthesia will be induced and maintained with propofol administered using the hermetic CLADS."|t|f|f|t
33785138|NCT04698291|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785139|NCT00815321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785140|NCT01759979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920139|NCT05972044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920140|NCT00251875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920141|NCT00694629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920142|NCT01889628|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33920143|NCT00318565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920144|NCT03428685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920145|NCT00537264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920146|NCT03495817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920147|NCT00002717|RANDOMIZED|||TREATMENT||||||||
33920148|NCT05552118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920149|NCT03728712|||CASE_CONTROL||PROSPECTIVE|||||||
33920150|NCT02488525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920151|NCT01830816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000448|NCT00714987|||CASE_CONTROL||PROSPECTIVE|||||||
34000449|NCT05190016|||CASE_CONTROL||PROSPECTIVE|||||||
34000450|NCT05575557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000451|NCT03750591|||COHORT||PROSPECTIVE|||||||
33785141|NCT00869570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785142|NCT06714591|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||BL-M11D1 will be administered on Day 1 by intravenous infusion every 28 days.||||
33785143|NCT05553041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920152|NCT01654042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920153|NCT00522574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920154|NCT01811355|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33920155|NCT04034043|||COHORT||RETROSPECTIVE|||||||
34000452|NCT04541173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000453|NCT01182324|||||RETROSPECTIVE|||||||
34000454|NCT01223755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000455|NCT01932905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000456|NCT02279277|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000457|NCT00968916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000458|NCT01087567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000459|NCT02740257|||COHORT||PROSPECTIVE|||||||
34000460|NCT02645487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000461|NCT01686217|RANDOMIZED|PARALLEL||||NONE||||||
34000462|NCT05659316|||COHORT||RETROSPECTIVE|||||||
34000463|NCT03277248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded, active-controlled study|Randomized, multi-center, double-blinded, active-controlled study|t|t|t|t
34000464|NCT03138044|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized and time series clinical trial.||||
34000465|NCT05999916|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The present study aims to assess the safety and feasibility of employing repeated (4 sessions at 4 days) transcranial alternating current stimulation (tACS) through the utilization of the Miamind Neurostimulator in a cohort of healthy participants.||||
33696736|NCT05397873|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The assessor does not know if the patient is in the control group, treatment group or cross over group.|A group of patients have the intervention and another group has control tests. The control group crosses over to the interventional group|f|f|f|t
33696737|NCT03275792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696738|NCT06096935|||COHORT||PROSPECTIVE|||||||
33696739|NCT04297059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920156|NCT01853436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920157|NCT05101395|||COHORT||CROSS_SECTIONAL|||||||
33920158|NCT03235817|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33920159|NCT01396239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920160|NCT05743751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and care provider were blinded to the interventions.||t|t|f|f
33920161|NCT06380712|||COHORT||PROSPECTIVE|||||||
33920162|NCT00789191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920163|NCT00003077|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33920164|NCT00296764|||CASE_ONLY||PROSPECTIVE|||||||
33920165|NCT00123149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920166|NCT04090437|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, double-arm, randomised, observational study that will recruit 20 HCM-AF patients (10 for each group)||||
33920167|NCT05541484|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will test the breath ketone analyzer under usual care conditions followed by usual care plus SGLT2i treatment (GROUP A) or with usual care plus SGLT2i treatment followed by usual care (GROUP B). At the end of each segment, participants will undergo a one-day insulin withdrawal period with more intense monitoring.||||
33920168|NCT00556192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920169|NCT03347812|||COHORT||PROSPECTIVE|||||||
33920170|NCT01108562|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33920171|NCT02853032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920172|NCT06530238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920173|NCT04437173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920174|NCT01503580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920175|NCT02521298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33920176|NCT04343209|||CASE_ONLY||PROSPECTIVE|||||||
33920177|NCT02146248|NA|SINGLE_GROUP||OTHER||NONE||||||
34000466|NCT03709953|NA|SINGLE_GROUP||TREATMENT||NONE||apatinib monotherapy||||
34000467|NCT00156650|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000468|NCT01609270|||COHORT||PROSPECTIVE|||||||
34000469|NCT02573662|||CASE_CONTROL||PROSPECTIVE|||||||
34000470|NCT05659680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000471|NCT00132457|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34000472|NCT04224662|||CASE_ONLY||PROSPECTIVE|||||||
34000473|NCT04440696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000474|NCT02375945|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34000475|NCT03313713|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34000476|NCT01220960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000477|NCT04839107|||COHORT||OTHER|||||||
34000478|NCT01354301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000479|NCT04372524|||COHORT||CROSS_SECTIONAL|||||||
34000480|NCT04260035|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34000481|NCT02955940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000482|NCT01978873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000483|NCT00466531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000484|NCT00002160||||TREATMENT||DOUBLE||||||
34000485|NCT03203642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000486|NCT03021876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000487|NCT03324815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000488|NCT03373630|NA|SINGLE_GROUP||OTHER||NONE||||||
34000489|NCT02515487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34000490|NCT02725619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000491|NCT04485819|||COHORT||PROSPECTIVE|||||||
34000492|NCT04498676|NA|SINGLE_GROUP||SCREENING||NONE||||||
34000493|NCT06173960|||OTHER||RETROSPECTIVE|||||||
34000494|NCT04662476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sachets containing vitamin D will be exactly similar to the ones containing the placebo. Both the intervention and placebo granules will be identical in colour, odour, taste and amount. Children will be randomized into treatment groups by order of entry in the study, based on a pre-determined blinded randomization list created and managed by an independent statistician.|331 children will be randomised to the intervention and another 331 to the placebo.|t|t|t|t
34089002|NCT05850715|||COHORT||CROSS_SECTIONAL|||||||
34089003|NCT01413802|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089004|NCT05091255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089005|NCT03858322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089006|NCT03025204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089007|NCT00540917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089008|NCT03653481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089009|NCT06222307|RANDOMIZED|PARALLEL||OTHER||SINGLE|One (Participant)|Parallel Assignment|t|f|f|f
34089010|NCT02572167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089011|NCT05709613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data extraction will be fully automated and the statistician will not know the identity of the participants or the sequence they were allocated to.||f|f|f|t
34089012|NCT04428749|||COHORT||PROSPECTIVE|||||||
34089013|NCT01311323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089014|NCT06433284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089015|NCT01462604|||CASE_ONLY||PROSPECTIVE|||||||
34089016|NCT05473845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089017|NCT01385605|||OTHER||OTHER|||||||
34089018|NCT03866694|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is used in this clinical trial.|Participants in this randomized controlled trial are assigned to one of two groups, BRIGHT or STAR. BRIGHT is a therapeutic parenting intervention that begins in the third trimester of pregnancy and continues through six months postpartum. BRIGHT and STAR receive the standard of care at a high risk maternal-fetal medical clinic and 7 psycho-educational handouts over the course of the study.||||
34089019|NCT01374737|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34089020|NCT05887492|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 (Dose Escalation) and Phase 2 (Dose Expansion)||||
34089021|NCT00424008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34089022|NCT04765904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|not possible, since interventions are different|||||
34089023|NCT03012737|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785144|NCT06711406|||COHORT||PROSPECTIVE|||||||
34089024|NCT05285007|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33785145|NCT05974826|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920178|NCT03617029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920179|NCT01947959|||COHORT||PROSPECTIVE|||||||
34089025|NCT02551146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089026|NCT03598296|RANDOMIZED|PARALLEL||TREATMENT||NONE||Total 60 patients accept video-Assisted thoracoscopic lobectomy are divided into two groups(Group A and Group B) equally and randomly.Different group takes different chest tube managements.||||
34089027|NCT06003764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, single blinded controlled trial|t|f|f|f
34089028|NCT04172233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696740|NCT00037960|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696741|NCT02595359|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33696742|NCT06680739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696743|NCT05790083|NA|SINGLE_GROUP||OTHER||NONE|Trade name of products was masked|||||
33696744|NCT06677567|||CASE_CONTROL||PROSPECTIVE|||||||
33696745|NCT04986644|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Clinician masking achieved by clinic coordinator dispensing lenses. Open label to participants.|Randomized cross-over with 1 week of lens wear with each contact lens type.|f|f|t|f
33696746|NCT02797015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33696747|NCT04409600|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants are masked to treatment injection arm. At 3 months post-injection, the treatment injection arm will be revealed to the participant.||t|f|f|f
33920180|NCT03117530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920181|NCT00562653|||CASE_CONTROL||PROSPECTIVE|||||||
33920182|NCT04297826|NA|SINGLE_GROUP||OTHER||NONE||||||
33920183|NCT01793519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920184|NCT02658344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920185|NCT00003856||||TREATMENT||||||||
33920186|NCT05393076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label study|This phase 1 study is an open-label, non-randomized, single-dose linerixibat study with 2 cohorts (moderate hepatic impairment and matched healthy control participants).||||
33920187|NCT01788982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920188|NCT01249534|||COHORT||RETROSPECTIVE|||||||
33920189|NCT03344848|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33920190|NCT02085057|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34000495|NCT03461341|||COHORT||RETROSPECTIVE|||||||
34000496|NCT02093377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000497|NCT05079230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000498|NCT05816655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000499|NCT00411268|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000500|NCT06505005|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized, double-blind, placebo controlled, crossover trial with functional measurements|t|t|f|t
34000501|NCT05626348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000502|NCT00160524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785146|NCT05743881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Parts A and B are blinded, and Part C is open-label.||t|f|t|t
33785147|NCT06120582|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785148|NCT05905289|||OTHER||RETROSPECTIVE|||||||
33785149|NCT05144789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785150|NCT05618652|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients and their caregivers will not know whether their clinical team has received or not yet received the communication intervention. Additionally, team members who assess outcomes (coding of audio-recorded transcripts) will be blinded to the clinical team intervention status.|The investigators will test the intervention in a randomized pilot with intervention and waitlist control arms. Half the clinical teams will receive the clinician communication intervention immediately upon enrollment and half will receive the intervention after 6 months. The investigators will assess recruitment, enrollment, and data collection feasibility as well as intervention fidelity to evaluate feasibility of implementation and skill uptake using audio-recordings of rounds. The investigators will develop a semi-structured interview and survey to assess acceptability as well as facilitators/barriers to implementation.|t|f|f|t
33785151|NCT05320796|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Esomeprazol administered in tablets (Esomeprazol MUT Sandoz® 40mg) ¨ or in solution (Esomeprazol MUT Sandoz® 40mg in 10ml tap water)|f|f|t|f
33785152|NCT00138632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33785153|NCT04878380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33785154|NCT03061344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785155|NCT06413303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33785156|NCT04762342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785157|NCT02938650|NA|SINGLE_GROUP||TREATMENT||NONE||15 healthy controls will participate in the study Another set of healthy controls (n=20) will be recruited so that they participate in blood draws.||||
33785158|NCT04449406|||COHORT||PROSPECTIVE|||||||
33785159|NCT01743729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785160|NCT03392337|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33785161|NCT02055482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785162|NCT06361940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785163|NCT01794377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785164|NCT03201809|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups, conventional treatment versus experimental treatment; blocked randomization scheme||||
33785165|NCT02983214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33785166|NCT06025734|NA|SINGLE_GROUP||OTHER||NONE||||||
33785167|NCT06631274|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||We are using a waitlist control model where half of the participants will be randomly assigned to the treatment condition. When that intervention is completed, the treatment will be offered to the waitlist participants.||||
33785168|NCT06487325|||COHORT||RETROSPECTIVE|||||||
33785169|NCT00506519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785170|NCT03596424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785171|NCT02223793|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33785172|NCT06508723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, controlled, prospective|t|f|f|f
34000503|NCT00210639|||COHORT||PROSPECTIVE|||||||
34000504|NCT00396630|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34000505|NCT02946255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34000506|NCT01978964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000507|NCT05799235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000508|NCT05634941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000509|NCT00916045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000510|NCT03831490|||COHORT||PROSPECTIVE|||||||
34000511|NCT01837537|||COHORT||PROSPECTIVE|||||||
34000512|NCT02002130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785173|NCT00928200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785174|NCT06063850|NA|SEQUENTIAL||TREATMENT||NONE||||||
33785175|NCT02502162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920191|NCT05942729|||COHORT||RETROSPECTIVE|||||||
33920192|NCT03529123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920193|NCT03262675|||COHORT||PROSPECTIVE|||||||
33920194|NCT04489927|||COHORT||PROSPECTIVE|||||||
33920195|NCT04990661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33920196|NCT01527019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920197|NCT04663984|||COHORT||RETROSPECTIVE|||||||
33920198|NCT03833817|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33920199|NCT04090905|||COHORT||PROSPECTIVE|||||||
33920200|NCT06017648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920201|NCT02521688|||CASE_CONTROL||RETROSPECTIVE|||||||
33920202|NCT06079866|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Both masks (Oran Park Mask and Evora Mask (Mask A and Mask B)) will be worn for a period of 7 nights sequentially. Participants will complete a series of questionnaires upon completion.||||
33920203|NCT06461312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920204|NCT05331456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Stepped wedge cluster randomized trial|f|f|f|t
33920205|NCT03609736|||COHORT||PROSPECTIVE|||||||
33920206|NCT05020093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors and statistician are blinded for the type of restoration placed||f|f|f|t
33920207|NCT04041908|NA|SINGLE_GROUP||OTHER||NONE||||||
33920208|NCT00995670|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089029|NCT03788330|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34000513|NCT03878550|||CASE_CONTROL||PROSPECTIVE|||||||
34000514|NCT01426334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000515|NCT04619225|NA|SINGLE_GROUP||OTHER||NONE||||||
34000516|NCT00494741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089030|NCT02490579|||COHORT||PROSPECTIVE|||||||
34089031|NCT01949896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089032|NCT04857177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696748|NCT03234777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34089033|NCT04796467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089034|NCT01785901|||CASE_ONLY||CROSS_SECTIONAL|||||||
34089035|NCT02934178|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696749|NCT05914922|RANDOMIZED|PARALLEL||OTHER||NONE||Phase I pertained to the development of authentic MSK case presentations. These cases were formulated into case presentations and a full content review was completed for each of the 20 MSK conditions. Phase II will now assess the impact of the case simulations on learning and patient care.||||
33696750|NCT00484627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33696751|NCT06680310|||OTHER||PROSPECTIVE|||||||
33785176|NCT04879134|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Upon entry to the study, all subjects will be assigned to a subject number. Eligible subjects will be randomized to receive either apomorphine injections or placebo on VISIT 2 in a double-blind manner according to a randomization schedule using computerized randomization tables prepared by a blinded clinical nurse. Participants will then cross over to the other treatment group to receive apomorphine or placebo injections on VISIT 3. The specific type of randomization used will be block randomization to ensure equal sample sizes of the apomorphine and placebo groups|We will perform a small pilot double-blind, randomized cross-over study evaluating the safety and efficacy of apomorphine injections vs. placebo injections on pain in PD. Subjects, caregivers, and investigators will be blinded to the assignment.|t|t|t|f
33696752|NCT03356054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785177|NCT02454907|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33696753|NCT04926376|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33696754|NCT00752024|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696755|NCT05503628|||COHORT||CROSS_SECTIONAL|||||||
34000517|NCT00481169|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34000518|NCT03806491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The project manager will inform study therapists of participant assignment to conditions. PI Miller and study therapists will be blinded to assessment outcomes, and the assessment RA will be blinded to participant condition.|In addition to Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT-AUD), participants will be randomized to receive sleep education or to participate in 5 individual sessions of Cognitive Behavioral Therapy for Insomnia (CBT-I).|t|f|f|t
34000519|NCT04891692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000520|NCT04893590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000521|NCT05358808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089036|NCT01811719|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34089037|NCT01250938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089038|NCT01560702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089039|NCT00054288|NON_RANDOMIZED|||TREATMENT||NONE||||||
34089040|NCT04002895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089041|NCT03646539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089042|NCT03101345|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089043|NCT02572154|NON_RANDOMIZED|PARALLEL||||NONE||||||
34089044|NCT05112705|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34089045|NCT02857153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089046|NCT01144832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089047|NCT01050153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089048|NCT03149315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089049|NCT00527059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696756|NCT04118933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696757|NCT06294236|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696758|NCT00147251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089050|NCT02130219|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34089051|NCT00808704|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34089052|NCT01865773|NA|SINGLE_GROUP||||NONE||||||
34089053|NCT04170413|||COHORT||PROSPECTIVE|||||||
34089054|NCT05964322|||CASE_ONLY||RETROSPECTIVE|||||||
34089055|NCT05092087|||CASE_ONLY||RETROSPECTIVE|||||||
34089056|NCT06524518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34089057|NCT06270615|||COHORT||OTHER|||||||
34089058|NCT05123950|||COHORT||RETROSPECTIVE|||||||
34089059|NCT00253942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089060|NCT06342882|||COHORT||CROSS_SECTIONAL|||||||
33785178|NCT06712498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33785179|NCT05766098|||COHORT||PROSPECTIVE|||||||
33785180|NCT03001362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785181|NCT06410508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will not be randomized to study conditions due to recruitment difficulties and ethical concerns related to randomizing participants to a condition that has previously been demonstrated to be efficacious. Instead, participants wanting to engage in the intervention will be included in the active treatment arm and those wishing to recieve treatment as usual will be included as controls. See description of study protocol above for more detailed explanation of interventional study design.||||
33785182|NCT04171661|NA|SINGLE_GROUP||TREATMENT||NONE||n-of-one||||
33785183|NCT03307746|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient will be randomised into Arm A (20 patients) or Arm B (20 Patients)||||
33785184|NCT06048341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33785185|NCT06345105|||COHORT||PROSPECTIVE|||||||
33920209|NCT03930420|RANDOMIZED|PARALLEL||PREVENTION||NONE||The research team will use a hybrid type III study design to conduct a randomized controlled trial (RCT) comparing the effect of standard Connect to Wellness training and TA to the effect of training plus enhanced TA on primary outcomes.||||
33920210|NCT05632224|RANDOMIZED|PARALLEL||PREVENTION||NONE||group 1:patient who receive aprepitant group 2: patient who receive granisetron||||
33920211|NCT04585451|||CASE_CONTROL||PROSPECTIVE|||||||
33920212|NCT00151125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920213|NCT01692912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33920214|NCT00155194|||DEFINED_POPULATION||PROSPECTIVE|||||||
33920215|NCT02855320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33920216|NCT02993055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920217|NCT02601443|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33920218|NCT05903937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920219|NCT00059618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920220|NCT02401243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920221|NCT01766479|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|t|f|f
33920222|NCT03260972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator and patients will be masked from the treatment options. The care providers will not be masked.|"Patients admitted for cesarean section and meeting inclusion criteria will be approached for consent. Consented patients will then be randomized into two groups.~Group 1: (intraabdominal chloroprocaine administration): These participants will have intraabdominal chloroprocaine administration at the time of cesarean section before fascial closure.~Group 2: (Intraabdominal instillation of placebo (sterile water): These participants will have placebo (normal saline) administered at the time of cesarean section before fascial closure. Cesarean section will proceed traditionally, including fascial and skin closure."|t|f|t|t
33920223|NCT02921763|||COHORT||PROSPECTIVE|||||||
33920224|NCT00143975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920225|NCT02397603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33920226|NCT01076738|||COHORT||PROSPECTIVE|||||||
33920227|NCT00406991|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33920228|NCT02976727|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33920229|NCT04284280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33920230|NCT02287402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920231|NCT02056717|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920232|NCT04649762|||COHORT||PROSPECTIVE|||||||
33920233|NCT01094951|NA|SINGLE_GROUP||OTHER||NONE||||||
33920234|NCT03398746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920235|NCT06480188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Device: Deep Brain Stimulation (DBS) of Gpi，PINS G106R Device: Deep Brain Stimulation (DBS) of STN，PINS G106R|t|f|t|t
33920236|NCT03703271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920237|NCT00965406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920238|NCT05971953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920239|NCT05474911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920240|NCT02729077|||COHORT||PROSPECTIVE|||||||
33920241|NCT04325945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33920242|NCT01590862|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920243|NCT04250012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920244|NCT02325817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920245|NCT00187629|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33920246|NCT00518232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920247|NCT00691093|||CASE_ONLY||PROSPECTIVE|||||||
33920248|NCT04385147|||COHORT||PROSPECTIVE|||||||
33920249|NCT06105567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The research will be conducted as a pretest-posttest randomized controlled study.|t|f|f|f
33920250|NCT02370940|RANDOMIZED|PARALLEL||||NONE||||||
33920251|NCT05046678|||CASE_CONTROL||PROSPECTIVE|||||||
34089061|NCT01735812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089062|NCT03042481|||COHORT||PROSPECTIVE|||||||
34089063|NCT06478914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind blinded randomized controlled trial||t|f|f|f
34089064|NCT00549055|||COHORT||OTHER|||||||
33785186|NCT01189955|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33785187|NCT06487364|||COHORT||PROSPECTIVE|||||||
33785188|NCT06313528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor-blind||t|f|t|f
33785189|NCT05862285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785190|NCT06614374|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33785191|NCT05099965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785192|NCT05464108|||OTHER||PROSPECTIVE|||||||
33785193|NCT05247840|||CASE_CONTROL||PROSPECTIVE|||||||
33785194|NCT03528629|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785195|NCT00182520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785196|NCT06634537|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Longitudinal|f|f|t|f
33785197|NCT00224796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785198|NCT06576895|||CASE_CONTROL||PROSPECTIVE|||||||
33785199|NCT05446389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only one person (the primary investigator, who will be implementing the intervention) will be unmasked for this study.|This study will utilize a clinical trial design. Participants will be randomized into two groups. One group will receive the PAL intervention, the other group serving as a no contact control. Participants will be matched based on sex, gestational age at birth, and neurologic injury. Infants in the intervention group will receive two PAL sessions a week until successfully transitioned to \<2L of respiratory support and then receive one PAL session within 24 hours of their first oral feeding attempt.|t|t|f|t
33785200|NCT06629558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785201|NCT06043271|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible participants will be randomized (1:1 allocation ratio) to receive the EMPOWER Program single session intervention (SSI) or to have their child remain on the clinic waitlist as usual.||||
33785202|NCT06530667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785203|NCT05515094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785204|NCT06712082|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33785205|NCT02837380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785206|NCT05407519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785207|NCT05588791|||OTHER||PROSPECTIVE|||||||
33785208|NCT03191955|||COHORT||PROSPECTIVE|||||||
33785209|NCT05569486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785210|NCT05705167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785211|NCT03519373|||CASE_CONTROL||PROSPECTIVE|||||||
33920252|NCT05511818|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
33920253|NCT01214941|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33920254|NCT03796234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920255|NCT01974986|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33920256|NCT03602261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920257|NCT02652312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33920258|NCT03894098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920259|NCT03744182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920260|NCT00405821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920261|NCT03161795|||OTHER||PROSPECTIVE|||||||
33920262|NCT06185569|||COHORT||RETROSPECTIVE|||||||
33920263|NCT02373241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920264|NCT05424991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This study was conducted as a randomized controlled trial.|t|t|t|t
33920265|NCT02107430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920266|NCT03130023|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33920267|NCT04745195|||COHORT||PROSPECTIVE|||||||
33920268|NCT04314518|||COHORT||PROSPECTIVE|||||||
33920269|NCT00889070|||COHORT||PROSPECTIVE|||||||
33920270|NCT03806634|||COHORT||RETROSPECTIVE|||||||
33920271|NCT03686865|||COHORT||PROSPECTIVE|||||||
33920272|NCT05022745|RANDOMIZED|PARALLEL||TREATMENT||NONE|The interventions described in the patient information brochure make masking impossible|Randomized controlled study in patients undergoing PLIA||||
33920273|NCT04093362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920274|NCT00553345|RANDOMIZED|||PREVENTION||DOUBLE||||||
33920275|NCT05872295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33920276|NCT02658201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920277|NCT05508685|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920278|NCT00333619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33920279|NCT01326117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785212|NCT06625151|RANDOMIZED|PARALLEL||TREATMENT||NONE||The four conditions will be: (a) waitlist control condition, (b) PCPM-EFI, (c) PERPM-EFI, and (d) PCPM-EFI plus PERPM-EFI.||||
33785213|NCT06628739|||COHORT||RETROSPECTIVE|||||||
33785214|NCT04994262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33785215|NCT04466566|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33785216|NCT06162351|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase II study||||
33785217|NCT01273701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785218|NCT03748732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||surgery||||
33920280|NCT06372054|||COHORT||PROSPECTIVE|||||||
33920281|NCT01891422|||COHORT||OTHER|||||||
33920282|NCT02104999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920283|NCT00643604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920284|NCT05977153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33920285|NCT00881361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920286|NCT06396572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomization trial||||
33920287|NCT03534726|||COHORT||PROSPECTIVE|||||||
33920288|NCT03619291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920289|NCT03728140|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33920290|NCT01812486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920291|NCT04046341|NA|SINGLE_GROUP||TREATMENT||NONE||Caregiver-child dyads (child ages 1-5 years with a sleep problem) will be recruited from CHOP urban primary care sites.||||
34089065|NCT02309359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089066|NCT04626505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34089067|NCT02383615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34089068|NCT00817791|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34089069|NCT05013801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920292|NCT06123910|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33920293|NCT03968341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920294|NCT03111264|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|One third of recruited childcare centers (control) will not receive any intervention (CHAMP nor CHAMP+). The remaining two-thirds of the recruited centers will receive the CHAMP intervention, of those, one third will also receive the CHAMP+ parenting intervention.|The investigators will examine the impact of the teacher-led CHAMP intervention individually and combined with a CHAMP+ parenting intervention versus control on child BMI z-score, food tasting, food preferences and knowledge, gross motor skills, and physical activity.|t|f|f|f
33920295|NCT01324609|||COHORT||PROSPECTIVE|||||||
33920296|NCT04449783|||COHORT||PROSPECTIVE|||||||
33920297|NCT03106948|RANDOMIZED|PARALLEL||TREATMENT||NONE||subjects will be assigned in an open labeled manner to Group 1 (Placebo), Group-2 (Ascorbic Acid), or Group-3 (Ascorbic acid \& D-penicillamine). Thus, there will be 10 placebo controls, 10 ascorbic acid patients, and 10 ascorbic acid and D-penicillamine patients. Subjects treated with ascorbic acid in combination with D-penicillamine may have the longest periods between serial angioplasties. Moreover, subjects receiving combination therapy may have greater post-angioplasty luminal diameters.||||
33920298|NCT00771173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920299|NCT00243958|||CASE_CONTROL||OTHER|||||||
33920300|NCT00333697|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920301|NCT04408066|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A Sample Collection \& Performance Evaluation Study.||||
33920302|NCT01623700|||COHORT||RETROSPECTIVE|||||||
33920303|NCT03136770|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33920304|NCT03302208|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33920305|NCT00656162|||COHORT||PROSPECTIVE|||||||
33920306|NCT05960110|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will be blinded to the treatment allocation of the participants. Coded data sheets are used to maintain the blinding|A parallel randomized single-blinded clinical trial|f|f|f|t
33920307|NCT03716518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920308|NCT02209649|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920309|NCT02420223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33920310|NCT04975542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920311|NCT02967094|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33920312|NCT02674672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920313|NCT03508661|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33920314|NCT06459622|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33920315|NCT02517853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33920316|NCT00935337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920317|NCT03472274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920318|NCT04663139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization list will be generated by a statistician not involved in the study using randomly permuted blocks and will be stratified by BMI category (overweight or obese) and sex.|"This study is designed as a First in Human, Phase I, clinical trial evaluating safety, tolerability and the impact on the gut microbiota of Xla1. The study will be performed in 2 parts:~Part 1: An open label phase in normal weight healthy adult volunteers receiving Xla1.~Part 2: A randomized, parallel, double-blind, placebo-controlled phase I in overweight and class 1 obese adult patients receiving either Xla1 or placebo."|t|t|t|t
33920319|NCT01238406|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920320|NCT01811901|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33920321|NCT00200018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920322|NCT00237445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33920323|NCT01896908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33920324|NCT05804448|||COHORT||PROSPECTIVE|||||||
34089070|NCT03977480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920325|NCT01546285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920326|NCT05454722|NA|SINGLE_GROUP||OTHER||NONE||||||
34089071|NCT05571813|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089072|NCT03946527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089073|NCT00468832|||CASE_CONTROL||PROSPECTIVE|||||||
33920327|NCT04105569|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920328|NCT04395963|||COHORT||PROSPECTIVE|||||||
33920329|NCT00399594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33920330|NCT01590394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920331|NCT03602534|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920332|NCT00866892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920333|NCT04765436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|observer-blinded||t|t|t|t
33920334|NCT00001906||||TREATMENT||||||||
33920335|NCT05256082|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33920336|NCT04419818|||CASE_CONTROL||PROSPECTIVE|||||||
33920337|NCT04037917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920338|NCT05555836|||COHORT||PROSPECTIVE|||||||
33920339|NCT00525408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089074|NCT02987868|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33785219|NCT05635331|||COHORT||PROSPECTIVE|||||||
33785220|NCT06510686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785221|NCT02091245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785222|NCT03404609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785223|NCT06711874|||COHORT||RETROSPECTIVE|||||||
33785224|NCT06429618|||COHORT||PROSPECTIVE|||||||
33785225|NCT04678128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33920340|NCT04529434|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an open-label household randomised controlled trial that will compare the 110 novel-design houses with 440 traditional African homes.||||
33920341|NCT05225051|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33920342|NCT05386121|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33920343|NCT05393921|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be a randomized clinical trial. The study team is interested in approaching and recruiting patients who were referred for HoLEP surgery for their urinary symptoms and also eligible for intravesical Botox injections. This cohort of patients will be recruited and randomized into two groups: a control group that would undergo HoLEP procedure only, and an experimental group that will undergo HoLEP procedure combined with an intravesical Botox injection.~This study will utilize a 1:1 randomization scheme to assign participants to either the control group or the experimental group. Participants will not be blinded to the procedure they are receiving. No one on the study team including those involved in data analysis will be blinded to the study arm assignment. The investigators plan to recruit a maximum of 50 participants in each arm.~The study's intervention is whether Botox injections are added during the surgery or not."||||
33920344|NCT03654755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920345|NCT02353039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920346|NCT01841528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920347|NCT02679443|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920348|NCT06189170|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33920349|NCT03302897|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920350|NCT01992848|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33920351|NCT00282568|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33920352|NCT00801853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920353|NCT04027101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multicenter double blinded randomized placebo controlled trial|t|f|t|f
33920354|NCT04111107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920355|NCT03637686|||COHORT||PROSPECTIVE|||||||
33920356|NCT05733364|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized, double-blind, placebo-controlled, 2-arm, cross over trial. Participants will receive both the investigational product and placebo, each administered separately for a duration of 28 days, separated by a washout period of 28 days.|t|f|t|t
33920357|NCT05304741|||OTHER||PROSPECTIVE|||||||
33920358|NCT04156828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920359|NCT04247815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded placebo drug is packaged to match the active study drug and will be stored under the same conditions.|Randomized, investigator and patient-blind, sponsor-unblinded, parallel group.|t|t|t|t
33920360|NCT05001061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920361|NCT00956215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33920362|NCT01894477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920363|NCT01811381|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33920364|NCT01608282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33920365|NCT04229472|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33920366|NCT01648829|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33920367|NCT00084942||||TREATMENT||NONE||||||
33920368|NCT01996891|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33920369|NCT03140423|RANDOMIZED|PARALLEL||PREVENTION||NONE||Non-inferiority cluster randomized controlled trial||||
33920370|NCT00761683|||COHORT||PROSPECTIVE|||||||
33920371|NCT00709033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920372|NCT05301023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920373|NCT00050986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920374|NCT05806021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920375|NCT05615766|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||f|f|t|f
33920376|NCT03987334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089075|NCT06531694|||COHORT||PROSPECTIVE|||||||
34089076|NCT01873144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089077|NCT00324155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089078|NCT02061657|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34089079|NCT01829347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696759|NCT06174064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized to protocol 1, 2, or sham but will not be aware of their assignment; investigators grading dry eye at baseline and after treatment will not be aware of which protocol the patients underwent.|Participants will be randomized to three arms: protocol 1, 2, and sham|t|f|t|f
34089080|NCT06091319|||COHORT||PROSPECTIVE|||||||
34089081|NCT04685811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089082|NCT02332759|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33696760|NCT03903601|||COHORT||RETROSPECTIVE|||||||
33696761|NCT05145192|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33696762|NCT02326675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696763|NCT00915356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696764|NCT03272516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigator will contact all participants in both groups via email or telephone to ask them to answer questionnaires.The investigator will not have information about which group which participant is. Participants will be contacted and invited to answer a questionnaire before, after, 6 and 18 months after 8 weeks of TAU and TAU plus MBCT.|"Randomized clinical trial, where patients are randomized to two groups. Group 1 receives treatment as usual, group 2 receives treatment as usual plus Mindfulness Based Cognitive Therapy (MBCT) for symptoms of mild to moderate depression or anxiety.~Our primary aim is to investigate whether MBCT added to TAU is more effective than TAU alone in reducing mild to moderate symptoms of depression and/or anxiety among primary care patients.~Our secondary aim is to investigate whether MBCT added to TAU is more effective than TAU alone in:~1. Increasing subjective wellbeing~2. Reducing antidepressant/anxiolytica use for primary care patients, with mild to moderate symptoms of depression and/or anxiety."|f|f|t|f
33696765|NCT05967026|||COHORT||RETROSPECTIVE|||||||
33696766|NCT01977937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696767|NCT00586066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696768|NCT05068310|||CASE_CONTROL||PROSPECTIVE|||||||
33920377|NCT03176173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920378|NCT00055536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33920379|NCT02584465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920380|NCT02394808|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33920381|NCT00213980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920382|NCT05510206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920383|NCT01292044|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920384|NCT01452178|||COHORT||PROSPECTIVE|||||||
33920385|NCT03700736|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33920386|NCT02374034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920387|NCT02747771|||CASE_ONLY||PROSPECTIVE|||||||
33920388|NCT01911299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33920389|NCT01352065|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33920390|NCT01188525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920391|NCT01682577|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33920392|NCT01824693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920393|NCT01911143|||COHORT||RETROSPECTIVE|||||||
33920394|NCT04925518|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients are initially mechanically ventilated with a conventional mechanical ventilation mode after ECMO installation, once steady state on the conventional mode is achieved for several hours, switch to the closed loop ventilation mode.||||
33920395|NCT01261546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920396|NCT05092295|||COHORT||PROSPECTIVE|||||||
33920397|NCT03812588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920398|NCT04060576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33920399|NCT05534035|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33920400|NCT05421221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33920401|NCT03332472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920402|NCT00451750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920403|NCT01790711||PARALLEL||TREATMENT||NONE||||||
33920404|NCT02604862|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33920405|NCT00869388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920406|NCT01756872|||COHORT||PROSPECTIVE|||||||
33920407|NCT02555657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920408|NCT03562754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920409|NCT06364761|||CASE_ONLY||CROSS_SECTIONAL|||||||
33920410|NCT01381718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33785226|NCT05203172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Each participant will continue to receive the same study treatment regimen at the same dose level as that received in the Parent Studies.~The details of study intervention and duration of treatment are specified in the applicable Encorafenib/Binimetinib Continuation Sub-Study Protocol."||||
33785227|NCT06137469|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE||This study is a single-center, randomized, double-blind, placebo-controlled, crossover study. Healthy subjects were randomly assigned to receive SHR20004 or placebo treatment. In the group receiving SHR20004, the pharmacokinetic changes of acetaminophen were compared before and after treatment with SHR20004.|t|t|t|t
33785228|NCT00389519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785229|NCT03356132|||COHORT||PROSPECTIVE|||||||
33785230|NCT02998827|NON_RANDOMIZED|PARALLEL||||NONE||||||
33785231|NCT06650787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785232|NCT00241644|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785233|NCT00521716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785234|NCT06295796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785235|NCT05553119|||COHORT||PROSPECTIVE|||||||
33785236|NCT05512390|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785237|NCT00108524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785238|NCT04542590|||COHORT||PROSPECTIVE|||||||
33785239|NCT05052983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33785240|NCT00221351|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33785241|NCT04962334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785242|NCT01154556|||||RETROSPECTIVE|||||||
33785243|NCT06364137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33785244|NCT06411145|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study, hence masking is not applicable|Cenegermin-bkbj (20 mcg/mL) ophthalmic solution contained in a multiple-dose vial. The topical drops are administered 6 times/day for a 6-week course.||||
33785245|NCT04689698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785246|NCT05599360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785247|NCT06485596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785248|NCT02746900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785249|NCT04857944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"After assignment to study conditions, participants and investigators will be blinded to one aspect of the specific experimental intervention (receiving or not motivational messages). Both will know whether participants have been allocated to experimental or control conditions but the specific experimental intervention (A or B) will not be revealed. To avoid assessment bias, an independent evaluator blinded to group allocation will complete follow-up assessments.~Clinicians, principal investigators, and statisticians will be also blinded to the randomization procedure and group allocation."||t|f|t|t
33785250|NCT00361309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785251|NCT05634213|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33785252|NCT00142766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785253|NCT00903721|||COHORT||PROSPECTIVE|||||||
33785254|NCT05964257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785255|NCT05304520|||COHORT||PROSPECTIVE|||||||
33785256|NCT02292043|||CASE_ONLY||PROSPECTIVE|||||||
33785257|NCT03999944|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Central sleep study scorer will be masked to assignment group|Prospective, open-label, randomized crossover assignment, multi-center study conducted in the United States|f|f|f|t
33785258|NCT04863885|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785259|NCT04713514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785260|NCT01683695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785261|NCT03879447|||CASE_ONLY||PROSPECTIVE|||||||
33920411|NCT06372886|||COHORT||RETROSPECTIVE|||||||
33920412|NCT05216068|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920413|NCT06521866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920414|NCT03040765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920415|NCT03143556|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920416|NCT03721237|NA|SINGLE_GROUP||OTHER||NONE||||||
33920417|NCT02356393|||CASE_CONTROL||PROSPECTIVE|||||||
33920418|NCT05896046|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33920419|NCT02229110|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920420|NCT01925651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920421|NCT01515280|||CASE_ONLY||CROSS_SECTIONAL|||||||
33920422|NCT06252857|||COHORT||PROSPECTIVE|||||||
33920423|NCT02709928|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33920424|NCT00703469|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33920425|NCT03277703|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920426|NCT03028584|||CASE_ONLY||PROSPECTIVE|||||||
33920427|NCT04527276|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||All patients were consecutively randomized (1:1) to receive either 0.12% CHX rinse solution or placebo applications using a computer generated balanced randomization table.|t|t|f|f
33920428|NCT02139384|||CASE_ONLY||PROSPECTIVE|||||||
33920429|NCT05336006|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33920430|NCT00339885|||CASE_CONTROL||OTHER|||||||
33920431|NCT06139861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33920432|NCT05871021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920433|NCT02312583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920434|NCT03209440|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||a 6-site, pre/posttest, randomized, controlled 4-step, stepped-wedge design to compare the effects of usual outpatient palliative care (arm 1) and usual outpatient palliative care along with nurse-led (arm 2) or chaplain-led (arm 3) DT on patient outcomes and palliative care processes. The study team will assign the 6 sites to usual care during the first-step period (approximately 12 months), and randomly assign 2 sites per step to begin and continue DT during each of the next 3 steps (12 months each).||||
33920435|NCT04007601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33920436|NCT02892825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33920437|NCT00039468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920438|NCT04771988|||COHORT||PROSPECTIVE|||||||
33920439|NCT02767856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920440|NCT04406935|RANDOMIZED|PARALLEL||OTHER||NONE||This is a Multi-arm, prospective, multi-center, baseline-controlled study, designed to evaluate the safety and efficacy of the NuEra Tight for circumferential reduction of the abdomen area at three different frequencies.||||
33920441|NCT04929756|||COHORT||PROSPECTIVE|||||||
33920442|NCT00992732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920443|NCT00010101|||CASE_ONLY||CROSS_SECTIONAL|||||||
33920444|NCT03355729|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33920445|NCT03033251|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will receive 2 treatments (non invasive ventilation and high flow nasal cannula). The high flow nasal cannula will be applied with 2 flows (50 L/min and 30 L/min). The order of application of the 2 high flow sequences will be randomized (sealed opaque enveloppes).||||
33920446|NCT00555906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920447|NCT00592657|||CASE_CONTROL||RETROSPECTIVE|||||||
33920448|NCT02115113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920449|NCT03406910|||COHORT||PROSPECTIVE|||||||
33920450|NCT05998655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|In the data collection process, double-blindness will be ensured by not specifying which group the interviewer collects data from and which group the participants are from.|Randomization will be made on a day-by-day basis due to the possibility of patients interacting in the outpatient clinic and waiting room during the research process. Before starting the research, a coin will be tossed to determine which group will be included on which day. If the money comes in summer, the patients who come on the first day will be taken to the experimental group, the patients who come on the second day will be taken to the control group. In the case of heads, the patients who come on the first day will be included in the control group, and the patients who come on the second day will be included in the experimental group.|t|t|t|t
33920451|NCT00503542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920452|NCT01745601|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33920453|NCT00440895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920454|NCT02307838|NA|SINGLE_GROUP||OTHER||NONE||||||
33920455|NCT04830228|||CASE_ONLY||PROSPECTIVE|||||||
33920456|NCT03184857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920457|NCT01204333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920458|NCT06414304|||COHORT||PROSPECTIVE|||||||
33920459|NCT02915107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920460|NCT06436729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920461|NCT03216278|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696769|NCT00791310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696770|NCT02706678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696771|NCT03048474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696772|NCT05430022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pilot, nonrandomized trial of a behavioral intervention for autistic adolescents.||||
33696773|NCT06561932|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, prospective, multicenter, observational study.||||
33696774|NCT04560790|NA|SINGLE_GROUP||TREATMENT||NONE||Single group target value: Since there is no similar products approved on the market and there is no similar comparative treatment methods, the single group target value method is adopted||||
33696775|NCT00997061|||||PROSPECTIVE|||||||
33696776|NCT01677546|RANDOMIZED|PARALLEL||||NONE||||||
34000522|NCT06257979|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|"Following the analysis of the bacteriological samples, the investigator will read the bacteriological results. These will be entered into the database.~During subsequent visits, the investigator will not provide this information to the patient who will thus remain as a single blind."|"The study procedure involves a re-intervention of the rotator cuff, which is conducted for the patients in accordance with standard practice. The patient undergoes local and/or general anesthesia, along with intravenous or oral antibiotic prophylaxis.~During the intervention, the surgeon collects the sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product) used during the re-intervention. These elements usually discarded, are collected for the bacteriological analysis.~Antibiotic treatment cannot be prescribed immediately and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."|t|f|f|f
33920462|NCT04968340|RANDOMIZED|PARALLEL||PREVENTION||NONE||Support of the lower uterine segment and bladder without introduction of the obstetrician hand in the uterine incision so as not to occupy more space ; this help rotation of the foetal head facilitating head delivery, protecting LUS incision from extension.||||
33920463|NCT04775472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920464|NCT00185354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920465|NCT02908009|||CASE_CONTROL||PROSPECTIVE|||||||
33920466|NCT04846348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920467|NCT05751057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920468|NCT04699214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The dose of Endostar is not adjusted, and the specific adjustment plan of the chemotherapy regimen is adjusted according to the clinical experience of the investigator.|Prospective, randomized controlled, open phase II clinical study|t|f|f|f
33920469|NCT01398267|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33920470|NCT05854251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo controlled, double-blind, randomized, cross-over proof-of-concept study|t|f|t|f
33920471|NCT05987189|||CASE_ONLY||PROSPECTIVE|||||||
33920472|NCT04660617|||COHORT||PROSPECTIVE|||||||
33920473|NCT03190096|||OTHER||PROSPECTIVE|||||||
33920474|NCT03700970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and plastic surgeons will be blinded to the study treatment arm||t|t|f|f
33920475|NCT05507060|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The measurements will be recorded in the patient file and the groups will be coded so that the researcher evaluating the data will be blinded to the groups||f|f|t|t
33920476|NCT00505102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920477|NCT01724112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920478|NCT05741086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|investigator-initiated, open-label, blinded endpoint assessment, controlled, randomized pilot trial|Patients meeting the enrollment criteria will be randomly assigned to one of the two treatment groups (1:1) and will be followed up for 1 year.|f|f|f|t
33920479|NCT01195831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696777|NCT02525276|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696778|NCT02549729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696779|NCT02121990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696780|NCT05116007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696781|NCT05405413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696782|NCT02554604|||COHORT||PROSPECTIVE|||||||
33696783|NCT00795925||||||NONE||||||
33696784|NCT06550271|||COHORT||RETROSPECTIVE|||||||
33696785|NCT02213237|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785262|NCT06712940|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920480|NCT03077113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920481|NCT04897438|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000523|NCT01367782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000524|NCT00777855|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34000525|NCT01903057|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34000526|NCT00939380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000527|NCT04334850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000528|NCT03984162|||COHORT||PROSPECTIVE|||||||
34000529|NCT00274625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696786|NCT04553354|||COHORT||PROSPECTIVE|||||||
33696787|NCT03300960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696788|NCT05290207|||COHORT||CROSS_SECTIONAL|||||||
33696789|NCT00853034|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33920482|NCT02466412|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33920483|NCT01392053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33920484|NCT01709981|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33920485|NCT05057741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|only the outcome assessor. at the time of reviewing the data and doing the analysis he was blinded to the data. No other form of blinding was used.|"A randomized clinical trial will be performed. Two study groups will be compared, an experimental group that will receive the educational intervention (multimodal prehabilitation program) and a control group that will continue with the usual management in the Hospital. The project activities will be carried out in Telehealth modality. When the patient accepts to participate in the study and signs the informed consent, he/she will be evaluated by nutrition and physiotherapy. After the initial evaluation that confirms the selection criteria, the patient will be randomly assigned to the study groups, by means of a computer based randomisation program.~The evaluators of the initial and final conditions of the patients will not know the group to which each patient entering the study has been assigned. The study will be conducted following good clinical practice. The estimated duration of recruitment is sixteen months."|f|f|f|t
33920486|NCT05833971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920487|NCT01697267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920488|NCT03421574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920489|NCT03945435|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920490|NCT01606839|||COHORT||PROSPECTIVE|||||||
33920491|NCT01410877|||||CROSS_SECTIONAL|||||||
33920492|NCT03053310|||COHORT||PROSPECTIVE|||||||
33920493|NCT01286116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920494|NCT05875129|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Through the VAVA (an Amazon Alexa provided as part of the study), participants will verbally provide information about their sleep habits and sleep quality and receive suggestions about how to improve their sleep. Via the VAVA, these interactions will happen through the prototype software More SHEEP (MediaRez LLC). The recommendations provided by the More SHEEP software will be tailored to the individual participant, based on the data provided verbally by each participant. The participant will be asked to engage with the VAVA prototype daily for a 2-week period.||||
33920495|NCT05443451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920496|NCT02861755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33920497|NCT05425719|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33920498|NCT02608229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920499|NCT03138018|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33920500|NCT05545904|RANDOMIZED|PARALLEL||PREVENTION||NONE||Following enrollment and baseline assessment, participants will be randomized to one of the two study groups (allocation ratio: 1:1) - SBI intervention or the control condition (an education session on harms of substance use.||||
33920501|NCT04526119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920502|NCT04091334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920503|NCT03404271|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|Investigators and participants will be blinded to dietary supplement (i.e. HMB or placebo). However, neither the investigators nor participants will be blinded to dietary intervention (TRF or ND) due to the nature of these dietary programs. When possible, outcome assessors will be blinded to group assignment.||t|f|t|t
33920504|NCT00002247|RANDOMIZED|||TREATMENT||||||||
33920505|NCT04289519|||CASE_CONTROL||RETROSPECTIVE|||||||
34000530|NCT06176885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000531|NCT01581164|||COHORT||PROSPECTIVE|||||||
34000532|NCT03330496|||COHORT||PROSPECTIVE|||||||
34000533|NCT04857593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000534|NCT00869115|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34000535|NCT03235141|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"There are 8 subjects will be enrolled in pre-test, each subject was sampled in two eyes and each subject participated in two cycles of the trial. 8 subjects, 16 eyes participated in the study, 32 samples of tears total .~There are 48 subjects will divided into group A and group B randomly . subjects of Group A will given the first test drug, elution after the control drug; Subjects of Group B will given the first control drug, elution given to the test drug."|t|f|t|f
34000536|NCT03622229|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34000537|NCT02413034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34000538|NCT02238587|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33920506|NCT04938388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Single center, 56-week, randomized controlled, parallel group, double blind study comparing OS (active group) with Placebo (control group) in adult Latinos with established type 2 diabetes treated with usual diet/exercise modification alone and/or Metformin at randomization, with both groups under the supervision of the licensed SDRI study physician/Co-Investigator and also receiving enhanced lifestyle care.|t|t|t|f
33920507|NCT02336139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920508|NCT02827994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920509|NCT01932281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920510|NCT03668535|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|closed envelop will be used for randomization. The patient and the investigator will be blinded.|Two groups of women with difficult Cesarean Section at risk of urinary bladder injury. Group A will receive the intervention. Group B will not receive the intervention.|t|f|t|f
33920511|NCT00442676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920512|NCT01110772|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000539|NCT04330547|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34000540|NCT00917787|||COHORT||CROSS_SECTIONAL|||||||
33696790|NCT02439879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000541|NCT02246296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000542|NCT00595673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000543|NCT02532192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000544|NCT03658434|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
34000545|NCT03492476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000546|NCT00991692|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34000547|NCT02023762|||COHORT||PROSPECTIVE|||||||
34000548|NCT02373839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000549|NCT00070759||||TREATMENT||||||||
34000550|NCT04043702|||COHORT||PROSPECTIVE|||||||
34000551|NCT05545228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A feasibility single-blinded randomised controlled trial|f|f|f|t
34000552|NCT01714284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000553|NCT00766493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000554|NCT00432705|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000555|NCT00057226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34000556|NCT02806063|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34000557|NCT04913545|||CASE_CONTROL||PROSPECTIVE|||||||
34000558|NCT03548480|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34000559|NCT01529164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000560|NCT04432077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000561|NCT04951856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000562|NCT06144060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000563|NCT02061358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000564|NCT05841693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients in CHO group will be offered carbohyrate rich preoperative fluid on the other hand the patients in Control Group will be offered placebo fluids resemble to carbohydrate rich preoperative drink. The investigators, care provider and outcome accessors also will be blinded to the group assignment of the patients.|Randomized, double blinded|t|t|t|t
34000565|NCT05497557|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000566|NCT02092701|RANDOMIZED|||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34000567|NCT01726803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34000568|NCT02086617||||SCREENING||||||||
34000569|NCT05237830|||COHORT||RETROSPECTIVE|||||||
34000570|NCT02378909|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34000571|NCT01427036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000572|NCT05598398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000573|NCT02269735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000574|NCT03136562|||COHORT||CROSS_SECTIONAL|||||||
34000575|NCT02260258|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34000576|NCT00245986||||TREATMENT||||||||
34000577|NCT00796874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000578|NCT02552082|||COHORT||RETROSPECTIVE|||||||
34000579|NCT04457115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000580|NCT05805241|||OTHER||CROSS_SECTIONAL|||||||
34000581|NCT05467540|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Multicenter, no control group||||
34000582|NCT01656564|||COHORT||PROSPECTIVE|||||||
34000583|NCT06074757|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||open label, sequential dosing , single ascending dose and multiple dose pharmacokinetic , safety , tolerability study||||
34000584|NCT01402128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34000585|NCT04218487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000586|NCT03924154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Following screening assessments, PAH patients who meet all entrance criteria will be randomly assigned to receive one of the following treatments in a ratio of 2:1:~* Arm 1 (n=24) - RVT-1201 Treatment: RVT-1201 immediate-release tablets will be administered orally, at a dose of 600 mg twice daily (BID), for a total of 6 weeks in addition to the patient's current standard of care (SOC) medication(s) for PAH.~* Arm 2 (n=12) - Placebo Treatment: Matching placebo tablets will be administered orally, at a dose of 600 mg twice daily (BID), for a total of 6 weeks in addition to the patient's current SOC medication(s) for PAH.~Participants will be followed in face-to-face visits with trial personnel every 2 weeks for 8 weeks (6 weeks of treatment plus a 2-week follow-up), with an additional phone call at Week 1, to assess drug effects and monitor safety during their treatments."|t|f|t|f
34000587|NCT05233670|||COHORT||CROSS_SECTIONAL|||||||
34000588|NCT03900234|||COHORT||CROSS_SECTIONAL|||||||
34000589|NCT00425009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000590|NCT04162327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000591|NCT02048696|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34000592|NCT05908617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000593|NCT06195865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000594|NCT02864524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000595|NCT00990041|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696791|NCT04979520|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open label||||
33696792|NCT02549053|NON_RANDOMIZED|PARALLEL||||NONE||||||
33920513|NCT06199622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a randomized controlled intervention trial||||
33920514|NCT01102218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920515|NCT02103036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696793|NCT03578757|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|||||
33696794|NCT01464944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33696795|NCT03293797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696796|NCT04137224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696797|NCT02046733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920516|NCT05948852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920517|NCT03685045|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The intervention is the campaign days where all participants will undergo a questionnaire, point of care and dried blood spot testing for hepatitis C, fibroscan and a clinical assessment.||||
33920518|NCT04113148|||COHORT||PROSPECTIVE|||||||
33920519|NCT03329599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SMAART incorporates (i) a pilot randomized controlled trial and (ii) a human capital/institutional capacity building component. We propose a randomized, open label, blinded endpoint clinical trial with the intervention arm assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule compared with the 'usual care' arm who will continue to take separate, individual secondary preventive medications as prescribed their physicians to assess CIMT changes as a robust intermediary outcome measure for CVD events, as well as adherence, tolerability, and risk factor control rates. Furthermore, a cadre of emerging investigators from Ghana will benefit from the rich learning environment to be created through the implementation of the RCT and the interactions (2 years) with experts from the Medical University of South Carolina.|t|t|t|t
33920520|NCT05501288|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomly allocated 2:1 to receive oral HSBDG for 5 consecutive days (intervention group) and to receive compound pholcodine oral solution for 5 consecutive days (control group)||||
33920521|NCT01819506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920522|NCT01431729|||CASE_ONLY||PROSPECTIVE|||||||
33920523|NCT05717959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920524|NCT01864824|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33920525|NCT00354497||||SCREENING||||||||
33920526|NCT05360823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33920527|NCT05937217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33920528|NCT00977015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33920529|NCT01115075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920530|NCT03094832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920531|NCT02204514|||COHORT||RETROSPECTIVE|||||||
33920532|NCT05118542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The care providers gave two choice of drug doses to the research assistant. The research assistant then give the participant their drugs based on the assignment from the randomisation.~The investigator and outcome assessor were blinded to the drugs which the participants received"|This study was a single blind, randomized clinical trial study, conducted in Cipto Mangunkusumo National Referral Hospital from January 2019 to August 2020. We included all adult patient aged 18-65 years with newly diagnosed Graves' disease or no prior anti-thyroid drugs medication for more than 1 month, who agreed to participate in the study. The exclusion criteria was pregnancy, history of coronary heart disease, known malignancy, current use of immunosuppressive medication, sepsis, thyroid crisis, or having allergic reaction to anti-thyroid drugs and other severe side effect.|f|t|t|t
33920533|NCT05572827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33920534|NCT00335998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920535|NCT05368129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33920536|NCT02142257|||COHORT||PROSPECTIVE|||||||
33920537|NCT03569306|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33920538|NCT00735085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920539|NCT05491655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be blinded to treatment arm. Echocardiographic evaluation will be performed by study physician blinded to lead placement||t|t|f|t
33920540|NCT05914961|||COHORT||PROSPECTIVE|||||||
33920541|NCT04498572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will not be aware of the group they were assigned|two groups. research group will receive dry needling and control group will receive sham dry needling.|t|f|f|f
33920542|NCT01310218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33920543|NCT03986190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33920544|NCT00503178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920545|NCT03769324|||COHORT||PROSPECTIVE|||||||
33920546|NCT04441736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920547|NCT01365377|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33920548|NCT04861558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920549|NCT02825147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920550|NCT02262884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920551|NCT01805102|||CASE_CONTROL||PROSPECTIVE|||||||
33920552|NCT04424199|||CASE_CONTROL||PROSPECTIVE|||||||
33920553|NCT01726413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920554|NCT01700985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920555|NCT00311558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920556|NCT02001675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000596|NCT03025451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000597|NCT04038645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the researcher responsible for conducting the treatments (who will open the envelopes of the randomization) will know which treatment is assigned to each patient. The identification of each group will be revealed only after statistical analysis of the data for all those involved in the study by this researcher. Therefore, the researcher responsible for data collection (evaluation of edema and all secondary variables), the microbiologist and the statistician will be blind regarding the treatments assigned to the groups. The patient will also be blinded to the type of treatment performed, since the treatment with PBM will be identical in both groups and the treatment with PBM will be simulated in the control group.|"36 patients will be allocated in the experimental and control groups: G1 - Experimental Group (n = 18 Photobiomodulation PBM) - the treatment will be performed in a conventional manner and the patient will receive laser at low intensity.~G2 - Control group (n = 18 -placebo of PBM) - treatment will be performed in a conventional manner and simulation of PBM treatment."|t|f|t|f
34000598|NCT02810223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000599|NCT04665817|||COHORT||PROSPECTIVE|||||||
34000600|NCT03790241|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33785263|NCT05885126|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The sample recruited for the research consisted of 38 individuals (19 individuals in the control group, 19 in intervention group) who were 18 years and older, were receiving a high emetogenic chemotherapy regimen for the first time, had sufficient fine motor skills to paint and were volunteering to participate in research. Exclusion criteria were any physical or mental disability that limited communication or coloring the mandala template. Homogeneity was ensured by including patients who received chemotherapy regimen with high emetogenicity. Patient lists numbered according to even and odd numbers were given in a sealed envelope to a practitioner independent from the researchers.|t|f|f|f
34000601|NCT06036927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785264|NCT05395481|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785265|NCT02851147|||COHORT||PROSPECTIVE|||||||
34000602|NCT03397667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor is blinded to which arm a dyad is enrolled.||f|f|f|t
34000603|NCT00748137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000604|NCT03736460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34000605|NCT03087435|||OTHER||CROSS_SECTIONAL|||||||
34000606|NCT06353724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785266|NCT01693094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785267|NCT01359137|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785268|NCT06629402|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Methodology: This will be a randomized, double-blind, placebo-controlled, 2-way crossover study to evaluate the onset of analgesia following administration of single oral doses of PF614 or placebo. The study will consist of 2 phases: Screening and Treatment.|t|f|t|f
33785269|NCT06711445|||OTHER||CROSS_SECTIONAL|||||||
33785270|NCT06707818|||COHORT||PROSPECTIVE|||||||
33785271|NCT01551615|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33785272|NCT06711588|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785273|NCT06253663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participant will be enrolled into the appropriate cohort depending on the type of disease in the two cohorts: r/r Mantle Cell Lymphoma (MCL) or r/r B-precursor Acute Lymphoblastic Leukemia(B-ALL)||||
33920557|NCT00799500|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33920558|NCT04504435|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study with respect to allocation of GSK3494245 or placebo to participants. The food effect part of the study will be open label.|The study will consist of 3 cohorts (Cohorts 1, 2 and 3), conducted in sequential order. Cohorts 1 and 2 will consist of a single dose, ascending, crossover design. Cohorts 1-2 will comprise of a 4-way crossover which includes 4 dosing regimens under fasted conditions. Cohort 3 will comprise of a 2-way crossover which includes 1 dosing regimen under fasted then fed condition and 1 regimen under fed then fasted condition in a 1:1 ratio.|t|f|t|f
33920559|NCT02702011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33920560|NCT04048655|NA|SINGLE_GROUP||TREATMENT||NONE||Single group with same study protocol to asses the incidence of postrecovery relaxation||||
33920561|NCT04824417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blinded|Randomized trial|t|f|f|t
33920562|NCT01796639|||COHORT||RETROSPECTIVE|||||||
33920563|NCT01923233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920564|NCT03522883|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33920565|NCT00606814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920566|NCT05387577|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920567|NCT04934306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920568|NCT02623296|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33920569|NCT01611272|||COHORT||PROSPECTIVE|||||||
33920570|NCT00589147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920571|NCT02574858|NA|SINGLE_GROUP||OTHER||NONE||||||
33920572|NCT04179435|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Between group comparison||||
33920573|NCT03114566|||COHORT||PROSPECTIVE|||||||
33920574|NCT06060756|||COHORT||PROSPECTIVE|||||||
33696798|NCT06681467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000607|NCT06335186|||COHORT||PROSPECTIVE|||||||
34000608|NCT01523236|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34000609|NCT00139815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000610|NCT05366231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000611|NCT01285076|||COHORT||RETROSPECTIVE|||||||
34000612|NCT02359539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33696799|NCT01434407|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34000613|NCT01398787|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34000614|NCT04900623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000615|NCT01341405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696800|NCT06515977|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34000616|NCT00716625|||CASE_ONLY||PROSPECTIVE|||||||
34000617|NCT04898504|RANDOMIZED|PARALLEL||TREATMENT||NONE||"3 armed parallel RCT randomizing between 2nd line chemotherapy + HAI-floxuridine or liver-Tx versus 2nd line chemotherapy alone (Excalibur 1).~2-armed parallell design RCT between HAI/FUDR and 2nd line chemotherpy versus next line chemotherapy alone (Excalibur 2)"||||
33696801|NCT05549219|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will randomized to receive either 10 mg/kg GLM101 or 20 mg/kg GLM101. Subsequently, if safety and tolerability are demonstrated at 10 and 20 mg/kg, 30 mg/kg groups will be added.||||
33696802|NCT00969813|NON_RANDOMIZED|PARALLEL||||NONE||||||
33696803|NCT04922671|||COHORT||PROSPECTIVE|||||||
33696804|NCT04300647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696805|NCT06484491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696806|NCT04502979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33696807|NCT03360565|||COHORT||PROSPECTIVE|||||||
33785274|NCT04986917|NA|SINGLE_GROUP||TREATMENT||NONE||"A total of 60 patients will be recruited to the study. Patients with a primary umbilical hernia under 2 cm will be recruited to the study and the hernia will be repaired with or without mesh according to the PI's decision.~Eligible patients with a primary or secondary ventral hernia, desiring an elective surgical repair, who amply the inclusion/Exclusion criteria will be offered to participate in the study.~Study includes 5 visits: Screening, Baseline/Surgery, and 14 days, 3 months, 12months Follow-Ups post-surgery. The actual point of enrollment for each subject is considered the day of surgery. Total study duration is up to 12months post-surgery."||||
33785275|NCT03106025|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|ophthalmologists will be blinded to the ultrasound result and formal ophthalmology assessment will be compared to the ultrasound assessment.|||||
33785276|NCT03199885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785277|NCT06292182|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000618|NCT05440305|||COHORT||RETROSPECTIVE|||||||
34000619|NCT01781117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000620|NCT02697708|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will receive a controlled diet containing 2340 mg potassium.(K) During the 4 - 16 day phases they will receive an additional 0 mg K, 1000 mg K from potatoes, 1000 mg K from French Fries, and 1000 mg K from supplement in randomized order. Blood pressure will be measured every other day during the intervention. There will be a 2 week washout phase during each phase.||||
34000621|NCT04955015|||COHORT||PROSPECTIVE|||||||
34000622|NCT04587258|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34000623|NCT00496067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000624|NCT06504511|||COHORT||PROSPECTIVE|||||||
34000625|NCT00162929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000626|NCT02340962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000627|NCT05006131|||COHORT||PROSPECTIVE|||||||
34000628|NCT04553406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment Arms 1 to 3 are masked while Treatment Arm 4 is open-label||t|t|t|t
34000629|NCT04125134|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34000630|NCT05002660|RANDOMIZED|PARALLEL||PREVENTION||NONE||Community-based cluster randomized controlled trial||||
34000631|NCT03250117|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects receive oral immediate release (IR) ropinirole for 7-10 days, and then are switched to ropinirole implant(s) for 12 weeks.||||
34000632|NCT04255849|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
34000633|NCT05530291|||COHORT||RETROSPECTIVE|||||||
34000634|NCT06678529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blind the patients: All patients were unaware of the group assignment. Surgeons, anesthesiologists, and ward and operating room nurses were blinded to group assignment and intervention regimen.~The researchers who assessed outcomes, conducted follow-up, and collected and processed the data were blinded to the intervention and group assignments."|The electrostimulationwas delivered through two electrodes placed in saline-soaked sponges.The electrodes were fixed by a stretchy hat, with the anode over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right orbitofrontal area.|t|t|t|t
34000635|NCT00213005|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34000636|NCT02034513|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34000637|NCT00586963|||COHORT||PROSPECTIVE|||||||
34000638|NCT02583048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696808|NCT01140685|||CASE_CONTROL||PROSPECTIVE|||||||
33696809|NCT02290327|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33696810|NCT05841836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696811|NCT02354183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33696812|NCT05107427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696813|NCT01163240|||COHORT||RETROSPECTIVE|||||||
33696814|NCT05047913|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696815|NCT03383471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33696816|NCT00876525|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, multicenter trial||||
33696817|NCT05644444|RANDOMIZED|PARALLEL||TREATMENT||NONE||The personal lubricants will be tested in a 2-arm parallel-design, where subjects will be randomised to an arm/lubricant. Subjects participating in the both the tolerance and treatment phases will be enrolled into an arm for each which includes the same IP/lubricant throughout both phases.||||
33696818|NCT01795638|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33696819|NCT01573351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089083|NCT04128995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label prospective clinical trial. Primary comparison is medical (n=45) vs surgical (n=45) groups. Patients with obesity and no diabetes (n=10) are a comparator group.||||
34089084|NCT00497107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089085|NCT02382627|||COHORT||CROSS_SECTIONAL|||||||
34089086|NCT05041465|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34089087|NCT04275037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089088|NCT05093114|||COHORT||PROSPECTIVE|||||||
33920575|NCT04949724|||OTHER||CROSS_SECTIONAL|||||||
34089089|NCT01330927|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34089090|NCT02339337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920576|NCT01205958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33920577|NCT02183623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920578|NCT04370964|NA|SINGLE_GROUP||OTHER||NONE||The family will be evaluated in two stages via the standardized situations LTP (parents and patient) and LFP (family) as well as self-assessments, before the start of the therapy then after 9 months of therapy, each family being its own control.||||
33920579|NCT06018935|||COHORT||PROSPECTIVE|||||||
33920580|NCT04457193|||COHORT||PROSPECTIVE|||||||
33920581|NCT01802554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920582|NCT06067282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920583|NCT01091909|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33920584|NCT06420596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920585|NCT00106821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33920586|NCT01611350|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"We conducted a series of sequential RCTs. The first RCT tests how willingness to pay for a fuel-efficient cookstove varies with 1. marketing messages and 2. sales offers that address household financial constraints The second RCT 2 tests the comparable purchase from a traditional cash-and carry sales offer to uptake of the novel offer- which includes a free trial of the cookstove and the right to return the stove with no payment and a rent-to-own model where the customer pays in time payments.~The third RCT examined the effects of fuel-efficient cookstoves on wood use, household air pollution, and cooking behaviors in rural Uganda RCT 4 examines the effect of peer usage on consumer demand for efficient cookstoves with a randomized controlled trial in rural Uganda."|t|f|f|f
33920587|NCT03799328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920588|NCT02003807|||CASE_CONTROL||RETROSPECTIVE|||||||
33920589|NCT05844904|||COHORT||CROSS_SECTIONAL|||||||
33920590|NCT04806516|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."|At the end of month 8 after DBS implant, all subjects will enter a one-month delayed onset withdrawal period in which the subject and Independent Evaluators are blinded to timing of discontinuation. See description below.|t|f|f|t
33920591|NCT00658710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33920592|NCT03902782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33920593|NCT02038569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920594|NCT02882815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920595|NCT00936117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920596|NCT03603834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920597|NCT04556656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920598|NCT04686318|||COHORT||PROSPECTIVE|||||||
33920599|NCT00126789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920600|NCT02168803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33696820|NCT05427591|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental, two separate randomized controlled groups with split mouth design, following the Consolidated Standards of Reporting Trials (CONSORT,2010) statement. The final sample consisted of 60 children who met the inclusion criteria and had contralateral open occlusal carious lesions in their primary molars. They were randomly allocated to either group (1) or group (2). In group 1, 30 children with 60 primary molars underwent caries removal by the CMCR method BRIX3000® (the experimental group) on one molar (n = 30) and the traditional surgical method (the control group) on the contralateral molar (n = 30). In group 2, 30 children with 60 primary molars underwent caries removal by the CMCR method Carie-CareTM (the experimental group) on one molar (n = 30) and the traditional surgical method (the control group) on the contralateral molar (n = 30)."||||
33696821|NCT05298774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000639|NCT04244643|||COHORT||RETROSPECTIVE|||||||
33696822|NCT05030324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Tablets identical in terms of composition, appearance and labeling to XC221 tablets, but without active substance will be used as Placebo|Patients will be randomized into three treatment groups (in a 1:1:1 ratio) receiving: study drug (ХС221) at 100 mg daily or at 200 mg daily, or placebo|t|f|t|f
34000640|NCT04698551|||COHORT||RETROSPECTIVE|||||||
33696823|NCT03572751|||CASE_CONTROL||PROSPECTIVE|||||||
34000641|NCT01118767|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34000642|NCT00043498|||COHORT||PROSPECTIVE|||||||
34000643|NCT00537641|||COHORT||PROSPECTIVE|||||||
34000644|NCT05919758|||COHORT||CROSS_SECTIONAL|||||||
34000645|NCT04589364|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double blinded|A 50-Week Prospective, Double-Blinded, Randomized, Cross-over design in Multicenter Study of 100 unit of Abobotulinum Toxin Type A (Dysport) versus 33.33 unit of Neubotulinum Toxin Type A (Neuronox) Injection For Hemifacial Spasm in Thai Patients|t|t|t|t
33696824|NCT01848197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696825|NCT01438073|NA|SINGLE_GROUP||OTHER||NONE||||||
33696826|NCT02857985|NA|SINGLE_GROUP||OTHER||NONE||||||
34000646|NCT06129123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103129|NCT06687993|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind design. Comparative analyzes will be carried out blindly|Multicenter, superiority study, in double-blind, randomized, parallel groups, controlled versus placebo, in using a sequential adaptive design by band.|t|t|t|t
33696827|NCT06552078|||COHORT||PROSPECTIVE|||||||
33696828|NCT03835910|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|It is not possible to blind participants to the social incentives they will receive. For the injection aspect of the study, the investigator will be aware of the injection being given but the syringe will be covered to obscure the view of the patient.|Participants are randomized with a software application to receive social incentives to promote physical activity. They will also be randomized to receive corticosteroid injections in a crossover design.|t|f|f|f
33696829|NCT00559754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696830|NCT01032902|||COHORT||PROSPECTIVE|||||||
33696831|NCT00678080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696832|NCT04269590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696833|NCT02428608|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label safety study|||||
33920601|NCT06375980|||COHORT||PROSPECTIVE|||||||
33920602|NCT02181010|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33920603|NCT00860418|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33920604|NCT03444870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920605|NCT04906993|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 camrelizumab combined with famitinib malate platinum-based chemotherapy||||
33920606|NCT04262401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920607|NCT00208494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920608|NCT05291637|||COHORT||RETROSPECTIVE|||||||
33920609|NCT04428359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patients will be blinded to the randomization and intervention.|Group A - will receive IL MMR Group B- will receive IL Vitamin D3|t|f|f|f
33920610|NCT02379390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920611|NCT05078580|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33920612|NCT05191355|||CASE_CONTROL||PROSPECTIVE|||||||
33920613|NCT01653002|||COHORT||PROSPECTIVE|||||||
33920614|NCT00159159|RANDOMIZED|PARALLEL||||NONE||||||
33920615|NCT00120653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920616|NCT05227482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Clinical Trial|t|f|f|t
33920617|NCT02201355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920618|NCT04009746|||COHORT||PROSPECTIVE|||||||
33920619|NCT03149926|||OTHER||OTHER|||||||
33920620|NCT03169049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33920621|NCT02152358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920622|NCT02941289|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33920623|NCT02046954|||CASE_CONTROL||RETROSPECTIVE|||||||
33920624|NCT05578482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators as well as the participating patients are blinded during the RCT of Dicloxacillin/Placebo \& Elocon|Randomized Controlled Trial, Double Blinded|t|f|t|f
33920625|NCT01921634|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||||||||
33920626|NCT02776956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920627|NCT00795509|||CASE_ONLY||PROSPECTIVE|||||||
33920628|NCT04441554|||COHORT||PROSPECTIVE|||||||
33920629|NCT04929613|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33920630|NCT06205394|||COHORT||PROSPECTIVE|||||||
33920631|NCT02469532|||CASE_ONLY||PROSPECTIVE|||||||
33920632|NCT01868776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920633|NCT02293902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920634|NCT00570531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103130|NCT06426927|NA|SINGLE_GROUP||OTHER||NONE||||||
34103131|NCT04920656|||COHORT||PROSPECTIVE|||||||
34103132|NCT06687395|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|pseudonymized|Group 1: training model 1 - re-assessment model 1 Group 2: training model 2 - re-assessment model 1|f|f|f|t
33920635|NCT03935607|||CASE_CONTROL||PROSPECTIVE|||||||
33920636|NCT01274455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920637|NCT00472615|||COHORT||PROSPECTIVE|||||||
33920638|NCT03442348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The study will be a randomised controlled parallel intervention study in which participants will be grouped into 2 different study arms.|t|f|f|f
33920639|NCT05678842|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920640|NCT03224481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33920641|NCT01536106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920642|NCT01989182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000647|NCT05514340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this double-blind study, the patient and all relevant personnel involved with the conduct and interpretation of the study (including the investigator, investigational site personnel, and the sponsor or designee's staff) will remain blinded to the identity of the Investigational Product (IP) assigned and the randomization codes. The final randomization list will be kept strictly confidential, filed securely by the independent biostatistician, and accessible only to authorized persons as per the sponsor's standard operating procedures until the completion of the study.|"In sovateltide group, 3 doses of sovateltide, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).~In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.~In both treatment groups, subjects will be provided the best available standard of care."|t|t|t|t
34000648|NCT00370851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000649|NCT06447441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000650|NCT00668395|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33696834|NCT06101563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000651|NCT02178891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696835|NCT02193477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34000652|NCT03699150|||COHORT||RETROSPECTIVE|||||||
34000653|NCT02791958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000654|NCT04685681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696836|NCT06427759|RANDOMIZED|PARALLEL||OTHER||NONE||Optimizing Aesthetic Outcome for Arm Contouring Surgery by Utilizing Anthropometric Measurements.||||
34000655|NCT01774058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000656|NCT01204944|||COHORT||PROSPECTIVE|||||||
34000657|NCT05604651|||OTHER||CROSS_SECTIONAL|||||||
34000658|NCT05187884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000659|NCT04817969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696837|NCT02946320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000660|NCT02707016|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34000661|NCT00833846|||||PROSPECTIVE|||||||
34000662|NCT02521051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000663|NCT00724958|||COHORT||PROSPECTIVE|||||||
33696838|NCT03671486|||COHORT||PROSPECTIVE|||||||
33696839|NCT05598021|||OTHER||RETROSPECTIVE|||||||
33696840|NCT02368782|||COHORT||PROSPECTIVE|||||||
33696841|NCT01474369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920643|NCT06145152|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33920644|NCT00779324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920645|NCT02565615|||COHORT||PROSPECTIVE|||||||
33920646|NCT00167440|||COHORT||PROSPECTIVE|||||||
33920647|NCT02616185|NA|SEQUENTIAL||TREATMENT||NONE||||||
33920648|NCT04508725|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000664|NCT00000698||||TREATMENT||NONE||||||
34000665|NCT01156441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000666|NCT02089516|||CASE_ONLY||CROSS_SECTIONAL|||||||
34000667|NCT02581527|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000668|NCT00569660|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000669|NCT01228552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000670|NCT04581122|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34000671|NCT01467362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000672|NCT02835755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696842|NCT00470847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000673|NCT05575245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000674|NCT00438750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000675|NCT00006273|||NATURAL_HISTORY|||||||||
34000676|NCT03538262|||COHORT||PROSPECTIVE|||||||
34000677|NCT04238962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000678|NCT00965731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000679|NCT00614276|||CASE_ONLY||PROSPECTIVE|||||||
34000680|NCT06152848|||CASE_CONTROL||PROSPECTIVE|||||||
34000681|NCT00697619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000682|NCT04517526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000683|NCT01567319|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34000684|NCT06458868|RANDOMIZED|PARALLEL||TREATMENT||NONE|Endpoint assessors blinded|Prospective single center open label three parallel group, adaptive randomized controlled trial||||
34000685|NCT01162980|||CASE_ONLY||PROSPECTIVE|||||||
33696843|NCT03668769|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33696844|NCT00215202|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920649|NCT01230749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920650|NCT06194981|||COHORT||RETROSPECTIVE|||||||
33920651|NCT02712177|||OTHER||RETROSPECTIVE|||||||
33920652|NCT00617656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920653|NCT01088269|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920654|NCT01668186|||COHORT||OTHER|||||||
33920655|NCT02160886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000686|NCT02336633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000687|NCT03977441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind placebo control|treatment group: treated with agomelatine control group: treated with placebo|t|t|t|t
34000688|NCT04473326|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34000689|NCT04400292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This will be a prospective single-arm study.||||
33696845|NCT04348461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696846|NCT02360111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000690|NCT02417571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000691|NCT05158660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000692|NCT01420614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000693|NCT01528293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920656|NCT04115618|NA|SINGLE_GROUP||TREATMENT||NONE||Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.||||
33920657|NCT06402968|||COHORT||PROSPECTIVE|||||||
34000694|NCT05865964|||COHORT||PROSPECTIVE|||||||
33920658|NCT01623141|||CASE_CONTROL||PROSPECTIVE|||||||
33920659|NCT00493974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696847|NCT06680609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920660|NCT00866515|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920661|NCT00971425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33920662|NCT01974726|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920663|NCT05010993|||COHORT||PROSPECTIVE|||||||
33920664|NCT00425568|||||PROSPECTIVE|||||||
33920665|NCT01969669|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920666|NCT02107651|||CASE_ONLY|||||||||
21464381|NCT06442839|||CASE_ONLY||RETROSPECTIVE|||||||
33696848|NCT04627701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696849|NCT00617227|||CASE_ONLY||PROSPECTIVE|||||||
33696850|NCT04386031|||COHORT||PROSPECTIVE|||||||
33696851|NCT02239627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33920667|NCT05699317|NA|SINGLE_GROUP||OTHER||NONE||||||
33696852|NCT02795793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696853|NCT00259454|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33696854|NCT05955053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In this study, in order to minimize the risk of bias, the pregnant women will not know which group they are in, and the statistician will not be informed which group is the intervention and which group is the control during the analysis phase, and the study will be conducted with a blinding method. However, since the person who made the intervention, the researcher (HYY), who took part in the research, is knowledgeable about the intervention and will do the intervention himself, it is not possible to blind the researcher.|Paralel designed randomized two armed study|t|f|f|t
33920668|NCT05740579|NA|SINGLE_GROUP||OTHER||NONE||||||
33920669|NCT03089970|||CASE_CONTROL||PROSPECTIVE|||||||
33920670|NCT01287481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920671|NCT02829866|||CASE_ONLY||PROSPECTIVE|||||||
33920672|NCT01718626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000695|NCT04927455|||OTHER||PROSPECTIVE|||||||
34000696|NCT02678780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696855|NCT05007093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696856|NCT00689078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696857|NCT05492110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomised and blinded to CS Reducer of sham procedure. All follow-up assessments will be performed by a blinded parallel team to ensure blinded outcomes analysis.|Randomised, double-blinded, sham-controlled pilot study with parallel arms of participants randomised to CS Reducer or sham procedure|t|t|f|t
33696858|NCT03971071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696859|NCT04893707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696860|NCT00111878|||DEFINED_POPULATION||PROSPECTIVE|||||||
33696861|NCT05659992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696862|NCT04562610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators are comparing the efficacy of commonly administered pre-emptive analgesic medications administered in a randomized fashion in parallel. In one group all medications will be administered by mouth and in one group two of the medications will be administered via the intravenous route.|t|f|f|f
33696863|NCT03204461|||OTHER||PROSPECTIVE|||||||
33696864|NCT05484778|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33696865|NCT06010706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696866|NCT01422252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696867|NCT03599245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000697|NCT01078350|||COHORT||PROSPECTIVE|||||||
34000698|NCT04883450|||COHORT||PROSPECTIVE|||||||
34000699|NCT00001217||||TREATMENT||||||||
34000700|NCT00016653|RANDOMIZED|||TREATMENT||DOUBLE||||||
34000701|NCT00000136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696868|NCT00975325|RANDOMIZED|CROSSOVER||||NONE||||||
33920673|NCT06429423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The design is a two-armed intervention with two groups (30+30), one which is patients with ED, and the other an age- and sex matched control group with overall healthy individuals. The two trial conditions will be performed in a counter-balanced randomized order on two separate days with at least one week apart. Participants will be randomized regarding order of two different intensities of physical activity bouts. The participants will perform the two conditions of physical activity bouts at approximately the same time in the morning/forenoon with at least 1 week in between conditions.||||
33920674|NCT03070561|NA|SINGLE_GROUP||OTHER||NONE||Open label, crossover, local pharmacokinetics study||||
33920675|NCT04107558|RANDOMIZED|CROSSOVER||OTHER||NONE||Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control||||
33920676|NCT02816372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920677|NCT04972734|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33920678|NCT04173871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33920679|NCT00571792|||COHORT||PROSPECTIVE|||||||
33920680|NCT00593840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920681|NCT02922192|||COHORT||RETROSPECTIVE|||||||
33920682|NCT05452876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-randomized, stepped-wedge, multi-clinic (cluster) prospective cohort design having multiple controls within a primary care setting||||
34000702|NCT03755596|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-group, self-paired study||||
33785278|NCT06711835|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study employs a quasi-experimental design. Participants will be divided into two groups based on their physical activity level: Group 1 (Normally Active Individuals), who engage in typical daily activities without regular sports participation, and Group 2 (Athletic Individuals), who regularly engage in athletic activities.||||
33785279|NCT02661997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785280|NCT03545490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cohort 1: nutritional supplements are given through oral route Cohort 2: nutritional supplements are given by tube feeding||||
33785281|NCT06183502|||COHORT||PROSPECTIVE|||||||
33785282|NCT06664112|||COHORT||PROSPECTIVE|||||||
33785283|NCT04513028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785284|NCT05032755|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33785285|NCT01393470|||COHORT||PROSPECTIVE|||||||
33785286|NCT02283138|||CASE_ONLY||PROSPECTIVE|||||||
33785287|NCT06463665|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Following selection of the dose and schedule from the three safety run-in cohorts, randomization is (1:1) either into the Experimental Arm (EA) which is Olvi-Vec with platinum-doublet + Physician's Choice of ICI and then ICI-based maintenance or in the Active Comparator Arm (ACA) which includes treatment with docetaxel. ACA patients with documented disease progression \[i.e., assessed by Blinded Independent Central Review (BICR)\] who are eligible may crossover to receive the same treatment as per the Experimental Arm.||||
33785288|NCT03495232|||COHORT||PROSPECTIVE|||||||
33785289|NCT06421597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785290|NCT05808764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785291|NCT06707701|||OTHER||CROSS_SECTIONAL|||||||
33785292|NCT03178201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785293|NCT06472453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785294|NCT05181306|||CASE_CONTROL||RETROSPECTIVE|||||||
33785295|NCT06712758|||CASE_ONLY||PROSPECTIVE|||||||
33785296|NCT05483907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785297|NCT06444009|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized, Controlled, Phase II Study||||
33785298|NCT05284058|NA|SINGLE_GROUP||OTHER||NONE||||||
33785299|NCT01064843|||OTHER||PROSPECTIVE|||||||
33785300|NCT04969822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785301|NCT06544928|||COHORT||PROSPECTIVE|||||||
33785302|NCT06709911|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785303|NCT03578731|||COHORT||PROSPECTIVE|||||||
33785304|NCT02692846|||CASE_CONTROL||PROSPECTIVE|||||||
33785305|NCT06629077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33785306|NCT06711952|NA|SINGLE_GROUP||SCREENING||NONE||||||
33785307|NCT06712992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785308|NCT05258006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785309|NCT01200953|||OTHER||PROSPECTIVE|||||||
33785310|NCT06700928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785311|NCT06711237|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||sequential design with a washout period|f|f|f|t
33785312|NCT02718443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920683|NCT06435182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel assignment: 0.5% OT202 eye drop group；1% OT202 eye drop group；OT202 solvent eye drop group with a 1:1:1 ratio.|t|t|t|t
33920684|NCT00131677|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33785313|NCT06713486|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33785314|NCT00512824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785315|NCT03829332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33785316|NCT03924856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33785317|NCT05671705|||COHORT||PROSPECTIVE|||||||
33785318|NCT00508690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920685|NCT02662413|||COHORT||PROSPECTIVE|||||||
33920686|NCT03483766|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Patients with tetraplegia under the care of our department will be recruited. Spinal cord resting-state fMRI and DTI, surface EMG tests from different muscles from arm will be detected to define 5 most possible suitable candidates for this project.|This study will apply spinal cord resting-state fMRI and DTI to patients with cervical spinal cord injury. Findings with fMRI/DTI will compare to clinical hand function evaluation by using American Spinal Injury Association (ASIA) with full ASIA sensory and motor examinations (International standards for neurological classification of spinal cord injury (ISNCSCI)). After baseline spinal cord MRI scan, those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.|f|f|t|f
33920687|NCT05100069|||COHORT||PROSPECTIVE|||||||
33785319|NCT06650852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785320|NCT04616482|||COHORT||PROSPECTIVE|||||||
33785321|NCT00408824|||CASE_CONTROL||OTHER|||||||
33785322|NCT05544136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785323|NCT06388421|||COHORT||PROSPECTIVE|||||||
33785324|NCT06377982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785325|NCT05133037|||COHORT||PROSPECTIVE|||||||
33785326|NCT05534633|NA|SINGLE_GROUP||SCREENING||NONE||||||
33785327|NCT05139732|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785328|NCT01368861|||CASE_CONTROL||PROSPECTIVE|||||||
33785329|NCT06609863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785330|NCT05653674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33785331|NCT06041087|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33785332|NCT06056674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785333|NCT03230591|||CASE_ONLY||PROSPECTIVE|||||||
33785334|NCT06491615|||COHORT||OTHER|||||||
33785335|NCT00586274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785336|NCT05202379|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|active and placebo capsules identical visually.|4 cohorts for SAD, with food cohort; 5 cohorts for MAD; 6 active and 2 placebo per cohort; 6 additional active in food cohort|t|t|t|t
33785337|NCT00494819|||CASE_CONTROL|||||||||
33785338|NCT03658941|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Due to the nature of the surgical procedures, the surgeon and the rest of the OR medical team will be aware of the current subject's allocation. However, in each case, the specific OR team aware of the subject's allocation will be different from the investigators performing further evaluation of the given subject. The following study procedures will be in place to ensure double-blind administration of the study.~* Access to the randomization code will be strictly controlled.~* The surgeon will receive information on subject's allocation after commencing the surgery.~The study blind will be broken:~1. During interim monitoring, after recruiting the first 100 patients.~2. On completion of the clinical study and after the study database has been locked.~3. When patients' safety requires access to allocation data."|"We plan to include 2000 subjects in this study. Each subject will undergo a craniotomy for unrelated pathology. Each of the subjects will be assigned in random order to an intervention or control group. The intervention group will not have dural tenting sutures during closure of their craniotomy while the control group will have at least three.~Both groups will be followed radiologically and clinically, in the exact same manner."|t|f|t|t
33785339|NCT01930279|||CASE_CONTROL||PROSPECTIVE|||||||
33785340|NCT06307795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000703|NCT01625390|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34000704|NCT03513224|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34000705|NCT05089890|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The patients will be divided in 3 cohorts and will be treated with 3 different devices. The choice of which dressing to use depends of the characters of the wounds.||||
34000706|NCT00004105||||TREATMENT||||||||
34000707|NCT03541057|||COHORT||PROSPECTIVE|||||||
34000708|NCT05114668|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000709|NCT00214864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000710|NCT00867919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000711|NCT04728620|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34000712|NCT01380522|RANDOMIZED|CROSSOVER||||NONE||||||
34000713|NCT04753541|||COHORT||PROSPECTIVE|||||||
34000714|NCT03447691|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"* The investigator who research the QoR-40 questionnaire before and after the surgery will not know which group the patient is assigned to.~* Because of the difference in anesthesia method, it is impossible to apply blindness to an anesthesiologist practicing anesthesia. Thus, the anesthesiologist will maintain anesthesia with the same target in both groups. (anesthesia depth, hemodynamic status and pain control)~* Blind is released to investigator and outcomes assessor after completion of QoR-40 questionnaire."||t|f|t|t
34000715|NCT00422253|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34000716|NCT01143467|||||PROSPECTIVE|||||||
34000717|NCT00897923|||COHORT||PROSPECTIVE|||||||
34000718|NCT00169130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000719|NCT02243137|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34000720|NCT04196296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34000721|NCT01363817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000722|NCT00017550|RANDOMIZED|||TREATMENT||NONE||||||
34000723|NCT01451541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000724|NCT04580615|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34000725|NCT03555136|||COHORT||PROSPECTIVE|||||||
34000726|NCT03599921|||COHORT||PROSPECTIVE|||||||
34000727|NCT04072003|||COHORT||PROSPECTIVE|||||||
34000728|NCT02889393|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34000729|NCT01541215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000730|NCT02132650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000731|NCT03485027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||investigator chose the optimal reintroduction regimen for chemotherapy according to criteria||||
34000732|NCT06147258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are masked to participant group assignment|Randomized controlled trial|f|f|f|t
34000733|NCT03567122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000734|NCT03886363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34000735|NCT06655337|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34000736|NCT04483349|||COHORT||CROSS_SECTIONAL|||||||
34000737|NCT04364763|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomization to receive RBT-9:Placebo||||
34000738|NCT00248092|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34000739|NCT04661280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000740|NCT00657787|||CASE_CONTROL||PROSPECTIVE|||||||
34000741|NCT04358627|||CASE_CONTROL||PROSPECTIVE|||||||
34000742|NCT02382601|||CASE_CONTROL||PROSPECTIVE|||||||
33920688|NCT01478919|||COHORT||PROSPECTIVE|||||||
33920689|NCT00003476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920690|NCT00795964|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33920691|NCT04078334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920692|NCT02173392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920693|NCT03049007|||COHORT||PROSPECTIVE|||||||
33920694|NCT05137730|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33920695|NCT03601208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920696|NCT04365647|||COHORT||PROSPECTIVE|||||||
33920697|NCT01013168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920698|NCT04569695|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785341|NCT05371405|||COHORT||PROSPECTIVE|||||||
34000743|NCT05269563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000744|NCT02500615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34000745|NCT00362505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000746|NCT06385158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000747|NCT04219527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000748|NCT01994018|||CASE_CONTROL||OTHER|||||||
34000749|NCT01169272|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000750|NCT03610386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000751|NCT03359941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000752|NCT00828828|||CASE_CONTROL||PROSPECTIVE|||||||
34000753|NCT03212820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920699|NCT01090219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33920700|NCT03323996|||OTHER||PROSPECTIVE|||||||
33920701|NCT03371342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920702|NCT01566058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920703|NCT04025801|||CASE_ONLY||CROSS_SECTIONAL|||||||
33920704|NCT02140619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920705|NCT00102557||||TREATMENT||||||||
33920706|NCT05409768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33920707|NCT00684112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33920708|NCT06197048|RANDOMIZED|PARALLEL||PREVENTION||NONE||the included patients will be randomized into two groups: one croup will receive nutritional counseling, while the other does not. All the participants will complete baseline and post-intervention measurements consisting of: mapping of diet, anthropometric measurements (weight, height, waist measurement), bloodpressure, biochemical measurements (total cholesterol, non-HDL cholesterol, LDL cholesterol, triglycerides, vitamin D, ferritin, fasting glucose, HbA1c, folate and AST/ALT. Then the two groups will be compared to reveal any differences.||||
33920709|NCT02683018|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920710|NCT05507970|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34000754|NCT05363241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34000755|NCT03612973|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||both study groups will be investigated at same time||||
34000756|NCT00325182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000757|NCT00668577|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34000758|NCT03483350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025072|NCT06474273|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|"As a single-blind study, all participants will be blinded to the allocation of the IV MP treatment comparisons. Other research staff including outcome assessors (such as the pathologists, members of the outcomes adjudication committee, and data analysts) will also be blinded to the IV MP allocation.~All investigators, clinicians, participants, research staff, data analysts and outcome assessors will be blinded to the oral prednisone dose allocations. The hospital pharmacy will provide the study oral prednisone drug in a blinded manner.~All key stakeholders including the global steering committee, the site investigators, and the trial management committee (TMC) will remain blinded to the individual patient randomization and the aggregate data that may reveal the unblinded outcomes. All researchers responsible for the analysis will remain blinded for the duration of the trial."|2x2 factorial, single-blind, non-inferiority, RCT of lower vs higher dose IV MP (methylprednisolone), and lower vs higher oral prednisone dose augmentation.|t|f|t|t
34025073|NCT04940559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Group 1 followed a 3-treatment, 3-period crossover study design. Group 2 followed a 2-treatment, 2-period crossover study design.||||
34025074|NCT05674851|NA|SINGLE_GROUP||OTHER||NONE||||||
34025075|NCT01713452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025076|NCT01893346|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33696869|NCT01209923|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33920711|NCT02797639|RANDOMIZED|PARALLEL||||NONE||||||
33920712|NCT02000648|||COHORT||PROSPECTIVE|||||||
33920713|NCT05137886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920714|NCT02825433|||COHORT||PROSPECTIVE|||||||
33920715|NCT03336762|||COHORT||PROSPECTIVE|||||||
33920716|NCT05275452|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34000759|NCT05955326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this double-blind study, the patient and all relevant personnel involved with the conduct and interpretation of the study (including the investigator, investigational site personnel, and the sponsor or designee's staff) will remain blinded to the identity of the Investigational Product (IP) assigned and the randomization codes. The final randomization list will be kept strictly confidential, filed securely by the independent biostatistician, and accessible only to authorized persons as per the sponsor's standard operating procedures until the completion of the study.|The Investigational product (IP) is Sovateltide. It is a lyophilized product, available as Sovateltide injection containing 30 μg of Sovateltide (IRL-1620) in a 5.0 mL vial. The investigational product will be provided by Pharmazz India Pvt. Ltd. Three doses of Sovateltide (each dose of 0.3 μg/kg body weight) will be administered as an IV bolus over one minute at 3 ± 1 hours interval on day 1. The dose will be repeated on day 3 and day 6 post-randomization. Sovateltide will be administered as an IV bolus dose over one minute within 24 hours of the stroke onset. All the patients in the Sovateltide group will continue receiving standard treatment. The reference product is Normal Saline therapy. Three doses of Normal Saline (Equal volume) will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.|t|t|t|t
34000760|NCT05846256|||COHORT||PROSPECTIVE|||||||
34000761|NCT02037854|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34000762|NCT00515216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089091|NCT05104593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is to be conducted in a simple-blind manner to minimize potential bias from investigators. It is not possible to conduct a double-blind study, because patients will know if they are using CAREPATH or not. In each site, two different investigators will be involved in the study. The first one will be responsible of initial assessments, randomization and management during follow-up. The investigator responsible of follow-up assessments for outcomes will be blinded to the assignment group in order to reduce the treatment effect bias.|Randomization will be performed centrally using a computerized system that uses stratified block randomization. After screening, patients who meet all eligibility criteria will be randomly assigned to 1 of 2 treatment groups (CAREPATH or control). Patients will be randomized in a CAREPATH to control ratio of 1:1. Randomization to intervention allocation will be stratified by sex, associated comorbidity and geographic region. Stratification factors will ensure balance of these factors across intervention arms and facilitate unbiased estimate of intervention effect in subgroups.|f|f|f|t
34089092|NCT05510492|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Evaluation of the skill training given to nurses on intramuscular injection with the z technique from the ventrogluteal region|f|f|t|f
34089093|NCT02481700|||COHORT||PROSPECTIVE|||||||
34089094|NCT04094428|||COHORT||PROSPECTIVE|||||||
34089095|NCT00472238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089096|NCT05195151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089097|NCT00397579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089098|NCT00481676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089099|NCT03212937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696870|NCT05049681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696871|NCT05957978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696872|NCT00032032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696873|NCT03751644|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients will be randomized by non-investigator from the present study|Patients with systemic autoimmune myopathies will receive or not the periphericalneuromuscular electrical stimulation in thigh muscles|f|f|t|f
33696874|NCT04021420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696875|NCT00894023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785342|NCT02924454|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785343|NCT06325553|||CASE_CONTROL||PROSPECTIVE|||||||
33785344|NCT06547645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33785345|NCT06033300|NA|SINGLE_GROUP||OTHER||NONE||||||
33920717|NCT02325687|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33920718|NCT04490317|||COHORT||PROSPECTIVE|||||||
33920719|NCT00553553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920720|NCT01958879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920721|NCT03553706|||COHORT||RETROSPECTIVE|||||||
33920722|NCT03623334|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33920723|NCT04084249|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34025077|NCT02026440|||CASE_CONTROL||PROSPECTIVE|||||||
34089100|NCT02593240|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33696876|NCT05934643|||COHORT||PROSPECTIVE|||||||
33696877|NCT05030818|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Each patient will be treated (Randomized) during 3 months with the polypill acetylsalicylic acid, ramipril and atorvastatin) and another 3 months with the same drugs and at the same doses than the polypill||||
33696878|NCT01354327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696879|NCT05389046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33696880|NCT01238185||||TREATMENT||NONE||||||
33696881|NCT00002895|RANDOMIZED|||TREATMENT||||||||
33696882|NCT01902238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696883|NCT05781373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33920724|NCT04440072|||COHORT||CROSS_SECTIONAL|||||||
33920725|NCT02453438|||OTHER||OTHER|||||||
33920726|NCT02982486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920727|NCT01963754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33920728|NCT00709917|||||PROSPECTIVE|||||||
33920729|NCT01059396|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33920730|NCT05883085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000763|NCT02297087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study is testing the specimens for genomic results. There are no other interventions.||||
34000764|NCT01613937|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34000765|NCT00398593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000766|NCT04726215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000767|NCT00776867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000768|NCT02597049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000769|NCT02663856|||CASE_ONLY||PROSPECTIVE|||||||
34000770|NCT03213548|RANDOMIZED|PARALLEL||TREATMENT||NONE||double blind clinical trial||||
33696884|NCT02612038|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33696885|NCT04920422|||OTHER||RETROSPECTIVE|||||||
34000771|NCT03594617|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33696886|NCT00003976||||TREATMENT||||||||
33696887|NCT06406790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be blinded to dural sealant until they have completed 90 day study.|Randomized 1:1 CraniSeal vs Comparator|t|f|f|f
34000772|NCT04317638|||COHORT||PROSPECTIVE|||||||
33696888|NCT05594810|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study design: a pilot study with a two-armed randomized controlled design is used in which AF-EMDR + Treatment As Usual (TAU) (Community Reinforcement Approach (CRA) aimed at SUD + a SCP) is contrasted with TAU-only with an intervention phase of three weeks pre- and post intervention assessments and a follow-up after one and three months.||||
33920731|NCT04826458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34000773|NCT01008709|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34000774|NCT04513327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785346|NCT05538754|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled subjects will undergo phakic eye surgery to have the STAAR EVO Implantable Collamer Lens (ICL) implanted in one or both eligible eyes.||||
34000775|NCT00356096||PARALLEL||TREATMENT||||||||
33785347|NCT06712823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000776|NCT03770130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785348|NCT06713174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920732|NCT03853512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920733|NCT01603030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920734|NCT01492296|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33785349|NCT06712108|||COHORT||PROSPECTIVE|||||||
33920735|NCT05055570|||COHORT||PROSPECTIVE|||||||
33920736|NCT02424422|||COHORT||PROSPECTIVE|||||||
33920737|NCT04432506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920738|NCT03717363|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomitzed interventional study with control group||||
33920739|NCT00592670|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34000777|NCT03039816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000778|NCT00960596|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34000779|NCT04956289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785350|NCT04321642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785351|NCT06366282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785352|NCT01763047|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920740|NCT01183338|||||PROSPECTIVE|||||||
33920741|NCT02919735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33920742|NCT01016548|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33920743|NCT04718324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33696889|NCT01995630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696890|NCT02367131|||COHORT||PROSPECTIVE|||||||
33696891|NCT02993718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33696892|NCT03417804|||COHORT||PROSPECTIVE|||||||
34000780|NCT03975439|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33785353|NCT06545786|||COHORT||PROSPECTIVE|||||||
33785354|NCT04436120|NA|SINGLE_GROUP||OTHER||NONE||||||
33785355|NCT05328973|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785356|NCT04679363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor will be masked by withholding information related to group allocation from him||f|f|f|t
33785357|NCT06628999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785358|NCT06111235|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by adjuvant cretostimogene versus TURBT alone for the treatment of participants with IR-NMIBC||||
33785359|NCT02922972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785360|NCT04413565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000781|NCT06445478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000782|NCT02646800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000783|NCT03368391|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|the dentist who administered the study medications will know their identity but the participant, investigator who tests the teeth, and person calling for later outcomes will not know.|triple blinded cross over randomized controlled trial|t|f|t|t
34000784|NCT00222040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089101|NCT02442908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089102|NCT05504915|||COHORT||PROSPECTIVE|||||||
33696893|NCT05241431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The medicine will be blinded by encapsulation of both active medicine and placebo in gelatine capsules, in order to blind treatment to both investigators and patients.||t|t|t|t
33696894|NCT06481839|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785361|NCT02219490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920744|NCT02913742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920745|NCT04521634|||COHORT||CROSS_SECTIONAL|||||||
33920746|NCT00410449|||||PROSPECTIVE|||||||
33920747|NCT02905903|NA|SINGLE_GROUP||OTHER||NONE||||||
33920748|NCT05521464|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled non-inferiority clinical trial of patients based on a parallel-group type with an allocation ratio of 1:1.||||
33920749|NCT05597917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920750|NCT03506100|NA|SINGLE_GROUP||OTHER||NONE||||||
33920751|NCT06100484|||COHORT||PROSPECTIVE|||||||
33920752|NCT01714297|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34089103|NCT05396690|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34089104|NCT05337826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089105|NCT02453022|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089106|NCT01499589|||COHORT||PROSPECTIVE|||||||
34089107|NCT05952999|||COHORT||PROSPECTIVE|||||||
34089108|NCT00191880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089109|NCT02745730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34089110|NCT01995916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34089111|NCT03951389|||CASE_ONLY||RETROSPECTIVE|||||||
34089112|NCT06195423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The proposed trial is a two-arm, assessor-blinded, superiority, hybrid effectiveness-implementation type 1 RCT.|f|f|f|t
34089113|NCT03707808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089114|NCT01568541|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34089115|NCT01610843|||COHORT||PROSPECTIVE|||||||
34089116|NCT02494024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089117|NCT00513799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785362|NCT02356159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34089118|NCT05363280|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The phase 2 study aims to find optimal biological dose (OBD) for Phase 2 expansion cohort clinical study. Patients will be randomized to a 3 different dosing daily AL8326 groups ( low. middle. high) in 1:1:1 ratio in OBD finding cohorts.~A phase 2 expansion cohort will be continued if a positive clinical result would have been observed after OBD determination."||||
34089119|NCT02811159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089120|NCT04044937|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34089121|NCT03407482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785363|NCT00319943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33785364|NCT06711458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785365|NCT00363285|RANDOMIZED|||TREATMENT||||||||
33785366|NCT00300703|||COHORT||RETROSPECTIVE|||||||
33785367|NCT00967369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785368|NCT06711640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785369|NCT03996239|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For cohort 3 only. Men with histologically-confirmed localized prostate cancer undergoing active surveillance. Both patients and investigators will be fully blinded to the ctDNA status of patients during study participation.||t|f|t|f
33785370|NCT01313182|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33785371|NCT06357364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"A researcher not having direct contact with participants will create a script generating random sequence using a computer random sequence generator (Matlab). Randomization will take place at an individual level, stratified by age, gender and procrastination severity (block randomization). Participants will be randomized into three groups with an allocation ratio of 1:1:1.~Pairs of experienced psychotherapists trained in one of the therapy protocols will deliver the interventions in an online group setting."||t|f|f|f
33785372|NCT02396940|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33785373|NCT03404960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785374|NCT06711536|||COHORT||PROSPECTIVE|||||||
33785375|NCT06711861|||CASE_ONLY||RETROSPECTIVE|||||||
33785376|NCT02712619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920753|NCT04269655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a parallel groups, randomized controlled trial (RCT) utilizing a 4:1 (Intervention: UC) ratio. This design was selected to maximize the number of Scripps patients receiving the CB CGM intervention, while also ensuring an adequate and representative UC group for comparison purposes.|f|f|f|t
33920754|NCT02308176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920755|NCT06123000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920756|NCT00642018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920757|NCT04609995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920758|NCT00970242|||||PROSPECTIVE|||||||
33920759|NCT04557163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920760|NCT04682353|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33920761|NCT01866761|||COHORT||PROSPECTIVE|||||||
33920762|NCT05178212|||COHORT||PROSPECTIVE|||||||
34089122|NCT04908501|||OTHER||RETROSPECTIVE|||||||
34089123|NCT04925440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089124|NCT00666250|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34089125|NCT00516646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089126|NCT00583544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089127|NCT05295589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920763|NCT03585699|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Separate individuals completed the random allocation sequence, patient enrollment and outcome assessment. Outcome assessors were blinded to group assignment.||f|f|f|t
33920764|NCT01117012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920765|NCT02589015|||CASE_ONLY||PROSPECTIVE|||||||
34089128|NCT00217230|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34089129|NCT02474641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089130|NCT00334399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089131|NCT04503460|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||All participants will receive salmeterol xinafoate monotherapy for 2 weeks, followed by a washout period for 2 weeks, followed by salmeterol xinafoate/fluticasone propionate combination therapy for 2 weeks.||||
34089132|NCT04139525|NA|SINGLE_GROUP||TREATMENT||NONE||The research will be performed as a prospective clinical trial. Every patient will have 2 HD procedures with PES-PVP membrane in a randomized order: 1 with unfractionated heparin (UFH) and 1 with 8% trisodium citrate.||||
34089133|NCT02953691|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089134|NCT04397861|||COHORT||PROSPECTIVE|||||||
34089135|NCT05165784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34089136|NCT04280952|NA|SINGLE_GROUP||TREATMENT||NONE||Tumor tissue identification with CONVIVO system||||
34089137|NCT02186041|||COHORT||PROSPECTIVE|||||||
34103133|NCT06686277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blinded|Randomized Clinical Trial|f|f|f|t
34103134|NCT04832854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000785|NCT01390948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000786|NCT04840355|||COHORT||PROSPECTIVE|||||||
33785377|NCT01460381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000787|NCT00522223|||CASE_ONLY||PROSPECTIVE|||||||
33785378|NCT02064751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785379|NCT06507735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000788|NCT02156453|||COHORT||PROSPECTIVE|||||||
34000789|NCT03417427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34000790|NCT00588783|||COHORT||PROSPECTIVE|||||||
34000791|NCT01841060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785380|NCT03401788|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2 Open Label||||
33785381|NCT05826431|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will use the equipment for two months as they choose, keep a log of their use, and answer pre- and post- participation questionnaires.||||
33785382|NCT05943938|||COHORT||PROSPECTIVE|||||||
33785383|NCT06378372|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||An intervention based on teaching the piano in an individualized way||||
33785384|NCT05579080|||COHORT||RETROSPECTIVE|||||||
33920766|NCT04105413|||CASE_CONTROL||PROSPECTIVE|||||||
33920767|NCT04855318|||CASE_CONTROL||PROSPECTIVE|||||||
33920768|NCT04393350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920769|NCT02465346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33920770|NCT00418379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920771|NCT00377429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920772|NCT01673191|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920773|NCT02925663|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are receiving an executive functioning intervention in an open trial design-pre-post||||
33920774|NCT03171311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920775|NCT03655574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed about which intervention arm they receive. Assessors will have the condition of the participant masked.|Two-arm randomized controlled trial|t|f|f|t
33920776|NCT02017613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920777|NCT04198233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All surgeons, patients and research staff will be blinded.||t|t|t|f
33920778|NCT04758858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920779|NCT03345433|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||interactive group drumming sessions||||
33920780|NCT01156207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920781|NCT00922350|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33920782|NCT05121909|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33920783|NCT04011748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||AA subjects will receive the treatment with Stem Cell Educator therapy|f|t|t|f
20452242|NCT00137618|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33785385|NCT06712654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785386|NCT04349384|||COHORT||RETROSPECTIVE|||||||
33920784|NCT03831308|||COHORT||PROSPECTIVE|||||||
33920785|NCT01889888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920786|NCT02083393|||COHORT||PROSPECTIVE|||||||
33920787|NCT01360515|||COHORT||PROSPECTIVE|||||||
34000792|NCT05682963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Total of two groups: Square stepping exercise program group and home exercise program group||||
34000793|NCT00869713|NA|SINGLE_GROUP||PREVENTION||NONE||"Open-label, Phase 2, uncontrolled, vaccine study to assess the safety, immunogenicity of RVF (inactivated) vaccine (1.0 mL subcutaneous, SQ).~Three primary series doses; for responders to the vaccine (PRNT80 ≥ 1:40), 6 month mandatory vaccine booster dose;~Three primary series doses; for non-responders to the vaccine (PRNT80 \< 1:40) may be boosted before 6 months."||||
34000794|NCT01573819|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34000795|NCT05606328|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This study is a pilot stepped wedge cluster randomized trial (SW-CRT) of three diverse emergency department (EDs) randomized to receive the intervention at 3-month intervals over a 15-month period. Time of crossover from the control to intervention period will be unidirectional, and each crossover sequence will allow for a 3-month implementation period where data will not be collected.||||
34000796|NCT02028416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000797|NCT00474188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696895|NCT02434120|||CASE_ONLY||CROSS_SECTIONAL|||||||
33696896|NCT01368432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696897|NCT03896685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696898|NCT05136131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The trial is a double blind (patient and physician blinded) at the time of cardioversion and during the four weeks of post intervention follow-up. The Informed Consent will clearly outline the importance of maintaining the blind to the patient. The blinded team will have no knowledge of treatment allocation. The blinded team will review the patient at all FUs and during any unscheduled hospital visits/admissions and will be point of contact for the patient's primary physician. This will include the MRP cardiologist and the study nurse / coordinator."|"All recruited patients will undergo a 4-week pre-cardioversion phase of medical optimization before randomization. One day prior to day of cardioversion, the patient will be randomized electronically using web-based software to shock or sham shock. The patient will remain blinded during the study period and will be unblended at the end of the study period."|t|f|t|t
33696899|NCT04134702|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696900|NCT01810432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33920788|NCT01430572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785387|NCT02537899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785388|NCT05982600|||CASE_ONLY||RETROSPECTIVE|||||||
33785389|NCT01120275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785390|NCT05978583|||COHORT||CROSS_SECTIONAL|||||||
33785391|NCT06196528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785392|NCT00530374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785393|NCT04054661|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785394|NCT01711918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785395|NCT06079593|RANDOMIZED|PARALLEL||OTHER||SINGLE|Images will be graded in a masked fashion||f|f|f|t
33785396|NCT02365298|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785397|NCT05342636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785398|NCT04138628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single country Investigator Initiated, Open-label, Single-arm, Non-randomized, Phase II study||||
33785399|NCT04370522|||COHORT||PROSPECTIVE|||||||
33785400|NCT06711926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Test beverages were presented to the participant in a dark bottle, and were not told which beverage they were consuming for each trial.|Randomised, crossover study.|t|f|f|f
33785401|NCT05030311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785402|NCT03458780|||CASE_ONLY||PROSPECTIVE|||||||
33785403|NCT02023944|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33920789|NCT03345732|||COHORT||PROSPECTIVE|||||||
33920790|NCT04665414|||COHORT||PROSPECTIVE|||||||
33920791|NCT03685526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785404|NCT05918133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785405|NCT06714266|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785406|NCT03751878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785407|NCT02076581|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785408|NCT02117869|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33785409|NCT00175435|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33785410|NCT04927598|||COHORT||PROSPECTIVE|||||||
33785411|NCT06703489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920792|NCT03201887|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33920793|NCT04493957|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single Blind||f|f|f|t
33920794|NCT03604068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920795|NCT04781569|||COHORT||PROSPECTIVE|||||||
33920796|NCT01019772|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920797|NCT04716153|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Ramdonized, controlled study with 2 parallel arms (interventional and control). Patients in the interventional arm will follow a multi-factor sensory rehabilitation program focused on smell and taste with daily use (3 times a day) of Liposomal sprays (LipoSaliva® : mouth and LipoNasal® : nose) between V0 and V1.~The control group will only receive the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional care."||||
33920798|NCT06281405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920799|NCT01208571|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33920800|NCT05701488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920801|NCT00475540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33920802|NCT03944070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920803|NCT05161637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920804|NCT03179579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920805|NCT03945734|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33920806|NCT01755312|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920807|NCT00484549|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33920808|NCT02835677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920809|NCT01233700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33920810|NCT00631540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920811|NCT05671926|||COHORT||RETROSPECTIVE|||||||
33920812|NCT04904965|RANDOMIZED|FACTORIAL||DIAGNOSTIC||TRIPLE||Patients will be randomized into 4 groups, of 5 patients each, to receive total intravenous anesthesia, with different propofol induction infusion rates: Group 1 (Propofol 2.0 mg/kg/hr); Group 2 (Propofol 4.0 mg/kg/hr); Group 3 (Propofol 6.0 mg/kg/hr); Group 4 (Propofol 8.0 mg/kg/hr).|t|t|f|t
33920813|NCT00602719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785412|NCT06707519|||COHORT||PROSPECTIVE|||||||
33785413|NCT05698940|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33785414|NCT04202575|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785415|NCT01400100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33785416|NCT02527889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33785417|NCT06703359|||COHORT||RETROSPECTIVE|||||||
33785418|NCT03401385|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single group, but in two study parts, therefore two sequential arms are identified||||
33785419|NCT06711549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33696901|NCT04516369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696902|NCT00879099|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33696903|NCT05828134|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000798|NCT02664350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34000799|NCT03478007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696904|NCT00702689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696905|NCT01908231|||COHORT||PROSPECTIVE|||||||
33696906|NCT00629772|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33696907|NCT06338150|||COHORT||PROSPECTIVE|||||||
33696908|NCT04194346|NA|SINGLE_GROUP||OTHER||NONE||Prospective, interventional||||
33696909|NCT01134315|||COHORT||PROSPECTIVE|||||||
33696910|NCT04210778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will take place only after the investigator will complete baseline assessment, so the assessment procedure wont be affected by group allocation. In addition, the investigator who will assess the outcomes post intervention and at 3 month follow up will be blind to the intervention allocation.|Randomized Controlled Trail (RCT)|f|f|t|t
33696911|NCT00569270|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33696912|NCT05182099|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|blinded to the reconstruction types||f|f|f|t
33696913|NCT03583723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785420|NCT03962192|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||An attitudinal survey will be completed by approximately 80 case note reviewers within the HiSLAC project||||
33785421|NCT04701060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785422|NCT06246422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The participants and the investigator will be kept blinded by the aid of closed sealed envelops. The measurements will be collected by the aid of assistant resident who will not participating into the study and blinded to it.|Prospective study|t|f|t|t
33920814|NCT03679429|||COHORT||PROSPECTIVE|||||||
33920815|NCT05706649|NA|SINGLE_GROUP||OTHER||NONE||||||
33920816|NCT02986685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920817|NCT05128682|NA|SINGLE_GROUP||OTHER||NONE||Subjects who meet all eligibility criteria will be enrolled in the study and will undergo urodynamic testing with UPP.||||
33920818|NCT03086681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920819|NCT02451202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920820|NCT04169854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000800|NCT04301817|||COHORT||PROSPECTIVE|||||||
34000801|NCT06103760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000802|NCT04793633|||COHORT||PROSPECTIVE|||||||
34000803|NCT00493883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000804|NCT02399891|||COHORT||PROSPECTIVE|||||||
34000805|NCT03318289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025078|NCT06164093|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33785423|NCT00557843|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920821|NCT06259864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920822|NCT04430946|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34025079|NCT04012151|||COHORT||PROSPECTIVE|||||||
33696914|NCT04025983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"The investigational product (IP) is compared with a placebo. The IP and placebo are manufactured by the sponsor and then sent to the trial pharmacist. They are only different in a number in the package label, and only the sponsor knows which number is the IP and will call them product I and product II. This labelling is not revealed to the study team, the trial pharmacist, and the biostatistician.~In the random number sequences generated by the biostatistician, the study numbers will be allocated to either product I or product II. The trial pharmacist is responsible for making product bags using study numbers and allocation given by the biostatistician. The product bags are transferred to the study team. In this way, the study team and patients are completely masked to the allocation."||t|t|t|t
34000806|NCT04618172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Effects of exercise on the symptoms of premenstrual syndrome and dysmenorrhoea and blood flow of genital tract. Different self-reported questionnaires and vaginal ultrasound flowmetry are used in the prospective observational study. The study has interventional and control groups.||||
33696915|NCT05055531|||COHORT||OTHER|||||||
33920823|NCT04011124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920824|NCT02452801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696916|NCT06665724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696917|NCT02350673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33920825|NCT00661102||PARALLEL||TREATMENT||NONE||||||
33920826|NCT01115881|||COHORT||PROSPECTIVE|||||||
34000807|NCT04600739|||CASE_ONLY||RETROSPECTIVE|||||||
34000808|NCT00509301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000809|NCT00162968|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34000810|NCT05198973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34000811|NCT04795245|||COHORT||RETROSPECTIVE|||||||
34000812|NCT00535353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000813|NCT01134822|||COHORT||PROSPECTIVE|||||||
34000814|NCT06007326|||COHORT||RETROSPECTIVE|||||||
34000815|NCT04153825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000816|NCT04540211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089138|NCT06113978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This retrospective study was conducted at the Department of pediatric surgery, Al-Azhar University Hospitals in the period from April 2008 to March 2023, involving patients of both sexes, below 18 years of age, suffering from severe bothersome bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathetic chain interruption.||||
34089139|NCT02402036|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34000817|NCT06527547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34000818|NCT01195220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34000819|NCT03310593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized and placebo controlled study|t|t|t|t
34089140|NCT04865705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089141|NCT02306668|||CASE_CONTROL||PROSPECTIVE|||||||
34089142|NCT00879177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696918|NCT04558281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study solution containing either local anesthetic (ropivacaine) or saline will be prepared by the UCSD Investigational Drug Study Service. Both ropivacaine and normal saline are clear and indistinguishable visually.|Randomized, double-masked, placebo-controlled, parallel group clinical study|t|t|t|t
33696919|NCT04665180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696920|NCT05089162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33696921|NCT02966873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33696922|NCT04102670|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive a combination of Ultherapy, Xeomin, Beletero Balance, Dilute Radiesse and Neocutis MicroFirm Face and Neck Cream||||
33920827|NCT01089829|||COHORT||PROSPECTIVE|||||||
33920828|NCT01017328|||CASE_ONLY||PROSPECTIVE|||||||
33920829|NCT05693870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920830|NCT04923620|||CASE_ONLY||PROSPECTIVE|||||||
34000820|NCT04970862|||COHORT||RETROSPECTIVE|||||||
34000821|NCT00999284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34000822|NCT05493358|||COHORT||RETROSPECTIVE|||||||
34000823|NCT05695651|||CASE_CONTROL||PROSPECTIVE|||||||
34000824|NCT03595241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34000825|NCT03467737|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34000826|NCT01492595|||COHORT||PROSPECTIVE|||||||
34000827|NCT04011787|RANDOMIZED|PARALLEL||PREVENTION||NONE||20 patients will be randomised to two arms with a control group of a further 10 patients||||
34000828|NCT02293616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000829|NCT06277076|||COHORT||PROSPECTIVE|||||||
34000830|NCT03291145|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000831|NCT00030511||||TREATMENT||||||||
34000832|NCT00453258|||COHORT||PROSPECTIVE|||||||
34089143|NCT00548327|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34089144|NCT00346437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089145|NCT03698149|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34089146|NCT02135198|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34089147|NCT02768155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089148|NCT00389870|RANDOMIZED|||TREATMENT||NONE||||||
33696923|NCT02623920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696924|NCT03722771|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33696925|NCT05239260|||COHORT||PROSPECTIVE|||||||
33696926|NCT04228783|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33696927|NCT03312998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920831|NCT05479305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920832|NCT05064332|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34000833|NCT00352807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34000834|NCT04817514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to what kind of protocol the participant is going through||f|f|f|t
34000835|NCT03634735|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blinded|RCT and crossover|t|t|t|f
34000836|NCT02571530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000837|NCT04153539|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34000838|NCT06285448|||COHORT||PROSPECTIVE|||||||
34000839|NCT04682587|||OTHER||RETROSPECTIVE|||||||
34000840|NCT02209857|||CASE_CONTROL||PROSPECTIVE|||||||
34000841|NCT05727579|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||While the treatment by ertugliflozin or placebo will be blinded, the sodium interventions are open-label.|t|f|t|f
34000842|NCT06000579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34000843|NCT04791007|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34000844|NCT03255980|RANDOMIZED|PARALLEL||OTHER||NONE||MONOCENTER, OPEN LABEL CLINICAL INVESTIGATION||||
34000845|NCT02451696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000846|NCT01158053|||COHORT||PROSPECTIVE|||||||
34000847|NCT00113919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000848|NCT01450800|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34000849|NCT00325780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696928|NCT05199493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000850|NCT01981044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000851|NCT00897676|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In a random crossover design, subjects were assigned to either intervention (6 hour infusion of exendin( 9-39) at a dose range of 100-500pmol/kg/min) or vehicle (6hr infusion of 0.9%NaCl)||||
34000852|NCT04943107|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34000853|NCT05492292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000854|NCT03735706|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"A computer random number generator prepares the randomization schedule in a 1:1:1:1 manner, which is balanced randomization. Stratification is performed, based on age (\< 60 and ≥ 60 years) and weight \< 75 and ≥ 75 kg). Variable block randomization will distribute patients equally over time.~The blinding and randomization process will be conducted by Clinical Trial Centre Maastricht (CTCM, www.CTCM.nl) with a randomization program (ALEA) designed for usage of different techniques."|randomized controlled trial with 4 study arms.|t|t|t|f
34000855|NCT01767753|NA|SINGLE_GROUP||||NONE||||||
34000856|NCT01435928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000857|NCT03470116|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34000858|NCT05685472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000859|NCT02082834|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000860|NCT06536049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000861|NCT03786705|||CASE_CONTROL||RETROSPECTIVE|||||||
34000862|NCT02753985|||COHORT||PROSPECTIVE|||||||
34000863|NCT05044533|||COHORT||PROSPECTIVE|||||||
34000864|NCT03901690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"In this clinical trial, the masking is triple because neither the participants nor the researchers nor the outcomes assessor will know exactly which drug will receive.~Only through a list created mathematically by Prof R Fentin will serve as a unique guide for the administration masked either beta-glucan gel or imiquimod in cream. Both packaged in the same tube without labeling on the outside."|prospective triple-blind randomized controlled clinical trial|t|f|t|t
34000865|NCT04077125|||COHORT||PROSPECTIVE|||||||
34000866|NCT03349632|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34000867|NCT05327322|RANDOMIZED|PARALLEL||OTHER||SINGLE|All staff collecting outcomes data will be randomized to treatment group (low GL vs standard GL).|Participants will be randomized to follow either a low GL or standard GL diet for 32 weeks. For the first 16 weeks, both groups will eat enough calories to maintain baseline weight. During the second 16 weeks, both groups will reduce calorie intake by 500 kcal/day,|f|f|f|t
34000868|NCT04884724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000869|NCT02227550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000870|NCT03281317|||COHORT||PROSPECTIVE|||||||
34000871|NCT01540045|||COHORT||PROSPECTIVE|||||||
34000872|NCT05909163|||COHORT||CROSS_SECTIONAL|||||||
34000873|NCT05259956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000874|NCT03428945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Active drug and placebo will be identical in appearance and packaging|Treatment assignment (active drug: placebo) will be assigned in a parallel, randomized, 2:1 model. Assignment will be stratified based on prior treatment for T1D prevention and age.|t|f|t|f
34000875|NCT00845949|||CASE_CONTROL||PROSPECTIVE|||||||
34000876|NCT03852745|NA|SINGLE_GROUP||TREATMENT||NONE||cognitive behavior therapy||||
34000877|NCT03391622|||COHORT||PROSPECTIVE|||||||
34089149|NCT02812043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000878|NCT04947150|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Outcomes assessors will be blind to condition.|This is a 2x2x2x2 design. There are four factors, each with two levels: ON vs OFF.|f|f|f|t
34000879|NCT00841620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000880|NCT02976064|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34089150|NCT00858286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696929|NCT01436006|||CASE_ONLY||RETROSPECTIVE|||||||
33696930|NCT05548309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33696931|NCT05788653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089151|NCT00998946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696932|NCT06403670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696933|NCT05579925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696934|NCT02030938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696935|NCT04629885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696936|NCT06533748|NA|SINGLE_GROUP||TREATMENT||NONE||This study utilizes a single arm phase II design enrolling eligible participants with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma.||||
33696937|NCT00395772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000881|NCT02917694|||COHORT||PROSPECTIVE|||||||
34089152|NCT01286350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089153|NCT01163799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089154|NCT02310607|||||PROSPECTIVE|||||||
34089155|NCT04067999|||COHORT||PROSPECTIVE|||||||
34089156|NCT00889434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696938|NCT03391310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
33696939|NCT06678919|||OTHER||OTHER|||||||
33696940|NCT04724980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089157|NCT02895737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34089158|NCT00254072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696941|NCT04625790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will not know their groups, and the transcranial magnetic stimulation applications will be done in similar conditions, except for no stimulation with the position of the coil. The masking will also be done for the care provider, investigator and the outcomes assessor, as the evaluator and the researcher who provides the randomization will be different, and the data recording will be kept without implying the groups.||t|t|t|t
33696942|NCT05133076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089159|NCT03650647|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Tooth receive one of the two test treatments: Stepwise Excavation (conservative treatment 1), Selective caries removal (conservative treatment 2) and are evaluated in parallel against a control group (indirect pulp capping treatment).|t|f|t|t
33696943|NCT00395954|||||PROSPECTIVE|||||||
34089160|NCT01018290|||CASE_ONLY||PROSPECTIVE|||||||
33696944|NCT02514603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696945|NCT01497327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089161|NCT00303186|||COHORT||PROSPECTIVE|||||||
33696946|NCT05168449|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33696947|NCT06198127|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be randomized controlled trial used to determine the effect of core stability exercises with and without kinesio-taping in CP children. Subjects with CP meeting the pre-determined inclusion and exclusion criteria will be divided into two groups using non-probability sampling technique.||||
33696948|NCT03696368|||COHORT||PROSPECTIVE|||||||
33696949|NCT04587544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, it is only possible to blind the evaluator of the study. The evaluator is blinded the group division either treatment or control group.|The randomized control trial study with two parallel-intervention-groups was employed to examine the effect of CWI (20-30C) therapy. All participants were randomly assigned to either CWI (20-30C) therapy intervention group or the control group. Block random sampling was then employed to generate the intervention and control group sequence. All participants were assessed on their pain as the primary outcome, joint mobility, stress, anxiety, depression, QOL (included PCS and MCS), physical activity (MET-h/week) at three times points: before the intervention, 2nd and 4th-week of the intervention.|f|f|f|t
33696950|NCT03496571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785424|NCT05348330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920833|NCT04631068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients participating will be randomised to either receive the Mono-EDoF ME4 Intraocular Lens (IOL) in both eyes or the TECNIS ZCB00 IOL in both eyes. Twice as many subjects will receive the Mono-EDoF ME4 IOL compared to the TECNIS ZCB00 IOL.~Both IOLs have received the CE marked. The aim with both IOLs is to provide patients good vision at distance with no glasses. The Mono-eDoF ME4 might offer the additional benefit of achieving good vision at intermediate distance without glasses."|t|f|f|f
33920834|NCT00502632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920835|NCT05424549|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33920836|NCT04154696|NA|SINGLE_GROUP||TREATMENT||NONE||Liver transplantation of a graft after assessment by normothermic perfusion||||
33920837|NCT03715959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920838|NCT02331524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920839|NCT04354064|||COHORT||OTHER|||||||
33920840|NCT03726333|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in the study will be assigned to different groups according to their liver function. Patients in each group will receive specific lorlatinib dose. Plasma samples for pharmacokinetic analysis will be collected in all patients. Safety and efficacy will also be followed in all patients until at least 28 days after the last study treatment.||||
33920841|NCT01469572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920842|NCT01480479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920843|NCT01654523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920844|NCT02007954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920845|NCT05602012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920846|NCT00304915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000882|NCT02134639|||CASE_ONLY||PROSPECTIVE|||||||
34000883|NCT02405793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34000884|NCT03510312|||COHORT||PROSPECTIVE|||||||
34000885|NCT03105193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089162|NCT02278211|||COHORT||PROSPECTIVE|||||||
34089163|NCT01614418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089164|NCT00569491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089165|NCT02446951|||COHORT||PROSPECTIVE|||||||
34089166|NCT02429466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089167|NCT01283347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089168|NCT05074537|||COHORT||PROSPECTIVE|||||||
34089169|NCT00689143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089170|NCT00066456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920847|NCT03248947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920848|NCT00003219||||TREATMENT||||||||
33920849|NCT00862121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920850|NCT01460745|||||RETROSPECTIVE|||||||
33920851|NCT06190743|||CASE_CROSSOVER||PROSPECTIVE|||||||
34000886|NCT00797576|||CASE_CONTROL||PROSPECTIVE|||||||
34089171|NCT06107023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000887|NCT05712564|||COHORT||CROSS_SECTIONAL|||||||
34000888|NCT05459116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000889|NCT03064867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089172|NCT02016118|||CASE_CONTROL||RETROSPECTIVE|||||||
34089173|NCT03258606|||COHORT||RETROSPECTIVE|||||||
34089174|NCT04211896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000890|NCT01505049|||||PROSPECTIVE|||||||
34000891|NCT01181830|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34000892|NCT00697918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000893|NCT00493727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000894|NCT03202251|||COHORT||PROSPECTIVE|||||||
34000895|NCT03699254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089175|NCT02689960|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34089176|NCT03710811|||CASE_ONLY||PROSPECTIVE|||||||
34089177|NCT06266013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the outcome assessor will not know in which group is each participant, and the investigator will receive the data without knowing which data is from which group||f|f|t|t
34089178|NCT03922932|||CASE_CONTROL||PROSPECTIVE|||||||
34089179|NCT03104023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34089180|NCT06433648|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"The goal of this study is to understand how providing power at the knee or ankle individually, or providing power at both the knee and ankle, impacts ambulation for transfemoral amputees with limited community mobility.~Aim 1: measure functional performance of transfemoral ambulators when using a commercially available passive microprocessor knee prosthesis (Ottobock Cleg/Ottobock foot) or a powered knee and ankle prosthesis (SRALab Hybrid Knee and SRAlab Polycentric Powered Ankle.~Aim 2: Participants will be evaluated on the contribution of adding power at the knee only or the ankle only.~Aim 3: The investigators will evaluate the functional performance after intensive clinical gait training on the powered knee and ankle prosthesis (SRALab Hybrid Knee and SRALab Polycentric Powered Ankle)."||||
33696951|NCT02570841|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34089181|NCT01692067|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34089182|NCT02803463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089183|NCT05422508|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"After the Protocol v4.1 was approved by Ministry of Food and Drug Safety (02Jun2023), Subject eligibility was change to 4 \~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination instead of 1st SUDUVAX inj. and Active Comparator: VARIVAX arm was deleted.~\*VARIVAX release has been discontinued."|t|f|t|t
34089184|NCT06078670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089185|NCT00984945|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34089186|NCT06281249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089187|NCT03572296|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Cross-over design. Each participant receives placebo plus 2 treatments.|t|f|t|f
33696952|NCT00378339|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33696953|NCT04267003|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33696954|NCT01756053|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920852|NCT04172337|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Using a within-person crossover design, participants were randomly assigned to one of six intervention sequences, which included the order of the three shops and when the actual purchase would take place, via random permuted blocks of size three with equal allocation for the six sequences (see Appendix Table A1) by a computer program. Participants were blinded to intervention allocation, which was allocated via the NUSMart system. Allocation results were recorded within NUSMart and all investigators, including the data analyst, were blinded to group allocation.|This will be a crossover study design with all participants exposed once to 3 shopping conditions (1xControl, 1x Arm 2 and 1x Arm 3) in random order. The total study duration for each participant is 3 weeks, with each participant spending 1 week in each shopping condition.|t|f|t|t
33920853|NCT03449745|||COHORT||PROSPECTIVE|||||||
33920854|NCT06191965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The person in charge of the randomization will manage a database with codes matched to the assigned treatment of each patient after the initial screening visit. Trial participants, clinicians, outcome assessors, and researchers involved in the assessments and analyses of collected data will remain blind concerning the MitoQ or placebo randomization. Unblinding is permissible at a clinician's request, for safety reasons, when the health condition of the participant may be or may have been affected by the administration of MitoQ or placebo. In such cases, study staff will find out from the person in charge of randomization which treatment the patient is receiving (MitoQ or placebo) and immediately communicate that information to the patient's clinician. After a participant's allocated intervention has been revealed, however, the subject will be excluded from the trial. The data collected to that point will be included in analyses.|Randomized controlled trial of MitoQ vs. placebo|t|t|t|t
33920855|NCT04509804|||OTHER||PROSPECTIVE|||||||
33920856|NCT02219841|||CASE_CONTROL||PROSPECTIVE|||||||
33920857|NCT00828334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920858|NCT01098825|||CASE_ONLY||RETROSPECTIVE|||||||
33920859|NCT00120289|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920860|NCT04008108|NA|SINGLE_GROUP||OTHER||NONE||||||
33920861|NCT01525355|||COHORT||PROSPECTIVE|||||||
33920862|NCT02098941|||COHORT||RETROSPECTIVE|||||||
33920863|NCT05244499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Tutors and researchers involved in the screening and baseline assessment will not be blind to the interventions provided during the trial. Participants, care providers and statistician will be kept blind to the study conditions.|A single-blind, individually randomised, two-arm parallel-group controlled feasibility trial design will be used.|t|t|f|f
33920864|NCT00839423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920865|NCT02725151|||COHORT||PROSPECTIVE|||||||
33920866|NCT02030613|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920867|NCT01722812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33920868|NCT04715256|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33920869|NCT01213069|||COHORT||PROSPECTIVE|||||||
33920870|NCT04511442|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920871|NCT00797485|RANDOMIZED|||TREATMENT||NONE||||||
33920872|NCT01517126|||||PROSPECTIVE|||||||
33696955|NCT05305339|||COHORT||CROSS_SECTIONAL|||||||
33696956|NCT05734833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Children will be randomly placed into either the probiotic group or no probiotic group in a 1:1 ratio. A 28-day supply of either probiotic or placebo will be given to each subject. Neither the research assistant nor the subject will be told which group they are in. All providers and research staff will be blinded, with the exception of Dr. Sharon Smith (Co-PI). The method for randomizing, labeling and packaging for home will be reviewed with the CT Children's pharmacy and we will follow their standard practices. The CT Children's pharmacy has been approached and agrees that for probiotics the pharmacy does not need to be directly involved|One group will receive the Probiotic and the other group will receive the placebo.|t|t|t|f
33696957|NCT00859183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696958|NCT02781779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920873|NCT05510609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920874|NCT04074824|||COHORT||PROSPECTIVE|||||||
33920875|NCT06335498|||CASE_ONLY||PROSPECTIVE|||||||
33920876|NCT02333591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33920877|NCT00012896|RANDOMIZED|FACTORIAL||||SINGLE||||||
33920878|NCT00790179|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33920879|NCT03558191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000896|NCT04391517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000897|NCT00556517|||CASE_ONLY||PROSPECTIVE|||||||
33920880|NCT03722914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920881|NCT03633565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920882|NCT05200156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study is a Prospective, Randomized, Controlled, single blinded study.|t|f|f|f
33920883|NCT05057143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920884|NCT02556424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920885|NCT00233818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920886|NCT00453843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33920887|NCT00329134|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920888|NCT04441879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000898|NCT02805517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000899|NCT04621617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696959|NCT00089856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000900|NCT02751424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000901|NCT02986139|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34089188|NCT00051597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089189|NCT04233229|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel assignment||||
34089190|NCT00283959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089191|NCT02565251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089192|NCT01179399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089193|NCT06551805|||OTHER||PROSPECTIVE|||||||
33696960|NCT04426201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unblinded Pharmacist will prepare blinded syringes of colorless drug or placebo|randomized controlled of treatment vs placebo|t|t|t|t
33696961|NCT05792423|NA|SINGLE_GROUP||OTHER||NONE||||||
33696962|NCT00512031|||COHORT||PROSPECTIVE|||||||
33696963|NCT05241483|||CASE_CONTROL||PROSPECTIVE|||||||
33696964|NCT00052780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696965|NCT01770028|||COHORT||PROSPECTIVE|||||||
33696966|NCT03182803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696967|NCT00003927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696968|NCT01499069|NA|SINGLE_GROUP||OTHER||NONE||||||
33920889|NCT00721318|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33920890|NCT03517306|||COHORT||RETROSPECTIVE|||||||
33920891|NCT01907841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920892|NCT00627835|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33920893|NCT03838445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920894|NCT06224972|||COHORT||PROSPECTIVE|||||||
33920895|NCT00201981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920896|NCT06481657|RANDOMIZED|PARALLEL||OTHER||SINGLE|The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).|Participants will be recruited for the study from all patients who apply to the Laniado Cardiac Rehabilitation Center. A cardiologist evaluation will be performed to examine the inclusion and research cartridges, as is customary at the venue participants will be asked to come up with echocardiogram results in an effort they have made in the community. At this point, participants who meet the criteria will be asked to be included in the study to participate in the study. After a detailed explanation they will be asked to give their written consent and will be randomly divided into groups. The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).|t|f|f|f
33920897|NCT00080886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920898|NCT02741219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33696969|NCT06169228|||COHORT||PROSPECTIVE|||||||
33696970|NCT02159612|||COHORT||PROSPECTIVE|||||||
33920899|NCT03766230|||COHORT||PROSPECTIVE|||||||
33920900|NCT04433728|||COHORT||PROSPECTIVE|||||||
33920901|NCT00111150|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33920902|NCT02950012|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33920903|NCT05079763|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33920904|NCT00270998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000902|NCT03239145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000903|NCT02121717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696971|NCT06319638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785425|NCT01269606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785426|NCT05824338|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785427|NCT06713070|||CASE_CONTROL||OTHER|||||||
33785428|NCT01720043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785429|NCT05556356|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants unblinded following final data collection.||t|t|f|f
33785430|NCT06711848|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000904|NCT01127776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000905|NCT05449080|||CASE_ONLY||RETROSPECTIVE|||||||
34000906|NCT06297408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000907|NCT00982228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000908|NCT05546398|||COHORT||RETROSPECTIVE|||||||
34025080|NCT05353387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103135|NCT06694116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The aim of this single arm prospective observational and intervational study is to investigate the detection rate, sensitivity, specificity, negative predictive value and positive predictive value of using charcoal carbon dye as a sentinel tracer in IFLN basin. Early stage primary vulvar tumors less than 4 cm with any histology but without any clinically or radiographically detectable inguinofemoral lymph nodes will be included. The parameters will be compared to pathologic results obtained from full IFLND.||||
33920905|NCT04328233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920906|NCT04231955|NA|SINGLE_GROUP||SCREENING||NONE||all 50 patients marked their pain intensity levels of their relevant tooth in four different rating scales.||||
33920907|NCT04066530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696972|NCT03418623|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|"The study will be double-blinded. At initiation visit the Investigator will be instructed on the method for blind breaking. The Contract Research Organization (CRO) will provide the Investigator with a set of sealed envelopes, each containing the unblinding information for a patient kit; the envelopes will be kept in the Pharmacy until the end of the study. A second set of sealed envelopes will be kept by the Sponsor pharmacovigilance officer.~Unblinding codes should only be used in emergency situations for reasons of patient safety. The Investigator should contact the Sponsor before breaking the blind or the Sponsor should be informed immediately afterwards. The reason for breaking the blind must be fully documented and entered on the case report form.~The unblinding envelopes will be checked for integrity by the Clinical Research Associate (CRA) and returned to the Sponsor at the end of the study.~The subjects for whom the blind will be broken will be withdrawn from the study."|After the eligibility of a subject has been determined in an initial screening period, the study will be conducted in 2 consecutive phases: in the first phase (phase A) the participant will be administered GET73 or placebo in a randomized order, in the other phase (phase B), the participant will be administered the treatment not received during phase A.|t|t|t|t
33696973|NCT04128371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785431|NCT00435786|||CASE_CONTROL||OTHER|||||||
33920908|NCT01933256|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33920909|NCT00671216|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920910|NCT06524596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33920911|NCT05486936|||COHORT||PROSPECTIVE|||||||
33920912|NCT01661868|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920913|NCT06416397|||CASE_ONLY||PROSPECTIVE|||||||
33920914|NCT01188096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920915|NCT04145869|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33920916|NCT01033487|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920917|NCT04801394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920918|NCT05535309|||OTHER||RETROSPECTIVE|||||||
33920919|NCT00003157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920920|NCT04055987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of hearing-impaired persons with cochlear implants.One group will have congenital hearing loss. The second group will include individuals with acquired hearing loss.||||
33920921|NCT00044486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920922|NCT03173612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920923|NCT04565600|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33920924|NCT04863937|NA|SINGLE_GROUP||PREVENTION||NONE|Devices were used in a randomized order. The outcomes assessor evaluated device differences based on device numerical assignment..|This study measured knee frontal plane projection angle (FPPA) and sports safety and performance perceptions of female athletes during a single leg triple hop for distance for 3 conditions (standard knee sleeve, no device and distal thigh compression garment (DTCG)).||||
33920925|NCT01303432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33920926|NCT00387270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920927|NCT04367441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920928|NCT03852914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920929|NCT00884715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920930|NCT01579266|||||PROSPECTIVE|||||||
33920931|NCT02463136|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33920932|NCT01541267|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33920933|NCT01839201|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33920934|NCT00434499|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33920935|NCT03865459|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33920936|NCT05164679|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Healthy, sedentary postmenopausal women aged below 70 years were eligible to participate in the present study.~Inclusion criteria were:~* non-smoker~* body mass index (BMI) \<30 kg/m2.~Exclusion criteria were:~* T-score \< -3 SD in the lumbar spine or hip~* high BMD in relation to age (Z-score \> 1.5 SD)~* use of hormone therapy, medical treatment, or supplements that affect bone metabolism~* previous or current medical condition affecting bone health~* engagement in regular and systematic weight-bearing training or strength training during the preceding two years.~Initially, twenty women were recruited to the training via an online advertisement and a local newspaper, but only 19 showed up for pre-testing. After a medical examination, one participant was excluded due to low BMD (T-score \< -3 SD), and two were excluded due to high BMI (≥30 kg/m2)."||||
33696974|NCT05787288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33696975|NCT04906460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696976|NCT03207893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785432|NCT05552547|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089194|NCT04563325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor (qualified pediatrician or pediatric surgeon) of the primary endpoint (sequelae 6 months after initiation of treatment) will be blinded for the intervention as well as any other details on the course of disease. The assessor will be informed about the age of the child as well as the approximate location of the infection and will perform a predefined systematic clinical examination of the relevant area (categories: 1) lower extremities, 2) upper extremities incl. claviculae and scapulae and 3) columna, costae and sternum). The exact anatomical location including side (left or right) will not be revealed. The child and parents will be followed by a study nurse who will secure that the blinding is respected. The primary endpoint is met if there are any positive findings related to the previously infected bone or joint.||f|f|f|t
33920937|NCT02005224|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920938|NCT05750420|||COHORT||CROSS_SECTIONAL|||||||
33920939|NCT02410096|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34089195|NCT06228989|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre prospective randomized controlled trial||||
33920940|NCT00861679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920941|NCT02483689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920942|NCT05565976|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Duoble-blinded study, only outcome assessor will have knowledge of labels.||t|t|t|f
33920943|NCT02535078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920944|NCT03450915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All parties are blinded except for the person who prepares the syringe for injection. The M-001 is cloudy white and its appearance is different from the transparent saline that is used for placebo. The person prepares the syringe with an opaque sticker that fully covers the syringe contents. People administering the syringe are not involved or present during syringe preparation, and are thus fully blinded.|Experimental group: 2 immunizations with M-001 Control group: 2 injection of saline (placebo)|t|t|t|t
33920945|NCT03116308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920946|NCT00003194||||TREATMENT||||||||
33920947|NCT02098460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33920948|NCT03277768|||COHORT||PROSPECTIVE|||||||
33920949|NCT04065191|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920950|NCT04739891|||CASE_ONLY||RETROSPECTIVE|||||||
33920951|NCT00634335|||COHORT||CROSS_SECTIONAL|||||||
33920952|NCT03046342|||CASE_ONLY||PROSPECTIVE|||||||
33920953|NCT04529421|||COHORT||PROSPECTIVE|||||||
33920954|NCT00022152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920955|NCT02199613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920956|NCT01916616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920957|NCT06446206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920958|NCT04015440|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is an online study. Volunteer assignment to each of the two experimental conditions is semi-randomized (i.e. random except that computer ensure equal sample sizes across experimental conditions). The randomized assigning of participants is done by the study web-page/program at volunteerscience.com. The computer program randomly assigned volunteers to one of the two conditions when they begin the study.|t|f|f|f
33920959|NCT02781350|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33920960|NCT02443571|||COHORT||RETROSPECTIVE|||||||
33920961|NCT02288611|RANDOMIZED|CROSSOVER||||NONE||||||
33920962|NCT04948463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920963|NCT05200052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920964|NCT05891691|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33920965|NCT01902862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920966|NCT01633671|||CASE_CONTROL||RETROSPECTIVE|||||||
33920967|NCT00866268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33920968|NCT06240494|||OTHER||RETROSPECTIVE|||||||
34089196|NCT00209482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089197|NCT00733434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089198|NCT00432432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089199|NCT06027437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33696977|NCT05273996|NA|SINGLE_GROUP||OTHER||NONE||Naturalistic study using FDA approved antidepressants to examine the effects of stress and neuroticism on outcomes||||
33696978|NCT05853120|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33696979|NCT05967000|||CASE_ONLY||PROSPECTIVE|||||||
33785433|NCT05087472|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33785434|NCT05274789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785435|NCT06041893|||CASE_ONLY||PROSPECTIVE|||||||
33785436|NCT00310362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33785437|NCT00246298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785438|NCT02014558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920969|NCT01159509|||CASE_CONTROL||PROSPECTIVE|||||||
33920970|NCT05366192|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33920971|NCT05708924|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33696980|NCT03815643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696981|NCT01348607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33696982|NCT03480035|||OTHER||PROSPECTIVE|||||||
33696983|NCT05233293|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel|t|t|f|f
34000909|NCT02229084|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This combined Phase I/II feasibility-and-efficacy study will have three parts. Part 1 will be a Phase I evaluation of the safety, tolerability, and feasibility of the Chemovax to assess the timing of vaccination relative to chemotherapy. Five different Chemovax schedules (Schedule A, B, C, D, and E) will be sequentially evaluated. Once such a feasible schedule is identified, the study will proceed with its second and third parts. Part 2 (primary efficacy) and Part 3 (expanded efficacy) will respectively constitute Stages 1 and 2 of the Phase II primary-efficacy evaluation of Chemovax using a Simon optimal two-stage design.||||
33785439|NCT05378581|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled, open-label, two arms parallel, multicenter therapeutic trial||||
33785440|NCT04341064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785441|NCT00512408|||||PROSPECTIVE|||||||
33920972|NCT01175213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33920973|NCT04695899|||COHORT||PROSPECTIVE|||||||
33920974|NCT02214485|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33920975|NCT04331990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both the outcome assessors and the study statistician will be blinded to group allocation.||f|f|f|t
33920976|NCT05572307|||CASE_CONTROL||PROSPECTIVE|||||||
33920977|NCT00276770|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33920978|NCT06511440|||COHORT||PROSPECTIVE|||||||
33920979|NCT01164865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33920980|NCT03549858|||COHORT||PROSPECTIVE|||||||
33920981|NCT01486173|||COHORT||PROSPECTIVE|||||||
33920982|NCT01626989|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33920983|NCT02236741|||COHORT||RETROSPECTIVE|||||||
33920984|NCT04268095|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33920985|NCT05423002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33920986|NCT02995122|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33920987|NCT04282681|||COHORT||PROSPECTIVE|||||||
33920988|NCT06315855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33920989|NCT03779893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33920990|NCT03008733|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33920991|NCT04713579|||CASE_ONLY||PROSPECTIVE|||||||
33920992|NCT02405650|||COHORT||PROSPECTIVE|||||||
34000910|NCT01896492|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34000911|NCT00157066|RANDOMIZED|PARALLEL||||DOUBLE||||||
34000912|NCT03043040|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a non-randomized non-blinded multicenter intervention study with control group. Patients from hospital A and B are included in the intervention group. Patients from hospital C are included in the control group.||||
34000913|NCT04817995|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated either to the intervention or control groups. The control group is a waiting list. The control group will participate in the intervention after it will be completed for the intervention group.||||
34000914|NCT02711527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000915|NCT01717040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000916|NCT05881733|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, single-center, study||||
34000917|NCT06369935|||COHORT||PROSPECTIVE|||||||
34025081|NCT04914455|||COHORT||PROSPECTIVE|||||||
34025082|NCT01002937|||COHORT||RETROSPECTIVE|||||||
33785442|NCT04166487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785443|NCT05960162|||COHORT||RETROSPECTIVE|||||||
33920993|NCT03017846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920994|NCT00566449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33920995|NCT05710965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33920996|NCT05269641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33920997|NCT05568498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, triple-blind, placebo-controlled study|t|t|t|t
33920998|NCT03288324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33920999|NCT02518100|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33921000|NCT06049615|NA|SINGLE_GROUP||OTHER||NONE||The Conscious Sedation Single Arm Sub-Study is designed to evaluate the safety and performance of the CLAAS device implantation procedure using conscious sedation.||||
33921001|NCT04285944|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921002|NCT01779713|||CASE_CONTROL||PROSPECTIVE|||||||
34025083|NCT04187417|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|sealed, numbered opaque envelopes||t|t|t|t
34000918|NCT04254809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant are blind to condition randomization, as are clinicians who provide suicide risk assessments throughout the follow-up period.|Participants are randomized upon enrollment to one of two conditions: Re-Evaluating Suicidal Thoughts (active condition) or Healthy Social Living (control condition).|t|f|f|t
34000919|NCT05676008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34000920|NCT05134571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000921|NCT04715139|||CASE_ONLY||PROSPECTIVE|||||||
34000922|NCT00662194|||COHORT||CROSS_SECTIONAL|||||||
34000923|NCT06677723|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34000924|NCT05797480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Baseline evaluation - Randomization to real dry needling or sham dry needling (6 sessions for 6 consecutive weeks) - post-treatment evaluation (2-week post-treatment)|t|f|t|t
34000925|NCT00951535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000926|NCT06113549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000927|NCT06343688|||CASE_ONLY||PROSPECTIVE|||||||
34000928|NCT01494090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000929|NCT01608906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000930|NCT00659815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34000931|NCT01181596|||CASE_CONTROL||PROSPECTIVE|||||||
34000932|NCT04631133|||COHORT||PROSPECTIVE|||||||
34000933|NCT06381323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000934|NCT04572854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000935|NCT00089973|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000936|NCT02213887|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34000937|NCT06667310|||OTHER||OTHER|||||||
34000938|NCT02625311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000939|NCT02156219|||COHORT||PROSPECTIVE|||||||
34000940|NCT00794053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34000941|NCT02414464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000942|NCT06200376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000943|NCT05564845|||COHORT||PROSPECTIVE|||||||
34000944|NCT00310492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000945|NCT00645944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34000946|NCT05919901|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will select 10 schools (\~60 parents/children per school) by a stratified random sampling approach. We will randomize schools in a 1:1 ratio to the intervention and control arms. Randomization, based on a computer-generated assignment, will occur after the 10 schools have been selected. Control participants will be eligible to receive the intervention materials at the end of the 1-year follow-up period.||||
34000947|NCT04011098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be randomized to one of two groups according to a 1:1 allocation with blinding of the intervention accomplished by providing the Anesthesia practitioner with either a 3 ml syringe filled with 2 ml of standard epidural mix (control) or 2 ml of Fentanyl (50 mcg/ml)(intervention):~1. Control group: will receive a 2 ml bolus of standard epidural mix solution after epidural placement followed by standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia.~2. Fentanyl bolus group: will receive a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia."|Prospective randomized control trial (RCT) utilizing parallel groups|t|t|t|f
34000948|NCT01845064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000949|NCT04975724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000950|NCT00709137|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000951|NCT02584166|||COHORT||PROSPECTIVE|||||||
34000952|NCT00907205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000953|NCT04988737|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial||||
34000954|NCT03409315|||COHORT||PROSPECTIVE|||||||
34000955|NCT04161950|||CASE_ONLY||PROSPECTIVE|||||||
34000956|NCT02836587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34000957|NCT03825198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The medication for the sham block with NaCl or the local anaesthetic will be prepared by an independent medical caregiver who has no connection with the patient. The anaesthetics performing the block, the patient and the observation nurses/doctors collecting the data are masked. The solutions used are not distinguishable from each other.|double blind randomised|t|t|t|t
34000958|NCT04194008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000959|NCT05998811|||CASE_CROSSOVER||PROSPECTIVE|||||||
34000960|NCT01089530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34000961|NCT00384592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000962|NCT05423873|NA|SINGLE_GROUP||OTHER||NONE||"Prospective, Multi-Center, Open-Label 33 female subjects between 35 to 60 years old with Fitzpatrick skin type I-V, moderate to severe global face hyperpigmentation, and moderate global face photodamage.~Washout period of 2 weeks refraining from active antiaging topical products, including vitamin C, retinoids, peptides, and growth factors."||||
34000963|NCT03458845|||CASE_CONTROL||PROSPECTIVE|||||||
34000964|NCT04758390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Adolescent girl and young women-female caregiver (AGYW-FC) dyads will be randomized to the IMARA intervention arm or a health promotion control arm matched in time and intensity. IMARA and the health promotion program will be delivered as group interventions.|f|f|f|t
34000965|NCT00417651|||CASE_ONLY||PROSPECTIVE|||||||
34000966|NCT01531023|||CASE_CONTROL||PROSPECTIVE|||||||
34000967|NCT03742063|||COHORT||RETROSPECTIVE|||||||
34000968|NCT00778453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000969|NCT00658034|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34000970|NCT00163709|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34000971|NCT01877122|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34000972|NCT05100680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34000973|NCT01937689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000974|NCT02924649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34000975|NCT02627274|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34000976|NCT02418754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089200|NCT03276299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33696984|NCT03143543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Starting lorcaserin dosage of 10 mg per day for 7 days in one arm, versus placebo for 7 days in parallel arm. An interim analysis will take place after 15 subjects have completed at each arm. Based on the interim analysis, if there is no significant effect and no trend towards significance for the lower dose of lorcaserin in the primary regions of interest for fMRI task, and no significant accumulation of adverse effects, testing will stop for the lower dose of lorcaserin, and testing will begin for the higher dose, which is the FDA approved usual dose for lorcaserin (20 mg per day, given as 10 mg twice per day). The higher dose of lorcaserin will be tested in a two group parallel arm design, initially with 15 subjects in lorcaserin arm and 15 subjects in the parallel placebo arm. Another interim analysis will take place after 15 subjects have completed at each arm in the higher dose lorcaserin study.|t|t|t|t
34089201|NCT01158677|||COHORT||PROSPECTIVE|||||||
34089202|NCT03507101|||CASE_ONLY||PROSPECTIVE|||||||
33696985|NCT05960942|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34089203|NCT03047252|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will be assessed for clinical outcomes by an independent rater blinded to the study arm||f|f|f|t
34089204|NCT03196141|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||3 groups: healthy volunteers (15) and normotensive (10) and pre-eclamptic (10) pregnant women during their visit to labor floor.||||
34089205|NCT00250588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089206|NCT03176914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data analysts will be provided with coded data that doesn't reflect which arm the data is from.|The study will have an intervention arm under which the study intervention will be implemented and this will be compared with the outcomes in the conventional intervention arm. Each arm will have 11 clusters of an average size of 50.|f|f|f|t
34089207|NCT04004182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This acute intervention study will have a randomised controlled crossover design where the volunteers will return for 4 stand-alone study sessions||||
34089208|NCT01562444|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089209|NCT01922193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089210|NCT04709887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089211|NCT01795612|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34089212|NCT03883373|||COHORT||RETROSPECTIVE|||||||
34089213|NCT00480116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089214|NCT02341079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089215|NCT06319833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089216|NCT01605903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089217|NCT00019071||||TREATMENT||||||||
34089218|NCT05073471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be randomly assigned to either PSE or PSE+tDCS group. There will be double blinding for tDCS sessions. The research assistant who administrates tDCS modulation will be blinded to whether participants are receiving active (right or left) or sham tDCS. The participants will also be blinded to whether they receive active (right or left) vs. sham tDCS.~Outcomes assessors will also be blinded whether the participant receives active (right or left) or sham tDCS modulation."|Participants will be randomly assigned to either PSE or PSE+tDCS group. Following baseline assessment, participants in both groups will receive 30 minutes long, twice a week for 3 weeks. Assessments will be conducted before and after each session. Follow-up assessment will be administrated one month after the last session (6th session).|t|f|t|t
34089219|NCT05106569|||COHORT||PROSPECTIVE|||||||
34089220|NCT05939167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33696986|NCT01039974|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33696987|NCT04456101|||COHORT||PROSPECTIVE|||||||
33696988|NCT00954304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696989|NCT02979197|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33921003|NCT02119026|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921004|NCT00804843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921005|NCT03153020|||COHORT||PROSPECTIVE|||||||
33921006|NCT03487406|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33921007|NCT04372342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921008|NCT00985296|||CASE_CONTROL||PROSPECTIVE|||||||
33921009|NCT04077736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921010|NCT00604435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921011|NCT03972826|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921012|NCT02823041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921013|NCT03351569|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Drug and placebo had the same appearance and are wrapped in foil paper before being shown to the patient.~Outcome evaluation is carried out by personnel not involved in the treatment at a distant site, one month after treatment."|sigle patient trial|t|t|t|t
33921014|NCT03933514|||CASE_CONTROL||OTHER|||||||
33921015|NCT02783144|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921016|NCT00448370|||COHORT||PROSPECTIVE|||||||
33921017|NCT01927393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921018|NCT04485234|||COHORT||PROSPECTIVE|||||||
33921019|NCT05939037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921020|NCT05913479|NA|SINGLE_GROUP||OTHER||NONE||Prospective, multicenter (France), open label without comparator study||||
34089221|NCT02969018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089222|NCT06530693|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34089223|NCT05470998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089224|NCT00071981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089225|NCT04690426|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089226|NCT04730492|||COHORT||RETROSPECTIVE|||||||
34089227|NCT00005988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089228|NCT01453231|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089229|NCT04146883|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a multi-center, prospective, randomized and open-labeled study.||||
34103136|NCT05262673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921021|NCT01790009|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33921022|NCT02664207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921023|NCT01462448|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785444|NCT06631131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of twenty-seven patients were initially included. However, five patients were excluded because they discontinued treatment (n=2), had poor treatment compliance (n=2), or had poor radiograph quality (n=1). Consequently, the final sample comprised 22 individuals, with 11 individuals (22 second molar, 22 first molar and 22 second premolar) in each group, ranging in age from 15 to 25. All patients were treated with clear aligners.The patients were divided into two groups, those who were treated with sequential distalization with aligners supported by Class II elastics (group 1) or IZC miniscrews (group 2).||||
33785445|NCT01090609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785446|NCT01912326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785447|NCT03246581|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33785448|NCT06711822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785449|NCT03988387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785450|NCT05797545|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33785451|NCT03416218|NA|SINGLE_GROUP||OTHER||NONE|There is only one condition to this study, so no masking will be used.|Participants enrolled in the study will play Prognosis, a game-based intervention designed to improve STEM skills.||||
33785452|NCT00256308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785453|NCT03193346|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785454|NCT04667988|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
33785455|NCT01002976|||CASE_CONTROL||PROSPECTIVE|||||||
33785456|NCT06085131|||COHORT||PROSPECTIVE|||||||
33785457|NCT06714084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785458|NCT03956199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785459|NCT05335681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled|t|f|f|f
33785460|NCT04956354|||COHORT||PROSPECTIVE|||||||
33921024|NCT03036449|||COHORT||PROSPECTIVE|||||||
33921025|NCT03256734|||COHORT||RETROSPECTIVE|||||||
33921026|NCT03151512|||COHORT||PROSPECTIVE|||||||
33921027|NCT00013481|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921028|NCT04014270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As the two interventions (SM-FES and SC) are different in appearance for both the participant and the therapist providing the therapy session, only the assessor (i.e., person administering the outcome tests) will be kept blinded to treatment condition.||f|f|f|t
33921029|NCT00695708|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33921030|NCT02293993|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33921031|NCT03519672|||COHORT||PROSPECTIVE|||||||
33921032|NCT03579992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Occupational Therapists were blinded to intervention group||f|f|f|t
33921033|NCT01602237|||COHORT||OTHER|||||||
33921034|NCT02700295|||COHORT||PROSPECTIVE|||||||
33921035|NCT03280069|||CASE_ONLY||PROSPECTIVE|||||||
33921036|NCT05713578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental: apantamide+docetaxel+ADT;Active.Comparator: apantamide+ADT treatment|t|t|f|f
33921037|NCT01762306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33921038|NCT05789849|NA|SINGLE_GROUP||OTHER||NONE||This is an open label, single-site, single arm, prospective, pivotal study including a training phase and a data collection phase.||||
33921039|NCT01074658|||COHORT||PROSPECTIVE|||||||
33921040|NCT00975429|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921041|NCT01127295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921042|NCT01184846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921043|NCT03728504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921044|NCT02004808|||COHORT||PROSPECTIVE|||||||
33921045|NCT03312868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921046|NCT03115112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921047|NCT05911464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921048|NCT00247260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921049|NCT00000384||||TREATMENT||||||||
33921050|NCT05435742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921051|NCT01512147|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921052|NCT03480958|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33921053|NCT04387318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921054|NCT01121003|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921055|NCT04782804|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921056|NCT05508399|||COHORT||PROSPECTIVE|||||||
33921057|NCT01175421|||COHORT||PROSPECTIVE|||||||
33921058|NCT06144242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921059|NCT01155596|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33921060|NCT00098020|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, open-label pilot study||||
33921061|NCT01252641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921062|NCT04917497|||COHORT||PROSPECTIVE|||||||
33921063|NCT01373424|||OTHER||OTHER|||||||
33921064|NCT02521623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921065|NCT03992209|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Two study arms to include:~1. Standard hand washing by anesthesia provider~2. Protocolized hand washing by anesthesia provider"|f|f|f|t
33921066|NCT02196987|||CASE_CONTROL||PROSPECTIVE|||||||
33921067|NCT06118164|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients who agreed to participate were randomly assigned to the experimental group or one of the two control groups (Control I and Control II) by outpatient nurses drawing lots from a lottery box. Once the group assignment was determined, on the day of admission, the researchers provided instructions on the respective intervention measures for that group (Pursed-lip breathing combined with aerobic walking exercise group, Pursed-lip breathing only group, Aerobic walking exercise only group). Data collection was carried out by registered nurses with at least two years of clinical experience in non-enrollment wards.|"The experimental group was given pursed-mouth breathing training combined with aerobic walking exercise.~Control group I was given pursed-mouth breathing training. Control group II was given aerobic walking exercise."|t|t|f|t
33921068|NCT03450525|||COHORT||PROSPECTIVE|||||||
33921069|NCT01676857|||COHORT||PROSPECTIVE|||||||
33921070|NCT01151540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025084|NCT01960712|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34025085|NCT03954834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089230|NCT04729517|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first group will receive AI201901 , whereas the second group will receive azelastine hydrochloride. Patients that will receive AI201901 are defined as the test arm and patients that will receive azelastine hydrochloride are defined as the active control arm.||||
34089231|NCT03697356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089232|NCT01551173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089233|NCT05660876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921071|NCT04141553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be managed by unblinded emergency department pharmacist. This individual will have knowledge of the assigned treatment group for each participant, knowing if diltiazem is provided as IV push or slow infusion. Unblinded pharmacist will also provide sham saline dose, opposite of assigned diltiazem treatment to maintain the blind to care providers.|"A parallel randomized blinded model. Eligible and consented participants will be randomized to diltiazem IV push or diltiazem slow bolus. Each will receive an opposite sham infusion of saline provided as IVP push or slow bolus t0 maintain the blind. All participants will receive 30 mg oral dose of diltiazem. Standard of care measures will be provided concurrently as per routine care of patients with atrial fibrillation or atrial flutter with rapid ventricular response~Participants will be randomized in 15 blocks of 20 to ensure there are equal numbers of participants in each group for interim analyses. The randomization scheme will allow for 300 participants to account for issues, including dropouts."|f|t|f|f
34089234|NCT00143507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089235|NCT02017717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089236|NCT01161888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33696990|NCT03728530|RANDOMIZED|PARALLEL||PREVENTION||NONE||Study was to determine the effects of deep breathing exercises in smokers. It was conducted on the general population of Isra Institute of Rehabilitation Sciences, Isra University, Islamabad Campus. 30 participants were selected through Non probability Convenience Sampling and later equally divided into experimental (n=15) and control group (n=15) through lottery method. Inclusion criteria were young smokers between 20-30 years of age and without any chronic pulmonary complication, smoking for past five years. Smokers with any pulmonary disease, acute infections, other systemic disease, chest deformity or any disability were excluded from study.||||
33696991|NCT00876876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33696992|NCT04108442|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33696993|NCT00729755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33696994|NCT04263961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33696995|NCT05804474|||CASE_ONLY||RETROSPECTIVE|||||||
33696996|NCT01645904|||FAMILY_BASED||PROSPECTIVE|||||||
33696997|NCT04609969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.||||
33696998|NCT01974154|||CASE_CONTROL||PROSPECTIVE|||||||
33696999|NCT00815711|||COHORT||PROSPECTIVE|||||||
33921072|NCT04879654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921073|NCT03509987|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921074|NCT04653857|||CASE_ONLY||RETROSPECTIVE|||||||
33921075|NCT03846219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Trial participants, treating and evaluating physicians, central MRI readers and all other personnel directly involved in the conduct of the trial will be blinded to treatment assignments during the main treatment period and for the initial time of the extended treatment period. The evaluating physician will also be blinded to any clinical outcome or treatment change.~Once the results of the main treatment period are available, treating physicians, participants, and other involved personnel, except for the evaluating physician, will be unblinded. The evaluating physician will remain blinded to patients' clinical characteristics and treatment assignment during the entire clinical trial."|"This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (30 mg/day and 45 mg/day) in the main study (10 mg/day for the patients in the substudy) in patients with RRMS and evidence of active disease. The trial consists of a screening period, a blinded 24-week main treatment period, and an optional initially blinded, then open-label extended treatment period of up to 9.5 years.~The trial includes 2 patient cohorts:~* Cohort 1 main trial: main Phase 2 trial with assessment of primary and key secondary endpoints.~* Cohort 2 sub-trial: additional sub-trial with a small double-blind, placebo-controlled, randomized, parallel-group assessment of 10 mg/day IMU-838 dose to provide additional data for pharmacodynamic modelling."|t|t|t|t
33921076|NCT02677220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921077|NCT05958758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921078|NCT02800720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33921079|NCT00718666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921080|NCT05883007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921081|NCT01232751|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33921082|NCT04238676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacist and injector will not be blinded to treatment allocation||t|t|t|t
34000977|NCT03428542|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel-group RCT with three arms during 5 weeks. Subjects were randomized to a control group, the Yin Yoga intervention group or the YOMI intervention group. YOMI intervention combines Yin yoga with psychoeducation and mindfulness practice.||||
34000978|NCT03757520|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||"According two Smartphone Addiction Proneness Scale (SAPS) the subjects will be divided into two groups: Regular user group with SAPS score 39 or less. Heavy user group with SAPS score 40 or more.~we have two variables to be assessed:~1. Pain pressure threshold for two muscles (upper fiber of trapezius and sternocleidomastoid muscle)~2. Hand grip force"||||
34000979|NCT00013364|||||PROSPECTIVE|||||||
34000980|NCT00850447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000981|NCT04252716|||OTHER||PROSPECTIVE|||||||
33697000|NCT04965051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697001|NCT01511965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697002|NCT05804097|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33697003|NCT04603716|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33697004|NCT02504996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34000982|NCT05889039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34000983|NCT06340698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33785461|NCT03441984|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study in healthy volunteers.|2-part study with 3-TPs each. Part 1, compares relative BA of TRIUMEQ dispersible tablets for pediatric populations (DTG, 5 milligram \[mg\]/abacavir \[ABC\] 60 mg/3TC 30 mg), when administered as direct-to-mouth and when dispersed into purified water, with adult TRIUMEQ conventional tablet (DTG 50 mg/ABC 600 mg/3TC 300 mg), administered as direct-to-mouth (reference). Additionally, part 2 will compare relative BA of DTG/3TC (DTG 5 mg/3TC 30 mg), dispersible tablets for pediatric populations, when administered as direct-to mouth and when dispersed into purified water, with adult DTG (50 mg) and 3TC (300 mg) conventional tablets, when administered as direct-to-mouth (reference). Each TP, in Part 1 and 2 will have, wash-out period of 7-days (with minus 4 hours) between each single dose, for flexible dosing. During TPs, subjects will be admitted, to clinic on Day-1, following completion of last study procedure on Day 4, post which follow-up visit conducted, 7 to 10 days after last dose.||||
33785462|NCT02433509|NA|SINGLE_GROUP||TREATMENT||NONE||acute ischemic stroke||||
34089237|NCT05255419|||COHORT||PROSPECTIVE|||||||
33785463|NCT06616688|||COHORT||CROSS_SECTIONAL|||||||
34089238|NCT02714647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34089239|NCT06241950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089240|NCT02598115|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33785464|NCT02892799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33785465|NCT06171789|NA|SINGLE_GROUP||TREATMENT||NONE||mTPI||||
33785466|NCT02766504|||COHORT||PROSPECTIVE|||||||
33785467|NCT06707324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33785468|NCT05231122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785469|NCT06713707|||OTHER||CROSS_SECTIONAL|||||||
33785470|NCT01511588|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785471|NCT06313684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785472|NCT00878384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089241|NCT00404313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089242|NCT04461392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103137|NCT03165695|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33785473|NCT06094140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785474|NCT06629376|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33785475|NCT05448755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785476|NCT02161510|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785477|NCT06711172|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34000984|NCT00890916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000985|NCT02386007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34000986|NCT05386134|||CASE_CONTROL||PROSPECTIVE|||||||
34000987|NCT06534164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded to which study arm participants have been allocated to. Due to the nature of the study, investigator's and participants cannot be blinded, althouhg intervention group participants will be blinded as to which intervention (High vs. Low tech) they have been allocated to.|This is an assessor-blinded, parallel, randomised controlled study. Participants will be block randomised by condition (stroke, MCI, long covid-19, vestibular disorders) using an online platform into either the intervention group (IG) or control group (CG). Within the IG, participants will be randomised into one of two groups; 1) High tech TeleRehab DSS system, 2) Low tech TeleRehab DSS system. Participants will not be able to choose their preferred group and must be willing to participate in the assigned group.|t|f|f|t
34000988|NCT01468688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34000989|NCT04474145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34000990|NCT02579226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34000991|NCT04540068|||COHORT||PROSPECTIVE|||||||
34000992|NCT01126606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34000993|NCT03576053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Only the third sub-study is conducted in a double-blind manner.||t|f|t|f
34000994|NCT05259852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000995|NCT03867773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34000996|NCT02658435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34000997|NCT00158925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34000998|NCT00490386|||DEFINED_POPULATION||OTHER|||||||
34000999|NCT00730652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001000|NCT04348955|||COHORT||PROSPECTIVE|||||||
34025086|NCT06579781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025087|NCT02598856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34025088|NCT02113553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025089|NCT01324531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001001|NCT05772858|RANDOMIZED|PARALLEL||OTHER||NONE||150 therapists will be randomly assigned to be trained by either the Family Therapy Training and Implementation Platform (FTTIP) or a Traditional in person Training as Usual (TAU). 150 families will all receive the Culturally Informed Flexible and Family based Treatment for Adolescents. 30 agency leaders will be randomly assigned to Family Therapy Training and Implementation Platform (FTTIP) agency readiness consultation or Agency readiness consultation as usual.||||
34001002|NCT05436626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001003|NCT01144845|||COHORT||RETROSPECTIVE|||||||
34001004|NCT02929927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001005|NCT00070239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001006|NCT06348576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001007|NCT02196467|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34001008|NCT03492567|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001009|NCT03033030|||COHORT||PROSPECTIVE|||||||
34001010|NCT04703933|||OTHER||CROSS_SECTIONAL|||||||
34001011|NCT01216540|||COHORT||RETROSPECTIVE|||||||
34001012|NCT05060458|||COHORT||PROSPECTIVE|||||||
33697005|NCT04462185|||COHORT||PROSPECTIVE|||||||
34089243|NCT06080815|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"According to the construction technique for the maxillary complete denture and mandibular overdentures, the patients will be classified randomly and equally into two groups.~Group I: patients receive maxillary complete denture opposed to four implant-assisted mandibular overdenture constructed with conventional method.~Group II: patients receive maxillary complete denture opposed to four implant-assisted mandibular overdenture constructed with CAD/CAM milling."|t|f|f|f
33697006|NCT06266312|NA|SINGLE_GROUP||PREVENTION||NONE||A prospective, single-centre, longitudinal mixed-methods feasibility study will be performed to investigate the feasibility of a multimodal prehabilitation programme consisting of MIET during neoadjuvant intravenous chemotherapy infusion, HITT and strength training during the last six weeks prior to surgery, and optimising nutritional intake throughout the total preoperative period in patients with breast cancer.||||
34001013|NCT02445846|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697007|NCT01460589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001014|NCT04305470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Phase 3, open-label, single arm study.||||
34089244|NCT06264687|||CASE_ONLY||PROSPECTIVE|||||||
34089245|NCT05502731|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, single center, two-arm, investigator-initiated, interventional clinical study||||
33697008|NCT02670434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697009|NCT00586131|RANDOMIZED|CROSSOVER||OTHER||NONE||Treatment with sodium citrate/citric acid or ammonium chloride chloride in each phase to achieve the desired arterial pH||||
34001015|NCT02591849|RANDOMIZED|CROSSOVER||||NONE||||||
33697010|NCT01242683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34001016|NCT02319603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089246|NCT02689622|NA|SINGLE_GROUP||OTHER||NONE||||||
34089247|NCT05929170|||COHORT||PROSPECTIVE|||||||
34089248|NCT03977207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697011|NCT03845543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697012|NCT02665312|||COHORT||PROSPECTIVE|||||||
33697013|NCT03260920|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double Blind|A Proof-of-Concept Double Blind Randomized Controlled, Cross-Over Adaptive Design Trial|t|t|t|t
33697014|NCT04408131|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921083|NCT06035588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The present study presents blinding of both the evaluator and the person who will carry out the statistical analysis, and therefore double-blind. The evaluators are considered blind in this study because they do not know the randomization of the patients, being a blind study. The operator and patients know the groups in which they are assigned, due to the delivery and placement of the splints.~A block randomization of the treatment applied to the patients will be carried out, to ensure that the sample size is similar in both groups. The operator will open an envelope for the group's allocation. The assignment of the groups will be carried out using opaque, sealed and sequentially numbered envelopes. The operator will open the envelope when the splints are delivered, and will give the pertinent explanations to the patient. Data will be collected from each patient that may influence treatment results such as age, sex, initial color, systemic pathologies and pharmacological treatments."|Each volunteer will be given 3 syringes of 16% carbamide peroxide bleaching gel to use on the splint. Volunteers will be instructed to use the whitening gel once a day for 2 hours, completing a total of 3 weeks of whitening procedure. Depending on the randomization, the whitening procedure will be performed on alternate days or daily. In the upper arch, the teeth to be whitened will be from 15 to 25 and in the lower one from 35 to 45.|f|f|t|t
34001017|NCT04735172|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34001018|NCT03860441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind randomized controlled trial|Participants in the intervention group followed a computerized cognitive training program for 2-months, 3x/week, 40min/session|t|f|f|f
34001019|NCT03827005|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|blinding performed by co-investigator not involved with data collection|double blind, placebo, controlled -cross over|t|f|t|f
34001020|NCT00721955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001021|NCT04070222|||CASE_CONTROL||PROSPECTIVE|||||||
34001022|NCT01160640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001023|NCT02856776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34001024|NCT02316457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001025|NCT02745860|RANDOMIZED|CROSSOVER||||NONE||||||
34001026|NCT05210049|NA|SINGLE_GROUP||SCREENING||NONE||||||
34001027|NCT01811433|||||PROSPECTIVE|||||||
34001028|NCT01710358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001029|NCT04385043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001030|NCT01095887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001031|NCT04436718|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open label controlled trial||||
34001032|NCT00530348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001033|NCT00006262||||TREATMENT||||||||
34089249|NCT03977818|||COHORT||RETROSPECTIVE|||||||
34089250|NCT05522530|||OTHER||CROSS_SECTIONAL|||||||
33697015|NCT00496509|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001034|NCT04172480|||CASE_ONLY||PROSPECTIVE|||||||
33697016|NCT03037801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001035|NCT05005013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001036|NCT03262883|||COHORT||RETROSPECTIVE|||||||
34001037|NCT03390257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001038|NCT04182555|NA|SINGLE_GROUP||SCREENING||NONE||200 newborns with varying degree of jaundice will be recruited.||||
34001039|NCT06265038|NA|SINGLE_GROUP||OTHER||NONE||Prospective, single-arm, open-label clinical trial. This clinical investigation addresses to collect data on clinical performance, effectiveness and safety of Sanatmetál's ReSpace TiCell Cage in human subjects following the good clinical practice according to the Medical Device Regulation (MDR) \& EN ISO 14155:2020. The study is conducted in Hungary at National Center for Spinal Disorders.||||
34001040|NCT04142658|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel control and treatment arm at a 1:1 ratio.||||
34001041|NCT01564901|||COHORT||PROSPECTIVE|||||||
34001042|NCT04673825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
34001043|NCT04800926|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34001044|NCT03791541|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Survey will be given to all participants|targeted, cost-effective interventions based on results of surveys and other factors studied will be applied to study arm to see if re-admissions can be prevented|t|f|f|f
34089251|NCT04153656|NA|SINGLE_GROUP||OTHER||NONE||||||
33697017|NCT00032097||||TREATMENT||||||||
33697018|NCT05694052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the type of intervention under study, the patient and the research team can not be blinded to the group assignment. Statisticians and the researchers responsible for analysis of PSG and actigraphy, as well as those performing long-term outcome assessments, will be blinded to the group allocation.|"Prospective, parallel-group, randomized trial in critically ill patients. The project will follow the CONSORT guidelines for this class of studies.~Patients randomized sequence will be generated by a computer program with an allocation 1:1. They will be randomized to receive a multifaceted intervention of environmental control in the ICU (intervention group) or standard care (control group)."|f|f|f|t
33697019|NCT00239902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697020|NCT03911154|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The SmartSleep device will be programmed by investigators not involved in study execution. Subjects will wear the SmartSleep device each night and will be unaware of the order of stimulation modalities. In addition, both study personnel and those assessing outcomes will not be aware of the order of stimulation modalities.|This study uses within subject randomization. Each subject will receive all of the 4 sleep conditions in a randomized order that will be unknown to the subject.|t|f|t|t
33697021|NCT06677918|RANDOMIZED|PARALLEL||OTHER||DOUBLE|During the study, study participants, investigators, the sponsor, and all other persons involved in the conduct of the study will be blinded to treatment.||t|f|t|f
33697022|NCT00085124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921084|NCT05511025|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33921085|NCT05378022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo Navax and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax suspension is unrecognizable to investigators except the PI and analyzer, nurses, patient's parents, and patients due to opaque plastic container.|Blind, randomized, and controlled clinical trial|t|t|t|f
33921086|NCT05161182|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33921087|NCT00836277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921088|NCT00870818|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33921089|NCT03844503|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33921090|NCT02440295|||COHORT||PROSPECTIVE|||||||
33921091|NCT04485117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921092|NCT03807232|||COHORT||RETROSPECTIVE|||||||
33921093|NCT03170557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician in charge for data analysis will be blind with respect to the identity of the assignment Groups (that will be coded so as not to be recognized) and will not be involved in filling data in the database to be analyzed.|Randomized comparative trial|t|f|f|t
33921094|NCT02802878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921095|NCT05297656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was designed as blinded, randomized and controlled. The person who evaluates the patients before and after the treatment is blind. In other words, the person evaluating the patients and the person giving the treatment are different.|Randomized Controlled Trial|t|f|f|t
33921096|NCT00305747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921097|NCT02531464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921098|NCT06333392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921099|NCT00209833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921100|NCT04256304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33921101|NCT00980421|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34001045|NCT05068661|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34001046|NCT01182792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001047|NCT02473055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001048|NCT02383628|||CASE_CONTROL||PROSPECTIVE|||||||
34001049|NCT00141505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001050|NCT04283851|||COHORT||PROSPECTIVE|||||||
34001051|NCT01581892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001052|NCT05311150|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The pathologist analyzing the biopsy specimen will be masked.|||||
34001053|NCT05642949|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single group, but in two study parts, therefore two sequential arms are identified||||
34001054|NCT02789839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001055|NCT00418041|||COHORT||PROSPECTIVE|||||||
34001056|NCT05245955|NA|SINGLE_GROUP||OTHER||NONE||||||
34001057|NCT05839886|||COHORT||PROSPECTIVE|||||||
34001058|NCT05123885|||COHORT||RETROSPECTIVE|||||||
34001059|NCT00967395|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34001060|NCT06251895|||COHORT||RETROSPECTIVE|||||||
34001061|NCT02261181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921102|NCT05838209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants - The randomization performed will use the coin heads or tails method, Investigators -Two treatments at randomly chosen sites separate in two groups: Ozone oil use as an adjunctive of scaling and root planing and saline solution 0.09%, as a control, associate as an adjunctive of scaling and root planing. Ultrasonic scaler and Gracey curets use to remove all calculus and biofilms during scaling and root planing. The oils are numbere syringes labeled 1 and 2 for blinded applications, and 1 ml of each oil were administrated in a previous selected site. After removing baseline samples of biofilm, the scaling and root planing were performed using ultrasonic devices and manual Gracey curettes.|This is a prospective clinical randomized controlled, split mouth designed, doble blinded study.|t|t|f|f
33921103|NCT00823524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921104|NCT05596786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921105|NCT01707368|||COHORT||PROSPECTIVE|||||||
33921106|NCT03129204|RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective, randomized, experimental design||||
33921107|NCT02067416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921108|NCT06341699|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33921109|NCT00405652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921110|NCT01943318|||COHORT||PROSPECTIVE|||||||
33921111|NCT04335604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921112|NCT02331615|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921113|NCT05314881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921114|NCT01476748|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33921115|NCT03685552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921116|NCT00178087|||CASE_CONTROL||PROSPECTIVE|||||||
34001062|NCT03727139|||COHORT||PROSPECTIVE|||||||
34001063|NCT02798406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001064|NCT02575456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34001065|NCT01633307|RANDOMIZED|PARALLEL||||NONE||||||
34001066|NCT00616096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001067|NCT06347627|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34001068|NCT05756218|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Blinding; groups 'X and Y are named as independent statistical posts statistical blinding, blinding the educational staff conducting the professional practice course, blinding the person preparing the randomization table and the control group. In order for the control group to be blinded, this group was planned from another faculty.~Randomization below will be performed by a statistical specialist other than randomization researchers for the purpose of preventing bias and ensuring confidentiality. He will not know which of the lecturers who are lecturing in both groups are in the experimental group and who are in the control group. Statistical analyzes were performed and after the research report is written, the encodings made for the intervention and control group will be opened. Blinding will be provided in terms of collecting and reporting departmental research data. By an independent statistic in random ranking list order random.org made on site."|It was designed as a parallel group randomized controlled trial. The reporting of the study was planned in accordance with the PEER criteria|t|f|f|t
34001069|NCT01424787|||COHORT|||||||||
34001070|NCT03944109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001071|NCT02229916|||COHORT||PROSPECTIVE|||||||
34001072|NCT05013619|||OTHER||CROSS_SECTIONAL|||||||
34001073|NCT01919827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001074|NCT04411251|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089252|NCT01767220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089253|NCT01859000|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34089254|NCT04660383|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33921117|NCT03240718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921118|NCT04950192|||CASE_ONLY||PROSPECTIVE|||||||
33921119|NCT05670431|||OTHER||PROSPECTIVE|||||||
34089255|NCT02733419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089256|NCT02511756|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34089257|NCT05072808|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34089258|NCT05958563|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control study||||
33697023|NCT04794634|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33921120|NCT03624764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33921121|NCT00749164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921122|NCT04591496|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants are assigned to one of three groups in parallel for the duration of the study|t|f|t|t
33921123|NCT05475912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921124|NCT00680953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921125|NCT03538132|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921126|NCT00453180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921127|NCT03918044|||COHORT||PROSPECTIVE|||||||
33921128|NCT06377722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697024|NCT04228393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785478|NCT06700993|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All outcomes are completed through surveys so the research team is not blinded, per se, but they are not involved in the participant responses.|Partnering primary care clinics will recruit study participants and provide them treatment as usual in their Collaborative Care or other Integrated Behavioral Health program. This will be followed by training in the experimental intervention, the Connections model. Trained clinicians will recruit study participants and provide them with the Connections model in their Collaborative Care or other Integrated Behavioral Health program. This is a pilot study in preparation for a larger stepped wedge or other cluster randomized trial.|f|f|f|t
33785479|NCT06627907|||COHORT||PROSPECTIVE|||||||
33785480|NCT00312312|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785481|NCT00004886||||TREATMENT||||||||
33785482|NCT01605968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785483|NCT00692562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921129|NCT06187311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921130|NCT00856258|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33921131|NCT03659760|RANDOMIZED|PARALLEL||OTHER||SINGLE||prospective randomize|t|f|f|f
33921132|NCT02625675|||COHORT||PROSPECTIVE|||||||
33921133|NCT00920036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921134|NCT02714504|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921135|NCT02992834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921136|NCT02850952|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33921137|NCT01993615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921138|NCT03200093|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|After enrollment, study pharmacists will randomize the participants to receive either oral vancomycin or placebo. Participants, care providers, investigators, and outcomes assessors will be masked.|Randomized, placebo-controlled|t|t|t|t
33921139|NCT03978104|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Primary investigator of the study will be blinded in this intervention trial through blinding of the intervention allocation to subjects.||f|f|t|t
33921140|NCT02494778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921141|NCT02750267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921142|NCT01006109|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921143|NCT04779632|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"A person, who was not involved in the data collection generated the randomization list (online tool) and packed both types of capsules in containers of similar appearance and labeled them with ID and period. The participants were allotted to ID numbers based on date and time of their first visit and supplied with the relevant capsule container in the beginning of each period.~The oil capsules were provided by two different companies and not the same size: 1 ml Eskimo-3 High 65% (Midsona Malmӧ, Sweden) and 0.75 ml SO (Natur-Drogeriet A/S, Hørning, Denmark). Containers were only handled by colleagues and participants and the investigator tried to prevent un-blinding due to differences in rattling sound by use of noise-cancelling in-ear headphones.~Blinding was checked by asking the participants and the investigator to guess which oil they had received at the end of the interventions. Formal un-blinding did not occur before the primary statistical analyses was completed."|Randomized 2 x 4 weeks head-to-tail crossover trial.|t|f|t|t
33921144|NCT04736329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921145|NCT06048653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system); and the study group (GII) will receive the same program as (GI) in addition to Vagus nerve stimulation.|t|f|f|f
33921146|NCT02780479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921147|NCT00442767|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921148|NCT00818207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921149|NCT02834091|||COHORT||PROSPECTIVE|||||||
33921150|NCT03245801|||COHORT||PROSPECTIVE|||||||
33921151|NCT03911778|||CASE_CONTROL||PROSPECTIVE|||||||
33921152|NCT03636568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33921153|NCT01829217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921154|NCT01181102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921155|NCT00254358|||COHORT||CROSS_SECTIONAL|||||||
33921156|NCT02190617|RANDOMIZED|FACTORIAL||||NONE||||||
33921157|NCT06213129|||CASE_CONTROL||PROSPECTIVE|||||||
33921158|NCT00019227||||TREATMENT||||||||
33921159|NCT01382173|||COHORT||PROSPECTIVE|||||||
33921160|NCT04965207|||CASE_ONLY||PROSPECTIVE|||||||
33921161|NCT04239079|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33921162|NCT03587571|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Comparison of two established treatment options. Prospective, randomised (central block randomisation) multi-center clinical trial.~The two treatment options (operative versus conservative) are split in two study arms and compared to each other. Patients are randomly allocated to one of the two study arms."||||
33921163|NCT02072382|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33921164|NCT03701646|||CASE_ONLY||PROSPECTIVE|||||||
33921165|NCT00337012|||||PROSPECTIVE|||||||
33921166|NCT02027415|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33921167|NCT04092998|NA|SINGLE_GROUP||TREATMENT||NONE||male infant presented for Circumcision||||
33921168|NCT01333306||||BASIC_SCIENCE||||||||
33921169|NCT03074149|||OTHER||PROSPECTIVE|||||||
33785484|NCT04159948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will not be blinded to which arm they have been allocated to. Outcome assessors will be unaware of group allocation.|3 arms with equal allocation.|f|f|f|t
33921170|NCT06202001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921171|NCT04627012|||COHORT||CROSS_SECTIONAL|||||||
33921172|NCT01707329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921173|NCT05517356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921174|NCT02277522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921175|NCT05575284|||COHORT||PROSPECTIVE|||||||
33921176|NCT01241019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001075|NCT02435433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001076|NCT04021407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participiant Investigator|Parallel assignment|t|f|f|t
34025090|NCT02345837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001077|NCT05183451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention neither the operator nor the patients could be blinded. The assessors will be blinded from the data to be investigated he will just measure the data needed without knowing the purpose of the study, and without knowing which records belong to which group. Two assessors will carry out the the analysis of the study, blindly and independently.||f|f|f|t
34001078|NCT06620757|||CASE_ONLY||PROSPECTIVE|||||||
33785485|NCT05309486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were evaluated at the beginning of the study and 8 weeks later by an experienced physical therapist blind to randomization. The group participants belonged to was not disclosed to the participants from the initial assessment to the end.|Using a computer program, the investigators randomly placed individuals who completed the initial assessment into the online pilates group (OPG) or face-to-face pilates group (FPG).|t|f|f|t
33785486|NCT03141788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785487|NCT04980222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785488|NCT00725413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785489|NCT02029053|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785490|NCT00234559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785491|NCT06287450|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785492|NCT06712693|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will know they are being fit with hearing aid, but will not be told which vent size or dome they are being fit with for any of the tests. The investigator scoring the speech test will not know which vent size/dome participant is wearing.|Each participant will be fit with the investigational devices under three conditions: Power dome, Vented dome, and Open dome. Participant will complete the same tests under each condition. All participants will complete the same conditions.||||
33785493|NCT04669405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33785494|NCT06107920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001079|NCT00231582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001080|NCT00379353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33785495|NCT03303105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001081|NCT03092167|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Open label|15 idiopathic inflammatory myopathies submmited to physical exercises 15 idiopathic inflammatory myopathies not submmited to physcial exercises 10 healthy individuals||||
34001082|NCT01899053|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001083|NCT01276496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001084|NCT04681586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089259|NCT03421457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider will be blind to the operation type. Outcomes will be assessed by a gynecologist who will be blind to the operation type, indications and complications. Assessor has wide experience in urogynecological sonography.||f|t|f|t
33785496|NCT04680897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"The early group will be given instructions that allow them to return to vaginal penetration/intercourse after 2 weeks. The standard group will be given postoperative instructions that allow them to return to intercourse after 6 weeks. Both groups will be able to return to other physical activities as they feel able"|f|t|f|t
33785497|NCT02749279|||COHORT||PROSPECTIVE|||||||
33785498|NCT01278862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785499|NCT02744079|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785500|NCT05869643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Initial randomization to Cohort 1 or 2 will not be blinded. However, randomization within each cohort to either receive STP0404 or matching placebo is blinded.||t|f|t|f
33785501|NCT02403323|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921177|NCT06071637|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization (simple) will be performed in permuted blocks using the REDCap® program, after inclusion in the study, by a member of the non-blinded team.|This is a phase III, double-blind, randomized intervention study that will use the low-power laser device to prevent oral mucositis and oropharyngeal pain in two protocols with different dosimetry (divided into Group A and Group B).|t|f|f|t
33921178|NCT05871229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized at the end of baseline visit|Randomized|t|f|t|f
33921179|NCT05516693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Advisor will be blind to the analysis of the results.|This is a randomized, controlled clinical trial with two intervention arms, involving severely obese adult patients of both sexes referred for bariatric surgery.|f|f|f|t
33921180|NCT05941169|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33921181|NCT02060318|||COHORT||PROSPECTIVE|||||||
33921182|NCT00370890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921183|NCT04354779|||COHORT||CROSS_SECTIONAL|||||||
33921184|NCT06252766|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Trio (Researcher, Child and Parent) The researcher, the child and the parent, who knows the groups and waives all rights to the research, will evaluate the children's pain and anxiety levels during the procedure.|The research is a randomized controlled experimental type study.|t|t|t|f
33921185|NCT00377585|RANDOMIZED|PARALLEL||PREVENTION||||||||
33921186|NCT02541448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921187|NCT03963713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-randomized trial||||
33921188|NCT04657653|||COHORT||OTHER|||||||
33921189|NCT05778019|||CASE_ONLY||PROSPECTIVE|||||||
33921190|NCT05754697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921191|NCT04981977|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34001085|NCT05694234|||COHORT||RETROSPECTIVE|||||||
33785502|NCT04204564|||COHORT||OTHER|||||||
33921192|NCT03495453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001086|NCT01425840|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34001087|NCT00818298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697025|NCT05310656|NA|SINGLE_GROUP||PREVENTION||NONE|Due to the nature of the research, it is not possible to blind the researcher and the participant because the researcher applied the mindfulness-based empowerment program, took part in the data collection and analysis phase, and the women in the intervention group were aware of the practice.|The universe of the research will be the women who have been subjected to violence staying in women's shelters in a province in Turkey. Women who volunteer to participate in the study will be included in the study. As a result of the power analysis using the G\*Power 3.1 program; With 95% power, 5% margin of error and d=0.84 effect size, a total of at least 42 samples was found to be sufficient (n₁=21; n₂=21). However, considering that losses may also occur, it was planned to work with a total of 60 women, 30 of whom were interventions and 30 were controls. Women who meet the inclusion criteria will be randomly assigned to the intervention and control groups, and at the same time, stratified block randomization will be performed (n₁= 30; n₂=30). The number of people in the group was determined as 10 for reasons such as keeping individuals active, increasing interactive working time, and providing more sharing opportunities.||||
33921193|NCT01478893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697026|NCT05027672|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All personnel involved in antibody determination shall remain blinded to the assigned strategy.||f|f|f|t
33697027|NCT06203574|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697028|NCT03181893|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33921194|NCT04257084|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||a randomized controlled crossover trial|t|f|f|t
33921195|NCT01473329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697029|NCT01457443|||COHORT||PROSPECTIVE|||||||
33785503|NCT06713395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33785504|NCT03120676|NA|SINGLE_GROUP||TREATMENT||NONE||This is a protocol comprised of a single institution phase II study in HL evaluating the efficacy of atezolizumab.||||
33921196|NCT03185104|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Application of the SDF/placebo is conducted by a dentist who is not involved in the clinical data collection.|Removable partial denture wearers are randomized assigned to either the fluoride group or the placebo group. The fluoride group receives semi-annually professionally applied 38% SDF solution to all exposed tooth and root surfaces while the placebo group receives distilled water using the same application method.|t|f|t|t
33921197|NCT03629691|||CASE_ONLY||RETROSPECTIVE|||||||
33921198|NCT02334670|||COHORT||PROSPECTIVE|||||||
33921199|NCT05782582|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cluster randomised trial. All of 47 primary health care centres in Region Östergötland are invited to take part. After acceptance the actual number of primary health care centres will be randomly allocated to to either package or standard investigation group. The aim is to include about 20 primary health care centers in the study.||||
33921200|NCT01729572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921201|NCT02330107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921202|NCT04799353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921203|NCT01853098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921204|NCT00249639|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921205|NCT01796262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921206|NCT03015558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921207|NCT00089271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921208|NCT06138327|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33921209|NCT00834886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921210|NCT00176124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921211|NCT04072185|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, randomized, two-group clinical trial, of 1 year follow-up.||||
33921212|NCT00472992|||COHORT||PROSPECTIVE|||||||
33921213|NCT04172311|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33921214|NCT03589820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921215|NCT02013128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921216|NCT02290964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921217|NCT04142216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921218|NCT02203669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921219|NCT04861519|||CASE_ONLY||RETROSPECTIVE|||||||
33921220|NCT03157440|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921221|NCT03697486|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33921222|NCT04190212|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34001088|NCT01532908|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001089|NCT03568604|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study of daily administration of 6.5 mg prasterone, approved for moderate to severe dyspareunia for vaginal atrophy in menopausal women, to see if there are changes to the vulva, vestibule, urethral meatus and vagina on vulvoscopy after 20 weeks||||
34001090|NCT01326351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001091|NCT06160180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001092|NCT02520193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001093|NCT01430286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001094|NCT03013036|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001095|NCT03367780|||COHORT||PROSPECTIVE|||||||
34001096|NCT00365053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001097|NCT06471725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a controlled, double-blinded (patients and assessors)|2X2 model|t|f|f|t
34001098|NCT03837158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001099|NCT01269645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001100|NCT04386213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001101|NCT06169709|||CASE_ONLY||CROSS_SECTIONAL|||||||
34001102|NCT06679608|||COHORT||PROSPECTIVE|||||||
34001103|NCT01108354|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001104|NCT02811341|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34001105|NCT04543084|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single-subject Design||||
34001106|NCT01942616|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34001107|NCT04587167|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized design||||
34001108|NCT05560139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anodal, or sham with a ratio 1:1 were placed in serially numbered opaque closed envelopes. Each patient was given a serial number from a computer generated randomization table, and was placed in the appropriate group after opening the corresponding sealed envelope.|A randomized clinical trial-controlled study to assess the ability of tDCS; anodal stimulation of left DLPC versus sham stimulation in improving fatigue in MS patients|t|f|t|f
34001109|NCT02971280|||COHORT||PROSPECTIVE|||||||
34001110|NCT04848207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697030|NCT03893175|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Administration of ibuprofen vs. placebo will be masked.|"Subjects will be randomized to receive either ibuprofen or placebo after third molar extraction when pain intensity is at least 4/10.~Four hours after the masked ibuprofen or placebo, all subjects will receive open-label ibuprofen + acetaminophen to be taken every 4 hours for the first 2 days and then as needed for up to 7 days after oral surgery.~Oxycodone will be available as a rescue medication if additional analgesic is requested."|t|t|t|t
33697031|NCT05275478|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation (sequential) followed by phase 2 dose expansion in 6 arms (parallel)||||
33697032|NCT03324529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697033|NCT06400212|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697034|NCT04139473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697035|NCT00544999||||TREATMENT||||||||
33697036|NCT04298372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697037|NCT05013034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Number of Subjects A total of 300 subjects will be enrolled: 150 will be randomized to the basiliximab arm and 150 to the placebo arm in a 1:1 distribution.~Treatment Assignments Qualified individuals will be randomized with a superiority design to either basiliximab (Simulect) or placebo. Study drug or placebo will be double blinded and administered on day 0 for all subjects. A second dose may be administered on Day 4 if first dose did not return the subject to a SpO2 ≥94% on room air.~Criteria for Study Termination Although the FWCSWG intends to complete the study, the FWCSWG reserves the right to discontinue the study at any time for clinical or administrative reasons, or if required by regulatory agencies. If the FWCSWG discontinues the study, all study drugs will be discontinued and the investigator will be responsible for securing any alternative therapy to be administered, as appropriate."|t|t|t|t
33697038|NCT03239158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697039|NCT02373722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33697040|NCT04710134|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will initially all receive 3 mg/kg of reslizumab. After 16 weeks of treatment, those patients that have uncontrolled sputum eosinophilia will be escalated to 4 mg/kg; the remaining patients will continue on 3 mg/kg. After a further 16 weeks of therapy, those that still have uncontrolled sputum eosinophilia will receive 5 mg/kg; the remaining patients will continue on the dose they were receiving (i.e., either 3 or 4 mg/kg).||||
33697041|NCT04543461|||COHORT||PROSPECTIVE|||||||
33697042|NCT00446420|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33697043|NCT02853851|||COHORT||RETROSPECTIVE|||||||
33697044|NCT00547196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697045|NCT03590873|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697046|NCT06556641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697047|NCT00857883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697048|NCT04758078|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33697049|NCT05560776|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Pathologist will be blinded to study arm when analyzing samples||f|f|f|t
33697050|NCT01892865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33697051|NCT04203810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697052|NCT03906136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697053|NCT03537170|||COHORT||PROSPECTIVE|||||||
33697054|NCT03533101|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Adaptive design using two different doses of tocilizumab prophylaxis||||
33697055|NCT00167557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697056|NCT01609231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697057|NCT02140242|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33697058|NCT05767970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments will be collected online or through professional data collection service (for dried blood spots and patient satisfaction reports) that will be blind to condition assignment. The investigators responsible for data analysis will be blind to condition assignment until after primary analyses are complete.|Random permuted block parallel assignment|f|f|t|t
33697059|NCT04406220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33697060|NCT05149599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697061|NCT04738409|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785505|NCT04406779|||CASE_CONTROL||PROSPECTIVE|||||||
33785506|NCT03468920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only pharmacy staff will have randomization scheme and be aware of whether patient received oral Acetaminophen with IV placebo OR if the patient received IV Acetaminophen with oral placebo|This study will use a randomized, double-blind, placebo controlled design with two arms.|t|t|t|t
34001111|NCT05683808|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open label study of apixaban for VTE prevention in patients with newly diagnosed grade 4 glioma||||
34001112|NCT04598958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a cluster randomized design. Two clusters of health facilities were randomized to receive either the intervention or standard of care. There are 6 facilities in each cluster. Individual participants are treated based on the cluster they fall into||||
34025091|NCT00609999|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025092|NCT04810637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded|Double blinded phase 2 controlled study|t|t|t|f
34025093|NCT01374074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34025094|NCT05987319|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025095|NCT00392912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025096|NCT01307111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025097|NCT02191761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697062|NCT05109845|||COHORT||CROSS_SECTIONAL|||||||
33697063|NCT02143700|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33697064|NCT05377008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Patient randomization is assigned after baseline is completed (i.e., the patient and assessor are not aware of random assignment until after the baseline is completed). The Principal Investigator and Clinical Research Coordinator will be the only ones with access to random assignments.|This is a pilot feasibility study comprising a randomized controlled trial involving 50 families (i.e., parent/guardian AND child ages 6 to 16 years with NF). Consented participants will be randomly allocated to the intervention (n=25) or control (n=25) arms.|t|t|f|t
33697065|NCT03470948|||COHORT||PROSPECTIVE|||||||
33697066|NCT06228885|||COHORT||CROSS_SECTIONAL|||||||
33697067|NCT02933112|NA|SINGLE_GROUP||OTHER||NONE||||||
33697068|NCT01528215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697069|NCT01242228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697070|NCT03810144|||COHORT||PROSPECTIVE|||||||
34001113|NCT04422652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Those eligible will be randomized via a computerized random number generator 1:1:1 to BAT, bupropion, or control, using block randomization, stratified by site and CKD stage (3b, 4, or 5). Randomization assignment will be obtained via the secure study web portal hosted at UTSW. As in previous trials that involve therapy for MDD, it is challenging to double-blind aspects of this study that involve BAT. However, we have made every effort to maintain blind as much as possible. Bupropion for Strategy 2 and double-blind matching placebo for the control arm will be administered by concealed allocation. Participants in Strategy 1 will receive matching placebo by single-blind allocation. Although it is impossible to conceal the allocation of the BAT to the research team, it is intended for the participants to remain single-blinded to BAT vs. CM. Using Computer Assisted Telephone Interviewing, the same assessor, blinded to interventions, will assess outcomes for both sites.||t|t|t|t
33785507|NCT06116266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785508|NCT05732818|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive one implant if they meet all inclusion/exclusion criteria after a review by the Medical Advisory Board (MAB).||||
33785509|NCT06711354|||OTHER||OTHER|||||||
33697071|NCT05890742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697072|NCT04709354|||COHORT||CROSS_SECTIONAL|||||||
33697073|NCT04612582|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who meet the entry criteria will randomly enter the BTD or BCD treatment group according to the proportion of 1:1. The random code will be generated by computer and the random envelope will be made according to the random code. Treatment group included. Each code has a corresponding random envelope. According to the time sequence of subjects meeting the entry criteria, the random number of subjects will be given from small to large. The corresponding random envelope can only be opened during grouping. If a random number falls off in the middle of use, it can no longer be used.||||
33697074|NCT04048122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be randomized to treatment arm: the intervention or the standard of care control. Participants will not be informed if their treatment group is the experimental intervention or standard of care.~Both treatments consist of 10, 1-hour sessions over 12 weeks delivered in an individual, face-to-face format in participants' homes and/or communities by trained licensed occupational therapists (OTs).~Members of the research team who are involved in the post-treatment testing will be blinded to which intervention (experimental or control) the study participant received from the trained OT."|Participants will be randomized to treatment arm (1:1 ratio, stratified by sex): the intervention or the standard of care control. Both arms will consist of 10 individualized treatment sessions within a 12-week period.|t|f|f|t
33697075|NCT03848442|NA|SINGLE_GROUP||OTHER||NONE||||||
33697076|NCT04867057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697077|NCT01303783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785510|NCT04470817|||COHORT||PROSPECTIVE|||||||
33785511|NCT00273455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33785512|NCT05928182|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive treatment and symptom severity will be measured pre and post-treatment.||||
33785513|NCT04660370|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785514|NCT06402435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785515|NCT00672256|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33785516|NCT04769024|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33785517|NCT06713447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open-label, single intervention, single site pharmacokinetic study.||||
33921223|NCT05568056|RANDOMIZED|FACTORIAL||TREATMENT||NONE||ASD participants randomly assigned to Experimental or Waitlist control groups. NT-EXP participants assigned to experimental group NT participants assigned to waitlist control group||||
33921224|NCT03842748|||COHORT||OTHER|||||||
33921225|NCT04323878|||COHORT||RETROSPECTIVE|||||||
33921226|NCT04401397|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Patients and outcomes assessor will be blinded to the protocol each patient will be treated with. Both intervention and standard care protocols will be implemented by a third party.|Prospective randomized controlled double-blind 2-group experimental design.|t|f|f|t
33921227|NCT05273658|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|Cannabis will be dispensed from the Research Pharmacy. Alcohol will be dispensed by a research staff member who is not involved in any assessments. All assessors, investigators, and participants are blinded to the THC and alcohol content.|Participants will be randomized to smoke a cannabis cigarette containing placebo (.02%) or 18.1% THC, and consume alcohol to achieve a breath alcohol level of .07, .10, or 0.|t|t|t|t
33921228|NCT02220946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921229|NCT03685487|||COHORT||PROSPECTIVE|||||||
33921230|NCT05391646|||COHORT||PROSPECTIVE|||||||
33921231|NCT03410927|NA|SEQUENTIAL||TREATMENT||NONE||In Phase 1, TAS0728 will be evaluated for safety and tolerability, and in phase 2 will be evaluated preliminary efficacy.||||
33921232|NCT04839536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33921233|NCT04649619|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective clinical trial with intentional sample selection that aims to describe the results of the gastric bypass surgery modified by De Melo, for the purpose of endoscopic access to the excluded remaining stomach, as well as to monitor the clinical conditions of comorbidities and the patient's quality of life.||||
33921234|NCT01428999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921235|NCT03051828|||COHORT||PROSPECTIVE|||||||
33921236|NCT00807300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921237|NCT02726529|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921238|NCT04311801|NA|SINGLE_GROUP||OTHER||NONE||||||
33921239|NCT01225978|||COHORT||PROSPECTIVE|||||||
33921240|NCT05174442|||OTHER||OTHER|||||||
33921241|NCT03783728|||CASE_ONLY||PROSPECTIVE|||||||
33921242|NCT02878629|||COHORT||PROSPECTIVE|||||||
33921243|NCT00095511|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33921244|NCT01030380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697078|NCT02047227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33697079|NCT02148107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921245|NCT00560222|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697080|NCT06680167|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33697081|NCT05400824|||COHORT||PROSPECTIVE|||||||
33697082|NCT06459765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697083|NCT06413927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The research staff who are unblinded will deliver the electronic surveys and cognitive battery (which is automatically scored) at baseline before participants are randomly assigned to an arm. The primary outcome variables are automatically scored, thus blindly to intervention arm. The Virtual Driving Assessment is a self-guided tool and is automatically scored. The smartphone app automatically records hard braking events and other behaviors without knowledge of intervention arm. Licensing tests will be conducted by state-sanctioned licensing examiners who will be blinded to which arm the participant is in (per state mandate).||f|t|f|t
33697084|NCT01624337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921246|NCT03789890|NA|SINGLE_GROUP||OTHER||NONE||||||
33697085|NCT05509166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be immediately assigned to either condition.||t|f|f|f
33697086|NCT06416033|||CASE_CONTROL||PROSPECTIVE|||||||
33697087|NCT04474249|||COHORT||PROSPECTIVE|||||||
33697088|NCT06215612|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697089|NCT02242669|||CASE_CONTROL||OTHER|||||||
33921247|NCT04535154|||COHORT||PROSPECTIVE|||||||
33697090|NCT02457481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921248|NCT00091936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921249|NCT00967109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33921250|NCT01011036|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33921251|NCT03833375|RANDOMIZED|PARALLEL||OTHER||NONE||Open-label, usual-care-controlled feasibility trial comparing decision aid intervention prior to the goals-of-care family meeting to standard of care (no intervention prior to family meeting).||||
33921252|NCT04721977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697091|NCT03890952|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two parallel arms, non-randomized, not for comparison||||
33697092|NCT01614600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921253|NCT04074278|||COHORT||CROSS_SECTIONAL|||||||
33921254|NCT01794728|||COHORT||PROSPECTIVE|||||||
33921255|NCT02862548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921256|NCT03001336|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33921257|NCT02401802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33921258|NCT02746354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921259|NCT03811886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921260|NCT00649441|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33921261|NCT04465123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921262|NCT04571918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participant and physiotherapist who are responsible for the testing will be masked.|Randomized controlled trial|t|f|f|t
33921263|NCT01444313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33921264|NCT06364644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and interventionists will be unblinded, while those assessing outcomes will be blinded to the randomization arm .|The design of the study is a randomized 2:1 parallel-arm clinical trial.|f|f|f|t
33921265|NCT05930990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921266|NCT02991066|||CASE_CONTROL||PROSPECTIVE|||||||
33921267|NCT06366295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921268|NCT00980785|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33921269|NCT04856956|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|No masking is possible for subjects, since they will know whether they are or are not using the software.|This study is a parallel-design, randomized, controlled study.|f|f|t|t
33921270|NCT05362331|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33921271|NCT02389686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921272|NCT04266106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Parallel Assignment|t|t|t|t
33921273|NCT00133835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921274|NCT05071144|||COHORT||PROSPECTIVE|||||||
33921275|NCT03367442|||COHORT||PROSPECTIVE|||||||
33921276|NCT05414370|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33921277|NCT01477515|||CASE_CONTROL||PROSPECTIVE|||||||
33921278|NCT04944550|||OTHER||OTHER|||||||
33921279|NCT01900756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33921280|NCT02858973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921281|NCT00337142|||COHORT||RETROSPECTIVE|||||||
33921282|NCT02405806|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33921283|NCT04717778|NA|SINGLE_GROUP||OTHER||NONE||The study was carried out in 21 first grade primary school children, they were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).||||
33921284|NCT01946919|||COHORT||PROSPECTIVE|||||||
33921285|NCT02720653|||COHORT||PROSPECTIVE|||||||
33921286|NCT03075735|||COHORT||PROSPECTIVE|||||||
33921287|NCT02475850|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33921288|NCT04965506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921289|NCT02322411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921290|NCT03841487|||COHORT||RETROSPECTIVE|||||||
33719897|NCT05955950|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Neither the researcher nor the participants will be blind to the group to which they were allocated. Because the first will give the necessary guidance and the second will have knowledge of the existing groups through the TCLE and at the time they receive the instructions. Blinding will only occur for the research participant (scientific initiation scholarship holder or volunteer) who must carry out the return interviews and the application of the questionnaires soon after the end of the intervention and in the 6-month follow-up.~Primary outcome: Self-care and negative psychological states Secondary outcomes: Change in behavior (physical activity, diet...) and gratitude."|Randomized, parallel clinical trial. The study will use a prospective experimental design with Condition and Time as independent variables. The condition has two levels that correspond to the experimental conditions: (a) Gratitude List (aspects of daily experience that one feels grateful for), (b) Any Event List (events of one's own choosing that impressed the participant during the day, whether positive or negative). Time is a repeated measures variable with three levels corresponding to the measurement times: (a) Pre-test (before the intervention), (b) Post-test (at 2 weeks after of the intervention - visit 1) and (c) ) Follow-up (from baseline to 6 months - visit 2).|f|f|f|t
33719898|NCT03472027|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation||||
33785518|NCT04191161|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be recruited if aged between 18 and 55 years old and suffering from chronic lumbar pain (Visual Analogic Scale (VAS) \> 3) associated with Modic type I changes diagnosed with a MRI achieved less than 6 months before the consultation and interpreted by a radiologist specialised in spine disease. Patients must also be capable of giving a clear consent. Will not be included patients suffering from other types of Modic change, or any other cause of back pain such as spondylolisthesis, fracture, spondylitis, scoliosis, rheumatoid arthritis and also patient not willing to wear the brace for at least 3 months. Patients will be recruited from the consultation in PMR units across 5 centres in France.||||
33785519|NCT05710744|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33785520|NCT05939726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The use of the investigational creams, i.e. moisturising creams with or without vitamin E concentrate will be double-blinded. Both creams will be the same in colour, texture, packaging, and labelling. The patients, investigators, and blinded study personnel will blinded the patients' assignment of the investigational creams. On the other hand, the use of urea cream will be open-labelled.||t|f|t|f
33785521|NCT05248035|||COHORT||PROSPECTIVE|||||||
33785522|NCT05549297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785523|NCT03985709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785524|NCT06633796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785525|NCT02731521|||CASE_ONLY||PROSPECTIVE|||||||
33785526|NCT05765734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785527|NCT02470104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785528|NCT06548477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33785529|NCT05633550|||COHORT||CROSS_SECTIONAL|||||||
33785530|NCT01833065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785531|NCT06078384|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort of patients with T1b/c N0 M0 TNBC aged \> 40 years with 30% ≤ sTILs \< 50% and those aged ≤ 40 years with 30% ≤ sTILs \< 75%: Pembrolizumab will be administered at a fixed dose of 200 mg every 3 weeks (Q3W), with a total of 9 cycles and Paclitaxel 80 mg/m² weekly for 12 cycles at adjuvant phase of the treatment; Cohort of patients with T1b/c N0 M0 TNBC aged \> 40 years and sTILs ≥ 50% and those aged ≤ 40 years with sTILs ≥ 75%: No treatment will be administered. These patients will undergo standard surveillance every 6 months according to local practice.||||
33921291|NCT05075629|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33921292|NCT03790384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after TURB and re-TURB prior to randomization and only subjects who fulfil the inclusion criteria will be included: patients with a diagnosis of High risk NMIBC: T1 tumor, G3, CIS, or multiple and recurrent and large (\>3 cm) Ta or patients in the last EAU recurrence category (EAU/EORTC recurrence score \>/=10). Patients selected for the study, are centrally randomized (randomization is performed at the Sant'Andrea Hospital) to receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG). Patients in group two received BCG treatment with the same protocol with a 40 mg mitomycin instillation the day before .|f|f|t|f
33921293|NCT01406652|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Randomization 1:1 with two arms: One versus two-stage bursectomy.||||
33921294|NCT03404635|||COHORT||PROSPECTIVE|||||||
33921295|NCT05613842|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Male patients 18 years or above with hormone sensitive disease, who demonstrate rising PSA levels (\>0.2ng/ml) following definitive therapy and a negative 68Ga-PSMA-11 PET scan (defined as SUV max \< 3); Male patients with metastatic castration resistant prostate cancer being considered for 177Lu-PSMA-617 therapy, with known metastatic disease on conventional imaging and sites with low PSMA expression on 68Ga-PSMA-11 PET scan (defined as SUV max \<10) in the presence of disease volume of \> 1cm.||||
33921296|NCT04291976|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a multicenter, non-blinded randomized trial with three parallel arms: back-to-back HDWLE, single-pass HDWLE and CE.||||
33921297|NCT06305221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921298|NCT01770899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921299|NCT03353532|||CASE_CONTROL||RETROSPECTIVE|||||||
33921300|NCT04825288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded study|Subjects in phase II portion will be randomized on a 1:1 basis to XB2001 plus ONIVYDE + LV + 5-FU (Arm 1) or placebo plus ONIVYDE + LV + 5-FU (Arm 2).|t|t|t|t
33921301|NCT01167218|||OTHER||PROSPECTIVE|||||||
33921302|NCT03641820|||OTHER||CROSS_SECTIONAL|||||||
33921303|NCT04093687|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33921304|NCT03736629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921305|NCT02680587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921306|NCT00370877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921307|NCT01815580|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921308|NCT05915936|||COHORT||RETROSPECTIVE|||||||
33921309|NCT05200455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001114|NCT04628975|RANDOMIZED|PARALLEL||OTHER||NONE||multi-center prospective randomized cross-over study||||
34001115|NCT04075916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001116|NCT04055233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two arm prospective randomized single center interventional trial. 1:1 randomization into experimental arm (irrigation with polyhexanide) and control arm (irrigation with saline).|t|f|f|t
33697093|NCT05929053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single blinding(Participant blinding) will be done; participants will not be told they are in the experimental or control group. The first researcher will invite mothers to the study, which will continue until the targeted sample number(74 participants) is reached. During the participant registration, the names and contact information of the mothers will be obtained; it will be stated that they will be contacted for the training process, that the training time may be extended, and that they will be given definite training. The second researcher in the research team will explain to the first researcher that the participants are in the experimental or control group. The mothers in the control group will be assigned to the waiting list. At the end of the study, a four-session vaccination training program will be applied to the mothers in the control group in the same way and within the same scope as the experimental group.|"Randomization and blinding are recommended in randomized controlled studies to prevent biases and show the experiment's success (15).~Allocation: Random assignment. Block randomization will be used in the randomization process. Randomizer.org will be used to select block combinations with eight blocks. Eligible participants will be randomly assigned to the intervention or waitlist group using the permuted block randomization method on a 1:1 basis. The waiting list group will form the second set of the research, which is planned to be attempted two months later. The participant assignment list will be generated by a non-research statistician with a random distribution sequence. Assignment confidentiality will be ensured using opaque sealed envelopes containing sequence numbers. The data analyst/statistician will be blind to the participants' group assignments."|t|f|f|t
33697094|NCT00006324||||TREATMENT||||||||
33697095|NCT01785407|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33697096|NCT06501690|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will complete 3, one week long intervention periods in a randomized order||||
33697097|NCT02808377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33697098|NCT03086278||SEQUENTIAL||SCREENING||NONE||||||
33697099|NCT00263770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785532|NCT06713096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33785533|NCT06172595|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785534|NCT06631196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33785535|NCT06714032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785536|NCT02901821|||CASE_CONTROL||PROSPECTIVE|||||||
33785537|NCT06445660|||COHORT||PROSPECTIVE|||||||
33785538|NCT06232226|NA|SINGLE_GROUP||OTHER||NONE||Cohort||||
33921310|NCT01729650|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33785539|NCT04751747|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785540|NCT02506426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785541|NCT06322342|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33921311|NCT03372603|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|All study staff involved in clinical assessments (which includes the investigator, sub-investigators, other site staff), and the subject will be blinded to the treatment allocated to individual subjects.|This is a multi-center, randomized, placebo-controlled, double-blind, two-period crossover study. Each subject will be screened (screening may be conducted across more than 1 visit); each subject will have 2 treatment periods (each 7 days) with a washout period of 14 to 21 days between the treatment periods; and each subject will have a follow-up visit (within 7 to 10 days after their last dose). Each subject will be involved in the study for a maximum of 10 and a half weeks.|t|f|t|f
33921312|NCT00707343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921313|NCT05065307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921314|NCT01873443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921315|NCT03470857|||COHORT||PROSPECTIVE|||||||
33921316|NCT03453918|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33921317|NCT05494749|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921318|NCT03181477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921319|NCT02671461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921320|NCT02887859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921321|NCT06015412|||OTHER||PROSPECTIVE|||||||
33921322|NCT02335112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33921323|NCT04080869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The topical preparations are packed in non-identifiable jars and coded by a person who is not involved in the study the patient.|A Prospective, split face comparative clinical study|t|t|f|t
33921324|NCT04671342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921325|NCT03856528|||COHORT||RETROSPECTIVE|||||||
33921326|NCT05205278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Forty-two adolescent female volleyball athletes (16.0±1.4 years) were randomly divided into two groups. Group 1 was the training group and, in addition to the routine volleyball training programmes, underwent an 8-week (3 days/week) progressive core stability training programme. Group 2 was the control group and only did routine volleyball training, with no core stability training.|f|f|t|t
33921327|NCT06312046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcome assessor will not participate in the provided training program. Care provider will not perform the analyses.|Randomized controlled trial|f|f|t|t
33921328|NCT01097148|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33921329|NCT00917085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921330|NCT02261883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921331|NCT00089479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921332|NCT00927264|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|For masking we were unable to mask the caregiver and child participant since they knew if they were receiving intervention component. The investigator was masked, but outcome assessor may have known group assignment.||f|f|t|f
33921333|NCT01061736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921334|NCT01957852|||COHORT||RETROSPECTIVE|||||||
34001117|NCT03650751|||CASE_ONLY||CROSS_SECTIONAL|||||||
34001118|NCT06678594|||CASE_ONLY||PROSPECTIVE|||||||
34001119|NCT05255549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001120|NCT04099433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921335|NCT05808842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blinded investigator will complete the - Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale of face and neck, the Scientific Assessment Scale of Skin Quality (SASSQ) to grade the subject's skin quality of face and neck, the Classification of Facial Wrinkles Assessment and the Blinded Investigator Neck Skin Crepiness/Laxity Grading Scale.|Subjects will be randomized to have one of two post-laser skincare regimens which will be applied to the face and neck following laser treatment.|f|f|t|f
33921336|NCT04162535|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33921337|NCT05647018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921338|NCT00485589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921339|NCT02155361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921340|NCT02790333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34001121|NCT04031560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001122|NCT05793645|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34001123|NCT05450809|||COHORT||PROSPECTIVE|||||||
34001124|NCT03710551|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34001125|NCT05462717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697100|NCT06403046|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|An independent staff member will randomly allocate the patients into (Tx group) and (Mx group) after labeling them|two groups each groups consists of 15 participants \& the total number of participants is 30 as the patients are divided into (Tx group) and (Mx group) after labeling them in sequential numbers|f|t|t|f
34001126|NCT04609397|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34001127|NCT01097694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001128|NCT06321055|||OTHER||RETROSPECTIVE|||||||
33697101|NCT04102943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001129|NCT02374216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001130|NCT03950674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001131|NCT06317428|||COHORT||PROSPECTIVE|||||||
34001132|NCT04520243|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective randomized controlled trial||||
34001133|NCT05001191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34001134|NCT01933009|||COHORT||PROSPECTIVE|||||||
33697102|NCT02648269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697103|NCT04512170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Ascending Single and Multiple Dose Study is Double-blind design; Food Effect Study is open-label design.||t|t|t|t
33697104|NCT03624231|RANDOMIZED|PARALLEL||TREATMENT||NONE||"2-arm, randomized, multicenter, phase II. Step 1 is Registration. All patients need to sign the informed consent form for registration. Tumor tissue then be send to the central lab for defining the HPV status. If the patient is HPV negative the site will be notified if they can further proceed to patient randomization.~Step 2 is Randomization of all eligible patients with a centrally diagnosed, HPV negative tumor one of the two arms Durvalumab plus Tremelimumab + radiotherapy; Durvalumab + radiotherapy) after signing the informed consent form for step 2."||||
33697105|NCT05982548|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33697106|NCT04148820|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into two parallel groups||||
33697107|NCT06414408|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be randomized to one of 4 doxycycline dosing patterns (daily, 3x weekly, weekly, every other week) and then will crossover to an alternate pattern once during the study.||||
33697108|NCT05063890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697109|NCT02660931|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33697110|NCT04094051|||COHORT||CROSS_SECTIONAL|||||||
33697111|NCT01385761|||CASE_CONTROL||PROSPECTIVE|||||||
33785542|NCT02306161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785543|NCT06321172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921341|NCT00979680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921342|NCT02600000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921343|NCT01445106|NON_RANDOMIZED|||TREATMENT||NONE||||||
33921344|NCT01283997|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34001135|NCT03645616|NA|SINGLE_GROUP||SCREENING||NONE|All data were color coded to guarantee that the investigator who processed the data was blinded to the conditions.|||||
34001136|NCT01120691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001137|NCT01510509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921345|NCT04240171|||CASE_CONTROL||PROSPECTIVE|||||||
33921346|NCT01887782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921347|NCT00892957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001138|NCT03462888|||COHORT||RETROSPECTIVE|||||||
34001139|NCT03807830|NA|SINGLE_GROUP||OTHER||NONE||||||
34001140|NCT05778890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Twenty patients were divided into two groups of ten each with randomisation (closed envelope method). outcomes assessor was blinded to group allocation.|20 patients were included in our pilot study and were randomised into two groups. Traditional physiotherapy program and home exercises program were applied to the intervention group (n=10; age 31.4±11.2 years), and only traditional physiotherapy to the control group (n=10, age 35.3±18.1 years). Traditional physiotherapy program included ultrasound (US), TENS and exercise.|t|f|f|t
34001141|NCT03247686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001142|NCT00338390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697112|NCT01303861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33697113|NCT06680440|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33697114|NCT03343067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697115|NCT05095038|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33697116|NCT01828879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697117|NCT02276326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697118|NCT05333328|NA|SINGLE_GROUP||TREATMENT||NONE||De-escalating treatment as ovarian-function suppression with endocrine treatments alone in ER+HER2- premenopausal women with N1||||
33697119|NCT01877018|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33697120|NCT01641874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785544|NCT06418906|||COHORT||PROSPECTIVE|||||||
33785545|NCT06315751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785546|NCT05962385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No blinding is possible|Repeated measures design - across two separate sessions (one week apart, counterbalanced between participants), participants will receive transcranial magnetic stimulation (TMS) whilst engaging in either a cognitive control or a perceptual task.||||
33785547|NCT02280161|||COHORT||PROSPECTIVE|||||||
33785548|NCT06358638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Sickle cell patients, who have matched sibling donors with anti-donor RBC antibodies.||||
33785549|NCT06253052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33785550|NCT06713317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785551|NCT05397470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A of this study will be performed in a double-blind fashion. Part B of the study will be performed in an open-label fashion. The investigator, study staff, subjects, sponsor, and monitor will remain blinded to the treatment in Part A until study closure (i.e., until closure of Part B).||t|t|t|t
33785552|NCT04810455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921348|NCT05780593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two arm parallel research involves two groups randomized into Interventional Group-A and Interventional Group-B. The unit of randomization will be Agile Institute of Rehabilitation Sciences. This study will use 2 (between groups: Effects of mobilization with passive stretching of lateral rotators along with inclined board standing vs Inclined board standing) ×3 (time: before vs. after vs. 4 weeks after follow-up) mixed design to measure the effects of mobilization, passive stretching of hip abductors and inclined board standing on low back patient.|t|f|t|f
33785553|NCT01739556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785554|NCT04499131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be evaluated by blinded gynecologist in order to prevent the application of personal criteria and protect the consistence of the study.|Exploratory, unicentric, with blind evaluators, randomized to six parallel arms in ratio 1:1:1:1:1:1 clinical trial conducted in healthy volunteers under an artificial endometrial preparation cycle and luteal phase support with exogenous progesterone administered by different doses and routes or natural menstrual cycles.|f|f|t|f
33785555|NCT06711263|RANDOMIZED|PARALLEL||SCREENING||SINGLE|participants are masked|In the Initial Visit-Baseline, and subsequent visits, participants will be called in the morning. Morning hours will be chosen for examination, as it will reduce the risk of bias and also help in quantifying results. plaque and gingival scores will be recorded and the First herbal mouthwashes will be given, participants will also be provided new tooth-brushes (Oral B-soft).|t|f|f|f
33785556|NCT06369220|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33785557|NCT01531231|||COHORT||PROSPECTIVE|||||||
33785558|NCT00868231|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33785559|NCT05123638|RANDOMIZED|PARALLEL||OTHER||NONE|Since there is only a single investigator conducting this study and due to the nature of exercise intervention, it is impossible to facilitate masking terms in this trial.|Stratified randomization (based os Cumulated-Ambulation Score of 6 vs. \<6) of geriatric inpatients to either VR assisted stationary cycling exercise or conventional stationary cycling exercise.||||
33785560|NCT02931149|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785561|NCT02799056|||OTHER||PROSPECTIVE|||||||
33785562|NCT04127539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785563|NCT05788094|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised open label non-inferiority trial||||
33785564|NCT05186818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785565|NCT04587791|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|participants will receive CBD (400 mg, 800 mg, 1200 mg) or placebo.|participants will receive CBD (400 mg, 800 mg, 1200 mg) or placebo.|t|f|t|f
33785566|NCT00504920|||CASE_ONLY||PROSPECTIVE|||||||
33785567|NCT06023030|||COHORT||PROSPECTIVE|||||||
33921349|NCT03095053|RANDOMIZED|PARALLEL||TREATMENT||NONE||single-centre randomized controlled trial||||
33921350|NCT02983058|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921351|NCT03216083|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921352|NCT02827279|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921353|NCT04046445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||8 cohorts||||
33921354|NCT01797991|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921355|NCT01379924|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921356|NCT02873364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921357|NCT05454930|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33921358|NCT03807076|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33921359|NCT06325306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921360|NCT00650598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921361|NCT03111017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33921362|NCT01257321|||CASE_CROSSOVER||PROSPECTIVE|||||||
33921363|NCT00466557|||||PROSPECTIVE|||||||
33921364|NCT05277233|||CASE_CONTROL||OTHER|||||||
33921365|NCT01613547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921366|NCT03428841|||CASE_CONTROL||PROSPECTIVE|||||||
33921367|NCT00170742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921368|NCT04019795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation was concealed by numbered device containers and is distributed by unblinded study administrators who are not involved with the interview of participants for study eligibility.|The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.|t|t|f|t
33921369|NCT03665012|||COHORT||PROSPECTIVE|||||||
33921370|NCT03050216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921371|NCT05680194|||COHORT||PROSPECTIVE|||||||
33921372|NCT00436293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921373|NCT05823168|||CASE_CONTROL||PROSPECTIVE|||||||
33921374|NCT00436111|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33921375|NCT00983359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921376|NCT05267197|||COHORT||PROSPECTIVE|||||||
33921377|NCT04737369|||COHORT||PROSPECTIVE|||||||
33921378|NCT03661450|||COHORT||PROSPECTIVE|||||||
33921379|NCT04141592|||CASE_CONTROL||PROSPECTIVE|||||||
33697121|NCT00003023||||TREATMENT||||||||
33719899|NCT05321732|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33719900|NCT02843932|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719901|NCT01217684|||COHORT||CROSS_SECTIONAL|||||||
33719902|NCT02051829|||COHORT||PROSPECTIVE|||||||
33719903|NCT05533450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719904|NCT06489769|||OTHER||PROSPECTIVE|||||||
33719905|NCT03042247|||CASE_ONLY||PROSPECTIVE|||||||
33719906|NCT00487851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719907|NCT06065033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be blinded to subject allocation|Our approach will consist of a randomized, blinded, 2-arm, parallel-group design|f|f|f|t
33719908|NCT04217746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785568|NCT06300840|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Data-analyst and test-observer are masked|Single-case-experiment (SCE) with a reversal design and with randomization of phases.|f|f|f|t
33785569|NCT04502719|||COHORT||CROSS_SECTIONAL|||||||
33785570|NCT05131919|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label||||
33785571|NCT06711250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785572|NCT02634008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719909|NCT02723669|RANDOMIZED|CROSSOVER||||NONE||||||
33719910|NCT00040937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785573|NCT00666120|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33785574|NCT06398899|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33785575|NCT06714643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921380|NCT05535101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921381|NCT04197986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|As a double-blind study, participants, investigators, study monitor(s) and the clinical study team will be blinded to the treatment administered.|Participants will be randomly assigned (1:1) to receive oral infigratinib phosphate or placebo|t|t|t|t
33921382|NCT03620812|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33921383|NCT05379894|||COHORT||PROSPECTIVE|||||||
33921384|NCT04503811|||CASE_ONLY||OTHER|||||||
33719911|NCT05273424|||COHORT||PROSPECTIVE|||||||
33719912|NCT06461533|||COHORT||PROSPECTIVE|||||||
33719913|NCT04226274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719914|NCT04278079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719915|NCT02939898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785576|NCT05222269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785577|NCT03643965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921385|NCT03188432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921386|NCT06504251|||OTHER||CROSS_SECTIONAL|||||||
33921387|NCT01626053|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33921388|NCT03027141|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921389|NCT01767012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921390|NCT02832596|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921391|NCT04871542|||COHORT||PROSPECTIVE|||||||
33921392|NCT04637971|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921393|NCT00979017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921394|NCT00397709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785578|NCT06678360|||COHORT||PROSPECTIVE|||||||
33785579|NCT04496674|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multicenter dose escalation and dose expansion phase I trial, designed to gain evidence of maximally tolerated and recommended phase-II dose of CC-1 in adult patients with SCC of the lung||||
33785580|NCT03742219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785581|NCT02851030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785582|NCT05764824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785583|NCT00119587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33785584|NCT00341497|||COHORT||PROSPECTIVE|||||||
33785585|NCT02483299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785586|NCT06098027|NA|SINGLE_GROUP||OTHER||NONE||||||
33785587|NCT01989442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785588|NCT04811287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|See Model Description above.|Participants will be randomized using permuted block randomization predetermined by our dedicated orthopedic biostatistician into two study groups: those that undergo CTR with adjuvant intra-operative PRP and those that undergo CTR without adjuvant PRP.|t|f|f|f
33785589|NCT02939690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33785590|NCT05616221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, randomized, placebo-controlled|t|t|t|f
33785591|NCT02596906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921395|NCT02395653|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33921396|NCT02362542|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33921397|NCT01207388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921398|NCT06182930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33921399|NCT01798017|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33921400|NCT00171028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921401|NCT05796804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921402|NCT00380211|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33921403|NCT00321269|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33921404|NCT05096702|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33921405|NCT04191603|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|MONOPOLAR HOOC VERSUS PLASMAKINETIC BIPOLAR SPATULA USAGE DURING COLPOTOMY|MONOPOLAR HOOC VERSUS PLASMAKINETIC BIPOLAR SPATULA USAGE DURING COLPOTOMY|f|f|t|f
33921406|NCT03742115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921407|NCT06215456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921408|NCT04047121|||COHORT||RETROSPECTIVE|||||||
33921409|NCT05768425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33921410|NCT06460597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921411|NCT02527148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921412|NCT01668030|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participants received both the test drug and the standard of care, one on each side of the face.||t|t|f|t
33921413|NCT03414554|||COHORT||PROSPECTIVE|||||||
33719916|NCT04832685|RANDOMIZED|CROSSOVER||TREATMENT||NONE|For sham sonication, a gel pad that absorbs ultrasound will be used with the transducer so that the ultrasound will not go through the skull and into the brain. For active sonication, a gel pad that allows the transmission of ultrasound waves will be used with the transducer. These gel pads look identical; this study will be double-blinded where study staff will not know which gel pad corresponded with active or sham LIFUP.|Participants will be divided into 2 groups, healthy controls and participants with depression. Both groups will receive sham and active modulation (order counterbalanced).||||
34001143|NCT04065646|RANDOMIZED|PARALLEL||OTHER||NONE||Baseline interviews will be conducted after participation in nutrition education activity. Upon completing baseline, participants will be randomized into intervention (HMM text messaging) or control (non-health-related texting) groups. Texting will begin the day after randomization is completed and will occur once daily during business days for a duration of one month. In addition to HMM access messages, intervention group participants will receive texts with links to four $5.00 incentive coupons for the Hartford Mobile Market, one during each of the four weeks that the texting will take place. Follow-up interviews will be conducted two weeks after the end of the one-month texting period.||||
34001144|NCT00656539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089260|NCT03514602|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicomponent behavioral intervention||||
33785592|NCT05603845|||COHORT||PROSPECTIVE|||||||
34089261|NCT00387842|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719917|NCT04229615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719918|NCT02890589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719919|NCT05301426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked participants. Masked data analyst.|Two intervention groups. One control group.|t|f|f|t
33719920|NCT01334268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719921|NCT03311815|||CASE_ONLY||PROSPECTIVE|||||||
34089262|NCT04674527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089263|NCT01856933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089264|NCT03370302|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34089265|NCT03641157|||CASE_CONTROL||PROSPECTIVE|||||||
34089266|NCT05258071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34089267|NCT04059250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Subjects are not aware, which side of the denture will harbor the gap model with the Nobio composite and which side harbors the traditional composite.~Laboratory microhardness measurements will be conducted while keeping the operator blind."|In-situ testing using a gap model inside the two flanges of a removable partial denture|t|f|f|t
34089268|NCT05771493|||COHORT||CROSS_SECTIONAL|||||||
34089269|NCT02362451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089270|NCT01840631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089271|NCT00998153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719922|NCT04743427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Care provider,investigator)|Double-Blinded Randomized Controlled Trial (one investigator to make the assessment,and another investigator for application of the treatment procedures)|f|t|t|f
34025098|NCT02918253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719923|NCT01867021|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785593|NCT02807753|||COHORT||PROSPECTIVE|||||||
33921414|NCT03945032|NA|SINGLE_GROUP||SCREENING||NONE||"8 parents of a childhood cancer survivor will participate in this study (baseline + three times per year). Parents will answer on the TICOP mobile app. Parents will pretest the TICOP mobile app. One year later, they will return to the laboratory in order to brainstorm with the principal investigator (an accredited psychologist) about the mobile App and its operation and usefulness."||||
33921415|NCT02586077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921416|NCT01736306|||COHORT||CROSS_SECTIONAL|||||||
33921417|NCT00792701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921418|NCT04765618|||OTHER||RETROSPECTIVE|||||||
34025099|NCT06066294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025100|NCT04480710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|placebo-controlled|Randomized, multi-center, single-blind|t|f|f|f
34025101|NCT04696289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025102|NCT05063435|||CASE_ONLY||PROSPECTIVE|||||||
34025103|NCT06389799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025104|NCT02907255|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34025105|NCT05950750|||COHORT||PROSPECTIVE|||||||
34025106|NCT06122376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner-blind only, subjects received treatment assignment and instructions in a room separate from the examiner and exam area.||f|f|f|t
34089272|NCT01201993|||CASE_ONLY||PROSPECTIVE|||||||
34089273|NCT06188000|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34089274|NCT01010100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719924|NCT00475176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785594|NCT06712290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089275|NCT00884975|||COHORT||PROSPECTIVE|||||||
34089276|NCT05441813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089277|NCT03617588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089278|NCT06387316|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|solutions are coded||t|f|f|f
34089279|NCT05827120|||COHORT||RETROSPECTIVE|||||||
34089280|NCT03655431|NA|SINGLE_GROUP||TREATMENT||NONE||An experimental and control group will be utilized. The experimental group will perform the telerehabilitation intervention.||||
34089281|NCT00390013|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34089282|NCT03716427||SEQUENTIAL||TREATMENT||NONE||This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)||||
34089283|NCT02891967|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33785595|NCT05227313|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|double blind|Parallel Assignment|t|f|t|f
33785596|NCT02008864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785597|NCT06288919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34001145|NCT04054258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization will be 1:1 to each treatment arm and will be stratified by the center. Block randomization with varying block sizes will be used to recruit equal numbers to each arm. A computer-generated randomizer will be used to generate the random allocation list. A statistician (DL) from the research team who is not involved in recruiting patients or collecting data will perform the randomization. Each eligible subject will be assigned a number generated by the computer. Subjects will be randomly allocated to different groups according to their number. In this study, the statisticians, outcome assessors, and research assistants assigned to perform data inputting will be blinded to the allocation sequence. Given the type of intervention, however, the intervention will be unmarked to the participants and the research nurse performing the intervention.|A prospective multi-center, parallel, randomized controlled trial with two arms: app support (ASP) group v.s. a telephone support (TS) group. Two-Armed study design may yield reliable evidence about the interventional use of app support v.s. telephone support, and will allow us to directly investigate the cause and effects. This design is guided by the CONSORT checklist.|t|f|f|f
34001146|NCT04733313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized controlled|t|f|f|f
34001147|NCT01632306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719925|NCT03442907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001148|NCT05549687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001149|NCT05762653|||CASE_CONTROL||PROSPECTIVE|||||||
34001150|NCT03152162|||COHORT||PROSPECTIVE|||||||
34001151|NCT05280080|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001152|NCT00769951|||COHORT||PROSPECTIVE|||||||
34001153|NCT04237220|||COHORT||PROSPECTIVE|||||||
34001154|NCT05975112|||COHORT||PROSPECTIVE|||||||
34001155|NCT03419962|||COHORT||PROSPECTIVE|||||||
34001156|NCT00622362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001157|NCT05241314|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34001158|NCT01388257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001159|NCT05430464|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33719926|NCT05284851|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The design of this trail is based on random, one-blind, placebo control. The subjects will not know the masking status, unless the specific subjects who required treatment for serious adverse events .|Totally 2520 health people aged 3-59 years old will be divided into two age group, containing 1260 in 18-59 years old and 1260 in 3-19 years old. All subjects will receive vaccination either LAVI(non freeze- dried), LAVI(freeze- dried) or placebo in a ratio of 2:2:1.|t|f|f|f
33719927|NCT01843751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719928|NCT03556189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719929|NCT03594292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785598|NCT05611580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785599|NCT01684046|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33785600|NCT05015972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785601|NCT03166319|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with suspected primary CNS vasculitis.||||
33785602|NCT05516342|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two quasi-experiments will be conducted. Experiment #1 will test the Beta 1 Version of the app with 24 PWD and use a pre-post design. Experiment #1's goal is to examine and improve new activities and to make final changes to the overall app structure. Experiment #2, which will test Beta 2, will be a cluster randomized trial (CRT), consisting of pre- and post-intervention measurements of two nonequivalent groups: a Treatment Group (TG)-i.e. 48 PWD who receive the intervention - and a Control Group (CG)- i.e., 48 PWD receiving standard programming / care. Since Experiment #2 will occur after all tweaking is complete, it will represent the definitive trial of LEAD IT!'s proximal and distal effects.||||
33785603|NCT06299605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785604|NCT05138172|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33785605|NCT01106703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33785606|NCT06712784|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785607|NCT05161702|||OTHER||OTHER|||||||
33785608|NCT06055712|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective clinical trial in which patients will be assigned a study arm in sequential fashion.||||
33785609|NCT04866043|||OTHER||CROSS_SECTIONAL|||||||
33785610|NCT05293470|||COHORT||PROSPECTIVE|||||||
33785611|NCT05947500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785612|NCT06223061|||COHORT||PROSPECTIVE|||||||
33785613|NCT05843656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33785614|NCT00119743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33785615|NCT04638777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785616|NCT05926505|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33785617|NCT04312126|||COHORT||PROSPECTIVE|||||||
33785618|NCT03861728|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|"A second investigator will randomize the patient to Treatment vs Placebo on initial visit. This second investigator will not be involved in screening or follow-up patient visits. At the end of the study the patient arms will be unmasked."||t|t|f|f
33785619|NCT04635436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785620|NCT06712862|||CASE_CONTROL||PROSPECTIVE|||||||
34001160|NCT01394133|||COHORT||PROSPECTIVE|||||||
34001161|NCT04425031|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34001162|NCT00555893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001163|NCT03414073|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Only the Principal investigator will know the intervention being done by subject. The outcome investigator(assessor) will be unaware (blinded) to which intervention the subject is undertaken|Subjects will be randomly allotted to three groups. each group will undergo three treatment phases with an in-between washout phase.In each treatment phase the group subjects will test a different intervention|f|f|f|t
34001164|NCT05481931|||OTHER||PROSPECTIVE|||||||
34001165|NCT01211262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785621|NCT01972139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785622|NCT04609553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33719930|NCT04840238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719931|NCT03494309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719932|NCT03564145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001166|NCT04880876|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001167|NCT00702793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001168|NCT00021541|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34001169|NCT06381622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001170|NCT02897934|||COHORT||PROSPECTIVE|||||||
33921419|NCT03809221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers (physicians, nurses and embryologists) and patients are not blinded due to the nature of both interventions while the data analysts are blinded.|After the evaluation, patients met the eligible criteria will be informed, sign the consent form and be included in this study. We will randomly assign women (1:1) to early follicular phase prolonged down-regulation group (intervention group) or luteal phase long down-regulation group (control group), using a central randomization system with block sizes of 4 to 6 (changing constantly) and setting hospital as a stratification factor.|f|f|f|t
34001171|NCT05492448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001172|NCT04531527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001173|NCT02207153|||COHORT||PROSPECTIVE|||||||
33719933|NCT01396460|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001174|NCT04186130|||OTHER||PROSPECTIVE|||||||
34001175|NCT05747976|||COHORT||PROSPECTIVE|||||||
34001176|NCT01152112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719934|NCT01413191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921420|NCT03454906|||CASE_ONLY||PROSPECTIVE|||||||
33921421|NCT05197140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Investigator will be blinded to group.||f|f|t|f
33921422|NCT05399849|NA|SINGLE_GROUP||TREATMENT||NONE|This pilot study has no masking.|||||
34001177|NCT03505008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001178|NCT00046839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001179|NCT03059329|||COHORT||PROSPECTIVE|||||||
34001180|NCT02671877|||OTHER||PROSPECTIVE|||||||
34001181|NCT06249451|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001182|NCT01096641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089284|NCT05470803|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"This study will be observer-blind. Due to the visual differences between the SCB-2019/Clover, Recombinant Covid-19 (AstraZeneca/Fiocruz) and mRNA Covid-19 (Comirnaty, Pfizer/Wyeth) study vaccines, the participants will be blinded before receiving the study vaccination. An unblinded dosing team, not involved with study participant's evaluation, will prepare and administer the study vaccines.~The investigational product syringe will be opacified to avoid unblinding of the participant."|This is a phase 3, cohort randomized, observer-blind, multi-center study to evaluate the safety and immunogenicity of a 4th dose of the following SARS-CoV-2 vaccines: recombinant COVID-19 vaccine -AstraZeneca/Fiocruz, mRNA covid-19 vaccine - Pfizer/Wyeth and SCB-2019-Clover.|t|f|f|f
34089285|NCT03646578|||CASE_ONLY||RETROSPECTIVE|||||||
34089286|NCT06093334|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34089287|NCT01703156|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34089288|NCT05507177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||First healthcare provider teams are recruited. After inclusion, a team is randomly allocated the group I (intervention, receiving a training before conducting medication reviews) or group II (control group, receiving training after conducting medication reviews). After the teams in group I have been trained, teams in both arms will conduct ten medication reviews per team in parallel.||||
34089289|NCT01171534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921423|NCT01630759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921424|NCT05100433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719935|NCT06519890|||OTHER||RETROSPECTIVE|||||||
33719936|NCT04002531|NA|SINGLE_GROUP||OTHER||NONE||Specific group of adults with Fabry disease who received Replagal infusions as children||||
33719937|NCT00528086|||CASE_CONTROL||PROSPECTIVE|||||||
33719938|NCT03566251|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33719939|NCT02852109|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33719940|NCT04765579|||CASE_CONTROL||PROSPECTIVE|||||||
33719941|NCT02461901|||CASE_CONTROL||PROSPECTIVE|||||||
33719942|NCT04520932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719943|NCT03642236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719944|NCT06321965|NA|SINGLE_GROUP||OTHER||NONE||Prospective, longitudinal, multicenter, international study||||
33719945|NCT02551731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719946|NCT02543008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33719947|NCT00598247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921425|NCT05412108|||COHORT||PROSPECTIVE|||||||
33921426|NCT03941691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001183|NCT04274829|||CASE_CONTROL||RETROSPECTIVE|||||||
34001184|NCT00787605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001185|NCT05920954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001186|NCT03774199|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001187|NCT04587245|||COHORT||RETROSPECTIVE|||||||
34001188|NCT00408577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34001189|NCT05103644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind|study group control group|t|f|f|f
34001190|NCT01937806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001191|NCT05341492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001192|NCT04409054|||COHORT||PROSPECTIVE|||||||
34001193|NCT05614115|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled|The study will be conducted in two phases, a dose-escalation phase (week 0-4) and a treatment phase (week 5-12).|t|t|t|t
34001194|NCT00640341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34001195|NCT04734574|||COHORT||RETROSPECTIVE|||||||
34001196|NCT04158427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded products, investigators and patients are blinded. Fecal transplant is either from a healthy donor or patient's own feces|Double-blinded study, treatment group and placebo-group|t|t|t|t
34001197|NCT00949091|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34001198|NCT02015351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001199|NCT00625157||||TREATMENT||||||||
34001200|NCT03494933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001201|NCT00002976|RANDOMIZED|||TREATMENT||||||||
33719948|NCT02143869|||COHORT||PROSPECTIVE|||||||
34001202|NCT01898845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001203|NCT01589835|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33921427|NCT06026007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Sixty pregnant women aged 25 to 35 years old and body mass index was ≥ 30 kg/m², will participate in this study. They will be assigned into three equal groups, Group A will receive only traditional physical therapy protocol in the form of advice including elevation, wearing supportive stocking, and avoiding standing in one position for extended periods, and Group B will receive the same traditional treatment as group A in addition to circulatory exercises, 3times per week for 4 weeks; while Group C will receive the same conventional physical therapy protocol in addition to foot acupressure 3times per week for 4 weeks.|t|f|f|f
34001204|NCT06678711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001205|NCT01092169|||COHORT||CROSS_SECTIONAL|||||||
33921428|NCT01369849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921429|NCT04562142|NA|SINGLE_GROUP||OTHER||NONE||CAD-det||||
34001206|NCT03294122|||COHORT||PROSPECTIVE|||||||
33921430|NCT05231993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001207|NCT04997551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001208|NCT03727763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001209|NCT02340780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719949|NCT00765375|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33921431|NCT00305604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719950|NCT05810792|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center, open-label study in subjects with resectable pancreatic cancer. Eligible subjects will be offered treatment with histamine dihydrochloride and low-dose interleukin-2. Secondary endpoints comparing matched historical controls (DFS, OS).||||
33921432|NCT01932658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719951|NCT02859779|NA|SINGLE_GROUP||OTHER||NONE||||||
33719952|NCT02675413|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719953|NCT06391164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding was carried out by using placebo equivalent to XC243 tablets without active pharmaceutical ingredients (API) and the corresponding labeling of the ID.|Parallel proup|t|f|t|f
33719954|NCT00224315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921433|NCT02881710|||CASE_ONLY||PROSPECTIVE|||||||
33921434|NCT03477071|||COHORT||RETROSPECTIVE|||||||
33719955|NCT00749918|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33921435|NCT01700361|||OTHER||CROSS_SECTIONAL|||||||
33921436|NCT01122030|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33921437|NCT04702048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921438|NCT02487277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921439|NCT04291872|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Control||||
33921440|NCT06001840|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||We will examine two promotion policies. In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only very-low nicotine cigarettes (VLNCs) in the LETM and preferred cigarettes will be available in the iETM. Additionally, we will model three mitigation strategies that may reduce iETM purchases: health communications, availability of nicotine replacement, and penalties. The three mitigation factors will be applied during both promotion policies described above.||||
33921441|NCT02779881|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34001210|NCT02508870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001211|NCT04305535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719956|NCT01593423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719957|NCT01717404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719958|NCT06033521|||COHORT||RETROSPECTIVE|||||||
33719959|NCT03658850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719960|NCT01973166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719961|NCT05611034|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33719962|NCT01524510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719963|NCT05713045|||COHORT||PROSPECTIVE|||||||
33719964|NCT04941235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719965|NCT00708643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719966|NCT05766475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33719967|NCT05181423|||COHORT||OTHER|||||||
33719968|NCT05178966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719969|NCT05335564|NA|SINGLE_GROUP||OTHER||NONE||||||
33719970|NCT03414424|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719971|NCT02100501|||CASE_CONTROL||PROSPECTIVE|||||||
33719972|NCT01012856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719973|NCT04177342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||patients will be devided randomly into two groups. One group will be given oxycodone and the other will be given fentanyl during the POEM procedure. Post procedure pain condition will be recorded.|t|f|t|f
33719974|NCT01411696|||COHORT||RETROSPECTIVE|||||||
33719975|NCT02983331|||||RETROSPECTIVE|||||||
33719976|NCT01174927|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33719977|NCT02829463|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33719978|NCT03872219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind randomized trial|The study consists of two arms, the intervention arm and the placebo arm. Children are randomized into the arms.|t|t|t|t
33719979|NCT00470639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33719980|NCT02550548|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719981|NCT03502226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33719982|NCT04989179|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33719983|NCT03043027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719984|NCT00220402|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33719985|NCT06468631|||OTHER||PROSPECTIVE|||||||
33719986|NCT01601249|RANDOMIZED|PARALLEL||||NONE||||||
33921442|NCT00821665|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34001212|NCT04809714|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The control group will undergo a graduated therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. This is compared to the intervention group that will have a therapeutic LOP of 60-100%. This means that patients will have a cuff on their limb and are thus blinded to their group allocation but the pressure is set to such a low level that no additional effect on muscle hypertrophy is expected based on prior research.||t|f|f|f
33785623|NCT06000969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"* The participants will be kept blind through the use of ultrasound assessment in both groups.~* Outcome assessors will be blinded as they will be anesthesia resident and nurse not participating in the study."|"Patients will be randomly allocated in one of the two equal groups using a computer-generated table of random numbers to :-~* Conventional group (group C); 30 patients:~* Ultrasound-guided group (group US); 30 patients:"|t|f|f|t
34001213|NCT04537520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001214|NCT01390051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001215|NCT03058640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001216|NCT01452035|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001217|NCT01134367|||||PROSPECTIVE|||||||
34001218|NCT00892749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001219|NCT02906917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001220|NCT06273709|||CASE_CONTROL||PROSPECTIVE|||||||
34001221|NCT06058806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001222|NCT03365063|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34089290|NCT01389232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089291|NCT00174395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089292|NCT02911116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785624|NCT02040844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785625|NCT02463162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34089293|NCT02022397|||COHORT||PROSPECTIVE|||||||
33785626|NCT05550480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785627|NCT06629246|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33921443|NCT02103452|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33921444|NCT05340322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921445|NCT02675179|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089294|NCT03080285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785628|NCT06425055|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm fixed dose escalation||||
33921446|NCT00838006|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33921447|NCT02727660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921448|NCT06283173|NA|SINGLE_GROUP||OTHER||NONE||This will be a single center, with no randomization or blinding, study design in 50 healthy adult subjects, age 18-70 years. Based on prior experience approximately 75 subjects will be enrolled to ensure 50 subjects complete the study.||||
33921449|NCT05634096|||COHORT||RETROSPECTIVE|||||||
33921450|NCT04280887|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Cohort||||
33921451|NCT03443609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All the imaging sequences will be done in an outpatient setting. There will be no premedication or other treatment before and after 68Ga-HBED-CC-PSMA PET scans. PET / CT will be performed at participating centers on a hybrid PET camera.~68Ga-HBED-CC-PSMA will be administered to the patient by single intravenous injection (Y-infused with isotonic saline infusion) within 60 min of reconstitution of the radiopharmaceutical.~The first TEP 68Ga-HBED-CC-PSMA whole body acquisition starts 60 min after the injection of 150 MBq of 68Ga-HBED-CC-PSMA and continues for 20-30 minutes, the second full-body acquisition of the same duration takes place 120 minutes after the injection is a total duration of 1 hour of imaging and 2:30 to 3:00 in the service."||||
33921452|NCT01848639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921453|NCT05396313|||COHORT||RETROSPECTIVE|||||||
33921454|NCT03922035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921455|NCT00997178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921456|NCT06138028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921457|NCT05355428|NA|SINGLE_GROUP||OTHER||NONE||Case series||||
33921458|NCT01661920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921459|NCT01047748|RANDOMIZED|PARALLEL||||NONE||||||
33921460|NCT04196205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921461|NCT01153477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921462|NCT05096013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients cannot be blinded due to the nature of the intervention. However, the personnel involved will be blinded to the collection of the primary endpoint. In order to be able to blind the nutritional calculations of the primary endpoint, the logged amounts of food eaten will be recorded on the neutral eating cards, on which the study group allocation will not be apparent.||f|f|t|f
34001223|NCT00844350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001224|NCT03141216|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||A parallel group study is a simple and commonly used clinical design which compares two treatments. Usually a test therapy is compared with a standard therapy. The allocation of subjects to groups is usually achieved by randomisation. The groups are typically named the treatment group and the control group. Parallel group designs do not require the same number of subjects in each group, although often similar numbers are observed. The design is commonly used in randomised controlled trials. Statistical analysis often boils down to a simple t-test of the between group difference in the outcome, which is usually a mean or a proportion.|t|f|f|t
34001225|NCT04937517|||CASE_ONLY||PROSPECTIVE|||||||
34001226|NCT00625339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001227|NCT02713139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001228|NCT03448692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Open label||t|t|t|f
34001229|NCT02604680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001230|NCT01693887|||CASE_CONTROL||PROSPECTIVE|||||||
34001231|NCT05361408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001232|NCT00522041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001233|NCT00157521|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
34001234|NCT01206439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089295|NCT02186639|||CASE_CONTROL||PROSPECTIVE|||||||
34089296|NCT04419168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||comparative effectiveness trial|t|f|f|f
34001235|NCT04848688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Double-blinded (Participant and Care provider) Additionally, the principal investigator and the statistician will be blinded.~PK substudy is single-blinded (Participant)"|Parallel study with 2 treatment arms|t|t|t|t
34089297|NCT03535415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089298|NCT01449084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34089299|NCT02084797|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34001236|NCT02383706|||COHORT||PROSPECTIVE|||||||
34001237|NCT00003751||||TREATMENT||||||||
34089300|NCT02640079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089301|NCT00167427|||COHORT||PROSPECTIVE|||||||
33921463|NCT03582735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to participant allocation|Participants will be allocated in two groups to receive either the experimental intervention (i.e., nerve gliding exercise program) or control intervention (i.e., no treatment)|f|f|f|t
34089302|NCT02259387|||CASE_CONTROL||PROSPECTIVE|||||||
34089303|NCT00128375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089304|NCT00864981|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089305|NCT03789006|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized clinical trial||||
34089306|NCT01181882|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33719987|NCT06209645|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"The study involves the use of transcranial electrical stimulation applied to the motor cortex at each subject's own cortical rhythm. The rhythm is previously obtained by electroencephalographic (EEG) recording. Fifty adult patients, recruited by the Pain Evaluation and Treatment Center of the Neurological hospital, at the Hospices Civils de Lyon, suffering from drug-resistant neuropathic pain for more than 12 months.~The stimulation (tACS) will be compared head-to-head with another reference active stimulation modality, namely anodal direct current stimulation (tDCS) of the motor cortex. The 2 types of active stimulation will be performed in cross-over mode, in randomized order, and compared with placebo stimulation.~Each stimulation modality will comprise 6 sessions spaced 2 weeks apart, with the first session in placebo mode and the next 5 in active mode."|t|f|t|f
33719988|NCT01967212|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089307|NCT04866108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089308|NCT01680796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785629|NCT04968132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study interventions, patients and the health care team cannot be blinded. An independent blinded surgeon will evaluate each adverse event to minimize the risk of bias for that outcome. The primary study outcome of non-opioid pain control will be collected using a daily e-diary up to 8 weeks. Other study outcomes will be collected by a research personnel not involved in the clinical care. Data analysts will be blinded for all outcomes|2 group parallel randomized controlled trial|f|f|f|t
33785630|NCT02374957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785631|NCT06712407|NA|SEQUENTIAL||TREATMENT||NONE||"There are 2 treatment periods with the study drug:~* TARPEYO® 16 mg (4 capsules) once a day for 6 months~* TARPEYO® 8 mg (2 capsules) once a day for 9 months."||||
33785632|NCT04269889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785633|NCT06713668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785634|NCT04093570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785635|NCT04355637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921464|NCT01225367|||CASE_CONTROL||PROSPECTIVE|||||||
33921465|NCT03148158|||COHORT||PROSPECTIVE|||||||
33921466|NCT01492699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921467|NCT06048926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921468|NCT03748277|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"1. group - decompression, MIS TLIF + Screw Fixation~2. group - decompression, open fusion + Screw Fixation"||||
33921469|NCT03273179|||CASE_ONLY||RETROSPECTIVE|||||||
34089309|NCT02191501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921470|NCT03634878|NA|SINGLE_GROUP||OTHER||NONE||||||
33921471|NCT00003809|RANDOMIZED|||TREATMENT||||||||
33921472|NCT00049218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921473|NCT04731623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921474|NCT06299579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This trial is designed as a multicenter, randomized, double-blind, placebo-parallel controlled trial using a multicenter, randomized, double-blind, placebo-parallel controlled trial design. Subjects are randomly assigned in a 1:1 ratio and random number tables are generated using SAS（Statistics Analysis System）software.|t|t|t|f
33921475|NCT04084340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921476|NCT00438893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921477|NCT00859989|RANDOMIZED|||||||||||
33921478|NCT05367219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921479|NCT01862432|RANDOMIZED|PARALLEL||||NONE||||||
34001238|NCT05204537|||COHORT||RETROSPECTIVE|||||||
34001239|NCT04000945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001240|NCT06468904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (investigator, outcome assessor)|cervical stabilization exercises|f|f|t|t
34001241|NCT01956565|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34001242|NCT01067521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001243|NCT06504355|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34001244|NCT02059811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001245|NCT00268515||||PREVENTION||DOUBLE||||||
34001246|NCT01643434|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089310|NCT01230008|||CASE_CONTROL||PROSPECTIVE|||||||
34089311|NCT00671749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089312|NCT00691379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089313|NCT01069211|||CASE_CONTROL||PROSPECTIVE|||||||
34089314|NCT00668239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34089315|NCT06248489|||CASE_ONLY||PROSPECTIVE|||||||
34089316|NCT00165698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089317|NCT01461551|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34089318|NCT01416662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001247|NCT00190541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001248|NCT04962139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001249|NCT05469958|RANDOMIZED|PARALLEL||PREVENTION||NONE|It is impossible to mask patients; they will notice whether are warmed or not. The care providers must know which protocol to carry on, so it's impossible to mask them. The PI will prepare the assignation groups by an randomization software.|||||
34001250|NCT00544167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921480|NCT04432844|||CASE_ONLY||PROSPECTIVE|||||||
34001251|NCT02837913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34001252|NCT00531128|RANDOMIZED|CROSSOVER||PREVENTION||||||||
34001253|NCT01278641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33921481|NCT01564667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001254|NCT05586386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group 1: Obese adults (BMI: 30-40): 200 mL (\~6.7 oz.) of dark sweet cherry (DSC) juice supplemented with 3g of DSC powder twice per day for 30 days.~Group 2: Obese adults (BMI: 30-40): 200 mL (\~6.7 oz.) of placebo juice twice per day for 30 days."|t|f|f|f
34001255|NCT05215873|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* 1st group (misoprostol group): induction of labor by 25µg misoprostol oral tablet every 4 hours with maximum200 µg.~* 2nd group (oxytocin group:control group): induction of labor done by administration of oxytocin infusion according to ASUMH local protocol."||||
34001256|NCT00942721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921482|NCT00735670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001257|NCT06630897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001258|NCT00757705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001259|NCT01201694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001260|NCT00391534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001261|NCT04022941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001262|NCT00908180||||TREATMENT||NONE||||||
34001263|NCT04836182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001264|NCT04122027|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34001265|NCT04392934|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Participants are grouped according to their acromion type. First group is flat shape acromion group, second is hook shape group and the third one is curved shape acromion group. All groups are treated with the same physiotherapy protocol.|t|f|t|f
33719989|NCT02393547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921483|NCT05698121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921484|NCT01877824|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33921485|NCT04968964|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921486|NCT02252237|||COHORT||PROSPECTIVE|||||||
33921487|NCT01915108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33921488|NCT05518799|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33921489|NCT01975246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921490|NCT02102984|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921491|NCT01178346|NON_RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33921492|NCT01440907|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921493|NCT02482259|||COHORT||PROSPECTIVE|||||||
33921494|NCT02523885|||COHORT||PROSPECTIVE|||||||
33921495|NCT00906867|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921496|NCT02241928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921497|NCT05317013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33921498|NCT03593863|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The Fit to Study brain imaging study is embedded in the Fit to Study trial, which is a parallel group, superiority cluster-randomised efficacy trial of a 10-month (one academic year) vigorous physical activity (VPA) intervention versus control.|f|f|f|t
33921499|NCT04943172|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33921500|NCT04776421|||COHORT||PROSPECTIVE|||||||
33921501|NCT05859048|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33921502|NCT00719953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921503|NCT02814695|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||control, vit E, vit C, Yeast|t|f|f|t
33921504|NCT00640952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921505|NCT01066455|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921506|NCT02272283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719990|NCT03352323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719991|NCT05202509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo to active|Placebo-Controlled, Double-Blind, Randomized|t|t|t|t
33921507|NCT02607332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921508|NCT06042842|||CASE_CONTROL||RETROSPECTIVE|||||||
33921509|NCT01975077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921510|NCT05052528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921511|NCT04922034|||OTHER||PROSPECTIVE|||||||
33921512|NCT01777971|||CASE_ONLY||PROSPECTIVE|||||||
33921513|NCT00388258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921514|NCT00960258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921515|NCT01511432|RANDOMIZED|CROSSOVER||||NONE||||||
33921516|NCT00363441|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921517|NCT04046757|||COHORT||PROSPECTIVE|||||||
33921518|NCT01737658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921519|NCT03581929|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Double Blind from Day 0 to Day 180. Open Label from Day 181 to Day 360.||t|f|t|f
33921520|NCT04410757|||CASE_CONTROL||OTHER|||||||
33921521|NCT00206778|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33921522|NCT01106742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921523|NCT02773394|||OTHER||RETROSPECTIVE|||||||
33921524|NCT04961918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921525|NCT00216541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921526|NCT00895648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921527|NCT04178135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921528|NCT02800486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921529|NCT00976248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921530|NCT05479721|||COHORT||PROSPECTIVE|||||||
33719992|NCT02953054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719993|NCT01991457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719994|NCT02884674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719995|NCT06418841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33719996|NCT06397898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized-controlled pilot study||||
33719997|NCT02963207|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33719998|NCT05419323|||COHORT||PROSPECTIVE|||||||
33719999|NCT02425150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720000|NCT00410553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720001|NCT05886608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720002|NCT02221284|||COHORT||PROSPECTIVE|||||||
33720003|NCT03844360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720004|NCT01512121|||OTHER||PROSPECTIVE|||||||
33720005|NCT06542952|||CASE_ONLY||RETROSPECTIVE|||||||
33921531|NCT03002103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921532|NCT02849249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921533|NCT00397176|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33921534|NCT02823600|NA|SINGLE_GROUP||SCREENING||NONE||||||
33921535|NCT05605977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors are blinded to the assigned group of participants|pretest-posttest control group design|f|f|f|t
33921536|NCT04690257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33921537|NCT01606735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921538|NCT02052934|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921539|NCT00821145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921540|NCT04868370|||COHORT||PROSPECTIVE|||||||
33921541|NCT05810844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921542|NCT03627494|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Part A is a Crossover group single ascending dose study with 2 arms per cohort that is subject and investigator blinded. Part B is a Parallel group repeat dose study with 2 arms per cohort that is subject and investigator blinded. Part C is a Crossover group food effect study with 2 arms per cohort that is not-masked."|t|f|t|f
33921543|NCT04697862|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33921544|NCT02861872|||COHORT||PROSPECTIVE|||||||
33921545|NCT00579293|||CASE_ONLY||PROSPECTIVE|||||||
33921546|NCT05053126|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, double-blind, double-dummy, placebo- and active-controlled, 6-treatment, 6-period crossover, single-dose, Williams square design study in healthy male and/or female adult, non drug-dependent recreational opioid users.|t|f|t|t
33921547|NCT00715312|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33921548|NCT05317702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921549|NCT00393068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921550|NCT05380349|NA|SEQUENTIAL||TREATMENT||NONE||single-center Phase 1 open-label study||||
33921551|NCT03061045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921552|NCT03703687|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical trial has a single arm: all the dyads will go through all the steps (apart from the qualitative assessment which are facultatives).||||
33921553|NCT06278129|||COHORT||PROSPECTIVE|||||||
33921554|NCT02681185|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental vs. Standard of Care||||
33921555|NCT05220241|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921556|NCT00013455|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921557|NCT00408759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921558|NCT03686696|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2 \* 2 Factorial Design||||
33921559|NCT05979233|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921560|NCT03329417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921561|NCT01486004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921562|NCT04462536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921563|NCT02162121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001266|NCT04230876|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are unaware if they are in the late or early intervention group.|All participants experience the same interventions and assessments. Subjects are divided into either early or late intervention groups.|t|f|f|f
34001267|NCT00616993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001268|NCT00001763||||TREATMENT||||||||
34001269|NCT04237350|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001270|NCT04912063|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001271|NCT02660541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720006|NCT01192282|||COHORT||PROSPECTIVE|||||||
33720007|NCT02204592|||||CROSS_SECTIONAL|||||||
33720008|NCT01830660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720009|NCT04461015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33720010|NCT00421187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720011|NCT05552768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785636|NCT04358861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921564|NCT03210220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|One anesthesiologist (JJC) performed all blocks in the Pecs group enrolled patients. After the intervention, the participants and the investigator responsible for the study outcome assessment were blinded.|Patients either received the Pecs II block (Pecs group) or did not receive it (control group).|t|t|t|t
33921565|NCT01788280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921566|NCT05536193|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will use salicylic acid 30% peeling on the right side of the face and topical metformin emulgel on the left side||||
33921567|NCT05991089|||COHORT||CROSS_SECTIONAL|||||||
33921568|NCT04004377|||CASE_CONTROL||PROSPECTIVE|||||||
33921569|NCT05861011|||COHORT||RETROSPECTIVE|||||||
33921570|NCT04480931|RANDOMIZED|PARALLEL||PREVENTION||NONE|The participant (as well as the study team and the health care provider) will know after randomization whether or not they are being provided access to the mobile app.|Pregnant women will be recruited \~20 weeks pregnant and after baseline assessments, randomized into the control or intervention group. The intervention group will utilize the mhealth intervention, while the control group will receive basic educational materials only.||||
33921571|NCT02637024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921572|NCT02814864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921573|NCT00681096|||COHORT||PROSPECTIVE|||||||
33921574|NCT04374279|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 1:1 to bicalutamide with standard of care, or standard of care alone.||||
33921575|NCT02080286|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33921576|NCT00168064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921577|NCT05536245|||COHORT||PROSPECTIVE|||||||
33921578|NCT01943422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921579|NCT02683304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921580|NCT06192953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921581|NCT00949910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921582|NCT03746808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33921583|NCT04315493|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33921584|NCT02861053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921585|NCT05885009|||OTHER||PROSPECTIVE|||||||
33921586|NCT04673604|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Only the dosing coordinator is aware of the treatment patients use.|Masked, prospective, placebo-controlled, crossover trial of glaucoma patients with moderate to severe GTR-OSD on preserved latanoprost and dorzolamide/timolol fixed combination therapy for well-controlled open-angle glaucoma was conducted. Patients were randomized to receive preservative-free tafluprost and dorzolamide/timolol fixed combination with either topical placebo or cyclosporine 0.1% for 6 months and will then be crossed over to the opposite therapy. Oxford score of staining will be the primary outcome; osmolarity, matrix-metalloproteinase-9 testing (MMP-9), meibomian gland dysfunction (MGD), adverse events and diurnal intraocular pressure (IOP) comprise the secondary outcomes.|f|f|f|t
33921587|NCT04157647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33921588|NCT02604615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921589|NCT01017822||||TREATMENT||NONE||||||
33921590|NCT05364229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921591|NCT04800120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Study Group: Provide 100% oxygen at 2.0 ATA for 90 minutes on consecutive days for a total of up to 5 treatment to COVID-19 patients meeting inclusion criteria Control Group: Any COVID-19 positive patient meeting study inclusion criteria that does not receive HBOT (historical)||||
34001272|NCT01787929|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34001273|NCT02505035|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34001274|NCT04012216|||COHORT||CROSS_SECTIONAL|||||||
34001275|NCT00429819|||CASE_CONTROL||PROSPECTIVE|||||||
34001276|NCT01866644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001277|NCT02172469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001278|NCT03885336|||COHORT||PROSPECTIVE|||||||
34001279|NCT01485718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001280|NCT05002140|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720012|NCT00229099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720013|NCT04072211|NA|SINGLE_GROUP||PREVENTION||NONE||All study participants will be screened for Hepatitis B Virus and those eligible for vaccination will receive the vaccine. Those already infected will be linked to care and those with a protective level of anti-HBs will not receive the vaccine.||||
33720014|NCT00627003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33720015|NCT01238679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001281|NCT04096547|||COHORT||PROSPECTIVE|||||||
34001282|NCT00862212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001283|NCT00409942|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001284|NCT05721157|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33785637|NCT00498186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785638|NCT06567015|NA|SEQUENTIAL||TREATMENT||NONE||||||
33785639|NCT01801319|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33785640|NCT06228807|||COHORT||RETROSPECTIVE|||||||
33785641|NCT06461156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785642|NCT00817050|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33720016|NCT06397352|RANDOMIZED|PARALLEL||OTHER||NONE||The participants were randomly assigned to ShotBlocker®, Buzzy®, and control groups.||||
33720017|NCT01647412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720018|NCT06159712|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Researchers compare immunologic, virologic and epigenetic factors in patients with multiple sclerosis in standard 2.line treatment with ocrelizumab, rituximab, ofatumumab and natalizumab by taking extra blood samples and compare it to a healthy control group.||||
33720019|NCT01924312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921592|NCT01066884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720020|NCT02282670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720021|NCT04489667|NA|SINGLE_GROUP||SCREENING||NONE||||||
33785643|NCT00691158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33921593|NCT00279851|||OTHER||PROSPECTIVE|||||||
33921594|NCT02990819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||T-depleted stem cell infusion||||
33921595|NCT05931185|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33921596|NCT03914495|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33921597|NCT03039920|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33921598|NCT03071003|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33921599|NCT02384772|||COHORT||PROSPECTIVE|||||||
33921600|NCT06528210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921601|NCT05793216|NA|SEQUENTIAL||OTHER||NONE|Outcome measures will be reviewed by a neutral party to avoid bias.|This program involves a multiple baseline design for a group of students ages 6-9 years. The intervention will last for 8 weeks with educational outcomes monitored before, during, and after the intervention. With final reporting at 6 months post intervention.||||
33921602|NCT04324138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921603|NCT06229587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921604|NCT01788150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921605|NCT04137419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo, masked evaluator||t|t|t|t
33921606|NCT01504048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921607|NCT00749268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921608|NCT02667379|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921609|NCT04045574|NA|SINGLE_GROUP||TREATMENT||NONE|the technique to be used for each site will be randomized|single center comparative controlled trials||||
33921610|NCT00307242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921611|NCT01641991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921612|NCT03108209|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921613|NCT03729934|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33921614|NCT00891163|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33921615|NCT03437317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blind to their assigned condition.|"Participants were randomly assigned to either an active training group or a control group. The active participants completed 8 blocks of a perceptual training task, while the control group performed 8 blocks of a gender discrimination task~that received the perceptual retraining protocol"|t|f|f|f
33921616|NCT03948126|||OTHER||CROSS_SECTIONAL|||||||
33921617|NCT02381548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921618|NCT04006080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921619|NCT04712266|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921620|NCT02223429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33921621|NCT02121470|||COHORT||PROSPECTIVE|||||||
33921622|NCT02826993|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921623|NCT06119451|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control trial using pre and post test control group design¸||||
33921624|NCT06436625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33921625|NCT04753138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be blinded to the type of treatment they receive to reduce bias in the reporting of postoperative pain.~Since it is not possible to blind the care providers, they will only be informed of the type of treatment once full chemo-mechanical debridement has been completed and the tooth is ready to be obturated. This would reduce care provider bias.~Assessors will be blinded to the treatment option to reduce bias during the assessment of healing."|Permuted block randomization (of block size = only known to statistician) will be used to randomly select 212 subjects (106 subjects in each group). Statistical software (NCSS, LLC© ver. 2020) will be utilized to generate the randomization list and subjects will be assigned to the selected treatment group accordingly.|t|f|t|t
33921626|NCT00988260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921627|NCT05893667|||COHORT||RETROSPECTIVE|||||||
33921628|NCT01356719|||CASE_ONLY||PROSPECTIVE|||||||
33921629|NCT04457128|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Micro-randomized trial||||
33921630|NCT00587769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921631|NCT03219567|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921632|NCT04503941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Since the acupuncture and sham-acupuncture cannot be blind to the researchers, considering the placebo effect of the subjects, this experiment was blind only to the subjects, namely single-blind. But the researchers did not hint at the treatments received by the patients, and avoided various factors that may have led to bias during the trial.|A total of 120 patients were enrolled and treated in either the sham-acupuncture (control group) or acupuncture group for 12 weeks, with 8 weeks' follow-up, three times per week.|t|f|f|f
33921633|NCT04438252|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33921634|NCT04203355|||COHORT||PROSPECTIVE|||||||
33921635|NCT04564066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921636|NCT04765748|||COHORT||PROSPECTIVE|||||||
33921637|NCT00489034|||COHORT||PROSPECTIVE|||||||
34001285|NCT04880954|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will know the group they are randomly assigned.|Participants will be randomly assigned to one of three groups 1) Manual Therapy, 2) Rehabilitation, or 3) Combination of both||||
34001286|NCT06317402|||COHORT||PROSPECTIVE|||||||
34001287|NCT01490138|||COHORT||PROSPECTIVE|||||||
33720022|NCT02964962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720023|NCT00501306|||CASE_CONTROL||PROSPECTIVE|||||||
33720024|NCT06542120|||COHORT||CROSS_SECTIONAL|||||||
34001288|NCT02832167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001289|NCT01442220|||CASE_CONTROL||PROSPECTIVE|||||||
34001290|NCT04416854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001291|NCT02577133|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34001292|NCT03757468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001293|NCT00450567|||CASE_ONLY||PROSPECTIVE|||||||
34001294|NCT00083772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001295|NCT06226259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001296|NCT03400774|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34001297|NCT01713166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001298|NCT02179151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001299|NCT06260982|||COHORT||PROSPECTIVE|||||||
34001300|NCT05065619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|MT-2766 High dose group and placebo group are randomized and observer-blinded. MT-2766 Low dose group is open label.||t|t|t|t
33697122|NCT06680414|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinding(Participant blinding) will be done; participants will not be told they are in the experimental or control group. A surveyor will invite pregnant mothers to the study, which will continue until the targeted sample number (58 participants) is reached. During the participant registration, the names and contact information of the mothers will be obtained; it will be stated that they will be contacted for the training process, that the training time may be extended, and that they will be given definite training. The participant registration is completed, the supportive vaccine communication process will begin. The second researcher(D-KT) in the research team will explain to the first researcher(DS-Y) that the participants are in the experimental or control group. The pregnant mothers in the control group will be assigned to the waiting list.|Random assignment. Block randomization will be used in the randomization process. Randomizer.org will be used to select block combinations with six blocks. Pregnant mothers will first be stratified according to their number of pregnancies. Eligible participants will be randomly assigned to the intervention or waitlist group using the permuted block randomization method on a 1:1 basis. The waiting list group will form the second set of the research, which is planned to be attempted two months later. The participant assignment list will be generated by a non-research statistician with a random distribution sequence. Assignment confidentiality will be ensured using opaque sealed envelopes containing sequence numbers. The data analyst/statistician will be blind to the participants' group assignments.|t|f|f|f
33697123|NCT01768767|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34001301|NCT05205096|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001302|NCT03953664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001303|NCT06503926|||OTHER||CROSS_SECTIONAL|||||||
34001304|NCT03585309||SEQUENTIAL||TREATMENT||NONE||||||
34001305|NCT04020016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This is a Phase 1, open-label PK and safety study of NAL ER in subjects with impaired liver function compared to healthy subjects. It will be performed in 2 parts:~Part 1: single-ascending-dose (SAD) cohorts~Part 2: multiple-ascending-dose (MAD) cohort~In Part 1 (SAD)-Dose Cohorts 1-5: Each of the cohorts will be dosed sequentially starting with the lowest dose. The drug kinetics in the hepatic impairment subject population will be compared relative to the healthy subject population (Cohort 5).~Part 2 (MAD) - Dose Cohort 6: 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment In Part 2 of the study (MAD), subjects will receive multiple doses ascending from 27 mg up to 162 mg over 13 days of dosing."||||
34001306|NCT01012180|||||OTHER|||||||
34001307|NCT01586208|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34001308|NCT00279760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001309|NCT01775722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001310|NCT02308696|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001311|NCT00000205||||TREATMENT||DOUBLE||||||
34001312|NCT00027417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001313|NCT03008941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001314|NCT02011451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001315|NCT01447758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697124|NCT00177996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33697125|NCT06681285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697126|NCT06376734|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|All participants will receive real open-label TMS, so there will be no conventional masking. However, participants and investigators will be blinded to which network is being stimulated.|Double-blind, randomized controlled crossover trial. Participants will be stimulated at a random location in the prefrontal cortex, which will be mapped to its underlying brain network to determine which network was stimulated.||||
33697127|NCT06680141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33697128|NCT03677908|||CASE_ONLY||RETROSPECTIVE|||||||
33697129|NCT06681506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33720025|NCT00723892|||COHORT||PROSPECTIVE|||||||
33720026|NCT05496933|||CASE_ONLY||CROSS_SECTIONAL|||||||
33720027|NCT00285597|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33720028|NCT03864471|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33720029|NCT02808026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001316|NCT03183141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001317|NCT03352960|||COHORT||PROSPECTIVE|||||||
34001318|NCT00650780|||COHORT||CROSS_SECTIONAL|||||||
34001319|NCT04763096|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34001320|NCT05921812|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001321|NCT03098693|||COHORT||PROSPECTIVE|||||||
34001322|NCT03853499|||CASE_CONTROL||RETROSPECTIVE|||||||
34001323|NCT06679595|||CASE_ONLY||PROSPECTIVE|||||||
34001324|NCT01077505|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34001325|NCT01916694|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34001326|NCT03044990|||COHORT||PROSPECTIVE|||||||
34001327|NCT02910687|||COHORT||RETROSPECTIVE|||||||
34001328|NCT00694486|||COHORT||PROSPECTIVE|||||||
34001329|NCT01183884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001330|NCT06105580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The first 130 patients have been recruited in the context of the CONSYST I study (ClinicalTrials.gov Identifier: NCT05187611).~It is planned to perform an interim analysis (intermediate analysis) for the primary endpoint in all randomized patients who received intervention. The formal limits of stopping the study will be determined by the limits of futility and effectiveness defined by the rules of sequential stopping using the O'Brien-Fleming method. The interim analysis will be performed with a sample recruitment of 50%. Members of the Data Monitoring Committee, but not any trial investigator, will be informed of the results of the interim analysis. A p of 0.0054 (two-sided alpha) will be required for the interim analysis and 0.049 in the final analysis."|t|f|f|f
34001331|NCT01466374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001332|NCT01081509|||COHORT||PROSPECTIVE|||||||
33697130|NCT03979131|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, non-randomized, multicentric phase II clinical trial in subjects with operable gastric or GEJ adenocarcinoma. Tissue biopsies before and after treatment will be required. Blood samples will be required at different points of the treatment for biomarker analyses. Tumor imaging assessments will be performed at baseline, after the neoadjuvant treatment, and after finalizing the adjuvancy with avelumab/FLOT, and every 6 months thereafter to determine response to treatment. Clinical decision making will be based on Investigator assessment of the scans using RECIST v1.1. Safety of avelumab/FLOT will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported.||||
33697131|NCT04560543|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34001333|NCT05302193|NA|SINGLE_GROUP||OTHER||NONE||Two measuring devices are active simultaneously during measurement of blood pressure and heart rate on each participant and their functioning is compared.||||
34001334|NCT04380233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The eligible subjects will be randomly assigned, with equal access to either the Chinese medicine treatment investigational drug group (Zhizhu Kuanzhong Capsule) or the placebo group.|Randomized, Double-Blind, Placebo-Controlled Parallel Group Clinical Trial|t|t|t|f
34001335|NCT02668991|||COHORT||PROSPECTIVE|||||||
34001336|NCT00945438|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001337|NCT01745887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001338|NCT02407496|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001339|NCT00388219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001340|NCT02342938|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001341|NCT02039635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34001342|NCT00115869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001343|NCT00127166|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33697132|NCT03285672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697133|NCT00555685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921638|NCT05573529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor will be masked to the intraocular lens implanted.|intra-individual comparison of two groups recieving predefined EDOF and multifocal intraocular lenses. In group one (I), the EDOF lens one (I) will be implanted in the dominant eye and the multifocal lens one (I) in the non-dominant eye. Subsequently, study participants in group two (II) will receive the EDOF lens one (I) in the dominant eye and the multifocal lens two (II) in the non-dominant eye.|f|f|f|t
33921639|NCT00974844|||CASE_ONLY||PROSPECTIVE|||||||
33921640|NCT03297216|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Phase III, double-masked, placebo-controlled, randomized controlled trial|t|t|t|f
33921641|NCT02483702|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921642|NCT00517283|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33921643|NCT03714347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921644|NCT03015025|||COHORT||PROSPECTIVE|||||||
33921645|NCT00034203|RANDOMIZED|||TREATMENT||DOUBLE||||||
33921646|NCT00489372|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33921647|NCT06386172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The primary healthcare network system of the region of Stockholm coordinates 66 public primary healthcare centers. Collectively, these centers offer care to an estimated population of 780.000. Since November 2022, a new platform for CDS (clinical decision support) triggers called ALMA has been implemented in these centers. ALMA is connected to patient records and uses CDS triggers to identify medical problems, issue alerts and propose solutions.~Using the ALMA platform, this project has the following objectives:~Objective 1: to develop a CDS trigger connected with the electronic healthcare records specific to the processes of screening, diagnosis, and nephrologist referral of patients with CKD, including individualized CKD management optimization, in primary care.~Objective 2: to evaluate the effectiveness of this CDS trigger (versus current basic advice) through a 2-arm pragmatic cluster RCT."|f|f|f|t
33921648|NCT00920478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921649|NCT00944788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33921650|NCT02486367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921651|NCT02034552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921652|NCT04655209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921653|NCT04791033|||COHORT||PROSPECTIVE|||||||
33921654|NCT03685370|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33921655|NCT00919477|||COHORT||PROSPECTIVE|||||||
33921656|NCT05815680|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921657|NCT04945213|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921658|NCT02836483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921659|NCT00347412|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33921660|NCT04159077|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921661|NCT03241238|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34001344|NCT02360007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697134|NCT02297048|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33697135|NCT01154829|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33921662|NCT05690971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921663|NCT01810549|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33921664|NCT05134155|||COHORT||PROSPECTIVE|||||||
33921665|NCT01905670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921666|NCT03036111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33921667|NCT00716638|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33921668|NCT02516150|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33921669|NCT05489120|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921670|NCT00003085||||DIAGNOSTIC||||||||
33921671|NCT00965146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921672|NCT02449408|||COHORT||PROSPECTIVE|||||||
33921673|NCT03427450|||COHORT||PROSPECTIVE|||||||
33921674|NCT03475901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921675|NCT01530282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921676|NCT00128583||||TREATMENT||NONE||||||
33921677|NCT04595357|||CASE_ONLY||RETROSPECTIVE|||||||
33921678|NCT04552431|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34001345|NCT05790460|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34001346|NCT05900323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001347|NCT05232487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized by using the web-based secuTrial randomization tool and by applying an allocation ratio of 1:1 to SLBA and SA therapy. Patients and data analysts will be blinded to the intervention (SLBA or SA), however, acupuncturists performing the acupuncture sessions will not be blinded to the intervention.|This study is a randomized, controlled, single-blind, parallel trial, allocating patients with CLBP 1:1 to either 9 weeks of SLBA or SA therapy.|t|f|f|t
33921679|NCT00353327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921680|NCT01459575|||COHORT||PROSPECTIVE|||||||
34001348|NCT02157896|||CASE_ONLY||PROSPECTIVE|||||||
34001349|NCT05129189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001350|NCT05547048|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will compare the Athena strategy to a decision aid-only intervention.||||
34001351|NCT02824757|||COHORT||PROSPECTIVE|||||||
34001352|NCT05009537|||COHORT||RETROSPECTIVE|||||||
34001353|NCT01071551|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089319|NCT03524209|RANDOMIZED|PARALLEL||OTHER||NONE||"A prospective selection of patients with pyogenic spondylitis fulfilling above mentioned inclusion criteria is performed with subsequent randomization into treatment group 1 versus treatment group 2 after informed consent. Group1 are patients treated by minimally invasive surgery and group 2 are patients treated by thoracolumbar brace.~Radiologic deformity assessment is performed on lateral thoracolumbar radiographs in standing position. A modified sagittal index measuring the angulation between cranial endplate of cranial vertebra and caudal endplate of the caudal vertebra as this parameter is normalized to 0°.~Assessment of osteolysis at vertebral bodies on CT expressed as a ratio of vertebral body height in the mid-sagittal plane in comparison to non-infected vertebral bodies adjacent to the index level. Assessment of complete fusion, partial fusion, pseudarthrosis is performed on CT at 1-year FU.~Type and length of antibiotic treatment"||||
34089320|NCT04464772|||COHORT||PROSPECTIVE|||||||
34001354|NCT05998980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Evaluator)|Individual Randomized Assignment|t|t|f|f
34089321|NCT00090688|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34001355|NCT03750695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single group crossover design of acute effects of resistance exercise, aerobic exercise or rest (control) on maternal vascular function and glucose metabolism||||
34001356|NCT02653235|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34001357|NCT01769222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase 1 ipilimumab 25 mg safety only. Subsequent Phase 2 ipilimumab 25 mg and radiation combination (treatment-escalation) was not conducted.||||
34001358|NCT05852873|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Double-blinded placebo-controlleded randomized clinical trial|t|t|t|f
34001359|NCT05433831|||COHORT||PROSPECTIVE|||||||
34001360|NCT04742608|||COHORT||PROSPECTIVE|||||||
34001361|NCT00530660|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001362|NCT05198635|||COHORT||PROSPECTIVE|||||||
34089322|NCT02402751|NA|SINGLE_GROUP||||NONE||||||
26582232|NCT06676150|||COHORT||PROSPECTIVE|||||||
34089323|NCT00700765|||COHORT||PROSPECTIVE|||||||
33697136|NCT04894292|||CASE_CONTROL||PROSPECTIVE|||||||
33921681|NCT04580212|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators and data analysts will be blinded to intervention assignment by using a numerical code for study arm during analysis.||f|f|t|f
33921682|NCT03255265|||COHORT||PROSPECTIVE|||||||
33921683|NCT05766436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921684|NCT04378699|RANDOMIZED|PARALLEL||TREATMENT||NONE||single-center interventional biomedical research with direct individual benefit, randomized with two active arms (without placebo)||||
33921685|NCT03557515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921686|NCT01758926|||CASE_CONTROL||PROSPECTIVE|||||||
33921687|NCT01929265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001363|NCT00218335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34001364|NCT04711317|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||One intervention group that is compared to a control group that is standard treatment.||||
34001365|NCT03968016|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34001366|NCT04064827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001367|NCT06253481|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001368|NCT02991313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001369|NCT01418235|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34001370|NCT00998595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34001371|NCT04807062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001372|NCT06562543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697137|NCT01874743|NA|SINGLE_GROUP||||NONE||||||
33697138|NCT01806558|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697139|NCT03250429|||COHORT||PROSPECTIVE|||||||
33697140|NCT05288478|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||"100 subjects with EB will be recruited, divided into groups according to their mayor type of EB and subtype, they will use Dentoxol® mouthrinse twice a day or 5 times each day.~Subjects will have a dose regimen assigned randomly, group A: first 6 weeks 5 times a day, following 6 weeks twice a day, and group B: first 6 weeks 2 times a day following 6 weeks 5 times a day, both with a 4 week washout period in between.~On week 0, 1, 3 and 6 of each regime patients living in the metropolitan area will be examined by the Oral Medicine specialist."|f|f|f|t
33697141|NCT03912064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697142|NCT04205253|||CASE_CONTROL||PROSPECTIVE|||||||
33697143|NCT06449417|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blind statistician|This study is a mixed-methods Randomized Control Trial evaluating the impact of Aurora, a human-centered design, on breast cancer patients undergoing neoadjuvant chemotherapy in the Metropolitan Region of Chile. The study measures quantitative and qualitative variables over a 9-week intervention. The control group comprises patients without Aurora. The primary outcome is quality of life, with secondary outcomes including functional capacity and tumor progression. The study includes sociodemographic data extraction, baseline and intervention end measurements, and correlations between variables. The Aurora program integrates motivation, peer learning, and community support. The hypothesis is that Aurora enhances the biopsychosocial effects and mitigates adverse physical and biological consequences of breast cancer by promoting physical activity.|f|f|f|t
33785644|NCT04676399|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Randomization to either hydrochlorothiazide or placebo using a crossover study design will occur via a 1:1 ratio determined by computer generated randomization|Mixed Model 2-way analysis of variance to asses pain and BP responses to the diuretic vs. placebo.|t|t|t|f
33697144|NCT01187433|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697145|NCT02828969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33697146|NCT00052273||||TREATMENT||||||||
33697147|NCT05186285|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33697148|NCT02208531|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697149|NCT05959083|||COHORT||PROSPECTIVE|||||||
33697150|NCT04562792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697151|NCT06681532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697152|NCT01934881|||COHORT||PROSPECTIVE|||||||
33697153|NCT03072732|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2-arm study||||
33697154|NCT00227773||||TREATMENT||||||||
33785645|NCT05581160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||12-months prospective multicenter longitudinal cohort with the biological samples collection.||||
33785646|NCT03425643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921688|NCT04126031|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Non-randomized, 2-part with three age cohorts in each part||||
33921689|NCT00141037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921690|NCT05109702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33921691|NCT00003828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697155|NCT00902668|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33921692|NCT00967733|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33921693|NCT00043212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921694|NCT03718702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Self-efficacy theory of behavioral change is adopted to guide the conceptual framework and development of the intervention. It was first introduced by Bandura in 1977. In the theory, self-efficacy would increase when a person participates actively in the activities to gain experience. There are two expectations in the model. The efficacy expectations of the person would contribute to the person's behaviour. The person performs the behaviour and would expect the outcomes and this is outcome expectations. The theory has been discussed for how to apply in health promotion. As the theory integrates self-efficacy and self-regulatory elements, people are benefited from the improved health outcomes which is resulted from the health behaviours.||t|f|t|t
33921695|NCT04605939|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921696|NCT05081596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921697|NCT03771404|NA|SINGLE_GROUP||OTHER||NONE||||||
33921698|NCT06304519|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33921699|NCT05561712|||OTHER||PROSPECTIVE|||||||
33921700|NCT04029324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921701|NCT05133544|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33921702|NCT02766595|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921703|NCT01203787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921704|NCT00031499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921705|NCT00796042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921706|NCT05034458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921707|NCT00606736|||CASE_CONTROL||PROSPECTIVE|||||||
33921708|NCT04766151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921709|NCT03428802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921710|NCT02279355|||CASE_CONTROL||RETROSPECTIVE|||||||
33921711|NCT02928926|||CASE_CONTROL||PROSPECTIVE|||||||
33921712|NCT03499587|||COHORT||PROSPECTIVE|||||||
33785647|NCT06381674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parties that will be masked include those collecting and analyzing data before and after rehabilitation (post-doctorate fellows, research assistants, and statistician).|There will be two groups in this study that will be randomized concurrently into two different rehabilitation programs.|f|f|f|t
33785648|NCT06694493|||OTHER||PROSPECTIVE|||||||
33921713|NCT04907318|||COHORT||RETROSPECTIVE|||||||
33921714|NCT01769469|||COHORT||PROSPECTIVE|||||||
33921715|NCT02022956|NA|SINGLE_GROUP||OTHER||NONE||||||
33921716|NCT05557669|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921717|NCT04861948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921718|NCT02067741|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001373|NCT04525677|||CASE_CONTROL||PROSPECTIVE|||||||
34001374|NCT01239498|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001375|NCT00072917|||COHORT||PROSPECTIVE|||||||
34001376|NCT01223027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001377|NCT05485727|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcomes assessors will not aware about the treatment procedures the participants had received before. The assessors also will be blinded about both groups( Treatment group or Control group)|stroke patients(28) will be enrolled in this thesis (6-12 months after stroke); the Patients will be randomly assigned into two equal groups of 14. Robotic-assisted gait training group (RG) will receive Lokomat gait training and conventional physiotherapy, while the other group is a control group (CG) will receive conventional physiotherapy.|f|f|f|t
34001378|NCT04754555|||COHORT||CROSS_SECTIONAL|||||||
33785649|NCT06598852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34001379|NCT04912739|||COHORT||PROSPECTIVE|||||||
34001380|NCT03969108|NA|SINGLE_GROUP||OTHER||NONE||||||
34001381|NCT02408536|||COHORT||RETROSPECTIVE|||||||
34001382|NCT04204096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study is observer blind:~1. Vaccine administrator and vaccine safety evaluator at site will be two distinct persons.~2. Laboratory personnel who analyzes immunogenicity at sponsor is also blinded."|Participants age 6 months to 45 years|t|t|t|t
34001383|NCT00073632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001384|NCT06075849|NA|SEQUENTIAL||TREATMENT||NONE||||||
34001385|NCT02349022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001386|NCT04695457|||COHORT||RETROSPECTIVE|||||||
33785650|NCT03315403|||COHORT||PROSPECTIVE|||||||
33785651|NCT01062386|||COHORT||CROSS_SECTIONAL|||||||
33785652|NCT05760690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921719|NCT04771143|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"This is a participant- and investigator-blinded study. Site staff may be unblinded to the treatment assignment of one or more participants if deemed appropriate to aid decision-making.~Drug product will be supplied in bulk, so an unblinded pharmacy team who is independent of the study team will be required in order to maintain the blind.~The following unblinded roles are required for this study:~* Unblinded field monitor(s)~* Unblinded sample analyst(s)"|Participants will undergo a screening infusion session with saline and cocaine on Day -2 as part of the eligibility determination. Once deemed eligible, participants will undergo screening infusion sessions 2 and 3 on Days 1 and 2 respectively. Starting Day 3, participants will receive either AFQ056 or matching placebo twice a day from Day 3 to Day 9. The AFQ056 treatment group will be up titrated to 200 mg according to the following dosing schedule: Day 3: 50 mg twice daily; Day 4: 100 mg twice daily and Days 5-9: 200 mg twice daily. On Day 10, participants will be administered only the morning dose of AFQ056 200 mg or placebo. On Days 9 and 10, participants will have infusion session 4 and 5 respectively. The participants will be discharged from the clinic on Day 12 and return for a follow-up visit between 7 to 14 days after clinic discharge. A safety follow-up call will be conducted on Day 40.|t|f|t|f
33921720|NCT00388323|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921721|NCT02638870|||CASE_ONLY||PROSPECTIVE|||||||
33921722|NCT06207695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921723|NCT00905619|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33921724|NCT04522791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A double-blinded, phase II randomized controlled trial (RCT). Older adults with MCI (n=114) will be randomly assigned to an 8-week combined intervention (RFB+VSOP), VSOP with imagery-guided relaxation control (IR+VSOP), or a IR control (IR only), with 2-week booster sessions provided at 3- and 9-months after intervention.|t|f|t|t
33921725|NCT06147713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921726|NCT03345940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921727|NCT01596530|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33921728|NCT01192620|||CASE_ONLY||PROSPECTIVE|||||||
33921729|NCT05246241|||COHORT||RETROSPECTIVE|||||||
33921730|NCT06091397|||COHORT||PROSPECTIVE|||||||
33921731|NCT03625141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921732|NCT05418569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33921733|NCT00737685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921734|NCT04902534|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||A randomized, double-blind, placebo-controlled, single dose and multiple dose escalation phase I clinical study.|t|f|t|f
33921735|NCT06338072|||COHORT||CROSS_SECTIONAL|||||||
33921736|NCT02879916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921737|NCT01874249|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33921738|NCT06088407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921739|NCT06299813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The nurse that will prepare and administer the treatment to the patient won't be masked|A double-blind, placebo-controlled randomized study|t|t|t|t
33921740|NCT04433819|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33921741|NCT01663844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001387|NCT04666753|||COHORT||RETROSPECTIVE|||||||
34001388|NCT04846686|||CASE_CONTROL||RETROSPECTIVE|||||||
34001389|NCT06533150|||COHORT||PROSPECTIVE|||||||
34001390|NCT03275623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001391|NCT00008060|RANDOMIZED|||TREATMENT||NONE||||||
34001392|NCT05726162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001393|NCT00274495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001394|NCT01711567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001395|NCT00942734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001396|NCT00929006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomized, placebo-controlled, crossover study|t|t|t|t
34001397|NCT02285491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001398|NCT05984823|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|For pre and post intervention outcome measures, the assessor will be blinded towards the participants group (Intervention group or control group)|Intervention group and control group|f|f|f|t
34001399|NCT06428162|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34001400|NCT06679218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697156|NCT04181320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Wound closure (CCC and PCC) will be assessed through ulcer photos by 2 independent and experienced clinicians unaware of treatment allocation (blind review).|Multicentre, prospective, randomized, European open label, assessor blinded, 2-arm parallel group study.|f|f|f|t
34001401|NCT06670651|||CASE_ONLY||PROSPECTIVE|||||||
34001402|NCT03142620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001403|NCT02364258|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001404|NCT00365690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001405|NCT02808169|||COHORT||PROSPECTIVE|||||||
34001406|NCT04002869|||COHORT||PROSPECTIVE|||||||
34001407|NCT00052949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001408|NCT02355262|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34001409|NCT03573336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001410|NCT01173536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001411|NCT01900457|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34001412|NCT04174118|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33697157|NCT02972853|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001413|NCT04640194|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study comprises two parts: Part 1 (dose-finding, Phase IIb) and Part 2 (confirmatory, Phase III)||||
34001414|NCT00380588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001415|NCT03993080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled single-center trial with two parallel arms|t|t|t|t
34001416|NCT00676169|||COHORT||PROSPECTIVE|||||||
33785653|NCT00507208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785654|NCT02862327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785655|NCT04015986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33785656|NCT06632132|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33785657|NCT05660967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785658|NCT04098250|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||1:1 randomization to erenumab or placebo|t|t|t|f
33785659|NCT06429527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33785660|NCT06294951|||CASE_CONTROL||OTHER|||||||
34001417|NCT01781416|||CASE_ONLY||PROSPECTIVE|||||||
34001418|NCT00827840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001419|NCT06241157|RANDOMIZED|FACTORIAL||OTHER||NONE||There are two experimental groups. The part containing the first group will be completed first, and then the other group will begin. Same dentist will carry out in the experimental part of the study.||||
34001420|NCT03261817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Randomization will be centralized and will be established for SCZ; Healthy Controls (HV) will be recruited by being matched to patients on age (according to 4 categories (18-25 years, 25-35 years, 35-50 years and\> 50 years), gender and level of activity estimated by the self-administered questionnaire of Ricci and Gagnon.~Randomization will be carried out in two arms:~* interventional (adapted physical activity APA)~* control (health education program)"||||
34001421|NCT00645827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001422|NCT06377007|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34001423|NCT03920449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001424|NCT01923818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001425|NCT02684539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001426|NCT04045015|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Each group of 10 individuals uses liqourice for 7 days and late night salivary cortisol and cortisone is analysed before (baseline), during and after (washout) intake.||||
34001427|NCT04495959|||COHORT||PROSPECTIVE|||||||
34001428|NCT00434590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001429|NCT06143527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001430|NCT01920750|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34001431|NCT05993754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After signed informed consent at the preoperative unit and during the post anesthesia unit care|Control group and intervention group|t|t|f|f
34001432|NCT05700890|||COHORT||PROSPECTIVE|||||||
33697158|NCT05438784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||the participants are assigned to two groups randomly A and B and receive two different intervention modality throughout the study and the results will be compared between the two groups|t|f|f|t
33697159|NCT04576104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697160|NCT01162928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697161|NCT00993876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33697162|NCT01232231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785661|NCT02492594|||CASE_ONLY||PROSPECTIVE|||||||
33785662|NCT06627738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785663|NCT06711575|||COHORT||PROSPECTIVE|||||||
33785664|NCT01366196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785665|NCT05584124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to their groups||t|f|f|f
33785666|NCT02148809|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785667|NCT00253240|||||OTHER|||||||
33785668|NCT06693050|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785669|NCT00828919|NA|||TREATMENT||NONE||This is a continuing access, open label study for patients to receive monotherapy or combination therapy based on previous treatment received in parent protocol||||
33785670|NCT02074566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785671|NCT02197689|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34001433|NCT00033150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34001434|NCT05692115|||CASE_CONTROL||RETROSPECTIVE|||||||
33921742|NCT04344262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Basal US assessment and its repetition in the recovery room, will be done by an anesthetist who is not involved in randomization or anesthetic technique except, after ending the surgery and after dressing, he will be responsible for reversal agent injection and the extubation with recording the extubation time|Patients will be randomly allocated via sealed opaque envelopes into 2 groups of 30 patients each; control (C) group and minimal dose (M) group|t|f|t|f
33921743|NCT04904003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One explorative group, one intervention group and one control group||||
33697163|NCT00195546|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33921744|NCT05987345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921745|NCT00002544|RANDOMIZED|||TREATMENT||||||||
33921746|NCT03539913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation-blinded study||f|f|t|f
33921747|NCT03384108|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In Vivo vs. Ex Vivo assessment of 5-13C-Glutamine incorporation by plasma cells via a bone marrow aspiration.||||
33921748|NCT05855681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor) (assessor by research assistant, patients and statistician)|Triple blinded Randomized controlled trial|t|f|t|t
34001435|NCT02694861|||COHORT||PROSPECTIVE|||||||
34001436|NCT02324335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34001437|NCT00176891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001438|NCT05543551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697164|NCT06419608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697165|NCT04926623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33697166|NCT04409405|||COHORT||PROSPECTIVE|||||||
33697167|NCT02554942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001439|NCT05343273|||CASE_CONTROL||OTHER|||||||
34001440|NCT03061903|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomly assigned to either the ciNPT intervention group (Prevena) or the control group (Aquacel) using computer-generated, randomized envelopes with equal numbers in each treatment arm. Both dressings will be applied under sterile conditions at the end of the THA surgery, while still in the operating room, and then removed after 7 days.||||
34001441|NCT01597349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001442|NCT00948909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001443|NCT05562648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001444|NCT02212236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34001445|NCT01984606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001446|NCT01198873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001447|NCT01226693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34001448|NCT01155427|||COHORT|||||||||
34001449|NCT04784169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001450|NCT01552330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001451|NCT02197416|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001452|NCT03206749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697168|NCT02840240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697169|NCT06623149|||COHORT||PROSPECTIVE|||||||
33697170|NCT03945695|NA|SINGLE_GROUP||TREATMENT||NONE|non-blinded|Prospective, non-randomized, non-blinded, interventional single-arm pilot study.||||
33697171|NCT00057954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697172|NCT00620347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697173|NCT01940562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697174|NCT06202417|||COHORT||RETROSPECTIVE|||||||
33921749|NCT05599698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921750|NCT02592395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921751|NCT04509323|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with hypertensive basal ganglia cerebral hemorrhage||||
33921752|NCT00629525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921753|NCT01371448|||OTHER||PROSPECTIVE|||||||
33921754|NCT01954888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33921755|NCT05720767|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921756|NCT05002699|||COHORT||PROSPECTIVE|||||||
33921757|NCT03164785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921758|NCT02850497|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33921759|NCT00247949|||COHORT||PROSPECTIVE|||||||
33921760|NCT01771536|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34001453|NCT03232450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697175|NCT06558019|||COHORT||RETROSPECTIVE|||||||
33921761|NCT00126815|||CASE_ONLY||RETROSPECTIVE|||||||
33921762|NCT05929885|NA|SINGLE_GROUP||TREATMENT||NONE||43 patients will be enrolled in two stages - In stage 1, a total of 19 patients will be recruited and evaluated for response and toxicity. In stage 2, another 24 patients will be recruited for further evaluation of response and toxicity. Up to 7 patients will be recruited to account for any drop outs (i.e. up to total of 50 patients).||||
33921763|NCT01480037|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33921764|NCT00889395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921765|NCT00444080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921766|NCT05126641|||COHORT||RETROSPECTIVE|||||||
33921767|NCT00950976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33921768|NCT02016469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921769|NCT02156401|||COHORT||PROSPECTIVE|||||||
33921770|NCT03467295|||COHORT||PROSPECTIVE|||||||
34001454|NCT04232540|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Dual Group Assignment||||
34001455|NCT05094349|||COHORT||RETROSPECTIVE|||||||
34001456|NCT02018796|||CASE_ONLY||PROSPECTIVE|||||||
34001457|NCT01610050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697176|NCT06115785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697177|NCT02280551|||COHORT||PROSPECTIVE|||||||
33697178|NCT06680999|||CASE_ONLY||RETROSPECTIVE|||||||
33720030|NCT04357392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, single center, pragmatic clinical trial|t|f|t|f
33720031|NCT02969824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33720032|NCT03414723|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33785672|NCT04774224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Prior to study initiation, an independent researcher is responsible for generating the randomization schedule. The randomization schedule including treatment group assignment (active or placebo) will be provided to the pharmacists at each one of the study sites. The study pharmacists will conceal the group assignment from study participants, investigators and study staff including the statistician.|Randomised placebo controlled trial|t|t|t|t
33785673|NCT01605331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785674|NCT02121574|||||CROSS_SECTIONAL|||||||
33785675|NCT03354390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785676|NCT05877638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785677|NCT05507203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785678|NCT05483842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients did not know which group they were assigned to.||t|f|f|f
33785679|NCT00001247|||COHORT||PROSPECTIVE|||||||
33785680|NCT06255444|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785681|NCT06713434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785682|NCT05893303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785683|NCT00331214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785684|NCT05989048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33921771|NCT05715944|NA|SINGLE_GROUP||PREVENTION||NONE||"AZD1222-00001 is a single-arm, Open-label, Phase 3b Study of the Incidence of Severe COVID 19 and Adverse Events Following AZD1222 COVID-19 Vaccination in Botswana Against SARS-CoV-2. Study participants are adults ≥ 18 years of age who have not already received a COVID-19 vaccine primary series and/or booster. Up to 50,000 participants are to be enrolled in the study. A total of 900 enrolled participants will also participate in a sub-study assessing the immunogenicity of AZD1222. These 900 participants in the sub-cohort will have additional assessments.~Safety is assessed for the duration of the study. AEs are recorded at 4 weeks post the first, second and booster vaccination dose and quarterly; participants are contacted via text, or telephone call as part of follow up."||||
33921772|NCT06055127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|computer-generated randomization table|parallel single blind masking randomized controlled clinical trail|t|f|f|f
33921773|NCT00166517|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33921774|NCT04759677|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"All 20 individuals with CP will participate in a total of 2 exercise sessions on consecutive days with 45 minutes of active video games. During the training sessions, exercise intensity will be evaluated with the accelerometer.~The accelerometer will be placed on the dominant wrist of 20 individuals during one training session. The same 20 individuals will participate in the other exercise session and the accelerometer will be placed on the dominant side hip area of the individuals this time. Exercise intensity values obtained from 2 different training sessions will be compared."|t|f|f|f
33921775|NCT00871091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921776|NCT02013089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921777|NCT00788697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921778|NCT04711759|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Analysis of work of breathing and of data derived from Electric impedance tomography will be performed blind to arm assignment||f|f|f|t
33921779|NCT02705599|||COHORT||PROSPECTIVE|||||||
33921780|NCT00810095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921781|NCT05514106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921782|NCT04828369|||COHORT||RETROSPECTIVE|||||||
33921783|NCT02297737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33921784|NCT00614653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921785|NCT00148850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921786|NCT02491398|||COHORT||CROSS_SECTIONAL|||||||
33921787|NCT04427462|||COHORT||PROSPECTIVE|||||||
33921788|NCT05035095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921789|NCT00574457|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921790|NCT00236522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921791|NCT00289744|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33921792|NCT00502528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921793|NCT04320290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921794|NCT04977154|||COHORT||OTHER|||||||
33921795|NCT05563714|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Neither patients, clinicians, or anticoagulation staff can practically be blinded. We will attempt to blind the research staff who are making patient calls at week 7-10 to the randomization group of the patient by not providing them with any information that would allow them to infer the randomization group, by not having them enter the electronic health record for the patients, where such information could be obtained, and by excluding any information from the call script that might help identify the randomization group. However, if due to staffing or personnel issues, blinded research staff are unable to complete all patient calls within the specified time frame, unblinded research staff will assist with completing patient calls.|Randomization (1:1) of clinicians and patients to CNNF vs. wait list control will be done at the cluster level according to the identity of the clinician to be contacted. Clinician randomization will be stratified by number of eligible patients, and by procedural vs. non-procedural specialty. Randomization will be carried out by the study statistician. For each included clinician, up to 4 patients will be included in their cluster. If a clinician is selected to participate who has more than 4 eligible patients, 4 of their patients will be randomly selected to participate.||||
33921796|NCT04732819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33921797|NCT05406557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921798|NCT02437487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33921799|NCT03334474|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921800|NCT05491044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785685|NCT06147830|||COHORT||OTHER|||||||
33785686|NCT06148272|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785687|NCT06357143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33921801|NCT03615118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33921802|NCT04270487|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Parallel study: diet vs medication (otilonium bromide)||||
33785688|NCT02689375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34001458|NCT00096005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001459|NCT06411392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001460|NCT06282406|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized into one of 5 groups and receive the designated stimulation/sham during a training protocol designed to facilitate motor learning.||||
34001461|NCT06070545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Controlled Trial||||
33720033|NCT05820555|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding of the study biostatistician and PI during the analysis will be ensured. Groups will be denoted by a variable that does not reveal its identity. The blinding will be broken after the data set is closed and analyses completed.|A 3-group randomized controlled trial design will be used in which children are assigned to receive one of 2 experimental conditions or a control condition|f|f|t|f
34001462|NCT05995769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001463|NCT02883439|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34001464|NCT01992406|||COHORT||PROSPECTIVE|||||||
34001465|NCT01942278|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33921803|NCT04818528|RANDOMIZED|PARALLEL||TREATMENT||NONE||It was a parallel group, randomized controlled trial of 40 Parkinson's disease patients enrolled between December 2020 to Feb 2021.||||
33921804|NCT03165942|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33921805|NCT01025687|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33921806|NCT01220986|||COHORT||PROSPECTIVE|||||||
33921807|NCT02472795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921808|NCT03805555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921809|NCT03618342|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33921810|NCT02128594|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921811|NCT01244958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921812|NCT01419015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921813|NCT00111930|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33921814|NCT05610917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33921815|NCT04430283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a double-blind study where all study staff and participants are blinded to whether the patient receives active drug or placebo.|All subjects who fulfill all study edibility criteria will be randomized to receive one of the 3 treatments.|t|f|t|f
33921816|NCT02063282|||COHORT||PROSPECTIVE|||||||
33921817|NCT02768324|||CASE_CONTROL||PROSPECTIVE|||||||
33921818|NCT01930929|||COHORT||RETROSPECTIVE|||||||
33921819|NCT01928082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921820|NCT03994393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921821|NCT01524237|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33921822|NCT04374812|||OTHER||RETROSPECTIVE|||||||
33921823|NCT03213483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Single blinded:~* Blinding of the participants is not applicable.~* Blinding of the operator is not applicable.~* Outcome assessor (primary and secondary outcomes) \& biostatistician will be blinded."|Parallel groups, randomized clinical trial|f|t|f|t
33921824|NCT02305875|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921825|NCT04950140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921826|NCT04344379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33921827|NCT02080156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921828|NCT02021825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921829|NCT00373490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921830|NCT06175442|||COHORT||RETROSPECTIVE|||||||
33921831|NCT04261452|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34001466|NCT00709514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001467|NCT05635630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34001468|NCT03588260|||CASE_CROSSOVER||PROSPECTIVE|||||||
34001469|NCT04381741|NA|SEQUENTIAL||TREATMENT||NONE||||||
33921832|NCT03801356|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects will be enrolled into a single treatment participant pool.||||
33921833|NCT02675738|||COHORT||PROSPECTIVE|||||||
33921834|NCT04226963|||COHORT||PROSPECTIVE|||||||
33921835|NCT03396978|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921836|NCT03607474|||COHORT||PROSPECTIVE|||||||
33921837|NCT01989754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921838|NCT00772694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921839|NCT00685841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921840|NCT00901381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921841|NCT01376401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921842|NCT00476996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921843|NCT03520439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The appearance of Mifepristone Tablets and placebo tablets is the same (size, shape and color). In different treatment groups, the packaging of research drugs is the same, so that researchers or subjects or applicants can not know the assigned treatment.||t|t|t|t
33921844|NCT04597892|||COHORT||PROSPECTIVE|||||||
33921845|NCT03120637|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33921846|NCT01160679|||CASE_ONLY||PROSPECTIVE|||||||
33921847|NCT05221788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33921848|NCT03893383|||OTHER||CROSS_SECTIONAL|||||||
33921849|NCT06315244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001470|NCT02649816|||COHORT||RETROSPECTIVE|||||||
34001471|NCT06669754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001472|NCT06167850|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34001473|NCT01086969|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001474|NCT01285505|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34001475|NCT05141474|NA|SINGLE_GROUP||TREATMENT||NONE||First-in-human, open-label, non-controlled, single-centre, phase I trial. Sequential recruitment: The first six patients will be included for safety assessment. If no more than one treatment-limiting toxicity (TLT) is observed, four additional patients will be included for the final safety population analysis (a total of 10 patients).||||
34001476|NCT05107739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33921850|NCT04632407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The 2 products (oat fibre milk and flax milk) are assigned a unique ID code."|"The study participants will be randomized to either oat fibre milk or flax milk"|t|t|t|f
34001477|NCT03565562|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster randomized, open parallel groups , controlled intervention study||||
34001478|NCT04860349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001479|NCT04656938|NA|SINGLE_GROUP||SCREENING||NONE||This is a pre-post study design with a single group and no control arm. The study aims to screen 700 participants, of which, 220 pre-frail seniors to be recruited into the intervention programme.||||
34001480|NCT06331650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921851|NCT02742857|NA|SINGLE_GROUP||OTHER||NONE||||||
33921852|NCT05296837|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All patients will be masked to their SDD allocation and informed that they will be taking a pill by mouth twice a day. Participants taking 40mg doxycycline will be taking one 20mg doxycycline pill twice a day. Participants taking 200mg doxycycline will be taking 100mg twice a day. Participants allocated to placebo will be taking a placebo pill twice daily All examining physicians responsible for TBUT determination and ocular photography will be masked to patient allocation assignment. The study analyst only will have access to the randomization key.|Randomized controlled trial|t|t|t|f
34001481|NCT02849106|NA|SINGLE_GROUP||OTHER||NONE||||||
33921853|NCT05238987|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Quasi-experimental single arm before-and-after (pre-post) study.||||
34001482|NCT03646162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921854|NCT00467714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33921855|NCT03159819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921856|NCT00017771|||CASE_CONTROL||PROSPECTIVE|||||||
33921857|NCT01193816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921858|NCT02452177|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34001483|NCT02771392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34001484|NCT01603667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001485|NCT06110819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Analyzes will not be made by the researcher.|In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health.|f|f|f|t
34001486|NCT06324305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921859|NCT01557764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921860|NCT02299713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33921861|NCT05991557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921862|NCT06528899|||COHORT||RETROSPECTIVE|||||||
33921863|NCT01125657|RANDOMIZED|CROSSOVER||||NONE||||||
33921864|NCT06195293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785689|NCT05919849|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants will be made aware of the writing intervention they will complete.|This study is a 3-arm randomized control trial (RCT) design in which an anticipated129 parents of SGMY will be randomized into one of three conditions.||||
33785690|NCT02397889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33785691|NCT04807517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785692|NCT05043961|||COHORT||PROSPECTIVE|||||||
33785693|NCT02735265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785694|NCT05541497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785695|NCT02513134|||||PROSPECTIVE|||||||
33785696|NCT04841486|||CASE_CONTROL||PROSPECTIVE|||||||
33785697|NCT06712446|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33785698|NCT01487564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785699|NCT06021574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785700|NCT02778308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785701|NCT06614348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785702|NCT00285558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785703|NCT05824351|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785704|NCT01045317|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33785705|NCT02594176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785706|NCT05191433|||COHORT||RETROSPECTIVE|||||||
33785707|NCT06081361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785708|NCT02959151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785709|NCT00364442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33785710|NCT05193669|||COHORT||CROSS_SECTIONAL|||||||
33785711|NCT05096884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785712|NCT04917757|||COHORT||OTHER|||||||
33785713|NCT06529120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785714|NCT05286541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785715|NCT06526585|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective||||
33785716|NCT06711692|||COHORT||PROSPECTIVE|||||||
33785717|NCT03397160|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This is a site-randomized, cluster-crossover clinical trial of a decision support intervention (DSI) vs. usual care, among men with low prognostic risk prostate cancer, to assess differences in informed decision making (i.e., knowledge), anxiety, and decision quality and self-efficacy.||||
33785718|NCT01744691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785719|NCT06683534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Subjects will be randomized to receive the supplement quercetin or placebo for 30 days to determine its effect on microvascular function.|t|f|t|f
33785720|NCT06609213|NA|SINGLE_GROUP||PREVENTION||NONE||This single arm intervention study will utilize validated indicators combined with clinical expertise to assess GI symptoms of feeding intolerance before and after the intervention in a way that each patient serves as their own control.||||
33785721|NCT05854628|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study is double blind, neither the participants nor the investigators will be aware of the groups.|Investigators will recruit up to 75 participants for the entire study. Approximately half will be randomly assigned to treatment group and half randomly assigned to placebo group. The treatment group participants will be given 0.1% red flavonoids facial cream while the control cohort will be given a placebo facial cream.|t|t|t|t
33785722|NCT04792099|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 parallel allocation of infants to CPAP or NC oxygen using randomization with stratified permuted block design||||
33785723|NCT01720719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801581|NCT04608305|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||"The study is comprised of two phases, a dose-escalation Phase I (sentinels + expansions) and expansion to Phase II that includes larger cohorts, elderly age groups and additional boost injection. Subjects will be randomly allocated to the study groups in both phases.~Dosing of prime during phase I occurred in a sequential fashion (partially overlapping), starting from low-dose and continuing to mid and high doses following safety reviews. Prior to expansion to phase II, cumulative data from phase I was evaluated (dose and regimen) by the data safety monitoring board. The DSMB's recommendations regarding expansion to phase II were the continuation of prime-boost regimens of medium, high and top doses."|t|t|t|t
33801582|NCT05207241|||COHORT||PROSPECTIVE|||||||
33921865|NCT01042951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33921866|NCT03005080|||COHORT||PROSPECTIVE|||||||
33921867|NCT00875303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33801583|NCT03580135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33921868|NCT06183632|||COHORT||PROSPECTIVE|||||||
33921869|NCT04235439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a phase 1 trial. The trial is a single center, randomized, doubleblind, single dose, there treatment, three period crossover, 12 - hour euglycaemic glucose clamp trial in healthy male subjects.|t|f|t|f
33921870|NCT01360853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921871|NCT04623463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921872|NCT00141856|RANDOMIZED|PARALLEL||||NONE||||||
33921873|NCT00992186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921874|NCT00970268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921875|NCT04995900|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Outcomes are collected blinded to the study allocation.|The stepped-wedge design is a uni-directional cross-over design - where the randomisation element is when the cluster crosses-over to the intervention following a control period.|f|f|f|t
33921876|NCT02943265|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33921877|NCT02227849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921878|NCT05752786|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921879|NCT05905757|RANDOMIZED|PARALLEL||SCREENING||SINGLE||prospective randomized controlled trial|t|f|f|f
33801584|NCT02709850|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33921880|NCT05460650|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33921881|NCT02924818|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921882|NCT04228562|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Each participant will only receive the instruction pertaining to the arm to which he/she is assigned. The Research Assistant who conducts the study does not know about the hypothesis.|"Factorial Assignment The study has a 2 (Factor: one modifiable cause vs. one modifiable + one non-modifiable causes) ✕ 2 (Anticipated regret induction: yes vs. no) between-subject design. Participants will be randomly assigned to one of the 4 between-subject conditions.~There is also a within-subject variable. Each subject will respond to 10 rounds of decision task with 5 different levels of overall disease risk reduction brought by the removal of X. The 5 levels of risk reduction are: (i) Removal of X reduces disease risk from 60% to 50% ; (ii) 60% to 40%; (iii) 60% to 30%; (iv) 60% to 20%; (v) 60% to 10%."|t|f|t|f
33921883|NCT00002577||||TREATMENT||||||||
33921884|NCT04800471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921885|NCT05399030|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33921886|NCT03532880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921887|NCT01357980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921888|NCT01419080|||COHORT||PROSPECTIVE|||||||
33921889|NCT03411707|||CASE_ONLY||PROSPECTIVE|||||||
33921890|NCT04740333|||CASE_CONTROL||RETROSPECTIVE|||||||
33921891|NCT02890043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001487|NCT05165654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded||t|f|t|f
34001488|NCT01251393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001489|NCT00856349|||COHORT||PROSPECTIVE|||||||
33921892|NCT01828918|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801585|NCT03549416|||OTHER||PROSPECTIVE|||||||
34001490|NCT05805527|||COHORT||CROSS_SECTIONAL|||||||
34001491|NCT04713982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001492|NCT03929328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001493|NCT02336308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001494|NCT05414162|||COHORT||PROSPECTIVE|||||||
34001495|NCT01894009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089324|NCT05333185|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|single bilinded|The child with type 1 diabetes will be divided into two as the experimental and control group. Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months. If the training is found effective after the study is completed, similar training will be given to the control group via the mobile application.|t|f|t|f
34089325|NCT03823625|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, phase II trial||||
34089326|NCT06418867|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089327|NCT02467309|||CASE_ONLY||PROSPECTIVE|||||||
34089328|NCT06254339|||COHORT||RETROSPECTIVE|||||||
33801586|NCT04542005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33921893|NCT04794946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921894|NCT00424294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921895|NCT01530555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921896|NCT03201848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921897|NCT02807844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921898|NCT04939870|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801587|NCT00198146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801588|NCT03669822|||COHORT||PROSPECTIVE|||||||
33801589|NCT04294173|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33801590|NCT02415088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921899|NCT02938767|||CASE_CONTROL||PROSPECTIVE|||||||
33921900|NCT02679495|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants are assigned to lifestyle intervention group or the control group without lifestyle intervention.|f|f|f|t
33921901|NCT01383642|||COHORT||PROSPECTIVE|||||||
33921902|NCT02849626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921903|NCT03351439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33921904|NCT04470128|RANDOMIZED|PARALLEL||TREATMENT||NONE|Stage I is open-label,Stage II is double-blind|||||
33921905|NCT04696237|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33921906|NCT01005446|||COHORT||PROSPECTIVE|||||||
33921907|NCT02436733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921908|NCT05995925|||COHORT||PROSPECTIVE|||||||
33921909|NCT03815123|||COHORT||PROSPECTIVE|||||||
34001496|NCT01937767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001497|NCT04682236|||CASE_CONTROL||RETROSPECTIVE|||||||
34001498|NCT03450629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001499|NCT03794245|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Care Provider and Outcomes Assessors do not know the arms to which an individual has been assigned|Men-Centered HIV Testing vs. Clinic-Based HIV Testing; Personalized Linkage to Care for HIV+ Men vs. Clinic Referral for HIV+ Men.|f|t|f|t
34001500|NCT06292364|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34001501|NCT04804839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001502|NCT01681862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001503|NCT05421260|||COHORT||PROSPECTIVE|||||||
34001504|NCT01348633|||COHORT||PROSPECTIVE|||||||
34001505|NCT05917119|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are not told which arm is active versus sham|single blind crossover design with randomized condition order|t|f|f|f
33921910|NCT05482282|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator) Observer Blind : Investigational Product and Active Comparator are masking Lot number is masking|Subjects neonates: Randomized, double blind, 2 arms parallel groups, prospective intervention study|t|f|t|f
33720034|NCT04890327|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34001506|NCT03490227|||COHORT||CROSS_SECTIONAL|||||||
33720035|NCT05575765|||CASE_ONLY||PROSPECTIVE|||||||
33921911|NCT04930211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720036|NCT01166763|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001507|NCT00907816|||CASE_CONTROL||PROSPECTIVE|||||||
33720037|NCT00651573|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34001508|NCT04789733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and assessors blinded to intraoperative management, postoperative antihypertensive management, and blood pressures.|Parallel group randomized trial.|t|f|f|t
34001509|NCT02995187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921912|NCT04721574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind, placebo-controlled|t|t|t|t
34001510|NCT00769496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001511|NCT04345016|NA|SINGLE_GROUP||PREVENTION||NONE||The investigators evaluated diabetic foot-related outcomes and associated resource utilization for each participant during three distinct phases: the two years before study participation, the one year during the foot temperature monitoring intervention, and the period after the intervention ended through the date of the analysis (January, 2020).||||
34001512|NCT01378013|||CASE_CONTROL||PROSPECTIVE|||||||
34001513|NCT05121441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study includes two arms: one placebo arm and one intervention arm.|t|f|f|f
34001514|NCT02941523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33921913|NCT00412906|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33921914|NCT05306548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in both strategy arms will have the site for injection/surgery covered with a adhesive bandage prior to assessment by blinded outcome assessors.|Two-arm, prospective, multi-center, parallel-group, open-label assessor-blinded non-inferiority treatment strategy study|f|f|f|t
33921915|NCT01508494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921916|NCT02448316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921917|NCT02960698|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921918|NCT00336778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001515|NCT01706809|||CASE_CONTROL||PROSPECTIVE|||||||
34001516|NCT00379509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001517|NCT04018690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001518|NCT04574739|||COHORT||PROSPECTIVE|||||||
34001519|NCT04915222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, parallel group randomized controlled trial of 72 participants.||||
34001520|NCT00966628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001521|NCT05203406|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34001522|NCT02980172|||COHORT||RETROSPECTIVE|||||||
33720038|NCT04994990|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33720039|NCT05216731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720040|NCT06126133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720041|NCT05571241|||OTHER||PROSPECTIVE|||||||
33720042|NCT00807807|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33720043|NCT05132829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720044|NCT06084546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720045|NCT01730209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720046|NCT03473808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720047|NCT04543435|||OTHER||CROSS_SECTIONAL|||||||
33720048|NCT05986162|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001523|NCT05971524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To maintain the blinding of the subject and investigators, the identifying labels will be removed from the intervention product at the AMC pharmacy. The study product will be labelled with subject specific information prior to delivery to the study physician, who will hand over the intervention to the participant.|A phase I/II, dose finding, placebo controlled, double blinded trial|t|f|t|f
34001524|NCT05913817|||COHORT||PROSPECTIVE|||||||
33697179|NCT05027464|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The study PIs and co-investigators, other research staff (except for the study statistician, see below), qualitative interviewers and participating VA staff will be unblinded because they are involved in delivering the intervention or, in the case of the qualitative researchers, will be tasked with interviewing study stakeholders about the intervention or implementation strategies. In contrast, the study evaluators, study statistician, and Veterans will be blinded to study arm assignment. Evaluators will conduct the study survey in Veterans, and while they will be aware of COVID-19 vaccination status, they will not be apprised of study arm. In addition, unless Veterans are unintentionally informed, Veterans will not know to which arm their VAMC has been randomized. Blinding of the study statistician conducting the outcomes analyses, survey evaluators, and the Veteran participants is important to protect the internal validity of study findings.|One-year cluster randomized parallel group trial, stratified by VISN, using covariate constrained randomization (e.g., rural/urban clinics, facility size). Specifically, the investigators will compare a Vaccine Acceptance Intervention versus Usual Care with randomization at the level of VA Medical Center (VAMC), with the intervention directed at VAMC clinic and CBOC PACT staff members.|t|f|f|t
33697180|NCT00921362|||COHORT||PROSPECTIVE|||||||
33921919|NCT04201938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
33697181|NCT03220984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697182|NCT04666480|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-arm registry||||
34001525|NCT01332968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697183|NCT05913648|||OTHER||CROSS_SECTIONAL|||||||
33697184|NCT03954353|||OTHER||RETROSPECTIVE|||||||
34001526|NCT06678451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697185|NCT03510754|||COHORT||RETROSPECTIVE|||||||
33697186|NCT04763928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697187|NCT06509139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Among the H. pylori-infected female patients, they are randomized to the 14-day bismuth-based quadruple therapy group and the 10-day bismuth-based quadruple therapy group to receive a 14-day and 10-day course, respectively, of the bismuth-based quadruple therapy. Afterward, the patients stop taking the proton pump inhibitor and antibiotics for 4 to 6 weeks, and then they receive 13C-urea breath test or an H. pylori stool antigen test to confirm successful eradication or not.~The study also investigates the efficacy of the 10-day bismuth quadruple therapy between females and males following the above interventional study model."|f|f|f|t
33697188|NCT03920410|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33921920|NCT01279304|||COHORT||PROSPECTIVE|||||||
33697189|NCT02951338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33697190|NCT05191563|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697191|NCT05400863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921921|NCT05992168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697192|NCT06162429|||CASE_CONTROL||RETROSPECTIVE|||||||
33921922|NCT00004696|RANDOMIZED|||||||||||
33697193|NCT00570167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921923|NCT04618926|||COHORT||PROSPECTIVE|||||||
33697194|NCT04151173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921924|NCT04024072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697195|NCT04840732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Investigator and Outcomes Assessor blind||f|f|t|t
33697196|NCT00903318|||CASE_ONLY||PROSPECTIVE|||||||
33697197|NCT02395666|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697198|NCT03487523|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||The study will be a cross sectional randomised controlled trial|t|f|f|f
33697199|NCT04793698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded to intervention arm||f|f|f|t
33697200|NCT06131398|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33697201|NCT00634400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33697202|NCT04753307|||COHORT||PROSPECTIVE|||||||
33697203|NCT06348680|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33697204|NCT01617525|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33921925|NCT01014949||PARALLEL||DIAGNOSTIC||NONE||||||
33921926|NCT06393894|||COHORT||PROSPECTIVE|||||||
33921927|NCT01601470|NA|SINGLE_GROUP||||NONE||||||
33921928|NCT06447571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|First visit, a blinded physiotherapist will evaluate the patient, then they will be randomly divided into two groups using a computer-generated system.||f|f|f|t
34001527|NCT02228889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Abdominal wall reconstruction using Strattice|t|f|f|f
34001528|NCT02988882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001529|NCT04602741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blocked randomization, stratified by gender, will be employed to ensure balance in sample size between treatment and control groups and gender representation. Stratification by study site (CAMH versus community agency) will also be undertaken to determine feasibility questions that may differ as a function of same. REDCap will be employed and will allocate based on the computer-generated randomization list. Allocation concealment will be achieved since the person making the assignment will have no awareness or control over the randomization schedule.||f|f|f|t
34001530|NCT03868631|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34001531|NCT06177405|||COHORT||PROSPECTIVE|||||||
34001532|NCT02556853|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34001533|NCT05892731|||COHORT||CROSS_SECTIONAL|||||||
34001534|NCT02069951|RANDOMIZED|PARALLEL||||NONE||||||
33921929|NCT02679196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921930|NCT03465176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921931|NCT01966263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921932|NCT03979027|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921933|NCT04248400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33921934|NCT01213693|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33921935|NCT00570440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001535|NCT05705791|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's two stage design: In the first stage, 23 evaluable patients will be accrued. If there are 7 or fewer responses (complete or partial response) in these 23 patients, the clinical investigation will be stopped for futility. Otherwise, 10 additional evaluable patients will be accrued for a total of 33.||||
34001536|NCT05898438|||COHORT||PROSPECTIVE|||||||
34001537|NCT00374361|||COHORT||PROSPECTIVE|||||||
34001538|NCT05331625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34001539|NCT01853176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025107|NCT03745716|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This will be a Phase III, multicenter, randomized study to compare the rate of CR and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.~Treatment will be administered on an outpatient basis. No investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's disease.~Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~* Experimental arm: APR-246 + azacitidine; or~* Control arm: Azacitidine"||||
34025108|NCT00006460||||TREATMENT||||||||
33921936|NCT00225888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921937|NCT02901444|||COHORT||PROSPECTIVE|||||||
33921938|NCT04801797|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, multicenter, phase II randomized clinical trial to compare the therapeutic activity of conventional induction chemotherapy (7+3 regimen or liposomal daunorubicin and cytarabine) (Standard arm) to the combination of venetoclax and azacitidine among fit, traditionally induction-eligible adults with newly diagnosed acute myeloid leukemia (AML).||||
33921939|NCT01990755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921940|NCT03300258|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921941|NCT00957255|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921942|NCT04142515|||OTHER||RETROSPECTIVE|||||||
33921943|NCT06528015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921944|NCT00546286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921945|NCT03858608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Unblinded, pragmatic, pilot, randomised, controlled trial||||
33921946|NCT06064903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921947|NCT04586556|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, multi-endoscopist, single center, clinical study at tertiary referral center (CHUM)||||
33921948|NCT01277848|||OTHER||PROSPECTIVE|||||||
34001540|NCT04894409|RANDOMIZED|CROSSOVER||OTHER||NONE||Eligible participants for the in vivo study were randomized using a computer generated block scheme and stratified according to duty position, work shifts and the area/department of the service at General Tijuana Hospital. Individuals from experimental group were provided with a 50 mL spray bottle containing AgNPs solution with 1 wt% concentration (0.6 mg/mL metallic silver). Participants were instructed to mix 4 to 6 spray shots (corresponding to volume \~ 0.5 mL) of this solution with 20 mL of water and to gargle with obtained solution for 15 to 30 seconds at least 3 times a day, also nasal lavages on the inner part of the nasal alae and nasal passage with the same solution using a cotton swap twice a day. As a second option, participants were instructed to cover evenly the oral cavity with the direct 1 to 2 spray shots of solution without its previous dilution in water.||||
34001541|NCT00151255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001542|NCT05595720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001543|NCT04781244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001544|NCT02861833|||||RETROSPECTIVE|||||||
34001545|NCT02966730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921949|NCT03049995|||CASE_ONLY||PROSPECTIVE|||||||
34001546|NCT00483145|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34025109|NCT03879434|||OTHER||PROSPECTIVE|||||||
34025110|NCT03914092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025111|NCT04628793|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34025112|NCT05850585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34025113|NCT02657265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921950|NCT01154881|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33921951|NCT04342520|||OTHER||PROSPECTIVE|||||||
33921952|NCT04213040|||COHORT||PROSPECTIVE|||||||
33921953|NCT03222440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921954|NCT01883869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921955|NCT04176744|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participant enrolled in the study will be tested with different stimulation settings on three different days in a randomized order.||||
33921956|NCT06202209|||COHORT||PROSPECTIVE|||||||
33921957|NCT04199793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33921958|NCT05530278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33921959|NCT00500838|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33921960|NCT01128335|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697205|NCT03553927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 sub-studies Study A (men with a normal sperm concentration) Study B (men with a low sperm concentration)|t|f|f|f
33697206|NCT02488850|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33697207|NCT00914485|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33697208|NCT05842876|||COHORT||PROSPECTIVE|||||||
33697209|NCT02444104|||CASE_ONLY||PROSPECTIVE|||||||
33697210|NCT02577874|||COHORT||CROSS_SECTIONAL|||||||
33697211|NCT06550687|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33697212|NCT03181815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921961|NCT00764946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33921962|NCT02789449|||COHORT||PROSPECTIVE|||||||
33921963|NCT05419271|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||A prospective cross-over trial testing the efficiency of internal convection on Beta2-microglobulin in daily home hemodialysis, intradialytic fall of B2m levels is compared in 16 patients treated by one session of dialysis with 9L internal convection and one usual session with free internal convection.||||
33921964|NCT04345302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research assistant blinded to the allocation of the participant will perform the follow-up assessments. Due to the nature of the intervention, the participants and the therapists will know in which group they are participating; however, they will be strongly instructed to not disclose their allocation at the follow-up assessments. At trial closure, a statistician blinded to allocation will conduct the data analysis.|The study is a parallel-group, single-blinded, randomized clinical trial to test the superiority of a Brief Motivational Treatment over enhanced usual care. The allocation ratio is 1:1 as per a computer-generated randomisation schedule stratified by site and the baseline SDSS-DAYS score using permuted blocks of random sizes.|f|f|f|t
33921965|NCT02473835|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33921966|NCT04403854|||CASE_CONTROL||PROSPECTIVE|||||||
33921967|NCT01294982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001547|NCT04598633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Study participants, meeting the inclusion criteria and not fulfilling the exclusion criteria, will be assigned to the study group or to the control group using a randomization plan. Randomization plan will be generated by the Center for Clincal Studies of the University Hospital of Erlangen. The lab manager will prepare storage boxes, in which exactly 168 lozenges will be stored. Half of the boxes will contain test-lozenges (study group), half or them will contain placebo-lozenges (control group). The storage boxes for the test and the placebo group will be identical and blinded. The storage boxes will be labelled with pseudonyms in accordance to the randomization plan generated by the Center for Clinical Studies. Therefore, study participants will not have knowledge of the group affiliation. The collection of the samples and the measuring of the clinical parameters will be performed by one orthodontist, who will be blinded to the randomization of the study participants.|Monocentric, randomized, double-blind, placebo-controlled, clinical study|t|f|t|f
34001548|NCT00476307|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001549|NCT01990807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001550|NCT01222364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697213|NCT06273436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697214|NCT03775031|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Randomized-Controlled (Subjects will serve as their own control)||||
33697215|NCT06098274|RANDOMIZED|PARALLEL||PREVENTION||NONE||The method of this research; It is a quasi-experimental study with pre-test and post-test, with intervention and control groups randomly selected.||||
33697216|NCT03180593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|alternating|Prospective, randomized, open label, blinded-endpoint (PROBE)|f|f|t|f
33697217|NCT00143117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33697218|NCT04901546|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Infants with esophageal atresia (EA) and comparison infants without esophageal atresia (but also in the neonatal intensive care unit, NICU) will be recruited. Infants with EA will be given their own saliva for 1 week, with every feed. Infants without EA will receive usual care. All subjects will have samples collected according to the same schedule.~Mothers of infants will also be recruited and have samples collected in order to understand the sources of the infant's gut microbiome."||||
33785724|NCT06600685|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1.) Single case research experimental design. N=10 participants will be asked to answer a set of questionnaires (Lickert-scales) every week for three weeks before the start of the treatment period and after completing FMT sessions 2, 4, 6, 8, and 10. This is to capture results based on patients' self-assessments during entire FMT treatment. Three measurement sessions will be completed before treatment begins to capture the baseline of their condition and pain in their daily life. Participants will begin their measurements on different weeks, to reduce the risk that the baseline measurement is due to any external factors that may affect participants if they are measured during the same time period/week.~Phase 2.) Pilot study with a mixed design. Relevant outcome measures (from phase 1) will be used to achieve valid and reliable results. N=60 participants will be recruited to participate in FMT treatment during a period of ten weeks."||||
33785725|NCT05608967|||CASE_CONTROL||PROSPECTIVE|||||||
33785726|NCT00150566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33785727|NCT03880422|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785728|NCT01019577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785729|NCT05288101|RANDOMIZED|PARALLEL||PREVENTION||NONE||Thirty-two chronic HD patients were included in a 6-month randomized pilot study. Patients in SUPL group received a simultaneous intervention consisting of a personalized diet, 245 mL/d ONS and dry weight adjustment through BIVA. Patients in CON group received a personalized diet and dry weight adjustment by BIVA. Anthropometrical, biochemical, dietary, QoL, handgrip strength (HGS) and bioimpedance measurements were performed. Malnutrition Inflammation Score (MIS) was applied.||||
33785730|NCT02216786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785731|NCT06712875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study evaluating toxicity and early efficacy||||
33785732|NCT04936217|||COHORT||RETROSPECTIVE|||||||
33921968|NCT01792245|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33921969|NCT00061503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921970|NCT01169441|||COHORT|||||||||
33921971|NCT03385499|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33921972|NCT05027256|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921973|NCT00141180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33921974|NCT04209530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921975|NCT02294006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921976|NCT01543139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33921977|NCT05864599|||OTHER||PROSPECTIVE|||||||
33921978|NCT05657509|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group will continue functional training exercises and the control group will exercise traditional type with coaches' guidelines. Each group has equally male players.|t|f|t|t
33921979|NCT04492878|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33921980|NCT03121066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The design of the study is a randomized, double blind, parallel clinical trial.|t|f|f|t
33921981|NCT04818541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Early Feasibility Study||||
33921982|NCT04447534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33921983|NCT05994677|||CASE_CONTROL||PROSPECTIVE|||||||
33921984|NCT03058822|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33921985|NCT00051129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33921986|NCT02602717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921987|NCT04783285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33921988|NCT03678376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33921989|NCT03714230|||COHORT||PROSPECTIVE|||||||
33921990|NCT05480254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33921991|NCT04072172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921992|NCT05397483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33921993|NCT04152148|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001551|NCT02763696|||COHORT||CROSS_SECTIONAL|||||||
33697219|NCT05597410|||COHORT||PROSPECTIVE|||||||
33785733|NCT00272610|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34001552|NCT00613041|||COHORT||PROSPECTIVE|||||||
33785734|NCT06713915|||COHORT||OTHER|||||||
33785735|NCT05951595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785736|NCT05920122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The provider making the diagnosis of wound infection will be blinded to the intervention|"Immediately prior to entering the operating room, participants will be randomly assigned in a 1:1 ratio to the CHG or CHG-IPA group. Groups will be stratified by laboring status defined as :~1. Regular contractions with cervical dilation of 4 cm or more OR~2. Documented cervical change of at least 1 cm of dilation or at least 50% effacement OR~3. Rupture of membranes"|f|f|f|t
33785737|NCT06277999|||COHORT||PROSPECTIVE|||||||
33785738|NCT05718297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785739|NCT02646592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785740|NCT06714656|NA|SINGLE_GROUP||OTHER||NONE|This will have an N of 1 design and will not be randomised.|The study will be conducted as a 24-week (\~ 6 months) interventional N-of-1 study with an A1-B-A2 design (8 weeks per study arm). The first A-period represents an observational phase, the B-period represents an intervention phase with personalised food swaps and dietary advice on how to incorporate these swaps into the diet, and the second A-period represents an observational/follow-up period.||||
33785741|NCT04077047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785742|NCT06701838|||COHORT||PROSPECTIVE|||||||
33785743|NCT02112734|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33785744|NCT05980468|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785745|NCT04411940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment||||
33785746|NCT06711302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785747|NCT06448572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785748|NCT04005521|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33785749|NCT05889390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785750|NCT01457079|||COHORT|||||||||
33785751|NCT04463264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Simple blind design|Randomized. Nitazoxanide : Placebo (2:1), parallel-group study|t|f|f|f
33785752|NCT02501629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785753|NCT04740255|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants in the Straberi by Epistamp device trial, are those who are seeking improvement for Postinflammatory Hyperpigmentation (PIH) caused by acne.||||
33921994|NCT00595595|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001553|NCT06504121|||COHORT||RETROSPECTIVE|||||||
33785754|NCT05687266|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33785755|NCT01474538|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33785756|NCT05629208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33785757|NCT03226730|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33785758|NCT06445374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785759|NCT03299491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33785760|NCT05822271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785761|NCT01642940|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33785762|NCT03349684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785763|NCT01773122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785764|NCT05875207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Lead statistician is also masked|This is a multi-site feasibility randomized clinical trial.|f|f|t|f
33785765|NCT06641037|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33785766|NCT04945694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33785767|NCT06696287|||CASE_ONLY||CROSS_SECTIONAL|||||||
33921995|NCT05544227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33921996|NCT01277497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33921997|NCT03441347|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients in the experimental arm start the 17 week experimental intervention right after they enter the study. Patients in the second arm first continue to receive their usual care for 17 weeks, after which they also receive the experimental intervention. Both groups are assessed at baseline and after the initial 17 weeks. The second group is assessed a third time, after they have completed the 17-week experimental treatment program.||||
33921998|NCT05781763|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomly assigned into intervention- and control groups. Simple randomization will be used for equal group allocation at three different rheumatology clinics in southern Sweden. The patients will choose a sealed note in which one of the words intervention or control is written, when the baseline assessment is completed at the first measurement occasion."||||
33921999|NCT03424577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33922000|NCT00002017||||TREATMENT||||||||
34001554|NCT04149509|||OTHER||PROSPECTIVE|||||||
34001555|NCT02180230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001556|NCT00752076|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001557|NCT03168906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001558|NCT04302935|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697220|NCT02604056|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33697221|NCT02121782|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697222|NCT03561961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697223|NCT00187031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697224|NCT05449769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the study, the participants and researchers will be unblinded. Although the participants will not be explicitly told which group they are in, they will become aware of their group after completing the eNutriCardio FFQ at baseline. Those randomised to the intervention group will receive their eNutriCardio PN advice and those randomised to the control group will not receive any PN advice from eNutriCardio and therefore know which group they have been allocated to.|||||
33785768|NCT01018511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785769|NCT02142439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001559|NCT04703751|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"Clinical evaluation of the CIRCULATE catheter will be performed in a group of 10 patients. Each will receive intracoronary NTG followed by labelled CardioCell.~This is a non-randomized study without any requirement for sample size calculation."||||
34001560|NCT03581994|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single-blind masking|Two-arm parallel intervention assignment using identical educational materials but different question prompt approaches. Control arm included.|f|t|f|f
34001561|NCT02528409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001562|NCT04723082|||OTHER||CROSS_SECTIONAL|||||||
34001563|NCT02687789|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34001564|NCT04158687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001565|NCT02763631|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001566|NCT00381849|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34001567|NCT00002923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001568|NCT02257437|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33922001|NCT05296408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded assessor will collect clinical outcomes|Individuals will be randomized to either receive motor learning combined with Myopro (M+ML) or motor learning alone (ML-alone)|f|f|f|t
34001569|NCT01829204|||COHORT||PROSPECTIVE|||||||
34001570|NCT03076645|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34001571|NCT06232837|||CASE_CONTROL||PROSPECTIVE|||||||
33922002|NCT00392119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922003|NCT05399550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922004|NCT06322706|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922005|NCT00238225||||TREATMENT||||||||
33922006|NCT00854555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922007|NCT05785130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33922008|NCT00745953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922009|NCT03225937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||two sequential cohorts: cohort A (lapatinib + trastuzumab); cohort B (pertuzumab + trastuzumab-emtansine).||||
33922010|NCT02278081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922011|NCT00099788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922012|NCT05708768|||CASE_ONLY||PROSPECTIVE|||||||
33922013|NCT06066957|NA|SINGLE_GROUP||TREATMENT||NONE||"This study is a prospective cohort design. Subjects exposed to letermovir for CMV prophylaxis following heart or lung transplantation will be compared with those who received standard valganciclovir prophylaxis in the two years before the study began (referred to as the pre-intervention period). The goal is to evaluate the efficacy and tolerability of letermovir."||||
33922014|NCT05974046|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33922015|NCT00660777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922016|NCT01337167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922017|NCT04097015|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention model is a single group assignment.||||
33922018|NCT04711499|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
33922019|NCT05730257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001572|NCT01008306|||COHORT||CROSS_SECTIONAL|||||||
34001573|NCT03563885|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34001574|NCT00398073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001575|NCT01652508|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34001576|NCT06349096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001577|NCT02466087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001578|NCT01237080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001579|NCT01941069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34001580|NCT02336906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001581|NCT00002727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001582|NCT02307032|||COHORT||PROSPECTIVE|||||||
34001583|NCT02046317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001584|NCT01407484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001585|NCT04903652|NA|SINGLE_GROUP||TREATMENT||NONE||Pyrotinib Maleate plus Vinorelbine||||
34001586|NCT00506116|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34001587|NCT00107016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922020|NCT01319916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922021|NCT03825263|RANDOMIZED|PARALLEL||TREATMENT||NONE||Observational control trial||||
33922022|NCT02878512|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34001588|NCT01107327|||CASE_ONLY||PROSPECTIVE|||||||
34001589|NCT06383091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This is meant to be a parallel study. However, The Speech Language Pathologists will not be blinded as the Speech Pathologists are providing each regimen. If a participant in either group requires more intensive sessions or a differing regimen given the severity of complaints, the participants will receive it as per the recommendation of the Speech-Language Pathologist so as not to unblind the PI. An intent to treat analysis will be performed to accurately describe the data in the case of crossover and/or dropout.|t|f|t|f
34001590|NCT00325312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001591|NCT03910361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001592|NCT02587806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001593|NCT02871050|||COHORT||OTHER|||||||
34001594|NCT04554264|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34001595|NCT00344643|RANDOMIZED|PARALLEL||||NONE||||||
34001596|NCT00273130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001597|NCT01476358|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34001598|NCT03271996|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
34001599|NCT03920280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001600|NCT02004067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001601|NCT02132624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697225|NCT03060733|||CASE_ONLY||PROSPECTIVE|||||||
34001602|NCT04293354|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34001603|NCT04411173|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The supplements were delivered in identical containers with rather an A or B marked on the outside of the bag. Once data collection, data entry, and statistical analysis was completely finished, the study code was broken."||t|f|t|f
34001604|NCT03023137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were not blinded, but visits of the two groups were scheduled so as to not coincide..||f|f|f|t
34001605|NCT00280930|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34001606|NCT02528045|||CASE_ONLY||RETROSPECTIVE|||||||
34001607|NCT05324891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697226|NCT06557525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697227|NCT04672720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|L-carnitine and placebo drugs can be identified only by special codes determined by a statistics specialist. The participant, care provider, investigator and outcome assessor are unaware of the type of study groups.||t|t|t|t
33697228|NCT02438657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Ascending dose model|t|f|t|t
33697229|NCT05231044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study tests KX01 Ointment 1% against a placebo.|t|t|t|t
33697230|NCT04162600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001608|NCT00267124|||CASE_CONTROL||PROSPECTIVE|||||||
34001609|NCT02328040|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33697231|NCT05355610|NA|SINGLE_GROUP||TREATMENT||NONE|"For Alleviation of Intractable symptoms of Meniere's disease will be treated with intratympanic steroids. Measured with pre and post therapy vestibular severity index.~At the same time intratympanic dexamethasone will be used to rescue hearing measured with speech reception threshold and speech discrimination threshold"|Patients with unilateral Meniere's disease with intractable vertigo will be administered two doses of intratympanic gentamicin plus dexamethasone 1 week apart||||
33697232|NCT05144841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697233|NCT00044720|RANDOMIZED|||||NONE||||||
33697234|NCT00805701|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33697235|NCT06382831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697236|NCT00365651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001610|NCT01759251|||||PROSPECTIVE|||||||
33697237|NCT03268837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001611|NCT04129255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001612|NCT02509260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697238|NCT04890847|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33697239|NCT03654859|||COHORT||PROSPECTIVE|||||||
33697240|NCT03634644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697241|NCT04533633|||COHORT||PROSPECTIVE|||||||
34001613|NCT03330860|RANDOMIZED|CROSSOVER||OTHER||NONE||Crossover randomized clinical trial||||
34001614|NCT03890757|||CASE_ONLY||PROSPECTIVE|||||||
34001615|NCT03258996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participant: Initially, the subject will not know what technique has been received, the complete information regarding the surgical technique used, as the results obtained in his case, will be given in the last visit of the year.~Observer: Another periodoncist (R.E.), outside the intervention, would be in charge of recording the clinical parameters.~Analyst: The statistician (X.M.) does not know which treatment corresponds to each variable."|We will perform the experimental or control technique according to the randomization sequence.|t|f|t|t
33697242|NCT00659360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785770|NCT01645852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33785771|NCT02212886|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785772|NCT04903028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Sixty-four treatment-seeking TUDs between the ages of 18 and 65 will be randomly divided into two groups on a 1:1 basis (32 participants/condition). The first condition will receive E-sham rTMS and the other condition will receive active 10 Hz personalized-fMRI and E-field modeling guided rTMS (3000 pulses/session) over the left DLPFC.|t|f|t|t
34001616|NCT02802462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34001617|NCT02769741|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34001618|NCT00024154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001619|NCT05648539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001620|NCT02834390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001621|NCT00560326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697243|NCT01270854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697244|NCT01147640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697245|NCT00005602||||TREATMENT||||||||
33697246|NCT05077735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697247|NCT05991388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Platform trial||||
33785773|NCT02795806|||OTHER||RETROSPECTIVE|||||||
33785774|NCT05117515|||COHORT||RETROSPECTIVE|||||||
34001622|NCT06678464|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34001623|NCT03201341|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34001624|NCT03930849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will test an intervention designed to improve antidepressant adherence and depression outcomes in Veterans initiating or changing antidepressant medication to treat depression. Veterans will be assigned to 1) use Annie, VA's short message service (SMS) in combination with My HealtheVet, VA's online patient portal, 2) use Annie plus receive a weekly phone call, or 3) to the control group who will not be enrolled in Annie.||||
34001625|NCT02672761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001626|NCT05123053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001627|NCT00613158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001628|NCT02825316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34001629|NCT00160745|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33697248|NCT05857384|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697249|NCT06157151|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized study.||||
33697250|NCT00772473|||CASE_ONLY||PROSPECTIVE|||||||
33922023|NCT00290589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922024|NCT01454479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922025|NCT04043715|NA|SINGLE_GROUP||TREATMENT||NONE||This study will compare the benefits of transcutaneous and epidural stimulation in individuals with SCI through a phased intervention program including: 1) baseline testing, 2) PT only, 3) PT + TransQ stimulation, 4) wash out/recovery, 5) PT + Epidural stimulation, 6) follow-up testing.||||
33922026|NCT03457103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697251|NCT00152360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697252|NCT06670365|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697253|NCT03011619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697254|NCT02268955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720049|NCT04262232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking due to this being a single arm study.|This is a single arm study in which all participants will be exposed to the intervention (Ca-HELP).||||
33720050|NCT06133192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720051|NCT01041898|||COHORT||CROSS_SECTIONAL|||||||
33922027|NCT06257537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922028|NCT05649644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. Patients will be blinded to the group allocation. Patients will also be unable to view the ultrasound monitor during block placement.~2. The research nurse (outcome assessor) will not be present in the procedure room during block placement and will be blind to group allocation."|Patients will be randomly allocated to receive either USG SeTB or supraclavicular BPB. The randomization sequence will be generated using an online randomization software (www.randomization.com) and prepared by a third party (Research assistant) not involved with the study. The randomization sequence will be assigned as 1 = SeTB group and 2 = SCBPB group and the group allocation card will be sealed within an opaque envelop by a research assistant.|t|f|f|t
33922029|NCT05576610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33922030|NCT03368326|||CASE_CROSSOVER||PROSPECTIVE|||||||
33922031|NCT00400712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922032|NCT06178900|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922033|NCT02128984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922034|NCT05202223|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33922035|NCT00713453|||CASE_ONLY|||||||||
33922036|NCT03700632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|care provider, investigator and outcome assessor will be unaware the group of participants. because of the nature of study, patch therapy vs no treatment, masking of participant will not be possible.|the experimental group will be treated with part time patch therapy and control group will be observed without any treatment.|f|t|t|t
33922037|NCT00045487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922038|NCT02528968|NA|SINGLE_GROUP||OTHER||NONE||||||
33922039|NCT01597011|||CASE_CONTROL||PROSPECTIVE|||||||
33922040|NCT05161312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33922041|NCT00353184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922042|NCT01682967|||CASE_CONTROL||PROSPECTIVE|||||||
33922043|NCT01142453|||CASE_ONLY||PROSPECTIVE|||||||
33922044|NCT02120144|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33922045|NCT01446679|||COHORT||PROSPECTIVE|||||||
33922046|NCT03860350|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Double blind placebo controlled prospective study|t|t|t|t
33922047|NCT00406211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922048|NCT04591210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922049|NCT06303349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective single-centre cohort study with prognostic aim, carried out in the neuro-resuscitation unit of the Bordeaux University Hospital.||||
33922050|NCT05145712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922051|NCT05027919|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The order of medication pre-treatment during the two Naloxone Challenges will be blinded to participants and the investigator.|||||
34001630|NCT05770804|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33922052|NCT04164329|||COHORT||PROSPECTIVE|||||||
33922053|NCT02402712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922054|NCT05113719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922055|NCT01237561|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922056|NCT05884359|||COHORT||PROSPECTIVE|||||||
33922057|NCT05560178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Since it is not possible to blind the experimental and control groups in the study, only statistical blinding will be applied.|Research, parallel group (experiment-control) randomized controlled trial|f|f|f|t
33922058|NCT02604810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33922059|NCT05560893|RANDOMIZED|CROSSOVER||PREVENTION||NONE||In this randomized controlled waitlist design, following a baseline assessment, the investigators will randomly assign CSPs into the experimental group (n = 40) or a waitlist group (n = 40). The experimental group will receive the intervention immediately, whereas the waitlist control will wait 4 weeks and have a second baseline assessment before receiving the intervention. All participants will complete an identical assessment battery at pre-intervention baseline, immediately post-intervention, and 3-months.||||
33922060|NCT03172481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922061|NCT05366530|||COHORT||PROSPECTIVE|||||||
33922062|NCT04223401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922063|NCT01754207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922064|NCT02079558|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33922065|NCT03159806|||COHORT||PROSPECTIVE|||||||
33922066|NCT03768141|||COHORT||PROSPECTIVE|||||||
33922067|NCT05880407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922068|NCT04278482|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33922069|NCT02902029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922070|NCT05349942|NA|SINGLE_GROUP||SCREENING||NONE||Intraoral scanner (Planmeca Emerald) data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.||||
33922071|NCT04387526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922072|NCT01916707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922073|NCT01390480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33922074|NCT00226395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922075|NCT01481090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001631|NCT06676813|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial.||||
33922076|NCT01752439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922077|NCT04320277|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Patients. All consecutive patients with mild to moderate COVID-19 infection, older than 18, Patients should present fever, cough and myalgia and weakness and radiological findings of pneumonia.~Controls. All consecutive patients with mild to moderate COVID-19 infection, older than 18, admitted during the previous 2 weeks, who were treated with antiviral and/or hydroxychloroquine."||||
33922078|NCT02636920|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922079|NCT05152277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||HRS9531 compared with placebo|t|f|t|f
33922080|NCT00002391||PARALLEL||TREATMENT||||||||
33922081|NCT00351091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922082|NCT02690207|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001632|NCT06048783|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34001633|NCT05048862|||COHORT||PROSPECTIVE|||||||
34001634|NCT05617612|||COHORT||PROSPECTIVE|||||||
34001635|NCT04385745|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking not possible.|Prospective, randomized, controlled clinical trial.||||
34001636|NCT03282539|||COHORT||PROSPECTIVE|||||||
34001637|NCT01867190|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous treatment for CLI open label||||
34001638|NCT04857333|||COHORT||PROSPECTIVE|||||||
34001639|NCT00997477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001640|NCT05014880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001641|NCT04449341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34001642|NCT03256227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are blinded to treatment condition|effectiveness-implementation Hybrid 1, 2-arm, pragmatic randomized controlled trial|f|f|f|t
34001643|NCT02761720|||COHORT||PROSPECTIVE|||||||
34001644|NCT06394492|RANDOMIZED|PARALLEL||TREATMENT||NONE||To evaluate the efficacy and safety of SHR-A1921 compared with investigator-chosen chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.||||
34001645|NCT02913287|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34001646|NCT00441961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001647|NCT00327691|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34001648|NCT04409379|||CASE_CONTROL||PROSPECTIVE|||||||
34001649|NCT04477863|||OTHER||OTHER|||||||
34001650|NCT02398734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34001651|NCT03481517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001652|NCT04167358|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label non-comparator study.|This is a non-comparator single group study.||||
34001653|NCT00026416||||TREATMENT||||||||
34001654|NCT03380325|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001655|NCT00654641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001656|NCT03430635|||COHORT||RETROSPECTIVE|||||||
34001657|NCT00380796|||CASE_ONLY||PROSPECTIVE|||||||
34001658|NCT05696327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001659|NCT01876745|||COHORT||RETROSPECTIVE|||||||
34089329|NCT05042297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and physicians allocated to each intervention group were aware of the allocation; however, the data analysts and the outcome assessors were kept blinded to the allocation.|An independent doctor created the randomization sequence using Excel 2016 (computerized random numbers) with a 1:1 allocation via random block sizes of 2, 4, and 6; he assigned the sample numbers equally to each group and assigned the block. Patients and physicians allocated to each intervention group were aware of the allocation; however, the data analysts and the outcome assessors were kept blinded to the allocation. We prospectively carried out this study on 40 patients with Tile B2 \& C1 injuries between March 2019 and July 2020 that met our inclusion criteria. The independent doctor allocated the 40 cases to two groups: Group A (20 cases): combined posterior and anterior ring fixation (APR fixation group), group B (20 cases): isolated posterior ring fixation (PR fixation group).|f|f|t|t
34089330|NCT05259215|||COHORT||RETROSPECTIVE|||||||
34089331|NCT02215759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089332|NCT00005047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089333|NCT02114684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089334|NCT06549634|||COHORT||PROSPECTIVE|||||||
34089335|NCT05441319|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34089336|NCT04689451|||COHORT||RETROSPECTIVE|||||||
34089337|NCT01562990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089338|NCT01828424|||COHORT||PROSPECTIVE|||||||
34089339|NCT04399291|||COHORT||CROSS_SECTIONAL|||||||
34089340|NCT01045200|||COHORT||PROSPECTIVE|||||||
34089341|NCT05802355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089342|NCT03033433|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
34089343|NCT02690129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089344|NCT03272204|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34089345|NCT03138681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089346|NCT03195712|||COHORT||RETROSPECTIVE|||||||
34089347|NCT01148732|||COHORT||PROSPECTIVE|||||||
34089348|NCT01644214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089349|NCT02052362|NON_RANDOMIZED|PARALLEL||||NONE||||||
34089350|NCT04701996|||COHORT||PROSPECTIVE|||||||
34089351|NCT00439998|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089352|NCT00870727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089353|NCT05040659|||COHORT||PROSPECTIVE|||||||
34089354|NCT01580956|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34089355|NCT00130364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089356|NCT03471819|||CASE_CONTROL||PROSPECTIVE|||||||
34089357|NCT01648764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089358|NCT06053190|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking -- participants are presented various stimuli in different experimental conditions.|"This basic science experiment meets the NIH criteria of a BESH (Basic Experimental Study with Humans) Trial. All participants are exposed to all experimental conditions (i.e., interventions) in a complete factorial 2 x 3 within-subjects experimental design. Interventions involve presenting various speech stimuli to participants."||||
34089359|NCT05471895|||COHORT||PROSPECTIVE|||||||
33720052|NCT02197507|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33720053|NCT06087783|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-group intervention study compared to matched historical controls|f|f|f|t
33720054|NCT02615054|||CASE_CROSSOVER||PROSPECTIVE|||||||
33720055|NCT02132325|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33720056|NCT00427258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720057|NCT00970190|||COHORT||PROSPECTIVE|||||||
33720058|NCT02097407|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33720059|NCT01125839|||COHORT||PROSPECTIVE|||||||
34089360|NCT00639093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089361|NCT04765631|||CASE_CONTROL||RETROSPECTIVE|||||||
34089362|NCT06297967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089363|NCT00376844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Exterbal beam radiation therapy versus vaginal brachytherapy||||
34089364|NCT02124174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089365|NCT02721888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089366|NCT04367896|||OTHER||PROSPECTIVE|||||||
34089367|NCT05426460|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The transcranial tDCS is delivered without the participant or investigator knowing if they are receiving tDCS or not.||t|f|t|f
34089368|NCT00092001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103138|NCT03539640|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The assessor of the MRI measurements will analyze the MRI data in a blinded fashion. The rest of the outcomes will not be analyzed in a blinded fashion.|All participants will receive the same protocol with different levels of PEEP ventilation during the first part of the study (physiological part), so the interventional study model for this part is single group. During the second part (MRI), participants are randomized for one of the three available PEEP levels (5, 10 or 15 cmH2O), so the study model for this part is parallel.|f|f|f|t
33922083|NCT03807115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a pilot stepped-wedge c-RCT. Data collection will take place over 16 weeks at 6 sites. Patient chart data (Functional Independence Measure (FIM), Functional Ambulation Category (FAC), 6-Minute-Walk-Test) will be collected weekly at all sites. Weeks 1-12: Participants at sites 1-6 will submit a weekly Calculation of Indicators (COI). Weeks 1-12: Sites 1 and 2 will receive 4 weekly online intervention packages and submit Information Assessment Method (IAM) and COI questionnaires for 12 weeks. Weeks 5-12: Sites 3 and 4 will receive 4 weekly online intervention packages and submit IAM and COI questionnaires for 8 weeks. Weeks 9-12: Sites 5 and 6 will receive 4 weekly online intervention packages and submit IAM and COI questionnaires for a total of 4 weeks. The longest exposure to the intervention will be 3 months and the minimum will be 1 month as per stepped-wedge c-RCT design. All participants will complete a My Guideline Implementation Barometer (MGIB) questionnaire at month 4.||||
33697255|NCT05821673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the histologist was blinded|Participants received either abutments with machine surface characterized by circular micro-threads with a furrow of less than 2 um (surface roughness: Ra=0.2 and Sa=0.11) or abutments with rough Ultrathin Threaded Microsurface with a triangular contour tread with a pitch of 50 μm (surface roughness: Ra=0.62 and Sa=0.60) abutments allocated to the test group were placed in an Argon plasma reactor (Diener Electronic GmbH, Jettingen, Germany) for decontamination and activation. in control group were allocated argon plasma non-treated abutmentsParticipants underwent 2-level randomization for allocation of abutments with different surface configurations and experimental treatment using permuted block technique to limit any selection bias. Allocation concealment was preserved by sealing the tested abutments in sterile envelopes sealed in opaque sleeves opened at the time of the second surgical step.|t|f|f|t
33697256|NCT03701399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697257|NCT00591266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697258|NCT02927782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697259|NCT06345131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33697260|NCT02493582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697261|NCT04665388|||OTHER||PROSPECTIVE|||||||
34103139|NCT04619888|||COHORT||PROSPECTIVE|||||||
33697262|NCT00796185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697263|NCT02759874|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697264|NCT06680791|||COHORT||PROSPECTIVE|||||||
33697265|NCT01356979|||CASE_CONTROL||PROSPECTIVE|||||||
33697266|NCT05411068|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33697267|NCT04750603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Medications and placebos were provided by the hospital pharmacy and medications were given by the nurse. Randomization was generated by computer, independently of trial staff as described (Salbutamol inhaler + Ellipta placebo or FF/VI + placebo Salbutamol inhaler). Technicians performing the ECT, investigators and patients were blinded to treatment choice|First phase: Randomized, double blind, double dummy. Second phase: open label|t|f|t|f
33697268|NCT04253314|||COHORT||PROSPECTIVE|||||||
33697269|NCT06060600|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33697270|NCT01475565|||COHORT||PROSPECTIVE|||||||
33697271|NCT03886662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922084|NCT03499080|||OTHER||PROSPECTIVE|||||||
33922085|NCT00781963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922086|NCT04715412|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33922087|NCT04638868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922088|NCT03693118|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33922089|NCT04804280|||CASE_CONTROL||PROSPECTIVE|||||||
33922090|NCT01379170|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33922091|NCT03099980|NA|SINGLE_GROUP||TREATMENT||NONE||secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections||||
33922092|NCT02685657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922093|NCT00734812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922094|NCT02155348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922095|NCT05381558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922096|NCT06057636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single-masking, participants|This is a two-arm, randomized clinical trial.|t|f|f|f
33922097|NCT00085917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922098|NCT01338935|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33697272|NCT04863547|||OTHER||OTHER|||||||
33697273|NCT04550910|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33697274|NCT05797662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697275|NCT05353309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697276|NCT04745923|||CASE_CONTROL||PROSPECTIVE|||||||
33697277|NCT01703273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697278|NCT01695148|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697279|NCT00361582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33697280|NCT01761851|||CASE_ONLY||PROSPECTIVE|||||||
33697281|NCT02841436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697282|NCT00326677|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33697283|NCT02633501|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33697284|NCT02656914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind study||t|f|t|f
33697285|NCT02029170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785775|NCT06364150|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open label interventional study||||
33697286|NCT03616132|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33697287|NCT01358773|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697288|NCT03793556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients was randomized in an open-label treatment (in a ratio 1:1) and treated with the investigational medical device (IMD) + proton pump inhibitor (PPI) or PPI only for 6 weeks. At the end of treatment visit (V4) only patients who were classified as responders and belonging to the GERDOFF®+PPI group were included in the follow-up phase for 12 further weeks. During the follow-up, patients were randomized to an open-label treatment (in a 1:1 ratio) to GERDOFF® group or control group that will not receive any treatment for 12 weeks in order to evaluate the maintenance of treatment effects. To safeguard the health and well-being of patients, and to keep under control the possible upper symptoms of GERD that could appear, all patients that continued in the follow-up period received omeprazole as rescue medication, in a quantity adequate to cover the entire follow-up period.||||
33697289|NCT01710046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697290|NCT04258514|RANDOMIZED|PARALLEL||TREATMENT||NONE|cannot make due to either wearing or not wearing the VR device|||||
33697291|NCT00885950|||COHORT||RETROSPECTIVE|||||||
33697292|NCT00752037|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697293|NCT03621774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697294|NCT00073801|||COHORT||PROSPECTIVE|||||||
33697295|NCT06557824|||OTHER||RETROSPECTIVE|||||||
33697296|NCT03455582|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33785776|NCT06456931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As the study involves two psychological/behavioural interventions, it will not be possible to mask the participants, care providers or the investigators. However, most outcomes are based on self-report ratings, and the outcome at the end of the intervention (relapse of depression) will be assessed using telephone interviews by investigators blind to the participant's study arm.||f|f|f|t
33785777|NCT00003743|RANDOMIZED|||TREATMENT||||||||
33785778|NCT05953350|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33922099|NCT00122421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922100|NCT00529698|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33922101|NCT00798577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922102|NCT01601808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922103|NCT04781907|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33922104|NCT01040754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33922105|NCT04436380|||COHORT||RETROSPECTIVE|||||||
33922106|NCT00673686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33922107|NCT02356640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922108|NCT03967275|||OTHER||PROSPECTIVE|||||||
33922109|NCT06068296|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697297|NCT01948037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697298|NCT05227378|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, open-label, single-arm exploratory study||||
33697299|NCT00312182|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33697300|NCT01033851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697301|NCT01173757|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33697302|NCT03877731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697303|NCT01927627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697304|NCT04223583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697305|NCT00215683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697306|NCT01134731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697307|NCT06058403|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized, controlled, double-blind, cross-over intervention trial|t|f|t|t
33697308|NCT04357340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All the enrolled participants will be allocated to the intervention of control groups using blocked-balanced randomization method.|f|f|f|t
33697309|NCT02470416|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697310|NCT03008226|||CASE_ONLY||PROSPECTIVE|||||||
33697311|NCT02703233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33697312|NCT00444652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785779|NCT04248764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785780|NCT04606264|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785781|NCT03559361|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33785782|NCT05701462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785783|NCT06712641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785784|NCT01835340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785785|NCT02094794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785786|NCT04947501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922110|NCT06517862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||8 arms (Full term Control, Full term Low Dose Zinc Sulphate, Full term High Dose Zinc Sulphate, Full term UDCA -- Preterm Control, Preterm Low Dose Zinc Sulphate, Preterm High Dose Zinc Sulphate, Preterm UDCA)|t|f|t|t
34001660|NCT02656316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001661|NCT02775058|||COHORT||PROSPECTIVE|||||||
34001662|NCT02319850|||COHORT||CROSS_SECTIONAL|||||||
34001663|NCT06488469|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot Randomized controlled trial:A cohort of 200 children with Type-1 Diabetes will be screened for Hypoglycemia Unawareness (HU) for a maximum period of 2 weeks. The prevalence of Hypoglycemia unawareness is 25% among children and adolescents with Type-1 Diabetes patients. (5) So, we expect a minimum of 50 children with HU who will be eligible for the study.||||
34001664|NCT02786927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001665|NCT02992548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001666|NCT01639664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001667|NCT02301741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34001668|NCT01170715|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be screened and enrolled based on inclusion/exclusion criteria. Those enrolled will have intervention for 52 weeks and assessed for outcome measures along the way.||||
34001669|NCT02050620|||CASE_ONLY||PROSPECTIVE|||||||
33697313|NCT05630755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697314|NCT06310915|||COHORT||PROSPECTIVE|||||||
33697315|NCT01957254|||||PROSPECTIVE|||||||
33697316|NCT00033605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33697317|NCT00141388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697318|NCT06051214|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697319|NCT04206007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697320|NCT05530031|NA|SINGLE_GROUP||TREATMENT||NONE||• trabeculotomy (with Metal Trabeculotome): a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.||||
33697321|NCT04093414|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, open label, randomized, prospective||||
33697322|NCT02224092|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33697323|NCT01024231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697324|NCT06287190|||OTHER||CROSS_SECTIONAL|||||||
33697325|NCT01303354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697326|NCT01938872|||COHORT||PROSPECTIVE|||||||
33697327|NCT01400815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697328|NCT01285453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697329|NCT02447562|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33697330|NCT01131156|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33697331|NCT00195572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697332|NCT01736462|NA|SINGLE_GROUP||||NONE||||||
33697333|NCT03082378|||CASE_CROSSOVER||PROSPECTIVE|||||||
33697334|NCT03451175|||COHORT||PROSPECTIVE|||||||
33697335|NCT02703220|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33697336|NCT03276793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697337|NCT05843955|||OTHER||CROSS_SECTIONAL|||||||
33697338|NCT00935298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785787|NCT06486974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785788|NCT06713733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PI does not have access to any of the groups. i.e PI is blinded.|group a - submucosal dexamethasone group b - oral trypsin chymotrypsin|f|f|t|f
33785789|NCT02999282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922111|NCT04263779|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants (i.e., patients/caretakers and case managers) will not be informed specifically of their assignment to different arms throughout the study, but case managers will be informed that Repisodic is continuing to undergo development and testing and that they may therefore notice different patients and colleagues receiving slightly different versions of Repisodic over time.|"Case managers (\~145) will be randomly assigned to conditions in a cluster-randomized trial design:~1. Default List: all eligible SNF options presented in Repisodic in rank order.~2. P-SNF Top-Sorted List: same as Default List, except relevant P-SNFs will be shown at the top of the otherwise ranked list.~Patients (\~5,000) will independently be randomized to conditions and tracked:~1. Full List/Full Map/Default Video: all SNF options preselected by case managers will be presented to patients ordered by Repisodic's ranking algorithm. A map will present SNFs on the list if selected, and a link to an introductory video on SNF selection and discharge will be available.~2. P-SNF List/P-SNF Map/P-SNF Video: same as Full List, except that both the list and map will present only the P-SNFs, with an opt-in button allowing patients to view all results. Moreover, the link to view the optional SNF video will be highlighted and the advantage of P-SNFs for care coordination will be presented."|t|f|f|f
33922112|NCT05082298|NA|SINGLE_GROUP||TREATMENT||NONE||Piloting dissemination and feasibility of a two-step dental fear treatment at private practices in a large metropolitan city.||||
33922113|NCT02427750|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922114|NCT02883777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922115|NCT02591238|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33922116|NCT04370730|NA|SINGLE_GROUP||OTHER||NONE||prospective cohort study||||
33922117|NCT06204302|||COHORT||RETROSPECTIVE|||||||
33922118|NCT00605722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001670|NCT04920058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants CGM record and biological samples will be de-identified to investigator.|To determine if a data driven behavioral tool incorporating Levels CGM software provides superior feedback, accountability, control, and reward mechanisms necessary to create positive, sustainable dietary behavioral change.|f|f|t|f
34001671|NCT00660491|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34001672|NCT04405908|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
34001673|NCT04432207|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001674|NCT01547507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001675|NCT00158535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001676|NCT03436316|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Part 1 of this study will be single-blind. Part 2 of this study will be open-label. Part 3 of this study will be single-blind.||t|f|t|f
34001677|NCT01710670|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34001678|NCT00351117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001679|NCT02557217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697339|NCT06679894|||COHORT||PROSPECTIVE|||||||
33697340|NCT04348279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33697341|NCT01417936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697342|NCT00882466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697343|NCT06150664|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33697344|NCT02063711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33785790|NCT03251651|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33785791|NCT05677659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785792|NCT04294082|||OTHER||PROSPECTIVE|||||||
33785793|NCT06138587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785794|NCT04866563|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33785795|NCT03818659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785796|NCT05756426|||COHORT||PROSPECTIVE|||||||
34001680|NCT00176943|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34001681|NCT04729101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34001682|NCT00376740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001683|NCT01969864|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34001684|NCT04260854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001685|NCT01402934|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34001686|NCT03990233|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Step 1 (Dose escalation \[Cohorts A and B\]) primary objective : In V1/V1 homozygous and V1/V2 heterozygous patients with advanced solid tumors, Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of BI 765063, as monotherapy (Cohort A) and in combination with BI 754091 (Cohort B).~* Step 2 (Expansion Cohorts \[Cohorts C\]) primary objective : In V1/V1 homozygous patients with selected advanced solid tumors (colorectal or endometrium), DLT-like events and RP2D confirmation of BI 765063 in combination with BI 754091."||||
34001687|NCT03624777|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025114|NCT03571412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The purpose to this study is to valuate the clinical effects of 5Hz rTMS over Left Dorsolateral Prefrontal Cortex and Dorsomedial Prefrontal Cortex|t|f|f|f
34025115|NCT00735605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025116|NCT04314648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697345|NCT04229979|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multicenter, randomized, parallel group study||||
33697346|NCT06431737|||COHORT||PROSPECTIVE|||||||
33697347|NCT05296733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697348|NCT03953417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697349|NCT01334892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025117|NCT00771459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697350|NCT06284096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697351|NCT04124653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|participant- and investigator-blind, sponsor-open||t|f|t|f
33697352|NCT05822986|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697353|NCT00914173|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33697354|NCT00144131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697355|NCT06403852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697356|NCT02607007|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33720060|NCT00091351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720061|NCT00167882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34025118|NCT01651897|||COHORT||PROSPECTIVE|||||||
34025119|NCT04139109|||CASE_ONLY||CROSS_SECTIONAL|||||||
34025120|NCT04928716|||COHORT||PROSPECTIVE|||||||
34025121|NCT01504958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34025122|NCT03231566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Outcome measures were mailed by patients in prepaid envelopes||t|t|t|t
33922119|NCT04908241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to participants' group allocation, whereby they will not be involved with delivering the TRAIL or EDUCATION programs. Participants are informed of their group assignment, however they will not know if they are in the experimental or control program, and instructed to withhold it from the assessors to ensure proper blinding and minimize internal bias.|Following baseline assessment, participants will be randomized into the TRAIL or EDUCATION arm. Following randomization, participants will remain in their allocated group until the completion of the study. A central research coordinator that is not involved in recruitment, assessments or study intervention, will be responsible for randomization of study participants, and will advise the participant and site coordinator of the group allocation. There will be four timepoints where outcome assessments will be conducted, which include baseline (T0), 1-month (T1), 3-months (T2), and 6-months (T3) follow-up.|f|f|f|t
33922120|NCT02467829|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33922121|NCT04984512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922122|NCT03203954|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33922123|NCT03084718|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33922124|NCT06063239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|SNOSE Sequentially Numbered, Opaque, Sealed Envelopes||t|t|t|t
34001688|NCT05788250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to their group allocation. This is possible because the incision and rehabilitation processes are consistent between groups. It is not possible for the treating surgeon to be blinded to group allocation, therefore a research team member (athletic or physical therapist) will remain blinded to group allocation and conduct all study related assessments as well as administer the patient-reported questionnaires. This will be maintained by the participant not removing their shirt during the study assessment. Patients will not be informed of which procedure they will undergo until the study is complete.|This a double-blind (patient and assessor), parallel, 1:1 multicentre randomized pilot study comparing patients 70 years and older randomized to SBS or RCR. 32 participants from eight orthopaedic surgeons at four sites will be recruited over a one-year period. Randomization will be generated using a web-based system pre-operatively and stratified to ensure 8 medium/large tears and 8 massive tears are allocated to each group.|t|f|f|t
34001689|NCT05080140|||COHORT||PROSPECTIVE|||||||
34001690|NCT02519543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001691|NCT04629170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind (Sponsor-open)|Part 1 - randomized, placebo-controlled multiple-dose escalation Part 2 - randomized, placebo-controlled crossover|t|t|t|f
34001692|NCT06217276|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34001693|NCT00613977|||COHORT||PROSPECTIVE|||||||
34001694|NCT02559219|||COHORT||PROSPECTIVE|||||||
34001695|NCT04791345|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Single-center, non-randomized, open-label clinical trial in healthy male volunteers. A single dose of DEX, MP and DEF, and multiple dose of DEX and MP will be administered to different subjects.||||
34001696|NCT05598164|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Parallel Assignment A comparative, randomized, prospective, single-center clinical study. Patients of the main group are treated with injection in internal sphincter Botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter Botulinum toxin type A with excision."||||
34001697|NCT03824834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study medications, both morphine sulphate and placebo, will be dispensed by the research pharmacist according to the patient's randomization assignment. Neither research staff, nor patients, nor the treating physicians will be aware of the treatment assignment before or after randomization.||t|t|t|t
34001698|NCT01580046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34001699|NCT05263505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34001700|NCT04280224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001701|NCT04046562|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to one of two arms. One arm is PAW plus standard of care and the second arm is pain education plus standard of care.||||
34001702|NCT02276625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34001703|NCT06348316|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34001704|NCT05543395|||CASE_ONLY||PROSPECTIVE|||||||
34001705|NCT05654025|||COHORT||OTHER|||||||
34001706|NCT00404053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001707|NCT02463630|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34001708|NCT03236363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001709|NCT06316180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001710|NCT00834236|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34001711|NCT00725764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001712|NCT03947398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720062|NCT00376350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720063|NCT03941431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720064|NCT01425346|||CASE_ONLY||PROSPECTIVE|||||||
33720065|NCT02059057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785797|NCT02688972|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33785798|NCT06714162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785799|NCT02018666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785800|NCT01809379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785801|NCT04643743|||COHORT||RETROSPECTIVE|||||||
33785802|NCT02465359|NA|SINGLE_GROUP||OTHER||NONE||||||
33785803|NCT05128942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects will be assigned to treatment cohorts by age.||||
33785804|NCT05423587|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A randomization algorithm (hidden and protected) allocates a random number to each of the 110 subjects. The outputs of this algorithm will only be accessible to those who are unrestricted by experimental blinding (operator, radiographer, scrub nurse). For safety reasons the interventional radiologist will be aware of the treatment arm (non-blind).|Single Site, Double Blind Sham Randomized Controlled Trial with Sham subject optional crossover to the treatment arm (GAE) at 6 months post randomization to determine if embolization of abnormal blood vessels arising from branches of the genicular arteries reduces pain in patients with knee osteoarthritis.|t|t|f|f
33785805|NCT00072475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785806|NCT01893320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785807|NCT05509439|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33922125|NCT04724304|NA|SINGLE_GROUP||SCREENING||NONE||||||
33922126|NCT03696940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Simple Blinded|Longitudinal|t|f|f|f
33922127|NCT01784588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922128|NCT04798313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922129|NCT05421429|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33922130|NCT05886179|||OTHER||RETROSPECTIVE|||||||
33922131|NCT00118911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922132|NCT05259930|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single Center randomised controlled trial||||
33922133|NCT03438578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33922134|NCT03411668|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assignment to the arms will be made by an independent researcher using random.org.||f|f|f|t
33922135|NCT02928380|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33922136|NCT06092632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922137|NCT02600741|||COHORT||PROSPECTIVE|||||||
33922138|NCT00378755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922139|NCT03071380|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33922140|NCT05374018|||CASE_ONLY||PROSPECTIVE|||||||
33922141|NCT04868747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33922142|NCT03655392|RANDOMIZED|PARALLEL||PREVENTION||NONE||64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 mensal intervals. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, collecting exhaled condensed (cytokine analysis) air and it's ph measure, Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI), and answered a symptoms diary, Statistical analysis: repeated measures (Sigma Plot Software 3.0).||||
33922143|NCT04045626|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922144|NCT04199195|||COHORT||PROSPECTIVE|||||||
33922145|NCT01823770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922146|NCT02398084|NA|SINGLE_GROUP||||NONE||||||
34001713|NCT02888743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001714|NCT05544656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization is done by non-transparent (opaque) sequentially numbered envelopes, prepared independently from the trial site. The number on the envelope corresponds to the number on the boxes of the trial medication (tolperisone or matching placebo). The envelopes can be opened only at the end of the trial, or in case of emergency. No interim analysis is planned.|Single center, randomized double blind study. Randomization is done separately for those with and those without radicular signs.|t|t|t|t
34001715|NCT03908307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001716|NCT04859140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Allocation concealment|Three independent groups, two measurement points|t|t|f|t
34001717|NCT01704534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001718|NCT04850027|||COHORT||PROSPECTIVE|||||||
34001719|NCT01643239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34001720|NCT04763473|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34001721|NCT05003882|||COHORT||PROSPECTIVE|||||||
34001722|NCT01691612|NA|SINGLE_GROUP||OTHER||NONE||||||
34001723|NCT02937207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34001724|NCT04721418|||COHORT||CROSS_SECTIONAL|||||||
34001725|NCT04190706|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34001726|NCT03484234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001727|NCT03647722|||COHORT||CROSS_SECTIONAL|||||||
34001728|NCT01746654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34001729|NCT03673592|||COHORT||PROSPECTIVE|||||||
34001730|NCT03442855|||COHORT||PROSPECTIVE|||||||
34001731|NCT03144063|||COHORT||PROSPECTIVE|||||||
34001732|NCT04532996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001733|NCT01205945|||COHORT||PROSPECTIVE|||||||
34001734|NCT02393560|||OTHER||PROSPECTIVE|||||||
34001735|NCT01614184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001736|NCT04370444|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34001737|NCT05258630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study staff completing post-treatment assessments will be blinded to study condition allocation.|The study team will use 1 to 1 allocation to intervention vs. comparison arms. They will stratify based on more and less stable housing in the 12 mo. prior to enrollment.|f|f|f|t
34001738|NCT01201486|||CASE_ONLY||PROSPECTIVE|||||||
34001739|NCT06117241|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34001740|NCT02783326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001741|NCT02054754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34001742|NCT02957760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720066|NCT00356369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001743|NCT04231292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720067|NCT06404606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922147|NCT04217083|||CASE_CONTROL||PROSPECTIVE|||||||
33922148|NCT02409758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922149|NCT00030355||||TREATMENT||||||||
33922150|NCT01584258|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, international phase 3 randomised controlled study comprising three parallel randomisations with a common experimental arm.||||
33922151|NCT03479216|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33922152|NCT01103778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922153|NCT00225147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922154|NCT03934710|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized|t|t|f|t
33922155|NCT03385174|NA|SINGLE_GROUP||OTHER||NONE||||||
33922156|NCT04257227|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label dose-finding study, to be followed by either a sham-crossover or sham-control randomized clinical trial based on results of the dose-finding study. Study design described here is for the dose-finding study, and information will be updated once the randomized clinical trial is started.||||
33922157|NCT04673487|||OTHER||PROSPECTIVE|||||||
33922158|NCT03264417|||COHORT||RETROSPECTIVE|||||||
33922159|NCT05551091|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants underwent measures of study outcomes at 4 time points: day 1 and day 7 of consuming GMP supplements twice daily (low-dose, 25 g before breakfast and dinner) and day 1 and day 7 of consuming GMP supplements thrice daily (high-dose, 25 g before breakfast, lunch and dinner). For each of the two baseline visits (day 1), participants consumed 300 kcal liquid breakfast meal tolerance test containing soy protein isolate, and then began the low-dose GMP or high-dose GMP for 7 days. On day 7 of each GMP diet, participants returned for a second GMP-based 300 kcal liquid breakfast meal tolerance test. Between the 2 weeks of GMP consumption, participants had a minimum washout period of 5 days.||||
33922160|NCT03621423|NA|SINGLE_GROUP||TREATMENT||NONE||Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.||||
33922161|NCT05220761|||COHORT||PROSPECTIVE|||||||
33922162|NCT02483078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922163|NCT00852306|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33922164|NCT03060967|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33922165|NCT03155633|RANDOMIZED|PARALLEL||OTHER||NONE||The first one performed rests during the 9 days after the race, the second performed continuous race monitored every 48h from the end of the race, and the third group performed aerobic work on an elliptical machine under the same conditions as the group of Continuous race||||
34001744|NCT02284139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001745|NCT02357927|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001746|NCT05040139|||CASE_CONTROL||PROSPECTIVE|||||||
34001747|NCT04746976|||COHORT||PROSPECTIVE|||||||
34001748|NCT03171064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001749|NCT03563560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open labeled|This study consists of 2 cohorts of the ACM regimen part and 1 cohort of the A+7+3 regimen part.||||
33720068|NCT06340828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720069|NCT00817921|||COHORT||PROSPECTIVE|||||||
33720070|NCT04689295|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720071|NCT04843774|||CASE_ONLY||PROSPECTIVE|||||||
33720072|NCT06101667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785808|NCT01674569|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922166|NCT03956888|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pre-post study||||
33922167|NCT01220505|||CASE_ONLY||PROSPECTIVE|||||||
33922168|NCT05594212|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study method adopts an experimental research design and divided into experimental group and control group by random sampling. Experimental group receives abdominal breathing training, whereas control group without receiving abdominal breathing training.||||
33922169|NCT03689387|||CASE_ONLY||RETROSPECTIVE|||||||
33922170|NCT04914117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922171|NCT04850612|||OTHER||PROSPECTIVE|||||||
33922172|NCT04077229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922173|NCT03393468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922174|NCT00255294|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33922175|NCT03694054|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33922176|NCT04947839|||CASE_ONLY||CROSS_SECTIONAL|||||||
33922177|NCT01057914|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33922178|NCT05716594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922179|NCT02394795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001750|NCT01897077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001751|NCT00105040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001752|NCT00000516|RANDOMIZED|||PREVENTION||DOUBLE||||||
34001753|NCT01329458|||CASE_ONLY||PROSPECTIVE|||||||
34001754|NCT06291454|||CASE_CONTROL||PROSPECTIVE|||||||
34001755|NCT05274191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001756|NCT03329209|NA|SINGLE_GROUP||OTHER||NONE||||||
34001757|NCT00987480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001758|NCT04795466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001759|NCT01044433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720073|NCT04329169|NA|SINGLE_GROUP||OTHER||NONE||||||
33720074|NCT01155687|||CASE_CONTROL|||||||||
33720075|NCT03900767|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33720076|NCT06441175|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33720077|NCT04247581|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33720078|NCT02697175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33720079|NCT03443284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697357|NCT06681701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Group A (control) received conventional physiotherapy in the form of deep breathing exercises (diaphragmatic, apical, lower costal), Intensive spirometery (improve deep inspiration) and active range of motion (AROM) of both upper extremities.~Diaphragmatic breathing exercise: S~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia."|"Group B (experimental) received conventional physiotherapy and manual therapy (chest mobilization and myofascial release techniques). Treatments were performed three times weekly for 8 weeks.~Chest mobilization (Grade III joint oscillations are administered in three bouts of thirty oscillations per second each repeated 3-5 times) was applied through the following techniques:~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Myofascial release techniques (MRT) applied through the following (MRT was applied for 3min for each release.).~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:"|t|f|f|f
33697358|NCT00002746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785809|NCT06067490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785810|NCT05998590|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33785811|NCT04619459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Study||||
33785812|NCT03067051|NA|SEQUENTIAL||TREATMENT||NONE||"As result of the accelerated titration design with light dose and verteporfin for injection (VFI), the final number of subjects depends on the outcome of the titration. If all dose levels enroll and complete at the minimum number of subjects, the number of subjects is 12 (1 each at dose levels 1-3, 3 each at dose levels 4-6). If all dose levels enroll and complete at the maximum number of subjects, the number of subjects is 36 (6 subjects at each dose level 1-6). The range is thus 12-36 subjects for the dose-escalation phase.~25-30 subjects will be treated in an expanded cohort."||||
33785813|NCT06041802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785814|NCT03942822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785815|NCT06710561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785816|NCT06711562|||COHORT||PROSPECTIVE|||||||
33785817|NCT06615310|||CASE_CONTROL||PROSPECTIVE|||||||
33785818|NCT02274402|||COHORT||PROSPECTIVE|||||||
33785819|NCT05985291|||COHORT||PROSPECTIVE|||||||
33785820|NCT04550156|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomised, multicenter trial||||
33785821|NCT04722276|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33785822|NCT03034252|||COHORT||RETROSPECTIVE|||||||
33785823|NCT03298113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Central reader||f|f|f|t
33785824|NCT03675737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785825|NCT02408562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785826|NCT04291521|||COHORT||PROSPECTIVE|||||||
33785827|NCT00106808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33785828|NCT05927571|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785829|NCT01188486|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33785830|NCT04343807|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785831|NCT02374580|||||CROSS_SECTIONAL|||||||
33785832|NCT06492031|||COHORT||OTHER|||||||
33785833|NCT02970461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33785834|NCT00031343||||TREATMENT||||||||
33785835|NCT06219785|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Following completion of the 3-month follow-up visit, subjects will be unblinded. Subjects who received the Placebo/control treatment will be offered treatment using the active device applicator.|t|f|f|f
33785836|NCT04796285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801591|NCT05758766|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both principal investigator and participants will be blinded to arm of study|Participants will cross over after a while on plant-based omega-3-FA.|t|f|t|f
33801592|NCT05576857|||CASE_ONLY||PROSPECTIVE|||||||
34001760|NCT02093962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34001761|NCT02894580|||COHORT||RETROSPECTIVE|||||||
34001762|NCT04624594|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34001763|NCT02571582|||||RETROSPECTIVE|||||||
34001764|NCT00428155|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34001765|NCT03105297|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This study consisted of 3 phases baseline and active phase in which participants used the nasal dilator strip followed by 2 nights cross over nasal resistance phase in which participants were randomized to receive a sequence of strip/no strip or no strip/strip.||||
34001766|NCT04327336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Two investigators (named Investigator 1 and Investigator 2) participate in each center, with different tasks. Investigator 1 is responsible of randomization and will be aware of the study group assigned to the patient. Investigator 2 will collect in each visit health resource utilization, specific and QoL tests and laboratory test results. Investigator 2 does not know the study arm.~Patients will not be informed about the ventilator settings and the menu of the ventilator will be locked, so they cannot access to ventilator data."|Prospective, Randomized, double arm, double blind controlled trial.|t|f|t|f
33801593|NCT01753986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801594|NCT02379819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801595|NCT04965272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801596|NCT03011489|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801597|NCT03189472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697359|NCT06565208|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Participants, Sponsor and Investigator are masked during Parts A-C. Part D is an open-label cohort.|Single ascending dose cohorts and multiple ascending dose cohorts||||
33697360|NCT06612424|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697361|NCT00335920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697362|NCT02699359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697363|NCT06679829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697364|NCT01834118|||COHORT||PROSPECTIVE|||||||
33697365|NCT04871074|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697366|NCT03210623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, stratified-randomized, single-blind, parallel assignment, active control|t|f|f|f
33697367|NCT03326726|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697368|NCT04291131|||COHORT||PROSPECTIVE|||||||
33697369|NCT01818661|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697370|NCT04885920|||COHORT||PROSPECTIVE|||||||
33697371|NCT04112524|||OTHER||PROSPECTIVE|||||||
33697372|NCT01841177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697373|NCT05803629|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697374|NCT00001966||||TREATMENT||||||||
33697375|NCT01437085|||CASE_ONLY||PROSPECTIVE|||||||
33697376|NCT03339687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697377|NCT05922956|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33697378|NCT03308955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|prospective,randomized,single blind|t|f|f|f
33697379|NCT00277446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697380|NCT05352373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, double blind|t|f|t|f
33922180|NCT05400187|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|During the randomization session, the generated random numbers will be placed in opaque and tamperproof envelopes and sealed. Another independent person (other than statistician) will open all envelopes for eligible participants and responsible for arranging participants to undertake their corresponding treatments. Participants, investigators, and statistician will be concealed about the random allocation until each participant has been registered and the assignments have been made. The research assistant who will perform the outcome measures and the statistician are blinded to treatment group assignment.|"The intervention group will receive a convenient body composition measurement and 6-month smart-phone based individualized counselling. Through close collaborations with the experts in nutrition, we can effectively disseminate the knowledge of weight management and control and healthy diet to the middle-aged population.~No specific intervention will be given to the control group except the common anthropometric and body composition measurement."|f|f|t|t
33922181|NCT01742078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33922182|NCT03330041|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).|f|f|f|t
33922183|NCT03076918|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Split face intraindividual comparison||||
33922184|NCT05099237|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||The EMBRaCE-GM study is a multi-cohort trial designed to efficiently evaluate the range of wearable vital signs monitors. Each cohort is a distinct group of patients who undertake a feasibility study.||||
33697381|NCT00250523|||COHORT||PROSPECTIVE|||||||
33697382|NCT00309478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697383|NCT00494455|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697384|NCT03633617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697385|NCT00675259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697386|NCT06285344|||OTHER||CROSS_SECTIONAL|||||||
33697387|NCT05722457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participant and evaluator do not know who the groups are|2 groups will be formed using the random randomization model|t|f|f|t
33697388|NCT04186936|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33697389|NCT04794088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded trial in which the study participant and legal representative, as well as the treating nurses, physicians and researchers are blinded from viewing randomisation allocation.|Randomised, double-blind, parallel-group, placebo-controlled multi-centre clinical trial|t|t|t|t
33697390|NCT04633356|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients recruited to the study would receive measurement of the portal pressure gradient with the use of the EUS-guided technique||||
33697391|NCT05229978|||COHORT||PROSPECTIVE|||||||
33697392|NCT03816982|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized prospective noninferiority trial to assess the difference, if any, in median pain scores between two block methods using bupivacaine HCl and/or Liposomal bupivacaine, with the catheter method or single shot administration.||||
33697393|NCT06428682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697394|NCT06681168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922185|NCT04752943|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922186|NCT00361894|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922187|NCT01926470|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33922188|NCT05610358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33922189|NCT01313832|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33922190|NCT03505749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were made unaware of whether they were being randomized to the treatment or control group condition.||t|f|f|f
33922191|NCT00532428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922192|NCT05570799|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33922193|NCT00429052|||COHORT||PROSPECTIVE|||||||
33922194|NCT01392378|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922195|NCT06431178|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922196|NCT06524427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922197|NCT00733759|||COHORT||PROSPECTIVE|||||||
33922198|NCT03125759|||CASE_CONTROL||PROSPECTIVE|||||||
33922199|NCT04635761|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922200|NCT03918772|||COHORT||RETROSPECTIVE|||||||
33922201|NCT02553317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922202|NCT00904995|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922203|NCT06016140|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33922204|NCT05066633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922205|NCT05950971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blinded randomized controlled trial|t|f|f|f
33922206|NCT00048789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922207|NCT05606978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922208|NCT03436771|||COHORT||PROSPECTIVE|||||||
33922209|NCT03119818|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33922210|NCT04409301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Hospitals will be randomized to deliver the intervention or to be a control site. Children will be enrolled to ensure equal sized groups of younger (ages 3-6) and older (ages 7-10) children.||||
33922211|NCT02278991|||COHORT||PROSPECTIVE|||||||
33697395|NCT03985111|||COHORT||PROSPECTIVE|||||||
33697396|NCT04040244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922212|NCT03516409|RANDOMIZED|PARALLEL||TREATMENT||NONE|A multicenter, double blind, parallel group, placebo controlled, randomized study.|"Treatment groups: 6 - 35 months old.~* Bio-Kult Infantis~* Placebo (maltodextrine DE19)"||||
33922213|NCT04202549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001767|NCT06030128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||75 participants will be randomized into the intervention group. Another 75 participants will be randomized into the waiting list control group.|t|f|t|f
34001768|NCT03077022|||COHORT||PROSPECTIVE|||||||
34001769|NCT02451644|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922214|NCT06410924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33922215|NCT02581982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922216|NCT00165581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697397|NCT01645137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697398|NCT06085794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|1st patient in the PCNL group , 2nd patient in ECIRS group and so on .||t|f|f|f
33697399|NCT00072631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697400|NCT05240599|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33697401|NCT00783965|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33697402|NCT03049618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697403|NCT02395016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697404|NCT06558136|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697405|NCT02830061|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697406|NCT01470859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922217|NCT04780945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, Dutch, multicenter, single arm phase II study||||
33922218|NCT03101046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922219|NCT02633839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922220|NCT01760369|||CASE_ONLY||PROSPECTIVE|||||||
33922221|NCT06031298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922222|NCT02487134|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34001770|NCT05098951|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34001771|NCT02090933|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001772|NCT00000680||||TREATMENT||NONE||||||
34001773|NCT02297230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025123|NCT03535155|||COHORT||PROSPECTIVE|||||||
34025124|NCT06632587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The collection of outcomes will be performed without regard to the treatment versus control arm.||f|f|f|t
34025125|NCT02121392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025126|NCT03239223|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Up to two ascending dose cohorts (8 subjects per cohort) may receive multiple doses in 2 ascending dose strengths of ABI-1968 Topical Cream. After completing the multiple ascending dose portion a Cohort Expansion group of 32 to 40 subjects will be initiated.|t|t|t|f
33922223|NCT04613999|NA|SINGLE_GROUP||TREATMENT||NONE||The study is planned to enroll 15 subjects with open-label, fixed sequence, non-randomized to take a single dose of ralinepag at 3 separate dose intervals. Ralinepag will be administered at doses of 50, 100 and 150 mcg single oral each time. Subjects will receive Regimen A (single dose of ralinepag 50 mcg) in the morning of Day 1 and pharmacokinetic assessments will be conducted pre-dose and over the 96 hours post-dose. There will be a washout period of 7 days between each IMP administration. Regimens B and C (single dose of ralinepag 100 mcg and ralinepag 150 mcg) will be administered following an overnight fast on Day 8 and 15, respectively, with 96 hours of pharmacokinetic assessments as performed with Regimen A. A Follow-up phone call will take place 10±1 days post-last dose to ensure the ongoing well-being of the subjects.||||
34025127|NCT04198259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025128|NCT01398514|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33922224|NCT01174758|||COHORT||CROSS_SECTIONAL|||||||
33922225|NCT01928992|||COHORT||RETROSPECTIVE|||||||
33697407|NCT01904058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697408|NCT02851940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922226|NCT00565214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33922227|NCT00889681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922228|NCT04325906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025129|NCT01596660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025130|NCT02971098|NA|SINGLE_GROUP||TREATMENT||NONE||2 weeks of physical inactivity||||
34025131|NCT00293943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025132|NCT02591186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34025133|NCT04746794|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025134|NCT00026299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697409|NCT04439149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697410|NCT04888078|||COHORT||RETROSPECTIVE|||||||
33697411|NCT03054753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697412|NCT05639465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697413|NCT01455831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697414|NCT05938530|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated in a 1:1 ratio into either the treatment (sirolimus DCB) arm or control (stent graft) arm||||
34025135|NCT03840369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1: Treatment of the right dorsolateral prefrontal cortex Group 2: Treatment of the right dorsomedial prefrontal cortex|t|f|t|f
34025136|NCT06494462|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34025137|NCT01831401|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
34025138|NCT01307176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697415|NCT00082589|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33697416|NCT00020774||||TREATMENT||||||||
33697417|NCT02080910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33697418|NCT00277979|||CASE_ONLY||RETROSPECTIVE|||||||
33697419|NCT01822704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720080|NCT02715323|||COHORT||CROSS_SECTIONAL|||||||
33720081|NCT00259077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33720082|NCT02457910|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001774|NCT05380726|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The study will be triple-blind since, due to its nature (intervention using an eHealth tool), it will be possible to blind both the participants, researchers and statisticians. All the subjects (experimental and control) will receive the same electronic wrist device and eHealth tool. While experimental group receive specific information related to the parameters assessed in real time by the wrist device, the control group will receive general information about obstructive sleep apnoea.|We will carry out a mixed-method exploratory sequential investigation with a realistic evaluation approach. The use of this mixed methodology allows us to use the strengths of the qualitative and quantitative phases while reducing their weaknesses. Specifically, the sequential exploratory design includes an initial qualitative phase followed by a quantitative phase, with the aim of developing an educational tool. In this project it is proposed that both phases should have the same relevance (QUAL-QUAN) for the development of the educational tool and the development of the study should be carried out in three stages. During all phases of the project, the realistic evaluation approach will be taken into account, especially after the intervention, carrying out different semi-structured interviews and focus groups to redefine the cycle and optimize future research.|t|t|f|t
34001775|NCT02697617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33697420|NCT03603054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study sample will be randomly divide into 2 groups, a control group subject to a placebo technique and an intervention group subject to an active mobilization of the sciatic nerve.|t|f|f|f
33697421|NCT01969643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697422|NCT01869491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801598|NCT04572945|||OTHER||PROSPECTIVE|||||||
33922229|NCT05567393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922230|NCT03293628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The allocation of patients to one group or another was only known moments before the surgical procedure was started.|Patients were allocated in two arms (50 patients each): without vaginal pack (group 1 - GP1) and with vaginal pack (group 2 - GP2).Randomization was generated through a computer program creating a random entry list in the study, separating in group 1 (local application of Monsel's solution without intra-vaginal gauze buffer) and group 2 (application of Monsel's solution with intra-vaginal gauze). In this way, all patients had an equal chance of being included in both groups.|t|f|f|f
33922231|NCT05473104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33922232|NCT03674333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants of both the groups will be unaware of whether they received placebo or folic acid.|Group A receives Folic Acid and Group B receives Placebo.|t|f|f|f
33922233|NCT00348413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922234|NCT03335787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both group will receive conventional stroke rehabilitation. Intervention group will receive Kinesio taping and control group would not receive a sham taping due to the possible sensory intervention of sham taping even though applying it without any stretch.~Outcomes will be recorded by physical therapist using SPSS and groups would not be specified with letter. Statistical analysis will be conducted by another researcher who does not aware of groups given numbers on SPSS."|Patients' information and contact will be obtained from neurologist and willing participant's gender, age and stroke onset data will be processed with a random number generator in order to form groups. Patients will divide into two groups as intervention and control with a normal distribution of gender, age and stroke onset.|t|f|f|t
33922235|NCT02871401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922236|NCT05897112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922237|NCT04234763|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The meal challenge test (MCT) models are designed to be high glycemic index (GI) (GI=63, GL=25) and low GI meal (GI=46, GL=16), isocaloric (300kcal) with identical macronutrient distribution. The meals will be prepared on the morning of the test, portioned by weighing and served warm.|t|f|f|f
33922238|NCT03962556|||COHORT||PROSPECTIVE|||||||
33922239|NCT05619588|||COHORT||OTHER|||||||
33922240|NCT04603040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922241|NCT00764088|||CASE_CONTROL||RETROSPECTIVE|||||||
33922242|NCT04088331|||COHORT||PROSPECTIVE|||||||
33697423|NCT00562029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697424|NCT02511990|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697425|NCT00309738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697426|NCT04350866|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33697427|NCT04779697|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33697428|NCT00175695|||CASE_ONLY||PROSPECTIVE|||||||
33801599|NCT03858413|||CASE_ONLY||CROSS_SECTIONAL|||||||
33801600|NCT02934789|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33801601|NCT00700986|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33801602|NCT03327870|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801603|NCT04353531|||COHORT||PROSPECTIVE|||||||
34001776|NCT03892291|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001777|NCT04899076|||COHORT||PROSPECTIVE|||||||
34001778|NCT01096602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001779|NCT05157750|||COHORT||PROSPECTIVE|||||||
34001780|NCT06024148|||COHORT||CROSS_SECTIONAL|||||||
34001781|NCT06678009|RANDOMIZED|PARALLEL||OTHER||NONE||A total of 42 runners were randomly assigned to either the isokinetic training group with blood flow restriction (BFR Group; n= 21) or the isokinetic training group without blood flow restriction (Control Group; n= 21).||||
34001782|NCT04397640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cohort study in a single center||||
34089369|NCT04364490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physicians (carrying out the clinical baseline assessment \[T0\] and post-treatment investigation \[T1\]), as well as, the primary researcher and data entry assistants were all blinded to the group membership of the patients.|After a stroke this ability may become worse or completely lost. It was demonstrated that hemiparetic patients with poor trunk function at admission stayed longer in a rehabilitation ward compared to patients who had better initial trunk function and could walk longer distances with speed at discharge. The reinforcement of trunk exercises in addition to conventional therapy seems to have a beneficial effect on erection station balance and locomotion in post-stroke patients. In the light of current knowledge, early verticalization and reinforcement of trunk exercises improve posture, balance and mobility. In this study, consecutive patients at first ischemic stroke (documented with TAC / RMN) will be evaluated. Patients in the study group will receive 60 minutes of conventional neuromotor rehabilitation treatment and 60 minutes of treatment with Copernicus®. The control group will receive 120 minutes of conventional neuro motor rehabilitation treatment.|f|f|t|f
34089370|NCT01991795|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089371|NCT04926415|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participants will not be told if transcutaneous auricular vagus nerve stimulation (taVNS) or the sham procedure will be performed. However, it is possible that participants will find out that the stimulation is being performed by a mild tingling sensation associated with taVNS.|Research participants in three groups (normal weight, overweight, obese) will undergo 2 study days (at least one week apart) during which either transcutaneous auricular vagus nerve stimulation (taVNS) or a sham procedure will be performed. The order of the intervention (taVNS or sham procedure) on the two study days is randomized.|t|f|f|f
34089372|NCT02050204|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34089373|NCT06377917|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34089374|NCT01712516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801604|NCT04445870|||OTHER||RETROSPECTIVE|||||||
33801605|NCT00692042|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33801606|NCT03853161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801607|NCT00676091|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33801608|NCT03182816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001783|NCT06435325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001784|NCT04338334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34001785|NCT03685617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001786|NCT00973050|RANDOMIZED|PARALLEL||||NONE||||||
34001787|NCT05561257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001788|NCT04933240|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697429|NCT06357312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of the patient included in the study and the investigator evaluating the results|Prospective, comparative, randomized and double-blind study|t|f|f|t
33697430|NCT02463968|||COHORT||CROSS_SECTIONAL|||||||
33697431|NCT00904306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697432|NCT04475211|||COHORT||RETROSPECTIVE|||||||
33697433|NCT05382533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||parallel design|f|t|f|f
33697434|NCT06169293|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33697435|NCT00315536|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33697436|NCT01543971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697437|NCT01296438|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33697438|NCT04416633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697439|NCT05750160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697440|NCT04924959|||CASE_CROSSOVER||PROSPECTIVE|||||||
33697441|NCT01526772|||COHORT||PROSPECTIVE|||||||
33697442|NCT00415350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697443|NCT06681129|||COHORT||PROSPECTIVE|||||||
33697444|NCT00348179|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697445|NCT06529575|||OTHER||PROSPECTIVE|||||||
33697446|NCT05361421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697447|NCT00736957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697448|NCT06679868|||COHORT||PROSPECTIVE|||||||
33697449|NCT00444444|||CASE_CONTROL||PROSPECTIVE|||||||
33697450|NCT03588871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697451|NCT00725504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697452|NCT03516812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697453|NCT03366012|NA|SINGLE_GROUP||SCREENING||NONE||||||
33697454|NCT05131360|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33697455|NCT04855929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697456|NCT04909931|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33697457|NCT05733377|||CASE_ONLY||PROSPECTIVE|||||||
33697458|NCT03459482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Design|t|t|t|f
33697459|NCT06019585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient receive the correspondant treatment based on the order of an aleatory numbers table|2 parallel groups, each one receives one treatment|f|f|f|t
33697460|NCT01050491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697461|NCT00302263|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33697462|NCT00449410|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33697463|NCT05085574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind|Subjects randomized 1:1, study drug:placebo|t|f|f|f
33697464|NCT04908709|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697465|NCT06680908|||OTHER||OTHER|||||||
33697466|NCT01670318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001789|NCT00353821|||||OTHER|||||||
34001790|NCT06099964|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34001791|NCT03799224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients enrolled in this study would receive decitabine 200mg·m-2·d-1 on day -12 and -11 pre-HSCT. The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was modified BU/CY plus ATG. In matched sibling transplantations, patients received hydroxycarbamide (80 mg·kg-1) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, but otherwise an identical regimen to the HLA-mismatched patients without ATG.BM samples from patients would be obtained to assess leukemia status after HSCT. The time points that we monitored BM samples included at time of allo-HSCT; 1 month, 2 months, 3 months, 4.5 months, 6 months, 9 months, and 12 months after allo-HSCT; and every 6 months thereafter to the defined endpoints or for at least until 5 year after transplantation.||||
34001792|NCT02199119|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34001793|NCT00904280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001794|NCT05667597|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||the intervention is the blood sampling||||
34089375|NCT02205645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089376|NCT04111315|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Comparison (A): participants, care provider, and Investigators will be blinded Comparison (B): Investigators will be blinded|Patients are assigned into one of the four groups metamizole + educational intervention metamizole + standard care ibuprofen + educational intervention ibuprofen + standard care Comparison (A): metamizole vs. ibuprofen for pain (NRS) at day 14 Comparison (B): short educational interventions vs. standard care for Disability (COMI) at day 42|t|t|t|t
33697467|NCT04697056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind||t|t|t|t
34089377|NCT04858711|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089378|NCT00475332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089379|NCT02606305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089380|NCT02039349|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34089381|NCT00953433|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34089382|NCT05035316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, researchers and clinicians will be masked for the intervention|Double-blinded randomized placebo-controlled trial|t|t|t|t
33697468|NCT05893875|||COHORT||RETROSPECTIVE|||||||
33697469|NCT06202690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator will explain the study at the time of consent for the surgery. Written consent will be obtained by the principal investigator or a sub-investigator. Once eligibility for surgery is confirmed, randomization will take place within 4 weeks prior to the surgery. Participants will be randomized in a 1:1 ratio to either SP-RATS or SP-VATS using a website software randomization system. While the surgeon will be informed of the group allocations, participants will remain unaware (maintaining a single-blind approach) until the completion of the follow-up period|This trial is a single-center, single blinded, randomized controlled trial). Participants will be randomized in a 1:1 ratio to either to single-port video-assisted thoracoscopic surgery (SP-VATS) or single-port robotic-assisted thoracic surgery (SP-RATS).|t|f|f|f
33697470|NCT01896336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697471|NCT03594734|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Randomized Controlled Trial (RCT).~Participants will be randomized into two group: (1) the GLB Intervention Group and (2) the Attention Control Group."|f|f|f|t
33697472|NCT02919098|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33697473|NCT00767949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922243|NCT00226967|||COHORT||PROSPECTIVE|||||||
33922244|NCT02428972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33922245|NCT00217516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922246|NCT05632029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922247|NCT04090268|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Analytical study, stratified, evaluating the impact of a non-pharmacological treatment (training)||||
33922248|NCT02243917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922249|NCT05351710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697474|NCT01642407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697475|NCT04953351|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33697476|NCT03193190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697477|NCT00718302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720083|NCT03707314|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre parallel design||||
33922250|NCT05161754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922251|NCT00951327|||COHORT||PROSPECTIVE|||||||
33922252|NCT04668794|||CASE_ONLY||RETROSPECTIVE|||||||
33922253|NCT00326521|||CASE_CONTROL||PROSPECTIVE|||||||
33922254|NCT04182789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922255|NCT06196918|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922256|NCT06226558|||COHORT||PROSPECTIVE|||||||
33922257|NCT00352950|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922258|NCT04545398|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33922259|NCT04514926|||COHORT||CROSS_SECTIONAL|||||||
33922260|NCT03716453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922261|NCT01324934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922262|NCT04849819|||COHORT||PROSPECTIVE|||||||
33922263|NCT05843812|||COHORT||PROSPECTIVE|||||||
33922264|NCT04087408|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922265|NCT03558451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only primary care midwives know and apply the intervention|Multicentre randomized clinical trial with groups in parallel, controlled single-blind, with blind evaluation of the response variable, held in the Community of Madrid|t|f|f|t
34001795|NCT03316157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised (1:1) unblinded feasibility trial of a rehabilitation programme (exercise and nutrition) versus waiting list control, in patients with advanced cancer||||
33697478|NCT06496464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The MASTER teacher education program is developed and designed based on the findings of a pilot study by the research team at the University of Newcastle. The basis of MASTER is the so-called positive teaching, and the concept is fostered and promoted through the teaching practices based on the games; its targets include six critical sports teaching elements, which are proven to promote well-being, health, and physical outcomes in children. Eather, Jones, et al. (2020) have demonstrated that PE teachers try to make use of the MASTER framework, which is not only user-friendly but also evidence-based, as a practical instrument when planning and delivering sessions of soccer training with high quality, which meets the interests of children such as exercise, teamwork, skill development, and success, and helps the children to improve learning and give full play to the potential."|t|f|f|t
33922266|NCT02109848|||COHORT||PROSPECTIVE|||||||
33922267|NCT00347035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922268|NCT02258945|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33922269|NCT01566201|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33922270|NCT03343470|||COHORT||PROSPECTIVE|||||||
33922271|NCT04007913|NA|SINGLE_GROUP||TREATMENT||NONE|True masking not possible due to single-arm design. However, independent evaluator is blind to treatment utilization and progress.|||||
33922272|NCT04083001|NA|SINGLE_GROUP||TREATMENT||NONE||open study||||
33922273|NCT04197518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922274|NCT04219969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922275|NCT00717535|||||PROSPECTIVE|||||||
33922276|NCT02451540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922277|NCT01372449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922278|NCT00783172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922279|NCT02543502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922280|NCT02986919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922281|NCT05568927|||COHORT||PROSPECTIVE|||||||
33922282|NCT01928563|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697479|NCT01066000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922283|NCT01529814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922284|NCT00373100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001796|NCT01824576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001797|NCT03358147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind vs Placebo, Open Label Spiriva Respimat|Linear repeated measures model|t|t|t|t
34001798|NCT06492551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001799|NCT05355519|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Megacode evaluators will be masked to the arm in which the participants are randomized.|The investigators will perform a prospective, single-blinded randomized cross-over trial of the OBLS intervention.|f|f|f|t
34001800|NCT00999362|||||PROSPECTIVE|||||||
34001801|NCT03519438|||COHORT||PROSPECTIVE|||||||
34001802|NCT03252717|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697480|NCT04288271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants (patient-, parent- and HCP-participants) will be blinded to group allocation but, given the nature of the intervention, study coordinators who will be acting as coaches must be aware of group allocation.||t|f|f|f
33697481|NCT02890667|||COHORT||RETROSPECTIVE|||||||
33697482|NCT03202888|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33697483|NCT03660345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697484|NCT05863338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was conducted as the randomized controlled experimental trial.||||
33697485|NCT05460260|||COHORT||PROSPECTIVE|||||||
33697486|NCT05838573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two groups were observed longitudinally for 24 weeks.|t|t|t|t
33697487|NCT00763048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697488|NCT04467931|||COHORT||RETROSPECTIVE|||||||
33697489|NCT01370850|||COHORT||PROSPECTIVE|||||||
33697490|NCT04872153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720084|NCT00745472|||||PROSPECTIVE|||||||
33720085|NCT03341533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720086|NCT00867425|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922285|NCT01236859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922286|NCT04715048|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The two different neurotoxins will be drawn into identical appearing syringes by an unblinded investigator. The injector will be a blinded investigator and will not know which syringe has which neurotoxin. There is no difference in appearance of the product when in a standardized syringe. The PI and co-investigator will be graders of these images and will be blinded during the grading process.||t|f|t|t
33922287|NCT01691287|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33922288|NCT00618995|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33922289|NCT04655963|NA|SINGLE_GROUP||TREATMENT||NONE||All participants would receive open-label treatment for approximately eight, 3-minute sessions of intermittent theta burst rTMS on each of three days within a seven-day span.||||
34001803|NCT00881231|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001804|NCT00399724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001805|NCT05694260|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001806|NCT06151002|||COHORT||OTHER|||||||
34001807|NCT04109430|||COHORT||PROSPECTIVE|||||||
34001808|NCT00547625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001809|NCT06293430|||COHORT||PROSPECTIVE|||||||
34001810|NCT00691704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001811|NCT04479735|RANDOMIZED|PARALLEL||OTHER||NONE||randomized non blinded study||||
34001812|NCT00666354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001813|NCT03241186|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34001814|NCT01214239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001815|NCT02043431|||COHORT||PROSPECTIVE|||||||
33697491|NCT05221307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatments will be carried out by the same physiotherapist. Evaluations will be made twice, before and after the treatment. All assessments will be made by a different physician physiotherapist who is unfamiliar with the treatment groups. Individuals with CP in the study groups will continue with a blind physiotherapist experienced in pediatric rehabilitation who has completed the training in modified pilates, is certified by The Australian Physiotherapy Pilates Institute (APPI) and has NDT-Bobath certification.|The intervention will be rehabilitation methods applied with different exercise trainings, Neurodevelopmental Therapy (NGT-Bobath) will be applied to one group and Modified Pilates Exercises (MPE) (non-invasive) will be applied to the other group.|f|f|t|f
33697492|NCT00815607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697493|NCT02907580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33922290|NCT02789605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922291|NCT04588831|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33922292|NCT04101058|||COHORT||PROSPECTIVE|||||||
33922293|NCT01778400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922294|NCT03181074|||COHORT||PROSPECTIVE|||||||
33922295|NCT03114878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922296|NCT01749813|||COHORT||PROSPECTIVE|||||||
33922297|NCT00284739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922298|NCT04225884|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33922299|NCT01634945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33922300|NCT05698043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697494|NCT05901311|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33697495|NCT05239442|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33697496|NCT06680011|||COHORT||PROSPECTIVE|||||||
33697497|NCT06025643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697498|NCT05862597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33697499|NCT00424801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697500|NCT03615573|||COHORT||PROSPECTIVE|||||||
33697501|NCT06173934|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922301|NCT00568282|||COHORT||PROSPECTIVE|||||||
33922302|NCT03874351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922303|NCT02340468|||CASE_CONTROL||PROSPECTIVE|||||||
33922304|NCT01736631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922305|NCT06236230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922306|NCT06155240|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort||||
33922307|NCT05836129|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The statistician will not be aware of which arm the participants are in.|This is a randomized controlled trial|f|f|f|t
33922308|NCT03982238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922309|NCT03350867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) The one who assess the patients in the beginning and in the final moment (investigator) not know what group the patient is. The participants don't know if they are using a placebo or personalized insole.|Two groups: a Personalized Insole Group and a Placebo Group.|t|f|f|t
33922310|NCT05602285|||COHORT||PROSPECTIVE|||||||
33922311|NCT02253641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922312|NCT03461432|NA|SINGLE_GROUP||TREATMENT||NONE||A case-control study design with pre- and post-therapy assessment.||||
33922313|NCT02521389|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33922314|NCT00671723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922315|NCT03199638|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34001816|NCT06677736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001817|NCT01780467|NON_RANDOMIZED|PARALLEL||||NONE||||||
33697502|NCT04920981|||COHORT||RETROSPECTIVE|||||||
33697503|NCT03861650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blinded|Case-control trial|t|t|f|f
33922316|NCT01746940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922317|NCT00387348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33922318|NCT03078023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922319|NCT01932931|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Vitamin D supplementation and placebo are given as tablets, manufactured by the same company, and with equal size, shape, and taste.|"Two models are used, both a cross sectional study and a RCT. Corss sectional study: Patients (n=21) treated with citalopram (SSRI) due to major depressive disorder (MDD) are investigated for changes in bone mineral density, physcial performance (muscle strength, mobility, and balance), and pain sensitivity when compared to healthy controls (n=50).~RCT: Half of the patients and half of the controls are randomised (by double-blinding) to recieve either high dose vitamin D supplementation (2000 IU/day) of placebo for 12 months. All the primary endpoints from the cross sectional study will be assessed again after 6 and 12 months."|t|t|t|t
33922320|NCT00357149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922321|NCT04130035|||COHORT||PROSPECTIVE|||||||
33922322|NCT02319213|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922323|NCT01617512|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33922324|NCT03082053|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||2 studies of single group in 1 protocol||||
33922325|NCT03602924|||COHORT||PROSPECTIVE|||||||
33922326|NCT01922245|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33922327|NCT00148421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922328|NCT02268448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922329|NCT05840978|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33922330|NCT02576457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922331|NCT05445518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922332|NCT06391944|NA|SINGLE_GROUP||TREATMENT||NONE||For cohort 1, patients received JMT101 6mg/Kg Q3W and Osimertinib 80mg QD. For cohord 2, patients received JMT101 6mg/Kg Q2W and Osimertinib 80mg QD.For cohort 3 and cohort 4, patients were randomized 1:1 to JMT101 6mg/Kg and Osimertinib 80mg or JMT101 6mg/Kg and Osimertinib 160mg.||||
33922333|NCT06042530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33922334|NCT04600219|||COHORT||PROSPECTIVE|||||||
33922335|NCT01226706|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34001818|NCT03318757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001819|NCT05419505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001820|NCT04411017|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|f|t
34001821|NCT04619862|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Both active drug and placebo will be masked in a liquid formulation, and administered via the same route (oral, direct gastric route, or direct jejunal route) depending on the subject's usual feeding approach. The label applied to the bottle will be blinded and identical flavouring will be added to the drug and placebo for additional masking.|This trial uses a single randomized multiple-measures cross-over design (N-of-1), with results aggregated over several subjects. In the trial, each patient will switch between gabapentin (G) and placebo (P). The sequence of whether G precedes P (GP) or P precedes G (PG) will be randomized and neither the clinician nor the subject (parent/caregiver) will know the sequence. Each subject will serve as their own control and experiment, allowing for a finer assessment of the treatment efficacy within each patient.|t|t|t|f
34001822|NCT02753465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922336|NCT00842361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922337|NCT01553071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922338|NCT01925612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922339|NCT05779345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922340|NCT02174783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001823|NCT02569528|||OTHER||PROSPECTIVE|||||||
34001824|NCT05317806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will have one metformin Treatment group (daily metformin administered) and one Observation group (no study drug administered)||||
33697504|NCT04932759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Control and study group||||
33697505|NCT00003099|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33697506|NCT06681493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697507|NCT04786392|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33922341|NCT02079051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922342|NCT00628758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922343|NCT01804036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922344|NCT01176370|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled/consented subjects receive study device: C-Pulse™ (Implantable Counterpulsation Therapy).||||
33922345|NCT01462682|||||RETROSPECTIVE|||||||
33922346|NCT01957709|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||100 mcg/m2 weekly injection for four weeks||||
33697508|NCT06019949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unidentified data sets will be processed and evaluated by the research staff not directly involved in experimental procedures.|"Thirty-six SCI participants will be randomly assigned to three groups (n=12 in each group): those who receive RT alone, scTS alone, or a combination of both (scTS+RT).~After screening and recruitment, primary and secondary outcome measurements will be obtained in the Lab at the following time points: 1) Pre-intervention, after 30-days without any stimulation and/or intervention, 2) Post mapping, (participants with scTS), 3) Post Session #40 (after 8 weeks of intervention), 4) Post Session #80 (after 16 weeks of intervention), and 5) twice during 16-weeks Follow-up Period. In total, it is anticipated that 6 measurements will be obtained for each participant with scTS and 5 measurements for participants without scTS."|f|f|f|t
33697509|NCT00343590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697510|NCT02739165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697511|NCT05464550|NA|SINGLE_GROUP||OTHER||NONE||||||
33697512|NCT02443116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697513|NCT01652443|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697514|NCT02955797|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697515|NCT00836030|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33697516|NCT05529381|||COHORT||PROSPECTIVE|||||||
33697517|NCT04043728|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697518|NCT00100061|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33697519|NCT04754243|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel groups each is receiving different intervention||||
33697520|NCT02484183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922347|NCT00083343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922348|NCT03905668|||CASE_ONLY||PROSPECTIVE|||||||
33697521|NCT05700318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697522|NCT04965909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind (researcher and statistician)|A Randomized Controlled Clinical Trial of two groups (experimental and control) will be carried out.|f|f|t|t
33922349|NCT06174883|||CASE_ONLY||PROSPECTIVE|||||||
33697523|NCT00514423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922350|NCT04280406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||double-masked parallel arm randomized clinical trial|t|t|t|t
33697524|NCT05490771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697525|NCT03328156|||COHORT||PROSPECTIVE|||||||
33697526|NCT06175975|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized controlled experimental study||||
33697527|NCT00261079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922351|NCT04248062|||COHORT||OTHER|||||||
33922352|NCT01216397|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922353|NCT06376370|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33922354|NCT02451033|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33922355|NCT05953571|||CASE_CONTROL||RETROSPECTIVE|||||||
33922356|NCT06207929|||OTHER||PROSPECTIVE|||||||
33922357|NCT04031404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The researcher that interacts with the subject will not know whether the subject consumed the glucose drink or the placebo.||f|f|t|f
33922358|NCT04219488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded|Parallel Assignment|t|f|f|t
33922359|NCT04929418|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Trial participants will participate sequentially in two tests that involve high intensity physical exercise (10 km continuous running and 1.5 km continuous swimming). Both tests will be separated from each other a minimum of 30 days.||||
33922360|NCT00653913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922361|NCT02894528|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922362|NCT02645279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33922363|NCT02895412|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922364|NCT02030470|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33922365|NCT02515708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922366|NCT02576015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922367|NCT06364683|||OTHER||CROSS_SECTIONAL|||||||
33922368|NCT01812070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922369|NCT00960713|||COHORT||PROSPECTIVE|||||||
33922370|NCT01019252|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33922371|NCT01359046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33922372|NCT00547898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697528|NCT05053711|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33922373|NCT02640066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922374|NCT03585673|NA|SINGLE_GROUP||TREATMENT||NONE||Docetaxel-PM + Oxaliplatin D1,8 every 3weeks until progression||||
33922375|NCT01847261|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33922376|NCT03746067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33922377|NCT05049447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922378|NCT04961060|||COHORT||PROSPECTIVE|||||||
33922379|NCT00168324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922380|NCT00984880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922381|NCT04129086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922382|NCT04365894|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33922383|NCT05006339|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922384|NCT00476177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922385|NCT01884961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025139|NCT04702243|||COHORT||CROSS_SECTIONAL|||||||
34025140|NCT01707719|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34025141|NCT03005912|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33697529|NCT05420792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025142|NCT03195335|||CASE_ONLY||PROSPECTIVE|||||||
34089383|NCT04512495|NA|SINGLE_GROUP||OTHER||NONE||||||
34089384|NCT00320996|||COHORT||PROSPECTIVE|||||||
34089385|NCT02078466|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089386|NCT02329158|||COHORT||RETROSPECTIVE|||||||
34089387|NCT05355220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089388|NCT00003308||||TREATMENT||||||||
34089389|NCT00942019|||COHORT||CROSS_SECTIONAL|||||||
34089390|NCT02452411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089391|NCT01579864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34089392|NCT01799083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089393|NCT02145819|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34089394|NCT00134719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089395|NCT03665545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089396|NCT02049658|||COHORT||PROSPECTIVE|||||||
34089397|NCT04305600|||COHORT||PROSPECTIVE|||||||
34089398|NCT06167902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922386|NCT05094895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the first period are the patients and investigators blinded. Afterwards there is an open label period.|Patients will receive the Stretta treatment or the Sham treatment. Patients assigned to the Sham treatment condition, will have an open label period and are able to receive the Stretta treatment as wel.|t|t|f|f
34089399|NCT00080626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089400|NCT03772236|||CASE_ONLY||CROSS_SECTIONAL|||||||
33922387|NCT03843736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will collect 50 healthy participants and 150 PCOS participants. At the same time, 150 patients with PCOS will be randomly divided into the lifestyle intervention group, lifestyle interventions + Probiotic Agent group, lifestyle intervention + oral contraceptive group by random number table method.|f|f|f|t
34089401|NCT01647178|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34089402|NCT00319371|||CASE_CONTROL||PROSPECTIVE|||||||
33697530|NCT03078907|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33922388|NCT04848415|||COHORT||PROSPECTIVE|||||||
33922389|NCT02839941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922390|NCT06177119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922391|NCT02014727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922392|NCT02016729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922393|NCT06315582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized using www.randomizer.org algorithm. They will be assigned to arm in the operating room where they will get that intervention. When they get to Post Anesthesia Care Unit, they will be unblinded. Surgeon will be blinded until patient is in operating room and envelope with randomization is opened.|Randomized single blinded study|t|t|f|f
33922394|NCT02401087|||COHORT||PROSPECTIVE|||||||
33922395|NCT02282176|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922396|NCT02637440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922397|NCT05246670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33922398|NCT02677818|||COHORT||PROSPECTIVE|||||||
33922399|NCT00356057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922400|NCT03852160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922401|NCT02565732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922402|NCT01081821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922403|NCT01165099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33922404|NCT03870685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients randomized to TAP block with liposomal bupivacaine OR surgical site infiltration of liposomal bupivacaine for postoperative analgesia after undergoing midline laparotomy|t|f|f|f
33922405|NCT04345406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089403|NCT03579537|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One group who perform 3 first month just with normal treatment of hemodialysis and the next 3 month exercise intervention. (6 months in total)||||
34089404|NCT04908618|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||control clinical trial|f|f|f|t
34089405|NCT00750334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089406|NCT03090906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34089407|NCT06432439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089408|NCT04966429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089409|NCT02196233|||COHORT||PROSPECTIVE|||||||
34089410|NCT02838355|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34089411|NCT02313155|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089412|NCT03641365|RANDOMIZED|PARALLEL||OTHER||SINGLE|An expert blinded mechanical engineer (FC) performed all the measurements. Post-operative STL files were sent with a code, without indicating patient's group.|Randomized controlled trial of parallel group design conducted at one centre.|f|f|f|t
33697531|NCT02298686|||COHORT||PROSPECTIVE|||||||
33697532|NCT04957160|||CASE_ONLY||RETROSPECTIVE|||||||
33697533|NCT01638767|RANDOMIZED|PARALLEL||||NONE||||||
33697534|NCT00394446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697535|NCT01863953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697536|NCT00585390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697537|NCT05840718|||OTHER||RETROSPECTIVE|||||||
33697538|NCT01457820|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33697539|NCT02091908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33697540|NCT00227929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001825|NCT05995873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the treater knows whether the participant receives the sham or active treatment.|130 participants will be treated with unilateral transcranial photobiomodulation to their brain hemisphere with a more positive emotional valence. Half will receive sham and half active. Treatment will be 2 times a week for 4 weeks, then once a week for 20 weeks and then a followup 1 week later. The study will be half at MindLight, LLC and half at McLean Hospital.|t|t|t|f
34001826|NCT06375187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001827|NCT00079495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001828|NCT05533034|NA|SINGLE_GROUP||OTHER||NONE||||||
34001829|NCT05797870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001830|NCT05760261|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study.|||||
34001831|NCT00377156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785837|NCT06630624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Firstly, a phase 1, dose-escalation study according to a classic '3+3' design will be performed to determine the maximum tolerated dose (MTD) of intra-tumoral IP-001 injection following MWA. In phase 2 part 1, a single arm study will be performed with the optimal dose found in phase 1 to assess efficacy of intra-tumoral IP-001 injection following MWA in patients with CRLM who will receive the ablation for curative intent. Phase 2 part 2 will be conducted in parallel to phase 2 part 1 as a randomized, 3-armed study assessing the efficacy and immunomodulation of intra-tumoral IP-001-injection following three ablative modalities (arm A (RFA), arm B (MWA) or arm C (IRE)) in patients with refractory metastatic CRC.||||
33785838|NCT01760044|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33785839|NCT02043717|||COHORT||PROSPECTIVE|||||||
33785840|NCT02419521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785841|NCT03474562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785842|NCT00265161|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33785843|NCT01007708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785844|NCT00143650|NON_RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33785845|NCT02405390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785846|NCT04827459|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785847|NCT01300832|NA|SINGLE_GROUP||SCREENING||NONE||||||
33801609|NCT00005677|||COHORT||PROSPECTIVE|||||||
33922406|NCT02651792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922407|NCT00854256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922408|NCT01833741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922409|NCT02031432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922410|NCT05566821|NA|SINGLE_GROUP||OTHER||NONE||||||
33922411|NCT02090985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922412|NCT06371664|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, triple-blind clinical trial|f|t|t|t
33922413|NCT04694625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922414|NCT03125577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922415|NCT05581706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922416|NCT02487888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33922417|NCT02169804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922418|NCT01146041|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922419|NCT04656288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922420|NCT05289076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922421|NCT03819218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922422|NCT00830960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922423|NCT04685499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801610|NCT06282822|||COHORT||PROSPECTIVE|||||||
33801611|NCT02538341|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33801612|NCT03949413|||COHORT||RETROSPECTIVE|||||||
33801613|NCT05802069|||OTHER||OTHER|||||||
33801614|NCT01307267|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801615|NCT01876602|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33801616|NCT02204982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801617|NCT01436708|||CASE_ONLY||PROSPECTIVE|||||||
33801618|NCT02730923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801619|NCT04570592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922424|NCT06355401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33922425|NCT01311232|||CASE_CONTROL||RETROSPECTIVE|||||||
33922426|NCT02320630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922427|NCT03056807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"The person measuring and recording the study data (timer) will be blinded."||f|f|f|t
33922428|NCT03131986|||CASE_ONLY||PROSPECTIVE|||||||
33922429|NCT02769078|||COHORT||RETROSPECTIVE|||||||
33922430|NCT05651217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001832|NCT00633698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001833|NCT04830007|||COHORT||PROSPECTIVE|||||||
34001834|NCT05820919|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a wedge- based cluster randomized, controlled trial (RCT) design with each NH acting as its own control. The unit of random assignment is the NH. There are 24 NHs - 8 from each of 3 corporations. Each NH serves as its own control. Control data are collected for 1 week, then the intervention will begin with intervention data collected for 15 weeks (10-week active intervention period, and five-week sustainment period). All NHs are assigned to the control group and then phased into the intervention group at 37-week intervals (steps). Our stepped wedge design has 4 steps with 6 NHs per step (2 NHs per corporation per step). We will randomly assign the order in which the 8 NHs within each corporation are phased into the intervention group. We will randomize NHs within corporations to steps after matching on bed size and number of long-stay residents with ADRD diagnoses.||||
34001835|NCT00926367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001836|NCT02214563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34001837|NCT03324217|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34001838|NCT04960761|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34001839|NCT04189120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34001840|NCT04634630|||COHORT||PROSPECTIVE|||||||
34001841|NCT04476563|||COHORT||PROSPECTIVE|||||||
34001842|NCT02571634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001843|NCT05074706|||COHORT||PROSPECTIVE|||||||
34001844|NCT03439995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes in donors and lung transplant recipients will be done by assessors who are blinded to ventilator treatment assignment|Enrolled donors will be randomly assigned to two different modes of mechanical ventilation for the duration of donor management|f|f|f|t
34001845|NCT05959616|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34001846|NCT00691041|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001847|NCT05252234|||COHORT||PROSPECTIVE|||||||
34001848|NCT01833754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001849|NCT02630316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001850|NCT05848440|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The participant and the Clinical Unit staff will remain blinded during the dosing phase of the study.|Placebo-control|t|f|t|f
34001851|NCT03700190|||COHORT||PROSPECTIVE|||||||
34001852|NCT00564343|||COHORT||PROSPECTIVE|||||||
34001853|NCT05389241|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34001854|NCT04188808|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34001855|NCT01557751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089413|NCT04919161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and care providers are unable to be masked to the intervention arm due to the nature of the study. As data was extracted, investigators were unable to blind the data prior to exporting.|Quasi-randomized controlled pilot study evaluating the efficacy of a recently developed, not yet reported, balance perturbation module for the ZeroG body weight support system known Training Responses in Postural rehabilitation (TRiP).||||
34001856|NCT01513395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34089414|NCT04866199|||COHORT||PROSPECTIVE|||||||
34089415|NCT00036426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089416|NCT03473197|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089417|NCT01513499|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34001857|NCT00943813|||COHORT||PROSPECTIVE|||||||
34001858|NCT06439394|||COHORT||PROSPECTIVE|||||||
34001859|NCT01524016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001860|NCT01507233|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34001861|NCT06090708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34001862|NCT04096651|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34001863|NCT02752334|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34001864|NCT05384457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001865|NCT00003700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001866|NCT01112891|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34001867|NCT00844870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34001868|NCT06423196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Three assessments will be made throughout the study: before the intervention (T0), after the experimental phase (T1) and after a 4-week follow-up period (T2). All variables will be assessed by an evaluator blinded to the assignment of the athletes to the study groups.||f|f|f|t
34001869|NCT02413008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001870|NCT01732679|||COHORT||PROSPECTIVE|||||||
34001871|NCT05814068|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697541|NCT00487682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697542|NCT06558084|||COHORT||PROSPECTIVE|||||||
33697543|NCT01744431|||CASE_ONLY||PROSPECTIVE|||||||
33697544|NCT06680778|||COHORT||PROSPECTIVE|||||||
33697545|NCT06557486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697546|NCT06623682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697547|NCT05686954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blinded to which group they are in and what oil they are receiving.|Four groups of 28-day parallel feeding trials with three groups receiving different amounts of cottonseed oil (low, mid, high) and one group serving as control receiving a mixture of oils that match the fatty acid profile of the average American diet.|t|f|f|f
33697548|NCT05029700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001872|NCT03510507|||COHORT||RETROSPECTIVE|||||||
34001873|NCT05333653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34001874|NCT03740191|NA|SINGLE_GROUP||OTHER||NONE||||||
34001875|NCT02910596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001876|NCT01209988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001877|NCT05983523|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
33697549|NCT06236620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34001878|NCT06678386|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34001879|NCT04997720|NA|SINGLE_GROUP||OTHER||NONE|The evaluation will be in charge of the teacher who will record the practical evaluation. Then all the videos will be analyzed blindly by a neurosurgeon with experience in microsurgery. Statistical analyzes will also be analyzed blindly.|||||
34001880|NCT03208517|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34001881|NCT04551183|NA|SINGLE_GROUP||OTHER||NONE||"This study is comparative, retrospective, monocentric, open, controlled. We compare the SaMD to the Gold Standard. The data used are CT scans which have already been analysed by the doctors. The study will be realised on a group of 40 subjects which is small enough to have one site of investigation. Subjects will be their own witness. This investigation is NRIPH regarding the Loi Jardé since it is on retrospective data.~Pivotal stage: pivotal, confirmatory, and interventional clinical investigation. This premarket study aims is to confirm the clinical performance, efficiency, and the security of the medical device PRAEVAorta. To do so, a hypothesis has been defined (cf. VI.2.) and the number of patients has been strictly defined and justified (VII.3).~CT scan images of patients are analyzed by the surgeons and then by the software under investigation. The results are then compared."||||
34001882|NCT04194151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|aleatory assignation, time measured by nurses, drugs administrated by principal investigator|2 time groups, divided into 3 dose groups|t|f|f|f
34001883|NCT02005562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001884|NCT01087034|||COHORT||PROSPECTIVE|||||||
34001885|NCT05189691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||prospective randomized controlled clinical trial|t|f|f|t
34001886|NCT05941611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34001887|NCT06604195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor is blinded to the treatment allocation to the participants.|The participants in this study are allocated in two groups, group 1 and group 2.|f|f|f|t
34001888|NCT03670719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the evaluator is blinded||f|f|f|t
34001889|NCT06363240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001890|NCT03541239|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34001891|NCT04939558|||COHORT||PROSPECTIVE|||||||
34001892|NCT03711357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All the participants will be blinded, as they will not know which interventional group they belong to|A trial with two parallel groups|t|f|f|f
34001893|NCT05701124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single masking||t|f|f|f
34001894|NCT01227070|||COHORT||PROSPECTIVE|||||||
34001895|NCT04192929|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Randomization cards will be sealed and opened after the subject is deemed eligible for the study by the PI. This will be done in an area away from the subject but due to the nature of the study, PI can't be blinded.||t|f|f|f
34001896|NCT05580887|||COHORT||PROSPECTIVE|||||||
34001897|NCT00003615||||TREATMENT||||||||
34089418|NCT03972033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors doesn't know the patient group assignment.|The design of the study is a randomized controlled clinical trial.|f|f|f|t
34089419|NCT05324189|||COHORT||PROSPECTIVE|||||||
34089420|NCT01614704|||COHORT||PROSPECTIVE|||||||
33697550|NCT01517685|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34089421|NCT05538845|||COHORT||RETROSPECTIVE|||||||
33697551|NCT03166878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697552|NCT01354587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697553|NCT02420158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697554|NCT00473473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697555|NCT05736510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Parallel Assignment A prospective randomized study|f|f|t|t
33697556|NCT05782712|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33697557|NCT01522807|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33697558|NCT00006223|RANDOMIZED|||TREATMENT||||||||
33697559|NCT01317381|||COHORT||PROSPECTIVE|||||||
33785848|NCT03613103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be assigned at the time of anesthetic induction in the surgery room. The allocation to the direct laryngoscopy group and the video laryngoscopy will be 1: 1 randomly using permuted blocks, generated by a computer operated by an external assistant to the investigation. The size of the blocks will be between 4, 6, and 8.~A person external to the research group will be responsible for concealment of allocation through opaque and sealed envelopes, listed sequentially."|A single-center randomized study is performed including non-cardiac surgical patients without predictable risk of difficult mask ventilation or of difficult tracheal intubation. For direct laryngoscopy group, we use a Macintosh blade and for videolaryngoscopy group we use videolaryngoscopy highly curved blade. Induction of anesthesia is performed using myorelaxation with rocuronium. We record each five minute the vital signs in the anesthesia record. The primary outcome is observed injuries in the mucosa of the airway: Erythema, edema, ecchymosis, laceration, excoriation and / or hematoma. Injuries to dental pieces: Partial and / or total loss of tooth integrity, loosening of dental piece, damage to dental and / or aesthetic prosthetic material. Laryngeal lesions: Edema, laceration, excoriation, erythema, ecchymosis and / or bleeding pharyngeal laryngeal mucosa, arytenoid luxation. Post-intubation symptoms: Sore throat, dysphonia and / or aphonia.|t|f|t|t
33785849|NCT03853733|||COHORT||RETROSPECTIVE|||||||
33785850|NCT02511704|RANDOMIZED|CROSSOVER||||NONE||||||
33785851|NCT06027151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind, patient was unaware of which drug they were administered. It was done by covering the syringes with colored tapes||t|f|f|f
33785852|NCT05753917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot, parallel-group, single-blinded, split-mouth, randomized clinical trial|t|f|f|t
33785853|NCT00953485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785854|NCT03518983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785855|NCT06200402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33697560|NCT02590926|||COHORT||PROSPECTIVE|||||||
33697561|NCT04634799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, randomized (1:1)||t|t|t|f
33697562|NCT06325371|||COHORT||CROSS_SECTIONAL|||||||
33697563|NCT01347229|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697564|NCT02329821|||CASE_CONTROL||PROSPECTIVE|||||||
33697565|NCT00221260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697566|NCT06046833|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Same intervention for two cohorts||||
33697567|NCT06337422|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33697568|NCT02502175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697569|NCT03325088|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33785856|NCT05365529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785857|NCT02770859|||CASE_ONLY||PROSPECTIVE|||||||
33785858|NCT06540196|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33785859|NCT02127476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785860|NCT01535430|||COHORT||PROSPECTIVE|||||||
33922431|NCT06282419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a study that evaluates the effects on mothers by involving fathers in the pregnancy follow-up process through the use of mobile ultrasound.||||
33922432|NCT02822846|||CASE_ONLY||PROSPECTIVE|||||||
33922433|NCT01593228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922434|NCT01637870|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922435|NCT03919838|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel Assignment|t|t|f|t
33697570|NCT05883423|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33697571|NCT00180466|||||PROSPECTIVE|||||||
33697572|NCT05140590|||COHORT||PROSPECTIVE|||||||
33697573|NCT02507973|||CASE_CROSSOVER||PROSPECTIVE|||||||
33697574|NCT04040270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697575|NCT04653675|||COHORT||PROSPECTIVE|||||||
33697576|NCT04765215|||CASE_CONTROL||PROSPECTIVE|||||||
33697577|NCT06352996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697578|NCT04940325|NA|SINGLE_GROUP||TREATMENT||NONE||One group of 100 patients treated with DS-102a||||
33697579|NCT02028312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33697580|NCT00643773|RANDOMIZED|FACTORIAL||||DOUBLE|||t|t|f|f
33697581|NCT06476600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||prospective, randomized, parallel-group, double-blinded clinical trial|t|f|t|t
33697582|NCT02738632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720087|NCT04425733|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33720088|NCT05882240|||COHORT||CROSS_SECTIONAL|||||||
33720089|NCT00827879|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33922436|NCT05155657|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33922437|NCT03120728|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922438|NCT06197022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922439|NCT05279105|||OTHER||CROSS_SECTIONAL|||||||
33922440|NCT01027013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922441|NCT00515580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697583|NCT05299723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This will be a two-phase pilot study.~Phase A of the study will be a single-arm open-label study of the home-based CC intervention in n=5 post-ACS patients. Please note that as Phase A is a single-arm open-label study, there will be no randomization of participants.~Phase B of the study will be a parallel-arm randomized clinical trial (RCT) in which n=15 post-ACS patients will be randomized (using a 2:1 allocation) to active CC treatment or sleep hygiene education control group.~The Allocation scheme below refers to Phase B."||||
33697584|NCT00737438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697585|NCT03169686|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33785861|NCT03631563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001898|NCT06570278|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||We plan to randomize one patient in the control group for two in the intervention group.||||
33922442|NCT06418334|||CASE_CONTROL||PROSPECTIVE|||||||
33922443|NCT04220385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922444|NCT04078542|||COHORT||PROSPECTIVE|||||||
33922445|NCT05483361|||OTHER||CROSS_SECTIONAL|||||||
33922446|NCT01403831|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33922447|NCT04928495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The clinical trial will be masked by participant, care provider, investigator and outcomes assessor.|(1) Placebo control; (2) N-acetylcysteine treatment (NAC); and (3) NAC + Bromhexine treatment.|t|t|t|t
33922448|NCT04060810|NA|SINGLE_GROUP||OTHER||NONE||||||
33922449|NCT05904353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33922450|NCT01539811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922451|NCT05957588|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study was a prospective randomized cohort study in which data was collected for over 14 days or until discharged to a lower level of care from the telemetry-monitored, acute care unit. Data collected on study participants included the need for escalating respiratory care as well as length of stay in the acute care unit. Comparative analysis was conducted with data collected from hospitalized patients (the control group) with a diagnosis of COVID-19 on a non-ICU acute care, telemetry-monitored unit that met the hypoxemia criteria, but that did not receive the proning intervention. The data from the control group was collected by a retrospective chart analysis after 14 days.||||
33922452|NCT01152489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33922453|NCT03967756|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922454|NCT03165864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922455|NCT00538746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922456|NCT00871377|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34001899|NCT00397254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34001900|NCT04966962|||COHORT||PROSPECTIVE|||||||
34001901|NCT01058122|||COHORT||PROSPECTIVE|||||||
34001902|NCT05125809|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34001903|NCT03860025|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001904|NCT06150079|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33720090|NCT02180633|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33720091|NCT03060239|NA|SINGLE_GROUP||OTHER||NONE||||||
33720092|NCT05054959|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33720093|NCT01346839|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33720094|NCT00361855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720095|NCT03506607|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34001905|NCT03668457|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34001906|NCT02641873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001907|NCT04233866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001908|NCT02305407|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34001909|NCT02111109|||COHORT||PROSPECTIVE|||||||
34001910|NCT01562132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001911|NCT02219009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089422|NCT02924961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089423|NCT00128388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089424|NCT04217980|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34089425|NCT05502172|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089426|NCT02916927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720096|NCT03775057|NA|SINGLE_GROUP||OTHER||NONE||||||
33720097|NCT04573595|NA|SINGLE_GROUP||OTHER||NONE||The purpose of this study is to provide supporting documentation for Noninvasive blood pressure measurement accuracy claims for Fresenius 5008S BPM Module and Cuffs on the intended population(s). The same arm sequential method with dual observer auscultation will be used to collect data.||||
33922457|NCT01686958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922458|NCT01817114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922459|NCT00525239|NA|SINGLE_GROUP||||NONE||||||
33922460|NCT05396794|||COHORT||PROSPECTIVE|||||||
33922461|NCT05424185|||COHORT||CROSS_SECTIONAL|||||||
33922462|NCT00303615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922463|NCT02307539|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33922464|NCT03379480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922465|NCT04370912|||CASE_ONLY||CROSS_SECTIONAL|||||||
33922466|NCT05650515|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33922467|NCT01371526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922468|NCT05353868|||COHORT||PROSPECTIVE|||||||
33922469|NCT02615067|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922470|NCT00453856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922471|NCT06327620|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33922472|NCT00306579|||||PROSPECTIVE|||||||
33922473|NCT01617655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922474|NCT01602549|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33922475|NCT05764460|||COHORT||PROSPECTIVE|||||||
33922476|NCT04072224|||OTHER||RETROSPECTIVE|||||||
33922477|NCT00108797|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922478|NCT06051825|||COHORT||PROSPECTIVE|||||||
33922479|NCT05285033|||COHORT||RETROSPECTIVE|||||||
33922480|NCT00776555|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33922481|NCT04134741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"None of the physiotherapists were personally involved in the preparation and the manner of performing the test.~The random placement was performed with the use of computer software."|The players were placed at random in the studied groups, 9 participants in each group: A - group with additional Kinetic Control neuromuscular training; and B - group with standard training.|f|f|t|f
33922482|NCT05066867|||COHORT||RETROSPECTIVE|||||||
33922483|NCT03713216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922484|NCT02993458|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33922485|NCT05562804|||COHORT||PROSPECTIVE|||||||
33922486|NCT00382213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089427|NCT05110612|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomized parallel group design|t|f|f|f
34089428|NCT02165527|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089429|NCT02836769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089430|NCT02920658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720098|NCT04101903|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33720099|NCT02557698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720100|NCT01895660|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33922487|NCT03053726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and the outcomes assessor are blinded in this study||t|f|f|t
33922488|NCT01078987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922489|NCT04671615|||COHORT||RETROSPECTIVE|||||||
33922490|NCT04373785|NA|SINGLE_GROUP||TREATMENT||NONE||Radiation: Radiotherapy Drug: Temozolomide Drug: NG101m||||
33922491|NCT02713789|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33922492|NCT06253234|NA|SINGLE_GROUP||TREATMENT||NONE||To evaluate the safety and tolerance of personalized DC vaccine in in recurrent or progressive high-grade gliomas.||||
33922493|NCT00067613|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089431|NCT06524531|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34089432|NCT05253027|||OTHER||PROSPECTIVE|||||||
34089433|NCT00112957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089434|NCT01794702||SEQUENTIAL||TREATMENT||NONE||"Starting with Dose level 1, the participants were enrolled by cohort of 3. Once the DLT assessment is completed, another cohort of 3 patients will be enrolled. If at any time, we see more than 30% patients experiencing DLT, we will de-escalate to dose level (-1).~Period 1: Dose level 1 Clofarabine 15mg/m\^2 daily x 4 days (days 6-9)~Period 2: Dose level-1 Clofarabine 15mg/m\^2 daily x 3 days (days 6-8)"||||
34089435|NCT01691651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089436|NCT03773783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34089437|NCT00410527||||TREATMENT||||||||
33720101|NCT06407544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720102|NCT02939235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720103|NCT05587400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922494|NCT01768312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922495|NCT03496129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922496|NCT04843969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922497|NCT03373110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922498|NCT01887106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922499|NCT00108953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922500|NCT04861311|RANDOMIZED|PARALLEL||TREATMENT||NONE||Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group will use the smartphone app which comprises of audio-guided mindfulness meditations and video lessons. Participants are asked to listen to at least one guided meditation daily and watch one video lesson each week. Participants will also receive a weekly phone call for emotional and technical support. The wait-list control group will have the option to use the app-based intervention after 10 weeks of being in the control group.||||
33922501|NCT04782037|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33922502|NCT04720495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697586|NCT02213042|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This was a two-cohort, three-arm, open-label Phase II study to evaluate the changes in the expression of biomarkers between pre-treatment and progression biopsy in subjects with Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Subjects were allocated to 1 of 2 cohorts depending on the molecular subtype of their biopsy.~Cohort 1 HER2 -enriched included HER2-positive subjects with a HER2-Enriched molecular subtype, and were randomized in a 1:1 ratio to receive either trastuzumab in combination with lapatinib (Arm A) or trastuzumab in combination with chemotherapy (Arm B).~Cohort 2 non-HER2-enriched, included HER2-positive subjects with luminal A, luminal B, and basal-like molecular subtypes and were to receive trastuzumab in combination with lapatinib (Arm C). Subjects with hormone receptor (ER and/or PgR)-positive MBC in this arm were required to be treated with an AI of the Investigator's choice."|Participants were randomized to Arms A and B but randomized to Arm C.||||
33697587|NCT02837068|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001912|NCT05079555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The performance of the SWalker platform was assessed at Albertia Servicios Sociosanitarios S.A. nursing homes. Clinical validation was conducted with hip fracture patients. The control group consisted of patients who followed conventional therapy, while the intervention group consisted of patients rehabilitated using SWalker. Allocation to groups was according to the choice of the participants. All patients had the possibility to use SWalker treatment. For those patients who received conventional rehabilitation, treatment duration was up to 6 months in the most severe case. Patient follow-up was conducted in parallel with the clinical trials.||||
34001913|NCT01003951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001914|NCT05777694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"The prospective randomized study was randomized into 3 groups:~Group 1: Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle ( Pencan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Group 2: Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle ( Atraucan® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany) Group 3: Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle ( Pencan ® 0.42 × 88 mm- G27 × 3½, B. Braun, Melsungen, Germany)"|pospective randomize study||||
34001915|NCT02166606|||COHORT||PROSPECTIVE|||||||
34001916|NCT03110380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001917|NCT05024487|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34001918|NCT00473616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001919|NCT05317858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001920|NCT06249893|||CASE_ONLY||PROSPECTIVE|||||||
34001921|NCT05609695|||COHORT||PROSPECTIVE|||||||
34001922|NCT05901116|NA|SINGLE_GROUP||OTHER||NONE||||||
34001923|NCT06428955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001924|NCT01757379|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34001925|NCT04190927|NA|SINGLE_GROUP||TREATMENT||NONE||Observational, single arm, prospective using a new dosing regimen of an existing biological drug.||||
34089438|NCT03907189|||COHORT||PROSPECTIVE|||||||
34089439|NCT00413803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089440|NCT04479046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697588|NCT03265665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697589|NCT04683562|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697590|NCT02791594|||COHORT||PROSPECTIVE|||||||
33697591|NCT05436275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697592|NCT04810481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Investigator will be blinded to the BIS value in the Standard Practice Group||f|t|f|f
33697593|NCT03227328|RANDOMIZED|PARALLEL||TREATMENT||NONE||group sequential response adaptive Randomized, open label, multicenter,||||
33697594|NCT05312073|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33697595|NCT04340297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697596|NCT01887223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697597|NCT01820156|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33697598|NCT03404427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|When analyzing the results (endurance, magnitude of the premotor potential), the outcomes assessor will not know if it is a normal night or a sleepless night|To compare the motor endurance of healthy subjects after a normal sleep night and after a sleepless night.|f|f|f|t
33697599|NCT04903665|||CASE_CONTROL||PROSPECTIVE|||||||
33697600|NCT01704521|RANDOMIZED|PARALLEL||||NONE||||||
33697601|NCT00978471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697602|NCT01193660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697603|NCT05304208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697604|NCT05816031|||CASE_CONTROL||PROSPECTIVE|||||||
34001926|NCT01467596|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34001927|NCT02913755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34001928|NCT04959032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001929|NCT06678308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001930|NCT04323215|||CASE_CONTROL||PROSPECTIVE|||||||
34001931|NCT01878773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34001932|NCT04622930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001933|NCT03435341|||COHORT||PROSPECTIVE|||||||
34001934|NCT04085744|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34001935|NCT06677619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34001936|NCT04006873|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34001937|NCT04016194|||COHORT||RETROSPECTIVE|||||||
33697605|NCT06680531|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Drug interaction|t|f|f|f
33697606|NCT04716088|||CASE_ONLY||PROSPECTIVE|||||||
33697607|NCT02302534|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697608|NCT03222011|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Randomised controlled trial||||
33697609|NCT06312956|||CASE_ONLY||PROSPECTIVE|||||||
33697610|NCT04484948|NA|SINGLE_GROUP||OTHER||NONE||||||
33697611|NCT06680895|||CASE_ONLY||PROSPECTIVE|||||||
33697612|NCT04603053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33697613|NCT05777343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785862|NCT05921409|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Treatment (extra virgin olive oil) and placebo (olive oil) were packed in 50 ml opaque envelopes for patients masking. Letters A and B were assigned randomly to each treatment by an external person not participating in the study design or analysis for investigator masking.|Randomized, Double-blinded, placebo controlled intervention|t|f|t|t
33785863|NCT03764345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785864|NCT04944693|||COHORT||PROSPECTIVE|||||||
33785865|NCT01382810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001938|NCT01774682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001939|NCT06332092|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Two different dosing regimens of FID-007 in combination with fixed-dose Cetuximab||||
34001940|NCT04164030|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001941|NCT00212654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34001942|NCT05645315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001943|NCT01932190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001944|NCT05761392|RANDOMIZED|PARALLEL||TREATMENT||NONE||After taking the stimulator implantation surgery, participants in the interventional group are asked to take conventional follow-up including 1-, 3-, 6-month post-operative. Other than that, participants will be asked to take additional self-assessments, including daily pain state and monthly health conditions.||||
34001945|NCT03160079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001946|NCT01256697|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34001947|NCT06400225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001948|NCT02578641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001949|NCT04084990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, parallel group, investigator-blinded, randomized controlled trial|f|t|t|t
34001950|NCT00540358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001951|NCT00812318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001952|NCT00428831|||CASE_ONLY||PROSPECTIVE|||||||
34001953|NCT04009876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001954|NCT04734782|||COHORT||PROSPECTIVE|||||||
34001955|NCT01590199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697614|NCT02275273|||COHORT||PROSPECTIVE|||||||
33697615|NCT06681064|||COHORT||PROSPECTIVE|||||||
33697616|NCT04430192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697617|NCT05446636|||OTHER||PROSPECTIVE|||||||
33697618|NCT00085904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697619|NCT02542982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697620|NCT06393543|||COHORT||PROSPECTIVE|||||||
33697621|NCT05184556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697622|NCT00400231|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33720104|NCT06102694|||COHORT||PROSPECTIVE|||||||
34001956|NCT05551741|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Within each cohort subjects are randomized to either active investigational product or placebo in a ratio 3:1|t|t|t|t
34001957|NCT06168903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be achieved using a computer-generated sequence. Concealment will be achieved using opaque envelopes|Obese patients with a body mass index (BMI) of ≥ 35 kg/m2 with comorbidities or \> 40 kg/m2 and American Society of Anesthesiologists (ASA) physical status I-III and aged between 18 and 70 years scheduled for laparoscopic bariatric surgery|t|f|f|t
34001958|NCT03237156|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34001959|NCT04099680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720105|NCT06367127|||CASE_ONLY||PROSPECTIVE|||||||
33720106|NCT05592782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720107|NCT06201533|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33720108|NCT00812370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720109|NCT00514540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001960|NCT03501485|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001961|NCT01677650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001962|NCT05894031|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding of outcome assessors|Randomized controlled trial with parallel arms|f|f|f|t
34001963|NCT05535621|||OTHER||PROSPECTIVE|||||||
34001964|NCT05427994|||OTHER||CROSS_SECTIONAL|||||||
34001965|NCT01201668|||COHORT||CROSS_SECTIONAL|||||||
34001966|NCT04442854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34001967|NCT05692154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001968|NCT06476782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single blinded as the assessor of study will be kept blinded||f|f|f|t
33697623|NCT06392191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding of medical staff and investigators: a study coordinator was developed to keep and distribute the randomisation numbers, an independent nurse anaesthetist prepared the medication for the study according to the randomisation result code, because bupivacaine liposomes are milky and bupivacaine is colourless, we set up an independent medication preparer and nerve block operator, and nerve block operators were not permitted to be associated with anaesthesia procedures and postoperative Patient assessment. The anaesthesiologist and the follow-up physician were unaware of the grouping.~Patients were blinded: all patients were anaesthetised and the nerve block was performed without the patients touching the drugs. The double blinding continued throughout the study period."||t|f|t|f
33697624|NCT02994134|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33697625|NCT06615739|||COHORT||OTHER|||||||
33697626|NCT03959072|||COHORT||PROSPECTIVE|||||||
33697627|NCT02715401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697628|NCT05701033|||OTHER||PROSPECTIVE|||||||
33697629|NCT02853344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697630|NCT04441671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697631|NCT04638296|||OTHER||PROSPECTIVE|||||||
33697632|NCT04510376|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720110|NCT03407378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33785866|NCT04586192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33922503|NCT03009240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922504|NCT03278652|||CASE_ONLY||PROSPECTIVE|||||||
33922505|NCT00222742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922506|NCT01170702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922507|NCT01646398|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922508|NCT00992602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922509|NCT01645085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33922510|NCT00003595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922511|NCT00545480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922512|NCT04543019|||CASE_CONTROL||RETROSPECTIVE|||||||
33922513|NCT05138237|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34001969|NCT00125541|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34001970|NCT06679556|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34001971|NCT04712734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001972|NCT03496298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34001973|NCT02361736|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34001974|NCT05608252|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34001975|NCT04912206|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922514|NCT02017899|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922515|NCT02271009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922516|NCT06024213|||CASE_ONLY||PROSPECTIVE|||||||
33922517|NCT01497080|||COHORT||PROSPECTIVE|||||||
33922518|NCT04070118|||COHORT||PROSPECTIVE|||||||
33922519|NCT03388086|||COHORT||RETROSPECTIVE|||||||
33922520|NCT03026049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922521|NCT03964883|||COHORT||PROSPECTIVE|||||||
33922522|NCT02978209|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33922523|NCT02138396|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33922524|NCT03865511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922525|NCT03371732|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922526|NCT02584868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922527|NCT03427138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922528|NCT02790463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922529|NCT00265967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922530|NCT02417896|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922531|NCT05079867|||COHORT||PROSPECTIVE|||||||
33922532|NCT05096494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922533|NCT05666661|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33922534|NCT00916513|||||CROSS_SECTIONAL|||||||
33922535|NCT04576572|||COHORT||RETROSPECTIVE|||||||
33922536|NCT01324687|||COHORT||PROSPECTIVE|||||||
33922537|NCT01340963|||COHORT||PROSPECTIVE|||||||
33922538|NCT06336343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922539|NCT00187889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922540|NCT01005056|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33785867|NCT04883762|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, non-randomized pilot trial.||||
33922541|NCT05279716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922542|NCT01918787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922543|NCT01043848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922544|NCT00897052|||CASE_ONLY||RETROSPECTIVE|||||||
33922545|NCT02282982|||COHORT||PROSPECTIVE|||||||
34001976|NCT05917262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33922546|NCT00267371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922547|NCT05757089|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33922548|NCT00254735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922549|NCT04871581|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants were advised that two different designs of device were being compared to each other.|Single blinded cross-over study|t|f|f|f
33922550|NCT05479266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922551|NCT04496557|NA|SINGLE_GROUP||OTHER||NONE||single-arm, open-label feasibility study||||
33922552|NCT05157711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922553|NCT02532426|||CASE_CONTROL||PROSPECTIVE|||||||
33922554|NCT01225757|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922555|NCT01670175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922556|NCT04893928|||COHORT||CROSS_SECTIONAL|||||||
33922557|NCT02969395|||OTHER||PROSPECTIVE|||||||
34001977|NCT05587023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Neither the experimenters nor the participants knew whether they were taking a Experimental drug or a placebo. To be as objective as possible, the description of the treatment effects and adverse reactions of the subjects, as well as the recording of the various reactions of the experimenters, should be given.|Sixty patients with cardiac Valve replacement undergoing cardiopulmonary bypass were randomly divided into experimental group and control group, with 30 patients in each group. All patients signed the informed consent form. Control Group: the control group was injected with 6ml normal saline. Test group: the test group was injected with 0.5% ropivacaine 6ml.|t|t|t|t
34001978|NCT00701194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922558|NCT04010370|||OTHER||CROSS_SECTIONAL|||||||
33922559|NCT03555240|||COHORT||PROSPECTIVE|||||||
33922560|NCT04747522|||COHORT||PROSPECTIVE|||||||
33922561|NCT06281379|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study group participants: total gastrectomy+mesogastrectomy Control group: Standard total gastrectomy + D2 lymph node dissection||||
33922562|NCT06314165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants included in the study will not know which group they are in. In this way, the study will be carried out in a single-blind manner.|Two groups: comparative experiment and control|t|f|f|f
33922563|NCT05066035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study protocol was masked to an outcomes assessor and the persons for this duty include an observer, a resident, or an anesthesia nurse during the anesthesia process but not to the care provider or the supervising physician.|Randomized prospective clinical trial|t|t|f|t
33922564|NCT00109772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922565|NCT05386927|||CASE_CONTROL||PROSPECTIVE|||||||
33922566|NCT04776564|||CASE_CONTROL||PROSPECTIVE|||||||
33922567|NCT01753388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001979|NCT05094596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34001980|NCT06679387|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34001981|NCT00159172|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
34001982|NCT02881359|||COHORT||OTHER|||||||
34001983|NCT05453409|||CASE_ONLY||RETROSPECTIVE|||||||
34001984|NCT03184649|RANDOMIZED|PARALLEL||PREVENTION||NONE|statistician will be blind only|three groups, two for intervention and one for comparative group||||
34001985|NCT06581081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785868|NCT00543725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922568|NCT05835713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922569|NCT05731232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized allocation to verum or placebo group of similar size|t|t|t|f
33922570|NCT06229067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922571|NCT01769703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922572|NCT04662411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33922573|NCT02818140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922574|NCT02565498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922575|NCT05679609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922576|NCT05988437|||CASE_ONLY||PROSPECTIVE|||||||
33922577|NCT01771211|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34001986|NCT02217709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34001987|NCT01098539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34001988|NCT05768386|||COHORT||PROSPECTIVE|||||||
34001989|NCT06222606|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34001990|NCT05006833|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33785869|NCT05275686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and investigators will be kept blinded until the end of the study.|"* Group 1 will get the EDS-FLU nasal spray and use at its normal twice a day dosing.~* Group 2 will get the placebo nasal spray in an identical spray canister and use it twice a day.~Patients will be randomized to receive placebo in the novel exhalation delivery system versus fluticasone in the device. Patients will take the spray twice daily for six weeks and then return for evaluation. An open label extension will be planned for both groups (placebo, non-placebo) at the end of the six weeks to use the EDS-FLU for an additional six weeks."|t|t|t|f
33785870|NCT03693443|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785871|NCT05507281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An anesthesiologist gave the block and outcomes were obtained by another one blinded to the study group. PHILIPS ultrasound machine and high frequency linear array probe with a frequency of 5-13 MHZ will be used.|Patients were randomly allocated into 3 equal groups (Control group, Ultrasound-guided Erector Spinae Plane Block group, Retrolaminar Block, 20 patients each) through sealed envelopes.|t|f|f|t
33785872|NCT05478122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785873|NCT04730336|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will undergo three sessions of treatments with the Investigation devise||||
33785874|NCT00003429||||DIAGNOSTIC||||||||
33785875|NCT02730767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785876|NCT06474546|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33785877|NCT05880238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785878|NCT02466295|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33785879|NCT05006690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33785880|NCT03075696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785881|NCT03916380|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785882|NCT05903066|||COHORT||PROSPECTIVE|||||||
33785883|NCT00700414|||OTHER||PROSPECTIVE|||||||
33785884|NCT04953897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785885|NCT06466473|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33785886|NCT01899222|||COHORT||PROSPECTIVE|||||||
33785887|NCT05252143|||COHORT||PROSPECTIVE|||||||
33785888|NCT04238624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785889|NCT05247216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33785890|NCT03617107|||COHORT||RETROSPECTIVE|||||||
33785891|NCT06622148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33785892|NCT00030381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785893|NCT04281264|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE||Randomized control trial, in which the experimental sample will be divided into 6 groups where different intervention programs will be performed|t|f|f|t
33785894|NCT04045366|||CASE_ONLY||PROSPECTIVE|||||||
33785895|NCT06489171|||COHORT||RETROSPECTIVE|||||||
33785896|NCT01134575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study started as a single arm study of Inotuzumab Ozogamicin administered at two different dose levels. The protocol was later amended to modify to weekly Inotuxumab Ozogamicin administration.||||
33785897|NCT04511650|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The study was planned to include 2 parts with Part 1 comprising the dose escalation period of the study and Part 2 comprising the proof-of-concept safety and efficacy period of the study. Although The Data Review Committee (DRC) recommended to continue with the study after the completion of Part 1, Step 1, the Sponsor elected to discontinue the study due to business-related reasons.|t|f|t|t
33785898|NCT00154713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785899|NCT05040269|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785900|NCT04487587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|COMICE is a double blind trial, the Investigator, Patient, Hospital Staff, Pharmacy and the COMICE trial team (Chief Investigator, Monitor, Trial Coordinator) are blinded to the treatment allocation|Patients are randomised 1:1 to either placebo Cediranib and Olaparib or active Cediranib and Olaparib|t|t|t|f
33785901|NCT06123117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study will be blinded to patients and recovery room personnel, as well as the ward nurses and physicians, but not to operating surgeon(s), anesthesiologist(s), and nurses, treating patients during the surgery.|"Patients are analyzed following the intention to treat in three subgroups:~1. Patients treated in day-care outpatient surgical unit (DS): TAP+local vs local.~2. Patients treated electively in the inpatient surgery unit (IS): TAP+local vs local.~3. Emergency surgery patients (ES): TAP+local vs local."|t|t|t|t
33785902|NCT05640596|||CASE_CONTROL||RETROSPECTIVE|||||||
33785903|NCT00192192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33785904|NCT04157712|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|double blind, placebo controlled, matching placebo|double blind, placebo controlled, matching placebo|t|f|t|t
33785905|NCT00387361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33785906|NCT02131740|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33785907|NCT02327039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33785908|NCT01086124|||COHORT||PROSPECTIVE|||||||
33785909|NCT06411418|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignment||||
33785910|NCT05602116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open dose titrating with two groups in extension of each other (thus not categorically parallel).||||
33922578|NCT04137146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33922579|NCT00014911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922580|NCT05514509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922581|NCT05448599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922582|NCT03167164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922583|NCT01493141|||COHORT||PROSPECTIVE|||||||
33922584|NCT01699412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922585|NCT01124019|||COHORT||PROSPECTIVE|||||||
33922586|NCT03687086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922587|NCT03013829|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33922588|NCT05069805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researcher responsible for the postoperative period, the surgical team and the patients were not aware of the allocated groups. The researcher responsible for the randomization list communicated the researcher responsible for performing the ESP or PECS II block and conducting the anesthesia.|Prospective, randomized, single-blind, superiority study|t|f|t|t
33697633|NCT03999853|NA|SINGLE_GROUP||TREATMENT||NONE||BKR-017: Delayed release butyrate which promotes endogenous incretin secretion to determine if this improves insulin action||||
33922589|NCT00339105|||DEFINED_POPULATION||PROSPECTIVE|||||||
33922590|NCT03361072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective open label study on oral immunotherapy with either milk, or peanut or egg white food products.||||
33922591|NCT04239547|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The investigator, the participant and outcomes assessor will be masked to the intervention. Only the caregiver will be aware of the group and intervention received.|Group 1, Alveolar Recruitment Maneuver+positive end expiratory pressure (PEEP) Group 2, PEEP|t|f|t|t
33922592|NCT05737407|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33697634|NCT00878670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697635|NCT00000612|RANDOMIZED|||PREVENTION||DOUBLE||||||
33697636|NCT04233463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697637|NCT05162846|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33697638|NCT05835531|||COHORT||PROSPECTIVE|||||||
33697639|NCT00000304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697640|NCT03250169|||COHORT||PROSPECTIVE|||||||
33697641|NCT00388830|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33697642|NCT00662688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697643|NCT00214643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697644|NCT05600426|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded, stratified, multi-center, phase 3, randomized controlled trial||||
33697645|NCT01069627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697646|NCT04863092|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||It uses a pre- and post-design to evaluate participants' changes in knowledge of and intentions to in CTs by comparing outcomes at baseline to outcomes after exposure to the CHE educational intervention.||||
33697647|NCT04300439|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33697648|NCT01469234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697649|NCT02899845|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697650|NCT04470271|||COHORT||CROSS_SECTIONAL|||||||
33697651|NCT04090073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697652|NCT01498978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697653|NCT00091416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33697654|NCT00660751|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33697655|NCT00428662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697656|NCT02977130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785911|NCT06630754|||COHORT||PROSPECTIVE|||||||
33922593|NCT04286464|||COHORT||PROSPECTIVE|||||||
33922594|NCT02644148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34001991|NCT01085890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697657|NCT06680635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697658|NCT03816865|||COHORT||PROSPECTIVE|||||||
33697659|NCT06680856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"* Experimental Group: Platelet Rich Plasma + Hyaluronic Acid (PRP+HA) (Group 1)~* Control Group: Hyaluronic acid gel (HA) (Group 2)"|t|t|t|t
33697660|NCT03577873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697661|NCT04852497|||COHORT||RETROSPECTIVE|||||||
33697662|NCT00496223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697663|NCT03036904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697664|NCT04543825|||COHORT||PROSPECTIVE|||||||
33697665|NCT04962581|||COHORT||PROSPECTIVE|||||||
33697666|NCT04334759|RANDOMIZED|PARALLEL||TREATMENT||NONE||First-line chemotherapy with cisplatin or carboplatin and pemetrexed + durvalumab OR physician's choice of either first-line chemotherapy alone, or ipilimumab and nivolumab.||||
33697667|NCT05763212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697668|NCT00161473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697669|NCT00058487||||TREATMENT||NONE||||||
33697670|NCT03585842|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33697671|NCT02130024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators were not masked. The patients, the BCVA assessors, and the Central Reading Center (who set the treatment intervals) were masked.||t|f|f|f
33697672|NCT04968847|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, single-arm||||
33697673|NCT04635059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697674|NCT04426708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697675|NCT00333177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785912|NCT05886751|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34001992|NCT03389763|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34001993|NCT04478526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study has been designed using a quasi-experimental design to allow patients the freedom to choose which treatment modality they would like to participate in. This research design aims to be naturalistic by mimicking the decisions made by patients and physicians regarding the course of treatment and type of pharmacotherapy prescribed within mental health services across Ontario. The treatments provided within the study also aim to replicate evidence-based best practice clinical guidelines for the treatment of GAD. Arms include eCBT, eCBT + Pharmacotherapy, Pharmacotherapy.||||
34001994|NCT04403945|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34001995|NCT04592653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34001996|NCT04734704|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Prospective, Monocentric (CHU de Bordeaux, Department of dermatology ), with 4 groups :~* vitiligo patients~* Metastatic melanoma patients receiving anti-PD-1 but without cutaneous irAEs~* Metastatic melanoma patients receiving anti-PD-1 who developed vitiligo lesions~* metastatic melanoma patients who developed vitiligo under anti-PD-1, who discontinued the treatment."||||
34001997|NCT01483794|||||RETROSPECTIVE|||||||
33697676|NCT00784641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697677|NCT01200524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697678|NCT02402829|||CASE_ONLY||PROSPECTIVE|||||||
33697679|NCT06277492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922595|NCT03283618|RANDOMIZED|PARALLEL||OTHER||SINGLE|Following baseline visits, participants were randomized to a video conference or control groups.|All subjects were randomized in a balanced fashion and stratified by sex into either one of the two groups video conferencing or a control group.|t|f|f|f
33922596|NCT05755997|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A two-period cross-over design, in which participants will be randomly allocated to either the Verum-Control sequence (sequence 1) or the Control-Verum sequence (sequence 2) in a 1:1 randomization.|t|t|t|t
33922597|NCT03969407|||COHORT||PROSPECTIVE|||||||
33922598|NCT01345370|||||PROSPECTIVE|||||||
33922599|NCT05583357|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33922600|NCT00556335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922601|NCT02704442|||COHORT||CROSS_SECTIONAL|||||||
33922602|NCT03874754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinded marking: The data collectors are blinded to the group allocation|This is a two-arm parallel assignment involving two groups of participants. One group receives exercise intervention, and the other group receives usual care (control group).|f|f|f|t
33922603|NCT01095068|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922604|NCT03119246|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922605|NCT02715583|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922606|NCT01351064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34001998|NCT01566851|||COHORT||RETROSPECTIVE|||||||
34001999|NCT05584462|||CASE_ONLY||CROSS_SECTIONAL|||||||
34002000|NCT01068704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002001|NCT04469400|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002002|NCT01489930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002003|NCT03113149|||COHORT||PROSPECTIVE|||||||
34002004|NCT04568577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002005|NCT05736796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34002006|NCT00506012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002007|NCT01936012|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34002008|NCT02464904|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002009|NCT03724682|NA|SINGLE_GROUP||TREATMENT||NONE||Baseline study session with standard PD therapy. Three study sessions with the Carry Life UF device at three different glucose dosages, starting with the lowest dose of 11g/h, increasing to 14g/h and finally 20g/h.||||
34002010|NCT05483608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician screening participants and the primary outcome assessor will be blinded to group allocation||f|f|f|t
34002011|NCT00875082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34002012|NCT04303624|||COHORT||CROSS_SECTIONAL|||||||
34002013|NCT05767762|NA|SINGLE_GROUP||OTHER||NONE||||||
34002014|NCT06018064|NA|SINGLE_GROUP||TREATMENT||NONE||Infants between the ages \>44 weeks gestational age to 18 months of age with complex medical conditions, particularly those with tracheostomies||||
34002015|NCT05414695|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The intervention is unknown to the patients, the acupuncturist and the persons who assess the outcomes. Both devices (placebo and real acupuncture) have the exactly same visual appearance. Its double blinding potential was confirmed in preliminary validation studies.|This is a randomized, placebo-controlled, crossover and triple blind study|t|t|t|t
34002016|NCT06245915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002017|NCT05193422|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be randomized to begin with Phase I followed by Phase II or Phase II followed by Phase I.||||
34002018|NCT03328390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34002019|NCT03494686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002020|NCT05212038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double|Parallel assignment|t|f|f|t
34002021|NCT02421627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34002022|NCT01041209|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34002023|NCT05486923|||COHORT||PROSPECTIVE|||||||
34002024|NCT05360849|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34002025|NCT05225467|||COHORT||PROSPECTIVE|||||||
34002026|NCT02377349|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34002027|NCT02190318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002028|NCT04167696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
34002029|NCT06334562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34002030|NCT03998592|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34002031|NCT01451996|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34002032|NCT05820789|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34025143|NCT01405014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34025144|NCT00338728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025145|NCT04675814|||COHORT||PROSPECTIVE|||||||
33922607|NCT04545099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|triple (Participant, Care Provider, investigator)||t|t|t|t
33922608|NCT05608330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind when administering rating scales at week 8 and 24, and statisticians will be blind to the allocated treatment during analysis.||f|f|f|t
33922609|NCT05070416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922610|NCT05723458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922611|NCT04003181|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33922612|NCT00799929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922613|NCT06123390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants and care providers will know which arm of the study they are part of, as the randomization occurs at the facility level. Only the statistician will be blinded to the arms at the time of analysis.|"In this study we are evaluating usual care (Arm 1) vs. the Responses to Illness Severity Quantification (Arm 2) in children children aged 6 to 59 months who are enrolled in the OptiMA nutrition program in Chad.~Community health centres will be the randomized clusters."|f|f|f|t
34025146|NCT04963543|NA|SINGLE_GROUP||OTHER||NONE||||||
34025147|NCT01192763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025148|NCT02301832|||COHORT||PROSPECTIVE|||||||
34025149|NCT06365918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025150|NCT04651413|||OTHER||RETROSPECTIVE|||||||
34025151|NCT04460560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697680|NCT05975359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients undergoing bilateral mastectomy will be eligible for this study. Each patient will receive both the Interi manifold (intervention arm) and the JP drain (comparison arm) placed in different breasts. Drain placement will be simultaneous. The laterality of different drain systems (intervention and comparison study arms) will be randomly assigned for each patient.|f|f|f|t
33697681|NCT03009409|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33697682|NCT03025841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697683|NCT05582031|NA|SINGLE_GROUP||TREATMENT||NONE||The trial will include 8 cohorts of patients. Each cohort is considered as a single-arm activity-estimating sub-study with PFS-6 as the primary endpoint. A strong primary endpoint signal seen in a cohort may allow for expansion of the cohort, independently of the status of the other cohorts. Similarly, a cohort may be opened and/or closed for enrollment independently of others.||||
33697684|NCT02682771|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||f|t|t|t
33697685|NCT06680583|||COHORT||CROSS_SECTIONAL|||||||
33697686|NCT01722773|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720111|NCT02384707|NA|SINGLE_GROUP||||NONE||||||
33720112|NCT00665847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720113|NCT03953573|||COHORT||PROSPECTIVE|||||||
33720114|NCT03173599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025152|NCT01261091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025153|NCT06516003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025154|NCT04777149|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Wash-in control design|t|f|f|t
34025155|NCT01688492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025156|NCT05369728|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34025157|NCT06079567|NA|SINGLE_GROUP||OTHER||NONE||||||
34025158|NCT01832779|||OTHER||PROSPECTIVE|||||||
34089441|NCT00724893|||COHORT||PROSPECTIVE|||||||
33922614|NCT05271903|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||MAMA intervention: a simulation training for labor and delivery providers||||
34089442|NCT03491592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089443|NCT04547699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, double-blinded and prospective study|t|t|t|t
34089444|NCT01007877|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33922615|NCT01713855|NA|SINGLE_GROUP||||NONE||||||
33922616|NCT01285791|||CASE_ONLY||PROSPECTIVE|||||||
33922617|NCT02595840|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open-label, phase II study||||
34089445|NCT03808246|RANDOMIZED|PARALLEL||OTHER||NONE||"2 profiles of participants (naïves vs. informed) x 2 types of test environment (realistic vs. laboratory-like).~Each participant, depending on her/his profile is assigned to one profile of participant group and randomly to one type of test environment group."||||
34089446|NCT05743894|||CASE_ONLY||PROSPECTIVE|||||||
34089447|NCT01858948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089448|NCT03304288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089449|NCT00676143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089450|NCT04828967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33697687|NCT06392802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both groups are assessed by a blinded physiotherapist, before and after the treatments. This does not know in which group the participant is involved.|Two groups of 25 subjects follow a motor rehabilitation treatment during 12 weeks. One group (Control group) uses the typical rehabilitation process (just doing exercises at home, written on a sheet of paper). The intervention group uses the telerehabilitation system Muvity during 12 weeks at home to perform motor exercises and play exergames.|f|t|t|f
33697688|NCT02140112|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33697689|NCT05690646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697690|NCT02755298|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33697691|NCT02059902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697692|NCT04060849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697693|NCT00394927|||COHORT|||||||||
33697694|NCT01192373|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33697695|NCT03467048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697696|NCT01932411|||COHORT||RETROSPECTIVE|||||||
33922618|NCT03831893|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33922619|NCT05984810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922620|NCT02877849|||CASE_CONTROL||OTHER|||||||
33922621|NCT02448004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922622|NCT00987519|||CASE_CONTROL||PROSPECTIVE|||||||
33922623|NCT02650297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922624|NCT03230617|||OTHER||CROSS_SECTIONAL|||||||
33922625|NCT01078558|||CASE_ONLY||PROSPECTIVE|||||||
33922626|NCT01576406|NON_RANDOMIZED|||BASIC_SCIENCE||NONE||||||
33922627|NCT04262622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33922628|NCT03448900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization was performed by one member of the research team who generated a blocked random number sequence, using EpiInfo version 7.0.9.7, and prepared the sealed opaque sequentially numbered envelopes (1-255) with the corresponding condition written inside. After each student agreed to participate in the study, the enve- lope was opened, determining the group to which he or she would be assigned. Students were unaware of the group assignments and randomization scheme.||t|f|f|f
33922629|NCT04437030|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922630|NCT05716815|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective multicenter randomized study||||
33922631|NCT04438772|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33922632|NCT05668676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922633|NCT00835003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922634|NCT02881983|||CASE_CONTROL||PROSPECTIVE|||||||
33922635|NCT05186272|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33922636|NCT01116687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922637|NCT03982745|||COHORT||PROSPECTIVE|||||||
33922638|NCT00036543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922639|NCT01003353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922640|NCT02360696|||COHORT||PROSPECTIVE|||||||
33922641|NCT00657722|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33922642|NCT04700436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922643|NCT02205398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922644|NCT03148106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922645|NCT04477109|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33922646|NCT05825196|||COHORT||OTHER|||||||
33922647|NCT03036423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922648|NCT04393077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33922649|NCT01060683|||COHORT||PROSPECTIVE|||||||
33922650|NCT04387929|||COHORT||PROSPECTIVE|||||||
33922651|NCT04771026|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922652|NCT03256838|NA|SINGLE_GROUP||OTHER||NONE||||||
33922653|NCT00951418|||||CROSS_SECTIONAL|||||||
33922654|NCT05514145|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized parallel controlled clinical trial|t|t|t|t
33922655|NCT00407173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089451|NCT05080491|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002033|NCT04943887|NA|SINGLE_GROUP||OTHER||NONE||Each participant will serve as his/her own control; after a 12-week waitlist control period, each participant will complete a 12-week treatment period \[note that the very first group of enrolled participants (N \~10) will not have a waitlist period, but will instead enter directly into the 12-week treatment period\].||||
34002034|NCT04684511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002035|NCT02968550|||COHORT||PROSPECTIVE|||||||
34002036|NCT01436448|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33922656|NCT02195817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922657|NCT04402346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922658|NCT04087603|RANDOMIZED|PARALLEL||TREATMENT||NONE|Group assignment is impossible to blind.|||||
33922659|NCT05559073|||COHORT||RETROSPECTIVE|||||||
33922660|NCT00526461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922661|NCT02625987|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33922662|NCT02999100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922663|NCT01666145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922664|NCT06093945|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-dose, two-period, fixed sequence, self-controlled study||||
33922665|NCT06034015|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33922666|NCT00708058|||||PROSPECTIVE|||||||
33922667|NCT05536154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922668|NCT04188002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This is a single institution, randomized clinical trial designed to evaluate a four week web-based tailored health behavior intervention in breast and colon cancer survivors.|f|f|t|f
33922669|NCT01179022|||COHORT||PROSPECTIVE|||||||
33922670|NCT02988401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922671|NCT04496648|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized patient-blind sham-controlled trial|t|f|t|t
33922672|NCT05543642|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922673|NCT04687488|NA|SINGLE_GROUP||OTHER||NONE||||||
33922674|NCT00212927|||||PROSPECTIVE|||||||
33922675|NCT02671955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922676|NCT01575899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922677|NCT04457570|||CASE_CONTROL||RETROSPECTIVE|||||||
33922678|NCT02535637|||COHORT||PROSPECTIVE|||||||
33922679|NCT03775590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||There are 3 study arms with 50 subjects in each arm. The 3 arms are: water, water + bleach, and water + vinegar|f|t|t|t
33922680|NCT04166656|RANDOMIZED|PARALLEL||PREVENTION||NONE|The trial will be open label. However, the assessment of the primary and secondary immunological endpoints will be carried out blind from the treatment arm.|||||
33922681|NCT04273542|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922682|NCT02801422|||COHORT||PROSPECTIVE|||||||
33922683|NCT03353779|||COHORT||PROSPECTIVE|||||||
33922684|NCT02111967|||CASE_CONTROL||PROSPECTIVE|||||||
33922685|NCT03670498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922686|NCT05825599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922687|NCT06291506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1 randomization|f|f|f|t
33922688|NCT05870319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922689|NCT02748122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922690|NCT03490435|||COHORT||PROSPECTIVE|||||||
33922691|NCT06391658|NA|SINGLE_GROUP||OTHER||NONE||||||
33922692|NCT02447120|||COHORT||PROSPECTIVE|||||||
33922693|NCT01463020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922694|NCT02224638|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-center, randomized open-label study with multiple application treatment of necrotic sacral or buttocks pressure ulcers with either TheraHoney HD or SkinTegrity Hydrogel.||||
33922695|NCT06531226|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34002037|NCT04204590|NA|SINGLE_GROUP||OTHER||NONE||A multicentre, unblinded, single group (pre-comparison and post-comparison) feasibility study.||||
34002038|NCT03567460|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089452|NCT00347490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922696|NCT06552923|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|Masking was not used|Federally Qualified Health Centers were randomized to start in 6-month phased entry and large, aggregate data for participating health centers was collected pre and post ECHO program||||
34002039|NCT01142908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002040|NCT02473237|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34002041|NCT02443285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002042|NCT01833169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002043|NCT04438044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089453|NCT02777177|||COHORT||PROSPECTIVE|||||||
34089454|NCT05112120|||COHORT||PROSPECTIVE|||||||
34089455|NCT04382482|||CASE_ONLY||PROSPECTIVE|||||||
34002044|NCT06408402|||CASE_CONTROL||PROSPECTIVE|||||||
34002045|NCT04199416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33697697|NCT03793478|NA|SEQUENTIAL||TREATMENT||NONE||A single group will progress through a multiple phase study design as described in the detailed description.||||
34002046|NCT04970498|||COHORT||PROSPECTIVE|||||||
34002047|NCT03366194|NA|SINGLE_GROUP||TREATMENT||NONE|3. The trial shall be blinded and bias minimized in that three (3) physicians who are either dermatologists or plastic surgeons (and not affiliated with the trial or Esthetic Education LLC) shall review the baseline and treatment photographs and score them using the VAS scale (Visual Analogue Scale).|"Each participant shall have at least one suitable ventral torso hypertropic scar of sufficient length that it may be easily visualized in two halfs. At the conclusion of the trial all participants shall be provided with a cross over treatment on the non-treated portion of the scar identical to that which was provided within the trial for the purpose of evening the ventral torso hypertrophic scar."||||
34002048|NCT06667232|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922697|NCT03594253|RANDOMIZED|PARALLEL||TREATMENT||NONE||Regulation Focused Psychotherapy for Children (RFP-C; Hoffman \& Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. RFP-C conceptualizes children's externalizing behaviors as expressions of maladaptive defenses or impaired emotion regulation (ER). The child's behaviors are understood as products of developmental delays in implicit ER (Rice \& Hoffman, 2014). Externalizing behaviors are conceptualized both as biologically-driven products and as functional attempts to defend against painful emotions by protecting the child from disturbing feelings such as sadness, shame, and guilt. This 16-session (plus four parent sessions) psychotherapy method iteratively addressing a child's disruptive behaviors as strategies to avoid painful affect. RFP-C is hypothesized to address developmental immaturity of the implicit ER system.||||
33697698|NCT01945827|||CASE_ONLY||PROSPECTIVE|||||||
33697699|NCT03576365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware of which treatment arm they are assigned.||t|f|f|f
33697700|NCT00319631|||CASE_ONLY||PROSPECTIVE|||||||
33697701|NCT04171765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33785913|NCT02509390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785914|NCT03426579|||COHORT||PROSPECTIVE|||||||
33785915|NCT06629948|||OTHER||CROSS_SECTIONAL|||||||
33785916|NCT06219603|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33785917|NCT04619654|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm open label descriptive case series||||
33785918|NCT05042271|||OTHER||PROSPECTIVE|||||||
33922698|NCT02700139|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33922699|NCT05248555|||COHORT||PROSPECTIVE|||||||
33922700|NCT02711904|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922701|NCT02287870|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33922702|NCT05268705|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33922703|NCT00546429|||CASE_ONLY||PROSPECTIVE|||||||
33922704|NCT01183312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33922705|NCT04404023|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33922706|NCT04676542|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).The independent variables are the two conditions and the dependent variables are processing speed, attention, executive function (Stroop Color and Word tests), and a stress visual analog scale||||
33922707|NCT01879319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922708|NCT06138886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922709|NCT02384395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922710|NCT00375960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33922711|NCT02423460|NA|SINGLE_GROUP||OTHER||NONE||||||
33922712|NCT04328922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, treating physician and study investigators will be blinded to the treatment intervention (FMT/ placebo).|A randomized double blinded controlled clinical trial|t|t|t|t
33922713|NCT05016791|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Participants will be randomised after enrollment to active or control arms of this study|A prospective, randomised controlled trial to compare the standard follow-up pathway after AF catheter ablation against the standard pathway augmented with Apple Watch-based rhythm monitoring. The endpoints will be the time to detection of AF recurrence and downstream sequelae such as the number of repeat ablation procedures, and longer-term freedom from AF.||||
33922714|NCT01793714|||CASE_ONLY||PROSPECTIVE|||||||
33922715|NCT06466824|||CASE_ONLY||RETROSPECTIVE|||||||
33922716|NCT03823040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922717|NCT01499719|||COHORT||PROSPECTIVE|||||||
33922718|NCT03350841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922719|NCT04672187|||COHORT||PROSPECTIVE|||||||
33922720|NCT01385267|||CASE_ONLY||PROSPECTIVE|||||||
33697702|NCT01346969|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33697703|NCT05376943|||COHORT||RETROSPECTIVE|||||||
33697704|NCT04357366|NA|SINGLE_GROUP||PREVENTION||NONE||Treatment with anakinra||||
33697705|NCT00110903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697706|NCT04638400|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33697707|NCT05526391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697708|NCT06681441|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A participant and investigator-blinded, randomized, placebo-controlled design will be used to minimize bias in this study.|This is a randomized, double-blind, placebo-controlled, 3-way cross-over, single-dose study to investigate the effects of QRL-101 on TMS-EMG-EEG, mNETT, and pEEG in healthy participants.|t|f|t|f
33697709|NCT05408013|||OTHER||PROSPECTIVE|||||||
33697710|NCT01736124|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33785919|NCT05397457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785920|NCT02473120|NA|SINGLE_GROUP||OTHER||NONE||||||
33785921|NCT04782999|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||Prospective evaluation of gastric bypass patients, who will be examined before, 1 week and 3 months after the gastric bypass operation.|t|f|f|f
33922721|NCT06490926|||COHORT||PROSPECTIVE|||||||
33922722|NCT05693038|||COHORT||PROSPECTIVE|||||||
33922723|NCT03921047|||CASE_ONLY||PROSPECTIVE|||||||
33922724|NCT02235402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002049|NCT03700398|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34002050|NCT01952691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002051|NCT06021106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants were not informed about which group they were in, patients in the experimental and control groups were recruited at different times, and separate consent forms were created for the experimental and control groups. The statistician was not informed about the experimental and control groups, and the experimental and control groups were coded as A and B.|Pretest posttest single blind parallel group randomized controlled experimental study|t|f|f|t
34025159|NCT01539499|||CASE_ONLY||RETROSPECTIVE|||||||
34025160|NCT00776750||PARALLEL||TREATMENT||NONE||||||
34089456|NCT06212583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089457|NCT04058912|||CASE_CONTROL||PROSPECTIVE|||||||
34089458|NCT02866981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089459|NCT05871801|||COHORT||CROSS_SECTIONAL|||||||
34089460|NCT03491488|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled trial at 60 public crèches in São Paulo, Brazil||||
34089461|NCT03042689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089462|NCT05218902|||COHORT||OTHER|||||||
34089463|NCT00795574|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34089464|NCT05391672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089465|NCT03726476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34089466|NCT00581204|||CASE_ONLY||PROSPECTIVE|||||||
34089467|NCT05324696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34089468|NCT03915067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089469|NCT01792232|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33697711|NCT03434769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697712|NCT05420675|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697713|NCT06681519|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Research model type: Indicate whether parallel group design, crossover design, causal comparison, etc. are used. For example: This study uses a parallel group design, randomly assigning subjects to the experimental group and the control group.~Details of the intervention model: If different intervention approaches or multiple intervention groups are involved, you can describe the details of each intervention group. For example: The experimental group received specific acupoint massage (Hegu LI4, Shenmen HT7), and the control group received standard care.~Allocation and randomization methods: Describe the allocation method, such as random assignment or stratified randomization.~Experimental controls: If there are control groups, placebo controls, or other controls, you can state this here."||||
33697714|NCT01953861|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33697715|NCT03316339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697716|NCT06678698|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33697717|NCT01538810|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33697718|NCT03400514|||CASE_ONLY||RETROSPECTIVE|||||||
33720115|NCT04187560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33720116|NCT03657706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720117|NCT04517565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785922|NCT05060185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785923|NCT04340245|||COHORT||PROSPECTIVE|||||||
33785924|NCT04068103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785925|NCT01174316|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33922725|NCT03713957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922726|NCT03342456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922727|NCT06283992|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Researchers will compare effectiveness between two arms: 1) patient education using a digital navigator on using digital tools after discharge and 2) usual care (educational sheet).|f|f|t|t
33922728|NCT01313481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922729|NCT03130712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922730|NCT04101578|||COHORT||PROSPECTIVE|||||||
33922731|NCT00326222|RANDOMIZED|PARALLEL||||NONE||||||
33922732|NCT04973891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922733|NCT01017341|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34089470|NCT06066775|||COHORT||PROSPECTIVE|||||||
33922734|NCT00961870|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33922735|NCT05454397|||CASE_ONLY||PROSPECTIVE|||||||
33922736|NCT05800379|||CASE_ONLY||RETROSPECTIVE|||||||
33922737|NCT00646568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922738|NCT01119157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33922739|NCT01273493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922740|NCT02924688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33922741|NCT03909555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33922742|NCT00877604|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33922743|NCT02166229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922744|NCT04383314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922745|NCT05264558|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The model will permit all interventions to be explored for their impact on testing and treatment numbers in the HCV care cascade||||
33922746|NCT00959530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922747|NCT01772836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922748|NCT01752972|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922749|NCT05655858|||COHORT||PROSPECTIVE|||||||
33922750|NCT04886518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922751|NCT05493540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922752|NCT04976296|||COHORT||PROSPECTIVE|||||||
33922753|NCT04813276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33922754|NCT00040547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922755|NCT03293186|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33922756|NCT01800279|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34089471|NCT03342768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785926|NCT06226987|||COHORT||PROSPECTIVE|||||||
33922757|NCT00813618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922758|NCT01692002|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33922759|NCT00180271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922760|NCT05871593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922761|NCT00181935|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33922762|NCT02727400|||CASE_CONTROL||PROSPECTIVE|||||||
33922763|NCT04377269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922764|NCT00334152|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33922765|NCT03924310|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The two interventions are commercially available myoelectric hand prostheses either with or without an additional feedback device.||||
33922766|NCT04740060|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33922767|NCT05657951|||CASE_ONLY||CROSS_SECTIONAL|||||||
34089472|NCT00761800|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089473|NCT01510756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089474|NCT02924870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089475|NCT04810156|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The aim is to enroll around 40 patients in Cohort A for prospectively characterize the various patterns of liver injury histopathologically, biochemically, and phenotypically that are induced by ICI, and the response to treatment (steroids and MMF).~Cohort B: 20 patients who experienced a relapse of ir-hepatitis (grade ≥2) during prednisolone tapering or within one month after ended tapering will be randomized to either 100% dose of current steroid dose or restart of steroid 0.5-1 mg/kg versus adding MMF (if the patient received prednisolone the tapering plan hereof is continued, prednisolone up to 25 mg can be added if clinical indicated). Treatment efficacy is evaluated after seven days, if sufficient response the patients continued treatment, in case of insufficient response a cross-over will be performed"||||
33785927|NCT05045872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785928|NCT06414980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34089476|NCT02722109|||OTHER||OTHER|||||||
33785929|NCT06628427|||COHORT||CROSS_SECTIONAL|||||||
33922768|NCT02197611|||COHORT||CROSS_SECTIONAL|||||||
33922769|NCT00648141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089477|NCT01373164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089478|NCT01881425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089479|NCT06535659|||COHORT||PROSPECTIVE|||||||
34089480|NCT02011399|||COHORT||PROSPECTIVE|||||||
34089481|NCT04172272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089482|NCT00658619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34089483|NCT01699984|||COHORT||PROSPECTIVE|||||||
34089484|NCT00297934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922770|NCT02611700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922771|NCT03706092|||COHORT||PROSPECTIVE|||||||
33922772|NCT05892263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922773|NCT00210379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922774|NCT05589480|||CASE_CONTROL||RETROSPECTIVE|||||||
33922775|NCT04426994|||CASE_CONTROL||RETROSPECTIVE|||||||
33922776|NCT01619163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922777|NCT06323694|||OTHER||PROSPECTIVE|||||||
33922778|NCT05647629|||CASE_ONLY||PROSPECTIVE|||||||
33922779|NCT01925391|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33922780|NCT06165380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922781|NCT03169517|||COHORT||PROSPECTIVE|||||||
33922782|NCT00012883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922783|NCT03963804|||COHORT||PROSPECTIVE|||||||
33922784|NCT05720273|NA|SINGLE_GROUP||OTHER||NONE||Maintenance hemodialysis patients with secondary hyperparathyroidism||||
33922785|NCT01605383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922786|NCT00505752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922787|NCT05812937|||COHORT||PROSPECTIVE|||||||
33922788|NCT01545024|||CASE_ONLY||PROSPECTIVE|||||||
33922789|NCT02182297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922790|NCT02378246|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33922791|NCT05622357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922792|NCT04350905|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants were all exposed to 5 uninfected Aedes aegypti mosquitos on their forearm. Biopsies were taken of bitten and unbitten skin.||||
33922793|NCT06044519|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33922794|NCT01606397|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33922795|NCT00373828|||COHORT||PROSPECTIVE|||||||
33922796|NCT03162458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922797|NCT03553550|||OTHER||PROSPECTIVE|||||||
33922798|NCT04420910|||CASE_CONTROL||PROSPECTIVE|||||||
33922799|NCT04938362|||CASE_ONLY||PROSPECTIVE|||||||
33922800|NCT03934424|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized to read a weight stigma article or control article and subsequently scanned for fMRI data||||
33922801|NCT05249712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922802|NCT02273037|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922803|NCT03595384|NA|SINGLE_GROUP||PREVENTION||NONE||This is a longitudinal pre-post pilot intervention study evaluating feasibility of implementation of a soccer-based Diabetes Prevention Program and preliminary changes in physical activity and diet-related measures.||||
34002052|NCT03234608|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will conduct the study in primary care clinics within three health systems. We will compare data from patients in 7 intervention clinics to patients from matched control clinics within the same systems.||||
33697719|NCT06652529|NA|SEQUENTIAL||TREATMENT||NONE||"This clinical trial is divided into two parts: dose escalation (part A), and dose expansion (part B). In part A (dose escalation), patients will be treated with AROG4-01 at different doses, starting at 9 mg/m2. Escalation to next dose levels will occur following the Safety Review Committee meeting for the most recently completed cohort.~The MTD decided as per part A (dose escalation) will be used for part B (dose expansion)."||||
33697720|NCT02156830|||||PROSPECTIVE|||||||
33697721|NCT00546650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33922804|NCT06187948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922805|NCT00003129||||TREATMENT||||||||
33922806|NCT01684891|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33922807|NCT05806736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)||t|f|f|t
33922808|NCT02983539|||COHORT||PROSPECTIVE|||||||
33922809|NCT00241163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922810|NCT03103880|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33922811|NCT03234400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33922812|NCT00615914|||COHORT||PROSPECTIVE|||||||
33922813|NCT01699295|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33922814|NCT04035629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33922815|NCT02087293|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33922816|NCT03005041|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33922817|NCT02759861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922818|NCT02521740|||CASE_CONTROL||PROSPECTIVE|||||||
34002053|NCT03973788|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and post test||||
34002054|NCT06613334|NA|SINGLE_GROUP||OTHER||NONE||Patients with schizophrenia are assigned prospectively to the following experimental interventions: blood tests to measure antipsychotics concentration and the administration of questionnaires/voice tests on the CALLYOPE application.||||
34025161|NCT00946816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025162|NCT06210919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025163|NCT02647827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697722|NCT02827916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697723|NCT00136071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33697724|NCT01270295|||||CROSS_SECTIONAL|||||||
33697725|NCT03659955|NA|SINGLE_GROUP||TREATMENT||NONE||Cross sectional study||||
33697726|NCT01148238|||COHORT||PROSPECTIVE|||||||
33697727|NCT00224848|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697728|NCT01542333|||CASE_ONLY||RETROSPECTIVE|||||||
33697729|NCT02337738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697730|NCT00178750|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785930|NCT04090320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002055|NCT01109849|RANDOMIZED|PARALLEL||TREATMENT||NONE||"initial randomization to behavior or extended release stimulant (ER stimulant) arms.~Participants in either arm meting criteria for a weight recovery intervention (based on change in zBMI) will be adaptively randomized to one of three weight recovery arms (Monitoring, Drug Holiday, Caloric Supplementation)"||||
34002056|NCT05833464|||COHORT||PROSPECTIVE|||||||
34002057|NCT01118234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002058|NCT00198536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089485|NCT05598268|NA|SEQUENTIAL||TREATMENT||NONE|Open Label|||||
34089486|NCT06197204|||COHORT||PROSPECTIVE|||||||
34089487|NCT03524001|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34089488|NCT05271487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089489|NCT00964704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089490|NCT02115152|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34089491|NCT00429247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089492|NCT01954615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089493|NCT06290817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089494|NCT01176929|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089495|NCT04376671|||CASE_ONLY||RETROSPECTIVE|||||||
34089496|NCT01415076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34089497|NCT04057768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089498|NCT00285922|||DEFINED_POPULATION||PROSPECTIVE|||||||
34089499|NCT01447966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089500|NCT00386828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089501|NCT05230732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089502|NCT00858546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089503|NCT05964972|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34002059|NCT02000115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002060|NCT03518723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will be masked to group allocation. The participants will be given repeated instructions not to reveal their group allocation to the outcome assessors. In case of failure in keeping the outcome assessor masked (i.e, a patient reveals his/her group allocation), a second trained outcome assessor will be available.|Prospective, assessor-blind, parallel-group randomized controlled multicenter trial with a pre- and post-intervention design|f|f|f|t
34002061|NCT01967901|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34002062|NCT00326326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002063|NCT02287220|||COHORT||PROSPECTIVE|||||||
34002064|NCT02919020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34025164|NCT04400682|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34025165|NCT02820207|||COHORT||PROSPECTIVE|||||||
34089504|NCT06030362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34089505|NCT00119704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089506|NCT01008644|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34089507|NCT03735576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, multi-center, single blind (observer-blinded), active-controlled, parallel group trial (therapeutic confirmatory) in 248 patients with late-life depression of both genders at 7 trial sites in Germany. The intervention includes 8 weeks of manual-based, individual, 15-session, twice weekly, outpatient treatment for patients with late life depression in each arm of the trial.|f|f|f|t
34089508|NCT02975596|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34089509|NCT04935632|||CASE_ONLY||PROSPECTIVE|||||||
34089510|NCT04736875|||COHORT||PROSPECTIVE|||||||
34089511|NCT01456117|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34089512|NCT04784689|||COHORT||PROSPECTIVE|||||||
34089513|NCT02818803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089514|NCT00937196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33922819|NCT03240952|||COHORT||CROSS_SECTIONAL|||||||
33922820|NCT00765713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922821|NCT04843826|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series trial||||
33922822|NCT03908541|||COHORT||PROSPECTIVE|||||||
33922823|NCT00603733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002065|NCT01819064|NA|SINGLE_GROUP||OTHER||NONE|Observer of ECG rhythm strips was unaware of the study hypothesis, the study drug administered, the dose given and the arrhythmias sought. Your statement that masking a single outcome implies a multi-arm study precludes a panoramic perspective of clinical research study designs and scenarios in which assessors may be effectively blinded.|This is a single arm study where a dose of atropine was administered and the ECG recorded.||||
33922824|NCT05291572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002066|NCT05489497|||CASE_CONTROL||RETROSPECTIVE|||||||
33922825|NCT01859572|||CASE_ONLY||PROSPECTIVE|||||||
33922826|NCT02853981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002067|NCT05118425|||CASE_ONLY||CROSS_SECTIONAL|||||||
34002068|NCT01361334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002069|NCT01898598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002070|NCT06127745|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled participants will be treated with the Discure System||||
34002071|NCT03803267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind (participant) study||t|f|f|f
34089515|NCT00001931||||TREATMENT||||||||
34089516|NCT04336683|NA|SINGLE_GROUP||OTHER||NONE||Patients who are assigned to gynecological brachytherapy.||||
34089517|NCT03217825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34089518|NCT01081990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089519|NCT04252729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089520|NCT00989885|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34089521|NCT03164824|||OTHER||RETROSPECTIVE|||||||
34089522|NCT02912052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089523|NCT02628977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922827|NCT00815204|||CASE_CONTROL||PROSPECTIVE|||||||
33922828|NCT05069285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922829|NCT05108688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922830|NCT01241955|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33922831|NCT00288522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922832|NCT01362699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922833|NCT04368468|||COHORT||RETROSPECTIVE|||||||
33922834|NCT01641965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922835|NCT03046017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33922836|NCT02281981|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33922837|NCT06210958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients will be divided into 2 groups: single injection of intertransverse process block and triple injection of intertransverse process block|f|f|t|t
33922838|NCT02668744|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922839|NCT02679807|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33922840|NCT04923698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|using closed envelope|Group A (Control group): It consisted of 20 women and treated by antidepressant drugs only for 12 weeks. Group B (Study group): It consisted of 20 women and treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily,7 days per week for 12 weeks (Total 84 sessions).|f|f|f|t
33922841|NCT05075707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922842|NCT06197737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922843|NCT03994536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33922844|NCT02528253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922845|NCT00460837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33922846|NCT00003735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089524|NCT02631681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089525|NCT01650376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089526|NCT02521480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089527|NCT01616927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089528|NCT06384924|||COHORT||PROSPECTIVE|||||||
34089529|NCT02145858|||COHORT||PROSPECTIVE|||||||
34089530|NCT02153281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922847|NCT05622344|RANDOMIZED|PARALLEL||TREATMENT||NONE||At each site, one group will receive the control and the second group will receive the experimental treatment (novel rehab device).||||
34002072|NCT05192096|||COHORT||PROSPECTIVE|||||||
33922848|NCT05106218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are not aware of the laparoscopic system that will be used during the operation.|"For laparoscopic camera system to be used in urological surgeries, the SurroundScope, 270-degree angle videoscope (270Surgical, Israel) is used. This will be compared to the standard laparoscopic system use.~The study will evaluate standard urological surgeries using the 270Surgical system vs same procedures using the standard scope. The procedure will be performed according to the institution's standard of care, using the SurroundScope or the standard scope for visualization. Each surgery will be captured on video."|t|f|f|f
34002073|NCT06679738|||OTHER||CROSS_SECTIONAL|||||||
34002074|NCT02171091|||OTHER||PROSPECTIVE|||||||
33922849|NCT00047307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922850|NCT01674894|||COHORT||PROSPECTIVE|||||||
33922851|NCT02204033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922852|NCT03179410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922853|NCT00184652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922854|NCT03258463|||OTHER||RETROSPECTIVE|||||||
34002075|NCT06679725|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind study using identical-looking package. The taste of the beverage was very similar for both WG and placebo (based on food survey)|This study is a double-blind, placebo-controlled crossover experiment with two trials (WG and placebo) separated with 2-week wash-out period.|t|f|t|f
34002076|NCT04909112|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002077|NCT02682134|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34002078|NCT04809844|||OTHER||RETROSPECTIVE|||||||
34002079|NCT02914457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002080|NCT05109520|||CASE_CONTROL||RETROSPECTIVE|||||||
33697731|NCT02575742|||CASE_CONTROL||PROSPECTIVE|||||||
33697732|NCT00532155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922855|NCT02375204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922856|NCT03271307|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study will include two arms and methodology: (Aim 1) A cluster-randomized trial comparing HIV testing strategies for OPD clients, clustered by health facility; and (Aim 2) A individual-randomized trial comparing HIV testing strategies for partners of HIV-positive clients.||||
34002081|NCT04909645|NA|SINGLE_GROUP||OTHER||NONE||||||
34002082|NCT05327712|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34002083|NCT04083534|NA|SEQUENTIAL||TREATMENT||NONE||||||
34002084|NCT03240120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002085|NCT01272024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089531|NCT06057857|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33697733|NCT02415257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697734|NCT04070144|NA|SINGLE_GROUP||OTHER||NONE||||||
33697735|NCT06323954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33697736|NCT01964131|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33697737|NCT04950023|||COHORT||PROSPECTIVE|||||||
33697738|NCT06400251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697739|NCT02969551|||COHORT||PROSPECTIVE|||||||
33697740|NCT03862859|RANDOMIZED|PARALLEL||PREVENTION||NONE|None (Open Label|A multicentre, randomized, open label, parallel group study.||||
33697741|NCT04855864|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33785931|NCT06526793|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The trial will assess AZD0486 monotherapy given by IV infusion. Module 1 will evaluate the efficacy and safety of AZD0486 monotherapy at the recommended Phase 2 dose (RP2D), in participants 18 to 80 years of age, with relapsed or refractory (R/R) follicular lymphoma (FL) who have received ≥ 2 prior therapies. Module 2 will evaluate the efficacy and safety of AZD0486 monotherapy at the RP2D for participants 18 to 80 years of age with (R/R) diffuse large B-cell lymphoma (DLBCL).||||
33785932|NCT04045470|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Expansion cohort may enroll only after initial cohort has completed enrollment||||
33785933|NCT05794022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785934|NCT05729373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Randomized, Double-blind, Parallel group, Placebo-controlled|t|t|t|t
33785935|NCT04440943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785936|NCT05313672|||CASE_CONTROL||RETROSPECTIVE|||||||
33785937|NCT02387346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785938|NCT06714500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785939|NCT05653089|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33785940|NCT02028884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33785941|NCT06629714|||COHORT||PROSPECTIVE|||||||
33785942|NCT02299921|||COHORT||PROSPECTIVE|||||||
33785943|NCT02537392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33785944|NCT02828605|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33785945|NCT02697799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33785946|NCT02148406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33785947|NCT05439655|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||"In a multi-phase structure, the project will investigate the feasibility of recording the HFOs with the BIC system (Cortec, Germany) and then delivering closed-loop stimulation.~In Phase-I, the feasibility of recording and transmitting iEEG data in robust fashion will be tested. For this 2 subjects will be recruited.~In Phase-II (if Phase-I is successful), the feasibility of capturing HFOs iEEG data with the implantable system will be tested. For this 10 subjects will be recruited.~In Phase-III (if Phase-II is successful), the feasibility of delivering of closed-loop stimulation with the implantable system will be tested. For this 8 subjects will be recruited.~Therefore, in this multiphase feasibility study, in total 20 subjects will be recruited in a sequential fashion. In each phase less than 10 subjects will be recruited to test device feasibility."||||
33785948|NCT01560143|NA|SINGLE_GROUP||||NONE||||||
33785949|NCT00486733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33785950|NCT00609648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785951|NCT06628466|||COHORT||PROSPECTIVE|||||||
33785952|NCT02324114|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33785953|NCT01436409|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33785954|NCT00323089|NA|SINGLE_GROUP||TREATMENT||NONE||Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)||||
33785955|NCT00722748|||CASE_ONLY||CROSS_SECTIONAL|||||||
33785956|NCT05665855|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33785957|NCT04465071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|To assess the use of additional lubricant eye-drops for 6 weeks following uncomplicated, routine cataract sur-gery to improve patient satisfaction and symptoms of dry eye in an NHS (public health care) setting, compared to no additional lubricating eye drops||||
33922857|NCT03201367|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|40 patients received rivaroxaban||||
33922858|NCT05566288|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Only the moxifloxacin treatment will not be blinded to site personnel and the participants, but moxifloxacin treatment will be blinded to the central cardiologist for assessments.||t|f|t|t
33922859|NCT00392548|||DEFINED_POPULATION||PROSPECTIVE|||||||
33922860|NCT02001363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922861|NCT03248180|||CASE_CONTROL||PROSPECTIVE|||||||
33922862|NCT05376098|||COHORT||PROSPECTIVE|||||||
33785958|NCT03032796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33922863|NCT01646463|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34002086|NCT01268839|NA|SINGLE_GROUP||||NONE||||||
34002087|NCT06618638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002088|NCT02208973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002089|NCT04590196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002090|NCT00474318|||OTHER||PROSPECTIVE|||||||
34002091|NCT05928234|||COHORT||CROSS_SECTIONAL|||||||
34002092|NCT00926445|||COHORT||PROSPECTIVE|||||||
34002093|NCT06060522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002094|NCT05263713|RANDOMIZED|FACTORIAL||OTHER||SINGLE||At the follow-up visit, two blinded observers will record their scores independently using the POSAS instrument.|f|f|f|t
34002095|NCT02465684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34002096|NCT06529133|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34002097|NCT00743860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002098|NCT02381197|||COHORT||PROSPECTIVE|||||||
34002099|NCT00851006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785959|NCT05541237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34002100|NCT01398839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785960|NCT06492577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33785961|NCT00540813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922864|NCT03783338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to which each child allocated to any one of the three arms.|Children will be assigned randomly using sealed envelopes into three intervention groups (A, B and C groups). Group A will receive the conventional physical therapy program (CPTP) only. Group B will receive the CPTP in addition to aerobic exercises, whereas group C will receive CPTP, aerobic exercises in addition to an oral daily dose of vitamin D3 1000 IU (Cholecalciferol). All groups will receive the treatment program for 12 weeks.|f|f|f|t
33922865|NCT05059938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922866|NCT03823807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002101|NCT04265287|||COHORT||PROSPECTIVE|||||||
34002102|NCT04789187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Pseudonymization|Randomized Controlled Trial|t|f|f|t
34002103|NCT02105701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002104|NCT05184803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002105|NCT02712294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002106|NCT05951751|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34002107|NCT00867386|||COHORT||PROSPECTIVE|||||||
34002108|NCT02581917|||CASE_ONLY||PROSPECTIVE|||||||
34002109|NCT00252447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002110|NCT01026649|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922867|NCT03400215|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922868|NCT06061640|||CASE_CONTROL||PROSPECTIVE|||||||
33697742|NCT01626495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697743|NCT06681636|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants (FSW groups) will be randomly assigned to either of the vaccine schedules and will be given IDs. The link between participant IDs and vaccine groups are only known by Investigator.~Barcodes will be used for samples and no personal identification nor participant ID is allowed in the samples."||t|f|f|t
33697744|NCT05632367|||CASE_CONTROL||PROSPECTIVE|||||||
34002111|NCT06326424|||COHORT||PROSPECTIVE|||||||
33697745|NCT05540444|||CASE_CROSSOVER||PROSPECTIVE|||||||
33922869|NCT01025947|||COHORT||PROSPECTIVE|||||||
34002112|NCT02269150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697746|NCT06276231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922870|NCT04965168|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33922871|NCT06016257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"At the first physical therapy appointment, subjects in Group 1 will be given access to and provided necessary materials for the VirtuaCare™ platform to use as an adjunct for the prescribed shoulder exercises when at home. Whereas Group 2's information will be obtained via a retrospective chart review.~For the subjects in Group 1, the physical therapist will set up the patients within the VirtuaCare™ system and build their treatment plan.~Each time a patient in Group 1 returns for a clinic visit, the physical therapist will review their VirtuaCare™ patient report displaying information such as exercises completed along with their measured form, pace, range of motion, and exertion. From the review, they will help the patient understand any corrections they need to make in the following week when at home. The therapist can add or adjust any exercises they deem necessary for the next phase of the patient's rehabilitation."||||
33697747|NCT00735254|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33785962|NCT02266810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intra-patient control|t|f|f|t
33697748|NCT05449522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33697749|NCT04882046|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697750|NCT02409810|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33697751|NCT04673448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697752|NCT01033188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33697753|NCT00342186|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33785963|NCT05068037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participant and the outcomes assessor will not know which intervention was used|Participants will be randomised to three arms regarding the type of intervention|t|f|f|t
33785964|NCT06282835|||COHORT||PROSPECTIVE|||||||
33785965|NCT05014204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785966|NCT05683301|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33785967|NCT02000505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785968|NCT06192576|||COHORT||PROSPECTIVE|||||||
33785969|NCT03220139|||COHORT||PROSPECTIVE|||||||
33785970|NCT04104464|||OTHER||PROSPECTIVE|||||||
33785971|NCT04442672|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33785972|NCT05521867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785973|NCT03877796|||OTHER||OTHER|||||||
33785974|NCT03270930|||COHORT||PROSPECTIVE|||||||
33785975|NCT02434393|||CASE_CONTROL||PROSPECTIVE|||||||
33785976|NCT00620516|||||PROSPECTIVE|||||||
33785977|NCT06631261|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33785978|NCT03363256|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33785979|NCT00536380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922872|NCT00439153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33922873|NCT00863421|||COHORT||PROSPECTIVE|||||||
33922874|NCT02532387|||CASE_ONLY||PROSPECTIVE|||||||
33785980|NCT01178515|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33785981|NCT01231282|NA|SINGLE_GROUP||||NONE||||||
33785982|NCT06630468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator was blinded||f|f|t|f
33785983|NCT03273530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785984|NCT01656304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785985|NCT01972802|||CASE_CONTROL||PROSPECTIVE|||||||
33785986|NCT01168401|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33785987|NCT06629194|||COHORT||PROSPECTIVE|||||||
33785988|NCT02144350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922875|NCT00054158||||TREATMENT||NONE||||||
34002113|NCT02248714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002114|NCT05754918|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: the patient and the investigator don't know the fitting.|"Two arms A and B:~Arm A: patient's fitting with tonotopy-based fitting without fine structure coding (TnoFS) --\> 6 weeks use --\> tests and patient's fitting with tonotopy-based fitting with fine structure coding (TFS) --\> 6 weeks use --\> tests; Arm B: patient's fitting with TFS --\> 6 weeks use --\> tests and patient's fitting with TnoFS --\> 6 weeks use --\> tests"|t|f|t|f
34002115|NCT01578317|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34002116|NCT02119052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002117|NCT02495987|||OTHER||PROSPECTIVE|||||||
34002118|NCT02738216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002119|NCT06170034|||OTHER||PROSPECTIVE|||||||
34002120|NCT02647515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002121|NCT06179693|||COHORT||RETROSPECTIVE|||||||
34002122|NCT03427801|||CASE_CONTROL||RETROSPECTIVE|||||||
34025166|NCT05445583|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34025167|NCT01755767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025168|NCT02072304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025169|NCT01229579|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33697754|NCT03906461|||COHORT||PROSPECTIVE|||||||
33697755|NCT01147588|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33697756|NCT03678883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697757|NCT04336410|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33697758|NCT04108702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697759|NCT05738018|||CASE_CROSSOVER||PROSPECTIVE|||||||
33785989|NCT02302209|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33785990|NCT04888585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33785991|NCT04759131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33785992|NCT01986374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785993|NCT05735847|||COHORT||PROSPECTIVE|||||||
33785994|NCT06631027|||CASE_ONLY||CROSS_SECTIONAL|||||||
33922876|NCT00863980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922877|NCT05518669|||COHORT||PROSPECTIVE|||||||
33922878|NCT02993913|NA|SINGLE_GROUP||||NONE||||||
33922879|NCT02366741|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922880|NCT05400356|||COHORT||PROSPECTIVE|||||||
33922881|NCT05996380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922882|NCT03380624|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Investigator instills eye drop masked to participant. While this is a single arm study in that all participants receive both eye drops, the order in which they are used is randomized and masked.|Double masked, randomized|t|f|f|t
33922883|NCT02739256|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33922884|NCT01913860|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34002123|NCT05697757|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Neither participants nor their caregivers will be told about the structure of the lighting conditions and the potential effects, just that the lighting could change daily.|Investigators will examine a series of participants (N=30), each of whom will participate in a seven-week experiment. The study will be conducted over seven successive one-week periods with two cohorts of participants experiencing the same series of lighting interventions in a counterbalanced manner.|t|t|f|f
34002124|NCT05214144|||COHORT||PROSPECTIVE|||||||
34002125|NCT01456260|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34002126|NCT03790137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002127|NCT05759156|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34002128|NCT00186693|||COHORT||PROSPECTIVE|||||||
34002129|NCT00000564|RANDOMIZED|||TREATMENT||||||||
34002130|NCT02088333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34002131|NCT02141945|||CASE_ONLY||PROSPECTIVE|||||||
34002132|NCT06232772|||COHORT||CROSS_SECTIONAL|||||||
34002133|NCT04229160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002134|NCT01470898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34002135|NCT06172439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a randomized controlled intervention trial||||
34002136|NCT02463019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002137|NCT00006467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002138|NCT05174754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002139|NCT01408888|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002140|NCT02169336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002141|NCT03316222|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34002142|NCT01176981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785995|NCT05973773|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33785996|NCT06488170|||COHORT||PROSPECTIVE|||||||
33785997|NCT05114109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33785998|NCT01123720|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33785999|NCT01710150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786000|NCT06550115|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786001|NCT00880490|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33786002|NCT01599325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786003|NCT05722951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786004|NCT03625037|NA|SEQUENTIAL||TREATMENT||NONE||||||
33922885|NCT01957787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002143|NCT02673086|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34089532|NCT03943082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002144|NCT01671657|||CASE_CONTROL|||||||||
33697760|NCT06345092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33922886|NCT00482300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922887|NCT01022385||||DIAGNOSTIC||||||||
34089533|NCT03163966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922888|NCT00599235|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34002145|NCT04937998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blinded randomized controlled trial with 1:1 allocation.Patient blinding will be provided during the injection treatment.|The study is a double-blinded RCT in which one group of patients will be treated with 1 intra-articular injection of fresh PRP, and one group will be treated with 1 intra-articular injection of HA.|t|f|f|t
34002146|NCT02114853|||COHORT||PROSPECTIVE|||||||
33697761|NCT02356315|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34002147|NCT05972564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Placebo consists of gelatin capsules. To ensure blinding, empagliflozin will be over-encapsulated in identical gelatin capsules as placebo.|Participants will be randomized to placebo or empagliflozin in a 1:1 ratio, stratified for race and sex. A study biostatistician will prepare the randomization and allocation schedule.|t|t|t|t
34002148|NCT05885386|NA|SINGLE_GROUP||TREATMENT||NONE||PPGLs could not be performed R0 resection due to the large tumor size and close relationship with surrounding tissues (blood vessels, kidneys, pancreas, liver, etc.)||||
33697762|NCT06235333|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Through Qualtrics programming, individuals will be randomly assigned to an intervention or control group. Because this happens automatically, the investigators will not know assigned conditions until after data collection is completed. Participants will be aware of their condition because they will either participate in a screening or receive problem/responsible gambling information before completing a survey.|There are two possible conditions: (1) intervention, which consists of a branching responsible/problem gambling information and gambling screening experience and (20 control, which consists of limited responsible/problem gambling information experience.|f|f|t|f
34002149|NCT05857345|||OTHER||CROSS_SECTIONAL|||||||
34002150|NCT00842309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002151|NCT01715649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002152|NCT01112462|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33697763|NCT02680509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697764|NCT01303328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697765|NCT05859256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All evaluations will be carried out by one evaluator, blinded to the study conditions and the assignment of the players to the two study groups.~In the subjects included in the control group, the same procedures will be carried out, but placing the flossing without tension and performing the Kaltenborn manual techniques without slipping and without joint mobilization."||t|f|f|t
33697766|NCT03098355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697767|NCT02256072|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33697768|NCT05218668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|Open label, two arms||||
33697769|NCT01672229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697770|NCT03468985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002153|NCT05540171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The research assistants (dentists) collecting data and the study statistician will be blinded as to which sites are the intervention and control arms.~The primary investigator and instructor will not be blinded as knowledge of the intervention will be necessary to ensure proper implementation of the intervention protocol."|"A 2-arm randomized control study which involves two groups of participants who will be recruited into the study at the sites. The sites would have been randomized into control and intervention arms using a simple lottery technique.~Four (4) identical slips of paper with 'control' printed on 2 on them and 'intervention' on the other 2 slips will be provided. Each paper will be sealed in envelopes which will all be identical, and they will be placed in a box. An individual unconnected to the study will be asked to select two (2) envelopes from the box and these will be assigned the control group while the two (2) envelopes left in the box will be the assigned the intervention group."|t|f|f|t
33697771|NCT06534749|||CASE_ONLY||CROSS_SECTIONAL|||||||
33697772|NCT03473951|||COHORT||RETROSPECTIVE|||||||
33697773|NCT06041113|||COHORT||RETROSPECTIVE|||||||
33697774|NCT02193581|||CASE_ONLY||PROSPECTIVE|||||||
33697775|NCT05593471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786005|NCT04661670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor and statistician will be blinded. It is not possible to blind neither the participant nor the care provider||f|f|f|t
33786006|NCT04262414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786007|NCT02824003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922889|NCT03678584|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33922890|NCT01473303|RANDOMIZED|||TREATMENT||NONE||||||
33922891|NCT01057134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922892|NCT06261112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single /investigatör)|Parallel Assigment|f|f|t|f
33922893|NCT01757977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922894|NCT04873869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922895|NCT06268587|||COHORT||RETROSPECTIVE|||||||
33922896|NCT06342570|||COHORT||PROSPECTIVE|||||||
33922897|NCT06053619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089534|NCT02258061|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34089535|NCT04609696|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34089536|NCT05322486|||COHORT||RETROSPECTIVE|||||||
33697776|NCT02836275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697777|NCT05514132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33697778|NCT04773119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697779|NCT02602392|RANDOMIZED|PARALLEL||||NONE||||||
33786008|NCT05541757|||CASE_CONTROL||PROSPECTIVE|||||||
33786009|NCT04966208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786010|NCT05622032|||COHORT||RETROSPECTIVE|||||||
33922898|NCT05955079|||COHORT||PROSPECTIVE|||||||
34002154|NCT03135340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the treatment received.|Two groups. One interventional group and one control group with random allocation as described below.|f|f|f|t
34002155|NCT01956162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002156|NCT00913536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002157|NCT04113616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002158|NCT05953506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34002159|NCT01878513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002160|NCT02126150|||COHORT||PROSPECTIVE|||||||
34089537|NCT03881787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089538|NCT03847207|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34089539|NCT05213130|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34089540|NCT03533933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analyst and Histometry: The statistician and the pathologist does not know which treatment corresponds to each variable.|Split mouth|f|f|f|t
34089541|NCT02729233|NA|SINGLE_GROUP||OTHER||NONE||||||
33922899|NCT00286364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922900|NCT01726283|||CASE_ONLY||PROSPECTIVE|||||||
33922901|NCT02020460|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33922902|NCT00321022|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33922903|NCT01985373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697780|NCT03630042|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, non randomised phase II trial||||
33697781|NCT00990353|||OTHER||PROSPECTIVE|||||||
33697782|NCT03157167|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33922904|NCT05278286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922905|NCT02029638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922906|NCT06182540|NA|PARALLEL||PREVENTION||NONE|Blinded analysis|Acute intervention in populations with and without colon||||
33922907|NCT04247035|||COHORT||PROSPECTIVE|||||||
33922908|NCT04889963|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33922909|NCT03046043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922910|NCT01852929|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33922911|NCT02709772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002161|NCT05196789|||OTHER||PROSPECTIVE|||||||
34002162|NCT00464386|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34002163|NCT02141048|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002164|NCT05756465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessor (Nurse who appointed by researcher to be responsible for collection of outcome data) and data analysts will be blinded from participant allocation. This blinding is carried out, due to the technical nature of VR interventions, making it difficult to blind study participant during the intervention, thus to minimize the potential for methodological bias, the study must blind the outcome assessor or data analysts.|This study is a two-arm parallel randomised controlled trial with a 1:1 allocation. This study divided two groups, namely the intervention group in the form of SVR therapy with the installation of a VR device (head-mounted display/HMD) on the respondent's head during chemotherapy. The control group received standard care through leaflets containing instructions for relaxation techniques with image visualization as guided imagery therapy. The group's determination, apart from randomization, will also use envelope concealment and outcome assessor will be blinded during data collection. The protocol is composed according to Standard Protocol Items: Recommendations for Interventional Trials and its checklist|f|f|f|t
34002165|NCT06361654|||COHORT||PROSPECTIVE|||||||
34025170|NCT06217211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002166|NCT05581134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An examiner blinded to group allocation will assess all patients. To keep blindness, the examiner will not ask for information about the treatment to the patients or the caregivers, and this last will be instructed not to give any extra information outside of the examiner's questions.||f|f|f|t
34002167|NCT03614455|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Prior to dosing on Day 1 of Treatment Period 1, subjects will be assigned to 1 of 2 sequences (sequences AB or AC), according to a pre-generated randomization scheme.||||
34002168|NCT02371837|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34089542|NCT05542602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two of the child outcome measures are completed by masked outcome evaluators including a test of social-cognition/knowledge and behavioral observations of the children's social performance during unstructured free-play periods with peers. These outcome evaluators work in a separate lab space and do not have access to information on the study condition of the children.|This study utilizes a parallel group design consisting of two study conditions (study arms). Condition one consists of the social intervention (intervention being tested) and condition two consists of a no-treatment control comparison group (i.e., waitlist control group).|f|f|f|t
34089543|NCT05320471|||OTHER||CROSS_SECTIONAL|||||||
34089544|NCT03799471|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34089545|NCT05946733|RANDOMIZED|PARALLEL||OTHER||NONE||Patients will be randomly divided into three equal groups using SPSS. Group A: will receive bilateral oblique subcostal TAP block Group B: will receive bilateral lateral TAP block. GroupC:will receive postoperative morphine by patient-controlled analgesia (PCA).||||
34089546|NCT00580281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089547|NCT02452190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089548|NCT01583361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089549|NCT06485505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089550|NCT05136638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome measures will be administered via online surveys||f|f|f|t
34089551|NCT05166096|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34089552|NCT03479827|||COHORT||PROSPECTIVE|||||||
34089553|NCT02556788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089554|NCT04412187|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||18 patients with cortical stroke and 18 patients with subcortical stroke||||
34089555|NCT02748993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089556|NCT00683137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089557|NCT00608179|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
34089558|NCT02664493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089559|NCT05255822|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089560|NCT03061942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089561|NCT01101854|||COHORT||PROSPECTIVE|||||||
34089562|NCT03600350|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, single-institution, two-stage phase II trial||||
34002169|NCT01148069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002170|NCT05819437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled Trial, monocentric||||
34002171|NCT06440278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002172|NCT00178724|||OTHER||PROSPECTIVE|||||||
34002173|NCT06635200|||OTHER||PROSPECTIVE|||||||
34002174|NCT06670560|||OTHER||RETROSPECTIVE|||||||
34002175|NCT03062176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002176|NCT03727945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Urolog was not involved in physiotherapy treatment, randomised patients previous of treatment.|2 aleatorized groups; control group (n=21) and intervention group|t|f|f|f
34002177|NCT02756858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002178|NCT03550196|||COHORT||PROSPECTIVE|||||||
34025171|NCT01920581|||CASE_ONLY||PROSPECTIVE|||||||
34025172|NCT03361930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089563|NCT00563173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089564|NCT03604003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089565|NCT00008697|RANDOMIZED|PARALLEL||TREATMENT||||||||
34089566|NCT02272270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089567|NCT03704077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089568|NCT03111433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697783|NCT01123850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697784|NCT02229331|||COHORT||CROSS_SECTIONAL|||||||
33697785|NCT00644657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697786|NCT05276154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720118|NCT05931250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720119|NCT01758783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720120|NCT03301142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025173|NCT03460392|||OTHER||PROSPECTIVE|||||||
34025174|NCT04430309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025175|NCT04197661|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34025176|NCT04627987|||COHORT||PROSPECTIVE|||||||
34089569|NCT01866371|||CASE_CONTROL||PROSPECTIVE|||||||
34089570|NCT02103842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089571|NCT06491758|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34089572|NCT00699751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089573|NCT04081181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089574|NCT01270659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34089575|NCT00123136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33922912|NCT03404518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomized to one of two groups prior to surgery. All patients will be prescribed both Hydrocodone/acetaminophen and Ibuprofen. Group 1 will take the narcotic medication for initial pain control followed by Ibuprofen if pain is not adequately controlled. Group 2 will take Ibuprofen for initial pain control followed by the narcotic medication if pain is not adequately controlled.|f|f|t|t
33922913|NCT05289856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922914|NCT02437552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922915|NCT01160471|||CASE_CONTROL||PROSPECTIVE|||||||
33922916|NCT04600921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922917|NCT05321095|||OTHER||CROSS_SECTIONAL|||||||
33922918|NCT00663598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33922919|NCT00871572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922920|NCT02665078|||OTHER||PROSPECTIVE|||||||
33922921|NCT03628950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33922922|NCT03384524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922923|NCT00450164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922924|NCT03944083|||CASE_ONLY||PROSPECTIVE|||||||
33922925|NCT02881879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922926|NCT01153841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922927|NCT05082402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922928|NCT04327518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922929|NCT05289206|NA|SINGLE_GROUP||PREVENTION||NONE||Experimental, single-arm study in participants with comorbidities, previously immunized with 2 doses of CoronaVac, who will receive a booster vaccine with 1 dose of the Oxford/AstraZeneca vaccine (ChAdOx1-S/nCoV-19 \[recombinant\]).||||
33922930|NCT06012292|||OTHER||CROSS_SECTIONAL|||||||
33922931|NCT03524794|||COHORT||PROSPECTIVE|||||||
33922932|NCT04550052|||COHORT||PROSPECTIVE|||||||
34089576|NCT00977418|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34089577|NCT03436719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089578|NCT00025467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089579|NCT04038827|||CASE_ONLY||PROSPECTIVE|||||||
34089580|NCT02886351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089581|NCT03175939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089582|NCT01604668|||COHORT|||||||||
34089583|NCT06515353|||COHORT||RETROSPECTIVE|||||||
34089584|NCT01680263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002179|NCT04556123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to avoid detection bias, FO patients in the non-BIS group as well as their treating physicians shall be blinded for BIS-results. Physicians and study participants will only be informed about the targeted dry body weight, if randomized to the BIS-guided decongestion group.|"Consecutive patients scheduled for TAVR fulfilling inclusion criteria will be enrolled. Patients with FO will be randomized in a 1:1 fashion to either BIS-guided decongestion or decongestion as per clinical judgement alone.~Patients without FO will serve as an euvolemic control cohort."|t|f|t|f
34002180|NCT01634854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002181|NCT04320888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002182|NCT02955004|||CASE_CONTROL||PROSPECTIVE|||||||
34002183|NCT04247841|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be masked to the primary purpose of the study during their preoperative consultation. Upon receiving and completing the survey responses they will be asked to recall their individualized risk of myocardial injury and provide feedback on the risk discussion they had with the anesthesiologist.|"During Phase 1 we will be completing data collection on a prospective cohort of patients attending Presurgical Screening (PSS) Clinic in preparation for elective total joint arthroplasty of the hip or knee.~During the Phase 2 we will utilize a randomized approach to generate 2 groups of patients who will have their preoperative risk discussion guided by the use of a structured script or have the risk discussion guided by the use of a structured script and the display of a visual aid outlining the risk of myocardial injury"|t|f|f|t
34002184|NCT06410976|||CASE_ONLY||PROSPECTIVE|||||||
34002185|NCT06035211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002186|NCT06408636|||COHORT||RETROSPECTIVE|||||||
33697787|NCT03769298|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II/III, Single-center, Prospective, Open-label, Single Arm Study of 30 Simultaneous Kidney Pancreas recipients who received a transplant at least 3 months, but no more than 2 years prior, with a history of tremors following transplantation.||||
34002187|NCT02036749|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
34089585|NCT02590783|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697788|NCT06307158|||COHORT||RETROSPECTIVE|||||||
33697789|NCT00549874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089586|NCT01462942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089587|NCT04228939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089588|NCT03644732|||COHORT||PROSPECTIVE|||||||
34089589|NCT01539200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697790|NCT05284877|||COHORT||PROSPECTIVE|||||||
34002188|NCT04025398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blindness of the psychologist for the secondary judgment criteria.|It's a study prospective, randomized, multicenter and controlled which compares two groups of people adults: group to remediation Réhabilitus versus group Control.|f|f|f|t
34002189|NCT03915977|||COHORT||PROSPECTIVE|||||||
34002190|NCT00743145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind, placebo-controlled||t|f|t|f
34002191|NCT02102919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002192|NCT00753350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002193|NCT06678048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002194|NCT03109041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002195|NCT01995968|||CASE_CONTROL||PROSPECTIVE|||||||
34002196|NCT01837186|||COHORT||RETROSPECTIVE|||||||
34002197|NCT05590390|||COHORT||CROSS_SECTIONAL|||||||
34089590|NCT02650583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089591|NCT04245761|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, open, non-comparative, multicenter study||||
34089592|NCT06250114|||CASE_CONTROL||RETROSPECTIVE|||||||
33697791|NCT06680427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697792|NCT00454701|||COHORT||PROSPECTIVE|||||||
33697793|NCT01392664|||CASE_CONTROL||RETROSPECTIVE|||||||
34089593|NCT06442358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089594|NCT06493162|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34089595|NCT02555878|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34089596|NCT04900272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089597|NCT04639440|||CASE_CONTROL||PROSPECTIVE|||||||
34089598|NCT03628326|||CASE_ONLY||RETROSPECTIVE|||||||
34089599|NCT03990974|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34089600|NCT02122276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089601|NCT03803137|NA|SINGLE_GROUP||OTHER||NONE||||||
34089602|NCT06004960|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089603|NCT02061800|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089604|NCT01392937|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34089605|NCT04892160|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34089606|NCT01069939|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089607|NCT03173755|||CASE_CONTROL||PROSPECTIVE|||||||
33697794|NCT06115746|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Eligible participants will be randomly assigned at the end of the baseline visit in a 1:1 ratio, in blocks of 6, to either a waitlist control group or the iDECIDE curriculum group. Randomization will be stratified by substance use frequency. Treatment will be assigned according to study number, assigned sequentially to eligible participants who enroll in the trial and attend the baseline visit. Investigators and outcome assessors will be fully blinded to allocation across the two arms. Facilitators of the iDECIDE curriculum will not be involved with the data outcome assessments.|Approximately 300 participants will be enrolled into a two-arm, assessor-blind, randomized controlled trial to compare substance use outcomes (i.e., knowledge, behavior, and attitudes) across a one-year follow-up period in adolescents randomly assigned to the iDECIDE drug curriculum or the waitlist control group.|f|f|t|t
33697795|NCT06447233|||OTHER||OTHER|||||||
33697796|NCT05126680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697797|NCT03405610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697798|NCT00338104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697799|NCT01663168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697800|NCT05285657|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697801|NCT06359379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786011|NCT00906698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786012|NCT04963621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator was unaware of the subjects' treatment status||f|f|f|t
33786013|NCT03795740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786014|NCT03074851|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786015|NCT03327155|NA|SINGLE_GROUP||PREVENTION||NONE||The study is proposed as implementation research to mimic the conditions that will occur when PrEP is rolled out at the population level. However, as the version of TDF/FTC used in this study, manufactured by Mylan, is not approved for use as PrEP in Australia, the study is conducted under the Clinical Trial Notification (CTN) scheme and within the CTN framework. After collection of consent and enrolment information, all follow-up information will be collected through electronic data capture to allow accurate and timely analyses.||||
33786016|NCT06135831|RANDOMIZED|PARALLEL||OTHER||SINGLE|It was a single blinded nutritional intervention, where only participants didn't know in which group was recruited.|Each study arm received different supplementation.|t|f|f|f
33786017|NCT04647162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A sample size of 60 would be required to demonstrate a significant level of 5% (two-sided) with 80% power. Considering the 6% missing rate during follow-up, the total sample size was 64 cases with 16 and 48 cases in MT and HE group, respectively.|f|f|f|t
33786018|NCT01087177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33786019|NCT04003428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786020|NCT05365139|||COHORT||CROSS_SECTIONAL|||||||
33786021|NCT04585347|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects were to receive a single oral dose of ALZ-801 in each of the 4 study periods (Regimens A, B, C and D) in a non-randomized, sequential manner, separated by a minimum washout period of 7 days.||||
33922933|NCT01165697|||CASE_ONLY||PROSPECTIVE|||||||
33922934|NCT02794090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922935|NCT00000324|RANDOMIZED|||TREATMENT||DOUBLE||||||
33922936|NCT05278676|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33922937|NCT01641757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720121|NCT03522974|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33720122|NCT02945033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720123|NCT00823914|||COHORT||PROSPECTIVE|||||||
33720124|NCT03866343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33720125|NCT05324995|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The investigator who performed the baseline and follow-up assessments and the patients were unaware of the study group; as the investigator was absent at the time of the surgery and all the patients administered a pill prior to the surgical procedure||t|f|t|f
33720126|NCT02757742|||COHORT||PROSPECTIVE|||||||
33786022|NCT03653975|||COHORT||PROSPECTIVE|||||||
33922938|NCT02017821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922939|NCT04416945|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33922940|NCT04705337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33922941|NCT03517449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922942|NCT00101153||PARALLEL||TREATMENT||NONE||||||
33922943|NCT03140683|||OTHER||PROSPECTIVE|||||||
33922944|NCT00221429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786023|NCT06224270|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, multicenter trial evaluating the safety and immunogenicity of recombinant herpes zoster vaccine in adults with IBD on immunosuppressive therapy.||||
33922945|NCT01113996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786024|NCT01124162|RANDOMIZED|CROSSOVER||||NONE||||||
33922946|NCT02378883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922947|NCT05008458|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33922948|NCT04006912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922949|NCT01818986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922950|NCT06580730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922951|NCT03032510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922952|NCT02493322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33922953|NCT04911699|||COHORT||PROSPECTIVE|||||||
33922954|NCT00125372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002198|NCT00002367||PARALLEL||TREATMENT||||||||
34002199|NCT05557656|||COHORT||RETROSPECTIVE|||||||
34002200|NCT02285868|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33697802|NCT03810391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||the Amsterdam preoperative anxiety and information scale was used to evaluated the degree of preoperative anxiety one day before the surgery. Patients in preoperative anxiety group were randomly allocated to two groups: butorphanol group (Group A) and physiological saline group (Group B); Patients in non-preoperative anxiety group were also randomly allocated to two groups: butorphanol group (Group C) and physiological saline group (Group D) In Group A and Group C, patients received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4 , Group B and Group D received an infusion of the same volume of physiological saline|t|t|t|t
33697803|NCT03697057|||CASE_CROSSOVER||PROSPECTIVE|||||||
33697804|NCT01836965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697805|NCT04371562|||COHORT||RETROSPECTIVE|||||||
33697806|NCT01504243|||CASE_CONTROL||PROSPECTIVE|||||||
33697807|NCT00876746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697808|NCT06431204|||OTHER||RETROSPECTIVE|||||||
33801620|NCT03287622|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|"Group assignment will be coded for parents and data collectors. Parents will be blinded to whether the information they receive is the Intervention vs. Control.~Group assignment will coded on data entry and unblinded after analyses."|Four-armed, randomized, control, factorial design|t|f|t|t
33801621|NCT06262282|||COHORT||PROSPECTIVE|||||||
33801622|NCT00175864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801623|NCT04015349|||OTHER||CROSS_SECTIONAL|||||||
33801624|NCT02754115|||COHORT||PROSPECTIVE|||||||
33922955|NCT02151682|RANDOMIZED|PARALLEL||TREATMENT||NONE||"There were 2 arms in Part 1: Randomization was carried out in blocks and in a 2:1 ratio (tapentadol PR to morphine PR). Participants were stratified using interactive response technology: by age group (6 years to less than 12 years and 12 years to less than 18 years, at the second visit \[Allocation Visit\]) so that at least 25% of participants were in the younger age group, and by underlying pain condition (cancer/non-cancer-related pain).~There were 4 arms in Part 2: The investigators/participants decided if participants from Part 1 switched to or continued on tapentadol PR (tapentadol arm) or if they received no treatment/standard of care treatment if needed (2 direct observation arms following treatment in Part 1 and 1 observation arm after initial treatment with tapentadol in Part 2)."||||
33922956|NCT05736562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the participants nor the investigators will know the group assignment. Supplements will be prepared by Ritual and marked with randomly generated ID numbers. Grouping will be revealed by Ritual at end of the trial.|Women who exclusively breastfeed will be randomized at week 5 postpartum to either receive the Ritual MVI or a blank placebo for 10 weeks.|t|f|t|f
33922957|NCT00903370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922958|NCT01084109|RANDOMIZED|PARALLEL||||NONE||||||
33922959|NCT05589844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33922960|NCT05646654|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33922961|NCT04742049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922962|NCT01758211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33922963|NCT02562872|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922964|NCT01977339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33922965|NCT00651612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922966|NCT00411086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922967|NCT04789863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33922968|NCT02294695|||CASE_CONTROL||PROSPECTIVE|||||||
33922969|NCT04562558|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective，multicenter，randomized trial with two arms||||
33922970|NCT03702426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922971|NCT01726712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33922972|NCT00747994|||FAMILY_BASED||RETROSPECTIVE|||||||
33922973|NCT00356395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33922974|NCT01061320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33922975|NCT05169346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33922976|NCT01078714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33922977|NCT01319279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922978|NCT00643344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922979|NCT02480894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922980|NCT03494426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922981|NCT02073903|||COHORT||PROSPECTIVE|||||||
33922982|NCT01237028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33697809|NCT02128477|||COHORT||PROSPECTIVE|||||||
33697810|NCT04091009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697811|NCT03688009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33697812|NCT01161732|RANDOMIZED|PARALLEL||TREATMENT||NONE||early aortic valve replacement||||
33697813|NCT05907590|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33697814|NCT02225769|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697815|NCT00913575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33922983|NCT02307656|NA|SINGLE_GROUP||OTHER||NONE||||||
33922984|NCT05037669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33922985|NCT06335420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33922986|NCT03316872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922987|NCT03788187||PARALLEL||OTHER||DOUBLE|Analyzing the concentrations of 46 POPs in both adipose tissue and serum samples from breast tumor patients (benign, malignant with and without lymph node metastasis).||t|f|t|f
33922988|NCT01882244|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33922989|NCT00129792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33922990|NCT00676208|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33922991|NCT04125173|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Research coordinator will have randomized the patient into one of the 3 arms. The randomized pneumoperitoneum pressure will be set for the surgical procedure and blinded to the surgeon and first assistant, either fellow or resident.|Three arms including those with pneumoperitoneum pressure of 15mmgHg versus 12mmgHg vs 10 mmHg during laparoscopic or robotic hysterectomy for benign indications.|t|t|t|t
33922992|NCT05351333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33922993|NCT06086756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922994|NCT00313027|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33922995|NCT04390568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33922996|NCT06418776|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients who could potentially undergo courses of intensive chemotherapy (fit) are randomisedrandomized into two arms:~* Arm 1 - intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)~* Arm 2 - low intensity therapy (Aza/Dac/LDARA-C + Ven) Randomization determines the intensity of the program, but not the specific therapeutic regimen. The treatment regimen is selected by the investigators based on accepted clinical practice, the availability of appropriate drugs at the participating centers, etc., after randomization. If a patient has FLT3 gene mutations, one of the available kinase inhibitors must be added to therapy: midostaurin, gilteritinib, sorafenib.~If remission of the AML has been achieved, patients in both groups undergo alloHSCT as soon as possible."||||
33922997|NCT06266585|||COHORT||OTHER|||||||
33922998|NCT00805610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33922999|NCT04318912|||CASE_ONLY||PROSPECTIVE|||||||
33923000|NCT02992704|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arm, parallel open label study||||
33923001|NCT04655703|RANDOMIZED|PARALLEL||TREATMENT||NONE||"DJO X4 Brace with Motion Intelligence Platform: Home discharge. Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.~Control group: Home discharge. Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient.~DJO X4 Brace with Motion Intelligence Platform: Discharge to rehabilitation center. Patients randomized to this group will be provided with the X4 brace and trained on the use of Motion Intelligence platform.~Cohort 4- Control group: Discharge to rehabilitation center. Patients randomized to this group will serve as the control group. There will be no changes to the standard of care recovery for a TKA patient."||||
33923002|NCT04758598|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||DSLT treatment vs. SLT treatment|f|f|f|t
33923003|NCT02366390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923004|NCT03782636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33923005|NCT03292393|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33923006|NCT02211183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923007|NCT06373276|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The primary investigator, who delivers the treatment, is blinded to to the performance outcome measures.|"Participants in the multiplanar balance training home-based exercise and educational group (group A) will have a video, as well as written instructions, of the intervention and dosage, along with the five educational brochures loaded on their phone via the SAFE beta app. In the SAFE beta app, the participants will be prompted daily to click on the beta app to watch the demonstration of the interventional exercise. They are then prompted to begin their daily prescriptive intervention, which is a 7-day-a-week program for 12 weeks. Participants can view a video of the exercise intervention in real-time in order to mirror the exercises as they are completing the exercises."|f|f|t|f
33923008|NCT00000118|RANDOMIZED|||TREATMENT||||||||
33923009|NCT06528743|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Initially, patients are included following a 3+3 design to find the maximum tolerated break length, followed by an expansion cohort (unless there are already 2+ patients drop out in schedule 1, then there will be no expansion cohort).||||
33923010|NCT06445894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923011|NCT02293096|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33923012|NCT05797688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923013|NCT01768234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33923014|NCT00898404|||||PROSPECTIVE|||||||
33923015|NCT01661166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923016|NCT05838547|||COHORT||PROSPECTIVE|||||||
33923017|NCT02854553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923018|NCT03922893|||COHORT||PROSPECTIVE|||||||
33923019|NCT02090946|||COHORT||CROSS_SECTIONAL|||||||
33923020|NCT03182127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923021|NCT01747811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923022|NCT05557123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923023|NCT03206112|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923024|NCT01175629|||COHORT||CROSS_SECTIONAL|||||||
33923025|NCT06422429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923026|NCT04535206|||COHORT||PROSPECTIVE|||||||
33923027|NCT05705895|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients and care providers know which group they are in, but the outcome assessor does not.||f|f|f|t
33697816|NCT06110572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697817|NCT02387177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697818|NCT02477839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697819|NCT01865188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002201|NCT04792580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002202|NCT05963269|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34002203|NCT05456022|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34002204|NCT05216523|||CASE_CONTROL||RETROSPECTIVE|||||||
34002205|NCT00131092|RANDOMIZED|PARALLEL||||SINGLE||||||
34002206|NCT04328259|||OTHER||PROSPECTIVE|||||||
34002207|NCT03368482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34002208|NCT06492408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002209|NCT04448041|||COHORT||PROSPECTIVE|||||||
34002210|NCT01460030||||TREATMENT||||||||
34002211|NCT06502925|||OTHER||PROSPECTIVE|||||||
34002212|NCT05150405|NA|SEQUENTIAL||TREATMENT||NONE||||||
34002213|NCT06361693|||COHORT||PROSPECTIVE|||||||
34002214|NCT05775120|||COHORT||PROSPECTIVE|||||||
34002215|NCT05775224|||OTHER||OTHER|||||||
34002216|NCT01204125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002217|NCT00514150|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34002218|NCT02214706|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002219|NCT02842723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002220|NCT02583191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002221|NCT00090753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002222|NCT03680261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002223|NCT01987934|||CASE_CONTROL||PROSPECTIVE|||||||
34002224|NCT05909241|NA|SEQUENTIAL||TREATMENT||NONE||||||
34089608|NCT05496764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were randomly assigned to one of two groups. Serially numbered opaque closed envelopes were used for allocation concealment. Allocation was maintained. To ensure double blinding, the random allocation sequence was kept by one investigator different from the one who enrolled the participants or assigned them to the interventions. Moreover, a third investigator was responsible for following the patients up and for assessment.||f|f|t|f
34089609|NCT02650323|||COHORT||PROSPECTIVE|||||||
34089610|NCT00482144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923028|NCT01621854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923029|NCT03965793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923030|NCT00113178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923031|NCT05666440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Double armed International study||||
33923032|NCT01567891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923033|NCT03819478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All participants will undergo a 6-month weight loss intervention of caloric restriction and supervised exercise followed by 12 months of follow-up with randomization to one of three groups (n=75/group): 1) Lower protein / higher CHO diet for the 6-month weight loss phase only (RecProt); 2) Higher protein / lower CHO diet for the 6-month weight loss phase only (6-mo HiProt); or 3) Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases (18-mo HiProt).|t|f|t|t
33923034|NCT01164592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923035|NCT03997929|||COHORT||PROSPECTIVE|||||||
33923036|NCT02317341|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33923037|NCT05505097|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33923038|NCT00740324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923039|NCT00030095||||TREATMENT||||||||
33697820|NCT06416722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697821|NCT01740973|||COHORT||RETROSPECTIVE|||||||
33697822|NCT03595774|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blind, placebo-controlled, crossover|t|f|t|t
33697823|NCT02396251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697824|NCT05965778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33697825|NCT04209062|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697826|NCT01943773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697827|NCT03178448|||COHORT||PROSPECTIVE|||||||
33697828|NCT04439279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697829|NCT05958732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be masked for the treatment groups. Non of the participants know to which treatment group they are assigned.|"Experimental group will be receiving conventional therapy and body awareness therapy for 30 minutes, 5 days a week for two weeks. Balance and coordination is measured before the treatment and after two weeks of treatment session it is again measured.~control group will receive conventional physical therapy treatment for 30 minutes, 5 days a week for two weeks. Balance and coordination is measured before the treatment and after two weeks of treatment session it is again measured."|t|f|f|f
33697830|NCT05996874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697831|NCT03624244|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II comparative multicentre prospective randomised (1:1 ratio) open-label study||||
33720127|NCT05815472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720128|NCT05542264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Double-Blind, Randomized, Multiple Dose|t|t|t|t
33923040|NCT01201707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923041|NCT03310736|||COHORT||PROSPECTIVE|||||||
33923042|NCT03714503|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Simon's two stage||||
33923043|NCT01445964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923044|NCT03823599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923045|NCT05816694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923046|NCT00369967|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34089611|NCT04402242|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized, multi-center, single blinded interventional study with 2 parallel groups: standard clinical care (SCC group, control group) and NOL-guided analgesia (NOL guided analgesia group, interventional group), stratified by site|t|f|f|f
34089612|NCT04233684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The pathologists will be blinded for the result of endoscopic finding and rapid urease test.|||||
33697832|NCT05586646|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This clinical trial will include 200 Egyptian Critically ill patients with bed sores equal or more than grade II selected from ward or ICU at Air Force specialized Hospital. They will be classified into 2 groups:~* Group I: 100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration).~* Group II: 100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations."||||
33697833|NCT06681402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697834|NCT03461263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group A, wherein patients received phonophoresis treatment using pumpkin seeds oil; Group B, where members of the group received trans-perineal continuous low-intensity ultrasound; and Group C, in which the participant received placebo low- intensity ultrasound. All of The three groups of the organized trail received their corresponding treatment daily up-to 3 weeks.||t|f|f|t
33697835|NCT04537195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded at 7-month follow-up when administering the Hamilton rating scales (secondary outcomes). Participants will be instructed not to disclose their group allocation until the interview is completed||f|f|f|t
34089613|NCT05273983|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Study||||
33697836|NCT01133041|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34089614|NCT05024942|||COHORT||PROSPECTIVE|||||||
34089615|NCT00417222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697837|NCT03625934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089616|NCT06400810|||COHORT||PROSPECTIVE|||||||
33697838|NCT06417125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089617|NCT05604950|||COHORT||CROSS_SECTIONAL|||||||
33697839|NCT05386576|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I single-arm, single-center study.||||
34089618|NCT05319470|||COHORT||PROSPECTIVE|||||||
33697840|NCT04488939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697841|NCT04120948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697842|NCT06680219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33697843|NCT04719637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697844|NCT05721222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089619|NCT03785821|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33697845|NCT05605782|||COHORT||RETROSPECTIVE|||||||
34089620|NCT03943485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34089621|NCT02207608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089622|NCT00619463|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089623|NCT00539396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089624|NCT04700943|||COHORT||PROSPECTIVE|||||||
33697846|NCT01315184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801625|NCT03221959|||CASE_ONLY||PROSPECTIVE|||||||
33801626|NCT05512858|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Two phases, First with no intervention (=control group), second with intervention(study group).||||
33801627|NCT00739531|||CASE_ONLY||CROSS_SECTIONAL|||||||
33801628|NCT04469543|||COHORT||RETROSPECTIVE|||||||
33801629|NCT03345901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923047|NCT04697602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923048|NCT01052753|||OTHER||OTHER|||||||
33923049|NCT02906956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923050|NCT01539278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923051|NCT03792802|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Care provider, participant and investigator did not know which type of surgery has applicated.|Model 1: Single dermatome laparoscopic appendectomy Model 2: Standard laparoscopic appendectomy|t|t|t|t
33923052|NCT03903120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data Collector also masked.|Parallel groups with delayed treatment control group (Study 1 and 2). Parallel groups with distributed or massed intervention (Study 3)|f|f|f|t
33923053|NCT01754675|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33923054|NCT06041685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33923055|NCT01752621|||CASE_CONTROL||RETROSPECTIVE|||||||
33923056|NCT03920865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923057|NCT06402279|||COHORT||PROSPECTIVE|||||||
33923058|NCT05884476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blind to condition randomization, as is the PI, who provides suicide risk assessments throughout the follow-up period.|Participants are randomized (1:1) upon enrollment to one of two conditions.|t|f|t|t
33923059|NCT03134924|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study statistician did not participate in randomization and the recruiter and laboratory personnel were blinded to the condition assignment. The participant was blind to their condition assignment. The reading of all the slides used to diagnose BV was performed by one trained laboratory technician blinded to the participant condition assignment. In case of unclear reading, the slide was reviewed by a second technician and the chief of the laboratory until an agreement was achieved; both the second technician and the chief of the laboratory were blind to the condition assignment of the participant.|The interventional study model used a parallel design, where an enhanced standard of care and intervention were used.|t|f|t|t
33923060|NCT03109756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923061|NCT05969912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923062|NCT01330641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923063|NCT01998438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33923064|NCT04950842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923065|NCT01899586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923066|NCT00206401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923067|NCT02233907|||COHORT||PROSPECTIVE|||||||
33923068|NCT05841108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002225|NCT05473767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will be blind to group assignment during intervention delivery and assessment.|This is a randomized controlled trial pilot study that will randomize 100 women into Family Check-Up Heart and 50 women into traditional Family Check-Up. The investigators will use an unbalanced design to enhance ability to evaluate feasibility and acceptability for the new Family Check-Up Heart intervention. The investigators will utilize a Type 1 hybrid effectiveness-implementation design using mixed methods that will simultaneously assess both the implementation of the Family Check-Up Heart and preliminary effectiveness on 6-month maternal cardiovascular health outcomes.|f|f|t|f
34002226|NCT04815460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697847|NCT01815983|NA|SINGLE_GROUP||OTHER||NONE||||||
34002227|NCT05194709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002228|NCT00268164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002229|NCT01346644|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34002230|NCT02571933|||||PROSPECTIVE|||||||
34002231|NCT02974647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002232|NCT02700971|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002233|NCT04346654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002234|NCT01913054|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34089625|NCT00756301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34002235|NCT06632236|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34002236|NCT03590834|RANDOMIZED|PARALLEL||PREVENTION||NONE|The parents of the children were informed that their Head Start center will be randomly assigned to one of the three study groups.|||||
34002237|NCT05594641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized clinical trial|t|f|f|t
34089626|NCT05073315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study is double-blind.||t|f|t|f
34089627|NCT02756897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697848|NCT03824418|||COHORT||PROSPECTIVE|||||||
33697849|NCT05568537|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, prospective, single-institution||||
33697850|NCT05403034|NA|SINGLE_GROUP||OTHER||NONE||||||
33697851|NCT04732416|NA|SEQUENTIAL||TREATMENT||NONE||||||
33697852|NCT01011270|||CASE_CONTROL||RETROSPECTIVE|||||||
33697853|NCT01488500|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33697854|NCT04363177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33697855|NCT05150145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697856|NCT03387683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002238|NCT00545116|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33697857|NCT03331250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002239|NCT04680780|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34002240|NCT05456438|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34002241|NCT01656798|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34002242|NCT06163937|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Triple-blind||t|f|t|t
33697858|NCT05749211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697859|NCT02725034|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33697860|NCT00167973|||COHORT||PROSPECTIVE|||||||
33697861|NCT03935412|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33697862|NCT05216003|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will evaluate matched-pair counties in a step-wedge design. As the intervention is implemented within a particular Indiana county, researchers will identify a matching Indiana county based on infant mortality rate. At the end of each year post-implementation, data will be compared between the intervention county and the match-paired county.||||
33697863|NCT00117195|||CASE_CONTROL||PROSPECTIVE|||||||
33697864|NCT01690429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002243|NCT06535711|||COHORT||RETROSPECTIVE|||||||
33697865|NCT03107663|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33697866|NCT00449527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697867|NCT03203070|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient and nursery staff evaluating postoperative pain do not know the applied intervention.||t|f|f|t
33697868|NCT02585583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002244|NCT05049772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697869|NCT02216760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002245|NCT02126657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697870|NCT02095067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697871|NCT03835104|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study is a cluster randomized controlled trial. The general practice is the unit of cluster.||||
33697872|NCT05324137|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33697873|NCT05350306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697874|NCT02276365|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697875|NCT06422195|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33786025|NCT03184545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The examiner who will be evaluating and assessing the outcome scores on each visit will be blinded to the patient's group.|It's a phase III study. A randomized, observer blinded, single center study. Patients will be divided in two groups based on randomization. One group will receive electrical muscle stimulation and Physical therapy and other group will receive only physical therapy. Electrical muscle stimulation device is The Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the Food and Drug Administration (FDA). Assessment and follow up will be performed before start of treatment, at 3 weeks, 6 weeks, 12 weeks, 6 months and 12 months post-start of treatment . Assessment will be done at each visit based on Kujala patellofemoral score, pain visual analog scale (VAS) during activities of daily life and isometric strength measurement.|f|f|f|t
33786026|NCT05584020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786027|NCT04088513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786028|NCT06628674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33786029|NCT05451082|||COHORT||PROSPECTIVE|||||||
33786030|NCT05846711|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33786031|NCT02521844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786032|NCT04599114|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will use a retrospective chart review to examine characteristics of patients who present to the emergency room with atrial fibrillation as well as a non-randomized prospective cohort who will be offered enrollment into the virtual platform.||||
33786033|NCT00024466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697876|NCT02883842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33697877|NCT02330484|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33697878|NCT06134908|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33697879|NCT02422316|||COHORT||PROSPECTIVE|||||||
33697880|NCT06680843|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33697881|NCT02806570|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33697882|NCT02055807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33697883|NCT06655285|||CASE_CONTROL||RETROSPECTIVE|||||||
33697884|NCT06281938|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Investigators and outcomes assessors will be blinded to the arm. Coded data will be used for masking.|Intervention cohort and control cohort will be used|f|f|t|t
33697885|NCT06254378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786034|NCT03329365|||COHORT||PROSPECTIVE|||||||
33786035|NCT06102174|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33786036|NCT04160689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801630|NCT02634892|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801631|NCT02057939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801632|NCT02241070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002246|NCT01611506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002247|NCT03372317|||COHORT||CROSS_SECTIONAL|||||||
34002248|NCT03211351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002249|NCT00490321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002250|NCT01616199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002251|NCT01611636|||COHORT||RETROSPECTIVE|||||||
34002252|NCT00762411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002253|NCT02183376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002254|NCT03133624|||COHORT||PROSPECTIVE|||||||
33697886|NCT00497315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697887|NCT04549961|||COHORT||CROSS_SECTIONAL|||||||
33697888|NCT00703196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33697889|NCT03102112|||COHORT||PROSPECTIVE|||||||
33697890|NCT05780697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002255|NCT01927991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720129|NCT00000609|RANDOMIZED|||TREATMENT||||||||
33720130|NCT01045889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786037|NCT06218186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All studies will be presented on the same viewing and scoring platform. The sleep study readers will be blinded to patient identification and the data collection device for each study.|Medical device, single arm. All subjects will be provided with the same medical device (Wesper Lab), a home sleep test.||||
33786038|NCT00002290||||TREATMENT||DOUBLE||||||
33786039|NCT04448743|||COHORT||PROSPECTIVE|||||||
33786040|NCT05520827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||SRD-Part: parallel-group design FE-Part: two-way crossover design|t|f|f|f
33786041|NCT03607799|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Those assessing the primary and secondary clinical outcomes are masked to treatment assignment.|Human|f|f|f|t
33786042|NCT01670019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720131|NCT03814291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720132|NCT03512509|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Subjets will not be aware of which test meal they will recieve first, and are not able to distinguish between the two potatoes.|Single-blind randomized crossover|t|f|f|f
33720133|NCT06155331|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Sealed envelope method||t|f|t|f
33720134|NCT00744627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720135|NCT04853927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.|t|t|t|t
33720136|NCT01382979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33720137|NCT05153044|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33786043|NCT01994161|||COHORT||PROSPECTIVE|||||||
33786044|NCT00469300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923069|NCT05533333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A person not involved in the study (student helper #1) will randomise the participants using a random number list prepared by Dr Chen Huijun Cynthia (statistician) before the baseline assessment. One HK-registered physiotherapist (RA1) will be recruited to conduct workshops on teaching the exercise interventions to all participants. One research postgraduate (RPg) student will be recruited to conduct all of the other methodological procedures involved in the project. Assessments will be performed by an existing postgraduate student of the PI, who is blind to treatment condition. An economic evaluation with healthcare utility estimation will be performed by Dr Chen Huijun Cynthia. The treatment allocation coding will be unblinded following the completion of the study.|Assessor-blinded, multi-centre parallel-group RCT with economic evaluation|f|f|f|t
33923070|NCT04249167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923071|NCT05130372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A single-blind, assessor-blinded, randomized controlled study.|Arm 1:Static Stretching Group Arm 2: PNF Stretching Method Group Arm 3:Roller Massager Group|f|f|t|t
33923072|NCT02703987|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33923073|NCT03611998|NA|SINGLE_GROUP||TREATMENT||NONE||One group, pretest-posttest design||||
33786045|NCT03374046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786046|NCT06500286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33786047|NCT06629480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786048|NCT06630494|NA|SINGLE_GROUP||OTHER||NONE||||||
34089628|NCT04415905|RANDOMIZED|PARALLEL||OTHER||SINGLE|Anesthesia machine and infusion pumps are shielded from assessors who measure ONSD.|There are 2 groups according to the type of main anesthetic agent. P group are anesthetized with propofol, so are S group with sevoflurane.|f|f|f|t
34089629|NCT01010178|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34089630|NCT02368392|||COHORT||CROSS_SECTIONAL|||||||
34089631|NCT02964871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720138|NCT03627689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720139|NCT04905173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786049|NCT01414166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786050|NCT06230562|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720140|NCT05501028|||COHORT||PROSPECTIVE|||||||
33923074|NCT02149485|||COHORT||PROSPECTIVE|||||||
33923075|NCT00828503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923076|NCT03235375|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720141|NCT02734979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923077|NCT00225680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923078|NCT05295745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not be notified about the intervention group or the control group and will be randomly assigned. The procedures of this study will be available only to the researchers, therapists, and the bioethics committee of the Autonomous University of Ciudad Juárez|This study has two arms, experimental and control group. The first one will receive the treatment and the control group that does not receive it until the intervention group completes the treatment. Both groups will be measured before and after completion, with three months follow-up|t|f|f|f
33923079|NCT01259635||PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33923080|NCT05105880|||COHORT||RETROSPECTIVE|||||||
33923081|NCT00110123|RANDOMIZED|||TREATMENT||NONE||||||
33923082|NCT04675606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923083|NCT04600687|NA|SINGLE_GROUP||OTHER||NONE|Neither the participant nor the person administering the questionnaires will know which placebo tablet the patient has been randomized to receiving first prior to study enrollment. The allocation of which placebo tablet is first swallowed will be randomized in a block randomization design.|Participants will be randomized to take the first placebo tablet and within 30 minutes then take the second placebo tablet. The participants will complete questionnaires prior to taking any placebo pill and after each dose.||||
33720142|NCT04567433|||COHORT||RETROSPECTIVE|||||||
33720143|NCT00156533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720144|NCT03755687|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective observational pilot study||||
33923084|NCT04871230|||CASE_CONTROL||PROSPECTIVE|||||||
33923085|NCT04751968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923086|NCT05143944|||COHORT||RETROSPECTIVE|||||||
33923087|NCT00250406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923088|NCT02212145|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33923089|NCT02302144|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33923090|NCT00966693|NA|SEQUENTIAL||TREATMENT||NONE||||||
33923091|NCT02234557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923092|NCT02481063|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33923093|NCT03163108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923094|NCT03645889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised Controlled Trial|t|t|t|t
33923095|NCT05862948|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923096|NCT02939599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923097|NCT05138341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|D90 evaluations of mRS, NIHSS, Barthel Index will be performed by an evaluator blinded to the intervention.|Subjects will be randomized to either minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management (MIS group) or best medical management alone (3:1) (MM)|f|f|f|t
33923098|NCT05408117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sutures will be removed in their entirety before scar assessment by a co-investigator such that the outcomes assessor is blinded to which suture was used on which side of the scar.|prospective, randomized split-wound study|f|f|t|t
34089632|NCT01936155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089633|NCT04989933|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34089634|NCT05488470|||OTHER||PROSPECTIVE|||||||
34089635|NCT00574639|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34089636|NCT01980758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089637|NCT00580840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089638|NCT02903108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089639|NCT03077776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089640|NCT05026918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720145|NCT00310531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720146|NCT01525550||||OTHER||NONE||||||
33720147|NCT03234751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This study is prospective randomized, double masked, 2-period cross over design, proof of concept study of the effects of intravenously administered rhBNP (nesiritide) on insulin sensitivity in otherwise healthy obese nondiabetic insulin resistant subjects.|t|f|t|f
33720148|NCT03580317|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33720149|NCT03874897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720150|NCT03527095|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720151|NCT06213168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a prospective multicentre open-label randomized controlled superiority trial with two parallel arms comparing two oxygenation strategies, HFNC plus CPAP versus HFNC alone, in patients admitted in ICU for de novo hARF.||||
33720152|NCT03715218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720153|NCT05164042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720154|NCT01721187|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33720155|NCT01214161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33720156|NCT00473460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720157|NCT03273790|||COHORT||RETROSPECTIVE|||||||
34089641|NCT04755517|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Frequent / Infrequent information of cytological screening results||t|f|f|f
34089642|NCT06199739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786051|NCT02525705|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34002256|NCT04501536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34002257|NCT00231751|||DEFINED_POPULATION||OTHER|||||||
33923099|NCT01525940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002258|NCT02189603|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34002259|NCT01044134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002260|NCT00498316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002261|NCT04313933|||CASE_CONTROL||PROSPECTIVE|||||||
34002262|NCT06403137|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Protein supplements are packed the same and look and taste similar.|Randomized, controlled, parallel-group trial.|t|f|t|t
33697891|NCT04069169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Following receipt of informed consent, participants will be randomized by the Pharmacy Research Support Pharmacist. Pharmacy research staff will prepare an appropriate randomization schedule (patients randomized to P-IVLT or control) and deploy blinded study drug to the operating room, anesthesia care unit, and post-surgical ward as required. Unless emergency unblinding is required, the following people will remain blinded to group allocation until the full cohort has been recruited and data collection has been completed:~1. All anesthesia, APS, nursing, clinical pharmacists and surgical staff involved in the patient's clinical care~2. The patient and their family~3. Research staff involved in recruitment and data collection"|"This will be a placebo-controlled, double-blind randomized control trial (RCT) comparing 48-hour postoperative morphine utilization amongst adolescents undergoing posterior spinal instrumentation and fusion who have been randomly assigned to one of two groups:~1. Intervention group will receive perioperative IV lidocaine therapy (1% preservative free lidocaine 10 mg/ml in 0.9% NaCl) in addition to the standard multi-modal analgesia.~2. Control group will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention."|t|t|t|t
34002263|NCT00357955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002264|NCT02563249|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33697892|NCT05271071|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33697893|NCT06679686|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33697894|NCT00994318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697895|NCT02001181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786052|NCT00603447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786053|NCT01359995|||COHORT||RETROSPECTIVE|||||||
33786054|NCT05967442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786055|NCT03433261|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Neither the investigator nor the outcomes assessor will no the ketone level of the participant during either arm of the study|Each subject will randomize to one of two arms and will crossover to the other arm at least one week later.|f|f|t|t
33786056|NCT04239339|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33786057|NCT00793806|||CASE_ONLY||PROSPECTIVE|||||||
33786058|NCT04313452|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study sample will consist of 50 participants of obese children and adolescents between 10 and 16 years of age who are diagnosed with insulin resistance clinically. Twenty five of participants (1:1, boys: girls) will follow Mediterranean diet, and 25 of participants (1:1, boys: girls) will follow regular diet. The two groups will be matched for age and gender. The Pediatric Endocrinologist will diagnose the children with insulin resistance clinically according to abdominal obesity and presence of acanthosis nigricans. The children and adolescents will be randomly assigned to one of the groups: Mediterranean diet group or the regular diet group.|f|f|t|f
33786059|NCT01066065|||COHORT||PROSPECTIVE|||||||
33786060|NCT06690151|||COHORT||PROSPECTIVE|||||||
33786061|NCT02627625|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33923100|NCT02198651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923101|NCT02420301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923102|NCT04403529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923103|NCT02138149|||CASE_CONTROL||PROSPECTIVE|||||||
33923104|NCT02452268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923105|NCT06446180|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33923106|NCT00472511|||||PROSPECTIVE|||||||
33923107|NCT00339118|RANDOMIZED|PARALLEL||||NONE||||||
33923108|NCT01612377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002265|NCT03121079|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group Assignment||||
34002266|NCT04175860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment|f|f|f|t
34002267|NCT00607191|||FAMILY_BASED||PROSPECTIVE|||||||
34002268|NCT05649150|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34002269|NCT01802216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002270|NCT00250315|||||PROSPECTIVE|||||||
34002271|NCT04013750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002272|NCT03084562|||COHORT||PROSPECTIVE|||||||
34002273|NCT04155840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002274|NCT00695383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002275|NCT05008120|||CASE_CONTROL||PROSPECTIVE|||||||
34002276|NCT05717387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002277|NCT00239824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002278|NCT04606017|||COHORT||RETROSPECTIVE|||||||
34002279|NCT02582554|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34002280|NCT04332211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|prospective randomized double-blind placebo control|The study will employ a prospective randomized double-blind placebo control study design (enrollment ratio 1:1) to compare whether pseudoephedrine is more effective than placebo in preventing barotrauma during HBOT|t|t|t|t
34002281|NCT00608634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002282|NCT03693833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002283|NCT00002633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002284|NCT02464670|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|In Part II only (Groups 3A and 3B), the current strength of the device will be masked from the study team administering the procedure and participant. All IP assignments will be open label and unmasked.||t|f|t|f
34089643|NCT01909102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089644|NCT04546698|||CASE_CONTROL||PROSPECTIVE|||||||
33697896|NCT05137704|||COHORT||RETROSPECTIVE|||||||
33697897|NCT00619593|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697898|NCT03368703|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33697899|NCT03170024|||CASE_ONLY||PROSPECTIVE|||||||
33697900|NCT03031158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697901|NCT00356733|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34002285|NCT04145245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|placebo controlled, double bind|Interventional Group- Patients with carnitine in addition to antidiabetic therapy Control Group- Patients with placebo and antidiabetic therapy|t|f|t|f
34002286|NCT04525898|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The hospital pharmacy will prepare two identical-appearing syringes; one will contain methadone and the other saline. The patients, care providers, and researchers will all be blinded to group assignment|One group of patients will be randomized to receive a dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)-methadone group)). The other group will be randomized to be administered an equal volume of saline in an identical appearing syringe (control group)|t|t|t|t
34002287|NCT05295524|NA|SINGLE_GROUP||OTHER||NONE||prospective, open-label, multicenter study||||
33697902|NCT04351997|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The investigators conducted a randomized controlled trial (RCT) ,(parallel group study wit(h 1:1 randomisation) comparing early cord clamping( ECC) (at 60 seconds) and delayed cord clamping DCC) (at 180 seconds) in 90 cases of normal birth by' two-step' delivery.||||
33786062|NCT02747992|||COHORT||RETROSPECTIVE|||||||
33786063|NCT02893228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33786064|NCT06714253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part 1 (Phase 1): single-arm open-label Part 2 (Phase2): randomized, double-blind, placebo-controlled, parallel-group|Part 1 (Phase 1): single-arm, open-label Part 2 (Phase 2): randomized, double-blind, placebo-controlled, parallel-group|t|f|t|f
33786065|NCT01877616|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786066|NCT01912001|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786067|NCT04188288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded as to whether they are receiving experimental or control neurofeedback.||t|f|f|f
33786068|NCT02121418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786069|NCT06632067|||CASE_CONTROL||RETROSPECTIVE|||||||
33786070|NCT04878042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786071|NCT05293301|RANDOMIZED|PARALLEL||OTHER||SINGLE|Follow up re-evaluation visits were performed by the same resident \~1month, 3 months, 6 months, and 1 year, who was blinded to lknowing which side of the mouth recieved what type of deep cleaning treatment.|prospective, randomized, split-mouth, single blinded|f|f|f|t
33786072|NCT06409195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34002288|NCT02409316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002289|NCT05099731|||OTHER||CROSS_SECTIONAL|||||||
34002290|NCT02415933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33697903|NCT01749774|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33697904|NCT06681311|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33697905|NCT04759144|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|An unmasked member of staff will undertake randomisation. The participants and the clinical staff will be blind to allocated treatment sequence.|"Device: CamAPS FX~The automated closed loop system (CamAPS FX) will consist of:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data.~Treatment: Two insulins will be used~* Faster insulin aspart (Fiasp)~* Standard insulin aspart (Novorapid)"|t|t|t|f
33697906|NCT05741060|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The ACE Trial is an early stage multi-center randomized, parallel, double-blind placebo-controlled trial of 10 mg/day of equol for 24 months.|t|t|t|t
34089645|NCT00909974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786073|NCT02258295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786074|NCT00409864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786075|NCT00762658|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|f|t
33786076|NCT02224833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786077|NCT02359435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33786078|NCT03044769|||COHORT||PROSPECTIVE|||||||
33786079|NCT03350737|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, randomized, open-label study design. These no-option patients will be allocated (16 for each group) to 2 treatments"||||
33786080|NCT04600180|||COHORT||PROSPECTIVE|||||||
33786081|NCT04832646|||COHORT||RETROSPECTIVE|||||||
33786082|NCT06193785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective therapeutic study comparing two groups, open, quasi-randomised, single-centre||||
34002291|NCT03962868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002292|NCT01478516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002293|NCT00005668||||TREATMENT||DOUBLE||||||
34002294|NCT06383949|||COHORT||PROSPECTIVE|||||||
34002295|NCT06678867|NA|SINGLE_GROUP||OTHER||NONE||This is a phase II, multicentre, non-randomised open-label trial with two cohorts.||||
34002296|NCT01292668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002297|NCT00919516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002298|NCT06679777|||COHORT||PROSPECTIVE|||||||
33697907|NCT03248336|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible participants received 12 weeks of office vergence/accommodative therapy||||
33923109|NCT04564716|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator)|Randomized double-blind placebo-controlled|t|f|t|f
33923110|NCT01315002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33923111|NCT05630898|||OTHER||CROSS_SECTIONAL|||||||
33697908|NCT03120559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher was blind to the patients||f|f|t|f
33697909|NCT01514331|RANDOMIZED|PARALLEL||||NONE||||||
33697910|NCT06666036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33923112|NCT04806633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923113|NCT06507085|||COHORT||PROSPECTIVE|||||||
33923114|NCT05102513|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||20 complete unilateral cleft lips are operated; 10 are treated with the Millard II technique and 10 are treated with the new hybrid technique||||
34002299|NCT04674228|||COHORT||PROSPECTIVE|||||||
34002300|NCT04152356|||COHORT||PROSPECTIVE|||||||
34002301|NCT03765190|NA|SINGLE_GROUP||TREATMENT||NONE||Proton Therapy+PD-1 Ab||||
34002302|NCT00954603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002303|NCT03119662|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34002304|NCT00874549|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002305|NCT04305730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34002306|NCT02876133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002307|NCT02838251|||COHORT||PROSPECTIVE|||||||
34002308|NCT01886534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34002309|NCT06161701|||COHORT||PROSPECTIVE|||||||
34002310|NCT06449391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002311|NCT03108820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34002312|NCT00591071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002313|NCT06137807|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter clinical trial. Subjects will be selected by their local Heart Team to be at high risk and deemed eligible by an independent eligibility committee (IEC).||||
34002314|NCT00304434|RANDOMIZED|PARALLEL||||NONE||||||
34002315|NCT02531490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002316|NCT05347394|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33697911|NCT00751166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33697912|NCT02460107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697913|NCT06680700|||COHORT||PROSPECTIVE|||||||
34002317|NCT00928057|RANDOMIZED|CROSSOVER||||NONE||||||
34002318|NCT04130685|||OTHER||OTHER|||||||
33697914|NCT00004920|RANDOMIZED|||TREATMENT||||||||
33697915|NCT05734495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697916|NCT06223919|RANDOMIZED|PARALLEL||PREVENTION||NONE||Vaccinate LC16m8 randomly assigned to two groups consisting of two groups of Immediate and Delayed vaccination 1:1 with a follow-up period of 180 days to evaluate newly MPXV-infected cases as well as immuno-responses including neutralizing antibody titers.||||
34002319|NCT00534430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002320|NCT04534140|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||This will be a 2-armed investigational group (botanical dietary supplement) and placebo group (supplement vehicle), double-blind, randomized, parallel-group study.|t|t|t|t
34002321|NCT02934633|RANDOMIZED|PARALLEL||||NONE||||||
34002322|NCT02208336|||CASE_ONLY||PROSPECTIVE|||||||
34002323|NCT01021501|NA|SINGLE_GROUP||||NONE||||||
34002324|NCT06134440|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open-label, single-centre study in patients candidate to elective curative surgery for colon-rectal cancer.||||
34002325|NCT06086314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34002326|NCT06111534|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE||Participants were recruited using random sampling. The group assignment was determined using the closed envelope method. Therefore, data were collected first from the MHC group, followed by the PHC and control groups.|t|f|t|t
33697917|NCT05908110|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The primary care provider will receive the same alert for a positive OSA screen regardless of randomization condition. The primary outcome (OSA referral completion) will be extracted from the medical record by team members who are not aware of the child's randomization status.|Participants will be assigned to: 1) intervention (seeing a health communication message about OSA) or 2) Usual care.|f|t|t|t
33697918|NCT01578421|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33697919|NCT06332859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697920|NCT06478706|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33697921|NCT06474325|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||To compare the Medication adherence rating scale scores before and after using mental health application for improving medication adherence in persons with schizophrenia and schizoaffective disorder||||
33697922|NCT03023462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computer generated randomization with allocation in opaque envelopes. Randomization performed by other study personell than care provider.|"* Group QLB: Anterior Quadratus Lumborum Block using ropivacaine 7,5 mg/ml, 20ml. Subcutaneous wound infiltration in all patients with ropivacaine 5 mg/ml,10 ml.~* Group TAP: Transversus abdominis plane block using ropivacaine 7,5 mg/ml, 20 ml Subcutaneous wound infiltration in all patients with ropivacaine 5 mg/ml,10 ml."|t|f|t|t
33697923|NCT01210131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697924|NCT03532958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697925|NCT03189485|||OTHER||OTHER|||||||
33697926|NCT03521427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33697927|NCT04442308|||OTHER||PROSPECTIVE|||||||
33697928|NCT05423054|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33697929|NCT05898659|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: The patient and the investigator don't know the fitting.|"Two arms A and B:~Arm A: Bimodal patient's fitting with tonotopy-based fitting without synchronization (ABFnoS) --\> 6 weeks use --\> tests and bimodal patient's fitting with tonotopy-based fitting with synchronization (ABFS) --\> 6 weeks use --\> tests; Arm B: Bimodal patient's fitting with ABFS --\> 6 weeks use --\> tests and bimodal patient's fitting with ABFnoS --\> 6 weeks use --\> tests"|t|f|t|f
33697930|NCT06512597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33697931|NCT00920933|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33697932|NCT02919371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697933|NCT01076231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697934|NCT00000519|RANDOMIZED|||PREVENTION||||||||
33697935|NCT03445520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697936|NCT02090075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33697937|NCT04858256|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each of the four disease-based cohorts will be run in parallel, independently, and under an identical two-stage design.||||
33697938|NCT03277157|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The B. lactis and placebo will be provided in identical capsules.||t|t|t|t
33697939|NCT06626360|||OTHER||CROSS_SECTIONAL|||||||
33697940|NCT03537612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized|t|t|t|t
33697941|NCT03561753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697942|NCT03059433|||COHORT||PROSPECTIVE|||||||
33697943|NCT05080868|||COHORT||RETROSPECTIVE|||||||
33697944|NCT06077448|||CASE_CONTROL||PROSPECTIVE|||||||
33697945|NCT04836312|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33697946|NCT02661685|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 statistics model||||
33697947|NCT05536479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697948|NCT02664610|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33697949|NCT02730689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33697950|NCT01387802|||COHORT||PROSPECTIVE|||||||
33697951|NCT00198926|RANDOMIZED|CROSSOVER||ECT||SINGLE||||||
33697952|NCT06293131|NA|SEQUENTIAL||OTHER||NONE||||||
33697953|NCT00657085|||CASE_ONLY||PROSPECTIVE|||||||
33697954|NCT03095833|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33697955|NCT00622973|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33697956|NCT01440452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697957|NCT04693117|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33697958|NCT04224389|||COHORT||PROSPECTIVE|||||||
33697959|NCT06335134|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33697960|NCT04336358|RANDOMIZED|PARALLEL||SCREENING||NONE||inferiority randomised controlled trial||||
33697961|NCT04578808|||COHORT||PROSPECTIVE|||||||
33697962|NCT01824342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697963|NCT06523647|||OTHER||PROSPECTIVE|||||||
33697964|NCT04410029|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33697965|NCT03714308|||COHORT||PROSPECTIVE|||||||
33697966|NCT00550849|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33923115|NCT01893684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923116|NCT04391972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923117|NCT02610205|||COHORT||PROSPECTIVE|||||||
33923118|NCT04183894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923119|NCT05599854|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||f|f|t|t
34002327|NCT02244554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002328|NCT03474393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002329|NCT00734825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002330|NCT03323411|||COHORT||PROSPECTIVE|||||||
34002331|NCT03733587||SEQUENTIAL||TREATMENT||NONE||||||
34002332|NCT04371263|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33697967|NCT02058173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697968|NCT00471146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33697969|NCT05294562|||CASE_CONTROL||RETROSPECTIVE|||||||
33697970|NCT00232089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33697971|NCT04741607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As this RCT concerns a surgical intervention, patients and treating clinicians can not be masked.|Multicenter randomized controlled study with 2 treatment arms (control: delayed implant placement; test: immediate implant placement) and 6 centers|f|f|t|t
33786083|NCT05042791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786084|NCT00517478|||DEFINED_POPULATION||PROSPECTIVE|||||||
33786085|NCT05526911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786086|NCT03568162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33786087|NCT00751036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786088|NCT00415675|||CASE_ONLY||PROSPECTIVE|||||||
33786089|NCT04639154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786090|NCT01282775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786091|NCT01076218|||COHORT||PROSPECTIVE|||||||
33786092|NCT05998668|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||The study was desined as a randomized controlled trial|t|f|f|f
33786093|NCT01024205||||TREATMENT||NONE||||||
33786094|NCT03532178|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The randomization of treatment groups will be blinded to the patients themselves, the psychiatrists and outcome assessors, except the anesthesiologists who will administer the drugs.|The participants will be randomized to one of the two drug groups to start with, and will switch to the other group for the next treatment period. For the study, each participant will take two treatments in a random order: (1) rocuronium to be reversed by sugammadex, and (2) succinylcholine plus normal saline placebo.|t|f|t|t
33786095|NCT03780309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786096|NCT02377531|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34089646|NCT00883181|||OTHER||PROSPECTIVE|||||||
33786097|NCT04876781|||COHORT||PROSPECTIVE|||||||
33786098|NCT05926765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33697972|NCT02592122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697973|NCT02066220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697974|NCT04367129|||COHORT||PROSPECTIVE|||||||
33697975|NCT04357782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study||||
33697976|NCT02662634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697977|NCT02524093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697978|NCT00930826|||CASE_CONTROL||PROSPECTIVE|||||||
33697979|NCT00561769|||CASE_CONTROL||PROSPECTIVE|||||||
33697980|NCT04637646|||COHORT||PROSPECTIVE|||||||
33697981|NCT01309165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697982|NCT04434066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697983|NCT06288009|RANDOMIZED|PARALLEL||OTHER||SINGLE|Two blinded observers will record their scores independently using the POSAS instrument.||f|f|f|t
33697984|NCT05209178|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33697985|NCT05570877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697986|NCT01783054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697987|NCT03042325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33697988|NCT00080275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697989|NCT04636151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786099|NCT01991093|||OTHER||PROSPECTIVE|||||||
33786100|NCT00151996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923120|NCT01684683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923121|NCT00939939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923122|NCT00532714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923123|NCT01079650|||CASE_ONLY||PROSPECTIVE|||||||
33923124|NCT03303287|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||: Three schools under the Aga Khan Education Service in Karachi will be included in a two-arm parallel cluster intervention trial. All schools belong to lower to middle income class, at different locations, all having the same school curriculum. Baseline data will be collected from all three schools during a three month period by trained research staff||||
34002333|NCT01041196|||COHORT||RETROSPECTIVE|||||||
34002334|NCT05215054|NA|SINGLE_GROUP||TREATMENT||NONE|Participants and investigators assessors will not know which filler was used on each side of the face (hemi-face design)|All participants will receive both fillers||||
34002335|NCT00063609|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34002336|NCT03665623|||COHORT||PROSPECTIVE|||||||
34002337|NCT06678217|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34002338|NCT04033484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33697990|NCT03369470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33697991|NCT00968318|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33697992|NCT00334607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33697993|NCT01481181|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33697994|NCT01529684|NA|SINGLE_GROUP||OTHER||NONE||||||
33697995|NCT02025166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33697996|NCT03587948|||COHORT||PROSPECTIVE|||||||
33697997|NCT02165709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923125|NCT04021459|NA|SINGLE_GROUP||SCREENING||NONE||women with endometrial cancer||||
33923126|NCT04839224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Three months after discharge, the independence assessment will be performed by the researcher who don't know the patients group.|"1. The study is a single center, prospective, randomized, open-label trial with blinded end-point assessment (PROBE) design study.~2. For the patients with neurological worsening after lacunar infarction, the carbogen group and the phenylephrine group will be randomized by 1: 1.~3. Patients will be enrolled from April 2021 to December 2022 (based on the date of stroke).~4. We will collect medical history, laboratory findings, neurological scores, and functional recovery.~5. Functional recovery scores are performed by independent researchers in the blind state.~6. All data is collected using e-CRF, and the image study will be anonymized and sent to the central adjudication.~7. Central adjudication will review the image study."|f|f|f|t
33923127|NCT02584777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923128|NCT02781012|||COHORT||PROSPECTIVE|||||||
33923129|NCT04913441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study would be double blinded as accessor and the participant of the study would be kept blind of the treatment group to which patient would be allocated. After the complete initial screening process, every recruited patient will be accessed by an independent assessor, expert will use outcome measuring tools. his will be recorded as baseline measurement assessment.||t|f|f|t
33923130|NCT02915887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923131|NCT01238913|||CASE_ONLY||PROSPECTIVE|||||||
33923132|NCT00593658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923133|NCT01906957|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923134|NCT05243277|||COHORT||PROSPECTIVE|||||||
33923135|NCT03476382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923136|NCT01345851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923137|NCT02204813||CROSSOVER||BASIC_SCIENCE||SINGLE||Patients with prior RYGB surgery receive all interventions, each on a separate day.|t|f|f|f
33923138|NCT00393003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923139|NCT05628155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923140|NCT00250185||||TREATMENT||||||||
33923141|NCT03949140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923142|NCT04690621|||COHORT||PROSPECTIVE|||||||
33923143|NCT05983835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923144|NCT05146583|||OTHER||PROSPECTIVE|||||||
33923145|NCT03457311|NA|SINGLE_GROUP||SCREENING||NONE||||||
33923146|NCT02990104|||CASE_ONLY||RETROSPECTIVE|||||||
33697998|NCT04937855|||OTHER||PROSPECTIVE|||||||
33697999|NCT04423783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923147|NCT01270230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698000|NCT01798420|||CASE_CONTROL||PROSPECTIVE|||||||
33698001|NCT03422042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698002|NCT01792271|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33698003|NCT06331026|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33923148|NCT02846805|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923149|NCT02205918|||CASE_ONLY||CROSS_SECTIONAL|||||||
33923150|NCT00191737|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923151|NCT03618602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33923152|NCT02422082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923153|NCT04019769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002339|NCT03065231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the type of intervention that took place.|There will be two arms of the study: patients randomly assigned to LD and patients randomly assigned to EVD. Randomization will account for Fisher Grade. The two treatment arms will have CSF diversion for 7 days. For patients treated with lumbar drain, patients will have CSF drainage of 10cc/hour for lumbar drain while patients treated with EVD at 15cm above the tragus.|f|f|f|t
34002340|NCT02275754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34002341|NCT06062316|||COHORT||PROSPECTIVE|||||||
34002342|NCT03179748|||COHORT||PROSPECTIVE|||||||
34002343|NCT02287636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002344|NCT01816789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002345|NCT05523960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002346|NCT02823327|||CASE_ONLY||RETROSPECTIVE|||||||
34002347|NCT05960422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002348|NCT00344513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698004|NCT05391529|||COHORT||PROSPECTIVE|||||||
33698005|NCT06556472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698006|NCT02605785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698007|NCT05024773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698008|NCT03412708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Prospective|f|f|f|t
33698009|NCT01544556|||CASE_CONTROL||PROSPECTIVE|||||||
33786101|NCT00941031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786102|NCT06551922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded assessor will be utilized to minimize bias in outcome measurements. The assessor will be unaware of the intervention group assignment for each participant.|"* Group A (Instrumental Soft Tissue Mobilization Technique with Conservative Treatment)~* Group B (Conservative Treatment Only)"|f|f|f|t
33786103|NCT06310564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801633|NCT05496842|||CASE_ONLY||RETROSPECTIVE|||||||
33698010|NCT01461980|RANDOMIZED|||PREVENTION||QUADRUPLE|||t|t|t|t
33698011|NCT00173888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698012|NCT02315573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33698013|NCT03814473|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33698014|NCT05264727|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33698015|NCT01051466|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33698016|NCT06573359|||CASE_CONTROL||PROSPECTIVE|||||||
33698017|NCT05744713|||COHORT||OTHER|||||||
33698018|NCT00000663||||TREATMENT||||||||
33698019|NCT06153446|||COHORT||RETROSPECTIVE|||||||
33698020|NCT02098252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698021|NCT05738629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923154|NCT04461028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research assistant collecting the data as well the patient will be blinded to the nature of the group assignments.|Randomization between Group 1 and Group 2|t|f|f|t
33786104|NCT03429387|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be randomized to either the PET/CT arm or the conventional CT arm||||
33923155|NCT00340834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33698022|NCT06556758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698023|NCT04078789|||COHORT||PROSPECTIVE|||||||
33786105|NCT00472147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923156|NCT04578015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002349|NCT05421195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698024|NCT05870774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698025|NCT03875768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786106|NCT00398502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786107|NCT06417489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786108|NCT02793609|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786109|NCT01696721|||COHORT||PROSPECTIVE|||||||
33786110|NCT00012467||||TREATMENT||DOUBLE||||||
33786111|NCT03586167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786112|NCT04965883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786113|NCT06480409|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786114|NCT04798521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786115|NCT04100044|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33786116|NCT03365856|||COHORT||CROSS_SECTIONAL|||||||
33786117|NCT02162238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33786118|NCT03588065|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The FMS as a diagnostic evaluation test was applied in two moments with three blind physiotherapeutic evaluators with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience. in sport over 6 years in sports clubs in the region.|For the process of imparting health education strategies in face-to-face (conference) and ICT-mediated mode, a 4-week time was estimated where 4 educational sessions were held at a rate of one each week, lasting about 40 minutes, for part of two physiotherapists experts in the theme of injury prevention around the conceptual elements of human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing. Interventions were carried out simultaneously in both groups of the study, so that one researcher taught the lecture modality in person (conference group), and the other supervised the participants while using the computers of the sports training institution.|t|f|t|f
33786119|NCT05264337|||COHORT||PROSPECTIVE|||||||
33786120|NCT04569578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786121|NCT05358730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786122|NCT00640874|||COHORT||PROSPECTIVE|||||||
33786123|NCT00533416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923157|NCT01229241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33698026|NCT02852889|||CASE_CONTROL||PROSPECTIVE|||||||
33698027|NCT05509751|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|The study statistician will be blinded to group allocation||f|f|f|t
33786124|NCT00028132||PARALLEL||PREVENTION||||||||
33786125|NCT00284401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786126|NCT02494830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786127|NCT05286424|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923158|NCT05718206|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923159|NCT00474344|||COHORT||RETROSPECTIVE|||||||
33923160|NCT00163904|RANDOMIZED|PARALLEL||||NONE||||||
33923161|NCT01688635|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33923162|NCT05374837|RANDOMIZED|PARALLEL||PREVENTION||NONE|Given the nature of the intervention, it will not be possible to mask the treatment group at endline data collection.|Cluster-randomized control trial||||
33923163|NCT03723499|||COHORT||RETROSPECTIVE|||||||
33923164|NCT06120309|||COHORT||RETROSPECTIVE|||||||
34002350|NCT01525680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002351|NCT01909115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002352|NCT03729557|||COHORT||PROSPECTIVE|||||||
34002353|NCT05991362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002354|NCT00005958||||TREATMENT||||||||
34002355|NCT02386761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002356|NCT01660516|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34002357|NCT05636891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698028|NCT01790776|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33698029|NCT04676412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698030|NCT06617026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698031|NCT05211986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 dose cohorts: Cohort A, IMM01-STEM 225μg; Cohort B, IMM01-STEM 450 μg; and Cohort C, IMM01-STEM 900 μg.||||
33698032|NCT01454960|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33698033|NCT04615897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698034|NCT05264688|||COHORT||PROSPECTIVE|||||||
33698035|NCT04433533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786128|NCT06393400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002358|NCT00032240|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34002359|NCT00002936||||TREATMENT||||||||
33786129|NCT01571921|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33786130|NCT03254329|||FAMILY_BASED||PROSPECTIVE|||||||
33786131|NCT04764019|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786132|NCT03613402|||CASE_CONTROL||PROSPECTIVE|||||||
33786133|NCT02473562|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33786134|NCT06518499|||CASE_ONLY||PROSPECTIVE|||||||
33786135|NCT02283255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786136|NCT06306846|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786137|NCT06712745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002360|NCT02571309|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33786138|NCT02253186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786139|NCT06366074|RANDOMIZED|CROSSOVER||OTHER||NONE||Prevalence of delayed Chemotherapy-induced nausea, emesis, and dyspeptic symptoms (CINEDS) is 75% in women vs 51% in men (60% to 40% ratio). Therefore, every effort will be made to recruit at least 60% female subjects into the clinical study.||||
33786140|NCT01854437|||CASE_CONTROL||PROSPECTIVE|||||||
33786141|NCT04888455|||COHORT||CROSS_SECTIONAL|||||||
33786142|NCT05121155|||COHORT||PROSPECTIVE|||||||
33786143|NCT01501630|||||PROSPECTIVE|||||||
33786144|NCT02702674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33786145|NCT05588154|||COHORT||PROSPECTIVE|||||||
33786146|NCT05481411|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33786147|NCT00286546|||DEFINED_POPULATION||OTHER|||||||
33786148|NCT04895579|NA|SINGLE_GROUP||TREATMENT||NONE||Dose finding cohort and dose expansion cohort up to 18 patients||||
33786149|NCT01394809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002361|NCT04417439|||CASE_CONTROL||PROSPECTIVE|||||||
33786150|NCT06630442|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923165|NCT06375252|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33923166|NCT01743885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33923167|NCT03471481|||CASE_ONLY||CROSS_SECTIONAL|||||||
33923168|NCT01639456|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923169|NCT04526067|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those with no preference for CAT or R-CAT will be Randomized, 1:1 done by statistician who has no patient contact through a random allocation program. If blinds are broken accidentally, new raters can be assigned, but blinds are kept by having raters and pill counters unaware of treatment group or study design.|Randomized parallel design|f|f|f|t
33923170|NCT01583985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923171|NCT02663479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33923172|NCT05534841|||CASE_CONTROL||RETROSPECTIVE|||||||
33923173|NCT01565590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923174|NCT05099536|NA|SEQUENTIAL||TREATMENT||NONE||||||
33923175|NCT03516955|||COHORT||PROSPECTIVE|||||||
33923176|NCT02675725|||CASE_CONTROL||PROSPECTIVE|||||||
33923177|NCT00870974|NA|SINGLE_GROUP||||NONE||||||
33923178|NCT05725330|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923179|NCT00001911||||TREATMENT||||||||
33923180|NCT01712217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923181|NCT03946293|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33923182|NCT00004732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33923183|NCT04114513|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33923184|NCT06403748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923185|NCT01962688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33923186|NCT01245205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923187|NCT03331224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002362|NCT02725164|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34002363|NCT01928615|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002364|NCT03895151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34002365|NCT06418243|||CASE_ONLY||PROSPECTIVE|||||||
34002366|NCT05079841|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33786151|NCT01182870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923188|NCT06040307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blinded to the primary endpoint (intraoperative amount of sufentanil). Participants are not informed about the group assignment (intervention takes place in general anesthesia). The attending anesthesiologists can not be blinded to the group-allocation, because the study involves intervention during the intraoperative treatment. The study is double-blinded regarding the secondary endpoints. Postoperative outcome parameters are assessed by members of the study team. These outcome-assessors are blinded to the group assignment.|Participants are assigned to intervention groups by chance|t|f|f|t
33698036|NCT03757338|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The study was conducted as a blinded study regarding dose administration and sample collection. In addition, the blood samples from each subject were coded in a manner to make the analyst blind to the identity of the samples, allowing efficient conduct of the analytical procedure.|Single centre, single dose, blinded, two treatment, two period, two sequence, two-way crossover, randomized study.|f|f|f|t
33786152|NCT00984282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786153|NCT03699735|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single (Participant)|Crossover Assignment Each participant will be treated with each test condition in a randomized order.|t|f|f|f
33786154|NCT02077738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786155|NCT00698659|||||PROSPECTIVE|||||||
33698037|NCT00743899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786156|NCT02071511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786157|NCT00870259|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923189|NCT04117399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33923190|NCT02810951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923191|NCT05008172|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the interventional nature of this study (embolization vs observation), it will not be possible to mask providers or participants.|Once the attending surgeon decides on NOM the patient will be approached for enrollment by the ED Resuscitation Team. Randomization to prophylactic SAE vs observation will occur in block fashion.||||
33923192|NCT02839824|||COHORT||RETROSPECTIVE|||||||
33923193|NCT02061579|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33923194|NCT00769236|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34002367|NCT06678490|||COHORT||PROSPECTIVE|||||||
34002368|NCT05435833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34002369|NCT00006009||||TREATMENT||||||||
34002370|NCT02004691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002371|NCT03647917|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34002372|NCT05740215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002373|NCT04776005|||COHORT||PROSPECTIVE|||||||
34002374|NCT01386125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002375|NCT03974893|||COHORT||PROSPECTIVE|||||||
34002376|NCT06678113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786158|NCT02757885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786159|NCT04656236|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Crossover design in 2 different groups, patients with type 1 diabetes and healthy controls.|t|f|f|f
33786160|NCT05448066|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||Pragmatic randomized controlled trial|t|t|t|t
33786161|NCT00926939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33786162|NCT03005249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923195|NCT04068428|||COHORT||PROSPECTIVE|||||||
33923196|NCT02806947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002377|NCT03476681|NA|SINGLE_GROUP||TREATMENT||NONE||"In the dose expansion phase subjects with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers will be treated with NEO-201 at 1.5 mg/kg every 2 weeks in combination with pembrolizumab at 400 mg IV every 6 weeks.~In each cycle the combination will be given sequentially with NEO-201 on Day 1, followed by pembrolizumab on Day 2 to reduce the risk of additive infusion reactions. NEO-201 will be administered IV every 2 weeks on Days 1, 15 and 29 of a 42-day cycle.~Response assessment will be done at the end of Cycle 2 Day 84."||||
34002378|NCT01065792|||||PROSPECTIVE|||||||
34002379|NCT03269955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34002380|NCT06459115|||COHORT||CROSS_SECTIONAL|||||||
34002381|NCT01362296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698038|NCT02301130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698039|NCT06680661|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately 20 subjects will be enrolled in this trial: 7 patients will be accrued for the Stage 1. Stage 1 must be complete and the 7th patient reach T+180 prior to enrolling 13 additional patients to Stage 2.||||
33698040|NCT01262573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698041|NCT04383158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, controlled, single-centre, prospective, parallel-group qualitative pilot study||||
33923197|NCT03368040|||COHORT||PROSPECTIVE|||||||
33923198|NCT03947567|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34002382|NCT01647997|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002383|NCT02625337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002384|NCT02049918|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34002385|NCT01499160|NA|SINGLE_GROUP||TREATMENT||NONE|No masking was done|sequential treatment assignment, no masking is done||||
34002386|NCT03245437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind Placebo controlled||t|t|t|t
34002387|NCT01475487|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34002388|NCT00640393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923199|NCT04950205|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33923200|NCT03256071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002389|NCT00310297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002390|NCT01351363|NA|SINGLE_GROUP||SCREENING||NONE||||||
33923201|NCT04965870|||COHORT||RETROSPECTIVE|||||||
33923202|NCT03683056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698042|NCT01556880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33698043|NCT00005017||||TREATMENT||||||||
33698044|NCT02810977|||OTHER||CROSS_SECTIONAL|||||||
33698045|NCT03989765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The control group will be masked, but it is not possible to mask the intervention group.|Cluster randomised controlled trial. 5 clusters per study arm||||
33698046|NCT06629207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698047|NCT05361785|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Coputer based randomization|RCT, randomaization 2/3 FMT, 1/3 placebo|f|f|t|f
33698048|NCT05419986|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33801634|NCT00088738||||TREATMENT||||||||
33923203|NCT01286701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923204|NCT01760187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923205|NCT01343017|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33923206|NCT02732353|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33923207|NCT00516984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923208|NCT02752724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923209|NCT01629901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923210|NCT05194501|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33923211|NCT03825107|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel for primary outcome; crossover for longterm effectiveness||||
33923212|NCT00475800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923213|NCT01828099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923214|NCT00160992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923215|NCT00473044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33923216|NCT00880763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923217|NCT05594368|NA|SINGLE_GROUP||TREATMENT||NONE||The study is designed as a one arm, multi-center dose escalation trial employing the i3+3 design.||||
33923218|NCT05285436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All study participants receive a CloudCath Device and use it at home adjunctively to their regular peritoneal dialysis system.||||
33923219|NCT03511820|||CASE_ONLY||PROSPECTIVE|||||||
33923220|NCT01002053|||OTHER||PROSPECTIVE|||||||
33923221|NCT04250376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923222|NCT04915326|||COHORT||OTHER|||||||
33923223|NCT03544632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923224|NCT05321966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33923225|NCT01541501|||COHORT||PROSPECTIVE|||||||
33923226|NCT02356146|||COHORT||PROSPECTIVE|||||||
33923227|NCT02027922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923228|NCT01867567|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33923229|NCT02576886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923230|NCT03550742|NA|SINGLE_GROUP||OTHER||NONE||||||
33923231|NCT03625154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923232|NCT00559416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923233|NCT01300364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923234|NCT02963896|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923235|NCT06048367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This Phase 1 clinical trial employs a dose escalation design for the investigation of Carbon Nanoparticle-Loaded Iron \[CNSI-Fe(II)\] in the treatment of advanced solid tumors. The study follows a Sequential Study Model and consists of unique arms for each dose level(30mg, 60mg, and 90mg), using the traditional 3+3 method for dose escalation."||||
33923236|NCT05488704|||CASE_CONTROL||PROSPECTIVE|||||||
33923237|NCT00292747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923238|NCT05464472|||COHORT||PROSPECTIVE|||||||
33923239|NCT05572346|||OTHER||PROSPECTIVE|||||||
33923240|NCT01690104|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33923241|NCT05431569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923242|NCT02090270|||COHORT||PROSPECTIVE|||||||
33923243|NCT02670928|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33923244|NCT05126940|||CASE_ONLY||PROSPECTIVE|||||||
33923245|NCT02433860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923246|NCT01651299|||||PROSPECTIVE|||||||
33923247|NCT01058733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923248|NCT01425749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923249|NCT01754077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33923250|NCT00050960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002391|NCT03256994|||COHORT||PROSPECTIVE|||||||
34089647|NCT05836623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open-label single center non-randomised study|Following administration of 89Zr-CB307, enrolled patients will undergo a number of PET scans where uptake of the radiolabelled drug will be assessed||||
33698049|NCT04871282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698050|NCT03425513|||CASE_ONLY||PROSPECTIVE|||||||
34089648|NCT04050605|NA|SINGLE_GROUP||OTHER||NONE|Study lenses will be transferred, by an assistant, out of their packaging to unmarked new contact lens cases filled with preservative free sterile saline just prior to dispensing to maintain subject masking of the study lenses.|First pair of study lenses (habitual lenses - somofilcon A toric) will be dispensed and worn for 4-weeks of daily wear, then second pair of lenses (test lenses - fanfilcon A toric) will be dispensed and worn for 4-weeks for daily wear.||||
34002392|NCT01449409|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34089649|NCT00304330|||OTHER||RETROSPECTIVE|||||||
34089650|NCT01334099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698051|NCT04968795|||COHORT||PROSPECTIVE|||||||
33698052|NCT06002243|NA|SINGLE_GROUP||SCREENING||NONE||||||
34002393|NCT04080999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34002394|NCT01526135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002395|NCT01137734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002396|NCT00344045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002397|NCT03426540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002398|NCT06359275|NA|SEQUENTIAL||TREATMENT||NONE||||||
34002399|NCT03562845|||CASE_ONLY||CROSS_SECTIONAL|||||||
34002400|NCT04519879|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002401|NCT03843125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002402|NCT02263768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34002403|NCT03473067|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002404|NCT00000449|RANDOMIZED|FACTORIAL||TREATMENT||||||||
34002405|NCT01726257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002406|NCT04594720|||CASE_CONTROL||RETROSPECTIVE|||||||
34002407|NCT03922139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002408|NCT00011609|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089651|NCT03809585|||CASE_CONTROL||PROSPECTIVE|||||||
34089652|NCT00609505|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34089653|NCT06244901|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34089654|NCT05123924|||COHORT||CROSS_SECTIONAL|||||||
34089655|NCT04321395|NA|SINGLE_GROUP||OTHER||NONE||Participants will receive vigabatrin||||
34089656|NCT04256200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34089657|NCT00396292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089658|NCT01136954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089659|NCT03346343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This will be a single center prospective observational study with pre-specified Aims and Hypotheses||||
34002409|NCT06463119|||COHORT||PROSPECTIVE|||||||
34002410|NCT03043898|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34089660|NCT03199105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33698053|NCT00402272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698054|NCT05625061|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This is a micro-randomized trial, a form of a sequential, factorial trial. At every time point, a participant is micro-randomized to receive or not receive an intervention message.|f|f|t|t
33698055|NCT05122871|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698056|NCT06383767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698057|NCT06047925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator-outcome Assessor)|one experimental group and one active comparator group|f|f|t|t
33698058|NCT05991323|||CASE_ONLY||PROSPECTIVE|||||||
33698059|NCT03785938|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The liquid probiotic/placebo will be blinded by the pharmacy team and LTHT|Double blinded randomised-controlled feasibility study|t|t|t|t
33698060|NCT01318642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698061|NCT02479269|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002411|NCT00138463|||COHORT||PROSPECTIVE|||||||
34002412|NCT06369610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002413|NCT04325516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002414|NCT03563794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002415|NCT02818296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34002416|NCT05061992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002417|NCT01628549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002418|NCT04030338|||COHORT||PROSPECTIVE|||||||
34002419|NCT00570206|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002420|NCT05530850|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34002421|NCT01465568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089661|NCT06109298|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34089662|NCT00112229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089663|NCT05568290|||OTHER||CROSS_SECTIONAL|||||||
34089664|NCT00448149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089665|NCT03474653|||COHORT||PROSPECTIVE|||||||
34089666|NCT03743194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089667|NCT00768053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089668|NCT03317496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089669|NCT02986776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089670|NCT06319118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089671|NCT03797053|||COHORT||PROSPECTIVE|||||||
34103140|NCT06691256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The Phase 2 study model for HiDO-ALZ uses a dual-study approach to refine and validate the platform:~In-Clinic Usability Study: This first study, conducted with dementia patients and caregivers, evaluates user interaction with the HiDO-ALZ device in a clinical setting. Key tasks, such as device setup and biometric data collection, are observed to inform usability improvements.~Field Efficacy Study: Building on in-clinic findings, this home-based trial enrolls participants in a 12-month randomized controlled study to assess the HiDO-ALZ's impact on medication adherence and health outcomes, such as adherence rates and biometric trends."||||
34002422|NCT06474845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, it is not possible to blind the patient or the healthcare professional; however, the professional who analyses the data will be unaware of the type of catheter used for each patient.|Comparative, randomized, controlled, multicentric clinical study with two arms|f|f|f|t
34002423|NCT04326933|||CASE_ONLY||PROSPECTIVE|||||||
34002424|NCT00999115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002425|NCT06615427|||OTHER||OTHER|||||||
34002426|NCT00139932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002427|NCT06062160|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blind|"There is a difference between the posttest pain scores of the intervention group and the control group.~There is a difference between the comfort level posttest scores of the intervention group and the control group."|t|f|f|f
34002428|NCT05077501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002429|NCT01611896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089672|NCT05863949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Enrolled subjects will be blinded to their treatment assignment. Both study staff and trial investigators will be blinded to treatment assignments and will remain blinded throughout the course of the trial. Randomization (treatment assignment) will be performed via computer algorithm based on subject ID. Randomization codes will be maintained in a password protected, encrypted file available only to the single unmasked investigator at each site, in order to prevent accidental unmasking of other trial personnel. All care will be taken to ensure that the study team are kept blinded.~Pills, which will be dispensed at 3-month intervals, will be indistinguishable between groups. They will be dispensed in kits that are labeled as outlined in section 6.2 Study Drug Packaging and Labeling."|This is an off-label, multicenter, randomized, clinical trial in vitamin D deficient adults aged 18 and above with recurrent BPPV. Its goal is to determine whether vitamin D supplementation, with or without calcium supplementation, compared with placebo will decrease the frequency of recurrent episodes of BPPV. A total of 860 vitamin D deficient adults diagnosed with recurrent BPPV will be enrolled at participating clinical study sites.|t|t|t|t
34089673|NCT04375124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This group will receive angiotensin peptide (1-7) during their treatment at hospital.||||
34089674|NCT04888312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089675|NCT05695313|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002430|NCT01134991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34002431|NCT04584086|NA|SINGLE_GROUP||OTHER||NONE||||||
34002432|NCT02506205|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34002433|NCT03000517|||COHORT||PROSPECTIVE|||||||
34002434|NCT00510419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002435|NCT01763658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002436|NCT04543331|||COHORT||PROSPECTIVE|||||||
34002437|NCT03506087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized 1:1 to an intervention arm or an enhanced control arm. Participants in the intervention group will receive printed educational materials plus one or more ACP coaching sessions. Participants in the enhanced control arm will receive printed materials only.||||
34002438|NCT01123291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34089676|NCT00976027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089677|NCT01879436|||OTHER||OTHER|||||||
34089678|NCT00970944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089679|NCT04921397|||OTHER||PROSPECTIVE|||||||
34089680|NCT03087032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089681|NCT04370496|NA|SINGLE_GROUP||TREATMENT||NONE|All patients enrolled in this clinical trial will undergo radical hysterectomy through minimally invasive surgery using an endoscopic stapler which both cuts and simultaneously sutures the open vaginal stump.|Patients enrolled in this clinical trial will undergo surgery for early stage cervical cancer. They will receive either laparoscopic or robotic radical hysterectomy using an endoscopic stapler. The efficacy and safety of this surgical technique will be compared to that of open radical hysterectomy studied in previous trials.||||
33698062|NCT04671524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34002439|NCT03721887|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34002440|NCT04883333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002441|NCT04926701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002442|NCT06507241|||COHORT||OTHER|||||||
34002443|NCT00912522|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34002444|NCT00440622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002445|NCT01931345|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002446|NCT01387152|||COHORT||PROSPECTIVE|||||||
34002447|NCT01151449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002448|NCT00609154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002449|NCT03161353|RANDOMIZED|PARALLEL||TREATMENT||NONE||This randomized, open-label phase II study will assess the efficacy of the combination of trastuzumab and pertuzumab, ± endocrine therapy according to HR (hormone receptor) status, as exclusive neoadjuvant and adjuvant treatment in patients with HER2-positive breast cancer through a FDG-PET response-adapted strategy.||||
34002450|NCT06030115|||COHORT||PROSPECTIVE|||||||
34002451|NCT03605992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002452|NCT00022555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002453|NCT00970749|||CASE_ONLY||CROSS_SECTIONAL|||||||
34002454|NCT02396927|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34002455|NCT02102269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002456|NCT06622486|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation followed by combination therapy||||
34002457|NCT04439123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002458|NCT03815409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089682|NCT03978767|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized non-inferiority clinical trial||||
34089683|NCT01947933|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34002459|NCT04543968|RANDOMIZED|PARALLEL||TREATMENT||NONE||Twelve subjects will be recruited, including MD patients with confirmed MD-associated nuclear DNA or mtDNA mutations. Subjects will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to either continue on or withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.||||
34002460|NCT05553496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089684|NCT04801082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089685|NCT01955304|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089686|NCT04764149|||COHORT||RETROSPECTIVE|||||||
34089687|NCT06291363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be done prior to the entrance in the OR, the day of the surgery.|"Two groups of patients randomized into Group ESMOLOL for esmolol and group Standard of Care for a total of 64 participants."|t|t|t|t
34089688|NCT00316004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089689|NCT05688228|||CASE_ONLY||PROSPECTIVE|||||||
34089690|NCT02271178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089691|NCT03695588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089692|NCT01159847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089693|NCT02705170|||COHORT||PROSPECTIVE|||||||
34089694|NCT05080985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089695|NCT03646890|||COHORT||RETROSPECTIVE|||||||
34089696|NCT00530166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089697|NCT01721902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698063|NCT03206437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since this study is focusing on a mind-body skill as a treatment it will be impossible to mask the participant.||f|f|t|t
33923251|NCT00006372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923252|NCT06213610|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33923253|NCT05411328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923254|NCT02084069|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33923255|NCT02016898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923256|NCT04254796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33923257|NCT03752333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923258|NCT04689841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923259|NCT00769808|NA|SINGLE_GROUP||TREATMENT||NONE||This was a medical device study with only one intervention used for lasik correction surgery||||
33923260|NCT03428451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923261|NCT03289871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923262|NCT05322057|||CASE_ONLY||PROSPECTIVE|||||||
33923263|NCT01540968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33923264|NCT02003729|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33923265|NCT03296852|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33923266|NCT04110860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33923267|NCT05867199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33923268|NCT01017887|||CASE_CONTROL||PROSPECTIVE|||||||
33923269|NCT05637801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study; the investigator, the subject and study partner, and all other study personnel involved with subject assessments will remain blinded to the actual treatment assignment of the subjects. The Sponsor and their delegates involved in the study will be blinded to actual treatment assignment with the exception of technicians who are necessarily unblinded to assign and maintain the Investigational Devices and data analysis personnel as indicated in the Statistical Analysis Plan (SAP). Technicians and customer service agents who interact with subjects, their study partners and clinical sites will be specially trained to not reveal the study assignment (Active or Sham).|Randomized, Double-blind, Sham-controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer's Disease|t|t|t|t
33923270|NCT04969341|||COHORT||OTHER|||||||
33923271|NCT03104998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923272|NCT03707158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923273|NCT03745300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923274|NCT04920539|NA|SINGLE_GROUP||OTHER||NONE||||||
33923275|NCT02375269|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33923276|NCT03954977|NA|SINGLE_GROUP||SCREENING||NONE|Investigator is blinded to xray result before doing ultrasound|A prospective comparative study evaluating chest x-ray determination of PICC line tip location and POC ultrasound PICC line tip location. NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.||||
33923277|NCT01865045|||CASE_ONLY||RETROSPECTIVE|||||||
33923278|NCT06442657|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923279|NCT00002718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923280|NCT04505150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The individual participant will not be randomly assigned but as a group of participants (intervention arm and control arm) will be randomly selected.|Cluster randomised||||
33923281|NCT05067452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The analyst(s) and investigator(s) conducting and reviewing the analyses of the data will be masked to whether participants were in the intervention or control arm.|Participants (n=72) will be randomized to the intervention (n=36) or control (n=36) arms. The intervention consists of providing diabetes-tailored food support and individualized case management over 12 weeks to patients with type 2 diabetes.|f|f|t|t
33923282|NCT04828356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled trial|t|f|f|t
33923283|NCT03234972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923284|NCT06248697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923285|NCT03148951|||COHORT||PROSPECTIVE|||||||
34002461|NCT06663475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34002462|NCT04763447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002463|NCT03278041|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Because the two interventions used in this trial are clearly different and easly recognized by the participants and investigators, neither investigator AlAdashi O nor Participants can be blinded.~Similarly, the Assessor (Participants) can't be blinded. The statistician will be blinded."|||||
34002464|NCT04688515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002465|NCT04410705|NA|SINGLE_GROUP||TREATMENT||NONE||ESWT||||
34002466|NCT05505825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923286|NCT04540835|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33923287|NCT06527196|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33923288|NCT04799067|||COHORT||PROSPECTIVE|||||||
33923289|NCT05474807|NA|SINGLE_GROUP||OTHER||NONE||One-armed study with baseline and post-intervention measurements.||||
33923290|NCT01192711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923291|NCT04212052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923292|NCT03957356|NA|SINGLE_GROUP||OTHER||NONE||Single Arm, Open Label, Single Center Exploratory Clinical Trial||||
33923293|NCT03496727|||CASE_CONTROL||RETROSPECTIVE|||||||
33923294|NCT03879876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002467|NCT01924364|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||split-person study in which different parts of the same person may be assigned to receive different interventions, randomization occurs in regards to which site receives TGI or no TGI per site.||||
34089698|NCT04040699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002468|NCT05611723|||OTHER||CROSS_SECTIONAL|||||||
34002469|NCT05981716|||CASE_ONLY||CROSS_SECTIONAL|||||||
34002470|NCT02684396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002471|NCT03103828|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33698064|NCT05886816|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The study participants and the investigators involved in the acquisition and analysis of key outcomes will be blinded to the group status of the subjects. The double-blind drugs will be labelled within the institutional investigational drug service pharmacy.|Group 1: Mito-MES 20 mg daily initiated within 3 days post exposure and taken daily during the study Group 2: Placebo.|t|t|t|f
34002472|NCT04894630|NA|SEQUENTIAL||TREATMENT||NONE||||||
34089699|NCT05247320|||COHORT||OTHER|||||||
34089700|NCT00085579||||TREATMENT||NONE||||||
34002473|NCT00159419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089701|NCT02049762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34089702|NCT03846479|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, non-inferiority study||||
33698065|NCT05342402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Baseline evaluation - Randomization to Somatosensory Rehabilitation Program or Educational Pain Management Program (12 sessions within 12 weeks) - 2 weeks post-treatment evaluation - 3 months follow-up|t|f|t|t
33786163|NCT04591184|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Unblinded study nurse with no other role in the trial administers VAX-001. Observer blinded.||t|f|t|t
33786164|NCT02441075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786165|NCT03031756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34002474|NCT02527330|||CASE_ONLY||PROSPECTIVE|||||||
33923295|NCT05831527|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Multiarm study, both arms receiving the same intervention drug.||||
33923296|NCT02598505|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33923297|NCT01790789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33923298|NCT00722709|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33923299|NCT05677295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002475|NCT04464603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinding to the outcomes will be maintained during recruitment to minimize preparation bias. Allocation concealment will be ensured with an allocation software and will not be released until the participants start the scenario. A post-scenario video review will be done without blinding by two reviewers, but undertaken independently with each blinded to the other's reviews. In the case of disagreement, a third independent evaluator will help reach a consensus. The data analyst will be blinded to group allocation.|A prospective, single center, randomized controlled trial|t|f|f|f
34089703|NCT03725553|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which was used.|Patients were randomized to two groups, patients according to a two -blocked randomization list which was coded (1 or 2) at 1:1 ratio. The study drug was administered immediately after delivery, as soon as the umbilical cord was clamped. The experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-s) Conversely, the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds).|t|t|t|t
33923300|NCT04197141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923301|NCT01080456|RANDOMIZED|CROSSOVER||||NONE||||||
34002476|NCT01970917|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34002477|NCT06444165|NA|SINGLE_GROUP||OTHER||NONE||||||
34002478|NCT01620281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002479|NCT05788432|||COHORT||PROSPECTIVE|||||||
34089704|NCT02995148|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089705|NCT00058032|RANDOMIZED|PARALLEL||SCREENING||NONE||202,638 participants randomised to: Multimodal Group: 50640 Ultrasound Group: 50639 Control Group: 101359||||
34089706|NCT01091259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089707|NCT03073759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089708|NCT02283567|||COHORT||PROSPECTIVE|||||||
34089709|NCT01724593|||COHORT||PROSPECTIVE|||||||
34089710|NCT00204737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089711|NCT00000935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786166|NCT06163521|NA|SINGLE_GROUP||OTHER||NONE||Pre-experimental, nested design in mixed methodology||||
33786167|NCT03059082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33786168|NCT00515086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923302|NCT02348424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089712|NCT02807259|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34089713|NCT01723059|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089714|NCT05927415|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34089715|NCT02371811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089716|NCT05213091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research data/output measurements, analysis and reporting||f|f|f|t
34089717|NCT00878865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34089718|NCT03188198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089719|NCT01997450|||CASE_CONTROL||PROSPECTIVE|||||||
34002480|NCT06678321|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34002481|NCT05363982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089720|NCT03149770|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34089721|NCT04131803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923303|NCT05496218|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Study participants will be subjected to blood sampling that is not part of the routine clinical practice, so it's an interventional study.|Single-center case-control study.||||
33923304|NCT04402229|||OTHER||PROSPECTIVE|||||||
33923305|NCT05395741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089722|NCT02112201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786169|NCT00186680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002482|NCT00726050|||||PROSPECTIVE|||||||
34002483|NCT02086916|||COHORT||PROSPECTIVE|||||||
34002484|NCT05147740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786170|NCT00134810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002485|NCT03519490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All lenses are identical in size, color and fitting characteristics. Lenses are supplied from the manufacturer with labels with full parameter information. This information will be removed or masked on the vials prior to being delivered to the office by the study coordinator.|Using a covariate adaptive randomization strategy, participants will be assigned to wear either multifocal or single vision Duette hybrid contact lenses for a period of two years. Additionally, subjects wearing the MFCLs will wear distance center in one eye and near center in the other eye, switching every six months.|t|t|t|t
34002486|NCT04785911|||COHORT||CROSS_SECTIONAL|||||||
34002487|NCT04598607|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34002488|NCT01129323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002489|NCT05219435|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive maintenance therapy with 4 cycles of Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg every three weeks (Q3W)(induction phase) followed by Nivolumab 480 mg every 4 weeks (Q4W)(consolidation phase) until unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.||||
34002490|NCT03385954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002491|NCT00006124|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34002492|NCT06289140|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34002493|NCT01773239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002494|NCT00833625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089723|NCT03113097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089724|NCT00574314|||COHORT||OTHER|||||||
34089725|NCT05175625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33786171|NCT02004613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33786172|NCT05626543|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Cognitive behavior therapy (CBT) and Mindfulness-based stress reduction (MBSR) programs will be used together.||||
33786173|NCT03052088|||COHORT||PROSPECTIVE|||||||
33786174|NCT06326866|||CASE_ONLY||CROSS_SECTIONAL|||||||
33786175|NCT04582357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786176|NCT05451810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33923306|NCT03794713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923307|NCT02767180|||COHORT||OTHER|||||||
33923308|NCT02376595|||CASE_ONLY||PROSPECTIVE|||||||
33923309|NCT06027944|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33923310|NCT06332027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923311|NCT01206790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923312|NCT01788072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923313|NCT03185416|RANDOMIZED|PARALLEL||PREVENTION||NONE||The present study is a randomized single-center therapeutic clinical trial including the following two prospective groups: Control group and the intervention group.||||
33923314|NCT00873288|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33923315|NCT02016222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923316|NCT01412060|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|There was no masking in the Open-Label Phase. There was masking in the Double-Blind Phase||t|t|t|t
34002495|NCT03755180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34002496|NCT01682187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002497|NCT01632449|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34002498|NCT04678063|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, double blind, cross-over study including two study groups|t|t|t|f
34002499|NCT01500005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089726|NCT02440867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089727|NCT01741662|NA|SINGLE_GROUP||||NONE||||||
34089728|NCT01390675|||OTHER||PROSPECTIVE|||||||
34089729|NCT04386941|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective randomized clinical study|f|f|f|t
33923317|NCT05831345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33923318|NCT02452112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923319|NCT04011800|RANDOMIZED|PARALLEL||TREATMENT||NONE|prospective, randomized, open - label, non-inferiority study|Patient will be randomized into catheter ablation (CA) arm or AADs and risk factor modification (RFM) arm||||
33923320|NCT00787540|||CASE_CONTROL||PROSPECTIVE|||||||
33923321|NCT00209170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923322|NCT06380582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33923323|NCT04446871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002500|NCT00032916|RANDOMIZED|||TREATMENT||DOUBLE||||||
34002501|NCT02077621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089730|NCT00805688|||COHORT||PROSPECTIVE|||||||
34089731|NCT02475668|||COHORT||PROSPECTIVE|||||||
34089732|NCT00000442||PARALLEL||TREATMENT||||||||
34089733|NCT01558843|||COHORT||RETROSPECTIVE|||||||
34089734|NCT01052415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33698066|NCT05491538|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-group, open pilot trial in which participants will receive a group-based social-cognitive skills training program in addition to supported employment services.||||
33698067|NCT02910362|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33698068|NCT02281565|||COHORT||RETROSPECTIVE|||||||
33698069|NCT00826761|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33698070|NCT00611533|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33698071|NCT04253912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698072|NCT06239025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|syringes with the study drug will be prepared by a study nurse. the patient, investigators and all carers will be blinded|multimodal analgesia + ultrasound-guided Transversus Thoracis Muscle Plane Block with ropivacaine 0.5 % vs multimodal analgesia alone|t|t|t|t
33698073|NCT02850354|NA|SINGLE_GROUP||||NONE||||||
33698074|NCT02706054|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33698075|NCT01666548|||COHORT||RETROSPECTIVE|||||||
33698076|NCT01315912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698077|NCT03610451|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomized controlled trial||||
33698078|NCT01164683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698079|NCT00851344|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33698080|NCT00076206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698081|NCT01054326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33698082|NCT00272428|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33698083|NCT01368978|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786177|NCT00697892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786178|NCT01922570|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923324|NCT02219997|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33698084|NCT05369676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923325|NCT01462916|||CASE_CROSSOVER||PROSPECTIVE|||||||
33786179|NCT06147245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786180|NCT04866056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786181|NCT02693626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33801635|NCT00654589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801636|NCT00386958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923326|NCT01919151|||COHORT||PROSPECTIVE|||||||
33923327|NCT00886717|NON_RANDOMIZED|||TREATMENT||NONE||||||
33923328|NCT03229681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923329|NCT02066519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923330|NCT01867645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923331|NCT02030665|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33923332|NCT00315978|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33923333|NCT03803202|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33923334|NCT06311110|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923335|NCT03411577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors were unaware of group assignment of participants.|Mother-daughter dyads were randomly assigned to either HIV risk-reduction intervention group or control group|f|f|f|t
33923336|NCT02146833|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923337|NCT04693923|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a randomized controlled study in parallel groups.||||
33923338|NCT03573440|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33923339|NCT03872726|||COHORT||CROSS_SECTIONAL|||||||
33923340|NCT05682313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923341|NCT03431909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923342|NCT02297113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923343|NCT00719862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923344|NCT03522194|||COHORT||PROSPECTIVE|||||||
33923345|NCT03967509|RANDOMIZED|PARALLEL||TREATMENT||NONE||Preschools randomized to either behavioral teacher training or as waiting list control preschools.||||
33923346|NCT05855395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923347|NCT01787799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923348|NCT00357422|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923349|NCT03956329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Note: Blinding not possible for usual care group||t|t|t|t
33923350|NCT01309867|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33923351|NCT06366334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923352|NCT00188968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923353|NCT01946412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923354|NCT06295406|||COHORT||CROSS_SECTIONAL|||||||
33923355|NCT02670915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923356|NCT00655161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923357|NCT03449121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923358|NCT00605696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923359|NCT05301413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923360|NCT01861145|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923361|NCT00855387|||COHORT||RETROSPECTIVE|||||||
33923362|NCT02403713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923363|NCT03962712|||COHORT||PROSPECTIVE|||||||
33923364|NCT06220552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923365|NCT03332901|||COHORT||PROSPECTIVE|||||||
33923366|NCT01080144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923367|NCT01730287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923368|NCT02521909|||CASE_ONLY||PROSPECTIVE|||||||
33923369|NCT02540772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923370|NCT01187836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923371|NCT04286828|||CASE_CONTROL||PROSPECTIVE|||||||
33923372|NCT00229229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33923373|NCT05843071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923374|NCT06105203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923375|NCT05904691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open-label, two-part safety assessment||||
33923376|NCT05019495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698085|NCT05098704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||placebo-controlled trial|t|t|t|f
33698086|NCT05741307|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33698087|NCT06229639|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33923377|NCT02157246|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33923378|NCT03890393|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923379|NCT03711877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923380|NCT01312324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923381|NCT02765503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923382|NCT05944653|||OTHER||CROSS_SECTIONAL|||||||
33923383|NCT00376246|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34002502|NCT05200364|NA|SEQUENTIAL||TREATMENT||NONE||The study is designed as a 3+3 dose escalation/de-escalation of STRO-002 given in combination with the labeled dose of bevacizumab. The patient population is relapsed ovarian cancer and the study treatment is the combination of STRO-002 plus bevacizumab. This study will be conducted in 2 parts, dose escalation and dose expansion.||||
34002503|NCT03205501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002504|NCT03693950|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34002505|NCT01618513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002506|NCT04000191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002507|NCT05568758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002508|NCT02458391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002509|NCT06227754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, multicenter, open-label, randomized controlled trial to compare clinical outcomes between optical coherence tomography (OCT)-guided versus angiography-guided PCI in AMI patients undergoing PCI.|f|f|f|t
34089735|NCT05251870|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34089736|NCT04948918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089737|NCT01169051|||CASE_CONTROL||RETROSPECTIVE|||||||
34089738|NCT01339169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089739|NCT02635035|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34089740|NCT02508792|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34089741|NCT05068115|||COHORT||RETROSPECTIVE|||||||
34089742|NCT03925155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded to the arm in which they have been assigned. Providers will need to perform vaginal preparation and solutions look different.|One arm is standard of care 10% povidone-iodine preparation, comparing with trial of chlorhexidine 4% vaginal preparation|t|f|f|f
34089743|NCT02188134|||||CROSS_SECTIONAL|||||||
34089744|NCT04428489|||COHORT||PROSPECTIVE|||||||
34089745|NCT03756675|||COHORT||PROSPECTIVE|||||||
34089746|NCT01249196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089747|NCT05488431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089748|NCT00849394|||COHORT||PROSPECTIVE|||||||
34089749|NCT02607072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34089750|NCT02415985|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34089751|NCT05778539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089752|NCT00000204||||TREATMENT||||||||
34089753|NCT03382093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||If participant meets eligibility criteria, the participant will be randomly assigned to complete a computer-delivered intervention: either the (a) Personalized Feedback Intervention or (b) smoking information control.|t|f|f|f
34089754|NCT02337582|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34089755|NCT00782067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103141|NCT03939494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103142|NCT06538987|||COHORT||RETROSPECTIVE|||||||
33698088|NCT00745940|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698089|NCT04956926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698090|NCT03614507|RANDOMIZED|PARALLEL||TREATMENT||NONE|The technology used does not allow blinding.|This is a multicenter, prospective, controlled, randomized, open-label study. Patients will be randomized to either the FreeO2 group for automatic oxygen titration or the manual group for oxygen therapy using manual flow titration.||||
33698091|NCT02932683|RANDOMIZED|PARALLEL||||NONE||||||
33923384|NCT03649334|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33923385|NCT04616495|||COHORT||PROSPECTIVE|||||||
33923386|NCT04469803|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking|Randomized crossover study design||||
33923387|NCT03398733|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 200 patients with rheumatic valvular heart disease waiting for heart valve replacement were screened for obstructive sleep apnea (OSA). Of them, 30 OSA patients were enrolled and randomly received CPAP treatment and non-CPAP treatment (15:15 patients).The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.||||
33923388|NCT00734487|||CASE_CONTROL||PROSPECTIVE|||||||
33923389|NCT03027843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923390|NCT00707460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002510|NCT02985788|||OTHER||PROSPECTIVE|||||||
34002511|NCT02860325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002512|NCT00131482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698092|NCT04047576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698093|NCT05731323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698094|NCT01649388|NA|SINGLE_GROUP||TREATMENT||NONE||approximately 15 Donor/Recipient pairs||||
33698095|NCT04188470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002513|NCT05196815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002514|NCT02153723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698096|NCT01333579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33698097|NCT04412473|||CASE_ONLY||RETROSPECTIVE|||||||
34002515|NCT04042402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002516|NCT04313296|NA|SINGLE_GROUP||TREATMENT||NONE||This is a retrospective and prospective cohort study of patients with atrial fibrillation (AF) identified at Pen Bay Medical Center (PBMC). Patients will be identified for inclusion in the study based on a previous documented diagnosis of AF, have a documented echocardiogram, and have undergone electrical cardioversion, with a study enrollment goal of 150 patients.||||
34103143|NCT00069953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002517|NCT01020617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34002518|NCT04316325|||CASE_ONLY||PROSPECTIVE|||||||
34002519|NCT01770834|||COHORT||PROSPECTIVE|||||||
34002520|NCT06086353|||COHORT||PROSPECTIVE|||||||
34002521|NCT03485716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34002522|NCT01307943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002523|NCT00153257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002524|NCT06679712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002525|NCT00988468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002526|NCT01436643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002527|NCT03224767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002528|NCT04011449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002529|NCT06574191|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089756|NCT05998863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To provide adequate blinding, each medication sachet will be labelled with the study name, IRB number, principal investigator's name, expiration date and identification number of the study subject. Labels will be applied to the appropriate medication sachets once the subject has been randomized and assigned to a treatment group. Labelling of the sachets will be done by personnel who are not engaged in patient care.||t|t|t|t
34089757|NCT03139162|||COHORT||RETROSPECTIVE|||||||
34089758|NCT05179629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic cholesistectomy surgery will be included in the study. Patients will be randomly divided into two groups (Group M = M-TAPA group, Group C = Control group) including 30 patients each, before entering the operating room.|t|f|f|t
34089759|NCT01379053|||COHORT||PROSPECTIVE|||||||
34089760|NCT03231176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089761|NCT02525523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34089762|NCT03778632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089763|NCT01039441|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34089764|NCT02419872|||COHORT||PROSPECTIVE|||||||
34089765|NCT00514696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698098|NCT00529984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698099|NCT03821207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomised Controlled Study||||
33698100|NCT05103631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698101|NCT02598726|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33698102|NCT06680453|||CASE_CROSSOVER||PROSPECTIVE|||||||
34002530|NCT01160445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786182|NCT03618095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Evaluation of Lotus Edge to treat patients with aortic stenosis. A single intervention is being evaluated in 3 study arms, the roll-in, main and bicuspid cohorts.||||
33786183|NCT05343884|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002531|NCT01579006|||COHORT||PROSPECTIVE|||||||
34089766|NCT06392997|||COHORT||PROSPECTIVE|||||||
33786184|NCT00399347|||COHORT||RETROSPECTIVE|||||||
33786185|NCT04315454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34002532|NCT02795026|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is difficult to mask the participants or care provider due to the nature of the therapy. The outcome questionnaires are filled in individually by the participants only.|||||
34002533|NCT00556699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002534|NCT02891213|||||RETROSPECTIVE|||||||
34002535|NCT05233787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002536|NCT06016153|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34089767|NCT05053464|||COHORT||CROSS_SECTIONAL|||||||
34089768|NCT06360484|||CASE_ONLY||CROSS_SECTIONAL|||||||
34089769|NCT03523637|NA|SINGLE_GROUP||TREATMENT||NONE||Replicated experimental case series, also called replicated single-subject design or replicated single-case research design.||||
34089770|NCT04324320|||OTHER||CROSS_SECTIONAL|||||||
34089771|NCT03422185|||OTHER||CROSS_SECTIONAL|||||||
34089772|NCT06134388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089773|NCT04491487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34089774|NCT00577226|||||PROSPECTIVE|||||||
34089775|NCT06180928|||COHORT||PROSPECTIVE|||||||
34089776|NCT01055327|||CASE_CONTROL||RETROSPECTIVE|||||||
33786186|NCT06398223|||CASE_CONTROL||PROSPECTIVE|||||||
34002537|NCT02203578|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34002538|NCT03432273|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34002539|NCT03113357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089777|NCT01348269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089778|NCT03618277|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089779|NCT00544882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089780|NCT04163263|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34089781|NCT03320915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089782|NCT01286324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089783|NCT04954144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089784|NCT01561105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923391|NCT06397742|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will recruit patients who underwent surgical therapy for head and neck cancer, with one-sided removal of lymph nodes, and who present symptoms of accessory nerve dysfunction. The group will be recruited from patients who underwent the surgical treatment in Greater Poland Cancer Centre. Outline of the two interventions will be presented to each patient, after which the patient will choose the preferred intervention.~All patients from the study group were treated at the Head and Neck Surgery and Laryngological Oncology Clinic at the Poznań University of Medical Science.~The study group comprised 9 women and 16 men with an average of 51.1 y.o., and the control group comprised 6 women and 17 men with an average of 50,8y.o."||||
33698103|NCT03629210|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible participants will be randomized in a 1:1 manner to one of the following groups:~* Combination treatment (Group A): 50 participants will receive an intravitreal AFL (2.0 mg) injection and DEX implant (0.7 mg) injection within 0 to 8 days of each other.~* Monotherapy treatment (Group B): 50 participants will receive DEX implant (0.7 mg) injection."||||
33698104|NCT01924507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698105|NCT03523234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698106|NCT06681831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698107|NCT03368612|||COHORT||PROSPECTIVE|||||||
33698108|NCT01386008|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33698109|NCT04166500|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923392|NCT00649051|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33923393|NCT05389384|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The support of the exoskeleton is concealed. The support will be 'no support' or 'support'.|counterbalanced randomized cross-over study|t|f|f|f
33923394|NCT00350311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923395|NCT05652413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923396|NCT04205695|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized to the catheter tip configuration as CEMP (closed-ended multiport catheter) group and OESP (open-ended single port catheter) group||||
33923397|NCT06108245|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned with equal likelihood to receive the values clarification prototype mobile application, the self-reflection prototype mobile application, or no treatment. After 8 weeks, participants who are in the no treatment group will be able to access both applications, and participants in either app group will be able to access the other app.||||
33923398|NCT01896856|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Phase 2, Arm B patients who have disease progression will be given the option to receive Arm A study drugs.||||
33923399|NCT01184729|||CASE_ONLY||PROSPECTIVE|||||||
34089785|NCT03421587|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34089786|NCT03275922|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study|t|t|t|t
34089787|NCT02006862|||||PROSPECTIVE|||||||
34089788|NCT02381691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34089789|NCT00544271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34089790|NCT03206138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089791|NCT05084326|||COHORT||PROSPECTIVE|||||||
34103144|NCT02767973|NA|SINGLE_GROUP||SCREENING||NONE||||||
34103145|NCT06695026|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103146|NCT02438397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698110|NCT01021306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698111|NCT05933824|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33698112|NCT00331422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698113|NCT05413421|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Interval 3+3 dose escalation design||||
34002540|NCT04063670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All clinicians and care providers are blinded to participants randomized group|Prospective, Randomized Controlled Clinical Trial|f|t|f|f
33698114|NCT04864418|NA|SEQUENTIAL||TREATMENT||NONE||||||
34002541|NCT04337229|NA|SINGLE_GROUP||OTHER||NONE|Researchers and family of newborns will know about all the details of the study. Verbal and written permission will be obtained from families.|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.||||
34002542|NCT03993639|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, single center, open label, non-control, dose setting study||||
34002543|NCT05595616|||COHORT||PROSPECTIVE|||||||
33698115|NCT01898208|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33698116|NCT05342792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002544|NCT04754854|||COHORT||PROSPECTIVE|||||||
33698117|NCT06681116|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|neither the participants nor the investigators or the care givers and the outcome assessors knew the group of patients|Three groups that run parallel and receive the different allocated modalities and are followed up for three consecutive years|t|t|t|t
33786187|NCT05974943|RANDOMIZED|PARALLEL||OTHER||NONE||These studies aimed to enable the evaluation of nurse managers' problem-solving and decision-making abilities from the perspective of their subordinates. The study was carried out using a systematic and randomized controlled design, incorporating elements such as pre-test-post-test, experimental, and control groups.||||
33786188|NCT05165030|NA|SINGLE_GROUP||OTHER||NONE||Blood sample for all participant during a consultation specific for the study||||
33786189|NCT01394666|||COHORT||RETROSPECTIVE|||||||
34002545|NCT03578809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this study, the participant and sponsor staff will be blinded. Sites will be trained to keep the investigator blinded. However, due to the acute nature of the study, members of the research team and, possibly, the investigator may be unblinded.||t|t|f|t
34002546|NCT01702415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786190|NCT04164628|NA|SINGLE_GROUP||OTHER||NONE||||||
34002547|NCT03788876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002548|NCT02051660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786191|NCT06708429|||COHORT||PROSPECTIVE|||||||
33923400|NCT01081717|||COHORT||PROSPECTIVE|||||||
34002549|NCT00117182|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002550|NCT02937363|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34002551|NCT02123732|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34002552|NCT05798637|||CASE_CONTROL||PROSPECTIVE|||||||
34002553|NCT03674957|||COHORT||OTHER|||||||
34002554|NCT02382822|||COHORT||PROSPECTIVE|||||||
33923401|NCT06145464|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The target population will be single-blinded towards the professional activity of providers of health literacy sessions about the prevention of skin cancer in the two interventional groups.|Exploratory pilot study, with a quasi-experimental design|t|f|f|f
33923402|NCT03926494|||COHORT||RETROSPECTIVE|||||||
33923403|NCT04617041|||COHORT||PROSPECTIVE|||||||
33923404|NCT03855033|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923405|NCT04768530|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33923406|NCT04186715|||COHORT||PROSPECTIVE|||||||
33923407|NCT03374644|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33923408|NCT04223063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923409|NCT06027879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923410|NCT04368221|||COHORT||OTHER|||||||
33923411|NCT05172037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923412|NCT03610906|||COHORT||PROSPECTIVE|||||||
34002555|NCT03417206|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34002556|NCT00662896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002557|NCT02250651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34002558|NCT05349240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002559|NCT00033436|RANDOMIZED|||TREATMENT||||||||
34002560|NCT03597724|||OTHER||PROSPECTIVE|||||||
34002561|NCT04697316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002562|NCT04547036|||COHORT||PROSPECTIVE|||||||
34002563|NCT01652638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002564|NCT06058364|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding of both study team and participants will be ensured by only providing access to the randomization list to the science and quality team. The relationship between the randomization number and the group assignment will be unknown to the participants, clinical study team, and the Sponsor, i.e. the study will be double-blinded.|This is a double-blind randomized placebo controlled trial for a dietary supplement with two parallel groups - triglyceride supplement and placebo.|t|f|t|f
34002565|NCT02112773|||COHORT||CROSS_SECTIONAL|||||||
34002566|NCT02961205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002567|NCT05761743|||CASE_CONTROL||PROSPECTIVE|||||||
34002568|NCT01463709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002569|NCT01362192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698118|NCT06119035|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study will be carried out as a single-arm, unblinded, intervention study. The total duration of the study is 4 hours and 30 minutes over one day, excluding screening and enrolment time (up to 1 hour).||||
33698119|NCT05092854|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33698120|NCT00983671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33698121|NCT05626582|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Application of pain or no stimulus cannot be masked from participants, nor from outcomes assessors.|||||
33698122|NCT02643173|||COHORT||RETROSPECTIVE|||||||
33698123|NCT00952042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698124|NCT03470961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786192|NCT05632120|||CASE_ONLY||CROSS_SECTIONAL|||||||
33786193|NCT00841282|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33786194|NCT05000229|||OTHER||OTHER|||||||
33923413|NCT04777318|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Individuals between the ages of 40-65 diagnosed with cervical spondylosis will be included in the study. The sample size was determined as 66 subjects, 22 in each group, under the assumption that the one-way ANOVA test would be applied in the comparison between groups and the effect size would be f = 0.40, α = 0.05, β = 0.20.~Considering the possibility of using the nonparametric equivalent instead of the parametric ANOVA test in the analyzes that will start after the data collection phase, this initial sample size was increased by 15% and corrected to 76 people. Considering that there may be people who may leave the study, this sample size was increased by 25% and the final sample size was determined as 96 people."|||||
33923414|NCT02424812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002570|NCT01203917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698125|NCT03237078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002571|NCT03755739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002572|NCT03538795|NA|SINGLE_GROUP||TREATMENT||NONE||Case series, with a no-treatment control period before the intervention||||
34089792|NCT03931122|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|One of the investigators will record patients' weight and external ear measurements in the study proforma. Patient's medical record (MR) number will then be send to the Research assistant/ Statistician for randomization into one of the groups (Group A or Group B). On the day of surgery, research assistant will hand over patient's group allocation in a sealed opaque envelop to one of the investigators who will not be the primary anesthetist. This investigator will determine the LMA size according to the group allocation. In case the dimensions fall between the two sizes of LMA in the ear size group, the closest one will be selected. After writing LMA size in the proforma it will be handed over to the primary anesthetist who will be blinded to patient's group allocation. Primary anesthetist (who has an experience of minimum 50 LMA insertions) will use the LMA.|"All Laryngeal Mask Airways (LMA) devices being used in the study will be Ambu® AuraOnce™ (Ambu® A/S Baltorpbakken 13 DK-2750 Ballerup, Denmark) LMA's.~LMA Size Selection: will be done for each patient according to group allocation:~Group A - Weight based method Group B - Ear Size Based method~Randomization technique:~Patients will be randomized according to computer-generated blocked randomization (https://www.sealedenvelope.com) with blocks size of 6, by independent statistician (Anaesthesia research cell). Allocation concealment will be ensured by enclosing assignments in sealed, opaque, sequentially numbered envelopes which will be opened by one of the investigator only upon arrival of the patient in the operation room."|t|f|t|t
33698126|NCT06427473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33786195|NCT03451643|RANDOMIZED|PARALLEL||TREATMENT||NONE||RANDOMIZED CONTROLLED TRIAL||||
34089793|NCT03871413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089794|NCT00154388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089795|NCT03052036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089796|NCT04957511|||OTHER||PROSPECTIVE|||||||
34089797|NCT03201107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The assignment to the groups will be of simple random type and hidden. Those responsible for admitting patients to the intervention phase will not know what group has been assigned each. This assignment will be made in advance by a researcher who will not intervene in the later stages of evaluation, intervention, data recording and elaboration of database. The assignment will be communicated through sealed and totally opaque envelopes.~All measurements given above will be made both to the control group and to the experimental group just prior to the start of the intervention, and immediately after and six months after the end of this period, and the results will be recorded in a data record"|Randomized controlled trial|f|t|t|t
34089798|NCT05055596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089799|NCT00958074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089800|NCT04863534|||COHORT||PROSPECTIVE|||||||
34089801|NCT06215495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089802|NCT01338389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34089803|NCT03723954|||COHORT||PROSPECTIVE|||||||
33786196|NCT00029380||||TREATMENT||||||||
33923415|NCT05142449|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33923416|NCT04829266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33923417|NCT03289741|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Two-arm randomized design||||
33923418|NCT05979714|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"This study proposes using mixed methods to tailor and evaluate implementation and client outcomes when CAB-RPV LA is delivered through this integrated delivery model. Our approach will be guided by a rigorous implementation science approach using the Proctor Model to evaluate our implementation strategies.~The Proctor Model posits that improvements in outcomes are dependent on the evidence-based intervention selected for implementation and on the strategies used to deliver the intervention. The model distinguishes between the intervention (CAB-RPV LA), different types of implementation strategies, and different levels of outcomes that are expected to build on each other"||||
34002573|NCT02845791|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002574|NCT02780063|NA|SINGLE_GROUP||SCREENING||NONE||||||
34002575|NCT03879486|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Prospective controlled study||||
34002576|NCT04273438|||COHORT||PROSPECTIVE|||||||
34002577|NCT04070651|||COHORT||PROSPECTIVE|||||||
34002578|NCT04677686|||CASE_ONLY||PROSPECTIVE|||||||
34002579|NCT00460850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002580|NCT05065541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002581|NCT05296941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34002582|NCT03943134|||COHORT||OTHER|||||||
33698127|NCT00244283|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698128|NCT00468468|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33698129|NCT02423837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698130|NCT04190667|||COHORT||PROSPECTIVE|||||||
33698131|NCT02242188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33698132|NCT06681090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Out of all the researchers, only one had knowledge of the patients' assigned groups. Neither the therapies nor their efficacy was evaluated by this unblinded researcher. There was a lack of treatment blinding for patients.||f|f|t|t
33698133|NCT06200493|||CASE_ONLY||PROSPECTIVE|||||||
33786197|NCT02714829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089804|NCT04681300|||COHORT||CROSS_SECTIONAL|||||||
34089805|NCT05460884|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|physically incorporated in the intervention||t|f|t|t
34089806|NCT00008177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089807|NCT04386785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089808|NCT02760888|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34089809|NCT06346158|||COHORT||PROSPECTIVE|||||||
34089810|NCT05651178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698134|NCT00194909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089811|NCT00542308|NA|SINGLE_GROUP||OTHER||NONE||||||
34089812|NCT03738280|||COHORT||PROSPECTIVE|||||||
33698135|NCT05378373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be randomly assigned to one of two interventions, and will not be told which intervention they are assigned to.|Digital Behavioral Intervention|t|f|f|f
33698136|NCT03397173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698137|NCT00384254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698138|NCT02225197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698139|NCT06679972|||CASE_CONTROL||PROSPECTIVE|||||||
33698140|NCT04199182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Behavioral intervention testing the effects of supervised exercise versus attention-control on PTSD symptoms and function.|f|f|t|t
33698141|NCT03298373|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33698142|NCT06293469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698143|NCT05522231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698144|NCT00759382|||COHORT||PROSPECTIVE|||||||
34089813|NCT01542281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33698145|NCT01636531|RANDOMIZED|PARALLEL||||NONE||||||
34089814|NCT04183478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded|Tow arms were design in the study. Group 1: Best Support Care (BSC) Plus K-001. Group 2: BSC Plus Placebo. The participants were assign into two groups in a 2:1.|t|t|t|t
34089815|NCT05798312|RANDOMIZED|PARALLEL||OTHER||SINGLE|Paticipants will receive a support material with information about breast cancer. Those in the intervention group will not know of the existence of a non-customizable material and those in the standard group will not know of the existence of a customizable material.|The intervention group will receive customizable support material while the standard group will receive a non-customizable material.|t|f|f|f
34089816|NCT04118400|||CASE_CONTROL||PROSPECTIVE|||||||
34089817|NCT05679310|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089818|NCT03351270|NA|SINGLE_GROUP||OTHER||NONE||||||
34089819|NCT05808959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089820|NCT04120818|||CASE_CONTROL||PROSPECTIVE|||||||
33698146|NCT03428607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698147|NCT03610360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698148|NCT02503709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698149|NCT00973674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698150|NCT06556524|||COHORT||CROSS_SECTIONAL|||||||
34089821|NCT05651256|NA|SINGLE_GROUP||TREATMENT||NONE||clinical trial||||
33698151|NCT05895071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698152|NCT04452032|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33698153|NCT03783975|NA|SINGLE_GROUP||SCREENING||NONE||||||
33698154|NCT05584332|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33698155|NCT05392257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698156|NCT05688007|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33698157|NCT00571610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698158|NCT05096728|||COHORT||PROSPECTIVE|||||||
33698159|NCT05840731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34089822|NCT03258242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089823|NCT01626716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698160|NCT00176527||||TREATMENT||NONE||||||
33698161|NCT05414110|||OTHER||PROSPECTIVE|||||||
33786198|NCT02755584|||COHORT||CROSS_SECTIONAL|||||||
33786199|NCT00776711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786200|NCT05152524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786201|NCT01928511|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arm parallel study randomised 1:2:2||||
33786202|NCT03955419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34089824|NCT01027845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089825|NCT02338830|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089826|NCT05611762|||COHORT||PROSPECTIVE|||||||
34089827|NCT02625649|||COHORT||CROSS_SECTIONAL|||||||
34089828|NCT00589264|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089829|NCT02716740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34089830|NCT01925794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786203|NCT03666234|||COHORT||PROSPECTIVE|||||||
33786204|NCT05243992|||CASE_ONLY||PROSPECTIVE|||||||
33786205|NCT05966051|||COHORT||PROSPECTIVE|||||||
33698162|NCT01561729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698163|NCT03091933|NA|SINGLE_GROUP||TREATMENT||NONE||exploratory, open-label||||
33698164|NCT04296110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698165|NCT06295536|NA|SINGLE_GROUP||SCREENING||NONE||||||
33698166|NCT03672643|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, open label study.||||
33698167|NCT06680349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698168|NCT06303921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698169|NCT02376387|||COHORT||PROSPECTIVE|||||||
33698170|NCT05015530|||OTHER||PROSPECTIVE|||||||
33698171|NCT03318900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698172|NCT05933447|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33698173|NCT03021304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698174|NCT00251173|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33698175|NCT02528175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698176|NCT01114152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698177|NCT06131723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel-arm control trial|t|t|f|f
33801637|NCT06288334|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923419|NCT06251869|||CASE_CONTROL||PROSPECTIVE|||||||
34089831|NCT04433598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study was a single blinded parallel-randomized controlled trial, where the blinding assignment was after assignment of intervention. Participants, care providers and medical lab technicians (those assessing outcomes) at FDEMC were blinded after assignment to intervention.|This is a single-blinded parallel-randomized controlled trial (RCT) where type 2 diabetes mellitus (T2DM) participants were recruited in the study. The nutrition education intervention was consisted of four components: (1) the curriculum (twelve weekly sessions, 1 to 1.5 hrs. each); (2) follow-up sessions (bi-monthly, each lasting 1 to 1.5 hrs.); (3) Educational materials and (4) reminder calling before each session. The nutrition education intervention sessions will be presented in ten groups of ten participants (10 participants each day). The participants were backed up to bring a friend or a family member. The groups have been formed based on recruitment time; therefore, the nutrition education intervention sessions were staggered over the study period. This study has been presented the nutrition education intervention in the form of an easy and simple dietary plan management like plate method or consumption of vegetables before carbohydrates.|t|t|f|t
33923420|NCT01388868|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34089832|NCT00576758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089833|NCT01349387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089834|NCT04650620|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"20 patients will be administered Plenhyage® thin for the treatment of mild wrinkles;~20 patients will be administered Plenhyage® medium for the treatment of moderate wrinkles;~20 patients will be administered Plenhyage® strong for improving the skin tones and irregularities (atrophies) of the skin surface in neck, abdomen, thighs and buttocks"||||
34089835|NCT01290809|||CASE_CROSSOVER||PROSPECTIVE|||||||
34089836|NCT01334359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34089837|NCT01715285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34089838|NCT02780388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33923421|NCT03258632|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33698178|NCT03138304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group assignment will be masked at the analysis phase.||f|f|f|t
33698179|NCT02448810|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34089839|NCT04489368|||COHORT||OTHER|||||||
34089840|NCT02410330|||CASE_CONTROL||PROSPECTIVE|||||||
33923422|NCT01234896|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33923423|NCT04433156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923424|NCT03029858|||CASE_ONLY||OTHER|||||||
34089841|NCT03186664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089842|NCT05901974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089843|NCT03416179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study.|Randomized, double-blind, multi-center, placebo controlled study.|t|t|t|t
34089844|NCT06075732|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089845|NCT01687699|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34089846|NCT05614076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and Outcomes Assessor|1:1|t|f|f|t
34089847|NCT04092764|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants with Sensory Neuropathy||||
33698180|NCT04517500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Since the patients will know if they have the Pursed Lipped Breathing Application and Spire tags, the outcome assessor will be blinded to which arm received the Application and tags.|Half of the participants will be randomized to receive the home-based PR with the mindful breathing module which consists of the Pursed Lipped Breathing Application and the Spire Health Tags (intervention) and half will receive the home-based PR (control).|f|f|f|t
33698181|NCT00806715|||COHORT||PROSPECTIVE|||||||
33698182|NCT04294667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698183|NCT04972149|||COHORT||PROSPECTIVE|||||||
33698184|NCT03090841|||COHORT||PROSPECTIVE|||||||
33698185|NCT04747639|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The test products (verum and control) are similar in flavour, color, texture, appearance and identical in packaging to ensure the double-blind, controlled design of the study.|a double-blind randomised controlled cross-over trial|t|t|t|t
33698186|NCT06302543|NA|SINGLE_GROUP||TREATMENT||NONE||single armed interventional study||||
33786206|NCT04886596|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is an observer blind study.||t|t|t|t
33786207|NCT01895140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923425|NCT01924156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923426|NCT00934401|||COHORT||PROSPECTIVE|||||||
33923427|NCT01572818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33698187|NCT02858011|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33923428|NCT04846985|||OTHER||PROSPECTIVE|||||||
33698188|NCT01869881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698189|NCT03061383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It will be a triple blinded study so that the participant, the researcher and the data analysis will be blinded.|Participants will be tested in this study having at least 3 sensitive sound teeth. Participants will be divided into 3 groups, according to the type of desensitizing agents (D); D1 treatment using 8% arginine based toothpaste (Colgate Pro-relief), D2 treatment using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) and D3 control group using placebo (gel without any active ingredient).|t|t|f|t
33698190|NCT01484041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698191|NCT02004600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698192|NCT01466179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698193|NCT05088720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|a double-blind placebo-controlled randomized trial|a double-blind placebo-controlled randomized trial|t|t|t|t
33698194|NCT05662202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698195|NCT06381466|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33698196|NCT04156477|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All subjects are, in random order, tested on three separate occasions with intake of weight adjusted and taste matched drink of i) a ketone ester (HVMN Ketone, 38 Mason St, 3rd Floor, San Francisco, CA 94102, USA) and ii) an isocaloric and -volumetric glucose drink, or iii) an isovolumetric tap water drink. Taste matching for the latter two are done by adding of a bitterness additive (Bitrex, Integriertes Trademarketing GmbH Herderstraße 16, 23564 Lübeck, Germany) with additional adding Stevia (Bodylab Stevia Drops; Bodylab,Plastvænget 3D, 9650 Hadsund, Denmark) for the tap water drink. Subjects will subsequently drink 50 mL of zero-calorie drink (Gatorade (Gatorade Company, Inc., Chicago, IL, USA) in order to eliminate any remaining flavour of the intervention drinks.|This is a experimental, randomized, single-center cross-over study.|t|f|f|f
33923429|NCT03529370|||COHORT||PROSPECTIVE|||||||
33923430|NCT05459792|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be done by computer generated numbers and concealed by serially numbered, opague and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. This study will be performed by 2 anaesthetists; one anaesthetist who is experienced in performing the blocks will be allocated to perform either the median or radial or local infiltration according to a computer-generated sequence of random numbers and sealed envelope, and the other anesthetist who is experienced in performing ultrasound examinations and radial cannulation, will be blinded to the technique performed.||t|t|t|t
33923431|NCT06122987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923432|NCT00806078|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33923433|NCT04099849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33923434|NCT01181778|||COHORT||PROSPECTIVE|||||||
33923435|NCT05506917|NA|SINGLE_GROUP||TREATMENT||NONE||pre-post comparison study||||
33923436|NCT01051115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923437|NCT02570646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923438|NCT05275296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923439|NCT02255643|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33923440|NCT00904878|||OTHER||PROSPECTIVE|||||||
34002583|NCT00451490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
34002584|NCT05745636|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Experimental and placebo capsules (2 consumed per day for 4 weeks) will look identical. Both the investigators and the subjects will be blinded, with the code held by the sponsor until the study and data analysis have been completed.|Randomized, double-blinded, placebo-controlled, crossover design with 4-week supplementation periods and a 2-week washout period.|t|f|t|f
34002585|NCT06076941|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study was conducted as a randomized controlled experimental study to determine the effect of the education given to pregnant women on their oral and dental health behaviors and knowledge levels. With the power analysis, α = 0.05, β = 0.20, 1-β = 0.80, a total of 60 pregnant women, 30 in the experimental group and 30 in the control group were included (the power of the test was found as p = 0.8056).||||
34002586|NCT06679673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002587|NCT06449027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002588|NCT06036342|||CASE_ONLY||PROSPECTIVE|||||||
34002589|NCT01644422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002590|NCT01861990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002591|NCT04489017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34002592|NCT01561924|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002593|NCT05194202|RANDOMIZED|PARALLEL||OTHER||NONE||Adolescents will be enrolled in one of two arms: Emergency Department Healthcare Education Assessment and Response for Teen Relationships (ED-HEART) (intervention arm) or Enhanced Usual Care (control arm). Adolescents will complete study surveys at baseline (Baseline Survey; intervention and control arms), immediately post-intervention (Exit Survey, intervention arm), and 12 weeks after intervention delivery (Follow-up Survey, intervention and control arms).||||
34002594|NCT03995550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34002595|NCT02594527|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34002596|NCT06543446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34002597|NCT01298609|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34002598|NCT01992874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002599|NCT04924751|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|At the time of the procedure, the endoscopy nurse opened an envelope containing computer-generated randomization assignments for the study patients.||t|f|f|t
34002600|NCT00170703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34002601|NCT06678100|||COHORT||PROSPECTIVE|||||||
34002602|NCT01958060|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34089848|NCT03349463|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002603|NCT04221594|||CASE_ONLY||PROSPECTIVE|||||||
34002604|NCT04937738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002605|NCT04458168|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089849|NCT01909271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34089850|NCT02905708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089851|NCT03129646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089852|NCT01134042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089853|NCT00304629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923441|NCT03468049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor will be blinded from knowing the nature of treatment that participants will be recieving either in the intervention groups or control group|participant will be randomly allocated into 4 groups Topical Application of Allum Cepa Extract, Phonophoresis of Allium Cepa Etract, Raw Mashed Allium Cepa Application and Standard Physiotherapy group ) the first 3 groups will be recieving standard physiotherapy management of shoulder pain post stroke just like those in the standard physiotherapy group in addition to specific treatment assigned to each of the groups|f|f|f|t
33923442|NCT03543670|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923443|NCT05287607|||COHORT||PROSPECTIVE|||||||
33923444|NCT05658263|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33698197|NCT02976922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923445|NCT03472599|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will take home skin surface electrodes and a simple one-channel electrical stimulators appropriate for extended use set to the stimulus parameters found effective during an initial urodynamics test. Genital nerve stimulation will be applied either continuously or on-demand when individuals turn stimulation on when they feel the onset of bladder leaking.||||
33923446|NCT03304327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923447|NCT06014580|||COHORT||RETROSPECTIVE|||||||
33923448|NCT02447458|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33923449|NCT03264833|||COHORT||PROSPECTIVE|||||||
33923450|NCT01196299|||COHORT||PROSPECTIVE|||||||
33698198|NCT03521219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698199|NCT06246760|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698200|NCT03094988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698201|NCT02635763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698202|NCT06452589|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm safety and feasibility study.||||
33698203|NCT06392698|||COHORT||PROSPECTIVE|||||||
33698204|NCT06308419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698205|NCT06557018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698206|NCT00723398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698207|NCT06111521|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33698208|NCT05768802|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33698209|NCT05353179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698210|NCT03020030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698211|NCT03318666|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33698212|NCT02787265|||CASE_ONLY||PROSPECTIVE|||||||
33698213|NCT02373878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698214|NCT04812730|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33698215|NCT00646789|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698216|NCT03576300|||CASE_CONTROL||PROSPECTIVE|||||||
33923451|NCT01441791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33923452|NCT01948869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33923453|NCT04066946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a prospective, single centre, two-arm, single blinded randomized controlled study|f|f|t|t
33923454|NCT00106288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923455|NCT03460925||SEQUENTIAL||TREATMENT||NONE||||||
33923456|NCT00603213|||CASE_ONLY||PROSPECTIVE|||||||
33923457|NCT02562183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923458|NCT03059472|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33923459|NCT03920878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923460|NCT04105855|||COHORT||CROSS_SECTIONAL|||||||
33923461|NCT05603754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33923462|NCT00730626|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33923463|NCT02750579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923464|NCT01335698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923465|NCT01744457|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34089854|NCT00469794|||CASE_CONTROL||RETROSPECTIVE|||||||
34089855|NCT02081209|NA|SINGLE_GROUP||OTHER||NONE||||||
34103147|NCT06253676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes assessor masked to trial arm.|Individual-Randomized Controlled Trial|t|f|f|t
34103148|NCT06687356|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34103149|NCT03239054|RANDOMIZED|PARALLEL||PREVENTION||NONE||participants will be randomized in a 1:1 fashion into the study group or the control group.||||
34103150|NCT02674256|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34103151|NCT04619849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698217|NCT02538328|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33698218|NCT02298023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698219|NCT05088395|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Interventional study (blood collections and possibly tumor sample collection depending on cohort type) on single group cohorts (each cohort is defined in the arms below).~Detection study of blood tumor biomarkers and correlation with clinicopathological characteristics."||||
33698220|NCT06680050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786208|NCT00823979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786209|NCT04984876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698221|NCT05542199|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Masking occurs after randomization. Participants and investigators and outcome assessors are masked to the assignment to the nutritional supplement vs placebo. Investigators responsible for the weight loss intervention, and outcome assessors, are masked to the assignment to the behavioral weight loss intervention versus the wait-list control.|A 2x2 factorial design in which participants are assigned to the multicomponent nutrition supplement or a placebo, and to participation in a behavioral weight loss intervention or to a wait-list control|t|f|t|t
34002606|NCT06624371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"In Stratum 1, six subjects will be enrolled for a Phase I safety evaluation of atovaquone with radiotherapy (RT). Patients will take atovaquone orally once daily for at least 7 days and up to 21 days before starting RT, continuing through RT without interruption. The study will use a Rolling-6 design with no dose escalation. If no more than one dose-limiting toxicity (DLT) or drug discontinuation for over two weeks due to intolerance occurs in the first six subjects, six additional patients will be enrolled to confirm the safety of the combination. If two or more DLTs or unique drug discontinuations are observed among these twelve patients, the regimen will be deemed too toxic.~In Stratum 2, six subjects will receive atovaquone daily for six months. Given prior safety in pediatric patients, DLTs are not expected. However, if two or more DLTs or prolonged discontinuations occur, the regimen will also be considered too toxic"||||
34002607|NCT02912767|||COHORT||RETROSPECTIVE|||||||
34002608|NCT02754492|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34002609|NCT01264198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002610|NCT05752552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34089856|NCT03076879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blindness in the study will be done by data collectors and statisticians. The data will be collected by the assistant investigator who does not know who is in the experiment and control group and the data will be recorded on the computer by the assistant investigator without specifying the experiment and control group. The experimental and control groups will be codified by the co-investigator. The analysis of the data encoded by the groups will be done by a statistical expert. Data collectors, statistical analyzes and report writing will be blinded.||f|f|f|t
34089857|NCT04012645|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33698222|NCT06064266|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||8-days preconditioning mild ketogenic controlled diet followed by a high fat shake challenge with a naso-intestinal catheter.||||
34089858|NCT02419950|||COHORT|||||||||
34089859|NCT06439680|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||double-blind randomised controlled pretest-posttest experimental research||||
34089860|NCT04156529|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34089861|NCT03844074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089862|NCT01995383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34089863|NCT04148404|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|sealed opaque envelopes prepared by an assistant blinded about the study targets and chosen by patient him/herself, allocated into two groups|Hypothermia may alter coagulation profile of patients undergoing CABG surgery; thus, affecting patients' outcome.|t|t|f|f
34089864|NCT01048424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089865|NCT01913184|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34089866|NCT01040819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089867|NCT02334189|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34089868|NCT01477983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698223|NCT02735408|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33698224|NCT05842733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698225|NCT04185376|||COHORT||OTHER|||||||
33698226|NCT06557135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002611|NCT05548920|||OTHER||PROSPECTIVE|||||||
34089869|NCT00647816|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34089870|NCT05257967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089871|NCT05755451|||COHORT||PROSPECTIVE|||||||
34089872|NCT05062473|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34089873|NCT05992727|||CASE_CONTROL||PROSPECTIVE|||||||
34089874|NCT00087802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089875|NCT00714818|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34089876|NCT05938738|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089877|NCT00865605|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34089878|NCT06407635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089879|NCT05648734|||COHORT||RETROSPECTIVE|||||||
34089880|NCT02661724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089881|NCT02094040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34089882|NCT03122106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089883|NCT02236377|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089884|NCT00769769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089885|NCT02852759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786210|NCT02616367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002612|NCT03129776|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Up to ten participants with newly diagnosed FIGO stage IB-IVA cervical cancer that are to receive definitive radiation with or without concurrent cisplatin, are to be recruited for this prospective single institutional study. Participants will receive a hyperpolarized carbon 13 MR spectroscopy and PET scan in addition to the standard imaging that is required for staging. A tumour biopsy will be obtained at the time of the initial clinic visit.||||
34002613|NCT03694938|NA|SINGLE_GROUP||SCREENING||NONE||||||
33801638|NCT00526006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801639|NCT01261312|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33923466|NCT05688072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923467|NCT05626244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This randomized controlled trial will have two arms, namely the intervention group and the waitlist control group.|t|t|f|t
33923468|NCT05592418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002614|NCT04491734|NA|SINGLE_GROUP||OTHER||NONE||||||
34002615|NCT01845753|||COHORT||PROSPECTIVE|||||||
34002616|NCT00708682|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34002617|NCT06641466|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34002618|NCT00001239||||TREATMENT||||||||
34002619|NCT01712451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002620|NCT01006954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002621|NCT00206245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089886|NCT02742688|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34089887|NCT04148456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089888|NCT00956189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089889|NCT01503424|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089890|NCT06287788|||COHORT||PROSPECTIVE|||||||
34089891|NCT03406676|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34089892|NCT06167057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicenter, double arm, single blinded randomized trial|t|f|f|f
34089893|NCT05428618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34089894|NCT02657863|||COHORT||PROSPECTIVE|||||||
34089895|NCT00850980|||OTHER||PROSPECTIVE|||||||
34089896|NCT01759927|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089897|NCT02212067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089898|NCT06397638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089899|NCT04150887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089900|NCT00234741|RANDOMIZED|PARALLEL||||DOUBLE||||||
33923469|NCT01039636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923470|NCT00418210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923471|NCT00074802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators were unaware of randomized condition in the augmentation phase (Phase 2).|Open trial of paroxetine (Phase 1) followed by randomization to either continued paroxetine or continued paroxetine plus cognitive behavioral therapy (Phase 2) for patients showing partial response to paroxetine in Phase 1.|f|f|f|t
33923472|NCT06230835|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34002622|NCT04884594|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34002623|NCT03864185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002624|NCT06269861|NON_RANDOMIZED|SEQUENTIAL||SCREENING||DOUBLE|"To avoid self-calibration, all measurements will be recorded by a different doctor other than the primary care physician.~The all calculations will be performed by a different doctor other than the primary care physician."||f|t|f|t
34002625|NCT00564096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34002626|NCT00196820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002627|NCT06461442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002628|NCT04667390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089901|NCT03134768|||COHORT||CROSS_SECTIONAL|||||||
34089902|NCT04621084|||COHORT||CROSS_SECTIONAL|||||||
34089903|NCT02583269|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34089904|NCT02096913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089905|NCT04841291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data collectors will not be informed about participants' group allocation.|Access to virtual simulation-based diabetes foot care education for once for 30 minutes.|f|f|f|t
34103152|NCT03242070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A two-arm parallel-group RCT||||
34103153|NCT04693715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103154|NCT02855385|||COHORT||CROSS_SECTIONAL|||||||
34103155|NCT03391791|||CASE_ONLY||PROSPECTIVE|||||||
34103156|NCT04386239|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric, escalation dose||||
33801640|NCT01556724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923473|NCT04318379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33923474|NCT06089070|RANDOMIZED|PARALLEL||TREATMENT||NONE|N/A both study team and participants will know the randomization assignment as to which group they are in.|Feasibility study of the FreeStyle Libre Continuous Glucose Monitoring System in Youth with Type 2 Diabetes||||
33923475|NCT00877006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923476|NCT01353755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923477|NCT02514772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923478|NCT04404803|||COHORT||PROSPECTIVE|||||||
34002629|NCT04733508|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34002630|NCT06176560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698227|NCT06074861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||There will be a Test group and a Control group|f|t|t|t
34002631|NCT03281096|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34002632|NCT03434145|||CASE_ONLY||PROSPECTIVE|||||||
33698228|NCT03038451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698229|NCT02518204|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698230|NCT06681324|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Participants will be randomized 2:1 to receive either AZD7798 or placebo during 12-week participant- and Investigator- blind induction period. At week 12 after induction period, all eligible participants will enter 40-week open label maintenance period.|t|t|t|f
33698231|NCT03866460|||COHORT||PROSPECTIVE|||||||
33698232|NCT05720507|NA|SINGLE_GROUP||PREVENTION||NONE||Single cohort double baseline design||||
33698233|NCT06632691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33698234|NCT05180097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698235|NCT04955132|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33698236|NCT02913612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698237|NCT03009500|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33698238|NCT06681714|||CASE_CONTROL||PROSPECTIVE|||||||
33698239|NCT00017017||||TREATMENT||||||||
33698240|NCT06680180|||COHORT||PROSPECTIVE|||||||
33698241|NCT06119399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698242|NCT01461083|NA|SINGLE_GROUP||||NONE||||||
33801641|NCT06241716|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33801642|NCT01076660|||COHORT||PROSPECTIVE|||||||
33801643|NCT04292834|||COHORT||PROSPECTIVE|||||||
33923479|NCT00177190|||||PROSPECTIVE|||||||
33923480|NCT04990375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sham tDCS protocol: 0 mA but 30s of 2 mA at the start and the end of the session|active tDCS vs. sham tDCS, while the patient is watching a documentary|t|f|f|f
33923481|NCT04655053|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||"Self-regulation condition (between-factor): Goal intention condition (IC), implementation intention condition focused on behavior initiation (IIC-Behavior), implementation intention condition focused on goal preference management (IIC-Motivational).~Pain catastrophizing (within factor): Low (equal or less 31 score on this variable) and high (more than 31 score in this variable)"|t|f|t|t
33923482|NCT03652272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2-arm, multi-site, physician-randomized pragmatic trial to evaluate the impact and scalability of the Phase I EMC2 strategy to promote safe medication use and adherence.||||
33923483|NCT03288740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33923484|NCT02266732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923485|NCT01263314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33923486|NCT01398527|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33923487|NCT01560611|||CASE_ONLY||PROSPECTIVE|||||||
33923488|NCT01179347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923489|NCT06424392|||COHORT||PROSPECTIVE|||||||
33923490|NCT02468206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923491|NCT05631262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923492|NCT04154943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923493|NCT00001777||||TREATMENT||||||||
33923494|NCT04141215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician will also perform trial analyses with treatment masking|"Randomized non-inferiority, two-arm, parallel, single-blind and monocentric clinical trial:~1. BIOBank bone paste (PPT322), derived from human living donor femoral heads~2. BIOBank cortico-cancellous bone powder (PPT6), derived from human living donor femoral heads, used in current practice as reference treatment"|t|f|f|t
33923495|NCT03129633|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33923496|NCT02776501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923497|NCT04211844|||COHORT||PROSPECTIVE|||||||
33923498|NCT03674658|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A: Rhynorm (A drug) Group B: Rytmonorm (B drug)||||
33923499|NCT03106012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002633|NCT05491850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002634|NCT06361550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002635|NCT01094262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002636|NCT06641154|NA|SEQUENTIAL||TREATMENT||NONE||||||
34002637|NCT01652963|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34002638|NCT05332691|NA|SINGLE_GROUP||TREATMENT||NONE||Beating-heart myectomy device||||
34002639|NCT02117505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34002640|NCT03945058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002641|NCT04580186|||OTHER||PROSPECTIVE|||||||
34002642|NCT04918992|||COHORT||PROSPECTIVE|||||||
34002643|NCT02176616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34002644|NCT02566096|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34002645|NCT03942211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002646|NCT03200535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Individuals with a body mass index between 25 and 30 are randomized 1:1 to the Usual Care or EHR Gap arms. Individuals with a body mass index \>=30 are randomized to all 4 arms, with n=1000 for the Personalized Outreach arm and 1:1:1 for the other three arms.||||
34002647|NCT06336967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33698243|NCT00326066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698244|NCT05893498|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33698245|NCT02672228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698246|NCT01225627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698247|NCT04005625|||CASE_ONLY||RETROSPECTIVE|||||||
33698248|NCT00896935|||OTHER||OTHER|||||||
33698249|NCT01031602|||CASE_ONLY||PROSPECTIVE|||||||
33801644|NCT00077493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002648|NCT00008398|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34002649|NCT03704974|||COHORT||RETROSPECTIVE|||||||
34002650|NCT05675995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, waitlist controlled design|f|f|f|t
34002651|NCT03526562|NA|SINGLE_GROUP||TREATMENT||NONE||phase I study with an exercise prescription as intervention||||
34002652|NCT03405064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002653|NCT00635336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002654|NCT01337596|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34002655|NCT06094192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34002656|NCT01618487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002657|NCT06586411|||COHORT||PROSPECTIVE|||||||
34002658|NCT01964872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002659|NCT06581601|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||Pre- and post-menopause group perform author's exercise program.||||
34002660|NCT02884258|||CASE_CONTROL||OTHER|||||||
34089906|NCT03595098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the interventions, it is not possible to blind the participants, the investigators administrating the interventions (therapists, i.e. medical doctors and clinical psychologists, and other caregivers), or parents. Blinding will be applied in all possible aspects of the trial such as: outcome assessment and MRI-scanning and neuropsychological testing. Additionally data managers, statisticians, and investigators drawing conclusions, will be fully blinded.|single-centre, parallel group superiority randomised clinical trial with blinded outcome assessment|f|f|f|t
33923500|NCT01235728|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34089907|NCT05389267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089908|NCT01431976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089909|NCT02543411|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089910|NCT04706338|NA|SINGLE_GROUP||TREATMENT||NONE||patients with postoperative motor deficits, especially for patients with SMA syndrome.||||
34089911|NCT02960451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34089912|NCT05497128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34089913|NCT00471965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089914|NCT06544590|||CASE_CONTROL||RETROSPECTIVE|||||||
34089915|NCT05046704|||COHORT||PROSPECTIVE|||||||
34089916|NCT00146068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089917|NCT05262179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089918|NCT00804271|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34089919|NCT06233656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33923501|NCT02170038|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33923502|NCT02030444|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923503|NCT03644108|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923504|NCT01646801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923505|NCT01827319|||COHORT||PROSPECTIVE|||||||
33923506|NCT04295356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923507|NCT05444985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The anesthetist who will perform the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another anesthetist blinded to the study.|One interventional group and one control group.|t|t|f|t
33923508|NCT02527486|||COHORT||PROSPECTIVE|||||||
33923509|NCT05480839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923510|NCT01998880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923511|NCT01332604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002661|NCT03941080|||COHORT||PROSPECTIVE|||||||
34002662|NCT01259830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002663|NCT03117205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002664|NCT00411333|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089920|NCT00932711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089921|NCT03185078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089922|NCT03626896|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34089923|NCT04144829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923512|NCT01287546|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923513|NCT00454272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002665|NCT05135377|||COHORT||PROSPECTIVE|||||||
34002666|NCT06588673|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34089924|NCT06475976|||COHORT||PROSPECTIVE|||||||
34089925|NCT01769586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089926|NCT03445429|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34089927|NCT00033644||||TREATMENT||||||||
34089928|NCT06361290|||COHORT||RETROSPECTIVE|||||||
34089929|NCT06238726|RANDOMIZED|PARALLEL||PREVENTION||NONE|Although patients will not be explicitly informed of which arm they were randomized to, they will be aware of the messages they receive.|||||
34089930|NCT05250869|||COHORT||RETROSPECTIVE|||||||
34089931|NCT03127059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Three assessors (physiotherapists) will perform the objective assessment of capacity and lung parameters. Nurses in the outpatient departments will obtain data from medical records. The assessors and the nurses will be blinded for the allocation.~The primary invenstigator will have no access to the data during the period of datacollection.~Primary and most of the secondary outcomes will be patient-reported."|Multi-centre, assessor-blinded, 2-arm randomised controlled trial.|f|f|t|t
34089932|NCT02263313|||COHORT||RETROSPECTIVE|||||||
33923514|NCT01877785|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33923515|NCT00833677|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923516|NCT03594864|||CASE_ONLY||RETROSPECTIVE|||||||
33923517|NCT03332303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923518|NCT06257329|||COHORT||PROSPECTIVE|||||||
33923519|NCT02938221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923520|NCT01453998|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923521|NCT04864678|||COHORT||RETROSPECTIVE|||||||
33923522|NCT02641314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089933|NCT03453736|||OTHER||PROSPECTIVE|||||||
34089934|NCT03786393|||COHORT||CROSS_SECTIONAL|||||||
33698250|NCT06450080|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698251|NCT04619836|||CASE_CONTROL||PROSPECTIVE|||||||
33698252|NCT02646462|||COHORT||PROSPECTIVE|||||||
33698253|NCT01055522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698254|NCT05735197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"100 patients with non-diabetic CKD with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2 will be randomized into two groups:~* Study group: includes 50 patients, they will receive SGLT2i as add on drug, Dapagliflozin 10 mg will be used once daily with or without food.~* Control group: includes 50 patients, they will receive placebo plus their medication."|t|f|f|f
33698255|NCT01878409|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923523|NCT05615103|||COHORT||PROSPECTIVE|||||||
33698256|NCT01588639|||COHORT||PROSPECTIVE|||||||
33698257|NCT06680037|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786211|NCT04222660|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study will be done in two phases. In the second phase the investigators will investigate whether increased intake of fish oil improves diabetic peripheral neuropathy including improvement in corneal nerve morphology and sensitivity. Subjects will receive 4g (2g twice a day) of fish oil per day in capsule form. The second phase of the study will be done in 2 of the 3 groups. The two groups for this phase of the study will be the control subjects and the diabetic subjects with neuropathy.||||
33786212|NCT00090272|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33786213|NCT06421831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786214|NCT01885364|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33786215|NCT06083233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786216|NCT06629493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786217|NCT00583843|||CASE_ONLY||PROSPECTIVE|||||||
33786218|NCT06156813|||OTHER||PROSPECTIVE|||||||
33786219|NCT06244108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups. Intervention and control groups.|f|f|t|f
33786220|NCT00515840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786221|NCT03639441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923524|NCT04155658|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33923525|NCT02884518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923526|NCT06157372|||COHORT||PROSPECTIVE|||||||
33923527|NCT04681729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923528|NCT06106243|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33698258|NCT04234997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698259|NCT05169268|||COHORT||PROSPECTIVE|||||||
33923529|NCT00753688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923530|NCT01519401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923531|NCT00444470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002667|NCT01953146|||COHORT||RETROSPECTIVE|||||||
34089935|NCT04840719|||CASE_ONLY||PROSPECTIVE|||||||
33786222|NCT02836665|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33786223|NCT06337110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786224|NCT01240356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786225|NCT03116750|||COHORT||PROSPECTIVE|||||||
33786226|NCT01484106|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33786227|NCT05009446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786228|NCT00316784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786229|NCT04264442|NA|SINGLE_GROUP||TREATMENT||NONE||This study is part two of NCT04003974 which was a randomized, double-blind placebo-controlled treatment period for 48 weeks. This study is an open-label extension with losmapimod in patients with FSHD1.||||
33786230|NCT02728271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786231|NCT00476203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786232|NCT06095310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786233|NCT03398616|||COHORT||PROSPECTIVE|||||||
33786234|NCT05380531|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional study with mother undergoing elective c-section and the infant||||
33786235|NCT02242942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002668|NCT02742701|||COHORT||PROSPECTIVE|||||||
34002669|NCT02926170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002670|NCT01599689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002671|NCT04604210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be blinded to which target is expected to improve which symptom.~Study investigators (with the exception of the treatment administrator), including the outcomes assessor, will be blinded to which participant is receiving which treatment."|Parallel-group double-blind randomized, controlled trial|t|f|t|t
34002672|NCT06218511|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34002673|NCT02828566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002674|NCT01189682|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002675|NCT00448227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698260|NCT05183763|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Data Manager will calculate the primary outcome measure from pharmacy refill data prior to merging with any data file indicating group assignment. Laboratory technicians who perform the liquid chromatography tandem mass spectrometry analysis of urine metabolites of antihypertensive medications will also be blinded to group assignment. Finally, participants' primary care providers will be notified of their patients' enrollment into the study but will not be given information about group assignment.||f|t|f|t
33698261|NCT01512342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33698262|NCT00005878|RANDOMIZED|||PREVENTION||DOUBLE||||||
34002676|NCT05298254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Data will be collected in an observer-blind manner.||t|t|t|t
34002677|NCT03846063|NA|SINGLE_GROUP||OTHER||NONE||A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.||||
34002678|NCT06563583|||CASE_CONTROL||PROSPECTIVE|||||||
34002679|NCT05862987|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Visually indistinguishable packages of hydrogen rich water and placebo.||t|f|t|f
34002680|NCT03434691|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34002681|NCT06503003|||COHORT||PROSPECTIVE|||||||
34002682|NCT06389838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants know which group they are assigned to, but the investigators are blinded.|Prospective, randomized, controlled, single-blinded, 2-arm design|f|f|t|f
34002683|NCT02480608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002684|NCT04427033|||OTHER||OTHER|||||||
33698263|NCT03951714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33801645|NCT03826875|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||double-blinded placebo-controlled randomized trial|t|t|t|f
34002685|NCT02937506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34002686|NCT00681473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002687|NCT04212819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002688|NCT06512519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002689|NCT04610580|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 2-period, 2-sequence, crossover study with a parallel group extension.||||
34002690|NCT03546049|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, non-randomized multicenter study (each center performs the intervention which can do best)|f|f|t|t
34002691|NCT05857917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002692|NCT01309854|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34002693|NCT05063539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Based on a common closed study design. Participants final endpoint time will be between 76-124 weeks.|t|f|t|f
34002694|NCT05619796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique.~A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain."|A randomized, controlled prospective clinical study|t|f|f|t
34002695|NCT04628481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will proceed under double-blind condition up to month 18 visit of the last patient randomized. Thereafter, the blind will be broken and remaining follow-up will proceed in an open fashion. This approach will allow to anticipate access to efficacy data without significantly affecting data integrity.|Patients will be randomly (2:1) assigned to receive either ladarixin treatment (400 mg b.i.d. for 13 cycles of 14 days on/14 days off - treatment group) or matched placebo (control group). The two groups will be balanced within centers.|t|t|t|t
34002696|NCT03038763|||COHORT||PROSPECTIVE|||||||
34002697|NCT04514133|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002698|NCT00669435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002699|NCT05989945|||COHORT||PROSPECTIVE|||||||
34089936|NCT06437171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698264|NCT06400875|||COHORT||PROSPECTIVE|||||||
33698265|NCT04526938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698266|NCT05504395|NA|SINGLE_GROUP||OTHER||NONE||||||
33698267|NCT00749060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002700|NCT06679335|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Both healthy and neck patient groups will receive the training for 4 weeks.|t|f|f|f
34002701|NCT01376037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34002702|NCT04286295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002703|NCT01385423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002704|NCT01026857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002705|NCT04740424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002706|NCT02079233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002707|NCT06109805|||COHORT||RETROSPECTIVE|||||||
34002708|NCT03147833|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34002709|NCT00379158|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002710|NCT06458751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002711|NCT03433703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002712|NCT03231345|NA|SINGLE_GROUP||OTHER||NONE||This study utilizes a convenience sample of patient who have difficult venous access with at least 2 attempts by nursing to achieve venous access. The patient will be consented and a physician placed ultrasound-guided peripheral IV will be placed in the internal jugular vein.||||
34002713|NCT04070079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002714|NCT03845491|||COHORT||PROSPECTIVE|||||||
33698268|NCT06136195|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33698269|NCT05556798|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ib study with trial treatment is a combination of belantamab mafodotin (GSK2857916) and nirogacestat. A standard 3+3 dose escalation design with three planned doses of belantamab mafodotin will be implemented. There will be a 1:1 randomization between nirogacestat 100 mg BID or 100 mg QD during the 4 day run-in period prior to starting belantamab mafodotin on Cycle 1 Day 1 (days -4 to -1).||||
34002715|NCT00409461|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34089937|NCT00724945|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34089938|NCT00908700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698270|NCT03606044|||COHORT||PROSPECTIVE|||||||
33698271|NCT00130676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34089939|NCT02842866|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089940|NCT00917696|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34089941|NCT02052635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089942|NCT02833909|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34089943|NCT02273947|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34002716|NCT03275857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002717|NCT00597428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089944|NCT00083278|NON_RANDOMIZED|||TREATMENT||NONE||||||
34089945|NCT01307163|||COHORT|||||||||
34089946|NCT06444698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089947|NCT04897243|||COHORT||PROSPECTIVE|||||||
34089948|NCT02682121|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34002718|NCT03312894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089949|NCT05445960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34089950|NCT00594139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089951|NCT04510168|||COHORT||PROSPECTIVE|||||||
34089952|NCT05321784|NA|SINGLE_GROUP||SCREENING||NONE||||||
34089953|NCT05707208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind. Participant will not know what study arm they have been randomized to.||t|f|f|f
34089954|NCT01307072|||CASE_CONTROL||RETROSPECTIVE|||||||
34089955|NCT01440920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089956|NCT04455932|NA|SINGLE_GROUP||SCREENING||NONE||||||
34089957|NCT02587416|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34089958|NCT04607031|||COHORT||PROSPECTIVE|||||||
34089959|NCT03570593|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698272|NCT04143087|||CASE_CONTROL||PROSPECTIVE|||||||
33698273|NCT03388385|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698274|NCT01498328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698275|NCT03993470|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blind||f|f|t|f
33801646|NCT03544515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind randomized clinical trial|t|f|t|t
34002719|NCT00587249|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002720|NCT01386034|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34002721|NCT04850287|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34002722|NCT02413424|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34002723|NCT06677710|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple ascending dose and dose-expansion study of IDP-023 in combination with interleukin-2 (IL-2) and ocrelizumab.||||
34002724|NCT01132417|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34002725|NCT00693589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002726|NCT04646694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The KAPA trial will be a single center, blinded (participant, caregiver, investigator, outcome assessor), parallel arm, randomized controlled feasibility trial of patients undergoing spine surgery.|This study will be a two arm, randomized controlled trial with a target enrollment of forty patients. Randomization will be performed with a 1:1 allocation with Ketamine or Placebo.|t|t|t|t
34089960|NCT03036943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34089961|NCT01537588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34089962|NCT00251472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089963|NCT06452550|||OTHER||PROSPECTIVE|||||||
33698276|NCT00294801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698277|NCT03899272|||COHORT||PROSPECTIVE|||||||
33698278|NCT05050773|||COHORT||PROSPECTIVE|||||||
33698279|NCT01180647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698280|NCT06558539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698281|NCT06157918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3-period Crossover Assignment||||
33801647|NCT00479700|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34002727|NCT05124496|||CASE_ONLY||CROSS_SECTIONAL|||||||
34002728|NCT03311945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089964|NCT06043297|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34089965|NCT01147445|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34089966|NCT05311865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Open-label, multicenter, randomized controlled intervention study with 1200 participants distributed 2: 1 in two groups of volunteers.||||
34089967|NCT02978807|||COHORT||PROSPECTIVE|||||||
34089968|NCT00502879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34089969|NCT06370819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089970|NCT06293820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The sponsor, investigators, and study staff will be masked throughout the study. The study site will have the capacity to unmask in case of emergency.~Following completion of the study, the randomization code will be unmasked once all data has been entered into the study database for every subject, and the database has been locked."||t|t|t|t
34089971|NCT05491577|||COHORT||PROSPECTIVE|||||||
34089972|NCT03424642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34089973|NCT02860078|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34089974|NCT00592293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089975|NCT06064240|||CASE_CROSSOVER||PROSPECTIVE|||||||
34089976|NCT00974870|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34089977|NCT04718701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002729|NCT02292550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a multi-center, open-label, dose finding, Phase Ib dose escalation study to estimate the maximum tolerated doses (MTD(s))||||
33698282|NCT05111704|RANDOMIZED|PARALLEL||TREATMENT||NONE||26 subjects experiencing pain in neck, back or shoulders were randomized into either an intervention group (n=12) or control group (n=14).||||
34089978|NCT02199587|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33698283|NCT05977712|||COHORT||PROSPECTIVE|||||||
33698284|NCT06680063|||OTHER||CROSS_SECTIONAL|||||||
33786236|NCT05615220|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.|This is a multicenter study which includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.|t|t|t|f
33786237|NCT06712563|||COHORT||RETROSPECTIVE|||||||
33786238|NCT06711315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786239|NCT04675255|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33786240|NCT03392662|||COHORT||PROSPECTIVE|||||||
33786241|NCT02054247|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33786242|NCT04109118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786243|NCT06453356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786244|NCT05074498|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33786245|NCT01113112|||CASE_ONLY||PROSPECTIVE|||||||
34002730|NCT00463281|||COHORT||PROSPECTIVE|||||||
33698285|NCT02416219|||CASE_ONLY||PROSPECTIVE|||||||
33698286|NCT00235469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698287|NCT06248736|||COHORT||PROSPECTIVE|||||||
33698288|NCT05073640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33698289|NCT00815399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698290|NCT05272462|NA|SINGLE_GROUP||TREATMENT||NONE|This study is an open-label Phase II trial|This is a non-randomized prospective single-site trial of minoxidil for patients living with recurrent platinum resistant ovarian cancer.||||
33698291|NCT02207023|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33698292|NCT03180697|||COHORT||PROSPECTIVE|||||||
33698293|NCT02196207|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two phase III randomized trials, each with two arms, including one inhibitor prevention trial and one inhibitor eradication trial.||||
33698294|NCT00467857|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698295|NCT05021081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In Phase 2, subjects will be randomized to a contralateral sequence where the study lenses will be worn throughout the duration of the study.|t|f|t|f
33698296|NCT04933695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698297|NCT03652883|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE||Stepped wedge trial design by which the time points at which implementation sites receive the ItFits-toolkit is randomised. By the end of the trial, all implementation sites have received the ItFits-toolkit sequentially acting as control and intervention condition. There are 6 groups and 2 implementation sites per group. Sites will be informed about the group they are allocated to three months before cross-over. Every three months, a new group crosses over from IAU to using the ItFits-toolkit.|t|t|f|t
33786246|NCT02799212|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33786247|NCT04797533|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||To determine whether the contactless body monitoring service can provide objective data to improve staff workload and service user experience. Additionally, the project will explore how the data from the devices can be combined and viewed.||||
33786248|NCT06411379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33786249|NCT06121999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to the control or experimental intervention on a rolling basis.||||
33786250|NCT00912587|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33786251|NCT05895929|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Nasal epithelial cells will be exposed to defined doses of mepolizumab in vitro culture (Arm 1) or control media without mepolizumab (Arm 2)||||
33786252|NCT04208737|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33786253|NCT03719677|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786254|NCT05732428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923532|NCT06140277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For randomization, The investigator will send a form to the study therapist who is not involved in assessing outcome of the study. This form will include a randomization number. In the clinic, closed envelopes with printed randomization numbers on it are available. For every randomization number the corresponding code for the therapy group of the randomization list will be found inside the envelopes. The therapist will open the envelope and will find the treatment protocol to be conducted in this patient. Staff responsible for recruitment and outcome assessor is not allowed to receive information about the group allocation.|There will be a total of 3 groups (10 patients for each), first group will be treated using chitosan as a replacement of bone particles with collagen membrane. 2nd group will be treated using the gold standard protocol which is the allograft bone particles with collagen membrane, and the last group will received nothing as control|t|t|f|t
33923533|NCT00879437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923534|NCT05129761|||COHORT||PROSPECTIVE|||||||
33923535|NCT01225172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923536|NCT01577199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923537|NCT06354699|||COHORT||PROSPECTIVE|||||||
33923538|NCT01677507|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923539|NCT02824848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923540|NCT01786863|||COHORT||PROSPECTIVE|||||||
33923541|NCT05877703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786255|NCT01370109|||COHORT||PROSPECTIVE|||||||
33801648|NCT06521541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002731|NCT06614491|||CASE_CONTROL||PROSPECTIVE|||||||
34002732|NCT02255487|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization methodology was controlled by the site.||||
34002733|NCT00655317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34002734|NCT03545399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-centre double-blind randomized placebo-controlled clinical trial on parallel arms of two groups of 45 subjects||||
34089979|NCT00105378|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33698298|NCT06666127|NA|SINGLE_GROUP||OTHER||NONE||Within-Subject Design: Each participant will have the left arm and leg as well as the right arm and leg randomly assigned to the LONG or SHORT condition. Each participant will perform both conditions, exclusively for the left or right sided limbs. This helps to control for genetics, nutrition, recovery, stress management and training history as each participant acts as a self-control group as well as both experimental conditions.||||
33698299|NCT03526575|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE||Experiment 1 will involve N=14 subjects randomized to placebo , 10 mg Zolpidem (Ambien) and 10 mg Zaleplon (Sonata) in counterbalanced order and will be awakened 90 min. post-placebo administration (half at 60 min and half at 90 min). The latter will be done to maintain some degree of blinding relative to the participants knowledge of conditions and the staff working on the protocol. Females and those subjects who have had a previous adverse experience with 10 mg zolpidem will be placed into Experiment 2, which will involve N=20 subjects randomized to placebo , 5 mg zolpidem and 10 mg zaleplon. Experiment 1 and 2 will provide data on zaleplon 10 mg compared to placebo on a total of 34 subjects consisting of astronauts and other subjects considered analogous to the astronaut population, which will provide the larger sample needed to identify those subjects who have cognitive performance deficits on abrupt awakening to the less sedating 10 mg zaleplon.|t|f|t|t
33698300|NCT02777710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698301|NCT02943031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698302|NCT02736994|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33698303|NCT01281137|||COHORT||PROSPECTIVE|||||||
33698304|NCT00067574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786256|NCT05468606|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Stage A will be randomized and double blind. Stage B will be open-label. The adjuvanted group of stage C will be open-label, the unadjuvanted group and the infectivity controls will be blinded.|"The study will consist of three stages (A, B, C). In stage A of the study, ten GA2 immunized participants will be compared to five infectivity controls in a blinded design. If the protective efficacy of the GA2 immunized group is ≤7/10 and some efficacy is seen in stage A (either ≥10% protection or significant increase in time to parasitemia) then the study will progress to stage B. In this stage, BCG (n=5), YF-17D (n=5) or imiquimod (n=5) will be applied/administered to the GA2 administration site. Additionally, two infectivity controls will participate in stage B.~Based on the data on safety, tolerability and immunogenicity, the most favorable adjuvant of stage B can be chosen to be further assessed in stage C. In stage C, additional participants will be immunized with 50 GA2 infected mosquitoes in combination with the selected adjuvant. Additionally, a group of five unadjuvanted GA2 immunized participants and three infectivity controls will participate."|t|f|t|f
33923542|NCT03000634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923543|NCT05772442|||COHORT||PROSPECTIVE|||||||
33923544|NCT01305304|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923545|NCT01978509|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33923546|NCT03095404|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33923547|NCT00378976|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33923548|NCT04373993|||COHORT||RETROSPECTIVE|||||||
33923549|NCT01622491|||CASE_CONTROL||RETROSPECTIVE|||||||
33923550|NCT03157921|||OTHER||CROSS_SECTIONAL|||||||
33923551|NCT01035008|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923552|NCT03384628|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subjects will be masked to lens type and lens codes. A sealed decoding envelope will be provided to the investigator. In the event of an emergency the investigator will break the masking and the medical monitor will be notified.|Each subject will wear the three contact lens types bilaterally in random succession|t|f|f|f
33923553|NCT02406053|||CASE_ONLY||PROSPECTIVE|||||||
33923554|NCT04733872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923555|NCT02920606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923556|NCT02571608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923557|NCT00193349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923558|NCT01040338|||CASE_CROSSOVER||PROSPECTIVE|||||||
33923559|NCT01677624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923560|NCT05304819|||COHORT||PROSPECTIVE|||||||
33923561|NCT00400439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923562|NCT03395756|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Participants in this study will be assigned to one of three groups based on leading follicle size: 12-14 mm, 15-17mm, and 18 mm or greater. Each group will receive the same medication (intramuscular depot medroxyprogesterone acetate), and be followed in the same manner for five consecutive days after administration with transvaginal ultrasound and blood draws for hormonal assays (progesterone, estradiol, and luteinizing hormone levels)||||
33923563|NCT05145400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923564|NCT03515018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923565|NCT06014294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The present research follows a cluster randomized controlled experimental design (CRCT), parallel type with three groups in multi-centers and being assessed in a pretest, posttest, and after three months of the completion of the intervention. The participants will be randomly allocated to one experimental group, one exercise control group, and one non-exercise control group. The non-exercise control group continue to maintain their daily routine and will be asked to attend workshop. While two exercise groups, one group performs a HIIT program, and the other group performs a Baduanjin exercise program.|t|f|f|t
33923566|NCT02455778|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33923567|NCT01459068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923568|NCT03852121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923569|NCT04694651|||COHORT||PROSPECTIVE|||||||
33923570|NCT06295068|||COHORT||PROSPECTIVE|||||||
33923571|NCT03444571|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33923572|NCT01683968|||COHORT||PROSPECTIVE|||||||
33923573|NCT05385627|||COHORT||PROSPECTIVE|||||||
34002735|NCT04707846|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The study utilizes a multiple crossover design to conduct N-of-1 trials in individuals.||||
34002736|NCT05187325|||OTHER||PROSPECTIVE|||||||
34002737|NCT05294367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34002738|NCT00502658|RANDOMIZED|PARALLEL||||SINGLE||||||
34002739|NCT05525702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002740|NCT02376257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002741|NCT04620941|||CASE_CONTROL||PROSPECTIVE|||||||
34002742|NCT06053840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002743|NCT06165640|||CASE_CONTROL||RETROSPECTIVE|||||||
34089980|NCT01523197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002744|NCT04495062|||COHORT||PROSPECTIVE|||||||
34002745|NCT04645186|||COHORT||PROSPECTIVE|||||||
34002746|NCT05626725|||COHORT||PROSPECTIVE|||||||
34002747|NCT01221649|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34002748|NCT05696041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Subjects were data randomized to the intervention group or control group in the order in which the signed consent forms were received.~Occupational therapy in the Primary Care received information, training, and a manual with study protocols on procedures and the names of the included subjects, approximately three weeks before the start of studies.~Neither OTs nor participants knew which intervention the subjects were randomized to until the envelopes were opened."|A Randomized Clinical Trial|t|t|f|f
34002749|NCT00357539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002750|NCT05318755|||COHORT||PROSPECTIVE|||||||
34002751|NCT06677905|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34002752|NCT02677662|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34089981|NCT05759871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Protocol using FSH alone with that of a protocol using FSH plus a GnRH antagonist for controlled ovarian hyperstimulation in cycles of elective freezing in the context of a donor/recipient programme.||||
34002753|NCT03388008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators examining lung biopsy results and blood for the development of donor-specific HLA antibodies will be blinded to study participants' treatment arm assignment.|Study participants will be randomized to 1 of 2 arms: Belatacept-based immunosuppression or standard of care immunosuppression|f|f|f|t
34002754|NCT01404962|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34002755|NCT06334016|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Both participants and clinical personnel will be blinded to the nicotine product sequence (active vs. placebo).|Within-subject crossover study|t|t|t|t
34002756|NCT05948033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002757|NCT02603549|||COHORT||PROSPECTIVE|||||||
34002758|NCT05341856|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34002759|NCT01517867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002760|NCT05009056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinding||f|f|f|t
34002761|NCT03517280|||COHORT||PROSPECTIVE|||||||
34002762|NCT05364606|||CASE_ONLY||PROSPECTIVE|||||||
34002763|NCT02246348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002764|NCT06064149|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34002765|NCT04226586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002766|NCT06593405|NA|SINGLE_GROUP||TREATMENT||NONE||This is a quasi-experimental study to determine outcomes with occupational therapy (OT) medication management interventions/strategies for persons with Age-related Macular Degeneration (AMD)||||
34089982|NCT06268223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698305|NCT02096237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698306|NCT04500730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698307|NCT05390931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the study, participants will be left unaware of whether they are in the study or control group (single-blind masking).||t|f|f|f
33698308|NCT02291276|||COHORT||PROSPECTIVE|||||||
33698309|NCT00392080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698310|NCT05352711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33698311|NCT01033721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698312|NCT04706910|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698313|NCT05129670|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Patients and the staff at the Investigative site, will remain un-masked to treatment administered. Masking of the investigation is not required as the investigation endpoints are objective measurements of oesophageal pH and impedance, patients will be randomised to a treatment order.|This clinical investigation is being conducted to characterise the acid neutralisation activity of the test product, a calcite chewing gum, by comparing the antacid action with an unmatched placebo chewing gum. In this clinical investigation, the test product's ability to increase the pH within the oesophagus will be evaluated against an unmatched placebo.||||
33698314|NCT05839587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698315|NCT01826071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698316|NCT03225742|||COHORT||PROSPECTIVE|||||||
33698317|NCT06680102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698318|NCT04494776|||COHORT||RETROSPECTIVE|||||||
33698319|NCT06681038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698320|NCT05355051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698321|NCT04889222|NA|SINGLE_GROUP||OTHER||NONE||||||
33698322|NCT06083857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698323|NCT00643396||||TREATMENT||||||||
33698324|NCT03658057|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33698325|NCT00112008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698326|NCT02600351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698327|NCT02266498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698328|NCT03835819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698329|NCT00398294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698330|NCT03250897|||COHORT||PROSPECTIVE|||||||
33698331|NCT06671457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698332|NCT06556966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698333|NCT00901407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698334|NCT00528827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786257|NCT04087044|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||66 patients (30 patients with surgically confirmed unilateral loss, 15 patients with absent ice water calorics and resulting from vestibular neuritis and 21 patients with vestibular migraine) 120 controls||||
33786258|NCT04423588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002767|NCT00526435|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34002768|NCT02005939|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34002769|NCT06094894|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The use of identical capsules will allow the blinding, the capsules will be deposited in bottles numbered sequentially according to the enrollment process and neither the participants nor the researchers will know the content of the capsules, or the group assigned.|Triple blind parallel placebo-controlled randomized clinical trial|t|t|t|t
34002770|NCT03485001|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34002771|NCT02578290|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002772|NCT02488109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002773|NCT04181164|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34002774|NCT02611323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002775|NCT06491979|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002776|NCT05795296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698335|NCT00185068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002777|NCT02248116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002778|NCT06188780|||CASE_ONLY||PROSPECTIVE|||||||
34089983|NCT01867255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34089984|NCT03890965|NA|SINGLE_GROUP||OTHER||NONE||Pretest-posttest trial||||
33698336|NCT04875429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698337|NCT06295757|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34002779|NCT06001762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002780|NCT05554965|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34002781|NCT01151891|||CASE_ONLY||CROSS_SECTIONAL|||||||
33698338|NCT05165407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698339|NCT00520832|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34002782|NCT01744964|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34002783|NCT06004934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698340|NCT05394350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002784|NCT06356987|RANDOMIZED|PARALLEL||TREATMENT||NONE|66 patients (33 patients in each group) of laparoscopic extraperitoneal closure and open herniotomy each|66 patients with inguinal hernia were randomly divided into two groups (A and B)||||
34089985|NCT05726253|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Pilot Feasibility Trial|t|t|t|t
34089986|NCT00088855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089987|NCT00003360||||TREATMENT||||||||
34089988|NCT03276143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34089989|NCT02827539|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34089990|NCT02617095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33698341|NCT04677790|RANDOMIZED|PARALLEL||OTHER||NONE||After obtaining informed consent from the parents and oral or written assent from the children (where appropriate) we will randomize the children 1:1 in two groups, anticipated to be 12 and 20 months. Randomization by dice: even: very-short arm (12 months), uneven: short arm (20 months).||||
33698342|NCT05759611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33698343|NCT04821856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698344|NCT05061966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33698345|NCT02519465|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33698346|NCT05188196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698347|NCT04997915|||COHORT||RETROSPECTIVE|||||||
33698348|NCT03342014|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698349|NCT06681844|||COHORT||RETROSPECTIVE|||||||
33698350|NCT04082143|RANDOMIZED|PARALLEL||TREATMENT||NONE||subjects will be randomized to one of two groups||||
33698351|NCT02439983|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33698352|NCT02232334|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33698353|NCT04045548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698354|NCT00634764|||COHORT||PROSPECTIVE|||||||
33698355|NCT02282358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698356|NCT03550664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33698357|NCT06609512|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33698358|NCT02183142|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698359|NCT06593106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698360|NCT00662454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786259|NCT05223413|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomization (1:1) will be stratified by LVEF on baseline CMR (as quantified by CMR core lab /CNIC), by research Centre and by patient's gender.|t|t|t|t
33698361|NCT00904319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698362|NCT01046162|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33786260|NCT04735354|||COHORT||RETROSPECTIVE|||||||
33786261|NCT03542708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The care provider will be aware of which ovary is being treated. A different physician will serve as the outcomes assessor.|One ovary will be randomly selected for treatment with PRP. The other ovary will serve as a control.|t|f|t|t
34002785|NCT04881513|NA|SINGLE_GROUP||OTHER||NONE||||||
34002786|NCT06677762|||CASE_CONTROL||RETROSPECTIVE|||||||
34002787|NCT04258709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Statistician completing final analysis of data will be blinded to group assignment. An unbiased, third party will conduct qualitative interviews.~Participants, obstetric providers in recruitment clinics, and lactation consultant interventionists will be blinded to outcomes of interest."||t|t|f|t
34002788|NCT03346850|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34089991|NCT05813561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34089992|NCT06098547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34089993|NCT06358833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be masked from the procedure||t|f|f|f
34089994|NCT03112538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34089995|NCT01147458|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34089996|NCT06340659|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||This study will use a single-blind, randomized trial will randomize 104 community-dwelling older adults to one of two arms for 3 months: home-based (asynchronous) Exergame (HbExergame) or home-based asynchronous aerobic exercise (HbAEx). Randomization will allocate subjects on a 1:1 allocation ratio within each age stratum (65-74 and ≥75) in random blocks of 8 or 4|f|f|t|t
34089997|NCT05500755|||COHORT||PROSPECTIVE|||||||
34089998|NCT00195741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34089999|NCT02729857|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33786262|NCT03697213|||COHORT||CROSS_SECTIONAL|||||||
33786263|NCT05039918|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Allocation sequence will be randomised in advance by a trusted member of LJMU staff who is not involved in the study, using a computerised website to generate random numbers. The sequences will be placed in sealed opaque envelopes and stored in a secure location on-site. The use of an off-site computerised system for group allocation will decrease the risk of allocation bias. Eligible infants whose person(s) with parental responsibility have provided consent will be assigned the next available envelope which will be accessed by the lead researcher prior to the intervention.||t|f|t|f
33786264|NCT02388555|||COHORT||PROSPECTIVE|||||||
33786265|NCT02180113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786266|NCT02874261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090000|NCT02750722|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33786267|NCT05203913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786268|NCT06630052|||COHORT||PROSPECTIVE|||||||
33786269|NCT06701331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786270|NCT02622230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786271|NCT06055907|||COHORT||PROSPECTIVE|||||||
33786272|NCT05310929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33786273|NCT02214667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786274|NCT03795077|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786275|NCT00501020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786276|NCT04666454|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Multinational, Multicentre, registry-based, open-label, randomized controlled trial with 2 × 2 factorial design||||
33786277|NCT02963142|||COHORT||PROSPECTIVE|||||||
33786278|NCT03836469|||COHORT||RETROSPECTIVE|||||||
33786279|NCT02774252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786280|NCT04457141|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||randomized clinical trial|f|f|f|t
33786281|NCT03667248|||COHORT||RETROSPECTIVE|||||||
33786282|NCT00635817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786283|NCT05621798|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|"Patients are having their hearing aids fitted by manufacturer's initial fit method or by REM. In both fittings participants will be hearing sounds at different intensities and frequencies but they are unaware of the exact fitting method used. The first fit and REM measurement sounds and procedures are different, but for first-time users unknown. Both procedures are conducted by audiologist but only the other of the fitting results is being used for the hearing aid adjusting. During the next fitting appointment the participant is also seen and the hearing aid is re-fitted by another audiologist than the first time."|"On the first fit visit the participants will be fitted either with the manufacturers first-fit or initial fit program or using the REM measurements. We will randomize all patients into two groups; Half of the participants will be fitted with the Phonak first fit fitting rule and the other half using the Phonak TargetMatch that utilizes REM fitting. After around 2-3 months, depending on the clinic schedule, the participants will be crossed-over to the other method, so that the group that first got the manufacturers fit will now receive the fit based on REM and vice versa. Third visit will take place 2-3 months after the second visit and the participants will get to choose which fit they will prefer for their hearing aids. Fourth visit takes place around 6 months after the third visit when the participants have been wearing their hearing aids for a year."|t|t|f|f
33786284|NCT01644162|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33786285|NCT04531514|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Care providers will not be told which condition they are participating in. Investigators will know because of familiarity with the stimuli.|Toddlers will be assigned randomly to one of four conditions: OR condition with a referent; OR condition without a referent; Family Resemblance condition with a referent; Family Resemblance condition without a referent.|t|t|f|f
33923574|NCT03307863|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||It is a non-randomized clinical trial (controlled clinical trial)|f|f|f|t
33923575|NCT00270413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923576|NCT04035538|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923577|NCT03638557|NA|SINGLE_GROUP||PREVENTION||NONE||pre-post quasi experimental design||||
33923578|NCT06066840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923579|NCT03858270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923580|NCT02485548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923581|NCT02821130|||CASE_ONLY||PROSPECTIVE|||||||
33923582|NCT00613717|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34090001|NCT03565289|||CASE_ONLY||PROSPECTIVE|||||||
34090002|NCT01481025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002789|NCT05722249|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The cluster randomized crossover design is selected for logistical and ethical reasons: first, we seek generalizable findings; second, randomizing individual members of the nightshift will inevitably contribute to cross-contamination of the intervention arms; having a control group will similarly be at risk of contamination from peers randomly assigned to intervention arms as nightshift workers are assigned to float to other units when staffing needs merit such assignments; and given the known potential health risks for some nightshift workers, not providing an intervention could be considered unethical. In the cluster cross-over design, the staff in the participating clinical inpatient units will each receive an intervention during each of two time periods.||||
34090003|NCT01812915|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34090004|NCT02774083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34090005|NCT05572918|||CASE_ONLY||PROSPECTIVE|||||||
34090006|NCT03342729|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34090007|NCT05983432|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34090008|NCT00117819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090009|NCT02716090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090010|NCT00737802|||CASE_CONTROL||PROSPECTIVE|||||||
33786286|NCT06631066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786287|NCT03873324|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Only PART B will be double-blind||t|f|t|f
33786288|NCT01385280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786289|NCT02573740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786290|NCT04320264|||COHORT||PROSPECTIVE|||||||
33786291|NCT06713343|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33786292|NCT05641896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786293|NCT03293264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33786294|NCT02943655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786295|NCT05133362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786296|NCT05048355|NA|SINGLE_GROUP||TREATMENT||NONE||single group repeated measures crossover design||||
33923583|NCT06108128|NA|SINGLE_GROUP||OTHER||NONE|This is an observational cross-sectional study with interventions ONLY at the measurement level. The research assistant administers the tasks and records the outcomes; therefore, no masking is used.|This is an observational, cross-sectional study that involves interventions ONLY at the measurement level.||||
33923584|NCT03482128|||COHORT||RETROSPECTIVE|||||||
33923585|NCT03663140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923586|NCT01896388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923587|NCT00682240|RANDOMIZED|CROSSOVER||||NONE||||||
33923588|NCT04730310|||COHORT||RETROSPECTIVE|||||||
33923589|NCT05218577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant did'n know what they had got. the investigator did'n know group.|The Intervention group were given HSFF and selenium suplemen, and control group was given placebo.|t|f|t|f
33923590|NCT04359342|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomized, double-blind placebo-controlled study. Participants and Outcome Assessors will not be aware of the arm to which the participants are allocated (double-blinded masking).|Parallel Assignment Parallel Assignment parallel-group, randomized, double-blind, placebo-controlled study|t|f|f|t
33923591|NCT00098189|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33923592|NCT00004938|RANDOMIZED|||TREATMENT||||||||
33923593|NCT03392987|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single arm study. All subjects will receive OTL-200 gene therapy and will be followed up for 8 years post-gene therapy.||||
33923594|NCT02177175|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33923595|NCT02299648|NA|SINGLE_GROUP||SCREENING||NONE||||||
33923596|NCT00753597|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33923597|NCT02863705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698363|NCT00415376||||SUPPORTIVE_CARE||||||||
33698364|NCT01568515|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33698365|NCT02530463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698366|NCT06469164|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Observer-blind||t|t|t|t
33698367|NCT02821637|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33698368|NCT03070444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698369|NCT05059795|||CASE_ONLY||PROSPECTIVE|||||||
33698370|NCT01719783|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33698371|NCT05663229|||CASE_CONTROL||PROSPECTIVE|||||||
33786297|NCT01102322|||COHORT||PROSPECTIVE|||||||
33786298|NCT05471232|||CASE_CONTROL||PROSPECTIVE|||||||
33786299|NCT00598013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786300|NCT05822609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698372|NCT00590889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698373|NCT05755165|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34002790|NCT06365320|NA|SINGLE_GROUP||OTHER||NONE|Given the nature of the study (pretest-posttest design), masking will not be possible.|Single-group pretest-posttest design (quasi- experimental)||||
34002791|NCT00223938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002792|NCT02643927|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34002793|NCT00003822||||TREATMENT||||||||
33698374|NCT06137560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33698375|NCT04558593|||COHORT||PROSPECTIVE|||||||
33698376|NCT05320185|||COHORT||RETROSPECTIVE|||||||
33698377|NCT02617888|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33698378|NCT02575131|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33698379|NCT06470763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698380|NCT02778061|||OTHER||RETROSPECTIVE|||||||
33698381|NCT04239092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will receive either single agent 9-ING-41 or 9-ING-41 plus Irinotecan or 9-ING-41 plus Irinotecan plus Temozolomide or 9-ING-41 plus Cyclophosphamide plus Topotecan||||
33698382|NCT02651350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698383|NCT02380001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698384|NCT02831244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698385|NCT05609318|||COHORT||PROSPECTIVE|||||||
33698386|NCT04112459|||OTHER||CROSS_SECTIONAL|||||||
33698387|NCT04393285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698388|NCT01050881|||CASE_ONLY||RETROSPECTIVE|||||||
33698389|NCT02258425|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33698390|NCT06229418|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33698391|NCT05181462|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase Ib: Single-arm (dose-escalation 3+3 design).~* Nadunolimab escalation (Dose Level (DL) -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.~* Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks.~* Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks.~Phase II: Randomized 1:1, non-comparative, open-label.~Patients randomized to arm A will receive:~* Nadunolimab Recommended Phase II Dose (RP2D) mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.~* Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks.~* Carboplatin AUC 2 mg/mL/min IV on days 1 and 8/15, in cycles of 3-4 weeks.~Patients randomized to arm B will receive:~* Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks.~* Carboplatin AUC 2 mg/mL/min IV on days 1 and 8/15, in cycles of 3-4 weeks."||||
33698392|NCT04820166|||COHORT||PROSPECTIVE|||||||
33698393|NCT03800173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698394|NCT04113720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33698395|NCT03228420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786301|NCT02647749|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786302|NCT05014555|||COHORT||CROSS_SECTIONAL|||||||
33786303|NCT02612584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786304|NCT01450943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786305|NCT03372733|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33786306|NCT05258695|||CASE_ONLY||CROSS_SECTIONAL|||||||
33786307|NCT03241888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786308|NCT02962336|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786309|NCT01208467|||COHORT||RETROSPECTIVE|||||||
33786310|NCT03438487|||COHORT||PROSPECTIVE|||||||
33786311|NCT00938340|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33923598|NCT02137837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33923599|NCT03779633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, Placebo-controlled|t|f|t|f
33923600|NCT05394103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923601|NCT03420443|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33923602|NCT00436202|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923603|NCT01015729|RANDOMIZED|CROSSOVER||||NONE||||||
33923604|NCT00880880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33923605|NCT05475600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923606|NCT03788863|||COHORT||RETROSPECTIVE|||||||
33923607|NCT00228930|||COHORT||PROSPECTIVE|||||||
33923608|NCT03750240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923609|NCT04758832|||OTHER||RETROSPECTIVE|||||||
33923610|NCT04449276|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|In the initial part of the dose escalation, participants will be enrolled in sentinel groups in an open manner. In the second part, participants will be enrolled in placebo-controlled groups in an observer-blind manner.||f|f|f|t
33923611|NCT02770118|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33923612|NCT05482035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002794|NCT01588548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002795|NCT00089427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002796|NCT02864550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34002797|NCT04320576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002798|NCT04510792|||COHORT||PROSPECTIVE|||||||
33698396|NCT06383065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698397|NCT06680466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multi center, randomized, double-blind, placebo-controlled, and positive drug parallel controls|t|t|t|t
33698398|NCT03211871|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the primary patient assessment, eligible participants were assigned in a 1:1 ratio to either the intervention (Group D) or control (Group C) groups using random assignment in blocks of four.||||
33698399|NCT01085435|||COHORT||PROSPECTIVE|||||||
33698400|NCT04080440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Stepped wedge, cluster randomised controlled design||||
33698401|NCT05581966|||CASE_ONLY||PROSPECTIVE|||||||
33698402|NCT05691036|||CASE_CONTROL||PROSPECTIVE|||||||
33786312|NCT00866996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786313|NCT04837495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786314|NCT00918541|||COHORT||PROSPECTIVE|||||||
34002799|NCT00004416||||TREATMENT||||||||
34090011|NCT02151201|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
34090012|NCT01668043|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090013|NCT04841265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090014|NCT03065660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, research midwives/nurses and other attending clinicians will remain blind to the trial drug allocation throughout the duration of the trial.|A randomised, parallel group, double-blind, placebo-controlled multicentre study, with health economic and mixed-methods evaluation.|t|t|t|f
34090015|NCT04626076|||OTHER||PROSPECTIVE|||||||
34090016|NCT02463383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Participants are randomized to an ibuprofen or placebo pill in the first period and are then provided with placebo or ibuprofen pills, respectively, in the second period in a crossover fashion. Alcohol (0.4g/kg bw) is provided as a challenge 30min after the pill has been swallowed.|t|t|t|t
34090017|NCT06306703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|healthcare provider performing USG evaluation person doing statistical analysis|prospective randomized|t|t|f|t
34090018|NCT02458417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090019|NCT02214082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923613|NCT01946789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090020|NCT04356651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090021|NCT06168214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090022|NCT04905290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090023|NCT00412620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090024|NCT00983970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090025|NCT03056053|NA|SINGLE_GROUP||OTHER||NONE||||||
33923614|NCT01268033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090026|NCT02863042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090027|NCT01402726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923615|NCT01104363|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34090028|NCT01124240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090029|NCT01164475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090030|NCT03723824|NA|SINGLE_GROUP||TREATMENT||NONE||grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®, 1# qd for 12 weeks||||
34090031|NCT05267457|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34090032|NCT02196129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923616|NCT04312451|||COHORT||PROSPECTIVE|||||||
34090033|NCT06281613|||CASE_CONTROL||RETROSPECTIVE|||||||
34090034|NCT04529174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized double-blind Placebo controlled trial. Dietary|t|f|t|f
34090035|NCT01806493|||COHORT||CROSS_SECTIONAL|||||||
34090036|NCT05342844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The injectate used for TAPB will be prepared according to the group by an anesthesiologist who won't be involved in the data collection|according to the computer-generated random number codes that will be placed in sealed envelopes, the patients will be randomly allocated into three groups; Group-Control, Group-Dexmedetomidine 0.5 and Group-Dexmedetomidine 1 according tho the local anesthetic injected in Ultrasound-guided bilateral Tranversus abdominis plane block|t|f|t|f
34090037|NCT01796522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34090038|NCT01104844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090039|NCT01926210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090040|NCT04159064|||COHORT||PROSPECTIVE|||||||
33923617|NCT06528730|||COHORT||PROSPECTIVE|||||||
33923618|NCT04552717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||wait-list controll and intervention group||||
33923619|NCT00005812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923620|NCT03998761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923621|NCT00588887|||COHORT||PROSPECTIVE|||||||
33923622|NCT05840341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923623|NCT00529893|||CASE_ONLY||OTHER|||||||
33923624|NCT03673696|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33923625|NCT01962285|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923626|NCT02376491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923627|NCT04178577|NA|SINGLE_GROUP||OTHER||NONE||||||
33923628|NCT00345501|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923629|NCT02897869|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923630|NCT02228564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923631|NCT02533193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923632|NCT04886193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923633|NCT04255017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923634|NCT02640118|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33923635|NCT00104156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923636|NCT03297333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923637|NCT02294422|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923638|NCT00615797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923639|NCT03682380|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33923640|NCT05096546|||COHORT||CROSS_SECTIONAL|||||||
33923641|NCT01769144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090041|NCT01031290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698403|NCT04923815|||COHORT||RETROSPECTIVE|||||||
33698404|NCT02550041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698405|NCT04483973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698406|NCT00035659|||COHORT||PROSPECTIVE|||||||
33698407|NCT00072657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698408|NCT00107783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698409|NCT06595121|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single dose, randomized, open-label, two-formations, three treatments, four-period, four-sequence, cross-over, at one study site.||||
33698410|NCT05435209|NA|SINGLE_GROUP||PREVENTION||NONE||Quadrivalent HPV vaccine||||
33923642|NCT00472251|||COHORT||PROSPECTIVE|||||||
33923643|NCT01383109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923644|NCT04507776|||COHORT||RETROSPECTIVE|||||||
33923645|NCT02816437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786315|NCT02662192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002800|NCT00939523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786316|NCT02817633|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Click here to enter text.|This is a multi-center, open-label, first-in-human Phase 1 study.||||
33786317|NCT04097886|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002801|NCT06678477|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||3D colonoscopy versus standard 2D colonoscopy in positive FIT groups|t|f|f|t
34002802|NCT06616389|NA|SINGLE_GROUP||TREATMENT||NONE||Ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX||||
34002803|NCT01471951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002804|NCT03660852|||CASE_CONTROL||PROSPECTIVE|||||||
34002805|NCT03676790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786318|NCT05566847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786319|NCT00420589|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33786320|NCT05478902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786321|NCT01385865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33786322|NCT02836678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923646|NCT04294654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923647|NCT05504577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923648|NCT04391855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33923649|NCT02573233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923650|NCT04265898|||CASE_CONTROL||PROSPECTIVE|||||||
33923651|NCT05996783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923652|NCT02746848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923653|NCT03748485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33923654|NCT00438542|||CASE_CONTROL||OTHER|||||||
33923655|NCT00936299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923656|NCT03291158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923657|NCT02685995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923658|NCT00627770|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923659|NCT06304675|||COHORT||PROSPECTIVE|||||||
33923660|NCT01510834|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33923661|NCT00554138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33923662|NCT01688063|||COHORT||RETROSPECTIVE|||||||
33923663|NCT04228887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923664|NCT04718337|||OTHER||CROSS_SECTIONAL|||||||
33923665|NCT03705312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized 1:1 to medical treatment or intervention with the MitraClip device|f|f|f|t
33923666|NCT00085488||||TREATMENT||||||||
33923667|NCT01760759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923668|NCT03801811|||COHORT||PROSPECTIVE|||||||
33923669|NCT03069898|RANDOMIZED|PARALLEL||PREVENTION||NONE||Paraticipants are randomly assigned to intervention (TRUE Dads) and Control tracks, assessed at Baseline and again one year later. The intervention primarily involves attendance at 12 3-hour workshops for fathers and their co-parents.||||
33923670|NCT03178799|||CASE_CONTROL||OTHER|||||||
33923671|NCT01450475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33923672|NCT02083146|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923673|NCT01573403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923674|NCT02762019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923675|NCT05671315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786323|NCT04921761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33786324|NCT00831597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923676|NCT04323150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923677|NCT03628599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923678|NCT00488995|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33923679|NCT04587596|||CASE_ONLY||CROSS_SECTIONAL|||||||
33923680|NCT01297309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923681|NCT01316029|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33923682|NCT02209038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33923683|NCT01797445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923684|NCT04117412|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Same participants will undergo two different exercise protocols after maximal exercise test.||||
33923685|NCT01892644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923686|NCT00806689|||COHORT|||||||||
33923687|NCT01676272|||COHORT||PROSPECTIVE|||||||
34002806|NCT06290765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002807|NCT04328688|||CASE_CONTROL||PROSPECTIVE|||||||
34002808|NCT02414763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002809|NCT05337644|||CASE_ONLY||RETROSPECTIVE|||||||
34090042|NCT03337412|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||uncontrolled, non-randomized, open-plan, multi-centre study||||
34103157|NCT00216658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103158|NCT06256159|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33786325|NCT02090309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786326|NCT06631820|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This is a pilot treatment crossover interventional trial||||
33786327|NCT05246553|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33786328|NCT04056104|NA|SINGLE_GROUP||OTHER||NONE||Non-invasive measurements of oxygenation and perfusion will be measured with pulse oximeters||||
33786329|NCT01444287|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34002810|NCT04083443|||COHORT||PROSPECTIVE|||||||
34002811|NCT03303417|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|MRI analysis will be performed blind to the intervention||f|f|f|t
34002812|NCT06263114|||COHORT||PROSPECTIVE|||||||
34002813|NCT04323722|NA|SINGLE_GROUP||OTHER||NONE||Monocentric, open prospective study||||
34002814|NCT04566549|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34002815|NCT00466479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34002816|NCT01917084|NA|SINGLE_GROUP||OTHER||NONE||||||
34002817|NCT02109835|||COHORT||PROSPECTIVE|||||||
33786330|NCT05708833|RANDOMIZED|PARALLEL||OTHER||NONE||Interventional study with randomisation (1:1)||||
33786331|NCT05365607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo (i.e., sham intervention) controlled parallel pilot study|t|t|t|t
34103159|NCT04255043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will remain blinded until the final study results released.|All subjects will undergo 1:1 randomization to either IVUS or Angiography-guided DCB treatment for coronary denovo lesions in patients with high bleeding risk.|f|f|f|t
34103160|NCT04677595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103161|NCT06690970|||COHORT||PROSPECTIVE|||||||
34103162|NCT03054012|||COHORT||RETROSPECTIVE|||||||
34103163|NCT05816590|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786332|NCT00779571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923688|NCT03277508|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|The blinding will be carried out in such a way that the therapist will provide conventional therapy and assess the arm function without knowing the group that the patients belong to. The BCI Robot and Passive Robot will be administered by other study team member. A third party study team member not participating in the intervention will keep the log book which contains information regarding patients study ID and group. Randomization codes will be broken when all interventional and follow-up sessions were completed or when the patient decides to quit participation. The third party team member will unmask according to PI's request in this occasion.|A randomization stratification method, with a computer generated random sequence will be used. Subjects will be grouped in strata according to their Fugl-Meyer scores(0-28 vs 29-45) and randomized separately according to a block randomization to receive either of following treatments:(1) Treatment A: 18 sessions for 6 weeks of 60 minutes of passive robot-assisted hand therapy+ 30 minutes of standard hand therapy.(2) Treatment B: 18 sessions for 6 weeks of 60 minutes of BCI controlled robot-assisted hand therapy + 30 minutes of standard hand therapy.|f|f|f|t
33923689|NCT00523653|||FAMILY_BASED||PROSPECTIVE|||||||
33923690|NCT04207268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923691|NCT01655238|||COHORT||RETROSPECTIVE|||||||
33923692|NCT00003777||||TREATMENT||||||||
33923693|NCT01280630|||||RETROSPECTIVE|||||||
33923694|NCT04261049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923695|NCT01624506|||OTHER||OTHER|||||||
33923696|NCT01442701|||COHORT||PROSPECTIVE|||||||
33923697|NCT02811796|||COHORT||PROSPECTIVE|||||||
33923698|NCT03957746|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33923699|NCT03457740|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind masking|Randomized, parallel group, placebo controlled, double blind|t|f|t|f
33923700|NCT04412070|||COHORT||PROSPECTIVE|||||||
33923701|NCT05911412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923702|NCT00609453|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33923703|NCT02360553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923704|NCT03341611|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923705|NCT04874532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33923706|NCT06365242|||COHORT||PROSPECTIVE|||||||
33923707|NCT00518401|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923708|NCT05660213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923709|NCT00851253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923710|NCT02251678|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923711|NCT00003882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923712|NCT02882737|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33698411|NCT03530800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34002818|NCT01480895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34002819|NCT03414034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002820|NCT06111664|||CASE_CONTROL||RETROSPECTIVE|||||||
34002821|NCT02971813|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002822|NCT03825744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002823|NCT03837171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002824|NCT05965986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34002825|NCT05397301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34002826|NCT02033317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002827|NCT02274662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002828|NCT04771767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants diagnosed with PTSD will be assigned either to the experimental treatment or a control. Data will be collected from participants in both groups at the same 4 time-points.||||
34002829|NCT00108550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34002830|NCT02340624|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34002831|NCT03744286|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a 2-visit clinical trial to test a novel prototype slip inducing platform device for feasibility and not health outcomes.||||
34002832|NCT03008538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34002833|NCT04776304|NA|SINGLE_GROUP||TREATMENT||NONE||This is both interventional, meaning SMs receive art therapy, and analytical, to understand qEEG outcomes.||||
34002834|NCT06398834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The enrolled participants were randomly allocated to either the butorphanol group (Group B) or the esketamine combined with butorphanol group (Group BK) at a 1:1 ratio.|t|t|t|t
34002835|NCT04933357|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103164|NCT03678857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|An independent researcher will label the placebo and creatine and only reveal which group is which after data has been analyzed.||t|f|t|t
34103165|NCT06674785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant Care Provider Outcomes Assessor||t|f|f|f
34002836|NCT03980275|||COHORT||PROSPECTIVE|||||||
34103166|NCT06593587|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study is double-blinded.~The participant, study coordinator, and all site staff will be blinded.~The majority of sponsor staff will be blinded to study intervention allocation. All laboratory testing personnel performing serological assays or diagnostic assays will remain blinded to the study intervention assigned/received throughout the study"|Parallel|t|t|t|t
34002837|NCT05482425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded grading based on VECTRA images and VISIA images will be performed on de-identified photography by a third-party vendor at the end of the study.|This study will include 2 cohorts, each consisting of approximately 13 subjects to undergo intervention, where each subject will have treatment of the skin of cheek area, upper lip, chin and superior neck regions, as well as the behind the ears with autologous fat graft. The subject will receive either a saline washed preparation or a non-washed preparation as determined by the randomization process. Autologous fat tissue will be harvested for the fat graft preparation (up to a maximum of 1 liter ) from the trunk or extremity donor site, consistent with standard clinical practice.|f|f|f|t
34002838|NCT00052520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002839|NCT00490932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002840|NCT00057967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002841|NCT04318431|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002842|NCT02135991|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34002843|NCT01731236|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002844|NCT05091632|||COHORT||PROSPECTIVE|||||||
34002845|NCT01140633|||COHORT||PROSPECTIVE|||||||
34002846|NCT03028155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002847|NCT04957615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002848|NCT03833427|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34002849|NCT03493035|||CASE_CONTROL||OTHER|||||||
34002850|NCT03022890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002851|NCT03004508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786333|NCT01757509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33786334|NCT03078920|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33923713|NCT03701204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923714|NCT01582802|||COHORT||PROSPECTIVE|||||||
33923715|NCT06121362|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|This study is a double-blind design. Neither the subject nor the research team will know which treatment arm (placebo or PCA) the enrolled subjects have been assigned to. Study drug bottles will be labeled with a code, and the linked treatment assignment (placebo vs PCA) will be kept with the Sponsor and not made available to the research team during the treatment period.|We will assign subjects to the placebo or PCA supplementation randomly using Statistical Analysis System (SAS) software that contains a random assignment generator. It will output 50 assignments, equal to the number of subjects that we expect to enroll. Subjects will be assigned to one of the groups in a prospective manner as they are recruited throughout the study period.|t|t|t|t
33923716|NCT02741089|||COHORT||PROSPECTIVE|||||||
33923717|NCT02181985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923718|NCT00759746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923719|NCT00884689|||CASE_ONLY|||||||||
33923720|NCT02828007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923721|NCT05220137|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Every condition in the experiment will begin with two initial core sessions (Rationale/Impact Statement and Working with Events, Thoughts, and Feelings) and end with a final core session. Each participant will then receive between one and five additional weekly sessions, as described below.~The following CPT components will be empirically tested in the fractional factorial design: (1) Modified A-B-C, (2) Challenging Questions, (3) Patterns of Problematic Thinking, (4) Challenging Beliefs, and (5) Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy). Each component will be taught in a single session. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.~All treatment sequences will end with a final session that consists of final homework review, review of treatment progress, and relapse prevention techniques. In total, participants will receive between 4 and 8 sessions."||||
33923722|NCT04193670|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002852|NCT01213407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002853|NCT00707187|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34002854|NCT05625139|||CASE_ONLY||RETROSPECTIVE|||||||
34002855|NCT04217538|||COHORT||PROSPECTIVE|||||||
34002856|NCT05974358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, multicenter,randomized study|t|f|f|t
34002857|NCT03837405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blood tests at LabCorp and 24-hour dietary recall interviews are done by research assistants blinded to treatment assignment.||f|f|f|t
34002858|NCT02310841|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002859|NCT02403973|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002860|NCT05761587|||COHORT||PROSPECTIVE|||||||
34002861|NCT02539368|||COHORT||PROSPECTIVE|||||||
34002862|NCT05455606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34002863|NCT03552367|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label trial|Randomized open clinical trial||||
34103167|NCT06606158|||COHORT||RETROSPECTIVE|||||||
34103168|NCT05541328|||COHORT||RETROSPECTIVE|||||||
34103169|NCT03224377|||CASE_CONTROL||PROSPECTIVE|||||||
33786335|NCT05479045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786336|NCT03874975|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||40 patients divided into two groups : group 1 :20 patients underoral vitamin D and UVB group 2 : 20 patients under uvb alone in psoriatic patients|t|f|f|f
33786337|NCT01805856|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33786338|NCT03638219|||COHORT||RETROSPECTIVE|||||||
33786339|NCT03010709|||COHORT||PROSPECTIVE|||||||
33786340|NCT06609850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002864|NCT03602027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002865|NCT06286670|RANDOMIZED|PARALLEL||TREATMENT||NONE||adult patients with extra-articular or complete articular distal femur fractures that will be operatively treated recruited from one of the participating sites during the index hospitalization||||
33786341|NCT01440244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786342|NCT00361621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786343|NCT03585361|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786344|NCT06628492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33786345|NCT04990791|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomised controlled open-label crossover study||||
33786346|NCT02690103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33786347|NCT04215978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923723|NCT04656392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study design is a multi-site prospective cohort study in eight general practices. All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.||||
33923724|NCT02226978||CROSSOVER||TREATMENT||NONE||||||
33923725|NCT04372043|||COHORT||PROSPECTIVE|||||||
33923726|NCT02492087|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33923727|NCT01436695|||COHORT||PROSPECTIVE|||||||
33923728|NCT04298190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923729|NCT01421537|||OTHER||PROSPECTIVE|||||||
33923730|NCT03518632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923731|NCT02174016|NA|SINGLE_GROUP||OTHER||NONE||Open label use of ketogenic diet in children with acute brain injury||||
34002866|NCT06293352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002867|NCT01691586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002868|NCT06520683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002869|NCT05659238|||CASE_CONTROL||RETROSPECTIVE|||||||
34002870|NCT05603858|||CASE_ONLY||PROSPECTIVE|||||||
33923732|NCT00351169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923733|NCT02017886|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34002871|NCT03644043|||COHORT||PROSPECTIVE|||||||
34002872|NCT03547830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002873|NCT02702986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002874|NCT05741502|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Open Label|Parallel open-label groups of Treatment-Refractory schizophrenia patients treated with Clozapine or non-Clozapine drug||||
34002875|NCT00234780|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002876|NCT02651064|RANDOMIZED|PARALLEL||||NONE||||||
34103170|NCT02571881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698412|NCT03947203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33698413|NCT03829774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33698414|NCT06467942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698415|NCT00335478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33786348|NCT05471167|||COHORT||RETROSPECTIVE|||||||
33786349|NCT01558102|||CASE_ONLY||RETROSPECTIVE|||||||
33786350|NCT05252624|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33786351|NCT02723851|||CASE_CONTROL||PROSPECTIVE|||||||
33786352|NCT02027935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923734|NCT03724617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923735|NCT05736978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923736|NCT03552627|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34002877|NCT01272076|||CASE_ONLY||PROSPECTIVE|||||||
34002878|NCT01388998|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34002879|NCT06676618|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34002880|NCT02185963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002881|NCT00084864|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002882|NCT00758719|||OTHER||PROSPECTIVE|||||||
34103171|NCT06276075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698416|NCT04080960|||COHORT||CROSS_SECTIONAL|||||||
33698417|NCT03454685|||CASE_ONLY||OTHER|||||||
34002883|NCT06678880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002884|NCT03996616|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, quasi-experimental, controlled, pre- and post-intervention trial, using a difference-in-differences design and involving two study sites||||
34002885|NCT04784637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698418|NCT05280639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698419|NCT05415683|||CASE_ONLY||PROSPECTIVE|||||||
33923737|NCT05414149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923738|NCT03525626|NA|SINGLE_GROUP||OTHER||NONE||||||
33923739|NCT01612117|||COHORT||PROSPECTIVE|||||||
33923740|NCT05561894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33923741|NCT01012349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923742|NCT03713606|||COHORT||PROSPECTIVE|||||||
33923743|NCT01754597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923744|NCT01429610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923745|NCT06415162|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group will fill in the 'Patient Information Form, Menopause Specific Hot Flash Scale, Pittsburgh Sleep Quality Index and FACT-B Quality of Life Scale' in the 1st week and will be given training on treatment side effects, training booklet and 'Hot Flash Diary' to record their hot flashes. The use of cooling pillowcase will be explained. In the 5th week, 'Practices for Coping with the Side Effects of Hormone Therapy Form' will be filled out to evaluate the training and the training will be repeated. In the 3rd and 7th weeks, 'Patient Follow-up Form' will be filled by telephone, and in the 5th week face to face. In the 9th week, 'Menopause Specific Hot Flush Scale, Pittsburgh Sleep Quality Index and FACT-B Quality of Life Scale' and 'Practices Form for Coping with Side Effects of Hormone Therapy' will be completed to evaluate the training given in the 5th week. The routine care and treatment of the control group will be continued.||||
33923746|NCT03492645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923747|NCT00829127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33923748|NCT00633308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923749|NCT04874688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Families and fieldworkers measuring outcome measures are not blinded. Analysts and laboratory scientists will be blinded to intervention arm.|Individually randomized, unblinded clinical trial|f|f|t|f
33923750|NCT05666882|||COHORT||RETROSPECTIVE|||||||
33923751|NCT02037451|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923752|NCT01548794|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33923753|NCT03831815|||OTHER||PROSPECTIVE|||||||
33923754|NCT02758613|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33923755|NCT00018629|RANDOMIZED|PARALLEL||||SINGLE||||||
33923756|NCT03224910|||CASE_ONLY||CROSS_SECTIONAL|||||||
33923757|NCT01877590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34002886|NCT04903340|||CASE_ONLY||PROSPECTIVE|||||||
34002887|NCT03447444|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||case studies||||
33698420|NCT06534034|||CASE_ONLY||RETROSPECTIVE|||||||
33698421|NCT01722396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698422|NCT05743608|||COHORT||PROSPECTIVE|||||||
33698423|NCT00914680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698424|NCT05115578|||COHORT||PROSPECTIVE|||||||
33698425|NCT04485910|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Evaluating the embryonic development and PGTai results for embryos cultured in sequential media versus single step media.||||
33698426|NCT04952285|||OTHER||RETROSPECTIVE|||||||
33698427|NCT04315701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698428|NCT06556264|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33698429|NCT00776724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698430|NCT04050072|||CASE_CONTROL||PROSPECTIVE|||||||
33698431|NCT01291953|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33698432|NCT05067907|||COHORT||RETROSPECTIVE|||||||
33698433|NCT05440188|||COHORT||PROSPECTIVE|||||||
33698434|NCT05648331|||CASE_ONLY||CROSS_SECTIONAL|||||||
33698435|NCT05038046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698436|NCT00320931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002888|NCT04736394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002889|NCT05678530|||CASE_CONTROL||PROSPECTIVE|||||||
33923758|NCT06173661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A research pharmacist who is not on the study team will randomize the study arms.|This is a randomized, single center, double blind, placebo-controlled clinical trial with a non-crossover, parallel group study design that will select 72 patients who meet criteria and randomize half to receive active medication and half to receive placebo. A research pharmacist will randomize the patients; the study team will be blinded.|t|t|t|f
34002890|NCT00163969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923759|NCT04489004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923760|NCT04101448|||COHORT||PROSPECTIVE|||||||
33923761|NCT04117568|||COHORT||PROSPECTIVE|||||||
33923762|NCT04467632|NA|SINGLE_GROUP||OTHER||NONE||||||
33923763|NCT00934011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923764|NCT02707679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923765|NCT03046160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923766|NCT04953065|||COHORT||PROSPECTIVE|||||||
33923767|NCT03943108|||CASE_ONLY||PROSPECTIVE|||||||
33923768|NCT01875705|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33923769|NCT02678312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923770|NCT04077411|||COHORT||PROSPECTIVE|||||||
33923771|NCT00897936|||OTHER||RETROSPECTIVE|||||||
33923772|NCT03481387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923773|NCT02803970|||COHORT||PROSPECTIVE|||||||
33923774|NCT05854069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923775|NCT05165550|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34002891|NCT03782662|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34103172|NCT04256018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103173|NCT06673485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103174|NCT01337310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923776|NCT01349972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923777|NCT00556621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923778|NCT05653804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, interventional, randomized controlled, open-label, single-center, multi-site||||
33923779|NCT02227056|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33923780|NCT02076048|||COHORT||PROSPECTIVE|||||||
33923781|NCT03703362|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
33923782|NCT05765292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
33923783|NCT01619592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923784|NCT03850418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923785|NCT01587300|||OTHER||PROSPECTIVE|||||||
33923786|NCT02059122|||CASE_ONLY||OTHER|||||||
33923787|NCT05520918|NA|SEQUENTIAL||DIAGNOSTIC||NONE||"Two parallel groups enrolled for baseline LIT scores, that are healthy subjects and COVID-19 pneumonia patients.~The sequential LIT score were recorded for COVID-19 pneumonia patients during ICU length."||||
33923788|NCT04560140|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33923789|NCT05594433|NA|SINGLE_GROUP||OTHER||NONE||||||
33923790|NCT00119236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923791|NCT01250756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698437|NCT01006460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002892|NCT03696043|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Target of 100 participants - 50% freehand EVD placement and 50% image guided EVD placement. Randomization is every other patient will received image guided EVD placement|Target of 100 participants - 50% freehand EVD placement and 50% image guided EVD placement. Randomization is every other patient will received image guided EVD placement|t|f|f|f
33698438|NCT00121095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698439|NCT00136123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698440|NCT04596800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-Blind (surgeons and anesthesiologists)||f|f|t|f
33698441|NCT05153538|||COHORT||RETROSPECTIVE|||||||
33698442|NCT05885854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698443|NCT02380027|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33698444|NCT04087174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will include up to approximately 87 evaluable patients, divided among the 4 study parts.||||
33786353|NCT03888820|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The participant, investigator, and statistician will be blind to the intervention received|Participants will be randomly assigned 1 of 2 topicals, Gel A or Gel B. Upon completion of study procedures they will return for a second testing session and receive the other topical|t|f|t|t
33786354|NCT06356207|||COHORT||PROSPECTIVE|||||||
33923792|NCT03979846|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33923793|NCT03299036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923794|NCT04397029|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33923795|NCT00309257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923796|NCT06206902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923797|NCT04791930|||CASE_CONTROL||PROSPECTIVE|||||||
33923798|NCT04142749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33923799|NCT04880265|||COHORT||PROSPECTIVE|||||||
33923800|NCT04906486|||CASE_CONTROL||PROSPECTIVE|||||||
33923801|NCT03182413|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33923802|NCT05794789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923803|NCT03097614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923804|NCT05382702|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33923805|NCT03342937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923806|NCT00345540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923807|NCT01601951|||COHORT||PROSPECTIVE|||||||
33923808|NCT02022033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923809|NCT01949298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33923810|NCT01106482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923811|NCT03228498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Participant, Investigator)||t|t|t|t
33923812|NCT04624217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923813|NCT04763590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923814|NCT02659475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923815|NCT05923892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923816|NCT06056128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923817|NCT01566591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33923818|NCT02621619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923819|NCT03556748|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial||||
34002893|NCT06048887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002894|NCT06160388|||COHORT||RETROSPECTIVE|||||||
34002895|NCT02262741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002896|NCT05586724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002897|NCT06239844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||The proposed study builds on a successful local model of asthma navigation and care coordination to support meeting social determinants of health (SDOH) needs using a lay health worker model that has improved asthma outcomes among urban racial/ethnic minority school children. This model is currently being disseminated via community-engaged processes to select school districts across Colorado. Community advisory board members from that initiative identified increasing language inclusivity as a priority in program dissemination.|f|f|t|t
34002898|NCT03716895|||COHORT||PROSPECTIVE|||||||
34002899|NCT02813382|||COHORT||PROSPECTIVE|||||||
34002900|NCT06074640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002901|NCT00065117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002902|NCT02277951|||COHORT||PROSPECTIVE|||||||
34002903|NCT06024382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002904|NCT04307849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34002905|NCT06677671|||OTHER||PROSPECTIVE|||||||
34002906|NCT01245491||CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34002907|NCT00799708|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34002908|NCT03460899|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002909|NCT04315779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698445|NCT06261060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698446|NCT04216121|||COHORT||PROSPECTIVE|||||||
33698447|NCT01747226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698448|NCT02674776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698449|NCT01349179|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698450|NCT06205966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33923820|NCT00595257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923821|NCT05497076|||COHORT||PROSPECTIVE|||||||
33923822|NCT00425113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923823|NCT02908633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33923824|NCT01570933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923825|NCT04735393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923826|NCT00795171|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33923827|NCT04397796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923828|NCT01837017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33923829|NCT01817647|||CASE_ONLY||PROSPECTIVE|||||||
33923830|NCT06379438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923831|NCT00554463|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33923832|NCT01882777|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923833|NCT01225120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923834|NCT03057951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923835|NCT00071851|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33923836|NCT02899377|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923837|NCT00810459|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33923838|NCT05200884|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant will be blinded, the drug administrator will be blinded too, and the investigator who will give the treatment and explain the pain scale to the participant and ask him\\her to point to the face that fits the degree of his pain that associated with the drug administration will also be blinded.|A randomized, controlled, crossover, double-blind clinical study, Comparison of articaine 4% and lidocaine 2%|t|f|t|f
33923839|NCT02790710|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33923840|NCT05082064|||COHORT||PROSPECTIVE|||||||
33923841|NCT05610657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33923842|NCT04948814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923843|NCT03966729|||COHORT||RETROSPECTIVE|||||||
34002910|NCT04436133|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090043|NCT03366584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The neonates outcomes, hyaline membrane disease and feeding intolerance, will be assessed for maximum period of 4 weeks by doctor who in charge in NICU. They are outside the research team and blind to maternal treatment allocation.|The research will be held in Cipto Mangunkusumo General Hospital. Each participant of each group will be given dexamethasone 2x6 mg intravenous for 2 days which aims to support lung maturation followed by planned delivery within 1 week due to indication of maternal or fetal. The maternal dan cord blood sample are obtained for zinc, vitamin A and 25(OH)D levels examinations. Randomly, subjects will be divided into 2 groups which are group who is given the oral beta-carotene 25,000 IU, oral vitamin D3 50,000 IU and oral zinc 50 mg/day for 3 days, and group who is not given the intervention. After the premature neonates was born, observation will be done for maximum period of 4 weeks. The presence and severity of HMD and feeding intolerance or NEC will be recorded.|f|f|f|t
34002911|NCT02296957|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33923844|NCT03277625|||CASE_ONLY||PROSPECTIVE|||||||
34002912|NCT00147914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090044|NCT03188185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002913|NCT03267654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002914|NCT05998291|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34090045|NCT05152784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Propensity-matched cohort study||||
33923845|NCT00110474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923846|NCT04645862|||COHORT||PROSPECTIVE|||||||
33923847|NCT04961086|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34002915|NCT00601406||||TREATMENT||NONE||||||
33923848|NCT00222417|||CASE_CONTROL||PROSPECTIVE|||||||
34002916|NCT01148225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002917|NCT06580561|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrolled participants will be randomized in blocks, stratified by biological sex, age, and baseline pain intensity (per protocol)||||
34090046|NCT00141921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090047|NCT02627716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34090048|NCT05442112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not know which arm they are assigned to, and neither will their provider.|Patients will be randomized 1:1 within provider schedules to either receive a secure message containing a set script on wellness-related topics in MS, or no additional information other than that provided by their clinician.|t|t|f|f
34090049|NCT02700841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090050|NCT00777842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090051|NCT00095329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698451|NCT05689710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34090052|NCT05700864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090053|NCT02908230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698452|NCT05906979|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||a pilot RCT will be performed where the first group will receive a BI, the second group will receive a text-only version of PAHO's BI, and the third group will receive information from PAHOLA about the risks of alcohol use.|t|f|t|t
33698453|NCT02103712|||COHORT||PROSPECTIVE|||||||
33698454|NCT06664606|||CASE_ONLY||CROSS_SECTIONAL|||||||
33698455|NCT05529927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923849|NCT05019651|NA|SINGLE_GROUP||OTHER||NONE||Apollo Wearable System||||
33923850|NCT04720937|||OTHER||CROSS_SECTIONAL|||||||
34002918|NCT01041235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002919|NCT02131935|||COHORT||PROSPECTIVE|||||||
34002920|NCT06678074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698456|NCT05883683|||COHORT||PROSPECTIVE|||||||
33698457|NCT00560768|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33923851|NCT00549510|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923852|NCT01826526|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923853|NCT03267771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923854|NCT01812785|||COHORT||PROSPECTIVE|||||||
33923855|NCT05491447|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Group 1 participation is open-label. For Group 1, subjects who consent to participate in the PK portion of the study will not be randomized and will receive BMX-010.~Group 2 is partially blinded. The identification of investigational product is done by lot numbers. The subject will be blinded to the treatment arm and efforts will also be made to maintain a blinded clinical center assessor in this clinical trial. This will be done by ensuring the assessor does not handle the investigational product. Additional efforts may be made to protect the study blinding to ensure at minimum the subject and assessor are blinded, and other staff as appropriate."|Group 1, Group 2|t|f|f|t
33923856|NCT04254432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002921|NCT02658019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002922|NCT03114345|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002923|NCT02441322|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33698458|NCT05770232|||COHORT||RETROSPECTIVE|||||||
33698459|NCT04352946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants in the study will be randomized to either the investigational drug (HCQ) or placebo. The investigational drug and placebo will have identical appearance and be taken at the same frequency and dosage. The administration of the drug and assessment will be blinded. Study arms will be unmasked at the end of the study for the final analysis.|HCW are randomized to either the study drug (HCQ) or placebo.|t|t|t|t
33698460|NCT04558580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698461|NCT00041288|RANDOMIZED|||TREATMENT||||||||
33698462|NCT01518023|||COHORT||PROSPECTIVE|||||||
33698463|NCT04956952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698464|NCT01527175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33698465|NCT00097292|||COHORT||PROSPECTIVE|||||||
33923857|NCT04344145|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923858|NCT01245764|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33923859|NCT00592917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923860|NCT01838590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923861|NCT00397878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923862|NCT04780256|||COHORT||RETROSPECTIVE|||||||
33923863|NCT06185894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923864|NCT03148821|||CASE_ONLY||PROSPECTIVE|||||||
33923865|NCT00051090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923866|NCT01634464|||COHORT||PROSPECTIVE|||||||
33923867|NCT01618318|||COHORT||CROSS_SECTIONAL|||||||
33923868|NCT02693236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923869|NCT03805971|||CASE_ONLY||PROSPECTIVE|||||||
33923870|NCT00617591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923871|NCT00943085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33923872|NCT01847898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923873|NCT01847612|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33923874|NCT02700919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923875|NCT01520584|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33923876|NCT02549248|||COHORT||PROSPECTIVE|||||||
33923877|NCT01977248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923878|NCT06314997|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33923879|NCT00089999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923880|NCT03279341|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||open-label, randomized, reader-blinded, 3-period cross-over study|f|f|t|t
33923881|NCT02889757|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33923882|NCT02715999|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33923883|NCT04568018|||COHORT||PROSPECTIVE|||||||
33923884|NCT03999112|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single case experimental design (SCED). Participants will be randomised to a baseline period, and after either 4, 6 or 8 weeks they will then be allocated to the same intervention.||||
33923885|NCT04919746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923886|NCT04369768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923887|NCT01595438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923888|NCT02545491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33923889|NCT01690715|||COHORT||RETROSPECTIVE|||||||
33923890|NCT05632848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923891|NCT02855138|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33698466|NCT04042181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698467|NCT03276988|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|At Part B, Both independent central efficacy assessors and participants will be masked. Investigators will be unmasked. (The Part A was open-label.)|The Part A (Phase 1) of study has been completed in which 3 single or multiple sequentially assenting doses of GX-30 were investigated. The Part B (Phase 2) is recruiting in current in which each study participant will receive the same multiple doses of GX-30 and THYROGEN® but at different period.|t|f|f|t
33698468|NCT04138069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698469|NCT05510531|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will examine the feasibility, acceptability and preliminary efficacy measures of a quasi-experimental non-equivalent control group 6-week intervention study with repeated measures at baseline, 6 weeks, and 12 weeks.||||
33698470|NCT02187705|||COHORT||PROSPECTIVE|||||||
33698471|NCT05829993|||COHORT||PROSPECTIVE|||||||
33698472|NCT03503136|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33698473|NCT00722800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698474|NCT05078242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698475|NCT00924079|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33923892|NCT02372097|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33923893|NCT04876586|||COHORT||PROSPECTIVE|||||||
33923894|NCT02524756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923895|NCT01610908|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34002924|NCT06678399|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34002925|NCT03473002|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34002926|NCT06043713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002927|NCT06220526|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34002928|NCT02979041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002929|NCT02613286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the surgical nature of the study, only participants were masked to treatment allocation|Proof of concept design (phase II non-inferiority trial)|t|f|f|f
34002930|NCT06073847|||COHORT||PROSPECTIVE|||||||
34002931|NCT02973269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002932|NCT06432140|NA|SINGLE_GROUP||TREATMENT||NONE||VGN-R09b will be injected into bilateral putamen by stereotactic surgery||||
34002933|NCT03638596|RANDOMIZED|PARALLEL||TREATMENT||NONE||random assignment to treatment and control arms||||
34002934|NCT01591915|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34002935|NCT03508154|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34002936|NCT06113913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698476|NCT01844557|||COHORT||PROSPECTIVE|||||||
34002937|NCT04309994|||COHORT||RETROSPECTIVE|||||||
34002938|NCT06003309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002939|NCT02998606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002940|NCT02710240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34002941|NCT03609333|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
34002942|NCT00404625|||CASE_CONTROL||OTHER|||||||
34002943|NCT00003387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698477|NCT00285818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698478|NCT01863420|||COHORT||PROSPECTIVE|||||||
33698479|NCT01743417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698480|NCT02024555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923896|NCT06530121|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled trial with experimental and control groups|t|f|f|t
33698481|NCT02486354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698482|NCT02020577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698483|NCT02437513|||CASE_ONLY||PROSPECTIVE|||||||
34002944|NCT02956135|||CASE_CONTROL||PROSPECTIVE|||||||
34002945|NCT05863845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090054|NCT05568004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33698484|NCT03048916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33698485|NCT03761693|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33698486|NCT02219035|||COHORT||PROSPECTIVE|||||||
33698487|NCT05657431|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33698488|NCT01864941|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33923897|NCT02539303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923898|NCT06000436|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33923899|NCT05460572|NA|SINGLE_GROUP||OTHER||NONE||||||
33923900|NCT01165918|||COHORT||PROSPECTIVE|||||||
33923901|NCT00650182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33923902|NCT05759546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923903|NCT03024840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33923904|NCT03358654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923905|NCT06114004|NA|SINGLE_GROUP||TREATMENT||NONE||each cohort (1 and 2) receives the same treatment.||||
33923906|NCT02494440|||COHORT||PROSPECTIVE|||||||
33923907|NCT03498547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33923908|NCT05129787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will be performed by large drapings on wounds and masking of operation notes||t|t|f|f
33923909|NCT01189799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923910|NCT06317922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"There are two teams:~1. MASKED TEAM: Sub-investigators and study coordinators delegated to perform the following tasks:~   * dispensation to the patient the Investigational medical device (Thealoz Duo) or saline solution (Hydrabak containing Sodium Chloride 0,9 g, Sodium Dihydrogen Phosphate Dihydrate, Disodium Hydrogen Phosphate Dodecahydrate);~  * accountability of Investigational medical device and saline solution;~  * verify the compliance and therapeutic adherence of the patient;~  * discussion with the patient regarding the respect of the masked condition of the study;~2. UNMASKED TEAMS:~   * informed consent process;~  * to perform the follow-up visit and assessments provided to test the ocular surface."|The participants will be randomized in two arms (treatment arm and control arm) in a ratio of 1:1.|f|t|t|t
33923911|NCT02751021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923912|NCT01721148|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34002946|NCT01958229|||COHORT||PROSPECTIVE|||||||
34002947|NCT05578794|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Valsalva-type Straining (Group I), Spontaneous Straining (Group II), Natural Straining (Group III))||||
34002948|NCT06051409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002949|NCT02773433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090055|NCT05434026|||CASE_ONLY||PROSPECTIVE|||||||
34090056|NCT00070525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090057|NCT00167076|||DEFINED_POPULATION||PROSPECTIVE|||||||
34090058|NCT03653741|NA|SINGLE_GROUP||TREATMENT||NONE||12 healthy males will undergo testing, then receive the drug intervention, followed by blood draw and testing again||||
34090059|NCT01418898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090060|NCT03181997|||COHORT||OTHER|||||||
34090061|NCT05671393|||COHORT||RETROSPECTIVE|||||||
34090062|NCT01104285|||||RETROSPECTIVE|||||||
34090063|NCT06438003|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698489|NCT04576429|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698490|NCT00891007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720158|NCT03637972|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Phase III randomized, open label, multi-center study assessing the impact of filter ventilation. Assigned to ventilated or unventilated cigarettes and either access to ANDS in an experimental marketplace, or no access to ANDS or any other products.||||
33720159|NCT00500851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720160|NCT00277433|||CASE_CONTROL||RETROSPECTIVE|||||||
33720161|NCT03063658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33720162|NCT05844189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720163|NCT04953221|||CASE_CONTROL||PROSPECTIVE|||||||
33720164|NCT00331279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33720165|NCT03032666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720166|NCT01127412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33720167|NCT00390325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720168|NCT02020395|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720169|NCT01818154|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33720170|NCT05990543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720171|NCT03071575|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|||||
33720172|NCT01019642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720173|NCT02979847|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized||||
33720174|NCT04351087|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-treatment parallel-design||||
34002950|NCT01658358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34002951|NCT04515420|||COHORT||PROSPECTIVE|||||||
34002952|NCT01500616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002953|NCT04791371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002954|NCT01360216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34002955|NCT05253430|||COHORT||RETROSPECTIVE|||||||
34002956|NCT04523480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002957|NCT01679431|||COHORT||PROSPECTIVE|||||||
34002958|NCT02077881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002959|NCT04346862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002960|NCT01961245|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002961|NCT00499824|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34002962|NCT06579417|||COHORT||PROSPECTIVE|||||||
34002963|NCT02833831|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34002964|NCT06440863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002965|NCT01861249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002966|NCT05122858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002967|NCT04437277|NA|SINGLE_GROUP||PREVENTION||NONE||Monocentric interventional longitudinal risk and minimal constraint study, consenting and consecutive in-patients recruited within the hospital||||
34002968|NCT03776929|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34002969|NCT00943280|||COHORT||PROSPECTIVE|||||||
34002970|NCT05824949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34002971|NCT05361343|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34002972|NCT04540692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002973|NCT05522634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002974|NCT05005637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34002975|NCT03264664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002976|NCT05517174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34002977|NCT00806962|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34002978|NCT05271227|||COHORT||PROSPECTIVE|||||||
33786355|NCT02513966|||OTHER||RETROSPECTIVE|||||||
34002979|NCT04162197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34002980|NCT05970614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only participants were blinded in the study.|randomized controlled trial with control and intervention groups|t|f|f|f
34002981|NCT00006434||||TREATMENT||NONE||||||
34002982|NCT01869556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34002983|NCT01559558|||CASE_ONLY||RETROSPECTIVE|||||||
34002984|NCT06569758|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34002985|NCT01546727|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34002986|NCT06660121|||COHORT||PROSPECTIVE|||||||
34002987|NCT03092388|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34002988|NCT04834895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090064|NCT05272917|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34090065|NCT03060928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34090066|NCT04089319|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34090067|NCT04084704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090068|NCT02687828|||CASE_ONLY||PROSPECTIVE|||||||
34090069|NCT06232343|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34090070|NCT05226377|||CASE_ONLY||PROSPECTIVE|||||||
33786356|NCT04795089|||CASE_CONTROL||PROSPECTIVE|||||||
34002989|NCT00516087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002990|NCT01571817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002991|NCT05306600|||COHORT||PROSPECTIVE|||||||
34002992|NCT04233216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34002993|NCT06468722|||COHORT||PROSPECTIVE|||||||
34002994|NCT04262739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34002995|NCT02254109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34002996|NCT00562120|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34002997|NCT01115933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34002998|NCT04374422|||COHORT||PROSPECTIVE|||||||
34002999|NCT00114322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34003000|NCT06239428|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34003001|NCT03710707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003002|NCT00002224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003003|NCT01042548|||CASE_CONTROL||PROSPECTIVE|||||||
34003004|NCT01535911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003005|NCT00388063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003006|NCT04834336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003007|NCT00915434|RANDOMIZED|CROSSOVER||||NONE||||||
34003008|NCT03911180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003009|NCT02874950|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003010|NCT05795439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group will be asked to stay on their usual diet.|One arm, the intervention group, will be randomly assigned to be on a low-fat vegan diet for the duration of the study. The other arm, the control group, will maintain their pre-study diet for the duration of the study.|f|f|t|f
34003011|NCT03316976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003012|NCT00200655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003013|NCT03127306|||COHORT||PROSPECTIVE|||||||
34003014|NCT01733576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34003015|NCT06677580|||COHORT||OTHER|||||||
34003016|NCT04636541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The research was a single blind randomized comparative study. After the screening evaluation, participants were randomly assigned to either group A or B, described below (block randomization, three blocks of four participants).|Comparison of two different cognitive intervention (two groups, randomized, single blinded)|t|t|f|t
33786357|NCT02334306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33786358|NCT01126840|||CASE_ONLY||PROSPECTIVE|||||||
33786359|NCT02430532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786360|NCT06540287|||COHORT||CROSS_SECTIONAL|||||||
33786361|NCT05021419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786362|NCT05493722|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|A study coordinator who is blinded to the chosen stimulation setting will check the data daily to ensure the patient is wearing the device properly and recording seizure events. At each optimization visit, the MoCA and QOLIE-10P surveys will also be administered to the participants by a member of the research team who is blinded to the group the participant is assigned to.|Participants will be randomly assigned to a stimulation order at the baseline visit with optimized settings (OS) stimulation occurring for a total of 8 months and physician-selected settings (PS) stimulation chosen for a total of 4 months. For example, a patient may undergo PS setting stimulation from 4-8 months, then undergo OS setting stimulation from 8-12 and 12-16 months. Thus, there are three possible stimulation groups (1. PS, OS, OS; 2.OS, PS, OS; 3. OS, OS, PS).|f|f|t|t
33786363|NCT01751997|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786364|NCT01579656|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33923913|NCT01532570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923914|NCT03007719|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923915|NCT04307173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923916|NCT00799760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33923917|NCT04712799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923918|NCT01641718|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33923919|NCT04469816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923920|NCT01265342|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33923921|NCT02213822|||CASE_ONLY||PROSPECTIVE|||||||
33923922|NCT01697852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923923|NCT05121831|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blind|Part 1 and Part 2 of the study will have a parallel assignment and Part 3 of the study will have a parallel assignment with a crossover design.|t|f|t|f
33923924|NCT02900807|||COHORT||PROSPECTIVE|||||||
33923925|NCT01725256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923926|NCT03428256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923927|NCT00200512|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33923928|NCT05438459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923929|NCT03907787|NA|SINGLE_GROUP||TREATMENT||NONE||One-group pretest-posttest quasi-experimental design||||
33923930|NCT01267604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923931|NCT01693718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923932|NCT00599170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923933|NCT03999541|RANDOMIZED|PARALLEL||OTHER||NONE|Blinding of the allocated intervention is not possible.|||||
33923934|NCT00383578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923935|NCT01280266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33923936|NCT01293006|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33786365|NCT00000988||||TREATMENT||NONE||||||
33786366|NCT06713798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923937|NCT00583661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923938|NCT04563819|||OTHER||OTHER|||||||
33923939|NCT04137562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and efficacy outcome assessor will be blinded||t|f|f|t
33923940|NCT03273504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923941|NCT01001364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923942|NCT05149612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will not be told which group they are in. In order to avoid bias in the data collection phase, support will be received from the nurses working in the general surgery service independently of the research, and from the independent statistical expert, apart from the researcher, in the database of the research.|The individuals in the sample group will be divided into two groups as the hot application group and the control group. Individuals in the control group will not be treated with heat.|t|f|f|t
33923943|NCT06244537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923944|NCT04932044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33923945|NCT00264121|||||PROSPECTIVE|||||||
33923946|NCT02593968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33923947|NCT02249026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923948|NCT04994080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multi-center, randomized, double-blind, parallel grouping, placebo-controlled phase 3 study|t|t|t|t
33923949|NCT04435561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33923950|NCT02156804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923951|NCT00249795|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33923952|NCT03437044|RANDOMIZED|PARALLEL||TREATMENT||NONE|Staff performing PK/PD assessments will remain blinded to treatment assignment.|Prospective randomized||||
33923953|NCT06282536|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients received Iruplinalkib neoadjuvant therapy.||||
34090071|NCT02691572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090072|NCT00358488|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34090073|NCT03434262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase 1 limited dose escalation to define RP2D of the doublets with an early expansion cohort to evaluate preliminary efficacy.||||
34090074|NCT00390962|||COHORT||PROSPECTIVE|||||||
33720175|NCT00157703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923954|NCT02584413|NA|SINGLE_GROUP||SCREENING||NONE||||||
33923955|NCT06528054|||COHORT||RETROSPECTIVE|||||||
33923956|NCT01539213|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720176|NCT02703909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33923957|NCT01272817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33923958|NCT00818311|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33923959|NCT01538147|||CASE_CONTROL||PROSPECTIVE|||||||
33923960|NCT06138990|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a randomised, controlled, parallel group, superiority interventional trial.||||
33923961|NCT04844242|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923962|NCT05445479|||CASE_CONTROL||RETROSPECTIVE|||||||
33923963|NCT03118011|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923964|NCT03772340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33923965|NCT03316677|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33923966|NCT01988597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33923967|NCT03124901|NA|SINGLE_GROUP||OTHER||NONE||||||
33923968|NCT04904380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized cluster trial||||
33923969|NCT02181036|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33923970|NCT06271928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923971|NCT03116334|||COHORT||CROSS_SECTIONAL|||||||
33923972|NCT03830255|||COHORT||PROSPECTIVE|||||||
33923973|NCT04255277|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The Thorough QT/QTc prolongation (TQT) study is a double-blind parallel study. The accelerated elimination and the combined oral contraceptive pharmacokinetic drug-drug-interaction are open-label.|Period 1: Pharmacokinetic study, Period 2: Thorough-QT and Drug-drug-interaction study. Period 3: Accelerated elimination study.|t|t|t|t
33923974|NCT04172701|||COHORT||RETROSPECTIVE|||||||
33923975|NCT04796428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33923976|NCT03260907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33923977|NCT02253017|||COHORT||PROSPECTIVE|||||||
33923978|NCT01213498|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33923979|NCT00745381|||COHORT||PROSPECTIVE|||||||
33923980|NCT02292498|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33923981|NCT01664858|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923982|NCT02705768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923983|NCT05194787|||COHORT||PROSPECTIVE|||||||
33923984|NCT06139536|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33923985|NCT01691053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720177|NCT05187793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720178|NCT02445482|||COHORT||PROSPECTIVE|||||||
33720179|NCT01909479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720180|NCT02402309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720181|NCT02188290|||COHORT||RETROSPECTIVE|||||||
33720182|NCT01364662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720183|NCT01453634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720184|NCT02993068|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33923986|NCT00655057|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33923987|NCT01924299|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33923988|NCT03655587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessor blinded to the intervention type|Each group gets one of the 2 types of orthotics.|f|f|f|t
34003017|NCT05099133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003018|NCT01785615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003019|NCT04832776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003020|NCT01422486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003021|NCT05413733|RANDOMIZED|PARALLEL||OTHER||SINGLE|Digital care pathway is part of the daily neurological treatment at HUS. Care providers will be clinical neuropsychologists who do not know if their patient is involved in the study or not.|A parallel-group randomized controlled trial|f|t|f|f
34003022|NCT03525249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003023|NCT06125002|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34003024|NCT00510003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003025|NCT03617120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003026|NCT06361472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Due to the nature of the study, blinding of both therapists and patients will not be feasible. However, to uphold the scientific validity of the study, specific descriptors and methodological details, such as terms like placebo or CFs, have been intentionally excluded from the consent disclosure. To prevent any potential bias in participants' perceptions, information regarding the potential involvement of CFs in outcomes will not be provided. Instead, participants will be informed that the study aims to assess changes resulting from standard treatment for MNP. The person in charge of data statistical analysis (FV) and the evaluators who will assess all participants' pre- and post-intervention assessments (MLL and AR) will be blinded to the allocated intervention."|The ContextualizAR trial is designed as a two-arm, randomized, controlled, and blinded assessor superiority trial conducted at a single center. Patients will be allocated to one of two groups: a CFs+SC group and the SC group.|f|f|f|t
34090075|NCT04089722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090076|NCT06018103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician performing the analysis will be masked. It is not possible to mask the participant nor the investigator due to the nature of the intervention (group learning programme on mindfulness)|Randomized Control Trial of two groups: Treatment (MBCT-vision), or Control (wait-list, standard of care)|f|f|f|t
34003027|NCT02255890|||COHORT||PROSPECTIVE|||||||
34090077|NCT00036400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003028|NCT06338423|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090078|NCT05472844|||COHORT||PROSPECTIVE|||||||
34090079|NCT02485769|RANDOMIZED|||TREATMENT||TRIPLE|||t|t|t|f
34090080|NCT06262867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003029|NCT02720549|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090081|NCT01816607|||COHORT||PROSPECTIVE|||||||
34003030|NCT01280227|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003031|NCT02650973|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34003032|NCT01545206|||COHORT||RETROSPECTIVE|||||||
34003033|NCT02569541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003034|NCT03681587|||COHORT||PROSPECTIVE|||||||
34003035|NCT00128141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003036|NCT00683592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090082|NCT04807413|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33720185|NCT05867472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open label trial that will be blinded to the outcome assessor and data analyst, but not to the clinical team. Blinding is not feasible for the clinical team and patient / family given the easily identifiable differences in the nature of the essential equipment used between the two arms.|Pilot, multicenter, vanguard randomized controlled trial (RCT) to assess the feasibility of accruing patients, delivering the intervention of inhaled sedatives, and ascertaining outcomes in preparation for a definitive trial to evaluate if inhaled sedatives (intervention) compared to IV agents (comparator) improves delirium (outcome) in mechanically ventilated children (population).|f|f|f|t
33720186|NCT04034173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33923989|NCT06271239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessments will be conducted by trained researchers|"In the Intervention Group (ViviFrail), participants will perform a six-month VIVIFRAIL® protocol-based exercise, adapted to their clinical profile.~The Group Suggestions for a Healthy Life (CG) will receive exercise suggestions and guidance for maintaining a healthy routine for three months. After, they will undergo a three-month intervention using the VIVIFRAIL® protocol.~Sample size determination was based on Casas-Herrero et al. (2022). The study assessed the impact of multicomponent training on intrinsic functional capacity, utilizing the Short Physical Performance Battery (SPPB) to gauge balance, gait speed, and lower limb strength on a 0 to 12 scale. Control group: -0.33±1.60 point difference; Treatment group: 1.07±1.52 point difference.~Considering a 5% alpha and 80% power, 20 participants per group are required. Anticipating a 25% dropout rate, as observed by Tiecker (2021), we plan to enroll 25 participants per group."|f|f|f|t
33923990|NCT02568163|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33923991|NCT02148211|||COHORT||PROSPECTIVE|||||||
33923992|NCT02549963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33923993|NCT05060172|NA|SINGLE_GROUP||OTHER||NONE||||||
33923994|NCT03780491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33923995|NCT04791787|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomized into 3 groups. Each group will be assigned to one of 4 arms.||||
33923996|NCT05389956|||COHORT||PROSPECTIVE|||||||
33923997|NCT01410799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33923998|NCT05798806|||COHORT||RETROSPECTIVE|||||||
33923999|NCT01052519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924000|NCT03779061|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single (Participant)||t|f|f|t
34090083|NCT02490163|RANDOMIZED|CROSSOVER||||NONE||||||
34090084|NCT00674297|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090085|NCT03345797|NON_RANDOMIZED|PARALLEL||OTHER||NONE||dual arm: naïve vs TRT experienced||||
34090086|NCT05330949|||CASE_CONTROL||PROSPECTIVE|||||||
34090087|NCT06066593|||CASE_CONTROL||PROSPECTIVE|||||||
34090088|NCT04454606|NA|SINGLE_GROUP||PREVENTION||NONE||N99 respirators will be tested in a group of subjects with qualitative fit test.The filters will be tested for filtration test.The results will be considered as pass or fail||||
34090089|NCT02323009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090090|NCT05926921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720187|NCT00519818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720188|NCT05742438|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33720189|NCT05766007|||COHORT||PROSPECTIVE|||||||
33720190|NCT06221904|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33720191|NCT02653560|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33720192|NCT02946047|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33924001|NCT04491214|||COHORT||PROSPECTIVE|||||||
33924002|NCT01270958|NA|SINGLE_GROUP||||NONE||||||
33720193|NCT02252198|||COHORT||PROSPECTIVE|||||||
33924003|NCT03472794|||CASE_ONLY||PROSPECTIVE|||||||
33924004|NCT01078519|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924005|NCT02578472|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33924006|NCT05868980|||CASE_ONLY||PROSPECTIVE|||||||
33924007|NCT03657810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924008|NCT00958516|NA|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33924009|NCT01511510|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33924010|NCT04746560|||OTHER||PROSPECTIVE|||||||
33924011|NCT04583761|||COHORT||PROSPECTIVE|||||||
33924012|NCT00728936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924013|NCT02267226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924014|NCT02482012|||COHORT||PROSPECTIVE|||||||
33924015|NCT03419936|||CASE_ONLY||PROSPECTIVE|||||||
33924016|NCT02972957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924017|NCT00738829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924018|NCT05186987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924019|NCT02309814|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924020|NCT04254055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924021|NCT01993056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924022|NCT04666025|||COHORT||PROSPECTIVE|||||||
33924023|NCT02131246|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924024|NCT01684735|||COHORT||PROSPECTIVE|||||||
33924025|NCT01367314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924026|NCT03917082|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase II study exploring reducing the duration of endocrine therapy from five to two years in low risk population with early breast cancer||||
33924027|NCT04392869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Investigator: researchers have no information on participants' allocation in the groups; a research assistant from the Cognitive Neuroscience Group is designated for this purpose. None of the participants are students of any of the researchers. For the purpose of communicating with the participants over group allocation, another lecturer from the Translation Department is appointed. Outcome Assessors: all measures except one are collected online via the UGR LimeSurvey platform and no recording of group assignment is introduced in the system. The only face-to-face measure is administered at the baseline by another member who is blind to hypothesis. Care providers: they are not informed about the outcome measures or specific research hypothesis regarding expected effects for each program. Participants: although it is not possible to blind their assignment to the groups, they are not informed about the specific hypothesis regarding the expected outcomes of the programs.|Students are randomly assigned to two groups: the MBSR group that receives an extended and adapted version of the MBSR program and the CRAFT group that receives an extended and adapted version of the CRAFT. All participants are asked to fill in an informed consent and a demographic questionnaire to determine eligibility. Eligible participants are randomly assigned to either the MBSR group or the CRAFT group. Both programs are taught simultaneously. The outcome measures will be evaluated against a third group who receives no intervention at all and could not be randomly assigned. This passive control group is formed with students from the same courses as experimental participants.|t|t|t|t
33924028|NCT02168881|RANDOMIZED|PARALLEL||||NONE||||||
33924029|NCT06334172|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The randomized order of infusions is blinded to both participant and investigator|Randomized, double-blinded, single-arm study. Each participant goes through three experimental days in a randomized order - acting as their own controls|t|f|t|f
33924030|NCT02958904|||||CROSS_SECTIONAL|||||||
33924031|NCT02409056|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33924032|NCT00395213|||COHORT||PROSPECTIVE|||||||
33924033|NCT03181841|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|double-blind||t|t|t|t
33698491|NCT03267251|RANDOMIZED|PARALLEL||PREVENTION||NONE||This research project will compare usual care clinic-based communication about HPV vaccination (UC) to usual care plus web-based dissemination (UC+GHG) of information on HPV vaccination to parents and adolescent girls using a pair-matched group-randomized pretest-posttest design protocol. Pediatric/family practice clinics in New Mexico (n=30 clinics) will be pair-mated and one clinic per pair will be randomized to UC+GHG condition via the website, GoHealthyGirls.org. The remaining clinic will continue to receive UC only. Assessment protocols will be conducted at pretest, 3-month follow-up, and 9-month follow-up points, measuring knowledge, compatibility and relative advantage principles in DI, shared decision making, and vaccine adoption by girls. Thus, the proposed trial design will be a 2 (UC v. UC+GHG) intervention x 3 (level of time - pretest vs. 3-month follow-up vs. 9-month follow-up) mixed factorial design with participants nested within clinics.||||
33698492|NCT02409212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698493|NCT00291889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698494|NCT04910958|||COHORT||RETROSPECTIVE|||||||
34003037|NCT00000243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698495|NCT00632840|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33698496|NCT04098848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698497|NCT01044706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786367|NCT06249789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome evaluators and analysts would be unaware of which treatment the participants received.|"Research Design \& Procedures: Patients will be categorized into two groups:~Arm A (spinal anesthesia):~Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block (FICB) injection.~A single-shot spinal anesthetic will be administered. Propofol will be used for intraoperative sedation, ensuring patient responsiveness.~Fentanyl will be given as needed for pain relief.~Arm B (general anesthesia):~Patients will receive an ultrasound-guided Fascia Iliaca Compartment Block (FICB) injection.~A general anesthetic will be administered using appropriate airway management devices, with Propofol infusion for maintenance."|f|f|f|t
33786368|NCT03582956|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33786369|NCT05809076|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33786370|NCT06631963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786371|NCT06517472|||CASE_ONLY||PROSPECTIVE|||||||
33786372|NCT04632615|||COHORT||CROSS_SECTIONAL|||||||
33924034|NCT02722772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924035|NCT05648838|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33924036|NCT03024255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924037|NCT05456412|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Clinical practice protocol is followed. Additional biopsies and blood samples are taken.||||
33924038|NCT02270801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698498|NCT04454164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698499|NCT02344862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698500|NCT04390061|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter open label randomized controlled trial||||
33698501|NCT04738487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698502|NCT01785420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698503|NCT02932423|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33698504|NCT06319131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698505|NCT01491971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786373|NCT06124118|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Bayes optimal interval design (BOIN)||||
33786374|NCT03824652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786375|NCT01718132|||COHORT||PROSPECTIVE|||||||
33786376|NCT01014338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924039|NCT03814005|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33924040|NCT01473862|||CASE_ONLY||PROSPECTIVE|||||||
33924041|NCT04757922|||COHORT||PROSPECTIVE|||||||
33924042|NCT01142193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924043|NCT05733260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924044|NCT01349985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924045|NCT03214926|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective uncontrolled pilot study||||
33924046|NCT00696436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924047|NCT06186804|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be instructed to take a specified dose of ABSK021 at the same time each day. In Cycle 1, the patient should take one dose every morning after waking up; After the 15th day of the 1st cycle, the specified dose may be taken in the morning or evening, but should be taken at the same time every day.||||
34003038|NCT05907148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003039|NCT04716829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003040|NCT06677775|||COHORT||PROSPECTIVE|||||||
34003041|NCT01135264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003042|NCT00781079|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34003043|NCT03407222|RANDOMIZED|PARALLEL||TREATMENT||NONE||Send text messages which encourage step-by-step increment of daily step count||||
34003044|NCT02346149|NA|SINGLE_GROUP||OTHER||NONE||IV administration of 0.15 g/kg of glucose in a 20% solution under standard hydration and fasting conditions||||
34003045|NCT02026362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003046|NCT04224948|NA|SINGLE_GROUP||SCREENING||NONE||||||
34003047|NCT04573309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003048|NCT02861651|||COHORT||RETROSPECTIVE|||||||
34003049|NCT02470182|||CASE_ONLY||CROSS_SECTIONAL|||||||
34003050|NCT00002228||||TREATMENT||||||||
34003051|NCT06679647|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34003052|NCT04694703|||COHORT||PROSPECTIVE|||||||
34003053|NCT05388474|||COHORT||PROSPECTIVE|||||||
34003054|NCT05034185|||COHORT||PROSPECTIVE|||||||
34003055|NCT05906927|||COHORT||CROSS_SECTIONAL|||||||
34003056|NCT00465660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34003057|NCT01688882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003058|NCT01105845|||||PROSPECTIVE|||||||
34003059|NCT00020839|RANDOMIZED|||TREATMENT||||||||
34103175|NCT00767312|||CASE_ONLY||PROSPECTIVE|||||||
34003060|NCT03852524|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants will be randomized in a 1:1 fashion to receive methylnaltrexone or placebo. Participants will remain in the group they are randomized to for the duration of the study.|t|t|t|f
34003061|NCT02058160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003062|NCT05413512|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003063|NCT06678425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial, Double-blind, Sham-controlled trial|t|f|f|t
34003064|NCT03544840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003065|NCT04802213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003066|NCT00199901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003067|NCT01186562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003068|NCT06401941|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34003069|NCT05911919|||COHORT||PROSPECTIVE|||||||
34003070|NCT02681588|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34003071|NCT00298987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003072|NCT03701126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698506|NCT03737604|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unable to mask based on physical characteristics of liposomal bupivacaine|||||
33698507|NCT01336296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698508|NCT04274387|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||one group took MBSR course the other group serve as passive control group||||
33698509|NCT00921401|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33698510|NCT05272878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Treatments will be conditioned and labelled by the Contract manufacturing organization AGEPS according to a list provided by an independent person and assigning a treatment arm to each treatment number.~Randomization and treatment numbers lists are kept strictly confidential until the time of unblinding, and will not be accessible by anyone involved in the study, with the exception of the independent, unblinded statistician approving the randomization scheme; the study will be kept blinded to patients, investigators and study personnel also during the entire study period; The identification of treatment will be concealed by the use of a matching placebo to the study product that will be provided in boxes identical in packaging, labeling and appearance"||t|f|t|f
33698511|NCT03855956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33698512|NCT02715245|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33698513|NCT01554085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698514|NCT01638364|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33698515|NCT01013350|||OTHER||PROSPECTIVE|||||||
33698516|NCT02932215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698517|NCT01800396|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33698518|NCT03839498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698519|NCT02337270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698520|NCT03403374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698521|NCT02772055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924048|NCT04154371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924049|NCT05826990|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33924050|NCT03487393|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective||||
33924051|NCT04593875|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All participants complete two identical in-person testing and LIFUP sessions. At one session, the device will be used with a gel pad that allows ultrasound to pass through, and at the other session, it will be used with a gel pad that blocks the ultrasound. The order of conditions is randomized and counterbalanced across participants. The two gel pads look identical beyond a label differentiating them, and neither the participants nor the person administering ultrasound will know whether sham or active is being administered at a given session.|Participants will be assigned to both study arms; the order in which they complete the arms will be randomized and counterbalanced. The two visits will be spaced apart by 2 weeks.|t|t|f|t
33924052|NCT03614819|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|"Diode laser group Prophylaxis of the selected region for the study and application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2.~Glass Ionomer Sealing Group Prophylaxis of the selected region for the study, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material."||||
33924053|NCT00789646|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33924054|NCT06006910|||COHORT||PROSPECTIVE|||||||
33924055|NCT00169910|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003073|NCT06471179|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34003074|NCT06462118|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34003075|NCT02502968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003076|NCT03095950|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
34003077|NCT00054834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003078|NCT04592419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For masking purposes, sham injections will be administered at every monthly visit if an active treatment is not administered. To preserve masking, two investigators are required for this study. The masked Investigator will be responsible for the examinations and safety assessments. The unmasked Investigator will perform the injections and post-treatment assessments.|"Participants will be randomized 1:1 into one of two treatment arms: KSI-301 or aflibercept.~Participants in the Extension Phase will be treated with KSI-301."|t|t|f|t
34003079|NCT00758758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003080|NCT02673034|||COHORT||PROSPECTIVE|||||||
34003081|NCT04952467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003082|NCT05891119|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003083|NCT05916716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698522|NCT06678971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090091|NCT04684316|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|Participants are partially masked: if a participant is invited for a consultation with the occupational physician, they do not know whether this is because they are in the control group, or because they were in the intervention group and selected on the basis of their scores. Participants that do not see the occupational physician can deduce that they are part of the intervention group. Care providers, investigators, and outcomes assessors know to which group an individual pertains as this is required for the intervention.|Employees within the same hospital are prospectively and randomly allocated to one of two groups: an intervention group receives an electronic survey with selective follow-up by the occupational physician, and a control group where all employees undergo a periodic health screening by the occupational physician. The survey is thus used as part of the intervention, as an algorithm (based on a scoring system of the survey) which determines who should be seen by the occupational physician is evaluated. However, the survey is also used to gather data on how the selective referral affects outcomes. There are three measurement moments (each time with the same survey, and in both groups). First, baseline outcomes are measured in June 2019, after which selective follow-up in the intervention group and contact with the OP in the control group is organised in June-December 2019. Differences in outcomes between groups are then measured in February 2020, and in September 2020.|t|f|f|f
34090092|NCT03310047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"The process of intervention-implementation and intervention will not be in the participant's line of sight.~Investigators will not be in the room during the intervention. Outcome assessors will not be in the room during the intervention."|"We will use a two-armed crossover design.~1. Day one; Right side low dose nerve block and left side high dose nerve block~   * Repeated after 24 hours Day three; Left side low dose nerve block and right side high dose nerve block~  * Repeated after 24 hours~2. Day one; Left side low dose nerve block and right side high dose nerve block~   * Repeated after 24 hours Day three; Right side low dose nerve block and left side high dose nerve block~  * Repeated after 24 hours"|t|f|t|t
34090093|NCT01755299|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34090094|NCT04244539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in the study group received pulsed Nd: YAG laser treatment, produced by a HIRO 3 device (ASA Laser, Arcugnano, Italy). The apparatus provided pulsed emission (1064 nm), very high peak power (3 kW), a high level of fluency (energy density; 360-1780 mJ/cm2), a short duration (120-150 μs), a mean power of 10.5 W, a low frequency (10-40 Hz), a duty cycle of about 0.1%, a probe diameter of 0.5 cm, and a spot size of 0.2 cm2 \[9\].||||
34090095|NCT03829384|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34090096|NCT04674956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participant and investigators are masked.|Patients are assigned into 2 arms randomly of 1：1.|t|t|t|t
34090097|NCT03658772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Cohort 1 to be enrolled before Cohort 2||||
34090098|NCT01887808|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34090099|NCT00636571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34090100|NCT04764890|RANDOMIZED|PARALLEL||TREATMENT||NONE||Electroacupuncture and manual therapy||||
34090101|NCT03777501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized double-blinded controlled trial|f|f|t|t
34090102|NCT03542383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assessors, tDCS administrators, and participants are masked to group assignment. Active and sham tDCS parameters are set up at each session by an experimenter who does not have contact with the participants.|Participants with Gulf War Illness and word finding difficulty will be randomly assigned to either receive active tDCS or sham.|t|t|f|t
34003084|NCT06679296|||COHORT||PROSPECTIVE|||||||
34090103|NCT06424353|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34090104|NCT05098561|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Randomize patients into music treatment group and non-music treatment control group. 30 patients per group. Patients will be enrolled into each group on an alternate bases.||||
33786377|NCT05244447|NA|SINGLE_GROUP||TREATMENT||NONE||"Arms Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 10 weeks. Participants also receive life coaching and ongoing job readiness support.~Assigned Interventions Primary services: Participants receive 12 hours of Relationships Smarts Plus, 3 hours of Mind Matters and 1 hour of Money Habitudes workshops over the course of 10 weeks. Participants also receive life coaching and ongoing job readiness support."||||
34090105|NCT05953727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090106|NCT02705430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786378|NCT00516711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786379|NCT06480656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786380|NCT01526603|NA|SINGLE_GROUP||OTHER||NONE||||||
33786381|NCT04489784|NA|SINGLE_GROUP||TREATMENT||NONE||To evaluate the immediate and long-term effects of infrared laser on classical ballerinas' feet.||||
33801649|NCT03836378|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|A random allocation will be completed (flip of coin) which side will receive the membrane placement. The care provider (hygienist) will be aware of the membrane placement. The investigator and outcome assessor (periodontist) will not know which sites received the membrane placement.|The participant will have half the mouth completed with scaling and root planing alone and half the mouth completed with scaling and root planing with the addition of membrane in deep probing depth sites.|f|f|t|t
33801650|NCT02724956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33801651|NCT02773524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003085|NCT00458159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003086|NCT01889550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34003087|NCT01863355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003088|NCT00842816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003089|NCT04139941|||COHORT||PROSPECTIVE|||||||
34003090|NCT02806791|||COHORT||RETROSPECTIVE|||||||
34003091|NCT05959486|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34003092|NCT01022255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003093|NCT01424098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003094|NCT05491512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003095|NCT00652002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003096|NCT04536506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003097|NCT03343639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003098|NCT00571480|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33698523|NCT02292342|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34003099|NCT01263561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090107|NCT04419259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698524|NCT05280171|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33698525|NCT05733390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698526|NCT04193358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Comparative, interventional, prospective, monocentric, double blind, randomized, placebo controlled trial.|t|t|t|t
33698527|NCT01558739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698528|NCT05882188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698529|NCT05055128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698530|NCT02643030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33698531|NCT03633136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33698532|NCT04613531|||COHORT||PROSPECTIVE|||||||
33698533|NCT00300105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698534|NCT02286583|NA|SINGLE_GROUP||SCREENING||NONE||||||
33698535|NCT00987545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698536|NCT06449898|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The sample size was determined based on the recommendations for validation studies, which suggest a minimum of 5 to 10 participants per item on the scale being validated. Given that the OSS comprises 12 items, a minimum of 60 participants was deemed necessary. However, to account for potential dropouts and to enhance the robustness of the findings, 130 participants were recruited.||||
33698537|NCT03645928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698538|NCT05631600|NA|SINGLE_GROUP||TREATMENT||NONE||Split-mouth study||||
33698539|NCT05117333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|This is a randomized experiment in which individuals receive different types of reminders. All outcome variables are based on administrative (secondary) data. Individuals receiving letters and care providers are not aware of the experiment. Investigators will not have any contact with the participants.|This is a randomized controlled trial with three active treatment arms and a control group (not assigned to any treatment, information and services as usual).|t|t|t|f
33698540|NCT00011661|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698541|NCT00657449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698542|NCT02015585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33698543|NCT05135338|||CASE_ONLY||PROSPECTIVE|||||||
33698544|NCT04044495|NA|SINGLE_GROUP||OTHER||NONE||||||
33698545|NCT06022250|NA|SEQUENTIAL||TREATMENT||NONE||||||
33698546|NCT06209437|||COHORT||PROSPECTIVE|||||||
33698547|NCT05586243|||COHORT||CROSS_SECTIONAL|||||||
33698548|NCT02213354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33698549|NCT03657446|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||3-way cross-over Phase 1 study|t|t|t|f
33698550|NCT05914012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33698551|NCT02759484|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33698552|NCT04379544|||COHORT||PROSPECTIVE|||||||
33720194|NCT04501367|RANDOMIZED|PARALLEL||TREATMENT||NONE||In patients who undergo vitrectomy with internal limiting membrane peel surgery , subjects will be randomized to three groups and be followed for a period of two months. One group will be selected to receive one DEXTENZA (in the lower canaliculus), the second group will receive two DEXTENZA (upper and lower canaliculi) and the third group will receive prednisolone acetate 1% (control eye) . All groups will receive a subconjunctival dexamethasone injection at the time of surgery.||||
33720195|NCT00954850|||CASE_CONTROL||PROSPECTIVE|||||||
33924056|NCT03250156|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"We aim to recruit three groups. Two groups will receive mindfulness training (MBAT) but will differ in their level of duty day support to engage in daily assigned mindfulness exercises. The Proctored group (n = 45) will receive mindfulness training and complete assigned exercises during the duty day, integrated into their daily physical training. The Non-Proctored group (n = 45) will receive identical mindfulness training, but complete their assigned exercises on their own time. These participants will not receive additional duty day support for their practice. A third group will receive no training and serve as a control group (No-Training Control, n = 45).~The design relies on group randomization at the level of individual platoons. This is due to the military requirement that organic unit structure is maintained during testing and course session scheduling. The number of participants is based on prior research (Jha et al., 2017)."||||
33924057|NCT05684588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an experimental (non-pharmacological) diagnostic, pilot and monocentric study||||
33924058|NCT02424006|RANDOMIZED|PARALLEL||TREATMENT||NONE||RHCIII-MPC Biosynthetic Cornea||||
33924059|NCT05015738|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study was conducted between Octorber and November 2020 on 70 volunteer students studying in the Department of Nursing at the Faculty of Health Sciences in Turkey. The inclusion criteria were as follows: (a) being 18 years old or over, (b) studying in the second year, (c) volunteering to take a diabetes course (d) not attending any course for diabetes before e) have a smart phone f) no internet connection problem g) not to be absent on the date when the data of the research will be collected. The second-year nursing students were selected for the study since they have not taken diabetes courses before. The students included in the study were randomly divided into two groups.The control group was taught with the traditional method and the experimental group was taught with learning activities based on animation and gamification.||||
33924060|NCT03771443|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924061|NCT06372197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924062|NCT05648981|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34003100|NCT01256060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003101|NCT02311517|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34003102|NCT01889797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003103|NCT02875028|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34003104|NCT00963430|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34003105|NCT04502706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003106|NCT02411149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103176|NCT03339765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801652|NCT05028673|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The first 3 periods will be randomized.||||
33924063|NCT03798587|||COHORT||OTHER|||||||
33924064|NCT01814826||SEQUENTIAL||OTHER||NONE||||||
33924065|NCT02660866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924066|NCT00648570|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33924067|NCT00422890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924068|NCT04303793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924069|NCT00924729|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33924070|NCT00177957|||COHORT||PROSPECTIVE|||||||
33924071|NCT06161857|||OTHER||PROSPECTIVE|||||||
33924072|NCT05652972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33924073|NCT00709124|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924074|NCT04954352|||COHORT||RETROSPECTIVE|||||||
33924075|NCT06580860|||COHORT||PROSPECTIVE|||||||
33924076|NCT02674685|||COHORT||PROSPECTIVE|||||||
33924077|NCT05113498|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-dose study where all participants consume one epicatechin supplement.||||
33924078|NCT05738772|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924079|NCT05082506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|As a result of the draw, group A was determined as acupressure, group B as sham acupressure and group C as the control group. Since pressure will be applied to the pressure points of the patients in the acupressure and sham group included in the study, the sham (placebo) acupressure and acupressure groups will be blinded, since the patients do not know whether acupressure or sham acupressure is applied. The control group and the researcher cannot be blinded due to the nature of the research.|Since the patients who will be included in the study are not known in advance, the patients will be randomized by the statistician using GraphPad software 3 and the block randomization technique, in order to assign the same number of participants to each group before the study, and will be divided into groups A, B, and C.|t|f|f|f
33924080|NCT01331720|||COHORT||PROSPECTIVE|||||||
33924081|NCT04152642|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||3-treatment crossover, with 4 days of use|t|f|t|f
33924082|NCT00086216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924083|NCT04376099|||COHORT||CROSS_SECTIONAL|||||||
33924084|NCT04712357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized double-blind|Control case|t|f|t|f
33924085|NCT02983799|NA|PARALLEL||TREATMENT||NONE||||||
33924086|NCT03628521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924087|NCT04347278|||OTHER||OTHER|||||||
33924088|NCT02819349|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924089|NCT01517412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924090|NCT03009812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924091|NCT03908905|||COHORT||PROSPECTIVE|||||||
33924092|NCT04063072|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A stepped-wedge cluster randomized clinical trial. Each center starts as control group (usual care) and switch to experimental group (ERAS protocol implementation) according to a randomized order.||||
33924093|NCT02322099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924094|NCT00848445|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33924095|NCT01600001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924096|NCT04809272|NA|SINGLE_GROUP||PREVENTION||NONE||This is a pre-post study with assessments at baseline and immediate post-intervention.||||
33924097|NCT03514888|NA|SINGLE_GROUP||TREATMENT||NONE||HIPEC with Mitomycin-C||||
33924098|NCT03040817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924099|NCT02995213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924100|NCT05364138|||COHORT||RETROSPECTIVE|||||||
33924101|NCT00091962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924102|NCT05800951|||COHORT||PROSPECTIVE|||||||
34103177|NCT05966727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103178|NCT06517927|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Interventionnal study, cohort study||||
34103179|NCT01341990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34103180|NCT06687109|||OTHER||PROSPECTIVE|||||||
34103181|NCT03023683|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34103182|NCT06668025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103183|NCT06627478|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34103184|NCT06683586|||OTHER||CROSS_SECTIONAL|||||||
34103185|NCT06679153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103186|NCT06691451|||COHORT||PROSPECTIVE|||||||
34103187|NCT01630083|RANDOMIZED|PARALLEL||TREATMENT||||||||
34103188|NCT05066139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103189|NCT02769416|||COHORT||PROSPECTIVE|||||||
33698553|NCT03849807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Successful blinding of patients or practitioners in a trial involving a physical intervention such as chiropractic care is virtually impossible.18 This is due to the manual nature of the interventions and the challenges associated with providing appropriate sham procedures.18, 19 However, participants in this trial are highly likely to be naïve to chiropractic care so it is possible they will remain unaware of whether they are in the chiropractic or control group. Some study personnel will be aware of the allocated arm as they will be responsible for logistical aspects of the trial. However, the research specialist collecting and analyzing data during the trial will be blinded to group allocation.||t|f|f|t
33698554|NCT03729466|RANDOMIZED|PARALLEL||TREATMENT||NONE||clinical pilates and control group||||
33698555|NCT01355055|||COHORT||PROSPECTIVE|||||||
33698556|NCT06557720|||COHORT||PROSPECTIVE|||||||
33698557|NCT00122096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698558|NCT00185835|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698559|NCT04423510|||COHORT||RETROSPECTIVE|||||||
33698560|NCT03463304|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33698561|NCT01527851|||COHORT||CROSS_SECTIONAL|||||||
33698562|NCT00092768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698563|NCT00562250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698564|NCT05054036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924103|NCT00617838|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33924104|NCT03419910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924105|NCT00861588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924106|NCT03129412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924107|NCT04035265|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"1. Lupus with synovitis~2. Lupus with joint pain~3. Lupus without synovitis/joint pain~4. Healthy subjects"||||
33924108|NCT02248857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33924109|NCT01692223|||FAMILY_BASED||PROSPECTIVE|||||||
33924110|NCT05102331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924111|NCT00006063||||TREATMENT||||||||
33924112|NCT05466734|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924113|NCT01478295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924114|NCT05306184|||COHORT||PROSPECTIVE|||||||
33924115|NCT00310349|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33924116|NCT04048538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33924117|NCT01185704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924118|NCT02818413|||COHORT||PROSPECTIVE|||||||
33924119|NCT01734096|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33924120|NCT00438919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924121|NCT04079387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924122|NCT01109550|||CASE_CONTROL||PROSPECTIVE|||||||
33924123|NCT00212485|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924124|NCT05152290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924125|NCT03439111|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Participants receive one of two (or more) alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study|t|t|t|f
33924126|NCT04203979|||COHORT||PROSPECTIVE|||||||
33924127|NCT02407912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924128|NCT03745235|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33924129|NCT04902898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924130|NCT05438810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924131|NCT00082043|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33924132|NCT01874119|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33924133|NCT02911818|RANDOMIZED|PARALLEL||TREATMENT||NONE|In the 12 week extension study, participants who are eligible will continue to take liraglutide 3.0 mg in an open fashion. Participants will be randomly assigned in a double-blind fashion to placebo or phentermine.|||||
33924134|NCT04576247|NA|SINGLE_GROUP||OTHER||NONE|Masking is not possible because this is a single-arm exercise study.|||||
33924135|NCT01274117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924136|NCT01055418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33924137|NCT01194869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924138|NCT02971527|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33924139|NCT05016804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924140|NCT03915912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Newly diagnosed malignant glioma patients will participate in six 1-hour mindfulness sessions over the phone, followed by one 1-hour in-person mindfulness session.||||
33924141|NCT01734707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33924142|NCT04238572|RANDOMIZED|PARALLEL||TREATMENT||NONE||200 patients will be randomized. 100 patients operated on in vitro fertilization (50 patients in intervention group, 50 patients in active comparator group) 100 patients operated on venous access port placement (50 patients in intervention group, 50 patients in active comparator group)||||
33924143|NCT05542693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33924144|NCT03509844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome is assessed with CAPS-V by research assistants blind to the patients allocation to treatment arms||f|f|f|t
34003107|NCT02953925|||OTHER||CROSS_SECTIONAL|||||||
34003108|NCT03941795|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003109|NCT04552522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698565|NCT06135480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698566|NCT04493580|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals who were referred to the Personality Disorders Service in Kingston, Ontario, Canada, with a diagnosis of BPD by a psychiatrist or family physician were offered the opportunity to either select in-person DBT skills-building program groups (MPE) or an online format of the program (iDBT).||||
34003110|NCT05486338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698567|NCT06203236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698568|NCT02228434|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33698569|NCT01691898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698570|NCT00253760|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698571|NCT06464575|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33698572|NCT01297920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698573|NCT03947996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel groups: Two groups: Walking exercise and stretching exercise|f|f|t|t
33698574|NCT06681779|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33698575|NCT03090438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698576|NCT01845818|||COHORT||PROSPECTIVE|||||||
33698577|NCT01306812|||||PROSPECTIVE|||||||
33698578|NCT05338359|||COHORT||PROSPECTIVE|||||||
33698579|NCT02340507|RANDOMIZED|CROSSOVER||||NONE||||||
33698580|NCT03733977|||OTHER||PROSPECTIVE|||||||
33698581|NCT05347277|||CASE_ONLY||RETROSPECTIVE|||||||
33698582|NCT03845751|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33698583|NCT05803473|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an investigator-initiated, two-site, prospective randomised open-label blinded endpoint (PROBE) trial.||||
33698584|NCT05959733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be unaware to the type of surgery that they received. The investigator will not be blinded, however, the individuals assessing the outcomes will be.||t|f|f|t
33698585|NCT03996304|||FAMILY_BASED||PROSPECTIVE|||||||
33698586|NCT04815278|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Random 2x2 factorial design. The temporal nature of the phenomenon under study requires individuals (DSS-E participants) are first randomized to the individual-level treatment group, follow them as they are naturally hired into employment settings, and then enroll / randomize / allocate employers to the employer-level treatment group|f|f|f|t
33698587|NCT05014217|||COHORT||RETROSPECTIVE|||||||
33698588|NCT02937428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698589|NCT03309644|||COHORT||RETROSPECTIVE|||||||
33698590|NCT05072366|||OTHER||OTHER|||||||
33698591|NCT03352310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study Group - autologous umbilcial cord blood transfusion~Control Group - standard care"||||
33698592|NCT06443996|||COHORT||PROSPECTIVE|||||||
33698593|NCT03234673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924145|NCT04429152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924146|NCT04868136|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized cross-over study with two conditions. Randomization was stratified by sex||||
33924147|NCT02994381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924148|NCT02328391|||COHORT||PROSPECTIVE|||||||
33924149|NCT03859960|||OTHER||OTHER|||||||
33924150|NCT05845489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924151|NCT01212198|||COHORT||PROSPECTIVE|||||||
33924152|NCT01779596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33924153|NCT05008068|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||Each patient received two implants, one on each side of the arch. One side was treated with PRF alone and the other side with PRF +Simvastatin, at the time of Osteotomy.|t|f|f|f
33924154|NCT00574444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003111|NCT05488119|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34003112|NCT04967651|||OTHER||PROSPECTIVE|||||||
34003113|NCT01489605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003114|NCT02079363|||COHORT||PROSPECTIVE|||||||
34003115|NCT01515150|||COHORT||PROSPECTIVE|||||||
34003116|NCT01990105|||COHORT||PROSPECTIVE|||||||
34003117|NCT02971787|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698594|NCT06221670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698595|NCT00580970|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33924155|NCT03177785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33924156|NCT03393689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924157|NCT06279663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924158|NCT01779648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33924159|NCT00589433|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33924160|NCT05382988|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients had dialysis within 24h before PTX, then were treated with PTX in Otolaryngology Head and Neck Surgery department in Guangdong Provincial People's Hospital by one experienced surgeon. The experimental group was required to take SZC 10g immediately after the blood test at 6 am, while no medical treatment was performed on patients in the control group.||||
33924161|NCT02780596|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33924162|NCT03364634|||COHORT||PROSPECTIVE|||||||
33924163|NCT03846973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924164|NCT03526315|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized controlled trial involving 127 children ages between 4 and 5 years. They will be examined and chosen randomly for the study. One hundred and twenty seven children will be divided equally into three groups: Group 1 will use CPP-ACP twice daily, Group 2 will apply fluoride toothpaste twice daily, Group 3 will apply fluoridated toothpaste and CPP-ACP twice daily. Oral swabs will be collected from children to measure MS levels in terms of (CFU) using Saliva Check Mutans kits ( GC, Asia) for this purpose. Samples will be analyzed for MS colonization before antibacterial agent application (baseline) and at 3, and 6 month intervals.||||
34003118|NCT00007787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003119|NCT06678139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003120|NCT03045822|NA|SINGLE_GROUP||OTHER||NONE|open|||||
34003121|NCT05126212|||OTHER||PROSPECTIVE|||||||
34003122|NCT05610007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34003123|NCT03722108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924165|NCT04386083|||COHORT||RETROSPECTIVE|||||||
33698596|NCT05798156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003124|NCT02760355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924166|NCT06446518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003125|NCT03712202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003126|NCT05426954|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Rehabilitation||||
34003127|NCT01157598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34003128|NCT02752269|||OTHER||CROSS_SECTIONAL|||||||
34003129|NCT04971863|||CASE_CONTROL||PROSPECTIVE|||||||
33698597|NCT06324760|||COHORT||PROSPECTIVE|||||||
34003130|NCT05730452|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Before and after study||||
34003131|NCT05934539|NA|SEQUENTIAL||TREATMENT||NONE||Escalating ALG.APV-527 doses with a starting dose of 0.1 mg/kg and projected 6 dose cohorts will be explored to determine the MTD and/or the RP2D. Part 1 consists of a 3 + 3 dose-escalation examination of ALG.APV-527 single agent therapy in adult patients with RECIST Version1.1-measurable advanced solid tumors. Part 2 consists of Dose Expansion using the RP2D, as determined during Dose Escalation.||||
33698598|NCT02421029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924167|NCT05955157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33924168|NCT03549117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924169|NCT00520637|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33924170|NCT00971633|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924171|NCT05215314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924172|NCT05419414|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924173|NCT00812240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924174|NCT03571217|||COHORT||PROSPECTIVE|||||||
34003132|NCT04795869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003133|NCT02725060|NA|SINGLE_GROUP||OTHER||NONE||||||
34003134|NCT05753982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003135|NCT02684331|||COHORT||CROSS_SECTIONAL|||||||
34003136|NCT02725411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103190|NCT01569763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698599|NCT03949842|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a retrospective pre-switch and prospective post-switch study design. Subjects will be on their usual care for the retrospective pre-switch period of the study, then they are enrolled into the study and switched onto Trelegy or FF/UMEC/VI for the prospective period.||||
33698600|NCT06218368|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33698601|NCT03813043|NA|SINGLE_GROUP||TREATMENT||NONE|The result be found out at the end of the study|Searching the ED90% of Midazolam using Biased coins method in 40 patients undergoing EGD||||
33698602|NCT04370223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924175|NCT00525785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924176|NCT02051205|||COHORT||PROSPECTIVE|||||||
33924177|NCT06526806|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled study||||
33924178|NCT00129194|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33924179|NCT05532540|||COHORT||PROSPECTIVE|||||||
33924180|NCT06295601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33924181|NCT01579552|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924182|NCT06252922|||CASE_CROSSOVER||PROSPECTIVE|||||||
33924183|NCT04213508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double Blind Study ( Both Participants and Investigator are masked ).||t|f|t|f
33924184|NCT02656901|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33924185|NCT02501902|NA|SEQUENTIAL||TREATMENT||NONE||||||
33924186|NCT01089816|||COHORT||PROSPECTIVE|||||||
33924187|NCT05507645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded-endpoint|A multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial|f|f|f|t
33924188|NCT00865189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924189|NCT05579119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924190|NCT03574415|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33924191|NCT05724017|NA|SINGLE_GROUP||OTHER||NONE||in a single group pretest-posttest research design||||
33924192|NCT02333006|NA|SINGLE_GROUP||OTHER||NONE||||||
33924193|NCT04896307|||OTHER||CROSS_SECTIONAL|||||||
33924194|NCT03226561|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924195|NCT03457480|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924196|NCT04991272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924197|NCT04477915|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34103191|NCT05371470|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103192|NCT06397183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698603|NCT03704987|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||To compare bone mineral density of klinefelter patients and normal population||||
33698604|NCT06033053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The recruiter and the person in charge of conducting the experiment will be blind to the experimental condition, as will the participants.|Randomized active-sham group controlled between-subject: Group of healthy individuals will be randomly assigned to the experimental or the sham condition. The experimental group, will learn how to modulate the vmPFC-amygdala functional connectivity, while the sham group will try to modulate the functional connectivity of sham regions not involved in emotion regulation.|t|f|t|f
33698605|NCT04757246|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33924198|NCT03159013|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33924199|NCT00347893|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33924200|NCT02043236|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924201|NCT00498849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103193|NCT02739880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103194|NCT06497829|NA|SINGLE_GROUP||OTHER||NONE||Patients with MVK deficiency compared to healthy controls and to subjects on statin therapy (statins target the same metabolic pathway)||||
34103195|NCT03434899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103196|NCT05698719|||COHORT||PROSPECTIVE|||||||
34103197|NCT02439411|||COHORT||RETROSPECTIVE|||||||
34103198|NCT03107299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924202|NCT02400489|||CASE_ONLY||OTHER|||||||
33924203|NCT04859972|||OTHER||RETROSPECTIVE|||||||
33924204|NCT02760160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924205|NCT05114148|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, interventional, treatment, non-randomized, open label, non-comparative, early clinical safety study. The study is a collaboration between UMC Utrecht and Erasmus MC Rotterdam.||||
33924206|NCT03174613|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind||t|f|t|f
33924207|NCT04696510|||CASE_CONTROL||PROSPECTIVE|||||||
33924208|NCT02238548|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33924209|NCT04051476|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33924210|NCT05797363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33924211|NCT00561613|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33720196|NCT00000901||||TREATMENT||||||||
33720197|NCT04895215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double Blind, Randomized, Placebo Controlled|t|t|t|f
33720198|NCT01362374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720199|NCT01102933|||CASE_ONLY||PROSPECTIVE|||||||
33924212|NCT01852708|||COHORT||PROSPECTIVE|||||||
33924213|NCT06338046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|neither the patient nor the investigator knows who is getting which treatment.|2 parallel arm, double blind, randomized, placebo-controlled|t|t|t|t
33924214|NCT02786108|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924215|NCT02629614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924216|NCT02945800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720200|NCT04945902|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720201|NCT05482009|||CASE_CONTROL||PROSPECTIVE|||||||
33924217|NCT03559192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924218|NCT03802656|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33924219|NCT00859807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924220|NCT03939611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All parents were only told that foot application would be done, without giving any expectations. In the statistical analysis, the groups were named Group-1 and Group-2, and the statistician was blinded when evaluating the outputs. The report was written by the statistician, who did not know which application was performed to which group blinding was provided in the report writing. The scales were evaluated by the researcher, who could not be blinded due to the nature of the study.|This was an experimental, single-blind, randomized, placebo-controlled trial.|t|f|f|f
33924221|NCT06131229|RANDOMIZED|FACTORIAL||PREVENTION||NONE||A randomized controlled trial of three experimental groups and three control groups is proposed, with pretest, posttest.||||
33924222|NCT05494983|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33924223|NCT04263194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be a double blind trial, i.e. both patients and clinicians involved in the assessment will be blind to treatment allocation.|After recruitment, patients will be randomized and assigned to one of three rTMS treatments: DMN (N=20), CEN (N=20) or placebo (N=20). The rTMS treatment will consist of 2 phases: an intensive phase and a maintenance phase. The intensive phase will involve 3 weeks of treatment, 5 days per week (15 sessions in total). The maintenance will consist of 1 session of treatment every 2 weeks for 5 months (10 sessions in total). Overall, the patients will undergo 25 sessions of rTMS delivered over 6 months. At baseline (T0), at the end of the intensive phase (T1) and at the end of the maintenance phase (T2) all patients will undergo a clinical and cognitive assessment and a multi-modal imaging data collection.|t|t|f|t
33924224|NCT02972112|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33924225|NCT06453772|||CASE_ONLY||PROSPECTIVE|||||||
33924226|NCT03471299|||CASE_ONLY||RETROSPECTIVE|||||||
33924227|NCT04491240|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.|The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.|t|t|f|f
33924228|NCT05860998|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924229|NCT03755999|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33924230|NCT00122304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924231|NCT00267228|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33924232|NCT02800772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33924233|NCT05848076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||blinding|f|f|f|t
33924234|NCT05163067|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924235|NCT03661892|NA|SINGLE_GROUP||TREATMENT||NONE||This a prospective single arm study enrolling patients (n=20) with bone metastases form breast cancer who have been on opioid therapy for bone pain for at least 4 weeks.||||
33924236|NCT00602511|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924237|NCT00050479||||TREATMENT||||||||
33924238|NCT00536848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924239|NCT04754113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924240|NCT05200429|||COHORT||PROSPECTIVE|||||||
33924241|NCT01249963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33924242|NCT02425280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924243|NCT01619605|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924244|NCT05178693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924245|NCT01001858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924246|NCT05974007|||COHORT||RETROSPECTIVE|||||||
33924247|NCT01998399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924248|NCT02562950|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924249|NCT00671983|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924250|NCT01250457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924251|NCT05094076|||OTHER||CROSS_SECTIONAL|||||||
33924252|NCT01332019|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924253|NCT02062398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003137|NCT04038606|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Participants completed a questionnaires that included the test sociodemographic characteristics and a number of standardized validated instruments translated in French language designed to assess for quality of life and psychological profile.~Participants will undergo blood test, electrocardiogram, blood pressure monitoring, geriatric standard evaluation."||||
33698606|NCT04978597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698607|NCT04138004|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Gastroenterologists and investigators were blinded to the allocation groups.|The research coordinator used a computer to generate a randomization table with blocks of 8. Allocation concealment was maintained through the use of consecutively numbered sealed envelopes. The allocation ratio was 1:1 in 2-L PEG with LB (Group A) or 4-L PEG (Group B). An endoscopy nurse assigned patients to their group and instructed them on the proper use of their assigned bowel preparation method as well as dietary advice.|f|f|t|t
34003138|NCT03853369|||CASE_ONLY||OTHER|||||||
33698608|NCT06397833|||CASE_ONLY||PROSPECTIVE|||||||
33698609|NCT04377243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither patients nor attending physician are aware||t|t|f|f
33698610|NCT02908451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090108|NCT03479554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study physicians and nurses will not be masked to patients' randomization assignments because of the different time points for initiating BP treatment between the two randomization groups. The data on BP will also be unmasked because they are management tools for attaining the specific treatment targets. However, the study neurologists and nurses who conduct the neurological and functional assessments and collect clinical outcome data at the baseline and follow-up examinations will be masked to patients' assignments. The members of the Outcome Adjudication Committee will also be masked to patients' randomization.|"Randomization will be conducted centrally at the SDCC. The randomization will be stratified by participating hospitals and use of antihypertensive medication. In each stratum, patients will be randomly assigned to the early antihypertensive treatment group or the delayed antihypertensive treatment group within each block. The block size will be random among 4, 6, and 8. The early BP lowering group will receive antihypertensive treatment immediately according to the study protocol, and the delayed BP lowering group will discontinue antihypertensive treatment for the first seven days after randomization.~The randomization schedules will be generated using SAS PROC PLAN in SAS and will be concealed at the SDCC. When an eligible participant is ready for randomization, the site investigator/study coordinator will log-in to a password-protected website to obtain the randomization assignment."|t|f|f|t
33786382|NCT04363762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The two interventions compared in this study were not possible to blind for the care provider or the patients. Outcome assessment was based on questionnaires why blinding was not considered necessary, although the investigator and outcomes assessor can be regarded as blinded.|An unblinded parallel-arm RCT pilot study with equal allocation was conducted. Participants were randomized to the iMPP or to an active control. They were recruited from a general dental care clinic (Fäladstorget) within the National Dental Care Skåne, Sweden. Examination and allocated treatment were free of charge for participants, and no other financial compensation was given. This study is part of a large research project with the primary objective to study changes in the brain after treatment in patients with chronic TMD pain. Therefore, participants went through magnetic resonance imaging (MRI) of the brain pre- and post-treatment. Results from neuroimaging data will be presented elsewhere, however, the feasibility of this additional examination will be addressed here. The study was approved by the Ethics Review Board in Lund, Sweden (No. 2016/6).|f|f|t|t
33786383|NCT01447914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786384|NCT05409404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786385|NCT05886335|||COHORT||RETROSPECTIVE|||||||
33786386|NCT05943795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090109|NCT03881371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786387|NCT05702203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786388|NCT06016686|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090110|NCT00932256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090111|NCT03838874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090112|NCT01118923|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34003139|NCT00676494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090113|NCT01188447|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003140|NCT01966809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698611|NCT04687995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090114|NCT05856487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103199|NCT03640624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698612|NCT02155881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786389|NCT05564988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786390|NCT06555029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34003141|NCT05256849|||COHORT||RETROSPECTIVE|||||||
34103200|NCT00382473|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33698613|NCT03115047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded randomized study: meperidine and dexmedetomidine will be prepared at the hospital pharmacy in a 10 mL seringue with equivalent dilution in order to gave mL/kg.|Comparing two groups: experimental (dexmedetomidine) versus control (meperidine)|t|t|t|t
33698614|NCT06680388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786391|NCT06713616|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized phase 3 drug treatment study. Subjects will be randomized, in randomly varying blocks of no more than 8 at each site, to receive either esketamine (Spravato®) or intravenous ketamine. This study is unblinded.||||
33801653|NCT04321603|NA|SINGLE_GROUP||PREVENTION||NONE||This within-subjects design will allow each subject to be utilized as their own control pre-intervention. With expectation of great inter-person variability of oxygen consumption results, this design will incorporate less error than separately recruited controls and decrease the needed sample size.||||
33801654|NCT03819829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801655|NCT03753308|||COHORT||PROSPECTIVE|||||||
33801656|NCT04527822|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Non pharmacological intervention with no blinding|2 groups Post test only||||
34003142|NCT05513469|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003143|NCT00769587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003144|NCT04480307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003145|NCT05314062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a double-blind study||t|f|t|f
34003146|NCT06080698|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible participants with GN-BSI will be randomized to (arm 1) IV antibiotics or (arm 2) oral antibiotics for the treatment of GN-BSI.||||
34003147|NCT01839838|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003148|NCT06407999|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be told which are they are in during any point of the study, although since they are adherent (use their device regularly), they likely will be able to tell.|Participants will sleep at home with their normal CPAP (continuous positive airway pressure)/APAP (auto-adjusting...) equipment for 4 nights with EPR (expiratory pressure relief) on, the 4 nights with EPR off. The starting therapy will be randomized.|t|f|f|f
34003149|NCT00680524|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34003150|NCT05129462|||COHORT||RETROSPECTIVE|||||||
33698615|NCT00282074|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33698616|NCT02935231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698617|NCT02149875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698618|NCT02949531|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34003151|NCT02199379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003152|NCT00067132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003153|NCT01000688|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34003154|NCT03976934|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34003155|NCT06039774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34003156|NCT01948401|NA|SINGLE_GROUP||||NONE||||||
34090115|NCT01271855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized to receive either a belladonna and opioid suppository or a glycerin suppository (placebo) every eight hours after delivery during the first 24 hours after delivery using a 1:1 allocation|t|t|t|t
33698619|NCT00537875|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34003157|NCT03480022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double- Blind 2:1 Drug: Placebo||t|t|t|t
34003158|NCT04747184|||CASE_CONTROL||PROSPECTIVE|||||||
34003159|NCT03826394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will take part in an exercise or dietary intervention in a non-randomised, parallel study.~Each intervention will be preceded by a four week tracked free-living period. Both interventions will be completed over a sixteen week period. Following the tracked period, participants will choose to take part in either the exercise or dietary intervention. Intervention information will be delivered in four, three week blocks. No new information will be provided during the final four weeks of the intervention."||||
34003160|NCT05924880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003161|NCT03581162|||CASE_CONTROL||PROSPECTIVE|||||||
34003162|NCT04208490|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34090116|NCT00144885|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34090117|NCT06374719|||COHORT||PROSPECTIVE|||||||
34003163|NCT05104502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786392|NCT04057456|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|No other parties will be masked for the study.|Eligible participants who consent to study participation will be randomized to one of four groups: 1) Nabilone and Placebo Diet, 2) Placebo Capsule and Anti-inflammatory Diet, 3) Nabilone and Anti-inflammatory Diet, and 4) Placebo Capsule and Placebo Diet. Following randomization, participants will begin a study agent titration period (nabilone or placebo) in order to determine a safe and effective nabilone dose for each participant. Once the appropriate nabilone (or placebo) dosage for each participant is determined, participants will begin their respective interventions over the course of the 4-week treatment period. All outcome measures will be at assessed baseline, after the study agent titration period, and post-testing (following the 4-week treatment period).|t|t|t|f
33786393|NCT04501224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786394|NCT03812159|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33786395|NCT03353584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786396|NCT05095428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be unaware of study hypotheses or arms and will be told the study is for stress reduction among people with trauma/PTSD.~The staff member responsible for final determination of study eligibility will be blinded to the randomization sequence.~The Data Analyst and methodologist will be blinded to participant identity prior to and during randomization and analysis.~The PI will be blinded to participant randomization status for the duration of the study.~Medical Review Officer: The MRO will not be blinded and will be responsible for advising on adverse events.~Independent Evaluators conducting the CAPS-5 assessments will be blinded to the participants' randomization status. To protect this, independent CAPS-5 evaluators will be located separately from group leaders and therapists. In the event of an unintentional unblinding, a new rater will be assigned to assess the relevant participant(s)."||t|f|t|t
33786397|NCT04994743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786398|NCT06582563|||COHORT||PROSPECTIVE|||||||
33786399|NCT00575978|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33786400|NCT00369135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33786401|NCT06629870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786402|NCT00069862|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786403|NCT05714033|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786404|NCT00713934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786405|NCT01506362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786406|NCT02157493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786407|NCT02575391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786408|NCT05290740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786409|NCT00785772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786410|NCT03772964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Subjects will act as their own controls: data will be collect on each subject at baseline, throughout exposure and following, exposure to metformin.|t|t|t|f
33786411|NCT01333514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786412|NCT04455048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The manipulation group will receive a single session thrust manipulation and the control group will receive a sham manipulation. Outcome assessment will be performed by another investigator.|Two groups with a sham control. Assessments will be performed before manipulation, immediately after first session, in the second week, and two months after the last session.|t|f|f|t
33786413|NCT03790397|||COHORT||RETROSPECTIVE|||||||
33786414|NCT05686356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786415|NCT06281717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786416|NCT04469218|RANDOMIZED|PARALLEL||PREVENTION||NONE|The use of devices is randomly assigned to subjects in the study, but it is not possible to blind the patient, the care providers, the investigators or the outcomes assessor as to which group received the study device.|A randomized clinical trial with a control group receiving the standard of care peripheral IV treatment and a second group that utilizes SafeBreak Vascular, a break-away connector, in the peripheral IV.||||
33786417|NCT00286689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786418|NCT06442995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801657|NCT03359317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801658|NCT06232889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924254|NCT00445731|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33924255|NCT06374862|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33924256|NCT02747446|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924257|NCT05750316|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33924258|NCT05966493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924259|NCT01848626|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924260|NCT03384225|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment open labled randomized controlled study||||
33924261|NCT04354441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized 1:1 to receive either the study medication (hydroxychloroquine) or an identical-looking placebo. Randomization will be in blocks of 4-6, stratified by province.|t|t|t|t
34003164|NCT06464874|||COHORT||RETROSPECTIVE|||||||
34003165|NCT01475786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003166|NCT05511441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003167|NCT04906096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003168|NCT00610506|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34003169|NCT06677944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003170|NCT03407729|||COHORT||PROSPECTIVE|||||||
34003171|NCT00000708||PARALLEL||TREATMENT||||||||
34003172|NCT01266603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003173|NCT01570231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34003174|NCT06361355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biological: Post-change CMAB807, Prolia|t|t|t|t
34003175|NCT02240004|||COHORT||CROSS_SECTIONAL|||||||
34003176|NCT02833636|||CASE_CONTROL||RETROSPECTIVE|||||||
34003177|NCT01921335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003178|NCT04256707|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two part study (monotherapy period and combination therapy period).||||
34003179|NCT03632148|||COHORT||CROSS_SECTIONAL|||||||
34003180|NCT03608735|||OTHER||RETROSPECTIVE|||||||
34003181|NCT02327325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003182|NCT01705483|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34003183|NCT03391050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698620|NCT04375618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003184|NCT06459960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were divided into 1) hydrotherapy group (Hydrotherapy) or 2) convention group (Convention)||||
34003185|NCT04666597|||CASE_ONLY||PROSPECTIVE|||||||
34003186|NCT03025776|||COHORT||PROSPECTIVE|||||||
34003187|NCT05995379|||COHORT||PROSPECTIVE|||||||
34003188|NCT01685216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698621|NCT04746196|||OTHER||OTHER|||||||
34003189|NCT01427881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698622|NCT06102915|||COHORT||RETROSPECTIVE|||||||
33698623|NCT04597775|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Prospective, Randomized, open-label, three-arm, parallel, adaptive phase II/III controlled study in which subjects will be randomly assigned in a 1:1:1 ratio as per the following:~Arm-1: hydroxychloroquine 800mg (400mg twice daily) given orally on day 1, (loading dose) hydroxychloroquine. Then 400mg (200mg 2 tablets) on day 2,3, 4 and 5.~Arm-2: hydroxychloroquine 400mg (200mg twice daily) Given orally first day (loading dose), then 200mg once daily on day 2,3, 4 and 5.~Arm-3: No Intervention- SARS-CoV-2 surveillance Standard control measures in the country of interest such as self isolation, good personal hygiene and good nutrition."||||
34003190|NCT00099580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003191|NCT05721469|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomized controlled pretest posttest applied art therapy|t|t|t|t
33698624|NCT06681545|||OTHER||PROSPECTIVE|||||||
33698625|NCT00606255|||CASE_CONTROL||PROSPECTIVE|||||||
34003192|NCT02729207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003193|NCT02400463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698626|NCT03130608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003194|NCT02751892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33698627|NCT01669928|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003195|NCT01040273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698628|NCT05340374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003196|NCT04073836|||COHORT||PROSPECTIVE|||||||
33698629|NCT03531931|||CASE_ONLY||PROSPECTIVE|||||||
33698630|NCT04904575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003197|NCT01406249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698631|NCT05745623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003198|NCT04608682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003199|NCT03391115|||OTHER||PROSPECTIVE|||||||
34003200|NCT02335372|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34003201|NCT04693221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003202|NCT01611415|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33698632|NCT00734370|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33698633|NCT04228874|||COHORT||PROSPECTIVE|||||||
33698634|NCT06662942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo-controlled clinical trial.|t|t|t|t
33698635|NCT02970916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698636|NCT01580358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34003203|NCT03632694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||3-arm randomized controlled trial; participants were block randomized with equal allocation to 3 arms within 2 strata defined by body mass index (BMI; \<30 vs. \>=30 kg/m2)|f|f|t|f
34003204|NCT06309784|NA|SINGLE_GROUP||TREATMENT||NONE||Participants undergoing orthopaedic Surgery||||
34003205|NCT00605150|||CASE_ONLY||OTHER|||||||
34003206|NCT05869916|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Volunteers working in the provinces affected by the earthquake were reached by snowball sampling (Patton, 1990). In order to provide blinding, only one of the researchers interviewed individuals by snowball sampling method. 34 people who wanted to be included in the study and were included in the inclusion criteria were assigned to the experimental and control groups by a simple random sampling method by a statistician who was not included in the study. In order to prevent contamination and bias between the groups and the researcher who applied the psychological first aid, attention was paid to avoid any interaction before the application.|This research is a single-blind randomized controlled experimental study to determine the effect of online psychological first aid intervention on the stress and resilience levels of volunteers who took part in the earthquake.|f|t|t|t
34003207|NCT02075840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003208|NCT05134116|||COHORT||OTHER|||||||
34003209|NCT04171401|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34003210|NCT05922709|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The study consists of 3 parts: single ascending dose (SAD), multiple ascending dose (MAD) and food effect (FE). Both SAD and MAD study use a randomized, double-blind, placebo-controlled dose-escalation design. The FE study use a randomized, open-label, two-period, two-crossover design.|t|t|t|t
34003211|NCT00501332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003212|NCT01601938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003213|NCT05171660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003214|NCT06559774|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34003215|NCT00712244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003216|NCT00348153|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34003217|NCT05013723|||CASE_CONTROL||RETROSPECTIVE|||||||
34003218|NCT05308563|||COHORT||PROSPECTIVE|||||||
34003219|NCT00499473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698637|NCT03841448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698638|NCT03873012|||COHORT||OTHER|||||||
33698639|NCT06058559|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33698640|NCT02635776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698641|NCT03540030|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698642|NCT04575454|NA|SINGLE_GROUP||OTHER||NONE||||||
33698643|NCT03465358|||OTHER||PROSPECTIVE|||||||
33698644|NCT04836754|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33698645|NCT03959254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33698646|NCT02737683|||OTHER||OTHER|||||||
33698647|NCT02808793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924262|NCT04030897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participating youths and parents will be aware of whether they are receiving the online interventions immediately or after the 3-month follow-up period (i.e., whether they are in the 'intervention group' or the 'waitlist group'). However, participating families will be assigned to these conditions via an online survey, which they complete remotely, and condition assignments will be unknown to the research team and the youth's primary care provider.|"Youths reporting elevated MD symptoms at a PC visit (N = 200) will be randomly assigned to one of two conditions (within a waitlist-control design): Information, Psychoeducation, and Referral (IPR; ie., usual care, or the control) or IPR enhanced with youth- and parent-directed online SSIs (IPR+SSI), designed to reduce youth MD symptoms and improve parents' expectancies of mental health treatment, respectively."|f|t|t|t
34003220|NCT01298245|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924263|NCT04179786|NA|SINGLE_GROUP||PREVENTION||NONE||This study was an open-label, single arm study. No control groups were deemed necessary since this was a phase IV trial for which the goal, set according to the European Pharmacopeia 1056, was to achieve 95% SPR after the third vaccination.||||
33924264|NCT00648661|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34003221|NCT01738217|NA|SINGLE_GROUP||||NONE||||||
34003222|NCT02957578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003223|NCT04228627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation concealment|Multi centre randomised trial|f|f|t|f
34003224|NCT06650124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"nterventional Study Model: Parallel Assignment Study Type: Interventional (Clinical Trial) Study Model: Parallel Assignment - Participants are randomly assigned to one of two groups (either receiving azathioprine or mycophenolate mofetil) and remain in their assigned group for the entire study.~Masking: Double-blind (both participants and investigators are unaware of which treatment is being administered to prevent bias).~Allocation: Randomized - Patients are randomly allocated to one of the two treatment groups."|t|t|t|f
34003225|NCT03506841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924265|NCT05588180|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE||group (F) FVD/FAD ratio guided|t|t|t|t
34090118|NCT02871102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003226|NCT00333853|RANDOMIZED|PARALLEL||||NONE||||||
34090119|NCT00306722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003227|NCT04995354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Containers supplied for groups I and II will be identical and will be supplied by a third party pharmacist not a member of this study to ensure participant and patient blinding.||t|t|f|f
34090120|NCT02994680|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The clinical team is masked in this study, and a portion of the investigators.||f|t|t|f
34090121|NCT03873103|||OTHER||PROSPECTIVE|||||||
34090122|NCT02441647|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33698648|NCT06122116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698649|NCT01460368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33698650|NCT05052658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33698651|NCT03897504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698652|NCT03120312|||CASE_ONLY||RETROSPECTIVE|||||||
34003228|NCT03971734|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Seven dose levels of Regadenoson will be studied in part 1, minimum 3 patients per dose level.~Part 2 will include 5 patients at each level that achieved thresh hold in part 1"||||
33698653|NCT03376048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698654|NCT02728622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698655|NCT05873062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Subjects will be randomized in a 1:1 ratio to one of the two treatments with 3-5 subjects per treatment sequence. Each subject will receive both treatments (100 mg AUT00201 and placebo) with a washout period of 1 day between single doses.|t|f|t|t
33698656|NCT05175027|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||TRIPLE||Two models:Newborns to be circumcised randomly were divided into two groups as Hypochlorosis group and Povidone iodine group.|t|f|t|t
33698657|NCT01882348|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33698658|NCT00658580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924266|NCT03487328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924267|NCT00247572|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33924268|NCT02026518|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33924269|NCT04733001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003229|NCT02774850|||COHORT||OTHER|||||||
34090123|NCT00334919|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090124|NCT00961415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090125|NCT00313170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103201|NCT06026696|||COHORT||CROSS_SECTIONAL|||||||
34103202|NCT01268072|||COHORT||PROSPECTIVE|||||||
34103203|NCT06645600|||CASE_ONLY||CROSS_SECTIONAL|||||||
34103204|NCT04908527|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103205|NCT05483140|||COHORT||PROSPECTIVE|||||||
34103206|NCT04594603|||OTHER||PROSPECTIVE|||||||
34103207|NCT06634004|||CASE_CONTROL||PROSPECTIVE|||||||
34103208|NCT05799157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103209|NCT05642975|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34103210|NCT00921544|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34103211|NCT03422887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698659|NCT00543543|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33698660|NCT00646919|||CASE_ONLY||PROSPECTIVE|||||||
33698661|NCT05089331|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33698662|NCT00016159||||TREATMENT||||||||
33698663|NCT02919696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698664|NCT06059183|||COHORT||PROSPECTIVE|||||||
33698665|NCT06676670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698666|NCT03954132|||COHORT||PROSPECTIVE|||||||
33698667|NCT03763864|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698668|NCT06151431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698669|NCT02387710|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33698670|NCT03200184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698671|NCT01635868|||COHORT||PROSPECTIVE|||||||
33698672|NCT02435147|||COHORT||RETROSPECTIVE|||||||
34003230|NCT04019054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assignment will be performed randomly and tracked by clinical staff involved with the TMS treatment itself, and research staff assessing outcomes and analyzing data will be blinded to groups until after analysis is complete.|Participants will be randomly assigned to either the study treatment (iTBS stimulation to the ventromedial prefrontal cortex) or control treatment (iTBS stimulation to the vertex). Treatments will occur immediately following exposure therapy (both groups will undergo identical exposure therapy), and groups will receive iTBS to the same site for all three treatments|t|f|t|t
33698673|NCT02806531|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34003231|NCT04091763|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either rubber band ligation or sclerotherapy with polidocanol foam, stratified by grade of hemorrhoidal disease||||
33698674|NCT00887406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34003232|NCT05714241|||COHORT||PROSPECTIVE|||||||
34003233|NCT04664881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003234|NCT04509050|||COHORT||PROSPECTIVE|||||||
34003235|NCT04487964|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot study||||
34003236|NCT05771935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003237|NCT00684944|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003238|NCT00093730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003239|NCT04815434|||COHORT||PROSPECTIVE|||||||
34090126|NCT04364256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"During Informed Consent, patients will be instructed to not presume group assignment. An unblinded study coordinator will then randomize each participant to NMES:Sham on a 1:1 basis, stratifying by diagnosis. The unblinded coordinator will ensure each participant performs the appropriate NMES or Sham stimulus on each training day; stimulation will only occur in private exam rooms. NMES and Sham stimulators will be outwardly identical apart from a concealed A or B label indicating NMES or Sham device; the designation of A or B will only be known to the unblinded study coordinator, and not to the PI. The PI will administer all outcome assessments and conduct all statistical analyses; therefore the PI will remain blinded to NMES vs Sham group assignment until study completion. In the study database, group assignment will be coded as A or B, the PI will not know the coding of A or B. A document containing the coding will be kept in a different electronic location than the study folder."|Neuromuscular electrical stimulation (active vs sham signal)|t|t|t|t
34090127|NCT05970458|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34090128|NCT03542760|||CASE_ONLY||PROSPECTIVE|||||||
34090129|NCT00218959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090130|NCT03213236|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090131|NCT01733953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786419|NCT04648046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The clinical trial is an open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules that target and kill HIV-1 gp120 expressing cells. Participants will be enrolled sequentially in up to three sequentially enrolled cohorts in a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed the safety-evaluation period (45 days) at a given dose level. No dose escalation will be allowed in an individual participant, and participants who have dose limiting adverse events will reinstate ART therapy at first available opportunity. There are 3 dose escalation cohorts with the first 3 participants starting at Cohort 1.||||
33786420|NCT04408183|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33786421|NCT04687527|||CASE_CONTROL||PROSPECTIVE|||||||
33698675|NCT05769998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698676|NCT06652919|||OTHER||PROSPECTIVE|||||||
33698677|NCT01922557|||CASE_CONTROL||PROSPECTIVE|||||||
33698678|NCT04592107|||CASE_ONLY||CROSS_SECTIONAL|||||||
33786422|NCT06332378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786423|NCT03310983|||COHORT||PROSPECTIVE|||||||
33786424|NCT01803490|||COHORT||PROSPECTIVE|||||||
33924270|NCT05274828|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33924271|NCT03434418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924272|NCT05898750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924273|NCT03055572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants assigned to the either of the olfactory training arms will not know if they are in the essential oil arm or the pure fragrance oil arm.|Participants are randomized into one of three study arms: essential oil arm, pure fragrance oil arm, and control arm.|t|f|f|f
33924274|NCT03626740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924275|NCT01812122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924276|NCT04744610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924277|NCT05610722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924278|NCT01559714|||COHORT||PROSPECTIVE|||||||
33924279|NCT02245867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924280|NCT00179517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33924281|NCT03255811|NA|SINGLE_GROUP||TREATMENT||NONE||At present, apatinib was approved for the treatment of advanced gastric cancer after second-line or gastroesophageal junction adenocarcinoma, is in the second one, experience of medication, clinical data, no chemotherapy so now intends to carry out 40 cases of small sample exploratory research, in the conventional chemotherapy after the onset, with APA for Nigeria maintenance treatment, with a preliminary understanding of apatinib in first-line advanced gastric cancer to maintain the efficacy and safety of the treatment, and explore the feasibility of anti generate small molecule targeted therapy in advanced gastric cancer vascular pattern.||||
33924282|NCT02980692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924283|NCT06342648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924284|NCT05386264|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label dose finding phase 1||||
34003240|NCT06458244|||COHORT||PROSPECTIVE|||||||
34003241|NCT01091766|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34003242|NCT04200911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698679|NCT04354961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698680|NCT01613365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698681|NCT06407271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698682|NCT04666675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698683|NCT01761864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33698684|NCT05939570|||OTHER||PROSPECTIVE|||||||
33924285|NCT04829942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"There will be 4th grade students of two primary schools in the Kyrenia region. In the study, it is expected that there will be a moderate increase in the scale scores of the experimental group children after the education.Similarly, 30 people will be taken for the control group, and the sample size is 60 people, 30 being experimental and 30 control groups.In the second stage, the development of the Child Health-Literacy Scale will be carried out with 6458 students in the 9-11 age group attending 4th and 5th grades of primary schools."|"School Health Nursing Application Program, which is included in the first stage of the research, will be applied. Similarly, 30 people will be taken for the control group, and the sample size is 60 people, 30 being experimental and 30 control groups.~In the second stage, the development of the Child Health-Literacy Scale will be carried out with 6458 students in the 9-11 age group who attend 4th and 5th grades of primary schools. Students will be determined by simple random sampling method among 4th and 5th grade students of primary schools in Kyrenia, Nicosia, Güzelyurt, Famagusta and İskele districts."||||
33698685|NCT03144531|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Dyadic intervention for school-age children and a parent||||
33698686|NCT01924988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698687|NCT04472533|||COHORT||PROSPECTIVE|||||||
33924286|NCT02911623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924287|NCT00232505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924288|NCT05929638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33924289|NCT02823080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924290|NCT03148756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924291|NCT06200285|||OTHER||OTHER|||||||
33924292|NCT02771678|||COHORT||PROSPECTIVE|||||||
33924293|NCT01136863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924294|NCT04946162|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will serve as a self-control, with values recorded pre-medication, 30 minutes after medication administration, and 4 hours after administration.||||
33924295|NCT05553912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a cluster randomized clinical trial of usual care with a behavioral intervention (use of conversation cards during routine clinical encounters) compared with usual care alone. The study will randomize 10-15 clinicians and 72 of their patients with type 2 diabetes to each arm. Data collected includes medical record data, patient and clinician surveys, and audio-visual recordings of clinical encounters.||||
34090132|NCT05578547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090133|NCT00662259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090134|NCT00901641||PARALLEL||TREATMENT||NONE||||||
34090135|NCT00406380|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34090136|NCT04997005|||COHORT||PROSPECTIVE|||||||
33698688|NCT05923528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33698689|NCT06005597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablets made to resemble active; placebo capsule made to resemble active|Placebo-controlled, double blind, randomized|t|t|t|t
33698690|NCT00447005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698691|NCT06270329|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled clinical trial design||||
33698692|NCT00734123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720202|NCT02577211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33720203|NCT05724069|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33786425|NCT03431779|RANDOMIZED|PARALLEL||TREATMENT||NONE||However, subjects in the lipofilling group will be able to undergo surgery (excision) 3 months after the lipofilling of this intervention did not have the requested effect.||||
33786426|NCT01605136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786427|NCT05731661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33786428|NCT06107517|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33786429|NCT05317962|||COHORT||CROSS_SECTIONAL|||||||
33720204|NCT02728895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786430|NCT02949817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720205|NCT01830582|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33720206|NCT05736107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720207|NCT02725242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090137|NCT04809753|NA|SINGLE_GROUP||OTHER||NONE||||||
34090138|NCT06086249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090139|NCT05312203|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Due to the intervention's nature, this will be a single-blind study in which the results will be assessed blindly, but participants will be aware of their group assignment. Most of the assessments are self-rated, and the clinician rating, HAM-D, will be assessed by an independent blinded evaluator not participating in the assignment and care providing.|This study is a single-blind, multicenter, randomized, controlled crossover trial.|f|f|f|t
33720208|NCT05454956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment assignment (BID or TID) will be unknown to the study participant, investigators and site staff performing study assessments.|"Arm 1: Two doses of TP-03, 0.25% and one dose of TP-03 vehicle to maintain masking daily~Arm 2: Three doses of TP-03, 0.25% daily"|t|t|t|t
33720209|NCT05451745|||COHORT||PROSPECTIVE|||||||
34090140|NCT00124319|||COHORT||PROSPECTIVE|||||||
33720210|NCT01755884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090141|NCT04065308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720211|NCT04731168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34090142|NCT00714480|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33720212|NCT01927666|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924296|NCT05876104|||COHORT||PROSPECTIVE|||||||
33924297|NCT03139929|||COHORT||PROSPECTIVE|||||||
33924298|NCT05779605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33924299|NCT04783220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33924300|NCT04487496|||OTHER||CROSS_SECTIONAL|||||||
33924301|NCT00431821|RANDOMIZED|PARALLEL||||NONE||||||
33924302|NCT03923439|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924303|NCT04114539|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33924304|NCT06306924|||COHORT||PROSPECTIVE|||||||
33924305|NCT04869670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33924306|NCT01631240|||||CROSS_SECTIONAL|||||||
33924307|NCT02522572|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33924308|NCT01374672|||COHORT||RETROSPECTIVE|||||||
33924309|NCT05550896|||CASE_CONTROL||PROSPECTIVE|||||||
33924310|NCT04020406|||COHORT||PROSPECTIVE|||||||
33924311|NCT00293150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind placebo vs eplerenone||t|t|t|f
33924312|NCT02674165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33924313|NCT05928676|NA|SINGLE_GROUP||OTHER||NONE||||||
33924314|NCT03154307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and outcomes assessor will be masked in the 3 arms of the long-term protocol. However, the short-term arm will be open label.||t|f|f|t
33924315|NCT04183946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924316|NCT03731338|||CASE_CONTROL||RETROSPECTIVE|||||||
33924317|NCT00990470|||COHORT||PROSPECTIVE|||||||
33924318|NCT06028425|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33924319|NCT03082976|||COHORT||PROSPECTIVE|||||||
33924320|NCT01255306|||CASE_CONTROL||PROSPECTIVE|||||||
33924321|NCT06087588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Group 1 - PENG sham block Group 2 - PENG neurolysis 95% ethanol|t|t|f|t
33924322|NCT03284346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924323|NCT00156910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924324|NCT01342952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924325|NCT01188538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33924326|NCT00028106||||TREATMENT||||||||
33924327|NCT04746209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090143|NCT00910975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720213|NCT02448654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720214|NCT05395468|||CASE_ONLY||PROSPECTIVE|||||||
33720215|NCT02116244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720216|NCT05398601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720217|NCT01172184|||COHORT||PROSPECTIVE|||||||
33720218|NCT05705986|||COHORT||PROSPECTIVE|||||||
33720219|NCT02234453|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720220|NCT05943145|NA|SINGLE_GROUP||OTHER||NONE||Uncontrolled pre-post intervention study. All participants will complete 14 1-hour dance intervention sessions together as a single group||||
33924328|NCT00518843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924329|NCT06392750|||COHORT||RETROSPECTIVE|||||||
33924330|NCT02581618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924331|NCT03412500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924332|NCT06100549|||CASE_ONLY||PROSPECTIVE|||||||
33924333|NCT02142504|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924334|NCT03029897|RANDOMIZED|PARALLEL||OTHER||NONE||clusters||||
33924335|NCT02284230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924336|NCT01149343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924337|NCT03449407|||CASE_ONLY||OTHER|||||||
33924338|NCT02330913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924339|NCT01537094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924340|NCT04569799|NA|SINGLE_GROUP||OTHER||NONE||||||
33924341|NCT02501837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33924342|NCT04962672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33924343|NCT00516412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924344|NCT00352313||||TREATMENT||NONE||||||
33924345|NCT05163717|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33924346|NCT04701047|||COHORT||PROSPECTIVE|||||||
33924347|NCT01001728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924348|NCT05308615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34090144|NCT06439069|||COHORT||PROSPECTIVE|||||||
34090145|NCT05499936|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090146|NCT03991975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090147|NCT06254313|||COHORT||PROSPECTIVE|||||||
34090148|NCT06009874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34090149|NCT00689832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003243|NCT06222229|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention, it will not be feasible to mask the received treatment at the time of care. Additionally, masking of the treatment group during clinical reviews will not be attainable, as some collected variables will be inherently related to the intervention itself. The data analyst specialist will also be unblinded to the group assignments.|Randomization sequence was created using the Epidat 4.2 software, ensuring allocation concealment, with a single, constant 1:1 allocation ratio||||
34003244|NCT06036550|||COHORT||PROSPECTIVE|||||||
34003245|NCT04381013|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
34090150|NCT01676662|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34090151|NCT02557997|||COHORT||PROSPECTIVE|||||||
34090152|NCT04323475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090153|NCT03238534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (patient+investigator)||t|f|t|t
34090154|NCT02826096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090155|NCT03359083|||OTHER||OTHER|||||||
34090156|NCT06551012|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The study will be double-blinded, with participant and investigator unaware of the treatment arm|Randomised, cross-over trial. Participants will perform exercise following consumption of nitrate-rich beetroot juice and beetroot juice with nitrate extracted|t|f|t|f
34090157|NCT02907372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090158|NCT05997589|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34090159|NCT03815305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34090160|NCT02363491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924349|NCT05493306|||OTHER||PROSPECTIVE|||||||
34090161|NCT03780192|||OTHER||PROSPECTIVE|||||||
34090162|NCT04335864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34090163|NCT05775653|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The trial attempts to blind clients and assessors. Clients are informed that they will be allocated to one of two occupational therapy intervention programs that both aims to improve ADL ability, but overall primarily differ in the format i.e. a group-based versus a one-to-one intervention program. Clients are however not informed, which of the two types of formats that are the new experimental intervention format (ADAPT). Baseline assessments are conducted prior to randomization by the local project coordinator and the project coordinator is instructed not to reveal which intervention that is the new experimental intervention. The post- and follow-up assessor, an externally recruited occupationa therapist from a nearby hospital research unit, is also instructed not to disclose which intervention that is the new. Finally, all clients are reminded not to disclose any details, that may provide the outcome assessor with insight regarding their group allocation.|A randomized controlled pilot and feasibility study|t|f|f|t
34090164|NCT02955693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34090165|NCT05662618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924350|NCT04562545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will carry out measurements blindly on pre-operative and post-operative radio-graphs|Type: Two arm, parallel, randomized clinical trial. allocation ratio 1:1 framework: superiority|f|f|f|t
33924351|NCT01613001|||CASE_CONTROL||RETROSPECTIVE|||||||
33924352|NCT02855242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924353|NCT03424317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single blind, randomized|t|f|f|f
33924354|NCT02620709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924355|NCT04749576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and care provider does not know whether the participant receiving placebo or saffron|randomize double placebo|t|t|f|f
33924356|NCT01854593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33924357|NCT04557670|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33924358|NCT01709214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924359|NCT01369407|||COHORT||PROSPECTIVE|||||||
33924360|NCT00703859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924361|NCT00643357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924362|NCT02168296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33924363|NCT00082329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924364|NCT01228487|||||PROSPECTIVE|||||||
33924365|NCT04668092|NA|SINGLE_GROUP||TREATMENT||NONE|assessor who helped to record the measurement was blinded|||||
33924366|NCT03073408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
33924367|NCT03961269|||COHORT||PROSPECTIVE|||||||
33924368|NCT00430963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924369|NCT02970227|||COHORT||PROSPECTIVE|||||||
33924370|NCT04294095|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial (control and intervention)||||
33924371|NCT00003091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924372|NCT05441540|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be in a single treatment group||||
33924373|NCT00306241|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33924374|NCT01299610|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33924375|NCT04913480|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Combination of stereotactic body radiation therapy and immune checkpoint inhibitor for inoperable/unresectable hepatocellular carcinoma||||
33924376|NCT03763799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924377|NCT05420415|||COHORT||RETROSPECTIVE|||||||
33924378|NCT00990249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924379|NCT01929213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924380|NCT03932539|||COHORT||PROSPECTIVE|||||||
33924381|NCT03838003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924382|NCT05752708|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33924383|NCT02904187|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33924384|NCT01768338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003246|NCT02922582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003247|NCT02463487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003248|NCT02476305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003249|NCT04912986|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003250|NCT04615494|||COHORT||PROSPECTIVE|||||||
34003251|NCT02474654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924385|NCT02185248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003252|NCT04621045|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will randomize 52 participants to either the PATH treatment group or wait-list control group.||||
34003253|NCT03012893|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34003254|NCT04993417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003255|NCT03182751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Using dynamic allocation will ensure that the study subjects will remain balanced on the stratification factors and the treatment group assignment throughout the entire subject accrual phase. This system will be utilized by Central pharmacy personnel to generate the treatment group assignments. Medications will then be delivered from the Central Pharmacy to the emergency department in packaging that does not delineate whether it contains placebo or tranexamic acid. Thus, the patient, treating surgeon, emergency department physician, residents, hospitalist group, anesthesiologist, and data collectors will remain blinded to the treatment assignment.|Subjects will be randomized into one of two study groups: TXA administration (treatment) or placebo (control). In order to ensure balance on the subject demographics between the two study groups, the subjects will be stratified on gender, age group (\<75 vs. ≥75) and body mass index (\<30 vs. ≥30). Within each stratum, subjects will be assigned to either the treatment group or control group using an electronic dynamic allocation program housed in a computer application developed by personnel in the Division of Biomedical Statistics and Informatics.|t|t|t|t
33924386|NCT03587584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34003256|NCT04245293|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open-label, comparative, multicenter study with two parallel group of subjects. The clinical investigation will be performed in three clinical sites.~The calculated sample size of subjects is 50 (25 subject for each arm). To obtain this number of evaluable subjects it will be needed to screen about 60 subjects (including 6 potential screening failure) and to enroll 54 subjects (estimating 4 subjects drop out). From the equal distribution per groups of treatment point of view, the minimum and maximum number of patients recommended for each of the three centers will be 8 and 25, respectively.~The research question is: in a population of menopausal transition women affected by vaginal dryness, will a 1-month treatment with polycarbophilic vaginal gel (Ainara®) significantly decrease the symptomatology evaluated by VHI and VAS in comparison with that occurred in a group of patients treated with a HA-based gel (HyaloGyn®)?"||||
34003257|NCT05307562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34003258|NCT01705717|||COHORT||RETROSPECTIVE|||||||
34003259|NCT00856622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003260|NCT02767947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003261|NCT03542734|||COHORT||PROSPECTIVE|||||||
34003262|NCT05884255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003263|NCT02128516|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34003264|NCT02288351|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090166|NCT01035788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090167|NCT03846791|||COHORT||PROSPECTIVE|||||||
34090168|NCT05665998|NA|SINGLE_GROUP||TREATMENT||NONE||single-site, single-arm, non-blinded, non-randomized, interventional||||
34090169|NCT02413762|||COHORT||CROSS_SECTIONAL|||||||
33720221|NCT02861794|NA|SINGLE_GROUP||TREATMENT||NONE|Non-blind|Prospective interventional single group cohort study||||
33720222|NCT04422002|||COHORT||PROSPECTIVE|||||||
33720223|NCT05406258|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33720224|NCT02864251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924387|NCT01679561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924388|NCT03928860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924389|NCT00092677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924390|NCT04026763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924391|NCT02285712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924392|NCT05806112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33924393|NCT04229238|||CASE_ONLY||CROSS_SECTIONAL|||||||
33924394|NCT06065904|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
33924395|NCT00004210|NA|SINGLE_GROUP||||NONE||||||
33924396|NCT01229891|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33924397|NCT03222622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924398|NCT03379896|||COHORT||PROSPECTIVE|||||||
33924399|NCT02277340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720225|NCT05814887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003265|NCT04522245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003266|NCT02440555|||COHORT||PROSPECTIVE|||||||
33786431|NCT01163578|||OTHER||PROSPECTIVE|||||||
34003267|NCT06159738|||COHORT||PROSPECTIVE|||||||
34003268|NCT04841967|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Parents will be randomized into two groups (either the TELL Tool group or the attention control eBook group) using a permuted block approach that is stratified by the age categories of the parent's children and using an online (REDCap) randomization module.|Parent participants will be randomized to one of two groups: (1) TELL Tool group, or (2) eBook attention control group. Data will be collected at baseline, immediate posttest (post-TELL tool/post-eBook attention control) and at 2 additional time points (months 1 and 3)|t|f|t|f
34003269|NCT01132261|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786432|NCT04815057|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|the researchers evaluating the outcomes were blinded in determining the groups.|||||
33786433|NCT05754463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33786434|NCT06518005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786435|NCT04488250|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Low-to-mid functioning HIV/AIDS patients with stroke co-morbidity. Stroke survivors greater than 18 years of age with hemiplegia with and without HIV/AIDS.||||
33786436|NCT06629597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003270|NCT06678126|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Randomized Phase II 2 by 2 factorial||||
34003271|NCT03866928|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003272|NCT03394716|||COHORT||PROSPECTIVE|||||||
34003273|NCT06678295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003274|NCT01104948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003275|NCT04149535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003276|NCT02171897|RANDOMIZED|PARALLEL||||NONE||||||
34003277|NCT03501420|||COHORT||CROSS_SECTIONAL|||||||
34003278|NCT03334045|||CASE_CONTROL||OTHER|||||||
34003279|NCT03980028|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34003280|NCT02874196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003281|NCT02128009|||CASE_CONTROL||PROSPECTIVE|||||||
34003282|NCT05619822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003283|NCT02277964|||COHORT||PROSPECTIVE|||||||
34003284|NCT01234324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003285|NCT03844230|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34003286|NCT05756244|||COHORT||PROSPECTIVE|||||||
34003287|NCT01067794|||CASE_ONLY||PROSPECTIVE|||||||
34003288|NCT02299687|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34003289|NCT03904836|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003290|NCT03111667|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Student Participants will be assigned in a 2:1 ratio to the Experimental Teen Marijuana Check Up or a Control Treatment as Usual condition.~Interventionist Participants will be assigned in a 1:1 ratio to Gold Standard or As Needed Coaching"||||
34003291|NCT00467311|||||CROSS_SECTIONAL|||||||
34003292|NCT03772756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003293|NCT04590339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003294|NCT04547179|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720226|NCT04356768|||OTHER||RETROSPECTIVE|||||||
33720227|NCT06153511|NA|SINGLE_GROUP||OTHER||NONE||||||
33720228|NCT01269424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720229|NCT00000633||||TREATMENT||||||||
33720230|NCT04659889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33720231|NCT00721773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720232|NCT04900831|||CASE_CONTROL||PROSPECTIVE|||||||
33720233|NCT00937443|||COHORT||PROSPECTIVE|||||||
33720234|NCT02063854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720235|NCT02697695|||OTHER||RETROSPECTIVE|||||||
33720236|NCT02286505|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720237|NCT02702440|||||PROSPECTIVE|||||||
33720238|NCT02266745|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects enrolled in Cohort D Part 2 will be randomized.||||
33720239|NCT04630418|NA|SINGLE_GROUP||OTHER||NONE||||||
33720240|NCT00294073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33720241|NCT05485298|||COHORT||OTHER|||||||
33720242|NCT01552252|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33720243|NCT06332846|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33720244|NCT02269020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720245|NCT04983992|||CASE_CONTROL||PROSPECTIVE|||||||
33720246|NCT01829581|||COHORT||RETROSPECTIVE|||||||
33720247|NCT00009854||||TREATMENT||||||||
33720248|NCT05204654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Lateral cephalometric radiographs and digital study models will be de-identified prior to landmarking and obtaining measurements. The appliances will not be present on the patient when these records are obtained and therefore, when taking measurements, the outcomes assessor will not know which intervention the subjects received.|"Subjects participating in the study and will then be randomly assigned to one of two treatment interventions:~1. Sagittal first approach using the CMA~2. Sagittal first approach using an in-office fabricated custom appliance~At the bonding appointment, the appliance will be bonded and AP correction will begin. Both treatment groups will have a button bonded to the mandibular first molars, and Essix retainers with 2 mm thickness will require to be worn at all times for mandibular anchorage during AP correction (only taken out to brush and eat). Both treatment groups will follow the CMA protocol for Class II correction, which consists of wearing Force 1 (1/4, 6 oz) Class II elastics for the first month of treatment, and Force 2 (3/16, 8 oz) Class II elastics for the remainder of Class II correction. Once Class II correction is complete, the appliance will be removed and a lateral cephalometric radiograph and digital model will be obtained"|f|f|f|t
33720249|NCT02066740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720250|NCT01857232|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33720251|NCT02649907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720252|NCT04389567|||CASE_ONLY||RETROSPECTIVE|||||||
33720253|NCT03532919|||CASE_CONTROL||PROSPECTIVE|||||||
33786437|NCT00886613|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090170|NCT03007940|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34090171|NCT03217097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720254|NCT00941018|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33720255|NCT01408030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720256|NCT04458545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are randomized among three arms i.e., to one of three doses of the opioid vaccine: Placebo, Low and High dose. Under each vaccine condition, the participant is administered 5 intranasal drugs.|t|f|t|t
34090172|NCT05022017|||COHORT||RETROSPECTIVE|||||||
33720257|NCT04687254|||COHORT||RETROSPECTIVE|||||||
33924400|NCT03098524|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Patients are ventilated or not during the time they are sedated, so they are blind to their study arm.~Anesthesiologists perform mechanical ventilation or not during cardiopulmonary bypass and log per-operative data (such as number of insufflations) on a separate leaflet of the eCRF. Investigators (cardiologists and critical care specialists) are not aware of the treatment arm as it is performed during surgery."||t|f|t|t
33924401|NCT02064205|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Breakfast meal with or without polydextrose|t|t|t|t
34003295|NCT05402917|||CASE_CONTROL||PROSPECTIVE|||||||
34003296|NCT01353716|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34003297|NCT02513537|||COHORT||PROSPECTIVE|||||||
34003298|NCT03592303|||COHORT||PROSPECTIVE|||||||
34003299|NCT00050076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003300|NCT04791956|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34003301|NCT06662617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Modified Perichondral Approach Thoracoabdominal Nerve block (M-TAPA block) group, and Transversus Abdominal Plane Block (TAP block) group|t|f|f|t
34090173|NCT05891275|||COHORT||RETROSPECTIVE|||||||
33720258|NCT04902456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors will be blind. The patients name will be sealed from pre and post radiographs and study models. Then two assessors will carry out, blindly and independently, the measurements and analysis of the study||f|f|f|t
33720259|NCT02401594|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33720260|NCT05681455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||triple-blind randomized controlled clinical trial|t|t|f|t
33720261|NCT02829281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720262|NCT01401868|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924402|NCT02890732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924403|NCT04309838|||CASE_ONLY||PROSPECTIVE|||||||
33924404|NCT01688440|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924405|NCT05552859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924406|NCT02476344|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924407|NCT00274040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924408|NCT01011218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33924409|NCT00196196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924410|NCT03590704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924411|NCT06068179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study grouping will be blinded to outcomes assessor.|Eligible patients will be randomly assigned to intervention group (Mycophenolate Mofetil combine with methimazole) or control group (methimazole standard therapy) for 12 months.|f|f|f|t
33924412|NCT06056765|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized prospective||||
33924413|NCT05003141|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1a: 3+3 dose escalation design Phase 1b: 3 Expansion cohorts (N=20 each). Expansion beyond N=20 in a cohort is predicated on an ORR of at least 35% (Futility threshold) observed in the initial N=20 in the cohort.||||
33924414|NCT03958539|RANDOMIZED|PARALLEL||PREVENTION||NONE||As this study involves a complex intervention in the form of a pathway, we chose a cluster randomisation design to mitigate the risk of contamination across the groups. The podiatry units will find it much easier to follow one pathway for all participants in their sites. We also reduce the cost by halving the number of foot scanners required to be purchased (and the staff training required) for the study by using cluster randomisation.||||
33924415|NCT01057004|||COHORT||PROSPECTIVE|||||||
33924416|NCT02963415|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924417|NCT03409419|||COHORT||PROSPECTIVE|||||||
33924418|NCT00284349|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924419|NCT00544479|||COHORT||PROSPECTIVE|||||||
33924420|NCT06495216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924421|NCT05367557|||COHORT||PROSPECTIVE|||||||
33924422|NCT04384432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924423|NCT01544686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924424|NCT03600493|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33924425|NCT03983226|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized umbrella clinical trial||||
34003302|NCT01705002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003303|NCT04499482|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Dose escalating cross over trial||||
34003304|NCT04068987|||CASE_CONTROL||PROSPECTIVE|||||||
34003305|NCT05740553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants complete tactile training for 6-8 weeks, and complete no additional training for 8 weeks. One group will begin with tactile training, and the other group will begin with no additional training, then they will swap. At each time point (before portion 1, after portion 1, and after portion 2) their tactile function will be assessed.||||
34003306|NCT01158807|||CASE_CONTROL||OTHER|||||||
34003307|NCT03079427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003308|NCT06574139|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003309|NCT03561987|||COHORT||PROSPECTIVE|||||||
34090174|NCT00556959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090175|NCT06038630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924426|NCT04001309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking for care providers and investigators is not feasible. Outcomes assessors will be blinded to study period and intervention arms when evaluating appropriateness of prescribing.|Randomized clinical trial|f|f|f|t
33924427|NCT03943446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33924428|NCT04777019|||COHORT||PROSPECTIVE|||||||
33924429|NCT01860963|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34003310|NCT03375749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003311|NCT06214637|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34003312|NCT03768817|||CASE_ONLY||RETROSPECTIVE|||||||
34003313|NCT04164758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003314|NCT05987631|||COHORT||PROSPECTIVE|||||||
34003315|NCT03869294|||CASE_CONTROL||PROSPECTIVE|||||||
34003316|NCT01350596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34003317|NCT00165516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003318|NCT04309162|NA|SINGLE_GROUP||TREATMENT||NONE|The neonates admitted in NICU are masked.|A single group Pretest-Posttest quasi experimental design||||
34003319|NCT01663467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003320|NCT03749915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003321|NCT01858922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003322|NCT01236495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003323|NCT03874026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003324|NCT02266940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34003325|NCT05502055|||OTHER||CROSS_SECTIONAL|||||||
33698693|NCT05007210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The pregnant women in control and prenatal massage therapy groups were appointed to different times to avoid each other. At the beginning of the study, they didn't know in which group they were taken to participate in the study. In the process of gathering data, the single-blind method has been applied, and the double-blind method has only been applied to data analysis (The double-blind method was not used in the data collection process in order to reveal the loss of the study conducted within the scope of the doctoral thesis and the fact that prenatal massage therapy practice is not performed routinely in country conditions). However, single blinding was performed in terms of the outcomes. The data obtained from the research were analyzed by Biostatistics and Medical Information Department at Ege University.|The study type is interventional.As a prospective, randomised, single masking, parallel trial design has been carried out with primipar pregnant women that came to obstetrics polyclinic of a university hospital to evaluate before 30th week.The participants were randomly allocated to the parallel comparison groups by a central office.The sample selection process in the study has been applied according to CONSORT criteria (Moher et al. 2010), and through the permutation method, blocked randomization (Kanık, Tasdelen, and Erdogan 2011) has been done to the records assigned from the centre that the study was applied. The completion decision of the data gathering process has been determined with power analysis that is carried out by the PASS program.|f|f|f|t
33698694|NCT00258284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003326|NCT05499416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003327|NCT06233851|||COHORT||PROSPECTIVE|||||||
34003328|NCT04079452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698695|NCT00248131|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003329|NCT05188417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003330|NCT06386601|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be stratified into junior residents (1st and 2nd year) and senior residents (3rd and 4th year) and then randomized to the intervention group or control group.||||
34003331|NCT06416371|||COHORT||CROSS_SECTIONAL|||||||
34003332|NCT06474598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003333|NCT01762228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090176|NCT04507321|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open-label study.|Participants will receive non-radiolabeled GSK3640254 oral tablets concomitantly with radiolabeled \[14C\]-GSK3640254 administered as an IV infusion in treatment Period 1 and radiolabeled \[14C\]-GSK3640254 as an oral suspension in treatment Period 2.||||
34090177|NCT01737086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090178|NCT06061419|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomised, open label crossover study||||
34090179|NCT03754647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090180|NCT03108690|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33924430|NCT03407170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924431|NCT03842215|||CASE_ONLY||CROSS_SECTIONAL|||||||
33924432|NCT00540306|||CASE_ONLY||PROSPECTIVE|||||||
33924433|NCT05269472|||COHORT||PROSPECTIVE|||||||
33924434|NCT04348539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003334|NCT00376233|||DEFINED_POPULATION||OTHER|||||||
34003335|NCT04271306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003336|NCT05260008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a Phase 2B, randomized, double blind, active comparator multicenter trial in participants undergoing total knee arthroplasty.|t|f|f|t
34003337|NCT01031238|||CASE_ONLY||PROSPECTIVE|||||||
34003338|NCT04937647|||OTHER||PROSPECTIVE|||||||
34003339|NCT05549076|||CASE_ONLY||PROSPECTIVE|||||||
34003340|NCT06461845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003341|NCT05603936|||OTHER||CROSS_SECTIONAL|||||||
34003342|NCT04356807|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Care Provider and Outcomes Assessor are masked to the objectives of the study||t|t|f|t
34003343|NCT00000317|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34003344|NCT06678152|||CASE_CONTROL||PROSPECTIVE|||||||
34003345|NCT03293719|||COHORT||PROSPECTIVE|||||||
34003346|NCT01207141|||COHORT||PROSPECTIVE|||||||
34003347|NCT03268096|||CASE_ONLY||CROSS_SECTIONAL|||||||
34003348|NCT03082651|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003349|NCT05476133|NA|SINGLE_GROUP||TREATMENT||NONE||the study was carried on a single group underwent initial assessment then intervention then final assessment||||
34003350|NCT03680716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003351|NCT05395767|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort Study||||
34003352|NCT02010034|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34090181|NCT05514119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003353|NCT06631729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34003354|NCT01030484|||COHORT||PROSPECTIVE|||||||
34003355|NCT02569281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34090182|NCT04739709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698696|NCT05496998|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with moderate-to-severe or severe symptomatic mitral regurgitation, or moderate symptomatic mitral regurgitation combined with mitral stenosis in the presence of MAC who, by agreement of the local site multidisciplinary heart team experienced in mitral valve therapies, are unsuitable for treatment with approved transcatheter repair or surgical mitral valve intervention.||||
33698697|NCT04619927|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an open label trial.|A randomized, controlled, open label, multicenter trial.||||
33924435|NCT05554718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded to the conditions, but blinding of participant and care provider is not possible due to the nature of the intervention.|Comparison of self-help app only, self-help app plus accompanying therapy sessions, and waitlist control group|f|f|f|t
33924436|NCT03842956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded in the 6- and 52-weeks examination. So the doctor doesn't know which pin-side is treated by primary woundclosure (Allgower) or by secondary wound healing||f|f|t|f
33924437|NCT02669199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924438|NCT02628951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924439|NCT06302998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be nurses - not invovled in the study - will be unware about the study drug.|Randomized controlled superiority trial|f|f|f|t
33924440|NCT04688216|||CASE_CONTROL||RETROSPECTIVE|||||||
33924441|NCT01877941|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33924442|NCT05470712|||CASE_CONTROL||RETROSPECTIVE|||||||
33924443|NCT02505594|||OTHER||PROSPECTIVE|||||||
33698698|NCT01558193|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33698699|NCT04130984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698700|NCT03071471|||COHORT||PROSPECTIVE|||||||
33698701|NCT02368704|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33698702|NCT01035580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698703|NCT03405896|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698704|NCT04264338|||COHORT||PROSPECTIVE|||||||
33698705|NCT01761175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698706|NCT02402101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33698707|NCT01050543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698708|NCT02907268|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33698709|NCT02120612|||COHORT||PROSPECTIVE|||||||
33698710|NCT02439294|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33698711|NCT02566668|||CASE_CONTROL||PROSPECTIVE|||||||
33698712|NCT02422173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698713|NCT05194657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698714|NCT01031706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698715|NCT01464892|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33698716|NCT01135602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698717|NCT00958789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698718|NCT05130918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698719|NCT04068779|||OTHER||RETROSPECTIVE|||||||
33698720|NCT05203289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786438|NCT06631885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786439|NCT01201187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924444|NCT03097029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924445|NCT01340391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924446|NCT00065442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924447|NCT04984564|||OTHER||CROSS_SECTIONAL|||||||
33924448|NCT00888615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924449|NCT02877667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924450|NCT04145713|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, placebo-controlled, blinded, multicentre|t|t|t|t
33924451|NCT03381209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33924452|NCT02098057|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33924453|NCT03241667|||CASE_ONLY||PROSPECTIVE|||||||
33924454|NCT03552185|||OTHER||CROSS_SECTIONAL|||||||
33924455|NCT05976477|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33698721|NCT03539146|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"Forty volunteers will be randomly distributed in 4 groups that will follow a sequence of treatments according to a balanced latin square design. Treatment days involve the ingestion in acute conditions of a yogurt formulation with a different dietary fiber dose:~* Cascara control yogurt with 0% dietary fiber.~* Cascara yogurt with 3% dietary fiber.~* Cascara yogurt with 7% dietary fiber.~* Cascara yogurt with 13% dietary fiber.~Subjects will have a 48h washout period between treatment days to avoid carry-over effects."|t|f|f|f
33698722|NCT04087304|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
33698723|NCT06079658|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||All participants were randomized in a balanced fashion and stratified by body fat percentage into either one of the two intervention groups.|t|f|f|f
33698724|NCT05343000|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot study||||
33698725|NCT02685046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698726|NCT03225729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698727|NCT02900976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698728|NCT04669327|||CASE_CONTROL||RETROSPECTIVE|||||||
33698729|NCT06271538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698730|NCT02819869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786440|NCT02375321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786441|NCT06123988|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33786442|NCT03545789|NA|SINGLE_GROUP||OTHER||NONE||||||
33786443|NCT03275896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786444|NCT02908620|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33786445|NCT02870543|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33786446|NCT06179095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33786447|NCT02870270|||COHORT||PROSPECTIVE|||||||
33924456|NCT03682939|NA|SINGLE_GROUP||OTHER||NONE||||||
33924457|NCT02465242|||COHORT||PROSPECTIVE|||||||
33924458|NCT02879370|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33698731|NCT01360528|||CASE_CONTROL||PROSPECTIVE|||||||
33698732|NCT03637023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698733|NCT02081183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698734|NCT00000432|RANDOMIZED|||PREVENTION||||||||
33698735|NCT04378907|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the power level and nicotine concentration used in each session.|The purpose of this study is to determine differences in nicotine delivery, use behavior, (puff topography), and carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.|t|f|f|f
33698736|NCT03364569|||COHORT||RETROSPECTIVE|||||||
33698737|NCT03325270|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33698738|NCT04877873|||CASE_ONLY||PROSPECTIVE|||||||
33786448|NCT04485221|||COHORT||PROSPECTIVE|||||||
33786449|NCT03688828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33786450|NCT03368001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786451|NCT04934228|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomized, double-blinded, parallel-design approach. Randomization to either the clonidine, diuretic vs. placebo will occur determined/generated by computer generated randomization and stratified by age and sex to balance the three groups.|Mixed Model ANOVA 3-way analysis of variance to assess pain and BP responses to the clonidine, diuretic vs. placebo.|t|f|t|f
33786452|NCT03557333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786453|NCT01725347|||OTHER||CROSS_SECTIONAL|||||||
33786454|NCT06220045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients meeting the inclusion criteria for the study will be randomized 1:1 using random number generation functions with SPSS v.21 software into either the PP or PVDF group. This randomization will be carried out using sealed opaque envelopes at the time immediately preceding the onset of the surgical intervention within the operating room. The envelope will be opened within the operating room once the closure of the midline laparotomy is initiated.||t|f|f|f
33786455|NCT04034121|NA|SINGLE_GROUP||TREATMENT||NONE||single arm||||
33786456|NCT03244566|||COHORT||PROSPECTIVE|||||||
33786457|NCT04465578|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33786458|NCT02797405|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786459|NCT01855464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786460|NCT05358093|||CASE_CONTROL||RETROSPECTIVE|||||||
33786461|NCT03491956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786462|NCT01139697|||CASE_ONLY||PROSPECTIVE|||||||
33786463|NCT00011284|||CASE_CONTROL||OTHER|||||||
33786464|NCT03523910|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center, open label, single-arm||||
33786465|NCT03612115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786466|NCT05765591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|open label|Randomized controlled longitudinal interventional study||||
33786467|NCT06629285|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33924459|NCT01022151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924460|NCT01551472|||COHORT||PROSPECTIVE|||||||
33924461|NCT01241656|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33924462|NCT01504971|||COHORT||PROSPECTIVE|||||||
33924463|NCT00346255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924464|NCT00878891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33924465|NCT01676441|NA|SINGLE_GROUP||TREATMENT||NONE||"posterior cervical laminectomy and Mesenchymal stem cells(cellgram-spine) tranplantation.~After laminectomy, 1.6X107 and 3.2 X107 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively"||||
33924466|NCT01896739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924467|NCT04639908|||OTHER||OTHER|||||||
33924468|NCT04367792|||CASE_CONTROL||RETROSPECTIVE|||||||
33924469|NCT01615315|||COHORT||RETROSPECTIVE|||||||
33924470|NCT03118076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33924471|NCT03182842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33924472|NCT04530396|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized double-blind placebo-controlled|t|f|t|f
33924473|NCT03461185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924474|NCT01095341|||CASE_CONTROL||PROSPECTIVE|||||||
33924475|NCT04969432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924476|NCT00456885|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33924477|NCT02966353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924478|NCT03437213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33924479|NCT04617899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924480|NCT01767181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924481|NCT05803369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924482|NCT05889351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, Double-blind, Placebo-controlled Randomization 2:1, active to placebo|t|t|t|f
33924483|NCT02320968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924484|NCT00567060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924485|NCT04702984|NA|SINGLE_GROUP||TREATMENT||NONE|Lens will be provided with investigational product labeling|||||
33698739|NCT05427162|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33698740|NCT06469515|||COHORT||PROSPECTIVE|||||||
33698741|NCT02122432|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33698742|NCT01469624|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33698743|NCT05975073|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720263|NCT03331549|||COHORT||PROSPECTIVE|||||||
33720264|NCT01430091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720265|NCT04995133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720266|NCT00517621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786468|NCT04026191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786469|NCT00263679|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33786470|NCT05857293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786471|NCT04371718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786472|NCT00686946|||COHORT||PROSPECTIVE|||||||
33786473|NCT05684003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786474|NCT00882648|||||RETROSPECTIVE|||||||
34003356|NCT05765617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study used calcitriol and a placebo, which were similar in shape; researchers and patients did not know who was getting the drug or placebo.|This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.|t|t|t|t
34003357|NCT04755621|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33698744|NCT04425356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary investigator and team (including those involved with the data analysis) have no knowledge of which participants were assigned to intervention or control groups. Group assignment was conducted by Life Cross Training independently of the AHA investigation team. Participants are not blinded to their group assignment.|Three experimental groups (1 from each of the 3 different implementation sites) will receive the intervention while 3 control groups will not. The control groups will be placed on a waitlist to receive the intervention once the study period is complete.|f|f|t|f
33698745|NCT06193525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003358|NCT01872715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003359|NCT05167617|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34003360|NCT00361387|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33698746|NCT04143893|||COHORT||PROSPECTIVE|||||||
34003361|NCT03394833|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Non-blinded randomization. Standardized method comparison.||||
34090183|NCT06126978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will apply randomization sequence available on an online site https://www.randomizer.org/procedure, which will be performed by an independent person who is not included in the study. Allocation concealment was completed by the method of sequentially numbering opaque sealed envelopes (SNOSE), which depicted block randomization to ensure the allocation of equal number of participants in each group (Doig \& Simpson, 2005). Based on the inclusion and exclusion criteria, participants will be randomly distributed in either group A or group B.||f|f|f|t
33698747|NCT04004962|||COHORT||PROSPECTIVE|||||||
33698748|NCT05996848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|f|t|f
34090184|NCT03040531|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Drugs will be labelled as A and B and so will be the groups. Patients and doctors involved will not be aware of the treatment."||t|t|t|f
33698749|NCT03830385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698750|NCT01938573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720267|NCT00690092|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33720268|NCT03597958|||COHORT||CROSS_SECTIONAL|||||||
33720269|NCT02355119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786475|NCT06629428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786476|NCT02566148|||CASE_ONLY||RETROSPECTIVE|||||||
33786477|NCT05603442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924486|NCT00367432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924487|NCT05730374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33924488|NCT05934721|||OTHER||CROSS_SECTIONAL|||||||
33924489|NCT00975026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924490|NCT01708616||CROSSOVER||||DOUBLE|||t|f|t|f
33924491|NCT01752725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924492|NCT02255617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924493|NCT01198717|||COHORT||CROSS_SECTIONAL|||||||
33924494|NCT03689881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924495|NCT00510484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924496|NCT01610206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924497|NCT00347477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33924498|NCT04866095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924499|NCT03700268|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924500|NCT00646113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924501|NCT00995579|||COHORT||CROSS_SECTIONAL|||||||
33924502|NCT02712281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924503|NCT05343741|||COHORT||PROSPECTIVE|||||||
33924504|NCT00646672|||||RETROSPECTIVE|||||||
33924505|NCT05004350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924506|NCT06178887|||COHORT||RETROSPECTIVE|||||||
34090185|NCT04452175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090186|NCT00038610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786478|NCT04478305|NA|SINGLE_GROUP||TREATMENT||NONE||Single group longitudinal study||||
33786479|NCT06631625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33786480|NCT05591079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924507|NCT04686877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors are masked.|A surgical intervention model of stereotactic hematoma punctural catheter placement, drainage and urokinase irrigation in spontaneous intracerebral hemorrhage.|f|f|f|t
33924508|NCT00943254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33924509|NCT03485222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924510|NCT04381572|||COHORT||PROSPECTIVE|||||||
33924511|NCT00089102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924512|NCT00637377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924513|NCT02103881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924514|NCT02818127|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33924515|NCT00214487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924516|NCT04406012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Paravertebral block group and Control group|f|f|t|f
33924517|NCT01705587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924518|NCT04475263|||CASE_ONLY||CROSS_SECTIONAL|||||||
33924519|NCT06015568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924520|NCT00472017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924521|NCT03838367|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924522|NCT00577343|||COHORT||PROSPECTIVE|||||||
33924523|NCT02917629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33924524|NCT04877665|||OTHER||PROSPECTIVE|||||||
33924525|NCT01125618|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33698751|NCT05613881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant does not know which group he is in.|Experimental and control groups will be formed by randomization from individuals who meet the inclusion criteria. At the beginning of the research, a pre-test will be applied to both groups at the first interview. The individuals in the experimental group will be given an education and training booklet prepared in line with the literature by the researcher at the first interview. Only the training booklet will be given to the control group. Individuals in the experimental group will be called every 15 days for 3 months, in line with the Telephone Monitoring Instruction Form, to be interviewed and monitored. At the end of the 3rd month, the final tests will be applied. Individuals in the control group will be given post-tests at the end of the 3rd month..|t|f|f|f
33698752|NCT03207204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698753|NCT05684900|||COHORT||PROSPECTIVE|||||||
33698754|NCT02572388|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924526|NCT03230513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Primary Investigator (PI) was blinded as to the exercise type that the patient had learned and used and evaluates all the outcomes of the study.|"Participants were assigned to either the SEM group (written as Group A) or the BDE group (written as Group B) throughout the duration of the study."|f|f|t|f
33924527|NCT05031429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924528|NCT02043184|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33924529|NCT06353360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924530|NCT03722472|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All clinical staff and the participants are blinded to treatment, with the exception of the clinical pharmacist who prepares the vaccines and syringes.||t|t|t|t
33924531|NCT02572011|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33924532|NCT00554476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924533|NCT02428673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924534|NCT02119468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924535|NCT06185413|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Study design:~A wait-list design will be applied to assess three-year effectiveness of the participatory system dynamics approach to promote (increase and sustain) healthy physical activity behaviour among approximately 3000 children aged 6- to 12 years. Five municipalities have agreed to participate: two in the Central Denmark Region, one in the Capital Region of Denmark and two in the Zealand Region. Each municipality will allocate two communities to be either intervention or comparison community. According to the wait-list design, the participatory system dynamics approach will be implemented in the comparison community by the municipal staff after follow-up."||||
33924536|NCT04581863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924537|NCT05565014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924538|NCT02706119|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33924539|NCT00260429|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33924540|NCT05193968|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924541|NCT04501835|||CASE_ONLY||RETROSPECTIVE|||||||
33924542|NCT05690698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded trial|Parallel random assignment to receive either oral quetiapine (25-50 mg/day) or haloperidol (1-2 mg/day)|t|t|f|f
33924543|NCT02131545|NA|SINGLE_GROUP||OTHER||NONE||||||
33924544|NCT02141217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003362|NCT01069614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003363|NCT04034654|||COHORT||PROSPECTIVE|||||||
34003364|NCT03092414|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34003365|NCT02806609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34003366|NCT04732650|||CASE_ONLY||PROSPECTIVE|||||||
34003367|NCT03793296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003368|NCT03737916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003369|NCT00719589|||CASE_CONTROL||PROSPECTIVE|||||||
34003370|NCT01207492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003371|NCT01007409|RANDOMIZED|CROSSOVER||||NONE||||||
34003372|NCT01591824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003373|NCT00496262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003374|NCT04511611|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34003375|NCT05352438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
34003376|NCT01806311|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003377|NCT01910831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003378|NCT05489796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003379|NCT04712643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003380|NCT02625376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34003381|NCT06183320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003382|NCT00349401|RANDOMIZED|||TREATMENT||DOUBLE||||||
34003383|NCT05868824|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003384|NCT04193579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34003385|NCT01745094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003386|NCT03880149|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34003387|NCT03206151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003388|NCT02177552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003389|NCT02795676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003390|NCT03900884|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1b, open-label, multicentre dose escalation study of venetoclax in combination with palbociclib and letrozole in patients with ER positive and BCL-2 positive metastatic breast cancer. The study will enrol up to 36 patients with metastatic breast cancer, with the objective of defining the MTD of venetoclax in combination with palbociclib and letrozole. There will be up to a total of 6 dose levels. Three 'step-down' levels will also be included to incorporate the options of reducing the dose of palbociclib if required. The MTD will be the RP2D of palbociclib, letrozole and venetoclax.||||
34003391|NCT05454085|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003392|NCT02431624|RANDOMIZED|CROSSOVER||||NONE||||||
34090187|NCT04568109|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34090188|NCT02143648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698755|NCT00969254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090189|NCT01934179|||CASE_ONLY||PROSPECTIVE|||||||
34090190|NCT05844046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924545|NCT01611766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924546|NCT02150213|NA|SINGLE_GROUP||||NONE||||||
33924547|NCT01258517|||COHORT||PROSPECTIVE|||||||
33924548|NCT04857788|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33924549|NCT00776321|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33924550|NCT03579225|||CASE_ONLY||PROSPECTIVE|||||||
33924551|NCT03942237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924552|NCT00067821|||COHORT||PROSPECTIVE|||||||
33924553|NCT02312115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786481|NCT05779722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study will use a crossover design on where research participants will undergo repetitions of the same scenario with different interventions in order to serve as their own control.~We intend to perform the experiments in an outdoor laboratory in order to achieve the most realistic conditions possible. The experiments will be conducted in Hemsedal, Norway in our Mountain Lab, a climate chamber built inside a snow cave.~Before the start of the experiment, the research participants will be positioned in a supine position in the snow cave on an insulated stretcher in wet clothes saturated with a standardized amount of water. They will stay in this position for 45 minutes to allow for a drop in the skin temperature without a drop in core body temperature. After 45 minutes, the research participant will be randomised into one of two scenarios, intervention or control."||||
33924554|NCT04084405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34003393|NCT04245358|NA|SINGLE_GROUP||TREATMENT||NONE||"Open-label, non-comparative, interventional multicenter study. The recently developed polycarbophilic, vaginal moisturizing gel (Ainara®) is widely used by gynaecologists in Europe to relieve vaginal dryness and related symptoms. Regarding the design choice, the adoption of a comparison versus placebo was not possible for technical reasons (the impossibility to use a real placebo without moisturizing effects).~The Research Question of the present study is the following: in a population of post-menopausal women affected by vaginal dryness, will a 1-month treatment with polycarbophilic vaginal moisturizing gel (Ainara®) significantly decrease the symptomatology evaluated by VHI and VAS in comparison with the baseline condition?"||||
34003394|NCT06358963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The research was conducted using a double-blind methodology. To ensure impartiality, both the omega-3, Coq10, and control groups were given medications that had identical appearance, packaging, and color. To further eliminate bias, a clinician who had no involvement in the study labeled teh medications as A, B, and C (empty) based on their content, and distributed them among teh patients.|Randomized, Double-blind, Controlled design.|t|t|t|t
34003395|NCT06608030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33786482|NCT06504875|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34003396|NCT05958381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, assessors, and technicians interacting with participants will be blind to assigned conditions. The software for the transcranial direct current system allows for maintaining blinds when uploading and running protocols.|"Participants will be randomly assigned to 1 of 2 treatment arms: (1) 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to presupplementary motor area for 20 minutes over 15 sessions to (2) sham tDCS following the same schedule.~Additionally, after completing the initial active or sham treatment and immediate and 2-month follow-up testing sessions, selected participants will be invited back for newly assigned treatment conditions, 20 minutes over 15 sessions and will be and re-evaluated at immediate- and 2-months follow-up testing sessions."|t|t|t|t
34003397|NCT00258856|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003398|NCT06347809|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34003399|NCT03927495|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003400|NCT05494632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003401|NCT00096239||||TREATMENT||NONE||||||
33698756|NCT03682887|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Sample Size Determination A. 276 subjects will be enrolled in this study. After enrollment, subjects will be randomized in a 1:1 fashion to Cryoballoon PV isolation group (138 subjects) or Cryoballoon PV isolation group with additional RA linear ablation group (138 subjects).~B. The difference in the recurrence of atrial fibrillation between the two groups will be identified based on the data, with 80% statistical power and a 5% two-sided alpha error rate, to examine the 16% estimated difference between the groups, considering an about 5% dropout rate. The clinical recurrence rate of atrial fibrillation in the general control group was set at 39.3% considering the existing literature and the data of this hospital.~C. Statistical hypothesis: There is a significant difference in the clinical recurrence and risk of complications after cryoballoon pulmonary vein isolation and additional right atrial linear ablation for persistent atrial fibrillation."||||
34003402|NCT04883788|||COHORT||RETROSPECTIVE|||||||
34003403|NCT01680367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003404|NCT04846439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003405|NCT04287608|||CASE_CONTROL||PROSPECTIVE|||||||
34003406|NCT03857724|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003407|NCT00361686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698757|NCT00586651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786483|NCT00956449|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33698758|NCT03326739|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33786484|NCT02624778|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33786485|NCT00926393|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33786486|NCT02696629|||COHORT||OTHER|||||||
33786487|NCT05113927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The pathologist at each participating site will be blinded to the study arm to ensure that the pathological assessment is unbiased. Additionally, the subject will be blinded to their randomization until the BREAST-Q questionnaire has been completed.|Multi-center, randomized, double-arm trial|t|t|t|f
33786488|NCT02534896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924555|NCT00326157|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33924556|NCT04183387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924557|NCT05276765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33924558|NCT06377072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698759|NCT04986579|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33698760|NCT02872168|||CASE_ONLY||PROSPECTIVE|||||||
33698761|NCT00753766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003408|NCT03578718|||COHORT||PROSPECTIVE|||||||
33698762|NCT01683019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698763|NCT03495427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698764|NCT02753933|||COHORT||PROSPECTIVE|||||||
33698765|NCT03421340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698766|NCT05734989|||COHORT||PROSPECTIVE|||||||
33698767|NCT02890095|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33698768|NCT04849104|||COHORT||PROSPECTIVE|||||||
33698769|NCT04799327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assign to SHR20004 or placebo|t|f|t|f
33698770|NCT04543838|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blind|Randomized prospective single-blind clinical trial|t|f|f|f
33698771|NCT06455449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003409|NCT00212433|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34003410|NCT05996770|||OTHER||RETROSPECTIVE|||||||
34003411|NCT01279109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003412|NCT02670785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003413|NCT01792453|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003414|NCT04194606|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, open Label randomized controlled trial||||
34003415|NCT02865148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34003416|NCT01566994|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34090191|NCT04796974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090192|NCT01697046|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34090193|NCT04792892|||COHORT||PROSPECTIVE|||||||
34090194|NCT04568200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34090195|NCT06238960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090196|NCT03053011|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090197|NCT02880176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698772|NCT03216642|||CASE_ONLY||OTHER|||||||
33698773|NCT02239354|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33720270|NCT03035708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720271|NCT04728581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled trial||t|t|t|t
34003417|NCT02964390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003418|NCT04162587|||CASE_CONTROL||RETROSPECTIVE|||||||
34090198|NCT05920265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34090199|NCT04341051|||CASE_ONLY||PROSPECTIVE|||||||
34090200|NCT00564980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090201|NCT06322303|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34090202|NCT01295411|NA|SINGLE_GROUP||||NONE||||||
33698774|NCT05655052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"According to the AP Polyclinic admission sequence number and from the list determined by randomization (determined from the www.randomizer.org site), which group it is in will be determined. Study and control group assignments will be made.~It will be applied by the health personnel working in the Family Planning Counseling Polyclinic."|: A randomized controlled trial|f|t|f|f
34003419|NCT05855824|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator and statisticians on the team will be blinded. A staff member outside of the team will be responsible for randomly assigning and dispensing the study foods.|Participants will be randomized to a low, medium, or high carotenoid food intervention.|f|f|t|t
34003420|NCT05756738|RANDOMIZED|PARALLEL||SCREENING||NONE||"A randomized study will be designed in which all persons attending the Social Insertion Center (CIS) to serve alternative sentences to prison will be invited to participate. In order to study the prevalence of these persons compared to persons in open system, the latter will be offered to take the diagnostic test in situ at the CIS premises.~Persons with alternative sentences to prison will be informed of the study and, according to the randomization code, will be: a) given an envelope with all the necessary material to carry out the test at home and send it to the hospital for processing or, b) be tested on site at the CIS premises, who will also send it to the hospital for processing by the Central Laboratory of the University Hospital of the Canary Islands.~All patients who have participated will be notified by telephone of the test result, and patients with a diagnosis of active infection will be contacted and given an appointment to be evaluated and treated."||||
34003421|NCT04330157|||COHORT||PROSPECTIVE|||||||
34003422|NCT03935737|||COHORT||PROSPECTIVE|||||||
34003423|NCT03803254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003424|NCT02298387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003425|NCT02104258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34003426|NCT02756949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003427|NCT03266055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34003428|NCT04936594|NA|SINGLE_GROUP||TREATMENT||NONE|All participants received iTBS (intermittent theta burst stimulation) first and sham subsequently but were blinded regarding treatment.|Single blind within participant design||||
34003429|NCT00230191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34003430|NCT06299709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003431|NCT05179161|NA|SINGLE_GROUP||OTHER||NONE||||||
34003432|NCT06593067|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003433|NCT05695417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2:1|t|t|t|f
34003434|NCT01006967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003435|NCT04387617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34003436|NCT03297151|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Double blind (participant and investigator)|Block randomised, between group study|t|f|t|f
34003437|NCT04654832|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34003438|NCT03981705|||COHORT||PROSPECTIVE|||||||
34003439|NCT06608355|NA|SEQUENTIAL||TREATMENT||NONE||||||
34003440|NCT00504179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003441|NCT05327439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003442|NCT05119049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The initial, intermediate and final evaluations were carried out by a blind researcher, not familiar with the group assigned to the patients.|Experimental study randomized controlled|f|f|t|f
34003443|NCT02930876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34003444|NCT01953289|||COHORT||PROSPECTIVE|||||||
34003445|NCT04989569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34003446|NCT04520061|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Intervention; enhanced usual care||||
34003447|NCT06679426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be conducted as a double-blind, placebo-controlled trial. The appearance of the prefilled device containing placebo will be indistinguishable from those containing conestat alfa. The blinding will be maintained throughout the duration of the study for the subject. As such, only investigators and study staff blinded to the treatment assignments will be responsible for monitoring the patient and assessing efficacy and safety outcomes.|This Phase III study is designed as a randomized, double-blind, two-armed, placebo-controlled study (Figure 2). It will be conducted at two centers in the United States. The primary aim is to compare the efficacy of conestat alfa with a placebo in the treatment of ACE-I-induced AE based on the TMDC endpoint, assess its safety and tolerability, as well as compare its efficacy compared to the placebo based on the TOSR endpoint. Moreover, the proportion of patients in each arm who are hospitalized, admitted to the ICU, or who require an airway intervention will be compared.|t|t|t|t
34003448|NCT06031337|||CASE_CONTROL||PROSPECTIVE|||||||
34003449|NCT06120660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34003450|NCT00593827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003451|NCT03041532|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34003452|NCT05766787|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34003453|NCT00427024|||DEFINED_POPULATION||OTHER|||||||
34003454|NCT05215938|||COHORT||PROSPECTIVE|||||||
34003455|NCT01279915|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34003456|NCT04906941|||COHORT||PROSPECTIVE|||||||
34003457|NCT04282694|||COHORT||PROSPECTIVE|||||||
34003458|NCT00818220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34003459|NCT03826901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090203|NCT00494117|||COHORT||PROSPECTIVE|||||||
34090204|NCT02954081|||OTHER||PROSPECTIVE|||||||
33698775|NCT01749631|||||PROSPECTIVE|||||||
33698776|NCT05693766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698777|NCT03439787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo-controlled, double-blinded design|t|t|t|t
33698778|NCT02165371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33698779|NCT04436731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720272|NCT05372328|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33720273|NCT01714154|NON_RANDOMIZED|PARALLEL||||NONE||||||
33720274|NCT02078609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720275|NCT01333059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720276|NCT00727883|||COHORT||RETROSPECTIVE|||||||
34003460|NCT03559127|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Certified endodontist (3) trained in the procedures, devices, and irrigating systems investigated took part in the research. All experts tracked a pre-established procedure for Reciproc instrument systems and cryotherapy.|Random Selection of different temperature of irrigating solution groups. Of the sample of 240 teeth, 80 were randomly assigned to the one of the 3 irrigating protocols. Treatment was performed by 3 experienced endodontists; each prepared and irrigated 80 teeth.|t|f|t|f
34003461|NCT00355524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003462|NCT02578745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003463|NCT05653362|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|t|f|f
34003464|NCT06069544|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Observer-blinded||t|t|t|t
34003465|NCT06331130|||OTHER||PROSPECTIVE|||||||
33786489|NCT04242758|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34003466|NCT00055809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003467|NCT02497235|NA|SINGLE_GROUP||OTHER||NONE||||||
34090205|NCT01913353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786490|NCT03047590|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786491|NCT06710405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786492|NCT00312078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090206|NCT03991143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34090207|NCT06518759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786493|NCT01464684|||COHORT||PROSPECTIVE|||||||
33786494|NCT02540213|||COHORT||PROSPECTIVE|||||||
33786495|NCT04692948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786496|NCT05583240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786497|NCT06688734|RANDOMIZED|PARALLEL||TREATMENT||NONE||Alternating each month, patients with traumatic pneumothoraces receiving chest tubes will have their chest tubes placed to either water seal or suction initially. The remainder of the chest tube management will be left to the provider.||||
33786498|NCT03201757|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33786499|NCT04417712|||COHORT||PROSPECTIVE|||||||
33786500|NCT02219906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33786501|NCT04454567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003468|NCT02683291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003469|NCT01294449|||COHORT||PROSPECTIVE|||||||
34003470|NCT03865225|RANDOMIZED|PARALLEL||OTHER||SINGLE|Sham biofeedback intervention||t|f|f|f
34003471|NCT06678607|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34003472|NCT00802373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003473|NCT04911205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003474|NCT02129517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103212|NCT06290193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103213|NCT04546243|||COHORT||RETROSPECTIVE|||||||
33786502|NCT01569906|||CASE_CONTROL||PROSPECTIVE|||||||
33786503|NCT00447434|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786504|NCT06614972|||COHORT||PROSPECTIVE|||||||
34003475|NCT03690089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked|Multicentre, randomised, double-masked, placebo-controlled superiority trial|t|t|t|t
34003476|NCT00671567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003477|NCT03787017|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33924559|NCT04783870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will receive either Dapagliflozin or Placebo. They will not know which arm they have been allocated to.||t|f|f|t
34003478|NCT00464113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003479|NCT02894827|||CASE_ONLY||RETROSPECTIVE|||||||
34003480|NCT06394115|||COHORT||PROSPECTIVE|||||||
34003481|NCT01066130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003482|NCT01023061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090208|NCT03315364|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Phase II clinical trial~   * Multicenter, Open-label, Single arm, Simon's optimal two-stage design~2. Phase III clinical trial~   * Multicenter, Prospective Randomized Open-label Blinded Endpoint (PROBE) design"||||
34090209|NCT02050100|||COHORT||PROSPECTIVE|||||||
34090210|NCT00000640||||TREATMENT||DOUBLE||||||
33786505|NCT05512936|||CASE_ONLY||CROSS_SECTIONAL|||||||
33786506|NCT06184789|||COHORT||RETROSPECTIVE|||||||
34090211|NCT03990753|||COHORT||PROSPECTIVE|||||||
34090212|NCT02392910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786507|NCT04859777|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part A: Each dose-escalation cohort will initially recruit single-subject cohorts until a subject has a Grade 2 or greater adverse event (AE) during the DLT period considered at least possibly related to MPT-0118, at which time 2 additional subjects will be enrolled in that cohort, and a 3 + 3 design will subsequently be utilized.~Part B: Each dose-escalation cohort will initially recruit 3 patients to receive MPT-0118 + pembrolizumab in a standard 3+3 design; the cohort will be expanded in the event of a DLT.~Part C: Once the RP2D has been established for MPT-0118 monotherapy and combination therapy with MPT-0118 + pembrolizumab, expansion cohorts will be enrolled to further evaluate combination therapy."||||
33786508|NCT00598897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003483|NCT01513044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003484|NCT01530945|||COHORT||PROSPECTIVE|||||||
34003485|NCT06210685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003486|NCT02725645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003487|NCT01808248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003488|NCT00778687|||COHORT||PROSPECTIVE|||||||
34090213|NCT01289977|||COHORT||PROSPECTIVE|||||||
33786509|NCT02350595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924560|NCT00907972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924561|NCT06420999|||COHORT||PROSPECTIVE|||||||
33924562|NCT05463159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924563|NCT04777604|||COHORT||PROSPECTIVE|||||||
33924564|NCT00751179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924565|NCT06306326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924566|NCT05119088|NA|SINGLE_GROUP||OTHER||NONE||||||
33924567|NCT01071668|||COHORT||PROSPECTIVE|||||||
34003489|NCT06044727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34090214|NCT01530919|||COHORT||CROSS_SECTIONAL|||||||
34090215|NCT02242344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34090216|NCT03564262|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34090217|NCT05104125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090218|NCT01663376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090219|NCT00738088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090220|NCT02806076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090221|NCT00232882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090222|NCT02359708|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34090223|NCT01422109|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698780|NCT05046184|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Subjects and study team members, including the PI, study-affiliated physicians, coordinator, nursing staff, and data analysts will be blinded to the drug assignment until the completion of the proposed project. Only the research pharmacist and study members involved in safety monitoring (medical monitor, independent safety monitor, and data analyst responsible for generating safety reports) will know the identity of the drug.|All subjects (Healthy Controls and MDD) will undergo resting-state and task-based fMRI and cerebral prefusion to characterize the (i) patterns of functional connectivity and (ii) neural responses to a behavioral task eliciting frustrative nonreward (FNR) that are associated with irritability \[quantified with the 5-item irritability domain of Concise Associated Symptom Tracking scale (CAST-IRR)\]. The MDD cohort (n=60) will then be randomized to four 40-minute intravenous infusions over two weeks of either ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg) in a double-blind, parallel-arm fashion. Clinical assessments and 3T MRI scans will be repeated after the last infusion to evaluate (i) pre-to-post treatment changes in neurocircuit function using resting-state and FNR task-based fMRI with ketamine versus midazolam and (ii) the association between changes in neurocircuit function and irritability.|t|t|t|t
33698781|NCT00423514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003490|NCT00290264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003491|NCT00004906||||TREATMENT||||||||
33698782|NCT00131508|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34003492|NCT01367938|||CASE_CONTROL||PROSPECTIVE|||||||
33698783|NCT06680206|||OTHER||RETROSPECTIVE|||||||
34003493|NCT05531617|RANDOMIZED|PARALLEL||SCREENING||NONE||A prospective,randomised, open label study||||
34003494|NCT01397266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33698784|NCT01074905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003495|NCT06630611|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 1:1 over the two study arms. Randomization will be stratified by cancer type (melanoma and non-melanoma) and center following a block randomization. Of the total 40 patients, the first 10 patients recruited in the study will be metastatic melanoma patients. Of the remaining 30 patients 10 of them must be melanoma patients (20 in total) and the other 20 patients will be preferably NSCLC or cervical cancer, but additional patients with melanoma can also be included.||||
34003496|NCT01536249|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698785|NCT06677021|NA|SINGLE_GROUP||OTHER||NONE||||||
33698786|NCT02504710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698787|NCT04515173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698788|NCT01565642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34003497|NCT04134637|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33698789|NCT01135212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698790|NCT04992910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698791|NCT00269594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003498|NCT06266754|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A placebo will be used.|Randomised trial|t|f|f|t
33786510|NCT03742713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786511|NCT05095623|||OTHER||PROSPECTIVE|||||||
34003499|NCT00297141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003500|NCT02159287|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786512|NCT01356225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786513|NCT02195557|||COHORT||PROSPECTIVE|||||||
33786514|NCT06713109|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||breastfeeding problems anxiety motivational interviewing||||
33786515|NCT06443021|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, multi-centric, interventional||||
33786516|NCT01823341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924568|NCT01003795|||COHORT||RETROSPECTIVE|||||||
33924569|NCT05474469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924570|NCT04883567|||COHORT||PROSPECTIVE|||||||
34003501|NCT03854409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34003502|NCT01253850|||COHORT||OTHER|||||||
34003503|NCT06409858|NA|SINGLE_GROUP||OTHER||NONE||||||
33786517|NCT00679276|||CASE_CONTROL||RETROSPECTIVE|||||||
33786518|NCT01266044|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33786519|NCT06626334|RANDOMIZED|PARALLEL||TREATMENT||NONE|This trial is unblinded due to the nature of a lighting intervention, in which participants and investigators will know which intervention is being administered.|Eligible participants who provide informed consent will be randomized 1:1:1 to bright blue light intervention, bright full-spectrum (white) light comparison, and usual light control arms. Permuted block randomization with random block sizes and stratified by age (less than 65 years, greater than or equal to 65 years) will be used for allocation to the three study arms. Assigned lighting interventions will be administered using commercially-available light therapy lamps (Day\*Light Classic Plus) fitted with appropriate filters (LEE Filters) and mounted on stands with rolling casters to facilitate bedside use.||||
33786520|NCT03158948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised, Double-blind, Two-Stage, Placebo Controlled|t|t|t|t
33786521|NCT06627582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924571|NCT03831737|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924572|NCT04952051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924573|NCT04814472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924574|NCT00033228||PARALLEL||TREATMENT||NONE||||||
33924575|NCT03067194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Assignment|t|t|t|f
33924576|NCT00801138|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33924577|NCT03052387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924578|NCT03330600|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33924579|NCT03822702|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33924580|NCT01803711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924581|NCT05931133|||OTHER||CROSS_SECTIONAL|||||||
34003504|NCT02867085|||COHORT||PROSPECTIVE|||||||
34090224|NCT02060162|||COHORT||PROSPECTIVE|||||||
34090225|NCT02412943|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090226|NCT06510127|||COHORT||CROSS_SECTIONAL|||||||
34090227|NCT01685554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090228|NCT02474368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003505|NCT06150599|NA|SEQUENTIAL||TREATMENT||NONE|"Device is turned on/off, or settings are modified throughout the study. The protocol specifies the exact timing of when the device is turned on/off and or settings are modified. All patients will be on the same schedule. To maintain study integrity, patients will not be informed how device settings are changed; however, since this is a single-arm study, open label has been chosen above. During the informed consent process, patients will be explained that throughout the study, the device settings will be modified and that some of these changes may result in symptoms improving while others may cause symptoms to worsen."|"Single arm and participant-blinded sequential treatment controlled clinical trial. The device will be turned on or off, and settings adjusted at each visit. To minimize bias throughout the study, patients will be blinded to the device settings; however, since there is only one arm, open label has been chosen below."||||
34003506|NCT04212728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003507|NCT03017014|||COHORT||PROSPECTIVE|||||||
34003508|NCT00110851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003509|NCT04956445|||COHORT||PROSPECTIVE|||||||
34003510|NCT06675227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34003511|NCT00275639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003512|NCT02230176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003513|NCT02406287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003514|NCT06677840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003515|NCT05999734|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34003516|NCT02314494|||||PROSPECTIVE|||||||
34003517|NCT03388099|||COHORT||PROSPECTIVE|||||||
34003518|NCT03468296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003519|NCT01487499|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003520|NCT05955937|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||After 1-2 month-long run-in periods to allow for integration and adoption of the interventions all sites will receive the multi-component implementation strategy, beginning with the Core HF and followed by Medly Uganda. Sites will be randomized using a randomization software to receive the interventions at different start points after the first six months, for varying durations throughout the 3-year study period.||||
34003521|NCT06190886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003522|NCT01029509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698792|NCT03883399|||OTHER||PROSPECTIVE|||||||
33698793|NCT00190970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698794|NCT03801083|NA|SINGLE_GROUP||TREATMENT||NONE||The Phase 2 study will follow the Simon's optimal two-stage design. Fifteen patients will be included in the first stage; if there are 1 or fewer patients responding to therapy the trial will be terminated. If at least 2 responses were observed, expansion into Stage 2 to a total of 47 patients will occur. If at least 6 patients respond to therapy, the study therapy would be considered to have met its primary study goal.||||
33698795|NCT01008176||PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924582|NCT04980898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The third blind person will have photographs of the wound at 10 weeks and all the surface readings on tracing paper necessary for the automated calculation of the surface with specific software. Readings will be sent in random order and third parties will not know the treatment, patient or date of the reading.|Superiority randomized controlled study, open label with blinded primary outcome assessor, multicentric|f|f|f|t
33924583|NCT01652937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924584|NCT00248378|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33924585|NCT00001127||||PREVENTION||NONE||||||
33924586|NCT06402903|||COHORT||OTHER|||||||
33924587|NCT02418767|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33924588|NCT03950999|NA|SINGLE_GROUP||OTHER||NONE||||||
33924589|NCT06580470|NA|SINGLE_GROUP||TREATMENT||NONE||Cognitive Behavioral Therapy for Menopause (CBT-Meno) is an evidenced-based intervention that includes psychoeducation, cognitive, and behavioral strategies for coping with common menopause symptoms and experiences. In Aims 1 and 2, CBT-Meno materials and procedures will be tailored for women Veterans through an iterative process involving: a) data from preliminary studies and a pre-pilot trial; b) input from content area experts; and c) stakeholder advisory panels. This tailored version of CBT-Meno will then be test in this clinical trial.||||
33924590|NCT00463879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924591|NCT01184456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924592|NCT03012282|NA|SINGLE_GROUP||OTHER||NONE||||||
34003523|NCT03377972|||COHORT||OTHER|||||||
34003524|NCT02129062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003525|NCT06678035|||COHORT||PROSPECTIVE|||||||
34003526|NCT02846233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003527|NCT05732350|||COHORT||PROSPECTIVE|||||||
34003528|NCT01545739|||CASE_ONLY||PROSPECTIVE|||||||
34003529|NCT01720849|||COHORT||PROSPECTIVE|||||||
34003530|NCT04037982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003531|NCT03310086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003532|NCT05257694|||COHORT||PROSPECTIVE|||||||
34003533|NCT05505760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34003534|NCT03109327|||COHORT||PROSPECTIVE|||||||
34003535|NCT01520987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003536|NCT04197258|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33698796|NCT01908920|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33698797|NCT00240695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698798|NCT05692167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698799|NCT06009029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698800|NCT04140838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-blind, parallel-group, randomized controlled trial|f|f|t|t
33698801|NCT04828460|||COHORT||RETROSPECTIVE|||||||
33924593|NCT01357889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003537|NCT00329160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003538|NCT06188585|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned with concealed allocation in a 1:1 ratio to receive treatment with UI-EWD hemostatic powder (Nexpowder) or conventional endoscopic hemostatic therapy (defined as bipolar electrocoagulation or clips with or without epinephrine injection therapy).||||
34090229|NCT01176175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698802|NCT01132274|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698803|NCT05971433|||COHORT||CROSS_SECTIONAL|||||||
33698804|NCT05578248|||COHORT||PROSPECTIVE|||||||
33698805|NCT06220279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698806|NCT00299182|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33698807|NCT01436916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33698808|NCT04308304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698809|NCT00412997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698810|NCT04215250|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698811|NCT04016233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33698812|NCT02805972|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33698813|NCT05543889|||COHORT||PROSPECTIVE|||||||
33698814|NCT05847361|||COHORT||PROSPECTIVE|||||||
33698815|NCT00484809|||||PROSPECTIVE|||||||
33698816|NCT06681883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698817|NCT02572362|||||RETROSPECTIVE|||||||
33698818|NCT03081468|||CASE_ONLY||CROSS_SECTIONAL|||||||
33698819|NCT02128906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786522|NCT01005992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786523|NCT03539159|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33924594|NCT03239639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned in 1:1 ratio to intervention or wait list control group||||
33924595|NCT04575831|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm feasibility study of multimodal intervention||||
33924596|NCT02666508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924597|NCT01939964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924598|NCT03555071|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33924599|NCT05049343|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33924600|NCT01082367|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33924601|NCT04869176|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924602|NCT00562016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924603|NCT04394143|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Evaluators, investigators and patients will be blinded to treatment allocation. Treatments will be prepared and conditioned by the Pharmacy Service of the University Hospital of Lausanne according to a randomisation list performed by an independent statistician. The Pharmacy service is completely independent from the Center for Investigation and Research in Sleep (CIRS). Unblinding will be performed after statistical analysis is completed by a statistician blinded to treatment assignment.|This is a randomized, placebo-controlled, double-blind crossover study|t|f|t|t
33924604|NCT02474823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924605|NCT02111512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924606|NCT04018703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924607|NCT02000557|||CASE_ONLY||CROSS_SECTIONAL|||||||
33924608|NCT04600843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924609|NCT00961662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924610|NCT01432093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924611|NCT03120364|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33924612|NCT04902768|||CASE_ONLY||CROSS_SECTIONAL|||||||
33924613|NCT04406389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924614|NCT06449846|||COHORT||PROSPECTIVE|||||||
33924615|NCT06180668|||COHORT||PROSPECTIVE|||||||
33924616|NCT01585493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924617|NCT00042562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924618|NCT04735965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924619|NCT04853589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924620|NCT02494219|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924621|NCT03621306|||COHORT||CROSS_SECTIONAL|||||||
33924622|NCT00295737|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33924623|NCT02219711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924624|NCT00324688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924625|NCT00531492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698820|NCT06106607|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Allocation status of study participants will not be revealed for the project nurses that conduct the outcome assessments||f|f|f|t
33698821|NCT00195273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698822|NCT03265301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698823|NCT05539131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698824|NCT01067066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698825|NCT00393354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698826|NCT02772887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33698827|NCT04523948|||COHORT||PROSPECTIVE|||||||
33698828|NCT01833988|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924626|NCT01781871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924627|NCT04749563|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The study subjects will be blinded to the treatment|3 dose escalation cohorts in same 12 subjects (5:1 randomization (active:placebo)|t|t|f|t
33924628|NCT03299309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924629|NCT00852319|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33924630|NCT00103597|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33924631|NCT00973622|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33924632|NCT01771367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33924633|NCT06403813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Kenyan study site personnel who carry out Time 2 family data collection will be masked to intervention conditions.||f|t|f|f
33924634|NCT02843919|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924635|NCT02832518|||CASE_ONLY||PROSPECTIVE|||||||
33924636|NCT06236308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924637|NCT05185817|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924638|NCT00854464|||CASE_CONTROL||RETROSPECTIVE|||||||
33924639|NCT01307553|||COHORT||PROSPECTIVE|||||||
33924640|NCT01320956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34090230|NCT02903654|||||CROSS_SECTIONAL|||||||
34090231|NCT00435942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090232|NCT00102973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090233|NCT02242630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090234|NCT05220735|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34090235|NCT00000142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090236|NCT02749734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090237|NCT01717508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090238|NCT04278313|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Participants will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP)|t|t|t|t
34090239|NCT04214782|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34090240|NCT00566033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34090241|NCT00479232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090242|NCT05709080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33924641|NCT01277471|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924642|NCT01422512|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33924643|NCT02504177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924644|NCT02458261|||OTHER||PROSPECTIVE|||||||
33924645|NCT00272545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924646|NCT05224440|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||To execute the Hybrid Type 2, we will use a stepped wedge design, which relies on sequential roll-out to participating cities over time. The cities in Texas with the largest population density of veterans were selected. Our design also enables us to make efficient use of all data available for within-site and between-site comparisons. The comparison examines cities as they cross-over from Transition as Usual (TAU) to intervention. The between-site comparison evaluates the intervention period for a city vs. all other intervention and TAU periods for all cities. We randomized at the city level and will use TSMVs as the unit of observation for primary quantitative outcome measures. Six cities are participating in the evaluation, with two cities allocated to each of the three start dates or steps. Because cities differ regarding organizational characteristics, we used the restricted selection method of randomization to balance cities based on the number of projected TSMV moving to target.||||
33924647|NCT01254578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924648|NCT04671069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924649|NCT01386957|||COHORT||PROSPECTIVE|||||||
33924650|NCT05304572|||CASE_ONLY||PROSPECTIVE|||||||
33924651|NCT03841526|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|CRC Phase was a fully masked double-blind crossover with each subject receiving each treatment 1 time. In the Outpatient Phase, the two arms with 50% insulin pump reduction were double-blind (fully masked) and the arm with Glucagon RTU and no insulin pump reduction was open-label.|CRC Phase: randomized, placebo-controlled, double-blind, two-treatment, two-period, crossover comparison in a clinical research center (CRC) setting. The subjects were re-randomized into the Outpatient Phase: randomized, placebo-controlled, partially double-blind, 3-arm parallel comparison in an outpatient setting.|t|t|t|t
33924652|NCT02251158|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924653|NCT00700843|||CASE_ONLY||PROSPECTIVE|||||||
33924654|NCT02711605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924655|NCT02264171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924656|NCT01541111|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33924657|NCT00756704|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33924658|NCT03094611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924659|NCT03491930|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A single group of participants will undergo study participation of listed interventions, over a 3 month outpatient period, to assess the effects on weight loss. A control group will receive all of the interactions and testing as the intervention group, except they will not use the weight loss app or receive weekly phone coaching.||||
33924660|NCT04231032|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blind, randomised, cross-over design|t|t|f|f
33924661|NCT01765946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924662|NCT03080467|||COHORT||PROSPECTIVE|||||||
33924663|NCT05072756|||CASE_ONLY||CROSS_SECTIONAL|||||||
33924664|NCT02942706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924665|NCT00035152|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924666|NCT05851794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090243|NCT02814019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698829|NCT05816720|||COHORT||RETROSPECTIVE|||||||
33698830|NCT04247776|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic RCT Effectiveness- Implementation Hybrid||||
33698831|NCT01408797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698832|NCT00860444|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33698833|NCT00694915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698834|NCT02060773|||COHORT||PROSPECTIVE|||||||
33698835|NCT01138839|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33698836|NCT00910273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720277|NCT02416258|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33720278|NCT05193864|||COHORT||PROSPECTIVE|||||||
33720279|NCT02637700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720280|NCT01968668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720281|NCT03785665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multi-Center, Open, Home Monitoring, Prospective Study||||
33924667|NCT05985070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924668|NCT02854007|||COHORT||PROSPECTIVE|||||||
33924669|NCT06109519|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"All patients in this study will be divided into two equal groups Group I (control): patients who would be delivered mandibular implant overdenture using conventional locator attachments.~Group II (study): patients who would be delivered mandibular implant overdenture using Locator RTX attachments"|t|f|f|f
33924670|NCT01972854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924671|NCT01144195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924672|NCT00418730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924673|NCT02581124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924674|NCT00881790|||COHORT||CROSS_SECTIONAL|||||||
33924675|NCT00661570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924676|NCT01577784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924677|NCT04693520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924678|NCT04992546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924679|NCT02479438|||COHORT||PROSPECTIVE|||||||
33924680|NCT04297410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924681|NCT04110184|||CASE_CONTROL||PROSPECTIVE|||||||
33924682|NCT03447821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924683|NCT00724815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924684|NCT04679558|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33924685|NCT02091947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924686|NCT01672528|||COHORT||PROSPECTIVE|||||||
33924687|NCT00344760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924688|NCT01601704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924689|NCT03371251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924690|NCT03295591|||COHORT||PROSPECTIVE|||||||
34003539|NCT06638398|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34003540|NCT00337558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003541|NCT04702126|||CASE_ONLY||RETROSPECTIVE|||||||
34003542|NCT01376544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003543|NCT03023189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003544|NCT03869424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924691|NCT03256409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The working protocol for determining the BOD Ra and BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator and the following working methodology was considered: Information to the patient and obtainment of clinical data and patient informed consent. Patients were randomly assigned to group 1 and group 2. The saliva sample was obtained in each patient for the microbiological before the installation of the overdentures. BODs and BJODs were installed in each patient and according to each case. The BOD and BJOD were removed at 30 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml). For the study at 180 days the BODs and the BJODs were installed in each patient. BODs and BJODs were removed after this time to proceed to the evaluation of surface roughness and adhesion of mold and yeast and mesophyll aerobe under the same parameters mentioned above.|The study presents the results of a sample of ten patients randomly assigned to receive implant-retained overdentures and divided into two parallel groups of five participants in a single-blind trial at a follow-up period of 30 - 180 days permanence in the mouth. Five overdentures were made for each group: Group 1: BOD: five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (BOD). Group 2: BJOD: five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra were used in two parallel groups of five participants, in an essay to simple blind person.|f|f|t|f
34003545|NCT06462144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003546|NCT03157869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34003547|NCT03169621|||OTHER||PROSPECTIVE|||||||
34003548|NCT01396694|||COHORT||PROSPECTIVE|||||||
34090244|NCT01644929|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34003549|NCT05127135|NA|SEQUENTIAL||TREATMENT||NONE||||||
34090245|NCT01529268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090246|NCT02706496|||COHORT||PROSPECTIVE|||||||
34090247|NCT01373619|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090248|NCT02387112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924692|NCT04099706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation will be masked. All patients will undergo the procedure under general anaesthesia. The randomized allocation will take place during surgery.||t|f|t|t
33924693|NCT01013493|||CASE_CONTROL||RETROSPECTIVE|||||||
33924694|NCT00002908||||TREATMENT||||||||
33924695|NCT01843361|||CASE_ONLY||PROSPECTIVE|||||||
34003550|NCT03230123|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with diabetes and Pre-diabetes were randomly allocated to receive diet alone or diet plus green banana biomass suplementation during a six-month intervention period.||||
33698837|NCT06242600|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The healthcare practitioner placing the catheter will know the allocation (whether it is a CytaCoat LIP Foley catheter or the comparator) but the participant will not know which catheter they have received.~The healthcare practitioner removing the catheter will not know the allocation. Urine samples that are analysed will not state which arm the participant is in."|Randomized 1:1 to CytaCoat LIP Foley catheter / uncoated silicone Foley catheter (15 patients in each arm).|f|f|f|t
33698838|NCT00318058|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698839|NCT06311851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003551|NCT06594588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003552|NCT01043250|||CASE_ONLY||RETROSPECTIVE|||||||
34003553|NCT03363698|||COHORT||PROSPECTIVE|||||||
34003554|NCT00260273|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34090249|NCT03081169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090250|NCT01571375|||CASE_CONTROL||PROSPECTIVE|||||||
34090251|NCT02660099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090252|NCT03279315|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants received a diet with iodized table salt or non-iodized table salt||||
34090253|NCT00327093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090254|NCT00469547|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33698840|NCT06680752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786524|NCT00192153|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33786525|NCT05038124|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study to evaluate the safety of preoperative stereotactic body radiotherapy (SBRT) with short-interval surgical stabilization.||||
33786526|NCT01762371|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786527|NCT00574886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786528|NCT02933320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786529|NCT06242964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786530|NCT05587140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33786531|NCT03767764|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786532|NCT06055595|||COHORT||PROSPECTIVE|||||||
33786533|NCT03842150|||COHORT||PROSPECTIVE|||||||
34090255|NCT00707200|||CASE_CONTROL||PROSPECTIVE|||||||
34090256|NCT03698461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090257|NCT02503046|||CASE_CONTROL||RETROSPECTIVE|||||||
34090258|NCT02358629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090259|NCT04808037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090260|NCT01344564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090261|NCT04877964|||COHORT||PROSPECTIVE|||||||
33698841|NCT01066403|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33698842|NCT00322101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698843|NCT04971707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This clinical trial is a double-blinded study. Patients, and research personnel performing the outcome assessments and investigators will be blinded to group allocation. Only the kinesiologists will be aware of the group allocation.|parallel assignment, 2 groups (1:1)|t|f|t|t
33698844|NCT06201663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003555|NCT03045133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Group assignments were sealed in sequentially numbered opaque envelopes that were opened after patient inclusion in the study. All care providers, researchers, and patients were blinded to group assignments. Study 10-mL syringes will be prepared by an anesthesiologist independent of the study. Methadone 0.1 mg.kg-1 (made up to 10 mL with normal saline) or morphine 0.1 mg.kg-1 (made up to 10 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope is opened.~The baseline QoR-40 questionnaire will be provided to subjects after informed consent is obtained in the preoperative holding area and 24 hours after surgery by a blinded investigator."|Prospective, randomized, double-blinded trial|t|t|t|t
34003556|NCT04601350|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34003557|NCT05659758|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003558|NCT06033313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34003559|NCT00676650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003560|NCT05638724|||COHORT||PROSPECTIVE|||||||
34003561|NCT04153318|||OTHER||PROSPECTIVE|||||||
34003562|NCT06227520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003563|NCT04139460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Trial participants will be blinded to the device type for the whole duration of the trial.~The randomizing and implanting physicians will not be blinded to the type of the device. These physicians will not take care in the subsequent patients' follow-up and sign a declaration of confidentiality.~The same will be true for the physicians / technicians attending to the device interrogation during follow-up visits. The device type will be hidden and physicians will sign a declaration of confidentiality. The patients' documentation will not reveal the device type.~A maximum effort will be done to hide the type of the implanted device. The implantation will be intramuscular and the device interrogation follow-up visits will not reveal the device type.~The physicians attending the follow-up visits and entering all patients' data into web-based CRF will be blinded to the implanted device type.~The outcomes assessors will also be blinded to the implanted device type."|Prospective, randomized, interventional parallel-design trial|t|t|t|t
34003564|NCT04392687|||OTHER||PROSPECTIVE|||||||
34003565|NCT05578469|||COHORT||RETROSPECTIVE|||||||
34003566|NCT06448637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003567|NCT06086496|||CASE_ONLY||PROSPECTIVE|||||||
34003568|NCT06280417|||CASE_ONLY||PROSPECTIVE|||||||
34090262|NCT02988609|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34090263|NCT00952913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698845|NCT00003742||||TREATMENT||||||||
33698846|NCT00814866|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698847|NCT03604458|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33698848|NCT05737849|||COHORT||RETROSPECTIVE|||||||
33698849|NCT06025305|||COHORT||RETROSPECTIVE|||||||
33698850|NCT01062672|||CASE_CONTROL||PROSPECTIVE|||||||
33698851|NCT03416907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33698852|NCT03316365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Home training instructions were provided by a certified physical therapist and board-certified neurologic music therapist blinded to treatment allocation of the subjects.~The TUG and the BBS were administered by an experienced physical therapist blinded to the study design."||f|t|f|t
33698853|NCT05047185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33698854|NCT03594526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Masking will be done to participant and outcomes assessor|The assigment of the mothers to each group will be like that: The allocation will be generated in the Epidat 4.1 program. This will be done by blocks in groups of equal size, randomized 1: 1, control and intervention group. The generation will be given by an statistician who will not perform the intervention, nor the initial or final evaluations.|t|f|f|t
33698855|NCT00418249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698856|NCT02478372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090264|NCT00439439|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34090265|NCT05994417|||COHORT||PROSPECTIVE|||||||
34090266|NCT00916734|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33698857|NCT05991700|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33698858|NCT03761667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698859|NCT00617851|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33698860|NCT06681584|||COHORT||PROSPECTIVE|||||||
33698861|NCT05530785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698862|NCT03644680|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this single-center, randomized, placebo-controlled, double-blind study a total of 36 patients will be recruited into this study on a voluntary basis and will be randomised to receive a nasal challenge with either birch pollen extract or placebo.|t|t|t|f
33698863|NCT04343820|||COHORT||PROSPECTIVE|||||||
33720282|NCT03125070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33720283|NCT05682781|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33720284|NCT04425265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090267|NCT02820389|||COHORT||PROSPECTIVE|||||||
34090268|NCT05166876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All staff will be blinded to treatment with the exception of the pharmacist and any staff recording study drug administration.|All subjects will receive standard of care. In addition, subjects will be randomly assigned to one of 3 treatments: brequinar (50 mg, 100 mg, 150 mg, or 200 mg), placebo (50 mg, 100 mg, 150 mg, or 200 mg), or brequinar + dipyridamole (75 mg TID) in a 2:1:1 ratio in Part 1 of the study using a dose escalation approach. An expansion cohort is planned with the highest safe brequinar dose.|t|t|t|f
34090269|NCT05290675|||COHORT||PROSPECTIVE|||||||
34090270|NCT06348043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924696|NCT03406364|NA|SEQUENTIAL||TREATMENT||NONE||"Phase I:~Eligible subjects will receive 1 of 3 different dosages of the combination therapy of GW5074 and sorafenib. The dose cohorts include:~* Monotherapy with 750 mg QD GW5074, followed by 750 mg QD GW5074 + 200 mg QD Sorafenib~* 1500 mg QD GW5074 + 200 mg QD Sorafenib~* 750 mg BID GW5074 + 200 mg QD Sorafenib"||||
33924697|NCT04140604|RANDOMIZED|PARALLEL||OTHER||DOUBLE|This is a double-blind study so neither investigator and site staff, nor the subject know which treatment has been assigned.|"Active:~1. Lactobacillus salivarius AP-32.~2. Bifidobacterium animalis subsp. lactis CP-9. supplied as 0.5 g capsules.~Placebo:~The placebo capsules are identical to the Lactobacillus salivarius AP-32 and Bifidobacterium animalis subsp. lactis CP-9 capsules except for the probiotics."|t|f|t|f
33924698|NCT05021796|||COHORT||CROSS_SECTIONAL|||||||
33924699|NCT00962754|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33924700|NCT05128526|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Two-way repeated analyses of variance were used to determine the statistical significance of muscles electromyography activity|Two-way repeated analyses of variance were used to determine the statistical significance of muscles electromyography activity|t|f|f|f
34003569|NCT02664987|||CASE_ONLY||CROSS_SECTIONAL|||||||
34003570|NCT04902911|||COHORT||PROSPECTIVE|||||||
34003571|NCT03795376|||COHORT||PROSPECTIVE|||||||
34003572|NCT00096122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003573|NCT03760874|||COHORT||PROSPECTIVE|||||||
34090271|NCT02936765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090272|NCT06044870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090273|NCT01197066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090274|NCT00992875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34090275|NCT04553315|RANDOMIZED|PARALLEL||PREVENTION||NONE||implementing chest expansion exercises on patient with pleural effusion to evaluate its efficacy on preventing pulmonary infection and complications||||
34090276|NCT04129541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34090277|NCT02661971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090278|NCT03661918|RANDOMIZED|FACTORIAL||OTHER||SINGLE||This study is a 2 x 2 x 2 randomized clinical trial. In addition to the 10 core coaching sessions, there will be three additional components available to participants, depending on the experimental condition to which they are randomized. These potential additional components include 1) the first session being conducted in person, 2) involving a second adult caregiver, and 3) a weekly weighing of child via WiFi-enabled scales.|t|f|f|f
34090279|NCT05690516|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Sequence generation. We will use a simple 1:1 randomization by means of computer-generated random numbers.~The allocation will be concealed as the participant themselves will be directly informed of their allocation as soon as they have agreed to take part in the trial and have completed the online consent and baseline form. Generation of allocation sequence, enrolment of participants and assignment of participants will all be handled by the digital recruitment platform."||||
34090280|NCT04201600|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34090281|NCT05714761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090282|NCT01677793|||OTHER||OTHER|||||||
34090283|NCT02772731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090284|NCT03018730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924701|NCT00781872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924702|NCT00162526|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33924703|NCT04401904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||20 completed subjects are planned. Each subject will be randomized to either the experimental group of dapagliflozin 10mg daily for 12 weeks or the control group of nutritional counseling for weight loss.||||
33924704|NCT03747991|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34003574|NCT02101073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003575|NCT06062550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34003576|NCT01960608|||||RETROSPECTIVE|||||||
34003577|NCT04386408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003578|NCT02855840|||OTHER||PROSPECTIVE|||||||
34003579|NCT06678763|||COHORT||RETROSPECTIVE|||||||
34003580|NCT04986098|||COHORT||PROSPECTIVE|||||||
34003581|NCT05983627|NA|SEQUENTIAL||TREATMENT||NONE||||||
34003582|NCT00681018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34003583|NCT05227677|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 200 patients with newly diagnosed T2DM will be 1:1 randomly assigned to two groups: intervention group (GA) and control group (NC). After testing baseline metabolic indexes including A1c, all the patients will be treated with antidiabetic therapy according to guideline for prevention and treatment of type 2 diabetes in China (2020) and followed up for 12 weeks. The GA concentration will be measured at 4-week intervals. In GA group, the anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks. In NC group, investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment. At the end of 12 weeks, A1c and other metabolic indexes will be measured again. All the anti-diabetic drugs are permitted in this study except sulfonylureas, glinides, insulin and insulin analogues.||||
34003584|NCT00962494|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34003585|NCT04863157|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34003586|NCT05926635|||OTHER||PROSPECTIVE|||||||
34090285|NCT02641041|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34090286|NCT04000724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090287|NCT02373072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34090288|NCT03176199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103214|NCT03109392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34103215|NCT06686706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103216|NCT02658188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720285|NCT02414334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003587|NCT03969641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34003588|NCT02695927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1/2 patients receive visual stimulation with rehabilitation glasses. 1/2 patients receive control stimulation with rehabilitation glasses.|t|f|f|f
34003589|NCT04302337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients are not going to be given the detail about the days, so that they would not know which group they would be in. Care provider and investigator would not know which patient is going to be operated on which day. Outcome assessor would not know which patient received which treatment while examining for the long term results.|One group will receive conventional cold curettage adenoidectomy treatment while the other group will receive curettage adenoidectomy with transoral endoscopic residue ablation treatment. The patients operated on Tuesdays and Fridays will receive the first treatment while on Mondays and Thursdays the second treatment.|t|t|t|t
34003590|NCT03674138|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Patients will be blinded to the genomic results for 12 weeks, with the 12 week time period starting at the time of antidepressant drug prescribing.||t|f|f|f
34003591|NCT04106817|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34003592|NCT01031992|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34090289|NCT04521803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Neither participants nor the investigators will be aware of the participant's treatment allocation until the end of the study (double blinding). Blinding will be maintained by manufacture of placebo tablets similar in appearance and packaging to that of the study drug, with centralized dispensing by the study pharmacist. Unmasking procedures are detailed by SOP.|"Participant identification numbers (PID), assigned at the screening visit, will be used throughout the study. After signing the informed consent document; eligible participants will be stratified by HIV status and then further stratified by GX-Ultra status to ensure equal allocation regardless of HIV status and likely subsequent culture status.~An electronic randomization tool will be used to randomize the subgroups in a 1:1 ratio. The randomization list will be generated and updated by the study coordinator, trial pharmacist, or statistician who will have no direct contact with trial participants or involvement with the assessment for eligibility in the trial."|t|t|t|f
34003593|NCT03038568|||COHORT||PROSPECTIVE|||||||
34090290|NCT06022055|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090291|NCT05559541|NA|SEQUENTIAL||TREATMENT||NONE||||||
34090292|NCT00257452|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33698864|NCT06243484|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be conducted in a double-blind randomized manner. The random allocation sequence will be provided sealed to the independent pharmacist (not involved in the study) by an independent statistician. The ratio of randomization between the verum and placebo groups will be 1:1. Stratification randomization will be performed according to LDL-c at V0 (\<160 mg/dL / ≥ 160 mg/dL) and site.|A MULTICENTER, RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLINDED STUDY|t|t|t|t
33698865|NCT04317404|||CASE_CONTROL||PROSPECTIVE|||||||
33698866|NCT02563977|||OTHER||PROSPECTIVE|||||||
33698867|NCT00997880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33698868|NCT05342610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective, parallel, two-arm, randomized controlled clinical trial|f|f|t|f
33698869|NCT05920694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698870|NCT01061216|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33698871|NCT06333093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698872|NCT02876094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698873|NCT05730699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698874|NCT04987268|||COHORT||PROSPECTIVE|||||||
33698875|NCT03945266|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to an intervention or control group||||
33698876|NCT04709471|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33698877|NCT03419520|RANDOMIZED|PARALLEL||PREVENTION||NONE||The present study is an observational and long-term intervention study. There is an initial evaluation carried out on all children involved in the study at 1st and 2nd grades and it is going to be followed by 3 monitoring actions in the following years where the progression of anthropometric measurements and dietary habits are going to be studied. Besides, the intervention group is going to receive nutritional education aimed to reduce the risk of developing obesity.||||
33698878|NCT01562158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698879|NCT01408264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698880|NCT05537896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698881|NCT04979104|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is open-label, not randomized, retrospective and longitudinal cohort clinical study. The follow up outcomes of each patient are compared with the baseline measurements of the same subject (preoperative assessment for clinician-based evaluations and patient-reported outcomes; immediate postoperative assessment for the radiographical evaluation)||||
33698882|NCT04081324|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33698883|NCT04134052|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|the participant, the researcher and the outcomes assesor don't know the drug used for sedation.|Simple finite randomization will be performed. The anesthesiologist will choose an envelope with an assigned folio divided into two groups 1) intravenous infusion midazolam and 2) intravenous infusion ketamine, For sedation, regional anesthesia will be applied and hemodynamic variables, administered drugs, type of surgery, surgery time and transoperative bleeding will be recorded, after that, the cognitive evolution will be evaluated with the minimental examination at 3 months postoperatively|t|t|t|t
33698884|NCT04540276|||COHORT||RETROSPECTIVE|||||||
33698885|NCT02540226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698886|NCT00147758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003594|NCT03716323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003595|NCT01781312|RANDOMIZED|PARALLEL||||NONE||||||
34003596|NCT05001009|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The primary outcome of goals of care conversation notes is determined by whether notes are entered into the electronic health record. The data manager queries the VA corporate data warehouse to determine if these notes are completed. Because the data manager can see who wrote the notes, the data manager is not blinded. However, the investigators do not expect the data manager to judge whether the notes were completed.|Sequential multiple-assignment randomized clinical trial (SMART)|f|f|t|f
34003597|NCT00590694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003598|NCT01610024|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||f|t|t|f
33698887|NCT05914376|NA|SEQUENTIAL||TREATMENT||NONE||||||
33698888|NCT00528177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720286|NCT00864149|RANDOMIZED|CROSSOVER||||NONE||||||
34090293|NCT05181384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090294|NCT03286790|||COHORT||PROSPECTIVE|||||||
33786534|NCT05001828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786535|NCT01554592|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34003599|NCT00198354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003600|NCT00915109|||CASE_CONTROL||PROSPECTIVE|||||||
34090295|NCT02552602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34090296|NCT01927588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090297|NCT05047926|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090298|NCT02019069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090299|NCT02328105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698889|NCT03645564|RANDOMIZED|PARALLEL||OTHER||NONE||It is an open, prospective, randomized, 2 arms study that will compare 2 groups of patients care for Atrial Fibrillation in the Cardiology-Electrophysiology and Cardiac Stimulation Department with direct oral anticoagulants prescription.||||
34090300|NCT00687518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34003601|NCT00511927|||COHORT||PROSPECTIVE|||||||
33698890|NCT00908609|||COHORT||PROSPECTIVE|||||||
34090301|NCT03991039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698891|NCT05192733|||OTHER||CROSS_SECTIONAL|||||||
33698892|NCT01431131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090302|NCT03399084|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33698893|NCT04161027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, placebo-controlled, multicenter clinical trial. Study subjects will be recruited from 4 medical centers in South Korea.|t|t|t|t
33698894|NCT03179696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698895|NCT02841189|NA|SINGLE_GROUP||OTHER||NONE||||||
33786536|NCT03767114|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33698896|NCT00202059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003602|NCT01138345|||COHORT||CROSS_SECTIONAL|||||||
33786537|NCT06249841|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33698897|NCT03408678|||COHORT||RETROSPECTIVE|||||||
33786538|NCT00462969|NA|SINGLE_GROUP||SCREENING||NONE||||||
33786539|NCT00317655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786540|NCT03877471|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be subjected into 3 groups, with a low (0.2×107), medium (0.5×107) and high dosage (1.0×107) of cells transplantation for each ovary. The investigator will first carry out the low dosage group, and then the medium dosage group, based on the safety evaluation of the previous group, the high dosage group will be executed in the same way.||||
33786541|NCT00225719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786542|NCT06140849|||COHORT||PROSPECTIVE|||||||
33786543|NCT00822913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786544|NCT00904527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786545|NCT00864682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698898|NCT02043275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33698899|NCT00200642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698900|NCT02320617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786546|NCT03976609|||CASE_ONLY||RETROSPECTIVE|||||||
33786547|NCT05235750|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786548|NCT00005890||||DIAGNOSTIC||||||||
33698901|NCT02413372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698902|NCT05276024|||COHORT||PROSPECTIVE|||||||
33786549|NCT00306683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786550|NCT06629610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786551|NCT03139175|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33786552|NCT01391013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786553|NCT01525433|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786554|NCT06529809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003603|NCT04505735|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34003604|NCT01986816|||COHORT||PROSPECTIVE|||||||
34003605|NCT05713227|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomised crossover placebo controlled||||
34090303|NCT02711137|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090304|NCT05066529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All treatments will be applied by an investigator and a different blinded investigator will evaluate all participants|Dry needling is a technique in which a fine needle is used to penetrate the skin, subcutaneous tissues and muscles to mechanically disrupt tissue without the use of anesthesia. Treatment is often used to treat myofascial trigger points.|f|f|t|t
34090305|NCT03860688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||On visit 2, participants will receive teduglutide and glucose 5 hours after a liquid meal||||
34090306|NCT00093938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34090307|NCT04673734|||COHORT||PROSPECTIVE|||||||
34090308|NCT01549509|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34090309|NCT05374928|||COHORT||PROSPECTIVE|||||||
34090310|NCT01403584|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34090311|NCT02959268|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34090312|NCT03267641|||COHORT||PROSPECTIVE|||||||
34090313|NCT05515419|NA|SINGLE_GROUP||TREATMENT||NONE||allogeneic cord blood for adult patients with neurological diseases||||
34090314|NCT01801254|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34090315|NCT03033888|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34090316|NCT02411955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090317|NCT04664309|||CASE_ONLY||PROSPECTIVE|||||||
34090318|NCT01143792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786555|NCT05647356|NA|SINGLE_GROUP||OTHER||NONE||||||
33786556|NCT06709209|||COHORT||PROSPECTIVE|||||||
33786557|NCT01017861|||COHORT||PROSPECTIVE|||||||
34003606|NCT04802551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003607|NCT05045612|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, open label, pragmatic randomized controlled non-inferiority stop trial||||
34003608|NCT03220750|||COHORT||PROSPECTIVE|||||||
34003609|NCT01174667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003610|NCT05550662|NA|SINGLE_GROUP||SCREENING||NONE||We will map lung ventilation (V), perfusion (Q), apparent diffusion coefficient (ADC) and gas exchange using 129Xe MRI in 15 LTx recipients. All MRI scans will be acquired in one visit||||
34003611|NCT02166801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003612|NCT00260793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003613|NCT02636673|||COHORT||RETROSPECTIVE|||||||
34003614|NCT03525340|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomly assigned 2:1 to intervention group with peer navigation or standard of care||||
34003615|NCT00859040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698903|NCT04142593|||OTHER||OTHER|||||||
34003616|NCT06678087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003617|NCT00462839|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34003618|NCT04042649|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003619|NCT01325038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34003620|NCT06179563|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic, multicentre, randomized controlled tria||||
34003621|NCT02633241|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34003622|NCT01115062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003623|NCT02412722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003624|NCT03845816|||COHORT||PROSPECTIVE|||||||
34003625|NCT03253744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003626|NCT00111462|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34003627|NCT00164372|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003628|NCT04966390|||CASE_ONLY||PROSPECTIVE|||||||
34003629|NCT06182085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003630|NCT05634707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003631|NCT03066934|||COHORT||PROSPECTIVE|||||||
34090319|NCT06115980|NA|SINGLE_GROUP||OTHER||NONE||"Open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction.~The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~A total of 10 patients, who are scheduled for lead extraction, will be recruited in order to ensure a total of at least 10 patients finishing the study procedures and follow up.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction."||||
34003632|NCT03255044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698904|NCT06556550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33698905|NCT06402643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation of the study participants will be concealed in opaque envelopes.|The allocation sequence will be generated by an investigator and will|t|f|t|t
33698906|NCT04375969|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|4 groups of obese patients will take part in the study. Qualification for the test is insulin resistance, abdominal obesity, lack of physical activity, lack of cold sensitivity.|The primary aim is to define, through a randomized controlled approach, the relative effectiveness of up to 10-20 consecutive sessions of either whole body cryostimulation (WBC), high-intensity intermittent training (HIIT), or their combination (WBC and HIIT) in improving the metabolic status of overweight subjects. The effects will be assessed, at different time-points, in terms of insulin sensitivity and modification in the profile of hormones regulating the energy metabolism (adipokines, myokines, bone-derived hormones) and the inter-organ cross-talk.|t|f|f|f
33698907|NCT03320226|NA|SINGLE_GROUP||OTHER||NONE||||||
33698908|NCT05698056|||COHORT||RETROSPECTIVE|||||||
33698909|NCT04886739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33698910|NCT02448186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698911|NCT04899427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698912|NCT06298526|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33698913|NCT05636826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698914|NCT03257371|||COHORT||PROSPECTIVE|||||||
33698915|NCT03565601|||CASE_CONTROL||RETROSPECTIVE|||||||
33698916|NCT04544332|||COHORT||PROSPECTIVE|||||||
34003633|NCT06321471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003634|NCT02427399|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34003635|NCT01691430|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants were randomized to cranberry or placebo capsules.|t|t|t|t
34003636|NCT05632796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003637|NCT06384287|||COHORT||PROSPECTIVE|||||||
34003638|NCT02631252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003639|NCT00197080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003640|NCT02389595|||COHORT||PROSPECTIVE|||||||
34003641|NCT06286241|||COHORT||OTHER|||||||
34003642|NCT06270095|||COHORT||PROSPECTIVE|||||||
34003643|NCT04646525|||CASE_ONLY||PROSPECTIVE|||||||
34003644|NCT02026479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003645|NCT01097551|||CASE_CONTROL||PROSPECTIVE|||||||
34003646|NCT05239182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003647|NCT05393323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003648|NCT04095624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698917|NCT02824783|||COHORT||RETROSPECTIVE|||||||
34003649|NCT06055309|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|brownies will contain different doses of cannabis product|Within-subject design||||
34003650|NCT06679140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind with matching placebo||t|t|t|t
34003651|NCT01493596|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34003652|NCT02497079|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003653|NCT02987634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003654|NCT01165476|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003655|NCT06490770|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698918|NCT06681571|||CASE_CONTROL||PROSPECTIVE|||||||
33698919|NCT05024201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In this study, two scales will be used to measure the loneliness and hopelessness levels of hemodialysis patients. Patients will fill in UCLA Loneliness Scale and BECK Hopelessness Scale.Therapeutic touch treatment method will provide nurses the holistic caregiver role for the feelings of loneliness and hopelessness experienced by the patients. When the literature is scanned, this study is unique because it has not been done before on hemodialysis patients.||||
33698920|NCT01872897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33698921|NCT00040339|NON_RANDOMIZED|||TREATMENT||||||||
33698922|NCT00817544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786558|NCT06631118|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33786559|NCT01311713|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786560|NCT05604274|||COHORT||PROSPECTIVE|||||||
33924705|NCT03612947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924706|NCT05420194|||CASE_ONLY||PROSPECTIVE|||||||
33924707|NCT02428907|||OTHER||PROSPECTIVE|||||||
33924708|NCT03118453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924709|NCT03731546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33924710|NCT05856669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924711|NCT03406715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924712|NCT01808404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924713|NCT05446194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924714|NCT01629979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924715|NCT05839847|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participant will experience the same setup in real and sham conditions. The gel puck used to couple the ultrasound signal will either have a blocking disk, or no blocking disk to either allow or block the ultrasound signal.|Participants will act as their own sham - sham vs real will be conducted in separate study visits. 2 arms exist for 2 variations of the NPU task.|t|f|f|f
33924716|NCT03126279|||CASE_CONTROL||PROSPECTIVE|||||||
33924717|NCT04146337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924718|NCT04101734|||CASE_CONTROL||PROSPECTIVE|||||||
33924719|NCT03358498|||COHORT||CROSS_SECTIONAL|||||||
33924720|NCT06054503|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The patient is his own control||||
33924721|NCT01163019|||COHORT||PROSPECTIVE|||||||
33924722|NCT05918588|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33924723|NCT00807014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33924724|NCT04578119|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33924725|NCT02954302|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924726|NCT02644837|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924727|NCT01329289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924728|NCT02907086|||CASE_CONTROL||PROSPECTIVE|||||||
33924729|NCT03973203|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants (healthy controls and mitochondrial myopathy patients) receive orally administered a slow-released form of niacin.||||
33924730|NCT00032617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33924731|NCT01223326|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924732|NCT03446989|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33924733|NCT01867866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924734|NCT05994963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This is an open-label study.|Two Parts, Crossover study||||
33924735|NCT01422772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924736|NCT06561438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924737|NCT01263093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924738|NCT01472991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924739|NCT00994162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924740|NCT02174861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924741|NCT05325398|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924742|NCT06164613|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The masking of the treatment will be carried out by a person external to the study; in this sense, white bottles with orange and green labels will be used.~To mask the cinnamon smell of the capsule, the preparation in soft gelatin capsules with cinnamon oil will be used. This preparation, since the capsule is sealed, has no smell or flavor. For the placebo, soft gelatin capsules containing canola oil will be used."|parallel group, efficacy, randomized, placebo-controlled, double-blind clinical trial.|t|t|t|f
33924743|NCT06264323|||COHORT||PROSPECTIVE|||||||
33924744|NCT01431261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924745|NCT02899624|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924746|NCT06359704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||controlled arm with waitlist treatment|t|f|t|t
33924747|NCT01297426|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924748|NCT01151358|||||PROSPECTIVE|||||||
33924749|NCT06124885|NA|SINGLE_GROUP||SCREENING||NONE||Single arm design. All eligible and consenting patients will have their time-point urine samples collected and biomarker levels measured.||||
33924750|NCT03689868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924751|NCT03753815|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33924752|NCT00313248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924753|NCT00158223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924754|NCT02591888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924755|NCT00415519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924756|NCT02375984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924757|NCT01147406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924758|NCT03768895|||COHORT||OTHER|||||||
33924759|NCT04559269|||COHORT||RETROSPECTIVE|||||||
33924760|NCT06468111|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized, controlled, open-label, two-arm clinical trial.||||
33924761|NCT05339880|||COHORT||PROSPECTIVE|||||||
33924762|NCT04942119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized, single-blinded, control study of 160 national UAE citizen patients who have been diagnosed with type 2 diabetes mellitus and will attend the endocrinology or chronic disease clinic (CDC) and having follow-up schedules in an ambulatory healthcare services (AHS) clinic, UAE.|t|f|f|f
33698923|NCT05437900|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients with one or more coronary stenoses will be randomized to either pressure microcatheter or pressure wire-based strategies for clinical decision making. Clinical decision making for PCI could be based either on FFR or NHPR. FFR or NHPR will support clinical decisions to defer or treat at the operator discretion. In cases with a positive FFR (≤ 0.80) or NHPR (≤0.89), patients will undergo a hyperemic FFR pullback to guide the PCI procedure further. PCI will be performed using last-generation drug-eluting stents (DES) at operator's discretion. After completing an angiographically successful PCI, patients will be randomized to FFR-guided stent optimization (PIOS) or standard of care (SOC).~The one-step randomization process in four groups permits an uninterrupted invasive procedure avoiding the logistic issues related to a second randomization during the invasive procedure while preserving the statistical power and balance between groups."||||
33786561|NCT03789799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|TIAGIN and placebo will be provided in identical non-distinguishable packaging and formulations. To each pack a unique random ID will be assigned based on an independently generated random scheme (www.randomization.com). Patients will blindly receive consecutively a single pack of 10 vaginal capsules. The same blinding procedure will also be present for health professionals (double-blind study) as only the manufacturer will be aware of the contents of the pack. For each enrolled patient, the patient ID will be associated to the packaging ID, the maintenance of the confidentiality of such data will be the responsibility of the Principal Investigator, to which the contents of the pack will be revealed only at the end of the study for the final data analysis.|Randomized controlled double-blind trial|t|t|t|t
33786562|NCT02060214|||CASE_CONTROL||PROSPECTIVE|||||||
33786563|NCT06433895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786564|NCT02518711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786565|NCT02157402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786566|NCT00282776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786567|NCT03441048|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786568|NCT04784741|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 40 were included in the study who full filled the inclusion criteria, athletes were randomly assigned into two groups: Control and Experimental group. Additionally, data was collected from healthy athletes doing their training at Pakistan Sports Board, Islamabad.||||
33786569|NCT00035230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786570|NCT04441242|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33698924|NCT02595138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698925|NCT05303363|||COHORT||PROSPECTIVE|||||||
33698926|NCT04603612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698927|NCT06100211|||COHORT||PROSPECTIVE|||||||
33698928|NCT05410015|||COHORT||PROSPECTIVE|||||||
33698929|NCT04743856|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Referring doctors and outcome assessors will be blinded to participant assignment while the study is active. After data collection ends, referring physicians will be informed as to each of their patients assignment. Outcome assessors will remain blinded to participant assignment. Investigators will be blinded to assignment as much as possible. However, certain events ( such as an adverse event report) may cause the study PI to become unblinded.|Participants will be randomized 1:1 to one of two intervention conditions.|f|t|f|t
33698930|NCT00387803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698931|NCT06393868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786571|NCT03602755|||CASE_ONLY||RETROSPECTIVE|||||||
33786572|NCT06026189|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|This is a stepped wedge cluster randomized clinical trial|A multicenter, stepped wedge cluster randomized trial||||
33786573|NCT02062827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786574|NCT05457361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786575|NCT04134325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786576|NCT01700569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786577|NCT04541641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924763|NCT01269047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924764|NCT03886441|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924765|NCT05993000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924766|NCT04559087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924767|NCT06376838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924768|NCT00436982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924769|NCT03242304|||CASE_CONTROL||PROSPECTIVE|||||||
33924770|NCT02789826|RANDOMIZED|PARALLEL||TREATMENT||NONE||Laparoscopic gastric cancer resection||||
33924771|NCT00445250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924772|NCT05445882|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33924773|NCT01937624|||CASE_ONLY||PROSPECTIVE|||||||
33924774|NCT06013267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924775|NCT01495923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924776|NCT04169113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33924777|NCT00143962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924778|NCT02513771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924779|NCT00103571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924780|NCT04006535|||FAMILY_BASED||PROSPECTIVE|||||||
33924781|NCT02397590|RANDOMIZED|CROSSOVER||||NONE||||||
33924782|NCT01639391|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924783|NCT00830115|||CASE_ONLY||PROSPECTIVE|||||||
33924784|NCT04505878|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot single-arm unblinded trial to assess whether parenterally administered ascorbic acid (vitamin C) is safe in the lung transplant population.The investigators will not randomize or control; a retrospective cohort of participants not treated with vitamin C will be reviewed from 2015-2020. Those participants who decline the intervention will have the choice to consent to having their data be considered as part of the (non-retrospective) controls and be considered in our statistical analysis for outcomes, including analysis between this group and the historical controls. All participants who consent will be administered the therapy and participants will be evaluated via an intention-to-treat analysis.||||
33924785|NCT02884856|||COHORT||CROSS_SECTIONAL|||||||
33924786|NCT05564442|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33698932|NCT06448078|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Within the scope of the study, external fixator will be applied to 14 patients in the form of external bonding to the rib fracture area for 15 days, along with standard medical treatment. Standard medical treatment will be applied to 20 patients and these patients will constitute the control group.||||
33698933|NCT00004195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698934|NCT04197531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33698935|NCT04010032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|triple (Participant, Care Provider, investigator)||t|t|t|t
33698936|NCT01364077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33698937|NCT05648578|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698938|NCT01739361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698939|NCT01578330|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33698940|NCT06463405|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786578|NCT04181632|RANDOMIZED|PARALLEL||OTHER||NONE||"Study Design and Duration This is a randomized controlled study. Approximately 100 children, age 4 - 17 years, who are currently receiving subcutaneous immunotherapy, will randomly select a blinded envelope which assigns the distraction technique to be utilized during their study participation. There will be 25 envelopes assigned to each study group for a total of 100 envelopes. Each envelope will contain a paper with a colored sticker for the associated group assignment and number sequence.~The distribution of group assignment by number sequence and color is as follows:~Interventional Groups~1. Shot Blocker® Number 1-25 (RED)~2. Buzzy I® (vibrating only) Number 26-50 (GREEN)~3. Buzzy II® (vibrating and ice wings) Number 51-75 (BLUE)~4. Control Group Ethyl Chloride/Pain Ease Spray Number 76-100 (YELLOW)"||||
33786579|NCT05999461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786580|NCT06711003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786581|NCT05438732|NA|SINGLE_GROUP||OTHER||NONE|since the IMT has a unique appearance in the eye, it cannot be masked to the Investigator or to the patient|Effectiveness: one-sided asymptotic normal test Safety: one-sided t-test||||
33786582|NCT05545332|||COHORT||PROSPECTIVE|||||||
33786583|NCT03837925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo manufactured as the treatment. Packaging identical.|2 groups of patients having treatment or placebo|t|t|t|t
33924787|NCT02035579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924788|NCT04879784|||OTHER||PROSPECTIVE|||||||
33924789|NCT02012881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924790|NCT01094990|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33924791|NCT06199505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924792|NCT05752071|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33924793|NCT00444964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924794|NCT03620435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924795|NCT00316654|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924796|NCT01938001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924797|NCT02522650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924798|NCT01645865|||COHORT||PROSPECTIVE|||||||
33924799|NCT00989612|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33924800|NCT04189991|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The same device will be used for both oxygen titration protocol and during 6 minutes walk tests.|Patients will undergo titration 6 minutes walk test using the standard and the automatic method in random order.|t|f|f|f
33924801|NCT05135351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33924802|NCT02718027|||COHORT||PROSPECTIVE|||||||
33924803|NCT01674192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924804|NCT04868227|NA|SINGLE_GROUP||PREVENTION||NONE||SINGLE GROUP INTERVENTION STUDY||||
33924805|NCT03771690|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33924806|NCT01659268|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33924807|NCT02773056|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34003656|NCT05956756|NA|SINGLE_GROUP||PREVENTION||NONE||This study will utilize a quasi-experimental design to explore the effectiveness of health and resilience programming for occupational therapy students while they are enrolled in the program. Pre and post data will be gathered through questionnaires. Additionally, qualitative data will be obtained from student discussion board posts/assignments, interviews or focus groups will be used to supplement the quantitative data.||||
34003657|NCT04873245|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who qualify will be randomized to receive either intensive behavioral therapy or treatment with semaglutide plus a less intensive behavioral therapy program.||||
34003658|NCT02999698|||||RETROSPECTIVE|||||||
34003659|NCT00557245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34003660|NCT00201136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34003661|NCT02707887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003662|NCT05892172|||COHORT||CROSS_SECTIONAL|||||||
34003663|NCT06604481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34003664|NCT03458364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003665|NCT05965557|||COHORT||PROSPECTIVE|||||||
34003666|NCT00422045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003667|NCT02351167|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34090320|NCT03144999|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This is a dose escalation study consisting of a low, mid, and high dose to evaluate the maximum tolerated dose (MTD). An additional 8 patients are enrolled at the MTD.||||
34090321|NCT06054425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33698941|NCT05548673|RANDOMIZED|PARALLEL||OTHER||NONE||It was conducted in a mixed method as a randomized controlled intervention study.||||
33698942|NCT00032942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33698943|NCT01528033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924808|NCT01350713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924809|NCT06527261|||OTHER||PROSPECTIVE|||||||
33924810|NCT04679441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes data wil be collected in an automated manner and will be entered directly into a database|"* Healthy individuals receive skills training only~* MCI Participants are randomized to skills training only or skills training combined with computerized cognitive training"|f|f|f|t
33924811|NCT02690324|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924812|NCT01118715|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786584|NCT03997123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind Randomised Study|t|t|t|t
33924813|NCT04568187|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||the sequential split-body trials||||
33924814|NCT01913197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924815|NCT04241146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924816|NCT00888069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924817|NCT00801892|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|The mask and equipment appeared similar to actual CPAP but does not give pressure required to prevent OSA. Only CPAP naive persons eligible.|Participants on sham-CPAP were allowed to try actual CPAP.|t|f|t|t
33924818|NCT00503737|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33924819|NCT03909672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33924820|NCT04103775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33924821|NCT00571688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003668|NCT00774241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003669|NCT01177891|||FAMILY_BASED||PROSPECTIVE|||||||
34003670|NCT00570128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003671|NCT02482558|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33786585|NCT06507657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||placebo-controlled, double-blinded, randomized pilot study|t|f|f|t
34003672|NCT05378308|||COHORT||RETROSPECTIVE|||||||
34003673|NCT00114595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34003674|NCT04086160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003675|NCT00779441|RANDOMIZED|CROSSOVER||||NONE||||||
34003676|NCT02288260|||COHORT||CROSS_SECTIONAL|||||||
34003677|NCT06595004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003678|NCT06045741|||CASE_ONLY||PROSPECTIVE|||||||
34003679|NCT02413528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003680|NCT02899312|||COHORT||PROSPECTIVE|||||||
34003681|NCT01396655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003682|NCT01715155|||COHORT||RETROSPECTIVE|||||||
34003683|NCT02449616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003684|NCT03985046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003685|NCT02872051|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34003686|NCT05625269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|t|f|f|f
34003687|NCT01954901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090322|NCT02761538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090323|NCT00820534|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090324|NCT00747513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090325|NCT05953467|||COHORT||RETROSPECTIVE|||||||
33786586|NCT00001129||FACTORIAL||TREATMENT||||||||
33786587|NCT02838316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase I open label clinical trial||||
34003688|NCT06073886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003689|NCT00002116||||TREATMENT||DOUBLE||||||
34003690|NCT03297541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003691|NCT00219986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090326|NCT00884442|RANDOMIZED|CROSSOVER||||NONE||||||
34090327|NCT00629577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090328|NCT02925754|||||CROSS_SECTIONAL|||||||
34090329|NCT00080418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786588|NCT04903483|RANDOMIZED|PARALLEL||OTHER||SINGLE|anesthesia with target-controlled infusion (propofol) with or without the depth of anesthesia (bispectral index) monitoring and evaluation of vital parameters, side effects, and postoperative delirium|the side effects of endolaryngeal laser surgery's anesthesia with or without bispectral index monitoring in patients with smoking|t|f|f|f
33924822|NCT04724512|RANDOMIZED|PARALLEL||OTHER||NONE||Comparison of different types of stitches to turn the eyelid outwards e.g. polypropylene Vs polyglactin 910 to establish if there is a difference in the level of post-operative inflammation.||||
33924823|NCT00383227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924824|NCT01608178|||||PROSPECTIVE|||||||
34003692|NCT04172545|||COHORT||PROSPECTIVE|||||||
34003693|NCT04155073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34003694|NCT00630903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003695|NCT06308263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003696|NCT06538792|||OTHER||CROSS_SECTIONAL|||||||
34003697|NCT01784237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003698|NCT03201263|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial, 2 groups, 1:1 randomisation||||
34003699|NCT02241798|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003700|NCT03084458|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized, between subjects design will allow for comparisons between the experimental and control groups.||||
34003701|NCT02118025|||COHORT||PROSPECTIVE|||||||
34003702|NCT01514513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003703|NCT02105909|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34003704|NCT03749733|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34003705|NCT01103596|||||RETROSPECTIVE|||||||
34003706|NCT03897829|||CASE_ONLY||CROSS_SECTIONAL|||||||
34003707|NCT05642533|||COHORT||CROSS_SECTIONAL|||||||
34003708|NCT02970760|||COHORT||PROSPECTIVE|||||||
34003709|NCT05239962|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34003710|NCT03422224|||CASE_CONTROL||PROSPECTIVE|||||||
34003711|NCT04976023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003712|NCT03604549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003713|NCT04957719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003714|NCT04087863|||CASE_ONLY||PROSPECTIVE|||||||
34003715|NCT03981978|||CASE_ONLY||CROSS_SECTIONAL|||||||
34003716|NCT06679257|||COHORT||PROSPECTIVE|||||||
34090330|NCT02701491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34090331|NCT04351815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090332|NCT02872441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003717|NCT00427063|||DEFINED_POPULATION||OTHER|||||||
34003718|NCT03853096|NA|SINGLE_GROUP||PREVENTION||NONE||20 patient pilot study, single arm prospectively collected with no blinding or randomization. Consenting patients will receive at time of surgery an additional subcutaneous cefazolin injection at the surgical site as well as timed tissue biopsies for colony count of P.acnes||||
34003719|NCT04201795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind masking|two arms parallel ( intervention and control) will be randomized asigned to compare pressure and traction tecnique versus laser placebo|t|f|f|f
34003720|NCT00006034|RANDOMIZED|||TREATMENT||||||||
34003721|NCT06678334|||COHORT||CROSS_SECTIONAL|||||||
34003722|NCT02518607|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34003723|NCT02963064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003724|NCT05700136|||COHORT||PROSPECTIVE|||||||
34003725|NCT02261220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003726|NCT00930592|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34003727|NCT01352364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003728|NCT00846898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003729|NCT01191606|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34003730|NCT00831987|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003731|NCT01734694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34003732|NCT04086524|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Study team members measuring outcome variables will be masked to treatment group.|TREATMENT = 2 weeks of treatment (additional 2 weeks if they agree) CONTROL = 2 weeks patching, 2 weeks treatment|f|f|f|t
34003733|NCT03296735|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34003734|NCT02319057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090333|NCT05841576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The mitoPO2 in the control group is covered and made invisible to the anaesthetists. During the procedure, the outcome assessor is present to troubleshoot the device when needed and is also not blinded. Patients, surgeons and healthcare professionals during the postoperative period are blinded to the treatment allocation.|A randomised, controlled, single-centre, parallel-arm, patient-blinded trial|t|f|f|f
34090334|NCT00259636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090335|NCT04999787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698944|NCT03956134|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomization was performed according to Williams' design, with 5 periods and 10 sequences. There was a washout of at least 3 days between the consecutive administrations.||||
33698945|NCT03253458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33698946|NCT05890339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698947|NCT01611610|NON_RANDOMIZED|PARALLEL||||NONE||||||
33698948|NCT03353207|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33698949|NCT05133908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome measures will be administered via online surveys||f|f|f|t
33698950|NCT05592951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized, placebo controlled study||||
33698951|NCT01423019|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33698952|NCT05208697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698953|NCT03032133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698954|NCT04766710|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Project coordinators and people living with HIV in the selected operational districts will not be masked to the intervention. However, all activities will be done without reference to the intervention group. The data analysts will be masked to intervention allocation and will only analyze de-identified data.|This quasi-experimental study will consist of two arms. People living with HIV in the intervention arm will receive services from the CAD model, and those in the control arm will receive the standard prevention, care, and support services. The investigators will compare the outcome between these two arms.|f|f|f|t
33698955|NCT03001882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698956|NCT03719443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The clinical study will be performed in a double-blind manner, for clinical research unit staff interacting with study participants, with the exception of the persons involved in the preparation of the IMPs. These persons will not be involved in any other study activities.|phase 1, randomized, placebo-controlled, double-blind, single ascending dose study|t|t|t|t
33786589|NCT05612243|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33786590|NCT01800474|||OTHER||CROSS_SECTIONAL|||||||
33786591|NCT03947164|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Monocentric case-control study (1: 1). The inclusion of cases and controls will be prospective. For each case, a control will be included with matching on parity (0, at least one child). Concerning the age, they will be matched according to the following age groups: 18-39 years old, 40-44 years old, 45-49 years old, 50-54 years old, over 55 years old.||||
33698957|NCT06574178|NA|SINGLE_GROUP||OTHER||NONE||||||
33698958|NCT06097338|||CASE_CONTROL||PROSPECTIVE|||||||
33698959|NCT05768971|||COHORT||PROSPECTIVE|||||||
33698960|NCT01680887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33698961|NCT01557803|||COHORT||PROSPECTIVE|||||||
33786592|NCT03732820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786593|NCT01988350|||COHORT||PROSPECTIVE|||||||
33786594|NCT01553825|||COHORT||PROSPECTIVE|||||||
33698962|NCT05108714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698963|NCT05012657|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33786595|NCT01701609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003735|NCT06215196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34003736|NCT04347330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003737|NCT04439331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003738|NCT02857387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003739|NCT06679231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003740|NCT05624762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003741|NCT06424691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003742|NCT01105182|||CASE_ONLY||PROSPECTIVE|||||||
34003743|NCT05465096|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional pilot study||||
34003744|NCT02332005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003745|NCT01849458|||COHORT||PROSPECTIVE|||||||
34090336|NCT01785316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698964|NCT05384678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||5-period random order, placebo-controlled, double-blind cross-over study with four active substance conditions and placebo: 1. 0.6 mg/min, 2. 1.2 mg/min, 3. 1.8 mg/min, 4. 2.4 mg/min, 5. Placebo. Additionally, a patient-guided titration will be performed at the sixth and last session (not randomized).|t|t|t|f
33698965|NCT00469651|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33924825|NCT05382962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomization will be done independently at each site (i.e., SickKids and Boston Children's Hospital), and will be stratified by type of surgery (i.e. pectus repair, scoliosis). Following consent and measure completion, study staff will randomize the participant using a 1:1 randomization allocation to intervention vs. control groups.|t|f|f|f
33924826|NCT05982834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924827|NCT00716339|RANDOMIZED|PARALLEL||TREATMENT||||||||
33924828|NCT00535691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33924829|NCT01072968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924830|NCT05461183|||COHORT||RETROSPECTIVE|||||||
33924831|NCT00546234|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924832|NCT01467661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924833|NCT04643665|||COHORT||RETROSPECTIVE|||||||
33924834|NCT00022958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924835|NCT01223040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924836|NCT03601793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924837|NCT06051851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924838|NCT05419804|||OTHER||PROSPECTIVE|||||||
33924839|NCT03815812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924840|NCT01667458|||COHORT||PROSPECTIVE|||||||
33924841|NCT01451398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924842|NCT06185478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924843|NCT00323024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924844|NCT00268463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924845|NCT04521920|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33924846|NCT01699646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924847|NCT03097718|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924848|NCT03162029|||OTHER||PROSPECTIVE|||||||
33924849|NCT04319406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924850|NCT03039738|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924851|NCT02692313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924852|NCT04377672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924853|NCT00927719|||COHORT||RETROSPECTIVE|||||||
33924854|NCT05281848|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 55 subjects will be grouped as: 18 non-smoker patients with periodontitis (Group 1), 19 smoker patients with periodontitis (Group 2), 18 non-smoker and periodontally healthy individuals who will refer to our department. Spitting method will be used for collecting saliva samples. The paper strip method will be used for gingival crevicular fluid (GCF) sample collection. Samples will be taken from the mesial and distal surfaces of the teeth (healthy or have greater than or equal to 5mm pocket depth) after isolation from the saliva. Paper strips will be transferred to polypropylene tubes and stored at -30 ° C until inspection. After collecting samples, non-surgical periodontal treatment will be performed to all individuals which are classified as Group 1 and Group 2. Collection of saliva and GCF samples will be repeated at the 1st month after the end of treatment. ELISA kits will be used for the detection of saliva and GCF's IL-17 and IL-35.||||
33924855|NCT02667457|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924856|NCT00562640|NA|SEQUENTIAL||TREATMENT||NONE||||||
33924857|NCT04975672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The operator responsible for making measurements of tongue position, mandibular advancement, orofacial muscle contraction, chin muscle activity, will be blinded to the assignment. A previous training will be carried out with an instruction manual for the clinical evaluation process|Randomized clinical trial with two parallel arms|f|f|f|t
33924858|NCT05320380|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I non-randomized study followed by a phase II randomized study||||
33924859|NCT01231607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924860|NCT02285504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924861|NCT02898142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33924862|NCT03368599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33924863|NCT05711680|||COHORT||PROSPECTIVE|||||||
33924864|NCT04041141|||COHORT||PROSPECTIVE|||||||
33924865|NCT05797194|||COHORT||RETROSPECTIVE|||||||
33924866|NCT05611515|||CASE_CONTROL||PROSPECTIVE|||||||
33924867|NCT06058936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Concealed allocation will be performed by a researcher who will not be involved in the treatment of assessment. Permuted blocks will be used to ensure an equal 1:1 allocation ratio. Due to the nature of the study, the assessor and the data analyzer will be blindfolded (double-blinded)|a randomized controlled trial with 2 arms parallel design|f|f|f|t
33924868|NCT04928391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33924869|NCT01934933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003746|NCT02479477|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33924870|NCT04078529|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be unaware whether they are in the comparison or intervention group.|Single-blind randomised control trial|t|f|f|f
34003747|NCT05688358|||CASE_CONTROL||RETROSPECTIVE|||||||
33924871|NCT02617017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090337|NCT02859012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003748|NCT00569777|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34003749|NCT06679569|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34003750|NCT03052855|NA|SINGLE_GROUP||OTHER||NONE||||||
33924872|NCT05097833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003751|NCT02686762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003752|NCT01224457|NA|SINGLE_GROUP||||NONE||||||
34090338|NCT02103075||PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003753|NCT04335188|||OTHER||PROSPECTIVE|||||||
33924873|NCT01871207|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33924874|NCT05871372|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33924875|NCT05054179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Patient Masking: Patients will be informed that they will receive one of two solutions (ropivacaine or saline) for infusion, without disclosing which group they are allocated to.~Anesthesiologists, cardiac surgeons, Cardiac Surgery Intensive Care Unit (CSICU) nurses, ward nurses, nurse practitioners, and acute pain service team Masking: blinded/masked to assignments.~Assessors Masking: Assessment of patients, data collection, and follow-up will be conducted by team members (i.e. research assistant, anesthesiologist, CSICU nurses, and ward nurses, acute pain service team) will be blinded/masked to group allocation of a patient participant.~Data Analyst Masking: The data analysts will be provided a table with two groups of the unique numbers, but which group corresponds with ropivacaine and which corresponds with normal saline will not be revealed until the data analysis has been fully completed."|"This will be a prospective, randomized, triple-blinded, placebo-controlled trial in which patients will be randomly allocated to two study groups on a 1:1 basis into:~1) Intervention Group: 20 mL of ropivacaine 0.2% will be bolused through PIFB catheters on each side, followed by 3 mL/hour infusion of ropivacaine 0.2% for 48 hours each side.~2) Control Group: 20 mL of ropivacaine 0.2% will be bolused through PIFB catheters on each side, followed by 3 mL/hour infusion of normal saline for 48 hours each side."|t|t|t|t
33924876|NCT05884281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33924877|NCT03917225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924878|NCT02245802|||COHORT||PROSPECTIVE|||||||
34003754|NCT00721916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003755|NCT04482933|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II Clinical Trial of HSV G207 with a Single 5 Gy Radiation Dose in Children with Recurrent High-Grade Glioma||||
34003756|NCT02698930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34003757|NCT06578091|||COHORT||PROSPECTIVE|||||||
34003758|NCT00800618|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34003759|NCT04379284|||CASE_ONLY||PROSPECTIVE|||||||
34003760|NCT04614714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34003761|NCT02824640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003762|NCT05798338|||CASE_CONTROL||PROSPECTIVE|||||||
34003763|NCT05721092|||COHORT||CROSS_SECTIONAL|||||||
34003764|NCT03635697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003765|NCT03033134|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34003766|NCT01015417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003767|NCT02976051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003768|NCT02476331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34003769|NCT06678659|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1a: Dose Escalation Phase 1b: Randomized Phase 2: Non-Randomized"||||
34090339|NCT04431544|||CASE_ONLY||PROSPECTIVE|||||||
34090340|NCT03010501|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34090341|NCT06006455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090342|NCT04186273|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|PRINCIPLE INVESTIGATOR/ INVESTIGATORS/ SPONSOR/ OUTCOME ASSESSOR/ PATIENT|QUADRUPLE-BLINDED, RANDOMIZED, VEHICLE-CONTROLLED STUDY INTRA-SUBJECT CONTROLS|t|t|t|t
34090343|NCT01800370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34090344|NCT04727008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090345|NCT05174624|||COHORT||CROSS_SECTIONAL|||||||
34090346|NCT04344444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003770|NCT00091286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003771|NCT00808262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003772|NCT05064267|||COHORT||CROSS_SECTIONAL|||||||
33924879|NCT04159818|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients are randomized between experimental cohorts and a control cohort.|Patients are randomized between experimental cohorts and a control cohort.||||
34003773|NCT02883491|||OTHER||PROSPECTIVE|||||||
34003774|NCT03293771|||OTHER||OTHER|||||||
34003775|NCT02301533|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34003776|NCT02993419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34003777|NCT04905693|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label Extension||||
34003778|NCT02564016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003779|NCT03184012|RANDOMIZED|PARALLEL||TREATMENT||NONE||one group assigned to be treated with Zirconia crowns, the other group assigned to be treated with resin composite strip crowns||||
34003780|NCT00566657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003781|NCT02725996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003782|NCT02629016|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34003783|NCT06227091|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34003784|NCT05787392|||COHORT||RETROSPECTIVE|||||||
34003785|NCT04952168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003786|NCT04539808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924880|NCT05247385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924881|NCT05227209|NA|SINGLE_GROUP||TREATMENT||NONE|open label|"This is a 12-month open-label safety extension study to evaluate the long-term safety, tolerability, and effectiveness of SEP-4199 CR 200-400 mg/day in the treatment of subjects with bipolar I depression who previously completed a lead-in study of SEP-4199 CR.~The study will consist of a 12-month open-label flexible-dose treatment period, and a safety follow-up period"||||
33924882|NCT00003203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924883|NCT01563107|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomization tables will be used to determine whether the 10 milliequivalents (mEq) sodium/day or 300 mEq sodium/day diet will be consumed first. Both diets will be completed on each subject (randomized crossover study), so all of the study procedures (after screening) will be repeated.||||
33924884|NCT05239312|||OTHER||PROSPECTIVE|||||||
33924885|NCT03275428|||CASE_CONTROL||PROSPECTIVE|||||||
33924886|NCT04516577|||COHORT||RETROSPECTIVE|||||||
33924887|NCT01800851|RANDOMIZED|CROSSOVER||||NONE||||||
33924888|NCT00987090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34003787|NCT00948337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34003788|NCT00442650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003789|NCT04709224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003790|NCT00250705|NA|SINGLE_GROUP||TREATMENT||NONE||open label trial||||
34003791|NCT03157349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The placebo and Biofreeze are in identical containers and only the manufacturer know the contents||t|f|t|f
34003792|NCT06679244|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Based on the different anastomotic methods used in proximal gastrectomy, patients are divided into a HEFT group (experimental group) and a double-tract reconstruction group (control group).~HEFT group:Patients included in this group will receive totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique(HEFT)，which is an innovative surgery that investigators first began to apply in patients with proximal gastric cancer.~double-tract reconstruction group:Patients included in this group will receive totally laparoscopic proximal gastrectomy with double-tract reconstruction group，which is a widely used and proven safe and effective surgical approach in proximal gastrectomy"||||
34003793|NCT00566722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003794|NCT04496037|||COHORT||PROSPECTIVE|||||||
34003795|NCT05585489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003796|NCT05357287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003797|NCT04832334|||COHORT||PROSPECTIVE|||||||
34003798|NCT02995564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003799|NCT03705871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003800|NCT02045355|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34003801|NCT03856034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003802|NCT01966939|||CASE_CONTROL||PROSPECTIVE|||||||
34003803|NCT03144479|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
34003804|NCT06641882|||OTHER||RETROSPECTIVE|||||||
34003805|NCT00003350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003806|NCT02749591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003807|NCT02938013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003808|NCT05696704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003809|NCT05028634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003810|NCT02879773|||COHORT||PROSPECTIVE|||||||
34003811|NCT04633616|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single-blinded|Tailored patient-provider communication versus non-tailored patient-provider communication on patient recruitment to clinical trials and patient engagement.|f|t|t|f
34003812|NCT05191745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34003813|NCT03086135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003814|NCT03934060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33924889|NCT02905916|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34003815|NCT02642523|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34003816|NCT00020358|RANDOMIZED|||TREATMENT||||||||
33924890|NCT05659667|||OTHER||CROSS_SECTIONAL|||||||
33924891|NCT04142385|||COHORT||PROSPECTIVE|||||||
33924892|NCT05468723|||OTHER||PROSPECTIVE|||||||
33924893|NCT03043807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924894|NCT01135017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33924895|NCT01624688|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924896|NCT03443895|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study. Subjects and investigator will be masked.||t|f|t|f
33924897|NCT05060796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924898|NCT01425229|||COHORT||PROSPECTIVE|||||||
33924899|NCT04670224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924900|NCT05334550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924901|NCT03310580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34003817|NCT04374188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Efficacy of ciprofloxacin therapy in sepsis avoidance.|f|t|f|t
34003818|NCT01974362|||CASE_CONTROL||PROSPECTIVE|||||||
34003819|NCT01146405|||CASE_CONTROL||PROSPECTIVE|||||||
34003820|NCT05829239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-center, randomized, double-blind, placebo-controlled study|t|f|t|f
34003821|NCT04396444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34003822|NCT05884970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003823|NCT05734339|||CASE_ONLY||PROSPECTIVE|||||||
34003824|NCT06025682|||CASE_ONLY||RETROSPECTIVE|||||||
34003825|NCT06003127|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34003826|NCT02103101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924902|NCT05159362|NA|SINGLE_GROUP||TREATMENT||NONE||Participants were enrolled and monitored through a 4-week field test.||||
33924903|NCT00686010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924904|NCT00612989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33924905|NCT04718584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924906|NCT02216890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924907|NCT05849896|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33924908|NCT05982639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34003827|NCT00924963|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34003828|NCT03129061|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003829|NCT02237547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003830|NCT01520545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003831|NCT03105271|||COHORT||PROSPECTIVE|||||||
34003832|NCT00112216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003833|NCT02259348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090347|NCT03477981||SEQUENTIAL||OTHER||NONE||Participants will consume their habitual diet with standard white bread for two week, then will be given the alginate bread for two weeks.||||
34090348|NCT01776489|||COHORT||PROSPECTIVE|||||||
34090349|NCT01136590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924909|NCT05005091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924910|NCT02165345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924911|NCT00702910|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33924912|NCT01929707|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33924913|NCT04095442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33924914|NCT01612442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924915|NCT01769495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924916|NCT03205982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33924917|NCT04777474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking is being used in the study|The study subjects will be enrolled into one study group.||||
33924918|NCT00702728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924919|NCT02467855|||COHORT||PROSPECTIVE|||||||
33924920|NCT00780507|||COHORT||PROSPECTIVE|||||||
33924921|NCT04167514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34003834|NCT06030544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both the OA-enriched olive oil and the control oil will be delivered labeled with alphanumeric codes, the correspondence of which will only be known by the Dr. Jose M. Castellano (Principal Investigator 1). This ensures blinding of the other researchers and trial participants with respect to the type of olive oil assigned.|prospective, parallel group, randomized, double-blind, controlled trial|t|t|t|t
34003835|NCT05709782|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003836|NCT02502331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34003837|NCT04912856|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Patients will enter a blinded titration period (24 days) before moving to the open label treatment period for the remaining 35 months.||t|t|t|t
33698966|NCT05099393|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Prospective, single-center, controlled, randomized, double-blind, three-period crossover study||||
34003838|NCT04205162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Investigators will be masked to which lens type (brand) the participants will be wearing in each eye during the study.||t|f|t|f
34003839|NCT05735028|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003840|NCT01689155|||COHORT||PROSPECTIVE|||||||
34003841|NCT02816424|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34003842|NCT01128868|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003843|NCT03752450|||COHORT||PROSPECTIVE|||||||
34003844|NCT03656263|||COHORT||PROSPECTIVE|||||||
34003845|NCT00493792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003846|NCT03460990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003847|NCT05167149|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34003848|NCT03285919|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34003849|NCT02845011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical provider was not involved in the study. S(he) was not blind during the resuscitation as they could see device, and it was not considered ethical to employ a sham device.||t|f|t|t
34003850|NCT01529593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003851|NCT04809662|||OTHER||PROSPECTIVE|||||||
33698967|NCT02634749|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33698968|NCT05234658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698969|NCT02330965|||CASE_CONTROL||PROSPECTIVE|||||||
33698970|NCT00931970|||COHORT||PROSPECTIVE|||||||
33698971|NCT02003365|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003852|NCT04288128|||COHORT||PROSPECTIVE|||||||
33698972|NCT00160589|RANDOMIZED|PARALLEL||||DOUBLE||||||
34003853|NCT00071539|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003854|NCT06401954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003855|NCT00576186|||CASE_ONLY||PROSPECTIVE|||||||
34003856|NCT01853540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003857|NCT00120315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003858|NCT05740748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003859|NCT04660032|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participant will be unaware of whether their obstetric provider received an electronic prompt.||t|f|f|f
34003860|NCT01459757|||||RETROSPECTIVE|||||||
34003861|NCT01530906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698973|NCT00376376|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34003862|NCT01853371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698974|NCT04574973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34003863|NCT02940522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090350|NCT03930433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1: Nebivolol group Group 2: Diltiazem group Group 2: Nebivolol + Diltiazem group|t|f|t|f
34090351|NCT00306488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090352|NCT02466503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924922|NCT00435994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33698975|NCT00966771|||OTHER||PROSPECTIVE|||||||
33698976|NCT06129877|||OTHER||PROSPECTIVE|||||||
33698977|NCT06205615|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, 2-way crossover|t|f|t|f
33698978|NCT04764487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33698979|NCT00989157|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698980|NCT05143021|||COHORT||PROSPECTIVE|||||||
33698981|NCT06430320|||COHORT||PROSPECTIVE|||||||
33698982|NCT05306431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The microbiologist will be kept blind to avoid risk of bias.||t|f|f|t
33698983|NCT00881673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33698984|NCT03675620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators recording data and the patients physician will be blinded to group assignment.|This is a prospective, randomized control trial. After consenting, subjects will be randomized to one of two groups by using a computer generated random number generator.|f|t|f|t
33924923|NCT01984736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924924|NCT04542512|||CASE_ONLY||PROSPECTIVE|||||||
33924925|NCT02718391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924926|NCT03459404|||CASE_ONLY||RETROSPECTIVE|||||||
33924927|NCT06261242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924928|NCT06309004|||CASE_ONLY||PROSPECTIVE|||||||
33924929|NCT04328012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double blind, placebo controlled clinical trial|t|t|t|t
33924930|NCT03457766|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Using high frequency ultrasound in identification of safety margins of skin cancers||||
34003864|NCT00265785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003865|NCT02101879|||COHORT||PROSPECTIVE|||||||
34003866|NCT01812473|||CASE_ONLY||PROSPECTIVE|||||||
34003867|NCT02959840|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003868|NCT05570630|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34003869|NCT04735887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant who will perform data collection will be blinded to the patient group.|Randomized clinical trial|f|f|f|t
34003870|NCT04117893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a prospective, randomized, open-label blind endpoint (PROBE) study||f|f|f|t
34003871|NCT01745081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090353|NCT05524129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090354|NCT03233217|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|QHD00008 was a modified double-blind study in which only the designated administrator at each study site knew which vaccine was administered to the participants. The participants and the Investigator/Sub-investigator in charge of the safety assessment were blinded in order to decrease the potential bias in safety assessment.|"Safety and tolerability was initially assessed in the first 10 participants in a smaller cohort (Cohort 1). Participants were randomized 1:1 into 2 groups in Cohort 1: QIV-HD by IM route (n=5) and QIV-HD by SC route (n=5).~After review of the local and systemic adverse events, the remaining 165 participants were enrolled (Cohort 2). Participants were randomized 1:1:1 into 3 groups in Cohort 2: QIV-HD by IM route (n=55), QIV-HD by SC route (n=55), and QIV-SD by SC route (n=55)."|t|f|t|f
34090355|NCT00523575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090356|NCT04174261|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Patient randomization in the ticagrelor and the clopidogrel group took place using sealed, opaque envelopes containing a computer-generated randomization scheme. Using a similar procedure, patients were then randomly assigned to RIPC or no RIPC within 1 hour before the procedure.|The TRIP study was a randomized, assessor-blind, active comparator-controlled, clinical trial using a 2×2 factorial design, with 1:1 patient allocation to ticagrelor or clopidogrel and within each treatment a 1:1 allocation to RIPC or control.|f|f|f|t
34090357|NCT05424055|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||f|t|t|t
34090358|NCT06535568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090359|NCT06121674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Surgery shall be performed for patients with VOD who are not responding to medical treatment and are candidate for penile prosthesis implantation. VOD will be documented by cavernosography to affect the deep system of veins; the internal pudendal vein, unilaterally.~Patients will be randomized into two groups: one to proceed to Penile Prosthesis Implantation (PPI Group), and another to be offered a choice between PPI or SHAEER-II. Patients opting for PPI will be assigned to the PPI group. Patients opting to SHAEER-II will be assigned to (SHAEER-II group)."|f|f|f|t
34090360|NCT01139879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090361|NCT06208332|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34090362|NCT05203016|||COHORT||PROSPECTIVE|||||||
34090363|NCT01386307|||OTHER||CROSS_SECTIONAL|||||||
34090364|NCT00574652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090365|NCT03346148|||OTHER||PROSPECTIVE|||||||
34090366|NCT03864432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090367|NCT05632991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34090368|NCT01095770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090369|NCT04024137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090370|NCT00146471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090371|NCT02712645|||COHORT||PROSPECTIVE|||||||
34090372|NCT03079492|||COHORT||PROSPECTIVE|||||||
34090373|NCT05941936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090374|NCT00304577|||DEFINED_POPULATION||PROSPECTIVE|||||||
34090375|NCT00315497|||COHORT||PROSPECTIVE|||||||
33924931|NCT01154595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924932|NCT06107036|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The administration of BI 1015550 and placebo will be blinded while the administration of moxifloxacin will be carried out open label.|This trial will be performed as a randomized, double-blind, 5-period crossover of BI 1015550 and moxifloxacin. Placebo will be given in two separate periods. There will be 15 treatment sequences based on a Prescott triple Latin square design for 5 treatments and 5 periods.|t|f|t|f
33924933|NCT00755872|RANDOMIZED|CROSSOVER||||NONE||||||
33924934|NCT04226287|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33924935|NCT06391749|||COHORT||PROSPECTIVE|||||||
33924936|NCT06085287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924937|NCT06210438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924938|NCT01153906|||COHORT||PROSPECTIVE|||||||
33924939|NCT05366257|||COHORT||RETROSPECTIVE|||||||
33924940|NCT00838721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924941|NCT05167721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Double-Blind Placebo-Controlled Adaptive Design Trial|t|t|t|t
33924942|NCT02759562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924943|NCT06130410|||CASE_ONLY||PROSPECTIVE|||||||
33924944|NCT00702247|NA|SINGLE_GROUP||TREATMENT||||||||
33924945|NCT04787211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33924946|NCT01670136|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33924947|NCT05148169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33924948|NCT06168825|||CASE_ONLY||PROSPECTIVE|||||||
33924949|NCT02538367|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33924950|NCT04108819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924951|NCT03396926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924952|NCT03923075|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|f|f|f|t
33924953|NCT06104319|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34090376|NCT00652041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33698985|NCT03145363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants do not know which group they were randomized into.|Intervention group (receives interactive text messages) and control group (receives informative text messages)|t|f|f|f
34090377|NCT05907265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090378|NCT00866320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090379|NCT04926584|||COHORT||PROSPECTIVE|||||||
34090380|NCT00463424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34090381|NCT06467734|||CASE_CONTROL||PROSPECTIVE|||||||
34090382|NCT00496457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090383|NCT04239664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090384|NCT03509090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34090385|NCT01730196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34090386|NCT00166816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090387|NCT05360264|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34090388|NCT00425919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34090389|NCT01405573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090390|NCT04426656|RANDOMIZED|PARALLEL||OTHER||NONE||Mixed methods study, including a 2-arm randomized controlled trial.||||
34090391|NCT01834794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698986|NCT03311529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786596|NCT04312191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients will be randomized 1:1 to standard of care only (Control Group) versus standard of care plus Meditation with a Mantra (MM) (Test Group) and will be followed for a total of 6 sessions of radiation therapy. Randomization will be executed using a computer-generated schema developed by the study biostatistician and stored in an electronic file.~The Test Group will be taught MM to use during each radiation treatment session and encouraged to practice MM ad libitum outside of the treatment setting.~For both the Control and Test Groups, validated questionnaires for anxiety and Quality Of Life will be administered at baseline, Session 3 and Session 6.~For the Test Group only, a log will be kept by the patient from Session 1 through follow-up, noting the times the MM is practiced. The Test Group will also receive a follow-up phone call on week 10 (one month after Session 6) to record whether the patient has continued to practice MM beyond the study requirements."||||
33698987|NCT00610623|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33698988|NCT06680570|||COHORT||CROSS_SECTIONAL|||||||
33698989|NCT00740077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33698990|NCT01237938|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786597|NCT04163484|||COHORT||PROSPECTIVE|||||||
33786598|NCT00121940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33924954|NCT04532073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924955|NCT03965871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924956|NCT00364819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698991|NCT03577288|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33698992|NCT01435070|||COHORT||PROSPECTIVE|||||||
33698993|NCT03825523|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stratified randomization will be generated by an electronic system, in blocks of 6 and 8, and a 1:1 ratio, according to the CD4+ T cell count.~Group A: Immediate treatment (iART). Start ART within 48 hours of admission and hospitalization; Group B: Conventional treatment (cART). Start the ART once the opportunistic infection is under control at the discretion of infectious disease specialist."||||
33698994|NCT01341197|||COHORT||PROSPECTIVE|||||||
33698995|NCT01879514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33698996|NCT00744276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33924957|NCT05572788|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33924958|NCT02500368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33924959|NCT01753830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33924960|NCT00860119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33924961|NCT05848180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participents of both groups and the outcome assessor will be blinded|There will be two groups .One is interventional and the other is control group. Interventional group will be taking ankle proprioceptive training and balance training, where control will be having only balance training exercises.|t|f|f|t
33924962|NCT01354613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924963|NCT05439018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||this trial has two groups ,one experimental and one control|f|f|t|t
33924964|NCT06151860|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924965|NCT04374578|||CASE_ONLY||PROSPECTIVE|||||||
33924966|NCT00206011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924967|NCT02414971|||COHORT||PROSPECTIVE|||||||
33924968|NCT04313088|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Randomization assignments will be handled by the statistician by means of a random number generator and assignments will be kept in opaque envelopes. The randomization scheme will be passed to the Temple Pharmacist. Based on the number, the Temple Pharmacist will dispense directly to the patient either drug or placebo in a labeled, child proof, pill bottle in a manner that does not disclose which group the patient is assigned. The Temple Pharmacist that is not a participant in the study will be responsible for dispensing study medication and will keep a secured log with the identity of that which is dispensed in case un-blinding becomes necessary.|Eligible patients will be randomized 1:1 via random number generator to either receive eluxadoline 100mg twice daily (BID) or matching placebo. Participants will take assigned medication or placebo as prescribed for 42 days. A washout phase will take place on days 43-70. On days 71-112, participants will crossover and take either eluxadoline 100mg BID or matching placebo based on their previously assigned group. Throughout the study, weekly phone calls with a study coordinator will take place and participants will keep a daily stool diary. Office visits with a physician will take place at the beginning of the pre-randomization phase and at Day 0, 42, 70 and 112 of the study phase. Participants will refrain from use of all additional anti-diarrheal medication during the entirety of the study.|t|t|t|t
33924969|NCT05127291|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33924970|NCT03025893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924971|NCT01535768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003872|NCT06678672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research coordinator will be blinded to the participants' condition to conduct assessments at Week 5.|This is a pilot randomized-controlled trial.|f|f|f|t
34090392|NCT01949987|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34090393|NCT01803542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33698997|NCT05248620|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Amoxicillin/placebo is provided in identical containers. Amoxicillin and placebo tablets are looking similar, but by decision of the Danish Medicines Agency amoxicillin tablets must not be removed from the original folio packing prior to use. Clindamycin active and placebo tablets look similar (incapsulated), and are provided in identical containers. Study medicine will be provided by 1-2 nurses at each site, who are unblinded. The patients and care providers are blinded|Multicenter, randomized, single-blinded, placebo controlled study, with blinded endpoint evaluation|t|t|f|t
34090394|NCT04294823|||CASE_CONTROL||RETROSPECTIVE|||||||
34003873|NCT01175473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003874|NCT03045627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090395|NCT04596423|||CASE_CROSSOVER||PROSPECTIVE|||||||
34090396|NCT01731496|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34090397|NCT00455624|||CASE_ONLY||PROSPECTIVE|||||||
34090398|NCT05951686|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33698998|NCT00484094|||COHORT||PROSPECTIVE|||||||
33698999|NCT02000934|NA|SEQUENTIAL||TREATMENT||NONE||||||
33699000|NCT03991858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003875|NCT03864458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34003876|NCT02206009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003877|NCT00263627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090399|NCT05338645|||FAMILY_BASED||PROSPECTIVE|||||||
34090400|NCT05564117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090401|NCT02072616|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090402|NCT05595954|||COHORT||PROSPECTIVE|||||||
34090403|NCT01091610|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33699001|NCT00332878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090404|NCT03738215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090405|NCT00358514|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090406|NCT05229900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090407|NCT03748524|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090408|NCT03585543|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34090409|NCT02714153|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33786599|NCT05920577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the baseline assessment, all eligible participants will be allocated randomly in a 1:1 ratio to either (1) experimental group which received exergaming and resistance training over a period of 12 weeks, or (2) control group which received resistance training over a period of 12 weeks. The research assistant, who is responsible for allocation, is independent from the data collection and anslysis, and the intervention. The participants will be reminded not to disclose information related to group allocation to the assessors to prevent possible bias during measurement. All assessments will be performed by an assessor who is blinded to the group allocation and not involved in the delivery of the intervention.|This pilot randomised controlled trial will conduct in a nursing home starting from Aug 2023 in Hong Kong|f|f|f|t
33786600|NCT05557721|||COHORT||PROSPECTIVE|||||||
33786601|NCT03163862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33786602|NCT01719536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090410|NCT05190432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Alphabetically labelled treatments, with de-blinding envelope held by an independent researcher at the University of Southampton.|A n=90 study (3 treatment arms, each n=30) providing participants with either 250mg/day Taxifolin/DHQ, 80mg/day Ergothioneine, or control.|t|t|t|t
34090411|NCT04286880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090412|NCT05770310|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33786603|NCT01539603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003878|NCT01085669|||COHORT||PROSPECTIVE|||||||
34003879|NCT05525676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The interviewer who evaluates clinical outcomes will not know the assigned condition of the participants.|Randomized controlled trial design. Participants in both arms will receive active treatments that are matched for length (three, 30-minute sessions) over a 45 day period. After that couples will be assessed for 6 months.|f|f|f|t
34003880|NCT03437330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003881|NCT05831579|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003882|NCT02907073|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34003883|NCT05338853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003884|NCT04536792|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34003885|NCT06677684|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||This randomized clinical trial included 105 children with CAP who were admitted to Bandar Abbas Children's Hospital. Participants were randomly assigned to two groups: a control group receiving standard antibiotic therapy and an intervention group receiving standard antibiotics plus vitamin A (25,000 IU for 2 days).|t|f|f|f
34003886|NCT00574769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003887|NCT05078827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003888|NCT01459198|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34090413|NCT05579704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090414|NCT01022580|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34090415|NCT02655341|||COHORT||PROSPECTIVE|||||||
34090416|NCT01809652|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34090417|NCT02819817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090418|NCT04120779|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot Randomised Controlled Trial||||
34090419|NCT06166797|||COHORT||CROSS_SECTIONAL|||||||
34090420|NCT02887001|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34090421|NCT01245751|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090422|NCT00260299|||CASE_ONLY||PROSPECTIVE|||||||
34090423|NCT01798290|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33699002|NCT05764408|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Size of varying blocks used within the permuted block design randomization will be masked to investigators. Efforts will be made to mask the physician who is interpreting the ultrasound from participant allocation; the participant and sonographer will be asked not to disclose the study arm to the interpreting physician, and no ultrasound images that would reveal study group allocation will be saved for the physician's view.|||||
34003889|NCT04973800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The simvastatin and the placebo tablets will be sourced from the Oxford Pharmacy Stores and HSC (www.hsconline.co.uk) respectively, and will be encapsulated at the Neurosciences Building according to our standard operating procedure (APPENDIX D: Neurosciences, SOP Number: Encapsulation Version 2: 22.10.2012). Blinding will be achieved by the identical matching of the simvastatin and placebo treatments. Participants will not be aware of the treatment that they will be receiving; neither will the researchers, as this study is double-blind. Allocation of treatments will be recorded on a randomisation list, which will be updated when each new participant enters the randomised phase. The list will be held at the Neurosciences Building by a scientist uninvolved in the study.||t|t|t|t
34003890|NCT02930135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003891|NCT01669824|||OTHER||PROSPECTIVE|||||||
33786604|NCT01339702|||COHORT||OTHER|||||||
34003892|NCT03211455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003893|NCT06646016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003894|NCT00691756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003895|NCT03675893|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34003896|NCT01098851|||CASE_CONTROL||PROSPECTIVE|||||||
33786605|NCT04252066|||COHORT||PROSPECTIVE|||||||
33786606|NCT02243592|||CASE_CONTROL||RETROSPECTIVE|||||||
33786607|NCT00409058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003897|NCT06260891|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|n/a the 2 zinc capsule dosages (25 and 40 mg) will be compounded to look identical|This is a delayed start parallel design where all subjects will have a usual care period, 2 baseline samples 4 weeks apart, followed by a 12 week zinc intervention, with samples at 8 and 12 weeks.|t|t|t|t
34003898|NCT03431896|||COHORT||PROSPECTIVE|||||||
34003899|NCT04648007|||COHORT||CROSS_SECTIONAL|||||||
34003900|NCT05626387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003901|NCT00935623|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34003902|NCT04117945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003903|NCT03786354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699003|NCT02207465|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33699004|NCT04844788|||OTHER||CROSS_SECTIONAL|||||||
33699005|NCT02586064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33699006|NCT05826808|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33699007|NCT03295500|||OTHER||PROSPECTIVE|||||||
33699008|NCT04308096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699009|NCT04595331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects originally randomized to Control Group at baseline in the pivotal 43USSA1812 study will be offered treatment with Sculptra Aesthetic in the extension study. Subjects originally randomized to Treatment Group at baseline in the pivotal 43USSA1812 study will be continued to be followed up during the extension study without further treatment.||||
33699010|NCT03271970|||COHORT||PROSPECTIVE|||||||
33699011|NCT05348473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33699012|NCT00252824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699013|NCT03548623|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33699014|NCT03509831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699015|NCT03860610|||COHORT||PROSPECTIVE|||||||
33699016|NCT04937361|||COHORT||PROSPECTIVE|||||||
33699017|NCT05353361|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicenter, open-label, dose exploration and efficacy expansion phase Ib / II study. The first stage is the dose exploration phase, which uses the 3 + 3 escalation design; The second stage is the curative effect expansion phase.||||
33699018|NCT00502944|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33699019|NCT06556784|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The trial will be conducted in a single-blinded structure, ensuring that all the participants are blinded to treatment or control related information. The experiment coordinators are unblinded and responsible for labelling the groups, allocating experimental equipment and materials, gathering data from participants and clinics, and analyzing all the relationships between and within the two groups.|A 2-armed, single blinded randomized controlled trial (RCT) will be applied to examine the therapeutic effects of at-home immersive virtual reality exergame in this exploratory study.|t|f|t|t
33699020|NCT01367093|||COHORT||PROSPECTIVE|||||||
33699021|NCT03378765|||COHORT||PROSPECTIVE|||||||
33699022|NCT00834678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699023|NCT02280538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699024|NCT03901885|NA|SINGLE_GROUP||OTHER||NONE||||||
33699025|NCT05371730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699026|NCT03911713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699027|NCT02983565|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participant not aware using iO2T or Fixed flow oxygen||t|f|f|f
33699028|NCT02896244|||COHORT||PROSPECTIVE|||||||
33786608|NCT01766856|||COHORT||PROSPECTIVE|||||||
34003904|NCT05281172|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34003905|NCT04961567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003906|NCT00063830||||TREATMENT||||||||
34003907|NCT02272309|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003908|NCT03514355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization of consenting eligible patients in intervention and control groups using separate permutated random blocks of 4||||
34003909|NCT05715307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003910|NCT06043375|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allotted to two groups. One group will receive licorice root powder capsules while the other group will not receive any treatment||||
34003911|NCT02064140|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34003912|NCT02069262|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34003913|NCT04623528|||COHORT||RETROSPECTIVE|||||||
34003914|NCT02330016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003915|NCT06326645|NA|SINGLE_GROUP||TREATMENT||NONE||Small exploratory study||||
34003916|NCT05155527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003917|NCT01107028|||CASE_ONLY||PROSPECTIVE|||||||
34003918|NCT02721550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003919|NCT05367037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|single-blind with double-blind evaluation (the actual evaluator of the primary endpoint is the pacemaker device's internal diagnostic algorithm, without intervention by the Investigator)|a prospective, randomized study in a 1:1 ratio, single-blind with double-blind evaluation (the actual evaluator of the primary endpoint is the pacemaker device's internal diagnostic algorithm, without intervention by the Investigator)|t|t|f|t
34090424|NCT06055582|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Patients were recruited from Fortis C-DOC OPD.|Patients with T2DM and non-diabetic subjects were randomized into two food groups- mango and bread for 3 days, then after a 7 days washout period, the cross-over took place.||||
34090425|NCT03424304|NA|SINGLE_GROUP||OTHER||NONE||||||
34090426|NCT02476162|||COHORT||PROSPECTIVE|||||||
33699029|NCT01135823|||COHORT||PROSPECTIVE|||||||
33699030|NCT02149719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699031|NCT00265551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33699032|NCT06681155|||COHORT||PROSPECTIVE|||||||
33699033|NCT01501396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699034|NCT03894787|||COHORT||PROSPECTIVE|||||||
33699035|NCT00100178|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34003920|NCT01758406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699036|NCT00891462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699037|NCT01967433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33699038|NCT05462743|||OTHER||RETROSPECTIVE|||||||
33699039|NCT00315146|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33699040|NCT06378151|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Clinician-level randomization|f|f|f|t
33699041|NCT01209507|||COHORT||PROSPECTIVE|||||||
34003921|NCT02919189|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34003922|NCT01937117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003923|NCT03359720|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34003924|NCT00653016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003925|NCT03310619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090427|NCT06050772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34090428|NCT00564356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090429|NCT04526054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090430|NCT00867880|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34090431|NCT04695678|||COHORT||PROSPECTIVE|||||||
34090432|NCT05323851|||OTHER||PROSPECTIVE|||||||
34090433|NCT04445415|||CASE_ONLY||RETROSPECTIVE|||||||
34090434|NCT04490707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699042|NCT04288180|||CASE_ONLY||PROSPECTIVE|||||||
33699043|NCT00992277|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33699044|NCT01430026|||CASE_ONLY||RETROSPECTIVE|||||||
33699045|NCT03980977|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699046|NCT04378127|RANDOMIZED|PARALLEL||OTHER||SINGLE||This was a single-blind,multicentric, prospective, randomized study comparing two arms: an intervention group undergoing a structured educational program associated to standard care and a control group who solely continued with traditional medical care|f|f|f|t
33699047|NCT04202471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33699048|NCT02334631|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33699049|NCT03719820|||COHORT||PROSPECTIVE|||||||
33699050|NCT02349542|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33699051|NCT00965809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699052|NCT06318234|||CASE_ONLY||PROSPECTIVE|||||||
33699053|NCT05267288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699054|NCT03623555|||CASE_CONTROL||RETROSPECTIVE|||||||
33699055|NCT00257608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699056|NCT03373071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786609|NCT02192554|||OTHER||PROSPECTIVE|||||||
33786610|NCT00000676||||PREVENTION||||||||
33786611|NCT06617689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699057|NCT04238585|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|Research staff performing data collection will be blinded to the intervention arm of the participants.|Families who present for a routine WIC visit will be referred for study staff recruitment if they meet either of the following criteria: 1) pregnant woman or 2) parent of child \<24 months enrolled in WIC.|t|f|t|f
33699058|NCT06680765|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study constitutes of an intervention and a comparison group. In Nigeria, the intervention group participants are drawn from the specific LGAs where the MMA program enhanced with the MNCH component is implemented. The comparison group is drawn from LGAs implementing MMA without the MNCH component. The study is conducted in specific PHCs purposely selected to host the evaluation and the catchment areas that are served by the PHCs. In Ethiopia, the study will be implemented in four out of the five regions that implement the Smart Start interventions. The intervention group is drawn from eight (8) woredas in the four regions where Smart Start with Smart pathways is implemented. The comparison group is based in 8 woredas geographically distant from those offering Smart Pathways.||||
33699059|NCT00946478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699060|NCT04401826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699061|NCT01020383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699062|NCT06557434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699063|NCT02902068|||COHORT||PROSPECTIVE|||||||
33699064|NCT03845777|||CASE_ONLY||PROSPECTIVE|||||||
33699065|NCT01812811|||||PROSPECTIVE|||||||
33699066|NCT00254761|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33699067|NCT06015464|||COHORT||OTHER|||||||
33699068|NCT00929123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699069|NCT05938062|RANDOMIZED|PARALLEL||PREVENTION||NONE|retrospective randomized study|retrospective randomized study||||
33699070|NCT01144208|||COHORT||PROSPECTIVE|||||||
33699071|NCT01751477|||COHORT||PROSPECTIVE|||||||
33699072|NCT06002126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699073|NCT02746172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699074|NCT05106894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699075|NCT06289985|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains.|f|f|f|t
33699076|NCT01706796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699077|NCT03750461|NA|SINGLE_GROUP||PREVENTION||NONE||Modified Simon-Two Step. An initial cohort of 5 patients will be enrolled and treated sequentially with 30 day follow-up. If stopping criteria are not met, the cohort will be expanded to an additional 15 patients followed concurrently for the duration of the study period||||
33786612|NCT02074956|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33924972|NCT03906175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33924973|NCT02197598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924974|NCT02527187|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33924975|NCT03214328|||COHORT||PROSPECTIVE|||||||
33924976|NCT02992301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924977|NCT02617576|||CASE_ONLY||PROSPECTIVE|||||||
33924978|NCT05048199|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|f|t
33924979|NCT03104985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924980|NCT01743170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924981|NCT00317564|||COHORT||PROSPECTIVE|||||||
33924982|NCT05089448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33924983|NCT02862470|||COHORT||PROSPECTIVE|||||||
33924984|NCT05535764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33924985|NCT06313853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Cluster-randomized|f|f|f|t
33924986|NCT03226548|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|f|f|f|t
33924987|NCT06396455|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patients, outcome assessors were blinded to the group allocation,|Group ISB (interscalene block group) received an ultrasound guided interscalene approach of brachial plexus plane block and group SSNB (suprascapular nerve block) received ultrasound guided suprascapular nerve block.|t|f|f|t
33924988|NCT00886106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33924989|NCT01886885|||COHORT||PROSPECTIVE|||||||
33924990|NCT05875246|RANDOMIZED|FACTORIAL||OTHER||TRIPLE||"30-day cycle involving the EMA Questions, along the micro-Intervention randomization and delivery. The application is coded to randomize each participant to one of the three intervention options. During this 30-day cycle physiological data will be collected from the Garmin Vivosmart 5 device worn by the participant and loaded into the Labfront app for storage and retrieval.~MYAPT.MIND (Daily for 30 days)~* Ecological Momentary Assessment (EMA) Survey Questions Set #1~* Micro-Intervention (None, Brief Messages, MYAPT.MIND Audios)~* Ecological Momentary Assessment (EMA) Survey Questions Set #2~* HRV (Heart Rate Variability) via Garmin Vivosmart 5 wrist wearable"|t|f|t|t
33924991|NCT06394557|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33924992|NCT00438464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33924993|NCT01914783|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33924994|NCT06174961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33924995|NCT01167153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003926|NCT05099510|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each subject will receive a single subcutaneous injection of Natrunix at one of the three doses (200 mg, 400 mg or 800 mg) or placebo. For each dose cohort, six subjects will be administered Natrunix and two subjects will be administered placebo. The study will not proceed to the next dose level unless the tested dose level has been deemed to have acceptable tolerability and safety. Subjects will undergo blood sampling for toxicity and pK analysis. Subjects will also be evaluated for the development of anti-drug antibodies (ADA).||||
34003927|NCT06325124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003928|NCT04485507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two-group randomized controlled pilot study|f|f|t|t
34003929|NCT02272894|||COHORT||PROSPECTIVE|||||||
34003930|NCT06415864|||COHORT||PROSPECTIVE|||||||
34003931|NCT04541680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699078|NCT06681298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699079|NCT03636165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33699080|NCT02026284|||COHORT||PROSPECTIVE|||||||
33699081|NCT02583126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699082|NCT03685695|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33699083|NCT04450888|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33699084|NCT06557538|||COHORT||PROSPECTIVE|||||||
33699085|NCT03299270|||COHORT||PROSPECTIVE|||||||
33699086|NCT03515252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699087|NCT00751218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699088|NCT04544085|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699089|NCT00491335|||||PROSPECTIVE|||||||
33699090|NCT02891694|||OTHER||CROSS_SECTIONAL|||||||
33699091|NCT02744703|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699092|NCT01297075|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33699093|NCT04212871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699094|NCT04525352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699095|NCT00820352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699096|NCT05758571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699097|NCT05931640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699098|NCT03901651|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patients submitted for screening, surveillance or diagnostic colonoscopy. First, a colonoscopy using a HD standard colonoscope using a forward viewing withdrawal technique. Then, a second colonoscopy using the Retroview colonoscope combining forward and retroflexed evaluation of the colon will be performed in the same patient.|f|f|f|t
33699099|NCT01973569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699100|NCT01837407|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33699101|NCT00002665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699102|NCT06285838|||COHORT||RETROSPECTIVE|||||||
33699103|NCT02773290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699104|NCT00562471|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33924996|NCT03682406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will remain blinded to the treatment condition for all participants.|Participants will be assigned in even numbers to CAMS-G or care as usual.|f|f|f|t
33924997|NCT03558971|NA|SINGLE_GROUP||TREATMENT||NONE||All participants follow the same treatment protocol: First, the participants ingest a defined dosage, 3-week treatment of cortisol tablets to achieve a minimum symptom state. Second, after the first is complete, participants are trained to self-administer small-dosage, 5-day regimens of cortisol tablets to quench disease exacerbations to maintain the minimum symptom state.||||
33924998|NCT01001234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33924999|NCT03617913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925000|NCT01010854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925001|NCT05845307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925002|NCT03339778|||COHORT||PROSPECTIVE|||||||
34003932|NCT05380050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor is not involved in treatment and is blind to group enrollment|63 randomized to three groups: In-patient intervention, Telehealth intervention and Control|f|f|f|t
33699105|NCT00302107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699106|NCT02173938|||COHORT||PROSPECTIVE|||||||
33699107|NCT02842307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699108|NCT05119673|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699109|NCT00854542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699110|NCT02127710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699111|NCT03901547|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Both groups get the same education intervention. Tier two gets additional measurement intervention and one additional system based intervention (e.g. priming) that Tier 1 does not.||||
33699112|NCT03499548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699113|NCT00808561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699114|NCT00524654|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33699115|NCT00257465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699116|NCT00864721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699117|NCT05538871|||OTHER||CROSS_SECTIONAL|||||||
33699118|NCT02020187|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33699119|NCT03442101|||COHORT||PROSPECTIVE|||||||
33699120|NCT00645723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699121|NCT02297191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925003|NCT03094819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33925004|NCT05294341|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33925005|NCT03883490|||COHORT||PROSPECTIVE|||||||
33925006|NCT02633046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925007|NCT02879981|||COHORT||PROSPECTIVE|||||||
34003933|NCT00519103|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003934|NCT04123015|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34003935|NCT06240065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003936|NCT04761445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The day of the surgery, each implantation site was given a number depending on the tooth missing. Then, using a random team generator software (Keamk) each site was randomly assigned to one of the two groups based on the implant system used.~Participants were blinded as to the assignment in the first or second group."|The study is designed as a prospective clinical trial with a parallel design comparing two different tissue-level implants placed adjacently in the posterior maxilla and mandible.|t|f|f|f
33699122|NCT01724931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003937|NCT03756701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"There will be 2 groups of participants. Group 1 will begin the intervention immediately. Group 2 will maintain their usual lifestyle for the first 10 weeks, and begin group sessions when group 1 has completed. There will be refresher sessions for group 1 once per month, and 3, 6 12 month follow up testing after the group sessions."||||
34003938|NCT03916562|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||For this study, the investigators will recruit two separate groups of participants who will complete the study procedures in parallel. One group will be comprised of individuals post-stroke and the second group will be comprised of adults who have not had a stroke.||||
34003939|NCT03711396|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||We will conduct four n-of-1 group visit interventions for advance care planning.||||
34003940|NCT00461669|||DEFINED_POPULATION||OTHER|||||||
33699123|NCT05312372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090435|NCT06549543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the participants, investigators and outcomes assessors were blinded throughout the study.|patients were assigned into two groups. Both groups received conventional physiotherapy and exercise therapy. Group 1 was the experimental group, and group 2 was the control group.|t|f|t|t
33925008|NCT03616847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Those collecting and analysis the data will be masked to the treatment groups. It is not possible to mask the participant or the care provider in this study|Two randomised study groups with one having standard care and the other the intervention.|f|f|t|t
34090436|NCT05193487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090437|NCT06356493|||CASE_CONTROL||RETROSPECTIVE|||||||
34090438|NCT01837342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090439|NCT03704688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090440|NCT00757900|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34090441|NCT01334047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090442|NCT05398588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090443|NCT05856435|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34090444|NCT01949272|||COHORT||PROSPECTIVE|||||||
34090445|NCT02354456|||CASE_ONLY||PROSPECTIVE|||||||
34090446|NCT04044508|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Disguise products (Oral supplements: Nutricia 'ketocal' (intervention) or Nutricia 'fortini' (placebo)|Randomized, blind, placebo-controlled, cross over study|t|f|t|f
34090447|NCT03797729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090448|NCT02758470|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34090449|NCT02949934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090450|NCT00137319|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090451|NCT03880565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090452|NCT06551558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090453|NCT04677257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||interventional, prospective, multicentre study||||
34090454|NCT01063907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090455|NCT04648176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090456|NCT01137786|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33699124|NCT06621719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699125|NCT00014261||||TREATMENT||||||||
33699126|NCT05490407|NA|SINGLE_GROUP||SCREENING||NONE||||||
33699127|NCT05031273|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The intervention arm will be exposed to the built environment intervention, and the control arm will not.||||
33699128|NCT02291185|||CASE_ONLY||PROSPECTIVE|||||||
33925009|NCT01902537|||COHORT||CROSS_SECTIONAL|||||||
33925010|NCT05190744|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925011|NCT03865238|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925012|NCT00198094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925013|NCT01799421|||COHORT||PROSPECTIVE|||||||
33925014|NCT02176304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925015|NCT00805922|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34090457|NCT05426525|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Pills will be prepared and dispensed by a pharmacy to blind participants and investigators.||t|t|t|t
34090458|NCT06373510|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34090459|NCT03236389|NA|SINGLE_GROUP||SCREENING||NONE||||||
34090460|NCT06310863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, Matched pairs, Active controlled|t|f|f|t
34090461|NCT05268289|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34090462|NCT03690544|NA|SINGLE_GROUP||TREATMENT||NONE||Apremilast 30mg orally twice daily for 16 weeks||||
34090463|NCT01684800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090464|NCT00705419|||COHORT||PROSPECTIVE|||||||
34090465|NCT01056536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090466|NCT00374400|||||PROSPECTIVE|||||||
34090467|NCT00309179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090468|NCT02508389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34090469|NCT00338078|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34090470|NCT04213131|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants are assigned to one of two or more groups in parallel for the duration of the study||||
34090471|NCT02662543|||COHORT||PROSPECTIVE|||||||
33699129|NCT01028885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699130|NCT04849923|RANDOMIZED|PARALLEL||OTHER||NONE||controll group, two groups of strength training with different effort||||
33699131|NCT01664065|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33699132|NCT03836703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33699133|NCT01282658|||COHORT||PROSPECTIVE|||||||
33925016|NCT03536650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786613|NCT06554483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|participants will not be informed whether they are in the experimental or control group|The participants will assigned to the experimental or control group by randomization method. Each group will include in an exercise program for 6 weeks, 2 sessions per week, each session for an average of 60 minutes. The exercise program of the experimental group consist of a combination of a 10-minute warm-up period with graded walking, mobility and stretching exercises, a 20-minute proprioceptive exercise program, a 20-minute nbpet using a laser pointer, and stretching and relaxation exercises that ended with a 10-minute cool-down period. Control group's exercise program consist of a 10-minute warm-up period with graded walking, mobility and stretching exercises, followed by a 40-minute proprioceptive exercise program and a 10-minute cool-down period consisting of stretching and relaxation exercises.|t|f|f|f
33786614|NCT01253824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925017|NCT01438307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925018|NCT01303458|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34003941|NCT02394288|||COHORT||PROSPECTIVE|||||||
34003942|NCT02978651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786615|NCT06713850|||COHORT||PROSPECTIVE|||||||
33925019|NCT00989404|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34003943|NCT03677843|||COHORT||PROSPECTIVE|||||||
34090472|NCT02136589|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34090473|NCT03518944|||COHORT||PROSPECTIVE|||||||
33925020|NCT01092026|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive either myeloablative or reduced intensity conditioning. One or 2 cord blood transplants will be transplanted, followed by infusion of a third-party mesenchymal stem cell transplant||||
33925021|NCT00293046|RANDOMIZED|PARALLEL||||NONE||||||
33925022|NCT03096444|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The antipruritic effect of 4 topical treatments and 1 vehicle treatment will be explored in each subject. Study visit 1 will consist of testing 3 topical formulations, and study visit 2 will test the remaining 2 topical formulations in each subject.|t|f|t|f
33925023|NCT05915325|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm intervention trial||||
33925024|NCT06079034|||COHORT||RETROSPECTIVE|||||||
33925025|NCT01287598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090474|NCT04215783|||COHORT||PROSPECTIVE|||||||
33925026|NCT02061748|||OTHER||RETROSPECTIVE|||||||
34090475|NCT02617251|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34090476|NCT01706627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699134|NCT02785315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33699135|NCT00507923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699136|NCT01571310|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33699137|NCT00287365|NA|SINGLE_GROUP||OTHER||NONE||||||
33699138|NCT03332290|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized opened clinical trial||||
33699139|NCT04876144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699140|NCT00955318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699141|NCT02236637|||COHORT||PROSPECTIVE|||||||
33699142|NCT01872221|NA|SINGLE_GROUP||OTHER||NONE||||||
33699143|NCT01759511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699144|NCT00232648|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925027|NCT04339322|||COHORT||PROSPECTIVE|||||||
33925028|NCT00091026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925029|NCT04138212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925030|NCT00289549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925031|NCT03714009|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33925032|NCT03519399|||CASE_CONTROL||PROSPECTIVE|||||||
33925033|NCT02600494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925034|NCT04939779|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925035|NCT02708992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003944|NCT06677632|||COHORT||PROSPECTIVE|||||||
34003945|NCT02369354|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34003946|NCT02102932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003947|NCT05275049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003948|NCT01922960|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003949|NCT00002244||||TREATMENT||DOUBLE||||||
34003950|NCT01619956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34003951|NCT01592552|||COHORT||CROSS_SECTIONAL|||||||
34003952|NCT04439760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34003953|NCT04178382|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34003954|NCT05058768|||CASE_CONTROL||PROSPECTIVE|||||||
34003955|NCT02870439|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34003956|NCT00243152|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34003957|NCT03247699|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34090477|NCT05472974|||COHORT||PROSPECTIVE|||||||
34090478|NCT06125665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090479|NCT00303953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090480|NCT04463706|||COHORT||RETROSPECTIVE|||||||
34090481|NCT05526768|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|The providers caring for the participating patients will be blinded to the data being collected by the remote monitoring system and no patient care decisions will be made based on the remote monitoring system.|||||
34090482|NCT01980888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090483|NCT04675879|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|When the treatments are completed, those who will evaluate the clinical and radiological results will not know the treatment method.|Previously randomized patients were divided into 3 groups to be treated with 3 different types of bandages.|f|f|t|t
33699145|NCT02785484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33699146|NCT02248909|||COHORT||PROSPECTIVE|||||||
33699147|NCT03368248|||OTHER||PROSPECTIVE|||||||
33699148|NCT04769661|||CASE_ONLY||RETROSPECTIVE|||||||
33699149|NCT03913468|||COHORT||RETROSPECTIVE|||||||
33699150|NCT03325049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This randomized controlled pilot study used a pre-test, post-test design with intervention and control groups||||
33699151|NCT00239109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33699152|NCT04783818|||CASE_CONTROL||RETROSPECTIVE|||||||
33699153|NCT01649050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699154|NCT02967432|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699155|NCT04798638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699156|NCT01934972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699157|NCT05979506|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, prospective, multicenter (Toulouse - Bordeaux - Paris Necker), comparative (baseline vs. short and medium term)||||
34003958|NCT00776568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003959|NCT01309724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699158|NCT03082482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699159|NCT02647242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699160|NCT01464996|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33699161|NCT06391840|||CASE_CONTROL||PROSPECTIVE|||||||
33699162|NCT00439023|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699163|NCT02403856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699164|NCT04835519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699165|NCT05966792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699166|NCT01254630|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33925036|NCT00175162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699167|NCT05412875|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090484|NCT03077867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699168|NCT03281707|||COHORT||PROSPECTIVE|||||||
33699169|NCT00090571|||FAMILY_BASED||PROSPECTIVE|||||||
33699170|NCT03749473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33699171|NCT04576325|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The investigators, study coordinators, study subjects and the Sponsor will be blinded to treatment assignment.|In each cohort, 8 eligible subjects will be randomized in a 3:1 ratio (6 on active and 2 on placebo) to receive 7 doses (over 3.5 days) of VIP BID or placebo|t|f|t|f
33699172|NCT05427734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699173|NCT01411618|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33699174|NCT02112006|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699175|NCT02180165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699176|NCT03427671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699177|NCT00932243|||COHORT||PROSPECTIVE|||||||
33699178|NCT00004857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699179|NCT04932460|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699180|NCT02869074|||COHORT||CROSS_SECTIONAL|||||||
33699181|NCT05925465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Nerve block will be done by an anesthesiologist who will not be involved in data collection to ensure blindness.|Patients will be randomized into one of two groups, each of 30 patients, by means of coded envelopes to receive bilateral combined maxillary and mandibular nerve block (MNB group) or not receive any nerve block (control group)|t|f|t|f
33699182|NCT01419626|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33699183|NCT03931824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Solutions were prepared by an investigator, and injectors were coated with an opaque layer in order to conceal the content from both the one performing the injection and the patients. Data was then analyzed by an investigator who was blind to the study groups||t|t|f|t
33699184|NCT03865771|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699185|NCT04096742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a single-center, prospective, double-blind, randomized, vehicle-controlled study|t|f|t|f
33699186|NCT00563355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699187|NCT02298634|||COHORT||PROSPECTIVE|||||||
33699188|NCT03118713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925037|NCT03183284|||COHORT||PROSPECTIVE|||||||
33925038|NCT03357666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925039|NCT04282070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925040|NCT01367860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925041|NCT03274180|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Experimental arm: Nurse consultation Non interventional arm: the medical consultation.|t|f|f|f
33925042|NCT00610285|||COHORT||PROSPECTIVE|||||||
33925043|NCT02790294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925044|NCT01545713|||CASE_ONLY||PROSPECTIVE|||||||
33925045|NCT04480541|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33925046|NCT01053702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925047|NCT05252923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925048|NCT04811001|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, non-comparative study investigating two EGFR-TKI sequences||||
33925049|NCT01809678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925050|NCT04169685|||CASE_ONLY||RETROSPECTIVE|||||||
33925051|NCT04714723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33925052|NCT00947843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925053|NCT04661852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925054|NCT03429322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Community-based randomized pragmatic clinical trial of a complex behavioral intervention delivered remotely||||
33925055|NCT05445141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study is a two-armed study including an intervention group and a control group. The groups consist of parents of children 1-2 years that are registered at any of the included CHCs in the study.|f|f|t|t
33925056|NCT02521857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925057|NCT06263660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33925058|NCT00377533|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925059|NCT00616291||PARALLEL||TREATMENT||NONE||||||
34090485|NCT02131883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090486|NCT01807455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090487|NCT02545192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090488|NCT00912119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090489|NCT00775034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090490|NCT04739163|||OTHER||CROSS_SECTIONAL|||||||
34090491|NCT06522659|||OTHER||CROSS_SECTIONAL|||||||
34090492|NCT02901860|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33699189|NCT05255211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699190|NCT01475409|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699191|NCT02235519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699192|NCT04041297|||COHORT||PROSPECTIVE|||||||
33699193|NCT01222624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699194|NCT03881670|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33699195|NCT05877573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699196|NCT01480648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33699197|NCT04020588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699198|NCT02876627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699199|NCT06210464|||OTHER||RETROSPECTIVE|||||||
33699200|NCT05089279|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699201|NCT00928395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699202|NCT02818361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699203|NCT03400995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003960|NCT04445701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1 Part 1: Up to 4 dose escalation cohorts will be enrolled; each cohort will initially recruit 3 patients to receive AO-176 monotherapy in a standard 3+3 design; the cohort will be expanded in the event of a DLT. Once the RP2D has been identified, an expansion cohort will be enrolled to evaluate AO-176 at the RP2D in combination with dexamethasone (DEX).~Phase 1 Part 2: Dose escalation cohorts will evaluate AO-176 in combination with DEX and bortezomib (BORT) to determine the RP2D of AO-176 + DEX + BORT in a standard 3+3 design; the cohort will be expanded in the event of a DLT.~Phase 2: Up to 48 patients will be enrolled to evaluate the preliminary efficacy of AO-176 + DEX + BORT using a Simon 2-stage design."||||
34003961|NCT05568173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34003962|NCT06186219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003963|NCT02666417|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34003964|NCT00387608||||TREATMENT||NONE||||||
34003965|NCT04631380|RANDOMIZED|PARALLEL||OTHER||SINGLE|RAMDOMIZED DOBLE-BLINDING|PROSPECTIVE RANDOMIZED DOUBLE-BLIND STUDY|t|f|f|f
34090493|NCT03243019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090494|NCT03094728|||COHORT||PROSPECTIVE|||||||
34090495|NCT05749419|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33699204|NCT02600065|||CASE_ONLY||PROSPECTIVE|||||||
33699205|NCT00169793|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33699206|NCT03510234|||COHORT||PROSPECTIVE|||||||
33699207|NCT03746171|||CASE_ONLY||PROSPECTIVE|||||||
33699208|NCT00658008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699209|NCT00705926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699210|NCT02722369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699211|NCT01995643|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33699212|NCT03344796|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|cohort study 1 and 2 were masked. Each participant was identified by a study number assigned in REDCap|Cohort study 1 is parallel and randomized Cohort Study 2 is a single group study with comparison of the participants' reported sunburns prior to intervention and during the intervention|t|f|t|t
33699213|NCT02764333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699214|NCT05143281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699215|NCT04970641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699216|NCT00066352||||TREATMENT||NONE||||||
33699217|NCT03243942|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699218|NCT05884788|||CASE_ONLY||PROSPECTIVE|||||||
33699219|NCT01817231|||CASE_CONTROL||PROSPECTIVE|||||||
33699220|NCT01501370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786616|NCT06053931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The population of the research is consisted of mothers who have just given birth and are hospitalized in the obstetrics and gynecology service at Izmir Bakırçay University Çiğli Training and Research Hospital.~No sample selection is made in the research, and all mothers who meet the inclusion criteria and accept the research is constituted the sample.~Randomization will be provided to newborns and mothers using the simple randomization method according to their protocol numbers and by using the website https://www.randomizer.org/."|A total of 90 mothers and newborns, 30 lullaby, 30 white noise and 30 control groups, will constituted the sample of the study|t|f|f|f
34003966|NCT05157035|RANDOMIZED|PARALLEL||TREATMENT||NONE||Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group will use the smartphone app which comprises of audio-guided mindfulness meditations and video lessons. Participants are asked to listen to at least one guided meditation daily and watch one video lesson each week. Participants will also receive a weekly phone call for emotional and technical support. The wait-list control group will have the option to use the app-based intervention after 10 weeks of being in the control group.||||
34003967|NCT02992457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003968|NCT01273480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34003969|NCT04347096|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34003970|NCT04840940|||COHORT||PROSPECTIVE|||||||
34003971|NCT06148662|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34003972|NCT05303948|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||A simulation study, in which participants alternatively perform oro-tracheal intubation on a manikin, either using a videolaryngoscope (McGrath model, Medtronic TM) or a direct laryngoscope||||
34003973|NCT01740791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090496|NCT00697164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090497|NCT01767415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090498|NCT01741818|||CASE_ONLY||PROSPECTIVE|||||||
34090499|NCT00223574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34090500|NCT05924932|||OTHER||PROSPECTIVE|||||||
34090501|NCT01067300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090502|NCT05485090|||COHORT||PROSPECTIVE|||||||
34090503|NCT03033615|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34090504|NCT04641637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090505|NCT02237664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090506|NCT01255020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34090507|NCT00386698|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090508|NCT00915525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090509|NCT02135289|||CASE_CONTROL||PROSPECTIVE|||||||
34090510|NCT01754948|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34090511|NCT02943759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090512|NCT00229528|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090513|NCT05743582|||COHORT||PROSPECTIVE|||||||
34090514|NCT00818272|||COHORT||PROSPECTIVE|||||||
34090515|NCT04324840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090516|NCT05363176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcomes assessors will not know what condition that the participant was allocated to, nor will the statistician who is one of the co-investigators.|Participants are randomized to one of two interventions.|f|f|t|t
34090517|NCT03044561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090518|NCT00975923|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34090519|NCT01965795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34090520|NCT04611217|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Aim 1- Participants are blinded to the treatment arm. The high fiber and low fiber foods are matched in palatability, appearance and energy. Laboratory staff will be blinded to the subject's diet assignment (SA1), all biochemistries, and the microbiome analysis (samples are identified by code and batch processed, all baseline and follow-up samples analyzed simultaneously).|Aim 1- 4-week parallel arm repeated measures Aim 2- 3 week single arm repeated measures|f|f|f|t
34090521|NCT05781802|||COHORT||PROSPECTIVE|||||||
34090522|NCT03724344|||CASE_ONLY||CROSS_SECTIONAL|||||||
34090523|NCT05550519|NA|SINGLE_GROUP||OTHER||NONE||||||
34090524|NCT00250484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34090525|NCT03442062|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34090526|NCT04939389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Paired measurements with two different measurement methods||||
34090527|NCT01044498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090528|NCT04226677|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||participants are grouped randomly, the first group is the aerobic exercise group, the second group is the video based exercise group and the third group is the combination of these.|t|f|t|f
34090529|NCT05766748|NA|SEQUENTIAL||TREATMENT||NONE||||||
34090530|NCT06490315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090531|NCT02189824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090532|NCT00568243|||CASE_ONLY||PROSPECTIVE|||||||
34090533|NCT04161352|||COHORT||PROSPECTIVE|||||||
34090534|NCT04235855|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The biopsy specimens would be reported independently by two pathologists who would be masked to the source of tissue ( right/ left lobe ).|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield.|f|f|f|t
34090535|NCT00022373||||SUPPORTIVE_CARE||||||||
34090536|NCT03402412|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090537|NCT00994539|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34090538|NCT04298853|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34090539|NCT03180372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090540|NCT04638244|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
34090541|NCT03578913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double blind (Patients and outcome assessors) both patient and assessor will be blinded to the assigned material. However the operator can't be blinded due to the difference in preparation and shade of the ceramic materials. Reem Gabr will be responsible for the try-in and final delivery of the crowns.~-The assessor will assess all outcomes blinded to the material assigned for each patient."|Patient will receive a restoration with superior function, ethetic, and excellent clinical performance.|t|f|f|t
34090542|NCT03606824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34103217|NCT06686381|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a non-comparative, randomized trial, where each arm is independent from the other. Arm A will receive drug A in both the induction and maintenance phases, while Arm B will receive drug A during the induction phase and then follow a watch and wait approach."||||
34103218|NCT04839601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103219|NCT02557919|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103220|NCT03965117|NA|SINGLE_GROUP||OTHER||NONE||||||
34003974|NCT00203320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003975|NCT04854408|||OTHER||PROSPECTIVE|||||||
34003976|NCT00973310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003977|NCT01122589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003978|NCT00438659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34003979|NCT05289557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34003980|NCT04381481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34003981|NCT01872624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003982|NCT01594034|||||PROSPECTIVE|||||||
34003983|NCT04315272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple: (Participant, Care Provider, Investigator, Outcomes Assessor)|Individually randomized placebo-controlled trial of azithromycin vs. placebo to establish the efficacy and safety of azithromycin.|t|t|t|t
34003984|NCT02773940|NA|SINGLE_GROUP||OTHER||NONE||||||
34003985|NCT00882479|||||CROSS_SECTIONAL|||||||
33699221|NCT04250922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"At the Screening Visit, the IRT will assign a unique number to the subject. The site will use the IRT to receive drug kit numbers and a unique randomization number.~Subjects will be randomized to Arm A or B in a 1:1 ratio. Drug kit numbers and treatment content will be assigned according to a list generated before the start of the study. At interim, the IRT vendor will transfer the list of attribution to the iSCs. After the final lock, the list of attribution will be transmitted to the company involved in analysis. The IRT vendor will be in charge of the stock management/logistics in each site and shipments. Upon receipt of study drug, the study site will acknowledge receipt in the IRT system.~The investigators, the study site personnel and subject will remain blinded to throughout the course of the study. The IRT will provide access to for a subject in case of medical emergency. If sponsor/clinical team should break the blind, the reason will be documented on the eCRF."|"This is a randomized, double-blind, placebo-controlled, 2 parallel arms (1:1), adjuvant trial to assess the efficacy of LAM561 vs placebo in patients with ndGBM. The 2 arms are: Arm A: SoC + placebo for LAM561; Arm B: SoC + 12g/day of LAM561~Treatment consists of 3 phases:~1. Chemoradiotherapy (6 to 7 weeks)~   * RT in daily fractions of 2Gy, 5 days per week (60Gy)~  * TMZ 75mg/m2 daily (maximum of 49 days)~  * Placebo or LAM561 for 4 weeks (from week 3 to week 6, both inclusive) -Washout period (4 weeks)~2. Maintenance (4-week cycles, maximum of 6 cycles)~   * Placebo/LAM561 daily in the first 3 weeks of each cycle, followed by 7 days washout~  * TMZ 150-200mg/m2 daily in the first 5 days of each cycle~3. Monotherapy: 4-week cycles until disease progression, unacceptable toxicity or lack of clinical benefit Placebo/LAM561 daily in the first 3 weeks of each cycle followed by 7 days washout"|t|t|t|f
34003986|NCT06531850|||COHORT||PROSPECTIVE|||||||
34090543|NCT02603133|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants are individually randomized to one of two cohorts. 1 cohort will serve as the waitlist control for Cohort 1 before starting their version of the intervention. Each cohort will experience slightly different versions of WISER, which only differ by the spacing of the intervention. Cohort 1 will receive a 10-day sequential (Seq) and a 10-day non-sequential (NSeq) rollout of the resilience tools. Seq will receive the tools on ten consecutive days. NSeq will receive messages daily with the exception of Thursdays, Fridays and Saturdays. Our tracking of attrition in the first study showed marked declines in participation on Thursdays, Fridays, and to some extent on Saturdays, but an increase on Sundays, hence this design to test a new way of counteracting attrition.||||
34090544|NCT05285969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699222|NCT05594654|||COHORT||PROSPECTIVE|||||||
33786617|NCT05730205|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be observed over two phases: 1) a 3-month phase with no hormonal contraceptive intervention and 2) a 6-month phase with the progestin implant.||||
33786618|NCT00233792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786619|NCT00281762|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33786620|NCT00218556|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786621|NCT05448261|RANDOMIZED|PARALLEL||OTHER||SINGLE|Group allocation will be sealed in an opaque envelope and will be given to the participants according to their sequence of study entry, and will be concealed from outcome assessors.|This research is a sequential mixed-method study that includes a randomized controlled trial and a descriptive qualitative study|f|f|f|t
33786622|NCT06627101|||OTHER||CROSS_SECTIONAL|||||||
33786623|NCT06714617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786624|NCT05876910|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786625|NCT01261065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786626|NCT06631651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients' ID will/did not be revealed|A retrospective analysis was conducted on 124 patients undergoing surgery for distal radius fractures. Patients were divided into groups based on whether they underwent brachioradialis release during surgery. Pre- and post-operative radiographs were analyzed for anatomical alignment using the Dresdner score. Functional assessments included hand, wrist, and elbow strength, proprioceptive function, and disability levels.|t|f|f|f
33786627|NCT00445406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786628|NCT03450876|||COHORT||PROSPECTIVE|||||||
34003987|NCT04241341|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized to one of two groups:~ALND with ILR (intervention group) and ALND without ILR (control group; current standard treatment at Memorial Sloan Kettering \[MSK\])."||||
34003988|NCT06678633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomised, comparative pilot study with two arms||||
34003989|NCT00760786|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34003990|NCT01056926|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34003991|NCT01149434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34003992|NCT03124303|||COHORT||PROSPECTIVE|||||||
34003993|NCT00826345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34003994|NCT05690035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34003995|NCT01235442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003996|NCT01598545|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34090545|NCT01251458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090546|NCT04785729|NA|SINGLE_GROUP||OTHER||NONE||||||
34090547|NCT06355973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34003997|NCT00942812|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34003998|NCT05305950|||COHORT||CROSS_SECTIONAL|||||||
34003999|NCT02247076|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34004000|NCT00277043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090548|NCT00470613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090549|NCT06201325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assesor will be different persons|"Patients will be randomly divided into 3 groups. They will be selected by simple random sampling using the closed envelope method.~In the first group, will be included in a VR-based exercise program for half an hour a day, 5 days a week for a total of 3 weeks, in addition to home exercise programs for half an hour a day, 5 days a week for a total of 3 weeks. These individuals will use the Microsoft Kinect for Azure VR system in the virtual environment.~In the second group, will be included in the traditional exercise group, will be included in the stretching and strengthening exercise program for half an hour a day, 5 days a week for a total of 3 weeks, in addition to home exercise programs for half an hour a day, 5 days a week for a total of 3 weeks.~In the third group, who will be included in the home exercise group, exercises will be taught to the patient and will be applied for half an hour a day, 5 days a week for a total of 3 weeks."|f|f|t|t
34090550|NCT05546762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090551|NCT04403139|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090552|NCT02321904|||CASE_CONTROL||PROSPECTIVE|||||||
34090553|NCT04177251|||CASE_CONTROL||PROSPECTIVE|||||||
34090554|NCT02705703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090555|NCT05180058|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34090556|NCT05143502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699223|NCT02922855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34090557|NCT02471183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090558|NCT01500083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090559|NCT02504164|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34090560|NCT03120273|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090561|NCT02115386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090562|NCT02395770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090563|NCT00090103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090564|NCT04168489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||(a) consistent with the diagnostic criteria for primary dysmenorrhea according to the American College of Obstetricians and Gynecologists; (b) regular menstrual cycles (27-32 days); and (c) the average intensity of dysmenorrhoeic pain in the past 6 months should be rated ≥4 on a visual analogue scale (VAS) (0 = no pain, 10 = the worst imaginable pain).|t|f|f|f
34090565|NCT05067270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34090566|NCT00001073||||TREATMENT||||||||
34090567|NCT02388009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34090568|NCT03561207|||COHORT||PROSPECTIVE|||||||
34090569|NCT03729284|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34090570|NCT01006629|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34090571|NCT00690651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34090572|NCT01890993|||COHORT||RETROSPECTIVE|||||||
34103221|NCT03825666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699224|NCT06324331|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
33699225|NCT00431678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699226|NCT00120523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699227|NCT01479023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699228|NCT03254290|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The teeth treated with each specific material will be randomly assigned by drawing a random number from a manilla folder|Children between the ages of 2 ½ and 9 years of age and be ASA I or ASA II. Patient must have two, primary teeth that are matched for, size of carious lesion (same level of approximation of carious lesion to the pulp) and are that are treatment planned for a pulpotomy. The teeth selected for the study must be vital and asymptomatic both clinically and radiographically or only display symptoms consistent with reversible pulptitis The teeth selected for the study must be anticipated to be retained in the mouth for at least eighteen months|t|f|f|f
33699229|NCT02906904|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33699230|NCT00844584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699231|NCT00787761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699232|NCT05593133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699233|NCT01469312|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33786629|NCT01737008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004001|NCT05120817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699234|NCT04355507|||COHORT||RETROSPECTIVE|||||||
33699235|NCT05780073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Dasatinib capsules re-capsulated with identical appearance with Placebo||t|t|t|t
33699236|NCT03576495|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|Resident program directors and research staff will not be blinded to the implementation of curriculum|Sites will be assigned to an early intervention/retention assessment group or a delayed intervention group (control) for examination of the effectiveness of the intervention as well as learner retention.||||
34004002|NCT03623893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and care providers are aware of allocation; masking is impossible because of the nature of the intervention.|Multicenter randomized controlled trial.|f|f|t|t
34004003|NCT04276012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004004|NCT03278158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The type of treatment is blinded for the subjects.|Each subject will be randomised to one of four treatments, placebo and three different single oral doses of XEN-D0501. Cohorts of 8 patients are run subsequently where of 2 patients receive placebo and 6 patients receive XEN-D0501 beginning with the 1 mg dose followed by the 2, 4 and 8 mg dose groups. Each treatment step will be completed consecutively and progression to next dose level depend on good safety and tolerability on the previous dose level.|t|f|f|f
34004005|NCT00564187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004006|NCT00566137|||COHORT||RETROSPECTIVE|||||||
34004007|NCT05772286|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34004008|NCT02289820|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34004009|NCT01226524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004010|NCT02906813|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34004011|NCT01843309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34090573|NCT05219890|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Healthy volunteers and obese patients will consume the same amount of omega-3 fatty acids for the same time.|f|f|t|f
34090574|NCT04136132|NA|SINGLE_GROUP||OTHER||NONE||||||
34090575|NCT02588508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34090576|NCT02760303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34090577|NCT04225156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090578|NCT03734341|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34090579|NCT03664258|||COHORT||PROSPECTIVE|||||||
34090580|NCT02239328|||COHORT||PROSPECTIVE|||||||
34090581|NCT01697241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34090582|NCT05420740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090583|NCT00093028|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34090584|NCT04363814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090585|NCT06280677|||COHORT||PROSPECTIVE|||||||
34090586|NCT01151436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090587|NCT05658549|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|This study used N acetyl cysteine capsules and placebo, which were made similar in shape; researchers and patients did not know who was getting the drug or placebo.|This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into four groups. The control group K0 received standard therapy without NAC, while the treatment group, K1, received NAC injections of 1200mg/day, K2 NAC tablets 3x400mg/day, and K3 NAC tablets 3x200mg/day. Different tests using Way ANOVA and LSD or Kruskal-Wallis and Mann-Whitney.|t|t|t|t
34090588|NCT06378970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised Controlled||||
34090589|NCT00367458|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34090590|NCT05361837|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33699237|NCT05894499|||COHORT||RETROSPECTIVE|||||||
33699238|NCT01620554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699239|NCT04087213|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective multi-center, open-label, single-arm, cross-over study.||||
33699240|NCT00163111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699241|NCT06651437|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33699242|NCT03018600|||COHORT||PROSPECTIVE|||||||
33786630|NCT01594502|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786631|NCT02978521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004012|NCT00001873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699243|NCT01154075|||COHORT||PROSPECTIVE|||||||
33699244|NCT00095992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699245|NCT05093140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004013|NCT00731991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004014|NCT04229290|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled, open label clinical trial||||
34004015|NCT04544852|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34004016|NCT01995331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004017|NCT01897987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34004018|NCT04405739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004019|NCT01543867|||COHORT||RETROSPECTIVE|||||||
34090591|NCT02797730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090592|NCT06093711|||OTHER||CROSS_SECTIONAL|||||||
34090593|NCT01986998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090594|NCT00486967|||CASE_CONTROL||PROSPECTIVE|||||||
34090595|NCT03407586|NA|SINGLE_GROUP||PREVENTION||NONE|All participants provided written informed consent to join the intervention of diagnostic rather than syndromic management.|Prospective cohort study||||
34090596|NCT05733299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Independent allocation, no masking.|||||
34090597|NCT00986141|||||PROSPECTIVE|||||||
34090598|NCT03956875|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The investigators designed a crossover study, a total of 60 patients divided equally to control group (massage for 6 weeks in home care) and treatment group (Yoga treatment for 12 times/6 weeks).||||
34090599|NCT01027156||||PREVENTION||||||||
34090600|NCT00167271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090601|NCT01928849|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34090602|NCT01531179|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34090603|NCT02876081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090604|NCT06256276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34090605|NCT05076500|||COHORT||PROSPECTIVE|||||||
34090606|NCT02222324|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34090607|NCT06294353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090608|NCT05415878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090609|NCT06327594|||COHORT||CROSS_SECTIONAL|||||||
33786632|NCT05165290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Treatment assignments will be masked to the Sponsor, subjects, Investigators and select investigative staff, until completion of the study and the final database is locked. The appearance of the bottles in the two treatment arms are not identical; however, the cartons and labeling on the cartons in which the bottles are supplied will be identical and identified with unique kit numbers. Therefore, the dedicated dosing coordinator will handle IP-related responsibilities but will be otherwise uninvolved in study assessments.~Appropriate precautions must be taken to prevent unauthorized access to the randomization scheme. Unless the subject's safety requires otherwise and if time permits, the decision to unmask an individual subject's treatment assignment is to be made jointly by the Investigator and Sponsor's medical monitor after consultation with the Sponsor, thus leaving the masking of the remaining subjects intact."||t|f|t|t
33786633|NCT01320371|||COHORT||CROSS_SECTIONAL|||||||
33786634|NCT02272517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786635|NCT00437866|||COHORT||PROSPECTIVE|||||||
34090610|NCT04249778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090611|NCT01223677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090612|NCT01655160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090613|NCT02213536|||CASE_ONLY||PROSPECTIVE|||||||
34090614|NCT02220101|||CASE_ONLY||PROSPECTIVE|||||||
34090615|NCT04490915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090616|NCT00005769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34090617|NCT02546570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090618|NCT04679207|||COHORT||PROSPECTIVE|||||||
33786636|NCT05926271|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot, genotype-guided clinical trial aims to assess the safety and efficacy of clopidogrel monotherapy in Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) patients post-successful percutaneous coronary intervention (PCI). Participants, identified as extensive or ultra-rapid metabolizers by CYP2C19 genotype, will receive clopidogrel monotherapy. The primary outcomes include the ischemic risk (efficacy) and bleeding risk (safety) during the first six months post-PCI. The trial hypothesizes that genotype-guided clopidogrel monotherapy is safe and efficacious in mitigating bleeding and ischemic complications.||||
33786637|NCT05776576|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33786638|NCT05495646|||COHORT||PROSPECTIVE|||||||
33786639|NCT03724513|||COHORT||RETROSPECTIVE|||||||
33786640|NCT04742855|||OTHER||PROSPECTIVE|||||||
33786641|NCT03299387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786642|NCT01600911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786643|NCT06141057|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925060|NCT03751423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|For the three treatment arms, the nurses, the study participants, and the abortion provider will be blinded to study arm assignment and will remain blinded throughout the course of the study. As such, all study personnel who will be administering questionnaires will be appropriately blinded to minimize bias. The provider of the IV medications will not be blinded. This decision was made in order to ensure participant safety in titrating medication doses, and to avoid the need to unblind all members if a reversal agent is required. The provider of the anesthetic will not disclose which study arm the participant belongs to and will not be involved in administering questionnaires or data analysis.|This study will be a randomized, controlled, double-blinded, single-centre superiority trial with three parallel groups.|t|t|f|t
33925061|NCT05906992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925062|NCT00461422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925063|NCT05541523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33925064|NCT01994317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925065|NCT00714298|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925066|NCT04207164|||COHORT||PROSPECTIVE|||||||
33925067|NCT01322451|RANDOMIZED|CROSSOVER||||NONE||||||
33925068|NCT02024841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004020|NCT06112054|NA|SINGLE_GROUP||OTHER||NONE||Single center, single group, non comparative study||||
34004021|NCT00890279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004022|NCT01333917|NA|SINGLE_GROUP||||NONE||||||
34004023|NCT04685850|||COHORT||PROSPECTIVE|||||||
34004024|NCT01857206|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34004025|NCT04692584|RANDOMIZED|PARALLEL||PREVENTION||NONE|The video recordings were evaluated by two academicians in the field of child health and disease nursing, including a researcher and a research assistant with a doctorate in child health and disease nursing who were not blinded to the group assignment. For each assessment, the observers watched the videos of the babies and conducted NIPS assessments during and after the intervention. These observers were blinded to the other's observations and did not discuss the scores.|This was an experimental, randomized controlled study. These babies were randomly assigned to one of two groups, including 30 babies in the lullaby group and 30 babies in the control group. Randomization was performed using a sealed envelope method. The video recordings were evaluated by two academicians in the field of child health and disease nursing, including a researcher and a research assistant with a doctorate in child health and disease nursing who were not blinded to the group assignment. These observers were blinded to the other's observations and did not discuss the scores.||||
34004026|NCT04542915|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34004027|NCT05507320|||OTHER||OTHER|||||||
34004028|NCT05507996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004029|NCT04306172|||COHORT||RETROSPECTIVE|||||||
34004030|NCT04393623|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be urn randomized to either an experimental (cognitive reappraisal) or control condition.||||
34004031|NCT01557686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004032|NCT04202458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004033|NCT00860600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004034|NCT01358253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004035|NCT01181531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004036|NCT02853916|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34004037|NCT04429867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004038|NCT00754052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004039|NCT04229914|NA|SEQUENTIAL||OTHER||NONE||||||
34090619|NCT04539704|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Subjects and coinvestigators making measurements are blinded to which devices are the active magnets and which are the sham magnets. Only the PI will have that information.||t|f|t|f
34090620|NCT05555017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090621|NCT00729586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090622|NCT00102921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33699246|NCT06679699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor was blinded to the participants allocation|A randomized controlled trial|f|f|f|t
33699247|NCT00037622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699248|NCT04239053|||OTHER||PROSPECTIVE|||||||
33699249|NCT03504254|||COHORT||PROSPECTIVE|||||||
33720287|NCT05028179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Following the stress echocardiogram examination, participants will follow the care pathway determined by the clinical team managing their care. If the participant is assigned to the study intervention arm the EchoGo report will inform this decision making process.~In order to minimise bias in any outcome assessment clinicians will be asked not to share the details of the EchoGo report received for participants within the intervention arm with the participant or with colleagues who may undertake future investigations eg: angiography.If a clinician subsequently considers there is a clinical need to know the details of the EchoGo report this can be made available at the discretion of the study team."|"A multi-centre, two-arm, randomised controlled trial. Randomised 1:1~* Standard care group (comparator)~* Standard care plus AI platform (EchoGo)"|t|f|f|f
33786644|NCT04295538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786645|NCT03095911|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
33786646|NCT00097253|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33786647|NCT05925712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786648|NCT04372992|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Multicenter controlled trial||||
33786649|NCT04157842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33786650|NCT01724255|||COHORT||PROSPECTIVE|||||||
33786651|NCT05189964|||COHORT||PROSPECTIVE|||||||
33786652|NCT06168123|||COHORT||PROSPECTIVE|||||||
33786653|NCT02197858|||CASE_ONLY||PROSPECTIVE|||||||
33786654|NCT02735187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33786655|NCT05358717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786656|NCT02374333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786657|NCT04517994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33786658|NCT06629974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This unblinded, randomized controlled interventional study with two parallel groups involved parents of children diagnosed with autism. Participants were stratified according to their educational status, and each participant was assigned a number. Participants within each stratum were assigned to either the intervention or control groups using simple randomization with a table of random numbers.The study was completed with a total of 69 participants: 34 in the intervention group and 35 in the control group.||||
33786659|NCT04700007|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786660|NCT06364033|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786661|NCT03481465|||COHORT||CROSS_SECTIONAL|||||||
33786662|NCT06231628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925069|NCT06063512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Blinding of the operator and the patients will not be feasible due to the difference between the used techniques. However, the statistician will be blinded.|"The two parallel groups will receive the maxillary anaesthesia injection by the same operator.~In the pre-operative period, MCDAS(f), a self-report measure of anxiety will be recorded for all the children.~Measuring preoperative dental anxiety (expressed by heart rate) using pulse oximeter~For Group A (sweet orange oil group): Aromatherapy with inhalers will be carried out, The children will be asked to inhale the aroma from the inhaler For Group B (Control Group): No aromatherapy inhalation . Administration of topical anesthesia . Administration of local anesthesia . After LA administration, Wong-Baker pain rating scale (WBS) will be recorded as a self report measure of pain for all the children.~After LA administration, anxiety will be recorded again using MCDAS(f) for all the children.~Measuring postoperative dental anxiety (expressed by heart rate ) using pulse oximeter."|t|f|t|f
33925070|NCT04775888|||COHORT||PROSPECTIVE|||||||
33925071|NCT01163136|||COHORT||PROSPECTIVE|||||||
33925072|NCT06057610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925073|NCT02141113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925074|NCT05897060|NA|SINGLE_GROUP||OTHER||NONE||||||
33925075|NCT01895712|||OTHER||PROSPECTIVE|||||||
33925076|NCT05924516|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be enrolled in two groups: control and experimental. Participants in the control group will continue with standard treatment, meanwhile participants in the experimental group will continue with standard treatment and will be enrolled in the digital intervention for 3 months.||||
33925077|NCT01395641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925078|NCT01566032|||COHORT||PROSPECTIVE|||||||
33925079|NCT03588611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925080|NCT03013257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925081|NCT00211874|RANDOMIZED|PARALLEL||||NONE||||||
33925082|NCT00930709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925083|NCT05569564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090623|NCT03831997|||OTHER||CROSS_SECTIONAL|||||||
34090624|NCT04076683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34090625|NCT02697045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090626|NCT01143012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090627|NCT05246748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34090628|NCT05963659|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34090629|NCT00974454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090630|NCT02842021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103222|NCT03654326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103223|NCT06054802|||COHORT||PROSPECTIVE|||||||
33925084|NCT03029676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participant is not performed about the type of premedication performed||t|f|f|f
34103224|NCT06607913|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel study design features a Cohort Arm who will undergo regular assessments and observations for a minimum of 2 years. Participants who are hospitalized during the course of the study will undergo random assignment to an Exercise Group or a Usual Care group for 16-weeks.||||
33925085|NCT05226351|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|blinding||t|f|t|f
33925086|NCT01716026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925087|NCT03203590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925088|NCT05399108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33925089|NCT00563368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925090|NCT03082417|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic Stepped Wedge Cluster Randomized Trial||||
33925091|NCT02186756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925092|NCT06508437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
33925093|NCT06025617|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Outcome data is blinded to the investigator during data analysis as to intervention vs. comparison arm assignment.||f|f|t|f
33925094|NCT04759313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925095|NCT05172531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925096|NCT05377307|||COHORT||PROSPECTIVE|||||||
33925097|NCT01683084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925098|NCT02755142|RANDOMIZED|PARALLEL||||DOUBLE||||||
33925099|NCT04454580|||CASE_ONLY||RETROSPECTIVE|||||||
33925100|NCT00925145|||COHORT||PROSPECTIVE|||||||
33925101|NCT06017778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33925102|NCT01162304|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925103|NCT02126670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33925104|NCT04664140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The core-laboratory will be blinded to patients randomization during the adjudication of the endpoint|Randomized clinical trial|f|f|f|t
33925105|NCT05215119|||CASE_CONTROL||PROSPECTIVE|||||||
33925106|NCT01266408|||COHORT||PROSPECTIVE|||||||
33925107|NCT02399904|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33925108|NCT03734562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ICD therapy analysis and outcome adjudication is performed by physicians blinded to the study group.||f|f|f|t
33925109|NCT01148693|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925110|NCT02661464|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33925111|NCT01509534|||COHORT||PROSPECTIVE|||||||
33925112|NCT01110226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925113|NCT00885885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925114|NCT04539925|||COHORT||CROSS_SECTIONAL|||||||
33925115|NCT05106335|RANDOMIZED|PARALLEL||TREATMENT||NONE||Camrelizumab Combined with Famitinib Malate Versus Docetaxel||||
33925116|NCT00045630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925117|NCT06528808|RANDOMIZED|PARALLEL||OTHER||SINGLE||Quasi-experimental randomized controlled trial|t|f|f|f
34004040|NCT05940259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004041|NCT06276296|||CASE_CONTROL||PROSPECTIVE|||||||
34004042|NCT04413968|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cross-sectional, multi-center, non-randomized study||||
34004043|NCT04810533|NA|SINGLE_GROUP||OTHER||NONE||||||
34004044|NCT06679764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34004045|NCT00037752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004046|NCT00959439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004047|NCT00599105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004048|NCT01642563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34004049|NCT05830682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The observer and data analysed was completed by independent researchers||f|f|t|t
34004050|NCT01321437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925118|NCT02023112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925119|NCT04306978|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925120|NCT01637818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925121|NCT02867163|||CASE_ONLY||PROSPECTIVE|||||||
33925122|NCT04570514|||CASE_CONTROL||PROSPECTIVE|||||||
33925123|NCT00167362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925124|NCT00154219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925125|NCT05678478|||COHORT||PROSPECTIVE|||||||
33925126|NCT06060249|||COHORT||PROSPECTIVE|||||||
33925127|NCT02923908|||COHORT||PROSPECTIVE|||||||
33925128|NCT03048942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004051|NCT00889252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004052|NCT03717584|||COHORT||PROSPECTIVE|||||||
34004053|NCT04232527|||COHORT||PROSPECTIVE|||||||
34004054|NCT05425368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Two blinded (patient, radiographic assessor of results)||t|f|f|t
34004055|NCT06359340|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34004056|NCT05629923|||COHORT||PROSPECTIVE|||||||
34004057|NCT00153205|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34004058|NCT02169791|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33720288|NCT02160158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33720289|NCT04954547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33720290|NCT01399138|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33720291|NCT06226766|NA|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
33720292|NCT06369194|||OTHER||RETROSPECTIVE|||||||
33720293|NCT03312933|||COHORT||PROSPECTIVE|||||||
33720294|NCT05160831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720295|NCT06297733|||COHORT||CROSS_SECTIONAL|||||||
33925129|NCT03895970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients were confirmed with advanced hepatobiliary malignancies by imaging and histological examination and meet with the inclusive criteria, including hepatocellular carcinoma, cholangiocarcinoma, ampullary carcinoma, gallbladder carcinoma, and mixed cancer)||||
33925130|NCT01991704|||CASE_ONLY||PROSPECTIVE|||||||
33925131|NCT00105755|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33925132|NCT04213937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925133|NCT00390494|||||PROSPECTIVE|||||||
33925134|NCT01619475|||COHORT||CROSS_SECTIONAL|||||||
33925135|NCT03261063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925136|NCT05616169|||COHORT||RETROSPECTIVE|||||||
33925137|NCT03246555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|t|t|f
33925138|NCT05766293|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||PCS-201-018 Fibroblast cell line (n=10) would be exposed to shockwave generator depending on Test group. Control group Fibroblast cell line (n=10) would be assessed without shockwave exposure. Cell proliferation and Cell viability will be assessed for both Test and Control Fibroblast cell lines using Scratch assay, MTT analysis and ATP analysis, accordingly.||||
33925139|NCT04977973|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33925140|NCT02238288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925141|NCT03869671|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925142|NCT00374270|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33925143|NCT02564029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33925144|NCT01618526|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33925145|NCT04911829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33925146|NCT02899741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925147|NCT06219668|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double blind|Prospective randomized controlled trial|t|t|f|t
33925148|NCT04991064|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33925149|NCT01090869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925150|NCT06202339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925151|NCT05134636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925152|NCT02082795|||COHORT||PROSPECTIVE|||||||
33925153|NCT02626364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925154|NCT05425095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925155|NCT00779311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925156|NCT03886922|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, double-blind, cross-over, placebo-controlled design in healthy volunteers.|t|t|t|t
34004059|NCT02939261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34004060|NCT02798328|||CASE_ONLY||PROSPECTIVE|||||||
34004061|NCT01347320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004062|NCT00040690||||TREATMENT||NONE||||||
34004063|NCT04674150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34004064|NCT04522505|||CASE_ONLY||PROSPECTIVE|||||||
33720296|NCT03358901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720297|NCT00759863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720298|NCT02987400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004065|NCT03509285|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind||t|f|t|f
34004066|NCT01658995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004067|NCT02418624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699250|NCT05570383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Because this test method is not consistent, so this topic will be using single blind method (blind) for the patients, but we will strictly implement spirit blinded phase separation principle, made random don't participate in the experiment, a researcher at the table, will conform to the criteria for the diagnosis of allergic rhinitis patients, according to the medical order, to give corresponding treatment, in the process of experiment, Research implementers do not participate in the statistics of experimental data; The efficacy evaluation index will be evaluated by a third party, blinded to the statistical analysis of the data, and the blind bottom was known only to the study designer and kept by a special person.|We will be collected 60 subjects and randomize them into two groups, the trial group and control group. The QC will use a computerized randomization method using EXCEL software to generate random numbers using a RAND function (a total of 60 random numbers). Sixty randomly selected subjects will have a 1 / 2 chance of being randomly assigned to either the experimental or control groups. Patients were randomly assigned to appropriate groups and treatment regimens based on a random number of visits.|t|f|t|t
34004068|NCT06678841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Primary and secondary endpoints are measured until 6 months post implant. At the 6-month visit, control group subjects will be crossed over and programmed to their personalized elevated pacing rate receiving treatment group therapy for the remainder of follow-up until the subject is exited.|t|t|f|f
33699251|NCT03868306|||COHORT||CROSS_SECTIONAL|||||||
34090631|NCT04857710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluating and comparing the force gains induced by 2 NMES training programs (CONV, WP) applied on knee extensors in healthy subjects for 6 weeks. Understanding the neuromuscular adaptations involved in these gains, as well as the functional benefit resulting from these improvements. To consolidate the benefit of NMES programs, a control (CONT) modality is used as a reference and is representative of a sedentary behaviour regularly observed in our populations. The CONV modality allows us to compare with the current clinical application and the majority of the literature on the adaptations induced by NMES training. Finally, the WP modality aims to assess the possible benefits linked to the use of wide-pulses during the application of NMES.||||
34090632|NCT01094093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699252|NCT04954287|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Progression will be by dose escalation (low dose to high dose) in healthy adults aged 18 to 55 years (N=up to 60), with approximately 12 months' follow-up. Safety data from sentinel subjects (4) will be assessed by a safety monitoring committee (SMC) if halting rules are met for 1) vaccine administration to the remaining subjects within the group, 2) progression from the low dose (1 x 106 PFU) group to the high dose (1 x 107 PFU) groups (without or with prior receipt of COVID vaccine), and 3) progression from the high dose adult group (18 to 55 years) with prior receipt of COVID vaccine to the adolescent (12-17 years) group (N= up to 20) with prior receipt of COVID-19 vaccine.||||
33699253|NCT01365247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699254|NCT01167842|||COHORT||RETROSPECTIVE|||||||
33699255|NCT01955564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699256|NCT00993681|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34090633|NCT01046942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699257|NCT05212519|||COHORT||PROSPECTIVE|||||||
33699258|NCT00747812|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33699259|NCT05089955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699260|NCT06681805|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33699261|NCT06402630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004069|NCT00497679|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004070|NCT01873339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004071|NCT02178969|||COHORT||PROSPECTIVE|||||||
34090634|NCT02036918|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33720299|NCT02394847|NA|SINGLE_GROUP||SCREENING||NONE||||||
34090635|NCT03417414|||COHORT||PROSPECTIVE|||||||
33720300|NCT03353545|||COHORT||OTHER|||||||
34090636|NCT05508802|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34090637|NCT01024595|||||PROSPECTIVE|||||||
33786663|NCT04131829|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||80 OCD patients and 40 healthy participants matched on demographics will be recruited and asked to complete Structural (sMRI) and Functional (fMRI) Magnetic Resonance Imaging. Patients with OCD will be randomized to immediate monotherapy or 6-week placebo-delayed monotherapy, with fluoxetine.|f|f|t|t
33786664|NCT02888613|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34004072|NCT06228248|||COHORT||PROSPECTIVE|||||||
34004073|NCT04187703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090638|NCT01571349|||CASE_ONLY||PROSPECTIVE|||||||
33720301|NCT02389088|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720302|NCT03848273|||COHORT||RETROSPECTIVE|||||||
34004074|NCT00843089|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004075|NCT01978691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34004076|NCT06400238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004077|NCT02881801|||COHORT||PROSPECTIVE|||||||
33720303|NCT01759030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720304|NCT06154954|||OTHER||CROSS_SECTIONAL|||||||
33786665|NCT03288220|||COHORT||PROSPECTIVE|||||||
33786666|NCT04582682|||COHORT||PROSPECTIVE|||||||
33786667|NCT03645356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786668|NCT02549443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33786669|NCT06127563|||COHORT||PROSPECTIVE|||||||
33786670|NCT04678934|||COHORT||PROSPECTIVE|||||||
34004078|NCT03209167|||CASE_CONTROL||RETROSPECTIVE|||||||
33786671|NCT06713135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786672|NCT06575959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786673|NCT06630741|||COHORT||PROSPECTIVE|||||||
33786674|NCT02755363|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33786675|NCT05717985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004079|NCT05995990|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34004080|NCT00345033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004081|NCT05542849|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004082|NCT05874648|||CASE_CONTROL||PROSPECTIVE|||||||
34004083|NCT05203146|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blinding to the outcomes will be maintained during recruitment to minimize preparation bias. Allocation concealment will be ensured with an allocation software (www.sealedenvelope.com) and will not be released until the participants start the scenario. A post-scenario review will be done without blinding by two study investigators, but undertaken independently with each blinded to the other's reviews. In the case of disagreement, a third independent evaluator will help reach a consensus. The data analyst will not be blinded to group allocation.|A prospective, single center, randomized, controlled trial|t|f|f|f
34004084|NCT01647360|||CASE_ONLY||PROSPECTIVE|||||||
34004085|NCT01630616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004086|NCT02224053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004087|NCT04133675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed using a table of random numbers. A unblinded RNC will be responsible for maintaining the enrollment and randomization log. Randomization envelopes will be provided by the study's biostatistician and will be securely stored in a locked cabinet. The study coordinator(s) will solely be responsible for opening the randomization envelopes and delivering the study treatments, according to group assignment. Ultimately, they will be responsible for maintaining the confidentiality and security of the randomization envelopes. After randomization, the study coordinator(s) will complete the Subject Enrollment and Randomization Log. The log may be stored in a locked cabinet with the randomization envelopes. At study completion the log will be stored in the regulatory binder.|Subjects will be randomized 1:1 to receive active Emsella chair treatments or sham treatments. Study will be performed in a single-blind manner.(Participant and biostatistician)|t|f|f|t
34004088|NCT04949386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004089|NCT01186016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004090|NCT06015672|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The TMS intensity and cortical location delivered at each TMS visit will be masked|Single-arm crossover study design with subjects receiving TMS at two different intensities and two cortical locations|t|f|f|t
34004091|NCT02522780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090639|NCT05045183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699262|NCT03333304|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized at 1:1 ratio by a separate list per study site into two treatment groups. The two groups of treatment will be as follows:~* Standard of care: these patients will receive antimicrobials according to standard practice of the attending physicians but PCT will not be measured and antimicrobials will be stopped according to the local standard practice.~* PCT group: these patients will receive antimicrobials according to standard practice of the attending physicians and antimicrobials will be discontinued according to PCT kinetics."||||
33699263|NCT04314154|||COHORT||PROSPECTIVE|||||||
33699264|NCT03023787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699265|NCT04873700|||COHORT||RETROSPECTIVE|||||||
33699266|NCT00002651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699267|NCT02037958|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33699268|NCT05613400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The computer-generated sequence will be supplied by the study statistician, independent of the investigators. To facilitate double-blinding, placebo tablets with the same shapes as simvastatin 10mg and ezetimibe 10mg, respectively.|Eligible participants will be randomly allocated 1:1 to 18 months of simvastatin 10mg/day or ezetimibe 10mg/day.|t|f|t|f
33699269|NCT01470937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699270|NCT05844410|||CASE_ONLY||RETROSPECTIVE|||||||
33699271|NCT06188533|||COHORT||CROSS_SECTIONAL|||||||
33786676|NCT05419557|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||concurrent groups||||
33786677|NCT00782041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786678|NCT04388488|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical investigation will be of a single group non-randomized open label prospective repeated measures (ABBA) design.||||
33786679|NCT00291707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786680|NCT03712293|NA|SINGLE_GROUP||TREATMENT||NONE||This study will enroll up to 10 patients who are eligible and recommended for the standard adjuvant phase of TMZ chemotherapy. The goal is for all subjects to undergo ExAblate Type 2.0 BBB disruption procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).||||
34004092|NCT03354208|||COHORT||PROSPECTIVE|||||||
34004093|NCT01370239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004094|NCT01671592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004095|NCT03788356|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34090640|NCT05177744|||CASE_CONTROL||PROSPECTIVE|||||||
34090641|NCT03997136|||COHORT||PROSPECTIVE|||||||
34090642|NCT01346150|||COHORT||RETROSPECTIVE|||||||
34090643|NCT04976257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090644|NCT02317549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090645|NCT02378181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090646|NCT03139201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34090647|NCT02202616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090648|NCT06049342|NA|SEQUENTIAL||TREATMENT||NONE||||||
34090649|NCT01405859|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33699272|NCT06112132|||CASE_ONLY||PROSPECTIVE|||||||
33699273|NCT05734300|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699274|NCT01400165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34090650|NCT06327061|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Both groups receive overdose prevention training|a standard two-group clinical trial, one group is the experimental, the other the control|t|f|f|f
34090651|NCT04124965|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090652|NCT05417113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699275|NCT05317624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups will be included|t|f|f|f
33699276|NCT06285331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33699277|NCT03005418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699278|NCT00913380|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33699279|NCT05668975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699280|NCT00920634|||OTHER||PROSPECTIVE|||||||
33699281|NCT01944033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699282|NCT00003821||||TREATMENT||||||||
34004096|NCT05389280|||COHORT||PROSPECTIVE|||||||
34004097|NCT03180255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor, investigator, subject will all be masked to study treatment assignment.|Double-masked, randomized, placebo-controlled, multi-center, Phase 2b clinical trial designed to evaluate the efficacy and safety of transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL.|t|t|t|t
34004098|NCT04161573|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34090653|NCT01063634|||||PROSPECTIVE|||||||
34004099|NCT05475431|||COHORT||RETROSPECTIVE|||||||
33699283|NCT03860597|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33699284|NCT01782547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699285|NCT04049643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699286|NCT02212470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized, single-center, single-blind, non-inferiority, clinical trial|t|f|f|t
33699287|NCT04703387|||COHORT||PROSPECTIVE|||||||
33699288|NCT04622293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded||t|t|t|f
33786681|NCT02751099|||COHORT||PROSPECTIVE|||||||
34004100|NCT05484609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||1:1 allocation||||
34004101|NCT06679179|||OTHER||PROSPECTIVE|||||||
34004102|NCT00176358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004103|NCT05716269|||COHORT||PROSPECTIVE|||||||
34004104|NCT00133679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004105|NCT04560517|||CASE_CONTROL||PROSPECTIVE|||||||
33699289|NCT02503410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor is blinded to treatment assignment.||f|f|f|t
33699290|NCT00239304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699291|NCT03642119|||COHORT||CROSS_SECTIONAL|||||||
33925157|NCT05959304|||CASE_ONLY||PROSPECTIVE|||||||
33699292|NCT04361825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925158|NCT00004685|RANDOMIZED|||TREATMENT||DOUBLE||||||
34004106|NCT00899535|||COHORT||PROSPECTIVE|||||||
34004107|NCT00804245|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004108|NCT02682108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004109|NCT05652309|||COHORT||PROSPECTIVE|||||||
34004110|NCT04334096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004111|NCT04720287|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34004112|NCT04196348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004113|NCT00347906|RANDOMIZED|PARALLEL||||NONE||||||
34004114|NCT01959802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004115|NCT02136836|||CASE_ONLY||RETROSPECTIVE|||||||
34004116|NCT01264835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699293|NCT04864301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699294|NCT02083081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720305|NCT01761656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720306|NCT03129958|||CASE_ONLY||CROSS_SECTIONAL|||||||
33720307|NCT04460547|||COHORT||RETROSPECTIVE|||||||
33720308|NCT01471106|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720309|NCT00677157|||OTHER||PROSPECTIVE|||||||
33720310|NCT01271660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33720311|NCT00503087|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||||||
33720312|NCT05003453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925159|NCT05500183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33925160|NCT00360048|||||PROSPECTIVE|||||||
33925161|NCT05656287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized using the 1:1:1 allocation ratio to the following arms: 1) SMS + incentives (Arm A) 2) SMS only (Arm B), and 3) no SMS (control). All participants will have adherence monitored in real-time for 6 months.||||
33925162|NCT03488238|NA|SINGLE_GROUP||OTHER||NONE||||||
33925163|NCT05226897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|a Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel group|t|t|t|t
33925164|NCT02483455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925165|NCT00422903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925166|NCT03983213|||CASE_CONTROL||PROSPECTIVE|||||||
33925167|NCT03326869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking.|The study will be a prospective, multicenter, open label clinical trial where a maximum of 30 non-dominant eyes are implanted with the Raindrop Near Vision Inlay. Each surgical site will be responsible for assigning patients to either the delayed or the non-delayed groupings.||||
33925168|NCT00209326|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925169|NCT03202745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925170|NCT05014399|||COHORT||PROSPECTIVE|||||||
33925171|NCT00860990|||||PROSPECTIVE|||||||
33925172|NCT06387030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925173|NCT04896190|NA|SINGLE_GROUP||OTHER||NONE||||||
33925174|NCT06024694|||OTHER||RETROSPECTIVE|||||||
33925175|NCT00605072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925176|NCT02629328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925177|NCT01594567|||||PROSPECTIVE|||||||
33925178|NCT01618422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925179|NCT02573337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004117|NCT03930069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004118|NCT05072821|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34004119|NCT04535193|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Study Cohort I will evaluate the myocardial update of 18F-mFBG (as a marker of sympathetic innervation) in control subject with a low likelihood of coronary heart disease.~Study Cohort II will evaluate the myocardial update of 18F-mFBG (as a marker of sympathetic innervation) in stable patients with heart failure and reduced left ventricular function"||||
34004120|NCT04950894|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|PSG results are masked from the Investigator and Outcomes Assessor.|All subjects are implanted and randomized. Stimulation treatment started at M1 for the Active group and M7 +1day for the Control group. Both groups followed through M13.|f|f|t|t
34004121|NCT00636324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090654|NCT06090240|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34090655|NCT05208320|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090656|NCT02075957|||COHORT||PROSPECTIVE|||||||
34090657|NCT01136915|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34090658|NCT04572815|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34090659|NCT05407896|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Pre-post study design|t|f|f|f
34090660|NCT03967873|||COHORT||PROSPECTIVE|||||||
33699295|NCT05169190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All assessments will be conducted by the Site Coordinator (SC) and clinical assessors at each time point blind to group allocation. The SGB assessor will conduct the Horner's syndrome evaluation after the procedure and will only share the results with data entry personnel. The primary data base in REDCap will show SID# only to keep the SC blinded while entering data. The minim program will assign each subject a Treatment ID number by site (e.g., TID# LB1S to LB20S for SGB at Long Beach site) and consecutive study ID numbers (e.g., SID# LB1 - LB90), which will be the only number on hard copies of documents in order to conceal allocation from all staff. The statisticians will be the only staff that will be able to link both SID and TID numbers to subject. The research pharmacy preparing the syringes will of course have both ID numbers and will label the syringes with only the SID#, keeping all personnel blinded.|This is a two-phase, three-arm (SGB vs Sham vs Wait List Control (WLC)), parallel-group (n=120 in each), triple-blind, prospective randomized controlled clinical trial (RCT). Phase I is 12-weeks and is the primary three-group RCT. Phase II is a 12-week open-label extension period where subjects in all groups are offered active SGB if eligible, defined as having PTSD scores \> study inclusion criteria scores at the Phase I endpoints.|t|t|t|t
33699296|NCT02068027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699297|NCT00237172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699298|NCT06319261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699299|NCT03873610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33699300|NCT05693116|||COHORT||OTHER|||||||
33699301|NCT05824091|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33699302|NCT03878238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925180|NCT06291467|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33925181|NCT05953207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925182|NCT06426498|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The device will be on either right or left V1, and the ultrasound will be cycling on or off during the session. Subjects and investigators will be masked to on/off timing and puck location.|||||
33925183|NCT01664819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33925184|NCT00810810|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Clinical teams caring for patients were not masked. Laboratory personnel were masked until all testing completed.|Individuals who consented for study were scheduled for cardiac surgery. They were randomized to one of three arms to receive blood components prepared by different, but clinically acceptable processes. If they required transfusion from 2 days prior to surgery until 30 days post surgery they received study product. Blood samples were collected prior to surgery and at two points after surgery.|f|f|t|t
33925185|NCT00184158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925186|NCT01565434||||SCREENING||||||||
33925187|NCT03263741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925188|NCT00055575|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33925189|NCT02722629|NA|SINGLE_GROUP||SCREENING||NONE||||||
33925190|NCT00747539|||CASE_CONTROL||PROSPECTIVE|||||||
33925191|NCT05964504|||COHORT||PROSPECTIVE|||||||
33925192|NCT05032417|RANDOMIZED|PARALLEL||TREATMENT||NONE||The AUGmeNt study is a hybrid effectiveness-implementation study, in that there are a priori plans to test an EBNPG implementation strategy and examine the clinical effectiveness of care congruent with EBNPG.||||
33925193|NCT02757092|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|After participants signed the consent form, they were randomly included into the control or experimental group on the day of discharge|This study employed a prospective, randomized, and controlled clinical design to determine the efficacy of home-based pulmonary rehabilitation in patients after thoracoscopy. After participants signed the consent form, they were randomly included into the control or experimental group on the day of discharge. The random assignment was performed based on simple randomization by using numbers from 1 to 36; numbered, sealed, opaque envelopes were used for allocation concealment. These envelopes were randomly distributed by non researchers and recorded.|t|f|f|f
33925194|NCT02031588|||COHORT||PROSPECTIVE|||||||
33925195|NCT04606641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925196|NCT03111342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The care provider will open the randomization envelope and will do one of three possible approaches (a intracervical lidocaine injection, a intracervical dry needling or no intervention). Then, a second care provider will insert the intrauterine contraceptive (IUC) blinding for the approach of the first care provider. After IUC insertion, the latter care provider will assess the pain felt by the woman using proper scales. The woman will be also blinded to the approach used before IUC insertion.|Nulligravida women will be block-randomized to one of three groups (intracervical anesthesia, intracervical dry needling or no intervention)|t|t|t|t
33925197|NCT02474914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33925198|NCT05966246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925199|NCT05563051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925200|NCT05322915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925201|NCT04629638|||CASE_CONTROL||PROSPECTIVE|||||||
33925202|NCT02358564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925203|NCT01804114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925204|NCT00870038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33925205|NCT01027104||PARALLEL||||NONE||||||
33925206|NCT02045251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925207|NCT04322162|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925208|NCT05242978|RANDOMIZED|CROSSOVER||PREVENTION||NONE||acute consumption of anti- and pro- inflammatory foods and beverages 2 hour prior to intense physical activity||||
33925209|NCT03217201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant does not know his or her study condition.|Stratified by adjuvant and neoadjuvant chemotherapy treatments, then randomly assigned to one of two light treatment conditions.|t|f|f|f
33786682|NCT03489265|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Patients will not be aware when Eluxadoline or Placebo are administered. Investigators will be masked to whether Eluxadoline is given in Treatment Period 1 or Treatment Period 2 unless there is an adverse event that requires unmasking the treatment for this patient to ascertain whether the adverse event is drug-related.|Patients will be randomized to 1 of 2 sequences. Each sequence includes 4 periods: Run-in, Treatment Period 1, Treatment Period 2, and Follow-Up. In Sequence A, Eluxadoline will be given 100 mg BID in Treatment Period 1 and Placebo will be given in Treatment Period 2. In Sequence B, Placebo will be given in Treatment Period 1 and Eluxadoline will be given in Treatment Period 2. Placebo will be given during Baseline and Follow-Up of both arms.|t|t|t|f
33699303|NCT04639531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Separate Certified Orientation \& Mobility Specialists (COMS) conduct training and outcome evaluation|randomized, controlled training trial with experimental, active control and placebo groups|f|f|f|t
33699304|NCT00304239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
33699305|NCT06132841|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33699306|NCT06525012|||COHORT||RETROSPECTIVE|||||||
33699307|NCT00416546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33786683|NCT01271270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786684|NCT05933720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open, prospective study is aimed at enrolling 120 patients with lower extremity atherosclerotic arterial occlusive disease. Patients are planned to undergo conservative therapy according to indications, including the use of a drug based on vascular polypeptides Slavinorm®, as well as a combination of conservative therapy, including a drug based on vascular polypeptides Slavinorm®, with surgical methods of treatment (femoral-popliteal bypass grafting with a synthetic graft above the knee). Subjects of similar age, gender, and ethnicity should be divided into four groups, respectively.||||
33699308|NCT05693883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786685|NCT04301674|||CASE_CONTROL||PROSPECTIVE|||||||
33925210|NCT05453006|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Hybrid Type 2 effectiveness-implementation study; difference-in-difference methods to compare between-period changes in 3 intervention and Fairview non-intervention clinics.||||
33925211|NCT05633680|||CASE_CONTROL||PROSPECTIVE|||||||
33925212|NCT02765698|||COHORT||PROSPECTIVE|||||||
33925213|NCT05484427|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Randomised prospective single-center trial||||
33699309|NCT01219673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699310|NCT06059573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33699311|NCT01604187|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33699312|NCT04342273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699313|NCT00871325|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33699314|NCT04099407|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a real-life, multicenter, open-label, proof of concept trial to determine the safety and efficacy of 12 months of treatment with PR-PFD in combination with standard of care treatment||||
33699315|NCT04200573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699316|NCT01716390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699317|NCT00970073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699318|NCT02624674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699319|NCT02359422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699320|NCT06000397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699321|NCT00003831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699322|NCT00422097|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699323|NCT00290277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33699324|NCT00669396|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786686|NCT01119703|||COHORT||PROSPECTIVE|||||||
33786687|NCT04675463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786688|NCT02492464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925214|NCT03926338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925215|NCT04355026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925216|NCT05455736|||COHORT||PROSPECTIVE|||||||
33925217|NCT05371938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004122|NCT00110734|RANDOMIZED|||TREATMENT||DOUBLE||||||
34004123|NCT05822674|||COHORT||CROSS_SECTIONAL|||||||
33925218|NCT05369546|||CASE_ONLY||CROSS_SECTIONAL|||||||
33925219|NCT05186012|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33925220|NCT03824535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925221|NCT01400074|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004124|NCT00526162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090661|NCT01695746|||COHORT||PROSPECTIVE|||||||
33925222|NCT01924962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090662|NCT02827968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090663|NCT04100057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699325|NCT03436004|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Concealed assignation|Randomized Multicenter prospective trial with medical device||||
33699326|NCT02239588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33925223|NCT04114344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090664|NCT01708603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090665|NCT01014091|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34090666|NCT02232230|||COHORT||RETROSPECTIVE|||||||
33699327|NCT05427006|||COHORT||OTHER|||||||
33699328|NCT01148888|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699329|NCT00810355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699330|NCT04263376|||COHORT||PROSPECTIVE|||||||
33699331|NCT02973828|||CASE_ONLY||PROSPECTIVE|||||||
33699332|NCT02387931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699333|NCT04275570|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient (participant) will not know the arm of randomization|Cluster randomized simple masking controlled trial|t|f|f|f
33699334|NCT00967629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34090667|NCT01474187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090668|NCT03882099|||CASE_CONTROL||PROSPECTIVE|||||||
34004125|NCT05999240|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Information regarding Masking will be communicated to the investigational pharmacy only - all other staff will remain blind to group assignment throughout the study.|This study plans to enroll 30 participants between the ages of 16-40 years old with a diagnosis of autism spectrum disorder to participate in a randomized, placebo-controlled, cross-over designed study. Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo (Visit 2) three hours before beginning a cognitive neuroscience battery. One week later (Visit 3), participants will take the other medication (placebo or pimavanserin 34 mg) three hours before beginning the cognitive neuroscience battery. After completing the second experimental day, participants will immediately enter the Open Label Trial, where they will take pimavanserin 34 mg for six weeks total, with study visits at 3 weeks (Visit 4) and 6 weeks (Visit 5) to complete safety and primary/secondary outcome measures, followed by a follow-up phone call within 30 days after completing the open label trial.|t|t|t|f
33699335|NCT03702517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33699336|NCT03292575|||COHORT||PROSPECTIVE|||||||
33699337|NCT05578079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33699338|NCT02960152|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33699339|NCT01166399|||COHORT||PROSPECTIVE|||||||
33699340|NCT05788120|||COHORT||PROSPECTIVE|||||||
33699341|NCT01146912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33699342|NCT04168697|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|no masking|Patient group vs a control group||||
34004126|NCT00214812|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34004127|NCT00162682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004128|NCT03467282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004129|NCT00264381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004130|NCT04869137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004131|NCT01830309|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33699343|NCT05376449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699344|NCT05271461|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|circulatory exercise only, circulatory exercises and LLLT.|Two groups of 30 patients, 1st circulatory exercise, 2nd LLLT and circulatory exercises.|f|t|f|f
33699345|NCT01245920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699346|NCT00122109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699347|NCT02007616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33925224|NCT01917708|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33925225|NCT01807767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925226|NCT06185608|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Staff performing perineural blocks will not be blinded to the concentration of ropivacaine used. Surgeons, patients, and research personnel collecting postoperative data will be blinded to group allocation.||t|f|f|t
34004132|NCT04946786|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33699348|NCT01089673|||CASE_ONLY||RETROSPECTIVE|||||||
33699349|NCT05501223|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699350|NCT00487487|||||OTHER|||||||
33699351|NCT06378138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699352|NCT04862377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"When eligibility of an infant is confirmed, consent will be obtained. Infants candidates to surfactant administration will be randomly assigned to either receive surfactant with budesonide, or surfactant alone, using a web-based randomisation system with an allocation ratio of 1:1.~Primary care provider in charge of the patient at the time of the enrolment will be responsible for the randomization, and for the preparation of the drug (surfactant alone, or surfactant with budesonide).~Participants will be masked."|"This is a randomised trial. Infants who fit criteria for surfactante administration will be randomly assigned into 2 groups: Standard treatment group receiving only intratracheal surfactant, and Interventional treatment group receiving intratracheal surfactant combined with budesoinde.~It will be a third group of patients ≤32 weeks (Control group) who won´t fit criteria for surfactant administration."|t|f|f|f
33699353|NCT02436681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699354|NCT05857943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699355|NCT04110678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be performed by the promoter institution Centro Inmunologia Molecular from Spanish CIM who assigned the selected patients to two groups neuroEPO and placebo giving a code. The specialists at CIREN didn't have access to the information. Both groups received a vial of the molecule with identical organoleptic characteristics.|Randomized, blinded, Physician lead trial|t|t|t|f
33699356|NCT01570556|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33699357|NCT05158634|||COHORT||PROSPECTIVE|||||||
33699358|NCT01293773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699359|NCT04996771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699360|NCT03570697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study. Treatment assignment will be blinded to all subjects, site personnel, and Amgen||t|t|t|f
33925227|NCT02361619|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33925228|NCT02567357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925229|NCT05376527|NA|SINGLE_GROUP||TREATMENT||NONE||Open Multi-cohort Study of Safety and Tolerability||||
33699361|NCT00111488|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33699362|NCT02589405|NA|SINGLE_GROUP||OTHER||NONE||||||
33699363|NCT01076920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925230|NCT03870009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925231|NCT04612803|||CASE_ONLY||PROSPECTIVE|||||||
33925232|NCT01999907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925233|NCT01009918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33925234|NCT02427100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925235|NCT02654470|||COHORT||PROSPECTIVE|||||||
33925236|NCT01040845|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33925237|NCT04630964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925238|NCT03287869||PARALLEL||TREATMENT||NONE||Group composed of eligible rollover participants who completed one of the double-blind, phase 3 efficacy trials (331-201-00080 (NCT03259555) or 331-201-00081 (NCT03257865)).||||
34090669|NCT04525820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinding is performed by the hospital pharmacy of the university hospital of Basel. They will provide us with packed and labeled study medication and placebo. They will provide us with medication packages for each patient which includes either high dose vitamin D and the standard medication or the placebo and the standard medication.|one group receives a single high dose of vitamin D in addition to treatment as usual (TAU) the other group receives a single dose of placebo in addition to TAU|t|t|t|t
34090670|NCT02787291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090671|NCT03205631|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34090672|NCT03547570|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention group only.||||
34090673|NCT02226900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090674|NCT03027934|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34090675|NCT05672056|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study.||||
34090676|NCT05393219|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Performance is evaluated by assessors who are blind to the intervention|4 parallels groups|f|f|t|t
34090677|NCT01816269|||COHORT||RETROSPECTIVE|||||||
34090678|NCT00368550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090679|NCT04795349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699364|NCT05688449|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33699365|NCT03285984|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The randomization schedule will indicate the treatment order sequence. Each subject will complete all four treatment regimens, one treatment regimen in each of the four treatment periods. This randomization will use a Williams Square layout and be provided by the Biostatistics Department, GSKCH.|f|f|t|t
33699366|NCT04685083|||CASE_CONTROL||PROSPECTIVE|||||||
33699367|NCT02269397|||COHORT||PROSPECTIVE|||||||
33699368|NCT01377571|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33699369|NCT06680544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699370|NCT00014482|RANDOMIZED|||||||||||
33699371|NCT04940767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study evaluators will be blinded to patient treatment group allocation.||f|f|t|f
33699372|NCT05838859|||OTHER||CROSS_SECTIONAL|||||||
33699373|NCT05792787|||CASE_CONTROL||OTHER|||||||
33699374|NCT02486302|||COHORT||PROSPECTIVE|||||||
33699375|NCT05745012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|operating gastroenterologist will be unblind while evaluating gastroenterologist will be blind||t|f|t|t
33699376|NCT04256226|||COHORT||RETROSPECTIVE|||||||
33699377|NCT03613480|RANDOMIZED|PARALLEL||TREATMENT||NONE||All eligible patients will be randomized to receive either counseling sessions or care as usual||||
33699378|NCT00215748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699379|NCT02653183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699380|NCT00082342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699381|NCT00728650|||||RETROSPECTIVE|||||||
33699382|NCT00170131|||||PROSPECTIVE|||||||
33699383|NCT05346497|||CASE_CONTROL||RETROSPECTIVE|||||||
33699384|NCT00478946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699385|NCT02976792|||COHORT||PROSPECTIVE|||||||
33699386|NCT00437892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925239|NCT06300346|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925240|NCT03115788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||2 groups; control and treated|t|f|t|f
33925241|NCT01522443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925242|NCT04376515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33925243|NCT02077946|||COHORT||RETROSPECTIVE|||||||
33925244|NCT02407314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925245|NCT03990090|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double||t|f|t|f
33925246|NCT03764579|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34090680|NCT02078167|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34090681|NCT03692962|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34090682|NCT02741999|||OTHER||PROSPECTIVE|||||||
34090683|NCT02469909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090684|NCT02588365|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34090685|NCT01115231|||COHORT||PROSPECTIVE|||||||
34090686|NCT02078037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090687|NCT00679198|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34090688|NCT03137004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090689|NCT01809067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699387|NCT03464877|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort study||||
33699388|NCT03212690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699389|NCT05806086|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33699390|NCT00441402|||||PROSPECTIVE|||||||
34090690|NCT03846232|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34090691|NCT05926713|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33699391|NCT04429048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind||t|f|f|f
33699392|NCT04108871|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33786689|NCT01315535|||COHORT||PROSPECTIVE|||||||
33786690|NCT01501214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786691|NCT01300858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786692|NCT02050594|||CASE_ONLY||PROSPECTIVE|||||||
33786693|NCT00364598|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34004133|NCT03066895|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
34004134|NCT03133728|||OTHER||OTHER|||||||
34004135|NCT03113435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34090692|NCT00844519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090693|NCT02996786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090694|NCT06023290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090695|NCT05289882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group.|Using Optimal Design Software, and on the basis of 7 observations per participant (in psychological flourishing), 134 participants are required to detect a medium effect size of δ = .50, with Power (1 - β) set at 80%, and p \<.05 with seven time points (baseline, Months 1, 2, 3, 4, 5, and 6). To account for 9 sites across Canada (necessitating 8 dummy variables) requires an additional 80 participants. To further account for 10% attrition, a minimum of n= 238 veteran participants are needed. The study will look to recruit 252 military veterans for study participation. The study will also look to recruit N = 252 currently serving members of the Canadian Armed Forces, although it should be noted that these participants do not constitute the population of primary interest for the trial. On the basis of N = 252 military veterans and N = 252 currently serving military participants the trial will look to recruit a total of N = 504 participants.|f|f|f|t
34090696|NCT02715557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090697|NCT02076841|||COHORT||PROSPECTIVE|||||||
34090698|NCT01886560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090699|NCT02981589|||COHORT||PROSPECTIVE|||||||
33699393|NCT01100346|||COHORT||PROSPECTIVE|||||||
33699394|NCT00591994|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33699395|NCT03198078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects randomized 1:1:1 to 1 of 3 double-blind treatment arms to evaluate safety \& efficacy|t|t|t|t
34004136|NCT04618419|||CASE_CONTROL||PROSPECTIVE|||||||
34004137|NCT04753853|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional Pilot study||||
34004138|NCT00368082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699396|NCT04964817|||COHORT||PROSPECTIVE|||||||
33699397|NCT06112548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699398|NCT01851811|||||RETROSPECTIVE|||||||
33699399|NCT05356078|||COHORT||RETROSPECTIVE|||||||
33699400|NCT04466176|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33699401|NCT00792415|||COHORT||PROSPECTIVE|||||||
33699402|NCT02103907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699403|NCT04304274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33699404|NCT00142610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699405|NCT04977557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720313|NCT05651633|RANDOMIZED|PARALLEL||TREATMENT||NONE||pragmatic, two arm, individually randomised, open, superiority trial||||
33720314|NCT01918904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720315|NCT01356966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720316|NCT06241079|||COHORT||RETROSPECTIVE|||||||
33720317|NCT01454869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720318|NCT02862613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720319|NCT03727490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720320|NCT00087581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004139|NCT05445570|||CASE_CONTROL||PROSPECTIVE|||||||
34004140|NCT01321177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004141|NCT01053091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004142|NCT04281524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004143|NCT02721368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004144|NCT01673841|||CASE_ONLY||PROSPECTIVE|||||||
34004145|NCT04083391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004146|NCT04012931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004147|NCT01863433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34090700|NCT05104346|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups of patients were created. Patients in group I (G1) had AA prior to the era of COVID, while patients in group II (G2) had AA during COVID|t|f|t|f
33720321|NCT03744923|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33720322|NCT01729507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720323|NCT02158338|||CASE_CONTROL||RETROSPECTIVE|||||||
33720324|NCT00261677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33720325|NCT00166088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720326|NCT05321433|||COHORT||PROSPECTIVE|||||||
33720327|NCT00249444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720328|NCT02889887|||COHORT||PROSPECTIVE|||||||
33720329|NCT06163846|||COHORT||PROSPECTIVE|||||||
33720330|NCT03559465|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720331|NCT04460950|||CASE_ONLY||PROSPECTIVE|||||||
33720332|NCT03193931|RANDOMIZED|PARALLEL||TREATMENT||NONE|opern label|Patients recieve pembrolizumab or methotrexate||||
33720333|NCT01354847|||COHORT||PROSPECTIVE|||||||
33720334|NCT03738891|NA|SINGLE_GROUP||OTHER||NONE||||||
33720335|NCT01631877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720336|NCT01304745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720337|NCT03480659|||CASE_CONTROL||RETROSPECTIVE|||||||
33720338|NCT05025111|||CASE_ONLY||CROSS_SECTIONAL|||||||
33720339|NCT02218710|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925247|NCT00897741|||CASE_ONLY||PROSPECTIVE|||||||
33786694|NCT05245487|||COHORT||PROSPECTIVE|||||||
33925248|NCT04335708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925249|NCT06308146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To minimize bias, the sponsor representatives involved in the study, the investigator, the participants, and any healthcare professionals or site personnel involved in participant management or outcome assessment remained blinded to interventional assignments|Participants will be randomly assigned in a 1:1 ratio to receive either the probiotic or placebo. Study products (i.e., TP and placebo) will be dispensed by the site as per the randomization scheme at the study visits.|t|t|t|t
33925250|NCT02169713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33925251|NCT05251298|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925252|NCT05726448|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be clients at local WIC agency sites where either the telehealth solution is offered or where only usual care is available (control).||||
33925253|NCT05320328|||CASE_CONTROL||PROSPECTIVE|||||||
33925254|NCT02339857|||COHORT||PROSPECTIVE|||||||
33925255|NCT04888364|||COHORT||PROSPECTIVE|||||||
33925256|NCT04273009|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both participants and first investigator will be masked from the actual treatment.|Patients who have completed the treatment can switch to the other treatment offered.|t|f|t|f
33925257|NCT00079820|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33925258|NCT02907671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925259|NCT01878097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925260|NCT00346138|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925261|NCT03107598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33925262|NCT03466307|||CASE_CONTROL||PROSPECTIVE|||||||
33925263|NCT04712487|||COHORT||PROSPECTIVE|||||||
33925264|NCT03248050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33925265|NCT02646150|||COHORT||PROSPECTIVE|||||||
33925266|NCT01047046|||COHORT||RETROSPECTIVE|||||||
33925267|NCT04643795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925268|NCT06096441|||CASE_ONLY||PROSPECTIVE|||||||
33925269|NCT00216268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925270|NCT04291924|||OTHER||PROSPECTIVE|||||||
33925271|NCT01271413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925272|NCT01091051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925273|NCT03487887|||COHORT||PROSPECTIVE|||||||
33925274|NCT01170221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925275|NCT05247541|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study will be performed as a prospective nonblinded pilot study.||||
33925276|NCT03509623|NA|SINGLE_GROUP||SCREENING||NONE||||||
33925277|NCT03729661|NA|SINGLE_GROUP||TREATMENT||NONE||Exploratory study||||
33925278|NCT02178072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925279|NCT04900207|||COHORT||PROSPECTIVE|||||||
33925280|NCT01782924|RANDOMIZED|PARALLEL||TREATMENT||||||||
33925281|NCT05816291|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The same number of capsules will be provided to each participant. Each capsule will be identical in color, shape, smell, and transparency. Participants will be instructed to consume their assigned dose with 8 - 12 fluid ounces of cool water.|Subjects will be assigned to ingest one of two supplement conditions in a randomized, double-blind, and crossover fashion. A randomized order of treatments will be generated by random.org.|t|f|t|f
33925282|NCT00443937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004148|NCT03195452|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34004149|NCT05647291|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34004150|NCT03114358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34090701|NCT04475510|NA|SINGLE_GROUP||PREVENTION||NONE||At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.||||
34090702|NCT02394275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786695|NCT06628973|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is an intention to treat, multicenter, open-labeled, randomized clinical trial.||||
33786696|NCT05450029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925283|NCT03864536|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A pre-post experimental design will be used, in which 150 AA participants aged 50-65 will complete a baseline assessment of cognitive testing and data-driven assessment of deficiencies across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity). Participants will be randomized to either: psychoeducation + CogRx, psychoeducation only, or no-contact control.|f|f|f|t
33925284|NCT00925691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925285|NCT06413368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925286|NCT05340101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925287|NCT03235726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blind, randomized study and subject and investigator will be blinded.|In this study, subjects will be randomized to receive either study drug or placebo in a parallel manner.|t|f|t|f
33925288|NCT03019705|||CASE_ONLY||PROSPECTIVE|||||||
33925289|NCT03900741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33925290|NCT00091546|||COHORT||RETROSPECTIVE|||||||
34004151|NCT03512249|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The unblinded persons in the study are the study vaccine manager (and designee) who manages the participant inventory log(s) at the trial site, the unblinded site staff, and the unblinded clinical trial site monitor(s) responsible for monitoring the investigational product at the trial site. All unblinded persons must take care to not reveal individual participant treatment assignments to any blinded member of the study team. There is an unblinded contact person at the sponsor's site in order to manage queries from the unblinded site staff or the unblinded monitors in the trial.~The study vaccine manager (and designee) should be a designated site team member, such as the study pharmacist. Unblinded site staff must not participate in the evaluation of adverse events.~The randomization list will be provided by the unblinded statistician and will be implemented as a module in the eCRF."|2 Cohorts - H56:IC31 and Placebo. First 150 participants will be in a safety group with additional scheduled evaluations.|t|t|t|f
34004152|NCT06679634|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Open Label Expanded Access||||
34004153|NCT04674826|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004154|NCT04560426|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34004155|NCT06677749|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34004156|NCT03200145|||COHORT||PROSPECTIVE|||||||
34004157|NCT02140424|||COHORT||PROSPECTIVE|||||||
34004158|NCT00142116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004159|NCT04526080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34004160|NCT01080586|RANDOMIZED|CROSSOVER||||NONE||||||
34004161|NCT02245698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004162|NCT02798419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004163|NCT01763554|||COHORT||RETROSPECTIVE|||||||
34004164|NCT06235138|||CASE_ONLY||RETROSPECTIVE|||||||
34004165|NCT02655224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004166|NCT00943865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004167|NCT03528096|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Blinding of the participants is impossible, as the stimulation is easy to perceive and cannot be confused with a baseline night. Therefore, participants are informed about the character of the night (max. 5 minutes) before the moment of lights off. For safety reasons the experimenter that is present is also aware of the condition.|Crossover Assignment|t|f|f|f
34004168|NCT04659486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33786697|NCT04630652|NA|SINGLE_GROUP||TREATMENT||NONE||The interventional study model is to treat moderate-to-severe psoriasis patients with risankizumab for 4 months and analyze pre- and post-treatment skin biopsy samples to (i) identify regulatory immune cell alterations induced by risankizumab administration in the skin of patients whose psoriasis is cleared without recurrence and (ii) develop pre-treatment predictive models for psoriasis patients that anticipate disease clearance and recurrence.||||
33786698|NCT03855644|||OTHER||CROSS_SECTIONAL|||||||
33786699|NCT06343285|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Randomization schedule maintained by non-Clinical personnel|Three different arms in a randomized order|t|t|t|t
34004169|NCT03046082|||COHORT||PROSPECTIVE|||||||
34004170|NCT03928236|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Multicenter, cluster-randomized, crossover trial||||
34004171|NCT00374166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004172|NCT05416112|||COHORT||PROSPECTIVE|||||||
34090703|NCT01372956|||CASE_ONLY||RETROSPECTIVE|||||||
34004173|NCT03887598|||CASE_ONLY||PROSPECTIVE|||||||
34004174|NCT05412121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004175|NCT05958056|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34004176|NCT02103582|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33925291|NCT05744323|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|in order to avoid the Contamination caused by the mutual interference between the experimental group and the control group, blinding was necessary in the study. In this study, a single-blind experiment will be used to blind the participating children. During sample selection and grouping, the participating children will not know the specific grouping situation, and will not be informed of the relevant experimental objectives|The study will be conducted using a randomized controlled trial (RCT), and the study will be divided into three parts: pre-study baseline testing, intervention training and post-study testing. The entire experiment will be conducted in the first academic year of 2023.2-2023.4. A pilot study will be carried out first, followed by the actual research, in order to provide the framework and offer support for the full-scale experiment that will follow. The subjects involved in this study are 6-year-old and 7-year-old children, all students participating in the study will be divided into experimental and control groups.|t|f|f|f
33925292|NCT03980626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925293|NCT05189132|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925294|NCT05316480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925295|NCT04131985|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||One group will receive erector spinae plane block, and the other will receive nothing|t|f|f|f
33925296|NCT04026971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925297|NCT00879983|RANDOMIZED|CROSSOVER||||NONE||||||
33925298|NCT04153643|||CASE_ONLY||PROSPECTIVE|||||||
33925299|NCT00388167|||CASE_ONLY||PROSPECTIVE|||||||
33925300|NCT06271694|NA|SINGLE_GROUP||OTHER||NONE||||||
33925301|NCT04833868|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Controlled Trial||||
33925302|NCT00869219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925303|NCT01455415|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34004177|NCT01617551|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34004178|NCT00324896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004179|NCT05359783|NA|SINGLE_GROUP||TREATMENT||NONE||A phase Ib/II interventional dose-escalation single arm study||||
34004180|NCT00005887|RANDOMIZED|||TREATMENT||NONE||||||
34004181|NCT05260203|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective, interventional, confirmatory investigation, pre-market study, with a historical group of comparison||||
34004182|NCT04153786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004183|NCT05796518|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Endometrial cancer survivors presenting for post-treatment surveillance visit.||||
34004184|NCT02776527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004185|NCT01875887|||CASE_ONLY||RETROSPECTIVE|||||||
34004186|NCT02966340|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
34004187|NCT01288924|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34004188|NCT01462578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004189|NCT04726852|||COHORT||PROSPECTIVE|||||||
34004190|NCT02701608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004191|NCT04201028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Following baseline visits, participants were randomized to a no device (NODEV) or device (DEV) group via the website https://www.randomlists.com/team-generator.|All participants were randomized in a balanced fashion and stratified by sex into either one of the two intervention groups no device (NODEV) group or a device (DEV) group.|f|t|f|f
34004192|NCT06594367|||COHORT||PROSPECTIVE|||||||
34004193|NCT05396950|NA|SINGLE_GROUP||TREATMENT||NONE||Within subject comparison||||
34004194|NCT00605176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090704|NCT00186511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090705|NCT02235740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786700|NCT02952261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925304|NCT06380790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090706|NCT01303497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090707|NCT00811408||||TREATMENT||||||||
34090708|NCT03301714|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34090709|NCT00178373|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33786701|NCT03569137|||COHORT||PROSPECTIVE|||||||
33786702|NCT04446689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786703|NCT04449744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786704|NCT03514589|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"Current stage is stage 3 (Sept 2023), an open label study of nasal Synacthen in healthy children aged 0-18 to derived normative reference data.~Previous stages:~1a: 12 healthy adult males, 4 arms (dose selection studying nasal synacthen 100 mcg + chitosan, 500 mcg and 500 mcg + chitosan against 1mcg IV Synacthen)~1b: 6 healthy adult males 1 arm (repeatability: two further 500 mcg + chitosan visits)~1c: 12 healthy adult males 3 arms (dose rangign study: 500 mcg + chitosan, 1mg + chitosan against 250 mcg IV Synacthen comparator) 2: Healthy children aged 2-15 (500 mcg + chitosan, against 145 mcg/m2 IV Synacthen comparator)"||||
33786705|NCT01843465|||COHORT||PROSPECTIVE|||||||
33786706|NCT04846101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blind Observers will be asked to assess the shade matching capacity of the restorative material on a Likert Scale.||t|f|t|t
33786707|NCT05164016|||COHORT||PROSPECTIVE|||||||
33786708|NCT04222270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786709|NCT03208270|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33925305|NCT03079245|RANDOMIZED|PARALLEL||PREVENTION||NONE||A pre-post intervention study followed by two years of use of randomly assigned interventions||||
33925306|NCT01599702|NON_RANDOMIZED|PARALLEL||||NONE||||||
33925307|NCT04208646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925308|NCT05453448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925309|NCT00606528|||COHORT||PROSPECTIVE|||||||
33925310|NCT01799304|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925311|NCT05687708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33925312|NCT00168909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925313|NCT03532776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925314|NCT00474825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925315|NCT02354092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925316|NCT00456833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925317|NCT01328197|NA|SINGLE_GROUP||TREATMENT||NONE||AAA device||||
33925318|NCT00358501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925319|NCT03212807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925320|NCT00145912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925321|NCT04625361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925322|NCT02645591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925323|NCT02964988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925324|NCT02268071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925325|NCT04374266|||CASE_ONLY||RETROSPECTIVE|||||||
33925326|NCT01600066|||COHORT||PROSPECTIVE|||||||
33925327|NCT02097485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925328|NCT05989295|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33925329|NCT06259045|||COHORT||PROSPECTIVE|||||||
33925330|NCT03380338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925331|NCT06527625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33925332|NCT00225056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925333|NCT00978224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925334|NCT03334552|||COHORT||PROSPECTIVE|||||||
33925335|NCT01797315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925336|NCT02729805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090710|NCT04214015|||CASE_ONLY||PROSPECTIVE|||||||
34090711|NCT02891824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090712|NCT00805532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090713|NCT03642314|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786710|NCT05751200|||COHORT||RETROSPECTIVE|||||||
34090714|NCT01850329|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34090715|NCT01059851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090716|NCT00090428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34090717|NCT04831658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090718|NCT05297708|||CASE_ONLY||PROSPECTIVE|||||||
33699406|NCT03610438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is divided in two cohorts; cohort 1 will enroll 38 Ph+ patients, cohort 2 will enroll 38 Ph- patients, as defined with statistical analysis. The two cohorts will have the same treatment, with the exception of short term and long term maintenance.||||
33699407|NCT03049722|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699408|NCT01982565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699409|NCT00328549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699410|NCT01160211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699411|NCT05931874|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The four Intervention components that are candidates for inclusion in the optimized intervention, each with 2 possible levels, will be tested in a 24-week intervention with a 24-week follow-up using a MOST approach. The effects of the four individual intervention components and their combinations will be examined via a full factorial experiment. The investigators chose a factorial experimental design because these designs have two characteristics essential to the success of MOST. They: a) separate component effects enabling the estimation of the main effect of each candidate component and interactions between components and b) are more economical compared to alternative designs because they often require substantially fewer subjects to achieve the same power and use less resources. The investigators are using a full factorial experiment with 2\^4=16 experimental conditions.||||
33699412|NCT02626767|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699413|NCT00193531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699414|NCT02650427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699415|NCT02414659|||CASE_CONTROL||RETROSPECTIVE|||||||
33699416|NCT01108120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699417|NCT05647057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|"In two consecutive randomized controlled trials, the investigators study the effect of prime fluid strategies on perfused vessel density (part I) and the effect of additional albumin during cardiopulmonary bypass compared with ringers on perfused vessel density (part II).~In this study part (I), the effect of prime fluid strategies on perfused vessel density.~A single centre, double-blind randomized trial"|t|f|t|f
33699418|NCT06681818|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699419|NCT02260440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699420|NCT06679881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699421|NCT04524806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699422|NCT03605212|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720340|NCT04826146|||COHORT||PROSPECTIVE|||||||
33720341|NCT05313074|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|All participants, including patients with solid tumor and healthy volunteers will be received 2 doses of CoronaVac at National Cancer Institute of Thailand between 2020-2021. Blood samples will be collected after second dose of Sinovac for 15 days and the neutralizing antibody (NAb) titers will be detected using live-virus neutralization|Cancer patients and healthy volunteers will be compared for effectiveness of CoronaVac vaccine in parallel after 2 doses of vaccination for 15 days by neutralizing antibody test||||
33720342|NCT01710033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33720343|NCT00123591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786711|NCT02781584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohorts 1-6 and 9 will be enrolled sequentially while Cohorts 7 and 8 will be randomized in parallel. Cohorts 10 and 11 will be randomized in parallel. Cohorts 12 and 13 will be randomized in parallel.||||
33786712|NCT01323660|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33786713|NCT01723670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33786714|NCT01392755|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786715|NCT06314256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be masked which side of her/his mouth treated with either i-PRF or HA.|A type of study used frequently in oral research: the mouth is divided into two or more subunits. Active and control (comparison) treatments are applied to the subunits (e.g., to the left and right sides).|t|f|f|f
33786716|NCT04756401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786717|NCT05879666|NA|SINGLE_GROUP||OTHER||NONE||||||
33786718|NCT00925730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786719|NCT04133363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925337|NCT03014921|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33925338|NCT05960513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33925339|NCT04813302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925340|NCT00132314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925341|NCT04105647|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The control group will receive a face-to-face group session and a package of instant messages related to healthy living information, but no information on lifestyle-integrated exercise and physical activity.~The experimental group will receive a face-to-face group session and a package of information on lifestyle-integrated exercise and physical activity."||||
33925342|NCT00961441|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925343|NCT00036062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925344|NCT02575677|||COHORT||PROSPECTIVE|||||||
33925345|NCT00126854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925346|NCT03808428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925347|NCT06011980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925348|NCT01746914|||COHORT||PROSPECTIVE|||||||
33925349|NCT00861380|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33925350|NCT01285063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925351|NCT05306353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925352|NCT01236794|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34090719|NCT01931605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090720|NCT05406089|||CASE_CONTROL||RETROSPECTIVE|||||||
34090721|NCT04142827|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34090722|NCT05283837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Multi-center, Comparative, Double-blind, Parallel study|t|f|t|t
34004195|NCT05862844|NA|SINGLE_GROUP||PREVENTION||NONE||In this study, the investigators will conduct a single-arm pilot trial using a pre-and post-test survey design to evaluate the effectiveness of a religiously tailored and culturally appropriate intervention program for promoting cervical cancer prevention among Muslim American women. 20 eligible participants who have not previously participated in our studies will be recruited. Before the intervention, participants will complete a pre-intervention survey to assess their knowledge and acceptance of cervical cancer prevention. Following the intervention, participants will undergo the post-intervention survey to measure any changes in their knowledge and acceptance levels. By utilizing this survey-based approach, the investigators aim to gather valuable data on the impact of the intervention and determine its potential effectiveness in improving participants' understanding and engagement with cervical cancer prevention activities.||||
34004196|NCT03996837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090723|NCT00487591|||COHORT||PROSPECTIVE|||||||
34090724|NCT03043781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090725|NCT00605254|||CASE_CROSSOVER||PROSPECTIVE|||||||
33925353|NCT02876679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925354|NCT03998904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925355|NCT05244538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925356|NCT00188357|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33925357|NCT01213264|||CASE_CONTROL||PROSPECTIVE|||||||
33925358|NCT04714489|||COHORT||PROSPECTIVE|||||||
33925359|NCT00004014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925360|NCT05976932|||COHORT||PROSPECTIVE|||||||
33925361|NCT05578768|||COHORT||PROSPECTIVE|||||||
33925362|NCT02284022|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33925363|NCT00139841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925364|NCT02836132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34004197|NCT00826137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004198|NCT02418442|||COHORT||PROSPECTIVE|||||||
34004199|NCT01616316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33720344|NCT03456674|NA|SINGLE_GROUP||TREATMENT||NONE||A single cohort of study subjects will receive study treatment.||||
34004200|NCT04487288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004201|NCT04433494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004202|NCT03930251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004203|NCT05478928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004204|NCT01609582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004205|NCT02714296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004206|NCT05419817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004207|NCT03455036|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The design of the study is a single-centre cross-sectional single-arm intervention study.||||
34004208|NCT00785876|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34004209|NCT02757339|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004210|NCT02150356|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34004211|NCT01723917|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34090726|NCT06305039|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34090727|NCT00591799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090728|NCT00226655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090729|NCT00147238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090730|NCT05410067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090731|NCT00762905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33720345|NCT00403793|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720346|NCT01673451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720347|NCT05501964|||COHORT||PROSPECTIVE|||||||
33720348|NCT01669915|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33720349|NCT04234321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720350|NCT02370979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720351|NCT04486781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720352|NCT00716118|||COHORT||PROSPECTIVE|||||||
33720353|NCT01264978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720354|NCT05200520|NA|SINGLE_GROUP||SCREENING||NONE||||||
33720355|NCT03362073|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single institution, Open-label, Phase 2||||
33720356|NCT04650802|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal intervention study with two consecutive baseline assessments and a five-week follow-up||||
33720357|NCT05877794|NA|SINGLE_GROUP||OTHER||NONE||||||
33786720|NCT00207649|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33786721|NCT03109015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786722|NCT04912362|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786723|NCT04278989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786724|NCT04060355|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786725|NCT05730764|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33786726|NCT06187701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786727|NCT05491161|||COHORT||PROSPECTIVE|||||||
33786728|NCT04378582|||CASE_ONLY||OTHER|||||||
33786729|NCT06314594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33786730|NCT05338242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786731|NCT06631404|||CASE_ONLY||PROSPECTIVE|||||||
33786732|NCT05224362|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33786733|NCT03697733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33786734|NCT00787956|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786735|NCT04977960|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, 1:1 randomized parallel arms, Simon's two stage design, single centre.||||
33786736|NCT05025449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The interpretation of the point-of-care emergency medicine (EM) physician (blind to the CT read) will be compared to the interpretations of board-certified radiologists (also blind to the CT read) for the presence or absence of solid organ injury.|||||
34004212|NCT02329431|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34004213|NCT03171324|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34004214|NCT04304339|||COHORT||PROSPECTIVE|||||||
34004215|NCT04874363|||CASE_CONTROL||RETROSPECTIVE|||||||
34004216|NCT06531915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004217|NCT03235336|||COHORT||PROSPECTIVE|||||||
34004218|NCT01463891|||COHORT||PROSPECTIVE|||||||
34004219|NCT05705973|||OTHER||PROSPECTIVE|||||||
34004220|NCT06096350|||COHORT||PROSPECTIVE|||||||
34004221|NCT00924586|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34004222|NCT03848858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluators will be blind to treatment. Participants cannot be blind to treatment due to the impossibility of creating a sham alternative to EMDR therapy, due to its use of bilateral stimulation.|Patients will be recruited from the Infectious Diseases Unit of the Hospital del Mar, Barcelona, Spain, and evaluations and therapy sessions will be carried in the Hospital del Mar and in the Hospital del Mar Research Institute. The study consists of a single-blind RCT with two parallel branches, 1) individual therapy with EMDR and TAU, and 2) TAU only, with participants matched by age, sex, and prior trauma burden. Following the initial evaluation, participants will be randomized to either receive up to 6 months of weekly 1 hour EMDR sessions (20 sessions) in addition to the standard medical treatment, or standard medical treatment only. The participants will be evaluated pre- and post- treatment.|f|f|f|t
34004223|NCT06571487|||COHORT||PROSPECTIVE|||||||
34004224|NCT03098186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|TX2THeart-Colombia is a single-blind trial. The laboratory personnel in charge of measurement LDL-C and 11 dhTxB2 levels will not have access to treatment allocation and they will only have access to internal numerical ID variable. The laboratory results will be conducted once trial follow-up is completed, and results will be sent directly to the database manager, who will link the results to the existing database. The staff in charge of measurement blood-pressure and heart rate will not have access to information on treatment allocation. Measurement of blood pressure and heart rate will be the first activity to be conducted with participants in visits 1 and 3 to minimize any potential subconscious bias introduced as a consequence of patients inadvertently revealing to trial staff the treatment allocation. The only person who will have access to the information of the participants is the engineer in charge of the management of Dimagi-Commcare Plataform.||f|t|t|t
34004225|NCT05222360|||COHORT||PROSPECTIVE|||||||
34004226|NCT05657353|||COHORT||PROSPECTIVE|||||||
34004227|NCT05484791|NA|SINGLE_GROUP||TREATMENT||NONE||The research was designed as a semi-experimental study with pre-test (before implementation), post-test (after implementation) and 2-month follow-up assessments||||
34090732|NCT00839137|||CASE_CONTROL||PROSPECTIVE|||||||
34090733|NCT02363660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34090734|NCT03630900|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34090735|NCT00870142|RANDOMIZED|CROSSOVER||||NONE||||||
33786737|NCT06478680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786738|NCT06226974|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33786739|NCT06630572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo control, double-blind trial.|t|t|t|t
33786740|NCT00010881||||TREATMENT||||||||
33786741|NCT00178984|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786742|NCT00362843|||COHORT||CROSS_SECTIONAL|||||||
33786743|NCT04679935|RANDOMIZED|PARALLEL||TREATMENT||NONE|open-label|two arm, multicenter||||
33786744|NCT05457491|NA|SINGLE_GROUP||OTHER||NONE||||||
33786745|NCT06629012|||CASE_CONTROL||PROSPECTIVE|||||||
33786746|NCT05349864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34004228|NCT01708655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004229|NCT06590350|||CASE_CONTROL||PROSPECTIVE|||||||
34004230|NCT06679192|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||three-intervention cross over study.|f|f|f|t
34004231|NCT01150396|||COHORT||PROSPECTIVE|||||||
34004232|NCT02726386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004233|NCT00866645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004234|NCT05560451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Concealment will be used to prevent the study staff from obtaining information on the sequence of assignment. Because of the nature of the intervention, we are unable to blind participants and staff to treatment assignment.|Hybrid type 1 trial with 294 Veterans with multimorbidity. Participants will be randomized to one of two groups -- the control or intervention group -- in parallel for the duration of the study.||||
34004235|NCT02970045|||CASE_ONLY||PROSPECTIVE|||||||
34004236|NCT02310503|||COHORT||PROSPECTIVE|||||||
34004237|NCT02055092|||COHORT||PROSPECTIVE|||||||
33786747|NCT02606734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699423|NCT04446572|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Volunteers were classified into 3 groups. All women in the RA group (n = 21) had a history of recurrent miscarriage with three or more pregnancy losses during the first 12 weeks of pregnancy. All women of the INF group (n = 23) had a history of infertility (inability to conceive) despite being the recipients of assisted-reproduction techniques (ART) for at least three times, including two cycles, at least, of in vitro fertilization (IVF). Finally, the control group (n = 14) included fertile women having at least two children after uncomplicated term pregnancies. Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with \~50 mg of freeze-dried probiotic (\~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).||||
33699424|NCT02856659|||COHORT||PROSPECTIVE|||||||
33699425|NCT02935842|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33699426|NCT02100800|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33786748|NCT00197457|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786749|NCT06206473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single-center cohort (Intensive Care Unit of the Toulouse University Hospital), prospective, longitudinal, interventional, proof of concept study||||
33786750|NCT05971225|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||one group with experience of in-office device monitoring \>6 months the other group without experience of in-office device monitoring||||
33786751|NCT03681730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786752|NCT04780828|||CASE_CONTROL||PROSPECTIVE|||||||
33786753|NCT06468657|||COHORT||RETROSPECTIVE|||||||
33786754|NCT04109690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786755|NCT02414230|||OTHER||PROSPECTIVE|||||||
33786756|NCT04872205|||CASE_ONLY||CROSS_SECTIONAL|||||||
33925365|NCT01536652|||COHORT||PROSPECTIVE|||||||
33925366|NCT04890106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33925367|NCT03792165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925368|NCT04116216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925369|NCT00498225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925370|NCT00543621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925371|NCT00884221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925372|NCT01496170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925373|NCT02186457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33925374|NCT05666570|||CASE_ONLY||PROSPECTIVE|||||||
33925375|NCT02232594|||COHORT||PROSPECTIVE|||||||
33925376|NCT03508284|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925377|NCT01171287|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33925378|NCT06193694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open Label|"Early career pediatric surgeons will be randomized, in a 1:1 fashion to either receive wellness materials or formal coaching as described above.~Randomization will occur after coaches are identified and have completed training in a 2:1 fashion to either participate as coaches or receive wellness materials."||||
33925379|NCT03310437|||OTHER||PROSPECTIVE|||||||
33925380|NCT01285973|||COHORT||PROSPECTIVE|||||||
33925381|NCT05811741|||COHORT||PROSPECTIVE|||||||
33699427|NCT02100579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699428|NCT02651831|||COHORT||PROSPECTIVE|||||||
33925382|NCT01613508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925383|NCT02379312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33925384|NCT03335644|||COHORT||PROSPECTIVE|||||||
33925385|NCT00868868|||COHORT||PROSPECTIVE|||||||
33925386|NCT04030949|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33925387|NCT02007967|||COHORT||PROSPECTIVE|||||||
33925388|NCT06260904|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, add-on, active-controlled, open-label, parallel-design clinical trial||||
33925389|NCT03742206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699429|NCT00397215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699430|NCT02391675|||COHORT||PROSPECTIVE|||||||
33699431|NCT01881373|RANDOMIZED|PARALLEL||PREVENTION||NONE||Community randomized intervention for child obesity prevention with multiple levels and components (policy, environment, messaging, and capacity)||||
33699432|NCT03561363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699433|NCT01146275|NA|SINGLE_GROUP||OTHER||NONE||||||
33699434|NCT01461395|||COHORT||PROSPECTIVE|||||||
33699435|NCT03419611|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Coders will be blind to condition.|"Following the selection of target words based on sounds in the child's speech repertoire as described below, participants will be randomly assigned with equal probability to either the multimodal or TAU treatment in phase one. If data indicates a positive slope in the number of words correct in speech production probes and at least 2 words produced with \> 80% accuracy, the participant will meet responder criterion, and continue in their originally assigned intervention. Participants who do not meet this criterion will be re-assigned to one of the stage 2 treatment conditions as depicted in figure 1. Participants who do not respond to the TAU will be randomly reassigned with equal probability to receive either the multimodal intervention or the high intensity multimodal intervention. Participants will continue in this second stage of intervention until 40 words have been learned or 12 weeks elapse (whichever occurs first)."|f|f|f|t
33699436|NCT01595672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699437|NCT06679959|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33699438|NCT00174330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699439|NCT06681376|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A research assistant, blinded to the initial assessment and ED care details, will conduct a phone interview 30 days (± 2 days) post-initial assessment.|This study will utilize a quasi-experimental, before-and-after design.|f|f|f|t
33699440|NCT00011518|||CASE_CONTROL||RETROSPECTIVE|||||||
33699441|NCT06557694|||OTHER||RETROSPECTIVE|||||||
33699442|NCT05421871|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33699443|NCT01680965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699444|NCT04507100|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not possible because the Ministry of Education specifically announces the implementation of Salud Escolar in each school.|||||
33699445|NCT00203073|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33699446|NCT02288598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699447|NCT01796756|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33699448|NCT04359108|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699449|NCT06253975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699450|NCT00640861|RANDOMIZED|||TREATMENT||||||||
33699451|NCT03071159|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33699452|NCT01554020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33699453|NCT01074372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699454|NCT01592682|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33699455|NCT05189080|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The first phase of the study will be an open trial to assess feasibility and acceptability of three different reminder messages, analyze preliminary data, and collect feedback from participants using interviews to identify the top one or two performing messages. Each reminder message will at minimum direct parents/guardians to reschedule by phone or by the patient portal.||||
33699456|NCT00994929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699457|NCT05669729|||COHORT||CROSS_SECTIONAL|||||||
33699458|NCT00408460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699459|NCT01044251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699460|NCT05772208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699461|NCT03497078|NA|SINGLE_GROUP||OTHER||NONE||||||
33699462|NCT04767620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study group took the No.1 Recipe for Rugden Zengsheng, and the control group took clinical observation and follow-up at the breast center. The study group and the control group were grouped randomly by envelope, and grouped according to 2:1.|non|t|t|t|t
33699463|NCT01205659|||COHORT||RETROSPECTIVE|||||||
33925390|NCT01310569|||CASE_CONTROL||PROSPECTIVE|||||||
33925391|NCT05516160|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925392|NCT00002257||||TREATMENT||||||||
33699464|NCT03388931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699465|NCT05153772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699466|NCT06327009|||COHORT||PROSPECTIVE|||||||
33699467|NCT02619669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699468|NCT02121522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925393|NCT04329000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized-controlled trial|f|f|t|t
33925394|NCT03634917|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33925395|NCT03271957|||COHORT||PROSPECTIVE|||||||
33925396|NCT01378299|NA|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
33925397|NCT04582604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699469|NCT02499276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699470|NCT02770833|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33699471|NCT05207254|||CASE_CONTROL||PROSPECTIVE|||||||
33699472|NCT04599829|||CASE_CONTROL||PROSPECTIVE|||||||
33699473|NCT04263831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925398|NCT02902822|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925399|NCT04682678|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33925400|NCT03543527|||COHORT||PROSPECTIVE|||||||
33925401|NCT05800509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is randomized-controlled trial, half of enrolled participants acquire the intervention of health education and regular health service from hospital, another half only acquire regular health service from hospital.|t|f|f|f
33925402|NCT02077842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925403|NCT05153447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925404|NCT06081699|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33925405|NCT00980434|||COHORT||PROSPECTIVE|||||||
33925406|NCT04742972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699474|NCT05444101|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The study uses a 2\^3 factorial design, randomizing participants to 8 experimental conditions. The seven active conditions consist of one, two, or three different treatment components. Participants receiving two or three treatment components will be randomized to receive them in different order.||||
33699475|NCT04686604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33699476|NCT05474235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925407|NCT01883804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925408|NCT02670850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33925409|NCT01125540|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33925410|NCT04463446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925411|NCT02915068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33925412|NCT01082978|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Primary outcomes, death and overnight hospitalisations, are obtained through record linkage and are masked outcomes. Outcome assessor, however, is not masked to patient-reported outcomes. Chief Investigator and statistical analyses are masked to randomisation/intervention group.||f|f|t|t
33925413|NCT00396825|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33925414|NCT02794623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925415|NCT04539691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Magnet and sham devices used weigh and look the same||t|f|t|f
34004238|NCT06494826|||CASE_CONTROL||PROSPECTIVE|||||||
34004239|NCT05887687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004240|NCT03267927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004241|NCT05385900|NA|SINGLE_GROUP||TREATMENT||NONE||Penpulimab in combination with anlotinib and chemotherapy||||
34004242|NCT05191511|||COHORT||RETROSPECTIVE|||||||
34004243|NCT03065699|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||The design is a multi-centre, randomised, controlled, study to generate data for the evaluation of safety (as measured by the percentage of subjects who experience at least one serious adverse event (SAE)) and performance (as measured by lowering of the plasma endotoxin concentrations, and improved albumin function) of DIALIVE in 24 evaluable patients with Acute on Chronic Liver Failure (ACLF) versus standard of care (SOC). During the study the sample size was increased to include a total 30 evaluable patients.||||
34004244|NCT04669457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The surgeon and post-operative nurses will be masked to the group allocation. Masking will only be revealed if medically necessary.|Randomized control trial|f|t|f|t
34004245|NCT03933267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|Both experimental and control groups will be treated simultaneously with one treatment option common to both groups|t|f|f|f
34004246|NCT02608476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004247|NCT01622660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004248|NCT01660477|RANDOMIZED|PARALLEL||||NONE||||||
34004249|NCT04906837|||COHORT||RETROSPECTIVE|||||||
33699477|NCT06544122|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33699478|NCT03274232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699479|NCT03926871|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The evaluators performed the biomechanical exposure analysis without knowing that the workers were from the novice and experienced group.|Two independents groups (Novice and Experienced). Both groups received ergonomics training in workplace.|f|f|f|t
33699480|NCT03025009|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33699481|NCT01026922|||CASE_ONLY||PROSPECTIVE|||||||
33699482|NCT03974360|NA|SINGLE_GROUP||TREATMENT||NONE||Exploratory Open-Label Study||||
33699483|NCT02547324|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33699484|NCT04958772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699485|NCT02969330|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33699486|NCT05180617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699487|NCT06231732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699488|NCT00516074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699489|NCT04043273|||COHORT||PROSPECTIVE|||||||
33699490|NCT04123275|||COHORT||PROSPECTIVE|||||||
33699491|NCT03252119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699492|NCT03402113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699493|NCT01919671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699494|NCT06560684|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699495|NCT05534529|NA|SEQUENTIAL||TREATMENT||NONE||||||
33699496|NCT03378661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Dummy|Parallel Assignment|t|t|t|t
33699497|NCT04930822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be assigned into A and B groups upon admission in alternating fashion. The control group A will be prescribed conventional (table top, pen and paper) vision interventions provided by an occupational therapist and will receive pre- and post- assessment of visual field awareness. Treatment group B will include a prescribed regimen with use of BITS touch screen technology. Group B participants will receive the same pre- and post- assessment of visual field awareness as Group A participants."||||
33699498|NCT04925908|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33699499|NCT03970642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In this randomized controlled trial, participants will be randomly assigned to the study or the control group. A total of up to 100 participants will be enrolled (50 participants assigned to each group).||||
33699500|NCT06180746|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||longitudinal mixed-method intervention study with a multi-center, multi-case explanatory sequential design||||
33699501|NCT04206904|||OTHER||CROSS_SECTIONAL|||||||
33699502|NCT03643354|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33699503|NCT00804622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699504|NCT03029442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699505|NCT01976195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699506|NCT01372228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699507|NCT05836181|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34004250|NCT04556734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-Blind, Placebo-Controlled|t|f|t|t
34004251|NCT04300998|||COHORT||PROSPECTIVE|||||||
34004252|NCT05740696|||COHORT||OTHER|||||||
33699508|NCT02556658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34004253|NCT04423445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This single-blinded randomized controlled trial||t|f|f|f
34004254|NCT04249622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004255|NCT06246734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor blind to treatment allocation|Single-blind randomized controlled trial|f|f|f|t
34004256|NCT00059709|RANDOMIZED|FACTORIAL||ECT||NONE||||||
34004257|NCT02972515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004258|NCT06038318|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34004259|NCT00396955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34004260|NCT02425501|||COHORT||PROSPECTIVE|||||||
34004261|NCT03799822|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004262|NCT01057173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004263|NCT06551129|||COHORT||PROSPECTIVE|||||||
34004264|NCT01117844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004265|NCT06677983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004266|NCT00600873|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34004267|NCT06616441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004268|NCT01432028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004269|NCT06677190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004270|NCT06381687|RANDOMIZED|PARALLEL||OTHER||SINGLE||The allocation of ECECs to the intervention versus control group will be randomised in a blinded procedure at the end of the first year, following the baseline assessment. Once ECEC centres meeting the selection criteria are identified, they will be randomised to one of the trial arms.|t|f|f|f
34004271|NCT03091868|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34004272|NCT01257191|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34004273|NCT04641403|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Anesthesia team, the patient, and the clinical nurses who carry out and record the postoperative evaluation will blinded to the group of patients.|prospective randomized double blind|t|t|f|f
34004274|NCT06678022|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomised trial using a non-inferiority design||||
34004275|NCT06130969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004276|NCT05747560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34004277|NCT00877994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004278|NCT02034448|||COHORT||PROSPECTIVE|||||||
33699509|NCT03002363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33699510|NCT02147184|||COHORT||PROSPECTIVE|||||||
33699511|NCT04242550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699512|NCT05147935|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33699513|NCT00011557|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699514|NCT00353665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699515|NCT03352479|NA|SINGLE_GROUP||PREVENTION||NONE||Each participant will be given on envelope to return unused opioids||||
33699516|NCT06680128|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||Stage 1: sequential, Stage 2 : parallel|t|t|t|t
33699517|NCT00729287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699518|NCT01549600|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33699519|NCT02250859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699520|NCT03601078|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699521|NCT00079768||||TREATMENT||||||||
33699522|NCT00599950|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699523|NCT02915796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699524|NCT01669135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699525|NCT05888454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699526|NCT03838146|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|the clinicians and investigators taking measures are blinded to group assignment|comparing 3 exercise interventions to a control (non-exercise) group|f|t|t|f
33699527|NCT03686670|||COHORT||PROSPECTIVE|||||||
34004279|NCT00804999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34004280|NCT01989299|||COHORT||PROSPECTIVE|||||||
34004281|NCT01843257|||OTHER||OTHER|||||||
34004282|NCT00559026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699528|NCT06530225|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33699529|NCT06051422|||OTHER||CROSS_SECTIONAL|||||||
33699530|NCT06047808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699531|NCT02985437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699532|NCT05191173|||COHORT||PROSPECTIVE|||||||
33786757|NCT00124956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786758|NCT06714396|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33786759|NCT03018145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786760|NCT03664661||SEQUENTIAL||TREATMENT||NONE||||||
33786761|NCT04968574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004283|NCT01024777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004284|NCT01898234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004285|NCT05132439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a triple-blinded randomized controlled trial. Therefore, the allocation of participants to either placebo or metformin is unknown by the participant, research personnel, and investigator. The study statistician will not be blinded.|Two arm randomization to 1000mg metformin ER or placebo daily with 1:1 parallel randomization, Randomization stratification will be based on baseline Maximum Walking Distance on the 6 Minute Walk Test and smoking status|t|t|t|t
34004286|NCT06539676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004287|NCT05835635|||COHORT||PROSPECTIVE|||||||
34004288|NCT00623558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004289|NCT05424380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004290|NCT06679322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004291|NCT05845372|||COHORT||PROSPECTIVE|||||||
34004292|NCT03039036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004293|NCT03446599|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is unfortunately not feasible due to characteristic side effects from each medication that alert most healthcare providers to its presence: methylene blue - transient interference with pulse oximetry, blue chromaturia; hydroxocobalamin - red chromaturia.|||||
34090736|NCT04632719|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study has two groups. The Study Group will be the group that was remissive for COVID-19 and has some of the mentioned comorbidities, even if controlled by drugs or treatments. The Control Group will be the group with remissive patients without the aforementioned comorbidities. We will assess whether comorbidities can worsen the impairment of cognitive functions after the remission of the symptoms of COVID-19. The purpose of the research is to verify; whether COVID-19 alone in moderate to severe cases causes cognitive impairment or whether predisposing factors for such comorbidities would cause further impairment in cognitive functions after COVID-19 contraction and remission.||||
34090737|NCT04493177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34090738|NCT00097968|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34090739|NCT03752827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is a double-blinded trial in which the subject, post-procedural investigator and imaging core laboratory radiologists are blinded.||t|f|t|t
34090740|NCT05456672|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090741|NCT02139319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34090742|NCT02331732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090743|NCT03518606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study divided in two parts:~* Phase I part: dose escalation study of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy,~* Phase II part: activity study of metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy."||||
34090744|NCT01766284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090745|NCT00877864|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
34090746|NCT03243799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090747|NCT00332397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090748|NCT00392041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699533|NCT06468852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were unaware of their group allocation. Due to the presence of the cardiac index trend monitoring device, care providers who supported to fluid strategy administration in the operating room could not be blinded. The outcomes assessor were blinded to the allocation.||t|f|f|t
34004294|NCT00328354|||OTHER||PROSPECTIVE|||||||
34004295|NCT06676449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699534|NCT05998707|||COHORT||PROSPECTIVE|||||||
33699535|NCT02987842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699536|NCT05894512|||COHORT||PROSPECTIVE|||||||
33699537|NCT04122534|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33699538|NCT03617510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34004296|NCT05805813|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004297|NCT05597839|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34004298|NCT02923063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004299|NCT01077258|||CASE_ONLY||PROSPECTIVE|||||||
34004300|NCT01504711|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004301|NCT03537911|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004302|NCT00793234|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004303|NCT00152516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004304|NCT06679049|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects Undergoing Tibial Fracture Repair||||
34004305|NCT00527917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004306|NCT03011879|||COHORT||PROSPECTIVE|||||||
34004307|NCT00024258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925416|NCT03620253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|25 participants will be randomly assigned to the modafinil treatment group, and 25 to the placebo group. The drug/placebo will be randomized and dispensed by the research pharmacy at St. Michael's Hospital. A research technician who is blind to the study will prepare the capsules and break the blind at the end of the study.|50 Participants (aged 18-55) who are experiencing cognitive deficits (measured as Neurocognitive Index \>1 standard deviation below the mean) despite remission from depression (Montgomery-Asberg Rating Scale for Depression (MADRAS) score \<7) will be eligible to receive modafinil (100-200mg daily) or two identical placebo capsules each morning for a period of 8 weeks.|t|t|t|t
33925417|NCT05185284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004308|NCT04983524|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34004309|NCT06120530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004310|NCT02221817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004311|NCT02964650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004312|NCT06678893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a pilot study of a randomized control trial. Consented participants will be randomized to either auricular acupuncture or placebo intervention. Blood pressure, heart rate, and VAS pain and anxiety scores will be recorded and compared pre and post intervention in both treatment arms.|t|t|t|t
34004313|NCT02941588|||COHORT||RETROSPECTIVE|||||||
34004314|NCT06106152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center, open-label, exploratory study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer||||
34004315|NCT06276621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34004316|NCT04931160|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* Sjögren patients~* Non-Sjögren controls (retrospective)"||||
34004317|NCT04469725|NA|SINGLE_GROUP||TREATMENT||NONE||subjects enrolled receive KN046||||
34004318|NCT02260635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004319|NCT04752319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004320|NCT00360490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004321|NCT02408120|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34004322|NCT01392001|||COHORT||PROSPECTIVE|||||||
34004323|NCT03878264|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33699539|NCT01268150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699540|NCT04234802|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is a parallel, comparison, group intervention study to evaluate the effectiveness of a multi-level Heat Education and Awareness Tools (HEAT) intervention, consisting of worker training and a supervisor heat awareness application, on reducing adverse heat health effects in agricultural workers across a growing season.||||
33699541|NCT03061097|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33699542|NCT05034718|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33699543|NCT06556901|||OTHER||RETROSPECTIVE|||||||
33925418|NCT04203940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925419|NCT01488409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925420|NCT00037544||||TREATMENT||||||||
33925421|NCT04466072|||CASE_CONTROL||RETROSPECTIVE|||||||
33925422|NCT05432024|||COHORT||PROSPECTIVE|||||||
33925423|NCT05569616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The research was planned as a pre-test-post-test randomized controlled and single-center study in order to examine the effects of hand massage and play activity on loneliness, comfort and psychological well-being in the elderly.||||
33925424|NCT01894763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925425|NCT06326671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925426|NCT05388955|||COHORT||RETROSPECTIVE|||||||
33925427|NCT02379611|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33925428|NCT04841694|NA|SINGLE_GROUP||OTHER||NONE||||||
33925429|NCT02581670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925430|NCT03223493|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33925431|NCT05376995|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Comparison of Graston technique versus muscle energy technique among patient of knee osteoarthritis||||
34004324|NCT01745068|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34004325|NCT00464139|||COHORT||RETROSPECTIVE|||||||
34004326|NCT03486938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004327|NCT03936894|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single ascending dose pilot trial||||
34004328|NCT02476188|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34004329|NCT02520453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004330|NCT04203433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004331|NCT06629142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34004332|NCT02814708|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Two different doses of rTSST-1 Variant Vaccine were tested in different administrational schedules. These were: a comparison of 10µg versus 100µg rTSST-1 Variant Vaccine administered one, two, or three times.|t|t|t|t
34004333|NCT02324231|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34004334|NCT02118987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004335|NCT02585245|||COHORT||PROSPECTIVE|||||||
34004336|NCT05083754|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34004337|NCT06450925|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004338|NCT05152615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004339|NCT05841524|||COHORT||PROSPECTIVE|||||||
34004340|NCT04743817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004341|NCT01445860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699544|NCT02145585|||CASE_ONLY||PROSPECTIVE|||||||
33699545|NCT00087165||||TREATMENT||NONE||||||
33699546|NCT04439344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699547|NCT04558684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699548|NCT06343233|||COHORT||PROSPECTIVE|||||||
33699549|NCT00698984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699550|NCT02505178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699551|NCT02969109|||OTHER||PROSPECTIVE|||||||
33699552|NCT02815410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004342|NCT05190276|||COHORT||RETROSPECTIVE|||||||
33925432|NCT03027219|||CASE_ONLY||PROSPECTIVE|||||||
33925433|NCT00093756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925434|NCT01126502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925435|NCT04018586|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925436|NCT02932644|||COHORT||PROSPECTIVE|||||||
33925437|NCT02661620|||CASE_ONLY||OTHER|||||||
33925438|NCT03162393|||CASE_ONLY||RETROSPECTIVE|||||||
33925439|NCT00832312|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33925440|NCT01141127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33925441|NCT00744848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33925442|NCT06345599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925443|NCT02249208|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925444|NCT06025903|||CASE_CONTROL||PROSPECTIVE|||||||
33925445|NCT03498118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the participants will be blinded to the medication type, which will be used.|Randomized Controlled Trial|t|f|f|f
33925446|NCT01433120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33925447|NCT05274594|||COHORT||RETROSPECTIVE|||||||
33925448|NCT00003852||||TREATMENT||||||||
33925449|NCT00984529|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925450|NCT03347240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925451|NCT00510068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925452|NCT01062009|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33925453|NCT05771506|||CASE_CONTROL||PROSPECTIVE|||||||
33925454|NCT02313922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925455|NCT02740218|||COHORT||RETROSPECTIVE|||||||
33925456|NCT02833519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33925457|NCT02771457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925458|NCT03405155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925459|NCT01570608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699553|NCT01319357|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33699554|NCT05888077|||OTHER||RETROSPECTIVE|||||||
33699555|NCT04242173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699556|NCT01229371|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33699557|NCT00283231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699558|NCT02084095|||CASE_ONLY||PROSPECTIVE|||||||
33699559|NCT02727413|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33699560|NCT04127942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||access the efficacy of ultrasound-guided PRP injection therapy of TMD, with normal saline used as control group.|t|f|t|f
33699561|NCT03071146|||COHORT||PROSPECTIVE|||||||
33699562|NCT01032174|||CASE_ONLY||PROSPECTIVE|||||||
33699563|NCT00907712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699564|NCT04313842|||OTHER||PROSPECTIVE|||||||
33699565|NCT02754154|||COHORT||RETROSPECTIVE|||||||
33699566|NCT00809848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699567|NCT01298310|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33699568|NCT06302478|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||A quasi-experimental research (two group pretest-posttest design)|t|f|f|f
33699569|NCT04046198|NON_RANDOMIZED|PARALLEL||OTHER||NONE||a non-randomized experimental design with pretest and posttest including intervention and control groups||||
33699570|NCT04470778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699571|NCT00199485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699572|NCT01628172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699573|NCT04398316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699574|NCT02628938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699575|NCT02927327|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699576|NCT01826721|RANDOMIZED|PARALLEL||||NONE||||||
33699577|NCT05380310|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33699578|NCT03064230|||CASE_CONTROL||PROSPECTIVE|||||||
33699579|NCT06009692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699580|NCT00757120|||COHORT||CROSS_SECTIONAL|||||||
33699581|NCT01006369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699582|NCT03714802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699583|NCT04961294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699584|NCT03491215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720358|NCT03305198|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Metabolomic analysis will be performed blinded to the exercise test results|Analysis of changes in metabolomic signature from rest to post exercise||||
33720359|NCT00750711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699585|NCT04863235|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The research assistant who is in charge of conducting the statistical analyses will not be involved in the randomization process or running the intervention or control groups.~Research assistants who will be conducting in-person eligibility and/or follow-up visits (e.g. handing out accelerometers) will be blinded to participant group assignment.~Participants will also be blinded to which group they are randomized into. The investigators will present the study as examining different education interventions to increase physical activity and will not let the participants know whether they are in the intervention or control condition."||t|f|f|t
33699586|NCT00590135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699587|NCT01635335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33925460|NCT03527316|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33925461|NCT02847845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33699588|NCT00194883|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699589|NCT02911038|||COHORT||PROSPECTIVE|||||||
33699590|NCT01595711|||COHORT||PROSPECTIVE|||||||
33699591|NCT05062967|||COHORT||CROSS_SECTIONAL|||||||
33699592|NCT04248751|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Patients that have consented to the study will be randomized into 2 groups with a 50% chance of being in either group. Patients will be blinded and assessed by blinded assessors. Only after the one-year mark will the patient become unblinded following being asked which intervention they believe they received.~Crossover design: Among those 38 patients without augmentation, we anticipate that 23 of them will have re-tear (assuming a 60% re-tear rate). We will offer them revision surgery with augmentation. Then those patients will be followed up 1 year and 2-years afterwards. MRI follow-up will be done at 1 year postoperatively to assess the healing rates. Outcome scores (as per above) will be collected at each follow-up and compared with their non-augmented scores to assess the improvement."|t|f|f|f
33699593|NCT03398200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699594|NCT02734082|||COHORT||RETROSPECTIVE|||||||
33699595|NCT01180101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699596|NCT02247531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699597|NCT05576675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699598|NCT01847742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699599|NCT00140933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33699600|NCT02826278|||COHORT||PROSPECTIVE|||||||
33699601|NCT04915027|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pragmatic RCT with allocation ratio 1:1. The permuted block randomization with stratification at each clinic will be used, with random block sizes between 2-8 to ensure participants randomly assigned to intervention respectively control group. All study participants will be followed-up at two occations, at 3- and 12-months after stroke onset. The patients will be identified by participating outpatient clinics.||||
33699602|NCT00417118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699603|NCT06453954|||COHORT||RETROSPECTIVE|||||||
33699604|NCT06170021|||COHORT||PROSPECTIVE|||||||
33699605|NCT05303077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The 2 infant formula arms are blinded for the participant, investigator and data analyst. The 3rd arm is an open control group conformed by breastfeed infants||t|f|t|f
33699606|NCT00578383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699607|NCT01298635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699608|NCT05972473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699609|NCT03528707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention.||t|f|t|t
33699610|NCT03239184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699611|NCT00137683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699612|NCT04651985|||COHORT||PROSPECTIVE|||||||
33699613|NCT01090284|||COHORT||PROSPECTIVE|||||||
33699614|NCT00398411|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33699615|NCT04737928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699616|NCT03844100|NA|SINGLE_GROUP||TREATMENT||NONE||single arm: patients with refractory functional dyspepsia||||
33699617|NCT05761041|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33699618|NCT00137215|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925462|NCT04467164|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33925463|NCT00816855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925464|NCT03748342|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34004343|NCT02212106|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34004344|NCT06519747|||COHORT||PROSPECTIVE|||||||
34004345|NCT04837833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004346|NCT04771247|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single center, pilot clinical trial||||
34090749|NCT04593602|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||In the stepped-wedge cluster design, there is random and sequential crossover of clusters from control (phase 1) to intervention (phase 2) until all clusters are exposed. The nature of the intervention requires randomization of entire units to the intervention with associated mobility culture change and this precludes a standard randomized controlled trial design (i.e., randomization of some patients to the intervention but not others). The stepped-wedge design allows each site to function as its own control.|f|f|f|t
34090750|NCT04558528|||COHORT||PROSPECTIVE|||||||
34090751|NCT02013414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699619|NCT05224414|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33699620|NCT04118842|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33699621|NCT00171743|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34004347|NCT06077929|||CASE_ONLY||CROSS_SECTIONAL|||||||
33925465|NCT04645823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The parturient and the midwife as well as the researcher doing the interview for analgesia will be masked. The anesthesiologist performing either spinal fentanyl administration or epidural analgesia will not be masked|60 parturients randomized to two different treatment arms (30 in each group)|t|f|t|t
34004348|NCT03399006|||COHORT||PROSPECTIVE|||||||
34004349|NCT05111990|||COHORT||PROSPECTIVE|||||||
33925466|NCT02803619|||COHORT||PROSPECTIVE|||||||
34090752|NCT00230737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090753|NCT01805336|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34090754|NCT04655872|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090755|NCT05759832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925467|NCT05158530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090756|NCT04445649|||COHORT||PROSPECTIVE|||||||
34090757|NCT00113139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090758|NCT00962767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090759|NCT03067415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Assignment|t|t|t|f
34090760|NCT02963324|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090761|NCT01670006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090762|NCT03965650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34090763|NCT02886663|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34090764|NCT00042978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090765|NCT04652648|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090766|NCT03874962|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34090767|NCT03210766|||COHORT||RETROSPECTIVE|||||||
34090768|NCT00898807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090769|NCT04659187|||COHORT||PROSPECTIVE|||||||
34090770|NCT03602001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090771|NCT02211651|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34090772|NCT02757014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699622|NCT00176787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699623|NCT00721123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699624|NCT01030068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699625|NCT05516277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be blinded to group assignment.|Individuals will be assigned to one of two educational programs simultaneously|t|f|f|t
33925468|NCT02639403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699626|NCT05767125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925469|NCT03418064|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925470|NCT01998152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33925471|NCT06034912|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33925472|NCT03611049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two parallel interventions in subjects with vitamin D insufficiency. A low dose vitamin D replacement arm and a high dose vitamin D replacement arm|t|f|t|f
33925473|NCT02590419|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925474|NCT05405907|||CASE_ONLY||RETROSPECTIVE|||||||
33925475|NCT04488081|RANDOMIZED|PARALLEL||TREATMENT||NONE||Platform Trial, Bayesian Design, from 2 arms up to 8 arms||||
33925476|NCT06277583|RANDOMIZED|PARALLEL||OTHER||NONE||Waitlist controlled trials: Participants from both the intervention and waitlist control groups will undergo the intervention 6 months apart.||||
33925477|NCT00976729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004350|NCT03442192|NA|SINGLE_GROUP||PREVENTION||NONE||Changed from randomization to provide PrEP Care Anywhere approach to everyone enrolled to determine differences in engagement, retention and adherence.||||
34004351|NCT02300987|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34004352|NCT06024031|NA|SINGLE_GROUP||TREATMENT||NONE||From the first day after the end of chemotherapy: NAC 400mg tid D1-D28 was added on the basis of routine supportive therapy (blood transfusion)||||
34004353|NCT04736758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090773|NCT00446875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind (subject, Investigator)||t|f|t|f
34090774|NCT02497014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090775|NCT03793153|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34090776|NCT06404528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090777|NCT03135795|NA|SINGLE_GROUP||SCREENING||NONE||||||
34090778|NCT06122545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090779|NCT00859118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090780|NCT05318326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090781|NCT02331420|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34090782|NCT06310629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090783|NCT01627717|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090784|NCT03797612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925478|NCT05289154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomised controlled, confirmatory intervention study with mixed methods approach|f|f|f|t
33925479|NCT03876145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925480|NCT05941663|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The assessment and the measurements were performed by a separate person, not the operator. The patient did not know in which quadrant SLActive® or SLA® implants were placed.|Split mouth design|t|f|t|t
33925481|NCT03820726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925482|NCT01293084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33925483|NCT04048629|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study is an observational cohort study with a baseline assessment, which will be used to conduct a difference in difference (DiD) analysis. The study design allows for assessment in more than one cross-section: 1) intervention clusters will be compared with control and 2) post-intervention clusters will be compared with an earlier baseline condition in control and intervention arms. The intervention (POC compared to centralized VL) is being offered at the facility level, as viral load testing is an intervention that is carried out on a clinic level, rather than at an individual patient level. The study is intended to investigate the effect of offering on-site POC VL testing on the proportion of enrolled PWLHIV who are virally suppressed at the time of delivery.||||
33925484|NCT05859360|||OTHER||CROSS_SECTIONAL|||||||
33925485|NCT03372564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004354|NCT05264831|RANDOMIZED|PARALLEL||TREATMENT||NONE|N/A, open label.|"The study procedure is the electric cardioversion as a discriminant factor between patients requiring PVI procedure alone or PVI procedure combined with substrate modulation. This electric cardioversion will be performed in all included patients up to 6 weeks before the ablative procedure.~On the day of the ablative procedure:~* If the patient presents with a Sinus Rhythm (= successful electric cardioversion, approximately 70% of patients) the patient will be treated as per SoC in accordance with ESC recommendations. It is recommended to perform PVI procedure alone in these patients. A prospective registry for these patients will be established for this study.~* If the patient presents with AF (= failure of electric cardioversion, approximately 30% of patients), randomization will be carried out according to the 2 strategies:~* Group 1: PVI procedure alone in accordance with ESC recommendations~* Group 2: PVI procedure associated with substrate modulation"||||
34004355|NCT02274558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004356|NCT01504087|||CASE_CONTROL||PROSPECTIVE|||||||
34004357|NCT00604916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34004358|NCT04983602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be unaware if the participant was in usual care, comprehensive geriatric assessment arm or the ED PLUS arm||f|f|f|t
34004359|NCT04618484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
34004360|NCT04767087|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34004361|NCT04781322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34004362|NCT05455164|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A Repeated Single-Arm Clinical Trial The aims of this study is to investigate the effect of eucaloric high protein and fiber diet on healthy subjects. Thirteen healthy subjects, age 29,85 ± 4,06 years old, with body mass index (BMI) 29,55 ± 4,12 kg/m2 were prescribed eucaloric high protein diet for two weeks, followed by washing period for two week. Then, they were prescribed with eucaloric high protein and high fiber diet for two more weeks. Twenty grams of dietary fiber were in the form of isomaltooligosaccharides (IMO) based creamer formulae. Their body composition, waist circumference, fasting blood glucose, blood uric acid and total cholesterol concentration were measured after every dietary intervention.||||
34004363|NCT04035954|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will include16 children with cerebral palsy (SP) diagnosed at the GMFCS I-II-III level with 8 controls and 8 treatment groups by random minimization between 7-14 years of age with 1 and 1+ spasticity on the lower extremity according to the Modified Ashworth Score.||||
34004364|NCT05768178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004365|NCT04602585|RANDOMIZED|PARALLEL||TREATMENT||NONE|We will mask participants at the point of randomization. They will pick a piece of paper that dictates which arm they will belong|Participants will be randomized to one of 2 arms. There will be no cross over||||
34004366|NCT05184179|||OTHER||PROSPECTIVE|||||||
34004367|NCT05795231|||COHORT||PROSPECTIVE|||||||
34004368|NCT03605979|||COHORT||PROSPECTIVE|||||||
34004369|NCT06467851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004370|NCT02318550|||OTHER||PROSPECTIVE|||||||
34004371|NCT02771028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004372|NCT04219358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A pharmacist, who will not have contact with the study subjects at any time, will prepare the hydrogels in transparent sealed syringes, which will be numerically coded and two spreadsheets with the codes will be generated and placed in sealed brown envelopes. One envelope will be held by the pharmacist and the other envelope will be placed in a safe place. Participants will not know which medication they received until the end of the experimental phase. The vehicle gel is identical in appearance to those containing imiquimod. If for any reason the information on which treatment has been allocated is required, the external assistant will take all possible measures to ensure that the masking is not broken. The examiners who will perform the treatment and clinical evaluation will be blinded to the experimental group. Primary outcome measure is based on clinical evaluation of lesions by photographs. The images will be coded in order to achieve blindness of outcome assessors.||t|t|t|t
34004373|NCT03981809|||OTHER||CROSS_SECTIONAL|||||||
34004374|NCT01261208|||CASE_ONLY||PROSPECTIVE|||||||
34004375|NCT06237348|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, parallel, Multicenter Randomized controlled trial,||||
34004376|NCT06077617|||OTHER||PROSPECTIVE|||||||
34004377|NCT04580420|NA|SEQUENTIAL||TREATMENT||NONE||||||
34004378|NCT01613794|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34004379|NCT00292591|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004380|NCT00917735|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004381|NCT05541640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004382|NCT01891058|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34004383|NCT06628609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34004384|NCT01120899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004385|NCT01487629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004386|NCT05226741|NA|SINGLE_GROUP||OTHER||NONE||||||
34004387|NCT04106323|||CASE_ONLY||PROSPECTIVE|||||||
34004388|NCT04561336|NA|SINGLE_GROUP||TREATMENT||NONE||combination treatment||||
34004389|NCT03863041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004390|NCT00206180|RANDOMIZED|PARALLEL||||DOUBLE||||||
34004391|NCT00645151|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004392|NCT06378788|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004393|NCT04362332|RANDOMIZED|PARALLEL||TREATMENT||NONE|cluster randomized design|"1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days~2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.~3. Supportive care only."||||
34004394|NCT05898763|NA|SEQUENTIAL||TREATMENT||NONE||A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort||||
34004395|NCT03078257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004396|NCT05155293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004397|NCT01754376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004398|NCT05940233|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"We devide patient into 2 groups, intervention and control group. In intervention group we give the Letrozole 10 mg PO daily at day 1-3 prior to Misoprostol 800 mcg SL in day 4.~In control group we give only Misoprostol 800 mcg SL."||||
34004399|NCT00071019|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004400|NCT05517096|RANDOMIZED|PARALLEL||OTHER||NONE||In the first phase subjects are block randomized (section 7.2) to either eHealth care and explorative observational home-monitoring or only explorative observational home-monitoring during regular care. The second phase is a follow-up period of 3 months to evaluate the effects of eHealth care compared to the control group and how long these effects can last.||||
34004401|NCT02123524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004402|NCT03929809|||COHORT||PROSPECTIVE|||||||
34004403|NCT04108962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090785|NCT03963388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will be blinded for treatment allocation.||f|f|f|t
34090786|NCT02525978|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699627|NCT04879225|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Participants will experience four marketplace conditions that differ in the availability of flavored e-liquids.||||
33925486|NCT03422640|NA|SINGLE_GROUP||TREATMENT||NONE||This is open label single side study involvement 20 patient treated with Apremilast. Each enrolled patient may be evaluated at by a dermatologist using the Lichen Planopilaris Activity Index and Frontal Fibrosing Alopecia Index. Other measures include physician global assessment, dermatology quality of life and patients analogue score for pruritus. Pt will have visits at Week 0,2,4,8,12,16,20,24||||
33925487|NCT03673956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925488|NCT04202978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925489|NCT01711541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925490|NCT02290340|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925491|NCT06270563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925492|NCT01229514|||CASE_CONTROL||PROSPECTIVE|||||||
33925493|NCT05745948|||COHORT||PROSPECTIVE|||||||
33699628|NCT06044389|||OTHER||PROSPECTIVE|||||||
33925494|NCT03817840|||COHORT||PROSPECTIVE|||||||
33925495|NCT02796612|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925496|NCT03525457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925497|NCT03276572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925498|NCT01997697|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33925499|NCT02840526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925500|NCT04628273|||COHORT||PROSPECTIVE|||||||
33925501|NCT02023268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33925502|NCT01256983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925503|NCT00391807|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33925504|NCT00018018||||TREATMENT||||||||
33925505|NCT03902041|||CASE_CONTROL||PROSPECTIVE|||||||
33925506|NCT02859987|RANDOMIZED|PARALLEL||||NONE||||||
33925507|NCT02915991|||CASE_ONLY||PROSPECTIVE|||||||
33925508|NCT00768625|||COHORT||PROSPECTIVE|||||||
34004404|NCT00470860|RANDOMIZED|PARALLEL||||NONE||||||
34004405|NCT04491916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004406|NCT04315324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004407|NCT05793632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090787|NCT01961492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090788|NCT00151515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699629|NCT04902131|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699630|NCT05059639|RANDOMIZED|PARALLEL||OTHER||NONE||forty-eight overweight/non-obese (BMI=24-30) adult (ages 40-65 years) men (n=24) and women (n=24) will be recruited to participate. A randomized, parallel-arm design will be utilized.||||
33699631|NCT02778087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699632|NCT03643159|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33699633|NCT00847470|||||CROSS_SECTIONAL|||||||
33699634|NCT06248060|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Before - After study||||
33925509|NCT00690417|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33925510|NCT04943666|||OTHER||PROSPECTIVE|||||||
33925511|NCT03760276|NA|SINGLE_GROUP||OTHER||NONE||||||
33925512|NCT02627833|||CASE_CONTROL||PROSPECTIVE|||||||
33925513|NCT01192204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33925514|NCT00891761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33925515|NCT06146842|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A Randomized Biased-Coin Sequential Allocation Trial|t|t|t|t
33925516|NCT02274415|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33925517|NCT02970396|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33925518|NCT00621088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925519|NCT04774614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004408|NCT04712916|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants were allocated based on their HbA1c values and blood pressure in to control and intervention groups. Participants were not aware if they were in intervention group or control group as they were not informed.||t|f|f|f
34004409|NCT06531876|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This study incluldes is an observational study of the Dreem 3S as compared to polysomnography in patients with hypersomnia. Arm A (undiagnosed) will include subjects who are being evaluated for a hypersomnia disorder, but do not yet have a diagnosis and are not yet under treatment. Arm B (Narcolepsy Type 1) will recruit subjects with known Narcolepsy Type 1, who will withdraw from their therapy and undergo a 7 night period of longitudinal sleep monitoring with the Dreem 3S device, followed by synchronous recording with polysomnography equipment and the Dreem device (see details).||||
33786762|NCT04393896|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|people living with schizophrenia, family caregivers, psychiatrists and researchers cannot be blinded for the allocated treatment. The program team conducting the intervention will not be involved in assessing any of the outcomes. The analyses of the data by the researcher will be blinded.|This is a stepped-wedge cluster randomized trial. The WeChat-based integrative family intervention (WIFI) program will be implemented in 12 communities affiliated with the Changsha psychiatric hospital through the free medicine delivery process in the 686 Program. The 12 communities will be randomized to one of four fixed sequences every two months during an 8-month intervention period in four clusters of 3 communities each. All clusters will receive the usual financial benefit of the Reward Policy as the control condition, and then successively and in random order, will cross over to the WIFI intervention at 2-month intervals until the study ends.|f|f|f|t
33786763|NCT04570761|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33786764|NCT00768443|||||PROSPECTIVE|||||||
33786765|NCT02728245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33786766|NCT01048151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786767|NCT06134505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786768|NCT06075706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786769|NCT02990858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786770|NCT06152029|||COHORT||PROSPECTIVE|||||||
34004410|NCT00508898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786771|NCT00587132|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33786772|NCT02377362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786773|NCT03666741|||CASE_ONLY||PROSPECTIVE|||||||
33786774|NCT02805387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786775|NCT06109779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind masking||t|t|t|t
33786776|NCT05390476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786777|NCT03681691|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Primary Objective: The primary objective is to determine whether the effects of glucose and ketone body uptake to the brain in response to 8-week administration of transdermal 17β-estradiol differ in postmenopausal women with and without type 2 diabetes.||||
33786778|NCT05020795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786779|NCT04046523|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||"In the first phase of the experiment, a total of 20 healthy controls will test the VO device to determine which camera is the most appropriate for ICP patients and to synchronize the VO, electrocardiogram (ECG), photoplethysmography (PPG), intraocular pressure (IOP) and respiratory signals.~The second phase of the experiment will enroll a total of 70 subjects who are undergoing ICP monitoring with a surgically placed probe will be randomly assigned into one of two groups. Each group will consist of 25 adult and 10 pediatric (aged 4-17) participants. Group A will undergo two inter-leaved examinations (up to 14 days apart). Data from the first exam will be used for SVP-ICP transfer function estimation and data from the second exam will serve for intra-group verification of the estimated transfer function. Group B participants will undergo only one examination and their data will serve as an inter-group re-test verification of the estimated transfer function."||||
33786780|NCT04084769|RANDOMIZED|PARALLEL||PREVENTION||NONE|The laboratory personnel who performed the serology testing were blinded to the group assignment.|Partially-randomized design: all participants primed with MenACYW Conjugate vaccine who meet the inclusion/exclusion criteria were randomly assigned to Group 1, 3, or 4, while participants primed with Menveo vaccine were automatically allocated to Group 2 (not randomized).||||
33786781|NCT04889261|||COHORT||CROSS_SECTIONAL|||||||
33786782|NCT02341989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786783|NCT02435901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786784|NCT00699738|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786785|NCT06629090|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786786|NCT00542386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786787|NCT04379986|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33786788|NCT01501435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786789|NCT05837676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors will conduct outcome assessments at 12-week post-test and 24-week follow-up.|Participants will be randomized 1:1 to either PST-Concussion or treatment as usual (TAU).|f|f|f|t
33786790|NCT06406543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786791|NCT03826693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||placebo-controlled 2:1 randomized clinical trial.|t|f|f|t
33786792|NCT01037933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786793|NCT05649098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786794|NCT01473719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786795|NCT03401398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, families, critical care providers and investigators will be blinded to study drug administration. Only the local performance site research pharmacist will be un-blinded.|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone (maximum 100 mg), followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued. Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule outlined above.|t|t|t|t
33786796|NCT02787967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786797|NCT01428895|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33786798|NCT05700539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004411|NCT06581120|||CASE_CONTROL||PROSPECTIVE|||||||
34004412|NCT01784016|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34004413|NCT02672969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004414|NCT04830982|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004415|NCT02569307|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34004416|NCT06467201|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34004417|NCT03423667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004418|NCT06401434|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34004419|NCT02632682|||COHORT||PROSPECTIVE|||||||
34004420|NCT02657005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004421|NCT03225352|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34004422|NCT02191124|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34004423|NCT00890942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34004424|NCT04640012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
34004425|NCT04560439|NA|SINGLE_GROUP||OTHER||NONE||||||
34004426|NCT06467097|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Control group: A group that undergoes standard treatment alone for metastatic renal cell carcinoma.~2. Experimental group: A group that receives concurrent radiotherapy for all metastatic lesions in addition to standard treatment.~We will compare the one-year progression-free survival rate between these groups, randomized from a random allocation point. Block randomization will be used, with 44 participants randomly assigned to each group using a random number table generated from a web-based program."||||
34004427|NCT06046326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004428|NCT02797379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004429|NCT04415047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004430|NCT03710616|||COHORT||RETROSPECTIVE|||||||
34004431|NCT00142987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34004432|NCT04735588|||CASE_ONLY||PROSPECTIVE|||||||
34004433|NCT00542360|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34004434|NCT00557895|||COHORT||PROSPECTIVE|||||||
33699635|NCT01976676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33699636|NCT04326829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699637|NCT05183815|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004435|NCT03405857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004436|NCT04511572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004437|NCT01119586|||CASE_ONLY||PROSPECTIVE|||||||
34004438|NCT05091086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two parallel group would be selected. One group of participants keep their denosumab treatment for 7 years. Another group of participants accept two cycles of treatment (one year of zoledronate and two years of denosumab) and complete with one year of zoledronate.|f|f|f|t
34004439|NCT01117987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004440|NCT01680016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004441|NCT00891098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090789|NCT04113993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomised to receive either activie treatment or identically packaged placebo|This randomized, double-blind, placebo-controlled, 12-week trial will be conducted at two sites- the lead site is the Monash Alfred Psychiatry research Centre in Melbourne (Investigator - Prof Jayashri KULKARNI) , and a second site in Melbourne - The Monash Medical Centre (Investigator - Prof Suresh Sundram). The trial will follow the parallel comparison design consisting of two arms over 12 weeks (treatment x time). Participants will be screened to ensure inclusion / exclusion criteria are met.|t|t|t|t
34090790|NCT01017250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090791|NCT02859116|||OTHER||PROSPECTIVE|||||||
34090792|NCT01779661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090793|NCT00274456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090794|NCT00739167|||COHORT||PROSPECTIVE|||||||
34090795|NCT04852822|||COHORT||PROSPECTIVE|||||||
34090796|NCT04601506|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||43 Primary Care Clinics will be randomized to be in one of 4 arms: 1) Care as usual, 2) Choice architecture nudge, 3) Prescription Drug Monitoring Program (PMP) Integration \& nudge, 4) Choice architecture nudge + PMP Integration \& nudge|f|f|f|t
34090797|NCT05428865|||OTHER||CROSS_SECTIONAL|||||||
34090798|NCT01318434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090799|NCT03954210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant will be blinded to the participant's intervention group.||f|t|f|f
34090800|NCT05311592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigator will run workshops virtually, through Zoom, and in person. Participants will be randomized either to the virtual condition, or to the in person condition.||||
34090801|NCT00632359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090802|NCT01614223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34090803|NCT04447248|||CASE_ONLY||RETROSPECTIVE|||||||
34090804|NCT04978779|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34090805|NCT00564239|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34090806|NCT02072044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090807|NCT05486728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-Blinded, Parallel, Vehicle-Controlled|t|f|t|f
34090808|NCT01498549|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34090809|NCT05173636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090810|NCT02290418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090811|NCT04656665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34090812|NCT04623151|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"1. Online leaflet about foot care in a narrative format~2. Online leaflet about foot care in a non-narrative format~3. No leaflet (control)"||||
34090813|NCT04892407|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The evaluator is blinded as to patient treatment. Patients are also not told what treatment they receive.|3:1 randomization to either study product or comparator. If subject loses volume in cheek and/or returns to baseline score at or after 12month visit, he/she may be treated with study product.|t|f|f|t
34090814|NCT03155698|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled subjects will be randomized to treatment with microneedling by using dermapen every two weeks while the contralateral side of the body will be treated by microneedling plus topical PRP every two weeks .Then both sides of the body will receive narrowband UVB twice weekly for 6 month,||||
34090815|NCT05401851|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090816|NCT05533190|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention, no blinding of participants will be possible in the study, as all participants will know whether or not they are using the app. Clinical treatment teams will also not be blinded as they will know through the electronic patient record if a participant has received the intervention. The evaluation team will be blinded to treatment using the randomisation algorithm.|Participants will be randomly allocated to the intervention condition or a standard care waitlist control condition.||||
34090817|NCT03695835|||CASE_ONLY||OTHER|||||||
34090818|NCT02278354|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090819|NCT04766333|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34090820|NCT01178931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34090821|NCT06214390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090822|NCT04760626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090823|NCT00123877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090824|NCT04942600|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34090825|NCT06101914|||CASE_CROSSOVER||PROSPECTIVE|||||||
34090826|NCT01199614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090827|NCT01968317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090828|NCT04621201|||COHORT||PROSPECTIVE|||||||
34090829|NCT02871596|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33699638|NCT04327674|||COHORT||PROSPECTIVE|||||||
33720360|NCT04959942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|scapular stabilization and postural correction exercise|t|f|f|t
34090830|NCT00704353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090831|NCT00840125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090832|NCT05649371|NA|SINGLE_GROUP||PREVENTION||NONE||Hybrid implementation-effectiveness study||||
34090833|NCT05986318|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|double-blinded, placebo controlled||t|f|t|f
34090834|NCT01802047|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34090835|NCT05721313|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot cohort study||||
34090836|NCT02595749|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34090837|NCT02077699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090838|NCT05783973|||COHORT||PROSPECTIVE|||||||
34090839|NCT02756520|||COHORT||PROSPECTIVE|||||||
34090840|NCT00532467|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34090841|NCT04448301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720361|NCT01750099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720362|NCT05629390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720363|NCT01170754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34090842|NCT00448045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34090843|NCT01522053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699639|NCT06449521|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|"This is a stepped wedge cluster randomized controlled trial. Since participants will receive routine care when they are not receiving the BECOME intervention (which we will randomly allocate using a stepped wedge fashion), we will blind outcome assessors for the follow-up assessment every three months until 12 months of follow up post intervention.~But, it's important to note that our response to masking outcome assessors cannot be recorded in above option."|"The study will use a stepped-wedge randomized controlled trial design. Randomization process involves sequential rolling out of the intervention in four cluster every three months. Each cluster is a ward (population \~6000), which includes one CHW and at least one basic health care clinic, with regional referrals available to higher levels of care. The 20 wards will be randomly assigned (using a random number generator) to one of five steps. All clusters begin in the control condition; every three months, four clusters will transition to the intervention condition.~Note: We have not seen better option than this one in the drop down menu above."||||
34004442|NCT00039910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33786799|NCT03321760|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase II single-institution trial with a 3 + 3 safety run-in period. SABR will be delivered per protocol, followed by a planned 4 cycles of sequential chemotherapy within 3-8 weeks after the completion of SABR. Four cycles of chemotherapy shall be planned as typically used for adjuvant chemotherapy following surgical resection for T1-2aN1 non-small cell lung carcinoma (NSCLC) unless otherwise indicated by institutional guidelines.||||
34004443|NCT05681819|RANDOMIZED|PARALLEL||OTHER||TRIPLE||SHR-1707 injection compared with placebo|t|t|t|f
33786800|NCT03804411|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33786801|NCT06343558|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786802|NCT04332653|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33925520|NCT06530108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analyse is going to be completed by a independent researcher.|The research will be conducted using randomized controlled, experimental type and single-blindresearch methods. For this purpose, after the data are collected, they will be coded as A and Bgroups, so the researcher who will make the research statistics will analyze the data withoutknowing the study and control groups. Randomization method will be used to determine thegroups. For this, the patients who meet the study criteria and volunteer will be assigned to thegroups using the randomization program 'Random Allocation Software 2.0' according to the orderof hospitalization.|t|f|f|f
33925521|NCT05222295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each patient will be interviewed and evaluated alone, and it will be ensured that they do not coincide with other patients who may be included in the study.|Randomized prospective clinical trial|t|f|f|f
33925522|NCT01062919|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33925523|NCT06117917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925524|NCT06388135|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925525|NCT00812604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925526|NCT00471003|||COHORT||PROSPECTIVE|||||||
34004444|NCT03222037|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34004445|NCT04888533|||COHORT||PROSPECTIVE|||||||
34004446|NCT03868826|||COHORT||PROSPECTIVE|||||||
34004447|NCT02681406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004448|NCT06677931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004449|NCT03547817|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34004450|NCT00001842||||TREATMENT||||||||
34004451|NCT00029211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34004452|NCT05133726|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Stepped edge design||||
34004453|NCT03217526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34004454|NCT02223286|||CASE_CONTROL||RETROSPECTIVE|||||||
34004455|NCT03561558|RANDOMIZED|CROSSOVER||OTHER||NONE|This study is an open label study; the subjects and the investigator will not be blinded towards the identity of the investigational products. However, analysts will be blinded towards identity of investigational products administered.|||||
34004456|NCT05105919|NA|SINGLE_GROUP||OTHER||NONE|All enrolled participants will receive the same treatment.|This is a single arm open-label feasibility phase 1 trial. The aim of the study if to determine the number of potentially eligible participants and the monthly recruitment rate at the MHI (Montreal Heart Institute), the Centre Épic and the IRCM (Institut de recherche clinique de Montréal) as well as participants adherence to study protocol to determine feasibility of a phase 2 trial within these centers.||||
34004457|NCT02197208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004458|NCT00481026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004459|NCT02889302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004460|NCT06229158|||COHORT||PROSPECTIVE|||||||
34004461|NCT06285006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090844|NCT04488952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090845|NCT02702856|||COHORT||PROSPECTIVE|||||||
34090846|NCT01898078|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34090847|NCT00040638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090848|NCT00397241|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34090849|NCT01402856|||COHORT||PROSPECTIVE|||||||
34090850|NCT00968487|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34090851|NCT03276416|||OTHER||PROSPECTIVE|||||||
34090852|NCT02421211|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34090853|NCT04026425|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34090854|NCT06076590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090855|NCT05296278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090856|NCT00153842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090857|NCT00250003|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34090858|NCT04728256|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was a nonrandomized study including a control group for which the post-test procedure was performed alone. The measurements were also repeated at intervals for those in the intervention group. The study intervention group was carried out with a total of 50 pregnant women, 25 of whom were controls.|f|f|f|t
33699640|NCT02350569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699641|NCT04928443|||CASE_CONTROL||PROSPECTIVE|||||||
33699642|NCT01092507|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699643|NCT00347360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699644|NCT02405780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699645|NCT04269707|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open-label, multi-center, multi-national, non-randomized study that will evaluate the efficacy and safety of a one course treatment with FCM in participants who had an unsatisfactory response to oral iron in study 1VIT17044.||||
33699646|NCT01355120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699647|NCT04729621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925527|NCT01907776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925528|NCT05601908|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post-test||||
33925529|NCT01549457|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33925530|NCT06508177|||COHORT||PROSPECTIVE|||||||
33925531|NCT05834101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33925532|NCT02842788|||COHORT||PROSPECTIVE|||||||
33925533|NCT00818896|||CASE_ONLY||PROSPECTIVE|||||||
33925534|NCT02468141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33925535|NCT02281344|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33925536|NCT00385034|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33925537|NCT06428240|||COHORT||PROSPECTIVE|||||||
33925538|NCT03770195|||COHORT||PROSPECTIVE|||||||
33925539|NCT00373412|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33925540|NCT03058848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925541|NCT03688685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925542|NCT02785991|||CASE_ONLY||PROSPECTIVE|||||||
33925543|NCT03791268|||CASE_ONLY||PROSPECTIVE|||||||
33925544|NCT00004226||||TREATMENT||||||||
33925545|NCT02783417|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Resistance Training with Blood Flow Restriction||||
33925546|NCT03911869|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33925547|NCT00858936|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33925548|NCT02856906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925549|NCT01002742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925550|NCT04970849|||OTHER||RETROSPECTIVE|||||||
33925551|NCT03962946|||COHORT||RETROSPECTIVE|||||||
33925552|NCT05903950|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33699648|NCT03815539|NA|SINGLE_GROUP||SCREENING||NONE||||||
33925553|NCT01069367|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33925554|NCT06456138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925555|NCT06425263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||comparison between injection of hyaluronic acids and adipose tissue in temporomandibular joint|t|f|f|t
33925556|NCT01105780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33925557|NCT04271670|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each participant receives all three footbath interventions (warm water only=WA, with added ginger powder=GI, with added mustard powder=MU) in a randomized order stratified by gender. For this, participants are randomly allocated to one of six possible footbath sequences (a: MU-WA-GI, b: MU-GI-WA, c: WA-GI-MU, d: WA-MU-GI, e: GI-MU-WA, f: GI-WA-MU). For the main analysis, groups are pooled together with regard to the intervention received (WA vs. MU vs. GI) after checking for potential carry-over effects.|t|f|f|t
33925558|NCT04232787|||COHORT||PROSPECTIVE|||||||
33925559|NCT01630941|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33699649|NCT02116231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699650|NCT01975051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699651|NCT00768183|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33699652|NCT05829031|NA|SINGLE_GROUP||TREATMENT||NONE||Intra-individually randomized design: Participants will be randomly assigned (50:50) to either the intervention condition or the control condition||||
33699653|NCT04406974|||COHORT||RETROSPECTIVE|||||||
33699654|NCT05677022|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a prospective, longitudinal, single-center, open-label study||||
33699655|NCT05530798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699656|NCT01811225|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33699657|NCT01914757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925560|NCT01874873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925561|NCT02592668|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33925562|NCT05687916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925563|NCT02938546|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33925564|NCT00228943|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33925565|NCT01281189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699658|NCT01078103|||CASE_CONTROL||PROSPECTIVE|||||||
33699659|NCT04275557|||CASE_ONLY||OTHER|||||||
33699660|NCT05392231|||COHORT||PROSPECTIVE|||||||
33699661|NCT01772160|||COHORT||PROSPECTIVE|||||||
33720364|NCT00907985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720365|NCT05280067|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33720366|NCT05289011|||OTHER||PROSPECTIVE|||||||
33720367|NCT00410046|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720368|NCT00385073|||DEFINED_POPULATION||PROSPECTIVE|||||||
33720369|NCT04834635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720370|NCT02438254|||COHORT||CROSS_SECTIONAL|||||||
33720371|NCT02847546|||CASE_ONLY||PROSPECTIVE|||||||
33720372|NCT03367481|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33720373|NCT01034462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720374|NCT02225990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925566|NCT00282867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925567|NCT00951769|||CASE_CONTROL||PROSPECTIVE|||||||
33925568|NCT06310837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925569|NCT03375138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925570|NCT00435357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925571|NCT01732107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925572|NCT05277116|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive a genome informed risk assessment (GIRA) report. Participants designated as high risk based on their genomic risks will be compared to those without such risks for each condition.||||
33925573|NCT05630560|||COHORT||RETROSPECTIVE|||||||
33925574|NCT01306032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925575|NCT06360471|||COHORT||PROSPECTIVE|||||||
33925576|NCT05690672|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33925577|NCT00819104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925578|NCT05599412|||CASE_ONLY||PROSPECTIVE|||||||
33925579|NCT00313755|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33925580|NCT03991182|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925581|NCT04508062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925582|NCT01296698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925583|NCT01875913|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33925584|NCT06380764|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34090859|NCT05115253|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon obtaining consent, eligible participants will be randomly assigned to either of the two intervention groups, a mHealth HAPA group or a JITAI group, or the control group. The study will run for four weeks with the first week acting as a baseline.||||
34090860|NCT03393572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090861|NCT00876395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090862|NCT04697706|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Given the nature of the two arms, it is not possible to blind the participants or investigators.|All participants will undergo the same two study periods. The order of the periods will be randomly assigned to each patient in order to eliminate the possibility of a sequence effect. The study periods can be done in non-consecutive weeks, chosen at the patients' discretion. The periods will each be 1 week in duration.||||
33925585|NCT04016688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind|Parallel Assignment|f|f|f|t
34090863|NCT03854227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Dose Escalation and Dose expansion||||
34090864|NCT04254211|||COHORT||RETROSPECTIVE|||||||
33925586|NCT06020573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090865|NCT05191784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925587|NCT02191280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925588|NCT06046547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925589|NCT03743207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The infants were randomly assigned using the last digit of their hospital identification number to two different groups with different feeding temperatures. Only the nurse giving the primary care was not blinded.||t|f|t|t
33925590|NCT00243685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34004462|NCT06024343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004463|NCT05617131|||CASE_ONLY||PROSPECTIVE|||||||
34004464|NCT04691700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004465|NCT04629339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004466|NCT03945786|||COHORT||PROSPECTIVE|||||||
34004467|NCT04766216|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004468|NCT05768789|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34004469|NCT00646503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004470|NCT03495206||SEQUENTIAL||TREATMENT||NONE||||||
34004471|NCT05426616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
34090866|NCT05475158|||COHORT||PROSPECTIVE|||||||
34090867|NCT04800796|||CASE_CONTROL||PROSPECTIVE|||||||
34090868|NCT03785028|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||basic science||||
34090869|NCT05469490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090870|NCT04085016|||COHORT||PROSPECTIVE|||||||
34090871|NCT04959513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090872|NCT01635140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090873|NCT02522845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090874|NCT03050567|||COHORT||PROSPECTIVE|||||||
34090875|NCT05571254|||COHORT||PROSPECTIVE|||||||
34090876|NCT01687803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34090877|NCT03619525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|numbered, sealed opaque envelope.|sixty patients aged from 18-60 years old, scheduled for elective cardiac surgery with CPB will be included in the study. Patients will be randomly allocated into one of two groups: Group A (n=30): will receive intermittent lung recruitment during CPB.Group B (n=30): control group.|f|f|t|f
34090878|NCT02686411|||COHORT||PROSPECTIVE|||||||
34090879|NCT05727644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090880|NCT05981105|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be randomized to the intervention group (adductor canal catheter, ACC) or control group (sham adductor canal catheterm, ACB). The research staff and participants will be blinded as to which group the participant is in. The primary investigator and co-investigators will not be blinded. The research staff will provide PI and Co-I with an envelope that informs them which group the participant is randomized to so the proper research activities are carried out.|Double-blinded randomized control trial|t|f|f|t
34090881|NCT05882136|||CASE_CONTROL||PROSPECTIVE|||||||
34090882|NCT02327481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090883|NCT01065168|||CASE_ONLY||PROSPECTIVE|||||||
34090884|NCT00228618|||COHORT||PROSPECTIVE|||||||
34090885|NCT03144232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There is a sham rTMS condition that will allow both participants and investigators to be blinded.||t|t|t|t
34004472|NCT04194554|NA|SINGLE_GROUP||TREATMENT||NONE||Time to Event Continual Reassessment Method (TITE-CRM) dose-finding clinical trial design.||||
34004473|NCT04066257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004474|NCT04355572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigators will be blinded to treatment modality until the end of the trial period||t|f|t|f
34004475|NCT03209024|RANDOMIZED|PARALLEL||OTHER||NONE||open, randomized controlled trial||||
34004476|NCT00004441||||TREATMENT||||||||
34004477|NCT04478240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a cluster randomized trial, where assignment to condition occurs at the school level. Randomization of schools to condition (intervention vs. control) occurs at the beginning of the study and there is no cross-over.|f|f|f|t
34004478|NCT06212674|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34090886|NCT03154606|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double-blind|tightly-controlled, randomized cross-over design|t|f|t|f
34090887|NCT02098551|||CASE_ONLY||PROSPECTIVE|||||||
33925591|NCT03179930|NA|SINGLE_GROUP||TREATMENT||NONE||This is a protocol comprised of a multicenter phase II study in FL and HL||||
34090888|NCT06109740|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Matching placebo. Dispensed from pharmacy.|Prospective randomized, double-blind, placebo-controlled crossover trial|t|t|t|f
34090889|NCT04403282|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||randomized, double-blinded, placebo-controlled, paired (right and left neck) comparison study examining eflornithine versus placebo for the treatment of PFB.|t|t|t|t
34090890|NCT06447051|||COHORT||PROSPECTIVE|||||||
34090891|NCT03187470|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34090892|NCT01416051|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34090893|NCT01949259|||COHORT||RETROSPECTIVE|||||||
34090894|NCT05084456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||At least 6 evaluable patients will be included in every of the three groups: a) Controls (Child-Pugh class A with normal biochemical liver tests), b) Child-Pugh class A patients with impaired biochemical liver tests, c) Child-Pugh class B patients. Therefore a minimum of 18 evaluable patients will be included.||||
34090895|NCT01784263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925592|NCT03351478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090896|NCT02761031|||CASE_ONLY||PROSPECTIVE|||||||
34090897|NCT02232347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090898|NCT05820438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090899|NCT01017315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090900|NCT02310594|||COHORT||PROSPECTIVE|||||||
34090901|NCT00025142||||TREATMENT||||||||
34090902|NCT05461495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090903|NCT00578526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720375|NCT02808260|||COHORT||PROSPECTIVE|||||||
33720376|NCT00314015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925593|NCT00898989|||CASE_CONTROL||PROSPECTIVE|||||||
34090904|NCT00308347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090905|NCT05521373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090906|NCT04350502|NA|SINGLE_GROUP||OTHER||NONE||||||
34090907|NCT04729712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The erector spinae plane and paravertebral blocks with catheter insertion will be performed after induction of general anaesthesia and therefore participants will be blinded to which intervention they have had.~The outcome assessors for this study will be unaware as to which group the participant will be randomised to and therefore they will be blinded to which intervention the participant had received."|This will be a multicentre, prospective, double-blinded, randomised controlled clinical trial. This study will take place between three level four academic hospitals in Co.Dublin, Ireland. One group will receive an Anaesthesiologist-administered, ultrasound guided erector spinae plane catheter and the other group will receive a surgeon-administered, video-assisted paravertebral catheter.|t|f|f|t
33720377|NCT02980887|||COHORT||PROSPECTIVE|||||||
33925594|NCT02867722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925595|NCT00432913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720378|NCT02049307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720379|NCT05423652|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33720380|NCT04122898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720381|NCT02045706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720382|NCT02588833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925596|NCT04197024|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Each individual will be evaluated by a traditional test and a virtual reality test.|f|f|f|t
33925597|NCT02527941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33925598|NCT04766983|||COHORT||OTHER|||||||
33925599|NCT00721617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33925600|NCT00602381|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699662|NCT05051995|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The person performing the data collection (assessor) will be blind to the randomization of the participant for the entire duration of the experimental phase.|"To investigate the efficacy of open-label placebo in the reduction of antidepressant discontinuation symptoms, patients experiencing moderate discontinuation symptoms after successful discontinuation (4 weeks) receive open-label placebo treatment or no treatment during the experimental phase (8 weeks).~For this purpose, a series of N-of-1 trials is implemented, consisting of multiple crossover trials within each participant. The factor treatment (open-label placebo vs. no treatment) varies intra-individually with a biweekly rhythm, to assess the treatment effect on discontinuation symptoms. A block-randomization is applied, with patients either receiving (A) open-label placebo or (B) no treatment in a biweekly rhythm (group 1: ABAB; group 2: BABA)."|f|f|f|t
33699663|NCT02854150|||COHORT||RETROSPECTIVE|||||||
33699664|NCT03502096|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The two factors were meal portion size and provision of a to-go container. The portion size factor was within-subjects (crossover). All subjects received each of the 4 portions served (the order in which portions were served was counterbalanced). The container factor was between-subjects. Subjects were randomly assigned to 1 of 2 groups: one group had uneaten food packaged to take home, the other group (control) did not.|t|f|f|f
33699665|NCT00904397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699666|NCT00451451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786803|NCT03679546|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The investigator will proceed to the patient randomization as follows :~* The investigator fulfill the electronic case report form (eCRF)~* The randomization will be performed through the eCRF.~* A mail will be sent to the pharmacy that included the inclusion number of the patient, the group allocated and the dose of infliximab or vedolizumab to be infused.~* A mail will be sent to the investigator that included only the inclusion number of the patient.~The trial is conducted in a double-blind manner. The biostatistician who generated the randomization list, the person in charge of pharmacovigilance, the pharmacy of the clinical trials of the Rennes university hospital and the pharmacist of the recruiting center can have access to the arm of treatment under study.~Patients and physicians will not know the nature of the molecules administered."|A prospective, multicenter, randomized, double blind clinical trial|t|t|t|f
33786804|NCT02678052|||COHORT||PROSPECTIVE|||||||
33786805|NCT06609356|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33786806|NCT01242085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786807|NCT01171924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786808|NCT00102414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786809|NCT05629598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786810|NCT04871607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786811|NCT03181724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786812|NCT05741944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33786813|NCT06321419|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Batched stepped-wedge cluster randomised trial. We will roll out the interventions to 30 clusters over six batches, so there will be five clusters in each batch. The clusters in each batch will be randomised to one of five implementation sequences, with one hospital randomised to each implementation sequence. All clusters will transition through three phases, first a standard care phase, then a one month transition phase during which the training is delivered, and finally an intervention phase, for a total of 13 months.||||
33786814|NCT04483843|||CASE_ONLY||RETROSPECTIVE|||||||
33925601|NCT00429390|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925602|NCT02858102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925603|NCT03720301|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient and Intubating Anesthesiology provider are blinded to subjects randomization into the sham treatment or protocol treatment arm of the study|Double blinded, randomized, sham controlled prospective|t|t|f|f
33925604|NCT02762799|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33925605|NCT03524911|NA|SINGLE_GROUP||PREVENTION||NONE||Delayed intervention||||
33925606|NCT00606853|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33925607|NCT03514004|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33925608|NCT03156855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925609|NCT00717002|||CASE_ONLY||CROSS_SECTIONAL|||||||
33925610|NCT02855112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090908|NCT01414296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699667|NCT06557915|||CASE_ONLY||PROSPECTIVE|||||||
33699668|NCT00607815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33699669|NCT03834727|||OTHER||CROSS_SECTIONAL|||||||
33699670|NCT03320317|||OTHER||PROSPECTIVE|||||||
33786815|NCT01802229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33786816|NCT02992275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786817|NCT04511663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind method was used, in which all the assessments were independently completed by trained psychiatrists who didn't know the grouping.||f|f|f|t
33925611|NCT00767351|||CASE_ONLY||PROSPECTIVE|||||||
33925612|NCT06134869|NA|SINGLE_GROUP||OTHER||NONE||||||
33925613|NCT01376362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090909|NCT02065557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090910|NCT01965873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090911|NCT01113749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34090912|NCT01432327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925614|NCT06037213|||COHORT||PROSPECTIVE|||||||
33925615|NCT03990259|||COHORT||CROSS_SECTIONAL|||||||
33925616|NCT03949998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925617|NCT02685787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090913|NCT04443829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090914|NCT05892198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090915|NCT05969691|NA|SINGLE_GROUP||OTHER||NONE||||||
34090916|NCT01067235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090917|NCT04007900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090918|NCT00896259|||CASE_CONTROL||PROSPECTIVE|||||||
34090919|NCT03834298|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090920|NCT03591419|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004479|NCT04409587|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an unblinded study as the two basal insulin delivery methods (degludec via injection vs. aspart via CSII) cannot be blinded. One group of patients will first use degludec for 20 weeks then switch to CSII for 20 weeks. As all eligible patients who sign the IRB consent form are identified, a random number will be generated to determine the treatment with which they begin first. The other group of patients will start with CSII and after 20 weeks switch to Tresiba for 20 weeks. Randomization sequence will be determined by computerized randomization program. All patients will receive both treatments unless they drop out. Dropouts are unlikely since the participants are all regular continuing patients of the site's clinical practice.|This will be a randomized, cross-over, open label, single-center study consisting of a 20 week period on each of two basal insulin delivery methods, both in combination with insulin aspart with boluses taken by insulin pump. Each 20 week period will consist of a 4 week insulin optimization period for titration of basal and bolus insulin doses, followed by a 16 week maintenance period. The final 2 weeks of the maintenance period during each treatment arm will be used for endpoint data collection. The treatment sequence will occur in random order. The study population will include patients with type 1 diabetes with good baseline glycemic control who are experienced in the use of both Continuous Subcutaneous Insulin Infusion and Continuous Glucose Monitor; the cross-over design allows each subject to serve as his or her own control.||||
34004480|NCT00137202|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34004481|NCT00133367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004482|NCT02962089|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34004483|NCT01874977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004484|NCT03017352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004485|NCT01109017|||COHORT||PROSPECTIVE|||||||
34004486|NCT05317195|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34004487|NCT01857973|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||subjects undergo treatment with the hybrid closed loop system under various experimental conditions||||
34004488|NCT02990078|||COHORT||PROSPECTIVE|||||||
34004489|NCT00497588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004490|NCT01093196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004491|NCT03816436|||COHORT||RETROSPECTIVE|||||||
34090921|NCT04717440|||COHORT||PROSPECTIVE|||||||
34090922|NCT02666599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34090923|NCT03831724|NA|SINGLE_GROUP||OTHER||NONE||||||
34090924|NCT00441389|||NATURAL_HISTORY||PROSPECTIVE|||||||
34090925|NCT03132896|||COHORT||PROSPECTIVE|||||||
34090926|NCT01363622|||CASE_CONTROL||PROSPECTIVE|||||||
34090927|NCT02056678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090928|NCT01680913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925618|NCT04323423|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||randomized crossover trial and reported in accordance with CONSORT guidelines. The study will involve a total of three seven-day conditions (2 experimental and 1 control) with a three-week washout period in-between to minimize practice effects for a total intervention period of nine weeks. Each condition will consist of one day supervised in the laboratory followed by six at-home days, following lab protocol as closely as possible.|f|f|f|t
33925619|NCT04639843|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33925620|NCT01989819|||COHORT||PROSPECTIVE|||||||
33925621|NCT05315141|||COHORT||PROSPECTIVE|||||||
33925622|NCT06376929|RANDOMIZED|CROSSOVER||SCREENING||NONE||randomized controlled||||
34090929|NCT01047501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699671|NCT05616273|||COHORT||PROSPECTIVE|||||||
33699672|NCT03724786|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33699673|NCT01634061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925623|NCT04874844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase II open label non-randomizedand ;Phase III randomized|Phase II single ;Phase III parallel|t|t|t|t
33925624|NCT04396288|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33925625|NCT02596685|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34090930|NCT04155554|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit||||
34090931|NCT00445718|||CASE_ONLY||PROSPECTIVE|||||||
34090932|NCT00002308|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34090933|NCT04329455|||COHORT||PROSPECTIVE|||||||
34090934|NCT02713620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090935|NCT04383678|||COHORT||RETROSPECTIVE|||||||
34090936|NCT04653883|||COHORT||RETROSPECTIVE|||||||
34090937|NCT05542641|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34090938|NCT00351247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090939|NCT04664114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized controlled experimental study. The study intervention group was carried out with a total of 100 pregnant women, 50 of whom were controls.||||
34090940|NCT01926535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34090941|NCT00696527|||COHORT||PROSPECTIVE|||||||
34090942|NCT02805491|||CASE_CONTROL||PROSPECTIVE|||||||
34090943|NCT05415007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34090944|NCT03787407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Healthy individuals recruited through advertisement||||
34090945|NCT00580086|||CASE_ONLY||RETROSPECTIVE|||||||
34090946|NCT02456064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34090947|NCT00007748|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34090948|NCT03834012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind double-dummy design for the test product and placebo for primary endpoint analysis. Evaluator blinded reference product||t|t|t|t
34090949|NCT03116867|||COHORT||PROSPECTIVE|||||||
34090950|NCT06249971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization only known to the surgeon and burn care coordinators, not the patient.|A prospective, randomized, controlled, intra-individual, single-blinded study in a mono-center setting|t|f|f|f
34090951|NCT02517788|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33699674|NCT04828239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The recruited patients were randomly divided into two groups of ''Laser Acupuncture Group'' and ''Manual Acupuncture Group"|f|f|f|t
33699675|NCT02486666|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot study||||
33699676|NCT01923987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720383|NCT00966173|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720384|NCT05704309|||COHORT||PROSPECTIVE|||||||
33720385|NCT01820481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925626|NCT02918656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33925627|NCT00789295|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925628|NCT01195194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925629|NCT01248403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925630|NCT02916810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925631|NCT05098418|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33925632|NCT06218199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925633|NCT02452710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699677|NCT03051750|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The statistical analysis will be supervised by staff of the Scientific Support Unit: Epidemiology and Biostatistics (i+12), Hospital Universitario 12 de Octubre with the variables coded to blind the analyst.|"3-month previous washout period; 3-week treatment phases; 3-month washout period between both treatment phases.~Open design: it is impossible during the treatment to blind the physiotherapists and patients, due to the observable differences between both therapies both during their application and in the hours after their removal, by the marks that leave in the skin.~Interventions: The two therapies compared are:~* CPT+ P.~* KT."|f|f|f|t
33699678|NCT02947555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004492|NCT05390398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The nature of the intervention does not allow for blinding of the participants or researchers. The baseline measurements are however blinded as both the participant and the researchers do not yet know in which group the participant will be classified. Randomization is done directly after the baseline measurements. After data collection, the database will be coded by an independent researcher to ensure that data analysis is conducted in a blinded way.|Randomized controlled trial with two parallel arms: intervention and control.|f|f|f|t
33699679|NCT01807039|||COHORT||RETROSPECTIVE|||||||
33699680|NCT00513656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004493|NCT04056663|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34004494|NCT05381051|||COHORT||RETROSPECTIVE|||||||
34004495|NCT04139863|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34090952|NCT06530329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34090953|NCT05548907|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial where participants are allocated to either a sleep restriction treatment condition or a sleep monitoring control condition. All participants keep a daily sleep diary and fill out weekly questionnaires||||
34090954|NCT06544538|||COHORT||RETROSPECTIVE|||||||
34090955|NCT00923312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090956|NCT02556450|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34090957|NCT03817983|||CASE_CONTROL||PROSPECTIVE|||||||
34090958|NCT05893641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090959|NCT04581512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090960|NCT02558569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34090961|NCT01068990|||COHORT||PROSPECTIVE|||||||
34090962|NCT06134700|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded.||t|f|f|f
34090963|NCT04370197|||CASE_ONLY||OTHER|||||||
34090964|NCT02520973|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34090965|NCT01288430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090966|NCT03801252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|One arm includes double placebo drugs that will be blinded from the investigator and participant|Randomized controlled clinical trial|t|t|t|f
34090967|NCT00485303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090968|NCT01940588|||CASE_ONLY||PROSPECTIVE|||||||
34090969|NCT06265025|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and dose expansion||||
34090970|NCT02826473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34090971|NCT05411978|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33699681|NCT01997853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699682|NCT04668573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925634|NCT03363919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In both phases of the study (phase I and phase II) participants and study team members completing clinical rating scales will be blinded to treatment assignment. The study team member completing clinical rating scales and analyzing TMS neurophysiology measures will not be allowed in the treatment suite during therapeutic rTMS sessions (10 Hz, 1 Hz, iTMS, or cTBS).||t|t|f|f
33925635|NCT05081817|||OTHER||PROSPECTIVE|||||||
33925636|NCT04443296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925637|NCT02562989|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925638|NCT00578604|||COHORT||PROSPECTIVE|||||||
34004496|NCT06468202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither participants, providers, investigators or outcome assessors will know to which of these groups participants are assigned. In case of an emergency, however, the study doctor can get this information.|A randomized double-blind, multicenter, comparative effectiveness trial|t|t|t|t
34004497|NCT03620617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34004498|NCT03336879|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomized, open label study||||
34004499|NCT04039490|RANDOMIZED|PARALLEL||OTHER||NONE|Because the SCENERGY is an attachment to the ultrasound probe, it cannot be masked.|two-arm study, comparing ultrasound-only pediatric vessel cannulations versus SCENERGY-guided pediatric vessel cannulations||||
34004500|NCT04445233|||COHORT||PROSPECTIVE|||||||
33925639|NCT02260895|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34090972|NCT02249325|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090973|NCT03100747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090974|NCT03514797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090975|NCT03003468|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34090976|NCT03579511|||OTHER||CROSS_SECTIONAL|||||||
34090977|NCT03846375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Control group only at pre-intervention.|Naturalistic cohort pre-post study. However, we also include a matched control sample of healthy controls to complete the battery of measurements at pre-intervention assessments.||||
33699683|NCT06083077|NA|SINGLE_GROUP||TREATMENT||NONE||"Infant will be recorded successively in 6 conditions (10 min each) :~* Without chest wall strapping at PEEP (Positive End Expiratory Pressure) 0 and PEEP 7~* With chest wall strapping at PEEP 0 and PEEP 7~* again without chest wall strapping at PEEP 0 and PEEP 7."||||
33699684|NCT01422174|||COHORT|||||||||
33699685|NCT04288752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial will be double-blind, meaning the subject and Investigator/staff will not have access to or knowledge of the subject's treatment assignment. Further, since the Sponsor will securely maintain the randomization schedules, the Sponsor and Sponsor's representatives will not be made aware of a given subject's randomization arm until the blind is broken. The Sponsor will ensure that the Study Monitor does not ever have access to the randomization assignments.|Randomized, double-blind, sham-controlled, 4-week parallel group study|t|t|t|t
34090978|NCT01194310|||COHORT||RETROSPECTIVE|||||||
34090979|NCT03456323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research coordinator who makes the baseline assessment and outcome assessments will be blinded to treatment allocation.|Older survivors of acute respiratory failure and their surrogates (i.e., patient-surrogate pairs, n = 80 participants total) will be randomized to an inpatient palliative care consultation versus usual care in a 1:1 ratio (i.e. 20 patient-surrogate pairs (40 participants total) in each study arm) once enrolled patients are registered to be transferred from the ICU to the general ward.|f|f|f|t
34090980|NCT02110693|NA|SINGLE_GROUP||SCREENING||NONE||This study examined the accuracy of a substance abuse screening test compared to gold standard measures Participants all received the experimental screening instrument (via self- and tablet computer administration. The order of administration was randomly selected in order to control for an order effect.||||
34090981|NCT03474575|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective and Biomedical Research excluding Health Product||||
34090982|NCT04135534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34090983|NCT01146483|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34090984|NCT04501692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|device for intubation may not be blinded for provider or investigator.|randomized 1:1|t|f|f|f
34090985|NCT03830606|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with untreated advanced biliary tract adenocarcinoma||||
34090986|NCT00884988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090987|NCT01732900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34090988|NCT04736433|||COHORT||RETROSPECTIVE|||||||
34090989|NCT01859819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34090990|NCT01073475|||COHORT||PROSPECTIVE|||||||
34090991|NCT04179682|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33925640|NCT00623285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925641|NCT00654953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34090992|NCT06520280|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Group I: First, patients will receive maxillary and mandibular complete dentures constructed by polyamide thermoplastic resin. Group II: First, patients will receive maxillary and mandibular complete dentures constructed by 3D printed|t|t|t|f
34090993|NCT00891397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699686|NCT06426433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699687|NCT05015439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699688|NCT02548533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699689|NCT04976062|||COHORT||PROSPECTIVE|||||||
33925642|NCT03410134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925643|NCT02091921|NA|SINGLE_GROUP||SCREENING||NONE||||||
33925644|NCT05007223|||CASE_CONTROL||PROSPECTIVE|||||||
33925645|NCT05090683|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants in the control group will be aware that they have are serving as controls that have been wait-listed for access to the mobile application.|Participants will be randomized into one of two groups: control (usual care, waitlisted) or intervention group (6-week mind-body mobile application use). Randomization will be stratified on pain intensity and gender using computer generated block randomization to create varying block sizes of 4 and 8.||||
33925646|NCT01186003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925647|NCT05216913|||COHORT||PROSPECTIVE|||||||
33925648|NCT00220584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925649|NCT02048267|||COHORT||PROSPECTIVE|||||||
33925650|NCT04101669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Investigators include interventional gastroenterologists (GI) and endocrinologists. The GI team: MD, PA and site coordinator, as well as radiology personnel will not be masked, while the endocrinologist team: the MDs, PAs, site coordinators and nutritionists, will be masked. The patient is also masked.|A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System. Patients will be randomized 3 (RESET):1 (Sham).|t|t|f|t
33786818|NCT05996133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"This is a double-blinded study, patients, research coordinators who collect data, spine surgeons, and other health care providers will all be blinded to the study group assignments to minimize bias and maximize the validity of study results. The block-performing anesthesiologists/investigators, the block nurse, and the senior scientist will not be blinded to the study group assignments.~Patients will not be unblinded after they complete the study or during the study unless a participant experiences a serious adverse event that is unexpected and related to the study intervention (MCP or sham block) and the course of treatment needs to be adjusted. Unblinding in this situation will be the decision of the principal investigator (PI). The PI will contact the Senior Scientist to get the patient's group assignment, and the PI will then unblind the patient (i.e., tell the patient about the assigned group), and take any additional necessary course of treatment."|Single-center, prospective, double-blinded, randomized controlled trial|t|t|f|f
33786819|NCT05755035|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study consists of crossover randomized epoch (participants aged \>=16 years) and single arm epoch (participants aged 2 to \<16 years).||||
33786820|NCT05312541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be done by computer generated numbers and concealed by serially numbered, opaque and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. Prior to surgery the appropriate numbered envelopes will be opened by the nurse, the card inside will determine the patient group.||f|f|t|t
33786821|NCT02885051|NA|SINGLE_GROUP||OTHER||NONE||||||
33786822|NCT02228811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786823|NCT03452306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|four-way crossover||||
33786824|NCT04732676|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"After randomization, the application will be installed on participant's smartphone (or smartphone loaned for the study).~Randomization code will unlock one of the 2 versions of the application:~* Restricted version (only EMA) for control group~* Full interventional (active) version (EMA + EMI) for experimental group"|This study is a randomized controlled trial comparing two parallel groups. This is a comparative study of superiority that evaluates the efficacy of using an interventional smartphone application,in reducing main problematic substance use/addictive behavior after 4 weeks, and after 4 months among participants requesting treatment for substance or behavioral addiction.|t|t|t|f
33786825|NCT02721511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786826|NCT00715390|||COHORT||RETROSPECTIVE|||||||
33699690|NCT04708379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699691|NCT04743076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33699692|NCT01052376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699693|NCT01039870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786827|NCT04544995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study.|||||
33786828|NCT06222619|||COHORT||RETROSPECTIVE|||||||
33786829|NCT01268345|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33786830|NCT00388011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786831|NCT03244176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786832|NCT03022903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786833|NCT02801110|||COHORT||PROSPECTIVE|||||||
33786834|NCT00535067|||CASE_ONLY||PROSPECTIVE|||||||
33786835|NCT04385342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786836|NCT05427357|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33786837|NCT05693155|||OTHER||CROSS_SECTIONAL|||||||
33925651|NCT04075539|RANDOMIZED|PARALLEL||TREATMENT||NONE|single-blind|||||
33925652|NCT06184542|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|In this study, participants are blinded, and part of the investigators are blinded.|Three stages (Children, Toddlers, and Infants) will be conducted according to the age-escalating principle. If safety assessed by DSMB meets the criteria, then the enrollment of the next stage could be continued.|t|f|f|f
33925653|NCT04411706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925654|NCT04635891|||COHORT||PROSPECTIVE|||||||
33925655|NCT00003340||||TREATMENT||||||||
33925656|NCT00654212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33699694|NCT01572350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699695|NCT03897023|||COHORT||PROSPECTIVE|||||||
33699696|NCT01988220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699697|NCT04442113|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33699698|NCT04232774|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center, non-randomized, open label first-in-human (FIH) study.||||
33925657|NCT03001323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925658|NCT06506838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925659|NCT04356209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925660|NCT03671772|||CASE_CONTROL||PROSPECTIVE|||||||
33925661|NCT01485432|||OTHER||PROSPECTIVE|||||||
33720386|NCT03032367|RANDOMIZED|CROSSOVER||OTHER||NONE||"Participants are randomized to receive study drug (bedaquiline (BDQ)) in either tablet form or crushed form in one of two sequences:~Sequence 1: BDQ 4 x 100mg administered in a whole tablet form, followed by BDQ 4 x 100mg administered in crushed form as a once only dose~Sequence 2: BDQ 4 x 100mg administered in crushed form, followed by BDQ 4 x 100mg administered in tablet form as a once only dose"||||
33699699|NCT03216187|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"study drugs (including identical placebos) and randomisation lists are prepared by the hospital pharmacy and are kept secret from the investigators until the end of the study and the freezing of the electronic data base (an interim analysis will be performed when data for the primary outcome are available for 60 patients per arm. Stopping rules are a difference in the incidence of the primary outcome of less than 8.2% (futility) or more than 19.9% (superiority))."|double-blinded, randomized, placebo-controlled trial|t|t|t|t
33699700|NCT00881257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699701|NCT02798146|NA|SINGLE_GROUP||OTHER||NONE||||||
33699702|NCT02325648|||CASE_ONLY||PROSPECTIVE|||||||
33699703|NCT02234570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699704|NCT05623839|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33699705|NCT00993993|||CASE_ONLY||PROSPECTIVE|||||||
33699706|NCT03584061|NA|SINGLE_GROUP||TREATMENT||NONE||The five patients included will all receive a fat graft in the area affected by PHN.||||
33699707|NCT00299351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699708|NCT03349931|||COHORT||PROSPECTIVE|||||||
33699709|NCT00839852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699710|NCT01275456|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33699711|NCT03864770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699712|NCT02160990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699713|NCT03307785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699714|NCT03239600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized, double blind (sponsor unblind) study and masking will be performed.|This is a parallel assignment where in Part II of the study, randomized subject will receive GSK2618960 and placebo drug simultaneously.|t|t|t|t
33699715|NCT05215886|||CASE_ONLY||CROSS_SECTIONAL|||||||
33699716|NCT04597229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004501|NCT01448148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34090994|NCT04612400|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|This will be a double-blinded study. Both SP amounts are dissolved into equal volumes of water so that subjects will not know which amount they are ingesting. Blood samples are coded so that lab staff and investigators will not know which amount of SP was consumed at each visit. Investigators will be unblinded after all samples have been processed and data analysis has taken place.|double-blinded, randomized, crossover pilot study|t|f|t|f
34090995|NCT00872118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090996|NCT01682525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090997|NCT05399771|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||20 healthy subjects with intact skin on their lower legs that meet inclusion criteria - Participants will serve as their own control, by heating one leg and no the other.||||
33699717|NCT00406718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699718|NCT00068328|||CASE_ONLY||PROSPECTIVE|||||||
33699719|NCT04156360|||COHORT||PROSPECTIVE|||||||
33699720|NCT00922233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33699721|NCT03760055|||COHORT||PROSPECTIVE|||||||
33786838|NCT03093610|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The operating surgeon does not know to which group the Patient will be attributed to.|Group 1: Removal of the chest tube after air leakage has ceased and fluid Drainage is \< 200ml/24h Group 2: Removal of the chest tube after air leakage has ceased and fluid Drainage is \< 5ml/kg/24h|f|t|f|f
33786839|NCT00664846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786840|NCT04472767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786841|NCT00631917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004502|NCT05210712|||COHORT||PROSPECTIVE|||||||
34004503|NCT03393481|NA|PARALLEL||PREVENTION||SINGLE|Open-label, blinded endpoint assessment||f|f|f|t
33699722|NCT03599388|NA|SINGLE_GROUP||OTHER||NONE||||||
33699723|NCT01601132|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699724|NCT04135742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699725|NCT03830632|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel Assignment|t|f|f|f
33699726|NCT04569656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699727|NCT02708901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double blind study of dietary supplement compared to placebo|t|t|t|t
33786842|NCT04842461|||CASE_CONTROL||PROSPECTIVE|||||||
33786843|NCT01346605|||||PROSPECTIVE|||||||
34004504|NCT00359671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699728|NCT01453725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699729|NCT06275009|||COHORT||PROSPECTIVE|||||||
33699730|NCT01436396|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|To ensure that objective safety data were obtained, the trial was designed using an observer-blind methodology since the products were visually different and may be recognized. For first trial vaccination (V01), the person who administered the injections knew which products were administered while either the participant or parent nor the Investigator in charge of safety evaluation knew which products were administered.||t|f|t|t
33699731|NCT04833673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Three Arms Randomized Trial||||
33699732|NCT02606084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699733|NCT04348643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004505|NCT05696509|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34004506|NCT05108259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004507|NCT04736862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34004508|NCT05553587|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, open label, non-randomized study||||
34004509|NCT03601494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004510|NCT03799848||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34004511|NCT00784979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004512|NCT04329182|||CASE_ONLY||CROSS_SECTIONAL|||||||
34004513|NCT01531257|||COHORT||PROSPECTIVE|||||||
34004514|NCT04413162|NA|SINGLE_GROUP||OTHER||NONE||||||
34004515|NCT03604432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34090998|NCT01155141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34090999|NCT04585542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and ER physicians are blinded to study drug allocation.||t|t|f|f
34091000|NCT01186406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786844|NCT00433810|||COHORT||PROSPECTIVE|||||||
33786845|NCT00387062|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33786846|NCT06460519|||COHORT||PROSPECTIVE|||||||
34091001|NCT03757923|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trail||||
33786847|NCT02309567|||CASE_CONTROL||PROSPECTIVE|||||||
33786848|NCT00227981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786849|NCT04731610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786850|NCT05623995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786851|NCT03459183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not know their group assignment (ultrasound - verum, ultrasound - placebo; infrasound - verum, infrasound - placebo).||t|f|f|f
33786852|NCT05709457|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33786853|NCT03752515|||COHORT||PROSPECTIVE|||||||
33786854|NCT04887688|RANDOMIZED|PARALLEL||TREATMENT||NONE||"At the baseline assessment, the wound dressing will be removed and wound status will be evaluated. Participants will then be randomly assigned to the intervention group (Group A) or control group (Group B).~Progressive changes in wound size, indicative of wound healing, will be determined using 3D digital stereophotogrammetry (LifeViz 3D system, Quantificare Inc., San Mateo, CA) together with wound swabs to collect wound bed fluid. The study cohort will comprise Veterans with ischemic wounds."||||
33786855|NCT00106431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786856|NCT01802203|||COHORT||PROSPECTIVE|||||||
34004516|NCT03417739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004517|NCT00919334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004518|NCT01157234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004519|NCT01380587|||COHORT||PROSPECTIVE|||||||
34004520|NCT05540522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34004521|NCT06248645|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34091002|NCT00927472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091003|NCT01750502|||COHORT||PROSPECTIVE|||||||
34091004|NCT00288821|||COHORT||PROSPECTIVE|||||||
34091005|NCT05112133|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091006|NCT03987048|||COHORT||RETROSPECTIVE|||||||
34091007|NCT03625674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091008|NCT05311969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091009|NCT06398587|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34091010|NCT04503005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091011|NCT00118287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091012|NCT01750346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091013|NCT03907436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will not be told which diet arm they are randomized to. Participants will not be told the two options are USDA or Mediterranean, only there are two healthy diets."|Participants will be randomized to one of two healthy diets (USDA or Mediterranean diet)|t|f|f|f
33786857|NCT06368180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Robotic-assisted gait training Body weight-supported treadmill training|t|t|t|t
33786858|NCT05650333|NA|SINGLE_GROUP||OTHER||NONE||||||
33786859|NCT02827162|||CASE_CONTROL||PROSPECTIVE|||||||
34004522|NCT00132834|||CASE_CONTROL||PROSPECTIVE|||||||
34004523|NCT02302716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004524|NCT04668274|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34004525|NCT06002178|||COHORT||PROSPECTIVE|||||||
34004526|NCT04187950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the order in which they receive the study treatments.|Randomized, controlled, single-blind, crossover study with two 2-week treatment conditions separated by at least a 4-week washout period between conditions. Participant flow through the study conditions will be counterbalanced. Participants will be randomly allocated to yogurt with honey first or control first.|t|f|f|f
34004527|NCT05287087|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|"We will inform GPs about the possibility of being assigned to one of two interventions expected to have each their advantages and disadvantages, hence being of equal value to patients. The GPs will know the content of their assignment but will not be informed about the specific content of the other intervention. Enrolled patients will only be informed whether they are to use the programme My Symptoms 1 or My Symptoms 2 accessed via a website.~Outcome assessment and data analyses in this feasibility study conducted by the project researchers will not be blinded."||t|t|f|f
34004528|NCT00857818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004529|NCT02086344|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004530|NCT02762994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004531|NCT00676741|||COHORT||PROSPECTIVE|||||||
34004532|NCT03055741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699734|NCT00316992|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33699735|NCT06167564|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Group of adult participants with IgE-dependent allergic reactions. Routine blood serum IgE levels will be compared with the newly developed microarray-based diagnostic test system.||||
33699736|NCT00722332|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33699737|NCT02827227|||COHORT||PROSPECTIVE|||||||
33699738|NCT06503055|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33699739|NCT02108782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004533|NCT02304978|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33699740|NCT02884882|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33786860|NCT00000821||||TREATMENT||||||||
34004534|NCT00003404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004535|NCT05424250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004536|NCT05066568|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|Blinding: The researcher will receive a device previously programmed by a research assistant. This way the researcher that perform the Transcranial direct current stimulation does not know if it's a active or sham intervention. The subjects will also be blinded to the nature of the stimulation. The subjects will be asked to answer what intervention they think they recieved after each one of the tDCS sessions.|Design: Randomized blinded factorial sham controlled clinical trial|t|t|t|f
33786861|NCT04375644|||COHORT||PROSPECTIVE|||||||
34004537|NCT04506320|||COHORT||RETROSPECTIVE|||||||
34004538|NCT02568280|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34004539|NCT02913131|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34004540|NCT06667141|NA|SEQUENTIAL||TREATMENT||NONE||"Dose escalation - Evaluable participants for dose limiting toxicity (DLT), maximum tolerated dose (MTD) determination for ACR-2316 administered per schedule A.~Dose expansion - participants with certain tumor types will be randomized 1:1 to receive1 of the 2 dose levels that will be selected for the determination of RP2D."||||
34004541|NCT03819920|RANDOMIZED|PARALLEL||PREVENTION||NONE||Usual care of generalized colorectal cancer screening education over telephone versus personalized risk assessment over telephone using National Cancer Institute Colorectal Cancer Risk Assessment Tool (CCRAT)||||
34004542|NCT03850964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Project Manager in operation will also be masked.|"After at least a 6-week baseline period, participants will be assigned low dose pazopanib (150 mg) or placebo.~At the termination of the 24-week Efficacy study participants will be provided the option to advance into an open label extension program including 24 weeks of treatment, followed by a 12-week non-drug follow up period. The extension would be on active drug, but otherwise blinded to the dose provided in the primary trial.~This decision to continue into the extension will be based on a physician-participant discussion of any efficacy and safety concerns at week 24. A decision would be reached whether to proceed into the extension study and whether to consider a dose modification. A top dose of 150 mg will be maintained.~After the extension, a 12 week follow-up time period will continue assessments to define maintenance of effect, and/ or relapse."|t|t|t|t
34004543|NCT06202534|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33786862|NCT02703129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786863|NCT00702429|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786864|NCT00124826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33786865|NCT02095158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786866|NCT04543513|NA|SINGLE_GROUP||OTHER||NONE||||||
34004544|NCT01143831|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34004545|NCT01486108|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34004546|NCT05427045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004547|NCT02740907|||CASE_ONLY||RETROSPECTIVE|||||||
34004548|NCT02498691|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34004549|NCT04621656|||CASE_CONTROL||PROSPECTIVE|||||||
33699741|NCT04148690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|the outcomes will be assessed through conduct of a cross sectional survey; those conducting the survey will not be informed as to which arm the women were in|This will be a cluster randomized controlled trial conducted over an 18-month period. Facilities will be randomized 1:1 to control and intervention arms.|f|f|f|t
33699742|NCT05748080|NA|SINGLE_GROUP||OTHER||NONE||||||
33699743|NCT01212458|||||PROSPECTIVE|||||||
33699744|NCT05489757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, Interventional, Monocentric Cohort Study on Medical Device (CE marked, according to indications for use) Prospective, Observational, Monocentric, Pharmacologic Cohort Study||||
33699745|NCT00014118||||TREATMENT||NONE||||||
33786867|NCT02141347|NON_RANDOMIZED|||OTHER||NONE||||||
33786868|NCT02920398|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33786869|NCT06628440|||COHORT||PROSPECTIVE|||||||
33786870|NCT05100966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33786871|NCT00999154|||||PROSPECTIVE|||||||
33786872|NCT01125228|||COHORT||PROSPECTIVE|||||||
33786873|NCT06306859|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The sample will be divided based on the schedule of hemodialysis. Intervention group will be chosen from Monday-Thursday.|The intervention group will be given access to m-health to monitor and education provision for about four weeks|t|f|f|f
33786874|NCT06367413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, outcomes assessor and the principal investigator will be blinded until the intervention and the outcomes' assessment is done.|A randomized, double-blind, placebo-controlled, parallel group model.|t|f|t|t
33786875|NCT05408455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786876|NCT06118736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004550|NCT03481855|||COHORT||PROSPECTIVE|||||||
34004551|NCT01166815|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34004552|NCT05086770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004553|NCT04848779|||COHORT||PROSPECTIVE|||||||
34004554|NCT04119557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33786877|NCT06316674|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786878|NCT05739123|||COHORT||PROSPECTIVE|||||||
33786879|NCT06085820|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||There will be three groups in total in the study, one control and two experimental groups.||||
33786880|NCT02611648|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33786881|NCT01311648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699746|NCT06255184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33699747|NCT05868759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699748|NCT02954250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699749|NCT05640804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699750|NCT03105804|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33699751|NCT06018571|||COHORT||RETROSPECTIVE|||||||
33699752|NCT04534972|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699753|NCT00333801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699754|NCT05273333|NA|SINGLE_GROUP||OTHER||NONE||A Prospective, Single-center, Open-label, Post-market Clinical Follow-up Study||||
33699755|NCT02830178|||CASE_CONTROL||PROSPECTIVE|||||||
33786882|NCT06122935|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33925662|NCT02820441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33925663|NCT01466478|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
33925664|NCT03141892|||COHORT||PROSPECTIVE|||||||
33699756|NCT03382275|||COHORT||PROSPECTIVE|||||||
33699757|NCT04633733|NA|SEQUENTIAL||OTHER||NONE||Fixed-sequential||||
33699758|NCT00108173||PARALLEL||DIAGNOSTIC||NONE||||||
33925665|NCT05073627|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33925666|NCT03667508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925667|NCT02648243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33925668|NCT04154917|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||A feasibility study including a pragmatic, rater-blinded, mixed-method pilot RCT will be conducted over a 2 year-period to prepare for our large-scale planned study design. 72 frail older adults will be consecutively recruited from 2 acute care wards (geriatric and medicine units) in a hospital located in a semi-urban area (Sherbrooke, Quebec). Participants will be randomly assigned to receive HOME (experimental; n=36) or customary discharge planning (control; n=36). The number of participants is achievable within the time frame as, based the number of beds and average length of stay, approximately 1200 potential eligible patients are admitted yearly. This number (n=72) would make it possible to detect a large effect size, based on calculation for primary outcomes (α = 0.05; power = 80%) and the expected dropout rate (a ≈ 16-20%). Randomization will occur after baseline assessment using randomly generated numbers provided by a statistician not involved in data collection.|t|f|t|f
33925669|NCT02681718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699759|NCT00936611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699760|NCT01891110|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699761|NCT03725215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will randomly be assigned to 1 of 4 different split-belt treadmill paradigms. Assessments will be performed pre and post training on day 1 and once again on day 2.|t|f|f|f
33699762|NCT06306989|||COHORT||PROSPECTIVE|||||||
33699763|NCT05171543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699764|NCT05744011|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
33699765|NCT02758314|||CASE_CONTROL||PROSPECTIVE|||||||
33699766|NCT01230723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925670|NCT02773368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925671|NCT02335203|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33925672|NCT04310878|||OTHER||PROSPECTIVE|||||||
33925673|NCT06094972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925674|NCT01410162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925675|NCT03954249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925676|NCT05340491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925677|NCT04667052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925678|NCT01525056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925679|NCT01039818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925680|NCT02089321|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925681|NCT01721512|||COHORT||PROSPECTIVE|||||||
33699767|NCT05182866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699768|NCT02154737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925682|NCT05430672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004555|NCT02656654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004556|NCT00418067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004557|NCT04755673|NA|SINGLE_GROUP||OTHER||NONE||All participants receive 4 weeks (28 days)supply of Atrantil- 2 capsules 3 times per day .||||
34004558|NCT05577494|||CASE_CONTROL||PROSPECTIVE|||||||
34004559|NCT05858775|||COHORT||PROSPECTIVE|||||||
34004560|NCT02676960|||CASE_CONTROL||PROSPECTIVE|||||||
34004561|NCT01027403|||||PROSPECTIVE|||||||
34004562|NCT02020967|||COHORT||CROSS_SECTIONAL|||||||
34004563|NCT01124435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004564|NCT06677814|||COHORT||PROSPECTIVE|||||||
33699769|NCT01781754|||CASE_ONLY||PROSPECTIVE|||||||
34004565|NCT01198249|RANDOMIZED|CROSSOVER||||NONE||||||
34004566|NCT00603512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699770|NCT05269433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33699771|NCT02353520|||||CROSS_SECTIONAL|||||||
33699772|NCT05352178|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, three-arm, phase III trial||||
33699773|NCT00601198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925683|NCT00497354|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33699774|NCT01892215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699775|NCT01389271|||COHORT||PROSPECTIVE|||||||
33925684|NCT03145597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split mouth comparison|t|f|f|f
33925685|NCT00705848|||CASE_CONTROL||PROSPECTIVE|||||||
33925686|NCT00291499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699776|NCT04200560|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699777|NCT04275934|||COHORT||PROSPECTIVE|||||||
33699778|NCT00775073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699779|NCT02269748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699780|NCT02123173|||COHORT||PROSPECTIVE|||||||
33699781|NCT05962671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699782|NCT06315023|||CASE_ONLY||PROSPECTIVE|||||||
33699783|NCT04273373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925687|NCT00962052|||COHORT||PROSPECTIVE|||||||
33925688|NCT00601146|NA|SINGLE_GROUP||SCREENING||NONE||Single arm study of low-dose Chest CT screening for long-term Hodgkin lymphoma survivors||||
33925689|NCT01376245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925690|NCT05625633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and Nurses share the role as Care Provider. Investigators will be blinded to the treatment allocation. Nurses, however, will be aware of the treatment allocation as they are administering the injections. Nurses are not involved in the study conduct in any other way.||t|f|t|t
33925691|NCT01009021|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33925692|NCT03413241|||COHORT||PROSPECTIVE|||||||
33925693|NCT00511849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925694|NCT01463657|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33925695|NCT01626534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925696|NCT05446623|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomized into two groups depending on the type of general anesthesia: Opioid free anesthesia (OFA), or anesthesia with opioid (OA)|"It is a monocentric, randomized study comparing two strategies of general anesthesia for programmed total hip arthroplasty.~Patients who gave their consent for the study during the anesthesia consultation, will be randomized into two groups depending on the type of general anesthesia: Opioid free anesthesia (OFA), or anesthesia with opioid (OA) The patients included in the OFA group will receive a bolus of Dexmedethomidine at the beginning of the surgery. The one in the OA group will be given a bolus of Sufentanil before and during the surgery. When the specific sequence will be completed, the care of all the patient will return to usual.~During the anesthesia induction and during the surgery cardiovascular data will be collected. The cardiac index will be measured thanks to a non invasive cardiac monitoring called NICCOMO® (v3.5.2)."|t|f|t|f
33925697|NCT06006442|||CASE_CONTROL||PROSPECTIVE|||||||
33925698|NCT01347632|NA|SINGLE_GROUP||PREVENTION||NONE|This is an open label study - there was no masking|Open Label||||
33925699|NCT01155193|||COHORT||PROSPECTIVE|||||||
33925700|NCT02533778|NA|SINGLE_GROUP||TREATMENT||NONE||with control group||||
33925701|NCT04088708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessors will be blinded to participant study group allocation|Randomized controlled trial|f|f|f|t
33925702|NCT04165733|||CASE_ONLY||CROSS_SECTIONAL|||||||
33925703|NCT05100108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be aware of the group they belong. Assessors and investigators will not be aware of the group participants belong.|Randomized controlled trial with two groups: a) the experimental group and b) a control group (waiting list)|f|f|t|t
33925704|NCT05224817|||OTHER||PROSPECTIVE|||||||
33925705|NCT00443846|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925706|NCT03010267|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925707|NCT03549429|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Every patient will have each tape on each eye -EyeGard® on one eye and the TegadermTM on the other eye according to the randomization schema.|t|f|t|t
33925708|NCT01879813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33925709|NCT00790127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925710|NCT02301754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925711|NCT01856842|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34004567|NCT01244308|||CASE_ONLY||PROSPECTIVE|||||||
34004568|NCT01652586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004569|NCT02715232|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34004570|NCT01245842|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34004571|NCT01785394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004572|NCT02339740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004573|NCT01230645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004574|NCT03019562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004575|NCT01662024|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34004576|NCT00697801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004577|NCT05021705|||CASE_ONLY||CROSS_SECTIONAL|||||||
33699784|NCT02397031|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33699785|NCT06529406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Ozanimod de-escalation of anti-CD20 treatment vs continued treatment.||||
33699786|NCT01286727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699787|NCT01542073|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33699788|NCT02245984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33699789|NCT02124486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699790|NCT01088750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699791|NCT02641132|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33699792|NCT02671409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699793|NCT05493332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699794|NCT00169754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699795|NCT02856698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699796|NCT02649088|||COHORT||PROSPECTIVE|||||||
33699797|NCT03677427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699798|NCT06121180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699799|NCT00292214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33699800|NCT01254292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004578|NCT06137781|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33699801|NCT01161784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699802|NCT00864578|||CASE_ONLY||PROSPECTIVE|||||||
33699803|NCT00004006||||TREATMENT||||||||
33699804|NCT03081312|||COHORT||CROSS_SECTIONAL|||||||
34004579|NCT00083694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699805|NCT04330274|||CASE_ONLY||PROSPECTIVE|||||||
33699806|NCT03178331|||COHORT||PROSPECTIVE|||||||
33699807|NCT02777619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699808|NCT02694809|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699809|NCT04136210|||COHORT||PROSPECTIVE|||||||
33699810|NCT05158608|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33699811|NCT01388595|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33699812|NCT01015144|||COHORT||PROSPECTIVE|||||||
33699813|NCT04459624|RANDOMIZED|PARALLEL||OTHER||TRIPLE|In the postoperative period, the effectiveness and safety of the block will be evaluated by another researcher (blind) who does not know which group the patient is in.|"Group E: ESP block will be applied at the end of the operation. Patients will receive paracetamol 1gr 4 \* 1 and tramadol 1mg/kg 30 minutes before the end of the operation. All patients will undergo IV morphine patient-controlled analgesia (PCA). Pain, opioid consumption, hemodynamic parameters and complications will be monitored in the first 24 hours in the postoperative period.~Group Q: QLB2 block will be applied at the end of the operation. Patients will receive paracetamol 1gr 4 \* 1 and tramadol 1mg / kg 30 minutes before the end of the operation. All patients will undergo IV morphine patient-controlled analgesia (PCA). Pain, opioid consumption, hemodynamic parameters and complications will be monitored in the first 24 hours in the postoperative period."|t|f|t|t
33699814|NCT02424448|||COHORT||PROSPECTIVE|||||||
33699815|NCT01904227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786883|NCT06065800|||COHORT||PROSPECTIVE|||||||
33786884|NCT06493435|||COHORT||PROSPECTIVE|||||||
33786885|NCT06631508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled intervention trial After informed voluntary consent is obtained, full randomization technique will be used to assign participants to follow-up and control groups. Full randomization will be done via the website http://www.randomizer.org/. Two computer-generated randomization sequences will be applied on a one-to-one basis.|t|f|f|f
33786886|NCT05403307|||CASE_CONTROL||PROSPECTIVE|||||||
33786887|NCT00261547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786888|NCT01320709|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33786889|NCT05781269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786890|NCT05993403|RANDOMIZED|PARALLEL||OTHER||NONE||The study was conducted with a randomized controlled experimental design to determine the effect of intercultural sensitivity training applied to nurses on intercultural sensitivity and compassion level.||||
33786891|NCT02126397|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33786892|NCT00744250|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33786893|NCT05187351|||CASE_ONLY||OTHER|||||||
33786894|NCT04853576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786895|NCT00567879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786896|NCT04482348|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||New and return patients seeing an orthopedic specialist were randomized to evaluate one of 7 brief explanations of the mind-body connection with variations in cognitive, emotional, or physiology-based explanations.|t|f|f|f
33786897|NCT00295867|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786898|NCT05283369|RANDOMIZED|PARALLEL||TREATMENT||NONE||One control group will receive conventional rehabilitation therapy, and one experimental group will receive telerehabilitation videogame therapy.||||
33786899|NCT02180087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786900|NCT03985150|||COHORT||PROSPECTIVE|||||||
33786901|NCT03007459|||CASE_CONTROL||PROSPECTIVE|||||||
33786902|NCT06118892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786903|NCT02949570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786904|NCT04286022|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor will not be aware of the group to which each subject has been assigned.|Two randomly allocated parallel groups|f|f|f|t
33786905|NCT01265758|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091014|NCT05534672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091015|NCT02641821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091016|NCT03881774|NA|SINGLE_GROUP||TREATMENT||NONE||CAR-T cell group||||
34091017|NCT00350285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786906|NCT04581837|||COHORT||CROSS_SECTIONAL|||||||
33786907|NCT00968240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786908|NCT06180148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786909|NCT03342651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786910|NCT04011033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786911|NCT00713739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786912|NCT03465488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786913|NCT01766167|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786914|NCT06617169|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will be dosed in cohorts of two, starting at Dose Level 1. TITE-BOIN evaluates the number of participants that have been dosed at a given dose level and their outcomes and determines if the next cohort should stay at the same dose, increase dose, or decrease dose using a predetermined rule.||||
33786915|NCT03580967|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive a 10 or 20 mg dose of vortioxetine to take daily for 8 weeks. Study PI and sub-investigator (psychiatrist Murali Rao, MD) will determine appropriate dose.||||
33786916|NCT06434857|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, controlled clinical trial|t|f|t|t
33786917|NCT05464134|||CASE_ONLY||PROSPECTIVE|||||||
33786918|NCT04529993|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33786919|NCT04172844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33786920|NCT06487975|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33786921|NCT04599946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadrupole|Parallel assignment|t|t|t|t
33786922|NCT00058058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33786923|NCT03419780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786924|NCT04204408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures|Part 1 placebo-controlled double-blind within cohorts (phase 1) Part 2 open-label (phase 2)|t|t|t|t
33925712|NCT03351010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible patients will 1) have any cancer type or stage, 2) be 18-60 years of age, 3) have a worst pain score \> 4 in the past 7 days, 4) be able to read and write the Thai language, 5) have a Karnofsky Performance status \> 70%, and be willing to travel to the temple. Exclusion criteria will be any diagnosed psychiatric illness that would prevent the patient from giving informed consent or from participating fully in the study. Patients with comorbidities (e.g., arthritis, bone metastasis, deformity, certain neurologic conditions such as biracial plexus nerve compression) that would impair the ability to perform the hand and arm movements also are ineligible.|Using a randomized controlled trial design, the investigators will test theTBbM intervention to improve pain in Thai outpatients (N=160) with cancer who are receiving cancer care at Sawanpracharak Hospital, Thailand. The control group (n = 80) will receive usual care and participate in a one-hour video educational program about cancer pain. The intervention group (n = 80) will receive usual care, participate in a one-hour video educational program about cancer pain, and receive an 8-week TBbM intervention.|t|f|f|f
33925713|NCT04112771|||COHORT||RETROSPECTIVE|||||||
33925714|NCT00888680|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925715|NCT00689169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925716|NCT03030768|||COHORT||PROSPECTIVE|||||||
33925717|NCT03286296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925718|NCT00219518|||CASE_ONLY||PROSPECTIVE|||||||
34091018|NCT02311478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34091019|NCT02325778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091020|NCT04767516|||COHORT||RETROSPECTIVE|||||||
34091021|NCT00533988|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34091022|NCT04993170|||OTHER||PROSPECTIVE|||||||
34004580|NCT01352052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004581|NCT05831735|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33699816|NCT06680492|||OTHER||CROSS_SECTIONAL|||||||
34004582|NCT01465932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699817|NCT03414281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34004583|NCT03527654|||COHORT||PROSPECTIVE|||||||
34004584|NCT05801029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091023|NCT04911504|||OTHER||CROSS_SECTIONAL|||||||
34091024|NCT05366998|||OTHER||OTHER|||||||
34004585|NCT02460835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699818|NCT03073187|||CASE_ONLY||CROSS_SECTIONAL|||||||
33699819|NCT02296281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699820|NCT06203379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33699821|NCT02664545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699822|NCT00454415|||COHORT||PROSPECTIVE|||||||
33786925|NCT03450109|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33786926|NCT05975554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Analysis blinded|||||
33786927|NCT05326334|||COHORT||PROSPECTIVE|||||||
33786928|NCT05825235|NA|SINGLE_GROUP||TREATMENT||NONE|Not masked.|Within the frame of the previous RCT study (Eudra CT 2022-001563-26) approximately 50% of the participants have been treated with the study product and 50% with placebo. In this study all participants receive the study product, so some will continue their ongoing treatment with the study product and some will start using the study product.||||
33786929|NCT01081379|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33786930|NCT02949648|||COHORT||PROSPECTIVE|||||||
33786931|NCT04322656|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33786932|NCT05461924|||CASE_CONTROL||RETROSPECTIVE|||||||
33786933|NCT00303849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004586|NCT00361478|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786934|NCT03643211|||CASE_ONLY||PROSPECTIVE|||||||
34004587|NCT00456482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34004588|NCT03429049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004589|NCT03634059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004590|NCT00700245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091025|NCT04777240|||OTHER||CROSS_SECTIONAL|||||||
33699823|NCT01561378|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699824|NCT06680973|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized controlled trial design will be employed. Block randomization will be performed using computer-assisted randomization software (https://www.graphpad.com/quickcalcs/randomize1/), and stratified randomization will be applied to ensure equal gender distribution across groups. Participants will be divided into three groups:~Hospital-based resistance training group Home-based resistance training group Control group~The individuals in the hospital-based and home-based resistance training groups will undergo a 12-week training program, with evaluations conducted twice: once before and once after the training. In the control group, no training will be provided, and evaluations will be performed twice, with a 12-week interval between assessments."||||
33699825|NCT05479331|||COHORT||OTHER|||||||
33786935|NCT00424216||||TREATMENT||||||||
33786936|NCT03852758|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33786937|NCT03103412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33786938|NCT03916614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786939|NCT02345200|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925719|NCT01599806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925720|NCT03228394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925721|NCT02490943|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants were randomized to warm compress (WC) for three injections, followed by cold compress (CC) for three injections, CC followed by WC, each for three injections or no treatment for six injections||||
33925722|NCT01231126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925723|NCT02538939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925724|NCT05644808|||COHORT||PROSPECTIVE|||||||
33925725|NCT02384304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925726|NCT01327001|||CASE_ONLY||RETROSPECTIVE|||||||
33925727|NCT05191732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||To investigate the result of clinical functional scoring, MRI, and biomechanical study between PRP augmentation, PRP+BMC augmentation and traditional ACL reconstruction.|t|t|f|t
33925728|NCT01821547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33925729|NCT00665678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925730|NCT06409611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|olhar em artigos|fes/parametros|f|f|f|t
33699826|NCT02788760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699827|NCT01122433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699828|NCT06558097|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33699829|NCT01261936|||CASE_CROSSOVER||PROSPECTIVE|||||||
33699830|NCT00659048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699831|NCT03321266|||COHORT||RETROSPECTIVE|||||||
33699832|NCT04642612|||COHORT||PROSPECTIVE|||||||
33699833|NCT05396846|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All data and samples will be identified by a participant ID number and visit number. Results will be unblinded with regard to study arm assignment during statistical analysis only.|Participants will be stratified by self-reported gender (male/female) and randomized across three study arms in a mixed block size, after baseline assessments are completed. Indeterminate gender will be classified as male for the purpose of randomization. The lists will be generated by the study statistician and opaque envelopes will contain the diet arm assignment for sequential participant IDs in the two strata.|f|f|f|t
33699834|NCT02905149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two group parallel arm. With study group receiving regional anesthestic block with levobupivacaine and control group receiving standard care with intravenous analgesia only|t|f|t|f
33699835|NCT04306029|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Hybrid Type II implementation and effectiveness study using a quasi-experimental stepped-wedge design.||||
33699836|NCT02081131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699837|NCT00994071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925731|NCT05220371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind, randomized controlled trial||t|f|t|f
33925732|NCT03402451|||COHORT||PROSPECTIVE|||||||
33925733|NCT00944216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699838|NCT03221699|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33699839|NCT04069962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699840|NCT03012971|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699841|NCT04820517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This study is pretest posttest randomized controlled clinical trial. The universe of this study was composed of 411 nursing students studying at Mersin University's faculty of nursing.The data were collected using the Bergen Social Media Addiction Scale from 384 nursing students who accepted to participate in the study between 09 January 2020 - 09 March 2020.From the scale developed by Andresan et al in 2017 and adapted to Turkish by Demirci in 2019, 110 nursing students who scored 3 or more out of at least 4 out of 6 items or scored 18 or more out of the total score constituted the sample of the study.110 nursing students were assigned to the experimental and control groups (55 experimental and 55 control groups) by block randomization.|t|t|f|t
33699842|NCT01580800|||COHORT||PROSPECTIVE|||||||
33925734|NCT02267369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|t|f|t
33925735|NCT02227472|||COHORT||PROSPECTIVE|||||||
33925736|NCT05380713|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B) before surgery.||||
33925737|NCT06145893|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33925738|NCT01985971|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925739|NCT04532255|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33925740|NCT06347783|||COHORT||PROSPECTIVE|||||||
33925741|NCT03521661|||COHORT||PROSPECTIVE|||||||
33925742|NCT02295306|||COHORT||PROSPECTIVE|||||||
33925743|NCT00000248||||TREATMENT||||||||
33925744|NCT03446001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925745|NCT00841269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925746|NCT03249948|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a cluster randomized study, with cluster units defined by EMS agency. Each cluster will crossover at three times during the one year trial so that each agency will spend 4 months in each arm of the study.||||
33925747|NCT00699309|||COHORT||PROSPECTIVE|||||||
33925748|NCT01115088|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33925749|NCT04507178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind|A single center, single blind, prospective, phase II randomized clinical trial.|f|f|f|t
33925750|NCT03337425|RANDOMIZED|CROSSOVER||TREATMENT||NONE||a Norwegian multicenter study||||
33925751|NCT00003635||||TREATMENT||||||||
33925752|NCT05468762|||OTHER||PROSPECTIVE|||||||
33925753|NCT00004234|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34004591|NCT05268419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding was performed at the level of participants, clinicians, Investigator, nurses and analysts.|"Based on the treatment-on or protocol per strategy, analysis was limited to participants who, according to the study protocol and inclusion criteria, received full interventions and informed the outcomes."|t|t|t|t
34004592|NCT00559741|NON_RANDOMIZED|||TREATMENT||NONE||||||
34004593|NCT01086228|||COHORT||PROSPECTIVE|||||||
34004594|NCT06310005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial is designed single-blind. The treatments administered (BI 3006337 or placebo) will be blinded to subjects but will be known to the investigators (outcome assessors).|Trial consists of a single-rising dose (SRD) and multiple dose (MD) part. In SRD part, the groups will be dosed consecutively in ascending order. The decision proceeding to MD part will be based upon safety and tolerability of all the preceding dose groups in SRD part. Within each dose group, patients will be randomized to either BI 3006337 or placebo.|t|f|f|f
34004595|NCT05374915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004596|NCT06235268|||OTHER||PROSPECTIVE|||||||
33925754|NCT02030587|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925755|NCT00818012|||COHORT||PROSPECTIVE|||||||
33925756|NCT01982526|||COHORT||PROSPECTIVE|||||||
33925757|NCT05839288|||COHORT||RETROSPECTIVE|||||||
33925758|NCT05340062|||COHORT||PROSPECTIVE|||||||
33925759|NCT03421509|||CASE_ONLY||CROSS_SECTIONAL|||||||
33925760|NCT01811199|||CASE_CONTROL||PROSPECTIVE|||||||
33925761|NCT02969694|||||PROSPECTIVE|||||||
33925762|NCT03986242|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33925763|NCT03854851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699843|NCT05776472|||COHORT||OTHER|||||||
33699844|NCT04634383|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Eligible participants for the study will be persons with blindness who meet the listed inclusion criteria. Individuals having any of the listed exclusion criteria will not be eligible to participate in the study. Enrolled participants will receive electrical stimulation devices implanted in the cortical region of their brain that is involved in vision processing. A maximum of five participants will be implanted. Written Informed Consent will be obtained from all participants before they are enrolled in the study.||||
33699845|NCT00424450|||COHORT||PROSPECTIVE|||||||
33699846|NCT06412224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699847|NCT03815474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699848|NCT02563665|||COHORT||PROSPECTIVE|||||||
33699849|NCT01662843|||CASE_CONTROL||PROSPECTIVE|||||||
33699850|NCT06105931|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33699851|NCT05574998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699852|NCT06057077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To compare the efficacy and safety of basal-bolus insulin degludec and semaglutide with the regular standard of care versus basal-bolus insulin with regular standard of care in early type 1 diabetic patients.|t|f|f|f
33699853|NCT06680804|||OTHER||CROSS_SECTIONAL|||||||
33699854|NCT00736814|RANDOMIZED|||TREATMENT||NONE||||||
33699855|NCT02186873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699856|NCT04214002|||CASE_ONLY||PROSPECTIVE|||||||
33699857|NCT01234831|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33699858|NCT03192956|||COHORT||PROSPECTIVE|||||||
33699859|NCT05516589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699860|NCT06468761|||COHORT||RETROSPECTIVE|||||||
33699861|NCT01342276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699862|NCT05363410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786940|NCT04733300|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All study staff will be blinded to the participant treatment allocation to promote equipoise with the exception of the instructor and staff member coordinating participants within each course. Participants randomized to low vs standard dose MBC will not know which dose they received as all participants are requested to reserve 2.5 hours for the program each week. Participants however will be unmasked about if they received MBC vs. health education due to how different the programs are in content. Data analyses will be performed by a statistician blinded to treatment allocation type. The data manager will be able to break blinding if needed for safety. Circumstances for breaking the blind would be a large number of adverse experiences (\>10% of enrolled participants reporting AEs rated as severe or life threatening) taking place in one or more study group.|The methodological approach includes a 3-arm trial of MBC (i.e, standard-dose vs. low-dose) vs. health education control, with n=100 per arm (total sample size 300 participants enrolled and randomized).|t|f|t|t
33786941|NCT00841958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786942|NCT02212717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786943|NCT00326027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786944|NCT04012606|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33786945|NCT00180102|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33786946|NCT01054430|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786947|NCT04691778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786948|NCT06632093|||COHORT||RETROSPECTIVE|||||||
33786949|NCT06409637|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33786950|NCT03377855|NA|SINGLE_GROUP||OTHER||NONE||This is a interrupted time series study model with one study group.||||
33786951|NCT05391048|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33786952|NCT06146985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786953|NCT02471391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699863|NCT02366988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786954|NCT02704481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786955|NCT00777556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786956|NCT02072005|||CASE_ONLY||PROSPECTIVE|||||||
33786957|NCT01909232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925764|NCT02481596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The outcomes assessor for the primary outcome for the larger trial (NCT02409329) was blinded, but outcomes assessors for these outcomes were not.|||||
34004597|NCT06311019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004598|NCT04130217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004599|NCT00880334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925765|NCT01045928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004600|NCT05762731|||CASE_CONTROL||PROSPECTIVE|||||||
33925766|NCT01887756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925767|NCT04649294|||COHORT||PROSPECTIVE|||||||
33925768|NCT06047106|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Monocentric, Prospective, Non-randomized, Exploratory Study||||
33925769|NCT04826913|||COHORT||PROSPECTIVE|||||||
33925770|NCT03177967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004601|NCT04583150|||CASE_CONTROL||PROSPECTIVE|||||||
34004602|NCT02573285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004603|NCT04643002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004604|NCT05392569|||CASE_ONLY||PROSPECTIVE|||||||
34004605|NCT00128817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699864|NCT04903756|||COHORT||PROSPECTIVE|||||||
33699865|NCT02524405|||COHORT||CROSS_SECTIONAL|||||||
33699866|NCT01355926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33699867|NCT05098899|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33699868|NCT06358131|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33699869|NCT01982578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699870|NCT05520099|||CASE_ONLY||PROSPECTIVE|||||||
33699871|NCT04048187|NA|SINGLE_GROUP||OTHER||NONE||||||
33699872|NCT00091754|||COHORT||OTHER|||||||
33699873|NCT05351021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33699874|NCT04537143|||COHORT||PROSPECTIVE|||||||
33699875|NCT00003591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699876|NCT00000862||PARALLEL||TREATMENT||||||||
34004606|NCT01763255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699877|NCT03509883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33699878|NCT02640573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699879|NCT05271591|||CASE_ONLY||OTHER|||||||
33699880|NCT06061341|||COHORT||PROSPECTIVE|||||||
33699881|NCT04295551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699882|NCT01624623|||COHORT||PROSPECTIVE|||||||
33699883|NCT05237232|||CASE_CONTROL||PROSPECTIVE|||||||
33699884|NCT02291874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699885|NCT05143450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33786958|NCT02900365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33786959|NCT01693965|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33786960|NCT06693817|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33786961|NCT04558996|||COHORT||PROSPECTIVE|||||||
33786962|NCT06189742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33786963|NCT00166985|||DEFINED_POPULATION||OTHER|||||||
33786964|NCT04243343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786965|NCT02017106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925771|NCT06229483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is a blinded study. The participant, surgeon and research team will not know the treatment allocation. Only the pharmacy preparing the medication will be unblinded|Participants will be randomized to receive a 20 mg/kg IV bolus of TXA, or identical volume of placebo 0.9 % NaCl will be administered intravenously push by the anesthesiologist approximately 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, or identical volume of placebo 0.9 % NaCl, for the duration of surgery|t|f|f|f
33786966|NCT02633189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786967|NCT04088188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786968|NCT03412942|NA|SINGLE_GROUP||OTHER||NONE||||||
33786969|NCT06068166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786970|NCT00005581|RANDOMIZED|||TREATMENT||||||||
33786971|NCT02175537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786972|NCT03761784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786973|NCT06630507|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33786974|NCT00000634||||TREATMENT||||||||
33786975|NCT02888509|||COHORT||CROSS_SECTIONAL|||||||
33925772|NCT05676801|NA|SINGLE_GROUP||PREVENTION||NONE||All patients get Photodynamic treatment in addition to skin antisepsis. (The contrallateral side of the leg is our control side, therefore only one arm)||||
34004607|NCT05301816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004608|NCT02746419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004609|NCT04290494|||COHORT||RETROSPECTIVE|||||||
34004610|NCT03532750|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1 randomization of participants in sequential order to either the control group (best medical management), particle embolization, and coil embolization.||||
34004611|NCT03885869|||OTHER||CROSS_SECTIONAL|||||||
34004612|NCT01937351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699886|NCT00808483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33786976|NCT06628518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786977|NCT03620929|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33786978|NCT03352388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33786979|NCT04783181|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will be assigned sequentially to one of 4 dose levels depending on the date of determination of eligibility.||||
33786980|NCT05819190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33786981|NCT05080192|||CASE_CONTROL||PROSPECTIVE|||||||
33786982|NCT02592837|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33786983|NCT06609928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786984|NCT01043549|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33786985|NCT01270789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786986|NCT03354533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786987|NCT00546520|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33786988|NCT04806919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33786989|NCT03901729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33786990|NCT05837780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33786991|NCT03881657|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment group participants were randomized to receive primary care in addition to behavioral health services within a behavioral health setting. Control group participants received behavioral health care services as usual.||||
34004613|NCT01310361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34004614|NCT06112834|NA|SINGLE_GROUP||OTHER||NONE||||||
34004615|NCT02274727|||COHORT||PROSPECTIVE|||||||
34004616|NCT03824561|||COHORT||PROSPECTIVE|||||||
34004617|NCT02020109|||CASE_ONLY||RETROSPECTIVE|||||||
34004618|NCT06222658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004619|NCT02193607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004620|NCT06506942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004621|NCT04073134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised control Trial|t|t|t|t
33699887|NCT00400738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925773|NCT01100645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925774|NCT03970707|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33925775|NCT05355935|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33925776|NCT02901340|||CASE_CONTROL||PROSPECTIVE|||||||
33925777|NCT02460978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925778|NCT00708903|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33925779|NCT00125437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33925780|NCT01746810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925781|NCT06045728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For insulin resistance the investigator will not know which group will be assessed||f|f|t|f
33925782|NCT01273987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925783|NCT00033371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925784|NCT04581070|||COHORT||PROSPECTIVE|||||||
33925785|NCT01277913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925786|NCT01425853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925787|NCT05285267|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Parent-child observations will be conducted by a masked observer.||f|f|f|t
33925788|NCT05565157|NA|SINGLE_GROUP||OTHER||NONE||||||
33925789|NCT04451291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925790|NCT06258863|||COHORT||RETROSPECTIVE|||||||
33925791|NCT03607812|||COHORT||PROSPECTIVE|||||||
33925792|NCT00143988|||CASE_ONLY||PROSPECTIVE|||||||
33925793|NCT00981747|NA|SINGLE_GROUP||TREATMENT||DOUBLE||Participants will receive sildenafil for three months then losartan for three months, then sildenafil and losartan for three months and then placebo for three months in a random order.|t|f|t|f
33925794|NCT00002204||PARALLEL||PREVENTION||||||||
33925795|NCT05656391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925796|NCT04969211|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925797|NCT00979108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33925798|NCT00607126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925799|NCT04239170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699888|NCT04153604|||CASE_ONLY||RETROSPECTIVE|||||||
34004622|NCT05515107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Outcomes Assessor)|Randomized Parallel Assignment|t|f|f|t
34004623|NCT05072119|||COHORT||PROSPECTIVE|||||||
34004624|NCT06677827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent anesthesiologist randomly using computer-generated random numbers divided the patients into 2 groups :(Group 1 and Group 2). Each group will include 34 patients. We discreetly placed the randomization results in envelopes until the end of the study. The researchers who were responsible for postoperative follow-up and data processing were blinded to the group allocation during the whole study period. All patients were also blinded to the group allocation|Patients will be divided into two groups Group 1: 20 ml bupivacaine 0.25%+200 mg magnesium sulphate Ultrasound guided external oblique intercostal plane block bilateral Group 2: 20 ml bupivacaine 0.25% only Ultrasound guided external oblique intercostal plane block bilateral|t|t|t|t
33925800|NCT02582931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004625|NCT03241745|NA|SINGLE_GROUP||TREATMENT||NONE||This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase 2 study.||||
34004626|NCT05589259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34004627|NCT02828280|||COHORT||PROSPECTIVE|||||||
34004628|NCT03438006|||COHORT||PROSPECTIVE|||||||
33925801|NCT03083275|RANDOMIZED|PARALLEL||PREVENTION||||||||
33925802|NCT02147509|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33925803|NCT03034057||PARALLEL||PREVENTION||NONE||||||
33925804|NCT02195609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33925805|NCT01084330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925806|NCT03690947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699889|NCT02019277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925807|NCT01548417|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33925808|NCT01866345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925809|NCT03466112|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33925810|NCT03904784|||COHORT||PROSPECTIVE|||||||
33925811|NCT06527209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|In order to minimize implementation biases, participants will be masked, and will not be told whether they are receiving the intervention or the control, to avoid any influence on the data they report on the scales, and the people in charge of administering the intervention will be masked by coding the data to allow the identification of the participants.|All participants will be assigned to the two interventions separately according to the random assignment sequence corresponding to the crossover design. The interventions consist of a control beverage or a coffee and inulin-based beverage. The beverage will consumed daily 30 minutes before breakfast for two weeks with a two-week washout period.|t|t|f|f
33925812|NCT05241665|||COHORT||PROSPECTIVE|||||||
34004629|NCT03431337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unlabeled bottles of study medications, identified only by participant #, prepared by the pharmacist member of research team. The placebo will be similar in appearance to plain amoxicillin. The pills inside the bottle will be difficult to see until the bottle is opened by the patient.|"1. Ill adult patients coming to a primary care office will be diagnosed by the treating physicians with acute bacterial sinusitis in accordance with the guidelines of the Infectious Disease Society of America.~2. If they do not meet exclusion criteria, they will be offered enrollment in the study.~3. If they agree, they will be provided unlabeled study medication, either amoxicillin/clavulanate 875/125 + placebo pills bid x 7 days (standard dose) or amoxicillin/clavulanate 875/125 + amoxicillin immediate-release 875 (high dose).~4. Outcomes will be assessed, by telephone or over the web (through Qualtrics), at 3 and 10 days after enrollment."|t|t|t|t
33699890|NCT02001103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699891|NCT06558487|||COHORT||PROSPECTIVE|||||||
33699892|NCT01499758|RANDOMIZED|CROSSOVER||||NONE||||||
33699893|NCT05438888|||COHORT||RETROSPECTIVE|||||||
33699894|NCT06451848|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33699895|NCT04004546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34091026|NCT05518552|RANDOMIZED|PARALLEL||TREATMENT||NONE||The group underwent manual lumbar traction with the patient lying prone on a couch using a manual technique by pulling from the ankles of the patient. Manual traction was performed by the therapist, pulling at the patient's ankles.||||
34091027|NCT01374386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091028|NCT06105437|NA|SINGLE_GROUP||PREVENTION||NONE||A mixed methods study with a convergent parallel design will be carried out in four primary care areas in Flanders (Belgium). Within this mixed methods study, the researchers gather information on and experiences with the implementation process of the BE-EMPOWERed program from the perspective of the older people, healthcare professionals, implementation facilitators, the working group of the primary care area and local policy makers. To evaluate the implementation process and outcomes, the following data are being collected: reach, fidelity, feasibility, acceptability, sustainability and cost of implementation. A variety of methods are being used to collect data on implementation outcomes and process such as self-reported implementation costs, surveys, interviews and focus groups.||||
34091029|NCT01613391|||COHORT||PROSPECTIVE|||||||
34091030|NCT05718713|||CASE_ONLY||PROSPECTIVE|||||||
34091031|NCT01218178|||CASE_CONTROL|||||||||
34091032|NCT05052281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091033|NCT01756755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091034|NCT01659905|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091035|NCT01976208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091036|NCT03286894|||OTHER||CROSS_SECTIONAL|||||||
33699896|NCT06680882|RANDOMIZED|PARALLEL||TREATMENT||NONE||slow transmission constipation||||
34091037|NCT05202951|||COHORT||PROSPECTIVE|||||||
34091038|NCT01025895|RANDOMIZED|PARALLEL||TREATMENT||||||||
34091039|NCT03557944|NA|SINGLE_GROUP||OTHER||NONE||Single-arm, longitudinal cohort feasibility study.||||
34091040|NCT05367999|||COHORT||CROSS_SECTIONAL|||||||
33699897|NCT00968890|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33699898|NCT05377879|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|Identity of the patient in any form is not provided.|OPT-IVF is a decision support tool which personalizes and optimizes dosage for each patient for each cycle.|f|f|t|t
33699899|NCT05661409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33699900|NCT06679946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925813|NCT04443842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33925814|NCT03529929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925815|NCT02015806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33925816|NCT05286996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes assessors will be blinded about treatment allocation.|Parallel-randomized participant-blinded control trial|t|f|f|t
33925817|NCT00560625|||CASE_ONLY||PROSPECTIVE|||||||
33925818|NCT01192841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925819|NCT00695500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925820|NCT04008199|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There is no placebo or masking for logistical reasons.|The researchers are conducting a field experiment of the Super Abbu platform. Some households will be invited to participate and others will not, at random.||||
33925821|NCT01608607|||||PROSPECTIVE|||||||
33925822|NCT02923310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925823|NCT03199508|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|According to cluster randomization, several centers use the 3-day voiding diary and the other centers use the 7-day voiding diary. Participants will be randomly assigned and don't know they are in which cluster.|The investigators use two sets of parallel controls. The experimental group use the 3-day voiding diary and the control group use the 7-day voiding diary.|t|f|f|f
33925824|NCT00305812|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925825|NCT04833920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925826|NCT01816256|NA|SINGLE_GROUP||SCREENING||NONE||||||
33925827|NCT01444898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925828|NCT03936270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925829|NCT01679522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925830|NCT00830154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925831|NCT04150354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33925832|NCT04458363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925833|NCT03954379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Block room and anesthesia staff performing nerve blocks and administering sedation will be informed to which study group patient is allocated. The patient and independent investigator carrying out follow up assessments will remain blinded to the end of the study. If the patient wishes to know the study group assignment, the patient will be informed at the end of their final 6 week follow up.||t|f|t|f
33925834|NCT00367029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699901|NCT03172819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699902|NCT05247593|||COHORT||PROSPECTIVE|||||||
33699903|NCT02121626|||COHORT||PROSPECTIVE|||||||
33699904|NCT03140228|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33699905|NCT03109730|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33699906|NCT00003052|RANDOMIZED|||TREATMENT||||||||
34004630|NCT04724499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699907|NCT00357357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699908|NCT04324619|RANDOMIZED|SEQUENTIAL||OTHER||NONE||After completing an online learning program about child abuse and its reporting, early childhood professionals will be randomized to receive follow-up micro-learning either immediately, or after a delay (3, 6, or 12 months). Decay in knowledge will be measured, as well as remediation of that decay following micro-learning.||||
33699909|NCT06145373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33786992|NCT05333887|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study attempts to modify a BPT program to be better suited to the needs of parents with mental health concerns. Modifications include ways to improve parent engagement and connection to the program. Parent engagement is often addressed by reducing practical barriers. All sessions are provided online, all strategies are presenting in a half-day group workshop, the remaining sessions only occur with 1-2 parents and are flexibly scheduled for the parent, a treatment menu is used to support easy tailoring of homework to family needs, and a general flexible approach is used. Programs also target parent connection via modifications to improve cognitions about treatment and ADHD, increase alliance, or increase treatment satisfaction. In the first two sessions barriers to treatment and unhelpful thoughts about treatment are discussed, the workshop is a group format, parents have the option to be put in pairs for social support, and they have a consistent therapist throughout the program.||||
33786993|NCT03722446|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33786994|NCT01025583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33925835|NCT00810589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925836|NCT00226278|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33925837|NCT05141734|||CASE_CONTROL||PROSPECTIVE|||||||
33925838|NCT01665768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925839|NCT02673723|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925840|NCT05426018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925841|NCT06386211|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925842|NCT02171949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004631|NCT00517192||PARALLEL||TREATMENT||||||||
34004632|NCT06616077|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34004633|NCT02751216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699910|NCT01173939|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33699911|NCT01067937||||||NONE||||||
33699912|NCT02650635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699913|NCT00448838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699914|NCT06229535|||OTHER||CROSS_SECTIONAL|||||||
33699915|NCT02540109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699916|NCT03039192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699917|NCT02162316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33699918|NCT06366100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are assigned to two groups in parallel for the duration of the study. The specific design is an reverse counterbalanced (ABBA) intrasubject experimental study where participants will be randomly assigned to first (and then the other) receive DBT-SUD or UP online training in the phase 1 of the study, and randomly assigned to first implement DBT-SUD or UP intervention in the phase two. A balanced randomization (1:1) will be conducted in order to eliminate possible biases and ensure equivalence between groups.||||
33699919|NCT03458975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699920|NCT00728624|||OTHER||PROSPECTIVE|||||||
33699921|NCT02219438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only individual aware of the treatment group assignments is the investigational pharmacist who has no interaction with the study subjects. Treatment group assignments were released by the investigational pharmacy only after completion of data collection.|This is a split-body study in which each study subject receives both treatments: one on each side of the body. Which treatment is applied to which side of the body is randomized (and masked).|t|t|t|t
33699922|NCT00286507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33786995|NCT03136263|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33786996|NCT05487703|||COHORT||RETROSPECTIVE|||||||
33925843|NCT02931526|||CASE_CONTROL||PROSPECTIVE|||||||
33925844|NCT03162341|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925845|NCT00496613|||COHORT||RETROSPECTIVE|||||||
33925846|NCT01383187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925847|NCT03872193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group only physiotherapy second group takes physiotherapy and virtual reality exercises.||||
33925848|NCT05193877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||double blind|t|f|f|f
33925849|NCT01253187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925850|NCT01146548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33925851|NCT01620450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925852|NCT02846051|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33925853|NCT01207713|||CASE_ONLY||RETROSPECTIVE|||||||
33925854|NCT00672295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925855|NCT01792297|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925856|NCT03419000|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33925857|NCT01875510|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33925858|NCT05444413|NA|SINGLE_GROUP||TREATMENT||NONE||patients with Intractable Postherpetic Neuralgia||||
33925859|NCT04503863|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33925860|NCT00630240|||||PROSPECTIVE|||||||
33925861|NCT00663468|||CASE_ONLY||PROSPECTIVE|||||||
34004634|NCT05853783|||COHORT||RETROSPECTIVE|||||||
34004635|NCT06613048|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34004636|NCT03840382|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33699923|NCT00895232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699924|NCT03812653|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible participants will be allocated in a 1:1 fashion to CPAP or no CPAP using a randomization method to protect subject treatment allocation and prevent potential selection biases.|Intervention group receives automatically adjusting continuous positive airway pressure (CPAP) plus usual care.The control group receives usual care.|f|f|f|t
33699925|NCT02829073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33699926|NCT01329536|||CASE_CONTROL||PROSPECTIVE|||||||
33699927|NCT06181591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699928|NCT00810472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33699929|NCT05122104|||COHORT||PROSPECTIVE|||||||
33699930|NCT05556330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699931|NCT00631696|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33699932|NCT05147584|NA|SINGLE_GROUP||OTHER||NONE|"Results of either the external sensor or the internal sensor will not be shown to the subject, the care provider, or the investigator and will not be used to guide or alter patient management. The outcomes assessor will review the subject CTG and sensor data retrospectively."|This is a prospective, investigator-blinded study that is for data collection only. The primary purpose is to verify accuracy during the training of the algorithm by comparing the external sensor to a known internal sensor.||||
33699933|NCT00602992|||COHORT||CROSS_SECTIONAL|||||||
33699934|NCT05661110|||COHORT||PROSPECTIVE|||||||
33699935|NCT06556836|||OTHER||PROSPECTIVE|||||||
33699936|NCT00002451||||TREATMENT||||||||
33699937|NCT02309593|||COHORT||PROSPECTIVE|||||||
33786997|NCT03105128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33786998|NCT03545217|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33786999|NCT02956499|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33787000|NCT06165731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33787001|NCT06356584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787002|NCT04272073|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A single-centre, cross-sectional analysis of the prevalence of SO in CR patients followed by a single-centre, 2x2 factorial, open label controlled trial||||
33787003|NCT00126009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787004|NCT00017277|RANDOMIZED|||TREATMENT||DOUBLE||||||
33787005|NCT02989012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33787006|NCT06117254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787007|NCT05831280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The women in the experimental and control groups did not know which group they were in. Data were collected online due to the pandemic. Therefore, the researchers and the people who would conduct the analyzes did not know the women in the experimental and control groups. The women used a nickname to fill in the questions on the measurement tools.|Randomized controlled trial|t|f|f|t
33787008|NCT01430702|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33787009|NCT05692258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|On account of the particularity of acupuncture research, it is impossible to blind acupuncture operators. Blinded evaluation will be adopted in the trial, and the third party who does not know the grouping will evaluate the efficacy. Blind statistical analysis was used in the data summary stage, and the researchers, operators and statisticians were separated.|This study is a randomized controlled study. According to the design of stratified random grouping, the subjects is stratified according to the degree of disease (moderate, severe) and age stage (30-59 years, \> 60 years), and then randomly assigned to the observation group and the control group within each stratum.|t|f|t|t
33787010|NCT06631690|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33925862|NCT05351463|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||RCT parallel study||||
33925863|NCT00351819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925864|NCT04598711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are masked to group assignment (RLIC vs. Sham conditioning) and the assessor will be masked to group assignment of the participants.|Double blinded, randomized controlled trial|t|f|f|t
33925865|NCT01319019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925866|NCT04436588|||COHORT||OTHER|||||||
33925867|NCT00716326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004637|NCT05504824|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34004638|NCT02682550|||COHORT||PROSPECTIVE|||||||
34004639|NCT06256549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004640|NCT01288391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004641|NCT05735158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||An intra-participant parallel study. Matched target areas will be randomized within the participant, such that one target area receives KB105 and the other target area will receive placebo. An additional target area may be selected to receive open-label treatment with KB105.|t|t|t|f
34004642|NCT01261624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004643|NCT02209116|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34004644|NCT00351351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004645|NCT05135273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33699938|NCT03194087|||COHORT||PROSPECTIVE|||||||
33699939|NCT03833960|||COHORT||RETROSPECTIVE|||||||
33699940|NCT00156897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925868|NCT02702947|NA|SINGLE_GROUP||||NONE||||||
33925869|NCT01469091|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34004646|NCT04072315|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|No masking|Open label, incomplete crossover, up to 2 single doses administered at two different times||||
34004647|NCT05244317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004648|NCT02095002|||CASE_CROSSOVER||PROSPECTIVE|||||||
34004649|NCT03538925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34004650|NCT05686824|||COHORT||PROSPECTIVE|||||||
33699941|NCT01931618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004651|NCT06617143|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants and researchers could not be blinded due to the natural course of the study and only the statistician was blinded.|pre-test post-test quasi-experimental design|f|f|f|t
34004652|NCT02902055|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34004653|NCT01304186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699942|NCT05955625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Because this is a behavioral intervention, the participants and clinicians cannot be blinded to the treatment condition they are randomized to. However, the evaluation of the outcome measures will be done with researchers blinded to the treatment condition.|Participants are assigned to two groups in parallel for the duration of the study.|f|f|f|t
33699943|NCT03805425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699944|NCT01928069|RANDOMIZED|||TREATMENT||||||||
33699945|NCT04172896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a two-arm parallel design. Participants will be randomly assigned to either vaginal intraperitoneal or extraperitoneal uterosacral ligament suspension.|t|f|f|f
33699946|NCT05929131|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33699947|NCT02400177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699948|NCT00358423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787011|NCT06388109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized control trial with observational cohort for eligible patients who decline participation||||
33787012|NCT00145535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787013|NCT02831114|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33787014|NCT00533039|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787015|NCT03771898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787016|NCT05181449|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomization is a 2 to 1 block design (2 intervention patients for each control patient), with the intervention group receiving Twin Precision Treatment (TPT) compared to the control group receiving usual care delivered by primary care providers managing T2D||||
33787017|NCT05115890|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with HFpEF assigned to 8 weeks of exercise training||||
33787018|NCT06630403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004654|NCT06157853|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Subjects will be randomly assigned to one of the following treatment arms: active post-procedure cream versus comparator anhydrous cream. The products will be packaged in the same container and labelled post-procedure cream. Double blinded study, where the investigator, study subject, and other study personnel involved in the evaluation of the efficacy or safety are blinded to treatment during the 14-day randomization study.|Randomized, single-center, double-blinded, controlled.|t|f|t|f
34004655|NCT03698487|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"This project is a prospective interventional implementation study with a pre-intervention control cohort; mixed methods will be used to explore the success and moderators of implementation.~Specifically, it consists of:~* A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).~* A before/after intervention~* A multiple case study (a sub-study of the before/after intervention)"||||
34004656|NCT06126328|RANDOMIZED|PARALLEL||OTHER||SINGLE|Ultrasound images are assessed by physicians blinded to randomization|Randomized Control Trial|f|f|f|t
34004657|NCT01345734|||COHORT||PROSPECTIVE|||||||
34004658|NCT02191449|||COHORT||RETROSPECTIVE|||||||
34004659|NCT06009588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeons are aware of randomisation results, however, participants and research staff are all blinded to the randomisation schemes.|Self-expandable valve group vs. Balloon-expandable valve group|t|f|t|f
34004660|NCT01265667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004661|NCT00568711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004662|NCT04618939|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blind||t|f|t|f
34004663|NCT02666027|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34004664|NCT06504654|||COHORT||CROSS_SECTIONAL|||||||
33699949|NCT05663502|||CASE_ONLY||CROSS_SECTIONAL|||||||
34004665|NCT06128187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were enrolled in treatment without being aware of differences in treatment between groups|Two groups. Study group and control group|t|f|f|t
34004666|NCT01030094|||COHORT||CROSS_SECTIONAL|||||||
34004667|NCT00332943|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34004668|NCT04067154|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004669|NCT06024967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004670|NCT04141878|RANDOMIZED|CROSSOVER||PREVENTION||NONE|There is no masking in this study. Everyone will know whether the participant is currently participating in the Aerobic Exercise Group or the Diet Skills Group. All participants will eventually complete both groups.|Subjects will be randomized to either the Aerobic Exercise Group or the Diet Skills Group. Each participant will eventually complete both groups.||||
34004671|NCT04214288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004672|NCT01776528|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34004673|NCT01413945|||COHORT||PROSPECTIVE|||||||
34004674|NCT00268086|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34004675|NCT02690935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004676|NCT00810706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787019|NCT05097573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787020|NCT03738137|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33787021|NCT03835546|||OTHER||PROSPECTIVE|||||||
33787022|NCT01536730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004677|NCT06367647|||OTHER||CROSS_SECTIONAL|||||||
34004678|NCT00428818|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004679|NCT03147924|NA|SINGLE_GROUP||OTHER||NONE||||||
34004680|NCT00040794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004681|NCT04878237|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34004682|NCT01752530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004683|NCT03227133|NA|SINGLE_GROUP||OTHER||NONE||||||
34004684|NCT03321045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004685|NCT06679205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004686|NCT00003317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004687|NCT01260337|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004688|NCT02824185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004689|NCT00292331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004690|NCT06453824|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This is a placebo controlled double blind study|2 sentinel patients will be treated with one dose of MDI-2517 or placebo and if safe after 48h, 6 additional patients will be dosed (5 on MDI-2517 and 1 on placebo). Progression to enroll the next new group of patients will happen after review of safety and available PK data by the Safety Review Committee (SRC). The SRC will decide to move to the next dose level, decrease the next dose level, repeat a dose level, or to not evaluate any additional doses. Patients are randomized to MDI-2517 or Placebo.|t|t|t|f
33787023|NCT06390592|NA|SEQUENTIAL||TREATMENT||NONE||Interventional, prospective, multi-centric, controlled, randomized, crossover||||
33787024|NCT01338727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33787025|NCT01738555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787026|NCT01207908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787027|NCT03213470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787028|NCT00849147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787029|NCT06288152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33787030|NCT04927975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787031|NCT06418529|||COHORT||RETROSPECTIVE|||||||
33787032|NCT05926050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind placebo controlled randomized clinical trial.|t|f|t|t
33787033|NCT02393898|||COHORT||PROSPECTIVE|||||||
34004691|NCT00485004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004692|NCT02910024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004693|NCT02579538|||COHORT||PROSPECTIVE|||||||
34004694|NCT00198224|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34004695|NCT03029117|||COHORT||PROSPECTIVE|||||||
34004696|NCT00480324|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004697|NCT01557920|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34004698|NCT06465875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004699|NCT02136706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004700|NCT01735786|||COHORT||RETROSPECTIVE|||||||
34004701|NCT00055549||||TREATMENT||||||||
34004702|NCT05496673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004703|NCT01463982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004704|NCT01632384|NA|SINGLE_GROUP||OTHER||NONE||||||
34004705|NCT04552028|||COHORT||PROSPECTIVE|||||||
34004706|NCT05678517|||COHORT||RETROSPECTIVE|||||||
34004707|NCT06678906|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|As a result, all centers will include patients both before (control period) and after the implementation of the intervention (experimental period). The timing of the intervention implementation (training period) for each center will be randomized among 4 training periods distributed throughout the study, with two centers per training period|"Cluster randomization will be conducted according to the stepped wedge design."||||
34004708|NCT04523246|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"Blinding is done to ensure staff and residents do not modify reports or reporting of COVID symptoms and to minimize other behaviors (such as sleeping, eating habits, physical activity) that may affect their innate immune system. It will also serve to minimize any bias in the processing/analysis of samples and the interpretation of the study results.~During the conduct of the study, only three people (the statistician and 2 research nurses who will reconstitute, draw up, and administer the injections) will have knowledge of the group assignments. Participants, the staff at the nursing home, the staff collecting the COVID symptom data, and study investigators are blinded to the subject assignments."|Two hundred nursing home residents, both men and women, aged \>65 years, who have not acquired COVID-19 (verified through a screening questionnaire and by both viral antigen and antibody testing at the screen and least one week before the first injection) will get two intramuscular injections containing either the Shingrix vaccine, and the other half, two injections containing a normal saline (comparison) approximately two months apart. Blood samples are collected before the baseline injection (day zero), 1 day after the second injection (61 days post) and 1 month following the second injection (90 days). Weekly symptom checks and monthly antibody testing around day 180- will identify residents with COVID-19 and the severity of COVID-19 symptoms.|t|t|t|t
34004709|NCT05889273|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open-label study||||
34004710|NCT05188924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004711|NCT06466005|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34004712|NCT00722839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004713|NCT04650750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004714|NCT05467982|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34004715|NCT04975451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699950|NCT03748108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participating patients, surgeons, anesthesiologists and medical investigators who will be involved in the data collection will be all blinded to the patient's group assignment until the collection of data for all cases will be complete.|This study will be a single-center, randomized double-blind, placebo-controlled, parallel group trial.|t|t|t|t
33699951|NCT00682942|||COHORT||PROSPECTIVE|||||||
33699952|NCT03996759|||COHORT||PROSPECTIVE|||||||
33787034|NCT05348577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study is double-blinded, neither the patients nor the investigator will know what study intervention was assigned.~Capivasertib and placebo film-coated tablets will be identical in appearance and presented in the same packaging to ensure blinding of the capivasertib.~All personnel involved with the statistical analysis of the study will remain blinded until database lock and CSP deviations have been identified."|Approximately 1350 participants will be enrolled and screened to achieve a total of approximately 1000 assigned in a 1:1 ratio to one of the two parallel groups to receive either capivasertib or placebo, in combination with docetaxel on a background of ADT for the duration of the study.|t|t|t|t
33787035|NCT00569946||||TREATMENT||NONE||||||
33787036|NCT06028932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787037|NCT06631378|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is a single center superiority randomized clinical trial with two parallel groups with 1:1 randomization to either transverse or longitudinal incision in the groin in vascular surgery with arterial reconstruction.||||
33787038|NCT04657991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787039|NCT04034758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787040|NCT00114933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787041|NCT00133588|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33787042|NCT02078934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787043|NCT02132702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787044|NCT00350831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787045|NCT03678116|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Three groups: placebo, caffeine (plus Teacrine and Cayenne) and caffeine (plus Teacrine)|t|f|t|f
33787046|NCT00946751|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787047|NCT03800004|||COHORT||PROSPECTIVE|||||||
33787048|NCT02113163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787049|NCT00502593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33925870|NCT05236959|RANDOMIZED|PARALLEL||TREATMENT||NONE|Use of remote assessments, initiated through automated email, will rule out any potential effects of assessors on assessments of outcomes. The statisticians will remain blind to treatment allocation throughout the analysis.|Randomised controlled trial with two arms and three sites||||
33925871|NCT00422123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925872|NCT01513863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925873|NCT04154657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||single cohort observational pathophysiologic study||||
33925874|NCT02597491|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33925875|NCT01125293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925876|NCT06436209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33925877|NCT03984838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925878|NCT02006498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925879|NCT01250652|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925880|NCT05255978|||CASE_CONTROL||PROSPECTIVE|||||||
33925881|NCT00425100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925882|NCT02333669|||CASE_CONTROL||PROSPECTIVE|||||||
33925883|NCT05444933|||COHORT||RETROSPECTIVE|||||||
33925884|NCT00308321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004716|NCT00585312|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34004717|NCT05806931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004718|NCT03935841|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34004719|NCT01458613|||COHORT||PROSPECTIVE|||||||
33699953|NCT02642302|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33699954|NCT06134492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699955|NCT04853030|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blinded insulin formulation (Faster and Standard Insulin Aspart)||t|t|t|f
33699956|NCT00004307||||TREATMENT||||||||
33699957|NCT05099081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33699958|NCT00789009|||COHORT||PROSPECTIVE|||||||
33699959|NCT02796703|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33699960|NCT01884532|||COHORT||CROSS_SECTIONAL|||||||
33699961|NCT00971880|||CASE_ONLY||RETROSPECTIVE|||||||
33699962|NCT02299882|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33699963|NCT05468710|||COHORT||RETROSPECTIVE|||||||
33699964|NCT01524757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699965|NCT05322733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004720|NCT02565017|||COHORT||PROSPECTIVE|||||||
33699966|NCT00489060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699967|NCT01035424|||CASE_ONLY||PROSPECTIVE|||||||
33699968|NCT00526942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699969|NCT02639546|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33699970|NCT00769522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33699971|NCT04568421|||COHORT||PROSPECTIVE|||||||
33699972|NCT02380144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33699973|NCT05626816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All participants will receive the intervention, but randomization will determine the order of presentation of sham and effective stimulation to ensure blinding of the participant.|t|f|f|f
33699974|NCT02645097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699975|NCT01482273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33699976|NCT00223171|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699977|NCT05598008|||COHORT||PROSPECTIVE|||||||
33699978|NCT04783038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is a single blinded randomization to True Reiki therapy, Sham reiki Therapy or No intervention||f|f|t|f
33699979|NCT03959631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator and outcomes Assessor don´t Know the intervention assigned to each patient|"Design: pragmatic randomized controlled trial, with two parallel arms, multicenter, 18 months of follow-up~Setting Primary Care Centres belonging to the Autonomous Communities of Catalonia, (329), Madrid (262) and the Canary Islands (102)."|f|f|t|t
33699980|NCT00000471|RANDOMIZED|||PREVENTION||||||||
33699981|NCT03134833|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33699982|NCT01120535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699983|NCT05682365|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33699984|NCT04295785|||CASE_ONLY||RETROSPECTIVE|||||||
33787050|NCT03980964|RANDOMIZED|CROSSOVER||TREATMENT||NONE||One-way crossover- Patients from the control cohort are allowed to crossover to the treatment cohort after 12 weeks of study enrollment, if a subject would request receiving knee intra-articular injections of hyaluronic acid (HA) or corticosteroids (CS) or opioids. Patients are also allowed to crossover to the treatment arm if they decide to drop out of the study due to the potential lack of clinical benefits from the sham treatment.||||
33787051|NCT01898676|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33787052|NCT03615001|NA|SINGLE_GROUP||OTHER||NONE||||||
33787053|NCT03172403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787054|NCT05088226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33699985|NCT02806245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33699986|NCT06681142|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33699987|NCT06228274|||OTHER||PROSPECTIVE|||||||
33699988|NCT00417508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787055|NCT05826834|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787056|NCT01495195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787057|NCT03960983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787058|NCT02963220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787059|NCT03043066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group A - scaling and root planing Group B - scaling and root planing along with antibiotic intervention of amoxicillin and metronidazole|t|f|t|f
33787060|NCT01935258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787061|NCT06411665|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33787062|NCT06118229|||COHORT||PROSPECTIVE|||||||
33787063|NCT05085184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787064|NCT02165059|||CASE_CONTROL||PROSPECTIVE|||||||
33925885|NCT05735613|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients divided into 3 groups:~Group 1:7patients treated by traditional closed sinus lift (osteotome) with bone grafting (xenograft) and implant placement.~Group 2:7patients treated by densah drills(Versah, Jackson, MI, USA) sinus lift with bone grafting (xenograft) and implant placement.~Group 3:7patients treated by piezoelectric (Piezotome; Satelec) crestal sinus lift with bone grafting (xenograft) and implant placement."||||
33925886|NCT02670018|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925887|NCT04191213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Participants, care providers, Investigator and outcome assessor will be masked regarding the type of intervention each group will receive|The intervention group will receive Gum Arabic. And The placebo group will receive pectin|t|t|t|t
33925888|NCT05143567|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open-label cohort longitudinal study||||
33925889|NCT00362050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925890|NCT04572581|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33925891|NCT03365947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33699989|NCT01852305|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33699990|NCT04680052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33699991|NCT02148159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33699992|NCT03855228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33925892|NCT04379609|||COHORT||PROSPECTIVE|||||||
33925893|NCT01494987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925894|NCT01789658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33925895|NCT01718964|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33925896|NCT03383627|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33925897|NCT03776097|||OTHER||PROSPECTIVE|||||||
33925898|NCT00271934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925899|NCT00278941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33925900|NCT05753007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925901|NCT02472015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33699993|NCT01787422|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33699994|NCT05096052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33699995|NCT00185562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33699996|NCT06069531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33699997|NCT03458962|||FAMILY_BASED||PROSPECTIVE|||||||
33699998|NCT00002532||||TREATMENT||||||||
33699999|NCT03813667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Care provider and outcome assessor including data collectors will be blinded to group assignment.|This study uses a random control group comparison design to test the implementation of the FamPALcare intervention with R-ALD patients and their primary family caregivers.|f|t|f|t
33700000|NCT06284187|||OTHER||RETROSPECTIVE|||||||
33700001|NCT05994365|||COHORT||PROSPECTIVE|||||||
33925902|NCT05525832|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized Pilot Controlled Trial|f|f|f|t
33925903|NCT03579030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925904|NCT04163055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925905|NCT05385575|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33925906|NCT02994095|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33925907|NCT03789968|||COHORT||RETROSPECTIVE|||||||
33925908|NCT06372808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925909|NCT03242590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925910|NCT06077201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study coordinator performing the remote study visits will be blinded to the treatment group allocation until the participant has completed the study visit assessments.|Participants are randomized 1:1:1 to 3 groups.|f|f|f|t
33925911|NCT06046365|||CASE_CONTROL||PROSPECTIVE|||||||
33925912|NCT03736811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925913|NCT06305026|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925914|NCT03300219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925915|NCT03161782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925916|NCT01494415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925917|NCT05991180|||COHORT||PROSPECTIVE|||||||
33925918|NCT05869786|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective, randomized and controlled study will be conducted with patients diagnosed with stroke. Among the patients who are admitted to outpatient or inpatient rehabilitation program in SBU Kanuni Sultan Süleyman PTR clinic, 30 patients diagnosed with stroke who meet the inclusion criteria will be included in the study. Patients diagnosed with stroke will be randomized into two groups using a computer program (Virtual reality group, control group).||||
33925919|NCT06170281|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33925920|NCT06300567|||COHORT||RETROSPECTIVE|||||||
33925921|NCT01666834|||COHORT||CROSS_SECTIONAL|||||||
33925922|NCT01858896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925923|NCT00317876||||TREATMENT||NONE||||||
33700002|NCT02231697|||OTHER||RETROSPECTIVE|||||||
33700003|NCT06292104|||COHORT||CROSS_SECTIONAL|||||||
33700004|NCT05105230|||CASE_CONTROL||RETROSPECTIVE|||||||
33700005|NCT00149734|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700006|NCT04046237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700007|NCT02885207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700008|NCT01515878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700009|NCT02890927|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700010|NCT00802087|RANDOMIZED|CROSSOVER||||NONE||||||
33700011|NCT01212107|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700012|NCT06391125|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Both participants and clinicians will be blinded to the contents of the syringe. The nurse filling the syringe will assign the syringes randomly to be injected into L or R gluteal muscle and will label them accordingly, logging the designation in a log book that will remain blinded until the analysis portion of the study. The participant will be blinded as they will receive one site of injection with lidocaine and the other with normal saline, serving as their own intervention and control group.|double blinded randomized placebo control trial of addition of the effect on pain of the addition of 0.5ml 1% lidocaine solution to prepackaged benzathine Penicillin G injection, compared to addition of 0.5 ml normal saline solution, in adults being treated for syphilis (Treponema pallidum) infections, within the Infectious Diseases Clinic at Washington University in St. Louis.|t|t|t|t
33700013|NCT04332133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700014|NCT02717273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700015|NCT01757327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700016|NCT01753141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700017|NCT03097913|||CASE_ONLY||PROSPECTIVE|||||||
33700018|NCT05859685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All evaluations will be carried out by one evaluator, blinded to the study conditions and the assignment of the players to the two study groups.~The patients included in the control group underwent the same techniques as those indicated for the experimental group, but without sliding or placing joint tension. The periodicity and administration times will be the same."||t|f|f|t
34004721|NCT04459676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004722|NCT04815018|||COHORT||PROSPECTIVE|||||||
34004723|NCT05458037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925924|NCT03061812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925925|NCT05438251|NA|SINGLE_GROUP||OTHER||NONE||Uncontrolled; Open-label; Randomized: N/A; Single Arm; Duration of treatment: up to 12 weeks; Titration: no; One-center(Taiwan)||||
33925926|NCT00083369|||||PROSPECTIVE|||||||
33700019|NCT00026962||||TREATMENT||||||||
33925927|NCT02267278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925928|NCT03810521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925929|NCT06214624|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33925930|NCT00954057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925931|NCT00442260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925932|NCT00561587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33925933|NCT04831567|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, unicentric, single-stage, phase 2 clinical study of therapeutic metaiodobenzylguanidine (MIBG) for patients with metastatic well-differentiated neuroendocrine tumors and radiological progression or intolerance after standard lines of treatment and with MIBG positive scan.||||
33925934|NCT02562261|||COHORT||PROSPECTIVE|||||||
33925935|NCT01565811|||CASE_ONLY||PROSPECTIVE|||||||
33925936|NCT04257604|||COHORT||PROSPECTIVE|||||||
33925937|NCT05824455|NA|SEQUENTIAL||TREATMENT||NONE||Sequential||||
33925938|NCT02576925|||COHORT||PROSPECTIVE|||||||
33925939|NCT04968353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925940|NCT06165523|RANDOMIZED|CROSSOVER||OTHER||NONE|Both participant and investigator are unmasked to treatment conditions|Randomized, crossover.||||
33925941|NCT04429321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925942|NCT02465255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925943|NCT05523804|||COHORT||RETROSPECTIVE|||||||
33925944|NCT06316687|||OTHER||CROSS_SECTIONAL|||||||
33925945|NCT02613702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33925946|NCT05837325|||COHORT||PROSPECTIVE|||||||
33925947|NCT02088541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925948|NCT03175562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33925949|NCT00190645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925950|NCT04698512|||COHORT||PROSPECTIVE|||||||
33925951|NCT05452109|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33925952|NCT02394418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33925953|NCT03958318|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33925954|NCT06216197|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The subjects were randomly categorized into two groups utilizing random numbers generated by computer software. A sealed envelope (containing the allocation numbers of groups) was opened at the time of patient enrollment.|Fifty-eight adult patients were categorized into two groups. Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg). The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).|f|f|t|f
33925955|NCT02971293|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925956|NCT05433636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925957|NCT04296916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and physicians are not masked as to the treatment assignment. The study outcomes will be obtained by masked ophthalmic technicians according to standard protocols and read by masked graders at the End Point Adjudication Committee. The masking status of the technicians collecting data will be recorded at each study visit. The study data will be analyzed by masked researchers.|Open-label, single-center, randomized controlled trial|f|f|f|t
33925958|NCT02979444|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33925959|NCT05190536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925960|NCT00756678|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33925961|NCT06527508|||COHORT||PROSPECTIVE|||||||
33925962|NCT04020276|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase IA: 4+4 dose-escalation design - patients will be treated to a maximum tolerated dose using MRI-guided SBRT with real time adaptation.~Phase IB: Confirmatory expansion cohort in patients with liver metastases from colorectal cancer."||||
33925963|NCT04489537|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33925964|NCT05883345|||COHORT||PROSPECTIVE|||||||
33925965|NCT01804491|||COHORT|||||||||
33925966|NCT05955430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925967|NCT02979366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33925968|NCT03822338|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33925969|NCT00735761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33925970|NCT04989881|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33925971|NCT04095468|||COHORT||PROSPECTIVE|||||||
33925972|NCT01992666|NA|SINGLE_GROUP||OTHER||NONE||||||
33925973|NCT04277832|||COHORT||CROSS_SECTIONAL|||||||
34004724|NCT00220727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004725|NCT03917355|||OTHER||PROSPECTIVE|||||||
34004726|NCT01936311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004727|NCT03756337|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34004728|NCT06267183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700020|NCT03076619|||OTHER||OTHER|||||||
33925974|NCT04511078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925975|NCT04839393|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|None (Open Label)|||||
33925976|NCT04104295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33925977|NCT04285710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33925978|NCT01592006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925979|NCT05301803|||COHORT||PROSPECTIVE|||||||
33925980|NCT06527859|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33925981|NCT03044470|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33925982|NCT04340960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33925983|NCT02937688|||COHORT||PROSPECTIVE|||||||
33925984|NCT01317693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004729|NCT04329234|||COHORT||PROSPECTIVE|||||||
34004730|NCT06230380|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled trial.||||
34004731|NCT04492397|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34004732|NCT06463639|||COHORT||RETROSPECTIVE|||||||
34004733|NCT01122316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004734|NCT02297841|NA|SINGLE_GROUP||SCREENING||NONE||||||
34004735|NCT06557408|||COHORT||RETROSPECTIVE|||||||
34004736|NCT03842670|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34004737|NCT02577068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004738|NCT04950686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be informed which conditions are considered intervention versus control. All measures are assessed using a web-based data collection system rather than a human outcomes assessor.||t|f|f|t
34004739|NCT02149394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004740|NCT05038891|||COHORT||PROSPECTIVE|||||||
34004741|NCT00238563|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34004742|NCT05876351|NA|SINGLE_GROUP||TREATMENT||NONE||open-label study||||
34004743|NCT01109576|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004744|NCT04702035|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|unmasked|Three groups of individuals are enrolled in parralel: 20 iNPH patients, 20 age- and gender-matched healthy individuals and 20 young individuals.||||
34004745|NCT00519506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004746|NCT05276076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004747|NCT06149728|||COHORT||PROSPECTIVE|||||||
34004748|NCT00640458|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34004749|NCT04225065|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004750|NCT00741754|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34004751|NCT03915561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The randomization list will be generated using computer sequence number, and patient allocation ratio will be 1:1. Written allocation group will be sealed in individual opaque envelopes marked externally only with study identification numbers. An anesthetic assistant not participating in the study prepared the drug solution after breaking the codes|a two-arm, individually randomized, double-blind, placebo-controlled trial|t|t|t|t
34004752|NCT01358396|||COHORT||PROSPECTIVE|||||||
34004753|NCT00658957|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34004754|NCT04408534|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34004755|NCT03513536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34004756|NCT03743610|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34004757|NCT02459886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004758|NCT01679054|||COHORT||RETROSPECTIVE|||||||
34004759|NCT06019117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single-centre, double-blind, placebo-controlled randomized clinical trial (RCT), Interventional Model: Parallel Assignment, phase III study.|f|f|t|f
34004760|NCT02868723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004761|NCT01772355|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004762|NCT00152906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004763|NCT02124902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004764|NCT04979923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34004765|NCT03476031|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34004766|NCT04987749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34091041|NCT04688788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|MRI scan data will be transfered to the MRI Reader Centre with pseudonymized identity and without any information regarding the treatment allocation of the patient.|A prospective, 2:1 randomized, open-label, multi-centre, phase 3 non-inferiority clinical trial with blinded primary endpoint.|f|f|f|t
34091042|NCT05491967|||COHORT||PROSPECTIVE|||||||
34091043|NCT04440384|||COHORT||CROSS_SECTIONAL|||||||
34004767|NCT03695211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and observers are blinded to the block position of the superficial cervical plexus|Randomize, double blind, prospective|t|f|f|t
34004768|NCT03904550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded|single site, randomized, controlled|t|t|t|t
34004769|NCT05002777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004770|NCT02057536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004771|NCT01325506|||COHORT||PROSPECTIVE|||||||
34004772|NCT05020106|||CASE_CONTROL||PROSPECTIVE|||||||
34004773|NCT05817006|NA|SINGLE_GROUP||PREVENTION||NONE||laboratory and physical examination of postcovid syndrome in children aged 6 to 18 years||||
34004774|NCT05148533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004775|NCT04773509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Investigator, and outcomes assessor are blinded to group assignment.|Randomly selected patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides. In contrast, PVB are not performed in the control group.|t|f|t|t
34004776|NCT05201079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004777|NCT03417609|||COHORT||PROSPECTIVE|||||||
34004778|NCT01142141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34004779|NCT03547414|||CASE_ONLY||RETROSPECTIVE|||||||
34004780|NCT05903339|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34004781|NCT02948426|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34004782|NCT01156896|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34004783|NCT05425745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablet made to resemble active|Placebo-Controlled, double-blind, randomized|t|t|t|t
34004784|NCT03847974|NA|SINGLE_GROUP||TREATMENT||NONE||open-label||||
34004785|NCT05795348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004786|NCT02993705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004787|NCT06260501|||CASE_CONTROL||RETROSPECTIVE|||||||
34091044|NCT01768273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091045|NCT02253498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091046|NCT00759096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091047|NCT03784495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091048|NCT02929004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091049|NCT04593472|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34091050|NCT01039675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004788|NCT06679751|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34004789|NCT06275178|||CASE_ONLY||RETROSPECTIVE|||||||
34004790|NCT02890225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34004791|NCT04815109|||COHORT||PROSPECTIVE|||||||
33925985|NCT01262599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700021|NCT05800171|||COHORT||PROSPECTIVE|||||||
33925986|NCT06378060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33925987|NCT01090102|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33925988|NCT00868335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925989|NCT03717116|||COHORT||PROSPECTIVE|||||||
33925990|NCT05434104|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|This is an open label trial and there will be no blinding to treatment allocation of the participants or researchers. However, the analysis of samples (Gram stain and microbiome analysis) will be done blind to treatment allocation|open label randomised feasibility study over 12 weeks with qualitative, economic and microbiological evaluations.|f|f|f|t
33925991|NCT00192595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925992|NCT03527771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004792|NCT04439110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004793|NCT06678815|||OTHER||OTHER|||||||
34004794|NCT03365791|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, open-label, study to determine the efficacy and safety of treatment with the combination of PDR001+LAG525 across multiple tumor types that are relapsed and/or refractory to available standard of care therapies. Patients will receive study treatment for a maximum of 2 years. All disease assessments will be performed locally by the investigator.||||
34004795|NCT06214013|||CASE_ONLY||OTHER|||||||
34004796|NCT00235417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004797|NCT00441233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34004798|NCT06002958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700022|NCT02925832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34004799|NCT04738838|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|All will remain blinded until completion of human subjects data collection except the research pharmacist providing intranasal oxytocin or placebo.|Double-blind, placebo-controlled, randomized crossover design|t|t|t|t
34004800|NCT00164918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004801|NCT05121168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All individuals other than the investigational pharmacist who prepares each infusion pump reservoir will be masked to treatment.|Randomized, Triple-Masked, Placebo-Controlled, Parallel-Arm Human Subjects Clinical Trial|t|t|t|t
33700023|NCT05221710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700024|NCT05357638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700025|NCT02616978|||CASE_ONLY||RETROSPECTIVE|||||||
33700026|NCT01820065|||COHORT||PROSPECTIVE|||||||
34004802|NCT06149091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700027|NCT01931930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33700028|NCT05788900|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33700029|NCT06680024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33700030|NCT04925726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33700031|NCT04047329|||CASE_CONTROL||RETROSPECTIVE|||||||
34004803|NCT00005858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004804|NCT00426179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34004805|NCT00550888|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34091051|NCT01180777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091052|NCT00214227|||COHORT||PROSPECTIVE|||||||
34091053|NCT01200914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091054|NCT03120793|||COHORT||PROSPECTIVE|||||||
34091055|NCT03543995|||CASE_CONTROL||PROSPECTIVE|||||||
34091056|NCT00788333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700032|NCT03384888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The parallel clinical trial simultaneously compares two groups of individuals, one of which receives the intervention of interest and the other is a control group (sham).|t|t|t|f
33700033|NCT00224731|||DEFINED_POPULATION||OTHER|||||||
33700034|NCT06557928|||CASE_ONLY||PROSPECTIVE|||||||
33700035|NCT06104176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787065|NCT06063330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There are 3 different treatment arms that subjects will be randomized in a 1:1:1 ratio. The arms will be evenly distributed with 22 subjects in each arm: 1) low dose of RQ-01; 2) high dose of RQ-01; 3) Placebo|t|t|t|t
33787066|NCT03425604|||CASE_CONTROL||RETROSPECTIVE|||||||
33787067|NCT02485743|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33787068|NCT02391246|||COHORT||RETROSPECTIVE|||||||
33925993|NCT01061567|||COHORT||PROSPECTIVE|||||||
34004806|NCT00172016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004807|NCT04681014|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34004808|NCT02090231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34004809|NCT05380219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004810|NCT03395015|||CASE_CONTROL||PROSPECTIVE|||||||
34091057|NCT06059859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787069|NCT03781804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787070|NCT04882722|||COHORT||PROSPECTIVE|||||||
33787071|NCT06487468|||COHORT||RETROSPECTIVE|||||||
34091058|NCT02502500|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34091059|NCT01516125|||CASE_ONLY||CROSS_SECTIONAL|||||||
33700036|NCT00268788|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33700037|NCT01219998|||COHORT||PROSPECTIVE|||||||
33787072|NCT02118506|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33925994|NCT04128527|||COHORT||PROSPECTIVE|||||||
33925995|NCT00649168|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33925996|NCT00703170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33925997|NCT00762268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33925998|NCT04734769|||COHORT||RETROSPECTIVE|||||||
33925999|NCT02189070|||COHORT||PROSPECTIVE|||||||
33926000|NCT01616784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926001|NCT00778726|RANDOMIZED|CROSSOVER||||NONE||||||
33926002|NCT00322179|||OTHER||OTHER|||||||
33926003|NCT03733457|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33926004|NCT00142402|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33926005|NCT02778945|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33926006|NCT04408170|||COHORT||PROSPECTIVE|||||||
33926007|NCT06333236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926008|NCT05710770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind.|Double-blinded, randomized, sham-controlled trial|t|t|t|t
33926009|NCT03848715|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Blinded infusion|Endotoxin vs Placebo|t|t|f|t
33926010|NCT05944159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926011|NCT05221255|RANDOMIZED|PARALLEL||TREATMENT||NONE||interventional prospective trial||||
33926012|NCT02198989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926013|NCT04562532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926014|NCT00991224|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33926015|NCT01293110|||CASE_ONLY||PROSPECTIVE|||||||
33926016|NCT04364347|||COHORT||PROSPECTIVE|||||||
34004811|NCT01358084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004812|NCT05465980|||COHORT||PROSPECTIVE|||||||
34004813|NCT02793713|||COHORT||PROSPECTIVE|||||||
34004814|NCT01814358|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34004815|NCT01788241|||COHORT||PROSPECTIVE|||||||
34004816|NCT03989011|||COHORT||PROSPECTIVE|||||||
34004817|NCT03180528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004818|NCT00055718|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34004819|NCT06044584|||COHORT||PROSPECTIVE|||||||
34004820|NCT04311944|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Patients will be randomized in a 1:1 ratio to early fast-track vs. standard care.||||
34004821|NCT00826072|||CASE_CONTROL||PROSPECTIVE|||||||
34004822|NCT00559364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34004823|NCT02887924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091060|NCT00182819|RANDOMIZED|||TREATMENT||NONE||||||
34091061|NCT03956706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34091062|NCT06217549|NA|SINGLE_GROUP||OTHER||NONE||||||
34091063|NCT04359212|||COHORT||PROSPECTIVE|||||||
33926017|NCT01825226|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33926018|NCT03835013|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Part A - 2 infusions Part B - 4 infusions|t|f|f|f
33926019|NCT02053558|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33926020|NCT04213183|||OTHER||PROSPECTIVE|||||||
33926021|NCT00868543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926022|NCT04907422|||CASE_CONTROL||PROSPECTIVE|||||||
33926023|NCT04231513|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33926024|NCT06357884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926025|NCT00611611|||CASE_CONTROL||PROSPECTIVE|||||||
33926026|NCT00055848|||CASE_ONLY||PROSPECTIVE|||||||
33926027|NCT03684941|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33926028|NCT02708615|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33926029|NCT06249009|RANDOMIZED|CROSSOVER||OTHER||NONE||The included patients will then be randomized into two separate groups: a CPAP group with PEEP at 7 cmH2O for 30 minutes and an HFNC group with increasing flow rates from 2L/kg/min to 5 L/kg/min with 30 minutes of study for each flow. After a wash-out period of 15 minutes, according to the cross-over procedure, the patients will change groups in order to perform the remaining analysis.||||
33926030|NCT01851863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926031|NCT05246488|||OTHER||CROSS_SECTIONAL|||||||
33926032|NCT02588560|||CASE_ONLY||PROSPECTIVE|||||||
34004824|NCT06503887|||CASE_CONTROL||PROSPECTIVE|||||||
34004825|NCT00294892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004826|NCT01228227|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004827|NCT01341587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004828|NCT02124473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700038|NCT02654847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004829|NCT01411488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 Groups were randomly assigned to 1 of 2 different fecal management systems||||
34004830|NCT06237101|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34004831|NCT06004024|||COHORT||CROSS_SECTIONAL|||||||
34004832|NCT03027908|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34004833|NCT00683787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004834|NCT02822196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004835|NCT06616558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33926033|NCT06383689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Like in psychological studies, only patients can participate in the study who consent to accept that complete study information can only be provided after the entire study was finished (with an option to withdraw consent at that point) as information on ingredients of the study pill (which is placebo) must be concealed for inherent reasons (study on effects of covered placebo).|"monocentric single-blinded randomized clinical study on the effectiveness of covered placebo on epileptic seizure occurrence and emotional well-being with 3 study conditions: seizure pill (PCB-S), well-being pill (PCB-W) and no pill (control)"|t|f|f|f
34004836|NCT01247844|RANDOMIZED|PARALLEL||||NONE||||||
33700039|NCT01197716|||COHORT||PROSPECTIVE|||||||
34004837|NCT02402491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004838|NCT01958515|||CASE_CONTROL||PROSPECTIVE|||||||
34004839|NCT06591572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004840|NCT04979845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34004841|NCT02405572|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34004842|NCT04329676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004843|NCT00498199|||COHORT||PROSPECTIVE|||||||
34004844|NCT05878041|||CASE_ONLY||PROSPECTIVE|||||||
34004845|NCT04922294|||OTHER||RETROSPECTIVE|||||||
34004846|NCT05484141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33700040|NCT00017199||||TREATMENT||||||||
33700041|NCT00885053|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700042|NCT03824184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized controlled trial|t|t|t|t
33700043|NCT01788046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700044|NCT00276146|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33700045|NCT02585154|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Blinded video assessment|blinded cross-over study of no deep brain stimulation, conventional deep brain stimulation and adaptive deep brain stimulation|t|f|f|t
33700046|NCT05192473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700047|NCT05522452|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33926034|NCT00929045|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926035|NCT03168555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926036|NCT05800834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926037|NCT05832099|||COHORT||PROSPECTIVE|||||||
33926038|NCT05359809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33926039|NCT02220361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33926040|NCT00414505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926041|NCT02193672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926042|NCT02293824|||COHORT||PROSPECTIVE|||||||
33926043|NCT01306851|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33926044|NCT00355134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926045|NCT01207284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926046|NCT00656084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004847|NCT00980408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34004848|NCT05049668|||COHORT||PROSPECTIVE|||||||
34004849|NCT00508833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34004850|NCT05103657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004851|NCT02654015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004852|NCT04282239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34004853|NCT03607045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||two groups homogeneous|t|f|t|f
34004854|NCT04220775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004855|NCT01755975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004856|NCT06612827|||COHORT||PROSPECTIVE|||||||
34004857|NCT01223209|NA|SINGLE_GROUP||||NONE||||||
34004858|NCT02785627|||CASE_CONTROL||PROSPECTIVE|||||||
34004859|NCT02285933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004860|NCT00235118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004861|NCT03686215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will only be applied until the standard of care surgery is complete. At time of randomization, the study arm will be revealed to the study team. The pathologist will be masked to the type of tissue obtained from the patient.|Subjects will be randomized to receive the device intervention. All subjects will receive the study drug.|f|f|t|t
34004862|NCT06668116|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34004863|NCT03797001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004864|NCT02093923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004865|NCT03516487|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind|Dose-escalating, randomized, double-blinded, placebo-controlled|t|t|t|t
33700048|NCT00113087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700049|NCT04693546|||COHORT||PROSPECTIVE|||||||
33700050|NCT02256371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700051|NCT03930758|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Study consisted of 5 experimental trials (or arms), of which 4 were compared to a sedentary (or control) arm. The five trials were: Uphill exercise before the meals (UBM), Uphill exercise after the meals (UAM), Downhill exercise before the meals (DBM), and Downhill exercise after the meals (DAM), and the Sedentary (Sed) or control trial.||||
33787073|NCT06629064|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization will occur using a code corresponding to intervention arm. Participant and provider will not know the number-condition link.|Two group randomized controlled trial of WMT versus a Sham training|t|f|f|t
34004866|NCT04759079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004867|NCT01195155|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34004868|NCT00035555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926047|NCT04905823|||COHORT||RETROSPECTIVE|||||||
33926048|NCT00139607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926049|NCT06344871|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926050|NCT00002707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926051|NCT01423955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926052|NCT04104373|||COHORT||PROSPECTIVE|||||||
33926053|NCT02449772|||COHORT||RETROSPECTIVE|||||||
33926054|NCT00391781|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33926055|NCT01256203|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33926056|NCT02785146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926057|NCT06343025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes ,Assesor, who will make the evaluations in the first week and after 12 weeks, will not know which group the people are in.|Individuals will be divided into 3 groups: Clinical Pilates group, Tai Chi group and Control group. 3 groups. 3 groups will be measured at the same time and then the exercise part will begin.|f|f|f|t
33926058|NCT03810378|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||40 adults will be randomized in cross-over design to a Ketogenic or Mediterranean diet for 12 weeks each (no washout) with a 1 month follow-up at the end of the second phase.|f|f|t|t
33926059|NCT02959112|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|As the two solutions are colourless, the endoscopist, nurse and patient were all blinded to the intervention. Investigators who participated in the evaluation of post-ERCP complications were also blinded to group allocation.|Participants were allocated into groups by block randomisation using computed-generated numbers. The two groups were rectal indomethacin and epinephrine sprayed on the ampulla versus rectal indomethacin and sham water spray.|t|t|f|t
33926060|NCT00431496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926061|NCT06403293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were blinded to the chosen root canal sealer and activation protocol.||t|f|f|f
33700052|NCT03659539|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The attending anaesthesiologist will not be blinded to the technique utilized to administer GA and also to the in-OR recovery profile immediately after tracheal extubation. However, they will be blinded to postoperative recovery parameters, which will be noted by an independent assessor unaware of the technique utilized for administering GA.|"120-patients aged 18-65 years, ASA physical status I/II, of either sex, and undergoing elective major robotic surgery will be randomly allocated to one of the following two groups:~Group-1 \[CLADS Group, n=60\]: Anaesthesia will be induced and maintained with propofol administered using the BIS feedback-based automated CLADS.~Group-2 \[Desflurane Group, n=60\]: Anaesthesia will be induced with propofol CLADS and will be maintained intraoperatively by Desflurane titrated to BIS monitoring."|t|f|f|t
33700053|NCT01790932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926062|NCT04086602|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Healthy volunteer section is double blind.||t|f|t|f
33700054|NCT00183820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700055|NCT00801320|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33926063|NCT05450744|NA|SEQUENTIAL||TREATMENT||NONE||3+3 ascending dose||||
33926064|NCT02456792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926065|NCT03108625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926066|NCT06456515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926067|NCT02808507|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926068|NCT00255879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926069|NCT01213914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926070|NCT00215241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926071|NCT02533687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926072|NCT01766219|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33926073|NCT02052141|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33926074|NCT04860011|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomised, active-comparator, multi-centre, open label study.||||
33926075|NCT03879993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blood collections and subsequent analyzes were done blindly.||f|f|f|t
33700056|NCT04937946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700057|NCT06450262|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33700058|NCT00812851|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700059|NCT05403658|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study investigators will not know which families were randomized to the experimental group or control group. Data analyses, both quantitative and qualitative, will be led by investigators who will have no direct contact with families and will not have access to information regarding group assignment. Interventions will be delivered by Family Navigators and data collection will be completed by research team members, although both groups will be aware of families' group assignments.||f|f|t|f
33700060|NCT05678907|||COHORT||PROSPECTIVE|||||||
33700061|NCT00413244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700062|NCT01050855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700063|NCT00843531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787074|NCT02957292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787075|NCT06630845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926076|NCT05886309|||COHORT||PROSPECTIVE|||||||
33926077|NCT02691364|||CASE_CONTROL||PROSPECTIVE|||||||
33926078|NCT00086736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926079|NCT03327519|RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental, longitudinal, randomized controlled trial||||
33926080|NCT04226612|||OTHER||RETROSPECTIVE|||||||
33926081|NCT02349737|||COHORT||CROSS_SECTIONAL|||||||
33926082|NCT04348994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926083|NCT05722314|||CASE_ONLY||PROSPECTIVE|||||||
33926084|NCT04836507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926085|NCT02382159|||CASE_CONTROL||RETROSPECTIVE|||||||
33926086|NCT00024193||||TREATMENT||||||||
33926087|NCT04202276|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33926088|NCT04687007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to 12 months of SMART-ALD intervention (experimental group; EG) or a waiting list control group (CG), in which patients receive 6 months of SMART-ALD after a 6-months waiting period.||||
33926089|NCT05188599|||CASE_ONLY||CROSS_SECTIONAL|||||||
33926090|NCT02050906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33926091|NCT05706961|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34004869|NCT00930033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004870|NCT01736748|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004871|NCT06678230|NA|SINGLE_GROUP||TREATMENT||NONE||Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.||||
34004872|NCT03466827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004873|NCT04851067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34004874|NCT00973089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33700064|NCT05038943|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Cardiac allografts recovered from donors after circulatory death with thoracoabdominal normothermic regional perfusion will be transported with Paragonix SherpaPak Cardiac Transport System to the recipient center||||
33700065|NCT02812173|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33700066|NCT00132210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700067|NCT04055961|||CASE_ONLY||OTHER|||||||
33700068|NCT05920278|||CASE_ONLY||PROSPECTIVE|||||||
33700069|NCT04781504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33700070|NCT01268020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700071|NCT03920748|||COHORT||PROSPECTIVE|||||||
33700072|NCT04789239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"For the 2nd part of study, ie randomized treatment, it is double-blinded with blinding for subjects, endpoint assessors and study personnel. Pharmacy is responsible for masking of differences in appearance, smell and taste, and also packaging and label-ling to ensure blinding.~Individual treatment codes, indicating the treatment randomisation for each random-ised subject, will be available to Pharmacy where the personnel are independent to the study evaluation.~The treatment code should not be broken except in medical emergencies when the appropriate management of the subject requires knowledge of the treatment randomisation. The Investigator documents and reports the action to PI, without revealing the treatment given to subject to the PI."|"A multicenter, 1:1 randomized, placebo-controlled, double-blinded study in Sweden of 230 heart failure patients with reduced ejection fraction.~This study consists of 2 phases: 1) open-label run-in within maximum 2 months, and 2) randomized, double-blinded and placebo-controlled treatment during 6 months.~The open-label phase, in turn, consists of three periods: run-in (1 - 2 weeks), correction (maximum 72 hours) and maintenance (at least 4 weeks).~After the open-label run-in phase, upon randomization (1:1 ratio to receive investigational product (IP), either Sodium Zirconium Cyclosilicate (SZC) or placebo, in a blinded manner), SZC will be switched to investigational drug (IP) but with the same dose individually as for SZC before randomization (pre-randomization dose)."|t|t|t|t
33700073|NCT02505295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a feasibility/pilot study|f|f|f|t
33700074|NCT06681480|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700075|NCT06680960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926092|NCT02010814|||OTHER||CROSS_SECTIONAL|||||||
33926093|NCT05685719|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33926094|NCT04840368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33926095|NCT05185648|NA|SEQUENTIAL||OTHER||NONE||||||
33926096|NCT05151224|||COHORT||PROSPECTIVE|||||||
33926097|NCT02969538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926098|NCT02701179|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33926099|NCT00354939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926100|NCT05466071|||COHORT||PROSPECTIVE|||||||
33926101|NCT00985413|||COHORT|||||||||
33926102|NCT01708707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926103|NCT03151135|||CASE_ONLY||PROSPECTIVE|||||||
33926104|NCT03043209|||CASE_ONLY||PROSPECTIVE|||||||
33926105|NCT00782301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926106|NCT04429412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will be blind to the group that owns the patients included.|This is a randomized clinical trial in which some patients receive the EMC+ and others treatment as usual.|f|f|f|t
33926107|NCT01274312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926108|NCT00460629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926109|NCT04586296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004875|NCT02710214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004876|NCT06437028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This study will be modified platform design in which two treatment groups will be compared to one control group initially. However, this study design will enable the inclusion of additional study groups over time while concomitantly increasing the control group size to maintain adequate power.|f|f|t|t
34004877|NCT01054352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004878|NCT01737255|||CASE_CONTROL||PROSPECTIVE|||||||
34004879|NCT02043158|||COHORT||PROSPECTIVE|||||||
34004880|NCT02754128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34091064|NCT01181479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091065|NCT00222781|||||PROSPECTIVE|||||||
34091066|NCT00672009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091067|NCT03602781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091068|NCT00562341|||CASE_ONLY||PROSPECTIVE|||||||
33926110|NCT03380000|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Treatment order will be randomly assigned to participants by Clinical Research Center (CRC) staff using computer-based mathematical software. The generated list that determines each participants treatment order will be kept in a secure location in the CRC which cannot be accessed directly by research team members.||t|f|t|f
34091069|NCT00962962|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33926111|NCT00038272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926112|NCT04266158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33926113|NCT00178061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926114|NCT03216161|||COHORT||CROSS_SECTIONAL|||||||
33926115|NCT00271271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926116|NCT06402786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926117|NCT03385408|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33926118|NCT01044797|||CASE_ONLY||PROSPECTIVE|||||||
34091070|NCT03877809|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, pilot, single centre, open-label phase II study with sirolimus in patients with transfusion dependent beta-thalassemia||||
34091071|NCT01609972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091072|NCT01277419|||COHORT||PROSPECTIVE|||||||
34091073|NCT05306288|||COHORT||PROSPECTIVE|||||||
34091074|NCT00528151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091075|NCT01814085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926119|NCT05764876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will not be present for treatment nor for outcome assessment, and data analysis (statistics) will be blinded.|Open-label, non inferiority, two arms and randomized clinical trial. Eligible patients will be randomized (1:1) to receive Linezolid (experimental arm) or Azithromycin (control arm).|f|f|t|f
34091076|NCT04194970|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE||First Step of Research: development of product that can provide live-feedback (insole with pressure sensors, mobile application) (approximately- 10 healthy volunteers) Second Step of Research: Testing this product on healthy volunteers Third Step of Research: Following up the post-operative patients with product ( Group I - monitoring with live feedback, Group II- monitoring without live-feedback) (approximately- 10 post-operative patients)|t|f|f|t
33926120|NCT03707262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926121|NCT04909216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926122|NCT02313415|NA|SINGLE_GROUP||TREATMENT||NONE||treatment of infertility caused by recurrent intrauterine adhesions by collagen scaffold loaded with UC-MSCs||||
33926123|NCT05668637|||OTHER||RETROSPECTIVE|||||||
33926124|NCT01773798|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33926125|NCT04147507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926126|NCT00379236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926127|NCT04753593|||OTHER||PROSPECTIVE|||||||
33926128|NCT00182507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926129|NCT05284357|||COHORT||RETROSPECTIVE|||||||
33926130|NCT00189787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926131|NCT04106973|||CASE_CONTROL||PROSPECTIVE|||||||
33926132|NCT01158066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926133|NCT06317220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926134|NCT03465384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent clinicians will perform diagnostic assessments at pre and post measurements. The clinicians will be blind to the experimental condition the participants they assess.|Participants are randomized to the standard intervention (Parent training in group format) or the experimental condition (Internet-based parent training).|f|f|f|t
33926135|NCT02117804|||CASE_CONTROL||PROSPECTIVE|||||||
33926136|NCT04000022|||COHORT||PROSPECTIVE|||||||
33926137|NCT02057068|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|This efficacy study was not blinded.|Randomization to an immediate intervention group or a no-contact wait list control group. Following post intervention assessments the wait-list control group received the intervention.||||
33926138|NCT00294827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926139|NCT06310070|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926140|NCT05106595|||COHORT||CROSS_SECTIONAL|||||||
33926141|NCT00216775|||COHORT||PROSPECTIVE|||||||
33926142|NCT02275910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926143|NCT01917240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004881|NCT04611581|||COHORT||PROSPECTIVE|||||||
34004882|NCT06677658|||COHORT||RETROSPECTIVE|||||||
34004883|NCT00756717|NA|SINGLE_GROUP||OTHER||NONE||||||
34004884|NCT04636450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessor will be blinded as the interventions can not be blinded to the participant and care provider.|Randomized controlled trial|f|f|f|t
34004885|NCT00000890|||NATURAL_HISTORY|||||||||
34004886|NCT01817686|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34004887|NCT03430011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004888|NCT03380416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34004889|NCT02466386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004890|NCT06427369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004891|NCT01589601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004892|NCT02077335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004893|NCT01514123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004894|NCT04646824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004895|NCT02436187|||COHORT||PROSPECTIVE|||||||
34004896|NCT04985838|RANDOMIZED|PARALLEL||TREATMENT||NONE||A mixed methods randomised controlled pilot trial||||
34004897|NCT03304431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|QTc (corrected QT), QT dispersion (QTd), P wave dispersion will calculated by a blind researcher.|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Vemcaine pump spray 10% 50 ml) 160 mg (16 puffs).|f|f|f|t
34091077|NCT00113685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33787076|NCT04244318|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the characteristics of the intervention and the allocation, neither caregivers nor the professionals will be blinded.|||||
34091078|NCT02516488|||OTHER||PROSPECTIVE|||||||
33787077|NCT01913340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091079|NCT05510453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091080|NCT03411551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787078|NCT02501772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926144|NCT06090448|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No masking will take place.|"Participants in all clinical groups of the study will perform identical at-home procedures and be asked to complete the same weekly and daily tasks and relevant questionnaires.~Participants in clinical groups 2,3 and 4 at PHU (Arm ) of the study will complete two additional in-person visits to Queen Alexandra Hospital at the beginning and end of the study, whereby additional data on the robustness of the EarSwitch will be tested."||||
33926145|NCT04716478|||COHORT||PROSPECTIVE|||||||
33926146|NCT04589962|||OTHER||RETROSPECTIVE|||||||
33926147|NCT01785108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926148|NCT05195268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and operators will be aware of the treatment arm. Researchers interpreting and assessing outcome data will be blinded to treatment received.|A randomised controlled trial with two arms: 1) Pulmonary vein isolation + posterior wall isolation; 2) Pulmonary vein isolation alone|f|f|f|t
33926149|NCT00933192|||COHORT||PROSPECTIVE|||||||
33926150|NCT05187585|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926151|NCT01170312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926152|NCT03925415|||COHORT||CROSS_SECTIONAL|||||||
33926153|NCT01879254|||CASE_ONLY||PROSPECTIVE|||||||
33926154|NCT03137017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The randomization will be realized using a Williams Square with a 4x4 design.||||
33926155|NCT04324788|||OTHER||PROSPECTIVE|||||||
33926156|NCT05776550|||COHORT||PROSPECTIVE|||||||
33926157|NCT03989856|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Allocation and concealment will be done by sequentially sealed opaque envelopes. 60 envelopes will be numbered serially from 1 to 60, 30 envelopes will contain the letter c and the other 30 will contain the letter S.~In each envelope, the corresponding letter which donates the allocated group will be put according to the randomization table and them all envelopes will be closed and put in one box. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside."|The study population comprises females in childbearing period underwent laparoscopic ovarian cystectomy at Ain Shams University Maternity Hospital, Obstetric and Gynecology Department, Faculty of medicine.|t|f|t|f
33926158|NCT06154499|||COHORT||PROSPECTIVE|||||||
33926159|NCT02025829|||CASE_ONLY||PROSPECTIVE|||||||
34091081|NCT04115059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091082|NCT01414309|||COHORT||PROSPECTIVE|||||||
34091083|NCT00162734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091084|NCT00080106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091085|NCT05347355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091086|NCT06392087|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Step Wedge Design||||
34091087|NCT00832806|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091088|NCT01942512|||COHORT||PROSPECTIVE|||||||
34091089|NCT06324617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091090|NCT03218527|||COHORT||PROSPECTIVE|||||||
34091091|NCT06189950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091092|NCT05862701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091093|NCT04585594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091094|NCT03036631|||CASE_CONTROL||PROSPECTIVE|||||||
34091095|NCT05967468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor is blinded|Children (N=100), ages 7-13 will be randomized to one of three conditions|f|f|f|t
34091096|NCT04167800|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial||||
34091097|NCT04552093|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with potentially resectable (i.e. unresectable or upfront resectable with an indication for upfront systemic therapy) will receive hepatic artery infusion pump chemotherapy, consisting of floxuridine (FUDR), combined with standard of care systemic therapy (FOLFOX or FOLFIRI).||||
34091098|NCT04916678|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The study is a multi-site cluster randomized cross-over trial with two comparative groups. In each site, the control period and intervention period span over a period of 10 days (5 days for control and 5 days for intervention). The sequence of the control and intervention periods will be set at random.||||
34091099|NCT01813643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091100|NCT01449487|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091101|NCT04424901|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Open Label Study Standard Care vs. Standard Care with Dipyridamole||||
34091102|NCT01651585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091103|NCT01837056|||CASE_ONLY||PROSPECTIVE|||||||
34091104|NCT02596087|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34091105|NCT04820504|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34091106|NCT04585360|||COHORT||PROSPECTIVE|||||||
33700076|NCT02175628|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700077|NCT01161108|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33700078|NCT01739114|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33700079|NCT02325986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700080|NCT02212795|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33700081|NCT02284542|||CASE_CONTROL||PROSPECTIVE|||||||
33700082|NCT04834232|||COHORT||PROSPECTIVE|||||||
33700083|NCT04160533|||COHORT||CROSS_SECTIONAL|||||||
33700084|NCT00909896|||COHORT||PROSPECTIVE|||||||
33700085|NCT00819299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700086|NCT06557213|||COHORT||PROSPECTIVE|||||||
33700087|NCT03714620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study investigators, patients and clinicians except the clinical pharmacist will be blinded to the study treatment allocation. Treatment will be prepared and blinded by the ED clinical pharmacist.|The sequence will be generated using randomization permuted blocks of 2 and 4 patients, with the allocated dose revealed using an online randomization module within the REDCap data management system.|t|t|t|t
33700088|NCT01570296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700089|NCT02469740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33700090|NCT05954455|||CASE_ONLY||PROSPECTIVE|||||||
33700091|NCT01175460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700092|NCT06307873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787079|NCT04157166|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"a group in which the conventional recording followed by complementary images in planar or TEMP, will be realized in first intention and the procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT), will be performed just before and,~* another group in which these recordings will be made in the reverse order"||||
33787080|NCT03563521|||CASE_CONTROL||PROSPECTIVE|||||||
33787081|NCT00308958|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33787082|NCT05687500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787083|NCT03556605|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787084|NCT04461106|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33787085|NCT03232684|||COHORT||PROSPECTIVE|||||||
33787086|NCT02086708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787087|NCT05623280|||OTHER||OTHER|||||||
33787088|NCT06630065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787089|NCT02476773|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33787090|NCT06047262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|randomised controlled trial|t|f|t|f
33926160|NCT04301583|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Sachets||t|f|t|f
33926161|NCT01053403|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33926162|NCT01181310|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33926163|NCT00416312|||COHORT||PROSPECTIVE|||||||
33926164|NCT02326389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926165|NCT01961089|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33926166|NCT04698681|||COHORT||PROSPECTIVE|||||||
33926167|NCT04820153|NA|SINGLE_GROUP||OTHER||NONE||||||
33926168|NCT04944381|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926169|NCT00063310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926170|NCT04018612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind, Placebo controlled|High Dose Acetaminophen (APAP) versus Placebo, Low Dose APAP versus Placebo|t|f|t|f
33926171|NCT03884023|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33926172|NCT04463225|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group will receive three opportunities to engage with a personalized internet-delivered brief intervention over the course of seven months and the second group will not be granted access.||||
34004898|NCT03092596|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34004899|NCT06502990|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34004900|NCT06012578|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34004901|NCT02221063|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34004902|NCT05333315|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34004903|NCT05082467|||COHORT||PROSPECTIVE|||||||
34004904|NCT02342041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004905|NCT06502210|||CASE_CONTROL||OTHER|||||||
34004906|NCT01896505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004907|NCT04869839|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34004908|NCT01601691|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004909|NCT06364072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004910|NCT04021758|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data analyses will be conducted by a quantitative psychology postdoctoral fellow under the supervision of Dr. Brian Baucom, PhD, at The University of Utah, and Kent Corso, PsyD, BCBA-D, at Xcelerate Innovations. Dr. Baucom serves on the University of Utah's Department of Psychology's Statistical Consulting Service, and has prior experience with clinical trial methodology and military research. Dr. Corso is a certified behavior analyst with extensive experience using single case design methodology and applying this approach to military settings. None of the data analysts will be involved in data collection procedures, and will remain therefore blind to treatment assignment. Prior to statistical analyses, data will be screened to identify distributional properties.|"The study design entails a dynamic wait list design in which participants are randomly assigned to either the Peer-to-Peer (P2P) program or a wait list control condition. Randomization will be conducted at the squadron level using a computerized randomization algorithm.~The proposed dynamic wait list design differs primarily from the traditional wait list designs with respect to timing of intervention. In the traditional wait list design, half of the squadrons (i.e., N/2) would be randomized to implement the P2P program early in the study and the remaining half would implement the P2P program later in the study. By contrast, the dynamic wait list randomizes the timing of the intervention over the entire course of the study period by first dividing the overall study period into m equal time blocks, and then randomizing N/m squadrons to receive the P2P program during each time block."|f|f|f|t
34004911|NCT04024319|||COHORT||PROSPECTIVE|||||||
34004912|NCT06677801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004913|NCT02301858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004914|NCT05301569|||OTHER||CROSS_SECTIONAL|||||||
33787091|NCT03822351|RANDOMIZED|PARALLEL||TREATMENT||NONE||"At study onset subjects will be randomized equally to all study treatment arms open for enrollment and will remain on study treatment for up to 12 months.~Study treatment will be discontinued upon disease progression, unacceptable toxicity, or other reason. The treatment arms are Control Arm, Arm A and Arm B."||||
33926173|NCT06059092|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants and their parents will not be aware of precise hypotheses. Nevertheless, for ethical reasons, they are informed that the interventions are meant to improve well-being (before random allocation to control or experimental conditions).|A pre-test assessment will precede all interventions (experimental conditions) and control group sessions delivered simultaneously, and followed by a post-test assessment and and follow-up assessment three months after that.||||
33926174|NCT03242161|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants assigned to have a lab patch-alcohol applied to skin and then receive a single dose of alcohol and then the patch measures how much alcohol appears in interstitial fluid. This is compared to the blood alcohol concentrations.||||
33926175|NCT00927758|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33926176|NCT00083876|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926177|NCT03126578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926178|NCT06195904|||COHORT||PROSPECTIVE|||||||
33926179|NCT01459770|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33926180|NCT01228188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926181|NCT03825510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004915|NCT01908205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004916|NCT03498924|||CASE_CONTROL||PROSPECTIVE|||||||
34004917|NCT01655251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004918|NCT00873834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004919|NCT02988271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34004920|NCT06679491|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This study uses a parallel-group, randomized, controlled interventional model with four arms. Participants are allocated to one of four groups based on menstrual cycle status and training intensity patterns:~Three groups consist of female athletes with natural menstrual cycles who are assigned to different training regimens based on specific menstrual phases (higher intensity in either follicular or luteal phases, or a continuous approach).~The fourth group includes female athletes on oral contraceptives who follow a continuous training regimen as a control.~Each participant completes a 13-week resistance training program with two weekly sessions. Randomization is stratified by BMI and age to ensure balanced group characteristics. The primary objective is to assess changes in neuromuscular function, with each group experiencing variations in training intensity aligned with hormonal influences across menstrual phases."||||
34004921|NCT00631007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004922|NCT05155579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|For groups 1, 2 and 3, participants and investigators will be blinded to group allocation. Study staff involved in storage and preparation of the vaccine will be aware of vaccine assignment but these staff will play no other role in the study. The Sponsor team will remain blinded with the exception of designated members of the laboratory team that will perform the final evaluation of the data. For groups 4 and 5, no study staff or participants will be blinded as the number of vaccinations in each group is different. For group 6, no study staff or participants will be blinded as the schedule of vaccinations in each group is different.|RCT|t|f|t|f
34004923|NCT05108376|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34004924|NCT00494351|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34004925|NCT06147414|||COHORT||PROSPECTIVE|||||||
34004926|NCT00878787|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34004927|NCT06617754|||COHORT||OTHER|||||||
34004928|NCT06300606|||COHORT||PROSPECTIVE|||||||
34004929|NCT01560819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004930|NCT05472896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the independent review committee (IRC) was used to evaluate the efficacy, and the readers reviewed the imaging data in a blinded state to make efficacy judgments. The following information was blinded to independent readers: subject's name, date of birth, personal information such as subject's initials, date of examination, statistical grouping, name of study unit, lesion selected by study unit for tumor evaluation, study Unit-determined tumor response and imaging reasons.|an open, parallel-controlled, multicenter randomized trial|f|f|f|t
34004931|NCT05655429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34004932|NCT03754504|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33787092|NCT04290429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787093|NCT04296032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787094|NCT03383887|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33787095|NCT01250002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787096|NCT01740557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787097|NCT05402891|NA|SINGLE_GROUP||PREVENTION||NONE||A prospective phase II, single arm pilot trial, with a duration of 18 months. The drug will be administered between month 6 and 12. All patients will be treated with Lithium with an oral dose of 300mg a day for six months, achieving a therapeutic serum level between 0.2-0.4 mmol/L. The duration of this study will be 18 months, and patients will undergo four colonoscopies in total (at t=0, t=6, t=12, t=18). During each colonoscopy biopsies from normal intestinal mucosa will be collected to determine stem cell dynamics.||||
33787098|NCT05107713|||OTHER||PROSPECTIVE|||||||
33787099|NCT02214108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787100|NCT05616559|||COHORT||PROSPECTIVE|||||||
34004933|NCT03876028|NA|PARALLEL||TREATMENT||NONE||"The study will enroll patients into two arms in parallel: Arm 1: Patients will start ibrutinib treatment before leukapheresis. Arm 2: Patients will start ibrutinib treatment after leukapheresis. Approximately 3-6 patients will be enrolled into each of the two arms in parallel. An early safety review will be performed after these patients have received sufficient ibrutinib treatment and tisagenlecleucel infusion, and have completed at least 21 days of follow up. Additional patients (up to 20 total) will be enrolled into both arms to further characterize the safety, tolerability and preliminary efficacy of ibrutinib in combination with tisagenlecleucel."||||
34004934|NCT02902133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004935|NCT04443569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor/statistician will not be made aware of the treatment group of the patients.|This will be a prospective randomized non-blinded controlled trial. All cesarean sections for women undergoing their first or second cesarean delivery will be included. Patients will be approached and consented during the pre-operative period when presenting for scheduled surgery or at the time of consent for a non-scheduled cesarean section. The lidocaine patch would be placed on the superior-lateral aspect of the Pfannenstiel incision in the PACU prior to being transferred to the postpartum floor.|f|f|f|t
34004936|NCT04857151|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34004937|NCT00512538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004938|NCT03938480|||COHORT||RETROSPECTIVE|||||||
34004939|NCT00983528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004940|NCT00786630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004941|NCT03683329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004942|NCT00726895|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34004943|NCT03400436|||COHORT||RETROSPECTIVE|||||||
34004944|NCT00820508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004945|NCT03907241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004946|NCT03448276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple: a researcher shall be exclusively responsible for the evaluations and reevaluations not having knowledge of what intervention group the patient will enter. The patient will be allocated among three groups. After the final evaluations, all data will be analyzed by another researcher directed solely to that purpose. Therefore, there will be a triple blinding (researcher, patient and statistician).|Two groups: The experimental group (GI) that will hold the training in the vibrating platform and the control group (GC) that will perform the walk, settling 1 treatment session.|t|t|t|f
34004947|NCT00244829||||TREATMENT||NONE||||||
34004948|NCT01848717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004949|NCT06353412|||COHORT||PROSPECTIVE|||||||
34004950|NCT03880591|||COHORT||PROSPECTIVE|||||||
34004951|NCT04319458|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34004952|NCT04467099|||COHORT||PROSPECTIVE|||||||
34004953|NCT00249990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004954|NCT02621216|||COHORT||PROSPECTIVE|||||||
34004955|NCT06233539|||COHORT||OTHER|||||||
34004956|NCT06382506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34004957|NCT01451320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34004958|NCT03746535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking, all subjects have endometriosis|2 cohort clinical trial||||
33787101|NCT05658562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787102|NCT05376605|||OTHER||PROSPECTIVE|||||||
33787103|NCT05428345|||COHORT||PROSPECTIVE|||||||
33787104|NCT00731380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787105|NCT04227158|||COHORT||RETROSPECTIVE|||||||
33787106|NCT02785744|||OTHER||CROSS_SECTIONAL|||||||
33787107|NCT04274751|||COHORT||RETROSPECTIVE|||||||
33787108|NCT03862170|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787109|NCT06049108|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787110|NCT01564875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787111|NCT06103734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study where neither the investigator nor participant will know which arm the participant is assigned (active/placebo).|Randomized by Interactive Web Response System in a 2:1:1 ratio of zavegepant:placebo:placebo stratified by 1)triptan resistant/refractory yes/no 2)stable migraine prophylactic medication yes/no|t|t|t|f
33787112|NCT01721564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787113|NCT04809402|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787114|NCT03378739|||OTHER||PROSPECTIVE|||||||
33700093|NCT04389216|NA|SINGLE_GROUP||TREATMENT||NONE||Radiofrequency ablation||||
33787115|NCT01606384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787116|NCT03826602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787117|NCT01954940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787118|NCT04163458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787119|NCT06242834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787120|NCT01501929|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33926182|NCT05133336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Masking|Multicenter, Randomized, Double-blind, Placebo controlled, Phase 2b/3 Safety and Efficacy Study . Initially, 192 subjects (64 subjects in each treatment arm) were planned be randomised in a ratio of 1:1:1 in Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, and Placebo arm, respectively. After an optimal dose selection, the subjects are randomised in 2:1 ratio of Saroglitazar Magnesium 1 mg or placebo. There would be approximately 140 evaluable subjects (90 of Saroglitazar 1 mg and 50 of placebo arm)|t|t|t|t
33926183|NCT03067480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926184|NCT04516655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926185|NCT03305601|NA|SINGLE_GROUP||OTHER||NONE||||||
33926186|NCT02680392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926187|NCT05742841|NA|SINGLE_GROUP||PREVENTION||NONE||20 patients designed to assess the feasibility of Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) and to explore changes in low-density lipoprotein-cholesterol (LDL-C) by initiating medical therapy in the ED||||
33926188|NCT00124332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926189|NCT02283957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926190|NCT02197897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926191|NCT00432211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926192|NCT03063853|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33926193|NCT04924010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to which intervention they will receive. The outcome assessors for this study will be unaware as to which group the participant will be randomised to and therefore they will be blinded to which intervention the participant had received||t|f|f|t
33926194|NCT02099487|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33926195|NCT03115125|NA|SINGLE_GROUP||OTHER||NONE||||||
33926196|NCT04781452|||COHORT||PROSPECTIVE|||||||
33926197|NCT00966069|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926198|NCT03725293|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective single-site, parallel, two-arm, randomized investigation||||
33926199|NCT04447924|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926200|NCT00802867|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33926201|NCT02650895|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33926202|NCT03086538|NA|SINGLE_GROUP||TREATMENT||NONE||Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous||||
33926203|NCT04298931|||COHORT||PROSPECTIVE|||||||
33926204|NCT06067308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926205|NCT01999023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926206|NCT00469209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926207|NCT01209975|||CASE_ONLY||PROSPECTIVE|||||||
33926208|NCT06179706|||COHORT||RETROSPECTIVE|||||||
33926209|NCT02271581|||OTHER||PROSPECTIVE|||||||
33926210|NCT00683813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926211|NCT04636320|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Single-centre case-control study||||
33926212|NCT04745078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926213|NCT06226207|||CASE_ONLY||CROSS_SECTIONAL|||||||
33926214|NCT03194620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomized, double-masked and cross-over dietary intervention study in healthy young adult males|t|t|t|t
33926215|NCT05552807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926216|NCT04499846|||CASE_ONLY||PROSPECTIVE|||||||
33926217|NCT04914767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||RCT|t|t|t|t
33926218|NCT02858284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926219|NCT01742091|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33926220|NCT00389441|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33926221|NCT00701103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926222|NCT01937481|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926223|NCT01729663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004959|NCT00558623|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34004960|NCT04449458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004961|NCT03558035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004962|NCT02024594|RANDOMIZED|PARALLEL||||NONE||||||
34004963|NCT03868345|||CASE_CONTROL||PROSPECTIVE|||||||
34004964|NCT01351051|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34004965|NCT00736398|||COHORT||PROSPECTIVE|||||||
34004966|NCT03132311|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004967|NCT04125615|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34004968|NCT03623035|||COHORT||PROSPECTIVE|||||||
34004969|NCT05252247|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a within-subject repeated measures comparisons study with one baseline session and two interventional sessions.||||
34004970|NCT00160888|NON_RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
34004971|NCT04118868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004972|NCT01291641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926224|NCT04402619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004973|NCT03504124|RANDOMIZED|PARALLEL||TREATMENT||NONE||A cluster randomized trial including 32 rural health districts managed by the Ministry of Health (MOH) of Guatemala. Sixteen health districts will be assigned to a multicomponent intervention and 16 to usual care. Each health district will recruit 55 patients aged ≥40 years with uncontrolled hypertension.||||
33787121|NCT05191251|||COHORT||RETROSPECTIVE|||||||
33787122|NCT02329041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787123|NCT04776486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787124|NCT00573703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700094|NCT00676338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700095|NCT01709565|||COHORT||PROSPECTIVE|||||||
33700096|NCT03896165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Mixed methods quasi-experimental one group design||||
33700097|NCT02002832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700098|NCT05420597|NA|SINGLE_GROUP||TREATMENT||NONE||Induction chemotherapy with toripalimab, followed by cisplatin-based concurrent chemoradiation. At 3-6 weeks post-radiation, maintenance toripalimab was administered for 8 cycles.||||
33700099|NCT01932359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700100|NCT05780190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||CABA+PE+standard drug therapy and PP+PE+standard drug therapy|t|f|t|f
33700101|NCT00482027|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33700102|NCT04680130|||COHORT||PROSPECTIVE|||||||
33700103|NCT02519218|||COHORT||OTHER|||||||
33700104|NCT01771042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700105|NCT03716193|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Four cohorts based on standard treatment will be given the same intervention||||
33700106|NCT01745185|||COHORT||PROSPECTIVE|||||||
33700107|NCT00423722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33700108|NCT06117397|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33700109|NCT03808129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|As the patients were under 18 years of age, the details of the procedure were explained to their parents and their consent was obtained. However, the patients were not included in the group. And also outcomes assessor staff were not aware of medication assignment.||t|f|f|t
33700110|NCT01228474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700111|NCT05742711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700112|NCT03040908|||COHORT||CROSS_SECTIONAL|||||||
33700113|NCT06556459|||COHORT||PROSPECTIVE|||||||
33700114|NCT05887232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700115|NCT02601599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700116|NCT01173354|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33700117|NCT05531331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking was not performed in this study.|This study is a parallel group randomized controlled study.||||
33700118|NCT01825525|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700119|NCT04238546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700120|NCT01330680|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33700121|NCT02037360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700122|NCT00630370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700123|NCT05613309|||OTHER||RETROSPECTIVE|||||||
33700124|NCT05568407|||OTHER||RETROSPECTIVE|||||||
33700125|NCT05283278|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|t|f
33926225|NCT02219217|NA|SINGLE_GROUP||||NONE||||||
33926226|NCT02693327|||CASE_CONTROL||PROSPECTIVE|||||||
33926227|NCT02343419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926228|NCT05713825|||COHORT||OTHER|||||||
33926229|NCT00162513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926230|NCT00750178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926231|NCT03395223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926232|NCT01484561|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33926233|NCT03625089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926234|NCT00426933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926235|NCT06124092|||COHORT||PROSPECTIVE|||||||
34004974|NCT00272272|NA|SINGLE_GROUP||SCREENING||NONE||||||
34004975|NCT01999088|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34091107|NCT02684175|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34091108|NCT00971828|||CASE_CONTROL||PROSPECTIVE|||||||
34091109|NCT03179267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Addition to standard care||||
33700126|NCT06404645|||CASE_ONLY||PROSPECTIVE|||||||
33700127|NCT05928260|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33700128|NCT01826773|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33700129|NCT06050369|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33700130|NCT03645590|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stroke Ready is a stepped wedge design to be delivered to each of the four Flint community quadrants over the course of 2 years.||||
33700131|NCT03920787|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700132|NCT04824976|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33700133|NCT01274650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700134|NCT00656877|||CASE_ONLY|||||||||
33700135|NCT02863276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33700136|NCT06285461|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This will be a crossover study in which participants undergo two postprandial test days with meals with high- or low-hedonic reward and two weeks of washout between interventions.||||
33700137|NCT05073978|||CASE_CONTROL||PROSPECTIVE|||||||
33700138|NCT04300231|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Thoracic Epidural Analgesia~2. Rectus Sheath Block~3. Surgeon Infiltration with Liposomal Bupivacaine~4. Standard Bupivacaine"||||
33700139|NCT01152983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700140|NCT06438939|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33700141|NCT03081975|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33700142|NCT00289016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926236|NCT02988492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926237|NCT02518776|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33926238|NCT00876070|||CASE_ONLY||RETROSPECTIVE|||||||
33926239|NCT00083629||||TREATMENT||||||||
33926240|NCT03078959|||COHORT||RETROSPECTIVE|||||||
33926241|NCT04694716|||COHORT||PROSPECTIVE|||||||
33926242|NCT05512312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926243|NCT02798562|NA|SINGLE_GROUP||SCREENING||NONE||||||
33926244|NCT05820009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926245|NCT01660776|||CASE_CROSSOVER||PROSPECTIVE|||||||
33926246|NCT00446758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926247|NCT04390789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091110|NCT05869747|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33700143|NCT00079248|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33700144|NCT02838446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700145|NCT03166059|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700146|NCT03330288|||COHORT||PROSPECTIVE|||||||
33700147|NCT03515083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, prospective||||
33700148|NCT02103231|||CASE_CONTROL||PROSPECTIVE|||||||
33700149|NCT03349385|||COHORT||PROSPECTIVE|||||||
33700150|NCT02645201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787125|NCT01007149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33787126|NCT04691544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Triple blind randomized, placebo controlled, parallell-group multi center trial|t|t|t|f
33787127|NCT03673709|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research team working on the effectiveness evaluation of group care is blinded to study condition and is charged with collecting the Aim 1 effectiveness data from the individuals.||f|f|f|t
33787128|NCT06631456|||OTHER||OTHER|||||||
33787129|NCT04622527|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Virtual Reality headgear and corresponding non-Virtual Reality are pre-programmed with paradigms. Participants were unaware of the order of the experience they will view.|Participants viewed/were exposed to all 4 paradigms but in different sequence according to the randomization. With 4 paradigms there are a total of 24 ordering sequences. With a sample of N=24, each subject was randomized to one of these 24 sequences with each subject having a unique sequence.|t|f|f|f
33787130|NCT02273869|||COHORT||PROSPECTIVE|||||||
33787131|NCT03006341|||COHORT||RETROSPECTIVE|||||||
33700151|NCT04743466|||CASE_CONTROL||RETROSPECTIVE|||||||
33787132|NCT00100659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787133|NCT06630988|||COHORT||RETROSPECTIVE|||||||
33787134|NCT06545175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787135|NCT02417311|||CASE_CONTROL||PROSPECTIVE|||||||
33787136|NCT04697069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787137|NCT02162667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787138|NCT06305988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787139|NCT04162366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||All participants will get the active drug, aprocitentan 25 mg, for at least 8 weeks. All participants will receive placebo for 2 weeks. During a certain period of the study, participants will receive aprocitentan 25 mg or placebo for 4 weeks.|t|t|t|t
33926248|NCT05768542|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Intervention single blinded to participant. Intervention blinded to person analyzing the MSNA.|Control group for primary outcome|t|f|f|t
33926249|NCT01574937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926250|NCT06410469|||CASE_CONTROL||RETROSPECTIVE|||||||
33926251|NCT05211609|NA|SINGLE_GROUP||OTHER||NONE||||||
33926252|NCT06517303|||OTHER||RETROSPECTIVE|||||||
33926253|NCT03558009|||COHORT||PROSPECTIVE|||||||
33926254|NCT05109078|NA|SINGLE_GROUP||OTHER||NONE||||||
33700152|NCT03102333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33700153|NCT00365222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700154|NCT05517551|||COHORT||PROSPECTIVE|||||||
33700155|NCT05637879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Blinded placebo-controlled randomized trial|t|t|t|t
33700156|NCT05978778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Effects of active video gaming on pre-handwriting skills of children with down's~syndrome."|"Effects of active video gaming on pre-handwriting skills of children with down's~syndrome."|t|f|f|f
33700157|NCT04222231|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787140|NCT03988062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787141|NCT04007302|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33787142|NCT06630182|||COHORT||PROSPECTIVE|||||||
33926255|NCT02382653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33926256|NCT05968716|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"The investigators will utilize a before-and-after trial design, whereby the control group consists of caregivers studied before a social needs screening protocol is implemented on a pediatric hospital ward, and the intervention group consists of caregivers studied after a social needs screening protocol is implemented on a pediatric hospital ward."||||
33926257|NCT03281408|||COHORT||PROSPECTIVE|||||||
33926258|NCT04132648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Patient, providers, and the investigative team will all be blinded to the randomization.|Randomized Double-Blind Placebo-Controlled Crossover Clinical Trial|t|t|t|t
33926259|NCT05564208|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33926260|NCT02553590|||||PROSPECTIVE|||||||
33787143|NCT05995574|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||single intervention arm with pre- and post- evaluation.||||
33787144|NCT01704846|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787145|NCT06631781|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will participate in both a 6-week experimental period and a 6-week waiting period||||
33787146|NCT00452465|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33787147|NCT05117450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926261|NCT03320538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926262|NCT00371813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926263|NCT01468493|||COHORT||PROSPECTIVE|||||||
33926264|NCT04683380|||OTHER||PROSPECTIVE|||||||
34004976|NCT03209349|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|"The study interviewer and the patient will be blinded to the procedure type both during and following the procedure type both during and following the procedure by concealing the monitors and relevant equipment from their sight.~The physician performing the procedure will be blinded to the procedure type until the patient is brought into the procedure room. They will open the allocation envelope once the patient has been placed and positioned on the procedure bed.~Neither the patient, the RN, nor the research assistant, who will be conducting the follow-up interviews, will be informed of the study arm. Patient assignment will be managed by the study project manager and will be kept in a password protected file and will remain separate from other study data until the time of the final analysis."||t|t|t|f
34004977|NCT00603395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091111|NCT02639533|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34091112|NCT04753112|NA|SINGLE_GROUP||TREATMENT||NONE||14 participants (the sample size was calculated accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided contrast, to detect a mean PAP difference equal or greater than 4mmHg, assuming a standard deviation of 5mmHg and a 10% loss to follow-up)||||
34091113|NCT04286646|||OTHER||PROSPECTIVE|||||||
34091114|NCT01922011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091115|NCT01054248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34004978|NCT02121041|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091116|NCT03860480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Control group : Postoperative patient-controlled analgesia (PCA) pumps with Hydromorphone + Sham Erector Spinae Plane Block Intervention group : Postoperative patient-controlled analgesia (PCA) pumps with Hydromorphone + Erector Spinae Plane Block|t|t|t|f
34091117|NCT00661440|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091118|NCT04543864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091119|NCT03528031|RANDOMIZED|PARALLEL||PREVENTION||NONE||This clinical trial aims to assess the effect of providing one avocado per day on established parameters of health in comparison with a control group maintaining their habitual diets. Participants are pre-screened over the telephone initially to assess eligibility and likelihood of compliance. For those that remain eligible, additional screening is conducted at a study visit. Participants' eligibility is confirmed by the data entry system on the trial website when the Inclusion/Exclusion form is complete and entered. Randomization is performed automatically by the data entry system using a block design and stratified by site. Participants are randomly assigned to one of two equally sized groups. Neither participants nor staff will be blinded to intervention assignment. Both groups are instructed to continue to follow their habitual diet but the intervention group will receive one avocado per day. Participants are followed for outcomes for a six-month period.||||
34091120|NCT06492694|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34004979|NCT06677853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||It was a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical study to evaluate the efficacy and the safety of TM gel in the treatment of superficial IH in the proliferative phase.|t|t|t|t
34004980|NCT05752435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|cure|Randomized Control Trial (RCT)|f|f|f|t
34004981|NCT01023776|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787148|NCT06204796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091121|NCT03220789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assignment|t|f|f|f
34004982|NCT00769314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091122|NCT01341470|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33700158|NCT00000488|RANDOMIZED|||PREVENTION||DOUBLE||||||
33700159|NCT01967342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787149|NCT04884399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787150|NCT06631898|NA|SINGLE_GROUP||OTHER||NONE||Primary Irritation Patch Test Study||||
33787151|NCT03213678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787152|NCT03360396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787153|NCT06631352|||COHORT||RETROSPECTIVE|||||||
33787154|NCT03824899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787155|NCT01002443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787156|NCT03772730|||COHORT||PROSPECTIVE|||||||
33787157|NCT02467491|NA|SINGLE_GROUP||||NONE||||||
33787158|NCT01500551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787159|NCT03076450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787160|NCT05852366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34004983|NCT01133717|||COHORT||PROSPECTIVE|||||||
34004984|NCT00957216|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34004985|NCT04386109|||COHORT||PROSPECTIVE|||||||
34004986|NCT00313508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004987|NCT05919745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34004988|NCT01831986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34004989|NCT04724460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004990|NCT06377202|||COHORT||PROSPECTIVE|||||||
34004991|NCT01218035|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34004992|NCT03860337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|neither the researcher or the participant will know if the participant is eating alginate or control sausages|Double blind randomised controlled trial|t|f|t|f
34091123|NCT04713683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The dermatologist will be blinded regarding the device implanted in the patients. The interventional cardiologist will be blinded regarding the results of skin tests. The outcomes assessor will be blinded for both skin patch tests and the implanted device of each participant.||f|f|t|t
34091124|NCT03783806|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34091125|NCT05009420|NA|SINGLE_GROUP||OTHER||NONE||Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado||||
33700160|NCT06680518|RANDOMIZED|CROSSOVER||OTHER||NONE||"The patient will be his or her own control, with one foot operated with a tourniquet and the other without.~Once the patient has been included, the surgeon will open the randomization envelope to determine which foot will receive the tourniquet. He will operate on the left foot first."||||
34091126|NCT03168724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091127|NCT01323218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091128|NCT01204515|||CASE_CONTROL||PROSPECTIVE|||||||
34091129|NCT05608655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091130|NCT00512668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091131|NCT01549197|||COHORT||PROSPECTIVE|||||||
33700161|NCT00961649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700162|NCT03866486|||COHORT||OTHER|||||||
33700163|NCT04443699|||OTHER||PROSPECTIVE|||||||
33700164|NCT05736471|||CASE_CROSSOVER||PROSPECTIVE|||||||
33700165|NCT03820271|NA|SINGLE_GROUP||OTHER||NONE||The pre-inclusion visit will be between 1 week and at the latest 2 days before the inclusion visit. The duration of the inclusion period is 24 months. After inclusion, samples at D5, D10 and D14 (additional samples) for sequential analysis of CRP and ammonemia and simple clinical reassessment will be scheduled for the period of hospitalization or routine consultations. Subsequent scheduled visits will take place quarterly until the transplant. Comprehensive nutritional , frailty and CT assessment of sarcopenia (psoas) by abdominal CT without contrast injection will be performed at 6 months as part of the protocol. Additional visits will be scheduled as part of the usual patient follow-up.||||
33700166|NCT03183531|||CASE_ONLY||RETROSPECTIVE|||||||
33787161|NCT04908982|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The Principal Investigator, Co-Investigators, and Sonographers will all be masked from knowledge of the intervention assigned to each participant. Participants and the Study Coordinator will not be masked.|Participants will be randomized to either receive 81mg of aspirin daily beginning between 12 and 16 weeks of pregnancy or to receive no aspirin.|f|t|t|t
33787162|NCT03738657|||OTHER||CROSS_SECTIONAL|||||||
33787163|NCT05656092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787164|NCT00886808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787165|NCT00556062|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33787166|NCT00623922|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33787167|NCT05633043|||OTHER||OTHER|||||||
33787168|NCT06076343|NA|SINGLE_GROUP||TREATMENT||NONE||consecutive recruitment||||
33787169|NCT06481124|||CASE_ONLY||PROSPECTIVE|||||||
33787170|NCT05771090|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Sokru device, prototype||||
33787171|NCT02661568|||COHORT||RETROSPECTIVE|||||||
33787172|NCT04699669|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33787173|NCT05602155|||COHORT||PROSPECTIVE|||||||
33787174|NCT04910880|||OTHER||CROSS_SECTIONAL|||||||
33787175|NCT05038969|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33787176|NCT03717987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33787177|NCT06714019|||CASE_CONTROL||PROSPECTIVE|||||||
33926265|NCT02383264|||CASE_CONTROL||PROSPECTIVE|||||||
33787178|NCT00318968|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33926266|NCT00054444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926267|NCT02954445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787179|NCT05533866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926268|NCT00331955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926269|NCT01221818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926270|NCT00978679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926271|NCT00909519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33926272|NCT00005806||||TREATMENT||||||||
33926273|NCT03379376|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33926274|NCT01952704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926275|NCT03012633|||CASE_ONLY||PROSPECTIVE|||||||
33926276|NCT02467023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926277|NCT02313532|||COHORT||RETROSPECTIVE|||||||
33926278|NCT00979719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926279|NCT01063218|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33926280|NCT03366818|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33926281|NCT02923648|||COHORT||CROSS_SECTIONAL|||||||
33926282|NCT04935970|||CASE_CONTROL||OTHER|||||||
33926283|NCT00796003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926284|NCT01268943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926285|NCT03454204|||OTHER||PROSPECTIVE|||||||
33926286|NCT04083118|||COHORT||PROSPECTIVE|||||||
33926287|NCT02560493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33926288|NCT00003613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091132|NCT03947723|NON_RANDOMIZED|FACTORIAL||OTHER||SINGLE|The person examining the slides will be blinded to the power setting used.|This will be a modified factorial trial. The tissue from all patients will be divided into 4 sections and undergo radiofrequency ablation at different settings in each section, giving us 4 groups. These 4 groups will be compared to each other.|f|f|f|t
34091133|NCT01432951|NA|SINGLE_GROUP||OTHER||NONE||||||
34091134|NCT03791931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091135|NCT01373229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091136|NCT05303285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33926289|NCT06280612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Since the possibility of patients being affected by each other was minimal, the study was continued with only one of the live cat groups, the simulation cat group, and the control group. For example, only the live cat group and those who received chemotherapy treatment were studied before Monday afternoon.|The sample number of the research was calculated in the G\*Power 3.1.9.6 program. While α=0.05 was the error amount, 0.628 was the effect size, and 0.90 (90%) was the targeted test power, it was calculated as 36 patients for three groups (living cat group, robotic cat group, control group). Since there was no previous study on the subject, a study examining happiness levels in a different sample group was used as a reference. Considering situations such as wanting to leave the study or death during the research, each group was increased by 25%, and a total of 45 patients, 15 patients for each group, were included in the study.|t|f|f|f
33926290|NCT00541736|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33926291|NCT01962857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33926292|NCT02657187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33926293|NCT03447119|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926294|NCT03753204|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be given a high salt diet and 2 liters of saline (salt loading), followed by low salt diet and furosemide or lasix (salt depletion).||||
33926295|NCT04373213|||CASE_CONTROL||RETROSPECTIVE|||||||
33926296|NCT01745913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091137|NCT01237730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091138|NCT05091827|||CASE_CONTROL||PROSPECTIVE|||||||
33926297|NCT02347852|||COHORT||PROSPECTIVE|||||||
33926298|NCT05229991|NA|SINGLE_GROUP||TREATMENT||NONE||LNF50/RTV200 QD will be administered orally, over a 48-week treatment period, with a 24-week post-treatment follow-up period, in patients with chronic HDV infection.||||
33926299|NCT00250081|RANDOMIZED|PARALLEL||||NONE||||||
33926300|NCT01567423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926301|NCT04989088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926302|NCT04580160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926303|NCT00723671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926304|NCT04591145|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33926305|NCT00026585||||TREATMENT||||||||
33700167|NCT04123652|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients are assessed for eligibility on their first visit (screening visit); additional visits may be required to address patient questions and collect baseline data. Qualified participants will be scheduled for their 5 infusions at 8 week intervals.~Dosing and infusion orders are completed by one of the physician-investigators prior to patient arrival based on body weight, and modified if required after individual evaluation. Based on published literature and clinical impression, higher doses seem to be more effective and result in longer pain relief. Therefore, subsequent infusion doses will be increased to the maximally tolerated doses (i.e. minimal side effects).~Participants will be asked to complete the follow-up questionnaires every four weeks starting from their first infusion up to 8 times. On their last study visit, 4 weeks following the last infusion, participants will have an exit interview in addition to completing study measures."||||
33700168|NCT01833429|||COHORT|||||||||
33700169|NCT03546062|||COHORT||OTHER|||||||
33700170|NCT00227448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700171|NCT05458934|||CASE_CONTROL||PROSPECTIVE|||||||
33700172|NCT02863744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700173|NCT01842100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700174|NCT04351854|||CASE_CONTROL||RETROSPECTIVE|||||||
33700175|NCT00621959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700176|NCT01284101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700177|NCT00508222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700178|NCT02833350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700179|NCT05350007|||COHORT||CROSS_SECTIONAL|||||||
33700180|NCT01690585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700181|NCT04442139|||COHORT||RETROSPECTIVE|||||||
33700182|NCT06679933|||COHORT||PROSPECTIVE|||||||
33700183|NCT04365920|RANDOMIZED|PARALLEL||TREATMENT||NONE||Re-Entry as Usual; Recovery Management Checkups (RMC); RMC-Adaptive||||
33700184|NCT02386631|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33700185|NCT01999751|||COHORT||PROSPECTIVE|||||||
33700186|NCT05225649|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will be identified by a participant code to the care provider, investigator, and outcomes assessor until primary analysis is complete.||f|t|t|t
33787180|NCT03922243|||OTHER||RETROSPECTIVE|||||||
33787181|NCT03098030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787182|NCT01809964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787183|NCT01805362|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787184|NCT00001421||||TREATMENT||||||||
33787185|NCT03683862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787186|NCT03758625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, multi-arm|t|t|t|t
33787187|NCT05241795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787188|NCT00731107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787189|NCT03537573|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||48 primary care clinics (N=19,855 patients participants anticipated) randomized to 4 arms in 2x2 factorial design|t|f|f|t
33787190|NCT06189716|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Measurement of the inspiratory (FiO2) and expiratory (FeO2) fractions of oxygen (FiСO2 and FeСO2, respectively), as well as the inspiratory and expiratory fractions of carbon dioxide (FiСO2 and FeСO2, respectively) in the hypopharynx of healthy volunteers during high-flow oxygen therapy through nasal cannulas in different physiological conditions||||
33787191|NCT05822141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, placebo controlled, parallel group trial|t|f|t|f
33787192|NCT04226469|||CASE_CONTROL||PROSPECTIVE|||||||
33700187|NCT03041987|||COHORT||PROSPECTIVE|||||||
33926306|NCT04450641|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No masking. All participants received the same condition and asked to play a mobile app. Participants who did not play the app during piloting were asked to complete study measures pre and post. These measures were compared against participants who did play the app.|All participants who complete baseline measures will be directed to download the GuessWhat app. Participants who do not download the GuessWhat app and elect not to play, will be assigned to the Inactive Users group during analysis.||||
33926307|NCT00436267||||TREATMENT||NONE||||||
33926308|NCT00005061||||TREATMENT||||||||
33700188|NCT03656770|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33700189|NCT06391320|||COHORT||PROSPECTIVE|||||||
33700190|NCT05983588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700191|NCT03676998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700192|NCT00609414|||||PROSPECTIVE|||||||
33700193|NCT00090168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700194|NCT04676698|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33700195|NCT04532502|||COHORT||RETROSPECTIVE|||||||
33700196|NCT01858376|NA|SINGLE_GROUP||OTHER||NONE||||||
33700197|NCT02526446|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33700198|NCT02472873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700199|NCT00716196|||||PROSPECTIVE|||||||
33926309|NCT02031042|||OTHER||PROSPECTIVE|||||||
33926310|NCT02194556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926311|NCT04394689|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Participant, care provider, and investigator blinding will occur through use of a double-dummy design; subjects randomized to the MRV-MNP group will also receive a placebo (PLA) saline injection, and subjects randomized to the MRV-SC group will also receive a PLA-MNP.|Subjects will be randomized to one of two arms: Active Comparator (subcutaneous measles rubella vaccine \[MRV\] via needle and syringe \[SC\]), or MRV as a microneedle patch \[MNP\].|t|t|t|t
33700200|NCT06556511|RANDOMIZED|PARALLEL||OTHER||NONE||Children with diagnosis of sepsis age 1 month to 18 years. Patients were divided into two groups, namely zinc group which received standard therapy with zinc, and placebo group which received standard therapy with placebo||||
33926312|NCT03981354|||COHORT||PROSPECTIVE|||||||
33700201|NCT03868761|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be a randomized, open label non-concurrent multiple-baseline experimental study with participants acting as their own controls.||||
33700202|NCT04032652|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33700203|NCT03867279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33700204|NCT03395665|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33700205|NCT01181908|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33700206|NCT00618683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700207|NCT05722093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33700208|NCT02848573|||COHORT||RETROSPECTIVE|||||||
33700209|NCT05021263|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700210|NCT04796545|NA|SINGLE_GROUP||OTHER||NONE||SING IMT(TM) System, model NG SI IMT 3X||||
33700211|NCT05776342|||COHORT||OTHER|||||||
33700212|NCT00480285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33700213|NCT06215807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700214|NCT00651391|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33787193|NCT06492954|NA|SEQUENTIAL||TREATMENT||NONE||"As the optimal SBRT dose needed to generate an immune response in osteosarcoma is unknown, two different SBRT doses will be tested:~* Dose Level 1: 8 Gy x 3~* Dose Level 2:18 Gy x 3~* Participants will receive the appropriate pediatric \[\<18 years: 15 mg/kg (max dose: 1200 mg)\] or adult (≥ 18 years: 1200 mg) recommended phase 2 dose of Atezolizumab IV q3 weeks. The investigator will enroll 6 patients on each dose level, safety permitting, to maximize the information gained about each regimen.~  * Patients will undergo surgical resection of all lung nodules~ * If ≤ 1/6 patients treated at dose level 1 experience dose-limiting toxicity (DLT), dose-escalation will proceed to dose level 2 where an additional 3-6 patients will be enrolled.~ * If ≥ 2/6 patients treated at dose level 1 experience DLT, enrollment to the trial will close pending further evaluation of subjects treated and consideration will be given to a protocol amendment to modify the therapeutic approach."||||
33700215|NCT01457573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787194|NCT05402228|||OTHER||CROSS_SECTIONAL|||||||
33787195|NCT05091164|NA|SINGLE_GROUP||SCREENING||NONE||||||
33787196|NCT00440986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787197|NCT05848141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33787198|NCT05933655|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Immediately after subjects complete the baseline surveys they will be randomized. The research coordinator will open a sealed envelope that specifies which group the subject is in. Neither the subject nor the research coordinator can choose the randomization group. The randomizations envelopes will be prepared|. Patients will be randomized at a 1:1 ratio, stratified by the clinician.|f|t|f|f
33787199|NCT04073355|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787200|NCT03049436|||COHORT||PROSPECTIVE|||||||
33787201|NCT05753137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33787202|NCT06628596|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33787203|NCT05986149|||COHORT||PROSPECTIVE|||||||
33787204|NCT05160675|||COHORT||PROSPECTIVE|||||||
33787205|NCT02431143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787206|NCT04497961|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-arm randomized pilot study.||||
33787207|NCT04765943|||COHORT||PROSPECTIVE|||||||
33787208|NCT00279058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787209|NCT06056154|||CASE_ONLY||OTHER|||||||
33787210|NCT02221700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33787211|NCT00025714|||COHORT||RETROSPECTIVE|||||||
33787212|NCT06631365|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized in a 2:1 ratio to the intervention (N=40) or control (N=20) conditions, using randomly-permuted blocks of randomly selected sizes 2 and 4, stratified by PrEP status (prescribed, non-prescribed). The randomization scheme will be generated and archived by the study statistician and implemented in RedCap.||||
33700216|NCT01149837|||COHORT||PROSPECTIVE|||||||
33700217|NCT00522015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700218|NCT06389500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700219|NCT05059171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33700220|NCT02949700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700221|NCT05820373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant and inform them the allocation result.~The participants are masked in terms of not knowing that the yoga therapy is hypothesized to yield larger effects than the others."|The investigators will use a block randomization structure with randomly permuted block sizes of 2, 4 and 6 to ensure a close balance of the numbers in each arm. Randomization (by a statistician) occurs prior to eligible patients attending the clinic to minimize opportunities for selection bias.|t|t|t|t
33700222|NCT00540319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33787213|NCT06628648|||COHORT||PROSPECTIVE|||||||
33787214|NCT04788927|||COHORT||RETROSPECTIVE|||||||
33926313|NCT00480207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33926314|NCT03230721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926315|NCT05625646|||COHORT||PROSPECTIVE|||||||
33926316|NCT01477138|||CASE_CONTROL||PROSPECTIVE|||||||
34091139|NCT00689936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091140|NCT05071404|||CASE_ONLY||RETROSPECTIVE|||||||
33787215|NCT04246697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33787216|NCT05613257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomly assigned to cohorts based on the operative technique used to treat their respective fractures.|t|f|f|f
33787217|NCT03210402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787218|NCT06631950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787219|NCT00727584|RANDOMIZED|||TREATMENT||||||||
33787220|NCT06299241|||COHORT||CROSS_SECTIONAL|||||||
33926317|NCT03874195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The Investigator will 1:1 randomize patients to an Active Control arm or Intervention arm. Both arms will receive a tablet computer (iPad or Galaxy Tab based on preference) connected to the internet with disposable headphones to use for up to 30 minutes. Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative_care). Intervention Arm subjects will receive access to PCforMe."||||
33926318|NCT05260606|||COHORT||PROSPECTIVE|||||||
33926319|NCT05500560|||COHORT||PROSPECTIVE|||||||
33700223|NCT03082261|NA|SINGLE_GROUP||TREATMENT||NONE||Post market, international, multicenter, interventional, prospective, single-arm study.||||
33700224|NCT00399620|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700225|NCT01612858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700226|NCT01628705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700227|NCT03055182|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33700228|NCT00246623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700229|NCT03531359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Anxiety will be determined by using a video recording of the child, which will be assessed by psychiatric|"Tablet Group: They'll receive a tablet with content adapted to every group. It will be divided into 4 groups (2-4 years, 4-6 years, 6-8 years and 9-10 years). The first one will receive cartoons, the second will also have games; for the other two groups will be assigned appropriate video games depending on the age.~Midazolam group: They'll receive 0,5mg/kg oral or it's equivalent in rectal administration 30 minutes to one hour prior to transfer to the theater. This patients will not be able to have contact with audiovisual devices."|f|f|f|t
33700230|NCT02973984|||COHORT||PROSPECTIVE|||||||
33700231|NCT04185948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700232|NCT04404062|||COHORT||PROSPECTIVE|||||||
33700233|NCT04875663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700234|NCT04823182|||CASE_ONLY||PROSPECTIVE|||||||
33700235|NCT05504473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700236|NCT00531401|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700237|NCT00381550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700238|NCT00427947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33700239|NCT02359344|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33700240|NCT01474083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33700241|NCT01925872|||COHORT||RETROSPECTIVE|||||||
33700242|NCT06061354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700243|NCT05366517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700244|NCT03646825|||COHORT||PROSPECTIVE|||||||
33700245|NCT04184544|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Implementation research to Scale up of evidence based interventions comprising four components 1) Designing of management protocol and revision of training curricula and Capacity building of outreach and facility based health care providers; 2) sustained supplies of essential drugs and commodities; 3) community engagement through Lady health worker program and 4) Health Management information data improvement and use of the data for decision making to improve provision and quality of services||||
33700246|NCT02888301|||COHORT||PROSPECTIVE|||||||
33700247|NCT06321562|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33700248|NCT03890315|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700249|NCT03468803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700250|NCT03141593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patient will be recruited by their general practitioners (GP) and allocated to the GP's form (liquid or solid). Patients will be randomly assigned to start weekly or monthly intake for 3 months, and switch to the other frequence for 3 more months.||||
33700251|NCT01727401|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33700252|NCT04624854|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This is an open-label trial, and the investigators and subjects will not be blinded. Under these conditions, the following methods will be employed to minimize bias:~1. Clinical Endpoint Committee (CEC) is an independent group of experts that reviews clinical trial data in order to give expert opinions about clinical safety or efficacy events of interest;~2. The statisticians are independent and blind to the grouping information."|All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a complete randomization. The treatment group will use aspirin + clopidogrel dual anti-platelet therapy for 12 months, and the control group will use aspirin monotherapy for 12 months.||||
33700253|NCT04292769|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787221|NCT02972008|||COHORT||PROSPECTIVE|||||||
33926320|NCT03638115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700254|NCT01501331|||COHORT||PROSPECTIVE|||||||
33700255|NCT01669499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33700256|NCT05254808|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label randomized non-inferiority / superiority study||||
33700257|NCT06309186|||OTHER||CROSS_SECTIONAL|||||||
33700258|NCT03950011|||COHORT||CROSS_SECTIONAL|||||||
33700259|NCT02277730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700260|NCT02371304|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700261|NCT05270122|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33700262|NCT05551208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700263|NCT04945577|||OTHER||RETROSPECTIVE|||||||
33700264|NCT00395733|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33700265|NCT05877768|||COHORT||PROSPECTIVE|||||||
33700266|NCT00354614|||COHORT||PROSPECTIVE|||||||
33700267|NCT04037046|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel Assignment||||
33700268|NCT02622620|||COHORT||PROSPECTIVE|||||||
33700269|NCT05297201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700270|NCT00789490|RANDOMIZED|CROSSOVER||||NONE||||||
33700271|NCT01693848|||CASE_CONTROL||PROSPECTIVE|||||||
33700272|NCT03417219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700273|NCT05981430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700274|NCT06284902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700275|NCT01332331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787222|NCT05923255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787223|NCT02322216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33787224|NCT02734264|||COHORT||PROSPECTIVE|||||||
33787225|NCT04474925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091141|NCT03917888|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33787226|NCT04025905|RANDOMIZED|PARALLEL||OTHER||NONE|Randomization will be stratified by site, and history of previous work in supported employment (≥ 1 year working in the ESAT prior to enrollment) so that each treatment is implemented in 3 groups of 10 people in each of the three centers.|Each participant is randomized in one of the two groups, defined by the type of treatment allocated: Social Cognition Training program or only Informations||||
33787227|NCT01560949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787228|NCT05177341|||COHORT||CROSS_SECTIONAL|||||||
33787229|NCT00635895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787230|NCT06554171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787231|NCT05887323|||COHORT||RETROSPECTIVE|||||||
33926321|NCT05702398|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33926322|NCT05745025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, providers of physical therapy, primary investigator, and outcome assessor will be blinded to group allocation. The provider delivering the rTMS will not be blinded.||t|t|t|t
34091142|NCT05075772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091143|NCT02845804|||CASE_ONLY||PROSPECTIVE|||||||
34091144|NCT05408988|||COHORT||PROSPECTIVE|||||||
34091145|NCT05436288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091146|NCT03600129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Solution used for block (local anesthetic or placebo) is known to anesthetist not involved in patient's care.|Double blind, placebo-controlled, randomised|t|t|t|t
34091147|NCT01246167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091148|NCT02821559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091149|NCT05793944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34091150|NCT05735470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34091151|NCT04464460|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33926323|NCT02109068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926324|NCT00647972|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33926325|NCT05782374|||OTHER||RETROSPECTIVE|||||||
33926326|NCT01015820|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926327|NCT04963881|||CASE_ONLY||PROSPECTIVE|||||||
33926328|NCT03486418|||COHORT||RETROSPECTIVE|||||||
34091152|NCT03156140|NA|SINGLE_GROUP||OTHER||NONE||||||
33926329|NCT01283867|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926330|NCT03846167|||CASE_ONLY||PROSPECTIVE|||||||
34091153|NCT02588287|NA|SINGLE_GROUP||OTHER||NONE||||||
34091154|NCT03999047|||COHORT||PROSPECTIVE|||||||
34091155|NCT00407875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091156|NCT01026597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091157|NCT04314089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091158|NCT00622518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091159|NCT02993809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091160|NCT01258868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091161|NCT00610948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091162|NCT03542799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091163|NCT01771926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091164|NCT05627115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091165|NCT03208699|||CASE_ONLY||CROSS_SECTIONAL|||||||
34091166|NCT01285089|||COHORT||PROSPECTIVE|||||||
34091167|NCT00892255|||CASE_ONLY||PROSPECTIVE|||||||
34091168|NCT04045171|||COHORT||PROSPECTIVE|||||||
34091169|NCT02208440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is blinded to the treatment type||t|f|f|f
34091170|NCT01653886|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34091171|NCT05225831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091172|NCT00969189|||COHORT||PROSPECTIVE|||||||
34091173|NCT01370915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34091174|NCT03483753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091175|NCT02341469|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33700276|NCT04448938|||CASE_CONTROL||PROSPECTIVE|||||||
34004993|NCT06466356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and treating clinician will be unblinded to treatment modality. To compensate for lack of blinding concerning the received treatment, the persons ratings, subsequent measurements and data collection at follow-up will be blinded to the treatment conditions to avoid confirmation bias.|"Patients acutely admitted to Department of acute psychiatry, St Olav University Hospital (SOH) or Levanger Hospital or acutely admitted to an outpatient team for acute and emergency psychiatry, SOH, or admitted to a district psychiatric centers (DPS) in Trøndelag county or evaluated by physicians or psychologists at the Consultation Liaison, SOH. Patients will be included with consecutive sampling of patients who meet the selection criteria and give an informed consent.~Participants will be equally randomized (1:1) in the intervention and control group and randomization will take place by digital randomization using WebCRF (KlinForsk/ Klinisk forskningsenhet Midt-Norge). Stratified randomization will be used regarding the baseline variable substance abuse, ensuring that this variable is more evenly distributed between the two groups than chance."|f|f|t|t
33700277|NCT05328674|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparison of the results of arthroscopic treatment of analogous areas of cartilage defects in the knee joint obtained in study groups using two methods: microfracture and autogenous PRP GF cartilage graft (Auto Cart - Arthrex method).||||
33700278|NCT05565131|NA|SINGLE_GROUP||OTHER||NONE||||||
34004994|NCT00930241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34004995|NCT02930668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34004996|NCT05283330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34004997|NCT03232736|||OTHER||PROSPECTIVE|||||||
34004998|NCT01438476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34004999|NCT02846844|||COHORT||PROSPECTIVE|||||||
33700279|NCT04668807|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Measurement of 3 constants (SpO2, heart rate and respiratory rate) in patients with a non-ambulatory surgical or interventional act lasting more than 2 hours whose constants are monitored by the reference device in the operating room and the Connected Medical Device.||||
33700280|NCT06258395|||OTHER||CROSS_SECTIONAL|||||||
33700281|NCT06681610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomised, double blind, sham controlled clinical study|t|f|t|f
33787232|NCT00931229|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787233|NCT00835016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787234|NCT02918916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787235|NCT06200636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787236|NCT04330443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787237|NCT01106729|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787238|NCT03425526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787239|NCT02896894|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33787240|NCT06230874|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Individual participants will only have knowledge of their own intervention protocol. The investigators will be blinded to the randomization process and will not have knowledge of the interventions assigned to individual participants.|Study participants will be randomly assigned to one of two groups in parallel for the duration of the study.|t|f|t|f
33787241|NCT03861949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787242|NCT01871818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33787243|NCT04241796|NA|SINGLE_GROUP||SCREENING||NONE||||||
33787244|NCT05233527|||COHORT||RETROSPECTIVE|||||||
33926331|NCT05166395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926332|NCT00045812||||TREATMENT||||||||
33926333|NCT03796884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926334|NCT01535612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926335|NCT01037972|||CASE_CONTROL||PROSPECTIVE|||||||
33926336|NCT00719537|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926337|NCT05182424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926338|NCT01841294|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33926339|NCT00006299||||TREATMENT||||||||
33926340|NCT01391338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926341|NCT03184116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33926342|NCT04090580|RANDOMIZED|PARALLEL||TREATMENT||NONE|open|dapagliflozin vs standard care||||
33926343|NCT01864317|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33926344|NCT00292955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926345|NCT04364711|||COHORT||PROSPECTIVE|||||||
33787245|NCT04668183|||OTHER||PROSPECTIVE|||||||
33787246|NCT01353638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787247|NCT03766438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33787248|NCT02652234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787249|NCT05068713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787250|NCT01571830|||||PROSPECTIVE|||||||
33926346|NCT03290170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926347|NCT04665713|||COHORT||PROSPECTIVE|||||||
33926348|NCT04813978|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Researcher provides music to one group and other group will not receive music. medical officer will assess anxiety by using Beck's Anxiety Inventory.||t|f|f|t
33926349|NCT03855241|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors are unaware of treatment assignment||f|f|f|t
34005000|NCT06679374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study. The study personnel (except for select staff at the Data Coordinating Center (DCC) and research pharmacy).||t|t|t|t
34005001|NCT04687241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005002|NCT01834560|||COHORT||PROSPECTIVE|||||||
33926350|NCT03148587|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926351|NCT03583788|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was designed as a parallel study, where two groups were compared: one receiving treatment as usual (motivational interviewing) and the intervention (hypnotherapy group).||||
33926352|NCT05913518|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33926353|NCT02122926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33926354|NCT00334646|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926355|NCT01002404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926356|NCT03114423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926357|NCT00555282|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926358|NCT06364384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926359|NCT04884672|||COHORT||PROSPECTIVE|||||||
33926360|NCT04819581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926361|NCT04252248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926362|NCT02841592|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926363|NCT01052181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33926364|NCT02366104|||COHORT||PROSPECTIVE|||||||
33926365|NCT01373918|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926366|NCT05293171|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||"This is a randomized, double-blind (in respect to BL-8040 and BL-8040-matching placebo dosing), placebo- and positive-controlled, 4-period, 4-way crossover study. On Day 1 of Period 1, subjects will be randomized to 1 of 12 treatment sequences.~Each treatment sequence comprises 4 treatment periods. Each subject will be assigned a unique identification number upon screening. Subjects who complete the study screening assessments and meet all the eligibility criteria will be assigned a unique randomization identification number at the time of the first dosing, different from the screening number, and will receive the corresponding study drug, according to a randomization scheme.~Subjects will receive each of the 4 Treatments in a pre-defined order according to the sequence scheme determined at randomization."|t|t|t|f
33926367|NCT04104061|||CASE_ONLY||CROSS_SECTIONAL|||||||
33787251|NCT04590989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eligible participants will be randomly allocated to either intervention group (personalized plan) or control group prior to commencement of the trial. The allocation will be computer generated, and stratified by metabolic clusters (oxidative stress; inflammation; carbohydrate metabolism; lipid metabolism; microbiota-generated metabolites) in a 1:1 randomization between control and intervention groups. The person responsible for generating the code will not take part in the inclusion and examination of study participants. Study staff at UCPH and participants will be blinded to the treatment group and analyses of results will be performed in a blinded fashion. Moreover, the statistical analyses of the main outcome variable will be done without breaking the code for the intervention treatment, before the primary analyses are finalized.|"Eurecat will grant Simple feast and ONMI access to users' profile via PREVENTOMICS Platform in order to know which group the subject is assigned to and intervene accordingly. The profile includes the assigned group/cluster along with nutritional recommendations of each subject.~100 individuals will be randomly assigned to one of the two intervention groups. Both groups will receive meals and recipes from Simple Feast. The control group (50 subjects) will receive meals based on general dietary recommendations whereas the meals of the personalized plan group (50 subjects) are personalized based on an analysis of their metabolic biomarkers, genetics, preferences, health status, and lifestyle habits.~In addition, ONMI will deliver a personally tailored and actionable behavior change program (Do-Omics) to the personalized plan group while the control group will receive general advice."|t|f|t|t
33787252|NCT06629636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"Dietary Supplement: NMN intervention NMN capsules (total of 900mg/day) for 8 weeks, NMN capsules (total of 900mg/day) for 8 weeks Placebo Comparator: Placebo intervention~Placebo NMN-free placebo capsules for 8 weeks Other:~Placebo, for 8 weeks"|t|f|t|t
33787253|NCT01387490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787254|NCT03601143|||COHORT||PROSPECTIVE|||||||
33787255|NCT03028363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787256|NCT06631911|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33787257|NCT01335789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787258|NCT05447013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787259|NCT00360126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787260|NCT03315390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||multi-center, observer-blinded, randomized, controlled trial with complex psychological intervention|f|f|f|t
33787261|NCT04344366|||COHORT||RETROSPECTIVE|||||||
33787262|NCT04238104|||COHORT||CROSS_SECTIONAL|||||||
33787263|NCT01720446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787264|NCT00181909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787265|NCT04348331|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33926368|NCT04042038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Two separate (but methodologically identical) RCTs will be conducted, one in a sample of children/adolescents with OCD (study 1) and another in a sample of adults with OCD (study 2). Within each study, one group of age and gender-matched healthy controls will also serve as a comparison group at baseline (clinical and neuroimaging assessment). Within each study, after baseline assessment, OCD participants will be randomized to either intensive CBT or waiting list for one month. Then, OCD participants will be assessed again (clinical and neuroimaging assessment).|f|f|f|t
33926369|NCT03825172|||CASE_ONLY||PROSPECTIVE|||||||
33926370|NCT04198519|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants do not know if they are classified as poor or intermediate/ideal cardiovascular health.|Prospective|t|f|f|t
33926371|NCT00254878|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33926372|NCT05954260|||COHORT||PROSPECTIVE|||||||
34005003|NCT06142292|NA|SINGLE_GROUP||OTHER||NONE||||||
34005004|NCT04599166|NA|SINGLE_GROUP||OTHER||NONE||||||
34005005|NCT03023709|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||3-5 participants will receive quadrivalent inactivated flu (IIV4) vaccine as a pilot study to establish protocols for immune cell isolation. Once the pilot study ends, all new participants will receive live, attenuated influenza vaccine and IIV4 will no longer be utilitzed.||||
34005006|NCT00867854|||CASE_CONTROL||PROSPECTIVE|||||||
34005007|NCT05193409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005008|NCT05810857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34005009|NCT03818386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The main endpoint will be evaluated by a blinded endpoint committee.|Prospective Randomized Open Blinded Endpoint phase II clinical trial.|f|f|f|t
34005010|NCT06417437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005011|NCT01324544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005012|NCT05741931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34005013|NCT00536588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005014|NCT03546829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005015|NCT05757037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005016|NCT03666325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005017|NCT05462353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005018|NCT04561713|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005019|NCT03237299|||CASE_CONTROL||PROSPECTIVE|||||||
33926373|NCT05390307|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this 6-month randomized control trial, 60 participants aged between 21-65 years, with a body mass index (BMI) above 25kg/m2 and T1D with CKD will be randomised to receive one of five possible treatments 1) Standard care (control), 2) GLP1RA alone, 3) SGLT2i alone, 4) combination of GLP1RA and SGLT2i, 5) combination of GLP1RA and SGLT2i with intensive lifestyle advice.||||
33700282|NCT04971421|||CASE_CONTROL||PROSPECTIVE|||||||
33926374|NCT04698109|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33926375|NCT01770041|||COHORT||PROSPECTIVE|||||||
33926376|NCT02096042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926377|NCT02307318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33926378|NCT05323487|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||This study will employ a randomized order, double-blind, repeated measures dose ranging design.|t|t|t|f
33926379|NCT04709718|||COHORT||RETROSPECTIVE|||||||
33700283|NCT02587949|||COHORT||RETROSPECTIVE|||||||
33700284|NCT00905827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33700285|NCT01403311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700286|NCT00477178|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700287|NCT04213482|||CASE_CONTROL||RETROSPECTIVE|||||||
33700288|NCT02041767|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926380|NCT04460248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926381|NCT03670901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926382|NCT03032289|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33926383|NCT02904525|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926384|NCT03000686|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33926385|NCT00385463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926386|NCT02726126|||CASE_CONTROL||PROSPECTIVE|||||||
33926387|NCT00592436|||CASE_ONLY||PROSPECTIVE|||||||
33700289|NCT00485433|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33700290|NCT01612104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700291|NCT00065208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700292|NCT06146205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700293|NCT05590494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700294|NCT01967173|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700295|NCT05467371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All data will be blinded prior to analysis. The outcomes assessor will not know study allocation.|This study is designed as a randomized controlled trial with maternal caregivers of infants 2 months and younger. Maternal caregivers who consent to be in the study will be randomized into one of two groups. One group will get Safe Kids home safety education and the other group will receive the Parenting Action Plan with motivational interviewing techniques.|f|f|f|t
33700296|NCT02280070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700297|NCT04686214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700298|NCT04512950|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cluster Cross Over||||
33700299|NCT03047655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700300|NCT01497717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700301|NCT04875962|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33700302|NCT04032392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700303|NCT02197273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700304|NCT03608683|||COHORT||PROSPECTIVE|||||||
33926388|NCT02182180|||CASE_CONTROL||PROSPECTIVE|||||||
33926389|NCT00889811|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33926390|NCT02591043|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33926391|NCT00511121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926392|NCT01896661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926393|NCT04521309|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33926394|NCT03347006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind placebo controlled|SPM Active is the supplement tested in this study|t|f|t|f
33926395|NCT00013767||||PREVENTION||||||||
34005020|NCT05547906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700305|NCT06205823|||CASE_CONTROL||RETROSPECTIVE|||||||
33700306|NCT00293527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700307|NCT05818098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700308|NCT01810731|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926396|NCT02352103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926397|NCT03091595|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926398|NCT05848973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data collection teams will be blinded to the allocation arms throughout the trial in order to minimise measurement bias.|The NutriMind trial will include three intervention groups, namely; the healthy diet group, the psychotherpay group (Mindfulness-Based Cognitive Therapy-MBCT), a combined healthy diet and MBCT group and a control group with no intervention. Pending the financial situation investigators may also consider having two arms: Intervention (Diet and MBCT) and control.|f|f|f|t
33926399|NCT01042938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926400|NCT03004976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926401|NCT05168176|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33926402|NCT05008133|||COHORT||PROSPECTIVE|||||||
33926403|NCT06166888|NA|SEQUENTIAL||TREATMENT||NONE||||||
33926404|NCT01153893|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926405|NCT00006234||||TREATMENT||||||||
34005021|NCT00578838|||CASE_CONTROL||PROSPECTIVE|||||||
34005022|NCT03096067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005023|NCT01550367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005024|NCT06679465|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34005025|NCT06674356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34005026|NCT00458289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005027|NCT01466036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005028|NCT01004445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005029|NCT02387047|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005030|NCT06199960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005031|NCT04855591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005032|NCT05531682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926406|NCT06508775|NA|SINGLE_GROUP||OTHER||NONE||Single dose treatment with CAR T cell therapy in previous trial, long-term follow-up in this trial with cohorts: MB-CART20.1 Lymphoma, MB-CART20.1 Melanoma, MB-CART19.1 pediatric ALL and progressive NHL, MB-CART19.1 adult ALL, MB-CART19.1 adult NHL/CLL, MB-CART2019.1 Lymphoma||||
33926407|NCT06297798|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33926408|NCT02268136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33926409|NCT01022645|||COHORT||PROSPECTIVE|||||||
33926410|NCT03916029|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data analyst will be blinded to the cluster allocation.|Stepped-wedge cluster randomised controlled trial|f|f|f|t
33926411|NCT05818384|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33926412|NCT05651841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926413|NCT04466787|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The images will be read without knowing the CT scan used||f|f|f|t
33926414|NCT01920438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33926415|NCT05103241|NA|SINGLE_GROUP||OTHER||NONE|Nonrandomized and open labeled study|Open-label, radiolabeled, single-dose study of an oral solution of \[14C\]GP681(40mg/100μCi) in 6 healthy male volunteer.||||
33926416|NCT03949621|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34005033|NCT01847924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005034|NCT01989676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005035|NCT00950716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005036|NCT06243172|||OTHER||CROSS_SECTIONAL|||||||
34005037|NCT02507817|||CASE_CONTROL||PROSPECTIVE|||||||
33787266|NCT03185663|RANDOMIZED|PARALLEL||OTHER||NONE||a pillow between the legs versus traction-stuck||||
33787267|NCT04461756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787268|NCT01776294|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33926417|NCT03636308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926418|NCT05970978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926419|NCT02620735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926420|NCT06318221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients were classified according to tumor location (oral cavity, oropharynx, larynx or hypopharynx) and body weight loss, approximately equally in both groups. Accordingly, patients were randomly assigned (by computer) into either the immunonutrition (intervention group) or standard EN (control group) groups.||||
34005038|NCT05538637|||COHORT||PROSPECTIVE|||||||
34005039|NCT05328700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005040|NCT06678958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005041|NCT05377294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005042|NCT02466854|||COHORT||RETROSPECTIVE|||||||
34005043|NCT03710044|NA|SINGLE_GROUP||OTHER||NONE||||||
34005044|NCT03888534|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34005045|NCT03769532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005046|NCT05193773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34005047|NCT04799223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005048|NCT01710605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005049|NCT01348204|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34005050|NCT03964363|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This trail is designed as a prospective, multicentre, randomized controlled study with two parallel groups with a total of four arms. Patients with a scheduled elective surgery will be randomly assigned into treatment and control group after having been screened for frailty. A subgroup will be formed by patients who will receive a transcatheter aortic valve implantation (TAVI). The preventative effect of a behaviour modification will subsequently be compared.||||
34005051|NCT01410760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005052|NCT04071145|||COHORT||PROSPECTIVE|||||||
34005053|NCT06456216|||OTHER||PROSPECTIVE|||||||
34005054|NCT05444543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005055|NCT03730181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34005056|NCT00623636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005057|NCT04742894|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34005058|NCT06057506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005059|NCT01544517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005060|NCT06535555|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33926421|NCT00246064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926422|NCT02918955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926423|NCT01817660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926424|NCT02178306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926425|NCT05895695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005061|NCT02767934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005062|NCT05685017|||OTHER||CROSS_SECTIONAL|||||||
34005063|NCT03145324|||OTHER||OTHER|||||||
34005064|NCT03658148|||COHORT||RETROSPECTIVE|||||||
34005065|NCT05536531|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Analysis of respiratory function (diaphragm) derived from Twitch maneuver and echography (posterior images analysis) will be performed blind to arm assignment. Given sedation, patients will be also be blinded to the intervention.||t|f|f|t
34005066|NCT00754468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005067|NCT01030887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005068|NCT01287455|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34005069|NCT00820599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005070|NCT05967936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Multicentric, prospective, randomized trial, single-blinded, where eligible patients will be randomized to either receive paracervical or transcervical anesthesia before outpatient surgical hysteroscopy|t|f|f|f
34005071|NCT01899196|NA|SINGLE_GROUP||||NONE||||||
34005072|NCT06533072|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34005073|NCT03441139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091176|NCT01900314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091177|NCT01125748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091178|NCT01592838|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34091179|NCT01460472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091180|NCT01454284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091181|NCT00474565|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34091182|NCT01486433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091183|NCT02150005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091184|NCT01937338|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091185|NCT02939664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091186|NCT05400668|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005074|NCT05103917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005075|NCT04546269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assesor was blinded to the group allocation of the participant|RCT|f|f|f|t
34005076|NCT01801917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005077|NCT00288925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34005078|NCT04647734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34005079|NCT03754387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005080|NCT01728740|RANDOMIZED|CROSSOVER||||NONE||||||
34005081|NCT03909399|||COHORT||PROSPECTIVE|||||||
34005082|NCT06293391|||OTHER||RETROSPECTIVE|||||||
34005083|NCT01287715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005084|NCT05864924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005085|NCT03992651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||One single group will have simultaneous measurements of capnia and tissue oxygenation by the new sensors and by the standard laboratory sensors||||
34005086|NCT03868111|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34005087|NCT01086930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005088|NCT04747132|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34005089|NCT02221440|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34091187|NCT06188234|||CASE_ONLY||PROSPECTIVE|||||||
34091188|NCT00677287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091189|NCT00034866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34091190|NCT02749929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34091191|NCT01695772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091192|NCT02540304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34091193|NCT02336503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091194|NCT00933127|||||RETROSPECTIVE|||||||
34091195|NCT06255548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor) Triple-blind (i.e., triple-masking) studies are randomized experiments in which the treatment or intervention is unknown to (a) the research participant, (b) the individual(s) who administer the treatment or intervention, and (c) the individual(s) who assess the outcomes|The study is a randomized controlled experimental study.|t|f|t|t
34091196|NCT03676829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091197|NCT03692806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091198|NCT01251432|||COHORT||CROSS_SECTIONAL|||||||
34091199|NCT01990781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926426|NCT04583969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700309|NCT01197664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091200|NCT05359068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926427|NCT05246475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will be scanned with both MRI and PET.||||
33926428|NCT05059704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926429|NCT03749941|||COHORT||RETROSPECTIVE|||||||
33926430|NCT04179019|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single group, pilot intervention to evaluate physiologic changes in hormonal parameters.||||
33926431|NCT04848012|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"12 weeks sequential (pre/post) study. Participants will receive usual NIV treatment for 6 weeks followed by novel ventilator for 6 weeks.~There will be a randomised crossover element for one night at the midpoint of the study to assess sleep parameters on the two ventilation modalities."|t|f|f|t
33926432|NCT01697904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926433|NCT04699006|||OTHER||PROSPECTIVE|||||||
33926434|NCT03312361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091201|NCT02295319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926435|NCT02784977|||COHORT||PROSPECTIVE|||||||
34091202|NCT02210195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091203|NCT02734667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091204|NCT05141994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091205|NCT02574208|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091206|NCT06290999|||COHORT||PROSPECTIVE|||||||
34091207|NCT06264492|||CASE_CROSSOVER||PROSPECTIVE|||||||
34091208|NCT01420939|||||PROSPECTIVE|||||||
34091209|NCT02734147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091210|NCT00505583|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34091211|NCT01424852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091212|NCT02450136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091213|NCT01369303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926436|NCT04737980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant was informed of which arm they were in after random draw as this information may have been important in the event they experienced side effects and needed to guide physician care at outside facilities. The anesthesiologist could not be masked regarding arm as the appearance of the medicine injected in both arms of the study was visibly different. The outcome assessor was masked by unique identifiers being applied to participants and outcome data kept separate from intervention arm until final analysis.|This study utilized two parallel arms for intervention. Participants were randomized to ultrasound guided PNB with liposomal bupivacaine combined with bupivacaine or PNB with ropivacaine combined with dexamethasone.|f|f|f|t
33926437|NCT03819270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33926438|NCT04378257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091214|NCT05891327|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind, matched-pair study design|assign 60 participants into the experimental group (n = 30) or placebo group (n = 30)|t|f|t|f
34091215|NCT03011853|||COHORT||PROSPECTIVE|||||||
34091216|NCT05594160|||COHORT||PROSPECTIVE|||||||
34091217|NCT04307394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091218|NCT00460798|||COHORT||PROSPECTIVE|||||||
34091219|NCT03588520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091220|NCT04680585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34091221|NCT02744456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787269|NCT02867501|||COHORT||CROSS_SECTIONAL|||||||
33700310|NCT05746494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will complete active and sham simulation sessions in a randomized, counterbalanced order about one week apart.|t|f|f|t
33926439|NCT00695513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926440|NCT05034614|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926441|NCT00030030|RANDOMIZED|||PREVENTION||DOUBLE||||||
33926442|NCT04445350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926443|NCT04430686|||COHORT||RETROSPECTIVE|||||||
33926444|NCT01248364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926445|NCT00830804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091222|NCT03569462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Intervention involves demonstration of HIV self-testing and access to a mobile health application to promote HIV self-testing and HIV behavioral risk reduction|f|f|f|t
34091223|NCT01890577|||COHORT||PROSPECTIVE|||||||
34091224|NCT04645108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091225|NCT04328194|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33700311|NCT04529915|||OTHER||RETROSPECTIVE|||||||
33700312|NCT04899102|NA|SINGLE_GROUP||TREATMENT||NONE||Every individual enrolled will follow a special type of diet for 6 weeks, called time-restricted, intermittent fasting.||||
33700313|NCT06078410|||CASE_CONTROL||PROSPECTIVE|||||||
33700314|NCT03898258|||COHORT||PROSPECTIVE|||||||
33700315|NCT01136031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700316|NCT01127035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700317|NCT02008175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700318|NCT06460922|||COHORT||PROSPECTIVE|||||||
33700319|NCT00860288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700320|NCT05454501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33700321|NCT03731845|NA|SINGLE_GROUP||SCREENING||NONE||||||
33700322|NCT00760500|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33700323|NCT06204978|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700324|NCT05375708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700325|NCT02214407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700326|NCT05869760|||COHORT||PROSPECTIVE|||||||
33700327|NCT05110222|||COHORT||PROSPECTIVE|||||||
33700328|NCT03993132|||COHORT||OTHER|||||||
33700329|NCT02173873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700330|NCT04402060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700331|NCT02210650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700332|NCT03110926|NA|SEQUENTIAL||TREATMENT||NONE||||||
33700333|NCT05412095|||COHORT||PROSPECTIVE|||||||
33700334|NCT01248208|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33700335|NCT03530358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A simple random number sequence will be generated by a computer and the allocation concealment will be guaranteed using sequentially numbered, opaque sealed envelopes. The therapists responsible for randomization and allocation procedures will be independent of the blind therapists and medical doctors involved in patients' screening and treatment.|Randomized Clinical Trial|f|f|t|t
33700336|NCT02046902|||COHORT||CROSS_SECTIONAL|||||||
33700337|NCT06238271|NA|SINGLE_GROUP||OTHER||NONE||||||
33700338|NCT06260813|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|PTTD patients (PTTD I, II and III) and a healthy control group.|Prospective interventional study that includes PTTD patients (PTTD I, II and III) and a healthy control group.|t|f|f|f
33700339|NCT05265715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700340|NCT00002449||||TREATMENT||||||||
33700341|NCT06283524|||COHORT||CROSS_SECTIONAL|||||||
33700342|NCT02697487|||COHORT||PROSPECTIVE|||||||
33700343|NCT02680535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700344|NCT02488161|||COHORT||PROSPECTIVE|||||||
33700345|NCT02248831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700346|NCT01415895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700347|NCT04365868|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33926446|NCT04285372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926447|NCT05972395|||OTHER||CROSS_SECTIONAL|||||||
33926448|NCT03872557|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33926449|NCT02505815|||COHORT||PROSPECTIVE|||||||
33926450|NCT05073172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33926451|NCT04863313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926452|NCT02804009|||COHORT||PROSPECTIVE|||||||
33926453|NCT06445465|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study population will be composed of up to 30 subjects, including healthy volunteers and participants with α-synucleinopathies.||||
33926454|NCT02463422|||COHORT||PROSPECTIVE|||||||
33926455|NCT05982145|||CASE_ONLY||RETROSPECTIVE|||||||
33926456|NCT06272630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926457|NCT05537610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926458|NCT06460831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926459|NCT05682404|||COHORT||PROSPECTIVE|||||||
33926460|NCT00659126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005090|NCT06143462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005091|NCT05600023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700348|NCT04977921|NA|SINGLE_GROUP||OTHER||NONE||A quasi-experimental, two groups, pre-posttest study was carried out in Nursing college, King Khalid University, Kingdome of Saudi Arabia.||||
33700349|NCT04234074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700350|NCT05246397|NA|SINGLE_GROUP||OTHER||NONE||||||
33700351|NCT03014557|||COHORT||PROSPECTIVE|||||||
33700352|NCT04067752|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"The patients will be randomized by computer generated sequence and study coordinators and co-investigators other than the primary investigator will be unblended to the treatment arms.~The data will be sent to biostatistician with no identifiable information regarding randomization arms."|The design is randomized, cross-over, double-blind, placebo-controlled. Once the subject is determined to be eligible for the study, we will randomly assign him/her to one of the study arms (Dialysate Na concentration 138 mEq/L versus 132 mEq/L)|f|f|t|t
33700353|NCT02231918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700354|NCT05249101|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In Phase 1b, 3 dose levels of ivaltinostat will be studied in combination with a fixed dose of capecitabine to determine the RP2D of ivaltinostat.~In Phase 2, patients will be randomized in a 1:1 ratio to the combination of ivaltinostat and capecitabine or to capecitabine monotherapy. A fixed dose for capecitabine 1000 mg/m2 orally twice daily will be taken on Days 1 to 14, and the RP2D of ivaltinostat will be administered intravenously once a week for 2 weeks, followed by 1 week of rest. One cycle consists of 21 days. Tumor response during study treatment will be assessed every 6 weeks up to Cycle 10, then every 9 weeks afterwards using RECIST v1.1 criteria."||||
33700355|NCT02151695|RANDOMIZED|PARALLEL||TREATMENT||||||||
33700356|NCT02774772|||COHORT||PROSPECTIVE|||||||
33700357|NCT01784757|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33926461|NCT05730101|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants and treatment providers is not possible.|three-arm randomized controlled trial with parallel group between-subject design||||
33926462|NCT01527110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700358|NCT03939754|||COHORT||PROSPECTIVE|||||||
33700359|NCT06450158|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700360|NCT04600570|||CASE_ONLY||PROSPECTIVE|||||||
33700361|NCT06149026|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|A person who do not participate in the recruitment and the evaluation of the patients randomize a number for each patient. If the number is even, the patient belongs to the intervention group and if the number is odd, the patient belongs to the control group.|The goal of this prospective, double blind randomized clinical trial is to compare the effectiveness of two interventions in improve frailty (measured by Liver Frailty Index) and quality of life (measured by Chronic Liver Disease Questionnaire - CLDQ) in listed patients with cirrhosis.|t|t|t|t
33700362|NCT01103336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700363|NCT01604915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700364|NCT03519971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33926463|NCT04374513|||OTHER||PROSPECTIVE|||||||
33926464|NCT02621255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33926465|NCT04592848|||CASE_ONLY||OTHER|||||||
33926466|NCT05117749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and investigators do not know whether the participant receiving a placebo or saffron.|Sixty eligible patients will be recruited and randomized into 6 groups to receive either saffron capsule or placebo.|t|f|t|f
33926467|NCT03326583|NA|SEQUENTIAL||TREATMENT||NONE||||||
33926468|NCT02334553|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33926469|NCT00343109|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926470|NCT00278096|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926471|NCT05678270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926472|NCT00948038|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33926473|NCT01343355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926474|NCT05112484|||CASE_ONLY||PROSPECTIVE|||||||
33926475|NCT03774368|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926476|NCT06508528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926477|NCT00419458|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33926478|NCT04559412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926479|NCT03931395|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926480|NCT01655745|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926481|NCT05852730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926482|NCT05242263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study design is a double-blind parallel-group RCT: two groups (ACT+feedback and ACT+sham feedback), and three assessment time points (pre-, post-treatment and follow up). The independent clinical evaluators, personnel staff who deliver the training, and participants are blind before and during treatment to group allocation, which is coded with a random number for each condition. Participants are randomly assigned to conditions in a 1:1 ratio using a list created with a random number generator. The random assignment list was created before enrollment to the study started. Group assignment is monitored by a staff member not involved in the study in any other capacity.|Participants are randomly assigned to either active or sham feedback in a 1:1 ratio.|t|t|f|t
33926483|NCT06162871|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||The experimental condition in the experimental group consists of a psychosocial intervention. The control group is initially inactive and after the experimental group post treatment will be involved in the experimental intervention|f|f|f|t
33926484|NCT00669032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926485|NCT02719067|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33926486|NCT02045056|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34005092|NCT04238208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double blinded study, the investigators, patients and care providers were not aware of the identity of the administered patch. The codes 11 were used for the capsaicin patch, 12 for the control patch and 33 for the lidocaine patch. These codes were retained by a hospital staff member who was not involved in the study and were revealed to the researchers after all the data was collected and analyses.|This present study was a double blinded, placebo controlled, parallel group study|t|t|t|t
33926487|NCT03738189|||COHORT||PROSPECTIVE|||||||
33926488|NCT06146608|||CASE_ONLY||CROSS_SECTIONAL|||||||
33926489|NCT00594087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926490|NCT05067712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33926491|NCT05308667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33926492|NCT04146051|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33926493|NCT03518489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926494|NCT00425126|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33926495|NCT03119272|||CASE_CONTROL||PROSPECTIVE|||||||
33926496|NCT02228824|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33926497|NCT01414517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926498|NCT00216515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926499|NCT02915640|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926500|NCT01923571|||COHORT||PROSPECTIVE|||||||
33926501|NCT05412212|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926502|NCT02416778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926503|NCT04796025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091226|NCT03323463|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091227|NCT00000629||||TREATMENT||NONE||||||
34091228|NCT01001156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787270|NCT01195675|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33787271|NCT02104609|||COHORT||PROSPECTIVE|||||||
33787272|NCT01881243|||COHORT||PROSPECTIVE|||||||
33787273|NCT03721016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787274|NCT06392932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interpreters of the esophageal capsule endoscopy will be blinded to study group.|Prospective open-label randomized controlled trial|f|f|f|t
33787275|NCT03947112|||OTHER||CROSS_SECTIONAL|||||||
33787276|NCT06630026|||OTHER||CROSS_SECTIONAL|||||||
33787277|NCT03627962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34005093|NCT03507686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005094|NCT04540380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005095|NCT02486614|||COHORT||PROSPECTIVE|||||||
34005096|NCT03097939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005097|NCT04330495|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, controlled, double-blind clinical trial|t|f|t|f
34005098|NCT05070962|||COHORT||PROSPECTIVE|||||||
34005099|NCT04066413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005100|NCT03712124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005101|NCT05793554|||COHORT||PROSPECTIVE|||||||
34005102|NCT02600208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005103|NCT03418740|||COHORT||PROSPECTIVE|||||||
34005104|NCT02396290|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34005105|NCT00959569|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005106|NCT00537017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005107|NCT01016340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005108|NCT01463839|||||CROSS_SECTIONAL|||||||
34005109|NCT05786417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single-blind, randomized (1:1), 640 Older Adults with SIHD and MCC and 320 caregivers|f|f|f|t
34005110|NCT05400798|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34005111|NCT03619876|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded- open label|RA patients will be randomized in an unblinded, 1:1 ratio to treatment with abatacept vs adalimumab. A cardiac FDG PET/CT will be performed at baseline and 16(±2) weeks post-biologic treatment. T cell subpopulations associated with myocardial FDG uptake will be evaluated at both points in time with their transcriptional phenotype outlined by RNAseq.||||
34005112|NCT00139438|RANDOMIZED|PARALLEL||||NONE||||||
34005113|NCT04547933|||COHORT||RETROSPECTIVE|||||||
34005114|NCT04869371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005115|NCT03380130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005116|NCT02688387|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005117|NCT04006119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005118|NCT01047033|RANDOMIZED|PARALLEL||||NONE||||||
34005119|NCT01029392|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients with clinically significantly low Vitamin D levels (\<30 ng/mL) were supplemented with Vitamin D and compared to patients with normal vitamin D levels (50-80 nG/mL).||||
34005120|NCT04984187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005121|NCT04395079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005122|NCT02192294||CROSSOVER||BASIC_SCIENCE||NONE||||||
34005123|NCT00196287|||||PROSPECTIVE|||||||
34005124|NCT01653795|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34005125|NCT04402606|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005126|NCT06674421|||OTHER||PROSPECTIVE|||||||
34005127|NCT02824887|||COHORT||PROSPECTIVE|||||||
34005128|NCT03857880|||COHORT||PROSPECTIVE|||||||
34091229|NCT02983656|||CASE_ONLY||RETROSPECTIVE|||||||
34091230|NCT02623764|||CASE_ONLY||PROSPECTIVE|||||||
34091231|NCT05185856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787278|NCT02245854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787279|NCT03203798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33787280|NCT05835115|||OTHER||RETROSPECTIVE|||||||
33700365|NCT05602350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33700366|NCT03830242|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33700367|NCT05615779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33926504|NCT05405218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926505|NCT03321370|||CASE_ONLY||PROSPECTIVE|||||||
33926506|NCT06532253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926507|NCT01972594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926508|NCT04821960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926509|NCT02269384|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33926510|NCT01220713|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33926511|NCT00996593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926512|NCT06102668|||COHORT||RETROSPECTIVE|||||||
34005129|NCT02078011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700368|NCT05005910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005130|NCT03334149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Note Women in BUMP 1 will transfer to BUMP 2 if they develop hypertension. Women in BUMP 2 can be randomised de novo or join from BUMP 1 maintaining their original randomisation. The enrolment number below therefore includes BUMP 1 (2262) plus BUMP 2 (512). Permission was granted by the ethics committee to continue recruitment passed the original sample size until the original planned end of recruitment date.||||
33700369|NCT01232335|||COHORT||PROSPECTIVE|||||||
33700370|NCT03680157|||OTHER||RETROSPECTIVE|||||||
33700371|NCT02215096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700372|NCT02848404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700373|NCT05634031|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700374|NCT02319512|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33700375|NCT03144765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700376|NCT00805454||||BASIC_SCIENCE||NONE||||||
33700377|NCT05744908|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||two models: with and without Hunner's ulcer|t|f|f|f
33700378|NCT00506337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33700379|NCT04768075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700380|NCT02992769|||COHORT||PROSPECTIVE|||||||
33700381|NCT00715455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700382|NCT00000503|RANDOMIZED|||TREATMENT||DOUBLE||||||
33700383|NCT06223074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective, comparative, randomized, controlled study in adult patients with confirmed Relapsing-Remitting Multiple Sclerosis that assits to the hospital with an acute relapse.|t|t|f|f
33700384|NCT04685967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700385|NCT06333301|||COHORT||PROSPECTIVE|||||||
33700386|NCT05498012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33700387|NCT02643602|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33926513|NCT00004041||||TREATMENT||||||||
33926514|NCT00023712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926515|NCT00169039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926516|NCT01611298|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926517|NCT00638755|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33926518|NCT00054236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926519|NCT05477446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926520|NCT06044129|||COHORT||PROSPECTIVE|||||||
33926521|NCT00786097|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33926522|NCT05595551|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926523|NCT00247559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926524|NCT04297293|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34005131|NCT05656690|||COHORT||PROSPECTIVE|||||||
34005132|NCT06678737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||The study is a double-blinded randomized control trial|t|f|t|t
33700388|NCT03350165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005133|NCT01402973|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34005134|NCT05316389|||COHORT||CROSS_SECTIONAL|||||||
34005135|NCT01992913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005136|NCT06328374|||COHORT||PROSPECTIVE|||||||
33700389|NCT04489459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind||t|f|f|f
34005137|NCT00785681|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005138|NCT03002792|||COHORT||PROSPECTIVE|||||||
34005139|NCT05229055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After initial medical evaluation, every patient who meet the inclusion criteria, will receive randomly either subcutaneous or intanasal dose of ketamine as detailed above according to the predetermined randomization. To ensure a double-blind administration of ketamine ; patients enrolled in the intranasal ketamine group will receive concomitantly 1ml of normal saline solution subcutaneously, and patients enrolled in the subcutaneous ketamine group will receive concomitantly a spray of normal saline solution in each nostril. None of the treating physician or nurses are aware about the medication received.|"The intranasal route Ketamine solution was used. Applying a nasal spray pump where each spray delivered 20 mg of ketamine. After initial evaluation, each patient having the inclusion criteria receives one pulverisation (0.4 ml) per nostril of ketamine corresponding to a total dose of 20 mg of ketamine.~The subcutaneous route :~Ketamine dosing by subcutanous route was based on previous reports use for post operative pain management. . The results of these reports revealed that low-dose ketamine 20-60 mg (0.5mg/kg for patients weighing 40-120 kg) showed an over all decrease in either the amount of opioid used or the amount of pain experienced (10, 11). For our study, we decided to chose a dose of 20mg of ketamine for all patients administered via 1ml insulin syringe once subcutaneously."|t|t|f|t
34005140|NCT05442437|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"We allocate 24 participants into 3 group, low-dose, medium-dose and high-dose group. It is going to proceeded sequential from low-dose group to high-dose group. Next group is allowed to be started only the last group has been finished.~1. Low-dose group: 100mL human umbilical cord mesenchymal stem cell preparation, containing 2.5×10\^7 cells;~2. medium-dose group: 100mL human umbilical cord mesenchymal stem cell preparation, containing 5.0×10\^7 cells;~3. High-dose group: 100mL human umbilical cord mesenchymal stem cell preparation, containing 1.0×10\^8 cells"||||
34005141|NCT04805385|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33700390|NCT00912860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34005142|NCT06320158|||COHORT||PROSPECTIVE|||||||
34005143|NCT04906876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005144|NCT05290493|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|NB-001 and matching placebo will be supplied to the Investigator or designee in blinded plastic bottles, each containing 40 capsules. Additionally, subject and parent/guardian, the Investigator, clinical trial site personnel, home health nurses, centralized rater(s), and the Sponsor will be blinded to treatment sequence assignment.|Subjects will be randomized in a 1:1 ratio to one of two treatment sequences: NB-001 (active drug product) followed by placebo (treatment sequence A/P) or placebo followed by NB-001 (treatment sequence P/A). Subjects will receive IP corresponding with their first treatment assignment for 6 weeks (Treatment Period 1), followed by an intervening wash-out period of 1 week, and then will receive their second treatment assignment for the subsequent 6-week period (Treatment Period 2).|t|t|t|t
34005145|NCT06679439|RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking|||||
33700391|NCT04088643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700392|NCT04757285|||COHORT||PROSPECTIVE|||||||
33700393|NCT04764773|||CASE_CONTROL||PROSPECTIVE|||||||
33700394|NCT04226560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700395|NCT06434012|||COHORT||RETROSPECTIVE|||||||
33700396|NCT00611208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700397|NCT03671980|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study||||
33700398|NCT05824572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients will be randomly allocated to AUDIO or UC alone using a block randomization technique with the clinician acting as the blocking variable; this strategy will ensure an equal number of patients per clinician will be randomly assigned to each study arm||||
33700399|NCT04255030|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33700400|NCT02048969|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33700401|NCT04040946|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Open, randomized, phase III study||||
33700402|NCT01191411|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33700403|NCT04280835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The research was using quasi-experimental research methods. The experimental group was composed of patients with schizophrenia registered at Community Mental Health Center and the control group was composed of outpatients diagnosed with schizophrenia who applied to Psychiatric Polyclinic.The patients met the inclusion criteria of the study and volunteered to participate in the study.The study was completed with 42 patients (n=21for the intervention group; n=21 patients for the control group).Psychoeducation program were applied to intervention group. No intervention was performed on the patients in the control group.To the experimental and control group, at screening (pre-test), eight weeks after screening (post-intervention/post-test), three months after the post tests (follow-up) was applied.The mesurements were taken simultaneously in the intervention and control groups.||||
33700404|NCT02751866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|There is no blind in the dietary intervention given that participants are aware of the nature of the foods they consume. However, each dietary approach is described as healthy. In the berry supplementation studies, there is double blinding using berry fruit and placebo powders that are packaged with a code.|Intervention with carbohydrate restriction designed to produce adaptation to ketone metabolism OR intervention with berry fruit powder supplementation.|t|f|t|f
33700405|NCT03695159|||CASE_ONLY||OTHER|||||||
33700406|NCT03624985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, controlled, double-blind study|t|t|t|t
33700407|NCT01321060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700408|NCT03664180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700409|NCT05345860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700410|NCT00547573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091232|NCT03673358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants with operatively managed extremity fractures 2-12 weeks post-fracture fixation will be randomized to receive either cognitive behavioural therapy (CBT) with participants having a choice of 6 weekly one-on-one telephone or video therapy sessions OR completion of online therapy modules or standard of care (control). Outcomes will be assessed at 3 months, 6 months, 9 months, and 12 months' post-fracture|f|f|f|t
34091233|NCT00238290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091234|NCT03505775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091235|NCT06061913|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||This study will use a randomized control trial design with 3 arms to compare the clinical effectiveness of three different breast pump suction patterns (BPSP) on lactation outcomes among pump dependent mothers of critically ill infants who demonstrate faltering lactation on day 6-8 postpartum. Mothers identified as having faltering lactation will be randomly assigned to one of 3 groups; (1) BPSP1, (2) BPSP 2, and (3) Standard BPSP.|t|t|t|t
34091236|NCT03731143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091237|NCT04201392|||COHORT||CROSS_SECTIONAL|||||||
34091238|NCT05574985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091239|NCT01577121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091240|NCT06480357|||CASE_ONLY||RETROSPECTIVE|||||||
34091241|NCT05162092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (care provider ,outcome assessor)|study participants will be randomized in two groups,conventional physiotherapy group and intervention group|f|t|f|t
34091242|NCT01932606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091243|NCT01246323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091244|NCT03597867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091245|NCT04093999|||COHORT||PROSPECTIVE|||||||
34091246|NCT01983930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091247|NCT02208622|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34091248|NCT02970266|||COHORT||RETROSPECTIVE|||||||
34091249|NCT03697590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091250|NCT06275399|||COHORT||PROSPECTIVE|||||||
34091251|NCT02383849|||COHORT||PROSPECTIVE|||||||
34091252|NCT01287247|||COHORT||PROSPECTIVE|||||||
34091253|NCT02998112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091254|NCT00002818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091255|NCT04994236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091256|NCT01860404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091257|NCT00874133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091258|NCT05525468|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-180935 Following Topical Administration in Healthy Male Subjects|t|t|f|f
34091259|NCT01988415|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34091260|NCT03510936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091261|NCT01617213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091262|NCT03740490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091263|NCT06400069|||CASE_CONTROL||PROSPECTIVE|||||||
34091264|NCT04889274|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700411|NCT00479323|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33700412|NCT00456157|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33700413|NCT00046878||||TREATMENT||NONE||||||
33700414|NCT03529331|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33700415|NCT00334685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700416|NCT03505554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700417|NCT03260101|||OTHER||PROSPECTIVE|||||||
33700418|NCT00359034|||COHORT||PROSPECTIVE|||||||
33700419|NCT01238354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700420|NCT01892267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33700421|NCT00159003|||OTHER||PROSPECTIVE|||||||
33700422|NCT01254071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091265|NCT03669471|||COHORT||CROSS_SECTIONAL|||||||
34091266|NCT04604860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700423|NCT00062946||||TREATMENT||||||||
33700424|NCT02394483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700425|NCT04609761|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single-arm trial||||
33700426|NCT00224705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700427|NCT02956070|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700428|NCT01115361|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700429|NCT02940080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33700430|NCT06434298|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33700431|NCT06247566|||COHORT||RETROSPECTIVE|||||||
33700432|NCT02655978|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700433|NCT02737280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700434|NCT05050344|||COHORT||RETROSPECTIVE|||||||
33700435|NCT03666624|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will utilize a 2-group randomized controlled trial design including 2 assessments, i.e. a pre-treatment and a post-treatment.||||
33700436|NCT00408538|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34091267|NCT01805050|||COHORT||OTHER|||||||
34091268|NCT06119529|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Part A, B are double blind and part C is open-label.||t|f|t|f
34091269|NCT05312112|||COHORT||RETROSPECTIVE|||||||
34091270|NCT03437954|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
34091271|NCT00145561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091272|NCT06554236|NA|SINGLE_GROUP||TREATMENT||NONE||quasi-experimental, one-group repeated measures design||||
34091273|NCT02781207|||COHORT||PROSPECTIVE|||||||
34091274|NCT02602327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091275|NCT04826731|||CASE_CONTROL||PROSPECTIVE|||||||
34091276|NCT03296683|NA|SINGLE_GROUP||SCREENING||NONE||||||
34091277|NCT04248179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700437|NCT04238416|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective interventional cohort study||||
33700438|NCT01191918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700439|NCT01593189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33700440|NCT03879395|||COHORT||RETROSPECTIVE|||||||
33700441|NCT03867188|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700442|NCT03564431|||CASE_CONTROL||PROSPECTIVE|||||||
33700443|NCT06419335|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700444|NCT02959983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787281|NCT03593070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data Collectors will be blinded to the intervention. Study participants will be asked to not disclose their treatment condition.|Study Design The study is a Stage I longitudinal randomized clinical trial. Alzheimer's disease or a related dementia (ADRD) caregivers whose family members are in long-term care facilities will be recruited, screened for inclusion criteria, and will be randomly assigned to either Chronic Grief Management Intervention-Video (CGMI-V) or a Minimal Treatment (MT) condition. Caregivers in the CGMI-V condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions. Those caregivers in the MT condition will receive written information materials about late-stage ADRD at baseline. For both conditions, data will be collected at baseline (pre-intervention), 8 weeks (immediately post-intervention) for intervention effects, and 24 week post baseline for maintenance effects. The design for this study was chosen to avoid the type of group clustering or contamination that would be engendered by the use of a randomized cluster design.|f|f|f|t
33926525|NCT04681924|RANDOMIZED|PARALLEL||TREATMENT||NONE||Low carbohydrate diet group received low carbohydrate food versus low fat diet group who received low fat food. Eight hundred adults (≥18year old) of both gender (358 males and 442 females) are surveyed in the 12 population clusters in Erbil city to estimate the prevalence of MetS. The population frame of household of Erbil population based on all 12 offices of Family ID card in Erbil city. The randomized cluster sampling survey method of the houses is used for sample selection. Out of 289 obese adult participants who had the inclusion criteria to participate in the study, only 94 of them agreed to participate in the intervention (23 males and 71 females). Those 94 are randomly assigned into two groups, the LCD (n=54) and LFD (n=40) group. All the adult participants are completed a comprehensive medical examination and routine blood tests||||
33926526|NCT02793089|||COHORT||RETROSPECTIVE|||||||
33926527|NCT00248105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926528|NCT03854812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33926529|NCT00105560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926530|NCT04858503|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33926531|NCT05474755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926532|NCT02206321|||COHORT||PROSPECTIVE|||||||
33926533|NCT01332097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926534|NCT02929862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926535|NCT02426112|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33926536|NCT01359852|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33926537|NCT05751694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926538|NCT00094835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926539|NCT00292578|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33926540|NCT03222219|||COHORT||PROSPECTIVE|||||||
33926541|NCT01990703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926542|NCT00706394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926543|NCT01981109|||CASE_ONLY||PROSPECTIVE|||||||
33926544|NCT04644484|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Blinding for drugs were carried out by the randomization statistician and other personnel who will not be involved in the implementation of the clinical trial. Under the guidance of the randomization statistician, blinding operators attach the printed labels with numbers to the outer packages of the study drug/control drug according to the blind codes and seal the packages with sealing stickers.~After the completion of blinding for drugs, the blind codes shall be sealed and kept by the randomization statistician. The entire blinding process must be documented. The personnel responsible for blinding must not participate in other relevant works during this clinical trial, and must not disclose the blind codes to any person participating in this clinical trial."|In this study, 1000 subjects aged 18 and over who had Grade 3 exposure to rabies virus were intended to be enrolled, and randomly assigned to the experimental group and the control group (3:1). Both groups were immunized according to PEP procedures for rabies.|t|t|t|t
34005146|NCT06535763|||COHORT||PROSPECTIVE|||||||
34005147|NCT05567627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005148|NCT02734524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005149|NCT00003850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005150|NCT05310539|||COHORT||PROSPECTIVE|||||||
34005151|NCT05418985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005152|NCT00387205||||TREATMENT||NONE||||||
34005153|NCT04339595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005154|NCT05362214|||COHORT||CROSS_SECTIONAL|||||||
34005155|NCT02438696|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005156|NCT05434351|||COHORT||RETROSPECTIVE|||||||
34005157|NCT06175715|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34005158|NCT01764750|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34005159|NCT01195116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005160|NCT05387070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Subjects will be randomized 3:1 to receive either TransCon PTH or placebo:~* TransCon PTH 18 μg/day\* , co-administered with SoC~* Placebo for TransCon PTH (excipient solution) 18 μg/day, co-administered with SoC"|t|t|t|t
34005161|NCT05345951|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The first group receives the e-PBI; the second group receives the e-PBI+; and the third group is the attention-matched control|f|f|t|f
34005162|NCT06678802|||OTHER||PROSPECTIVE|||||||
34005163|NCT05829850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005164|NCT03813225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participant: The Patients will not know about intervention group they will be. Care Provider : The medical, nursing and pain clinical will not know the group to which the patient belongs Outcomes Assessor: during the analysis the staff will not know which group the patient belong|"Intervention: BILATERAL SERRATUS INTERCOSTAL- PLANE BLOCK plus usual multimodal analgesia~Control:~Usual multimodal analgesia"|t|t|f|t
34005165|NCT02176057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34005166|NCT03510338|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34005167|NCT00337896|||CASE_CONTROL||PROSPECTIVE|||||||
34005168|NCT04501094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005169|NCT00754871|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34005170|NCT03079388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005171|NCT02868996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005172|NCT06678061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34005173|NCT03703453|NA|SINGLE_GROUP||TREATMENT||NONE||REBOA in medical cardiac arrest patients||||
34005174|NCT05386173|||COHORT||PROSPECTIVE|||||||
34005175|NCT01894230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005176|NCT00291473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005177|NCT05814393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005178|NCT04461340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blinded randomized clinical trial in which participants will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1.|t|f|f|f
34005179|NCT03066791|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34005180|NCT05950217|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34005181|NCT04263233|||OTHER||OTHER|||||||
34005182|NCT03026517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005183|NCT03307811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005184|NCT05592483|||OTHER||PROSPECTIVE|||||||
34005185|NCT03904901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005186|NCT05947097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005187|NCT06350994|||COHORT||PROSPECTIVE|||||||
34005188|NCT02484430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005189|NCT06601751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005190|NCT00685750|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34005191|NCT01074008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005192|NCT05120791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||4 arm parallel groups|t|f|t|t
34091278|NCT03818568|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Design. A multicenter, controlled, randomized, open label clinical trial. Group were: Low Protein Diet (LPD) and LPD Supplemented with Ketoanalogs (LPD+KA). The follow-up period was 1 year.~Inclusion criteria: Adult patients with Type 2 Diabetes Mellitus, either sex, in stage 3b-4 of CKD. Exclusion criteria: Previous treatment with KA, kidney transplantation, cancer, HIV-AIDS, hepatitis B or C, patients receiving immunosuppressors, hypercalcemia, intolerance to KA or disorders of amino acid metabolism.~Intervention. In both groups diet composition was the same: Energy, 35 kcals/kg, Lipids 35% and, Carbohydrate 55-60% of the total energy intake, fiber 20-25 g, NaCl \~5 g, K 50-60, Phosphate 800-1000 mg. Protein intake was 0.6 g/kg/day.~Patients in LPD+KA received KA (1 tablet/5 kg/day). Each tablet contains: Keto-analogs of Isoleucine, Leucine, Phenylalanine, and Valine; hydroxyl analog of Methionine, and aminoacids Lysine, Threonine, Tryptophan, Histidine, and Tyrosine."||||
34091279|NCT06342141|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34091280|NCT05847127|||CASE_ONLY||CROSS_SECTIONAL|||||||
34091281|NCT03727867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091282|NCT00643253|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34091283|NCT00942630|||COHORT||PROSPECTIVE|||||||
34091284|NCT03148340|||COHORT||PROSPECTIVE|||||||
34091285|NCT01822990|||CASE_CONTROL||PROSPECTIVE|||||||
34091286|NCT04256408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091287|NCT02930070|||COHORT||PROSPECTIVE|||||||
34091288|NCT00339560|||CASE_CONTROL||PROSPECTIVE|||||||
34091289|NCT04032223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||It is Randomized Controlled Trial|t|f|f|t
34091290|NCT01997931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091291|NCT03906994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091292|NCT03329001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091293|NCT04398134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091294|NCT01952951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091295|NCT00933933|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091296|NCT02818543|NON_RANDOMIZED|PARALLEL||||NONE||||||
34091297|NCT03270488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091298|NCT02783625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091299|NCT04288791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091300|NCT03759184|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34091301|NCT05508256|RANDOMIZED|PARALLEL||TREATMENT||NONE||The CABA-HFPEF is an investigator-initiated, prospective, parallel-group, randomized, open, blinded endpoint assessment, interventional multicenter strategy trial. CABA-HFPEF compares two treatment strategies that employ established therapies within their approved indications.||||
34091302|NCT00539474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091303|NCT03354377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34091304|NCT04447365|||CASE_ONLY||PROSPECTIVE|||||||
34091305|NCT00895713|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34091306|NCT00262379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091307|NCT01417962|||COHORT||PROSPECTIVE|||||||
34005193|NCT01529086|||COHORT||RETROSPECTIVE|||||||
34005194|NCT00236886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005195|NCT06678555|||COHORT||RETROSPECTIVE|||||||
34005196|NCT06122155|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34005197|NCT05303961|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34005198|NCT03895229|NA|SINGLE_GROUP||OTHER||NONE||A single group of 16 subjects will receive a single oral dose of Empagliflozin 10 MG Oral Tablet \[Jardiance\] at the morning(Period I) and the same group will receive the same dose of the same drug at the evening(Period II) after a seven days washout period||||
34005199|NCT04316195|||COHORT||PROSPECTIVE|||||||
34005200|NCT00879541|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34005201|NCT06591182|||COHORT||RETROSPECTIVE|||||||
34005202|NCT03723837|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005203|NCT00080431||||TREATMENT||||||||
34005204|NCT06427044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787282|NCT02716909|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091308|NCT01332162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091309|NCT00709670|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091310|NCT00005849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700445|NCT03475680|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double Blind : both participants and investigators are unaware of the intervention assignment||t|f|t|f
33700446|NCT01398553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700447|NCT02009306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700448|NCT03872323|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33700449|NCT00005673||||TREATMENT||||||||
33700450|NCT00507091|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700451|NCT02135770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700452|NCT00191906|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700453|NCT03189420|||COHORT||PROSPECTIVE|||||||
33700454|NCT03820180|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33700455|NCT05290792|NA|SINGLE_GROUP||SCREENING||NONE||Single centre, controlled, before and after, longitudinal, intra-individual assessment||||
33700456|NCT00566111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700457|NCT02436252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700458|NCT04216498|||COHORT||CROSS_SECTIONAL|||||||
33700459|NCT01685866|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33700460|NCT04898387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The 2 different treatment kits should be identical in external packaging in order to respect the masked evaluation for efficacy and safety.~The identity of the IMP given to each patient will not be known by the masked investigator"||f|f|t|f
33700461|NCT01632917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700462|NCT04612439|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33700463|NCT00702104|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33700464|NCT05909683|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"According to protocol study intervention is not study drug administration; intervention includes two steps: modification of antibiotics administered; duration of antibiotic treatment. SOC patients will receive antibiotics according to standard practice of the attending physicians.~MODIFY strategy group patients will start antibiotics according to standard practice. They will be informed after randomization about the results of BCID2, Reveal Rapid AST and PCT. Physicians and investigators receiving this information are obliged to change the empirically prescribed antibiotics (escalate, de- escalate or stop) aiming to improve patient outcomes. Exceptions to overrule this algorithm will be accepted for medically unstable patients."||||
33700465|NCT03468829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700466|NCT00011973||||TREATMENT||||||||
33787283|NCT03586544|RANDOMIZED|CROSSOVER||PREVENTION||NONE||2x3 mixed ANOVA. 2 between groups: children with and without obesity. 3 within groups: control, interval warm-up, pretreatment with bronchodilator||||
33787284|NCT02634216|NA|SINGLE_GROUP||OTHER||NONE||||||
33787285|NCT04310059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787286|NCT05505929|||COHORT||PROSPECTIVE|||||||
33787287|NCT05139264|||COHORT||CROSS_SECTIONAL|||||||
33787288|NCT06063356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787289|NCT02824432|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787290|NCT04138433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33926545|NCT05564676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33926546|NCT05508295|||COHORT||CROSS_SECTIONAL|||||||
33926547|NCT03684070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926548|NCT02699853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926549|NCT04745468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926550|NCT04661267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33926551|NCT06301594|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926552|NCT00718523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926553|NCT05506696|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33926554|NCT03387891|||CASE_ONLY||PROSPECTIVE|||||||
33926555|NCT05906667|NA|SINGLE_GROUP||PREVENTION||NONE||single-arm study; all participants are assigned to the experiment||||
33926556|NCT05351905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients, study staff, care providers, adjudicators, data analysts and investigators will be blinded to the active ingredient(s) in the study medication and group allocation. Blinding of all research team members who interact with the patient will avoid biases in communications with, or treatment of, participants based on group allocation. Blinding of research participants will avoid any bias in reporting (e.g., of pain ratings, side effects) and actions/behaviours during the study (e.g., opioid medication dose adjustments) based on group allocation and/or expectations.|Participants will be randomized to receive either a placebo, CBD oil (medical cannabis) or CBD+THC oil (medical cannabis) in a 1:1:1 ratio.|t|t|t|t
33926557|NCT03578380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926558|NCT01202682|||CASE_ONLY||PROSPECTIVE|||||||
33926559|NCT05428449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926560|NCT01975038|||COHORT||PROSPECTIVE|||||||
33700467|NCT03997604|||CASE_ONLY||PROSPECTIVE|||||||
33700468|NCT06049043|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700469|NCT01910948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33700470|NCT05047068|||COHORT||OTHER|||||||
33700471|NCT06022601|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33787291|NCT02742142|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33787292|NCT01234532|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|no masking||||
33787293|NCT01750554|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33787294|NCT04511806|||COHORT||PROSPECTIVE|||||||
33787295|NCT03906630|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787296|NCT04816890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787297|NCT01129778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787298|NCT05384132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33787299|NCT06629363|||OTHER||PROSPECTIVE|||||||
33926561|NCT05471206|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926562|NCT02791360|NA|SINGLE_GROUP||OTHER||NONE||||||
33700472|NCT04265053|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Aims 1-2: Both male (n=48) and female (n=48) groups. Participants complete both aims in 2 visits. Participants assigned to one of 2 drug treatments in Aim 2 (n=24/sex/drug). These drugs are mechanistic studies, not treatment studies. Drugs inhibit NOS or COX signaling in blood vessels and are given intravenously during one MRI visit.~Aim 3: Both male (n=20) and female (n=20) groups (a subset of participants enrolled in Aims 1-2) enroll for \~14 days. All 14 days participants suppress endogenous sex hormones with a GnRH agonist/antagonist, and repeat Aim 1-2 visits around days 5-7. Subsequently, males start taking exogenous testosterone, and females take exogenous estrogen for the remaining 7-9 days. On days 12-14 (depending on MRI and participant schedule), participants repeat visits like Aim 1-2. During half those MRI visits, participants will receive one of the two FDA drugs (same as in original Aim 1-2 visit)."||||
33700473|NCT04721951|||COHORT||PROSPECTIVE|||||||
33700474|NCT03273543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700475|NCT03128034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700476|NCT04386551|||CASE_ONLY||PROSPECTIVE|||||||
33700477|NCT02043314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700478|NCT02536651|||COHORT||CROSS_SECTIONAL|||||||
33700479|NCT02540616|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will be randomized to a real vs a sham stimulation arm. The sham arm will be offered real treatment after unblinding.|t|f|f|f
33700480|NCT06180291|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"Prospective multicenter comparative non-randomized study evaluating the effectiveness of a new management strategy for children at high risk of cerebral palsy compared to the management of the control group.~The research will take place in 6 centers, 4 centers offering early intervention (Lyon Croix-Rousse, Lyon Hôpital Femme-Mère-Enfant, Montpellier, Nîmes), and 2 centers not offering standardized early intervention (Toulouse and Bordeaux). The control centers were recruited on the basis of common characteristics of neonatology level of care and active queue.~Each center will consecutively include newborns during the neonatology stay. The study will compare the intervention group composed of children cared for in intervention centers to the control group composed of children cared for in control centers."||||
33700481|NCT01801826|||CASE_ONLY||PROSPECTIVE|||||||
33700482|NCT05234385|||COHORT||PROSPECTIVE|||||||
33700483|NCT04017000|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|"Clinician performing patient Urodynamics will be different from the clinician who undertakes the bladder shape test.~Urodynamics clinician will be blinded to the results of the bladder shape test."||f|f|f|t
33700484|NCT02029001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700485|NCT03731039|||COHORT||PROSPECTIVE|||||||
33700486|NCT06041490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700487|NCT03301701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700488|NCT05476458|||COHORT||PROSPECTIVE|||||||
33700489|NCT01391754|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33700490|NCT05244993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700491|NCT01663220|||CASE_CROSSOVER||PROSPECTIVE|||||||
33700492|NCT01689103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700493|NCT05037981|||CASE_ONLY||PROSPECTIVE|||||||
33700494|NCT04882280|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33700495|NCT02083614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700496|NCT05329532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, uncontrolled study.||||
33700497|NCT05538533|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study will use a time-to-event continual reassessment method (TITE-CRM) for assigning subjects to the radiation therapy dosages.||||
33700498|NCT00842582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700499|NCT01751893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33700500|NCT03788629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized|f|t|f|f
33700501|NCT04509869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700502|NCT05637229|||COHORT||OTHER|||||||
33787300|NCT02637544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787301|NCT05090384|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients start on the same dose of steroids for treatment of GVHD, blood samples are taken at week 1 and 2 post study start and biomarkers plus clinical response determines how steroid treatment is continued||||
33926563|NCT00033111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926564|NCT02953613|||COHORT||PROSPECTIVE|||||||
33926565|NCT05304598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926566|NCT02305290|||COHORT||RETROSPECTIVE|||||||
33926567|NCT00947934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926568|NCT06087523|||OTHER||CROSS_SECTIONAL|||||||
33926569|NCT06365372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33926570|NCT02398981|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33926571|NCT01302691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926572|NCT00259467|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33926573|NCT02382783|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926574|NCT03867110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926575|NCT01832857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926576|NCT05457738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926577|NCT04005807|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33926578|NCT03625297|RANDOMIZED|CROSSOVER||OTHER||NONE||This study uses a two-group randomized, repeated measures design with a delayed treatment control group.||||
33926579|NCT01902004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926580|NCT01562678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33926581|NCT05247125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||patients will be randomized into 4 parallel groups|t|f|f|t
33926582|NCT04518345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926583|NCT01261598|NON_RANDOMIZED|PARALLEL||||NONE||||||
33926584|NCT05223699|NA|SEQUENTIAL||TREATMENT||NONE||||||
33926585|NCT04182906|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomized twice. The first randomization will result in 3 arms (No ACEs screen, Identified ACEs screen, De-Identified ACEs screen). Participants in the No ACEs screen group or who screen ACEs=0 will receive care as usual. The second randomization will occur for those who screen with ACEs =\> 1, into two treatment groups (Care Coordination or Resiliency Clinic).||||
33926586|NCT04864600|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||A randomized cross-over double-blind study under controlled conditions in a climate chamber having three different exposures; A) a standard (Scandinavian) stearin candle, B) a modified low emitting version of the same candle, and C) clean air|t|t|t|t
33926587|NCT04492787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926588|NCT03037606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700503|NCT01349231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926589|NCT03432117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The subjets were randomized(1:1:1) to 3 group(A: Fixed respiratory rehabilitation program group, B: Mixed respiratory rehabilitation program group( Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks) and C: Control group(Ordinary rehabilitation service of the site).||||
33926590|NCT00159718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926591|NCT02919410||||PREVENTION||||||||
33926592|NCT01395355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926593|NCT00555568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926594|NCT01712503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926595|NCT05221593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926596|NCT05163834|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926597|NCT03318601|NA|SINGLE_GROUP||OTHER||NONE||cirrhotic patients with ascites requiring prolonged hospitalization in the Hepato-gastroenterology departments of the Besançon, Nancy and Reims hospitals.||||
33926598|NCT00062647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926599|NCT02678637|||CASE_ONLY||CROSS_SECTIONAL|||||||
33926600|NCT04113512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926601|NCT00545467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926602|NCT01676792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926603|NCT06122246|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Community Based Organizations (CBO) will be randomized in a cluster-randomized stepped-wedge design in which CBOs will be randomized to one of 5 sequences.||||
33926604|NCT02738762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926605|NCT06071390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a randomized controlled experimental study.||||
33926606|NCT04593836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33926607|NCT04018157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|patient and outcomes assessor||t|f|f|t
33926608|NCT00006030||||TREATMENT||||||||
33926609|NCT02040155|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33926610|NCT01278771|||CASE_CONTROL||RETROSPECTIVE|||||||
33926611|NCT04720339|NA|SINGLE_GROUP||OTHER||NONE||||||
33926612|NCT01227304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926613|NCT03460288|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a randomly controlled study with 2 conditions: Condition 1: Computer-based training program (retraining), condition 2: Wait-list control group (access to the training after the post-assessment).~Two assessments-points, the intervention period (pre-post) is eight weeks. Sociodemographic and pathological data are obtained with an internet survey on Unipark®."||||
33926614|NCT02969967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926615|NCT02441192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33926616|NCT05103475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Eligible patients will be randomly assigned to the RAP or control (Hatha yoga) group.||||
33926617|NCT03970018|||COHORT||RETROSPECTIVE|||||||
33926618|NCT03471104|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33926619|NCT06140628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926620|NCT01734278|||COHORT||PROSPECTIVE|||||||
33926621|NCT04451317|||CASE_CONTROL||PROSPECTIVE|||||||
33926622|NCT05793957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926623|NCT04227067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926624|NCT01576120|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33926625|NCT06162689|||CASE_CONTROL||PROSPECTIVE|||||||
33926626|NCT03307369|||COHORT||RETROSPECTIVE|||||||
33700504|NCT04696523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blind; participants, outcomes assessors are blinded|Study design is a single blind randomized two-armed parallel follow-up study.|t|f|f|t
33700505|NCT01320631|||OTHER||PROSPECTIVE|||||||
33926627|NCT00004898||||TREATMENT||||||||
33700506|NCT06239831|||COHORT||PROSPECTIVE|||||||
33700507|NCT03420625|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34005205|NCT06417151|||COHORT||CROSS_SECTIONAL|||||||
34005206|NCT00985231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005207|NCT02671682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005208|NCT06616519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005209|NCT03212378|||COHORT||PROSPECTIVE|||||||
34005210|NCT01863186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700508|NCT05262881|||COHORT||RETROSPECTIVE|||||||
33700509|NCT01954160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700510|NCT05314738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700511|NCT01566734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33700512|NCT00644189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700513|NCT03288285|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33700514|NCT01941693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700515|NCT03882190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700516|NCT02112344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700517|NCT00555451|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33787302|NCT04966156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|biostatician will provide the randomized grouping for each of the participants.|Participants will be informed when consented that they will be grouped into one of two (control or intervenion) study groups for the duration of the study. Following their baseline assessment, patients will be randomized (1:1 stratified by age and clinical frailty score at pre-transplant consultation).|t|f|f|f
33787303|NCT06416280|||COHORT||PROSPECTIVE|||||||
33787304|NCT00459264|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33787305|NCT00387491|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33787306|NCT04452955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787307|NCT01356134|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787308|NCT05091593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research Study Coordinators will be masked.|Randomized controlled trial|f|f|f|t
33787309|NCT03232268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787310|NCT05872321|||CASE_ONLY||RETROSPECTIVE|||||||
33787311|NCT06628635|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787312|NCT06548334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926628|NCT04926844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each enrolled child will be assigned a unique identification number. Pharmacy will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, and investigators will be unaware of group assignment and drug/placebo therapy.|"Two groups of children with continuing seizures after stabilization phase (5 minutes):~1. Study group; will receive intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).~2. Control group will receive intravenous isotonic saline (as a placebo) in the same way. At the same time, both groups will receive intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes."|t|t|t|t
33926629|NCT04016103|NA|SINGLE_GROUP||OTHER||NONE||||||
33926630|NCT01280019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33926631|NCT03470311|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005211|NCT06396637|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1 Antibody combined with Sapropterin Dihydrochloride||||
34005212|NCT04608201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005213|NCT05302219|NA|SINGLE_GROUP||OTHER||NONE||All participants go through all assigned interventions in one study arm.||||
34005214|NCT04868565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed by someone who are not involved in this study. Outcomes assessor will review the patients' medical record masked for the type of intervention.The investigators performing the final statistic analyses will also be blinded to the treatment allocation.||f|f|t|t
34005215|NCT02503813|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005216|NCT01133236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005217|NCT01811368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005218|NCT06678204|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005219|NCT00566280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005220|NCT06198647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34005221|NCT05476744|||COHORT||PROSPECTIVE|||||||
33787313|NCT02111343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787314|NCT04040543|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33787315|NCT01588015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787316|NCT04083651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787317|NCT04183166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787318|NCT03704311|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Assessor doing high Resolution respirometry was blinded with respect to diagnosis, location of biopsy and all Patient related data|||||
33787319|NCT00965536|||CASE_CONTROL||RETROSPECTIVE|||||||
33787320|NCT03677206|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Initially, patients will receive White LED exposure, then they will be crossed over to Green LED exposure. The patients will not be told which one is the treatment and which one is the control.|f|f|t|f
33787321|NCT03573362|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33787322|NCT02578212|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33787323|NCT02954055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787324|NCT00618280|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33787325|NCT04745702|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33787326|NCT02694848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33787327|NCT05702294|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"We aim to demonstrate error in eye-ball (traditional method of estimating voided volumes) and increased accuracy of the automated vessel to within the internationally recognized standard of 3% using a flowmeter as the gold standard.~We will achieve that by:~A. Performing Bench testing. In vitro assessment to demonstrate error in eye-ball (traditional method of estimating voided volumes) and increased accuracy to within the internationally recognized standard of 3% using a flowmeter as the gold standard.~B. Recruiting a control group to develop more accurate nomograms of bladder function. The control group will be blinded to the automatic cup measurements.~C. Using the tool with women presenting to the Urogynaecology service using the conventional eye-balling  method and automated uroflowmetry system to assess error from eye-balling and assess how the bladder diary changes comparing the two methods."||||
33787328|NCT01646502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787329|NCT05609578|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33787330|NCT01107262|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787331|NCT02213692|||CASE_CONTROL||PROSPECTIVE|||||||
33787332|NCT03514199|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized clinical trial will be conducted and the sample will consist of 50 participants who performed portable respiratory polysomnography. Cases with AHI between 15 and 50 events per hour will be sent for medical evaluation to identify inclusion/exclusion criteria. Eligible individuals who agree to participate in the study, after signing the Informed Consent Term, will perform physical, biochemical, questionnaire and randomized to receive guidelines on the Mediterranean-type diet or low-fat diet.||||
33787333|NCT05709873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787334|NCT02974010|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33787335|NCT06494748|||COHORT||RETROSPECTIVE|||||||
33787336|NCT06178315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787337|NCT03572413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33787338|NCT04993963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787339|NCT06629415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33787340|NCT03426072|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|control sites are propensity matched to intervention sites. All sites have comprehensive dataset. Trial status of each home is unknown to assessor and statistician|cluster randomised controlled trail with nursing home unit as the cluster, care aides and residents as the unit of analysis|f|t|t|t
33787341|NCT02271607|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33787342|NCT00711646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33787343|NCT00522600|||||PROSPECTIVE|||||||
33787344|NCT03426514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787345|NCT01403792|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787346|NCT01916889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787347|NCT01122524|||CASE_CONTROL||PROSPECTIVE|||||||
33787348|NCT03852433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787349|NCT06631924|||COHORT||RETROSPECTIVE|||||||
33787350|NCT04443153|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33926632|NCT00185536|||DEFINED_POPULATION||OTHER|||||||
33926633|NCT06054438|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926634|NCT00215072|||||RETROSPECTIVE|||||||
33787351|NCT00763282|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33926635|NCT03067844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926636|NCT03271060|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Posterior inter body fusion and inter transverse process bone graft||||
33926637|NCT01089569|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects were randomized and then told the medications they were randomized to. Since the medications were already on the market, there was no need for masking for any involved individuals.|||||
33926638|NCT04274634|||COHORT||CROSS_SECTIONAL|||||||
33926639|NCT04655924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and Rater blinded, Physician partially blinded|The Clinical Decision Aid is a digital health platform that collects patient data and provides reports and analyses to clinicians that can assist them in their decision making about treatment selection and management.|t|f|t|f
33926640|NCT05168852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Individuals aged 18-65 years with a D1 or D2 class II carious lesion|After the restorations are applied, the patients are checked in the 1st week and 6th months.|t|f|f|f
33926641|NCT01945268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926642|NCT03148964|||COHORT||PROSPECTIVE|||||||
33700518|NCT03511664|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study population included patients with progressive PSMA-positive mCRPC who received at least one novel androgen axis drug \[NAAD\] (such as enzalutamide or abiraterone) and were previously treated with 1 to 2 taxane containing regimens. Patients treated with only 1 prior taxane regimen were eligible if the patient was unwilling or the patient's physician deemed the patient unsuitable to receive a second regimen.||||
33700519|NCT00002561|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700520|NCT06453902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700521|NCT04058873|||CASE_ONLY||PROSPECTIVE|||||||
33700522|NCT04644003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700523|NCT03516825|NA|SINGLE_GROUP||TREATMENT||NONE|All participants were given no information about this intervention. Participants only followed the direction by student music therapist.|The same intervention has been used for all participants (two) for this study.||||
33700524|NCT02840721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700525|NCT01497275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700526|NCT02429843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700527|NCT01414608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700528|NCT02259101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700529|NCT03980431|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.||||
33700530|NCT05616975|||OTHER||OTHER|||||||
33700531|NCT02474381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700532|NCT05027061|||COHORT||RETROSPECTIVE|||||||
33700533|NCT03396705|||COHORT||PROSPECTIVE|||||||
33700534|NCT03626168|NON_RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|In this crossover design, the participants principal investigators, and outcomes assessors were blinded as to which treatment (100% watermelon juice or placebo) was consumed at each time.|In a double-blind crossover design, women ages 55-69 years were randomized to two 12-ounce servings of 100% watermelon juice per day or an isocaloric placebo for four weeks each with a 2-week washout period in between.|t|f|t|t
33700535|NCT01252147|||COHORT||PROSPECTIVE|||||||
33700536|NCT04171154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33700537|NCT02328417|||COHORT||PROSPECTIVE|||||||
33787352|NCT04566874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|subjects will be blinded prior to surgery. Following surgery, maintaining masking may not be feasible as subjects will have access to medical records and/or radiographs.|single blind randomized 1:1|t|f|f|f
33787353|NCT06618898|||OTHER||PROSPECTIVE|||||||
33700538|NCT01663025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787354|NCT02034149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926643|NCT00500812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926644|NCT03672357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33926645|NCT03212599|||CASE_CONTROL||PROSPECTIVE|||||||
33926646|NCT02994797|||COHORT||PROSPECTIVE|||||||
33926647|NCT05071443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This committee comprises experts (a dermatologist, a plastic surgeon, and a nurse specialized in wound care) tasked with validating in a consistent manner, blinded to the randomization arm, the aspect of the primary endpoint relating to cutaneous healing, based on standard photographs taken on a weekly basis by the clinical research nurse. Photographs will be made available to members of the adjudication committee through an online platform (Dispose AP-HP) or a digital support.||f|f|f|t
33926648|NCT05621590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926649|NCT03056729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926650|NCT02558985|||CASE_ONLY||PROSPECTIVE|||||||
34005222|NCT06493409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700539|NCT05929976|||COHORT||PROSPECTIVE|||||||
33700540|NCT01596387|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700541|NCT05249699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700542|NCT05636644|||CASE_CONTROL||OTHER|||||||
33700543|NCT05769309|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700544|NCT02954627|||COHORT||PROSPECTIVE|||||||
33700545|NCT04686695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700546|NCT03270644|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33700547|NCT04141046|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"The research team and the participants will not know the intervention assignment until data is un-blinded for analysis.~The Principal Investigators (PI) and Co-Investigators (Co-I) will be blinded since they may be outcome assessors and/or sub-specialty care providers for some of the participants."||t|t|t|t
33700548|NCT00144690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33700549|NCT01934244|||COHORT||PROSPECTIVE|||||||
33700550|NCT01287078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787355|NCT06058182|||OTHER||PROSPECTIVE|||||||
33787356|NCT04417556|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787357|NCT06240039|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787358|NCT04705857|||COHORT||PROSPECTIVE|||||||
33787359|NCT00135967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787360|NCT05914558|||COHORT||PROSPECTIVE|||||||
33787361|NCT00059917||||TREATMENT||||||||
33787362|NCT03211325|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787363|NCT05139160|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study design will be a randomized, double blind, crossover trial.|The study design will be a randomized, double blind, crossover trial.|t|f|t|f
33787364|NCT00368719|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33787365|NCT05464212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787366|NCT04059562|NA|SINGLE_GROUP||TREATMENT||NONE||Combination of Lonsurf® and Irinotecan in 28 patients with cholangiocarcinoma.||||
33787367|NCT04928872|||OTHER||PROSPECTIVE|||||||
33926651|NCT01153308|||COHORT||PROSPECTIVE|||||||
33926652|NCT02186561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926653|NCT03584438|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||30 healthy controls will undergo four Active TMS treatment sessions (separated by at least 24 hrs), along with a Sham TMS treatment session. The theta-burst treatments will be counterbalanced across participants.|t|f|t|f
33926654|NCT02641639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005223|NCT05964673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787368|NCT03966794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787369|NCT06631599|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33787370|NCT01749787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787371|NCT01025869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787372|NCT02889822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787373|NCT06245109|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||"Synopsis of study design:~The goal of this study is to identify predictors of treatment response, using quantitative sensory testing (QST), neuroimaging, and patient-reported outcome measures (PROs)."|t|t|t|t
33787374|NCT05249179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33787375|NCT04766437|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot study||||
33787376|NCT06286982|||COHORT||PROSPECTIVE|||||||
33787377|NCT05939557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33787378|NCT05022342|||COHORT||PROSPECTIVE|||||||
33787379|NCT06629701|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33787380|NCT02646670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787381|NCT01278693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787382|NCT05634317|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33787383|NCT03274102|RANDOMIZED|PARALLEL||PREVENTION||NONE|open-labelled|||||
33787384|NCT02702921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787385|NCT01532232|||CASE_CONTROL||PROSPECTIVE|||||||
33787386|NCT03223883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient, providers, and the investigative team will all be blinded to the randomization.|Randomized Double-Blind Placebo-Controlled Clinical Trial|t|t|t|t
33787387|NCT00470795|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33787388|NCT02898051|||CASE_CONTROL||PROSPECTIVE|||||||
33787389|NCT05905406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787390|NCT04444115|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33787391|NCT04097899|||COHORT||RETROSPECTIVE|||||||
33787392|NCT04989322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926655|NCT00753961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33926656|NCT03432767|||COHORT||PROSPECTIVE|||||||
33926657|NCT01570309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926658|NCT01476761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926659|NCT06145659|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33926660|NCT03908580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926661|NCT01433692|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33926662|NCT03127553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926663|NCT01603212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926664|NCT01915017|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33926665|NCT01670812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926666|NCT02577367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926667|NCT06418568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926668|NCT00696397|||CASE_CONTROL||PROSPECTIVE|||||||
34005224|NCT04751630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005225|NCT03785769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Patient and Examiner) will not be able to blinding the operator due to the obvious difference between the techniques||t|f|f|t
34005226|NCT04234555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005227|NCT04912375|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34005228|NCT05310617|||COHORT||RETROSPECTIVE|||||||
33787393|NCT04282902|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study planned to randomize approximately 147 adult subjects. They will be stratified according to whether the onset time is ≤14 days and randomly divided into groups of 1: 1, receiving standard treatment or pirfenidone orally 3 times a day, 2 tablets each time. The course is 4 weeks or more. Subjects and all research center staff were not blinded.||||
33787394|NCT01348087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787395|NCT06047821|||COHORT||PROSPECTIVE|||||||
33787396|NCT01019616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787397|NCT06629792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926669|NCT02524067|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005229|NCT02226991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787398|NCT00802919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787399|NCT01540929|||COHORT||RETROSPECTIVE|||||||
33787400|NCT01730274|||CASE_CONTROL||PROSPECTIVE|||||||
33787401|NCT02775981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787402|NCT05868226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, multi-site, multi-arm platform study, where each drug regimen arm may have different study designs and eligibility. In particular, dose finding parts may employ different designs (e.g., 3+3, Bayesian Optimal Interval Design \[BOIN\], continual reassessment method \[CRM\], etc.) for each arm in the PRE-I-SPY program. See each arm for specific study model details.||||
33787403|NCT01178242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787404|NCT04392635|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787405|NCT03503773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded (The subject, sponsor, and hypertensionist/nephrologist performing the screening and follow-up assessments are blinded. The interventionalist and cath lab staff are unblinded.)|"Subjects who continue to be eligible at the end of the run-in period will be randomized in a 1:1 ratio to one of the following 2 groups via central randomization (stratified by study site):~* Treatment Arm: renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter~* Sham Control Arm: only renal angiography performed"|t|f|f|t
33787406|NCT02317705|NA|SINGLE_GROUP||OTHER||NONE||||||
33787407|NCT04539951|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||In phase I all the participants will be initially treated for sertraline for 12 weeks.non-remmitters will be randomly allocated to five treatment arms for another 12 weeks in phase II.|f|f|f|t
33787408|NCT02279342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787409|NCT05753852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787410|NCT03943719|||CASE_CONTROL||PROSPECTIVE|||||||
33787411|NCT02063607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787412|NCT01506843|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33787413|NCT00602589|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787414|NCT06064032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All the recruited participants will be assigned serial numbers and will be randomly divided into two groups using lottery method.The participants file will be prepared and will be kept under custody of Principal Investigator. List will be provided to outcome assessor for respected treatment and directing the participant to care giver. Outcome assessor will collect the data before and after each session in a separate assigned space. Score will be recorder on 1st , 7th and 15th day of treatment session by the investigator. After that respected scores will be computed \& analyzed by the outcome assessor.|The subjects in the experimental group will be given a 10 minute session of Progressive Muscle Relaxation (PMR), 2 minutes deep breathing exercises,3 minutes training for life style modification which includes the use of planners, setting alarms, breaking a difficult task into parts, positive reinforcement and communication combined with a 3 minute session of drawing a specific pattern with installing pegs on pegboard, 2 minutes session of balance board training, 3 min session of solving jigsaw puzzles, 1 minute session of squeezing a ball with maximum repetition and 1 minute session of finding beads in puttey. . After the completion of therapy, the participants will be assessed by the proforma used to diagnose the ADHD and their respective scores will be noted and compared with the previous ones.|t|t|f|t
33787415|NCT02533167|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33787416|NCT00370448|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787417|NCT06475599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787418|NCT06619639|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787419|NCT00535197|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787420|NCT03141619|||COHORT||PROSPECTIVE|||||||
33787421|NCT06285175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787422|NCT04878341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787423|NCT01981356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787424|NCT06357572|||CASE_ONLY||CROSS_SECTIONAL|||||||
33787425|NCT03690856|NA|SINGLE_GROUP||OTHER||NONE||||||
33787426|NCT05527483|||COHORT||PROSPECTIVE|||||||
34005230|NCT05735418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind, randomized controlled trial|t|t|t|t
34005231|NCT04731493|||CASE_ONLY||PROSPECTIVE|||||||
33787427|NCT05903482|||COHORT||CROSS_SECTIONAL|||||||
33787428|NCT05159141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Trial participants and individuals assessing the outcomes are blinded to the participant's condition|Infants are randomly assigned to one of two groups: Behavioral Sleep Intervention or Control.|t|f|f|t
33787429|NCT06393569|||CASE_CONTROL||RETROSPECTIVE|||||||
33787430|NCT02750397|||COHORT||PROSPECTIVE|||||||
33787431|NCT04950751|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005232|NCT01062334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005233|NCT06480604|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34005234|NCT01919541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34005235|NCT02091310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005236|NCT05703841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787432|NCT03425539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787433|NCT05187767|||CASE_CONTROL||PROSPECTIVE|||||||
33787434|NCT05585580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787435|NCT06037681|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33787436|NCT06501079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"The aim of the current study is to compare the effect of adding dexamethasone versus magnesium sulphate to bupivacaine in ultrasound-guided erector spinae plane block on the severity of postoperative pain.~Primary Objectives to compare the effect of ESPB without additives to the effect of adding dexamethasone and to the effect of adding magnesium sulphate in the form of post-operative visual analogue scale (VAS) after 30 hours at rest."|t|f|t|f
33787437|NCT05165914|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005237|NCT02241317|||COHORT||PROSPECTIVE|||||||
33700551|NCT03958435|||CASE_ONLY||RETROSPECTIVE|||||||
34091311|NCT05439564|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34091312|NCT05619341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|psyllium / maltodextrin added to 500ml water + inulin 20g|3 way cross-over|t|f|f|f
34091313|NCT00327327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091314|NCT04278664|||COHORT||PROSPECTIVE|||||||
33700552|NCT03124446|RANDOMIZED|PARALLEL||PREVENTION||NONE|Data analysts will be blinded to treatment allocation and randomization.|Overall, a superiority randomized controlled trial with parallel groups will be performed with 30 participants per arm. Participants will be randomly assigned to MB-College or enhanced usual care control.||||
34091315|NCT05804903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091316|NCT04682613|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091317|NCT04366804|||COHORT||PROSPECTIVE|||||||
34091318|NCT00140439|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34091319|NCT01242007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091320|NCT01823900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700553|NCT06432231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091321|NCT04079959|||COHORT||PROSPECTIVE|||||||
34091322|NCT06190366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700554|NCT05583565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700555|NCT02666885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700556|NCT03545100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700557|NCT03257696|||CASE_ONLY||PROSPECTIVE|||||||
33700558|NCT00462631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787438|NCT04146818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787439|NCT02540642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787440|NCT02760381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787441|NCT01134419|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34005238|NCT00647894|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34005239|NCT00367016|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34005240|NCT04544137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research staff who completes assessments will not be aware of random assignment||f|f|f|t
34005241|NCT02178124|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34091323|NCT01580644|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700559|NCT01910961|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700560|NCT00292396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700561|NCT03656107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700562|NCT00853346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700563|NCT05061706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700564|NCT04223973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial (RCT), open-label with two arms, multicentric national, prospective, non-inferiority methodology versus reimbursed comparator.||||
33700565|NCT04553679|||COHORT||PROSPECTIVE|||||||
33700566|NCT02291354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787442|NCT01964859|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Sites are labeled as A, B and C and masked for outcomes assessors-- but these are all in the same subject.|||||
33787443|NCT05586451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787444|NCT04181931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787445|NCT02289560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787446|NCT06631807|||CASE_CONTROL||PROSPECTIVE|||||||
34005242|NCT03706391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005243|NCT02593019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005244|NCT03355352|||CASE_CONTROL||PROSPECTIVE|||||||
34005245|NCT02156154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005246|NCT02495376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005247|NCT06078020|||COHORT||PROSPECTIVE|||||||
34005248|NCT06390865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005249|NCT01899326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005250|NCT00187265|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34005251|NCT01334957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005252|NCT00491257|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34091324|NCT06212778|||COHORT||CROSS_SECTIONAL|||||||
34091325|NCT00747136|||CASE_ONLY||PROSPECTIVE|||||||
34091326|NCT02142543|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34091327|NCT03589703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091328|NCT01567410|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
34091329|NCT00585182|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34091330|NCT06452303|||COHORT||PROSPECTIVE|||||||
34091331|NCT03527602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind. (Participants)||t|f|f|f
34005253|NCT06617650|||CASE_CONTROL||PROSPECTIVE|||||||
34005254|NCT00277030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005255|NCT02583308|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34005256|NCT03526614|||COHORT||PROSPECTIVE|||||||
33700567|NCT03078400|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Arm I: N=6 to 12, Safety Phase, 3 + 3 design with 2 cohorts.~* Cohort 1 SPL-108 150 mg daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~* Cohort 2 SPL-108 300 mg daily (150 mg q12 hours) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~Arm II: N=up to 12, Exploratory Expansion Phase~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."||||
33700568|NCT03804008|RANDOMIZED|PARALLEL||TREATMENT||NONE|Analyses will be carried out by a blinded data analyst|||||
33700569|NCT04725422|||COHORT||PROSPECTIVE|||||||
33700570|NCT01118871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700571|NCT02836444|||COHORT||PROSPECTIVE|||||||
34005257|NCT00236145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700572|NCT00407160|||COHORT||PROSPECTIVE|||||||
33700573|NCT00152620|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33700574|NCT01715935|NA|SINGLE_GROUP||||NONE||||||
33787447|NCT04018417|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787448|NCT06478043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787449|NCT02396979|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33787450|NCT00712166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787451|NCT01881919|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33787452|NCT01483287|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33787453|NCT04266561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787454|NCT06480903|||COHORT||PROSPECTIVE|||||||
33787455|NCT02013986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926670|NCT04322955|NA|SEQUENTIAL||TREATMENT||NONE||"Initially patients enrolled on the study will be assigned to Cohort 1. Patients assigned to Cohort 1 will have the cabozantinib held for three weeks prior to removal of the kidney. A patient in cohort 1 will be evaluable for assessment of the cabozantinib washout interval (evaluable patients) if they~1. complete at least 10 of the 14 scheduled cabozantinib doses in the two week period prior to stopping cabozantinib AND~2. have surgical resection of the primary tumor.~In cohort 2, subjects will receive cabozantinib until 14 days prior to nephrectomy."||||
33926671|NCT00220454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926672|NCT04399980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926673|NCT03934203|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33926674|NCT00050622|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33926675|NCT01191632|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005258|NCT04504006|||COHORT||PROSPECTIVE|||||||
34005259|NCT01485471|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005260|NCT05770557|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34005261|NCT01426087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34005262|NCT00819767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005263|NCT04681508|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700575|NCT03334110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700576|NCT03929510|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33700577|NCT02193230|||OTHER||PROSPECTIVE|||||||
33700578|NCT04391491|||COHORT||CROSS_SECTIONAL|||||||
33700579|NCT01856907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33700580|NCT04203329|||COHORT||PROSPECTIVE|||||||
33700581|NCT02910115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700582|NCT02439190|RANDOMIZED|PARALLEL||||NONE||||||
33926676|NCT03432611|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized, three-armed pragmatic study||||
34005264|NCT01318161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005265|NCT04554147|NA|SINGLE_GROUP||PREVENTION||NONE||This is a nonrandomized, single arm feasibility study testing the preliminary efficacy of an app-enhanced intervention with a patient-provider-community health worker triad to promote hypertension control among AA patients within FQHCs.||||
34005266|NCT06214416|RANDOMIZED|PARALLEL||PREVENTION||NONE||It is intended to recruit a total of 100 participants, including two observational cohorts of abstainers and drinkers. The intervention will be carried out in drinkers willing to change their alcohol consumption, divided into 2 groups of 150 participants, the abstention group and the Mediterranean alcohol-drinking pattern group.||||
34005267|NCT03069417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005268|NCT00416468|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005269|NCT02351635|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005270|NCT04366284|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700583|NCT00154557|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33700584|NCT05155150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized trial||||
33700585|NCT03979612|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33700586|NCT01001013|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700587|NCT00646074|RANDOMIZED|PARALLEL||||NONE||||||
33700588|NCT04674202|||COHORT||PROSPECTIVE|||||||
33787456|NCT02359838|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787457|NCT00125151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787458|NCT01771887|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787459|NCT05421975|||COHORT||PROSPECTIVE|||||||
33720387|NCT03742154|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized into one of the two study groups, like drawing numbers from a hat. One group will receive a mailed sample of varenicline, and the other will not. Participants have 50/50 chance of being in either group. Both groups will contain equal numbers of smokers motivated to quit and smokers not currently motivated to quit.||||
33720388|NCT01834014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787460|NCT05695573|||COHORT||PROSPECTIVE|||||||
33787461|NCT04091672|NA|SINGLE_GROUP||TREATMENT||NONE|The participant and blinded evaluator will be not be told which treatment area received which treatment (RECELL or Control).|||||
33926677|NCT04241172|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care providers are not aware about the research study protocol.|patients with total knee prosthesis divided into three groups, to receive a traditional rehabilitation (TR) program, traditional hydrotherapy (TH) or hydrotherapy through immersive virtual reality (HIVR) using Bts-Nirvana|f|t|f|f
33926678|NCT01482572|||CASE_CONTROL||PROSPECTIVE|||||||
33926679|NCT02540876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700589|NCT04746222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects will be randomised to either FMT-capsules or placebo (subject and investigator-blinded) immediately prior to capsule administration. Subjects who are randomised to FMT by capsule will receive 30 FMT-containing capsules under direct-observed therapy. Subjects who are randomised to placebo capsules will receive 30 placebo capsules under direct-observed therapy.|Double-blinded, randomised controlled trial to evaluate the clinical efficacy of oral capsule administered FMT for CPE-intestinal decolonisation compared with placebo (1:1)|t|t|t|t
33926680|NCT00263250|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926681|NCT00809861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926682|NCT01966861|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926683|NCT04009460|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33926684|NCT04190589|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm study with historical controls||||
33926685|NCT01441518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926686|NCT06112067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926687|NCT04134169|||CASE_ONLY||PROSPECTIVE|||||||
33926688|NCT05387213|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700590|NCT05024604|||COHORT||PROSPECTIVE|||||||
33926689|NCT03020264|NA|SINGLE_GROUP||OTHER||NONE||||||
33926690|NCT00263835|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926691|NCT01046656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926692|NCT00044642|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33926693|NCT02062242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33926694|NCT02479295|RANDOMIZED|PARALLEL||TREATMENT||NONE||straight versus coiled Tenckhoff catheters||||
34005271|NCT06513949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical-appearing placebo prepared by research pharmacist|Patients hospitalized with ARDS will be randomized to treatment with anti-CD14 monoclonal antibody, IC14, or placebo and evaluated for impact of treatment on severity of lung injury as measured by day 4 oxygenation index. Secondary objectives include determination of systemic and alveolar inflammatory responses; indices of oxygenation and illness severity; safety; and IC14 levels in bronchoalveolar lavage fluid and serum. Exploratory objectives include determining the effect of treatment on duration of mechanical ventilation, mortality, and feasibility of measuring presepsin, a CD14 pathway-specific biomarker at baseline using rapid testing|t|t|t|t
34005272|NCT01302457|||CASE_CONTROL||PROSPECTIVE|||||||
34005273|NCT01422928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005274|NCT00559637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005275|NCT04590781|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33700591|NCT00595465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33700592|NCT04424810|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel, 2 groups, 1:1 randomization||||
33700593|NCT04635228|||COHORT||PROSPECTIVE|||||||
33700594|NCT01232777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700595|NCT02008630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700596|NCT06324383|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33700597|NCT05634915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700598|NCT00002008||||TREATMENT||NONE||||||
33700599|NCT02422472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700600|NCT05100901|NA|SINGLE_GROUP||OTHER||NONE||||||
33700601|NCT04225546|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700602|NCT05169996|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were not informed about in which arm of the study they were allocated.|"In a 2 (game: real vs virtual) x 2 (product: food vs non-food) between-subjects design lab experiment, the effectiveness of pre-exposure to food in a VR game is tested. A fifth condition was added (VR x branded food) in order to examine brand effects."|t|f|f|f
33700603|NCT03848065|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33700604|NCT01462643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700605|NCT00486473|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33700606|NCT01880619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700607|NCT01415167|||OTHER||PROSPECTIVE|||||||
33700608|NCT04845477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700609|NCT06301217|||COHORT||PROSPECTIVE|||||||
33700610|NCT04140097|||COHORT||PROSPECTIVE|||||||
33700611|NCT05861869|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700612|NCT00003678|RANDOMIZED|||TREATMENT||||||||
33700613|NCT06033144|||COHORT||PROSPECTIVE|||||||
33700614|NCT01229826|||COHORT||PROSPECTIVE|||||||
33700615|NCT05295056|||COHORT||PROSPECTIVE|||||||
33700616|NCT05194865|||COHORT||RETROSPECTIVE|||||||
33700617|NCT00446615|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720389|NCT02318511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720390|NCT01768481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787462|NCT01867580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787463|NCT03817736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787464|NCT01359371|||COHORT||CROSS_SECTIONAL|||||||
33787465|NCT02047461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787466|NCT05075031|||COHORT||RETROSPECTIVE|||||||
33926695|NCT05134597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005276|NCT05966207|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926696|NCT04011319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926697|NCT05870670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33926698|NCT03385694|||COHORT||PROSPECTIVE|||||||
33926699|NCT01693861|||CASE_ONLY||PROSPECTIVE|||||||
33926700|NCT02104323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926701|NCT05703139|||COHORT||OTHER|||||||
33926702|NCT04285853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and PI (orthopaedic surgeon) will be blinded. Placebo pills will be closely matched to oxycodone pills, so patients will not know to which group they are allocated. The PI will be blinded to group allocation.|Prospective, double-blind, randomized controlled clinical trial|t|f|t|f
33926703|NCT04653389|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment A Phase II Single-arm, Open-label Study||||
33926704|NCT05452317|||COHORT||RETROSPECTIVE|||||||
33926705|NCT00428883|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33926706|NCT03028467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926707|NCT03295604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926708|NCT00740363|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926709|NCT02157103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926710|NCT06374524|||COHORT||PROSPECTIVE|||||||
33926711|NCT05034471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005277|NCT00817141|||COHORT||PROSPECTIVE|||||||
34005278|NCT05377125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed which of the two training conditions they are assigned to. Independent outcome (IE) evaluator will remain blinded to the assigned condition of participants.|Participants are assigned to one of the two training groups in parallel for the duration of the study.|t|f|f|t
34005279|NCT05008562|||CASE_ONLY||PROSPECTIVE|||||||
34005280|NCT06615011|||CASE_ONLY||OTHER|||||||
34005281|NCT00108979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34005282|NCT04655235|||CASE_CONTROL||PROSPECTIVE|||||||
34005283|NCT05774652|RANDOMIZED|PARALLEL||PREVENTION||NONE||The objective of the LiPO-Teen project is to perform a clinical follow-up study of the eligible 301 mothers who completed the trial until delivery with a liveborn child, and their 14 year-old offspring.||||
34005284|NCT05049031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34005285|NCT01322334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34005286|NCT04174573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926712|NCT04725539|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33926713|NCT01176188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926714|NCT04107116|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33700618|NCT04433663|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The research student, who collected the data was blind to treatment groups. Therapists and participants were blinded to the research aims and hypothesis.|Six experienced therapists (more than 10 yrs. in the eating disorders' treatment) within one eating disorder center, were randomly allocated using the excel randomization function to the intervention group and control group. All participants in the clinical sample were drawn consecutively from admitted population to these therapists in a community-based eating disorder center between September 2018 to April 2019.|t|t|f|t
33926715|NCT06375226|||OTHER||CROSS_SECTIONAL|||||||
33700619|NCT03916575|||CASE_ONLY||RETROSPECTIVE|||||||
33700620|NCT00763529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700621|NCT04108234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HR071603 monotherapy|t|t|t|t
33700622|NCT00061477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787467|NCT04504903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research personnel conducting outcomes assessments will be blinded to condition assignment|Unemployed participants with serious mental illness will be randomized to receive group-based cognitive behavioral therapy geared toward improving competitive work outcomes or a time and format matched psychoeducation intervention|f|f|f|t
33787468|NCT04384146|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, prospective trial.||||
33787469|NCT02772614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787470|NCT00439933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33926716|NCT01678157|||COHORT||PROSPECTIVE|||||||
33926717|NCT02995941|||COHORT||CROSS_SECTIONAL|||||||
33926718|NCT01693497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926719|NCT02727517|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33926720|NCT02439736|||COHORT||PROSPECTIVE|||||||
33926721|NCT02500277|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33926722|NCT03355768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926723|NCT05150314|||CASE_ONLY||RETROSPECTIVE|||||||
33926724|NCT01363856|||COHORT||PROSPECTIVE|||||||
33926725|NCT05595603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926726|NCT01502358|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926727|NCT01729104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700623|NCT01332084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700624|NCT02570360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700625|NCT03242889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700626|NCT06282393|NA|SINGLE_GROUP||OTHER||NONE||||||
33700627|NCT05258643|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787471|NCT04392349|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33787472|NCT03936829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787473|NCT04216823|||COHORT||PROSPECTIVE|||||||
33787474|NCT05702723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926728|NCT04549415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926729|NCT00203255|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33926730|NCT00647946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926731|NCT03139903|||FAMILY_BASED||RETROSPECTIVE|||||||
33926732|NCT01809197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33926733|NCT01607294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926734|NCT03043846|||COHORT||PROSPECTIVE|||||||
33926735|NCT01141218|||CASE_ONLY||PROSPECTIVE|||||||
33926736|NCT04371354|||OTHER||PROSPECTIVE|||||||
33926737|NCT05946707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants will be randomized after induction of general anesthesia and thus are not aware of the treatment arm, which solely differs at the time of lung isolation.|non-blinded, randomized, controlled trial|t|f|f|f
33926738|NCT01288586|||CASE_CONTROL||PROSPECTIVE|||||||
33926739|NCT00440336|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926740|NCT03358615|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33926741|NCT00418717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926742|NCT02120352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926743|NCT01754441|||OTHER||PROSPECTIVE|||||||
33926744|NCT02316626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926745|NCT01324427|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33926746|NCT02945995|||COHORT||RETROSPECTIVE|||||||
33926747|NCT01656811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926748|NCT00157170|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33926749|NCT04459494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926750|NCT01451151|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33926751|NCT04648618|||CASE_CONTROL||PROSPECTIVE|||||||
33926752|NCT00759083|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33926753|NCT00750217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926754|NCT00640146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926755|NCT04454138|||COHORT||RETROSPECTIVE|||||||
33926756|NCT06507761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926757|NCT05134168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926758|NCT06076772|||COHORT||PROSPECTIVE|||||||
33926759|NCT01843634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926760|NCT02580838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926761|NCT06103019|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A crossover design was conducted. Each patient received two prostheses: 1) Conventional Maxillary and mandibular complete denture. 2) 3D printed Maxillary and mandibular complete denture.Each denture was used for 3 months followed by 2 weeks rest period without wearing the denture then the other type of denture was delivered and used for another 3 months.|t|f|f|f
33926762|NCT05343585|NA|SINGLE_GROUP||OTHER||NONE||||||
33926763|NCT04537754|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33926764|NCT02709109|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33926765|NCT04281017|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700628|NCT04569253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926766|NCT04835571|NA|SINGLE_GROUP||PREVENTION||NONE||Single group, repeated measures design. The treatment is||||
33926767|NCT01378403|||CASE_ONLY||PROSPECTIVE|||||||
33926768|NCT02455388|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Study 1: Crossover design Study 2: Cross-sectional design|t|f|f|f
33926769|NCT05410899|||OTHER||PROSPECTIVE|||||||
33926770|NCT05410197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926771|NCT01665872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926772|NCT04615780|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because of the nature of the intervention, only the data analyst was blinded to the meaning of the group assignment code.|Patients were randomly assigned to 2 groups: mouthwash with green tea (intervention) group or tap water (control) group. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily, and the control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.||||
33926773|NCT03934541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926774|NCT01742533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926775|NCT04225390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926776|NCT01407848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700629|NCT01254331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700630|NCT05485155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700631|NCT01825070|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33700632|NCT01691274|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33720391|NCT05871268|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The control group will have usual care, meaning that the physician will NOT see the patient's survey results. The patient is blinded to randomization and will not know whether or not the physician is aware of their preferred level of shared decision making.|Spanish speaking women will be randomly assigned to physician awareness or treatment as usual (control) using a 1:1 allocation.|t|f|f|f
33720392|NCT03539874|||COHORT||PROSPECTIVE|||||||
33720393|NCT03600974|||OTHER||PROSPECTIVE|||||||
33720394|NCT01018368|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787475|NCT05763004|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926777|NCT02360371|NA|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|Neither participants nor staff were informed of the class of drugs under investigation. Strict blinding was maintained.|Within-subject, double-blind, randomized, placebo-controlled, human laboratory design wherein each participant completed each of the study conditions (outlined below as four arms). Participants were genotyped for rs-1799971and data were analyzed using between-group designs based upon rs-1799971 status.|t|t|t|t
33700633|NCT01899664|NA|SINGLE_GROUP||TREATMENT||NONE||"Subjects will undergo the following:~A full International Standards for Neurological Classification of SCI exam will be completed to determine exact function and type of spinal cord injury.~A phone interview will be completed at both preoperative and postoperative time points.~Quality of life before and after surgical intervention will be derived from standardized questionnaires: Spinal Cord Independence Measure (SCIM), SF-36, Novak scale, and pain questionnaires.~Additional qualitative and quantitative data on donor and recipient nerve function and tissue will be derived from preoperative electrodiagnostic studies.~Specimens of the donor and recipient nerve are collected for histologic analysis during the operative procedure. Those trimmed nerve specimens are then analyzed for clinical purposes to give patients an idea of expected outcome in a more timely fashion."||||
33926778|NCT05210972|||COHORT||PROSPECTIVE|||||||
33926779|NCT04854577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will not be made aware of what has been administered. The outcome assessor will be blinded for the group allocation of patients. The investigator, as one of the care providers, nor the care providers can be blinded for the administered anesthetic regimen. The opioid free anesthetic regimen will be conducted by the same anesthesiologist.|A randomized controlled, outcome assessor blinded study using two parallel study groups|t|f|f|t
33926780|NCT02865265|||||RETROSPECTIVE|||||||
33926781|NCT01909609|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33926782|NCT05474872|||COHORT||PROSPECTIVE|||||||
33926783|NCT05239884|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33926784|NCT03006796|||COHORT||PROSPECTIVE|||||||
34005287|NCT06504303|NA|SINGLE_GROUP||OTHER||NONE||"Participants will be measured for a prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. Subjects will be given a patient experience survey to score their experience with each shape capturing process. Two sockets, one made from each of the two shape-capturing methods, will be 3D printed.~Both sockets will be fitted to the subject. The immediate socket fit will be recorded by the number of filler sock plys needed to be added in the socket. Subjects will continue therapy using the socket that is more comfortable and fits better, based on both the subject's judgment and the judgment of their clinician. If the subject finds both sockets as equally comfortable, he/she will get to choose the preferred socket to continue with for therapy."||||
34005288|NCT00232479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005289|NCT04792489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005290|NCT05762627|||COHORT||PROSPECTIVE|||||||
33700634|NCT03148314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700635|NCT01020149|||COHORT||PROSPECTIVE|||||||
33700636|NCT03608371|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|double-blind study|The study will consist of 3 sequential, single ascending dose cohorts of 8 subjects each with a 6:2 randomization to BTRX-246040 or placebo|t|t|t|t
33700637|NCT01768052|||CASE_ONLY||PROSPECTIVE|||||||
33700638|NCT01966601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700639|NCT00437931|||CASE_CONTROL||PROSPECTIVE|||||||
33700640|NCT05043675|NA|SINGLE_GROUP||OTHER||NONE||||||
33700641|NCT00834223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700642|NCT05444621|||COHORT||PROSPECTIVE|||||||
33700643|NCT04516330|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33700644|NCT00179543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33700645|NCT02221024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700646|NCT03084731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700647|NCT06681025|||COHORT||OTHER|||||||
33700648|NCT00331864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700649|NCT04185064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33700650|NCT06352983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both participant, care providers, dental technicians and the investigator are blinded in the process.|Randomized controlled trial|t|t|t|t
33700651|NCT03798847|||OTHER||RETROSPECTIVE|||||||
33700652|NCT01585870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700653|NCT06681233|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, single-arm, single-site feasibility study designed to generate data evaluating the quality and applicability of the HyperSight on-couch high-performance CBCT imaging technology.||||
33700654|NCT05226273|||OTHER||CROSS_SECTIONAL|||||||
33700655|NCT03727607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized control trial.|t|f|f|f
33700656|NCT04394611|||CASE_CONTROL||PROSPECTIVE|||||||
33700657|NCT03088371|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33700658|NCT05627297|||COHORT||RETROSPECTIVE|||||||
33700659|NCT04307784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33700660|NCT04245072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700661|NCT04195282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700662|NCT00579592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700663|NCT03157661|||COHORT||PROSPECTIVE|||||||
33700664|NCT01117948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700665|NCT03584100|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700666|NCT04711434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700667|NCT01291680|||CASE_ONLY||PROSPECTIVE|||||||
33700668|NCT00515177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700669|NCT01419522|RANDOMIZED|PARALLEL||TREATMENT||||||||
33700670|NCT02188771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700671|NCT04562467|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787476|NCT00013650||||TREATMENT||||||||
33787477|NCT00668174|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33787478|NCT06630520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787479|NCT00404079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787480|NCT03365609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005291|NCT00792207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700672|NCT00529334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700673|NCT02059252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700674|NCT00698048|||COHORT||PROSPECTIVE|||||||
33700675|NCT01678261|||COHORT||CROSS_SECTIONAL|||||||
33700676|NCT00053573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700677|NCT00065988|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34005292|NCT00249717|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700678|NCT01265251|||||CROSS_SECTIONAL|||||||
33700679|NCT04948515|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700680|NCT04231890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33700681|NCT04531839|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700682|NCT00276497|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33700683|NCT01448161|||CASE_ONLY||PROSPECTIVE|||||||
33700684|NCT05649566|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A clinical trial is proposed with young men and women between 18 and 25 years old and physically active (targeted with the International Physical Activity Questionnaire, IPAQ).||||
33700685|NCT06170892|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The newborns were placed in the kangaroo position in a single session, and the variables were identified before, during and after the application of the technique.||||
34005293|NCT06435832|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33700686|NCT06558474|||COHORT||PROSPECTIVE|||||||
33700687|NCT00788073|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700688|NCT02295410|||COHORT||PROSPECTIVE|||||||
33700689|NCT05195190|||COHORT||PROSPECTIVE|||||||
33700690|NCT03598543|||CASE_ONLY||PROSPECTIVE|||||||
33700691|NCT00002240||||TREATMENT||||||||
33700692|NCT04930978|||CASE_CONTROL||PROSPECTIVE|||||||
33700693|NCT04043975|||COHORT||PROSPECTIVE|||||||
33700694|NCT02651467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700695|NCT02235805|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33787481|NCT03538054|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participant will not know when they are taking placebo or the study medication.||t|f|f|f
33787482|NCT06713941|||COHORT||RETROSPECTIVE|||||||
33787483|NCT06591897|||CASE_ONLY||PROSPECTIVE|||||||
33787484|NCT01434303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787485|NCT02799095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787486|NCT06628583|||CASE_CONTROL||RETROSPECTIVE|||||||
33787487|NCT03837769|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787488|NCT00637676|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33787489|NCT05337072|||COHORT||PROSPECTIVE|||||||
33700696|NCT03401736|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33700697|NCT03431766|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33700698|NCT00535457|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33700699|NCT01025154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700700|NCT00630643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700701|NCT01512212|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33700702|NCT03437512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher who is not involved in any aspect of the study will randomize participants into the sham and active study arms using a minimization procedure. Allocation concealment will be achieved by assigning a unique 6-digit random code per participant, which will be provided to the researcher. The code is used to deliver stimulation. The participants and the researchers who deliver stimulation, assess outcomes, and analyze data will be masked to trial arm.||t|t|t|t
33700703|NCT03971123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33700704|NCT00812682|||CASE_ONLY||PROSPECTIVE|||||||
33700705|NCT03459261|||COHORT||PROSPECTIVE|||||||
33700706|NCT00004868||||TREATMENT||||||||
33700707|NCT01492569|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33700708|NCT01829737|||||PROSPECTIVE|||||||
33700709|NCT03687112|||COHORT||PROSPECTIVE|||||||
33700710|NCT01363648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787490|NCT04258774|NON_RANDOMIZED|PARALLEL||OTHER||NONE||All arms will receive the same study conditions.||||
33787491|NCT05163756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator) Double-blind||t|f|t|f
33926785|NCT04494958|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicentric, single-arm, open label, phase IB clinical trial.||||
34005294|NCT02752386|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005295|NCT01374724|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34005296|NCT03110016|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34005297|NCT02909517|||COHORT||PROSPECTIVE|||||||
34005298|NCT05660863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005299|NCT04029454|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Pragmatic Stepped-wedge cluster randomized trial||||
33700711|NCT04778657|||COHORT||OTHER|||||||
33700712|NCT00181155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700713|NCT01446926|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33700714|NCT03914482|NA|SINGLE_GROUP||OTHER||NONE||||||
33700715|NCT06240130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700716|NCT05316285|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33700717|NCT03484637|||COHORT||PROSPECTIVE|||||||
33700718|NCT01890746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700719|NCT04374071|||COHORT||RETROSPECTIVE|||||||
33700720|NCT00821483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700721|NCT06436261|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Subjects were randomly assigned to use the active post-procedure cream on one side of the face and the comparator moisturizer on the opposite side of the face.~The products were packaged in the same container and labelled post-procedure cream. This was a double-blinded study, where the investigator, study subject, and other study personnel involved in the evaluation of efficacy or safety were blinded to the group during the study."|Randomized, Multi-Center, Double-Blinded, Split-Face, Controlled|t|f|t|f
33700722|NCT04587271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33700723|NCT02433301|||||PROSPECTIVE|||||||
33926786|NCT03228706|RANDOMIZED|PARALLEL||OTHER||TRIPLE|A person who is independent of this study and invited by principal investigator will carry out the randomization based on the list of participants who are eligible and agreed to participate. The list of participants with their randomization information will be kept by the committee member without informing any of the researchers including principal investigator or respondents to assure the blinding of both parties throughout the study. On the day of the intervention, that person will register the attendance of respondents and inform them about the actual venue of the program without informing the researchers or the facilitators of the KYM-TIFH. Each HCKS and HCKS will have two venues prepared and available during the period of the study with one venue allocated for intervention group and the other one with for control group. None of the respondents were aware of the difference between the with assigned.|To achieve the objectives, positivist approach with experimental study design will be employed. In specific, it is a double blinded, randomized controlled trial (RCT) which involve two study sites. Nonetheless, the reporting of the SGBI will be in accordance with the checklist recommended by Borek et al. (2015).|t|f|t|t
33926787|NCT03483116|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a Phase II, randomised, double-blind, placebo-controlled, four-arm parallel group study of two different dosing schedules of oral RV3-BB|t|t|t|t
33926788|NCT00493480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33926789|NCT03339401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926790|NCT00088972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33926791|NCT01369225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926792|NCT05531968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33926793|NCT02866734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926794|NCT05833555|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33926795|NCT03370198|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be a hepatic transarterial administration of NKR-2 every 2 weeks for a total of 3 administrations within 4 weeks (28 days). Three dose-level will be assessed (dose escalation with 3 dose-levels or 3 cohorts).||||
33926796|NCT01018693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091332|NCT04681378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A computer-generated random numerical table (Randomization Generator Version 1.0) was used by our statistical department to prepare sealed opaque envelopes containing a group assignment. Three groups of envelopes-corresponding to the study groups were given to an anesthesia nurse. The nurse distributed envelopes to patients, alternating between groups during preanesthetic consultation. The patients were blinded the groups, and two authors performed the operations randomly. Another author who was blinded to the suturing technique performed all of the ultrasonographic examinations at 6 week follow up visit.|This trial enrolled 120 patients scheduled for primary cesarean delivery. Patients were randomized into either classical double layer uterine closure, purse string double layer uterine closure (Turan), or our new approach of uterine closure (double layer step up-step down technique). For short term comparison, transvaginal ultrasonography was planned for all patients 6 weeks after surgery|t|f|f|t
34091333|NCT05595434|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be informed about the nature (active or placebo) of the stress test they will perform.|Randomized, controlled, single-blind study including 40 healthy subjects who will be randomly divided into 2 groups.|t|f|f|f
34091334|NCT04230070|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33926797|NCT00525226|||COHORT||PROSPECTIVE|||||||
33926798|NCT00602771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926799|NCT04550936|||CASE_ONLY||RETROSPECTIVE|||||||
34091335|NCT00063622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926800|NCT00002657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926801|NCT02822651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926802|NCT06423105|||COHORT||PROSPECTIVE|||||||
34091336|NCT05593458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091337|NCT01626313|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34091338|NCT03834116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091339|NCT00001956||||TREATMENT||||||||
34091340|NCT04624243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091341|NCT04360720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091342|NCT01334515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091343|NCT05010967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091344|NCT04571034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34091345|NCT04154345|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-group study design||||
34091346|NCT04601376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091347|NCT02825602|||OTHER||CROSS_SECTIONAL|||||||
34091348|NCT01021384|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34091349|NCT01331434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091350|NCT02162563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091351|NCT06077851|||COHORT||PROSPECTIVE|||||||
34091352|NCT02229604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091353|NCT06454539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091354|NCT01177176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091355|NCT01208246|||COHORT||PROSPECTIVE|||||||
34091356|NCT05911568|||COHORT||PROSPECTIVE|||||||
34091357|NCT06398288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091358|NCT04946643|||COHORT||PROSPECTIVE|||||||
33926803|NCT02910219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33926804|NCT01297946|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091359|NCT02505061|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34091360|NCT02593864|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091361|NCT03412032|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34091362|NCT01130402|||||RETROSPECTIVE|||||||
34091363|NCT02194075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700724|NCT06404671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787492|NCT03307980|NA|SEQUENTIAL||TREATMENT||NONE||"This study was originally designed as a long-term follow up study for individuals dosed in Study C0371005 to evaluate the overall long-term safety, durability of transgene expression, and effect on clinical outcomes of PF-06838435 mediated gene transfer. For these individuals this study will last for 5 years providing a minimum of 6 years of follow up post vector administration.~Amendment 2 of this study introduces a dose-escalation substudy to evaluate the safety, tolerability, and kinetics of a single IV infusion of PF-06838435 at a higher dose(s) than that used in the C0371005 study. For these participants this study will last for a total of 6 years post vector administration."||||
33787493|NCT03518541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are masked about which group they are randomized in|"Randomization into two study arms:~1. Classic control of derotation using a Moeltgen goniometer intraoperatively~2. Control of derotation using an electromagnetic tracking device intraoperatively"|t|f|f|f
33787494|NCT04735939|||COHORT||PROSPECTIVE|||||||
33787495|NCT01182454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700725|NCT03608254|||OTHER||CROSS_SECTIONAL|||||||
33700726|NCT03159117|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1 non-randomized, open-label, single-center, single-arm multiple dose escalation||||
33700727|NCT04414748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926805|NCT05401591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33700728|NCT06680713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700729|NCT00001624||||TREATMENT||||||||
33700730|NCT04604314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700731|NCT02789631|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700732|NCT05181033|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a multi-centre study comprising two phases: a lead-in phase II (Part A) followed by a randomized phase II portion (Part B).~Part A: Lead in phase II study A total of up to 10 patients will be enrolled. Patients will be treated with letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression or unacceptable toxicity. ' Part B: Randomised phase II study~Patients will be randomized in a 1:1 fashion to one of 2 arms:~* Control arm: intramuscular (IM) fulvestrant 500mg on day 1 and day 15 during cycle 1, then day 1 only from cycle 2 onwards of every 4-weekly cycle~* Experimental arm: oral (PO) letrozole 2.5mg daily plus lenvatinib 14mg daily A total of 110 patients with ER positive breast cancer and measurable primary tumor will be enrolled over a period of 24-30 months."||||
33700733|NCT03101787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700734|NCT05218720|||CASE_ONLY||CROSS_SECTIONAL|||||||
33700735|NCT01488305|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33700736|NCT01823146|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33700737|NCT03883360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A matched placebo is employed. Only the biostatistician performing the randomization and the pharmacists will know the treatment assignment.|Participants will be randomized 1:1 to either the cannabidiol group or the placebo group.|t|t|t|t
33700738|NCT03463174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700739|NCT01975961|RANDOMIZED|CROSSOVER||||NONE||||||
33700740|NCT00341055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700741|NCT06556355|||COHORT||RETROSPECTIVE|||||||
33700742|NCT04027829|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Dexmedetomidine infusion at intensive care unit||||
33700743|NCT01578070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33700744|NCT01172262|||COHORT||PROSPECTIVE|||||||
33700745|NCT02842359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700746|NCT04471246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eligible patients will be randomized (1:1) to high-dose versus standard-dose arms. The randomization sequence will be computer-generated by a statistician|The Investigators will conduct a parallel arm double-blind randomized controlled pilot trial.|t|t|t|f
33700747|NCT00921128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700748|NCT05704231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant)|This study is a parallel group randomized controlled study.|t|f|f|f
33700749|NCT00027716||||TREATMENT||NONE||||||
33700750|NCT05401968|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The municipalities recruit and include citizens in osteoporosis patient education. We have already received information on participants from 2016 until 2020, and thereafter we will create a matched control group, who have not participated in osteoporosis patient education.||||
33700751|NCT05330572|||CASE_ONLY||PROSPECTIVE|||||||
33700752|NCT04314934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700753|NCT00647361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700754|NCT02406183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787496|NCT01611909|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33787497|NCT03060187|||CASE_ONLY||PROSPECTIVE|||||||
33787498|NCT03994471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study cannot be blinded. The assessment of the primary end-point will be performed by a blinded, third party, independent assessor.|Randomization will be performed centrally via a web-based system, with stratification according to the presence or absence of diabetes.|f|f|f|t
33926806|NCT01631045|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33926807|NCT03915106|||COHORT||PROSPECTIVE|||||||
33926808|NCT01458496|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33926809|NCT05300646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Group affiliation will be concealed for the researcher performing the statistical analyses.|A single-center, parallel group, randomized controlled trial|f|f|f|t
33926810|NCT02840513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926811|NCT01630798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926812|NCT01647425|||COHORT||PROSPECTIVE|||||||
33926813|NCT03636113|||COHORT||PROSPECTIVE|||||||
33700755|NCT03010670|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33700756|NCT03678025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700757|NCT03869983|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|This is a double-blind study with limited access to the randomization code.|Single center, randomized, double-blind, 2-period, crossover study|t|t|t|t
33700758|NCT05895617|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700759|NCT05466929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention group (TeACH System psychoeducation and recommendations) and control group (evidence-based online educational materials)||||
33700760|NCT06681753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Sampling Inclusion Criteria:~* Being a senior student in the SAU Faculty of Health Sciences, Midwifery Department~* The student agrees to participate in the study~Sampling Exclusion Criteria:~* The student does not agree to participate in the study~* Being a 1st, 2nd or 3rd year student in the SAU Faculty of Health Sciences, Midwifery Department"|Pretest-posttest matched control group quasi-experimental|t|f|f|f
33926814|NCT04776915|||CASE_CONTROL||PROSPECTIVE|||||||
33700761|NCT03591185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700762|NCT00934479|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33700763|NCT01706978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700764|NCT02218255|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33700765|NCT02515396|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33700766|NCT00333840|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700767|NCT04289623|||CASE_CONTROL||PROSPECTIVE|||||||
33700768|NCT06556290|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33700769|NCT01735760|||CASE_CROSSOVER||PROSPECTIVE|||||||
33700770|NCT01903031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700771|NCT05531383|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700772|NCT03451578|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700773|NCT01022749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700774|NCT04798456|||COHORT||PROSPECTIVE|||||||
33700775|NCT02637154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33700776|NCT05485454|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33700777|NCT02437812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700778|NCT00241358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700779|NCT04659720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787499|NCT00718055|||COHORT||PROSPECTIVE|||||||
33787500|NCT03317353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Double (Investigator, Outcomes Assessor)~After the first screening visit, the patients who grant their consent will be included in the study and randomised to one of the following study arms. Randomisation will be performed by C.H.U de Santiago Clinical Epidemiology and Biostatistics Unit. Once the informed consent form is signed, the care provider will contact the unit, which will give him the code of the arm to which the patient is assigned. A n= 20 block balanced randomisation sequence will be used. The investigator will analyse results and evolution, being blind type and duration of vestibular rehabilitation."|Experimental study, single-center, open, randomized (balanced blocks of patients) in four branches in parallel, in 139 elderly patients (over 65 years) with high risk of falls; follow-up period: twelve months.|f|f|t|t
33787501|NCT03758339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787502|NCT05680012|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33787503|NCT00073970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787504|NCT04808635|||OTHER||CROSS_SECTIONAL|||||||
33787505|NCT02934958|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33787506|NCT02664376|||COHORT||PROSPECTIVE|||||||
33926815|NCT04714138|||COHORT||PROSPECTIVE|||||||
33926816|NCT06045143|||COHORT||PROSPECTIVE|||||||
33926817|NCT06057649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|a third person will be involved as second assessor for blinding|Participants will be randomly allocated to control and experimental group. participants in control group will continue with their routine care and experimental group will receive effleurage abdominal massage alongwith routine practices|f|f|f|t
33926818|NCT02157012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926819|NCT00407550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926820|NCT00856986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926821|NCT03170258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33926822|NCT05171881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm interventional study to maintain cerebral oxygen saturation in targeted range||||
33926823|NCT02925208|||||RETROSPECTIVE|||||||
33926824|NCT00005018||||TREATMENT||||||||
33926825|NCT06195098|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33926826|NCT00609804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926827|NCT02145832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926828|NCT00129207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926829|NCT05729269|||COHORT||RETROSPECTIVE|||||||
33926830|NCT01101243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091364|NCT04808921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The purpose of this study is to validate the performance of the SARS-CoV-2 Antigen Test bioassay for rapid detection of infection when using a nasopharyngeal swab. A prospective randomized and blinded study to evaluate a rapid point of care bioassay for the detection of virus particles compared with the currently validated RT-PCR detection standard. Nasopharyngeal samples will be collected along with the current standard of care collection.||||
34091365|NCT04810962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700780|NCT05515315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700781|NCT00166465|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700782|NCT00004431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33926831|NCT04149847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33926832|NCT00000937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33700783|NCT01361568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700784|NCT02878642|||COHORT||PROSPECTIVE|||||||
33700785|NCT01373489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700786|NCT02545257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700787|NCT00155753|||CASE_CONTROL|||||||||
33700788|NCT06201442|||CASE_CONTROL||PROSPECTIVE|||||||
33700789|NCT05136287|||COHORT||PROSPECTIVE|||||||
33700790|NCT01817244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700791|NCT06070896|||COHORT||RETROSPECTIVE|||||||
33700792|NCT03661710|||COHORT||PROSPECTIVE|||||||
33700793|NCT02551861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700794|NCT01538511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787507|NCT05132205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787508|NCT04179240|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787509|NCT05275842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787510|NCT05092906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787511|NCT00413491|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33787512|NCT01255033|||COHORT||PROSPECTIVE|||||||
34091366|NCT00800540|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33787513|NCT00705991|||||PROSPECTIVE|||||||
33787514|NCT04509713|||COHORT||OTHER|||||||
33787515|NCT00995709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787516|NCT02491736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787517|NCT05215652|||CASE_ONLY||PROSPECTIVE|||||||
33787518|NCT02923284|||CASE_CONTROL||PROSPECTIVE|||||||
33787519|NCT04724369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparison of PET imaging interpretation and expert assessment for presence or absence of neuroblastoma tumor||||
33787520|NCT06629129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787521|NCT06194643|||COHORT||PROSPECTIVE|||||||
33787522|NCT04293783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo chewable caps are identical in shape and taste to the test product, without the Lactobacillus reuteri components Both study products are delivered in identical containers and labelled as XXX.|double-blind randomized, parallel-group, placebo-controlled study|t|t|t|f
33787523|NCT01530009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787524|NCT03768206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787525|NCT06620302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787526|NCT00950144|||CASE_ONLY||PROSPECTIVE|||||||
33787527|NCT05891977|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Intervention A: Habitual diet + consumption of low to moderate tomato or tomato products and other food sources of lycopene + 0.5 g of tomato paste / kg of body weight (experimental intervention) for 3 months.~Intervention B: Habitual diet + consumption of low to moderate tomato or tomato products and other food sources of lycopene (control) for 3 months."||||
33787528|NCT02024308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787529|NCT05463276|||OTHER||CROSS_SECTIONAL|||||||
33787530|NCT02004561|||COHORT||PROSPECTIVE|||||||
33787531|NCT03102242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787532|NCT01391442|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787533|NCT05873556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two conditions: (1) Personalized feedback based on reports from baseline and lab-session and (2) assessment-only control group.||||
33787534|NCT05484310|||COHORT||PROSPECTIVE|||||||
33787535|NCT00518362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787536|NCT03971747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787537|NCT01027286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787538|NCT02272699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787539|NCT06628414|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Statistician|Double-blind, parallel, randomised, sham-controlled pilot trial|t|t|t|t
33787540|NCT02440373|||COHORT||PROSPECTIVE|||||||
33787541|NCT02784379|||CASE_CONTROL||PROSPECTIVE|||||||
33787542|NCT05972239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787543|NCT01217554|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787544|NCT01953809|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33787545|NCT02661646|||COHORT||PROSPECTIVE|||||||
33787546|NCT06015594|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787547|NCT01211665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787548|NCT05805124|||COHORT||RETROSPECTIVE|||||||
33787549|NCT00714636|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787550|NCT00643838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787551|NCT02648529|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34091367|NCT05791110|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091368|NCT03390660|||COHORT||RETROSPECTIVE|||||||
34091369|NCT04943406|||COHORT||PROSPECTIVE|||||||
34091370|NCT03816917|||COHORT||PROSPECTIVE|||||||
33787552|NCT06714487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787553|NCT02416674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787554|NCT00425503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787555|NCT03563053|NA|SINGLE_GROUP||TREATMENT||NONE|It's a open label extension study, so no blinding was applicable.|Open-label, Long-term, Extension Treatment||||
33787556|NCT03404843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|A person not associated with any data collection or data analysis is randomizing the treatment and preparing it in a separate room. All data is collected as visit 1 or visit 2.|This is a randomized, double-blind, placebo-controlled, crossover study. Approximately 20 young and 20 older adults will be recruited for participation and randomly assigned to either a placebo (saline) infusion or a fasudil hydrochloride infusion. The dose of fasudil hydrochloride is 60 mg/ 60 min.|t|f|t|t
34091371|NCT02115698|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33787557|NCT00395811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787558|NCT00061672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787559|NCT00196365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787560|NCT05425264|NA|SINGLE_GROUP||TREATMENT||NONE||Exercise tele-rehabilitation||||
33787561|NCT01267838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787562|NCT06629883|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33787563|NCT03920163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787564|NCT00533234|||OTHER||PROSPECTIVE|||||||
33787565|NCT05378282|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787566|NCT00346411|||COHORT||PROSPECTIVE|||||||
33787567|NCT03035656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Randomization of arms are conducted by the pharmacy department, and drug or saline preparation are prepared by the pharmacy department.|Patients are randomized into either the experimental arm (administration of Ropivaciane) or the control arm (administration of saline).|t|t|t|t
33787568|NCT03093792|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33787569|NCT00913328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787570|NCT05664581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926833|NCT02905825|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The investigator and treating physician will remain blinded to the breath test results until the end of the study. There is only one arm.|A 13C labeled substrate is used as part of a combination product; a diagnostic breath test.||||
34005300|NCT05393349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926834|NCT02127528|||COHORT||PROSPECTIVE|||||||
33926835|NCT05211258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926836|NCT03914534|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33926837|NCT00418899|||FAMILY_BASED||PROSPECTIVE|||||||
33926838|NCT03136484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926839|NCT00704431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926840|NCT05954364|||COHORT||PROSPECTIVE|||||||
33926841|NCT02658981|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926842|NCT03186261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926843|NCT01854671|NON_RANDOMIZED|PARALLEL||||NONE||||||
33926844|NCT04994704|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33926845|NCT05428553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926846|NCT05022472|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33926847|NCT03717636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926848|NCT02666690|NA|SINGLE_GROUP||||NONE||||||
33700795|NCT05132634|NA|SINGLE_GROUP||PREVENTION||NONE||Paralel Assignment randomized controlled trial||||
33926849|NCT02569021|||CASE_ONLY||PROSPECTIVE|||||||
33926850|NCT05110599|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind|48 h after hospitalisation patients can be randomized to the Bryophyllum group or the placebo group.|t|t|t|t
33926851|NCT06211127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926852|NCT03706820|||CASE_ONLY||PROSPECTIVE|||||||
33926853|NCT01062828|||COHORT||PROSPECTIVE|||||||
33926854|NCT03135288|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926855|NCT01157546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926856|NCT01763983|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33926857|NCT00239356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926858|NCT02458677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926859|NCT00647257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926860|NCT02571972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005301|NCT03610919|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34005302|NCT02076516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005303|NCT06353750|||COHORT||PROSPECTIVE|||||||
34005304|NCT01083862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005305|NCT03440333|||CASE_ONLY||RETROSPECTIVE|||||||
34005306|NCT03911596|||CASE_ONLY||PROSPECTIVE|||||||
34005307|NCT00571415|||COHORT||PROSPECTIVE|||||||
34005308|NCT01251016|||COHORT||PROSPECTIVE|||||||
34005309|NCT01583634|||COHORT||PROSPECTIVE|||||||
34005310|NCT03969316|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34005311|NCT01719562|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||For the exercise capacity portion of this trial, participants will be randomized to 1 of 2 arms.||||
34005312|NCT00006228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005313|NCT02810249|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34005314|NCT00602615|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700796|NCT05748197|NA|SEQUENTIAL||TREATMENT||NONE||This is a phase I, open-label, dose-escalation/dose expansion trial.||||
33700797|NCT01495975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926861|NCT00587301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926862|NCT01978600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926863|NCT04019457|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33926864|NCT03023241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926865|NCT00961116|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33926866|NCT04424316|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double-blinded, placebo-controlled study.||t|t|t|t
33926867|NCT00636441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926868|NCT05750238|||CASE_ONLY||CROSS_SECTIONAL|||||||
33700798|NCT03918473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700799|NCT00239395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700800|NCT01440296|||COHORT||PROSPECTIVE|||||||
33700801|NCT01520597|||CASE_CONTROL||PROSPECTIVE|||||||
33700802|NCT01681940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700803|NCT05310448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700804|NCT04211402|||CASE_ONLY||PROSPECTIVE|||||||
33926869|NCT00323310|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926870|NCT06362447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926871|NCT04204798|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926872|NCT01045434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926873|NCT06269718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005315|NCT03559725|RANDOMIZED|CROSSOVER||OTHER||NONE||In part A each subject will have the opportunity to use either their own brand cigarette, nicotine gum or VLN menthol cigarettes ad libitum for 4 hours after which they will answer a questionnaire on using the product again. In Part B the subjects will have a controlled use session with each product followed by and uncontrolled session.||||
34005316|NCT05654194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005317|NCT02911935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005318|NCT02928458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005319|NCT02822482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005320|NCT03957694|NA|SINGLE_GROUP||TREATMENT||NONE||multi-national, open-label, phase 2/3 study||||
34005321|NCT01487434|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34005322|NCT03992313|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34005323|NCT02365909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005324|NCT04611594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005325|NCT01992341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005326|NCT02231996|||COHORT||PROSPECTIVE|||||||
34005327|NCT04692857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33700805|NCT00375037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700806|NCT03439917|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33787571|NCT00186420|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33926874|NCT01444508|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33926875|NCT01203722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926876|NCT05739357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33926877|NCT06070636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926878|NCT05823870|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926879|NCT05281224|||COHORT||PROSPECTIVE|||||||
33926880|NCT05073913|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926881|NCT05307341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant will not be informed whether participant is in the standard of care arm or treatment arm.|two arm, patient blinded, randomized, post market|t|f|f|f
33926882|NCT06363123|||COHORT||RETROSPECTIVE|||||||
34005328|NCT05780996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005329|NCT00964353|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34005330|NCT02505724|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34005331|NCT02528058|||CASE_ONLY||RETROSPECTIVE|||||||
34005332|NCT03037424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005333|NCT04664634|||COHORT||PROSPECTIVE|||||||
34005334|NCT02246686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005335|NCT02837133|NA|SINGLE_GROUP||||NONE||||||
34005336|NCT01625117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005337|NCT00768352|NA|SINGLE_GROUP||||NONE||||||
34005338|NCT02435316|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34005339|NCT04546152|||CASE_CROSSOVER||PROSPECTIVE|||||||
34005340|NCT01098617|||CASE_CONTROL||PROSPECTIVE|||||||
34005341|NCT04310254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant and Outcomes Assessor) The patients were unaware as to which study group they had been allocated.|Parallel Assignment The patients were assigned to 3 medication groups randomly with an equal allocation rate between groups.The patients in the groups had same characteristics.|t|f|f|t
34005342|NCT01835535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005343|NCT00838981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005344|NCT00324883|||COHORT||PROSPECTIVE|||||||
34005345|NCT05534048|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Efficacy cohort and safety cohort are parallel conducted.|t|t|t|f
34005346|NCT04847999|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Chocolate bars will be identical and wrapped equally and labeled as A and B, by Ross Chocolates (prepared in the same mold and packaged identically) who are not involved in any other aspects of the study, allowing for blinding of research team and participants.||t|t|t|f
34005347|NCT02248662|||OTHER||RETROSPECTIVE|||||||
34005348|NCT04423120|||OTHER||PROSPECTIVE|||||||
34005349|NCT06615999|||COHORT||RETROSPECTIVE|||||||
34005350|NCT02735694|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34005351|NCT04223284|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33700807|NCT03643575|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33700808|NCT00168701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700809|NCT02973490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700810|NCT00163878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33700811|NCT05952596|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study pharmacist and study staff who administer the investigational vaccine (e.g., medication nurse) will not be blinded in this study since a control vaccine that can be visually distinguished from the study vaccine will be used. The study staff including the investigator will remain blinded, except the unblinded staff.|active-controlled model|t|f|t|f
33700812|NCT06462638|||COHORT||PROSPECTIVE|||||||
33700813|NCT06175130|||OTHER||CROSS_SECTIONAL|||||||
33700814|NCT04416659|||COHORT||PROSPECTIVE|||||||
33700815|NCT03676283|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33700816|NCT01374828|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33700817|NCT01633073|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33700818|NCT05034562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700819|NCT06266689|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700820|NCT01085474|||||PROSPECTIVE|||||||
33700821|NCT02409082|||COHORT||PROSPECTIVE|||||||
33926883|NCT05668026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Dose-escalation study and an expansion cohort based on dose-limiting toxicities.|t|t|t|t
33926884|NCT00700063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926885|NCT04472637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|a double blinded study as participants, health care providers as well as the outcome assessor will be unaware about the type of treatment each patient receive.|"This research is a double-blinded , placebo-controlled, randomized clinical trial. Fifty patients with end-stage renal disease (ESRD) receiving hemodialysis treatment will be enrolled in the study.~Patients will be randomly assigned using block randomization method into two study groups:~Experimental group (25 patients): They will receive atorvastatin 10 mg, as one tablet /day for 24 weeks.~Control group (25 patients): They will receive a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks).~Allocation concealment: will be ensured using sealed closed envelop randomization technique, every patient will be given an identification code."|t|t|f|t
33926886|NCT04253808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blinded from the group they are assigned to.|Randomized controlled trial|t|f|f|f
34005352|NCT01264913|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005353|NCT00084799|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005354|NCT02312479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005355|NCT04593303|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial.||||
34005356|NCT03304717|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34005357|NCT06678282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005358|NCT01947309|||COHORT||PROSPECTIVE|||||||
33700822|NCT02432742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700823|NCT01132365|||COHORT||PROSPECTIVE|||||||
33700824|NCT01545804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700825|NCT01615666|||CASE_CONTROL||PROSPECTIVE|||||||
33700826|NCT05185323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700827|NCT01322659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700828|NCT06345352|||COHORT||RETROSPECTIVE|||||||
33700829|NCT02201849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700830|NCT05486754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700831|NCT02030704|||COHORT||PROSPECTIVE|||||||
33700832|NCT03907228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)||t|t|t|f
33700833|NCT04067882|||COHORT||PROSPECTIVE|||||||
33700834|NCT02308189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700835|NCT05175508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787572|NCT02041676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787573|NCT06435468|NON_RANDOMIZED|PARALLEL||OTHER||NONE||prospective, multicenter, national study||||
34005359|NCT05321875|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Identical placebo tablets manufactured by the same Manufacturer of active marketed Candesartan (KERN PHARMA). Double-blind labelling specific for the study.||t|t|t|t
34005360|NCT03091257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005361|NCT04928664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects, the investigators, and all the parties involved in patient management or data collection will be blinded throughout the study period.|A separate anaesthetist will then prepare 10 ml of LB or SB, and a covered elastomeric pump that is either filled with 300ml NS or with 300ml 0.2% SB according to the group assigned for the attending anaesthetist.|t|f|t|f
34005362|NCT06097702|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34005363|NCT02735330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005364|NCT05367635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005365|NCT01150162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005366|NCT03102879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"2 interventions:~1. Endodontic regenerative treatment with Biological product of umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.~2. Endodontic treatment with inert product gutapercha."|t|f|t|t
34005367|NCT01806610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700836|NCT05991167|||COHORT||PROSPECTIVE|||||||
34005368|NCT06599138|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34005369|NCT05135819|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34005370|NCT05372497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700837|NCT00121381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700838|NCT01081288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700839|NCT05128318|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Collection of subcutaneous and visceral adipose tissue from patients with BMI \< 30 kg/m2||||
33700840|NCT03015857|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700841|NCT05755438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700842|NCT03814083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33700843|NCT00833820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700844|NCT01888757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700845|NCT01769989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700846|NCT01536743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700847|NCT06473948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33700848|NCT00547547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700849|NCT02360995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700850|NCT02624960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700851|NCT02688049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700852|NCT01874600|||COHORT||PROSPECTIVE|||||||
33787574|NCT01568996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787575|NCT01107626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787576|NCT02680093|||COHORT||PROSPECTIVE|||||||
33787577|NCT04881799|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Participants during the first six months of the study will be randomized to receive either phentermine/topiramate or placebo. Neither the participant, care provider, investigator or study team will know whether the participant is receiving phentermine/topiramate or placebo.|"This is a pilot, pragmatic, randomized trial with a 6-month placebo-controlled period followed by a 6-month open label extension investigating the effects of phentermine/topiramate on BMI, insulin sensitivity, and glycemic control compared to placebo plus standard treatment (metformin + insulin) in adolescents with T2D.~Individuals, when randomized to phentermine/topiramate therapy will initiate treatment at 3.75 mg/23 mg orally once daily in the morning for 14 days. It will then be increased to 7.5 mg/46 mg orally once daily in the morning for 14 days. It will the be increased to 11.25 mg/69 mg orally once daily in the morning for 14 days and finally to 15 mg/92 mg orally once daily in the morning."|t|t|t|t
33787578|NCT04738435|||COHORT||PROSPECTIVE|||||||
33787579|NCT06713200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will include pacients randomized into three treatment groups: high-intensity percutaneous electrolysis, low-intensity and a control group with sham treatment.|t|f|f|t
33787580|NCT03219502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33787581|NCT03810482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In this first study, the links between variables and discordance between walking test and pedometer results will be searched.||||
33787582|NCT01219855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787583|NCT06714097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005371|NCT00006371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700853|NCT02351999|NA|SINGLE_GROUP||OTHER||NONE||||||
33700854|NCT02124161|RANDOMIZED|||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33700855|NCT00092157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700856|NCT04601402|NA|SEQUENTIAL||TREATMENT||NONE||Dose Escalation: Seqeuntial Group Assignment, Dose Expansion: Parallel Group Assignment||||
33700857|NCT03498066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700858|NCT01658631|||COHORT||PROSPECTIVE|||||||
33700859|NCT00005865|RANDOMIZED|||TREATMENT||||||||
33700860|NCT04948788|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34005372|NCT02114112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700861|NCT00923325|||CASE_ONLY||PROSPECTIVE|||||||
33700862|NCT02410551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787584|NCT05582616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, researcher, and care providers will be blinded until after the analysis period, researchers will be assessing outcomes.|Double blind randomized placebo controlled clinical trial.|t|t|t|t
33787585|NCT01703520|||COHORT||RETROSPECTIVE|||||||
33787586|NCT03703479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||spilt mouth design|t|t|t|t
33787587|NCT00465985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787588|NCT03991949|NA|SINGLE_GROUP||OTHER||NONE||||||
33787589|NCT03134235|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated measures, single group design.||||
33787590|NCT05406180|||OTHER||PROSPECTIVE|||||||
33787591|NCT05701592|||COHORT||PROSPECTIVE|||||||
33787592|NCT06173570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized with equal distribution across 5 parallel treatment arms to either placebo or one of four AZD0780 doses.|t|t|t|t
33787593|NCT03247348|||CASE_ONLY||PROSPECTIVE|||||||
33787594|NCT00013143|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33787595|NCT03363061|||COHORT||PROSPECTIVE|||||||
33926887|NCT04625985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Parallel Assignment Experimental and placebo tablets will have same physical appearance and medicine box will be identified by kit number.|"Experimental: Metformin glycinate 620 mg bid (PO) for 14 days plus standard treatment Control group: placebo bid (PO) for 14 days plus standard treatment~Comparator: Placebo Placebo pill bid (PO) for 14 days plus standard treatment"|t|t|t|t
33926888|NCT05755022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926889|NCT05979155|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33926890|NCT04124055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926891|NCT06177171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33926892|NCT02140892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33926893|NCT04867200|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33926894|NCT00054184|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926895|NCT02854670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926896|NCT04203017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926897|NCT01521806|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33926898|NCT01719016|||OTHER||PROSPECTIVE|||||||
33926899|NCT06275997|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel/Crossover Study Model; Patients will be randomized 1:1:1:1||||
33926900|NCT04709913|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The study will be conducted in one phase: a single dose, dose escalation phase in up to 4 cohorts|t|t|t|t
33926901|NCT01960829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926902|NCT02019017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005373|NCT01391845|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34005374|NCT04157972|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The visits include sessions (test 1 and 2) with SIMEOX or a positive expiratory pressure device (PEP) (chosen according to the subject's randomization) lasting 20 minutes, each followed by a rest period of 30 minutes.~Lung function tests will be performed before, after and 30 minutes after performing the devices (SIMEOX and PEP)."||||
33700863|NCT02552784|NA|SINGLE_GROUP||OTHER||NONE||||||
33700864|NCT02846545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700865|NCT01557049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700866|NCT00376883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33700867|NCT04945512|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study group and control group||||
33700868|NCT02154074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700869|NCT01126086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700870|NCT01610531|NA|SINGLE_GROUP||OTHER||NONE||||||
33787596|NCT03328117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926903|NCT01915680|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33926904|NCT05525312|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"the standard protective ventilation versus an open lung protective ventilation protocol during a pulmonary resection surgery"|t|f|f|f
33926905|NCT00829777|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33926906|NCT04066699|||COHORT||PROSPECTIVE|||||||
33926907|NCT01838421|||COHORT||RETROSPECTIVE|||||||
33926908|NCT04616404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33926909|NCT00259038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926910|NCT04252261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and researchers are blind to the treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.||t|t|t|t
33926911|NCT00927329|NA|SINGLE_GROUP||OTHER||NONE||||||
33926912|NCT03209362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926913|NCT03643016|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926914|NCT05999149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926915|NCT01633229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926916|NCT05767372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787597|NCT03238482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787598|NCT05892913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787599|NCT06475807|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33787600|NCT05671094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All treating physicians including surgical team, attending anesthetist and surgeon, all researcher assessing outcomes (i.e. study nurse + surgeon) and the data-managers will be blinded for group allocation until the end of the study.||f|f|t|t
33787601|NCT02683824|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787602|NCT06630429|||COHORT||PROSPECTIVE|||||||
33787603|NCT06628570|||COHORT||PROSPECTIVE|||||||
33787604|NCT06290089|NA|SINGLE_GROUP||OTHER||NONE||||||
33787605|NCT01545674|||COHORT||PROSPECTIVE|||||||
33787606|NCT05482386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is open-label, with blinded outcome adjudication. Identification of potential outcome events is performed by blinded study team members. Participants, care providers, investigators and outcomes assessors are blinded to the baseline biomarker levels.||f|f|f|t
33787607|NCT04760301|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33787608|NCT02973243|||COHORT||PROSPECTIVE|||||||
33787609|NCT05707052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787610|NCT03686813|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Placebo controlled|Double blind, randomized|t|t|t|t
33787611|NCT01345292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33787612|NCT04545606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787613|NCT04204330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787614|NCT00469118|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33787615|NCT03396913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects in the study arm will receive a series of IPL pulses using the M22 IPL handpiece. In subjects of the control arm, the device will be disabled. The subject will feel the lightguide on the skin, will hear clicking sounds, but no light will be actually produced by the M22 device. Since during treatment both eyes of the subject will be fully occluded, no subject will be able to see if the treatment is actual or sham. There is no way to completely mask the subjects, since the IPL generally causes slight redness of the skin, and in some patients is may also cause some discomfort|Subjects will be randomized 1:1 to a study arm and a control arm. Subjects in the study arm will be treated with IPL and meibomian gland expression. Subjects in the control arm will be treated with sham and meibomian gland expression.|t|f|f|f
33787616|NCT02174211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787617|NCT04898803|||COHORT||PROSPECTIVE|||||||
33787618|NCT00567164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787619|NCT02701361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787620|NCT06631794|||CASE_CONTROL||PROSPECTIVE|||||||
33787621|NCT05767411|||COHORT||CROSS_SECTIONAL|||||||
33787622|NCT02462655|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787623|NCT05678296|||COHORT||RETROSPECTIVE|||||||
33787624|NCT00578214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787625|NCT06505824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787626|NCT03828695|NA|SINGLE_GROUP||SCREENING||NONE||||||
33787627|NCT04653714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787628|NCT05215457|||COHORT||PROSPECTIVE|||||||
33787629|NCT03265873|||CASE_ONLY||CROSS_SECTIONAL|||||||
33787630|NCT00475813|RANDOMIZED|PARALLEL||||NONE||||||
33787631|NCT01601314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33926917|NCT02899806|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33926918|NCT01854489|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33926919|NCT06112912|||CASE_ONLY||PROSPECTIVE|||||||
33926920|NCT04199546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926921|NCT01385319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926922|NCT02657876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005375|NCT04779034|NA|SINGLE_GROUP||SCREENING||NONE||to explain the relationship between heart rate variability and their sportive performance in basketball players.||||
33926923|NCT06516458|||COHORT||PROSPECTIVE|||||||
33926924|NCT04503850|||OTHER||PROSPECTIVE|||||||
34005376|NCT02976350|||COHORT||CROSS_SECTIONAL|||||||
33926925|NCT05940441|||COHORT||PROSPECTIVE|||||||
33926926|NCT06211452|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a randomized model, the evaluation is based on event time (overall survival, event free survival, cumulative incidence relapse with treatment related mortality as competitive event). Comparator log rank test.||||
33926927|NCT00005092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005377|NCT06465758|||CASE_ONLY||PROSPECTIVE|||||||
34005378|NCT03889691|||OTHER||PROSPECTIVE|||||||
34005379|NCT02908386|||COHORT||RETROSPECTIVE|||||||
33700871|NCT00923780|||||PROSPECTIVE|||||||
33700872|NCT00117455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33700873|NCT03622814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not know if they are in a site that is receiving the treatment or in the usual condition site. Randomization is by site, not by individuals.|A randomized cluster-design trial will be conducted in two large respite care centers (RCCs) with five sites that serve primarily white and African American persons with dementia. RCCs will be randomized to the intervention condition (Partners at Meals; 3 sites) or \['enhanced usual care' (EUC)\] (2 sites). The primary unit of analysis is the person with dementia (PWD) and caregiver (CG): 60 PWDs, 60 CGs will be enrolled; it is estimated that up to 60 volunteers/staff/managers may be enrolled. The caregivers and RCC volunteer is another dyad for analysis, as is the RCC volunteer and the PWD. Additionally, RCC Managers at both PaM and EUC sites will be interviewed regarding barriers to implementation, ways to enhance the project, and possible causes of discharge of PWD from the study related to nutritional problems.|t|f|f|f
33700874|NCT06005896|||COHORT||RETROSPECTIVE|||||||
33700875|NCT01330784|||COHORT||PROSPECTIVE|||||||
33700876|NCT01015599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700877|NCT03307642|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||SLIV will be offered at all schools in an urban school district. Students will be randomized into either SLIV + standard communication about SLIV or SLIV + standard communication + text message reminders.|t|f|f|t
33787632|NCT04206046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33787633|NCT05404230|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33787634|NCT05555108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787635|NCT03085017|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33787636|NCT00742573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787637|NCT06352086|||CASE_ONLY||CROSS_SECTIONAL|||||||
33787638|NCT01286402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787639|NCT00631475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787640|NCT00814281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33787641|NCT04337489|||COHORT||PROSPECTIVE|||||||
33787642|NCT00743821|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33787643|NCT05470374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Glioma extent of resection will be assessed by radiologists blinded for the treatment arm||f|f|f|t
33787644|NCT06250816|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33787645|NCT01573195|||||RETROSPECTIVE|||||||
33787646|NCT05143476|||COHORT||PROSPECTIVE|||||||
33787647|NCT03315507|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33787648|NCT04491890|||OTHER||OTHER|||||||
33787649|NCT01383863|||COHORT||PROSPECTIVE|||||||
33787650|NCT04820101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787651|NCT02712866|||CASE_ONLY||PROSPECTIVE|||||||
33787652|NCT00146978|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33787653|NCT00104754||||TREATMENT||NONE||||||
33787654|NCT00422201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787655|NCT02343744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926928|NCT05063617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be assigned to either a wait-list control or intervention group. The wait-list control group will be instructed to maintain their current health habits and not to engage in any new physical activity or health programs for the next 8-weeks. The wait-list control group will be invited to access the intervention after 8-weeks.||||
33926929|NCT01525303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926930|NCT01759160|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33926931|NCT02053519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926932|NCT04397315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926933|NCT04042012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33926934|NCT00002268||||TREATMENT||||||||
33926935|NCT02944669|||CASE_ONLY||PROSPECTIVE|||||||
33926936|NCT03030183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926937|NCT00066508||||TREATMENT||NONE||||||
33926938|NCT03057912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|||||
33926939|NCT04517227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926940|NCT05463172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926941|NCT05387798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926942|NCT00993304|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33926943|NCT04503512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33926944|NCT01605201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926945|NCT04260841|||COHORT||PROSPECTIVE|||||||
33926946|NCT02883920|||CASE_ONLY||CROSS_SECTIONAL|||||||
33926947|NCT00398307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926948|NCT05890560|||COHORT||PROSPECTIVE|||||||
33926949|NCT03472963|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33926950|NCT05228756|NA|SINGLE_GROUP||OTHER||NONE||||||
33926951|NCT06114030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926952|NCT01842646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787656|NCT01468324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787657|NCT06423313|||COHORT||PROSPECTIVE|||||||
33787658|NCT05846165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33787659|NCT00458432|||||PROSPECTIVE|||||||
33787660|NCT05200650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787661|NCT04542148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787662|NCT02582411|||COHORT||CROSS_SECTIONAL|||||||
33926953|NCT01604096|NON_RANDOMIZED|PARALLEL||||NONE||||||
33926954|NCT00438022|||CASE_CONTROL||PROSPECTIVE|||||||
33926955|NCT04391088|||COHORT||PROSPECTIVE|||||||
33926956|NCT00807820|||CASE_ONLY||PROSPECTIVE|||||||
33926957|NCT04724681|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective controlled cohort study||||
33926958|NCT00100646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926959|NCT05986825|||OTHER||PROSPECTIVE|||||||
33926960|NCT05201482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005380|NCT01461291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005381|NCT03583528|||COHORT||PROSPECTIVE|||||||
34005382|NCT00051818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005383|NCT05815368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical assessments will be performed before and after the treatment by a physical therapist not involved in training and blinded to the purpose and group allocation.|Randomized-Controlled Trial (RCT)|f|f|f|t
34005384|NCT05141786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005385|NCT06472271|||COHORT||OTHER|||||||
34005386|NCT06286761|||COHORT||PROSPECTIVE|||||||
33787663|NCT01496638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787664|NCT05112315|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized 1:1 , controlled, open label study||||
33787665|NCT02404454|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787666|NCT03265704|||COHORT||RETROSPECTIVE|||||||
33926961|NCT04605159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Following the decision to stop enrollment and vaccination, the study/site staff and maternal participants no longer stayed blinded.||t|t|t|t
33926962|NCT04415190|||COHORT||RETROSPECTIVE|||||||
33926963|NCT05446974|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005387|NCT04172324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005388|NCT02126410|||COHORT||RETROSPECTIVE|||||||
34005389|NCT05708482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005390|NCT06616584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005391|NCT06422481|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34005392|NCT00679250|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34005393|NCT03022539|||COHORT||PROSPECTIVE|||||||
33926964|NCT01754285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33926965|NCT00152945|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33926966|NCT03341234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926967|NCT06192667|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33926968|NCT05190107|||OTHER||CROSS_SECTIONAL|||||||
33926969|NCT05702970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and examining physicians will be aware of the allocated arm, whereas, outcome analysts will be kept blinded to the treatment allocation arm. This will be accomplished by blinding the investigators assessing: NHYA class, distance walked at 6MWT, KCCQ, vital signs. Echocardiography data will be measured offline or by an independent physician, blinded to the treatment allocation. Events at follow-up will be assessed by an adjudication committee blinded to the treatment arm.|Interventional, randomized, controlled, open-label, sequential recruitment study|f|f|f|t
33926970|NCT02566616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33926971|NCT00791804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33926972|NCT03418272|||CASE_CONTROL||PROSPECTIVE|||||||
33926973|NCT03347617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926974|NCT03167541|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33926975|NCT04925947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926976|NCT02945540|||COHORT||PROSPECTIVE|||||||
33926977|NCT06014957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926978|NCT06053970|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Recruitment of twenty patients. The order of the virtual reality scenes will be randomly selected.||||
33926979|NCT02677623|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33926980|NCT03520205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33926981|NCT01264068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33926982|NCT00377104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33926983|NCT05957848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33926984|NCT02391974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33926985|NCT00056836|RANDOMIZED|||TREATMENT||DOUBLE||||||
33926986|NCT01778270|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33926987|NCT06276842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33926988|NCT01511991|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33926989|NCT03530618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33926990|NCT02089724|||COHORT||PROSPECTIVE|||||||
33926991|NCT03402269|||COHORT||PROSPECTIVE|||||||
33926992|NCT04985240|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study were designed by two cohorts The control group and the interventional group. The intervention lasted for 10 days and 100gr of lettuce per day was consumed.||||
33926993|NCT04957680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33926994|NCT00635245||||TREATMENT||NONE||||||
33926995|NCT02167113|||COHORT||PROSPECTIVE|||||||
33926996|NCT06051656|||COHORT||PROSPECTIVE|||||||
33926997|NCT04307901|||COHORT||PROSPECTIVE|||||||
33926998|NCT06397534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33926999|NCT05640700|||COHORT||PROSPECTIVE|||||||
33927000|NCT05968872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927001|NCT02987244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927002|NCT00883454|||COHORT||RETROSPECTIVE|||||||
33927003|NCT03313804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927004|NCT03091699|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential two stage trial. Stage 1 will utilize a within-counterbalanced approach while stage 2 will utilize a randomized trial.||||
33927005|NCT00207012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927006|NCT01080612|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33927007|NCT04807101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927008|NCT00133172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927009|NCT06572787|||COHORT||PROSPECTIVE|||||||
34091372|NCT03185351|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"* Group A: patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.~* Group B: patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.~* Group C: patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block."|t|t|t|t
34091373|NCT04393948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091374|NCT01435941|||COHORT||RETROSPECTIVE|||||||
34091375|NCT04375046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091376|NCT01089595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091377|NCT00637182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33700878|NCT05736614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Randomized Controlled Trial (RCT)~Study arms:~1. Stage 1 Standard of Care (SOC) Control Condition~2. Stage 1 Strength Based Case Management (SBCM) Condition~3. Stage 2 SOC Control Condition~4. Stage 2 PrEPare for Work Intervention Condition"|f|f|f|t
33700879|NCT03652740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"As part of instructions during the informed consent process, volunteers will be given a list of drugs they may receive rather than informing them only of the specific drugs being administered. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Researchers will be blind to the drug conditions on any given session because a pharmacy member with no participant interaction will assign the randomized dose sequence and prepare the study drugs."|Participants are not assigned to different groups/arms \[Note: we indicated 2 arms below because the form does not allow masking in a single arm study - this study involves administration of drug conditions in different dose sequence orders\]. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Participants will be randomly assigned to one of several different dose sequences.|t|f|t|t
33700880|NCT04805762|||COHORT||PROSPECTIVE|||||||
33700881|NCT02681601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700882|NCT01407822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700883|NCT05157438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33720395|NCT00319917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787667|NCT03970811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This parallel arms, randomized controlled clinical trial will involve 22 systemically free patients with an unrestorable tooth in the upper esthetic zone. They will be randomly allocated to two equal groups. Group A (test group) will receive immediate implants with simultaneous immediate temporization, while group B (control group) will receive immediate implants with no temporization.|f|f|f|t
33787668|NCT01459549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787669|NCT05851417|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787670|NCT06264830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787671|NCT03146351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-randomised clinical trial||||
33787672|NCT01131247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787673|NCT00322582|||FAMILY_BASED||PROSPECTIVE|||||||
33787674|NCT04031417|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787675|NCT02140554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787676|NCT02282527|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33787677|NCT04601311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and treatment providers will not be blinded to the allocated trial intervention. The treatment providers are not involved in the analyses. All other medical personnel will be blinded by blinding of notes in the participant's electronic records. Outcome assessors and external statisticians at the Copenhagen Trial Unit will be blinded to the randomisation status of the participants. The statistical analyses will be conducted with the intervention groups coded as X and Y. The steering committee will write two abstracts while the blinding is intact, one assuming the experimental intervention group is X and the control intervention group is Y, and one assuming the opposite. After this, the code will be broken.||f|f|f|t
33927010|NCT03889964|||COHORT||PROSPECTIVE|||||||
33927011|NCT01360229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927012|NCT00553657|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33927013|NCT04569084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927014|NCT04055467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927015|NCT02403141|||OTHER||PROSPECTIVE|||||||
33927016|NCT05307627|||COHORT||RETROSPECTIVE|||||||
33927017|NCT06294041|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the nature of the SRT intervention, the research nurse, patients and most of the study team cannot be blinded to treatment allocation. However, the statistician will be blinded to treatment allocation (i.e., SRT or SHE) until after analysis is complete||f|f|f|t
33927018|NCT01109069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927019|NCT01174888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927020|NCT05098587|||COHORT||PROSPECTIVE|||||||
33927021|NCT03649516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927022|NCT01077869|||COHORT||PROSPECTIVE|||||||
33927023|NCT00533611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927024|NCT00493194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927025|NCT05369624|RANDOMIZED|PARALLEL||OTHER||NONE||"Clinical trial with parallel groups (Parallel treatment design):~Clinical trial in which one group of patients is assigned to receive the home pulmonary rehabilitation program (PHRP), while another group (control) does not receive PHRP"||||
33927026|NCT03027388|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927027|NCT01500941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927028|NCT02733679|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927029|NCT00149383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927030|NCT01495364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927031|NCT05674604|||COHORT||PROSPECTIVE|||||||
33927032|NCT00255996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927033|NCT01547013|||CASE_CONTROL||PROSPECTIVE|||||||
33927034|NCT02894489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927035|NCT00361023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005394|NCT06069856|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The trial is quadruple blind with all trial participants, outcome assessors (research staff and care providers), investigators, and trials statistician and data analysts being unable to determine the allocated trial arm for any trial participant or identify trial participants who are on the same trial regimen.||t|t|t|t
34005395|NCT05108844|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
34005396|NCT04467320|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised to either the online intervention group (Teaching Recovery Techniques) or the care-as-usual group. Any young people entering into the trial who live in the same household will be randomised together. If randomised to the TRT condition, each child will be offered participation in the next age-appropriate group.||||
33700884|NCT03631875|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|A nurse not involved in the study prepared two syringes with ketamine or normal saline, and administrated it according randomization (by computer generated random numbers) one minute before induction with propofol|After inhalatory induction with sevoflurane7%until abolition of the eye lash reflex, an intravenous canula was inserted in the dorsum of the hand. The sevoflurane concentration was then decreased to 2% in 100% O2.A nurse not involved in the study prepared two syringes with ketamine or normal saline, and administrated it according randomization , one minute before induction with propofol. The administration of propofol was realized on 60 seconds. An experimented anesthesiologist evaluated the LM conditions insertion. When the jaw was relaxed, and deglutition and cough reflex and member movement were absent, the conditions were considered acceptable. The LM was then inserted. For analgesia,we proceeded by a locoregional bloc adapted to the surgery. We recorded systolic and diastolic blood pressure, HR and SpO2 at the induction time at LM insertion and at the 3rd,5th and10th min.|f|f|f|t
34005397|NCT04456933|||COHORT||PROSPECTIVE|||||||
34091378|NCT06255483|NA|SINGLE_GROUP||TREATMENT||NONE||The harvest of a pedicle osteoperiosteal clavicular flap was performed in the same way on ten fresh cadaveric specimens. The vascular supply was studied by colored latex and methylene blue injections.||||
34091379|NCT00150553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34091380|NCT00594737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700885|NCT05473208|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators in charge of doing the statistical analysis and assessing the outcome measures (e.g., physical performance tests) will be blinded to group allocation. Due to the characteristics of the study (use of the exoskeleton during working hours) blinding of the participants is not possible.||f|f|t|t
33700886|NCT04356742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091381|NCT04017455|NA|SINGLE_GROUP||TREATMENT||NONE||single group, open label||||
34091382|NCT01502852|||ECOLOGIC_OR_COMMUNITY|||||||||
34091383|NCT02468453|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33700887|NCT04495933|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE||Cohort 1: SARS-CoV-2 Sclamp vaccine 5 mcg, or placebo Cohort 2: SARS-CoV-2 Sclamp vaccine 15 mcg, or placebo Cohort 3: SARS-CoV-2 Sclamp vaccine 45 mcg, or placebo|t|t|t|f
34091384|NCT04051801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind safety study. The pharmacist is unblinded.||t|t|t|f
34091385|NCT02382302|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33700888|NCT05553314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective, randomized, double-blinded, placebo-controlled study|t|t|f|f
34091386|NCT04304703|||COHORT||PROSPECTIVE|||||||
33700889|NCT02651818|||COHORT||PROSPECTIVE|||||||
33700890|NCT04862429|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Pathology results will be blindly reviewed by external pathologists.|Test and treat randomized trial.|f|f|f|t
33700891|NCT01049568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700892|NCT05890950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700893|NCT04402918|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700894|NCT00806975|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33787678|NCT03640273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"this study is a double blind randomized controlled trial study. the volunteers will be divided into 2 groups. One is received Prapchompoothaweep crude drug capsule at 1,000 mg 3 times a day before meals and the other is received Loratadine 10 mg per day before meals. it takes 6 weeks to complete the project for each volunteers.~Before enrolling, volunteers will stop using any anti-histamine drug for 1 week (wash-out period). All volunteers will be followed up in the 3rd and 6th week to evaluate the efficacy and adverse effect after received drugs.~The researcher will record characteristic data such as gender, age, BMI, vital signs and symptoms . The adverse effect will be monitored by hematology test e.g. liver function test, renal function test, lipid profile and blood sugar test."|t|f|t|f
33787679|NCT00403208|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33787680|NCT05749029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All the outcome measures will be self-report questionnaires that will be completed by an online automated system with no involvement of the research team.||f|f|f|t
33787681|NCT06628882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091387|NCT01699828|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34091388|NCT04908033|||OTHER||PROSPECTIVE|||||||
34091389|NCT06217471|||OTHER||CROSS_SECTIONAL|||||||
34091390|NCT02530242|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091391|NCT02082951|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34091392|NCT02909426|||COHORT||PROSPECTIVE|||||||
34091393|NCT01986712|||COHORT||PROSPECTIVE|||||||
34091394|NCT02286674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091395|NCT01410253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34091396|NCT04837170|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental group : Control group=2:1||||
34091397|NCT03110835|||CASE_CONTROL||PROSPECTIVE|||||||
34091398|NCT01709448|||COHORT||PROSPECTIVE|||||||
34091399|NCT02210754|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34091400|NCT01939392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091401|NCT01301092|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091402|NCT05967091|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, non-randomized||||
34091403|NCT06099483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||randomized controlled double-blind study|t|f|t|t
34091404|NCT00886236|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33700895|NCT05820607|||CASE_CONTROL||RETROSPECTIVE|||||||
33700896|NCT04112420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||200 patients \> 60 years with unplanned admission to the intensive care unit are to be included in the study.||||
33787682|NCT01874184|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33787683|NCT05245097|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787684|NCT05765851|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33787685|NCT04268563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33787686|NCT03183232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33787687|NCT03248232|||COHORT||PROSPECTIVE|||||||
33787688|NCT06267365|||COHORT||PROSPECTIVE|||||||
33787689|NCT06317883|||COHORT||PROSPECTIVE|||||||
33787690|NCT05512260|NA|SINGLE_GROUP||SCREENING||NONE||||||
33787691|NCT00012987|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787692|NCT06433037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomised, double-blinded, placebo-controlled intervention study with parallel design and four arms.|t|f|t|t
33787693|NCT02491931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787694|NCT01121783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33787695|NCT06457607|NA|SINGLE_GROUP||OTHER||NONE||||||
34005398|NCT02007668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33787696|NCT02197871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787697|NCT03893591|||COHORT||PROSPECTIVE|||||||
33787698|NCT00069459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787699|NCT01575470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787700|NCT06290544|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective collection of data with diagnostic procedures different from standard clinical care in a specific cohort of patients.||||
33787701|NCT06096428|||CASE_CONTROL||PROSPECTIVE|||||||
33700897|NCT01613534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700898|NCT05862142|||COHORT||RETROSPECTIVE|||||||
33700899|NCT04905966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Three lists of schools were built, according to type of institution and area where the school is located. The first list corresponded to rural public schools, the second to urban public schools and the last to urban private schools.~Each of the lists contained the type of institution (public / private), the area where it is located (urban / rural), the name of the school and the district to which it belongs. The schools were masked with an identifier number in order to avoid bias during the assignment to the groups (intervened / control). Schools were selected using a computer based list (...)"|Four groups of participants received four different interventions: (1) Nutrition education + Physical Activity; (2) Control|t|f|f|f
33700900|NCT06390033|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33700901|NCT05653193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700902|NCT03730675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700903|NCT01276600|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700904|NCT04203498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700905|NCT02537028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700906|NCT06253884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700907|NCT05095454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33700908|NCT00075218|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33700909|NCT02293161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700910|NCT05942300|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33787702|NCT02771418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33787703|NCT02908659|||COHORT||PROSPECTIVE|||||||
33787704|NCT00067639|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33787705|NCT06111508|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, randomized, parallel group, active-comparator clinical trial of CGM based titration of insulin Degludec vs. standard titration by SMBG.||||
34091405|NCT00498550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787706|NCT05094284|||OTHER||PROSPECTIVE|||||||
34091406|NCT03286504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091407|NCT04302285|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34091408|NCT04878900|||OTHER||CROSS_SECTIONAL|||||||
33700911|NCT06206642|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33700912|NCT02107404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700913|NCT02866708|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Two experienced outcome assessors/outcome adjudicators (certified wound nurse or physician or wound trained health care specialist) will assess the wound photographs using Photographic wound assessment tool (PWAT 0-24 score). At least one of the PWAT assessors will be blinded to the study group's assignments, and will not be involved in the study otherwise (intervention or in the standard wound care).|16 week crossover pilot study comparing intermittent negative pressure (40mmHg) applied to the lower leg and foot plus standard best practice wound care comapred to standard best practice wound care alone.|f|f|f|t
33700914|NCT00723580|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33787707|NCT00006413||||TREATMENT||||||||
33787708|NCT06146803|||COHORT||PROSPECTIVE|||||||
33787709|NCT00282438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927036|NCT01976169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927037|NCT00638417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927038|NCT02394327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927039|NCT05825092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|This is a prospective, phase II, multi-centre, double blind, randomised, controlled, parallel group study.|t|t|t|t
33927040|NCT03949543|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33927041|NCT05488912|||OTHER||CROSS_SECTIONAL|||||||
33927042|NCT03514238|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33927043|NCT00360685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927044|NCT02539914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927045|NCT02655406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927046|NCT03073343|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two cohorts of patients will be studied: Cohort 1 (diabetic) will consist of patients with a clinical diagnosis of non-insulin dependent type II diabetes mellitus; Cohort 2 (non-diabetics) will consist of patients without a clinical diagnosis of type 2 diabetes mellitus. 24 patients will be enrolled in each cohort (total of 48 patients enrolled in the study) with an anticipated drop out of 4 subjects per cohort.||||
34091409|NCT01617109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700915|NCT00222560|RANDOMIZED|PARALLEL||||NONE||||||
33700916|NCT05591807|||COHORT||PROSPECTIVE|||||||
33700917|NCT01171040|||COHORT||PROSPECTIVE|||||||
33700918|NCT00867685|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33700919|NCT03098459|||COHORT||PROSPECTIVE|||||||
33700920|NCT00776282|RANDOMIZED|CROSSOVER||||NONE||||||
33700921|NCT01423578|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700922|NCT01791322|||COHORT||PROSPECTIVE|||||||
33700923|NCT04436159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33700924|NCT06076954|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33700925|NCT05626062|NA|SINGLE_GROUP||TREATMENT||NONE||A feasibility sample of 30 adults with learning disabilities with incontinence||||
33700926|NCT02777333|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33700927|NCT03114774|||COHORT||PROSPECTIVE|||||||
33700928|NCT02389062|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33700929|NCT06248567|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33700930|NCT02758132|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700931|NCT05625542|||COHORT||CROSS_SECTIONAL|||||||
33700932|NCT03269604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"A single blinding will be performed. To the database will be categorized the variable duration of prophylaxis so that the person in charge of analysing the data, does not know the true allocation of each of the participants. At the end of the tabulation and analysis of the data, the true allocation will be known."||f|f|t|t
33700933|NCT02817074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33700934|NCT01732042|||COHORT||PROSPECTIVE|||||||
33700935|NCT02623140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700936|NCT01724879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700937|NCT01072422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700938|NCT00032461|||||RETROSPECTIVE|||||||
33700939|NCT01699490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700940|NCT02061618|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33700941|NCT03439059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700942|NCT03582878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700943|NCT04324931|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group pre-test, post-test design||||
33787710|NCT04590651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will not know which group he or she has been randomised to during the duration of the study. The care provider and investigator will not know the randomisation before the patient is enrolled in the study. The care provider and investigator will know the randomisation group at the time of randomisation, which will take place after the preoperative data collection.|Participants are assigned to one of two groups in parallel for the duration of the study|t|t|t|f
33927047|NCT03305757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomisation is achieved using a web based randomization programme (RANDI2). Randomization will take place on the day of surgery, after the start of the operation and 30 minutes before wound closure. Blocked randomisation will take place with randomly selected block sizes (6/9/12) with an allocation ratio of 1:1:1. Randomisation will be stratified per site. Both patients and surgeons will be blinded. Patients will be informed preoperatively that their post-operative check ups will NOT be performed by the surgeon that performed the surgery. Randomisation will take place 30 minutes before wound closure in the operating theatre. Post-operatively, patients will not be evaluated by their own surgeon. The OR report will contain the following information (in Dutch) so as to ensure that blinding of the physicians will not be compromised.|"Study design is a double-blind randomized controlled trial. All patients are \> 18 years and will be enrolled after obtaining informed consent in the surgical out patient clinics of Zuyderland Medical Center (Heerlen and Sittard), Maastricht University Medical Center, St Jans Gasthuis, Weert and Albert Schweitser Hospital, Dordrecht. All patients have an indication to undergo mastectomy due to invasive breast cancer or DCIS.~Follow up will be performed until 1 year after surgery. Patients will be evaluated in the out patient clinic 2 weeks, 6 weeks, 3 months, 6 months and 12 months postoperatively."|t|t|t|f
33927048|NCT05022043|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33927049|NCT03771807|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33927050|NCT00897091|||||RETROSPECTIVE|||||||
34005399|NCT04440280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind trial, where neither the study participant nor the investigators will know to which treatment group the study participant has been assigned.|"Initially, 30 eyes from up to 30 participants will be randomized 1:1 to one of two groups, a group administering N-acetyl cysteine (NAC) 10% and a group administering Visine Tears Dry Eye Relief artificial tears ophthalmic solution (the placebo).~After interim analysis of the study with 30 eyes, if a significant difference in the primary endpoint between NAC 10% and placebo is not found, an additional 15 eyes from up to 15 participants will be enrolled to investigate 20% NAC."|t|f|t|f
34005400|NCT02084368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005401|NCT01909739|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34005402|NCT05177913|||COHORT||PROSPECTIVE|||||||
34005403|NCT04167618|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive up to two cycles in Part 1 and up to five cycles in Part 2 of intracerebroventricular 177Lu-DTPA-omburtamab. Safety and efficacy will be investigated during treatment and follow-up period.||||
34005404|NCT04390230|||COHORT||RETROSPECTIVE|||||||
34005405|NCT00470587|||COHORT||PROSPECTIVE|||||||
34005406|NCT05920330|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients experiencing olfactory impairment and/or nasal obstruction, self-referred to participate in the research study.||||
34091410|NCT01967277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091411|NCT06196359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33700944|NCT05646095|RANDOMIZED|CROSSOVER||TREATMENT||NONE||multi-phase hybrid effectiveness-implementation trial||||
33700945|NCT00092573||||TREATMENT||||||||
33700946|NCT04734951|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel assignment||||
33700947|NCT05825781|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33700948|NCT00946361|||CASE_ONLY||PROSPECTIVE|||||||
33700949|NCT04260711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33700950|NCT03368534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005407|NCT05840471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Two similar size syringes will be prepared and labeled as A (experimental group) containing 1 g/10mL Tranexamic acid diluted with 20mL of 5% glucose water, and syringe B (placebo group) containing 30 mL of 5% glucose water.~The 2 groups of syringes will be labeled with different numbers not known by the investigator or the patient"|"Randomization for both groups will be done using the Randomization Allocation Software program. Blindness in each group will be confirmed by a pharmacist who is not involved in the study and will have the codes belonging to the type of intervention with him until the end of the research.~Random Allocation Software(https://random-allocation-software.software.informer.com/2.0/)"|t|f|t|f
34091412|NCT01233830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091413|NCT06293144|NA|SEQUENTIAL||OTHER||NONE||||||
34091414|NCT03620279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700951|NCT02364622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33700952|NCT02437383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700953|NCT03080454|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The sham stimulation condition preceded the anodal stimulation condition for all participants, and subjects were told they would receive both conditions, but were blinded to order of assignment.|All participants received both stimulation conditions (sham Doublestim and anodal Doublestim), separated by a 1-week washout period.|t|f|f|f
33700954|NCT02017418|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33700955|NCT05879601|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Outcomes Assessor)|Assignment|f|f|f|t
33700956|NCT02527993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700957|NCT05444517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33700958|NCT04165473|||COHORT||CROSS_SECTIONAL|||||||
33700959|NCT03352973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double blind: both participants and experiment won't know the stimulation condition|within-subject, sham-controlled design: all subjects will receive active and sham tDCS in a randomized order|t|f|t|f
33700960|NCT06558058|RANDOMIZED|CROSSOVER||OTHER||NONE||This was a bioequivalence study.||||
33700961|NCT06405958|||COHORT||PROSPECTIVE|||||||
33700962|NCT06557902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700963|NCT00004397||||TREATMENT||||||||
34005408|NCT03248986|||COHORT||PROSPECTIVE|||||||
34005409|NCT06519760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700964|NCT05948787|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||"Method~* Caregivers will complete a battery of questionnaires, right before intervention(Time 1), two weeks post intervention (Time 2) and also six weeks post intervention (Time 3)~* Semi-Structured interviews with a selected group of parents that have completed the Strong Families programme and facilitators~Caregiver measures~1. Family Demographics Questionnaire: FDQ~2. Strengths and Difficulties Questionnaire: SDQ (Goodman, 1997) - behavioral screening questionnaire (25 items)~3. Parental and Family Adjustment Scale: PAFAS (Sanders, Morawska, Haslam, Filus \& Fletcher, 2014) measures parenting practices and parental adjustment (30 items), this has been developed to be used in low resource settings~4. (Person Most Knowledgeable) Child and Youth Resilience Measure: PMK-CYRM-R (Jefferies, P., McGarrigle, L., \& Ungar, M. (2018)"|t|t|f|f
33700965|NCT02974478|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33700966|NCT04545385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33700967|NCT03808831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33700968|NCT02108873|||COHORT||RETROSPECTIVE|||||||
33700969|NCT04136366|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33700970|NCT01717911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700971|NCT05751044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700972|NCT06419738|RANDOMIZED|PARALLEL||TREATMENT||NONE||"66 patients were divided into 3 groups.Patients without treatment (because of economic or geographical conditions) were persuaded to join the control group. Group 3 includes 22 patients who will be counseled on changing habits, adjusting behavior, exercising and will be taken in order of examination. 44 patients will be randomized into the remaining 2 groups by using Excel software to create a random number table, patients will draw even numbers into group 2, odd numbers into group 1.~* Group 1: wear stabilization splint at night for 2 months combined with counseling, behavior modification, and exercise.~* Group 2: recieve low level laser treatment 3 times aweek, 20 seconds each time, 10 times in total, combined with counseling, behavior modification, and exercise."||||
33700973|NCT01341119|||COHORT||RETROSPECTIVE|||||||
33700974|NCT03123367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33700975|NCT06101550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700976|NCT02597231|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33700977|NCT00687895|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33700978|NCT01126333|||COHORT||PROSPECTIVE|||||||
33700979|NCT03950479|||COHORT||PROSPECTIVE|||||||
33787711|NCT02469064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34005410|NCT02077296|||COHORT||PROSPECTIVE|||||||
34005411|NCT04602793|||CASE_CROSSOVER||PROSPECTIVE|||||||
34005412|NCT00000953||||TREATMENT||||||||
34005413|NCT00081172||||TREATMENT||NONE||||||
34005414|NCT02126384|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33700980|NCT03726944|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study was a 4-group randomized trial design in which participants were randomly assigned to 4 unique groups that lasted for 8 weeks in total. Each group received two 4-week conditions involving one of three different conditions/arms.||||
33700981|NCT00111982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700982|NCT05552755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33700983|NCT00761631|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33700984|NCT04384783|||COHORT||PROSPECTIVE|||||||
33700985|NCT03882112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33700986|NCT02423109|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33700987|NCT00629720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700988|NCT04584970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33700989|NCT02891109|||CASE_CONTROL||PROSPECTIVE|||||||
33700990|NCT05101642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33700991|NCT04167969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33700992|NCT05384964|||COHORT||PROSPECTIVE|||||||
33700993|NCT00082420|||CASE_ONLY|||||||||
33700994|NCT01381484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33700995|NCT00579098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33700996|NCT01462487|||COHORT||RETROSPECTIVE|||||||
34005415|NCT04152369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34005416|NCT01593969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005417|NCT01503333|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005418|NCT02992613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005419|NCT00565513||PARALLEL||PREVENTION||NONE||||||
34005420|NCT01443689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33700997|NCT05928793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33700998|NCT05712434|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Each enrolled units will start with iodine protocol, and then switched to CHG protocol at designated time, followed by CHG plus protocol subsequently. Each unit will be randomized in to three different groups (A, B, and C):~Group A) 2 months of iodine protocol, followed by 4 months of CHG protocol, followed by 6 months of CHG plus protocol.~Group B) 4 months of iodine protocol, followed by 4 months of CHG protocol, followed by 4 months of CHG plus protocol.~Group C) 6 months of iodine protocol, followed by 4 months of CHG protocol, followed by 2 months of CHG plus protocol."||||
33700999|NCT06005571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients who participated in the study and the assessor of the treatment outcome did not know the type of treatment procedure received.|Three groups of patients were randomly assigned to three different treatment protocols of defective composite restoration repair.|t|f|f|t
33701000|NCT05405465|||COHORT||RETROSPECTIVE|||||||
33787712|NCT01306669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787713|NCT06629337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34005421|NCT02586363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34005422|NCT06013111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005423|NCT02463838|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34005424|NCT03012659|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005425|NCT04141644|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a Phase 1b, open label study of osimertinib in combination with ipilimumab in eligible adult patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer. The study will focus on the safety and long term tolerability of the combination.~The study will begin with a safety lead-in evaluation consisting of a cohort of six patients. Once safety has been established, the trial will open enrollment to the expansion cohort. The expansion cohort will enroll an additional 14 patients at the same doses evaluated during the safety lead-in."||||
34005426|NCT02553655|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005427|NCT01134198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005428|NCT04359537|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Participants fulfilling the eligibility criteria will be randomized to 4 arms by using Random Allocation Software version-2~Arm Intervention /treatment Experimental group 1: Hydroxychloroquine 400 mg twice a day 1,followed by 400 mg weekly for a total of 12 weeks~Experimental group 2:Hydroxychloroquine 400 mg on day 1 followed by 400 mg once every 3 weeks for a total of 12 weeks~Experimental group 3:Hydroxychloroquine 200 mg on day 1 followed by 200 mg once every 3 weeks for a total of 12 weeks~Control Group :Placebo 200mg will be given on day 1 followed by Placebo 200mg every three weeks for a total of 12 weeks.."|t|f|f|f
34005429|NCT06616467|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The present research will be a phase II intervention study (Gitlin \&amp; Czaja, 2016), of the Pilot Randomized Clinical Trial (RCT) type, because it is intended to manipulate the independent variable that will be the intervention that integrates the components of: knowledge, beliefs, infant temperament, self-efficacy and sedentary practices, to measure the effect on the variables dependent on Tummy Time practice practice and healthy weight control. The Experimental Group (EG) and Control Group (CG) will be randomized, the intervention will be with a single-blind approach and repeated measurements (Grove \&amp; Burns, 2015).|t|f|f|f
34005430|NCT05632692|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34005431|NCT01241682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005432|NCT00908882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34005433|NCT04619550|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34005434|NCT00432055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005435|NCT01085448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005436|NCT00615849|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34005437|NCT00932594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005438|NCT05135624|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Cohort 1 - 7 subjects will be randomized to receive SP16 6 mg or placebo in a 7:3 ratio. Cohort 2 - 7 subject will be randomized to receive SP16 12 mg or placebo in a 7:3 ratio.|t|t|t|t
33701001|NCT00371072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33701002|NCT05875571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The provider and participant will be masked and will not know if the patient is getting the study drug or placebo||t|t|t|f
33701003|NCT05446441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
33701004|NCT00689780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787714|NCT03736785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005439|NCT00250133|||DEFINED_POPULATION||OTHER|||||||
34005440|NCT01965717|||CASE_CONTROL||PROSPECTIVE|||||||
34005441|NCT02711033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005442|NCT00115024|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34005443|NCT01877694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005444|NCT01275716|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34005445|NCT01832519|||COHORT||PROSPECTIVE|||||||
34005446|NCT03818295|NA|SINGLE_GROUP||OTHER||NONE||||||
34005447|NCT00491907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34005448|NCT00929058|NA|SINGLE_GROUP||||NONE||||||
34005449|NCT06401408|||CASE_CONTROL||PROSPECTIVE|||||||
34005450|NCT05680792|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34005451|NCT03381937|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||monocentric, open, randomize, crossover study||||
34005452|NCT05906069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The psychologist performing the assessment of the main psychometric outcomes will be blind to the group allocation of each participant.|OCD patients will be randomly allocated into two groups - iCBT group (experimental group) and wait list group (comparator control group). The experimental group will receive a 14-week iCBT intervention program and the wait list group will receive the same intervention but at a later time.|f|f|f|t
34005453|NCT02526589|||COHORT||PROSPECTIVE|||||||
34005454|NCT00685035|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34005455|NCT03589196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005456|NCT05188976|||CASE_ONLY||PROSPECTIVE|||||||
34005457|NCT03657238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005458|NCT06015022|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded|Randomized placebo-controlled trial|t|t|t|t
34005459|NCT06090890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005460|NCT01188226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005461|NCT02853539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005462|NCT03877926|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005463|NCT06309914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005464|NCT03586401|||COHORT||PROSPECTIVE|||||||
34005465|NCT00030407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005466|NCT00341692|||OTHER||CROSS_SECTIONAL|||||||
34005467|NCT03454880|||COHORT||PROSPECTIVE|||||||
34005468|NCT04703517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005469|NCT04478708|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34005470|NCT01268241|||COHORT||OTHER|||||||
34005471|NCT05291351|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Randomized, controlled, crossover acute trial|t|f|f|f
34005472|NCT04845841|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34005473|NCT04998448|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005474|NCT04479748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005475|NCT05766111|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34005476|NCT06031220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005477|NCT01657526|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34005478|NCT04744428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34005479|NCT02462434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005480|NCT03788135|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34005481|NCT05302479|||COHORT||PROSPECTIVE|||||||
34005482|NCT05671952|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005483|NCT02243345|||COHORT||RETROSPECTIVE|||||||
34005484|NCT01531504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005485|NCT00317434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005486|NCT04359407|||CASE_ONLY||PROSPECTIVE|||||||
34005487|NCT04060914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005488|NCT05746130|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Nonrandomised controlled trial|t|f|f|t
34005489|NCT02067702|||CASE_CONTROL||PROSPECTIVE|||||||
34005490|NCT01134341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005491|NCT03064243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005492|NCT03259724|||OTHER||OTHER|||||||
34005493|NCT06555289|||COHORT||PROSPECTIVE|||||||
33787715|NCT00116740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33787716|NCT01068249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787717|NCT02304822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34005494|NCT01213836|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34005495|NCT00272649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005496|NCT02206841|||COHORT||PROSPECTIVE|||||||
34005497|NCT05460962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005498|NCT03263078|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005499|NCT01590251|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34005500|NCT01527838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005501|NCT02966496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005502|NCT05140668|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787718|NCT05795829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787719|NCT03226158|||COHORT||PROSPECTIVE|||||||
33787720|NCT06161064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787721|NCT04622436|||OTHER||PROSPECTIVE|||||||
33787722|NCT04744597|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||In a single-blind design children will be randomized into three groups: 1st - real execution, 2nd - motor imagery, 3rd - control (skip counting)|t|f|f|f
33787723|NCT04986722|||CASE_ONLY||PROSPECTIVE|||||||
33787724|NCT01386086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787725|NCT01989637|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33927051|NCT01525667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927052|NCT03807245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33927053|NCT00964600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927054|NCT03621189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927055|NCT05151367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33927056|NCT00116987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927057|NCT03175419|||COHORT||PROSPECTIVE|||||||
33927058|NCT01068717|RANDOMIZED|CROSSOVER||||NONE||||||
33927059|NCT01136213|||COHORT||CROSS_SECTIONAL|||||||
33927060|NCT03182153|||CASE_ONLY||PROSPECTIVE|||||||
33927061|NCT01661309|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33927062|NCT06167278|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33927063|NCT04088565|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33927064|NCT00212212|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33927065|NCT03350971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trial|t|t|t|f
33927066|NCT03790540|RANDOMIZED|CROSSOVER||OTHER||NONE|The operator will not be blinded to the type of treatment. However, the statistician will be blinded to the treatment groups.|Each group will receive 2 mandibular nerve block injections with two different injection techniques, with 1-2 weeks apart as a washing out period .Mandibular nerve block injection will be either with vibration using DentalVibe at the injection side or topical analgesic (benzocaine 20%) gel will be applied before the injection of local anesthesia at first the appointment, and the alternative technique will be used at the second appointment. Injection with the aid of DentalVibe tool will act as the experimental group while the control group will be the use of topical analgesic (benzocaine 20%).||||
33927067|NCT05477225|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927068|NCT00175071|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33927069|NCT02612883|||OTHER||PROSPECTIVE|||||||
33927070|NCT00505804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927071|NCT05670249|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|a senior neurologist (E.K. or M.D.) who was not involved in screening, randomization, or patient care, blinded to the therapeutic arm assignment of the patient assessed the mRS (primary outcome), Barthel Index, NIHSS (National Institute of Health Stroke Scale), and SF-36 (secondary outcomes) scores|Participants assigned to either conservative medical or SDC group with a 1:1 allocation assignment using a random number table by co-decision of a neurologist, neurosurgeon and statistician|f|t|f|f
33927072|NCT03380507|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, prospective, randomized, two-arm parallel-group trial||||
33701005|NCT02428023|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927073|NCT01807949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927074|NCT02639923|||COHORT||PROSPECTIVE|||||||
33927075|NCT00263315|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33927076|NCT01392742|||COHORT||PROSPECTIVE|||||||
33927077|NCT01590667|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33927078|NCT01421069|NA|||TREATMENT||NONE||||||
33927079|NCT01855113|||CASE_CONTROL||PROSPECTIVE|||||||
34005503|NCT04104516|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005504|NCT02361957|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34005505|NCT02966158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005506|NCT04867811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005507|NCT04258280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34005508|NCT03126422|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34005509|NCT06230159|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants and data collection staff will be blinded to the order/conditions|Using a cross-over double-blinded study design, we will study the abuse liability (including sensory characteristics and appeal) of newly introduced cooling agent non-menthol cigarettes.|t|f|f|t
34005510|NCT02419625|NA|SINGLE_GROUP||SCREENING||NONE||||||
34005511|NCT03561922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005512|NCT00792441|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34005513|NCT05918341|NA|SINGLE_GROUP||OTHER||NONE||Prospective, single center, open-label, uncontrolled study in 10 healthy volunteers who will receive various subtherapeutic doses of piracetam.||||
34005514|NCT03482206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005515|NCT03655119|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34005516|NCT03342430|||COHORT||PROSPECTIVE|||||||
34005517|NCT03785691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All oral tablets will be encapsulated in gelatine to ensure identical look, smell and taste.|Randomized placebo controlled multicenter trial testing already marketed drugs on a new indication.|t|t|t|t
33701006|NCT04923464|||COHORT||PROSPECTIVE|||||||
33701007|NCT02272478|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33701008|NCT02550262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33701009|NCT04567823|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|It is not visible whether the smoothie is fortified with microalgae or not.|parallel design|t|t|t|f
33701010|NCT02083965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33701011|NCT03870100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701012|NCT00900107|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701013|NCT05204251|||COHORT||CROSS_SECTIONAL|||||||
33701014|NCT06125548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All mothers included in the sample were assigned to experimental and control groups using the randomization table.|PROSPECTIVE RANDOMIZED CONTROLLED STUDY|t|f|f|t
33701015|NCT01765907|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701016|NCT05285800|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Both the groups after injecting 0.5% hyperbaric Bupivacaine intrathecally the outcomes are monitored and compared.||||
33701017|NCT05235087|NA|SINGLE_GROUP||SCREENING||NONE||||||
33701018|NCT00697788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701019|NCT01418313|||COHORT||CROSS_SECTIONAL|||||||
33927080|NCT01930240|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33927081|NCT02653313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927082|NCT04683172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Bicentre, double blinded, randomized, parallel-arm, sham-controlled trial|t|f|t|f
33927083|NCT00260195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927084|NCT00002941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927085|NCT03025152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927086|NCT02565446|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927087|NCT02559557|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927088|NCT00293241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927089|NCT04641910|||CASE_ONLY||PROSPECTIVE|||||||
33927090|NCT05779800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927091|NCT00127088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927092|NCT00646438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927093|NCT00430898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005518|NCT04721184|||COHORT||PROSPECTIVE|||||||
34005519|NCT04622124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
34005520|NCT01953172|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34005521|NCT03170869|NA|SINGLE_GROUP||TREATMENT||NONE||Fifty (50) subjects will be enrolled in the prospective arm.||||
33701020|NCT05012033|||CASE_ONLY||CROSS_SECTIONAL|||||||
33701021|NCT04741711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701022|NCT00667160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33701023|NCT02389985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701024|NCT06558591|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot study.||||
33701025|NCT01638221|||||PROSPECTIVE|||||||
33787726|NCT06628505|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial which will randomize subjects into one of two aims. Each aim will have a 1:1 randomization of participants into either the investigational or the control group||||
33787727|NCT06049524|||COHORT||PROSPECTIVE|||||||
33787728|NCT06073171|NA|SINGLE_GROUP||OTHER||NONE||||||
33927094|NCT01967472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927095|NCT04822311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927096|NCT04362813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927097|NCT04983810|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation in Phase 1 part.||||
33927098|NCT02520960|||COHORT||PROSPECTIVE|||||||
33927099|NCT01578538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927100|NCT01402024|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33927101|NCT05875389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927102|NCT03948451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927103|NCT01692834|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33701026|NCT02006888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701027|NCT05431660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The people participating in the study will not know in which group they are in the study, but since the physiotherapist who gives the training and gives the treatment is the only person, the study will continue as a single blind.|randomized controlled trial|t|f|f|f
33701028|NCT04970784|||CASE_CONTROL||PROSPECTIVE|||||||
33701029|NCT01529242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701030|NCT03395392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and Care Providers will be masked with regard to medication administered.||t|t|t|t
33927104|NCT00052936|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33927105|NCT06189248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927106|NCT00683007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005522|NCT02902887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005523|NCT03468712|NA|SINGLE_GROUP||TREATMENT||NONE||Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy||||
34005524|NCT03993587|||CASE_ONLY||PROSPECTIVE|||||||
34005525|NCT05091216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701031|NCT04846842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701032|NCT04221178|||COHORT||PROSPECTIVE|||||||
33787729|NCT06475170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33787730|NCT00555867|||COHORT||PROSPECTIVE|||||||
33787731|NCT03261661|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Random assignment through stratification on the screening score to one of three groups: Study 1: (a) Reading Intervention Plus Mindset, (b) Reading Intervention, or (c) Business as Usual comparison.~Study 2: (a) Reading Intervention Embedded with Mindset or (b) Business as Usual comparison."||||
33787732|NCT02664220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787733|NCT00322699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787734|NCT03148938|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Patients will perform one or two visits at 15 days interval. Healthy volunteers will only perform one visit. Patients and healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.||||
33787735|NCT03410667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787736|NCT05550922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787737|NCT02620254|||COHORT||PROSPECTIVE|||||||
33787738|NCT05186545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787739|NCT00449657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927107|NCT02992873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33927108|NCT01924741|||COHORT||PROSPECTIVE|||||||
33927109|NCT05521971|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||before-after study||||
33927110|NCT00194727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927111|NCT00912340|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927112|NCT06212206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927113|NCT01906476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927114|NCT04535505|||OTHER||PROSPECTIVE|||||||
33927115|NCT00109005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927116|NCT00178698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927117|NCT04486989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927118|NCT01320813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927119|NCT01907555|||COHORT||PROSPECTIVE|||||||
33927120|NCT03134612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33927121|NCT06376188|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33927122|NCT06120413|||COHORT||PROSPECTIVE|||||||
33927123|NCT00813917|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34005526|NCT06479278|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787740|NCT00403884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33787741|NCT01982643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787742|NCT01549652|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33787743|NCT03684733|||OTHER||OTHER|||||||
33787744|NCT01548391|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33787745|NCT00966966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787746|NCT04895566|NA|SINGLE_GROUP||TREATMENT||NONE|This trial is an open-label, Phase 0, a non-randomized trial that will enroll up to 10 participants|||||
33787747|NCT05257733|||COHORT||RETROSPECTIVE|||||||
33927124|NCT00696098|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33927125|NCT01753700|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33927126|NCT03512470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927127|NCT06055049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||There will be 2 groups (kinesio taping and sham taping) and each group will consist of at least 28 people.|t|f|f|f
33927128|NCT05245994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927129|NCT02920229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927130|NCT04569617|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is a cross-over clinical trial||||
33927131|NCT06043947|||COHORT||OTHER|||||||
33927132|NCT00732641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927133|NCT04373707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Multicenter randomized (1:1) controlled open-label trial, stratified on disease severity (admission to ICU or not)|f|f|f|t
33927134|NCT02320240|||COHORT||RETROSPECTIVE|||||||
33927135|NCT04663542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927136|NCT05467488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927137|NCT03577951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927138|NCT00154193|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927139|NCT00908622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927140|NCT00953225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927141|NCT02471209|||CASE_ONLY||PROSPECTIVE|||||||
33927142|NCT02288039|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33701033|NCT04057508|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|"Investigators are double-blinded for both experimental procedures and data analyzes.~Volunteers are blinded to the site of stimulation."|Randomized, controlled, double-blind, cross-over study|t|f|t|f
33701034|NCT04399226|||CASE_CROSSOVER||PROSPECTIVE|||||||
34091415|NCT04073277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The gross appearance of the two groups of needles were the same. They could be identified under microscope only.|This was a double-blinded prospective cohort study. The acupuncture needles were first separated into two groups. One group of needles was subjected to SCF-N treatment while the other was not. The needles were then randomly analyzed with scanning electron microscope and energy dispersive X-ray spectroscopy to ensure quality and minimize experimental error. For each participant, one hand was randomly assigned to the treatment group with SCF-N-treated acupuncture needles and the other hand was assigned to the control group with the stainless steel needles. The time interval between the acupuncture treatment of the two groups was about two hours. In order to examine and distinguish the difference between the two groups, de-qi VAS score was recorded by the volunteers during needle insertion and the electrical resistance by electrical measurement.|t|f|f|t
33701035|NCT02104752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701036|NCT05490303|NA|SINGLE_GROUP||OTHER||NONE||||||
33701037|NCT01649804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701038|NCT04578483|||COHORT||PROSPECTIVE|||||||
33701039|NCT00659750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701040|NCT02810522|NON_RANDOMIZED|||DIAGNOSTIC||NONE||||||
33701041|NCT01565720|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33701042|NCT05058716|||OTHER||PROSPECTIVE|||||||
33701043|NCT00115648|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701044|NCT04520412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701045|NCT00411944|||DEFINED_POPULATION||PROSPECTIVE|||||||
33701046|NCT06144892|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33701047|NCT00887653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701048|NCT05819281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33701049|NCT02256657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33701050|NCT02592525|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33701051|NCT04693455|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33701052|NCT06427824|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701053|NCT02938429|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33701054|NCT00156520|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33701055|NCT06043882|||CASE_CROSSOVER||PROSPECTIVE|||||||
33701056|NCT01105962|||COHORT||PROSPECTIVE|||||||
33701057|NCT01042678|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701058|NCT03259217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701059|NCT05072704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701060|NCT04610385|||COHORT||PROSPECTIVE|||||||
33701061|NCT02357979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33701062|NCT05787184|||COHORT||PROSPECTIVE|||||||
33701063|NCT03945214|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Investigator will be blind to condition throughout data accrual|"Randomization to one of 4 conditions:~1. Digital meditation condition~2. Healthy eating condition~3. Digital meditation + healthy eating condition~4. Wait-list control"|f|f|t|f
33701064|NCT02202525|||COHORT||PROSPECTIVE|||||||
33701065|NCT04857957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701066|NCT01083485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701067|NCT03278756|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Between subjects-design with two training conditions. The training condition is the only difference between the two groups during the study.|t|t|t|t
33787748|NCT05216237|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients who meet the inclusion criteria will receive with sintilimab combined with apatinib and chemotherapy(Oxaliplatin plus Tegafur gimeracil oteracil potassium capsules). At the same time, tumor samples were collected for tissue PD-L1 detection and blood samples for CTC detection according to the wishes of patients.~Patients underwent contrast-enhanced thoracoabdominal and pelvic Computer Tomography(CT) at baseline and every 6 weeks after enrollment. Patients with stable or remission after 2 to 6 cycles of combined treatment can reduce the evaluation frequency to once every 12 weeks during the maintenance treatment period."||||
33787749|NCT01756287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787750|NCT04018118|||COHORT||PROSPECTIVE|||||||
33787751|NCT00798772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Treatment group (Group A): Will receive micronutrients and antioxidants. Control group (Group B): Will receive identical appearing RDA multivitamins and minerals|t|t|t|t
33787752|NCT04083092|||COHORT||PROSPECTIVE|||||||
34091416|NCT05370482|NA|SINGLE_GROUP||TREATMENT||NONE||CLS, Tranberg, Laser system||||
34091417|NCT01521091|||COHORT||PROSPECTIVE|||||||
34091418|NCT04125459|||OTHER||CROSS_SECTIONAL|||||||
33701068|NCT01733784|NA|SINGLE_GROUP||OTHER||NONE||||||
33701069|NCT01854996|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33701070|NCT04354103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701071|NCT04154930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787753|NCT01779882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787754|NCT06630481|||COHORT||RETROSPECTIVE|||||||
34091419|NCT02638493|||CASE_CONTROL||PROSPECTIVE|||||||
33701072|NCT05544812|||OTHER||PROSPECTIVE|||||||
33701073|NCT02652065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33701074|NCT02318875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33701075|NCT04912960|||COHORT||PROSPECTIVE|||||||
33701076|NCT05224089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor)|single-center, prospective, triple blinded, randomized, controlled trial.|t|t|f|t
33701077|NCT04325646|||COHORT||PROSPECTIVE|||||||
33701078|NCT04894695|||COHORT||PROSPECTIVE|||||||
33701079|NCT00810108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33701080|NCT00225550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701081|NCT03917459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701082|NCT00238888|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005527|NCT06615778|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the RCT, blinding the trial participants, school officials, and teachers is not possible. Also, the investigator and the outcome assessor cannot be masked in the research.|||||
34005528|NCT03624855|||COHORT||RETROSPECTIVE|||||||
33701083|NCT01392417|||CASE_CONTROL||RETROSPECTIVE|||||||
33701084|NCT00074984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701085|NCT05235451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Children among 4 reading groups will be randomly assigned to a HAI intervention or control group. The 2 HAI intervention reading groups will receive visits from a registered canine team during children's small group reading sessions twice a week over 12 weeks. The 2 control reading groups will receive care as usual and offered a 1-time visit from the dog at the end of the study (after T3 completed).||||
33701086|NCT00032955||||TREATMENT||NONE||||||
33701087|NCT05193552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701088|NCT00001688||||TREATMENT||||||||
33701089|NCT03221270|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|This is a double blind, randomized clinical trial.|Participants will initially be randomized to either sham or 10 Hz tACS for the 5 consecutive days of stimulation. Participants will then be re-randomized to either sham or 10 Hz tACS for the 8 weeks of maintenance stimulation.|t|t|t|t
33787755|NCT06269874|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Patients and outcome assessors will be blinded to the randomization group.|Patients will be randomized 1:1 to one of the two study arms and then the following study procedures will repeated in cross-over. Randomization will be done by using a computer-generated random sequence (medcalc, mariakerke, BE).|t|f|f|t
33787756|NCT02200952|||OTHER||PROSPECTIVE|||||||
33787757|NCT05974072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two armed, parallel groups, single blind, unicentric, randomized feasibility study||f|f|f|t
33787758|NCT01440556|||CASE_CONTROL||RETROSPECTIVE|||||||
33787759|NCT00789789|||COHORT||PROSPECTIVE|||||||
33701090|NCT00033774|||CASE_ONLY||PROSPECTIVE|||||||
34005529|NCT02508116|RANDOMIZED|PARALLEL||OTHER||NONE||Patients undergoing PCI are randomized to genotype guided antiplatelet therapy vs. usual care.||||
34005530|NCT02546024|||COHORT||PROSPECTIVE|||||||
34005531|NCT03355196|NA|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005532|NCT00894933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005533|NCT04253236|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34005534|NCT05917691|||COHORT||RETROSPECTIVE|||||||
34005535|NCT00019734|RANDOMIZED|||TREATMENT||||||||
34005536|NCT05563688|||CASE_CROSSOVER||PROSPECTIVE|||||||
34005537|NCT02400515|NA|SINGLE_GROUP||||NONE||||||
34005538|NCT05509959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34005539|NCT04169555|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005540|NCT04414033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091420|NCT01149967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091421|NCT01107015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091422|NCT05548374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091423|NCT00168298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091424|NCT00207688|||COHORT||PROSPECTIVE|||||||
33701091|NCT05433012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701092|NCT03314142|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33701093|NCT04172623|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group randomized trial design comparing smoking outcomes when receiving standard treatment vs. standard treatment plus real-time smoking intervention.||||
33701094|NCT03600701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701095|NCT01413061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701096|NCT05734573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701097|NCT04046055|NA|SEQUENTIAL||TREATMENT||NONE|Participants will be blind to the different stimulation intensities (sham, 2 mA, 4 mA)|All participants completed all 5 randomly ordered tDCS sessions (sham, unilateral 2 mA, unilateral4 mA, bilateral 2 mA, and bilateral 4 mA.||||
33701098|NCT01846390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701099|NCT04726670|||COHORT||PROSPECTIVE|||||||
33701100|NCT01384942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701101|NCT01570088|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33701102|NCT02508831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701103|NCT05901454|NA|SINGLE_GROUP||OTHER||NONE||human infection model of yellow fever with the yellow fever 17D vaccine and viruria (virus in urine) as readout||||
33701104|NCT02279446|||||CROSS_SECTIONAL|||||||
33701105|NCT03343379|NA|SINGLE_GROUP||SCREENING||NONE||1 group of participants was screened at the start of the study and followed prospectively for 2 years||||
33701106|NCT01978418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701107|NCT00214760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701108|NCT03027102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701109|NCT03380715|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701110|NCT04354142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701111|NCT03177057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33701112|NCT04811378|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34005541|NCT00354562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005542|NCT02885428|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005543|NCT04439188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005544|NCT04559750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005545|NCT01454440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005546|NCT02919111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005547|NCT00535028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005548|NCT06319248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005549|NCT00144079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005550|NCT04415437|||CASE_CONTROL||PROSPECTIVE|||||||
34005551|NCT02223468|||CASE_CONTROL||PROSPECTIVE|||||||
34005552|NCT04184934|||COHORT||PROSPECTIVE|||||||
34005553|NCT03806335|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34005554|NCT03558139|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34005555|NCT04701424|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005556|NCT02240186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005557|NCT02758548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091425|NCT00328536|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34005558|NCT05139758|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34005559|NCT01985464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005560|NCT06494098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005561|NCT05623852|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Type : Interventional (Clinical Trial) Actual Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment, matching sex, age, and performance status||||
34005562|NCT02958930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005563|NCT01910337|||COHORT||PROSPECTIVE|||||||
34091426|NCT04666298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091427|NCT02329288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091428|NCT04855500|||COHORT||PROSPECTIVE|||||||
34091429|NCT03647007|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34091430|NCT04547920|NA|SEQUENTIAL||TREATMENT||NONE||||||
34091431|NCT02173951|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091432|NCT00699725|||||PROSPECTIVE|||||||
33701113|NCT04139668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701114|NCT01141452|||COHORT||RETROSPECTIVE|||||||
33701115|NCT03267836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701116|NCT01235624|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701117|NCT01937754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33701118|NCT02489578|||COHORT||RETROSPECTIVE|||||||
33701119|NCT06438302|||COHORT||PROSPECTIVE|||||||
33701120|NCT02182102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787760|NCT01174329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787761|NCT03302156|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005564|NCT05878431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, patients were randomized to the experimental and control groups by using a simple random numbers table from the computer-assisted randomization program in accordance with the simple random sampling method. In this study, participants in the experimental and control groups were blind to each other; however, the researcher was not blinded to the group allocation as he was also the practitioner.|This study was conducted as a single-blind randomized controlled study with pretest-posttest|t|f|f|f
33787762|NCT03552926|||COHORT||PROSPECTIVE|||||||
33787763|NCT01726023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787764|NCT06631716|||COHORT||PROSPECTIVE|||||||
33787765|NCT02718118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33787766|NCT05759819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005565|NCT01795235|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33787767|NCT00857480|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33787768|NCT03916926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"We will attempt blinding of participants to the study group (participants). The hygienists (care providers) will be unaware of the treatment assignment when they go to their respective housing facilities. For all treatment visits, assessments will be conducted prior to the intervention delivery.~Two hygienists will go to the housing facility randomized to the SDF arm and the other two will go to the ART + FV arm. The baseline treatment to be applied will be revealed only after the baseline caries exam has been completed. At the 6 month follow-up visit, the two hygienists that applied SDF will now go to the facilities randomized to the ART + FV facilities and vice-versa to conduct the 6-month follow up caries assessment exam and treatment. We will follow similarly for the 12-moth follow-up visit. By this strategy, we will make sure that potential bias of the hygienist evaluating their own work is minimized."|"The comparative effectiveness of simple medical, i.e. SDF versus typical dental, i.e. atraumatic restorative treatment (ART) + fluoride varnish (FV) intervention in this study is focused on the person level to address the unique oral health needs of low-income older adults.~The interventions proposed for this study are in current clinical use. Both coronal and root surface tooth decay lesions will be treated. The two evidence-based strategies in older adults will be compared as follows:~Arm 1 (N=295 participants): A simple medical strategy consisting of SDF versus Arm 2 (N=295 participants): A typical dental strategy consisting of ART + FV"|t|f|f|f
33787769|NCT01609894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005566|NCT04975347|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787770|NCT05515770|NA|SINGLE_GROUP||PREVENTION||NONE||We will use both quantitative (surveys, laboratory tests, service statistics) and qualitative (in-depth interviews and focus group discussions) methods. HIV incidence in the CAB LA cohort (N=1200) in this study will be compared with a similar cohort accessing oral PrEP through the public health system. The effectiveness of the mHealth intervention will be assessed using interrupted time series analysis. The WhatsApp intervention will be randomized at the individual level and data analyzed using logistic mixed models.||||
33787771|NCT04061408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005567|NCT02863549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787772|NCT06629818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005568|NCT05053724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study was conducted in a single 12-bed ICU clinical center, during 2018-2019. Subjects who met the inclusion criteria were asked for informed consent from the responsible guardian and were subsequently randomized (1:1) into Start to move group and conventional treatment group. Sequentially numbered sealed envelopes were used for allocation, which were accessed only by research personnel not participating in the clinical trial.|"Methods: Randomized, single-blind, controlled clinical trial. Computational random assignment of the intervention using sealed envelopes (1:1), non-probabilistic, consecutive sampling of subjects admitted to Clínica Ensenada ICU between January 2018 - July 2019 and who met selection criteria.~Participants: All subjects admitted to Clínica Ensenada ICU, adults ≥15 years with invasive mechanical ventilation requirement \>48 hours were recruited. Subjects with neuromuscular disease; psychiatric history (attempted autolysis, schizophrenia, senile dementia or others, who due to their condition are not able to follow a logical sequential order, which could bias the evaluation and functional treatment); limb amputation; pregnancy; cardiorespiratory arrest with severe hypoxic-ischemic brain damage; total dependence prior to hospitalization, according to Barthel index (\<20 points); and not consenting to participate in the study were excluded."|t|f|f|t
34005569|NCT05607563|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients sequentially receive PM1009 120 mg, 300 mg, 600 mg, 1200 mg, intravenously, Q2W||||
34005570|NCT03095755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005571|NCT05811819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005572|NCT04108832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34005573|NCT03668951|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34005574|NCT06352203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005575|NCT00095862||||TREATMENT||NONE||||||
34005576|NCT01413763|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34005577|NCT01866176|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34005578|NCT03078478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701121|NCT03715101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701122|NCT02249442|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701123|NCT03764007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701124|NCT01479127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701125|NCT06199336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|Placebo and active controlled|t|f|t|t
33701126|NCT01227317|||CASE_ONLY||PROSPECTIVE|||||||
33701127|NCT04412460|||COHORT||PROSPECTIVE|||||||
33701128|NCT03949972|||COHORT||PROSPECTIVE|||||||
33701129|NCT02005731|||COHORT||PROSPECTIVE|||||||
33701130|NCT02040948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701131|NCT04748146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will receive theta-burst stimulation and sham stimulation, meaning that each participant will be their own control.||||
33701132|NCT04111809|||CASE_ONLY||PROSPECTIVE|||||||
33701133|NCT01984983|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701134|NCT02398656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701135|NCT03214315|||COHORT||PROSPECTIVE|||||||
33701136|NCT06557044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787773|NCT03972813|RANDOMIZED|FACTORIAL||PREVENTION||NONE||In this educational intervention, there are three dimensions of variability: cancer messaging, communicability messaging, and age messaging. For cancer messaging there are two possibilities: one message focused more on cervical cancer, one message on cancer in general. For communicability, one message will have information on sexual transmission, a second on infectiousness in general, and a third will have no information about communicability. For age, one will mention that the vaccine is available for 9-45 year olds, the second will mention that and additionally recommend children 11 years old to receive the vaccine, and the third will recommend children 18 years old to receive the vaccine.||||
33787774|NCT01943162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787775|NCT01884389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787776|NCT02828683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787777|NCT02565056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005579|NCT01447225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005580|NCT02621463|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005581|NCT03356106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005582|NCT05486832|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single arm, open label, multi center||||
34005583|NCT00003862||||TREATMENT||NONE||||||
34005584|NCT00302614|||NATURAL_HISTORY||RETROSPECTIVE|||||||
34005585|NCT00334763||||TREATMENT||NONE||||||
34005586|NCT05925725|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34005587|NCT02981316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005588|NCT05050981|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005589|NCT03081910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005590|NCT04690569|||COHORT||PROSPECTIVE|||||||
34005591|NCT00399893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005592|NCT04204226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of the intervention families will not be blind to the intervention they are receiving. During phase 1 the investigator providing the clinical global impression (CGI) scores will be blind to the child's group assignment. Families will be asked not to discuss their work with a social worker or ABHN when completing interview questions at the interim assessments.|Study Phase 1- Children with autism spectrum disorder (ASD) and disruptive behavior will be randomized to social work (SW) or autism behavioral health navigation (ABHN) Study Phase 2- Children who are responding to their Phase 1 intervention will remain in that intervention; children who are not responding to their Phase 1 intervention in the social work arm will be randomly assigned to either ABHN or ABHN+Complex Autism Program (CAP). Those not responding in the ABHN arm will receive ABHN + CAP.|t|f|f|f
34005593|NCT03170102|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A The study involved a one-group (n=19) mixed methods design using using pretest-posttest surveys and qualitative analysis of written reflections.||||
34005594|NCT04323462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and the Outcome assessor will not be aware of group allocation and the treatment thus offered.||f|f|t|t
34005595|NCT03614533|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34005596|NCT05775848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|2:1 Randomization|"Randomization will be stratified by mutation status (L276I homozygous or other), age (\<12 years \[to allow for possible addition of this age group in a future protocol amendment\], 12 to \<18 years, and 18 to 60 years of age), and qualification status for the Primary Efficacy Analysis Population (qualifies or does not qualify).~\[NOTE: EU region will only enroll 18 to 60 years of age\]"|t|t|t|t
34005597|NCT05213533|||COHORT||PROSPECTIVE|||||||
34005598|NCT05499234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants and the medical staff administrating epidural drugs will not be told about the concentration. Because volumes will be same, they would not predict which group.|70 ASA II primigravid women with cervical dilatation between 4-6 cm and demanding epidural analgesia during spontaneous vaginal delivery|t|t|f|t
34005599|NCT03856606|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34005600|NCT00129116|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34005601|NCT01416467|||CASE_ONLY||OTHER|||||||
33701137|NCT01611155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33701138|NCT00608660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787778|NCT03910478|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33787779|NCT05803967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787780|NCT03584295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787781|NCT03685188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787782|NCT03722433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33787783|NCT04773808|||COHORT||PROSPECTIVE|||||||
33787784|NCT02037243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33787785|NCT06610344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787786|NCT00768131|RANDOMIZED|PARALLEL||||NONE||||||
33787787|NCT00258518|||COHORT||PROSPECTIVE|||||||
33787788|NCT04194502|NA|SINGLE_GROUP||OTHER||NONE||The purpose of the study is to establish normal coronary artery pulse Doppler flow patterns and velocities using transoesophageal echocardiography (TEE) in patients with a variety of congenital heart disease||||
33787789|NCT01176799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787790|NCT05302843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787791|NCT04550767|||OTHER||RETROSPECTIVE|||||||
33701139|NCT02883686|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to the Alma intervention or to Usual Care||||
33701140|NCT02391701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005602|NCT02251509|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34005603|NCT03191838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005604|NCT02071368|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005605|NCT03388502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787792|NCT00832884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787793|NCT01680276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787794|NCT03965702|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All microvascular parameters will be analyzed at the end of the study by a blinded physicians (not linked to the study and not author of the future manuscript)||t|f|f|t
33787795|NCT04987606|||COHORT||PROSPECTIVE|||||||
33787796|NCT02667730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are aware of their allocation. The treating physiotherapists will not be aware of allocation and patients are asked to not discuss their medication (allocation) with physiotherapists||f|t|f|t
33787797|NCT00099437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787798|NCT04716933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787799|NCT04231474|||CASE_ONLY||OTHER|||||||
33787800|NCT01168453|||CASE_ONLY||PROSPECTIVE|||||||
33787801|NCT03069781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Both forms of supplementation (estrogen and placebo) will be packaged and administered in identical fashion.|Parallel-group, double-blinded, randomized controlled trial.|t|t|t|t
33787802|NCT05266144|||COHORT||PROSPECTIVE|||||||
33787803|NCT05479539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33787804|NCT01280591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787805|NCT03465007|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33787806|NCT01678196|RANDOMIZED|PARALLEL||||NONE||||||
33787807|NCT06631248|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The research was divided into groups according to the convenience sampling method. Convenience sampling is a non-random sampling method in which the sample to be selected from the main mass is determined by the judgement of the researcher. In convenience sampling, data are collected from the main mass in the easiest, fastest and most economical way \[73,74\]. At this point, two classes in the same kindergarten, which accepted to participate in the study and met the conditions for participation in the study, was assigned as the control group (CG; n= 23) and the other class as the exercise group (EG; n= 18).||||
34005606|NCT03001024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34005607|NCT06535802|||COHORT||PROSPECTIVE|||||||
34005608|NCT01216410|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005609|NCT05424133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005610|NCT01405469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005611|NCT00297245|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34005612|NCT04969354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005613|NCT05365035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005614|NCT03105973|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label trial||||
34005615|NCT02438540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005616|NCT04832971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005617|NCT06098651|NA|SEQUENTIAL||TREATMENT||NONE||"This is a sequential, ascending-dose, multicenter study conducted in patients with refractory solid tumors designed to evaluate the safety, tolerability, and pharmacokinetics of DCR-STAT3. Participants will be enrolled across 4 ascending-dose cohorts. Each treatment cycle will consist of multiple IV doses. Dose escalation decisions will be evaluated in conjunction with a Safety Review Committee (SRC).~The study will be conducted over 4 dose cohorts in a 3+3 design and will initially comprise 12 to 24 participants. Should one DLT occur within a given cohort, an additional 3 participants will be enrolled in that cohort. Two cohorts will be backfilled or expanded to a total of at least 10 participants in each cohort, for a total enrollment of approximately 32 participants. The cohorts and associated dose levels will be chosen in a data-driven fashion as the study proceeds, in conjunction with the SRC."||||
34005618|NCT03143517|||CASE_ONLY||PROSPECTIVE|||||||
34005619|NCT00458445|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34005620|NCT05348837|||COHORT||PROSPECTIVE|||||||
34091433|NCT00308776|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091434|NCT02421510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005621|NCT06617663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Block randomization will be conducted by an independent researcher who is not involved in the study assessments or therapies. This process will assign clients to either online or in-patient treatment to ensure approximately equal distributions of individuals aged 12-15 and 15-18, as well as balanced representation of different sexes. For both video call treatment and treatment at a physical location, the waiting time until the start of treatment will be the same; treatment will begin within a maximum of 2 months from registration.|"A randomized non-inferiority design will be used to demonstrate whether or not online treatment is inferior to treatment as usual (TAU). Data will be analyzed according to the intention-to-treat principle, with all randomized clients included in the analysis, as well as \&#34;per protocol\&#34; (where a minimum of 12 sessions must be completed).~In both the intention-to-treat and \&#34;per protocol\&#34; analyses, mixed general linear (or nonlinear, depending on score distribution) models will be performed, where the main effect of treatment and the interaction between effect and treatment setting are our main measures of interest. Mixed models have the advantage that they 1) account for multiple measures within the same individual, and 2) account for missing values. All analyses are adjusted for baseline value on the outcome measure, gender, and age. To detect age- and gender-specific effects, analyses will also be performed separately by gender and age group."|t|t|f|f
34005622|NCT04480372|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, single-arm, open label phase II trial with two cohorts.||||
34005623|NCT02543151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005624|NCT04028856|||CASE_CONTROL||RETROSPECTIVE|||||||
34005625|NCT03671187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091435|NCT05788380|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||In total, 200 individuals aged between 17-25 years, who had no neurological and orthopedic problems participated. Individuals who had surgical stabilization, previous shoulder complex fractures, positive impingement test results, and systemic diseases were excluded. Participants were categorized into the Regular Exercising (n = 100) and Sedentary (n = 100) Groups. The young adults who were using the fitness center by their preference (unprofessional), and who were regularly exercising, were included in the Regular Exercising Group. The volunteer young adults who were not exercising were included in the Sedentary Group. All participants gave written-informed consent before participation, and the study protocol conformed to the standards for human experiments set by the Declaration of Helsinki and was approved by Ethics Committee for Human Investigations of Mustafa Kemal University Ethics Committee (4298783/05022/4).||||
34091436|NCT01260051|||COHORT||RETROSPECTIVE|||||||
34091437|NCT02829125|||COHORT||PROSPECTIVE|||||||
34091438|NCT02852044|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34091439|NCT03506126|NA|SINGLE_GROUP||OTHER||NONE||||||
34091440|NCT01199770|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34091441|NCT01459159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091442|NCT05423678|||CASE_CROSSOVER||PROSPECTIVE|||||||
34091443|NCT02489201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091444|NCT00198120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091445|NCT05123417|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single (Care Provider)||f|t|f|f
34091446|NCT05743855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34091447|NCT03076242|||COHORT||PROSPECTIVE|||||||
34091448|NCT03870386|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34091449|NCT02896023|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34091450|NCT02448108|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34091451|NCT03331081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091452|NCT01651884|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34091453|NCT01136122|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34091454|NCT01817478||CROSSOVER||DIAGNOSTIC||NONE||||||
34091455|NCT03208452|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34091456|NCT05235607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091457|NCT05998447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091458|NCT01026766|||CASE_CONTROL||PROSPECTIVE|||||||
34091459|NCT05124548|||CASE_CONTROL||PROSPECTIVE|||||||
34091460|NCT03121274|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091461|NCT00399932|||CASE_ONLY||PROSPECTIVE|||||||
34091462|NCT02184156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091463|NCT03948490|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34091464|NCT04257864|||COHORT||RETROSPECTIVE|||||||
34091465|NCT04373733|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Open-label parallel group randomised control trial. One trial treatment arm and one standard of care comparator arm.||||
34091466|NCT00393367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091467|NCT01642160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091468|NCT01245062|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091469|NCT05699681|||COHORT||PROSPECTIVE|||||||
34091470|NCT00464464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091471|NCT05949840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants were recruited online, and were anonymized to the researchers.||t|f|f|t
34091472|NCT00056264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34091473|NCT00637897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091474|NCT00004055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091475|NCT00435058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34091476|NCT02610673|||COHORT||PROSPECTIVE|||||||
34091477|NCT03841292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind|Sham Controlled Randomized Trial|t|f|t|f
34091478|NCT03983109|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34091479|NCT01819662|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34091480|NCT04726904|NA|SINGLE_GROUP||OTHER||NONE||||||
34091481|NCT04580680|||COHORT||PROSPECTIVE|||||||
34091482|NCT02560467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091483|NCT02507284|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34091484|NCT04223037|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091485|NCT00034632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091486|NCT02612155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091487|NCT00713375|||COHORT||PROSPECTIVE|||||||
34091488|NCT05694585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005626|NCT05420116|RANDOMIZED|PARALLEL||PREVENTION||NONE||Model pre-post test in intervention group and pre-post usual follow up in control group||||
34005627|NCT00269334|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34005628|NCT04088747|||CASE_CONTROL||RETROSPECTIVE|||||||
34005629|NCT01139606|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34005630|NCT06535490|||COHORT||PROSPECTIVE|||||||
34005631|NCT05507528|NA|SINGLE_GROUP||TREATMENT||NONE||open label, prospective, single arm, interventional study||||
33701141|NCT05730283|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|If not specifically designated by protocol to be unblinded, all study patients, Sponsor, other entities and individuals will be blinded to study drug assignments. Site pharmacy personnel, one or more statisticians, patient dose monitor, and designated central project management personnel will be unblinded. Data Safety Monitoring Board (DSMB) members may choose to unblind themselves.||t|t|t|t
34005632|NCT00000425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005633|NCT00529217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005634|NCT01009515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005635|NCT04082806|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34005636|NCT03195673|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34005637|NCT03474328|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005638|NCT06679023|||COHORT||PROSPECTIVE|||||||
34005639|NCT06052813|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34005640|NCT05557370|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34005641|NCT01231373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005642|NCT03749954|||COHORT||PROSPECTIVE|||||||
34005643|NCT01429831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005644|NCT00258778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005645|NCT01703377|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33701142|NCT05915221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The group that received SMS was selected as the intervention group. Patients in the control group did not receive any SMS within the scope of the study||||
33701143|NCT06012487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a feasibility study of the feasibility of helping physicians select a protocol to reduce BPV in hypertensive patients on antihypertensive therapy. The duration of the study for Aim 2 is 2 visits, the first with a 48 hour ABPM and the second for a repeat 48 hour ABPM following any changes made at the discretion of the treating provider.~The optional sub-study is also a feasibility study, designed to demonstrate the ability to simultaneously capture ABPM and SKNA data."||||
33701144|NCT05334914|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, feasibility trial||||
33701145|NCT04983082|||COHORT||RETROSPECTIVE|||||||
33701146|NCT00645749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701147|NCT04962620|||COHORT||PROSPECTIVE|||||||
33787808|NCT04950855|||CASE_CONTROL||PROSPECTIVE|||||||
33787809|NCT01969279|||CASE_ONLY||PROSPECTIVE|||||||
33787810|NCT03693755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Patient will not be told in which Group he belongs|1 Group will be compared to another|t|f|f|f
33927143|NCT02672683|||COHORT||PROSPECTIVE|||||||
33927144|NCT00558766|||||PROSPECTIVE|||||||
33927145|NCT04907162|||CASE_CONTROL||PROSPECTIVE|||||||
33927146|NCT04122586|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33927147|NCT01256320|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33927148|NCT03693404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927149|NCT02438046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927150|NCT00633802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927151|NCT01053572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927152|NCT05373316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927153|NCT01072448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927154|NCT05878691|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927155|NCT00603850|||COHORT||PROSPECTIVE|||||||
33927156|NCT04090983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927157|NCT04614350|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, within subjects-controlled design||||
33927158|NCT02841917|||COHORT||PROSPECTIVE|||||||
33927159|NCT03536923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927160|NCT02121444|||COHORT||PROSPECTIVE|||||||
33927161|NCT04194515|||COHORT||PROSPECTIVE|||||||
34005646|NCT00468338|||CASE_ONLY||PROSPECTIVE|||||||
34005647|NCT03767062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005648|NCT03457090|NA|SINGLE_GROUP||PREVENTION||NONE||Patient treated with Venoarterial Extracorporeal membrane oxygenation (ECMO) Realization of transcranial doppler (TCD) of the right and left middle cerebral artery in the first 48 hours of the setting up of the ECMO with joint realization of an Trans-thoracic echocardiography (TTE) then every 24 hours until the end of the using of the ECMO and the realization of TCD and TTE during the 24 hours after removal of the ECMO.||||
34005649|NCT02666924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005650|NCT00117806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005651|NCT05298592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005652|NCT04745949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005653|NCT06428851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants: stroke patients with shoulder pain Care provider: physiotherapist who applied the treatments to the patients Investigator: Researchers who were blinded to the treatment groups|"1. Laser therapy~2. Neuromuscular electrical nerve stimulation therapy (NMES)~3. Control: classical physical therapy exercises~3)"|t|t|t|f
34005654|NCT02496208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005655|NCT00757549||||DIAGNOSTIC||||||||
34005656|NCT01668823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005657|NCT04526899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927162|NCT04956081|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I open-label, 12 subjects||||
34005658|NCT03735511|||OTHER||RETROSPECTIVE|||||||
34091489|NCT01398683|||||PROSPECTIVE|||||||
34091490|NCT05592691|||COHORT||PROSPECTIVE|||||||
34091491|NCT05540899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927163|NCT06508853|||OTHER||OTHER|||||||
33927164|NCT03343782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091492|NCT01084720|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34091493|NCT00767871|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091494|NCT00918307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701148|NCT05679518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to ConquerFear or CALM or control arms.~The participants are masked in terms of not knowing that the interventions (i.e. Conquer fear and CALM) are hypothesized to yield larger effects than the other (i.e. control)."|The investigators will use a block randomization structure with randomly permuted block sizes of 3 and 6 to ensure a close balance of the numbers in each arm. Randomization (by a statistician) occurs prior to eligible patients attending the clinic to minimize opportunities for selection bias.|t|t|t|t
33701149|NCT03781427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787811|NCT03864484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701150|NCT02433561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091495|NCT00748800|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091496|NCT01723605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34091497|NCT04832217|RANDOMIZED|CROSSOVER||OTHER||NONE||A cross-over randomized controlled study||||
34091498|NCT02894138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091499|NCT01648959|||COHORT||PROSPECTIVE|||||||
33701151|NCT04035109|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Anakinra and matching saline placebo will be provided by the investigational drug service||t|f|t|f
33701152|NCT00709657|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701153|NCT05146310|NA|SINGLE_GROUP||TREATMENT||NONE||One group of patient treated with I.SPACE® (instilled in the anterior chamber of the eye and adjusted according to the volume of the aqueous humour)||||
33701154|NCT05686889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33701155|NCT00227006|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33701156|NCT05395689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701157|NCT01497431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33701158|NCT05933902|||COHORT||RETROSPECTIVE|||||||
33701159|NCT01816529|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33701160|NCT01513096|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33787812|NCT03483337|||COHORT||PROSPECTIVE|||||||
33701161|NCT03567577|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33701162|NCT05060848|||CASE_CONTROL||PROSPECTIVE|||||||
33701163|NCT06400303|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701164|NCT01328431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701165|NCT03947892|||COHORT||PROSPECTIVE|||||||
33701166|NCT06295107|||CASE_CROSSOVER||PROSPECTIVE|||||||
33701167|NCT03766568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective observational cohort study (single arm study)||||
33787813|NCT03127709|||COHORT||PROSPECTIVE|||||||
33787814|NCT03691961|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Half of the patients is enrolled in each group according to the individual dose decided by the clinician in charge as the optimal dose to treat the disease. The optimized dose to treat the disease is decided independently of the participation to the study.||||
33787815|NCT00908947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091500|NCT01360476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787816|NCT02512042|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33927165|NCT00660075|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33927166|NCT06149689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927167|NCT02334085|||COHORT||PROSPECTIVE|||||||
33927168|NCT02595268|NA|SINGLE_GROUP||||NONE||||||
33927169|NCT01351311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701168|NCT05373277|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33787817|NCT00217711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787818|NCT01327469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787819|NCT00140673|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787820|NCT00612001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787821|NCT04835038|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787822|NCT01167036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927170|NCT02747407|||CASE_CONTROL||PROSPECTIVE|||||||
33927171|NCT01757587|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33927172|NCT02025803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927173|NCT01082341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927174|NCT05863702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33927175|NCT03029949|RANDOMIZED|PARALLEL||TREATMENT||NONE|Statisticians are blinded.|||||
33927176|NCT03081598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927177|NCT03068936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927178|NCT03622541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091501|NCT06005376|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The participants did not know which bread was received; the bags were color-coded. The personnel meeting the participants did not know which color belonged to which bread. Only the principal investigator (and the bakery) not meeting participants knew which color belonged to which bread type.|Randomised double-blind crossover intervention|t|t|f|f
34091502|NCT03572218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091503|NCT01972828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091504|NCT00820300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091505|NCT00226213|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091506|NCT05468307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091507|NCT00694161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091508|NCT02695459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091509|NCT05548894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel clinical trial||||
33701169|NCT03499925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33701170|NCT01024335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701171|NCT04234607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701172|NCT02655133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701173|NCT05488171|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Identical white hard gelatin capsules|"The protocol comprises a pilot study (n= 12) and a definitive study (n=17, 14 men and 3 women).~The pilot study was a phase I dose-finding study that included 4 cohorts of 3 subjects (cohort 1,2,3 and 5). The conditions of each cohort were: 50 and 100 mg of methylone and placebo in cohort 1 (n= 3); 100 and 150 mg of methylone and placebo in cohort 2 (n= 3); 150 and 200 mg of methylone and placebo in cohort 3 (n= 3); 200 mg of methylone, 100 mg of MDMA and placebo in cohort 5 (n= 3). For safety reasons in cohorts 1-2-3, lower doses were allocated before the higher doses.~After completion, the pilot study allowed defining the treatment conditions and interventions of the definitive study. The present definitive study was designed as double-blind, placebo-controlled, crossover and randomized. Each subject will participate in three experimental sessions, in each one treatment will be administered. Study treatment conditions are 200 mg of methylone, 100 mg of MDMA and placebo."|t|t|t|t
33787823|NCT04414878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787824|NCT04238234|||COHORT||PROSPECTIVE|||||||
33787825|NCT01511250|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33787826|NCT01325870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787827|NCT02653079|||CASE_ONLY||PROSPECTIVE|||||||
34005659|NCT05308368|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The central objective of this study is to collect experimental data to develop tremor models and suppression methods and validate these methods on participants with tremor.~This study is performed with two sets of subjects: people with Parkinson's Disease and Essential Tremor and people without any neurological disorders"||||
34005660|NCT04139031|||CASE_ONLY||PROSPECTIVE|||||||
34005661|NCT04060134|||COHORT||RETROSPECTIVE|||||||
34005662|NCT04767958|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a cohort study of participants falling into one of four groups.||||
34005663|NCT06669663|||COHORT||PROSPECTIVE|||||||
34005664|NCT06227351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective randomized (1:1) clinical trial study formed of 2 competitive groups where 12 implants will be placed in 2 groups (6 for each group) to compare the accuracy of completely limiting computer generated surgical three-dimensional guide versus partially limiting computer generated surgical three-dimensional guide during placement of zygomatic implants in patients with atrophic maxillae.|f|f|f|t
34005665|NCT00602537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005666|NCT04096339|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34005667|NCT02091349|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34005668|NCT04381676|||CASE_CROSSOVER||PROSPECTIVE|||||||
34005669|NCT04266652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33701174|NCT04157543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701175|NCT01980940|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33701176|NCT04279405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701177|NCT03477123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator does not have information on the group the patient was enrolled.||f|f|f|t
33701178|NCT00589901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701179|NCT04806503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701180|NCT06556771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701181|NCT05446896|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787828|NCT01004328|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33927179|NCT05462405|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Indirect evidence \[see reference 1\] shows that CNT may decrease the level of sympathetic activity locally (in the heart) and systemically. However, this effect was never directly measured in an experiment. It is also theorized that the decrease of sympathetic activity may persist for some time after CNT delivery is stopped, but this has to be verified using direct sympathetic activity level measurement. Such direct evidence of sympathetic activity reduction may enable application of CNT therapy to other diseases and patients that do not have adequate therapies today, such as heart failure.||||
33927180|NCT02254551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927181|NCT01700881|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33927182|NCT02679794|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34091510|NCT01940861|||COHORT||PROSPECTIVE|||||||
34091511|NCT06419166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091512|NCT01310283|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33701182|NCT01422018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091513|NCT02015156|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34091514|NCT03360968|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091515|NCT06023407|RANDOMIZED|PARALLEL||OTHER||SINGLE|Primary Investigators will be blinded to participants group. Due to the type of intervention we are unable to blind participant or certain members of the study team|1:1 allocation to either heat therapy intervention or thermoneutral control group|f|f|t|f
34091516|NCT01034423|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33701183|NCT01404273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701184|NCT03020173|||CASE_CONTROL||PROSPECTIVE|||||||
33701185|NCT04555421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701186|NCT05768074|||COHORT||PROSPECTIVE|||||||
33701187|NCT01951222|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33701188|NCT01310153|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33701189|NCT00000315||||TREATMENT||||||||
33787829|NCT00286741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787830|NCT02430181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787831|NCT05167253|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787832|NCT06169904|||COHORT||RETROSPECTIVE|||||||
33787833|NCT05151523|||COHORT||PROSPECTIVE|||||||
33787834|NCT02600442|||COHORT|||||||||
33787835|NCT02593565|||COHORT||PROSPECTIVE|||||||
33787836|NCT05997654|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33787837|NCT03076736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927183|NCT04504461|||COHORT||RETROSPECTIVE|||||||
33927184|NCT01766544|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33787838|NCT03455361|||COHORT||RETROSPECTIVE|||||||
33787839|NCT00941356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787840|NCT03578523|||COHORT||PROSPECTIVE|||||||
33787841|NCT03870360|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33787842|NCT03279666|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33787843|NCT02628691|||COHORT||PROSPECTIVE|||||||
33787844|NCT04075708|||CASE_CONTROL||PROSPECTIVE|||||||
33787845|NCT01353482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787846|NCT04662203|||COHORT||RETROSPECTIVE|||||||
33787847|NCT04425434|||COHORT||PROSPECTIVE|||||||
33787848|NCT03426280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787849|NCT00207129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787850|NCT04631549|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787851|NCT06081803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Evolocumab group vs control group|f|f|f|t
33787852|NCT05295082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor is not involved in the study. he doesn't know the type of intervention.|guided dental implant placement through guided trephine-based implant site preparation|f|f|f|t
33787853|NCT06037616|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33787854|NCT01861678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787855|NCT04483882|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Subjects will be blinded to product to be provided for visual and tactile definition of label product and type and frequency of prescription.|Single Group, Blinded, Sham controlled study|t|f|f|f
33927185|NCT05698108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was single-blinded as the assessor was blinded|Randomized Controlled Trial|f|f|f|t
33787856|NCT02916719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787857|NCT05590312|||COHORT||PROSPECTIVE|||||||
33787858|NCT06281080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787859|NCT05523258|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33787860|NCT04477746|||COHORT||PROSPECTIVE|||||||
33787861|NCT04094064|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33787862|NCT02064569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787863|NCT00432653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787864|NCT04053829|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only the outcome assessor will be masked in this study|"This multi-centre, assessor-blinded, randomised proof of concept study will explore the acceptability and feasibility of providing a home-based balance tele-rehabilitation programme to older adults at risk for falls. It will 1) compare acceptability of the tele-health programme (e.g. compliance, drop-out rate) to an established home exercise programme (the OTAGO HEP) and 2) explore trends for effectiveness across a number of validated outcome measures to explore whether a future trial is warranted, and if so to provide data for a sample size estimate.~Data will be collected at baseline (week 0) and at completion of the intervention (week 9). The flow of participants through the trial will be recorded in compliance with the CONSORT statement. The blinded outcome assessor will collect all measures at baseline and follow up and will be asked to record any incidences of unblinding and detail how this occurred."|f|f|f|t
33787865|NCT00633412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33787866|NCT01624636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787867|NCT00604006|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33787868|NCT05609266|||COHORT||PROSPECTIVE|||||||
33787869|NCT04917432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33927186|NCT05933798|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33927187|NCT04054102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant does not know the allocation.||t|f|f|f
33927188|NCT04415619|NA|SINGLE_GROUP||TREATMENT||NONE||A group of 10 patients will receive immediate implant placement with buccal pad of fat coverage||||
33927189|NCT01574261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927190|NCT06346613|||COHORT||PROSPECTIVE|||||||
33927191|NCT06043245|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three parallel groups (patients with severe obesity and Type 2 Diabetes) assigned 1:1:1 to undergo duodenal switch (DS), Single anastomosis duodeno-ileal (SADI-S) or Minigastric bypass (MGB).||||
33927192|NCT00045591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33927193|NCT02682160|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927194|NCT04158310|||COHORT||RETROSPECTIVE|||||||
33927195|NCT00596804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927196|NCT00111111|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34005670|NCT00030641|RANDOMIZED|||TREATMENT||NONE||||||
34005671|NCT01280344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005672|NCT00983476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091517|NCT00859846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091518|NCT01713517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787870|NCT05955599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787871|NCT04740359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were divided in two groups. Two groups will get two different intervention.|f|f|f|t
33787872|NCT02759731|NA|SEQUENTIAL||TREATMENT||NONE||||||
33787873|NCT00639613|||CASE_CONTROL||PROSPECTIVE|||||||
33787874|NCT04697251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787875|NCT06479018|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33787876|NCT00385658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787877|NCT06628856|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33787878|NCT03379363|||CASE_ONLY||RETROSPECTIVE|||||||
33787879|NCT02434718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787880|NCT03092557|NA|SINGLE_GROUP||OTHER||NONE||Prospective, interventional, cohort study||||
33787881|NCT06631157|||COHORT||PROSPECTIVE|||||||
33787882|NCT04167709|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study has a pre-post experimental design.||||
33787883|NCT03787875|||CASE_CONTROL||PROSPECTIVE|||||||
33787884|NCT01061229|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34005673|NCT05342987|||COHORT||PROSPECTIVE|||||||
34005674|NCT01979198|||CASE_CONTROL||PROSPECTIVE|||||||
34005675|NCT03730779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005676|NCT00440115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701190|NCT05837585|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The air quality sensors will install at the designated places and only serve to provide air quality indexes for the study site to improve air quality. The sensors will detect air quality at 2 weeks during the pre-test period and the alarm threshold will be set base on the 2-week data. During the 12 weeks trial period, based on the analysis on past 2-week air quality indexes, the managers of service unit will decide the changes of activities to improve air quality and long-term measures. The respiratory symptoms, blood pressure, pulse rate of participants will be collected during the pre-test and trial period.||||
33701191|NCT00635375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701192|NCT02704260|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701193|NCT01278836|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34005677|NCT04823130|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Healthy participants served as control group providing normal skin reference for baseline skin biopsy derived outcome measure and were matched for gender, age, race and anatomical site of skin biopsy.||||
33701194|NCT02387138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701195|NCT04609371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33701196|NCT04977674|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33701197|NCT03948581|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787885|NCT04708743|||COHORT||CROSS_SECTIONAL|||||||
33787886|NCT00588965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33787887|NCT00466791|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33927197|NCT04414527|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In a two-arm cluster randomized trial, 675 eligible pregnant women in their first trimester (12 weeks of gestation) will be recruited and followed up until delivery, and in pair with their infant up-to six months postpartum.~1. Eligible pregnant women in the intervention group will receive video-based nutritional and hygienic education package (Health-Video) for six months until delivery and then for another six-month postpartum.~2. Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines.~The intervention will include home-to-home visit for delivery of healthy nutrition and hygiene messages using prepared video-based messages, and participation in monthly forums facilitated by nurses using also videos for demonstration of nutritional and hygienic care."||||
33787888|NCT06631495|||CASE_ONLY||CROSS_SECTIONAL|||||||
33787889|NCT04822129|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups||||
33927198|NCT01789892|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33787890|NCT00175240|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33787891|NCT04310579|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing. Subjects and staff will be blinded to treatment assignment. The blind will be maintained through a randomization schedule held by the dispensing pharmacist. Drugs will be over-encapsulated to maintain blinding during oral study drug administration.|"This clinical study consists of 3 parts:~1. Up to 10 subjects in the Lead-In reproducibility assessment will have no drug treatment, only Read Rebreathing assessments.~2. Approximately 20 subjects in Part 1 will be randomized to complete four treatments over four 1-day periods. Each period will be followed by 2 days of washout. Thus, Part 1 will have a cross-over component.~3. Approximately 20 subjects in Part 2 will be randomized to complete three treatments over three 5-day periods. Each period will be followed by 7 days of washout. Thus, Part 2 will have a cross-over component.~A maximum of 10 additional replacement subjects may be enrolled."|t|t|t|t
33787892|NCT06530030|||COHORT||PROSPECTIVE|||||||
33927199|NCT02996955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787893|NCT03581968|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is an open-label, randomized, two-way, cross-over study.|t|f|f|f
34005678|NCT01867606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34005679|NCT06679010|NA|SINGLE_GROUP||PREVENTION||NONE||The study is a feasibility trial with an uncontrolled, within-group, pre-post design||||
33787894|NCT06630351|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33787895|NCT00194142|||COHORT||RETROSPECTIVE|||||||
33787896|NCT02860260|NON_RANDOMIZED|PARALLEL||||NONE||||||
33701198|NCT02317588|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33701199|NCT00494299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701200|NCT01848730|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33787897|NCT00340613|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787898|NCT05790941|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Unlabeled bottle.||t|f|f|f
33787899|NCT02144935|||CASE_ONLY||PROSPECTIVE|||||||
33787900|NCT04898192|||COHORT||PROSPECTIVE|||||||
33787901|NCT05289830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33787902|NCT01842971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701201|NCT04053322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927200|NCT02072694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33927201|NCT01397045|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33701202|NCT03318510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701203|NCT03086993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701204|NCT05776368|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33927202|NCT05462340|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005680|NCT06635876|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34005681|NCT01065389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34005682|NCT01263886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005683|NCT02041858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34005684|NCT05220969|||CASE_CONTROL||RETROSPECTIVE|||||||
34005685|NCT00916695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005686|NCT01696565|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34005687|NCT00807209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005688|NCT04721496|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34005689|NCT06677879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701205|NCT03386474|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701206|NCT04205981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701207|NCT01744873|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33701208|NCT04135365|||COHORT||PROSPECTIVE|||||||
33701209|NCT02640859|||COHORT||PROSPECTIVE|||||||
33787903|NCT06166719|||COHORT||PROSPECTIVE|||||||
33787904|NCT00751790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787905|NCT06172660|||CASE_CONTROL||RETROSPECTIVE|||||||
33787906|NCT03370406|RANDOMIZED|PARALLEL||TREATMENT||NONE||10 participants will serve as a control group, and will receive neither 5FU injection nor topical imiquimod. 10 participants will receive one 1ml intralesional injection of 50mg/ml 5FU aqueous injectable solution every week for 3 weeks. 10 participants will receive intralesional 5FU as in the previous group, additionally they will also receive concomitant three-times-weekly topical application of 5% imiquimod to the same lesion. At the end of week two, a 2mm punch biopsy of the lesion will be obtained for mid-point analysis, and will be stored for tissue banking. A week after the last injection (week 4), the lesion will be surgical resected in all participants including the control group, to render the participants disease free. Resection is the current standard of care. A portion of the resected tumor and skin will also be stored for tissue banking, for future study.||||
33787907|NCT01227707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33787908|NCT05742984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787909|NCT06110195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33787910|NCT06390891|||COHORT||RETROSPECTIVE|||||||
33787911|NCT01052818|||COHORT||PROSPECTIVE|||||||
33701210|NCT04230395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927203|NCT04251624|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants assigned to the experimental group (Goal Management Therapy) will receive either 6 (phase 1) or 9 (phase 2 and phase 3) group therapy sessions.~The matched control group (psychosocial education) will receive an equal number of group therapy sessions.~Each session will be 2 hours long."||||
33927204|NCT02560480|||CASE_CONTROL||PROSPECTIVE|||||||
33927205|NCT00209872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927206|NCT03267407|||COHORT||PROSPECTIVE|||||||
33927207|NCT03175874|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample from resected femoral heads during laying of a total hip prosthesis.||||
33927208|NCT01242254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005690|NCT05931393|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701211|NCT02552589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701212|NCT01068834|||COHORT||PROSPECTIVE|||||||
33927209|NCT00034151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005691|NCT01118507|||CASE_CONTROL||PROSPECTIVE|||||||
34005692|NCT05452434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005693|NCT01439724|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33701213|NCT04045275|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design was a randomized control trial with baseline and post-intervention assessments (8 wks from baseline). Individuals reporting sleep difficulties were randomized to either a meditation mobile app intervention (Calm) group or a delayed response group. Participants were randomized after the completion of baseline and informed consent.||||
33701214|NCT01212939|||CASE_ONLY||PROSPECTIVE|||||||
33701215|NCT02508857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701216|NCT03177369|||COHORT||RETROSPECTIVE|||||||
33701217|NCT01835483|||CASE_CONTROL||RETROSPECTIVE|||||||
33701218|NCT00799422|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33701219|NCT00456248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701220|NCT05069610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787912|NCT02380742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787913|NCT05386758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787914|NCT04428554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787915|NCT00554801|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33787916|NCT04312568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||8 dose groups within 12.5mg\~500mg for single dose tolerability study to carrried out from low-dose group to high dose group|t|t|t|f
33787917|NCT03126084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787918|NCT02488174|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33787919|NCT03635567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33787920|NCT05251285|||CASE_ONLY||PROSPECTIVE|||||||
33787921|NCT03784963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787922|NCT02210702|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33787923|NCT06076759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33787924|NCT03874156|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE||Prospective, randomized double-blinded placebo controlled cross-over phase 4 study.|t|t|t|t
33927210|NCT03958994|||OTHER||OTHER|||||||
33927211|NCT02077504|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927212|NCT02051738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005694|NCT03480685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005695|NCT05470595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005696|NCT02973581|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34005697|NCT00987025|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005698|NCT03408431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
34005699|NCT02001155|||CASE_CONTROL||PROSPECTIVE|||||||
34005700|NCT05396417|||COHORT||PROSPECTIVE|||||||
34005701|NCT00704496|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34005702|NCT04211766|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34005703|NCT02093871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005704|NCT05373667|||COHORT||PROSPECTIVE|||||||
34005705|NCT00400582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005706|NCT05389670|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34005707|NCT04783545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005708|NCT04208256|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34005709|NCT01110317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091519|NCT02896842|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091520|NCT04018001|||COHORT||RETROSPECTIVE|||||||
34005710|NCT04983342|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm pilot design -pre and post||||
34005711|NCT01876368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005712|NCT03244605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33701221|NCT02544646|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005713|NCT05425342|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||single group, open||||
33701222|NCT03509311|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005714|NCT02293460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005715|NCT03710096|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701223|NCT04575623|||CASE_ONLY||CROSS_SECTIONAL|||||||
33701224|NCT05209269|||COHORT||PROSPECTIVE|||||||
33701225|NCT01596374|||COHORT||RETROSPECTIVE|||||||
33701226|NCT06151132|||COHORT||RETROSPECTIVE|||||||
33701227|NCT02543580|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|For all patients, electrodes were placed at the bilateral PC6 and RN17 and connected to the Hwato Electric Acupuncture Treatment Instrument. No patients in the study had previous experience of undergoing transcutaneous electrical stimulation treatment. Patients were told that they might or might not feel the electrical stimulation. Interventions were performed by a designated investigator who was not involved in the anaesthesia or the follow-up. The stimulator was placed in an opaque box to blind the surgical team and the anaesthetists to the group allocation.||f|t|t|t
33701228|NCT05291325|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33701229|NCT04875169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701230|NCT02514525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701231|NCT01193699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701232|NCT04813640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787925|NCT00994149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33787926|NCT03778593|NA|SINGLE_GROUP||TREATMENT||NONE||mFOLFIRINOX (5-FU, Irinotecan, oxaliplatin, Leucovorin)||||
33787927|NCT01939158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787928|NCT00440284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33787929|NCT06629909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787930|NCT04565249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787931|NCT04187157|||COHORT||RETROSPECTIVE|||||||
33787932|NCT05931107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787933|NCT02543216|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787934|NCT03551132|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||A randomized controlled trial|f|f|t|f
33927213|NCT01806285|||CASE_CONTROL||PROSPECTIVE|||||||
33927214|NCT05264480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The persons responsible to measure on the cephalogramms and CBCTs are blinded to the study design|Subjects are randomly allocated either to test (bone augmentation with corticotomy) or control (without corticotomy) groups|f|f|f|t
33927215|NCT00002004||||TREATMENT||||||||
33927216|NCT04589338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927217|NCT05004519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927218|NCT00249314|||DEFINED_POPULATION||OTHER|||||||
33927219|NCT01428440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927220|NCT00967226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927221|NCT00825149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927222|NCT02135900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927223|NCT02703142|||COHORT||PROSPECTIVE|||||||
34005716|NCT00625326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927224|NCT03215667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927225|NCT05148793|||COHORT||PROSPECTIVE|||||||
33927226|NCT02692118|||CASE_ONLY||PROSPECTIVE|||||||
33927227|NCT01154738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005717|NCT02675374|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34005718|NCT05622994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled|Placebo controlled parallel design|t|t|t|t
34005719|NCT04651920|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005720|NCT01626651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005721|NCT06207292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005722|NCT01956708|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34005723|NCT02626208|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005724|NCT05753813|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34005725|NCT04193319|NA|SINGLE_GROUP||OTHER||NONE||||||
34005726|NCT06617416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005727|NCT00683254|||COHORT||CROSS_SECTIONAL|||||||
34005728|NCT01999894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005729|NCT01155102|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005730|NCT04998812|NA|SINGLE_GROUP||OTHER||NONE||||||
34005731|NCT04383717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005732|NCT03237117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assignments are concealed in sealed opaque envelopes until the time of enrollment: group I (GH patients) and group II (non-GH patients). All injections are performed by an independent nurse who is informed by the trial coordinator of each woman´s number and the treatment allocation. Consequently, both the clinician and the patients are blinded as to the treatment received.|105 infertile women are enrolled in the randomized controlled trial: 70 women are with a history of RIF with donated oocytes and 35 infertile women undergoe the first oocyte donation attempt. 35 RIF patients are treated with GH (GH patients, study group) while the rest 35 RIF patients (non-GH patients, negative control group) and 35 first-attempt patients (positive control group) are not.|t|t|f|f
33701233|NCT03364933|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33701234|NCT05578911|||CASE_ONLY||CROSS_SECTIONAL|||||||
33701235|NCT02758769|||CASE_ONLY||PROSPECTIVE|||||||
33701236|NCT03530527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701237|NCT02837146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701238|NCT01500031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701239|NCT03872154|RANDOMIZED|PARALLEL||OTHER||SINGLE||cluster randomized|t|f|f|f
33701240|NCT02343107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701241|NCT00002982||||TREATMENT||||||||
33701242|NCT01631110|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701243|NCT02053870|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091521|NCT04649723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||To observe the effect of rifampicin on the pharmacokinetics of SHR1459 and to evaluate the safety of SHR1459, rifampicin and their coadministration in Chinese healthy subjects. The subjects will take SHR1459 at first single dose, then washout period, and take it at second single dose after multiple administration of rifampicin to get a full induction condition.||||
33701244|NCT00627185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091522|NCT03611062|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34091523|NCT03117270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091524|NCT04426032|||COHORT||PROSPECTIVE|||||||
33787935|NCT05288517|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Patients identified as at risk for suicide using a prediction model were randomized using a 1:1 allocation to receive invitation to visit Lock to Live (L2L) or control.|t|f|f|f
34091525|NCT03090295|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34091526|NCT02006654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091527|NCT05546970|||CASE_ONLY||RETROSPECTIVE|||||||
34091528|NCT01108159|||COHORT||PROSPECTIVE|||||||
34091529|NCT06263491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091530|NCT02393755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091531|NCT01125553|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091532|NCT03229811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Comprehensive pre-dialysis program incorporating conservative and advance care planning education|f|f|t|f
33927228|NCT05606380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927229|NCT03480347|||COHORT||PROSPECTIVE|||||||
34091533|NCT01610193|||COHORT||PROSPECTIVE|||||||
34091534|NCT00145067|RANDOMIZED|PARALLEL||||NONE||||||
34091535|NCT06357767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701245|NCT04565470|||COHORT||PROSPECTIVE|||||||
33701246|NCT05559398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double blinded, multicentre, placebo controlled study|t|t|t|t
33701247|NCT00611507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701248|NCT00098956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701249|NCT04745000|||CASE_CONTROL||PROSPECTIVE|||||||
33787936|NCT04142567|||COHORT||PROSPECTIVE|||||||
33787937|NCT03697772|||COHORT||RETROSPECTIVE|||||||
33927230|NCT06125457|||CASE_ONLY||RETROSPECTIVE|||||||
33927231|NCT00763243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927232|NCT03836352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927233|NCT00953004|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33927234|NCT01911208|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33927235|NCT01072903|||CASE_CONTROL||PROSPECTIVE|||||||
33927236|NCT03609489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927237|NCT06018870|||COHORT||OTHER|||||||
33927238|NCT02023918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927239|NCT02280486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927240|NCT05150795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927241|NCT04812860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Multicenter,randomized, double-blind, Dose Ranging , controlled with active treatment and placebo, parallel groups, Phase II clinical trial|t|t|t|t
33927242|NCT00396305|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927243|NCT06231914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091536|NCT05217264|||COHORT||PROSPECTIVE|||||||
34091537|NCT04256499|||COHORT||RETROSPECTIVE|||||||
34091538|NCT06305325|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||coparenting framework: it has 3 levels. First is the individual level, which consists of the parent's individual characteristics, which comprises of attitudes, parental beliefs, and emotional and mental health. It has a bidirectional relationship with coparenting and the overall inter-parental relationship. Individual child factors, such as temperament may also play a role in shaping the coparenting relationship. The second level is the family level. It comprises the overall interpersonal relationship, referring to the existing ability of couples to demonstrate support and respect for each other. It could influence the coparental relationship or in reverse, the coparental relationship may influence the overall inter-parental relationship. The third level is the extra-familial level. It has two components: support and stress that are based on a stress-coping perspective. The role of environmental support is viewed as enhancing the coparenting relationship|t|t|t|t
34091539|NCT02806167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091540|NCT04542564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701250|NCT04958668|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33701251|NCT05276596|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33787938|NCT04347135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787939|NCT01868217|||COHORT||RETROSPECTIVE|||||||
33787940|NCT03089346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787941|NCT00996372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33787942|NCT06630949|||COHORT||PROSPECTIVE|||||||
33787943|NCT06628700|||OTHER||PROSPECTIVE|||||||
33787944|NCT03829267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be enrolled in an internet-based intervention to increase physical activity. Only the PI will know whether participants are in the SNAP or eJournal condition.|Patients will be randomized to (a) SNAP treatment, (b) active control condition (eJournaling), or (c) waitlist control|f|f|t|f
33927244|NCT02532569|NA|SINGLE_GROUP||PREVENTION||NONE|Open Label|||||
33927245|NCT02536157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927246|NCT06556667|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|participants will not know which defibrillator was used during their cardioversion.|two arms will be compared using the Chi squared test|t|f|f|f
33927247|NCT01200160|||CASE_ONLY||PROSPECTIVE|||||||
33927248|NCT04657354|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33927249|NCT01418924|||CASE_ONLY||PROSPECTIVE|||||||
33927250|NCT00179569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927251|NCT00399867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927252|NCT05459207|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33701252|NCT03319173|RANDOMIZED|PARALLEL||TREATMENT||NONE||To assess differences between the control and experimental groups, a mixed model will be fit for each variable separately using both baseline (week 0) and post program (week 12) values for each subject. Models will include week, group, and their interaction as fixed effects, gender as a covariate, and subject as a random effect. To assess significant differences, we will use the difference at week 12 adjusted for the baseline difference, and will report p-values, least squares means, and 95% confidence intervals. Further analysis of treatment effects over time will be examined by comparing the within-group differences over time.||||
33701253|NCT06361160|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Only the person conducting the experiment will know which condition each patient is in.|Patients (20) suffering from resistant schizophrenia will be enrolled over a 12-month period and will be randomized in a (1:1) ratio to start with either active or sham Transcranial Magnetic Stimulation (TMS) for the first of their 12 sessions, which will then alternate from one condition to the other for each patient.|t|t|f|t
33701254|NCT03074955|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33701255|NCT06680622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701256|NCT04941560|||OTHER||PROSPECTIVE|||||||
33701257|NCT04359667|||CASE_ONLY||PROSPECTIVE|||||||
33701258|NCT00691223|||OTHER||PROSPECTIVE|||||||
33701259|NCT01034150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33701260|NCT04394975|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34005733|NCT01774331|||COHORT||OTHER|||||||
34005734|NCT06030856|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005735|NCT03815240|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33701261|NCT04001933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33701262|NCT05714059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701263|NCT02169479|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33701264|NCT04667481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33701265|NCT01323959|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701266|NCT05592262|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, open-label, single-dose, two-cycle, two-sequence, cross-controlled||||
33701267|NCT02761070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701268|NCT01484275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005736|NCT05440695|||OTHER||PROSPECTIVE|||||||
34005737|NCT00139906|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33701269|NCT04222153|||OTHER||CROSS_SECTIONAL|||||||
33701270|NCT01713608|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33701271|NCT04789083|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a double blind randomized controlled study||||
33701272|NCT05975879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33701273|NCT00897208|||COHORT||PROSPECTIVE|||||||
33701274|NCT02002273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701275|NCT00436241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701276|NCT00044083|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
33701277|NCT01593410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701278|NCT04206059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701279|NCT02242266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33701280|NCT02138773|RANDOMIZED|CROSSOVER||||NONE||||||
33927253|NCT02678728|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33927254|NCT01631292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33927255|NCT00582699|||CASE_ONLY||PROSPECTIVE|||||||
33927256|NCT05694793|||COHORT||PROSPECTIVE|||||||
33927257|NCT04013165|RANDOMIZED|PARALLEL||PREVENTION||NONE||A community-based randomized controlled pilot study||||
33927258|NCT04161612|||OTHER||CROSS_SECTIONAL|||||||
33927259|NCT01386892|||CASE_ONLY||PROSPECTIVE|||||||
33927260|NCT05018637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927261|NCT03127579|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33927262|NCT00537680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927263|NCT01432457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927264|NCT05599113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927265|NCT04194957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927266|NCT01291849|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33927267|NCT01020032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927268|NCT04797312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The arm allocation is open for the anesthesia team and caregivers but the patient is blind.||t|f|f|f
33927269|NCT02370550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927270|NCT00014170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927271|NCT00409916|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33927272|NCT04383613|RANDOMIZED|PARALLEL||OTHER||NONE|The study will be unblinded|This study is a multicenter, pragmatic, unblinded, 2-arm, parallel, randomized controlled trial.||||
33927273|NCT03879629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927274|NCT03770676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"The investigator will be blinded to which (intervention) flavour each participant is assigned to.~Both the investigator and the participant will be blinded to the participant's plasma selenium concentration."|There are three study groups (three 'test' biscuit flavours). Each study group will be assigned one test flavour ('intervention' flavour/biscuit). They begin consumption of their intervention biscuits on day 1 and finish on day 14. Plasma selenium concentration and sensory perception of biscuits will be measured on day 1 (baseline), 8 (post-7 days of intervention) and 15 (post-14 days of intervention).|t|f|t|f
33927275|NCT04173039|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33927276|NCT03769337|||OTHER||PROSPECTIVE|||||||
33927277|NCT01933321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927278|NCT02726334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927279|NCT06099353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927280|NCT05941676|||COHORT||PROSPECTIVE|||||||
33927281|NCT02469727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33927282|NCT00708747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005738|NCT04505826|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701281|NCT03482765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Apart from the participant and Investigator, the study team is also blinded.||t|f|t|f
34005739|NCT02656251|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34005740|NCT04440709|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005741|NCT04010734|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33701282|NCT01395667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701283|NCT02210546|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33701284|NCT00270439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701285|NCT05352100|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701286|NCT02028143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701287|NCT04088942|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be performed as a randomized, open label, superiority, 2-arm intervention study in active smokers with COPD. A total of 600 participants will be included with startup 1st January 2020 and is expected to be completed 3 years later, January 2023. Participants are randomized (random allocation) 1:1 to a low-intensity group and a high-intensity group. Stratified for age (\>65 years vs. ≤65 years) and number of daily cigarettes (\>10/day vs. ≤10/day). Blocked randomization through REDCap with blocks of varying sizes (4-8), which will not be disclosed. Participants, their data and laboratory specimens etc. will be assigned a coded identification number (ID) to maintain participant confidentiality.~Participants will be randomized to either a low-intensity or a high-intensity smoking cessation intervention."||||
33701288|NCT02564549|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005742|NCT04346563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocated participants, they do not know which group they would be in. Assessor do not know which group of participant that would perform.|RCT among two groups,|t|f|f|t
34005743|NCT03916224|||COHORT||PROSPECTIVE|||||||
34005744|NCT01302509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005745|NCT01860872|||CASE_CONTROL||PROSPECTIVE|||||||
34005746|NCT00808717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005747|NCT02721719|||CASE_CONTROL||PROSPECTIVE|||||||
34005748|NCT00468208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005749|NCT06602492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005750|NCT05352724|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Neither the patients themselves nor the researchers involved in the study will know the assigned treatment, since these will be coded. The bottles will be labeled with these numbers and will not show distinctive signs of the treatment group. These lists will be kept by the head of the randomization center, and will be hidden from the study staff and participants. For each new inclusion, the researcher will have to contact the randomization center, which will obtain the assigned treatment code.|The clinical study has a randomized, double-blind, placebo-controlled design. The patients on the list will be randomized to each of the two intervention groups in a 1:1:1 ratio (33% probability for intervention group 1, 33% for intervention group 2 and 33% for the placebo group)|t|t|t|f
34005751|NCT03436953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005752|NCT01914016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005753|NCT00263887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005754|NCT05567016|RANDOMIZED|PARALLEL||PREVENTION||NONE|This will be an open label randomized controlled trial. Participants and personnel administering the intervention will be unblinded. Assessment of the primary outcome will be unblinded. Assessment of several secondary outcomes will be blinded as feasible.|Individual randomized controlled trial||||
34005755|NCT05487573|||CASE_ONLY||PROSPECTIVE|||||||
34005756|NCT04273087|||CASE_ONLY||PROSPECTIVE|||||||
34005757|NCT06105801|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34005758|NCT04290234|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34005759|NCT00089167||||TREATMENT||NONE||||||
34005760|NCT06676293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005761|NCT01556867|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34005762|NCT00384124|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33701289|NCT03000933|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33701290|NCT03363997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701291|NCT02856646|||CASE_ONLY||PROSPECTIVE|||||||
33701292|NCT05276531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701293|NCT01177930|||COHORT||PROSPECTIVE|||||||
33701294|NCT00469378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701295|NCT01854242|||COHORT||PROSPECTIVE|||||||
33701296|NCT02211625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701297|NCT03524742|RANDOMIZED|PARALLEL||OTHER||SINGLE|open-label, blinded outcome assessment|Academic, open-label, blinded outcome assessment (PROBE design), clinical trial.|f|f|f|t
34091541|NCT05900154|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|This study is open-label therefore no blinding requirements are in place since all participants will receive RSVPreF.|This is an open-label dose-finding study. A single dose of RSVpreF 120 µg will be given to 40 participants in the 5 to \<18 age group first. Upon safety review and approval, a dose of 60 µg will be given to 20 participants in the 2 to \<5 age group. If, 60 µg is safe, another 20 participants in the 2 to \<5- age group will receive the 120-µg dose. Approximately 60 to 120 participants are expected to be enrolled.||||
34091542|NCT02709902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005763|NCT06093204|||CASE_CONTROL||PROSPECTIVE|||||||
34005764|NCT00578968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701298|NCT02502318|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701299|NCT01424709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701300|NCT03938467|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, Randomized, Controlled Trial|t|f|f|f
33701301|NCT02824237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34005765|NCT03319069|RANDOMIZED|PARALLEL||TREATMENT||NONE|Check none|Assignment Masking: open label||||
34005766|NCT00005696|||||RETROSPECTIVE|||||||
34005767|NCT01474915|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091543|NCT02194465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005768|NCT04406194|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34005769|NCT03635983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005770|NCT01004315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005771|NCT04376359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005772|NCT05772572|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005773|NCT01489735|||COHORT||PROSPECTIVE|||||||
34091544|NCT00598403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005774|NCT03821792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005775|NCT06674135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091545|NCT01653418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091546|NCT06417047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Double (Participant, Outcomes Assessor) The patients will be informed about the study and their consent will be obtained without explaining which group they are in. Since the researcher manages the implementation process of the study, researcher blinding cannot be done. In addition, it will be ensured that the researcher learns which group the patients are in after the patients accept to participate in the study. Thus, the internal validity of the research will be ensured.~At the same time, blind technique will be applied in terms of statistical analysis in the research. The data will be recorded on the computer by the researcher without using the expression of experimental and control groups, and data analysis will be done by another statistician other than the person who made the randomization."|Parallel Assignment|t|f|f|t
34091547|NCT02296697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34091548|NCT02403271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701302|NCT05475561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33701303|NCT06367361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The laboratory personnel processing the stool microscopy tests will be blinded to the treatment assignment. Thus, the intervention will be blinded to the assessors of the primary endpoint.|"Study arm 1: Oxfendazole 100 mg capsules at 20 mg/kg of body weight as a single oral dose administered with a lipid containing meal under direct observation.~Study arm 2: Oxfendazole 100 mg capsules at 20 mg/kg of body weight per dose in two oral doses separated 24 hours each administered with a lipid containing meal under direct observation.~Study arm 3: Triclabendazole 250 mg tablets at 10 mg/kg of body weight per dose in two oral doses separated 24 hours each administered with a lipid containing meal under direct observation."|f|t|f|t
33701304|NCT06340516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a national multicentre phase II trial investigating the sensitivity and specificity of NT-proBNP for the diagnose of cardiac toxicity during primary anti-HER2 blockade. NT-proBNP is compared with the todays´ standard (ECHO/MUGA).||||
33701305|NCT05927584|||COHORT||PROSPECTIVE|||||||
33701306|NCT05393011|||OTHER||CROSS_SECTIONAL|||||||
33701307|NCT01252004|||COHORT||CROSS_SECTIONAL|||||||
33701308|NCT06157255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927283|NCT04933409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes will be evaluated by a blinded researcher.|Parallel randomized controlled tria|f|f|f|t
34005776|NCT05554172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, assessment staff, and investigators will be blind to condition. When stimulation starts, both conditions will experience an effect from the device and participants will not be told which stimulation indicates real stimulation or sham.|Participants will be randomized to one of two conditions (vagal nerve stimulation or sham stimulation) according to a ratio of 2:1. The Vagal Nerve Stimulation group includes use of the vagus nerve stimulator with stimulation and the Sham Stimulation group includes use of the vagus nerve stimulator with no stimulation. Participants will be openly-enrolled until the recruitment goal of 30 is reached.|t|f|t|t
34005777|NCT04556916|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005778|NCT02562287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701309|NCT04948489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Investigators will recruit 80 adolescents for participation in a double-blind, randomized trial of NETA (n=40) vs. placebo (control group, n=40) for adjunct treatment to the levonorgestrel-containing IUD for pelvic pain due to endometriosis.|t|t|t|t
33701310|NCT00917501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701311|NCT02202837|||COHORT||PROSPECTIVE|||||||
33701312|NCT02213640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33701313|NCT02322073|||COHORT||PROSPECTIVE|||||||
33927284|NCT05584904|||CASE_ONLY||OTHER|||||||
33927285|NCT01075009|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33927286|NCT05609851|||OTHER||PROSPECTIVE|||||||
34005779|NCT04217148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701314|NCT05403788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701315|NCT03088839|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701316|NCT02883959|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701317|NCT00657358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701318|NCT04672343|||COHORT||RETROSPECTIVE|||||||
33927287|NCT05023850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blocks will be administered after induction of General Anesthesia so participants will be blinded to which intervention they have had.~Study investigators will not be aware of what group the participant belongs to when assessing the patient's post-operative period"|Randomized control trial one group receives Thoracolumbar Interfascial Plane Block the other receives Erector Spinae Plane Block|t|t|t|t
33927288|NCT02158455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927289|NCT00601679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927290|NCT02821091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005780|NCT02252445|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34005781|NCT04336332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701319|NCT02961673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701320|NCT06134960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701321|NCT05945628|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33701322|NCT02716805|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701323|NCT02031796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701324|NCT02765269|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33701325|NCT02988167|||CASE_ONLY||PROSPECTIVE|||||||
33701326|NCT04592978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Stage 1A will consist of 3 focus groups of 7 individuals used to develop and refine the pain-alcohol personalized feedback intervention (PFI).~Stage 1B will employ a randomized controlled trial to compare the effects of the pain-alcohol PFI to a control PFI."|t|f|f|f
33787945|NCT04358328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will not be possible to mask for either patients nor participating health care professionals if patients are enrolled in the control- or intervention group. Hence, the study will not be blinded. When the final data analysis is performed the person performing the analysis will not be aware of which group each patient was a part of.|Patients will be randomized into two parallel groups. This will result in two equally sized groups which will be stratified for the planned surgical procedure (colon- or rectal surgery), gender and age. One group will be randomized to preoperative geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions (CGA and care). The other group will be randomized to conventional preoperative assessments by anaesthesiologist and standard ERAS care. The study population is constituted of all patients in the participating hospitals with a newly diagnosed colorectal cancer available for colorectal cancer surgery with curative intent and who fulfil the inclusion criteria and no exclusion criteria.|f|f|f|t
33787946|NCT06632145|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre post pilot feasibility study||||
33787947|NCT05825170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787948|NCT02524444|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33787949|NCT03040843|||COHORT||PROSPECTIVE|||||||
33787950|NCT05395429|||CASE_ONLY||PROSPECTIVE|||||||
33787951|NCT02661035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787952|NCT04936789|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33787953|NCT05379127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"A multicentre pragmatic randomized trial design with two arms, combined with a patient preference cohort for each arm (partially randomized preference trial; PRPT).~The PRPT consists of three separate randomized controlled trials (RCTs) including patients in the pre-treatment phase, post-brace phase or post-operative phase. Alongside the RCTs prospective preference cohorts are included for each treatment arm (patient empowered follow up \[PE-FU\] or standard follow up \[standard FU\]). In the preference cohorts all patients are monitored who are not willing (i.e. who have a preference for either the standard FU or PE-FU) to be randomized to either treatment arm, but who are still willing to participate in the study. By including preference cohorts the generalizability of study results is studied while the internal validity is assured.~* Half of participants (n=406) allocation: randomized (RCT)~* Half of participants (n=406) allocation: based on preference (preference cohorts)"|f|f|f|t
33787954|NCT01841827|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33787955|NCT05605743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33787956|NCT04902586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787957|NCT00759837|NON_RANDOMIZED|PARALLEL||||NONE||||||
33787958|NCT03478501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33787959|NCT02155686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927291|NCT03446612|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study. However, a central FBF reader, who will read and evaluate the FBF data, will be blinded to the treatment assignment.|Participants will be randomized to either daprodustat or darbepoetin alfa. A central randomization approach will be used with stratification by center.||||
33927292|NCT00033982||||TREATMENT||||||||
33927293|NCT00642967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927294|NCT04410081|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927295|NCT06173609|||COHORT||CROSS_SECTIONAL|||||||
33927296|NCT02143960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927297|NCT03608046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927298|NCT04767126|||COHORT||PROSPECTIVE|||||||
33927299|NCT06149754|||COHORT||PROSPECTIVE|||||||
33927300|NCT05466981|NA|SINGLE_GROUP||TREATMENT||NONE||We conducted a single-arm pilot study in order to test the feasibility and preliminary efficacy of a smoking cessation intervention for people with HCV while they received standard of care treatment: antiviral medication and provider/laboratory visits.||||
33927301|NCT05754801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33927302|NCT02021916|||CASE_ONLY||CROSS_SECTIONAL|||||||
33927303|NCT03777085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103225|NCT06687551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be a simple blinded trial, because the investigator in charge of the primary outcome assessment (CDAI) will be blinded to the randomisation arm. This independent investigator will also collect all the disease activity index (CDAI, SDAI and DAS28-ESR) in the other follow-up visits, since the results of the definition of the flares and strategy changes will be based on these disease activity index.|"This study will take the format of a prospective therapeutic research. The design will be a pragmatic multicentre open-label simple-blinded, non-inferiority randomised controlled trial with two parallel groups, ratio 1:1, comparing the two following groups:~1. JAK inhibitor dose-tapering strategy.~2. JAK inhibitor continuous therapy strategy."|f|f|t|f
33701327|NCT03412526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701328|NCT03801460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessed in a blinded manner|Prospective, multicenter, randomized trial with objective end points assessment|f|f|f|t
33701329|NCT00981240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701330|NCT02605304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701331|NCT01483300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701332|NCT03495037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33701333|NCT03449875|||COHORT||PROSPECTIVE|||||||
33701334|NCT00394160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701335|NCT06334458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701336|NCT05023707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701337|NCT02229383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701338|NCT01923831|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33701339|NCT04276337|||CASE_ONLY||PROSPECTIVE|||||||
33701340|NCT03638622|NA|SINGLE_GROUP||TREATMENT||NONE||Trial with single arm||||
33701341|NCT04647864|||COHORT||PROSPECTIVE|||||||
33701342|NCT04339686|||COHORT||RETROSPECTIVE|||||||
34091549|NCT04678102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||According to the accelerated 3+3 design, the accelerated dose escalation scheme, which assesses DLT in 1 subject in each cohort, is applied until an adverse drug reaction (ADR) ≥ \[CTCAE version 5.0\] grade 2 occurs. If an ADR ≥ grade 2 occurs in a specific cohort, the accelerated 3+3 design will be immediately switched to the standard 3+3 scheme, and 3 to 6 subjects will be enrolled in each cohort. If a DLT is observed in \> 1 out of 6 subjects in a specific cohort (χ) and a DLT is observed in ≤ 1 out of 6 subjects in the cohort (χ-1) that is one level lower than the specific cohort, the one level lower cohort (χ-1) will be considered as the MTD. The dose of PHI-101 will be escalated until an MTD is determined. If the MTD is not determined at the MPD, dose escalation will be ended at that dose.||||
33701343|NCT03650556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701344|NCT05376462|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||One group of trauma patients will receive blood products based on information provided by the Quantra with the QStat Cartridge. The second group will receive blood products based on information provided by standard laboratory coagulation tests.||||
33701345|NCT06540027|||COHORT||PROSPECTIVE|||||||
33787960|NCT04820582|||OTHER||PROSPECTIVE|||||||
33787961|NCT06181383|||COHORT||PROSPECTIVE|||||||
33787962|NCT06214468|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Sample will be assigned a unique identifier to de-identify samples from the study team. This unique identifier will be assigned by the clinical manager, who will be providing the informed consent. Each sample will be labeled to include gender, race and ethnicity.|"This study takes place over 2 days, and the study runs twice, two weeks apart. Upon enrolment and consent, the participant will provide a urine sample then be given acetaminophen and Nicotinamide Riboside (NR). Participant are asked to collect 4 urine samples over a 24 hour period and record the time of the collection each time. Two weeks after this first collection, participants are asked to repeat the process but this time with only acetaminophen ingestion.~Tubes will be provided for the collection of the urine and zip lock bags will be provided to place the tubes in after samples have been collected. All samples should be stored in the freezer until completion of the samples at which time they should be brought to the USA Mitchell Cancer Institute. Some volunteers will participate in 4 total blood draws collected on the first day at the time of the consent then again 6 hours after taking NR and Acetaminophen. Blood samples will be taken again during the second collection period."|t|f|t|f
33787963|NCT01582945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701346|NCT06029738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The research was planned as two groups randomized controlled trial study.|t|f|f|f
33701347|NCT01444131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701348|NCT01701921|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33787964|NCT00064571|RANDOMIZED|PARALLEL||TREATMENT||||||||
33787965|NCT00590850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33787966|NCT03543839|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study drug or placebo look identical.|This is not a true cross-over study. Subjects are randomized to receive true drug or placebo in the initial phase and then those patients who were randomized to receive belimumab will be rerandomized to receive either study drug or placebo. Subjects randomized at baseline to receive placebo continue to receive placebo through the study.|t|t|t|t
33787967|NCT00640666|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33787968|NCT02887261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787969|NCT05481502|NA|SINGLE_GROUP||OTHER||NONE||||||
33787970|NCT00243334|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33787971|NCT04778410|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||After completion of Safety Run-in cohorts and identification of the RP2D for the specific cohorts, participants may be enrolled to the corresponding Phase 2 cohorts.||||
33787972|NCT03284632|||COHORT||PROSPECTIVE|||||||
33787973|NCT04833192|||COHORT||PROSPECTIVE|||||||
33787974|NCT04570475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33787975|NCT06059820|||COHORT||PROSPECTIVE|||||||
33787976|NCT06141577|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, multiple-dose crossover phase 1 clinical||||
33787977|NCT06057220|||COHORT||PROSPECTIVE|||||||
33787978|NCT01834235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091550|NCT03284554|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Double-blind|A double-blind, randomized crossover design with four arms including three experimental conditions and placebo|t|t|t|t
33787979|NCT04495634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33787980|NCT01530074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091551|NCT01143324|||CASE_ONLY||PROSPECTIVE|||||||
33701349|NCT05306392|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric controlled study, with randomization in two groups (induced hypothermia group and control group), at the Nancy Hospital - Intensive care Unit||||
33701350|NCT05075239|||COHORT||PROSPECTIVE|||||||
33701351|NCT02086292|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33701352|NCT04638660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||All subjects will be randomized into the study in a 1:1 ratio to one of the treatment arms (Nyxol or placebo), with a stratification by light/dark irides.|t|t|t|t
33701353|NCT03949439|||OTHER||RETROSPECTIVE|||||||
33787981|NCT01432158|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33787982|NCT05560828|||OTHER||RETROSPECTIVE|||||||
33787983|NCT03016130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33787984|NCT06550193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will receive the intervention, which involves utilizing AR/VR technology during ultrasound-guided procedures.||||
33787985|NCT05608499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787986|NCT06053788|NA|SINGLE_GROUP||SCREENING||NONE||||||
33787987|NCT04610294|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Identical-looking test devices are either active or inactive. None of the investigators, clinicians, patients, or outcome assessors knows which are which.|Randomized multiple crossover cluster trial|t|t|t|t
33701354|NCT01031381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005782|NCT03639220|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A participating researcher who programmed the PBMT device (Multi Radiance Medical™, Solon, OH) based on the randomization results performed the randomization. He will be instructed not to inform the participants or other researchers of the PBMT dose (active or placebo). Thus, the researcher who performed the PBMT will be blinded to the dose administered to the participants. To further maintain blinding, participants used opaque goggles to prevent them from seeing whether a light will be irradiated.|Randomization will be held by drawing lots, which we use to determine whether the active combination of superpulsed lasers, LEDs, comprising the PBMT or the placebo will be given during the first session. During the second session, participants will receive the opposite treatment compared to their first session. Randomization labels will be created using a randomization table at a central office where a series of sealed, opaque, and numbered envelopes ensured confidentiality.|t|f|t|f
34005783|NCT01267916|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33701355|NCT03144973|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|operating surgeons or surgeons in the surgical ward do not get to know the test result so it won't affect in patient care|All the patients that have upper-gi surgery in our time frame are asked to join in the study|f|t|f|f
33701356|NCT00981201|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33701357|NCT04799574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The researchers in this study are the leaders of the activities and the nurses who had completed training in music therapy courses, and had obtained leadership certificates and qualifications in senior music activities.|one Experimental group and one Control group|t|f|f|t
33701358|NCT00532324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701359|NCT05968131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single-blinded. The assessor will be unaware of the treatment given to both groups.||t|f|f|f
33701360|NCT03404232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients requiring lumbar spinal surgery by the use of a hybrid spinal implant (DTO): (1) patients with their first surgical intervention at the lumbar spine, (2) patients with a previous surgical decompression but non-fusion procedure after LSS and (3) patients with medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment.||||
33701361|NCT06349018|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Both isotonic drinks (high nitrate or no nitrate) are deidentified and labelled (coded) by a third party not involved with the research. Randomization and allocation are completed by a third party not involved in the testing.||t|f|t|f
33701362|NCT05916820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701363|NCT02128932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701364|NCT05406362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The patients will be randomised into VAD044 30 mg or 40 mg or placebo group in the ratio 1:1:1, according to a centralised randomisation process|t|t|t|t
33701365|NCT00519454|||COHORT||PROSPECTIVE|||||||
33701366|NCT00827528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701367|NCT03488355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33787988|NCT05037851|RANDOMIZED|PARALLEL||PREVENTION||NONE|The study will be an open-label study. For the purposes of the exploratory efficacy assessments, however, the Data Review Committee determining the presence of pulmonary fungal disease will be blinded as to treatment assignment. The Sponsor will limit knowledge of treatment assignment to as few sponsor personnel as possible to reduce bias.|Open-label, randomized, active-controlled, parallel-group multi-center study||||
33787989|NCT04789850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33787990|NCT01243255|||CASE_ONLY||CROSS_SECTIONAL|||||||
33787991|NCT05652530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33787992|NCT05169255|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two parallel groups with placebo versus antibiotics||||
33787993|NCT06479785|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33787994|NCT02715063|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33787995|NCT03098290|||COHORT||PROSPECTIVE|||||||
33787996|NCT05394402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR0410 Injection compared with placebo|t|t|t|t
33787997|NCT01611441|||COHORT||PROSPECTIVE|||||||
33787998|NCT05528536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33787999|NCT02722356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788000|NCT04905316|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, prospective, phase I/II study.||||
33788001|NCT03276039|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34005784|NCT06384482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005785|NCT06388031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005786|NCT05920161|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34005787|NCT06347926|NA|SINGLE_GROUP||OTHER||NONE||Questionnaires given before and after photobiomodulation||||
34005788|NCT01954914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005789|NCT04750668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005790|NCT01692886|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005791|NCT03111381|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34005792|NCT03941834|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34005793|NCT06291090|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This intervention will be implemented across 12 hospitals||||
34005794|NCT06148779|||COHORT||RETROSPECTIVE|||||||
33788002|NCT02226835|||COHORT||CROSS_SECTIONAL|||||||
33788003|NCT04520165|||COHORT||PROSPECTIVE|||||||
33788004|NCT00711542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788005|NCT02313844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005795|NCT03888521|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|All participants receive the intervention, serving as their own controls|Efficacy of a non-invasive intervention is being tested, while exploratory data is also being collected to better understand tinnitus||||
33788006|NCT00545844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788007|NCT02805244|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788008|NCT03728725|||COHORT||CROSS_SECTIONAL|||||||
34005796|NCT02084927|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34005797|NCT00705315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005798|NCT00709306|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34005799|NCT03370822|||COHORT||PROSPECTIVE|||||||
33701368|NCT00165984|||COHORT||PROSPECTIVE|||||||
33701369|NCT03555760|||COHORT||PROSPECTIVE|||||||
33701370|NCT00785928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701371|NCT06462885|||COHORT||RETROSPECTIVE|||||||
33701372|NCT02480920|||COHORT||RETROSPECTIVE|||||||
34005800|NCT04353258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701373|NCT02264639|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701374|NCT03363269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701375|NCT06435728|||COHORT||RETROSPECTIVE|||||||
33701376|NCT03490708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701377|NCT02837276|||COHORT||PROSPECTIVE|||||||
33788009|NCT03557385|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788010|NCT03234816|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33788011|NCT02396056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788012|NCT00530335||FACTORIAL||TREATMENT||NONE||||||
33788013|NCT05082883|||COHORT||PROSPECTIVE|||||||
33788014|NCT02153606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788015|NCT00029523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788016|NCT06118489|||COHORT||PROSPECTIVE|||||||
33788017|NCT01793272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788018|NCT03426696|||CASE_ONLY||PROSPECTIVE|||||||
33788019|NCT01888406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788020|NCT02680756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788021|NCT04470102|RANDOMIZED|PARALLEL||TREATMENT||NONE|no data|A randomized clinical trial comparing mitral valve repair using the edge-to-edge technique for surgical treatment of hypertrophic cardiomyopathy||||
33788022|NCT02882646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788023|NCT05711498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34005801|NCT05385367|RANDOMIZED|PARALLEL||OTHER||NONE||Mulicentre trial||||
34005802|NCT05683691|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Multicenter, Single-Arm Study||||
34005803|NCT05712317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34005804|NCT05044663|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005805|NCT04608630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005806|NCT01629537|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34005807|NCT00105495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005808|NCT03298516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701378|NCT00263731|||CASE_CONTROL||PROSPECTIVE|||||||
33701379|NCT05265416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701380|NCT06097182|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Study design: The study will be carried out according to a randomized, placebo-controlled, double-blind, 3 arm parallel-groups design. It will be executed as a hybrid study (partially decentralized). Total study duration is 9 days (day 0 to day 8), excluding screening and enrolment.|t|f|t|t
33788024|NCT01249092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788025|NCT04859595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single-center, open-label, prospective study||||
33788026|NCT03321955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788027|NCT00657280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788028|NCT04874012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The generation of the sequence of numbers will be done by a blinded researcher, after selecting the participant by the inclusion and exclusion criteria. The concealment of allocation will be implemented by a central randomization routine, conducted by researchers with access to the list and by the researcher responsible for requesting the code for placement of individuals in the study.|Randomized, double-blind, placebo-controlled clinical trial|t|f|t|t
33788029|NCT05054062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788030|NCT05660395|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788031|NCT06629311|||COHORT||PROSPECTIVE|||||||
33788032|NCT02551354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788033|NCT06620614|RANDOMIZED|PARALLEL||TREATMENT||NONE||"An approval from the Institutional Review Board (IRB), NAMS was taken prior to commencing the study. 72 Patients of ASA physical status I or II scheduled for Transurethral Resection of prostate under Sub-arachnoid block were enrolled in the study. . Patient's characteristics including name, gender, age, body weight, height and body mass index were recorded.~Patients were kept nil per oral as per American society of anesthesiologist guidelines prior to surgery. Study pouplation were divided into two groups:~* Bolus group~* Fractionated group"||||
33788034|NCT05994092|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel Group Randomized Controlled Trial||||
33788035|NCT01520350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788036|NCT04519450|||COHORT||PROSPECTIVE|||||||
33788037|NCT01887041|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788038|NCT00001999||||TREATMENT||||||||
33788039|NCT06411405|||OTHER||PROSPECTIVE|||||||
33788040|NCT05100472|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II single arm trial.||||
34005809|NCT01136928|NA|SINGLE_GROUP||OTHER||NONE||||||
34005810|NCT06555263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701381|NCT00567372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701382|NCT05075460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701383|NCT02683720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701384|NCT06277596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701385|NCT02243969|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701386|NCT00932126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701387|NCT03493620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33701388|NCT05476367|||CASE_CONTROL||RETROSPECTIVE|||||||
33701389|NCT03155282|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701390|NCT03711318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701391|NCT05447897|NA|SINGLE_GROUP||OTHER||NONE||||||
33701392|NCT03468101|||CASE_ONLY||PROSPECTIVE|||||||
33701393|NCT00594048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701394|NCT02699593|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33701395|NCT02835742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701396|NCT02864602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701397|NCT03270371|RANDOMIZED|CROSSOVER||TREATMENT||NONE|no masking|Medium cut off Dialyzer compared with standard of care High-Flux Dialyzer (Fx Cor Diax 60®). No others changes in our standard of care maintenance dialysis is planned, dialysis specific parameters such as blood flow will be kept unchanged during the study period).||||
33701398|NCT04997278|NA|SINGLE_GROUP||TREATMENT||NONE||A single group will be studied, comparing the new stimulation paradigm with the standard paradigm||||
33701399|NCT04046692|||CASE_ONLY||CROSS_SECTIONAL|||||||
33701400|NCT02125968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33701401|NCT03108274|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Part 1, Part 2, and Part 3 could be conducted concurrently or separately, and the order of the parts could be determined according to the needs of the program.||||
33788041|NCT01760291|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788042|NCT01191788|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788043|NCT03834753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788044|NCT05747599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33788045|NCT00175942|||DEFINED_POPULATION||OTHER|||||||
33788046|NCT03001986|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788047|NCT02561403|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33788048|NCT04257851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788049|NCT05689216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788050|NCT05532813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788051|NCT05644262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788052|NCT03595943|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33788053|NCT00825435|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33788054|NCT06277622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective multicenter cohort study is to compare the post-operative implant failure rate between the patients with femoral intertrochanteric fracture (AO classification 31-A) using Proximal Femoral Universal Nail (PFUN) versus Proximal Femoral Nail Antirotation (PFNA) at 21-month follow up.The patients are divided into the PFUN group and the PFNA group according to the internal fixation they choose.||||
33927304|NCT05483660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The person in charge of assigning patients to treatment groups does not know which treatments the patients receive, so they do not select patients in order of their own volition.~Patients themselves do not know what treatment they are receiving, so they do not change their compliance or reporting of symptoms."||t|t|t|f
33927305|NCT04279704|||COHORT||CROSS_SECTIONAL|||||||
33927306|NCT06531005|||COHORT||PROSPECTIVE|||||||
33927307|NCT00677560|||COHORT||PROSPECTIVE|||||||
33927308|NCT00565812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927309|NCT04026945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927310|NCT04510402|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Fifty healthy volunteers to use single application or double application of PVP-I nasal swabs and assess for safety and tolerability||||
33927311|NCT00092404|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33927312|NCT01804257|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33927313|NCT04037007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be allocated to one group of the intervention conventional guidewire biliary cannulation or fistulotomy based on program software|We aim to perform a randomized clinical trial comparing fistulotomy (F) precut vs guidewire cannulation (CC), as a primary cannulation technique, and compare outcomes between high experienced endoscopists (\> 200 ERCPs) and low experienced endoscopists (\< 200 ERCPs).|t|f|f|f
33927314|NCT00217009|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33927315|NCT03948269|RANDOMIZED|PARALLEL||TREATMENT||NONE||Mixed-effects models (random intercept) with interaction effects of group and time will be conducted on primary and secondary repeating outcomes.||||
33927316|NCT03930303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927317|NCT02057367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927318|NCT05548257|||CASE_ONLY||RETROSPECTIVE|||||||
34005811|NCT03702634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research staff conducting interviews with study participants will be masked to study group allocation, until all outcome assessments for that participant have been completed.|Arm 1- Control group Arm 2- Intervention group|f|f|f|t
34005812|NCT04564404|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33927319|NCT03929523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927320|NCT00635557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927321|NCT06248463|||OTHER||CROSS_SECTIONAL|||||||
33927322|NCT02866604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927323|NCT00118469|RANDOMIZED|FACTORIAL||||NONE||||||
33927324|NCT01774292|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33927325|NCT00321009|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33927326|NCT02337686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927327|NCT03497611|||CASE_ONLY||RETROSPECTIVE|||||||
33927328|NCT05286268|||COHORT||PROSPECTIVE|||||||
33927329|NCT01202318|||COHORT||PROSPECTIVE|||||||
33927330|NCT00707538|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927331|NCT01660230|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34005813|NCT06675890|||CASE_ONLY||CROSS_SECTIONAL|||||||
34005814|NCT03825367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005815|NCT06321354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34005816|NCT02148445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005817|NCT05249972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, assessor blind, parallel group, three arms, active and placebo controlled study|t|t|t|f
34005818|NCT02263417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005819|NCT06614907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005820|NCT00545688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005821|NCT02872350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005822|NCT00400062|||COHORT||PROSPECTIVE|||||||
34005823|NCT01884064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005824|NCT01996423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005825|NCT03471988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005826|NCT06056934|||OTHER||RETROSPECTIVE|||||||
34005827|NCT03146117|||COHORT||PROSPECTIVE|||||||
33701402|NCT03227185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will be randomly assigned to two possible sequences of stimulation conditions. Group 1 will receive real tDCS stimulation to the left dlPFC during encoding on the first day and sham stimulation on the second day, and group 2 will receive sham stimulation during encoding on the first day and real tDCS on the second day. The participants will be randomized with equal probability to each of the two groups, using block randomization..|t|f|t|f
33701403|NCT03592654|NA|SEQUENTIAL||TREATMENT||NONE||single subject multiple baseline design||||
33701404|NCT06452238|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34005828|NCT06678750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091552|NCT03439839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking used in the study|Open label, non-randomized study||||
34091553|NCT02401295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091554|NCT00149643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701405|NCT01595633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005829|NCT00378027|||COHORT||PROSPECTIVE|||||||
34005830|NCT01940263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005831|NCT06274424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005832|NCT04226339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005833|NCT05284084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005834|NCT05683860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005835|NCT06494397|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005836|NCT01418950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005837|NCT03139240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
34005838|NCT03770793|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34005839|NCT01889472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005840|NCT02550587|||COHORT||RETROSPECTIVE|||||||
34005841|NCT02615184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091555|NCT05382065|||COHORT||RETROSPECTIVE|||||||
34091556|NCT02935387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091557|NCT05141799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091558|NCT04597450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091559|NCT04137549|||COHORT||PROSPECTIVE|||||||
33701406|NCT03604484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701407|NCT03854110|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation||||
33701408|NCT05263375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701409|NCT03375008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701410|NCT01250431|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33701411|NCT01264783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701412|NCT02841865|||OTHER||CROSS_SECTIONAL|||||||
33701413|NCT05197621|||COHORT||PROSPECTIVE|||||||
33701414|NCT02727842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701415|NCT03985306|NA|SINGLE_GROUP||TREATMENT||NONE||"The trial is a single-center single-group feasibility trial in outpatient clinical settings.~The trial will be reported with reference to the extended CONSORT guidelines."||||
33701416|NCT01850693|||COHORT|||||||||
33701417|NCT05600660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701418|NCT02528604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701419|NCT01781364|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701420|NCT06556381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788055|NCT03780790|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||RANDOMISED DOUBLE BLINDED INTERVENTIONAL|t|f|t|t
33788056|NCT06629350|||COHORT||RETROSPECTIVE|||||||
33788057|NCT01516892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788058|NCT04991259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788059|NCT02952950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34005842|NCT05535660|||COHORT||PROSPECTIVE|||||||
34005843|NCT02106533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005844|NCT00830167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788060|NCT00349908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005845|NCT03631173|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2-armed, multicenter, randomized, open label, parallel-group controlled trial (RCT)||||
34005846|NCT01114997|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34005847|NCT01876953|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34005848|NCT01007019|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34005849|NCT06442410|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two study treatment groups:~* DTM™ SCS programming approach with Conventional Medical Management (CMM)~* CMM alone~There is an optional two-way crossover to the other treatment group available for all subjects who remain in the study at the 6-months visit."||||
34005850|NCT02056652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005851|NCT02063217|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005852|NCT00403949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005853|NCT05231369|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||If 25 ug dose is safe, then will proceed to enroll participants to receive 50 ug.||||
34005854|NCT04148105|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005855|NCT06212193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005856|NCT05672745|NA|SINGLE_GROUP||OTHER||NONE||||||
34091560|NCT04940221|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34091561|NCT06460129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091562|NCT03295916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091563|NCT01902069|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34091564|NCT00408954|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34091565|NCT02724436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091566|NCT05457543|||COHORT||CROSS_SECTIONAL|||||||
34091567|NCT04727788|||COHORT||PROSPECTIVE|||||||
34091568|NCT00261040|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34091569|NCT06047327|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091570|NCT05339074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091571|NCT00742677|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34091572|NCT05231967|||COHORT||PROSPECTIVE|||||||
34091573|NCT00340483||||TREATMENT||||||||
34005857|NCT03636087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is single blind since the patient will not be aware of what technique is being used. The study cannot be double blind because the dentist will need to identify the protocol to follow. Randomization by blocks (block size 4) will be performed by a statistician at Kings College Dental Institute.|f|f|f|t
33701421|NCT02875912|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective before and after intervention evaluation||||
33788061|NCT03525041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005858|NCT05260034|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the current study, participants and intervention trainers are unmasked to the treatment and know which group they are working on. Only the assessor will be masked to the groups of participants.||f|f|f|t
34005859|NCT01150006|||CASE_ONLY||CROSS_SECTIONAL|||||||
34091574|NCT03006679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701422|NCT01845142|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33701423|NCT02123342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33788062|NCT06388447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788063|NCT00704756|||CASE_ONLY|||||||||
34091575|NCT04056026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091576|NCT03603704|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Cohort 3 is open-label.||t|f|t|f
34091577|NCT03483103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091578|NCT00128427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091579|NCT01875237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091580|NCT05169905|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The interventional study model was planned to be crossover, but this is no longer applicable as there were no more study activities planned.||||
34091581|NCT03399344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will undergo an additional MRI, including a diffusion-weighted sequence, for assessing the extent of peritoneal carcinomatosis. Whether or not cytoreductive surgery is feasible will be scored using the peritoneal cancer index on diffusion-weighted magnetic resonance imaging||||
34091582|NCT02627807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091583|NCT03181555|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking. A convenience sample of pregnant AA women will be recruited based on race/ethnicity and body mass index.|||||
34091584|NCT04888104|||COHORT||PROSPECTIVE|||||||
34091585|NCT02984137|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34091586|NCT05883488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091587|NCT05580120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|They did not know if they were in the control and intervention group at the time of randomization.||t|f|f|f
34091588|NCT00867932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091589|NCT03339362|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Patients with persistent low back pain, referred to a community or hospital-based pain clinic by their general practitioner, will be reviewed and assessed by a pain physiotherapist and pain physician. They will be screened and recruited based on clinical history and examination. Participants will receive diagnostic injections (medial branch nerve blocks); those with a positive response will randomly receive either steroid FJIs or a sham procedure, under x-ray guidance.|t|f|f|t
34091590|NCT04640896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091591|NCT06478095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|surgeons were blinded to the patient group assignments.||f|t|f|f
34091592|NCT06354751|||OTHER||OTHER|||||||
33701424|NCT04736082|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34091593|NCT02772588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091594|NCT01800760|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701425|NCT01689636|NA|SINGLE_GROUP||OTHER||NONE||||||
33701426|NCT02758704|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33788064|NCT06343584|||COHORT||PROSPECTIVE|||||||
33788065|NCT03149406|||COHORT||PROSPECTIVE|||||||
33788066|NCT02197299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33788067|NCT04251351|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Prior to randomization, participants will be stratified into two groups: (i) Patients with no acute kidney injury (AKI) at enrolment, and (ii) Patients with AKI at enrolment. Both groups will be randomised into two arms:~Arm 1: Paracetamol 15 mg/kg/dose 6 hourly for 72 hours~Arm 2: Mechanical antipyresis"||||
34005860|NCT02289937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34005861|NCT00069030|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34091595|NCT05167539|||COHORT||PROSPECTIVE|||||||
33701427|NCT01080742|||COHORT||PROSPECTIVE|||||||
33701428|NCT03302650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701429|NCT00425347|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701430|NCT06155136|||COHORT||RETROSPECTIVE|||||||
33701431|NCT03024879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33701432|NCT04639700|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701433|NCT02326662|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33701434|NCT04732143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701435|NCT04120441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33701436|NCT05138107|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|blinded||t|t|t|f
33788068|NCT00028301||||TREATMENT||NONE||||||
33788069|NCT05513651|||COHORT||PROSPECTIVE|||||||
33788070|NCT04010643|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a two-group parallel-design randomised controlled trial comparing online cognitive behavioural therapy (oCBT) to oCBT enhanced with neurocognitive remediation for depression||||
33788071|NCT02205151|RANDOMIZED|CROSSOVER||||NONE||||||
34005862|NCT05531604|||CASE_CONTROL||PROSPECTIVE|||||||
34005863|NCT03627598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005864|NCT03011060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005865|NCT00005087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005866|NCT02462486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005867|NCT01082224|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005868|NCT03649425|||COHORT||PROSPECTIVE|||||||
34005869|NCT03762837|||COHORT||PROSPECTIVE|||||||
34005870|NCT03212287|||CASE_ONLY||PROSPECTIVE|||||||
34091596|NCT02984345|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34091597|NCT01952860|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701437|NCT04826523|||COHORT||PROSPECTIVE|||||||
33701438|NCT03093766|||COHORT||PROSPECTIVE|||||||
33701439|NCT05780684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788072|NCT04036162|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Right-handed healthy volunteers||||
33788073|NCT03872869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators did not know which group the patients had been assigned to.|After an advertisement in a local paper, over 300 volunteers applied to participate in the study. All 300 received information about the study by mail or telephone. One hundred volunteers fulfilled the inclusion criteria: X-ray-verified hip OA, 40-75 years of age, no walking aid and no joint replacements in the hips or knees. Each individual had to specify at which hospital and when they had been X-rayed and/or received their diagnosis. A total of 89 subjects attended the baseline appointment and were randomized to one of the three groups. The randomization procedure, in blocks of 15, was generated by a computer-based system|f|f|t|f
33701440|NCT02284516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005871|NCT05138926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005872|NCT01706263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701441|NCT05807230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788074|NCT04794296|||COHORT||PROSPECTIVE|||||||
33701442|NCT02677064|||COHORT||PROSPECTIVE|||||||
33701443|NCT04935281|||CASE_CONTROL||PROSPECTIVE|||||||
33701444|NCT02168127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701445|NCT00770939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701446|NCT04227873|||COHORT||PROSPECTIVE|||||||
33701447|NCT03558087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788075|NCT02966743|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33788076|NCT01367912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33788077|NCT04616365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788078|NCT01512966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788079|NCT06630377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788080|NCT02387749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788081|NCT05825079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788082|NCT02714803|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33788083|NCT02028130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788084|NCT05478772|NA|SINGLE_GROUP||OTHER||NONE||||||
33788085|NCT06225999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788086|NCT04672473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788087|NCT00819884|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33788088|NCT05502211|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33788089|NCT05954169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-dose, open||||
33788090|NCT02480335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788091|NCT03515720|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33788092|NCT01192256|||COHORT||PROSPECTIVE|||||||
33788093|NCT00658060|||COHORT||CROSS_SECTIONAL|||||||
33788094|NCT00184561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788095|NCT06028113|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will not be notified of group status or details of participants.|This is a Phase 2 pragmatic pilot and feasibility randomized controlled trial (RCT) of an obesity prevention intervention compared to usual pediatric care with 144 mother-infant dyads randomized n=72 per arm. Consistent with the definition of a pilot and feasibility clinical trial, our aims are to assess trial protocol feasibility based on THRIVE 2.0 and obtain effect sizes to inform the design of a Phase 3 multi-site efficacy trial.|f|f|f|t
33788096|NCT04767230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34005873|NCT05909969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be a Pretest-Postest Design with parallel assignment of patients into two groups.|f|f|f|t
34005874|NCT04904445|||COHORT||PROSPECTIVE|||||||
34005875|NCT00476437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005876|NCT04299776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34005877|NCT06207669|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005878|NCT03107130|||COHORT||RETROSPECTIVE|||||||
34005879|NCT02991352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005880|NCT00260689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005881|NCT04533906|NA|SINGLE_GROUP||TREATMENT||NONE||The saliva of subjects will be collected before and during sucking a Coldamaris lozenge.||||
34091598|NCT04572035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005882|NCT05783037|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A decentralized, randomized, controlled trial of healthy term breastfed and formula-fed infants for 16 weeks|t|t|t|t
34005883|NCT06204016|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34005884|NCT06679361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will employ single masking, where participants will be unaware of their specific group assignment (motor, sensory, or combined motor-sensory exercise groups) to minimize bias. Researchers will know the group assignments to ensure correct administration of interventions, but participants will remain blinded to the type of intervention they receive.|Participants in this study will be randomized into three parallel groups to assess the effects of motor, sensory, and combined motor-sensory exercises on hand function. Each group will receive a specific intervention type (motor, sensory, or combined exercises), and outcomes such as muscle reaction time and hand dexterity will be measured pre- and post-intervention for both dominant and non-dominant hands.|t|f|f|f
34091599|NCT01750437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091600|NCT00784875|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34091601|NCT06229938|||COHORT||PROSPECTIVE|||||||
34091602|NCT02401230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091603|NCT02257151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091604|NCT05134818|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel assignment, not blinded, randomized study||||
34091605|NCT02597114|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34091606|NCT05478590|||COHORT||RETROSPECTIVE|||||||
34091607|NCT00590473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091608|NCT00683995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091609|NCT03394573|||COHORT||PROSPECTIVE|||||||
34091610|NCT01017497|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091611|NCT02413268|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34091612|NCT01754428|||CASE_ONLY||PROSPECTIVE|||||||
34091613|NCT05877105|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||certain VAP bundle as an evidence-based practice will be implemented as the intervention also the needed related nursing education will be given to ensure that the intervention will be implemented properly, and we will examine its effect on VAP incidence and severity among the intervention group as a dependent variable; then, we will compare the finding against the comparative no intervention group who receives the traditional care. Two arms (intervention and non-intervention comparative groups)||||
34091614|NCT00886457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091615|NCT06153550|||COHORT||PROSPECTIVE|||||||
34091616|NCT00979511|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34091617|NCT01055912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091618|NCT04770974|||COHORT||PROSPECTIVE|||||||
34091619|NCT06026306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be blinded to their study arm because of the nature of the intervention, but outcome assessors will be blinded.||f|f|f|t
33701448|NCT01272973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701449|NCT01102270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33701450|NCT00487604|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33701451|NCT03862560|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701452|NCT04590131|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized, open-label, pilot study||||
33701453|NCT01669265|||COHORT||RETROSPECTIVE|||||||
33701454|NCT06217380|NA|SINGLE_GROUP||OTHER||NONE||||||
33701455|NCT03867344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33701456|NCT05727436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The allocation concealment will be performed by the use of sealed containers numbered by a third party (person, who will not participate in the study). The tablets in the bottles without any titles will be placed in the containers. The tablets in different groups will look similar. The patient on enrollment will receive a container with tablets. Each patient will receive a sealed container with tablets on enrollment. Neither patients nor researchers will be aware of the type of a tablets received by each patient (double blinding)."|Parallel Assignment double-blind, randomized, two-arm parallel-group study|t|t|t|t
33701457|NCT03381131|||CASE_ONLY||CROSS_SECTIONAL|||||||
33701458|NCT00004635|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33701459|NCT04932993|RANDOMIZED|PARALLEL||TREATMENT||NONE||All new, adult (18+ years old) patients seeing an orthopedic surgeon for a consultation will be invited to participate in this study. Patients randomly will be assigned to: write down goals their goals for their medical care (intervention) or not (usual visit control group). The research assistant will ask the patient to fill out a survey entailing demographics, JSPPE, the communication effectiveness score, the PAM score and a satisfaction scale at the end of the visit. A research assistant will record the diagnosis,||||
33701460|NCT01468675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701461|NCT01263977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701462|NCT00685542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701463|NCT05783375|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33701464|NCT00549380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701465|NCT05582239|||COHORT||PROSPECTIVE|||||||
33788097|NCT02175212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005885|NCT04055545|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34005886|NCT02722616|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005887|NCT02574338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091620|NCT02281877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091621|NCT03720847|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Identical placebos provided by the UNC investigational drug service.|Crossover 2-Condition Placebo-Controlled Trial|t|f|t|t
34091622|NCT00355641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091623|NCT01475773|||||PROSPECTIVE|||||||
34091624|NCT01127360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091625|NCT02232698|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34091626|NCT04691934|||COHORT||RETROSPECTIVE|||||||
34091627|NCT02568423|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091628|NCT02190058|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34091629|NCT02891330|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34091630|NCT02957448|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701466|NCT05904912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant will be blinded to the study|Sixty patients aged 20-95 years old with American Society of Anesthesiologists (ASA) classification I-IV and scheduled for TAVI will be included in the study. Patients will be randomly divided into two groups (Group PENG = PENG block group, Group Control = local infiltration group) including 30 patients each, before entering the operating room.|t|f|f|t
33701467|NCT06259123|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-center phase II study||||
33701468|NCT05664074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This will be a prospective study where patients will be randomized into either rectal indomethacin or IV ketorolac.|t|f|f|f
34005888|NCT05373641|RANDOMIZED|PARALLEL||OTHER||SINGLE||Units serve as a statistical units. Number of units 30, number of individual participants 800-1000.|t|f|f|f
34005889|NCT02389842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005890|NCT00076245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34005891|NCT05722028|||COHORT||PROSPECTIVE|||||||
34005892|NCT02010996|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34005893|NCT06157463|||COHORT||PROSPECTIVE|||||||
34005894|NCT02119962||||TREATMENT||||||||
34005895|NCT04025294|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34005896|NCT02116894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005897|NCT00117117|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701469|NCT04594343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In order to minimize bias due to key baseline characteristics that can impact clinical outcomes, the randomization will be stratified 1:1 to placebo or active product based on age and comorbidities.|"Subjects will be randomized to receive either the active product (disulfiram) or placebo.~Disulfiram will be dosed 500 mg daily for a total of 14 days of treatment. A matching placebo will be given using the same dosing schedule."|t|t|t|t
34005898|NCT05939804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34005899|NCT05054049|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patient is randomised to control or intervention arm after consent obtained.|Single site feasibility study|t|f|f|f
34005900|NCT06471478|||OTHER||RETROSPECTIVE|||||||
34005901|NCT04366596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients are randomly allocated into intervention and control group. The investigator and outcomes assessor only kwow the random number. The participants will not be told the exact group that they were allocated.|intervention group: treated with drug eluting balloon control group :treated with plain old balloon|t|f|t|t
34005902|NCT04861740|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We propose a pilot clustered interventional trial with two arms. Clinics in the intervention arm (Screening + Autism ALERT) receive Autism ALERT plus an ASD screening intervention, and clinics in the comparison intervention arm (Screening Only) receive the ASD screening intervention only (START Autism). As this is a pilot trial, primary outcomes of interest are feasibility and acceptability. We will additionally assess mechanism of outcome, preliminary efficacy, and protocol fidelity. Feasibility and acceptability will be assessed in intervention clinics. Mechanism of action and preliminary efficacy will be assessed by comparing intervention to control clinics. Fidelity is assessed in both arms. We will pilot test Autism ALERT in 6 safety-net primary care clinics in Oregon.||||
34005903|NCT01362673|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34005904|NCT02748655|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34005905|NCT02618382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005906|NCT02249117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34005907|NCT04459130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|participants do not know they are in the experimental or control group|Child Obesity Program (COP), The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.The research was determined as randomized controlled pretest-posttest control group design type.|t|f|f|f
34005908|NCT05550831|NA|SINGLE_GROUP||TREATMENT||NONE||"Performing a radiofrequency procedure prior to the removal of morton's neuroma. This procedure would be performed to check in which percentage of the nerve ablation has been performed, and whether the current protocol is performed correctly or parts of the nerve remain intact.~* Step 1: Visualize the needle on the long axis of the probe.~* Step 2: Neurostimulate~* Step 3: Deposit of 1-2cc of anesthetic and wait about 2 minutes.~* Step 4: we apply the continuous radiofrequency at that point and once done we change the position of the needle to more dorsal planes anatomically and we made 2 more applications (in this case we will no longer have neurostimulation because the patient will be anesthetized)."||||
34005909|NCT02968719|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
34005910|NCT01185860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34005911|NCT04284553|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34005912|NCT03934996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher will not know who belongs to each group||f|f|t|f
34005913|NCT00109850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005914|NCT05595122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005915|NCT00622687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005916|NCT02270034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005917|NCT00261417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34005918|NCT06317389|||COHORT||PROSPECTIVE|||||||
34005919|NCT01662934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34005920|NCT04917627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005921|NCT00587431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005922|NCT00401154|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34005923|NCT06358001|||COHORT||PROSPECTIVE|||||||
34005924|NCT00732160|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34005925|NCT06611150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005926|NCT01182519|||COHORT||PROSPECTIVE|||||||
34005927|NCT05614219|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Step wedge cluster randomized controlled trial.||||
34005928|NCT04849364|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005929|NCT05157048|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants will be blinded to both the marketing and cigarette condition manipulations|Single-session study utilizing a 2 x 2 mixed factorial design|t|f|f|f
34005930|NCT00999934|||COHORT||PROSPECTIVE|||||||
34005931|NCT02096822|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091631|NCT04999969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005932|NCT02083172|||COHORT||PROSPECTIVE|||||||
34005933|NCT06390566|||COHORT||PROSPECTIVE|||||||
34005934|NCT00209547|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33701470|NCT00281307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005935|NCT01632163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34005936|NCT03988101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Researchers, research coordinators, and subjects are all blind.|A prospective placebo-controlled, double-blind, phase IV clinical study to evaluate the efficacy and safety of statin in patient with venous dysfunction|t|t|t|f
34005937|NCT05676983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33701471|NCT03866954|NA|SEQUENTIAL||TREATMENT||NONE||"This will be a multi-centre, multiple dose, open label study to investigate the safety, tolerability, PD, and efficacy of EE TP in patients with MNGIE. The study will be conducted in an open label manner with all patients receiving EE TP.~The study will enrol 12 adult treatment naïve patients with MNGIE, aged 18 years or older at Screening. With IDMC approval, a further four juvenile patients (aged 16-17) will be recruited after at least 24 patient-months exposure to treatment. With IDMC approval, a further four juvenile patients (aged 12-15) will be recruited after at least 24 patient-months exposure to treatment in the 16-17 year old patient group."||||
33701472|NCT04789499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The pharmacy will maintain the blind until the completion of the study.||t|f|t|f
33701473|NCT01497457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701474|NCT00503295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701475|NCT03592056|||CASE_ONLY||PROSPECTIVE|||||||
33701476|NCT02037022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701477|NCT05952817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|children with Blood diseases|control group,i ntervention group|t|f|f|f
33701478|NCT00398788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701479|NCT04771312|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33701480|NCT03127046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33701481|NCT00076843||||TREATMENT||||||||
33701482|NCT02819739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701483|NCT03519555|||COHORT||PROSPECTIVE|||||||
33701484|NCT03094403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects in this randomized, double-blind, placebo controlled, parallel-group, multiple-center study will be randomly assigned in a 2:2:1 ratio to treatment with the test product, reference product or placebo control, respectively|t|f|f|f
33701485|NCT04177121|||COHORT||PROSPECTIVE|||||||
33701486|NCT01549678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701487|NCT05097612|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701488|NCT00000337||||TREATMENT||||||||
33701489|NCT01809730|||COHORT||PROSPECTIVE|||||||
33701490|NCT04112407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701491|NCT01033812|||COHORT||CROSS_SECTIONAL|||||||
33701492|NCT02583282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33701493|NCT01228864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701494|NCT05969808|RANDOMIZED|PARALLEL||OTHER||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment|Randomized control trial will be conducted with sample size 30, used to compare the effectiveness of adaptive physical activity on visual motor integration in children with developmental delay. subjects with developmental delay meeting the predetermined inclusion and exclusion criteria will be divided into two groups using non-probability convenient sampling. pre and post assessment will be done by Box and Block Test, Box and Ball Test, Discrete horizontal finger tapping test, Discrete vertical finger tapping with ball and continuous Vertical tapping with ball. subjects in group A will receive Baseline therapy and conventional therapy and group B will receive baseline therapy and adaptive physical activity.|t|f|f|f
33927332|NCT04208217|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Modeling to Learn: Modeling to Learn is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.~Usual Quality Improvement: Usual quality improvement is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.~Anticipate that 720 frontline providers will participate across both arms of this trial. There will be no interaction with current patients for the purposes of research. No new data will be collected beyond data generated during routine care."||||
33927333|NCT00450489|||COHORT||RETROSPECTIVE|||||||
33927334|NCT04423757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33927335|NCT00198458|NA|SINGLE_GROUP||||NONE||||||
33927336|NCT03254862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927337|NCT05316493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled participants will receive enhanced lifestyle management to control weight and take LNG-IUS or Megestrol Acetate (MA) for treating EAH||||
33927338|NCT00424346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927339|NCT02846857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927340|NCT01431651|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33927341|NCT05812768|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects meeting all inclusion/exclusion criteria and scheduled for an EVAR procedure.||||
33927342|NCT03010722|||COHORT||PROSPECTIVE|||||||
33927343|NCT00720824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927344|NCT00640276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927345|NCT00035477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927346|NCT05750888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33927347|NCT01146951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927348|NCT04089436|||COHORT||PROSPECTIVE|||||||
34005938|NCT05140317|||COHORT||PROSPECTIVE|||||||
34005939|NCT02447887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005940|NCT05183087|||COHORT||PROSPECTIVE|||||||
34005941|NCT02951195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34005942|NCT04569058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091632|NCT01044667|NA|SINGLE_GROUP||OTHER||NONE||||||
33788098|NCT03384537|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A third party will perform the allocation sequence and assign the participants to rinsing agent in sequentially numbered opaque envelop.|"The participants in this study will be randomly divided into two groups according to the application of the mouth rinse agent (M); the first group M1) The participants will use Tropolone containing as a mouth rinse, the second group (M2) The participants will use chlorhexidine 0.2% as a mouth rinse.~Then each participant will be monitoring at the base line T0: before using any mouthwash, T1: immedially after using tested mouthwash, T2: after one week and finally, T3: after two weeks of using the tested mouthwash.~Each participant will be the reference/counted for self as a record."|f|f|f|t
34005943|NCT03722862|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|fiber is provided in pouches; coded to treatment|3 arm crossover, randomized|t|f|t|f
34005944|NCT04155827|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701495|NCT05235048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Independent outcome assessor|This will be a parallel group, standard of care-controlled, assessor-blind, randomized, multicenter, superiority clinical trial|t|f|f|t
33701496|NCT04687384|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33701497|NCT03450538|||COHORT||PROSPECTIVE|||||||
33701498|NCT04730687|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33701499|NCT01172522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701500|NCT01953107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33701501|NCT05004714|||COHORT||PROSPECTIVE|||||||
34005945|NCT00179673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788099|NCT00545324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701502|NCT03924635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701503|NCT00446862|||CASE_CONTROL||PROSPECTIVE|||||||
33701504|NCT05379777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701505|NCT03030807|||COHORT||PROSPECTIVE|||||||
33788100|NCT06421181|||COHORT||PROSPECTIVE|||||||
33788101|NCT00851942|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788102|NCT06454773|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Bioactive extract vs placebo|double-blind placebo controlled|t|f|t|f
33788103|NCT00019318||||TREATMENT||||||||
33788104|NCT03296371|||FAMILY_BASED||PROSPECTIVE|||||||
33788105|NCT01450878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788106|NCT06627439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788107|NCT01710514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788108|NCT03526081|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Investigator doing data analysis and statistical analyses|Cross-over dietary intervention study in healthy young adult males|f|f|t|f
33788109|NCT06630923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788110|NCT04768920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788111|NCT00271258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788112|NCT01253499|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34005946|NCT02805309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788113|NCT05178758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessor will assess participants' outcomes after they complete the rehabilitation training. The assessor does not know who is undergoing the VR (intervention) or non-VR (control) rehabilitation training||f|f|f|t
34005947|NCT01942447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788114|NCT05794373|||CASE_CONTROL||PROSPECTIVE|||||||
33788115|NCT06630780|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II trial||||
33788116|NCT04742751|NA|SINGLE_GROUP||TREATMENT||NONE|The schema was changed the to an adaptive trial design with a 12 week lifestyle run-in followed by a combined metformin+lifestyle intervention for 12 weeks|||||
33788117|NCT03132324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788118|NCT03964285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788119|NCT06630104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34005948|NCT03730740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005949|NCT02690051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005950|NCT04993131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005951|NCT02809768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005952|NCT05934357|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34005953|NCT04429542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005954|NCT04674709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple: Triple (Participant, Care provider, Investigator)|This is a randomized, double-blind, placebo-controlled Phase I study that will investigate the safety and efficacy of OLEANDER 4X HPUS in Healthy Volunteers.|t|t|t|f
34005955|NCT01040793|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34005956|NCT05751876|||COHORT||RETROSPECTIVE|||||||
34005957|NCT02769650|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005958|NCT06458257|||COHORT||PROSPECTIVE|||||||
34005959|NCT05017649|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34005960|NCT05746052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005961|NCT06461377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005962|NCT04982367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005963|NCT00487331|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34091633|NCT02326883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33701506|NCT01346579|||CASE_ONLY||RETROSPECTIVE|||||||
34091634|NCT00492869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091635|NCT05279079|||OTHER||PROSPECTIVE|||||||
34091636|NCT01400048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091637|NCT06425614|RANDOMIZED|PARALLEL||OTHER||SINGLE||Multicentre clinical trial, Randomized, Comparative, controlled, single blinded, superiority design, two groups.|t|f|f|f
34091638|NCT04575012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701507|NCT01517620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701508|NCT04805177|NA|SINGLE_GROUP||TREATMENT||NONE||single arm pilot study||||
33701509|NCT05554588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701510|NCT04745884|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33701511|NCT01570166|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33701512|NCT00500383|||CASE_CONTROL||PROSPECTIVE|||||||
33701513|NCT02903641|RANDOMIZED|FACTORIAL||PREVENTION||||||||
33701514|NCT02451111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701515|NCT00239590|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Pharmacy dispensing of study medication that was randomized by supplier||t|t|t|t
33701516|NCT00216710|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33701517|NCT06556420|||COHORT||PROSPECTIVE|||||||
33701518|NCT00654121||PARALLEL||PREVENTION||NONE||||||
33701519|NCT00607984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701520|NCT06068023|||CASE_CONTROL||PROSPECTIVE|||||||
33701521|NCT00261456|||CASE_CONTROL||PROSPECTIVE|||||||
33701522|NCT06362070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701523|NCT05824988|||COHORT||PROSPECTIVE|||||||
33701524|NCT00808626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701525|NCT05894226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701526|NCT00867620|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788120|NCT01701154|||COHORT||PROSPECTIVE|||||||
33788121|NCT02735915|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788122|NCT04784013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788123|NCT05266365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34005964|NCT05665517|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"At the first meeting, the participants completed the pre-test of the CKD patient's simple health literacy evaluation and were invited to use the Chatbot Little K Nurse, which was an intervention of CKD chat-based instant messaging support health education system.~After the first week, the first System Usability Scale (SUS) measurement was completed, whereas the second SUS measurement was completed in the fourth week. After completing the intervention in the 12th week, the participant's health literacy was reassessed through a post-test, and the third SUS assessment was performed."||||
33788124|NCT02687646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788125|NCT02325050|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34005965|NCT02653729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34005966|NCT04979858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The PI will not know which subjects have been assigned to which arm.|One group will receive the focal mask and the other group will choose its own mask.|f|f|t|f
33788126|NCT05788224|||COHORT||PROSPECTIVE|||||||
33788127|NCT00359619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788128|NCT05141890|NA|SINGLE_GROUP||OTHER||NONE||||||
33788129|NCT03094104|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
34005967|NCT03843515|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Phase I safety and feasibility study with additional pilot biomarker assessments||||
34005968|NCT05840276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34005969|NCT02310763|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34005970|NCT06210204|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34005971|NCT00350987|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34005972|NCT06166758|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701527|NCT06421116|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701528|NCT02210923|||COHORT||PROSPECTIVE|||||||
33701529|NCT04478981|||COHORT||PROSPECTIVE|||||||
33701530|NCT02846324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33701531|NCT04763785|||COHORT||PROSPECTIVE|||||||
33701532|NCT00418639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33701533|NCT06189690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788130|NCT06631612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005973|NCT05057793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34005974|NCT00469053|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34005975|NCT00225563|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study model used pre-post design of 15 providers who adopted e-prescribing with concurrent controls of 15 paper-based providers from September 2005 through June 2007.||||
34005976|NCT01947686|||CASE_ONLY||RETROSPECTIVE|||||||
34005977|NCT02349074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005978|NCT01339377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005979|NCT05074407|||OTHER||PROSPECTIVE|||||||
34005980|NCT03779568|NA|SINGLE_GROUP||OTHER||NONE||||||
34005981|NCT02157363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701534|NCT00677482|||COHORT||PROSPECTIVE|||||||
33701535|NCT05952934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each study site will received a separate randomization scheme, and the research pharmacy at each site will implement and maintain randomization schedule.|This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin.|t|t|t|f
33701536|NCT00731068|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33701537|NCT03967301|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33701538|NCT00689325|||||PROSPECTIVE|||||||
33701539|NCT03566862|||COHORT||CROSS_SECTIONAL|||||||
33701540|NCT04213729|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701541|NCT01521546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701542|NCT03623841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701543|NCT01748266|||COHORT||PROSPECTIVE|||||||
33701544|NCT04403360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788131|NCT05019781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788132|NCT04802824|||COHORT||PROSPECTIVE|||||||
33788133|NCT02989662|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33788134|NCT03601507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788135|NCT05148572|||COHORT||PROSPECTIVE|||||||
33788136|NCT02358187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788137|NCT04416139|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Mesenchymal Stem Cell from umbilical cord allogenic from de bank laboratory, will be applied IV to 5 patients con pneumonia bilateral due to COVID 19, complicated with acute respiratory distress syndrome. The clinical, biochemical, inflammatory and immune changes will be described and compare against historical cases treated in the Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán||||
34005982|NCT06348524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34005983|NCT00402519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005984|NCT04053673|NA|SEQUENTIAL||TREATMENT||NONE||Dose Expansion||||
34005985|NCT03801317|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34005986|NCT01812629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005987|NCT00952224|||COHORT||PROSPECTIVE|||||||
34005988|NCT03255434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005989|NCT05750706|||CASE_ONLY||PROSPECTIVE|||||||
34005990|NCT03883555|||COHORT||PROSPECTIVE|||||||
34005991|NCT02710253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34005992|NCT03684889|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34005993|NCT01142661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701545|NCT04641858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to treatment. The physicians administering the BCG vaccine or placebo will not be blinded. Those assessing outcomes will be blinded to the randomization allocation. In case of serious adverse events, the participant can be unblinded after consultation with the coordinating PI or sponsor.|Multi-center randomized placebo-controlled trial|t|f|f|t
33701546|NCT05508711|||OTHER||PROSPECTIVE|||||||
33701547|NCT00764296|||COHORT||PROSPECTIVE|||||||
33701548|NCT02285647|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33701549|NCT05968456|||COHORT||PROSPECTIVE|||||||
33701550|NCT03611491|NA|SINGLE_GROUP||OTHER||NONE||||||
34005994|NCT04542707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The treating clinician will not be aware off the brainwave and pupilometry data|This experiment will be cross sectional study. Convenience sampling technique asymptomatic healthy subjects|f|f|t|t
34005995|NCT06079255|||COHORT||PROSPECTIVE|||||||
34005996|NCT01058798|||COHORT||RETROSPECTIVE|||||||
34005997|NCT00503113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34005998|NCT06252207|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Patients will not be told which type of volatile anesthetic they received.|Randomized cluster cross-over trial|t|f|f|f
34005999|NCT04593394|||CASE_CONTROL||PROSPECTIVE|||||||
34006000|NCT05602779|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There will be four distinct treatment groups, each participant will be randomly assigned to one of the four groups.|t|f|f|f
34006001|NCT03437057|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34006002|NCT05240092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006003|NCT03934827|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Part A: open Label; Part B: double blinded|20 participants will receive open label MRx0518 in an initial preliminary safety phase. A further 100 participant will then receive MRx0518/Placebo in a 4:1 ratio in a double blinded randomised phase.|t|f|t|f
34006004|NCT00387517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34006005|NCT04266431|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The randomization scheme will be generated by the senior biostatistician, and access will be restricted for the duration of the trial. The participants and interventionists will not be blinded to study arm. The study staff involved in data collection, staff involved in laboratory measurements, and the biostatistician conducting the data analysis will be blinded to the random assignment.|Eligible consented men will be stratified for randomization according to prostate specific antigen doubling time (PSADT; \<6 months or 6-12 months) calculated using 3 values (≥1 week apart; ≤ 3 months from randomization; Memorial Sloan Kettering Cancer Center prediction tool: http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx), and body mass index (BMI) at baseline (25 kg/m2 ≤BMI \<30 kg/m2 or BMI≥ 30 kg/m2). Following stratification, men will be randomized 1:1 using a computer-generated, password protected randomization enrollment system by the biostatistician. Men will be informed of the random assignment after consenting to the study and completing the baseline questionnaires and blood collection. Study visits will take place at 6 months, 12 months, and 24 months after baseline.|f|f|f|t
34006006|NCT06083987|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||96 participants randomly assigned to one of the 16 combinations of the four study intervention principles|f|f|f|t
34006007|NCT03655288|||OTHER||PROSPECTIVE|||||||
34006008|NCT01311427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006009|NCT01518335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34006010|NCT05312476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006011|NCT06351696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006012|NCT04522804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006013|NCT05098132|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34006014|NCT01745198|||CASE_CONTROL||RETROSPECTIVE|||||||
34006015|NCT06677645|||OTHER||PROSPECTIVE|||||||
34006016|NCT05827640|||COHORT||PROSPECTIVE|||||||
34006017|NCT03699033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006018|NCT00648245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006019|NCT00314782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006020|NCT02094261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006021|NCT00865449|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006022|NCT00190450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006023|NCT00166452|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34006024|NCT05290233|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|blood sample analysis will be blinded|A 12-week randomized, parallel-arm pilot trial will compare the effects of 1) TRE combined with resistance training (TRE-RT) to 2) TRE combined with aerobic training (TRE-AT) in older adults with overweight or obesity and pre-diabetes|f|f|f|t
34006025|NCT00004188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701551|NCT05619250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701552|NCT01050283|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701553|NCT02829060|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701554|NCT04539353|||CASE_ONLY||CROSS_SECTIONAL|||||||
33701555|NCT02998983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701556|NCT00805246|||COHORT||OTHER|||||||
33701557|NCT03944031|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701558|NCT05667987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701559|NCT06288139|||CASE_ONLY||PROSPECTIVE|||||||
33701560|NCT02762578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788138|NCT00017004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788139|NCT05223192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33788140|NCT02192034|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|f|t|t
33701561|NCT03254979|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Since the new program is an optimization of the type-2 diabetes prevention services already offered in Osakidetza, it is expected that the participating patients will be blind to group allocation.|The implementation strategy to facilitate the adoption of the recommended clinical intervention in primary prevention of T2DM will be common to both comparison groups. In order to differentiate and isolate the effect of the procedure of creation of the Multi-professional Community of Practice, the centers have been randomly assigned to two comparison groups: 5 centers assigned to the sequential procedure and the other 4 centers to the group procedure.|t|f|f|t
33701562|NCT05652881|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Cytokine analysis and radiographic assessment will be performed by a blinded assessor.|Parallel randomized controlled trial|f|f|f|t
33701563|NCT00875979|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701564|NCT03549169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research assistant (nurse trained in the measurement instruments) applies the instruments that allow the evaluation of the outcomes of interest: self-care, quality of life regarding health and follow up of clinical events: emergency attention, hospitalization, death by HF.|The participants are assigned to two groups during the duration of the study. A group receives the standard attention and the intervention protocol and the other group only the standard attention.|f|f|f|t
33701565|NCT00003870||||TREATMENT||||||||
33701566|NCT05679778|||OTHER||CROSS_SECTIONAL|||||||
33701567|NCT03400566|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33701568|NCT05645354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701569|NCT01573260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701570|NCT06126926|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Random assignment clinical trial. Participants are randomly assigned to the intervention group or treatment as usual.||||
33701571|NCT06364475|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||One group 16:8 time-restricted intermittent fasting and the other group energy-restricted six-meal eating. Both of groups with an eating plan suitable with their groups and 400 kcal lower than the total daily energy requirement and with similar macronutrient content (50% carbohydrates, 25% fat and 25% protein).||||
33701572|NCT01539083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701573|NCT01784848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701574|NCT05997550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33701575|NCT04040205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091639|NCT03520010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091640|NCT00477022|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34091641|NCT03318068|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a feasibility study to determine if a yoga intervention can be delivered via to outpatients receiving chemotherapy.||||
34091642|NCT05658991|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34091643|NCT00985374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091644|NCT05391152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701576|NCT04198116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701577|NCT02370381|||COHORT||PROSPECTIVE|||||||
33701578|NCT05000723|||COHORT||PROSPECTIVE|||||||
33701579|NCT02436304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33701580|NCT02122458|RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary study was diagnostic, with a goal of better understanding and determining the best diagnostic assessment battery for capturing the hearing and auditory problems reported by blast-exposed Veterans. The secondary purpose was to implement a preliminary treatment study to determine if blast-exposed Veterans with hearing complaints, but normal audiometric data benefited from low-gain hearing aids. This secondary treatment study is the clinical trial portion of this study.||||
33701581|NCT02264431|||COHORT||PROSPECTIVE|||||||
33701582|NCT05248737|||CASE_CROSSOVER||PROSPECTIVE|||||||
33701583|NCT03096483|NA|SINGLE_GROUP||OTHER||NONE||||||
33701584|NCT06025825|||COHORT||PROSPECTIVE|||||||
33701585|NCT03231657|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33701586|NCT02016573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701587|NCT00978770||||DIAGNOSTIC||||||||
33701588|NCT00605163|||COHORT|||||||||
33701589|NCT04198597|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701590|NCT05823532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33701591|NCT02882412|||COHORT||PROSPECTIVE|||||||
33788141|NCT03052946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Bulking agents|t|f|t|f
33788142|NCT05737784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|No masking in the 2 open-label parts, masking as indicated in the 2 double-blind, randomized parts.|Seamless study design with sequential study parts, including an open-label safety part; a double-blind, randomized dose-escalation part; a double-blind, randomized confirmatory part; and an open-label extension part.|t|t|t|t
33788143|NCT01553513|||COHORT||PROSPECTIVE|||||||
33701592|NCT03106350|||CASE_CONTROL||PROSPECTIVE|||||||
33701593|NCT04213417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701594|NCT04786938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 72 H. pylori-positive patients were enrolled, and they were randomly assigned to group conventional (A) and group conventional plus S. boulardi (B). Patients in group A received 14-day triple therapy consisting of amoxicillin 1 g three times a day, tinidazole 1 g once a day, and omeprazole 40 mg twice a day. Patients in group B received triple therapy supplemented with S. boulardii CNCM I-745 (approximately 22.5 x 10\^9 CFU) for 14 days.|t|f|f|f
33788144|NCT03113487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927349|NCT05885048|||COHORT||PROSPECTIVE|||||||
33927350|NCT06120959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927351|NCT00833807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927352|NCT04432740|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33927353|NCT00241878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927354|NCT02171819|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33927355|NCT05448989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927356|NCT03064347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33927357|NCT02988219|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33927358|NCT04382469|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33927359|NCT02314871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006026|NCT05988424|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"The patient will not be aware which mapping catheter they are randomised to have used in their case first.~The data will be processed for analysis blinded to the catheter used to collect the map"|Crossover from one mapping catheter to the other with randomisation as to which catheter is used first|t|f|f|t
33788145|NCT06279819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34006027|NCT00136890|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006028|NCT04100096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006029|NCT05443919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788146|NCT01715909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788147|NCT00145002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788148|NCT04518930|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33788149|NCT05060679|||COHORT||PROSPECTIVE|||||||
34006030|NCT02508259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006031|NCT05829967|||OTHER||PROSPECTIVE|||||||
34006032|NCT04593147|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants.|Formula feed infants will be randomized to receive either a new infant formula formulated for healthy term infants (BBN) or a commercially available infant formula for healthy term infants (Brand). Infants will consume the formula for a total of 16-weeks.|t|t|t|t
34006033|NCT01324856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006034|NCT05530941|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006035|NCT00351286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34006036|NCT00630578|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34006037|NCT05486299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006038|NCT04264819|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label study||||
34006039|NCT06165692|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34006040|NCT04015531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiation toxicity will be analysed by a blind second investigator.||f|f|f|t
34006041|NCT00779220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006042|NCT02452879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006043|NCT03554317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006044|NCT04458961|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants and trial personnel will not be possible due to the nature of the intervention|||||
34006045|NCT03269734|||CASE_ONLY||CROSS_SECTIONAL|||||||
34006046|NCT05693831|||COHORT||PROSPECTIVE|||||||
34091645|NCT02990962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091646|NCT04549441|||CASE_CONTROL||PROSPECTIVE|||||||
34091647|NCT04301284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091648|NCT01182363|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34091649|NCT04490356|NA|SINGLE_GROUP||OTHER||NONE||||||
34091650|NCT03362320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091651|NCT04714671|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34091652|NCT02811107|||COHORT||PROSPECTIVE|||||||
34091653|NCT03510000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091654|NCT02703363|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34091655|NCT02323334|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34091656|NCT00764517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788150|NCT00717743|||CASE_ONLY||PROSPECTIVE|||||||
33788151|NCT06629545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788152|NCT02338739|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788153|NCT03674190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788154|NCT04973852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788155|NCT00378677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788156|NCT04304534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006047|NCT04226131|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"15 participants with early RA defined as duration of disease/symptoms of less than 6 months (where duration denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic DMARD therapy and 15 age-, sex-, and BMI-matched controls"||||
34091657|NCT03719664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091658|NCT06364527|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34091659|NCT04453995|||COHORT||PROSPECTIVE|||||||
34091660|NCT02342730|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34091661|NCT06390215|NA|SINGLE_GROUP||OTHER||NONE||||||
34091662|NCT00627978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091663|NCT02133963|||CASE_CONTROL||PROSPECTIVE|||||||
34091664|NCT05814835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091665|NCT06532773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091666|NCT02187055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091667|NCT05233176|||COHORT||PROSPECTIVE|||||||
33788157|NCT04371926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Symptomatic patients will be randomized to hydroxychloroquine (HCQ) vs no-HCQ group.~Similarly, hospital staff with high risk of exposure will be randomized to HCQ vs no-HCQ group"|f|f|t|f
33788158|NCT06101030|||CASE_CONTROL||PROSPECTIVE|||||||
33788159|NCT02057354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788160|NCT04406168|||COHORT||RETROSPECTIVE|||||||
33788161|NCT02930278|||COHORT||PROSPECTIVE|||||||
33788162|NCT04985487|||COHORT||PROSPECTIVE|||||||
33788163|NCT02873676|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33788164|NCT04008420|||OTHER||PROSPECTIVE|||||||
33788165|NCT03967925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006048|NCT01405274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091668|NCT02847767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103226|NCT00236795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103227|NCT02144246|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34103228|NCT06689176|NA|SINGLE_GROUP||TREATMENT||NONE||This is single center, open-label study where the participants will be identified from the principal investigator and sub-investigator's clinic. All the participants who meet the study criteria and sign the consent form will be assigned to the study intervention.||||
33701595|NCT01138774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33701596|NCT00004488|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33701597|NCT02487433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33701598|NCT03451266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788166|NCT04178343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006049|NCT03695055|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006050|NCT03297086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34006051|NCT06101732|||COHORT||RETROSPECTIVE|||||||
34006052|NCT05815849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blinding was used in the study. For this purpose, the participants were not specified in which group they belonged to the research. Therefore, a separate informed consent form was prepared for each group. In order to avoid bias in the analysis of the research data, statistician blinding was also applied. While coding the research data, the research groups were coded as A and B, and the statistician was prevented from knowing which letter represented which group.||t|f|f|t
33701599|NCT05785351|||COHORT||RETROSPECTIVE|||||||
34006053|NCT02148354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006054|NCT00267358|RANDOMIZED|PARALLEL||||DOUBLE||||||
33927360|NCT03528824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006055|NCT04066920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701600|NCT04903678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701601|NCT03875404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701602|NCT05038670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant will not be informed which type of prosthesis was used in their particular case.~Outcomes Assessor, who will be not present during surgery, will not be informed which type of prosthesis was used in particular patient."||t|f|f|t
33701603|NCT01551901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701604|NCT04761510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788167|NCT06082076|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33927361|NCT05215678|||COHORT||CROSS_SECTIONAL|||||||
33927362|NCT06443749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927363|NCT03390088|||COHORT||PROSPECTIVE|||||||
33927364|NCT01664156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927365|NCT03515213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33927366|NCT01614912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927367|NCT02293941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006056|NCT00833573|||COHORT||CROSS_SECTIONAL|||||||
34006057|NCT04876937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006058|NCT02805413|NA|SINGLE_GROUP||||NONE||||||
34006059|NCT05904262|||OTHER||PROSPECTIVE|||||||
34006060|NCT00964106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34006061|NCT06428513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006062|NCT00932724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006063|NCT02594813|||COHORT||PROSPECTIVE|||||||
34006064|NCT00049296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006065|NCT04529876|||COHORT||RETROSPECTIVE|||||||
34006066|NCT01710124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006067|NCT02466334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34006068|NCT02791802|||COHORT||PROSPECTIVE|||||||
34006069|NCT00925873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006070|NCT05363579|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"Only the Principal Investigator would not be blinded. The randomizing scheme will be produced by using statistical analysis software SAS 9.3 with proc plan program or excel randomization program to generate the randomization codes. After production, it will be signed and sealed by the Principal Investigator. It will not be allowed to be checked by anyone except the Principal Investigator. Blinded research assessors in each center will be responsible for getting random envelopes from the PI."|This is a randomized, single-blind, parallel-controlled study. The test group is TUINA group and the TUINA combined with PT group, the control group is PT group.|f|f|f|t
34103229|NCT06686953|||COHORT||RETROSPECTIVE|||||||
34103230|NCT06166641|||COHORT||PROSPECTIVE|||||||
33701605|NCT04605042|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33701606|NCT01522508|||||PROSPECTIVE|||||||
33701607|NCT02030418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701608|NCT06323187|||CASE_CONTROL||PROSPECTIVE|||||||
33788168|NCT02556034|||CASE_ONLY||PROSPECTIVE|||||||
33788169|NCT02328820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927368|NCT05145803|||COHORT||PROSPECTIVE|||||||
33927369|NCT01374191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927370|NCT00430885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927371|NCT02003118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33927372|NCT06328660|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927373|NCT01000025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927374|NCT01590212|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33927375|NCT01449955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927376|NCT04157075|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be blinded to which arm they are in, surgeon will not as they will be performing injection however will not be assessing pain scores||t|f|f|f
33927377|NCT05250518|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927378|NCT06221072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|multicenter, randomized, double-blind clinical Trail|t|t|t|t
33927379|NCT01372644|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006071|NCT02761603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34006072|NCT01600339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006073|NCT00924131|||||OTHER|||||||
34006074|NCT05791734|||OTHER||PROSPECTIVE|||||||
34006075|NCT06678932|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006076|NCT06679101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006077|NCT06679036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006078|NCT03316040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103231|NCT05836025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006079|NCT05186753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In Part 1a and 1b of the study, patients with NonAdvSM will be randomly assigned to 1 of 2 dose levels of bezuclastinib plus BSC, or to placebo plus BSC. Upon analysis of the Part 1 data, a dose will be selected for Part 2. In Part 2, patients with NonAdvSM will be randomly assigned to the selected dose of bezuclastinib plus BSC, or to placebo plus BSC.~Patients who complete Part 1 or Part 2 may participate in Part 3 in which all patients will receive bezuclastinib plus BSC."|t|t|t|t
34103232|NCT05809830|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A Phase I dose-finding stage for the LB-100 plus doxorubicin combination is planned for an initial set of 9-18 patients (21-day cycles) In the Phase II part, patients will be enrolled in the trial via randomization. A randomization module (integrated in the eCRF system) will be used to assign patients to either the experimental arm (LB-100 plus doxorubicin) or to the control arm (doxorubicin alone) (1:1 ratio)||||
33701609|NCT01162070|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33701610|NCT04464057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|According to age and disease, the first pairing design, three pairs (experimental group: control group = 1:2), after pairing three subjects randomly assigned to the experimental group, the other two to the control group|The study is a prospective, randomized controlled clinical study. A total of 285 inpatients (95 experimental groups and 190 control groups) were enrolled to evaluate the safety and effectiveness of early feeding in neonates and infants after intestinal anastomosis|t|f|f|f
34006080|NCT00927251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006081|NCT00378924|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34006082|NCT00460109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006083|NCT00687882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006084|NCT04718649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34006085|NCT00973934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34006086|NCT00067717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006087|NCT05536908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Provider conducting CAPS-5 will not have access to treatment condition|Veterans are assigned to the combined PTSD/ residential substance use treatment (resWET) or Treatment as Usual (TAU: residential substance use treatment program).|f|f|f|t
34006088|NCT00004241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006089|NCT06678165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006090|NCT03858127|||COHORT||PROSPECTIVE|||||||
34006091|NCT04980456|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006092|NCT00089076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006093|NCT03129230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006094|NCT01617616|||COHORT||PROSPECTIVE|||||||
34006095|NCT05429489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34006096|NCT05457634|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34006097|NCT06137508|||COHORT||PROSPECTIVE|||||||
34006098|NCT06267872|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34006099|NCT06596499|||COHORT||RETROSPECTIVE|||||||
34006100|NCT04283370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34006101|NCT01110044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701611|NCT01145625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33701612|NCT01743183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006102|NCT02374203|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients were randomized 1:1 to two tube feeding regimens: general formula and high protein formula (1.5\~2.0 gm/kg BW).||||
34006103|NCT01148524|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701613|NCT00216476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701614|NCT06267248|||COHORT||PROSPECTIVE|||||||
33701615|NCT05073211|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||a double-blind split-face randomized controlled design|t|f|t|t
33701616|NCT00579878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701617|NCT00546559|||CASE_CONTROL||PROSPECTIVE|||||||
33701618|NCT03214978|||COHORT||RETROSPECTIVE|||||||
33701619|NCT03047876|||COHORT||PROSPECTIVE|||||||
33701620|NCT01975714|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33701621|NCT03250221|||COHORT||RETROSPECTIVE|||||||
33701622|NCT02670720|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701623|NCT00074269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701624|NCT00147212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701625|NCT02296073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701626|NCT06465095|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006104|NCT01159444|||CASE_ONLY||RETROSPECTIVE|||||||
33701627|NCT04913051|||COHORT||PROSPECTIVE|||||||
33701628|NCT00697359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006105|NCT05700396|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34006106|NCT04830241|||CASE_ONLY||RETROSPECTIVE|||||||
34006107|NCT01770002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34006108|NCT05043857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701629|NCT03948243|NA|SINGLE_GROUP||OTHER||NONE||||||
33701630|NCT03540212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006109|NCT00500318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006110|NCT05539534|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006111|NCT04871867|||COHORT||PROSPECTIVE|||||||
34006112|NCT01903564|||COHORT||PROSPECTIVE|||||||
34006113|NCT04595032|||OTHER||PROSPECTIVE|||||||
34006114|NCT05312411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006115|NCT02608424|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103233|NCT06691243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103234|NCT02071654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103235|NCT03308773|||COHORT||OTHER|||||||
34103236|NCT01217047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103237|NCT02898675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33701631|NCT01805128|NON_RANDOMIZED|PARALLEL||||NONE||||||
34103238|NCT04636580|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701632|NCT05657925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33701633|NCT02855073|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33701634|NCT05850065|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701635|NCT04311775|||CASE_CONTROL||PROSPECTIVE|||||||
33701636|NCT02880488|||||CROSS_SECTIONAL|||||||
33701637|NCT04277169|||COHORT||PROSPECTIVE|||||||
33701638|NCT04715425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701639|NCT01034189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701640|NCT02544178|||COHORT||PROSPECTIVE|||||||
33701641|NCT00310648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33701642|NCT00762216|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701643|NCT05797259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33701644|NCT00366977|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33701645|NCT05381844|||CASE_ONLY||PROSPECTIVE|||||||
33701646|NCT01540266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33701647|NCT00239538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701648|NCT02345226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701649|NCT00839722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701650|NCT06534684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701651|NCT01630057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701652|NCT02705872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701653|NCT00778544|RANDOMIZED|CROSSOVER||||NONE||||||
33701654|NCT05775354|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33701655|NCT02194855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33701656|NCT06272201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701657|NCT00142935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701658|NCT05534685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33701659|NCT02298231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788170|NCT03189134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788171|NCT06165549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33788172|NCT00957086|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33788173|NCT00454792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701660|NCT05332730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701661|NCT03774758|||COHORT||PROSPECTIVE|||||||
33701662|NCT03253575|||COHORT||PROSPECTIVE|||||||
33701663|NCT01780571|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33927380|NCT04144049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927381|NCT05808023|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The patients will be blinded to both the dose and the tested powder sugar.|The patients will follow both reintroductions of fructans and mannitol in a randomized crossover way. The reintroduction periods are separated by a washout period of three days.|t|f|f|f
33927382|NCT06104722|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33927383|NCT00421772|||DEFINED_POPULATION||PROSPECTIVE|||||||
33927384|NCT01156532|||COHORT||PROSPECTIVE|||||||
33927385|NCT01300585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927386|NCT01176240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927387|NCT00423592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927388|NCT06479434|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33927389|NCT01522560|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33927390|NCT01215669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927391|NCT00224276|||DEFINED_POPULATION||OTHER|||||||
33927392|NCT02529670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33927393|NCT01915095|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33927394|NCT02680106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927395|NCT02151968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927396|NCT04460040|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||16 overweight (body mass index: 25-30 kg/m2) men (n=8) and women (n=8) aged 21 to 45 years will exercise for 3 months in a moderate intensity regimen of 20 kcal/week/kg body weight||||
33927397|NCT00250367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927398|NCT06115057|NA|SINGLE_GROUP||OTHER||NONE||open-label, single-arm, single-site||||
33927399|NCT03770780|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33927400|NCT04696978|||CASE_CONTROL||PROSPECTIVE|||||||
33927401|NCT00006190||||DIAGNOSTIC||DOUBLE||||||
33927402|NCT03797508|NA|SINGLE_GROUP||OTHER||NONE||||||
33927403|NCT04965116|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33927404|NCT01457924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927405|NCT04163913|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927406|NCT00635440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33927407|NCT03091426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927408|NCT06261476|NA|SINGLE_GROUP||OTHER||NONE||||||
33927409|NCT02090465|||COHORT||PROSPECTIVE|||||||
33927410|NCT02695576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927411|NCT03708757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a single blinded study.Participants will be randomly allocated to PIRT Group (I) or EMET Group (II)|Experimental Study|t|f|f|f
33927412|NCT05107518|||OTHER||CROSS_SECTIONAL|||||||
33927413|NCT06058884|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consisted of two distinct groups. The first group consisted of 456 patients who experienced favourable outcomes (mRS two or less), while the second group comprised 136 patients who experienced unfavourable outcomes (mRS more than two).||||
33927414|NCT00004999||||TREATMENT||DOUBLE||||||
33701664|NCT03632200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||a pilot study to compare experimental group (improved coverage) and control group (classic coverage)||||
33701665|NCT01358851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701666|NCT00760422|||CASE_CONTROL||RETROSPECTIVE|||||||
33701667|NCT03909646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006116|NCT04360707|||CASE_ONLY||PROSPECTIVE|||||||
34006117|NCT06054477|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|"Phase 1 will consist of i) a dose escalation of ALE.C04 monotherapy evaluating approximately 3 dose levels of ALE.C04, ii) a dose escalation of ALE.C04 and pembrolizumab combination evaluating approximately 2 dose levels of ALE.C04 and iii) a randomized two RDEs evaluating two dose level of ALE.C04 combined with pembrolizumab to establish Recommended Phase 2 Dose (RP2D).~Phase 2 will consist of a 1:1 randomized 2 arms comparing ALE.C04 (at the RP2D dose determined in the phase 1) combined to pembrolizumab with pembrolizumab alone."||||
34006118|NCT03041207|||COHORT||PROSPECTIVE|||||||
34091669|NCT04598113|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The participant is treated with the same traction devise in the two interventions with just a traction intensity difference.~The care provider who manipulate the traction device can't be blinded to allocation The investigator (performing balance tests) is blinded to the intervention type The outcome assessor is blinded to allocation"|Two interventions: Effective Traction (ET) and Sham Traction (ST) Two arms: Arm 1: Effective Traction/Sham Traction (ET than ST) and Arm 2: Sham Traction/Effective Traction (ST than ET) Wash out period = 1 week|t|f|t|t
34091670|NCT06545864|||CASE_CONTROL||PROSPECTIVE|||||||
34091671|NCT02130141|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34091672|NCT02262871|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091673|NCT03022448|||CASE_ONLY||PROSPECTIVE|||||||
34091674|NCT02689778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091675|NCT02961660|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34091676|NCT03669679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091677|NCT05422885|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33701668|NCT06454435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927415|NCT02321683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927416|NCT02036268|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927417|NCT02480504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927418|NCT05665660|RANDOMIZED|CROSSOVER||SCREENING||NONE||Women randomized to receive CARE who have not received a mammography at 3 months will be offered CARE+COACH to facilitate completion of their screening and contacted at 4 months.||||
33927419|NCT03048357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927420|NCT01179867|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33927421|NCT05198427|||COHORT||RETROSPECTIVE|||||||
33927422|NCT02893657|||COHORT||PROSPECTIVE|||||||
33927423|NCT05359588|||COHORT||RETROSPECTIVE|||||||
33701669|NCT03992014|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|Subjects will receive linerixibat tablets concomitantly with \[14C\]-linerixibat IV infusion in treatment Period 1 and \[14C\]-linerixibat oral solution in treatment Period 2.||||
33701670|NCT03179527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701671|NCT04640857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Experimental: Silk'n Toothwave|t|f|t|f
33701672|NCT06162975|||COHORT||PROSPECTIVE|||||||
33701673|NCT03154593|||COHORT||PROSPECTIVE|||||||
33701674|NCT05456009|||COHORT||PROSPECTIVE|||||||
33701675|NCT04225962|||COHORT||PROSPECTIVE|||||||
33701676|NCT01830231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701677|NCT02178085|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33701678|NCT05491109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Assessor would be blinded to the participants identity because a block randomization with a randomly varying block size will be used. \[Online\] Available from: https://www.sealedenvelope.com/simple-randomiser/v1/lists.https://www.sealedenvelope.com/simple-randomiser/v1/lists.|Randomised Controlled Trial, Assessor blinded. The randomization method: A block randomization with a randomly varying block size. \[Online\] Available from: https://www.sealedenvelope.com/simple-randomiser/v1/lists.|f|f|f|t
33927424|NCT00853541|||COHORT||PROSPECTIVE|||||||
33927425|NCT00865046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33927426|NCT02715804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006119|NCT06437184|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34006120|NCT04890964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A randomized, double-blind, factorial, parallel-group, controlled trial with simulated treatment will be performed. The study follows the CONSORT guideline and will be registered in the ClinicalTrials.gov database: Home|HB-a-tDCS - M1 (n=33); HB-s-tDCS - M1 (n=17); HB-a-tDCS-DLPFC (n=33); HB-a-tDCS- DLPFC (n=17)|t|t|t|f
34006121|NCT03576950|||COHORT||RETROSPECTIVE|||||||
34006122|NCT01090817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006123|NCT06380257|||CASE_CONTROL||PROSPECTIVE|||||||
34006124|NCT02358551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006125|NCT06283121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006126|NCT00781430|NON_RANDOMIZED|PARALLEL||||NONE||||||
34006127|NCT01683123|||OTHER||RETROSPECTIVE|||||||
34006128|NCT00109486|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006129|NCT05167045|||COHORT||PROSPECTIVE|||||||
34006130|NCT03691688|||COHORT||PROSPECTIVE|||||||
34006131|NCT06589297|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006132|NCT02414373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006133|NCT04986124|||CASE_ONLY||CROSS_SECTIONAL|||||||
34006134|NCT00432627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006135|NCT00230594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006136|NCT06678776|||COHORT||RETROSPECTIVE|||||||
34006137|NCT03432091|||OTHER||PROSPECTIVE|||||||
34006138|NCT03649945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006139|NCT04118946|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with diagnosis of Interstitial cystitis/ Bladder pain syndrome||||
34006140|NCT05111886|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34006141|NCT00860327|||COHORT||PROSPECTIVE|||||||
33701679|NCT00579137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006142|NCT00869661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701680|NCT02912078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||we propose to conduct a prospective, randomized controlled trial to compare the initiation of labor with room temperature epidural medication (pharmacy-prepared 0.125% Bupivacaine with Fentanyl 2mcg/ml - 10mL) to the same epidural medication that has been pocket warmed for a minimum of 1 hour|t|f|f|f
33701681|NCT02617043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091678|NCT04871113|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label study|The is a sequential treatment, two-part study which will include a screening phase, a randomized monotherapy phase and a standard of care follow-up phase.||||
33701682|NCT04195906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701683|NCT04027543|||COHORT||RETROSPECTIVE|||||||
34006143|NCT00588315|||CASE_CONTROL||PROSPECTIVE|||||||
34006144|NCT05848258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006145|NCT06117787|||OTHER||PROSPECTIVE|||||||
34091679|NCT03139513|||COHORT||OTHER|||||||
34091680|NCT00003090||||TREATMENT||||||||
34091681|NCT03097263|||COHORT||RETROSPECTIVE|||||||
33701684|NCT06034847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091682|NCT00382512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34091683|NCT02749825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091684|NCT00243321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091685|NCT01002105|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33701685|NCT05510375|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33701686|NCT04980781|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking, as this is a non-controlled intervention trial.|"Employees and management in a ECR receive training in PED-t, and successively arrange the therapy. Experiences with the program training, and expectations to and experiences from giving the therapy, are the main research questions. Managements will be interviewed according to experiences with management of- and suitability of the therapy in the ECR~Eligible participants with bulimia nervosa or binge eating disorder are recruited for therapy in the ECR. Their expectations to- and experiences from having therapy in the ECR are the main research questions, in addition to evaluation of therapy success.~A previous RCT has evaluated the treatment efficiency by comparing it to a control group and another standardized treatment intervention. As such, the main focus of the current study is to evaluate experiences from arranging PED-t in a naturalistic setting, and secondly to evaluate if treatment efficiency can be replicated."||||
33701687|NCT00414271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701688|NCT03472651|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788174|NCT03152799|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Participants, Care Provider / Clinician Health Professional, Investigator, and Outcomes assessors will be blinded to the allocation and randomisation of study participatants. It is anticipated that|pilot, single-centre, double-blind, sham-controlled (non-clinical trial of investigational medicinal product \[non-CTIMP\]) study of repeated daily remote ischaemic conditioning vs placebo/sham in the context of acute anterior circulation stroke|t|t|t|t
33788175|NCT05946824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a two cohort Phase II single center, prospective trial, with a safety lead-in component. The cohorts will be defined by location of recurrence - either prostate bed alone, or a pelvic node with or without a prostate bed recurrence. This design will allow an initial toxicity assessment phase of a novel radiation treatment schema that is based on other literature, but with limited evidence. There is no plan to escalate the dose. Pending assessment of the safety lead in, complete enrollment will be permitted. Each cohort will be analyzed separated for the safety lead in.||||
33788176|NCT04081506|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33788177|NCT00479180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788178|NCT02451943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091686|NCT03892733|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized clinical trial||||
34091687|NCT01415674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701689|NCT04917887|||OTHER||PROSPECTIVE|||||||
33701690|NCT01601860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33701691|NCT03542123|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33701692|NCT02495831|RANDOMIZED|CROSSOVER||||NONE||||||
34006146|NCT02998541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006147|NCT05796596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Children were randomly assigned to one of three conditions: VR distraction group, book distraction control group, and no distraction group. Random assignments were generated with a random numbers table before recruitment by the researcher.||||
34006148|NCT05381896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006149|NCT00825864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006150|NCT04502849|||COHORT||PROSPECTIVE|||||||
34006151|NCT04335331|||OTHER||PROSPECTIVE|||||||
34006152|NCT03454282|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm and three cohorts of patients||||
34006153|NCT04854213|NA|SINGLE_GROUP||OTHER||NONE||||||
34006154|NCT01623804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006155|NCT01317979|||CASE_ONLY||PROSPECTIVE|||||||
34006156|NCT05853393|||COHORT||PROSPECTIVE|||||||
34006157|NCT03477383|||COHORT||PROSPECTIVE|||||||
34006158|NCT04899492|RANDOMIZED|PARALLEL||TREATMENT||NONE||pilot study, monocentric, prospective, randomization according to Zelen's design||||
34006159|NCT00175097|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091688|NCT03012776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091689|NCT01843231|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091690|NCT00809198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091691|NCT05652842|||COHORT||CROSS_SECTIONAL|||||||
34091692|NCT04735302|||OTHER||RETROSPECTIVE|||||||
34091693|NCT06215937|||COHORT||PROSPECTIVE|||||||
34091694|NCT01320449|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34091695|NCT03590470|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized stepped-wedge design||||
34091696|NCT00296335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091697|NCT04192344|NA|SEQUENTIAL||TREATMENT||NONE||||||
34006160|NCT03890562|NA|SINGLE_GROUP||TREATMENT||NONE||This feasibility study is a single group longitudinal pretest/posttest design||||
34006161|NCT02812654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006162|NCT02820740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006163|NCT03076749|||COHORT||CROSS_SECTIONAL|||||||
34006164|NCT03966950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|triple masking|randomized, parallel assignment|t|t|t|t
34006165|NCT05683782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006166|NCT05463406|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Pragmatic stepped-wedge cluster-randomized controlled clinical trial investigating a new algorithm combining a clinical score, LUS and PCT results (The PLUS algorithm) for the management of LRTIs among adults in EDs. The unit of randomization will be the ED.||||
34006167|NCT05103449|RANDOMIZED|PARALLEL||OTHER||SINGLE|Attending physicians evaluating the laparoscopic salpingectomy videos will be blinded||f|f|f|t
34006168|NCT04234061|NA|SINGLE_GROUP||TREATMENT||NONE||single arm||||
34006169|NCT05404451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34006170|NCT02702869|||COHORT||PROSPECTIVE|||||||
34006171|NCT06456814|||OTHER||CROSS_SECTIONAL|||||||
34006172|NCT00665951|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006173|NCT03311919|||COHORT||PROSPECTIVE|||||||
34006174|NCT05990231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006175|NCT06427187|NA|SINGLE_GROUP||TREATMENT||NONE||"Each presenting Patient subjected to:~* careful history including Age, Sex, comorbid diseases (hypertension, Diabetes, dyslipidemia, cardiac disease...), time from onset to treatment~* examination: Vital signs~* NIHSS at admission~* Lab investigation: basic lab, metabolic profile \& Lipid profile~* The diagnosis was made using a standard CT stroke protocol including CT head Aspect score, arterial CT angiography, and perfusion CT. In some cases, primary stroke MRI was performed including fluid attenuated inversion recovery (FLAIR), diffusion weighted imaging (DWI): in order to evaluate location of occluded vessel, size of ischemic core \& penumbra).~All patients received either mechanical thrombectomy (MT) with or without intra-venous thrombolysis (IVT) according to standard medical guidelines. MT was performed using approved aspiration catheters or stent-retrievers or both."||||
34006176|NCT06025552|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"5 cohorts with 5 dose levels will sequentially be escalated after safety review.~8 subjects in each cohort who will be randomly assigned to placebo or TU7710 group in 2:6 ratio."|t|f|t|f
34006177|NCT06393764|||CASE_ONLY||PROSPECTIVE|||||||
34006178|NCT00183196|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34006179|NCT05825768|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized, open-label, double-center trial including female participants with early breast cancer planned for breast conserving surgery randomised 1:1 in a Magnetic Resonance Imaging, MRI-group (preoperative MRI, ultrasound and mammography) and a control group (preoperative ultrasound and mammography).||||
34006180|NCT06056791|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation using mBOIN design||||
33701693|NCT03823508|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33701694|NCT02754557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701695|NCT00431288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All measurements were made in the Cincinnati Children's Hypertension Clinic by trained clinic staff blinded to treatment assignment.||f|f|f|t
33701696|NCT06058026|||CASE_CONTROL||PROSPECTIVE|||||||
33701697|NCT03789396|||CASE_CONTROL||PROSPECTIVE|||||||
33701698|NCT02869607|||COHORT||PROSPECTIVE|||||||
33701699|NCT05491720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701700|NCT03821909|||COHORT||PROSPECTIVE|||||||
33701701|NCT01811680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701702|NCT02261454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701703|NCT00569465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701704|NCT01865097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701705|NCT02601027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33788179|NCT00603356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788180|NCT06434051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This intervention involves cervical mobilization that constitutes elements of cervical rotation and traction.|t|f|t|t
33788181|NCT04439513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788182|NCT01805349|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788183|NCT01379287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788184|NCT05320913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33788185|NCT05528380|NA|SINGLE_GROUP||TREATMENT||NONE||Open Trial||||
33788186|NCT04087746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091698|NCT04798950|||COHORT||RETROSPECTIVE|||||||
34091699|NCT04498507|||COHORT||PROSPECTIVE|||||||
34091700|NCT03080623|||COHORT||PROSPECTIVE|||||||
34103239|NCT04970589|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Group 1: BMI 18-23: 400g of mango and a placebo capsule every day for 8 weeks Group 2: BMI 18-23: 400g of mango and a probiotic capsule every day for 8 weeks Group 3: BMI 27-35: 400g of mango and a placebo capsule every day for 8 weeks Group 4: BMI 27-35: 400g of mango and a probiotic capsule every day for 8 weeks|t|f|f|f
33701706|NCT03455127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701707|NCT06292234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded clinical trial|Parallel randomized controlled trial with 1:1 allocation ratio and superiority framework|t|f|f|f
33701708|NCT03022435|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33701709|NCT00537004|||COHORT||PROSPECTIVE|||||||
33701710|NCT00752102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701711|NCT00438711|||COHORT||CROSS_SECTIONAL|||||||
33701712|NCT05070195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701713|NCT00006274|||NATURAL_HISTORY|||||||||
33701714|NCT05406648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701715|NCT02718066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701716|NCT01952145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701717|NCT01810861|||OTHER||RETROSPECTIVE|||||||
33701718|NCT02044445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701719|NCT02081287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701720|NCT05138211|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927427|NCT01784003|||OTHER||CROSS_SECTIONAL|||||||
33927428|NCT06153069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927429|NCT00568607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927430|NCT04637191|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927431|NCT04295707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor was responsible for measuring the axial length and was unaware of the replacement modality of intervention used by the subjects. Another independent examiner will be responsible for grading surface coating from the images taken without disclosure of the information on the cleaning procedures.|"All subjects will be randomly assigned to use monthly or yearly replacement orthokeratology for a period of 24 months. Subjects on monthly replacement modality will be randomly assigned to normal cleaning and intensive cleaning groups. Subjects in normal cleaning group will be provided with complimentary contact lenses solutions for daily cleaning and disinfection. In addition to the daily procedures for lens case, subjects in the intensive cleaning group will be required to perform weekly protein removal.~Intensive cleaning is indicated for yearly replacement modality, thus, no randomization of care procedures in this group."|f|f|f|t
33927432|NCT01624610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927433|NCT01234909|||COHORT||PROSPECTIVE|||||||
33927434|NCT02583516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927435|NCT01857024|||CASE_ONLY||PROSPECTIVE|||||||
33927436|NCT02755025|||COHORT||PROSPECTIVE|||||||
34006181|NCT04684680|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label randomized controlled trial|open label randomized controlled trial||||
34006182|NCT02724826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701721|NCT04442412|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, multicenter, randomized phase III trial. The study plans to randomize patients with a 1 to 1 ratio to Arm A (Standard arm) or Arm B (Experimental arm). All patients of both arms will receive a prephase with oral prednisone before 6 cycles Q21 of immunochemotherapy with R-CHOP or R-miniCHOP at standard doses; patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.||||
34006183|NCT05409352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization will be performed using software that allows for replication by an independent randomizer. To aid allocation concealment, permuted blocks of varying sizes will be used. The randomizer will place the assignment results in sealed, sequentially numbered opaque envelopes and keep a secure copy of the randomization codes. Neither the research assistant (RA) conducting recruitment nor the participants will know the group assignments until the envelope is opened. All outcome assessments will be carried out by research staff blinded to allocation. Neither the specialist delivering exercise intervention nor the TCM practitioner delivering acupressure intervention will be told about the study design or involved in outcome assessment. The statistician performing data analysis will be blinded.||f|f|f|t
34006184|NCT04225260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701722|NCT01634997|||COHORT||PROSPECTIVE|||||||
33701723|NCT02555774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701724|NCT00454623|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33701725|NCT05409495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two different treatment modalities to treat deep periodontal intrabony defects were compared in this split-mouth, randomized, parallel and clinical study. The control group defects were treated with OFD only while the test group defects were treated with OFD supplemented with T-PRF. The same periodontal treatment procedure was applied in both groups, except for the use of T-PRF. Clinical and radiographic parameters were measured from baseline to 9 months after surgery.||||
33701726|NCT00876421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701727|NCT00968864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701728|NCT04150055|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927437|NCT03481569|NA|SINGLE_GROUP||OTHER||NONE||Pharmacokinetic study||||
33927438|NCT01632072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927439|NCT02539719|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927440|NCT06047990|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Randomization was performed by the Institute of Biostatistics and Analysis of Masaryk University Brno.||f|f|t|f
33927441|NCT05721560|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot phase: single-arm prospective non-comparative single-centre study phase||||
33927442|NCT01180764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927443|NCT02081560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927444|NCT01931150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927445|NCT01821404|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33927446|NCT00577915|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927447|NCT01726816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927448|NCT06506981|||COHORT||OTHER|||||||
34006185|NCT03278509|RANDOMIZED|PARALLEL||TREATMENT||NONE||A registry-based, randomized, parallel, open-label, multicenter trial||||
34006186|NCT01848210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006187|NCT05016687|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34006188|NCT00575380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006189|NCT01247792|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34006190|NCT01923311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006191|NCT00503633|||COHORT||PROSPECTIVE|||||||
34006192|NCT06106334|NA|CROSSOVER||TREATMENT||NONE||||||
34006193|NCT03944161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006194|NCT04231331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006195|NCT06418997|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34006196|NCT03367936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006197|NCT02609516|||COHORT||RETROSPECTIVE|||||||
34006198|NCT06679166|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006199|NCT06036680|||COHORT||RETROSPECTIVE|||||||
34006200|NCT04991012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||full contralateral split-mouth|t|f|t|f
34006201|NCT03793530|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34006202|NCT06616402|NA|SINGLE_GROUP||OTHER||NONE||||||
33927449|NCT05766423|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33927450|NCT04705610|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, descriptive, comparative (case-control), monocentric study. Control are healthy volunteers. Pathological groups are Radiologically Isolated Syndrome (RIS), Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS) and Primary Progressive MS (PPMS).||||
34091701|NCT05563857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once enrolled, participants are randomized into one of the three arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.|Randomized, blinded, cohort study divided into three arms: 1) control group (placebo), 2) condition-based supplement, 3) precision-supplement|t|f|f|f
34091702|NCT04029597|NA|SINGLE_GROUP||TREATMENT||NONE||open trial||||
33701729|NCT05834569|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701730|NCT05660226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33701731|NCT04104230|||CASE_CONTROL||PROSPECTIVE|||||||
33927451|NCT00279032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927452|NCT02896192|NA|SINGLE_GROUP||TREATMENT||NONE|During the 8 week double-blind placebo-controlled withdrawal period, participants received 4 weeks of daily setmelanotide and 4 weeks of daily placebo. Participants, investigators, and sites remained blinded as to when placebo treatment was administered.|Open-label with an 8 week Double-Blind Placebo-Controlled Withdrawal Period||||
33927453|NCT01646853|NA|SINGLE_GROUP||TREATMENT||||||||
34091703|NCT00869180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091704|NCT02107898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091705|NCT00366769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091706|NCT03033706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091707|NCT05190133|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33927454|NCT00702260|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091708|NCT02290093|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34091709|NCT01334775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091710|NCT01679470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091711|NCT01325766|RANDOMIZED|PARALLEL||||NONE||||||
34091712|NCT02967887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091713|NCT06157424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34091714|NCT03897621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double-blinded randomized controlled trial|t|t|f|f
33701732|NCT03277690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701733|NCT01858571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33701734|NCT01660204|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33701735|NCT02423993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701736|NCT03531983|||CASE_ONLY||PROSPECTIVE|||||||
33701737|NCT03028103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788187|NCT02528591|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927455|NCT00349037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33927456|NCT00317057|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34091715|NCT01177410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091716|NCT00077194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103240|NCT04989517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103241|NCT00410436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103242|NCT05240976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006203|NCT04158778|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34006204|NCT05550792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006205|NCT06357156|||OTHER||CROSS_SECTIONAL|||||||
34006206|NCT00325104||||TREATMENT||||||||
34006207|NCT03080376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34091717|NCT04189523|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We will perform a small prospective non-randomized interventional pilot study to assess feasibility of a future full scale RCT to test our hypotheses. Interventional study subjects will be compared to controls enrolled simultaneously during the study period who meet the inclusion criteria and do not have documentation of one of the exclusion criteria. We will enroll subjects 2 controls to 1 intervention to ensure the ability to select controls as similar to the intervention population as possible.||||
34091718|NCT03404375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091719|NCT06049537|||COHORT||PROSPECTIVE|||||||
34091720|NCT00868556|||CASE_CONTROL||PROSPECTIVE|||||||
34091721|NCT04790201|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-arm individually randomized trial||||
34091722|NCT03395964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091723|NCT00543465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927457|NCT00484276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927458|NCT00436020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927459|NCT02352532|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33927460|NCT05960136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927461|NCT04023136|NA|SINGLE_GROUP||OTHER||NONE||||||
33927462|NCT01190072|||COHORT||PROSPECTIVE|||||||
33927463|NCT00049504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927464|NCT06338007|||OTHER||PROSPECTIVE|||||||
33927465|NCT04246125|||COHORT||CROSS_SECTIONAL|||||||
34006208|NCT04934020|||COHORT||RETROSPECTIVE|||||||
34006209|NCT06630260|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34006210|NCT00307970|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006211|NCT02426541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006212|NCT06060184|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel Assignment||||
34091724|NCT06068400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091725|NCT01644838|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34091726|NCT05375305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33927466|NCT04478110|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33927467|NCT04751058|||COHORT||PROSPECTIVE|||||||
33927468|NCT01131442|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927469|NCT04556448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized RCT|f|f|t|t
33927470|NCT01171014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34091727|NCT03991767|NA|SINGLE_GROUP||SCREENING||NONE||||||
34091728|NCT03191968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34091729|NCT04077359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|one investigator evaluates the experimental arm a second investigator evaluates the control arm without knowledge of the other|One sample, paired, non-inferiority study with a 7.5% non-inferiority limit. Each patient undergo the experimental CT and the control CT||||
34091730|NCT00839826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091731|NCT03034928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091732|NCT03003689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091733|NCT01060488|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091734|NCT04832061|||COHORT||RETROSPECTIVE|||||||
34091735|NCT00932854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701738|NCT04915898|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Audits on two control units with no change in oral care practices. Emphasizing that we are supporting patient hygiene|Cluster randomization of control and intervention groups|f|t|f|f
33701739|NCT02153333|||||RETROSPECTIVE|||||||
33701740|NCT03282370|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701741|NCT06541847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701742|NCT03951155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor responsible for evaluating child behavior \& cooperation will be masked||f|f|f|t
33927471|NCT03027193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927472|NCT02967484|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34091736|NCT02937922|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34091737|NCT01482221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927473|NCT03210064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental: apatinib combined with 5-Fu|t|f|f|f
33927474|NCT06249022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33927475|NCT02152449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927476|NCT04764968|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|A Randomized, Open-Label, Two-Period, Two-Week Crossover Outpatient Study||||
33927477|NCT04327050|NA|SINGLE_GROUP||TREATMENT||NONE|No masking required|||||
33927478|NCT00901589|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34006213|NCT02404857|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006214|NCT01859026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006215|NCT00978887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006216|NCT04124250|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34006217|NCT01737541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34006218|NCT01337882|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34006219|NCT00217334|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34006220|NCT04916275|||COHORT||PROSPECTIVE|||||||
34006221|NCT00875888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006222|NCT02176278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006223|NCT03067740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091738|NCT06310135|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34091739|NCT03593629|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34091740|NCT02019537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091741|NCT00260442|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103243|NCT06634160|||CASE_ONLY||PROSPECTIVE|||||||
34103244|NCT00290628||||TREATMENT||NONE||||||
33927479|NCT04903704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927480|NCT03249753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927481|NCT01719679|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33927482|NCT00361218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927483|NCT01674738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006224|NCT01149382|||COHORT||PROSPECTIVE|||||||
34006225|NCT02194816|||COHORT||PROSPECTIVE|||||||
33701743|NCT02505763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006226|NCT05218109|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34006227|NCT02588820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701744|NCT00251212|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33701745|NCT02400229|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33701746|NCT04628741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33701747|NCT05856188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33701748|NCT00664989|||OTHER||PROSPECTIVE|||||||
33701749|NCT00810914|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33701750|NCT01685944|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33701751|NCT05708170|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33701752|NCT03985254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34103245|NCT05500131|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34103246|NCT00005880|RANDOMIZED|||PREVENTION||||||||
34103247|NCT04256538|||OTHER||PROSPECTIVE|||||||
33701753|NCT05414877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study could not be blinded to the treating anesthesiologists. However, blinding was maintained for the patients and the assessors of outcome indicators. Postoperative follow-up was performed by a specially trained physician who did not have access to any information about the patients' cases and subgroups.||t|f|f|t
33701754|NCT02609828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701755|NCT05462483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701756|NCT02281773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701757|NCT05945706|||CASE_CROSSOVER||PROSPECTIVE|||||||
33788188|NCT06628544|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Vaccines (BCG) and Drugs (Metformin)||||
33788189|NCT01967030|||COHORT||PROSPECTIVE|||||||
33788190|NCT03359031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788191|NCT03832660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006228|NCT04973813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34006229|NCT06580652|||CASE_CONTROL||PROSPECTIVE|||||||
34006230|NCT02187380|||CASE_CONTROL||PROSPECTIVE|||||||
34006231|NCT00280969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701758|NCT01529047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701759|NCT03358797|RANDOMIZED|PARALLEL||PREVENTION||NONE||Stage 1: interventional, Pre - Post study, with quasi-experimental comparison group Stage 2: interventional, Pre - Post study, with cluster randomization (Pilot study to develop the resiliency training manual will be part of stage 2)||||
33701760|NCT01919138|||CASE_ONLY||RETROSPECTIVE|||||||
33701761|NCT02713373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701762|NCT02829255|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788192|NCT01202851|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33788193|NCT02455687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788194|NCT04621539|||COHORT||PROSPECTIVE|||||||
33788195|NCT04826055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33788196|NCT06185400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006232|NCT03130985|||COHORT||PROSPECTIVE|||||||
34006233|NCT06430073|||COHORT||PROSPECTIVE|||||||
34006234|NCT04829812|||COHORT||PROSPECTIVE|||||||
34006235|NCT00628082|||COHORT|||||||||
34006236|NCT06437392|||OTHER||CROSS_SECTIONAL|||||||
34006237|NCT00996424|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006238|NCT01256333|||CASE_ONLY||PROSPECTIVE|||||||
34103248|NCT06501183|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and 3+3 design dose escalation phase followed by dose expansion phase||||
34103249|NCT02370147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34006239|NCT06531642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Partial blinded, only the laboratory testing technician/outcome assessor will be blinded to the study arms.|Study group patients will receive pantoprazole early (40 mg iv q12H, within 2 hours of ED arrival and after study enrollment) and control group patients will receive the usual timing (40 mg iv daily, at routine timing, usually in the intensive care unit), then for 2 additional days after the initial injury insult.|f|f|f|t
34006240|NCT04063319|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34006241|NCT03600181|||OTHER||PROSPECTIVE|||||||
34006242|NCT01962649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006243|NCT04789967|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34006244|NCT03584217|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006245|NCT04712084|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient during general anesthesia are not aware of the technique applied. The radiologist calculating the surface of atelectasis is not aware of the technique applied|prospective double-blinded study Randomization was performed when spontaneous ventilation resumed at the end of the surgery|t|f|f|t
34006246|NCT04340531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006247|NCT04871009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006248|NCT04904484|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Environmental contamination of SARS Co-V2 (air and surface) will be tested around COVID patients receiving Non-invasive ventilation or high flow oxygen therapy before using the iZephyr hood and then with the iZephyr hood in place, to determine if the hood changes the amount of environmental contamination||||
34006249|NCT00745134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006250|NCT06315517|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized controlled, double-blinded, double-crossover trial|t|f|t|t
34006251|NCT00168116|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34006252|NCT01622530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006253|NCT02096367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006254|NCT04291508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Vitamin C or Vitamin C-placebo will be refrigerated. Acetaminophen or acetaminophen-placebo will be stored at room temperature and the volume will be reduced for patients less than 50 kg. Investigators will be informed of which of the two placebo controlled groups the patient was randomized to.|Patients will be randomized to at a ratio of 2:1 active versus placebo.|t|t|t|t
34006255|NCT02154802|RANDOMIZED|FACTORIAL||||NONE||||||
34006256|NCT03020849|||COHORT||PROSPECTIVE|||||||
34006257|NCT00979212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006258|NCT00964873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006259|NCT00051831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006260|NCT00423709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006261|NCT02451306|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34006262|NCT06674694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006263|NCT02310516|RANDOMIZED|PARALLEL||||NONE||||||
34006264|NCT02969876|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006265|NCT00098891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006266|NCT01072799|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006267|NCT05794087|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Subjects and laboratory personnel will not be informed of the type of exposure.|Subjects will be randomly assigned to either clean air or ozone for the first exposure then crossed over to the alternate arm for the second exposure.|t|f|f|t
34006268|NCT01525576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006269|NCT05667948|||CASE_ONLY||PROSPECTIVE|||||||
33701763|NCT04511104|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Trial phase 1: All eligible subjects will be allocated to the intervention group until n=20 has been reached. To reduce staff workload during phase 1, patients will be allocated to the control group if staff capacity (max. 2 patients per full time employed physiotherapist) is saturated.~Trial phase 2: When n=20 has been reached in the intervention group, all further eligible patients will be allocated to the control group for the remaining recruitment period."||||
33701764|NCT02965300|||COHORT||PROSPECTIVE|||||||
33701765|NCT05324722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The enumerator will not know about the interventions used for the side of the body|RCT|f|t|t|t
33701766|NCT03745807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788197|NCT00771667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788198|NCT03379961|||OTHER||PROSPECTIVE|||||||
33788199|NCT01130064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788200|NCT05015868|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34006270|NCT06269913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006271|NCT01125826|||CASE_ONLY||PROSPECTIVE|||||||
34006272|NCT02215772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006273|NCT05704673|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34006274|NCT02756637|||OTHER||RETROSPECTIVE|||||||
34006275|NCT01544439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006276|NCT02107222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006277|NCT03856905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006278|NCT03798340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006279|NCT00602966|||CASE_CONTROL||PROSPECTIVE|||||||
34006280|NCT03342235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* Surgical Group: treatment with PRK and patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.~  o Surgery will be performed within 60 days of randomization~* Non-surgical Control Group: patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able."|f|f|f|t
34006281|NCT00689845|NON_RANDOMIZED|||TREATMENT||||||||
34006282|NCT01659034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006283|NCT05376137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34006284|NCT04249596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006285|NCT05846464|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33788201|NCT00608907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788202|NCT06631313|NA|SINGLE_GROUP||OTHER||NONE||||||
33788203|NCT00198172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788204|NCT01942967|||CASE_CROSSOVER||PROSPECTIVE|||||||
33788205|NCT01188629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34006286|NCT02845089|||COHORT||RETROSPECTIVE|||||||
34006287|NCT05719831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006288|NCT06616792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006289|NCT01935648|||CASE_ONLY||PROSPECTIVE|||||||
34006290|NCT01669031|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34006291|NCT03594825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006292|NCT02040519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006293|NCT03028623|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34006294|NCT05681416|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Men with family history or already known BRCA1 or BRCA2 mutation and their family members will be offered a combined clinical, imaging and genetic profiling to tailor their risk to develop PCA. In addition, men with prostate cancer and positive family history will be offered genetic testing and mutational profiling of tumor tissue in order to exclude or detect hereditary cancer syndromes.||||
34006295|NCT04167384|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34006296|NCT06360029|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||f|f|t|t
34006297|NCT03496987|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomly assigned immediately before performing the procedure to either of the two investigational arms: manual drainage or vacuum bottle drainage.||||
34006298|NCT03616002|NA|SINGLE_GROUP||OTHER||NONE||||||
34006299|NCT05144464|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects received 2 doses of an inactivated quadrivalent influenza vaccine, 4 weeks apart. Blood samples were obtained from children at 3 time points-before receipt of dose 1, 4 weeks after receipt of dose 1 and before dose 2, and 4 weeks after dose 2.||||
34091742|NCT03912636|RANDOMIZED|CROSSOVER||TREATMENT||NONE|When the investigators analyze the data, the investigator will be blinded to the conditions of the participants and the types of breathing exercises.|In study 1 for the pathophysiology of rumination syndrome, the investigators will recruit 10 healthy volunteers and 10 patients. In study 2 for the treatment, the investigators will recruit 10 patients and perform the cross-over test, in which the patients will perform 2 breathing exercises and the investigators will compare the effects.||||
34006300|NCT04154358|NA|SINGLE_GROUP||SCREENING||NONE||||||
34006301|NCT04775095|||COHORT||RETROSPECTIVE|||||||
34006302|NCT01557062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091743|NCT03915899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34006303|NCT02104869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006304|NCT06013930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The PI will randomly assign participants to condition and coordinate treatment group scheduling; the assessor will be blinded to condition.|Participants will be randomized to receive either: 1) External Qigong, 2) Mindfulness Meditation, or 3) Psychoeducation.|f|f|f|t
34091744|NCT02333032|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||randomised controlled study experimental group : training with slope N=15 control group training with no slope N=15||||
34006305|NCT04292015|RANDOMIZED|CROSSOVER||SCREENING||NONE||Each premature infant recruited into the study will undergo retinal imaging with the Optos ultra-widefield retinal imaging device as well as the gold standard method of examination with the binocular indirect ophthalmoscope. The order of the procedures to be carried out in each infant will be determined by randomisation via sealed envelopes prepared remotely by a member of the pilot team not involved in the recruitment of patients or their screenings.||||
34006306|NCT03689894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006307|NCT00770068|||COHORT||PROSPECTIVE|||||||
34006308|NCT03902301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34006309|NCT03285464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the subjects will not know which group they are being assigned to|One group will do current hip focused intervention published previously second group will receive a new hip intervention and then pre/post testing will take place for static and dynamic kinematics and hip strength|t|f|f|f
34006310|NCT03033524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006311|NCT03582241|||COHORT||RETROSPECTIVE|||||||
34006312|NCT00876356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006313|NCT03747653|||COHORT||CROSS_SECTIONAL|||||||
34006314|NCT05308823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006315|NCT00981227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006316|NCT05338476|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34006317|NCT00392782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091745|NCT02596672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34091746|NCT02534961|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006318|NCT03280940|||COHORT||RETROSPECTIVE|||||||
34006319|NCT04526093|||COHORT||PROSPECTIVE|||||||
34006320|NCT01782755|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091747|NCT03084484|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Single-centre randomized, parallel design, clinical trial with a 5-month follow|f|t|t|t
34091748|NCT06117137|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group (stander treatment of Type 2 diabetes mellitus without SGLT2-I ) SGLT2-I groups (stander treatment of Type 2 diabetes mellitus plus SGLT2-I )||||
34091749|NCT03104803|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091750|NCT04925323|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091751|NCT02957643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091752|NCT01397747|||CASE_ONLY||PROSPECTIVE|||||||
34091753|NCT00394667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34091754|NCT03070652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091755|NCT00699127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091756|NCT00248547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34091757|NCT04115722|||CASE_CONTROL||RETROSPECTIVE|||||||
34091758|NCT02487836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091759|NCT01379612|||CASE_ONLY||PROSPECTIVE|||||||
34006321|NCT00781092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006322|NCT02262559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006323|NCT05529368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34006324|NCT02483936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006325|NCT05524428|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||The investigators will use a mixed methods approach involving qualitative focus groups with health center providers and staff to identify barriers and facilitators to screening, and implementation science methods to test multilevel implementation strategies at the health centers.||||
34091760|NCT02691338|||COHORT||PROSPECTIVE|||||||
34091761|NCT03942731|||OTHER||RETROSPECTIVE|||||||
34091762|NCT05834621|||COHORT||CROSS_SECTIONAL|||||||
34091763|NCT03748667|||COHORT||CROSS_SECTIONAL|||||||
34091764|NCT01508897|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34091765|NCT03365245|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091766|NCT03743818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091767|NCT03334097|NA|SINGLE_GROUP||TREATMENT||NONE|There will be no masking as the purpose of the study is to analyse responsiveness of a questionnaire after educational intervention|A single groupof pregant women will complete the spanish version of Delivery Expectancy/Experience Questionnaire, Version A (WDEQ-A, spanish version) before and after an educational information.||||
34091768|NCT01320540|||COHORT||PROSPECTIVE|||||||
34091769|NCT03399292|||COHORT||PROSPECTIVE|||||||
34091770|NCT01499511|||OTHER||RETROSPECTIVE|||||||
34091771|NCT04602650|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34091772|NCT03268863|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34091773|NCT00785889|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34091774|NCT04867148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091775|NCT01963806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091776|NCT00957710|NA|SINGLE_GROUP||||NONE||||||
34091777|NCT01422902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34091778|NCT00870701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091779|NCT00624260|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091780|NCT02602951|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34091781|NCT04058691|||COHORT||RETROSPECTIVE|||||||
34091782|NCT04177199|||COHORT||PROSPECTIVE|||||||
34091783|NCT01564407|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34091784|NCT06237491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091785|NCT01211249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006326|NCT03187587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006327|NCT03077009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006328|NCT02844010|||CASE_ONLY||PROSPECTIVE|||||||
34006329|NCT00377572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927484|NCT03382197|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Two experienced researchers will participate in the study, one being responsible for the evaluation of the outcomes (researcher 1) and the other responsible for the application of the intervention in each patient (researcher 2). The researcher 2 will receive in opaque and sealed envelopes the randomized order of the interventions of each patient, keeping them in secrecy until the end of the whole study.|"Patients will be randomized regarding the order of intervention they will receive:~Group 1 - control intervention, will only perform nebulization; Group 2 - intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP); Group 3 - intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;~All patients will be evaluated BEFORE, DURING and AFTER each intervention through Electrical Impedance Tomography, Pulmonary Scintigraphy and Spirometry."|f|f|t|t
33927485|NCT03658798|NA|SINGLE_GROUP||TREATMENT||NONE|No masking of the intervention to participant or assessor because there is only 1 arm.|"Participant will be compared to themselves in a pre-post analysis"||||
34006330|NCT02389699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006331|NCT00047047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006332|NCT05568316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006333|NCT05183711|||COHORT||PROSPECTIVE|||||||
34006334|NCT01327417|||CASE_CONTROL||PROSPECTIVE|||||||
34006335|NCT02305173|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34006336|NCT05739734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006337|NCT01829815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006338|NCT05085782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006339|NCT02595827|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34006340|NCT03304340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927486|NCT00219388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927487|NCT00358709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33927488|NCT02820558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927489|NCT06178094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927490|NCT06122753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927491|NCT01956994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33927492|NCT01478178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927493|NCT04658810|||COHORT||RETROSPECTIVE|||||||
34006341|NCT04948671|||CASE_CONTROL||PROSPECTIVE|||||||
34006342|NCT01477424|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34006343|NCT03398590|NA|SINGLE_GROUP||OTHER||NONE||||||
34006344|NCT05848401|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Participants were aware they would be placed in the treatment or control group after providing informed consent.|||||
34006345|NCT04759534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Central laboratory uses random number table to generate random sequence||t|t|t|f
34006346|NCT04044560|NA|SEQUENTIAL||TREATMENT||NONE||Participants will be monitored for MRD post transplant during the testing phase of the trial. If they have detectable MRD, they will be enrolled into the blinatumomab treatment phase.||||
34006347|NCT04826289|||OTHER||PROSPECTIVE|||||||
34006348|NCT06534541|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34006349|NCT00271557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701767|NCT06009731|||CASE_ONLY||PROSPECTIVE|||||||
33701768|NCT05231304|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34006350|NCT02145624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006351|NCT05910528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006352|NCT03257215|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34006353|NCT01625507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006354|NCT05116059|||OTHER||RETROSPECTIVE|||||||
33701769|NCT00590746|||CASE_ONLY||PROSPECTIVE|||||||
33701770|NCT06322069|RANDOMIZED|PARALLEL||OTHER||NONE||In study 2, we conducted a randomized control trial, and there are two groups: self-compassion intervention group and waitlist group.||||
33701771|NCT00135564|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701772|NCT06285708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701773|NCT02761733|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701774|NCT02390908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701775|NCT04537429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701776|NCT00325702|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701777|NCT00000546|RANDOMIZED|||TREATMENT||||||||
33701778|NCT03943160|||OTHER||PROSPECTIVE|||||||
33927494|NCT02331641|||CASE_CONTROL||RETROSPECTIVE|||||||
34006355|NCT03518216|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34006356|NCT03992339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006357|NCT03884725|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34006358|NCT01951287|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34006359|NCT05352282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006360|NCT01185379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33788206|NCT05939648|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788207|NCT00396058|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33927495|NCT03260348|||COHORT||PROSPECTIVE|||||||
33927496|NCT00567957|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33927497|NCT00611988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006361|NCT05791747|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34006362|NCT05065437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006363|NCT01767610|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34006364|NCT04493476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a prospective, placebo-controlled, double-blind randomized trial|t|f|t|f
34006365|NCT02042833|||COHORT||PROSPECTIVE|||||||
34006366|NCT03983798|||COHORT||PROSPECTIVE|||||||
34006367|NCT00176930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006368|NCT01722955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34091786|NCT00694746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091787|NCT02478788|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34091788|NCT05183620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091789|NCT02475447|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34091790|NCT04575324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34091791|NCT00515190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091792|NCT04687722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|Both experimental and control groups will be treated at the same time following their respective protocols.|t|f|f|f
34091793|NCT04225650|||COHORT||PROSPECTIVE|||||||
34091794|NCT00608998|||CASE_ONLY||CROSS_SECTIONAL|||||||
34091795|NCT04913298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091796|NCT01845857|NA|SINGLE_GROUP||||NONE||||||
34091797|NCT00303043|||COHORT||PROSPECTIVE|||||||
34091798|NCT05708651|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|All study data recorded on-site will be masked for investigational device or comparator (and recorded in individually randomized order) in the study protocols. For practical reasons, study participants, care providers and on-site investigators cannot be masked for investigational device versus comparator.|Four-part preclinical \[I-II\] and clinical \[III-IV\] trial carried out, in 12 + 12 volunteer study participants \[I-II\] and in 16 + 16 study patients \[III-IV)\], according to an intra-individual randomised paired crossover study design, where the investigational device is compared with standard procedure (comparator; biteblock \[I-II\] or no device \[II-IV\]) for airway patency (tidal volume \[I\], transpharyngeal distance \[II\], signs of airway obstruction \[III-IV\], use of manual airway support \[III-IV\]).|f|f|f|t
34091799|NCT05382728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091800|NCT05362084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091801|NCT01426126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091802|NCT05316467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled patients will receive enhanced lifestyle management to control weight and take Megestrol Acetate (MA) for treating EEC.||||
34091803|NCT03266497|||OTHER||CROSS_SECTIONAL|||||||
34091804|NCT03594838|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"A non-randomized 3 arm-interventional study at eight HRSs to evaluate two novel approaches of HCV viremia testing and compare them to the current standard of care. The HRS will be assigned to one of three study arms.~Six HRSs will provide HCV viremia testing on-site using one of two approaches as follows and two HRS will refer patients off-site for testing (current standard of care).~The three arms will be compared to determine differences in the proportion of anti-HCV-positive patients that receive HCV viremia test results."||||
34091805|NCT02189447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091806|NCT03818594|||COHORT||PROSPECTIVE|||||||
34091807|NCT03336970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091808|NCT02679105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091809|NCT03908853|||COHORT||CROSS_SECTIONAL|||||||
33927498|NCT06095544|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||prospective randomized controlled tiral|t|t|t|t
34091810|NCT01562691|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34091811|NCT03848468|RANDOMIZED|PARALLEL||TREATMENT||NONE||Covidien 5mm ligasure||||
34091812|NCT02316613|||COHORT||PROSPECTIVE|||||||
34091813|NCT02126332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091814|NCT01991951|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927499|NCT00471783|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33927500|NCT04493593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091815|NCT03691532|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Mixed-crossover: three separate groups (paraplegia, tetraplegia, and neurologically intact) undergo two conditions (seated control and exercise) in a randomized order.||||
34091816|NCT04697901|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34091817|NCT03863912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091818|NCT03667716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091819|NCT05494918|NA|SEQUENTIAL||TREATMENT||NONE||The starting dose of JSKN003 is 1.0 mg/kg, followed by 2.1, 4.2, 5.3, 6.3, 7.3, 8.4, 9.4 and 10.5 mg/kg.||||
34091820|NCT02649699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091821|NCT00577408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927501|NCT03374813|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33927502|NCT05194111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Cardiac magnetic resonance studies will be de-identified and assigned a study number. The identification key will not be available to cardiac magnetic resonance readers so that they are blinded to treatment allocation||f|f|f|t
33927503|NCT05380960|||COHORT||CROSS_SECTIONAL|||||||
33927504|NCT02077803|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927505|NCT00158405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927506|NCT03669406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927507|NCT05857007|||COHORT||PROSPECTIVE|||||||
33927508|NCT04584931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927509|NCT04218604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927510|NCT03442504|NA|SINGLE_GROUP||OTHER||NONE||||||
33927511|NCT03550365|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33927512|NCT03269136|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927513|NCT03499769|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33927514|NCT00129740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927515|NCT06452368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927516|NCT01041469|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927517|NCT06207071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091822|NCT03559309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091823|NCT01355367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091824|NCT01905072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34091825|NCT03237754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind|Patients receive either Placebo or real neurostimulation|t|f|t|f
34091826|NCT06278649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091827|NCT00957697|||COHORT||RETROSPECTIVE|||||||
33927518|NCT04516733|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||in addition to oncology care, there will be a care with palliative team and neuropsychological care||||
33927519|NCT03182621|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33927520|NCT06252246|||CASE_ONLY||RETROSPECTIVE|||||||
33927521|NCT03261570|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33927522|NCT04961879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927523|NCT04447118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, the Blinded Independent Review Committee (BIRC) will perform a blinded evaluation on the primary endpoint.||f|f|f|t
33927524|NCT02074904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927525|NCT04917120|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927526|NCT03371927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blinded||t|f|f|f
33927527|NCT00447538|||||RETROSPECTIVE|||||||
33927528|NCT01901978|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33927529|NCT02319408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33927530|NCT04907864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||An open-label, randomized phase 2 trial||||
33927531|NCT00366223|||OTHER||RETROSPECTIVE|||||||
33927532|NCT02957084|||COHORT||PROSPECTIVE|||||||
33927533|NCT01279980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006369|NCT01049347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006370|NCT06327737|||COHORT||PROSPECTIVE|||||||
34006371|NCT03847194|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial with 2 groups: PRISM (intervention) arm or standard of care||||
34006372|NCT01858987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006373|NCT02371928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34006374|NCT02802215|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34006375|NCT06359119|||OTHER||CROSS_SECTIONAL|||||||
34006376|NCT06678685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006377|NCT02898701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34006378|NCT05860517|||OTHER||PROSPECTIVE|||||||
34006379|NCT03245307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006380|NCT02130778|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34006381|NCT02966184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006382|NCT04821739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006383|NCT05962268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34006384|NCT04741529|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34006385|NCT03176524|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34006386|NCT00855231|||COHORT||PROSPECTIVE|||||||
33927534|NCT00047008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927535|NCT00481741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927536|NCT04759222|||COHORT||PROSPECTIVE|||||||
33927537|NCT01985919|||COHORT||PROSPECTIVE|||||||
34006387|NCT03920306|NA|SINGLE_GROUP||PREVENTION||NONE||Single prospective arm; historical control||||
34006388|NCT03448991|||COHORT||PROSPECTIVE|||||||
34006389|NCT02514395|||OTHER||CROSS_SECTIONAL|||||||
34006390|NCT05274048|NA|SEQUENTIAL||TREATMENT||NONE||||||
33927538|NCT02720250|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33927539|NCT03114098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927540|NCT02989311|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33927541|NCT02929628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927542|NCT00004300|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33927543|NCT03616262|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33927544|NCT03572153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be randomized and either be assigned to the self-hypnosis group or a self-administered white noise hypnosis group.|f|f|t|t
33927545|NCT04121689|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927546|NCT01181141|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927547|NCT05823792|||OTHER||PROSPECTIVE|||||||
33927548|NCT01598207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927549|NCT03932019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006391|NCT03781531|||COHORT||PROSPECTIVE|||||||
34006392|NCT03181048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be randomized in a 1:1 fashion. The first arm will be the PAO alone group who will receive a standard periacetabular osteotomy (PAO) on the day of surgery. The second arm will be the PAO + HA group who will receive a PAO and hip arthroscopy (HA) on the day of surgery. Any pathology if present that can be corrected with the arthroscope (cartilage and labral abnormalities) will be addressed. This will be followed by a standard PAO. Patients from both groups will have dressings placed in the location of hip arthroscopy portals to remain blinded to the treatment arm during the perioperative period. Only patients in the PAO + HA group will have incisions and sutures under these dressings. The dressings will come off for all patients after 2 weeks, which is standard of care. All other study team members will remain unblinded."||t|f|f|f
33927550|NCT04397926|NA|SINGLE_GROUP||TREATMENT||NONE||Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks||||
34006393|NCT02172196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006394|NCT01813435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927551|NCT05300893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006395|NCT02483819|||COHORT||PROSPECTIVE|||||||
34006396|NCT06176755|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomised Control Trial||||
34006397|NCT05777382|||OTHER||CROSS_SECTIONAL|||||||
34091828|NCT02632942|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091829|NCT01588275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091830|NCT04790799|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33927552|NCT04186663|NA|SINGLE_GROUP||TREATMENT||NONE||Open label exposure--response study||||
33927553|NCT02967770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927554|NCT02608372|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34091831|NCT05707169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Laser Ablation of varicose veins|t|t|t|t
34091832|NCT00897845|||OTHER||RETROSPECTIVE|||||||
34091833|NCT00561327|||||RETROSPECTIVE|||||||
34103250|NCT01724385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103251|NCT01887600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927555|NCT01960426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33927556|NCT06067932|||COHORT||CROSS_SECTIONAL|||||||
33927557|NCT05263349|||CASE_CONTROL||PROSPECTIVE|||||||
33927558|NCT03340311||SEQUENTIAL||OTHER||NONE||Quasi-experimental pre-post design||||
33927559|NCT03345368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham rTMS will be administered with the coil held in contact with the head but at 180 degrees from scalp to avoid stimulation.|Study participants will be randomly assigned to one of two groups: the experimental group receiving rTMS and a placebo group receiving sham rTMS. Both groups will be on the low-carb diet.|t|f|f|f
33927560|NCT02957474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927561|NCT02851368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927562|NCT02894255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091834|NCT04825522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients will not know if they received vancomycin or not.|"Experimental Group: For surgeries involving one level, 500mg of vancomycin will be applied. For surgeries involving greater than 1 level and less than 3 levels, 1gm will be applied and for surgeries greater than 3 levels, 2gms will be applied.~Control Group: Will not receive any extra treatment."|t|f|f|f
34091835|NCT02197156|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34091836|NCT01025050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091837|NCT05852288|||COHORT||PROSPECTIVE|||||||
34091838|NCT04972721|||COHORT||PROSPECTIVE|||||||
34091839|NCT02738515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091840|NCT05482789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091841|NCT03016637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091842|NCT04176523|||CASE_ONLY||PROSPECTIVE|||||||
34091843|NCT00478036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091844|NCT00845000|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091845|NCT05201001|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised, open-label, three arm study||||
34091846|NCT06398691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Premature newborns (gestational age \<370/7 weeks) who did not require intubation, who were diagnosed with RDS, and who were treated with surfactant in the first 72 hours of life were included in the study. Written informed consent was obtained from all of the infants' families before the infants were enrolled in the study. Noninvasive respiratory support was provided by nasal CPAP or HHHNFC, respectively, according to the time of admission to the intensive-care unit, so the patients were divided into two groups. During the study period, the noninvasive respiratory support method (nasal CPAP or HHHNFC) that the babies received did not change.~Post-hoc, one-way difference between two independent means (two groups) statistical analysis was used. Significance P \< 0.05; effect size 0.9; power (1-ß err prob) was found to be 82%."||||
34091847|NCT01966783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091848|NCT04278352|RANDOMIZED|PARALLEL||PREVENTION||NONE||Waitlist control design||||
34091849|NCT04883853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091850|NCT04393012|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Evaluation of impact||||
34091851|NCT05075369|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||patients with a diagnosis of normal tension glaucoma and noted to have a disc hemorrhage||||
34091852|NCT02530840|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34091853|NCT06493747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34091854|NCT06430528|||COHORT||PROSPECTIVE|||||||
34091855|NCT02560805|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34091856|NCT00744835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927563|NCT05440487|||COHORT||PROSPECTIVE|||||||
33927564|NCT00410904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091857|NCT06467019|||OTHER||OTHER|||||||
34091858|NCT04528225|||COHORT||PROSPECTIVE|||||||
34091859|NCT04557644|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In this study both the staff and the infested family are to complete questionnaires addressing CI, disgust and empathy||||
34091860|NCT00177671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34091861|NCT00843973|||COHORT||PROSPECTIVE|||||||
34091862|NCT00397124|RANDOMIZED|PARALLEL||||NONE||||||
34091863|NCT01985659|||COHORT||RETROSPECTIVE|||||||
34091864|NCT04454502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind (researchers are not blind) randomization will be provided since the mothers will be provided with education on the importance of oral colostrum administration and milking techniques by the researchers. The statistician was also blinded for the data analysis purpose|: Randomized Controlled Trial|f|f|f|t
33927565|NCT05680818|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927566|NCT05885490|||OTHER||PROSPECTIVE|||||||
33927567|NCT04446299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927568|NCT00105183|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33927569|NCT01512472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927570|NCT02638272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927571|NCT06274268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
33927572|NCT00608842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091865|NCT00097435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091866|NCT04232137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking|||||
33927573|NCT03180242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927574|NCT04914871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The research will be conducted using the double-blinded model since the children, parents, and research assistants who will carry out the pre- and post-test measurements, will not know the assignment of the groups, control, and intervention.|According to the stated objectives, this study has a quantitative approach, Randomized Controlled Clinical Trial (RCT), with an experimental and control group and pre- and post-test measures; to explore the response of children to the intervention UN Lifeguard Kids in the Tunja version and approximation can be made its effectiveness.|t|f|f|t
33927575|NCT04436783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927576|NCT01521572|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006398|NCT05012176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701779|NCT05511194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be assigned to a control group or an experimental group based on simple random probabilistic sampling, using software (OxMaR: Oxford Minimization and Randomization, 2019) for minimization and randomization of clinical studies, single blind. A different postoperative treatment scheme will be applied for each of the groups.|Randomized controlled clinical trial, single blind.|t|f|f|f
33701780|NCT03691181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701781|NCT00704678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701782|NCT00413400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701783|NCT02389517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701784|NCT03534362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients eligible for the study and consenting to participate will be randomly assigned to one of two treatment groups: 1) Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract and 2) Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.|Single-blind (Subject) randomized, active control study. Subjects will be randomized 1:1 using the rand function in Microsoft Excel program.|t|f|f|f
33701785|NCT06319378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Controlled Trial, active placebo, randomization ratio 2:1|t|t|t|t
33701786|NCT02867150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701787|NCT06422767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double-blind study.||t|f|t|f
33701788|NCT05773443|||CASE_CONTROL||PROSPECTIVE|||||||
33701789|NCT02506465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701790|NCT02058693|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33701791|NCT00534066|||DEFINED_POPULATION||OTHER|||||||
33701792|NCT02476201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701793|NCT03336034|||OTHER||PROSPECTIVE|||||||
33701794|NCT06141018|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple-blind||t|f|t|t
33701795|NCT03414229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-center, phase II study to evaluate the efficacy of the IDO1 inhibitor, epacadostat, given in combination with the anti-PD1 monoclonal antibody, pembrolizumab, for patients with metastatic and/or locally advanced grade sarcomas.||||
33701796|NCT04534543|NA|SINGLE_GROUP||PREVENTION||NONE||• In this study we will investigate whether biochemical imaging of change (Δ, figure 1) in the metabolic phospholipid ratios of PME and PDE between baseline and after 2 weeks of therapy are predictive for RECIST progression in gastrointestinal cancer patients after the first 9 week treatment period.||||
33701797|NCT01870050|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33701798|NCT01723657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701799|NCT03012009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701800|NCT00370071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788208|NCT04245319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two groups Group A: patients will receive three NB-UVB sessions per week for 48 sessions. Group B: patients will receive three NB-UVB sessions per week for 48 sessions combined with acitretin in a dose of 0.3 mg/kg/day daily.|f|t|t|t
33788209|NCT03465254|||COHORT||PROSPECTIVE|||||||
33701801|NCT05944211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788210|NCT00083499|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33788211|NCT00816829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701802|NCT03827265|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|This is a single-blind study and only the participant will not be aware of when they will be undergoing the sham stimulation arm.||t|f|f|f
33701803|NCT00298116|||CASE_CONTROL||PROSPECTIVE|||||||
33701804|NCT02906332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788212|NCT04622150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788213|NCT05818306|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Both the Investigator and the subjects are not aware of the treatment administered.|Randomized, parallel-group, double-blind, placebo-controlled, single-center, multiple dose safety \& tolerability Phase Ia study|t|t|t|f
33788214|NCT02082366|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33788215|NCT00450151|||CASE_ONLY||PROSPECTIVE|||||||
33788216|NCT01649791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788217|NCT06631742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33788218|NCT00630513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34006399|NCT03776617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006400|NCT03651908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed envelopes|"In this study the patients are divided into two test groups-group A, group B. Each patient will be given careful instructions on proper oral hygiene measures. Under local anesthesia full-mouth supragingival and subgingival scaling and root planning procedure will be performed. After therapy, a periodontal evaluation will be done and the selected sites will be divided into group A and group B.~The Group A subjects will be treated with conventional flap surgery using Bioactive silica graft with PRF as a graft.~Group B will be treated with conventional flap surgery +bioactive silica graft alone in intrabony defects."|t|f|f|f
33701805|NCT04032548|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33788219|NCT05381662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788220|NCT05937906|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE|Non applicable|"Phase 1 (escalation dose)~* Level 1: mirdametinib 4 mg twice/day for 7 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab until progression (3-6 patients)~* Level 2: mirdametinib 4 mg twice/day for 14 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab until progression (3-6 patients)~* Level 3: mirdametinib 6 mg twice/day for 7 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab until progression (3-6 patients)~* Level 4: mirdametinib 6 mg twice/day for 14 days per cycle for the 4 first cycles + carboplatin/pemetrexed/pembrolizumab until progression (3-6 patients)~Phase 2 (randomized)~* Standard arm : Carboplatin/pemetrexed/pembrolizumab for the first 4 cycles until progression (26 patients)~* Experimental arm : Carboplatin/pemetrexed/pembrolizumab + mirdametinib for the first 4 cycles until progression (52 patients)"||||
34006401|NCT01765270|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33788221|NCT02689349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788222|NCT03762330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788223|NCT01664104|||COHORT||PROSPECTIVE|||||||
33788224|NCT01173614|||||PROSPECTIVE|||||||
33788225|NCT06157879|NA|SINGLE_GROUP||OTHER||NONE||||||
33788226|NCT00092716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788227|NCT02267980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788228|NCT04637750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788229|NCT03054220|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788230|NCT00465751|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33788231|NCT06165926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33788232|NCT05139095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788233|NCT05644652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33788234|NCT05778071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-controlled, double-blind study, with patients randomized in a 2:1 ratio to receive eneboparatide or placebo|t|t|t|t
33788235|NCT04551417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006402|NCT01780480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006403|NCT06189911|||COHORT||RETROSPECTIVE|||||||
34006404|NCT00560924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006405|NCT06617403|||COHORT||RETROSPECTIVE|||||||
34006406|NCT01816568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006407|NCT05108506|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34006408|NCT05927467|||COHORT||PROSPECTIVE|||||||
34006409|NCT01836614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006410|NCT00099957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34006411|NCT03662724|||COHORT||OTHER|||||||
34006412|NCT02625506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34006413|NCT02039063|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33701806|NCT05815173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701807|NCT05668429|NA|SINGLE_GROUP||OTHER||NONE||||||
33701808|NCT04852770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized clinical trial|f|f|t|t
33701809|NCT03502460|NA|SINGLE_GROUP||OTHER||NONE||||||
33701810|NCT06556654|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, multi-center, single-arm pivotal study using a propensity score stratification analysis for comparison of safety outcomes of prospectively treated subjects who underwent two-stage implant-based breast reconstruction with the TRBR Device (TRBR Device group) to historical control subjects who underwent two-stage implant-based breast reconstruction with no mesh/ADM (Control group). Effectiveness of TRBR will be evaluated by comparing change from baseline (pre-index procedure) at 1-year post-index procedure in BREAST-Q Physical Well Being, Chest Score to minimum clinically important difference (MCID) of 4 points.||||
33701811|NCT02051231|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701812|NCT04635189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701813|NCT05882357|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701814|NCT02701699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701815|NCT02231632|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34006414|NCT05799196|||COHORT||OTHER|||||||
34006415|NCT06614309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006416|NCT02665884|||COHORT||PROSPECTIVE|||||||
34006417|NCT01159106||CROSSOVER||DIAGNOSTIC||NONE||||||
34091867|NCT02768181|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34091868|NCT00657566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006418|NCT00552149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006419|NCT05445076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006420|NCT06678412|||COHORT||CROSS_SECTIONAL|||||||
34091869|NCT04307563|NA|SINGLE_GROUP||OTHER||NONE||||||
34091870|NCT02719795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006421|NCT03408522|||COHORT||PROSPECTIVE|||||||
34091871|NCT02693418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34091872|NCT02832999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34091873|NCT02608645|||||PROSPECTIVE|||||||
34091874|NCT04806451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34091875|NCT01308710|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34091876|NCT05117476|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34091877|NCT05276700|||CASE_CONTROL||PROSPECTIVE|||||||
34091878|NCT03875417|||CASE_CONTROL||RETROSPECTIVE|||||||
34091879|NCT05413642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091880|NCT04615507|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34091881|NCT03406468|NA|SINGLE_GROUP||TREATMENT||NONE||Given the objective of this phase II trial and the limited number of patients, no formal statistical analyses are planned. Analysis will be limited to presentation of frequencies and proportions and the report of descriptive statistics (e.g. mean, median and/or range) in tabulated form.||||
34091882|NCT06023797|||COHORT||RETROSPECTIVE|||||||
34091883|NCT05443854|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34091884|NCT04582071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091885|NCT03886623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091886|NCT04015063|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34091887|NCT04554251|||COHORT||PROSPECTIVE|||||||
34091888|NCT06476730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be two groups, experimental and control|f|f|f|t
34091889|NCT04248361|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized, Open-label, Multi-Center, Prospective Study||||
33701816|NCT02760797|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33788236|NCT06460363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788237|NCT05268198|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33788238|NCT03136523|||COHORT||RETROSPECTIVE|||||||
34091890|NCT00782444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701817|NCT00734474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701818|NCT00004756|RANDOMIZED|||ECT||||||||
33701819|NCT01298531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701820|NCT01428271|||||PROSPECTIVE|||||||
33701821|NCT04209192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33701822|NCT02598960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701823|NCT01206166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788239|NCT04702503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788240|NCT01396109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006422|NCT06269354|||COHORT||PROSPECTIVE|||||||
34006423|NCT03357354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006424|NCT01717937|||COHORT||PROSPECTIVE|||||||
34006425|NCT03245892|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single center, non-randomized, open label, pilot study to evaluate the safety and tolerability of neoadjuvant and post-surgical dose dense paclitaxel and carboplatin chemotherapy in combination with nivolumab for the treatment of advanced high grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin.||||
34006426|NCT04651595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34006427|NCT05482204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006428|NCT06533280|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind (sponsor-unblinded) study.||t|f|t|f
34006429|NCT04202341|||COHORT||PROSPECTIVE|||||||
34006430|NCT00328484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091891|NCT04058301|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34091892|NCT06069518|||CASE_ONLY||PROSPECTIVE|||||||
34091893|NCT05584436|||COHORT||PROSPECTIVE|||||||
34091894|NCT04664387|||OTHER||CROSS_SECTIONAL|||||||
34091895|NCT00042146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091896|NCT05054881|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34006431|NCT00987142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701824|NCT05567315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The person collecting the endpoints will be blinded to the treatment group|Single-centre, comparative, randomised, parallel group study|f|f|f|t
34006432|NCT06347718|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1:~Evaluating the safety of CAR-T-Cells in systemic autoimmune diseases with 8 patients~Phase 2:~Evaluating the efficiency of CAR-T-Cells in systemic autoimmune diseases with 16 patients"||||
34006433|NCT03296813|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a randomized, unblinded, two-arm, multi-center clinical trial of patients with heart failure who are hospitalized. Patients will be randomized 1:1 to either oral torsemide OR oral furosemide prior to hospital discharge.||||
33701825|NCT02095418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701826|NCT02740439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701827|NCT01979965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33701828|NCT00740571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701829|NCT02587793|||CASE_ONLY||PROSPECTIVE|||||||
33701830|NCT01601730|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33701831|NCT01518348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701832|NCT05243355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701833|NCT02725931|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701834|NCT04346082|NA|SINGLE_GROUP||TREATMENT||NONE||participants receiving online mindfulness session(s)||||
33701835|NCT00747461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701836|NCT04752683|||COHORT||CROSS_SECTIONAL|||||||
33701837|NCT02904993|RANDOMIZED|PARALLEL||||NONE||||||
33701838|NCT01868503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701839|NCT06555497|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33701840|NCT02515448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701841|NCT06261918|||CASE_CONTROL||PROSPECTIVE|||||||
33701842|NCT05133752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701843|NCT06487416|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33701844|NCT01435902|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33701845|NCT02831140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701846|NCT01971242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701847|NCT00499239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701848|NCT00089414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701849|NCT01971996|||CASE_ONLY||PROSPECTIVE|||||||
33701850|NCT05571670|||CASE_ONLY||PROSPECTIVE|||||||
33701851|NCT03995433|||CASE_ONLY||PROSPECTIVE|||||||
33701852|NCT02927886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701853|NCT06281574|||COHORT||PROSPECTIVE|||||||
33701854|NCT05345977|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A prospective non-randomised feasibility trial||||
33701855|NCT02358681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701856|NCT05148065|||CASE_ONLY||PROSPECTIVE|||||||
33701857|NCT03473171|NA|SINGLE_GROUP||OTHER||NONE||||||
33788241|NCT04124068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788242|NCT05112250|||COHORT||CROSS_SECTIONAL|||||||
33788243|NCT00005813||||TREATMENT||||||||
33788244|NCT04598529|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33788245|NCT01632930|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006434|NCT02250924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34006435|NCT00108628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006436|NCT05394805|||COHORT||PROSPECTIVE|||||||
34006437|NCT05375331|||CASE_CROSSOVER||PROSPECTIVE|||||||
34006438|NCT03992547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006439|NCT06535464|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34006440|NCT05263284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006441|NCT02194140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006442|NCT00895037|||COHORT||PROSPECTIVE|||||||
34006443|NCT00251316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788246|NCT03921489|||COHORT||PROSPECTIVE|||||||
33927577|NCT05308160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927578|NCT01579149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927579|NCT00905372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927580|NCT02791867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33927581|NCT04992637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Women will be randomized to receive either the ClockWork intervention or Usual Care.||||
33927582|NCT02998255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927583|NCT03245502|||CASE_CONTROL||PROSPECTIVE|||||||
33927584|NCT05881512|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33927585|NCT03966495|||OTHER||PROSPECTIVE|||||||
33927586|NCT01969513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927587|NCT04675736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927588|NCT06067750|||OTHER||PROSPECTIVE|||||||
33927589|NCT00400556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927590|NCT02162459|||CASE_CONTROL||PROSPECTIVE|||||||
33927591|NCT04368897|||CASE_CONTROL||PROSPECTIVE|||||||
33927592|NCT01949857|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33927593|NCT00014001|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33927594|NCT00000361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34091897|NCT05392478|||CASE_CONTROL||OTHER|||||||
34091898|NCT06370585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase I, controlled, comparative, double-masked, single-center, randomized, controlled clinical trial.|t|t|t|t
34091899|NCT00990288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34091900|NCT05804968|NA|SINGLE_GROUP||OTHER||NONE||Single Case Experimental Design||||
34091901|NCT02661477|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091902|NCT01078597|||COHORT||PROSPECTIVE|||||||
34091903|NCT01860092|||COHORT||PROSPECTIVE|||||||
34091904|NCT04705753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091905|NCT00219271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091906|NCT00410488|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34091907|NCT02779296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34091908|NCT00017160||||TREATMENT||||||||
34091909|NCT02399020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927595|NCT00977717|||COHORT||PROSPECTIVE|||||||
33927596|NCT03633591|NA|SINGLE_GROUP||OTHER||NONE||||||
34091910|NCT04896294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091911|NCT02789748|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34091912|NCT04327271|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2wT clients will receive automated daily texts from days 1-13. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity||||
34091913|NCT06315166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091914|NCT01744821|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34091915|NCT00541229|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091916|NCT06201091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091917|NCT05984459|||COHORT||RETROSPECTIVE|||||||
33927597|NCT01128881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927598|NCT01311895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927599|NCT03597503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing|t|t|t|f
33927600|NCT04787926|||COHORT||PROSPECTIVE|||||||
33927601|NCT03499613|||COHORT||PROSPECTIVE|||||||
33927602|NCT03919006|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|f|f|f|t
33927603|NCT05432037|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33927604|NCT05817981|||COHORT||CROSS_SECTIONAL|||||||
33927605|NCT03012594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927606|NCT05799209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigator and participant are masked to study arm until after the participant completes their baseline assessment visit, at which point they are randomized using a sealed envelope.|Participants complete both arms of the study on separate days.|t|t|f|f
33927607|NCT04334772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33927608|NCT03504436|||COHORT||PROSPECTIVE|||||||
33927609|NCT00005969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927610|NCT05218304|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||This is an observational, descriptive and cross-sectional study|t|t|t|t
33927611|NCT02687932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006444|NCT05332886|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"In the study, there will be interventions in both groups, as metaverse-based education and activity programme will be given to the MetaHealth Group and digital health education with a mobile application materials will be given to the MobileHealth Group. In both groups, the participants will be aware that an attempt has been made on them, but since they will not know which group they are in, the participant will be blinded. Since the interventions will be managed by the research team, researcher blinding will not be possible. However, the statistician will be blinded. At the end of the research, the groups will be coded as A and B. Statistical analysis will be made by the statistics expert who is blinded to the groups in the project partner company. After the statistical analysis are made and the research report is written, the situations expressed by A and B will be explained to the statistician. In this way, it is planned to control the bias in statistics and reporting."|Parallel Desing Active Comparative Group Randomized Controlled Trial|t|f|f|t
34006445|NCT01085578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006446|NCT06616324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of VR, it is impossible to mask the patients and the healthcare providers administering the shockwave treatment.||f|f|t|f
34006447|NCT04138784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006448|NCT03567525|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Neither the patient nor the surgeon (who is also the investigator) will know to which arm patients are randomized (standard surgical approach) or experimental approach||t|t|t|f
34006449|NCT01701973|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34006450|NCT00968500|||COHORT||CROSS_SECTIONAL|||||||
34006451|NCT05930158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006452|NCT04043819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006453|NCT00792584|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006454|NCT01637831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006455|NCT01913717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006456|NCT04954690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an exercise intervention. Therefore participation and coaching cannot be masked. In order to ensure safety, the primary nephrologist and dialysis clinic will be informed of patients participation in the trial. However, they will not be involved with coaching or assessing outcomes.|Randomized controlled trial|f|f|f|t
34006457|NCT01711996|||COHORT||PROSPECTIVE|||||||
34006458|NCT01114581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006459|NCT01747577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006460|NCT01279382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701858|NCT04871971|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|single-blind|single-blind, randomised, repeat measure, crossover design trial|t|f|f|f
33701859|NCT05124535|||OTHER||CROSS_SECTIONAL|||||||
33701860|NCT00837356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701861|NCT04382300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701862|NCT03888586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927612|NCT01913743|||CASE_ONLY||CROSS_SECTIONAL|||||||
33927613|NCT03554850|||CASE_ONLY||PROSPECTIVE|||||||
33701863|NCT05081765|||CASE_CONTROL||PROSPECTIVE|||||||
33701864|NCT00865670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33701865|NCT05562687|||CASE_CONTROL||PROSPECTIVE|||||||
34006461|NCT04551287|||COHORT||OTHER|||||||
34006462|NCT03446365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||6th to 8th grade middle schoolers will be enrolled then randomly assigned to one of three conditions: 1) ASMAS, 6th to 8th grade middle schoolers will be enrolled then randomly assigned to 1) ASMAS, or 2) Asthma Education plus Child Health control condition, or 3) a no treatment control condition||||
34006463|NCT00063258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006464|NCT03990116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788247|NCT04656002|NA|SINGLE_GROUP||TREATMENT||NONE||"TEW-7197 300 mg BID 5D on/2D off~+ Ramucirumab IV 8 mg/kg every 2weeks +Paclitaxel 80 mg/m2 day1.8.15 every 28days"||||
34091918|NCT02101177|||COHORT|||||||||
34091919|NCT05915377|||OTHER||PROSPECTIVE|||||||
33788248|NCT04618913|||COHORT||RETROSPECTIVE|||||||
33788249|NCT00119899|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33788250|NCT00454662|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34006465|NCT01383850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091920|NCT04203056|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|Randomized Controlled Trial; 12-month longitudinal follow-through study (anticipate enrolling at least 128 patients of whom 90 will be randomized to one of the two arms)||||
34006466|NCT05576506|||COHORT||PROSPECTIVE|||||||
34006467|NCT03424655|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Certified endodontists trained in the procedures, devices, and systems investigated took part in the research. All experts tracked a pre-established procedure for the Balanced Force technique, Twisted File Adaptive, WaveOne, and Reciproc instrument systems.|teeth selected for conventional RCT for prosthetic reasons detected with only vital pulps. Of the sample of 224 teeth, 56 were selected to the 4 instrumentation methods. For hand instrumentation, Balanced Force were used. All canals were clean and shaped with hand Flex-R files (fMoyco/Union Broach, York PA, USA). For mechanical shaping, all instruments were used with a micro motor (VDW, Munich Germany). Twisted files adaptive, WaveOne and Reciproc instruments. Final irrigation with cold (6oC) 17% EDTA served as a lubricant.|t|f|t|f
34006468|NCT04916613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded placebo controlled trial|Phase III, international, multicenter, randomized|t|t|t|t
34091921|NCT04909788|||OTHER||PROSPECTIVE|||||||
34006469|NCT01273857|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34006470|NCT02957916|||OTHER||OTHER|||||||
34006471|NCT03754530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091922|NCT00092729|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34091923|NCT04028505|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental Arm: Standard of care being given at AKUH + Continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours Comparator Arm: Standard of care being given at AKUH + Bolus infusion of Terlipressin at a frequency of 2mg every six hourly for first 24 hours||||
34091924|NCT00211367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34091925|NCT04906798|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34091926|NCT02332707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701866|NCT00066638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701867|NCT04673968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701868|NCT01897714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701869|NCT03397615|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33701870|NCT00671333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701871|NCT01047670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701872|NCT02759497|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701873|NCT05203432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701874|NCT04074031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788251|NCT02013037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788252|NCT02793297|RANDOMIZED|CROSSOVER||||NONE||||||
33788253|NCT01735240|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788254|NCT02909699|||OTHER||PROSPECTIVE|||||||
33788255|NCT02050958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091927|NCT00314106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091928|NCT00143572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091929|NCT01023997|||COHORT||PROSPECTIVE|||||||
34091930|NCT06343701|||OTHER||PROSPECTIVE|||||||
34091931|NCT05256368|||COHORT||PROSPECTIVE|||||||
34091932|NCT02099552|||COHORT||OTHER|||||||
34091933|NCT03934801|||COHORT||PROSPECTIVE|||||||
34091934|NCT00590876|||COHORT||PROSPECTIVE|||||||
34091935|NCT01235819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091936|NCT03969420|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Two-stage||||
34091937|NCT04718753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788256|NCT03114722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006472|NCT05845957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The research was a randomized controlled, experimental study.|f|f|t|f
34006473|NCT03010852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006474|NCT01069731|||COHORT||PROSPECTIVE|||||||
34006475|NCT04908280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006476|NCT03898531|||CASE_CONTROL||PROSPECTIVE|||||||
34006477|NCT02536469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006478|NCT01341678|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34006479|NCT02835963|||COHORT||PROSPECTIVE|||||||
34006480|NCT06105021|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase I, FIH, multicenter, open-label study of AFNT-211 consisting of a dose escalation part and a dose expansion part. During dose escalation the optimal biological dose (OBD) will be determined as well as the recommended phase 2 dose (RP2D). Additional subjects will enroll in expansion cohorts treated at OBD/RP2D found in escalation.||||
34006481|NCT00522990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006482|NCT06617741|||COHORT||PROSPECTIVE|||||||
34006483|NCT03026309|||COHORT||PROSPECTIVE|||||||
34006484|NCT00533806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006485|NCT01677208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006486|NCT00005086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006487|NCT00116493|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34006488|NCT01780376|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091938|NCT03233750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group assignment will be masked from the assessors of performance. Expert educators will score videotaped performances of the participants obtained pre and post intervention. Assessors will be blinded to group allocation as well as to whether the video they are scoring is of the pre or the post intervention scenario.|This is a cohort study, comparing two interventions aimed at decreasing stress responses during acute events, with a pre and a post intervention assessment.|f|f|f|t
34091939|NCT02858258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091940|NCT01428245|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091941|NCT03325439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701875|NCT03798197|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33701876|NCT04736693|||COHORT||RETROSPECTIVE|||||||
33701877|NCT04510142|||COHORT||CROSS_SECTIONAL|||||||
33701878|NCT03954691|||CASE_ONLY||RETROSPECTIVE|||||||
33701879|NCT01524731|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33701880|NCT03822182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a double-blinded study, thus, neither the surgeon nor the patient will know which type of interscalene block is used. A total of 78 envelopes containing will be generated consisting of 26 with Group 1, 26 with Group 2 and 26 with Group 3 designation. Envelopes will be sealed and randomly chosen by the anesthesiologist prior to surgery. The anesthesiologist will randomly select one of the envelopes which will determine the treatment group and indicate medications that will be included in the interscalene block. Patients will be blinded to the medication utilized as well as the treating surgeon."|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control) Group 2 Group 3 30 ml of 0.5% bupivacaine and 0.4ml. of dexamethasone 15ml 0.5% bupivacaine and 10ml of LB (Exparel) and 5.4ml normal saline 15ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml dexamethasone and 5ml normal saline"|t|t|t|f
33701881|NCT06070272|||CASE_CROSSOVER||PROSPECTIVE|||||||
33701882|NCT02520830|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33701883|NCT05413070|||COHORT||PROSPECTIVE|||||||
33701884|NCT00003962||||TREATMENT||||||||
33701885|NCT00573937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701886|NCT01014000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701887|NCT04034836|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33701888|NCT01199172|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33701889|NCT05369767|RANDOMIZED|PARALLEL||OTHER||TRIPLE||SHR-2004 injection compared with placebo|t|t|t|f
33701890|NCT04337268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33701891|NCT01354457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701892|NCT02620722|NA|SINGLE_GROUP||OTHER||NONE||||||
33701893|NCT01548287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701894|NCT03491267|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|assesors will be blinded|Areas on a single scalp will be treated or untreated and monitored|f|f|f|t
33788257|NCT02584517|||COHORT||PROSPECTIVE|||||||
34025177|NCT03058289|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|There were no masking and all patients received INT230-6 treatments.|"There were 6 cohorts in the escalation portion of the protocol. Five dosed INT230-6 alone and one was combined with pembrolizumab. Cohorts A and B1 treated superficial tumors at a 1:4 ratio of drug to tumor with a low tumor load once per month. Cohort EA was similar to cohort A with INT230-6 every 2 weeks. Cohort EC escalated the total and maximal dose per any one tumor to a ratio of 1:2 \& dosed every two weeks. Cohort EC2 explored a drug load ratio of 1:3 and escalated the dose per tumor further. Cohort DEC combined INT230-6 with a fixed amount of pembrolizumab.~Completed, non-escalation cohorts include 1) monotherapy INT230-6 cohort (EC3) dosed every two weeks 2) INT230-6 in a combination with pembrolizumab (DEC2) and 3) INT230-6 in combination with ipilimumab (FEC). Other specific regimens or combinations of INT230-6 may be designated by the Study Steering Committee."||||
34025178|NCT04522115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group 1 received aerobic exercises and group 2 received resistance exercises.|t|f|f|f
34025179|NCT05176795|||CASE_CONTROL||PROSPECTIVE|||||||
34025180|NCT06357806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025181|NCT01751737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34091942|NCT03807843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Study medication is available as liquid frozen vaccine product or saline for injection (placebo). The actual study injections will be forwarded to the investigator (injector) in a blinded fashion (injection ready syringes containing either vaccine or placebo).|Placebo-controlled, randomized, double-blinded, interventional, safety study|t|f|t|f
34091943|NCT02516436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34091944|NCT02512419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091945|NCT01660542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091946|NCT03228914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701895|NCT02213523|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34091947|NCT05405842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||n= 60 3 groups : gastroparesis (n=20); functional dyspepsia (n=20) ; health controls (n=20)||||
34091948|NCT03227237|||CASE_CONTROL||RETROSPECTIVE|||||||
34091949|NCT04665232|||COHORT||PROSPECTIVE|||||||
34091950|NCT04792268|RANDOMIZED|PARALLEL||OTHER||NONE||"This is a feasibility study of a two-arm randomized controlled cluster trial conducted in general adult psychiatry inpatient ward settings.~Wards will be the unit of recruitment and assigned to either the intervention or control group in a 1:1 ratio, to receive either the eCDSS platform or to follow usual care process."||||
34091951|NCT00002470||||TREATMENT||||||||
34091952|NCT02200081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091953|NCT03860753|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091954|NCT03062839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091955|NCT05813496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|"After signing the ICF, eligible patients were randomized in a 1:1 allocation ratio, into one of the two treatment groups, to receive either ALA or placebo. Randomization will be done using an interactive web response system (IWRS).~Randomization was stratified by baseline body mass index (BMI) (\< 25 Kg/m2 or 25-40 Kg/m2) followed by age (\<45 years or ≥ 45 years) and gender (male or female)."|t|t|t|t
33701896|NCT04776109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||First group (Group of continous thoracic epidural bupivacaine infusion \[CEI\]) Second group (Group of continous bilateral erector spinae bupivacaine infusions\[CESI\])|t|t|f|f
33701897|NCT04594811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701898|NCT02465645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701899|NCT06374212|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants, if eligible, will receive the study drug (anifrolumab).||||
33701900|NCT04652427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701901|NCT06208865|||OTHER||RETROSPECTIVE|||||||
33788258|NCT02376036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33788259|NCT03092440|||COHORT||PROSPECTIVE|||||||
34091956|NCT04521452|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open-label trial||||
33788260|NCT05407129|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33788261|NCT04584021|||CASE_ONLY||PROSPECTIVE|||||||
33788262|NCT03702543|NA|SINGLE_GROUP||PREVENTION||NONE||In this feasibility study, a customized electronic diary will be provided to collect data 1) from bluetooth devices, 2) from Apple Health app information, and 3) from self-reported diary information. Researchers will provide feedback via charts and reminders/text messages to encourage management of vascular risk factors.||||
34091957|NCT03060681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33788263|NCT04904757|NA|SINGLE_GROUP||SCREENING||NONE||||||
33788264|NCT02729272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788265|NCT01353092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34091958|NCT00857389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091959|NCT05726136|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 randomized parallel groups, with 20 patients in each group. Each group receives a prespecified fluid regime with: 1. acetated Ringers 2. albumin 5% or 3. albumin 20%||||
34091960|NCT02529332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091961|NCT01860508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091962|NCT05835700|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Gastermin D and Pentaxin 3 levels were measured in the patients participating in the study. These are not routinely checked markers. Participants were assigned prospectively to an intervention or interventions according to a protocol to evaluate the effect of the intervention(s) on preeclampsia or HELLP related outcomes. Due to this, our work is interventional.||||
34091963|NCT01704079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788266|NCT04547348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006489|NCT03396588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will mask parents and child caregivers, and NICU nurses giving the drug, other personnel, residents and attending physicians, and research staff. Since initial dose is set using weight based-dosing, a physician's order can be entered in the electronic medical record to give the initial study drug with the infant's weight stated in the order. Increase in dosing will be ordered as to increase by 25% of initial dose or decrease of dose by 10% of maximum dose. During the pilot study, masking of treating personnel was maintained while the hospital pharmacist was the only person aware of which study drug the infant was receiving. The examiners for administration of the NNNS and the research nurse and research case worker will be masked to treatment received. Those seeing the infant in the clinic will also be masked to the treatment assignment. Morphine and clonidine are dispensed in identical appearance, color, smell, and volume.|The study is intended to treat NAS using a randomized and double-blind study design to compare the use of opiate (morphine) or non-opiate (clonidine). Newborns meeting the study criteria for drug withdrawal and treatment will be randomized to receive one of the drugs (morphine, clonidine). Newborns requiring a second drug to help relieve the symptoms will be treated with phenobarbital for both groups. Randomization, blinding and dispensing will occur in the Investigational Drug Services Unit. Nursing personnel in the NICU will be masked to the treatment administered to each baby.|t|t|t|t
33701902|NCT00169546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701903|NCT00747331|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33701904|NCT01422460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701905|NCT06297317|||COHORT||PROSPECTIVE|||||||
33701906|NCT05342935|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Subjects will pursue their usual manual PD exchanges, followed by the treatment with the investigational device and then back to their manual PD.||||
33701907|NCT00737243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701908|NCT01902823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33701909|NCT00246753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788267|NCT05687799|||CASE_ONLY||PROSPECTIVE|||||||
34006490|NCT01363466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006491|NCT06367699|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34006492|NCT05955469|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: The patient and the Investigator don't know the fitting.|"Crossover Assignment~Two arms A and B:~Arm A: Bimodal patient's fitting with default fitting (FS4) --\> 6 weeks use --\> tests and bimodal patient's fitting with tonotopy-based fitting (TFS4) --\> 6 weeks use --\> tests; Arm B: Bimodal patient's fitting with TFS4 --\> 6 weeks use --\> tests and bimodal patient's fitting with FS4 --\> 6 weeks use --\> tests"|t|f|t|f
34006493|NCT01417325|||CASE_ONLY||CROSS_SECTIONAL|||||||
34006494|NCT06105164|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34006495|NCT01675076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701910|NCT01758523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006496|NCT04221126|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization|||||
34006497|NCT01938235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006498|NCT05386095|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded||t|f|f|t
34006499|NCT03579134|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33701911|NCT03531125|||COHORT||PROSPECTIVE|||||||
33701912|NCT00472719|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33701913|NCT05432375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788268|NCT03014102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788269|NCT02908464|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788270|NCT04958811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788271|NCT03162887|NA|SINGLE_GROUP||SCREENING||NONE||||||
33788272|NCT04338165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788273|NCT06313138|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33788274|NCT03919617|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-center, open label, multi-dose study.||||
33701914|NCT06558175|NA|SINGLE_GROUP||TREATMENT||NONE||"This multi-institution phase I dose-escalation study for patients undergoing thoracic re-irradiation will use a time-to-event continual reassessment method (TITE-CRM).~Accrual will start at level 1 (recovery factor = 10% at 6 months + 0.75% per month thereafter). Patients will be assigned to recovery factors using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3-5 toxicity of 35% or less."||||
33701915|NCT04812171|||COHORT||PROSPECTIVE|||||||
33701916|NCT04689269|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blind to the data collected|"A single-center, interventional, crossover, single-blind (participant), prospective, trial in simulated easy and difficult airway. The study will be conducted according to Good Clinical Practice (GCP) Guidelines and abide by the principles of the Declaration of Helsinki."|t|f|f|f
33701917|NCT01307982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701918|NCT03695744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701919|NCT05687175|||COHORT||CROSS_SECTIONAL|||||||
33701920|NCT00991120|||OTHER||OTHER|||||||
33701921|NCT01457222|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33701922|NCT06045780|||COHORT||OTHER|||||||
33701923|NCT05830773|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A convenience sample of participants are chosen for the intervention. There is no waitlist or control condition,||||
33701924|NCT03026361|||COHORT||PROSPECTIVE|||||||
33701925|NCT01130675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701926|NCT06429488|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701927|NCT00493623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33701928|NCT02698878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701929|NCT02498587|||COHORT||PROSPECTIVE|||||||
33701930|NCT03789214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701931|NCT00241943|RANDOMIZED|PARALLEL||||NONE||||||
34091964|NCT02041572|NA|SINGLE_GROUP||TREATMENT||NONE|The transition point from the assessment only version of the attention bias program to the retraining/ bias correction version was randomized at the participant level and occurred between weeks 4 and 7 of the 10-week study.|||||
33701932|NCT01141673|||COHORT||PROSPECTIVE|||||||
33701933|NCT02023593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701934|NCT00510497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091965|NCT06106997|NA|SINGLE_GROUP||OTHER||NONE||||||
34091966|NCT04023253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091967|NCT02842099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091968|NCT03587597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34091969|NCT03672084|||COHORT||PROSPECTIVE|||||||
34091970|NCT03423472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091971|NCT06036238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34091972|NCT06285903|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 20 patients were randomly divided into two groups: Group1: patients received dental implant using osseodensification via Densah bur, Group2: patients received dental implant using hydrodynamic piezoelectric sinus lifting. The patients in both groups underwent bone grafting under sinus membrane. Modified bleeding index and probing depth were evaluated at 3, 6 and 12months intervals. An Osstell device was used to de-termine implant stability by recording the values of implant stability quotient (ISQ) im-mediately after implant placement and after 3 months. CBCT was performed before, af-ter 6 months and after 12 months to evaluate ridge height, bone density. Marginal bone loss was evaluated after 3 months via periapical radiograph, after 6 months and after 12 months via CBCT.||||
34091973|NCT00135655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34091974|NCT03419650|NA|SINGLE_GROUP||TREATMENT||NONE||treatment arm will then be observed.||||
34091975|NCT03819127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34091976|NCT03319888|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34091977|NCT00435643|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091978|NCT06379126|||COHORT||PROSPECTIVE|||||||
34091979|NCT03415256|RANDOMIZED|PARALLEL||OTHER||NONE||"* After completing the tests, you will be randomly assigned by the computer to either the treatment group or control group.~* The treatment group will receive a passive vibration treatment for 15 minutes twice a week for 4 weeks.~* The control group will not receive any treatment and they will continue their usual lifestyle."||||
34091980|NCT01476072|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34091981|NCT04302324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091982|NCT04087590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091983|NCT05771870|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34091984|NCT04085640|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34091985|NCT03877822|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will firstly undergo 2 days of habitual physical activity, followed by 2 days of bed rest||||
34091986|NCT04790383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34091987|NCT05920239|||CASE_CONTROL||PROSPECTIVE|||||||
34091988|NCT06104293|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The grass pollen allergen (Phl p 5) concentrations corresponding to concentrations A, B, C and D are assigned randomly by the technician and the pharmacist of the exposure chamber so that neither the investigator, the participants nor the clinical and medical staff are aware of the exposure doses.|Single-center, randomized, crossover, double-blind, controlled study.|t|t|t|t
34091989|NCT02992379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091990|NCT04645706|||COHORT||PROSPECTIVE|||||||
33701935|NCT04752969|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701936|NCT00145782|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33701937|NCT05469191|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A group that will perform the 5 STS will be compared with a group that will perform the 10 STS for 8 weeks, and there will also be a control group.||||
33701938|NCT00344708|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788275|NCT05903807|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Fifty consecutive patients newly diagnosed with ovarian cancer are recruited||||
33701939|NCT00369824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788276|NCT03049202|||COHORT||CROSS_SECTIONAL|||||||
34091991|NCT00430326|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34091992|NCT00691964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33701940|NCT06322680|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Multicenter, Controlled, Superiority Trial||||
33701941|NCT03479073|||COHORT||RETROSPECTIVE|||||||
34006500|NCT05021887|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Laboratory blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33701942|NCT03406767|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"As both intervention arms are exercise-based it is impossible to mask the participants or individuals delivering the programs.~All outcome measurements will be performed by a research assistant who is blinded to participant group assignment."|"This study involves evaluation of knee osteoarthritis patients who are participating in one of two existing community-based exercise programs (i.e., the GLA:D® or the JointEffort program). Given the pre-experimental design participants will be enrolled after they have registered for one of the two programs (i.e., participants will not be allocated to group assignment) and there is no control group.~1. The GLA:D® program consists of 1) pre and post program self-reported and functional outcome measures; 2) 2, 1.5 hour education sessions; and 3) neuromuscular exercise training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.~2. The Joint Effort program consists of: 1) one visit aimed at individualized program design; 2) registered dietician led nutrition seminar; and 3) individualized exercise training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks."|f|f|f|t
33701943|NCT03482921|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33701944|NCT05202028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701945|NCT05449548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701946|NCT02018068|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33701947|NCT04901676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701948|NCT03285854|||CASE_CONTROL||PROSPECTIVE|||||||
33701949|NCT00005044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701950|NCT06558331|||COHORT||PROSPECTIVE|||||||
33701951|NCT02702453|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33701952|NCT02549534|||COHORT||PROSPECTIVE|||||||
33701953|NCT00236587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701954|NCT02158975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701955|NCT01629992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34006501|NCT04769115|NA|SINGLE_GROUP||PREVENTION||NONE||Diabetics who have no history of lower extremity (LEX) complications Diabetics who a history of LEX complications||||
34006502|NCT06267209|||COHORT||CROSS_SECTIONAL|||||||
34006503|NCT01794754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34006504|NCT02294448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006505|NCT01873781|||COHORT||PROSPECTIVE|||||||
34006506|NCT05675358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The child's pain and fear were evaluated blindly to each other by the parent and the nurse who performed the phelobotomy attempt.||f|f|f|t
34006507|NCT06353308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006508|NCT04596397|RANDOMIZED|PARALLEL||TREATMENT||NONE|The women included will be randomized from number 1 -20 where number 1-10 are inpatient and number 11-20 are outpatient.|All eligible women will be recruited form a midwife and/or doctor. After the inclusion they will be randomized to either inpatient or outpatient setting.||||
34006509|NCT03795389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006510|NCT00706719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006511|NCT04271072|||COHORT||PROSPECTIVE|||||||
34006512|NCT03690167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006513|NCT05831384|||OTHER||PROSPECTIVE|||||||
34006514|NCT00083434||||TREATMENT||||||||
34006515|NCT00202839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006516|NCT04458558|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective Cohort||||
34006517|NCT05762887|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All blind clinical assessments will be done by Psychiatrists, members of the University of São Paulo (USP) Bipolar Research Program managed by Michelle Flores. In this study, the intervention will be double-blind: All participants will receive the exact same pill, whether placebo or intervention, with equal packaging-manufacturing.|A Randomized, Double-Blind, Placebo-controlled|t|t|t|t
34006518|NCT00459823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701956|NCT04903444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33701957|NCT01171417|||COHORT||PROSPECTIVE|||||||
33701958|NCT02302807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701959|NCT05986786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701960|NCT01552993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33701961|NCT04149379|NA|SINGLE_GROUP||TREATMENT||NONE||Single subject SSED||||
33788277|NCT06234280|||CASE_ONLY||PROSPECTIVE|||||||
33788278|NCT04720781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788279|NCT05691179|||COHORT||PROSPECTIVE|||||||
33788280|NCT06279429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006519|NCT04101695|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34006520|NCT02075034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006521|NCT04313426|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34006522|NCT00523289|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34006523|NCT01510860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006524|NCT00024349|RANDOMIZED|||TREATMENT||||||||
34006525|NCT02491996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006526|NCT01961687|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788281|NCT01624558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788282|NCT01159158|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788283|NCT00093795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788284|NCT02814266|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34006527|NCT00056381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006528|NCT02225106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006529|NCT03090490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006530|NCT03527680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006531|NCT06024317|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This type 1 effectiveness-implementation hybrid study uses a cluster-randomized trial design to evaluate intervention effectiveness.||||
34006532|NCT05586035|||COHORT||PROSPECTIVE|||||||
34006533|NCT00638833|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006534|NCT04526652|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blinded study|Randomization of paediatric patients for general anaesthesia one arm: Intranasal dexmedetomidine another arm: Intranasal normal saline (placebo)|t|t|t|t
34006535|NCT05612139|||COHORT||RETROSPECTIVE|||||||
34006536|NCT02510261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All the participants received only patisiran but divided into 3 arm groups based on administration in the parent study (placebo or patisiran in 003 \[NCT01961921\] or 004 \[NCT01960348\] studies).||||
34006537|NCT00206596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006538|NCT02371993|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006539|NCT06001801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006540|NCT04126343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34006541|NCT05996692|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006542|NCT04184206|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34006543|NCT04703855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006544|NCT02434263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006545|NCT00804024|||COHORT||PROSPECTIVE|||||||
34006546|NCT00835939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006547|NCT01661634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006548|NCT02821949|||COHORT||PROSPECTIVE|||||||
34006549|NCT04314544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006550|NCT02512055|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34006551|NCT01007279|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006552|NCT00984516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006553|NCT00386646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34006554|NCT06021054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study design is a randomized, double-masked, and placebo-controlled trial, where participants, site personnel (except pharmacy personnel preparing the infusate), and sponsor will be masked to treatment|The study will be comprised of approximately 159 participants randomized to either 5 IV infusions of 10 mg/kg veligrotug (VRDN-001) administered at 3-week intervals or placebo IV infusions administered at 3-week intervals.|t|f|t|t
34006555|NCT01401335|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34006556|NCT01027767|||COHORT|||||||||
34006557|NCT00688298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006558|NCT03224520|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Using a 2×2 factorial design, we will compare individually and collectively the enhancements (recruitment, use, and effectiveness) offered by the S2S functions over the standard version of Decide2Quit (online recruitment and standard CTHC), an active comparison group that was demonstrated to be effective in our previous trial.|t|f|t|f
34006559|NCT01503463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34006560|NCT00808509|RANDOMIZED|PARALLEL||||NONE||||||
34006561|NCT02931292|||COHORT||PROSPECTIVE|||||||
34103252|NCT04112368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Identical placebos provided by the University of Illinois at Chicago investigational drug service.|Crossover 2-Condition Placebo-Controlled Trial|t|t|t|t
33701962|NCT06326099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701963|NCT03710005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701964|NCT05708209|||OTHER||OTHER|||||||
33701965|NCT00311844|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33701966|NCT05335629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33701967|NCT06022393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients are randomly assigned to a group and do not know whether that is the intervention or the control group.~The physicians conducting the preliminary assessments do not know which group the patient was placed in."|The patients are randomly assigned to one of two groups. The intervention group completes CBT-training to improve their cognitive reappraisal and consequently their emotion-regulation-skills and the control group completes tasks that ask them to reflect about their daily lifes.|t|f|f|t
33701968|NCT00531973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33701969|NCT01453361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788285|NCT02873884|||COHORT||PROSPECTIVE|||||||
33788286|NCT00669461|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801659|NCT03224390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||"The service (intervention) is available to anyone living in the catchment area, so it is not possible to randomly assign access to the service and estimate impact through a traditional randomized controlled trial (RCT). Likewise, at this early stage it is not be feasible to randomize access at a higher level, such as counties or subcounties. In situations like this, a variation on the traditional randomized controlled trial called a randomized encouragement design can be very effective.~In a randomized encouragement design (RED), participants are randomized to receive an invitation or special encouragement to receive a treatment. Not everyone who is encouraged will take up the service, but as long as those randomly selected to receive the encouragement (the treatment group) use the service at a higher rate than the control group, the impact of the service can be estimated.~For more details, see http://bit.ly/RED17protocol (linked in this record)."|f|t|f|t
33801660|NCT03308292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006562|NCT05210361|||COHORT||PROSPECTIVE|||||||
34006563|NCT01199120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006564|NCT03659227|||COHORT||PROSPECTIVE|||||||
34006565|NCT02900482|||CASE_CONTROL||PROSPECTIVE|||||||
34091993|NCT04853875|RANDOMIZED|PARALLEL||TREATMENT||NONE||"104 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing Tetracycline, Metronidazole, and Bismuth versus Amoxicillin, Metronidazole, and Clarithromycin."||||
34091994|NCT04898556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, prospective, open, randomized and controlled clinical study||||
34091995|NCT03125733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34091996|NCT03240380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34091997|NCT05850507|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34091998|NCT05758454|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34091999|NCT02711787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092000|NCT01345799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092001|NCT05484947|||COHORT||RETROSPECTIVE|||||||
34092002|NCT05494138|||COHORT||PROSPECTIVE|||||||
34092003|NCT00498732|||COHORT||PROSPECTIVE|||||||
34092004|NCT00176137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092005|NCT01736059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092006|NCT04120324|||CASE_CONTROL||RETROSPECTIVE|||||||
34092007|NCT02547935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092008|NCT02266017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092009|NCT04325347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34092010|NCT02095860|RANDOMIZED|CROSSOVER||||NONE||||||
34092011|NCT01859091|NA|SINGLE_GROUP||||NONE||||||
34092012|NCT06508814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927614|NCT04648228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Principal Investigators will be blinded. Co-investigators and study physicians involved in the treatment and control conditions will not be blinded, as these individuals will handle the delivery of treatment. The study coordinators located within each VA will not be blinded, as they will be involved in coordinating participant screening and randomization. Data analysis will be conducted by a study statistician blinded to participant condition.|This trial will determine the efficacy of an integrated Acceptance and Commitment Therapy and Mindfulness-Based Relapse Prevention (ACT+MBRP) treatment program for veterans with co-occurring chronic pain and opioid use disorder (OUD) who are prescribed buprenorphine, compared to an education control (EC) consisting of pain, opioid, and buprenorphine education. To test the efficacy of ACT + MBRP compared to EC with regard to primary and secondary outcomes, participants will be randomized to one of 2 treatment arms and followed for a total of 15 months (3-month active treatment period, 6 month follow-up, 12 month follow-up). All study treatments will be delivered via the VA Video Connect telehealth platform.|f|f|t|t
34092013|NCT00375297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092014|NCT02578797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092015|NCT02115477|||COHORT||PROSPECTIVE|||||||
34092016|NCT05177094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092017|NCT03848078|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The investigator is blinded for the result of the punch biopsy.|Multi-centre randomised controlled non-inferiority trial|f|f|t|f
34092018|NCT03645447|NA|SINGLE_GROUP||OTHER||NONE||Taste tests will be undertaken, in order to establish taste thresholds. Observation of changes in taste thresholds with change in mood following antidepressant treatment may help develop a diagnostic test for depression. The taste test will not assist diagnosis of depression for the group of participants in this study, so the primary purpose is not diagnostic.||||
34092019|NCT02018107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a diagnostic imaging study, involving FDA-approved radiopharmaceuticals. Applying a Phase to the study is N/A, even though the Study Phase had to be entered above."||||
34092020|NCT05742295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34092021|NCT03757442|||COHORT||RETROSPECTIVE|||||||
34092022|NCT05540327|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801661|NCT05619952|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind, randomized||t|f|t|f
33801662|NCT05004558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927615|NCT04675697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927616|NCT00838695|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33927617|NCT02654275|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927618|NCT01667055|||COHORT||CROSS_SECTIONAL|||||||
33927619|NCT06031376|||COHORT||RETROSPECTIVE|||||||
33927620|NCT01939093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33927621|NCT06158282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927622|NCT01471639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927623|NCT00954928|||CASE_CONTROL||PROSPECTIVE|||||||
33927624|NCT00931060|NON_RANDOMIZED|PARALLEL||||NONE||||||
33927625|NCT04233710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927626|NCT03320889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1: Educational Intervention includes Pamphlets plus Review with Expert Educator Group 2: Educational Intervention includes Pamphlets only||||
33927627|NCT00014547||||TREATMENT||||||||
33927628|NCT03154177|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33927629|NCT06285188|||COHORT||PROSPECTIVE|||||||
33927630|NCT01405378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927631|NCT03450993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33927632|NCT01819441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927633|NCT02019745|||COHORT||PROSPECTIVE|||||||
33927634|NCT03949192|||CASE_ONLY||PROSPECTIVE|||||||
34092023|NCT01674855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103253|NCT05272176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34103254|NCT05071027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103255|NCT00880503|||COHORT||PROSPECTIVE|||||||
34103256|NCT05856747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103257|NCT02573896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103258|NCT00551993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103259|NCT01951729|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34103260|NCT06690684|||CASE_CONTROL||PROSPECTIVE|||||||
34103261|NCT00044122|||COHORT||PROSPECTIVE|||||||
33701970|NCT05799170|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33701971|NCT05058235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701972|NCT02364726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701973|NCT00660673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701974|NCT01021722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33701975|NCT04342377|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||A prospective pan-Canadian, multicentered, non-inferiority crossover study design||||
33701976|NCT00391729|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33701977|NCT00408629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33701978|NCT01828736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701979|NCT01139931|||CASE_ONLY||RETROSPECTIVE|||||||
33701980|NCT01861860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33701981|NCT04014946|NA|SINGLE_GROUP||PREVENTION||NONE||"The study model is single group. At the analysis the patients will be divided in two groups bij outcome of ICD therapy/no ICD therapy.~The endpoints related to the primary hypothesis are appropriate ICD intervention (shock or ATP) and Relative Infarct Transmurality (RIT = transmural infarct mass / total infarct mass) obtained from LGE-CMR. ICD interventions will be labeled appropriate or non-appropriate by an independent endpoint committee.~* RITshock or ATP: RIT expectation value in patients with ≥1 appropriate shock or ATP therapy until the 24mo follow-up~* RIT no shock or ATP: RIT expectation value in patients without any appropriate shock or ATP therapy until the 24mo follow-up"||||
33701982|NCT06557291|||COHORT||RETROSPECTIVE|||||||
33701983|NCT03812120|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants stay masked during the trial, care provider and investigators are unblinded at the surgical procedure and from thereon.|randomized controlled clinical trial|t|f|f|f
33701984|NCT03849248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33701985|NCT02573688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33701986|NCT06441448|||COHORT||PROSPECTIVE|||||||
33701987|NCT06332820|||COHORT||PROSPECTIVE|||||||
33701988|NCT00000209||||TREATMENT||SINGLE||||||
33701989|NCT03344133|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701990|NCT00766025|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33701991|NCT04708106|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33701992|NCT00933829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701993|NCT02676115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33701994|NCT01790425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33701995|NCT05586893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33701996|NCT03774264|||CASE_ONLY||PROSPECTIVE|||||||
33701997|NCT03475498|||COHORT||PROSPECTIVE|||||||
33701998|NCT00316472|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33801663|NCT03237975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were assigned to two groups in parallel for the duration of the study. One group received usual care for diabetes patients. One group received strengths-based intervention.|f|f|f|t
33801664|NCT00891332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801665|NCT05424796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801666|NCT02335554|RANDOMIZED|PARALLEL||||NONE||||||
33801667|NCT02851667|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33927635|NCT03253133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927636|NCT03476434|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients are randomized into two groups with tandem explorations: in the group A or white light group (HR-WLE) where inspection is performed with white light in both colonoscopies, and in the group B or chromoendoscopy group (HR-CE) where a first inspection is performed with white light and the second with panchromoendoscopy with indigo carmine.||||
33927637|NCT01263444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927638|NCT05235100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927639|NCT03392441|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927640|NCT02452749|NA|SINGLE_GROUP||OTHER||NONE||||||
33927641|NCT03012542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927642|NCT00033592|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33927643|NCT06233214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||PIC placement attempt will be performed with the help of a vein imaging device in the study/experiment group, and with the traditional application method without device support in the control group.|f|t|t|f
33927644|NCT02566109|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927645|NCT00651313|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33927646|NCT04798846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927647|NCT01955395|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33927648|NCT01106391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006566|NCT04300023|RANDOMIZED|PARALLEL||TREATMENT||NONE||12 participants randomly assigned to social cycling group or solo cycling group||||
34006567|NCT01886937|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34006568|NCT03417063|||CASE_ONLY||PROSPECTIVE|||||||
33927649|NCT02880462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.||t|t|t|t
33927650|NCT05625880|NA|SINGLE_GROUP||SCREENING||NONE||||||
33927651|NCT02561780|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33701999|NCT04188587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702000|NCT05614232|||COHORT||RETROSPECTIVE|||||||
33927652|NCT03648463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not know if they received the surgical intervention that entails removing of the calcified cartilage or not.||t|f|f|t
34092024|NCT05661968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092025|NCT01847209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092026|NCT05587725|||COHORT||CROSS_SECTIONAL|||||||
34092027|NCT01069640|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092028|NCT04029844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092029|NCT05587153|||COHORT||PROSPECTIVE|||||||
34092030|NCT02806999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092031|NCT03915457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A monocentric open parallel randomized and controlled study.||||
34092032|NCT03682640|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a 2-arm, randomized, open, clinical trial comparing the AIDIT protocol with treatment as usual.||||
34092033|NCT02522182|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092034|NCT01324752|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34092035|NCT05861271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092036|NCT01634594|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33702001|NCT05708274|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blind, placebo-controlled, single-dose, randomized crossover investigation to one of four conditions: 1) CPH + hand training; 2) CD-LD + hand training; 3) ATX + hand training; and 4) placebo + hand training, performed at least a week apart. Outcomes measures will be assessed before and 60 minutes after study drug administration.|t|f|t|f
33702002|NCT03117920|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label study.||||
33702003|NCT04785092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702004|NCT01067690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702005|NCT06557031|NA|SINGLE_GROUP||OTHER||NONE||In situ used for near patient In vitro Medical device.||||
33702006|NCT01706822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927653|NCT00353990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33927654|NCT04374201|||OTHER||PROSPECTIVE|||||||
33927655|NCT02564692|||COHORT||PROSPECTIVE|||||||
33927656|NCT03261141|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927657|NCT04445012|||COHORT||PROSPECTIVE|||||||
33927658|NCT03858296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927659|NCT01363258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33927660|NCT00977587|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33927661|NCT01822223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33927662|NCT00582023|||COHORT|||||||||
33927663|NCT05200728|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33927664|NCT00742846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33927665|NCT00102934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006569|NCT00311220|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006570|NCT02376660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34092037|NCT03546959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|outcome assessor blinded to participants' allocated group|Paralel group randomized controlled study|f|f|t|t
34092038|NCT04524923|||COHORT||PROSPECTIVE|||||||
33927666|NCT04896762|||COHORT||PROSPECTIVE|||||||
34006571|NCT00406016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006572|NCT06132048|NA|SINGLE_GROUP||OTHER||NONE||||||
34006573|NCT01042873|NA|SINGLE_GROUP||OTHER||NONE||||||
34006574|NCT05954819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34006575|NCT00810628|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34006576|NCT05933473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006577|NCT05928767|||OTHER||PROSPECTIVE|||||||
34006578|NCT06326528|||CASE_CONTROL||PROSPECTIVE|||||||
34006579|NCT00885612|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092039|NCT02092935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092040|NCT02166879|||COHORT||RETROSPECTIVE|||||||
33927667|NCT04023890|||CASE_ONLY||PROSPECTIVE|||||||
33927668|NCT06453863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927669|NCT01709968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927670|NCT03549468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927671|NCT02715050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33927672|NCT04504019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927673|NCT02251067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092041|NCT00427596|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092042|NCT02722291|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927674|NCT01268904|||CASE_ONLY||PROSPECTIVE|||||||
33927675|NCT04743271|RANDOMIZED|CROSSOVER||OTHER||NONE|As it will be easy to discern meal fat content, participant blinding is not possible. Participants will be blinded to clock time and light-dark cues and statisticians will be blinded of condition.|||||
33927676|NCT00224692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927677|NCT00289861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927678|NCT01620697|||COHORT||PROSPECTIVE|||||||
33927679|NCT01251822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927680|NCT02766907|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33927681|NCT02312011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927682|NCT06156904|||CASE_ONLY||PROSPECTIVE|||||||
34092043|NCT01855906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092044|NCT03677401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092045|NCT01016587|||COHORT||PROSPECTIVE|||||||
33702007|NCT04029506|||CASE_CONTROL||RETROSPECTIVE|||||||
33702008|NCT00000842||||TREATMENT||DOUBLE||||||
33702009|NCT02318537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702010|NCT05881369|||CASE_CROSSOVER||PROSPECTIVE|||||||
33702011|NCT00144196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33702012|NCT06142708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702013|NCT04548583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927683|NCT05620069|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927684|NCT06339606|||CASE_CONTROL||PROSPECTIVE|||||||
33927685|NCT00606177|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927686|NCT00631618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927687|NCT02679781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927688|NCT01609725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33927689|NCT01311739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927690|NCT03147599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927691|NCT00141934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927692|NCT04919772|||COHORT||CROSS_SECTIONAL|||||||
33927693|NCT04633031|||CASE_ONLY||RETROSPECTIVE|||||||
33927694|NCT05678088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702014|NCT06132516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The evaluator of the main measurement criterion (Holter-ECG/24h) receives anonymous data by secure e-mail, without ever meeting the patients or their records.~A blind component is introduced for patients, via the information given about a comparison between 2 types of physical activity."|A randomized controlled 2-arms parallel trial, with intention-to-treat procedure.|t|f|f|t
33702015|NCT02201875|||COHORT|||||||||
33702016|NCT01907997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702017|NCT02620657|||OTHER||RETROSPECTIVE|||||||
33702018|NCT00633555|||CASE_CONTROL||PROSPECTIVE|||||||
33702019|NCT02315989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702020|NCT01595035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33702021|NCT03314194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pre Post Design||||
33702022|NCT00993902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702023|NCT04330053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor-blind randomized control trial. A masked assessor conducted the measurements.|An assessor-blind randomized control trial with a duration of six months and a 6-month follow up will be performed in 150 seniors with a history of a previous fall. The participants will be allocated into two groups of 75 persons each (one intervention group and one control group). The first group will receive consulting about home modification for home safety related to fall prevention and training on how to avoid a fall and how to act if a fall occurs. Additionally, the first group participants will follow a fall prevention exercise program based on the OTAGO exercise program. The second group (control group) will receive only the consulting and training part excluding the fall prevention exercise program.|f|f|f|t
33702024|NCT02293057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702025|NCT06429111|||CASE_CONTROL||PROSPECTIVE|||||||
33702026|NCT01101373|||COHORT||RETROSPECTIVE|||||||
33927695|NCT03598127|||COHORT||PROSPECTIVE|||||||
33927696|NCT02357888|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33927697|NCT00290524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927698|NCT00753623|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33927699|NCT03765710|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33927700|NCT05263687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927701|NCT01983878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927702|NCT00820807|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33927703|NCT01917890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33927704|NCT05117593|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Double-blind|A maximum of 4 dose levels (0.1 mg, 0.33 mg, 1 mg and 2.5 mg) is preplanned to be investigated in separate sequential cohorts. Each cohort will consist of 8 healthy male and female subjects (3 subjects of either sex on FBL-MTX, 1 of either sex on placebo).|t|t|t|t
33927705|NCT03954990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, providers, PI, investigators will be blinded.|Patient with bacterial vaginosis will be randomized to either treatment group to receive 2 g of metronidazole or control group to receive 2 g of placebo. Randomization to either control or treatment group will be done according to a randomization sequence that is computer generated and maintained by investigational drug pharmacy.|t|t|t|t
33927706|NCT01501669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927707|NCT04578340|||COHORT||PROSPECTIVE|||||||
33927708|NCT02645071|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33927709|NCT04397692|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33927710|NCT05965206|||COHORT||PROSPECTIVE|||||||
33927711|NCT03364491|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The patient nor the clinical staff will be aware of the treatment assignment. The TXA or placebo solutions will be prepared by the center research pharmacies.|Participants will be randomized to receive either TXA (1 gram \[10cc\] mixed with 40 cc of normal saline) administered intravenously or a placebo control of 50 cc of normal saline administered intravenously|t|t|t|t
33927712|NCT05619003|NA|SINGLE_GROUP||PREVENTION||NONE||The clinical investigation is an open-labelled, non-comparative, single-arm, prospective, multi-center investigation.||||
33927713|NCT00829218|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33927714|NCT01082003|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33927715|NCT06268483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized, crossover||||
33927716|NCT00921427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702027|NCT03041857|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927717|NCT03275415|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is a double blind randomized trial. The infants will be randomly assigned into 2 groups: Control (C) (curosurf + saline) and Intervention (I) (curosurf+ budesonide).|This is a double blind randomized trial. The infants will be randomly assigned into 2 groups: Control (C) (curosurf + saline) and Intervention (I) (curosurf+ budesonide).|t|t|t|f
33927718|NCT02275520|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927719|NCT01582867|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927720|NCT05482555|||COHORT||PROSPECTIVE|||||||
33927721|NCT02533401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006580|NCT04941131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006581|NCT00673764|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34006582|NCT03574337|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34006583|NCT05148078|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34006584|NCT02812771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006585|NCT01020526|NON_RANDOMIZED|||TREATMENT||NONE||||||
34006586|NCT02179593|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33702028|NCT02899299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702029|NCT02351375|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33702030|NCT05642988|||COHORT||RETROSPECTIVE|||||||
33702031|NCT06535165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33702032|NCT05770453|||COHORT||OTHER|||||||
33702033|NCT05143541|||CASE_ONLY||PROSPECTIVE|||||||
33702034|NCT06428617|||COHORT||PROSPECTIVE|||||||
33702035|NCT04432259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomly assigned to one of two groups, treatment or no treatment. Randomizations will be balanced at random accrual points.|t|t|t|t
33702036|NCT05361161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702037|NCT00001438||||TREATMENT||||||||
33702038|NCT03616275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33788287|NCT04518566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Patients will be screened and recruited for the RCT by research coordinators positioned in the SingHealth polyclinics. They will identify eligible patients according to the inclusion and exclusion criteria. Informed consent will be taken and they will be referred to the research coordinators who will randomly assign the patients to the intervention or control arm using a site-specific pre-generated randomization list. A research coordinator will keep custody of the 3 randomization lists (1 for each recruitment site), and assign treatment accordingly to the intervention listed and not be involved in the recruitment or assessment of patients.|A pragmatic 2-arm (1:1) randomized controlled trial (RCT) on 1,000 eligible diabetes patients using the Pragmatic Explanatory Continuum Indicator Summary Framework-2 (PRECIS-2) criteria for pragmatic trials. Patients with diabetes will be randomly allocated in a 1:1 ratio to either the intervention or control group. The intervention group will receive the personalized feedback intervention through the personalized and adaptive intervention platform app on a FitBit wearable on top of their usual clinical care for their diabetes condition. The control group will receive the FitBit wearable on top of their usual clinical care for their diabetes condition but will not receive the personalized and adaptive intervention platform.|f|t|t|t
33788288|NCT06628791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33788289|NCT00223054|||||RETROSPECTIVE|||||||
33788290|NCT04286165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006587|NCT06146855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788291|NCT06158958|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33788292|NCT05301556|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788293|NCT01769391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788294|NCT02119624|||COHORT||PROSPECTIVE|||||||
34006588|NCT06313060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|f|f|t|f
34006589|NCT04248517|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective cohort with comparison group|f|f|f|t
34006590|NCT01921231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006591|NCT01450241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006592|NCT01121588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702039|NCT03847714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|similar looking and tasting placebo||t|t|t|t
33702040|NCT05520112|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006593|NCT03899519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006594|NCT00695539|||CASE_ONLY||PROSPECTIVE|||||||
34006595|NCT02246764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006596|NCT06436287|||CASE_CONTROL||PROSPECTIVE|||||||
34092046|NCT04622956|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase I / II multicenter open-label clinical trial with prospective nonrandomized arm and historical control group||||
33702041|NCT01880281|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33702042|NCT02436746|||COHORT||CROSS_SECTIONAL|||||||
33702043|NCT00887874|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33702044|NCT03998566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702045|NCT06110078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702046|NCT02800343|||COHORT||PROSPECTIVE|||||||
34092047|NCT01587404|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34092048|NCT00940173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092049|NCT03731013|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Parallel group 2x2 factorial design clinical trial according to which participants will be randomly assigned to one of four 16-week intervention groups: 1- Mediterranean Diet alone; 2- Physical Activity alone ; 3- Combination of Mediterranean Diet and Physical Activity; 4- Control Group (no intervention).|f|f|f|t
34092050|NCT01600859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702047|NCT05049616|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control trial||||
33702048|NCT01252381|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33702049|NCT05968339|||COHORT||PROSPECTIVE|||||||
33702050|NCT01172236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702051|NCT00775346|||COHORT||PROSPECTIVE|||||||
33702052|NCT00795847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788295|NCT03403699|||COHORT||OTHER|||||||
33788296|NCT04587479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788297|NCT01010165|||COHORT||PROSPECTIVE|||||||
33788298|NCT01236989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788299|NCT00000433|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33788300|NCT05518487|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788301|NCT01761396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788302|NCT03735771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788303|NCT04820621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788304|NCT00964314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788305|NCT03007758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788306|NCT05954507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Prognostic study of a prospective multicenter cohort of patients with suspected cardiac involvement in sarcoidosis.~All patients with suspected cardiac sarcoidosis meeting the inclusion criteria will be prospectively and consecutively included in each of the study centers. Patients will undergo cardiac PET/MRI within 15 days of inclusion, and will be followed up for 24 months."||||
33788307|NCT01668342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788308|NCT06421948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788309|NCT02741167|||COHORT||PROSPECTIVE|||||||
33788310|NCT00114803|RANDOMIZED|PARALLEL||||DOUBLE||||||
33788311|NCT02584153|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006597|NCT01129739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006598|NCT04599621|||OTHER||PROSPECTIVE|||||||
34006599|NCT00496028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006600|NCT02518217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34006601|NCT04000243|||COHORT||PROSPECTIVE|||||||
33702053|NCT04859673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patients in control group will be treated by sham radial extracorporeal shock wave therapy in addition to, the same design physical therapy program. Stimulation will not deliver as the transmitter head will be removed.~The patients will receive the same frequency of air pressure and sound"|"The selected patients will be randomly assigned to two equal groups (study group (GI), and control group (GII).The study group (GI) will be treated by the radial extracorporeal shock wave in addition to design physical therapy program.~• The control group (GII) will be treated by sham radial extracorporeal shock wave in addition to the same design physical therapy program of (GI)."|t|f|f|f
33702054|NCT02022020|||COHORT||RETROSPECTIVE|||||||
33702055|NCT04477889|||OTHER||PROSPECTIVE|||||||
34006602|NCT05783856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo X-secret and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo X-secret suspension is unrecognizable to investigators except the PI and analyzer due to opaque plastic container|Parallel Assignment Blind, randomized, and controlled clinical trial|t|t|t|f
34025182|NCT01377987|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34025183|NCT05543408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702056|NCT00779740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702057|NCT00880984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702058|NCT05072782|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
33702059|NCT04412434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702060|NCT04920344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702061|NCT03831789|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All participants will be masked as to which of the three study arms they have been allocated. All participants over the course of three visits will either have: unilateral cerebellar rTMS or bilateral cerebellar rTMS. However, as specified earlier the order in which they will receive these interventions will be randomly allocated.|All participants over the course of three visits will either have: unilateral cerebellar rTMS or bilateral cerebellar rTMS. However, the order in which they will receive these interventions will be randomly allocated.|t|f|f|f
33702062|NCT02256592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702063|NCT02470832|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702064|NCT05106387|||COHORT||PROSPECTIVE|||||||
33702065|NCT04810871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702066|NCT06232694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702067|NCT04298515|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33702068|NCT01951937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702069|NCT02848170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702070|NCT01393223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702071|NCT01409434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702072|NCT06556303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized controlled experimental study model|t|t|t|t
33702073|NCT01426438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702074|NCT02421471|||COHORT||PROSPECTIVE|||||||
33702075|NCT04727073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788312|NCT01976689|||CASE_CONTROL||RETROSPECTIVE|||||||
33788313|NCT06092931|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34025184|NCT03683030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702076|NCT02646943|||COHORT||PROSPECTIVE|||||||
33702077|NCT00384410|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33702078|NCT05602870|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702079|NCT03031132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702080|NCT01961362|||COHORT||PROSPECTIVE|||||||
33702081|NCT03617185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neuropathy outcomes assessors will be blinded to the exercise protocol that the patients are randomized to and the surgical status for the duration of the study.|Patients will be assigned to one of 4 arms, bariatric surgery/HIIT, bariatric surgery/routine exercise, no bariatric surgery/HIIT, no bariatric surgery/routine exercise.|f|f|f|t
33702082|NCT06178497|||COHORT||CROSS_SECTIONAL|||||||
33788314|NCT05158192|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34006603|NCT06059417|NA|SINGLE_GROUP||OTHER||NONE||A cohort of consenting, healthy physicians, nurses, and ancillary staff at a teaching facility who did not have known hypersensitivity to foam tape were enrolled. Study investigators applied a 2x2 inch piece of 3M micro-foam adhesive to the medial aspect of each subject's upper arm. The contralateral arm served as a reference for comparison. The adhesive remained in place for 48 hours and the study authors assessed patients utilizing the previously validated Cutaneous Irritancy Scoring System (CISS).||||
34006604|NCT03860207|NA|SINGLE_GROUP||TREATMENT||NONE||This phase I/II trial will assess the toxicity and pharmacokinetics (PK) of the humanized anti-GD2 x anti-CD3 bispecific antibody (hu3F8-BsAb) in phase I and the anti-tumor activity of hu3F8-BsAb in phase II.||||
34006605|NCT00388934|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006606|NCT02010294|||CASE_CONTROL||PROSPECTIVE|||||||
34006607|NCT05709769|||COHORT||PROSPECTIVE|||||||
34006608|NCT00060294||||TREATMENT||||||||
34006609|NCT03769831|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33702083|NCT03120234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33702084|NCT05854862|||COHORT||RETROSPECTIVE|||||||
33702085|NCT05004077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702086|NCT03133130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702087|NCT00551447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702088|NCT03072498|||CASE_CONTROL||PROSPECTIVE|||||||
33702089|NCT00384501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702090|NCT00306189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702091|NCT00581243|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33702092|NCT05981339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial Study and Control Group|t|f|f|t
33702093|NCT02047383|||CASE_ONLY||PROSPECTIVE|||||||
33702094|NCT04214171|||OTHER||PROSPECTIVE|||||||
33702095|NCT01574456|||CASE_CONTROL||PROSPECTIVE|||||||
33702096|NCT01216670|||COHORT||PROSPECTIVE|||||||
33702097|NCT05719376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702098|NCT06098092|NA|SINGLE_GROUP||OTHER||NONE||Interventional prospective single-arm study||||
33702099|NCT02633813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702100|NCT02995031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702101|NCT05661123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702102|NCT04571320|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Teachers and outcomes assessors will be masked to group; however, it will not be possible to mask parents and adolescents to group because they will be actively receiving a behavioral intervention.||f|f|f|t
33702103|NCT02587884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702104|NCT01157923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702105|NCT05251246|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33702106|NCT03354078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33702107|NCT04928417|||COHORT||CROSS_SECTIONAL|||||||
33702108|NCT05992181|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702109|NCT06556940|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33702110|NCT05815641|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be given a test meal (breakfast) that provides 20% of the individual's daily energy requirement. The breakfast composition is 56 kcal% carbohydrates, 12 kcal% protein and 34 kcal% lipids and comprises yogurt, cereals and almonds. Participants will be asked to consume the entire breakfast in less than 15 min and to complete a visual analog scale (VAS) questionnaire every 15 min. Blood sampling will be repeated at 60 min after starting breakfast (postprandial).||||
33788315|NCT06555224|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator will be masked to study group allocation||f|f|t|t
33788316|NCT04893980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788317|NCT04571333|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33788318|NCT04300933|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788319|NCT03308487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33788320|NCT06278064|||CASE_CONTROL||RETROSPECTIVE|||||||
33788321|NCT05988125|||COHORT||PROSPECTIVE|||||||
33788322|NCT00589212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788323|NCT04035512|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The sample will be divided into two group, in a randomized way. The expressive writing group that will perform the writing task and the control group that will not perform the writing task. The study includes two measurements, pre-operatively (T0) and 3 months after surgery (T1)||||
33788324|NCT01267409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788325|NCT00757718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788326|NCT06080971|||OTHER||PROSPECTIVE|||||||
33788327|NCT06113939|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label randomized||||
33788328|NCT01254591||||DIAGNOSTIC||||||||
33788329|NCT03201614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788330|NCT02648425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788331|NCT05484024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788332|NCT04791124|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788333|NCT03380975|NA|SINGLE_GROUP||TREATMENT||NONE|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor.Montelukast should be taken once daily in the evening|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis||||
33927722|NCT00137670|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33927723|NCT05167188|||COHORT||PROSPECTIVE|||||||
33927724|NCT05062551|NA|SINGLE_GROUP||TREATMENT||NONE||the 50 patients will be subjected to three steps hysteroscopic resection of an isthmocele by removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.||||
33927725|NCT04705987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927726|NCT01067651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927727|NCT01060098|||CASE_CONTROL||PROSPECTIVE|||||||
33927728|NCT03006081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927729|NCT01487291|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927730|NCT04814524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33927731|NCT00428376|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34006610|NCT02803086|||COHORT||PROSPECTIVE|||||||
34006611|NCT03164109|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34006612|NCT03901157|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34006613|NCT01363011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006614|NCT05122351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006615|NCT02523794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006616|NCT03978416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The purpose of this project is to develop a lifestyle intervention for weight loss by conducting three pilot studies where small groups of participants undergo progressively developed versions of the intervention. There will not be masking as both subjects and investigators will be aware of the intervention.|A prototype bilingual English-Spanish lifestyle intervention for weight reduction will be created. The prototype will then be iteratively refined during a series of short-term tests (two tests lasting 4 weeks, followed by a final test lasting 12 weeks) of intervention delivery. In these interventions, % weight loss, % drop-out, and safety benchmarks will be monitored. Participant-reported barriers to adherence identified during group meetings and exit interviews will be targets for improvement in successive iterations.||||
34006617|NCT04583696|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006618|NCT01505361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34006619|NCT04645940|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34006620|NCT00384306|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006621|NCT04836351|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study, one group pre-post design||||
34006622|NCT00429624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34006623|NCT00668096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006624|NCT05187741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized control trial||||
34006625|NCT04380545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006626|NCT03088852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006627|NCT01877902|||COHORT||RETROSPECTIVE|||||||
34006628|NCT05494502|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34006629|NCT06474481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006630|NCT01249014|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34006631|NCT01839695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006632|NCT00981799|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34006633|NCT04810169|||COHORT||PROSPECTIVE|||||||
34006634|NCT01563458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927732|NCT06262594|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33927733|NCT03284021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927734|NCT03223207|||COHORT||PROSPECTIVE|||||||
33927735|NCT02578355|||COHORT||PROSPECTIVE|||||||
33927736|NCT05847036|||COHORT||PROSPECTIVE|||||||
34006635|NCT04688372|||COHORT||RETROSPECTIVE|||||||
34006636|NCT06193187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006637|NCT04035382|NA|SINGLE_GROUP||TREATMENT||NONE||Simon two-stage||||
33927737|NCT04771546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, longitudinal, prospective, open label trial with a control group with randomized, consecutive recruitment for each group, to evaluate the safety and efficacy of carboxymethyl-beta-glucan and polycarbophil as a treatment for low-grade CIN associatedto HR-HPV infection.||||
33927738|NCT00550277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702111|NCT03045731|||COHORT||PROSPECTIVE|||||||
33702112|NCT05668884|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33720396|NCT04356274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Participatory System Dynamics: Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.~Audit and Feedback: Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.~Anticipate that 720 frontline providers will participate across both arms of this trial. There will be no interaction with current patients for the purposes of research. No new data will be collected beyond data generated during routine care."||||
33720397|NCT00075582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927739|NCT00821860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927740|NCT06142968|||CASE_ONLY||PROSPECTIVE|||||||
33927741|NCT02238782|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33927742|NCT02448914|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33927743|NCT02025049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927744|NCT03713983|||COHORT||PROSPECTIVE|||||||
34006638|NCT00381823|RANDOMIZED|PARALLEL||ECT||NONE||||||
34006639|NCT01782287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006640|NCT06136416|NA|SINGLE_GROUP||OTHER||NONE||||||
34006641|NCT03716635|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|After determining the eligibility of the patient, the assistant supervisor will be contacted to assign the participant to either the intervention (cryotherapy) or the control (normal saline) groups according to the random sequence generated.|"A random sequence will be generated by computer software, (http://www.random.org/).~The table will be kept with the assistant supervisor."|t|f|f|f
34006642|NCT02244424|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34006643|NCT00002616||||TREATMENT||||||||
34006644|NCT04087317|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Women following a vaginal delivery, with no exclusion criteria to participate in the study, will be addressed. After receiving all the information about the study, women who choose to participate will be consented.~All participants will be randomized to either scheduled analgesic administration (study group) or analgesic administration per women's request (control group) as accustomed at the investigator's unit."||||
34006645|NCT06441903|||COHORT||PROSPECTIVE|||||||
34006646|NCT01540292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006647|NCT02036801|||COHORT||PROSPECTIVE|||||||
34006648|NCT00224484|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34006649|NCT02001051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006650|NCT06163417|||COHORT||RETROSPECTIVE|||||||
33927745|NCT04587921|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927746|NCT03758872|||COHORT||PROSPECTIVE|||||||
33927747|NCT04767295|NA|SINGLE_GROUP||TREATMENT||NONE||Patients fulfilling Eligibility Criteria will be included in our study. ESCC participants in this study will be given intravenous administration of SHR-1210 (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration. Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment.||||
33927748|NCT02843750|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33927749|NCT06201169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|each participant enrolled in the study randomly and the results of both groups were serialized and assessed by the outcome assessor|completely edentulous mandibular arch opposing natural dentition were selected|t|f|f|t
33927750|NCT02156752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927751|NCT02420795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006651|NCT04573296|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective randomized controlled study evaluates efficacy of lifestyle intervention using digital application Vitadio as compared to conventional high-intensity lifestyle intervention program administered at a specialized clinic at a University hospital.||||
34006652|NCT03870724|||COHORT||PROSPECTIVE|||||||
34006653|NCT02555319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006654|NCT06077461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is an experimental study with pre-test and post-test control groups|t|f|f|f
34006655|NCT06533657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092051|NCT05405712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The biostatistician will be blinded to the intervention/control group assignment throughout the course of the study and the assignments. Additionally, the principal investigator will remain blinded to the randomization.|Participants randomized to receive the APP intervention will receive login and sign up instructions to use the Marigold Health app. Both arms will receive standardized peer recovery support resources from SAMHSA|f|f|t|t
33720398|NCT05014451|||COHORT||CROSS_SECTIONAL|||||||
33720399|NCT04371887|RANDOMIZED|PARALLEL||OTHER||NONE||This prospective study will use a cluster randomization design to compare two system-level implementation strategies for primary HPV screening, with outcomes measured at multiple levels. KPSC has 13 service areas linked to over 200 ambulatory clinics. Randomization will be performed at the service area level, since these are system-level implementation strategies. Service areas will first be matched in pairs on key attributes that may be associated with implementation success prior to randomization, such as the size and the number of clinics, access, and current screening rates. Thus, the two service areas in a matched pair will be most like each other in those attributes. Within each pair, the two service areas will then be randomized to determine which receives the local-tailored vs. hybrid usual care approach. The intervention period for both arms will take place immediately after the roll out of primary HPV screening.||||
33788334|NCT06164249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Investigator is blind. Participants know in which group they are as each group is composed of no exercise (control), Nordic hamstring exercise (Nordic), or Deadlift exercise (Deadlift)|"Three independent groups :~* Control (no strengthening)~* Nordic (strengthening in Nordic Hamstring exercise)~* Deadlift (strengthening in Deadlift exercise)"|f|f|t|t
33788335|NCT00140881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788336|NCT02923128|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788337|NCT02777879|||COHORT||CROSS_SECTIONAL|||||||
33788338|NCT00140166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788339|NCT03677154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788340|NCT03608670|NA|SINGLE_GROUP||OTHER||NONE||||||
33788341|NCT00651885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788342|NCT02903836|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33788343|NCT02888431|||COHORT||PROSPECTIVE|||||||
33927752|NCT02776852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927753|NCT00150345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927754|NCT04708769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927755|NCT01386567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927756|NCT05843305|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927757|NCT04159922|||COHORT||PROSPECTIVE|||||||
33927758|NCT04342429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927759|NCT03384004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927760|NCT03314779|||COHORT||PROSPECTIVE|||||||
33927761|NCT02484898|||COHORT||PROSPECTIVE|||||||
34006656|NCT00130234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34006657|NCT05746117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006658|NCT00455962|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No masking.|Comparisons will be made between response to estradiol and progesterone infusion in young African-American and Caucasian women.||||
34092052|NCT06008002|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, single-blind, observational study|f|f|f|t
34092053|NCT00293891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092054|NCT00774748|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34092055|NCT02782104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006659|NCT04228978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors performing outcome measures will be unaware of participants' group assignment.||f|f|f|t
34006660|NCT00490503|||CASE_ONLY||PROSPECTIVE|||||||
34006661|NCT00510731|||COHORT||PROSPECTIVE|||||||
34006662|NCT05644756|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34006663|NCT02050035|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34006664|NCT00176540||||SUPPORTIVE_CARE||NONE||||||
34006665|NCT01604369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006666|NCT00930657|||COHORT||PROSPECTIVE|||||||
34006667|NCT03259789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006668|NCT05965817|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"In total 10 patients will be included who are scheduled for resection of colorectal liver metastases and meet at least one of the following criteria:~1. Scheduled for resection of \>3 CRLM or,~2. Completed neo-adjuvant chemotherapy, of which the last course was completed within 3 months before surgery or,~3. Scheduled for surgery because of a locally recurrent liver metastasis."||||
34006669|NCT03186716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006670|NCT03936933|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Goserelin acetate 3.6 mg Injection Eurofarma Laboratorios S.A Dose: 3.6 mg, Subcutaneously at every 28 days~Reference product -R ZOLADEX® 3.6mg Injection. Dose: 3.6 mg, Subcutaneously at every 28 days"||||
34006671|NCT05778240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34006672|NCT01469741|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34006673|NCT05247268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006674|NCT01956487|NA|SINGLE_GROUP||OTHER||NONE||||||
34006675|NCT02425384|RANDOMIZED|PARALLEL||||NONE||||||
34006676|NCT03700645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006677|NCT02176668|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34006678|NCT01483014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006679|NCT00627081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006680|NCT04985955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34006681|NCT02938442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006682|NCT00003348||||TREATMENT||||||||
34006683|NCT03287687|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Randomization will be done 1:1, double blinded. - Procedure nurse will randomly choose an envelope from a box; the envelope contains a card listing either CO2 or Air. The envelopes will be unmarked and will be prepared with an equal number of cards for each arm. The procedure nurse then turns on either CO2 or air insufflation according to the card in the envelope. The air/CO2 controls will be kept covered to preserve blinding of the endoscopist. She will also record the patient's arm allocation in a logbook, which will be kept in a locked cabinet.~* These events will precede entry of the patient and endoscopist into the procedure room.~* Therefore, all study participants are blinded and allocation is also blinded also."|Double blinded, placebo controlled study|t|t|t|t
34006684|NCT01010035|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092056|NCT01051804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34092057|NCT01279200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092058|NCT04591015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34092059|NCT00000678||||TREATMENT||NONE||||||
34092060|NCT01725399|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|t|f|t
34092061|NCT03672162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092062|NCT01910441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092063|NCT03909503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092064|NCT05527080|||COHORT||PROSPECTIVE|||||||
34092065|NCT05219786|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34092066|NCT04940806|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092067|NCT02630654|||COHORT||PROSPECTIVE|||||||
34092068|NCT01550185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092069|NCT01866670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092070|NCT06461884|RANDOMIZED|PARALLEL||OTHER||SINGLE||The group A will receive percussions and diaphragmatic breathing with 1 session a day for 3 days in a week for 4 weeks. In this way total 12 sessions will be given to the patients. And group B will receive only diaphragmatic breathing with 1 session a day for total 3 days in a week for 4 weeks|t|f|f|f
34092071|NCT04870086|||COHORT||PROSPECTIVE|||||||
33702113|NCT05367492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Eligible participants will be assigned to one of three groups using a computer-generated randomization code conducted by MGH Research Pharmacy personnel with no other interactions with participants.~The full randomization code of the two double blind treatment arms (arm 1 active varenicline and arm 2 identical placebo), and the single blind monitoring arm (arm 3) will be held in the MGH research pharmacy and available to study PIs for urgent medical need only. Participants, investigators and outcome assessors will be fully blind to all 3 arms.~A partial randomization code identifying those assigned to double-blind treatment (a combined list of study IDs assigned to either study arm 1 or 2) vs single blind monitoring (study arm 3) will be held by a scheduler who is not associated with outcomes assessment, data analysis or interpretation. Assignment to Arm 3, single blind monitoring only, will be masked to investigators and outcomes assessors."|300 participants will be enrolled and approximately 225 participants will be randomized in a double blind, placebo-controlled, parallel-group trial comparing vaping abstinence rates in participants randomly assigned to (1) varenicline added to behavioral and texting support for vaping cessation and (2) identical placebo added to behavioral and texting support for vaping cessation (primary comparison). Exploratory secondary comparisons will be made between double blind arms 1 and 2 and the single blind (3) monitoring only arm.|t|f|t|t
33702114|NCT01786148|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927762|NCT00105209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33927763|NCT03355404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702115|NCT05720260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927764|NCT04434105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927765|NCT03759028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization envelopes used to allocate treatment groups|double blinded, randomized trial|t|f|t|f
33927766|NCT01947894|||COHORT||PROSPECTIVE|||||||
34006685|NCT05642169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The present research follows a randomized controlled experimental design (RCT), sequential type, with parallel groups with three groups and repeated measures, being evaluated in a pretest, posttest and after the end of the follow-up period.~The sample, of casual or incidental type, were randomly distributed in two experimental groups and one CG, thus avoiding selection bias. The CG continued to maintain their lifestyle on a daily basis. On the other hand, we found two experimental groups, which performed a HIIT program with a frequency of 3 workouts per week. In one of them (HIIT+AF), the focus was on increasing their daily physical activity through the execution of 10,000 steps per day. The other experimental group (HIIT) followed the same HIIT program."|t|f|f|t
34006686|NCT01071850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006687|NCT02087891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006688|NCT00707317|||COHORT||PROSPECTIVE|||||||
34006689|NCT06013345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Study arms, analgosedation and TIVA protocols:~1. Conventional propofol analgosedation (arm P): current standard practice in most centres, a combination of short-acting benzodiazepine (midazolam) at the beginning, short-acting opioid (sufentanil in this study) and propofol boluses before and during the application of ablation pulses with unsecured airway~2. Optimised continuous intravenous analgosedation (arm R): ultrashort-acting benzodiazepine (remimazolam) and ketamine with unsecured airway~3. Total intravenous anaesthesia with secured airway (arm TIVA): continuous propofol infusion using target controlled infusion (TCI) and short acting opioid boluses - sufentanil"|t|f|f|f
34006690|NCT05562453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, controlled, parallel design|t|t|t|t
34006691|NCT06535035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During the initial evaluation, data collection, informed consent, a complete clinical and oral evaluation, as well as a radiological study with cone beam computed tomography (CBCT) were carried out. Subsequently, surgical intervention was performed with the placement of dental implants. In the experimental group, low-level laser therapy (LLLT) was applied, while a placebo procedure (SHAM) was used in the control group. Pain and inflammation were evaluated using visual analog scales (VAS) from day 0 to 7 days postoperatively. Additionally, MDA levels were measured and the OHIP-14 questionnaire was used to assess oral health-related quality of life||t|f|f|f
34006692|NCT06615856|||OTHER||CROSS_SECTIONAL|||||||
34092072|NCT04289948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT||t|t|t|f
33702116|NCT05849701|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34006693|NCT02485158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33702117|NCT00491764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33702118|NCT01331122|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33702119|NCT02969564|||CASE_ONLY||PROSPECTIVE|||||||
33702120|NCT05331651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702121|NCT04368676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the treatment hypothesis while the data analyst will be blinded to treatment allocation.||f|f|f|t
34092073|NCT04241731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702122|NCT04137627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|double-blind masking|one group receive standard treatment with melatonin, while the other group receive standard treatment with placebo|t|t|t|t
33702123|NCT01193270|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34092074|NCT01514175|NA|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34092075|NCT01350973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092076|NCT04253730|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Repeat Measures||||
34092077|NCT01989975|||CASE_ONLY||PROSPECTIVE|||||||
34092078|NCT03318458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The assignment to the groups will be of simple random type and hidden. Those responsible for admitting patients to the intervention phase will not know what group has been assigned each. This assignment will be made in advance by a researcher who will not intervene in the later stages of evaluation, intervention, data recording and elaboration of database. The assignment will be communicated through sealed and totally opaque envelopes.~All measurements given above will be made both to the control group and to the experimental group just prior to the start of the intervention, and immediately after and six months after the end of this period, and the results will be recorded in a data record"|Randomized controlled trial|f|t|t|t
34092079|NCT03972917|||COHORT||PROSPECTIVE|||||||
33702124|NCT01986946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702125|NCT01203631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702126|NCT05487352|||COHORT||PROSPECTIVE|||||||
33702127|NCT06018220|||COHORT||RETROSPECTIVE|||||||
33702128|NCT02738034|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33702129|NCT00400764|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702130|NCT02322476|||COHORT||PROSPECTIVE|||||||
33702131|NCT00748735|||||RETROSPECTIVE|||||||
33702132|NCT01952925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702133|NCT03383458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702134|NCT04710264|||COHORT||PROSPECTIVE|||||||
33927767|NCT04984213|||COHORT||PROSPECTIVE|||||||
33927768|NCT05586815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, Placebo Controlled|A Phase 4 Randomized, Double blind, Placebo Controlled|t|f|t|f
33927769|NCT04399252|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33927770|NCT04827810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33927771|NCT02575989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927772|NCT04083404|||COHORT||PROSPECTIVE|||||||
33927773|NCT04513405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092080|NCT02841735|||COHORT||PROSPECTIVE|||||||
34006694|NCT02759549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33702135|NCT01338103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702136|NCT01153074||SEQUENTIAL||TREATMENT||NONE||||||
33702137|NCT05244304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible subjects will be randomly assigned to begin treatment in 2:1 ratio to receive the study drug (either Tinlarebant 5 mg or matching placebo)|This is a Phase 3 randomized, double-masked, parallel group, multicenter study to evaluate the efficacy and safety of Tinlarebant 5 mg in the treatment of adolescent subjects with STGD1.|t|f|t|f
33702138|NCT03775330|||OTHER||PROSPECTIVE|||||||
33702139|NCT04423276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788344|NCT06375356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788345|NCT03462199|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized, double-blind, placebo controlled, parallel study|t|t|t|t
33788346|NCT00728637|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788347|NCT02490982|||COHORT||PROSPECTIVE|||||||
33788348|NCT03404336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed if they will receive the WBT or the control condition. Of course, after the end of the study they will receive this information and they will be told why they were blind.|This is a pilot study, designed as a randomized (1:1) controlled trial, comparing WBT vs a control condition. The patients will receive a baseline assessment to confirm the diagnosis of chronic migraine, then socio-demographic information, information on pharmacological/non-pharmacological treatments, on the history of medical diseases and on the psychological status will be collected as well as the number of migraine attacks per month, the duration of migraine attacks, the occurrence of migraine exclusively with menses, and the level of disability related to migraine. Thereafter, the subjects will be randomly assigned to WBT or to a control condition. The subjects will be re-assessed at the end of session 4, 8 of treatment, at 3-month and 6-month follow-ups.|t|f|f|f
33788349|NCT01398930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788350|NCT05761509|||COHORT||PROSPECTIVE|||||||
33788351|NCT02414919|||COHORT||RETROSPECTIVE|||||||
33788352|NCT06494124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The intervention arms are Experimental (tACS), Active comparator (tDCS) and control comparator (sham). The patients in all 3 arms will continue to receive the ongoing antipsychotics.|t|f|f|t
33788353|NCT06514105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be done by the physiotherapist who applies the physiotherapy program and high-intensity laser. The patient, the measuring radiologist, and the investigator will be blinded.|The study was planned as double-blind, randomized controlled. There are two groups in the study. The groups consist of the control group and high intensity laser group.|t|f|t|t
33788354|NCT02580812|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006695|NCT04625673|RANDOMIZED|CROSSOVER||OTHER||NONE||"Two part, open-label, randomized, crossover study. Part 1 will enroll 3 healthy subjects. Part two will enroll 15-20 in-patient subjects. Part two will have two arms.~Arm A will wear the OsciPulse then wear the standard IPC device. Arm B will wear the standard IPC device then wear the OsciPulse device."||||
33788355|NCT02620072|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33788356|NCT04550416|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788357|NCT06629051|||COHORT||RETROSPECTIVE|||||||
33788358|NCT02759029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788359|NCT03521323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A 2:1 ratio of randomization (intervention group:control group) was used.|t|f|f|f
33788360|NCT03997006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788361|NCT02453724|||COHORT||PROSPECTIVE|||||||
33788362|NCT05949203|||COHORT||PROSPECTIVE|||||||
34006696|NCT03977168|||COHORT||PROSPECTIVE|||||||
34006697|NCT04726189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34006698|NCT06004180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006699|NCT05532007|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants will be aware if they received the intervention or not, however, the cognitive testers and FMRI techs would not be aware of the participant randomization group and neither will the data analyst.|This is a free living , randomized, controlled, parallel design study with 30 subjects, who will be randomized to either receive peanuts or abstain from them for 12 weeks.|f|t|f|t
34006700|NCT03361124|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Covering of labels on IV fluids|Randomized double-blinded controlled|t|f|t|f
34006701|NCT06399861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34006702|NCT03768349|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006703|NCT00638040|||COHORT||CROSS_SECTIONAL|||||||
34006704|NCT01571726|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006705|NCT04013698|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients included will receive volume assist-control ventilation with PEEP set at 5 cmH2O and 15 cmH2O in a randomized order (crossover design). Each setting will be applied during 45 minutes.||||
34006706|NCT02497131|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.||||
34006707|NCT02620059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34006708|NCT02360306|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092081|NCT03607084|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702140|NCT02494674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702141|NCT06270771|||COHORT||PROSPECTIVE|||||||
33702142|NCT04785248|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33702143|NCT00354861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33702144|NCT01374841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702145|NCT03175978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702146|NCT03652168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants.||f|f|t|t
33702147|NCT04049864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702148|NCT05189431|||COHORT||PROSPECTIVE|||||||
33702149|NCT00091442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702150|NCT02327689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702151|NCT03334591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788363|NCT06526949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|It will not be possible for the researcher to be blinded due to the Reiki application and data collection forms. Blinding in the study will be performed only at the assignment-randomisation stage. Patients will be assigned to the intervention and control groups by the third person (preferably the nurse in charge of intensive care) who is not involved in the research according to the random numbers table in the database sent by the statistician, in the order of group 1 and group 2, using the blinding method.|"Intervention group: Reiki application will be applied to the patients for 2 consecutive days or 2 times (1st and 3rd day) for 30 minutes every other day. Pain, anxiety and haemodynamic parameters will be recorded on data collection forms before and at the end of the application. The duration of intubation, intensive care unit stay and haemodynamic stability of the patients will be limited due to the rapid changes.~Placebo Control Group: In the sham (Sham Reiki) group, sham practitioners (not involved in the study) who have no experience in energy work will prepare screens and headphones for the patients as in the intervention group. Then, they will place their hands gently on or above the patient's head and eyes, upper body from the neck to the pelvic region, arms and legs (standard reiki hand positions) for 30 minutes every other day for 2 days in a row or 2 times (Day 1 and Day 3) like the practitioner in the intervention group."||||
33788364|NCT04596579|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34006709|NCT00037687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34006710|NCT05824858|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34006711|NCT00233155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006712|NCT03946917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006713|NCT06110286|||COHORT||PROSPECTIVE|||||||
34006714|NCT04299217|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Triple masking|Balanced crossover|t|f|t|t
33702152|NCT04458207|RANDOMIZED|PARALLEL||TREATMENT||NONE|The investigator doing the cognitve assements is not informed about the allocation of the participants.It is not possible to mask the participants during the neuropsycological assessements.|Longitudinal randomized controlled trial. After screening and informed consent the participants are randomly allocated to exeperimental or control group. Both groups undergoing intervention but the participants in the control group undergo one more test before the intervention to rule out the test-retest effect.||||
34006715|NCT00001554||||TREATMENT||||||||
34006716|NCT03776578|||OTHER||OTHER|||||||
34006717|NCT06338631|||COHORT||PROSPECTIVE|||||||
34006718|NCT02302937|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34006719|NCT05025631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006720|NCT03844724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006721|NCT03540849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006722|NCT03847363|||OTHER||PROSPECTIVE|||||||
34006723|NCT01621906|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006724|NCT02979691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006725|NCT04552912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34006726|NCT06616805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|quadruple (participant, care provider, investigator, outcome assessor)|patients will be randomly assigned into two groups group A and group B. group A will receive low-volume high intensity interval training and group B will receive moderate intensity continuous training.|t|t|t|t
34006727|NCT05911087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study uses an observer-blinded design, and the investigators and participants will all remain blinded before unblinding and do not know which group the participant belongs to.|randomized#double-blinded # parallel controlled trial#mRNA vaccine# and positive control group#|t|f|t|f
34006728|NCT02676245|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34006729|NCT05858268|||COHORT||PROSPECTIVE|||||||
34006730|NCT02230111|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34006731|NCT02672540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006732|NCT02607137|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006733|NCT00801294||PARALLEL||TREATMENT||||||||
34006734|NCT03188601|||COHORT||PROSPECTIVE|||||||
34006735|NCT01787110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006736|NCT02926651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006737|NCT04157452|||COHORT||RETROSPECTIVE|||||||
34006738|NCT04187924|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006739|NCT06461793|NA|SINGLE_GROUP||TREATMENT||NONE||- A single institution with a single group, a phase II study, we plan to evaluate grade 1 or higher rectal bleeding within 3 years in high-risk prostate cancer patients who received biodegradable substance injection followed by curative radiotherapy in combination with hormone therapy.||||
34006740|NCT01608828|||CASE_CONTROL||PROSPECTIVE|||||||
34025185|NCT06532851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study, the outcomes assessor and the investigators will be blinded to the group allocation. The outcomes assessor will be unaware of the participants' group assignments to minimize the potential bias in evaluating outcomes. Similarly, the treatment assignment will only be displayed to the principal investigator once it has been determined that the subject meets all eligibility criteria, thus preserving concealed allocation of the randomization assignment from the study investigators and the individuals responsible for subject recruitment and follow-up. To minimize bias throughout the study, individuals responsible for collecting the outcome measures will remain blinded to group assignment for the duration of the study.|In this model, participants are assigned to one of the three groups (PRE, aerobic exercise, control) and remain in that group for the duration of the study. Each group receives a different intervention, allowing for direct comparisons between the interventions.|f|f|t|t
34025186|NCT00140348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092082|NCT02132468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092083|NCT04235075|NA|SINGLE_GROUP||OTHER||NONE||Creation of a multimodal database||||
33702153|NCT03137342|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Outcome assessor will be blind to the participant's assigned intervention.|Intervention Condition: Pepped-for-PrEP intervention counseling plus standard of care adherence counseling as part of their PrEP related care via The Miriam Hospital Control Condition: only the standard of care adherence counseling as part of their PrEP related care via The Miriam Hospital.|f|f|f|t
33702154|NCT01597531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702155|NCT00666172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702156|NCT00795145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33702157|NCT02008318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702158|NCT05545007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006741|NCT06192641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To control possible measurement biases, in the present study, the following measures will be taken: for the pharmacological intervention (use of melatonin or placebo), the evaluators and patients will be blinded to the intervention. The randomization codes will remain in the care of two evaluators not involved in the care of the patients, which allows better control of manipulations to favor any intervention to be carried out. Patients will be instructed to discuss all aspects related to pharmacological interventions with the researcher during treatment. The sealed envelope method will be used for confidential allocation. Before the recruitment phase, envelopes containing protocol materials will be prepared. Each envelope containing the allocated treatment will be sealed and numbered sequentially. After each participant agrees to participate in the study, the envelope will be opened and the results will be reported to the researcher who will carry out the interventions.|This is a randomized, double-blind, parallel, placebo-controlled clinical trial. 40 patients will be recruited to participate in the study, 20 of whom will receive the treatment and 20 will receive the placebo.Patients will receive 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).|t|f|t|f
34006742|NCT03209609|RANDOMIZED|PARALLEL||PREVENTION||NONE||In each patient, one SVG bypass will be randomized to be supported by the VEST, while another will not be supported and serve as control.||||
34006743|NCT01359579|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34006744|NCT06152705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This study is a two-arm triple-blind randomized parallel assignment clinical trial as neither the participant, care provider, nor the outcomes assessor know the arm (or condition) assigned to the participants. There are two treatment arms in which half will receive fMRI navigated iTBS and the other half will receive neuronavigated iTBS determined by a study randomizer software.~Master randomization list of treatment blinding will be kept by a scientist of the research centre that is not involved in the research project. This can be broken in case of emergency and they can then inform required medical professionals directly if necessary. Directly involved research staff will be blinded (including the PI)."||t|t|f|t
34006745|NCT01011556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006746|NCT05895578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006747|NCT02913820|||COHORT||RETROSPECTIVE|||||||
34006748|NCT04688047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34092084|NCT02069184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702159|NCT01950169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702160|NCT03240354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Participants will be split into two age groups, 'under 8 years' and '8 years and over', and a stratified randomisation method will be used to randomise each group, using a previously verified, sealed envelope, method and using blocks of unequal size.~* Envelopes will be prepared using a random number table by an individual with no further role in the study~* Each participant will be given a unique randomisation code matching the randomisation list~* A record of each randomisation will be recorded on the Enrolment Log (TAFR01502)"|Prospective, blinded, randomised, parallel group control trial|t|f|f|t
33702161|NCT02412995|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33702162|NCT00660699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702163|NCT04752384|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33702164|NCT01703325|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33702165|NCT00265629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006749|NCT04380649|NA|SINGLE_GROUP||OTHER||NONE||||||
34006750|NCT05377606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeon will be masked to the tamponading agent (silicone oil or gas) till the end of the operation when either agent will be injected.||f|t|f|f
34006751|NCT01834898|||||PROSPECTIVE|||||||
34092085|NCT03588468|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092086|NCT00087412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092087|NCT05349123|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Half of the subjects will be randomized to receive home-based PR with the mindful breathing module (intervention group) and half will receive home-based PR (control group).||||
33702166|NCT02498132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702167|NCT03204201|NA|SINGLE_GROUP||OTHER||NONE||||||
33702168|NCT03905408|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Escalating dose:~Arm 1: 50 mL dextrose 50% Arm 2: 100 mL dextrose 50% Arm 3: 150 mL dextrose 50% Arm 4:, 200 mL dextrose 50%"||||
33720400|NCT03733691|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open label, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib monotherapy (with steroids if applicable) and the combination of ixazomib and lenalidomide (with steroids if applicable) as maintenance therapy for patients with MM who have achieved at least PR after receiving a bortezomib and lenalidomide (with steroids if applicable)-containing combination frontline therapy.||||
34006752|NCT01236417|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006753|NCT04944316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34092088|NCT04882800|NA|SINGLE_GROUP||OTHER||NONE|Participants will not know which device is in each ear, only that they are being fit with Lyric devices.|Participants will be fit with commercially available extended wear hearing aid device A in the right ear and extended wear hearing aid with fitting modifications device B in the left ear for two weeks (first intervention); then fit with extended wear hearing aid with fitting modifications device B in the right ear and commercially available extended wear hearing aid device A in left ear for two weeks (second intervention). There will be no washout period.||||
34092089|NCT02178956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006754|NCT03244982|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The primary outcomes assessors will be retinal surgeons and residents, masked to the dosing of fluorescein. They will assess the subjective quality of images.|Patients will be randomly assigned to receive either a half-dose (250mg) or a full-dose (500mg) of intravenous fluorescein prior to their angiography procedure. If they return for a second fluorescein angiography study during the proceeding four months, they will receive the dose of fluorescein (250mg or 500mg) which they did not receive during their first study. Images will be evaluated subjectively by a masked panel of retinal surgeons for image quality, and image quality will be compared between images that are full dose and images that are half dose.|f|f|f|t
34006755|NCT00692315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006756|NCT04219787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006757|NCT03233451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006758|NCT05849688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Physical Therapy and Bicycle Ergometry|t|f|f|t
34006759|NCT03348488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The 2 arms applied to the same subject studied twice (case controlled)||||
34006760|NCT00891072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006761|NCT01607190|||COHORT||PROSPECTIVE|||||||
34006762|NCT06490406|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and the data analyst will be masked.|This study is a parallel group-randomized controlled trial.|t|f|f|t
34006763|NCT02020148|||COHORT||PROSPECTIVE|||||||
34006764|NCT05587257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006765|NCT03485846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006766|NCT02196064|||COHORT||RETROSPECTIVE|||||||
34006767|NCT03630419|NA|SINGLE_GROUP||TREATMENT||NONE||Mito Food Plan and Cellular Repair Therapy||||
34006768|NCT02839798|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, unblinded treatment series, all participants receive active treatment with the investigational device (NeoSync sTMS), as adjunct to ongoing stable pharmacotherapy||||
34006769|NCT05518032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006770|NCT01397981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006771|NCT06616649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006772|NCT00707421|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34006773|NCT06492564|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34006774|NCT03087786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006775|NCT00063882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006776|NCT00872326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006777|NCT04431635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788365|NCT03079882|||COHORT||PROSPECTIVE|||||||
34006778|NCT03070015|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34006779|NCT03239496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006780|NCT03964441|||COHORT||PROSPECTIVE|||||||
34006781|NCT05763849|RANDOMIZED|PARALLEL||TREATMENT||NONE||This RCT includes a parallel group design including two psychological treatments (Exposure-based Family Therapy vs. Family Based Therapy) for low weight eating disorders with 12 month follow-up.||||
34006782|NCT05582109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006783|NCT03305276|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34006784|NCT01043926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006785|NCT03328429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34006786|NCT00944684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006787|NCT01983176|||CASE_ONLY||RETROSPECTIVE|||||||
34006788|NCT06377020|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group pilot and feasibility study||||
34006789|NCT00164255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006790|NCT05744401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006791|NCT01388452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702169|NCT05840380|RANDOMIZED|PARALLEL||TREATMENT||NONE||Thirty patients (mean age; 38.46±9.03 years) with CNLBP were included in the study. The patients have randomly divided into two groups Graston technique (GT) and control. Graston was applied three times a week for four weeks in addition to the exercise program in the GT group, while only the exercise program was applied to the control group. Pain intensity (Visual analog scale), pressure pain threshold (algometer), proprioception (digital inclinometer), flexibility (sit and reach test), disability (Oswestry disability index), and quality of life (Short form-36) were evaluated at the beginning and end of the study.||||
33702170|NCT02257307|||COHORT||PROSPECTIVE|||||||
33702171|NCT01010373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702172|NCT06314867|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33702173|NCT00261274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092090|NCT04870203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||placebo-controlled trial|t|t|t|f
34092091|NCT05319704|RANDOMIZED|CROSSOVER||PREVENTION||NONE||participants may receive 4 differents interventions sequentially during the protocol||||
34092092|NCT01970371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092093|NCT03392857|||COHORT||PROSPECTIVE|||||||
33702174|NCT06036823|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|after consent. the care provider will take an envelope and give it to the nurse in charge of that patient without looking for the dose of insulin. as the same time will take the randomization code and stick it to the data collection sheet of that patient.|the study group will receive 5 units of intravenous insulin control group will receive 10 unites of IV insulin|t|t|t|f
33702175|NCT03561116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple blind||t|t|t|t
33702176|NCT03402646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This will be a single-blind three-arm cluster randomized controlled trial involving post-partum mothers and/or caregivers of infants (age 0-12months) attending immunization clinics in 12 randomly selected Primary Health Care Centres (clusters) across Sokoto, Jigawa, Kano, Ogun, Oyo and Lagos States of Nigeria. Additionally, the investigators will be implementing a photovoice methodology in 6 community clusters (one in each State) involving group discussions between community members (pregnant women in their third trimester, parents/caregivers of infants age 0-12 months), community leaders, service providers and policy makers on benefits of timely immunization and consequences of non-vaccination.|f|f|t|t
33702177|NCT04664192|||COHORT||CROSS_SECTIONAL|||||||
33702178|NCT04044586|||OTHER||CROSS_SECTIONAL|||||||
33702179|NCT04633577|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33702180|NCT04841538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702181|NCT03391089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702182|NCT03780543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702183|NCT05188170|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33702184|NCT05899088|RANDOMIZED|PARALLEL||TREATMENT||NONE||Rolling admission of participants. Each participant completes 12 weeks of intervention with weekly follow-up if in treatment arm. No follow-up in control arm.||||
33702185|NCT03428932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702186|NCT05253846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702187|NCT06201364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702188|NCT00404235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702189|NCT02793544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702190|NCT05543967|||COHORT||CROSS_SECTIONAL|||||||
33702191|NCT01402765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788366|NCT04966572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded||f|f|f|t
33788367|NCT01809808|||COHORT||PROSPECTIVE|||||||
33788368|NCT04037735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927774|NCT05359679|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This is a pragmatic cluster randomized trial across two Accountable Care Organizations. (ACOs) Within each ACO 15 primary care clinics will be randomized to the intervention arm or control arm of the study. From each intervention clinic, one clinician will participate in a clinical champion training program and subsequently work to decrease the prescribing of potentially inappropriate medications among patients with dementia among their colleagues. Medicare Part D pharmacy claims data will be analyzed at the end of the 12-month intervention for the primary outcome, the medication possession rates (MPR) for three groups of potentially inappropriate medications: antipsychotic medications, benzodiazepines, and hypoglycemic medications (sulfonylureas and insulin) among patients with a diagnosis of dementia.|f|f|f|t
33927775|NCT03698422|||OTHER||PROSPECTIVE|||||||
33927776|NCT00816283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927777|NCT05537454|||COHORT||PROSPECTIVE|||||||
33927778|NCT03380026|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||open-label, split-face study||||
33927779|NCT02525406|||OTHER||RETROSPECTIVE|||||||
34006792|NCT04214665|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006793|NCT03731728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to treatment group allocation by not involving them in discussions about study participants and not granting them access to the database which contains the randomization code. In addition, study participants will self-complete all outcome assessments on a tablet with the assessor only guiding the process. Moreover, these assessors will not be involved in data analysis.||f|f|f|t
34006794|NCT05785806|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34006795|NCT01957150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006796|NCT02695979|||COHORT||PROSPECTIVE|||||||
34006797|NCT02087917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006798|NCT00256529|||||PROSPECTIVE|||||||
34092094|NCT02884687|||COHORT||RETROSPECTIVE|||||||
34092095|NCT06169670|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, prospective study enrolling patients undergoing an aesthetic fat grafting procedure to the face. A total of 20 patients will be enrolled in the study, all patients will receive lipoaspirate processed with Viality.||||
34092096|NCT00134576|RANDOMIZED|FACTORIAL||||NONE||||||
34092097|NCT04361175|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34092098|NCT04264585|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34092099|NCT01325441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34092100|NCT02967029|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34092101|NCT01901562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092102|NCT00876343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092103|NCT01815619|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34092104|NCT02054949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092105|NCT01549067|||||CROSS_SECTIONAL|||||||
34092106|NCT05186155|||COHORT||PROSPECTIVE|||||||
34092107|NCT05926531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092108|NCT02512562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702192|NCT03459170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702193|NCT02198872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702194|NCT02298530|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33702195|NCT02481908|||COHORT||PROSPECTIVE|||||||
33702196|NCT02110238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927780|NCT04679389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Randomized, double blind, placebo controlled, with optional extension period|t|t|t|t
33927781|NCT02691481|RANDOMIZED|CROSSOVER||||NONE||||||
33927782|NCT03683004|||COHORT||PROSPECTIVE|||||||
33927783|NCT04547998|NA|SINGLE_GROUP||TREATMENT||NONE|The Central Review Committee (CRC) will be blinded to treatment assignment when adjudicating data.|||||
34103262|NCT06686290|RANDOMIZED|PARALLEL||OTHER||SINGLE|Assessor Blinded|Group A will be treated with Postisometric relaxation technique and Group B will be treated with Static stretching technique. Postisometric relaxation will be performed with the frequency of 5 times, such that it includes (30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold. Stretching exercise will be performed with 30 second hold and with 5 repetitions. All Exercises will be performed 3 times per week for total of 4 weeks.|f|f|f|t
33927784|NCT04795492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927785|NCT04238611|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33927786|NCT03608644|||COHORT||PROSPECTIVE|||||||
33927787|NCT05225480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants are masked as to which intervention (conversation) is considered the actual intervention. Therapists doing physical tests are blinded to treatment allocation|randomized single blind controlled trial|t|f|f|t
33927788|NCT01454024|||COHORT||PROSPECTIVE|||||||
33927789|NCT05557097|||COHORT||PROSPECTIVE|||||||
33927790|NCT01918267|||COHORT||PROSPECTIVE|||||||
33927791|NCT05713942|||COHORT||PROSPECTIVE|||||||
33927792|NCT01270724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927793|NCT04010162|||OTHER||OTHER|||||||
33927794|NCT05825313|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33927795|NCT04853199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a randomized double-blind study|t|t|t|f
33927796|NCT04220138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006799|NCT05164835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006800|NCT00920114|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006801|NCT03577886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Dose-escalating, Randomized, Double-blinded, Placebo-controlled.|t|t|t|t
34006802|NCT05907655|||CASE_CONTROL||PROSPECTIVE|||||||
33702197|NCT06254651|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702198|NCT00821106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702199|NCT04629807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702200|NCT00831025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702201|NCT06315959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Sealed opaque envelopes containing study participation numbers will be used to assign each patient. A researcher not involved in patient follow-up will use the web-based Research Randomizer (Urbaniak and Plous 2013) tool to give each participation number to a random group with a 1:1 ratio. A nurse not an active investigator in the study will have each participant choose an envelope containing the study participation number. They will inform the anesthetist administering the block/blocks about which group the patient is in immediately before administration. Researchers, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program, 'Research Randomizer (Urbaniak and Plous, 2013)'.|t|t|t|t
33702202|NCT03676192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702203|NCT00553943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702204|NCT01442454|||||PROSPECTIVE|||||||
33702205|NCT00386386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702206|NCT03607396|||COHORT||RETROSPECTIVE|||||||
33702207|NCT02568774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702208|NCT05875701|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702209|NCT01590459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702210|NCT04696055|NA|SEQUENTIAL||TREATMENT||NONE||||||
33702211|NCT01928173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702212|NCT06090396|||COHORT||PROSPECTIVE|||||||
33702213|NCT04057365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702214|NCT03206411|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33702215|NCT02566447|||OTHER||PROSPECTIVE|||||||
33702216|NCT03712020|||OTHER||PROSPECTIVE|||||||
33702217|NCT00111501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702218|NCT04691271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33702219|NCT06203171|||COHORT||PROSPECTIVE|||||||
33788369|NCT00346931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788370|NCT06328946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927797|NCT00524043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927798|NCT04632745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927799|NCT04988321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33927800|NCT01708538|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34006803|NCT01275976|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34006804|NCT01269476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006805|NCT03034161|||CASE_ONLY||PROSPECTIVE|||||||
34006806|NCT02421016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927801|NCT00932009|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33927802|NCT01577355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006807|NCT04838119|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34006808|NCT02285348|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006809|NCT02074267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006810|NCT00784030|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34006811|NCT03208673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006812|NCT05907408|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34006813|NCT04532177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006814|NCT01242618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788371|NCT03278288|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Family participants are masked and control group is not aware of the intervention condition. PHN participants are not masked.|Two-arm cluster randomized controlled trial and conducted in four municipalities located in the Southwest Finland. The unit of randomization is one cluster, with one municipality with its Child health clinics representing one cluster. Two municipalities with all together eight Child health clinics are randomly allocated into the intervention arm and two municipalities with all together seven Child health clinics are randomly allocated into the control arm.|t|f|f|f
33788372|NCT06567743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788373|NCT00973141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788374|NCT06293547|NA|SINGLE_GROUP||TREATMENT||NONE||The study group of this non-randomized, prospective, single-arm clinical research consisted of pediatric patients and their parents who presented to the Department of Pediatric Dentistry, Faculty of Dentistry, Cumhuriyet University, selected using convenient sampling method. For determining the sample size in this study, assuming a 5% alpha error, 80% power, and a cessation rate (35.7%) from a previous study, it was calculated that at least 40 participants should be included. Considering potential patient loss/follow-up, the study group was increased by 20%, resulting in a final decision to include 48 children and their parents in the study.||||
33788375|NCT03391908|||COHORT||PROSPECTIVE|||||||
33788376|NCT00853424|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33788377|NCT00611832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788378|NCT06632002|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33788379|NCT06145256|||OTHER||PROSPECTIVE|||||||
33788380|NCT06630208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788381|NCT05716542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788382|NCT02588482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788383|NCT01105572|RANDOMIZED|PARALLEL||||NONE||||||
33788384|NCT01030003|||COHORT||PROSPECTIVE|||||||
33788385|NCT01768143|||COHORT||PROSPECTIVE|||||||
34006815|NCT06350617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, assessors, and investigators will be blinded, not be aware of the group allocation. Statistical analysis will also be conducted by data analysts without awareness of the group allocation. Only clinicians applying rTMS intervention will not be blinded, as they will apply rTMS over different stimulation sites based on the protocols. Blinding will be continued until the end of the study, including data analysis.|prospective, single-blind with blind observer, parallel-group design, multi-center, randomized controlled clinical trial|t|f|t|t
33788386|NCT02772315|||COHORT||PROSPECTIVE|||||||
33788387|NCT05963308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33788388|NCT02947815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788389|NCT00283374|||DEFINED_POPULATION||PROSPECTIVE|||||||
33788390|NCT00037388|||||RETROSPECTIVE|||||||
33788391|NCT03594331|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33788392|NCT01249040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33788393|NCT00296426|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33788394|NCT01003015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006816|NCT00986219|||CASE_ONLY||CROSS_SECTIONAL|||||||
34006817|NCT05610449|||COHORT||PROSPECTIVE|||||||
34006818|NCT00050882||||TREATMENT||||||||
34006819|NCT04411368|||COHORT||PROSPECTIVE|||||||
34006820|NCT01595841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006821|NCT00277524|||||PROSPECTIVE|||||||
34006822|NCT02344745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34006823|NCT01997723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006824|NCT03304782|||COHORT||PROSPECTIVE|||||||
34006825|NCT01477099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006826|NCT01301482|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006827|NCT03895619|NA|SINGLE_GROUP||PREVENTION||NONE||Proof of Concept Research||||
34006828|NCT02928978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006829|NCT00816452|||COHORT||PROSPECTIVE|||||||
34006830|NCT00838123|||CASE_CONTROL||PROSPECTIVE|||||||
34006831|NCT06571500|||COHORT||PROSPECTIVE|||||||
34006832|NCT02991560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34006833|NCT03837678|||OTHER||RETROSPECTIVE|||||||
33788395|NCT00353067|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33788396|NCT06458127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33788397|NCT04836793|||COHORT||PROSPECTIVE|||||||
33788398|NCT03243656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788399|NCT03771885|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006834|NCT04725591|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006835|NCT02051595|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006836|NCT05673993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006837|NCT03263793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006838|NCT06277050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006839|NCT05080608|||CASE_ONLY||CROSS_SECTIONAL|||||||
34006840|NCT05002881|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double-blind, Cross-over|Randomized, Double-blind, Cross-over, Placebo controlled study|t|t|t|t
33788400|NCT04564313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788401|NCT00578435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788402|NCT03416751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006841|NCT02184741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006842|NCT00893451|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34006843|NCT03497819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006844|NCT00308360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34006845|NCT05044494|||COHORT||RETROSPECTIVE|||||||
34006846|NCT03907917|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomization will be administrated by independent research staff. Double-blind software will be used to ensure that the experimenter and subject remain blind during task administration.|Subjects will be randomly assigned to receive Active (real) or Sham (placebo) transcranial direct current stimulation.|t|f|t|t
34006847|NCT02904538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006848|NCT02076776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006849|NCT06472180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double blinded Data analyst, statistician and patient will be blinded||t|f|f|f
34006850|NCT05927779|NA|SEQUENTIAL||TREATMENT||NONE||||||
34006851|NCT05521022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind (Part 1) Open Label (Part 2) Open Label (Part 3)||t|f|t|f
34006852|NCT06123260|||COHORT||PROSPECTIVE|||||||
34006853|NCT00442351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006854|NCT01177163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34006855|NCT00678327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006856|NCT03085368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006857|NCT02215668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34092109|NCT04954872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The persons without mental health professional training who are randomized to either training as usual or Equip-based training will not be informed about how the two training arms differ. Outcome assessors will not be told if the trainees are in training as usual or Equip-based training.|Persons without mental health professional experience will be randomized to either training as usual to develop Problem Management Plus competencies or they will be randomized to Problem Management Plus training that uses Equip principles of competency-based training.|f|t|f|t
34006858|NCT02419573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006859|NCT00145613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092110|NCT03568617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092111|NCT00107588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092112|NCT03489564|||COHORT||PROSPECTIVE|||||||
34092113|NCT00214435|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092114|NCT04804488|||CASE_ONLY||RETROSPECTIVE|||||||
34092115|NCT03513731|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is a single-blinded trial in which the radiologists are blinded. Subjects and the Investigator are unblinded.|||||
34092116|NCT01101048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092117|NCT06369272|||COHORT||RETROSPECTIVE|||||||
33927803|NCT05263544|||CASE_CONTROL||PROSPECTIVE|||||||
33927804|NCT05693688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|International, multicenter, double blinded, placebo controlled RCT|t|t|t|t
33927805|NCT02345044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927806|NCT01920971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927807|NCT04209400|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33927808|NCT04673188|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33927809|NCT02945319|||COHORT||RETROSPECTIVE|||||||
33927810|NCT04262908|||COHORT||PROSPECTIVE|||||||
33927811|NCT05441943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927812|NCT02925559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702220|NCT05036590|RANDOMIZED|PARALLEL||OTHER||NONE||Multicentric Stepped-wedge Randomized Control Trial||||
33702221|NCT01202565|||||PROSPECTIVE|||||||
33702222|NCT01770496|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33702223|NCT01932307|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702224|NCT01581710|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33702225|NCT04478266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702226|NCT03562910|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33927813|NCT02078661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006860|NCT00549341|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34006861|NCT01805635|||COHORT||RETROSPECTIVE|||||||
34006862|NCT00975390|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34006863|NCT03566238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-Blind, Randomized, Placebo-Controlled|t|t|t|t
34006864|NCT00869687|NA|SINGLE_GROUP||OTHER||NONE||||||
34006865|NCT03814915|||COHORT||PROSPECTIVE|||||||
34006866|NCT06109857|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702227|NCT01747148|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34006867|NCT00004490|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34006868|NCT00688402|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34006869|NCT02636829|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34006870|NCT05583877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After completing the informed consent, study staff will enter the participant's information into pre-populated REDCap identification numbers. This will assign allocation based on the randomization table. Using this technique, participants will be blinded to allocation. However, research staff will not be blinded to provide personalized training for intervention and control. The investigator will be blinded to randomization for all participants during the study.|The purpose of this study is to culturally-adapt a patient-centric intervention designed to improve implementation of diabetes self-management training in Spanish-speaking patients. To accomplish cultural adaptation of the DM-BOOST intervention, a Patient Research Expert Panel (PREP) (n\</=4) will participate in Community Engagement Studios to inform adaptations (Aim 1) and usability test the intervention (Aim 2). A randomized pilot with new patients (n\</=70) will then be conducted to assess feasibility (Aim 3).|t|f|t|f
34006871|NCT06251960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006872|NCT04403399|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34006873|NCT04643392|||COHORT||PROSPECTIVE|||||||
34006874|NCT02951936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33702228|NCT03301805|NA|SINGLE_GROUP||TREATMENT||NONE||"Study Objectives Part I To determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.~Part II To assess the efficacy and safety of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy at the recommended dose."||||
34006875|NCT05531851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled trial|t|t|f|t
34006876|NCT02558465|||COHORT||PROSPECTIVE|||||||
34006877|NCT06292975|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Feasibility study||||
34006878|NCT03993327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092118|NCT06324591|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092119|NCT01104051|||CASE_CROSSOVER||PROSPECTIVE|||||||
34092120|NCT00004059||||TREATMENT||||||||
34092121|NCT01208909|||CASE_CONTROL||PROSPECTIVE|||||||
34092122|NCT05175365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702229|NCT01128842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702230|NCT06557096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702231|NCT04521816|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702232|NCT06274320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33702233|NCT04480008|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33702234|NCT04395404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702235|NCT02904889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702236|NCT05552521|||COHORT||PROSPECTIVE|||||||
33702237|NCT03726307|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose-escalation, phase 1 clinical trial.||||
33702238|NCT02431338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702239|NCT00085709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702240|NCT03474861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702241|NCT02677961|||COHORT||PROSPECTIVE|||||||
33702242|NCT01259765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702243|NCT02182739|||COHORT||PROSPECTIVE|||||||
33702244|NCT01987635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702245|NCT04387331|||COHORT||PROSPECTIVE|||||||
33702246|NCT01821196|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702247|NCT02418429|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34092123|NCT01765491|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34092124|NCT06522802|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092125|NCT03893708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702248|NCT00935948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702249|NCT05472753|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio||||
33702250|NCT01672008|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33702251|NCT03628794|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33702252|NCT02504684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702253|NCT02646514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702254|NCT05436093|NA|SINGLE_GROUP||SCREENING||NONE||||||
33702255|NCT04763356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessor grading the only reported outcome measure (mTCNS) will be blinded to the group allocation.|This is a single blinded (outcome assessor) randomized controlled trial with 2 arms.|f|f|f|t
33702256|NCT05607615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This is a randomized, placebo-controlled, double-blind, parallel-group study|t|t|t|t
33702257|NCT03151343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be treated with either empagliflozin or placebo|t|t|t|t
33702258|NCT02272075|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702259|NCT01315964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33702260|NCT01522248|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720401|NCT03770390|NA|SINGLE_GROUP||TREATMENT||NONE||This single group study documents changes before and after surgical correction of pectus excavatum.||||
33720402|NCT05251545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33702261|NCT05383521|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"For patients who failed to conventional treatment (recommended by the guidelines including tinidazole, 2g once daily for 5-7 days), the following regimens were selected: Tinidazole , 2g twice daily for 14 days. At the same time, metronidazole, 400 mg, daily, vaginal administration for 14 days.~Tinidazole , 1g three times daily for 14 days. At the same time, metronidazole, 400 mg, daily, vaginal administration for 14 days."||||
33702262|NCT01126970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702263|NCT04948528|||COHORT||PROSPECTIVE|||||||
33702264|NCT01827514|||COHORT|||||||||
33702265|NCT01589978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702266|NCT01773252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702267|NCT05058820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702268|NCT01192659|||||PROSPECTIVE|||||||
33702269|NCT02433457|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788403|NCT06631989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Part A (Dose escalation and expansion study) ; Part B (single-arm extension study).||||
33788404|NCT06252727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702270|NCT04716907|||CASE_CONTROL||PROSPECTIVE|||||||
33702271|NCT00679666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702272|NCT02663908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702273|NCT05728021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927814|NCT03936478|NA|SINGLE_GROUP||TREATMENT||NONE||This study will have a lead-in phase consisting of 10 patients, followed for 6-months from the date of completion of radiotherapy for the tenth patient. The second phase of accrual (20 patients) will commence only if three or fewer patients (3/10=30%) have CTCAE v 5.0 grade 3 or higher skin toxicity (radiation dermatitis) or Lövey et al. grade 3 or higher fat necrosis.||||
33927815|NCT04438304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927816|NCT03152396|NA|SINGLE_GROUP||TREATMENT||NONE||A non-randomized prospective pre-post-intervention design.||||
33927817|NCT00028119|||COHORT||PROSPECTIVE|||||||
33927818|NCT03043261|NA|SINGLE_GROUP||OTHER||NONE||||||
33927819|NCT02468960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927820|NCT01329341|NA|SINGLE_GROUP||OTHER||NONE||||||
33927821|NCT05152667|||COHORT||OTHER|||||||
33927822|NCT06178757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic cholecystectomy surgery will be included in the study. Patients will be randomly divided into two groups (Group TAPB = TAP group, Group EOIB = EOB group) including 30 patients each, before entering the operating room.|t|f|f|t
33927823|NCT00848770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927824|NCT02829008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927825|NCT00586638|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33927826|NCT01163123|||COHORT||PROSPECTIVE|||||||
33927827|NCT00854438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33927828|NCT05037916|||CASE_ONLY||PROSPECTIVE|||||||
33927829|NCT00000339||CROSSOVER||TREATMENT||SINGLE||||||
33927830|NCT02213549|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33927831|NCT02379403|||CASE_CROSSOVER||PROSPECTIVE|||||||
33927832|NCT01085019|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33927833|NCT03117309|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
33927834|NCT03125018|NA|SINGLE_GROUP||OTHER||NONE||||||
33927835|NCT01586650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927836|NCT00224783|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33927837|NCT00964262|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33927838|NCT01196312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927839|NCT03241589|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33927840|NCT01514006|||COHORT||PROSPECTIVE|||||||
33927841|NCT00535444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927842|NCT02134067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927843|NCT02327156|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33927844|NCT03602989|||CASE_ONLY||CROSS_SECTIONAL|||||||
33927845|NCT03969836|||COHORT||PROSPECTIVE|||||||
34092126|NCT00536835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092127|NCT00525304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33702274|NCT00092807||||TREATMENT||||||||
33702275|NCT04862455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702276|NCT00713856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702277|NCT04118504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33702278|NCT03713892|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33702279|NCT01893203|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33702280|NCT00692861|||||PROSPECTIVE|||||||
33702281|NCT05943028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were assigned to the management and control groups, and neither group of researchers nor subjects was clear about their group. Data statistical analysts and clinical trial participants maintain independence in their work.|The control group chose the original preset value of 36 as the baseline value of EEG closed-loop feedback guidance (derived from the team's previous research results.The experimental group selected the preset value of 36+N as the baseline value of the new EEG closed-loop feedback guidance (the N value was 6-8 from the pre-experiment).Samples that met the inclusion criteria were randomized and randomly included in the experimental and control groups.|t|f|t|t
33702282|NCT06257628|||OTHER||CROSS_SECTIONAL|||||||
33927846|NCT02687360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927847|NCT00415545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33927848|NCT02945306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927849|NCT02583997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927850|NCT05952960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927851|NCT05676827|||COHORT||PROSPECTIVE|||||||
33927852|NCT04959604|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention group. Participants will receive a state of the art surgical procedure with additional lymph node mapping||||
33927853|NCT06196619|||OTHER||CROSS_SECTIONAL|||||||
33927854|NCT00838370|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006879|NCT04413032|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A group of patients with Multiple Sclerosis and a group of healthy volunteers will use the dreaMS App over the period of 6 weeks.||||
34006880|NCT00311649|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34006881|NCT02321124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006882|NCT04691440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006883|NCT03224078|||OTHER||PROSPECTIVE|||||||
34006884|NCT03153826|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006885|NCT04938973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006886|NCT03629106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open-label trial to compare two arms: 1) contingent reinforcement and 2) non-contingent reinforcement.||||
34006887|NCT04581876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006888|NCT03882411|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-post single group design with 8 clinic clusters randomized to timing of receipt of intervention with patients nested within providers nested within clinic clusters.||||
34092128|NCT01830686|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34092129|NCT04121013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34092130|NCT01878266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092131|NCT02195323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092132|NCT01222351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702283|NCT01719978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33702284|NCT00866788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702285|NCT04775069|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702286|NCT03572244|RANDOMIZED|PARALLEL||TREATMENT||NONE||6 subjects will be randomized to Laser-Lok placement, and 6 subjects will be randomized to machined healing abutment placement. The assignment will be a 1:1 scheme, with the study coordinator randomly opening pre-assigned envelopes to determine implant.||||
33702287|NCT04488796|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This will be a 2 (automated vs. choice of automation) by 3 (Opt-in, active choice or enhanced active choice) factorial design pilot randomized control trial||||
33702288|NCT02167425|||COHORT||PROSPECTIVE|||||||
33702289|NCT06557993|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33702290|NCT01163331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702291|NCT03602820|||COHORT||PROSPECTIVE|||||||
33702292|NCT00002688|RANDOMIZED|||TREATMENT||||||||
33702293|NCT00167648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702294|NCT00813020|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33702295|NCT04184583|||OTHER||OTHER|||||||
33702296|NCT03429660|||COHORT||PROSPECTIVE|||||||
33702297|NCT01757522|||COHORT||PROSPECTIVE|||||||
33702298|NCT02051842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702299|NCT05118243|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The study is double-masked - neither the researchers or the participants know which cracker they are eating.||t|f|t|f
33702300|NCT01020981|||COHORT||CROSS_SECTIONAL|||||||
33702301|NCT01553383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702302|NCT03585062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801668|NCT05075694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, while the intervention group was administered Therapeutic Touch , the control group was administered Sham Therapeutic Touch (STT). The interventions in the study were implemented using the literature information as well as the Therapeutic Touch Practice Procedure (TTPP) and Sham Therapeutic Practice Procedure (STPP). To administer the TT practice, the researcher received a certificate by participating in the first and second-level courses held by the International Therapeutic Touch Association.|This study was conducted as a parallel randomized-controlled, single-blind, single-centered, interventional study with a pre-test and post-test design|t|f|f|f
33801669|NCT02787031|||COHORT||RETROSPECTIVE|||||||
33801670|NCT00891631|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34006889|NCT04099641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006890|NCT00759278|||CASE_CONTROL||PROSPECTIVE|||||||
34006891|NCT00802178|||COHORT||PROSPECTIVE|||||||
34006892|NCT05250206|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006893|NCT01215903|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34006894|NCT02009709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006895|NCT02596633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34092133|NCT05125432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092134|NCT05796817|||COHORT||PROSPECTIVE|||||||
34092135|NCT03344393|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34092136|NCT03737019|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective non-randomized trial with one interventional group and a parallel group without intervention||||
34092137|NCT02981641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092138|NCT00031993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092139|NCT02737618|NA|SINGLE_GROUP||SCREENING||NONE||||||
34092140|NCT00848432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092141|NCT01407367|||COHORT||PROSPECTIVE|||||||
34092142|NCT00900120|||CASE_ONLY||PROSPECTIVE|||||||
34092143|NCT02648906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092144|NCT02657941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092145|NCT02774278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092146|NCT00318604|||||PROSPECTIVE|||||||
33702303|NCT03460275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702304|NCT03473483|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33702305|NCT04749706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702306|NCT01817530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702307|NCT01136148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702308|NCT03974243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702309|NCT01509365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702310|NCT05984472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Evaluator)|Individual Randomized Assignment|t|t|f|f
33702311|NCT01995110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33702312|NCT02322346|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33702313|NCT02700113|||CASE_ONLY||CROSS_SECTIONAL|||||||
33702314|NCT06556979|||COHORT||CROSS_SECTIONAL|||||||
33702315|NCT03851757|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomised, controlled, examiner-blinded, two-period crossover study|f|f|t|f
33702316|NCT04116788|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702317|NCT00809354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702318|NCT03918148|||COHORT||PROSPECTIVE|||||||
33702319|NCT03219541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702320|NCT04965727|NA|SINGLE_GROUP||TREATMENT||NONE||Single site, interventional, non-randomized||||
33702321|NCT01804023|||||PROSPECTIVE|||||||
33702322|NCT00885287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702323|NCT02269306|NA|SINGLE_GROUP||||NONE||||||
33702324|NCT03758443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Integrated and Adaptive Design|t|t|t|t
34006896|NCT05118477|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092147|NCT02151942|||CASE_CONTROL||PROSPECTIVE|||||||
33702325|NCT06356519|||COHORT||RETROSPECTIVE|||||||
33702326|NCT05905900|||CASE_ONLY||RETROSPECTIVE|||||||
33702327|NCT01679925|||COHORT||PROSPECTIVE|||||||
33801671|NCT03401372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801672|NCT06005857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33801673|NCT00179751|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33801674|NCT04784026|||CASE_CONTROL||PROSPECTIVE|||||||
34006897|NCT00855764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34006898|NCT02945345|||COHORT||PROSPECTIVE|||||||
34006899|NCT05555927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006900|NCT03336918|||OTHER||PROSPECTIVE|||||||
34092148|NCT04028960|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34092149|NCT03945136|||COHORT||RETROSPECTIVE|||||||
34092150|NCT04871945|||CASE_CONTROL||PROSPECTIVE|||||||
34092151|NCT04529408|||COHORT||PROSPECTIVE|||||||
34092152|NCT03770455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092153|NCT02518269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092154|NCT03558724|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092155|NCT00296595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006901|NCT06534840|||COHORT||PROSPECTIVE|||||||
34006902|NCT05287399|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34006903|NCT00717782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34006904|NCT05212441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006905|NCT00664287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006906|NCT03245216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34006907|NCT06616038|||COHORT||PROSPECTIVE|||||||
34006908|NCT05029934|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will not be informed about the use of EndoClot adhesive|use of EndoClot adhesive after resection vs no use of any preventive action against delayed bleeding (control group)|t|f|f|f
33702328|NCT02938312|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33702329|NCT02462252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702330|NCT03653338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702331|NCT03725137|||COHORT||PROSPECTIVE|||||||
33702332|NCT04105582|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702333|NCT04304742|||CASE_ONLY||RETROSPECTIVE|||||||
33702334|NCT00369707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702335|NCT03069443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702336|NCT05343923|||COHORT||PROSPECTIVE|||||||
33702337|NCT06557382|||COHORT||PROSPECTIVE|||||||
33702338|NCT04254861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, both participants and clinicians performing the surgical intervention will be unblinded. Conversely, outcome examiners will be blinded to treatment allocation.|This is a randomized, single-blind, parallel-group controlled trial comparing the efficacy of GTR and PRGF ENDORET® in the treatment of periodontal intrabony defects. The trial will follow the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement.|f|f|f|t
33702339|NCT04002739|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The target sample size (for primary aim) is 37. Patients to be enrolled: 50 Patients to be screened: 70~This sample size (n=37) has been defined as sufficient to detect a difference of 15.0 in mean AHI Index between baseline and 3-month follow up with a power of 95% and a 5% (two-sided) significance level. The sample size was calculated and based on a previous pilot study from our institution and reported in More information section.~Notably, attrition has been proposed due to the possible loss of follow up at 90-day: thus, we decided to enroll 13 more patients affected by OSA for a total of 50 patients.~Moreover, given a CCU prevalence of OSA in ACS of 73%, a total of 70 patients affected by ACS are expected to be screened in order to collect 50 OSA target sample size population."||||
33702340|NCT05757596|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33801675|NCT00123903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801676|NCT00220038|||COHORT||PROSPECTIVE|||||||
33801677|NCT06336473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-center study performed on biopsied skin samples||||
34006909|NCT00843830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006910|NCT06028646|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092156|NCT02825810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34092157|NCT00433290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092158|NCT02088320|||COHORT||PROSPECTIVE|||||||
34092159|NCT02594111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092160|NCT00497510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34092161|NCT05845073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092162|NCT03119311|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34092163|NCT00922389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006911|NCT03729518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006912|NCT06082908|||CASE_ONLY||CROSS_SECTIONAL|||||||
34006913|NCT00513617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006914|NCT05808166|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34103263|NCT05751941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702341|NCT01443208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33702342|NCT00575991|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33702343|NCT05727930|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Blinded assessors will be utilized at baseline, post-training and follow-up assessments.|2X2 factorial design with primary independent variables of specificity of practice and intensity of practice during physical rehabilitation.|f|f|f|t
33702344|NCT05514483|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Because of the single sequence of administration, blinding of study personnel would not be possible. As the primary outcome is a continuously electronically recorded physiological parameter that does not require any human interpretation, single blinding should not result in any observation bias.|Non-randomized crossover controlled trial with two interventions and one sequence. The sequence of treatment is first placebo and secondly ondansetron.||||
33702345|NCT06278519|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702346|NCT04456257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702347|NCT02652754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702348|NCT01696071|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33702349|NCT05192967|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33702350|NCT02736838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702351|NCT00180050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927855|NCT05263921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33927856|NCT03767998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33927857|NCT02031198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927858|NCT01871272|||COHORT||PROSPECTIVE|||||||
33927859|NCT04388813|||COHORT||PROSPECTIVE|||||||
33927860|NCT03356808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006915|NCT05062148|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Patients will be randomly assigned using R software (https://www.r-project.org) to three groups - Float-REST, PBM, or no intervention.~All subjects will return to RNI three times per week (intervention visits). Subjects receiving Float-REST will float for 60 minutes, those receiving PBM will undergo a 20-minute therapy session, and both will complete the weekly testing afterwards. Subjects in the no intervention group will complete the weekly testing only. This will continue until the subjects' physicians clear them to return to play."||||
34006916|NCT03549455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006917|NCT03381196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006918|NCT02546050|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006919|NCT00774943|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34006920|NCT01567241|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34006921|NCT04542694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006922|NCT03822273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All the patients are told that they will receive one kind of acupuncture treatment in addition to the original oral analgesics and assess the efficacy of acupuncture. The patients are randomly assigned to three groups after providing written informed consent, without being mentioned which kind of acupuncture treatment is applied as control. Patients are not blinded to TA or LA treatment, but they can be blinded to LA or SLA treatment. The outcome assessor is also blinded to the group assignments and is trained to apply the pain scales and conduct physical tests. To avoid unblinding of the assessment of outcomes, the patients are instructed not to discuss any aspect related to their treatment with the assessor.|"1. Acupuncture group~2. Laser acupuncture group~3. Sham laser acupuncture group"|f|f|f|t
34006923|NCT03546647|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34006924|NCT01104571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006925|NCT01115855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34006926|NCT05352477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006927|NCT06026059|||COHORT||PROSPECTIVE|||||||
33702352|NCT01903174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702353|NCT04249531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927861|NCT02295800|||COHORT||PROSPECTIVE|||||||
33927862|NCT01350011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927863|NCT05817955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927864|NCT02587858|||COHORT||PROSPECTIVE|||||||
33927865|NCT04080492|||COHORT||PROSPECTIVE|||||||
33927866|NCT01668381|||CASE_ONLY||PROSPECTIVE|||||||
33927867|NCT03620604|||COHORT||PROSPECTIVE|||||||
33927868|NCT00136838|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33927869|NCT02884271|||COHORT||PROSPECTIVE|||||||
33927870|NCT01191281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927871|NCT01803113|||||PROSPECTIVE|||||||
33927872|NCT05480241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For evaluation the response to PERT in patients with acute pancreatitis and EPI, the study will be doubleblind (for the patient who will not know which therapy he will be taking (PERT/placebo) and for the researchers responsible for sequencing and immunological analyses) randomized placebo-controlled clinical trial.|Double-blind randomized placebo-controlled trial for patients with EPI after acute pancreatitis for PERT and collection of stool and blood samples before and after PERT/placebo|t|f|t|f
33927873|NCT02281968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33927874|NCT04631614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33927875|NCT02448017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927876|NCT02182089|||COHORT||PROSPECTIVE|||||||
33927877|NCT00405717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927878|NCT00254163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927879|NCT06337162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927880|NCT00228033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33927881|NCT03349580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33927882|NCT04815538|||CASE_CONTROL||RETROSPECTIVE|||||||
33927883|NCT01997281|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33927884|NCT00790530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33927885|NCT04690712|NON_RANDOMIZED|CROSSOVER||SCREENING||DOUBLE||Health screening was done to the experimental group with one group. Surveys were conducted. Later, health education was given to this group. Six months later, the same group was screened for health again and a questionnaire was applied.|f|f|t|t
33788405|NCT03523962|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The orthopaedic team (including the study coordinators) cannot be blinded to the treatment allocation as the antiseptic solutions are visually distinguishable and these individuals need to lead the implementation of the cluster-crossover protocol at their clinical site. The Adjudication Committee Members and data analysts will be blinded to the study treatment. All interpretation of study results will initially be done in a blinded manner by developing two interpretations of the results. One interpretation will assume treatment A is iodine povacrylex, the other interpretation will assume it is CHG. Once the data interpretations for each assumption are finalized, the data will be unblinded and the correct interpretation will be accepted.|Treatment allocation will be determined using a cluster-randomized crossover trial design. The open and closed fracture populations will be treated with the same allocated solution at all times during the trial. The order of treatment allocation for each orthopaedic practice will be randomly assigned using a computer-generated randomization table. Each site will start with the initially allocated study solution and eventually crossover to the other solution for their second recruitment period. This process of alternating treatments will repeat approximately every 2 months as dictated by the initial randomization.|f|f|f|t
34006928|NCT00877617|||CASE_ONLY||PROSPECTIVE|||||||
34006929|NCT05527158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34092164|NCT03853928|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|A randomized, double-blind, randomized controlled trial of probiotics versus placebo in patients with Child Pugh A-B cirrhosis at 3-year follow-up.|Multicenter, randomized, double-blind, placebo-controlled study of nutritional supplementation with probiotics to prevent the development of hepatocellular carcinoma in cirrhosis.|t|f|t|t
34092165|NCT01603147|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34092166|NCT00000335||||TREATMENT||||||||
34092167|NCT05220930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Double-blind|Parallel Assignment|t|f|f|f
34092168|NCT06322498|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092169|NCT02918799|NA|SINGLE_GROUP||PREVENTION||NONE||Intervention will be evaluated with community cohort and use of pre- post-intervention analysis plan||||
33702354|NCT06276673|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Unable to blind due to differences in cuff size and appearance.|Participants will undergo three treatment sessions (control (no BFR), SC BFR, and MC BFR) in a randomized order separated by one week.||||
33702355|NCT00435864|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702356|NCT04432025|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly allocated to the control arm (bariatric surgery- either RYGB or SG) or intervention (bariatric surgery- either RYGB or SG + goal directed medical therapy for t2DM)||||
33788406|NCT06630715|||COHORT||PROSPECTIVE|||||||
33788407|NCT00290706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788408|NCT00233740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927886|NCT02299804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927887|NCT04297345|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Health personnel not belonging to the research team will be responsible for randomizing patients with a table of random numbers in a proportion 1 control: 1 dialysis.~The identity of the treatment will remain masked for the analysis of clinical and laboratory data:~The researchers will not know the determination of the concentration of Glu and proinflammatory cytokines in the serum and in the dialysate fluid of the patients until the end of the study, once the database is closed and the randomization codes are opened. Neuroimaging tests Multimodal CT and simple CT) will be evaluated by a single Neuroradiologist of the Radiology Service of the Hospital de La Princesa, blind to the clinical and biological variables of the patients."|"Randomized, Controlled, Open-label~The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions in the acute phase of stroke.~The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied."||||
33927888|NCT03191812|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34006930|NCT05511649|||COHORT||RETROSPECTIVE|||||||
34006931|NCT05407818|NA|SINGLE_GROUP||OTHER||NONE||||||
34006932|NCT02430207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006933|NCT05607433|RANDOMIZED|PARALLEL||OTHER||SINGLE|only participants will be masked|Randomized comparative study|t|f|f|f
34006934|NCT05141630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006935|NCT04333381|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Quasi-experimental design study, pre-post intervention type||||
34006936|NCT06125756|NA|SEQUENTIAL||TREATMENT||NONE||Low dose group will be administrated with 2.5×10\^12 vg/kg; Middle dose group will be administrated with 5.0×10\^12 vg/kg; High dose group will be administrated with 1.0×10\^13 vg/kg.||||
34006937|NCT00320853|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34006938|NCT02510950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092170|NCT05592197|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092171|NCT00954083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34092172|NCT02008370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092173|NCT01281072|NA|SINGLE_GROUP||||||||||
34092174|NCT00743093|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34092175|NCT00001270||||TREATMENT||||||||
34092176|NCT01967953|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092177|NCT04406831|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34092178|NCT05249751|||CASE_ONLY||PROSPECTIVE|||||||
33702357|NCT04861909|||OTHER||CROSS_SECTIONAL|||||||
33702358|NCT03840928|||COHORT||PROSPECTIVE|||||||
33702359|NCT03441269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702360|NCT02513342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702361|NCT05933148|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-blind sham-controlled randomized trial||||
33702362|NCT05285072|||COHORT||PROSPECTIVE|||||||
33702363|NCT02339285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702364|NCT00985478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702365|NCT05664607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33702366|NCT02016001|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33702367|NCT00066729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006939|NCT05487755|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* This is a randomized, controlled, prospective study.~* Ninety diabetic nephropathy patients at stage 3(micro-albuminuria) will be divided into three groups as follow -Group 1: (n=30) control group will receive traditional therapy blood glucose lowering agent +RAAS blockade ACEI or ARBs for six months.~  * Group 2 :( n=30) will receive traditional therapy +tadalafil PO 20 mg every other day for six months.~Group 3 :( n=30) will receive traditional therapy+ pentoxifylline PO 400 mg twice daily for six months."||||
33702368|NCT06040840|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
34006940|NCT04080596||SEQUENTIAL||TREATMENT||NONE||||||
33702369|NCT03128827|NA|SINGLE_GROUP||OTHER||NONE||||||
33702370|NCT04335032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702371|NCT03663946|||COHORT||PROSPECTIVE|||||||
33702372|NCT05449119|||COHORT||PROSPECTIVE|||||||
33702373|NCT01069016|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33702374|NCT03722069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33702375|NCT00137631|RANDOMIZED|PARALLEL||||NONE||||||
33788409|NCT06629896|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Due to the nature of the intervention, it is not possible to blind the study arm to patients or investigators. However, pathologic tumor size will be assessed blinded by local pathologists, while radiologic tumor size, which initially cannot be assessed blinded, will be examined independently by outside radiologists according to the procedure described in Pattacini et al. 2022 \[Pattacini P, Nitrosi A, Giorgi Rossi P, Duffy SW, Iotti V, Ginocchi V, Ravaioli S, Vacondio R, Mancuso P, Ragazzi M, Campari C; RETomo Working Group. A Randomized Trial Comparing Breast Cancer Incidence and Interval Cancers after Tomosynthesis Plus Mammography versus Mammography Alone. Radiology. 2022 May;303(2):256-266\]. This approach ensures an unbiased assessment of tumor size.|The study focus on the ability to early detect breast cancer. The study will compare efficacy in reducing the incidence of BC in women who tested negative in the first screening and cumulative recall rates over 2 screening rounds. All women will be followed up for 2.5 years.|f|f|f|t
33788410|NCT04033237|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788411|NCT03960255|||COHORT||PROSPECTIVE|||||||
33788412|NCT02672813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006941|NCT06495580|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The study will enroll adult (18 y.o. and older) patients undergoing open or endonasal endoscopic surgery for suprasellar tumors including meningiomas, craniopharyngiomas and pituitary adenomas||||
33702376|NCT04716465|||COHORT||PROSPECTIVE|||||||
33702377|NCT04204343|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||RANDOMISED DOUBLE BLINDED INTERVENTIONAL|t|f|t|t
34092179|NCT00209820|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34092180|NCT02883556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702378|NCT01739309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702379|NCT00342940|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33702380|NCT05772429|||COHORT||PROSPECTIVE|||||||
33702381|NCT02223312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702382|NCT03413345|||CASE_CONTROL||PROSPECTIVE|||||||
33702383|NCT03921073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006942|NCT06300827|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research data/output measurements are made by a research assistant not involved in the research.|"Experimental Group: Structured digital-based training will be implemented. Control Group: The nursing student will be expected to continue their daily life.~Nursing students who meet the inclusion criteria will be randomly assigned to the experimental group by a statistician."|f|f|f|t
34006943|NCT02320162|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33702384|NCT00354887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702385|NCT01722123|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34006944|NCT04296955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Block randomization|"Interventional study model: Parallel assignment. 2- arm un-blinded RCT design. The arms are:~1. The intervention: 4 individual patient counseling sessions using adapted motivational interviewing techniques in addition to usual care.~2. Usual care: patients undergo standard patient education program for renal transplant recipients at OUS."||||
34006945|NCT01662362|NA|SINGLE_GROUP||||NONE||||||
33702386|NCT02718560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702387|NCT01788228|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702388|NCT05656508|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"The volunteers will be divided into 2 arms:~Group 1 will receive a vaccination schedule of 2 doses of 25 µg of antigen Group 2 will receive a vaccination schedule of 2 doses of 50 µg of antigen"||||
33702389|NCT03398044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking was provided by a nurse not participating upon the research.|The study subjects were randomised into two arms, one group with active treatment using dexamethasone, and the other arm of subjects receiving placebo.|t|f|t|f
33702390|NCT05115669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702391|NCT06203093|||OTHER||PROSPECTIVE|||||||
33702392|NCT03643107|NA|SINGLE_GROUP||TREATMENT||NONE||"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."||||
33702393|NCT02923596|||COHORT||RETROSPECTIVE|||||||
33702394|NCT02460445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702395|NCT01595607|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33702396|NCT04925661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The positive drug is Masking and the placebo-controlled is open.||t|t|t|t
33702397|NCT01349088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702398|NCT00180622|||OTHER||PROSPECTIVE|||||||
33702399|NCT01387620|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33702400|NCT05456165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702401|NCT04610970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702402|NCT05464810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathologists are blinded to each other's data and data from earlier analyses of samples.||f|f|f|t
33702403|NCT05533177|||OTHER||RETROSPECTIVE|||||||
33702404|NCT02564796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702405|NCT00310167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702406|NCT03344237|||OTHER||RETROSPECTIVE|||||||
33702407|NCT05212922|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignmen||||
33702408|NCT05594056|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A transorbital ultrasound to measure the optic nerve sheet will be performed in patients with severe preeclampsia and then compared with normal controls.||||
33702409|NCT03969732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702410|NCT02328300|||COHORT||PROSPECTIVE|||||||
33702411|NCT01805440|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33702412|NCT06556498|RANDOMIZED|PARALLEL||TREATMENT||NONE|Compared progrip mesh with proflor mesh|we use progrip mesh and proflor mesh in different arms of patients||||
33788413|NCT02971306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788414|NCT03095209|||CASE_CONTROL||PROSPECTIVE|||||||
34006946|NCT03332251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092181|NCT04854746|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34092182|NCT03117127|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34092183|NCT05693220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33702413|NCT01418287|||COHORT||PROSPECTIVE|||||||
33702414|NCT05343442|NA|SINGLE_GROUP||TREATMENT||NONE||Observational study||||
33788415|NCT01901770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788416|NCT02841891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788417|NCT05779514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702415|NCT03477136|||COHORT||PROSPECTIVE|||||||
33702416|NCT05364190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702417|NCT00199875|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients were enrolled sequentially in cohorts of 3 to 6 patients to receive escalating doses of study treatment until determination of the MTD.||||
33702418|NCT06467968|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702419|NCT06038214|||CASE_CONTROL||PROSPECTIVE|||||||
33702420|NCT01435603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33702421|NCT02270008|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702422|NCT00939640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702423|NCT03414320|NA|SINGLE_GROUP||OTHER||NONE||proof-of-concept, open label, single arm||||
33702424|NCT00963222|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33702425|NCT05702918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be divided into two groups. Group A will follow resistance training protocol and receive ESWT. Group B will follow resistance training only.||||
33702426|NCT05852184|||COHORT||PROSPECTIVE|||||||
33702427|NCT02846831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702428|NCT04710173|||COHORT||PROSPECTIVE|||||||
33702429|NCT01812031|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33702430|NCT01913678|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33702431|NCT05577780|||COHORT||RETROSPECTIVE|||||||
33702432|NCT01788488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702433|NCT06189014|||CASE_ONLY||OTHER|||||||
33702434|NCT06097169|||CASE_CONTROL||PROSPECTIVE|||||||
33702435|NCT05578170|||COHORT||PROSPECTIVE|||||||
33702436|NCT00446056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33702437|NCT00693849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702438|NCT01554683|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33702439|NCT00231842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702440|NCT02095223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702441|NCT04016064|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The present study was designed as a controlled clinical study with a randomized design. The study protocol was approved by the local ethical committee of Clinical Studies of Ondokuz Mayis University. The study population consisted of 37 participants (19 women, age 23.10±2.78, 18 men age 21.11±2.63).|t|f|f|f
33702442|NCT01049100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702443|NCT04295772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702444|NCT04335097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Sensor monitoring can not be masked since it is the prerequisite for the measures.|Two groups, control and intervention.||||
33702445|NCT04487106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702446|NCT04051281|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33702447|NCT01907581|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702448|NCT01217983|||CASE_ONLY||PROSPECTIVE|||||||
34092184|NCT00754923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092185|NCT03942588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Exercise Intervention group and Usual Activity Control group||||
33702449|NCT01754870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702450|NCT03904173|||COHORT||PROSPECTIVE|||||||
34092186|NCT00048659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33702451|NCT02837289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092187|NCT04661631|||OTHER||PROSPECTIVE|||||||
33702452|NCT02191137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702453|NCT06181578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study employs a single-blind design, where the research staff is aware of the patient's group assignment, but the patients themselves are unaware of their group allocation. This approach is implemented to minimize potential subjective bias. The research staff will make efforts to maintain blinding during interactions with the patients to ensure objectivity in data collection and outcome assessment.||t|f|f|f
33702454|NCT01869439|NA|SINGLE_GROUP||OTHER||NONE||||||
33720403|NCT04342039|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Visually indistinguishable placebo and budesonide nasal sprays will be coded by research staff not connected to the study and pre-packaged for participants. All assays will be performed by personnel who do not know the exposure conditions of individual samples.|"Participants will visit our lab for 2 trial cycles (each cycle involves one arm):~1) Budesonide, and 2) placebo. Within each cycle, there are periods with and without pollution exposure, so there is a secondary comparison of pre- versus post-pollution exposure."|t|f|t|t
33720404|NCT01124136|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Heart failure treatment standard of care (SOC) consists of medication management to support heart and manage symptoms. In this study, patients will receive the neurostimulator + SOC or SOC only.|t|f|t|f
33788418|NCT04241653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788419|NCT01304394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788420|NCT02396992|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33927889|NCT03511300|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will not be told which group they are assigned to.|The study is a single-blind randomized controlled trial. It employs a mixed design, with a between-subjects (instruction type: goal-setting or standard instructions) and a within subjects (pre- and post-instruction manipulation) variable. Seventy-two stroke patients will undergo baseline cognitive testing to assess their verbal ability, learning, memory, attention, visuospatial ability, and exective functioning, with standardized instructions. After completing baseline testing and ratings of apathy (AES), depression (CES-D), anxiety, motivation, and fatigue, participants (N = 72) will either be assigned to the standardized instruction condition (n = 30) or the goal-setting instruction condition (n = 30).|t|f|f|f
33927890|NCT04514588|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34092188|NCT01044199|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720405|NCT01844089|||||PROSPECTIVE|||||||
33720406|NCT06466291|||CASE_ONLY||OTHER|||||||
33720407|NCT05547074|||CASE_ONLY||RETROSPECTIVE|||||||
33788421|NCT06389318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both participant and the care-provider in this trial were blinded.|Group A (40 patients): Children received oral placebo syrup, Group B (40 patients): Children received oral chloral hydrate (Chloral Hydrate mixture)|t|t|f|f
33788422|NCT05688280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open-label study with 3 Cohorts~* Cohort 1: 18 patients with Stage 3 or Stage 4 Colorectal Cancer (CRC)~* Cohort 2: 17 patients with Stage 3 or Stage 4 Non-Small Cell Lung Cancer (NSCLC)~* Cohort 3: 3 patients with Stage 3 or Stage 4 Soft Tissue Sarcoma (STS)~There will be 3 study periods: a Pretreatment Period, a Treatment Period, and a Follow-up Period."||||
33788423|NCT02540135|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33788424|NCT01025206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927891|NCT00430391|RANDOMIZED|PARALLEL||||NONE||||||
33927892|NCT05660889|||CASE_CONTROL||PROSPECTIVE|||||||
33927893|NCT02252757|||COHORT||PROSPECTIVE|||||||
33927894|NCT04783714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Treatment arm and Placebo arm|t|t|t|t
33927895|NCT02033850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33927896|NCT02936336|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33927897|NCT00822562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927898|NCT01153672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092189|NCT00034385||||TREATMENT||||||||
34092190|NCT00084253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092191|NCT01620346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092192|NCT00610519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092193|NCT04581746|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34092194|NCT03517215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092195|NCT02080078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092196|NCT03232944|||COHORT||PROSPECTIVE|||||||
34092197|NCT06321848|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34092198|NCT05031130|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34092199|NCT05870436|||OTHER||OTHER|||||||
34092200|NCT00357162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092201|NCT02690376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092202|NCT02467244|||COHORT||PROSPECTIVE|||||||
34092203|NCT04640402|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34092204|NCT03624036|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34006947|NCT04761471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will be not informed which stimulation they receive active or placebo/sham. They will be debriefed at the end of the experiment.|"The same participants receive placebo/sham stimulation and active stimulation on different sessions separated with 1 week or within the same session.~The sequence of sham/placebo and active stimulation will be randomized."||||
34006948|NCT05368558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092205|NCT01492036|||COHORT||PROSPECTIVE|||||||
34092206|NCT05057520|||OTHER||PROSPECTIVE|||||||
34092207|NCT00001903||||TREATMENT||||||||
34092208|NCT00073931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092209|NCT04925934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, parallel-arm study|t|f|t|f
34092210|NCT02331407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092211|NCT04924790|||COHORT||PROSPECTIVE|||||||
34006949|NCT02343965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720408|NCT02068586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006950|NCT06184594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34006951|NCT04228965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720409|NCT06024057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720410|NCT04140864|||CASE_ONLY||CROSS_SECTIONAL|||||||
33720411|NCT01685996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720412|NCT02069743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720413|NCT05581758|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33720414|NCT03078647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720415|NCT05667038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a 12-week, a single center, double-blind, placebo-controlled, randomized, trial, 90 overweight or first-class obese subjects will be divided equally into two groups, a probiotics group, and a placebo group.|t|f|t|f
33720416|NCT02970409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720417|NCT04915833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"A non-blinded, non-randomized prospective diagnostic trial.~Two interventions:~* Standard colonoscopy: 1 expert~* AI-assisted colonoscopy: another expert"||||
33788425|NCT05356403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Difelikefalin and placebo will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance. Difelikefalin tablets will be provided at doses of 1 mg.|Randomized, double-blind, placebo controlled study|t|f|t|f
33788426|NCT01521585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34006952|NCT01011335|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006953|NCT00650273|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34006954|NCT04522999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006955|NCT00245817|RANDOMIZED|PARALLEL||||NONE||||||
34006956|NCT05743634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Placebo and active controlled|t|t|t|t
34006957|NCT05567887|NA|SEQUENTIAL||TREATMENT||NONE||||||
34006958|NCT05118360|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Randomized in 2:1 ratio to receive either oral ASC41 2 mg or oral matching placebo. Randomized in 2:1 ratio to receive either oral ASC41 4 mg or oral matching placebo.|t|t|t|t
34006959|NCT05598034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single-blind||t|f|f|f
34006960|NCT00791986|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34006961|NCT05945810|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Eligible subjects screened will be randomly assigned to sequence A and sequence B in a 1:1 ratio. In cycle 1, subjects in sequence A receive a 50-mg single dose of TLL-018 extended-release tablet on day 1, and once daily for 5 consecutive days from day 3 onwards. After a 3-day washout period, subjects enter the cycle 2 at day 11 when they receive a 20-mg single dose of TLL-018 immediate-release tablet on the morning and another dose 12 hours later at night. From day 13 onward, they continue to receive 20 mg TLL-018 immediate-release tablets twice daily for 5 consecutive days. The subjects will be hospitalized for observation for 3 days after the end of medication.~Subjects randomly assigned to sequence B received 20 mg of TLL-018 immediate-release tablets in cycle 1 and 50 mg extended-release tablet in cycle 2. The medication pattern was consistent with that of the subjects in sequence A. All the subjects took medicine after meal."||||
34006962|NCT03111576|||CASE_CONTROL||PROSPECTIVE|||||||
34006963|NCT03838341|||COHORT||PROSPECTIVE|||||||
34006964|NCT05575726|||COHORT||PROSPECTIVE|||||||
34006965|NCT02369549|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006966|NCT02807441|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006967|NCT04022031|||COHORT||PROSPECTIVE|||||||
34006968|NCT02208752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34006969|NCT03124134|RANDOMIZED|CROSSOVER||PREVENTION||NONE||4-way crossover with the option for 2 more crossover arms after interim analysis||||
34006970|NCT05721651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006971|NCT04239495|||COHORT||CROSS_SECTIONAL|||||||
34006972|NCT05860387|||COHORT||PROSPECTIVE|||||||
34006973|NCT02251977|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34006974|NCT06613269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006975|NCT06346106|||FAMILY_BASED||RETROSPECTIVE|||||||
34006976|NCT00248937|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34006977|NCT02423317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34006978|NCT01636817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34006979|NCT05780450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006980|NCT04629274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34006981|NCT01305876|NA|SINGLE_GROUP||TREATMENT||||||||
34006982|NCT03490409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34006983|NCT06331117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34006984|NCT02985398|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34006985|NCT02238132|||COHORT||PROSPECTIVE|||||||
34006986|NCT00735930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34006987|NCT04407832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092212|NCT00102635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092213|NCT04999397|||COHORT||RETROSPECTIVE|||||||
34006988|NCT02095886|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34006989|NCT04285827|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34006990|NCT05405049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006991|NCT06343363|||COHORT||PROSPECTIVE|||||||
34006992|NCT04476186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34006993|NCT06337513|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinding of the the health care professionals and patients is not possible in the rehabilitation intervention. The person analysing the data will be blinded to the group allocation.|In the rehabilitation feasibility study: pre-post design. In the rehabilitation RCT, participants are allocated to either the intervention or control group with standard care.|f|f|f|t
34006994|NCT06532409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34006995|NCT00898768|NA|SINGLE_GROUP||SCREENING||NONE||||||
34006996|NCT04322357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006997|NCT05787067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34006998|NCT01069224|||COHORT||PROSPECTIVE|||||||
34006999|NCT04382430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Study Group for this study will include 1 US experienced Electrophysiology (EP) attending, 4 US inexperienced EP attendings, and 1 US inexperienced EP fellow performing US cardiac device implantation (CDI). Each provider will perform 5 conventional CDI, 2 assisted US CDI to learn the procedure (except for experienced US attending), and 10 solo US CDI for a total of 17 procedures per provider (15 for experienced US attending). 100 patients will be needed for this study. This study will take approximately 16 weeks to complete.||||
34007000|NCT00170144|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007001|NCT06289829|NA|SEQUENTIAL||OTHER||NONE||||||
34007002|NCT03003364|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34007003|NCT06185972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007004|NCT06468540|||CASE_ONLY||RETROSPECTIVE|||||||
34007005|NCT00703976|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007006|NCT06616896|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34007007|NCT05792319|||CASE_CONTROL||PROSPECTIVE|||||||
34007008|NCT05206799|||COHORT||PROSPECTIVE|||||||
34007009|NCT04346940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007010|NCT06261619|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The care provider will not know the recorded lung function recordings.|Study Design: A superiority trial; a single two-group cross over randomized trial.|t|f|f|f
34007011|NCT03738787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007012|NCT03397953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007013|NCT04093154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective, parallel trial design|t|f|f|f
34007014|NCT04380727|||CASE_CONTROL||PROSPECTIVE|||||||
34007015|NCT05922488|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|all involved neonates will be randomized to DCC or UCM according to the randomization table and double-blinded method.|all involved neonates will be randomized to DCC or UCM according to the randomization table and double-blinded method.||||
34007016|NCT01321697|||CASE_ONLY||PROSPECTIVE|||||||
34007017|NCT01083238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34007018|NCT02003781|||COHORT||PROSPECTIVE|||||||
34007019|NCT01314768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34025187|NCT06233331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study utilizes a dose escalation phase across a total of 3 dose escalation levels using a standard 3+3 design. Initial three study participants will be enrolled in Dose Level 1 for 4 weeks. If there are no dose-limiting toxicities (DLTs) then 3 new study participants will proceed to Dose level 2. If these 3 study participants do not demonstrate any DLTs then the last 3 study participants will proceed to Dose level 3 for 4 weeks.||||
34025188|NCT05253963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025189|NCT01878461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025190|NCT05855122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025191|NCT05134337|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34092214|NCT05419440|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective randomized controlled clinical trial included all patients who developed the manifestations of appendicular abscess and referred to the Zagazig University Hospital Emergency Department between January 2020 and February 2022. The study was prospectively approved by Zagazig University Faculty of Medicine Institutional Review Board (Approval Number: 55342/24.1.2020), The sample size was 172 patients divided into two equal group group (1) laparoscopic group involved 86 patients \& group (2) interventional radiology group involved 86 patients.||||
34092215|NCT01537796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092216|NCT02582632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092217|NCT04038125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092218|NCT05913947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702455|NCT05166564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Sealed opaque envelopes have been prepared by a member of the research team (independent of data collection). Envelops numbered with study IDs will conceal the allocated group assignment from the research team involved in screening and recruitment. Participants will be allocated a study ID number at baseline once written consent to participate has been provided. After completion of baseline measurements, a researcher (independent of outcome measurements) will open the sealed envelope corresponding to the participant's study ID to reveal the allocated group and arrange intervention delivery if required.|This study is a single blind parallel randomised controlled trial design, recruiting n=105 eligible participants and randomising into one of three groups with n=35 participants assigned into each group. Group 1: a Protein enriched Mediterranean diet (PROMED) Intervention; Group 2: a Protein enriched Mediterranean diet and exercise (PROMED-EX) intervention; and Group 3: the control group. The active intervention arms will last for three months with an additional three months of follow-up. Data will be collected from participants at study baseline, 3months and 6 months. The study statistician - independent of study recruitment, intervention delivery and data collection - has generated the randomisation scheme using a computer generated random number sequence (Release 14 StataCorp LP, College Station) assigning participant ID numbers to either the PROMED, the PROMED-EX or the control group using block randomisation in blocks of 6.|f|f|f|t
33702456|NCT01870284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702457|NCT02120378|||COHORT||PROSPECTIVE|||||||
33702458|NCT04910945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702459|NCT06030050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702460|NCT04224038|||COHORT||PROSPECTIVE|||||||
33702461|NCT01999153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702462|NCT04131725|||CASE_ONLY||PROSPECTIVE|||||||
33702463|NCT06558045|RANDOMIZED|CROSSOVER||OTHER||NONE||This was a bioequivalence study||||
33702464|NCT03134404|||COHORT||PROSPECTIVE|||||||
33702465|NCT00531934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702466|NCT04137029|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are two groups: the first group is smokers, the second group is non - smokers. The participants of both groups will receive metacholine on the first visit, formoterol 12 micrograms on the second visit, then tiotropium bromide 18 mkg on the third visit.||||
33702467|NCT00942448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702468|NCT00508755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702469|NCT02343237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702470|NCT03602430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33702471|NCT00134030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702472|NCT01795196|||CASE_ONLY||PROSPECTIVE|||||||
33702473|NCT01504620|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025192|NCT04518293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||International, multicenter, randomized, double-blind, active-controlled, parallel group.|t|t|t|t
34025193|NCT03878667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34025194|NCT00499421|||CASE_ONLY||PROSPECTIVE|||||||
34025195|NCT03749083|||COHORT||PROSPECTIVE|||||||
34025196|NCT00741286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702474|NCT04930991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702475|NCT00586625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702476|NCT04652440|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluate the safety and tolerability of radiofrequency ablation combined with PD-1 monoclonal antibody in the treatment of patients with hepatocellular carcinoma.||||
34025197|NCT05521659|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34092219|NCT04144764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092220|NCT06142552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702477|NCT00252746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025198|NCT04285164|||OTHER||OTHER|||||||
33702478|NCT03570944|||COHORT||PROSPECTIVE|||||||
33702479|NCT04784039|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702480|NCT05642767|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702481|NCT06442332|||CASE_CONTROL||RETROSPECTIVE|||||||
34025199|NCT06381713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092221|NCT00959452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092222|NCT03974906|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients were assigned to one of the two groups (control group and GDT group) using a computer-generated randomization scheme.Allocation concealment was obtained using number labeled opaque envelopes that were opened just before the surgery. Data were collected by persons unaware of treatment allocation.||t|t|f|t
34092223|NCT02233088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702482|NCT01803061|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025200|NCT00660400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025201|NCT02612259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025202|NCT05499949|||COHORT||PROSPECTIVE|||||||
34025203|NCT05432063|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34025204|NCT00306930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702483|NCT02297984|||CASE_ONLY||PROSPECTIVE|||||||
33702484|NCT00183989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702485|NCT03191422|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome Assessor's for 2 of the outcome measures were blinded to the order of the pre and post assessment videos for rating, as well as being unfamiliar with the intervention protocol.|Single-Case experimental design One repetition||||
33702486|NCT01195246|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33702487|NCT04382391|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Controlled||||
33702488|NCT04211181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702489|NCT06483178|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single centred, parallel group, randomised controlled trial||||
33702490|NCT03918161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients will realize Magnetic Resonance Elastography exam||||
33702491|NCT01237743|||CASE_ONLY||PROSPECTIVE|||||||
33702492|NCT01315665|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702493|NCT02454725|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702494|NCT00875264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702495|NCT01868464|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702496|NCT02077283|||COHORT||PROSPECTIVE|||||||
33702497|NCT03835871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double -blind, double-dummy||t|t|t|t
33927899|NCT02783209|NA|SINGLE_GROUP||OTHER||NONE||||||
34092224|NCT05252975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092225|NCT02941497|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34092226|NCT03108001|||COHORT||PROSPECTIVE|||||||
34092227|NCT00799669|||CASE_CONTROL||PROSPECTIVE|||||||
33702498|NCT03308786|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092228|NCT05396391|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34092229|NCT05011435|||COHORT||PROSPECTIVE|||||||
34092230|NCT02749890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092231|NCT01102283|||COHORT||PROSPECTIVE|||||||
34092232|NCT04027309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092233|NCT00002940||||TREATMENT||||||||
33702499|NCT02479607|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33702500|NCT02401022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702501|NCT06556628|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702502|NCT00938236|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702503|NCT06558448|||COHORT||PROSPECTIVE|||||||
33702504|NCT03172169|||COHORT||PROSPECTIVE|||||||
33702505|NCT00794703|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702506|NCT04076878|NA|SINGLE_GROUP||TREATMENT||NONE||"Mechanism substudy: explorative single group design with three different stimulation paradigms provided to all participants by double blinded randomisation.~Clinical substudy: explorative single group design."||||
33702507|NCT03925311|||OTHER||PROSPECTIVE|||||||
33702508|NCT00956969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702509|NCT01000402|NA|SINGLE_GROUP||||NONE||||||
33702510|NCT02957929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33702511|NCT00911547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702512|NCT01786655|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33702513|NCT02659293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702514|NCT04622306|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33702515|NCT01869517|RANDOMIZED|PARALLEL||TREATMENT||||||||
33927900|NCT03309904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Statistician performing outcome analyses are blinded to group belonging|Parallell group cluster-randomized trial|f|f|f|t
33927901|NCT02622438|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33927902|NCT03363165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927903|NCT06109077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinding||t|f|f|f
33927904|NCT01313078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927905|NCT05236660|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927906|NCT04865445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927907|NCT03375723|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, controlled, intervention study. Evaluation of the addition of information and breathing technique for patients with respiratory associated chest pain in acute pulmonary embolism compared to standard care||||
33927908|NCT01175590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33927909|NCT02076334|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33927910|NCT05765552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702516|NCT00978978|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
33702517|NCT03846804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702518|NCT02152800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702519|NCT01599195|||CASE_ONLY||PROSPECTIVE|||||||
33927911|NCT00001669||||TREATMENT||||||||
33927912|NCT01181440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33927913|NCT00519883|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927914|NCT00612339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092234|NCT02667834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092235|NCT00731003|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34092236|NCT02148627|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34092237|NCT01718496|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34092238|NCT00554697|||COHORT||PROSPECTIVE|||||||
34092239|NCT01746875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092240|NCT01848808|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34092241|NCT05688657|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All participants received Lens A and then Lens B in fixed-sequence order.|t|f|f|f
34092242|NCT01989273|||COHORT||PROSPECTIVE|||||||
34092243|NCT02013362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092244|NCT00634556|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
34092245|NCT03918200|||CASE_CONTROL||PROSPECTIVE|||||||
34092246|NCT00152022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092247|NCT06118320|||COHORT||PROSPECTIVE|||||||
34092248|NCT00303797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092249|NCT05331898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33702520|NCT05686031|||OTHER||CROSS_SECTIONAL|||||||
33702521|NCT06199778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a prospective multicenter randomized controlled study, including severe Traumatic Brain Injury patients with tracheostomy transferred to the department of rehabilitation medicine in 3 hospitals from intensive care unit in China between June 2022 and June 2023. Patients enrolled were firstly numbered and then randomly divided into the observation group and the control group. In addition to routine treatments, Intermittent Oro-esophageal Tube Feeding or Nasogastric tube feeding, as nutrition support, was given to patients based on their group. The study lasted 4 weeks for each patient.|f|f|t|t
33702522|NCT03610282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33702523|NCT05170464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702524|NCT03488732|||COHORT||PROSPECTIVE|||||||
33702525|NCT02014571|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33702526|NCT06440902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702527|NCT00285233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702528|NCT02033187|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33702529|NCT02440971|||COHORT||PROSPECTIVE|||||||
33720418|NCT01411709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720419|NCT04250571|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720420|NCT03487861|||COHORT||PROSPECTIVE|||||||
33720421|NCT03761381|||CASE_CONTROL||PROSPECTIVE|||||||
33788427|NCT02242162|||CASE_CONTROL||PROSPECTIVE|||||||
33788428|NCT01358916|RANDOMIZED|PARALLEL||||NONE||||||
33788429|NCT06473519|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open-label|||||
33788430|NCT03645174|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Manikin model Intubators are residents of Anesthesiology||||
34025205|NCT00046241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025206|NCT02101307|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34025207|NCT05866185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025208|NCT02346591|RANDOMIZED|PARALLEL||||NONE||||||
34025209|NCT01282008|||CASE_ONLY||CROSS_SECTIONAL|||||||
34025210|NCT00261092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092250|NCT04611412|||COHORT||RETROSPECTIVE|||||||
34092251|NCT03291691|||COHORT||PROSPECTIVE|||||||
34092252|NCT03583346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788431|NCT01051583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788432|NCT01649635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788433|NCT05304013|||COHORT||PROSPECTIVE|||||||
33788434|NCT00005113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788435|NCT04444180|||COHORT||PROSPECTIVE|||||||
33927915|NCT01349296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927916|NCT04841252|||CASE_ONLY||CROSS_SECTIONAL|||||||
33927917|NCT00005808|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927918|NCT01148355|||||PROSPECTIVE|||||||
33927919|NCT00773851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927920|NCT02443805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927921|NCT02324738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927922|NCT00273299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927923|NCT05628402|||COHORT||PROSPECTIVE|||||||
33927924|NCT00688545|||COHORT||PROSPECTIVE|||||||
33927925|NCT00570362|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33927926|NCT03402282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927927|NCT03496441|||CASE_CONTROL||PROSPECTIVE|||||||
33927928|NCT01600794|||CASE_ONLY||PROSPECTIVE|||||||
33927929|NCT02657434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927930|NCT04213118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927931|NCT00546507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927932|NCT03753724|||OTHER||PROSPECTIVE|||||||
33927933|NCT03938610|||COHORT||PROSPECTIVE|||||||
33927934|NCT01999712|||CASE_ONLY||PROSPECTIVE|||||||
33927935|NCT05400538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927936|NCT01937013|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34092253|NCT04181645|NA|SINGLE_GROUP||TREATMENT||NONE|An open label study|Patients will be assigned to accept the combination treatment of SHR-120 with Paclitaxel-albumin and gemcitabine after meeting the inclusion criteria.||||
34092254|NCT05392660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Allocation of the women to study or control group was carried out through a person not involved in the study nurses in charge during the shift. This allocation was concealed from person allocating a woman into the trial (nurses)||f|t|f|f
34092255|NCT01810952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092256|NCT05378152|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34092257|NCT00850642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092258|NCT03941821|||COHORT||PROSPECTIVE|||||||
34092259|NCT04991805|||COHORT||RETROSPECTIVE|||||||
34092260|NCT00257530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092261|NCT02904343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092262|NCT05502887|||COHORT||PROSPECTIVE|||||||
34092263|NCT05690243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor and fidelity monitor will be blinded to treatment group.|two-arm, single-blind, pilot randomized controlled trial with 1:1 randomization. Wait List Control.|f|f|f|t
34092264|NCT05594199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092265|NCT03626675|NA|SINGLE_GROUP||OTHER||NONE||||||
34092266|NCT01405911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092267|NCT03274297|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34092268|NCT00016172||||TREATMENT||||||||
34092269|NCT04505917|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized controlled trial|double blind randomized controlled trial|t|t|t|t
34092270|NCT04926233|||COHORT||RETROSPECTIVE|||||||
34092271|NCT03049566|||OTHER||CROSS_SECTIONAL|||||||
34092272|NCT00740740|||CASE_CONTROL||PROSPECTIVE|||||||
34007020|NCT04105114|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, research staff, or participants during the Treatment Phase. The following study procedures will be in place to ensure double-blind administration of study treatments. Access to the randomization code will be strictly controlled.~* Packaging and labeling of test and control treatments will be identical to maintain the blind.~* The study blind will be broken on completion of the clinical study and after the study database has been locked.~BuSpar (buspirone) and matching placebo tablets (2x/day) will be obtained and dispensed by the investigational pharmacy.~Study drug and placebo will be labeled with the required FDA warning statement, the protocol number, a treatment number, the name of the sponsors, and directions for patient use and storage."|This is a double blinded crossover study with three experimental groups. Each group will receive a combination of activity based neuromodulation interventions while receiving oral Buspirone or placebo. The crossover between drug or placebo administration will occur at the study phase midpoint.|t|f|t|t
34007021|NCT02965664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092273|NCT05731596|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* This study will be a randomized, controlled, parallel study.~* It will be conducted on 46 patients diagnosed with NASH~* The patients will be randomized into two groups:~  1. Group 1(n=23): patients will receive Rosuvastatin 20mg/day orally~ 2. Group 2(n=23): patients will receive Coenzyme Q10 100 mg/day orally"||||
34092274|NCT01388426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702530|NCT05938842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||DBT is a modified version of cognitive-behavioural therapy that places additional emphasis on emotion regulation, distress tolerance, self-acceptance, and validation of experience, and consists in several types of interventions, including the skills training group. One of the module os DBT is Mindfulness, which practice the ability to observe thoughts and feeling as temporary, as opposed to reflections of the reality that are necessarily tru.|t|f|f|f
33702531|NCT01604408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702532|NCT03424408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702533|NCT02420340|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33702534|NCT02407795|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33702535|NCT00305214|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702536|NCT05218135|||OTHER||RETROSPECTIVE|||||||
33702537|NCT02056639|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702538|NCT04877483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702539|NCT02898129|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33702540|NCT04299542|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702541|NCT01848496|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33702542|NCT01201785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720422|NCT03158051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33720423|NCT04600674|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092275|NCT01995201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092276|NCT00592111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092277|NCT04680039|||COHORT||RETROSPECTIVE|||||||
34092278|NCT03763981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092279|NCT01870037|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||sequential, dose escalation|t|f|t|t
34092280|NCT00601627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092281|NCT01767285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092282|NCT02361931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092283|NCT00195793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092284|NCT01015196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092285|NCT02861976|||COHORT||PROSPECTIVE|||||||
34092286|NCT02515253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092287|NCT06178224|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092288|NCT03355924|||COHORT||RETROSPECTIVE|||||||
34092289|NCT01132755|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092290|NCT02752477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092291|NCT02331498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092292|NCT02871362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092293|NCT01449032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092294|NCT05491889|||COHORT||PROSPECTIVE|||||||
34092295|NCT00258661|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34092296|NCT02011334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092297|NCT06010615|||COHORT||RETROSPECTIVE|||||||
34092298|NCT01182961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092299|NCT05855720|||COHORT||PROSPECTIVE|||||||
34092300|NCT05570422|NA|SINGLE_GROUP||PREVENTION||NONE||Phase 1 open label||||
34007022|NCT05344287|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702543|NCT03489148|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Tamarkoz® class instructor was not informed about which of her students from the class was participating in the study.|Participants were recruited from the University of California, Berkeley for an 18-week quasi-experimental study with pretest-posttest and follow-up in three groups. Assessments were conducted with blood pressure, heart rate, the 10-item perceived stress scale, the 38-item dispositional positive emotions scale, and the 16-item daily spiritual experiences scale in a Tamarkoz® group, a wait-list control, and a third group utilizing the campus health center's stress management resources. Blood pressure and heart rate measurements were taken by the researcher using a validated home monitoring device. Additionally, all participants provided 3 diurnal saliva samples to determine changes in salivary immunoglobulin A and salivary cortisol. All data were collection was through non-evasive procedures and were assessed at baseline, end of the school semester (12 weeks) and 18 weeks.|f|t|f|f
33720424|NCT06527131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33720425|NCT04585022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the care provider and patient were blinded until day of surgery. The laboratory analyzing blood metal concentrations were blinded to treatment allocation throughout the study.||t|t|f|t
33720426|NCT01862562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007023|NCT03667859|||COHORT||PROSPECTIVE|||||||
34007024|NCT06557278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007025|NCT00134329|||||PROSPECTIVE|||||||
34007026|NCT06021470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Research Fellow conducting neuropsychological assessments will be blinded to random allocation and will not be involved in delivering the intervention. The neuropsychologist clinician will deliver the intervention and will not be involved in assessment or data analysis. The objective measures of cognition collected during the neuropsychological assessments are less subject to response bias than subjective assessments as patients cannot be blinded to treatment allocation; at post-assessment, patients will be asked not to reveal whether they have received the intervention or not in order to maximise researcher blinding.||f|f|t|t
34007027|NCT05799716|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34007028|NCT02588196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007029|NCT01854255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927937|NCT04572893|NA|SEQUENTIAL||TREATMENT||NONE||||||
33927938|NCT00490867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33927939|NCT05156333|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The randomization (1: 1) will take place in each center, using the same allocation sequence, in blocks of 4, with the indication of the treatment code inserted in a white, closed envelope. The code will correspond to the number written on the packages to be administered and the list of codes containing the definition of the treatments, will be kept in a sealed envelope, by a collaborator of the PI (Head Nurse), and opened upon completion of the study or at the time of need, in case maternal-fetal or neonatal serious adverse event.~No member of the research team knows which treatment the patients receive because both the active and the placebo are packaged identically and are contained in identical white boxes. Only the randomization numbers distinguish them."|Multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group study aimed at underestimating the feasibility and effect of the use of probiotic starting from week 30 on vaginal / rectal colonization of GBS in women at low obstetric risk.|t|t|t|f
33927940|NCT03132441|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm pilot study||||
34007030|NCT05853809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007031|NCT05120687|||COHORT||PROSPECTIVE|||||||
34007032|NCT00386815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702544|NCT04851457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Images from each study site will be uploaded to the central server and all analyses will be performed by a trained physician at the study coordinating center who is unaware of group assignments. Similarly, follow-up assessments at 90 days after stroke will be conducted by a trained accessor in a blinded manner.|A prospective, randomized, controlled, open-Label, assessor-blind, multicenter clinical study|f|f|f|t
33702545|NCT01072383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702546|NCT00886561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702547|NCT05880641|||COHORT||PROSPECTIVE|||||||
33702548|NCT00875992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702549|NCT00983762|||CASE_CONTROL||PROSPECTIVE|||||||
33702550|NCT05932966|||COHORT||RETROSPECTIVE|||||||
33702551|NCT05341687|||COHORT||RETROSPECTIVE|||||||
33788436|NCT01695317|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33788437|NCT05300451|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702552|NCT05274373|||COHORT||PROSPECTIVE|||||||
33702553|NCT06410599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702554|NCT00202683|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33702555|NCT04208997|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients that meet inclusion criteria and agree to participate will be randomized and allocated to continue class III AADs or discontinuation using block randomization, stratified by type of AADs and type of cardiomyopathy (ischemic vs nonischemic) used until goal enrollment is achieved. The randomization sequence was created using STATA 14.2 (StataCorp, College Station, TX, USA) statistical software.||||
33702556|NCT03137420|||COHORT||PROSPECTIVE|||||||
33702557|NCT02326051|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33702558|NCT06558461|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled open-label parallel-arm clinical trial, with allocation 1:1, was conducted to investigate whether nebulizing 3% hypertonic saline will improve clinical symptoms and reduce the length of hospital stay in bronchiolitis compared with the control group.||||
33702559|NCT01058655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788438|NCT02856711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33788439|NCT04074551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788440|NCT00677248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788441|NCT02780362|RANDOMIZED|CROSSOVER||||NONE||||||
33788442|NCT04666337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization established using the computer-generated closed envelopes method.||t|t|f|t
33788443|NCT05737550|NA|SINGLE_GROUP||OTHER||NONE||The investigation aims to enroll up to 30 SUD subjects. As this is an early feasibility and explorative investigation, the sample size is not derived from a sample size calculation as no hypothesis is pre-defined. It is based on available subjects from the clinic.||||
33788444|NCT00247156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788445|NCT00601029|||COHORT||PROSPECTIVE|||||||
33927941|NCT05103072|||CASE_ONLY||RETROSPECTIVE|||||||
33788446|NCT03737669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788447|NCT04655118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788448|NCT05880316|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33788449|NCT01117441|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33788450|NCT01921140|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788451|NCT03210727|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||a single arm design will be used to pilot test the Ready to CARE program with 20 caregivers (while also measuring outcomes in the 20 patients receiving HSCT)..||||
33927942|NCT03127436|||COHORT||PROSPECTIVE|||||||
33927943|NCT02574481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007033|NCT02111434|NA|SINGLE_GROUP||SCREENING||NONE||||||
34007034|NCT01015924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025211|NCT01354379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788452|NCT05159128|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33788453|NCT01297972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702560|NCT03784703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|prospective, double blind trial|160 patients were randomly assigned to receive either 40 mg per day atorvastatin tablets (ATROVA group, n= 80) or 10 mg per day Rosuvastatin tablets (ROSUVA group, n= 80) as recommended in NCEP ATP III (21). Patients included in the study were maintained on oral hypoglycemic agents (OHA) according to their treatment regimen.|t|f|t|f
33927944|NCT05419947|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects included in this CT will be treated with VI \[Verdye (Diagnostic Green GMBH, Aschheim-Dornach, Germany)\]. Single dose and weight-adjusted dose and different administration intervals will be analyzed. Low-intervention clinical trial.||||
33702561|NCT06503913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702562|NCT02607930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702563|NCT05527197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33702564|NCT06395129|||COHORT||PROSPECTIVE|||||||
33702565|NCT01052571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33702566|NCT01691131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702567|NCT02599896|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702568|NCT01199965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702569|NCT01971840|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33702570|NCT04674644|NA|SINGLE_GROUP||OTHER||NONE|Dental professionals working in public and university hospitals|Dental professionals||||
33702571|NCT04205708|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33702572|NCT03720353|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33702573|NCT01269411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702574|NCT00332280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702575|NCT00400283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702576|NCT01824875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702577|NCT02171065|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33702578|NCT02932202|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to either a medical student assisted program comprising nutritional counselling and web based nutrition tracking methods (i.e., longitudinal nutritional counseling program) or routine follow-up with their primary healthcare specialist (standard of care) using a 1:1 random numbers block allocation||||
33702579|NCT04234022|||COHORT||PROSPECTIVE|||||||
33702580|NCT03500575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Pilot study, single center, randomized controlled trial, single blind, 2 parallel arms|f|f|t|t
33702581|NCT02176343|NA|SINGLE_GROUP||OTHER||NONE||||||
33702582|NCT05615168|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33788454|NCT00413868|NON_RANDOMIZED|PARALLEL||||NONE||||||
33788455|NCT00781690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788456|NCT05046158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Prospective, Multi-Center, Open-Label, Comparison, Human, Interventional||||
33927945|NCT03219801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927946|NCT03942146|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|Care provider will not be informed about the study Participant is not informed about the study until the follow-up questionnaire 2 months after surgery|"When smoking is reported by the participant in the web-based health declaration, she is automatically randomized to one of four alternatives. The allocation ratio of randomization is 1:4 between the 4 arms: Group 1 serves as a control group and receives no specific information about smoking cessation; In Group 2 the patient receives directly the following written recommendation in the web-based health declaration You have increased risks due to smoking. Smoking cessation 6 weeks before surgery and 6 weeks after surgery is recommended; Group 3 The smoking status of the participant is alerted to the surgeon when filling in the preoperative form with the text  the patient smokes, recommend smoking cessation; and Group 4, is a combination of Group 2 and 3, i.e. a written recommendation is included in the web-based health declaration as in group 2 and in addition the surgeon is alerted that the patient is a smoker and instructed to recommend smoking cessation as in group 3."|t|t|f|f
33927947|NCT02320214|NA|SINGLE_GROUP||SCREENING||NONE||||||
33927948|NCT01320969|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33927949|NCT00087048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927950|NCT01952288|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33927951|NCT05243719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927952|NCT02844673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927953|NCT00634465|||CASE_ONLY||PROSPECTIVE|||||||
33927954|NCT02925312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927955|NCT04826120|RANDOMIZED|PARALLEL||TREATMENT||NONE||parturients randomized in 2 groups and receiving 2 different interventions||||
33702583|NCT05541042|||CASE_ONLY||PROSPECTIVE|||||||
33702584|NCT01871142|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33702585|NCT06260215|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33702586|NCT02692222|||||PROSPECTIVE|||||||
33702587|NCT04961307|||COHORT||PROSPECTIVE|||||||
33702588|NCT06161922|||COHORT||PROSPECTIVE|||||||
33702589|NCT02364921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33702590|NCT00632879|||COHORT||PROSPECTIVE|||||||
33788457|NCT05866510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788458|NCT00618319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788459|NCT00390403|NON_RANDOMIZED|||TREATMENT||NONE||||||
33720427|NCT06155942|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720428|NCT00897247|||CASE_CONTROL||PROSPECTIVE|||||||
34092301|NCT02395367|||OTHER||PROSPECTIVE|||||||
34092302|NCT05052008|||COHORT||CROSS_SECTIONAL|||||||
34092303|NCT03530228|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Cohort 1: crossover Cohort 2: parallel Cohort 3: single group||||
34092304|NCT04890990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092305|NCT05205395|||COHORT||RETROSPECTIVE|||||||
34092306|NCT06038552|||COHORT||RETROSPECTIVE|||||||
34092307|NCT01597232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092308|NCT06145074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092309|NCT00675480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092310|NCT01141309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092311|NCT01594541|||||RETROSPECTIVE|||||||
33702591|NCT03153527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blinding of trial participants, treating physicians, study doctors, study nurses, outcome assessors and data analysts will be ensured by using identical-looking placebo, packaged in identical vials as the prednisone verum. Vials will be labeled with Prednisone or Placebo in an identical fashion."|"Standard treatment arm: Prednisone, a synthetic glucocorticoid with intermediate duration of action (biological half-life 18-35 hrs). The detailed characteristics of the compound, marketed under several brand names, can be found at www.swissmedicinfo.ch: Prednison Streuli (Swissmedic registration number: 29349); Prednison Axapharm (Swissmedic registration number: 58761); Prednison Galepharm (Swissmedic registration number: 50821).~Interventional treatment arm: matching placebo."|t|t|t|t
33702592|NCT04882384|NA|SINGLE_GROUP||OTHER||NONE||||||
33702593|NCT05960552|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33702594|NCT03802695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702595|NCT02707107|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34007035|NCT06421142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In the MIBC diagnostic study and neoadjuvant efficacy prediction study, each patient underwent FAPIPET/MRI, FDGPET/MRI and MRI examinations, and were grouped and analyzed according to different examination methods.||||
34007036|NCT02857790|||COHORT||PROSPECTIVE|||||||
34007037|NCT02656264|||CASE_ONLY||PROSPECTIVE|||||||
34007038|NCT00876720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007039|NCT03215459|||COHORT||PROSPECTIVE|||||||
34092312|NCT02751905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092313|NCT01107457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702596|NCT05747287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092314|NCT04678674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092315|NCT04822519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702597|NCT04935463|||COHORT||RETROSPECTIVE|||||||
33702598|NCT03110094|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33702599|NCT03493074|||CASE_ONLY||PROSPECTIVE|||||||
33702600|NCT06021197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702601|NCT03476278|||COHORT||PROSPECTIVE|||||||
33702602|NCT04747080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702603|NCT02964975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702604|NCT03155971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702605|NCT06101511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702606|NCT01168583|||COHORT||PROSPECTIVE|||||||
33702607|NCT02255903|||CASE_CONTROL||PROSPECTIVE|||||||
33702608|NCT00310401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702609|NCT02275858|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33788460|NCT03058783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007040|NCT02070354|||COHORT||PROSPECTIVE|||||||
34007041|NCT04968106|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (1:1) phase II trial. Patients will be randomized between arm A (neodjuvant chemotherapy by doxorubicin + ifosfamide) and arm B (neodjuvant chemotherapy by doxorubicin + ifosfamide and retifanlimab) with one patient randomized in arm A for one patient randomized in arm B||||
34007042|NCT02456987|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007043|NCT06172530|||CASE_ONLY||PROSPECTIVE|||||||
34007044|NCT03346954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007045|NCT06425367|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||cluster cross-over randomized trial|t|f|f|f
34007046|NCT01938352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007047|NCT00754494|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34092316|NCT04292951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient is anesthetized, thus unaware type of treatment. The assessor is blinded of the monitor|Group GDT: fluid and inotropic/vasoactive drugs management guided by FloTrac/EV1000 Group Control: fluid and inotropic/vasoactive drugs management guided by central venous pressure (CVP), blood pressure, heart rate, and clinical signs|t|f|f|t
34092317|NCT05897151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092318|NCT01859741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092319|NCT02741817|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34092320|NCT04187521|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34092321|NCT01257438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092322|NCT00421993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092323|NCT00782093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092324|NCT02612675|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34092325|NCT06444373|||COHORT||RETROSPECTIVE|||||||
34092326|NCT01543841|||COHORT||RETROSPECTIVE|||||||
33927956|NCT02067572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33927957|NCT02690168|||CASE_ONLY||PROSPECTIVE|||||||
33927958|NCT05316818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33927959|NCT04975490|||COHORT||PROSPECTIVE|||||||
33702610|NCT01058187|||COHORT||PROSPECTIVE|||||||
33702611|NCT06476327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702612|NCT01931592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702613|NCT04544423|||CASE_CONTROL||PROSPECTIVE|||||||
33702614|NCT02254941|||COHORT||PROSPECTIVE|||||||
33702615|NCT02585843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33702616|NCT04418674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"0.4ml from one 1 ml ampule of 50mg ketamine will be diluted with 9.6ml NS to make a concentration of 2mg Ketamine in each ml in a 10 ml syringe.~One 2ml ampule of 100mcg Fentanyl will be diluted with 8 ml NS to make a concentration of 10mcg in each ml in a 10ml syringe~Ketamine and Fentanyl will be administered as clear fluid from a 10ml syringe labelled as Study drug, therefore, both the patient and investigator will be blinded."|"Ketamine Group: Ketamine 0.3mg/kg intavenously before changing the position from supine to sitting for subarachnoid block.~Fentanyl group: Fentanyl 1.5mcg/kg intravenously before changing the position from supine to sitting position for subarachnoid block."|t|t|t|t
33702617|NCT03580993|||COHORT||PROSPECTIVE|||||||
33702618|NCT06409715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702619|NCT02368197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702620|NCT03738033|||CASE_CONTROL||PROSPECTIVE|||||||
33788461|NCT03284749|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"After inclusion all patients will be randomised for a wound dressing or maternity pad with (study group) or without copper (control group). The two sets of wound dressings and pads will be marked A or B. Both the clinician and the patient will be blinded to the randomised group. Only the manufacturer will be aware of which group contains copper."|All women are randomised to either the copper or the control group. Randomisation will be done separately for the caesarean section and vaginal delivery group.|t|t|t|t
33788462|NCT00591903|||||PROSPECTIVE|||||||
33788463|NCT02809300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788464|NCT01360190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33788465|NCT04554823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Verificar o efeito de um Programa de exercicios fisicos e de educacao em saude em mulheres com cancer de mama submetidas a quimioterapia sobre a taxa de conclusao da quimioterapia e sobre as toxicidades do tratamento.||||
33788466|NCT04579510|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788467|NCT01672320|||COHORT||PROSPECTIVE|||||||
33788468|NCT06199687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental - Randomised Controlled||||
33788469|NCT04164524|||CASE_CONTROL||PROSPECTIVE|||||||
33788470|NCT06607705|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective, non-randomized, controlled, single country pre-post intervention study.||||
33788471|NCT05317793|||CASE_ONLY||PROSPECTIVE|||||||
33788472|NCT03072355|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33788473|NCT01066741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33788474|NCT02840994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788475|NCT06425237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788476|NCT06259448|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788477|NCT06125678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33927960|NCT06396260|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Longitudinal imaging study. Baseline acquisition of DKI and resting state MEG of ALS and matched healthy controls. Participants with ALS will be monitored for a period of 6 months for symptoms of PBA. If developed, or not developed after 6 months, follow-up DKI and MEG will be acquired.~An additional sub-study will be performed in patients with ALS and newly developed PBA, where resting state MEG will be acquired after at least 7 days of symptomatic treatment independent of the study."||||
33927961|NCT05267418|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The participant was not inform about what kind of oxygen support was provided during exercise||t|f|f|f
33927962|NCT04006704|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33927963|NCT01670682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927964|NCT01107704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927965|NCT00517413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927966|NCT02099760|||CASE_ONLY||CROSS_SECTIONAL|||||||
34007048|NCT01433887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007049|NCT02685696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007050|NCT01644149|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34007051|NCT05276687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007052|NCT05934838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007053|NCT01767727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007054|NCT05872464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007055|NCT01672047|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007056|NCT00996437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007057|NCT02073136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007058|NCT04238637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two randomized Treatment arms||||
34007059|NCT01355302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007060|NCT02280187|||COHORT||RETROSPECTIVE|||||||
34007061|NCT04640779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007062|NCT05838456|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This is a stepped wedge cluster-randomized trial with 4 clusters (4 different hospitals). In a stepped wedge fashion over 3 month intervals, the 4 clusters will initiate use of the software package (Viz.AI). The order of implementation of the Viz.AI software at the four hospitals will be randomly determined.||||
34007063|NCT04826666|||COHORT||RETROSPECTIVE|||||||
34007064|NCT00595335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007065|NCT04231487|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34007066|NCT00851409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007067|NCT04224194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007068|NCT06503354|||COHORT||PROSPECTIVE|||||||
33702621|NCT05190367|||CASE_CONTROL||RETROSPECTIVE|||||||
33702622|NCT05232071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702623|NCT00302185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702624|NCT03738085|||COHORT||RETROSPECTIVE|||||||
33702625|NCT02234388|||COHORT||PROSPECTIVE|||||||
33702626|NCT01003392|||||PROSPECTIVE|||||||
33702627|NCT06161870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702628|NCT05327426|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33702629|NCT02898805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33702630|NCT03525366|||CASE_ONLY||CROSS_SECTIONAL|||||||
33702631|NCT01694264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702632|NCT00319501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702633|NCT06357858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702634|NCT01095926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788478|NCT00982254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788479|NCT03045692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind randomized trial|t|t|f|t
33788480|NCT02823496|NA|SINGLE_GROUP||||NONE||||||
33788481|NCT05657327|||COHORT||RETROSPECTIVE|||||||
33788482|NCT01227642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788483|NCT04213222|||COHORT||PROSPECTIVE|||||||
33788484|NCT01816113|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788485|NCT01343654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788486|NCT03437746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927967|NCT00259350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927968|NCT00469872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927969|NCT01283113|||COHORT||CROSS_SECTIONAL|||||||
33927970|NCT01468701|||COHORT||PROSPECTIVE|||||||
33927971|NCT05872256|NA|SINGLE_GROUP||TREATMENT||NONE|All subjects will receive Duobrii lotion for scalp application to all areas afflicted with scalp psoriasis.|All subjects will receive the currently marketed and FDA approved Duobrii lotion to the scalp for the treatment of scalp psoriasis.||||
33927972|NCT01056419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927973|NCT00342004|||COHORT||PROSPECTIVE|||||||
33927974|NCT06020833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33927975|NCT04371185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702635|NCT05898685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702636|NCT01182142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927976|NCT05027113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be aware of whether they were randomized to the intervention group or the wait-list control group. The intervention is self-guided and automated through the use of a smartphone app. As such, masking is not an issue. The principal investigator will not be involved with randomization. Assessments are self-administered via online questionnaires. As such, masking is not relevant in terms of outcomes assessors.|Individuals who meet eligibility criteria will be randomized to either the intervention group (n = 40) or a wait-list control group (n = 40),|f|t|t|t
33927977|NCT05795868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33927978|NCT01496274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927979|NCT01333098|NA|SINGLE_GROUP||TREATMENT||NONE||In the first week, participants were randomly assigned to mifepristone 300mg daily or placebo. In the subsequent 3 weeks, all participants received mifepristone 300mg.||||
33927980|NCT00778713|RANDOMIZED|CROSSOVER||||NONE||||||
33927981|NCT05834699|||COHORT||PROSPECTIVE|||||||
33927982|NCT02068950|NA|SINGLE_GROUP||||NONE||||||
33927983|NCT04359225|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Patient will be blinded to form of telemedicine. Clinician will not be blinded|Randomised controlled trial|t|f|t|t
33927984|NCT00202345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927985|NCT01890317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927986|NCT02990559|||OTHER||PROSPECTIVE|||||||
33927987|NCT03736668|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702637|NCT03985059|||CASE_CONTROL||PROSPECTIVE|||||||
33702638|NCT01655797|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702639|NCT00440414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702640|NCT02447939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702641|NCT01297556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788487|NCT05108896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multi-center prospective single cohort study||||
33788488|NCT01360619|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33788489|NCT06628726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788490|NCT03237936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788491|NCT05717686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788492|NCT00478855|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33788493|NCT05386602|||OTHER||CROSS_SECTIONAL|||||||
33788494|NCT00477100|||COHORT||PROSPECTIVE|||||||
33788495|NCT01912495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788496|NCT06631703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This single-blind, randomized, controlled study was conducted with a pre-test and post-test control group.|f|f|t|f
33927988|NCT06047067|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702642|NCT04746339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33927989|NCT02327312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927990|NCT05247983|||CASE_CONTROL||RETROSPECTIVE|||||||
33927991|NCT02580240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33927992|NCT01587274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788497|NCT00606866|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33788498|NCT05627557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788499|NCT03650322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788500|NCT05080595|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33927993|NCT03073213|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33927994|NCT06340672|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007069|NCT00883935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007070|NCT01086345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007071|NCT05467826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33927995|NCT02999815|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|t|f
34007072|NCT03458143|||OTHER||PROSPECTIVE|||||||
34025212|NCT03358186|||COHORT||PROSPECTIVE|||||||
33702643|NCT03299465|NA|SINGLE_GROUP||OTHER||NONE||||||
33702644|NCT01156259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702645|NCT00087503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33927996|NCT01006213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33927997|NCT00028639||||TREATMENT||||||||
34025213|NCT02492659|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34025214|NCT03040700|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34025215|NCT04670094|||COHORT||RETROSPECTIVE|||||||
34025216|NCT02383810|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33702646|NCT05321108|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Procedures of the study:~The assessment procedures~1. Measuring of functional capacity and health-related quality of life in Systemic Lupus by: The Systemic Lupus Erythematosus Quality of Life (SLEQOL) questionnaire (Arabic version of the SLEQOL) 2- Measuring of functional capacity in Systemic Lupus by: Health Assessment Questionnaire (HAQ) The Arabic- Health Assessment Questionnaire (HAQ) 3- Measuring of fatigue in Systemic Lupus by: Fatigue severity scale (Arabic version of the FSS-Arabic) (FSS-Ar):~Therapeutic procedures:~1. Aerobic exercise~2. Whole-body vibration (WBV)"||||
33702647|NCT02678273|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702648|NCT03225534|||COHORT||PROSPECTIVE|||||||
33702649|NCT00028782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720429|NCT06131242|||COHORT||PROSPECTIVE|||||||
33720430|NCT05149846|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33720431|NCT02069990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720432|NCT01669733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720433|NCT06428344|||OTHER||PROSPECTIVE|||||||
33788501|NCT06428786|||COHORT||PROSPECTIVE|||||||
33788502|NCT06256445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Masking||t|f|t|f
33788503|NCT05576051|||COHORT||RETROSPECTIVE|||||||
33927998|NCT02089503|||COHORT||RETROSPECTIVE|||||||
33927999|NCT01052636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33928000|NCT05752240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33928001|NCT02608125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928002|NCT06502145|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33928003|NCT00412113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928004|NCT01482455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33928005|NCT01759355|||COHORT||PROSPECTIVE|||||||
33928006|NCT05333042|||OTHER||RETROSPECTIVE|||||||
33928007|NCT02758119|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33928008|NCT00352066|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33928009|NCT04827615|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"The study design is stepped wedge randomized cluster trial (4 villages in the first 6 months; additional 4 villages added every 6 months over the next 12 months) - randomized implementation.~Staff will visit 10 target villages to screen participants for high NCD risk using Community Based Assessment Checklist scoring. For adults meeting eligibility criteria, trained enumerators will (1) complete 2 brief surveys (2) measure waist circumference (3) measure blood pressure. Follow-up visits will be scheduled to measure fasting blood glucose. For adults who meet high-risk criteria for diabetes \& hypertension, an additional survey will be conducted on the 2nd day covering dietary intake \& clinical history. 3 additional follow-up visits will be completed every 6 months for 18 months. Each visit will include: 2 surveys like baseline, measurements of waist circumference, blood pressure, \& fasting blood glucose.~All participants identified as high risk will be referred to a public hospital."||||
33928010|NCT01787955|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928011|NCT03970824|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33702650|NCT03144921|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Dyads will be randomized (assigned by chance) to one of two groups: 10 EPIC A or 2) EPIC B (Wait List Control - WLC. Randomization with stratification by language preference (English vs. Spanish) and geographic setting will occur in sets of 4 to 8 (average 6) eligible dyads.~The RCT ends at T2 with comparison of changes in outcomes between EPIC and WLC participants from Assessment 1 (baseline) to Assessment 2 (3 months post baseline). T2-T3 assessments will be used for within-group and maintenance of gains analyses from about 3 months to 6 months post baseline."||||
33702651|NCT03781843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33702652|NCT00371826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702653|NCT04793087|||COHORT||RETROSPECTIVE|||||||
33702654|NCT04569903|NA|SINGLE_GROUP||SCREENING||NONE||||||
33702655|NCT04742075|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized phase 2 trial||||
33702656|NCT02426944|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702657|NCT01742000|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33702658|NCT02486523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702659|NCT02566486|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33702660|NCT03940287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant blinded (Single blinded)|Two group pre test post test Randomized Clinical Design|t|f|f|f
33702661|NCT04184713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33702662|NCT00270335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702663|NCT03464071|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33702664|NCT05065814|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33702665|NCT05934578|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two groups, one of them (10) will be submitted to an exercise program, and the other (10) will be maintained usual care.|A longitudinal clinical trial, controlled and no-randomized. Intervention: Exercise (aerobic and light muscle resistance exercise)|f|f|f|t
33702666|NCT02084693|||CASE_ONLY||PROSPECTIVE|||||||
33702667|NCT02418078|||CASE_CONTROL||RETROSPECTIVE|||||||
33702668|NCT03252860|||COHORT||PROSPECTIVE|||||||
33702669|NCT05681663|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33702670|NCT00892047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702671|NCT02000180|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33702672|NCT01514071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702673|NCT01136473|||CASE_ONLY||CROSS_SECTIONAL|||||||
33702674|NCT02173808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702675|NCT03960814|||COHORT||RETROSPECTIVE|||||||
33702676|NCT06183177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702677|NCT02328183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702678|NCT02272426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33702679|NCT03998488|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blinded study|Eligible subjects will be randomly assigned to one of the three (Placebo or Investigational FMT +/- Psyllium) treatment groups. A series of randomized blocks of 6-10 will be generated with a 1:1:1 allocation ratio.|t|t|t|f
33702680|NCT01182610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702681|NCT00972010|||OTHER||PROSPECTIVE|||||||
33702682|NCT03673579|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Prospective control data will be collected before the study devices are installed in all the NICU rooms. At the point of clinical go-live, there will be a single intervention group that all parents/clinicians will have the opportunity to participate in.||||
33702683|NCT04947358|||COHORT||PROSPECTIVE|||||||
33702684|NCT04824950|NA|SINGLE_GROUP||OTHER||NONE||||||
33702685|NCT04627246|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 12 evaluable patients will be recruited. They will receive the same investigational products.||||
33702686|NCT03727269|RANDOMIZED|PARALLEL||OTHER||SINGLE||Experimental group|t|f|f|f
33702687|NCT03939026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702688|NCT00005118||||TREATMENT||||||||
33702689|NCT06103539|||COHORT||PROSPECTIVE|||||||
33702690|NCT00576784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702691|NCT05933616|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702692|NCT01957774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702693|NCT02911857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702694|NCT04967378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33702695|NCT05843045|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All participants, care providers, and investigators will be blinded to the indoor air quality data as it is collected and the responses of the indoor air quality to mitigation.|The study will consist of two phases with each participant acting as their own control. Data will be collected from participants and their homes for approximately 1 year without mitigation and compared to a second period of approximately 1 year with mitigation.|t|t|t|f
33702696|NCT03417323|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33702697|NCT06436274|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||Participants will be randomized 1:1 into two different Groups. Group 1: Will receive nonavalent HPV vaccine at Day 0 and meningococcal vaccine at Month 18. Group 2: Will receive the meningococcal vaccine at Day 0 and nonavalent HPV at Month 18.|t|t|t|t
33702698|NCT01254097|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33702699|NCT02702219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702700|NCT05259358|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients included in the treatment group had 10 sessions postural smoothness, Chin tuck exercises, Range of motion exercises at all angles of the cervical joint, Neck isometric exercises, Cervical stabilization exercises (with ball), Pectoralis, latissimus dorsi, trapezoidal upper part, rhomboid and scalene muscle stretching exercises will be done face-to-face with a physiotherapist. At the end of 10 sessions of face-to-face training, the patients will perform the same exercises at home for 1 month. The patients will not given any exercises in the control group. Measurements and evaluations of the patients in both groups will be made twice that is before and after the treatment.||||
33702701|NCT02489760|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702702|NCT06353854|||COHORT||OTHER|||||||
33702703|NCT06441669|||COHORT||PROSPECTIVE|||||||
33702704|NCT01224964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33720434|NCT00674453|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33720435|NCT06447727|||COHORT||PROSPECTIVE|||||||
33788504|NCT00371020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788505|NCT01472536|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33788506|NCT02199145|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788507|NCT04726046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33788508|NCT03367117|||COHORT||RETROSPECTIVE|||||||
33788509|NCT04520204|||COHORT||CROSS_SECTIONAL|||||||
33788510|NCT02594215|NA|SINGLE_GROUP||OTHER||NONE||||||
33788511|NCT04428320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial|t|f|f|f
33788512|NCT03554837|||COHORT||PROSPECTIVE|||||||
33788513|NCT02135809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788514|NCT02801929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788515|NCT05787444|||CASE_ONLY||PROSPECTIVE|||||||
33788516|NCT01723436|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33788517|NCT02458534|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788518|NCT02955498|RANDOMIZED|CROSSOVER||||NONE||||||
33788519|NCT01872429|||COHORT||RETROSPECTIVE|||||||
33788520|NCT02750709|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33788521|NCT05925842|||COHORT||CROSS_SECTIONAL|||||||
33788522|NCT05173493|||COHORT||PROSPECTIVE|||||||
33788523|NCT02932293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788524|NCT02756104|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33928012|NCT01635036|||COHORT||PROSPECTIVE|||||||
33928013|NCT04258007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind (Participant, Care Provider)||t|t|f|f
33928014|NCT05534152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33928015|NCT04194411|||COHORT||PROSPECTIVE|||||||
33788525|NCT04732039|RANDOMIZED|CROSSOVER||OTHER||NONE||"Randomized crossover study:~1. Peak oxygen uptake vs VO2 measure during specific daily life activities in LVAD recipients~2. Peak oxygen uptake vs VO2 measure during specific daily life activities in healthy controls"||||
33928016|NCT01010269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928017|NCT04898127|RANDOMIZED|PARALLEL||SCREENING||NONE||Individually randomised trial.||||
33928018|NCT02667522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33928019|NCT01043783|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928020|NCT03785444|||CASE_CONTROL||PROSPECTIVE|||||||
33928021|NCT00425074|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33928022|NCT00617617|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33928023|NCT00493467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928024|NCT01437267|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928025|NCT02556671|||COHORT||PROSPECTIVE|||||||
33928026|NCT04206670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are randomly assigned to treatment arms by People Power. All participants complete the same questionnaires at the same intervals. University of California, Berkeley investigators are blind as to participants' treatment arm assignment.||f|f|t|f
33928027|NCT02938507|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33928028|NCT00915538|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33788526|NCT03907007|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788527|NCT00470743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788528|NCT04663802|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33928029|NCT00501462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928030|NCT00004467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025217|NCT00575887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025218|NCT06039189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025219|NCT01639196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025220|NCT04400032|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"CIRCA-1901 is is a dose-escalating and safety trial using a 3+3+3 design to determine the safety, and maximum feasible tolerated dose (MFTD) of intravenously (IV) delivered umbilical cord derived MSCs (UC-MSCs). If no safety issues are identified, we will continue to the Phase 2a trial.~CIRCA-1902 is a single-arm, open-label extension of the CIRCA-1901 trial to assess early signs of efficacy (major morbidity and mortality). The Phase 2a trial (CIRCA-1902) will enroll 12 patients to assess early signals of benefit on mortality and major morbidity in a high risk, high mortality population."||||
34025221|NCT03543436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025222|NCT02644005|||COHORT||PROSPECTIVE|||||||
34025223|NCT01922440|||OTHER||PROSPECTIVE|||||||
34025224|NCT01336452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025225|NCT05408936|||COHORT||PROSPECTIVE|||||||
34025226|NCT05249673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025227|NCT03450252|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"Taking part in this study will involve recording the information at a pre-implant visit, a visit for cardiac pacemaker implantation and follow-up visits four and eight months later.~At the pre-implant visit, participants will undergo assessment of symptoms, physical performance and blood test for a protein, Brain natriuretic peptide (BNP).~During the pacemaker implantation, the investigators will record the pressures within the heart using a catheter during both active pacing and back-up pacing settings.~The day after the pacemaker implant participants will undergo double-blind randomisation into either the treatment or non-treatment arm (active or back-up pacing respectively). At four months, cross-over takes place with assessment as above, before device reprogramming into either the treatment or non-treatment arm depending on which was completed first.~At the end of the second four month period, participants will undergo repeat assessment as above. That will conclude the study."|t|t|t|f
34025228|NCT05054478|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm phase 2 trial||||
33702705|NCT04842734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is planned to include 60 individuals diagnosed with AD according to DSM-IV diagnostic criteria by the neurologist. Individuals will be randomly divided into three groups; as the physical exercise group (n=20), physical exercise and cognitive stimulation (n=20) and the control group (n=20) according to inclusion criteria|t|f|f|f
33702706|NCT03185988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928031|NCT03878225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be stratified according to gender and body-weight. The randomization uses stratified permuted block randomization. Selected un-blinded personnel will carry out the randomization procedure. After randomization is carried out, the ketone mono ester or placebo beverages will be delivered to the patients by blinded personnel. Patients, investigators, other caregivers and persons performing data analysis will remain blinded from the time of randomization until the time of database unlock. Un-blinded project personnel will prepare and pack the ketone mono ester/placebo beverage in identical bottles. The placebo beverage will consist of water added with a colorless, bitter flavor enhancer (Bitrex®) and a sweetening agent (Stevia) to approximate the taste of the ketone mono ester beverage as closely as possible.|Double blinded, randomized, placebo controlled|t|t|t|f
34092327|NCT04022694|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will be told the researchers are interested in cafeteria purchase preferences, but participants will not know which condition has been assigned to individual participants.|Three private schools will be enrolled in the study (two larger, one smaller) that have students between the ages of 12 and 18. There will be no posters displayed at any of the schools during the baseline period. The two larger schools will be randomized to either an SSB warning/non-SSB promoting poster or a calorie/control poster that will be implemented in the school cafeterias during a four-week intervention period. To increase the sample size for the intervention condition, the intervention will also be implemented at a smaller school. For the primary analysis, data only from schools that were randomized to condition will be used. Data was collected from both a sample of participants \& from the cash registers directly.||||
33928032|NCT05425303|||COHORT||PROSPECTIVE|||||||
33928033|NCT02527564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702707|NCT00492141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702708|NCT04206800|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702709|NCT05040048|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702710|NCT01741090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702711|NCT02106975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702712|NCT04953754|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective open label melatonin compared to control||||
33702713|NCT00066365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702714|NCT03463512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702715|NCT03529812|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study aims to enroll 30 hospital chaplain residents, 15 will have the CBCT intervention early and the other 15 will learn about CBCT later. Additionally, 500 patients who have spiritual services provided by the chaplains participating in the study will be enrolled in order to examine patient outcomes.||||
33702716|NCT00097318||||TREATMENT||||||||
33702717|NCT03812471|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33702718|NCT00772304|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33702719|NCT00561457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702720|NCT04515394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702721|NCT04435587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PCR for SAR-CoV2 detection will be performed by technician without knowledge of treatment arm||f|f|f|t
33702722|NCT03208127|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702723|NCT04053231|||COHORT||PROSPECTIVE|||||||
33788529|NCT04716803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788530|NCT04785066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788531|NCT06629935|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33788532|NCT06629805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33788533|NCT00698802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788534|NCT00427557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788535|NCT04962100|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788536|NCT00220350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788537|NCT00820118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928034|NCT00455936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928035|NCT00527969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33928036|NCT04824105|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33928037|NCT02228577|||CASE_ONLY||RETROSPECTIVE|||||||
33928038|NCT05671237|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33928039|NCT04814511|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33928040|NCT04432467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928041|NCT05950555|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33928042|NCT05477017|||COHORT||PROSPECTIVE|||||||
33928043|NCT00805012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928044|NCT04134299|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33928045|NCT05255341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928046|NCT02425436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928047|NCT01070238|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33928048|NCT03066297|||COHORT||PROSPECTIVE|||||||
33928049|NCT03002285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928050|NCT02672618|||||CROSS_SECTIONAL|||||||
33928051|NCT04163367|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to the control condition (intervention as usual) or the experimental condition (intervention as usual + Safer Kids - manualized parent training)||||
33928052|NCT00701246|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
33928053|NCT02428335|||COHORT||PROSPECTIVE|||||||
33928054|NCT03455062|||COHORT||PROSPECTIVE|||||||
33928055|NCT01135745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928056|NCT00981682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092328|NCT00126945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092329|NCT04877054|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 2:1 to the intervention versus an education-only control condition||||
34007073|NCT05321823|RANDOMIZED|PARALLEL||SCREENING||NONE||The study will be carried out in 2 local counties (Local Government Areas) in Osun State, South-West, Nigeria, Ife North Local County and Ife East Local County. Three districts in Ife North Local County with an estimated screening population (women 40-70 years) of 5,800 will be randomly selected to serve as the intervention community, while 2 districts in Ife East Local County with an estimated screening population of 4,500 will be randomly selected to serve as the control community. Both communities will receive awareness and education, but only the intervention community will receive screening and navigation.||||
33702724|NCT00815698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33702725|NCT01554436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007074|NCT02658786|||COHORT||PROSPECTIVE|||||||
34007075|NCT00004988||||TREATMENT||||||||
34007076|NCT03695809|||COHORT||RETROSPECTIVE|||||||
34007077|NCT00732524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092330|NCT04298203|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Participants, care providers, study investigators and the study team will be blinded to the phentermine/topiramate or placebo assignment.|"All participants, regardless of drug/placebo assignment, will receive the same lifestyle/behavioral modification counseling monthly throughout the study: delivered at each in-person study visit and on the phone for months when there is no study visit.~All participants will engage in a meal replacement induction period for six weeks with a goal of reducing individual BMI by at least 5%. Those who are successful will be randomized to the study treatment outlined below. Those who are not successful will be discontinued from the study at this point.~Participants will be randomized (1:1) to phentermine/topiramate or placebo immediately following the meal replacement induction period (if successful in achieving \>/= 5% BMI reduction within the allotted six weeks)."|t|t|t|t
33788538|NCT03470987|||CASE_CONTROL||PROSPECTIVE|||||||
34092331|NCT02905864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092332|NCT04046653|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702726|NCT05469035|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled, pre-post-test, mixed-method||||
33702727|NCT00002854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702728|NCT00880542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788539|NCT03737175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788540|NCT04259632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788541|NCT00683410|||CASE_ONLY||PROSPECTIVE|||||||
33788542|NCT00789906|||||PROSPECTIVE|||||||
33788543|NCT06369090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Monitoring of 22 subjects, each subject was measured twice with electrode belt in two different positions.||||
33788544|NCT02107014|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33788545|NCT01403519|||CASE_CONTROL||PROSPECTIVE|||||||
33788546|NCT03728738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prospective randomized open blinded endpoint (PROBE) clinical trial using clinical assessors blinded to the intervention to determine neurologic deterioration on the NIH Stroke Scale Score following positioning to either zero degree or thirty degree heights.||f|f|f|t
33788547|NCT00434278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788548|NCT00371566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33788549|NCT00523731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788550|NCT02484534|||COHORT||PROSPECTIVE|||||||
33788551|NCT03910543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||open-label trial||||
33788552|NCT00929591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788553|NCT06492356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blinded randomized controlled trial|t|f|f|f
33788554|NCT06286163|||COHORT||PROSPECTIVE|||||||
33788555|NCT00821925|NA|SINGLE_GROUP||SCREENING||NONE||||||
33788556|NCT03729804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788557|NCT00436137|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33788558|NCT04168814|||CASE_ONLY||CROSS_SECTIONAL|||||||
33788559|NCT03124108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788560|NCT05564325|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788561|NCT01317134|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33788562|NCT04265625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788563|NCT00673296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788564|NCT05067127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788565|NCT06104969|||CASE_CONTROL||PROSPECTIVE|||||||
34007078|NCT05050227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007079|NCT00625924|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34007080|NCT05186779|||OTHER||PROSPECTIVE|||||||
33702729|NCT02925117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702730|NCT03766074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33702731|NCT03469934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702732|NCT06557707|||COHORT||PROSPECTIVE|||||||
33702733|NCT02898870|||COHORT||RETROSPECTIVE|||||||
33702734|NCT03483025|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|The six hair cleansing products will be packaged in identical 1 ml capped tuberculin syringes (with no needles) and provided to participants. Each syringe will be labeled with the forearm location for application. Identical syringes containing the six hair cleansing products will be dispensed. Treatment site allocation will be determined by a computer-generated randomization log.|randomized, double-blind, controlled|t|f|t|t
33720436|NCT02618174|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33788566|NCT02175290|||COHORT||PROSPECTIVE|||||||
33788567|NCT04395755|||COHORT||PROSPECTIVE|||||||
33788568|NCT02438800|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33788569|NCT05543811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33788570|NCT04122807|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective model with two groups based on PR interval on ECG, normal and prolonged PR||||
34007081|NCT06355830|||COHORT||PROSPECTIVE|||||||
34007082|NCT00316940||||TREATMENT||NONE||||||
34007083|NCT06123780|||COHORT||PROSPECTIVE|||||||
34007084|NCT04067193|||COHORT||PROSPECTIVE|||||||
34007085|NCT04572204|||COHORT||PROSPECTIVE|||||||
34007086|NCT04234464|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34092333|NCT00473499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702735|NCT03925597|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant will be given the unlabeled fiber supplement.|Participants will be randomized to the order of the fiber supplementation and they will take each fiber for three weeks. After a washout period, they will switch fibers. Blood and stool samples will be collected through the intervention and once during each washout period.|t|f|f|f
33702736|NCT01170143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702737|NCT01485575|||COHORT||PROSPECTIVE|||||||
33702738|NCT06277557|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Waitlist-control study||||
33702739|NCT06405451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will involve the evaluators, who will be unaware of which intervention group each subject belongs to|This is a quasi-experimental pre-post trial. The research will be conducted in accordance with the Helsinki Declaration and the Personal Data Protection and Guarantee of Digital Rights Act (Organic Law 3/2018). The design of this project will adhere to the standard protocol elements of a clinical trial: SPIRIT statement.|f|f|f|t
33702740|NCT02428270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702741|NCT00000702||||TREATMENT||DOUBLE||||||
33702742|NCT04765982|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||"* The study will be a prospective cohort study~* We will select patient without diabetes who will undergo cardiac surgery, patient will be divided into two groups group 1) Patients with uncontrolled blood sugar in the ICU; and group 2) patient with adequate control of blood sugar in ICU settings~* The sample size will be calculated based on previous studies in critically ill patients"|t|f|f|t
33702743|NCT00458562|||CASE_CONTROL||PROSPECTIVE|||||||
33702744|NCT05328063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702745|NCT01313312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702746|NCT00518687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33788571|NCT00021112||||TREATMENT||||||||
33788572|NCT02072122|||COHORT||PROSPECTIVE|||||||
33788573|NCT06445231|RANDOMIZED|PARALLEL||SCREENING||NONE|Not relevant|Nursing home randomization in 1:1 ratio between echocardiography and no-echocardiography||||
33788574|NCT04606251|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled Research Study||||
33788575|NCT00002896|RANDOMIZED|||TREATMENT||||||||
33702747|NCT05717179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702748|NCT04821115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702749|NCT00000430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788576|NCT06437002|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788577|NCT04102449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788578|NCT06611163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788579|NCT05542342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788580|NCT01895517|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33788581|NCT03037190|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||•The trial is designed as a 2-arm not randomized, open, multicentre study comparing 1 year of gluten free diet with normal diet||||
33788582|NCT02703155|NA|SINGLE_GROUP||SCREENING||NONE||||||
33788583|NCT04729296|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Active drug and placebo will be identical in appearance and packaging|Treatment assignment (active drug: placebo) will be assigned in a parallel, randomized, 1:1 model. Randomization will be conducted using block randomization with variable block sizes with stratification on TrialNet study site and age group (\< 12 years old vs. 12 years old or older).|t|f|t|f
33788584|NCT05189587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788585|NCT02057718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788586|NCT04332757|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||An independent group design with participants at one site receiving usual care/no formal intervention (acting as a control group \[CON\]) and participants at a second site receiving usual care and additionally completing an 18-week phased physical development (rehabilitation and training) programme between weeks 6 and 24 postpartum (acting as the intervention group \[INT\]).||||
33788587|NCT00343824|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788588|NCT04617600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33788589|NCT06631300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788590|NCT04228055|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and Post Study Model||||
33788591|NCT04201119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788592|NCT01813903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788593|NCT04437979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788594|NCT03719209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788595|NCT03269019|||COHORT||PROSPECTIVE|||||||
33788596|NCT01846169|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788597|NCT06130878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33788598|NCT03552770|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The enrolled patients are randomized to the following therapeutic regimens: i. group A, a single intra-vitreous injection of bevacizumab pro-re-nata repeated after monthly periodic monitoring of the patient (IVIBx1 regimen); ii. group B, two combined intra-vitreous injections of bevacizumab, spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of the patient (IVIBx2 regimen).||||
33801678|NCT03298789|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||19 subjects will be devided into two groups. The first group will conduct the control condition on Saturday and the second group will conduct the experimental condition on Sunday. One week later, the subjects will undergo the second visit, each group of subjects performing the opposite condition.||||
33801679|NCT04565119|||COHORT||PROSPECTIVE|||||||
33928057|NCT03927911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928058|NCT01420029|||COHORT||PROSPECTIVE|||||||
33928059|NCT01258946|||CASE_CONTROL||PROSPECTIVE|||||||
33928060|NCT04616092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928061|NCT01917552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928062|NCT04126603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928063|NCT01852916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007087|NCT02608840|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34007088|NCT04159194|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007089|NCT00006102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007090|NCT04395599|NA|SINGLE_GROUP||PREVENTION||NONE||COVID19 patients undergoing visceral surgery||||
34007091|NCT02614833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092334|NCT02960685|||COHORT||PROSPECTIVE|||||||
33702750|NCT06354062|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|First Line Nurse Managers received talent Management intervention program|A quasi-experimental design|t|f|f|f
33702751|NCT01551992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702752|NCT05862831|NA|SINGLE_GROUP||TREATMENT||NONE||"In dose escalation stage, three subjects will be enrolled at the protocol starting dose of PM1032 for 21 Days DLT observation, followed by same dose every 2 weeks (Q2W) until they meet the discontinuation criteria.~Dose escalation will proceed to the next dose level according to the 3+3 design.~Dose expansion stage of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose escalation stage."||||
34092335|NCT03186365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702753|NCT06221462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702754|NCT03062007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928064|NCT05452824|RANDOMIZED|PARALLEL||OTHER||SINGLE|Although it is not possible to blind participants or interventionists to group allocation, the random allocation sequence will be blinded from study staff conducting data management and analyses. The randomization schedule, generated by the project data analyst, will be kept by project staff who will deliver it, in a sealed envelope, to a research assistant who will then assign qualified individuals to intervention groups. Randomization will occur after informed consent is obtained and baseline assessments have been completed. Participants will be notified of their allocation through phone calls.|Single-centered, single-blind, parallel design randomized controlled trial|f|f|f|t
33702755|NCT03266731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788599|NCT05866081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeons will remain blinded to this allocation until the surgeon has confirmed secondary eligibility.|"Participants that consent for the randomization cohort (264 anticipated) will be randomized using an online computer-based system to either stent omission or stent placement in a 1:1 ratio following secondary eligibility criteria. Blocked, stratified randomization based upon surgeon classified stone location (renal only versus ureteral with or without renal), with random block sizes will be used to ensure group balance.~Observational study participants (528 anticipated) will not be randomized."|f|t|f|f
33788600|NCT03095508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788601|NCT00885508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788602|NCT05811728|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||The study is a randomized controlled clinical trial, involving the split-mouth design, with one side of the maxillary arch serving as the control group, and the other side serving as the experimental group.|t|f|f|f
33928065|NCT03412123|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33928066|NCT00383877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928067|NCT06135389|||OTHER||PROSPECTIVE|||||||
33702756|NCT05893355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33702757|NCT02040571|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702758|NCT03434574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33702759|NCT05962931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702760|NCT02693119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702761|NCT02997709|||COHORT||PROSPECTIVE|||||||
33702762|NCT00562835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702763|NCT03973710|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.||t|t|t|t
33702764|NCT05435677|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33788603|NCT04830254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788604|NCT05181579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788605|NCT02589210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788606|NCT04543162|||COHORT||RETROSPECTIVE|||||||
33801680|NCT01346254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801681|NCT00031694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801682|NCT01718041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928068|NCT00800475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928069|NCT00968708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928070|NCT04971369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928071|NCT00134017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928072|NCT03990818|||COHORT||PROSPECTIVE|||||||
33928073|NCT04511936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928074|NCT00643799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928075|NCT05967208|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928076|NCT00028418|NON_RANDOMIZED|||TREATMENT||NONE||||||
34007092|NCT03932279|||COHORT||PROSPECTIVE|||||||
34007093|NCT00531362|||COHORT||PROSPECTIVE|||||||
34007094|NCT00757679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007095|NCT02823847|NA|SINGLE_GROUP||SCREENING||NONE||||||
34007096|NCT02203617|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|t|f|t
34007097|NCT02882269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007098|NCT01192399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007099|NCT02335957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007100|NCT05301686|||COHORT||OTHER|||||||
34007101|NCT05659329|||COHORT||RETROSPECTIVE|||||||
34007102|NCT03588650|NA|SEQUENTIAL||TREATMENT||NONE||||||
33702765|NCT01284218|||COHORT||RETROSPECTIVE|||||||
33702766|NCT01232595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702767|NCT05918432|||CASE_CROSSOVER||PROSPECTIVE|||||||
33702768|NCT05757687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702769|NCT05890144|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants were not informed of the unannounced Indigenous standardized patient (UISP) visit and thus blinded to this primary outcome measure. UISPs, research and site team members were blinded to participants' study arm allocation with the exception of the study coordinator, who facilitated enrollment in intervention and control training groups||t|t|f|f
33702770|NCT04218695|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded placebo-controlled trial||t|t|t|t
33702771|NCT06178185|||CASE_ONLY||PROSPECTIVE|||||||
33702772|NCT06534710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Creditease Medical Device Technology，YXB-AJY-06||||
33702773|NCT03191279|||COHORT||PROSPECTIVE|||||||
33702774|NCT01890473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702775|NCT00142298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702776|NCT01210469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33702777|NCT03728920|||COHORT||PROSPECTIVE|||||||
33702778|NCT02563171|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702779|NCT02404220|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33702780|NCT04750512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"According to the randomization arm patients will receive:~* sham US-guided ESP block + US-guided TAP block before laparoscopic hernia repair~* US-guided ESP block + sham US-guided TAP block before laparoscopic hernia repair Allocation will take place immediately before the intervention by the means of access to centralized, real-time allocation through a computer program.~Personnel not directly involved with patient care will prepare a saline solution and a ropivacaine solution which will be allocated respectively to ESP or TAP block according to randomization.~This will allow blinding of patients, care providers and data collectors. Analysis will be done on allocation-concealed data, permitting blinded analysis.~Unbliding will be permitted if by doing so harm to one or more patients can be avoided or treated. After information of one of the principal investigators, specific patient allocation will be retrieved from the randomization program."|"This is a single center, prospective, randomized, double-dummy placebo-blinded, controlled superiority trial in 2 parallel arms comparing the efficacy and safety of the ESP Block and the TAP block on patients undergoing elective robot-assisted inguinal hernia repair."|t|t|t|t
33702781|NCT04099095|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will employ a randomised wait-list trial design with mixed methods using a co-productive participatory approach.||||
33702782|NCT05923034|||COHORT||RETROSPECTIVE|||||||
33702783|NCT00313118|||CASE_ONLY||PROSPECTIVE|||||||
33702784|NCT05123170|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
33702785|NCT05465460|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33702786|NCT04792320|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33702787|NCT01582568|||COHORT||PROSPECTIVE|||||||
33702788|NCT03159221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702789|NCT05712967|||CASE_CONTROL||PROSPECTIVE|||||||
33702790|NCT03828175|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33702791|NCT06366932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IV, low-intervention clinical trial to develop prediction models that allow to determine the most appropriate therapeutic strategy in patients diagnosed with atopic dermatitis that need second-line systemic treatment.||||
33702792|NCT02038881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702793|NCT02890472|||COHORT||PROSPECTIVE|||||||
33702794|NCT03873025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702795|NCT00851630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702796|NCT03886480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702797|NCT04952675|||COHORT||PROSPECTIVE|||||||
33702798|NCT04306848|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot / feasibility study||||
33702799|NCT00321308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702800|NCT01390688|||COHORT||CROSS_SECTIONAL|||||||
33702801|NCT00585962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702802|NCT06454019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33702803|NCT01674114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702804|NCT01164800|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702805|NCT00362557|||CASE_ONLY||PROSPECTIVE|||||||
33702806|NCT05732246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702807|NCT00742378|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702808|NCT03757156|RANDOMIZED|PARALLEL||PREVENTION||NONE||Aspirin maintenance group versus aspirin interruption group||||
33702809|NCT00255125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33702810|NCT05092646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, investigators, and outcome assessors will be blinded to the treatment allocation until completion of the 6-month follow-up visit.|Randomized, Placebo-controlled, Double-blinded|t|f|t|t
33702811|NCT02146664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702812|NCT04521374|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All samples provided to the participant are labelled with 3 digit random codes||t|f|f|f
33702813|NCT06385951|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702814|NCT00335361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702815|NCT02747290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702816|NCT05182190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||5 x 5 crossover study with 3 treatments and two controls||||
33702817|NCT05600803|||CASE_ONLY||PROSPECTIVE|||||||
33702818|NCT00282100|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702819|NCT00593008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702820|NCT02845934|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33702821|NCT05954702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702822|NCT03847246|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study||||
33702823|NCT05585060|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092336|NCT06031129|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34092337|NCT04027621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092338|NCT04250480|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34092339|NCT05227235|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Due to the nature of Telemedicine it is not possible to blind the participant (patient) or the care provider (clinician performing consultation). The investigator and outcomes assessor will be blinded, with group allocation blinded.|The study will use a combination of within-subjects design (crossover) and between-subjects design (standard randomised controlled trial with 2 arms).|f|f|t|t
34092340|NCT03199066|||CASE_ONLY||PROSPECTIVE|||||||
34092341|NCT03838705|NA|SINGLE_GROUP||SCREENING||NONE||||||
34092342|NCT03166176|NA|SINGLE_GROUP||TREATMENT||NONE||Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle||||
34092343|NCT03451032|||COHORT||PROSPECTIVE|||||||
33702824|NCT02538081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33702825|NCT03294759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Bone marrow aspirate will be collected through the surgical site from the distal femur with a trocar designed for this purpose. Therefore patients will be unable to determine if they have had stem cells harvested|"ACL harvested for autograft reconstruction of the ACL with either hamstring or patellar tendon grafts. The graft will be wrapped in a collagen wrap and injection with aspirate from the patient's bone marrow.~The control group will have standard ACL reconstruction with either hamstring or patellar tendon grafts."|t|f|f|t
33702826|NCT03922126|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33702827|NCT02248701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33702828|NCT05622695|||COHORT||PROSPECTIVE|||||||
33702829|NCT00550121|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33702830|NCT03258931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702831|NCT00214110|RANDOMIZED|PARALLEL||||SINGLE||||||
33702832|NCT02041832|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33702833|NCT03925753|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33702834|NCT01275820|||COHORT||PROSPECTIVE|||||||
33702835|NCT05568823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Stratification on two groups of patients subsequently identified as responders or non-responders, after 8 weeks of treatment. Patients will be classified as responders or non-responders on the basis of the evolution of the MADRS depression scale score, i.e. an improvement of more than 50% in the intensity of symptoms between the beginning of the treatments and 8 weeks afterwards.||||
33702836|NCT03064750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702837|NCT02173223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702838|NCT00406354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702839|NCT00376064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702840|NCT00219739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702841|NCT02043080|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702842|NCT01627483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702843|NCT04330287|||COHORT||PROSPECTIVE|||||||
33702844|NCT06679816|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33702845|NCT02653872|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33702846|NCT05802212|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Metformin intervention for 12 weeks||||
33702847|NCT04746248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702848|NCT05409248|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"The intervention platform will randomly assign participants in a 1:1 ratio to one out of two groups (control/experimental), so both participants and researchers are blinded.~Activities presented to the experimental group will target specific cognitive domains (mainly executive functions) and will be automatically adjusted in difficulty and requirement according to each participant's performance. Thus, maximum cognitive effort is always required.~Activities presented to the active control group will target orthogonal unrelated cognitive domains (i.e. artistic cognitive processes) and will be of constant difficulty."|A home-based intervention will be set through the CogniFit® online platform. Participants will access remotely from home using a personal computer or smart device. The cognitive stimulation program will be held for 5 consecutive days (Monday to Friday) for 8 weeks, completing a total of 40 training sessions. Researchers will supervise the participant's performance daily and will periodically contact participants via telephone.|t|f|t|f
33702849|NCT03113071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.~For Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1."||||
33788607|NCT03239925|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Experimental group: we planned that all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.~Control group: these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode."||||
33788608|NCT06306365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking.|A quasi-experimental methodology will be employed, involving both a control group and an experimental group. Randomized control trial.||||
33788609|NCT06142240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study design: Interventional study. The study will be carried out at the Ricard i Fortuny Social and Health Centre (CSSV RiF) in Vilafranca del Penedès (Barcelona).|f|f|f|t
33788610|NCT02540044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33788611|NCT04570644|RANDOMIZED|CROSSOVER||TREATMENT||NONE|A Phase I/ II Randomized, Open-Label Study to Evaluate Pharmacokinetic and Pharmacodynamic Effects and Safety of ALZT-OP1 (co-administration of ALZT-OP1a and ALZT-OP1b) in Subjects with Alzheimer's Disease and Normal Healthy Volunteers|ALZT-OP1a (cromolyn) and ALZT-OP1b (Ibuprofen) are being evaluated in this study.||||
33788612|NCT02260739|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33788613|NCT05392738|||COHORT||PROSPECTIVE|||||||
33788614|NCT03836417|||COHORT||PROSPECTIVE|||||||
33788615|NCT02833155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007103|NCT05509088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007104|NCT06073899|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigator administering Pressure Pain Threshold will be blinded to the intervention.||f|f|t|f
34007105|NCT06616363|||COHORT||PROSPECTIVE|||||||
34007106|NCT04747795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007107|NCT04846647|||COHORT||PROSPECTIVE|||||||
34007108|NCT02079337|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34007109|NCT05021484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007110|NCT02576717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007111|NCT01134627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007112|NCT03990480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Thirty control healthy individuals and 200 patients with uncomplicated, essential hypertension were enrolled and followed up for 3 months in a controlled randomized study.||||
34007113|NCT04924699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007114|NCT02370836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34007115|NCT06302348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007116|NCT05458245|||CASE_ONLY||RETROSPECTIVE|||||||
34007117|NCT02806687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007118|NCT03635268|||COHORT||RETROSPECTIVE|||||||
34007119|NCT04401111|||COHORT||PROSPECTIVE|||||||
34007120|NCT03259685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007121|NCT05670145|||COHORT||PROSPECTIVE|||||||
34007122|NCT01017094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007123|NCT00508040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007124|NCT03952988|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||At Day 1, hypolactasic subjects will perform a Hydrogen Breath Test (HBT) with a placebo ice-cream with 20g lactose (Negative Control). A second HBT will be carried at Day-8 with the same product + an exogenous lactase (Positive control). A 3° HBT will be carried out at Day 15 with the probiotic ice cream with 20g lactose to determine the acute effect of the probiotic. Posteriorly, the subjects will be randomly assigned in one of 2 groups to consume an ice-cream/d, with or without the probiotic, for 4 weeks. At Day-43, they will carry out a 4° HBT with ice cream with 20g lactose and without probiotic (Evaluation of the chronic effect). At Day 71, after 4 weeks washout period, a 5° HBT will be carried out with the ice cream with lactose and without probiotic, to evaluate the remanence of the effect. A fresh stool will be obtained at days 15, 43 and 71 to determine the presence of the probiotic, microbiota composition, ß-galactosidase activity and short chain fatty acid concentrations.|t|t|t|f
34007125|NCT00813345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34007126|NCT05435976|||CASE_ONLY||PROSPECTIVE|||||||
34007127|NCT05559463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007128|NCT00468871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007129|NCT03760016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007130|NCT00388037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007131|NCT06236412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors are data collectors who will be trained for only outcome data collection. They will not be involved in any manipulations other than outcome data collection. They will not be involved in baseline data collection as well. They will not have information about which group receive the intervention and which group not. Their only purpose is to interview participants about the outcome status, which will be prepared by the investigators.|Cluster randomized controlled trial using a three-arm parallel group design will be implemented. A post-test only trial design. The three arms are: pregnant woman alone, pregnant woman with mother-in-law, and pregnant woman in routine care (control).|f|f|f|t
34007132|NCT05318976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"* (2:1) XPro1595 (1mg/kg), placebo~* Weekly subcutaneous injections"|t|t|t|t
33788616|NCT00667693|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34007133|NCT00398684|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34007134|NCT01074645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34007135|NCT01622608|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007136|NCT04458467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007137|NCT01706718|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34007138|NCT06081140|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007139|NCT03460145|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34007140|NCT01069796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007141|NCT00867412|||||PROSPECTIVE|||||||
34007142|NCT05315245|||COHORT||PROSPECTIVE|||||||
34007143|NCT05606952|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prospective study||f|f|f|t
34007144|NCT04124029|||CASE_CONTROL||PROSPECTIVE|||||||
33788617|NCT04536077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788618|NCT01607047|||COHORT||PROSPECTIVE|||||||
33788619|NCT01839877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788620|NCT03096184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788621|NCT03821922|||CASE_CONTROL||PROSPECTIVE|||||||
33788622|NCT02523872|||COHORT||PROSPECTIVE|||||||
33801683|NCT00962702|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33801684|NCT04856826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007145|NCT03566407|NA|SINGLE_GROUP||OTHER||NONE||All study subjects will undergo a protocol required 6 month colonoscopy||||
34007146|NCT00561171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007147|NCT02151175|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007148|NCT05051878|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34007149|NCT04889391|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007150|NCT04448496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007151|NCT03300908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were not aware of which intervention they were assigned to. A randomization scheme was developed and participants were assigned to treatment groups accordingly.|Participants were randomly assigned to Project ADHERE, or the control condition, MACE. The randomization process was described to participants during the informed consent process.|t|f|f|f
34007152|NCT06537232|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover trial||||
34007153|NCT04429841|||CASE_CONTROL||OTHER|||||||
34007154|NCT01275157|NA|SINGLE_GROUP||||NONE||||||
34007155|NCT06471491|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34007156|NCT04372784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34007157|NCT04619199|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal prospective cohort study||||
34007158|NCT00333476|RANDOMIZED|PARALLEL||||NONE||||||
34007159|NCT01987726|||CASE_ONLY||PROSPECTIVE|||||||
34007160|NCT00466843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007161|NCT01281241|||CASE_ONLY||PROSPECTIVE|||||||
34007162|NCT06166264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092344|NCT04817982|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The trial medication will be identical in appearance and will be prepared in syringes of identical appearance with an identical volume of trial medication by an un-masked nurse who is not otherwise involved in the trial. The participant, anaesthesiologist performing the blocks, the investigators, and the outcome assessors for all outcomes will be masked to treatment allocation.|Randomised, blinded, placebo-controlled, paired, non-inferiority trial in healthy volunteers.|t|t|t|t
34092345|NCT00440687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092346|NCT05370326|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092347|NCT02626611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092348|NCT05573282|||COHORT||PROSPECTIVE|||||||
34092349|NCT06021379|||CASE_ONLY||PROSPECTIVE|||||||
34092350|NCT02871427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092351|NCT01709344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34092352|NCT03575156|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092353|NCT06286943|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34092354|NCT05827744|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092355|NCT04267042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788623|NCT05193630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anthropometric outcomes will be blinded to assessors and analyst until at least the primary outcomes have been analysed to reduce bias.|A randomised, open label, controlled intervention study|f|f|f|t
33788624|NCT04814940|||COHORT||RETROSPECTIVE|||||||
33788625|NCT06234865|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928077|NCT05459480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Students will be given information about the study, but not in which group they are included. Thus, blinding will be ensured.|Randomized controlled trial|t|f|f|f
33928078|NCT05367713|||COHORT||RETROSPECTIVE|||||||
33928079|NCT04269837|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33928080|NCT01827241|||COHORT||PROSPECTIVE|||||||
33928081|NCT03940456|||COHORT||PROSPECTIVE|||||||
33928082|NCT02444936|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33928083|NCT05565326|||COHORT||PROSPECTIVE|||||||
33928084|NCT02788591|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33928085|NCT03639922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is double-blind, only after the study is completed or terminated the treatments will be made available, or if requested by the data safety board, or if requested by treating clinician in association with possible SAE/SUSAR|randomized, double-blind, placebo-controlled, parallel-arm|t|t|t|f
33928086|NCT05560152|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33928087|NCT06357390|||COHORT||PROSPECTIVE|||||||
33928088|NCT04030468|RANDOMIZED|PARALLEL||OTHER||NONE||"According to the Local Health Unit (LHU), general practitioners (GPs) with their patients will be assigned to one of the following intervention arms:~1. intervention on GPs (LHUs of Napoli 1 Nord and Bergamo)~2. intervention on patients (LHUs of Avellino and Val Padana-Mantova District)~3. intervention on GPs and patients (LHUs of Napoli 2 Centro and Brianza-Lecco District)~4. no intervention (LHUs of Caserta and Brianza-Monza Brianza District)"||||
33928089|NCT00615459|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33928090|NCT00718250|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33928091|NCT01769638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007163|NCT02668094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007164|NCT01075061|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007165|NCT05695391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007166|NCT00273416|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34007167|NCT05486845|NA|SEQUENTIAL||SCREENING||NONE||||||
34092356|NCT00562328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092357|NCT04166331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092358|NCT06019988|RANDOMIZED|PARALLEL||SCREENING||NONE||"All enrolled patients will initially receive one of three screening tools (The Accountable Health Communities Health-Related Social Needs Screening Tool \[AHC-HRSN\], Health Leads Social Screening Tool, or National Comprehensive Care Network Distress Thermometer and Problem List \[NCCN DT+PL\]) via the MyPennMedicine patient portal and be given 48 hours to respond. Those patients who do not respond will be randomized to one of two intervention arms, each of which is an alternative modality to receive and respond to the assigned screening tool: a bidirectional text-based conversational agent (chatbot) or interactive voice response system administered by phone.~There exists three instrument arms (AHC-HRSN, Health Leads, and NCCN DT+PL) and two modality arms (chatbot and IVR)."||||
34092359|NCT01584583|||||PROSPECTIVE|||||||
34092360|NCT03415009|||CASE_ONLY||PROSPECTIVE|||||||
34092361|NCT01495247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34092362|NCT00785629|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34092363|NCT04498104|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092364|NCT03320369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092365|NCT04510415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092366|NCT01889030|||||CROSS_SECTIONAL|||||||
34092367|NCT04796896|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Parts 1 and 3 are Open-label; Part 2 Randomized and Observer-blind||t|t|t|t
34092368|NCT04167670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The triple therapy arms will be blinded to participants, care providers, investigators and outcome assessors. The dual therapy arm will only blinded to the outcomes assessor.||t|t|t|t
33928092|NCT03984812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is double-blind (sponsor-unblinded) study with subjects and the site staff blinded, except for an unblinded pharmacist at the site who will prepare the blinded drug product. The blind may be broken if, in the opinion of the investigator, it is in the subject's best interest for the investigator to know the study treatment assignment.|In Part 1 of the study each of the subjects in the SAD cohorts (SAD Cohorts 1-5; SAD Cohort 6 is a possible expansion cohort that will be added as needed) will receive a single dose of blinded GSK3732394 or blinded PBO (GSK3732394: PBO = 6:2), per their randomization assignment. Part 2 will consist of up to three ascending repeat-dose cohorts (MAD Cohorts 1, 2, and 3), each with 8 subjects (blinded GSK3732394: blinded PBO = 6:2) will receive four weekly doses of GSK3732394 or PBO on Days 1, 8, 15, and 22.|t|f|t|f
34092369|NCT06189963|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34092370|NCT05407948|||COHORT||RETROSPECTIVE|||||||
34092371|NCT04733885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092372|NCT02769520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928093|NCT05914740|NA|SINGLE_GROUP||TREATMENT||NONE|Open trial|A certain number of patients meeting the requirements (meeting the inclusion criteria, but not meeting the exclusion criteria) were selected for preoperative hemodynamic evaluation of lower extremity vein ultrasound to determine the reflux points and reflux points, identify the blood circulation pattern, and design an individualized surgical program. Intraoperative venous valve was reconstructed in situ under ultrasound guidance. Postoperative ultrasound was used to assess venous valve function and complications in the operative area.||||
34092373|NCT01618591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092374|NCT02680275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092375|NCT06347588|||COHORT||PROSPECTIVE|||||||
34092376|NCT05817604|||COHORT||PROSPECTIVE|||||||
34092377|NCT01101100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092378|NCT03750630|||CASE_ONLY||PROSPECTIVE|||||||
34092379|NCT02233413|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34092380|NCT00154466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092381|NCT00447278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092382|NCT05207358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928094|NCT06349850|||CASE_CROSSOVER||PROSPECTIVE|||||||
33928095|NCT06306352|NA|SINGLE_GROUP||OTHER||NONE||||||
33928096|NCT00987610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928097|NCT01855425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Predicate CT Scan and Investigational Cone Beam Scan||||
33928098|NCT05131529|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|"Participants are not randomly allocated to treatment groups, but rather, dining halls are randomly allocated to treatments. This is what Randomized refers to under Allocation below.~Under Enrollment below, the number of participants refers strictly to the number of participants in an e-mail survey that will go out to students during each of the three semesters of the project. We anticipate 1,000 respondents during each semester. These respondents do not include the entire population of dining hall patrons that will interact with the dining halls (and therefore the interventions) during the three semesters of the study."|"We will carry out the proposed project within six of the University of Michigan's MDining's nine residential dining halls on the Ann Arbor campus. Using a cluster-randomized controlled trial, we will create three matched pairs among the six dining halls based on the size of each facility. One dining hall from each of the pairs will be randomly assigned to a treatment and control group, respectively.~Participants will receive interventions based on which dining halls they visit regularly and most often."||||
33928099|NCT03065725|||CASE_ONLY||PROSPECTIVE|||||||
33928100|NCT03431142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928101|NCT03431506|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|f|t
33928102|NCT05767229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928103|NCT00936793|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33928104|NCT06076005|||COHORT||PROSPECTIVE|||||||
33928105|NCT02884128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928106|NCT04814407|||COHORT||PROSPECTIVE|||||||
34092383|NCT03947034|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092384|NCT05356663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702850|NCT03204578|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, randomised, single-dose crossover design||||
33702851|NCT03376269|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34092385|NCT06549972|||CASE_CONTROL||PROSPECTIVE|||||||
33702852|NCT02206542|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34092386|NCT03164707|||COHORT||PROSPECTIVE|||||||
34092387|NCT04039269|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34092388|NCT05504278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092389|NCT02756468|||CASE_ONLY||PROSPECTIVE|||||||
34092390|NCT05076123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment Randomized|t|f|f|f
34092391|NCT05150288|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092392|NCT03975634|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34092393|NCT01584388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092394|NCT00827242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092395|NCT03796663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All participants will receive the Mindful Parenting program at the start of their involvement in the study. Following the completion of the Mindful Parenting group sessions, half of the participants will be randomly selected to receive individually-implemented MATCH BPT sessions. The other half of families will have the opportunity to also receive the MATCH BPT program following the completion of data collection.||||
34092396|NCT01485835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092397|NCT02852083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092398|NCT05983055|||COHORT||PROSPECTIVE|||||||
34092399|NCT00095966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702853|NCT05205525|||CASE_CONTROL||OTHER|||||||
34092400|NCT02183974|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092401|NCT04605913|NA|SEQUENTIAL||TREATMENT||NONE||The trial will compose of 2 parts with a total of 40 subjects. The 1st part would be a safety run-in phase (phase I). In this phase, 6 patients will be treated after completing screening procedures and meeting eligibility criteria. If 6 patients tolerate this dose level of GCN+TTF through the 1st cycle without defined dose limiting toxicities (DLTs) or grade 4 treatment related adverse events (TRAE), the 2nd part of the study (phase Ib portion) will commence. An additional 34 patients will be enrolled in the expansion cohort (phase Ib).||||
34092402|NCT05072951|||COHORT||PROSPECTIVE|||||||
34092403|NCT04676776|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's two-stage design||||
34092404|NCT00005790||||DIAGNOSTIC||||||||
34092405|NCT02022930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092406|NCT01250665|||COHORT||CROSS_SECTIONAL|||||||
33720437|NCT04299204|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||the data into two groups. In group-1, PCNL was performed in the first 10 years period (1997-2007); in group-2, PCNL was performed in the second ten years period from 2008 to the present.|t|f|f|f
33720438|NCT02614430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33720439|NCT04720846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33720440|NCT00843102|||CASE_CROSSOVER||PROSPECTIVE|||||||
33720441|NCT03794557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928107|NCT00081328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928108|NCT04152746|||CASE_CONTROL||PROSPECTIVE|||||||
34007168|NCT00374049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007169|NCT06311006|||COHORT||PROSPECTIVE|||||||
34007170|NCT02785653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007171|NCT00989209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007172|NCT04006938|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The proposed study is a crossover randomized controlled study. There will be two intervention groups - a single 30-minute bout of moderate intensity aerobic exercise before breakfast and three (3) 10-minute bouts of moderate intensity aerobic activity before breakfast, lunch and dinner.||||
34007173|NCT02415387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34007174|NCT05945992|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Every intervention of each arm will have four components, in varying combination. For each intervention component (mindfulness, self-acceptance, resource activation, emotion regulation) there will exist a control component, when this specific component is not included in the arm.|t|f|f|f
34007175|NCT00348816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007176|NCT02244931|RANDOMIZED|CROSSOVER||||NONE||||||
34007177|NCT02492815|||COHORT||RETROSPECTIVE|||||||
34007178|NCT02146976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007179|NCT00703131|||COHORT||PROSPECTIVE|||||||
34007180|NCT00282581|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34007181|NCT02838940|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34007182|NCT02709629|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34007183|NCT00744172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007184|NCT00855127|||COHORT||PROSPECTIVE|||||||
34007185|NCT00146796|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007186|NCT05450991|||COHORT||OTHER|||||||
34007187|NCT02000323|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34007188|NCT05565261|||CASE_CONTROL||RETROSPECTIVE|||||||
34007189|NCT05758909|||COHORT||PROSPECTIVE|||||||
34007190|NCT04200625|||CASE_CONTROL||RETROSPECTIVE|||||||
34007191|NCT04194437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007192|NCT02118168|||OTHER||PROSPECTIVE|||||||
34007193|NCT05677217|||COHORT||PROSPECTIVE|||||||
33702854|NCT05695352|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This open label study will be masked by not allowing the analysis of the urine samples collected for determining the day of the follicular luteal transition (ovulation) to be known to the laboratory director and technicians.|"The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG). An n of 21 was calculated using the Log-Rank Test method and setting the Power to 80% and alpha to 0.05 to test the hypothesis that there was no difference between the survival curves for the placebo and drug-treated cycles."|f|f|f|t
34007194|NCT06325280|||CASE_ONLY||PROSPECTIVE|||||||
33702855|NCT01193530|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34007195|NCT06298214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007196|NCT01723150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007197|NCT00588731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007198|NCT03980210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007199|NCT04336384|||COHORT||PROSPECTIVE|||||||
34007200|NCT03293888|||CASE_ONLY||PROSPECTIVE|||||||
34007201|NCT01675284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34007202|NCT04079582|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007203|NCT06615804|NA|SINGLE_GROUP||SCREENING||NONE||Treatment resistant depression patient group will be evaluated before and after Transcranial Magnetic stimulation (TMS) treatment. There is a control group consist of healthy participants that will be only evaluated for ophthalmologic measurements.||||
34007204|NCT00346164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007205|NCT05220891|||COHORT||PROSPECTIVE|||||||
34092407|NCT02465970|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34007206|NCT03297619|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two active self-help interventions for the duration of the study.||||
34092408|NCT04109963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed masked to treatment assignment. Participants will be aware of treatment assignment.|Prospective, randomized, parallel arm, open-label, blinded end-point (PROBE) design.|f|f|f|t
34092409|NCT03608332|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34092410|NCT00131300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092411|NCT01567800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092412|NCT03543267|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092413|NCT02038205|||CASE_CONTROL||PROSPECTIVE|||||||
34092414|NCT00728923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007207|NCT02377388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007208|NCT01522079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007209|NCT05386056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007210|NCT05643716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007211|NCT03274037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007212|NCT01392326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007213|NCT05902468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007214|NCT01071031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34092415|NCT06529887|||OTHER||PROSPECTIVE|||||||
34092416|NCT00310518|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34092417|NCT05118269|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Subjects will be randomized in a 1:1 ratio between treatment group and control group. Subjects randomized to the Control Group may be allowed to cross over to the treatment group and offered the InterVapor treatment at 12 months, once they have completed the protocol defined follow-up period.|f|f|f|t
34092418|NCT03729440|||CASE_CROSSOVER||PROSPECTIVE|||||||
34092419|NCT05309850|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants get access to the tool or get assigned to a control group without access||||
34092420|NCT02323815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092421|NCT00992836|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34092422|NCT02562885|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092423|NCT00078494||||TREATMENT||||||||
34007215|NCT00074750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007216|NCT06429514|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with depressive symptoms after papillary thyroid carcinoma surgery 300 cases ; there were 200 cases in the experimental group and 100 cases in the control group. From the first day after enrollment, the subjects were given 4 g of the test drug ( Ganoderma lucidum spore powder or placebo ) every day for 90 days.||||
34007217|NCT05305131|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a single-centre, open label, randomised phase II study of induction cisplatin and gemcitabine with or without bevacizumab in patients with locally advanced or metastatic NPC. 50 Eligible patients will be randomised 1:1 into either of the two study arms: induction chemotherapy cisplatin and gemcitabine, or induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.||||
34007218|NCT02147587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007219|NCT05331391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor did not aware of which groups the patients belongs to.|"The Experimental group will receive a brief SMART Exercise individual face-to-face session, and a package of information on lifestyle-integrated exercise and physical activity delivered through instant messaging and telephone calls.~The Control group will receive a face-to-face individual session on general hygiene (GH) information, and a package of information on GH delivered through instant messaging and telephone calls."|f|f|f|t
34007220|NCT01396954|||COHORT||PROSPECTIVE|||||||
34007221|NCT00810862|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34092424|NCT01327703|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092425|NCT04215770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single blinded clinical trial|t|f|f|f
34092426|NCT02260622|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092427|NCT01571739|||||PROSPECTIVE|||||||
34092428|NCT05714332|||COHORT||PROSPECTIVE|||||||
33702856|NCT01118481|||OTHER||PROSPECTIVE|||||||
33702857|NCT01823302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702858|NCT01907243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702859|NCT01446315|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702860|NCT04712383|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702861|NCT01198678|NA|SINGLE_GROUP||||NONE||||||
33702862|NCT05114070|||COHORT||RETROSPECTIVE|||||||
33702863|NCT01133873|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33702864|NCT05763095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702865|NCT02352129|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33788626|NCT01626274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788627|NCT01565928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788628|NCT04642261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo pills will be manufactured in identical appearance to the study drug (empagliflozin)|Eligible subjects will be randomly allocated to either the empagliflozin group or placebo group (i.e. control group)|t|t|t|t
33788629|NCT00988286|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788630|NCT06492889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33788631|NCT03603418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788632|NCT03973424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788633|NCT03706963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788634|NCT03172208|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33788635|NCT00603538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928109|NCT05968625|RANDOMIZED|PARALLEL||SCREENING||SINGLE|"This is a single-blinded study, where the statistician that analyzes the data is blinded. The subjects are impossible to blind due to subtle differences in the physical appearance of both appliances.~Blinding of the operator will not be possible due to the differences in clinical procedures involved in fabrication of TFR and 3DPR."|Direct 3D-printed retainers|f|f|f|t
33928110|NCT00639262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928111|NCT02149472|||COHORT||PROSPECTIVE|||||||
33928112|NCT05851092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928113|NCT00244777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928114|NCT01661946|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33928115|NCT03907592|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33928116|NCT06240624|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928117|NCT04786730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928118|NCT05191849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928119|NCT02613091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928120|NCT02137707|||CASE_ONLY||PROSPECTIVE|||||||
33928121|NCT05254652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788636|NCT02410291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33788637|NCT02186405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788638|NCT05483374|||COHORT||PROSPECTIVE|||||||
33788639|NCT03679962|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33788640|NCT06630728|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33788641|NCT00281918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928122|NCT01712776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928123|NCT03947255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928124|NCT01912911|||CASE_ONLY||PROSPECTIVE|||||||
33928125|NCT05924126|||OTHER||RETROSPECTIVE|||||||
33928126|NCT01570205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928127|NCT06423872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928128|NCT01886404|||OTHER||CROSS_SECTIONAL|||||||
33928129|NCT01002898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928130|NCT02517268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928131|NCT01985165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928132|NCT00519168|||CASE_CONTROL||PROSPECTIVE|||||||
33928133|NCT01324128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928134|NCT02873208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928135|NCT06481020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33928136|NCT06082375|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928137|NCT03532724|||COHORT||RETROSPECTIVE|||||||
33928138|NCT01210755|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33928139|NCT01582958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928140|NCT06094114|||COHORT||PROSPECTIVE|||||||
33928141|NCT00095719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928142|NCT03255304|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33928143|NCT00162708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928144|NCT02438761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928145|NCT02291445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33928146|NCT06206707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a double-blind, placebo controlled, randomised trial|t|f|t|f
33702866|NCT03606512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702867|NCT01594671|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702868|NCT02385682|||COHORT||PROSPECTIVE|||||||
33702869|NCT04397601|||COHORT||PROSPECTIVE|||||||
33928147|NCT04511988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928148|NCT04019392|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A 2 x 4 repeated measures design to determine decreases in triceps surae intramuscular tissue temperature will be used for this study. The independent variables will be the cryotherapy modalities (Game Ready® and wetted ice bag with elastic wrap) and time (baseline, 10 minutes, 20 minutes, and 30 minutes). The dependent variable will be the medial triceps surae intramuscular tissue temperature.||||
33928149|NCT05286567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928150|NCT04425460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multi-center, randomized, double-blind, placebo-controlled (1:1) clinical study to explore the efficacy and safety of Favipiravir|t|f|t|f
33928151|NCT04825249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Whereas patients and surgeons were aware of the group assignments, the outcome assessors and data analysts were remained blinded during the study period.||f|f|f|t
33928152|NCT00442182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702870|NCT03585231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702871|NCT06069908|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|Participants will be randomly divided into three groups. Subjects will be instructed to draw an envelope from a secret box. Each envelope will contain a yellow, red and blue card and they will be assigned to one of the 3 groups of the study accordingly. Only the Complex Decongestive Treatment (manual lymph drainage, skin care, special exercises, compression) approach will be applied to the first group, Complex Decongestive Treatment and sham transcutaneous vagus nerve stimulation to the second group, and transcutaneous vagus nerve stimulation in addition to Complex Decongestive Treatment to the third group. The third party who has access to the box containing the envelopes will not be involved in the study.|Demographic data related to the patient will be questioned with the Demographic Data and Anamnesis form prepared by the researchers. Circumference measurement was determined as the primary outcome measure, and gross grip strength, dexterity and quality of life were determined as the secondary outcome measures. To this end; Patients' upper extremity circumference was measured with a tape measure, gross grip strength was measured with Jamar Dynanometer, manual dexterity was measured with 9-Hole Peg Test, upper extremity problems were measured with Arm, Shoulder and Hand Problems Quick Questionnaire (Quick DASH), items related to people's quality of life and specific arm symptoms were measured. Lymphedema Functionality will be evaluated with the Disability and Health Survey (LFÖSA) and quality of life will be evaluated with the Quality of Life Questionnaire in Upper Extremity Lymphedema Patients (ULL-27).|t|t|f|t
33702872|NCT01139983|||CASE_CONTROL||RETROSPECTIVE|||||||
33702873|NCT00762229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702874|NCT02170493|||COHORT||PROSPECTIVE|||||||
33720442|NCT05034770|||CASE_CONTROL||RETROSPECTIVE|||||||
33720443|NCT05358171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33720444|NCT04249037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720445|NCT02116400|||COHORT||CROSS_SECTIONAL|||||||
33720446|NCT02962804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720447|NCT01141439|||COHORT||RETROSPECTIVE|||||||
33720448|NCT03130842|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720449|NCT05634460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720450|NCT01037608|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33788642|NCT04527614|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33788643|NCT05349097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788644|NCT04720599|||COHORT||PROSPECTIVE|||||||
33788645|NCT05198089|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33788646|NCT02997618|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33788647|NCT03879642|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized control pilot using a waitlist control group||||
33788648|NCT05542953|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788649|NCT00580801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788650|NCT03199417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized using a random number generator to either intervention. Interventions will be identically packaged and labeled either A or B by a pharmacist who will be uninvolved with the trial administration. Participants and study personnel will be blinded to the treatment groups.|Single center blinded randomized controlled trial with a random number generator determining the allocation of patients to either the placebo or intervention groups.|t|t|t|t
33788651|NCT03152149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788652|NCT03298464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788653|NCT06629116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788654|NCT04408287|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed study will deliver an online physical activity program to persons with SCI across Ontario through the WebEx platform at Parkwood Institute. Participants will be recruited from across Ontario through SCI rehabilitation centers and established service providers. Strategic advertising through community partners such as Spinal Cord Injury Ontario, Canadian SCI Alliance and Ontario Neurotrauma Foundation will also be conducted. Study participants will include those with a spinal cord injury that have completed rehabilitation and are living in the community. Participants must have some upper limb function permitting arm movement against gravity. All participants must have physician clearance to participate in the study.||||
33788655|NCT03256344|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33928153|NCT03357770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928154|NCT01528995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928155|NCT02593461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788656|NCT02485834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788657|NCT00006204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788658|NCT00438555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928156|NCT05276427|||OTHER||CROSS_SECTIONAL|||||||
33928157|NCT04785937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928158|NCT00661284|||CASE_ONLY||PROSPECTIVE|||||||
33928159|NCT02378493|||CASE_CONTROL||PROSPECTIVE|||||||
33928160|NCT01400139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928161|NCT05677529|||COHORT||CROSS_SECTIONAL|||||||
33928162|NCT00334698|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33928163|NCT00074867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928164|NCT04192760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007222|NCT02668042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007223|NCT01944384|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34007224|NCT04233138|NA|SINGLE_GROUP||PREVENTION||NONE||Participants enrolling in the study have access to the online platform for 12 months (6 months with reminders, 6 months no reminders).||||
34025229|NCT01449812|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025230|NCT06633653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025231|NCT02720874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025232|NCT04799301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34025233|NCT01045538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025234|NCT03006302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025235|NCT02712580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025236|NCT01258712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025237|NCT04562155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025238|NCT05996562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928165|NCT02920450|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33928166|NCT00926666|NON_RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33928167|NCT01301755|||CASE_ONLY||PROSPECTIVE|||||||
33928168|NCT03177746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928169|NCT01802541|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33928170|NCT06348758|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33928171|NCT02046382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34007225|NCT03514186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the nature of the intervention, neither the treating SLPs nor the subjects can be masked regarding the scheduling of treatment. To minimize outcome ascertainment bias, an evaluator (testing speech-language pathologist) who is not directly associated with the daily activities of the trial and, therefore, blind to the treatment arm will administer and score all the assessments. Subjects will be introduced to the treatment arm to which they have been assigned with a script that emphasizes similar expectations from the intervention, regardless of the treatment group. This will reduce subject bias resulting from such beliefs that one of the therapies is less effective.|Both treatment arms will provide 60 hours of comprehensive aphasia therapy. In the ICAP arm, the 60 hours of treatment will be applied intensively, 4 hours per day, 5 days a week for three weeks. In the Distributed Treatment arm, the 60 hours of comprehensive treatment will be distributed over 15 weeks (i.e. two 2-hour visits per week).|f|f|f|t
34007226|NCT03747185|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The assessor and investigator will be blinded to the random order. This process will be handled by the research manager.|Participants will be randomly assigned to either stretching exercise with lumbopelvic stiffening technique or lumbopelvic relaxing technique. They will be provided a 2-day wash-out period. Then, participants will cross-over to another technique.|f|f|t|t
34007227|NCT04843618|||OTHER||CROSS_SECTIONAL|||||||
34007228|NCT02220595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007229|NCT03474809|||COHORT||RETROSPECTIVE|||||||
34007230|NCT00458107|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34007231|NCT01676129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007232|NCT05657106|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Type 1 hybrid effectiveness study involving a community-level, controlled quasi-experimental trial and a mixed methods evaluation of implementation outcomes.||||
34007233|NCT05927142|NA|SEQUENTIAL||OTHER||NONE||Exploratory, non-randomized, open-label, single center, phase I-II study||||
34007234|NCT03206567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind study||t|t|t|f
34007235|NCT00739973|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34007236|NCT00611325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007237|NCT06411015|||OTHER||PROSPECTIVE|||||||
34007238|NCT06222593|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal||||
34007239|NCT04813562|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34007240|NCT06613061|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34007241|NCT05310045|||OTHER||PROSPECTIVE|||||||
34007242|NCT00136760|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34007243|NCT05942976|||COHORT||CROSS_SECTIONAL|||||||
34007244|NCT04475276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and the physician will be blinded|A randomized, parallel design placebo-controlled clinical trial|t|t|f|f
34007245|NCT03643926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007246|NCT05042440|NA|SEQUENTIAL||TREATMENT||NONE||||||
34007247|NCT02136238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092429|NCT05621473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092430|NCT01671059|||COHORT||PROSPECTIVE|||||||
34092431|NCT06551493|||OTHER||PROSPECTIVE|||||||
34092432|NCT04227717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092433|NCT01275027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092434|NCT04700605|||OTHER||CROSS_SECTIONAL|||||||
34092435|NCT03476642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||This will be a randomized,double blinded, controlled study.|t|t|t|t
34092436|NCT06471803|||COHORT||PROSPECTIVE|||||||
34092437|NCT02406612|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33788659|NCT00065390||||TREATMENT||||||||
33788660|NCT02165891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788661|NCT03646669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33928172|NCT03771495|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33928173|NCT03725449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928174|NCT03336060|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928175|NCT01452724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928176|NCT03465046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928177|NCT02563925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928178|NCT01464814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33928179|NCT05663476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three arm clinical trial||||
33788662|NCT04066751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788663|NCT02710968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788664|NCT05553145|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788665|NCT00000456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801685|NCT04967742|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928180|NCT02450500|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33928181|NCT02155244|||COHORT||RETROSPECTIVE|||||||
33928182|NCT04322240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928183|NCT02686892|||COHORT||OTHER|||||||
33928184|NCT02318745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928185|NCT04016987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928186|NCT05184127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928187|NCT00843557|||COHORT||PROSPECTIVE|||||||
33928188|NCT04301193|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092438|NCT04876183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded about the two conditions of the study and told that the assigned waiting time for the web-based intervention varies randomly. Therefore, participants in the control group do not know that the other group starts the intervention immediately. However, complete masking of participants is precluded as all subjects are aware of when they get access to the intervention.|Randomized controlled trial with an intervention group and a waiting list control group|f|t|t|t
34092439|NCT02666248|||COHORT||PROSPECTIVE|||||||
33788666|NCT06631664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator was blinded to the interventions|A prospective single-blind randomized clinical trial|f|f|t|f
33788667|NCT04362501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blind randomized placebo controlled|t|t|t|t
33788668|NCT05025124|||CASE_ONLY||CROSS_SECTIONAL|||||||
33788669|NCT04559724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788670|NCT04103736|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33788671|NCT04002128|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|Postoperative outcomes were registered by doctor who did not know type of anesthesia delivered|To investigate whether productive cough, dyspnea and hoarseness were different between two groups of patients. Group Air received sevoflurane anesthesia with 35% O2 in air, and Group N2O received sevoflurane anesthesia with 35% O2 in N2O|t|t|f|t
33788672|NCT01645111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788673|NCT01556256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33801686|NCT04093752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801687|NCT01777373|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092440|NCT05051839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34092441|NCT04951960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants, their legal representatives, and outcomes assessor are blinded.||t|f|f|t
34092442|NCT02788045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702875|NCT03116360|NA|SINGLE_GROUP||SCREENING||NONE|Subjects will be required to have already undergone the initial step of the traditional diagnostic algorithm with x-ray of the suspicious region. All subjects will then be scheduled to undergo diagnostic ultrasound at a separate appointment with ultrasound procedure performed by a blinded clinical physician. All patients will then undergo a confirmatory MRI of the region of concern. A statistician in the Department of Public Health at the University of Virginia will be performing statistical analysis. All x-ray and MRI obtained for this study will be read by a Radiologist board certified in Musculoskeletal Radiology. Diagnostic ultrasound performance: The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam.|Subjects suspected to have an acute stress fracture of the lower extremity will be recruited. Subjects will be required to have already undergone the initial step of the traditional diagnostic algorithm with x-ray as part of clinical care of the suspicious region on the day of enrollment. A physical exam and vital signs will be obtained as part of standard clinical care. All subjects will then be scheduled to undergo diagnostic ultrasound for research purposes at a separate appointment with ultrasound procedure performed by a blinded clinical physician boarded in Physical Medicine and Rehabilitation, competent in performing and reading diagnostic ultrasound. All subjects will then undergo a confirmatory MRI without contrast of the region of concern. The MRI may be ordered as part of clinical care or for research if not required for clinical purposes. MRI screening per standard processes will be done by the MRI staff.||||
33702876|NCT05602142|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Disease group and healthy controls will receive the same drug||||
33702877|NCT04262570|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33702878|NCT06558396|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||All participants enter a control phase for 12 weeks where they receive no intervention. After 12 weeks, the same group of participants receive the ACE intervention.||||
33702879|NCT04462770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients are randomized 1:1 to EPX-100 or placebo.|t|t|t|f
33702880|NCT00148161|||DEFINED_POPULATION||OTHER|||||||
33702881|NCT06428422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702882|NCT05108285|||COHORT||PROSPECTIVE|||||||
33801688|NCT02510690|||COHORT||RETROSPECTIVE|||||||
33801689|NCT06290882|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34007248|NCT04679142|||OTHER||PROSPECTIVE|||||||
34007249|NCT00521482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007250|NCT00193973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007251|NCT03700827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007252|NCT05507034|||COHORT||PROSPECTIVE|||||||
34007253|NCT03261024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007254|NCT03739216|||OTHER||PROSPECTIVE|||||||
34007255|NCT04030013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34007256|NCT00440609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007257|NCT02037282|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34007258|NCT05247333|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34007259|NCT00476593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007260|NCT06462131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007261|NCT01709812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007262|NCT04783194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007263|NCT01575262|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34007264|NCT06600750|||COHORT||RETROSPECTIVE|||||||
34007265|NCT06167473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Before enrollment, all patients and/or their relatives will be informed about the study protocol, and sign the written informed consent forms. Eligible patients are randomly assigned at a ratio of 1:1 to low-dose stem cell group (1×10\^6cells/kg per infusion) and a medium-high-dose stem cell group (3×10\^6cells/kg per infusion).|t|f|f|f
34007266|NCT05992987|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34007267|NCT01102452|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34007268|NCT04686994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment 3:1 ratio|t|t|t|f
34007269|NCT01453153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007270|NCT00672776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34007271|NCT01332721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007272|NCT04880226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007273|NCT05371639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007274|NCT04046549|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34007275|NCT06318871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007276|NCT06490887|||OTHER||PROSPECTIVE|||||||
34007277|NCT03756883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007278|NCT03684681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007279|NCT05922631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants are blinded to accept APRV or LTV after inclusion.|Patients with ARDS who met the inclusion criteria were randomized to APRV or LTV mechanical ventilation. Ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate. For LTV mechanical ventilation, ARDSnet method was used to set the tidal volume according to 4-8ml/kg, so that Pplat\<30cmH2O|t|f|f|f
34007280|NCT02315261|||COHORT||PROSPECTIVE|||||||
34007281|NCT00412204|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34007282|NCT04372719|NA|SINGLE_GROUP||OTHER||NONE||single group||||
34007283|NCT02330952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007284|NCT02427087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34007285|NCT02390310|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007286|NCT04888949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007287|NCT03230734|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34007288|NCT04270006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007289|NCT01978652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007290|NCT05725902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007291|NCT03314363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007292|NCT03788915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34092443|NCT00471042|||OTHER||PROSPECTIVE|||||||
34092444|NCT03782597|||FAMILY_BASED||PROSPECTIVE|||||||
34092445|NCT00116909||||TREATMENT||||||||
34092446|NCT01214720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092447|NCT02558751|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092448|NCT03422809|||COHORT||PROSPECTIVE|||||||
34007293|NCT01118117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007294|NCT03908528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Double-blind study, Patients will be classified as follow:~* Group one: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus placebo.~* Group two: 32 patients will receive four cycles of AC followed by weekly taxol for 12 weeks plus oral 600 mg alpha lipoic acid (ALA) once daily."|t|f|t|f
34007295|NCT04210349|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Open-label (single arm for early safety review) in step 1. Modified double-blind in step 2 with an unblinded administrator used at each trial site. The administrator will not be involved in any of the blinded study assessments (e.g., safety).||t|f|t|t
34007296|NCT03529565|||COHORT||PROSPECTIVE|||||||
34007297|NCT02593344|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007298|NCT04110509|||CASE_ONLY||PROSPECTIVE|||||||
34007299|NCT04874896|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single-center, randomized, intervention pilot study with a sample size of 50 patients (25 patients in intervention group who will receive gut microbiota autotransplantation and 25 group in control group without intervention) for a follow-up time of 6 months||||
34007300|NCT05628441|||COHORT||PROSPECTIVE|||||||
34007301|NCT04455971|||COHORT||PROSPECTIVE|||||||
34007302|NCT02865941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007303|NCT00931463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092449|NCT00466219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092450|NCT05838599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092451|NCT04058405|||OTHER||RETROSPECTIVE|||||||
34092452|NCT00635284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092453|NCT01019551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092454|NCT02451878|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34092455|NCT05943704|NA|SINGLE_GROUP||SCREENING||NONE||||||
34092456|NCT03415880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator measuring the outcome measures will be blinded to patient allocation. Patients are asked not to mention their allocated group or the programme they follow and not to wear or mention the wrist-worn activity tracker during measurements.|The study consists of an intervention group and a control group. Both arms run parallel and both groups are measured at the same time points.|f|f|t|f
34092457|NCT01603914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092458|NCT02314429|NA|SINGLE_GROUP||||NONE||||||
34092459|NCT01290250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34092460|NCT03927391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor does not know the treatment arm|Normal enzalutamide dose versus reduced dose in two patient groups|f|f|f|t
34092461|NCT05074147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092462|NCT00176332|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34092463|NCT02709369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092464|NCT05367830|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34092465|NCT05891444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092466|NCT04268511|||OTHER||PROSPECTIVE|||||||
34092467|NCT01751685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092468|NCT02960906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092469|NCT05855187|RANDOMIZED|CROSSOVER||OTHER||NONE||Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study||||
34092470|NCT01525771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702883|NCT05964387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subject, care provider/outcomes assessor, and investigator will be blinded to which arm the tooth is randomized.|Subjects randomized for application of 38% silver diamine fluoride or placebo on hypomineralized permanent molar two weeks before operative dentistry.|t|t|t|t
33702884|NCT05542160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702885|NCT01752985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702886|NCT00907231|||COHORT||PROSPECTIVE|||||||
34007304|NCT01869426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007305|NCT00921284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007306|NCT03775941|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33702887|NCT04926142|||COHORT||PROSPECTIVE|||||||
33702888|NCT03146377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702889|NCT01593085|||COHORT||PROSPECTIVE|||||||
33702890|NCT03777488|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33702891|NCT04835480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007307|NCT00682552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007308|NCT00537199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007309|NCT02875041|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34007310|NCT01469507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007311|NCT05436132|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007312|NCT02409940|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007313|NCT03400917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007314|NCT00755378|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34092471|NCT02622685|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34092472|NCT02441283|NA|SINGLE_GROUP||OTHER||NONE||||||
34092473|NCT01225744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928189|NCT00829660|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928190|NCT04344704|||OTHER||PROSPECTIVE|||||||
33928191|NCT04606368|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, non-randomized, interventional cohort study||||
33928192|NCT04242459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will commence with a Feasibility Radiotherapy planning CT study consisting of 13 participants, then will recruit to the the main phase I/II interventional study consisting of 3 independent cohorts.||||
34007315|NCT02663882|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007316|NCT05505305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025239|NCT00734396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025240|NCT04286451|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
34025241|NCT01484327|||OTHER||PROSPECTIVE|||||||
34025242|NCT01288144|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34025243|NCT00933361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025244|NCT00292058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702892|NCT06246929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33702893|NCT01223131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702894|NCT04321070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702895|NCT05929157|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Phase I monocentric clinical trial with a two-armed crossover design||||
33702896|NCT02467075|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33702897|NCT05613361|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702898|NCT04753528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928193|NCT01688999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928194|NCT05409846|||OTHER||CROSS_SECTIONAL|||||||
33928195|NCT02477306|RANDOMIZED|CROSSOVER||||NONE||||||
33928196|NCT03955055|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33928197|NCT05688293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient won't know the type of the procedures done to him The outcome assessor won't know which group he the is assessing it's results|Three parallel groups|t|f|f|t
33928198|NCT04816045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients and investigators are blinded. The allocation list is located at the pharmacy.||t|t|t|t
33928199|NCT04085042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33928200|NCT02314598|||COHORT||PROSPECTIVE|||||||
33928201|NCT01117025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702899|NCT05106517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702900|NCT03889574|||COHORT||RETROSPECTIVE|||||||
33702901|NCT00082979||||DIAGNOSTIC||||||||
33702902|NCT01334346|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702903|NCT02789995|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33702904|NCT03530969|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33702905|NCT03614364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702906|NCT00194948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702907|NCT05164796|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33702908|NCT05289427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702909|NCT03892187|RANDOMIZED|PARALLEL||OTHER||NONE||We will randomize patients in a 1:1 fashion into intervention and control groups using a prespecified table generated by our study statistician. Patients not considered frail||||
33702910|NCT00806351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702911|NCT06378580|||CASE_CONTROL||RETROSPECTIVE|||||||
33702912|NCT05084131|||COHORT||PROSPECTIVE|||||||
33702913|NCT06326385|||COHORT||RETROSPECTIVE|||||||
33702914|NCT00018031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702915|NCT01348672|||COHORT||PROSPECTIVE|||||||
33702916|NCT00989105||||DIAGNOSTIC||NONE||||||
33702917|NCT03722823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702918|NCT00763711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702919|NCT00113503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702920|NCT06556797|||COHORT||PROSPECTIVE|||||||
33702921|NCT02055833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702922|NCT04905888|RANDOMIZED|PARALLEL||TREATMENT||NONE||hbo||||
33702923|NCT03385512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patient and health care team participants and the clinics in which they practice will be randomly assigned to one of three groups for the duration of their participation in the study: 1) OPEN High Tech, 2) OPEN High Touch and 3) ASK. Unit of randomization is clinic. Physicians will be clustered in clinics and patients clustered within physicians.||||
33788674|NCT03460574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator randomly assigns participants to one of the experimental conditions. Participants are not aware which experimental condition they are allocated to.|Parallel Assignment Participants are assigned to one of four experimental groups in parallel for the duration of the study|f|f|t|f
33788675|NCT03631199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788676|NCT03171896|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788677|NCT03564626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788678|NCT02762318|||FAMILY_BASED||PROSPECTIVE|||||||
33702924|NCT01480089|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702925|NCT02987556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Closed loop vs. Open loop,||||
33702926|NCT04419675|||COHORT||PROSPECTIVE|||||||
33702927|NCT01030536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702928|NCT00691301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702929|NCT05274737|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, controlled model||||
33702930|NCT02399371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702931|NCT00809393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33702932|NCT01228643|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33702933|NCT00969696|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33702934|NCT04367233|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"A professional who will not participate in other stages of the study will conduct the drawing and envelopes preparation.~Masking: at the end of the surgery, the anesthesiologist will perform the blocking corresponding to the patient's group and will not participate in other stages of the study. A professional who does not know the group to which each patient belongs will perform the collection and analysis of the endpoint variables."|Prospective, controlled, randomized and double blinded.|t|t|t|t
33702935|NCT02004522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33082518|NCT05848726|||OTHER||RETROSPECTIVE|||||||
33702936|NCT05000281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702937|NCT03056404|NA|SINGLE_GROUP||OTHER||NONE||||||
33702938|NCT01321307|||CASE_CONTROL||PROSPECTIVE|||||||
33702939|NCT01393301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For formative stage of the study, no masking was used as that phase was an open pilot. Outcomes assessor masked during the pilot RCT.||f|f|f|t
33788679|NCT04204837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788680|NCT03492632|||CASE_CONTROL||PROSPECTIVE|||||||
33702940|NCT01853423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702941|NCT02536560|||COHORT||PROSPECTIVE|||||||
33702942|NCT03062982|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33702943|NCT03195764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788681|NCT02454205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801690|NCT02544880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801691|NCT03159273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33928202|NCT04107428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized double-blinded placebo-controlled trial|t|t|t|t
33928203|NCT03487315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928204|NCT02944513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928205|NCT00371540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33928206|NCT01659359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928207|NCT02951897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928208|NCT02732249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928209|NCT04581798|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928210|NCT02693691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928211|NCT05825989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33928212|NCT02839811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928213|NCT00513994||CROSSOVER||TREATMENT||NONE||||||
33928214|NCT03345992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients assigned to either intravenous clarithromycin or placebo|t|t|t|t
33928215|NCT02251171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928216|NCT03437629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928217|NCT02244008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092474|NCT01710085|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33702944|NCT05487846|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33702945|NCT05023629|NA|SINGLE_GROUP||OTHER||NONE||A single-center, single-arm, prospective study||||
33702946|NCT02061774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702947|NCT06557941|||CASE_CONTROL||PROSPECTIVE|||||||
33702948|NCT06081712|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33702949|NCT02654314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33702950|NCT03317340|||COHORT||PROSPECTIVE|||||||
33702951|NCT00242216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702952|NCT00154622|NON_RANDOMIZED|PARALLEL||||NONE||||||
33702953|NCT00293215|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33702954|NCT04966832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this double-blind study, participants will be randomized to XW10508 or placebo.|t|f|t|f
33702955|NCT00124228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702956|NCT00933738|||CASE_ONLY||PROSPECTIVE|||||||
33702957|NCT04883229|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
33928218|NCT06238011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial was conduct between January2024 and March2024 at Sawanpracharak hospital, Thailand, Of 60 patients undergoing elective CABG surgery, 30 were assigned to group dexmedetomidine and 30 to group control. Dexmedetomidine prepared by nurse anesthetist in contraction 0.1mcg/kg/ml total volume 50 ml. Loading 60ml/hour in 10 minutes before induction of anesthesia then 5ml/hour until on cardiopulmonary bypass (1mcg/kg in 10 min then 0.5mcg/kg/hour). Group control received normal saline 60ml/hour in 10 minutes then 5ml/hour|f|f|t|f
33928219|NCT02533856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928220|NCT04319640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant blind|1:1 parallel randomized controlled trial|t|f|f|f
33928221|NCT00195481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007317|NCT05678738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants who opt-in for antioxidant berry supplementation will be randomly assigned to either the group receiving the bioactive ingredient (berry fruit juice) or the placebo group. Both groups will receive 300mL to consume every morning and afternoon during participation.|Participants will consist of both male and female subjects who will be exposed to similar bouts of exertional heat stress. Analysis will be completed to assess for potential sex-based differences in outcomes measured (male vs. female). Participants (both male and female) who opt-in for antioxidant berry supplementation will be assigned to a subgroup parallel study model where subjects will be exposed to similar bouts of exertional heat stress while consuming either the antioxidant or placebo supplement.|t|f|t|f
34007318|NCT04004845|||CASE_ONLY||PROSPECTIVE|||||||
34007319|NCT04584996|||CASE_CONTROL||PROSPECTIVE|||||||
34007320|NCT06616883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007321|NCT01235715|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34007322|NCT03176433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007323|NCT02123420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007324|NCT00603564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007325|NCT04676880|RANDOMIZED|PARALLEL||PREVENTION||NONE||This trial is set-up as an open-label, national multicentre, superiority randomized controlled trial where patients will be randomized in a 2:1 fashion to the device arm or the usual care arm.||||
34007326|NCT06208423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The grading of responses will be performed by assessors blinded to participant identity and treatment assignment.|The trial will be designed as a randomized, two-arm, single-blind parallel group study.|f|f|f|t
34025245|NCT02628327|||COHORT||PROSPECTIVE|||||||
34025246|NCT04815655|NA|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34025247|NCT02335918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928222|NCT02589743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33928223|NCT03037567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788682|NCT05821127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It was noted to which group the patient was allocated by referring to the list of random numbers created by a computer program by a researcher participating in the study. The treatment process for the intervention group and the control group was managed by the same researcher. Outcome evaluations before treatment and after 8 weeks of treatment follow-up were made by a second researcher who was blind to group distribution. The list of random numbers was hidden from the researcher making the evaluations, ensuring that the participants did not know which group they belonged to. Analysis of the data was done by a third researcher. The intervention group was coded as 'group 1' and the control group was coded as 'group 2'. With this method, it was ensured that the researcher performing the analysis did not know which group the patients belonged to. With this randomization and blinding process, the impartiality of the researchers was ensured.|A random number table containing numbers from 1 to 60 was created for 2 groups through the computer program. Participants were numbered in order of application. Participants were assigned to groups to which their numbers belonged in the table of random numbers.|f|f|f|t
33788683|NCT03332134|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788684|NCT06632158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-arm design comparing the new intervention (MindBoba) to an active control (Mindshift CBT) and business-as-usual.||||
33788685|NCT01282437|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788686|NCT04153344|||CASE_CONTROL||PROSPECTIVE|||||||
33788687|NCT04858425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788688|NCT03071497|||COHORT||PROSPECTIVE|||||||
33788689|NCT04852575|||COHORT||PROSPECTIVE|||||||
33788690|NCT02293421|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788691|NCT01155869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788692|NCT05444179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a parallel-group study design, which employed block randomization via a computer-generated randomisation list for allocation of the participants, with the block size of 8, and equal randomization ratio (1:1) between intervention and control groups. The block randomization process is conducted by an investigator that had no clinical involvement in the trial, in which the allocation sequence was concealed from the principal investigator who are enrolling and assessing the eligible participants. Due to nature of intervention, blinding of principal investigator and participants are not possible. Measurement of the outcome will commence at the baseline, at week 4 and week 8 of the randomised controlled trial.||||
33788693|NCT00268606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788694|NCT01643291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788695|NCT01972152|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33788696|NCT03067584|||FAMILY_BASED||OTHER|||||||
33788697|NCT06631859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928224|NCT01024101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928225|NCT03626480|||COHORT||PROSPECTIVE|||||||
33928226|NCT03161171|||CASE_ONLY||PROSPECTIVE|||||||
33928227|NCT04287439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33928228|NCT03419845|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm, open trial to qualitatively explore the user's experience of the Step Right Buddy after a one week pilot trial and to assess the introduction of new risks to the patient as a result of the adaptation.||||
33928229|NCT00435149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928230|NCT02024945|||COHORT||PROSPECTIVE|||||||
33928231|NCT03199742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomized to receive one of 2 forms of the mobile phone application being tested in this study: with and without personalized coaching. Among those who receive coaching, participants will receive either peer-based coaching messages, clinician-based coaching messages, or automated messages.|t|f|f|f
33928232|NCT03907813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Randomized, controlled, double blind trial|t|t|t|t
33928233|NCT05330624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928234|NCT00587834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928235|NCT01933204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928236|NCT00228410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928237|NCT00517205|||CASE_ONLY||PROSPECTIVE|||||||
33928238|NCT02281149|||CASE_ONLY||PROSPECTIVE|||||||
33928239|NCT02082028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928240|NCT03391076|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33928241|NCT04992377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928242|NCT01115517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928243|NCT00715013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928244|NCT00228189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007327|NCT06010745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The primary intervention will utilize anonymized/coded products - anonymized/coded by the manufacturer and product codes only kept by supply chain and not directly maintained by study sponsor. The clinical test site will re-code the products, so the study will actually be triple-blind.~Open-label products will be made with the active ingredients and this product will be labeled as an active - with no masking of identity to study sponsor, clinical site, or study participants."|This is a six (6) month triple-blind, randomized, placebo-controlled study in women with self-perceived hair thinning/loss, with a six (6) month open-label arm in men using only the active product that will be conducted in parallel with the intervention study in women.|t|t|t|f
34007328|NCT05306197|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34007329|NCT05040126|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic Clinical Trial||||
34007330|NCT02339090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007331|NCT03519282|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34092475|NCT03822416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will not be made aware of the participant's study status, although it may become obvious during the assessments.||f|f|f|t
34092476|NCT02071160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092477|NCT02869035|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34092478|NCT04662268|||COHORT||RETROSPECTIVE|||||||
34092479|NCT05230927|||COHORT||CROSS_SECTIONAL|||||||
34092480|NCT03823131|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33702958|NCT01005108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33702959|NCT02077478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702960|NCT00293033|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33702961|NCT05921201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33702962|NCT03359772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702963|NCT03816384|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multi-center, Randomized-Controlled-Trial||||
33702964|NCT00724932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33702965|NCT04450719|||CASE_CONTROL||RETROSPECTIVE|||||||
33702966|NCT06134752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092481|NCT05202405|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33702967|NCT03665454|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigational Drug Services, which is the investigational drug pharmacy at Hershey Medical Center, will be preparing and dispensing the drug. They will be the only party that is unblinded. Pfizer will provide placebo pills that are identical in appearance to the PF-06412562 study drug. The standard of care treatment, carbidopa/levodopa, is different in appearance to PF-06412562 and its corresponding matching placebo. In order to blind for this, Investigational Drug Services will encapsulate the carbidopa/levodopa pills. Thus, subjects may receive either an encapsulated carbidopa/levodopa pill or an empty non-active capsule, depending on the treatment arm and dosing they are scheduled to receive.|Subjects will participate in study for 2 consecutive weeks. Days 2-3 of Week 1, they will be blindly and randomly assigned to one of two treatment arms (study drug PF-06412562 or standard of care carbidopa/levodopa). Whichever treatment arm they did not receive during Week 1, they will receive during Days 2-3 of Week 2.|t|t|t|t
33702968|NCT02917850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33702969|NCT00699764|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702970|NCT05821400|||COHORT||PROSPECTIVE|||||||
33702971|NCT06450353|||COHORT||PROSPECTIVE|||||||
33702972|NCT05481606|||COHORT||PROSPECTIVE|||||||
33702973|NCT05781620|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind, matched-pair study design|An independent samples and dose titration design will be used to assign participants to the experimental group or placebo group.|t|f|t|f
33702974|NCT04680091|RANDOMIZED|PARALLEL||TREATMENT||NONE||To observe the effect of efavirenz on the pharmacokinetics of pyrotinib and to evaluate the safety of pyrotinib, efavirenz and their coadministration in Chinese healthy subjects. The subjects will take pyrotinib at first single dose, then washout period, and take it at second single dose after multiple administration of efavirenz to get a full induction condition.||||
33702975|NCT03619278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo||t|t|t|f
33702976|NCT05073601|||CASE_CONTROL||PROSPECTIVE|||||||
33702977|NCT02639767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702978|NCT05922111|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be an open-label,1:1, randomized controlled trial.||||
33702979|NCT00570765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702980|NCT04528732|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adolescents will be randomly assigned to one of three study arms: 1) Usual care to receive the currently implemented usual care addressing HIV/AIDS-associated stigma (educational materials from the Ugandan Ministry of Health); 2) G-CBT intervention + Usual care; and 3) MFG intervention + Usual care.||||
33702981|NCT00434954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702982|NCT05669209|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33788698|NCT06138951|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33788699|NCT01769781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788700|NCT01523717|||CASE_ONLY||PROSPECTIVE|||||||
33788701|NCT06629922|||CASE_CONTROL||PROSPECTIVE|||||||
33788702|NCT00514280|||||OTHER|||||||
33788703|NCT06713213|NA|SINGLE_GROUP||OTHER||NONE||"INTERVENTIONS:~* RIP belts will be calibrated and outfitted on participants chests during each visit. RIP belts will be stored on-site and will be calibrated and outfitted by a designated member of the study~* FRNDS cannulas will be placed inside nasal cavity, identical to clinical practices. FRNDS cannulas will be transported between the two sites according to participant enrollment~* Digital calipers to measure both vertical and horizontal dimensions of the nasal cavity 1cm from the opening. Calipers will be appropriately cleaned before and after each use."||||
33788704|NCT06631040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788705|NCT03526835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788706|NCT01494662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788707|NCT02842658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33788708|NCT02389192|NA|SINGLE_GROUP||OTHER||NONE||||||
33788709|NCT03523091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 arm parallel study with 1 to 1 randomization|t|f|f|f
33788710|NCT06106659|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33702983|NCT03094429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33702984|NCT04125888|||COHORT||RETROSPECTIVE|||||||
33702985|NCT03734575|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33702986|NCT04377984|||OTHER||PROSPECTIVE|||||||
33702987|NCT06535425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702988|NCT05490784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||total 26 participants will be randomly assigned to experimental group (Lee Silverman Voice Treatment BIG along with conventional therapy) and control group( conventional treatment)|f|f|f|t
33702989|NCT03485391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33702990|NCT00313300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33702991|NCT00298584|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33702992|NCT00908973|||CASE_CONTROL||PROSPECTIVE|||||||
33702993|NCT00277615|||||PROSPECTIVE|||||||
33702994|NCT02866916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33702995|NCT01760720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702996|NCT00191269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33702997|NCT00366132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788711|NCT00404794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788712|NCT00768066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092482|NCT02979288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34092483|NCT00555191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092484|NCT02181738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928245|NCT00261794|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33928246|NCT02009930|||OTHER||CROSS_SECTIONAL|||||||
33928247|NCT03494023|||COHORT||PROSPECTIVE|||||||
33928248|NCT02283918|||COHORT||PROSPECTIVE|||||||
33928249|NCT03994276|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Cross-over design: Each participant will receive a control plus 2 treatments|t|f|t|f
33928250|NCT05796349|||CASE_CONTROL||PROSPECTIVE|||||||
34092485|NCT03259308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092486|NCT06214715|||COHORT||PROSPECTIVE|||||||
33928251|NCT01989572|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33928252|NCT03975712|||COHORT||RETROSPECTIVE|||||||
33928253|NCT03905824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928254|NCT01499797|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928255|NCT05550389|||COHORT||PROSPECTIVE|||||||
33928256|NCT06239324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928257|NCT02121314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092487|NCT02013427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34092488|NCT02174172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092489|NCT00588224|||||PROSPECTIVE|||||||
34092490|NCT01771913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092491|NCT01614119|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34092492|NCT04339387|||COHORT||OTHER|||||||
34092493|NCT02927483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092494|NCT06349954|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will be randomly allocated into single-session group or two-session group.||||
34092495|NCT01590875|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092496|NCT02890186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33702998|NCT02399553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33702999|NCT03405116|||COHORT||PROSPECTIVE|||||||
33703000|NCT01602120|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703001|NCT01460017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33703002|NCT05692128|||COHORT||CROSS_SECTIONAL|||||||
33703003|NCT03816488|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will be randomized on the day of their pre-operative assessment by our department statistician using a computer-generated table, with an allocation ratio of 1:1:1 in random permuted blocks of 3 or 6. Only the pharmacist and statistician will know the allocation sequence. Concealed medications (over-encapsulated) will be provided to the RC upon confirming the allotment with a unique identification number (UIN), recorded on the patient-specific case record form (CRF).|Parallel, placebo-controlled trial with block randomization|t|t|t|t
33928258|NCT02019498|RANDOMIZED|PARALLEL||||NONE||||||
33928259|NCT00334204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928260|NCT05912036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||CRT involves the completion by patients of a series of tasks on a computer while a trained facilitator engages them in a discussion about the tasks. Patients are encouraged to verbalize their process and to do self-check-ins to gauge their performance|t|f|f|f
33928261|NCT05603494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092497|NCT05702268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703004|NCT03878953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703005|NCT01688518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33703006|NCT03909386|||COHORT||PROSPECTIVE|||||||
33703007|NCT01360593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703008|NCT02840955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703009|NCT02581787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703010|NCT04259320|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized clinical trial||||
33703011|NCT01062204|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703012|NCT06125561|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703013|NCT00061347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703014|NCT03832777|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single|The aim of this study is to evaluate the clinical effects of 5Hz rTMS over Dorsomedial Prefrontal Cortex on an active versus placebo modality stimulation.|t|f|f|f
33703015|NCT03803995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703016|NCT06311825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two parallel groups randomized control study||||
33703017|NCT04621630|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Part 1 blinded, Part 2 blinded, Part 3 unblinded||t|f|t|t
33703018|NCT05886504|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"prospective cohort study comparing PWID diagnosed with a psychiatric disorder (depression, psychotic disorder, suicide risk) and getting benefit from a community-based psychiatric intervention to a control group of PWID free of psychiatric disorders. They will be mainly compared in terms of HIV/HCV exposure, severity of substance disorder, quality of life, sustainability of mental health improvement.~Estimated enrolment: 600 participants (200 in the intervention group and 400 - 200 HIV-positive and 200 HIV-negative - in the control group)."||||
33703019|NCT03875339|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment via Stepped Wedge Trial Design||||
33703020|NCT00255112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703021|NCT06463834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703022|NCT05397431|||COHORT||PROSPECTIVE|||||||
33703023|NCT03605407|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33703024|NCT03913988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|Three group, randomized, controlled design||||
33703025|NCT01216423|||COHORT||PROSPECTIVE|||||||
33703026|NCT01963273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092498|NCT00444249|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092499|NCT02818257|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33703027|NCT01508598|||CASE_ONLY||CROSS_SECTIONAL|||||||
33703028|NCT01325961|NA|SINGLE_GROUP||OTHER||NONE||||||
33703029|NCT01476956|||CASE_ONLY||PROSPECTIVE|||||||
33703030|NCT04147702|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33788713|NCT01043471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788714|NCT06629571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized controlled trial||||
33788715|NCT03879967|NA|SINGLE_GROUP||TREATMENT||NONE||A group of thirteen patients were selected for lateral ridge augmentation using cortico-cancellous allogenic block with guided bone regeneration. After the first surgery a healing phase was given and then a second surgery for implant placement in these augmented sites was carried out. Post healing, the implants were prosthetically restored and followed up upto three years.||||
34007332|NCT06173596|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33928262|NCT00628225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007333|NCT02999984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007334|NCT00958802|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007335|NCT05294835|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single arm||||
33703031|NCT03484377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly allocated, using a computer generated code, to receive either anodal tDCS or sham. For sham stimulation, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session|Concurrent tDCS-MEG parallel arms single-blinded experimental design (right anodal v sham tDCS).|t|f|f|f
33703032|NCT00876057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703033|NCT00395681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33703034|NCT01586065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703035|NCT01761630|||COHORT||PROSPECTIVE|||||||
33703036|NCT03820141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703037|NCT00678093|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33703038|NCT05720208|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33703039|NCT05468060|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33703040|NCT00696800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703041|NCT00324909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703042|NCT03685123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703043|NCT06175455|||CASE_CONTROL||PROSPECTIVE|||||||
33703044|NCT02059408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703045|NCT00767962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703046|NCT03565978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703047|NCT05919589|||OTHER||OTHER|||||||
33703048|NCT03298906|NA|SINGLE_GROUP||OTHER||NONE||||||
33703049|NCT02980783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788716|NCT04977128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788717|NCT03569683|NA|SINGLE_GROUP||TREATMENT||NONE||"The patients will be equally divided into three groups. (Groups A,B\&C) All the cases will be prepared preoperatively with scaling and root planing, oral hygeine instructions, occlusal equilibration and dietary evaluation. External bevel gingivectomy will be performed wherein the inflamed gingiva will be excised and shaped.~Group A- The Surgical site will be treated with diode laser following gingivectomy procedure, immediately and on the 1st,3rd and 7th day after surgery.~Group B- Hyaluronic acid will be applied topically to the surgical site immediately after gingivectomy, tin foil would be placed and periodontal dressing given, and on the 1st,3rd and 7th day postoperatively.~Group C- Herbal gel will be applied topically and tin foil placed over which a periodontal dressing would be given immediately after the surgery and on the 1st,3rd and 7th day postoperatively."||||
33788718|NCT01183533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788719|NCT05826444|||OTHER||PROSPECTIVE|||||||
33788720|NCT02315885|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33928263|NCT04396119|||COHORT||PROSPECTIVE|||||||
33928264|NCT02719080|||COHORT||PROSPECTIVE|||||||
33928265|NCT05229419|||OTHER||CROSS_SECTIONAL|||||||
33928266|NCT03862495|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pilot Randomized Controlled Trial||||
33928267|NCT01232192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33928268|NCT02155894|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33928269|NCT00832481|RANDOMIZED|PARALLEL||||NONE||||||
33928270|NCT02232724|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928271|NCT04227210|RANDOMIZED|PARALLEL||PREVENTION||NONE||Each enrolled subject will be allocated to 1 of 2 study groups. Group 1 will receive one dosage of the investigational RSV vaccine, and Group 2 will receive a different dosage of the same vaccine.||||
33928272|NCT03714061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single blind, randomized clinical trial, controlled|t|f|f|t
33928273|NCT01776944|||CASE_ONLY||CROSS_SECTIONAL|||||||
33928274|NCT00403351|||COHORT||CROSS_SECTIONAL|||||||
33928275|NCT02882022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928276|NCT03257618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928277|NCT00499460|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33928278|NCT04677049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928279|NCT00300534|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928280|NCT01375738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928281|NCT00308984|||COHORT||PROSPECTIVE|||||||
33928282|NCT06022172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||30 people in the experimental group and 30 people in the control group, a total of 60 people will be included in the study|t|f|t|t
33928283|NCT00085345||||TREATMENT||||||||
33928284|NCT01103700|||COHORT||PROSPECTIVE|||||||
33928285|NCT03964506|NA|PARALLEL||TREATMENT||NONE||||||
34007336|NCT02142231|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34007337|NCT05270486|||CASE_CONTROL||PROSPECTIVE|||||||
34007338|NCT00487929|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007339|NCT00828022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007340|NCT05234814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants with perimenopausal insomnia were randomly divided into a control group and an observation group. Participants in the control group were treated with the traditional Chinese medicine nursing intervention of burying seeds at auricular points. And participants in the observation group were additionally treated with fire dragon pot moxibustion.|t|f|f|f
34007341|NCT04657250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007342|NCT01048463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34007343|NCT00022841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007344|NCT00472953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007345|NCT02429375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007346|NCT01879631|||CASE_ONLY||RETROSPECTIVE|||||||
33788721|NCT05129982|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|With the cumulative average method, latency estimation will be made blindly.|self-controlled study||||
33788722|NCT00079482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788723|NCT00651378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788724|NCT04517331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* All TPVB procedures were performed by the same 3 senior anesthesiology residents, always under the supervision of 2 attending anesthesiologists (1 senior resident with 1 attending anesthesiologist at a time)~* Preoperatively, the anesthesiologists who were blinded to the group of that specific patient evaluated the sensorial blockade of dermatomes separately on both sides~* Postoperatively, different anesthesiologists who did not participate in the TPVB performance process of that specific patient and were totally blinded to the group again collected the data.~* Surgeons were also blinded."|Patients undergoing reduction mammaplasty, received single or double injection bilateral thoracic paravertebral block (TPVB) for postoperative analgesia|f|t|t|t
33788725|NCT05603650|RANDOMIZED|PARALLEL||OTHER||DOUBLE|White tape over receptacle||t|f|t|f
33788726|NCT02020018|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788727|NCT04280913|||COHORT||RETROSPECTIVE|||||||
33788728|NCT03338218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007347|NCT05968963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007348|NCT05701618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This research study is a double-blinded randomized controlled trial. The participants will not be made aware which education video they watch is the control and which is the intervention. The study staff will be blinded to group allocation until after measurements are completed.||t|f|t|t
34007349|NCT04398979|||CASE_ONLY||RETROSPECTIVE|||||||
34007350|NCT04297800|||COHORT||PROSPECTIVE|||||||
34007351|NCT03844828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007352|NCT01897168|||COHORT||PROSPECTIVE|||||||
34007353|NCT06080659|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007354|NCT03223909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The double-blind study is a procedure in which the patient and the treating doctor ignore to which intervention group the study patient was assigned. To achieve the blinding of both the drug in research and both comparator drugs, these will be labeled in the same way (masking). Besides the figure of an unblinded pharmacist, who is responsible for the delivery of the medication to the patient, will be added. Blinding codes are protected by an outsider appointed by the study sponsor. The codes are also available in the research center (fully sealed), so that they can be consulted by the investigator in case a subject presents a serious adverse event, prior authorization from the study sponsor; the blinding also continues rigorous during the data analysis and interpretation.|Controlled, double-blind, randomized, clinical trial comparing the safety and efficacy parameters between a group of subjects with a diagnose of mild to moderate tear film dysfunction syndrome under a regimen of ophthalmic solution lubricant drops PRO-087 versus subject under Systane® Ultra or Systane® Ultra preservative free, with the same diagnosis, with a follow-up of 90 days.|t|f|t|f
34007355|NCT04438850|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Ivermectin and placebo treatment will be double blinded, i.e. the treatment will be unknown to both the subject and the treating physician. The hospital pharmacist will be unblinded to study treatment because in charge to prepare the study treatment according to randomization arm.||t|t|t|t
34007356|NCT01472926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007357|NCT00729417|||||RETROSPECTIVE|||||||
33788729|NCT04758897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788730|NCT03198546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788731|NCT04628858|||COHORT||PROSPECTIVE|||||||
34007358|NCT00749411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007359|NCT03417830|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Part A of the study will include 3 subjects with ATTR-CM who will participate in two dosing sessions and Part B of the study will include 3 subjects with ATTR-CM who will participate in one dosing session. A single dosing session will constitute treatment with carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC), total mass dose (TMD) administration of anti-serum amyloid P (SAP) monoclonal antibody (mAb) consisting of in vivo mixing of a single infusion of unlabeled anti-SAP mAb and a separate infusion of 89Zr-GSK2398852 via a different peripheral venous line, and up to 3 serial PET scanning procedures after administration of 89Zr-GSK2398852.||||
34007360|NCT03427476|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007361|NCT01940302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007362|NCT04003818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007363|NCT04122781|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective Comparative Study|f|f|f|t
34007364|NCT06525857|||CASE_ONLY||PROSPECTIVE|||||||
34007365|NCT02563418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007366|NCT00436917|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007367|NCT03816462|||COHORT||PROSPECTIVE|||||||
34007368|NCT04451928|||COHORT||PROSPECTIVE|||||||
34007369|NCT02457819|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34007370|NCT00574067|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007371|NCT03270592|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33788732|NCT05381701|||COHORT||PROSPECTIVE|||||||
34007372|NCT00075686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007373|NCT00463996|||CASE_CONTROL||PROSPECTIVE|||||||
33703050|NCT03925857|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"One Dose: 3 Sepsis patients will be treated with Allocetra-OTS, following safety assessment additional 3 patients will be treated (total 6 patients).~Two doses: Once safety is established 4 sepsis patients will be treated with 2 doses of Allocetra-OTS; The first, as in the first six patients and the second 48 hr following the first treatment."||||
33703051|NCT03267017|||COHORT||PROSPECTIVE|||||||
34007374|NCT01501968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703052|NCT06012474|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33703053|NCT04437563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A stepped wedge cluster randomized controlled trial. All clusters (i.e., participating oncological departments) will start as controls and will change to intervention at various times determined by randomization. In this way, all departments will contribute to control and intervention groups, thus accounting for variation between departments.||||
33703054|NCT00099541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703055|NCT00981370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703056|NCT01577680|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33703057|NCT05658913|||COHORT||CROSS_SECTIONAL|||||||
33703058|NCT04310046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703059|NCT00492531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788733|NCT05455346|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Each eligible participant will be block randomized (1:1 allocation) to either the RDL or the NHE intervention group|f|f|t|t
33788734|NCT06068907|||OTHER||CROSS_SECTIONAL|||||||
33788735|NCT02611414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788736|NCT01404221|||COHORT||PROSPECTIVE|||||||
33788737|NCT04208243|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The subjects and/or parents will be tested with all instruments before the intervention, and approximately every 30 days for no less than 3 months and a max participation of 6 months. Treatment time points will be at least 30 days apart. For those subjects who are scheduled to come into clinic every 1-2 months for SOC appointments, study participation may take up to 6 months. This 6 month time period would allow for the completion of 4 time points of CAT. The testing will take place in an exam room after vital signs have been completed upon intake. The study staff will administer the questionnaires. The PedsQL includes a subject report (ages 5 and over) and a parent report. The Resilience Scale is a self-report and will be used for ages 12 and over. The Faces Scale will use parent report for ages less than 5 and self-report for ages 5 and over. For consistency, the posture measure will be completed by study staff after training with the manual included with the inclinometer tool.||||
33788738|NCT03317639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788739|NCT01245439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788740|NCT00722215|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33788741|NCT00710307|||COHORT||CROSS_SECTIONAL|||||||
33788742|NCT03180905|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33788743|NCT04895007|||CASE_CROSSOVER||PROSPECTIVE|||||||
33788744|NCT04451889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788745|NCT00944801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007375|NCT00544817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007376|NCT01911104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007377|NCT00641199|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703060|NCT04721171|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Sham versus real device|t|t|t|f
33703061|NCT04232254|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33703062|NCT01851460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788746|NCT06555471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788747|NCT05250817|||COHORT||PROSPECTIVE|||||||
34007378|NCT01397526|||CASE_ONLY||PROSPECTIVE|||||||
34007379|NCT05554289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007380|NCT04819854|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blinded, placebo-controlled|Single and multiple ascending doses|t|t|t|t
34007381|NCT01451476|||OTHER||CROSS_SECTIONAL|||||||
34007382|NCT02644798|||OTHER||PROSPECTIVE|||||||
34007383|NCT05234541|||CASE_CONTROL||PROSPECTIVE|||||||
34007384|NCT03562949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007385|NCT02369120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34007386|NCT06074263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Dexamethasone 8mg is being provided in a capsule. The placebo is also being provided in the same capsule.|Impacted Mandibular 3rd Molar Extraction Model|t|t|f|f
34007387|NCT06215131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34007388|NCT02330744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007389|NCT05952453|NA|SINGLE_GROUP||TREATMENT||NONE||single- arm phase II trial||||
34007390|NCT02244073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007391|NCT04296201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007392|NCT01140737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703063|NCT02538029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703064|NCT04850820|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|All investigators involved with the study, as well as participants, will be blinded to treatment conditions (double-blind design) until data analysis is completed.|In a randomized, counterbalanced order, participants will receive all treatments arms (essential amino acids, branched-chain amino acids, and placebo).|t|f|t|t
33703065|NCT00384657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703066|NCT03011710|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703067|NCT05232045|||CASE_CONTROL||RETROSPECTIVE|||||||
33703068|NCT06114160|||CASE_ONLY||CROSS_SECTIONAL|||||||
33703069|NCT05469581|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomly assigned to two groups: experimental and control.|f|f|f|t
33703070|NCT01041326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007393|NCT06263140|||CASE_CONTROL||PROSPECTIVE|||||||
34007394|NCT05025280|||CASE_CONTROL||PROSPECTIVE|||||||
34025248|NCT03267563|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Sequential, multiple assignment, randomized trial (SMART) design||||
34025249|NCT03271723|||COHORT||PROSPECTIVE|||||||
34025250|NCT00729573|||COHORT||PROSPECTIVE|||||||
34025251|NCT03125980|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33703071|NCT00752180|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33703072|NCT04004130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703073|NCT00219973|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33703074|NCT03569085|NA|SINGLE_GROUP||SCREENING||NONE||Same patients will receive two different arms/interventions and compared||||
33703075|NCT00844181|||COHORT||CROSS_SECTIONAL|||||||
33703076|NCT01435278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703077|NCT01660061|||COHORT||PROSPECTIVE|||||||
33703078|NCT06306820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703079|NCT00615108|||COHORT||PROSPECTIVE|||||||
33703080|NCT06275347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible patients were assigned to a one of the four VIME Weight Loss and Wellness Center for management and follow up according to their preference, a sequential number in inclusion order was given, with all the patients coded with a 4-digit number. This code was sent to the people in the food production plant where the patients were randomized in a double blinded study, with a 2:1 allocation for low-fat, normo-protein, controlled ketogenic diet (Zélé method) or low calories diet|A Randomized Clinical Trial was conducted in patients with obesity type I patients|t|t|f|f
33703081|NCT03169543|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703082|NCT04312581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33703083|NCT02917733|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703084|NCT02234232|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33703085|NCT03421535|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Each player was randomly assigned to either a sleeper stretch group or an opposite SI joint stretch group. The investigators were blinded to the treatment groups.|All 23 players of a minor league baseball team voluntarily participated in the study.|t|f|t|t
33703086|NCT02158130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703087|NCT02195336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703088|NCT01984788|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33703089|NCT03424083|||COHORT||PROSPECTIVE|||||||
33703090|NCT05595096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"non-intubation group: thoracic paravertebral nerve block was performed before anesthesia induction,after anesthesia induction laryngeal mask airway(LMA) is placed.~intubation group:were given routine induction with double-lumen endotracheal intubation."|t|f|f|f
33703091|NCT02007993|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33703092|NCT04083196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33703093|NCT02966769|||OTHER||RETROSPECTIVE|||||||
33703094|NCT04068935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703095|NCT02633605|||COHORT||PROSPECTIVE|||||||
33703096|NCT04376463|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intevention.|It was an experimental design, controlled, non-randomized, with a convenience sample of 16-week supplementation combined or not with exercise. All participants in the groups ME+BCAA and BCAA received at the beginning of the protocol a bottle with assigned codes with flavourless powder (BCAA), and a dosage of 0.21g/kg/session. They took the supplement with 200 ml of water immediate after exercise, in the ME+BCAA group, and at the same time in the BCAA group (Ispoglou et al., 2016). Throughout the intervention period, all tests and intervention were done after breakfast and before lunch (supplementation, physical exercise, data collection, questionnaires, physical tests), and 30-60 minutes before lunch. The ME group just folowed the exercice protocol, and CGne group did not alter their usual routine.|f|f|t|f
33703097|NCT00736424|||CASE_ONLY|||||||||
33703098|NCT03519620|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33703099|NCT05586659|||CASE_CONTROL||RETROSPECTIVE|||||||
33703100|NCT02833363|||COHORT||PROSPECTIVE|||||||
33703101|NCT00392860|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33703102|NCT01500889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703103|NCT05439941|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Label Extension Study.||||
33703104|NCT05777746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An investigator and outcome assessor blinded design is chosen to reduce bias. All investigators collecting data by physical examination will be blinded to the allocation of the patients. Similarly, lab technicians performing the blood measurements will be blinded to the patient allocation. Lastly, the statistical analyses will be performed blinded to the allocation of patient groups.||f|f|t|t
33703105|NCT05333016|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33703106|NCT03473535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703107|NCT00450255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703108|NCT05101785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703109|NCT05890508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All patients and the investigators including the research assessors, the statistician, and the researchers interacting with the patients except the one who conducts the acupuncture therapy will be blinded.||t|t|f|t
33703110|NCT02672800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703111|NCT03374969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703112|NCT04450173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703113|NCT00573183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703114|NCT01725711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703115|NCT05239975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703116|NCT02027519|||||CROSS_SECTIONAL|||||||
33703117|NCT02944032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703118|NCT05617950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720451|NCT06069960|NA|SINGLE_GROUP||TREATMENT||NONE||SALT operation plan for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.||||
33788748|NCT03764943|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective cohort study, 2 groups; alloplastic reconstruction and autologous reconstruction, same intervention||||
33788749|NCT03357224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788750|NCT01111903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788751|NCT04667065|NA|SINGLE_GROUP||OTHER||NONE||Patient with non-small cell bronchial cancer with indication of curative surgical resection.||||
33788752|NCT06345612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007395|NCT05883397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Care providers, Investigator and assessors will be blinded to the participants' allocation.|"Participants will be recruited from veterans' clinics and veterans' organizations. After screening, eligible participants will undergo baseline evaluation. Enrolled participants will be 1:1 randomly assigned to the HBOT or HBOT + hippocampal training, according to a computer-generated randomization list. Assessors will be blinded to the participants' allocation.~During the study period, all the participants will continue their psychological and pharmacological treatment as prior to their inclusion in the study. Any changes in the frequency of psychologic treatment or pharmacotherapy dose will be reported and documented.~The study is designed as a per protocol trial, and thus, participants will only be included in the analysis if they completed the treatment protocol and attained study analysis."|f|t|t|t
33703119|NCT05159284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded study for the PI or person designated to conduct the study (blinded investigator). Study medication will be labelled as blinded medication. The prescription will be done by the blinded investigator using a kit number, and study medication delivery will be done by a person designed by the PI for this topic through the study (unblinded collaborator). Patients will be instructed not to inform the investigators who perform the ophthalmological evaluation about the group they will be assigned to. Patient assessments will be performed by blinded investigator.|Phase IV, interventional, prospective, randomized, single blind, of parallel groups with two treatment arms clinical trial in one center.|f|f|t|f
33703120|NCT02530684|||CASE_CROSSOVER||PROSPECTIVE|||||||
33703121|NCT04766060|||COHORT||PROSPECTIVE|||||||
33703122|NCT01857856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703123|NCT00686283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703124|NCT06044831|||COHORT||PROSPECTIVE|||||||
33703125|NCT01881074|||COHORT||PROSPECTIVE|||||||
34007396|NCT01960868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007397|NCT02333188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007398|NCT00661921|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007399|NCT03359837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007400|NCT06617078|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007401|NCT03670732|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover non-inferiority trial||||
34007402|NCT04462744|||OTHER||OTHER|||||||
34007403|NCT00779402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007404|NCT03439631|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Tiered OR set up design will be compared to standard OR set up design as related to patient satisfaction with surgical experience||||
34007405|NCT04674683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All Eligible patients will be randomized within the appropriate stratum at a 1:1 ratio to the Test arm or the Control arm, with the exception of Cohort for special population.|This is a double-blind, placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab.|t|t|t|t
34007406|NCT00200317|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007407|NCT00471991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007408|NCT06234748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007409|NCT05540379|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||the efficacy of VR simulator training in improving basic gynecological hysteroscopic skills|t|f|f|f
34007410|NCT01847365|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34007411|NCT00170339|||||PROSPECTIVE|||||||
34007412|NCT00493064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007413|NCT06617208|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33703126|NCT03105583|||COHORT||CROSS_SECTIONAL|||||||
33703127|NCT02320539|||CASE_CONTROL||PROSPECTIVE|||||||
33703128|NCT01484223|RANDOMIZED|PARALLEL||||NONE||||||
33703129|NCT03055156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33703130|NCT00001067||||TREATMENT||||||||
33703131|NCT03320057|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective cohort||||
33703132|NCT05701605|||CASE_CONTROL||PROSPECTIVE|||||||
33703133|NCT03629431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a study phase III, multicentre, comparative, randomized, controlled, superiority and open||||
33703134|NCT04396301|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33703135|NCT04334057|||COHORT||PROSPECTIVE|||||||
33788753|NCT06554067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be assigned a Study ID that will determine the assigned procedure. At the study's completion the blind will be broken, and data will be turned over for analysis.|This is a parallel-group, double blinded, randomized trial where 200 subjects will be randomized following a 2x2 structure.|t|f|t|f
33788754|NCT00964366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788755|NCT02048709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788756|NCT05579886|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788757|NCT06281821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor at follow-up timepoint is masked to condition. Baseline assessment occurs prior to randomization|Compare an intervention to an assessment only control condition|f|f|f|t
33788758|NCT00183638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788759|NCT00003656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788760|NCT00197015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788761|NCT00009984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788762|NCT02989961|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33788763|NCT02786693|||OTHER||PROSPECTIVE|||||||
33788764|NCT00678158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788765|NCT01465243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788766|NCT04044664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be randomized to receive placebo or NYX-783.|t|f|t|t
33788767|NCT04397172|||COHORT||PROSPECTIVE|||||||
33788768|NCT06630559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788769|NCT05640817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33788770|NCT05639023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788771|NCT00455754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788772|NCT04467515|NA|SEQUENTIAL||TREATMENT||NONE||"This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, PD, and efficacy of the targeted radionuclide therapeutic CAM H2 in patients with progressive, advanced/metastatic HER2 positive breast, gastric, and GEJ cancer with disease progression following anti-HER2 standard of care treatment. The study is comprised of a Treatment Period, consisting of a maximum of 4 cycles (12 weeks per cycle) of study drug, and a Long Term Follow Up Period.~The study will be comprised of the following:~* Dose Escalation Phase Followed by a Long Term Follow Up (LTFU) period~* Dose Expansion Phase Followed by a LTFU period~In the dose expansion phase of the study, the patients will be given the recommended dose for Phase 2 (RDP2) determined in the dose escalation phase. Similar to the dose escalation phase, all patients will receive at least 1 cycle of CAM-H2."||||
33788773|NCT06630884|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33788774|NCT06213051|||COHORT||PROSPECTIVE|||||||
33788775|NCT04950218|||COHORT||PROSPECTIVE|||||||
33788776|NCT01636206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788777|NCT02716324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788778|NCT06435338|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788779|NCT03982199|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33788780|NCT05230680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007414|NCT00003707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007415|NCT00401167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007416|NCT04569786|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34007417|NCT04580849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||individuals with parkinson's disease and healthy control individuals will be assigned to the same online dance class via zoom platform.||||
34007418|NCT02625116|||COHORT||PROSPECTIVE|||||||
34007419|NCT06012513|||CASE_CONTROL||PROSPECTIVE|||||||
34007420|NCT05265299|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||6-sequence, 3-period, 3-treatment sequential crossover trial|t|t|t|t
34007421|NCT01367717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34007422|NCT04231409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007423|NCT03980301|||COHORT||PROSPECTIVE|||||||
34007424|NCT05010824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007425|NCT04823507|||COHORT||RETROSPECTIVE|||||||
34007426|NCT03618329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007427|NCT06616090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessment team will be blind to the treatment condition of the mothers.|A randomized controlled trial will be conducted. The sample will consist of 120 mothers with 9- to 12-month-old babies from Family Health Centers (FHC) in Istanbul. FHCs will be randomly assigned to intervention and control conditions so that mother-infant dyads will be divided into intervention (N = 60) and control (N = 60) groups. A comprehensive training will be provided to intervention nurses. Mother-infant dyads in the intervention group will receive the regulare well child check up procedures along with the attachment-based intervention modules, following the pretest measurements. Mother-infant dyads in the control group will receive the routine well-child check up procedures. Changes in maternal sensitivity and infant attachment security from pre- to posttest will be compared across two groups measures. Control mothers will receive a condensed form of the intervention after the follow up assessments.|f|f|f|t
34007428|NCT01482182|||CASE_ONLY||PROSPECTIVE|||||||
34007429|NCT05498493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007430|NCT01471834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007431|NCT05886257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007432|NCT01856387|||CASE_ONLY||RETROSPECTIVE|||||||
33703136|NCT00443092|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33703137|NCT01670396|||CASE_CONTROL||RETROSPECTIVE|||||||
33703138|NCT00894166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703139|NCT05248867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703140|NCT03078972|||COHORT||PROSPECTIVE|||||||
33703141|NCT05684705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703142|NCT06224257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703143|NCT04685785|||CASE_ONLY||CROSS_SECTIONAL|||||||
33720452|NCT02232633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928286|NCT06118554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study was single-blinded as the MG patients unavoidably knew of their experimental group assignment due to the provided 3D-printed nasal model. However, patients in BG and CG were not told the existence of other groups. Clinical providers were blinded to the patients' assigned group when assessing clinical outcomes and Lund-Mackay score, and the principal investigator was blinded to the patients' clinical outcomes.|All patients were prescribed an 8-week course of daily 2 mg of mometasone irrigation (Advanced Rx Compounding Pharmacy, Fort Washington, Pennsylvania) using 240 mL Sinus Rinse bottles (NeilMed Pharmaceuticals Inc, Santa Rosa, CA). The control group (CG) irrigated in the standard FDA consumer-recommended position, defined as leaning forward with a natural ear-to-shoulder head tilt. Backfill group (BG) subjects irrigated with a head tilt of 90 degrees ear-to-shoulder and used the nostril closest to the ground. Finally, the model group (MG) irrigated in an optimal position based on their 3D nasal replica. This patient-specific position was communicated to each MG patient with clear instructions during an in-person training session. All patients were required to record their daily compliance, if they changed head position, and what head position they changed to during the course of the treatment.|f|t|t|f
33928287|NCT00114218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928288|NCT04570969|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled prospective trial||||
33928289|NCT05635370|||COHORT||RETROSPECTIVE|||||||
33928290|NCT06145204|||COHORT||PROSPECTIVE|||||||
33928291|NCT00712933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928292|NCT02951455|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33928293|NCT01157455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007433|NCT02191566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007434|NCT02638519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007435|NCT05899920|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007436|NCT00268892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007437|NCT01634412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007438|NCT00607295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34007439|NCT00750048|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34007440|NCT04751474|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007441|NCT02564848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007442|NCT03302572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007443|NCT00026923||||TREATMENT||||||||
34007444|NCT06616818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||6 months of produce delivery.|t|f|f|f
34007445|NCT03608306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007446|NCT01017939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007447|NCT04729608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703144|NCT05084014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, the outcome assessor will be blinded. He will just take the data regarding pain, functional mobility and measure the range of motion of the knee joint at the baseline, mid of the treatment and at the end of the treatment.|In this study there are two groups, one receiving deep longitudinal stripping technique with conventional physical therapy and the second group receiving kneading technique with conventional physical therapy|f|f|f|t
34007448|NCT04366180|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703145|NCT04676178|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33703146|NCT02564497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33703147|NCT00244062|RANDOMIZED|PARALLEL||||DOUBLE||||||
33703148|NCT05253638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703149|NCT02836392|||CASE_ONLY||PROSPECTIVE|||||||
33703150|NCT01146990|||OTHER||PROSPECTIVE|||||||
33788781|NCT04480593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual who evaluates the results of interest to the study will not have access to the study steps before the analysis.|three parallel groups randomly assigned|f|f|f|t
33788782|NCT00570869|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33788783|NCT05534711|||COHORT||PROSPECTIVE|||||||
33788784|NCT05996757|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33788785|NCT03012919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788786|NCT01186848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007449|NCT01212549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007450|NCT04829760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||A randomized, single-blind, placebo-controlled parallel study in which participants consume 10 grams of psyllium, coarse wheat bran, or a placebo (maltodextrin) for eight weeks.|t|f|f|f
34007451|NCT05423093|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34007452|NCT01272089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007453|NCT06612034|||COHORT||CROSS_SECTIONAL|||||||
34007454|NCT05201638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007455|NCT00606138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007456|NCT04752488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34007457|NCT02413294|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33703151|NCT04707508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703152|NCT00479726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703153|NCT04774796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703154|NCT03928158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703155|NCT00366574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703156|NCT01597960|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703157|NCT00352339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703158|NCT01814384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788787|NCT02323386|NA|SINGLE_GROUP||OTHER||NONE||||||
33788788|NCT01930019|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33788789|NCT03211637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33788790|NCT02611232|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788791|NCT06018194|||COHORT||RETROSPECTIVE|||||||
33788792|NCT05388344|||CASE_ONLY||CROSS_SECTIONAL|||||||
33788793|NCT04005313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788794|NCT00466414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33788795|NCT05040750|||COHORT||RETROSPECTIVE|||||||
33788796|NCT03141658|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34007458|NCT02165514|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007459|NCT01718730|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34007460|NCT05412524|NA|SINGLE_GROUP||TREATMENT||NONE||Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.||||
34007461|NCT00932217|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007462|NCT03606031|||COHORT||PROSPECTIVE|||||||
34007463|NCT01196117|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007464|NCT06471309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703159|NCT06166589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703160|NCT03356756|||COHORT||PROSPECTIVE|||||||
33788797|NCT00942149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788798|NCT03155152|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788799|NCT01364519|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33788800|NCT05971355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788801|NCT05950113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788802|NCT04810884|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703161|NCT02962388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703162|NCT05210907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703163|NCT02183896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703164|NCT04158752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703165|NCT03100097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703166|NCT05142111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33703167|NCT03881475|||COHORT||PROSPECTIVE|||||||
33703168|NCT06024655|||COHORT||PROSPECTIVE|||||||
33703169|NCT03340636|||COHORT||PROSPECTIVE|||||||
33703170|NCT02206997|||COHORT||PROSPECTIVE|||||||
33703171|NCT06191640|||COHORT||PROSPECTIVE|||||||
33703172|NCT05367427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The masking of the study will be achieved through the identical presentation and characteristics of the product to be consumed. The principal investigator will supply the participants with both the experimental product and the placebo, depending on the randomization. Randomization will be done blindly, so that the participants and the researcher will not know which treatment has been assigned (Experimental or Placebo). Six codes have been generated, 3 for each arm (arm 1: 2325, 2329, 2324; arm 2: 2338, 2333, 2331). The unmasking will take place at the end of the experimental period.|Parallel, randomized, double-blind, controlled pilot clinical trial|t|t|t|f
33703173|NCT00479193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703174|NCT01223430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788803|NCT06530875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The research was planned as a cross section (pre-test post-test, experimental and control group) randomized controlled study.|t|f|f|t
33788804|NCT02944955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788805|NCT02454569|||COHORT||PROSPECTIVE|||||||
33788806|NCT04900155|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33788807|NCT00175708|||COHORT||PROSPECTIVE|||||||
33788808|NCT01193153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788809|NCT06141980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788810|NCT04448717|||COHORT||PROSPECTIVE|||||||
33928294|NCT05158179|NA|SINGLE_GROUP||TREATMENT||NONE||Cottonoid pledgets soaked in 4% lidocaine and neo-synephrine will be placed on this side. The pledgets will be kept in place for 5 minutes to allow adequate decongestion and anesthetization. The aesthesiometer will be placed through the 2.0 mm working channel of the Olympus Corporation (Tokyo, Japan) ENF-VT2 channeled flexible video rhinolaryngoscope with a 4.9 mm outer diameter. The flexible laryngoscope and aesthesiometer assembly will then be advanced into the pharynx and positioned for target testing. The operator field of view will be adjusted in the craniocaudal axis to optimize visualization of the stimulation target, monofilament tip, and both vocal folds to assess for a stimulation evoked LAR response. The monofilament will then be advanced to within several mm of the target laryngopharyngeal subsite and subsequently applied orthogonally until it buckled by 10-30%, followed by quick retraction to assess for triggering of the rapid LAR response.||||
33928295|NCT05419115|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not possible|randomised, parallel-group, active comparator controlled trial||||
33928296|NCT06119425|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007465|NCT06678646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007466|NCT06428695|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The subject population will consist of adults 18 years of age and older with a Body Mass Index (BMI) greater than 25 kg/m2||||
34007467|NCT01901172|RANDOMIZED|CROSSOVER||||NONE||||||
34007468|NCT02323802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703175|NCT05140785|NA|SINGLE_GROUP||OTHER||NONE||||||
33703176|NCT05644769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703177|NCT05232175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703178|NCT04760821|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients admitted for moderate to severe acute respiratory distress syndrome caused by the SARS-CoV2 will be randomized to usual care or usual care + trimetazidine.||||
33703179|NCT03593096|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low alitude and High altitude||||
34025252|NCT05434637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025253|NCT01915758|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34025254|NCT04686552|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025255|NCT04688892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33703180|NCT01956435|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33703181|NCT02264561|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33788811|NCT06261333|||COHORT||PROSPECTIVE|||||||
33788812|NCT04460898|||COHORT||RETROSPECTIVE|||||||
33788813|NCT00099515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788814|NCT06351280|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33788815|NCT00006369||||TREATMENT||||||||
33788816|NCT02355535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788817|NCT02442466|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33788818|NCT02261688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33788819|NCT06220058|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients meeting the inclusion criteria will be randomized 1:1 using random number generation in SPSS v.21, assigning them to either the Mesh or Bites group. Sealed opaque envelopes will be used just before the surgical intervention within the operating room. The envelope will be opened in the operating room upon initiation of midline laparotomy closure.|||||
33788820|NCT04553302|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788821|NCT00464672|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33788822|NCT02280655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703182|NCT05857059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pregnant women seen at the obstetric clinic of Maternidade Daniel de Matos, with a first trimester ultrasound pregnancy dating at our institution; with a maternal BMI measurement in the first trimester ≥ 30 kg/m2 and with a maternal or obstetric indication for IOL, who agreed to participate in the study. They will be randomized into two groups: one will consist of pregnant women undergoing the basic IOL protocol of Maternidade Daniel de Matos (oral misoprostol 25µcg every 2 hours); the other will be submitted to a 50µcg dosage every 2 hours, maximum of 7 doses per day (maximum 2 days). The pregnant woman will have a choice of an envelope, which will be her group assignment and will be coded until the end of the trial.|t|f|f|f
33703183|NCT05020782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703184|NCT02624752|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:~1. Ensure Enlive (enhanced ONS) + standard menu; or~2. Standard of care (including standard menu and possibly ONS) Patients randomized will receive standard menu or standard menu plus enhanced oral nutritional supplements (ONS). Patients randomized to enhanced ONS, will receive one bottle of ONS Abbott Ensure Enlive (235 mL, 350 calories), or similar product, two times daily for 90 days."||||
33703185|NCT00619736|RANDOMIZED|PARALLEL||||DOUBLE||||||
33703186|NCT01044875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703187|NCT02096679|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720453|NCT00739544|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33788823|NCT02939495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788824|NCT01243801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788825|NCT00470106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788826|NCT03990220|||CASE_CONTROL||PROSPECTIVE|||||||
33788827|NCT02225600|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33788828|NCT01316978|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33788829|NCT05060562|||COHORT||PROSPECTIVE|||||||
33788830|NCT00943605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788831|NCT03030924|||COHORT||PROSPECTIVE|||||||
33788832|NCT04092985|||COHORT||PROSPECTIVE|||||||
33788833|NCT01749761|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33788834|NCT04058743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be blinded to the type of implant that they receive.|Prospective randomized controlled trial with two groups: Total knee replacement with standard cobalt chromium components vs Total Knee Replacements with nickel free components.|t|f|f|f
33788835|NCT03682328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33788836|NCT01006746|||COHORT||PROSPECTIVE|||||||
33788837|NCT00768781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788838|NCT00864812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788839|NCT05085496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788840|NCT00685893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788841|NCT01156116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788842|NCT06630975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788843|NCT02869958|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788844|NCT01559480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788845|NCT04813393|||FAMILY_BASED||PROSPECTIVE|||||||
33788846|NCT00380627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788847|NCT00215306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788848|NCT00975806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788849|NCT03992495|||CASE_CONTROL||PROSPECTIVE|||||||
33788850|NCT00325923|RANDOMIZED|PARALLEL||||SINGLE||||||
33788851|NCT05460806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788852|NCT05512949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788853|NCT01190150|RANDOMIZED|CROSSOVER||||NONE||||||
33788854|NCT01821586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788855|NCT04868799|||COHORT||RETROSPECTIVE|||||||
33788856|NCT03234621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33788857|NCT00243256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33788858|NCT03761654|||CASE_ONLY||PROSPECTIVE|||||||
33788859|NCT05993949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788860|NCT01180621|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025256|NCT05831241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34092500|NCT03470766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind. Implanter is blinded, research staff are blinded, subject is blinded. One unblinded research personnel at each recruiting site programming the patients at device activation.|Multicentre, randomised, double-blinded, sham-controlled trial with parallel economic evaluation. Patients will be allocated 1:1 to activated 10kHz SCS plus usual care (intervention) or sham 10kHz SCS plus usual care (control) and followed up to 6 months.|t|t|t|t
34092501|NCT03401333|NA|SINGLE_GROUP||PREVENTION||NONE||A brief motivational interview and four weeks of text messaging.||||
34092502|NCT02188732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34092503|NCT02962466|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092504|NCT04948437|||COHORT||PROSPECTIVE|||||||
34092505|NCT00103506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092506|NCT01344200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092507|NCT05387525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092508|NCT02314884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092509|NCT04991584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092510|NCT00884949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092511|NCT01294540|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34092512|NCT05710172|RANDOMIZED|PARALLEL||TREATMENT||NONE|Concealment of treatment allocation is not possible|||||
34092513|NCT04075084|||CASE_ONLY||PROSPECTIVE|||||||
34092514|NCT01107990|||CASE_CONTROL||PROSPECTIVE|||||||
34092515|NCT05625464|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34092516|NCT05486286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092517|NCT02347787|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34092518|NCT06333964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Main study(0\~12 weeks) Experimental: AST-001 Comparator: Placebo of AST-001~Extension study(12\~24 weeks) Experimental: AST-001 Comparator: AST-001"|t|t|t|t
34092519|NCT01181128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092520|NCT03950804|||COHORT||PROSPECTIVE|||||||
34092521|NCT05268770|||CASE_CONTROL||PROSPECTIVE|||||||
34092522|NCT05277259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092523|NCT00032487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092524|NCT04651712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be blinded, and the investigator will be blinded to POC-PCR results, data management and analysis, but not allocation. Outcome assessors will not be blinded||t|f|f|f
34092525|NCT04899206|||COHORT||PROSPECTIVE|||||||
34092526|NCT03474744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092527|NCT04767750|||CASE_CONTROL||RETROSPECTIVE|||||||
34092528|NCT03358953|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||E-cigarette versus nicotine replacement patches||||
34092529|NCT04433312|||OTHER||CROSS_SECTIONAL|||||||
34092530|NCT02063776|||CASE_CONTROL||PROSPECTIVE|||||||
34092531|NCT03617432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092532|NCT02939391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092533|NCT04540198|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34092534|NCT06052124|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34092535|NCT05004285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||compare PET/CT Imaging Diagnosis with MRI Diagnosis for one subject||||
34092536|NCT00554723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092537|NCT02692079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092538|NCT00614393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092539|NCT02319382|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092540|NCT03988647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092541|NCT01452087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092542|NCT05015023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcome assessors will be masked.|The study will have two arms, i.e., intervention and control groups.|f|f|f|t
34092543|NCT04324489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092544|NCT01184807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092545|NCT05869409|||OTHER||PROSPECTIVE|||||||
34092546|NCT04002700|||COHORT||RETROSPECTIVE|||||||
34092547|NCT02214810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092548|NCT00330018|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092549|NCT00049829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092550|NCT04909255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092551|NCT01533220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092552|NCT05482243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be randomized to either start with the habitual lifestyle period or the exercise training period. All randomization procedures will be executed by an independent researcher. Due to the nature of the intervention, blinding of participants and investigators during the exercise training period is not possible. During the analysis, the research technicians will only receive the participant codes to ensure blinding during analysis of blood, saliva, and muscle 2H-enrichment. Thereafter, an independent researcher will provided a blinded dataset to the research team.|Randomized crossover study (1-week intervention vs. 1-week habitual lifestyle) for both patients with advanced CKD and healthy controls|f|f|f|t
33703188|NCT04216966|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The scanning electron photographs were assessed by assessors who were blinded to the study groups.||f|f|f|t
33703189|NCT02114671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703190|NCT02505906|||COHORT||PROSPECTIVE|||||||
33703191|NCT02874157|||COHORT||PROSPECTIVE|||||||
33720454|NCT01685931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720455|NCT05791266|NA|SINGLE_GROUP||OTHER||NONE||||||
33720456|NCT02075658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33720457|NCT04299412|||CASE_CONTROL||RETROSPECTIVE|||||||
33720458|NCT04877470|||COHORT||RETROSPECTIVE|||||||
33720459|NCT02546557|||COHORT||PROSPECTIVE|||||||
34092553|NCT05557682|||CASE_CONTROL||PROSPECTIVE|||||||
34092554|NCT04410822|||COHORT||PROSPECTIVE|||||||
34092555|NCT03776786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092556|NCT05125497|||COHORT||PROSPECTIVE|||||||
34092557|NCT06363500|||OTHER||CROSS_SECTIONAL|||||||
33703192|NCT05176743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No blinding will be used in this pilot trial.|This is a randomized pilot trial. Eligible individuals will be identified from breast and gynecologic clinics in the New Mexico Cancer Care Alliance. Participants will be screened for food insecurity and asked to complete a baseline survey. Participants will then be randomized to either Usual Care or to the UCT intervention. All participants will complete a 3-month follow-up, survey and a qualitative exit interview.||||
33928297|NCT05031572|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||clinical study: randomized, cross-over design, study participants will consume either lifestyle recommendations for a healthy Mediterranean diet under a continued caloric restriction diet (DCR) or will undertake an intermittent (IF) protocol|f|f|f|t
33703193|NCT02384161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33703194|NCT03385200|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parellel Assignment||||
33720460|NCT05318599|||CASE_CONTROL||PROSPECTIVE|||||||
33928298|NCT00220857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33928299|NCT04172077|||FAMILY_BASED||PROSPECTIVE|||||||
33928300|NCT04721938|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33928301|NCT00959881|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33928302|NCT00676156|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928303|NCT04127461|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|retrospective data collection||t|t|f|f
33928304|NCT00653328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928305|NCT01673269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928306|NCT02705443|||COHORT||PROSPECTIVE|||||||
33928307|NCT05531513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be blinded to baseline assessment.|After providing consent, potential participants will complete an initial screening with the demographic intake form. Participants who do not meet inclusion or exclusion criteria will be informed that they will be unable to participate in the current study. Participants who meet study criteria will then be asked to complete the baseline survey containing the battery of outcome measures. Upon completion of the baseline measures, participants will be randomly assigned to one of two conditions: the experimental (Virtual Reality) condition or the active control (Psychoeducational Pamphlet) condition. Randomization will occur using a computerized random number generator following a matched random assignment via block procedure. An individual at arm's length (not involved with the intervention, assessment, or analysis) will perform the randomization. Control group participants will be allowed access to the virtual reality program after follow-up data collection is completed (after Week 9).|f|f|f|t
33928308|NCT02744560|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33928309|NCT00088114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928310|NCT03892707|||COHORT||PROSPECTIVE|||||||
33928311|NCT00161811|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33928312|NCT04444492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded BCVA assessor||f|f|f|t
34007469|NCT05397795|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Before enrollment in the study, all patients will be subjected to routine medical evaluation to make sure of presence of inclusion criteria and absence of exclusion criteria. Then women will be randomized using computer-based randomization (Random Digit Software).~All included women will undergo a fixed GnRH antagonist protocol of COH.~At the day of triggering, number of follicles and the number of oocytes expected to be retrieved will be documented and women will be given the trigger according to the randomization done at the enrollment.~Two main groups will be created depending on the trigger protocol used:~Group A: 80 subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly.~Group B: 80 subjects will be triggered by 10000 IU of hCG (Choriomon5000 IU; IBSA) intramuscular injection in addition to the GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously."||||
34007470|NCT01618630|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34007471|NCT06384794|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Embryologists performing IVF/ICSI are blinded to the treatment the sample has undergone. All samples are labeled with the patients Identification number. This is a unique code per patient that does not allow identification of which arm the sample belongs to.|Multicentric, prospective, experimental study.|f|f|f|t
34007472|NCT03480672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007473|NCT05647616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34007474|NCT04244799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007475|NCT02451150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007476|NCT01013428|||COHORT||PROSPECTIVE|||||||
34007477|NCT02483338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007478|NCT02087176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007479|NCT02675959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007480|NCT01301924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34007481|NCT04785131|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007482|NCT03755089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007483|NCT06616662|||COHORT||RETROSPECTIVE|||||||
34092558|NCT04051580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092559|NCT03869437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092560|NCT05730673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092561|NCT05823454|||COHORT||OTHER|||||||
34092562|NCT03248895|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"A randomised intervention trial will be used. Participants will be randomised to either an immediate (I-med) or a delayed (D-med) intervention. Randomisation will be restricted based on two factors including age and patient gender.~Both subject groups will receive standard-of-practice asthma education and management in the Asthma Clinic prior to study enrolment. Participants allocated to the I-med group will take part in the mobile technology DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up. Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care."||||
34092563|NCT02448043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928313|NCT01219491|||||PROSPECTIVE|||||||
34092564|NCT03615729|||CASE_CONTROL||RETROSPECTIVE|||||||
33703195|NCT04887844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be evaluated at baseline, 6 weeks later by an another investigator who does not aware of groups.|Group I was received physiotherapy+lidocaine injection, Group II was received physiotherapy+betamethasone dipropionate injection, and group III was only received conventional physiotherapy.|f|f|f|t
33703196|NCT00768950|||COHORT||PROSPECTIVE|||||||
33928314|NCT06360497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33928315|NCT02715492|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928316|NCT03537092|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will insert a placebo extended release vaginal film at Day 0. They are randomized to the timing of their first follow up visit (Day 3, 7, 10 or 14) to assess how long the film can be detected visually and/or one of its components remains detectable by biochemical assay in the lower genital tract.||||
33928317|NCT02814448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928318|NCT00067626|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33928319|NCT05438706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928320|NCT03101527|NA|SINGLE_GROUP||TREATMENT||NONE||A single group model was used: pregnant women.||||
33928321|NCT00112684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928322|NCT00007982||||TREATMENT||||||||
33928323|NCT05431712|||CASE_CONTROL||RETROSPECTIVE|||||||
33928324|NCT05721196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33928325|NCT03712527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33928326|NCT04685538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928327|NCT05920200|||COHORT||PROSPECTIVE|||||||
33928328|NCT03054740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928329|NCT03437291|||COHORT||PROSPECTIVE|||||||
33928330|NCT01727557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928331|NCT02887365|NON_RANDOMIZED|PARALLEL||||NONE||||||
33928332|NCT04717895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Randomization will be carried out after inclusion and allocation of a selection / inclusion number of subjects and will be carried out as follows:~* Subjects included and who will be identified with an even selection number will begin the virtual reality session by viewing a rocking environment followed by a translation environment~* Subjects included and who will be identified with an odd selection number will start the virtual reality session by viewing a translation environment followed by a rocking environment"||||
33928333|NCT01244204|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33928334|NCT04390997|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33928335|NCT01983618|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928336|NCT05725200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703197|NCT00589992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703198|NCT06088108|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703199|NCT00499499|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703200|NCT01102517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928337|NCT02870257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928338|NCT01089218|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33928339|NCT01138397|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928340|NCT04717661|||COHORT||PROSPECTIVE|||||||
33928341|NCT00225212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928342|NCT01390038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928343|NCT03251872|NA|SINGLE_GROUP||TREATMENT||NONE||The design is open-label. A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given progressive doses of olaparib up to 400mg BID for 16 weeks.||||
33928344|NCT03247010|||COHORT||PROSPECTIVE|||||||
33928345|NCT03924648|||CASE_CONTROL||PROSPECTIVE|||||||
33928346|NCT01351857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928347|NCT00004125|RANDOMIZED|||TREATMENT||||||||
33928348|NCT03048409|||COHORT||RETROSPECTIVE|||||||
33928349|NCT03658317|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33928350|NCT05212402|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double-blinded of the subjects and research staff.|Between subjects study design.|t|f|t|t
33928351|NCT04606407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703201|NCT04471142|RANDOMIZED|PARALLEL||PREVENTION||NONE||All patients undergoing mastectomy will be evaluated for eligibility criteria after the first dressing, those considered eligible will be randomized to the intervention or control group. 27 blocks will be available containing 10 envelopes where 05 will contain a code that allocates the patients in group A and 05 in group B. Group A: intervention group with preventive application of compressive bandage in addition to the suction drain (routine adopted in the institution). The bandage will be applied on the day of discharge after the first dressing, withdrawal and new bandage applied on the fourth day and permanently removed on the seventh day when they will be reevaluated. Group B: control group. Patient will follow the routine of the institution only with the suction drain.||||
33703202|NCT01217801|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703203|NCT02737397|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33801692|NCT05437952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will involve 60 elderly women with sarcopenic obesity who will be randomly distributed into 4 groups: 1) GPL, submitted to placebo supplementation (n=15); 2) GTAU, submitted to taurine supplementation (n=15); 3) GPL+EX, submitted to placebo supplementation associated with physical exercise (n=15) and 4) GTAU+EX, submitted to taurine supplementation associated with physical exercise (n=15).|Randomized, double-blind clinical trial|t|f|t|f
33928352|NCT01020968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928353|NCT05068999|||COHORT||PROSPECTIVE|||||||
33928354|NCT06216106|||OTHER||RETROSPECTIVE|||||||
33928355|NCT02574819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720461|NCT03417453||PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720462|NCT02527460|NA|SINGLE_GROUP||OTHER||NONE||||||
33720463|NCT03386942|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1 study of farletuzumab ecteribulin in participants with solid tumors. This study will be conducted in 2 parts (Part 1 and Part 2). Part 1 will be the dose escalation portion of this study to evaluate dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) of farletuzumab ecteribulin in participants with solid tumors. Considering efficacy, safety, and the pharmacokinetic (PK) profile, two doses may be selected from Part 1 for Part 2. Part 2 will comprise cohort expansions to further characterize the safety of farletuzumab ecteribulin and to evaluate the preliminary efficacy of farletuzumab ecteribulin in participants with FRA-positive platinum-resistant ovarian carcinoma and non-small cell lung cancer (NSCLC). The recommended dose for future studies will be determined based on the data from Part 1 and Part 2.||||
33720464|NCT03245008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720465|NCT03251508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928356|NCT02451488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928357|NCT03368352|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomized, double-blind, placebo controlled|t|t|t|t
33928358|NCT02003768|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33928359|NCT04140539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928360|NCT00187850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33928361|NCT05256316|||COHORT||RETROSPECTIVE|||||||
33928362|NCT00528008|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928363|NCT04546867|NA|SEQUENTIAL||DIAGNOSTIC||NONE|Neither the investigator nor the patient will know before the sonographic approach, if the pancreatic stent is still in place. The diagnosis will be confirmed either by endoscopic findings or by x-ray depending on sonographic diagnosis and further algorithm.|The participants will start with a diagnostic ultrasound to visualize a pancreatic stent. If a stent is being displayed in the pancreatic duct. The participants will undergo endoscopy for removal of the pancreatic stent. Otherwise, x-ray will be performed to confirm the sonographic diagnosis. Stents, that are visulized in the duct by x-ray will than be removed. If sonography and x-ray confirm a spontanous dislodgement of the pancreatic stent, no further investigation will be performed.||||
33928364|NCT05178290|RANDOMIZED|PARALLEL||PREVENTION||NONE|As this is community engaged research, full transparency is required.|Participating ECE sites (N=40) will be block randomized to receive child and family back-to-ECE testing OR child and family testing plus ECE personnel biweekly testing. Of this same group of sites, half will be block randomized to complete an outdoor learning garden condition (SAGE) and have will receive waitlist. Waitlist sites will receive the garden condition delayed by one year.||||
33928365|NCT01769625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33928366|NCT04823546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928367|NCT03674541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be assigned randomly to receive either pyridostigmine or placebo, both study participants and investigators will be blinded.|t|t|t|f
33928368|NCT03504267|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33928369|NCT00001036||||TREATMENT||||||||
33928370|NCT01026350|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33928371|NCT02408926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928372|NCT06009068|||OTHER||CROSS_SECTIONAL|||||||
33928373|NCT03105245|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both participants and the outcome assessor (analysing EEGs) will be blinded.|Each participant will receive all four treatment conditions in randomly allocated sequence during their ECT course. That is, participants will receive either short or long anaesthetic-ECT stimulus time interval treatments, and normal or hyperventilation treatments - this results in four possible combinations, which individual participants will cycle through in random order during their ECT course (e.g. short-hyperventilation, long-normal ventilation, short-normal ventilation, long-hyperventilation).|t|f|f|t
33928374|NCT03835988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928375|NCT02842541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928376|NCT05515445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928377|NCT04734977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928378|NCT05065268|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Visual rehabilitation using home based audiovisual rehabilitation in immersive virtual reality.||||
33928379|NCT03874416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical assessment will be performed by an assessor blinded to group allocation.|"Single blind trial with 2 parallel arms:~Specific rehabilitation of working memory vs. non-specific rehabilitation"|f|f|f|t
33928380|NCT00441480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928381|NCT03950960||SEQUENTIAL||TREATMENT||NONE||||||
33928382|NCT05338658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007484|NCT05462314|||COHORT||PROSPECTIVE|||||||
33720466|NCT02694237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720467|NCT01391390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720468|NCT01324388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928383|NCT01024920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928384|NCT05612594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, study personnel, and outcomes adjudicators will be blinded to the treatment assignment until the end of study procedures and database lock. Blinding codes will be broken at the end of the trial. Blinding codes will only be broken before the end of trial if a participant develops a serious adverse event requiring knowledge of the treatment allocation. At such time, the participant will be considered to have completed the trial and will not undergo any further trial treatment but may be asked to undergo assessment of trial endpoints when feasible. Whenever a code is broken, the person breaking the code must complete the unblinding form in Redcap. If the participant should be withdrawn following a code break, a withdrawal session should be completed in the computerized randomization system.||t|t|t|t
33928385|NCT05653856|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007485|NCT04329416|NA|SINGLE_GROUP||OTHER||NONE||A prospective observational single-center open-label study||||
34007486|NCT05850884|||CASE_CONTROL||OTHER|||||||
34007487|NCT01409798|||CASE_ONLY||PROSPECTIVE|||||||
34007488|NCT01010815|||CASE_CONTROL||PROSPECTIVE|||||||
34007489|NCT02654587|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-step open-label study with a planned interim OS futility in experimental arm per Fleming design (Step1) Central randomisation (2:1) with stratification by histology (non-squamous versus squamous), best response to first-line treatment \[complete response (CR) or partial response (PR) versus stable disease (SD) or PD\] and line of prior anti-PD(L)1 treatment (first-line when combined with platinum-based chemotherapy versus second-line when administered as sequential treatment after first-line platinum-based chemotherapy).||||
34007490|NCT00489099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007491|NCT06617039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720469|NCT04853342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720470|NCT01335555|||COHORT||PROSPECTIVE|||||||
33720471|NCT00002222||||TREATMENT||NONE||||||
33720472|NCT03190655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The person that assess the degree of epithelization will be presented with photos of the burn conditions and will not be given information of the patient's treatment.|Patients who attend the clinical sites, presenting with untreated partial thickness burns less than 4 hours, and meet the inclusion and exclusion criteria|f|t|f|t
33720473|NCT01966640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720474|NCT00528099|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33720475|NCT01618552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720476|NCT06320730|||COHORT||RETROSPECTIVE|||||||
33801693|NCT03185650|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Healthy subjects will use each nebulizer device in random order at separate study visits.||||
33928386|NCT00814307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928387|NCT02666040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33928388|NCT02104141|||COHORT||OTHER|||||||
33720477|NCT02391740|||CASE_ONLY||PROSPECTIVE|||||||
33928389|NCT04553367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||200 patients included in our study from those who showed no improvement and still had respiratory failure and completed ventilation for 4 days and fulfilled \> 2 parameters on SOFA score \[9-10\] and \> 6 on CPIS score and randomly allocated in two groups 100 patients in each.|f|f|t|f
33928390|NCT06507605|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33928391|NCT02464267|||OTHER||OTHER|||||||
33928392|NCT05375162|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The four Intervention components that are candidates for inclusion in the optimized intervention, each with 2 possible levels, will be tested in a 12-week intervention with a 12-week follow-up using a MOST approach. The effects of the four individual intervention components and their combinations will be examined via a full factorial experiment. The investigators chose a factorial experimental design because these designs have two characteristics essential to the success of MOST. They: a) separate component effects enabling the estimation of the main effect of each candidate component and interactions between components and b) are more economical compared to alternative designs because they often require substantially fewer subjects to achieve the same power and use less resources. The investigators are using a full factorial experiment with 2\^4=16 experimental conditions.||||
33928393|NCT01569087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928394|NCT03582852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928395|NCT02414113|||COHORT||PROSPECTIVE|||||||
33928396|NCT05813613|||OTHER||CROSS_SECTIONAL|||||||
33928397|NCT00845845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928398|NCT02911519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928399|NCT01016678|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33928400|NCT03381625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33928401|NCT04238689|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Five groups will receive a single dose of mAb TB31F administered intravenously (groups 1-4) or subcutaneously (group 5). Group 1 (n=5) will receive 0.1 mg/kg TB31F, group 2 (n=5) will receive 1 mg/kg TB31F, group 3 (n=5) will receive 3 mg/kg TB31F, group 4 (n=5) will receive 10 mg/kg mAb TB31F, and group 5 will receive 100mg TB31F. Twenty-five (n=25) subjects will be enrolled.||||
33788861|NCT04594330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and care provider are blinded to the type of treatment that the participants receive.|The COVID-19 patients are recruited according to the inclusion and exclusion criteria, then divided into two groups. Group I, the intervention group, consists of COVID-19 patients receiving standard therapy and 15 mL of VCO twice a day for 14 days. Group II, the control group, consists of COVID-19 patients receiving standard therapy and 15 mL of placebo twice a day for 14 days.|t|t|f|f
33788862|NCT04458831|||COHORT||PROSPECTIVE|||||||
33928402|NCT03136900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33928403|NCT02150512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928404|NCT04518722|||CASE_CONTROL||PROSPECTIVE|||||||
33928405|NCT01152411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007492|NCT06412211|||COHORT||CROSS_SECTIONAL|||||||
34007493|NCT01739413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007494|NCT03309917|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007495|NCT00982501|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34007496|NCT01226537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007497|NCT05445609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007498|NCT06361095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007499|NCT03068949|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34007500|NCT04922450|NA|SINGLE_GROUP||TREATMENT||NONE||Patients fulfilling Eligibility Criteria will be included in our study.Participants will be given intravenous administration of Camrelizumab (200mg)，Albumin Paclitaxel(260mg/m²) and Cisplatin（80mg/m²）,After completing three times every three weeks of neoadjuvant therapy, The Participants will undergo surgery and Postoperative intensity modulated chemotherapy.Treatments will be administrated until death, or unacceptable toxicity.||||
34007501|NCT04047953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007502|NCT01955512|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007503|NCT03307486|||COHORT||PROSPECTIVE|||||||
34007504|NCT05762484|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT with intervention and control group||||
34007505|NCT05388812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||eligible and consenting participants will be randomized to either individual placement and support (IPS) or treatment as usual vocational rehabilitation (TAU-VR).||||
34007506|NCT04959851|||COHORT||PROSPECTIVE|||||||
34007507|NCT03705949|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34007508|NCT00784134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007509|NCT06617377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||anoxo-ischemic coma patients||||
34007510|NCT04314843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007511|NCT03553563|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||An open label, parallel four group, multi-centre, phase III study||||
33788863|NCT05001906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788864|NCT03942042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788865|NCT02404337|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788866|NCT05779007|||COHORT||RETROSPECTIVE|||||||
33788867|NCT05803330|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788868|NCT02636985|||CASE_ONLY||RETROSPECTIVE|||||||
33788869|NCT04858217|||CASE_ONLY||PROSPECTIVE|||||||
33788870|NCT00016913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788871|NCT04621708|NA|SINGLE_GROUP||TREATMENT||NONE||This study is designed as an open-label pilot study||||
33788872|NCT00551772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788873|NCT00770978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788874|NCT00647205|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33788875|NCT04975243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788876|NCT02596035|NA|SINGLE_GROUP||OTHER||NONE||||||
33928406|NCT03489070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33928407|NCT02957110|||OTHER||OTHER|||||||
33928408|NCT00544804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928409|NCT02949557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33788877|NCT01284153|||CASE_ONLY||CROSS_SECTIONAL|||||||
33788878|NCT00781612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788879|NCT01191086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788880|NCT06431035|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Using placebo chewing gum|The participants were divided into caffeine gum trial (CAF) and placebo trial (PL) with a randomized, double-blind study design.|f|f|t|f
33788881|NCT02007499|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33788882|NCT05901558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788883|NCT02959957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788884|NCT06216119|||COHORT||PROSPECTIVE|||||||
33801694|NCT02215707|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928410|NCT04437316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, randomized study|split-mouth design|t|t|t|f
33928411|NCT03907449|||CASE_ONLY||PROSPECTIVE|||||||
33928412|NCT06422572|||COHORT||RETROSPECTIVE|||||||
33928413|NCT00776698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928414|NCT00318370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928415|NCT03619837|NA|SINGLE_GROUP||OTHER||NONE||||||
33928416|NCT03063398|||COHORT||PROSPECTIVE|||||||
33928417|NCT02548741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928418|NCT04826029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928419|NCT04703049|||COHORT||PROSPECTIVE|||||||
34007512|NCT01524029|||COHORT||PROSPECTIVE|||||||
34007513|NCT06227910|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34007514|NCT02080507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007515|NCT00670033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007516|NCT00831233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720478|NCT05298280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The observer (BA) who performed all the measurements was blinded to the group assignment. The study was blinded in regard to the statistical analysis: blinding was obtained by eliminating from the elaboration file every reference to patient group assignment.|"Subjects enrolled in the study were randomly assigned to the two groups: Pendulum Group (PG) Clear Aligner Group (CAG). All subjects were treated by the same clinician.~A computer-generated random number list was used to allocate patients to treatments. Block randomization was used to assign the same number of patients to each treatment. The allocation sequence was concealed by the statistician, who used opaque and sealed envelopes, sequentially numbered for each patient."|f|f|t|t
34007517|NCT02932917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007518|NCT00319787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34007519|NCT03642067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007520|NCT04021355|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34007521|NCT01494103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007522|NCT02173652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007523|NCT01191476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007524|NCT06184867|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Treating clinicians will be blind their patients group assignment. While participants cannot be blinded to group, they will be blinded to the study's specific hypotheses. Statisticians and outcome assessors will be blinded to allocation.|This study will employ a 2-arm parallel group randomized controlled trial to evaluate the efficacy of the relational agent/chatbot (RA) intervention compared to Enhanced Usual Care (EUC) among 30 cancer survivors.|f|t|f|t
34007525|NCT00610324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007526|NCT00508027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007527|NCT00191464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007528|NCT01783652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007529|NCT01047891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007530|NCT04751045|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Study the safety, efficacy of EUS guided liver biopsy in comparison to percutaneous liver biopsy||||
34007531|NCT02443324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007532|NCT06535503|||COHORT||RETROSPECTIVE|||||||
34007533|NCT02555982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007534|NCT04431414|||COHORT||PROSPECTIVE|||||||
34007535|NCT06207630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007536|NCT01891552|||COHORT||PROSPECTIVE|||||||
34007537|NCT05418634|||OTHER||PROSPECTIVE|||||||
34007538|NCT02893280|||COHORT||PROSPECTIVE|||||||
34007539|NCT01501110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007540|NCT06172855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007541|NCT04420624|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, phase IIb, monocentric, randomized, open labeled with 2 parallel study arms.||||
34092565|NCT06368362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not informed of the conditioned they are randomised to in this psychological intervention.|Two groups of participants (chronic musculoskeletal pain, healthy) were recruited, and within each group participants were randomised to one of two experimental conditions with a 1:1 allocation ratio with a parallel design. Participants with chronic musculoskeletal pain were randomised to benign CBM-I or no CBM-I, and healthy participants were randomised to benign CBM-I or pain-related CBM-I.|t|f|f|f
34092566|NCT00693459|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34092567|NCT06101446|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34092568|NCT00001818||||TREATMENT||||||||
34092569|NCT02492386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092570|NCT00899275|||OTHER||RETROSPECTIVE|||||||
33720479|NCT04937296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720480|NCT03198533|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720481|NCT05624437|||COHORT||OTHER|||||||
34092571|NCT04333498|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33720482|NCT04061096|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|no need|||||
33720483|NCT01782664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720484|NCT01599871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720485|NCT00003443||||TREATMENT||||||||
33720486|NCT02450110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720487|NCT04057079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Research staff used a computer-based tool to allocate the ligasure haemorrhoidectomy patients randomly to either Group 1 (n=56) who received standard anal gelatine sponge (SpongostanTM) or Group 2 (n-54) to a layered hydrogel sponge (AnugelTM) following surgery. Encryption concealed the allocation until the patient's details had been logged.||||
33720488|NCT00732147|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33720489|NCT05652998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720490|NCT02089633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788885|NCT03613129|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is comprised of a recruitment and screening period, enrollment (Visit 1), a 4-week (at least) pre-treatment assessment period, a 1-week interventional treatment period with drug infused at Visits 3, 4 and 4b, a 4-week (at least) post-treatment assessment period, and a close-out (Visit 6).||||
33788886|NCT05541263|RANDOMIZED|PARALLEL||PREVENTION||NONE|Baseline Measurements will occur before group assignments and therefore both participants and researchers are blinded to these measurements. Post-treatment measurements are de-blinded.|We will perform a randomized, wait-list controlled trial with a Mindfulness-Based Stress Reduction (MBSR) intervention, based on the programme developed by Kabat-Zinn (1982).||||
33788887|NCT01638624|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33788888|NCT02968004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788889|NCT05357365|||COHORT||PROSPECTIVE|||||||
33788890|NCT01876654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788891|NCT05171218|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Participants taking anxiolytics (n = 163) were randomly assigned to a single 24- minute session of sound-based treatment: combined (Music with theta auditory beat stimulation), music-alone, theta auditory beat stimulation-alone, or pink noise (control). Pre- and post-intervention somatic and cognitive state anxiety measures (STICSA State) were collected along with trait anxiety (STICSA Trait), personality measures (Short Form Eysenck Personality Inventory) and musical preferences (Short Test of Music Preferences).||||
33788892|NCT02373228|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33788893|NCT02783157|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788894|NCT00610753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788895|NCT04854993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient as well as the investigator (care provider) who will administer the different blinded sugammadex dosage and collect postoperative data will be blinded to the group allocation. The randomization and preparation of the drug will be performed by the unblinded staff of hospital experimental pharmacy who will carry out the randomization with a 1: 1 ratio and will assign the different dose to each patient. The drug will be prepared in a shielded pre-filled syringe in order to maintain blindness. In case of emergency, the pharmacy staff will immediately open the randomization code of interest disclosing the group assignment (sugammadex dose).||t|t|t|t
33788896|NCT04921423|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788897|NCT03126409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33788898|NCT02098902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788899|NCT06631560|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788900|NCT01043406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788901|NCT01103973|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788902|NCT00569738|||COHORT||PROSPECTIVE|||||||
33788903|NCT02601053|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33788904|NCT01190566|||CASE_ONLY||PROSPECTIVE|||||||
33788905|NCT02570295|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788906|NCT01175707|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33788907|NCT02321748|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33788908|NCT02191852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788909|NCT01461213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007542|NCT06416852|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007543|NCT00426530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007544|NCT03014986|||CASE_ONLY||PROSPECTIVE|||||||
34007545|NCT01658917|||CASE_ONLY||PROSPECTIVE|||||||
34007546|NCT03201731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34007547|NCT02004184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007548|NCT00775528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007549|NCT06475625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788910|NCT01254981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788911|NCT03511885|||COHORT||CROSS_SECTIONAL|||||||
33788912|NCT00728845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788913|NCT00315055|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007550|NCT05398835|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34007551|NCT01560884|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34007552|NCT01961258|||COHORT|||||||||
34007553|NCT00571389|||CASE_ONLY||PROSPECTIVE|||||||
34007554|NCT03288402|RANDOMIZED|CROSSOVER||SCREENING||NONE||double crossover (ongoing fasted; or caffeine containing beverages; of 5-item English breakfast)||||
34007555|NCT04689893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007556|NCT05924867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007557|NCT03785145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720491|NCT00898157|||OTHER||RETROSPECTIVE|||||||
33720492|NCT00385242|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720493|NCT05317533|||COHORT||PROSPECTIVE|||||||
33720494|NCT01566461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720495|NCT00882193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720496|NCT03572140|||COHORT||PROSPECTIVE|||||||
33720497|NCT02627430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720498|NCT03056391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720499|NCT04264637|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33720500|NCT05153031|||COHORT||RETROSPECTIVE|||||||
33720501|NCT06420440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788914|NCT06556134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33788915|NCT01230346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788916|NCT03921684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33788917|NCT00908336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788918|NCT00939848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788919|NCT03872297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788920|NCT06628934|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788921|NCT05655442|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33788922|NCT03297749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788923|NCT02145182|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788924|NCT01971892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788925|NCT00319085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788926|NCT01544569|||CASE_ONLY||RETROSPECTIVE|||||||
33788927|NCT05104905|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33788928|NCT03985917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants, singing group facilitators and researchers conducting the study cannot be blinded to allocation. However, the collection of the data, namely, cognitive, psychosocial, motor and physiologic outcome measures will be assessed by independent researchers, blinded to group allocation.|Participants were recruited by invitation in the day-care centers, nursing homes and home care units run by Santa Casa da Misericórdia (a Portuguese Charity Institution, partner in the project). All older adults received an invitation with a brief description of the program and the study. In case they were interested in participating, they were invited to a meeting where the musical intervention team provided additional information about the intervention and clarified any questions from the participants. At the end of the session a detailed informed consent was signed.|f|f|f|t
33788929|NCT02934035|||||PROSPECTIVE|||||||
33788930|NCT01909336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33788931|NCT04180267|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Subject will be randomized to either LMHFV group or control group. Subject assigned to LMHFV group will receive Low-magnitude High-frequency Vibration (35Hz, 0.3g, 20min/day, at least 3 times/week) for half year. The primary outcome is the effect of LMHFV on BMD at the lumbar spine, it will be assessed by dual-energy X-ray absorptiometry (DXA) that is clinically recommended for the diagnosis of osteoporosis. Secondary outcomes include muscle strength assessment, balancing ability and quality of life (QoL). All primary and secondary outcome assessments for all groups will be performed in the investigators' institute at baseline and 6 months post treatment.|t|f|f|f
34007558|NCT00437190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720502|NCT05433961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720503|NCT03261947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788932|NCT03843164|||CASE_ONLY||RETROSPECTIVE|||||||
33788933|NCT04073914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||To evaluate the complete program the investigators conducted a modest randomized clinical trial, randomizing parents to the Type1Teamwork program or a wait-list control group. Results were analyzed using general linear repeated measures models with training group, and time as fixed effects. The primary hypotheses comparing changes in domain totals over time will be tested by the interaction effect of time by treatment group.||||
33788934|NCT03658499|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be divided by strata (court mandated vs. voluntary) and randomly assigned to either the experimental or control condition, after completing the two-day skills group, via a research randomizer (Urbaniak \& Plous, 2013), which randomly generates numbers that designate the assignment condition of each participant.||||
33788935|NCT04417270|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Patients will use the Freestyle 14 day CGM reader or their phone to check their glucose. A clinical staff member will check the patient's blood sugar by performing a glucose finger stick with the Accuchek inform II meter.||||
33788936|NCT01090024|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33788937|NCT03517579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a pilot experimental study||||
33788938|NCT00333541|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33788939|NCT00018681|||||PROSPECTIVE|||||||
33928420|NCT05829395|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|With the simple randomization method, students will be assigned to the experimental and control groups. But students will not know which group is the experimental group.|This study will be conducted as a randomized controlled experimental study in order to determine the effect of nursing process teaching in the metaverse environment on the learning motivation and academic achievement of nursing students. this study will be conducted from March 2023 to April 2023 in the nursing department of a university. The sample consisted of 42 students who volunteered to participate in the research and met the inclusion criteria. Scales and Forms to be used in the Study; Personal Information Form, The Instructional Materials Motivation Scale, and Academic Success Assessment (Quiz)|t|f|f|f
33928421|NCT01779297|||COHORT||PROSPECTIVE|||||||
33928422|NCT02737176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928423|NCT03619850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928424|NCT04777123|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34007559|NCT05246696|||CASE_ONLY||CROSS_SECTIONAL|||||||
34007560|NCT02293473|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34007561|NCT06467578|NA|SINGLE_GROUP||OTHER||NONE||||||
33720504|NCT02378701|||COHORT||PROSPECTIVE|||||||
33720505|NCT04779489|NA|SINGLE_GROUP||TREATMENT||NONE|open label|single-arm interventional study||||
33720506|NCT02140788|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33720507|NCT04790760|NA|SINGLE_GROUP||OTHER||NONE||||||
33720508|NCT00233896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33720509|NCT03138395|||COHORT||PROSPECTIVE|||||||
33720510|NCT05890807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"A prospective, single-center, open-label, cross-sectional study to evaluate the concordance of an intervention versus the gold standard."||||
33720511|NCT03054545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720512|NCT00242957|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33720513|NCT02040454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720514|NCT03638024|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33720515|NCT04032041|||COHORT||PROSPECTIVE|||||||
34007562|NCT02067767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092572|NCT04452006|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Part A: Single-ascending dose study in healthy male subjects (including investigation of the effect of food); Part B: Single-dose, three-way crossover study in healthy male subjects to investigate specific/additional parameters related to safety and tolerability; Part C: Multiple-ascending dose study in healthy male and female subjects (including healthy male and female elderly subjects).|t|t|t|t
34007563|NCT03573817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blind, placebo-controlled, parallel-group study. Each participant will receive treatment daily for a total of 42 days. One group will receive placebo and formoterol and one group will receive revefenacin and formoterol.|t|t|t|t
34007564|NCT02504814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007565|NCT02725424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007566|NCT06132152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Before the operation, all patients are scheduled to perform an open hemorrhoidectomy, which includes radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Patients are not informed about which instrument will be used.~All collected information will be stored in electronic databases, where patient names and group numbers are anonymized and encrypted. Thus, during the statistical calculation, a person will not know about the name of the group."|In case of meeting inclusion criteria of patient the selection of the group will be determined by randomization, so both groups will be recruited simultaneously|t|f|f|t
34007567|NCT05777824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007568|NCT03965728|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007569|NCT04094740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007570|NCT04500132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007571|NCT04936919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007572|NCT01884402|||||PROSPECTIVE|||||||
34007573|NCT01813071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007574|NCT01935479|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007575|NCT03766217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007576|NCT02996019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007577|NCT03979833|||COHORT||RETROSPECTIVE|||||||
34007578|NCT03677219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The caregiver obtaining consent for lumbar puncture does not know if the parent will be randomized to see the video; the parent is not aware they may be randomized to see a video when they respond to the first survey about their concerns.|Parents are randomized to either view an educational video or not|t|t|f|f
34007579|NCT00004424|RANDOMIZED|||TREATMENT||DOUBLE||||||
34007580|NCT05235425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment and data analysis will be masked||f|f|f|t
34007581|NCT00067171|RANDOMIZED|||||||||||
34007582|NCT06331234|||COHORT||PROSPECTIVE|||||||
34007583|NCT00785096|||COHORT||PROSPECTIVE|||||||
34007584|NCT03307798|||OTHER||PROSPECTIVE|||||||
34007585|NCT05110131|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|The attending physician and patient will be blinded to the randomized group and which method of biopsy (needle or forceps) would be performed first. The pulmonologist performing the ENB procedure will be informed just before the start of the procedure which group the patient is affiliated to.|Randomized crossover design|t|t|t|f
34007586|NCT04529395|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34007587|NCT00699530|||COHORT||PROSPECTIVE|||||||
34007588|NCT05556226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34092573|NCT00248326|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092574|NCT00571090|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092575|NCT03454958|||OTHER||PROSPECTIVE|||||||
34092576|NCT02932943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092577|NCT01023321|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34092578|NCT05145114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34092579|NCT01328119|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092580|NCT00692796|NA|SINGLE_GROUP||TREATMENT||||||||
34092581|NCT00792480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34092582|NCT03334266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092583|NCT05679505|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34092584|NCT00277563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092585|NCT03778372|||CASE_CONTROL||PROSPECTIVE|||||||
34092586|NCT00717080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092587|NCT02082288|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34092588|NCT02557789|RANDOMIZED|CROSSOVER||||NONE||||||
33720516|NCT04659850|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Dietary Challenge|t|f|t|f
33720517|NCT04234035|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33720518|NCT00614315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720519|NCT04246060|||COHORT||OTHER|||||||
33720520|NCT00289315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788940|NCT02793427|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33788941|NCT05990569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007589|NCT03404401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720521|NCT05047679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Only the participant and the person responsible for the monitoring of the baseline and follow-up assessments will be masked.||t|f|f|t
33720522|NCT05127889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double|assignment|t|f|f|f
33720523|NCT06412939|||COHORT||RETROSPECTIVE|||||||
33720524|NCT01881230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720525|NCT02154581|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720526|NCT06493708|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33720527|NCT01053689|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720528|NCT05769790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720529|NCT01893073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720530|NCT02502539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007590|NCT04012073|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will be stratified according to Recruitment/cmH2O ≥ or \< 19 ml/cmH2O across the range between the lowest and highest PEEP tested during the initial PEEP trial||||
33720531|NCT00842712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720532|NCT03556007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33788942|NCT03552913|||COHORT||RETROSPECTIVE|||||||
33788943|NCT01501006|||COHORT||PROSPECTIVE|||||||
33788944|NCT05147506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788945|NCT02271048|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33788946|NCT00048828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788947|NCT01612754|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33788948|NCT04822155|||COHORT||PROSPECTIVE|||||||
33928425|NCT03561636|||COHORT||RETROSPECTIVE|||||||
33928426|NCT01487707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928427|NCT04120727|||COHORT||PROSPECTIVE|||||||
33928428|NCT02366247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928429|NCT00250068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007591|NCT04377906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|subject with random allocation Investigator do not know the group the analysator do not know the group|"four arm parallel group with 56 young obesity:~1. high protein-fiber diet and exercise~2. high protein-fiber diet~3. exercise~4. control"|t|f|t|f
34007592|NCT06617390|||COHORT||RETROSPECTIVE|||||||
34092589|NCT01489423|||OTHER||RETROSPECTIVE|||||||
33788949|NCT01457560|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33788950|NCT05753644|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007593|NCT03284502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720533|NCT04919278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720534|NCT04816279|||OTHER||PROSPECTIVE|||||||
33788951|NCT04590794|||COHORT||PROSPECTIVE|||||||
34007594|NCT03635502|||COHORT||PROSPECTIVE|||||||
34007595|NCT00698087|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34007596|NCT00939627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007597|NCT05876533|||COHORT||RETROSPECTIVE|||||||
34007598|NCT01118026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720535|NCT01769014|||COHORT||RETROSPECTIVE|||||||
33720536|NCT03175510|||OTHER||RETROSPECTIVE|||||||
33720537|NCT04996888|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33788952|NCT06111690|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single group pre-post design study||||
33788953|NCT04899323|||COHORT||PROSPECTIVE|||||||
33928430|NCT01461824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928431|NCT04378439|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33928432|NCT01364285|||COHORT||PROSPECTIVE|||||||
33928433|NCT01398228|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928434|NCT04281836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928435|NCT02411513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928436|NCT03949010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928437|NCT06227806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007599|NCT03201978|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34007600|NCT01257581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092590|NCT04841174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The researcher in the study is also the person who will implement the initiative. The researcher has caregiver, researcher, and outcome evaluator roles throughout the process.|The study will be conducted in a randomized controlled experimental and single-blind study design.|f|t|t|t
34092591|NCT00202488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092592|NCT02590315|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34092593|NCT04994184|||COHORT||RETROSPECTIVE|||||||
34092594|NCT01719276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092595|NCT01588509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092596|NCT00159809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703204|NCT03823456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In this study, due to the nature of the intervention, a partial double-blinded design will be employed. Participants randomize in standard care group will know their group assignment, but participants randomize to true and sham self-acupressure group will not know whether they receive true or sham self-acupressure treatment. Nevertheless, the outcomes of the study are all self-reported instruments, therefore, to some extent, the participants themselves could be viewed as outcome assessors. Therefore, participants and outcome assessors located in true or sham self-acupressure group will be blinded on the treatment allocation. To ensure the successful blinding design, healthcare provider working in the wards will not know the group allocation, the main researcher will also work with the head-nurse of the department to arrange patient in intervention group and control groups into different wards."|"True self-acupressure group \[Enhanced standard care + True self-acupressure\]:~Participants will practice the four-week acupressure protocol plus standard care. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers.~Sham self-acupressure group \[Enhanced standard care + Sham self-acupressure\]:~Patients will practice the four weeks sham self-acupressure protocol plus standard care. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers.~Enhanced standard care group The enhanced standard care in this study refers to standard care provided by the hospital includes health assessment, nutrition advice during taking chemotherapy treatment, hypnotics (Prescribe only where necessary by a doctor), and the enhanced care provided by the main researcher includes patient leaflet of tips on managing insomnia, depression, and anxiety; weekly follow-up phone call in four weeks."|t|t|f|f
33703205|NCT02681783|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703206|NCT00776204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703207|NCT00236444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703208|NCT03050099|||COHORT||PROSPECTIVE|||||||
34092597|NCT00558883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092598|NCT01217450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092599|NCT01748682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092600|NCT04890613|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Eligible patients will be enrolled into two cohorts; Main study cohort: Patients with histologically-confirmed pancreatic, ovarian, prostate, or breast cancers with pathogenic/likely pathogenic germline BRCA2 and/or PALB2 mutation. Exploratory cohort: women with ovarian cancer and pathogenic/likely pathogenic BRCA1 and/or other HRD-associated mutation.~An initial 16 eligible patients for the main cohort and 10 eligible patients for the exploratory cohort will be enrolled to receive CX-5461 at 250mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle. Upon completion of enrollment of all patients in the initial arms, if there are no safety concerns after review of the safety data, another two arms will open to enroll an additional 16 patients for the main cohort and 10 patients for the exploratory cohort to receive CX-5461 at 325mg/m2, delivered as a 60-minute IV infusion on Day 1 and Day 8 of a 28-day cycle."||||
34092601|NCT02128750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092602|NCT00766103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092603|NCT04386148|||COHORT||PROSPECTIVE|||||||
34092604|NCT06420583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703209|NCT02416570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33703210|NCT03188315|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
34092605|NCT00818844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33703211|NCT03342963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703212|NCT06426810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703213|NCT03607487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33703214|NCT03824730|||COHORT||PROSPECTIVE|||||||
33703215|NCT02836093|||COHORT||PROSPECTIVE|||||||
33703216|NCT01542320|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33703217|NCT06217341|||COHORT||PROSPECTIVE|||||||
33703218|NCT00841919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703219|NCT00677131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33703220|NCT03089320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703221|NCT00487708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801695|NCT00062907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801696|NCT06137105|||COHORT||PROSPECTIVE|||||||
33801697|NCT01222039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801698|NCT01193894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092606|NCT04337073|RANDOMIZED|PARALLEL||PREVENTION||NONE||propofol (P) group and normal saline (N) group||||
34092607|NCT05993143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Test (Ivermectin) and reference (placebo) tablets will be identical in size, colour, taste and appearance. The packaging and labelling will not allow for any distinction between the test and reference drug.||t|t|t|t
34092608|NCT00183898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092609|NCT03611660|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
34092610|NCT06511128|||CASE_ONLY||PROSPECTIVE|||||||
34092611|NCT01137760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33801699|NCT05946421|||COHORT||PROSPECTIVE|||||||
33801700|NCT05447871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind (participant) study||t|f|f|f
33801701|NCT02233595|||COHORT||PROSPECTIVE|||||||
33801702|NCT03390296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703222|NCT05227183|NON_RANDOMIZED|PARALLEL||OTHER||NONE|non applicable|||||
33703223|NCT05325060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720538|NCT00840294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703224|NCT06086275|RANDOMIZED|CROSSOVER||OTHER||NONE|All portions will be open label|All participants will first receive the IV arm in fixed order, in an open-label fashion. Subsequently, participants will be randomized to the two PO.||||
33703225|NCT06556862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703226|NCT03353246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092612|NCT06121505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788954|NCT05086809|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The participants are blinded to the tested conditions in the lab, used for assessment of the primary objective, but the participants are not blinded to the sound processors used during the three trial periods, due to different appearance of the sound processors, making it possible to distinguish between the sound processors.|The study includes four laboratory visits and three field trial periods. The first trial period is included to ensure a homogenous baseline. After the first trial period, the study is designed as a two-period, two-sequence crossover trial to compare two sound processors (Device A \& Device B). Each participant is randomized into one of two sequences: (1) Device A then B, or (2) Device B then A, such that (about) half of the participants are assigned to one sequence and the other half to the second sequence.|t|f|f|f
33788955|NCT01352507|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33788956|NCT06360042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788957|NCT05012644|||COHORT||RETROSPECTIVE|||||||
33788958|NCT01189006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788959|NCT00646308|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33788960|NCT06486818|||CASE_CONTROL||RETROSPECTIVE|||||||
33788961|NCT00541697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33788962|NCT01213706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33788963|NCT00238316|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33788964|NCT02559258|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33788965|NCT04303182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|f|t
33788966|NCT02885350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33788967|NCT03952195|||COHORT||RETROSPECTIVE|||||||
33788968|NCT02727972|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33788969|NCT01063023|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33788970|NCT02988596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788971|NCT02882048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788972|NCT02735486|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33788973|NCT05787730|NA|SINGLE_GROUP||SCREENING||NONE||||||
33788974|NCT06169033|||COHORT||PROSPECTIVE|||||||
33788975|NCT02287649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788976|NCT03107611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33788977|NCT04089046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33788978|NCT02337010|RANDOMIZED|PARALLEL||||NONE||||||
33928438|NCT03125993|NA|SINGLE_GROUP||PREVENTION||NONE||This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study. Every participants will be followed up in community visits every month.||||
33928439|NCT03870906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33928440|NCT00232414|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34092613|NCT03586193|||COHORT||PROSPECTIVE|||||||
33703227|NCT00252395|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33703228|NCT03754569|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33928441|NCT02384993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928442|NCT03373318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33928443|NCT00904176|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928444|NCT04720690|||COHORT||PROSPECTIVE|||||||
34007601|NCT06117943|||CASE_ONLY||CROSS_SECTIONAL|||||||
33703229|NCT03218878|||COHORT||PROSPECTIVE|||||||
33703230|NCT00545766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703231|NCT04782661|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33703232|NCT04682028|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703233|NCT06557187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703234|NCT02027961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703235|NCT05139121|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34007602|NCT00992563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007603|NCT01765517|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34007604|NCT04102345|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Non-randomized, pragmatic, clinical study.||||
34007605|NCT03634410|||COHORT||PROSPECTIVE|||||||
34007606|NCT02388698|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34007607|NCT00217724|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34007608|NCT03609242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster RCT study design will test the impact of the bundle (communication still training, performance feedback and prompts) to reduce missed opportunities and raise HPV vaccine rates.||||
34007609|NCT04733248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703236|NCT01137396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703237|NCT01439633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788979|NCT05567952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33788980|NCT05128305|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33788981|NCT03086512|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups. Group I consists of 45 patients receiving a subtalar fusion with fully threaded screws (Acutrak 2® - 7.5). Group II consists of 45 patients receiving a subtalar fusion with partially threaded screws (Synthes® 7.3 Cannulated Screw).||||
33788982|NCT02931851|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33788983|NCT05992064|||COHORT||PROSPECTIVE|||||||
33788984|NCT05457478|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33788985|NCT00882635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928445|NCT04366713|NA|SINGLE_GROUP||OTHER||NONE||||||
33928446|NCT01952093|||COHORT||PROSPECTIVE|||||||
33703238|NCT02632331|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703239|NCT02388919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703240|NCT00154635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703241|NCT05749965|||COHORT||RETROSPECTIVE|||||||
33703242|NCT01965821|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33703243|NCT00332592|||COHORT||PROSPECTIVE|||||||
33703244|NCT01696695|||COHORT||PROSPECTIVE|||||||
33703245|NCT02834728|||COHORT||PROSPECTIVE|||||||
34007610|NCT03534908|||COHORT||RETROSPECTIVE|||||||
34007611|NCT02807779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007612|NCT03745417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007613|NCT03142659|||OTHER||PROSPECTIVE|||||||
33703246|NCT02198521|||COHORT||PROSPECTIVE|||||||
33703247|NCT01970657|||COHORT||PROSPECTIVE|||||||
33703248|NCT01275040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703249|NCT01560403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703250|NCT02609204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703251|NCT05944887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|computered randomisation, sealed enveloppes linisol versus placebo prepared by anesthesist not involved in the study or in patient care||t|t|t|t
33720539|NCT06136923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33928447|NCT05826041|RANDOMIZED|PARALLEL||OTHER||NONE||Other: INSPIRE support group Other: Intervention as usual||||
33928448|NCT06398444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928449|NCT00997555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928450|NCT04745312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized crossover||||
33928451|NCT00368472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928452|NCT02833818|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928453|NCT00169806|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33928454|NCT03326661|RANDOMIZED|PARALLEL||TREATMENT||NONE|masking is not possible|patients randomized to treatment by needle aspiration or tonsillectomy a chaud||||
33928455|NCT01847079|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33928456|NCT05757479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928457|NCT02229253|||COHORT||PROSPECTIVE|||||||
33928458|NCT04334512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a Randomized, Double-Blind, Placebo-Controlled Phase II interventional Study|t|f|t|f
33928459|NCT04815733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"t is planned to recruit patients in two groups: group 1-patients who will undergo General anesthesia with deep neuromuscular block and PCV-VG; group 2-patients with partial neuromuscular block and PSVpro.~Randomization of patients into two 1:1 groups will be performed by random number generation."|t|f|t|f
33928460|NCT01923649|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33928461|NCT03374436|RANDOMIZED|CROSSOVER||OTHER||NONE|It is not possible to mask the exercise or diet interventions.|Participants complete three conditions in a repeated crossover design.||||
33928462|NCT02871518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007614|NCT04812574|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center prospective before-after (pre-post) interventional study, in which the effectiveness and safety of periurethral hypertonic saline injection were evaluated in female stress urinary incontinence and stress-predominant mixed urinary incontinence patients.||||
34007615|NCT05099523|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34007616|NCT06617117|RANDOMIZED|CROSSOVER||OTHER||NONE|Outcomes will be assessed by the same experts in every time point. Participants and evaluators will be blinded until arrival of the participant for the first experimental condition.|Parallel group crossover randomized trial||||
34007617|NCT02031237|||COHORT||PROSPECTIVE|||||||
34007618|NCT02571803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007619|NCT06133309|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007620|NCT00094367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007621|NCT03721627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007622|NCT01764867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720540|NCT02607891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720541|NCT04597996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|students|pre test post test model design|t|f|f|f
33720542|NCT01358591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33720543|NCT04814576|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||A sequential and transformative mixed methods design is proposed.|t|f|f|f
33720544|NCT04251598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928463|NCT03627000|||COHORT||RETROSPECTIVE|||||||
33928464|NCT04587960|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomized to delayed primary closure (group A, n=40) or primary closure (group B, n=30)||||
33928465|NCT01606943|||COHORT||RETROSPECTIVE|||||||
33928466|NCT06238115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928467|NCT01515488|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928468|NCT01715272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33928469|NCT01668134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928470|NCT04880772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|CPET clinician/physiologist will be blinded|1:1 randomisation to standard care or prehabilitation|f|f|f|t
33928471|NCT06133985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928472|NCT00048009||||TREATMENT||||||||
33928473|NCT03314012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928474|NCT04282876|||COHORT||PROSPECTIVE|||||||
33928475|NCT03700346|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33928476|NCT04229108||SEQUENTIAL||OTHER||NONE||Medopad application||||
34007623|NCT06616870|||COHORT||PROSPECTIVE|||||||
34007624|NCT00673192|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007625|NCT00242229|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34007626|NCT02339415|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34007627|NCT02370459|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007628|NCT01417351|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007629|NCT04372134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34007630|NCT01377896|||||RETROSPECTIVE|||||||
33788986|NCT00605033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33788987|NCT04472338|||COHORT||PROSPECTIVE|||||||
33788988|NCT06366594|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|A quasi-experimental design utilized one group for pre-, post, and follow-up intervention.|A quasi-experimental research design|t|f|f|f
33788989|NCT03235349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007631|NCT00236249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33788990|NCT04995887|||OTHER||OTHER|||||||
33788991|NCT00335023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33788992|NCT04247711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"A two-fold strategy will be used to keep the blind. First, external interviewers with experience in conducting clinical evaluations will be hired and trained. These interviewers will be blind to study hypotheses and participant assignment. A mental health professional at each clinic (ie., Local Coordinator) will do the consent procedures and a member of the Research Staff (ie., Registration Designee) will randomly assign consented participants to the interviewers. The latter will be blinded to treatment allocation. Second, every assessment will be conducted at a location different from the clinic where a participant receives treatment. This location could be the participant's home, an office in UOH or UCH, or any place in the community where the participant feels comfortable (e.g., a park). This approach was successfully used in a previous U-19 study led by this research team in which most of the follow-up assessments were conducted in participants' neighborhoods."|The 21 participating clinics will be divided into two groups based on poverty level of catchment area and expected enrollment of individuals with FEP for each clinic. The largest site will be matched with two clinics of similar poverty level and clinic size. The matching will be done based on visual inspection of a scatter plot of expected enrollment by income of each site. The nearest neighbor matching approach will be used to choose pairs. Blocks of size 2, and one block of size 3, will be randomly generated. This procedure will entail 1) generating a random number 0 or 1 ten times, and 2) assigning 0 to the Usual FEP care clinic and 1 to the OTCH clinic in each matched pair. For the block of size 3, two sites will be assigned to either OTCH or Usual FEP care, and the remaining site to either OTCH or Usual FEP care as well. The random allocation will enable us to bring into the study one OTCH and one Usual FEP Care clinic per month (except for the block of size 3, as noted above).|f|f|f|t
34007632|NCT00501163|||COHORT||CROSS_SECTIONAL|||||||
33788993|NCT02129933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788994|NCT00161447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33788995|NCT02987335|||CASE_CONTROL||PROSPECTIVE|||||||
33703252|NCT04721730|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Participants will be allocated to groups after completion of pre-assessment. Thus, outcome assessors and participants will be blind to group allocation at pre-assessment. The implementation of the intervention will be conducted by different research staff (program coordinators and facilitators) than the assessments. Thus, data assessors are not aware of the group allocation of participants at the later assessment points (post, follow-up). To make sure that participants do not reveal their group allocation during the post- and follow-up assessment to the assessor, the data assessor will ask the participants to not share the group allocation at the beginning of the interview. Unblinding will only happen in case the participant reports a (serious) adverse event during the interview (at post- or follow-up assessment).~Also, the data analysis team (Klagenfurt) will remain blind to group allocation, because the unrevealing of assignment will be done in Bremen."|"Participants will be randomly allocated 1:1 to the intervention group (5 sessions parent training Parenting for Lifelong Health for Young Children), and the control group (one lecture on parenting Raising Healthy Children)."|f|f|f|t
34007633|NCT04509986|||COHORT||PROSPECTIVE|||||||
34007634|NCT01139294|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34007635|NCT02452528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34007636|NCT03266952|||COHORT||PROSPECTIVE|||||||
33703253|NCT01846104|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33703254|NCT02959242|||COHORT||PROSPECTIVE|||||||
33703255|NCT04798755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33788996|NCT00810550|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33788997|NCT03662399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33788998|NCT00624546|||COHORT||PROSPECTIVE|||||||
33788999|NCT02577484|||COHORT||PROSPECTIVE|||||||
33789000|NCT01923948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789001|NCT01205750||PARALLEL||BASIC_SCIENCE||NONE||||||
33789002|NCT00514332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789003|NCT02023372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789004|NCT06116812|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33789005|NCT01191619|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33789006|NCT04729244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will be taking CBD tincture, the other will be using CBD cream||||
33789007|NCT02678624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33789008|NCT06112119|||COHORT||RETROSPECTIVE|||||||
33789009|NCT00946114|||OTHER||PROSPECTIVE|||||||
33789010|NCT01976754|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33928477|NCT01643304|||||CROSS_SECTIONAL|||||||
33928478|NCT02786836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928479|NCT06267807|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928480|NCT04798690|||COHORT||OTHER|||||||
33928481|NCT01233180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928482|NCT05718661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This research was designed using the experimental (intervention) research method. Under the same environment and conditions, to determine the effect on the same dependent variable, the intervention (experimental) group using virtual reality and the placebo group not using virtual reality (watching the same video with the naked eye), pre-test (measurement of the dependent variable before the intervention), post-test (dependent measurement of the variable after intervention). In addition, the group that was not interfered with will form the control group and a data collection form will be applied with an interval of 30 minutes.||||
33928483|NCT00019214||||TREATMENT||||||||
34007637|NCT06453525|||COHORT||PROSPECTIVE|||||||
34007638|NCT03190772|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34007639|NCT03197545|||COHORT||OTHER|||||||
34007640|NCT05247931|||CASE_CONTROL||PROSPECTIVE|||||||
34007641|NCT01696136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007642|NCT03334968|||CASE_CONTROL||PROSPECTIVE|||||||
33789011|NCT01573858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33789012|NCT06217354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801703|NCT01794858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007643|NCT03134430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||the patients in treatment group will received reginoal nerve block with 0.35% Ropivacane and 0.5% lidocaine in normal saline under ultrasound guide, while those in control group received equal volume of normal saline.|t|t|t|t
34007644|NCT06616961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007645|NCT04791488|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703256|NCT05154396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703257|NCT01981980|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703258|NCT04496700|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The participants will take part in one of three tasks, and will be tested in their respective task twice: both before and after blood donation (the intervention).||||
33703259|NCT01206075|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703260|NCT05808114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703261|NCT05766852|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The participants will be assigned to Group A or Group B and either Monday or Thursday class according to their availability. Participants who are not able to attend either Monday or Thursday will have the option to complete the intervention virtually. Intervention Group A will be provided the intervention including breath and psychoeducation and Group B will be provided the intervention including breath, movement, and psychoeducation.||||
33703262|NCT03872544|||COHORT||PROSPECTIVE|||||||
33703263|NCT00889408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703264|NCT01400763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33703265|NCT01086761|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703266|NCT01899261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703267|NCT01787331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703268|NCT00462683|||||PROSPECTIVE|||||||
33703269|NCT02364492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703270|NCT06002607|||CASE_CONTROL||PROSPECTIVE|||||||
33703271|NCT04050345|||COHORT||PROSPECTIVE|||||||
33703272|NCT06372301|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703273|NCT03896048|||COHORT||PROSPECTIVE|||||||
33703274|NCT02929914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703275|NCT01850706|||CASE_CONTROL||PROSPECTIVE|||||||
33703276|NCT01332370|||COHORT||RETROSPECTIVE|||||||
33703277|NCT01682954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33703278|NCT04142632|||COHORT||PROSPECTIVE|||||||
33703279|NCT02430623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703280|NCT04167982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703281|NCT04840004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703282|NCT04878497|||COHORT||RETROSPECTIVE|||||||
33703283|NCT02371148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703284|NCT04447794|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703285|NCT04325178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703286|NCT02768363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703287|NCT01431170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703288|NCT03000569|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33703289|NCT02885896|||CASE_CONTROL||PROSPECTIVE|||||||
33703290|NCT00546104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703291|NCT04336293|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double-blind|double blind, sham controlled RCT|t|t|t|t
33703292|NCT04558944|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two randomized groups with twenty patients per group. The control group received the standard treatment for postburn scars. The treatment group (ESWT) received the standard treatment and treatment of postburn scars with ESWT 512 impulses of o.15mJ/mm 2 in each session, twice per week for 4 weeks.||||
33703293|NCT04253262|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation will follow the standard 3+3 design. Once the maximum tolerated dose is achieved in Phase I, Phase II will proceed.||||
33703294|NCT06219200|||CASE_ONLY||PROSPECTIVE|||||||
33703295|NCT00023946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703296|NCT00957554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703297|NCT06068608|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720545|NCT01499550|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33720546|NCT05796765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study. The injecting investigator(s) will not be blinded, but subjects and the evaluators performing safety and efficacy assessments will be blinded as to which treatment the subject received until the end of the study.||t|f|t|t
33720547|NCT03396614|||COHORT||CROSS_SECTIONAL|||||||
33720548|NCT01375985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720549|NCT06489652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801704|NCT00840229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33801705|NCT03902132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized controlled trial|t|f|f|f
33801706|NCT00945789|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928484|NCT01820767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928485|NCT01082588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703298|NCT04261036|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Vitamin C and Placebo pills will be blindly labeled and assorted in opaque containers in the Pharmacy department according to a computer generated list that allocated random assignment of vitamin C or placebo to a 200 positions (serial numbers from 1 to 200).~The research assistant in charge of the recuitment will not be aware of the content of each opaque container and would be providing them to patients according to the order in which they are recruited starting with container number 1, then 2 and so on.~The primary care provider and the investigators are blinded as well as they are not aware of the assignment of each recruited patient to placebo vs interventional arm.~It is only upon completion of data collection that results would be compared with the randomized generated list in order to link the recruited patients and their collected data with their original assignment to placebo vs intervention."||t|t|t|f
33703299|NCT01332643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703300|NCT06128473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703301|NCT02105883|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33703302|NCT06341075|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703303|NCT03158896|NA|SEQUENTIAL||TREATMENT||NONE||||||
33703304|NCT04608279|||CASE_ONLY||PROSPECTIVE|||||||
33703305|NCT01786941|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33703306|NCT01067664|||COHORT||PROSPECTIVE|||||||
33703307|NCT06176521|NA|SINGLE_GROUP||TREATMENT||NONE||before and after surgery results of a single group||||
33703308|NCT01024075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703309|NCT02021227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703310|NCT06424574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33703311|NCT04479930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703312|NCT05400746|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703313|NCT01738542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33789013|NCT04830722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Enrolled subjects will be randomized to 2 treatment groups: Right side treated and Left side treated. All subjects will receive three, single-sided injections of Sculptra Aesthetic, performed 1 month apart. Treatments will be provided to one side randomly assigned to either right side or left side. The non-treatment side will receive bacteriostatic water, injected in the same manner as Sculptra Aesthetic."|t|f|f|t
33789014|NCT06630091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789015|NCT01291004|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789016|NCT01394315|||COHORT||PROSPECTIVE|||||||
33789017|NCT00731211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789018|NCT01303835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789019|NCT04096144|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33789020|NCT04709744|||CASE_ONLY||PROSPECTIVE|||||||
33789021|NCT05126329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789022|NCT04555954|||OTHER||PROSPECTIVE|||||||
33789023|NCT02795650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928486|NCT06171815|RANDOMIZED|CROSSOVER||OTHER||NONE||This research is a prospective, randomized, crossover-designed experimental type research.||||
33928487|NCT00823160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928488|NCT01913171|RANDOMIZED|CROSSOVER||||NONE||||||
33928489|NCT00092482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33928490|NCT03183960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33928491|NCT03108300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928492|NCT04039789|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Intervention can't be masked. We will objectify primary outcome by photography images and adherence to exercise through the use of pedometers.~Statistician conducting the analysis will not know to which study arm a given patient has been assigned."|Randomised, multicentre clinical trial, parallel, pragmatic, with 6 months of follow-up.||||
34007646|NCT04351347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007647|NCT04614584|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34007648|NCT03214302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007649|NCT04661449|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized controlled trial|f|f|f|t
34007650|NCT02775578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007651|NCT02617641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007652|NCT04176679|||COHORT||RETROSPECTIVE|||||||
34007653|NCT02781935|||COHORT||PROSPECTIVE|||||||
33703314|NCT06169046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||2 parallel groups|t|t|t|t
33703315|NCT02791997|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703316|NCT00855673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703317|NCT05759078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A drip will be prepared by unblinded personnel using masked bottle, light brown lines for infusion, and administered immediately after preparation using a special curtain (screen).|Non-commercial, multicentre, randomised, double-blind, parallel group, placebo-controlled clinical trial. Eligible patients were randomly assigned (1:1) using a secure, central, interactive, web-based response system, to intervention FCM or placebo arm. Time of observation 12 months \[12 main study + 3 years follow up in substudy B\].|t|t|t|f
33703318|NCT02362581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703319|NCT04894448|||COHORT||PROSPECTIVE|||||||
33703320|NCT01582204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703321|NCT05455268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants for both the intervention and control arms will be recruited simultaneously and allocated using block randomisation to achieve fairly equal numbers of participants in both study sites. At the end of the 8-week intervention period, participants in the waitlist control arm will receive access to the intervention.||||
33703322|NCT04600141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703323|NCT06169384|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703324|NCT05492214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720550|NCT00423150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789024|NCT02165605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33789025|NCT04164537|||COHORT||PROSPECTIVE|||||||
34007654|NCT00931996|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789026|NCT04923139|||COHORT||RETROSPECTIVE|||||||
33789027|NCT00048529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789028|NCT05885828|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33789029|NCT00541580|||COHORT||PROSPECTIVE|||||||
33789030|NCT03054636|||COHORT||PROSPECTIVE|||||||
33789031|NCT00004192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized, open label, multicenter study. Patients are randomized to one of two treatment arms. All patients receive etoposide IV over 1 hour on days 1-4, cisplatin IV continuously on days 1-4, methylprednisolone IV over 15 minutes on days 1-5, and cytarabine IV over 2 hours on day 5. Treatment is repeated every 21 days for up to 4 courses. Arm I: Patients receive filgrastim-SD/01 subcutaneously (SQ) on day 6. Arm II: Patients receive filgrastim (G-CSF) SQ daily beginning on day 6 and continuing for 12 days or until blood counts recover.||||
33789032|NCT03797235|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33789033|NCT03178396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789034|NCT02535624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789035|NCT04756050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participant will not know which group he or she is in. The diaphragm thickening fraction and evaluations (outcomes) will be made by another experienced anesthesiologist, double-blindness will be achieved by being blind to the patient's group.~Block evaluation and measurements will be made by a different experienced anesthesiologist ."|"Three groups involved. 3 different approaches of supraclavicular block will be compared. Approaches share the same probe position and needle entry point but differ in where the local anesthetic is given.~Group 1: Local anesthetic mixture will be given to the corner pocket - where the artery and the first rib intersect in the sonoanatomical image.~Group 2: 10 ml of the local anesthetic mixture will be given to the described corner pack and the remaining 10 ml into the largest nerve cluster (Intracluster injection).~Group 3: Local anesthetic mixture will be administered by multi injection method between the nerve groups seen in the sonoanatomical image."|t|f|f|t
33789036|NCT03724370|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33703325|NCT05116878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients and clinical providers, including outcomes assessors, will be blinded to treatment vs placebo arms. Masking will be performed by an independent trial coordinator not involved with data collection, data analysis, or patient care.|Randomized, double-blinded, placebo-controlled clinical trial|t|t|t|t
33703326|NCT05501275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703327|NCT00138372|||COHORT||CROSS_SECTIONAL|||||||
33703328|NCT03877549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703329|NCT00227838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703330|NCT03771820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703331|NCT05159219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigational product, with matching placebo|Feasibility, double-blind, placebo-controlled randomized controlled trial (RCT)|t|t|t|t
33703332|NCT04526860|RANDOMIZED|PARALLEL||PREVENTION||NONE||Calibration of infant breast milk and formula intake: We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.||||
33703333|NCT03337295|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33703334|NCT01443078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703335|NCT01706146|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33703336|NCT01593657|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33703337|NCT00711139|||||PROSPECTIVE|||||||
33703338|NCT00762060|||COHORT||PROSPECTIVE|||||||
33703339|NCT06341101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703340|NCT01797731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33789037|NCT06477926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33789038|NCT00462410||||HEALTH_SERVICES_RESEARCH||NONE||||||
33789039|NCT01513642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789040|NCT03061513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789041|NCT02116855|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33789042|NCT05599399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open labelled, prospective, two-arm, parallel group, non-placebo controlled clinical trial||||
34007655|NCT02419833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007656|NCT04615312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007657|NCT03160586|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007658|NCT02218307|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33703341|NCT05779969|||CASE_CONTROL||RETROSPECTIVE|||||||
33703342|NCT02124525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703343|NCT00119834|||CASE_ONLY||OTHER|||||||
33703344|NCT03505190|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34007659|NCT05816200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007660|NCT00000302||||TREATMENT||DOUBLE||||||
34007661|NCT05814133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703345|NCT03410329|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33703346|NCT04314726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized, split-mouth, placebo-controlled, single blind clinical trial, a pilot study|t|f|f|f
33703347|NCT03768232|||OTHER||PROSPECTIVE|||||||
33703348|NCT03286738|||CASE_ONLY||PROSPECTIVE|||||||
33703349|NCT04066647|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703350|NCT03700593|||COHORT||PROSPECTIVE|||||||
33703351|NCT03829839|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33789043|NCT05264467|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized one blinded experimental design||||
33789044|NCT03176030|||COHORT||PROSPECTIVE|||||||
33789045|NCT03999021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789046|NCT02824367|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007662|NCT00799942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007663|NCT06256835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34007664|NCT02598245|RANDOMIZED|PARALLEL||||NONE||||||
34007665|NCT02803931|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33928493|NCT02126813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928494|NCT05571904|RANDOMIZED|PARALLEL||TREATMENT||NONE||(1) Patients had skin defects at functional sites or joint sites; (2) Patients aged 20-80 years; (3) The lateral thighs were chosen as the donor sites.||||
33928495|NCT04246346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33928496|NCT04228107|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33928497|NCT04360772|||COHORT||PROSPECTIVE|||||||
33928498|NCT02299271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928499|NCT05097157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928500|NCT00127699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928501|NCT01113840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928502|NCT05024617|||COHORT||PROSPECTIVE|||||||
33928503|NCT00458367|||||PROSPECTIVE|||||||
33928504|NCT01396746|||CASE_ONLY||CROSS_SECTIONAL|||||||
33928505|NCT03322397|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be told that the investigatos are studying the daily lives of teens. They will not be informed of the other arms of the experiment.|90 participants will randomly be assigned to one of three interventions. Participants will complete a 4-week intervention. All outcomes will be measured before and after the intervention, and some psychological measures will be collected weekly throughout the intervention.|t|f|f|f
33928506|NCT05297799|NA|SINGLE_GROUP||TREATMENT||NONE||Lactating women||||
34007666|NCT05288166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007667|NCT03166124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007668|NCT04231123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Injected solutions will be prepared by an anesthetist not involved in the study protocol.||t|t|t|t
34092614|NCT03355456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to whichever ablation arm they are randomized to. Events adjudicator will be blinded to randomization arm.|"Randomized comparison of two ablation techniques:~1. Pulmonary vein isolation (PVI) alone to~2. PVI plus total left atrial low voltage-directed ablation."|t|f|f|t
34092615|NCT01764581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092616|NCT00708669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092617|NCT06116851|||COHORT||PROSPECTIVE|||||||
34092618|NCT02320396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007669|NCT05119660|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34092619|NCT04691232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007670|NCT02846883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34092620|NCT00620607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092621|NCT04512872|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34007671|NCT03442569|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single-arm, open-label, multicenter Phase II clinical trial investigating the clinical efficacy of nivolumab, ipilimumab, and panitumumab in subjects with unresectable refractory KRAS/NRAS/BRAF wild-type microsatellite stable metastatic colorectal cancer after an initial safety lead-in cohort to ensure the three drug combination is well-tolerated.||||
34007672|NCT03823287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092622|NCT02323438|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34092623|NCT04500652|||OTHER||CROSS_SECTIONAL|||||||
34092624|NCT02196103|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092625|NCT00462462|RANDOMIZED|PARALLEL||||NONE||||||
33703352|NCT03000283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703353|NCT01773733|||COHORT||PROSPECTIVE|||||||
33789047|NCT04878796|||OTHER||OTHER|||||||
34007673|NCT04805619|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-arm, open-label study, including patients presenting at least one long or very long lesion (≥ 30 mm), who will undergo angioplasty with a tapered DES||||
34007674|NCT00271024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007675|NCT02304406|||OTHER||RETROSPECTIVE|||||||
34007676|NCT00929981|||COHORT||PROSPECTIVE|||||||
34007677|NCT06276699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007678|NCT01698593|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34007679|NCT01338662|||CASE_CONTROL||PROSPECTIVE|||||||
34007680|NCT06323135|||COHORT||RETROSPECTIVE|||||||
33703354|NCT01644539|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33703355|NCT01033760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789048|NCT00248391|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33789049|NCT06341491|||COHORT||PROSPECTIVE|||||||
33789050|NCT05230641|||COHORT||PROSPECTIVE|||||||
33928507|NCT05690919|||CASE_CROSSOVER||PROSPECTIVE|||||||
33928508|NCT05706818|||CASE_ONLY||CROSS_SECTIONAL|||||||
33928509|NCT05009238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928510|NCT00895778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928511|NCT00204412|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928512|NCT05820646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors (patients, microbiologist and statistician) will not know Which group the participants will be related to?|Parallel randomized clinical trial|t|f|f|t
33928513|NCT03907969|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label study; there will be no blinding.|||||
33928514|NCT01787851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928515|NCT04890561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928516|NCT00383708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928517|NCT04435548|||COHORT||PROSPECTIVE|||||||
33928518|NCT00633048|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33928519|NCT01522768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007681|NCT00375791|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34007682|NCT05694130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092626|NCT01529996|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34092627|NCT01594684|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34092628|NCT02117154|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092629|NCT03295851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092630|NCT02504203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092631|NCT04464447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092632|NCT01631253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928520|NCT02484950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928521|NCT02070341|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33928522|NCT04563572|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will receive a PPG sensor in form of a smartwatch or a bracelet and will be instructed to wear them continuously for 48 hours. Assigning patients to the smartwatch or the bracelet group will occur in an alternating fashion.||||
33928523|NCT02196220|||COHORT||PROSPECTIVE|||||||
33928524|NCT04007627|||COHORT||RETROSPECTIVE|||||||
33928525|NCT03785470|NA|SINGLE_GROUP||OTHER||NONE||||||
33928526|NCT00422669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928527|NCT05386849|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Early Feasibility Safety Study||||
34007683|NCT05454358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007684|NCT03858023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007685|NCT03886649|NA|SINGLE_GROUP||TREATMENT||NONE||In the dose escalation phase, relapsed/refractory B-cell NHL patients are included. In the dose expansion phase, patients with MZL (Marginal zone lymphoma) and FL (Follicular lymphoma) will be treated.||||
34007686|NCT00277160|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34007687|NCT05332054|||COHORT||PROSPECTIVE|||||||
34007688|NCT06605625|||COHORT||PROSPECTIVE|||||||
34007689|NCT04782752|NA|SEQUENTIAL||TREATMENT||NONE||3+3 radiation dose escalation||||
34007690|NCT04159181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Healthy men studied on three occasions. Study A and B will be conducted in random order. Day C wil always be conducted as the last study day.||||
34007691|NCT02152462|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34007692|NCT04904055|||COHORT||RETROSPECTIVE|||||||
34092633|NCT04065620|||COHORT||PROSPECTIVE|||||||
34092634|NCT02605239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092635|NCT01837303|||COHORT||CROSS_SECTIONAL|||||||
33703356|NCT05143385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|- As an open-label clinical trial, the allocation to each group is known. The possibility of blinding is not contemplated. Blinded third-party assessment will be carried out, as a third party will be used who will not know which treatment each patient is receiving.|RANDOMISED CLINICAL TRIAL||||
33703357|NCT03855865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703358|NCT00861653|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33703359|NCT01253473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703360|NCT04284358|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized into the control or intervention NMT warm-up workshop. The integration of peer to peer learning technology into the workshop is the intervention aspect.||||
33703361|NCT01720056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33703362|NCT03196856|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be randomly selected to the yogurt group or a placebo group. Although participants within the yogurt group will be aware that they are consuming yogurt, the placebo group will not be aware of the contents of the placebo supplement.|Randomized Controlled Trial||||
33703363|NCT01186536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703364|NCT05899985|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-centre, partially blinded, side-by-side comparator study||||
33703365|NCT02326792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703366|NCT05406778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703367|NCT04710602|||COHORT||PROSPECTIVE|||||||
33703368|NCT01934946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703369|NCT00931879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703370|NCT00900237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703371|NCT05464693|||COHORT||PROSPECTIVE|||||||
33703372|NCT03315546|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomised feasiblity study||||
33703373|NCT02741856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703374|NCT06192368|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33703375|NCT04521660|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33703376|NCT02336373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703377|NCT01622803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703378|NCT00463931|||CASE_CONTROL||PROSPECTIVE|||||||
33703379|NCT01673217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928528|NCT03046563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33928529|NCT04368104|||COHORT||PROSPECTIVE|||||||
33928530|NCT06042192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928531|NCT03322085|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928532|NCT05300854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928533|NCT01239238|||COHORT||PROSPECTIVE|||||||
33928534|NCT04155125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928535|NCT02565953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928536|NCT06369038|||OTHER||CROSS_SECTIONAL|||||||
33928537|NCT04613271|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Group 1: Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days.~* Group 2: Azithromycin 500 mg once a day for 5 days."||||
33928538|NCT03010904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33928539|NCT01595100|||COHORT||CROSS_SECTIONAL|||||||
34007693|NCT05633238|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive each level of visual information (target or distractor)||||
34007694|NCT00761176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007695|NCT01483625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007696|NCT00108576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007697|NCT00656968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34092636|NCT01178606|||CASE_ONLY|||||||||
34092637|NCT03436927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34092638|NCT03257397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092639|NCT02249780|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092640|NCT05130697|||CASE_ONLY||PROSPECTIVE|||||||
34092641|NCT00297011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092642|NCT04607109|||COHORT||RETROSPECTIVE|||||||
34092643|NCT01761344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092644|NCT02487121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928540|NCT05321693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Based on the nature of the intervention, participants and physicians (health care providers/investigators) shall be blinded. Only one investigator will have access to the randomization list and will program the stimulation according to the list. The device comes programmed to perform the task input by the investigator, which will be trained by previous enrollment to the study onhow to perform the intervention. Sham stimulation occurs only for the initial 30seconds, afterwhich the patient should feelthat the body adjusts to the stimuli.|This is a single-center, randomized, double-blinded, parallel-group, sham-controlled trial to evaluate the superiority of tPCS in pain reduction in women with FM|t|t|t|t
33703380|NCT04292483|||COHORT||PROSPECTIVE|||||||
33703381|NCT03485313|||COHORT||PROSPECTIVE|||||||
33703382|NCT02706184|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703383|NCT04974983|||COHORT||RETROSPECTIVE|||||||
33928541|NCT04917250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928542|NCT06078891|NA|SINGLE_GROUP||PREVENTION||NONE||A single group in treated patients to follow changes in plasma biomarkers levels.||||
33928543|NCT01801761|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703384|NCT06198283|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33703385|NCT01684956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703386|NCT00108433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703387|NCT05706493|NA|SINGLE_GROUP||TREATMENT||NONE|there will be two outcome assessor one before the non surgical periodontal treatment and the other one will be after non surgical periodontal treatment with 3 months|According to the periodontal parameters measured the cases will be categorized according to the latest classification of the 2017 World Workshop of classification of periodontal diseases and conditions as follows: staging of periodontitis is mainly based on the interdental CAL at the site of greatest loss and on radiographic bone loss and on tooth loss, over 4 stages-stage I, initial; stage II, moderate; stage III, severe; and stage IV, advanced periodontitis, Patient periodontal status will be assessed using William's graduated periodontal probe.Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes||||
33703388|NCT03814174|||CASE_CONTROL||PROSPECTIVE|||||||
34092645|NCT04136678|NA|SINGLE_GROUP||OTHER||NONE||Those who are between 6 and 18 years old and have a medical report on the diagnosis of cerebral palsy,||||
34092646|NCT01228045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703389|NCT03605589|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study to assess the safety, tolerability, and preliminary anti-tumor activity of the combination of pembrolizumab and blinatumomab in children and young adult patients with relapsed and/or refractory CD19 positive B-cell hematologic malignancies.||||
33703390|NCT00150709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703391|NCT01065597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703392|NCT00037804||||TREATMENT||||||||
33703393|NCT05973474|||COHORT||RETROSPECTIVE|||||||
33703394|NCT00844675|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33703395|NCT01387789|||COHORT||PROSPECTIVE|||||||
33703396|NCT06558071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703397|NCT00645385|||CASE_ONLY||PROSPECTIVE|||||||
33789051|NCT00149630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789052|NCT05547750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be classified into two intervention groups at a ratio of 1:1, using a computer-generated randomized sequence with varying unknown block sizes for all study centers without stratification. A research assistant not involved in clinical care and participant evaluations will prepare sequentially numbered, opaque, sealed envelopes based on a random list and ensure that anyone will not access or influence the allocation data. The participants, outcome assessor, and statistician will be blinded to group allocation and not involved in the treatment procedures.||t|t|t|f
33789053|NCT03425890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to which group the participants are in|Randomised Blinded Controlled Pilot Trial|f|f|f|t
33789054|NCT02276131|NA|SINGLE_GROUP||||NONE||||||
33789055|NCT04470193|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33789056|NCT00586014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789057|NCT00699686|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789058|NCT04089618|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Case Research (SCR), also known as single case experimenal design (SCED). This is a reserach methodology using a single unit of analysis and characterized by repeated measures over time.||||
33789059|NCT02181348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789060|NCT03476109|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The analysis of the response rate and magnitude, as well as of biomakers predicting the response, will be performed by an independent assessor and a biostatistician.|Severe asthma patients who are eligible to both anti-IgE (omalizumab) and anti-IL-5 (mepolizumab) therapies, will be randomized to decide the first treatment to start. Patients will then be prolonged or switched to the other according to the clinical response. There will be 5 possibilities: oma(lizumab) group, mepo(lizumab) group, oma-mepo switch, mepo-oma switch, and oma/mepo failure.|f|f|f|t
33789061|NCT00247143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789062|NCT00062062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928544|NCT01015690|||CASE_CONTROL||PROSPECTIVE|||||||
33928545|NCT04714944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33928546|NCT06526598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928547|NCT02187341|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33928548|NCT00928512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703398|NCT05610683|RANDOMIZED|CROSSOVER||OTHER||NONE||The E-FLUX is a prospective randomized open-label cross over study. The study will include 38 patients established on HF-HD randomly assigned to receive either 3 months of SHFVE-HD followed by 3 months of MCO-HD, or vice versa.||||
33703399|NCT04773756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703400|NCT04118439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Clinical Trial|t|t|f|t
33703401|NCT00850070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928549|NCT03960658|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study||||
33928550|NCT01553721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928551|NCT02763241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928552|NCT02394990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928553|NCT04356924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33928554|NCT00000314||||TREATMENT||||||||
33928555|NCT01721629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928556|NCT03154034|||COHORT||PROSPECTIVE|||||||
33928557|NCT02302755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928558|NCT06165861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analyse is going to be completed by a independent researcher.|The research will be conducted using randomized controlled, experimental type and single-blind research methods. For this purpose, after the data are collected, they will be coded as A and B groups, so the researcher who will make the research statistics will analyze the data without knowing the study and control groups. Randomization method will be used to determine the groups. For this, the patients who meet the study criteria and volunteer will be assigned to the groups using the randomization program 'Random Allocation Software 2.0' according to the order of hospitalization.|f|f|f|t
33928559|NCT00323427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092647|NCT02315625|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092648|NCT01484002|||COHORT||RETROSPECTIVE|||||||
34092649|NCT01762189|||COHORT||PROSPECTIVE|||||||
34092650|NCT00171288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092651|NCT03994159|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Quasi experimental before-after study, with a mixed qualitative and quantitative approach.||||
34092652|NCT02460003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092653|NCT04486144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092654|NCT00766818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092655|NCT04926545|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092656|NCT03021915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092657|NCT00009893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092658|NCT04227600|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34092659|NCT02520466|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34092660|NCT01430884|||||CROSS_SECTIONAL|||||||
34092661|NCT03150186|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34092662|NCT04779723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092663|NCT01575990|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34092664|NCT03884426|||FAMILY_BASED||PROSPECTIVE|||||||
33703402|NCT03185871|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Due to the characteristics of the design of this clinical trial, the patient will not be blinded but the researcher completing analysis will be. The researcher will be handling deidentified patient samples and comparing whether there are changes of biological markers within the same patient before and after celecoxib intake. It is important that the researcher be as unbiased as possible when analyzing collagen alignment and amount of other breast cancer biological markers.|||||
33703403|NCT05791955|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel-arm randomized control trial|t|t|f|f
33703404|NCT01446107|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33703405|NCT00412542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703406|NCT04111575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Design, setting and subjects: The randomized controlled trial was conducted on 126 women who delivered via cesarean section in a tertiary hospital. The subjects were allocated to three groups (n=42 each) Interventions: In the experimental group 1 (once a day) and group 2 (twice a day) were made to listen to music for 30 minutes for two consecutive days. The control group routine care of 30 min a day in bed rest. The Personal Information Form, Visual Analog Scale, State-Trait Anxiety Inventory were administered to participants.|t|t|f|f
33703407|NCT04512014|||CASE_ONLY||PROSPECTIVE|||||||
33703408|NCT05771012|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703409|NCT02187744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703410|NCT05704062|||COHORT||PROSPECTIVE|||||||
34092665|NCT02328729|||CASE_ONLY||PROSPECTIVE|||||||
34092666|NCT04519398|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34092667|NCT01377506|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092668|NCT03491917|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34092669|NCT03171870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092670|NCT01060176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092671|NCT01402700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092672|NCT04558242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703411|NCT05145595|NA|SINGLE_GROUP||OTHER||NONE||||||
33703412|NCT02170194|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33703413|NCT01776411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789063|NCT04175886|||CASE_CONTROL||PROSPECTIVE|||||||
33789064|NCT02209740|||COHORT||PROSPECTIVE|||||||
33789065|NCT06476925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33928560|NCT02421146|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33928561|NCT00742040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928562|NCT00121680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928563|NCT04199403|||COHORT||PROSPECTIVE|||||||
33928564|NCT05797298|||COHORT||PROSPECTIVE|||||||
33928565|NCT04716010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928566|NCT05177289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33789066|NCT04163471|||CASE_ONLY||PROSPECTIVE|||||||
33928567|NCT04128618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, coordinators, and Investigators are blinded.||t|f|t|t
33789067|NCT00336232|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789068|NCT01360840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928568|NCT02979028|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33928569|NCT00468611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928570|NCT04054739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928571|NCT00816608|||CASE_ONLY||PROSPECTIVE|||||||
33928572|NCT00004604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928573|NCT04062799|||COHORT||PROSPECTIVE|||||||
33928574|NCT04598841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928575|NCT00167024|||DEFINED_POPULATION||OTHER|||||||
33928576|NCT01958554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928577|NCT00308243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928578|NCT02699671|||COHORT||PROSPECTIVE|||||||
33928579|NCT05333003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928580|NCT01413828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092673|NCT03380572|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092674|NCT05309005|||COHORT||PROSPECTIVE|||||||
34092675|NCT03982953|||COHORT||PROSPECTIVE|||||||
34092676|NCT03353051|||COHORT||PROSPECTIVE|||||||
34092677|NCT00469313|||||PROSPECTIVE|||||||
34092678|NCT02508064|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34092679|NCT04811547|||COHORT||PROSPECTIVE|||||||
34092680|NCT03697746|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34092681|NCT01379209|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34092682|NCT02733328|||COHORT||CROSS_SECTIONAL|||||||
34092683|NCT00002874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092684|NCT02090257|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34092685|NCT03061643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092686|NCT02654509|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34092687|NCT06166173|||CASE_ONLY||PROSPECTIVE|||||||
34092688|NCT01111760|||CASE_ONLY|||||||||
33703414|NCT06213246|NA|SINGLE_GROUP||TREATMENT||NONE||The study is monocentric, prospective, and observational.||||
33703415|NCT00910026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33703416|NCT00078182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33703417|NCT03423082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703418|NCT06129162|RANDOMIZED|PARALLEL||OTHER||NONE||"Selected children will be divided randomly into 3 groups:~* Control group (Group I).~* STA group (Group II).~* Star pen group (Group III)."||||
33703419|NCT03689530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33789069|NCT02081898|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33789070|NCT00470626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789071|NCT04311229|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||REPEATIVE MEASUREMENT EXPERİMENTAL AND CONTROL GROUPS|t|f|t|f
33789072|NCT00042588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789073|NCT04251143|||COHORT||PROSPECTIVE|||||||
33789074|NCT00045916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33789075|NCT03606005|||CASE_CONTROL||RETROSPECTIVE|||||||
33789076|NCT05498337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789077|NCT03917329|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will take part in a three session Acceptance and Commitment Therapy and Positive Behaviour Support group workshop and a focus group at a six week follow-up point. Pre-intervention, post-intervention and follow-up quantitative outcome questionnaire data will be gathered.||||
33789078|NCT04682756|||CASE_CONTROL||OTHER|||||||
33789079|NCT01022489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33789080|NCT01756417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789081|NCT04744779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789082|NCT03467724|NA|SINGLE_GROUP||TREATMENT||NONE|The blinded reviewer will review the baseline photographs of the surgical scar(s) and compare them to the photographs taken at follow-up Month 12.|The subject will act as their own control. Each surgical scar will be compared at the 12-month follow-up to the pre-treatment baseline.||||
33789083|NCT05273281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789084|NCT05838664|||COHORT||RETROSPECTIVE|||||||
33789085|NCT05511454|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pilot pathophysiological study of comparative ELISA proteomic analysis of salivary and crevicular samples in periodontitis patients vs. control subjects.||||
33789086|NCT01209039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34092689|NCT01656499|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34092690|NCT00195325|NON_RANDOMIZED|FACTORIAL||ECT||NONE||||||
33703420|NCT01622231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703421|NCT00473850|||CASE_ONLY||RETROSPECTIVE|||||||
33703422|NCT02807519|||CASE_CONTROL||PROSPECTIVE|||||||
33703423|NCT00114530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703424|NCT06546657|||OTHER||RETROSPECTIVE|||||||
33703425|NCT00532558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789087|NCT03255772|||COHORT||PROSPECTIVE|||||||
33789088|NCT03809299|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789089|NCT01221337|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33789090|NCT01705249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789091|NCT03897309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study subjects, study site and study team will remain blinded to treatment during study period 1 (initial vaccination through Day 29 visits and subsequent database lock)|Open-label sentinel followed by Randomized, double-blind, placebo-controlled|t|t|t|t
33789092|NCT04240730|||CASE_ONLY||RETROSPECTIVE|||||||
33789093|NCT04993391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789094|NCT02030028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789095|NCT03068637|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789096|NCT03883438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A computer program was used to randomize 22 volunteers to treatment groups by a person who was not involved in the study. The result of this randomization process was written on a paper and then put in the sealed opaque envelope by a blinded examiner, in which the treatment procedure for the specific patient was defined. The envelope was opened by surgeon, immediately before starting the surgical procedure.|A total of 22 patients with 55 recessions were included in this single blind randomized controlled trial. Each patient had at least two recessions with a depth of ≥ 3 mm (Miller Class I\&II) in the upper jaw. The entry criteria were esthetic indication for root coverage; absence of caries or restorations at the selected sites; no history of previous mucogingival therapy; being a non-smoker and a systemically healthy patient.|t|f|f|f
33789097|NCT05739513|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33789098|NCT02026076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789099|NCT01477619|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789100|NCT04688268|||COHORT||PROSPECTIVE|||||||
33789101|NCT03688035|||COHORT||PROSPECTIVE|||||||
33789102|NCT06630637|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an N-of-1 trial involving a single participant.||||
33789103|NCT00004560|RANDOMIZED|||TREATMENT||||||||
33789104|NCT02733250|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33789105|NCT05490654|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-centre feasibility randomised controlled trial.||||
33789106|NCT06022536|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Single-dose , dose escalation, placebo-controlled study|t|t|t|t
33789107|NCT04163224|||COHORT||RETROSPECTIVE|||||||
33789108|NCT06469840|||OTHER||PROSPECTIVE|||||||
33789109|NCT03890640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789110|NCT06630663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789111|NCT04367376|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33789112|NCT02375516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789113|NCT01249300|||COHORT||CROSS_SECTIONAL|||||||
33789114|NCT00587288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801707|NCT04166903|||COHORT||PROSPECTIVE|||||||
33801708|NCT03655262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33703426|NCT04516174|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33703427|NCT02699814|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33703428|NCT04560036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||FAZA PET/MRI scan||||
33703429|NCT04185311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703430|NCT06547099|||CASE_CONTROL||PROSPECTIVE|||||||
33703431|NCT04817631|||CASE_CONTROL||RETROSPECTIVE|||||||
33703432|NCT03325127|||COHORT||RETROSPECTIVE|||||||
33703433|NCT05309408|||COHORT||CROSS_SECTIONAL|||||||
33703434|NCT00949260|||COHORT||PROSPECTIVE|||||||
33703435|NCT05954975|||COHORT||PROSPECTIVE|||||||
33703436|NCT03348137|||COHORT||PROSPECTIVE|||||||
33703437|NCT00223015|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33703438|NCT04608487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703439|NCT06377475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703440|NCT03941405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703441|NCT03622073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703442|NCT05009264|||COHORT||PROSPECTIVE|||||||
33703443|NCT03166007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703444|NCT00867893|||CASE_CONTROL||PROSPECTIVE|||||||
33703445|NCT05426772|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703446|NCT01784445|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33703447|NCT04677205|||COHORT||CROSS_SECTIONAL|||||||
33703448|NCT05757102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703449|NCT01821638|||COHORT||PROSPECTIVE|||||||
33703450|NCT04850001|||COHORT||PROSPECTIVE|||||||
33703451|NCT00645112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703452|NCT02168361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703453|NCT03697473|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The principal investigator responsible for the statistical analysis was blinded to the group allocation of participants||f|f|f|t
33703454|NCT01214343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703455|NCT04941859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703456|NCT03557853|||COHORT||PROSPECTIVE|||||||
33703457|NCT00354822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703458|NCT04795960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703459|NCT04293237|||COHORT||PROSPECTIVE|||||||
33789115|NCT05593042|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A specialized company designed the randomization algorithm of vaccines (IRT algorithm). The algorithm was designed considering the vaccination schedule of the subjects and the number of subjects assigned to each center. Once randomized, each participant will be assigned to a treatment branch/group. Neither the personnel administering it nor the rest of the team nor the participant will know which product was administered.||t|t|t|t
33789116|NCT00614406|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33789117|NCT00920296|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789118|NCT00241540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789119|NCT04490148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A longitudinal parallel group study of repeated measures of remote PFTs, nurse coaching, and their impact on respiratory outcomes.||||
33789120|NCT04727723|||COHORT||PROSPECTIVE|||||||
33703460|NCT02067130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703461|NCT03763175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703462|NCT00524381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703463|NCT01007539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703464|NCT00843856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703465|NCT03884959|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking applied.|This is a single group, open label study||||
33703466|NCT00478231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703467|NCT05340075|||CASE_ONLY||RETROSPECTIVE|||||||
33703468|NCT00039078||||TREATMENT||||||||
33703469|NCT01056029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789121|NCT03013348|||CASE_ONLY||RETROSPECTIVE|||||||
33801709|NCT05172323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of the IVUS images will be blinded to treatment arm|A prospective, investigator-initiated, single-centre, randomized-controlled, assessor blinded pilot trial.|f|f|f|t
33801710|NCT05916001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33928581|NCT04545034|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a randomized crossover clinical trial carried out with 25 hypertensive women. The study procedures took place over three days with an interval of 48 hours, and included evaluation session, an experimental protocol (EP) and a control protocol (CP).|t|f|f|f
33928582|NCT02270099|||COHORT||PROSPECTIVE|||||||
33928583|NCT02108834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928584|NCT02820038|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
33928585|NCT02713295|||COHORT||PROSPECTIVE|||||||
33703470|NCT00406965||||TREATMENT||||||||
33703471|NCT02241252|NA|SINGLE_GROUP||SCREENING||NONE||||||
33703472|NCT03218709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703473|NCT05092594|||COHORT||RETROSPECTIVE|||||||
33703474|NCT03698409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703475|NCT06043726|||COHORT||PROSPECTIVE|||||||
33703476|NCT00526370|||CASE_ONLY||CROSS_SECTIONAL|||||||
33703477|NCT04222907|||COHORT||OTHER|||||||
33703478|NCT00539656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703479|NCT04767685|||COHORT||CROSS_SECTIONAL|||||||
33703480|NCT03949309|||COHORT||PROSPECTIVE|||||||
33703481|NCT03555032|NA|SINGLE_GROUP||TREATMENT||NONE||"Four Cohorts of patients staggered. Cohort 1: The first patient will need to be 30 days from the end of study treatment before patients can be consented to Cohort 2.~Cohort 2: Assuming no Dose Limiting Toxicities in Cohort 1, two further patients will be recruited. Once these patients have passed 30 days from the end of study treatment Cohort 3 will open.~Cohort 3: Three further patients will be recruited and be 30 days post before Cohort 4 opens.~Cohort 4: Open recruitment for the remaining 9 patients."||||
33703482|NCT04450446|||CASE_CONTROL||RETROSPECTIVE|||||||
33703483|NCT03553771|||COHORT||PROSPECTIVE|||||||
33703484|NCT02902900|||COHORT||RETROSPECTIVE|||||||
34007698|NCT06677788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study was a randomized controlled parallel study. Patients were recruited from out-patient clinic of Tropical medicine department, Tanta university hospital, Tanta, Egypt. The study involved 55 patients with NASH who were randomized using sealed envelope methods with assignment codes for each available allocation into vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily and roflumilast group (n=31) which received roflumilast 500 μg once daily. The study duration was 3 months whereas patients were assessed at baseline and 3 months after intervention. The study was conducted following the ethical standards of Helsinki declaration in 1964 and its later amendments. The study was approved by Research Ethical committee of Tanta University (approval code:35336/3/22).participants gave their written informed consent.|t|f|f|f
34007699|NCT06307041|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|The investigator who performed the measurements was blinded to which side of patients was the test group|single-center, single-blinded, split-mouth, randomized clinical trial|f|f|t|f
34007700|NCT00402025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092691|NCT03298061|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects who participated in clinical study MEA115921 and require a dose of prednisolone (or equivalent) of \>=5 mg/day for adequate control of their EGPA will be included in this study based on the confirmation of their eligibility by GSK Medical Monitor. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.||||
34092692|NCT05554432|||COHORT||PROSPECTIVE|||||||
34092693|NCT04021797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participant's will not be aware which configuration represents the sham vs active stimulation condition. Data analyses will be conducted blind to sham or active stimulation.|We will employ a within-subjects, crossover, sham-controlled design. Each participant will be exposed to both active and sham conditions over two visits (5-days apart).|t|f|f|t
34092694|NCT00295685|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34092695|NCT02819388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33928586|NCT04950660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study will be a prospective, randomized control trial and will be double-blinded, with the patient, provider, and researcher blinded to the treatment.|This study will be a prospective, randomized control trial and will be double-blinded, with the patient, provider, and researcher blinded to the treatment.|t|t|t|f
34092696|NCT04555148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092697|NCT03361345|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split-face study in which topical tranexamic acid will be applied to one side of the face and the other side of the face will be the placebo/vehicle as a control.||||
34092698|NCT00469729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092699|NCT06392126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092700|NCT04530851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092701|NCT01191749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092702|NCT04529460|||COHORT||PROSPECTIVE|||||||
34092703|NCT00005850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092704|NCT00005774|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092705|NCT04987905|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and the researcher who carried out the application Hilal Altundal (H. A.) cannot be blinded due to the nature of the study. When the study is completed, the control and experimental groups will be coded as A and B and the data will be transferred to the computer environment by an independent researcher. The data coded as A and B will be analyzed by a statistician and the findings will be reported.|Prospective, parallel, two-arm, randomized controlled clinical trial|f|f|f|t
34092706|NCT01365572|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34092707|NCT02944266|||||PROSPECTIVE|||||||
34092708|NCT02517229|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34092709|NCT00475046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092710|NCT05613868|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study|open label, single group||||
34092711|NCT01346683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092712|NCT02145676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703485|NCT04608929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092713|NCT00164723|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092714|NCT00363168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092715|NCT04521140|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In patient who undergo corneal transplant (PKP,DSEK,DMEK), subjects will be randomized to 6 arms and be followed for a period of 3 months.~First arm will Receive Dextenza with PKP, Second arm will receive Prednisolone Acetate 1% with PKP, Third arm will Receive Dextenza with DSEK, Forth arm will receive Prednisolone Acetate 1% with DSEK Fifth arm will Receive Dextenza with DMEK, Sixth arm will receive Prednisolone Acetate 1% with DMEK"||||
34092716|NCT04557774|||COHORT||PROSPECTIVE|||||||
34092717|NCT02397837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33703486|NCT03047707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703487|NCT04053075|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled trial||||
33703488|NCT00850343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703489|NCT04690933|||COHORT||PROSPECTIVE|||||||
33703490|NCT05586932|||CASE_CONTROL||OTHER|||||||
33703491|NCT06066125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928587|NCT04709874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928588|NCT01956058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928589|NCT04594018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928590|NCT06430645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33928591|NCT00107822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703492|NCT00001183|||CASE_ONLY||PROSPECTIVE|||||||
33703493|NCT03137537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928592|NCT01594346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928593|NCT00466661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928594|NCT03905876|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33928595|NCT01844427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928596|NCT03591913|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33928597|NCT01517906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928598|NCT01507571|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34092718|NCT06543732|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the PA intervention, it is not possible to blind the researchers and process facilitators. However, workers randomized to the intervention or control group are not aware of the research design. Process facilitators providing the PA are informed about the research design and the outcome of randomization, and they are asked not to communicate the research design to the employees.|Randomized controlled trial comparing intervention group with care as usual group. Randomization is carried out at the individual level stratified by organisation type and whether problems are perceived as work-related or not.|t|f|f|f
33703494|NCT05654935|||COHORT||PROSPECTIVE|||||||
33703495|NCT01216514|||COHORT||PROSPECTIVE|||||||
33703496|NCT03683160|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm design with two blocks.||||
33703497|NCT05760560|||COHORT||PROSPECTIVE|||||||
33703498|NCT05867303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703499|NCT03352349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703500|NCT02422303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33703501|NCT04715633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703502|NCT03434197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703503|NCT01816074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33703504|NCT00963131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703505|NCT02432482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703506|NCT03145233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703507|NCT00929383|||COHORT||PROSPECTIVE|||||||
33703508|NCT06354309|NA|SINGLE_GROUP||OTHER||NONE||||||
33789122|NCT04653350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Females participating in a clinical trial will be kept blind with respect to their allocated exercise group. The assessor doing reporting for the DEXA scan will also be kept blind about the patient group.|This will be a Single factor, Pretest-Postest Control group Design with parallel assignment of patients into two groups.|t|f|f|t
33789123|NCT02817217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789124|NCT00906620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789125|NCT00001934||||TREATMENT||||||||
33789126|NCT05903963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33789127|NCT01899872|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33789128|NCT04043767|||COHORT||PROSPECTIVE|||||||
33789129|NCT05506709|NA|SINGLE_GROUP||TREATMENT||NONE|Product-blinded (the brand name of the product is not available for subjects)|||||
33789130|NCT05452993|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33789131|NCT02677974|||COHORT||PROSPECTIVE|||||||
33789132|NCT06112717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are 2 group in the study. Intervention Group and Control Group. The control group received no intervention by principal researcher.||||
33789133|NCT02357784|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789134|NCT02703727|||||PROSPECTIVE|||||||
33789135|NCT03669562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789136|NCT03265717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789137|NCT05887310|||COHORT||PROSPECTIVE|||||||
33789138|NCT00001994||||TREATMENT||||||||
33789139|NCT05027087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789140|NCT05245851|NA|SINGLE_GROUP||SCREENING||NONE||16 Bit intends to study the impact of RhoTM by performing a prospective trial to assess its impact. A selected pilot site must have both x-ray and dual energy x-ray absorptiometry (DXA) imaging services, with the anticipation that DXA referrals will be made to the same imaging center which performed the x-ray which underwent RhoTM screening. The study population to assess the impact of RhoTM will consist of patients aged 50 and above who are opportunistically screened by RhoTM while undergoing an x-ray of the lumbar spine, thoracic spine, hand, knee, pelvis or chest.||||
34092719|NCT02756442||PARALLEL||PREVENTION||NONE||||||
34092720|NCT04606719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|f|t
34092721|NCT04247971|||COHORT||PROSPECTIVE|||||||
34092722|NCT00408226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092723|NCT06109688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"patients with Urinary Tract Infections were recruited subjects were randomized into two groups:~* the experimental group received bLF~* the control group received placebo without bLF"|t|t|t|t
34092724|NCT01595828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092725|NCT05455398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092726|NCT05625750|||COHORT||PROSPECTIVE|||||||
33703509|NCT02439060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703510|NCT04803539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703511|NCT02050243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703512|NCT06171295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||PK study||||
33703513|NCT02802943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow \<10-4 6-10 weeks after the end of first line treatment).~MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)"||||
33703514|NCT00824941|||CASE_CONTROL||PROSPECTIVE|||||||
33703515|NCT00178633|||COHORT||PROSPECTIVE|||||||
33703516|NCT03805399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The refractory mTNBC participants will be classified into four subtypes based on immunohistochemistry tests namely luminal androgen receptor (LAR), immunomodulatory (IM), basal-like immune suppressed (BLIS), and mesenchymal (MES).Then according to gene sequencing outcomes, different subtypes would receive different targeted therapy (combined with chemotherapy in three treatment arms).||||
33703517|NCT04749875|||COHORT||PROSPECTIVE|||||||
33703518|NCT01729182|||COHORT||PROSPECTIVE|||||||
33703519|NCT02877134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703520|NCT03226860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703521|NCT05136352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703522|NCT05257655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single treatment group.||||
33703523|NCT06042504|||OTHER||CROSS_SECTIONAL|||||||
33703524|NCT04969874|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Monocentric prospective longitudinal pilot study||||
33789141|NCT04101123|||COHORT||PROSPECTIVE|||||||
33928599|NCT02130752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007701|NCT01151319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34007702|NCT04325854|||CASE_ONLY||RETROSPECTIVE|||||||
34007703|NCT06614751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34007704|NCT05529199|||CASE_ONLY||RETROSPECTIVE|||||||
34007705|NCT05430841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007706|NCT00446706|||CASE_ONLY||PROSPECTIVE|||||||
34007707|NCT02561234|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34007708|NCT01398202|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34007709|NCT01187030|||COHORT||PROSPECTIVE|||||||
34007710|NCT01435824|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants underwent 2 arms in a cross-over design: 1 ) amoxicillin disolved in water; and 2) amoxicillin dissolved in human milk. The order of the 2 arms were randomized.||||
34007711|NCT04472858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007712|NCT04158635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007713|NCT05931276|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a multicenter clinically integrated prospective randomized open-label blinded-endpoint (PROBE) trial||||
34007714|NCT02917252|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34007715|NCT05612087|||COHORT||PROSPECTIVE|||||||
34007716|NCT06616064|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007717|NCT00043576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34007718|NCT03321474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092727|NCT00954538|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092728|NCT03173963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092729|NCT02038842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092730|NCT03735342|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|To minimize selection bias, study research assistants and enrolled discharging providers are blinded to participants' (patients') study arm allocation until after participants are enrolled in the study.||f|f|t|f
34092731|NCT02451735|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34092732|NCT06225453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092733|NCT01889459|||COHORT||PROSPECTIVE|||||||
34092734|NCT02941003|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
34092735|NCT04095013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients were randomly allocated into two groups and will be blinded to the study drugs. The drugs will be chosen by seal envelope method by principal investigator and co-investigator. The drugs will be filled in the syringes and the syringes handed over to on floor consultant anesthetist who are blinded to the study.|Randomize controlled trial (RCT)|t|t|f|f
34092736|NCT00395382|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34092737|NCT03494179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092738|NCT02965833|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34092739|NCT05145036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34092740|NCT04502524|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33703525|NCT03719586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789142|NCT03248011|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Group assignment will be masked to investigator.|This is a prospective, randomized, repeated measures single- blind clinical trial.|f|f|t|f
33789143|NCT01947179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007719|NCT03743090|||COHORT||PROSPECTIVE|||||||
34007720|NCT00076531||||TREATMENT||NONE||||||
34007721|NCT01034852|||CASE_ONLY||RETROSPECTIVE|||||||
34007722|NCT00337974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007723|NCT00982631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007724|NCT04473716|NA|SEQUENTIAL||TREATMENT||NONE||||||
34007725|NCT05375890|||COHORT||PROSPECTIVE|||||||
34007726|NCT00551616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007727|NCT05025852|||COHORT||CROSS_SECTIONAL|||||||
34007728|NCT02139618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007729|NCT02580084|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34007730|NCT05345782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007731|NCT03939949|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants are not aware of how the conditions differ, nor are they aware of how many conditions there are.||t|f|f|f
34092741|NCT03033628|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34092742|NCT06197282|||COHORT||RETROSPECTIVE|||||||
34092743|NCT03297697|||COHORT||PROSPECTIVE|||||||
34092744|NCT00849472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092745|NCT04217356|||COHORT||PROSPECTIVE|||||||
34092746|NCT01431742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092747|NCT01618877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092748|NCT04877028|||COHORT||PROSPECTIVE|||||||
34092749|NCT01849809|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34092750|NCT01291342|||CASE_CONTROL||PROSPECTIVE|||||||
34092751|NCT03524378|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subject control||||
34092752|NCT02665117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34092753|NCT01015079|||COHORT||RETROSPECTIVE|||||||
34092754|NCT03466372|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092755|NCT04229576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34092756|NCT02340325|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34092757|NCT04831112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental randomised trial|t|t|f|f
34092758|NCT05055219|||COHORT||CROSS_SECTIONAL|||||||
34092759|NCT03419468|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34092760|NCT05707325|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The dose escalation part is carried out according to the 3+3 increasing principle. At least four dose groups are predefined based on the number of engineered red blood cells, specifically 1e11, 2e11, 3e11, 3.5e11,etc.~Dose expansion part will be decided according to dose escalation part."||||
34092761|NCT00580398|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092762|NCT04472741|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34092763|NCT04520100|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34092764|NCT04619537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092765|NCT02763358|NA|SINGLE_GROUP||OTHER||NONE||||||
34092766|NCT02302456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928600|NCT02676453|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33928601|NCT01617928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928602|NCT05587608|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928603|NCT00032006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928604|NCT00628316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928605|NCT06374589|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33789144|NCT02718768|||OTHER||PROSPECTIVE|||||||
34007732|NCT04541420|||COHORT||RETROSPECTIVE|||||||
33928606|NCT05526781|||COHORT||PROSPECTIVE|||||||
34007733|NCT06387979|||COHORT||PROSPECTIVE|||||||
34007734|NCT03732131|||COHORT||PROSPECTIVE|||||||
34007735|NCT02770144|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007736|NCT01337726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007737|NCT00959322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007738|NCT05645211|||COHORT||CROSS_SECTIONAL|||||||
34007739|NCT05986136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|f|t|f
33928607|NCT02376478|||CASE_CONTROL||PROSPECTIVE|||||||
34092767|NCT03910946|||COHORT||PROSPECTIVE|||||||
34092768|NCT03970512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092769|NCT03113955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092770|NCT00778180|RANDOMIZED|CROSSOVER||||NONE||||||
34092771|NCT00321412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092772|NCT01253486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092773|NCT01895998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092774|NCT05710822|||COHORT||OTHER|||||||
34092775|NCT04399005|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33928608|NCT02262676|||COHORT||CROSS_SECTIONAL|||||||
34092776|NCT02458170|||COHORT||RETROSPECTIVE|||||||
34092777|NCT00673829|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928609|NCT06156891|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33928610|NCT01489267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928611|NCT01211119||PARALLEL||TREATMENT||NONE||||||
34092778|NCT01935804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092779|NCT01407419|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092780|NCT02805998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092781|NCT03209960|||COHORT||CROSS_SECTIONAL|||||||
34092782|NCT06494163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34092783|NCT02104102|RANDOMIZED|PARALLEL||||NONE||||||
34092784|NCT00471120|NA|SINGLE_GROUP||SCREENING||NONE||||||
34092785|NCT04488185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092786|NCT00361153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092787|NCT02747160|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33928612|NCT01526005|||CASE_CONTROL||PROSPECTIVE|||||||
33928613|NCT00196807|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33928614|NCT01095666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928615|NCT02143323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928616|NCT01564602|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33928617|NCT05146037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and outcome assessors will be blinded to intervention.|Patients will be randomised to CO2 and Saline flushing versus saline flushing only.|t|f|f|t
33928618|NCT00302770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928619|NCT02657772|||COHORT||PROSPECTIVE|||||||
33928620|NCT03002740|||COHORT||RETROSPECTIVE|||||||
33928621|NCT03892525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928622|NCT00660946|||COHORT||PROSPECTIVE|||||||
33928623|NCT03508544|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33928624|NCT05135429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33928625|NCT01174836|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33928626|NCT05381675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928627|NCT06120933|NA|SINGLE_GROUP||OTHER||NONE||||||
33928628|NCT04978480|||CASE_ONLY||PROSPECTIVE|||||||
33928629|NCT05054231|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007740|NCT02710591||SEQUENTIAL||TREATMENT||NONE||||||
34007741|NCT05744700|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34007742|NCT03715686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007743|NCT05044728|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, single-arm, open cohort study (randomly stratified within the group).||||
34007744|NCT05386394|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This is a crossover design of tDCS + behavioral language therapy that crossovers to sham + behavioral language therapy in Arm 1, and sham + behavioral language therapy that crossovers to tDCS + behavioral language therapy in Arm 2.|t|t|f|t
34007745|NCT02098070|||OTHER||PROSPECTIVE|||||||
34007746|NCT04305873|||COHORT||CROSS_SECTIONAL|||||||
34007747|NCT03965624|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective interventional uncontrolled single arm open study evaluating the rate of patients achieving 5 cycles without severe toxicity and response on therapy: Interventional clinical study phase IIb , Non-comparative, Not randomised, Not controlled, Unblinded.~Oral ixazomib will be given on days 1, 8, 15 of a 28-days cycle, in combination with dexamethasone 20 mg weekly. The investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 or de-escalation in case of response and severe adverse events."||||
34007748|NCT00739843|||COHORT||PROSPECTIVE|||||||
34007749|NCT03523845|||CASE_CONTROL||OTHER|||||||
34007750|NCT03800225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34092788|NCT05444127|||CASE_CONTROL||PROSPECTIVE|||||||
34092789|NCT03672825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092790|NCT00504309|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34092791|NCT05302050|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|The study population consists of approximately 500 total participants, ages 18 - 75 years old, inclusive, who have type 2 diabetes. They will be randomized to the treatment or control group at a 3:1 ratio||||
34092792|NCT02315820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092793|NCT04384874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789145|NCT05112718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928630|NCT02556190|||COHORT||PROSPECTIVE|||||||
33928631|NCT04883918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928632|NCT02098005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928633|NCT05305001|||COHORT||PROSPECTIVE|||||||
33928634|NCT04310865|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928635|NCT02366793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928636|NCT02983513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33928637|NCT03245710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703526|NCT05942560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|We will ensure that the assessors are unaware of the treatment assignments or intervention details for each participant. We will use anonymized coded data that does not reveal the group allocation during the outcome assessment. The data will be presented in a standardized format that prevents any identification of treatment groups.|The study will be a parallel, multicenter, randomized controlled trial.|f|f|f|t
33703527|NCT03095885|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703528|NCT00432419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703529|NCT03966144|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Participants will undergo computer based testing using the device to determine the number of haptic stimuli that are correctly interpreted as phenomes.||||
33703530|NCT00428792|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33703531|NCT05962437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33703532|NCT05944289|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to a treatment condition (parent support control group or ACT intervention group). The design of the study will be randomized, two-group mixed model design with 1) a group-based Acceptance and Commitment Therapy (ACT)intervention and 2) a parent support group.||||
33928638|NCT00390429|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928639|NCT01277978|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928640|NCT04862741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928641|NCT01136746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928642|NCT01117168|||COHORT||PROSPECTIVE|||||||
33928643|NCT00451334|||||OTHER|||||||
33928644|NCT04707378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928645|NCT01085656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928646|NCT00873145|||COHORT||RETROSPECTIVE|||||||
33928647|NCT04897646|||COHORT||PROSPECTIVE|||||||
33928648|NCT04790539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928649|NCT03542149|RANDOMIZED|PARALLEL||OTHER||NONE||Based on safety and tolerability data up to Day 35 post-dose, and pharmacokinetic/pharmacodynamic (PK/PD) analysis outcomes (based on PD data up to Day 35 and PK data up to Day 28 post-dose) of the drugs given in combination, the dose(s) for the subsequent cohort will be determined. A similar analysis will be done at the end of cohort 2 combining cohorts 1 and 2 data to decide the dose(s) to be tested in cohort 3.||||
33928650|NCT03374761|RANDOMIZED|PARALLEL||PREVENTION||NONE|It is not possible to mask as it is a behavioral intervention and the outcomes are self-reported.|Stratified, clustered randomized pragmatic trial||||
33928651|NCT04019210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928652|NCT03438513|||COHORT||PROSPECTIVE|||||||
33928653|NCT01391468|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928654|NCT04464577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928655|NCT02519062|||COHORT||RETROSPECTIVE|||||||
33928656|NCT02017704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928657|NCT01671891|||COHORT||PROSPECTIVE|||||||
33928658|NCT04955509|||COHORT||OTHER|||||||
34007751|NCT00124462|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34007752|NCT01885351|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007753|NCT03527004|||OTHER||CROSS_SECTIONAL|||||||
34007754|NCT05637476|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34007755|NCT03655275|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is randomized, placebo controlled trial.|This study is randomized, placebo controlled trial.||||
34007756|NCT02640742|||CASE_ONLY||CROSS_SECTIONAL|||||||
34007757|NCT04638270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007758|NCT03443791|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34007759|NCT02537509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007760|NCT00661232|||COHORT||PROSPECTIVE|||||||
34007761|NCT01143649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34007762|NCT05105659|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34007763|NCT00782561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007764|NCT05996406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007765|NCT04944472|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34007766|NCT00003430||||TREATMENT||||||||
34007767|NCT06473402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007768|NCT01396382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007769|NCT03358095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007770|NCT01978769|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34007771|NCT02241694|||COHORT||CROSS_SECTIONAL|||||||
34007772|NCT03330314|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33703533|NCT01932619|||CASE_ONLY|||||||||
33703534|NCT00001963||||TREATMENT||||||||
33703535|NCT03748784|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose-ranging clinical study to evaluate the safety and tolerability of ADVM-022 in subjects with wet AMD.||||
33703536|NCT03352297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703537|NCT05612711|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Study drug vs placebo filler will be over-encapsulated for masking."|Eligible subjects will be randomization to either dronabinol or placebo (1:1 assignment ratio) for a total of 8 weeks (1 week of titration, followed by 6 weeks of treatment at target dose, followed by 1 week of taper). All subjects will then undergo a 3-week placebo washout phase, followed by the crossover intervention for 8 weeks.|t|t|t|t
33703538|NCT00245661|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33703539|NCT02680717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703540|NCT04497935|||CASE_CONTROL||PROSPECTIVE|||||||
33703541|NCT02241707|||CASE_CONTROL||PROSPECTIVE|||||||
33703542|NCT02824575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703543|NCT00437983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703544|NCT04015492|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703545|NCT01993706|RANDOMIZED|PARALLEL||PREVENTION||||||||
33703546|NCT03583697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703547|NCT00193258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703548|NCT03734042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups parallel|t|f|f|f
33703549|NCT01447433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703550|NCT01045525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703551|NCT06308367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703552|NCT02465515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703553|NCT04711382|||CASE_CONTROL||RETROSPECTIVE|||||||
33703554|NCT03476993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703555|NCT05532917|||OTHER||PROSPECTIVE|||||||
33703556|NCT05579236|||COHORT||PROSPECTIVE|||||||
33703557|NCT00165659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703558|NCT04033575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"CRO-2019-03-PG-SNF-FL-BGS Product XXX Brush your teeth twice daily (morning and evening) for two (2) minutes each time.~Cover the length of the toothbrush bristles with the toothpaste. For investigational use only by the study participant. Not for sale. For Adult Use Only. Keep out of reach of children under 6 years.~In case of emergency or for further information contact:"|This was a 6-month, randomized, single-center, parallel group, double-blinded, clinical research study to assess the clinical efficacy of two toothpastes containing stannous fluoride (SnHW and CPH) as compared to Regular Fluoride Toothpaste on the reduction of established dental plaque and gingivitis in adults.|t|f|t|t
33703559|NCT06298331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703560|NCT00722423|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33703561|NCT02063633|||CASE_CONTROL||PROSPECTIVE|||||||
33703562|NCT04548037|||CASE_CONTROL||PROSPECTIVE|||||||
33703563|NCT05106738|||COHORT||CROSS_SECTIONAL|||||||
33703564|NCT03532061|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33703565|NCT00509041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703566|NCT00682422|||FAMILY_BASED||RETROSPECTIVE|||||||
33703567|NCT01457144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703568|NCT06154187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703569|NCT00874107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720551|NCT03184350|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation. Platinum-based chemotherapy can be administered if indicated. For treatment planning rectum, sigma, large and small bowel, bladder and femoral heads are defined as organs at risk. The CTV is defined according to the EORTC consensus guidelines. Treatment-associated toxicity and Quality of life will be evaluated regularly.||||
33720552|NCT04322747|||COHORT||PROSPECTIVE|||||||
33720553|NCT03988192|NA|SINGLE_GROUP||OTHER||NONE||||||
33789146|NCT00137605|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33928659|NCT05051033|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible and consented patients will be randomized 1:1 to a TEER versus surgical repair. Patient randomization will be stratified by clinical site and by surgical risk profile, namely low, intermediate, and high surgical risk. Primary effectiveness will be analyzed by intention-to-treat; that is, the patients will be grouped by their assignment at randomization whether or not they actually received the treatment to which they were assigned.||||
33928660|NCT04957303|||COHORT||RETROSPECTIVE|||||||
33928661|NCT00292812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33928662|NCT04419662|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Ultrasound analysis is performed offline and details on participants and time of measurement are blinded for the person doing the analysis. The personnel responsible for obtaining data will not be blinded towards any of the interventions.|||||
33928663|NCT03186872|RANDOMIZED|PARALLEL||OTHER||NONE||Comparison between cognitive behavioral app and care as usual.||||
33928664|NCT01634113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928665|NCT03464890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928666|NCT04306757|RANDOMIZED|PARALLEL||TREATMENT||NONE||controlled, prospective||||
33928667|NCT05097170|||COHORT||PROSPECTIVE|||||||
33928668|NCT02178163|NA|SINGLE_GROUP||OTHER||NONE||This study will assess the percentage of advanced NSCLC patients whose tumor samples can undergo genomic analysis and in whom therapy can begin based on the results of this analysis.||||
33928669|NCT04425798|||CASE_CONTROL||PROSPECTIVE|||||||
33928670|NCT00517218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928671|NCT04799704|||CASE_ONLY||PROSPECTIVE|||||||
33928672|NCT04506944|||COHORT||PROSPECTIVE|||||||
33928673|NCT00005945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928674|NCT02923050|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928675|NCT06380348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928676|NCT01781663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928677|NCT04804904|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33928678|NCT04315597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092794|NCT03105388|||COHORT||PROSPECTIVE|||||||
34092795|NCT02315183|||COHORT||PROSPECTIVE|||||||
34092796|NCT02193893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092797|NCT03087552|||COHORT||PROSPECTIVE|||||||
34092798|NCT04289038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092799|NCT00920816|RANDOMIZED|||TREATMENT||NONE||||||
34092800|NCT02445560|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34092801|NCT01158586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092802|NCT02100631|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34092803|NCT02659904|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092804|NCT01227811|RANDOMIZED|CROSSOVER||||NONE||||||
34092805|NCT02057991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092806|NCT05100667|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|We will inform the participants in a way that explains the study as an investigation about the influence of different cognitive tasks on a subsequent physical task at various altitudes looking at other physiological outcome measures.|randomized blinded placebo-controlled counterbalanced crossover design|t|f|f|f
34092807|NCT05510817|NA|SINGLE_GROUP||OTHER||NONE||||||
34092808|NCT00223431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092809|NCT04278092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092810|NCT04170933|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective study of magnetic recanalization in treatment of biliary stricture||||
34092811|NCT03651492|||COHORT||CROSS_SECTIONAL|||||||
34092812|NCT01001104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092813|NCT05665842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34092814|NCT05144906|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092815|NCT06413329|||COHORT||PROSPECTIVE|||||||
34092816|NCT06181851|||CASE_CONTROL||PROSPECTIVE|||||||
34092817|NCT03110276|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind study|Planned single doses of 30 mg, 60 mg, 120 mg, 250 mg, 500 mg, and 800 mg, and planned multiple doses of 60 mg, 120 mg, 250 mg, and 500 mg, of EYP001a will be explored in this study. Subjects will be enrolled in dose escalation cohorts that will occur sequentially based upon review of safety and PK parameters.|t|t|t|t
34092818|NCT03594552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators were blinded to the drug condition|Repeated-measures cross-over study, where each subject received each one of the three pharmacological probes in separate visits (i.e., placebo, arbaclofen low dose and arbaclofen high dose), with the order of tablet administration being pseudorandomized.|t|f|t|f
33720554|NCT03060447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720555|NCT03510520|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-centre, pilot, open-label, interventional, randomised controlled study.||||
33720556|NCT02591147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33720557|NCT02806310|||CASE_ONLY||PROSPECTIVE|||||||
33720558|NCT00694213|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33789147|NCT02061111|||COHORT||PROSPECTIVE|||||||
33789148|NCT05070104|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, Open label||||
33928679|NCT05839639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928680|NCT05616039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Feasibility Randomized Controlled Study|f|f|f|t
33928681|NCT00205751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928682|NCT01810380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928683|NCT02190630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928684|NCT05241938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928685|NCT05287204|||COHORT||PROSPECTIVE|||||||
33928686|NCT06022146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928687|NCT03037307|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33928688|NCT04302987|||COHORT||PROSPECTIVE|||||||
33928689|NCT02914197|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33928690|NCT03563261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and researchers will not know if participants are allocated to the control or active product group.|Double-blinded randomized control study|t|f|t|f
33928691|NCT00615212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928692|NCT06169995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928693|NCT05146934|||CASE_CONTROL||RETROSPECTIVE|||||||
33928694|NCT00880607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928695|NCT06332040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33789149|NCT04816825|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized clinical controlled study||||
33789150|NCT04420286|||OTHER||RETROSPECTIVE|||||||
33789151|NCT04462081|||COHORT||PROSPECTIVE|||||||
33928696|NCT00212758|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33928697|NCT04273425|||COHORT||PROSPECTIVE|||||||
33928698|NCT03292341|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928699|NCT03498092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33928700|NCT06440265|||CASE_ONLY||PROSPECTIVE|||||||
33928701|NCT03079557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092819|NCT01666977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092820|NCT02412657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092821|NCT00229216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092822|NCT01922297|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34092823|NCT00487149|||CASE_CONTROL||PROSPECTIVE|||||||
34092824|NCT05043870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928702|NCT05378776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|It is a blinded study for participants, treating physician and statistician. However, for practical reasons and to minimize cost related to the study preparation, the research nurses/assistants will not be blinded to the treatment.||t|t|t|t
33928703|NCT00044525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928704|NCT00004910||||SUPPORTIVE_CARE||||||||
33928705|NCT01113190|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928706|NCT03504462|NA|SINGLE_GROUP||OTHER||NONE||||||
33703570|NCT04392752|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.|f|f|t|t
33703571|NCT01956383|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33703572|NCT01580085|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703573|NCT04763668|||CASE_CONTROL||PROSPECTIVE|||||||
33703574|NCT03147677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703575|NCT04710394|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||"Two-by-two factorial interventional study design will lend to achieving the study aims. Participants meeting eligibility criterion will be randomized to one of four arms:~1. Unimodal Olfactory Training with Conventional Odors~2. Unimodal Olfactory Training with Patient-Preferred Odors~3. Bimodal Visual, Olfactory Training with Conventional Odors~4. Bimodal Visual, Olfactory Training with Patient-Preferred Odors"|t|t|f|f
33703576|NCT03221283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703577|NCT00726375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703578|NCT04105270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703579|NCT02595814|||OTHER||PROSPECTIVE|||||||
33703580|NCT04061265|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33703581|NCT05840640|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized||||
33703582|NCT05429060|||COHORT||PROSPECTIVE|||||||
33703583|NCT05804578|||COHORT||PROSPECTIVE|||||||
33703584|NCT00651560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703585|NCT01686061|||OTHER||OTHER|||||||
33703586|NCT01095211|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33703587|NCT03805269|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33703588|NCT01543958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789152|NCT02930343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789153|NCT00284973|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33789154|NCT02837237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789155|NCT06479772|||CASE_ONLY||RETROSPECTIVE|||||||
33789156|NCT01428349|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33789157|NCT06629649|RANDOMIZED|CROSSOVER||SCREENING||NONE||The initial design implements the eye screening intervention in 4 FHQC clinics operated by Southeast Alabama Rural Health Associates (SARHA) for a duration of 18 months. Four other FQHC clinics operated by SARHA are the control, or non-interventional clinics, which are followed during the same time period. After 18 months the control clinics become the interventional clinics and the previous intervention clinics become the control clinics.||||
33789158|NCT06140680|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789159|NCT03746418|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33789160|NCT00764413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789161|NCT04300335|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1: Individual exercise prescription (high fracture risk and/or high risk of fall patients) Group 2: Group exercise (low fracture risk and low risk of fall patients)||||
33789162|NCT01975467|||CASE_CONTROL||RETROSPECTIVE|||||||
33789163|NCT02700867|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789164|NCT02008734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789165|NCT04157257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789166|NCT04763213|||OTHER||RETROSPECTIVE|||||||
33928707|NCT05060198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928708|NCT02408185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928709|NCT03121807|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33928710|NCT00888212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928711|NCT05074862|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||A randomized double-blind isocaloric placebo-controlled cross-over study.|t|f|t|f
33928712|NCT04657445|||COHORT||PROSPECTIVE|||||||
33928713|NCT02356328|||COHORT||PROSPECTIVE|||||||
33928714|NCT02984280|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33928715|NCT03175016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928716|NCT01489228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928717|NCT02794025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928718|NCT03582969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The placebo capsules are blocked capsules containing a mixture of saline and glycerine, identical in appearance and consistency to the FMT capsules.|This is a placebo-controlled, double blinded interventional study evaluating oral, fecal microbiota transplantation, administered in patients with mild-moderate UC.|t|t|t|f
33928719|NCT04379947|||CASE_CONTROL||RETROSPECTIVE|||||||
33928720|NCT00259246|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33928721|NCT05319223|||CASE_CONTROL||PROSPECTIVE|||||||
33928722|NCT01831804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33928723|NCT03530202|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A research assistant who is not involved in the study in any other way will be responsible for randomization.|The study will be a double-blind, repeated measures design. Participants will be randomized on a 1:1 basis to one of two groups: high-velocity resistance training and creatine or high-velocity resistance training and placebo.|t|f|t|f
33928724|NCT06203483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Adductor canal block group, and pericapsular nerve group block group|t|f|f|t
33703589|NCT02244112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703590|NCT05562414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of the principal investigator and research assistant towards group allocation is ensured by a unique subject identification code given to each participant.|Single-centre Randomized Controlled Trial (RCT)|f|f|t|t
33703591|NCT00628485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703592|NCT00334321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703593|NCT05720169|||COHORT||PROSPECTIVE|||||||
33703594|NCT02675985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703595|NCT05622331|||COHORT||RETROSPECTIVE|||||||
33703596|NCT02678975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703597|NCT01276405|||COHORT||PROSPECTIVE|||||||
33703598|NCT03824288|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33703599|NCT02202187|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33703600|NCT00034541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703601|NCT04525846|RANDOMIZED|PARALLEL||PREVENTION||NONE||To compare urinary incontinence, qaulity of life, duration of second stage of labor between pelvic floor muscle training(PFMT) group and nonPFMT group Researcher assess pelvic floor muscle strength by Brink score who verified by urogynecologist , given PFMT program and VDO education, follow up by telephone for compliance, and reassess pelvic floor muscle strength at 4 weeks after consented||||
33703602|NCT04534582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part I: open label Part II: masking||t|t|t|t
33703603|NCT05123196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703604|NCT06209931|||CASE_CONTROL||PROSPECTIVE|||||||
33703605|NCT04489797|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is open-label, randomized, single-dose study. The participants will be divided in 2 treatment arms as follows:~1. Arm A (only acalabrutinib)~2. Arm B (acalabrutinib + rabeprazole)"||||
33703606|NCT03641339|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703607|NCT06365112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703608|NCT06041659|||COHORT||PROSPECTIVE|||||||
33703609|NCT00944671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703610|NCT01390649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703611|NCT00936156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703612|NCT02721160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33703613|NCT03031197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open Label|||||
33703614|NCT05560360|NA|SINGLE_GROUP||TREATMENT||NONE||Compare the pharmacokinetic effects of efavirenz on SHR1459 in healthy subjects.||||
33703615|NCT03095612|NA|SINGLE_GROUP||TREATMENT||NONE||Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Dose limiting toxicities (DLTs) will be assessed based on the first cycle (7-day lead-in plus 21-day cycle = 28 days) toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 4.03. A standard 3 + 3 dose escalation paradigm will be used.||||
33703616|NCT00845143|||CASE_CONTROL||PROSPECTIVE|||||||
33703617|NCT00769210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703618|NCT00001880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703619|NCT02534714|||COHORT||OTHER|||||||
33703620|NCT01686828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703621|NCT02978898|||COHORT||RETROSPECTIVE|||||||
33703622|NCT00250055|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703623|NCT02774954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician who is conducting the data analysis will not know the content of the intervention assignment.|This study compares 2 active listening, information-motivation-behavior skills interventions aimed at improving health behaviors among very low-income, drug using participants.|f|f|f|t
33703624|NCT02323243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703625|NCT02847975|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33928725|NCT04931472|||COHORT||PROSPECTIVE|||||||
33928726|NCT00568204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928727|NCT06383819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928728|NCT04978402|||COHORT||RETROSPECTIVE|||||||
33928729|NCT00587444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33928730|NCT02896738|||OTHER||PROSPECTIVE|||||||
33928731|NCT06423170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928732|NCT01308294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||open label, non comparative study in patients suffering from stage II, III or IV melanoma||||
33928733|NCT03429764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092825|NCT04529980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized into two study groups using randomization and utilizing a sealed envelope randomization plan. Both the care providers and study participants (parents/LAR) will be masked from which treatment assignment the participant was randomized to.|Those randomized to the treatment group will be given probiotic therapy until discharge, while those randomized to the placebo group will be given a placebo until discharge.|t|t|f|f
34092826|NCT04649983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703626|NCT03219138|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|"Immediately after extubation the blinded anaesthesiologist (care provider), who performs anesthesia, tests the patient in the operating room.~The blinded anaesthesiologist is unable to see the data on the EMG monitor and the movement of the adductor pollicis muscle."|"During anaesthesia calibrated neuromuscular function is monitored using evoked EMG of the adductor pollicis muscle (immobilised forearm) with a NMT module by a non-blinded investigator. During surgery, the (blinded) attending anaesthesiologist administers maintenance doses of atracurium according to clinical needs, i.e. without knowing the TOFR.~After surgery patients' trachea is extubated according to clinical judgement. Immediately after extubation blinded anaesthesiologist tests the patient. The postoperative evaluation of neuromuscular function consists of eight clinical tests applied in a random order.~Thereafter, an uncalibrated acceleromyography (50 mA, 2 Hz) is started on the contralateral arm and TOF ratio is measured.~During the validation part of the developed algorithm the anaesthesiologist additionally had to judge tactile fading of the adductor pollicis.~If a patient had any clinical signs of neuromuscular dysfunction, reversal with neostigmine is administered."|f|t|f|f
33703627|NCT00354744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703628|NCT00398918|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33703629|NCT04344548|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I/II immunotherapy with NK cells for mild infected COVID-19 patients||||
33703630|NCT02055313|||OTHER||RETROSPECTIVE|||||||
33703631|NCT01984411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928734|NCT01894334|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928735|NCT02843178|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33928736|NCT01001572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928737|NCT01812499|||||RETROSPECTIVE|||||||
33928738|NCT01197794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928739|NCT00280605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928740|NCT01415908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928741|NCT05437913|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No blinding can be used however the researcher will be blinded when coding observational data.|single case multiple randomized baseline design||||
33928742|NCT01361880|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33928743|NCT03481504|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The particpant is kept naieve about the fact that the moment of starting the intervention is randomized but coiuld not be blinded for the intervention. The outcome assessor and investigator are blinded for randomization|Single case methodology with a multple baseline design in a mixed methods approach in which a quantitative approach will be followed by a qualitative approach. The star of the experiemental intervention will be randomized|t|f|t|t
33928744|NCT00591240|||COHORT||PROSPECTIVE|||||||
33928745|NCT05038358|||COHORT||PROSPECTIVE|||||||
33928746|NCT02285517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928747|NCT00973180|RANDOMIZED|PARALLEL||||NONE||||||
34007773|NCT05070390|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34007774|NCT06375369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007775|NCT02281682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34007776|NCT02190279|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007777|NCT04414137|||COHORT||RETROSPECTIVE|||||||
34007778|NCT01974076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007779|NCT04868864|||COHORT||PROSPECTIVE|||||||
33928748|NCT01155960|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007780|NCT04703543|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients with metastatic prostatic cancer||||
34007781|NCT02997137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007782|NCT03934749|||CASE_CROSSOVER||PROSPECTIVE|||||||
33928749|NCT05214404|||CASE_CONTROL||PROSPECTIVE|||||||
33928750|NCT01187134|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34007783|NCT06285240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Panel A participants will receive a loading dose of MK-1167 6 mg or matching Placebo on Days 1 to 7 followed by once daily (QD) dosing of MK-1167 3 mg or matching Placebo for 14 consecutive days (Days 8 to 21). Panel B participants will receive QD dosing of MK-1167 6 mg or matching Placebo for Days 1 to 31. Panel B will be initiated following review of safety and tolerability data from Panel A.|t|t|t|t
34007784|NCT06227377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092827|NCT05363904|||CASE_CONTROL||PROSPECTIVE|||||||
34092828|NCT06283108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092829|NCT02538198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092830|NCT04407520|||COHORT||RETROSPECTIVE|||||||
34092831|NCT04948125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092832|NCT04136301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092833|NCT01543191|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34092834|NCT03996213|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34092835|NCT04061629|||COHORT||PROSPECTIVE|||||||
34092836|NCT06323993|||COHORT||RETROSPECTIVE|||||||
34092837|NCT00742456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34092838|NCT03650270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The specific treatment protocol was blinded to the data analyser|random allocation to 2 study protocols|f|f|f|t
34092839|NCT02931097|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34092840|NCT00902967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34092841|NCT06370975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092842|NCT05047380|||COHORT||PROSPECTIVE|||||||
34092843|NCT01433913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092844|NCT01718067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092845|NCT00754780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092846|NCT04569370|||COHORT||PROSPECTIVE|||||||
34092847|NCT01757847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092848|NCT01142921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703632|NCT00067405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092849|NCT05492435|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34092850|NCT05791331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled trial|t|t|f|t
34092851|NCT05574049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The physician investigator, and all of the test subjects will be masked from knowing which intervention that they are receiving.|Subjects will be divided into three groups for daily doses. One group with get single dose (8mg THCV/10mg CBD), one group will get double dose (16mg THCV/20mg CBD) and the placebo group will get mouth strip only.|t|t|t|t
34092852|NCT03026725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092853|NCT04251494|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092854|NCT03033836|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group receiving the same intervention, to evaluate retention at 48 weeks||||
34092855|NCT02205021|||COHORT||RETROSPECTIVE|||||||
34092856|NCT02119000|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34092857|NCT02177357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34092858|NCT02233335|||CASE_CONTROL||RETROSPECTIVE|||||||
34092859|NCT00446784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928751|NCT04484051|||COHORT||PROSPECTIVE|||||||
33928752|NCT04955496|||COHORT||RETROSPECTIVE|||||||
33928753|NCT04758741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sequencing will be centralized in such a way that the list of random allocation sequences is provided to someone outside the research team. As soon as a person is eligible to participate in the study, the sampler contacts the person who has the random assignment sequence and he or she, according to the sequence list, gives the code to the participants to enter the study. Acceptance and commitment therapy sessions are held by a trained researcher. At the evaluation stage, one week and one month after the intervention, the questionnaires are completed by trained questioners. The statistical consultant who will assist in the data analysis will be unaware of the codes of the participants in the groups. Therefore, the study will be of the three-blind type.|"Individuals are randomly divided into two groups: intervention (n = 40) and control (n = 40). The members of the intervention group in groups of 10 will receive acceptance and commitment treatment in 8 90-minute sessions once a week according to Hayes (2006) approach in Mashhad Al-Koubeh Health Center by a consultant (researcher) trained. The control group also receives 8 counseling sessions per week by the same Health Education consultant in groups of 10 in the same center. One week after the end of the eighth session and one month later, the questionnaires are completed again by trained questioners for both groups"|t|t|t|t
33928754|NCT05822648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and follow-up assessors will be blinded to condition||f|f|t|t
33928755|NCT00278863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928756|NCT04616924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928757|NCT05481970|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928758|NCT01750840|||COHORT||PROSPECTIVE|||||||
34007785|NCT02129309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34007786|NCT03259191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007787|NCT05924334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"In the research, practitioners and evaluator are different from each other. While the International Researcher with the International IAOTH -approved Kundalini Reiki Master certificate, he will be the Primary practitioner, one of the two other researchers will be a placebo practitioner and the other evaluator. In this way, the bias of the practitioners and the evaluation will disappear and triple blinding will be performed and reliable results will be obtained."|Prospective, randomized controlled trial|t|f|t|f
34007788|NCT02095340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33703633|NCT06050005|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental: rehabilitation activity All participants will be included in this arm.||||
34007789|NCT03862534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703634|NCT03060499|||COHORT||PROSPECTIVE|||||||
33703635|NCT03412760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All cases of unexplained non-immune hydrops fetalis (NIHF) or other birth defects enrolled in the study will be offered exome sequencing (ES) for the affected fetus or neonate.||||
33703636|NCT01506258|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703637|NCT02921542|||COHORT||PROSPECTIVE|||||||
33703638|NCT01304680|||CASE_ONLY||RETROSPECTIVE|||||||
33703639|NCT00503529|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33703640|NCT04226872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33703641|NCT00004762||||TREATMENT||||||||
33703642|NCT04085393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703643|NCT05521620|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A before- and-after intervention study||||
33703644|NCT06273462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded, patients will receive visually identical capsules from research pharmacist with study label indicating PEA vs Placebo|Prospective Randomize Double Blind Placebo Controlled study comparing the supplement palmitoylethanolamide (PEA) to a visually identical placebo|t|t|t|t
33703645|NCT01237821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703646|NCT05629078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|investigators will be blinded to which types of IOLs implanted to the cataract patients|randomised control trial|f|f|t|f
33703647|NCT02233114|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33703648|NCT00335413|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33703649|NCT05979259|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33703650|NCT03039452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703651|NCT03386318|||COHORT||PROSPECTIVE|||||||
34007790|NCT05049811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34007791|NCT02464241|||COHORT||PROSPECTIVE|||||||
34007792|NCT05598879|||COHORT||PROSPECTIVE|||||||
34007793|NCT02845726|||COHORT||PROSPECTIVE|||||||
34007794|NCT02719704|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703652|NCT06000332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703653|NCT06557590|||COHORT||PROSPECTIVE|||||||
33703654|NCT06026709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33703655|NCT03890406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33703656|NCT03857399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703657|NCT01741974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33703658|NCT04289142|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33703659|NCT00194259|||COHORT||PROSPECTIVE|||||||
33703660|NCT03609879|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33703661|NCT02369016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703662|NCT02236442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703663|NCT03095339|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a pre-post community-based randomized controlled trial. The unit of randomization is the village (community)||||
33703664|NCT01728350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703665|NCT04391361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703666|NCT00407329|||CASE_ONLY||PROSPECTIVE|||||||
33703667|NCT06489925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703668|NCT06132295|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33703669|NCT04781023|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, longitudinal, prospective, open label trial with a control group with randomized, consecutive recruitment for each group, to evaluate the safety and efficacy of carboxymethyl-beta-glucan and polycarbophil as a treatment for high-risk HPV infection in women without cytological alterations.||||
33703670|NCT03403088|RANDOMIZED|PARALLEL||TREATMENT||NONE||60 participants with NCCLs and positive for DH are enrolled in the study to receive randomly the followed treatments: LA= 780 nm and 70mW GaAlAs Laser/ 4 sessions; LAP= placebo laser/ four sessions; CP= ClinproTM XT Varnish/ in-office single session; RX= adhesive RelyXTM Arc/ in-office single session; DE= stannous fluoride dentifrice/30-days-home-use; DE-P= placebo dentifrice/30-days-home-use||||
34007795|NCT00515034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007796|NCT06483087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||A Parallel Randomized Control Trial (RCT) design will be utilized to test the study hypotheses. It is an experimental design where participants are assigned randomly to either receive the intervention or not, and the outcome of interest is then evaluated after the intervention.|f|t|t|t
34007797|NCT04083859|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34007798|NCT01033578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007799|NCT01491633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007800|NCT05494216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007801|NCT03658863|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34007802|NCT04027257|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to start the intervention immediately after baseline assessment (i.e., treatment) or approximately 15 weeks later after the baseline assessment (i.e., waitlist control).||||
34007803|NCT04017559|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007804|NCT03968926|||COHORT||RETROSPECTIVE|||||||
34007805|NCT04628845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34007806|NCT04490226|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||all subjects are undergoing each intervention||||
34007807|NCT00258505|||DEFINED_POPULATION||PROSPECTIVE|||||||
33703671|NCT03859778|||COHORT||CROSS_SECTIONAL|||||||
33703672|NCT03979378|||COHORT||RETROSPECTIVE|||||||
33703673|NCT03659734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703674|NCT03361163||SEQUENTIAL||BASIC_SCIENCE||NONE||Observational, sequential, dose-escalation||||
33703675|NCT04207021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703676|NCT02358837|||CASE_CONTROL||PROSPECTIVE|||||||
33703677|NCT06180720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703678|NCT04259567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703679|NCT04260308|||CASE_ONLY||PROSPECTIVE|||||||
33703680|NCT02972671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703681|NCT04111198|||CASE_ONLY||CROSS_SECTIONAL|||||||
33703682|NCT02272660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703683|NCT06324812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703684|NCT05250778|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33703685|NCT06057831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703686|NCT00515489|||COHORT||PROSPECTIVE|||||||
33703687|NCT02982668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33703688|NCT04759573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"The intervention is performed by mothers who have to administer the speech or singing or they have to observe.~The research assistant will support mothers to deliver the intervention The outcome assessors will be blinded"|A four-site randomized controlled trial will be conducted to investigate the short- and long-term physiological and neurobehavioral effects of Early Vocal Contact.|f|f|f|t
33703689|NCT05570292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703690|NCT03751683|||COHORT||PROSPECTIVE|||||||
33703691|NCT06282510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33703692|NCT06016920|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-finding trial, including a dose escalation phase (phase 1) where participants are allocated sequentially to one of the 3 escalating doses; and a dose expansion phase (phase 2a) where participants are randomized to one of two doses||||
33703693|NCT00917371|||OTHER||OTHER|||||||
33703694|NCT04121026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||TB-Speed HIV is a prospective, multicentre management study evaluating the safety and feasibility of the recently proposed PAANTHER TB treatment decision algorithm for HIV-infected children with presumptive TB.||||
33703695|NCT04672395|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Each subject will receive 2 doses of their assigned treatment on Days 1 and 22. Booster dose will be given at least 4 months after the second dose (Day 1A for booster dose). The treatment will be administered IM in the deltoid region of the upper non-dominant arm|t|t|t|t
33703696|NCT01313858|||COHORT||PROSPECTIVE|||||||
33703697|NCT05476406|RANDOMIZED|PARALLEL||TREATMENT||NONE||One Active group and one Control group||||
33703698|NCT02002091|||COHORT||PROSPECTIVE|||||||
33703699|NCT01705730|||COHORT||PROSPECTIVE|||||||
33703700|NCT02657538|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33703701|NCT04281303|||COHORT||PROSPECTIVE|||||||
33703702|NCT04261868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703703|NCT03191188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703704|NCT00194285|||COHORT||PROSPECTIVE|||||||
33789167|NCT06465667|RANDOMIZED|CROSSOVER||OTHER||NONE||"This is be a stepped wedge randomized controlled trial of precision feedback. One hundred urologists will be randomized into four groups, stratified by case volume. The trial will consist of four steps of three months each, at the beginning of which one group will cross over from control to intervention arm. This is preceded by a three-month pre-rollout period, comprising a total study length of 15 months. The duration of the trial was chosen based on a desire to deliver rapid results to inform the scale-up of the intervention, and to mirror the period of time over which a typical dashboard project may be conceived, designed, and delivered. Case volume may predict dashboard engagement, stenting practices, and privileged awareness of ongoing study efforts, and is therefore suitable for stratification."||||
33789168|NCT03709446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789169|NCT00927823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007808|NCT02870894|||||CROSS_SECTIONAL|||||||
33703705|NCT01924000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703706|NCT04694781|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33703707|NCT03186495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703708|NCT05123820|NA|SINGLE_GROUP||OTHER||NONE||Two-period, fixed-sequence study||||
33703709|NCT06178289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Single: Investigator (central assessor of the photographs) will be blinded.~The participants and care providers cannot be blinded."||f|f|t|f
33703710|NCT03884491||SEQUENTIAL||TREATMENT||NONE||||||
33703711|NCT01086722|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007809|NCT02856087|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703712|NCT02787382|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33703713|NCT06271213|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703714|NCT00431769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703715|NCT00825682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703716|NCT04021771|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Standardized patients will score the residents upon completion of each simulation encounter, and they will be masked to the assignment of the participant.|This study will employ a 2-arm wait-list control trial. Participants will be evenly randomly assigned to Group A or Group B. Investigators will use a control arm (Group B) to compare the impact of exposure to the educational curriculum to the impact of the baseline testing (T1) alone on subsequent test scores. However, to maintain the goal of mastery learning curriculum of allowing all learners to achieve mastery, following the second test (T2), the Group B participants will also be exposed to the intervention. All participants will return for a third test (T3). For participants in Group A, T3 will provide information about the decay of learned skills and if performance on the task is maintained by a single intervention or would require further follow-up education.|f|f|f|t
34007810|NCT06360757|||OTHER||PROSPECTIVE|||||||
33703717|NCT05203094|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33703718|NCT02850601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703719|NCT04200950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703720|NCT02652832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33703721|NCT06088875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703722|NCT04797078|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33703723|NCT04969575|||COHORT||RETROSPECTIVE|||||||
33703724|NCT01790854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703725|NCT05866406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703726|NCT00003970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703727|NCT05820945|RANDOMIZED|PARALLEL||OTHER||SINGLE|The intervention will be carried out unblinded for the patients/physicians, and the results will be blindly measured by the outcomes assessor.|Participants will be randomly assigned to one of two groups in parallel for the duration of the study: (a) intervention group (medication review), in which the patients will receive pharmacist-led medication review, and change proposals through their physician, and (b) control group, in which the patients will be subjected to usual pharmacotherapy management.|f|f|f|t
33703728|NCT04094129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33703729|NCT04007926|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not possible due to nature of intervention (exercise training programme).|Randomised controlled trial||||
33703730|NCT06311786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703731|NCT06051370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A final number of 51 patients were enrolled in the trial and randomly assigned to either the glenohumeral ultrasound-guided injection group (Group GH) or the subacromial ultrasound-guided injection group (Group SA). Double-blinded randomization was performed by an independent nurse using a computer-generated random sequence. A musculoskeletal radiologist, blinded to group allocation, performed the diagnostic ultrasound and MRI interpretations. A blinded orthopaedic resident and nurse carried out the physical examination and clinical scoring.|"Study group underwent ultrasound-guided posterior approach of glenohumeral space injection for impingement syndrome with mild stiffness of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline.~Control group underwent ultrasound-guided anterolateral approach of subacromial space injection for impingement syndrome with mild stiffness of the shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 7 mL normal saline."|t|f|f|t
33703732|NCT04556630|||COHORT||PROSPECTIVE|||||||
33703733|NCT00006111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703734|NCT04996108|||CASE_CONTROL||PROSPECTIVE|||||||
33703735|NCT00684099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703736|NCT05241743|||OTHER||CROSS_SECTIONAL|||||||
33703737|NCT02304718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928759|NCT00758407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928760|NCT05615038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928761|NCT06263244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|After informed consent has been obtained, patients will be randomized via computer randomization to either 15 mg ziltivekimab (n=20) or placebo (n=20). On the eCRFs or other documents subjects will be identified by subject ID and randomization number only.|randomized, double blind, placebo-controlled trial|t|t|t|t
34007811|NCT04838379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Age: 8-12years.~* Weight: 20-60 kg.~* Sex: both males and females.~* ASA physical status: I-II."|t|f|f|t
34007812|NCT01546922|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33703738|NCT01779778|||COHORT||PROSPECTIVE|||||||
33703739|NCT03659500|||COHORT||RETROSPECTIVE|||||||
33703740|NCT03328767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A 30 patient, multicentre, randomised, trial of early individualised physical training compared to standard care.|f|f|f|t
33703741|NCT00915122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703742|NCT04779346|||COHORT||PROSPECTIVE|||||||
33703743|NCT00828412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703744|NCT00675948|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33703745|NCT03175757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33703746|NCT05430152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded placebo-controlled|Randomized parallel group double-blinded placebo-controlled trial|t|t|t|t
33703747|NCT01685034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703748|NCT06349330|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"This is a parallel-arm randomized controlled trial and subjects are randomized into test and control groups via block randomization.~To investigate the immediate effectiveness on the use of 3D intraoral scanner in the improvement of oral hygiene in two (2) parallel arm study with 52 subjects (n=52). The study will take place over 1 visit."|f|f|t|f
33703749|NCT03532841|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A randomised double-blind placebo-controlled trial.|t|t|t|t
33703750|NCT00094172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007813|NCT06078540|NA|SINGLE_GROUP||OTHER||NONE||||||
34007814|NCT02361814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007815|NCT01098110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007816|NCT00267163|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34007817|NCT02023008|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007818|NCT04502498|||OTHER||PROSPECTIVE|||||||
34007819|NCT01121107|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34007820|NCT00104247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34007821|NCT00275275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007822|NCT00148720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007823|NCT05478187|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34007824|NCT05429697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007825|NCT05290337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007826|NCT05930431|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two distinct physical activity groups occurring at the same time.||||
34025257|NCT04530435|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be blinded to treatment allocation where possible. This is of outmost importance, and participants are requested not to disclose their allocation when outcomes are assessed. To test the blinding efficacy, the outcome assessors are asked what treatment strategy they think a patient has received after assessments.|"This study is designed as a randomised, controlled, open-label trial with two parallel groups and a primary endpoint of CAT-score after 30 days of intervention.~Randomization lists will be computer-generated using an appropriate statistical software and based upon permuted random blocks. The allocation ratio will be 1:1 stratified for the following baseline conditions:~* Sex~* Age (≥60 and \<60 years)"|f|f|f|t
33928762|NCT05953324|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible participants were randomly assigned to either a non-kiwifruit feeding group (controls) or consumed two medium-size kiwifruit group \[21\] (cases) 1 hour before bedtime every night for 6 weeks (42 days in total). Total number of kiwis consumed should be (14 kiwis (number of kiwis in one week) x 6 (number of weeks) = 84 kiwis in total. Participants consuming the kiwifruit were asked to keep a diary to record if they consumed them every day. During the 6-week intervention period, participants received their kiwifruit every week on the first day of the week (Sunday) that is adequate for a week (14 kiwi fruits brand name: Sharbatly Co. Ltd, variety: Hayward, country of origin: Italy). The kiwifruits were supplied at optimum ripeness for consumption and were instructed to keep the kiwi in the fridge to prevent damage.||||
33928763|NCT03290794|||OTHER||PROSPECTIVE|||||||
34007827|NCT05230602|RANDOMIZED|CROSSOVER||TREATMENT||NONE||At the start of the study (T1), the participants will fill the above scales. The participants will then be divided randomly into two equal groups. Group A will be instructed to eat the tzabar fruit twice a day for two weeks, while Group B, the control group, will be instructed not to change their diet. At the end of 14 days (T2) all participants will be re-assessed again. Then Group B will be instructed to eat the tzabar fruit twice a day for 14 days, while Group A, will be instructed to eat their regular diet. During the research period, the participants will be instructed to continue their regular treatment routine, whether this includes taking medication, performing sporting activity, and so on in order to avoid undesirable influences that could bias the research results. The tzabar fruits will be supplied by the research team, in a neutral location. After a month all participants will fill the above scales.||||
34007828|NCT06200584|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34007829|NCT03653026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007830|NCT04251858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The groups of participants should be divided by the oral condition of the participants (with oral problems and without oral problems)||||
34007831|NCT04612530|RANDOMIZED|PARALLEL||TREATMENT||NONE||Step-up design. Arms A (monotherapy Nivolumab, 6 patients) and B (IRE + Nivolumab, 6 patients) will open first. A safety and toxicity analysis will be performed after the inclusion of patient 6 and patient 12. Arm C (CpG + IRE + Nivolumab, 6 patients) will open if the interim results demonstrate safety of arms A and B.||||
34007832|NCT04307472|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Investigators, statisticians, and analysts will be blinded during the intervention and analysis. Study staff (project director, manager, and research coordinators) will be unblinded throughout the study in order to deliver the appropriate interventions and to manage participant communications. The project manager will be tasked with maintaining codes to associate the blinded assignments to the clinical practices.|"The four-arm factorial trial will randomly assign primary care practices to one of the following arms for the intervention:~1. Control~2. Clinician nudge using an active choice prompt in the electronic health record at the time of the patient visit and a monthly peer comparison message on statin prescribing performance relative to peer clinicians at Penn Medicine delivered through the electronic health record~3. Patient nudge using a text message sent 72 hours prior to their primary care clinician appointment that informs them of their eligibility for a statin, the risks and benefits, and asking them to discuss the role of starting a statin with their clinician~4. Both clinician nudge and patient nudges"|f|f|t|t
34007833|NCT01765751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34007834|NCT01376206|||OTHER||OTHER|||||||
34007835|NCT00699244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007836|NCT06404541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007837|NCT02367287|||OTHER||CROSS_SECTIONAL|||||||
34007838|NCT02604576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703751|NCT04512417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703752|NCT01161459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703753|NCT03904732|||OTHER||OTHER|||||||
33703754|NCT01355003|||COHORT||CROSS_SECTIONAL|||||||
33703755|NCT02144623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703756|NCT01372592|||COHORT||PROSPECTIVE|||||||
33703757|NCT02281201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703758|NCT06049953|||COHORT||PROSPECTIVE|||||||
33703759|NCT04767763|||CASE_CONTROL||PROSPECTIVE|||||||
33703760|NCT00968201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703761|NCT02649270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703762|NCT00593502|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703763|NCT03006107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703764|NCT00638482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703765|NCT06240871|||COHORT||PROSPECTIVE|||||||
33703766|NCT03625622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind for study site and participants|After the first 26 weeks, subjects can participate in an optional extension study to receive either 10 mg or 30 mg AR1001 for another 26 weeks.|t|t|t|t
33703767|NCT05424302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care provider(s) being masked to interventions assigned to participants in this clinical trial are the physiotherapists providing standard vestibular rehabilitation sessions to study participants. No other parties will be masked in this clinical trial.|Patients will be divided into two groups using a computer-generated randomization schedule. These groups will undergo 4 or 8 weeks of vestibular rehabilitation for patients diagnosed with unilateral vestibular hypofunction or bilateral vestibular hypofunction respectively (Hall et al. 2016). This involves once a week 40-45 minute in-person sessions with a registered physiotherapist and three 20 minute sessions a day of at-home independent exercises (Hall et al. 2016). Standard vestibular rehabilitation involves a combination of exercises to promote gaze stability, to habituate symptoms, balance and gait training, and aerobic exercise (Hall et al. 2016). The virtual reality (VR) group will undergo an additional VR vestibular rehabilitation protocol. This will require them to utilize a head-mounted display device to play a video game projected on an android or apple device in a VR headset for 20 minutes daily until vestibular rehabilitation is complete (Micarelli et al. 2017, 2019).|f|t|f|f
33703768|NCT05392829|||CASE_ONLY||PROSPECTIVE|||||||
33928764|NCT02818270|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33928765|NCT04564794|||COHORT||RETROSPECTIVE|||||||
33928766|NCT00995267|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928767|NCT04594356|||COHORT||RETROSPECTIVE|||||||
33928768|NCT00509652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092860|NCT03247114|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34092861|NCT03339453|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34092862|NCT03341429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator who will conduct the follow-up assessments and the trial subjects will be blinded to participants' allocation and will not be involved in delivering any of the intervention. The statistician conducting the data analysis will be blind to group allocation.|This study is a double-blind, randomised, placebo-controlled, two-arm, parallel group, single-site trial|t|t|t|t
34092863|NCT04803500|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Split-mouth design|t|f|t|t
34092864|NCT02034591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34092865|NCT01248975|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34092866|NCT02615353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092867|NCT01723943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34092868|NCT03086343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092869|NCT00255333|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092870|NCT04737694|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blinded|Double blinded randomized crossover design|t|f|t|f
34092871|NCT00228852|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34092872|NCT02417181|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34092873|NCT00287820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092874|NCT02636452|||OTHER||PROSPECTIVE|||||||
34092875|NCT03641729|NA|SINGLE_GROUP||TREATMENT||NONE||The exercise training program was performed once daily during the hospital stay. The program included 2- to 5-minute warm-up session which consisted of stretching, coordination and balance exercises, followed by 10 to 20 minutes of moderate-intensity aerobic exercise using a lower limb cycle ergometer (Live up Sports, 1023, Araucária, Paraná, LS9055). Participants also performed three sets of five to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. All exercises were performed within the participant's room. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve. The HR reserve was estimated using the following equation: \[(220-age in years) - resting HR\] x \[50 to 70%\] + resting HR.||||
34092876|NCT01104766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092877|NCT01021319|||COHORT||CROSS_SECTIONAL|||||||
34092878|NCT02626013|||COHORT||PROSPECTIVE|||||||
34092879|NCT04408079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092880|NCT00236431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928769|NCT03150199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092881|NCT04864769|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Design and Method: Randomized, controlled, double-blind cross-study, in which 12 healthy adult young men in randomized order ingest 35 g of protein of crude protein from one of the three protein sources or water on four different experimental days. Before and up to three hours after ingestion of the test beverage, blood samples are collected for 8 time points during each experimental day.||||
33703769|NCT03935360|||COHORT||PROSPECTIVE|||||||
33789170|NCT02246621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33789171|NCT04564391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"For the preliminary meal tests all drinks and food supplements are provided in neutral bottles and cannot be identified by visual appearance, taste, texture or odour. Masking applied to participants, care providers, investigators and outcomes assessors.~For the interventional study provided drinks and food supplements were masked best possible for the participants."|parallel-designed randomised controlled trial|t|f|f|f
33789172|NCT03925194|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33789173|NCT03168646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928770|NCT01544478|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33928771|NCT00235664|||||PROSPECTIVE|||||||
33928772|NCT04494529|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Pilot double-blind randomized controlled trial|t|t|t|t
33928773|NCT01728727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928774|NCT01779804|||COHORT||PROSPECTIVE|||||||
33928775|NCT05499598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928776|NCT06145087|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||two-armed parallel group, randomised, controlled, double-blind clinical trial.|t|t|t|t
33928777|NCT00064636|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928778|NCT05189704|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33928779|NCT05850013|||OTHER||PROSPECTIVE|||||||
33928780|NCT00492414|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928781|NCT03483376|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel arms of the study will be used. One arm will receive dental plaque removal using standard protocol. The other arm will receive the standard plaque removal, followed by antimicrobial photodynamic therapy.||||
33928782|NCT00461240|||CASE_CONTROL||PROSPECTIVE|||||||
34092882|NCT04469244|||CASE_ONLY||RETROSPECTIVE|||||||
34092883|NCT00820092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092884|NCT05053828|||COHORT||RETROSPECTIVE|||||||
34092885|NCT02193152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092886|NCT01808742|||COHORT||PROSPECTIVE|||||||
34092887|NCT03791372|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel assignment|f|f|f|t
34092888|NCT00082316|RANDOMIZED|||TREATMENT||NONE||||||
33928783|NCT05281068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928784|NCT06180876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928785|NCT01201304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928786|NCT06397976|||COHORT||PROSPECTIVE|||||||
33928787|NCT05774613|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Clinical trial in which both treatments under study (experimental and control) are administered to each patient at successive administered to each patient in successive periods that have been randomly determined, allowing each subject to be his or her own control. Randomly determined, allowing each subject to be his or her own control.|t|f|f|f
33928788|NCT00257868|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33928789|NCT04313101|||CASE_CONTROL||PROSPECTIVE|||||||
33928790|NCT05379205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928791|NCT03198104|||COHORT||PROSPECTIVE|||||||
33928792|NCT05845008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007839|NCT05488886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The order of intervention foods (A-D) will be randomized for each participant upon study enrollment. Wash-in and wash-out periods are 6 days long, and food consumption and sampling durations are 24 hours.|t|f|f|f
34092889|NCT04569344|||COHORT||RETROSPECTIVE|||||||
34092890|NCT05569941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092891|NCT04115228|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34092892|NCT02298491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007840|NCT04174716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092893|NCT00430365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007841|NCT05854706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092894|NCT03876353|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
34007842|NCT04977596|||CASE_CONTROL||RETROSPECTIVE|||||||
34092895|NCT02272101|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34007843|NCT01431443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34007844|NCT06433206|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092896|NCT00088153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092897|NCT05851755|||COHORT||PROSPECTIVE|||||||
34092898|NCT03974009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two group pretest postest randomized control group design|t|f|f|f
33703770|NCT04996017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This is a randomized, placebo-controlled, double-blind study. Patients will be randomized to one of the following treatment arms in a 2:1 ratio (experimental to control arm):~* Arm A (experimental arm): atezolizumab~* Arm B (control arm): placebo~Randomization will be stratified by the following factors:~* Histology (epithelioid vs non epithelioid)~* Stage (I vs \>I) Blinding Investigators and patients will remain blinded to treatment assignment until the final analysis of OS, except in the event unblinding is necessary for a medical emergency or to help guide decisions on subsequent treatment.~If the investigator wishes to know the identity of the study drug for any reason other than a medical emergency, he or she should contact the Scientific Responsible. In case of unblinding, patient will be withdrawn by the study."|"This is a multicentric double-blind, placebo controlled, phase III trial. In this study, patients who underwent to a surgical resection of pleural mesothelioma and are without signs of macroscopic residual disease will be randomized 2:1 to receive atezolizumab or placebo. Patients will be treated for 12 months or until recurrence, unacceptable toxicity or patient/physician decision, whichever occurs first. Randomization will be done via a centralized system and patients will be stratified histology (epithelioid vs non epithelioid) and stage (I vs~\>I)."|f|t|f|f
33703771|NCT04689009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703772|NCT06361433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703773|NCT03070028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703774|NCT04775407|||COHORT||PROSPECTIVE|||||||
33703775|NCT04067700|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who receive invasive coronary treatment will undergo additional coronary perfusion PET/CT and CPET tests six months after the treatment.||||
34092899|NCT05648851|||COHORT||CROSS_SECTIONAL|||||||
33703776|NCT00133029|RANDOMIZED|PARALLEL||||NONE||||||
33703777|NCT01481597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33703778|NCT00003661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703779|NCT04131426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703780|NCT00385710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703781|NCT02432495|||COHORT||RETROSPECTIVE|||||||
33703782|NCT06343740|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot study is a pre-post study.||||
33703783|NCT04722887|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33703784|NCT04121923|NA|SINGLE_GROUP||SCREENING||NONE||||||
33703785|NCT04903275|RANDOMIZED|CROSSOVER||PREVENTION||NONE||randomized, split-mouth controlled, clinical trial||||
33703786|NCT00474760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703787|NCT01484678|||CASE_CONTROL||PROSPECTIVE|||||||
33703788|NCT02420522|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33703789|NCT00808990|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703790|NCT02543970|||CASE_ONLY||PROSPECTIVE|||||||
33789174|NCT05972694|NA|SINGLE_GROUP||OTHER||NONE||subjects will continue to consume their usual diet (excluding all grapes/berries) and consume 46g/d freeze-dried grape powder daily (consumed as 22.5g packets twice daily for 21 days. A stool and blood sample will be collected at the start and end of the intervention.||||
33789175|NCT02710864|||OTHER||CROSS_SECTIONAL|||||||
33789176|NCT04148937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789177|NCT02784704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789178|NCT06554132|||OTHER||CROSS_SECTIONAL|||||||
34092900|NCT04742179|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092901|NCT05462678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092902|NCT06018168|RANDOMIZED|PARALLEL||OTHER||NONE||The study will be conducted as a randomized, controlled trial in which participants will be split into two groups. Both will use the skincare routine, but one group will also take the MINDBODYSKIN supplement in combination with the skincare routine.||||
34092903|NCT03038139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34092904|NCT05503069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This project will utilize a cohort case-controlled study design. There will be two arms with equally enrolled participants in each arm (1:1). Participants will be allocated in the control and intervention arm utilizing simple randomization with fixed number (n=60) for each arm distributed in group A (control) and group B (intervention). The participants will randomly select an envelope concealing the group label after signed the consent form.||||
34092905|NCT01955018|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34092906|NCT01129128|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33703791|NCT00669656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703792|NCT03181035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703793|NCT06044454|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33928793|NCT00264667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928794|NCT02157259|||CASE_ONLY||PROSPECTIVE|||||||
33928795|NCT04071171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928796|NCT03432572|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The interventions will be blinded to the investigator, the care providers (surgeons), and will be blinded to the patients in the study|This will be a 3 arm randomized controlled double blinded study. The arms will all be studied in parallel to each other and compared in their effectiveness for evaluation for urine jets on cystoscopy.|t|t|t|f
33928797|NCT02395289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33928798|NCT03006900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928799|NCT01255293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928800|NCT02989441|||COHORT||PROSPECTIVE|||||||
33928801|NCT00053638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928802|NCT05480761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928803|NCT01085604|||COHORT||PROSPECTIVE|||||||
33928804|NCT02623387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33928805|NCT04049812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928806|NCT00080184|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33928807|NCT04501172|||OTHER||PROSPECTIVE|||||||
33928808|NCT00145197|NA|SINGLE_GROUP||||NONE||||||
33928809|NCT05666908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33928810|NCT00602069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33928811|NCT01202760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928812|NCT01204307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928813|NCT05265962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928814|NCT05621018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928815|NCT04628611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participant does not know which group the patient belongs to as every patient was consented for both devices which were ready in the operating theatre|two equal groups; group (V) using video laryngoscope(53) and group (F) using flexible intubating laryngoscopy(53).|t|f|f|f
34092907|NCT02408822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092908|NCT02800252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092909|NCT02930941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703794|NCT00389597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703795|NCT01286233|||CASE_CONTROL||PROSPECTIVE|||||||
33703796|NCT05715697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703797|NCT05085730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703798|NCT04034628|||COHORT||PROSPECTIVE|||||||
33703799|NCT06166485|RANDOMIZED|CROSSOVER||OTHER||NONE||This study was planned as a randomized controlled experimental study. Computer-assisted randomization will be used to create groups (https://www.randomizer.org/). Power analysis was performed using the G\*Power (v3.1.9) program to determine the sample size. The power of the study is expressed as 1-β (β = probability of type II error) and in general, studies must have 80% power.||||
33703800|NCT02856035|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||feasibility testing||||
33703801|NCT05822661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Drug vs placebo|t|f|f|t
33703802|NCT03840798|||COHORT||OTHER|||||||
33703803|NCT00229073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703804|NCT05159544|||COHORT||PROSPECTIVE|||||||
33703805|NCT02004483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703806|NCT02341040|||COHORT||PROSPECTIVE|||||||
33703807|NCT00761904|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33703808|NCT01233258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703809|NCT01280474|||||PROSPECTIVE|||||||
33703810|NCT02434978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703811|NCT01771744|||CASE_CONTROL||RETROSPECTIVE|||||||
33703812|NCT02221687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33703813|NCT04794309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Seventy young males with obesity participated in this study. They were divided randomly into two groups. Group 1 received circuit training with low-carbohydrate (LC) diet intervention and Group 2 was the control group. The study variables such as exercise capacity, body composition, skinfold thickness, percentage of body fat (BF%), and lipid profile were measured at the baseline and at the end of a 12-week intervention.|t|t|t|f
33703814|NCT06469593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label study comparing type-1 diabetes patients receiving usual treatment, with patients transitioning to AID systems||||
33703815|NCT04326673|||COHORT||PROSPECTIVE|||||||
33703816|NCT06378931|||COHORT||PROSPECTIVE|||||||
33703817|NCT05497609|||COHORT||PROSPECTIVE|||||||
33703818|NCT00992290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703819|NCT05427708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized by the undergraduate student coordinator for the project who is uninvolved with (1) running subjects through treatment; and (2) with data analysis. The study personnel involved in completing participants' treatment will not be blind. However, these personnel will not be involved in data maintenance or analysis.|This study will utilize a 3 x 3 randomized controlled trial design with intervention type as a between-subjects factor with three levels (IE, CGRI, PsyEd) and time points (baseline, posttreatment, 2-month follow-up) as a three-level within-subjects factor.|f|f|f|t
33703820|NCT02074930|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703821|NCT04960631|||CASE_ONLY||RETROSPECTIVE|||||||
33703822|NCT05351502|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In Part A, the following gNO doses will be studied to determine MTD and/or OBD: 25,000 ppm, 50,000 ppm and 100,000 ppm. Additional dose levels may be evaluated based on the emerging data as determined by the Safety Review Committee.~Once the MTD and/or OBD is determined, additional patients will be treated in Part B Dose Expansion to further characterize the safety and biomarkers of gNO and determine RP2D."||||
33703823|NCT06287008|||COHORT||RETROSPECTIVE|||||||
33703824|NCT06202430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33703825|NCT05679323|||COHORT||PROSPECTIVE|||||||
33703826|NCT01817829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928816|NCT00671398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928817|NCT01205919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928818|NCT03024385|||COHORT||PROSPECTIVE|||||||
33928819|NCT05018169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928820|NCT06110104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"interventions; the first intervention: The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.~the other intervention : Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.~the last intervention is whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week."|t|t|f|t
33928821|NCT02194517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928822|NCT05228080|||OTHER||PROSPECTIVE|||||||
33928823|NCT02822157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928824|NCT04261881|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33928825|NCT01492842|||COHORT||CROSS_SECTIONAL|||||||
33928826|NCT04499638|||CASE_CONTROL||PROSPECTIVE|||||||
33928827|NCT04735809|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Randomized, Double-blind, Placebo-Controlled, Crossover Study|t|t|t|t
33928828|NCT00810251|||COHORT||PROSPECTIVE|||||||
33928829|NCT01149772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33928830|NCT00001890||||TREATMENT||||||||
33928831|NCT03870672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be told they will receive brain stimulation, but will be given no indication as to which target will be stimulated. Investigators analyzing functional outcome data, neurophysiology data and MRI data will receive coded data that conceals the identity of the subject. Therapists involved in training patients will not know which type of rTMS the participant receives.|In a randomized-controlled, assessor-blinded clinical trial, an anticipated 72 patients will be assigned to receive 12 weeks of CCFES + cHMC facilitation, or CCFES + iM1 facilitation, or CCFES + sham rTMS. Assessments of upper limb motor function and neurophysiology will be completed at baseline, 6, 12, 24, and 36 weeks. This study will 1) determine whether cHMC facilitation augments the effects of CCFES to produce greater improvements in upper limb function in severe patients, 2) investigate the underlying neurophysiologic mechanisms contributing to restored paretic limb motor control, and 3) evaluate and identify patient factors that affect efficacy of CCFES + cHMC facilitation.|t|f|t|t
33928832|NCT03818711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928833|NCT03483831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928834|NCT05225506|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and post test with assessments at baseline and after 3 and 6 months of intervention||||
33928835|NCT05570513|||CASE_CONTROL||RETROSPECTIVE|||||||
34007845|NCT04913519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 Following a Fixed-Volume Topical Single Administration in Healthy Male Subjects with Androgenetic Alopecia|t|t|t|t
34007846|NCT02138981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007847|NCT00478049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007848|NCT02340689|||COHORT||RETROSPECTIVE|||||||
34007849|NCT00113724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007850|NCT01684059|||CASE_CONTROL||RETROSPECTIVE|||||||
34007851|NCT04675775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092910|NCT05448937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33703827|NCT02204956|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33703828|NCT06227260|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Study 1 and 2 were parallel model, study 3 was crossover model.|f|f|t|t
34007852|NCT01473147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007853|NCT04281732|||COHORT||PROSPECTIVE|||||||
34007854|NCT00900016|||COHORT||PROSPECTIVE|||||||
34007855|NCT00159835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007856|NCT00333723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34007857|NCT02317250|RANDOMIZED|FACTORIAL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34007858|NCT03777345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007859|NCT04815850|||COHORT||PROSPECTIVE|||||||
34007860|NCT02375087|||COHORT||PROSPECTIVE|||||||
34007861|NCT01955044|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34007862|NCT00628979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007863|NCT00475917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007864|NCT04421976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34007865|NCT01446224|||COHORT||RETROSPECTIVE|||||||
34007866|NCT03371329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34007867|NCT04252287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703829|NCT01109238|||CASE_ONLY||PROSPECTIVE|||||||
33703830|NCT06069323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind randomized, placebo-controlled study|t|t|t|t
33703831|NCT03396185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703832|NCT05100459|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33703833|NCT04793867|||COHORT||PROSPECTIVE|||||||
33703834|NCT05276037|||COHORT||PROSPECTIVE|||||||
34007868|NCT03877341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007869|NCT01950676|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007870|NCT02235714|||CASE_CONTROL||PROSPECTIVE|||||||
34007871|NCT00865007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34007872|NCT00686244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025258|NCT05418504|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||The recruited participants will then be divided into 2 groups the control group represented by dental patients who are not a tramadol addict \& The study group with patients seeking dental service but also are tramadol addict.||||
34025259|NCT06397417|||COHORT||PROSPECTIVE|||||||
33703835|NCT05705388|RANDOMIZED|CROSSOVER||TREATMENT||NONE||6 months of liraglutide (titrated to 3mg daily or maximal tolerated dose) or 6 months of POSE 2.0 with both groups receiving combination of both therapies for 6 months if they did not reach a BMI less than 30kg/m2 at the time of cross-over at 6 months.||||
33703836|NCT01468883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928836|NCT02297646|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33928837|NCT01543113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928838|NCT01802268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703837|NCT03431870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703838|NCT00781274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703839|NCT03078244|||CASE_ONLY||RETROSPECTIVE|||||||
33703840|NCT01480752|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703841|NCT00822042|||COHORT||PROSPECTIVE|||||||
33703842|NCT04333550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703843|NCT06556888|||COHORT||CROSS_SECTIONAL|||||||
33703844|NCT03750955|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Split-mouth||||
33703845|NCT03566784|||CASE_CONTROL||PROSPECTIVE|||||||
33703846|NCT02554695|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33703847|NCT02418650|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703848|NCT02886832|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33703849|NCT05740124|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33703850|NCT03668275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33703851|NCT03838952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703852|NCT00734175|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33703853|NCT01272674|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703854|NCT06066814|||COHORT||PROSPECTIVE|||||||
33703855|NCT02137265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703856|NCT03407625|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomized trial||||
33703857|NCT05047770|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open-label study; participants randomly assigned to either the co-administration or sequential study group.|||||
33703858|NCT06150625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All data will be collected through REDcap. The treating therapist will have no knowledge pertaining to the outcomes being collected.|The outcome assessor needing access to REDcap will be blinded the treatment group. The clinician providing treatment will be blinded to outcomes.|f|f|f|t
33703859|NCT05723302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703860|NCT05705518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the 1-week initial period during which all subjects will use the run-in solution, subjects will be randomly assigned one of the 4 study solutions, and neither the subject nor the clinician researchers or technicians conducting examinations and taking measurements will be aware of which solution is assigned. All 4 solutions will be dispensed in color- and name-coded identical dispensing bottles prepared by study personnel not involved in collecting data.||t|f|t|f
33703861|NCT02727673|||COHORT||PROSPECTIVE|||||||
33703862|NCT01887665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703863|NCT02592252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703864|NCT01441180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703865|NCT02850107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703866|NCT03519178|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33703867|NCT01090492|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33703868|NCT02343679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703869|NCT01126801|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33703870|NCT02041078|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33703871|NCT03057678|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open Label|||||
33703872|NCT03764800|||COHORT||PROSPECTIVE|||||||
33703873|NCT02128802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703874|NCT00991718|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33703875|NCT06013904|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33703876|NCT04164355|||COHORT||PROSPECTIVE|||||||
33703877|NCT04076397|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The randomization list is established by the Brest CHRU data management unit before the start of the trial. Based on a ratio (1: 1) with stratification on the center, the type of initial surgery (directed or flap scarring) and the duration of change of dysesthesia (≤ or\> 1 year at baseline).||||
33703878|NCT03211533|||COHORT||PROSPECTIVE|||||||
33703879|NCT05809882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703880|NCT03207477|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Longitudinal cohort study with a control group||||
33703881|NCT01064596|||COHORT||PROSPECTIVE|||||||
33703882|NCT04972292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703883|NCT02530359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33703884|NCT06220773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703885|NCT05763693|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33703886|NCT03334630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703887|NCT06193317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33703888|NCT01848860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703889|NCT04862117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703890|NCT01344785|||COHORT||CROSS_SECTIONAL|||||||
33703891|NCT06103175|||COHORT||CROSS_SECTIONAL|||||||
33703892|NCT00252915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703893|NCT06157359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33703894|NCT02564237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33703895|NCT00792272|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703896|NCT02694965|||CASE_ONLY||PROSPECTIVE|||||||
33703897|NCT01142752|||CASE_CONTROL||PROSPECTIVE|||||||
33703898|NCT01960634|||||PROSPECTIVE|||||||
33703899|NCT05213481|NA|SEQUENTIAL||TREATMENT||NONE||This is a single sequence cross-over trial.||||
33703900|NCT02552875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33703901|NCT01944696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928839|NCT04628598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The experiment and control group will be put into study at the same time.||||
33928840|NCT00971360|||COHORT||PROSPECTIVE|||||||
33928841|NCT00770224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928842|NCT04364906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The anesthesia doctor who will perform the interfascial plane block (QLB 2, 3) will be informed with a sealed envelope by an independent assistant outside the study, and the patient will not know which block is performed.|Randomization of the study will be done by a doctor who will not participate in patient follow-up with closed envelopes using computer generated randomization codes.|t|t|t|t
33928843|NCT04884529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blinded to participant randomization||f|f|f|t
33928844|NCT00159380|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33703902|NCT01577108|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33703903|NCT01796509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33703904|NCT03556774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33703905|NCT00002734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703906|NCT04158492|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled, open-label clinical trial with two parallel groups (1:1) settled in two tertiary care hospitals||||
33703907|NCT00106197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703908|NCT06256965|||COHORT||CROSS_SECTIONAL|||||||
33703909|NCT00610766|||CASE_ONLY||PROSPECTIVE|||||||
33703910|NCT04821648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703911|NCT01355757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703912|NCT01040975|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33703913|NCT01610661|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33703914|NCT00037141|RANDOMIZED|PARALLEL||TREATMENT||||||||
33703915|NCT02776865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33703916|NCT02671305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33703917|NCT01414660|||CASE_ONLY||OTHER|||||||
33703918|NCT04486911|NA|SINGLE_GROUP||TREATMENT||NONE||single arm study||||
33703919|NCT02001402|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33703920|NCT02657915|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This was a follow-up study with no investigational product; however, the allocation method in RENEW Study (NCT01721161) was randomised-controlled and to maintain the blind from RENEW, the treatment disclosure for RENEW was not shared with study sites or participants until the end of this study.||t|f|t|t
33703921|NCT05618366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703922|NCT06197971|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor who will take the readings is blind|Randomized Clinical Trail|f|f|f|t
33703923|NCT00560105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703924|NCT05608759|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33703925|NCT06556992|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm behavioral intervention feasibility trial||||
33703926|NCT01060813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703927|NCT00105417||||TREATMENT||||||||
33703928|NCT00622284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33703929|NCT03836248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective monocentric study randomized into three parallel arms.|t|f|t|t
33703930|NCT03875365|||CASE_ONLY||RETROSPECTIVE|||||||
33703931|NCT00958100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703932|NCT03392467|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33703933|NCT01418170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33928845|NCT00520299|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33928846|NCT05204758|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34025260|NCT02359994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33703934|NCT02902432|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33703935|NCT06289569|NA|SEQUENTIAL||TREATMENT||NONE|Self-report measures will be not blinded, assessors will be blinded to treatment phase (SOC or telerehabilitation)|||||
33703936|NCT01099137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33703937|NCT05251766|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33703938|NCT05170984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703939|NCT02028793|||CASE_ONLY||PROSPECTIVE|||||||
33703940|NCT04849754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703941|NCT03948711|||COHORT||PROSPECTIVE|||||||
33703942|NCT01006174|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33789179|NCT05255718|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Use of placebo juice matched in flavor, color, and macronutrient content to interventional Aronia juice. Assignment of participants to placebo versus intervention treatments performed by independent researcher and masked until completion of study.|Double-blind, parallel, control trial with participant randomization to control versus intervention groups.|t|f|t|f
33789180|NCT00304980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789181|NCT02155829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789182|NCT01673113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789183|NCT05174286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33789184|NCT01559506|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33789185|NCT01549379|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33789186|NCT05125367|||COHORT||RETROSPECTIVE|||||||
33928847|NCT02839473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928848|NCT02959697|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33928849|NCT02661945|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33928850|NCT00432562|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928851|NCT04961476|||OTHER||PROSPECTIVE|||||||
33928852|NCT04368000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928853|NCT05013294|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33928854|NCT01335490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928855|NCT01505972|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928856|NCT00972972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33928857|NCT05739240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928858|NCT02172846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928859|NCT02177812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928860|NCT00826488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928861|NCT00650312|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33928862|NCT05718453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.|t|f|f|f
33703943|NCT05236400|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This clinical trial is a multicenter, randomized, parallel design, open-label, confirmatory clinical trial.~Subjects who sign the clinical trial consent form and satisfy the inclusion/exclusion criteria are enrolled in this trial, and are randomly assigned to a test group and a control group in a 1:1 ratio.~Airway aspiration is performed through the unmanned electric airway aspiration procedure using the test device (LMECA.A1000), which is the test group, and the manual airway aspiration procedure, which is the control group. Subjects will be evaluated for efficacy and safety on Day 3, Day 7, and Day 14 after application of the clinical trial medical device."||||
33703944|NCT03093220|||COHORT||PROSPECTIVE|||||||
33703945|NCT03063242|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Project I will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Thus, Project II and III treatment will only begin once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing||||
33703946|NCT00493025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703947|NCT02623023|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33703948|NCT05879679|||CASE_ONLY||CROSS_SECTIONAL|||||||
33703949|NCT01285154|||CASE_ONLY||RETROSPECTIVE|||||||
33703950|NCT02386865|||||RETROSPECTIVE|||||||
33703951|NCT01168141|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33703952|NCT04997083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703953|NCT05781854|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33703954|NCT01216761|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33703955|NCT06557200|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants, Care providers, and outcome assessors will be blinded|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.|t|t|f|t
33703956|NCT04482257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33703957|NCT03836599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Cohort 1 is double blind Cohort 2 is open-label||t|f|t|f
33703958|NCT00324792|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703959|NCT06127615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33703960|NCT02051686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33703961|NCT00446251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33703962|NCT03691155|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33703963|NCT04886128|||COHORT||CROSS_SECTIONAL|||||||
33703964|NCT00187200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789187|NCT05688956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will be randomly assigned to either consume the oral nutritional supplement or not.~Each participant will know if they are either taking the oral nutritional supplement or not. There is no placebo, ONS being provided. Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups."|A randomised, parallel group, 12-week clinical trial with two groups of older adults aged 70+ years requiring supportive home care will be undertaken.|t|f|f|f
33789188|NCT01037530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789189|NCT05638204|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial using permuted block randomization with variable block sizes.||||
33928863|NCT01160861|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33928864|NCT05645653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a single Centre open label, two-arm randomized controlled trial with 1:1 randomization at the participant level. The patient population will be patients with at least two comorbidities. The patient recruitment will be done in the National Centre for Cancer Care and Research (NCCCR) in the outpatient department in the clinical nurse specialist counselling room.||||
33928865|NCT03656666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blinded, randomized, placebo-controlled trial|t|t|t|f
33928866|NCT02069249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928867|NCT03317483|||COHORT||PROSPECTIVE|||||||
33928868|NCT03249701|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The intervention administered randomly to the participants. The participants, care providers, investigator, outcomes assessor done their job, separately. The blind will be controlled by a assigned investigator.|The participants divided into 3 groups randomized, one group receive transcutaneous electrical acupoint stimulation, one group receive electroacupuncture, the third group only connect to acupoints without stimulation.|t|t|t|t
33928869|NCT02482740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928870|NCT04748770|||CASE_ONLY||PROSPECTIVE|||||||
33928871|NCT03582267|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33928872|NCT06325540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and the researcher who evaluates the follow-up results of the patients will not know which material was used for indirect pulp coating.|Indirect pulp capping will be applied to primary molar teeth with deep dentin caries in 3 groups with 3 different materials(biodentine, thermal pt, therabase).|t|f|f|t
33928873|NCT02512276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928874|NCT02382757|||COHORT||PROSPECTIVE|||||||
33928875|NCT06075368|||CASE_ONLY||PROSPECTIVE|||||||
33928876|NCT05414513|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928877|NCT06391567|||COHORT||PROSPECTIVE|||||||
33928878|NCT05401903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pragmatic feasibility trial comparing the effects of chiropractic maintenance care versus a control group, no chiropractic care, on heart rate variability in healthy male adults.|f|f|f|t
33928879|NCT02351739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928880|NCT01856803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928881|NCT02867384|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33928882|NCT03549819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34092911|NCT03155477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928883|NCT04939532|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients will not know if they are in the TM or TM+PN intervention arm.|Patient-level, two-arm randomized design for the Population Health Management interventions, TM or TM+PN.|t|f|f|f
33928884|NCT00681122|||COHORT||PROSPECTIVE|||||||
33928885|NCT00430547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928886|NCT03123484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928887|NCT00013819|||||PROSPECTIVE|||||||
33928888|NCT03454945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928889|NCT05392049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928890|NCT05380908|||CASE_CONTROL||RETROSPECTIVE|||||||
33928891|NCT02237794|||||PROSPECTIVE|||||||
33928892|NCT01465451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928893|NCT06431412|||CASE_ONLY||RETROSPECTIVE|||||||
33928894|NCT00890669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928895|NCT01213290|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33928896|NCT02699125|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33928897|NCT04260672|RANDOMIZED|PARALLEL||PREVENTION||NONE||A clustered non-blinded randomised controlled trial (RCT) with two arms to determine the effectiveness (including costs and cost effectiveness) of 1) usual care (n = 3015 children) and 2) CCHD (n = 3032 children). The RCT includes 35 Child Health Centres (CHCs), located both in the country side as well as in 2 of the major cities, including areas with diverse social-economic settings.||||
33928898|NCT02225236|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928899|NCT01941303|||COHORT||RETROSPECTIVE|||||||
33928900|NCT04518436|||COHORT||RETROSPECTIVE|||||||
33928901|NCT06089707|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||single-ascending dose||||
33928902|NCT02079519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928903|NCT06450457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928904|NCT06370949|||COHORT||PROSPECTIVE|||||||
33928905|NCT04203108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928906|NCT01627223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928907|NCT00922519|||COHORT||PROSPECTIVE|||||||
33928908|NCT03354572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study will be a single centre double blinded randomized placebo controlled trial|t|t|t|t
33928909|NCT02500472|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33928910|NCT02077491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33928911|NCT02226419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703965|NCT05026411|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The radiologist will be blinded to who the films are from and at what stage of the treatment they were taken.|Diffusion tensor imagings will be taken from the patients at the beginning of the orthodontic treatment, in the first year of treatment and 6 months after the treatment ends.||||
33703966|NCT01866774|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33789190|NCT03701230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789191|NCT00683735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33928912|NCT03704805|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster-randomized, controlled, two-arm multicenter, superiority trial||||
33928913|NCT01391455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928914|NCT02687607|||CASE_ONLY||PROSPECTIVE|||||||
33928915|NCT03082807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928916|NCT00906906|||COHORT||PROSPECTIVE|||||||
33928917|NCT00910728|NA|SINGLE_GROUP||OTHER||NONE||||||
33928918|NCT03526341|||OTHER||RETROSPECTIVE|||||||
33928919|NCT02658968|NA|SEQUENTIAL||TREATMENT||NONE||||||
33928920|NCT05944913|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization (1:1 ratio) will be stratified according to STS location (upper limb vs lower limb vs trunk) and ASA class (1 or 2 vs ≥ 3).||||
33928921|NCT01000818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928922|NCT05488418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928923|NCT04165005|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33928924|NCT05587634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33928925|NCT01233570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928926|NCT00778310|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|f|t
33928927|NCT03825445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Odd even rule|A prospective randomized comparative study was conducted at Hue University Hospital in Vietnam. Total of 197 infertile women were randomly assigned to receive either GnRHa trigger (n=98 cycles) or hCG trigger (n= 99 cycles) for ovulation trigger. Patients returned for ultrasound monitoring 24 hours after IUI to confirm ovulation.|t|f|t|f
33928928|NCT02066545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928929|NCT03009149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789192|NCT02667418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789193|NCT05529589|||COHORT||PROSPECTIVE|||||||
33789194|NCT00622830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789195|NCT03651531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789196|NCT02371135|||COHORT||PROSPECTIVE|||||||
33789197|NCT00094809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33789198|NCT03699488|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33928930|NCT05920070|||OTHER||RETROSPECTIVE|||||||
33928931|NCT06060704|NA|SINGLE_GROUP||TREATMENT||NONE||Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab||||
33928932|NCT04673955|||COHORT||PROSPECTIVE|||||||
33928933|NCT00405236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34007873|NCT03839277|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).||||
34007874|NCT04906330|||COHORT||PROSPECTIVE|||||||
34007875|NCT05282108|||COHORT||PROSPECTIVE|||||||
34007876|NCT05863559|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two group randomized controlled trial - treatment, waitlist control||||
34007877|NCT05685524|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928934|NCT02629536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33928935|NCT01591811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928936|NCT02575300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928937|NCT01052831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33928938|NCT02201667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007878|NCT00042549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34007879|NCT01520883|||COHORT||CROSS_SECTIONAL|||||||
34007880|NCT01897623||||SCREENING||||||||
34007881|NCT06617000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007882|NCT03322020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007883|NCT01221831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092912|NCT02710747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33789199|NCT01405235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007884|NCT05265065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participants and those evaluating reactogenicity will be blinded to the vaccine allocation for the first 28 days following vaccination. After that, both clinical investigators and participants will be aware of their investigational product allocation. Laboratory staff will remain blinded to the investigational product allocation during the immunology testing.|Study participants who have received two doses of either Sinopharm, AstraZeneca or Sputnik vaccine as their primary vaccine will be randomised into one of two groups. The two groups consist of a standard or fractional dose of Pfizer vaccine.|t|t|t|t
33789200|NCT04301687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The anesthesiologist performing the nerve block will be aware of group allocation; but a separate anesthesiologist providing intra-operative care will remain blinded. The patient and the research staff collecting outcome data will remain blinded until all data are collected.|Patients will be randomized between one of two treatment groups. The intervention of femoral articular branch block or the control group (non-invasive placebo).|t|t|t|t
34092913|NCT04373941|RANDOMIZED|PARALLEL||TREATMENT||NONE||GCSF or No-GCSF||||
34092914|NCT02846402|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||1:1:1 cluster randomized controlled trial||||
34092915|NCT06415331|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092916|NCT05389696|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34092917|NCT00620919|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092918|NCT04416542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092919|NCT01258894|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092920|NCT03933033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34092921|NCT01056679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789201|NCT06185192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded for this study.||t|f|f|f
33789202|NCT05723991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789203|NCT05283044|NA|SINGLE_GROUP||OTHER||NONE||Proportion of patients presenting for whom ct DNA sequencing has allowed to propose a systemic treatment that was not considered before by the clinician.||||
33789204|NCT04572672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This was a single-blinded randomized controlled trial.|f|f|f|t
33789205|NCT06317688|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial- Random Assignment-Random Selection||||
33789206|NCT06553573|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33789207|NCT05396976|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34007885|NCT06449755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007886|NCT04615533|||OTHER||PROSPECTIVE|||||||
34007887|NCT04077242|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34007888|NCT01168687|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34007889|NCT05069233|||CASE_ONLY||RETROSPECTIVE|||||||
34092922|NCT01538303|||COHORT||PROSPECTIVE|||||||
34092923|NCT04182893|||CASE_ONLY||PROSPECTIVE|||||||
34092924|NCT01801332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092925|NCT01838811|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34092926|NCT03134807|||COHORT||PROSPECTIVE|||||||
34092927|NCT06152315|||CASE_CONTROL||PROSPECTIVE|||||||
34092928|NCT00176215|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092929|NCT02280954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092930|NCT03976128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34092931|NCT00800514|NA|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34092932|NCT04758338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092933|NCT05732714|||COHORT||PROSPECTIVE|||||||
34092934|NCT00696592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092935|NCT05516069|NA|SINGLE_GROUP||PREVENTION||NONE||Implementation science research: Cross-sectional, prospective, field trial.||||
34092936|NCT00225030|||NATURAL_HISTORY||PROSPECTIVE|||||||
34092937|NCT03508115|||CASE_ONLY||PROSPECTIVE|||||||
34092938|NCT04167462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092939|NCT04229901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092940|NCT04863521|NA|SINGLE_GROUP||SCREENING||NONE||Users recruited at Obstetrix Medical Group of Houston will participate in a pilot study that includes facilitating access to the app and will be followed throughout their pregnancy using online surveys. Users at the UPMC Healthcare System are already using the app as part of their routine care and will be asked to complete an online survey about their user experience.||||
34092941|NCT00191100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092942|NCT05579340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34092943|NCT00667966|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34092944|NCT06505148|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group will be prescribed the acetaminophen and ibuprofen alternating every 3 hours. And the other group will be prescribed acetaminophen and ibuprofen combine treatment.||||
34092945|NCT00226733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092946|NCT03670628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092947|NCT00972738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34092948|NCT04137536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092949|NCT05876494|||COHORT||PROSPECTIVE|||||||
33789208|NCT03758651|||COHORT||CROSS_SECTIONAL|||||||
33789209|NCT00921739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789210|NCT00010946|RANDOMIZED|||TREATMENT||SINGLE||||||
33789211|NCT05731648|||CASE_ONLY||OTHER|||||||
34007890|NCT04418531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007891|NCT03034434|||COHORT||PROSPECTIVE|||||||
34007892|NCT00745719|NA|SINGLE_GROUP||TREATMENT||NONE||Parathyroidectomy group versus natural disease control group||||
33789212|NCT00370799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33789213|NCT00344435|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33789214|NCT00127647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789215|NCT01886014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33789216|NCT00090467|||CASE_CONTROL||PROSPECTIVE|||||||
33789217|NCT03121950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be placed in one of two groups. One group will participate 2 times a week in a dance class. The other group will listen to live music once a week.||||
33789218|NCT05580796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789219|NCT01076335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007893|NCT05892484|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|If the thermal imaging is done first, the radiographer taking the x-ray won't be informed of the outcome of the imaging assessment, so two independent assessments can be compared.|Comparison between thermal imaging and x-ray.|f|t|f|f
34007894|NCT06474299|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2x2 factorial screening trial||||
34007895|NCT02853175|||CASE_CONTROL||PROSPECTIVE|||||||
34092950|NCT02511353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092951|NCT05650892|||COHORT||PROSPECTIVE|||||||
34092952|NCT06532994|||COHORT||PROSPECTIVE|||||||
34092953|NCT02305147|||COHORT||PROSPECTIVE|||||||
34092954|NCT02997670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007896|NCT06422494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded tot the co-infusion during hypoglycaemia. This will be achieved by similar labelling, with phentolamine having the label infusion A and the propranolol infusion having the label infusion B. When administering saline the 50 milliliter syringes will be filled with saline instead of the solution containing either phentolamine or propranolol. Both saline syringes will still have the labels infusion A and infusion B. The investigators will not be blinded as they will be preparing the adrenergic solutions and the saline solutions. The participants will receive the same amount of millilitres during both infusions, determined by the amount infused during adrenergic blockade. Participants will be block-randomized with blocks of 2 using a randomisation list allocated to receive either the adrenergic blockade or the saline first. The coordinating investigator will have access to this list.|Potentially eligible adult ( 16 - 75 years) participants will be recruited through social media, the Radboudumc outpatient clinic and other advertisements. We will recruit a total of 24 individuals, i.e. 12 healthy participants and 12 participants with type 1 diabetes. Participants with type 1 diabetes will be twice ( as there are two investigational days) equipped with a blinded continuous glucose monitoring device (CGM) during the test, which will measure interstitial glucose levels for a total of 10 days.|t|f|f|f
34007897|NCT04980495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007898|NCT01731886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007899|NCT01343875|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34007900|NCT01058928|||CASE_CONTROL||PROSPECTIVE|||||||
34092955|NCT04903977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092956|NCT01026038|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34092957|NCT05607043|NA|SINGLE_GROUP||OTHER||NONE||Pilot study to assess feasibility of testing asymptomatic dental patients for SARS-CoV-2 antigen using lab-based RNA RT-PCR testing||||
34092958|NCT01402466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34092959|NCT00807872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092960|NCT00446277|||CASE_ONLY||PROSPECTIVE|||||||
34092961|NCT02140827|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34092962|NCT03852576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092963|NCT04057235|||CASE_ONLY||RETROSPECTIVE|||||||
34092964|NCT04938947|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34092965|NCT01051284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34092966|NCT04212156|||COHORT||PROSPECTIVE|||||||
34092967|NCT00502437||CROSSOVER||||DOUBLE||||||
34092968|NCT00816270|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34092969|NCT04072471|||COHORT||PROSPECTIVE|||||||
34092970|NCT01239680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34092971|NCT04649307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092972|NCT01908244|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34092973|NCT00055107|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34092974|NCT04924491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34092975|NCT02786966|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34092976|NCT01756235|||||PROSPECTIVE|||||||
34092977|NCT04293536|||OTHER||RETROSPECTIVE|||||||
34092978|NCT06165874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34092979|NCT04171076|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
34092980|NCT05564078|||COHORT||PROSPECTIVE|||||||
34092981|NCT01615718|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34092982|NCT02197637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092983|NCT04453683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34092984|NCT05354934|||CASE_ONLY||CROSS_SECTIONAL|||||||
34092985|NCT00589368|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092986|NCT00790036|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34092987|NCT01272895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092988|NCT03847077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703967|NCT03306563|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Analytical evaluation and testing laboratories will get the samples blinded (coded).|"Total of 160 patients Phase 2a, 60 patients divided in three groups with TBI, orthopedic injury, and healthy volunteers (controls).~Phase 2b: 100 patients with concussion and mild traumatic brain injury."|f|f|f|t
33789220|NCT03370055|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A blinded assessor will evaluate wound healing at the first woundhealing and 2 weeks after woundhealing|observer blinded, randomised, controlled study|f|f|f|t
33789221|NCT04957654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|statistician will be blind||f|f|f|t
33789222|NCT04747457|NA|SINGLE_GROUP||OTHER||NONE||||||
33789223|NCT02906878|||CASE_ONLY||PROSPECTIVE|||||||
33789224|NCT05961670|||COHORT||PROSPECTIVE|||||||
33789225|NCT02521116|NA|SINGLE_GROUP||OTHER||NONE||||||
33789226|NCT04533139|||COHORT||PROSPECTIVE|||||||
34007901|NCT02878408|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34007902|NCT00338130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007903|NCT04999696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007904|NCT05687734|||COHORT||PROSPECTIVE|||||||
34007905|NCT03290313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703968|NCT02980497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33703969|NCT02717520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703970|NCT00168870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33703971|NCT06505174|||COHORT||PROSPECTIVE|||||||
33703972|NCT06129175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33703973|NCT03190590|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33703974|NCT03360604|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are not told which condition they are taking part in during each test day.|All participants took part in both conditions|t|f|f|f
33703975|NCT01176383|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33703976|NCT01004965|||COHORT||PROSPECTIVE|||||||
33703977|NCT01628133|||COHORT||PROSPECTIVE|||||||
33703978|NCT06192784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33703979|NCT06313489|||CASE_ONLY||PROSPECTIVE|||||||
33703980|NCT05246683|||OTHER||PROSPECTIVE|||||||
33703981|NCT04843020|NA|SINGLE_GROUP||TREATMENT||NONE||open label study of investigational antisense oligonucleotide targeting TTR||||
33703982|NCT02732756|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33703983|NCT00002190||||TREATMENT||||||||
33703984|NCT00276120|||FAMILY_BASED||PROSPECTIVE|||||||
33703985|NCT03475823|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All treatment was prepared and randmised by a third-party researcher who had no further involvement in the study.||t|f|t|t
33703986|NCT05618860|||OTHER||PROSPECTIVE|||||||
33703987|NCT02021032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007906|NCT04360408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007907|NCT01997684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007908|NCT02354807|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007909|NCT01290237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007910|NCT05310708|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34007911|NCT02900053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007912|NCT04051216|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789227|NCT02980380|||CASE_ONLY||RETROSPECTIVE|||||||
33789228|NCT04178395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trained investigators, blinded to group assignment, performed the patients' neurostimulation. Patients were also blinded to the type of stimulation they were going to receive. Patients were randomized in 2 parallel groups. A serial number from a computer-generated randomization list was given to each patient for group allocations. Patients allocated to the real tDCS group (11 patients) received one daily session of bihemispheric tDCS + rPNS for 5 consecutive days. The patients allocated to the sham tDCS group (9 patients) received sham tDCS + rPNS also daily, for 5 consecutive days. Group allocation of each patient was only disclosed for analysis of data after the end of all evaluations, 1 year after treatment application. Outcome assessor was also blind to group assignment.|The study was prospective, randomized, double-blind and placebo controlled. Twenty acute stroke patients (ischemic and haemorrhagic) with Upper limb Fugl-Meyer (ULFM) score\<19 were randomized in two parallel groups: one group received 5 consecutive daily sessions of anodal transcranial direct current stimulation (tDCS) over the affected hemisphere and cathodal over unaffected hemisphere combined with repetitive peripheral nerve stimulation (rPSN) and the other received sham tDCS associated to rPNS. Patients were examined before tDCS, 5 days and 3, 6 and 12 months after tDCS.|t|t|t|t
33789229|NCT03030950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789230|NCT00728286|||COHORT||PROSPECTIVE|||||||
33789231|NCT06631209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"There will be 4 parallel groups of 30 participants, each receiving either one of the 3 possible stimulation sites or receiving placebo Sham. The total number of subjects to be recruited locally to complete all study activities will be n=120. Due to prior experience with similar multi-day studies, it is expected that \~20% dropout before completion. Therefore, assuming this dropout rate (i.e., 24 consented participants), the plan is to enroll a total of 144 participants to achieve the final sample of 120 unable datasets."|t|f|f|t
33789232|NCT05864482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized Controlled Study|t|f|f|t
33789233|NCT03944343|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Randomized crossover study design. Healthy young adult volunteers.|t|f|f|f
33789234|NCT02952053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33789235|NCT00522756|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33789236|NCT02904928|||COHORT||PROSPECTIVE|||||||
33789237|NCT04118374|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789238|NCT06421090|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33789239|NCT03668327|||COHORT||PROSPECTIVE|||||||
33789240|NCT05914506|||COHORT||PROSPECTIVE|||||||
33789241|NCT01006551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789242|NCT04308746|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants are assigned to 1 out of 2 culture orientation priming tasks (Individualistic or Collectivistic)|t|f|f|f
33789243|NCT04591301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789244|NCT03034915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789245|NCT00300456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789246|NCT04845269|||COHORT||PROSPECTIVE|||||||
33789247|NCT05982041|||COHORT||PROSPECTIVE|||||||
33789248|NCT01700790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789249|NCT06442254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both the participants and the person analyzing the study do not know which is the study and control group.||t|f|f|t
33789250|NCT03485859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789251|NCT04411836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007913|NCT00894517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007914|NCT00637091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007915|NCT01734135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34007916|NCT03102151|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34007917|NCT04553835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007918|NCT05659134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007919|NCT05767216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34007920|NCT00703560|||COHORT||PROSPECTIVE|||||||
34007921|NCT06614595|||COHORT||PROSPECTIVE|||||||
34007922|NCT04565496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007923|NCT04313010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34092989|NCT06241443|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The students who participated in the research were unaware of their assigned group.|prospective, parallel, randomized, controlled quasi-experiment|t|f|f|f
34092990|NCT00065546|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34092991|NCT00692016|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34092992|NCT04574557|||COHORT||PROSPECTIVE|||||||
34092993|NCT01331902|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34092994|NCT01718691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34092995|NCT04208932|||COHORT||PROSPECTIVE|||||||
34092996|NCT06403722|||COHORT||RETROSPECTIVE|||||||
34092997|NCT03343028|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34092998|NCT05521477|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"The study design will allow to evaluate the dose dependent effect of probiotic consumption on AD blood-based biomarker by comparing each individual to its baseline sampling.~Each participant will follow a 3 phases program of identical procedures:~* Phase I - baseline control: no probiotic will be consumed~* Phase II - Low dose probiotic consumption: 1 dose of probiotic will be taken in the morning for 5 days~* Phase III - High dose probiotic consumption: The subject will receive 1 dose of probiotic in the morning and one dose in the evening for 5 days~In all phases (2 weeks time) blood, stools, cardiometabolic parameter, food frequency, cognitive, anxiety and depression assessment will be collected at specific time points (either shortly before, during or shortly after the treatment period)."||||
34092999|NCT05375799|||CASE_ONLY||OTHER|||||||
34093000|NCT00915187|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093001|NCT05052645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093002|NCT00474032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093003|NCT06095193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34093004|NCT06552195|RANDOMIZED|CROSSOVER||OTHER||SINGLE|outcomes (knowledge test, adverse health symptoms and user experience) will be assessed blindly||f|f|f|t
33703988|NCT03989700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"1. Enroll children with heart disease receiving diuretic drugs~2. Evaluate thiamin status by measuring thiamin pyrophosphate effect, cardiac function by echocardiography~3. Randomize subjects into 3 arms: 2 groups receive different dosages of thiamin supplementation and 1 group receives placebo for 4 weeks~4. After 4 weeks, thiamin status and echocardiography are evaluated."|t|t|t|t
33703989|NCT02095977|NA|SINGLE_GROUP||SCREENING||NONE||||||
33703990|NCT02579837|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33703991|NCT05693948|NA|SINGLE_GROUP||OTHER||NONE||||||
33703992|NCT03717246|RANDOMIZED|PARALLEL||TREATMENT||NONE||6th to 8th grade middle school students will be enrolled then randomly assigned to one of three conditions: 1) Sleep Smart Latino intervention condition , 2) child health topics education control condition; 3) a no treatment control condition||||
33703993|NCT05964101|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33703994|NCT05210673|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33703995|NCT05303181|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33789252|NCT04335591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789253|NCT01368406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33789254|NCT03714750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789255|NCT05348226|||COHORT||PROSPECTIVE|||||||
33789256|NCT02183246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789257|NCT04473950|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The participant, investigator, medical personnel administering study drug, and outcomes assessor will be blinded to drug being administered.|This proposal is a randomized double-blind placebo controlled Phase 1 clinical trial / human laboratory study|t|f|t|t
33789258|NCT05453864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789259|NCT05424159|NA|SINGLE_GROUP||TREATMENT||NONE||Radiation: carbon ion radiotherapy for tumors without invasion of GI||||
33789260|NCT05968352|||CASE_ONLY||PROSPECTIVE|||||||
33789261|NCT06183710|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, individually randomized pilot trial||||
33789262|NCT03328949|NA|SINGLE_GROUP||TREATMENT||NONE||Intravascular Coronary Lithotripsy System||||
33789263|NCT00457990|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33789264|NCT01137266|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33789265|NCT06262919|||COHORT||PROSPECTIVE|||||||
33789266|NCT00162071|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789267|NCT00220935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789268|NCT02794064|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789269|NCT03097237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789270|NCT03025464|NA|SINGLE_GROUP||SCREENING||NONE||||||
33789271|NCT03153865|||CASE_ONLY||PROSPECTIVE|||||||
33789272|NCT04648436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial with parallel group design|f|f|f|t
33789273|NCT05222750|||COHORT||OTHER|||||||
33789274|NCT04001049|||COHORT||PROSPECTIVE|||||||
33789275|NCT03978533|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33789276|NCT06126536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789277|NCT01837641|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33789278|NCT02305576|||COHORT||PROSPECTIVE|||||||
33789279|NCT05082649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33789280|NCT05708066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33789281|NCT04009070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Group A: Acupuncture Group Group C: Control Group|t|t|t|t
33789282|NCT04814043|NA|SINGLE_GROUP||TREATMENT||NONE||systemic PD-1 antibody and lenvatinib plus TACE-HAIC for potential resectable HCC||||
33789283|NCT05356923|||COHORT||PROSPECTIVE|||||||
33789284|NCT03244787|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33789285|NCT03161392|||COHORT||PROSPECTIVE|||||||
33789286|NCT02971930|||OTHER||PROSPECTIVE|||||||
33789287|NCT04117451|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33789288|NCT00208104|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33789289|NCT01469949|||CASE_CONTROL||PROSPECTIVE|||||||
33789290|NCT00290732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789291|NCT00480805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789292|NCT06607731|||COHORT||RETROSPECTIVE|||||||
33789293|NCT01424579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789294|NCT03773861|NA|SINGLE_GROUP||OTHER||NONE||||||
33789295|NCT03360422|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789296|NCT06630013|||COHORT||CROSS_SECTIONAL|||||||
33789297|NCT05283460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|participants will not known wich type of group|This study was designed as a randomized controlled prospective double-blind clinical trial.|t|t|f|f
33789298|NCT00695006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789299|NCT01372163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33789300|NCT03795701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789301|NCT03046290|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33789302|NCT00782639|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33789303|NCT03355053|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Single-center, prospective, phase II, double-blind, placebo-controlled, three-arm, parallel-group, mechanistic, randomized clinical trial|t|t|t|t
33789304|NCT00392678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789305|NCT06630702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789306|NCT04423484|||COHORT||PROSPECTIVE|||||||
33789307|NCT00831792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007924|NCT03110796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34007925|NCT02498535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025261|NCT05343546|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Designated study nurses and doctors will be responsible for recruiting and examining study participants at the outpatient clinic. Eligible women who choose to participate in the study and who sign an informed consent form will be randomized into either:~Group 1; early insertion (insertion within 1 week of PAC) or Group 2; standard insertion (follow-up and insertion at 2-4 weeks post abortion) Women will be free to decide between the Cu-IUD (Nova T, Bayer AG, Berlin, Germany) and the LNG-IUS (Mirena H, Bayer AG, Berlin, Germany)."||||
33928939|NCT03853304|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|All salt formulations will be similar in taste, appearance, and texture. Salt will be packaged in bags labeled with color codes known only to the salt manufacturers and a statistician unaffiliated with the study. A statistician unaffiliated with this study will generate a random number sequence for intervention allocation. Blinding will be maintained until initial data analysis is completed.|"After confirming eligibility and informed consent/assent, women will be randomly assigned to one of the 4 intervention arms, using a 2 X 2 factorial design:~1. Quadruple-fortified salt (QFS; i.e., iron, iodine, folic acid, and vitamin B12)~2. DFS + folic acid~3. DFS + vitamin B12; and~4. Double-fortified salt (DFS; i.e., iron and iodine)"|t|f|t|t
33928940|NCT01170949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928941|NCT03912792|||CASE_ONLY||OTHER|||||||
33928942|NCT03713424|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33928943|NCT02716662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025262|NCT05212389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Single-blinded placebo-controlled trial|t|f|f|f
34093005|NCT05701735|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Given the nature of the intervention, true blinding could not be done on the participant, who is also the assessor. Blinding is necessary to control for participant expectation bias and participant performance bias. The provider (gynecologic oncologist) of the standard of care (standard consultation) is blinded to the subsequent assignment to either arm.|Phase 1: Embedded mixed-methods design Phase 2: Experimental, block-randomized two-arm trial design|t|t|f|t
34093006|NCT05463770|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, fixed sequence, multiple dose design.||||
34093007|NCT04096859|||COHORT||PROSPECTIVE|||||||
34093008|NCT01540734|RANDOMIZED|CROSSOVER||||NONE||||||
34093009|NCT04871438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093010|NCT02455414|||COHORT||PROSPECTIVE|||||||
33703996|NCT03466567|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 3-period cross-over study. The participants will be randomised to three treatment sequences each consisting of three treatment periods. One treatment period with a single dose of 3 mg oral semaglutide alone, one treatment period with a single dose of 600 mg ciclosporin 1 hour prior to administration of a single dose of 3 mg oral semaglutide and one treatment period with 500 mg probenecid administered twice daily for 3½ days with the last dose 2 hours prior to administration of a single dose of 3 mg oral semaglutide. Pharmacokinetics of sodium N-(8-(2-hydroxybenzoyl) amino) caprylate (SNAC) and SNAC metabolites will be assessed after each single dose of 3 mg oral semaglutide.||||
33703997|NCT02996578|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33703998|NCT04899154|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33703999|NCT01173575|||COHORT||PROSPECTIVE|||||||
33704000|NCT00515411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704001|NCT05840783|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients to be divided randomly into three groups after fulfilling the Inclusion Criteria, and not told about the specific intervention being done. Care provider/investigator knows which device they are using, while outcomes accessor is also masked.||t|f|f|t
33704002|NCT01406743|||COHORT||PROSPECTIVE|||||||
33704003|NCT00002588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704004|NCT03953820|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study consisted of 2 periods. In Period 1 , participants received a single dose of Diazepam Buccal Film or Diastat Rectal Gel in a randomized sequence following a moderate fat meal with a 28-day washout between doses. Subjects who completed Period 1 were asked to participate in a second period (Period 2) on a voluntary basis. Those subjects who agreed to participate in Period 2 received a second dose of DBF in exactly the same dose and manner as the earlier dose with the exception it was administered following a high fat meal.||||
33704005|NCT01488370|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33704006|NCT04845854|||COHORT||CROSS_SECTIONAL|||||||
33704007|NCT00967603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789308|NCT04431206|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group Oxytocin infusion||||
33789309|NCT00613301|||COHORT||PROSPECTIVE|||||||
34025263|NCT00002282||||TREATMENT||||||||
34025264|NCT03891745|||CASE_CONTROL||PROSPECTIVE|||||||
34025265|NCT02547090|||CASE_CONTROL||PROSPECTIVE|||||||
34093011|NCT01957800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093012|NCT01056575|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093013|NCT02004795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093014|NCT00142753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093015|NCT00879359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093016|NCT04807530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and care providers and all clinical outcomes assessors will be blinded as to whether participants will receive the active nrTMS or control nrTMS.|The investigators propose a longitudinal randomized controlled trial (RCT) in which 80 SZ and 80 HC are randomly assigned to either active high-frequency 10Hz nrTMS to increase activity in medial/superior prefrontal cortex (mPFC) or a control posterior parietal site. The investigators assess durability and generalizability of how active 10Hz nrTMS modulation of mPFC activity in HC and SZ causally induces neural network changes that mediate behavioral changes in self-agency to impact overall cognition, clinical and daily functioning, compared to the control parietal site and baseline.|t|t|f|t
34093017|NCT03010865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093018|NCT02346422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093019|NCT05350423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093020|NCT05057208|||OTHER||RETROSPECTIVE|||||||
34093021|NCT06190119|||CASE_CONTROL||PROSPECTIVE|||||||
34093022|NCT04303637|||COHORT||CROSS_SECTIONAL|||||||
34093023|NCT00205062|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093024|NCT03421561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093025|NCT03014362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704008|NCT04337801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, it was ensured that the women participating in the study did not know which group they were in, and thus, a one-way blinding was performed. This was performed by using closed envelope method. The participants were masked so that the women in the acupressure and placebo groups were not informed about the pressure score applied to the acupressure points.||t|f|f|f
33704009|NCT01458236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33704010|NCT06474702|||CASE_ONLY||RETROSPECTIVE|||||||
33704011|NCT00035997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704012|NCT04993820|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either a physical activity group oran education control group for the the length of the intervention (12 weeks).||||
33704013|NCT01681472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33704014|NCT04282642|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will be randomly assigned to either the cognitive training or waitlist control(WLC). In both conditions, they will receive the intervention, but the waitlist control will receive this later. Both groups will complete 6 weeks of the cognitive training game either immediately after 1 week baseline (cognitive training group) or after the week 8 assessments (WLC).|f|f|f|t
33928944|NCT04059471|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigators and participants will be blinded to the allocations. Only the pharmacist and the nurse administering the vaccine will be unblinded. The allocation will be to one of the four treatment arms per a computer-generated randomization schedule. Allocations will be concealed until a member of the unblinded study team scratches the randomization booklet to reveal the participants' randomization arm.|Adult participants (n=480) will be randomized for vaccination with full standard dose or with 1000, 500 or 250 IU (i.e. 4 arms) with a 1:1:1:1 allocation ratio. Results for the safety and primary outcome of the adult study will then be reviewed by the DSMB, and the lowest non-inferior dose in the adult study selected for assessment in children aged 9 months to 5 years (n=420) in comparison to full standard dose (i.e. 2 arms) with a 1:1 allocation ratio.|t|f|t|t
33704015|NCT00736944|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704016|NCT03479970|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33928945|NCT02597192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33928946|NCT05955872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33928947|NCT02762708|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789310|NCT06556069|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|We will not utilize masking.|This is a stepped wedge, cluster randomized study design that evaluates the impact of the PACT intervention. Our unit of randomization is at the cluster (i.e., ED site) level. A sample of five ED sites will complete the stepped-wedge cluster randomized trial with six time periods (including the baseline), five steps, and each site randomized from control to intervention at each step. The trial will be conducted over three years, with each period duration being six months.||||
33789311|NCT06374056|||COHORT||PROSPECTIVE|||||||
33789312|NCT04841733|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33789313|NCT04703699|||CASE_ONLY||RETROSPECTIVE|||||||
33789314|NCT06196190|||CASE_CONTROL||PROSPECTIVE|||||||
33789315|NCT04231695|||COHORT||PROSPECTIVE|||||||
33789316|NCT01372852|||COHORT||CROSS_SECTIONAL|||||||
33928948|NCT02522078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928949|NCT03647176|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704017|NCT06013397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007926|NCT04632524|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patients were randomly allocated by a computer-generated table into one of two study groups. The randomization sequence was concealed in opaque sealed envelopes. The envelopes were opened by the study investigators just after recruitments and admission to the operation room.|sixty (60) patients ASA ǀ \&ǁ patients of both sex aging 16-78 years (with primary or secondary thyrotoxic goiter and will be presented for thyroidectomy) will be allocated into one of two groups: Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume.|f|f|t|f
34007927|NCT00810602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704018|NCT04328766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704019|NCT05158465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be blinded to condition.|Intervention and control groups will be enrolled and followed over one-month.|f|f|f|t
33704020|NCT05116215|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704021|NCT01196507|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33789317|NCT03408860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789318|NCT05318950|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Randomisation control and E-learning Randomisation Diet A and B||t|f|f|f
33789319|NCT00219999|||CASE_CONTROL||PROSPECTIVE|||||||
33789320|NCT01805921|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789321|NCT01570660|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789322|NCT05575895|||COHORT||CROSS_SECTIONAL|||||||
33789323|NCT00087269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789324|NCT01407601|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33789325|NCT04218669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding of the surgeons and patients is not feasible due to the obviously different characteristics of the two types of biliary drainage.~Investigator and outcome assessors will be blinded to the trial intervention."|Patients were randomized to choledochojejunostomy arm or T tube drainage arm|f|f|t|t
33789326|NCT05043818|||OTHER||PROSPECTIVE|||||||
33789327|NCT00586339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33789328|NCT02705235|||COHORT||CROSS_SECTIONAL|||||||
33789329|NCT06221332|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33789330|NCT03252106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789331|NCT05537766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789332|NCT01167426|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33789333|NCT00195078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789334|NCT02085356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789335|NCT03802786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789336|NCT01365403|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33789337|NCT01670110|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34007928|NCT06532968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704022|NCT00699569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33789338|NCT04330430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704023|NCT03226288|||CASE_CONTROL||PROSPECTIVE|||||||
33928950|NCT04983199|||COHORT||PROSPECTIVE|||||||
33928951|NCT02157168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33928952|NCT01628393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928953|NCT01576666|NA|SINGLE_GROUP||OTHER||NONE||||||
33928954|NCT00000608||PARALLEL||PREVENTION||||||||
34007929|NCT01965626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007930|NCT01636934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007931|NCT00913796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34007932|NCT04244006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Dupilumab and placebo will be provided in identically matching 2 mL pre-filled syringes. To protect the blind, each treatment kit of 2 mL (dupilumab/placebo) glass pre-filled syringes will be prepared such that the treatments (dupilumab and its matching placebo) are identical and indistinguishable and will be labeled with a treatment kit number.|one arm with dupilumab (2/3 of patients) and one arm with placebo (1/3 of patients)|t|t|t|f
34007933|NCT01497119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704024|NCT06558409|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Like the intervention Safer Still web-based program, the control website will be branded with a Nationwide Children's Hospital affiliation, as opposed to an outside organization that will be less familiar to our central Ohio sample. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.|80 families will be randomly assigned to either the Safer Still intervention (n=40) or EUC (n=40) in a parallel groups design. A stratified randomization procedure will balance the groups of participating parents on recruitment site.|t|f|f|f
34007934|NCT06618300|||COHORT||PROSPECTIVE|||||||
34007935|NCT02726282|||OTHER||PROSPECTIVE|||||||
34007936|NCT05528302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34007937|NCT04649489|||COHORT||PROSPECTIVE|||||||
34007938|NCT02896543|||CASE_CONTROL||PROSPECTIVE|||||||
34007939|NCT02056067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007940|NCT04514497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007941|NCT00864799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007942|NCT00968019|||COHORT||PROSPECTIVE|||||||
34007943|NCT01605643|||COHORT||PROSPECTIVE|||||||
34007944|NCT02846168|||COHORT||PROSPECTIVE|||||||
34025266|NCT01565057||CROSSOVER||BASIC_SCIENCE||NONE||||||
34025267|NCT03972735|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||stepped-wedge|f|f|t|f
33704025|NCT02615314|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33704026|NCT04649320|||COHORT||OTHER|||||||
33704027|NCT00566995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025268|NCT06256107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Device Feasibility||||
34025269|NCT00828737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025270|NCT00298844|||DEFINED_POPULATION||PROSPECTIVE|||||||
34025271|NCT03620968|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093026|NCT02600793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093027|NCT02127541|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34093028|NCT04398966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093029|NCT00360204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704028|NCT03499977|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33704029|NCT04613050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704030|NCT01330030|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33704031|NCT00096798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928955|NCT01607073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928956|NCT01761136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928957|NCT04834050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928958|NCT01943188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928959|NCT05030597|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928960|NCT00763178|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33928961|NCT00437203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928962|NCT01225276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704032|NCT01945281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704033|NCT05658822|||COHORT||RETROSPECTIVE|||||||
33704034|NCT02740556|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33928963|NCT02997774|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Neither subjects nor the investigator at the study visits will be blinded; however, analysis of imaging data will be performed with the operator blinded to allocation.||f|f|f|t
33928964|NCT01617642|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33928965|NCT04407624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33928966|NCT01531361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928967|NCT00527072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928968|NCT03459157|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33928969|NCT03507192|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928970|NCT02106572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind Review in accordance with with ICH-Biostatistics Guideline ICH E9||f|f|f|t
33928971|NCT05597241|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33928972|NCT01261260|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33928973|NCT01307371|||CASE_CONTROL||PROSPECTIVE|||||||
34093030|NCT02736214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The randomization was blind to the participants, but they were made aware of their allocation during the intervention||t|f|f|f
34093031|NCT04601285|NA|SEQUENTIAL||TREATMENT||NONE||||||
34093032|NCT04589767|||COHORT||PROSPECTIVE|||||||
33704035|NCT06318429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704036|NCT02012283|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33704037|NCT04639167|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants, the local coordinators and the volunteer peers cannot be blinded to the group allocation. The REDCap randomization tool will be used to facilitate randomization. To ensure concealment, the randomization schedule is stored away from the research team and the block sizes are not disclosed. The allocation is performed by a not-blinded research coordinator, who informs the participants allocated to the control group through a central telephone. Moreover, the research coordinator informs the local coordinators in each municipality about participants allocated to the intervention group through submitting the record id via secure email. The local coordinators will be able to identify the participants through their access to REDCap. The researchers will be blinded to group allocation during the process of data analysis.|"A randomized, two-arm, investigator initiated, multi municipal, parallel-group superiority trial comparing the effect on self-reported personal recovery of the following interventions: (1) 10-week group-based peer support intervention Paths to everyday life (PEER) added to servide as usual (SAU) and (2) SAU alone"|f|f|t|t
33704038|NCT05510440|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33704039|NCT02715180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704040|NCT00004211||||TREATMENT||||||||
33704041|NCT04075760|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Endoscopic performing EUS evaluation on follow-up will be masked to initial patient allocation|Randomized control trial, parallel location , 1:1 allocation|t|t|f|t
33704042|NCT00990405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704043|NCT02040493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928974|NCT00614991|RANDOMIZED|FACTORIAL||||NONE||||||
33928975|NCT04520308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928976|NCT02244229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33928977|NCT04605692|||COHORT||PROSPECTIVE|||||||
33928978|NCT05007262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928979|NCT04490304|NA|SINGLE_GROUP||TREATMENT||NONE|the x-ray measurements after the surgery were done by a care provider, not by the investigator|prospective randomised trial||||
33928980|NCT01944488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33928981|NCT05591651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33928982|NCT05589740|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33928983|NCT05272657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789339|NCT05216419|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Since the concentration of D-mac 30,000 IU in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.~In the case of the control group, there is no drug to be taken."||||
33789340|NCT01735474|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33789341|NCT05209854|||COHORT||PROSPECTIVE|||||||
33789342|NCT04753463|||COHORT||PROSPECTIVE|||||||
33789343|NCT03999554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This is a randomized, double-blind, placebo-controlled Phase 1 study evaluating the safety and immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 influenza vaccines delivered intranasally to healthy adults. Eligible subjects will be screened and randomized to receive two administrations 28 days apart of Sing2016 M2SR at three dose levels, Bris10 M2SR at one dose level, or placebo in a 1:1:1:1:1 ratio.|t|t|t|t
33789344|NCT06401018|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigator who evaluates the trial will not know which method has been used on which patient, and will be blinded.|In our study, the patient population was divided into three groups according to the type of exposure to ambient noise during surgery.|f|f|f|t
34093033|NCT00382070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093034|NCT04149353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093035|NCT02707744|||COHORT||PROSPECTIVE|||||||
34093036|NCT00000964||||TREATMENT||||||||
34093037|NCT03888274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093038|NCT00494312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789345|NCT00280033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33789346|NCT01819038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789347|NCT04270604|||OTHER||PROSPECTIVE|||||||
33789348|NCT01850992|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33789349|NCT04437056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789350|NCT02699801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33928984|NCT01250743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928985|NCT01752075|||CASE_ONLY||PROSPECTIVE|||||||
33928986|NCT03708952|||COHORT||PROSPECTIVE|||||||
34093039|NCT06173648|NA|SINGLE_GROUP||TREATMENT||NONE|Blinding occurred when analyzing the histological and morphological results. Blinded assessor provided a rating of the samples on an individual basis, not knowing if the sample was from a treated or control tooth.|Single study group requiring extraction of mandibular incisors for other reasons. Controls selected from among the extraction candidates were not subject to exposure to the laser and ICG solution, but to all other aspects of the pulpectomy procedure. Remaining teeth had the laser and ICG exposure added to the treatment regimen. Treated and control specimens then extracted, prepared, stained, and examined for histological morphological condition of the periodontal ligament, cementum, and collagen attached to the external surface of the extracted tooth root.||||
34093040|NCT03255954|NA|SINGLE_GROUP||OTHER||NONE||||||
34093041|NCT04200924|||CASE_CONTROL||PROSPECTIVE|||||||
34093042|NCT00166400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093043|NCT06480955|||COHORT||PROSPECTIVE|||||||
34093044|NCT05432453|||CASE_CONTROL||PROSPECTIVE|||||||
34093045|NCT00377481|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34093046|NCT00112333|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093047|NCT00174668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704044|NCT04853550|||COHORT||CROSS_SECTIONAL|||||||
33704045|NCT03928496|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The project statistician used a computer-based random number generator to create a randomized treatment allocation schedule that was provided to the pharmacist and nurse practitioner who did not disclose this information. The pharmacist provided the nurse practitioner with the medication in an unlabeled bag, which either included BoNT-A or Normal Saline. Patients were randomized to receive BoNT-A or Normal Saline as first injection. The nurse practitioner reconstituted the medication in a separate room and then provided the investigator with unlabeled syringes.||t|f|t|f
33789351|NCT04431934|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an investigator-initiated, single center, parallel-group, randomized, open-label, clinical research with non pharmacological products.||||
33789352|NCT03344809|||COHORT||PROSPECTIVE|||||||
33789353|NCT04880733|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Data collector will be masked to study outcomes via electronic data collection||f|f|t|t
33789354|NCT02675972|||CASE_CONTROL||PROSPECTIVE|||||||
33789355|NCT01247558|||COHORT||RETROSPECTIVE|||||||
33789356|NCT04381494|NA|SINGLE_GROUP||OTHER||NONE||||||
33789357|NCT01862848|||COHORT||PROSPECTIVE|||||||
33789358|NCT04245501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and outcome assessors will be blind to condition. Unblinding occurs following all post-intervention assessment (i.e., after 16 CBM-I or ICC sessions).|Eligible youth will be randomly assigned to receive either 16 sessions of a personalized cognitive bias modification for interpretation bias (CBM-I) intervention or a computerized interpretation control condition (ICC). Regardless of randomization, participants will complete 16 sessions of their assigned condition within 4 weeks (1 in-lab training per week, and 3 at-home trainings per week).|t|f|f|t
33789359|NCT02891629|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33789360|NCT00762333|||CASE_CONTROL||PROSPECTIVE|||||||
33789361|NCT03080792|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789362|NCT03461991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789363|NCT02113488|||CASE_CONTROL||RETROSPECTIVE|||||||
33789364|NCT02907593|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33789365|NCT05302791|RANDOMIZED|PARALLEL||OTHER||NONE||Each Subject acts as their own control in a de facto repeated measures design, where there is a Single bilateral exercise bout, with experimental and control assignment to individual limbs.||||
33801711|NCT05369936|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The randomization will be performed according to patients' sequences where all odd numbers of patients will be incorporated into control group, while even numbers will be included in lavender group. The patients will not be informed about the type of the essential oil. T This was achieved by inserting lavender vaporizers in all setting rooms and clinics. So that the patients will believe that there is no extraordinary maneuver in the clinics. Also, all the dentists who treated the patients and evaluators who will interview the patients and questionnaires, will not be informed of the type of the essential oil which will be used. The statistician who will analyze the questionnaires will be informed that the study's groups are named as group A or B.|The patients will be divided into a control group in which the patients will be subjected to vapors of plain distal water, and lavender group where the patients will inhale vapors of the lavender oil to stimulate olfaction|t|t|t|t
33801712|NCT00516477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33928987|NCT01478061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928988|NCT00761358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33928989|NCT01510223|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33928990|NCT02872324|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093048|NCT06267404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093049|NCT01276652|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects were randomized in 1:1 fashion to receive the Environmental Modification protocol or usual care. Subsequently a third, observational arm was opened to acquire more physiologic data.||||
34093050|NCT05546528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the researcher responsible for applying the laser will know which treatment was assigned to each participant. The researcher responsible for data collection will be blinded to the type of treatment received. The participant will be blind. The treatment with the control group will simulate the laser in operation.|two groups: 1) the photobiomodulation experimental group (G1) , 2) the photobiomodulationn placebo group (G2) .|t|f|f|t
34093051|NCT05288257|||OTHER||PROSPECTIVE|||||||
34093052|NCT02673385|||CASE_CONTROL||PROSPECTIVE|||||||
34093053|NCT01463345|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093054|NCT05095337|NA|SINGLE_GROUP||OTHER||NONE||||||
34093055|NCT01311661|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33704046|NCT00313261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704047|NCT05814289|NA|SINGLE_GROUP||OTHER||NONE||||||
33704048|NCT02031159|||CASE_ONLY||PROSPECTIVE|||||||
33704049|NCT04944420|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This project consists of a pragmatic randomized controlled trial. Participants will be randomly allocated in a 1:1 ratio to either the intervention group or a wait-list control group. Participants in both groups will complete self-assessments, including key outcome measures, at baseline, and 3 and 6 months post-randomization. Participants in the intervention group will receive the full Health enSuite Caregivers program immediately after being randomized to this group.~Participants in the control group will be wait-listed and receive only treatment as usual during the study. After their participation is the study has ended, participants in the control group will be given access to the full Health enSuite Caregivers program."||||
33704050|NCT04511546|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33704051|NCT02060123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33704052|NCT03345914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704053|NCT01289080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704054|NCT03916991|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||A cross-over study to investigate the effect of hip-focused neuromuscular activation exercise on foot posture and neuromuscular control|t|f|f|t
33704055|NCT05451225|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Feasibility and Acceptability Study||||
33704056|NCT01404858|||COHORT||PROSPECTIVE|||||||
33704057|NCT05013489|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704058|NCT02985372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704059|NCT03243604|||CASE_ONLY||RETROSPECTIVE|||||||
33704060|NCT03081533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessors will be blind to groups allocation (experimental and control group).||f|f|f|t
33704061|NCT00489138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704062|NCT00171483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704063|NCT00382304|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704064|NCT04446000|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33704065|NCT03751696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704066|NCT04669652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A sibling study randomizing oocytes to 2 study groups.|t|t|t|t
33704067|NCT04087265|NA|SINGLE_GROUP||OTHER||NONE|The endoscopist who performs the colonoscopy will be blinded to the ultrasound results.|||||
33704068|NCT02010710|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33704069|NCT04779814|||COHORT||OTHER|||||||
33704070|NCT00057889||||TREATMENT||NONE||||||
33704071|NCT03841812|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33704072|NCT06177522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704073|NCT01769807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704074|NCT01577368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704075|NCT03461978|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704076|NCT04286399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801713|NCT06013137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801714|NCT06212843|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34093056|NCT02724644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093057|NCT06470464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704077|NCT05234996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704078|NCT02424760|||COHORT||PROSPECTIVE|||||||
33704079|NCT00158574|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33704080|NCT05194553|||COHORT||PROSPECTIVE|||||||
33704081|NCT02560909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704082|NCT00747656|||COHORT||PROSPECTIVE|||||||
33704083|NCT05956691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704084|NCT05817643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704085|NCT03675087|||CASE_ONLY||CROSS_SECTIONAL|||||||
33704086|NCT02933723|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33704087|NCT05604677|||COHORT||PROSPECTIVE|||||||
33704088|NCT02021773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704089|NCT02939430|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33801715|NCT01651767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093058|NCT05903443|||CASE_CONTROL||RETROSPECTIVE|||||||
34093059|NCT02602197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093060|NCT00634387|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34093061|NCT02007772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704090|NCT04562688|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33704091|NCT06085378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704092|NCT03300284|||COHORT||PROSPECTIVE|||||||
34093062|NCT01091467|||COHORT||PROSPECTIVE|||||||
33801716|NCT03465527|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801717|NCT04067219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093063|NCT05496010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All participants will be blinded regarding treatment. A total of 30 patients will be recruited and assigned into two groups. Group A will receive Dry needling sessions and group B will receive Ischemic compression technique.|"Group A: Dry Needling treatment given for 6 sessions, 3 days/week for 2 weeks on the trigger points located in Upper Trapezius, Sternocleidomastoid, Sub occipitalis and Temporalis muscles.~Group B:~Ischemic Compression technique given for 6 sessions, 3 days/week for 2 weeks on the trigger points located in Upper Trapezius, Sternocleidomastoid, Sub occipitalis and Temporalis muscles."|t|f|f|f
34093064|NCT05813301|||COHORT||RETROSPECTIVE|||||||
34093065|NCT02265744|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33704093|NCT06230185|||COHORT||PROSPECTIVE|||||||
33704094|NCT03588416|||COHORT||OTHER|||||||
33704095|NCT02321410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704096|NCT00633750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801718|NCT04034771|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|patient will be under general sedation||t|f|f|f
33801719|NCT03751449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801720|NCT00025610||||TREATMENT||||||||
33801721|NCT05487118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801722|NCT02250430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801723|NCT06229301|||OTHER||OTHER|||||||
33801724|NCT05493644|||COHORT||PROSPECTIVE|||||||
33704097|NCT02423759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33704098|NCT01544283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704099|NCT02527161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704100|NCT00727636|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33704101|NCT05499715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704102|NCT02662829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704103|NCT02692274|||||CROSS_SECTIONAL|||||||
33704104|NCT06558305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33704105|NCT02938455|||CASE_ONLY||PROSPECTIVE|||||||
33789366|NCT03636451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study coordinator, who will be blinded to the intervention, will pick the designated sealed, opaque envelope containing the type of paracervical block and hand it to the physician performing the procedure. The physician will then open the envelope and prepare the designated paracervical block, as it is standard practice for physicians to prepare their own paracervical blocks prior to performing any D\&C in-clinic. The paracervical block will contain 2U Vasopressin, 2cc of 8.4% sodium bicarbonate, and either 1% lidocaine or 0.5% lidocaine, depending on the study group. The physician will bring the paracervical block into the clinic room where the procedure will be performed on a covered tray. The physician will perform the standardized procedure for the D\&C, and the study coordinator will assess pain control during the procedure.|This is a double center, randomized, 2 arm (1:1), single blinded clinical trial comparing pain control at the time of cervical dilation with two different paracervical blocks in women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management.|t|f|f|t
33704106|NCT00797771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704107|NCT02067897|||COHORT||PROSPECTIVE|||||||
33704108|NCT00915278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704109|NCT06044610|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33704110|NCT03233607|||COHORT||PROSPECTIVE|||||||
33704111|NCT00119431|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33704112|NCT03596008|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single blinded|Randomized, single-blind, 2-arm, placebo-controlled, within subject cross-over trial, featuring a repeated postprandial sampling paradigm|t|f|f|f
34093066|NCT04370600|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Biological drug + placebo (Group A) or placebo + biological drug (Group B)|t|t|t|f
33704113|NCT00189995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704114|NCT02606448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704115|NCT05076487|||COHORT||PROSPECTIVE|||||||
33704116|NCT06403228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704117|NCT02368015|NA|SINGLE_GROUP||||NONE||||||
33704118|NCT02187497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704119|NCT03033485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704120|NCT02398396|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704121|NCT02364960|||COHORT||PROSPECTIVE|||||||
33704122|NCT05509270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Providers who prescribe vaccination and diagnose conditions will not be randomized to study arms or informed of patient assignment. Although patients will not be explicitly informed which arm they have been randomized to, they will be aware of the messages they receive.||f|t|f|f
33704123|NCT05405868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-masked|Eligible participants will be randomised 1:1 to receive oral Nicotinamide 3g/day or matching Placebo|t|f|t|t
33704124|NCT04094883|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the group B meningitis vaccine (brand name Bexsero™).||||
33704125|NCT03349697|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33704126|NCT03959553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704127|NCT01194466|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33704128|NCT00443495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704129|NCT04470323|||CASE_CONTROL||PROSPECTIVE|||||||
33704130|NCT01854658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704131|NCT03864978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704132|NCT05722197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704133|NCT05868395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704134|NCT01519232|||CASE_ONLY||PROSPECTIVE|||||||
33789367|NCT03203018|NA|SINGLE_GROUP||PREVENTION||NONE||This is a pre/post study.||||
33789368|NCT06627426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, open controlled||||
33789369|NCT06627205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789370|NCT00605904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33928991|NCT06090929|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Investigator was blinded to the status of DBS or non-DBS during the scoring of DRS, DSFS and drooling rate examination.|A total of 234 participants were enrolled between June 2019 and July 2021; 198 patients with PD receive STN-DBS (n=99) or medication (n=99)|f|f|t|f
33928992|NCT06409767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928993|NCT01120821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928994|NCT00201760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928995|NCT02736396|||CASE_CONTROL||PROSPECTIVE|||||||
33928996|NCT02228772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33928997|NCT06123741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33928998|NCT02176980|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33928999|NCT04750655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929000|NCT02511275|NA|SINGLE_GROUP||OTHER||NONE||||||
33929001|NCT02613988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929002|NCT04938089|||COHORT||RETROSPECTIVE|||||||
33929003|NCT01963780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929004|NCT03793283|||COHORT||CROSS_SECTIONAL|||||||
33929005|NCT02491827|||COHORT||PROSPECTIVE|||||||
34093067|NCT03546543|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34093068|NCT04071886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093069|NCT03149224|||CASE_ONLY||CROSS_SECTIONAL|||||||
34093070|NCT05013775|||COHORT||RETROSPECTIVE|||||||
34093071|NCT03022175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093072|NCT03480074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093073|NCT03940534|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking is to be used in this study.|This study is a randomized crossover design.||||
33929006|NCT00645515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929007|NCT03979118|||COHORT||CROSS_SECTIONAL|||||||
33929008|NCT05826002|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be blinded to what condition they are randomized to, and will not receive information concerning what features are being manipulated in the experiment.|A 2x2x2 randomized factorial experiment, where adult participants with insomnia get to use a digital self-guided intervention for insomnia. Three factors/treatment features will be manipulated in the experiment, namely: 1) an optimized graphical user interface (yes or no), 2) an adaptive treatment strategy (yes or no), and 3) daily prompts to use the intervention (yes or no). The factorial experiment will create 8 equally large groups (1:1:1:1:1:1:1:1), who will receive the different combinations of features.|t|f|f|f
33929009|NCT04839406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929010|NCT02738580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929011|NCT00457756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929012|NCT01666860|||COHORT||PROSPECTIVE|||||||
33929013|NCT00439504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929014|NCT06508151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33929015|NCT02805062|||COHORT||PROSPECTIVE|||||||
33929016|NCT00965549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929017|NCT01267344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929018|NCT01057862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929019|NCT01996436|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33929020|NCT03685110|||COHORT||PROSPECTIVE|||||||
33929021|NCT01469962|||COHORT||PROSPECTIVE|||||||
33929022|NCT05539872|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33929023|NCT01128166|||CASE_ONLY||PROSPECTIVE|||||||
33929024|NCT01011088|||CASE_ONLY||PROSPECTIVE|||||||
33929025|NCT02201719|||CASE_CONTROL||PROSPECTIVE|||||||
33929026|NCT00003413||||TREATMENT||||||||
33929027|NCT03229473|||COHORT||PROSPECTIVE|||||||
33929028|NCT01031199|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929029|NCT05410808|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33929030|NCT03174561|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929031|NCT04177875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929032|NCT04824222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase II/III - open label Phase III - double blind|"Phase II/III : 20 subjects - standard of care (SOC) + FMT capsules~Phase III :~173 subjects - arm with SOC + FMT capsules 173 subjects - arm with SOC + Placebo capsules"|t|f|t|f
33929033|NCT03642028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blind will be maintained through completion of the entire study at all sites and will only be broken once data are cleaned to an acceptable level of quality, except for medical necessity.|The investigators propose a multi-site parallel group, randomized, double-blind, placebo-controlled Phase IV clinical trial to test the efficacy and safety of suvorexant on trauma-related sleep disturbance and PTSD symptoms in Veterans. The investigators will use a flexible dose design of suvorexant with a 2-week titration followed by a 10-week steady-dose phase.|t|t|t|t
33929034|NCT05116891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Dose Escalation Phase (Phase 1):~mFOLFOX and Gemcitabine/Cisplatin Arm: Subjects with any type of locally advanced or metastatic cancer who have no therapeutic alternatives with proven survival benefit or who are eligible for mFOLFOX or gemcitabine/cisplatin (G/C) backbone chemotherapy as standard of care (SoC) for the next-line treatment.~Docetaxel Arm: Subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) cancer who have no therapeutic alternative with proven survival benefit or who are eligible for docetaxel (DTX) backbone chemotherapy as SoC for the next-line treatment.~Phase 2: Subjects with locally advanced or metastatic colorectal cancer (mCRC), NSCLC, or biliary tract cancer (BTC) who are eligible for mFOLFOX, DTX, or G/C treatment, respectively."||||
33929035|NCT01186367|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33929036|NCT05709314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Phase 2, open-label, single arm, masked endpoint multicenter study||||
33929037|NCT02585076|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929038|NCT06332612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It would be a single-blind, placebo-controlled design|"1. In Vitro (Cell Line) Study Design: Experimental in vitro study using OSF cell lines.~Groups:~* Metformin-treated~* Control (untreated)~* Vehicle control Clinical Trial Study Design: A pilot Randomized Controlled Trial (RCT) translating the in vitro findings into a clinical setting. It would be a single-blind, placebo-controlled designAll groups will undergo a 24-week intervention phase. Group 1 will receive standard treatment including topical cream betamethasone thrice daily and Pentoxifylline tablet 400 mg twice daily. Group 2 will receive Metformin 500 mg thrice daily. Group 3 will receive topical cream metformin thrice daily. All groups will be instructed to perform a stick mouth opening exercise twice daily, alternating sides, holding the stick for 10 minutes on each side, with a 10-minute rest in between. All groups will be single blinded to the intervention."|t|f|f|f
33929039|NCT05936593|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34093074|NCT03600792|||FAMILY_BASED||PROSPECTIVE|||||||
34093075|NCT03893214|RANDOMIZED|CROSSOVER||TREATMENT||NONE|"All roles are aware of the fact that the virtual reality exposure is the primary intervention. No information is given to the participant about the impact of the video in the waitlist control group."|Participants are assigned to one of two conditions (virtual reality vs. waitlist control) for the initial phase. In the second phase the waitlist control group receives the virtual reality exposure while the other group does not receive a second intervention.||||
33789371|NCT02970708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789372|NCT06632106|||COHORT||RETROSPECTIVE|||||||
33929040|NCT00552994|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33929041|NCT05059847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The masking of the study will be for the principal investigator, only knowing the maneuver person in charge of the routine and the patient. The patients who will practice the exercise intervention will be carry out in certain space and time that does not interfere with the medical intervention and in which the treating medical personnel will not be present.|Clinical randomized single blinded trial|f|f|t|f
33789373|NCT00887640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801725|NCT05990816|||COHORT||PROSPECTIVE|||||||
33801726|NCT01365598|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33704135|NCT05993819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|pilates and cognitive behavioral therapy|f|f|t|t
33704136|NCT02903355|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704137|NCT01112553|||COHORT|||||||||
33704138|NCT00072566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704139|NCT03817879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33704140|NCT02930330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704141|NCT00325273|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33704142|NCT01390129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704143|NCT01197560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704144|NCT00372671|RANDOMIZED|PARALLEL||OTHER||SINGLE||||||
33704145|NCT01189604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704146|NCT03748693|||CASE_CONTROL||PROSPECTIVE|||||||
33704147|NCT01296217|NA|SINGLE_GROUP||||||||||
33704148|NCT04467606|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study adopted a single blind study design. The research assistants who do not know the research object group perform pre- and post-test data collection, including interviews, medical record data collection and foot evaluation. Due to the different intervention measures received by the experimental group and the control group, we specifically advise the research subjects not to disclose the status of the intervention measures to the research assistant.|Subjects will be randomly assigned to either the experimental or the comparison group.|f|t|f|t
33704149|NCT01524107|||CASE_CONTROL||RETROSPECTIVE|||||||
33929042|NCT03044080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Parallel assignment|t|f|f|t
33929043|NCT02606396|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007945|NCT06615908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The group assignments to active (25mg) and control (1mg) psilocybin-assisted therapy will be based on a blocked randomization list (10 participants per block) using sealed envelopes created by an employee of the University of Calgary, who will not be involved in the conduct, or the analysis of the study.~The pharmacy administering the psilocybin will be responsible for maintaining the master randomization code list and only the technician preparing the samples will have access to the envelopes and code list.~When a new study ID is generated, the technician is to verify the randomization and prepare the participant's study intervention accordingly. Unblinding will only occur once the entire study is completed, and the database has been locked.~The trials active intervention and comparator will be provided by the manufactures and will be identical in shape, colour, and weight."|Double-blinded randomized control trial|t|t|t|t
34007946|NCT01253928|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34007947|NCT06610539|||OTHER||PROSPECTIVE|||||||
33704150|NCT02445508|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33704151|NCT03949036|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patients do not know which group they will be enrolled. The outcome assessor will be blind to the group assignment of the participants.|A randomized controlled trial of two parallel groups.|t|f|f|t
33704152|NCT00318448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704153|NCT01059591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33704154|NCT03515278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704155|NCT01365052|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33704156|NCT04925583|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation, Arm 1: Level 0, 5.0 Gy, 10 fractions Arm 2: Level 1, 5.5 Gy, 10 fractions Arm 3: Level 2, 6.0 Gy, 10 fractions Arm 4: Level 3, 6.5 Gy, 10 fractoins||||
33704157|NCT05764421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704158|NCT01225692|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
33704159|NCT04079946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704160|NCT03988088|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704161|NCT06451003|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stepped wedge randomized controlled trial||||
33704162|NCT06402071|||CASE_CONTROL||PROSPECTIVE|||||||
33704163|NCT01086085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704164|NCT03119233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093076|NCT00696566|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704165|NCT05132673|||COHORT||PROSPECTIVE|||||||
33704166|NCT03217357|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"The subject will be blind of the treatment he receives (active or placebo).~- The experimenter will also be blinded from stimulation (active or placebo) Each subject will be assigned a randomization code, corresponding to the code to enter the tDCS device. This system allows the person who administers tDCS and the subject receiving the stimulation to be blind ."|In a randomized controlled double blind study, 30 subjects, first-degree relatives of schizophrenic patients, were randomly assigned to 2 groups. A group of 15 participants will receive 30 minutes of active tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC); A group of 15 participants will receive 30 minutes of placebo stimulation. During this stimulation session, all participants will undergo a standardized stress test combining psychosocial stress and physical stress|t|t|t|t
33704167|NCT04302896|RANDOMIZED|PARALLEL||OTHER||NONE||randomized, open-label||||
33704168|NCT02221830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789374|NCT05227469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the care provider will know which patients had only twin block treatment and which patients had both twin block and egzersize treatment. Control group will have unrevealant egzercises or no egzercises.|Double blinded controlled clinical study|t|f|t|t
33789375|NCT05825950|||COHORT||OTHER|||||||
33929044|NCT05592041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929045|NCT06185868|||COHORT||PROSPECTIVE|||||||
33929046|NCT05265793|NA|SINGLE_GROUP||TREATMENT||NONE||Regimen: Apatinib: 250mg qd, po, 4 weeks as a cycle, continuous medication until disease progression, death or intolerable toxicity; Carrelizumab: administered intravenously with a fixed dose of 200mg, administered intravenously (without preventive medication), each infusion for 30min (no less than 20min, no more than 60min), administered once every two weeks until disease progression, death or intolerable toxicity. The maximum period is 2 years.||||
33929047|NCT05830526|NA|SINGLE_GROUP||OTHER||NONE|Groups of 5 people were formed.|||||
33929048|NCT04029623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33789376|NCT03807102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789377|NCT00921830|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33929049|NCT00294684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929050|NCT00909818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929051|NCT01475318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929052|NCT01282567|NA|SINGLE_GROUP||||NONE||||||
33929053|NCT02546310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33929054|NCT03842501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929055|NCT02336048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007948|NCT01939431|||COHORT||OTHER|||||||
34007949|NCT05987085|||COHORT||PROSPECTIVE|||||||
34007950|NCT02983032|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34007951|NCT02910414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34007952|NCT02283190|NA|SINGLE_GROUP||OTHER||NONE||||||
34007953|NCT05299567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly assigned by pharmacy staff in blocks of 4|Placebo-controlled, double-blind, randomized study|f|t|t|f
34007954|NCT02407067|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007955|NCT00503230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007956|NCT01826916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34007957|NCT04403763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007958|NCT06259877|||CASE_CONTROL||PROSPECTIVE|||||||
34007959|NCT02539784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007960|NCT05528731|||CASE_ONLY||PROSPECTIVE|||||||
34007961|NCT03782480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34007962|NCT01546519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007963|NCT02122614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34007964|NCT02228109|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34007965|NCT05987072|NA|SINGLE_GROUP||OTHER||NONE||single-arm to investigate PK, safety and tolerability of 200 mg sisunatovir given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state in Chinese healthy participants.||||
34007966|NCT00014391||||SUPPORTIVE_CARE||||||||
34007967|NCT02247518|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34007968|NCT05915364|||COHORT||OTHER|||||||
34007969|NCT03465150|||COHORT||PROSPECTIVE|||||||
34007970|NCT01845116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929056|NCT03933280|RANDOMIZED|PARALLEL||OTHER||DOUBLE|An independent anaesthesiologist not involved in the study will open the randomisation envelope just before the premedication and will prepare the appropriate drug-filled syringes according to the code and will not take part in the management and observations. (Syringes and infusion lines will be concealed by wrapping with an aluminium foil). A blinded investigator that will not be involved in the anaesthetic management of the patients, will collect the intra-operative and postoperative data.||t|f|f|t
33929057|NCT05951543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efferts will be put to mask the both groups about their treatment|It is a randomize control trail ,used to evaluate the effects of plyometric exercises on static and dynamic balance of children with down syndrome.subjects with down syndrome meeting the predetermine inclusion and exclusion criteria will be devided into two groups using simple random sampling technique.|t|f|f|f
33929058|NCT06438965|||COHORT||PROSPECTIVE|||||||
33929059|NCT04373018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33929060|NCT04134728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blinded|Participants will be randomized to one of six intervention arms in ratio of 6:6:6:1:1:1|t|f|t|t
33929061|NCT01482468|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929062|NCT02530099|RANDOMIZED|FACTORIAL||||NONE||||||
33929063|NCT03780413|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinded assessors|RCT in which participants are randomized to active group (PR-ESSENCE for 10 weeks) or control group (treatment as usual for 10 weeks, followed PR-ESSENCE for 10 weeks)|f|f|f|t
33929064|NCT04393909|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||We will conduct a pre-post interrupted time series design study in which we compare the relative effectiveness of the intervention over pre-post intervention for enrolled patients for our main outcomes.||||
33929065|NCT03373344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929066|NCT00291083|||COHORT||PROSPECTIVE|||||||
33929067|NCT05883839|||OTHER||CROSS_SECTIONAL|||||||
33929068|NCT03983460|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33929069|NCT03661372|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized||||
34007971|NCT01774630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007972|NCT05824494|NA|SINGLE_GROUP||TREATMENT||NONE||cadonilimab 10mg/kg Q3W and nab-paclitaxel ≤260mg/m2 Q3W||||
34007973|NCT02842684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007974|NCT05483387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007975|NCT03225014|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||f|t|f|t
34007976|NCT06087718|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm prospective interventional pilot trial in 10 patients with feasibility and safety checks and early stopping/intermission rules||||
34007977|NCT04958252|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Part A and Part B of the trial are designed single-blind (to participants). Part C is designed as open-label trial.|"Part A and Part B of the trial is designed as single-blind, partially randomised, and placebo-controlled within parallel dose groups.~Part C is designed as a randomised, two-sequence, open-label, two period, two-way cross over trial."||||
34007978|NCT01647373|||CASE_ONLY||CROSS_SECTIONAL|||||||
33789378|NCT01407900|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34007979|NCT04927325|NON_RANDOMIZED|PARALLEL||OTHER||NONE||10 central lines with a reddened exit site 10 central lines without a reddened exit site||||
34007980|NCT02618226|||COHORT||PROSPECTIVE|||||||
34007981|NCT01841541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34007982|NCT04007471|||COHORT||PROSPECTIVE|||||||
34007983|NCT05389709|||COHORT||PROSPECTIVE|||||||
34007984|NCT01408225|||COHORT||PROSPECTIVE|||||||
34007985|NCT00024388||||TREATMENT||||||||
34007986|NCT03605823|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34007987|NCT05735626|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blinding will be applicable for clinical and instrumental assessments for investigators, and for intervention condition for patients.|"2 days randomized crossover study with 60 patients in 3 treatment groups:~* Piperine 150μM + tDCS 2mA 20'~* Piperine 1mM+ tDCS 2mA 20'~* Capsaicin 10μM + tDCS 2mA 20"|t|t|f|t
34007988|NCT03451604|||COHORT||PROSPECTIVE|||||||
34007989|NCT05180409|||COHORT||PROSPECTIVE|||||||
34007990|NCT06092190|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34007991|NCT06573970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a standard placebo-controlled, double-blind clinical trial. Within each stratum, participants will be block randomized with random block sizes of 2 and 4. Participant age and sex are randomization stratum and should retain balance.|t|t|t|t
34007992|NCT06368024|||OTHER||RETROSPECTIVE|||||||
34093077|NCT00211094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34093078|NCT05818033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34093079|NCT05179512|||COHORT||RETROSPECTIVE|||||||
34093080|NCT00669344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093081|NCT05965895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093082|NCT04175756|||COHORT||PROSPECTIVE|||||||
34093083|NCT01331005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093084|NCT03247244|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The participants, investigators and analysts will be masked as to the treatment arm and product of each participant and visit. Only the pharmacists will be aware of the strain.|There are four treatment schemes. All subjects will be randomized in a 1:1:1:1 ratio to one of the four treatment schemes. Participants will receive a single dose of each of the 3 cannabis products + placebo, with the order determine by their assigned treatment arm.|t|f|t|t
34093085|NCT06280105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093086|NCT00731198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34093087|NCT00186797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34007993|NCT02551679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34007994|NCT05247073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||25 Patients of controlled group with routine closure of the episiotomy 25 Patients of study group with Mostafa Maged technique for closure of the episiotomy|t|f|f|f
34007995|NCT04227041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007996|NCT01104090|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
34093088|NCT02908321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093089|NCT00407667|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34093090|NCT03447145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093091|NCT00623129|RANDOMIZED|||SUPPORTIVE_CARE||SINGLE||||||
34093092|NCT02204462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093093|NCT02843607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093094|NCT02551575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093095|NCT05129085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093096|NCT03976700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093097|NCT05314725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093098|NCT06071988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093099|NCT02550210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34007997|NCT05889013|||COHORT||CROSS_SECTIONAL|||||||
34007998|NCT00006399||||TREATMENT||DOUBLE||||||
34007999|NCT05369091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008000|NCT04491695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008001|NCT05952089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008002|NCT02851732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34093100|NCT02867852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093101|NCT05619523|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34093102|NCT05341245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093103|NCT05562921|||CASE_CONTROL||PROSPECTIVE|||||||
34008003|NCT00035321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34008004|NCT06397222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008005|NCT01333202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008006|NCT01076556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008007|NCT02588079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008008|NCT00339872|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
34008009|NCT00576303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008010|NCT04926064|||OTHER||CROSS_SECTIONAL|||||||
34008011|NCT03493321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008012|NCT02073006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008013|NCT05269992|NA|SINGLE_GROUP||OTHER||NONE||||||
34008014|NCT06617494|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33704169|NCT05913258|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The examiner who clinically evaluated the restorations using Ryge criteria did not know which tooth had received which treatment.|A randomized, blinded split-mouth study. The children were randomly assigned into one of two groups randomly. The first group included were assigned to receive the conventional treatment at the first visit and the laser treatment at the second visit. The second group was assigned to receive the laser treatment at the first visit and the conventional treatment at the second visit.|f|f|f|t
34008015|NCT04735107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008016|NCT01258088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704170|NCT04806997|||COHORT||PROSPECTIVE|||||||
34008017|NCT03558620|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34008018|NCT02409329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34008019|NCT06121258|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34008020|NCT00909571|RANDOMIZED|PARALLEL||||NONE||||||
34008021|NCT02666391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008022|NCT01582594|||CASE_ONLY||PROSPECTIVE|||||||
34008023|NCT02382367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008024|NCT03746106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Part 1: Three-arm randomized crossover study design Part 2: Two-arm randomized crossover study design||||
34008025|NCT02994290|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34008026|NCT02997722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008027|NCT01293370|||COHORT||RETROSPECTIVE|||||||
34008028|NCT02363439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008029|NCT05095649|NA|SINGLE_GROUP||TREATMENT||NONE||The doses of Treg-enriched cells will be 2x10\^6 cells/kg||||
34008030|NCT06276530|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008031|NCT03241316|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33704171|NCT05624593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704172|NCT03638609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704173|NCT00662246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704174|NCT00816296|||CASE_CONTROL||PROSPECTIVE|||||||
33704175|NCT05457426|||COHORT||RETROSPECTIVE|||||||
33704176|NCT03656432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33704177|NCT02937675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704178|NCT05107674|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33704179|NCT00372762|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33801727|NCT05957016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801728|NCT02184806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801729|NCT05851677|||COHORT||OTHER|||||||
34008032|NCT01758341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008033|NCT01470417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008034|NCT06345963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008035|NCT05480306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008036|NCT00468949|||COHORT||PROSPECTIVE|||||||
34008037|NCT01533649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008038|NCT03571659|||OTHER||RETROSPECTIVE|||||||
34008039|NCT02741154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008040|NCT02347319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008041|NCT00209287|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34008042|NCT00026052||||TREATMENT||||||||
34008043|NCT00668447|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34008044|NCT03791294|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34008045|NCT02696941|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33704180|NCT05039073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704181|NCT00962910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33801730|NCT02764645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34008046|NCT03379155|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial design, comparing to a waitling list||||
34008047|NCT04157478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008048|NCT05115617|||COHORT||PROSPECTIVE|||||||
34008049|NCT05811221|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34008050|NCT00897286|||CASE_ONLY||PROSPECTIVE|||||||
34008051|NCT06616727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008052|NCT02457611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008053|NCT04649697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008054|NCT01665651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008055|NCT05391659|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008056|NCT06038396|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34008057|NCT01557582|NA|SINGLE_GROUP||||NONE||||||
34008058|NCT05931120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008059|NCT06446388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008060|NCT00002194||PARALLEL||TREATMENT||||||||
34008061|NCT04540718|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Data statisticians (2) are blind to participant allocation|3 groups of which; 1 serves as a control group, 1 exercise group, and 1 exercise and sauna group|f|f|f|t
34008062|NCT03711916|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||f|f|t|f
34008063|NCT01902030|||COHORT||RETROSPECTIVE|||||||
34008064|NCT02495532|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34008065|NCT04674982|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33789379|NCT03700658|RANDOMIZED|CROSSOVER||OTHER||NONE|The study will be partially blinded due to differences in appearance and volume of the treatments. Designated unblinded study staff will conduct randomization procedures. The staff preparing and administering injections will also be unblinded to treatment sequence but will be trained to shield the syringe prior to and at the time of injection from view of the participant and study staff assessing injection site reactions (ISRs).|||||
33789380|NCT02163915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789381|NCT03861221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789382|NCT06335836|||COHORT||PROSPECTIVE|||||||
33789383|NCT00130637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789384|NCT05701111|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||At Time 1, all participating students undergo a mindfulness curriculum in the classroom, and a subset that reports PTSD symptomatology will continue to receive Cue Centered Therapy at TIme 2 after completing the mindfulness curriculum. A subset of Time 1 students will be randomly selected for DNA buccal swabs at all three time points. All participating teachers undergo training for and implementation of the mindfulness curriculum. All participating counselors undergo training for and implementation of Cue-Centered Therapy.||||
33789385|NCT00123747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789386|NCT04563455|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33789387|NCT01188252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789388|NCT00897637|||COHORT||RETROSPECTIVE|||||||
33789389|NCT00153218|||CASE_ONLY||RETROSPECTIVE|||||||
33789390|NCT03939572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33789391|NCT00807430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789392|NCT00966199|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789393|NCT02664194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789394|NCT06441656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator assessing the outcome was masked to the type of surgery done|Prospective comparative|t|t|f|t
33789395|NCT01514734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789396|NCT02504970|||COHORT|||||||||
33789397|NCT01429779|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33789398|NCT05689047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789399|NCT03644537|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33789400|NCT05242926|NA|SINGLE_GROUP||TREATMENT||NONE||Six evaluable patients will receive bidaily dosing on day 1 of week 1, whereafter collection of plasma, faeces and urine samples will take place until 168 hours after the first dosing.||||
33789401|NCT00138606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789402|NCT01535989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789403|NCT02785978|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33789404|NCT00906282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789405|NCT03143309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789406|NCT03705819|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Open Label Study|||||
33789407|NCT05252871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Progressive addition lens designs are unknown to participants, investigators, and outcomes assessors.||t|f|t|t
33789408|NCT03313206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789409|NCT00778804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789410|NCT05890521|NA|SINGLE_GROUP||PREVENTION||NONE||"Subjects who have not received any Novel Coronavirus vaccine or the full dose of recombinant Novel Coronavirus protein vaccine (CHO cells) shall receive 3 doses of the experimental vaccine intramuscular in the deltoid muscle of the upper arm or complete the remaining doses of the experimental vaccine as per the vaccination schedule at 0, 1, and 2 months, with a dose of 0.5ml for each person.~Immunized subjects: intramuscular injection of one dose of the experimental vaccine into the deltoid muscle of the upper arm, 0.5ml for each person."||||
33789411|NCT04041999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Experimental, randomized, stratified, prospective, longitudinal study using a parallel scheme of fixed allocation experimental group and control group|t|f|f|f
33789412|NCT04373187|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33789413|NCT02706067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008066|NCT06214559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008067|NCT03766139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sites will be randomly (computer generated tabulation method) assigned into control group (treated with PRFM alone) and test group (treated with Supercell Glue).|The study will be a Double Blinded Randomized controlled clinical trial with a split mouth design.|t|f|t|f
34008068|NCT04661592|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal||||
33789414|NCT02205762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801731|NCT02369289|||COHORT|||||||||
34008069|NCT03592329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34008070|NCT04763278|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34008071|NCT00249015|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33704182|NCT05711784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Subjects will be randomly assigned in a 1:1:1 ratio to receive either treatment A or B or C. The randomization code will be generated by NovoBliss Research. The randomization schedule will be maintained under controlled access. Double Blind will be followed.~The Investigator/Evaluator will be blinded to the randomization schedule. The sequence number as per the randomization schedule will be used as Randomization ID.~Subjects will be randomly allocated to one of the three treatment groups, as per the randomization code. Neither the subject nor the Investigator/Evaluator shall be aware of the treatment allocation (Double Blind). To maintain blinding, the study staff who involves in treatment dispensing and distribution will not be involved in any other study-related activities."|Randomized, Three-arm, Comparative, Double-blinded, Placebo-controlled, Single-center, Dose-response, Safety and Efficacy|t|f|t|f
33929070|NCT03723408|NA|SINGLE_GROUP||PREVENTION||NONE|Three sites - Loma Linda Medical Center, Johns Hopkins, Miami Nicklaus Children's|An observational prospective trial was conducted in operating room settings across multiple study sites. 120 surgical patients undergoing a variety of interventional and surgical procedures were selected, representing multiple patient populations, case types and anesthesia setups. The ClearLine IV, a device that detects and removes air from IV tubing, was inserted into the IV circuit. Clinicians followed standard protocols. Blood warmers were used at the practitioner's discretion. IV fluid was administered at a constant flow rate or through a bolus given over 30-60 seconds per standard of care. The volume and duration of fluid administration was recorded, along with the frequency, duration and amount of air captured by ClearLine IV.||||
33929071|NCT03706040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008072|NCT04328870|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33704183|NCT01642979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704184|NCT06456112|||COHORT||PROSPECTIVE|||||||
33704185|NCT02243696|||CASE_ONLY||PROSPECTIVE|||||||
33704186|NCT03273270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704187|NCT00113022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704188|NCT00317512|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34008073|NCT04425122|||COHORT||PROSPECTIVE|||||||
33789415|NCT01162057|||CASE_ONLY||PROSPECTIVE|||||||
33789416|NCT02167243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789417|NCT01145456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789418|NCT03460210|||CASE_ONLY||PROSPECTIVE|||||||
33789419|NCT02979899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789420|NCT04555044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789421|NCT00004367||||DIAGNOSTIC||||||||
33789422|NCT06628817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33789423|NCT02526680|NA|SINGLE_GROUP||OTHER||NONE||||||
34008074|NCT02833207|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789424|NCT04671108|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Clinician masking achieved by clinic coordinator dispensing lenses. Open label to participants.|Randomized cross-over with 1 week of lens wear with each contact lens type.|f|t|f|f
33789425|NCT02875665|NA|SINGLE_GROUP||OTHER||NONE||The intervention is the using geko device||||
34008075|NCT01397955|||CASE_ONLY||PROSPECTIVE|||||||
34008076|NCT01953887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34008077|NCT05472155|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible due to the study design. Only statistician who will perform the analysis will be blind to the arm allocation.|||||
34008078|NCT02582788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008079|NCT05209997|||OTHER||RETROSPECTIVE|||||||
34008080|NCT03882073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008081|NCT02915926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008082|NCT05601778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008083|NCT05872334|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34008084|NCT01118845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008085|NCT06196944|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008086|NCT03633552|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized to 6-cycle and 12-cycle adjuvant Temozolomide groups using block randomization method (1:1).||||
34008087|NCT05202288|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The trial will have 5 arms. The control arm (vaccination alone) will serve as a comparator of vaccine response in the intervention arms. The 4 intervention arms will assess the minimum time between Mab and vaccination.~The early, intermediate and late arms of the IMOVA trial will therefore assess the immunological response when the vaccine is administered 3, 6 or 12 weeks after Mab and thus determine the optimal time between the two interventions."||||
34008088|NCT01456429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789426|NCT04369807|||COHORT||PROSPECTIVE|||||||
33789427|NCT06523855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33789428|NCT05460663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Control Trial||||
33789429|NCT01565161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008089|NCT05422313|||CASE_CONTROL||RETROSPECTIVE|||||||
34008090|NCT05196100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008091|NCT00116480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008092|NCT02568709|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34093104|NCT02011763|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34093105|NCT03969537|||COHORT||PROSPECTIVE|||||||
33704189|NCT04267822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigators, Sponsor, Independent Adjudication Committee members, and any personnel involved in the subject's care, assessment, monitoring, data collection, or analysis will be blinded to the subject treatment assignment throughout the conduct of the study. Exceptions to this are limited to a fire-walled-protected, unblinded Data Safety Monitoring Board (DSMB) statistician at the Contract Research Organization (CRO) who will prepare output for the closed session of all DSMB meetings.|A Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study.|t|t|t|t
33789430|NCT00628940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929072|NCT05128695|||COHORT||PROSPECTIVE|||||||
34008093|NCT05335850|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Crossover Assignment A partial crossover model ensures that both experimental and waitlisted control group participants get to experience the effects of a proposed intervention. For our study, we are providing these practices as an intervention and both experimental and waitlisted control group participants get to experience the benefits of meditation and breathing exercises.|f|f|f|t
34008094|NCT01455818|||COHORT||PROSPECTIVE|||||||
34008095|NCT05790707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008096|NCT03222986|||COHORT||PROSPECTIVE|||||||
33704190|NCT04729374|||COHORT||PROSPECTIVE|||||||
33704191|NCT02028754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789431|NCT03423394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789432|NCT00299702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789433|NCT02520570|||OTHER||PROSPECTIVE|||||||
33789434|NCT02638415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789435|NCT01177852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789436|NCT03255018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789437|NCT00957229|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33789438|NCT01161719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789439|NCT05000450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789440|NCT05522699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33789441|NCT04312776|||FAMILY_BASED||PROSPECTIVE|||||||
33789442|NCT04885595|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33789443|NCT02886897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789444|NCT05658198|||COHORT||PROSPECTIVE|||||||
33789445|NCT05481294|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group was given transpersonal supportive coaching and ARV therapy. Meanwhile, comparison group 1 was given basic support and ARV therapy, and comparison group 2 was only given ARV therapy without any support.||||
33789446|NCT02877199|||COHORT||RETROSPECTIVE|||||||
33789447|NCT02380729|||FAMILY_BASED||PROSPECTIVE|||||||
33789448|NCT03154944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789449|NCT03881358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789450|NCT00198848|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33789451|NCT01467700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789452|NCT06388707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789453|NCT01489176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789454|NCT05449002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants, 9-17 years old, will be: randomized to a 30-45-minute Qualtrics-based, digital program teaching Practicing the Opposite (PTO, followed by psychotherapy) or to the usual care (i.e., usual waitlist procedures, followed by psychotherapy) control.|f|t|t|t
33789455|NCT02503202|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33789456|NCT05911256|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Sequential Multiple Assignment Randomized Trial (SMART)|f|f|t|t
33789457|NCT04288492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33789458|NCT05722652|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinics will know if they are assigned to the intervention or control condition. However, individual participants (parents of children ages 5 to 17) will not know if their clinic is in the intervention or control condition.|"The investigators will be using a cluster, randomized control trial design, in which clinics are assigned to either the intervention or control group. Clinics in the control group or waitlist condition, will receive the intervention approximately 12 months later."|t|f|f|f
33789459|NCT02220569|||COHORT||PROSPECTIVE|||||||
33789460|NCT00608348|RANDOMIZED|FACTORIAL||||NONE||||||
33789461|NCT04486729|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33789462|NCT04401917|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33789463|NCT03667547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008097|NCT02432118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008098|NCT04239482|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33704192|NCT00289133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789464|NCT03087539|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33789465|NCT06532760|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||3 groups||||
33704193|NCT01977742|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704194|NCT01162460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704195|NCT05875428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704196|NCT01146665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33704197|NCT01215565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704198|NCT01122771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789466|NCT01549314|||COHORT||PROSPECTIVE|||||||
33789467|NCT00590603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789468|NCT03333655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33789469|NCT01276990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929073|NCT00655811|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929074|NCT01444872|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33929075|NCT01197092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929076|NCT01614795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929077|NCT01614041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929078|NCT03162094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|phase I/II, double-blind|"Phase I: patient will be included on 3 arms of treatment ( Placebo, Low dose or High dose AVX-012) TID~Phase II: Patient will be included on 4 arms of treatment (Placebo/Dose) BID/TID"|t|t|t|f
33929079|NCT02475629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929080|NCT03571503|||CASE_ONLY||PROSPECTIVE|||||||
33929081|NCT04949828|||COHORT||PROSPECTIVE|||||||
33929082|NCT03926637|||CASE_ONLY||PROSPECTIVE|||||||
33929083|NCT03696446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The facilitators will not know that the participants are part of the study. Participants will know which group they are allocated to as they are aware of both groups (described in the consent form).||f|t|f|f
33929084|NCT01674985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929085|NCT06283225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||intervention group and control group|f|f|t|t
33929086|NCT05854797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929087|NCT00844324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33929088|NCT00630708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929089|NCT05042557|||CASE_CONTROL||RETROSPECTIVE|||||||
33929090|NCT01178723|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34008099|NCT06472544|NA|SINGLE_GROUP||TREATMENT||NONE|As there is only one group which the intervention group there is no need for masking as to treatment type.|||||
34008100|NCT02488824|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008101|NCT02170831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704199|NCT06071208|||CASE_CONTROL||PROSPECTIVE|||||||
33704200|NCT03329508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind study|4 arms|t|t|t|f
33929091|NCT00701441|||CASE_CONTROL||PROSPECTIVE|||||||
33929092|NCT02017496|||COHORT||PROSPECTIVE|||||||
33929093|NCT01936272|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33929094|NCT05522296|||COHORT||PROSPECTIVE|||||||
33929095|NCT02754661|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929096|NCT00000440|RANDOMIZED|||TREATMENT||DOUBLE||||||
33929097|NCT04566757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929098|NCT05199883|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective study involving a series of consecutive patients.||||
33929099|NCT06383000|||COHORT||PROSPECTIVE|||||||
33929100|NCT06343454|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33929101|NCT02255760|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008102|NCT05323513|||COHORT||PROSPECTIVE|||||||
34008103|NCT02953678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008104|NCT01858350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093106|NCT02624089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093107|NCT00914212|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34093108|NCT01779362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093109|NCT02840565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704201|NCT02539446|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33704202|NCT04449601|||COHORT||RETROSPECTIVE|||||||
33704203|NCT03622723|||OTHER||PROSPECTIVE|||||||
33929102|NCT04697160|||COHORT||RETROSPECTIVE|||||||
33929103|NCT04477525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929104|NCT00510367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929105|NCT02030249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929106|NCT00516958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093110|NCT04649554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704204|NCT05882942|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Randomized, placebo-controlled, crossover design|t|f|f|f
33704205|NCT02605070|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704206|NCT00481143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704207|NCT05259514|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||study phase 1 (feasibility/power-analysis): 5 treated with CytoSorb study phase 2: 40 (20 standard of care and 20 Cytosorb).||||
33704208|NCT00725374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33704209|NCT02349529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704210|NCT05216783|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||This study was designed as a randomized controlled trial|t|f|f|f
33704211|NCT02095093|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33704212|NCT00318422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704213|NCT02179866|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33704214|NCT00653120|RANDOMIZED|CROSSOVER||||NONE||||||
33704215|NCT06556589|||COHORT||PROSPECTIVE|||||||
33704216|NCT01932346|||CASE_ONLY||CROSS_SECTIONAL|||||||
33704217|NCT01423370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704218|NCT01902199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704219|NCT00250120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929107|NCT03301233|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Ninety opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table. Then all envelopes will be closed and put in one box. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside.||t|f|f|f
33704220|NCT06027294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704221|NCT05664490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704222|NCT04939116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33704223|NCT01431989|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33704224|NCT00972582|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33704225|NCT04148352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||dupilumab or placebo arm|t|t|t|f
33704226|NCT01608620|||||PROSPECTIVE|||||||
33704227|NCT01918384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704228|NCT05832801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomly assigned into two groups, group A and group B .Patients in both groups will receive a traditional dietary advice for IBS, but group (A) will receive additional pilates exercises.|t|t|t|t
33704229|NCT03643796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704230|NCT04239859|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"To evaluate the real-life effectiveness of secukinumab as first-line systemic treatment in participants with moderate to severe PsO, the investigators would recruit a pragmatic control arm.~⦁ Intervention arm Eligible participants will be offered secukinumab as first-line systemic treatment for PsO. Standard dose of subcutaneous secukinumab for moderate to severe PsO will be given at 300 mg at weeks 0, 1, 2, 3, and 4, then monthly thereafter, for a total duration of 6 months.~Secukinumab will be withdrawn after 6 months. For some participants, there may be relapse of PsO. Relapses will be managed as per standard care.~⦁ Pragmatic control arm~Eligible participants will be recruited to pragmatic control arm in these circumstances:~* Patient disagree to secukinumab for personal reasons.~* The quota for secukinumab is exhausted.~* The management of PsO in this pragmatic control arm will be the same as that in the standard care."||||
33704231|NCT05091359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The procedure was elected by participant randomization.|A two group comparison|t|f|f|f
33704232|NCT02981043|||COHORT||PROSPECTIVE|||||||
33704233|NCT03295084|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open labelled study with enrollment in the order of confirmation of eligibility. Escalating doses of study drug in sequential patient cohorts for identification of DLT and MTD (Phase 1)||||
33929108|NCT03636880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Baseline assessment is completed prior to randomization. Assessments conducted at 2 weeks and 6 months post-intervention are completed by an assessor blinded to participants' assigned condition.||f|f|f|t
33929109|NCT03690674|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33929110|NCT00841672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704234|NCT04431180|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33704235|NCT00388596|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704236|NCT05703516|||COHORT||PROSPECTIVE|||||||
33704237|NCT04340648|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients are divided in two groups and both groups are enrolled sequential and undergo the same procedures||||
33704238|NCT01205204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33704239|NCT01112358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704240|NCT02703831|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33704241|NCT06350396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704242|NCT03651544|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Taking into account the fact that the drug is being studied for the first time with the participation of people, initially 5 volunteers will be hospitalized, who will receive the study drug at a dose of 1. If the safety of the drug is confirmed by the results of observation on the 7th day of the study, the study will continue with the participation of 7 more volunteers in this dosing group.~Further, according to a similar scheme (each time after an interim safety assessment on day 7), volunteers receiving the drug at a dose 2 and dose 3 will be included in the study."||||
33704243|NCT03922997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704244|NCT04315883|||COHORT||PROSPECTIVE|||||||
33704245|NCT02025322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704246|NCT01814631|||CASE_ONLY||PROSPECTIVE|||||||
33704247|NCT02537106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789470|NCT04376814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789471|NCT00496379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704248|NCT03145974|||COHORT||PROSPECTIVE|||||||
33704249|NCT04650022|||COHORT||RETROSPECTIVE|||||||
33704250|NCT05378178|NA|SEQUENTIAL||TREATMENT||NONE||||||
33704251|NCT02933606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33704252|NCT03120000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704253|NCT03005145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704254|NCT04930965|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704255|NCT06356909|||COHORT||PROSPECTIVE|||||||
33704256|NCT01613300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704257|NCT02461602|||COHORT||PROSPECTIVE|||||||
33704258|NCT02856178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33704259|NCT02646657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704260|NCT02308605|||CASE_CONTROL||PROSPECTIVE|||||||
33704261|NCT03507803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinician involved in rehabilitation will not know if participant has been enrolled in the gait biofeedback arm or the control (no biofeedback) arm.|Participants will be randomized at the baseline visit to either the intervention or control group. The intervention group will receive gait biofeedback. Participants will remain within their designated allocation for the entire study.|f|t|f|f
33704262|NCT00261222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704263|NCT03475914|||COHORT||OTHER|||||||
33704264|NCT04790929|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized control trial||||
33704265|NCT00223262|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33704266|NCT05768217|RANDOMIZED|PARALLEL||PREVENTION||NONE||This 2-armed cluster-randomized-controlled community-partnered project will examine the effectiveness of a community-centered intervention that promotes thriving and resiliency to reduce community violence, Community Resiliency Collective Efficacy Intervention (CRCEI). The comparison intervention will be health education sessions, which will occur monthly as a 'light touch' intervention in control neighborhoods to recruit a similar number of community members as in the intervention neighborhoods. The study will be located in Allegheny County in Pennsylvania across 20 neighborhoods (i.e., clusters), such that assigned intervention neighborhoods (n=4) will be matched to similar comparison neighborhoods (n=4), and 12 neighborhoods will be randomized either to receive the Collective Efficacy program (i.e., intervention neighborhood, n=6) or to health sessions (comparison neighborhood, n=6). Community surveys will examine neighborhood perspectives before and after program implementation.||||
33704267|NCT05912244|NA|SEQUENTIAL||TREATMENT||NONE||Sequentially in a single-arm, nonrandomized two-stage trial design||||
33704268|NCT01477593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704269|NCT04614597|||COHORT||CROSS_SECTIONAL|||||||
33704270|NCT06557668|||COHORT||RETROSPECTIVE|||||||
33704271|NCT05350410|NA|SINGLE_GROUP||OTHER||NONE||"This pilot study will be a longitudinal study of an inception cohort exposed to the HALT AD online educational program for a four month study. It will utilize pre- and post- intervention collection of quantitative and qualitative data to evaluate the program's first prototype. Cognitively normal midlife and older-adult participants will be eligible to participate in this pilot study with the following inclusion criteria:~* Ages 50-85~* Montreal Cognitive Assessment-Telephone/Blind version (T-MoCA) Score equal to or greater than 18/22~* Sufficient proficiency in English or Spanish to undergo clinical assessment and participate~* Technical ability to participate~* Sufficient vision and hearing to participate 20 participants will be enrolled at UCSD~* 10 will complete the English version~* 10 will complete the Spanish version~Aim to recruit 50% women and enroll a diverse participant sample across varied age ranges within both language groups"||||
33704272|NCT03740633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704273|NCT01752270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704274|NCT01236482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704275|NCT05892120|||CASE_ONLY||CROSS_SECTIONAL|||||||
33704276|NCT06504706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|participants will be blinded to the type of tea they are drinking and investigators will be blinded as well|Randomized Controlled Trial|t|f|f|t
33704277|NCT00567307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704278|NCT03538002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704279|NCT00134459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704280|NCT01634334|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704281|NCT02138500|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33704282|NCT06263920|||CASE_CONTROL||PROSPECTIVE|||||||
33704283|NCT02056938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704284|NCT03777072|||COHORT||PROSPECTIVE|||||||
33704285|NCT00673504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789472|NCT01119950|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33789473|NCT03456817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789474|NCT02904707|||COHORT||PROSPECTIVE|||||||
33789475|NCT06191406|||COHORT||RETROSPECTIVE|||||||
33789476|NCT02664337|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33789477|NCT02428088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789478|NCT03183024|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind||t|f|f|f
33789479|NCT04704102|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Include elements of both longitudinal (three groups) and cross-sectional (four-weeks intervention) research designs|t|f|f|f
33789480|NCT02749045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789481|NCT00163085|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33789482|NCT02092844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789483|NCT02834689|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704286|NCT04275531|||COHORT||PROSPECTIVE|||||||
33704287|NCT03523130|||COHORT||PROSPECTIVE|||||||
33704288|NCT06201520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704289|NCT03782961|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704290|NCT05363631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789484|NCT04542369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789485|NCT00584051|||COHORT||PROSPECTIVE|||||||
34008105|NCT02487082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The study is conducted in 2 main phases, supplemented by an initial Run-In Phase and a Final Wash-Out Phase.~The Run-In phase (5 weeks) - All subjects receive Placebo and instructions about how to improve sleep hygiene. This allows us to evaluate a) response to placebo and b) the effect of improved sleep hygiene in the absence of study drug in both groups.~Phase 1 (5 weeks) - Group A receives study drug (donepezil \& melatonin). Group B receives Placebo. Here we assess the benefit of study drug vs. Placebo in a parallel group design.~Phase 2 (5 weeks) - Both groups receive study drug (donepezil \& melatonin). Here we assess the effect of switching from Placebo to study drug in Group B, and the effect of an extra 5 weeks of study drug in Group A.~Wash-Out Phase (variable length, 2-12 weeks) - study drug is discontinued."|t|t|t|t
34008106|NCT04357886|||COHORT||PROSPECTIVE|||||||
33704291|NCT02831452|||||PROSPECTIVE|||||||
33704292|NCT01721993|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33704293|NCT05222737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33704294|NCT02206074|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33704295|NCT04210596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It concerns a surgical intervention. Hence, the treating surgeon and patient cannot be masked. The investigators and outcome assessors are masked.|Multicenter randomized controlled study with 2 treatment arms (control: connective tissue graft; test: collagen matrix) and 6 centers|f|f|t|t
33789486|NCT04173572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33789487|NCT02111148|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33789488|NCT01662180|||COHORT||PROSPECTIVE|||||||
33789489|NCT00234377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789490|NCT00365027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789491|NCT02235857|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with focal segmental glomerulosclerosis treated by LIPOSORBER® LA-15 system||||
33789492|NCT03231436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33789493|NCT03386929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789494|NCT02577523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789495|NCT02033096|||COHORT||PROSPECTIVE|||||||
33789496|NCT00109967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704296|NCT01629030|||||RETROSPECTIVE|||||||
33704297|NCT03068455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704298|NCT06039397|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33704299|NCT01171430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704300|NCT05456269|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33704301|NCT01070498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704302|NCT01299129|||CASE_ONLY||PROSPECTIVE|||||||
33704303|NCT03460938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33704304|NCT05749107|||COHORT||PROSPECTIVE|||||||
33704305|NCT06405230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704306|NCT02329392|||COHORT||PROSPECTIVE|||||||
33789497|NCT05386446|||COHORT||PROSPECTIVE|||||||
33789498|NCT00100984|RANDOMIZED|||TREATMENT||||||||
33704307|NCT03651505|||COHORT||PROSPECTIVE|||||||
33704308|NCT04443010|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label phase I/II study in subjects with newly diagnosed glioblastoma. The study will be conducted in three consecutive parts: (i) first the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, (ii) followed by a signal seeking part that investigates first signs of activity and (iii) then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.||||
33704309|NCT03046758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789499|NCT06315400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789500|NCT00857363|||CASE_CONTROL||PROSPECTIVE|||||||
33789501|NCT03018119|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929111|NCT03457636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929112|NCT05449210|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34008107|NCT04489186|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study is intended to evaluate the feasibility of a prototype wearable device for continuous cardiorespiratory monitoring in an inpatient and outpatient population with CF in preparation of a larger ambulatory clinical trial.||||
33704310|NCT00053443|RANDOMIZED|||TREATMENT||||||||
33704311|NCT02772107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704312|NCT00115635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704313|NCT02974283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704314|NCT04010058|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a feasibility study of the use of an approved device (CE-marked) in a cohort of postoperative patients.||||
33704315|NCT02501226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704316|NCT05864755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704317|NCT01469754|||COHORT||PROSPECTIVE|||||||
33704318|NCT02419105|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33789502|NCT01985399|||COHORT||PROSPECTIVE|||||||
33789503|NCT04278820|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33789504|NCT04127058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789505|NCT04159636|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33789506|NCT00557804|||CASE_ONLY|||||||||
33789507|NCT01813825|||||PROSPECTIVE|||||||
33789508|NCT06249633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789509|NCT05014529|||COHORT||PROSPECTIVE|||||||
33789510|NCT00697411|||OTHER||PROSPECTIVE|||||||
33789511|NCT03250104|||COHORT||PROSPECTIVE|||||||
33789512|NCT04443452|||COHORT||PROSPECTIVE|||||||
33789513|NCT06253130|NA|SEQUENTIAL||TREATMENT||NONE||||||
33929113|NCT02792049|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33929114|NCT06183736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929115|NCT05342142|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929116|NCT04348435|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929117|NCT00876486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929118|NCT02055170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929119|NCT04324086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33929120|NCT01216345|NA|SINGLE_GROUP||TREATMENT||||||||
33929121|NCT05970068|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Once eligible patients have been identified, they would be randomized into one of two groups - the intervention group or the control group.~Randomization will help ensure that the two groups are comparable in terms of baseline characteristics, which can minimize the risk of bias in the study. The program used will be https://www.random.org/lists/.~Group 1: Surgery + best medical treatment The intervention group would receive the novel treatment of implantation of hydrophobic tubes for edema fluid drainage, in addition to the best medical treatment available.~Group 2: best medical treatment This control group would receive only the best medical treatment available."||||
33929122|NCT00003408||||TREATMENT||||||||
33929123|NCT00618813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929124|NCT03568695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929125|NCT04140370|||COHORT||PROSPECTIVE|||||||
33929126|NCT00064077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929127|NCT01716988|||CASE_ONLY||PROSPECTIVE|||||||
33929128|NCT03979872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"4 different parallel intervention groups:~* Education only~* Education + MC1R genetic testing~* Education + UV photo~* Education + MC1R genetic testing + UV photo"|t|f|f|f
33929129|NCT03581682|NA|SINGLE_GROUP||OTHER||NONE||||||
33929130|NCT02533661|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33929131|NCT05130268|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, prospective, randomized, open-label, pragmatic clinical trial||||
33929132|NCT02509676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33704319|NCT04614558|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be a single arm, prospective, multi-center, phase II, open- label study including 27 subjects in total. The study will consist of a screening phase, treatment phase, post-treatment observation phase and follow-up phase||||
33704320|NCT04203797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704321|NCT02746146|NA|SINGLE_GROUP||SCREENING||NONE||||||
33704322|NCT04067674|||COHORT||PROSPECTIVE|||||||
33704323|NCT05401357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double-blinded study|Participants are randomly assigned to either group|t|f|f|f
33789514|NCT02465086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704324|NCT04211883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704325|NCT03438929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704326|NCT01796483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33704327|NCT02046681|||COHORT||PROSPECTIVE|||||||
33704328|NCT05599191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704329|NCT03160417|||COHORT||PROSPECTIVE|||||||
33704330|NCT04340180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704331|NCT00771069|||COHORT||RETROSPECTIVE|||||||
33704332|NCT06222190|||COHORT||PROSPECTIVE|||||||
33789515|NCT01654705|RANDOMIZED|CROSSOVER||||NONE||||||
33789516|NCT05427890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33789517|NCT02699970|||CASE_ONLY||CROSS_SECTIONAL|||||||
33789518|NCT01942083||SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33789519|NCT01859312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789520|NCT00548964|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789521|NCT01967407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789522|NCT05663619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929133|NCT01003613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929134|NCT05459766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33929135|NCT01589263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929136|NCT00568620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33929137|NCT04949425|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929138|NCT04568811|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33929139|NCT02445703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34008108|NCT05621187|NA|SINGLE_GROUP||OTHER||NONE||||||
34008109|NCT05415124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008110|NCT03723278|||CASE_ONLY||CROSS_SECTIONAL|||||||
34008111|NCT03327350|||COHORT||PROSPECTIVE|||||||
34008112|NCT01779388|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34008113|NCT04862962|||CASE_ONLY||RETROSPECTIVE|||||||
34008114|NCT03345758|||CASE_ONLY||PROSPECTIVE|||||||
34093111|NCT05962372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be unaware of which educational messages are considered intervention or control. Investigators will not be in contact with participants and will only receive coded data. Outcome assessor will be unaware of treatment allocation of participant. Senior investigators, Research Assistants, and laboratory personnel will be blinded to the participants' group allocation.||t|f|t|t
33704333|NCT04924907|||COHORT||CROSS_SECTIONAL|||||||
33929140|NCT03747536|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study drug will be dispensed as a metered-dose spray bottle of ipratropium bromide or identical placebo prepared by the Hospital Pharmacy. Clinician, investigator, care provider, as well as outcome assessor will be blinded to the treatment.||t|t|t|t
33929141|NCT03436147|||OTHER||PROSPECTIVE|||||||
33929142|NCT03498976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704334|NCT01209611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704335|NCT02015754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789523|NCT04577170|||OTHER||CROSS_SECTIONAL|||||||
33789524|NCT00920686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789525|NCT04355130|||COHORT||PROSPECTIVE|||||||
33789526|NCT00117364|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33789527|NCT03142646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789528|NCT03045900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33789529|NCT06386913|NA|SINGLE_GROUP||OTHER||NONE||Clinicians completed pre- and post-training surveys. Patient satisfaction was assessed prior to and after clinician training.||||
33789530|NCT00962793|||||PROSPECTIVE|||||||
33789531|NCT01923857|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33789532|NCT00706693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789533|NCT03641950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789534|NCT04285125|||CASE_ONLY||PROSPECTIVE|||||||
34093112|NCT04664296|||CASE_ONLY||PROSPECTIVE|||||||
34093113|NCT01843881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34008115|NCT04114942|RANDOMIZED|FACTORIAL||TREATMENT||NONE||A sequential multiple assignment randomized trial (SMART) will be conducted, with data collected at 4 major time points (baseline, post P1 (20 weeks), post P2 (10 weeks), 10-week follow up). After baseline assessments, participants will be randomized to receive the 20-week didactic training either with the assistance of a career coach or without (Phase 1). In Phase 2, individuals randomized to the coach condition will continue in the internship phase with a coach. Individuals randomized to the no-coach condition will be re-randomized to either receive assistance from a career coach during their 10-week internship or complete the internship alone. A follow-up, 10-weeks post internship, will be conducted to measure maintenance of treatment gains.||||
34008116|NCT03297294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704336|NCT00143767|||CASE_CONTROL||PROSPECTIVE|||||||
33704337|NCT00460096|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33704338|NCT00141843|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33704339|NCT05111925|||COHORT||PROSPECTIVE|||||||
33704340|NCT02552992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704341|NCT03941392|||OTHER||PROSPECTIVE|||||||
33704342|NCT02586129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704343|NCT06557226|||COHORT||CROSS_SECTIONAL|||||||
33704344|NCT03917238|NA|SINGLE_GROUP||OTHER||NONE||||||
33704345|NCT04873115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blinded randomised phase followed by open label treatment.|t|t|t|t
33704346|NCT03681665|||COHORT||PROSPECTIVE|||||||
33704347|NCT02126917|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33704348|NCT05010057|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Coded, capsules|Randomised, parallel design.|t|f|t|f
33704349|NCT03373292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704350|NCT00049192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704351|NCT05938491|||CASE_ONLY||PROSPECTIVE|||||||
33704352|NCT01164930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704353|NCT06557564|||COHORT||PROSPECTIVE|||||||
33704354|NCT01274078|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33704355|NCT04738331|||OTHER||RETROSPECTIVE|||||||
33704356|NCT06544889|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704357|NCT05230420|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704358|NCT04822324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704359|NCT03566160|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33704360|NCT05791188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33704361|NCT04555343|NA|SINGLE_GROUP||TREATMENT||NONE||convenience sampling of patients presenting to the emergency, all receiving intervention, no blinding||||
33704362|NCT06558266|||COHORT||PROSPECTIVE|||||||
33704363|NCT05399654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704364|NCT02000583|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704365|NCT03197454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704366|NCT02292121|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704367|NCT03424200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704368|NCT02236403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34093114|NCT00552903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093115|NCT00620542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093116|NCT04003571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704369|NCT02341365|||COHORT||RETROSPECTIVE|||||||
33704370|NCT03719612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704371|NCT03994107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704372|NCT03108677|||COHORT||PROSPECTIVE|||||||
33704373|NCT05274880|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704374|NCT04493112|||COHORT||PROSPECTIVE|||||||
33704375|NCT00846235|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33704376|NCT03854201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the screening phase, all electronic questionnaire data will be collected in the form of pseudonymity i.e. using only the numeric identification codes. All data (results of blood samples, fitness tests, research accelerometers) will be saved and analysed using only the codes.|"Randomized Controlled Trial with two-arm study design:~1. Intervention-arm: Face-to-face Personalized Exercise Counseling combined with interactive ExSed® accelerometer (PEC)~2. Non-treament-arm: Participation in the study measurement only, and written information with individual feedback on blood sugar and lipid profile, fitness test results and objectively measured physical activity 24/7 after each of the four measurement points (Control-arm)"|f|f|t|f
33704377|NCT04489628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704378|NCT01872364|||COHORT||RETROSPECTIVE|||||||
33704379|NCT00242320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704380|NCT02761785|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33704381|NCT02747875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704382|NCT01421914|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
33704383|NCT04203654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704384|NCT04567498|NA|SINGLE_GROUP||SCREENING||NONE|The research subjects, breath sample takers, and laboratory sample examiners do not know the results of each sampling that has been done. The final data processor is also blinded to the results of Xpert or other laboratory examinations. The breath sampling data is saved in graphic form which interpretation will be carried out later by the data processor at the final stage.|The Validation phase involves presumptive TB patients (Group 1) and the Screening phase involves residents of area with high risk of TB (Group 2)||||
33704385|NCT03837860|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Double-blinded, crossover study|t|f|t|t
33704386|NCT06533917|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33704387|NCT06004362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704388|NCT02164214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704389|NCT00853775|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33704390|NCT02720809|||COHORT||CROSS_SECTIONAL|||||||
33704391|NCT06453278|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33704392|NCT03534414|||OTHER||PROSPECTIVE|||||||
33704393|NCT06250777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789535|NCT06331754|RANDOMIZED|PARALLEL||TREATMENT||NONE||non-blinded pragmatic cluster-randomized controlled trial with a single intervention||||
33789536|NCT02460484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789537|NCT05233137|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 allocation||||
33789538|NCT02404064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704394|NCT03506789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704395|NCT04502433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Seventy patients will be randomized in the study with a ratio 3:2 (i.e. 42 patients in the poractant alfa arm and 28 in the control arm).||||
33704396|NCT03791138|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704397|NCT04747509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704398|NCT01743352|||CASE_CONTROL||PROSPECTIVE|||||||
33704399|NCT04128085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704400|NCT04819308|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33704401|NCT04505631|||COHORT||PROSPECTIVE|||||||
33704402|NCT06298825|||COHORT||PROSPECTIVE|||||||
33789539|NCT00136721|||||PROSPECTIVE|||||||
33789540|NCT00001886||||TREATMENT||||||||
33789541|NCT05903027|||CASE_ONLY||PROSPECTIVE|||||||
33789542|NCT05130060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789543|NCT05826704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33789544|NCT03603717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be informed that they are receiving one of two non-medication sleep interventions. Assessors are blinded to study condition. Study staff entering data will be blinded to condition. It is not possible to blind staff delivering the interventions. The PI's are providing some supervision of the interventionists, so they will be unblinded for those participants they supervise interventionists on.|Two parallel study arms: (1) cognitive behavioral therapy for insomnia (the experimental condition) and (2) sleep hygiene (the control condition).|t|f|f|t
33929143|NCT04290403|RANDOMIZED|CROSSOVER||OTHER||NONE||Crossover trial of briefs with tapes versus pull ups for the containment of urinary incontinence||||
33929144|NCT01455233|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33929145|NCT04631913|||OTHER||PROSPECTIVE|||||||
33929146|NCT01150760|||CASE_CONTROL||RETROSPECTIVE|||||||
33929147|NCT02175303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929148|NCT00381719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33789545|NCT03396835|NA|SINGLE_GROUP||OTHER||NONE||||||
33789546|NCT00286663|||||PROSPECTIVE|||||||
33929149|NCT04153929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial has a double blind design within each dose group. Patients, investigators and everyone involved in trial conduct or analysis or with any other interest in this trial will remain blinded with regard to the randomized treatment assignments until after database lock. The semaglutide group is open label.||t|t|t|t
33929150|NCT02731976|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929151|NCT02266004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929152|NCT03976518|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label clinical trial||||
33789547|NCT02135458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33789548|NCT05337657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929153|NCT01999348|||CASE_ONLY||PROSPECTIVE|||||||
33929154|NCT01107288|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33929155|NCT05351190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929156|NCT05210621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929157|NCT03064269|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33929158|NCT00055094|||DEFINED_POPULATION||PROSPECTIVE|||||||
33929159|NCT00198367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929160|NCT02395575|||COHORT||PROSPECTIVE|||||||
33929161|NCT01489761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789549|NCT03553446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789550|NCT05518201|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33789551|NCT03665090|||COHORT||PROSPECTIVE|||||||
33789552|NCT00431808|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33789553|NCT00580073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789554|NCT04741971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33789555|NCT06630910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789556|NCT00866554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33789557|NCT01085279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33789558|NCT01178762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093117|NCT03601052|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The treatment administered to each of two wound sites will be randomized (left versus right), such that all subjects will receive both remlarsen and placebo in a double-blinded fashion.|Up to 6 cohorts of 12-16 subjects each may be enrolled to study various dose levels and dosing regimens.|t|f|t|t
34093118|NCT04197973|||COHORT||PROSPECTIVE|||||||
34093119|NCT01013753|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34093120|NCT00576615|||CASE_CONTROL||PROSPECTIVE|||||||
33789559|NCT03593291|||COHORT||PROSPECTIVE|||||||
33789560|NCT04333069|NA|SINGLE_GROUP||SCREENING||NONE||||||
33789561|NCT00221078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789562|NCT05586230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789563|NCT05969860|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33789564|NCT02588638|||OTHER||OTHER|||||||
33929162|NCT02180490|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789565|NCT02317016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789566|NCT00639366|RANDOMIZED|||PREVENTION||||||||
33789567|NCT06009419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789568|NCT02906306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33789569|NCT03875248|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"The arm 1 of the study has been designed as a multicentric prospective pilot study.~The arm 2 of the study has been designed as a monocentric prospective pilot study.~The arm 3 of the study has been designed as a monocentric prospective pilot study."||||
33789570|NCT05936242|||COHORT||CROSS_SECTIONAL|||||||
33789571|NCT03100162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789572|NCT02770040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789573|NCT06502769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33789574|NCT02390557|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Randomization was performed at the level of primary care practice. Providers and patients were unaware of assignment to study arms|control v Survey v YESHealth|t|t|f|f
33789575|NCT02333630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789576|NCT02308358|||COHORT||PROSPECTIVE|||||||
33789577|NCT00329732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789578|NCT03357341|||COHORT||PROSPECTIVE|||||||
33929163|NCT01927887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929164|NCT02020291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929165|NCT00588523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929166|NCT05872698|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Triple-blinded||t|t|t|t
33929167|NCT04953845|||COHORT||RETROSPECTIVE|||||||
33929168|NCT00889980|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929169|NCT06043934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929170|NCT02239367|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33929171|NCT06241820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929172|NCT03678818|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33929173|NCT04111653|NA|SINGLE_GROUP||OTHER||NONE||||||
33929174|NCT04493463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33929175|NCT05983042|||COHORT||PROSPECTIVE|||||||
33929176|NCT05719077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Nurses and social workers are organized into interdisciplinary teams (IDTs) based on geographic location. Patients and families in those geographic are assigned to clinicians' individual caseloads. The investigators will randomize up to 14 IDTs of 6-8 clinicians each to the intervention and control groups. Six teams will be randomized at the beginning of the study. The remaining 8 teams will be adaptively randomized as they enter the study to maintain balance between the number of Black and White family caregiver participants in each arm. Family caregivers will be assigned to the same group (intervention or control) as the clinician they are assigned to. IDT assignment to intervention and control groups will be balanced based on characteristics including patients' racial/ethnic group membership and neighborhood socioeconomic status.||||
34008117|NCT06615947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The eligibility of the subjects from the neurorehabilitation and neurology outpatient clinics of the Multiple Sclerosis Center of Catalonia (Cemcat) will be evaluated.~And the blinded outcome assessor comes in for just one day to assess each individual, without any information about the therapy that was given to each patient."|"This trial is a prospective, randomized, rater-blinded study (cRHB (N=30) vs RAGT (N=30)).~For the control group, this protocol includes 24 one-hour sessions of cRHB training during 8 weeks three times per week, under the supervision of a qualified rehab team.~For the intervention group (RAGT) this protocol includes 24 one-hour sessions of RAGT during 8 weeks three times per week, under the supervision of a qualified rehab team.~Informed consent will be obtained from patients prior to inclusion in the study, which will be carried out in accordance with the Declaration of Helsinki."|f|f|f|t
33789579|NCT02586454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33789580|NCT01608971|||COHORT||PROSPECTIVE|||||||
33789581|NCT00423007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789582|NCT03624582|||COHORT||CROSS_SECTIONAL|||||||
33789583|NCT03955640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789584|NCT03203356|||CASE_CONTROL||PROSPECTIVE|||||||
33789585|NCT02364518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789586|NCT01322919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789587|NCT04097626|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929177|NCT00084604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929178|NCT03023605|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33929179|NCT03065920|||COHORT||PROSPECTIVE|||||||
34093121|NCT00834938|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093122|NCT00532103|||COHORT||PROSPECTIVE|||||||
34093123|NCT00139516|RANDOMIZED|||PREVENTION||||||||
34093124|NCT03204825|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Primary outcome assessors will be blinded for patient group allocation|2x2 randomised feasibility controlled trial blinded for primary outcome|t|f|f|t
34093125|NCT02649933|||COHORT||PROSPECTIVE|||||||
34093126|NCT01410604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093127|NCT02328274|||CASE_ONLY||RETROSPECTIVE|||||||
34093128|NCT01348698|||COHORT||PROSPECTIVE|||||||
34093129|NCT01078545|||CASE_ONLY||PROSPECTIVE|||||||
34093130|NCT05371704|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34093131|NCT04565938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34093132|NCT01851512|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34093133|NCT01888588|||COHORT||RETROSPECTIVE|||||||
34093134|NCT03570424|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Participants are block randomised to one of three nutrient conditions on provision of informed consent. This information is held by the PI and members of the research team independent of the outcomes assessor (masked). All three beverages are made up by members of the research team independent of the outcomes assessor (masked) and the participants (masked). Each participant (masked) is provided with a drink in a black, non-transparent, container with no details of its contents other than that is a nutrient supplement."|A randomly assigned, parallel group, simple pre-post design has been adopted to answer this question. 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Fasted placebo (0.33g.kg-1 body artificially flavoured and textured placebo); ii) Fed Whey protein (0.33g.kg-1 body mass intact whey protein 45 minutes prior to exercise); iii) Fed Whey protein hydrolysate (0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to exercise). Participants will undergo biological sampling (venous blood and muscle biopsy) and measures of performance pre and post the intervention.|t|f|f|t
34093135|NCT05276453|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomised to either an experimental (Lower limb compression suit) or active comparator group||||
33704403|NCT05546502|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Vaccine candidate and active comparator are masking|Vaccine candidate and active comparator are masking|t|f|t|t
33704404|NCT00109122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33704405|NCT05190237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33704406|NCT00983437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704407|NCT00273546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704408|NCT01896050|||COHORT||PROSPECTIVE|||||||
33704409|NCT03127410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator is blinded to intervention|||||
33704410|NCT03597880||SEQUENTIAL||SCREENING||NONE||retrospective clinical trial||||
33704411|NCT01523535|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants were randomized to condition. Vascular reactivity testing was performed by operator who was blind to condition and outcomes assessment from that testing was also blind.||f|f|t|t
33704412|NCT03441711|||CASE_CONTROL||PROSPECTIVE|||||||
33704413|NCT05428046|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704414|NCT00247871|||CASE_ONLY||RETROSPECTIVE|||||||
33704415|NCT06212154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704416|NCT03873974|||OTHER||PROSPECTIVE|||||||
33704417|NCT02130297|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704418|NCT01523262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704419|NCT00583973|||COHORT||PROSPECTIVE|||||||
33704420|NCT03889106|||COHORT||PROSPECTIVE|||||||
33704421|NCT05306977|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Aim 1: Outcome measures. Anxiety potentiated startle (APS) Statistical Analysis. The main analysis will be a paired-sample t-test (pre vs. post stimulation).~Aim 2: Outcome measures. Accuracy and reaction time during the visual short term memory task (VSTM). Statistical Analysis. The main analysis will be a 2 \[stimulation: pre-stimulation vs. post-stimulation\] by 2 \[load: low vs. high\] repeated-measures ANOVA. Safety and Adverse Events"||||
33789588|NCT02642419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789589|NCT02685280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789590|NCT06103240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789591|NCT02156635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929180|NCT04984460|||CASE_ONLY||PROSPECTIVE|||||||
33929181|NCT03513289|||COHORT||RETROSPECTIVE|||||||
33929182|NCT01852630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929183|NCT02499575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33929184|NCT00365768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33929185|NCT02435862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929186|NCT03703960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929187|NCT00126672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929188|NCT03420313|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized parallel two-group trial||||
33929189|NCT00719524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929190|NCT01462968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929191|NCT04673669|NA|SINGLE_GROUP||OTHER||NONE||||||
33929192|NCT02338167|||CASE_ONLY||OTHER|||||||
33929193|NCT04466813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33929194|NCT01562145|||CASE_CONTROL||PROSPECTIVE|||||||
33929195|NCT00821899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929196|NCT03359304|||FAMILY_BASED||PROSPECTIVE|||||||
33929197|NCT01143714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929198|NCT04572698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008118|NCT06532357|||COHORT||RETROSPECTIVE|||||||
34093136|NCT06520059|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, blinding (masking) will be applied to the outcome assessors. Patients will notice which specific type of PRP injection (intraosseous or intra-articular) they are receiving. Outcome assessors who evaluate the VAS scores, KOOS, and MRI results will also be blinded to the group assignments to prevent bias in the assessment of the results.|This study is a prospective cohort, parallel design clinical trial comparing the efficacy of intraosseous versus intra-articular injections of PRP for treating advanced knee osteoarthritis. Patients are matched for sex and age, and outcomes are assessed using VAS scores, KOOS, and MRI evaluations over a 12-month period. The study aims to determine which injection method provides superior pain relief and functional improvement.|f|f|t|f
34008119|NCT06616480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008120|NCT02827396|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34008121|NCT06015113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008122|NCT06029582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093137|NCT02214732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093138|NCT04625166|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093139|NCT01053468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093140|NCT06053229|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized, parallel design||||
34093141|NCT02482844|NON_RANDOMIZED|PARALLEL||||NONE||||||
34093142|NCT00380094|||COHORT||PROSPECTIVE|||||||
34093143|NCT05278091|||COHORT||RETROSPECTIVE|||||||
34093144|NCT01609387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093145|NCT00119639|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093146|NCT00744198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093147|NCT06302036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||EFT will be applied and surveys will be administered to the intervention group. No application will be made to the control group and surveys will be asked.|t|f|f|f
34093148|NCT05098990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093149|NCT01980576|||COHORT||PROSPECTIVE|||||||
34093150|NCT05297838|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093151|NCT04567589|||OTHER||OTHER|||||||
34093152|NCT02927145|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929199|NCT04123431|||COHORT||PROSPECTIVE|||||||
33929200|NCT04229069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929201|NCT03121768|||COHORT||PROSPECTIVE|||||||
33929202|NCT01755741|RANDOMIZED|CROSSOVER||OTHER||NONE||IPM 029 is an open-label, randomized, two-period, crossover non-inferiority trial conducted at two research centers in the U.S. to assess condom functionality during vaginal intercourse in healthy, monogamous heterosexual, sexually active couples.||||
33929203|NCT05521646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participants do not know if they go to an intervention or control clinic|cluster randomized controlled trial|t|f|f|f
33929204|NCT03705260|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929205|NCT00899678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929206|NCT05636904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929207|NCT00003250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929208|NCT06245681|||COHORT||PROSPECTIVE|||||||
33929209|NCT01559701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929210|NCT05474989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929211|NCT02928666|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33929212|NCT04913571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008123|NCT03753776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither patients receiving pills nor doctors evaluating radiodermatitis know the nature of treatment (placebo or homeopathy)|A first randomization will establish two groups : placebo versus homeopathy (Radium bromatum), and if patients develop a radiodermatitis of grade 2 or higher, a second randomization will take place, with two groups : placebo versus homeopathy (Radium bromatum, Apis mellifica, and Belladonna)|t|t|t|t
34008124|NCT05120024|||OTHER||OTHER|||||||
34008125|NCT06151067|||COHORT||RETROSPECTIVE|||||||
34008126|NCT04987008|||COHORT||RETROSPECTIVE|||||||
33704422|NCT01213329|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1: 50 subjects were to receive study intervention. If any subjects demonstrated persistent donor specific unresponsiveness at the 12 month post-transplant time point, they would proceed into Phase 2. In that phase, the unresponsive subjects would have been randomized to one of three arms that would modify their standard of care immunosuppression.~None of the 50 subjects from Phase 1 demonstrated persistent donor specific unresponsiveness, therefore, phase 2 was never started."||||
33704423|NCT04811885|||COHORT||CROSS_SECTIONAL|||||||
33704424|NCT05282329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704425|NCT04286750|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33704426|NCT03109249|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704427|NCT00719108|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33704428|NCT05499858|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33704429|NCT05236296|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All study participants will receive the EASE-CG intervention.||||
33704430|NCT04907903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704431|NCT00760123|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704432|NCT01362569|||COHORT||PROSPECTIVE|||||||
33704433|NCT02758990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704434|NCT00392015|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33704435|NCT02896387|||OTHER||CROSS_SECTIONAL|||||||
33704436|NCT03844932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be conducted as a double-blind study. Both the Investigator and subjects will be blinded with respect to the treatment the subject will receive. In addition, the central reader of the endoscopy assessment will be blinded to subject treatment for the entire study.|The study will investigate ST-0529 doses of 18.75 mg BID, 37.5 mg BID, or 75 mg BID, versus matching placebo BID.|t|f|t|t
33704437|NCT01459081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704438|NCT02846714|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33704439|NCT00860483|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33704440|NCT00462566|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33704441|NCT04624646|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33704442|NCT00487175|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33704443|NCT00540774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking other than an anonymization of data.|||||
33704444|NCT04863040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704445|NCT05046899|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intra-patient design.||||
33704446|NCT06464796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704447|NCT03851523|||OTHER||PROSPECTIVE|||||||
33704448|NCT03214146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008127|NCT04305990|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will not be told the order the gas flow delivery method (DD or FF) they will be receive. To assist with masking participants, the same device and nasal hood will be used throughout, they will be told to face forward away from the device and device display, which indicates the setting of the gas flow. It will not be feasible to blind the researcher as the researcher will need to change the device setting (FF or DD).|The study design is a within-subjects, single-blinded, randomized controlled trial. Each participant will receive both the free-flow (FF) and demand-driven (DD) gas delivery methods in a randomized sequence.|t|f|f|f
34008128|NCT05804435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008129|NCT06609434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was divided into two groups, the interventional group was: systemic therapy combined with radiofrequency therapy, the control group was: systemic therapy alone.||||
34008130|NCT05802446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704449|NCT01267045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704450|NCT05133232|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be conducted by a study staff who is blinded to the allocation of the subject.|Prospective cohort study|f|f|f|t
33704451|NCT03844880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704452|NCT01768286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704453|NCT06371443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704454|NCT01206348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704455|NCT02152722|||COHORT||CROSS_SECTIONAL|||||||
33704456|NCT00303173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704457|NCT01337700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801732|NCT05087758|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a multicenter, randomized, controlled, open-label trial designed to evaluate the safety and efficacy of Matrion on the wound healing rate of diabetic foot ulcers.||||
33704458|NCT06442280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be categorized into 4 groups: the first group will undergo 15 minutes intravenous infusion of furosemide combined with hypertonic saline solution (100 mL) twice daily along with severe water restriction (\< 500 mL); the second group will receive intravenous furosemide as a bolus twice daily and severe water restriction (\< 500 mL) without hypertonic saline solution; the third group will undergo 15 minutes intravenous infusion of furosemide combined with hypertonic saline solution (100 mL) twice daily, severe water restriction (\< 500 mL), and SGLT2 inhibitors (Dapagliflozin); the fourth group will receive intravenous furosemide as a bolus without hypertonic saline solution twice daily, severe water restriction (\< 500 mL), and SGLT2 inhibitors (Dapagliflozin).|t|f|f|f
33704459|NCT00531271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704460|NCT01813188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704461|NCT03572972|||COHORT||RETROSPECTIVE|||||||
33704462|NCT03203616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704463|NCT01253408|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33704464|NCT03840174|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33704465|NCT05047835|||COHORT||PROSPECTIVE|||||||
33704466|NCT02339935|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33704467|NCT05167929|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704468|NCT00261183|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33704469|NCT01397890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704470|NCT03228433|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33704471|NCT00222443|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704472|NCT02846584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704473|NCT03416725|||CASE_ONLY||PROSPECTIVE|||||||
33704474|NCT04271527|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33704475|NCT02408627|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33704476|NCT03433157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704477|NCT01373242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704478|NCT03076320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704479|NCT02283619|||COHORT||PROSPECTIVE|||||||
33704480|NCT04987398|||CASE_ONLY||RETROSPECTIVE|||||||
33704481|NCT00399750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704482|NCT01139489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704483|NCT02086383|||COHORT||PROSPECTIVE|||||||
33704484|NCT03998930|NA|SINGLE_GROUP||OTHER||NONE||||||
33704485|NCT02624609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33704486|NCT04549857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33704487|NCT05737589|||COHORT||RETROSPECTIVE|||||||
33704488|NCT00069940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704489|NCT06069505|||COHORT||PROSPECTIVE|||||||
33704490|NCT05472831|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704491|NCT00259610|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33929213|NCT05169736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929214|NCT00578422|||CASE_CONTROL||PROSPECTIVE|||||||
33929215|NCT00475371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704492|NCT06270810|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33704493|NCT04530526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704494|NCT04299074|NA|SINGLE_GROUP||SCREENING||NONE||||||
33704495|NCT05190588|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled clinical study||||
33704496|NCT02077816|||||PROSPECTIVE|||||||
33929216|NCT05904938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind||t|t|t|t
33929217|NCT02539524|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929218|NCT03087708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33929219|NCT06372613|||COHORT||PROSPECTIVE|||||||
33929220|NCT03208049|RANDOMIZED|PARALLEL||TREATMENT||NONE||Our hypotheses will be tested in a randomized parallel groups design. Randomization will be based on type of treatment assignment: either to Sleep Restriction (SR) or to Cognitive Therapy (CT). After screening and randomization in the 2-week baseline phase, subjects will receive SR or CT in the 6-week treatment phase. There will be no more treatment after this point. At the end of the 6-week treatment, subjects will return to repeat many of the psychological tests.||||
33929221|NCT02758912|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33929222|NCT00671619|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33929223|NCT05446922|NA|SINGLE_GROUP||OTHER||NONE||||||
33929224|NCT01551927|||||PROSPECTIVE|||||||
33929225|NCT00735098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929226|NCT03940014|||COHORT||RETROSPECTIVE|||||||
33929227|NCT03688945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929228|NCT04602702|||CASE_ONLY||PROSPECTIVE|||||||
33929229|NCT02999191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929230|NCT02095990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929231|NCT06052189|||OTHER||PROSPECTIVE|||||||
33929232|NCT00846469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929233|NCT02840032|||CASE_ONLY||PROSPECTIVE|||||||
33704497|NCT01466153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704498|NCT02821169|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33704499|NCT05903170|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomized to undergo cardioversion with one of two defibrillators at either 200J or 360J. Randomization will occur by a random number generator, and the chance of being in either arm is 50%.~Participants in each arm will undergo up to three shocks at the energy-level to which they have been randomized, using a standardized procedure. For participants randomized to the lower energy level who fail to return to normal rhythm after three shocks, they will be given a fourth shock at the higher energy level."||||
33704500|NCT05086926|NA|SINGLE_GROUP||OTHER||NONE||||||
33704501|NCT01235689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704502|NCT02403986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704503|NCT02118883|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33704504|NCT00092638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704505|NCT02459301|NA|SINGLE_GROUP||OTHER||NONE||||||
33704506|NCT03180073|||CASE_ONLY||PROSPECTIVE|||||||
33704507|NCT03059758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704508|NCT05834374|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33704509|NCT00547495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704510|NCT02911220|NA|SINGLE_GROUP||OTHER||NONE||||||
33929234|NCT01921452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929235|NCT00081939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929236|NCT01318668|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33704511|NCT00968214|||CASE_CONTROL||PROSPECTIVE|||||||
33704512|NCT00570570|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33704513|NCT02916589|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33704514|NCT00411528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704515|NCT01760629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704516|NCT06144281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33704517|NCT06383936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704518|NCT04099628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Sequential assignement||||
33704519|NCT01254032|||||PROSPECTIVE|||||||
33704520|NCT02178735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929237|NCT00017628||||TREATMENT||||||||
33929238|NCT01046513|||||OTHER|||||||
33929239|NCT02645461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33929240|NCT03120741|||CASE_CONTROL||OTHER|||||||
33929241|NCT04516031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929242|NCT01918683|RANDOMIZED|PARALLEL||TREATMENT||NONE||two arms||||
33929243|NCT05939271|||COHORT||RETROSPECTIVE|||||||
33929244|NCT03718676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929245|NCT02605941|||COHORT||PROSPECTIVE|||||||
33929246|NCT05381207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929247|NCT03460613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929248|NCT05906576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929249|NCT00251589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929250|NCT01733836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929251|NCT01831778|||COHORT||PROSPECTIVE|||||||
33929252|NCT00113711|RANDOMIZED|||PREVENTION||||||||
33929253|NCT04571476|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929254|NCT03370913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929255|NCT05176860|NA|SINGLE_GROUP||OTHER||NONE||This is a single-site study designed to generate data describing the quality and applicability of on-couch high-performance CBCT imaging for anatomy visualization and radiation treatment dosimetry planning.||||
33929256|NCT02420990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704521|NCT03386448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and physician are both blinded to medication vs. control medication|Double blinded, randomized, controlled parallel design|t|t|f|f
33929257|NCT00692588|||CASE_CONTROL||PROSPECTIVE|||||||
33929258|NCT05063968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929259|NCT01498588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929260|NCT01689766|NA|SINGLE_GROUP||OTHER||NONE||||||
33929261|NCT06307977|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||This study utilizes a randomized controlled trial design to evaluate the efficacy of couples motivational interviewing (MI) to reduce the frequency and severity of illicit drug use and frequency of HIV transmission risk behavior (TRB). Participants are randomized to one of two conditions: couples MI or standard couples HIV testing and counseling (CHTC).||||
33929262|NCT05409690|||COHORT||PROSPECTIVE|||||||
33929263|NCT01675206|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33929264|NCT06269757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929265|NCT02409147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929266|NCT03381911|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There are 2 study arms: ECA and E-Consent. In the ECA group subjects will have the consent form reviewed with them by the Embodied Conversational Agent character. In the E-Consent group (the standard of care), subjects will review the consent form on a computer screen with the option to have it read to them verbatim.||||
33929267|NCT01112982|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929268|NCT04337723|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33929269|NCT01314469|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929270|NCT00004852||||TREATMENT||DOUBLE||||||
33704522|NCT04728399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33704523|NCT01826188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704524|NCT02990689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704525|NCT00509444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704526|NCT00667407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704527|NCT05953311|||COHORT||PROSPECTIVE|||||||
33704528|NCT00791570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704529|NCT00765557|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to laxative versus placebo arms.|A prospective randomized, double-blind, placebo controlled study was performed to determine whether placebo-controlled versus Polyethylene glycol (MiraLAX) was effective for decreasing OAB symptoms.|t|f|t|f
33704530|NCT00303901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704531|NCT06487585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704532|NCT04937231|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704533|NCT05871775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704534|NCT03857893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704535|NCT06188338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704536|NCT05597371|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33704537|NCT05593588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704538|NCT06506682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704539|NCT01142271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33704540|NCT01895062|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33704541|NCT00940160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704542|NCT01533077|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704543|NCT01064310|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33704544|NCT03974191|||COHORT||PROSPECTIVE|||||||
33704545|NCT01705990|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704546|NCT06533722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704547|NCT00272012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704548|NCT01785264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704549|NCT04258163|||COHORT||RETROSPECTIVE|||||||
33704550|NCT03084770|||COHORT||PROSPECTIVE|||||||
33704551|NCT03098121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704552|NCT04557631|||COHORT||PROSPECTIVE|||||||
33704553|NCT01128556|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33704554|NCT03423641|||COHORT||RETROSPECTIVE|||||||
33704555|NCT00639431|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33704556|NCT01972100|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33704557|NCT05847855|||COHORT||PROSPECTIVE|||||||
33704558|NCT03405584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704559|NCT02834039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704560|NCT05902520|RANDOMIZED|PARALLEL||TREATMENT||NONE||Autologous adoptive T cell therapy provided to three cohorts of patients receiving supportive subcutaneous IL-2 therapy for one, two ,or three weeks. Each cohort will be randomized between therapy with DP CD8 TIL or DP CD8 TIL having PD-1 expression reduced by silencing RNA during invitro cell expansion||||
33704561|NCT03806972|||COHORT||PROSPECTIVE|||||||
34008131|NCT04374799|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33929271|NCT02715596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Placebo (EPA)|eicosapentanoic acid (EPA) versus placebo|t|t|t|f
33929272|NCT01620008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized trial (with a preference arm)|f|f|f|t
34008132|NCT04512326|||COHORT||RETROSPECTIVE|||||||
34008133|NCT04116151|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind: both the patient and the healthcare professional do not know if the cream to be tested or the placebo is applied|Experimental, prospective, controlled clinical trial, with two parallel arms, double blind, multicenter study|t|t|f|f
34008134|NCT01254461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008135|NCT06615934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704562|NCT04352569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704563|NCT03326544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704564|NCT01884480|||COHORT||RETROSPECTIVE|||||||
33704565|NCT00816920|||COHORT||PROSPECTIVE|||||||
33704566|NCT06358820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704567|NCT06251752|NON_RANDOMIZED|PARALLEL||OTHER||NONE||cohort 1: lateral closing wedge high tibial osteotomy cohort 2: medial opening wedge high tibial osteotomy||||
33704568|NCT05108662|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704569|NCT01146834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704570|NCT00985023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704571|NCT05043909|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704572|NCT02938104|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008136|NCT01100450|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34008137|NCT02219308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008138|NCT02045524|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33704573|NCT06323057|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blinded to the TMS condition (active or sham)||t|f|f|f
33704574|NCT03809676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33929273|NCT05070741|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective, observational cohort pilot study will recruit 20 patients with prediabetes with or without peripheral neuropathy (painful and non-painful) to participate in a 4-week heat therapy intervention. After screening, informed consent, and enrollment into the study, subjects will undergo a pre-intervention evaluation that will assess metabolic biomarkers and heat shock protein levels (blood), peripheral neuropathy, and epidermal evaluation (skin biopsy). After the skin biopsy has the appropriate time to heal (approximately 7-14 days), the subjects will undergo 45-minute heat treatments in 40°C water, three times weekly, for 4 weeks. After completion of heat treatments, subjects will undergo a repeated post-intervention evaluation and skin biopsy. Statistical approaches will compare pre- and post-heat therapy measures.||||
33929274|NCT06013319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008139|NCT05164913|||COHORT||RETROSPECTIVE|||||||
34008140|NCT06534931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were unaware of the existence of a control group.||t|f|f|f
34008141|NCT00925756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008142|NCT00707447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008143|NCT05041114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801733|NCT03344588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients accept to participate have to sign a written informed consent and will be unaware of randomization.||t|f|f|f
33929275|NCT04857892|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study|This is a 2-part crossover study.||||
33929276|NCT03551184|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34008144|NCT03669016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34008145|NCT05183698|||COHORT||PROSPECTIVE|||||||
34008146|NCT04778306|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008147|NCT00401245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929277|NCT06394076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008148|NCT05997940|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34008149|NCT02420626|||CASE_CONTROL||PROSPECTIVE|||||||
34008150|NCT05549050|||COHORT||PROSPECTIVE|||||||
34008151|NCT01778478|||COHORT||PROSPECTIVE|||||||
34008152|NCT00005026||||TREATMENT||||||||
34008153|NCT02210052|NA|SINGLE_GROUP||SCREENING||NONE||||||
33929278|NCT05544071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929279|NCT05132595|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33929280|NCT00643448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929281|NCT02671760|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33929282|NCT01292525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929283|NCT03429504|||CASE_CONTROL||RETROSPECTIVE|||||||
33929284|NCT00076921|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34008154|NCT00090116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34008155|NCT05601076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008156|NCT05433259|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34008157|NCT02060045|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34008158|NCT03253094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, double-dummy, active-controlled, dose-finding|t|t|t|t
34008159|NCT05409521|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34008160|NCT00715091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008161|NCT01758133|||CASE_CONTROL||PROSPECTIVE|||||||
34008162|NCT03936218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008163|NCT01144403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008164|NCT05976724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator and Outcomes Assessor are different people. The Outcome Assessor was blind to groups.|Randomized Controlled Trial|f|f|f|t
34008165|NCT02397213|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008166|NCT01525654|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008167|NCT04499378|||COHORT||PROSPECTIVE|||||||
34008168|NCT06224855|NA|SEQUENTIAL||TREATMENT||NONE||Dose 1:Drug(DXC006), Dose 2:Drug(DXC006), Dose 3:Drug(DXC006), Dose 4:Drug(DXC006), Dose 5:Drug(DXC006), Dose 6:Drug(DXC006).||||
34008169|NCT01913795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008170|NCT06617676|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of of the three groups in parallel for the duration of the study. The variable in the intervention will be the number of treatments they receive per week.||||
34008171|NCT00122447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008172|NCT03899649|||COHORT||PROSPECTIVE|||||||
34008173|NCT02506218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093153|NCT04077398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed with software excel or spss. This randomization will be kept in an envelope. After the patient consents participation in the study, the investigator and the care provider will open the envelope and will perform the block according to the established in the randomization. The patient or the outcomes assessor will not have access to the volume and concentration used during the block. Will be the responsibility of investigators to keep in a safe place the information about the block received by the patients.|The study will be conducted as a prospective, randomized, double blinded, parallel trial at the University of Pittsburgh Medical Center (UPMC) Shadyside Hospital.|t|f|f|t
34093154|NCT04339972|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34093155|NCT02587286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093156|NCT04106284|||OTHER||PROSPECTIVE|||||||
34093157|NCT04441398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomized to receive either nitazoxanide (n=150) or placebo (n=150)|t|t|t|t
34093158|NCT04413851|||COHORT||PROSPECTIVE|||||||
34093159|NCT00062504||PARALLEL||TREATMENT||||||||
33929285|NCT03771989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"4.4.1 Randomization Randomization is computer based, performed in blocks of twelve.~4.4.2 Blinding Blinding of the patient is secured as follows: The liposuction and microfragmentation of the fatty tissue is performed in the operating theatre. When the graft is ready for use the randomization envelope is opened by the project nurse; if the patient is allocated to active treatment syringes containing the microfragmented fatty tissue are prepared; if the patient is allocated to placebo syringes containing saline are prepared. The 10ml syringe is placed in the hand of the treating surgeon. Injection is performed with a 21G cannula. Due to the difference in viscosity of the graft and saline, the surgeon cannot be blinded.~In order to investigate if the blinding is working the patients will be asked at 6 months follow up which group he/she believe he/she was assigned to."|"The study is performed as a blinded, multicenter, randomized, controlled trial with participants individually randomized to one of two parallel groups:~1. The intervention group: Participants receive one intra articular injection with autologous, microfragmented adipose tissue.~2. The control group: Participants receive one intra articular injection with Saline (placebo)."|t|f|t|t
33704575|NCT04979468|RANDOMIZED|PARALLEL||OTHER||NONE||Phase III, randomized, open-label, multicentre, active-controlled, non-inferiority study evaluating the efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) in single-pill, in HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA \<50 copies/mL||||
33704576|NCT01942343|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33704577|NCT04383483|||CASE_ONLY||RETROSPECTIVE|||||||
34093160|NCT03387046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704578|NCT05325788|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33704579|NCT03636984|||COHORT||PROSPECTIVE|||||||
33704580|NCT01264757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704581|NCT03209531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704582|NCT04799977|||COHORT||RETROSPECTIVE|||||||
33704583|NCT04815681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33704584|NCT02548416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33704585|NCT04010695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704586|NCT04099147|||COHORT||OTHER|||||||
33704587|NCT04879628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part A is a 12-week, double-blind, placebo-controlled part; Part B is an open-label SAR441344 treatment part.|t|t|t|t
33704588|NCT03366038|||COHORT||PROSPECTIVE|||||||
33704589|NCT00329004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704590|NCT02136810|||COHORT||PROSPECTIVE|||||||
33704591|NCT02543710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704592|NCT05637866|||OTHER||OTHER|||||||
33704593|NCT01352104||CROSSOVER||PREVENTION||NONE||||||
33704594|NCT02509481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704595|NCT00330746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704596|NCT00316719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704597|NCT05097274|||CASE_ONLY||PROSPECTIVE|||||||
33704598|NCT03397537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929286|NCT00706615|NON_RANDOMIZED|||TREATMENT||NONE||||||
33929287|NCT01616069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33929288|NCT02574390|||CASE_ONLY||PROSPECTIVE|||||||
33929289|NCT04675801|||COHORT||PROSPECTIVE|||||||
33704599|NCT03948672|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||Randomized, single blinded, crossover clinical trial|t|t|t|t
33704600|NCT01298375|||COHORT||CROSS_SECTIONAL|||||||
33704601|NCT06271122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704602|NCT00438308|||COHORT||PROSPECTIVE|||||||
33704603|NCT00132652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704604|NCT02327065|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34093161|NCT04713995|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|All recruitment happens online. All nutritional recommendations look the same, but may be different between participants.|400 Participants are enrolled and paired matching for HLA-B27+ and control (mASDAS \<1.3) and case group (mASDAS = or \> 1.3) and compared to a healthy control group. Samples and surveys are collected from all participants. Then again at 3 months and 6 months if they agree to complete the longitudinal arms of the study.||||
34093162|NCT03543774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093163|NCT00200382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093164|NCT05875480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093165|NCT00222274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093166|NCT06374290|NA|SINGLE_GROUP||OTHER||NONE||||||
34093167|NCT05639595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34093168|NCT02927626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093169|NCT06523790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093170|NCT06430060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704605|NCT01589133|||CASE_CONTROL||PROSPECTIVE|||||||
34093171|NCT01146353|||COHORT||PROSPECTIVE|||||||
34093172|NCT01639521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093173|NCT04002271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an observer blinded randomized controlled trial. The patients will be aware of whether they received spinal anaesthesia (SA) or general anaesthesia (TIVA or GAS). The investigators responsible for assessing outcomes and collecting data will be blinded to patient allocation. The anaesthetist performing anaesthesia will be aware of patient allocation, but will not be involved in data collection.|Patients in group SA will undergo spinal anaesthesia. Patients in group GAS will undergo general inhalational anaesthesia using sevoflurane. Patients in group TIVA will undergo general anaesthesia using propofol total intravenous anaesthesia|f|f|t|f
34093174|NCT04822415|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093175|NCT04163380|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be blocked (four participants by block) and then randomized to start in one of the four menstrual cycle phases (EFP, LFP, ELP, or LLP). Their will be complete once they have gone through the four phases.||||
33704606|NCT01723345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704607|NCT04573712|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704608|NCT00231205|||CASE_CONTROL||PROSPECTIVE|||||||
33704609|NCT03868046|||COHORT||PROSPECTIVE|||||||
33704610|NCT00508365|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33704611|NCT05514418|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33704612|NCT03274596|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The placebo was made by a pharmacologist and was the only person who knows the treatment of A and B. The placebo was administered by nursing staff and had the same appearance and amount as vitamin E. Neither the parents of the participants nor the researchers involved in the care or analysis of the data knew the content of the treatment and B until the end of the study.|participants were randomly assigned to one of two treatmenst (A and B) using a computarized random number generator sequence; this process was handled by the hospital pharmacy staff. Group A: received vitamin E 12.5 IU orally every 12 hours, from 72 h after birth until 28 days of age, Group B: received orally sterile water (placebo) orally every 12 hours, from 72 h after birth until 28 days of age,|t|t|t|t
33704613|NCT03576612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Newly diagnosed HGG: surgically eligible patients AdV-tk into wall of resection cavity; 1-3 days post-surgery Valacyclovir d1-14; Day 8 RT for 6 wks; day 15 TMZ 75mg/m2 daily; Nivo 240mgIV every 2 weeks||||
33789592|NCT04409210|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization will be performed using a computerized randomization program in a uniform 1:1 allocation ratio for the family physician teams. Patients managed by the same family physician team will be assigned to the same group.||||
33929290|NCT06330090|||COHORT||PROSPECTIVE|||||||
33929291|NCT03273231|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34093176|NCT03526146|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Study participants will be randomly assigned to receive the PLIE intervention program (1 hour, 2 days/week, 4 months) or Usual Care (UC) control (standard senior center activities, 1 hour, 2 days/week, 4 months) (N=40, 20/group) using a wait-list design. After 4 months, the groups will cross-over. The UC group will receive the PLIE intervention while the first PLIE group will participate in standard senior center activities for 4 months.||||
34093177|NCT00429299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093178|NCT00848185|||COHORT||PROSPECTIVE|||||||
34093179|NCT02109224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093180|NCT06369181|||COHORT||PROSPECTIVE|||||||
34093181|NCT05909423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704614|NCT03556735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704615|NCT02544360|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704616|NCT01399814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704617|NCT04718571|||CASE_ONLY||RETROSPECTIVE|||||||
33704618|NCT05344365|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33704619|NCT04022850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33789593|NCT04800302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33789594|NCT00574184|||COHORT||CROSS_SECTIONAL|||||||
33789595|NCT04831684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33789596|NCT02242929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789597|NCT00092898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789598|NCT01362491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789599|NCT02487056|||COHORT||PROSPECTIVE|||||||
33929292|NCT03489850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789600|NCT05043987|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33789601|NCT00846313|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789602|NCT03635112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789603|NCT01696292|||CASE_ONLY||CROSS_SECTIONAL|||||||
33789604|NCT02835911|||COHORT||PROSPECTIVE|||||||
33789605|NCT01306331|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789606|NCT01496209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789607|NCT06003608|||COHORT||CROSS_SECTIONAL|||||||
33789608|NCT04837313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789609|NCT02347163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929293|NCT03990701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||11C-metomidate will be manufactured in Clinical Imaging Research Centre in compliance with good manufacturing practice using a General Electric Medical Systems PET trace 860 cyclotron. Non-contrast CT images will be acquired over the adrenal. After an intravenous injection of 11C-metomidate, PET images will be acquired within the first 45 min. Attenuation and decay-corrected images will be converted to standardized uptake value (SUV) maps through division by (injected activity per patient weight). The maximum SUV values over regions of interest will be determined for 10-min static images starting 35 min after the injection.||||
33929294|NCT02792660|NA|SINGLE_GROUP||OTHER||NONE||||||
34093182|NCT03061318|||COHORT||PROSPECTIVE|||||||
33789610|NCT06347952|||COHORT||PROSPECTIVE|||||||
33789611|NCT04386733|||OTHER||PROSPECTIVE|||||||
33789612|NCT04107129|||COHORT||PROSPECTIVE|||||||
33789613|NCT04265703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789614|NCT06631014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33789615|NCT02116829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33789616|NCT01233154|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33789617|NCT04923984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789618|NCT00347191|||COHORT||PROSPECTIVE|||||||
33789619|NCT04455009|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33789620|NCT02533908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929295|NCT00255034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929296|NCT03294772|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929297|NCT06148350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929298|NCT04250025|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomised into two groups:Experimental Group: 60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation Control Group: 60 patients benefit from standard treatment for 6 months i.e elastic compression and anticoagulation if needed. Notably, if patients were no longer on anticoagulant treatment at the time of screening and inclusion, this treatment will not be reintroduced.||||
33929299|NCT01628042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929300|NCT01234519|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 : conventional 3+3 design. Phase 2: Simon's two-stage design will be utilized. In Stage I, 22 patients will be treated with the dose determined in Phase I. The study will be terminated for futility if no more than 2 patients out of the 22 patients in Stage I are responders. If 3 or more responders are observed, an additional 18 patients will be enrolled. If at least 8 out of the 40 patients are responders, the treatment will be considered worthy of further development.||||
33929301|NCT05355818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929302|NCT04908969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929303|NCT00141401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929304|NCT03466671|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33929305|NCT00643097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929306|NCT00836303|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33929307|NCT05369533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded, placebo controlled, randomized. Participants and investigators will be blinded to the study group allocations (placebo vs Sinemet).|Patients are randomized to TR + placebo, TR + Sinemet, or usual care|t|t|t|t
33929308|NCT01821885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929309|NCT01378819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929310|NCT04125992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients enrolled to the study were randomized into Forearm Radial or Distal Radial groups. Care providers operated on patients and investigators collected their data during and after the operation. The independent variable - Access site (Forearm Radial or Distal Radial) - was coded into X or Z groups, then data was sent to the outcomes assessor.||f|f|f|t
33929311|NCT05045105|||COHORT||PROSPECTIVE|||||||
33929312|NCT05370079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929313|NCT06231641|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomised, double-blind, placebo-controlled crossover multi-center feasibility study|t|f|t|f
33929314|NCT00464711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929315|NCT03013621|||||PROSPECTIVE|||||||
33929316|NCT02011672|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33929317|NCT01847690|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33929318|NCT02835898|||||PROSPECTIVE|||||||
33929319|NCT06101316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929320|NCT05183646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study||t|t|t|t
33929321|NCT03788616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929322|NCT06330974|||COHORT||OTHER|||||||
33929323|NCT04409626|||CASE_CONTROL||PROSPECTIVE|||||||
33929324|NCT02402621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093183|NCT00552162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093184|NCT02428647|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093185|NCT05791084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT with an intervention and control group||||
34093186|NCT01483651|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34093187|NCT03685513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|f|t
34093188|NCT01696253|||CASE_ONLY||OTHER|||||||
34093189|NCT04675476|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34093190|NCT05737147|||COHORT||PROSPECTIVE|||||||
33789621|NCT02814305|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33789622|NCT04603014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789623|NCT00015457|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33929325|NCT02802072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929326|NCT02681731|||COHORT||RETROSPECTIVE|||||||
33929327|NCT04262791|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33929328|NCT04181957|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The research is double-blind. The pharmacists have prepared active and placebo capsules of LDX identical in appearance, and a scientist on the project who is not associated with data collection randomises the condition based on a random, counter-balanced design. The resulting capsule's contents are blind to the participant, data collectors, and the prescribing physician.|Counter-balanced, double-blind, placebo-controlled, crossover, within-subject design.|t|t|t|f
33929329|NCT00591162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929330|NCT04989660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929331|NCT01709708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929332|NCT05722977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929333|NCT04892680|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929334|NCT06034041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929335|NCT06033690|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the two groups were randomized by online program, into intervention group and control group||t|f|f|f
33929336|NCT05051176|||COHORT||PROSPECTIVE|||||||
33929337|NCT05691712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929338|NCT00300716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929339|NCT04437680|||CASE_ONLY||RETROSPECTIVE|||||||
33929340|NCT03538275|||COHORT||PROSPECTIVE|||||||
33929341|NCT03208075|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33929342|NCT03633994|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929343|NCT01340560|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33929344|NCT05846672|||COHORT||PROSPECTIVE|||||||
33929345|NCT04259060|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33929346|NCT04511338|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33929347|NCT00264095|||||CROSS_SECTIONAL|||||||
33929348|NCT03313856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Simple random. It was done with a table of numbers using random selection program Excel 2010.|Two study groups were formed that were randomly assigned with the closed envelope technique to the corresponding group. Group Placebo vs. Guazuma ulmifolia plusTecoma stans|t|f|t|f
33929349|NCT04401410|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704620|NCT04361318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|a double blind randomized controlled parallel study||t|t|f|f
33704621|NCT00628056|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33704622|NCT05984095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator in charge of reviewing the questionnaires and calculating the scores was not informed about the group of the participant.||f|f|f|t
33704623|NCT00282412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704624|NCT03225573|||OTHER||RETROSPECTIVE|||||||
33704625|NCT04792008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704626|NCT06295302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929350|NCT02713945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704627|NCT00002946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704628|NCT05399732|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ciclosporin soft capsules（25mg） are produced by North China pharmaceutical Group Corporation||||
33704629|NCT06557746|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Due to the nature of the intervention and the outcome measurement methods, it is difficult to blind both the participants and outcome assessors in this study. The investigators estimate that the impact of knowing the intervention group should be minimal, because the measurement of the outcomes in this study is relatively objective.|Stepped-wedge cluster randomized controlled trial||||
33704630|NCT03681431|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||A phase II, single-centre, open, non-randomized, cross-over, clinical trial.||||
33704631|NCT05747430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment assignment will be unknown (or masked) to the study subjects, the evaluating physician, the Sponsor and its agents (with the exception of personnel performing randomization, unmasked drug accountability study monitors, and corporate compliance staff). The treating physician will be unmasked.|Subjects will be randomized to IRX-101 or Providone-Iodine|t|f|t|f
33704632|NCT02656732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704633|NCT00423904|RANDOMIZED|FACTORIAL||ECT||SINGLE||||||
33704634|NCT01358045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704635|NCT00003568|RANDOMIZED|||TREATMENT||||||||
33704636|NCT04242329|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Phase II Randomized Controlled Open-Label Parallel Group Interventional Multicenter Trial||||
33704637|NCT00001071||||TREATMENT||||||||
33704638|NCT00533897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704639|NCT01479478|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704640|NCT01147523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704641|NCT01708161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704642|NCT05720221|||COHORT||PROSPECTIVE|||||||
33704643|NCT00143182|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704644|NCT02573168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33704645|NCT02122172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704646|NCT00176033|||||PROSPECTIVE|||||||
33704647|NCT05580393|||OTHER||CROSS_SECTIONAL|||||||
33704648|NCT02477683|||CASE_ONLY||PROSPECTIVE|||||||
33704649|NCT01325883|||||PROSPECTIVE|||||||
33704650|NCT02518074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704651|NCT01262911|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33704652|NCT00659997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704653|NCT02989545|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704654|NCT02509273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704655|NCT02296320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33789624|NCT00208507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789625|NCT05266352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33929351|NCT01947647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929352|NCT02927184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929353|NCT03926260|NA|SINGLE_GROUP||OTHER||NONE||||||
33929354|NCT02060968|||COHORT||PROSPECTIVE|||||||
33929355|NCT04857086|||COHORT||RETROSPECTIVE|||||||
33929356|NCT06050577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929357|NCT01844791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929358|NCT05845411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929359|NCT02205164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929360|NCT03490019|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot study without control group||||
33929361|NCT00453661|||CASE_CONTROL||PROSPECTIVE|||||||
33929362|NCT05108441|NA|SINGLE_GROUP||OTHER||NONE||||||
33929363|NCT04774952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929364|NCT03429608|||CASE_ONLY||PROSPECTIVE|||||||
33929365|NCT00543868|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33929366|NCT00866060|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33929367|NCT02537223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929368|NCT02021851|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33929369|NCT04220567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Parallel assignment|t|f|f|t
33929370|NCT00565019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929371|NCT03401697|||CASE_CONTROL||OTHER|||||||
33929372|NCT02304419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929373|NCT00134407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929374|NCT01804660|||COHORT||PROSPECTIVE|||||||
34093191|NCT05383703|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a multicenter, open-label, dose-escalation Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of live bacterium MNC-168 as a single oral agent in subjects with advanced malignant solid tumors. To explore the changes of biomarkers and intestinal flora related to curative effect, mechanism of action, safety and/or pathological mechanism.||||
34093192|NCT04656119|||CASE_CONTROL||PROSPECTIVE|||||||
33789626|NCT03429855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled|f|f|f|t
33789627|NCT01225939|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789628|NCT05999864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929375|NCT01686100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929376|NCT02100202|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34093193|NCT04894240|NA|SEQUENTIAL||TREATMENT||NONE||||||
34093194|NCT01665027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34093195|NCT03015701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093196|NCT05548855|||COHORT||RETROSPECTIVE|||||||
34093197|NCT04689243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093198|NCT03426150|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34093199|NCT04772235|NA|SEQUENTIAL||TREATMENT||NONE||This is a single arm, open-label, non-randomized Phase I study with a first dose escalation phase in 3 cohorts to find the RP2D and MTD followed by an expansion phase at the RP2D.||||
34093200|NCT04267315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized as they enter the study (T0). Only one of the researchers will have access to the randomization list. The researcher responsible for the procedure will receive an email at the day of the first injection, informing of the participant's allocation group. The outcomes assessor, patient, attending Physiatrist and the Rehabilitation team will be blinded to the patient's allocation group until the end of the study. Only the researcher the performed the TPI, and the researcher responsible for the allocation list will have access to that information.|Double-blind randomized controlled trial comparing the efficacy of TPI + standard of care (ACTIVE) versus sham TPI + standard of care(PLACEBO), with an intention-to-treat analysis|t|t|f|t
34093201|NCT00455455|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34093202|NCT00602784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093203|NCT02995889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093204|NCT03838913|||COHORT||RETROSPECTIVE|||||||
34093205|NCT04558827|NA|SINGLE_GROUP||TREATMENT||NONE||prospective cohort study||||
34093206|NCT02153827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789629|NCT02204618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093207|NCT05415657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33789630|NCT00383188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789631|NCT00503282|||DEFINED_POPULATION||PROSPECTIVE|||||||
33789632|NCT05819450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33789633|NCT02458599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33789634|NCT03038399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801734|NCT05979467|||COHORT||PROSPECTIVE|||||||
33929377|NCT04673344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929378|NCT01399255|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33929379|NCT03513718|||OTHER||RETROSPECTIVE|||||||
33929380|NCT04208880|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are assigned to one of six groups in parallel for the duration of the study.||||
33929381|NCT05975372|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|By nature of the visible device, participants and care providers cannot be blinded to the treatments. Analysis of data generated during the trial will be blinded to the treatment groups.|Participants will be randomized to either undergo tissue expansion with the Blossom device (intervention group) or standard tissue expansion methods (control group).|f|f|f|t
33929382|NCT01674660|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33929383|NCT04443894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PATIENT OUTCOME ASSESSOR||t|f|f|t
33929384|NCT03491969|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|t|f|f
33929385|NCT00044993||||TREATMENT||NONE||||||
33929386|NCT04564703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929387|NCT05821036|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||A randomized controlled trial.|f|f|f|t
33789635|NCT05001919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator Malak. Shoukheba screened the patients and randomly assigned them to test and control groups and performed the treatment procedures for all participants. Investigator Ahmed. Bader recorded the clinical parameters and she was masked to the randomization for the extent of the study.|Twenty intra-bony defects in 10 patients were randomly assigned to either test or control group in split-mouth technique (10 sites in each group).|t|f|f|t
33929388|NCT01846689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929389|NCT00134953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929390|NCT01960504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789636|NCT01991912|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33929391|NCT02152072|||COHORT||PROSPECTIVE|||||||
33929392|NCT01927068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789637|NCT00329979|||||PROSPECTIVE|||||||
33789638|NCT03055767|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33929393|NCT00748865|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33929394|NCT02955771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008174|NCT06590376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The numbers from 1 to 96 were randomly allocated into two groups on the random.org website and randomly selected numbers were assigned to the intervention and control groups. This process ensured that the participants were equally and randomly distributed to the intervention and control groups. The group to which the case would be assigned was determined according to the order of hospitalisation and recorded in the Excel list.~Since the care intervention and data collection in the study were carried out by the researcher, one-way blinding was performed."|The research was designed as a randomized controlled, 2-group (intervention and control) pre-test post-test comparative experimental research.|t|f|f|f
34008175|NCT02253069|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008176|NCT00368563|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34008177|NCT01790113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008178|NCT03692091|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34008179|NCT00783887|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34008180|NCT00727077|||CASE_ONLY||PROSPECTIVE|||||||
34008181|NCT04474093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34008182|NCT06312423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A total of 12 healthy adult volunteers of both sexes will be included, who will be progressively incorporated into 3 groups of 4 volunteers each. All volunteers will be evaluated at a research site authorized by the Regulatory Authority (ANMAT) to conduct phase 1 studies.||||
34008183|NCT01363063|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34008184|NCT05116137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCTwith 1:1 allocation to intervention or wait-list control||||
34008185|NCT00869440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008186|NCT04034355|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind, placebo-controlled|"Patients with colorectal cancer (CRC), who are indicated for adjuvant modified FOLFOX6 (mFOLFOX6) chemotherapy for up to 6 months, will be randomized in a 1:1 ratio to 1 of 2 treatment arms:~* Arm A: PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy~* Arm B: Placebo + mFOLFOX6 chemotherapy"|t|t|t|f
34008187|NCT06163872|||OTHER||PROSPECTIVE|||||||
34008188|NCT04039048|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34008189|NCT04204031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34008190|NCT02733627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008191|NCT02394691|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34008192|NCT03956589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008193|NCT06353191|||COHORT||PROSPECTIVE|||||||
34008194|NCT02401841|||CASE_CONTROL||PROSPECTIVE|||||||
34008195|NCT03068884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34008196|NCT02044250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008197|NCT04443491|||COHORT||PROSPECTIVE|||||||
34008198|NCT02718287|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33929395|NCT01801189|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33929396|NCT03157843|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33929397|NCT01190020|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33929398|NCT04220710|||COHORT||PROSPECTIVE|||||||
33929399|NCT04725201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective randomized double-blinded clinical trial|t|t|t|t
33929400|NCT01902693|||CASE_ONLY||PROSPECTIVE|||||||
33929401|NCT02338856|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33929402|NCT00005905||||TREATMENT||||||||
33929403|NCT00056550|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34008199|NCT06368752|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The infusion is mixed by an external coordinator. Neither the investigator or the participants knows whether is the GIP\[3-30\]NH2 infusion or saline infusion that is being given. Which infusion that is given on each trial day is randomized for each participant.|The trial is a randomized, double-blind, crossover study. We give intravenous infusion of GIP\[3-30\]NH2, and thus describe the effects of GIP by comparing with what happens during a saline infusion (placebo).|t|f|t|f
34008200|NCT00867048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008201|NCT06099990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008202|NCT05943041|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Group Assignment (3+3 model)||||
34008203|NCT00489749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34008204|NCT02850172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34008205|NCT00078741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008206|NCT02776553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008207|NCT06603181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008208|NCT00965016|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34008209|NCT01396421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008210|NCT03203772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008211|NCT00949195|||COHORT||CROSS_SECTIONAL|||||||
34008212|NCT05624528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008213|NCT02018094|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33704656|NCT06557980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The operator, the assessor as well as the data analyst will be blinded to material assignment.|"Each toothpaste will be applied uniformly twice per day (morning and bed time) to the hypersensitive surfaces for30 seconds. After that, the patient will rinse their mouth with plain water.~Responses to the various stimuli will be evaluated using the same tactile and thermal stimuli used previously, and scores will be recorded 1day1,2 ,4 ,8 ,12 , weeks then 6 and 12 months after their application, respectively.~Furthermore, the patients will be advised to report to the operator any unanticipated pain seizures, erroneous usage as well as the number of applications of a specific desensitizing agent required to elicit a positive response will also be recorded. The results will be statistically analyzed after 8 weeks."|t|f|t|t
33704657|NCT00242437|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33704658|NCT04312880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929404|NCT02569333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929405|NCT02005783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929406|NCT00093470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929407|NCT05229640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929408|NCT04356872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929409|NCT00222248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929410|NCT04548167|||COHORT||RETROSPECTIVE|||||||
33929411|NCT01042054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929412|NCT01105936|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33929413|NCT04113278|||COHORT||PROSPECTIVE|||||||
33929414|NCT03997760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929415|NCT02235168|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33929416|NCT04914819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929417|NCT04173390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929418|NCT00661167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929419|NCT00554255|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33929420|NCT00113412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929421|NCT01953367|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33929422|NCT05865210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929423|NCT00748306|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33929424|NCT02566876|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33929425|NCT03030014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33929426|NCT01851525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929427|NCT01783470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929428|NCT04565236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929429|NCT04266249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929430|NCT01151176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929431|NCT00882336|||||CROSS_SECTIONAL|||||||
33929432|NCT03254888|||CASE_CONTROL||RETROSPECTIVE|||||||
33929433|NCT05031104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective, dual-arm, randomized controlled trial with a 6-month follow-up|f|f|f|t
33929434|NCT03193450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33929435|NCT03383068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929436|NCT01025297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929437|NCT05786534|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants groups|Case Control Study||||
33929438|NCT01016808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929439|NCT04963634|||OTHER||PROSPECTIVE|||||||
33929440|NCT04452422|||CASE_ONLY||OTHER|||||||
34093208|NCT05573009|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The women included in the sample of the study do not know which group they are involved in. The data of the experimental and control group was also hidden from the staff of the clinic. One by one interviews were performed in order to prevent the women from contacting each other in the experimental, and control groups.|"The study was planned as an experimental study with a randomized control group including pre-test, post-test and follow-up measurements to examine the effect of stress reduction program based on cognitive behavioral approach on the maternal mental health, pregnancy, and childbirth process of the high risk pregnant women."|t|t|f|f
34008214|NCT06616376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.|The study was conducted as a randomized controlled single-blind intervention study to determine the effect of the AES use protocol on the development of early VTE in patients undergoing knee arthroplasty.|t|f|f|f
34008215|NCT00030524||||TREATMENT||NONE||||||
34008216|NCT06439199|||CASE_ONLY||PROSPECTIVE|||||||
34093209|NCT04622995|||COHORT||RETROSPECTIVE|||||||
34093210|NCT03678662|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will not be aware of which group they are allocated to. The experimenter who is assessing pressure pain threshold and tolerance is blinded to the study group of the participant.||t|f|t|f
34093211|NCT01973400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34093212|NCT04073576|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093213|NCT01003626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093214|NCT06043570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093215|NCT03850106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093216|NCT04006730|||COHORT||PROSPECTIVE|||||||
34093217|NCT04118972|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blinded to their study conditions. Investigators are aware of the study conditions but are not present for or delivering the active portions of the intervention directly. Participants in either active condition receive digitally delivered interventions.|Participants are randomly assigned to one of two active conditions or a control group.|f|f|t|f
34093218|NCT00853385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704659|NCT00094705|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33704660|NCT01999114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33704661|NCT03883711|||COHORT||PROSPECTIVE|||||||
34008217|NCT05647707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|each patient will take a code number and data were analyzed anonymously|Parallel Assignment randomized controlled clinical trial (phase II)|f|f|f|t
34093219|NCT00112853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093220|NCT01807520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704662|NCT04617171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008218|NCT00414349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008219|NCT05972018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A prospective, single-center, open-label, interventional randomized controlled trial||||
34008220|NCT04385095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|"Randomised double-blind placebo-controlled~Pilot phase - 100 patients randomised in the hospital setting, 120 patients randomised in the home setting.~Pivotal phase - estimated at an additional 100 to 300 patients per arm, but the actual number will be determined after the data review at the end of the Pilot phase"|t|t|t|t
34093221|NCT01908842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704663|NCT06246175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a single-dose, parallel design trial.||||
33789639|NCT05711095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomization of interventional drinks will be performed by an independent researcher who will also prepare the drinks on the morning of the test day. Drinks will be prepared in a non-transparent shaker and matched for taste.|Randomized, parallel-group, double-blind, combined superiority non-inferiority, intervention trial|t|f|t|t
33929441|NCT01453933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929442|NCT03718273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929443|NCT01316380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929444|NCT05987475|||OTHER||PROSPECTIVE|||||||
33929445|NCT03771001|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study||||
33929446|NCT03024710|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929447|NCT03788824|||COHORT||PROSPECTIVE|||||||
33929448|NCT04279652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929449|NCT00274066|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34008221|NCT00697970|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33929450|NCT04216706|||CASE_CONTROL||RETROSPECTIVE|||||||
33929451|NCT00662389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008222|NCT02400476|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34008223|NCT00955721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008224|NCT01117467|RANDOMIZED|PARALLEL||||NONE||||||
34008225|NCT04963608|||COHORT||RETROSPECTIVE|||||||
34008226|NCT00393601|||CASE_CONTROL||RETROSPECTIVE|||||||
34008227|NCT02593487|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093222|NCT01381640|RANDOMIZED|CROSSOVER||||NONE||||||
34093223|NCT01490528|||COHORT||RETROSPECTIVE|||||||
34093224|NCT01381510|||COHORT||RETROSPECTIVE|||||||
34093225|NCT03795909|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34093226|NCT00594555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093227|NCT04548128|||CASE_ONLY||PROSPECTIVE|||||||
34093228|NCT03112252|||OTHER||PROSPECTIVE|||||||
34093229|NCT01625182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093230|NCT04134871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093231|NCT01461837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093232|NCT04242745|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34093233|NCT03639389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome observer blinded to method of analgesia (spinal/no-spinal)|Prospective, randomized, observer-blinded|f|f|f|t
33929452|NCT03528590|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33929453|NCT03035136|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093234|NCT01932463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093235|NCT02716285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093236|NCT00404118|||OTHER||RETROSPECTIVE|||||||
34093237|NCT02575625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093238|NCT05460247|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34093239|NCT01319968|||CASE_ONLY||PROSPECTIVE|||||||
34093240|NCT03568903|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33704664|NCT04617587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704665|NCT00521326|||DEFINED_POPULATION||OTHER|||||||
33704666|NCT00880997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704667|NCT02398578|NA|SINGLE_GROUP||OTHER||NONE||||||
33704668|NCT06450821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The moderate and high-risk patients will then be randomised. Those randomised to the PRIOR intervention arm will be assessed in a consultant-led Restorative Dentistry department \& treatment offered to stabilise primary dental diseases (periodontal disease, caries, and odontogenic infection). The treatment plan (by a dentist) will be delivered within the therapeutic window (the PRIOR window), defined as the period between MDT decision to offer ASCT/allo-SCT up to 7 days prior to commencement of CT for ASCT/allo-SCT. Participant treatment plans are highly personalised and therefore number of visits within the therapeutic window to deliver PRIOR are not strictly defined. PRIOR will aim to stabilise the oral health of the participant and remove obvious sources of oral health infection. Participant follow-up will monitor febrile event rate and OM incidence between groups, within the participant therapeutic window, defined as day one of SCT/CT+100 days.||||
33704669|NCT06095804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704670|NCT01158157|NA|SINGLE_GROUP||OTHER||NONE||||||
33704671|NCT02273232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33704672|NCT01553253|||COHORT||PROSPECTIVE|||||||
33704673|NCT03975036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704674|NCT01766596|NA|SINGLE_GROUP||||NONE||||||
33704675|NCT00552565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704676|NCT05042154|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704677|NCT04028778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, Randomized, Double-Blind Study|t|t|t|t
33704678|NCT01468363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704679|NCT02004119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704680|NCT01303393|||COHORT||PROSPECTIVE|||||||
33704681|NCT02557555|||CASE_CONTROL||PROSPECTIVE|||||||
33704682|NCT00871533|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704683|NCT00287482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704684|NCT03478657|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects from the age group of 5 to 11 years with documented history of symptoms of asthma or diagnosis of asthma for at least 6 months prior to Visit 1 will be assessed for the ease of use of ELLIPTA DPI.||||
33704685|NCT01513343|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33704686|NCT00844129|||COHORT||PROSPECTIVE|||||||
33704687|NCT00728793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704688|NCT04258865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704689|NCT04273204|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33929454|NCT01188460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929455|NCT05410977|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929456|NCT01216904|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34008228|NCT06369506|RANDOMIZED|PARALLEL||SCREENING||NONE||"Participants were divided into two different classifications: thin and thick. The first classification was made by measuring the GT of the point corresponding to the base of the gingival sulcus. GT was defined as thin if ≤1 mm, and thick if \>1 mm. In the second classification, GT was measured from three different points. And according to the average GT of three points, they were equally classified as thin and thick."||||
33929457|NCT02939313|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33929458|NCT04748913|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33929459|NCT02556411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929460|NCT06242093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929461|NCT06338033|||COHORT||PROSPECTIVE|||||||
34008229|NCT05967871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008230|NCT04440722|||COHORT||PROSPECTIVE|||||||
34008231|NCT00330460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008232|NCT04760587|||CASE_ONLY||PROSPECTIVE|||||||
34008233|NCT05390125|||COHORT||PROSPECTIVE|||||||
33704690|NCT04427371|||COHORT||PROSPECTIVE|||||||
33704691|NCT05116475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|placebo-controlled trial||t|t|t|f
33704692|NCT01645345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704693|NCT03026660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33704694|NCT01677117|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33704695|NCT01234285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704696|NCT02672826|NA|SINGLE_GROUP||OTHER||NONE||||||
33929462|NCT03250624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33704697|NCT05540457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704698|NCT04798963|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704699|NCT00312559|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33704700|NCT06230432|||CASE_CONTROL||RETROSPECTIVE|||||||
33704701|NCT01015209|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33704702|NCT02354495|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33704703|NCT06556732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33704704|NCT05595941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will not have access to participants' allocations, will never attend tele-yoga sessions, and patients will be told never to reveal their allocations to the evaluator.|This is a single-blind pilot randomised controlled trial.|f|f|f|t
33704705|NCT03307967|NA|SINGLE_GROUP||SCREENING||NONE||||||
33704706|NCT03453008|||CASE_ONLY||PROSPECTIVE|||||||
33704707|NCT02294955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929463|NCT04863495|||COHORT||PROSPECTIVE|||||||
33929464|NCT04738604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929465|NCT03816397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929466|NCT05894772|NA|SINGLE_GROUP||TREATMENT||NONE||Implementation-effectiveness quasi-experimental design||||
33929467|NCT02866929|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33929468|NCT01480232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929469|NCT00253929|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929470|NCT04600453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34008234|NCT01566526|||COHORT||RETROSPECTIVE|||||||
34008235|NCT02997878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008236|NCT02013531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008237|NCT06469619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotherapists, occupational therapists and speech therapists who are responsible for rehabilitation and perform the testing||f|t|f|f
33704708|NCT02092831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704709|NCT05853185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704710|NCT05281679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704711|NCT00977860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704712|NCT01972568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
10087541|NCT06399965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704713|NCT02562534|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33704714|NCT00386438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929471|NCT05778357|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33929472|NCT05505149|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Preschool age group, school age group, adolescent age group|t|f|f|f
33929473|NCT02976545|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929474|NCT01769599|||COHORT||RETROSPECTIVE|||||||
33929475|NCT00044655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929476|NCT04586075|||COHORT||PROSPECTIVE|||||||
34008238|NCT04048031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind with a 6 month Open-Label Exension|This is a six (6) month double-blind, randomized, placebo-controlled study with a six (6) month open-label extension to assess the safety and efficacy of Nutrafol® Women's Balance oral supplement in improving hair growth in perimenopausal, menopausal and post-menopausal female subjects with self-perceived thinning hair. After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: Nutrafol® vs. Placebo for the initial 6 months of the trial. All subjects (Nutrafol® and placebo groups) will receive the active treatment (Nutrafol®) throughout the latter 6-month open-label extension/follow-up period.|t|t|t|f
34008239|NCT00919178|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34008240|NCT05093881|NA|SINGLE_GROUP||OTHER||NONE||||||
33929477|NCT02848313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Both arms received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.||||
34008241|NCT06295094|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008242|NCT00337987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008243|NCT01883791|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34093241|NCT00081458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093242|NCT02993900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093243|NCT02035293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093244|NCT04952896|||CASE_CONTROL||PROSPECTIVE|||||||
34093245|NCT00002246||||TREATMENT||||||||
34093246|NCT00500890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093247|NCT06062069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093248|NCT00111059|||CASE_CONTROL||OTHER|||||||
34093249|NCT05297760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704715|NCT00677729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704716|NCT01449539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704717|NCT00025363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704718|NCT02225561|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704719|NCT00003257||||TREATMENT||||||||
33704720|NCT06447740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704721|NCT05739188|NA|SEQUENTIAL||TREATMENT||NONE||"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%."||||
33704722|NCT04572971|||COHORT||PROSPECTIVE|||||||
33704723|NCT03694587|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929478|NCT03395067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial including 2 arms: intervention group and control group.|f|f|t|t
33704724|NCT01988688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093250|NCT03142750|NA|SINGLE_GROUP||OTHER||NONE||||||
34093251|NCT03308643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be performed by an online software and the list will be given to anesthesiologist so that neither the surgeon nor patient will know which intervention was performed. Randomized cards will be in sealed envelopes and will be open by anesthesiologist at the time of surgery.|The abdominal myomectomy cases will be randomized into 2 separate groups in a parallel fashion using an online software at 1:1 ratio.|t|f|t|f
34093252|NCT00766220|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34093253|NCT03982654|NA|SINGLE_GROUP||OTHER||NONE||||||
34093254|NCT00075374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093255|NCT01457027|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33704725|NCT05638178|||COHORT||PROSPECTIVE|||||||
33704726|NCT02008760|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34093256|NCT04663217|||COHORT||PROSPECTIVE|||||||
33704727|NCT01626430|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33704728|NCT03742830|||CASE_ONLY||PROSPECTIVE|||||||
33704729|NCT04279457|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The investigators will randomize into each arm|"Design:~This is a prospective randomized controlled trial."||||
33704730|NCT04253223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704731|NCT06435676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, placebo-controlled|t|t|t|f
33704732|NCT00705289|||COHORT||PROSPECTIVE|||||||
33704733|NCT02554500|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33704734|NCT05961579|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be treated with Barrier Renew Cleanser, Barrier Renew PM Moisturizer, and mineral sunscreen. Cleanser and Barrier Renew PM moisturizer will be used twice daily. Mineral sunscreen will be used every morning and throughout the day as indicated.||||
33704735|NCT00568997|||CASE_CONTROL||PROSPECTIVE|||||||
33929479|NCT01468038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704736|NCT00000557||||PREVENTION||||||||
33704737|NCT04507334|||CASE_ONLY||RETROSPECTIVE|||||||
33704738|NCT03573739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This multicentre randomised controlled open trial compares two parallel groups of patients receiving mechanical ventilation and vasoactive amine therapy and given early nutritional support according to one of two strategies: early calorie/protein restriction (6 kcal/kg/d/0.2-0.4 g/kg/d: Low group) or standard calorie/protein targets (25 kcal/kg/d/1.0-1.3g/kg/d: Standard group) at the acute phase of ICU management (D0-D7).||||
33704739|NCT02711592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704740|NCT01234441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33704741|NCT02300246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33704742|NCT05191342|||CASE_CONTROL||PROSPECTIVE|||||||
33704743|NCT03385564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929480|NCT05355181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929481|NCT02578992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929482|NCT06118762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929483|NCT01909219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929484|NCT01609738|||COHORT||PROSPECTIVE|||||||
33929485|NCT00005015||||TREATMENT||DOUBLE||||||
33929486|NCT00611767|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33929487|NCT06436820|||COHORT||PROSPECTIVE|||||||
33929488|NCT02032186|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33929489|NCT02321072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929490|NCT03385525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929491|NCT00788918|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33929492|NCT03838380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929493|NCT05376956|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34093257|NCT01794416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093258|NCT00243061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093259|NCT00286455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093260|NCT05355207|NA|SINGLE_GROUP||TREATMENT||NONE||single group, all subjects will receive 15 mg/kg of TRL1068 on Day 1||||
34093261|NCT02687737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093262|NCT04032288|||COHORT||PROSPECTIVE|||||||
34093263|NCT01326221|||COHORT||PROSPECTIVE|||||||
34093264|NCT01196611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704744|NCT01149226|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33704745|NCT00926484|||CASE_ONLY||RETROSPECTIVE|||||||
33704746|NCT06455176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704747|NCT01457469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33704748|NCT00713960|||||PROSPECTIVE|||||||
33704749|NCT05374733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, single-arm, observational study with invasive measurements in two cohorts (TAVI cohort and TMVr cohort).||||
33704750|NCT02019693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704751|NCT06199596|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33704752|NCT01426594|||||PROSPECTIVE|||||||
33929494|NCT05240612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093265|NCT00536614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789640|NCT00983164|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789641|NCT05976243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This masking applies to the core period. There is no masking in the open-label extension (OLE).||t|f|t|t
33789642|NCT06238375|||CASE_ONLY||PROSPECTIVE|||||||
33789643|NCT02857283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34093266|NCT04781465|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789644|NCT01451814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33789645|NCT01324726|||COHORT||PROSPECTIVE|||||||
33929495|NCT04488757|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will undergo fMRI and stress physiology measurement. Intervention outcomes will be compared across two groups: 1. pediatric chronic widespread pain and 2. age and gender matched healthy controls.||||
33929496|NCT00262314|||COHORT||PROSPECTIVE|||||||
33929497|NCT02929368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33929498|NCT00040469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929499|NCT04938271|NA|SINGLE_GROUP||TREATMENT||NONE||Open label telemedicine home-based study to ascertain the potential effects of an App-driven wearable microcurrent electroceutical docked with an e-textile sports sleeve to relieve pain and improve function in subjects with mild to moderate knee arthritis||||
33929500|NCT01392768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929501|NCT04121572|||CASE_ONLY||PROSPECTIVE|||||||
33929502|NCT04936204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At Screening/Baseline visit patients who signed the informed consent and are eligible for the study will be screened by the Investigator who will gather demographic and medical history data and perform the randomization procedure. After the allocation of the patient to Group 1 or 2, the Un-blinded Investigator will perform the treatment, according to the group allocation and instruct the patients on dressing daily renewal. The Investigator, who won't take part in the administration of study treatments and won't be aware on the patient.s group assignment, will perform all the evaluations for primary and secondary endpoint, during the visits (Blinded Evaluator).|A prospective, randomized, controlled, single-blind clinical investigation|f|f|f|t
33929503|NCT01431469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929504|NCT06089655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blinded randomized clinical trial|t|t|t|t
33929505|NCT00001753||||TREATMENT||||||||
33929506|NCT03820908|NA|SINGLE_GROUP||TREATMENT||NONE||The patientswith Rel /Ref AML will receive bisantrene in conjunction with the conventional supportive care. In the event of a CR, patients will receive a 3-day consolidation course of bisantrene 250mg/m2/d (optional).||||
33929507|NCT00821782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929508|NCT00656760|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33929509|NCT06330324|||COHORT||RETROSPECTIVE|||||||
33929510|NCT01680939|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789646|NCT06007144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929511|NCT01061645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929512|NCT01230918|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929513|NCT03997981|||COHORT||PROSPECTIVE|||||||
33929514|NCT06257940|||COHORT||PROSPECTIVE|||||||
33929515|NCT04111146|||COHORT||RETROSPECTIVE|||||||
33929516|NCT04308954|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||15 male subjects with FXS will be compared to 15 subjects with idiopathic intellectual developmental disorder, who will be the control group. Young male adults with idiopathic intellectual developmental disorder will be (group) matched to FXS participants for mean age (and age range), handedness, socioeconomic status and ethnicity.||||
33929517|NCT03274245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008244|NCT00660088|||COHORT||PROSPECTIVE|||||||
34008245|NCT00934596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008246|NCT00279539|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34093267|NCT02826551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093268|NCT05664945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be informed that the trial is assessing the impact of pulmonary rehabilitation models on predetermined outcomes, but not the specific nature of the models of interest, and the predetermined hypothesis of the intervention group allocated to.~All assessors are blinded to group allocation and previous test results. In case of failure keeping the outcome assessor blinded (that is, if a participant reveals his/her allocation) a second assessor will be available to step in and conduct the assessment on another day.~To avoid investigators (subconscious) bias the biostatistician who perform the data analyses and validate the results is blinded to group allocation.~The research group will interpret the results, before the allocation code is broken."|A randomized clinical, assessor- and statistician blinded multicentre trial with three parallel-groups|f|f|t|t
33789647|NCT06406101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789648|NCT04573374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789649|NCT03775447|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33789650|NCT05420168|||OTHER||RETROSPECTIVE|||||||
34008247|NCT03211039|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients (NICU infants) and their parents, the patient's providers, and the enrollment staff will be blinded to the randomization arm they receive.|"The initial symptom-driven analysis will be conducted on the patient's (NICU infants) sample only (singleton analysis). Patients will be randomized to receive either whole genome sequencing or whole exome sequencing. If a diagnosis is not found promptly (within 24 hours) via singleton analysis, sequential analysis of the family (or any combination of parents and/or other family members) will be analyzed using the same technology that the patient was randomized to receive.~The study includes parental and physician questionnaires to understand perceptions regarding testing. There is no randomization of parents or physicians nor a requirement to respond to the questionnaires for the patient (NICU infant) to participate in the study.~Enrollment: 213 patients (NICU infants)"|t|f|f|f
34008248|NCT05259904|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34008249|NCT02399631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929518|NCT03607071|NA|SINGLE_GROUP||TREATMENT||NONE||Moderate dose steroid therapy||||
33929519|NCT02635685|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929520|NCT05270967|||COHORT||PROSPECTIVE|||||||
33929521|NCT02690389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33929522|NCT05078671|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part A: cross-over normal olaparib versus boosted olaparib. Part B: normal olaparib versus boosted olaparib in two patient groups.||||
33929523|NCT06075498|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Postoperative follow-up was evaluated by a research assistant blind to the procedure.~groups 1 and 2 were presented to the Outcome Assessor."|patients who underwent open retropubic prostatectomy|t|f|t|t
34008250|NCT01010750|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33929524|NCT04326881|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008251|NCT06368557|RANDOMIZED|FACTORIAL||TREATMENT||NONE|As the study concerns itself with psychotherapy and examines the difference in therapist support, it is practically impossible to blind participants and clinicians, and thus they are not blinded. The research team is involved in the day-to-day operation of the project, including the screening for suicidality, why blinding of the research team is also practically impossible with the current setup. However the analyzes of the trial results will be pseudo-anonymized, so that only the ID number appears on the data sheet in order to get as close to blinding as possible in relation to the research design.|The RCT is designed as a superiority RCT with the three conditions 1) iCBT with planned feedback 2) iCBT with on-demand feedback and 3) waitlist control. The allocation ratio is 1:1:1 for each condition. The participants will be stratified by aged into the age groups 12-14 years and 15-17 years respectively to secure an even age distribution across conditions. Additionally upon completing session 8 in the program, participants will be randomized to receive or not receive a booster session 12 weeks after finishing the intervention with an allocation ratio of 1:1. The design of the randomized trial is thus factorial including two factors: type of therapist feedback (factor 1) and booster or no booster (factor 2). Data will be collected with parent and adolescent questionnaires at five time points: pre-treatment, post-treatment and at follow-ups after 3, 6 and 12 months.||||
34008252|NCT00655278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008253|NCT06120634|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008254|NCT02274948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008255|NCT04934852|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34008256|NCT01714739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008257|NCT06083415|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34008258|NCT03088878|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34008259|NCT05719337|||CASE_CONTROL||PROSPECTIVE|||||||
34008260|NCT06396507|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomly assigned to one of the five groups (Permethrin 5% P1, P2, P3, P4, and sulfur S).~Participants will be followed every two weeks for a month to evaluate primary and secondary outcomes."||||
34008261|NCT06494800|||COHORT||RETROSPECTIVE|||||||
34093269|NCT04679246|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Monitoring and evaluation of the impact of the intervention will be carried out through a community trial. There will be three schools in each study group (intervention and control). There will be three measurement periods: a baseline in the 2015-2016 school year, an intermediate measurement in the 2016-2017 school year, and a final measurement in the 2017-2018 school year. The measurement periods will have an estimated duration of two months.~In the measurement periods, the body composition of the children from 1st to 4th grade will be obtained, and they will be followed up for two years; The dynamics of water and food consumption, physical activity, functional physical capacities, as well as availability and accessibility of food in schools will be identified. In addition, from a sub-sample of the study subjects, questionnaires on the frequency of food consumption, additional anthropometric measurements, and venous blood will be obtained to determine glucose and blood lipid levels."||||
34093270|NCT04922528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the procedural nature of the intervention, we have chosen to run this trial single-blinding, with only the participant being masked to the intervention.|The intervention and comparator arms will be ran in parallel, with a block randomization sequence determining the participants allocations.|t|f|f|f
34093271|NCT00331487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093272|NCT01572142|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929525|NCT03662555|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In a multi-arm parallel randomised controlled trial design. The randomisation scheme will be generated via online software (http://www.randomization.com). Participants will be recruited to 6 weeks of training, 3 sessions a week and randomised to one of three groups.~Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.~Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.~Group 3, participants will undergo NMES alone (Control) applied to the quadriceps for 25 min."||||
33929526|NCT02485613|||CASE_ONLY||RETROSPECTIVE|||||||
33929527|NCT06454162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|Modified Ketogenic Diet and exercise program|f|f|t|t
33929528|NCT00138229||||TREATMENT||NONE||||||
33929529|NCT02667028|||CASE_ONLY||RETROSPECTIVE|||||||
33929530|NCT00224003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929531|NCT02361489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789651|NCT03161691|||COHORT||PROSPECTIVE|||||||
34008262|NCT05190523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008263|NCT00991510|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008264|NCT05994248|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008265|NCT05296876|||COHORT||PROSPECTIVE|||||||
34008266|NCT00006263||||TREATMENT||||||||
34093273|NCT03372421|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not be told whether they are in the experimental or control group.||t|f|f|f
34093274|NCT04922281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Physicians and subjects will be blinded to SCAF detected by the ICM/CIED/non-invasive LT-ECG monitor, but will be provided by the DCC upon request with full ICM/CIED/non-invasive LT-ECG monitor information on any clinical episodes. Cause-specific hospitalization and ED will be adjudicated by an independent and blinded Events Committee.|The study population will include 120 subjects with history of paroxysmal or persistent AF who have been referred for a CA procedure based on conventional clinical indications and who will be randomized 1:1 to conventional (control arm) or ICM/CIED/non-invasive LT-ECG monitor-guided management (early intervention arm).|t|t|t|t
33789652|NCT03533036|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Time series study with 15 controls and 15 experimental group. Investigators plan to enroll 30 patients in order to obtain an effect size for future studies. The mean and standard deviation of anxiety scores for each group will be used to calculate power for future studies.||||
34093275|NCT02251392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093276|NCT02448082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093277|NCT00002265||||TREATMENT||NONE||||||
34093278|NCT00565786|||OTHER||PROSPECTIVE|||||||
34093279|NCT06216366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093280|NCT00033345|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33789653|NCT04943380|||COHORT||PROSPECTIVE|||||||
33789654|NCT06309342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators performing the health and function examinations will not be informed about the group to which the participant is allocated. All examinations are performed identically for participants from both groups.|Initial examinations and data collection are made before randomisation. Randomisation then leads to the two groups of participants receiving different amounts of feedback and support. Follow-up examinations and data collection are made after one year in both groups.|f|f|t|f
33789655|NCT00666939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33789656|NCT04691973|||CASE_CONTROL||PROSPECTIVE|||||||
33789657|NCT03926819|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33789658|NCT02814825|||COHORT||PROSPECTIVE|||||||
33789659|NCT06001372|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open label pilot study||||
33789660|NCT03437642|||CASE_CONTROL||OTHER|||||||
33789661|NCT01142713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789662|NCT03558204|||COHORT||PROSPECTIVE|||||||
33789663|NCT04968119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33789664|NCT00073138|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801735|NCT03396900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The orthodontist (HA) who performed the relevant treatment after PAOO was different from the orthodontist (MRR) randomizing the subjects into C or C+BMP groups and hence was blinded to the treatment received by the patient. One periodontist performed the PAOO surgeries (KM) and another periodontist (RVC) blinded to the therapy received by the subjects recorded the clinical and radiographic data pertinent to the study. The blind was not broken until the end of study period.|This study is a randomized controlled clinical trial where systemically healthy individuals undergoing orthodontic therapy and willing to participate in the study were referred from the Department of Orthodontics and were followed up over a 6 month period after treatment.|t|t|t|f
33801736|NCT00928824|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34008267|NCT05244018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33801737|NCT04163536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801738|NCT05376436|||COHORT||PROSPECTIVE|||||||
33801739|NCT00780234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33801740|NCT06028672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801741|NCT06104449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801742|NCT06003517|||CASE_CONTROL||RETROSPECTIVE|||||||
33801743|NCT04227457|||CASE_ONLY||PROSPECTIVE|||||||
33801744|NCT05900921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008268|NCT02918331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008269|NCT05850299|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34008270|NCT01530308|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008271|NCT03185182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008272|NCT03997786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will follow a two-component study design such that Part A will be an open label PK lead-in cohort of approximately 20 subjects. Part B will be a randomized trial component with approximately 100 subjects||f|f|f|t
34008273|NCT05723198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008274|NCT06142331|||OTHER||CROSS_SECTIONAL|||||||
34008275|NCT01063959|NON_RANDOMIZED|PARALLEL||||NONE||||||
34008276|NCT00186823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008277|NCT02153684|||CASE_CONTROL||PROSPECTIVE|||||||
34008278|NCT06153160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008279|NCT00611884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008280|NCT04838938|||COHORT||PROSPECTIVE|||||||
34008281|NCT02563769|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33704753|NCT05075902|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|The Care Providers followed the standard of care for all participants during the training sessions, with a standardized approach such as: measuring the blood pressure of all participants before starting the training session, intensity control during training was done by zone of individualized heart rate, regardless of the group, presented in a spreadsheet without information about the group to which the patient was assigned. The outcomes assessor were not aware of the formation of groups and access only to the participants' codes, were objective and with generation of saved files for later conference by the Investigator.|This is a quasi-experimental controlled trial with a 12-week aerobic training intervention in postmenopausal women with and without cardiometabolic multimorbidity. Participants were allocated into groups according to the amount of cardiometabolic diseases, with the Morbidity group (MORB) being composed of women with one or no chronic cardiometabolic disease and the Multimorbidity group with two or more chronic cardiometabolic diseases.|f|t|f|t
34008282|NCT00004079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704754|NCT00036270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704755|NCT00002711||||TREATMENT||||||||
33704756|NCT01950975|NON_RANDOMIZED|PARALLEL||||NONE||||||
33704757|NCT01686308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704758|NCT00572988|||OTHER||PROSPECTIVE|||||||
33704759|NCT06143813|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704760|NCT01842321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704761|NCT05792501|||CASE_CONTROL||RETROSPECTIVE|||||||
33704762|NCT05852015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33704763|NCT04992598|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704764|NCT05582473|RANDOMIZED|PARALLEL||OTHER||SINGLE|The research assistant will collect follow-up data and will be blinded to group assignment. Caregivers will be asked not to discuss whether they were in a group program prior to follow-up data collection with the research assistant. The statistician will also be blinded, with group assignment designated using a binary variable in anonymous study data. In order to conduct study activities, other team members will not be blinded.|A randomized wait-list control group design with blinded outcomes assessment to examine the effectiveness of LST-LC on caregiver confidence and self-efficacy in performing complex care tasks. This design has the advantage of making enrollment more feasible as participants may find the intervention highly desirable and will eventually receive it. Yet, the design provides a randomized comparison with a non-intervention control group. Participants will be individually randomized 1:1 to an immediate intervention group (IG) and a wait-list (delayed) control group (WLC).|f|f|f|t
33704765|NCT03004742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704766|NCT00811707|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33704767|NCT00107393||||TREATMENT||NONE||||||
33704768|NCT01998776|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33704769|NCT03378193|||COHORT||RETROSPECTIVE|||||||
33704770|NCT05018975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704771|NCT04832620|||COHORT||PROSPECTIVE|||||||
33704772|NCT02027207|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33704773|NCT06159985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704774|NCT05412303|||CASE_CONTROL||RETROSPECTIVE|||||||
33704775|NCT04103983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and statistician will be blinded to treatment allocation. Outcome measures will be self reported by the participants. The care provider will not be blind, as they are required to provide specific instructions for each group.|Randomised, single blind, controlled, mixed-methods study.|t|f|f|t
33704776|NCT02236975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704777|NCT04312750|NA|SINGLE_GROUP||OTHER||NONE||||||
33704778|NCT03801343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704779|NCT00014937|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33704780|NCT03070366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704781|NCT03566888|||CASE_ONLY||CROSS_SECTIONAL|||||||
33704782|NCT04343469|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Obese and healthy ones are compared at baseline and obese are compered to healthy ones 6 months after bariatric surgery.||||
33704783|NCT00003710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704784|NCT02698046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704785|NCT02656537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704786|NCT02179489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33704787|NCT02055417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008283|NCT06319079|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The powder milk containers (both SMM and commercial milk) will be packaged by Addvance SA (in the Province of Santa Fe), each of the products will have a label that differentiates them but only the company Addvance SA will know that information. In this project, neither the participating mothers, researchers, and technical staff assigned to the project nor the professional who performs the data analysis knows what product each participant will receive.||t|t|t|t
33704788|NCT05596344|||CASE_CONTROL||PROSPECTIVE|||||||
33704789|NCT06395545|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle.|This study was a single-blind, randomized, controlled trial. We enrolled patients who underwent local infiltrative anesthesia in an area \>5 cm during scalp surgery at Dr. Hwang's Hair Clinic, Seoul, Korea, between March 2022 and August 2022.||||
33704790|NCT01581775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704791|NCT01536470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704792|NCT00811759||||TREATMENT||NONE||||||
33704793|NCT00318123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008284|NCT06357780|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34008285|NCT01998243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008286|NCT04030663|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008287|NCT04915911|||CASE_ONLY||CROSS_SECTIONAL|||||||
34008288|NCT02771106|||CASE_CONTROL||PROSPECTIVE|||||||
34008289|NCT03059485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704794|NCT01492985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704795|NCT05141591|||OTHER||PROSPECTIVE|||||||
33704796|NCT04242719|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, comparative||||
33704797|NCT04121975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704798|NCT01781975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704799|NCT00371280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704800|NCT01999868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704801|NCT01034631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704802|NCT03289858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704803|NCT00045968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704804|NCT01880502|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34008290|NCT04719611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||interventional, single-arm, open-label, pilot study||||
33704805|NCT04764279|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two arm, open-label randomized study will be conducted with a total of 30 patients being randomly assigned (1:1) to either of the two study arms: VLCD ( OPTIFAST®) intervention or best-practice care (control). The sample size was determined assuming a 46% partial remission rate of DMII in the VLCD group at year 1 and 4% in the usual care group and power of 80%. These rates are based on the findings of the DiRECT study.||||
34008291|NCT01629576|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008292|NCT01754987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704806|NCT01403181|||||PROSPECTIVE|||||||
34008293|NCT04814459|RANDOMIZED|PARALLEL||PREVENTION||NONE||Experimental group (EG) participated in the 7-month HOP-UP-PT control group (CG) included only baseline, 3-month, and 7-month assessments. The CG was instructed to continue their normal level of activity throughout the 7-months after which they were offered the opportunity to receive the HOP-UP-PT program. This study reports only the 7-month time frame during which the EG and CG can be directly compared.||||
34008294|NCT04015960|||OTHER||CROSS_SECTIONAL|||||||
34008295|NCT04344132|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008296|NCT00908557|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34008297|NCT05276505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Study||||
34008298|NCT06616623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704807|NCT04470141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704808|NCT02318251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33704809|NCT01655771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704810|NCT04009785|||COHORT||PROSPECTIVE|||||||
33704811|NCT00868608||||TREATMENT||NONE||||||
33704812|NCT04824352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704813|NCT02438020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789665|NCT01315886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704814|NCT04923256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded (Participant, Outcomes Assessor)|Randomised controlled trial|t|f|f|t
34008299|NCT02965872|||||PROSPECTIVE|||||||
34008300|NCT03187496|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008301|NCT01620723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008302|NCT02283671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008303|NCT04134026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008304|NCT03081728|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups: 1- block + GA 2- GA with multimodal analgesia||||
34008305|NCT01607177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008306|NCT01611207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008307|NCT06617533|||COHORT||PROSPECTIVE|||||||
33704815|NCT01841788|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34008308|NCT01566279|NA|SINGLE_GROUP||OTHER||NONE||||||
34008309|NCT05867524|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Groups defined by autoantibodies status (high or low)||||
34008310|NCT00823381|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33704816|NCT03531697|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33704817|NCT02218749|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33704818|NCT01849783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704819|NCT06557083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33789666|NCT05372094|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will be blinded as to which noise reduction setting they are listening to during lab visit objective testing only.|All participants will be fit with hearing aids with the same noise reduction feature. This feature has distinct, discrete levels of noise reduction which will be evaluated by the participants.||||
34008311|NCT00604084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008312|NCT00860743|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34008313|NCT00006331|||DEFINED_POPULATION||OTHER|||||||
34008314|NCT02061176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008315|NCT01730560|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34008316|NCT00094094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093281|NCT05878314|||COHORT||PROSPECTIVE|||||||
34093282|NCT03959475|||CASE_ONLY||PROSPECTIVE|||||||
33704820|NCT04712994|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A difference-in-difference design will be used; this is a quasi-experimental design that compares data before an intervention is introduced to data after the intervention is introduced and compares that with the expected change before and after in comparison clinics. One package of interventions (video-based PrEP counseling, HIV Self-Testing \[HIVST\], and optimized PrEP delivery) will be implemented at four intervention facilities and here will be 4 comparison facilities will undergo the same data collection procedures.||||
33704821|NCT02500420|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704822|NCT00437177|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33704823|NCT01567696|||CASE_ONLY||PROSPECTIVE|||||||
34008317|NCT02642237|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34093283|NCT02617862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704824|NCT04677231|||OTHER||CROSS_SECTIONAL|||||||
33704825|NCT03893370|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomized, sham-controlled|t|t|t|t
33704826|NCT00622401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704827|NCT02918201|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704828|NCT03857048|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Persons with obesity will be randomized to receive weight loss with or without supervised exercise. Metabolic phenotyping studies will be performed in both groups in the weight reduced state and compared to a group of obese persons not undergoing weight loss. All participants will be followed for a period of 1 year following metabolic phenotyping to track longitudinal changes in weight and other relevant outcomes measures.||||
33704829|NCT03307681|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33704830|NCT01906632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704831|NCT04872582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704832|NCT05550285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33704833|NCT05276518|||CASE_CONTROL||PROSPECTIVE|||||||
33704834|NCT00214344|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33704835|NCT05382663|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33704836|NCT00913172|||||PROSPECTIVE|||||||
33704837|NCT04994600|||COHORT||PROSPECTIVE|||||||
33704838|NCT03986398|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group Assignment||||
33704839|NCT03475368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704840|NCT01251939|||CASE_CONTROL||PROSPECTIVE|||||||
33704841|NCT00003487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704842|NCT03539328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704843|NCT01655914|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704844|NCT02606162|||COHORT||PROSPECTIVE|||||||
33704845|NCT00480883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704846|NCT03041077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789667|NCT03518112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008318|NCT06614608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704847|NCT04737382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704848|NCT05334160|||CASE_CONTROL||PROSPECTIVE|||||||
33704849|NCT06291974|||OTHER||PROSPECTIVE|||||||
33704850|NCT03265639|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open label|||||
33704851|NCT05678569|||COHORT||PROSPECTIVE|||||||
33704852|NCT04424888|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33704853|NCT05561569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704854|NCT03865914|||COHORT||PROSPECTIVE|||||||
33704855|NCT00783237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704856|NCT06001645|||CASE_CONTROL||PROSPECTIVE|||||||
33704857|NCT03218514|||COHORT||PROSPECTIVE|||||||
33704858|NCT00731627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704859|NCT03142178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Investigator|Double-blind, placebo controlled, randomized|t|t|t|f
33704860|NCT04755790|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704861|NCT00769392||SEQUENTIAL||TREATMENT||NONE||Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparcacaine used prior to Injection 1; Tetracaine used prior to Injection 2; Lidocaine sponge used prior to Injection 3; Lidocaine suconjunctival injection used prior to Injection 4).||||
33704862|NCT06127654|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33704863|NCT00469274|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704864|NCT04152655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789668|NCT01848249|||COHORT||PROSPECTIVE|||||||
33789669|NCT04694573|||CASE_CONTROL||PROSPECTIVE|||||||
33789670|NCT02299635||||TREATMENT||NONE||||||
33789671|NCT02449499|||CASE_CONTROL||PROSPECTIVE|||||||
33704865|NCT03778840|||COHORT||PROSPECTIVE|||||||
33704866|NCT02011971|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double-blind single dose crossover with 1-month follow-up open label in patients.|t|t|t|t
33704867|NCT02696460|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704868|NCT05099120|||OTHER||OTHER|||||||
33704869|NCT04425512|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33789672|NCT00652119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789673|NCT04131933|||COHORT||PROSPECTIVE|||||||
33789674|NCT00516503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33789675|NCT00155363|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789676|NCT03684096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789677|NCT05699213|||COHORT||PROSPECTIVE|||||||
34008319|NCT01182662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008320|NCT05546268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|Single Group||||
33789678|NCT01602042|||COHORT||PROSPECTIVE|||||||
34008321|NCT01588535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33801745|NCT03593876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801746|NCT04802382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized in 1:1:1 ratio to one of the three arms.|t|t|t|t
33801747|NCT00998881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008322|NCT02378051|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34008323|NCT03349229|||COHORT||PROSPECTIVE|||||||
34008324|NCT04487899|||CASE_ONLY||CROSS_SECTIONAL|||||||
34008325|NCT03002480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008326|NCT00003467||||TREATMENT||||||||
34008327|NCT06616259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008328|NCT02629250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34008329|NCT00088387||||TREATMENT||||||||
34008330|NCT00190580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008331|NCT01705431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008332|NCT02380313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008333|NCT06135376|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33704870|NCT05997160|||OTHER||CROSS_SECTIONAL|||||||
33704871|NCT00259337|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33704872|NCT06134622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomized, double-blind trial||t|t|t|t
33704873|NCT01552694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704874|NCT02946528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704875|NCT00394823|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33704876|NCT00550524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704877|NCT03033004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704878|NCT00762385|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33704879|NCT01898637|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33704880|NCT01057095|||CASE_ONLY||RETROSPECTIVE|||||||
33704881|NCT02599714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Study was originally designed as randomized and double blinded. Currently (CSP v.8.0 of 14-Dec-2021) no masking and no randomization is planned.|||||
33704882|NCT01805375||||TREATMENT||||||||
33704883|NCT05248061|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients who were diagnosed with subacromial impingement syndrome, between the ages of 45 and 65, without a history of shoulder injury other than subacromial impingement in the last 1 year and/or shoulder symptoms requiring treatment, who had not had any previous shoulder surgery and who agreed to participate in the study will be included in the study. Not meeting the inclusion criteria, a history of shoulder fracture, dislocation and/or cervical radiculopathy, presence of frozen shoulder, previous shoulder surgery, local corticosteroid injection/treatment to the shoulder joint in the last 3 months, presence of neuromuscular disease, pregnancy, history of cancer Patients with unstable angina, systemic inflammatory joint disease, conditions where exercise is contraindicated, orthopedic, rheumatic or congenital disease in the affected upper extremity, and communication problems will be excluded from the study.|Factorial Assignment randomized controlled trial 2 groups|t|f|f|f
33704884|NCT01685892|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33704885|NCT01702961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704886|NCT04996043|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33704887|NCT01675791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704888|NCT04999488|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Randomized, parallel arm trial in which the supplementation with oral BPM 31510 or placebo will be blind.|Randomized, parallel arm trial in which the supplementation with oral BPM 31510 or placebo will be blind.||||
33704889|NCT03848429|||COHORT||RETROSPECTIVE|||||||
33704890|NCT02072083|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704891|NCT03764696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789679|NCT04026620|RANDOMIZED|PARALLEL||PREVENTION||NONE||A total of 400 women who screen positive for drinking will be asked if they want to be enrolled in the efficacy trial. Once a participant enrolls into the efficacy trial study, they are then randomly assigned to either the MET (Motivational Enhancement Therapy) group or informational pamphlet-only group. The MET group will be provided: 1.) a one (1) hour and 30 minute MET session, 2.) an information pamphlet on FASD written in simple Afrikaans. Women in the control condition will receive two informational pamphlets (one on FASD advising abstinence from alcohol use and one describing fetal development, both in Afrikaans). The data obtained by nurses during a woman's initial prenatal clinic visit for all 400 participants (Self-administered Questionnaire and AUDIT), will be matched with deliveries of the newborns to monitor the birth outcomes of newborns of participating mothers.||||
33789680|NCT06037135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33789681|NCT03311958|NA|SINGLE_GROUP||TREATMENT||NONE||Regular testing of DLBCL patients who have successfully undergone chemotherapy and are negative for ctDNA. Treatment of patients who become positive for ctDNA with Nivolumab||||
33789682|NCT00907218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789683|NCT06417450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789684|NCT01597128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789685|NCT04172948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Care provider will be blinded to the intervention.|randomized controlled trial|f|t|f|f
33704892|NCT00917995|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33789686|NCT06137846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789687|NCT03495284|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33704893|NCT00668707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33789688|NCT01979913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789689|NCT02170636|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008334|NCT00483548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008335|NCT04768634|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704894|NCT02487667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704895|NCT05066854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789690|NCT02247063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704896|NCT01739452|||CASE_CONTROL||RETROSPECTIVE|||||||
33704897|NCT02128971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704898|NCT00544518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33704899|NCT03160183|||COHORT||PROSPECTIVE|||||||
33704900|NCT00753571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704901|NCT05663567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704902|NCT03947801|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33789691|NCT03621761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Rater blinded||f|f|f|t
33789692|NCT00294697|||COHORT||PROSPECTIVE|||||||
33789693|NCT02560519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789694|NCT00959920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789695|NCT03829410|NA|SEQUENTIAL||TREATMENT||NONE||||||
33789696|NCT05324631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||SHR0302 compared with placebo|t|f|t|f
33789697|NCT06258980|||COHORT||PROSPECTIVE|||||||
33704903|NCT03147560|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33704904|NCT00986830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704905|NCT03144960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704906|NCT02925390|||COHORT||PROSPECTIVE|||||||
33704907|NCT05212571|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized non-inferiority study||||
33789698|NCT03663218|NA|SEQUENTIAL||TREATMENT||NONE||||||
34008336|NCT05083377|||COHORT||RETROSPECTIVE|||||||
34008337|NCT02752802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008338|NCT03084809|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: chemotherapy (5-Fluorouridine, leucovorin and oxaliplatin \[FOLFOX4\]) combined with cytokine-induced killer cells (CIK) Group 2: chemotherapy (5-Fluorouridine, leucovorin and oxaliplatin \[FOLFOX4\])||||
34008339|NCT04938986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008340|NCT00003531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704908|NCT00487877|NON_RANDOMIZED|PARALLEL||||NONE||||||
33704909|NCT00384566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704910|NCT00727428|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33789699|NCT00855153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704911|NCT05947383|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33704912|NCT05541120|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized controlled trial of the use of RPM compared to usual care among MaineHealth's rural patients with poorly controlled diabetes, where the participant's diabetes is managed primarily by primary care (as opposed to endocrinology). Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program, PCP evaluation and management at the providers' discretion, including medication adjustment or interventions, and other types of interventions depending on clinical judgement. This may include eConsults between the provider and a pharmacist, in-person visits between the provider and the patient, synchronous telemedicine visits between the provider and the patient, and synchronous telemedicine visits between the pharmacist and the patient.||||
33704913|NCT04020380|NA|SINGLE_GROUP||TREATMENT||NONE||single centre, open label study||||
33704914|NCT02164942|||COHORT||PROSPECTIVE|||||||
33704915|NCT05620771|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789700|NCT03693742|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|For randomization, a computer generated random list will determine the order of the scans (MSG first, placebo first). Sealed envelopes will be prepared. A study coordinator or technologist not involved in measuring vital signs or collecting adverse events will prepare the tomato juice solution based on the randomization envelope. The rest of the team will not be informed of which tomato juice is used (placebo or MSG) but this information will be recorded and will be immediately accessible should a participant experience a severe adverse event.|This is a prospective double blind intra-participant comparison of \[18F\]-DCFPyL PET/CT scans performed after orally administered MSG or placebo. The participants will receive oral administration of MSG or placebo, in two different examination sessions, 30 minutes before \[18F\]-DCFPyL injection.|t|t|f|t
33789701|NCT02982213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929532|NCT04128605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be blinded from knowing the intervention they're receiving.~Both suprascapular nerve block and intraarticular shoulder steroid injection will be performed at posterior aspect of shoulder while participant is in seated position and facing forward.~The assessor will also be blinded from knowing which group the participants belong to.~All the medical record related to this study will be inaccessible by the assessor."|"1. Patients referred to Rehabilitation Clinic for hemiplegic shoulder pain (HSP) will be recruited.~2. Patients will be randomly allocated using a computer program into suprascapular nerve block (SSNB) (Intervention) vs intra-articular shoulder steroid injection (IAS) (Control) group~3. Intervention Group~   SSNB performed by skilled interventionist who is not blinded for safety reason 5 mls of Bupivacaine, 5 mls Lidocaine and 10 mls of saline~4. Control group~   IAS performed by skilled interventionist who is blinded on patient's initial measurement 40 mg of Triamcinolone Acetate + 2 ml of Lidocaine 1%~5. Evaluations will be repeated at:~   * 1 hour, 1 month and 3 months for maximum (max) passive range of motion (PROM), numerical rating scale (NRS) at max PROM~  * 1 month and 3 months for shoulder disability questionnaire (SDQ) and shoulder pain and disability index (SPADI)"|t|f|f|t
34008341|NCT04733209|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34008342|NCT05290038|||COHORT||RETROSPECTIVE|||||||
34008343|NCT06495190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Investigators and study participants will be blind to treatment allocation, with the blueberry and placebo supplements administered in identical packets.|This study will employ a randomized, double-blind, placebo controlled, parallel research design, with participants assigned to one of 4 arms for the 12-week trial period: 1) blueberry + walking; blueberry + stretching; placebo + walking; placebo + stretching.|t|f|t|f
33704916|NCT00463112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704917|NCT05723978|||COHORT||RETROSPECTIVE|||||||
33929533|NCT01980225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929534|NCT05344612|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929535|NCT00971542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33929536|NCT04142710|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008344|NCT04005963|||COHORT||PROSPECTIVE|||||||
34093284|NCT00032760|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33704918|NCT02107170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33704919|NCT00807170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704920|NCT05938517|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects satisfying all selection criteria were included in the open-labeled trial receiving 3 different dosages of Betahistine alone in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline.||||
33704921|NCT02655796|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33704922|NCT05820672|||COHORT||PROSPECTIVE|||||||
33704923|NCT02492269|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33704924|NCT04709107|||COHORT||PROSPECTIVE|||||||
33704925|NCT00053937||||PREVENTION||NONE||||||
33704926|NCT01848691|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704927|NCT03533296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704928|NCT04092400|||COHORT||PROSPECTIVE|||||||
33704929|NCT03562533|||CASE_CONTROL||RETROSPECTIVE|||||||
33704930|NCT04263077|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33704931|NCT06061536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704932|NCT05620927|||COHORT||CROSS_SECTIONAL|||||||
33704933|NCT01862900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704934|NCT00210483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33704935|NCT05004103|NA|SINGLE_GROUP||OTHER||NONE||Pre-post study||||
33704936|NCT03714971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study was designed as a single-blind study. The physicians (except the first author) were blind to the allocation to intervention or control groups and they conducted their routine smoking cessation counseling work. As long as the patient did not comment on the messages, the physicians were blind throughout the follow ups as well. After the first routine counseling, participants were informed by the first author about the study, thus they were not blind to the intervention. The analysis of the study was conducted by the first author who was not blind to the intervention/ control status of the participants. The first author could not be blind as he was to send out the WhatssApp messages. However, contact numbers of the participants were labeled with numbers (I-01 to I-44) to secure anonymity and to prevent any bias.|The study was designed as a RCT including two parallel arms: an intervention group receiving messages through WhatsApp Messenger operating on smart phones and a control group not receiving these messages, with an allocation ratio of 1:2. Both groups received the standard outpatient care of the clinic including a 45-60 minutes face-to-face individual counseling at first contact ending with the decision of treatment and quit date, and a support booklet on quitting and subsequent follow-ups by the same clinician at 1st, 2nd, 4th weeks and 3rd month after quit date, either face-to-face at the clinic or by telephone if the patient does not come to the clinic for follow-up. The study was carried out in the smoking cessation clinic of Ege University Medical School's Public Health Department.|t|t|f|f
33704937|NCT00991731|RANDOMIZED|FACTORIAL||||NONE||||||
33704938|NCT00601211|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33704939|NCT01610570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704940|NCT00448981|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33704941|NCT00884169|RANDOMIZED|||||DOUBLE||||||
33704942|NCT04076475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33704943|NCT01478880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33704944|NCT05344170|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind: Eligible participants will be assigned to one of six possible treatment orders using a pre-populated randomisation schedule. Study staff (including the study investigators, the clinical trials coordinator and the study medical officer) and the participants will be blinded. Allocation concealment will be managed by the trial epidemiologist and drug distributor who will not have any contact with participants or involvement in day-to-day trial activities. Traditional polysomnographic (PSG) measures will be scored by a PSG technician who will not be aware of participant treatment, nor will they meet the participant. The study drug and matched placebo are expected to be identical in their visual appearance, taste, or smell. A mint-flavoured lozenge will be administered immediately prior to the study drug to mask any possible differences in taste.|Single site allocation: Randomised Intervention model: Crossover Masking: Double-blind (participant, investigator) Primary purpose: Pilot|t|t|t|t
33704945|NCT03737942|||COHORT||PROSPECTIVE|||||||
33704946|NCT04984330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704947|NCT03154164|||CASE_ONLY||PROSPECTIVE|||||||
33704948|NCT02657369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704949|NCT01790880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33704950|NCT00726869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704951|NCT00133913|||COHORT||PROSPECTIVE|||||||
33789702|NCT00001575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789703|NCT06430125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789704|NCT03015974|||CASE_ONLY||PROSPECTIVE|||||||
33789705|NCT03294980|||COHORT||PROSPECTIVE|||||||
33789706|NCT03931044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789707|NCT00585455|||COHORT||PROSPECTIVE|||||||
33789708|NCT06552390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789709|NCT03121963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789710|NCT03317106|||COHORT||PROSPECTIVE|||||||
33789711|NCT02732678|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33789712|NCT01648140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789713|NCT04124263|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33789714|NCT02087306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789715|NCT05591001|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|. The details of the series will be unknown to the investigators and the group assignment will be kept in a set of sealed envelopes, each bearing only the case number on the outside. a person who will prepare the drugs and data collector is not one of the trial investigators.|forty six Children undergoing untethered spinal cord surgery will be randomly allocated into two equal groups using computerized generated random tables.|t|t|t|t
34008345|NCT03710902|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinical endpoints will be assessed according to PROBE principles, i.e. outcomes assessors are masked to treatment allocation.||f|f|f|t
34008346|NCT03105934|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34008347|NCT03910764|||CASE_ONLY||RETROSPECTIVE|||||||
33704952|NCT05178771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed by coin toss method|A split-mouth procedure will be formed. Two quadrants in each participant will be selected; the sites will be divided into two groups: control site( will treat by ScRp only) and test sites( will treat by ScRp and PRF)|t|f|t|f
33704953|NCT00785694|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33704954|NCT00579150|||COHORT||PROSPECTIVE|||||||
33704955|NCT01062659|||COHORT||PROSPECTIVE|||||||
33704956|NCT04868175|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Patients are not exposed to the eye drop bottle (taped) and the doctors measuring pressure and performing the intravitreal injections are not shown the eye drops given|"Group 1: control (hypromellose), then Timolol, then Travatan Group 2: Timolol, then Travatan, Hypromellose Group 3: Travatan, then Hypromellose, Timolol~There are three groups of different treatments. Patients recruited will undergone all three groups of treatments. During the first injection visit, patients will be randomized (by envelope method upon recruitment) to start with one of the three groups by envelope method. Treatment given to each group according to randomization in the first visit, then rotated to second and third group at two subsequent injections accordingly.~Injection doctors masked to treatments given."|t|t|f|f
33704957|NCT02265068|||CASE_ONLY||RETROSPECTIVE|||||||
33704958|NCT02481583|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33704959|NCT04495270|||COHORT||PROSPECTIVE|||||||
33704960|NCT04843137|||CASE_CROSSOVER||PROSPECTIVE|||||||
33704961|NCT03772925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704962|NCT03985904|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789716|NCT02606409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34093285|NCT06118073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789717|NCT02797249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33789718|NCT04213560|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33789719|NCT00886054|||COHORT||PROSPECTIVE|||||||
33789720|NCT02884583|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789721|NCT00765492|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33789722|NCT05768932|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33801748|NCT02795052|NA|SINGLE_GROUP||TREATMENT||NONE||Intravenous and intranasal bone marrow derived stem cells.||||
34008348|NCT00700817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008349|NCT02419924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008350|NCT05478733|||OTHER||RETROSPECTIVE|||||||
34008351|NCT03536494|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"Intervention group: Patients with mirabegron prescription from 1st January 2017 to 31st December 2017 assigned to any of the 17 urban primary health care centers located in the northern area of Barcelona belong to the Catalan Institute of Health (CIH).~Control group (CG): All the other patients with mirabegron prescription assigned to any of the other 34 PHC located in Barcelona belonging to the CIH."|f|f|t|f
34008352|NCT00617916|||COHORT||PROSPECTIVE|||||||
34008353|NCT05674799|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Professional research assistants who will be collecting data and conducting the research visits will not be told if participants are in the treatment or control group, although this may be disclosed by the participant.|Participants will be randomized 1:1 to a 12-month lifestyle intervention promoting healthy diet and activity to reduce body weight (NDPP-NextGen), or usual care|f|f|f|t
34008354|NCT02306837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008355|NCT05022407|||COHORT||PROSPECTIVE|||||||
34008356|NCT03431064|||COHORT||PROSPECTIVE|||||||
34008357|NCT06294977|||COHORT||RETROSPECTIVE|||||||
34093286|NCT00976898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093287|NCT00652132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093288|NCT03549195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093289|NCT02801773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093290|NCT01454999|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34093291|NCT05148507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093292|NCT02463877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093293|NCT03457584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093294|NCT06329557|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34093295|NCT05711147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093296|NCT01205308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093297|NCT00546273|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33929537|NCT04771481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All participating endoscopists and patients were blinded to the randomization allocation.|"* Double-blind, Double centers, RCT~* The standardized set of endoscopic landmarks, including the esophagus, gastro-esophageal junction, fundus, gastric body, incisura, antrum, duodenal bulb, and second part of the duodenum were examined.~* The simple validate objective scoring system was applied; estimated coverage of blood clot on mucosa on reference endoscopies view in 4 locations, including fundus, corpus, antrum and duodenal bulb.~* Each location was scored between 0 and 2 Score 0 (worst vision), less than 25% of the surface was visible Score 1 25-75% visible surface Score 2 (best vision), more than 75% visible surface ( total score range 0-8)~* 'Adequate visualization' = total score six or higher.~* All photos was internally validated by another endoscopist who was blinded to the randomization allocation."|t|f|t|t
33929538|NCT01119963|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929539|NCT04907890|||CASE_CONTROL||RETROSPECTIVE|||||||
33929540|NCT02657837|||COHORT||PROSPECTIVE|||||||
33704963|NCT00300274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704964|NCT01323283|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33704965|NCT02099370|||OTHER||PROSPECTIVE|||||||
33704966|NCT04447651|||COHORT||PROSPECTIVE|||||||
33704967|NCT06136078|||CASE_ONLY||RETROSPECTIVE|||||||
33704968|NCT01602354|||COHORT||PROSPECTIVE|||||||
33929541|NCT03437252|||CASE_CROSSOVER||PROSPECTIVE|||||||
33704969|NCT02628470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33704970|NCT00670150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704971|NCT01471808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929542|NCT01333462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34008358|NCT02136303|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008359|NCT05501808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||patient with endo treated first molar|f|f|f|t
34008360|NCT03550534|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008361|NCT04057248|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34008362|NCT04126954|||COHORT||RETROSPECTIVE|||||||
34008363|NCT04350008|||CASE_ONLY||PROSPECTIVE|||||||
34008364|NCT00670241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008365|NCT06217796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects receive the same intervention||||
34008366|NCT05344716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008367|NCT00724620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008368|NCT02630290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008369|NCT02928536|||OTHER||CROSS_SECTIONAL|||||||
34008370|NCT01358799|||COHORT||CROSS_SECTIONAL|||||||
33704972|NCT01317654|||CASE_ONLY||PROSPECTIVE|||||||
33704973|NCT03296098|NA|SINGLE_GROUP||OTHER||NONE||||||
33704974|NCT04311502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704975|NCT03092921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33704976|NCT00951548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33704977|NCT05911529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33704978|NCT06129838|||OTHER||PROSPECTIVE|||||||
33704979|NCT00882063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704980|NCT02718157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33704981|NCT04336540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33704982|NCT01352546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33704983|NCT04216238|||COHORT||PROSPECTIVE|||||||
34093298|NCT03349515|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group A - povidone-iodine ophthalmic solution, or Group B - ophthalmic balanced salt solution. This randomization will be determined using a simple randomization scheme provided by the study's statistician|t|f|f|f
34093299|NCT02221414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093300|NCT05301634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093301|NCT04895176|||COHORT||RETROSPECTIVE|||||||
33929543|NCT04205110|||COHORT||PROSPECTIVE|||||||
33929544|NCT03682055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929545|NCT02637804|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be allocated in to 2 parallel groups: Group 1: stenfilcon A and narafilcon A, and Group 2: stenfilcon A and delefilcon A. Each participant will be randomized to wear either lens pair in a bilateral design for 1 week, and then cross over to the alternative pair.||||
33929546|NCT04058158|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33929547|NCT03158090|||COHORT||OTHER|||||||
33929548|NCT05543824|||CASE_ONLY||PROSPECTIVE|||||||
33929549|NCT03423563|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|In this prospective randomized controlled study 60 patients with ASA physical status Ӏ-ӀӀ, aging 20-50 years will be randomly allocated into two groups, 30 patients in each group|In this prospective randomized controlled study 60 patients with ASA physical status Ӏ-ӀӀ, aging 20-50 years will be randomly allocated into two groups, 30 patients in each group||||
33929550|NCT01458795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33929551|NCT02062476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929552|NCT00716989|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929553|NCT05401604|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants are blinded as to which beer (i.e. normal or probiotic) they are receiving for each intervention arm.|The experimental design used in this study is a randomised, controlled, within-subject cross-over design. Each individual will undergo a 2-week intervention each of moderate beer consumption and moderate probiotic beer consumption, with a 1-week period of washout in between. The total study duration will be 5 weeks.|t|f|f|f
33929554|NCT06056401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929555|NCT04960462|||CASE_ONLY||RETROSPECTIVE|||||||
33929556|NCT05911737|||COHORT||PROSPECTIVE|||||||
33929557|NCT02177214|||COHORT||PROSPECTIVE|||||||
33929558|NCT01229280|RANDOMIZED|CROSSOVER||||NONE||||||
33929559|NCT02853149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929560|NCT02168712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929561|NCT02829775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929562|NCT02457299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929563|NCT06097325|||OTHER||OTHER|||||||
33929564|NCT05545878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The procedure adopted in this study for assuring the allocation concealment will be the use of sequentially numbered, opaque, and sealed envelopes (SNOSE).~Blinding : In our study, the clinicians (opticians) performing the assessment and follow-up and the patients receiving and wearing the spectacles will be blinded to the treatment."|This is a double-blind, randomised controlled trial. Participants will be required to have a full eye exam at the UCLan Eye Health Clinic to assess eligibility to enrol in the study. Once participants have been screened and completed the Computer Vision Syndrome Questionnaire (CVS-Q), ensuring that they meet the inclusion criteria, they will be randomly allocated to the Intervention or Control Groups. After the eye exam and CVS-Q score, eligible participants will have the following tests measured as baseline data:1. LogMAR Vision and Visual Acuity (6/6 minimum monocular distance VA and N6 monocular). 2. Monocular and binocular amplitude of accommodation. 3. Near point of convergence. 4. Wilkins Rate of Reading. 5. Accommodative Facility in cycles per minute. 6. Thomson Clinical Eye Tracking. The tests and CVS-Q will be repeated at intervals of 4 weeks for a further three times. The 4-week interval period will start from the date of the spectacle collection.|t|t|t|f
33929565|NCT01614340|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33704984|NCT05866783|||COHORT||PROSPECTIVE|||||||
33704985|NCT03217812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33704986|NCT04800744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Single-center Prospective, Randomized, Double-blind, Active comparator trial involving patients undergoing unilateral hip replacement and patients undergoing unilateral or bilateral mastectomy that score ≥19 on the PROMIS Emotional Distress - Anxiety - Short Form 8a|t|t|t|f
33704987|NCT00932100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704988|NCT03795454|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Assessors do not know the intervention that took place before outcome assessed|In Helsinki, block randomization, one intervention at the time in the hospital. In Stockholm, both groups simultaneously cared in the hospital|f|f|f|t
33704989|NCT01116323|||COHORT||PROSPECTIVE|||||||
33704990|NCT01801878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33704991|NCT04916821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||first group treated with water extracts of propolis second group treated with olive oil extracts of propolis including perga third group treated with no bee product||||
33789723|NCT05602857|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|This is a single-blinded randomized controlled trial. Participants will be blinded, that is, they will not know whether we expect more EF benefit from the balance training or music condition. During recruitment we will tell the families that we are investigating whether either Balance Training (BT) and/or Music Training (MT) can improve EFs, and that we have reasons to believe that both interventions can do so. Assessment of outcomes will not be blinded, however, because the investigator (Dr. Priscilla Paz) responsible for monitoring the interventions will also be conducting the assessments.|Participants will be randomly allocated to one of 3 groups: Balance Training, Music Training, and business as usual (control). All groups will receive assessment of EFs and balance upon their entry into the study, 12 weeks later, and 3 months after that.|t|f|f|f
33789724|NCT05676294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33789725|NCT03917706|||COHORT||PROSPECTIVE|||||||
33789726|NCT06345833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33789727|NCT00203840|||CASE_ONLY||PROSPECTIVE|||||||
33789728|NCT00639015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929566|NCT01878227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929567|NCT01963936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929568|NCT04916756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929569|NCT04977024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929570|NCT05337150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929571|NCT02680119|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929572|NCT00621010||||TREATMENT||||||||
33929573|NCT06243549|||COHORT||PROSPECTIVE|||||||
33929574|NCT02021071|||COHORT||PROSPECTIVE|||||||
33929575|NCT05197309|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants will complete 8 weeks of the Metabolic Diet while meeting with a clinician weekly.||||
33929576|NCT04995614|||COHORT||PROSPECTIVE|||||||
33929577|NCT05407493|||OTHER||PROSPECTIVE|||||||
33929578|NCT00871936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929579|NCT02899260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929580|NCT02945228|||COHORT||PROSPECTIVE|||||||
33929581|NCT00866398|||COHORT||PROSPECTIVE|||||||
33929582|NCT01402388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929583|NCT02017457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929584|NCT00668252|||||CROSS_SECTIONAL|||||||
33929585|NCT04329325|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label single arm phase II study with a Simon's minimax two-stage for the treatment of adults with newly diagnosed Ph+ ALL.||||
33929586|NCT03163173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093302|NCT04613570|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with EGGIM \> 5 or OLGA/OLGIM III/IV (premalignant stomach group - SUPREME I) will be randomized to endoscopic surveillance every one (12 to 16 months) or three years (32-40 months);||||
33704992|NCT03428724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single-blind||f|f|t|t
33929587|NCT03773627|||COHORT||PROSPECTIVE|||||||
33704993|NCT00251784|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
33704994|NCT04794842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intervention choice blinded to the patient|Single-Blinded Randomized Cohort|t|f|f|f
33929588|NCT02558283|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33929589|NCT00987636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929590|NCT06298760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"After randomization, participants were divided into 30 participants in each group.~were divided into five groups:Groups; It consisted of 1) Reflexology with Black Cumin, 2) Placebo Reflexology, 3) Knee Massage with Black Cumin, 4) Placebo Knee Massage and 5) Control groups. Patient Information Form, Kellgren and Lawrence, Pain Visual Analog Scale (A-VAS), Fatigue Severity Scale and Western Ontario and McMaster Universities Osteoarthritis Index WOMAC were applied to the participants. Participants in the application groups were administered once a week for 6 weeks. The session lasted 30 minutes. The control group was allowed to continue routine treatment and care without any intervention. Data were collected by applying questionnaires to the participants in the 1st and 6th weeks."||||
33929591|NCT00327977|||||RETROSPECTIVE|||||||
33789729|NCT01071967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789730|NCT01109095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789731|NCT03935308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789732|NCT02526641|||COHORT||PROSPECTIVE|||||||
34008371|NCT04010916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Ninety patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for arthroscopic knee surgery will be included in the study. Patients will be randomly divided into three groups (Group Pre = preoperatively before inflation of the tourniquet group, Group Pre-T = preoperatively after inflation of the tourniquet group, Group Post = Postoperatively group) including 30 patients each, before entering the operating room.|t|f|f|t
34008372|NCT04490473|NA|SINGLE_GROUP||OTHER||NONE||This research will be conducted in a methodological manner in order to conduct the validity and reliability studies of the Coronary Virus Anxiety Scale in Turkish.||||
34008373|NCT06616103|||COHORT||PROSPECTIVE|||||||
34008374|NCT05470322|NA|SINGLE_GROUP||TREATMENT||NONE|No masking will be performed.|||||
34008375|NCT02540837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33704995|NCT02237131|RANDOMIZED|PARALLEL||||NONE||||||
33704996|NCT01029834|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33704997|NCT05343598|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The subjects, care providers, investigators and outcome assessors will all be blinded as to the randomization sequence, and thus will be blinded as to sham vs active TMS status. Blinding codes are used to determine which side of an active/passive Magpro coil (cool B65 A/P, Magventure A/S, Denmark) is used for stimulation.||t|t|t|t
33789733|NCT03128658|||COHORT||PROSPECTIVE|||||||
33789734|NCT03356665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The reference laboratory, generating the results for 4 index tests, is masked for index test and reference test results obtained at the clinical trial site|Sequential assignement||||
33929592|NCT04115345|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33789735|NCT05539248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33789736|NCT05054400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789737|NCT02286765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789738|NCT04258410|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Enrolled participants who complete the pre-treatment assessment will be randomly assigned to Quercetin or placebo. The trial manager who is not involved in any outcome assessments will carry out randomization following the protocol designed by the study biostatistician (Dr. Leng) prior to the study's start. The randomization sequence list will remain concealed from the investigators. Participants will be randomized using a computer-generated, password-protected randomization list, and simple randomization scheme. All staff involved in data collection and management will be kept unaware of the participants' group assignments and will explicitly inform participants that they (staff) are to remain blinded during the course of the study. The biostatistician will also be unaware of treatment assignment.|Double blind randomized controlled parallel pilot trial of Quercetin vs placebo oral administration in 24 postmenopausal women.|t|t|t|t
33789739|NCT06450977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33789740|NCT01639638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789741|NCT00270426|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33789742|NCT03402711|||CASE_ONLY||PROSPECTIVE|||||||
33789743|NCT05100329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789744|NCT05845242|||COHORT||PROSPECTIVE|||||||
33789745|NCT06187480|||CASE_CONTROL||RETROSPECTIVE|||||||
33789746|NCT04910919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33789747|NCT01558921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||standard arm: 5.5 weeks chemoradiation -\> surgery -\> optional chemotherapy experimental arm: 5x5Gy -\> 12 wks chemotherapy -\> surgery|f|f|f|t
33789748|NCT00431795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929593|NCT01009736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929594|NCT00849199|||COHORT||PROSPECTIVE|||||||
33929595|NCT04904315|||COHORT||PROSPECTIVE|||||||
33789749|NCT03147456|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Investigators and researchers in this study will be blinded to the intervention, i.e. they will not be aware of who is on protein supplement and who is on placebo. Patients will also be blinded to the intervention, i.e. they will not know whether they are taking protein or zero protein supplement. For the blinding there will be a dietician who will assign the treatment and the control to patients as per the above randomization results. This dietician will also be responsible for filling the intervention \& control ready-to-feed shakes into identical bottles labeled either A or B, the dietician will not have any other responsibility such as data entry or follow up of participants as this will be done by the PI and research team, he will only be responsible for the blinding process.||t|t|t|f
33789750|NCT01490112|||COHORT||PROSPECTIVE|||||||
33789751|NCT06552533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the investigator and participant will be blind.|randomized clinical trial|t|f|t|f
33789752|NCT02488317|RANDOMIZED|PARALLEL||OTHER||||||||
33789753|NCT04534712|||COHORT||PROSPECTIVE|||||||
33929596|NCT01597440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929597|NCT00638586|||CASE_CONTROL||PROSPECTIVE|||||||
33929598|NCT00899600|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33929599|NCT03732521|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929600|NCT01316939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929601|NCT02882165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929602|NCT04024241|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33789754|NCT01272648|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33929603|NCT03786406|||OTHER||PROSPECTIVE|||||||
33704998|NCT04497831|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind|"The study is a randomized, double-blind, placebo-controlled analysis conducted with crossover arms. The study consists of two treatment periods lasting a total of 5 days: 2 days of nebulization with 0.9% NaCl and 2 days of nebulization with 2.0% morphine hydrochloride solution separated by 1 day intended for elimination of the drug from the body (wash-out). The order of treatment periods (morphine -\> placebo, placebo -\> morphine) will be randomized for each patient by a hospital pharmacist using online software: Research Randomizer 4.0. The draw will assign the participant to one of two sequences:~A. 2 days - 0.9% NaCl; 1 day - wash-out; 2 days - morphine hydrochloride. B. 2 days - morphine hydrochloride; 1 day - wash-out; 2 days - 0.9% NaCl"|t|f|t|f
33789755|NCT04855513|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized control trial into two groups using block randomization based on predefined criteria||||
33789756|NCT04696250|||CASE_ONLY||CROSS_SECTIONAL|||||||
33789757|NCT05172154|||COHORT||PROSPECTIVE|||||||
33789758|NCT05079061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33789759|NCT04074902|||CASE_ONLY||PROSPECTIVE|||||||
33789760|NCT06555276|||COHORT||RETROSPECTIVE|||||||
33789761|NCT06202118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789762|NCT06629324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789763|NCT00268047|||||RETROSPECTIVE|||||||
33929604|NCT03823443|||COHORT||PROSPECTIVE|||||||
33929605|NCT04801641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929606|NCT00956462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929607|NCT03628495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The ultrasound data will be processed and the data will be analysed by analysts who are blinded.||t|f|f|t
33929608|NCT03146403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929609|NCT06449989|||COHORT||RETROSPECTIVE|||||||
33929610|NCT01899651|||COHORT||PROSPECTIVE|||||||
33929611|NCT02448797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929612|NCT04876963|||COHORT||PROSPECTIVE|||||||
33929613|NCT03148795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929614|NCT04063644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blinded: The physician performing the recruiting will be different and cannot be related to the investigator evaluating the follow-up.||f|f|f|t
33929615|NCT05027698|||OTHER||PROSPECTIVE|||||||
33929616|NCT02279979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929617|NCT02311790|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33929618|NCT05057325|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33929619|NCT02264015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929620|NCT03507881|||COHORT||PROSPECTIVE|||||||
33929621|NCT05193851|NA|SINGLE_GROUP||OTHER||NONE||||||
33929622|NCT04445688|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33929623|NCT01160263|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929624|NCT06436560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929625|NCT03140124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants receive both conditions, with randomized order||||
33929626|NCT02881671|||FAMILY_BASED||PROSPECTIVE|||||||
33929627|NCT03828500|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Not masked|||||
33929628|NCT05302102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blinded to the treatment allocation.|A prospective, randomized controlled clinical trial|f|f|f|t
33929629|NCT02435394|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929630|NCT00236405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929631|NCT00768768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929632|NCT00632996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929633|NCT02217683|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929634|NCT04541732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blind study|Single blind study|t|f|f|f
33929635|NCT03476967|||COHORT||PROSPECTIVE|||||||
33929636|NCT05490498|NA|SINGLE_GROUP||OTHER||NONE||||||
33704999|NCT02094183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33705000|NCT04490343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705001|NCT03951233|||COHORT||RETROSPECTIVE|||||||
33705002|NCT02911714|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705003|NCT01437969|||COHORT||PROSPECTIVE|||||||
33705004|NCT01354912|||COHORT||PROSPECTIVE|||||||
33929637|NCT06239285|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized control trial (RCT) in a large sample of violently injured adults (18+ years) from VCU Health.||||
33929638|NCT02901080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929639|NCT03882853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33929640|NCT03039049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33929641|NCT06229210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008376|NCT06372925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|IVUS/OCT will be conducted in local lab and blinded analyzed to Independent Review Committee(IRC).||f|f|f|t
34008377|NCT04235257|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705005|NCT02370134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705006|NCT05845736|||CASE_CONTROL||RETROSPECTIVE|||||||
33929642|NCT03650036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical evaluations will be performed by two Paediatric Dentists who will not participate in the clinical part and will not know which group the teeth belong to. Participants also will not know in which group they will be allocated.|The patients will be allocated into two groups and will remain in the group until the end of the experiment.|t|f|f|t
33705007|NCT01822795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705008|NCT01596478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929643|NCT01619813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705009|NCT04612673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705010|NCT03240484|||CASE_CONTROL||PROSPECTIVE|||||||
33705011|NCT01039935|||||PROSPECTIVE|||||||
33705012|NCT04888468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705013|NCT01160315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929644|NCT05231421|||COHORT||PROSPECTIVE|||||||
33929645|NCT01674816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33929646|NCT03880006|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929647|NCT01386229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929648|NCT02396693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705014|NCT03736733|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705015|NCT03372096|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an open label pilot study with a small population undergoing an intervention to determine initial safety and potential for efficacy as measured by improvement of LUTS and decrease in prostate size||||
33705016|NCT01130454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705017|NCT04574011|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33705018|NCT04981548|||OTHER||CROSS_SECTIONAL|||||||
33705019|NCT01268969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705020|NCT02967731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705021|NCT05252455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705022|NCT01527799|||COHORT||CROSS_SECTIONAL|||||||
33705023|NCT04153942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors blind to the subject's treatment/arm will do the evaluations at 90 days||f|f|f|t
33705024|NCT01270516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705025|NCT03128411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705026|NCT02605824|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33705027|NCT02710474|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33705028|NCT04808544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Naldebain (active drug in solvent containing benzyl benzoate and sesame oil) or placebo drug (solvent containing benzyl benzoate and sesame oil) will be prepared by the clinical pharmacists in an identical injection syringe within 30 min before injection. The participants, anesthesiologists, surgeons, investigators and outcomes assessors will be blinded to the treatment groups.||t|t|t|t
33705029|NCT01112865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705030|NCT04693988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33705031|NCT05161767|||COHORT||PROSPECTIVE|||||||
33705032|NCT03799016|||COHORT||RETROSPECTIVE|||||||
33705033|NCT00672646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705034|NCT01397162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705035|NCT00229593|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705036|NCT03129178|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blind, randomised control trial. Supplements will be dispensed by nurses or a member of the research team.||t|f|t|t
33705037|NCT03712956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929649|NCT04306666|||OTHER||RETROSPECTIVE|||||||
33929650|NCT02949713|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929651|NCT04150328|||COHORT||RETROSPECTIVE|||||||
33929652|NCT04283357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One group only are treated with short foot exercises. Second group are treated with short foot exercises and virtual reality.|t|f|f|f
33929653|NCT01158638|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33929654|NCT03860623|||COHORT||CROSS_SECTIONAL|||||||
33929655|NCT02072746|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008378|NCT05468372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34008379|NCT05628181|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be a total of four primary care clinics at University of Michigan Health and Henry Ford Health; potentially more clinics will be engaged if necessary.||||
34008380|NCT05290779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705038|NCT00777114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008381|NCT05215782|||COHORT||CROSS_SECTIONAL|||||||
34008382|NCT03008837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Percutaneous electrical neural field stimulator (PENFS) using the military field stimulator, a device that uses small needles inserted in the ear (like auricular acupuncture), which are connected by electrodes to a battery pack that is attached externally using adhesive to the back of the ear. The stimulator is meant to stimulate branches of the cranial nerves via the ear.|f|f|f|t
34008383|NCT05307133|NA|SINGLE_GROUP||OTHER||NONE||||||
34008384|NCT04514016|||COHORT||CROSS_SECTIONAL|||||||
34008385|NCT02632175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008386|NCT00538655||CROSSOVER||TREATMENT||NONE||||||
33705039|NCT05057182|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705040|NCT02329912|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705041|NCT01460004|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33929656|NCT05152368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929657|NCT04756349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33929658|NCT00901862|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33929659|NCT00728663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929660|NCT01714713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929661|NCT05462457|||COHORT||PROSPECTIVE|||||||
33929662|NCT01946113|||COHORT|||||||||
33929663|NCT02636738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929664|NCT04853277|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33929665|NCT04526704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929666|NCT01514604|||COHORT||PROSPECTIVE|||||||
34008387|NCT02754284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789764|NCT03143192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and technicians (measuring ocular coherence tomography, fluorescein auto fluorescence and visual acuity) will be masked. The investigator and study coordinator will be unmasked to direct the patient.|This will be a parallel study comparing the results of patients who receive aflibercept and micropulse laser versus those who only receive aflibercept. The second group will receive sham laser to prevent placebo effects.|t|f|f|t
33705042|NCT02066142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33705043|NCT06006741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705044|NCT00828932|NA|SINGLE_GROUP||OTHER||NONE||||||
33789765|NCT05481333|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33789766|NCT05702710|||OTHER||RETROSPECTIVE|||||||
33789767|NCT03663101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929667|NCT02437968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929668|NCT03232229|||COHORT||CROSS_SECTIONAL|||||||
33929669|NCT02837809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929670|NCT02542670|||CASE_CONTROL||RETROSPECTIVE|||||||
33929671|NCT03332407|||CASE_ONLY||PROSPECTIVE|||||||
33929672|NCT06280053|NA|SINGLE_GROUP||OTHER||NONE||The patients' wound conditions were divided into four types: venous ulcers, bedsores, diabetic foot wounds and burn wounds.||||
33929673|NCT05911113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|sensory re-education and traditional therapy|t|f|f|t
34008388|NCT06043622|NA|SINGLE_GROUP||OTHER||NONE||||||
34008389|NCT00151216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be carried out in two populations of children with LINCL. Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al. Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease. All of the study population of 11 children (Group A, n= 5 and Group B, n=6) will receive 3x10\^12 particle units of the AAV2CUhCLN2 vector divided among 12 locations delivered through 6 burr holes (2 locations at varying depths through each hole), 3 burr holes per hemisphere. The choice of the locations for the burr holes and needle placement will be on a case-by-case basis due to the diffuse and variable nature of the disease presentation.||||
34008390|NCT04282655|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective quasi-experimental controlled trial||||
34008391|NCT02025088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008392|NCT03783988|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pharmacokinetic study to study the systemic levels of DHEA, DHEAs and TRIAC, before and after application of a new topical combination gel containing DHEA and TRIAC. MS-based validated methods will be used.||||
33705045|NCT05629169|||COHORT||PROSPECTIVE|||||||
33705046|NCT04138238|||COHORT||PROSPECTIVE|||||||
33705047|NCT00004771||||TREATMENT||||||||
33705048|NCT03434093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33705049|NCT02649595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705050|NCT05593926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be randomised to Placebo or the Myota Metabolic Regulator, with a 1:1 randomisation ratio stratified by gender and BMI.|Two-arm, individually randomized, single-blind placebo-controlled trial|t|f|f|f
33705051|NCT04312204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705052|NCT00000371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705053|NCT04838483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705054|NCT00650650|||COHORT||PROSPECTIVE|||||||
33789768|NCT05395832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33789769|NCT01008670|||CASE_ONLY||PROSPECTIVE|||||||
33789770|NCT02889341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929674|NCT04269941|||CASE_ONLY||RETROSPECTIVE|||||||
33705055|NCT03555916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33705056|NCT03454542|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This will be a double-masked study, with both the study participants and study investigators being masked to the order of lens wear for the initial and modified DD lens design. Study lenses will be dispensed to the participants at V2 and V4 by unmasked research assistants from paper cups. Lenses and blister-pack solution will be directly transferred into the paper cups, and only the paper cups will be taken to the examination room where lenses are being dispensed.|This will be a double-masked, cross-over, bilateral wear study design with five (5) study visits across three (3) study visit days. Participants will be dispensed and wear both the initial and modified lens design for a total of six (6) hours each on two (2) separate visit days, with the order of lens wear being randomized; participants will be allowed to leave the CCLR on their lens wearing days between dispense and follow-up visit.|t|f|t|f
34093303|NCT03657953|RANDOMIZED|PARALLEL||TREATMENT||NONE||single-center prospective randomized study design||||
33705057|NCT04971343|||OTHER||OTHER|||||||
33929675|NCT05610241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical research nurse applying the compression interventions will be blinded from interface pressure measurements|Healthy volunteer study where participants serve as their own control, the control condition will be assigned to one leg and the experimental condition applied to the other leg.|f|t|f|f
33929676|NCT04901104|||COHORT||PROSPECTIVE|||||||
34093304|NCT00019123||||TREATMENT||||||||
33929677|NCT00703404|||||PROSPECTIVE|||||||
33929678|NCT00116194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33929679|NCT02463760|||OTHER||PROSPECTIVE|||||||
34093305|NCT02871557|||COHORT||PROSPECTIVE|||||||
34093306|NCT02846428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093307|NCT05520775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized parallel group design.|t|f|t|t
34093308|NCT01601795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093309|NCT02658474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093310|NCT06478030|||COHORT||PROSPECTIVE|||||||
34093311|NCT00433537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093312|NCT00221104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093313|NCT00232921|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34093314|NCT03608969|||CASE_ONLY||CROSS_SECTIONAL|||||||
34093315|NCT03791021|||CASE_ONLY||PROSPECTIVE|||||||
33929680|NCT06067724|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33929681|NCT01496144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33929682|NCT05033678|||COHORT||PROSPECTIVE|||||||
33929683|NCT02769013|||CASE_CONTROL||PROSPECTIVE|||||||
33929684|NCT01711658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929685|NCT06391476|||COHORT||RETROSPECTIVE|||||||
33929686|NCT03137056|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33929687|NCT00172562|||DEFINED_POPULATION||OTHER|||||||
33929688|NCT02905110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929689|NCT04731922|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33929690|NCT04379323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929691|NCT00308646|||||OTHER|||||||
33929692|NCT02637648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929693|NCT02305550|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33929694|NCT02061904|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929695|NCT02114489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929696|NCT00607919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008393|NCT06443255|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34008394|NCT01561794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008395|NCT04598360|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008396|NCT02137382|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34008397|NCT00000745||||PREVENTION||DOUBLE||||||
34008398|NCT02194023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34008399|NCT03071913|||CASE_ONLY||PROSPECTIVE|||||||
34008400|NCT02127073|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008401|NCT05471609|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Double-blinded|3 different assemblies with 3 different formulations (A,B \& C) will be used.|t|f|t|f
34008402|NCT00368316|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008403|NCT00798681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093316|NCT01526382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093317|NCT00479518|||COHORT||PROSPECTIVE|||||||
34093318|NCT03116815|NA|SINGLE_GROUP||OTHER||NONE||This single arm study will examine use of the MyChart web-application whereby patients directly record their home blood pressure readings into their electronic health record with this web-based application.||||
34093319|NCT05776719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants will be informed that they will be randomized to one of two groups but will not be informed which group is expected to perform better.|1:1 randomization to either targeted group intervention or control group intervention; groups separated by gender|t|f|f|f
34093320|NCT06091033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093321|NCT05139147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093322|NCT01857518|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33705058|NCT02829554|||OTHER||CROSS_SECTIONAL|||||||
33705059|NCT02557711|||CASE_ONLY||CROSS_SECTIONAL|||||||
33705060|NCT04676074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant|Participants had randomly divided into two equal groups. Group (A) which is the control group receive normal routine medication. Group (B) will receive normal routine medication with the treatment program of moderate intensity upper limb ergometer for 15 minute with frequency three times per week for four weeks.|t|f|f|f
33705061|NCT04049357|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The investigators will include 124.214 consecutive citizens from the Region of Southern Denmark when they are invited for screening. The participants will be randomized into two groups using an automated randomization tool provided by Odense Patient data Explorative Network (OPEN). The randomization will be based on Zelen's pre-randomization principle and will take place prior to citizens receiving the invitation. The individuals are randomized into 62.107 people allocated in the intervention group and 62.107 allocated in the control group.||||
33705062|NCT05678777|||CASE_CONTROL||PROSPECTIVE|||||||
33705063|NCT05305820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|It will not be possible to be blinded to the to the allocation of participants due to their active involvement in the behavioural exercise and nutritional interventions during the study.|Parallel group randomised 1:1 controlled multi-centre trial||||
33705064|NCT04636229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All clinic staff who may be involved in making assessments of safety will be blinded to treatment assignment.|This is a prospective, multicenter, randomized, double-blind, placebo-controlled study of ASA in patients with OA of the knee. Patients will be randomly assigned in a 1:1 ratio to receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline) or 4 mL of normal saline.|t|t|t|t
33705065|NCT01259596|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33705066|NCT03081988|||COHORT||PROSPECTIVE|||||||
33705067|NCT00386659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705068|NCT05397964|||CASE_CONTROL||RETROSPECTIVE|||||||
33705069|NCT02085122|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33789771|NCT00145041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789772|NCT00595218|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33929697|NCT04498468|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The patient and the examining physician/outcomes accessor will be masked. The treating physician cannot be masked.|Prospective, Double Masked, Interventional Study.|t|f|f|t
33929698|NCT01855841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929699|NCT04336865|||CASE_ONLY||RETROSPECTIVE|||||||
33929700|NCT06311253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33929701|NCT01871415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929702|NCT04836546|NA|SINGLE_GROUP||OTHER||NONE||||||
33929703|NCT01122888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929704|NCT01553045|||CASE_CONTROL||PROSPECTIVE|||||||
34093323|NCT01755637|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093324|NCT01309711|||COHORT||PROSPECTIVE|||||||
34093325|NCT00267670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093326|NCT02219542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34093327|NCT00456118|||COHORT||PROSPECTIVE|||||||
34093328|NCT05963230|||CASE_ONLY||PROSPECTIVE|||||||
34093329|NCT02939781|||COHORT||PROSPECTIVE|||||||
34093330|NCT03837834|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093331|NCT02632214|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34093332|NCT03073447|NA|SINGLE_GROUP||OTHER||NONE||||||
34093333|NCT04483037|RANDOMIZED|PARALLEL||OTHER||NONE||The 1st group: split dose, day before, colonoscopy in the morning. The 2nd group: split dose, day before, colonoscopy in the afternoon. The 3rd group: same day, colonoscopy in the afternoon.||||
34008404|NCT01297322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705070|NCT04758104|NA|SINGLE_GROUP||TREATMENT||NONE||To estimate the efficacy of intracavitary application of 90Yttrium colloid for the treatment of an adult with a cystic tumor in the brain by a single neurosurgeon.||||
33705071|NCT01282632|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34008405|NCT06204575|||COHORT||RETROSPECTIVE|||||||
34008406|NCT03474029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705072|NCT06445296|RANDOMIZED|CROSSOVER||OTHER||SINGLE|While complete blinding is not possible (participants will see/taste the food they eat), the investigators will not tell participants whether they are consuming beef or Beyond Meat.||t|f|f|f
34008407|NCT02959008|||COHORT||PROSPECTIVE|||||||
33705073|NCT01061411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705074|NCT04827381|RANDOMIZED|PARALLEL||OTHER||NONE||Single-site, three-arm, parallel group, patient-randomized, blocked, controlled, pilot trial with two-week follow up||||
33705075|NCT03464578|||COHORT||PROSPECTIVE|||||||
33705076|NCT04650490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008408|NCT02722252|||CASE_ONLY||PROSPECTIVE|||||||
33705077|NCT05875363|||CASE_ONLY||RETROSPECTIVE|||||||
33705078|NCT05890885|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"During a routine visit in the Department of Neurology for monitoring MS disease, patients undergo a routine neurological exam which will serve later on to check inclusion/exclusion criteria (i.e., this exam will help rating the disability using the Expanded Disability Status Scale that is also routinely performed in all patients with MS). If a patient is interested in this research, the information form will be given to him/her by one of the study investigators (screening visit).~Then, after a period of reflection of at least one week after the screening visit, one study investigator will call the patient to inquire about her/his willingness to participate to the study. If the patient agrees to participate in this research, (s)he will be invited for a baseline visit in the Department of Clinical Neurophysiology for inclusion in the study."|t|f|f|t
33705079|NCT05707975|||COHORT||PROSPECTIVE|||||||
33705080|NCT00925041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705081|NCT02727361|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33705082|NCT00871897|||CASE_CONTROL||PROSPECTIVE|||||||
33705083|NCT05717946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind trial, independent researcher is responsible for randomization and blinding.|Prospective, randomized, placebo-controlled, and double-blind trial|t|t|t|t
33705084|NCT00319995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705085|NCT00951223|||CASE_ONLY||PROSPECTIVE|||||||
33705086|NCT06142071|||OTHER||PROSPECTIVE|||||||
33705087|NCT05509036|||COHORT||PROSPECTIVE|||||||
33705088|NCT05950256|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33705089|NCT02138682|||COHORT||PROSPECTIVE|||||||
33705090|NCT04808999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705091|NCT01797744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33705092|NCT03372044|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33705093|NCT03045185|NA|SINGLE_GROUP||TREATMENT||NONE|Single group so no masking|Prospective interventional uncontrolled trial||||
34008409|NCT00930904|||OTHER||PROSPECTIVE|||||||
34008410|NCT03630094|NA|SINGLE_GROUP||OTHER||NONE||||||
34008411|NCT02853864|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34008412|NCT00001108||||TREATMENT||||||||
34008413|NCT03016741|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008414|NCT03223454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34008415|NCT03669575|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The randomization block of four. Participants, research coordinators, and study clinicians are blinded.|Eligible participants are randomly assigned to one of two crossover arms, i.e verum-placebo or placebo-verum sequence. The verum groups are dosed approximately 900 mg a day omega-7 fatty acid, and placebo group contains other fatty acids except for omega-7. After the baseline assessment, a participant is on the supplement bottle for three weeks before re-assessed, and starts the second bottle without a washout period. The participant is re-assessed at the end of the six weeks before exits the study.|t|f|t|f
34008416|NCT00846859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008417|NCT01404052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008418|NCT00504478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008419|NCT00062101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008420|NCT05934487|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34008421|NCT03286608|||COHORT||PROSPECTIVE|||||||
34008422|NCT06616545|||COHORT||PROSPECTIVE|||||||
34008423|NCT06616220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008424|NCT03242616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008425|NCT03365999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Prior to being included in the study, the patient will be mentioned the times when he will receive the medication as well as the dosage of administration (which is the same for each of the two medications). The patient will not know what medication is being administered to him / her. no time The pills will be given to you in a medicine cup without access to any information legend.|Two study groups will be generated, each consisting of 40 research subjects, randomly each recipient will receive 3 doses of one of the two study drugs (tranexamic acid or aminocaproic acid). The group to which the patient belongs will be assigned through a computer program, the patient will not know to which group he belongs or what medication he will receive. The patients will be extracted from the external traumatology clinic.|t|f|f|f
34008426|NCT00190489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008427|NCT02717078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008428|NCT06484985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008429|NCT06402682|||COHORT||RETROSPECTIVE|||||||
34008430|NCT04923516|||COHORT||CROSS_SECTIONAL|||||||
33705094|NCT00951444|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705095|NCT00209534|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33705096|NCT00087607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705097|NCT04084431|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized 2-armed Phase II Pilot-Trial||||
33705098|NCT01745406|||COHORT||PROSPECTIVE|||||||
33705099|NCT05437536|||CASE_ONLY||OTHER|||||||
33705100|NCT04336306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705101|NCT02925923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705102|NCT00528463|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705103|NCT01238510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705104|NCT02644642|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33705105|NCT05076292|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single-blinded|A randomized, single-blinded, placebo-controlled three-arm cross-over study|t|f|f|f
33705106|NCT06303908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705107|NCT00701922|||COHORT||PROSPECTIVE|||||||
33705108|NCT01348165|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33705109|NCT04449081|||COHORT||CROSS_SECTIONAL|||||||
33705110|NCT04926428|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705111|NCT01109797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705112|NCT01837108|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33705113|NCT04638257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705114|NCT04042896|RANDOMIZED|PARALLEL||PREVENTION||NONE||exergame group, treadmill group and control group||||
33705115|NCT02793921|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33789773|NCT02118935|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33789774|NCT00762619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789775|NCT03640455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705116|NCT02000479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705117|NCT01890369|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33705118|NCT05021601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705119|NCT03593603|||COHORT||PROSPECTIVE|||||||
33705120|NCT01188421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705121|NCT01131611|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33705122|NCT03928353|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33705123|NCT00751933|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33789776|NCT02476890|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Chronic cough and healthy participants were randomly assigned to receive gefapixant and placebo in one of two treatment sequences: Sequence A (placebo in treatment period 1, then gefapixant in treatment period 2) or Sequence B (gefapixant in treatment period 1, then placebo in treatment period 2). There was at least a 48-hour washout between the treatment periods. Daytime cough monitoring was performed in chronic cough participants only.|t|f|t|t
33789777|NCT00303836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789778|NCT03439904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008431|NCT01331577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008432|NCT01067716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008433|NCT00760526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008434|NCT04954859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008435|NCT03559335|||COHORT||PROSPECTIVE|||||||
34008436|NCT00890331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34008437|NCT02188992|||COHORT||PROSPECTIVE|||||||
34008438|NCT00885677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008439|NCT05255952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008440|NCT01010789|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34008441|NCT05985694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008442|NCT03551873|||COHORT||PROSPECTIVE|||||||
34008443|NCT03151564|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34008444|NCT00962884|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34008445|NCT02860819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008446|NCT01035476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34008447|NCT02132052|||CASE_ONLY||RETROSPECTIVE|||||||
34008448|NCT01699919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008449|NCT03509571|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34008450|NCT02419235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008451|NCT02498249|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34008452|NCT06617130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"We hypothesize that adding 12 mg/day of indispensable amino acids (IAA) to corn-soy blend blended flour porridge will reduce gut permeability amongst 6-36 month old rural Malawian children at risk of stunting compared to providing only corn-soy blended flour porridge without addition of indispensable amino acids for a period of 4 weeks.~This will be a randomized, controlled open label parallel group efficacy clinical trial. Eligible children will be identified through a Demographic Surveillance System implemented by the study group at Mangochi district hospital. 66 children meeting set criteria will be randomised to receive corn-soy blended flour porridge (control group) or corn-soy blended flour porridge to which is added indispensable amino acids. The standard complementary food will provide 30% daily energy requirement while the amino acids in the intervention group will provide 1.5 times the estimated average requirement (EAR) for a healthy child."|t|f|f|f
34008453|NCT04746079|RANDOMIZED|PARALLEL||PREVENTION||NONE||The sealed envelope method.||||
34008454|NCT06614699|||OTHER||RETROSPECTIVE|||||||
34093334|NCT05142059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The patients will be recruited in the PMR and neurology departments within the framework of their pathology (current care) and via an older cohort of CMT1A. During a follow-up medical consultation, patients will be informed about the study. If patients express an interest, participants will be listed as a potential attendee. After reflection, patients will be contacted to confirm their participation and an appointment will be set. An assessment will be carried out within the PMR Department of Clermont-Ferrand University Hospital. The doctor will present the protocol in detail to the patients. Upon reading the information form, the doctor will obtain written consent. Clinical information and the results of the various tests will be recorded. Participants will then be compared with each other and over time. Secondly, patients will be contacted by telephone at 6 months to receive any self-reported fall via a standardized questionnaire.||||
34093335|NCT06357702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093336|NCT04895124|||COHORT||CROSS_SECTIONAL|||||||
34093337|NCT00954135|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093338|NCT03478878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093339|NCT02058277||CROSSOVER||BASIC_SCIENCE||NONE||||||
34093340|NCT04088955|||OTHER||PROSPECTIVE|||||||
34093341|NCT03388944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Children with suspected or proven sepsis will be randomized to the PCT guided group or the standard practices group and will be followed up for the primary outcome measure that includes treatment failure. We would also be comparing the duration of antibiotic therapy and mortality between the two groups as secondary outcome measures.|t|f|f|t
34093342|NCT04628910|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Weeks 0-1: Testing battery; begin daily surveys and at home monitoring via smartphone applications. This will serve as baseline and will be collected for, at minimum, 5 days prior to the first experimental condition.~Weeks 2-4: Complete daily surveys and at home monitoring via smartphone applications; Complete the first experimental condition (Float-REST or Dry Float) in 60 minute sessions, twice a week.~Week 5: Complete daily surveys and at home monitoring via smartphone applications. A second round of the testing battery will be completed prior to beginning the next condition.~Week 6-8: Complete daily surveys and at home monitoring via smartphone applications; Complete the first experimental condition (Float-REST or Dry Float) in 60 minute sessions, twice a week.~Week 9: Complete daily surveys and at home monitoring via smartphone applications. The testing battery will be completed for the final time toward the end of the week and will signify their completion of the study."||||
33705124|NCT00891592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705125|NCT04601415|||COHORT||PROSPECTIVE|||||||
33705126|NCT00074204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705127|NCT02021578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Interviewers who assess diagnostic outcomes are masked to participant condition.||f|f|f|t
33705128|NCT06484738|||COHORT||RETROSPECTIVE|||||||
34008455|NCT04135729|||COHORT||CROSS_SECTIONAL|||||||
34008456|NCT00734942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34008457|NCT04387071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008458|NCT03998319|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All parties involved will be blinded.|Multi-Centre double-blind, placebo controlled randomised phase IIIb clinical trial, stratified and balanced between groups on important prognostic factors.|t|t|t|t
34008459|NCT00778882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008460|NCT02148224|||COHORT||CROSS_SECTIONAL|||||||
34008461|NCT04272489|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be explicitly informed which type of control they will be using during each 8-week period.|The study is a randomized crossover home trial consisting of two 8-week periods with an intermittent 1-week washout period (17 weeks total). Participants will use either adaptive control or non-adaptive control during the first 8-week period then switch to using the opposite control style during the second 8-week period.|t|f|f|f
34008462|NCT06494280|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34008463|NCT00793117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34008464|NCT01099631|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33705129|NCT04420442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In this prospective monocentric non-randomized trial the intervention group and the control will be compared to each other. Furthermore, within the intervention group an intra-individual comparison will be carried out over the study period.||||
34008465|NCT05116787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008466|NCT00466895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008467|NCT06616246|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008468|NCT01275560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008469|NCT04576715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008470|NCT05477719|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34008471|NCT02404077|||COHORT||RETROSPECTIVE|||||||
34008472|NCT01619579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705130|NCT05702554|||COHORT||PROSPECTIVE|||||||
33705131|NCT03208712|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
33705132|NCT03087643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33789779|NCT05401916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, Randomized Double Blind Clinical Trial|t|f|f|f
33789780|NCT06145854|||COHORT||PROSPECTIVE|||||||
33705133|NCT02500160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789781|NCT04016818|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33789782|NCT00684528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789783|NCT03450278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789784|NCT02128789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33789785|NCT05906225|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33789786|NCT01671644|||CASE_CONTROL|||||||||
33789787|NCT00090298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789788|NCT04588285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinded phase (placebo or ambroxol) will last for 18 months and an open extension with ambroxol will be offered to all participants for one additional year. Randomisation to placebo or ambroxol will be done by the system Viedoc.|Each participant will receive 5 intra-participant dose escalations at 60 mg TID (day 1-7), 120 mg TID (day 8-14), 315 BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550) with ambroxol or placebo for the duration of 18 months.|t|t|t|t
33789789|NCT00930813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008473|NCT01022684|||COHORT||CROSS_SECTIONAL|||||||
34008474|NCT01745952|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34008475|NCT02268539|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34008476|NCT05402306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008477|NCT03130348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789790|NCT02791217|||COHORT||PROSPECTIVE|||||||
33789791|NCT05527236|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33789792|NCT01762241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34008478|NCT02284347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008479|NCT02105155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008480|NCT05176379|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will receive a placebo instead of fluconazole|Randomized, single-blind, Placebo controlled, crossover design|t|f|f|f
34008481|NCT05367765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008482|NCT01719887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008483|NCT03178721|||CASE_CROSSOVER||OTHER|||||||
34008484|NCT01706861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008485|NCT00455026|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34093343|NCT01640106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093344|NCT02390388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008486|NCT06072157|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blind (placebo) essentially identical in appearance to the investigational drug (AK006)|Single (Part A) and multiple (Part B) ascending IV dose study in healthy participants with a multiple dose expansion (Part C) in participants with chronic spontaneous urticaria. Single ascending (Part D) subcutaneous (SC) dose study in healthy participants|t|f|t|f
34008487|NCT01682642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008488|NCT02721706|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34008489|NCT03143387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008490|NCT05239533|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 design to establish the maximal tolerated dose (MTD)||||
34093345|NCT06359522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who are being treated for PDA closure either via transcatheter occlusion or medical closure as part of routine care are eligible for this study.||||
34093346|NCT01434797|||CASE_CONTROL||PROSPECTIVE|||||||
34093347|NCT00450749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093348|NCT04693728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34093349|NCT02412319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093350|NCT06285604|||CASE_CONTROL||PROSPECTIVE|||||||
34093351|NCT05680701|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34093352|NCT00120718|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34093353|NCT05340595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093354|NCT04094389|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized prospective pre-post test case series was chosen for this study. This case series will provide feasibility data in preparation for a randomized controlled study of this topic in the future.~The primary research question for this case series is as follows: Do the three proposed orthotic wearing schedules provide varying results in the reduction of digital triggering severity and level of pain experienced by those with trigger finger? The following three orthotic wearing schedules will be investigated: only during waking hours, only while sleeping, and continuously."||||
34093355|NCT02885675|||CASE_CONTROL||PROSPECTIVE|||||||
34093356|NCT02260986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093357|NCT01374464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34093358|NCT01305629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093359|NCT02325895|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34093360|NCT03555344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093361|NCT00312611|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34093362|NCT06152354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093363|NCT05011032|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34093364|NCT03253822|RANDOMIZED|PARALLEL||SCREENING||NONE|"Since baseline questionnaire is filled out before randomizasion, and citizens will know if they receive the DA or not, participants will not be masked.~No care providers are involved in the screening program in the phases we study (invitation, reminder, and stool sample), hence no masking in this groups.~The outcomes are assessed via questionnaire data or from registries (Statistics Denmark and the screening IT system), and no masking is necessary in neither investigators nor outcomes assessors."|"The LEAD trial is conducted as a two arm, randomised controlled trial nested into a population-based, organized CRC screening programme conducted in the Central Denmark Region. Citizens who are scheduled to be invited for CRC screening within the study period will be randomly allocated into one two study arms. Further, a historic study arm will be included, in order to be able to assess the effect of receiving the baseline questionnaire:~1. To receive the DA along with the screening reminder and to receive both baseline and follow-up questionnaires (intervention group)~2. To receive both baseline and follow-up questionnaires (control group)~3. To receive a questionnaire comprisng scales from both baseline and follow-up questionnaires (historic cohort)~Regardless of study arm, all citizens receive standard CRC screening information material according to the CRC screening program procedures."||||
34093365|NCT02537470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093366|NCT03940677|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093367|NCT04955925|||COHORT||PROSPECTIVE|||||||
34093368|NCT02217033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34093369|NCT00369759|||COHORT||PROSPECTIVE|||||||
33789793|NCT03264456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789794|NCT02232178|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33789795|NCT00269399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33789796|NCT04114383|||COHORT||PROSPECTIVE|||||||
33705134|NCT03277664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Due to the nature of the intervention, the caregivers of the participants and follow-up nurse were not blinded. But the doctors and statisticians were blinded. Both in the intervention group and control group, adherence data were not available to clinicians.|The Study of Asthma Adherence study was a multicentre, single-blind, parallel group randomised controlled trial, with an allocation ratio of 1:1.|f|f|t|t
33705135|NCT05397574|||COHORT||PROSPECTIVE|||||||
33789797|NCT06030908|||CASE_ONLY||OTHER|||||||
33789798|NCT00001318||||TREATMENT||||||||
34008491|NCT02591563|||COHORT||PROSPECTIVE|||||||
34008492|NCT01556282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008493|NCT03998709|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008494|NCT05453786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008495|NCT06020482|||CASE_CONTROL||PROSPECTIVE|||||||
34008496|NCT00640263|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008497|NCT03321526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008498|NCT04570176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008499|NCT00746291|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008500|NCT00143299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34008501|NCT00813826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008502|NCT00114231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008503|NCT01553201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008504|NCT03543709|||COHORT||PROSPECTIVE|||||||
34008505|NCT04591652|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008506|NCT00435305|||||PROSPECTIVE|||||||
34008507|NCT01745354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093370|NCT05509621|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Preterm neonates to be included in the study will be placed in 5 different positions using a crossover design.In order not to repeat the order of positions,5 groups will be created as follows:ABCDE;BCDEA;CDEAB;DEABC;EABCD.The number of the groups created for not repeating the order of positions will be determined using the lottery method;Group1=CDEAB;Group2=BCDEA;Group3=EABCD;Group4=DEABC;Group5=ABCDE.Then,which position corresponds to which letter will be determined using the lottery method;A=quarter prone position,B=prone position,C=supine position,D=left lateral position,E=right lateral position.Afterward,40 preterm neonates will be randomly assigned to 5 groups using the block randomization method in line with the sample calculation. The order of the positions for the preterm neonate will be determined according to the position order of the group including the preterm infant.||||
34093371|NCT06137053|||COHORT||PROSPECTIVE|||||||
33705136|NCT00001872|||||PROSPECTIVE|||||||
34093372|NCT04321499|||COHORT||RETROSPECTIVE|||||||
34093373|NCT02604745|||COHORT||PROSPECTIVE|||||||
33705137|NCT01402011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"For the 25% dextrose and .1% lidocaine and the .1% lidocaine enthesis injections, only the pharmacist knew the contents of each participant's numbered bottle. For the .1% subcutaneous injections, both the pharmacist and the physician where aware of the contents. There was a small c on the label. Only one participant asked the meaning of this letter, and he was told it stood for contents."|Participants were randomly allocated into 3 groups to receive injections of 25% dextrose in .1% lidocaine or .1% lidocaine in the shoulder entheses, the 3rd group received .1% lidocaine subcutaneously above the shoulder entheses.|t|t|f|t
33705138|NCT01652209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705139|NCT03892096|||COHORT||PROSPECTIVE|||||||
33705140|NCT03619317|||COHORT||PROSPECTIVE|||||||
33705141|NCT00702195|||OTHER||PROSPECTIVE|||||||
33705142|NCT00268359||||TREATMENT||NONE||||||
33929705|NCT03289052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929706|NCT01005199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929707|NCT00454480|RANDOMIZED|||TREATMENT||||||||
33929708|NCT03959956|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929709|NCT06147778|NA|SINGLE_GROUP||OTHER||NONE||||||
33929710|NCT04509401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929711|NCT01502670|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929712|NCT01611922|||COHORT||PROSPECTIVE|||||||
33929713|NCT02881450|||COHORT||CROSS_SECTIONAL|||||||
33929714|NCT03268642|||COHORT||RETROSPECTIVE|||||||
33929715|NCT05884268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33929716|NCT01983449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929717|NCT04309357|||COHORT||PROSPECTIVE|||||||
33929718|NCT04894357|||COHORT||RETROSPECTIVE|||||||
33929719|NCT00155688|||DEFINED_POPULATION||OTHER|||||||
33929720|NCT00550992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929721|NCT03086590|||OTHER||CROSS_SECTIONAL|||||||
33929722|NCT04051775|||COHORT||PROSPECTIVE|||||||
33929723|NCT05374291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blinded|The RENAL LIFECYCLE trial consists of a screening period and a double blind treatment period with two arms. Participants will be randomly assigned in a 1:1 ratio to double blind treatment with dapagliflozin 10 mg/d or matching placebo. Randomization will be stratified by enrolment stratum (pre-dialysis, dialysis, kidney transplantation), centre and type 2 diabetes mellitus status yes/no) to ensure balanced distribution across the two treatment arms.|t|f|t|f
33929724|NCT03857178|||COHORT||CROSS_SECTIONAL|||||||
33929725|NCT06373536|||COHORT||CROSS_SECTIONAL|||||||
33929726|NCT04611061|||COHORT||PROSPECTIVE|||||||
33929727|NCT05480800|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Data will be collected in an observer-blind manner.||t|f|t|t
33929728|NCT05226143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929729|NCT03641794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929730|NCT04836923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929731|NCT00408291|||COHORT||PROSPECTIVE|||||||
33929732|NCT02726048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929733|NCT02725268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929734|NCT04078074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929735|NCT00136357|RANDOMIZED|PARALLEL||||NONE||||||
33929736|NCT05132101|||COHORT||RETROSPECTIVE|||||||
33929737|NCT01722903|||COHORT||PROSPECTIVE|||||||
33705143|NCT05165836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093374|NCT00512863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705144|NCT01218243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33789799|NCT05969730|RANDOMIZED|PARALLEL||TREATMENT||NONE||BAAZ-AD-IR is a single-center, open-label, randomized trial which will be conducted in Iran. Patients who meet eligibility criteria will randomize (1:1) to receive baricitinib 4 mg daily or azathioprine 1.5-2.5 mg/kg for 12 weeks. All patients will receive emollient daily. Four weeks prior to randomization, patients will discontinue tropical and systemic treatments for atopic dermatitis and will not be allowed to use them during the study. The drugs will be prescribed at visit 1 (randomization day, or four weeks after screening). All demographics and baseline information will be gathered at visit 1. Six weeks after visit 1, visit 2 will be scheduled for each patient. At visit 2, patients will be followed up. Twelve weeks after visit 1, visit 3 will be scheduled, and final assessments will be done.||||
33789800|NCT00494442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789801|NCT03597698|||COHORT||RETROSPECTIVE|||||||
33789802|NCT01985061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008508|NCT06035276|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||"This study is a single-center research project with a 2-period, sequential, cross-over (clean vs. versus urban air) design, which supports the development of the REMEDIA sensor toolkit with clinically relevant data and bio samples. The approach is exploratory, blinding or randomization are not applicable. Two populations will participate: healthy subjects and COPD subjects with GOLD stage 1 to 2."||||
34008509|NCT02788513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34008510|NCT04454528|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34008511|NCT00255151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34008512|NCT06176625|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Initial portion of study is observational in nature.~For the interventional portion, a baseline period of data collection will first be completed on all three hospital units. Intervention will be initially implemented in one unit and added in each subsequent unit in succession following equivalent time periods."||||
34008513|NCT01225055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008514|NCT05123781|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34093375|NCT03693898|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093376|NCT01642966|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34093377|NCT02916875|||OTHER||PROSPECTIVE|||||||
34093378|NCT02029547|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34093379|NCT01620099|RANDOMIZED|PARALLEL||||NONE||||||
34093380|NCT03562507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There are 2 cohorts for accrual with Cohort A being accrued first. Cohort B will follow and will have 2 stages of accrual. Cohort A will accrue 11 patients to monotherapy treatment. Then Cohort B will begin accrual of 17 patients to the first stage and if the interim permits, the second stage will accrue an additional 19 patients.||||
34093381|NCT01149538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093382|NCT03131661|||COHORT||PROSPECTIVE|||||||
34093383|NCT01452217|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093384|NCT06462872|||CASE_ONLY||PROSPECTIVE|||||||
34093385|NCT00032539|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34093386|NCT02233153|||OTHER||PROSPECTIVE|||||||
34093387|NCT00031005||||TREATMENT||||||||
34093388|NCT01765998|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34093389|NCT02898506|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093390|NCT01692015|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093391|NCT03240445|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34008515|NCT04061577|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Traditional 3+3 (rule-based, modified Fibonacci) dose-escalation design|t|f|f|f
34093392|NCT03908008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093393|NCT06161090|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34093394|NCT05551897|NA|SINGLE_GROUP||OTHER||NONE||||||
34008516|NCT06216860|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34008517|NCT06616142|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All study participants will receive an adrenal vein sampling and a \[18F\]CETO PET/CT scan.||||
34008518|NCT03923231|||COHORT||PROSPECTIVE|||||||
34008519|NCT01021631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34008520|NCT00810173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008521|NCT03167502|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008522|NCT05195177|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093395|NCT04491994|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.|Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled||||
34093396|NCT03483220|||COHORT||CROSS_SECTIONAL|||||||
34093397|NCT00694343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705145|NCT05336838|||COHORT||PROSPECTIVE|||||||
33705146|NCT01597401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705147|NCT03756077|||COHORT||PROSPECTIVE|||||||
33705148|NCT05412615|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33705149|NCT06557395|||OTHER||PROSPECTIVE|||||||
33705150|NCT05399641|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, 3 group, stratified||||
33705151|NCT05134675|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34008523|NCT00088049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34008524|NCT06214754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008525|NCT06617780|||COHORT||PROSPECTIVE|||||||
33929738|NCT05458362|RANDOMIZED|PARALLEL||TREATMENT||NONE|During the consent process, participants are provided information that some of them may receive additional phone app intervention. This is not stressed at any other time during the study. After randomization has been completed, treatment session groups will be formed including participants from both conditions. After the the session, participants receive an email reminding them about the surveys and reminders they will be getting through the app during the upcoming 2 weeks.|"A 1.5-hour intervention session will be completed by all participants. We will ask all participants to complete homework exposure exercises. They will receive phone app reminders about completing homework.~Treatment group (EMI group): For two weeks after the session, four times a day, the EMI group will receive prompts via the HIPAA-compliant EMI application (metricwire.com). The prompts will ask them about their current anxiety level. If they endorse elevated anxiety, they will be provided with a brief message reminding them about the coping skills covered during the session. They will also receive daily prompts to do exposures and enter the results in the app.~Control group: The control group will not receive EMI prompts and will be offered to complete EMI after the follow-up assessment."||||
33929739|NCT05859906|||CASE_CONTROL||PROSPECTIVE|||||||
34008526|NCT05545618|||COHORT||RETROSPECTIVE|||||||
34008527|NCT06365684|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single center, cross-over randomized clinical trial with non-inferiority design||||
34008528|NCT03092882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008529|NCT02104817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34008530|NCT00004294||||TREATMENT||||||||
34008531|NCT05992090|||COHORT||PROSPECTIVE|||||||
34008532|NCT05184699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Sixty patients with psoriatic disease will be randomized to receive food supplement Endocalyx (n=30) or placebo (n=30) for 4 consecutive months.|t|f|t|f
34008533|NCT02278458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008534|NCT00988208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008535|NCT02874014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008536|NCT01220609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008537|NCT04373629|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34008538|NCT03764735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel-group study of two strengths of ophthalmic solution versus placebo solution|t|t|t|t
34008539|NCT04474431|NA|SINGLE_GROUP||OTHER||NONE||||||
34008540|NCT00847743|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34093398|NCT05919251|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are not aware of other arm of study ongoing. Care providers are only part of the training arm that they are involved in. Independent Outcomes assessor is performing all testing|pretest posttest 2 groups x 2 test sessions|t|t|f|t
33789803|NCT05302713|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Participants will be randomized to take either an ionic calcium (IC) supplement or calcium carbonate (CC) supplement for 12 weeks. At the 12 week time point, all participants, whether having taken IC or CC for the first 12 weeks, will take the IC supplement for the final 12 weeks of the study in an open label fashion.|t|t|t|t
33789804|NCT04806113|NA|SINGLE_GROUP||PREVENTION||NONE||Non-randomized, open label, comparative clinical trial with pragmatic features.||||
33789805|NCT00673413|||CASE_ONLY||CROSS_SECTIONAL|||||||
33789806|NCT03245060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Research Assistant will complete the psychosocial outcome measures at all time points in face to face interview format. The Research Assistant will be blinded to treatment allocation.|"Wait-list control feasibility study with nested qualitative research.~Participants will be randomly assigned to the intervention group or wait-list control group. Both groups will be assessed on psychosocial outcome measures at T1 (baseline, prior to randomisation), T2 (three months post randomisation) and T3 (six months post randomisation). Participants will also take part in in-depth interviews at T3 exploring their experiences of taking part in the project as well as complete a resource use questionnaire. All participants will receive all usual care, and up to six SFBT sessions spaced over three months delivered by Speech and Language Therapists (SLTs). The intervention group will receive the therapy immediately post randomisation, while the wait-list control group will be offered the intervention after T3. The wait-list control will additionally be reassessed at T4 (nine months post randomisation)."|f|f|f|t
33789807|NCT05977933|||COHORT||PROSPECTIVE|||||||
33789808|NCT04972812|||CASE_ONLY||PROSPECTIVE|||||||
34008541|NCT05856513|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008542|NCT05181800|||COHORT||PROSPECTIVE|||||||
34008543|NCT04973098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008544|NCT05945667|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008545|NCT04184999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized, controlled prospective study.|t|f|f|f
34008546|NCT01687829|||CASE_CONTROL||RETROSPECTIVE|||||||
34008547|NCT00003098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34008548|NCT05103709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking will be mixed. Since the third arm will not receive product of any kind it is not possible to mask the volunteers assigned to this group. The packaging of the products will be neutral to blind the volunteers in the groups that will receive products. The investigators will be blinded to randomization at all times.||t|f|t|t
34008549|NCT02674386|NA|SINGLE_GROUP||OTHER||NONE||||||
34008550|NCT03605524|NA|SINGLE_GROUP||OTHER||NONE||||||
34008551|NCT01338714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34008552|NCT03667495|||OTHER||PROSPECTIVE|||||||
34008553|NCT00504803|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34008554|NCT04329299|||COHORT||PROSPECTIVE|||||||
33789809|NCT06024564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789810|NCT02987543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789811|NCT00829751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33789812|NCT04687553|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The order of the administration was randomly selected. All patients' total scores assessed by rater A were recorded to test the internal consistency of SECONDs (A1). Meanwhile, to assess the concurrent validity, the scores of the CRS-R were recorded together with SECONDs by rater A on day 1. In order to analyze the test-retest reliability, rater A complete the second evaluation of SECONDs on day 2 (A2).|t|f|t|f
33789813|NCT00999492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789814|NCT00964184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789815|NCT05943652|||COHORT||CROSS_SECTIONAL|||||||
33789816|NCT02754011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789817|NCT05155371|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
34008555|NCT04830917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008556|NCT04144426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33789818|NCT00076180||SEQUENTIAL||TREATMENT||NONE||||||
33789819|NCT06629441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789820|NCT06495424|||COHORT||PROSPECTIVE|||||||
33789821|NCT04851730|NA|SINGLE_GROUP||TREATMENT||NONE|The researcher providing the orthopedic intervention will be blinded from the participant's pelvic floor muscle examination results.|ABA single subject design||||
33789822|NCT05679037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929740|NCT03654560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929741|NCT00086294||||TREATMENT||||||||
33929742|NCT00776490|RANDOMIZED|CROSSOVER||||NONE||||||
33929743|NCT06398951|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929744|NCT00053222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929745|NCT06031025|||COHORT||PROSPECTIVE|||||||
33929746|NCT05527106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33929747|NCT01131845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929748|NCT04263415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a randomized, single-blind, placebo-controlled clinical trial|t|f|f|f
33929749|NCT00425945|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33929750|NCT05367167|||OTHER||CROSS_SECTIONAL|||||||
33929751|NCT03624439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929752|NCT01159821|NA|SINGLE_GROUP||||NONE||||||
33929753|NCT04165304|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33929754|NCT04961827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34008557|NCT00025740||||TREATMENT||||||||
34008558|NCT02092337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008559|NCT03676647|||COHORT||OTHER|||||||
34008560|NCT02343354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34008561|NCT01230892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008562|NCT03072654|||COHORT||PROSPECTIVE|||||||
33929755|NCT05068388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929756|NCT04757376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008563|NCT02999451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705152|NCT04665700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This trial consists of a single dose part and a multiple rising dose (MRD) part. The first dose group is conducted in the single dose part and the second dose group onwards are conducted in the MRD part.|t|f|t|f
33929757|NCT02733471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33929758|NCT06427148|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Feedback was gathered from 10 pediatricians and nurses. Additionally, 5 inpatient children at Koç University Hospital provided their opinions on GoldenBreath, assessing ease of use, clarity, content appropriateness, sound volume, instruction clarity, game duration, and improvement suggestions. Based on feedback from 2 children suggesting more gold coins and longer game duration, options were added to adjust these elements in the game's menu.~Stage 2: Following expert and child evaluations, a preliminary trial was conducted with 13 children at Koç University Hospital's pediatric outpatient clinic. The researcher met with children and parents ten minutes before the procedure. Children tried the game, using VR headsets and earphones during the procedure while receiving routine care."||||
33929759|NCT01394367|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705153|NCT05200832|||COHORT||PROSPECTIVE|||||||
33705154|NCT03724032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705155|NCT04803461|||COHORT||PROSPECTIVE|||||||
33705156|NCT00787384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929760|NCT01285752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929761|NCT03871465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929762|NCT01240304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008564|NCT00528268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093399|NCT04377386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The assignment of treatment in real time will be made with the support of a computer program. The procedure will take place by means of a single assignment sequence that determines the assignment code for each participant's treatment. This process allows all participants in the study to be assigned to any of the treatment groups.~Supplements will be packaged in individual packages with the total number of doses per participant (105 doses). The coding of the packages will be in charge of the laboratory in charge of providing the supplements, which in turn will send to the designated person at the data center by institutional e-mail, a document with the list of codes and the dose of the supplement.~The 1000 IU and 200 IU doses of VD will be provided in white containers and will be identical in terms of physical and organoleptic characteristics, to ensure that both participants and investigators are blinded to the treatment."|"Pilot study of a two-arm, triple-blind, parallel randomized controlled clinical trial, in 150 adolescents and young adults in the city of Bucaramanga-Colombia. All participants will be given 105 doses of VD. The 75 participants assigned to the intervention group will take one 1000 IU VD capsule daily for 15 weeks. On the other hand, the 75 participants in the control group will take 1 capsule of VD of 200 IU for the same time. The participants in both the intervention and the control group must record in a calendar the time of the daily intake of the supplement during the 15 weeks.~The main outcomes are: serum levels of 25 (OH) D, body mass index and lipid profile; Secondary measures complement the previous ones (skin folds, waist-to-hip ratio). Other variables will be analyzed such as: assessment of dietary intake, physical activity, sun exposure, cigarette and tobacco consumption and adherence to supplementation with DV."|t|t|t|t
34093400|NCT00670384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093401|NCT02748031|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093402|NCT02016508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093403|NCT02416271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093404|NCT05455866|||COHORT||PROSPECTIVE|||||||
34093405|NCT06295952|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label single-center pilot study.||||
34093406|NCT02405962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093407|NCT04426162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093408|NCT02299167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093409|NCT03363035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705157|NCT05900271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those carrying out clinical assessments will be blinded. However, participants and those who will be administering the rTMS or SNT treatment will not be blinded. Participants and research staff will be requested not to reveal information about treatment allocation to the raters.|multicentre, two-phase, randomized clinical trial|f|f|f|t
33705158|NCT01151007|||CASE_ONLY||RETROSPECTIVE|||||||
33705159|NCT03493399||SEQUENTIAL||TREATMENT||NONE||||||
33705160|NCT01133522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705161|NCT00705484|||COHORT||PROSPECTIVE|||||||
33705162|NCT02188108|NA|SINGLE_GROUP||OTHER||NONE||||||
33929763|NCT03615989|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Those completing the analyses were masked to the treatments.|Randomized acute Crossover Trial|f|f|f|t
33929764|NCT03348566|||COHORT||PROSPECTIVE|||||||
33929765|NCT05392166|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929766|NCT05417659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33929767|NCT04038385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33929768|NCT00910013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929769|NCT02746770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929770|NCT00774969|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
33929771|NCT03519841|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||Non-randomized interventional study comparing device and blood reference measurements in diabetic patients|f|f|f|t
33929772|NCT02393222|||COHORT||PROSPECTIVE|||||||
33929773|NCT00905268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929774|NCT00483418|||COHORT||CROSS_SECTIONAL|||||||
33929775|NCT04646226|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study will determine if placement of a graft access will be more effective at having access switched from catheter to using the graft; have fewer interventions on the graft access; have better arm function; have better self-sufficiency with daily activities; and better quality of life compared to those who receive a fistula - identify strategies that decrease dialysis access failure and improve quality of life||||
33929776|NCT04258293|||COHORT||PROSPECTIVE|||||||
33929777|NCT00259389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929778|NCT01257672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929779|NCT04107636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929780|NCT01376388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929781|NCT04753723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929782|NCT06009198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929783|NCT04307953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||6-month double blind randomized controlled trial of AZD0530 versus placebo, followed by a 12 month open label extension phase|t|t|t|t
33929784|NCT01448707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929785|NCT05934136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33929786|NCT00281567|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33929787|NCT06350006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicenter Phase Ib/III clinical study. Phase Ib consists of two phases, IB-A for dose escalation and IB-B for efficacy extension. The Phase III multi-center, randomized controlled, double-blind study was designed to evaluate the efficacy and safety of SHR-A1904 combined chemotherapy and immunotherapy versus chemotherapy combined immunotherapy in first-line treatment of CLDN18.2-positive solid tumors patients.||||
33929788|NCT00220259|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33929789|NCT02527902|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33929790|NCT02989480|||OTHER||PROSPECTIVE|||||||
33929791|NCT02947490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929792|NCT00442949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929793|NCT05702736|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929794|NCT01784614|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33929795|NCT01985386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33705163|NCT02292875|||COHORT||PROSPECTIVE|||||||
34008565|NCT00111566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008566|NCT06097845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008567|NCT06070805|||COHORT||PROSPECTIVE|||||||
34008568|NCT00983606|||COHORT||PROSPECTIVE|||||||
34008569|NCT06609538|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE||"1. Control Group with Propofol: Receives standard preoperative instructions and propofol infusion.~2. Suggestion Group with Propofol: Receives positive preoperative suggestions and propofol infusion.~3. Control Group with Ketamine: Receives standard preoperative instructions and ketamine infusion.~4. Suggestion Group with Ketamine: Receives positive preoperative suggestions and ketamine infusion."|t|t|f|t
34008570|NCT01353846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008571|NCT02052791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008572|NCT01789957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008573|NCT04308720|||COHORT||PROSPECTIVE|||||||
34093410|NCT05883878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093411|NCT06040619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Pilot randomized control trial comparing treatment group to usual care. The usual care group will have the option to cross over to the treatment group after 8 weeks.||||
33929796|NCT05038787|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34093412|NCT05442632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34093413|NCT02470572|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33705164|NCT04532970|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will use permuted block randomization with random block sizes between 6 and 9 and stratified by sex and depressive symptoms. The blocks will ensure near 1:1 balance throughout the study. The random block sizes will protect against selection bias by preventing staff from predicting which intervention any one individual will be assigned. We will stratify by sex to ensure balance of women in both arms since smoking is more common in men. We will stratify by depressive symptoms to ensure balance in testing whether the effect of BAPS is differential between those with and without greater degrees of distress. While a Mood Module of PRIME-MD score of \>5 symptoms is commonly used as a threshold for depression (Spitzer et al., 1994), we are also targeting lower level symptoms with this intervention having found that lower levels are associated with health behaviors such as medication adherence (Gross et al., 2017).||||
34008574|NCT01304381|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705165|NCT01646762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929797|NCT02795455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929798|NCT05270083|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34008575|NCT02288494|||||CROSS_SECTIONAL|||||||
33929799|NCT02820688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929800|NCT01364857|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33929801|NCT05537493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator is blind to study groups|Romdomised controlled|f|f|f|t
33929802|NCT05795257|||CASE_ONLY||PROSPECTIVE|||||||
33929803|NCT03189407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008576|NCT02241135|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093414|NCT03415269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093415|NCT04860921|||COHORT||PROSPECTIVE|||||||
34093416|NCT04241523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705166|NCT00687960|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33705167|NCT02722460|||CASE_ONLY||PROSPECTIVE|||||||
33705168|NCT06199817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705169|NCT00129428|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33929804|NCT05166551|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33929805|NCT01703104|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33929806|NCT04800094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929807|NCT05810298|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33929808|NCT01227720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929809|NCT06512831|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929810|NCT04828850|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008577|NCT06163092|||COHORT||PROSPECTIVE|||||||
34008578|NCT03399578|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093417|NCT00908778|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34093418|NCT00471354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929811|NCT01300949|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Contrast sensitivity, another means of testing vision, will be measured two ways for each participant. One method uses the Pelli-Robson Contrast Sensitivity Chart which is mounted on the wall, the other method uses a new computerized program called Spaeth/Richman Contrast Sensitivity Test also known as SPARCS.||||
33929812|NCT05316519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single-blind|Sham-controlled|t|f|f|f
33929813|NCT00049140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929814|NCT00391248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929815|NCT02069704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093419|NCT02638441|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093420|NCT01290731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093421|NCT01800058|||CASE_ONLY||PROSPECTIVE|||||||
34093422|NCT01566162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929816|NCT01181752|||CASE_CONTROL||PROSPECTIVE|||||||
33929817|NCT01781624|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33929818|NCT01770145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008579|NCT01332786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008580|NCT05687682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||AM-928||||
34008581|NCT05332834|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Biological Product: SM17 monoclonal antibody or Placebo|t|t|t|t
34008582|NCT06258161|||COHORT||PROSPECTIVE|||||||
34008583|NCT05468008|||COHORT||PROSPECTIVE|||||||
34008584|NCT02678871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008585|NCT00605917|||CASE_ONLY||PROSPECTIVE|||||||
34008586|NCT03401554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008587|NCT04430127|||OTHER||PROSPECTIVE|||||||
34008588|NCT02247050|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34008589|NCT04065061|RANDOMIZED|PARALLEL||OTHER||TRIPLE|to be completed|Randomized Double Blinded placebo study|t|t|t|f
34008590|NCT02082249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705170|NCT01607242|||COHORT||PROSPECTIVE|||||||
34008591|NCT02990806|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34008592|NCT03353311|||COHORT||PROSPECTIVE|||||||
34008593|NCT00003894||PARALLEL||SUPPORTIVE_CARE||||||||
34008594|NCT04837079|||COHORT||CROSS_SECTIONAL|||||||
34008595|NCT01937819|RANDOMIZED|PARALLEL||||NONE||||||
34008596|NCT00872924|RANDOMIZED|CROSSOVER||||NONE||||||
33705171|NCT00651352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008597|NCT03112148|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008598|NCT06068777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008599|NCT00117741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008600|NCT04783116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008601|NCT00353652|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Capsule was made to appear identical in appearance so that subjects are blinded to treatment assigned.||t|f|f|f
34008602|NCT01380249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008603|NCT00108082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008604|NCT02605252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705172|NCT06506656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008605|NCT03378414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093423|NCT04124796|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* Fifteen to twenty target subjects patients are expected, corresponding to the average population received each year for a CBCa in the unit.~* Fifteen members of the health care team managing these patients"||||
33705173|NCT03481075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705174|NCT06362174|||COHORT||PROSPECTIVE|||||||
33705175|NCT02664259|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705176|NCT06557629|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705177|NCT00153907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705178|NCT04372082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33705179|NCT00084383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705180|NCT03813849|||CASE_ONLY||PROSPECTIVE|||||||
33705181|NCT02222740|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705182|NCT04493073|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33705183|NCT04789135|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental. Nature of descriptive analysis of the exploratory type, as it seeks to gather characteristics and information about the studied phenomena||||
33705184|NCT04571879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705185|NCT06328101|||COHORT||RETROSPECTIVE|||||||
33705186|NCT04589455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33705187|NCT05898360|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Investigators analysing study outcomes will be blinde|daily time-restricted eating (TRE) protocol and a control protocol for each two weeks, separated by a four-week wash-out period|f|f|f|t
33705188|NCT05780580|||COHORT||RETROSPECTIVE|||||||
33705189|NCT04450472|||COHORT||RETROSPECTIVE|||||||
33705190|NCT03167905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cross over or switch to the other group of analgesia is allowed.|f|f|f|t
33705191|NCT03471520|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705192|NCT04341077|NA|SINGLE_GROUP||OTHER||NONE||||||
33705193|NCT06409923|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008606|NCT01832402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34008607|NCT03889834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008608|NCT02956616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34008609|NCT02277431|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34008610|NCT02851719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008611|NCT02341521|NA|SINGLE_GROUP||||NONE||||||
34008612|NCT06469762|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be unaware of their treatment condition.|Randomized trial with an intervention and placebo group. 2 x 2 x 3 mixed design, measures will be taken pre- and post-treatment in all 3 treatment sessions.|t|f|f|f
34008613|NCT04241133|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Participants are assigned to an intervention group or control group (nonrandomized).||||
33705194|NCT02963792|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705195|NCT05002452|||COHORT||PROSPECTIVE|||||||
34008614|NCT04260321|||COHORT||PROSPECTIVE|||||||
34008615|NCT03653624|||CASE_ONLY||PROSPECTIVE|||||||
34008616|NCT02994394|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008617|NCT02541084|||COHORT||PROSPECTIVE|||||||
34008618|NCT01961752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34008619|NCT02866591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705196|NCT03533543|||COHORT||RETROSPECTIVE|||||||
34008620|NCT00759720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008621|NCT04075851|||COHORT||CROSS_SECTIONAL|||||||
33929819|NCT04125875|||COHORT||PROSPECTIVE|||||||
33929820|NCT00531908|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929821|NCT06309498|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929822|NCT05167968|||COHORT||PROSPECTIVE|||||||
33929823|NCT03431792|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment of fetuses with severe CDH with an observed / expected total fetal lung volume ratio (o/e TFLV) ratio \< 25% or with o/e TFLV ratio \< 35% combined with herniation of the liver in thorax using the intrauterine fetoscopic tracheal occlusion (FETO) with the long tail latex balloon of 2.5 ml.||||
33929824|NCT05373082|||COHORT||PROSPECTIVE|||||||
33929825|NCT02330445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parts of recipients are assigned for this Phase I/II open label, single site study. Part A subjects are all who had RA while Part B subjects are healthy volunteers. All subject are allocated to the single treatment group at a fixed dose of 6.0μg/kg of IV PRTX-100.||||
33929826|NCT01319513|RANDOMIZED|CROSSOVER||||NONE||||||
33929827|NCT00297128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929828|NCT05664555|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33929829|NCT05824767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929830|NCT01993667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929831|NCT01451866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929832|NCT04176536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929833|NCT04066010|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33705197|NCT05327257|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Participant, care provider, investigator and outcomes assessor blinded to treatment arm||t|t|t|t
33929834|NCT03126240|||CASE_ONLY||PROSPECTIVE|||||||
33705198|NCT04209517|||COHORT||PROSPECTIVE|||||||
34008622|NCT00277407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008623|NCT06103279|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The work is a prospective, randomized, controlled study. A total of 40 cancer patients who will receive DOX-based chemotherapy will be enrolled in the study~These patients will be randomly assigned to either Group I or Group II (each group contains 20 patients) Group I: will receive the standard chemotherapy protocol (DOX-based chemotherapy) only.~Group II: will receive the standard chemotherapy protocol (DOX-based chemotherapy) plus Empagliflozin."||||
34008624|NCT01355848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008625|NCT02857647|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008626|NCT05755087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008627|NCT04014582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned to condition, and they will not be aware if they are in the intervention or control group. The control group is more than usual care, so they may also believe they are in the intervention group.|Participants will be assigned to one of two groups, either the intervention or the control (diabetes education) condition|t|f|f|t
34008628|NCT05685277|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34093424|NCT04404556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures are patient-reported and thus masking will not occur at the level of participant, investigator or outcomes assessor.|Participants will be randomized to one of two conditions: 1) Diabetes Journey or 2) Enhanced Standard of Care.|f|t|f|f
34093425|NCT03126149|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34093426|NCT03122665|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinded drug containers.|Volunteers given two doses of nefopam in a crossover protocol.|t|f|t|f
34093427|NCT01386177|NA|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33705199|NCT00420693||PARALLEL||TREATMENT||NONE||||||
33705200|NCT00473993|||||RETROSPECTIVE|||||||
33929835|NCT04456595|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008629|NCT03810573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093428|NCT00308685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093429|NCT04308694|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34093430|NCT05150470|NA|SINGLE_GROUP||PREVENTION||NONE||cohort||||
34093431|NCT00538252|||FAMILY_BASED||PROSPECTIVE|||||||
34093432|NCT03843216|||COHORT||RETROSPECTIVE|||||||
34093433|NCT00003969||||TREATMENT||||||||
34093434|NCT01011725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093435|NCT02539693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929836|NCT00558233|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33929837|NCT00301470|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33929838|NCT00135525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929839|NCT05475444|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Group I (negative control group): Root canals were not treated after cleaning and shaping.~* Group II (positive control group): Root canals were treated with calcium hydroxide paste~* Group III: Root canals were treated with CIP paste conventionally used by the dentist which was formed by mixing CIP with saline to form a paste.~* Group IV: Root canals were treated with (F1) which is the prepared in-situ gel formulation containing CIP loaded chitosan coated PLGA nanoparticles.~* Group V: Root canals were treated with (F2) which is the prepared in-situ gel containing ciprofloxacin hydrochloride."||||
33929840|NCT03013959|||CASE_CONTROL|||||||||
33929841|NCT00444418|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34008630|NCT02744755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705201|NCT02675283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008631|NCT06130787|NA|SINGLE_GROUP||OTHER||NONE||||||
34008632|NCT00625755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093436|NCT01227395|||CASE_ONLY||RETROSPECTIVE|||||||
34093437|NCT01625767|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34093438|NCT02032784|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34093439|NCT01138046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093440|NCT00308282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093441|NCT06381843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34093442|NCT00120484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093443|NCT05362019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705202|NCT00565045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705203|NCT03999593|||COHORT||RETROSPECTIVE|||||||
33705204|NCT04858633|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33929842|NCT06506851|RANDOMIZED|PARALLEL||OTHER||NONE||"Experimental Group (AR-based Training):~Nurses receive AR-based training with Microsoft HoloLens 2®, immersing them in interactive simulations for hands-on learning.~Control Group (Traditional Self-Learning):~Nurses follow traditional guideline-based self-learning methods without augmented reality technology."||||
34008633|NCT06617637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers conducting the evaluations in the study will be masked to the treatment groups, and the researcher conducting the statistical analysis will be masked to the evaluations.|Participants to be included in the study will be randomly grouped into three groups. Two groups will be the intervention group and one group will be the control group.|f|f|t|t
34008634|NCT00699478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008635|NCT02008708|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008636|NCT03419104|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008637|NCT01230294|||CASE_CONTROL||PROSPECTIVE|||||||
34008638|NCT00873106|||COHORT||CROSS_SECTIONAL|||||||
34008639|NCT04837963|||CASE_CONTROL||RETROSPECTIVE|||||||
34008640|NCT06230627|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There were two control groups in this study, the first were people with SCI who only conducted the pre-post1 and post2-tests, additionally, the second group were healthy people also they just conducted the pre-post1 and post2-tests. The authors used these groups to control the changes which may happen with time which could affect the results|"Eternal Intervention (Home-Based Rehabilitation Program) Three groups :~Experimental group with SCI + Control group 1 with SCI + Control group 2 Healthy people"|t|t|f|t
34008641|NCT02387567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008642|NCT00986024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008643|NCT04172025|||COHORT||RETROSPECTIVE|||||||
34008644|NCT04744155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor will not be aware.|Adolescents will be enrolled into one of two arms: The Multi-level intervention (MLI) or Enhanced Standard of Care (eSOC). Adolescents in both arms will receive motivational interviewing enhanced counseling and a referral for follow up care. Those randomized in the MLI arm will be offered immediate ED-based contraception in addition to receiving a warm referral (providing help with scheduling follow-up care)|f|f|f|t
34008645|NCT05365490|||CASE_ONLY||PROSPECTIVE|||||||
33705205|NCT04982679|||CASE_ONLY||CROSS_SECTIONAL|||||||
33705206|NCT02834260|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705207|NCT04802317|||COHORT||PROSPECTIVE|||||||
33705208|NCT02679404|||COHORT||PROSPECTIVE|||||||
33705209|NCT04044378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705210|NCT04394117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trial Statistician and sponsor staff will remain blinded to treatment allocation throughout the trial.|"CLARITY is a randomised control trial of two parallel groups;~1. Standard Care + Angiotensin Receptor Blocker (ARB)~2. Standard Care~Participants will be randomised in a 1:1 ratio. Randomisation will be stratified according to country and whether the participant is planned for hospital admission or home-based care."|f|f|f|t
33705211|NCT03540173|||OTHER||PROSPECTIVE|||||||
33705212|NCT01939808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705213|NCT05210335|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33705214|NCT03680560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705215|NCT01509092|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705216|NCT01697488|||COHORT||PROSPECTIVE|||||||
33705217|NCT00702923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705218|NCT05086848|NA|SINGLE_GROUP||TREATMENT||NONE||a dose-escalation and expansion study||||
33705219|NCT03795623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33705220|NCT03616626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705221|NCT04532047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705222|NCT03892070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients do not know if they are placebo or HMB group. Investigators who perform measurement and patients visit do not know the group of patients|Parallel Assignment|t|f|t|f
33705223|NCT02476383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705224|NCT00549081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705225|NCT03609905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705226|NCT06043531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705227|NCT00524862|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705228|NCT05140915|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33705229|NCT01918436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705230|NCT05792709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients of study were screened for following information before randomization such as age, gender, location duration of disease and medical history. Each participant of current study was undergoing through questionnaire regarding demographic information. For oral motor therapy assessment and the Functional Feeding Assessment (FFA) subscale of the multidisciplinary Feeding Profile (MFP) were used. A blinded pedagogue who was not involve in the training sessions performed the Bayley scales of infant development (BSID-II) before and after the training.||t|f|f|f
33705231|NCT02053051|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705232|NCT04257734|||CASE_ONLY||RETROSPECTIVE|||||||
33705233|NCT06057844|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705234|NCT00330070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705235|NCT00013962|||CASE_CONTROL|||||||||
33705236|NCT02352974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705237|NCT02044393|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705238|NCT02450591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705239|NCT04342884|||COHORT||PROSPECTIVE|||||||
33705240|NCT05791175|||COHORT||PROSPECTIVE|||||||
33705241|NCT04036903|||CASE_ONLY||RETROSPECTIVE|||||||
33705242|NCT01041833|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33705243|NCT06342752|||COHORT||PROSPECTIVE|||||||
33705244|NCT01823978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705245|NCT03342365|||CASE_ONLY||PROSPECTIVE|||||||
33705246|NCT05536583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of obese patients with PCOS and simple obesity after laparoscopic sleeve gastrectomy||||
33705247|NCT06284031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705248|NCT01878279|||COHORT||PROSPECTIVE|||||||
33929843|NCT06257134|RANDOMIZED|PARALLEL||OTHER||NONE||"F-SWIFT is a large-scale, multi-center, randomized controlled trial (qualitative and quantitative) nested in a national registry.~Experimental group~* Quarterly measurement for 18 months of patients' symptoms using the IPOS-Renal questionnaire, which will be systematically reported to professionals.~* Measurement every 6 months for 18 months of patients' health-related HRQoL using the EQ-5D-5L, KDQoL-36 and SONG-Fatigue questionnaires.~Control group~* No systematic symptom monitoring will be organized, and patients will receive usual care.~* Measurement of health-related HRQoL every 6 months for 18 months, using the EQ-5D-5L, KDQoL-36 and SONG-Fatigue questionnaires.~The F-SWIFT project includes a process analysis to underpin the transferability of F-SWIFT in the event of proven effectiveness with a view to large-scale deployment."||||
33929844|NCT06066606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33929845|NCT06039150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33929846|NCT02283333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929847|NCT03595449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33929848|NCT04176718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929849|NCT02456454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929850|NCT04775394|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Enrolment will healthy subjects first, followed by subjects with COPD||||
33929851|NCT05996679|||OTHER||PROSPECTIVE|||||||
33929852|NCT02200068|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33929853|NCT05475704|||CASE_CONTROL||PROSPECTIVE|||||||
33929854|NCT01883219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929855|NCT05359445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929856|NCT00422357|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33929857|NCT01451983|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33929858|NCT01868594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33929859|NCT00453583|||||RETROSPECTIVE|||||||
33929860|NCT02580591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33929861|NCT03561168|||COHORT||RETROSPECTIVE|||||||
33929862|NCT02031757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929863|NCT05145673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929864|NCT00693693|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929865|NCT02443155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929866|NCT01203124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33929867|NCT00251017|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33929868|NCT04254445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929869|NCT03397550|||COHORT||PROSPECTIVE|||||||
33929870|NCT01989871|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33705249|NCT00679432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705250|NCT00002914||||TREATMENT||||||||
33705251|NCT01940601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705252|NCT03857958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705253|NCT03493607|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group, open label||||
33705254|NCT04431453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705255|NCT00262171|||FAMILY_BASED||PROSPECTIVE|||||||
33705256|NCT01216631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705257|NCT06358716|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33705258|NCT04623112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705259|NCT02106260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705260|NCT06120296|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33705261|NCT00078793|||COHORT||PROSPECTIVE|||||||
33705262|NCT00621582|||||PROSPECTIVE|||||||
33929871|NCT05267483|||COHORT||RETROSPECTIVE|||||||
33929872|NCT00117728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929873|NCT00252876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929874|NCT00035568||||TREATMENT||||||||
33929875|NCT06248242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33929876|NCT04713111|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"All Interested and enrolled participants in the main Stress and Recovery were invited to participate in a lifestyle intervention arm. Participants were instructed to self-select into either a physical activity arm, or a meditation arm.~Participants were excluded if they were already partaking in both regular physical exercise, and meditation."||||
33929877|NCT03933124|RANDOMIZED|PARALLEL||TREATMENT||NONE||An explorative study using a randomized controlled parallel design.||||
33705263|NCT06004336|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33705264|NCT05827731|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705265|NCT04465110|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33705266|NCT05801965|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center prospective randomized open label pilot study||||
33705267|NCT02449252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705268|NCT00004075||||TREATMENT||||||||
33705269|NCT00144391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Testosterone and Placebo|Testosterone and Placebo|t|f|t|f
33929878|NCT04342416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929879|NCT00405106|||DEFINED_POPULATION||PROSPECTIVE|||||||
33929880|NCT01646567|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33929881|NCT05430204|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33929882|NCT02617329|RANDOMIZED|PARALLEL||||NONE||||||
33929883|NCT05818072|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33929884|NCT00852423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929885|NCT03672669|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||patients with bilateral impacted mandibular third molar which surgically operated at different times|t|f|f|t
33929886|NCT03938012|||CASE_ONLY||PROSPECTIVE|||||||
33929887|NCT00757640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33929888|NCT03968081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33929889|NCT00003519|RANDOMIZED|||TREATMENT||||||||
34008646|NCT02156921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34093444|NCT00416949|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929890|NCT03080051|NA|SINGLE_GROUP||OTHER||NONE||||||
33929891|NCT00639496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929892|NCT04115527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929893|NCT02565277|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33929894|NCT01954810|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33929895|NCT05495191|||COHORT||RETROSPECTIVE|||||||
33929896|NCT03101449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929897|NCT01481506|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929898|NCT02685111|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929899|NCT03503812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following the eligibility assessment, we will randomize each group of participants (group with asthmatic children and group with AF patients) with a 1:1:1 ratio to three parallel groups to receive: a) no intervention for DDS, b) intervention for outdoor exposure reduction, by reducing the time spend outdoors and by avoiding physical activity, c) interventions for outdoor (as above) and indoor exposure reduction (by minimizing home ventilation and filtering indoor air). In the indoor intervention arm of the study, exposure reduction measures will be applied in the asthmatic child's classroom/school and bedroom/household settings and in the AF patient's household/bedroom settings. The study design offers also the opportunity to assess: 1.outdoor exposures to PM, and 2.indoor exposures to PM and related health outcomes in three parallel groups during the same DDS events with and without intervention measures.||||
34008647|NCT05340582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|Pragmatic, multicenter, double-blinded, placebo controlled, parallel, two-armed, superiority randomized trial comparing two treatment regimens for the first treatment course of PDA in ELGANs|t|f|t|t
34008648|NCT00663715|||CASE_ONLY||PROSPECTIVE|||||||
34008649|NCT05274633|||COHORT||OTHER|||||||
34008650|NCT05736484|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||This is a 2-arm randomized control trial over 26 weeks with 26 weeks follow-up (total of 52 weeks) that compares a control group wearing a wearable activity tracker to the intervention group that uses the same device and receives a supportive social incentive-based gamification intervention.|t|f|t|t
34008651|NCT02010255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008652|NCT03105817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008653|NCT01423279|||OTHER||OTHER|||||||
34008654|NCT01758237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008655|NCT04347525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008656|NCT04257214|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34093445|NCT03952741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|f|f|t|t
34008657|NCT05305664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008658|NCT05435586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The research data were collected on a web-based platform by the researcher, who did not know who was in the experimental and control groups, and transferred to the computer by someone else. A statistician analyzed the coded data in groups. Statistical analyzes have been completed.|The study is an experimental study with pretest-posttest parallel group randomized controlled.|f|t|t|t
33705270|NCT02323867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||intervention with device: Alpha Beta T cell depletion||||
33705271|NCT04731181|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||parallel-group and allocation ratio (1:1) Intervention: mobile application (little lovely dentist). Control: Tell-Show-Do technique.||||
33705272|NCT04599140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705273|NCT01778972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008659|NCT00763555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008660|NCT02762617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34008661|NCT04079049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008662|NCT03056768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34008663|NCT03662256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The randomization assignments will be kept confidential within the study team until hearing screening day, when masking the referral process assignment to participants will no longer be possible. All outcome assessors, including audiologists and ear, nose, and throat (ENT) surgeons reading telemedicine consults within the Alaska Native healthcare system and study team members performing medical record abstraction, will be masked to intervention allocation throughout the trial. Study team members who read telemedicine consults as a part of their clinical responsibilities will abstain from reading any study-related consults. The results of the preschool screen, mHealth screen, and audiometric assessments will also be masked, such that study team members performing the mHealth screen or audiometric assessment will be masked to the other results.||f|f|f|t
34008664|NCT05022563|||COHORT||RETROSPECTIVE|||||||
34008665|NCT05076513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008666|NCT00707564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008667|NCT02038504|||COHORT||PROSPECTIVE|||||||
34008668|NCT06238557|||COHORT||PROSPECTIVE|||||||
34008669|NCT02105311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008670|NCT06085937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008671|NCT04865484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008672|NCT03367689|NA|SINGLE_GROUP||TREATMENT||NONE||This is an international, multi-centre, non-controlled, open-label, single arm, two-stage Simon Design phase II study.||||
34008673|NCT05227586|||COHORT||RETROSPECTIVE|||||||
34008674|NCT01992016|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093446|NCT02691663|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093447|NCT00000599|RANDOMIZED|||TREATMENT||||||||
34093448|NCT05916248|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical trial adopts Bayesian optimal interval (BOIN) design method to determine the maximum tolerated dose (MTD). BOIN design is simple to operate, similar to traditional 3+3 design, but with excellent statistical performance similar to continuous reassessment CRM method||||
33705274|NCT04977193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093449|NCT00815737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093450|NCT02292225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705275|NCT02572401|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33705276|NCT00845858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705277|NCT00758537|||||PROSPECTIVE|||||||
33705278|NCT03243071|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705279|NCT05095597|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Recruitment period:~* Umbilical cord donors: throughout the study. Although the aim is to recruit the maximum number of umbilical cord samples during the first 10±3 months of the study. 30±15 donors will be recruited.~* Patients (group A and B): from month 4 of the first year until the end of the study.~* Expected duration of treatment per patient:~* Group A (arms 1 and 2): 22±8 days (visit 2 to visit 3).~* Group B: 22±8 days (visit 2 to visit 3)."||||
33705280|NCT03959943|||COHORT||PROSPECTIVE|||||||
33705281|NCT05962957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
33705282|NCT04247880|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705283|NCT03726411|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705284|NCT04584281|||COHORT||RETROSPECTIVE|||||||
33705285|NCT02435446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705286|NCT01839123|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33705287|NCT06050148|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Unblinded team takes care of fecal microbiota transplantion but does not participate in other parts of the trial.|"Part A: Double-blinded randomised trial for volunteers with recurrent UTIs with 1:1 FMT and placebo (PT) arms undergoing transfer of feces or placebo, respectively (Groups 1 and 2). Randomisation with respect to ESBL positivity (equal numbers of ESBL-positive in FMT and PT arms) and menopause. The groups will undergo an intensive 12-month follow-up.~(Part B: a concomitant separate non-randomised follow-up study for non-trial participants, recruited separately, groups 3 and 4, no further description)"|t|f|t|t
33705288|NCT00727220|||COHORT||PROSPECTIVE|||||||
33705289|NCT03173313|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705290|NCT01667484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705291|NCT01809106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705292|NCT01273597|||COHORT||PROSPECTIVE|||||||
33705293|NCT05211362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705294|NCT00003433||||TREATMENT||||||||
33705295|NCT02499822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705296|NCT00654017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705297|NCT01372696|NA|SINGLE_GROUP||OTHER||NONE||||||
33705298|NCT05627323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two dose levels investigated, with both dose levels proceeding in parallel. Expansion or de-escalation decision rules are based on a traditional 3+3 clinical study design.||||
33705299|NCT04922970|NA|SINGLE_GROUP||PREVENTION||NONE||The same interventon will be applied to two groups, a group of previously recipients of bone marrow transplantation, and a group of age- and sex-matched controls.||||
33705300|NCT03019783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33705301|NCT05858242|||COHORT||PROSPECTIVE|||||||
33789823|NCT05122312|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|they don't know the type of intervention used|A total of ninety (90) samples were used in the study, for dentin permeability test (dye penetration test) and Scanning Electron Microscopic examination (SEM) which were randomly divided into two main groups; group A1, completely removed smear layer, group A2, partially removed smear layer. Each group was subdivided into three subgroups according to the desensitizing agent applied: OliNano SEAL, Curodont D'Senz and the control group that were left untreated. Seventy (70) hypersensitive teeth in ten patients were enrolled for the current study. The subjective assessment of dentin hypersensitivity was done prior to the application of the desensitizing agent (baseline) then immediately, 2 weeks, 4 weeks and 3 months after application of the tested materials. Patients were informed to rate their perception to tactile, air and cold stimuli by using Verbal Rating Score (VRS) and Visual Analogue Scale (VAS).|t|t|f|f
33789824|NCT04046965|||OTHER||CROSS_SECTIONAL|||||||
33789825|NCT03319017|||CASE_ONLY||PROSPECTIVE|||||||
33789826|NCT01105884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789827|NCT04208802|||COHORT||PROSPECTIVE|||||||
33929900|NCT05041062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929901|NCT06221956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929902|NCT00762580|||COHORT||PROSPECTIVE|||||||
33929903|NCT06153199|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34008675|NCT01357434|||COHORT||PROSPECTIVE|||||||
34008676|NCT02082132|||OTHER||CROSS_SECTIONAL|||||||
34008677|NCT03186599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008678|NCT06227117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008679|NCT05108116|||CASE_ONLY||PROSPECTIVE|||||||
33705302|NCT05247775|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705303|NCT01643356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705304|NCT06063278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705305|NCT00536679|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789828|NCT03490851|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33789829|NCT06054269|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929904|NCT01858597|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33929905|NCT05227768|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33929906|NCT00949806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929907|NCT02877316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33929908|NCT04737967|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33929909|NCT01192100|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33929910|NCT02163772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929911|NCT00656578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929912|NCT01113788|||COHORT||PROSPECTIVE|||||||
33929913|NCT02116361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929914|NCT05915117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929915|NCT04472013|||COHORT||PROSPECTIVE|||||||
33929916|NCT05013697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008680|NCT05665153|||COHORT||PROSPECTIVE|||||||
34008681|NCT06503549|||CASE_CONTROL||PROSPECTIVE|||||||
34008682|NCT04714281|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, open, controlled, cross-over (with randomized treatment sequences), interventional, multi-center||||
34008683|NCT02283593|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34008684|NCT04741152|||CASE_ONLY||OTHER|||||||
34008685|NCT02614963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008686|NCT03482219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial|t|f|f|f
33705306|NCT04219657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|cases included in study were randomly divided into two group. patients were masked about group. Every odd patients were kept in group A and every Even patients were kept in group B.|Cases were divided into two groups. Group A included cases with skin graft only and group B included cases with skin graft and application of mesenchymal stem cells. Every odd patients were kept in group A and every Even patients were kept in group B.|t|f|f|f
33705307|NCT03351933|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705308|NCT04920552|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||monocentric, randomized, placebo-controlled, double-blind, crossover phase II trial with an open-label treatment extension phase|t|f|t|f
33705309|NCT05561738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33705310|NCT02573207|||COHORT||PROSPECTIVE|||||||
33705311|NCT06210971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705312|NCT04812899|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705313|NCT02339584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34008687|NCT02629588|||||RETROSPECTIVE|||||||
34008688|NCT05410028|||COHORT||PROSPECTIVE|||||||
34008689|NCT00737737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008690|NCT02403739|||COHORT||CROSS_SECTIONAL|||||||
34008691|NCT02607020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008692|NCT04403516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||In patients who undergo pterygium surgery, eyes will be consecutively assigned to receive either DEXTENZA (15 eyes) into both the upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then discontinued or receive topical prednisolone acetate 1% (15 eyes) q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks then discontinued.||||
34008693|NCT06191601|||CASE_CONTROL||RETROSPECTIVE|||||||
34008694|NCT05342311|||OTHER||PROSPECTIVE|||||||
34008695|NCT02862249|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34008696|NCT00585260|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008697|NCT06468696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705314|NCT00818480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705315|NCT01786668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705316|NCT01212523|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33705317|NCT04305418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant, therapists and outcome assesors are blind to the condition the individual participant was assigned to, by encrypting the names of the individual into a number-letter codes.~The therapists led the intervention group was not aware of the participants condition."|The current study is a randomized- Control Trial (RCT), 26 patients diagnosed with Systemic Lupus Erythematosus (SLE) were randomly assigned either to mindfulness-based intervention group (MBI) or to a wait-list control group (WL).|t|t|t|t
33705318|NCT04208633|RANDOMIZED|PARALLEL||OTHER||SINGLE||Fellow eye comparison when one eye has the intraocular lens placed in horizontal and other in vertical axis.|t|f|f|f
33705319|NCT04119544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705320|NCT00241085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705321|NCT03241875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33705322|NCT03338010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705323|NCT03658239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705324|NCT05840510|NA|SEQUENTIAL||TREATMENT||NONE||||||
33705325|NCT03942666|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Part II: double blind Part II: open label|Part I: 5-way, 5-period crossover Part II: single group|t|t|t|t
33705326|NCT03136354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705327|NCT05085873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants won't be aware of the sedative treatment administered.||t|f|f|f
33705328|NCT04751565|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Compare resolution of inflammation of naturally-occurring peri-implant mucositis (PM) at tissue-level (TL) and bone-level (BL) implants after non-surgical mechanical debridement.|t|f|f|f
33929917|NCT04450342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929918|NCT02997462|||COHORT||PROSPECTIVE|||||||
33929919|NCT03285399|||COHORT||PROSPECTIVE|||||||
33929920|NCT00251277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929921|NCT00329784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929922|NCT02813863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929923|NCT02491216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929924|NCT00272480|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33929925|NCT00398138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929926|NCT03661255|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will have a stepped wedge design with 3 cohorts (in successive years) of 3 villages each. In each village, we will collect baseline data and follow-up data on knowledge, attitudes, and behavior related to suicide prevention from participants and non-participants. Participants will also provide data on these topics after each learning circle they attend. Intervention participants will be self-selecting.||||
33929927|NCT02198560|||COHORT||PROSPECTIVE|||||||
33929928|NCT00074620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929929|NCT00937326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929930|NCT00845507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33929931|NCT00288041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929932|NCT01002495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929933|NCT02797769|||COHORT||RETROSPECTIVE|||||||
33929934|NCT01007513|||COHORT||PROSPECTIVE|||||||
33929935|NCT04838041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929936|NCT03751969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929937|NCT04010812|||CASE_ONLY||CROSS_SECTIONAL|||||||
33929938|NCT02734199|||COHORT||PROSPECTIVE|||||||
33929939|NCT02868164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929940|NCT00916591|||COHORT||PROSPECTIVE|||||||
33929941|NCT03288441|||COHORT||PROSPECTIVE|||||||
33929942|NCT05983016|||OTHER||PROSPECTIVE|||||||
34008698|NCT03467854|||COHORT||PROSPECTIVE|||||||
34008699|NCT02240576|||CASE_CONTROL||RETROSPECTIVE|||||||
34008700|NCT04352270|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33929943|NCT02644772|||COHORT||PROSPECTIVE|||||||
34008701|NCT01915342|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008702|NCT01128582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008703|NCT02959476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008704|NCT01443377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008705|NCT02593396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008706|NCT04845516|||COHORT||RETROSPECTIVE|||||||
34008707|NCT05981495|||COHORT||PROSPECTIVE|||||||
34008708|NCT03955939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008709|NCT03384433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008710|NCT01584895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34008711|NCT00493779|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34008712|NCT00332124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008713|NCT04341272|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34008714|NCT03576287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008715|NCT05865392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008716|NCT02153892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008717|NCT01685359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008718|NCT05260021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008719|NCT04883424|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
34008720|NCT00139724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34008721|NCT06452329|||COHORT||RETROSPECTIVE|||||||
34008722|NCT00660868|||||PROSPECTIVE|||||||
34093451|NCT03707730|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|placebo controlled|randomized double-blind, placebo-controlled crossover trial|t|t|t|t
34093452|NCT01456338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929944|NCT01407406|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34093453|NCT03432962|||OTHER||CROSS_SECTIONAL|||||||
33929945|NCT00809055|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33929946|NCT04980287|||CASE_ONLY||PROSPECTIVE|||||||
33929947|NCT00047853|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33929948|NCT01369446|||CASE_ONLY||PROSPECTIVE|||||||
33929949|NCT00744640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008723|NCT04815395|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design|t|f|t|t
34008724|NCT05229822|||OTHER||PROSPECTIVE|||||||
34008725|NCT05999279|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34008726|NCT01315028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008727|NCT00265772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008728|NCT02418455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008729|NCT05436704|||COHORT||PROSPECTIVE|||||||
34008730|NCT03115606|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34093454|NCT01761227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093455|NCT05265754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||6 sessions in 2 weeks in total of sujok therapy will be applied to the interventional group.|t|f|f|f
34093456|NCT02324595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093457|NCT06120972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093458|NCT00989027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093459|NCT00221325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093460|NCT06135259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093461|NCT03390153|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34093462|NCT01368770|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093463|NCT03132389|||COHORT||PROSPECTIVE|||||||
34093464|NCT03346317|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34093465|NCT05552131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093466|NCT00910390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929950|NCT00420342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929951|NCT03955497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008731|NCT06563245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008732|NCT00535041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008733|NCT03793920|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34008734|NCT02870036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008735|NCT02775539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008736|NCT00184184|||||PROSPECTIVE|||||||
34008737|NCT05387148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34008738|NCT03762746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|We apply blinding status of trial participants, care providers, and outcome assessors. We are using TMS sham-coil with similarities in appearance, sound, heavy; also we have the timing of final unblinding of all trial participants|Forty schizophrenic or schizoaffective patients with predominant audiotoric hallucinatory symptoms will be given rTMS 1 Hz intervention, 1000-pulse train, 20 min, 90% strength, 1000 pulse in left temporo-parietal cortex for 10 consecutive days (except holidays). Assessment of DN network connectivity in the brain using the results of brain wave decomposition analysis with EEGLAB. For measurement of auditor hall of hallucinations used Indonesian-Psychosis Symptom Rating Scale (INA-PSYRATS) instrument. Source monitoring capability using the INA-Source Monitoring instrument.|t|t|f|t
34008739|NCT03216109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34008740|NCT02927834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008741|NCT05365282|||COHORT||PROSPECTIVE|||||||
33705329|NCT04360668|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will not know which research group they will belong to. Each participant will draw a number that will be specific to the given research group. The investigator will also not know which group the participant belongs to (he will only use the participant's number). The outcomes assessor will not know which group is experimental and which are active comparators (they will be marked numerically instead of using a name). The correct course of the study will be supervised by a person who acts as a coordinator.|The first stage will involve recruitment. 60 people will be gathered based on the qualifying and disqualifying criteria. This group of participants will be randomized. Each participant will draw a number that will determine the assignment to a specific group (MET plus TPT group, single MET or single TPT group). Preliminary measurements will be collected before the intervention. Each participant will have a specific intervention depending on which research group they belong to. The therapist will be responsible for performing the given therapeutic technique. Immediately after the intervention and on the second day, data will be collected by the researcher. The person conducting the function of coordinator will supervise the proper conduct of the scientific research. The collected data will be analyzed by the outcomes assessor.|t|f|t|t
33705330|NCT00002554||||TREATMENT||||||||
33705331|NCT00003165||||TREATMENT||||||||
33789830|NCT05824377|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Caregivers, study personnel and nurses will not be blinded, as blinding will be hard for the treating team. Parents will not be blinded as we inform about the infant's progress and plan routinely. Statisticians will be blinded during (they will receive de-identified data).|"Infants will be randomized into 2 groups; one will receive continuous nasogastric feeding and the other group will receive intermittent bolus feeds.~Each group will be stratified as per weight, thus (\<1000 g, 1000-1500 g, and \> 1500 g). It will be 1-1 randomization and will be randomized into each group by pulling a sealed envelope. Protected Health Information (PHI) will be de-identified by assigning a study code.~Sample size: A sample size of at least 23 in each arm was calculated using the SAS system. A power of 80% and a mean difference of 40% decrease in the length of time to achieve full feeds; and an SD of 8.5 was considered while calculating the number of patients. The mean length of time to achieve full feeds in our NICU as per chart review was 17 +/- 8.5 days."|f|f|f|t
33929952|NCT04119401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34008742|NCT05011006|||COHORT||PROSPECTIVE|||||||
33929953|NCT01632176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33929954|NCT05948319|NON_RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE|obese and non obese pregnant women|case control|t|f|f|f
33929955|NCT01569997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33929956|NCT04906824|||COHORT||PROSPECTIVE|||||||
33929957|NCT04557618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All participants will be fitted with an auricular stimulator, but blinded to whether they are receiving stimulation or not. Outcome scores will be assessed and recorded by clinicians blinded to treatment arm.|Participants are assigned to either stimulation or sham stimulation arms|t|t|f|t
34008743|NCT06610760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929958|NCT06506292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929959|NCT01503619|||COHORT||RETROSPECTIVE|||||||
33929960|NCT01318525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33929961|NCT03125161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929962|NCT03600870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929963|NCT00259519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008744|NCT04489303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008745|NCT04567758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, outcomes assessor, and the analyzer of the statistics of the study will be blinded.|A double-blind randomized controlled trial|t|f|f|t
34008746|NCT03462836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008747|NCT05631535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008748|NCT02262195|||COHORT||PROSPECTIVE|||||||
34008749|NCT05528861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008750|NCT01981317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008751|NCT01572519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008752|NCT05593731|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34008753|NCT05852925|NA|SINGLE_GROUP||OTHER||NONE||The study is an interventional single-group model, using a single-arm design in which all participants receive the same interventions, which includes the traditional venipuncture and Tasso+ blood self-collection. Both collection procedures are performed sequentially at the study site, with a phlebotomist performing the traditional venipuncture followed by the participant collecting blood using the Tasso+ device following provided instructions independently. The lab results will be analyzed to assess the correlation of biomarkers between blood samples obtained using the Tasso+ device and those collected via venipuncture.||||
34008754|NCT03485482|RANDOMIZED|CROSSOVER||OTHER||NONE||open label, randomized, single-dose, three-period, crossover design||||
34008755|NCT02241109|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|f|t
34008756|NCT03891329|NA|SINGLE_GROUP||OTHER||NONE||||||
34008757|NCT04972331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008758|NCT03136406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008759|NCT05516888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34008760|NCT05707455|||OTHER||CROSS_SECTIONAL|||||||
34008761|NCT02403076|||||PROSPECTIVE|||||||
34008762|NCT01358149|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34008763|NCT04923126|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34008764|NCT00975741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008765|NCT00823199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008766|NCT05380921|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|study investigators will score EEG quality in a blinded fashion.|study subjects will receive first a standard EEG study and then after this a dry electrode EEG study (in this sequence) at each study visit.|f|f|f|t
34008767|NCT03701711|NA|SINGLE_GROUP||OTHER||NONE||Single arm dose escalation study||||
34008768|NCT01749358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008769|NCT04964674|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-subjects measures, individual differences analysis||||
34008770|NCT05379556|||CASE_ONLY||PROSPECTIVE|||||||
34008771|NCT02394639|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34008772|NCT00814606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705332|NCT00004037||||TREATMENT||||||||
33705333|NCT02425020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705334|NCT03375606|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33705335|NCT01012271|||CASE_ONLY||PROSPECTIVE|||||||
33705336|NCT00137579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34008773|NCT04027881|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to start the intervention immediately after baseline assessment (i.e., treatment) or approximately 15 weeks later after the baseline assessment (i.e., waitlist control).||||
34008774|NCT03085225|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|This is a multicenter, prospective open-labeled phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of trabectedin when prescribed in combination with durvalumab followed by two expansion cohorts (Soft-tissue sarcomas and ovarian carcinomas) once the MTD is established||||
34008775|NCT01162278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008776|NCT05550376|||COHORT||PROSPECTIVE|||||||
34008777|NCT03836482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008778|NCT05532488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008779|NCT06616428|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Outcomes were assed by the same experts in every time point. Participants, evaluators and fitness instructors were blinded until arrival of the participant for each visit.|Parallel group crossover randomized trial|t|t|f|f
34008780|NCT05524311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093467|NCT06277726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In order to ensure randomization and prevent contamination between groups, data will be collected in a sequence such that emotional freedom technique is collected one week, music is collected one week, and control group data is collected one week. It will be decided by drawing lots which group's data will be collected first.|Randomized controlled study with pre-test post-test group|t|f|t|f
34093468|NCT02650557|||CASE_CONTROL||PROSPECTIVE|||||||
34093469|NCT06449664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093470|NCT01470807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093471|NCT03395990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Group allocation by sealed envelope; unblinded investigator prepared syringes of study drug (chloroprocaine vs. saline), which look identical to blinded investigator and assessor.|randomized, blinded observational study|t|t|f|t
34093472|NCT05901961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34093473|NCT00709800|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34093474|NCT00136474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093475|NCT04094480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093476|NCT03172000|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093477|NCT06097572|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093478|NCT03435419|||CASE_CONTROL||PROSPECTIVE|||||||
34093479|NCT03166254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093480|NCT04405661|||COHORT||PROSPECTIVE|||||||
34093481|NCT06407570|||COHORT||PROSPECTIVE|||||||
34093482|NCT02219204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34093483|NCT01033942|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34093484|NCT06330025|||CASE_ONLY||CROSS_SECTIONAL|||||||
34093485|NCT05467202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093486|NCT04490655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093487|NCT03959319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principle investigator and research staff who will be completing outcome assessments and measurements will be blinded to treatment group. Given the nature of the treatment, it is not possible to blind the care provider or the participant from the treatment group.|Participants will complete self-report questionnaires and participate in a clinical examination that will include movement pattern, range of motion and quantitative sensory assessment. Participants will be randomized into one of two treatment groups, movement pattern training (MoveTrain) or manual therapy (ManTher). Both groups will participate in 10 supervised sessions within a 12 week time frame. MoveTrain will include task-specific training to optimize biomechanics during daily tasks and patient-specific tasks including work and fitness. ManTher will include select manual techniques including joint and soft tissue mobilization. Both groups will receive a home exercise program. At 13 weeks after enrollment, participants will return for testing to assess post-treatment improvements in primary and secondary outcomes. We also obtain 6 and 12 month questionnaires to assess patient outcomes.|f|f|t|t
34093488|NCT04073407|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34093489|NCT02879162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093490|NCT05259293|||CASE_ONLY||RETROSPECTIVE|||||||
34093491|NCT01106950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093492|NCT01467804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705337|NCT05946928|||COHORT||RETROSPECTIVE|||||||
33705338|NCT05087108|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705339|NCT00115739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705340|NCT02858960|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705341|NCT01122654|||COHORT||PROSPECTIVE|||||||
33705342|NCT03781869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705343|NCT06558292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008781|NCT04334928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomized double-blind clinical trial||t|f|t|f
34093493|NCT04320875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093494|NCT03165903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093495|NCT03390491|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33705344|NCT03224715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705345|NCT00007683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705346|NCT04749277|||COHORT||PROSPECTIVE|||||||
33705347|NCT05530759|||COHORT||OTHER|||||||
34093496|NCT00875329|||COHORT||CROSS_SECTIONAL|||||||
34093497|NCT01804335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093498|NCT01897389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093499|NCT00551356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093500|NCT02011464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705348|NCT00000308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705349|NCT03460730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705350|NCT04733404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008782|NCT03670134|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705351|NCT00538291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705352|NCT01281709|||CASE_ONLY||RETROSPECTIVE|||||||
33705353|NCT02824614|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34008783|NCT02270749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008784|NCT05925244|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33705354|NCT05898113|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"1. EXPERIMENTAL: Extra virgin olive oil (EVOO): should add 0.7 g of Corbella EVOO/ kg body weight to their usual diet per day, either raw or cooked, for one month~2. CONTROL: Olive oil low in polyphenols (OOLP): should add 0.7 g of OOLP/ kg body weight to their usual diet per day, either raw or cooked, for one month"||||
33705355|NCT01530360|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34008785|NCT01594359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34008786|NCT03503006|||COHORT||PROSPECTIVE|||||||
34008787|NCT02754024|||COHORT||PROSPECTIVE|||||||
34008788|NCT00675298|||FAMILY_BASED||PROSPECTIVE|||||||
34008789|NCT04546048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008790|NCT01712815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093501|NCT04847921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705356|NCT00307645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008791|NCT05782569|||COHORT||PROSPECTIVE|||||||
34008792|NCT00240617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34008793|NCT04652544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants having a vitamin D status ≤ 75 nmol/L at baseline, will be randomly assigned to one of the three intervention groups.|t|t|t|t
34008794|NCT01758419|||CASE_CONTROL||PROSPECTIVE|||||||
34008795|NCT05150756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34008796|NCT00172068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008797|NCT01657084|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34008798|NCT05340192|NA|SINGLE_GROUP||OTHER||NONE||This is a healthy volunteer pilot study. Subjects will be asked to provide a saliva sample after a 2 hour fast and 5 minutes after rinsing their mouth with tap water. The sample will be collected in an Eppendorf vial. After providing the saliva sample, each subject will be injected subcutaneously with 100 mcg (1 ml) of Octreotide by either a physician or registered nurse. A second sample of saliva will be collected using the same protocol 45-55 minutes after administering the drug.||||
34008799|NCT02792218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705357|NCT06535542|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Investigative site personnel will obtain the subject's identification number and study treatment assignment from the randomizer. Participants and all personnel directly involved in the study conduct will be blinded to the arm assignment until 2-3 months after enrollment when the whole-genome sequencing (WGS) report is generated.|A randomized controlled clinical trial of whole-genome sequencing.|t|t|t|f
33705358|NCT06089499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Recruitment will take place for 30 days, and the study duration will be 30 days from the time of enrollment. A 1:1 randomization will be used to assign participants to the treatment or control group. The goal of 15 participants in each arm of the pilot study.||||
33705359|NCT01752361|||CASE_CONTROL||PROSPECTIVE|||||||
33705360|NCT04597723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705361|NCT01908283|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705362|NCT06507787|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705363|NCT00791856|RANDOMIZED|CROSSOVER||||NONE||||||
33705364|NCT01954992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705365|NCT00001381||||TREATMENT||||||||
33705366|NCT02114801|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33705367|NCT01242462|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705368|NCT01934023|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33705369|NCT05780372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705370|NCT02087735|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33705371|NCT05113758|||COHORT||PROSPECTIVE|||||||
33705372|NCT03209661|RANDOMIZED|CROSSOVER||OTHER||SINGLE|E-cigarettes being utilized are of the same brand and design. Additionally, the device will be covered by a sheath to ensure labeling is not visible to the subject.|Subjects will be asked to inhale one of three mediums; 5.4% NBV e-ciggarette, 0% NBV cigarette, and sham menthol inhaler (no vapor). Baseline measurements will be conducted upon arrival and followed immediately post inhalation, 1-hour post, and finally 2-hours post. All trials will require a minimum of 48 hours washout.|t|f|f|f
33705373|NCT06421792|||OTHER||OTHER|||||||
33705374|NCT03342183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33789831|NCT06553807|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"An educational booklet will be prepared, and a three-week educational program will be conducted for the intervention group, with one topic covered each week. The training sessions will be held three days a week, and the women will be divided into groups. Since the sample size is planned to be 40 participants, the training sessions will be organized into three separate groups, with sessions held on three designated days of the week (Monday, Tuesday, and Wednesday).~Before the study begins, women who meet the inclusion criteria and agree to participate will be briefed about the study's purpose and process in a designated private room at the FHC.~The data will be collected face-to-face in a private room at the FHC by the researcher during the application dates. Each training session is planned to last an average of 30-45 minutes. At the beginning of the first session, participants will be given the educational booklet."|t|f|t|f
33789832|NCT05984641|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study population was randomized into two treatment arms: Group A, active treatment (CONAN® Proctological Cream, Medical Device, Omikron Italia Srl) and Group B, the control group (bowel-function regulation).||||
33789833|NCT05192707|||OTHER||OTHER|||||||
33789834|NCT05038072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789835|NCT02628093|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33789836|NCT00147355|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33789837|NCT03771027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789838|NCT02545062|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705375|NCT00397345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705376|NCT03741062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33705377|NCT01065259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705378|NCT05254886|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705379|NCT03225885|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial where participants are assigned to 1 of 2 groups for the duration of the study. One group will receive verbal counseling and a printed gestational age handout. The other group will receive verbal counseling and a bedside iPad with the multimedia information about prematurity.||||
33705380|NCT00032409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705381|NCT05795075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The involvement of patients and the public was not or will not be included in the design, implementation, reporting or dissemination of the research.||t|t|t|f
33705382|NCT02433405|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33789839|NCT00607503|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705383|NCT02363842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705384|NCT03584178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705385|NCT00690105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705386|NCT03855592|||OTHER||PROSPECTIVE|||||||
33705387|NCT03963596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705388|NCT02753114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705389|NCT01390805|||OTHER||PROSPECTIVE|||||||
33705390|NCT03574831|||COHORT||OTHER|||||||
33705391|NCT05490810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789840|NCT02777632|||COHORT||PROSPECTIVE|||||||
33789841|NCT01872819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929964|NCT03438760|RANDOMIZED|PARALLEL||TREATMENT||NONE|Although it is impossible to mask the assessors of the proximal outcome measures, those assessing some of the distal outcomes can be masked. Specifically, the people scoring the results of the Lens on Science Assessment (a distal measure of generalized scientific content and process) will be masked to the treatment arm assignments. Also, the people transcribing, coding, and analyzing the words and gestures used in the science story retell task (a distal measure of generalized scientific practice outcomes) will be masked to the treatment arm assignments.|Participants will assigned to one of three groups in parallel for the duration of the study.||||
33929965|NCT00356668|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929966|NCT02154334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929967|NCT05362461|||OTHER||PROSPECTIVE|||||||
33929968|NCT01301417|||||RETROSPECTIVE|||||||
33929969|NCT01778036|||COHORT||PROSPECTIVE|||||||
33929970|NCT00373906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929971|NCT03049072|||COHORT||PROSPECTIVE|||||||
33929972|NCT01006694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929973|NCT02836080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33929974|NCT02323308|||||PROSPECTIVE|||||||
33929975|NCT03599544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator(s) will be blinded to assigned study group and intervention.||f|f|f|t
33929976|NCT02001688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33929977|NCT01930656|||CASE_ONLY||PROSPECTIVE|||||||
33929978|NCT05572541|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33929979|NCT00397553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33929980|NCT02353338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33929981|NCT00810043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929982|NCT04076618|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33929983|NCT01063946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929984|NCT01578590|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33929985|NCT04541095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33929986|NCT02101671|||CASE_CONTROL||PROSPECTIVE|||||||
33929987|NCT03796195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929988|NCT06349343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929989|NCT02164604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929990|NCT03895918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33929991|NCT00853190|RANDOMIZED|CROSSOVER||||NONE||||||
33929992|NCT05601050|||COHORT||PROSPECTIVE|||||||
33929993|NCT01698177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008800|NCT00505648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008801|NCT06457620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008802|NCT06365294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008803|NCT03727698|NA|SINGLE_GROUP||TREATMENT||NONE||To assess delivery of radiotherapy on the MR Linac for multiple tumour sites||||
34008804|NCT02524184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008805|NCT03492658|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, single center, two-arm, investigator-initiated, interventional clinical study||||
34008806|NCT05403619|||COHORT||RETROSPECTIVE|||||||
34008807|NCT03572842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008808|NCT03678935|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group receives advice on following the low-FODMAP diet, and the control group follows their regular gluten free diet.||||
34008809|NCT04415502|||CASE_CONTROL||PROSPECTIVE|||||||
34008810|NCT00305916|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34008811|NCT05363995|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm open feasibility study||||
34008812|NCT04756778|||COHORT||RETROSPECTIVE|||||||
34008813|NCT01537731|||CASE_ONLY||PROSPECTIVE|||||||
34008814|NCT04411823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008815|NCT05706064|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34008816|NCT03776734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008817|NCT00612677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008818|NCT02270216|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34008819|NCT03418792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008820|NCT03030326|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093502|NCT06091384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093503|NCT00306072|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34093504|NCT00621530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093505|NCT02286830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093506|NCT00440024|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34093507|NCT00184509|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093508|NCT04093284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093509|NCT00665639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093510|NCT00769405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093511|NCT01198548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093512|NCT00291915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093513|NCT06334198|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34093514|NCT02186067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093515|NCT04093076|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The Sponsor will be blinded up to Week 6; at that time the Sponsor will become group-level unblinded.||t|t|t|f
33789842|NCT01187576|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093516|NCT05752604|||CASE_ONLY||PROSPECTIVE|||||||
34093517|NCT01870570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34093518|NCT03147287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093519|NCT02591303|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34093520|NCT06418815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093521|NCT03343574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093522|NCT02837653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093523|NCT02450474|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093524|NCT04669522|||COHORT||OTHER|||||||
34093525|NCT02949453|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34093526|NCT00046943||||TREATMENT||NONE||||||
34093527|NCT04740970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789843|NCT02009358|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33789844|NCT03583021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33789845|NCT05246956|RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental group control group||||
33929994|NCT01673490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33929995|NCT06321276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient|three groups with a conventional therapy control group|f|f|t|f
34008821|NCT03668431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008822|NCT05594446|||COHORT||PROSPECTIVE|||||||
34008823|NCT06358196|||COHORT||PROSPECTIVE|||||||
34008824|NCT03176784|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Active and placebo medications are identical in appearance. Medication labeling and the dispensing protocol are designed to prevent participants and care providers from knowing if the medication is active or placebo.|Double Blinded Placebo Controlled Factorial|t|t|f|f
34093528|NCT03006120|||CASE_CONTROL||RETROSPECTIVE|||||||
34093529|NCT00180453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705392|NCT01723488|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33705393|NCT02012101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705394|NCT02544399|||COHORT||PROSPECTIVE|||||||
33705395|NCT02147470||PARALLEL||DIAGNOSTIC||NONE||||||
33705396|NCT00217061|RANDOMIZED|PARALLEL||||SINGLE||||||
33705397|NCT05477693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33705398|NCT00000409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705399|NCT06556953|||COHORT||RETROSPECTIVE|||||||
33705400|NCT04734938|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Open label crossover trial||||
33705401|NCT02201485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33705402|NCT02129114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705403|NCT03308201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705404|NCT00080470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705405|NCT02556554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705406|NCT02283385|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33705407|NCT02875054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008825|NCT05303935|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Double-blind, randomized, placebo-controlled, cross-over study|t|t|t|t
34008826|NCT05659524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study will be blinded to the Otolaryngologist involved in the study. The research team and the patient will not be blinded. The goal of blinding the Otolaryngologist is to minimize the bias in grading the Lund Kennedy endoscopic scores which are a subjective metric interpreted in the office setting.|Multicenter randomized single-blinded, intervention trial involving 70 patients from this site (140 treated patients total from all sites), undergoing endoscopic transsphenoidal surgery for pituitary lesions. The same cohort will simultaneously be used to evaluate the role of sinonasal irrigations in those patients who undergo nasoseptal flap reconstructive procedures as part of their treatment.|f|t|f|f
34008827|NCT04424966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008828|NCT05209906|||COHORT||PROSPECTIVE|||||||
34008829|NCT04468906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008830|NCT05533099|||COHORT||PROSPECTIVE|||||||
34008831|NCT06522269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008832|NCT02849236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34093530|NCT05188794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34093531|NCT00294398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008833|NCT05694182|NA|SINGLE_GROUP||OTHER||NONE||||||
34008834|NCT00730951|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34008835|NCT05287503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group trial|t|t|t|t
34008836|NCT02053896|||CASE_ONLY||PROSPECTIVE|||||||
34008837|NCT01283646|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008838|NCT05382156|||OTHER||PROSPECTIVE|||||||
34008839|NCT01039454|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33705408|NCT02320669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34008840|NCT04083352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705409|NCT05406141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008841|NCT02081716|||COHORT||PROSPECTIVE|||||||
34008842|NCT00855075|||CASE_ONLY||PROSPECTIVE|||||||
34008843|NCT05309720|NA|SINGLE_GROUP||TREATMENT||NONE||prospective case series||||
34008844|NCT00613860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008845|NCT03791034|||COHORT||PROSPECTIVE|||||||
34008846|NCT05633082|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All participants received Lens 1 and then Lens 2 in fixed-sequence order.|t|f|f|f
34008847|NCT02800031||SEQUENTIAL||DIAGNOSTIC||NONE|"Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).~Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method."|||||
34008848|NCT03337217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008849|NCT00465231|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008850|NCT03767517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34008851|NCT00941720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705410|NCT00742430|||COHORT||PROSPECTIVE|||||||
34008852|NCT05146726|||COHORT||PROSPECTIVE|||||||
34008853|NCT06437314|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34008854|NCT05162729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly allocated into groups. Assessors do not know about which group participants were allocated in|"Intervention group: receive 5 weeks working memory online training, three times per week, each lasts 15 minutes.~Active control group: receive 5 weeks social-emotional online training, three times per week, each lasts 15 minutes.~Control group: no training"|t|f|f|t
34008855|NCT06123026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008856|NCT01610063|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093532|NCT00968942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093533|NCT05886023|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Given the nature of the interventions, participants, and the investigators responsible for delivering the interventions will be unblinded throughout the trial. However, all researchers performing the laboratory analyses and data analyses will be blinded to the interventions that the participants received until after the data analysis has been performed.|prospective, mono-centre, randomised, controlled, crossover study|f|f|f|t
34093534|NCT04979013|NA|SINGLE_GROUP||OTHER||NONE||||||
34093535|NCT05598489|||COHORT||CROSS_SECTIONAL|||||||
34093536|NCT02295449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093537|NCT00000853||||PREVENTION||DOUBLE||||||
33705411|NCT05334966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705412|NCT02817997|||COHORT||OTHER|||||||
33705413|NCT02144415|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34008857|NCT01841073|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33705414|NCT03350581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093538|NCT02097277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093539|NCT00159042|||OTHER||OTHER|||||||
34093540|NCT02792127|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34093541|NCT05084404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093542|NCT00725660|||COHORT||PROSPECTIVE|||||||
33705415|NCT05762198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705416|NCT03674671|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33705417|NCT05995483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705418|NCT06194630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705419|NCT01313793|RANDOMIZED|CROSSOVER||||NONE||||||
33705420|NCT01259128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008858|NCT02751827|||COHORT||PROSPECTIVE|||||||
34008859|NCT01293266|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34008860|NCT04871568|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34008861|NCT05434130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study PI, Co-Is, and the biostatistician will not know group assignments until after the primary analyses are complete.|The study will use a block stratified RCT design. Our stratum factors are the biological variable of sex and recruitment location|f|f|t|t
34008862|NCT04592523|||COHORT||PROSPECTIVE|||||||
34008863|NCT05769426|||COHORT||CROSS_SECTIONAL|||||||
34008864|NCT02900274|||COHORT||PROSPECTIVE|||||||
34008865|NCT02538835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008866|NCT04407299|||OTHER||CROSS_SECTIONAL|||||||
34008867|NCT04825002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008868|NCT05882734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008869|NCT00328679|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34008870|NCT01959490|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008871|NCT01459263|||CASE_ONLY||PROSPECTIVE|||||||
34008872|NCT02610270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34008873|NCT02399384|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34008874|NCT01782534|||CASE_ONLY||RETROSPECTIVE|||||||
34008875|NCT03743259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008876|NCT03659084|||COHORT||PROSPECTIVE|||||||
34008877|NCT06533371|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093543|NCT05616897|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33929996|NCT04732572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators will be blinded to the intervention group while they perform outcome assessment.|"All participants in the Part II study will receive the following interventions throughout the course of the trial: (1) sleep and healthy lifestyle education, and (2) other supportive care.~Arm 1 - Adenotonsillectomy Within 1 to 4 weeks (30 days) of randomization, participants randomized to the adenotonsillectomy arm will undergo surgery under general anesthesia, as occurs as part of routine standard of care. Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs.~Arm 2 - Watchful waiting with supportive care Within 1 to 4 weeks after the 7-month visit, participants in the Arm 2 group will be referred for re-evaluation of surgical candidacy. Symptoms and polysomnographic findings (baseline and month 7) will be reviewed by the ENT and a decision whether to proceed with adenotonsillectomy as part of routine clinical care will be made."|f|f|f|t
33929997|NCT05646719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33929998|NCT01520688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33929999|NCT01570062|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33930000|NCT04006067|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33930001|NCT05094804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930002|NCT02455362|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33930003|NCT02955368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930004|NCT00618904|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34008878|NCT01461941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008879|NCT03250455|||COHORT||PROSPECTIVE|||||||
34008880|NCT02033135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008881|NCT02111122|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34008882|NCT02377180|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34008883|NCT01416116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093544|NCT06025370|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34093545|NCT00105508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093546|NCT01769872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093547|NCT04701320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093548|NCT00004859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093549|NCT01105130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34093550|NCT01406912|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34093551|NCT02839460|||CASE_CONTROL||PROSPECTIVE|||||||
34093552|NCT01088893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093553|NCT03174522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093554|NCT02989389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34093555|NCT00298194|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34093556|NCT01286649|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34093557|NCT02509702|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
34093558|NCT00771602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093559|NCT05786300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093560|NCT02194491|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093561|NCT06111625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093562|NCT03544203|||COHORT||PROSPECTIVE|||||||
34093563|NCT04560218|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093564|NCT01016002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930005|NCT05212376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930006|NCT00429572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930007|NCT00800930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33930008|NCT02033655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008884|NCT04253015|||COHORT||PROSPECTIVE|||||||
34008885|NCT02488031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008886|NCT04509999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008887|NCT01731522|NA|SINGLE_GROUP||OTHER||NONE||||||
34008888|NCT02704195|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34008889|NCT02688296|||COHORT||OTHER|||||||
34093565|NCT06313151|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34093566|NCT05795335|||COHORT||OTHER|||||||
34093567|NCT02802475|||COHORT||PROSPECTIVE|||||||
34093568|NCT02746939|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093569|NCT01815463|||COHORT||PROSPECTIVE|||||||
34093570|NCT03469973|||CASE_ONLY||CROSS_SECTIONAL|||||||
34093571|NCT04245163|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants who will be randomized in control group will receive normal care (the care that each clinic provides to the patients) and will be given an educational material (without telling them that they are in the control group). They will receive, however, the education class later (at the end of the study). Participants in the intervention group will be invited for the training program|t|t|f|f
34093572|NCT02473744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093573|NCT02049879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093574|NCT02339207|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34093575|NCT03790969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34093576|NCT05872126|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Clinical Trial with 2 groups; Case group for VATS mechanical abrasion and Control group for tube drainage||||
34093577|NCT05667129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093578|NCT02981251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093579|NCT06125990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each children were be interviewed and evaluated alone.|Randomized controlled trial|t|f|f|f
33930009|NCT05833568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093580|NCT02676427|||COHORT||PROSPECTIVE|||||||
34093581|NCT00126217|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093582|NCT04387188|||COHORT||OTHER|||||||
33930010|NCT02200250|||COHORT||RETROSPECTIVE|||||||
34093583|NCT03406975|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34093584|NCT03509155|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The intervention is running parallel in three arms.~1. The first arm as a control group obtaining only routine IYCF counseling by the cadre and without the provision of biscuits. If there are respondents at the first three months data collection who experience a decrease in nutritional status, then the respondent will be given biscuits immediately~2. The second arm as the first intervention group to get biscuit with portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist~3. The third arm as the second intervention group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food In the 2nd and 3rd arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment."||||
33930011|NCT05573568|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34093585|NCT02581423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093586|NCT03070145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930012|NCT04500067|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open-label multicenter randomized controlled in parallel groups.~Patients undergoing screening are randomized into groups in equal proportions:~* Study Group (receive IVIG Bioven with base therapy).~* Control group (receive base therapy only)~At the stage of Data Analysis to ensure comparability of data and homogeneity of the sample, the possibility of additional comparison of groups based on the actually prescribed base therapy and other identified covariates is provided."||||
33930013|NCT01142544|||COHORT||PROSPECTIVE|||||||
33930014|NCT05126134|||CASE_ONLY||PROSPECTIVE|||||||
33930015|NCT01841489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930016|NCT03648606|||CASE_ONLY||RETROSPECTIVE|||||||
33930017|NCT01894867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930018|NCT02996994|||COHORT||RETROSPECTIVE|||||||
33930019|NCT02473224|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33930020|NCT02398721|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930021|NCT02348840|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33930022|NCT00966680|||||PROSPECTIVE|||||||
33930023|NCT03639987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930024|NCT02114060|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33930025|NCT00641706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930026|NCT04695236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment by independent investigators||f|f|f|t
33930027|NCT05283824|||COHORT||PROSPECTIVE|||||||
34093587|NCT01191385|||COHORT||PROSPECTIVE|||||||
34093588|NCT02819375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930028|NCT04021576|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Intervention with historical control group||||
34093589|NCT00138320|||||PROSPECTIVE|||||||
34093590|NCT03611127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093591|NCT00266812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093592|NCT04983732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705421|NCT04066023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, care providers, investigator, and outcomes assessors are blinded to randomized treatment assignment. Study drugs are blinded and identical in appearance.|Qualified subjects are assigned to received a single administration of one of three blinded treatment assignments (one of two dose levels or placebo)|t|t|t|t
33705422|NCT04990557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705423|NCT01783431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705424|NCT00438646|||||PROSPECTIVE|||||||
33705425|NCT01500577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33705426|NCT01805804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33705427|NCT01945528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705428|NCT06062134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking was required for this study.|All subjects enrolled in the study received the same interventional regional analgesia technique (the pericapsular nerve group block) as part of the standard multimodal analgesia protocol. The local anesthetic was mixed with a radiocontrast agent in order to evaluate the spread of the injectate by using CT scan imaging.||||
33705429|NCT03711461|RANDOMIZED|PARALLEL||OTHER||SINGLE|the swallowing function assessor is blind|intubated and nonintubated patients|f|f|f|t
33705430|NCT02518256|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705431|NCT04851080|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33705432|NCT03024619|||COHORT||RETROSPECTIVE|||||||
33705433|NCT04089475|||OTHER||PROSPECTIVE|||||||
33705434|NCT05361889|||COHORT||RETROSPECTIVE|||||||
33705435|NCT00767130|||COHORT||RETROSPECTIVE|||||||
33705436|NCT00378378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705437|NCT00453063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789846|NCT06489860|NA|SINGLE_GROUP||TREATMENT||NONE|"Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2 Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.~Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity)."|"SARS-CoV-2. Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2.~Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g."||||
33930029|NCT04449991|RANDOMIZED|PARALLEL||TREATMENT||NONE||At baseline, patients will be randomised 1:1 to either undergo or not undergo a per-protocol repeat kidney biopsy at month 12 from baseline.||||
33930030|NCT00049972|NON_RANDOMIZED|||TREATMENT||NONE||||||
33930031|NCT01463124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930032|NCT02341404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930033|NCT03185312|||CASE_CONTROL||PROSPECTIVE|||||||
33930034|NCT02103595|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33930035|NCT05406440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33930036|NCT03556865|||OTHER||CROSS_SECTIONAL|||||||
33930037|NCT03938025|||COHORT||PROSPECTIVE|||||||
33930038|NCT03472040|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33930039|NCT05317260|||COHORT||RETROSPECTIVE|||||||
33930040|NCT03999385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pretest-Posttest Waitlist Control Design||||
33930041|NCT02257125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930042|NCT04623255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930043|NCT01255540|||CASE_CONTROL||PROSPECTIVE|||||||
33930044|NCT03062267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930045|NCT04447911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentric prospective randomized double-blind placebo-controlled study|t|t|t|t
33930046|NCT03529890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930047|NCT04207008|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial||||
33930048|NCT02324868|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33930049|NCT01126684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930050|NCT05823610|||COHORT||OTHER|||||||
33930051|NCT03857607|||COHORT||PROSPECTIVE|||||||
33930052|NCT00864344|RANDOMIZED|CROSSOVER||||NONE||||||
33930053|NCT03156413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930054|NCT02401113|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930055|NCT00858676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930056|NCT06321640|||COHORT||PROSPECTIVE|||||||
33930057|NCT00853619|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930058|NCT05941910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930059|NCT01529619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930060|NCT03590093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The examiner were not aware of group allocation||f|f|t|t
33930061|NCT06153914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930062|NCT00674375|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33930063|NCT05467072|||COHORT||RETROSPECTIVE|||||||
33930064|NCT06240793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008890|NCT04625062|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All perceptual ratings will be obtained from blinded, naive listeners recruited through online crowdsourcing. Following protocols refined in previous published research, binary rating responses will be aggregated over at least 9 unique listeners per token.|In this within-subjects single-case randomization design, each participant will receive an equal number of sessions of visual-acoustic biofeedback and traditional treatment (n = 10 each), with randomized allocation of treatment types to individual sessions. Randomization will be blocked, with each week of treatment serving as a block; within each week/block, one session will be randomly assigned to feature visual-acoustic and one to feature traditional treatment.|f|f|f|t
34008891|NCT00546910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008892|NCT02466802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008893|NCT00480649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008894|NCT05655455|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A repeated-measurement and 3-arm randomized controlled trial with pretest-posttest control group|t|f|f|f
34093593|NCT06181500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093594|NCT02629458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093595|NCT01512186|||CASE_ONLY||PROSPECTIVE|||||||
33705438|NCT04882618|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single arm study||||
34008895|NCT05178914|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients with a symptomatology of angina pectoris who have at least one epicardial lesion greater than or equal to 50% on coronary angiography evaluation~The interventional group is defined by the disclosure of the IMR value. The initial IMR is used to guide therapy.~The control group is defined as follows: the initial IMR has been performed but its result is not undisclosed (sham procedure) ; patients will receive standard medical treatment according to the physician's preference."||||
34008896|NCT00000202||||TREATMENT||||||||
34008897|NCT01222949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789847|NCT01566513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930065|NCT01824862|||CASE_CONTROL||PROSPECTIVE|||||||
33930066|NCT00663338|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33930067|NCT04460365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008898|NCT02285205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008899|NCT05373381|NA|SINGLE_GROUP||OTHER||NONE||||||
34008900|NCT02720133|||COHORT||PROSPECTIVE|||||||
34008901|NCT05149924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008902|NCT01828645|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
34008903|NCT02070757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008904|NCT00858013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008905|NCT00697840|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34008906|NCT03244475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham treatment, double-blind design: During the sham treatment, we will prep and preplace the electrodes for common reference, A-, B-, plus the set of electrodes on the scalp of the participant following the 10-20 EEG configuration for A+ and A-, just like the procedure for real TES treatment. However, no LIP-tES pulses will be sent from the system during sham treatment, based a code entered to the system. A staff member (SRA #1) will assign a mTBI Veteran to either the mTBI-TES or the mTBI Sham group, with an attached code from an existing code bank. Then, the TES treatment operator (SRA #2) who is blind to the group assignment will enter the code to the TES system during treatments. Based on the code, the system automatically loads the protocol for either TES or Sham treatment. Only at the end of the study (after V16), the group assignment is revealed. Therefore, both the participant and TES treatment operator (SRA #2) are blind to the group assignment during the study.|After consent, Visit 1 (V1) for all 3 groups will include baseline NP and MHA. Then, baseline rs-MEG and MRI will be performed in V2 for all groups. At V3 the mTBI Veterans in TES and sham groups will undergo a pre-session MEG, the first TES/Sham treatment Session (S1), and a post-session MEG. Next, the mTBI Veterans continue their TES/Sham treatments S2-6 in V4-8. During V9, a pair of pre- and post-MEG exams and NP will be performed. The mTBI Veterans will continue treatments S8-11 in V10-13. During V14, a pair of pre- and post-MEG exams will be performed. 1 week after the Veterans finish their final TES/Sham treatment S12, a 1-week follow-up MEG and NP will be conducted during V15. A subset of TES group will be tested 1 month after the final treatment for a follow-up MEG V16. Veterans in the mTBI-sham group will be offered the real TES treatment.|t|t|f|f
33930068|NCT00003000|||COHORT||PROSPECTIVE|||||||
33930069|NCT02157584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930070|NCT02635529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930071|NCT05240963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930072|NCT02446860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930073|NCT05932394|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33930074|NCT06300892|||CASE_CONTROL||PROSPECTIVE|||||||
33930075|NCT03975530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930076|NCT02204410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930077|NCT01685203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930078|NCT00879047|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34008907|NCT01647958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008908|NCT06615830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930079|NCT03736551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study outcome measures performed by assessor blinded to treatment arm|Parallel arm, single blinded, randomised controlled feasibility study|f|f|f|t
34093596|NCT01597362|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34093597|NCT01555931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093598|NCT05713448|||COHORT||PROSPECTIVE|||||||
34093599|NCT02318979|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||10 athletes with a unilateral and 5 athletes with bilateral transtibial amputations used 15 different running-specific prosthetic configurations while they ran at one speed and we measured metabolic rates and biomechanics. 10 athletes with a unilateral and 5 athletes with bilateral transtibial amputations used 15 different running-specific prosthetic configurations while they ran at multiple speeds and we measured top speeds and biomechanics.||||
34093600|NCT02273453|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34093601|NCT05752864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34093602|NCT03853200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093603|NCT03870321|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34093604|NCT03523351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In this trial patients will be divided into 2 cohorts. Patients in Cohort 1 will undergo standard of care therapy for bone metastases. Patients in Cohort 2 will undergo upfront RT to ≤5 highest risk bone metastases first followed by standard of care therapy.||||
34093605|NCT04916249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study coordinators, patients, PI, co-investigators, biostatisticians will be blinded to which treatment group the patient was assigned to.|This is a single-center, two-arm, randomized, placebo-controlled trial comparing Tibetree PRP with a placebo control plaster.|t|t|t|t
34093606|NCT00436709|NON_RANDOMIZED|||TREATMENT||||||||
34093607|NCT06259838|||COHORT||RETROSPECTIVE|||||||
34093608|NCT04359459|||COHORT||PROSPECTIVE|||||||
34093609|NCT00668564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093610|NCT02115503|||COHORT||PROSPECTIVE|||||||
34093611|NCT05768464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093612|NCT00489268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093613|NCT05672069|||COHORT||PROSPECTIVE|||||||
34093614|NCT03316560|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34093615|NCT00918450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093616|NCT02736812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093617|NCT02990377|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34093618|NCT01122953|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34093619|NCT02940379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093620|NCT00790933|NA|SINGLE_GROUP||OTHER||NONE||||||
34093621|NCT04098120|||COHORT||PROSPECTIVE|||||||
34093622|NCT01505335|||CASE_ONLY||PROSPECTIVE|||||||
34093623|NCT06011226|||CASE_ONLY||PROSPECTIVE|||||||
34093624|NCT04462172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective multicenter cohort study is to compare the post-operative implant failure rate between the patients with femoral neck fracture (AO classification 31-B) using Femoral Neck System (FNS) versus Multiple Cancellous Screws (MCS) at 2-year follow up.The patients are divided into the FNS group and the MCS group according to the internal fixation they choose.||||
34093625|NCT06493799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008909|NCT04355299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008910|NCT03297255|||COHORT||PROSPECTIVE|||||||
34008911|NCT06004869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093626|NCT04386837|||OTHER||PROSPECTIVE|||||||
34093627|NCT04041128|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008912|NCT04974619|||COHORT||CROSS_SECTIONAL|||||||
34008913|NCT04031092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers performing the analyses will be blinded|A parallel group design with two groups|f|f|t|f
34008914|NCT00031811|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34008915|NCT01713088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34008916|NCT04828434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind. The assessor will be blinded. Due to the nature of the intervention, the facilitator, and participants cannot be blinded.||f|f|f|t
33930080|NCT03265925|||COHORT||PROSPECTIVE|||||||
33930081|NCT01094808|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33930082|NCT03630016|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33930083|NCT03771781|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34008917|NCT01099306|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33705439|NCT04383262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|We have partnered with Froedtert Hospital's Investigative Drug Services in order to randomize subjects to either treatment or placebo. Only FH IDS will have the key linking subjects to treatment groups, and the power to conduct an emergency unblinding.|Proof-of-Concept|t|t|t|t
33705440|NCT02785120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930084|NCT03825497|RANDOMIZED|PARALLEL||TREATMENT||NONE|All patients at the intervention wards will receive the intervention why neither investigators nor outcome assessors will be blinded to the intervention. Patients at intervention and control wards will get equal information regarding the study and will be asked to participate in equal assessments|A feasibility study at Medical Wards (intervention wards) in Oct 2018, January 2019 and February 2019 prior to a cluster randomized trial. Medical wards at 4 different hospitals representing clusters - 2 intervention clusters and 2 control clusters.||||
33930085|NCT03814681|||COHORT||PROSPECTIVE|||||||
33930086|NCT05243004|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33930087|NCT05849636|RANDOMIZED|PARALLEL||PREVENTION||NONE||A Cluster Randomized Controlled Trial is conducted to test the effectiveness of ALERTA CANNABIS in students aged 14 to 18 years. The study Will be carried out in 34 high schools from Andalusia (southern Spain), which will be randomized either to the experimental or the control condition (EC and CC). The EC will receive the ALERTA CANNABIS intervention, which consists of four sessions at school.The CC just completes the baseline and the evaluation questionnaires.||||
33930088|NCT02685124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930089|NCT05634876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930090|NCT01328678|||CASE_ONLY||PROSPECTIVE|||||||
33930091|NCT03882723|NA|SINGLE_GROUP||TREATMENT||NONE||randomized crossover trial||||
33930092|NCT01763112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930093|NCT03237429|||COHORT||PROSPECTIVE|||||||
33930094|NCT05070325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomized controlled trial||||
33930095|NCT03801694|||COHORT||PROSPECTIVE|||||||
33930096|NCT04585672|NA|SINGLE_GROUP||OTHER||NONE||||||
33930097|NCT05154578|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants will be randomized to one of 5 groups|t|f|t|t
33930098|NCT04319770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930099|NCT00561340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930100|NCT01412151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930101|NCT04755283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All care providers are blinded with the exception of the pharmacist and study team member assigned to administer the subcutaneous injection of abelacimab.|This is an event-driven, randomized, active-controlled, blinded endpoint, parallel-group study to evaluate the effect of two blinded doses of abelacimab relative to open-label rivaroxaban on the rate of major or clinically relevant non-major (CRNM) bleeding events in patients with atrial fibrillation (AF) who are at moderate-to-high risk of stroke.|t|t|t|f
33930102|NCT01048047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930103|NCT02215616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930104|NCT02122055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930105|NCT03039790|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33930106|NCT02137304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930107|NCT06405685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930108|NCT01674946|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33930109|NCT04212936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33930110|NCT04595409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930111|NCT06126406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930112|NCT04882358|RANDOMIZED|PARALLEL||OTHER||NONE||Multicenter, randomized, open label, feasibility and safety study||||
33930113|NCT03638713|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A total of 200 patients were allocated into one of two groups by computerized randomization. Patients in the group A (colonoscopy first group) received colonoscopy followed by EGD and those in the group B (EGD first group) received EGD followed by colonoscopy.||||
33930114|NCT00005675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930115|NCT06347965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33930116|NCT00398125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930117|NCT00292136|||||PROSPECTIVE|||||||
33930118|NCT02621372|||CASE_ONLY||OTHER|||||||
33930119|NCT03499340|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33930120|NCT04673812|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33930121|NCT04734626|||CASE_CONTROL||PROSPECTIVE|||||||
33930122|NCT02372110|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33930123|NCT01496989|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930124|NCT00100867|||COHORT||PROSPECTIVE|||||||
33930125|NCT01193049|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34008918|NCT02367625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34008919|NCT05039476|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||Split face intervention|t|f|f|f
34008920|NCT04819373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008921|NCT06216171|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34008922|NCT00994435|||CASE_ONLY||PROSPECTIVE|||||||
34008923|NCT01784198|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33789848|NCT06345534|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both healthcare provider and patient know the treatment|Patients participating in the study will be randomized 1:1 between the FAST-FORWARD schedule and the HAI5 schedule. The first group is treated according to the FAST-FORWARD schedule, consisting of 5 radiation sessions on 5 consecutive working days (e.g. Monday to Friday). 2 rest days are allowed in the schedule, so that the treatment lasts a maximum of 7 days. The second group is treated according to the HAI5 schedule, developed by the radiotherapy department of Ghent University Hospital. In this schedule, at least 1 day of rest is scheduled between each treatment session, so the treatment is administered over 10-14 days.||||
33789849|NCT06062706|||COHORT||PROSPECTIVE|||||||
33789850|NCT00741988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789851|NCT01570751|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789852|NCT03554902|||COHORT||PROSPECTIVE|||||||
33789853|NCT01168011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789854|NCT05305989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789855|NCT04009356|||COHORT||PROSPECTIVE|||||||
33789856|NCT00956982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789857|NCT05279092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study medication mixture for nerve blocks for each study group will be prepared by an unblinded block nurse who will not be involved in block procedure or subsequent assessments. The patients, and the clinical team including the investigators who will perform the nerve blocks and assessors for subsequent patient follow ups will remain blinded to the group assignment throughout the study. Unblinding will occur after the 3-month follow-up is complete for the last enrolled patient.||t|t|t|t
33789858|NCT05817331|||COHORT||CROSS_SECTIONAL|||||||
33789859|NCT02563704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789860|NCT01847248|||CASE_CONTROL||PROSPECTIVE|||||||
33789861|NCT01369589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33789862|NCT02061332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789863|NCT00768651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789864|NCT00868595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789865|NCT02418806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789866|NCT00828672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789867|NCT00209443|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789868|NCT02770248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789869|NCT06452446|||CASE_ONLY||PROSPECTIVE|||||||
33789870|NCT03318536|||COHORT||RETROSPECTIVE|||||||
33789871|NCT05225935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33789872|NCT05107297|||OTHER||CROSS_SECTIONAL|||||||
33789873|NCT05534100|||CASE_CONTROL||PROSPECTIVE|||||||
33930126|NCT04062370|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, controlled, parallel, open-label, exploratory clinical trial. Including 100 patients, 50 : 50 in each arm. Different frequency of Ranibizumab is applied in this study.||||
33930127|NCT05058404|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, multicenter, phase III, two arms randomized trial with a non-inferiority design with Progression-Free Survival (PFS) as primary endpoint. Patients who meet all eligibility criteria will be centrally randomized to one of the two treatment arms in a 1:1 ratio, using random sequences blocks of variable size. The web-based allocation process, completely concealed to researchers, will be stratified according Follicular Lymphoma International Prognostic Index 2 (FLIPI2) score (0-2, 3-5), chemotherapy regimen (CHOP, Bendamustine, CVP) and anti-CD20 Monoclonal Antibody (MoAb) (rituximab, obinutuzumab). A non-inferiority design has been adopted to demonstrate that a shortened exposure to chemotherapy in patients responding to the first four cycles of immunochemotherapy is not detrimental in terms of PFS compared to full dose standard treatment. The primary comparison will be done as an Intention To Treat (ITT) analysis including all randomized patients.||||
33930128|NCT01749800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34008924|NCT05596292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-center randomized parallel controlled trial|f|f|t|t
34008925|NCT06368141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008926|NCT01790230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008927|NCT03318887|||COHORT||RETROSPECTIVE|||||||
33789874|NCT05824442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789875|NCT06555861|||COHORT||RETROSPECTIVE|||||||
33789876|NCT02733913|||COHORT||PROSPECTIVE|||||||
33789877|NCT06175923|||COHORT||PROSPECTIVE|||||||
33789878|NCT03675139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789879|NCT01808807|||CASE_CONTROL||RETROSPECTIVE|||||||
33789880|NCT00866762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789881|NCT02555631|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33789882|NCT03392558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33789883|NCT01616654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789884|NCT05565391|||COHORT||RETROSPECTIVE|||||||
33789885|NCT01814644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33789886|NCT00643708|||CASE_ONLY||PROSPECTIVE|||||||
33789887|NCT00629200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789888|NCT05725018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789889|NCT04915599|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm pilot trial||||
33789890|NCT02639429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789891|NCT03398551|||COHORT||PROSPECTIVE|||||||
33789892|NCT02534441|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33789893|NCT05678491|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with GERD will be examined at baseline and after three and six months. Variables of GERD will be compared between the three different time points.||||
33789894|NCT05425836|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two arm parallel group||||
34008928|NCT05061914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008929|NCT01825837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34008930|NCT04629599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930129|NCT01934868|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is possible at this point in time.|This is a study comparing prolotherapy treatments with an active control, which happens to be the gold standard treatment for radicular pain.||||
33930130|NCT00324740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930131|NCT04773847|NA|SINGLE_GROUP||TREATMENT||NONE||Since the studied medical device is a custom-made product, only one group is considered.||||
33930132|NCT00156013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930133|NCT03105661|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to treatment or non treatment group||||
33930134|NCT04432571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930135|NCT01813968|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33930136|NCT02957344|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33930137|NCT01038089|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34008931|NCT02396082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34008932|NCT05752188|||COHORT||RETROSPECTIVE|||||||
34008933|NCT01933919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008934|NCT03509662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In this multicentre, placebo controlled double-blind randomized clinical trial patients will be recruited from the Intensive Care Units of 8 hospitals.~270 comatose patients suffering an out-of-hospital cardiac arrest with ventricular fibrillation/tachycardia as first registered cardiac rhythm and EMV-score ≤8 will be included.~As soon as possible patients will be randomly allocated to one of 3 treatment groups of 90 patients each and vitamin C or placebo will be started for 96 hours. Group 1 will be treated with placebo, group 2 with 2 times a day a bolus of 1.5 gr vitamin C and group 3 with 2 times a day a bolus of 5 gr vitamin C.~All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate."|t|t|t|t
34093628|NCT05129709|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The Social Cognitive Theory (SCT) and the Health Belief Model (HBM) inform this proposal. The SCT posits that human behavior is determined by expectancies- of culture, potential outcomes, and self-efficacy- and incentives. The HBM holds that health-related behavior depends on motivation, the belief that one is susceptible to serious illness, and the belief that following provider advice will reduce the threat. Concepts of health beliefs, self-efficacy, and culture must be considered when developing effective interventions for value solicitations and behavior change. This is especially true for older AAs in the Deep South, who report different lived experiences and experiences with medical icare than Whites. Patient-centered care cannot be realized for AAs without reshaping interventions to consider factors important to seriously ill older AAs with MCCs. Reframing discussion in a culturally-responsive manner is necessary to establish patient and FCG preferences prior to a health crisis.||||
34093629|NCT05049694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093630|NCT01789775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093631|NCT03274089|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33930138|NCT03518034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930139|NCT03121456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705441|NCT05801133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930140|NCT03039569|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930141|NCT06451276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930142|NCT04248686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930143|NCT05118711|||COHORT||CROSS_SECTIONAL|||||||
33930144|NCT03869216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients are the unit of randomization and physicians do not know what patients are assigned to the intervention or control arm.|Parallel assignment|f|t|f|f
33930145|NCT02253472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930146|NCT05402722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930147|NCT02167412|||COHORT||PROSPECTIVE|||||||
33930148|NCT02262338|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33930149|NCT01027572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930150|NCT05610969|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1||||
33930151|NCT01770756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930152|NCT00333047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930153|NCT02027974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930154|NCT02323399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930155|NCT02004925|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33930156|NCT00076856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930157|NCT01379560|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33705442|NCT00003997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930158|NCT01228981|||COHORT||PROSPECTIVE|||||||
33930159|NCT03049943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930160|NCT01209806|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33930161|NCT01766245|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33930162|NCT05022641|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only participants will be masked to the intervention||t|f|f|f
33930163|NCT05136040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33930164|NCT02062372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930165|NCT06025084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930166|NCT02542813|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33930167|NCT02294669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930168|NCT05702372|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|double-blind (investigator and outcomes assessor)|Crossover assignment|f|f|t|t
33930169|NCT05750485|||COHORT||PROSPECTIVE|||||||
33930170|NCT01068613|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33930171|NCT00322387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930172|NCT06350357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789895|NCT01000129|NA|SINGLE_GROUP||TREATMENT||||||||
34008935|NCT01736787|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34008936|NCT01915641|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33705443|NCT06060743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the study, groups were determined by block randomization. The randomization list was created by block randomization according to age and gender.|It consists of two groups, application and control, and three follow-ups.|t|f|f|t
33705444|NCT04657731|||COHORT||CROSS_SECTIONAL|||||||
33705445|NCT05344911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705446|NCT06247514|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This is a pilot feasibility trial.~BHPs will be randomized and trained to deliver the intervention or the comparator. They will be encouraged to deliver the programs as they typically would in a clinical setting while maintaining fidelity to session content."||||
33705447|NCT04526431|||COHORT||PROSPECTIVE|||||||
33705448|NCT00530309|RANDOMIZED|PARALLEL||TREATMENT||||||||
33705449|NCT00247975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705450|NCT01646307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705451|NCT03747588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705452|NCT03953196|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33705453|NCT01077570|||COHORT||PROSPECTIVE|||||||
33705454|NCT01389388|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33705455|NCT01559467|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705456|NCT02192359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705457|NCT02569658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705458|NCT00390065|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Randomization in the neonatal period. Blinding maintained at the time of the follow-up study|This is a follow-up study, at 6 years of age, of infants randomized in the neonatal period with one other group studied as a reference group (ie 3 groups)|t|t|t|t
33789896|NCT01524536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930173|NCT02394223|||CASE_CONTROL||PROSPECTIVE|||||||
33930174|NCT03510910|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930175|NCT03379441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930176|NCT03823430|||COHORT||PROSPECTIVE|||||||
33930177|NCT06219109|||COHORT||RETROSPECTIVE|||||||
33930178|NCT00470678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930179|NCT02975349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33930180|NCT00445341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930181|NCT05318040|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double Blinded|This is a 4-Part study. Parts 1, 2, and 3 are randomized, double blind, placebo-controlled investigations of SAD (Part 1) and MAD (Part 2) in healthy young adult subjects and multiple doses in healthy elderly subjects (Part 3) of orally administered CMS121. Part 4 is an open label, 2 way crossover study to assess the effect of food on a single oral dose of CMS121 in healthy young adult subjects.|t|t|t|f
33930182|NCT04841850|||COHORT||RETROSPECTIVE|||||||
33930183|NCT05248646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930184|NCT06244719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930185|NCT02953067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930186|NCT00739960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930187|NCT05793684|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind study||t|f|t|f
33930188|NCT04645004|NA|SINGLE_GROUP||OTHER||NONE||One arm PK/PD study of aspirin in pregnancy1||||
33930189|NCT01039311|||CASE_ONLY||PROSPECTIVE|||||||
33930190|NCT00110591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930191|NCT00798473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930192|NCT00572728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008937|NCT00442546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008938|NCT01592721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008939|NCT04575714|||CASE_ONLY||CROSS_SECTIONAL|||||||
34008940|NCT04045808|||OTHER||PROSPECTIVE|||||||
34008941|NCT01909934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008942|NCT02729779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008943|NCT02326363|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|||||
34008944|NCT05746377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization protocol instituted by pharmacy, patient and endoscopist blinded to treatment assignment.||t|t|f|f
34008945|NCT01350934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789897|NCT05140564|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33789898|NCT00951886|||COHORT||RETROSPECTIVE|||||||
33930193|NCT05843591|||OTHER||OTHER|||||||
33930194|NCT02740712|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
34008946|NCT02605213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705459|NCT03363958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33705460|NCT04436367|||COHORT||RETROSPECTIVE|||||||
33705461|NCT01550731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34008947|NCT05631821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Twenty (20) patients prospective and Twenty (20) retrospective. Retrospective matched cohort of patients from the investigating surgeon. The patients will have had surgery using rods but without the MESA™ Spinal Fixation System. The prospective patient will have surgery using rods with the MESA™ Spinal Fixation System.||||
34008948|NCT00510315|||COHORT||PROSPECTIVE|||||||
34008949|NCT01012141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34008950|NCT02071056|||CASE_ONLY||PROSPECTIVE|||||||
33705462|NCT03115086|||COHORT||PROSPECTIVE|||||||
34008951|NCT03490916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705463|NCT02655640|||COHORT||PROSPECTIVE|||||||
33705464|NCT03652597|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705465|NCT00223366|||CASE_ONLY||CROSS_SECTIONAL|||||||
33930195|NCT05693103|||CASE_ONLY||CROSS_SECTIONAL|||||||
33930196|NCT01496404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930197|NCT00524667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930198|NCT00571519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930199|NCT00969488|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33930200|NCT05244941|||OTHER||CROSS_SECTIONAL|||||||
33930201|NCT06180733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930202|NCT04742036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930203|NCT05076097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930204|NCT00124813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930205|NCT00247273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930206|NCT03486561|NA|SINGLE_GROUP||TREATMENT||NONE||Open Labelled Phase IV clinical trial||||
33930207|NCT00530491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930208|NCT04909294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930209|NCT01807091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930210|NCT03423862|||COHORT||PROSPECTIVE|||||||
34008952|NCT03808584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34008953|NCT01559935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008954|NCT01766388|||CASE_ONLY||PROSPECTIVE|||||||
34008955|NCT03662763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705466|NCT04301037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705467|NCT06257797|||CASE_CONTROL||RETROSPECTIVE|||||||
33705468|NCT01771952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705469|NCT03104543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized clinical trial of an educational intervention||||
33705470|NCT02467400|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33705471|NCT04378556|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Repeated measures design||||
33705472|NCT03150017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705473|NCT00115752||||TREATMENT||||||||
33705474|NCT06306781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705475|NCT05574738|||CASE_ONLY||PROSPECTIVE|||||||
33705476|NCT00261469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705477|NCT02577549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705478|NCT02867462|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33705479|NCT03236025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33705480|NCT05509114|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705481|NCT00717093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930211|NCT02970539|NA|SEQUENTIAL||TREATMENT||NONE||"Part 1 of the study will follow the standard 3+3 study design to determine the MTD of Oraxol administered continuously for 3 consecutive days per week (3-day MTD) in combination with ramucirumab. And Part 2 will obtain confirmatory activity, safety, and tolerability data."||||
33930212|NCT00706940|||CASE_ONLY||PROSPECTIVE|||||||
33930213|NCT02106104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930214|NCT02136550|NA|SINGLE_GROUP||SCREENING||NONE|Fluid analysis and other physical measurements|Subjects that entered in the Smoking Cessation Program at Institute Dante Pazzanese of Cardiology State of Sao Paulo||||
33930215|NCT01870791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930216|NCT03787095|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33930217|NCT01574417|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33930218|NCT02668952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930219|NCT03375970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930220|NCT05936346|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open label, Parallel-arm, Two-dose Study||||
33930221|NCT04314609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930222|NCT00381589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33930223|NCT01769482|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33930224|NCT00354952|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
34008956|NCT03146273|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34008957|NCT02825576|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34008958|NCT03548662|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34008959|NCT00805402|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008960|NCT03959995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding attempt of participants by sham exercise. Outcome assessors were unaware of participant's group status (exercise or control) and were not allowed to ask correspondingly.||t|f|f|t
34008961|NCT05965791|||OTHER||CROSS_SECTIONAL|||||||
34008962|NCT00319046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705482|NCT01419691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705483|NCT00182884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33705484|NCT03268993|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Thirty-six individuals who have previously been treated for tobacco-related, HPV-negative HNSCC will be recruited for this study.~After being deemed eligible, subjects will be assigned a patient number and be registered into the CTMA database.~At registration, they will be randomized to receive either 4 tablets/day in Cycle 1 or 8 tablets/day in Cycle 1 (and the other dose in Cycle 2). This randomization is not blinded. Randomization will be stratified by history of head and neck radiation therapy (yes or no)."||||
33705485|NCT00911560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705486|NCT01676571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705487|NCT00578708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705488|NCT05098301|||COHORT||PROSPECTIVE|||||||
33705489|NCT03708016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33705490|NCT00349531||PARALLEL||TREATMENT||||||||
33705491|NCT01100541|NA|SINGLE_GROUP||||NONE||||||
33705492|NCT00275457|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33705493|NCT03470870|||COHORT||RETROSPECTIVE|||||||
33705494|NCT04868214|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33930225|NCT02447640|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34008963|NCT00521989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008964|NCT03460158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008965|NCT06329791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705495|NCT03999177|NA|SINGLE_GROUP||OTHER||NONE||||||
33705496|NCT02369432|NA|SINGLE_GROUP||OTHER||NONE||||||
33930226|NCT04880681|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patient and pathologist are unaware of which needle/device is used. All biopsies are taken from behind the back of the patient enabling masking from the patient. To assess masking success, patients will be asked to guess which device was used after the procedure is complete.|60 patients eligible for prostate biopsy are randomized into 2 arms (30+30 patients) using either the novel needle and actuator device or standard Tru Cut needle and actuator device used in the clinic today. On average 12 biopsies are taken from each patient. Biopsy length (primary outcome) is evaluated by a pathologist who is blinded to device used.|t|f|f|t
33789899|NCT04701294|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Regarding the patient data, it will only be handled by the programmer who will be in charge of coding, randomizing the first permanent molars, randomizing the materials to be used so that it is placed in the first permanent molars and this information will be given to the coordinator so that the put in sealed envelopes and then these sealed envelopes will be given to an outside assistant so that such data is not disclosed or published.~Assistant 3 (in charge of labeling with kraft paper and listing the intervention material(giomer F03 beautifil-shofu and Tetric N-Flow ivoclar vivadent) with the research coordinator.~The evaluators did not do the intervention."|A split mouth (120 teeth) study design will be adopted (19.20), which consists of a simple division of the mouth into two parts (right and left) for the first four permanent molars of each patient, where the placement of the materials will be on the right / left side of the mouth and contralateral.|t|t|t|t
33930227|NCT05759390|||COHORT||PROSPECTIVE|||||||
33930228|NCT02167724|NA|SINGLE_GROUP||||NONE||||||
33930229|NCT01376895|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33930230|NCT05460390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930231|NCT01425645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33930232|NCT05618327|NA|SEQUENTIAL||TREATMENT||NONE||||||
33930233|NCT03953885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930234|NCT02562027|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33930235|NCT06360536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930236|NCT05793112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008966|NCT05664217|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This is a double-blinded study. The Investigator, the patients, and all study site and Nektar personnel involved in study activities, other than those involved in dispensing the study drugs, conducting PK, PD sample analyses, and personnel supporting unblinded monitoring for drug accountability, must remain blinded to each patient's treatment assignment.|The study is conducted in two stages, with routine safety monitoring being conducted by the Data Monitoring Committee (DMC) on a regular basis. An enrollment pause will be implemented at the end of Stage 1 (ie, after approximately 56 patients are randomized), and the DMC will review safety and efficacy data from all available cohorts to make go/no-go and dose selection recommendations for Stage 2. The study team will be unblinded at the end of Stage 1 to review totality of the data including efficacy, safety, PK, and PD data before the study proceeds to Stage 2. The protocol will be updated with, at least, an identification of the selected dose and its justification prior to Stage 2 activation.|t|t|t|t
34008967|NCT05085769|||CASE_CONTROL||PROSPECTIVE|||||||
34008968|NCT05621954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|Pragmatic, single-centre, individual patient, randomized controlled trial||||
34008969|NCT04769752|||COHORT||PROSPECTIVE|||||||
33705497|NCT01121653|RANDOMIZED|||TREATMENT||DOUBLE|||t|t|f|f
34008970|NCT03585426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34008971|NCT04311151|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34008972|NCT05650086|||COHORT||PROSPECTIVE|||||||
34008973|NCT06210945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008974|NCT02248506|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34008975|NCT03355209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1: Double-Blind Part 2: Open-Label|Part 1: Double-Blind ZX008 - (0.2 mg/kg/day or 0.8mg/kg/day) or Placebo and Part 2: Open-Label|t|t|t|t
34008976|NCT03553875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705498|NCT04369287|||COHORT||PROSPECTIVE|||||||
33705499|NCT05219175|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study comparing outcomes before and after treatment with MDMA Assisted Therapy||||
33705500|NCT01262131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705501|NCT02365831|||COHORT|||||||||
33705502|NCT02901405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705503|NCT03342677|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705504|NCT05500157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705505|NCT04988139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes measurements will be performed by researchers who are blind to the groups' allocation.|A total of 20 children with developmental delays who are receiving traditional rehabilitation programs will be enrolled. The participants will be randomized into two groups, including the intervention group (traditional rehabilitation program with additional educational training) and the control group (traditional rehabilitation program without educational training). The intervention group will receive 1 month of individualized educational training, 50 min per session, 1 session per week, a total of 4 sessions. All of the evaluations will be performed before training, re-evaluated 1 month after completion of treatment, and 3 months after completion of the treatment in the study group. The control group will be evaluated at the baseline, 1 month, and 6 months later, respectively.|f|f|f|t
33789900|NCT00756743|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33789901|NCT05818800|RANDOMIZED|PARALLEL||OTHER||NONE||This will be a randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions or to standard care.||||
33789902|NCT04369534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789903|NCT02117843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930237|NCT01975675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930238|NCT03676205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient doesn't know the treatment. The person who analyze the data (outcomes assessor) doesn't know the treatment.|Two homogeneus groups with 1:1 possibilities to receive PRP or a homeopathic product.|t|f|f|t
33930239|NCT02482649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103264|NCT05513170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This trial is considered a randomized double blind clinical trial due to the following:~1. The participant will be blinded to the technique that will be used during the surgical operation.~2. The outcome assessor will be blinded~3. The operator (DR.B.S.) will not be blinded for both techniques during the surgical operation, as the two techniques are different. (Dr. M.O.).~The purpose of double blinding procedure is to reduce assessment bias and to increase accuracy and objectivity of clinical outcomes"|Patients' data will be enrolled in database of the Outpatient clinics of the Department of Oral and maxillofacial surgery, Faculty of Dentistry, Cairo University. If there is a potential eligibility, the patient will be examined thoroughly as described before. Consecutive sampling is done through screening of patients. This will continue until the target population is achieved. Identifying and recruiting potential subjects is achieved through patient database.|t|f|f|t
34103265|NCT04389632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705506|NCT03022136|NA|SINGLE_GROUP||OTHER||NONE||||||
33705507|NCT05947175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705508|NCT05499000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705509|NCT05146895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705510|NCT04790773|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33705511|NCT04816266|||CASE_ONLY||CROSS_SECTIONAL|||||||
33705512|NCT01631773|||COHORT||PROSPECTIVE|||||||
33705513|NCT03725852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705514|NCT02184481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705515|NCT01647646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705516|NCT03854695|||COHORT||PROSPECTIVE|||||||
33705517|NCT00716703|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705518|NCT00332163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705519|NCT01750983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705520|NCT00199693|||COHORT||PROSPECTIVE|||||||
33705521|NCT05825859|||COHORT||PROSPECTIVE|||||||
33789904|NCT03852836|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33789905|NCT05541393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33789906|NCT06106087|NA|SINGLE_GROUP||OTHER||NONE||||||
33930240|NCT06021847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients didn't know which treatment they received.|Two groups ( complete denture wearers with oral stomatitis). Group I treated with ozonated water while group II treated with chlorhexidine mouthwash.|t|f|f|f
33930241|NCT00723853|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930242|NCT01291706|||COHORT||PROSPECTIVE|||||||
33930243|NCT02551913|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33930244|NCT03554304|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33930245|NCT02342613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930246|NCT00714337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33930247|NCT01408134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930248|NCT05932381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|complete decongestive therapy and routine medical treatment|f|f|t|t
33930249|NCT06400693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||single-center, randomized, controlled simulation study||||
33930250|NCT06382961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33930251|NCT05185219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930252|NCT02939651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930253|NCT03486249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients will have a cardiac echo examination and diaphragm function assessment.||||
33930254|NCT00838383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930255|NCT04889612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930256|NCT05480501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930257|NCT00756093|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33930258|NCT03625492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930259|NCT04073641|||OTHER||CROSS_SECTIONAL|||||||
33930260|NCT00369746|||CASE_CONTROL||PROSPECTIVE|||||||
33705522|NCT03196726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants randomized by offering 2 opaque envelope to group them into either as control or intervention group.~Medical officers were responsible in the management of all participants using standard Clinical Practice Guideline (CPG). Participants from intervention group will see Medical Officer first before being given CBT by nurse"|Management of postnatal depression mothers at primary care clinics using Cognitive-behavioural therapy treatment by nurses as adjunct to management by Medical Officer in intervention arm, compared to management by Medical Officer alone in control arm.|t|t|f|f
33789907|NCT02385669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789908|NCT06155253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33789909|NCT03692520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789910|NCT05485129|NA|SINGLE_GROUP||SCREENING||NONE||||||
33789911|NCT03906734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930261|NCT02417675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930262|NCT03441594|||OTHER||CROSS_SECTIONAL|||||||
33930263|NCT01690819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930264|NCT03456180|||CASE_ONLY||PROSPECTIVE|||||||
33930265|NCT06268509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930266|NCT04544124|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given incentivization will occur for attendance, it is not possible to blind conditions.|Participants who use methamphetamine and participants who use substances other than methamphetamine will randomly be assigned to one of two treatment arms: contingency management which incentivizes participants for their treatment attendance or treatment-as-usual with no contingency management.||||
33930267|NCT01269177|||COHORT||PROSPECTIVE|||||||
33930268|NCT02959970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930269|NCT05999812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930270|NCT03338036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will include two intervention arms and two control arms. The intervention arms will include 1) heart rate variability biofeedback, 2) a combination of heart rate variability biofeedback and neurofeedback. The control arms will be 1) age-matched post-concussive individuals and 2) age-matched individuals who have not been diagnosed with a concussion in the last two years.||||
33930271|NCT00881699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34093632|NCT05134844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A first group of 26 children formed the core group with the Halliwick philosophy - hydrotherapy in water in a multi-sensory Snoezelen environment. A second group of 27 children was the Snoezelen on-site control-intervention group with two sessions per week,|"The design of the present study included two groups of children with autism. A first group of 26 children formed the core group with the Halliwick philosophy - hydrotherapy in water in a multi-sensory Snoezelen environment. A second group of 27 children was the Snoezelen on-site control-intervention group with two sessions per week, which was the measure of comparison and support of reasonable hypotheses, in order to evaluate the hypothesis that Halliwick hydrotherapy in a multi-sensory environment in combination with intervention on land leads to better therapeutic results.~The application of the tests was done by the 2 examiners, who were pediatric physiotherapists - hydrotherapists with many years of experience (more than 10 years) in approaching motor problems of children with stroke. The tests were videotaped and then graded by the two examiners separately, which was considered important in order to ensure the objective grading of the assessment tests."|t|f|f|f
34093633|NCT06025461|||COHORT||RETROSPECTIVE|||||||
34093634|NCT01166334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093635|NCT03149419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093636|NCT00207428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34093637|NCT04894188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705523|NCT03703622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Cluster randomization was done by an independent statistician from the University of Bergen who is not part of the study. The health workers from randomised facilities were randomly assigned to two groups of 24 participants, each to be trained for two days. The participants and the assessors did not know the intervention groups which they belonged to until the day of training. During follow-up the assessors and the PI will not know which intervention arms the participants are in.|The AAP HBB curriculum will be used to train participants. Lectures will be delivered by the PI (Master Trainers), followed by demonstration of HBB skills using NeoNatali Mannequin. The participants will then be divided into two groups. One group for practical sessions with master trainers and the other group video-debriefing. The video-debriefing group will have their practical sessions filmed and then the film used for debriefing feedback. First the experiences of the team performing resuscitation will be obtained then positive feedback and learning points from other learners will be given in a respectful safe environment. All participants will be encouraged to contribute in the discussion. Pre- and Post-Test knowledge and skills will be assessed will be done using MCQs, and bag mask ventilation, OSCE A and B checklists from 2nd edition AAP HBB training manual.|t|t|t|t
33930272|NCT04682249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705524|NCT00465036|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33705525|NCT02346552|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705526|NCT01300650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705527|NCT03021941||PARALLEL||OTHER||NONE||||||
33705528|NCT06040931|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective correlational study||||
33705529|NCT02211079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705530|NCT03919331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Tidal volume (TV) during high flow nasal canula (HFNC) will be measured using chest Electrical Impedance Tomography (EIT). To calibrate EIT data, i.e. to be able to convert changes in thoracic impedance into TV, thoracic impedance signal, flow and volume will be collected during a 4 cmH2O continuous positive airway pressure (CPAP) test, using a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece. Such a level of CPAP is supposed to reproduce the majority of the physiological effects of HFNC. The quantification of respiratory distress index will be recorded by respiratory inductance plethysmography (RIP), obtained using two elastic bands equipped with a sensor sensitive to their stretching, one positioned at the level of the thorax, the other at the level of the abdomen. The stretching changes of the two bands during the respiratory cycle allow evaluating their possible asynchronism by calculating the phase angle.||||
33705531|NCT04929574|||COHORT||RETROSPECTIVE|||||||
33705532|NCT03680690|||COHORT||PROSPECTIVE|||||||
33930273|NCT02253628|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33930274|NCT03020212|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33930275|NCT02189304|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33930276|NCT03948113|||COHORT||RETROSPECTIVE|||||||
33930277|NCT01304472|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33930278|NCT06260072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930279|NCT01689324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705533|NCT05297331|||COHORT||PROSPECTIVE|||||||
33705534|NCT00183677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705535|NCT01850628|||COHORT||PROSPECTIVE|||||||
33705536|NCT05600452|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel groups design||||
33705537|NCT03158025|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33705538|NCT04188847|NA|SINGLE_GROUP||TREATMENT||NONE||A combination of cisplatin, paclitaxel and apatinib would be given for all patients||||
33705539|NCT01011777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705540|NCT00808860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705541|NCT03477097|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33705542|NCT01507012|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33705543|NCT04252781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705544|NCT04862819|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33705545|NCT02261896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33705546|NCT05207046|||COHORT||PROSPECTIVE|||||||
33705547|NCT05618197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930280|NCT00340171|||COHORT||OTHER|||||||
33930281|NCT02855645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930282|NCT04445051|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33930283|NCT02879071|||OTHER||PROSPECTIVE|||||||
33930284|NCT01352845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930285|NCT02025530|||CASE_CONTROL||PROSPECTIVE|||||||
33930286|NCT02315105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930287|NCT05264636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|intervention products are coded||t|t|t|t
33789912|NCT05426538|||COHORT||CROSS_SECTIONAL|||||||
34093638|NCT01509807|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34093639|NCT06063343|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"This is a double-blind study and the allocation of treatments (KAND145 or placebo) will not be disclosed to the participants or to the personnel at the investigational site (except for an unblinded pharmacist), until the database has been locked.~The KAND145 and placebo products will be delivered from the manufacturer to the investigational site in an unblinded fashion. At the site, the KAND145 and placebo products will be prepared for use by an unblinded pharmacist. The dosing syringes that will be handled by other site personnel will be blinded.~The KAND145 oral solution is slightly yellowish and may have a bitter taste, while the matching placebo oral solution is colorless and tasteless. Therefore all dosing syringes will be amber-colored or masked to hide the appearance of the product, and participants will be asked to use a nose clamp during administration of KAND145/placebo.~Treatment with midazolam (applicable for Cohort 2:1 and Cohort 2:2) will not be blinded."|"Part 1 - SAD: Up to 48 participants will be sequentially enrolled into up to 6 cohorts (8 participants per cohort). The first 2 participants in all cohorts will be randomized to KAND145 or placebo in a 1:1 ratio. The 6 remaining participants will be randomized to KAND145/placebo in a 5:1 ratio. FE-part: After a wash-out period of 6-14 days after dosing with KAND145/placebo, Cohort 1:3 will receive a second dose of KAND145/placebo (as per initial randomization) together with a meal.~Part 2 - MAD: Up to 40 participants will be sequentially enrolled into up to 5 cohorts (8 participants per cohort). Participants in each cohort will be randomly assigned to KAND145 or placebo in a 3:1 ratio. Midazolam-part: Two cohorts will receive a single dose of 4 mg midazolam. After a wash-out period of 6-14 days, the participants will start dosing of KAND145/placebo."|t|t|t|t
34008977|NCT03207958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093640|NCT02019251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789913|NCT05384392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789914|NCT01228851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930288|NCT04097080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930289|NCT04446767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930290|NCT01712490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930291|NCT01024660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33930292|NCT00653068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930293|NCT03491904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930294|NCT02892175|||COHORT||PROSPECTIVE|||||||
33930295|NCT00014586|RANDOMIZED|||TREATMENT||||||||
33930296|NCT00481221|||OTHER||RETROSPECTIVE|||||||
33930297|NCT00002097||||TREATMENT||||||||
33930298|NCT03683043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930299|NCT03015623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930300|NCT06291545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008978|NCT00399737|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33930301|NCT03778580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34008979|NCT03648879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34008980|NCT06358274|||COHORT||PROSPECTIVE|||||||
33930302|NCT02866461|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33930303|NCT00779363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930304|NCT01502761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930305|NCT00077922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930306|NCT05423704|NA|SINGLE_GROUP||TREATMENT||NONE||Single group feasibility study||||
34008981|NCT04417751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34008982|NCT02354911|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33930307|NCT01207674|NON_RANDOMIZED|||OTHER||||||||
33930308|NCT01346020|||COHORT||RETROSPECTIVE|||||||
33930309|NCT04012333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study staff performing the functional outcome measurements will be blinded to study treatment group|Intervention: enteral and parenteral nutrition to reach protein target of 2.2g/kg/day Control: only enteral nutrition to stay below protein target of 1.2g/kg/day|f|f|f|t
34008983|NCT01748955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008984|NCT04212377|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single arm exploratory, single-centre study||||
34008985|NCT02166853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008986|NCT04778618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705548|NCT05988008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33705549|NCT02631759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705550|NCT02994992|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705551|NCT00129272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705552|NCT02367443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789915|NCT05381571|NA|SINGLE_GROUP||TREATMENT||NONE||All recruited participants will use the reminiscence based physical therapy technology, three times weekly for a total of 12 weeks (average admission duration). The expected study enrolment period is 6 months to allow for multiple sets of participants to be recruited from the same medical unit.||||
33789916|NCT03109886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789917|NCT01277445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33789918|NCT00531518|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33789919|NCT05465811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789920|NCT00241735|||COHORT||PROSPECTIVE|||||||
34093641|NCT01370538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705553|NCT02579187|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33705554|NCT03454711|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705555|NCT04473391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705556|NCT00934089|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33705557|NCT03918785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33705558|NCT01594983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093642|NCT02785042|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093643|NCT05880043|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose escalation phase: up to 30 subjects / Dose expansion phase: up to 20 subjects||||
33705559|NCT03308032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705560|NCT03789474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Draping of the legs was done in both the groups.the care observer nor investigator were blinded for the allocation.|About 60 patients of age group 25 to 50 belonging to American Society of Anesthesiologists (ASA) grade 1 and 2 were allocated to either control or sequential pneumatic compression device group .Allocation was done by sealed envelop technique.In the operating room,in the control group,the device was placed on operating table and was placed next to the patients calves.in the intervention group,the device was placed over calves and inflated during induction of General Anaesthesia (GA) and maintenance.legs were draped in both the groups.Femoral vein velocities were assessed using ultrasound in preoperative period , intraoperatively 15 minutes after induction of anaesthesia and in post-operative period.|t|t|t|f
33705561|NCT01408927|||COHORT||PROSPECTIVE|||||||
33705562|NCT05306275|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705563|NCT06273085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33705564|NCT02324257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789921|NCT04588480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33789922|NCT01409512|||CASE_ONLY||PROSPECTIVE|||||||
33789923|NCT00324038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789924|NCT05918159|||OTHER||CROSS_SECTIONAL|||||||
33789925|NCT01651949|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33789926|NCT05857358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789927|NCT04747106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789928|NCT05966389|||COHORT||PROSPECTIVE|||||||
33789929|NCT00730002|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093644|NCT05644509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093645|NCT01111669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789930|NCT05496517|||COHORT||RETROSPECTIVE|||||||
33930310|NCT05768893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary assessor was given two photographs of each lesion, the first is the unmarked photograph copy (doesn't indicate to what group each lesion belongs) that was taken prior to the procedure, the second is the photograph that was taken in the follow up 5 weeks later. Assessments based on the two photographs were conducted by the primary assessor.|"This randomized controlled trial included 240 lesions from 24 patients diagnosed with recalcitrant warts. Each wart of the 240 was given a number and photographed. In cases when the patient had an uneven number of warts, one wart was excluded randomly. Then, the warts of each patient were randomly divided into two groups using computerized randomization and assigned to group 1 or group 2. Each group consisted of 120 warts.~Group 1: Combined Er:YAG laser and long-pulsed Nd:YAG laser group. Group 2: Er:YAG laser group."|f|f|f|t
33930311|NCT06022224|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"The first 200 subjects randomized will comprise the phase 2 portion of the study.~Enrollment may continue during this period and these subjects would be included in the phase 3 portion of the study."|t|t|t|f
33930312|NCT05117268|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking strategy is selected because intervention to be performed in all 3 groups is different. Operator cannot be blinded. Consent is necessary for SDF application. For the reasons listed, patient cannot be blinded for the procedure to be done.|"A facial image scale shall be shown to participants before treatment and immediately after treatment to determine child anxiety with each treatment where the child will be asked to identify the face that best expressed their feeling at that point of time.~Possible adverse events of each treatment shall be recorded by registering any complaint of sensitivity, gingival irritation, tattoo formation, burning, unpleasant taste, silver allergy and nausea. To assess parental aesthetic perception, a questionnaire will be presented that specifically asks if they were annoyed by the appearance of their child, or the child avoided smiling."||||
33930313|NCT06337994|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel assignment||||
33930314|NCT03147573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930315|NCT06294093|||COHORT||CROSS_SECTIONAL|||||||
33930316|NCT03401476|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930317|NCT03441555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930318|NCT02347462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930319|NCT00741806|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930320|NCT02480998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930321|NCT03258944|NA|SINGLE_GROUP||OTHER||NONE||||||
33705565|NCT04754152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33930322|NCT04555408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930323|NCT03799627|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open-Label, Active-Controlled||||
33930324|NCT02509611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33930325|NCT04645576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"During the period of this clinical trial (18 months), only two products will be used for the aesthetic procedures (Art Filler Volume and Juvéderm Voluma).~This prospective study will analyze 120 patients maximum who will receive dermal filler injections to the midface, temple, chin and jaw-line (cross-injection is authorized with maximum 2 zones per subject). The injections will be administered in a randomly assigned split-face design, except for the chin. One side of the subject's face will receive Art Filler Volume according to the randomization table, whereas the other side will receive Juvéderm Voluma injections in a blinded manner for the subjects (single blinded). The chin will only receive one injection of Art Filler Volume."|t|f|f|f
33930326|NCT06000241|||CASE_ONLY||CROSS_SECTIONAL|||||||
33930327|NCT00766064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930328|NCT02353689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33930329|NCT03352128|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33930330|NCT00735527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930331|NCT04236219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930332|NCT04841213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeons will be blinded to the endocrinologic status of patients who underwent or will undergo the dental implantation|Interventional retrospective prospective randomized clinical trial (RCT) in parallel groups.|f|t|f|t
33930333|NCT01039428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930334|NCT03534791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants will be blinded to allocation. The author who will communicate with the participants will not be blinded. Other authors and outcome assessors who will analyze data will be blinded to allocation of study participants; anonymized data will be analyzed.|"All study participants who accept participation in the study will be initially assigned 3 PLSs, and subsequently they will be assigned more PLSs when they translated the previous ones. Intervention group will receive one customized e-mail reminder two weeks after the PLS assignment if they do not translate it within two weeks.~Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned."|t|f|f|t
33930335|NCT00074542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34093646|NCT02508974|||COHORT||PROSPECTIVE|||||||
34093647|NCT05212142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34093648|NCT03022214|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34093649|NCT06278168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093650|NCT03479151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093651|NCT05714436|||COHORT||PROSPECTIVE|||||||
33705566|NCT00622817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33705567|NCT04253444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and outcomes assessors will be masked.|A randomised, sham-controlled, single-blinded, parallel study|t|f|f|f
33705568|NCT03912168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33789931|NCT00362206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705569|NCT06192277|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Participants are initially screened to confirm they are at a low risk of reacting to a direct oral penicillin challenge. Low-risk participants are provided oral penicillin and observed for a reaction. If no reaction occurs, (immediate or delayed up to 28 days) patients have their penicillin allergy removed from their electronic medical record with their primary care provider and the local hospital.||||
33930336|NCT05651984|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Intra-individual comparison of 2 treatments divided into 2 time periods, so as to constitute 4 experimental conditions. The order of the treatments allocation, organised according to 2 sequences (A-B and B-A), induces a randomisation of the included patients into 2 groups. The wash-out period between the 2 periods is not applicable in this study."||||
33930337|NCT04061941|||COHORT||PROSPECTIVE|||||||
33930338|NCT05298228|NA|SINGLE_GROUP||OTHER||NONE||||||
33930339|NCT02212080|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33705570|NCT02385942|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33930340|NCT01882192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33789932|NCT05895760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized controlled trial, including 110 older adults (68.45±5.54 years), were divided into two parallel groups: an MPE group (n = 55) and a control group (n = 55).|t|f|f|f
33789933|NCT02206386|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33705571|NCT00691314|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930341|NCT05333640|||CASE_CONTROL||PROSPECTIVE|||||||
33930342|NCT03362203|||OTHER||CROSS_SECTIONAL|||||||
33930343|NCT04965285|||CASE_CONTROL||PROSPECTIVE|||||||
33930344|NCT02478918|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33930345|NCT00736593|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33930346|NCT03189849|||COHORT||PROSPECTIVE|||||||
33930347|NCT04536493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Topical anesthetic applied by RN not involved in procedure.|Randomized controlled trial comparing two different applications of LET gel in pediatric patients with minor lacerations.|f|t|t|t
33930348|NCT02708472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930349|NCT00717015|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33930350|NCT00218361|||CASE_ONLY||PROSPECTIVE|||||||
33930351|NCT00106249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930352|NCT05668325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The block randomization method was applied. The coin flip method was used to determine the exercise and control groups, and the exercise group was determined as A and the control group B. In our study, in which octal blocking was performed with four A and four B blocks in each block, the possible number of blocks was calculated as 70. Five numbers between 1 and 70 were generated (for 40 people, it is enough to choose five random blocks) using the in randomear command in Excel, and the numbers 27, 11, 13, 18, 51 were obtained. Patients were randomized according to the blocks corresponding to these numbers. In addition, in the post-hoc power analysis performed at the end of the study, the power of the study was determined to be 85%, and this result showed that the sample size of the study was sufficient."|The number of samples was determined by using the G\*Power 3.1.9.6 program with a 95% confidence interval of 0.05 error rate, a study in which the effects of the mini trampoline exercise program performed with diabetic polyneuropathy patients on foot mobility and foot sensation in the literature were evaluated, with a power of 80% and an effect size of 0.90. calculated. As a result of the statistical analysis, it was found that a total of 28 patients, 14 in the mini trampoline exercise group and 14 in the control group, should be included in the study. Considering that if the sample size increases, the standard error will decrease and the working power will increase, each group was increased by 43% and a total of 40 patients were included in the study, 20 patients for each group.|t|f|f|f
33930353|NCT00918346|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33930354|NCT02852590|||COHORT||PROSPECTIVE|||||||
33789934|NCT01958541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930355|NCT00116324|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33930356|NCT03900663|||CASE_ONLY||CROSS_SECTIONAL|||||||
33705572|NCT03039140|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705573|NCT03245684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705574|NCT06376292|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks.||||
33705575|NCT00978198|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33789935|NCT05912751|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33930357|NCT02958085|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33705576|NCT02208479|||COHORT||PROSPECTIVE|||||||
33705577|NCT03348150|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33705578|NCT05540756|||CASE_ONLY||PROSPECTIVE|||||||
33705579|NCT02331342|||COHORT||PROSPECTIVE|||||||
33705580|NCT00191139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705581|NCT02050997|||COHORT||PROSPECTIVE|||||||
33705582|NCT04944251|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized prospective study||||
33705583|NCT01525563|||||PROSPECTIVE|||||||
33789936|NCT04277689|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705584|NCT00873015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705585|NCT00192569|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705586|NCT06429436|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|There will be no masking.|We will be using an interrupted time series design to evaluate naloxone distribution before and after vending machine implementation in each community.||||
33705587|NCT03855969|||COHORT||RETROSPECTIVE|||||||
33705588|NCT03747458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705589|NCT02609009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33705590|NCT05825339|||COHORT||PROSPECTIVE|||||||
33705591|NCT03980041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705592|NCT00536185|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33705593|NCT05496400|||CASE_CONTROL||PROSPECTIVE|||||||
33705594|NCT03389620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705595|NCT03247751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705596|NCT04090866|||OTHER||PROSPECTIVE|||||||
33789937|NCT00504114|||CASE_CONTROL||PROSPECTIVE|||||||
33789938|NCT00606580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33789939|NCT02165137|||COHORT||OTHER|||||||
33789940|NCT01158196|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33789941|NCT03489317|||COHORT||PROSPECTIVE|||||||
33789942|NCT00023725|RANDOMIZED|||TREATMENT||||||||
33930358|NCT02463318|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705597|NCT02849431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930359|NCT01855945|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930360|NCT00159614|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33930361|NCT01506219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The geriatrician was blinded to the primary endpoint data that were drawn from the National Patient Registry via Researcher Service. The dataset was generated by the Registry's staff blinded to the patient allocation.~It was impossible to blind the participants and their relatives or the geriatrician and the rehabilitation units' staff to the allocation group.~The research nurse was not blinded to patient allocation for practical reasons. The research occupational therapist was blinded to treatment allocation."|A pragmatic open assessor-blinded clinical randomized controlled trial with two parallel groups.|f|f|f|t
33930362|NCT05164263|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.||||
33930363|NCT03914521|||COHORT||RETROSPECTIVE|||||||
33930364|NCT02732184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930365|NCT06231030|||CASE_ONLY||PROSPECTIVE|||||||
33930366|NCT05083949|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The bioanalytical staff involved are blinded to treatment|||||
33930367|NCT02428933|NA|SINGLE_GROUP||||NONE||||||
33930368|NCT03702855|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930369|NCT00971230|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930370|NCT03582436|||COHORT||PROSPECTIVE|||||||
33930371|NCT04695418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705598|NCT05626855|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Extension Study||||
33930372|NCT04123171|||COHORT||PROSPECTIVE|||||||
33930373|NCT02985489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930374|NCT03981185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930375|NCT01111786|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33930376|NCT04618406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705599|NCT03842514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Diet trial with randomised sequence of delivery of two diets.|t|f|f|f
34008987|NCT04528576|NA|SINGLE_GROUP||TREATMENT||NONE||The clinical trial was designed as a single group assignment study. The participants with moderate to severe and severe mitral valve regurgitation will receive a transseptal mitral valve repair using Dragonfly mitral valve repair system.||||
34008988|NCT01303068|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33705600|NCT04396340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, dose escalation to reach MTD. The MTD will be confirmed in 2 parallel cohorts: (1) patients with platinum-resistant ovarian cancer; (2) patients with non-squamous NSCLC, adenocarcinoma subtype.||||
34008989|NCT02488668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34008990|NCT02406794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33705601|NCT01466647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930377|NCT05141357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930378|NCT06068647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930379|NCT05021172|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33930380|NCT03512119|||COHORT||OTHER|||||||
33930381|NCT00010803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33789943|NCT06250270|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinded pre-made packets of protein or placebo with sample coding in a sealed envelope until the end of the study||t|f|t|f
33789944|NCT06553248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789945|NCT00697229|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33930382|NCT00424034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930383|NCT05778929|||COHORT||PROSPECTIVE|||||||
33930384|NCT02757404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34008991|NCT03164837|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789946|NCT06327919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34008992|NCT01694082|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33789947|NCT04188028|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34008993|NCT06616974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789948|NCT01137292|||COHORT||PROSPECTIVE|||||||
33930385|NCT04263493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33930386|NCT03571113|||COHORT||PROSPECTIVE|||||||
34008994|NCT05085795|||COHORT||PROSPECTIVE|||||||
34008995|NCT05684224|||COHORT||CROSS_SECTIONAL|||||||
34008996|NCT02601768|||COHORT||RETROSPECTIVE|||||||
34008997|NCT01481857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34008998|NCT00161681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34008999|NCT03761576|||CASE_ONLY||PROSPECTIVE|||||||
34009000|NCT05735886|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009001|NCT06327217|||COHORT||PROSPECTIVE|||||||
34093652|NCT01669850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093653|NCT00991432|||COHORT||PROSPECTIVE|||||||
34093654|NCT03474835|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34093655|NCT01415570|||COHORT||PROSPECTIVE|||||||
33930387|NCT04994522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930388|NCT03880617|||CASE_ONLY||PROSPECTIVE|||||||
33930389|NCT06269588|NA|SINGLE_GROUP||TREATMENT||NONE||prospective single arm intervention cohort||||
33705602|NCT02761252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The principal investigator and study staff, subjects and monitors remained blinded to the treatment until study closure in this double-blind, double-dummy study. The identity of the study drug was revealed only if the subject experienced a medical emergency the management of which would be improved by the knowledge of the blinded treatment assignment.~As the combination therapy of Bilastine + Montelukast consisted of two tablets in contrast to monotherapy with either Bilastine or Montelukast, the double-dummy technique was applied with matching placebo for each Investigation Medicinal Product (IMP) (monotherapy with Bilastine or Montelukast) to ensure the maintenance of double-blind conditions. Therefore, each patient took 2 tablets with each dose administered.~As by randomisation list, each Patient Kit consisted of two IMP treatments (either active + placebo or active + active) in separate blisters packed in two different boxes."|The study was a randomised (1:1:1), double-blind, double-dummy, interventional, active-controlled, parallel groups (three groups), multi-centre, multi-national, superiority clinical trial. The study plan included a 7-day (± 4) run-in period to ensure wash-out from previous forbidden treatments and to perform the tests required to ensure appropriate patient enrolment into the study. The active treatment period was 12 weeks (85 days) with a follow-up visit (phone call) at 28 days (± 4) after the End of Treatment.|t|t|t|t
34009002|NCT05335382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will only be informed that the study is assessing the quality of primary care, and will not know that PCBH has been or will be implemented. Since primary and most secondary outcomes are patient-rated, outcomes assessors are also deemed to be blind.|Primary care centers are cluster randomized between implementing PCBH directly or implementing later. Patients seeking care at each PCC are not individually randomized, but are given the form of care that is currently offered at their PCC (pre- or post-implementation).|t|f|f|t
34009003|NCT01109758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705603|NCT01388738|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33705604|NCT05146167|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors will be masked to arm through completion of outcome assessments.|Participants will be individually randomized at a 1:1 ratio to 1 of 2 smartphone app conditions: (1) Bodhi AIM (Action In Mindfulness), a 30-day mindfulness-based intervention, or (2) HIB (Health In Balance), a health promotion control app matched to Bodhi AIM for time and structure.|f|f|f|t
33705605|NCT02167399|||COHORT||CROSS_SECTIONAL|||||||
33705606|NCT03525171|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||We prospectively studied 23 prepubertal children with GH deficiency treated with GH for at least 12 months and 12 healthy subjects with short stature, matched for age and pubertal status||||
33705607|NCT04661904|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33705608|NCT06082492|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a multicenter randomized controlled clinical trial with a superiority design. At approximately 4 months after the end of curative intent treatment patients will be randomized 1:1 to either the intervention (18F FDG PET/CT) or the control group (usual care, CT-based follow-up). Randomization will be done stratifying for histology and treatment.~After the start of the study all patients will have regular follow-up visits at 6, 12, 18, 24 months and 36 months after the end of curative intent treatment, as is stated in the Dutch guidelines. In the intervention group these visits will be complemented by a 18F FDG PET/CT scan, while in the control group the visits will only contain a CT scan.~For patients in the intervention group who give consent for participation in the collection of blood, blood will be drawn around the scan.~At all time points patients will be asked to fill in the HRQOL and cost-effectiveness questionnaires."||||
33705609|NCT02230800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705610|NCT05234255|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33705611|NCT06037070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Split-mouth trials|f|f|f|t
33789949|NCT03114020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|treatment has blinded labeling||t|f|t|f
33789950|NCT01103219|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33789951|NCT03361059|||COHORT||PROSPECTIVE|||||||
33789952|NCT01875484|||COHORT||PROSPECTIVE|||||||
33789953|NCT00548119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789954|NCT04826536|||COHORT||RETROSPECTIVE|||||||
33789955|NCT01285258|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34009004|NCT03926325|||COHORT||PROSPECTIVE|||||||
34009005|NCT03499366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009006|NCT01906424|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34009007|NCT05402787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind (researchers are not blinded) randomization will be provided as the virtual visitation to mothers will be implemented by researchers. The statistician was also blinded for the data analysis purpose|Randomized Controlled Trial|f|f|f|t
33789956|NCT03645850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Parallel Assignment Because the comparator will be in commercial packaging, the blinding of the subject is not possible.~However, the study will be blinded for the investigator: evaluations will be done by an independent investigator, different than the person who will distribute the product. Subjects will be identified by a patient number. Each patient number will be associated to a treatment number, according to a randomization list provided before the beginning of the clinical investigation, and randomized either in one of both treatment groups (Vismed Gel Multi 3% or Vismed Multi 0.18%)."|f|f|t|f
33789957|NCT00391547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33930390|NCT05460689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930391|NCT00351806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33930392|NCT05757024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930393|NCT03793634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The supervisor(AA) will be blind. The principle investigator(EN) will supply the patient with the treatment.~The supervisor (AA) will assess the clinical parameters before treatment , between visits and at the end of the treatment.~Statistician will be blind. Double - blind study."||f|f|f|t
33930394|NCT02518542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930395|NCT00931294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009008|NCT05890092|||OTHER||PROSPECTIVE|||||||
34093656|NCT04607382|||COHORT||PROSPECTIVE|||||||
34093657|NCT06476249|||COHORT||PROSPECTIVE|||||||
33789958|NCT00344019|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized trial of 80 mg atorvastatin vs. placebo pre PCI|t|t|t|t
33789959|NCT04482205|||OTHER||RETROSPECTIVE|||||||
33789960|NCT06413940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789961|NCT03353467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705612|NCT03894800|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Labeling of the IMPs will be done by one a nurse anesthetist not participating in the study. The study drugs, will be distributed in a pre-packed in identical, opaque envelopes (the same day as the drugs will be used). The envelopes are not to be broken until randomization of the patient is done|This is a randomized, double blind, placebo-controlled crossover study.|t|f|t|f
33705613|NCT03206775|||COHORT||PROSPECTIVE|||||||
33705614|NCT01980134|||COHORT||CROSS_SECTIONAL|||||||
34009009|NCT06613087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705615|NCT04375371|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33705616|NCT05958667|RANDOMIZED|PARALLEL||PREVENTION||NONE||A two-group parallel randomized controlled trial with 1,200 Spanish- and English-speaking young Latino adult smokers in South Texas (ages 18-29) to assess the effects of Quitxt on smoking cessation.||||
33705617|NCT00169026|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33705618|NCT01517074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705619|NCT03651869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33789962|NCT00100100||||DIAGNOSTIC||||||||
33789963|NCT04546997|||COHORT||PROSPECTIVE|||||||
33789964|NCT00525850|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33789965|NCT04940676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33789966|NCT04461418|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, two cohort, permuted block randomization phase II study.||||
33789967|NCT05850130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"A multicenter, 2-cohort phase II study:~Cohort 1: randomization into Arm A = Experimental or Arm B = Control~Cohort 2: a single arm."||||
33789968|NCT00917358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33789969|NCT01137903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34009010|NCT02063087|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33705620|NCT02226146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789970|NCT04167917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789971|NCT05827354|||COHORT||PROSPECTIVE|||||||
33789972|NCT06081829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789973|NCT04683159|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The surgeon (care provider/investigator) will be masked to the intervention at the time of operation and during follow-ups (day 0, week 1, month 1). Outcomes assessor will be blinded to the investigation when quantifying degree of hemorrhage|Participants will be randomly assigned to one of three groups (control, brimonidine 0.15%, or brimonindine 0.025%), running in parallel.|f|t|t|t
33789974|NCT03273608|||CASE_ONLY||PROSPECTIVE|||||||
33789975|NCT00862680|||COHORT||OTHER|||||||
33789976|NCT04408274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930396|NCT00774956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930397|NCT02687711|||COHORT||PROSPECTIVE|||||||
33930398|NCT06156449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In the study, patients will be stratified according to their gender (male and female) status and the blocking process will be performed. In this study, block randomization will be done according to age groups in order to assign the participants to the experimental and control groups. Patients will be listed according to the hospitalization list and numbered up to 140. Numbers will be assigned to the experimental and control groups according to the random numbers list. Thus, the probability of each patient in the groups being in either of the intervention or control groups will be equalized.~Group 1: experimental 2. Group: Control"|t|f|f|f
33930399|NCT03904576|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34009011|NCT06334185|||COHORT||RETROSPECTIVE|||||||
34009012|NCT00271739|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34009013|NCT03631368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009014|NCT05630625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants will be randomly assigned to receive the Drinking Dashboard or assessment only.|t|f|f|t
34009015|NCT05086198|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Blinding of trial participants and care providers is not possible because of obvious differences between the interventions. However, participants will be blinded in terms of which intervention is considered the experimental one.|A randomized controlled trial of three groups is proposed, with pretest, posttest and four follow-ups at 1, 2, 3 and 6 months.|f|f|t|t
34009016|NCT01104428|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34009017|NCT00278174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093658|NCT05810662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34009018|NCT06177847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesia protocol used in closed BIS is carried out like general anesthesia without using BIS.|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided|t|t|f|f
34009019|NCT01359748|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34009020|NCT03135899|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34009021|NCT04858659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009022|NCT05058560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009023|NCT05876117|||CASE_CROSSOVER||PROSPECTIVE|||||||
34009024|NCT06617507|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34009025|NCT05081245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Multi-center, randomized, double-blind, placebo-controlled study|t|t|t|t
34009026|NCT00992212|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009027|NCT04485416|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009028|NCT05551702|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either the treatment group or the waitlist control group. The treatment group will receive 8 weeks of the text based intervention (CBT-txt) and complete surveys at baseline, 1 month, 2 months and 3 months. The waitlist control group will only do surveys at baseline, 1 month, 2 months, and 3 months and will then have the option of receiving the intervention after their 3 months of study participation.||||
33705621|NCT02240732|||COHORT||PROSPECTIVE|||||||
34009029|NCT04143282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009030|NCT04138706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Double-blinded placebo-controlled randomized controlled trial:~A double blind and placebo will be used because the knowledge of being on active drug might influence patient reporting on gastrointestinal symptoms or physician interpretation of such symptoms leading to asymmetrical workup of CDI recurrence and hence bias in the results.~To avoid other sources of bias post-randomization, patients, research personnel, investigators, endpoint adjudicators, and study analysis will all remain blinded to the intervention status until completion of the analysis and reporting of results. Analysis will be performed by intention to treat."||t|t|t|t
34009031|NCT00638144|||COHORT||PROSPECTIVE|||||||
34009032|NCT02358733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34009033|NCT06071195|||COHORT||PROSPECTIVE|||||||
34009034|NCT00265044|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34009035|NCT05279638|||CASE_CONTROL||PROSPECTIVE|||||||
34009036|NCT00671073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009037|NCT02574715|||COHORT||CROSS_SECTIONAL|||||||
34009038|NCT05895487|||COHORT||RETROSPECTIVE|||||||
34009039|NCT00443482|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34009040|NCT02549846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009041|NCT03239977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Longitudinal Randomized Clinical Trial|t|f|f|t
34009042|NCT01317784|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
34009043|NCT04351230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009044|NCT00846794|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33705622|NCT02050841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705623|NCT02334358|||OTHER||PROSPECTIVE|||||||
33705624|NCT02545556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705625|NCT03398785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol. Patients in the Control group will be treated with conventional anti-hypertensive drugs||||
33705626|NCT02260544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705627|NCT01489397|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705628|NCT00818597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093659|NCT06305065|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects will be randomly assigned to the KUNWU navigational or CORI Surgical System or conventional manual instrumentation groups according to a balanced randomization procedure using a 1:1:1 allocation ratio. To ensure balanced group assignment, a block randomization schedule will be generated. All subjects who sign the ICF and meet all inclusion and exclusion criteria will be randomized in a 1:1:1 randomization allocation ratio. The block size should be sufficiently small to allow approximately equal allocation of subjects in each group should the study be terminated prematurely whilst also being large enough so as the next treatment cannot be guessed. The study is non-blinded.|||||
34093660|NCT00246207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093661|NCT05461898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||f|f|f|t
34093662|NCT01938937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093663|NCT05413460|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All participants are placed with electrodes at acupoints. The stimulator is put in an opaque box.||t|t|t|t
34093664|NCT04358562|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34093665|NCT01174459|||COHORT||PROSPECTIVE|||||||
34093666|NCT03033901|||COHORT||PROSPECTIVE|||||||
34093667|NCT05527522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093668|NCT02122952|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093669|NCT02866383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093670|NCT06114199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093671|NCT03899090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and participant are masked to study arm until after the participant completes their baseline session, at which point they are randomized using a sealed envelope.|"Participants are randomized to one of three arms:~1. floating supine in a pool for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)~2. floating supine in a zero-gravity chair for a prescribed amount of time (6 total sessions, 1 hour/session, 1 session/week)~3. floating supine in a pool for a preferred amount of time (6 total sessions, up to 2 hours/session, as frequently as they prefer within a 12-week period with a minimum of 24 hours between sessions)"|t|f|t|f
34093672|NCT05832983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34093673|NCT04783948|||CASE_ONLY||PROSPECTIVE|||||||
34093674|NCT02487199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093675|NCT04721262|||CASE_ONLY||PROSPECTIVE|||||||
34093676|NCT01948778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093677|NCT02153853|||COHORT||RETROSPECTIVE|||||||
34093678|NCT00432120|RANDOMIZED|PARALLEL||||NONE||||||
34093679|NCT04588272|||COHORT||PROSPECTIVE|||||||
34093680|NCT02948387|||||RETROSPECTIVE|||||||
34093681|NCT03489525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open-label|||||
34093682|NCT04828525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants will be randomized divided into two groups. each group will be given dexamethasone or 0.9% normal saline. only the pharmacist will not be masked to the procedure.|The research is a multi-centered, prospective, placebo-control, randomized controlled trial.|t|t|t|f
34093683|NCT03615534|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34093684|NCT04078308|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34093685|NCT05842707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093686|NCT01806792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705629|NCT01317485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705630|NCT02151110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093687|NCT04607551|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34093688|NCT05697692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093689|NCT03535688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple||t|f|t|t
34093690|NCT03594344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705631|NCT03745131|||COHORT||PROSPECTIVE|||||||
33705632|NCT02015572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705633|NCT01546805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33789977|NCT05836935|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33789978|NCT04601467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33789979|NCT01833832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789980|NCT01376141|||OTHER||PROSPECTIVE|||||||
33789981|NCT00426036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789982|NCT01598948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093691|NCT02850562|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093692|NCT00712049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705634|NCT04584151|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled prospective trial||||
33705635|NCT03963310|||COHORT||PROSPECTIVE|||||||
33705636|NCT02383498|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33705637|NCT03254875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Intervention status will be blinded in analyses.|During a 2-year period, 758 patients newly diagnosed with breast cancer will be screened for inclusion at the Section of Breast Surgery at Rigshospitalet, Copenhagen. Of these 324 participants enter the RCT and are randomized in a computer-generated sequence of 1:1 to the intervention (nurse-navigation) or control group (standard care). A total of 432 participants will enter an observational questionnaire study. All participants are followed for 1,5 years.|f|f|f|t
33705638|NCT01867788|||CASE_CONTROL||PROSPECTIVE|||||||
33705639|NCT00989560|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705640|NCT05647460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705641|NCT06210607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705642|NCT05178888|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33705643|NCT01374997|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705644|NCT04345042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Single- Blind Randomized Controlled Trial|f|f|f|t
33705645|NCT01423318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705646|NCT01943500|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33705647|NCT04218630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapist performing evaluation was blind to the study.|This study is a randomized controlled parallel group model. Participants were randomly divided into two groups as reformer pilates group and home mat pilates group.|f|f|f|t
33705648|NCT00005073|RANDOMIZED|||TREATMENT||||||||
33705649|NCT02771431|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705650|NCT04005911|||COHORT||PROSPECTIVE|||||||
33705651|NCT01976338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705652|NCT02743169|||COHORT||RETROSPECTIVE|||||||
34009045|NCT03710317|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|a double-blinded randomized placebo-controlled trial|"Study drug administration Group 1 100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby~Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min."|t|t|t|f
34009046|NCT02697539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34009047|NCT04624659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093693|NCT03237663|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34093694|NCT02928432|NA|SINGLE_GROUP||TREATMENT||NONE||One-arm prospective||||
34093695|NCT05643508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705653|NCT05518019|NA|SINGLE_GROUP||OTHER||NONE||||||
33705654|NCT01667029|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33705655|NCT05476471|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The intervention consisted of one 60-minutes group exercise session once a week in first 8 weeks, and self-management in next 8 weeks. The control arm received an education leaflet.|t|f|f|f
33705656|NCT00828997|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34009048|NCT02612181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930400|NCT02919917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Therapists administering rehabilitation will be blinded to the randomization of patients enrolled in the study.|Newly injured individuals with SCI will be eligible to participate if they demonstrate hypotension (systolic blood pressure \</= 110 mmHg in males or \</= 100 mmHg in females) upon admission to acute in-patient rehabilitation at Mount Sinai Medical Center, New York, NY. Eligible participants will be randomized to usual care (administered anti-hypotensive therapy only if they demonstrate symptoms of hypotension: dizziness, lightheadedness, nausea, blurred vision, syncope) or treatment of hypotension based on a systolic blood pressure below the hypotensive threshold. Time spent in active rehabilitation program will be compared between the usual care and treatment groups.|f|t|f|f
33930401|NCT03898388|NA|SINGLE_GROUP||TREATMENT||NONE||1||||
33930402|NCT06086457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930403|NCT01755325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930404|NCT06048380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33930405|NCT03168841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789983|NCT06368609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930406|NCT03346291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930407|NCT00303576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33930408|NCT03696004|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930409|NCT04904341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A single centre, prospective, open-label, single-arm study of consecutive 50 patients who will be treated with MT in the reference centre according to local standards and additional Cerebrolysin compared to 50 historical controls treated with MT alone - matched for age, clinical severity, occlusion location, baseline perfusion lesion volume, onset to reperfusion and use of iv rt-PA prior to MT||||
33930410|NCT01428778|||COHORT||PROSPECTIVE|||||||
33930411|NCT03554785|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930412|NCT04979962|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Patients will be randomized 1:1, inspection with computer assisted colonoscopy: inspection with conventional colonoscopy.||t|f|f|f
33930413|NCT02151799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930414|NCT02663180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930415|NCT03225560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients will be aware of the arm they were assigned to. Colonoscopist performing the colonoscopy will be masked to the intervention and will be providing the assessment of the quality of bowel preparation.~The investigators will be masked to the assignment."|Randomized Controlled Trial|f|t|t|t
33930416|NCT02498327|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33930417|NCT00995605|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33930418|NCT02152150|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33705657|NCT06467448|||COHORT||PROSPECTIVE|||||||
33705658|NCT04737746|||COHORT||PROSPECTIVE|||||||
33705659|NCT04942899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705660|NCT02416401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705661|NCT01091974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33705662|NCT02920385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705663|NCT01614080|||COHORT||PROSPECTIVE|||||||
33705664|NCT05719662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705665|NCT01921387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705666|NCT03859193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705667|NCT01376284|||||PROSPECTIVE|||||||
33705668|NCT06187584|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, two-arm, parallel-group, randomized study conducted at a single center||||
33789984|NCT01491698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33789985|NCT02983370|NA|SINGLE_GROUP||OTHER||NONE||||||
33789986|NCT00686517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789987|NCT04220359|||COHORT||PROSPECTIVE|||||||
33930419|NCT00481988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930420|NCT03224260|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33930421|NCT01885949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930422|NCT02259946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930423|NCT00366418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930424|NCT02556970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33930425|NCT03077243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930426|NCT04313504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33789988|NCT03533556|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||2.5 mg/kg body weight of L-theanine, 2.0 mg/kg body weight of caffeine and their combination each dissolved in 100 ml of water (solvent) or the solvent alone (i.e. placebo) will be administered on 4 separate days (at least 5 days apart) in a random counter-balanced order.|t|f|f|f
33789989|NCT04322643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930427|NCT04967911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33789990|NCT00641381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930428|NCT01802515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930429|NCT00550290|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33930430|NCT02273414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930431|NCT01678313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930432|NCT05287269|||COHORT||PROSPECTIVE|||||||
34009049|NCT06250751|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009050|NCT01877460|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34009051|NCT00935831|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34009052|NCT02107079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34009053|NCT03808740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009054|NCT03401073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009055|NCT03932331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009056|NCT02295813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009057|NCT02023840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34009058|NCT03900117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009059|NCT06607718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Ultrasound measurements, MNA and bioimpedance are being performed at all three visits by an investigator blinded to the assigned group. In addition, the person carrying out the data analysis will also be blinded to the assigned group.|Randomised, controlled, pragmatic study with blinded outcome measurement.|f|f|t|t
34009060|NCT05982249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open label randomized controlled trial||||
34009061|NCT06322615|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33930433|NCT04331925|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33930434|NCT03425851|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930435|NCT04424004|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34009062|NCT06616701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33930436|NCT03051269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009063|NCT06267794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Placebo will be identical to medication.~Methods to assign treatment:~Before assigning numbers to subjects, the researcher must confirm that the inclusion criteria have been met, that none of the exclusion criteria apply, that written and signed informed consent has been obtained, that the evaluations of the scrutiny (of admission) and that the required laboratory results are available and meet the admission criteria. To do this, the centers will be assisted with a check list format that contains all the selection criteria.~The person responsible for the medication at the research site will contact the Randomization center, where the treatment will be assigned to the patient."|Double blind, placebo-controlled multicenter study|t|t|t|f
33930437|NCT06508788|||COHORT||PROSPECTIVE|||||||
33930438|NCT00608881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930439|NCT04992299|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33930440|NCT05730127|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33930441|NCT02907281|||OTHER||PROSPECTIVE|||||||
33930442|NCT01191970|||COHORT||PROSPECTIVE|||||||
33930443|NCT01830244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930444|NCT03021044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930445|NCT02758925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930446|NCT00688623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930447|NCT04888728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930448|NCT01090674|||COHORT||PROSPECTIVE|||||||
33930449|NCT02508519|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930450|NCT06127511|RANDOMIZED|PARALLEL||PREVENTION||NONE||A multi-school, two-arm parallel cluster-randomized controlled trial||||
33930451|NCT02980549|||COHORT||PROSPECTIVE|||||||
34009064|NCT01682629|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
34009065|NCT05569330|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34009066|NCT05773534|||OTHER||PROSPECTIVE|||||||
34009067|NCT00003330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009068|NCT00329628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009069|NCT01905059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009070|NCT00615524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009071|NCT03610828|||OTHER||PROSPECTIVE|||||||
34009072|NCT03123978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009073|NCT02512614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705669|NCT01471171|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34009074|NCT04801719|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two study arms with histologically proven malignant biliary stenosis treated either by endoluminal radiofrequency ablation with subsequent metal stent insertion or metal stent insertion only.||||
34009075|NCT02989298|||COHORT||PROSPECTIVE|||||||
33705670|NCT05279339|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33705671|NCT05269043|||COHORT||PROSPECTIVE|||||||
33705672|NCT00077961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705673|NCT05827380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705674|NCT06260852|||COHORT||PROSPECTIVE|||||||
33705675|NCT01218113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705676|NCT03131921|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33705677|NCT05638581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care providers will be blinded to assignment until the point of randomization, which is when the cooler is opened, in the trauma bay, to remove blood products for transfusion.||t|f|f|t
33705678|NCT00133497|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33705679|NCT00103883|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33705680|NCT02043171|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33789991|NCT05593822|NA|SINGLE_GROUP||OTHER||NONE||||||
33789992|NCT03854006|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will examine long-term efficacy of Cryo-AF using the two proposed dosing algorithms in a nonrandomized fashion.||||
33789993|NCT00055432|NON_RANDOMIZED|||TREATMENT||NONE||||||
34009076|NCT05522218|||COHORT||PROSPECTIVE|||||||
34009077|NCT05151393|||CASE_CONTROL||PROSPECTIVE|||||||
34009078|NCT01610609|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34009079|NCT02309424|RANDOMIZED|CROSSOVER||||NONE||||||
33705681|NCT04174846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33789994|NCT06353243|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33789995|NCT04073732|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33789996|NCT00023218||||TREATMENT||||||||
33789997|NCT04442984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789998|NCT03202849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930452|NCT05166603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33930453|NCT02050451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930454|NCT04843943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930455|NCT04430790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Doxapram versus placebo|t|t|t|t
33930456|NCT00646581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930457|NCT05801172|RANDOMIZED|PARALLEL||TREATMENT||NONE||Women are randomly assigned to 3 arms - A: NSAID (ketoprofen 100 mg intravenously), B: A+infiltration anesthesia (20 ml 1% lidocaine), C: A+paracervical block (20 ml 1% lidocaine).||||
33930458|NCT00062205||||TREATMENT||NONE||||||
33930459|NCT05549414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930460|NCT00663104|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33930461|NCT01665976|RANDOMIZED|CROSSOVER||||NONE||||||
34009080|NCT02012231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009081|NCT03829215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will be comatose on inclusion. Outcome assessor will not be aware of group assignment|Single centre randomized controlled two arm clinical trial|t|f|f|t
33705682|NCT00541684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009082|NCT05500768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33930462|NCT06216990|||COHORT||RETROSPECTIVE|||||||
33930463|NCT01399840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930464|NCT02816476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930465|NCT03383614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930466|NCT01519349|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34009083|NCT05361486|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34009084|NCT01309217|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705683|NCT02829528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705684|NCT03302234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705685|NCT05675176|||COHORT||PROSPECTIVE|||||||
33705686|NCT01727999|||COHORT||PROSPECTIVE|||||||
33705687|NCT02579239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705688|NCT02560532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705689|NCT05679583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930467|NCT00003110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930468|NCT06507332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930469|NCT04099836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930470|NCT06322017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930471|NCT03285204|||CASE_CONTROL||PROSPECTIVE|||||||
33930472|NCT02891252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930473|NCT00962468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930474|NCT05609383|||COHORT||PROSPECTIVE|||||||
33930475|NCT03238352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930476|NCT04494477|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930477|NCT02868255|||COHORT||PROSPECTIVE|||||||
33930478|NCT02758041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705690|NCT05198999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective pre-test post-test randomized controlled trial|f|f|f|t
33705691|NCT03834441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705692|NCT01184391|RANDOMIZED|CROSSOVER||||NONE||||||
33705693|NCT05405374|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this study, all subjects will be treated at 2 levels of the anterior lumbar spine. One of the levels will be grafted with OSTEOAMP SELECT and the other with Infuse housed within the same type of interbody cage. The assignment of the bone graft product to each treated motion segment will be randomized in a 1:1 ratio. Every subject will serve as his/her own control.||||
33705694|NCT00082251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705695|NCT03641859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705696|NCT01699360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705697|NCT05947045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blind||f|f|f|t
33705698|NCT01086033|||||PROSPECTIVE|||||||
33705699|NCT00745329|||CASE_CONTROL||PROSPECTIVE|||||||
33705700|NCT06055101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33705701|NCT01837433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705702|NCT01964833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33705703|NCT04173559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|f|f|f|t
33705704|NCT05241912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705705|NCT05231057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705706|NCT00398580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705707|NCT03236285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705708|NCT03661671|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel assignment||||
33705709|NCT04388878|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33705710|NCT04343339|||COHORT||PROSPECTIVE|||||||
33705711|NCT05806073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705712|NCT00003805|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33705713|NCT01204554|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705714|NCT02218320|||OTHER||PROSPECTIVE|||||||
33705715|NCT02915016|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705716|NCT04159571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33705717|NCT02384486|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33705718|NCT05528185|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|"Health care providers will be blinded to participants who are randomized to usual care.~The investigator and outcomes assessor will be blinded to treatment assignment."||f|t|t|t
33705719|NCT05846204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33705720|NCT06271382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33705721|NCT03226483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930479|NCT04443036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009085|NCT02384291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009086|NCT04287868|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009087|NCT03547635|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, randomized, parallel-group study comparing the outcomes associated with the use of AMNIOEXCEL Plus Placental Allograft Membrane, a marketed comparator and SOC alone in the management of diabetic foot ulcers (DFUs).||||
33705722|NCT04273711|||COHORT||RETROSPECTIVE|||||||
33705723|NCT06184386|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33705724|NCT03068260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705725|NCT05876975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705726|NCT03940222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705727|NCT03813069|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"This is a within-subject, non-masked, trial of the use of commercially available insect repellents against Musca sorbens, with two consecutive participant groups in the laboratory and in the field, and a primary endpoint of measuring the protective efficacy of each repellent product.~The first (laboratory-based) study has one arm, in which all participants test all repellent products. Those that are found to generate at least 30 % protective efficacy will be tested in the second (field-based) study, which will have four arms. Up to three arms will test a repellent product and there will be a control arm."|f|f|f|t
33705728|NCT00799383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705729|NCT00334958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705730|NCT00356291|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705731|NCT06255964|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33705732|NCT02425371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705733|NCT00674362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705734|NCT04401423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blinded, placebo-control, randomized clinical trial|t|t|t|f
33705735|NCT01575587|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705736|NCT00917397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33789999|NCT03673943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790000|NCT05633199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790001|NCT02511639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705737|NCT04912193|||CASE_CONTROL||OTHER|||||||
33705738|NCT06032468|RANDOMIZED|PARALLEL||TREATMENT||NONE||Early feasibility study||||
33705739|NCT06438068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705740|NCT02981264|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33705741|NCT00145522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705742|NCT01332903|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705743|NCT05087459|||COHORT||PROSPECTIVE|||||||
33705744|NCT05856071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomized||t|f|t|f
33790002|NCT04448418|||COHORT||CROSS_SECTIONAL|||||||
33790003|NCT03844854|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The aim of the first stage is a development of the sonoelastography methodology with precise determination of the positioning of the sonography head and the patient's condyle in temporomandibular joints as well as a determination of the normal range of masticatory muscle structure in the population of healthy subjects. This stage includes people without a history of temporomandibular disorders.~The second stage is devoted to the assessment of the sonoelastography in the monitoring of the efficacy of treatment. The study group will undergo treatment of masticatory muscles disorders using manual therapy and stabilization occlusal splint. The assessment of severity of pain with Numerical Rating Scale (NRS) and quality of life associated with oral health using standardized international questionnaire will be conducted at baseline and after 12 weeks of treatment."||||
33790004|NCT06269536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790005|NCT00320489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790006|NCT02046616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930480|NCT04517110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo capsules|Double-blinded randomized controlled trial|t|t|t|t
33930481|NCT06181227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930482|NCT04072536|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|To minimize bias, this study will be randomized and conducted in single blind. The patient will not be aware of the activation or not of the assistance module placed on the electric wheelchair. Indeed, the investigative team will be in charge of the activation of the robotic module.|"Each patient included will test a wheelchair equipped with a collision avoidance assistance module in 2 conditions, assistance activated or not.~This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance, in a random order established upstream."|t|f|f|t
33930483|NCT02353676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33930484|NCT03716687|RANDOMIZED|PARALLEL||PREVENTION||NONE||50-50% randomisation into interventional (ciNPWT) and control (traditionaltreatment) groups.||||
33930485|NCT04538261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators and participants will not know whether participants have undergone inflation of the balloon device.|Randomized trial using control and interventional arms.|t|t|t|f
33930486|NCT03879460|NA|SINGLE_GROUP||PREVENTION||NONE||Open label safety assessment||||
33930487|NCT03365336|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Parallel follow up of two groups randomly allocated through a central randomization process.||||
33930488|NCT04480346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930489|NCT04869111|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33930490|NCT04974268|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio||||
33930491|NCT01186094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930492|NCT05228197|||COHORT||CROSS_SECTIONAL|||||||
33930493|NCT04250740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33930494|NCT04300881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930495|NCT03538990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930496|NCT01442441|||||RETROSPECTIVE|||||||
33930497|NCT05981378|||OTHER||PROSPECTIVE|||||||
33930498|NCT00003551||||TREATMENT||||||||
33930499|NCT00291187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930500|NCT05819840|||CASE_ONLY||RETROSPECTIVE|||||||
34009088|NCT03255863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009089|NCT00171340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009090|NCT01246713|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34009091|NCT01205893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009092|NCT03887988|||CASE_ONLY||PROSPECTIVE|||||||
34009093|NCT02506231|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705745|NCT00006477||||TREATMENT||||||||
33930501|NCT03797690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary outcome (main metacarpophalangeal joint contracture during passive extension) will be assessed using low energy computed tomography before treatment, 3 months and 36 months after treatment for blinded assessment. Furthermore, in addition to the clinical follow-up, the patient will be followed by a blinded assessor. At each follow-up visits with the blinded assessor, patient will be asked to wear white opaque gloves to ensure the blinding for the treatment during assessment including the main outcome. Clinicians, nurses and patients will be instructed to the importance of avoiding communication about the treatment to the blinded assessor.|multicenter, non-inferiority PROBE (Prospective Randomized Open Blinded End-point) trial. Two groups (ratio 1:1) will be compared in this phase III pivotal study: experimental group versus control group.|f|f|t|t
33705746|NCT04937764|||CASE_ONLY||RETROSPECTIVE|||||||
33930502|NCT00022893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009094|NCT00914979|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009095|NCT06293443|NA|SINGLE_GROUP||OTHER||NONE|participants underwent functional testing at clinical centers|||||
33705747|NCT02023606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705748|NCT06241508|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33930503|NCT00920946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930504|NCT05326568|RANDOMIZED|PARALLEL||OTHER||SINGLE|After the research report is written, a third person will assign an intervention and control group to the letters.|Prospective, parallel, two-arm randomized controlled clinical trial|f|f|f|t
33930505|NCT05862298|||CASE_ONLY||PROSPECTIVE|||||||
33930506|NCT02732223|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34009096|NCT00000555|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34009097|NCT02246088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705749|NCT03802760|||COHORT||PROSPECTIVE|||||||
34009098|NCT02623907|||COHORT||PROSPECTIVE|||||||
34009099|NCT01164215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009100|NCT04309526|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33930507|NCT05341284|||COHORT||PROSPECTIVE|||||||
33705750|NCT01066208|||CASE_CONTROL||PROSPECTIVE|||||||
33705751|NCT01780077|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33705752|NCT01815801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930508|NCT01055457|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705753|NCT02805010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705754|NCT00043771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705755|NCT03758066|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-post quasi-experimental design||||
33705756|NCT01669226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930509|NCT06117904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33930510|NCT01722357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930511|NCT05944029|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective Clinical Trial||||
34009101|NCT02808819|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705757|NCT04152473|NA|SEQUENTIAL||OTHER||NONE||open labelled sequential Phase I ascending dose study||||
33705758|NCT00042900||||TREATMENT||||||||
33705759|NCT00548223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705760|NCT05269823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705761|NCT00037596||||TREATMENT||||||||
33705762|NCT05274061|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single group treatment study in which every couple will receive the intervention (AIM-CBCT).||||
33705763|NCT00785265|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33705764|NCT03690531|||CASE_CONTROL||PROSPECTIVE|||||||
33705765|NCT06293222|||COHORT||PROSPECTIVE|||||||
33705766|NCT00362310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705767|NCT02027883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705768|NCT02326532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33705769|NCT03705520|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33705770|NCT00002989|RANDOMIZED|||TREATMENT||||||||
33705771|NCT04405414|||OTHER||CROSS_SECTIONAL|||||||
33705772|NCT05667844|NA|SINGLE_GROUP||OTHER||NONE||Study case||||
33705773|NCT01926236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705774|NCT05738603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The studied patients will be blinded to the enrolled group.|This prospective, randomized, controlled clinical trial will be performed in Poznan University of Medical Science Hospital. Patients fulfilling the inclusion criteria (see below) will be randomly assigned to receive invasive blood pressure monitoring + standard medical therapy (group A) or the hemodynamic monitoring with the Hypotension Prediction Index software (group B).|t|f|f|f
33705775|NCT06492967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Multicenter study with blind evaluators, evaluating the feasibility of a lifestyle intervention over two years|Multicenter study with blind evaluators, evaluating the feasibility of a lifestyle intervention over two years.|f|f|f|t
33705776|NCT00816595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009102|NCT04766229|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009103|NCT02527239|||||PROSPECTIVE|||||||
34009104|NCT05661461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009105|NCT01718171|||CASE_CONTROL||PROSPECTIVE|||||||
34009106|NCT02371421|||COHORT||PROSPECTIVE|||||||
34009107|NCT03246906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009108|NCT02291367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705777|NCT05923983|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Prospective, multicentre, controlled, single-blind, randomised cluster study with stepped-wedge permutations. The centres (hospitals) will be the clusters.|t|f|f|f
33705778|NCT03981770|||CASE_CONTROL||PROSPECTIVE|||||||
33705779|NCT04655378|||COHORT||RETROSPECTIVE|||||||
33705780|NCT04720066|||CASE_ONLY||PROSPECTIVE|||||||
33705781|NCT00358852|||CASE_ONLY||CROSS_SECTIONAL|||||||
33705782|NCT02527135|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705783|NCT03044678|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Masked or blinded to hypotheses||t|t|f|t
33705784|NCT06192134|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study of intervention compared to historic controls||||
23834448|NCT03543124|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"1. 1) The patients will not be informed of the technique, and what the cap at the tip looks like; 2) The colonoscope will be set up in the absence of the patient; 3) Before the start, a small towel will cover the eye of the patients, and care will be taken not to uncover the eyes when the patient is moved.~2. There will be a preliminary statistical analysis of the coded data, followed by a complete review by the assessor, who will conduct the final analysis."||t|f|f|t
33705785|NCT02477150|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33705786|NCT04457635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor of primary outcome (sickness benefit) is masked for intervention allocation. Other outcome measures are assessed by patient questionnaires.|Pragmatic randomized controled trial|f|f|f|t
33705787|NCT00149162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705788|NCT06469424|||COHORT||PROSPECTIVE|||||||
33790007|NCT04749433|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||There will be two groups of participants in this study, healthy control participants and participants with a diagnosis of ALS. All patients will receive the same radiotracer and scan.||||
33930512|NCT03803449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Participants are randomly assigned to group A or B. Participants of group A are given propofol midazolam and fentanyl; while participants of group B are given propofol with midazolam without fentany|f|t|f|t
33930513|NCT05560295|||COHORT||RETROSPECTIVE|||||||
33930514|NCT06119555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930515|NCT00223652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930516|NCT01379729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930517|NCT04483297|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33930518|NCT02557334|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33930519|NCT03127852|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33930520|NCT01761994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930521|NCT03372447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930522|NCT04377789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705789|NCT05746793|||COHORT||PROSPECTIVE|||||||
33705790|NCT01960400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33705791|NCT01724918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930523|NCT04831268|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single (Investigator)|Crossover Assignment|f|f|t|f
33705792|NCT03223142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705793|NCT03870074|||COHORT||PROSPECTIVE|||||||
33705794|NCT01529502|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33705795|NCT04269252|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33705796|NCT00695877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33790008|NCT00219687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790009|NCT03434392|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants are assigned to one of four groups in parallel for the duration of the study based on prior clinical history.||||
33790010|NCT05237219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33790011|NCT02246816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790012|NCT02444013|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33790013|NCT02079714|||COHORT||PROSPECTIVE|||||||
33790014|NCT05662891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled single-blind study|f|f|t|f
33790015|NCT02590913|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33790016|NCT02414906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790017|NCT04297982|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled trial|t|f|f|f
33790018|NCT01803646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790019|NCT03844464|||CASE_ONLY||PROSPECTIVE|||||||
33790020|NCT06544382|||COHORT||PROSPECTIVE|||||||
33790021|NCT05663918|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcomes assessor will be unaware of the allocation of participants to specific groups because the data will be anonymized.||f|f|f|t
33790022|NCT02044718|||CASE_ONLY||RETROSPECTIVE|||||||
33790023|NCT03908424|||CASE_CONTROL||PROSPECTIVE|||||||
33930524|NCT03154294|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The demographic and clinical characteristics of the study patients will be summarized using descriptive statistics~* Primary objective: The maximum tolerable dose will be assessed, which is the dose level at which \< one-third of patients will experience a dose-limiting toxicity~* Secondary objectives:~  1. Adverse events will be defined according to the Common Terminology Criteria for Adverse Events v4 and will be summarized with descriptive statistics~ 2. Response rate will be determined according to the Response Evaluation Criteria in Solid Tumors 1.1 response criteria. Number and type of responses will be summarized with descriptive statistics~* Exploratory objectives~  1. Response rate and relationship with genomic alterations will be examined by using a two-sided Fisher Exact test due to the small sample sizes~ 2. Therapy-Related Symptom Checklist and Health-Related Quality of Life Linear Analogue Self-Assessment scores will be summarized with descriptive statistics"||||
33930525|NCT03967847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930526|NCT02683707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930527|NCT00040950||||TREATMENT||||||||
33930528|NCT00367341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930529|NCT04831593|||COHORT||PROSPECTIVE|||||||
33930530|NCT01033604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705797|NCT02627521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33705798|NCT01016197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790024|NCT00199641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930531|NCT03561246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930532|NCT01856855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930533|NCT03613818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930534|NCT01600417|||CASE_ONLY||PROSPECTIVE|||||||
33930535|NCT05255705|||COHORT||RETROSPECTIVE|||||||
33930536|NCT06278155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930537|NCT02714608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930538|NCT02944734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930539|NCT05798819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930540|NCT00868361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930541|NCT02287662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930542|NCT05905770|||COHORT||PROSPECTIVE|||||||
33930543|NCT04119388|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33930544|NCT01063504|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930545|NCT04253470|||COHORT||RETROSPECTIVE|||||||
33930546|NCT01024062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930547|NCT03296280|||COHORT||PROSPECTIVE|||||||
33930548|NCT00772746|||CASE_CONTROL||PROSPECTIVE|||||||
34009109|NCT02026544|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705799|NCT03503175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009110|NCT00384293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009111|NCT06287437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009112|NCT03451006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Arms Assigned interventions Placebo Comparator: Metformin Chronic metformin administration through augmentation of cellular regeneration and reduction of senescence will improve frailty and physical functioning as studied by the short physical performance battery (SPPB) test. Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score \<9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months.~Placebo comparator: Placebo Placebo will be compared to chronic metformin administration Drug: Metformin versus placebo This will be a pilot, feasibility study. Twelve subjects ≥60 years with stable CAD and prediabetes, who score \<9 on SPPB test will be randomized to receive up to 2gm of oral metformin or placebo for 12 months."|t|f|t|f
33705800|NCT04546815|||OTHER||PROSPECTIVE|||||||
33705801|NCT06506721|RANDOMIZED|PARALLEL||OTHER||NONE|due to nature of the induction method, blinding of women an/ or doctors is considered non-feasible|Open (unblinded) prospective randomized trial||||
33705802|NCT03159624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705803|NCT05452031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33705804|NCT01275885|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705805|NCT03677921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33705806|NCT06556342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705807|NCT02601391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705808|NCT04742959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study will consist of three arms: Arm A (TT-00420 Tablet Monotherapy), Arm B (TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)) and Arm C (PK Run-in Study of TT-00420 Tablet).||||
33705809|NCT01941667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705810|NCT02736760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705811|NCT02257008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790025|NCT04620018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An independent investigator who was blind to participants (groups) evaluated all subjects|subjects were aligned randomly into three groups.In group 1, subjects received prophylactic antibiotic orally (Amoxicillin 2mg ,1 hour before surgery) and post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days), subjects received only prophylactic antibiotic (Amoxicillin 2mg ,1 hour before surgery) in group 2 ,and in group 3, subjects received post-surgical antibiotic (Amoxicillin 500 mg , q8h for five days) .|t|f|f|f
33790026|NCT02274493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930549|NCT02603406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33930550|NCT00250497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930551|NCT05106439|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization scheme||||
33930552|NCT06269575|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||non-randomized controlled||||
33930553|NCT04629586|||COHORT||PROSPECTIVE|||||||
33705812|NCT00544830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705813|NCT04456946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705814|NCT01989897|NA|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33930554|NCT00473291|||COHORT||PROSPECTIVE|||||||
33930555|NCT02590640|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33930556|NCT00784706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930557|NCT03030391|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930558|NCT04518020|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial (RCT)||||
33930559|NCT03961295|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33930560|NCT06007755|||COHORT||PROSPECTIVE|||||||
33930561|NCT04520178|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33930562|NCT00549653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930563|NCT03472768|||COHORT||PROSPECTIVE|||||||
33930564|NCT00374036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009113|NCT04975893|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34009114|NCT01998386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009115|NCT04417647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009116|NCT03359915|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||RCT Phase - Parallel Groups: 240 in total Control arm - 120 participants Intervention Arm - 120 participants||||
34009117|NCT01660022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009118|NCT06253338|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009119|NCT02345291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009120|NCT03396874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009121|NCT05871333|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group I: Patients will receive only their standard therapy for 4 months. Group II: will receive the studied drug orally in addition to their standard therapy||||
34009122|NCT04091802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705815|NCT04923061|RANDOMIZED|PARALLEL||OTHER||SINGLE|"As a result of the draw, group A was determined as acupressure and group B as sham acupressure group. Information showing that the nurses included in the research sample were assigned to groups A and B according to the randomization table will be placed in an opaque envelope. This envelope will be kept by the coordinator researcher (MG) and when the researcher with acupressure practice certificate (EC) goes to the nurse for the application, fills out the Informed Consent Form and opens the envelope to find out which group the nurse is in. Since all nurses included in the study will be taught to apply pressure to the pressure point, the participants will be blinded as the nurses do not know whether acupressure or sham acupressure is applied. The researcher (EC) cannot be blinded due to the nature of the research."|Prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
33705816|NCT01220050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705817|NCT02639065|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33705818|NCT04224480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705819|NCT04199910|||COHORT||PROSPECTIVE|||||||
33705820|NCT03340688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009123|NCT04397289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33705821|NCT06304428|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33705822|NCT06263556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized and assigned to either group.|t|f|f|f
33705823|NCT00945893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705824|NCT05846971|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33705825|NCT05473910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705826|NCT01302756|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33790027|NCT06359054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790028|NCT01387113|||COHORT||PROSPECTIVE|||||||
33930565|NCT05160662|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"A prospective cohort study involving all women with a BMI \>35 who give birth at the women's clinic, between 2019-2023. New guidelines for this group are being developed using NICE guidelines (UK) as a model and will be tested in clinical practice~The material will be grouped into:~Women with BMI\>=35 delivered at the hospital 2019-2020 (control group) Women with BMI\>=35 delivered at the hospital 2021-2023 (where new guidelines have been used)"||||
33930566|NCT01735097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930567|NCT00130468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930568|NCT05980676|RANDOMIZED|PARALLEL||OTHER||SINGLE|The statistician performing statistical analysis will be blinded to group assignment.||f|f|f|t
33930569|NCT03395327|||COHORT||PROSPECTIVE|||||||
33930570|NCT03723785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930571|NCT05578313|||COHORT||PROSPECTIVE|||||||
33930572|NCT00048490||||TREATMENT||||||||
34009124|NCT04776746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009125|NCT00949728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009126|NCT02833194|||COHORT||PROSPECTIVE|||||||
34009127|NCT01606228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009128|NCT04115735|||COHORT||PROSPECTIVE|||||||
34009129|NCT04201470|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34009130|NCT06616493|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34009131|NCT00497250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009132|NCT04475250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009133|NCT01876238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009134|NCT02117388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009135|NCT05237128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment and data analysis will be masked.||f|f|f|t
34009136|NCT05364437|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Double-blinded, randomised, cross-over|t|f|t|t
34009137|NCT02814955|||COHORT||PROSPECTIVE|||||||
34009138|NCT05583682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||One of the Nano-filled glass ionomer or sub-micron hybrid resin composite restorative materials were applied to carious mandibular first molar teeth|t|f|f|t
34009139|NCT04332952|||COHORT||PROSPECTIVE|||||||
34009140|NCT00006245||||TREATMENT||||||||
34009141|NCT01953094|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34009142|NCT05732272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009143|NCT06318832|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34009144|NCT04654234|||COHORT||PROSPECTIVE|||||||
34009145|NCT01046578|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009146|NCT01279655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009147|NCT05022368|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34009148|NCT05217589|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34009149|NCT04147962|||COHORT||RETROSPECTIVE|||||||
34009150|NCT02464488|||CASE_ONLY||PROSPECTIVE|||||||
34093696|NCT03977688|||OTHER||RETROSPECTIVE|||||||
34093697|NCT03805139|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 60 subjects (30 in each group) will be included in the study. The total duration of study will be upto 6 months. The AKU faculty and staff will be invited to MDL lab for screening and initial baseline, enrolled participant will be informed for inclusion in the research on the basis of our criteria of HDL levels. Written informed consent (a copy will also be provided to the participant) will be taken from each individual. A questionnaire regarding their diet and life style will be filled. Following vitals will be measured body weight, height and blood pressure. Blood sample will be taken for lipid profile (LDL, HDL, total cholesterol and triglycerides). Total period for each participant will be 6 weeks for interventions. In Ajwa Dates group, number of interaction will be 5 days a week for 6 weeks (30 doses will be provided).||||
34093698|NCT04076215|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093699|NCT00778414|RANDOMIZED|CROSSOVER||||NONE||||||
34093700|NCT05676645|||COHORT||PROSPECTIVE|||||||
34093701|NCT04731116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093702|NCT03972228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093703|NCT01479530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093704|NCT04225143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093705|NCT00685282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34093706|NCT05058456|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34093707|NCT00762788|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34093708|NCT03560596|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34093709|NCT00949936||||TREATMENT||||||||
34093710|NCT02439619|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34093711|NCT04747002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103266|NCT05689736|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Multiphase Optimization Strategy (MOST) factorial experiment. There are 4 experimental factors; each corresponds to the presence vs. absence of an engagement-focused intervention element. This experiment enables the estimation of the individual and combined effects of each element.|t|f|f|f
34103267|NCT06668220|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Masking Description|Model Description|t|f|f|t
33705827|NCT03507231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33705828|NCT03692468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705829|NCT02966431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705830|NCT00543010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705831|NCT05199181|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal prospective single-arm cohort clinical study||||
33705832|NCT04960514|||COHORT||PROSPECTIVE|||||||
33705833|NCT01951274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705834|NCT00180544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705835|NCT04847856|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a 12 months randomized clustered trial that recruited individuals with type II diabetes mellitus attending primary health care clinics in Tabuk city, Saudi Arabia.~Health centres will be divided into two groups( intervention\& control) using Random Number Generator."||||
33705836|NCT06276283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705837|NCT02598804|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705838|NCT03138278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multicentre study with ≥ 100 ICUs from Europe. Randomisation at ICU level to give support to caregivers or not (cluster-randomisation)||||
33705839|NCT05616663|||CASE_ONLY||RETROSPECTIVE|||||||
33705840|NCT00976040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705841|NCT02347280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705842|NCT02189460|||OTHER||PROSPECTIVE|||||||
33705843|NCT05310838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705844|NCT03026322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705845|NCT02973061|||CASE_CONTROL||PROSPECTIVE|||||||
33705846|NCT06429748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705847|NCT00385762|||CASE_ONLY||PROSPECTIVE|||||||
33705848|NCT03460860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705849|NCT03758001|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103268|NCT06480461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705850|NCT02156986|||||CROSS_SECTIONAL|||||||
33705851|NCT01446978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705852|NCT06180772|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705853|NCT02200432|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790029|NCT02633358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790030|NCT01803516|||COHORT||PROSPECTIVE|||||||
33790031|NCT00798122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790032|NCT01550978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790033|NCT03206554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790034|NCT05975788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790035|NCT04462107|||CASE_ONLY||CROSS_SECTIONAL|||||||
33790036|NCT03725371|||CASE_ONLY||PROSPECTIVE|||||||
33790037|NCT04138862|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Single Blind (participant unaware of the meal manipulations)|"Mixed Design:~4 x Beverage Contexts (assessed in parallel to reduce demand awareness) 2 x Energy Density (assessed as full crossover)"|t|f|f|f
33790038|NCT02470936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790039|NCT06161051|||COHORT||RETROSPECTIVE|||||||
34009151|NCT00692952|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34009152|NCT04823819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009153|NCT02449473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009154|NCT04735731|||COHORT||PROSPECTIVE|||||||
34009155|NCT01008514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009156|NCT01868282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34009157|NCT04436926|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34009158|NCT04945018|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33705854|NCT02738060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009159|NCT01136330|||COHORT||RETROSPECTIVE|||||||
34009160|NCT02040311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009161|NCT05966987|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Factorial Assignment||||
34009162|NCT01223235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009163|NCT03331159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
34103269|NCT05668507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to the intervention group (access to the mobile app/support program right away) or the wait-list control group (access granted to the mobile app/support program after 6 months).||||
34103270|NCT06290687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-center, prospective, phase II trial.||||
33705855|NCT02202980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705856|NCT01048177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705857|NCT02032225|||CASE_ONLY||PROSPECTIVE|||||||
33705858|NCT04536701|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal descriptive||||
33705859|NCT01528475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33705860|NCT01926015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705861|NCT04157491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705862|NCT03569618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study assessment administrator is blinded to what digital tool the subject has been assigned.||t|f|t|t
33705863|NCT00896246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705864|NCT02726152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705865|NCT01216748|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705866|NCT05866900|||COHORT||RETROSPECTIVE|||||||
33705867|NCT04289662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705868|NCT04817397|||COHORT||PROSPECTIVE|||||||
33705869|NCT02056977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705870|NCT05536050|||OTHER||PROSPECTIVE|||||||
33705871|NCT02685410|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33705872|NCT04138810|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33705873|NCT01593098|||CASE_CONTROL||PROSPECTIVE|||||||
33705874|NCT06107400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705875|NCT06373796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705876|NCT04535648|||CASE_ONLY||OTHER|||||||
33705877|NCT05587803|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33705878|NCT05229406|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to two groups in a 1:1 ratio||||
33705879|NCT02767843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790040|NCT00466076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33790041|NCT00141830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790042|NCT00139737|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790043|NCT00202748|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790044|NCT03683628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor who measure the pain free walking distance, ABI, TBI,TCOM do not know the result of randomization||f|f|f|t
33790045|NCT03036735|NA|SINGLE_GROUP||TREATMENT||NONE|At the end of surgery, the Surgery Fellow will insert either the Drug Eluting Spacer or the Silastic spacer into each side of the subject's nose. The subject will receive one of each spacer. The fellow will record which spacer was placed on which side using a special coding system to keep this information private. This maintains the blinding for the primary surgeon/outcome assessor and subject.|Subjects undergoing endoscopic sinus surgery (ESS) will receive one steroid eluting spacer placed into the surgical site on one side, and one spacer without steroid placed on the other side.||||
34009164|NCT01805739|||COHORT||OTHER|||||||
34009165|NCT01853241|||CASE_ONLY||PROSPECTIVE|||||||
34009166|NCT00693225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009167|NCT00852917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009168|NCT02266394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009169|NCT05128214|||COHORT||RETROSPECTIVE|||||||
34009170|NCT04621916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009171|NCT02923414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705880|NCT03562832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705881|NCT06504914|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
33705882|NCT05062356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705883|NCT01936805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705884|NCT00903396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33705885|NCT00272740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33705886|NCT01306396|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705887|NCT05500105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790046|NCT01765686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790047|NCT06081231|||COHORT||OTHER|||||||
33790048|NCT03138473|||COHORT||PROSPECTIVE|||||||
33790049|NCT00914823|NA|SINGLE_GROUP||OTHER||NONE||||||
33790050|NCT00044928||||TREATMENT||||||||
33790051|NCT01322958|||COHORT||PROSPECTIVE|||||||
33790052|NCT01672489|||COHORT||OTHER|||||||
33790053|NCT06629662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930573|NCT04055025|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The study visits will be performed in randomized orders and participants will not now if they will receive ghrelin or saline.|||||
33930574|NCT05728762|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33930575|NCT06361420|RANDOMIZED|PARALLEL||PREVENTION||NONE||open, randomised control trial||||
33930576|NCT03781388|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Blinded study drugs will be prepared by an anesthesia provider not involved in the study. The anesthesia provider providing care to the patient will be blinded to the dosage of the hyperbaric bupivacaine. In order to preserve the blinding of the provider, the total volume of study drug will be maintained at a constant of 2.05mL. The difference in total volume based on the variation of hyperbaric bupivacaine dosing will be replaced with preservative free normal saline.|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).|t|t|f|t
33930577|NCT05637957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Physiotherapists providing treatment, physiotherapists conducting assessment, research coordinator, principal investigators, participants are all blinded to treatment allocation. Research assistants administered the transcranial direct current stimulation are not blinded.|Parallel group randomized feasibility trial|t|t|t|t
33930578|NCT04773704|||COHORT||PROSPECTIVE|||||||
33930579|NCT00474006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930580|NCT01690988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930581|NCT00544466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930582|NCT04749160|||COHORT||PROSPECTIVE|||||||
33930583|NCT01581996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930584|NCT02607462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33930585|NCT05753202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930586|NCT00806650|||CASE_ONLY||RETROSPECTIVE|||||||
33930587|NCT04461704|||CASE_ONLY||PROSPECTIVE|||||||
33930588|NCT01048255|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33705888|NCT03097172|||COHORT||PROSPECTIVE|||||||
33705889|NCT00459225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705890|NCT01120145|||COHORT|||||||||
33705891|NCT04177667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind placebo controlled trial||t|f|t|f
33705892|NCT04795011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705893|NCT05373745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705894|NCT00424983|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790054|NCT05301400|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790055|NCT03895788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790056|NCT01346930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790057|NCT01072357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930589|NCT00776334|RANDOMIZED|CROSSOVER||||NONE||||||
33930590|NCT03417505|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Randomized, double-masked crossover study|t|t|f|f
33930591|NCT02525887|||CASE_ONLY||RETROSPECTIVE|||||||
33930592|NCT00338260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34009172|NCT00493454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009173|NCT00804206|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009174|NCT06064825|||COHORT||CROSS_SECTIONAL|||||||
34009175|NCT02972021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009176|NCT06595147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All MRI outcomes will be performed blinded to group allocation. Outcome assessors for post-outcome assessments will be blinded to baseline values.||f|f|f|t
34009177|NCT06580327|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34009178|NCT06471543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009179|NCT05131477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009180|NCT00731224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705895|NCT03147898|||COHORT||PROSPECTIVE|||||||
33790058|NCT00394069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34103271|NCT03747263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790059|NCT05042193|||COHORT||OTHER|||||||
34103272|NCT00842465|||||CROSS_SECTIONAL|||||||
34103273|NCT04481503|||COHORT||CROSS_SECTIONAL|||||||
33790060|NCT05759585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705896|NCT04674410|||COHORT||RETROSPECTIVE|||||||
33705897|NCT05370534|||COHORT||PROSPECTIVE|||||||
33790061|NCT04765163|||CASE_CONTROL||PROSPECTIVE|||||||
33705898|NCT03577769|||COHORT||RETROSPECTIVE|||||||
33790062|NCT04370782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790063|NCT01212757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705899|NCT02155790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790064|NCT00367055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790065|NCT02319785|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33790066|NCT00484575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790067|NCT03082430|NA|SINGLE_GROUP||TREATMENT||NONE|study for knee osteoarthritis patients treated in the center|descriptive study||||
33790068|NCT02466048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790069|NCT06357169|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33790070|NCT01343173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790071|NCT04366882|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33790072|NCT00513734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33790073|NCT02925052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790074|NCT04324242|||CASE_ONLY||PROSPECTIVE|||||||
33790075|NCT01181089|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33790076|NCT02012166|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33790077|NCT05756998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33790078|NCT02772653|||OTHER||PROSPECTIVE|||||||
33790079|NCT03414710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33790080|NCT01936753|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective paired cohort study||||
33930593|NCT03058302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|until the 4th sessions participants receiving CETA and providers will be masked with respect to whether treatment is short or long CETA.||f|f|f|t
33930594|NCT00813267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790081|NCT03771846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790082|NCT01552304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790083|NCT02452294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705900|NCT06199154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705901|NCT03128567|||CASE_CONTROL||PROSPECTIVE|||||||
33790084|NCT01596725|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33790085|NCT04744519|||COHORT||RETROSPECTIVE|||||||
33930595|NCT04969627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930596|NCT01100294|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33930597|NCT04884906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930598|NCT05347771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930599|NCT02044315|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33705902|NCT03875651|||COHORT||PROSPECTIVE|||||||
33705903|NCT05694767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705904|NCT06362577|||COHORT||OTHER|||||||
33705905|NCT02616081|||COHORT||PROSPECTIVE|||||||
33705906|NCT00379093|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790086|NCT02780947|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790087|NCT00627874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790088|NCT06394791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790089|NCT02313441|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33790090|NCT01130818|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33790091|NCT01020838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790092|NCT03888755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790093|NCT01434563|||COHORT||PROSPECTIVE|||||||
33790094|NCT02517307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790095|NCT00301509|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33930600|NCT04421612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group one recieve a new module every three days. Group two recive a new module every 5 days.||||
33930601|NCT00850928|||COHORT||PROSPECTIVE|||||||
33930602|NCT00271791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930603|NCT02869685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930604|NCT04319445|NA|SINGLE_GROUP||OTHER||NONE||||||
33930605|NCT02020928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33930606|NCT00502619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930607|NCT02142855|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930608|NCT00952601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930609|NCT02027272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930610|NCT01492166|||COHORT||PROSPECTIVE|||||||
33930611|NCT02880735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930612|NCT04363944|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The purpose of the intervention was to provide proof of concept that it is feasible for individuals with stroke to use mRehab in a home program and to examine if changes in motor function were enhanced following the home program.||||
33930613|NCT00355329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930614|NCT01298895|||COHORT||PROSPECTIVE|||||||
33930615|NCT01729676|||COHORT||PROSPECTIVE|||||||
33930616|NCT02007252|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33930617|NCT00319683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930618|NCT03366597|NA|SINGLE_GROUP||TREATMENT||NONE||one group is treated with sevoflurane, the other is not.||||
33930619|NCT01779583|||CASE_CONTROL||PROSPECTIVE|||||||
34009181|NCT00274885|NON_RANDOMIZED|||TREATMENT||NONE||||||
34009182|NCT00406588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103274|NCT06054178|NA|SINGLE_GROUP||OTHER||NONE||"Experimental: Fluorescein sodium during surgery~Subjects undergoing parotid surgery for benign conditions will have fluorescein sodium administered intravenously after induction, and fluorescence imaging will be performed to visualize nerves intraoperatively"||||
33930620|NCT00653094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790096|NCT04611360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790097|NCT05904535|||COHORT||PROSPECTIVE|||||||
33790098|NCT00844571|||COHORT||PROSPECTIVE|||||||
33930621|NCT04894227|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33930622|NCT06445569|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants will consume their assigned study product for 3 months, after which all participants will be assigned to consume the KH-1 for the remaining 3 months in an open-label fashion.|t|t|t|t
33930623|NCT05339204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930624|NCT04884945|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patient, Family, and Nursing Staff on Surgical Floor|"For Aim 2: For the RCT, patients are randomized to either RALP or OP by using a pool of 20 cards of which 10 say robotic surgery and 10 say open surgery."|t|t|f|f
33930625|NCT00012207||||TREATMENT||NONE||||||
34009183|NCT00345215|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34009184|NCT06516913|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34009185|NCT06035484|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Within-subjects repeated measures design||||
34009186|NCT02085850|||COHORT||CROSS_SECTIONAL|||||||
34009187|NCT00190281|||DEFINED_POPULATION||PROSPECTIVE|||||||
34009188|NCT02978352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33930626|NCT01470365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930627|NCT05704842|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33930628|NCT02768103|NA|SINGLE_GROUP||TREATMENT||NONE||All participants complete 10 week task based training in home setting.||||
33930629|NCT04427228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33930630|NCT06039969|||CASE_CROSSOVER||PROSPECTIVE|||||||
33930631|NCT00333424|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33930632|NCT03689972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930633|NCT01255150|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33790099|NCT05720546|||COHORT||PROSPECTIVE|||||||
33930634|NCT05622513|||CASE_CONTROL||RETROSPECTIVE|||||||
33930635|NCT04240912|||CASE_ONLY||PROSPECTIVE|||||||
34009189|NCT06616233|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinded analysis of data|Randomised trial of the effect of remote ischemic conditioning with or without lower intensity exercise on hyperaemic myocardial blood flow in patients with or at risk of heart failure.||||
34009190|NCT06026631|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34009191|NCT03389087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790100|NCT00579202|||OTHER||OTHER|||||||
33930636|NCT05406245|||CASE_ONLY||PROSPECTIVE|||||||
33930637|NCT03859804|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pain levels after standard transrectal prostate 12 core biopsy and MRI -US fusion prostate biopsy were detected and compared in 2 groups.||||
33930638|NCT05076331|||COHORT||PROSPECTIVE|||||||
33930639|NCT00675662|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33930640|NCT02120560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930641|NCT00107172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930642|NCT05912348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized Cross-Sectional Study Design||||
33930643|NCT04083794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"This is a Basic Experimental study with Humans with able-bodied individuals and individuals with spinal cord injury (SCI). This study is a cross sectional assessment and will have 1 or 2 visits consisting of 2 protocols where individuals will undergo several physical maneuvers during which bone perfusion response will be assessed. Protocol #1 will investigate tibial perfusion response to tibial loading. Protocol #2 will investigate tibial perfusion response to isometric handgrip exercise and tilt. Volunteers can choose to do one or both protocols during 1 or 2 laboratory visits.~Study completion update: In able bodied adults, we have investigated tibial perfusion in response to isometric handgrip exercise, cold pressor test, leg dependency, reactive hyperemia, and sublingual nitroglycerin. In adults with spinal cord injury, we have investigated tibial perfusion in response to isometric handgrip exercise."||||
33705907|NCT05745571|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Our study will be interventional, prospective, and single-center. At the time of enrollment in the study, peripheral blood will be drawn, then patients will be recalled for follow-up visits at 1 and 6 months, during which new venous blood draws will be performed, together with the echocardiographic examination. Patients will undergo the treatment required by the current and most recent guidelines for heart failure and adherence to this study will not involve any modification of the current therapy.||||
33705908|NCT03021070|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33705909|NCT05371431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33705910|NCT00923156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705911|NCT06005480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomized to which arm will receive a nerve block.||||
33705912|NCT01970397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930644|NCT02134041|||CASE_CONTROL||RETROSPECTIVE|||||||
34009192|NCT05017779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009193|NCT06239688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34009194|NCT06326034|NA|SINGLE_GROUP||TREATMENT||NONE||This interventional randomized clinical study was conducted from May to December 2022, at the National Diabetic Centre for treatment and research/ Mustansiriyah University/ Baghdad/ Iraq. Ethical approval from the diabetic center and college of pharmacy/ Mustansiriyah University, was taken prior to the study initiation. All investigations/ procedures carried out in this study involving human participants were in accordance with the 1975 Declaration of Helsinki and its later amendments.||||
34009195|NCT06467552|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34009196|NCT01142531|||CASE_ONLY||PROSPECTIVE|||||||
34009197|NCT02507440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705913|NCT05512767|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33705914|NCT04923438|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33705915|NCT00804284|||COHORT|||||||||
33790101|NCT04038229|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33790102|NCT02881125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790103|NCT01393912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790104|NCT02438124|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790105|NCT05154942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790106|NCT02028637|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009198|NCT00881413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33930645|NCT00005883||||PREVENTION||||||||
33930646|NCT03885609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Assessors will not be exposed to the type of brush the subject is using or to the group they are assigned to (treatment or control).|Double arm, single blind prospective study|f|f|f|t
33930647|NCT04745390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930648|NCT04568876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930649|NCT01801657|||CASE_CONTROL||PROSPECTIVE|||||||
33930650|NCT04885127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33930651|NCT00553761|||COHORT||PROSPECTIVE|||||||
33930652|NCT05267145|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33930653|NCT00128752|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33930654|NCT01863901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930655|NCT05015322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were followed up and questioned by the evaluator, who was blind to the type of injection administered to the patient.|prospective,randomized controlled, single blind|f|f|f|t
33930656|NCT02349204|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33930657|NCT03254940|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The investigators will use a full factorial design to randomize participants to experimental conditions that reflect the texting intervention components: motivational messaging (self- vs expert-generated), texting frequency (daily vs weekly), reminders (one reminder v. multiple reminders), feedback type (summary score v. specific feedback) and comparison unit (to self v. to a group of people). The full factorial design is power efficient, logistically feasible (because we manipulate conditions using technology) and will allow the investigators to examine the most important main and interaction effects among components.|f|f|t|f
33930658|NCT06018142|||CASE_ONLY||PROSPECTIVE|||||||
33930659|NCT02071641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930660|NCT02808013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930661|NCT04573192|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label phase I/II study in subjects with glioblastoma at first progression.||||
34009199|NCT02078921|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33790107|NCT04836624|NA|SINGLE_GROUP||OTHER||NONE||||||
34009200|NCT01200979|||CASE_CONTROL||PROSPECTIVE|||||||
33790108|NCT04179227|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34009201|NCT06430918|||CASE_ONLY||CROSS_SECTIONAL|||||||
33790109|NCT04480814|||OTHER||PROSPECTIVE|||||||
34009202|NCT04272476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790110|NCT03860220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009203|NCT01065116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009204|NCT00519974|||COHORT||PROSPECTIVE|||||||
33790111|NCT04767828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009205|NCT04301622|||COHORT||PROSPECTIVE|||||||
34009206|NCT05375019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33790112|NCT03612804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790113|NCT00653029|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33930662|NCT00539318|||||PROSPECTIVE|||||||
33930663|NCT00111436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930664|NCT00557323|||COHORT||PROSPECTIVE|||||||
33930665|NCT00646750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930666|NCT01570452|||CASE_CONTROL||PROSPECTIVE|||||||
33930667|NCT00004916||||TREATMENT||||||||
33930668|NCT02296294|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33930669|NCT04930952|||COHORT||OTHER|||||||
33930670|NCT00565357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930671|NCT02109978|||COHORT||RETROSPECTIVE|||||||
33930672|NCT00223912|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33930673|NCT02058641|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790114|NCT02742896|||COHORT||PROSPECTIVE|||||||
33790115|NCT00363116|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34009207|NCT06061406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790116|NCT04142788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790117|NCT05652322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790118|NCT03002844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930674|NCT02864134|||COHORT||PROSPECTIVE|||||||
33930675|NCT02031627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930676|NCT06318260|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-centre, one arm clinical explorative study, with consecutive enrolment.||||
33930677|NCT03136913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930678|NCT05137275|NA|SEQUENTIAL||TREATMENT||NONE||||||
33930679|NCT02811172|||COHORT||PROSPECTIVE|||||||
34009208|NCT03645499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009209|NCT06469112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34009210|NCT05158140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34009211|NCT06232239|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33705916|NCT04002661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Study medication (flibanserin 100 mg or identically matched placebo) will be provided in a randomized fashion. Randomization will be 1:1 with a block size of 4. Each individual kit will contain three bottles of 30 tablets of study medication. Each individual bottle within the kit will be labeled sequentially, for example kit 201 will include three bottles of 30 tablets labeled 201A, 201B, 201C. Kits will be numbered consecutively in the randomized order. Once a patient is confirmed eligible to participate in the study, the site will select the lowest numbered kit that has not been assigned to a subject. Subjects will be provided with the A bottle at their first visit. The site will mark the subject's study number on the kit and document which subject received that kit number. As subjects return for interim visits, they will be provided the B and C bottles from their previously assigned kit."|"Arm 1 will receive investigational product.~Arm 2 will receive placebo."|t|t|t|f
33790119|NCT03718793|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790120|NCT03059264|||COHORT||PROSPECTIVE|||||||
33790121|NCT01128530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790122|NCT02920359|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790123|NCT02169102|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33790124|NCT01989624|||COHORT||PROSPECTIVE|||||||
33790125|NCT02454244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33790126|NCT00430300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790127|NCT05098340|||CASE_CONTROL||PROSPECTIVE|||||||
33790128|NCT05416671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093712|NCT04545372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator) Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (study group) and Group B (control group),|"study group (GA) and control group (GB) in addition to normal matched subjects (GC).The control group (GB)was treated by the disease modifying drug (interferon beta-1a) Rebif, (GA) treated by the same drug in addition to a physical therapy program of aerobic exercises for 40 min included bicycle ergometry training"|t|f|t|f
34093713|NCT00694122|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705917|NCT03949530|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33705918|NCT00227097|||DEFINED_POPULATION||PROSPECTIVE|||||||
33705919|NCT03312478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705920|NCT05626803|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705921|NCT00221403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705922|NCT02590003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705923|NCT01180985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705924|NCT02349061|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33705925|NCT03876093|||COHORT||CROSS_SECTIONAL|||||||
33705926|NCT02577978|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33790129|NCT00207532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33790130|NCT02722668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790131|NCT06067178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Pragmatic, cluster-randomized trial|f|f|t|f
33790132|NCT00680537|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33790133|NCT05451199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790134|NCT00880906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790135|NCT01070251|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33790136|NCT03651713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized||||
33790137|NCT06020651|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants will undergo the same cardiovascular assessment; only cancer therapies differ according to standard of care.||||
33790138|NCT01187394|||COHORT||PROSPECTIVE|||||||
33790139|NCT06628375|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790140|NCT01295918|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790141|NCT01896258|||||CROSS_SECTIONAL|||||||
33790142|NCT04103671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790143|NCT04617717|||COHORT||PROSPECTIVE|||||||
33790144|NCT02351180|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33790145|NCT01413113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790146|NCT02054299|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790147|NCT06031350|||CASE_CONTROL||PROSPECTIVE|||||||
33790148|NCT03355833|||OTHER||RETROSPECTIVE|||||||
33790149|NCT01670058|||COHORT||RETROSPECTIVE|||||||
33790150|NCT01145885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790151|NCT05339971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790152|NCT06343987|RANDOMIZED|PARALLEL||TREATMENT||NONE||Continuous inclusion. Randomized 2:1 - intervention group and observational group, respectively.||||
33790153|NCT02236559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790154|NCT00132717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790155|NCT00961142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790156|NCT04030559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790157|NCT02306564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33790158|NCT03532191|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The proposed intervention study will be implemented using a stepped-wedge design, which is a type of one-way crossover design in which all clinics will begin the study without the PrEP-OI intervention. Each clinic will cross over to receive the intervention one-by-one every month, with the order of clinic crossover determined at random to maximize internal validity.||||
33790159|NCT04374708|||CASE_CONTROL||PROSPECTIVE|||||||
33790160|NCT00387465|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790161|NCT04074148|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster randomized controlled trial||||
33790162|NCT04850482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two arm, parallel-group, non-blind feasibility trial with 1:1 allocation to the intervention group (immediate access to MyJourney) or waitlist control group (receives access to MyJourney after 10 weeks).||||
33790163|NCT01126632|||||PROSPECTIVE|||||||
33790164|NCT06086899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Pragmatic randomized controlled trial|f|f|f|t
33790165|NCT04898322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790166|NCT03264248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790167|NCT00006450||||TREATMENT||||||||
33790168|NCT02853474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790169|NCT00424320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33790170|NCT03610750|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|De-identified aggregate clinic will be collected|Effectiveness-Implementation Hybrid 1 Trial|f|f|t|f
33790171|NCT02794948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790172|NCT02228408|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790173|NCT01235949|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33790174|NCT04045743|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Patients assigned to either subcutaneous Bermekimab or placebo for 12 weeks ( 1:1 randomization, blind period ), then all patients are assigned to subcutaneous Bermekimab for 12 weeks ( open label period )|t|t|t|t
33790175|NCT02711982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790176|NCT05451017|RANDOMIZED|PARALLEL||OTHER||NONE||This is a single center, randomized, parallel-group, 2-arm, open-label, single-dose trial in healthy male and female volunteers aged 18-55 years to obtain data on the effect of food on the oral bioavailability of AEF0117.||||
33790177|NCT05754281|||COHORT||CROSS_SECTIONAL|||||||
33790178|NCT06133452|||OTHER||OTHER|||||||
33930680|NCT03224104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930681|NCT00668772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930682|NCT02817750|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33930683|NCT04964557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930684|NCT01041001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930685|NCT05018468|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33930686|NCT03944304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093714|NCT00256607|||COHORT||PROSPECTIVE|||||||
34093715|NCT02279251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093716|NCT04273789|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Prior to the study participants are informed about the study protocol, measurements and risks, but not about the study purpose. Debriefing is conducted verbally, as well as in written form and includes the signing of a second consent form.~The experimenters conducting the measurements and analysis is not aware of the randomization. Unblinding is planned for interim analysis after 10 datasets have been collected and at study end."||t|f|t|t
33790179|NCT01087684|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33790180|NCT05708014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and relationship partner will not know in advance which arm they are assigned and randomized to in the trial.|16-month randomized control trial with delayed, educational control condition of 8 months.|t|f|f|f
33790181|NCT01855815|||CASE_ONLY||RETROSPECTIVE|||||||
33790182|NCT01672840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790183|NCT02951117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790184|NCT00845611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930687|NCT03157336|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will implement a novel cassava processing method (wetting method, WTM) that safely removes cyanogenic compounds from cassava flour prior to human consumption in a stratified village-cluster randomized non-inferiority trial so as to compare the effectiveness of a peer-led intervention (Arm 1 = women training other women in the WTM) with that by community-health worker specialists (Arm 2= specialist led intervention arm)||||
33930688|NCT00829062|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33930689|NCT03382262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930690|NCT02705222|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33930691|NCT03869164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930692|NCT00439725|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930693|NCT00929136|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33930694|NCT01455506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930695|NCT05616845|NA|SINGLE_GROUP||SCREENING||NONE||||||
33930696|NCT01313039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930697|NCT02736097|||COHORT||PROSPECTIVE|||||||
33930698|NCT05455307|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|single group without control||||
33930699|NCT02596828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930700|NCT00647907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930701|NCT00914238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093717|NCT03565653|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34093718|NCT06139640|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34093719|NCT06334900|||COHORT||RETROSPECTIVE|||||||
33930702|NCT02219737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930703|NCT02915289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930704|NCT00236613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930705|NCT02748525|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930706|NCT05171855|NA|SINGLE_GROUP||TREATMENT||NONE||Open label treatment with weekly Lonapegsomatropin||||
33930707|NCT01620593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930708|NCT01652170|||COHORT||PROSPECTIVE|||||||
33930709|NCT01332695|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33930710|NCT01176890|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33930711|NCT04602819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930712|NCT03362489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930713|NCT04822441|||OTHER||PROSPECTIVE|||||||
33930714|NCT02883426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930715|NCT01603706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930716|NCT02918539|||OTHER||PROSPECTIVE|||||||
33930717|NCT00493610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930718|NCT03809247|||OTHER||RETROSPECTIVE|||||||
33930719|NCT02392468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930720|NCT00961558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930721|NCT01229956|||CASE_ONLY||RETROSPECTIVE|||||||
33930722|NCT03713827|RANDOMIZED|FACTORIAL||TREATMENT||NONE||double blinded, split mouth, randomized clinical trial||||
33930723|NCT00610207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930724|NCT04148768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be aware of the treatment groups given to them.|Intervention SWD \& IFT: 4 SESSIONS OF TREATMENT and measurement of balance|t|f|f|f
34009212|NCT04802408|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|We plan to provide the number and proportion of the primary outcome of participants who have completed 5 days of follow up from randomization, by treatment arms to an independent biostatistician, as well as participant accrual rate, and withdrawals from study. A formal interim analysis (as detailed in the analysis section) will be completed when 67% of final sample size reaches day 5 and the results will be provided masked to the independent biostatistician, who will decide whether to halt the trial or not.|This is a prospective, randomized, controlled, 2x2 factorial, phase 2/phase 3 trial to compare the impact of a 4-day intervention of nasal washes with 1% baby shampoo solution and/or oropharyngeal gargles with Listerine Antiseptic® solution compared to that of nasal washes with buffered saline solution and/or oropharyngeal rinses with saline solution on naso-oropharyngeal SARS-CoV-2 viral load in a population of adults (aged 18-65 years) with SARS-CoV-2 infection diagnosed within 5 days who are asymptomatic or mildly symptomatic for COVID-19 disease.|f|f|f|t
34009213|NCT00618137|||COHORT||PROSPECTIVE|||||||
34009214|NCT00444236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093720|NCT03882749|||COHORT||PROSPECTIVE|||||||
34093721|NCT02691611|||CASE_CONTROL||PROSPECTIVE|||||||
33790185|NCT05015517|RANDOMIZED|PARALLEL||OTHER||DOUBLE|computer-generated sequence. Concealment will be achieved using opaque envelopes. All data will be collected blindly and the authors will perform the blocks without interference in data collection.||t|f|t|f
33790186|NCT00931593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790187|NCT05126719|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study consists of two stages. Part A of this study is a single arm IIa clinical study and Part B is a parallel IIb study.||||
33790188|NCT02089243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790189|NCT04237896|||COHORT||PROSPECTIVE|||||||
33790190|NCT02082405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790191|NCT06628895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790192|NCT03610997|NA|SINGLE_GROUP||TREATMENT||NONE||Photorefractive Keratectomy||||
33790193|NCT00105820|NON_RANDOMIZED|PARALLEL||||NONE||||||
33790194|NCT03254394|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|At enrollment, each patient will be assigned a study number, which will match a previously prepared computer-generated list of randomization numbers to determine the interventions. The participants and all other study personnel will be blinded to the treatment allocation.|Tolerability phase: prospective, open-label Efficacy pilot study: randomized, parallel, double blind, placebo controlled|t|t|t|t
33790195|NCT05671198|||COHORT||PROSPECTIVE|||||||
33790196|NCT00640029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790197|NCT05395013|||COHORT||RETROSPECTIVE|||||||
33790198|NCT05991986|||OTHER||OTHER|||||||
33790199|NCT05076656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33790200|NCT06020131|RANDOMIZED|PARALLEL||PREVENTION||NONE||The sample of study consist of patients with chronic ankle instability who gets 27 and less point from Cumberland Ankle Instability Tool. The study was conducted between November 2022 - January 2023 in Noi Physio Pilates Studio in İstanbul.||||
33790201|NCT00412230|||CASE_CONTROL||RETROSPECTIVE|||||||
33790202|NCT00178230|||COHORT||PROSPECTIVE|||||||
33790203|NCT00909935|||COHORT||PROSPECTIVE|||||||
33790204|NCT02012543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790205|NCT04538248|||CASE_CONTROL||PROSPECTIVE|||||||
33790206|NCT05784688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33790207|NCT01712594|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790208|NCT06429670|||COHORT||RETROSPECTIVE|||||||
33790209|NCT05005819|NA|SINGLE_GROUP||OTHER||NONE||||||
33790210|NCT01806714|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33790211|NCT01689519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790212|NCT05095675|||COHORT||PROSPECTIVE|||||||
33790213|NCT00195897|||COHORT||PROSPECTIVE|||||||
33790214|NCT05298111|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The respondents consumed Formulation 3 (A) and control (B) with study breakfast based on randomly assigned treatment sequences (AB, BA). Each visit was separated with three days washout period and lasted about 3 hour (starting around 8 am and finishing at approximately 11 am).||||
33790215|NCT06223529|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The person collecting data on quality of life and arm function in participants' homes will be blinded to whether pre- or post intervention|Single case series pre-/post EEG with repeated upper limb measures||||
33790216|NCT03223090|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33790217|NCT02943993|||COHORT||PROSPECTIVE|||||||
33790218|NCT00095004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790219|NCT05380505|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||The intervention is exposure to Facebook food ads that are either race congruent or race incongruent, and that have varying numbers of likes.|t|f|t|f
33790220|NCT03835572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be assigned a study ID such that the investigators cannot determine the identify of the participants or which arm of the study each participant is in.|Participants will be assigned to receive the online educational course or materials on sleep hygiene for six weeks.|f|f|t|f
33790221|NCT04290585|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33790222|NCT03743246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790223|NCT02168335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790224|NCT03478696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a phase 4 double blind study, which will use a triple dummy design for dosing.|This is a parallel group study. Eligible subjects will be randomized in a ratio of 1:1 to receive either FF/UMEC /VI single inhaler triple therapy or multiple inhaler triple combination therapy (budesonide/formoterol plus tiotropium) during the treatment period.|t|f|t|f
33790225|NCT00237107|NA|SINGLE_GROUP||||NONE||||||
33790226|NCT03182036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790227|NCT02572024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33790228|NCT04034901|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33930725|NCT04833790|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The study participants are private health care providers in India who treat child diarrhea. Providers will be masked to which type of patient they are assigned to but not whether they receive free treatment for child diarrhea. Outcomes will assessed by anonymous standardized patients and these will be blind to whether the provider received free treatment for child diarrhea.|The two interventions are patient type (4 types) and free distribution of treatment for child diarrhea (2 groups). These will be cross-randomized creating 8 study arms.|t|t|f|t
33930726|NCT00678236|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33930727|NCT00703430|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33930728|NCT01608529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930729|NCT03525314|||COHORT||PROSPECTIVE|||||||
33790229|NCT05026034|||COHORT||PROSPECTIVE|||||||
33790230|NCT01679262|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33790231|NCT00130013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790232|NCT02967016|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790233|NCT00117988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790234|NCT05053009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple|Parallel assignment|t|f|t|t
33790235|NCT03920371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790236|NCT03265210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants will be blind to who is receiving Relief and who is not.||f|f|f|t
33790237|NCT04422535|||COHORT||RETROSPECTIVE|||||||
33790238|NCT05612659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33790239|NCT05253339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the patient is blinded.|When administering cefoxitin, the standard administration method and the target concentration control injection method are randomly assigned 1:1.|t|f|f|f
33790240|NCT00300040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790241|NCT00444613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790242|NCT03646006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790243|NCT02138331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790244|NCT02139449|||COHORT||PROSPECTIVE|||||||
34009215|NCT04553913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking. The PACU nurse will know the patient has the device; the only thing that he/she will not know is when the patient pushed the button to turn off the device.|All participants will have the device placed in the recovery room to determine resolution of regional anesthetics.||||
34009216|NCT00097786|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34009217|NCT03645382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009218|NCT05393128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009219|NCT06402344|||OTHER||CROSS_SECTIONAL|||||||
34009220|NCT03449199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009221|NCT03122717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009222|NCT00332111|||||PROSPECTIVE|||||||
34009223|NCT05353036|||COHORT||PROSPECTIVE|||||||
34009224|NCT02216799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009225|NCT02914769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009226|NCT04768296|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009227|NCT04660487|||CASE_ONLY||PROSPECTIVE|||||||
34009228|NCT03512912|||COHORT||PROSPECTIVE|||||||
34009229|NCT00933881|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34009230|NCT04030520|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790245|NCT03949686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009231|NCT05844631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009232|NCT00362817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009233|NCT02622659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009234|NCT01999426|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33790246|NCT04548011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34009235|NCT01567826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34009236|NCT04157517|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34009237|NCT02450877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009238|NCT00920894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009239|NCT02842463|||COHORT||PROSPECTIVE|||||||
34009240|NCT03887416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Type of study: Randomized, multicentric, placebo-controlled, single-blind pilot study.~Primary Objective: To investigate the effect of the addition of 10 mg daily of dapagliflozin to the treatment of diabetic patients compared to the addition of placebo on the change in nighttime blood pressure (measured by ABPM) over 12 weeks among patients with albuminuria levels ≥ 30 and \< 3000 mg/g creatinine and estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2."|t|f|f|f
34009241|NCT04944082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009242|NCT02801435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009243|NCT01523587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009244|NCT05125562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009245|NCT05818982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009246|NCT02244853|||COHORT||PROSPECTIVE|||||||
34009247|NCT06615700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009248|NCT06183450|||COHORT||PROSPECTIVE|||||||
34009249|NCT02617082|||COHORT||PROSPECTIVE|||||||
34009250|NCT01253317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009251|NCT01637649|||||CROSS_SECTIONAL|||||||
34009252|NCT06193369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009253|NCT01849016|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930730|NCT03892434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930731|NCT05703113|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33930732|NCT04713670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930733|NCT02774044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930734|NCT00493155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930735|NCT04829461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930736|NCT06396988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Split-mouth study|t|t|t|t
33930737|NCT02756546|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33930738|NCT00003838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790247|NCT00750750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930739|NCT05029336|NA|SINGLE_GROUP||TREATMENT||NONE||open label single arm pilot study||||
33930740|NCT00023205|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33930741|NCT01494025|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33930742|NCT04739241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930743|NCT03437993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705927|NCT05799586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers who perform the outcome measurement and those researchers who conduct data analysis will be blinded to group allocation.|"Two-arm parallel assignment involves two groups of participants. In this study, one group will receive Traditional Chinese Medicine health preservation for depression, and the other group will receive the waitlist control. Thus, during the trial, participants in one group receive Traditional Chinese Medicine health preservation in parallel to participants in the waitlist control group."|f|f|f|t
33705928|NCT02851095|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33705929|NCT04171440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705930|NCT04998110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician will be blinded.||f|f|f|t
33705931|NCT01949831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33705932|NCT06101758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705933|NCT02021331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705934|NCT01651910|||COHORT||PROSPECTIVE|||||||
33705935|NCT02782728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705936|NCT05496478|||OTHER||RETROSPECTIVE|||||||
33705937|NCT04544397|||COHORT||OTHER|||||||
33705938|NCT03879278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33705939|NCT04523220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790248|NCT03460327|||CASE_ONLY||PROSPECTIVE|||||||
33790249|NCT05204342|||COHORT||RETROSPECTIVE|||||||
33790250|NCT04643405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790251|NCT02023554|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790252|NCT01959412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33930744|NCT03795636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930745|NCT00644124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930746|NCT02005510|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Eligibility is assessed weekly over 2.5 years. Study participants are assigned to the control arm or to the intervention arm. After follow-up is complete, control arm participants are re-assessed for eligibility and re-randomization.|f|f|t|f
33930747|NCT01353183|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33930748|NCT01285336||||HEALTH_SERVICES_RESEARCH||||||||
33930749|NCT00215592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790253|NCT04593797|||OTHER||PROSPECTIVE|||||||
33930750|NCT03945201|RANDOMIZED|PARALLEL||OTHER||SINGLE|Consent and enrollment process does not mention virtual reality to maintain blinding between control and intervention arms.||t|f|f|f
33930751|NCT00329394|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33790254|NCT05037266|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790255|NCT05936892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790256|NCT02439372|||COHORT||PROSPECTIVE|||||||
33790257|NCT00565708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790258|NCT01455051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790259|NCT05629364|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33790260|NCT00890786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790261|NCT02120313|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33790262|NCT05823181|||COHORT||PROSPECTIVE|||||||
33790263|NCT03831529|||COHORT||RETROSPECTIVE|||||||
33790264|NCT02709616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790265|NCT01179243|||CASE_ONLY||CROSS_SECTIONAL|||||||
33790266|NCT00271167|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33790267|NCT01703130|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33790268|NCT00479141|RANDOMIZED|PARALLEL||||NONE||||||
33790269|NCT03376399|||COHORT||PROSPECTIVE|||||||
33790270|NCT02888535|||COHORT||PROSPECTIVE|||||||
33790271|NCT02931435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790272|NCT04330469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930752|NCT01762527|NA|SINGLE_GROUP||TREATMENT||NONE||Daily adaptation of radiotherapy||||
33930753|NCT01235338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930754|NCT00427791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790273|NCT03172533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded study|randomized, placebo-controlled Phase IIa clinical trial in patients with anorexia nervosa|t|t|t|t
33790274|NCT00646451|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33790275|NCT03904199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33705940|NCT05000463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33705941|NCT03018769|||||PROSPECTIVE|||||||
33705942|NCT00905411|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33790276|NCT04582344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-Blind|Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial|t|t|t|f
33790277|NCT02509780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790278|NCT01425983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790279|NCT02993471|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33705943|NCT05909644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705944|NCT04312048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33705945|NCT04988178|||COHORT||RETROSPECTIVE|||||||
33705946|NCT04811781|||COHORT||PROSPECTIVE|||||||
33705947|NCT00150748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705948|NCT06139965|||COHORT||PROSPECTIVE|||||||
33705949|NCT04453722|||COHORT||PROSPECTIVE|||||||
33705950|NCT06209177|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1, participants are randomized to receive either ARO-CFB or placebo. Participants, care providers, investigator and outcomes assessors are all blinded to treatment assignment. Part 2 in patients with IgAN is open-label and there is no masking.||t|t|t|t
33705951|NCT00261144|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33705952|NCT02267083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705953|NCT04524897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705954|NCT05005793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705955|NCT05915078|||COHORT||PROSPECTIVE|||||||
33705956|NCT00261807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705957|NCT01334164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930755|NCT02795611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33705958|NCT00363883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705959|NCT03642457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient, surgeon, and anesthesiologist in the case will be blinded.||t|t|t|t
33705960|NCT03974425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705961|NCT01393847|||||PROSPECTIVE|||||||
33930756|NCT01498536|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33930757|NCT03657589|||COHORT||CROSS_SECTIONAL|||||||
33930758|NCT00863941|RANDOMIZED|CROSSOVER||||NONE||||||
33930759|NCT05299138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outside evaluators will remain blind to each condition throughout the study.|The Intervention group will start with assigning a Case Manager and begin Marriage and Relationship Enhancement Skills (MRES) class weekly and meet with their Case Manager as needed.|f|f|f|t
33930760|NCT01747824|||COHORT||PROSPECTIVE|||||||
33930761|NCT02377271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930762|NCT04399824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930763|NCT04057040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part 1 open label, Part 2 blinded, Part 3 open label|"Part 1:~28 week open-label dose escalation phase in which each subject's dose of PTG-300 is titrated to achieve a hematocrit \<45%.~Part 2:~12-week blinded randomized withdrawal phase. Subjects are randomized 1:1 to continue PTG-300 or to receive placebo.~Part 3:~Up to 3 year open label extension."|t|f|t|t
33930764|NCT01886755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930765|NCT04597515|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33930766|NCT03478462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930767|NCT05899894|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients will act as their own control. They will be randomised on day 1 to receive either standard dose or low dose morphine and on day two they will receive the alternate dose. Ventilation levels will be titrated as per a titration protocol.||||
33930768|NCT01352013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930769|NCT05581355|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study method adopts the research design of experimental randomized controlled trials. The persons receiving the intervention of abdominal breathing training are in the experimental group, while those who do not receive it are in the control group.||||
33930770|NCT00044213|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33930771|NCT05263726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33930772|NCT04752917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unblinded|Randomised trial of control and intervention groups|t|f|f|f
33930773|NCT00531895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930774|NCT02480803|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial||||
33930775|NCT04912661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33930776|NCT03596970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930777|NCT00379886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930778|NCT01067313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930779|NCT02422394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930780|NCT04955301|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33705962|NCT00003331||||TREATMENT||||||||
33705963|NCT01710969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33705964|NCT01036893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705965|NCT00060008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33705966|NCT05045131|NA|SINGLE_GROUP||TREATMENT||NONE||The PeAF - Box study is observational and investigates single procedure PVI+PWI. Adding PWI to PVI substantially increases the amount of ablation close to the esophagus raising concerns of the risk of esophageal thermal injury. Accordingly, the study includes a formal analysis of the safety of PVI+PWI in terms of risk of esophageal thermal injury. The study includes 24 participants based on power calculations showing that at least 23 participants were required to illustrate a non-inferior risk of inducing esophageal thermal injury by PVI+PWI compared to relevant recently published data.||||
33705967|NCT04911881|NA|SEQUENTIAL||TREATMENT||NONE||||||
33705968|NCT02386735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33705969|NCT01136603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33705970|NCT04970355|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33930781|NCT04282460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The medical treatment of participants will be given by a doctor who does not know the study group of the patient. The investigator of the primary outcome and secondary outcome will also be unaware of the grouping of the patient. One psychiatrist blind of grouping will ask parents about the ADHD Hyperactivity/Impulsivity symptom of their children and rate it with SNAP-IV Hyperactivity/Impulsivity score. Another Chinese traditional medical doctor blind of grouping will evaluate the severity of traditional Chinese medicine symptoms of children and rate it with TCM symptom scale.|The present study will be carried out using a parallel randomized study design. Each participant will be randomly assigned either to the Baduanjin intervention or to the regular physical exercise control group.|f|f|t|t
33930782|NCT00331084|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33930783|NCT04509362|||COHORT||PROSPECTIVE|||||||
34009254|NCT00743509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930784|NCT03565991|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|"Single arm study with two cohorts enrolled in parallel.~* Cohort 1 will enroll patients with locally advanced or metastatic solid tumors with one or more defects in the BRCA1 or BRCA2 genes~* Cohort 2 will enroll patients with locally advanced or metastatic solid tumors with one or more defects in the ATM gene"||||
33930785|NCT01651312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33930786|NCT00074464|||||CROSS_SECTIONAL|||||||
33930787|NCT03777397|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33930788|NCT05109611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Identical labeled nasal spray bottles||t|t|t|t
33930789|NCT03945448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930790|NCT06265467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|it is a double blinded study, both the outcome assessor and statistician will be blinded|Parallel Assignment|f|f|t|t
34093722|NCT04040855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Closed envelopes|Patients were blindly randomized to intervention or control group in 2011. This study is a follow-up with additional data collection for the included patient, a total of 369.|t|t|t|f
34093723|NCT01926600|||CASE_CONTROL||PROSPECTIVE|||||||
34093724|NCT00012246|RANDOMIZED|||TREATMENT||||||||
34093725|NCT02416141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093726|NCT05979597|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will not know which study group he is in. The anesthetist, who will perform the regional block, will give the block to be applied in a sealed envelope by an assistant staff outside the study, and at the same time, the patient will not know which block has been made. The anesthesiologist who made the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another investigator blinded to the study.||t|t|t|f
33930791|NCT04439812|||COHORT||RETROSPECTIVE|||||||
34093727|NCT00422435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093728|NCT02471742|||COHORT||PROSPECTIVE|||||||
34093729|NCT01149252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093730|NCT03107000|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two-arm, parallel group comparison||||
33930792|NCT03557736|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33930793|NCT03460470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930794|NCT03073382|||COHORT||RETROSPECTIVE|||||||
33930795|NCT02667392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel: participants are assigned to one of two or more groups in parallel for the duration of the study.|f|f|f|t
33930796|NCT06212388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930797|NCT02857894|||COHORT||PROSPECTIVE|||||||
33930798|NCT04059874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, open, single-arm, exploratory phase Ib trial||||
33930799|NCT06093568|||CASE_CROSSOVER||PROSPECTIVE|||||||
33930800|NCT06032572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930801|NCT05211245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930802|NCT02619006|||COHORT||PROSPECTIVE|||||||
33930803|NCT05561608|||COHORT||PROSPECTIVE|||||||
33930804|NCT04599972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930805|NCT01603979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093731|NCT05791591|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33930806|NCT01794546|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33930807|NCT04761952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930808|NCT02656862|||CASE_ONLY||CROSS_SECTIONAL|||||||
33930809|NCT03746314|||CASE_ONLY||CROSS_SECTIONAL|||||||
33930810|NCT00173589|||CASE_CONTROL||OTHER|||||||
33930811|NCT05685394|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, controlled trial||||
33930812|NCT00221663|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33930813|NCT03647748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients randomly assigned to either the active 532nm treatment group, or the sham device (placebo) group using a modified device rigged to not treat patients.|t|t|f|f
33930814|NCT03121482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930815|NCT05326074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33930816|NCT02123394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930817|NCT01148576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930818|NCT03512275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790280|NCT04454892|||COHORT||PROSPECTIVE|||||||
33790281|NCT01320436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790282|NCT04075357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790283|NCT00345202|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33930819|NCT01436357|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33930820|NCT00654420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009255|NCT04530279|||COHORT||RETROSPECTIVE|||||||
34009256|NCT04424849|||COHORT||RETROSPECTIVE|||||||
34009257|NCT02577224|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33705971|NCT00941005|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33705972|NCT04568733|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33705973|NCT01205711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33705974|NCT01261910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33705975|NCT05431192|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participants will not be masked to intervention allocation. The PI, the co-investigators, and personnel responsible for data management and analysis will be blinded to participants' exposure status.~Unblinded personnel will include the PD, the RA, and the MT instructors. Blinding the PD would be impossible given that she will be responsible for randomization and AEs monitoring.~The RA will be responsible for data collection and will not be blinded. We note, however, that study participants will independently perform all assessments via computer interface with no RA involvement.~The mindfulness instructors will be aware of the allocation status of the participants but will remain masked to the study hypotheses."||f|t|t|t
33705976|NCT05369325|||COHORT||PROSPECTIVE|||||||
33705977|NCT03750617|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33705978|NCT02496585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705979|NCT02975336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705980|NCT04172142|||CASE_CONTROL||PROSPECTIVE|||||||
33705981|NCT03005600|||COHORT||PROSPECTIVE|||||||
33705982|NCT03445208|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33705983|NCT04274413|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaporimeter TEWL probes, model RG-1||||
33790284|NCT06632015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790285|NCT02796976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33790286|NCT04848649|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801749|NCT03844919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible subjects will be randomly assigned to receive one of the two treatment regimens in a 1:1 ratio. Dr. Nettel-Aguirre will generate the sequence with random sized blocks of 2,4 and 6 and use the REDCap randomization module for recruiters to access the allocation for the subjects. The algorithm will stratify each by sex and age group (6-10, 11-14, 15-18 years). Dr. Zewdie will set up the rTMS accordingly for active or sham delivery. Participants and their parents will be blind to group status regarding sham vs. active rTMS. Dr. Wilcox, and all raters responsible for clinical evaluation under Dr. Wilcox's supervision, will also be blinded to group status.|Children (N = 50, 6-18 years) with TS will be randomized to either a (1) rTMS+CBIT arm, or a (2) sham rTMS+CBIT arm.|t|f|f|t
33801750|NCT02222493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801751|NCT04691024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930821|NCT04296604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930822|NCT00519025|||COHORT||RETROSPECTIVE|||||||
33930823|NCT04857736|||COHORT||PROSPECTIVE|||||||
33930824|NCT03633513|||CASE_CONTROL||PROSPECTIVE|||||||
33930825|NCT03945656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930826|NCT00862394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930827|NCT03454724|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 Randomization of Study Device and Control||||
33930828|NCT06445010|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33930829|NCT03903913|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single center, open label, Phase IIa, sequential, multiple-ascending dose study||||
33930830|NCT03679988|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33930831|NCT04180917|||COHORT||OTHER|||||||
33930832|NCT03169114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors - Histopathologists will be masked in terms of allocation of the study participants, when reporting histology specimen of appendix removed.|Non-Inferiority Randomized Controlled Trial|f|f|f|t
33930833|NCT04827719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705984|NCT04745130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705985|NCT02367937|NA|SINGLE_GROUP||||NONE||||||
33705986|NCT05197556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33705987|NCT05251987|||COHORT||PROSPECTIVE|||||||
33705988|NCT00672932|RANDOMIZED|PARALLEL||||NONE||||||
33705989|NCT01382095|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930834|NCT03382327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009258|NCT05021237|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Therapeutic Study||||
34009259|NCT06185387|||OTHER||PROSPECTIVE|||||||
34009260|NCT06612229|NA|SINGLE_GROUP||SCREENING||NONE||||||
34009261|NCT03968731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009262|NCT02334241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009263|NCT03718117|||COHORT||PROSPECTIVE|||||||
34009264|NCT01838382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009265|NCT01445418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009266|NCT04877587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705990|NCT00714883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33705991|NCT02763462|||CASE_ONLY||PROSPECTIVE|||||||
33705992|NCT05289791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33705993|NCT01959074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33705994|NCT00202800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33705995|NCT01696084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705996|NCT03794271|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33705997|NCT00004779||||TREATMENT||||||||
33705998|NCT01987297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33705999|NCT02207244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706000|NCT00473278|||COHORT||PROSPECTIVE|||||||
33706001|NCT01100697|||COHORT||RETROSPECTIVE|||||||
33706002|NCT03502083|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33706003|NCT00150202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706004|NCT03568734|NA|SINGLE_GROUP||PREVENTION||NONE||12 mothers participating in the study (due for caesarean section) are screened for transmissible diseases. A transplant sample is gathered from the mother, processed, and given to the infant at delivery by caesarean section.||||
33706005|NCT04454294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706006|NCT01591759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790287|NCT05515042|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants, investigators, and site staff (except for site pharmacists) will be blinded to participant treatment group assignment for the full duration of the study. Study product assignments are accessible to the site pharmacists and unblinded monitors who are required to know this information in order to ensure proper trial conduct. Any discussion of study product assignment between pharmacy staff and any other staff is prohibited. The DSMB members may be unblinded on request to treatment assignment, in order to conduct review of trial safety data.|This is a multicenter, randomized, observer blind clinical trial. A total of 750 evaluable HIV-infected (660) and HIV-uninfected (90) adult participants meeting all entry criteria (all inclusion and no exclusion criteria) will be enrolled in 3 treatment strategies in 3 participant groups dependent on prior vaccination with a single dose Janssen (Group 1), 2 doses of Pfizer (Group 2) or no prior COVID-19 vaccination with evidence of prior SARS-CoV-2 infection (Group 3). A total of 300 participants per group will be enrolled in Groups 1 and 2 (255 HIV-infected and 45 HIV-uninfected per group), and 150 HIV-infected, unvaccinated participants in Group 3. Each treatment regimen (Vaccine Arm: A, B or C) will evaluate 250 participants. Groups 1 and 2 will enrol 85 HIV-infected and 15 HIV-uninfected per vaccine arm.|t|f|t|f
33706007|NCT05539612|||OTHER||PROSPECTIVE|||||||
33706008|NCT00837057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706009|NCT01964430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706010|NCT06024460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The interventional study model in this study is a pragmatic, multi-centered, randomized controlled, parallel-grouped design. This means that the study will involve multiple centers, random assignment of participants into different treatment groups (non-pharmacological treatment arm and pharmacological treatment arm), and a parallel-grouped comparison of the effectiveness of the interventions. The study aims to assess the real-world effectiveness of the treatment strategies in a pragmatic setting, allowing flexibility in treatment decisions based on clinical judgment.|f|f|f|t
33790288|NCT02321306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790289|NCT00786448|||COHORT||PROSPECTIVE|||||||
33801752|NCT00709098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801753|NCT02332577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801754|NCT03752957|||COHORT||PROSPECTIVE|||||||
33801755|NCT03050957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009267|NCT04412057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Participant, Investigator)||t|f|t|f
34009268|NCT04657276|||OTHER||PROSPECTIVE|||||||
34009269|NCT00518622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009270|NCT00377078|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34009271|NCT01885416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34009272|NCT02700555|||COHORT||PROSPECTIVE|||||||
34009273|NCT01253395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009274|NCT02096484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009275|NCT04213209|||COHORT||PROSPECTIVE|||||||
34009276|NCT00468793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009277|NCT06467565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706011|NCT03692247|NA|SINGLE_GROUP||OTHER||NONE||This is a cohort study of one group of 60 healthy volunteers without a diagnosis of neuropathy or chronic pain.||||
33706012|NCT04563702|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Open-label, repeat dose, dose ranging||||
33706013|NCT03255798|NA|SINGLE_GROUP||TREATMENT||NONE|IOP outcome is masked|G2 and G3||||
33706014|NCT04176666|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention and control group||||
33706015|NCT01755221|||COHORT||PROSPECTIVE|||||||
33706016|NCT02927756|||COHORT||RETROSPECTIVE|||||||
33706017|NCT04719286|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706018|NCT00225069|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33706019|NCT02687633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706020|NCT05269498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009278|NCT03172052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34009279|NCT03663790|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33930835|NCT03389269|||CASE_CONTROL||PROSPECTIVE|||||||
33930836|NCT02814136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33930837|NCT03230357|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33930838|NCT02377908|||||CROSS_SECTIONAL|||||||
33930839|NCT02428075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930840|NCT05479006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The sequence of the stimulations will be randomized (generated in RedCap) and double-blinded (assessor and participants).|This sham-controlled cross-over study design will include four visits: 1) anodal stimulation targeting the ipsilesional hemisphere, 2) cathodal one at the contralesional hemisphere, 3) bilateral stimulation with anodal on the ipsilesional hemisphere and cathodal on the contralesional hemisphere and 4) a sham stimulation visit. After each intervention, there will be at least 2 weeks wash-out period before participants receive the next intervention and assessments.|t|f|f|t
33930841|NCT00588757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930842|NCT03964493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||TNP-2092 300 mg intravenous every 12 hours vancomycin 1 g intravenous every 12 hours|t|t|t|t
33930843|NCT04716049|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33930844|NCT04431804|||CASE_ONLY||PROSPECTIVE|||||||
33930845|NCT03135639|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a double-blind study, meaning that neither the participant nor the experimenter knows what kind of stimulation the participant is receiving. An unblinded monitor (separate from the staff that interacts with the participant) is responsible for creating the stimulation codes that run each session and for ensuring that these codes worked correctly.|Each participant will receive sham stimulation or stimulation at their individual alpha frequency (8-12 Hz) during a study visit. The order is randomized (i.e., half of participants will receive sham stimulation during the first stimulation session and half will receive sham stimulation during the second stimulation session).|t|f|t|f
33930846|NCT02945839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930847|NCT02128204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706021|NCT01223794|||COHORT||RETROSPECTIVE|||||||
33706022|NCT03830424|||CASE_CONTROL||PROSPECTIVE|||||||
33706023|NCT05473598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706024|NCT03792191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009280|NCT02948725|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706025|NCT00939770||SEQUENTIAL||TREATMENT||NONE||||||
33706026|NCT02983825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930848|NCT03102463|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33930849|NCT01529450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930850|NCT06087731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930851|NCT02187224|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33930852|NCT03032250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930853|NCT00422240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930854|NCT04154397|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33930855|NCT02451865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930856|NCT02948504|||COHORT||PROSPECTIVE|||||||
33930857|NCT03813199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009281|NCT00141661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009282|NCT01139684|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34009283|NCT00180076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009284|NCT03275584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009285|NCT06188507|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Click here to enter text.||t|f|t|f
34009286|NCT01303237|||COHORT||PROSPECTIVE|||||||
33706027|NCT03038932|||CASE_CONTROL||PROSPECTIVE|||||||
34009287|NCT03444441|||COHORT||PROSPECTIVE|||||||
34009288|NCT06369649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Single blinding (participants) will be used in the research and the researchers will not have information about the other group.~While applying both scales, care will be taken to ensure that children, parents and observers do not see each other's evaluations and are not influenced by each other. In this way, the child, parent and independent observer will score blindly before and after the procedure."||t|f|f|f
34009289|NCT03623620|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34009290|NCT02930629|||COHORT||PROSPECTIVE|||||||
33706028|NCT03249675|||COHORT||PROSPECTIVE|||||||
34093732|NCT05967559|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|The aim of the research was to reduce the bias by using a single-blind technique.|The students who were informed about the research, and after obtaining their individual consent, the Chemotherapy Symptom Management Knowledge Test , the Marmara Critical Thinking Dispositions Scale , and the Self-Directed Learning Skills Scale were administered using an online questionnaire. Chemotherapy symptom management training was conducted online for six weeks, one hour per week, for experiment and control groups. The research began with the control group to minimize the interaction between the students in the experiment and control groups. Then the experiment group practices were carried out after the control group's program was completed.|t|f|f|f
34093733|NCT04995159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093734|NCT06469125|||CASE_CONTROL||PROSPECTIVE|||||||
34093735|NCT04561453|||CASE_ONLY||PROSPECTIVE|||||||
34093736|NCT00514527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093737|NCT06100445|||OTHER||OTHER|||||||
33706029|NCT04315909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34093738|NCT04570800|||COHORT||PROSPECTIVE|||||||
34093739|NCT03718000|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093740|NCT00999076|||CASE_ONLY||PROSPECTIVE|||||||
34093741|NCT02730130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093742|NCT03606070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093743|NCT00369018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706030|NCT00533598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706031|NCT00170495|||COHORT||PROSPECTIVE|||||||
33706032|NCT01292811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706033|NCT03693300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706034|NCT01099553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706035|NCT00282984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706036|NCT01844440|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706037|NCT01897844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093744|NCT00368485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706038|NCT06446011|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33706039|NCT01410422|||CASE_CONTROL||PROSPECTIVE|||||||
33706040|NCT02400333|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33706041|NCT01084083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930858|NCT03418220|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34009291|NCT05814432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical assessments will take place at the start of the study (patient enrollment), day 3, day 7, day 14 (survival status) and week 10. During the study visits, some data and tests will be collected such as: maximum temperature, presence of dyspnea, respiratory rate, need for mechanical ventilation, systolic blood pressure, World Health Organization performance status, Karnofsky scale, Glasgow coma scale, biochemical laboratory tests, documentation of HIV infection, CD4 and CD8 counts, pregnancy test, urine test for Histoplasma antigen, blood sample for Histoplasma PCR. A 10-week visit will be carried out to also determine survival status, including whether or not there was a need for additional courses of amphotericin B, whether or not the patient had immune reconstitution syndrome, whether they had any serious adverse events, and finally, the DOOR score.||||
34009292|NCT05944250|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intra-patient randomization of wound pairs into control wounds vs matrix treated wounds, followed by an open-label (extension) phase without randomization||||
34009293|NCT01702077|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34009294|NCT03297567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigations of the level of physical activity, functional outcome, peripheral muscle strength and clinical complications will be performed by a blind investigator. Data analysis will be performed by a blind investigator in the control and intervention groups.|The patients will be randomized into two groups: intervention and control. The intervention group will receive verbal guidance and a booklet developed by the authors on the deleterious effects of hospitalization and the importance of staying active during hospital admission on the day they are included in the study. The control group will not receive any type of intervention, nor even verbal guidance.|f|f|t|t
34009295|NCT05735002|||COHORT||PROSPECTIVE|||||||
34009296|NCT03717493|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Assessors were blinded with regard to study condition|Randomized controlled trial; group x time|f|f|f|t
34009297|NCT01579760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009298|NCT02137694|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009299|NCT05709652|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34009300|NCT02427984|||COHORT||PROSPECTIVE|||||||
33801756|NCT03803748|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind|This is a national, prospective, multicenter, comparative, randomized, double-blinded non-inferiority study performed in two parallel groups.|t|f|t|f
34009301|NCT01946984|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34009302|NCT05132725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009303|NCT02012452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009304|NCT00251914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009305|NCT03901391|||COHORT||PROSPECTIVE|||||||
34009306|NCT01551147|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34009307|NCT01216657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009308|NCT06601621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009309|NCT04635332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In the sub parishes, women group leaders and participants will be blinded about the study arms.|The intervention will be delivered through institutional religious women groups. A collaboration has been established with Our Lady of Africa Parish, Mbuya. Mbuya Catholic Parish has six sub parishes. These sub parishes will act as the clusters and will be the unit of randomization. The six sub parishes will be randomized to treatment and control arms. The six sub parishes (clusters) will be listed alphabetically. A cluster randomization with a 1:1 allocation will then be applied to randomize the sub parishes to either the treatment or control arm.|t|f|f|f
34009310|NCT06364254|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34009311|NCT03489226|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Supplement and placebo capsules with identical appearance|4 arm crossover trial|t|f|t|f
34009312|NCT05746819|||CASE_CONTROL||PROSPECTIVE|||||||
34009313|NCT02079675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009314|NCT05419349|||COHORT||RETROSPECTIVE|||||||
34009315|NCT00003130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009316|NCT00004150|RANDOMIZED|||TREATMENT||||||||
34009317|NCT00680069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34093745|NCT01937442|NA|SINGLE_GROUP||OTHER||NONE||||||
33930859|NCT04745689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
33930860|NCT06357962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33930861|NCT02802956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930862|NCT02963766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930863|NCT00255008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930864|NCT01444183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33930865|NCT00321360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930866|NCT05825586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930867|NCT04055844|NA|SEQUENTIAL||TREATMENT||NONE||||||
33930868|NCT06168890|||COHORT||RETROSPECTIVE|||||||
33930869|NCT02043509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33930870|NCT00638690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930871|NCT03185468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930872|NCT03051061|||COHORT||OTHER|||||||
34093746|NCT01341041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093747|NCT02874898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093748|NCT03974958|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34093749|NCT02641353|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34093750|NCT03734094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093751|NCT04415918|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34093752|NCT01200355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093753|NCT04080284|NA|SINGLE_GROUP||TREATMENT||NONE||Niraparib maintenance treatment will be given to patients for 1 year on study or until disease progression. Patients not tolerating the treatment will stop the niraparib treatment based on criteria described below. Patients who are benefitting from treatment will have access to their assigned treatment as long as considered acceptable by their treating physician or until they are discontinued for one of the below reasons.||||
34093754|NCT03915379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34093755|NCT05959291|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093756|NCT01972178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093757|NCT03590002|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||All study ICUs will begin as control sites (i.e., no electronic medical transfer tool available). ICUs will be randomly allocated to cross over to the intervention (i.e., electronic medical transfer tool available) at regular intervals (approximately every eight weeks) until all ICUs receive the intervention.||||
34093758|NCT02803541|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093759|NCT04234230|||COHORT||CROSS_SECTIONAL|||||||
34093760|NCT03537456|NA|SINGLE_GROUP||TREATMENT||NONE||"mRDX-02-17 is recommended for correction and treatment of wrinkles and dermal depressions, when administered by intradermal injection.~This is a multi-center, open-label, non-randomized, single-group clinical investigation in subjects aged 35-65 years old seeking facial rejuvenation.~Because it is a medical device with an innovative composition and that it is a first-in-human investigation, we preferred an exploratory approach for the investigation design. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device.~The total study duration will be approximately 3 months or 90 days."||||
33706042|NCT03415334|NA|SINGLE_GROUP||PREVENTION||NONE|care providers were not the same persons who did the assessment and the evaluation .|The study passed through three phases; first phase pre-interventional assessment of level of the recommended behavior development towards eradication of HCV, dominance of current risky behaviors and the wrong believes regarding HCV . The second phase included: community based interventions and the setting of the educational activation plan for HCV elimination in the village and the third was post-intervention evaluation of the change of level of community behaviors adoption according to a preset indicators.||||
33706043|NCT02045810|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33706044|NCT00594659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706045|NCT02654834|||CASE_CONTROL||PROSPECTIVE|||||||
33706046|NCT02091492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706047|NCT03584360|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient will not say the treatment he puts on each treatment area|patients apply different treatment to two areas with psoriasis|f|f|t|f
33706048|NCT06066164|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706049|NCT00970970|||COHORT||PROSPECTIVE|||||||
33706050|NCT00730132|||COHORT||PROSPECTIVE|||||||
33706051|NCT01156870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706052|NCT00172900|||DEFINED_POPULATION||OTHER|||||||
33706053|NCT05338515|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33706054|NCT01205906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706055|NCT06467383|||COHORT||RETROSPECTIVE|||||||
33706056|NCT01995474|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33706057|NCT01347944|||COHORT||OTHER|||||||
33706058|NCT06349772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively|t|f|f|t
33706059|NCT03501459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706060|NCT01211730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706061|NCT01212315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706062|NCT06498830|||COHORT||RETROSPECTIVE|||||||
33801757|NCT02348866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34093761|NCT00520468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093762|NCT03188471|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093763|NCT04517539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093764|NCT05665647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093765|NCT02958670|NA|SINGLE_GROUP||OTHER||NONE||||||
34093766|NCT00548561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093767|NCT03802110|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34093768|NCT02275091|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093769|NCT05431790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind the participant (Due to the particularity of implanted devices, blindness needs to be maintained as far as possible until the subject is automatically unblinded)|Random assignment of patients with anterior cruciate ligament reconstruction (The test group uses the test product; the control group uses the marketed product)Blind the subjects.|t|f|f|f
34093770|NCT05031221|NA|SINGLE_GROUP||OTHER||NONE||Proof-of-Concept, single-arm study||||
34093771|NCT04631276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093772|NCT00191919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34093773|NCT06260293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34093774|NCT06023537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093775|NCT05609227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be stratified according to type of planned transplantation by preparatory outpatient clinic nurse; then will randomly assigned to two groups either intervention or control. The intervention group will get a mobile application developed compatible with IOS or android systems, containing information about the stem cell transplantation process, stem cell transplantation and nutrition, lifestyle recommendations, and answering possible questions of the patients and their relatives. The control group will receive standard care. The data of both groups will be collected on the first day of hospitalization, at controls during the first and third month.|t|f|f|t
34093776|NCT06207890|||CASE_CROSSOVER||PROSPECTIVE|||||||
34093777|NCT02723422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093778|NCT03357055|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34093779|NCT04616521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093780|NCT04860882|||COHORT||RETROSPECTIVE|||||||
34093781|NCT00189670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093782|NCT06240182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham piezoelectric setup for patients undergoing conventional surgery.||t|f|t|t
34093783|NCT04385992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093784|NCT02909595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093785|NCT06279624|||CASE_CONTROL||OTHER|||||||
34093786|NCT06329310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093787|NCT01091207|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093788|NCT02580071|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093789|NCT00494156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093790|NCT05779644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093791|NCT06218550|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo controlled, double blind drug administration|A within-subjects design. At the time of study randomization, participants will be assigned to complete Sub-Study 1 followed by Sub-Study 2, or vice versa, using a counter-balanced randomization sequence. The order in which dose conditions are administered within each sub-study will be randomized across participants because there are too many drug conditions to fully counterbalance dosing within sub-studies at the proposed sample size.|t|f|f|t
34093792|NCT01857440|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093793|NCT06016751|||COHORT||PROSPECTIVE|||||||
34093794|NCT05165043|||CASE_ONLY||RETROSPECTIVE|||||||
34093795|NCT02120079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093796|NCT04055519|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34093797|NCT01501097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706063|NCT05309642|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomly allocated two groups; ICR (intermittent calorie restriction) group and SoC (standard-of-care) group||||
33706064|NCT04458597|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33706065|NCT04456959|||COHORT||RETROSPECTIVE|||||||
33706066|NCT01505725|||||OTHER|||||||
33706067|NCT00402415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706068|NCT04345809|||OTHER||PROSPECTIVE|||||||
33706069|NCT02288052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706070|NCT04092933|||CASE_ONLY||RETROSPECTIVE|||||||
33706071|NCT05581862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706072|NCT01831648|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33706073|NCT02030041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33706074|NCT02489162|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706075|NCT04132258|||CASE_ONLY||PROSPECTIVE|||||||
33706076|NCT02154178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706077|NCT02814578|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706078|NCT05186857|||COHORT||PROSPECTIVE|||||||
33706079|NCT06099366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706080|NCT01317030|||CASE_CONTROL||PROSPECTIVE|||||||
33801758|NCT02886195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009318|NCT04806620|||COHORT||PROSPECTIVE|||||||
34009319|NCT06236256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009320|NCT04492852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009321|NCT00101413|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009322|NCT05443906|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-test post-test design. Based on pre-test assessments participants will be instructed in an individualized exercise program. Participants will participate in 18 hours of remotely supervised and home practice exercises.||||
34009323|NCT03323060|||FAMILY_BASED||PROSPECTIVE|||||||
33706081|NCT04768595|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Fish oil or placebo are given as gelatin capsules packaged in identical white bottles.||t|f|t|f
34093798|NCT03464838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be allocated either to a tDCS Stimulation condition or to a tDCS Sham condition. Neither the investigator nor the participant will know to which condition the participant has been allocated.|Investigation of the effects of transcranial direct current stimulation (tDCS) in combination with cognitive behavioural therapy (CBT) against the effects of CBT alone.|t|f|t|f
34009324|NCT05258851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open-label, multicenter, parallel-group, stratified, non-inferiority randomized controlled trial|f|f|f|t
34093799|NCT04652310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093800|NCT05775705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093801|NCT06245707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093802|NCT04518410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Unblinded data will be provided to the Data and Safety Monitoring Board for interim analyses. Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation.||t|t|t|f
34093803|NCT00890162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093804|NCT01251679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093805|NCT05316870|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single Blind|Each community health service center randomly included patients with atrial fibrillation who met the admission criteria into the trial group or the control group. The intervention measures are the standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions.|t|f|f|f
34093806|NCT00074191||||TREATMENT||NONE||||||
34093807|NCT03630601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093808|NCT01193985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093809|NCT05364255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093810|NCT00250718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093811|NCT02668419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33706082|NCT02975518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706083|NCT01847378|||COHORT||PROSPECTIVE|||||||
33706084|NCT03906838|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706085|NCT01628315|||COHORT||RETROSPECTIVE|||||||
33706086|NCT02207296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706087|NCT02033109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706088|NCT02993757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706089|NCT03498144|||CASE_CONTROL||PROSPECTIVE|||||||
33706090|NCT01186471|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33706091|NCT05001256|||CASE_ONLY||CROSS_SECTIONAL|||||||
33706092|NCT05205811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33706093|NCT02126995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706094|NCT03760978|||COHORT||PROSPECTIVE|||||||
33706095|NCT02428517|||COHORT||PROSPECTIVE|||||||
33706096|NCT04568044|||COHORT||PROSPECTIVE|||||||
33706097|NCT04713930|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33706098|NCT03437096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706099|NCT01471678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706100|NCT02158273|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33706101|NCT00110838|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33706102|NCT01826877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706103|NCT02516046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706104|NCT03538548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706105|NCT01582165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706106|NCT00549731|||OTHER||OTHER|||||||
33706107|NCT02085083|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706108|NCT04459728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706109|NCT03105791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33706110|NCT00401531|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33706111|NCT00873912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706112|NCT02610725|NA|SINGLE_GROUP||OTHER||NONE||||||
33706113|NCT01814514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009325|NCT03470584|||COHORT||PROSPECTIVE|||||||
34009326|NCT02265406|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34009327|NCT00845325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009328|NCT04199117|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors collecting follow-up data on quit attempts, use of treatment, and smoking status will be blind to experimental condition.|2 x 2 x 2 x 2 factorial experiment|f|f|f|t
33706114|NCT03069300|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33706115|NCT03703115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706116|NCT01637935|||COHORT||PROSPECTIVE|||||||
33706117|NCT05425134|||COHORT||PROSPECTIVE|||||||
33706118|NCT01534962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706119|NCT02940912|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33706120|NCT05176145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706121|NCT00017446||||TREATMENT||||||||
33706122|NCT04579575|||COHORT||PROSPECTIVE|||||||
33706123|NCT04905758|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Maxi-Z plus dental implant|t|f|f|t
33706124|NCT02298608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009329|NCT04047563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).~In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.~In both treatment groups, subjects will be provided the best available standard of care."|t|t|t|t
34009330|NCT03370107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sham coil of the Hcoil procedure produces a similar acoustic artefact and scalp sensation as the active coil and mimics the facial muscle activation induced by the active coil. The sham stimulation of the conventional rTMS will be carried out with the opposite face of the coil (biface coil) of identical size, color and shape emitting a sound similar to that emitted by the active coil (B65 A/P Butterfly Coil Magventure).|Patients will be randomly assigned to one of 2 treatment groups: active rTMS and Hcoil or sham rTMS and sham Hcoil, according to a 2 : 1 ratio (2 for active, 1 for placebo).|t|t|t|t
33706125|NCT03620487|||CASE_ONLY||PROSPECTIVE|||||||
33706126|NCT03989895|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm dose-finding study||||
34009331|NCT02854228|||COHORT||PROSPECTIVE|||||||
34009332|NCT05016934|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34009333|NCT06210802|||COHORT||PROSPECTIVE|||||||
34093812|NCT04706221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study is a prospective, single-arm, non-randomized, non-controlled, single-center study enrolling adult subjects.||||
33706127|NCT01116115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34009334|NCT02994628|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34009335|NCT02439632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009336|NCT00583518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009337|NCT03442959|||COHORT||PROSPECTIVE|||||||
34009338|NCT05717244|||COHORT||PROSPECTIVE|||||||
34009339|NCT03187028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706128|NCT00304746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706129|NCT03210311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33706130|NCT04110574|||CASE_ONLY||PROSPECTIVE|||||||
33706131|NCT00603174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706132|NCT03954665|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33706133|NCT05806411|||CASE_CONTROL||PROSPECTIVE|||||||
33706134|NCT06294782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706135|NCT03267108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706136|NCT04782154|||COHORT||PROSPECTIVE|||||||
33706137|NCT01487200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706138|NCT04571814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790290|NCT04800224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The capsules will be coated, in opaque and equal packaging, so that the researchers involved in the care of patients could not distinguish between propolis and placebo. Neither the participants, nor the principal investigator, nor the health professionals involved in the care will know which group the patients will be allocated.|A randomized, double-blind, placebo-controlled trial|t|t|t|t
33790291|NCT05461547|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790292|NCT00578617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801759|NCT04274881|||COHORT||PROSPECTIVE|||||||
33801760|NCT00002900|||||PROSPECTIVE|||||||
33706139|NCT00036517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33706140|NCT03404115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706141|NCT00415168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706142|NCT00916942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706143|NCT04377620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
33706144|NCT02759783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706145|NCT04338074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy prepares 5 day packs of medications that are coded|Randomized, placebo-controlled, double-blind comparison|t|t|t|t
33706146|NCT00903799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33706147|NCT02276001|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33706148|NCT06264414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930873|NCT02606344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33930874|NCT03480646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930875|NCT03423615|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||We will use a stepped-wedge cluster controlled model to reflect the pragmatic enrollment and crossover of schools between intervention arms.||||
33930876|NCT03531606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study has been designed for randomized, double Blinded, placebo clinical trial.|f|t|f|f
33930877|NCT04678024|||COHORT||RETROSPECTIVE|||||||
33930878|NCT02621645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930879|NCT05182541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33930880|NCT04904536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930881|NCT02959190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930882|NCT02746445|||COHORT||PROSPECTIVE|||||||
33930883|NCT03889990|NA|SINGLE_GROUP||OTHER||NONE||||||
33930884|NCT02826876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930885|NCT06233838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33930886|NCT01966653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930887|NCT02353403|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33930888|NCT00252317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930889|NCT01098032|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930890|NCT01240967|NON_RANDOMIZED|||||NONE||||||
33930891|NCT04553978|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33930892|NCT03850171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors of outcome data and analysis will be blinded to the intervention arm.|Randomised, controlled; parallel arm design.|f|f|f|t
33930893|NCT02108223|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930894|NCT05248529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The sample was composed of 78 individuals 41 experimental and 37 control. The intervention group was given practical training in accordance with the adaptation booklet prepared by the researcher. Patients' physical adaptation and mobility were evaluated using the Patient Mobility Scale and Observer Mobility Scale and Physical Adaptation Assesment Form. Data of the control and intervention groups were collected two times: preoperative and within 12 hours before the discharge.|t|f|t|f
33930895|NCT04605185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930896|NCT01297023|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930897|NCT01459887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930898|NCT01135394|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33930899|NCT05447260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930900|NCT03807778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930901|NCT03243955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the patient is unaware which group he is assigned to the researchers discussing this with the patients are unaware of group assignment the investigator is unaware of group assignment the outcomes assessor is unaware of group assignment until data analysis is complete||t|t|t|t
33930902|NCT00348491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930903|NCT05445336|||COHORT||PROSPECTIVE|||||||
34009340|NCT06529939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34009341|NCT00642421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930904|NCT00748514|||COHORT||RETROSPECTIVE|||||||
34009342|NCT03395639|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009343|NCT04022824|||COHORT||PROSPECTIVE|||||||
33706149|NCT04921839|||OTHER||PROSPECTIVE|||||||
34009344|NCT02669160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009345|NCT02224066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009346|NCT03802617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009347|NCT05039437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009348|NCT02470117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706150|NCT03533868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized to have their viral load monitored by either the standard of care or point-of-care method at their follow-up clinical visits up to 12 months.||||
33930905|NCT02803814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009349|NCT03146637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were randomly assigned to two groups,receive activated CIK or activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody,every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, randomized (1:1of targeted activation CIK and traditional CIK therapy ).|t|t|t|t
33930906|NCT00493441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930907|NCT05784870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930908|NCT02327078|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930909|NCT01651234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930910|NCT03753386|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009350|NCT03052972|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34093813|NCT06475378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researcher performing the statistics and outcome assessors will be blinded to group allocation.|Randomized controlled trial (RCT)|f|f|t|t
33706151|NCT05733780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Blinding will be maintained throughout the trial until database is locked after last patient last visit. Emergency unblinding will be allowed through a 24/7 helpline set up for any investigator / ethics committee member or others authorized to request for unblinding. Given|A Phase 1b/2a Randomized, Blinded, placebo-controlled Study|t|t|t|f
33930911|NCT04212546|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)|"This study has two phases. First phase had a randomised, double blind, placebo-controlled crossover study design.~The second phase had a randomized, double-blind, placebo-controlled parallel study design. The second phase is going to be described below."|t|f|t|t
33930912|NCT04552626|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33930913|NCT05656118|||COHORT||PROSPECTIVE|||||||
33930914|NCT03510728|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||There are three conditions at the start of the study regarding assignment to a single-session intervention: none (control), standard BMI (CDCU), and the standard BMI plus a PBS-component. These are crossed with the type of application for their phone: an ecological momentary assessment-only or an ecological momentary intervention.|t|f|f|f
33706152|NCT05998044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pilates exercises will be given to the experimental group|f|f|f|t
33930915|NCT03383055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930916|NCT05148689|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34009351|NCT05810025|NA|SINGLE_GROUP||PREVENTION||NONE||RealRisks is a patient-facing, web-based decision support tool that was developed using multiple design sessions, participatory workshops, and usability studies to arrive at guiding principles that focus on 1) personalized breast cancer risk calculation, 2) interactive games to communicate breast cancer risk, and 3) patient preferences elicitation to elicit values supporting breast cancer options. The FHIR enhanced-RealRisks functionality that this research focuses on will allow RealRisks to utilize a patient's electronic health record data to support accurate risk assessment.||||
34009352|NCT03765996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009353|NCT04523610|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a mixed-methods (qualitative and quantitative) model||||
34009354|NCT04266873|NA|SINGLE_GROUP||TREATMENT||NONE|CT scans will be anonymised before being sent to Radiographer to Brody score|Feasibility interventional study using intervention for 6 weeks||||
33706153|NCT02292797|||||PROSPECTIVE|||||||
33706154|NCT02587234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33706155|NCT00064558|||COHORT||RETROSPECTIVE|||||||
33706156|NCT03298867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706157|NCT04051528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33706158|NCT01548820|||COHORT||RETROSPECTIVE|||||||
33706159|NCT03513458|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The randomization to study arms will be done by the department biostatistician and communicated to Investigational Drug Services to maintain the double-blind nature of the study.|Subjects are randomized to one of two arms, either taking Anakinra or placebo. After a washout period, the subjects will be moved to the opposite arm.|t|f|t|f
33706160|NCT06187532|||COHORT||RETROSPECTIVE|||||||
33706161|NCT01306903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706162|NCT02532088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706163|NCT00307177|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33706164|NCT00190671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706165|NCT00060788|||DEFINED_POPULATION||PROSPECTIVE|||||||
33706166|NCT06284291|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706167|NCT02239068|||CASE_ONLY||PROSPECTIVE|||||||
33706168|NCT00753467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706169|NCT00845104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930917|NCT04509557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose is administered by differentiated into 5 groups (6 subjects each) and sequentially elevated starting from a low dose to a high dose (50±5 mCi, 75±8 mCi, 100±10 mCi, 125±13 mCi, 150±15 mCi).||||
33930918|NCT06382740|||COHORT||PROSPECTIVE|||||||
33930919|NCT02724280|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33930920|NCT01237301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930921|NCT05537961|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930922|NCT03304652|||COHORT||PROSPECTIVE|||||||
33930923|NCT00299416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930924|NCT01144091|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34009355|NCT02568007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009356|NCT05839145|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34093814|NCT00809146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093815|NCT01680172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34093816|NCT04964388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093817|NCT04389138|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706170|NCT01842022|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33706171|NCT03307525|||COHORT||PROSPECTIVE|||||||
33706172|NCT00511446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706173|NCT04194580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706174|NCT00055250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706175|NCT02054273|||COHORT||CROSS_SECTIONAL|||||||
33706176|NCT02707939|||COHORT||PROSPECTIVE|||||||
33706177|NCT06317727|||COHORT||PROSPECTIVE|||||||
33706178|NCT06108388|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33706179|NCT01020175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706180|NCT05497154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706181|NCT02082860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706182|NCT04176497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093818|NCT02909647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093819|NCT02536794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093820|NCT03222128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093821|NCT02357433|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34093822|NCT06021496|RANDOMIZED|PARALLEL||OTHER||SINGLE|single blind study, participants do not know their group|randomised control trial|t|f|f|f
34009357|NCT04437888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator, participant, research staff and medical provider will all be masked. The pharmacy will maintain the randomization and will provide the code at the conclusion of the study prior to data analysis.|This study will be a randomized, prospective double-blind, placebo controlled trial to evaluate the efficacy of intra-operative ketamine administration in patients undergoing elective total hip or knee arthroplasty, who have high pain catastrophizing scores.|t|t|t|f
34009358|NCT04553991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34009359|NCT06334861|||COHORT||PROSPECTIVE|||||||
34093823|NCT02129556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093824|NCT03837938|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is an open-label clinical trial|||||
34093825|NCT05327738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093826|NCT05702151|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Open Clinical Trial||||
34093827|NCT00158730|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34093828|NCT03427281|NA|SINGLE_GROUP||TREATMENT||NONE|the investigator is blinded for the identity of the participating surgeons in the questionnaire|||||
33706183|NCT00608816|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33706184|NCT00147342|||||PROSPECTIVE|||||||
33706185|NCT03880734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All the eligible patients were randomly assigned to either 'Study (A)' or 'Control (B)' group||||
34093829|NCT04915066|||COHORT||RETROSPECTIVE|||||||
33930925|NCT00755391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930926|NCT05264740|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33930927|NCT01553760|NON_RANDOMIZED|PARALLEL||||NONE||||||
33930928|NCT05668806|||COHORT||PROSPECTIVE|||||||
33930929|NCT01231828|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33930930|NCT00396422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33930931|NCT00366938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706186|NCT00807729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706187|NCT01211886|||COHORT||PROSPECTIVE|||||||
33706188|NCT00722657|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33706189|NCT04742998|||COHORT||PROSPECTIVE|||||||
33706190|NCT04198298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706191|NCT02728596|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706192|NCT02509767|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706193|NCT02497339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33706194|NCT00347568|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33790293|NCT05421988|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|Participants in the two treatment arms, and data analysts, will be blind to group assignment.||t|f|f|t
33790294|NCT02575235|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790295|NCT04743128|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790296|NCT02612571|||COHORT||PROSPECTIVE|||||||
33790297|NCT06629727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790298|NCT01949909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790299|NCT05422716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||participants will be randomized into either the baclofen group or epidural stimulation|t|f|f|f
33790300|NCT04769609|||CASE_ONLY||PROSPECTIVE|||||||
33790301|NCT02621593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790302|NCT02987049|||COHORT||PROSPECTIVE|||||||
33790303|NCT02684565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790304|NCT04243213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Through a random selection process, the patients are divided into three groups of 10 patients each and receive the following treatment in addition to standard clinical physiotherapy:~A: Intervention group I receives a unit of 10 minutes daily on the vibrating plate with an upright posture of 15 ° postoperatively from the 2nd to the 7th day B: Intervention group II is positioned postoperatively from day 2 to day 7 for 15 minutes at 15 degrees, but without vibration C: The control group only receives standard physiotherapy and no further treatments"||||
33790305|NCT04715373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790306|NCT01805414|NON_RANDOMIZED|PARALLEL||||NONE||||||
33790307|NCT00591838|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33790308|NCT02161653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790309|NCT01637324|||COHORT||PROSPECTIVE|||||||
33790310|NCT04658615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790311|NCT04756258|||CASE_ONLY||CROSS_SECTIONAL|||||||
33790312|NCT01923103|||COHORT||PROSPECTIVE|||||||
33790313|NCT03664336|||COHORT||RETROSPECTIVE|||||||
33790314|NCT05380583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790315|NCT06548880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||10 participants were included in the study group, and 10 participants were included in the control group.||||
33790316|NCT04249388|||COHORT||PROSPECTIVE|||||||
33930932|NCT01577004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33930933|NCT03197350|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The investigators will compare 3 different groups: controls and HFpEF patients and HFrEF patients, in order to better understand the pathophysiology in HF with preserved ejection fraction.||||
33790317|NCT04833491|||COHORT||RETROSPECTIVE|||||||
33930934|NCT00373880|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||In order to achieve steady-state concentrations, participants (n=8 men) were administered placebo and aripiprazole (15 mg/day) capsules in counter-balanced order for 21 days. A smoked cocaine dose-response curve (0, 12, 25, 50 mg) was determined twice under placebo and aripiprazole maintenance.|t|f|t|f
33930935|NCT04941157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790318|NCT03140176|||COHORT||PROSPECTIVE|||||||
33790319|NCT04927143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790320|NCT01094041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790321|NCT06553222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the outcome assessor will assess the bone gain (Radiographic) and Clinical attachment level (clinical) in both groups. the assessor is blinded whether a graft was loaded at the time of surgery|2 parallel groups study group - The interventional group where minimally invasive debridement flap and a putty bone graft is tested and the Control group - where minimally invasive debridement flap is performed without graft|f|f|f|t
33790322|NCT02752399|||COHORT||CROSS_SECTIONAL|||||||
33790323|NCT02294643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790324|NCT04697576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790325|NCT03923725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790326|NCT06235606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790327|NCT02499471|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790328|NCT05860140|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790329|NCT02274025|||COHORT||PROSPECTIVE|||||||
33790330|NCT02637908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790331|NCT03677999|||CASE_ONLY||PROSPECTIVE|||||||
33790332|NCT02931656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790333|NCT05309980|||OTHER||RETROSPECTIVE|||||||
33790334|NCT01099891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790335|NCT02615522|||CASE_ONLY||PROSPECTIVE|||||||
33790336|NCT04135209|||CASE_CONTROL||PROSPECTIVE|||||||
33790337|NCT01890889|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33790338|NCT01122420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790339|NCT02160106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790340|NCT06631222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930936|NCT01248585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930937|NCT03914651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801761|NCT05141136|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Medical staff performing patient care, including pain management, and investigators who investigate and record observations and evaluations, and those who analyze magnetic resonance imaging, are kept unaware of group assignments.|Patients with chronic cervical radiculopathy due to degenerative spinal disease for more than 3 months|t|t|t|t
34093830|NCT05017155|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Participants will be recruited from University College London Hospital (UCLH). After screening and consent, randomisation will occur to one of two arms. The participant will participate in two consecutive time periods. A time period will consist of 8 weeks of Mexiletine or Lamotrigine. The second time period will then occur after 7 days of washout. The patient will then take the alternative drug. Visits will occur at the end of each period and can be undertaken remotely as required. At each visit, the Interactive Voice Response (IVR)-Diary score will be performed and secondary measures including the Brief Pain Inventory, Modified Fatigue Severity Scale and Medical Outcomes Study Questionnaire (SF-36). Objective recordings including Timed up and Go (TUG), Timed Sit to Stand (TST). Safety data will be recorded simultaneously. A participant diary will be utilised to record daily IVR-Diary scores, medication compliance and activity measures.|t|t|t|t
33801762|NCT02590432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093831|NCT03195530|||COHORT||PROSPECTIVE|||||||
34093832|NCT04481282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093833|NCT00649948|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34093834|NCT05663788|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Non-pharmacological multi-centre, stratified (by the centre and experience, with balance randomisation \[1:1\]), randomised, controlled, parallel trial conducted in Spain.||||
34093835|NCT04608864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093836|NCT04705584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093837|NCT04056429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093838|NCT04776772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34093839|NCT02158598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093840|NCT04428944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093841|NCT01834261|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34093842|NCT04650945|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34093843|NCT04145271|||COHORT||PROSPECTIVE|||||||
34093844|NCT03390192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34093845|NCT00220714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093846|NCT03483584|||COHORT||PROSPECTIVE|||||||
34093847|NCT03071744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34093848|NCT05396300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093849|NCT01049828|||COHORT||PROSPECTIVE|||||||
34093850|NCT01573377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093851|NCT02053116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34093852|NCT04627584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093853|NCT01124539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093854|NCT01010438|||||RETROSPECTIVE|||||||
34093855|NCT06465056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093856|NCT06231121|||COHORT||RETROSPECTIVE|||||||
33801763|NCT04907513|||COHORT||PROSPECTIVE|||||||
33801764|NCT03710798|NA|SINGLE_GROUP||TREATMENT||NONE||prospective observational study with a diet intervention||||
33930938|NCT02470429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930939|NCT04631367|NA|SINGLE_GROUP||PREVENTION||NONE||A single arm, pre-test/post-test trial design will be used to evaluate the effectiveness of a RANAS-informed WhatsApp Social Group intervention on uptake of COVID-19 prevention practices (i.e. hand and respiratory hygiene, physical distancing) with displaced/refugee youth in Kampala, Uganda. A control group design is intentionally not used based on recommendations regarding ethical concerns over the potential withholding of any intervention benefits from a vulnerable group (refugee youth living in informal settlements) in the midst of a pandemic.||||
33930940|NCT04923321|||COHORT||RETROSPECTIVE|||||||
33930941|NCT02778373|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33930942|NCT06257862|||COHORT||PROSPECTIVE|||||||
33930943|NCT02911051|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33930944|NCT00619606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33930945|NCT00877760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930946|NCT04803890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930947|NCT01340404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930948|NCT05991895|||COHORT||PROSPECTIVE|||||||
33930949|NCT00725829|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33930950|NCT04481945|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Blinding; Assessor blinding, where both the evaluators and statisticians will be blinded to the treatment groups.|Nanosilver and chitosan inserted to BC sealer and so the antibacterial activity will be assessed on E. faecalis using direct contact test after the setting of the sealer, and the results will be reported using percentage reduction of the colony forming units.|t|f|t|t
33930951|NCT00964249|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33930952|NCT01150604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930953|NCT02280525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930954|NCT02774668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33930955|NCT00394693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930956|NCT02126527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930957|NCT02623491|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33930958|NCT05255536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930959|NCT04321278|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] + azithromycin \[500mg 1x/day\]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.~2. Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine \[400mg 2x/day, 12/12h\] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection."||||
33930960|NCT02623699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930961|NCT01256918|||||CROSS_SECTIONAL|||||||
33930962|NCT03749213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009360|NCT06045520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants were unaware of which group they were assigned to. The data will be entered using A and B codes, and the researcher doing the statistical analysis will be blind to the participants' groups.|The research has a randomized controlled interventional study design. An impartial investigator who is not participating in the study will conduct the randomization. Six alternative combinations with a block size of four (ABAB(1), ABBA(2),...) containing codes A and B will be constructed using the block randomization method. From 1 to 6, combinations will be numbered. By sorting the integers (1-6) via randomizer.org 33 times in a random order, a random assignment sequence will be formed. By drawing lots with coins, it will be established which of the A and B codes is the intervention group and which is the control group. Participants who meet the inclusion criteria will be asked to sign an informed consent form, and their group will be shared with the researcher after the pre-tests (T1) are completed. In the intervention group, participants will get a web-based training based on the family-centered approach.|t|f|f|f
34009361|NCT06175247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009362|NCT00666887|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34009363|NCT06185595|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33706195|NCT06556407|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-center feasibility study||||
33706196|NCT03415568|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34009364|NCT01368302|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009365|NCT02014441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009366|NCT01281787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009367|NCT01552031|||COHORT||PROSPECTIVE|||||||
34009368|NCT01467479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009369|NCT05440019|||COHORT||PROSPECTIVE|||||||
34009370|NCT00707434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009371|NCT04013074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706197|NCT05707767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009372|NCT05093465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009373|NCT00005075||||TREATMENT||||||||
34009374|NCT05893316|||COHORT||PROSPECTIVE|||||||
34009375|NCT01487655|||||PROSPECTIVE|||||||
34009376|NCT01139749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009377|NCT01038037|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34093857|NCT03418974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two or more groups in parallel for the duration of the study.||||
34093858|NCT03011151|||COHORT||PROSPECTIVE|||||||
34093859|NCT01527669|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34093860|NCT00997126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093861|NCT04400747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixty patients with spinal cord injury with serum 25 (OH) D3 levels less than 20 ng / ml will be included in the study. One of the treatment groups will receive 6,000 IU of vitamin D daily, and the other group 50000 IU of vitamin D per week for 8 weeks. 20 Patients who don't receive vitamin D will be included in the control group.||||
34093862|NCT00593073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34009378|NCT01616017|||||PROSPECTIVE|||||||
33706198|NCT04035798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009379|NCT04330911|RANDOMIZED|PARALLEL||TREATMENT||NONE||"High-Intensity Interval Training Group (HIIT): The HIIT exercise protocol involved 28 minutes of treadmill efforts. The patients performed the interval training for 4 minutes with 80%HRmax and active recovery period maintained for 3 minutes with 60% HRmax on the treadmill with Karvonen formula.This protocol repeated 4 times in a session for 6 weeks.~Moderate Intensity Continous Training (MICT): The MICT exercise protocol performed with %60 HRmax for 28 minutes for 6 weeks."||||
34009380|NCT00643734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009381|NCT02948257|||COHORT||PROSPECTIVE|||||||
34009382|NCT06502652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant will get seperate treatment protocols and possible effort will be put to mask the both group about the treatment.|it will be randomized controlled trial which is non probability sampling will be used. two groups of 6-14 years age will be performed in which participants will be randomly divided.group a will recieve hippotherapy and group b will recieve balance training.|t|f|f|f
34093863|NCT05721027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093864|NCT05480371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34093865|NCT02820636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093866|NCT04067245|NA|SINGLE_GROUP||OTHER||NONE||||||
33706199|NCT02809404|||CASE_ONLY||PROSPECTIVE|||||||
33706200|NCT04405583|||CASE_ONLY||PROSPECTIVE|||||||
33706201|NCT05051371|||COHORT||PROSPECTIVE|||||||
33706202|NCT02782637|||COHORT||CROSS_SECTIONAL|||||||
33706203|NCT05626023|NA|SEQUENTIAL||TREATMENT||NONE||||||
33706204|NCT03017495|NA|SINGLE_GROUP||OTHER||NONE||||||
33706205|NCT03822078|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33706206|NCT00207350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706207|NCT04466020|||OTHER||PROSPECTIVE|||||||
33706208|NCT00635674||PARALLEL||TREATMENT||NONE||||||
33706209|NCT03217656|||COHORT||PROSPECTIVE|||||||
33706210|NCT01190345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706211|NCT05970185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706212|NCT02695901|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33706213|NCT02493140|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33706214|NCT05346770|||CASE_ONLY||RETROSPECTIVE|||||||
33706215|NCT00484432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706216|NCT02051504|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33706217|NCT00216814|||COHORT||PROSPECTIVE|||||||
33706218|NCT04504357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706219|NCT03036007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Outcomes Assessor)||f|f|f|t
33706220|NCT03425877|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706221|NCT02191683|||OTHER||PROSPECTIVE|||||||
33706222|NCT01762878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33930963|NCT03757260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Once selected the patient will see two clinicians: the examiner (hygienist) and operator (resident).~The examiner records the data (PPD, CAL, BOP, PI) of the teeth, and provides preliminary hygiene treatment; the operator delivers the test treatments.~The treatment assignments are concealed to the patient and the examiner. The operator is unaware of previously recorded data except for pocket depth measurements and is not involved in the post-treatment evaluations (3,6,12 months)"||t|t|t|f
33930964|NCT04701749|||COHORT||PROSPECTIVE|||||||
33930965|NCT00804986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33930966|NCT05514925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33930967|NCT05990166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants, researchers, and the study physician will be blinded to the treatment group (active intervention or placebo) to which participants have been randomised. A delegated unblinded staff member will be permitted to unblind participants for safety purposes, if requested by the principal investigators or the study physician.|Double-blind randomised placebo-controlled trial|t|f|t|f
33930968|NCT01351389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930969|NCT04776889|RANDOMIZED|PARALLEL||TREATMENT||NONE||A cohort of 70 newly diagnosed metastatic prostate cancer patients were recruited. Blood samples were withdrawn from all patients at baseline to monitor parameters under investigation. Then, all patients were subjected to surgical castration and divided in to two groups. Group I included 30 patients and served as control (statin non-users). Group II included 40 patients treated with Rosuvastatin (20 mg/day) for 6 months and served as statin users.||||
33930970|NCT00041704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930971|NCT06234072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33930972|NCT04746781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930973|NCT04434261|||COHORT||PROSPECTIVE|||||||
33930974|NCT02725736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930975|NCT02027064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930976|NCT02825940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930977|NCT04921657|||CASE_ONLY||RETROSPECTIVE|||||||
33930978|NCT02781415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930979|NCT06508970|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participants were assigned to groups using the simple randomization method. Participants were not informed about which group they were in. Unique 2-group columns were created with the registration numbers of elderly individuals in nursing homes by using the Random Integer Generator method under the numbers subheading on the Random.org website. The researcher was blind to all conditions until participants started the computer program and the intervention began. Participants were also unaware of whether the group they were assigned to was an experimental or control group. Additionally, researchers who coded and analyzed the data were blinded to randomization and interventions."|RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.|t|f|t|t
33930980|NCT00882167|||COHORT||PROSPECTIVE|||||||
33930981|NCT00336661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33930982|NCT06252740|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33930983|NCT04763551|||COHORT||PROSPECTIVE|||||||
33930984|NCT04409730|NA|SINGLE_GROUP||SCREENING||NONE||||||
33930985|NCT04144179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33930986|NCT02583711|||COHORT||PROSPECTIVE|||||||
33930987|NCT06187285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930988|NCT00115544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33930989|NCT01505244|NA|SINGLE_GROUP||||NONE||||||
34009383|NCT05727449|||OTHER||RETROSPECTIVE|||||||
33706223|NCT04726800|||COHORT||PROSPECTIVE|||||||
33706224|NCT02546453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706225|NCT02443766|||OTHER||PROSPECTIVE|||||||
33706226|NCT02798601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706227|NCT05833074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants are not given access to information about study condition.|Participants are randomized (with equal allocation) to either couples HIV testing and counseling retesting or an individual HIV testing control.|f|f|f|t
33706228|NCT04137705|||OTHER||PROSPECTIVE|||||||
33706229|NCT00393029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706230|NCT05419869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706231|NCT03675477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706232|NCT03172442|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking could be applied|The patients will be randomly assigned to one of the two groups, case or control.||||
33706233|NCT06008431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706234|NCT02714374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009384|NCT04596124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, controlled, multicentric study|f|f|f|t
34009385|NCT05634135|||COHORT||PROSPECTIVE|||||||
33930990|NCT03299452|NA|SINGLE_GROUP||TREATMENT||NONE||This single center, open-label, single arm, non-randomized study is designed to evaluate safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor.||||
33930991|NCT05154071|||COHORT||RETROSPECTIVE|||||||
34009386|NCT01961882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009387|NCT05738655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parallel Assignment|t|f|t|f
33930992|NCT04479449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33930993|NCT02380482|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33930994|NCT00068484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33930995|NCT02224274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33930996|NCT01707095|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33930997|NCT00605358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34009388|NCT05653635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706235|NCT01999179|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33706236|NCT01546883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009389|NCT00020267||||TREATMENT||||||||
34009390|NCT04329715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgical treatment teams and outcome assessors will be blinded to patient's treatment arm.|Randomized controlled non-inferiority trial|f|t|t|t
34009391|NCT04177641|||CASE_CONTROL||PROSPECTIVE|||||||
34009392|NCT04225286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706237|NCT04896541|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33706238|NCT04498520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009393|NCT06617624|||CASE_CONTROL||PROSPECTIVE|||||||
34009394|NCT02063308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009395|NCT01281345|||CASE_ONLY||PROSPECTIVE|||||||
33930998|NCT01505660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33930999|NCT00469807|||||PROSPECTIVE|||||||
34009396|NCT04052698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706239|NCT05173805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790341|NCT06188962|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional randomized multiple baseline design: We are using a multiple baseline design, where all participants are offered the same intervention (e.g., Knowledge Insight Tools; KIT), but start the intervention after a randomly varying baseline period where no intervention is offered. Participants will be randomly assigned to a baseline wait period of either three, four, five, six, seven, or eight weeks. Randomization controls for extraneous factors such as maturation and test-retest effects, thereby improving the study's internal validity compared to single-group uncontrolled designs. We are using a non-concurrent design, in which participants start their baseline wait period on different (absolute) start dates.||||
33790342|NCT02169154|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33790343|NCT01740570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790344|NCT00773019|||COHORT||PROSPECTIVE|||||||
33790345|NCT01141933|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33790346|NCT03896828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Fourteen men and women will visit the lab on three separate occasions and will remain seated at a desk all-day (Visit 1) or interrupt this sitting every 30-minutes with either 2-minute walking-breaks (Visit 2) or with 15 body-weight squats (repeatedly rising from a chair and onto tip-toes, Visit 3).||||
33790347|NCT02121899|||COHORT||PROSPECTIVE|||||||
33790348|NCT00288691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790349|NCT03313128|||COHORT||PROSPECTIVE|||||||
33790350|NCT05019729|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33790351|NCT05593952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931000|NCT03234270|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33931001|NCT03300427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931002|NCT00923468|||||PROSPECTIVE|||||||
34009397|NCT02372591|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33706240|NCT03752983|||CASE_CONTROL||RETROSPECTIVE|||||||
33706241|NCT02370745|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33706242|NCT05106686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706243|NCT05465434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706244|NCT06475586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participant, investigator)||t|f|t|f
33706245|NCT04769804|||CASE_CONTROL||PROSPECTIVE|||||||
33706246|NCT04959422|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33706247|NCT03534960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706248|NCT04966039|||CASE_CONTROL||RETROSPECTIVE|||||||
33706249|NCT00757497|RANDOMIZED|PARALLEL||TREATMENT||||||||
33706250|NCT05909748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009398|NCT06615960|||COHORT||PROSPECTIVE|||||||
33706251|NCT00636558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009399|NCT03500367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706252|NCT04013204|RANDOMIZED|PARALLEL||OTHER||DOUBLE|This study is patient and assessor blinded; that is, both groups of patients are unaware of the endothelial function results. This study will use blind methods for endpoint data collectors; that is, the data collectors will collect secondary prevention medication and cardiovascular event data for coronary artery disease without an awareness of patient grouping.|"Multicenter, randomized, patient and assessor blinded, parallel control, two-stage, clinical trial.~Phase I: a feasibility study to collect data on key process outcomes including physician's prescription behaviors, patients' cardiovascular risk, and trend of reduction in cardiovascular events, To create an initial and to inform for the Phase II larger multicenter trial on choosing clinical endpoints and sample size.~Phase II: will extend all patients from Phase I to a longer period of follow up and recruit more new patients to enlarge the sample size, in order to have a full study on the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with NOCAD."|t|f|f|t
33706253|NCT01935297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706254|NCT02840500|||COHORT||PROSPECTIVE|||||||
33790352|NCT01724788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34009400|NCT02112279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009401|NCT05202041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009402|NCT01674439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706255|NCT05496530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706256|NCT00172133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706257|NCT01972113|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706258|NCT01203098|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706259|NCT04351685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study is designed as a double-blind study.||t|t|t|t
33790353|NCT01928004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790354|NCT00891618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790355|NCT04481386|NA|SINGLE_GROUP||TREATMENT||NONE||A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery||||
33931003|NCT03209011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931004|NCT03790072|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation, 3 cohorts, x10 dose increments between cohorts (10\^6, 10\^7, 10\^8 of cells per kg of body weight).||||
33931005|NCT03986567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931006|NCT05376189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be masked from the intervention by giving a similar vitamin D preparation in each group. Investigator, Care Provider, and Outcome Assessor are blinded from allocation and only the Allocator knows the participants assigned groups|This study involves three arms intervention consists of one control group with standardized tuberculosis treatment, and two intervention groups with different level of vitamin D supplementation;|t|t|t|t
33931007|NCT02242760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931008|NCT01604395|||COHORT||OTHER|||||||
34009403|NCT01215071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009404|NCT04935788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||a randomized, single-blinded within-subject (cross-over) trial in which a group of 12 subjects receive 4 different conditions|t|f|f|t
33790356|NCT03979651|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33790357|NCT04419181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to an arm of the trial based on their outcomes after surgery.||||
33790358|NCT01992354|NA|SINGLE_GROUP||OTHER||NONE||||||
33790359|NCT03753152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790360|NCT03692949|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33790361|NCT01585038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931009|NCT00477139|||||RETROSPECTIVE|||||||
33706260|NCT04054505|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Unmarked plan packet|Triple blind|t|t|t|f
33931010|NCT01769612|||COHORT||PROSPECTIVE|||||||
33931011|NCT00321438|||||PROSPECTIVE|||||||
33931012|NCT04449497|||OTHER||CROSS_SECTIONAL|||||||
33931013|NCT00666380|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931014|NCT05882123|||OTHER||RETROSPECTIVE|||||||
33931015|NCT05887089|||CASE_CONTROL||PROSPECTIVE|||||||
33931016|NCT02707601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009405|NCT02641002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009406|NCT00908219|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34009407|NCT01972035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706261|NCT05136404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33706262|NCT06143644|||COHORT||PROSPECTIVE|||||||
33706263|NCT04669132|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33706264|NCT00204230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706265|NCT01387932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are blinded to the treatment they are randomized to (cTACE or hqTACE). Central Reviewers (two interventional radiologists) will evaluate study participant's liver MRIs to assess the tumor response. The Central Reviewers will be blinded to the treatment the participant received.|Participants are randomized 1:1 to receive either 1. A Conventional TACE (Trans Arterial Chemoembolization) procedure using PVA, lipiodol and doxorubicin (cTACE), or 2. HepaSphere/QuadraSphere Microspheres loaded with doxorubicin for Trans Arterial Chemoembolization (hqTACE). Participants in both treatment arms will be followed for overall survival, the primary study endpoint.|t|f|f|t
33706266|NCT04404205|||COHORT||CROSS_SECTIONAL|||||||
33706267|NCT00955071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33706268|NCT03685968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33706269|NCT04153669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706270|NCT03673046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706271|NCT04751526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706272|NCT00358371|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706273|NCT01930864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706274|NCT05614505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Given the very different characteristics of the RUTFs, full masking is not possible. Caregivers/mothers are only given 1 product, and do not know of the existence of the other intervention products|randomized controlled trial|t|t|f|f
33706275|NCT03674684|||OTHER||RETROSPECTIVE|||||||
33706276|NCT05495620|||COHORT||RETROSPECTIVE|||||||
33706277|NCT01427101|||COHORT||CROSS_SECTIONAL|||||||
33706278|NCT04993521|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Controlled Study||||
33706279|NCT02420171|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706280|NCT03954197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706281|NCT01072331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706282|NCT06506448|||COHORT||PROSPECTIVE|||||||
33706283|NCT05960799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A list of 72 names, corresponding 36 of them to contiplex C and 36 to regular contiplex will be randomized and will be introduced into sealed envelopes. Before, in order to perform the nerve block the anesthesist will open the envelope and will know wich is the catheter he has to use.|Randomized control trial|t|f|f|f
33706284|NCT00003473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706285|NCT04218422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know whether they got battlefield acupuncture or sham acupuncture|Blinded, randomized trial|t|f|f|f
33706286|NCT00179556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706287|NCT03600818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706288|NCT06359392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790362|NCT01228513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790363|NCT02372019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790364|NCT00339469|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33790365|NCT05670951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790366|NCT05341518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790367|NCT04358640|||OTHER||PROSPECTIVE|||||||
33790368|NCT05554692|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33790369|NCT00520208|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931017|NCT00626769|||COHORT||PROSPECTIVE|||||||
34009408|NCT00179868|||CASE_ONLY||PROSPECTIVE|||||||
34009409|NCT05488717|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33790370|NCT01064765|||||PROSPECTIVE|||||||
34009410|NCT03498599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34009411|NCT03328728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009412|NCT04590768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33790371|NCT05623384|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33931018|NCT00560794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931019|NCT06455384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931020|NCT00003760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009413|NCT01672359|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33931021|NCT00533169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931022|NCT02049229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931023|NCT00004772|RANDOMIZED|||TREATMENT||DOUBLE||||||
33931024|NCT01450969|||COHORT||PROSPECTIVE|||||||
33931025|NCT03221712|||COHORT||RETROSPECTIVE|||||||
34009414|NCT01215799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009415|NCT04243096|NA|SINGLE_GROUP||TREATMENT||NONE|Since this is a single-arm study, no masking is included.|Single-arm interventional study||||
34009416|NCT00000239||||TREATMENT||||||||
34009417|NCT01286558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009418|NCT01552369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009419|NCT01529658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33706289|NCT01753505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706290|NCT05431842|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33706291|NCT01478477|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33706292|NCT02358174|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34009420|NCT00783575|||FAMILY_BASED||PROSPECTIVE|||||||
34009421|NCT06084741|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34009422|NCT04134754|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Basic Experimental Studies in Humans (BESH)||||
34009423|NCT04869709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009424|NCT03829007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093867|NCT01987674|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706293|NCT00451308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706294|NCT04407364|||COHORT||RETROSPECTIVE|||||||
33706295|NCT01524471|NA|SINGLE_GROUP||||NONE||||||
33706296|NCT04580069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|t|f|t|f
33706297|NCT02717585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33706298|NCT03909841|||COHORT||PROSPECTIVE|||||||
33706299|NCT04214769|||COHORT||PROSPECTIVE|||||||
33706300|NCT00868985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706301|NCT03733470|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33706302|NCT03633656|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34093868|NCT05151614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009425|NCT01644487|RANDOMIZED|PARALLEL||TREATMENT||NONE||Provisional stenting with SMART(n=173), Provisional stenting with Complete SE(n=173)||||
34009426|NCT01471587|||COHORT||PROSPECTIVE|||||||
34093869|NCT00723242||||BASIC_SCIENCE||||||||
34093870|NCT01481779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093871|NCT01836822|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34093872|NCT01906164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706303|NCT06064812|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33706304|NCT06046885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706305|NCT05960968|||COHORT||PROSPECTIVE|||||||
33706306|NCT02996513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706307|NCT01555450|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
33706308|NCT06504940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706309|NCT00258869|||COHORT||PROSPECTIVE|||||||
33706310|NCT05209425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel, randomized blinded study|t|f|t|f
33706311|NCT00002133||||TREATMENT||NONE||||||
33706312|NCT01626456|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33706313|NCT03485339|||CASE_CONTROL||OTHER|||||||
34093873|NCT01565551|||COHORT||PROSPECTIVE|||||||
33706314|NCT04263220|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Blinding is not possible in this testing set-up, participants however are not informed about the exact purpose of the tests and which exoskeleton is a prototype and which exoskeleton is a commercially available exoskeleton|Randomized counterbalanced cross-over design|t|f|f|f
33706315|NCT04600557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not told which arm they are assigned to|Participants are randomly assigned to one of four conditions throughout the study.|t|f|f|f
33706316|NCT02959307|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33706317|NCT03460821|||COHORT||PROSPECTIVE|||||||
34093874|NCT03161054|NA|SINGLE_GROUP||TREATMENT||NONE||phase II, multicentre, non-randomized study, single arm study||||
34093875|NCT02086045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706318|NCT01434667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790372|NCT04166682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33790373|NCT00002937|RANDOMIZED|||TREATMENT||||||||
33801765|NCT01256840|||COHORT||CROSS_SECTIONAL|||||||
33801766|NCT00722046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009427|NCT06206603|||CASE_CONTROL||PROSPECTIVE|||||||
33706319|NCT03746652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009428|NCT05663372|RANDOMIZED|CROSSOVER||OTHER||NONE||Two-period, two-sequence, two-way, crossover, single dose study||||
34093876|NCT01732783|||COHORT||PROSPECTIVE|||||||
34093877|NCT03423693|||COHORT||RETROSPECTIVE|||||||
33706320|NCT05459038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multi-center randomized controlled trial||||
34009429|NCT02299219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34009430|NCT01294566|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34009431|NCT00894842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009432|NCT00451152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009433|NCT04845646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009434|NCT02428582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009435|NCT04377048|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's two-stage design||||
34009436|NCT01885182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009437|NCT00500006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009438|NCT00138957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093878|NCT02753673|||COHORT||PROSPECTIVE|||||||
34093879|NCT04899037|||OTHER||PROSPECTIVE|||||||
34093880|NCT00068848|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34093881|NCT04310228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093882|NCT01684605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34093883|NCT02988388|||CASE_ONLY||CROSS_SECTIONAL|||||||
34093884|NCT00727064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34093885|NCT02959762|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34093886|NCT04913675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093887|NCT05598983|||COHORT||OTHER|||||||
34093888|NCT05678114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093889|NCT01209468|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33931026|NCT05369780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33931027|NCT00655304|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34009439|NCT01684215|NON_RANDOMIZED|||TREATMENT||NONE||||||
34009440|NCT05265221|||COHORT||RETROSPECTIVE|||||||
34009441|NCT01047618|||COHORT||PROSPECTIVE|||||||
34009442|NCT03083977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931028|NCT02111629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093890|NCT03312907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931029|NCT02135549|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34093891|NCT01621919|||COHORT||PROSPECTIVE|||||||
33931030|NCT04463238|RANDOMIZED|PARALLEL||TREATMENT||NONE||GCRM-3020\\GCRM-4030||||
33931031|NCT04125381|||COHORT||OTHER|||||||
33931032|NCT00246376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931033|NCT02792283|NA|SINGLE_GROUP||SCREENING||NONE||||||
33931034|NCT05021380|||CASE_CONTROL||PROSPECTIVE|||||||
34093892|NCT04727749|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Consent will be obtained using a deceptive consent form, which will explain that this is a pain study, but will omit any information regarding therapy dogs. Once all measures are taken, the participants will be explained the deception and asked to sign the true consent form.|Data is to be collected 5 days a week, with animal testing days alternating with control days.|t|f|f|f
34093893|NCT01221909|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34093894|NCT04309630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093895|NCT03404167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093896|NCT01244282|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34093897|NCT03419871|||COHORT||PROSPECTIVE|||||||
34093898|NCT00580099|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34093899|NCT05833932|||COHORT||PROSPECTIVE|||||||
34093900|NCT01271738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093901|NCT01370889|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093902|NCT06552026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this clinical trial, a double-blind design will be implemented. Neither the participants nor the researchers conducting the trial will be aware of the specific objectives or the allocation of treatment conditions. This approach is intended to eliminate bias and ensure the integrity of the study's outcomes.|a parallel two-arm model ,Participants were randomized to two groups by coin toss, and delivered rTMS or iTBS over the lDLPFC-NAcc once daily for 15 consecutive days.|t|f|t|f
33706321|NCT04946383|NA|SINGLE_GROUP||TREATMENT||NONE||prospective non-randomized clinical study||||
33706322|NCT00353795|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706323|NCT06267105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706324|NCT03138603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind masking|Single-center, double blinded placebo controlled|t|t|t|f
33706325|NCT04123600|||COHORT||PROSPECTIVE|||||||
33706326|NCT05367622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The research investigators and care provider do not participate in the research processes of recruitment, allocation, and intervention. Simple randomization will be assigned subjects into two groups with prepared envelopes in advance. Both groups had intervention, so the participants did not know whether they belonged to the experimental group or the control group. Outcomes assessor and care provider are different persons. Data will be collected according the list of participants.||t|t|t|t
33706327|NCT04468854|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||"* randomized~* double-blind~* placebo-controlled~* cross-over~* counter-balanced"|t|t|t|t
33706328|NCT01489800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706329|NCT05332197|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33706330|NCT00875875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706331|NCT05478369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33706332|NCT04307303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706333|NCT05698030|||COHORT||RETROSPECTIVE|||||||
33706334|NCT05648383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706335|NCT04432285|||COHORT||CROSS_SECTIONAL|||||||
33706336|NCT01785069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706337|NCT06045884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33706338|NCT05666609|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible due to study design.|Group A: duration of placed seton 4 weeks Group B: duration of placed seton 12 weeks||||
33706339|NCT01095055|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706340|NCT03787732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706341|NCT02542904|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33931035|NCT06244524|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The recruited healthy donors will be randomly distributed into ventilated or closed bedrooms. We will assess the epithelial barrier function on their forearm by electrical impedance spectroscopy before and after 8 hours of sleep in each bedroom. The level of CO2 in the bedrooms will be monitored. In addition, the skin biopsy samples will be collected from fore arm.||||
33931036|NCT03199144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009443|NCT01529307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009444|NCT03081039|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized 1:1 to one of two treatment arms.||||
34009445|NCT04826068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009446|NCT01132664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009447|NCT00458419|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34009448|NCT03989531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009449|NCT02985619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009450|NCT00168207|||COHORT||RETROSPECTIVE|||||||
34009451|NCT03040752|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34009452|NCT02837406|||OTHER||PROSPECTIVE|||||||
34009453|NCT03070691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093903|NCT03090269|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single site, national, pilot study, non-comparative before/after||||
34093904|NCT04456790|||OTHER||PROSPECTIVE|||||||
34093905|NCT05298839|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093906|NCT06159036|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|One of the main researchers evaluated the post-test without knowing who belonged to the control and experimental group, in addition to this, the other investigator was asked to evaluate the pre-test so as not to have biases or generate some type of modification in the results obtained by both groups.|The athletes were divided into two experimental and control groups, for which the experimental group was asked to carry out a protocol that consisted of 12 weeks of intervention divided in a randomized manner, resulting in a pre and post intervention measurement|f|f|t|f
34093907|NCT02478671|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093908|NCT02855983|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706342|NCT03716037|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33706343|NCT05617469|||OTHER||RETROSPECTIVE|||||||
33706344|NCT01634009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33706345|NCT00843947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706346|NCT01392443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706347|NCT06245031|NA|SINGLE_GROUP||TREATMENT||NONE||This is an Open-Label Extension of a previous randomized, sham-controlled study. All subjects in this study will receive treatment with a device with Active treatment settings. Analysis is planned to compare Active-Active treatment group to Sham-Active treatment group (delayed start model).||||
33706348|NCT03399721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706349|NCT00730769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706350|NCT00786734|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706351|NCT05633823|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706352|NCT02116946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33706353|NCT03282643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706354|NCT02998567|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790374|NCT03163953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessor will not involve with the process of subject recruitment and allocation into three groups throughout the 6 months follow-up.||f|f|f|t
33790375|NCT06628453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790376|NCT01514903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790377|NCT04316234|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Vaping was done in another chamber and thereby led into the exposure chamber, so it could not be observed. On days with clean air, vapers were chewing nicotine gum instead of vaping.|A randomised double-blinded cross-over study|t|f|t|t
33790378|NCT01847651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790379|NCT00751491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790380|NCT06412406|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33790381|NCT02377505|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33931037|NCT03587922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931038|NCT04523467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931039|NCT05187845|||COHORT||PROSPECTIVE|||||||
33931040|NCT02697058|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33931041|NCT04171063|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be allocated to use the thoracic compressor for 16 months||||
33931042|NCT05378048|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients are randomized to PDO-guided treatment or standard of care.||||
33931043|NCT04703062|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33931044|NCT01199497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093909|NCT03997305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706355|NCT03787264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706356|NCT05744284|||COHORT||RETROSPECTIVE|||||||
33706357|NCT05901428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009454|NCT01755117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009455|NCT05589350|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34009456|NCT06617091|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomized controlled Double - blinded||t|t|t|f
34009457|NCT02356211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
33706358|NCT02702804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706359|NCT02951065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34009458|NCT05965102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706360|NCT04924556|||COHORT||PROSPECTIVE|||||||
34009459|NCT02529202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706361|NCT06556446|||COHORT||PROSPECTIVE|||||||
34093910|NCT01359423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093911|NCT03510702|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093912|NCT05529953|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Double-blind trial. Each recruited participant is assigned a random alphanumeric ID code. Assignment of participants to study groups is done by randomization of their ID.~The olive oils (functional and control) used in the postprandial trial are labeled with alphanumeric codes known only to the principal investigator of the project."||t|t|f|f
34093913|NCT03042637|||CASE_ONLY||CROSS_SECTIONAL|||||||
34009460|NCT05690815|||COHORT||PROSPECTIVE|||||||
34009461|NCT06311669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009462|NCT02915237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009463|NCT04190563|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigator and data analyst will be blind to study condition.||f|f|t|f
34009464|NCT00961454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009465|NCT01640184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009466|NCT06306092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009467|NCT05248204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments will be performed by two dental examiners that are independent of the dentist that placed the restorations and are blinded to the treatment arms.|This is a prospective, randomized, controlled, open-label, assessor-blinded, split-mouth, single-center post-market clinical follow-up study.|f|f|f|t
34009468|NCT02221596|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
34009469|NCT06429982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be double-blinded. The pharmacy will determine which patients are in the study group.|There will be a 2: 1 treatment ratio of dexamethasone treated group versus placebo.|t|t|t|t
34093914|NCT01456923||||TREATMENT||||||||
34093915|NCT01363440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093916|NCT05143775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093917|NCT03802357|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into two Intervention Groups (high vs. moderate Training intensity).||||
33931045|NCT04289194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931046|NCT00625014|NA|SINGLE_GROUP||OTHER||NONE||||||
33931047|NCT03275805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931048|NCT00698776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931049|NCT00666536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931050|NCT01900223|||CASE_ONLY||CROSS_SECTIONAL|||||||
33931051|NCT02260388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931052|NCT02650440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931053|NCT05145790|||CASE_ONLY||RETROSPECTIVE|||||||
33931054|NCT06305091|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931055|NCT04399057|||CASE_ONLY||PROSPECTIVE|||||||
33931056|NCT05143918|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931057|NCT01546090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931058|NCT01736709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33931059|NCT02979561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931060|NCT03699904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be randomised, double-blind trial with matching placebo.|Parallel assignment.|t|t|t|t
33931061|NCT05409118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931062|NCT00333970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931063|NCT05058118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931064|NCT04823741|||CASE_ONLY||PROSPECTIVE|||||||
33931065|NCT03523949|NA|SINGLE_GROUP||OTHER||NONE||||||
33931066|NCT03007628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009470|NCT05403957|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009471|NCT05530473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009472|NCT03121014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706362|NCT01671800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706363|NCT02885103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706364|NCT05164185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009473|NCT04531787|||COHORT||PROSPECTIVE|||||||
34009474|NCT06079918|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial is quadruple blind with all trial participants, outcome assessors (research staff and care providers), investigators, and trials statistician and data analysts being unable to determine the allocated trial arm for any trial participant or identify trial participants who are on the same trial regimen.||t|t|t|t
33706365|NCT01698515|||CASE_ONLY||CROSS_SECTIONAL|||||||
33931067|NCT01339208|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931068|NCT05258526|NA|SINGLE_GROUP||TREATMENT||NONE||This a feasibility trial to assess a home-based exercise intervention individuals with breast or prostate cancer during treatment.||||
33931069|NCT00083304|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009475|NCT03917511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009476|NCT00407745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009477|NCT02740179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009478|NCT03020719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34009479|NCT06616116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009480|NCT03768284|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34009481|NCT01911806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009482|NCT03532230|||COHORT||PROSPECTIVE|||||||
34009483|NCT04451187|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34009484|NCT05329285|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, multicentre randomized registry trial||||
34009485|NCT03063216|||OTHER||PROSPECTIVE|||||||
34009486|NCT00003242||||TREATMENT||||||||
34009487|NCT01684878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093918|NCT00693264|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34093919|NCT03005756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093920|NCT02646059|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34093921|NCT00585650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093922|NCT02517489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706366|NCT05893576|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a single-dose, parallel design trial, consisting of two parallel groups: a reference formulation group (R: original formulation) and a test formulation group (T: new formulation). Both R and T groups receive a same dose of HRS9531.||||
33706367|NCT00886574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706368|NCT02576002|||COHORT||RETROSPECTIVE|||||||
33706369|NCT03873844|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study. Two baseline assessments precede intervention, which is followed by post-treatment testing.||||
33706370|NCT01425996||SEQUENTIAL||TREATMENT||NONE||||||
33706371|NCT05111873|||CASE_CROSSOVER||PROSPECTIVE|||||||
33706372|NCT06535386|||COHORT||PROSPECTIVE|||||||
33790382|NCT04299360|||CASE_CONTROL||PROSPECTIVE|||||||
34093923|NCT06099379|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||In this crossover design, participants will be administered all phytocannabinoid doses contained in the four CBD:THC products and the control product (THC only) during participation in the study. Participant will be randomly assigned to one of the predetermined sequences with a CBD:THC product or control product at 5 dosages (CBD:THC of 0:20 mg, 20:20 mg, 40:20 mg, 80:20 mg and 120:20 mg). Participants will be randomized based on a balanced 5 by 5 Latin square.|t|t|t|t
34093924|NCT01899885|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093925|NCT05550181|||COHORT||PROSPECTIVE|||||||
34093926|NCT04657900|||COHORT||RETROSPECTIVE|||||||
34093927|NCT04939584|NA|SINGLE_GROUP||OTHER||NONE||A prospective non-randomized feasibility study involving acute evaluation of the perception and acceptance of MPT as a therapy to stop episodes of AF in subjects having a history of AF during clinically indicated acute electrophysiology procedures including AF ablation, SVT ablation or diagnostic EP procedures (indicated procedure).||||
34093928|NCT05408221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093929|NCT04970108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093930|NCT00690898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093931|NCT03411538|||COHORT||PROSPECTIVE|||||||
34093932|NCT02845388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34093933|NCT05426668|||CASE_ONLY||PROSPECTIVE|||||||
34093934|NCT02156661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093935|NCT00051727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34093936|NCT04620538|||CASE_CONTROL||PROSPECTIVE|||||||
33931070|NCT04039763|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomised controlled crossover study||||
34093937|NCT03573856|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34093938|NCT00330096|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34093939|NCT02911467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093940|NCT00299221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093941|NCT03476577|||CASE_ONLY||PROSPECTIVE|||||||
34093942|NCT02293499|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the overt nature of the intervention, blinding either participants or investigators was not achieved although we did not inform participants of their group membership explicitly.|||||
34093943|NCT05257187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study team will randomize patients to one of the following two groups: foley balloon removal after 6 hours or foley balloon removal after 12 hours. All patients will receive simultaneous pitocin and foley balloon. The remainder of the induction course (i.e. rupture of membranes, etc.) will be left to the discretion of the obstetric provider. The study is intention-to-treat meaning that if the foley balloon falls out earlier than the 6 hour or the 12 hour mark, the patient will still be included in the study.|f|f|f|t
33790383|NCT01960803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931071|NCT04644055|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931072|NCT02552667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931073|NCT00345514|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931074|NCT05628129|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33931075|NCT06395740|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"All participants are to be resuscitated at first and second days of admission keeping all of them NPO then to be randomly divided according to the method of obtaining their nutritional needs into two groups. Energy target will be set at 30 kcal/ kg IBW in males and 25 Kcal/kg IBW in females, while protein requirements will be set at 1.2 g/kg IBW~First group (group A):~Group A patients will be scheduled for continuation of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route guided by Aspen2020 guidelines.~Second group (group B):~Group B patients will be scheduled for enteral nutrition via nasogastric tube."|f|f|f|t
33931076|NCT02373306|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33931077|NCT03385434|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33931078|NCT01782404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931079|NCT02572804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931080|NCT04090697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931081|NCT00815776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931082|NCT00466024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33931083|NCT02977533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931084|NCT05658419|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Operator Data collector Examiner|Study group (socket shield) vs. Control group (immediate implants)|t|t|t|t
34093944|NCT01692587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706373|NCT04571177|||COHORT||PROSPECTIVE|||||||
33706374|NCT02647060|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34093945|NCT00143520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34093946|NCT02399800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093947|NCT02625012|||CASE_ONLY||PROSPECTIVE|||||||
34093948|NCT04862208|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34009488|NCT01219452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706375|NCT02362269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009489|NCT00233987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009490|NCT03001999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009491|NCT01197768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706376|NCT01301352|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34093949|NCT03653078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|during the insertion procedure the principle investigator and the co supervisor couldn't be blinded, as the two insertion techniques are completely different.|adult orthodontic participants|t|f|f|t
34093950|NCT04740190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093951|NCT01554813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093952|NCT04825899|||CASE_ONLY||PROSPECTIVE|||||||
34093953|NCT01503801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093954|NCT04038398|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33790384|NCT04538820|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33790385|NCT03561428|||OTHER||CROSS_SECTIONAL|||||||
33931085|NCT04347616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is divided in two phases. In phase I, we will determine the safety of our UCB-NK cell product with or without sc IL-2, following a non-myeloablative immunosuppressive conditioning regimen in patients with AML. Three patients will receive NK cells without IL-2. If no dose limiting toxicities occur another three patients will receiving NK cells with a low dose IL-2, and if safe, another six patients will receive NK cells with a higher dose IL-2.~The primary objective of phase IIa of the study is to evaluate the effect of UCB-NK cell adoptive immunotherapy in combination with SC IL-2 following a non-myeloablative immunosuppressive conditioning regime on disease activity in patients with AML. Therefore 17 patients will be evaluated using a Simon's optimal two-stage single-arm study design, with 10 patients in the first stage and an additional 7 patients in the second stage. These patients will receive NK cells with the highest tolerable dose IL-2, established after phase I."||||
33931086|NCT03137875|||OTHER||CROSS_SECTIONAL|||||||
33931087|NCT02225925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931088|NCT04486612|||CASE_CONTROL||PROSPECTIVE|||||||
33931089|NCT02597985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931090|NCT04442386|||OTHER||PROSPECTIVE|||||||
33931091|NCT01706991|||CASE_CONTROL||PROSPECTIVE|||||||
33931092|NCT03896906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009492|NCT01456741|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34009493|NCT01131962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009494|NCT03074864|NA|SINGLE_GROUP||TREATMENT||NONE||EGFR-TKI intercalted with radiotherapy||||
34009495|NCT02181296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009496|NCT04847596|||COHORT||PROSPECTIVE|||||||
34009497|NCT05796232|||OTHER||CROSS_SECTIONAL|||||||
34009498|NCT02624167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009499|NCT04893122|||COHORT||RETROSPECTIVE|||||||
34009500|NCT03327090|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34009501|NCT02730468|||CASE_ONLY||PROSPECTIVE|||||||
34009502|NCT05254158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009503|NCT04881162|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with acute ischemic anterior circulation stroke due to large vessel embolic occlusion who are candidates for endovascular therapy and in whom transfemoral therapy failed.||||
33706377|NCT02504840|||OTHER||PROSPECTIVE|||||||
33706378|NCT03132818|||CASE_CONTROL||PROSPECTIVE|||||||
33706379|NCT01234948|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33706380|NCT00824720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706381|NCT03996733|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706382|NCT02981017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706383|NCT03204019|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33706384|NCT01204437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706385|NCT01201005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33706386|NCT06145672|RANDOMIZED|PARALLEL||TREATMENT||NONE||To hide alopecic scars with some hairs harvested as FUs at the back of the scalp under local anaesthesia without leaving any residual deformity or adding more scars to the donor area and implant it in the non-hairy scars.||||
33706387|NCT04444895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706388|NCT00764283|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706389|NCT06114225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706390|NCT06504797|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33706391|NCT00092612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706392|NCT02330237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706393|NCT05544734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706394|NCT04452682|||CASE_ONLY||RETROSPECTIVE|||||||
33706395|NCT06315348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded parties will not be aware of the type augmentation used during the intervention.|Comparative 2-arm parallel double-blinded randomized controlled clinical trial|t|f|t|t
33706396|NCT03582189|||COHORT||PROSPECTIVE|||||||
33706397|NCT01564914|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 6 initial patients were treated with 10 mg/kg of TRC105 monotherapy. All patients progressed within 2 months of initiating treatment, reflecting the rapid progression. Due to the lack of activity in this disease setting with TRC105 alone, the study was amended to treat patients with 10 mg/kg TRC105 weekly in combination with 10 mg/kg bevacizumab every two weeks.||||
33706398|NCT05223933|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study was a two-arm cluster randomized community intervention trial, with 11 fokontany in the intervention arm implementing malaria pro-CCM and 11 in the control arm. In both arms, CHWs provided passive integrative community case management (iCCM) among children under five per usual standard of care, including diagnosis with RDT for febrile illness, treatment with artesunate-amodiaquine according to RDT results, along with diagnosis and management of acute respiratory infections and diarrhea, and referral to a higher level of care if indicated. Oral rehydration salts, antibiotics were distributed to CHWs in the intervention arm to reinforce the iCCM activities already implemented.||||
33706399|NCT05662007|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33706400|NCT05656495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706401|NCT01211470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706402|NCT01577420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33706403|NCT06558513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706404|NCT00948636|||COHORT||PROSPECTIVE|||||||
33706405|NCT02984111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706406|NCT01815216|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706407|NCT05142163|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patient were masked about belonging to SVV Guided or PVI Guided Group to receive Intraoperative Fluid Therapy|Patients were allotted to either SVV Guided or PVI Guided Intraoperative Fluid Therapy|t|f|f|f
33706408|NCT03617497|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||The investigators will perform 48-hour ambulatory scalp-EEG and polysomnography in 100 participants with Alzheimer disease and 30 age-and gender-matched healthy participants. The investigators will determine the prevalence of 1.) epileptic discharges and epileptic seizures, 2.) sleep wake disorders and 3.) the interaction of epilepsy and sleep wake disorders in these two groups. A subgroup of 15 of these 100 participants with Alzheimer disease, with interictal epileptic spikes or sleep wake disorders (e.g., frequent nocturnal awakenings) will be invited to undergo an invasive EEG study with foramen ovale electrodes to determine the prevalence of hippocampal seizures, which are usually clinically silent and not detected with scalp EEG.||||
33706409|NCT02165969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33706410|NCT02166905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706411|NCT04158115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706412|NCT03021460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706413|NCT00750997|||CASE_CONTROL||PROSPECTIVE|||||||
33706414|NCT03978832|NA|SINGLE_GROUP||TREATMENT||NONE||The study will enroll subjects currently on a stable dose of 5 or 6 mg of oral risperidone. After screening, eligible subjects will be admitted to the clinical unit and stabilized on 6 mg daily (3 mg oral risperidone twice a day) for 5 days, followed by an additional 3 days, during which the first injection of PERSERIS will be administered. Subjects will then return to the clinical unit every 28 days for an additional 3 admit periods for subsequent PERSERIS injections (2 injections per visit).||||
33790386|NCT02834143|||COHORT||PROSPECTIVE|||||||
33790387|NCT04302155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790388|NCT00697814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33790389|NCT03707678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind study where the investigators and subjects will be blinded and sponsor remains unblinded.|This will be a parallel-group study. Subjects will be randomized in 1:1 ratio to receive GSK2245035 or placebo once weekly for 8 weeks.|t|f|t|f
33790390|NCT03319589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790391|NCT01419730|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33790392|NCT02327104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790393|NCT05703204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790394|NCT02341924|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33790395|NCT05547191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790396|NCT04095403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled trial||||
33790397|NCT04930393|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patient and Provider won't be aware of what block will be administered until just before the nerve block is done||t|t|f|t
33790398|NCT02533206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790399|NCT00530842||CROSSOVER||TREATMENT||||||||
33931093|NCT02767206|||OTHER||PROSPECTIVE|||||||
33931094|NCT03111589|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34009504|NCT06335459|||OTHER||CROSS_SECTIONAL|||||||
34009505|NCT00031928||||TREATMENT||||||||
33790400|NCT04107805|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33790401|NCT04270734|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33790402|NCT01851928|||COHORT||PROSPECTIVE|||||||
33931095|NCT01426724|NA|SINGLE_GROUP||||NONE||||||
33931096|NCT06119997|||COHORT||PROSPECTIVE|||||||
33931097|NCT04556201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931098|NCT05783492|NA|SINGLE_GROUP||OTHER||NONE||Intranasal ketamine 10 mg/kg single dose||||
33931099|NCT01000519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33931100|NCT06087094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931101|NCT04459104|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
33931102|NCT04679714|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-arm registry||||
33931103|NCT04907812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Prospective, Randomized Controlled, Double-Blinded Pilot Study|t|f|t|f
33931104|NCT04693806|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33931105|NCT03868670|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34009506|NCT04625192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009507|NCT00519922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009508|NCT02440035|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33706415|NCT06135753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed if they will receive the psychosomatic intervention or the control condition. At the end of the study they will receive this information.|This is a pilot study, designed as a cross-sectional observation study (study 1) and as a randomized (1:1) controlled trial, comparing a multidisciplinary psychosomatic intervention based on cognitive restructuring vs a control condition both followed by museum therapy (study 2). The participants will receive a baseline psychosomatic assessment to confirm the diagnosis of fibromyalgia, then socio-demographic information, information on pharmacological/non-pharmacological treatments, on the history of medical diseases and on the psychological status will be collected. Thereafter, the subjects will be randomly assigned to experimental group or to a control condition. The subjects will be re-assessed at the end of session 4, and at the end of session 7, 8, 9 of museum therapy and at 3 and 6-month follow-up.|t|f|f|f
33706416|NCT03305835|||COHORT||RETROSPECTIVE|||||||
33706417|NCT02333097|||CASE_ONLY||PROSPECTIVE|||||||
33706418|NCT02147236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33706419|NCT06504836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790403|NCT00678795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33790404|NCT02595398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790405|NCT00619645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790406|NCT05689268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790407|NCT04565522|||COHORT||PROSPECTIVE|||||||
33790408|NCT05644080|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with recurrent grade 3 and grade 4 glioma will be recruited for treatment with 177Lu-PSMA.||||
33790409|NCT02967237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790410|NCT04914936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790411|NCT04856228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790412|NCT04279171|||COHORT||PROSPECTIVE|||||||
33790413|NCT06417593|||COHORT||CROSS_SECTIONAL|||||||
33790414|NCT01711307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790415|NCT04586036|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33790416|NCT01729819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790417|NCT04580108|||COHORT||PROSPECTIVE|||||||
33790418|NCT02573792|||COHORT||PROSPECTIVE|||||||
33790419|NCT04689321|||COHORT||CROSS_SECTIONAL|||||||
33790420|NCT00207844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790421|NCT03275077|||CASE_CONTROL||PROSPECTIVE|||||||
33931106|NCT04922710|NA|SINGLE_GROUP||TREATMENT||NONE||A single group assigned a remote exercise intervention||||
33931107|NCT00262327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931108|NCT04727645|||COHORT||PROSPECTIVE|||||||
33931109|NCT02429349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790422|NCT03012230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931110|NCT02318069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931111|NCT05735236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931112|NCT05483283|RANDOMIZED|PARALLEL||SCREENING||NONE||Empowerment and navigation and Standard of Care (SOC) (Control)||||
33931113|NCT05370846|||OTHER||PROSPECTIVE|||||||
33931114|NCT04682106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33931115|NCT05795400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a single-center, pilot, prospective, randomized, placebo-controlled clinical trial|t|f|f|f
33931116|NCT01300767|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33931117|NCT02394262|NA|SINGLE_GROUP||OTHER||NONE||||||
33931118|NCT00433667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931119|NCT00054756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009509|NCT04969042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009510|NCT04682509|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34009511|NCT03920683|||COHORT||OTHER|||||||
34009512|NCT06616935|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention one: community activities. Intervention two: online exercises and activities.||||
34009513|NCT04664816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34009514|NCT06126861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009515|NCT03028896|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34009516|NCT00833508|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009517|NCT00966381|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009518|NCT03991442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790423|NCT02929511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009519|NCT02647528|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34009520|NCT03758573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Compare the effectiveness of early inspiratory muscle training (IMT) versus non-IMT in patients undergoing mechanical ventilation to improve the outcome of mechanical ventilation weaning time.|f|f|t|t
33790424|NCT00271765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33790425|NCT04346524|||COHORT||PROSPECTIVE|||||||
33801767|NCT02973594|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009521|NCT02336620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009522|NCT01464151|||COHORT||PROSPECTIVE|||||||
33931120|NCT05157776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009523|NCT05008016|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34009524|NCT04755582|||COHORT||CROSS_SECTIONAL|||||||
34093955|NCT05285449|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The CBD and placebo formulations are prepared, bottled, and coded by Caliper Foods. The participants will receive a coded bottle to consume of the different formulations of CBD and placebo.|Double-Blind random assignment to either placebo or active CBD (2 x 30 mg daily)|t|f|t|t
34093956|NCT03555786|||CASE_ONLY||PROSPECTIVE|||||||
34093957|NCT03923920|||COHORT||PROSPECTIVE|||||||
33931121|NCT02885272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931122|NCT02708966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931123|NCT05337345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931124|NCT04100291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931125|NCT02049788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093958|NCT01910532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093959|NCT05729191|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34093960|NCT05664594|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009525|NCT02918682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;|f|t|f|f
34009526|NCT05546242|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel open-label phase 3b study. Participants will be randomised to continuing current therapy or switching to injectable therapy.||||
33706420|NCT00297583|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34009527|NCT01914523|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34093961|NCT02239055|||CASE_CONTROL||RETROSPECTIVE|||||||
34093962|NCT03368677|||CASE_CONTROL||PROSPECTIVE|||||||
34093963|NCT02703025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||open level||||
34093964|NCT03967327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093965|NCT04332120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093966|NCT05788965|NA|SINGLE_GROUP||TREATMENT||NONE||This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with CFRD.||||
34093967|NCT05982119|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34093968|NCT00133354|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34093969|NCT01280994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34093970|NCT00990769|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34093971|NCT00109369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093972|NCT04795323|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706421|NCT02859311|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706422|NCT03342716|||COHORT||PROSPECTIVE|||||||
33706423|NCT00365911|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706424|NCT01463488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706425|NCT05545709|||COHORT||RETROSPECTIVE|||||||
33706426|NCT01744574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931126|NCT04046276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Study participants will be unaware of the hypothesis.~* All investigator assessors, clinical, cardiological, biomechanical or through SPECT \[123I\] beta-CIT striatal uptake measurements, will be unaware of the participant group"|"Single-blind randomized study, three parallel groups (n= 7 or 8 per group and per center, over 3 centers):~* Group 1 Conventional Physical Therapy, CPT~* Group 2 Medium Intensity Aerobic program, MIA (50% VO2 max);~* Group 3 High Intensity Aerobic program, HIA (70% VO2 max); HIA and MIA groups are experimental groups and CPT group is the control group. Each group will attend 3 weekly 45-minute sessions at the hospital for 9 months."|f|f|t|t
33931127|NCT05770739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33931128|NCT01898962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931129|NCT06350149|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33931130|NCT02947334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931131|NCT02161523|||OTHER||PROSPECTIVE|||||||
33931132|NCT04820036|NA|SINGLE_GROUP||OTHER||NONE||Prospective pilot observational study||||
33931133|NCT02885389|||CASE_ONLY||PROSPECTIVE|||||||
33931134|NCT03387930|||CASE_CONTROL||PROSPECTIVE|||||||
33931135|NCT05843617|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33931136|NCT06237673|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33931137|NCT00946023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931138|NCT01249157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931139|NCT04143425|||COHORT||PROSPECTIVE|||||||
33931140|NCT02352649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931141|NCT02525952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931142|NCT04323891|||CASE_CONTROL||PROSPECTIVE|||||||
33931143|NCT04485468|||CASE_ONLY||PROSPECTIVE|||||||
33931144|NCT04929847|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931145|NCT00440141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931146|NCT05369793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931147|NCT01209572|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931148|NCT01834976|||COHORT||PROSPECTIVE|||||||
33931149|NCT03099798|||COHORT||PROSPECTIVE|||||||
33931150|NCT05476380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009528|NCT04831320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009529|NCT06052787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34093973|NCT01384409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093974|NCT00169260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093975|NCT04481659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34093976|NCT00150527|||COHORT||PROSPECTIVE|||||||
34093977|NCT05728229|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional randomized controlled pilot study||||
34093978|NCT03189953|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparison of 68Ga-NODAGA-exendin PET/CT with standard diagnostic methods||||
33706427|NCT02559271|||||PROSPECTIVE|||||||
33706428|NCT01039415|||CASE_ONLY||PROSPECTIVE|||||||
33706429|NCT04153331|NA|SINGLE_GROUP||OTHER||NONE||||||
33706430|NCT04036890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The examiners (PI and Outcomes Assessors) will be blinded during the clinical examination of the patients. The topical antibiotic will be administered by a trained and delegated clinician who is not involved in the outcome assessment.~Patients will be blinded to their treatment group as well."|Randomised, double blinded trial in parallel group|t|f|t|t
33706431|NCT03569436|||COHORT||RETROSPECTIVE|||||||
33801768|NCT06384820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009530|NCT03068845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, referring physicians, outcomes assessors and data analysis team will be masked. The procedurist will not be masked since it is not possible to perform the procedure without masking. The procedurist will not be involved in outcomes assessment.||t|t|f|t
34009531|NCT01119807|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009532|NCT03407612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009533|NCT02656082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009534|NCT04615845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009535|NCT05410821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||classic 3+3 dose escalation||||
34009536|NCT02235584|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009537|NCT00120276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706432|NCT05209360|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded to the testing conditions to the greatest extent possible.|Participants will be evaluated without a CDO (NoCDO), with a CDO and no wedge (CDO), with a CDO and a wedge placed on the medial aspect of the shoe (Medial), and with a CDO and a wedge placed on the lateral aspect of the shoe (Lateral)|t|f|f|f
34093979|NCT03805048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized to either native vessel PCI or PCI of the venous bypass graft in a 1:1 fashion. Randomization will be performed using an interactive Web-based randomization system, Open Clinica|t|f|f|f
34093980|NCT02050295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34093981|NCT01422447|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34093982|NCT00516854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34093983|NCT00231192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093984|NCT01635647|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34093985|NCT06516848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|t|f
34093986|NCT03531658|||COHORT||PROSPECTIVE|||||||
34093987|NCT02274428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093988|NCT01911325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093989|NCT03144206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34093990|NCT04565223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34093991|NCT00344825|||COHORT||PROSPECTIVE|||||||
34093992|NCT06217146|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34093993|NCT02829814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34093994|NCT01292538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34093995|NCT05044988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34093996|NCT03509597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are trained to not comment about the type of treatment they have been assigned to with the investigator who performs the assessments.|Randomized parallel assignment: Cognitive Training, Aerobic Exercise \& Treatment as usual.|f|f|t|t
34093997|NCT01171573|||CASE_CONTROL||PROSPECTIVE|||||||
34093998|NCT05840406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be randomly allocated to either a group SA receiving the standard postoperative analgesia or groups receiving the TAP block with levobupivacaine (group L) or levobupivacaine with the addition of dexmedetomidine (group D). The allocation sequence will be generated by a random number table. After signing an informed consent, participants and an anesthesiologist performing the TAP block will be informed about patients' group allocation. An independent observer, who will not know which group the participant belongs to, will assess wound healing using the standardized REEDA scale 72 hours after the cesarean delivery. The same independent observer will assess every participant at 4, 8, 12, 18, 24, and 72 hours after surgery for pain by using the pain numerical rating scale.|Prospective single-blind randomized control trial|f|f|f|t
34093999|NCT00267982|||COHORT||RETROSPECTIVE|||||||
34094000|NCT04344093|NA|SINGLE_GROUP||TREATMENT||NONE||Connected patch validation||||
34094001|NCT00688779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706433|NCT04600375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706434|NCT01044628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33706435|NCT02486497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706436|NCT03220360|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34094002|NCT05890820|||CASE_CONTROL||PROSPECTIVE|||||||
34094003|NCT01144806|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706437|NCT02399722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790426|NCT05037032|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Randomized double-blind, placebo controlled crossover trial||t|f|t|t
33790427|NCT00128596||||TREATMENT||NONE||||||
33790428|NCT04856540|||CASE_CONTROL||RETROSPECTIVE|||||||
33790429|NCT02711826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790430|NCT01912703|||COHORT||RETROSPECTIVE|||||||
34094004|NCT02022527|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34094005|NCT00709631|||COHORT||PROSPECTIVE|||||||
34094006|NCT01940146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790431|NCT03563391|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A prospective, open-label, multi-site, growth, safety and tolerance study.||||
34009538|NCT02201979|||CASE_ONLY||PROSPECTIVE|||||||
33790432|NCT00143689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790433|NCT06374667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790434|NCT06214221|RANDOMIZED|PARALLEL||TREATMENT||NONE||In an open-label randomization model, participants and researchers both know the treatment each participant is receiving. This model involves randomly assigning participants to different treatment groups, ensuring unbiased distribution across interventions, but without concealing the nature of the treatment from either the participants or the study team.||||
33931151|NCT00029289|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33931152|NCT03349593|||COHORT||PROSPECTIVE|||||||
33931153|NCT01427660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33931154|NCT05560919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant will be blinded, the drug administrator will be blinded too, and the investigator who will give the treatment and explain the pain scale to the participant and ask him\\her to point to the face that fits the degree of his pain that associated with the drug administration will also be blinded.|Parallel Assignment, A randomized, controlled, parallel, double-blind clinical study|t|f|t|f
33931155|NCT01894425|||COHORT||PROSPECTIVE|||||||
33931156|NCT04359121|||COHORT||PROSPECTIVE|||||||
33931157|NCT05538429|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33931158|NCT00002146||||TREATMENT||DOUBLE||||||
33931159|NCT04569760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931160|NCT03408886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In Part 1, everyone is blinded except for the research pharmacist. In Part 2, the participants and study coordinator are unblinded, but the professional evaluators are blinded.|There are two groups. In Part 1, group A receives treatment and group B receives placebo. In Part 2, group A continues to receive treatment, and group B is switched to treatment.|t|t|t|t
33931161|NCT00186472|RANDOMIZED|PARALLEL||||NONE||||||
33931162|NCT06175754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931163|NCT02673528|||CASE_CONTROL||RETROSPECTIVE|||||||
33931164|NCT04723004|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33931165|NCT04044313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790435|NCT04673851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790436|NCT02446223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790437|NCT03755440|NA|SINGLE_GROUP||TREATMENT||NONE||PD-1 antibody, SHR-1210||||
33790438|NCT02960139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790439|NCT01891968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801769|NCT01598870|||COHORT||PROSPECTIVE|||||||
33801770|NCT04810260|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33931166|NCT06228443|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931167|NCT01922739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931168|NCT03935490|||CASE_ONLY||RETROSPECTIVE|||||||
33931169|NCT01561040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931170|NCT03903276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931171|NCT00322751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931172|NCT01379430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931173|NCT04617106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||In patients undergoing elective surgery who need arterial catheter placement, radial artery cannulation will be done using either the conventional palpation method or USG-guided dynamic needle tip positioning method before the induction of anaesthesia. In one group, radial artery cannulation will be done using the conventional palpation method, and in the second group, USG-guided dynamic needle tip positioning method will be employed.|f|f|f|t
33931174|NCT00151541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931175|NCT00307814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931176|NCT00069017|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34009539|NCT04082936|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009540|NCT01548989|||CASE_ONLY||CROSS_SECTIONAL|||||||
34009541|NCT05308680|||CASE_CONTROL||PROSPECTIVE|||||||
34009542|NCT05451940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009543|NCT01716884|||COHORT||PROSPECTIVE|||||||
34009544|NCT05004064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009545|NCT05878379|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental (pre-test post-test) design with follow-up / Behavioral intervention, based on the Health Belief Model||||
34009546|NCT00777933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009547|NCT04651322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009548|NCT03978312|||COHORT||PROSPECTIVE|||||||
34009549|NCT03261362|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34009550|NCT01729026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009551|NCT01398059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34009552|NCT00009035|||CASE_ONLY||PROSPECTIVE|||||||
34009553|NCT01279252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009554|NCT03851588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel assignment of randomised groups with stratification by ART-naïve versus first-line interrupter status|t|t|t|f
33790440|NCT05853224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double-blinded: patients and the treating investigator will not know which variant of each product (with and without lidocaine) will be injected in the left/right side of the face (or in the upper/lower lip for CLHA Hydrogel 20 mg/ml) and the evaluating investigator will be different from the treating investigator.|"Each Subject, after signing the Informed Consent (ICF), will enter into a screening phase during which the baseline tests will be conducted.~At baseline visit (V0), according to the Instruction For Use (IFU) and to Investigator's judgment based on the patient's starting clinical situation, the subject will be treated with one of the three variants of Crosslinked Hyaluronic Acid (CLHA) Hydrogel as indicated below:~* CLHA Hydrogel 26 mg/ml (with and without lidocaine) will be injected in the hypodermis of the nasolabial folds (NLFs);~* CLHA Hydrogel 20 mg/ml (with and without lidocaine) will be injected in the lips mucosa/submucosa;~* CLHA Hydrogel 18 mg/ml (with and without lidocaine) will be injected in the superficial dermis of the perioral lines."|t|f|f|t
34009555|NCT02866240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706438|NCT04180358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The impact group who is randomly selected will receive the intervention in Physical Education and Health Education classes. The control group will receive the general health and physical education curriculum provided by New Mexico's Public Education Department. No students will take a class twice unless there is a failing grade. Student will be tracked throughout the school year to ensure there is no cross contamination. Additionally, Counselors will work closely with Capacity Builder's program staff to ensure that in between semesters, students will remain in their original group. Program staff will double check at the beginning of each semester to crosswalk student assignments. Additionally, participants in the past Capacity Builder's Inc. Teen Pregnancy Prevention programs will be excluded to minimize the risk that the comparison group participants are exposed to teen pregnancy prevention curricula and, thus, to increase contrast between the intervention and control conditions.|CBI will implement the Youth Builders PREIS Native STAND curriculum, a comprehensive sexual health curriculum designed for Native high school students that focuses on STI's, HIV/AIDS, and teen pregnancy prevention and covers drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Youth Build will enroll 834 youth in 3 cohorts with 42 clusters of 20 students, each who will be randomly assigned to an impact or a comparison group. Students will complete pre and post survey questionnaires and be provided incentives to maintain program participation. The program will have 4 staff: Project Director, Project Coordinator, and 2 Prevention Educations responsible for collecting data and tracking progress as well as implementing the curriculum|t|f|f|f
34009556|NCT04666688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1/2, two part, open-label study, which will enroll Part 1 and Part 2 sequentially. Part 1 is a single agent dose escalation design utilizing a continuous reassessment method (CRM) and a combination portion using a 4+2 study design. Part 2 is dose expansion into specific disease indications based on outcomes from Part 1.||||
34009557|NCT00141141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094007|NCT02619513|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33706439|NCT00134082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706440|NCT02592356|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33706441|NCT05797675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706442|NCT03764384|||CASE_CROSSOVER||PROSPECTIVE|||||||
33790441|NCT02076919|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33790442|NCT00518557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790443|NCT00127829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790444|NCT05901519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790445|NCT00803933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790446|NCT00526955|||||PROSPECTIVE|||||||
33790447|NCT03591809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To ensure blinding, the assessor physiotherapist will not be aware of the arm to which the subjects belong|Randomized, controlled, single-blind trial|f|f|f|t
33790448|NCT05359913|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33790449|NCT00699673|||CASE_ONLY||PROSPECTIVE|||||||
33790450|NCT00377455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790451|NCT03724838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|both participants and researchers will be blinded to the intervention given|We will conduct a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of Esomeprazole alone or with Sildenafil Citrate in preterm pregnancies complicated by preeclampsia.|t|t|t|t
33790452|NCT00597350|||CASE_ONLY||PROSPECTIVE|||||||
33790453|NCT00089258||||TREATMENT||NONE||||||
33790454|NCT05672446|RANDOMIZED|PARALLEL||OTHER||SINGLE||The research was carried out using a convergent parallel design, which is a mixed method, which includes a randomized controlled study with a pretest-posttest control group, which is one of the quantitative research methods, and a phenomenological approach, one of the qualitative research designs.|t|f|f|f
33931177|NCT03205189|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized, prospective, study||||
33931178|NCT01802034|||COHORT||PROSPECTIVE|||||||
33931179|NCT03875222|||COHORT||PROSPECTIVE|||||||
33931180|NCT05553262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is possible because caregivers must accept and comply a strict schedule of visits for three years. The dentists are aware of the participation to the protocol because they use additional supports and strategies, like a longer duration of the visit.|Both treated and control groups will receive the same clinical intervention (dental care) when needed. Treated group will have visits every two months, visual pedagogy and caregiver instructions for oral hygiene maintenance at home. Control group will receive dentist visits twice a year (or more often if clinically required) according to Italian Ministry of Health guidelines for pediatric dentistry.||||
33931181|NCT02230839|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33931182|NCT01929018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706443|NCT01108952|||COHORT||PROSPECTIVE|||||||
33706444|NCT00899574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706445|NCT03480178|||COHORT||PROSPECTIVE|||||||
33706446|NCT00795496|||COHORT|||||||||
33790455|NCT05584046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
33790456|NCT04977271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790457|NCT03525119|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33790458|NCT02410538|||||PROSPECTIVE|||||||
33790459|NCT00837616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790460|NCT00107835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790461|NCT03425162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective,randomized,single blind|t|f|f|t
33790462|NCT03994146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Two syringes will be simultaneously infused during the operation. One will contain normal saline solution and the other remifentanil solution. Prior to the end of the operation one of the syringes will have a step wise decrease in infusion rate whilst the other will be abruptly stopped at the end of surgery.~The syringes will be prepared according to randomisation in the hospital pharmacy and the identity of each syringe will be masked from all those involved in the study. The syringe randomisation will be de-coded following completion of recruitment."|Double blind, randomised, placebo controlled trial.|t|t|t|t
33790463|NCT05725889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790464|NCT00684034|NON_RANDOMIZED|PARALLEL||||NONE||||||
33790465|NCT02485626|||COHORT||CROSS_SECTIONAL|||||||
33790466|NCT06208696|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention group will participate in an evidenced-based intervention from chronic disease self-management and the control group will receive usual care and published information for chronic disease management.||||
33790467|NCT03870854|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Canadian multi-centre prospective cohort study of 40 participants.||||
33790468|NCT02942290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009558|NCT06615232|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Women will be randomized in groups of 20 to either the vaginal washing cessation intervention or control (no intervention) arm. Women randomized to the intervention arm will attend 3 small group sessions over the course of a month focused on sexual health education and vaginal washing cessation. Women in both groups will be asked to provide samples (vaginal swabs, cervical swabs, cervicovaginal fluid, cervical biopsy specimens) at baseline and then at pre-specified timepoints after the intervention.||||
34009559|NCT05312086|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706447|NCT02914119|||OTHER||CROSS_SECTIONAL|||||||
34009560|NCT04651192|||CASE_CONTROL||PROSPECTIVE|||||||
33706448|NCT00626223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094008|NCT00202150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094009|NCT06264622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094010|NCT02169999|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34094011|NCT02960789|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33706449|NCT00557128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706450|NCT00687466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706451|NCT00171548|||||PROSPECTIVE|||||||
33706452|NCT04508101|||CASE_CONTROL||RETROSPECTIVE|||||||
33706453|NCT01443182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706454|NCT00120731|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706455|NCT02109211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33790469|NCT05577611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706456|NCT04706091|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant, investigator, and clinical research coordinator will remain masked throughout the duration of the study.|Subjects will be randomized in a 1:1 ratio to suvorexant 10-20 mg or equivalent placebo for four weeks followed by crossover (after a 2-week washout) to the alternate treatment.|t|f|t|f
33706457|NCT03894332|||CASE_CONTROL||PROSPECTIVE|||||||
34009561|NCT06239714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094012|NCT05442931|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34094013|NCT01752387|||||RETROSPECTIVE|||||||
34094014|NCT05331924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706458|NCT01364818|||CASE_CONTROL||PROSPECTIVE|||||||
33790470|NCT01196988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790471|NCT04361253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009562|NCT01246141|||CASE_CONTROL||RETROSPECTIVE|||||||
34094015|NCT04069520|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34094016|NCT00004201|RANDOMIZED|||TREATMENT||||||||
34094017|NCT01138800|||CASE_ONLY||PROSPECTIVE|||||||
34094018|NCT00947466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094019|NCT02447029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790472|NCT02425254|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33790473|NCT06319664|||CASE_CONTROL||RETROSPECTIVE|||||||
33790474|NCT05292638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Active-controlled|t|f|t|f
33790475|NCT00877435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790476|NCT05328076|||COHORT||PROSPECTIVE|||||||
33931183|NCT05904314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||68 participants, control group theory training experimental group Electronic fetal monitor management simulation||||
33931184|NCT02490839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931185|NCT01895634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009563|NCT04549922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo used in the present study will consist of 0.9% NaCl Solution, which has the same physical characteristics as the ISIS 721744 drug. The placebo solution will be prepared by the nurse or pharmacist of the research team at the time of application. The nurse will be trained on the procedures for adequate blinding of the intervention. The pharmacist at the site level will not be blind, but the rest of the ream (nurse, physicians, patients, etc) will be blinded.||t|t|t|t
34009564|NCT03543852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||20 pediatric cancer survivor clinics will be pair matched based on patient population size, level of current survivorship care, and location (urban/rural). The pairs will be randomized to receive the intervention immediately or after 12 months. Selection and randomization of clinics will occur in 2019. Participants (survivors aged 18-22, or caretakers of survivors under age 18) will be recruited from the participating centers.||||
33706459|NCT00443261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009565|NCT03074084|||COHORT||PROSPECTIVE|||||||
34009566|NCT06287268|||COHORT||OTHER|||||||
34009567|NCT04081441|RANDOMIZED|FACTORIAL||PREVENTION||NONE||In this natural experiment, we have two connected randomized intervention deployments. The cookstove/fuel program was randomly rolled out to 750 households in Kigeme camp over a 6-month period (September 2018-March 2019) by Inyenyeri (a Rwandan social business). A second intervention (I-ACT empowerment training) was rolled out by Plan, International (December 2018-March 2019). I-ACT was deployed to women and their male partners (if applicable and available). After March 2019, the cookstove/pellet program was available to the whole camp. Assessments of impacts are done at 6 months after deployment of the interventions. Due to the staggering of the intervention roll-outs, the midline follow-up includes a six-month follow-up of the cookstove deployment and approximately 2-3 months of the I-ACT intervention and includes both partnered and non-partnered women. The 12-month assessment includes a 6-month follow up of the I-ACT empowerment intervention for partnered women only.||||
34009568|NCT03221452|NA|SINGLE_GROUP||OTHER||NONE||Single group study for intervention feasibility||||
34009569|NCT00686439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009570|NCT02676791|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34009571|NCT01469260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009572|NCT06055673|||CASE_CROSSOVER||PROSPECTIVE|||||||
34009573|NCT01915940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009574|NCT05643274|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33706460|NCT02014025|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706461|NCT03240965|||CASE_ONLY||PROSPECTIVE|||||||
33706462|NCT00237094|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706463|NCT02378259|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomisation between Bariatric surgery (mainly Roux-en-Y gastric bypass) or Intensive Medical treatment||||
33931186|NCT03891615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931187|NCT01751360||||TREATMENT||||||||
33931188|NCT01405027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931189|NCT01853852|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33931190|NCT01501734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931191|NCT04630210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33931192|NCT05569499|||COHORT||RETROSPECTIVE|||||||
33931193|NCT01224106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931194|NCT03766204|||CASE_CONTROL||PROSPECTIVE|||||||
33931195|NCT04746313|||CASE_CONTROL||PROSPECTIVE|||||||
33931196|NCT01638481|||CASE_ONLY||PROSPECTIVE|||||||
33931197|NCT00805038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931198|NCT05394012|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931199|NCT03272971|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33931200|NCT01029327|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33931201|NCT02390960|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33931202|NCT02120469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931203|NCT04614467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931204|NCT03218189|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33931205|NCT02360449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931206|NCT01308372|||COHORT||CROSS_SECTIONAL|||||||
33931207|NCT03221660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931208|NCT04882904|NA|SINGLE_GROUP||OTHER||NONE||All patients undergo clinical evaluation and wear Actimyo device in daily living to evaluate their evolution.||||
33790477|NCT05207982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931209|NCT04251741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Rheumatologists and patients remain blinded for allocation.|"Patients with rheumatoid arthritis starting another bDMARD after adalimumab failure (defined as DAS28CRP\>2.9) are randomly assigned to usual care (with randomized switch to etanercept or to a non-TNF-inhibitor) or 'drug concentration' guided switch.~When randomized to the usual care group, the treating rheumatologist gets the advice from an independent coworker to switch patients to etanercept 1\*50 mg/week or a non-TNFi (abatacept, rituximab, tocilizumab, or sarilumab), based on random allocation. When randomized to a non-TNFi, the treating rheumatologist will choose the non-TNFi. In the 'drug concentration guided' group, in patients with a concentration \<1.0 mg/L a switch to etanercept (standard dosing regimen of 50mg once a week) is advised by an independent coworker and in patients with a concentration ≥ 1.0 start of a non-TNF-inhibitor (the same drugs and dosing as in usual care group) is advised."|t|t|t|t
33931210|NCT04314492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931211|NCT05838794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors who will measure the outcomes will be blinded to the group allocation of participants. However, participants and the treating physiotherapist will not be blinded to the group allocation due to the nature of the intervention. Participants will be instructed not to reveal their group allocation to the assessor during the outcome assessment. To ensure blinding, the assessors will be instructed not to ask any questions that may reveal the group allocation of the participants. In addition, the assessors will be instructed not to discuss the study with the participants to avoid any potential unblinding.||f|f|f|t
33931212|NCT02533076|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33931213|NCT02684734|||OTHER||CROSS_SECTIONAL|||||||
33931214|NCT00856817|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33931215|NCT04969185|||CASE_CONTROL||PROSPECTIVE|||||||
34009575|NCT05171894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009576|NCT04340999|||CASE_CROSSOVER||PROSPECTIVE|||||||
34009577|NCT05765799|||COHORT||PROSPECTIVE|||||||
34009578|NCT02560428|||CASE_ONLY||CROSS_SECTIONAL|||||||
33706464|NCT02687997|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009579|NCT05910255|||CASE_CROSSOVER||PROSPECTIVE|||||||
34009580|NCT02868541|||COHORT||PROSPECTIVE|||||||
34009581|NCT04862481|||OTHER||CROSS_SECTIONAL|||||||
34009582|NCT03714555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009583|NCT01684527|||CASE_CONTROL||PROSPECTIVE|||||||
34009584|NCT04978636|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34009585|NCT02309853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706465|NCT00436839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094020|NCT03185507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The was a randomized single-blind study. Only the clinician was blinded to which intervention was administered to each randomly assigned participant.|Thirty-four healthy participants were recruited from a large urban university. Participants were included if they were healthy and between the age of 18 and 25 years old. After obtaining consent, participants completed symptom, mood and medical history inventories. After determining if a participant met inclusion criteria, the subject remained seated at a testing station for a 10-minute rest period prior to NIRS data collection. Randomization was performed a priori using a random number generator and was stratified on sex. Participants either received superficial cryotherapy or sat quietly for 20 minutes.|f|f|t|f
34094021|NCT00200824|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34094022|NCT05531097|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34094023|NCT03459586|NA|SINGLE_GROUP||OTHER||NONE||The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease.||||
34094024|NCT03718260|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34009586|NCT06399796|||CASE_CONTROL||PROSPECTIVE|||||||
34009587|NCT03358043|||COHORT||PROSPECTIVE|||||||
34009588|NCT01658202|RANDOMIZED|CROSSOVER||||NONE||||||
34009589|NCT03347357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009590|NCT01731899|||COHORT||PROSPECTIVE|||||||
34094025|NCT02480361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706466|NCT05009654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33706467|NCT02946944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706468|NCT05765396|||CASE_CONTROL||PROSPECTIVE|||||||
33706469|NCT02124083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706470|NCT02167087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706471|NCT01326143|||COHORT||PROSPECTIVE|||||||
33706472|NCT03123913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706473|NCT00260481|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33706474|NCT02688478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33706475|NCT00257374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706476|NCT00419276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931216|NCT01503892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931217|NCT03256136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931218|NCT01556789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931219|NCT01894555|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009591|NCT02598895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009592|NCT01587521|||||CROSS_SECTIONAL|||||||
33706477|NCT04995991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706478|NCT00709761||||TREATMENT||NONE||||||
34009593|NCT04801108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This pilot randomized controlled trial is expected to enroll a total of 20 subjects with a follow-up period of 3 months. All interventions and follow-up will be performed at the BIDMC. Patients will be randomized to an intervention or medical management group using an opaque envelope technique in a 2-4 block pattern to assure a random and evenly distributed patient population.~After the patient allocated to the medical management, the arm is followed for 3 months, they will be offered the robotic or VATS fissure completion procedure. It will be completely up to the candidates to undergo the intervention. If they decide that they want to proceed with surgery, the previously described methods will be used including the same surgical technique, same postoperative management, and same follow-up timelines and datapoints."||||
33706479|NCT03365492|NA|SINGLE_GROUP||TREATMENT||NONE||Commercially available BioFreedomTM (stainless steel BA9TM drug-coated stent)||||
33706480|NCT03282682|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study is 3 arms 12-week strength training program to assess the effect of testosterone replacement therapy (TRT) with strength training (ST) and strength training (ST) for hypogonadal patients without testosterone replacement therapy (NON-TRT) with control healthy eugonadal group, that is also engaged in strength training.||||
34009594|NCT05600881|||CASE_ONLY||CROSS_SECTIONAL|||||||
33931220|NCT02282930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009595|NCT05734209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Masking was not possible in the current study, since it was obvious if you were eating virtual or real food. However, participants were not aware of the aim of the study.|Randomized crossover study with 2 repeats. Each person participated in two virtual meals and two real meals in random order.||||
34009596|NCT01776567|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34009597|NCT06444321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open intervention study with a matched control-group||||
34009598|NCT05305768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009599|NCT02804282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706481|NCT04846296|||OTHER||CROSS_SECTIONAL|||||||
33931221|NCT04898868|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will recruit 80 women normal term pregnancy; 40 with vaginal delivery and 40 with elective CS for previous CS or fetal malpresentation.~Participants will be randomized into 4 groups: group 1, vaginal delivery with cord blood spontaneous drainage; group 2, vaginal delivery with cord milking; group 3, CS with cord blood spontaneous drainage; group 4, CS with cord milking. In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps. The newborns will be taken care by the nurse after delivery. The clamp on the placenta site will be removed and record the drainage time and amount of cord blood to a measuring glass. In women allocated to groups of cord milking group, the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood after delivery. The number of cord milking and the volume of blood collected will be recorded."||||
33931222|NCT02505802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931223|NCT04720313|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple Myeloma and AL amyloidosis Patients||||
33931224|NCT05469100|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33931225|NCT05788029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009600|NCT01997294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009601|NCT03123757|NA|SINGLE_GROUP||OTHER||NONE||All subjects enrolled in our trial performed the 6-minute walk test and completed an EQ-5D quality of life questionnaire.||||
34009602|NCT03652831|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned randomly into two groups: Soft tissue mobilization with neural mobilization and Soft tissue mobilization without Neural mobilization.A coin will be flipped at start of data collection for the first patient to be assigned odd number and included in Soft tissue mobilization with Neural mobilization group. Later on odd and even numbered subjects will be included in specific group.||||
34009603|NCT05951348|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34009604|NCT05567939|||COHORT||PROSPECTIVE|||||||
34009605|NCT04480801|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||prospective randomized controlled clinical trial|t|f|f|t
34009606|NCT05181826|||OTHER||PROSPECTIVE|||||||
34009607|NCT02765672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009608|NCT06433635|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009609|NCT06615869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34009610|NCT03003260|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34009611|NCT03836924|||COHORT||PROSPECTIVE|||||||
34009612|NCT04865315|||OTHER||PROSPECTIVE|||||||
34009613|NCT00194792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009614|NCT02230618|||COHORT||PROSPECTIVE|||||||
34009615|NCT05197777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34009616|NCT02408445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009617|NCT00385788|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009618|NCT06085339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009619|NCT03231826|||COHORT||PROSPECTIVE|||||||
34009620|NCT00280176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706482|NCT01503918|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706483|NCT01208792|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34009621|NCT01347047|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33706484|NCT03155568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706485|NCT03509558|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706486|NCT03773263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706487|NCT04329403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706488|NCT02809612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706489|NCT05881915|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706490|NCT02201641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009622|NCT05445531|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34009623|NCT05341804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded assessor|the cognitive and balance dual task training group (COG\&BAL), the balance training group (BAL), and the treatment as usual group|f|f|f|t
34009624|NCT01975194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009625|NCT01592916|||CASE_CONTROL||PROSPECTIVE|||||||
34009626|NCT00203541|RANDOMIZED|PARALLEL||||DOUBLE||||||
34094026|NCT04185727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study is a randomized controlled open trial, comparing the effect of Standard of care (SOC) with Standard of care + strength training.~The interventional clinical trial design includes two parallel groups and 12 weeks exposure. The goal is to include 24-30 patients.~The study will allocate patients to groups consisting of 4 members who receive either SOC or SOC + strength training for 12 weeks. All participants are assessed at baseline, after 1 week, after 6 weeks, post-treatment (12 weeks), and at 6 months' post follow-up (24 weeks) and monitored for changes in physiological, biological and psychological variables. Some tests are also done more frequently. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session."||||
34094027|NCT03595748|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094028|NCT02960672|||COHORT||PROSPECTIVE|||||||
34094029|NCT06304571|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34094030|NCT00021255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094031|NCT05158803|||CASE_ONLY||PROSPECTIVE|||||||
34094032|NCT05420454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094033|NCT05831072|NA|SINGLE_GROUP||TREATMENT||NONE||Students who have suitable cognitive capacity and minor and above level of depressive symptoms will be included in the study. Each single group will be 16 students or below.||||
34094034|NCT00114777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094035|NCT03899493|||OTHER||PROSPECTIVE|||||||
34094036|NCT02807090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094037|NCT00906581|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34094038|NCT05563974|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34094039|NCT06271980|||CASE_CONTROL||RETROSPECTIVE|||||||
34009627|NCT03628742|||OTHER||CROSS_SECTIONAL|||||||
34009628|NCT05724368|||OTHER||CROSS_SECTIONAL|||||||
34009629|NCT04865913|||COHORT||PROSPECTIVE|||||||
34009630|NCT03945799|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34009631|NCT02788799|||CASE_CONTROL||OTHER|||||||
34009632|NCT03302377|NA|SINGLE_GROUP||PREVENTION||NONE||As this is a feasibility study, all participants will receive the intervention||||
34009633|NCT01941108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34009634|NCT00003020||||TREATMENT||||||||
34009635|NCT05241418|||COHORT||PROSPECTIVE|||||||
34009636|NCT06052020|||COHORT||PROSPECTIVE|||||||
34009637|NCT01680874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009638|NCT06168318|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009639|NCT03661866|||COHORT||OTHER|||||||
34009640|NCT04873180|||CASE_ONLY||PROSPECTIVE|||||||
34009641|NCT03124290|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34009642|NCT05523570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009643|NCT02264535|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34009644|NCT04924244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009645|NCT01002352|||COHORT||PROSPECTIVE|||||||
34009646|NCT05518916|RANDOMIZED|PARALLEL||OTHER||SINGLE|After the researh report is written, a third person will assign an intervention and control group to the letters.|Prospective, parallel, three-arm randomized controlled clinical trial|f|f|f|t
34009647|NCT00727519||||PREVENTION||||||||
34009648|NCT05197829|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34009649|NCT01573533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009650|NCT02201459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009651|NCT05715476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34009652|NCT05743049|||COHORT||PROSPECTIVE|||||||
34009653|NCT01562626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009654|NCT04079491|||COHORT||CROSS_SECTIONAL|||||||
34009655|NCT04572061|||COHORT||RETROSPECTIVE|||||||
34009656|NCT03400280|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Stepped-wedge cluster randomized trial||||
34009657|NCT00909584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706491|NCT03925480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Matched drug and placebo|Blinded, randomized, placebo-controlled trial|t|t|t|t
33706492|NCT02398760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706493|NCT00926328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009658|NCT03534193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomized to one of 2 arms:~Group 1 - standard Diabetic education-consisting of one on one education with a Registered Nurse in addition to the Molly Center Diabetes Care Guide (paper based) Group 2 - standard Diabetic education plus Bedside tablet with interactive Diabetic modules"||||
33706494|NCT04058730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009659|NCT03925935|NA|SEQUENTIAL||TREATMENT||NONE||AB-205 dose escalation based on safety.||||
34009660|NCT00945334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706495|NCT04564261|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33706496|NCT05409326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094040|NCT03938870|||CASE_CONTROL||PROSPECTIVE|||||||
34094041|NCT01118091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094042|NCT02305615|||COHORT||PROSPECTIVE|||||||
34094043|NCT05412420|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094044|NCT01113957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094045|NCT02786667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009661|NCT03326986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009662|NCT00284882|||||PROSPECTIVE|||||||
34009663|NCT00128037|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009664|NCT05730712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094046|NCT05638984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094047|NCT01500096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094048|NCT05824585|NA|SEQUENTIAL||TREATMENT||NONE||||||
34094049|NCT02027571|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094050|NCT03971526|||OTHER||RETROSPECTIVE|||||||
33706497|NCT00884728|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33706498|NCT00840892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094051|NCT05551988|||COHORT||RETROSPECTIVE|||||||
34094052|NCT00704834|||COHORT||PROSPECTIVE|||||||
34094053|NCT03310515|||COHORT||PROSPECTIVE|||||||
34094054|NCT02513199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094055|NCT03611270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094056|NCT05232526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094057|NCT00768677|NA|SINGLE_GROUP||TREATMENT||||||||
34094058|NCT03878459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||placebo controlled intervention|t|f|t|f
33706499|NCT06171971|||CASE_ONLY||RETROSPECTIVE|||||||
33706500|NCT03896386|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33706501|NCT03673852|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33706502|NCT01743716|||OTHER||CROSS_SECTIONAL|||||||
33706503|NCT05239208|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33706504|NCT06445881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706505|NCT01935791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33706506|NCT05121896|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706507|NCT04219007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706508|NCT02109471|||COHORT||PROSPECTIVE|||||||
33706509|NCT03452423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706510|NCT03357991|||COHORT||PROSPECTIVE|||||||
33706511|NCT01737320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706512|NCT03924453|||COHORT||PROSPECTIVE|||||||
33706513|NCT05002062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed Envelopes|A Single Blinded, Randomized Controlled Trial|t|f|f|f
33706514|NCT04456530|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both the participant and analyzing MRI Radiologist will be blind.||t|f|f|t
33706515|NCT01207791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706516|NCT03513328|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study builds in rules for escalation of thiotepa dose based on graft failure by day 42. Patients are stratified in two groups A (lower risk of graft failure) and B (higher risk of graft failure). Patients undergoing 10/10 HLA matched bone marrow and peripheral blood transplants are assigned to Group A, and patients receiving \<10/10 matched bone marrow or peripheral blood, or receiving cord blood, even if fully matched, are assigned to Group B.~If criteria for thiotepa dose escalation are met first in Group A, which has a lower risk of graft failure, thiotepa dose will be escalated for all subjects (Groups A and B). If criteria for thiotepa dose escalation are met first in Group B, dose will be escalated only in Group B and Group A will continue enrolling patients at a lower dose level."||||
33706517|NCT00070889|||DEFINED_POPULATION||PROSPECTIVE|||||||
33706518|NCT03682133|||OTHER||PROSPECTIVE|||||||
33706519|NCT00740389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706520|NCT05497583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
33706521|NCT02393183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34009665|NCT04355949|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"In a case-controlled clinical study, it will be carried out on 30 patients with lifelong PE and 30 healthy control subjects.~Serum vitamin D, vitamin B12, and folic acid levels will be assessed in all subjects included in the study."|assess serum levels of vitamin D, vitamin B12 and folic acid among patients with lifelong PE and non-responding to dapoxetine treatment.|f|f|t|f
33706522|NCT03400878|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomised trial of 15,600 infants 1:1 to BCG-Japan or BCG-Russia|f|t|f|t
34094059|NCT04685122|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34009666|NCT00702208|NA|SINGLE_GROUP||SCREENING||NONE||||||
33706523|NCT04561830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009667|NCT02674633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Minimum number of subjects = 300, Anticipated number of subjects = 330, Maximum number of subjects = 1,000|t|t|t|t
34009668|NCT05585931|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094060|NCT05804500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||In this prospective, single-arm study, we will look at the initiation, participation, sustained engagement, and safety of 100 adult subjects (ages 45 years or older) with recent (within the past 60 days) clinician referral to CR who are offered CTR via the RecoveryPlus platform.||||
34094061|NCT01092156|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34094062|NCT05615441|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34094063|NCT03462147|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
34094064|NCT06294613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094065|NCT06314971|||CASE_CONTROL||RETROSPECTIVE|||||||
33706524|NCT00440583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706525|NCT03706079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|"Subjects previously randomized in one of the predecessor studies to tezepelumab will be assigned and remain on tezepelumab dosing in the Destination Study.~Subjects randomized to placebo arm in the predecessor studies will be re-randomized in a 1:1 ratio to either tezepelumab or placebo.~Given the randomization scheme of subjects in the predecessor studies, this will give an overall subject distribution of 3:1 (tezepelumab:placebo), assuming a similar number of subjects rollover from each arm in the predecessor studies."|t|t|t|f
33706526|NCT03280901|RANDOMIZED|CROSSOVER||TREATMENT||NONE||monocentric, block randomized, open, crossover study||||
33706527|NCT00813306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33706528|NCT05163977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706529|NCT05909150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706530|NCT03738683|||CASE_ONLY||PROSPECTIVE|||||||
33801771|NCT03192215|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Eligible patients will be allocated in a 1:1 ratio to apixaban or aspirin using the minimal sufficient balance randomization method to prevent serious treatment imbalances by study site.|"Active treatment will be either apixaban 5 mg or aspirin 81 mg. An adjusted dose of apixaban 2.5 mg will be used for subjects with at least two of the following: age greater than or equal to 80 years, body weight less than or equal to 60 kg, or known serum creatinine greater than or equal to 1.5 mg/dL. There will be six possible study tablets: apixaban 5 mg (regular dose), apixaban 2.5 mg (adjusted dose), apixaban 5 mg placebo, apixaban 2.5 mg placebo, aspirin 81 mg, and aspirin placebo.~All subjects will be randomized to receive active treatment with either active apixaban or active aspirin. Study treatments will be supplied in a double-dummy fashion as apixaban 5 mg (2.5 mg for the adjusted dose) or matching placebo, and aspirin 81 mg or matching placebo."|t|t|t|t
33801772|NCT03706521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706531|NCT02645825|||COHORT||PROSPECTIVE|||||||
34094066|NCT03851991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094067|NCT00538538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094068|NCT01076933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094069|NCT01757210|||CASE_ONLY||PROSPECTIVE|||||||
34094070|NCT04733105|||OTHER||OTHER|||||||
34094071|NCT05581264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|To reduce performance bias after the randomization process, blinding is adopted. However, due to the conflicting requirements of ethical and methodological aspects in designing a randomized controlled trial with a psychosocial intervention, double-blinding and randomizing each individual participant posits a huge challenge. Patients and outcome assessors were blinded in a way that none of them will know which group is considered the experimental group and the control group.|This study is a two-arm - experimental vs. control group Randomized Controlled Trial. The sampling frame was patients with uncontrolled type 2 diabetes registered in two outpatient diabetes clinics located in two cities in Jordan. Diabetes self-management program is delivered by a trained diabetes educator facilitator in diabetes management. In addition to the usual care, the intervention group was provided with an education program that consisted of nine 60-min sessions, which included face-to-face interactive sessions with the dissemination and presentation of written and visual materials. The education and counseling were maintained through follow-up (24 weeks) via phone for the intervention group. The control group received only usual care and they were followed according to the institution's diabetes follow-up protocol.|t|f|f|t
34094072|NCT06412367|||COHORT||PROSPECTIVE|||||||
34094073|NCT03157791|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The endoscopist and endoscopy nurse will not know to which treatment arm the patient belongs as only the interviewing nurse will have taken down this information. This information does not travel with the patient to the endoscopy room. The patient is also instructed to not reveal to the endoscopist or endoscopy nurse if he or she has taken simethicone or not.||f|f|t|t
34094074|NCT06144307|||COHORT||PROSPECTIVE|||||||
34094075|NCT01773902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34094076|NCT01732692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094077|NCT02353741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094078|NCT03453970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33706532|NCT04340778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706533|NCT02508181|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33706534|NCT01885403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33706535|NCT06290479|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Masking: Triple (Participant, Care Provider, Investigator)|Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator)|t|t|t|t
33801773|NCT05942092|||COHORT||RETROSPECTIVE|||||||
34009669|NCT05327855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a Phase 2, multicenter, randomized, placebo-controlled, multiple-arm, adaptive study investigating the safety, pharmacokinetics, and potential efficacy of OPL-0301, along with standard of care, in post-myocardial infarction (MI) participants with left ventricular dysfunction (LVD).~Participants will have been admitted to the hospital for acute MI and treated with primary percutaneous coronary intervention (PPCI) before entering the study. A fixed oral dose will be administered once daily, according to the blinded treatment assignment."|t|t|t|t
34009670|NCT03345264|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009671|NCT01688726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34009672|NCT05282979|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded assessed of the improvement would be done between Last FU images and baseline, following randomization of the images.|All participates will undergo treatment with the Tixel 2 Device up to 4 treatments, 4 weeks apart and 2 Follow Up Visits||||
34009673|NCT03988452|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34094079|NCT01892852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009674|NCT00392457|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706536|NCT05292508|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|A study investigator will make the assessment of outcome for each patient after reviewing the patients electronic clinical records. This electronic record will not have information about the health post where the trial recruitment took place. The allocation arm will also not be disclosed in this record.|We will conduct a Cluster Randomized Controlled Trial (cRCT) at eight Health Posts of Gulmi District. Eight Health Posts will be randomly allocated to the intervention arm (use of rapid diagnostic test for C-reactive protein) and the other will be allocated to the control arm. Thus, there will be four Health Posts each in the intervention and control arms.|f|f|f|t
33706537|NCT01809483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706538|NCT00415805|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33706539|NCT03501290|NA|SINGLE_GROUP||OTHER||NONE||All patients will be in one group, receiving the product.||||
33706540|NCT05534737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, open, multicenter clinical trial||||
33706541|NCT00827333|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009675|NCT01918579|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34009676|NCT00987831|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009677|NCT03439579|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pilot study||||
34009678|NCT00099268|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094080|NCT00934882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094081|NCT00441896|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094082|NCT01866592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706542|NCT05756491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||standard care: accompanied patients Remote surveillance: unaccompanied patients||||
33706543|NCT02849041|NA|SINGLE_GROUP||SCREENING||NONE||||||
33706544|NCT06557798|||COHORT||PROSPECTIVE|||||||
33706545|NCT01540838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706546|NCT03807518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigator will be blinded to the allocation of the participants|Parallel group randomised 1:1 controlled multi centre trial|f|f|t|f
33706547|NCT06139107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706548|NCT02571075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706549|NCT01185756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706550|NCT02563743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706551|NCT05959031|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|t|f|t
33706552|NCT03812107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706553|NCT05014893|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33706554|NCT06300931|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33706555|NCT02022852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706556|NCT00244010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706557|NCT02478775|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706558|NCT00454883|||COHORT||PROSPECTIVE|||||||
33706559|NCT01100671|||COHORT||CROSS_SECTIONAL|||||||
33706560|NCT02221791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33706561|NCT01629524|||COHORT||CROSS_SECTIONAL|||||||
33706562|NCT06069882|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single Case Experimental Design||||
33706563|NCT01264900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706564|NCT00667875|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33706565|NCT03166735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706566|NCT05846074|||CASE_CONTROL||PROSPECTIVE|||||||
34009679|NCT00221962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009680|NCT00058214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009681|NCT02682186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34009682|NCT03060850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009683|NCT02297750|RANDOMIZED|PARALLEL||||NONE||||||
34009684|NCT01768819|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009685|NCT04919759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms, non-randomized||||
34009686|NCT06453460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009687|NCT05460975|||COHORT||PROSPECTIVE|||||||
34009688|NCT01083680|||CASE_ONLY||PROSPECTIVE|||||||
34009689|NCT05031247|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094083|NCT04328285|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized double-blind placebo-controlled clinical trial|t|f|t|t
34009690|NCT06616571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009691|NCT05699291|||COHORT||PROSPECTIVE|||||||
33706567|NCT06327035|||COHORT||PROSPECTIVE|||||||
34009692|NCT05215171|||CASE_CONTROL||PROSPECTIVE|||||||
33706568|NCT02041884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706569|NCT04303819|||COHORT||RETROSPECTIVE|||||||
33706570|NCT05751460|||OTHER||OTHER|||||||
33706571|NCT04736407|||CASE_CONTROL||PROSPECTIVE|||||||
33706572|NCT05094583|||OTHER||PROSPECTIVE|||||||
33706573|NCT02185092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706574|NCT01901120|||CASE_ONLY||PROSPECTIVE|||||||
33706575|NCT06292520|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33706576|NCT00008372||||TREATMENT||||||||
34009693|NCT02182167|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34009694|NCT05966311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants prospectively enrolled are assigned to the interventional treatment procedure using the PUMA-G Peds System. A retrospective comparator is used as a means of comparing outcomes with a similar, historical cohort of patients who received the standard of care treatment procedure.||||
34009695|NCT02013752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009696|NCT05354089|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34009697|NCT02471937|NA|SINGLE_GROUP||SCREENING||NONE||||||
34009698|NCT05909917|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be blinded to intervention arm randomization of participants.||f|f|f|t
33706577|NCT05089877|||CASE_ONLY||OTHER|||||||
33706578|NCT04718298|NA|SEQUENTIAL||TREATMENT||NONE||feasibility study||||
33706579|NCT01968759|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706580|NCT06204887|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33706581|NCT00001535||||TREATMENT||||||||
33706582|NCT00417469|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33706583|NCT06258941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33706584|NCT04556188|||CASE_CONTROL||PROSPECTIVE|||||||
34009699|NCT06318039|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
34009700|NCT05542316|||COHORT||PROSPECTIVE|||||||
34009701|NCT04992793|||COHORT||PROSPECTIVE|||||||
34009702|NCT04188548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009703|NCT04196452|||COHORT||RETROSPECTIVE|||||||
34009704|NCT01402154|||COHORT||PROSPECTIVE|||||||
34009705|NCT05577806|||COHORT||CROSS_SECTIONAL|||||||
34009706|NCT00380549|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34009707|NCT01079819|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33706585|NCT03915392|||CASE_ONLY||RETROSPECTIVE|||||||
33706586|NCT05267886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Parallel randomized control trial|t|t|t|f
33706587|NCT02695225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009708|NCT05543694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The biased-coin allocation after each successful response will be implemented by flipping a virtual biased coin (10% vs. 90% probability of randomizing the next patient to the lower vs. same dose than received by the last patient with the same epidural technique) using R statistical software (R Foundation for Statistical Computing, Vienna, Austria). Care Provider (Clinical Anesthesiologist) will administer the identified dose, then summon blinded observer.|Randomized Controlled Trial Using Biased Coin Design to Determine Effective Dose for 90% (ED90) of Subjects|t|f|t|t
34009709|NCT05540873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009710|NCT04341259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009711|NCT03176355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009712|NCT05362006|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34009713|NCT01118819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706588|NCT00238810|||||RETROSPECTIVE|||||||
34009714|NCT06586151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants, but not researchers, will be blinded to study assignment.||t|f|f|f
34009715|NCT03171441|||OTHER||CROSS_SECTIONAL|||||||
34009716|NCT02113371|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094084|NCT00396669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094085|NCT02689479|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706589|NCT00882895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094086|NCT02390375|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34094087|NCT01181843|||OTHER||PROSPECTIVE|||||||
34094088|NCT03838718|||COHORT||PROSPECTIVE|||||||
34094089|NCT02202655|||CASE_ONLY||PROSPECTIVE|||||||
34094090|NCT00986232|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34094091|NCT00775086|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
34094092|NCT00231933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094093|NCT04035083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34094094|NCT03459651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094095|NCT02530866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094096|NCT04698486|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34094097|NCT00152958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34094098|NCT01855620|||COHORT||PROSPECTIVE|||||||
34094099|NCT03035539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotherapists evaluating the physical capacity were masked.||f|f|f|t
34009717|NCT06616285|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Baseline assessments will be conducted at the research centre prior to randomisation. After baseline assessments and randomisation, two members of the research team will be unblinded to group allocation in order to coordinate the intervention. Post-intervention measurements and data analyses will be conducted by researchers and trained research assistants who are blind to participant randomisation and are not present during the intervention sessions. Participants will be instructed not to disclose their randomisation status during any of the assessment sessions or in-house visits. Participants and intervention staff will be aware of their group allocation. The intervention staff will not conduct any assessment of participants.|Randomised controlled trial. Participants will be randomised either into the Folk Dance Multidomain Lifestyle Intervention Group or the Self-Guided Multidomain Lifestyle Intervention Group. The intervention will be delivered over a period of 6 months.|f|f|t|t
34009718|NCT04845620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009719|NCT02650141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009720|NCT01761669|||||PROSPECTIVE|||||||
34009721|NCT04397575|||COHORT||PROSPECTIVE|||||||
34009722|NCT05304026|||CASE_CONTROL||PROSPECTIVE|||||||
34009723|NCT06355479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009724|NCT01381263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34009725|NCT02589886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009726|NCT04978844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessors: Post graduate students in clinical psychology, lab technicians|I-WotCH, Dyadic and Controls|f|f|f|t
34009727|NCT05861219|NA|SINGLE_GROUP||SCREENING||NONE||Chronic kidney disease stage 3,4||||
34009728|NCT00951951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009729|NCT05370261|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34009730|NCT04333017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009731|NCT03294616|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34009732|NCT04884061|||CASE_CONTROL||RETROSPECTIVE|||||||
34009733|NCT05139277|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Adult patients (age\>18) presenting with suspected intracranial gliomas (including glioblastoma), cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who are surgical candidates and provide informed consent.||||
33706590|NCT05021055|||OTHER||PROSPECTIVE|||||||
34009734|NCT06118502|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||An Adaptive, Multi-Randomization Design||||
33706591|NCT04916431|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009735|NCT06490120|||COHORT||PROSPECTIVE|||||||
34009736|NCT02810158|||CASE_ONLY||PROSPECTIVE|||||||
34009737|NCT04627831|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Subjects, and site personnel evaluating the subjects, will be blinded to the contrast media administered.|"Patients with impaired renal function scheduled for coronary angiography will be assessed for study eligibility. Prior to the planned coronary angiography procedure on Day 1, eligible patients will be randomized 1:1 to receive either CE-Iohexol Injection or iohexol. Randomization will be stratified by the following 2 factors.~* Diabetes mellitus status:~  * Diabetics; or~ * Non-diabetics; and~* Baseline eGFR, defined as the eGFR obtained as part of eligibility screening:~  * \<45 mL/min/1.73 m2; or~ * 45 mL/min/1.73 m2.~Contrast volumes will be determined according to medical need. All subjects will be well hydrated before and after the examination, according to good clinical practice and institution's standard procedures."|t|t|t|t
34009738|NCT04452695|||COHORT||PROSPECTIVE|||||||
34009739|NCT00384488|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34094100|NCT00929032|||COHORT||PROSPECTIVE|||||||
33706592|NCT02570074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34094101|NCT02777788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706593|NCT00967057|RANDOMIZED|||TREATMENT||||||||
34094102|NCT06188546|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094103|NCT05455450|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|The assessing RA and project statistician will be blind to treatment allocation.|Participants will be randomised into EMDR (plus neuropsychiatric care; NPC) or NPC. A stratified block randomisation will be used to ensure similar numbers of patients with predominant functional seizures or functional motor disorder, and PTSD/non-PTSD are relatively equal across arms.|f|f|f|t
34094104|NCT01851369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094105|NCT02606253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094106|NCT05577104|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients with diabetic foot ulcers (DFUs)||||
34094107|NCT02931110|NA|SEQUENTIAL||TREATMENT||NONE||||||
34094108|NCT05226000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094109|NCT01933425|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34094110|NCT01761188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094111|NCT01186081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094112|NCT04964232|NA|SINGLE_GROUP||OTHER||NONE||||||
34094113|NCT01427946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094114|NCT03306381|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34094115|NCT02548182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706594|NCT02519257|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706595|NCT01002222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706596|NCT05250882|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open label multicenter trial with historic controls||||
33706597|NCT03133169|||COHORT||CROSS_SECTIONAL|||||||
33706598|NCT03390816|||COHORT||PROSPECTIVE|||||||
33706599|NCT00249756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706600|NCT02178371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094116|NCT01792466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094117|NCT05700838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094118|NCT03888079|||COHORT||PROSPECTIVE|||||||
34094119|NCT00005585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094120|NCT03634150|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental: IV Nerofe 96 mg\\m2 followed by IV Doxorubicin 10mg\\m2, once weekly||||
33706601|NCT02737696|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094121|NCT01714440|||COHORT||PROSPECTIVE|||||||
34094122|NCT03736369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094123|NCT04000256|||COHORT||PROSPECTIVE|||||||
33931226|NCT04085692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research group and the participants will not be blinded to the allocation, except for the study statistician (A.K.E.), who will conduct all analyses blinded to the intervention group. Thus, the study statistician will not have access to the randomisation scheme or the random seed and will receive a dataset with the actual groups replaced with the numbers 0 and 1|"After enrolment and consent from the EMDs, the EMDs will be randomly assigned to receive either LDHF simulation-based dispatcher training (intervention arm) or no LDHF simulation-based dispatcher training (comparison arm).~The EMDs will be randomly assigned to intervention or comparison group in a 1:1 ratio.~Randomisation will be stratified by the EMDs' medical backgrounds (paramedic, approximately 30% of the EMDs, or registered nurse, approximately 70% of the EMDs), to balance the number of EMDs with different medical backgrounds randomly assigned to each arm."|f|f|f|t
33706602|NCT03727230|NA|SINGLE_GROUP||TREATMENT||NONE||"A single-arm clinical trial of Chinese Asian-type DEL patients receiving RhD+ RBC transfusion was conducted.~Although truly RhD-negative patients receiving RhD+ RBC transfusion were recognized as the ideal control group, they were not included in this study because it did not comply with the Chinese Clinical Blood Transfusion Standard and ethics principles. The truly RhD-negative patients could receive RhD+ blood only in emergency situations under conditions of an insufficient stock of RhD-negative RBCs. Thus, the summarized alloanti-D rate (203/720, 28.2%; 95% CI, 19%-32%) in truly RhD-negative patients with similar mixed diseases after RhD+ RBC transfusion reported in the meta-analysis （Vox Sang 2021, http://doi.org/10.1111/vox.13232）was used as the control for comparison."||||
33931227|NCT04971993|||COHORT||PROSPECTIVE|||||||
33931228|NCT02094729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931229|NCT00131170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33931230|NCT01283178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931231|NCT01452191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33931232|NCT00415753|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33931233|NCT01313468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33931234|NCT01086449|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33931235|NCT00132522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094124|NCT05993169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary care provider will be blind to subject arm,||f|t|f|f
34094125|NCT04578132|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33706603|NCT04452240|||CASE_ONLY||PROSPECTIVE|||||||
33706604|NCT02721485|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33706605|NCT04530916|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33706606|NCT06413381|||CASE_CONTROL||PROSPECTIVE|||||||
33790478|NCT05603767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients who agree to participate will be randomized through the randomlists web page to the two study groups. The following day the study collaborators will be in charge of taking the preliminary measurements. Afterwards the patient who has been assigned to RMT + VR will receive the session conducted by the principal investigator The control group will receive no intervention and will continue with their usual care. Between 1-2 hours later, both groups will be visited by the collaborators for subsequent measurements. Which will be recorded again by the collaborators the following 24 hours. In no case will the collaborators know whether the patient received the RMT+ VR intervention or was assigned to the control group."|(RMT+ VR) a) Background settings; b) VR video and music selection; c) Listening experience and VR; and e) Return to alert status (Figure 2).60 patients will be included. All of them are treated by the Palliative Care Unit of the Austral University Hospital. Individuals ≥ 18 years of age with advanced cancer defined from the use of the NECPAL-CCOMS Instrument \[20\]. They can be hospitalized in the medical clinic service (AUH) or in the Integral Care Unit (ICUA) within the hospital, and must sign the informed consent after being duly explained by the principal investigator. Likewise, they must have (1) a minimum previous ESAS-r of at least 7 points in a symptom, (2) they must be able to adopt a posture of at least 45º in bed and a state of alertness and adequate response, (3) they should not present cognitive impairment (measured by Pfeiffer scale \[21\] \> 2 errors) and (4) have functional hearing (with or without hearing aids or other devices).|f|t|f|f
33790479|NCT06189105|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33790480|NCT03898986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33790481|NCT03745118|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790482|NCT00223314|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33790483|NCT04147416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790484|NCT02887313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790485|NCT01801930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790486|NCT04472806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790487|NCT06227286|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33790488|NCT04314830|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcome measures pretraining were collected pre-randomization. Post-training, the assessors were masked for the arm.|Only the experimental intervention was offered in the second phase of the trial, to the participants who received the control intervention in the first phase|f|f|f|t
33790489|NCT03168191|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33790490|NCT01450072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790491|NCT05578352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931236|NCT01791465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931237|NCT06438744|NA|SINGLE_GROUP||TREATMENT||NONE||One-group pretest-posttest clinical trial||||
33931238|NCT01141699|||COHORT||RETROSPECTIVE|||||||
33931239|NCT00948428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931240|NCT00552344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094126|NCT03112551|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931241|NCT01861613|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33931242|NCT01039038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931243|NCT04587895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094127|NCT00004897||||TREATMENT||||||||
34094128|NCT03622840|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094129|NCT05016050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706607|NCT03245515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706608|NCT03543150|||CASE_ONLY||PROSPECTIVE|||||||
33706609|NCT03438747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706610|NCT02099994|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931244|NCT05194605|||COHORT||OTHER|||||||
33931245|NCT02755012|||COHORT||PROSPECTIVE|||||||
33706611|NCT04898595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective quasi-experimental (before-after) study of patients with acute kidney injury requiring continuous renal replacement therapy in the intensive care unit. This will be a quasi-experimental study design due to the nature of the intervention and the processes of care leading to making a clinical decision. Patients with AKI on CRRT will be prospectively recruited. Patients recruited during the first half of the study will be in the control arm where usual process of care will not be altered. After accrual, patients recruited for the second half will receive the intervention where discontinuation of CRRT will be guided by a set of criteria based on the patient's hemodynamic status and other factors.||||
33931246|NCT03415113|||OTHER||PROSPECTIVE|||||||
33706612|NCT06049862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the research, the third stage will do double-blinding for the care provider and outcome assessor, who will evaluate blood pressure and questionnaires. Allocation concealment for dividing into groups, intervention and control will use the SNOSE (sequentially numbered, opaque sealed envelopes ) method. The envelope closed will be sorted by order randomization, given paper carbon with appearance. The same is true for envelopes with the inscription intervention or control.|"The intervention was given in the third phase of the research, namely MaRiTensi, which was developed in the first and second stages of the research."|f|t|f|t
33706613|NCT00477256|||||PROSPECTIVE|||||||
33790492|NCT04327063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|t|f
33790493|NCT00273949|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33931247|NCT00241449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931248|NCT01997138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931249|NCT00059319|RANDOMIZED|||TREATMENT||||||||
33931250|NCT01201967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790494|NCT05101694|||CASE_CONTROL||PROSPECTIVE|||||||
33931251|NCT02547519|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33931252|NCT01844570|||COHORT||PROSPECTIVE|||||||
33931253|NCT01525745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790495|NCT00882882|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790496|NCT06521892|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Pharmacies participating in the study did not know which group they were assigned to. Standardized patient surveyors also did not know which group of pharmacies they surveyed.|In parallel arm design, subjects are randomized to one or more study arms and each study arm will be allocated a different intervention. After randomization each subject stays in their assigned treatment arm for the duration of the study. Subjects receive the same treatment throughout the trial. The results are then compared|t|f|t|f
33790497|NCT06554431|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Repetitive Artmaking||||
33790498|NCT03646370|||COHORT||RETROSPECTIVE|||||||
33790499|NCT03369587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor Blind to group allocation|A phase II exploratory randomised controlled trial of a handwriting intervention with an active comparator control group and blinded assessments|f|f|f|t
33931254|NCT04348188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009740|NCT00880087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009741|NCT04372849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34009742|NCT04832048|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-center, randomized, parallel-group, controlled, and open-label study was conducted.||||
34009743|NCT05789758|||COHORT||PROSPECTIVE|||||||
33790500|NCT00334451|||COHORT||PROSPECTIVE|||||||
33790501|NCT00471029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790502|NCT04471467|||CASE_ONLY||PROSPECTIVE|||||||
34094130|NCT06039475|||CASE_CONTROL||RETROSPECTIVE|||||||
33931255|NCT00310063|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34009744|NCT00549952|||||PROSPECTIVE|||||||
34009745|NCT04836520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009746|NCT01951755|||COHORT||PROSPECTIVE|||||||
34009747|NCT06415968|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34009748|NCT02280720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009749|NCT01030211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009750|NCT03331614|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data collected by the investigator will be submitted to the assessor without indication of which group is active and which is control.|Subjects will be sequentially divided into a control group or an active treatment group.|f|f|f|t
34009751|NCT05336435|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|A diagnosis of acute MI will be adjudicated for all individuals in the primary cohort by an endpoint committee consisting of three cardiologists from another region in Denmark.|"A nationwide cluster-randomized trial with stepped-wedge design"|f|f|f|t
34009752|NCT04422522|||CASE_ONLY||RETROSPECTIVE|||||||
34009753|NCT04060511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094131|NCT03853837|||COHORT||PROSPECTIVE|||||||
34094132|NCT05842980|||COHORT||PROSPECTIVE|||||||
33706614|NCT01948297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706615|NCT04778930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As masking techniques, the persons responsible for the assessment of the subjects and the data collection, the random assignment and the intervention in each group will be independent from each other.||f|f|f|t
34009754|NCT00798382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009755|NCT01655355|||COHORT||PROSPECTIVE|||||||
33706616|NCT02764060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009756|NCT00092950||||TREATMENT||||||||
34009757|NCT00078481||||TREATMENT||||||||
34009758|NCT00794417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009759|NCT04461210|||COHORT||PROSPECTIVE|||||||
33706617|NCT01135420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706618|NCT02941991|||COHORT||PROSPECTIVE|||||||
33706619|NCT00592930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706620|NCT01881347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33706621|NCT01832831|||CASE_CONTROL||PROSPECTIVE|||||||
33706622|NCT05128500|||COHORT||PROSPECTIVE|||||||
33790503|NCT02021760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790504|NCT06114342|||CASE_CONTROL||PROSPECTIVE|||||||
33790505|NCT03550937|||CASE_ONLY||PROSPECTIVE|||||||
33790506|NCT00241423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790507|NCT03838796|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33790508|NCT05312866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790509|NCT02704819|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33790510|NCT04364269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will receive a randomisation number using a validated centralised procedure (IWRS) that automates the random assignment of treatment groups to randomisation numbers. The randomisation plan will be kept strictly confidential, accessible only to authorised persons, until the time of unblinding.~The study drugs (VIT-2763 or placebo) are provided in identical white opaque hard capsules in packaging of identical appearance."|Multiple dose, multicenter, double-blind, placebo-controlled parallel group study in adult and adolescent male and female subjects with non-transfusion dependent thalassemia (NTDT)|t|t|t|t
33790511|NCT02294929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790512|NCT02950194|||CASE_CONTROL||PROSPECTIVE|||||||
33790513|NCT00580437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790514|NCT04878328|RANDOMIZED|PARALLEL||SCREENING||NONE||The investigators will conduct a randomized trial to assess the effectiveness of an onsite Point-of-Care testing and education intervention (O-PoC) compared to standard of care (SoC) at The Fortune Society (Fortune). The current SoC includes a referral to offsite community testing. Guided by Social Cognitive Theory, in O-PoC we will employ CHWs with lived experience of incarceration to provide: 1) COVID-19 education; 2) SARS-CoV-2 testing with Cepheid XpertXpress PCR tests at Fortune facilities; 3) Needs assessments and facilitated access to masks and hygiene supplies; 4) Navigation to vaccination sites (when available) and single-room housing at Fortune's supportive housing sites and partnering shelters, or alternative strategies that will maximize the ability to socially distance for those who test PCR positive; 5) Supportive counseling.||||
33790515|NCT02930590|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33790516|NCT00942058|||COHORT||PROSPECTIVE|||||||
33790517|NCT01606995|||COHORT||PROSPECTIVE|||||||
34009760|NCT05487768|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009761|NCT02947620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009762|NCT02761213|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34009763|NCT01884584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009764|NCT01868763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34009765|NCT04155593|||OTHER||RETROSPECTIVE|||||||
34009766|NCT05178576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706623|NCT02050516|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33706624|NCT06059794|||COHORT||CROSS_SECTIONAL|||||||
33706625|NCT00619177|||COHORT||PROSPECTIVE|||||||
33706626|NCT04961931|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will be prospective, interventional and will be conducted in two parallel groups selected on the basis of clinical diagnosis (diabetic nephropathy or other chronic nephropathies).||||
33706627|NCT00067665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706628|NCT00327275|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33706629|NCT00615511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706630|NCT01933061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706631|NCT06223178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009767|NCT01529931|NA|SINGLE_GROUP||OTHER||NONE||||||
34009768|NCT00528684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009769|NCT00115934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009770|NCT06257316|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34009771|NCT03778723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34009772|NCT02244294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009773|NCT04025684|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Examiner-blind; Monitor and Data-analyst||f|f|t|t
34009774|NCT01295086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009775|NCT01917435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009776|NCT06115304|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009777|NCT05914545|NA|SEQUENTIAL||TREATMENT||NONE||||||
34009778|NCT04253353|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34009779|NCT00006143||||TREATMENT||||||||
34009780|NCT03463018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34009781|NCT05802199|||COHORT||PROSPECTIVE|||||||
34009782|NCT06286059|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single Blinded|Randomised controlled clinical trial|t|f|f|f
33790518|NCT01194778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094133|NCT03520387|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Some investigators are not masked, for safety monitoring purposes.|"The proposed research assesses the feasibility of using a 2 x 2 factorial randomized controlled trial (RCT) design to examine the individual and combined effects of 1) lumbar medial branch nerve radiofrequency ablation (LRFA) (vs. simulated LRFA control), and 2) a novel video telehealth tablet- and personal computer (PC)-based Activity Tracker-Informed Video-Enabled Cognitive Behavioral Therapy program (AcTIVE-CBT) (vs. a telephone-based self-directed CBT and education control). This pilot RCT will involve 30 Veterans with chronic low back pain (CLBP) who will be followed to evaluate functional recovery for 3 months."|t|t|f|t
33790519|NCT05949554|||COHORT||PROSPECTIVE|||||||
33790520|NCT03107286|||OTHER||OTHER|||||||
34009783|NCT03220113|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Open Label Study||||
33790521|NCT01080131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790522|NCT06353958|||CASE_CONTROL||RETROSPECTIVE|||||||
33790523|NCT01603719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790524|NCT04027972|NA|SINGLE_GROUP||TREATMENT||NONE||Same group receives all 2 treatments but in a randomized order after the IV phase.||||
34009784|NCT03662308|RANDOMIZED|CROSSOVER||OTHER||NONE||"After the heated vest has 1) been fully bench-tested and 2) satisfied safety and tolerability testing in able-bodied subjects, it will be tested in persons with tetraplegia using a crossover design with the order of the two visits randomized.~1. Thermal Challenge with heated vest (subjects with tetraplegia only): Subjects with tetraplegia, while seated and wearing only a standard T-shirt and shorts, will be fitted with an appropriately sized heated vest. Subjects will be transferred to a pre-cooled thermal chamber and data will be collected for up to 2 hours with the self-regulating heated vest.~2. Thermal Challenge with non-heated vest (subjects with tetraplegia only): The same subjects with tetraplegia (from Visit 2), while seated and wearing only a standard T-shirt and shorts, will be fitted with an appropriately sized, similar, but non-heated vest. Subjects will be transferred to a pre-cooled thermal chamber and data will be collected for up to 2 hours."||||
34009785|NCT04434781|||OTHER||PROSPECTIVE|||||||
34009786|NCT04017754|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34009787|NCT00332267|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009788|NCT00729131|||CASE_CONTROL||PROSPECTIVE|||||||
34009789|NCT02266849|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34009790|NCT00176631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009791|NCT01123096|||COHORT||PROSPECTIVE|||||||
34009792|NCT02459717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790525|NCT02215278|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33790526|NCT04209049|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009793|NCT05604079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009794|NCT04691375|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part A: Dose escalation of PY314 alone and in combination with pembrolizumab in a standard 3+3 design~Part B: Dose expansion of one or more dose levels of PY314 administered alone and in combination with pembrolizumab for predefined tumor histology"||||
34009795|NCT04673708|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34009796|NCT04897191|||COHORT||CROSS_SECTIONAL|||||||
34009797|NCT06617299|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The present study will be a phase II intervention study of the pilot clinical trial type because the preliminary effect of an intervention will be evaluated where the Experimental Group (EG) will receive the intervention aimed at increasing the practice of RP and maintaining a healthy weight. The Control Group (CG) will receive the usual care, there will be randomization to both groups through a list with the number of rooms, the pilot clinical trial will be of repeated measurements by virtue of which measurements will be made at three times: before the intervention (baseline) and follow-up (post-test 3 and 6 months later) (Grove, Burns \&amp; Gray, 2015).|t|f|f|f
34009798|NCT01625481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009799|NCT01158326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009800|NCT01270620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094134|NCT03360669|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094135|NCT00143351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094136|NCT04208711|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34094137|NCT03137368|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, open-label, parallel, active-controlled superiority clinical study||||
33790527|NCT05856708|||COHORT||RETROSPECTIVE|||||||
33790528|NCT03091712|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open label, randomized, controlled, parallel intervention study.||||
33790529|NCT00395018|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33790530|NCT03960619|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931256|NCT02868099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo-controlled, Double-blinded then Open-label|multi-center, Randomized, Placebo-controlled, Double-blinded then Open-label|t|f|t|f
33931257|NCT03555968|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33931258|NCT02001506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931259|NCT01637090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931260|NCT05448508|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33931261|NCT01442519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931262|NCT00618865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094138|NCT02259322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094139|NCT02802722|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34094140|NCT01060956|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34094141|NCT02919332|||COHORT||PROSPECTIVE|||||||
34094142|NCT01033071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094143|NCT06208631|NA|SINGLE_GROUP||OTHER||NONE||||||
34094144|NCT00095771||||TREATMENT||||||||
34094145|NCT01872936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094146|NCT05644483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34094147|NCT03508297|||COHORT||PROSPECTIVE|||||||
33931263|NCT05620173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931264|NCT04691557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A self-efficacy theory based, randomized, 4-week, parallel group study||||
33931265|NCT00724646|||COHORT||RETROSPECTIVE|||||||
33931266|NCT05391620|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33931267|NCT05728749|||COHORT||PROSPECTIVE|||||||
33931268|NCT06063525|||CASE_ONLY||PROSPECTIVE|||||||
34094148|NCT02288871|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33706632|NCT00143637|NON_RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33706633|NCT00496652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706634|NCT06301334|NA|PARALLEL||TREATMENT||NONE||||||
33706635|NCT05752630|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33706636|NCT04915144|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized phase II study two-arm study of efficacy and safety of 177Lu-DOTATOC for treatment of patients with NETs who are referred to BC Cancer - Vancouver for treatment of progressive tumours.||||
33706637|NCT01544933|||COHORT||RETROSPECTIVE|||||||
33706638|NCT06087120|||COHORT||PROSPECTIVE|||||||
33706639|NCT02584816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706640|NCT04352712|||COHORT||PROSPECTIVE|||||||
33790531|NCT02504619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094149|NCT04462146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094150|NCT06033664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094151|NCT02851524|NA|SINGLE_GROUP||OTHER||NONE||||||
34094152|NCT02523638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094153|NCT04329741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094154|NCT03414632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094155|NCT02411136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931269|NCT03405974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Due to the objectives of the study, the identity of ASA and Placebo treatments will not be known to investigators, research staff, or patients. Access to the randomization code will be strictly controlled in order to ensure double-blind administration of study treatments. Packaging and labeling of ASA and Placebo treatments will be identical to maintain the blind.~All of the study drug profiles will be prepared in order to be identical in appearance to preserve the study blinding. The investigator and the subject, as well as all staff involved in the conduct or management of the study will be blinded to which treatment is assigned."|This study is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that aims to test the efficacy of the proposed medical intervention (ASA). The design is intended to be parallel group where a total of 114 patients will be randomized in a 1:1 ratio to the treatment (ASA) and the control (Placebo) arms.|t|t|t|t
33931270|NCT05254587|||COHORT||OTHER|||||||
33931271|NCT01636453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094156|NCT02665936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34094157|NCT02068599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706641|NCT06265246|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In this 24-month randomized controlled trial, the investigators will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Ninety-nine free-living adults aged 19-30 years with low dietary calcium intake will be randomly assigned to one of the following three intervention arms.~1. Habitual diet (control) (n=33)~2. Habitual diet + 1.5 servings of milk providing approx. 500 mg Ca/day (either 1% fat milk, or 2% fat milk) (n=33)~3. Habitual diet + 2 servings of yogurt providing approx. 500 mg Ca/day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt) (n=33)"||||
33706642|NCT01578187|NA|SINGLE_GROUP||||NONE||||||
33706643|NCT06095583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706644|NCT02571777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706645|NCT02619175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
33706646|NCT01949077|||COHORT||RETROSPECTIVE|||||||
33706647|NCT00934830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706648|NCT00561808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706649|NCT03895541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||stratification||||
33706650|NCT04205968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706651|NCT00310960|||COHORT||PROSPECTIVE|||||||
33706652|NCT00200616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706653|NCT04324775|||CASE_ONLY||PROSPECTIVE|||||||
33706654|NCT02552771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706655|NCT00317668|||DEFINED_POPULATION||OTHER|||||||
33706656|NCT00957580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706657|NCT00304291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706658|NCT05434000|NA|SINGLE_GROUP||SCREENING||NONE||||||
33790532|NCT06237062|||COHORT||PROSPECTIVE|||||||
33706659|NCT06097286|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33706660|NCT00286312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33706661|NCT05235555|||COHORT||PROSPECTIVE|||||||
33706662|NCT00707720|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790533|NCT01185522|||COHORT||PROSPECTIVE|||||||
33790534|NCT06182319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be allocated into 3 groups: One treated without NG tubes. The other 2 groups will have an NG tube and be randomized into treatment with water-soluble contrast or saline.||||
33931272|NCT02293590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931273|NCT02549521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33931274|NCT02482792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931275|NCT04159701|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931276|NCT04803019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931277|NCT01650441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931278|NCT00780104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931279|NCT00287846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931280|NCT02494271|||CASE_CONTROL||RETROSPECTIVE|||||||
33931281|NCT04430699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790535|NCT03987451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33790536|NCT02945267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790537|NCT01863004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790538|NCT02286999|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706663|NCT00640068|||COHORT||PROSPECTIVE|||||||
33706664|NCT01519271|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33790539|NCT03899818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790540|NCT05190913|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Due to the design of the study, single or double masking cannot be done.|Intervention I group (n:40) from two different experimental groups will be given instrumental perineal massage, and intervention II group (n:40) from the other experimental group will be given non-instrumental perineal massage. No intervention is planned for the control group (n:40).|f|f|f|t
33790541|NCT03906890|||COHORT||CROSS_SECTIONAL|||||||
33790542|NCT03736005|||COHORT||PROSPECTIVE|||||||
33790543|NCT04232592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931282|NCT02211950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931283|NCT04117594|||OTHER||PROSPECTIVE|||||||
33931284|NCT01804842|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33706665|NCT03162588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009801|NCT01343069|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34009802|NCT05500092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009803|NCT03027011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34009804|NCT00490334|||COHORT||PROSPECTIVE|||||||
34009805|NCT01270490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009806|NCT05560555|||OTHER||RETROSPECTIVE|||||||
34009807|NCT06609161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34009808|NCT05118516|NA|SINGLE_GROUP||OTHER||NONE||||||
34009809|NCT05246787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|attempt will be videotaped, outcome evaluators will be blind||f|f|f|t
34009810|NCT04626544|||OTHER||CROSS_SECTIONAL|||||||
33706666|NCT00099008|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33706667|NCT02437266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706668|NCT02044705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706669|NCT05206578|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33706670|NCT00230204|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706671|NCT01125267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706672|NCT02958514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706673|NCT01160978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706674|NCT04836572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706675|NCT05089149|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790544|NCT00094185|||COHORT||PROSPECTIVE|||||||
33790545|NCT03545984|RANDOMIZED|PARALLEL||OTHER||SINGLE|The staff anesthesiologist evaluating a resident on spinal drain placement would NOT be aware of the resident's group allocation.|Prospective randomized educational trial|f|f|f|t
33931285|NCT05241288|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study.|All participants will receive the intervention consisting of Albuterol eMDPI DS (ProAir® Digihaler®). Participants will be asked to use the ProAir Digihaler as their primary mode of SABA therapy as they would in usual treatment and indicated in the product package insert and Instructions for Use. They will answer a daily self-assessment on the DAQ App, as well as Digihaler metric algorithm-triggered DAQ on the DAQ app. The DAQ will collect yes/no responses to questions focused on change in symptoms. The participants will be contacted once per month to collect COPD Assessment Test (CAT) score and self-reported average albuterol use over the preceding month. They will also be asked about any AECOPD events requiring treatment.||||
33931286|NCT03325010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931287|NCT01554189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790546|NCT02580448|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931288|NCT03812783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931289|NCT02128958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009811|NCT05447806|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"The study is single-blinded. Participants will be masked from the intervention due to the GlucAlert CDS tool only being viewed by physicians. Investigators will remain unblinded and know when the tool is turned On or Off. The outcomes statisticians and assessors will analyze deidentified data and remain blinded for their analysis."|This prospective quasi-experiment will use an interrupted time series analysis to determine the impact of our novel glucose management CDS tool on the care of adult hospitalized patients outside of intensive care units in an academic and a community hospital. The tool will be intermittently active in the EMR hospital-wide every 3 months during 36-months to enable an intervention (active) and a control (inactive) group of 18 months each in each hospital.|t|f|f|t
34009812|NCT00759434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009813|NCT04510129|||CASE_ONLY||PROSPECTIVE|||||||
34009814|NCT00898534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009815|NCT03212794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009816|NCT05289934|NA|SINGLE_GROUP||TREATMENT||NONE||The children will listen to Mozart K.448 (1st movement) and instrumental age-appropriate songs with 10 minutes wash out in between, each lasting up to 9 minutes in the daytime (between 1-5 pm). The order of music stimuli will be randomly played in 2 to 7 days during the Epilepsy Monitoring Units (EMU) stay. Standard clinical care recording continuous video electroencephalography (EEG) in the EMU will be completed, epileptiform discharges (e.g., the number of spikes per 100 seconds, the number of seconds with spikes, and clinical seizures) will be counted before, during, and after music procedures. Heart rate variability and blood pressure will also be measured before, during, and after music stimuli. Participants' behavior changes will be recorded as a standard of care.||||
34009817|NCT04649450|RANDOMIZED|PARALLEL||PREVENTION||NONE|Music vs. standard clinical care. No blinding of treatment was conducted.|Patients will be randomly allocated to either the intervention (music) or control (standard care) group.||||
34009818|NCT04667247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009819|NCT02515292|||CASE_CONTROL||PROSPECTIVE|||||||
34009820|NCT00990847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009821|NCT03648619|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Clinically-indicated PET/CT and additional study-related MRI as a single Intervention.||||
34009822|NCT00860678|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009823|NCT03483311|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34009824|NCT00389220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34009825|NCT00719979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009826|NCT01485484|||CASE_ONLY||PROSPECTIVE|||||||
34009827|NCT04235972|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34009828|NCT05470829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009829|NCT01311401|||COHORT||PROSPECTIVE|||||||
34009830|NCT01856439|NA|SINGLE_GROUP||OTHER||NONE||||||
34009831|NCT04373382|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Hospital staff will receive support from Peer Resilience Champions, whose activities will, in part, be modelled on the role that psychiatrists acting as support coaches have played in during the acute phase of the pandemic. These include support, identification of needs, education, advocacy and resource navigation. In doing so, they follow evidence-based principles and guidelines.~A randomized cluster stepped wedge design will be used, with five clusters of clinical units and departments constructed in order to approximate the following goals: similar number of staff, comparable COVID-19 exposure, similar mix of staff by discipline and gender, number of clusters small enough to allow for the PRC intervention to be provided with at least six months of implementation within the two-year study after cross-over occurs. (Two arms).~The Enriched survey intervention will be a randomized controlled trial design with equal allocation (1:1) to both the express and enriched surveys. (Two arms)."||||
34009832|NCT02310789|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34009833|NCT06234319|||COHORT||PROSPECTIVE|||||||
34009834|NCT06616181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician||t|f|f|t
34009835|NCT06615765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be maintained for participants, outcome assessors, and statisticians to prevent bias in evaluation. However, the practitioner administering the intervention will not be blinded.||t|f|f|t
34009836|NCT00942331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009837|NCT06406322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931290|NCT04459078|NA|SINGLE_GROUP||TREATMENT||NONE||Patients fulfilling Eligibility Criteria will be enrolled into our study. Participants are given intravenous administration of Camrelizumab (200mg/3w) in addition with intravenous administration of Albumin Paclitacxel (135mg/m2, d1, d8/3w, 4-6 cycles) and Apatinib (250mg Qd po for 5 days, take rest for 2 days every week). Treatment terminates when disease progression, death or unacceptable toxicity||||
33931291|NCT02903368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931292|NCT03527186|NA|SEQUENTIAL||TREATMENT||NONE||This is an open-label, 1-sequence study to evaluate the PK, safety, and tolerability of risperidone ISM® in subjects with schizophrenia who are on stable oral risperidone treatment. The study consists of a screening visit, 1 treatment period with inpatient and outpatient visits, and a follow-up visit.||||
33931293|NCT01287767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33931294|NCT00878813|||COHORT||PROSPECTIVE|||||||
33931295|NCT00802724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34009838|NCT03087487|||COHORT||RETROSPECTIVE|||||||
34009839|NCT02784678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009840|NCT00779415|||CASE_ONLY||RETROSPECTIVE|||||||
34009841|NCT06308133|||COHORT||RETROSPECTIVE|||||||
34009842|NCT00949988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009843|NCT02369718|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009844|NCT02858726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706676|NCT01354340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34009845|NCT03226119|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Clinical Sites and the Reference Core-Lab will be masked of specimen disease state|Cohort A: 100 Neurological Disorder Specimens Cohort B: 50 HTLV Known Positive Specimens|f|f|t|f
34009846|NCT03118219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009847|NCT04862884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||HRS4800 tablets single administration in healthy male|t|t|t|f
33706677|NCT00690183|||COHORT||CROSS_SECTIONAL|||||||
34009848|NCT05261789|RANDOMIZED|PARALLEL||TREATMENT||NONE||Including healthy male individuals between the ages of 18-25. The participants will randomly be allocated three groups (TGU exercise group, core stability exercise group and control group).||||
34009849|NCT03536182|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized in a 2:1 fashion (carbon:photon) between carbon ion radiotherapy or intensity modulated radiation therapy. Assuming a 10% dropout risk, the study will have 82% power to detect an increase in 2-year survival from 22% to 48% with carbon ion radiotherapy.||||
34009850|NCT06142188|||CASE_ONLY||RETROSPECTIVE|||||||
34009851|NCT01337765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009852|NCT03842852|||COHORT||RETROSPECTIVE|||||||
34009853|NCT04676815|||COHORT||PROSPECTIVE|||||||
34009854|NCT01730040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009855|NCT02639728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706678|NCT05196204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009856|NCT05567913|||COHORT||PROSPECTIVE|||||||
34009857|NCT04497272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient with COVID-19 disease||||
33706679|NCT01826630|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33706680|NCT05386810|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The clinical trial is divided into two stages: the first stage is an open design, and the second stage is a randomized ,blind control design||t|f|t|f
34009858|NCT06142669|||COHORT||PROSPECTIVE|||||||
33706681|NCT01423305|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706682|NCT05278767|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33706683|NCT06437496|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706684|NCT01281865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706685|NCT00726986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706686|NCT04079608|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706687|NCT01844128|||COHORT||PROSPECTIVE|||||||
33706688|NCT01225432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706689|NCT04257981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Children will be randomly allocated to one of the two groups by the lottery method. The researcher involved in randomization will not be involved in the assessment or treatment of the participants. The participants and therapists will also be blinded about the subjects allocated to a group by assigning a unique random number to the participants. Pre and post assessment will be performed by the same therapist. The therapist involved in the treatment is blinded about the treatment received by other groups. Each participant will undergo 3 weeks of treatment, 4 days a week. The total number of treatment sessions for each participant will be 12. Each participant will be assessed on the baseline, 2nd week, 3rd week and on 8th week follow up.|Group 1: Transcranial direct stimulation + virtual related group: The group will receive the tCDS and VR Group 2: Sham Transcranial direct stimulation Group + virtual related group: The groups will only receive sham tCDS and VR.|t|t|t|f
33706690|NCT01113567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009859|NCT06400485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706691|NCT00283452|RANDOMIZED|PARALLEL||||NONE||||||
33706692|NCT03355716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"At the end of the procedure, all the subjects will be randomly allocated to groups using computer-generated random numbers. Each group of 30 subjects, that is,~Group A (placebo):~instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion;~Group B :~Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)~Group C :~Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)~Group D :~Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg)."|t|t|t|f
33790547|NCT00408928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931296|NCT01086904|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33931297|NCT00269295|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931298|NCT00988377|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34009860|NCT05571033|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will serve as their own control.||||
33931299|NCT01784497|||COHORT||PROSPECTIVE|||||||
33931300|NCT00520650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009861|NCT01353807|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34009862|NCT04156412|NA|SINGLE_GROUP||OTHER||NONE||||||
34009863|NCT00131755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931301|NCT06153394|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a phase III pilot trial where 50 participants will be randomized 1:1 to receive extended duration thromboprophylaxis via Redesca or standard of care thromboprophylaxis via Fragmin. Participants will be followed for 3 years after surgery.||||
33931302|NCT03739736|||OTHER||OTHER|||||||
33706693|NCT00483639|||CASE_CONTROL||PROSPECTIVE|||||||
33706694|NCT00917566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706695|NCT00375648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706696|NCT05977140|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part 1: 5 randomized single ascending dose cohorts of 8 participants and 1 open-label single ascending dose cohort of 6 participants. In Part 2, 3 multiple ascending dose cohorts, each with 8 participants|t|t|t|t
33706697|NCT04746963|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33706698|NCT04779125|NA|SINGLE_GROUP||TREATMENT||NONE||All patients, who have an abdominoperineal reconstruction for rectal cancer, will have a mesh enhanced gluteus plasty. The patients will be compared to historical cohort.||||
33706699|NCT02023281|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706700|NCT06260332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33706701|NCT04186728|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Randomized double blinded placebo controlled experiment|t|f|t|f
33706702|NCT01581788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33706703|NCT01201850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706704|NCT06127680|||COHORT||PROSPECTIVE|||||||
33706705|NCT03445715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706706|NCT05548816|||OTHER||CROSS_SECTIONAL|||||||
33706707|NCT01819298|||COHORT||PROSPECTIVE|||||||
33706708|NCT01876420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706709|NCT00210405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706710|NCT06266910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|By employing a single simulation technology for blinding, both the 2D group and the 3D group share identical training equipment and a consistent video background. The only distinction lies in the subtle variation in the configuration of training markers. It is difficult for participants to differentiate their respective groups.|randomized controlled trial|t|f|f|t
33706711|NCT05419999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to whether they receive actual tDCS or sham treatment. All study team members will also be blinded to randomization, with the exception of the study team coordinator who will allocate device codes. This will allow for the blind to be broken in case of an emergency or serious adverse event.|Early phase II, two-arm, partially double-blind pilot research clinical trial|t|f|f|f
33706712|NCT04036019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706713|NCT06065397|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706714|NCT05346874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706715|NCT02121431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33706716|NCT01466335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33706717|NCT02621697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706718|NCT02929667|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33706719|NCT05987228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33706720|NCT00870883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706721|NCT06273410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706722|NCT03256097|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A-B-A vs B-A-B|t|f|f|f
33706723|NCT00270790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706724|NCT00702039|||CASE_CONTROL||PROSPECTIVE|||||||
33706725|NCT03118635|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706726|NCT04874584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706727|NCT03885258|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm, single-center, proof-of-concept study||||
33706728|NCT06297577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the type of intervention, only the outcome assessor and the statistician will be blinded||f|f|f|t
33706729|NCT05821478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentric randomized double-blind phase 3 trial|t|t|t|t
33706730|NCT02607150|||COHORT||PROSPECTIVE|||||||
33706731|NCT02661659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706732|NCT03600571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"64 osteoarthritic knees of cadavers were randomly assigned to two groups: the anteromedial (AM) group (n=32) and the medial midpatellar (MMP) group (n=32).~100 patients with unilateral mKOA were enrolled and randomly divided into two groups according to the injection portal of HA: the AM group (n=50) and the MMP group (n=50)."|t|f|f|t
33706733|NCT03944421|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33706734|NCT03048734|||COHORT||PROSPECTIVE|||||||
33706735|NCT04080375|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706736|NCT05700097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706737|NCT04326556|NA|SINGLE_GROUP||OTHER||NONE||||||
33706738|NCT01941875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706739|NCT04238260|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Assessors at each site will be blinded to intervention. Site study coordinators will be unblinded.|"This clinical trial uses a stepped-wedge design. Unlike typical studies where participants are randomized to two different interventions, this design has all sites start in the Usual Care period, and then switch-over to Enhanced Care at predetermined times, which will then be the new Usual Care (termed Enhanced Usual Care)."|f|f|f|t
33706740|NCT01399515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931303|NCT00432185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931304|NCT02845999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931305|NCT02451254|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931306|NCT04069624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931307|NCT00047593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931308|NCT01507623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931309|NCT04921410|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33931310|NCT02837861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931311|NCT01335594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931312|NCT04301011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931313|NCT02245880|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33931314|NCT05905861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33931315|NCT01666990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33931316|NCT04483752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931317|NCT04268303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind, Placebo-Controlled|Phase III, Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
33931318|NCT02615262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931319|NCT01337518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931320|NCT05421091|||COHORT||PROSPECTIVE|||||||
33931321|NCT05556915|RANDOMIZED|PARALLEL||OTHER||NONE||Open label, randomized clinical study comparing two AVF cannulation methodes (conventional vs ultrasound-guided method) in pediatric patients with end-stage renal disease undergoing hemodialysis therapy.||||
33931322|NCT00595868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931323|NCT04011644|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will have rolling enrollment over two years. Patients will be enrolled and randomized to one of three interventions for 12 months.||||
33931324|NCT01916187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931325|NCT01041404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931326|NCT05258513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, parallel, randomized, placebo controlled, dose-escalation trial|t|f|t|t
33931327|NCT02524535|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931328|NCT01973972|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931329|NCT01526317|RANDOMIZED|CROSSOVER||||NONE||||||
33931330|NCT06074718|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931331|NCT00671970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931332|NCT05956262|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931333|NCT02283541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931334|NCT00063388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931335|NCT04327622|||COHORT||RETROSPECTIVE|||||||
33931336|NCT01638169|||CASE_ONLY|||||||||
33931337|NCT02971007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931338|NCT05977803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931339|NCT01498497|||COHORT||PROSPECTIVE|||||||
33706741|NCT02742441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706742|NCT00481078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706743|NCT06044883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706744|NCT01496248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706745|NCT01744197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706746|NCT02485197|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33706747|NCT01539538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706748|NCT04372901|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is based on different technical procedures of fabrication of the frameworks. Since these differences are visible, the operator, the assessor and the technician involved in the study cannot be blinded. Since blinding was not possible, randomization was delayed till the prosthetic phase to avoid any performance bias in the surgical steps. But the statistician will be blinded .|Trial design to be conducted is RCT, split mouth , two arms, and Equivalence frame with 1:1 allocation ratio.||||
33706749|NCT01500161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706750|NCT04765696|||COHORT||PROSPECTIVE|||||||
33706751|NCT01482845|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33706752|NCT05543733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706753|NCT06275724|||COHORT||PROSPECTIVE|||||||
33706754|NCT06324669|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Coded, known only to independent individual|Randomised cross over trial counterbalanced for trial order|t|t|t|t
33706755|NCT04173585|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's Optimal Two-Stage Design: The Matched Threshold Crossing (MTC) Design||||
33706756|NCT01929005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706757|NCT03744091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomly assigned to either 10 mg or 20mg arm||||
33706758|NCT01408446|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706759|NCT01782820|||CASE_CROSSOVER||PROSPECTIVE|||||||
33706760|NCT00560456|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33706761|NCT02265874|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33706762|NCT03481244|||COHORT||PROSPECTIVE|||||||
33706763|NCT05772000|||COHORT||PROSPECTIVE|||||||
33706764|NCT06505512|||CASE_CONTROL||PROSPECTIVE|||||||
33706765|NCT01786083|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33706766|NCT03060811|||COHORT||CROSS_SECTIONAL|||||||
33706767|NCT03147261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706768|NCT03375775|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open controlled study||||
33706769|NCT03322631|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33706770|NCT02969369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706771|NCT01427972|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33706772|NCT05096793|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The experimental design applied was randomized cross-over and double-blind|t|f|t|t
33706773|NCT04496271|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33706774|NCT05722782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706775|NCT00508716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706776|NCT00437307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706777|NCT03876379|||OTHER||PROSPECTIVE|||||||
33706778|NCT01667380|||COHORT||PROSPECTIVE|||||||
33790548|NCT01253226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931340|NCT00741260|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33931341|NCT02804373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931342|NCT04059991|||COHORT||PROSPECTIVE|||||||
33931343|NCT00882830|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931344|NCT00723268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931345|NCT03954704|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33931346|NCT01095939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931347|NCT02082665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931348|NCT05642065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931349|NCT03972605|||CASE_CONTROL||RETROSPECTIVE|||||||
33931350|NCT01071369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomly assigned to groups||t|f|t|f
33931351|NCT04146038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931352|NCT02237898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931353|NCT01934608|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33931354|NCT05549089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931355|NCT05007340|||COHORT||PROSPECTIVE|||||||
33931356|NCT00925067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009864|NCT01008137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34009865|NCT02279784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009866|NCT05196516|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34009867|NCT04859387|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||quasi-experimental|t|f|t|t
34009868|NCT05208879|||CASE_CONTROL||PROSPECTIVE|||||||
34009869|NCT03276676|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Both arms will undergo the same interventions, however, Group A will undergo three imaging sessions and Group B will undergo one imaging session||||
34009870|NCT02971722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009871|NCT01920984|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33706779|NCT05947396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009872|NCT04955366|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized controlled non-inferiority trial||||
34009873|NCT03393416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706780|NCT03571425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Oral conditions are double blinded to participant and investigator, but enteral vs oral feeding is not blinded|||||
34009874|NCT02746627|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned to Positive Affect - Phone, Positive Affect - Text, or Education groups for the duration of the study.||||
33706781|NCT00839891|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33706782|NCT01325584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706783|NCT02647814|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790549|NCT04487236|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33931357|NCT04046601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|no masking|Observation group: patient who are planned for endoscopic resection because of known esophageal cancer. Immediately after retrieval the resected specimens will be investigated for their electrical impedance properties. The results of the impedance measurement are compared to the histological results.||||
33931358|NCT01091142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931359|NCT02030093|||COHORT||PROSPECTIVE|||||||
33931360|NCT05592158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931361|NCT04783376|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931362|NCT05412836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931363|NCT04485598|||COHORT||PROSPECTIVE|||||||
33931364|NCT01070706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931365|NCT03103776|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33931366|NCT02680561|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33931367|NCT02000219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931368|NCT05885568|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33931369|NCT04905810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931370|NCT04846972|||OTHER||PROSPECTIVE|||||||
33931371|NCT02584023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33931372|NCT01553591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931373|NCT03815760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors are blinded to group allocation.||f|f|f|t
33931374|NCT04737759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931375|NCT04389268|||CASE_CONTROL||PROSPECTIVE|||||||
33931376|NCT04842877|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study||||
33931377|NCT00226876|||COHORT||PROSPECTIVE|||||||
33931378|NCT02844140|NA|SINGLE_GROUP||OTHER||NONE||||||
33931379|NCT06004440|||COHORT||PROSPECTIVE|||||||
33931380|NCT05666206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931381|NCT01438359|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33931382|NCT05187572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Treatment allocation will be done per institution, after a centralized randomization process. Care providers and outcome assessors will be blinded to the allocation process.||t|t|f|t
33931383|NCT04290260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931384|NCT00195624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931385|NCT03562624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931386|NCT06224868|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The anesthesiologist will not tell the radiologist making ultrasonography (USG) measurements which PEEP she set on the mechanical ventilator.|Group 1: PEEP 0 Group 2: PEEP 5 Group 3: PEEP 10|t|f|t|f
33931387|NCT01121952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931388|NCT06353789|||COHORT||CROSS_SECTIONAL|||||||
33931389|NCT00148525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33931390|NCT04838795|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label, single-arm phase 3B vaccine implementation study||||
33931391|NCT03395041|||CASE_CONTROL||PROSPECTIVE|||||||
33931392|NCT03783013|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33931393|NCT06109129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All assessments will be performed by an experienced pediatric physiotherapist blinded to the study hypothesis and design.~Statistical analysis of the study will be performed by a biostatistician blinded to the study hypotheses."|A Double-Blınd Randomızed Controlled Study|f|f|t|t
33931394|NCT05016440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931395|NCT00092391|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33931396|NCT05263401|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33931397|NCT02599857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931398|NCT01896414|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34009875|NCT04310488|||OTHER||PROSPECTIVE|||||||
34009876|NCT02269631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34009877|NCT01463150|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34009878|NCT03680976|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34009879|NCT04100824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33931399|NCT05226767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomly assigned a 1: 1 ratio to receive NLC-V or placebo|"Patients who receive treatment with the NLC-V research product depending on the weight of the patients, as follows - Patients weighing less than 70 kg will receive 2 capsules, 4 times a day (80 mg in total per day) Patients weighing between 70 kg and 100 Kg will receive 3 capsules, 4 times a day (a total of 120 mg per day). Patients weighing over 100 kg will receive 4 capsules, 4 times a day (a total of 160 mg per day). NLC-V capsules Will be taken during days 1-10 for the patient's hospitalization NLC-V capsules will be taken during days 1-10 for the patient's hospitalization~Patients who receive placebo in addition to the usual treatment for COVID-19. The placebo consists of the same solvent, but without the active ingredients of NLC-V. Placebo will be given to patients in the same manner and with the same frequency as NLC-V"|t|t|t|t
33931400|NCT03444467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33706784|NCT06555536|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is an Interventional Clinical Trial without a Control Group that was carried out in a population of patients with Osteogenesis Imperfecta.||||
33706785|NCT03162991|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33706786|NCT06045351|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Infertile females with Polycystic Ovarian Syndrome|t|f|f|f
33706787|NCT01874405|||CASE_ONLY||RETROSPECTIVE|||||||
33706788|NCT04201093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706789|NCT06404502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All instruments and questions will be administered online.|The pilot RCT will inform us about the feasibility of PRISMA under usual practice conditions.|f|f|f|t
33706790|NCT04891952|||CASE_CONTROL||PROSPECTIVE|||||||
33931401|NCT00796224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931402|NCT05524558|||COHORT||PROSPECTIVE|||||||
33931403|NCT03681834|||COHORT||PROSPECTIVE|||||||
33931404|NCT01604434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931405|NCT06097741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009880|NCT00928226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009881|NCT01651611|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009882|NCT01544218|||CASE_ONLY||CROSS_SECTIONAL|||||||
34009883|NCT00652756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009884|NCT05601960|||COHORT||PROSPECTIVE|||||||
34009885|NCT01711749|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34009886|NCT01045616|||COHORT||RETROSPECTIVE|||||||
34009887|NCT00915837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009888|NCT05132569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009889|NCT04491578|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Dyads of participants recruited from all elderly community centres will receive the ACP intervention||||
34009890|NCT06115863|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized controlled trial with two parallel groups will be used in the current study.|t|t|t|f
34009891|NCT00918918|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34009892|NCT02457884|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34009893|NCT04360395|NA|PARALLEL||TREATMENT||SINGLE||"Cerebral Palsy participants will undergo baseline mobility/brain imaging/cognitive testing, receive gait therapy, and then repeat mobility/brain imaging testing.~Non-Cerebral Palsy controls will undergo the same baseline testing once as a reference group to determine a normative state for mobility. No gait therapy will be conducted."|f|f|f|t
34009894|NCT04126486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009895|NCT06083636|||OTHER||CROSS_SECTIONAL|||||||
34009896|NCT00173030|||CASE_CONTROL||OTHER|||||||
34009897|NCT04756596|||COHORT||PROSPECTIVE|||||||
34009898|NCT02958319|||COHORT||PROSPECTIVE|||||||
34009899|NCT00137657|NON_RANDOMIZED|PARALLEL||ECT||NONE||||||
34009900|NCT00489164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34009901|NCT05644886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the intervention masking is not feasible|The study uses a two arm parallel facility based randomized controlled trial with on-going intervention of training and technical support for six-month.||||
34009902|NCT04368234|||COHORT||PROSPECTIVE|||||||
33706791|NCT01845831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009903|NCT04831138|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706792|NCT04636190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009904|NCT03389256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009905|NCT01032460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009906|NCT02963584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34009907|NCT01362426|||CASE_ONLY||PROSPECTIVE|||||||
34009908|NCT03028064|||COHORT||PROSPECTIVE|||||||
33706793|NCT04545060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009909|NCT00079521|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34009910|NCT05227131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009911|NCT00258375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009912|NCT06461117|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Beetroot juice or a placebo drink with the same organoleptic properties was given to the swimmers participating in the study. Participants did not know whether the drink they drank was placebo or beetroot juice.|This study designed as a single-blind intervention study.|t|f|f|f
34009913|NCT05450484|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34009914|NCT04309786|||COHORT||PROSPECTIVE|||||||
34009915|NCT04412486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706794|NCT00695409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706795|NCT06101108|||COHORT||PROSPECTIVE|||||||
33706796|NCT02271568|||CASE_CONTROL||PROSPECTIVE|||||||
33706797|NCT00003211|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706798|NCT04149626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706799|NCT02160535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009916|NCT03153787|NA|SINGLE_GROUP||OTHER||NONE||||||
34009917|NCT03973099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study : Participants and investigators do not know which treatment is placebo or treatment.|Double blinded, randomized, placebo-controlled clinical study for evaluating anti-stress effects of Nelumbinis Semen|t|f|t|f
34009918|NCT00021216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931406|NCT05243147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009919|NCT02000531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706800|NCT03329573|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This study is an open-label treatment period; hence, masking will not be performed.|In this study, each subject will receive paroxetine IR 40mg A or B in a cross-over manner||||
34009920|NCT05981287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009921|NCT06330350|||COHORT||PROSPECTIVE|||||||
34009922|NCT05619159|||CASE_ONLY||RETROSPECTIVE|||||||
34009923|NCT02390648|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34009924|NCT04750382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009925|NCT02946606|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33706801|NCT00392795|||OTHER||PROSPECTIVE|||||||
33706802|NCT00690274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009926|NCT03258879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009927|NCT02749760|NA|SINGLE_GROUP||SCREENING||NONE||||||
34009928|NCT05187858|NA|SEQUENTIAL||TREATMENT||NONE||||||
34009929|NCT01904422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34009930|NCT03844997|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open label study of the combination of Palbociclib with CPX-351 in adults with AML. The trial consists of two components: phase I to evaluate the safety with dose escalation of Palbociclib in combination with CPX-351 and phase II to evaluate the overall response rate of the combination in the targeted patient population. A cycle is 28 days.||||
33706803|NCT04356391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, split-mouth, double blinded design clinical trial.|t|t|t|f
33706804|NCT01929096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706805|NCT06262880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706806|NCT01328691|||COHORT||RETROSPECTIVE|||||||
33706807|NCT01393496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706808|NCT06440096|||OTHER||CROSS_SECTIONAL|||||||
33706809|NCT05662150|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33706810|NCT02985957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706811|NCT00916097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706812|NCT04057612|||CASE_CONTROL||PROSPECTIVE|||||||
33706813|NCT00838747|||COHORT||PROSPECTIVE|||||||
33706814|NCT02998944|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33706815|NCT04406376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will be randomized to recieve one of the following steroids regimens:~1. Prednisone 1 mg/kg (max. 60 mg) daily for 7 days, 40 mg for 2 days, 20 mg for 2 days (Total 11 days)~2. Prednisone 1 mg/kg (max. 60 mg) daily for 7 days (Total 7 days)"|f|f|f|t
33706816|NCT02817308|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33706817|NCT00746083|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706818|NCT05802511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706819|NCT01764672|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33706820|NCT06557655|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The order of participants was determined through the use of computerized randomization software||f|f|t|f
33706821|NCT01919606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706822|NCT01056653|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33706823|NCT01227759|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33706824|NCT04688970|||CASE_ONLY||PROSPECTIVE|||||||
33706825|NCT01558232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706826|NCT03483740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pilot, parallel design, randomized, controlled trial (RCT) that will allocate a sample (n=16) of people (≥ 40 yrs old) aging with HIV who have been diagnosed with MND from St. Michael's Hospital (SMH) in Toronto to either arm 1: 8 weekly 3-hour sessions of CRGT; or arm 2: 8 weekly 3-hour sessions of HIV group therapy.||||
33706827|NCT01631344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706828|NCT01906398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706829|NCT01602159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706830|NCT02107508|||||CROSS_SECTIONAL|||||||
33706831|NCT01186965|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33706832|NCT04167579|||CASE_ONLY||OTHER|||||||
33706833|NCT05097755|||COHORT||PROSPECTIVE|||||||
33931407|NCT02774291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931408|NCT02515188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33931409|NCT02038725|||COHORT||PROSPECTIVE|||||||
33931410|NCT01548209|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931411|NCT04787263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931412|NCT00651768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931413|NCT04308928|||COHORT||PROSPECTIVE|||||||
33931414|NCT04556929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931415|NCT04362189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931416|NCT01072240|||COHORT||PROSPECTIVE|||||||
33931417|NCT05682768|||COHORT||RETROSPECTIVE|||||||
34094158|NCT05740592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the trial, it is impossible to blind the investigator to the group once it is allocated. But the radiologist who uses CBCT will be blinded for the image capturing and thus allow for the blindness of the measurements extracted from the CBCT images that will be made at the soft tissue and skeletal and dental levels.|The first part of this study will involve a clinical trial to evaluate the efficacy of adjunctive piezoelectric sutural incision and MOPs along with maxillary expansion in terms of dentoalveolar and skeletal transverse induction in late adolescent patients.|t|f|f|f
34094159|NCT02216409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094160|NCT05122819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094161|NCT00239291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094162|NCT04195412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094163|NCT05548504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094164|NCT06072313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
34094165|NCT00926120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094166|NCT00726557|||CASE_ONLY||PROSPECTIVE|||||||
34094167|NCT03723070|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized study designed to validate the safety and performance of the Cryterion Cardiac Cryoablation System when used as intended||||
33706834|NCT05169385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be masked to study condition.|Effectiveness Trial|f|f|f|t
33706835|NCT03129165|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34009931|NCT03282149|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Unblinded pharmacy provides injection preparation for blinded administration|Inflammation and pain due to osteoarthritis in the knee|t|t|t|t
34009932|NCT05220553|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Pilot Study||||
34009933|NCT05717270|||COHORT||OTHER|||||||
34009934|NCT00577148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009935|NCT02278718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009936|NCT05801302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Raters and outcomes assessor will be blinded to the participants' allocation in each group.||f|f|t|t
34009937|NCT05155605|NA|SINGLE_GROUP||SCREENING||NONE||||||
34009938|NCT00003396||||TREATMENT||||||||
34009939|NCT00618033|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33706836|NCT03824314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34009940|NCT01652976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009941|NCT05896215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009942|NCT00237419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094168|NCT06147154|||CASE_CONTROL||RETROSPECTIVE|||||||
34094169|NCT04921163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||double blinded cross over study|t|t|t|f
33706837|NCT00365508|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33706838|NCT05622175|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular. A standard 3+3 dose escalation design from 0.5 to 10 mg of F8IL10 until the first instance of a DLT in the observation period from Day 1 to Day 28. In the absence of DLTs, such dose increase will continue until the MAD level is reached and won't exceed 10 mg dose level. With the occurrence of a DLT, the same dose level cohort will be expanded to 6 patients and, if additional DLTs do not occur, the dose escalation will continue to the next dose level. When two DLTs are recorded in the same dose level, MAD is automatically reached. The RD will be then defined by the DSMB .||||
33706839|NCT01221792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706840|NCT05248048|NA|SEQUENTIAL||TREATMENT||NONE||||||
33706841|NCT05487144|NA|SINGLE_GROUP||OTHER||NONE||||||
33706842|NCT00032123||||TREATMENT||||||||
33706843|NCT05976048|||COHORT||RETROSPECTIVE|||||||
33706844|NCT01292759|||CASE_ONLY||PROSPECTIVE|||||||
33706845|NCT04490850|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33706846|NCT05663190|||OTHER||CROSS_SECTIONAL|||||||
33706847|NCT03490136|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33706848|NCT06236672|||COHORT||RETROSPECTIVE|||||||
33706849|NCT00401596||||TREATMENT||||||||
33706850|NCT01696825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706851|NCT04945122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706852|NCT01430000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706853|NCT05560477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A vial of AM3101 is inverted to mix and aspirated into the barrel of a 5cc syringe in a controlled area to ensure sterility. The saline control will be prepared in a similar fashion. The syringes will be labeled with blinding tape and transferred to the surgical suite.|Prospective, randomized, controlled, double-blinded, multi-center study|t|t|t|t
33706854|NCT01728597|||OTHER||OTHER|||||||
33706855|NCT02252913|NA|SINGLE_GROUP||||NONE||||||
33706856|NCT05182528|||COHORT||RETROSPECTIVE|||||||
33706857|NCT03890445|||COHORT||PROSPECTIVE|||||||
33706858|NCT04246450|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Based on the presence of noninvasive risk factors patients will be submitted to invasive programmed ventricular stimulation and receive an ICD if ventricular tachycardia / fibrillation (VT/Vf) are inducible||||
33706859|NCT03704480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706860|NCT00383461|RANDOMIZED|||||NONE||||||
33706861|NCT06233617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33706862|NCT06251648|||CASE_ONLY||RETROSPECTIVE|||||||
33706863|NCT05840367|||COHORT||PROSPECTIVE|||||||
33706864|NCT03368794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790550|NCT06052176|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Subjects will be blinded to which infusions are albumin versus placebo. All infusion tubing and bag will be covered in foil and the subjects will not be aware of the timing of the saline vs albumin infusion to maintain blinding for the patient.||t|f|f|t
34009943|NCT04500548|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34009944|NCT02592772|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34009945|NCT03994367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34009946|NCT06193031|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34009947|NCT03803111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094170|NCT02112591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009948|NCT06416917|||COHORT||CROSS_SECTIONAL|||||||
34009949|NCT01419899|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33706865|NCT05219305|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator completed randomization program and delivered grafting material to patient/dentist at time of grafting. Patients and providers still blinded as to which group they were assigned.|"All participants originate from previous study Alveolar Ridge Preservation with evenly distributed experimental groups of FDBA, Mineralized, and Partially Demineralized Dentin Grafts. They have already been assigned and treated with different types of bone grafts. They were assigned groups via a computer randomization program."|t|t|f|f
34094171|NCT02677389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706866|NCT02412618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790551|NCT04963049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790552|NCT01848548|||CASE_ONLY||PROSPECTIVE|||||||
33790553|NCT02954848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009950|NCT05589038|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33706867|NCT05509920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790554|NCT02272400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009951|NCT02676284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706868|NCT05442814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sealed envelope|participant with anterior suprascapular block ,group 1 participant with posterior suprascapular block, group 2|f|f|f|t
34009952|NCT03647124|||OTHER||RETROSPECTIVE|||||||
34009953|NCT05307406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094172|NCT01666405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094173|NCT00849329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706869|NCT03265769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094174|NCT04368910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094175|NCT04270773|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase IV (post-authorization study), open, single-arm trial||||
34094176|NCT05188612|||COHORT||CROSS_SECTIONAL|||||||
34094177|NCT00369083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33706870|NCT05673889|NA|CROSSOVER||OTHER||NONE||||||
33790555|NCT00415558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790556|NCT05990517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790557|NCT04621682|RANDOMIZED|PARALLEL||OTHER||SINGLE||TECRISIS is a study designed as a controlled clinical trial of superiority with parallel groups, random allocation and blinding of investigators who measure outcome.|f|f|f|t
33790558|NCT01955694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790559|NCT00641472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790560|NCT04174495|||COHORT||RETROSPECTIVE|||||||
33790561|NCT01457534|||CASE_CONTROL||RETROSPECTIVE|||||||
33790562|NCT05866939|||COHORT||PROSPECTIVE|||||||
33790563|NCT06630546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790564|NCT01460342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790565|NCT06485427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790566|NCT00789919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790567|NCT00660478|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33790568|NCT01406262|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33931418|NCT02155504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33790569|NCT01282840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931419|NCT06168474|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Neither study subjects nor research staff administering consent will be masked to intervention allocation, as masking of the two different consent processes is not feasible. However, to minimize bias in measurement of outcomes, the assessor of the secondary outcomes of participant satisfaction and understanding will not be directly involved in the consent process and will be masked to the intervention allocation. Analysis of outcome results will also be performed masked.||f|f|f|t
33931420|NCT03104959|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931421|NCT02108444|||CASE_CONTROL||RETROSPECTIVE|||||||
33931422|NCT06066853|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm open label||||
33931423|NCT05068427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931424|NCT05837507|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, two-armed, interventional controlled study versus multicenter, open-label study.||||
33931425|NCT04386473|||COHORT||PROSPECTIVE|||||||
33931426|NCT04974957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931427|NCT04625088|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33931428|NCT05428540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33931429|NCT04469257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pretest-posttest randomized controlled experimental study||||
34094178|NCT06165965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094179|NCT03963830|NA|SINGLE_GROUP||PREVENTION||NONE||Implementation research for adapted effective intervention||||
34094180|NCT03312166|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094181|NCT05132946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094182|NCT01536509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094183|NCT05735496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094184|NCT00714038|||||PROSPECTIVE|||||||
34094185|NCT04379115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple|single-center, double-blinded, placebo controlled, randomized study.|t|f|t|t
34094186|NCT02478502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094187|NCT01343914|||COHORT||RETROSPECTIVE|||||||
34094188|NCT01351558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34094189|NCT03317262|||OTHER||PROSPECTIVE|||||||
33706871|NCT03589560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790570|NCT01682200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931430|NCT00502398|||||PROSPECTIVE|||||||
33931431|NCT00885560|||CASE_ONLY||CROSS_SECTIONAL|||||||
33931432|NCT02451189|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34009954|NCT04449224|||COHORT||PROSPECTIVE|||||||
34009955|NCT01796964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009956|NCT01052324||||PREVENTION||||||||
34009957|NCT05923970|||COHORT||PROSPECTIVE|||||||
34094190|NCT03106805|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931433|NCT03788967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931434|NCT05434936|NA|SINGLE_GROUP||OTHER||NONE||This is a tissue bank protocol in which prospectively collected specimens of ovarian tissue and a sample of whole blood will be obtained from patients who elective to cryopreserve ovarian tissue to preserve fertility. The portion of tissue designated for patient use will be cryopreserved using the slow freeze method while the portion designated for research purposed will be divided and cryopreserved using the slow freeze versus vitrification methods.||||
33931435|NCT05154643|||COHORT||PROSPECTIVE|||||||
33931436|NCT01838213|||||PROSPECTIVE|||||||
33931437|NCT00314041|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33931438|NCT03999463|||COHORT||PROSPECTIVE|||||||
33931439|NCT05324956|||COHORT||PROSPECTIVE|||||||
33931440|NCT04333992|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33931441|NCT01948349|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009958|NCT02220725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009959|NCT01914172|||COHORT||CROSS_SECTIONAL|||||||
34009960|NCT03442010|||COHORT||PROSPECTIVE|||||||
34009961|NCT02646917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33706872|NCT04329897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment Two study groups. The intervention group and the control group that does not receive the intervention||||
33931442|NCT01826448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34009962|NCT02644161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009963|NCT00031850||||PREVENTION||||||||
34009964|NCT01489618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34009965|NCT05073250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009966|NCT00006473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009967|NCT06109701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34009968|NCT01456416|||COHORT||PROSPECTIVE|||||||
34009969|NCT00412724|||||CROSS_SECTIONAL|||||||
34009970|NCT06610474|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34009971|NCT06213350|||COHORT||CROSS_SECTIONAL|||||||
34009972|NCT03711214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Clinical treatment of periodontal disease in pSS patients and healthy individuals||||
34009973|NCT06011382|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm parallel randomized controlled trial with 1:1 allocation ratio||||
34009974|NCT00977431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009975|NCT01901848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34009976|NCT01546142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34009977|NCT01647711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931443|NCT05743257|||CASE_CONTROL||PROSPECTIVE|||||||
34009978|NCT05338372|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34009979|NCT03669068|||COHORT||PROSPECTIVE|||||||
34009980|NCT00190879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34009981|NCT03226171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009982|NCT02346851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34009983|NCT04464109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34009984|NCT02288208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34009985|NCT03416556|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"* The participant were assigned to the treatment group with a computer program.~* Outcomes assessor did´t know the treatment applied to the participants"||t|f|f|t
34009986|NCT03093935|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort- Prospective, multi-center to collect population specific outcome measures in post-stroke patients||||
34009987|NCT02198924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34009988|NCT01082887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009989|NCT04191824|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate versus delayed return of Apolipoprotein L1 (APOL1) gene testing results to provider and participant.||||
34009990|NCT04815252|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are assigned, based on childcare center, to the intervention or waitlist control group.||||
34009991|NCT04306094|||COHORT||PROSPECTIVE|||||||
34009992|NCT00466804|||CASE_ONLY||PROSPECTIVE|||||||
34009993|NCT03472742|||COHORT||PROSPECTIVE|||||||
34009994|NCT00890552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009995|NCT00766831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009996|NCT04593342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham control|Single center, Prospective, Double Blind, Randomized, Sham-Controlled, Parallel Group, Superiority comparison|t|f|f|t
34094191|NCT06272656|||COHORT||PROSPECTIVE|||||||
33931444|NCT00033449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931445|NCT01791790|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33931446|NCT03530761|||COHORT||PROSPECTIVE|||||||
33931447|NCT01204424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931448|NCT05148117|||CASE_CONTROL||PROSPECTIVE|||||||
33931449|NCT04228445|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33931450|NCT00767793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931451|NCT05001568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will be separated into two stages. Each patient will initially try a control brace and a test brace in a crossover study model to evaluate the immediate correction. Each patient will then use one brace from either the control arm or test arm to evaluate the long-term correction of the brace.|t|f|f|t
33931452|NCT05810389|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33931453|NCT03081572|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931454|NCT00493714|||COHORT||PROSPECTIVE|||||||
33931455|NCT03515239|||COHORT||PROSPECTIVE|||||||
34009997|NCT02154724||CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34009998|NCT01130779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34009999|NCT05993598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010000|NCT02897817|||COHORT||PROSPECTIVE|||||||
34010001|NCT00467987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|matching placebo||t|f|t|f
34010002|NCT05767736|||COHORT||RETROSPECTIVE|||||||
34010003|NCT05686759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010004|NCT03015064|||COHORT||PROSPECTIVE|||||||
33931456|NCT06450808|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Crossover: Three single-dose treatment periods|This study is a prospective blinded intervention study in a cross-over design with three single-dose treatment periods (2 %, 3 % and 4 % PT content in the investigational product) and a 14-day washout phase between the treatment periods.|f|t|f|f
34094192|NCT04416789|||FAMILY_BASED||PROSPECTIVE|||||||
34094193|NCT03750084|||OTHER||PROSPECTIVE|||||||
34094194|NCT02464358|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34094195|NCT01993303|||CASE_CONTROL||RETROSPECTIVE|||||||
34094196|NCT04801693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"single rising dose part is single-blind, randomized, placebo-controlled within parallel dose groups.~food effect part is randomized, open-label, two-way, two-period, crossover design."|t|f|f|f
34094197|NCT02466542|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33706873|NCT01101880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094198|NCT02324322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094199|NCT05957523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706874|NCT01552941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706875|NCT03334539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931457|NCT01505114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33931458|NCT06462430|||CASE_ONLY||PROSPECTIVE|||||||
33931459|NCT03932890|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931460|NCT05228704|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33931461|NCT06262204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|does get the information only after 2 years at the end of teh study||t|f|f|f
33931462|NCT01226472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931463|NCT04276779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33931464|NCT03184727|||COHORT||PROSPECTIVE|||||||
33706876|NCT00012311||||TREATMENT||||||||
33706877|NCT00002307|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33706878|NCT06468332|||OTHER||PROSPECTIVE|||||||
33706879|NCT01954719|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33706880|NCT05374369|||CASE_CONTROL||RETROSPECTIVE|||||||
33706881|NCT00149201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790571|NCT06443320|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790572|NCT03573791|||CASE_CONTROL||PROSPECTIVE|||||||
33931465|NCT04580888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931466|NCT04053218|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be unaware of whether the capsules are supplement or placebo. The investigators will know that all persons in the exercise group will receive omega-3 supplements and that those not exercising will be receiving placebo capsules.|"Participants will be enrolled in one of two groups, exercise and omega-3 supplementation or placebo group. Subjects and controls in the first group will receive supervised aerobic exercise on a treadmill, targeting 75-85% heart rate reserve for 45 minutes per session, three days per week. Each participant's heart rate reserve will be calculated using the formula: Heart rate reserve=maximal heart rate - resting heart rate. Each participant in this group will also receive an omega-3 supplement containing 2 grams /day.~The placebo group will receive 2 grams of olive oil (mainly oleic acid, a monounsaturated fatty acid) and standardised health education, face-to-face and written (American Heart Association educational materials), including recommendations for regular physical activity and nutrition."|t|f|f|f
33931467|NCT01055470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706882|NCT03993795|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33706883|NCT04399317|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Due to the technical facts (use of a different mechanical ventilator) only the participants (who are sedated) and the outcome assessor will be blinded for the treatment arm.|randomization to treatment or control group|t|f|f|t
33706884|NCT02543437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706885|NCT02154776|NA|SINGLE_GROUP||OTHER||NONE||||||
33706886|NCT03804697|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33706887|NCT05112471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Split Mouth, RCT||||
34094200|NCT06529705|NA|SINGLE_GROUP||OTHER||NONE||Adults with type 1, type 2 diabetes or pancreatogenic diabetes treated by multiple daily insulin injections||||
33706888|NCT00970372|||||PROSPECTIVE|||||||
33706889|NCT03591991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094201|NCT05675085|NA|SINGLE_GROUP||SCREENING||NONE||||||
34094202|NCT03745781|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1: open-label placebo Arm 2: treatment as usual control||||
34094203|NCT03901209|NA|SINGLE_GROUP||TREATMENT||NONE||The study design is a prospective, bi-national, multi-center (3 centers), open-label single arm, confirmatory clinical study - with an initial explorative sequential phase.||||
34094204|NCT02847273|||CASE_ONLY||PROSPECTIVE|||||||
34094205|NCT02966925|NA|SINGLE_GROUP||TREATMENT||NONE||case-series||||
34094206|NCT05345587|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094207|NCT05388175|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Statistician will be blinded of the treatment group||f|f|f|t
34094208|NCT02702310|||COHORT||PROSPECTIVE|||||||
34094209|NCT00420264|NA|SINGLE_GROUP||||NONE||||||
34094210|NCT05390554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094211|NCT05549245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094212|NCT02744768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094213|NCT03939832|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34094214|NCT01749839|||CASE_CONTROL||PROSPECTIVE|||||||
34094215|NCT04825977|||COHORT||PROSPECTIVE|||||||
34094216|NCT02004171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094217|NCT00346528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094218|NCT05430295|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a prospective comparative interventional clinical study,||||
33706890|NCT02753868|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33706891|NCT05581628|||COHORT||CROSS_SECTIONAL|||||||
34094219|NCT03549260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind and Placebo-Controlled - Study drug administered by unmasked nurse who is not involved in any other aspects of the trial|Randomized, Double-Blind, Placebo-Controlled trial to evaluate LDL-C reduction with 3 different doses of LIB003 compared to placebo|t|t|t|t
34094220|NCT05416177|||CASE_ONLY||PROSPECTIVE|||||||
34094221|NCT06268119|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The control group received standard care. The intervention group received care in line with postoperative delirium prevention, diagnosis, and intervention.||||
33706892|NCT02320383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706893|NCT03713359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The first two volunteers will be assigned to the MRVAC group (code named A) and coded A001 and A002. The 3rd Volunteer will be assigned to the control group (code named B) and coded as B001. Volunteers arriving later will also be coded in this order until they meet enough subjects as required.|Eligible participants will be randomized receiving either MRVAC or MR vaccine produced by Serum Institute, India, which was using in Vietnam National Expanded program on Immunization in the ratio of 2:1. The Participants will be received only 1 dose of vaccine at the age from 1 year to 45 years.|t|f|f|f
33706894|NCT01377883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706895|NCT00518284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706896|NCT01670240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706897|NCT01511198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706898|NCT03964623|||CASE_CONTROL||PROSPECTIVE|||||||
33706899|NCT00285805|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33706900|NCT00635167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706901|NCT02955160|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33706902|NCT01929343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706903|NCT02895230|||COHORT||PROSPECTIVE|||||||
33706904|NCT01742702|||COHORT||PROSPECTIVE|||||||
33706905|NCT05772416|||COHORT||PROSPECTIVE|||||||
33706906|NCT06317207|||CASE_ONLY||RETROSPECTIVE|||||||
33706907|NCT04958135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This will be a balanced, 2-period, 2-sequence, 2-way crossover study in healthy participants. All participants will receive 1 treatment in each period.||||
33706908|NCT01798511|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706909|NCT03544658|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Neither the patient, the investigator that made the color acquisition or the spectrophotometer had knowledge of tooth color assessed by the other person/method|||||
33706910|NCT00117481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706911|NCT05489744|NA|SINGLE_GROUP||OTHER||NONE||||||
33931468|NCT04336111|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34094222|NCT03274661|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible participants will receive pembrolizumab intravenously at a dose of 200 mg every 3 weeks.||||
33706912|NCT01944592|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33706913|NCT06193291|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33706914|NCT01403961|||COHORT||PROSPECTIVE|||||||
33706915|NCT04632810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706916|NCT04586907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33706917|NCT06486376|RANDOMIZED|PARALLEL||OTHER||SINGLE|The intervention is WASHED-UP (Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia), a 2-week health awareness campaign that will train children and teachers to deliver the program on hygiene promotion in schools.|School Cluster randomized trial study of 50 schools|f|f|f|t
33706918|NCT00506480||PARALLEL||DIAGNOSTIC||NONE||||||
33706919|NCT01927172|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33706920|NCT01277991|RANDOMIZED|CROSSOVER||||NONE||||||
33931469|NCT05287724|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931470|NCT05720962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||randomized controlled study with two groups as control and experimental group|t|f|f|t
33931471|NCT00001827||||TREATMENT||NONE||||||
33931472|NCT01105949|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931473|NCT02002065|||COHORT||PROSPECTIVE|||||||
33931474|NCT00654823|||COHORT||PROSPECTIVE|||||||
33931475|NCT06362395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931476|NCT05597904|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33706921|NCT03725202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094223|NCT05206539|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a double-blinded trial, i.e., where patients and outcomes assessor are not aware which white spot lesion what treatment will receive, unlike the operator which is not blinded for the study due to the nature of the investigated techniques.|The trial to be conducted is a randomized controlled clinical crossover experimental study with split-mouth design. The within-subject design randomly allocates experimental and control interventions to different areas in the oral cavity (teeth, surfaces, arches, quadrants) and has the advantage of reducing outcome variability estimation since each patient is its own control, leading to potential increase in statistical power.|t|t|f|t
33706922|NCT04835532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790573|NCT05632068|RANDOMIZED|CROSSOVER||TREATMENT||NONE|A number generated by random sequence before enrollment will be assigned to each subject to separate all subjects to two groups. Diet education/monitoring will be given with or without XHC depending the phase of trial course. Since XHC is a mixture of herbal products and difficult to make proper placebo, we adopt the crossover with open-label design in this study.|All eligible subjects will be allocated randomly to 2 groups. Each group will have a 7-month course, including 3-month XHC treatment and 3-month no XHC treatment period (control). One month washout period will be arranged between these two 3-month treatment periods.||||
34094224|NCT03209999|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34094225|NCT00927082|RANDOMIZED|PARALLEL||||NONE||||||
33790574|NCT04524832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790575|NCT03413319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094226|NCT00141375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094227|NCT04602000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706923|NCT01847274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790576|NCT01830166|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33790577|NCT02260310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706924|NCT01191333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706925|NCT05679219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33706926|NCT06440720|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study Design: Parallel Two-Group Randomized Controlled Trial~Objective:~To compare the effectiveness of the Elongation Longitudinaux Avec Decoaptation Osteo Articulaire (ELDOA) method versus upper thoracic mobilization and mobility exercises in treating forward head posture (FHP).~Participants:~Total sample size: 36 (18 in each group) Inclusion: Males and females, ages 20-40 years Exclusion: History of neck surgery, severe neck trauma~Randomization:~Participants will be randomly assigned to either the ELDOA group or the upper thoracic mobilization group using a computer-generated sequence.~Interventions:~Group A (ELDOA): Specific ELDOA exercises for FHP Group B (Upper Thoracic Mobilization): Exercises targeting thoracic mobility and FHP~Outcome Measures:~Primary outcomes: Numeric Pain Rating Scale (NPRS), goniometer measurements, Neck Disability Index (NDI), Web Plot Digitizer (WPD) Software"||||
33706927|NCT01409330|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33706928|NCT04803071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33790578|NCT00337818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790579|NCT04115436|||COHORT||PROSPECTIVE|||||||
33790580|NCT00380705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931477|NCT04412772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931478|NCT01378845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931479|NCT04273841|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33931480|NCT05776693|||COHORT||CROSS_SECTIONAL|||||||
33931481|NCT00797810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931482|NCT03304262|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Participants will be blinded to treatment group, investigator administering tDCS will be blinded to which treatment arm subject is assigned to, and the data analyst will be conducting analysis off site and is different than investigator applying stimulation.|This is a randomized, sham-controlled, double blinded crossover trial.|t|f|t|f
33931483|NCT00174928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931484|NCT00904111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931485|NCT02382965|||COHORT||PROSPECTIVE|||||||
33931486|NCT06082349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researcher, research nurse and patients will be blinded. The blinded researcher and research nurse will perform the measurements during follow-up, as well as the assessment of the outcomes. Due to the nature of the study, the surgeon performing both procedures cannot be blinded.|Multicenter, double-blind, randomized sham-controlled trial|t|f|t|t
33931487|NCT05255627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931488|NCT02192619|||OTHER||PROSPECTIVE|||||||
33931489|NCT01820494|NA|SINGLE_GROUP||||NONE||||||
33931490|NCT02193854|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931491|NCT05225441|||COHORT||PROSPECTIVE|||||||
33931492|NCT05328414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931493|NCT01770886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931494|NCT03029767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931495|NCT04127240|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33931496|NCT04078191|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931497|NCT01577498|||||PROSPECTIVE|||||||
33931498|NCT05288855|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind (participant, care provider, investigator and outcome assessor) for period 1 and Open-label for period 2 and period 3||t|t|t|t
33931499|NCT03430336|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the character of the intervention, blinding is not possible.|||||
33931500|NCT01083225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931501|NCT00650897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790581|NCT02631499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931502|NCT02782247|||COHORT||PROSPECTIVE|||||||
33931503|NCT02404584|||COHORT||PROSPECTIVE|||||||
33931504|NCT00054418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33931505|NCT04350424|||COHORT||PROSPECTIVE|||||||
33931506|NCT04104204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33931507|NCT02653352|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931508|NCT03991936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706929|NCT04497493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33790582|NCT05857306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double (Participant, Investigator) Both types of capsules were made and packed in blisters and identical boxes. Every box was identified and tagged with a specific number by an associate researcher who is not involved in the recruitment, attention, or follow-up of the enrolled subjects.~Finally, block randomization was the selected technique for this purpose."|Parallel Assignment Double-blind randomized parallel clinical trial|t|f|t|f
33790583|NCT02308137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931509|NCT04746157|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33931510|NCT06136455|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33931511|NCT00111891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931512|NCT03821480|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||open-label, randomized, single dose, 2-treatment, 2-period crossover study||||
33931513|NCT02221960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931514|NCT05888532|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33931515|NCT01865838|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33931516|NCT05522855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, prospective, interventional pilot study||||
33931517|NCT05305976|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Grup 1: Ambulant Group Grup 2: Non-ambulant Group||||
33931518|NCT06166290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931519|NCT06071780|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Only care provider was not masked as she had to insert the lens and to record the randomization|Both eyes of subjects will be instilled with either one of the study contact lens or the control lens at random.|t|f|t|f
33931520|NCT05181241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is single center, open-label, prospective, non-randomized with sequential enrollment of volunteers with dose escalation||||
33931521|NCT04728815|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||"Participants will be randomized to one of three treatments delivered via a hybrid model: (1) a suicide-focused treatment - Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks (n=35); (2) Treatment as Usual (TAU) for 4-8 weeks (n=15); or (3) Comprehensive Dialectical Behavior Therapy (DBT) for 16 weeks (n=35), which includes individual therapy, skills training, phone/text coaching for the clients, and peer consultation for the counselors.~Sufficient responders to CAMS or TAU will discontinue services/be stepped down after 4-8 weeks. Non-responders to CAMS or TAU will be re-randomized to one of two higher intensity/dosage intervention options for an additional 8 weeks of treatment: (1) CAMS (either continued or administered for the first time) or (2) Comprehensive DBT.~There is an 8th Arm/Group of Consented Study Counselors from each of the 4 sites."|f|f|f|t
33931522|NCT01624467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931523|NCT01764022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931524|NCT02029560|||CASE_ONLY||PROSPECTIVE|||||||
33931525|NCT05488925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study was designed to be a double blinded study, where the operators and the patients both were unaware of the groups of drugs that were used; this anonymity was achieved by marking the groups A, B, C and D on boxes for drugs containing a placebo, diclofenac sodium, piroxicam, and tramadol respectively.|The visual analogue scale was used to assess the patients' pain levels prior to the drug ingestion. The patients were then given their respective group of drug where the control group received vitamin E and three experimental groups received one tablet/capsule of diclofenac sodium (Voltral SR100, 100 mg), piroxicam (Feldene, 20 mg), and tramadol (Tramal, 50 mg). The patients were instructed to wait for 1 hour before they were administered an inferior alveolar nerve block. Standard root canal treatment was initiated after lip numbness was achieved, and pain levels were reassessed by visual analogue scale.|t|t|f|f
33931526|NCT00173095|||CASE_CONTROL||OTHER|||||||
33931527|NCT06435962|||CASE_CONTROL||PROSPECTIVE|||||||
33931528|NCT01406158|RANDOMIZED|CROSSOVER||||NONE||||||
34010005|NCT00848042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010006|NCT04670406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010007|NCT02231424|||COHORT||PROSPECTIVE|||||||
34010008|NCT04910828|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010009|NCT06043791|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010010|NCT03589131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010011|NCT00841152|||CASE_CONTROL||PROSPECTIVE|||||||
34010012|NCT00418522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706930|NCT05315401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|. The randomization will be performed by the study statistician, who had no contact with the patients and not involve in the research project. The allocation sequence will not be available to any member of the research team until databases had been completed and locked. Since this is a double-blinded study, both the research team and subject will not know in which group the subject is assigned to.|A double-blind three-armed randomized controlled trial design has been chosen. Randomization for the parallel prevention phase will be carried out after checking the inclusion and exclusion criteria|t|t|t|f
33706931|NCT05493046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be unaware of the treatment assignment before the completion of the study||f|f|f|t
34010013|NCT00919984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010014|NCT04788537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants randomly assigned to either the intervention group (50%) or nonintervention group (50%).|f|f|f|t
34010015|NCT06412926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"The study will be conducted in a single-center, randomized, open label, cross over design.~The study will investigate the relative bioavailability, pharmacokinetics, safety and tolerability of single doses of 2 formulations of emodepside and assess the effect of food on Test formulation (Formulation B) in healthy male participants and healthy female participants of non-childbearing potential.~The crossover design is used for intra-individual comparison of treatment effects to reduce impact of inter-individual variability. A preliminary PK analysis is planned after Period 2 to determine the appropriate dose to be tested for food effect.~Treatment allocation is conducted in a randomized manner prior to Period 1 in order to reduce the likelihood of period or seasonal effects confounding the study assessments."||||
34010016|NCT06412302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The PY group will be provided with two yogurts and 50 of water (220g per serving, containing 24.6g protein, 1.4g fat, and 16.6 carbohydrates), while the WP will be provided with a shake with water (25g per serving containing; 25g protein, 0g fat, and 1g carbohydrates, dissolved in water), immediately after the exercise session which a trainer will monitor. Both groups will submit to a resistance training group every 8 weeks.|t|f|f|f
34010017|NCT02861027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094228|NCT04845971|NA|SINGLE_GROUP||TREATMENT||NONE||we reserve the possibility that the study may become parallel||||
33706932|NCT01714011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706933|NCT01193595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706934|NCT03634657|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33706935|NCT05267847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33706936|NCT01865110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706937|NCT02285192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706938|NCT00920998|RANDOMIZED|CROSSOVER||||NONE||||||
33790584|NCT04282980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790585|NCT05864586|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33790586|NCT06026358|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790587|NCT01492387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790588|NCT04456920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706939|NCT04753645|RANDOMIZED|FACTORIAL||PREVENTION||NONE||From each of 20 sub-district, out of potential villages for a public handwashing stations (HWS) we randomly selected 10 villages, of which 5 are assigned to control group or non-HBCC intervention villages and 5 are assigned to treatment group receiving the interventions. We have 98 control and 96 treatment villages due to an insufficient number of selected villages in one sub-district. First round survey revealed significant increase in soap use and not-significant decrease in handwashing (HW) frequency and soap expenditure. Our hypothesis is that there might be causality between HW and soap use. To test this, we provide soap to randomly selected 50% of our surveyed households, stratified at the sub-district level. 1,909 and 1,933 hhs from treatment and control villages received soap. Due to nationwide lockdown, we conducted follow-up phone survey. Also, to minimize Ramadan effect, we randomly divided the sample into two groups- to be surveyed before (44%) and during Ramadan (56%).||||
33706940|NCT06434259|||CASE_CONTROL||PROSPECTIVE|||||||
33706941|NCT05693389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706942|NCT03355820|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094229|NCT01197235|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094230|NCT02204735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094231|NCT01540539|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34094232|NCT01124474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094233|NCT04094805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706943|NCT06062082|||COHORT||RETROSPECTIVE|||||||
34094234|NCT04913636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33706944|NCT06141187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33706945|NCT02957669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706946|NCT06354400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706947|NCT05493475|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706948|NCT04538430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33706949|NCT01748084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706950|NCT02003846|||||PROSPECTIVE|||||||
33706951|NCT00277147||||TREATMENT||||||||
34094235|NCT00860925|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34094236|NCT00368849|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094237|NCT06299072|||OTHER||CROSS_SECTIONAL|||||||
34094238|NCT00442689|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34094239|NCT01074580|||COHORT||PROSPECTIVE|||||||
34094240|NCT02310347|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34094241|NCT03509584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094242|NCT05161936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094243|NCT00235313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094244|NCT05124782|||COHORT||PROSPECTIVE|||||||
34094245|NCT02497755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094246|NCT01882790|||CASE_ONLY||CROSS_SECTIONAL|||||||
34094247|NCT01436500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790589|NCT05463354|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34094248|NCT06283030|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34094249|NCT02387918|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094250|NCT02612467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094251|NCT00152854|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33790590|NCT00608933|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33790591|NCT00191035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790592|NCT01906060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790593|NCT03780816|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33790594|NCT03357640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both trial participants and research coordinator will be blinded about the treatment after assignment. Oral contraceptive pills and placebo will be put in 2 packages with different colors and only the main researcher will know the type of treatment used for each group. Unbinding is only permissible, if sever morbidity or even mortality occur to any participants.||t|t|f|f
33790595|NCT01751724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790596|NCT00545376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790597|NCT04164563|RANDOMIZED|PARALLEL||PREVENTION||NONE|Both patients and providers are aware that patients are being assigned to either control or experimental group.|Randomized controlled trial||||
33790598|NCT04319796|||COHORT||PROSPECTIVE|||||||
33790599|NCT00111020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790600|NCT01286415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094252|NCT05643690|||COHORT||PROSPECTIVE|||||||
33706952|NCT03100500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094253|NCT02804646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094254|NCT01909401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094255|NCT05556018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094256|NCT04221152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094257|NCT01063582|||COHORT||CROSS_SECTIONAL|||||||
33790601|NCT00768664|NON_RANDOMIZED|||TREATMENT||NONE||||||
33790602|NCT00755781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931529|NCT02762045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931530|NCT05799547|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33931531|NCT04642378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The intervention group will receive iNCDSS assisted recommendation for insulin dose titration. The control group will receive insulin dose titrated by senior attending physicians.|t|f|f|f
33931532|NCT03598660|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931533|NCT01755338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094258|NCT05169775|||COHORT||PROSPECTIVE|||||||
34094259|NCT02280499|||COHORT||PROSPECTIVE|||||||
34094260|NCT02595710|||CASE_ONLY||PROSPECTIVE|||||||
34094261|NCT02212977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931534|NCT06266871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931535|NCT02218762|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931536|NCT00923962|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34094262|NCT00490997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094263|NCT00663143|||CASE_ONLY||PROSPECTIVE|||||||
34010018|NCT03680079|NA|SINGLE_GROUP||OTHER||NONE||The intervention being studied is a group education program||||
33931537|NCT02611518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931538|NCT05292573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931539|NCT02995473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931540|NCT01785498|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010019|NCT06200428|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010020|NCT00891423|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010021|NCT03840499|||COHORT||PROSPECTIVE|||||||
33931541|NCT00533351|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33931542|NCT05421546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33931543|NCT06508398|||COHORT||CROSS_SECTIONAL|||||||
34010022|NCT05329818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33931544|NCT00432640|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931545|NCT05903378|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33931546|NCT03307018|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33931547|NCT02579902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010023|NCT03136874|||CASE_ONLY||PROSPECTIVE|||||||
34010024|NCT05203445|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is designed as a single-arm, open-label, non-randomized study.||||
34010025|NCT04187209|NA|SINGLE_GROUP||OTHER||NONE||||||
34010026|NCT01178164|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931548|NCT03286881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34010027|NCT06060548|||COHORT||PROSPECTIVE|||||||
34010028|NCT01044394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010029|NCT02292511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010030|NCT06094998|||COHORT||PROSPECTIVE|||||||
34010031|NCT04880382|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized phase II study in which eligible patients will be randomized (1:1) according to two therapeutic strategies||||
34010032|NCT01478828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010033|NCT03617796|||COHORT||PROSPECTIVE|||||||
34010034|NCT03475628|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm: Daratumumab||||
34010035|NCT04881734|||COHORT||RETROSPECTIVE|||||||
34010036|NCT04683588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The study was planned as a randomized controlled study to determine the pre- and postoperative nursing care patients' anxiety level, pain control, self-care capacity, nursing care service and hospital re-hospitalization in patients who underwent total knee prosthesis|t|f|t|t
34010037|NCT02958852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010038|NCT05866718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants will not be made aware that there are two experimental conditions. All will be told that they are receiving the intervention.|Participants will be randomized to the SCT or SCT+HABITS using the randomizer elements in Qualtrics.|t|f|f|f
34010039|NCT05281926|NA|SINGLE_GROUP||SCREENING||NONE||||||
34010040|NCT00708708|||COHORT||PROSPECTIVE|||||||
34010041|NCT03704857|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34010042|NCT01353248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010043|NCT00360737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to maintain the blind of the study, equivalent volumes will be administered to each subject. Each subject will receive 1 infusion consisting of 2 bags. Subjects randomized to receive 2 vials of NP 018 will be administered approximately 224 mL of NP 018 in saline while subjects receiving 1 vial of NP 018 will be administered approximately 112 mL of NP 018 in saline followed by 112 mL of 0.9% saline. This will ensure the blind is maintained, as equivalent volumes will be administered and the rate of protein administration will be equivalent during the first 112 mL of fluid infused.|40 subjects will receive 1 or 2 vials of NP-018 intravenously. 20 subjects will be randomized into each arm of the study.|t|f|t|f
34010044|NCT04663438|||COHORT||PROSPECTIVE|||||||
34010045|NCT04601233|NA|SINGLE_GROUP||TREATMENT||NONE||Single open label||||
34010046|NCT02377921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010047|NCT02507245|||CASE_ONLY||PROSPECTIVE|||||||
34010048|NCT02316158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010049|NCT00772616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34010050|NCT01543711|||COHORT||CROSS_SECTIONAL|||||||
34010051|NCT05592093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|A Phase 2/3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Korean red ginseng capsule Administered by taking orally in Middle-aged and Elderly Sub-health population.|t|t|t|t
34010052|NCT03056079|NA|SINGLE_GROUP||TREATMENT||NONE||This study will contain 3 populations of patients which will all receive aflibercept injections: one with neovascular age-related macular degeneration, other with diabetic macular edema and a third with macular edema secondary to retinal vein occlusion.||||
34010053|NCT06133218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010054|NCT04703842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010055|NCT02166320|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34010056|NCT06463717|||COHORT||PROSPECTIVE|||||||
34010057|NCT00653159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010058|NCT04919382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010059|NCT01358539|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010060|NCT00697216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010061|NCT05918809|||COHORT||RETROSPECTIVE|||||||
34010062|NCT00055484|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34010063|NCT02839993|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34010064|NCT00172419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010065|NCT06061705|NA|SINGLE_GROUP||OTHER||NONE||||||
34094264|NCT00853047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34094265|NCT05655988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, the paramedic providing post-operative care, and the radiologist measuring the mesh migration will not know whether mesh fixation has been applied to the patient.|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.|t|t|t|f
34010066|NCT00901355|||COHORT||PROSPECTIVE|||||||
34010067|NCT01344616|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010068|NCT04558333|||COHORT||PROSPECTIVE|||||||
34010069|NCT02269956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010070|NCT04821752|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-arm trial with rolling enrollment||||
34010071|NCT02044432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010072|NCT02640365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010073|NCT05414864|RANDOMIZED|FACTORIAL||TREATMENT||NONE|team that evaluate the results of complementary exams|||||
34010074|NCT04446988|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sacroiliac joint injection with local anesthetic and steroid using ultrasound Versus fluoroscopy in sacroiliitis||||
33706953|NCT06278701|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study utilizes a grouping method based on patient preference. You will learn about the 2 dietary modalities, the late-evening snacks and the regular diet, and then you will be placed in the different groups according to your preference. Patients who volunteer for the 1h bedtime meal will be in the test group and those who volunteer for the regular diet will be in the control group. Dietary counseling and follow-up visits will be conducted in both groups, the difference being the presence or absence of the 1h bedtime meal pattern.||||
33706954|NCT02887638|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34010075|NCT00631306|||CASE_CONTROL||PROSPECTIVE|||||||
33706955|NCT04889807|||COHORT||PROSPECTIVE|||||||
33706956|NCT00763620|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094266|NCT05921500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094267|NCT00211939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094268|NCT02560766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094269|NCT04981054|||COHORT||RETROSPECTIVE|||||||
34094270|NCT00810745|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34094271|NCT04370899|||COHORT||PROSPECTIVE|||||||
34094272|NCT02429739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33706957|NCT03210571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010076|NCT00811434|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34010077|NCT02551393|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34010078|NCT04206722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34010079|NCT04344626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking. Participants as well as caregivers and investigators will all be aware that patients are undergoing intra-operative brain tonometry (single arm study).|There are no possible controls for such a study. Post-mortem brain tissue undergoes irreversible biomechanical changes and no healthy patient undergoes comparable neurosurgical procedures. To overcome this issue, an experimental model involving intra- and inter-participant comparisons is used. A single group of participants will undergo brain tonometry and resulting brain tissue stiffness measurements will be compared in predicted normal and abnormal brain tissue (as identified by pre-operative work-up) in each participant and between participants.||||
34010080|NCT05487560|||COHORT||PROSPECTIVE|||||||
34094273|NCT04607759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094274|NCT01917773|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094275|NCT04945200|||COHORT||PROSPECTIVE|||||||
34094276|NCT00683384|||CASE_ONLY||PROSPECTIVE|||||||
34094277|NCT04042428|RANDOMIZED|PARALLEL||OTHER||NONE||Samples from treatment group are compared to samples from control group (not receiving treatment). It is not possible to use a basal sample of the subjects receiving treatment as a comparator since a minimum period of 2 months' time is required between a 450 mL extraction and another.||||
34094278|NCT02868528|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33931549|NCT03403855|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"All patients will have a regular full length Rocket catheter inserted at baseline, with an external length of 16cm. All patients will have their catheter length modified at 2 weeks in clinic and shortened to an external length of 5cm. Patient satisfaction will be collected at 2 weeks prior to the modification, and 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient. It is done with the tool kit that comes along with the catheter.~All patients will be referred to palliative home care services for assistance with drainage. Drainage catheters are usually provided by Ontario Medical Supplies. However, the drainage catheters to be used in this study will be those supplied by Rocket Medical Inc., as they will be providing Dr. Amjadi with some samples to evaluate their product."||||
33931550|NCT01494181|||OTHER||PROSPECTIVE|||||||
34010081|NCT06084169|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label Study|"The study will encompass a total of 58 patients:~29 patients will be implanted bilaterally with Intensity SL IOL 29 patients will be implanted bilaterally with PanOptix IOL"||||
34010082|NCT04276935|||COHORT||PROSPECTIVE|||||||
33706958|NCT06149832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010083|NCT02809820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33931551|NCT00415623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931552|NCT00628342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931553|NCT02977507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931554|NCT03342404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931555|NCT04066608|||COHORT||PROSPECTIVE|||||||
34010084|NCT05326620|||COHORT||PROSPECTIVE|||||||
34010085|NCT05343221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will conducted between April and July 2022 on 60 volunteer students studying in the Department of Nursing Faculty in Turkey. The inclusion criteria were as follows being 18 years old or over, being a fourth year student, be in the classroom on training day. The students included in the study were randomly divided into two groups.The Haptic group will use the Haptic Device with 3D technology and the High Fidelity Simulator group will use High Fidelity CPR Simulator.||||
33706959|NCT02790203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34010086|NCT00373425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010087|NCT00946491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010088|NCT02731963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010089|NCT02597582|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33706960|NCT02062021|||COHORT||RETROSPECTIVE|||||||
33931556|NCT00668850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931557|NCT05907772|||COHORT||RETROSPECTIVE|||||||
33931558|NCT04762264|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33931559|NCT04934293|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Open-label, monocentric, randomized (1:1), stratified, cross-group cohort study (cross-over), comparing the use of the virtual reality headset from the first session (Arm A) versus the use of the virtual reality from the sixth session (Arm B) of proton therapy.||||
33931560|NCT05119972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial has two parts, a part 1 and a part 2, in part 1 will be unblinded||t|t|t|t
34010090|NCT02096588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010091|NCT04722328|||COHORT||OTHER|||||||
34010092|NCT05944458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010093|NCT00613587|||||PROSPECTIVE|||||||
34010094|NCT01556152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706961|NCT00268593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706962|NCT03799731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706963|NCT03613844|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||double blind and randomized placebo controlled|t|t|t|t
33706964|NCT00571545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931561|NCT01500863|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33931562|NCT00132158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931563|NCT02734095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931564|NCT05193604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931565|NCT05579223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931566|NCT04567134|||CASE_ONLY||PROSPECTIVE|||||||
33931567|NCT00034892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34010095|NCT05650424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010096|NCT01198834|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34010097|NCT01678651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34010098|NCT00922324|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34010099|NCT02445287|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34010100|NCT01803269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010101|NCT01741467|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010102|NCT03717519|||COHORT||RETROSPECTIVE|||||||
34010103|NCT04632706|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|The study is double-blinded. Patients will be randomised to receive 1 of 3 doses of the Active IMP or a matching placebo.|The study is a placebo-controlled, double-blinded exploratory study to investigate safety, Pk and tolerability of a continuous daily dosing of the active drugs (at 3 different doses) in healthy participants.|t|f|t|f
34010104|NCT04193384|||COHORT||RETROSPECTIVE|||||||
34010105|NCT06017206|||COHORT||RETROSPECTIVE|||||||
34010106|NCT03184532|||CASE_CONTROL||PROSPECTIVE|||||||
34010107|NCT00738361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010108|NCT01205841|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010109|NCT03795584|||CASE_ONLY||PROSPECTIVE|||||||
34010110|NCT06616909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010111|NCT05178108|NA|SINGLE_GROUP||OTHER||NONE||||||
34010112|NCT01090999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790603|NCT03310996|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Both sham and active treatment arms will have electrodes places on the scalp. The sham arm will have the current turned off in 10 seconds.|NeuroConn DC-STIMULATOR PLUS (NeurConn, GmbH), model number: 0021; serial number: 0351|t|f|t|t
33931568|NCT03766542|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial.||||
33931569|NCT06450223|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33931570|NCT02403960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931571|NCT01695213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931572|NCT02972281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931573|NCT04974190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A control group is allocated a placebo solution|t|t|t|f
33931574|NCT02792036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931575|NCT05154357|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33931576|NCT02002624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931577|NCT04567420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931578|NCT05024890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931579|NCT01283893|||CASE_CONTROL||PROSPECTIVE|||||||
33931580|NCT00598806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931581|NCT03702140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931582|NCT02801006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931583|NCT00584779|NA|PARALLEL||TREATMENT||NONE||||||
33931584|NCT03858569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931585|NCT02849184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931586|NCT00944580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931587|NCT06204289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33931588|NCT02619058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931589|NCT05840523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were randomly divided into three groups using the sealed envelope method (on the evaluation day, participants chose one of the sealed envelopes and determined the treatment group).|Participants were randomly divided into three groups using the sealed envelope method (on the evaluation day, participants chose one of the sealed envelopes and determined the treatment group). Group I comprised the Proprioceptive Neuromuscular Facilitation (PNF) group, Group II the Range of Motion(ROM) group, and Group III the Control (CG) group. Evaluations were made at baseline and at sixth week.|t|f|f|f
33931590|NCT02329145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931591|NCT04247789|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33931592|NCT02321397|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931593|NCT06444594|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33931594|NCT00625040|||CASE_ONLY||PROSPECTIVE|||||||
33931595|NCT01796249|||COHORT||PROSPECTIVE|||||||
33931596|NCT05299645|NA|SINGLE_GROUP||PREVENTION||NONE||With this study, it is expected to evaluate the modification associated with the BeT intervention in prevention (engagement and adherence to PrEP) and in HIV treatment (attachment to care). Clinical trials are a powerful tool for the evaluation of health interventions, whether drug or not. Through this study, it will be possible to assess the effectiveness of a digital intervention based on peer browsing in HIV prevention and care. As this is a study with only one arm, this can interfere with obtaining measurements or verifying outcomes. To minimize the possibility of bias, the assessment of outcomes will be performed by people other than those administering the intervention. In addition, we will benchmark against an outside group, with information from the Ministry of Health's national registry systems, to determine the effect of our intervention on engagement and adherence to PrEP and linkage to HIV care.||||
33931597|NCT04033380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931598|NCT02388672|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33931599|NCT05856279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded clinical randomized controlled trial (research assistant for assessment and patients will be blinded to about treatment).|mulligan SNAG and mulligan lion position|t|f|f|t
33931600|NCT01756638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931601|NCT04601844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931602|NCT04718402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931603|NCT01562197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010113|NCT01167517|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34010114|NCT00356629|||CASE_ONLY||PROSPECTIVE|||||||
34010115|NCT06218992|||OTHER||PROSPECTIVE|||||||
34010116|NCT01191242|||CASE_ONLY||PROSPECTIVE|||||||
34010117|NCT03798379|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Non randomized, single blind, prospective|Parallel Assignment|t|f|f|f
34010118|NCT02286973|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34010119|NCT02270424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010120|NCT01631682|RANDOMIZED|PARALLEL||||NONE||||||
34010121|NCT04233879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010122|NCT02375217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010123|NCT00467831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010124|NCT00500279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010125|NCT05236842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|placebo||t|f|t|f
34010126|NCT01872702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010127|NCT03479931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010128|NCT01026259|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34010129|NCT01850719|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010130|NCT04104984|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34010131|NCT05291052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010132|NCT02092883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010133|NCT05424718|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||The intervention arm receives the intervention from baseline to 3 months and at the 3 month visit, access to the intervention is removed and the control/ delayed intervention arm then receives the intervention.|t|f|f|f
34010134|NCT00282750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094279|NCT05619419|RANDOMIZED|FACTORIAL||OTHER||NONE|Research assistant will be aware of participant randomization, as necessary for providing the correct study instructions and procedures (e.g., pain psycho-education and meditation audio recording). Participants will not be masked, as they will receive specific instructions on and audio recorded meditation practice based on their group.|Participants will be randomized to one of three groups: mindfulness-enhanced positive affect induction (MPAI), breathing meditation (BM), or natural response (NR). Pain will be induced via a cold pressor test (CPT), as the CPT can closely resemble tonic increasing pain similar to that of pain flares. Participants will be instructed to either respond naturally, use the MPAI, or breathing meditation for managing pain during the CPT. Relevant pain related outcomes and covariates will be assessed via baseline and post-CPT questionnaires. The MPAI is the primary intervention being examined, with the BM and NR groups as active comparison and control groups respectively.||||
34094280|NCT01567085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094281|NCT03100292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094282|NCT02184117|||COHORT||PROSPECTIVE|||||||
34094283|NCT00272090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010135|NCT04274582|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010136|NCT02864004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010137|NCT00548379|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33706965|NCT04670198|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The study has been designed as a waiting-list randomised controlled trial (RCT). Young people will be randomised to either the phase 1 YES group or the waiting-list control group. The phase 1 YES group will then attend the programme, both groups will be followed-up initially for 6 months, at which point the waiting-list control participants will attend the YES programme in phase 2. Both groups will then be followed-up for a further 6 months.||||
34010138|NCT01095523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094284|NCT06007443|NA|SINGLE_GROUP||SCREENING||NONE||||||
34094285|NCT01131585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094286|NCT03537677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094287|NCT05027282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094288|NCT01506076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094289|NCT02061592|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34094290|NCT01361672|||OTHER||PROSPECTIVE|||||||
34094291|NCT06061159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094292|NCT00890318|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34094293|NCT06179875|NA|SINGLE_GROUP||TREATMENT||NONE||Single treatment assignment||||
34094294|NCT05348694|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blinded|Randomized placebo-controlled trial|t|f|t|t
34094295|NCT04791826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The intervention in an EMR-based clinical decision support tool that informs providers of the HF risk among patients with type 2 DM that are being seen by the provider in an outpatient setting. Based on the 5-year HF risk as estimated by the WATCH-DM score or existing biomarker levels, the providers will be provided guidance regarding the use of SGLT-2i to modify the HF risk.|f|t|f|f
34094296|NCT00724503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094297|NCT04551924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|To maintain objectiveness, the study drug will be managed and administered by an independent unblinded team. Subjects, investigators, and all other site staff who directly interact with subjects, evaluate safety and efficacy, and collect subject data, will remain blinded and must not communicate or discuss any study information with the unblinded team.||t|t|t|t
33706966|NCT06208683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706967|NCT03416946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will occur after enrolment and subjects will be blinded to assignment group. All subjects will be scheduled for and receive the same MRI experience. It is not possible to blind the surgeon to the surgical technique.|The block randomization process will be stratified by surgeon to ensure equal distribution between the two surgical techniques.|t|f|f|f
33790604|NCT01792648|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33790605|NCT01329328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34010139|NCT00005090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010140|NCT03199313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010141|NCT02736630|||||PROSPECTIVE|||||||
34010142|NCT04532398|NA|SINGLE_GROUP||OTHER||NONE||||||
34010143|NCT03544814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010144|NCT03316326|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's two-stage optimum design||||
34010145|NCT00006182|RANDOMIZED|||PREVENTION||||||||
34010146|NCT04894279|||OTHER||CROSS_SECTIONAL|||||||
34010147|NCT02759341|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34010148|NCT02412462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010149|NCT01602172|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34094298|NCT02375997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094299|NCT03039725|||COHORT||RETROSPECTIVE|||||||
34094300|NCT02603029|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34094301|NCT05673850|||COHORT||RETROSPECTIVE|||||||
34094302|NCT01586182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094303|NCT04874168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|computer-generated table of random numbers||t|t|f|t
34094304|NCT02845492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34094305|NCT01365611|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094306|NCT03763383|||CASE_ONLY||RETROSPECTIVE|||||||
34094307|NCT04396275|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34094308|NCT02745405|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34094309|NCT00819195|||COHORT||PROSPECTIVE|||||||
34094310|NCT01028391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094311|NCT00111332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094312|NCT04351971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants will be assigned a random number and will be divided into two research groups (control group and intervention group). In this sense, both the patient and the therapist in charge of carrying out the evaluation will not know which group each subject belongs to.||t|t|f|f
34094313|NCT05404659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094314|NCT02161666|||COHORT||PROSPECTIVE|||||||
34010150|NCT00111956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010151|NCT02469818|||CASE_ONLY||PROSPECTIVE|||||||
33706968|NCT05865067|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a Pilot efficacy, randomized intervention, wait-list controlled clinical trial to evaluate the feasibility of Yoga Therapy for Latino Preschool children aged 4 to 6 years old with ODD. This design makes it comparable to the pilot efficacy study done in the same age and diagnostic group by Dr. Matos, which evaluated PCIT efficacy. We will recruit participants by flyers to obtain 34 patients and 68 parents; after confirming ODD trait with DBRS, they will be randomized to intervention and wait-list control groups. Randomization will be performed in a 3:2 ratio (Yoga-Therapy: Wait-List; 21:13). Flyers, newspapers, radio, and television ads will recruit participants.||||
34010152|NCT03447340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010153|NCT04395248|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34010154|NCT05640687|||COHORT||PROSPECTIVE|||||||
33706969|NCT02701400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010155|NCT05394766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094315|NCT02950584|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
34094316|NCT02092103|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34094317|NCT03792997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094318|NCT00001647||||TREATMENT||||||||
34094319|NCT03695796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||biopsy-proven NAFLD patients||||
34094320|NCT00307255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094321|NCT01284764|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34094322|NCT03361020|||CASE_CONTROL||PROSPECTIVE|||||||
34094323|NCT02162433|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094324|NCT04914663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34094325|NCT01726686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094326|NCT01799395|||COHORT||PROSPECTIVE|||||||
34094327|NCT00461968|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34094328|NCT00315822|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34094329|NCT02825459|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34094330|NCT06381284|||COHORT||PROSPECTIVE|||||||
34094331|NCT01258855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094332|NCT05495802|||COHORT||PROSPECTIVE|||||||
34094333|NCT03030781|||COHORT||RETROSPECTIVE|||||||
34094334|NCT00508846|||CASE_ONLY||PROSPECTIVE|||||||
34094335|NCT03128164|NA|SINGLE_GROUP||TREATMENT||NONE||This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II). Dose escalation will be performed according to a modified toxicity probability interval scheme-2 (mTPI-2). Expansion stage of the study enrolled 143 patients with B cell lymphoma, including CLL/SLL, FL, MZL, DLBCL, MCL and PTCL, Patients were treated with RP2D as starting dose.||||
34094336|NCT00672815|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34094337|NCT03890939|RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no masking involved in this study.|"Participants will receive three (3) randomized PSG's during which they will receive treatment from the following devices in a randomized manner:~* FDA released Philips BiPAP AutoSV Advanced System One~* FDA released Philips Dreamstation BiPAP AutoSV~* FDA released ResMed S7 VPAP Adapt"||||
34094338|NCT01271829|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34094339|NCT04711577|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094340|NCT04288037|||COHORT||PROSPECTIVE|||||||
33706970|NCT06197750|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34094341|NCT00215956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094342|NCT00991562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094343|NCT01769443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094344|NCT04517799|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33706971|NCT03517098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094345|NCT05477394|||CASE_CONTROL||RETROSPECTIVE|||||||
34094346|NCT06403059|||COHORT||PROSPECTIVE|||||||
34094347|NCT04710433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094348|NCT04505111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-Blind (surgeons and anesthesiologists)||f|f|t|f
34094349|NCT01277068|NON_RANDOMIZED|PARALLEL||||NONE||||||
34094350|NCT01783938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094351|NCT00158613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094352|NCT04639063|||COHORT||RETROSPECTIVE|||||||
34094353|NCT03621670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Observer-blind study Data will be collected in an observer-blind manner. By observer blind, it is meant that during the course of the study, the subject/parent/caregiver, site and sponsor personnel involved in the clinical evaluation of the subjects are blinded while other study personnel are aware of the treatment assignment. To do so, vaccine preparation and administration will be done by authorized medical personnel who will not participate in any of the study clinical evaluation assays or procedures.~The serological data, which would lead to the unblinding of the study groups, will not be available during the course of the study to any investigator or any person involved in the clinical conduct of the study. The laboratory in charge of the laboratory testing will be blinded to the treatment, subject and visit number, and codes will be used to link the subject, visit and study to each sample."||t|t|t|t
34094354|NCT03398109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094355|NCT05501379|||OTHER||PROSPECTIVE|||||||
34094356|NCT01719094|||CASE_CONTROL||PROSPECTIVE|||||||
34094357|NCT05974514|||OTHER||CROSS_SECTIONAL|||||||
33706972|NCT02036697|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33706973|NCT05163236|||COHORT||RETROSPECTIVE|||||||
34010156|NCT03987555|||COHORT||PROSPECTIVE|||||||
34010157|NCT03221231|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||RCT|t|t|f|f
34010158|NCT05021913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blinded (blinded evaluator and subject) study and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.|Pivotal, prospective, active-controlled, randomized, double blinded (blinded evaluator and subject), intra-individual split-face comparison|t|f|f|t
34010159|NCT01991288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34094358|NCT02137460|||COHORT||PROSPECTIVE|||||||
34094359|NCT06133166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790606|NCT01738867|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33790607|NCT05359224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790608|NCT05585567|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33790609|NCT03598972|||COHORT||RETROSPECTIVE|||||||
33790610|NCT00197236|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790611|NCT04082169|||COHORT||CROSS_SECTIONAL|||||||
33790612|NCT01014858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790613|NCT05280964|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33790614|NCT05257785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33790615|NCT01363362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790616|NCT03227523|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790617|NCT02537522|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33931604|NCT02412527|||CASE_ONLY||PROSPECTIVE|||||||
33706974|NCT04113109|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33706975|NCT05547685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33706976|NCT02381145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790618|NCT00202358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790619|NCT03052361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790620|NCT00395434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790621|NCT02615912|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790622|NCT04622826|NA|SEQUENTIAL||PREVENTION||NONE||||||
33790623|NCT00551226|||COHORT||PROSPECTIVE|||||||
33790624|NCT00773435|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33790625|NCT02276508|NA|SINGLE_GROUP||||NONE||||||
33790626|NCT02114840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790627|NCT03312439|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention group are tested and given advice based on the results with the general aim to increase physical activity and reduce obesity. The risk of future non-communicable disease is compared to the general Swedish population of the same age. Different models will be used. The first model will include a control group consisting of all Swedish citizens of the same age, and the results will be adjusted for differences in baseline characteristics. In a second each participant in the intervention group will be matched against 3 controls (or more) from the general population based on propensity scores.||||
33790628|NCT04878627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and research coordinator administering the medication will be blinded to the randomization schedule. The research subject will be blinded to what medication she receives.|Placebo-controlled, randomized, double-blind study|t|f|t|f
33931605|NCT00087386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931606|NCT05093569|||OTHER||PROSPECTIVE|||||||
33931607|NCT04809025|||COHORT||PROSPECTIVE|||||||
33931608|NCT02497053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931609|NCT05911945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931610|NCT06005272|||CASE_CONTROL||PROSPECTIVE|||||||
33931611|NCT02685618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931612|NCT05874336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931613|NCT05635279|||COHORT||RETROSPECTIVE|||||||
33931614|NCT01961102|||CASE_ONLY|||||||||
33931615|NCT00610077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931616|NCT03049930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No other parties are masked in the clinical trial|The intervention study model is a randomized block design using a 1:1 allocation scheme|t|t|t|f
33931617|NCT04183049|||OTHER||PROSPECTIVE|||||||
33931618|NCT00081744|RANDOMIZED|||TREATMENT||DOUBLE||||||
33931619|NCT04702204|||COHORT||PROSPECTIVE|||||||
33931620|NCT03026205|NA|SINGLE_GROUP||OTHER||NONE||||||
33931621|NCT02668172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931622|NCT00926991|||COHORT||PROSPECTIVE|||||||
33931623|NCT00045357||||TREATMENT||||||||
33931624|NCT05478057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931625|NCT02495090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931626|NCT05381389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931627|NCT01025232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931628|NCT05698004|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients with acute hypoxemic respiratory failure attending the participating centres will receive either prone positioning + standard treatment or standard treatment only. All new acute hypoxemic respiratory failure patients will receive prone positioning + standard treatment for the first two weeks of the study. During the following two weeks, all new patients will receive standard treatment only. These cycles will be repeated until completion the study.||||
33931629|NCT04583345|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931630|NCT00591175|||COHORT||PROSPECTIVE|||||||
33931631|NCT05425524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931632|NCT03074318|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects were enrolled into Phase 1, first into 1.5 mg/m\^2 trabectedin dose, then 1.0 mg/m\^2 trabectedin, then 1.2 mg/m\^2 trabectedin. Once the recommended Phase 2 dose was selected at 1.0 mg/m\^2 trabectedin, all subsequent subjects were enrolled into Phase 2.||||
33931633|NCT03304093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931634|NCT03638336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931635|NCT05882604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931636|NCT04214041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neither the operator nor the participants could be blinded to the treatment type as the intervention procedures were markedly different between test and control groups. To enable blinding during outcome assessment, the stereolithography (STL) files of digitized casts were given a code different from that of the allocation procedure and were kept confidential. The volumetric analysis was performed and the groupings were shared with the biostatistician as groups A and B. Only during the interpretation the codes and groups were translated into test and control groups|This non-inferiority study was designed as a randomized controlled clinical trial including 26 localized horizontal ridge defects that were equally allocated (1:1) into one of two parallel groups.|f|f|f|t
33931637|NCT02377076|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33931638|NCT01789255|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931639|NCT05048225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931640|NCT06039657|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931641|NCT05427175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931642|NCT04767776|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33931643|NCT01591993|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33931644|NCT00006968||||TREATMENT||||||||
33931645|NCT04462978|||COHORT||PROSPECTIVE|||||||
33931646|NCT04331028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931647|NCT06384625|NA|SINGLE_GROUP||OTHER||NONE||||||
33931648|NCT04265092|||COHORT||PROSPECTIVE|||||||
33931649|NCT01751204|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33931650|NCT00305734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931651|NCT00278551|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931652|NCT05218538|||CASE_ONLY||PROSPECTIVE|||||||
33931653|NCT00030160|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33931654|NCT01619488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931655|NCT04173403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931656|NCT04432181|||CASE_CONTROL||PROSPECTIVE|||||||
34010160|NCT02285634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010161|NCT05128370|||COHORT||CROSS_SECTIONAL|||||||
34010162|NCT01518751|||CASE_CONTROL||PROSPECTIVE|||||||
34010163|NCT02854696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010164|NCT03340987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34010165|NCT04667936|||CASE_ONLY||RETROSPECTIVE|||||||
34010166|NCT06142149|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010167|NCT00314431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010168|NCT06094907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010169|NCT04554706|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Participant blind to condition assigned to (compared to alternatives), assignment is automatic/random via computer so investigator blind to participant assignment; analyst is blind to meaning of condition codes.|There are three conditions: a JITAI interactive narrative condition, a JITAI non-narrative condition, and a wait-list control condition.|t|f|t|t
34010170|NCT06295744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010171|NCT02304549|||COHORT||PROSPECTIVE|||||||
34010172|NCT03660215|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094360|NCT01656746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094361|NCT06466265|NA|SEQUENTIAL||TREATMENT||NONE||||||
33790629|NCT06457568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790630|NCT03629119|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33790631|NCT04270175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931657|NCT01793090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931658|NCT00549406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931659|NCT00746473|||COHORT||PROSPECTIVE|||||||
34010173|NCT04183179|NA|SINGLE_GROUP||PREVENTION||NONE||The program will be evaluated with about 100 Head Start children, aged 3 to 5 years, and their parents (one parent per family) in four urban and three rural Head Start centers to compare the program outcomes between urban and rural settings.||||
34010174|NCT03703024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Double blind model|A double-blind, randomized, placebo-controlled clinical study.|t|f|t|f
33790632|NCT04215198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||treatment versus placebo|t|t|t|t
33790633|NCT01062880|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33790634|NCT02644239|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931660|NCT02644694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931661|NCT01766765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931662|NCT01623960|||COHORT||CROSS_SECTIONAL|||||||
34010175|NCT01246362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010176|NCT05183412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Two independent assessors will gather data in this study: one blinded and one unblinded.||f|f|f|t
34094362|NCT03687255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094363|NCT06458400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094364|NCT01756001|||COHORT||PROSPECTIVE|||||||
34094365|NCT00390351|||DEFINED_POPULATION||OTHER|||||||
34094366|NCT03504969|||COHORT||PROSPECTIVE|||||||
34094367|NCT00653562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34094368|NCT00770484|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931663|NCT02756845|NA|SINGLE_GROUP||TREATMENT||NONE||"Approximately 18 to 24 treated pediatric subjects are expected to be enrolled into 2 cohorts stratified by age (permissible based on the incidence of DLTs, a minimum of 6 subjects/cohort and a minimum of 18 subjects total).~* Cohort A1 (12 to ≤ 21 years of age)~* Cohort B1 (2 to \< 12 years of age) Initially, 3 subjects 12 to ≤ 21 years of age are to be enrolled and treated at 100% of the recommended adult dose regimen of talimogene laherparepvec (cohort A1). The dose level review team (DLRT) will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If a DLT occurs in the first 3 DLT-evaluable subjects in the older age cohort (A1 or A2), the younger age cohort will not open until a DLT rate \< 33% is observed with at least 6 DLT-evaluable subjects in the older age cohort (A1 or A2)."||||
33931664|NCT01838655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931665|NCT03581799|NA|SINGLE_GROUP||OTHER||NONE||||||
33931666|NCT00185172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931667|NCT06059833|||CASE_CONTROL||PROSPECTIVE|||||||
33931668|NCT04687267|||COHORT||PROSPECTIVE|||||||
33931669|NCT06009575|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33931670|NCT02996500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931671|NCT04770298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"3 groups, 80 children with CP~1. group: Intervention in water- halliwick, 40 children~2. group: On land therapy- bobath, 40 children~3. group: No intervention"|t|t|t|t
34094369|NCT05849974|NA|SINGLE_GROUP||OTHER||NONE||"Prospective, longitudinal, multicentric, non-randomized cohort study with constitution of a biological collection.~This study will include major and minor patients with high myopia"||||
34094370|NCT04677166|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either the treatment group (negative pressure wound therapy coupled with instillation) or the control group (standard negative pressure wound therapy). Both groups will receive four days of intervention and outcomes will be measured at day four of negative pressure wound therapy and at thirty days post-operatively.||||
33931672|NCT05267938|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Every volunteers has received bilateral pre-treatment with microneedles or the negative control in the palatal mucosa, in both sessions, which each session was 2 minutes of topical anesthetic or 5 minutes.||t|f|f|f
34094371|NCT04508075|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Observer blind Investigational Product and Active Comparator was masking Number of lot was masking|Subjects 18-59 years of age: Randomized, observer blind, placebo-controlled two arms parallel group, prospective intervention study, to evaluate efficacy, safety, immunogenicity SARS-CoV-2 vaccine (inactivated)|t|f|t|f
34094372|NCT01532427|||COHORT||PROSPECTIVE|||||||
34094373|NCT00357604|NON_RANDOMIZED|PARALLEL||||NONE||||||
34094374|NCT00639379|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33931673|NCT02340572|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34094375|NCT05389787|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34094376|NCT02845349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094377|NCT04462679|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34094378|NCT03182712|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"The selected subjects were referred to the University laboratory. During their first visit, the subjects were submitted to perform the first high intensity sub-maximal test. In the same day, volunteers received the supplementation capsules that should be taken throughout eight weeks, as described in the supplementation section.~The subjects were randomly assigned to two groups: (1) group placebo and (2) n-3 PUFA group. After the supplementation period, all subjects reported back to hospital to biochemical testing and thereafter to the university exercise laboratory for the second high intensity sub-maximal test, following the same protocol described above."|t|f|f|f
34094379|NCT05138640|||COHORT||PROSPECTIVE|||||||
34094380|NCT01053936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094381|NCT03964129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094382|NCT03722888|NA|SINGLE_GROUP||PREVENTION||NONE||single group study with pre-post design||||
34094383|NCT04317027|NA|SINGLE_GROUP||OTHER||NONE||||||
34094384|NCT01526369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094385|NCT02842671|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931674|NCT06283134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931675|NCT02799628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931676|NCT04350372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931677|NCT03577522|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33931678|NCT01599572|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33931679|NCT01428986|||CASE_CONTROL||PROSPECTIVE|||||||
33931680|NCT00443625|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931681|NCT03634176|||CASE_ONLY||PROSPECTIVE|||||||
33931682|NCT04246541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931683|NCT04528004|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Randomization with a 2:1 nicotinamide riboside:matching placebo allocation ratio. Dispensing of nicotinamide riboside and matching placebo will be performed by the University of Washington Investigational Drug Services.|Randomized, interventional trial|t|t|t|t
34094386|NCT01522027|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094387|NCT03432429|||CASE_ONLY||PROSPECTIVE|||||||
34094388|NCT03794063|||OTHER||CROSS_SECTIONAL|||||||
34094389|NCT04627753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931684|NCT02741310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931685|NCT00881140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931686|NCT00917137|||COHORT||PROSPECTIVE|||||||
33931687|NCT06229808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931688|NCT01596192|||COHORT||PROSPECTIVE|||||||
33931689|NCT04781049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931690|NCT02125630|||COHORT||PROSPECTIVE|||||||
33706977|NCT05877352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This is a double-blinded trial, which means both the participant and clinicians will not know the treatment allocation. The surgeon, oncologist and patient will remain blinded throughout the study, while the radiotherapy delivery team will know the outcome of the randomisation.~Patient allocation will be provided to the unblinded radiotherapy staff via an Interactive Web Response System (IWRS). The randomisation code will be retained by the system. Deaths and serious adverse events (SAE) will be reviewed in a blinded manner.~Unblinding will be required in the event that any participants further treatment may benefit from further radiotherapy, and if potential IOERT treatment and its dose may impact this."|A single centre double-blinded three-arm randomised controlled trial of extended margin surgery + IOERT at standard dose (10 Gy) versus extended margin surgery + IOERT at higher dose (15 Gy) versus extended margin surgery alone (no IOERT) in a 1:1:1 ratio in patients with LARC or LRRC.|t|t|t|f
33706978|NCT06147362|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately ten patients (with primary/recurrent or metastatic cancer) in each of the following six cancer groups, prostate cancer, breast cancer, colorectal cancer, gastrointestinal carcinoid, gastric cancer, and lung cancer, will be recruited and examined.||||
33931691|NCT03802240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706979|NCT05037071|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33931692|NCT04363463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled multicenter trial Ratio 1:1||||
33931693|NCT03329664|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33931694|NCT04537572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931695|NCT00000345||||TREATMENT||NONE||||||
33931696|NCT05386875|||COHORT||PROSPECTIVE|||||||
33931697|NCT06323499|||CASE_CONTROL||RETROSPECTIVE|||||||
33931698|NCT01833806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931699|NCT01942408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931700|NCT06152692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33931701|NCT00404638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931702|NCT02150460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931703|NCT01639300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931704|NCT02163668|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931705|NCT02667236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931706|NCT00626340|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33931707|NCT04880993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931708|NCT05849545|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33931709|NCT03655080|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931710|NCT04116190|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Consecutive sampling||||
33931711|NCT00024674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931712|NCT03128307|NA|SINGLE_GROUP||TREATMENT||DOUBLE|The data is compiled and analyzed by an outside, independent organization|Patient serves as their own control|f|t|t|f
33931713|NCT04771104|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33931714|NCT04922580|||COHORT||RETROSPECTIVE|||||||
33931715|NCT00825968|||COHORT||PROSPECTIVE|||||||
33931716|NCT04123444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient, investigator, outcome assessor and care provider will be blinded.|Randomization in 2 parallel arms Adaptive phase 2b/3 trial|t|t|t|t
33931717|NCT05645276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931718|NCT05346861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931719|NCT05001776|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective single-centre open-label randomized||||
33931720|NCT04011306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931721|NCT02348294|NON_RANDOMIZED|PARALLEL||||NONE||||||
33931722|NCT01226589|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931723|NCT06189066|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33931724|NCT02126241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931725|NCT01799161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931726|NCT05928104|||OTHER||PROSPECTIVE|||||||
33931727|NCT05154565|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to two (2) groups. Group A is an immediate intervention group while Group B is a delayed intervention group. This allows the short-term effects of intervention to be estimated by comparing study outcomes in the treated group (Group A) with the comparison group (Group B) in Phase 1.||||
33931728|NCT03167125|RANDOMIZED|CROSSOVER||SCREENING||NONE||"Phase I: The investigators will conduct a three-arm patient-randomized trial to compare 1) usual care, 2) automated prompts, and 3) automated plus live prompts. (Number of Arms: 3)~Phase II: This spread trial will use a stepped-wedge design, which is a variant of a crossover randomized trial, where clinics cross over from usual practice to the best practices program. In the stepped-wedge design, a baseline period controls for the level and rate of change of the outcomes prior to program implementation and the staggered implementation minimizes confounding due to changes in the secular trend. By randomizing practices to when they receive an intervention instead of whether they receive it, the stepped wedge design ensures that all practices eventually receive the intervention, an important consideration for clinic leadership. Furthermore, the wedge-defined clusters act as their own controls as they each receive both intervention conditions. (Number of Arms: 2)"||||
33931729|NCT04414488|||COHORT||PROSPECTIVE|||||||
33931730|NCT01978392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33931731|NCT00963313|||CASE_ONLY||PROSPECTIVE|||||||
33931732|NCT03148184|||COHORT||CROSS_SECTIONAL|||||||
33931733|NCT02282891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33931734|NCT03764462|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33931735|NCT02528838|||COHORT||PROSPECTIVE|||||||
33931736|NCT01964287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931737|NCT03228992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931738|NCT02785666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931739|NCT01037751|||CASE_ONLY||PROSPECTIVE|||||||
33931740|NCT03297944|NA|SINGLE_GROUP||OTHER||NONE|Participants and outcomes assessors were masked with respect to each individual intervention.|||||
33931741|NCT01156363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931742|NCT01255189|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33931743|NCT00837239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931744|NCT03229304|||COHORT||PROSPECTIVE|||||||
33931745|NCT04873843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33931746|NCT02506491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931747|NCT04672902|||CASE_ONLY||RETROSPECTIVE|||||||
33931748|NCT00817037|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33931749|NCT00028795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931750|NCT05352867|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931751|NCT00120510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931752|NCT05056636|||CASE_ONLY||PROSPECTIVE|||||||
33931753|NCT05064540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931754|NCT02779530|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33931755|NCT06086236|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluations were carried out by the second researcher|After the participants were included in the study, heart rate variability was measured and divided into 4 groups according to PNS and SNS indexes.|f|f|f|t
33931756|NCT02408484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931757|NCT03022513|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33931758|NCT01600391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931759|NCT05187546|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33931760|NCT02733146|||COHORT||PROSPECTIVE|||||||
34010177|NCT06083090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluators of the secondary endpoints relating to measurements of respiratory and biomechanical parameters will be blinded to the patient randomization group.|Multicenter, comparative, randomized study in two parallel groups (yogatherapy versus physiotherapy), of superiority.|f|f|f|t
34010178|NCT01087021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010179|NCT03020381|||COHORT||PROSPECTIVE|||||||
34010180|NCT01593072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010181|NCT04782128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010182|NCT06332313|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34010183|NCT00384475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34010184|NCT03064087|||OTHER||CROSS_SECTIONAL|||||||
34010185|NCT02034695|||COHORT||PROSPECTIVE|||||||
34010186|NCT05064774|RANDOMIZED|PARALLEL||TREATMENT||NONE||"randomised controlled study this study was conducted with rotator cuff tear patients who underwent arthroscopic rotator cuff treatment.~The patients' pain intensity, joint range of motion, flexibility of shoulder muscles, grip and muscle strength, shoulder function evaluations and physical characteristics, age, differences between body mass index were evaluated with Mann Whitney-U test.Measurements before and after treatment were evaluated with the Wilcoxon test. Friedman test was performed for the measurements made at postoperative 3, 7, and 12 weeks before in-group treatment. Bonferoni correction was done for possible differences."||||
34094390|NCT03383939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||2 parallel groups of patients with bronchictasis were investigated: 1 receiving inhaled prolastina and 1 receiving placebo (saline solution) all bronchiectasis patients were initially compared with 10 control patients with no bronchiectasis|f|f|t|f
34094391|NCT01170130|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094392|NCT05787509|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010187|NCT05172102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010188|NCT04633642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized and controlled parallel clinical trial|t|f|f|f
34010189|NCT06148545|RANDOMIZED|PARALLEL||TREATMENT||NONE||children with a diagnosis of iron deficiency anemia age 1-5 years. Patients were divided into two groups, namely group A which received standard therapy (Fe preparations) 3 mg/kgBW/day, and group B (which received standard therapy combination vitamin D, 400IU).||||
34010190|NCT03113578|||COHORT||PROSPECTIVE|||||||
34010191|NCT02774486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094393|NCT01610388|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34094394|NCT03609840|||OTHER||PROSPECTIVE|||||||
34094395|NCT00387127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931761|NCT04681365|||COHORT||PROSPECTIVE|||||||
33931762|NCT00626834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33931763|NCT00801710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931764|NCT04516824|||OTHER||RETROSPECTIVE|||||||
33931765|NCT02620046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931766|NCT03358004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931767|NCT01309373|||CASE_CONTROL||RETROSPECTIVE|||||||
34094396|NCT00004785|RANDOMIZED|||TREATMENT||DOUBLE||||||
34094397|NCT02475837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094398|NCT02355834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33706980|NCT02099578|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33706981|NCT01540240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706982|NCT03750708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33706983|NCT00483730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706984|NCT00196755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33706985|NCT01245621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33706986|NCT05435495|||COHORT||PROSPECTIVE|||||||
33706987|NCT04959903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33706988|NCT01664546|||CASE_ONLY||PROSPECTIVE|||||||
33931768|NCT06401252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Single (Outcomes Assessor) The data were collected by a research assistant with good nursing experiences who were not involved in any other parts of the study.~Also, the participants were randomly assigned equally to the study groups using a computerized random numbers procedure carried out by a research assistant who was not involved in any other parts of the study"|two-group, randomized controlled design|f|f|f|t
33931769|NCT04559997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931770|NCT01801124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931771|NCT01481766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931772|NCT01577628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931773|NCT04935372|||COHORT||PROSPECTIVE|||||||
33931774|NCT02772224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931775|NCT06507358|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A sampling will assign participants equally to a gardening group (Parent-Child Interaction) (N=30) and a waiting group (N=30). The gardening group (Parent-Child Interaction) will participate in group gardening activities for six to eight weeks, while the waiting group will join after eight-weeks waiting period.||||
33931776|NCT04418739|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a randomized controlled trial conducted at the University Kebangsaan Malaysia Medical Center (UKMMC) with two arms; a control a treatment arm. The treatment arm will receive intravenous human albumin intraoperatively whilst the control arm will receive standard intraoperative fluid regimes.|t|f|f|f
33931777|NCT05375825|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33931778|NCT02253992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931779|NCT01687049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931780|NCT06328855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931781|NCT05280236|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34010192|NCT02587312|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33706989|NCT03336671|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Controlled Trial||||
33706990|NCT06278350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33706991|NCT04188782|||COHORT||PROSPECTIVE|||||||
33706992|NCT05262127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, assessors and care providers (if participants are in treatment) are masked to trial allocation.|Parallel group, double-blind randomized controlled trial|t|t|f|t
33706993|NCT04048928|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups is compared pre and post, where one is given treatment (strength training), and the other acts as control||||
33706994|NCT01140893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33706995|NCT06087081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33706996|NCT05214885|||CASE_CONTROL||PROSPECTIVE|||||||
33706997|NCT00404937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34010193|NCT02658916|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010194|NCT02515214|||COHORT||PROSPECTIVE|||||||
34010195|NCT03452124|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34010196|NCT00284804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010197|NCT03323723|NA|SINGLE_GROUP||TREATMENT||NONE||Efficacy and Safety Study, Single Group, Open Study, Open Label||||
34010198|NCT00596206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010199|NCT04917237|||COHORT||PROSPECTIVE|||||||
34010200|NCT05200910|||CASE_CONTROL||PROSPECTIVE|||||||
33706998|NCT00043901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33706999|NCT06338371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33707000|NCT05912010|||CASE_CONTROL||PROSPECTIVE|||||||
33707001|NCT02989714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707002|NCT03863054|||CASE_ONLY||PROSPECTIVE|||||||
33707003|NCT04367428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707004|NCT04653545|||COHORT||PROSPECTIVE|||||||
34094399|NCT04976972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010201|NCT04647617|RANDOMIZED|PARALLEL||OTHER||SINGLE|single|Forty adult diagnosis with T2DM with pre-sarcopenia patient randomly assigned to experimental group and control group. Experimental group wearing 0.5 kg quantitative sandbag 12\~15 Repetitions/set X 5 set X 3day.control group keep normal lives|t|f|f|f
33707005|NCT05182905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707006|NCT00835913|||COHORT||PROSPECTIVE|||||||
33707007|NCT04997382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Based on the treatment preferences of each patient, they received either chemotherapy alone or in combination with immune checkpoint inhibitors, as well as chemotherapy in combination with immune checkpoint inhibitors (ICI), either with or without bevacizumab.||||
34010202|NCT04432519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34010203|NCT04871516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010204|NCT04776057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094400|NCT01312129|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094401|NCT05033457|||CASE_CONTROL||RETROSPECTIVE|||||||
34094402|NCT03778333|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label phase 1, single-center, pre-post comparison study||||
33707008|NCT00329238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34094403|NCT05644418|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||PCV at baseline, followed by 90 minutes of FCV and finished with 30 minutes of PCV||||
34094404|NCT02250638|||COHORT||PROSPECTIVE|||||||
34094405|NCT01535105|||COHORT||CROSS_SECTIONAL|||||||
34094406|NCT01996995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094407|NCT01815190|||COHORT||RETROSPECTIVE|||||||
34094408|NCT03132272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707009|NCT00163839|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33707010|NCT03258268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A double-blind design is not feasible due to the need for physicians to use respectively not use the EASY DSS.|Multicenter, randomized controlled trial|f|f|f|t
33707011|NCT00820846|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33707012|NCT01197261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707013|NCT05152030|||CASE_CONTROL||PROSPECTIVE|||||||
33707014|NCT04720469|NA|SINGLE_GROUP||TREATMENT||NONE|This study is open label. CRST rating will be performed by a trained neurologist who will be blinded to whether the CRST data were collected pre- or post- treatment.|Single-arm, pre/post designl study||||
33707015|NCT04883931|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant and Ophthalmologist who is the responsible the follow -up the ROP stages will be blind in the study. The neonatologist who is responsible for the care and follow-up of the patients will not be blind.|Porspective Randomized Placebo Controlled Trail|t|f|f|t
33707016|NCT00563498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33707017|NCT02784431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707018|NCT04144660|||COHORT||RETROSPECTIVE|||||||
33707019|NCT00686933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707020|NCT04650711|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All eligible participants as a cohort, accept P16INK4A testing, with cytology and/or hrHPV assay||||
33707021|NCT02356575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707022|NCT02304679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931782|NCT03879954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33931783|NCT03422055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931784|NCT05604404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931785|NCT03611036|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, prospective, randomized, open-label study.||||
34010205|NCT06483737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010206|NCT04692025|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094409|NCT02370862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094410|NCT00335075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094411|NCT01574560|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34094412|NCT01319370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094413|NCT00793065|||COHORT||PROSPECTIVE|||||||
34094414|NCT00002619||||TREATMENT||||||||
34094415|NCT03812250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094416|NCT04541654|||FAMILY_BASED||OTHER|||||||
34094417|NCT03864562|||COHORT||CROSS_SECTIONAL|||||||
34094418|NCT02345343|||COHORT||PROSPECTIVE|||||||
34094419|NCT05922085|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094420|NCT05985551|||OTHER||PROSPECTIVE|||||||
34094421|NCT02123875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094422|NCT05229081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Controlled Study||||
34094423|NCT01121926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094424|NCT03812328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This was an adaptive design study. The first two arms of the study enrolled patients in a 1:1 ratio to receive either SelK2 or an active comparator. The adaptive arm (SelK2 plus active comparator) was initiated at the discretion of the Steering and Safety Committee. The study then enrolled patients in a 2:1 ratio to receive either SelK2 with an active comparator or an active comparator only.|f|f|f|t
34094425|NCT02609633|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094426|NCT03501277|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34094427|NCT00424164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094428|NCT05752409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094429|NCT02106273|||CASE_ONLY||PROSPECTIVE|||||||
34094430|NCT00949663|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34094431|NCT05419258|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||feasibility study on medical device||||
34094432|NCT00523380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094433|NCT01271166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094434|NCT06216340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and care providers are all masked. Investigators randomly cluster the participants, and the actual mask of the participant is not available to care providers and the participants|Participants are randomly divided into two groups: control group and intervention group. In control group, Placebo and diet-exercise therapy is used. In intervention group, 10mg of henagliflozin and diet-exercise therapy is used.|t|t|f|f
34094435|NCT05628350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33931786|NCT05338944|RANDOMIZED|PARALLEL||PREVENTION||NONE||90 youth will be randomized (2:2:1) into one of the three arms of the trial; DBT + lifestyle, lifestyle alone, control||||
33931787|NCT04391153|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33931788|NCT02295436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34010207|NCT04808349|||OTHER||RETROSPECTIVE|||||||
34010208|NCT02439476|||COHORT||PROSPECTIVE|||||||
34010209|NCT02523482|||COHORT||CROSS_SECTIONAL|||||||
34010210|NCT05836415|||COHORT||CROSS_SECTIONAL|||||||
34010211|NCT04247984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010212|NCT01929395|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010213|NCT05742919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010214|NCT00337428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010215|NCT04071054|||COHORT||PROSPECTIVE|||||||
34010216|NCT06616129|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010217|NCT03082235|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34010218|NCT02771041|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34010219|NCT06139055|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Part 1 is open-label, 2-period, 2-sequence, cross-over and Part 2 is double blinded||t|t|t|t
34010220|NCT04965857|||OTHER||PROSPECTIVE|||||||
34010221|NCT01355159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34010222|NCT05311761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm single center prospective interventional study.||||
34010223|NCT04916483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The questionnaire is distributed and applied by another researcher (non-investigator)|Participants were divided into experimental group and control group through block randomization|f|t|f|t
34010224|NCT01553747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010225|NCT03585907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010226|NCT00442754|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010227|NCT06304714|||CASE_ONLY||PROSPECTIVE|||||||
34010228|NCT05790148|NA|SINGLE_GROUP||OTHER||NONE|"Scan post information used for direct digitalization was not shared with the patient during the procedure.~The investigator, who performed the statistical analysis, did not learn the scan post, in which the primary and secondary data were collected, until all evaluations were completed."|||||
34010229|NCT04227938|NA|SINGLE_GROUP||TREATMENT||NONE||A single dose of ALPN-101 will be administered via intravenous (IV) infusion. Multiple, ascending dose levels will be evaluated in cohorts of 3-6 subjects in Part A. In Part B, a single dose level-as identified in Part A-is planned.||||
34010230|NCT00539370|||OTHER||PROSPECTIVE|||||||
34010231|NCT03749694|||COHORT||PROSPECTIVE|||||||
34010232|NCT00201916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010233|NCT05117047|||COHORT||PROSPECTIVE|||||||
34010234|NCT05160636|||COHORT||PROSPECTIVE|||||||
33707023|NCT00250302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707024|NCT01822171|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707025|NCT00867568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707026|NCT03041883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931789|NCT01028040|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33931790|NCT02400060|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931791|NCT04259346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33931792|NCT02688153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931793|NCT02809118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931794|NCT01041391|||CASE_CONTROL||PROSPECTIVE|||||||
33931795|NCT00916396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931796|NCT00659906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33931797|NCT01698073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931798|NCT00419237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931799|NCT02363855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931800|NCT04328441|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Unblinded are the pharmacist and the research nurse that administers the study medication. These persons are not involved in the further conduction of the trial or in the assessment of outcomes.||t|t|t|t
33931801|NCT03984006|||COHORT||PROSPECTIVE|||||||
33931802|NCT04819867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33931803|NCT02891772|||OTHER||PROSPECTIVE|||||||
33931804|NCT04235088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931805|NCT04479007|||CASE_ONLY||CROSS_SECTIONAL|||||||
33931806|NCT05394207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigational and comparator product have similar appearance. All study products will be packaged in identical packs with identical labelling, except for the randomization number. Study patients, the clinical team, statisticians and the Sponsor will be blinded during the entire study until database lock. Only the Production Department of Sponsor will be un-blinded as necessary to perform labelling.|Double-Blind, Exploratory, Randomized, Controlled|t|t|t|t
33931807|NCT02932319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931808|NCT03632668|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33931809|NCT01543646|||COHORT||PROSPECTIVE|||||||
33931810|NCT00369044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931811|NCT01555736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931812|NCT03931980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010235|NCT03452618|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study compare the diagnostic's variables in patients who received NIV one year after diagnosis and those who did not.||||
34010236|NCT01211899|||COHORT||PROSPECTIVE|||||||
34010237|NCT01729988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010238|NCT04375995|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34010239|NCT01514084|||COHORT||PROSPECTIVE|||||||
34010240|NCT00616174|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931813|NCT04973085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33931814|NCT01840436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33931815|NCT02415504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931816|NCT05791006|||CASE_CONTROL||PROSPECTIVE|||||||
33931817|NCT02719457|RANDOMIZED|CROSSOVER||||NONE||||||
34010241|NCT06420414|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|The researcher who completed the data analysis (JR) was blinded to the participants and specifics of the intervention.|"This parallel-design pilot randomised controlled trial (RCT) had two arms, each representing a different intervention: one group used a virtual reality (VR) exergaming system (FitXR on the Facebook Oculus Quest 2) and the other performed traditional High-Intensity Interval Training (HIIT), mirroring the same movements and durations as in the VR game. Participants were allocated to the two arms via block randomisation, stratified by gender. Both groups underwent a 15-minute HIIT session with 10-second intervals, aimed at comparing physiological and psychological effects between VR and non-VR interventions."||||
34010242|NCT06050876|||CASE_ONLY||RETROSPECTIVE|||||||
34010243|NCT03235609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34010244|NCT00498342|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34010245|NCT05143203|||COHORT||PROSPECTIVE|||||||
34010246|NCT00049842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010247|NCT01739634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010248|NCT05540652|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single arm trial testing an internet delivered mindfulness-based intervention.||||
34010249|NCT01174524|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707027|NCT02863952|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707028|NCT01695187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707029|NCT05310461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707030|NCT02724345|||COHORT||PROSPECTIVE|||||||
33707031|NCT04607954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707032|NCT01703039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707033|NCT06262516|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is designed as a 1:1 two armed randomized-controlled trial.||||
33707034|NCT00172640|||DEFINED_POPULATION||OTHER|||||||
33707035|NCT06081205|||COHORT||PROSPECTIVE|||||||
33707036|NCT02958293|||COHORT||RETROSPECTIVE|||||||
33707037|NCT03119298|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33707038|NCT04353518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, double-blind, two arms, placebo controlled, clinical trial|t|t|t|t
33707039|NCT00006426|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707040|NCT02186990|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33707041|NCT00608686|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33707042|NCT04821947|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33707043|NCT00855569|||CASE_CONTROL||PROSPECTIVE|||||||
33790635|NCT06184451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two physiotherapists will be responsible for recruiting and assessing inclusion and exclusion criteria. Therefore, a rheumatologist will be responsible for confirming the OA diagnosis of research participants. A researcher will be responsible for the randomization process. Two physiotherapists, blinded to randomization, will be responsible for the assessment procedures. Two other physiotherapists, one for each group, will apply the interventions.|Controlled clinical trial, two arms randomized and blind.|f|f|f|t
33790636|NCT03862833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||a group of patient will received IL2+ zoledronic acid a group of patient will not received IL2+ zoledronic acid||||
33790637|NCT00088673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790638|NCT03977116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790639|NCT02305485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790640|NCT01927965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790641|NCT01539655|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790642|NCT00837499|||CASE_CONTROL||PROSPECTIVE|||||||
33790643|NCT03242135|||COHORT||PROSPECTIVE|||||||
33790644|NCT00597103|||CASE_CONTROL||PROSPECTIVE|||||||
33790645|NCT04875858|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931818|NCT05325606|||CASE_CROSSOVER||PROSPECTIVE|||||||
33931819|NCT06507098|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33931820|NCT04280484|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931821|NCT03377569|||CASE_ONLY||PROSPECTIVE|||||||
33931822|NCT01236768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931823|NCT05309369|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33931824|NCT01878240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931825|NCT06032988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomly assigned (using a computer generator \[www.randomization.com\], which randomizes each subject to a single treatment using randomly permuted blocks) to receive probiotic or placebo treatment, blinded to participants, study investigators, and physicians caring for the patients.|The present study will be a single-center, randomized, double-blind, placebo-controlled trial of a 6-month duration involving persons with T2D. Participants will receive either a multi-strain probiotic supplement (in the form of a capsule) or a matching placebo capsule once a day.|t|t|t|t
33931826|NCT01816386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33931827|NCT00540527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931828|NCT02392676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931829|NCT00593775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33931830|NCT04746989|||COHORT||RETROSPECTIVE|||||||
33931831|NCT01873807|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931832|NCT04064372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will remain masked to which program the participant will use. However the experimenter will engage with participants while in their training groups and thus will not be masked to condition.||f|f|f|t
33931833|NCT01838304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931834|NCT05933772|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33931835|NCT02211781|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33931836|NCT00558740|||||PROSPECTIVE|||||||
33931837|NCT04246424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931838|NCT03246711|||COHORT||PROSPECTIVE|||||||
33931839|NCT05838820|||OTHER||CROSS_SECTIONAL|||||||
34010250|NCT06365099|NA|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34010251|NCT02331238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010252|NCT00479388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790646|NCT01281020|||COHORT||PROSPECTIVE|||||||
33790647|NCT04415333|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Only the participants with hypertension will perform the enema in a randomized order. The participants, nursing research staff (e.g., care providers), nor the PI's will know which enema the subjects are receiving. The study Biostatistician (e.g., statistical outcome assessor) will only be given the treatment IDs and not be given the sodium butyrate concentrations during statistical analyses. Randomization will be performed by 1 member of the research team at the beginning of the study who is also not involved in any informed consent process. Enemas will be assigned a letter (e.g., A or B) and each letter will be placed in an envelope (blinded allocation concealment). The research team member will reveal the key upon the conclusion of the study.|In this blinded study, participants with Hypertension will self-administer a \[5 mmol\] and a \[80 mmol\] sodium butyrate enema in a randomized order 1 week (7 days) apart.|t|t|t|t
33790648|NCT05937919|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790649|NCT05837468|||CASE_ONLY||PROSPECTIVE|||||||
33790650|NCT00307307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790651|NCT06533527|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33790652|NCT04891887|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33790653|NCT04040530|||COHORT||PROSPECTIVE|||||||
33790654|NCT05334758|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open label, prospective study to evaluate the sensitivity and specificity of the Bio-Self COVID-19 Antigen Home Test when a lay person conducts the test on themselves or another study participant. Potential subjects will be those presenting for COVID-19 testing. The study will evaluate the performance of the Bio-Self COVID-19 Antigen Home Test by comparing it to a high sensitivity EUA SARS-CoV-2 RT-PCR assay to calculate both the positive percent agreement \[(PPA) sensitivity\] and negative percent agreement \[(NPA) specificity\].||||
33931840|NCT00004194||||SUPPORTIVE_CARE||||||||
33707044|NCT03963037|||FAMILY_BASED||PROSPECTIVE|||||||
33707045|NCT00113984||||TREATMENT||||||||
33707046|NCT04688957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707047|NCT03588039|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707048|NCT06005883|||COHORT||RETROSPECTIVE|||||||
33707049|NCT02158234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707050|NCT04667871|||CASE_CONTROL||RETROSPECTIVE|||||||
33707051|NCT01552200|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33707052|NCT05965154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707053|NCT00517816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707054|NCT01134276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707055|NCT03691259|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707056|NCT04741282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33707057|NCT02313792|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33707058|NCT03856892|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707059|NCT02871895|||COHORT||PROSPECTIVE|||||||
33931841|NCT00901004|||COHORT||CROSS_SECTIONAL|||||||
33931842|NCT06289504|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33931843|NCT01116804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33931844|NCT00260091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931845|NCT05234190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931846|NCT02108522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931847|NCT03225651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33931848|NCT00565240|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931849|NCT03320486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931850|NCT01245231|||CASE_ONLY||RETROSPECTIVE|||||||
33931851|NCT02054936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931852|NCT01976624|||COHORT||PROSPECTIVE|||||||
33931853|NCT04710992|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33931854|NCT02437877|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33931855|NCT02371018|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33931856|NCT04261283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Coding will be used and assessor will not have access to treatment allocation|Two groups|f|f|f|t
33931857|NCT06507137|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33931858|NCT03704389|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931859|NCT03200795|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|To eliminate bias, the assessment of outcome will be performed by (experienced) blinded assessors, who will be blinded to the type of intervention as well as the intervention groups of the participants. Participants will also be instructed not to disclose their individual intervention groups to the assessors|There will be 3 group, the rebound exercise group, circuit training group and the control group. The rebound exercises group will received rebound exercise therapy while circuit training will received circuit exercises that comprises progressive resistance exercise and aerobic exercises, while control group will be treated based on the guideline of the management of diabetes by international diabetes federation. Also the two exercise group will received their routine care plus exercises.|t|f|f|f
33931860|NCT02139267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931861|NCT01194414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931862|NCT00553618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931863|NCT01197781|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33931864|NCT01465373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931865|NCT01823757|||CASE_CONTROL||PROSPECTIVE|||||||
33931866|NCT04861636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Both the standard behavioral weight control (SBWC) and HealthTRAC interventions include 4 months of intensive treatment, followed by monthly maintenance sessions for a 12-month program. SBWC includes attention to diet and activity coupled with behavioral modification strategies. HealthTRAC integrates these key constructs with an emotion regulation intervention with documented efficacy in teens.|f|f|f|t
33931867|NCT03396640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stratified, permuted block randomization with a 1:1 allocation ratio. Block sizes will be 4, 6, 8 and 10. Stratification will be two-dimensional, where surgeon is one dimension and patient sex the other. The randomization will be done immediately preceding surgery. Randomization is blinded to everyone (patient, staff, GP, physiotherapists etc.) except theatre staff, for the first year following surgery.|Double Blinded, randomized controlled trial.|t|t|t|t
33931868|NCT03975049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790655|NCT04263545|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants who are randomised to the standard care arm will receive very brief advice (VBA) and signposting to local organisations to support a quit smoking.|meeting with a smoking cessation counsellor to discuss their individual requirements for smoking cessation and be offered their choice of pharmacological intervention. They will be provided with their choice of pharmacotherapy on site.They will then be invited to attend a group session, where they will have some brief lung function tests and check carbon monoxide levels. Participants will be offered refreshments and receive a bespoke group session to address various aspects of smoking cessation.||||
33790656|NCT04559243|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33790657|NCT01499108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790658|NCT05602909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790659|NCT00876837|||COHORT||PROSPECTIVE|||||||
33790660|NCT03347318|||COHORT||PROSPECTIVE|||||||
33931869|NCT00200889|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Participants are not made aware of the expectation manipulation nor their group assignment until the end of the final visit, at which point they are debriefed.~Outcomes assessors will be blind to group assignments until analysis is complete."|"Participants will be randomized 1:1 to Congruent or Incongruent briefing groups. The Congruent group receives briefings including expectations of stimulation effects on gastric motility consistent with prior research in the literature. The Incongruent group receives briefings including expectations of stimulation effects on gastric motility inconsistent with prior research in the literature."|t|f|f|t
33931870|NCT04677023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931871|NCT03214419|||OTHER||RETROSPECTIVE|||||||
33931872|NCT03804827|||COHORT||PROSPECTIVE|||||||
33931873|NCT02776306|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33931874|NCT05516940|||COHORT||RETROSPECTIVE|||||||
33931875|NCT01964729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010253|NCT00346892|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34010254|NCT04892316|||OTHER||PROSPECTIVE|||||||
34010255|NCT06279806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data obtained from the research will be coded as A and B by an independent researcher and transferred to the SPSS program. The data will also be analyzed by an independent statistician.|In order to ensure similarity between the groups, stratified block randomization will be used to assign the women in the sample group to the experimental and control groups. In this method, after stratification according to risk factors, block randomization is performed within each stratum. Since the type of treatment applied in breast cancer and marital status will significantly affect posttraumatic development, stratification was made in terms of these parameters. Stratum 1 in terms of treatment type: Mastectomy, 2nd stratum: Breast conserving surgery or reconstructive surgery during mastectomy; Stratum 1 in terms of partner presence: Has a partner, Stratum 2: No partner. In order to determine which stratum group the women who were found to meet the research criteria and who agreed to participate in the study were in, blocks will be formed with a combination of 4 and the assignment list will be determined through the www.randomizer.org website.|f|f|f|t
33790661|NCT04842669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790662|NCT03184558|NA|SINGLE_GROUP||TREATMENT||NONE||Extension to Simon's 2-stage design allowing termination at the end of Stage 1 for either futility or efficacy.||||
33931876|NCT05808660|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33931877|NCT00722098|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33931878|NCT01775800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931879|NCT06434025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"HFrEF, LVEF \<40%, SGLT2i naive, and iron deﬁciency. Assigned to receive:~1. intravenous iron + SGLT2i;~2. intravenous iron + placebo of SGLT2i;~3. placebo of both therapies."|f|t|t|t
33931880|NCT01170468|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34010256|NCT02327793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010257|NCT00321594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010258|NCT05253222|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010259|NCT01267006|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34010260|NCT05421793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34010261|NCT02731014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010262|NCT03752398|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34010263|NCT04707586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The quasi-experimental, two-group, pretest-posttest study|f|t|f|f
34010264|NCT01726114|NA|SINGLE_GROUP||||NONE||||||
34010265|NCT04604119|||OTHER||CROSS_SECTIONAL|||||||
34010266|NCT03699241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34010267|NCT05605912|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010268|NCT00824369|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34010269|NCT03122587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34010270|NCT02498275|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33707060|NCT03739593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single injection of either of 2 formulations of AR-1105 dexamethasone intravitreal implant (CF1 or CF2) administered in a single eye. An initial safety cohort of up-to 5 subjects may be enrolled onto CF1 prior to the randomized phase. During the randomized phase of the study, subjects will be assigned in a 1:1 ratio to either CF1 or CF2. Each subject will complete a 6-month primary evaluation period. Residual implant assessment will be performed by 3-field fundus photography at Day 7 and at Months 3, 4, 5, and 6, and if necessary at monthly visits thereafter until the subject requires retreatment, or until 1 month after the implant is no longer visible, or to Month 9, whichever comes first.||||
33707061|NCT05430932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707062|NCT05310890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33707063|NCT05389397|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790663|NCT04767035|RANDOMIZED|CROSSOVER||TREATMENT||NONE||4-period 4-arm crossover relative bioavailability||||
33790664|NCT01845896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790665|NCT00601848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790666|NCT02178540|NA|SINGLE_GROUP||||NONE||||||
33931881|NCT06356415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The sealed-envelope technique will be used. An assistant who is not involved in patient care will make and combine bupivacaine, whether it contains adjuvants or not. Thus, all patients, operators, and outcome assessors remain blinded to the nature of the perineural adjuvant||t|f|f|f
33790667|NCT00819819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33790668|NCT00562913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790669|NCT02072226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931882|NCT02550119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931883|NCT04962490|||COHORT||RETROSPECTIVE|||||||
33931884|NCT05831423|||OTHER||CROSS_SECTIONAL|||||||
33931885|NCT01159457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931886|NCT02933372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All participants (Parkinson's disease patients and healthy controls) will receive the study drug varenicline.|t|t|t|f
33931887|NCT01759628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931888|NCT04142944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Observational, within-subject, crossover study||||
33931889|NCT02211105|||CASE_CONTROL||PROSPECTIVE|||||||
33931890|NCT02756234|||COHORT||PROSPECTIVE|||||||
33931891|NCT02335034|RANDOMIZED|CROSSOVER||TREATMENT||NONE|single-blind|||||
33931892|NCT02480062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33931893|NCT03850210|RANDOMIZED|PARALLEL||TREATMENT||||||||
33931894|NCT05418725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open-label randomised non-comparative trial, in two parallel groups with a 2:1 allocation ratio|t|f|f|f
33931895|NCT05459506|||COHORT||PROSPECTIVE|||||||
33931896|NCT02019758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931897|NCT04614376|||CASE_CONTROL||RETROSPECTIVE|||||||
33931898|NCT00479934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931899|NCT00862498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931900|NCT00383006|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931901|NCT03959345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931902|NCT03828565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33931903|NCT05681897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|this is a double-blind masking study||t|t|t|t
33931904|NCT05402904|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33931905|NCT05047016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33931906|NCT00476398|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790670|NCT04176692|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790671|NCT04730999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790672|NCT00213746|||||PROSPECTIVE|||||||
33790673|NCT01156935|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33790674|NCT06121596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790675|NCT02212535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931907|NCT04624672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33931908|NCT02389530|||COHORT||PROSPECTIVE|||||||
33931909|NCT00511108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931910|NCT01155791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931911|NCT04260529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931912|NCT02465489|RANDOMIZED|CROSSOVER||||NONE||||||
33931913|NCT01301404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33931914|NCT05129683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33931915|NCT00887068|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931916|NCT00245349|||COHORT||PROSPECTIVE|||||||
34010271|NCT01363141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010272|NCT04894084|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm, open label study. Subjects are allocated to use test product for 3 weeks. Subjects will complete questionnaires at baseline (V1) and again after 3 weeks use of test product (V2). Comparative tests included: Baseline vs. follow-up measures.||||
34010273|NCT03786419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010274|NCT04540055|||COHORT||PROSPECTIVE|||||||
34010275|NCT04059549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931917|NCT04741295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33931918|NCT03486184|||COHORT||PROSPECTIVE|||||||
33931919|NCT03516552|||COHORT||PROSPECTIVE|||||||
33931920|NCT00330239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931921|NCT02520713|||COHORT||PROSPECTIVE|||||||
33931922|NCT02109744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931923|NCT01493934|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33931924|NCT01518634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931925|NCT01100762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931926|NCT00683501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33931927|NCT06272357|||OTHER||CROSS_SECTIONAL|||||||
33931928|NCT05784103|NA|SINGLE_GROUP||OTHER||NONE||||||
33931929|NCT01901367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33931930|NCT05433974|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931931|NCT00554853|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33931932|NCT05478538|||CASE_ONLY||PROSPECTIVE|||||||
33931933|NCT04986111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931934|NCT03998891|||CASE_CONTROL||PROSPECTIVE|||||||
34010276|NCT00518882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010277|NCT06097559|||COHORT||PROSPECTIVE|||||||
34010278|NCT02971982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010279|NCT02523937|||COHORT||PROSPECTIVE|||||||
34010280|NCT02187107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010281|NCT06610461|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study will be a non-blinded, randomized, controlled trial comparing two study groups (intervention and control). Participants are assigned to one of two groups in parallel for the duration of the study."||||
34094436|NCT05466253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All the patients included in the study will receive a detailed periodontal evaluation and all periodontal parameters (osseous and non-osseous) will be recorded at the baseline and Phase I periodontal therapy will be provided. This will include oral hygiene instruction, scaling and root planning and re-evaluation after one weeks. If the patients are able to maintain oral hygiene after preliminary periodontal intervention they will be included in further stages of the study. All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group 10 days after periodontal surgery whereas the control group will receive orthodontic intervention 3 months after periodontal surgery. Supragingival scaling will be done in both the groups at 3 month intervals as per requirement.|f|f|f|t
34094437|NCT04151732|||COHORT||PROSPECTIVE|||||||
34094438|NCT05587647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Study|f|f|f|t
34094439|NCT00710970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094440|NCT03243188|||OTHER||OTHER|||||||
34094441|NCT03475563|||CASE_ONLY||PROSPECTIVE|||||||
34094442|NCT01332201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094443|NCT04667429|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Ascending Multiple Dose Study is Double-blind design; Food Effect Study is open-label design.||t|t|t|t
34094444|NCT04086667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Segments chosen for intervention The most painful segment will be chosen from the MPA findings and the stiff segment from VT.~It is possible to measure the absolute values of both, but it might be that there is a natural difference between segments, especially for stiffness.~Therefore, the stiffness and pain sensitivity for each individual (0-100%) will be normalized. For each segment we calculate the normalized difference:~norm_diff(segment) = (segment_indent - min_indent) / (max_indent - min_indent) - (segment_pain - min_pain) / (max_pain - min_pain) This will determine the biggest difference between stiffness and pain sensitivity and each segment will be chosen according to this. The lowest limit would equal the stiffest segment, while the highest limit would indicate the most painful segment."|t|t|f|t
34094445|NCT03066076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Observer blinded analysis||f|f|t|f
34094446|NCT04145934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34094447|NCT02933476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094448|NCT00408915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931935|NCT03647462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094449|NCT03097471|||CASE_ONLY||PROSPECTIVE|||||||
34094450|NCT02511158|||COHORT||PROSPECTIVE|||||||
33931936|NCT02142491|||CASE_CONTROL||PROSPECTIVE|||||||
33931937|NCT02790684|NA|SINGLE_GROUP||OTHER||NONE||||||
33931938|NCT06332183|||CASE_CONTROL||PROSPECTIVE|||||||
33931939|NCT01427114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931940|NCT05044351|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and related health care staff will be blinded for the allocated intervention until the day of surgery|Randomized Clinical Trial|t|t|f|f
33931941|NCT00002413||||TREATMENT||NONE||||||
33931942|NCT02052323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931943|NCT00675688|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34010282|NCT01957345|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010283|NCT02433119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790676|NCT06555523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790677|NCT00019669||||TREATMENT||NONE||||||
33931944|NCT04869189|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33931945|NCT00024128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931946|NCT03295149|||COHORT||PROSPECTIVE|||||||
33931947|NCT01140776|||CASE_ONLY||PROSPECTIVE|||||||
33931948|NCT00479167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931949|NCT00289393|||DEFINED_POPULATION||OTHER|||||||
33931950|NCT03190967|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33931951|NCT02116738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931952|NCT04672070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be done to the outcomes assessors to reduce bias during radiographic healing assessment. Participants also will not be informed of which treatment they are undergoing.|Study subject (tooth) will be randomized in a 1:1 allocation ratio between the two treatment groups.|t|f|f|t
33931953|NCT00369278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931954|NCT04931550|||COHORT||PROSPECTIVE|||||||
33931955|NCT05831514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the study, it will be ensured that the parents participating in the research do not know which group they are in. Therefore, one-way blinding will be applied in the study.|The research type is a pre-test-repeated post-test randomized controlled single blind study.|t|f|f|f
33790678|NCT02747563|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33931956|NCT04572685|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single dose study in three parallel dosing groups of schizophrenia patients||||
33931957|NCT04539262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931958|NCT01641081|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33931959|NCT00058188|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33931960|NCT01071590|||||PROSPECTIVE|||||||
33931961|NCT05345938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931962|NCT01184339|||||PROSPECTIVE|||||||
33931963|NCT00260572|||CASE_ONLY||PROSPECTIVE|||||||
33931964|NCT03597672|||COHORT||PROSPECTIVE|||||||
33931965|NCT05384795|||COHORT||PROSPECTIVE|||||||
33931966|NCT05210413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Pediatric cohort:~Multicentre, open-label, non-randomized, phase I clinical study, with dose-finding and expansion phases.~Adult cohort:~Multicenter phase II single-arm open-label clinical trial, with a pre-screening phase to identify patients with mature tertiary lymphoid structure (TLS)."||||
33931967|NCT00633360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33931968|NCT05076994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two Randomized Groups|f|f|t|t
33931969|NCT03928444|RANDOMIZED|PARALLEL||TREATMENT||NONE||split face||||
33931970|NCT03248219|||CASE_ONLY||PROSPECTIVE|||||||
33790679|NCT04709796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33931971|NCT06392178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33931972|NCT06437548|NA|SINGLE_GROUP||OTHER||NONE||Percutaneous temporary spinal cord stimulator. Parameters for upper extremity motor function will be assessed with the stimulation turned on and off. Muscle strength and force will be assessed with the stim turned on and off.||||
34010284|NCT06617559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There are two standard autografts used for ACL reconstruction in the investigators\&#39; clinic: quadriceps and hamstring autografts. Patients will be randomly assigned to groups based on the order of their hospital admission. It is planned to have at least 25 patients in each group.|f|f|f|t
34010285|NCT02380079|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||2x2 crossover|t|t|t|t
33790680|NCT00961636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790681|NCT04276987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790682|NCT02812459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790683|NCT05747313|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|"The experiment was a single-arm study design. The study is divided into two phases.~Phase I : single-arm, open, dose-climbing Phase Ib clinical study to determine the safety and tolerability of the combination regimen and to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or recommended dose for Phase II studies of this combination regimen.~Phase II : Single-arm, open, single-center Phase II clinical study to assess the efficacy and safety of the recommended dose administered in Phase II."||||
33790684|NCT04768361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33790685|NCT04283825|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010286|NCT04714151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010287|NCT01513031|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34010288|NCT04359563|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study uses a randomized staggered within-subjects design in which participants are randomized to a baseline assessment phase of 14 to 28 days duration. During the subsequent intervention phase, all participants receive an 8-week Mindfulness-Based Intervention. Participants complete daily (every 3 days during intervention and follow-up phases) experience sampling method (ESM) measurements throughout the baseline, intervention and follow-up phases. Before randomisation, directly post-intervention and at 3 months follow-up, participants complete self-report questionnaires and ESM measurements.||||
34010289|NCT04776954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34010290|NCT02974491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010291|NCT02560974||PARALLEL||TREATMENT||NONE||||||
34010292|NCT03018093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010293|NCT06023862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010294|NCT04417049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010295|NCT04073017|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010296|NCT00474604|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010297|NCT01726127|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34010298|NCT05633914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094451|NCT05249920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790686|NCT01740817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790687|NCT05538988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790688|NCT05824403|||COHORT||PROSPECTIVE|||||||
33931973|NCT03174769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33931974|NCT02054234|||COHORT||CROSS_SECTIONAL|||||||
33931975|NCT01900405|||COHORT||PROSPECTIVE|||||||
33931976|NCT01655940|||CASE_ONLY||PROSPECTIVE|||||||
33931977|NCT03003130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33931978|NCT06037512|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33931979|NCT00141310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33931980|NCT06417008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931981|NCT01126294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010299|NCT03042468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931982|NCT05841641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931983|NCT03556982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33931984|NCT02910089|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33931985|NCT06092086|NA|SINGLE_GROUP||TREATMENT||NONE||Single drug administration||||
33931986|NCT02201472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Magnetic resonance elastography on infants with suspected liver disease||||
33931987|NCT02940197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33931988|NCT02665468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34010300|NCT06012721|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, 2-part, 2-sequence, 2-period, open-label, crossover||||
34094452|NCT05783219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be randomized with a stratified block randomization scheme (with a random block size of 4, 6, and 8 participants). Randomization sequence will be generated by statistician collaborator~A patch (intervention or control) will be removed by a medical assistant prior to provider entering the room in order to secure blinding. 1% lidocaine 10cc will be injected into the sacral procedure site for adequate pain relief. PNE procedure will then be performed. If inadequate analgesia is reported by the Patient during the procedure, additional injectable lidocaine will be administered in 5 cc increments, not to exceed 4.5 mg/kg of injectable lidocaine. The volume of injectable lidocaine used will be recorded."|This is a single-center, double-blinded, placebo-controlled, randomized trial.|t|t|t|t
34094453|NCT01164605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094454|NCT00383825|RANDOMIZED|PARALLEL||SCREENING||SINGLE||||||
34094455|NCT00263536||||TREATMENT||||||||
34094456|NCT01203371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094457|NCT05992038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094458|NCT02323061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34094459|NCT03309059|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34094460|NCT01159353|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33931989|NCT01222897|RANDOMIZED|CROSSOVER||||NONE||||||
34094461|NCT05379608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|participant and the specialists who will carry out investigations (blood and urine analysis, electrocardiography, a flow mediated dilatation procedure, transthoracic echocardiography).||t|t|f|f
34094462|NCT02112227|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34094463|NCT04849832|RANDOMIZED|CROSSOVER||TREATMENT||NONE|There will be no masking as the ferrous sulfate solutions will be colourless compared to the green color solution of SIC|The study will be a randomized, single centre cross over study where every participant will receive all the four interventions.||||
33931990|NCT01368952|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33931991|NCT05385926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010301|NCT01929772|||COHORT||PROSPECTIVE|||||||
34010302|NCT05886231|NA|SINGLE_GROUP||SCREENING||NONE||Retrospective||||
34010303|NCT01473550|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34010304|NCT02152202|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34010305|NCT01577693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010306|NCT00992095|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010307|NCT01616121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In this study the interventional group was treated preemptively according to the lung-impedance protocol and the control group was treated only according to clinical assessment.|t|f|f|f
34010308|NCT02130531|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34010309|NCT01722682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010310|NCT06260020|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and post intervention study||||
34010311|NCT01704937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010312|NCT05927181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010313|NCT02466789|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34010314|NCT04681196|||CASE_CONTROL||RETROSPECTIVE|||||||
34010315|NCT04413734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010316|NCT00827086|||COHORT||PROSPECTIVE|||||||
34010317|NCT02885818|||COHORT||PROSPECTIVE|||||||
34010318|NCT02255188|||COHORT||PROSPECTIVE|||||||
34094464|NCT02952677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094465|NCT03289000|||COHORT||RETROSPECTIVE|||||||
34094466|NCT03842800|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34094467|NCT00452257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010319|NCT04784884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010320|NCT00402220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010321|NCT00754442|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010322|NCT05082324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010323|NCT01387425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010324|NCT05754424|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34010325|NCT02062801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34010326|NCT01232491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094468|NCT00066170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010327|NCT03363477|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This study will be double blinded in that the subjects and laboratories will be blinded. While the enoxaparin (manufactured by Rovi, Spain) and Clexane (manufactured by Sanofi, EU) solutions for SC injection may be identical in appearance, the prefilled syringes for both study drugs may not be identical. Therefore, the unblinded pharmacist will be responsible for dispensing the study drug in a manner consistent with maintaining the blind and a dedicated unblinded team member will perform study drug administration.|single-dose, randomized, double-blind, 2-period, 2-sequence crossover study|t|t|t|f
34010328|NCT05088031|||OTHER||PROSPECTIVE|||||||
34094469|NCT03457831|||COHORT||PROSPECTIVE|||||||
34094470|NCT05898880|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Patients included in the study will not be blinded as they will be in acupressure (administered by the therapist), self-acupressure or control groups.~Researchers will be blinded only during group assignment. The data will be transferred to the computer environment by the researchers, and a biostatistician independent of the research will analyze the data and report the findings without knowing which of the three groups are. Thus, the biostatistician will be blinded."|This is a prospective, three-armed (1:1:1), randomized controlled experimental single-blind clinical trial.|f|f|t|f
34094471|NCT03130322|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33790689|NCT05607953|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1: Two doses of SD-101 (given over two 52-day cycles) in dose-escalation fashion (0.5mg, 2mg, 4mg, 8mg-optional) via pancreatic retrograde infusion using pressure enabled drug delivery with the TriSalus Infusion System device.~Phase 1b: Two doses of SD-101 (given over two 52-day cycles) at the maximum tolerated dose or optimal biologic dose defined in Phase 1b via pancreatic retrograde infusion using pressure enabled drug delivery with the TriSalus Infusion System device will be administered with systemic CPI."||||
33790690|NCT02652936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790691|NCT02888002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094472|NCT00283582|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33790692|NCT01604018|||COHORT||PROSPECTIVE|||||||
34094473|NCT04822571|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094474|NCT00435721|RANDOMIZED|PARALLEL||ECT||NONE||||||
33790693|NCT05582317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790694|NCT02678104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790695|NCT00487578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790696|NCT02298907|||CASE_ONLY||PROSPECTIVE|||||||
33790697|NCT03360552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33790698|NCT03800667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790699|NCT02686554|||COHORT||RETROSPECTIVE|||||||
33790700|NCT01544140|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790701|NCT02712411|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790702|NCT04481906|||COHORT||PROSPECTIVE|||||||
33790703|NCT06188988|||COHORT||PROSPECTIVE|||||||
33790704|NCT05145517|||COHORT||PROSPECTIVE|||||||
33790705|NCT00166192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790706|NCT03761966|||COHORT||PROSPECTIVE|||||||
33790707|NCT04473638|||CASE_ONLY||RETROSPECTIVE|||||||
33790708|NCT02830152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010329|NCT00539708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010330|NCT01344382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094475|NCT01542099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790709|NCT00208767|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34010331|NCT06151782|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Participants will be challenged by single bolus four times four weeks apart.|f|f|t|f
34010332|NCT03010618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094476|NCT04769401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33931992|NCT05133206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomisation will take place through a sealed envelope method controlled by the cardiac research team; patients will be allocated 1:1 to either fasting or non-fasting groups using random blocks of sizes 4, 6, and 8 to minimise imbalance in treatment groups and preserve blinding up until the point of randomisation. This information (whether fasting or not) will be relayed to the patient at the time of pre-procedure assessment. The people who collate the data (the cath lab team or research nurses) and the operator performing the procedure will be blinded to the patient allocation group and will not be involved in conducting the analysis. The treatment group will be relabelled before analysis (i.e. group A and group B for not-fasting and fasting, respectively).||||
33931993|NCT04510155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33931994|NCT05439304|||CASE_ONLY||PROSPECTIVE|||||||
33931995|NCT00633893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33931996|NCT01695460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33931997|NCT04898660|||COHORT||RETROSPECTIVE|||||||
33931998|NCT00351390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33931999|NCT04836091|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-month pilot randomized controlled trial with a a waitlist control condition of one month||||
33932000|NCT02047968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932001|NCT05153863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluation of the performance and safety of the C Scope Visualization System in the illumination and visualization of joints during diagnostic procedures||||
33932002|NCT05944445|||COHORT||RETROSPECTIVE|||||||
33932003|NCT04381533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932004|NCT03912324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932005|NCT02112461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932006|NCT03224156|||COHORT||PROSPECTIVE|||||||
33932007|NCT02628704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932008|NCT03185273|||COHORT||PROSPECTIVE|||||||
33932009|NCT05179057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study with option for blinded crossover to assess the safety and efficacy of posoleucel as compared to placebo for the treatment of AdV infection in pediatric and adult recipients of HCT with AdV infections receiving SoC.|t|t|t|t
33932010|NCT02866318|||COHORT||RETROSPECTIVE|||||||
33932011|NCT04951180|||CASE_ONLY||RETROSPECTIVE|||||||
33932012|NCT03962634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932013|NCT02978872|||COHORT||PROSPECTIVE|||||||
33932014|NCT03408288|||OTHER||PROSPECTIVE|||||||
33932015|NCT03966664|||CASE_CONTROL||PROSPECTIVE|||||||
33932016|NCT03696849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932017|NCT04151446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932018|NCT04954391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932019|NCT01012804|||CASE_ONLY||PROSPECTIVE|||||||
33932020|NCT03011775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932021|NCT03782844|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33932022|NCT03216980|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34010333|NCT01627925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010334|NCT00996970|||COHORT||PROSPECTIVE|||||||
34010335|NCT06164275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010336|NCT05333848|RANDOMIZED|FACTORIAL||OTHER||NONE||A 2x2 factorial design randomized controlled trial||||
34010337|NCT04815694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.||||
34010338|NCT04654897|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label, single dose||||
34010339|NCT00288665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010340|NCT04470206|||COHORT||PROSPECTIVE|||||||
34010341|NCT03358160|||OTHER||CROSS_SECTIONAL|||||||
34010342|NCT03420612|||COHORT||PROSPECTIVE|||||||
34010343|NCT01872845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010344|NCT01863056|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34010345|NCT03352375|RANDOMIZED|PARALLEL||TREATMENT||NONE||All pediatric patients, who were scheduled to undergo laparoscopic surgery||||
34010346|NCT00601757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010347|NCT04686227|||COHORT||PROSPECTIVE|||||||
34010348|NCT00523328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010349|NCT05766020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010350|NCT02056964|||COHORT||PROSPECTIVE|||||||
34010351|NCT04912115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010352|NCT00864617|RANDOMIZED|CROSSOVER||||NONE||||||
34010353|NCT06048094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010354|NCT02244749|||CASE_ONLY||PROSPECTIVE|||||||
34010355|NCT01788891|||COHORT||PROSPECTIVE|||||||
34010356|NCT00146406|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34010357|NCT05545111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010358|NCT00068081|RANDOMIZED|||TREATMENT||DOUBLE||||||
34010359|NCT00462891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34010360|NCT02262858|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010361|NCT00002787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010362|NCT04554095|||COHORT||PROSPECTIVE|||||||
34010363|NCT01237314|||CASE_CONTROL||PROSPECTIVE|||||||
34010364|NCT01886482|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34010365|NCT06615895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment tests are conducted before and after the intervention. The assessor is the same person, who is a single-blind and professionally trained therapist who does not know the group assignment of the case.|"Subjects are assigned to the \&amp;amp;#34;telehealth group\&amp;amp;#34; or the \&amp;amp;#34;waiting group\&amp;amp;#34;.~The \&amp;amp;#34;telehealth group\&amp;amp;#34; participates in an online video course for 6 weeks. The therapist will provide online video courses 3-5 times a week and record the implementation on the online platform every week. The course includes action plans, two Lateral integration/cross-midline, vestibular system, visual perception, opto-motor integration, eye movements, core strength activities and balance ability, etc.~The \&amp;amp;#34;waiting group\&amp;amp;#34; is to provide explanation of course objectives and wait for 6 weeks after explaining the objectives of this research in the first course."|f|f|f|t
34010366|NCT03569488|||COHORT||PROSPECTIVE|||||||
34010367|NCT03543345|||COHORT||PROSPECTIVE|||||||
34010368|NCT03128736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010369|NCT01066117|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010370|NCT03182387|||OTHER||PROSPECTIVE|||||||
34010371|NCT02940730|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34010372|NCT05077956|||COHORT||PROSPECTIVE|||||||
34010373|NCT02214719|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010374|NCT05421104|||COHORT||RETROSPECTIVE|||||||
34010375|NCT01002313|||CASE_CONTROL||PROSPECTIVE|||||||
33707064|NCT03273114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical outcomes will be obtained in the evaluations carried out by a blinded assessor 8 weeks, 6 and 12 months after randomization. Both arms include active treatments, and participants will not know whether they are in the experimental group or control group.|Randomized controlled trial with concealed allocation, blinded assessor, blinded participants and intention to treat analysis. Patients will be evaluated at baseline, 8 weeks, 6 and 12 months after randomization, to assess the maintenance of any effect of treatment. The patients in the CFT group will be treated by a physical therapists that attended twice the CFT workshops with two of the tutors of the method. She completed 106 hours of training including workshops, patient examinations and a pilot study with the supervision of a physical therapist with more than three years of clinical experience in CFT. Patients in CORE group will be treated by a physical therapist with clinical experience in manual therapy and core training exercises.|t|f|f|t
33707065|NCT04779060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707066|NCT06467474|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33707067|NCT01858389|NON_RANDOMIZED|||TREATMENT||NONE||||||
33790710|NCT01541358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790711|NCT01668212|||CASE_ONLY||PROSPECTIVE|||||||
33932023|NCT04616794|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The Luci intervention is a personalized lifestyle behaviour change program delivered via an interactive mobile platform with the online support of a coach. The system will allow participants to communicate with their coach through video calls and a messaging/chat system. The coaching sessions will focus on providing personalized support to help participants improve their eating habits, cognitive engagement and/or physical activity. The coach will offer assistance, feedback, information where appropriate, and motivational support throughout the trial. The Proof-of-Concept study is a 10-week pre-post within-subject parallel group treatment-only study. There will be three single-domain groups, and one multidomain group. Participants will receive coach-assisted counselling for up to 9 weeks.||||
33932024|NCT03551106|||OTHER||PROSPECTIVE|||||||
33932025|NCT01136460|||CASE_ONLY||RETROSPECTIVE|||||||
33932026|NCT03535025|||COHORT||PROSPECTIVE|||||||
33932027|NCT03606655|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-Arm Pre- and Post- Trial||||
33932028|NCT04594304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The sequence will be concealed to primary care providers and study staff other than the research coordinator who will apply the allocation. Study staff, including analysts, will also be blind to treatment allocation. Patients and healthcare professionals who may interact with study participants cannot be blinded due to the nature of the intervention, but outcome assessment will be blind.|An independent statistician following a 2:1 ratio to increase opportunities to learn about the intervention processes during this pilot trial will randomly allocate consenting patients following the completion of their baseline survey to intervention or usual care using a computer-generated sequence.|f|f|t|t
33932029|NCT04545411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double-blind|Single-center, randomized, double-blind, cross-over, multi-dose study.|t|t|t|f
33932030|NCT02047708|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33932031|NCT00591032|||COHORT||PROSPECTIVE|||||||
33932032|NCT02714023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932033|NCT00986804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025272|NCT04263324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each patients will have a medical and a psychological consultation and will have to fill-in questionnaires (T0). Then, they will receive a psycho-education training (5 sessions) and will have to complete the same questionnaires (T1). After that, they will again have a medical (pain doctor) and a psychological consultation. Afterwards, the care staff will have a multidisciplinary discussion about their diagnosis. Then functional Magnetic Resonance Imaging (fMRI; 1 hour) and HdEEG (1 hour) data will be acquired in resting state. After that, participants will receive a 7 months (2 hours session a month) learning program of self-hypnosis/self-care animated by a therapist specialized in hypnosis. After the 7 months learning-program they will complete the same questionnaires (T2) and be scanned again by means of fMRI and HdEEG. Patient who do not want to participate to the learning program will not have a treatment but will be scanned in the fMRI and the HdEEG.||||
33707068|NCT02829632|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33707069|NCT05192109|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33707070|NCT02123888|NA|SINGLE_GROUP||||NONE||||||
33707071|NCT02285842|||COHORT||PROSPECTIVE|||||||
33707072|NCT06167824|||COHORT||RETROSPECTIVE|||||||
33707073|NCT06298591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707074|NCT06469541|||COHORT||RETROSPECTIVE|||||||
33707075|NCT05678933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707076|NCT05817825|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is an open-label, single-arm, pilot feasibility trial.||||
33707077|NCT04833543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707078|NCT02217878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707079|NCT02231008|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33707080|NCT02287857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932034|NCT03855761|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33932035|NCT00681291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932036|NCT00253799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932037|NCT00163163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932038|NCT05110404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932039|NCT03921606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33932040|NCT02244619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33932041|NCT02544204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932042|NCT05412667|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33932043|NCT05137210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932044|NCT02397967|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33932045|NCT01681290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932046|NCT02556580|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33932047|NCT02940860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932048|NCT03348813|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Enrolled participants were randomized to either the targeted intervention group or the attention control group at the diagnostic visit. The permuted-block randomization technique was used with a block size of 4 and a 1:1 allocation ratio. Dr. Alex Hanlon (biostatistics consultant) generated the randomization list using a pseudo-randomizer computer program. The Research Coordinator maintained the spreadsheet for tracking and allocation concealment. To reduce the risk of encountering a floor or ceiling effect with intervention responsiveness, participants were stratified based on their PHQ-9 total scores (none/moderate depression versus moderately severe/severe depression) and gender.|f|f|t|t
33932049|NCT00899366|||OTHER||RETROSPECTIVE|||||||
33932050|NCT02298673|||COHORT||PROSPECTIVE|||||||
33932051|NCT02562976|||CASE_CONTROL||PROSPECTIVE|||||||
33932052|NCT02972593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932053|NCT03625804|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Single-blind randomized cross-over study|t|f|f|f
33932054|NCT05400369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932055|NCT03411434|NA|SINGLE_GROUP||OTHER||NONE||Interventional study designed to evaluate routine care. The patients are their own controls. Oculomotor and neurocognitive performances are assessed at baseline (V0), during the methylphenidate test (V1), and after 6 months of methylphenidate treatment||||
33932056|NCT01845519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33932057|NCT04125303|NA|SINGLE_GROUP||PREVENTION||NONE|Outcomes assesor|||||
33932058|NCT02896452|||COHORT||PROSPECTIVE|||||||
33932059|NCT00118404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932060|NCT03139877|||CASE_CONTROL||PROSPECTIVE|||||||
33932061|NCT04629976|RANDOMIZED|PARALLEL||TREATMENT||NONE||After Screening procedures, eligible subjects will be randomized 1:1:1 to receive either open-label NCO-48 Fumarate 4 mg (2 x 2 mg) or 20 mg (2 x 10 mg), or open-label TAF 25 mg for 28 days.||||
33932062|NCT00235053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932063|NCT02324712|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33932064|NCT04893876|||COHORT||PROSPECTIVE|||||||
33932065|NCT01779895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932066|NCT01171313|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33932067|NCT00616772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932068|NCT04095793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932069|NCT02564068|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|All members of the research team except the IP dispensing staff will be blinded for the duration of the research study. Once all the subjects have finished in the research study, and all data is data-locked, the outcomes assessor will then unblind the research data for the statistical analysis.||t|t|t|f
33932070|NCT05655728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932071|NCT02664389|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932072|NCT04843072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932073|NCT05632913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932074|NCT05855213|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single center prospective randomized controlled open label trial of high velocity nasal insufflation (HVNI) in the immediate post-extubation period versus noninvasive positive pressure ventilation (NIPPV). Allocation arm failure , assessed after 72 hours of extubation, will be the primary outcome. Cross-over from HVNI to NIPPV may be allowed in case of HVNI failure and potential benefit as judged by the treating clinical team prior to reintubation.||||
33932075|NCT00899860|||OTHER||PROSPECTIVE|||||||
33932076|NCT05690906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932077|NCT01365013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33932078|NCT04379960|||OTHER||PROSPECTIVE|||||||
33932079|NCT06086782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932080|NCT04525313|||COHORT||RETROSPECTIVE|||||||
33707081|NCT06005350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707082|NCT03615378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized controlled trial|t|f|f|t
33707083|NCT05417282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707084|NCT04524910|||COHORT||RETROSPECTIVE|||||||
33707085|NCT02975505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707086|NCT04355520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707087|NCT04967144|||COHORT||CROSS_SECTIONAL|||||||
33707088|NCT00182286|||DEFINED_POPULATION||OTHER|||||||
33707089|NCT01443871|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33707090|NCT00258401|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707091|NCT00583609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707092|NCT01202812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707093|NCT02099175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707094|NCT00069056||||TREATMENT||||||||
33707095|NCT02050191|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33707096|NCT02468674|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33707097|NCT01269632|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707098|NCT01637272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707099|NCT03176498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707100|NCT04352816|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33707101|NCT06376396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707102|NCT03521908|||COHORT||RETROSPECTIVE|||||||
33707103|NCT01862874|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33707104|NCT00850590|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33707105|NCT05124314|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, parallel group, single center study. Before receiving vaginal misoprostol (800 mcg, repeated after 24 hours if no pregnancy tissue is lost), patients will be randomized to either oral mifepristone (600 mg) or nothing.||||
33707106|NCT02582983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707107|NCT00491816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707108|NCT00694174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707109|NCT05561699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707110|NCT05337228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707111|NCT06312605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Coding of the groups|All participants receive surgical depigmentation then either vitamin C is applied following 2 regimens|f|f|f|t
33707112|NCT02779829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707113|NCT01018966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707114|NCT06309732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707115|NCT01826604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33707116|NCT05488730|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33707117|NCT01407315|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33790712|NCT01414231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790713|NCT02808442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790714|NCT04964479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932081|NCT03966872|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33932082|NCT05839236|NA|SEQUENTIAL||TREATMENT||NONE||||||
33932083|NCT01424319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932084|NCT05278936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932085|NCT03435276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single-blind (in which the study center staff have to remain blinded during the clinical conduct of a given cohort) with regard to treatment (AZD9977 or placebo) at each dose level. In the event of a medical emergency when management of a subject's condition requires knowledge of the trial medication, the treatment received may be revealed by personnel authorized by the PI. Reasons for breaking a code will be clearly explained and justified in ClinBase. The date on which the code was broken together with the identity of the person responsible will also be documented.||t|f|f|f
33932086|NCT05889169|||CASE_CONTROL||PROSPECTIVE|||||||
33932087|NCT05551260|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This study uses standard neuropsychological tests and a computerized experimental task, submitted to two parallel groups: participants with ASD and control participants matched in age, gender and level of education (1:1 ratio). Participants in both groups completed the neuropsychological tests and the experimental task successively (fixed order for all participants). Within the experimental task, the experimental conditions appear randomly.||||
33932088|NCT03278444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932089|NCT06262672|||OTHER||CROSS_SECTIONAL|||||||
33932090|NCT05689749|||CASE_CONTROL||PROSPECTIVE|||||||
33932091|NCT00760045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33932092|NCT02738346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025273|NCT00827437|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34025274|NCT06393517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094477|NCT03234452|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double-blind|randomized, double-blind, placebo-controlled, cross-over trial performed at one centre|t|t|t|t
34094478|NCT00086307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094479|NCT05965934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707118|NCT05081973|||COHORT||PROSPECTIVE|||||||
33707119|NCT05894408|||COHORT||PROSPECTIVE|||||||
33707120|NCT04276571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707121|NCT01695590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707122|NCT00156052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707123|NCT00040365|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707124|NCT00211510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707125|NCT03367221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707126|NCT04817748|||CASE_CONTROL||PROSPECTIVE|||||||
33707127|NCT00159120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707128|NCT04449926|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707129|NCT03467815|||COHORT||PROSPECTIVE|||||||
33707130|NCT02993393|||||CROSS_SECTIONAL|||||||
33707131|NCT03008603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707132|NCT06290661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707133|NCT04254497|||COHORT||PROSPECTIVE|||||||
33707134|NCT01909674|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707135|NCT01021046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707136|NCT02576795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707137|NCT02318771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790715|NCT00159796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790716|NCT00423254|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790717|NCT03687996|||CASE_ONLY||RETROSPECTIVE|||||||
34010376|NCT02696031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This was a randomized, double-blind, placebo-controlled study. Approximately 555 patients were randomized to one of three treatment groups (secukinumab 150 mg Load, secukinumab 150 mg No Load or placebo in a ratio of 1:1:1):~* Group 1 (secukinumab 150 mg Load): secukinumab 150 mg (1 mL, 150 mg/mL) s.c. prefilled syringe (PFS) at baseline (BSL), Weeks 1, 2 and 3, followed by administration every four weeks starting at Week 4~* Group 2 (secukinumab 150 mg No Load): secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS at BSL, placebo at Weeks 1, 2 and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4~* Group 3 (placebo): placebo (1 mL) s.c. PFS at BSL, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4 Based on the clinical judgment of disease activity by the investigator and the patient, background medications, such as NSAIDs and DMARDs, may have been modified or added to treat signs and symptoms of nr-axSpA from Week 16 on."|t|t|t|t
34010377|NCT04507594|||COHORT||PROSPECTIVE|||||||
33707138|NCT03968770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind (Subject, Outcomes Assessor)||t|f|t|f
34010378|NCT00004481|||NATURAL_HISTORY|||||||||
34010379|NCT01272921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34010380|NCT02172677|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34010381|NCT00285584|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707139|NCT00758836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707140|NCT00534391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707141|NCT00249860|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33707142|NCT04959916|NA|SINGLE_GROUP||OTHER||NONE||"This is a benchmark study, whereby a single group will receive the Group-MCT intervention and this group will be compared to (i.e benchmarked against) data from patients who completed 'Treatment as Usual' within the service.~The treatment as usual data is collected in the course of normal care. Patients personally identifiable information will be removed from the data base before being shared with the study team"||||
33707143|NCT05279183|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707144|NCT02510196|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33707145|NCT06022744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707146|NCT04342156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707147|NCT05469828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment and Control||||
33707148|NCT05830968|NA|SINGLE_GROUP||TREATMENT||NONE||Study Design Prospective, multicenter clinical study||||
33707149|NCT05073783|||COHORT||PROSPECTIVE|||||||
33707150|NCT00194597|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33707151|NCT05770687|||COHORT||PROSPECTIVE|||||||
33707152|NCT04739904|||CASE_CONTROL||PROSPECTIVE|||||||
33707153|NCT04185545|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33707154|NCT05021497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707155|NCT02228200|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707156|NCT01251237|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707157|NCT02410122|||COHORT||PROSPECTIVE|||||||
33707158|NCT01930123|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707159|NCT01416272|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707160|NCT06505876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33707161|NCT05253729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707162|NCT04848298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33707163|NCT05981898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and outcomes assessor Dr. Urmila Diwekar will only know the de-identified patient details in each arm after the treatment.|This is a multi-centered randomized clinical trial study with two arms (one arm for OPTIVF and one arm for the conventional approach) In this study, the tool will be using the patient's age and day three serum AMH and FSH levels to decide the starting dose for the patient's cycle. Tool will use the first two days of data collected (Follicular size distribution, estrogen levels) for that patient to determine the optimal dosage profile for the entire cycle for that patient with the help of the decision support tool (OPTIVF )for this intervention in the clinical trial.|t|f|f|t
33790718|NCT00223548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33790719|NCT03696251|||COHORT||CROSS_SECTIONAL|||||||
33790720|NCT05095558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010382|NCT04664868|||COHORT||PROSPECTIVE|||||||
34010383|NCT04028154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010384|NCT01563237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010385|NCT03766451|||OTHER||PROSPECTIVE|||||||
34010386|NCT04203121|RANDOMIZED|PARALLEL||TREATMENT||NONE||"arm 1 :subjects 1-5 - 9Gy in 5 daily fractions~arm 2 :subjects 6-10 - 5.4Gy in 3 daily fractions"||||
34010387|NCT00635518|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Study Withdrawn||||
34010388|NCT03349359|||COHORT||RETROSPECTIVE|||||||
33707164|NCT03670888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707165|NCT03052491|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label field trial without a placebo.||||
33707166|NCT04713215|||CASE_ONLY||RETROSPECTIVE|||||||
33707167|NCT04850521|||COHORT||PROSPECTIVE|||||||
33707168|NCT05195580|||COHORT||PROSPECTIVE|||||||
33707169|NCT02780375|||COHORT||PROSPECTIVE|||||||
33790721|NCT05192863|||COHORT||PROSPECTIVE|||||||
33790722|NCT03244436|||OTHER||RETROSPECTIVE|||||||
33790723|NCT05815992|||OTHER||PROSPECTIVE|||||||
33790724|NCT03245541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010389|NCT05270928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010390|NCT03392675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Using a stratified and blocked randomization scheme.||t|f|f|f
34010391|NCT05349747|||CASE_ONLY||OTHER|||||||
33707170|NCT01893632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33707171|NCT00030290||||TREATMENT||||||||
33707172|NCT01864655|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33707173|NCT03441308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707174|NCT02792881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707175|NCT01961193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707176|NCT04107610|NA|SINGLE_GROUP||OTHER||NONE||||||
34010392|NCT06363630|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010393|NCT01077817|||COHORT||RETROSPECTIVE|||||||
34010394|NCT05592353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010395|NCT06440187|NA|SINGLE_GROUP||TREATMENT||NONE||gemcitabine + nivolumab||||
34010396|NCT01385826|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34010397|NCT03702049|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010398|NCT00904748|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34010399|NCT03446352|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010400|NCT05827484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010401|NCT02841748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010402|NCT01002794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010403|NCT04452279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010404|NCT00363155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34010405|NCT01913379|RANDOMIZED|PARALLEL||||NONE||||||
34010406|NCT00147160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010407|NCT05342649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010408|NCT04625075|||CASE_CONTROL||RETROSPECTIVE|||||||
34010409|NCT06616454|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study was planned as a randomized controlled parallel design study in 60 adolescents with obesity (BMI% ≥ 95th percentile) aged 12-18 years (between puberty stage: 5) who were followed at Erciyes University Mustafa Eraslan and Fevzi Mercan Children's Hospital. Patients will be randomized to one of two treatment groups for a 12-week intervention.~Group 1: Intervention group - Time-restricted feeding - Ad libitum feeding between 10:00-18:00 hours~Group 2: Control group - Calorie-restricted feeding - Nutrition plan prepared in line with the principles of the Mediterranean Diet without time restrictions"||||
34010410|NCT01158352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010411|NCT00717496|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34010412|NCT02227459|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010413|NCT02792348|||COHORT||PROSPECTIVE|||||||
34010414|NCT01373060|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34010415|NCT06357923|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010416|NCT01647503|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34010417|NCT06188052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All procedures will be performed by the same team, all of whom will be blind to the group assignment (except for the resident who will prepare the drug formula whether intravenous or the topical irrigation and will be responsible for randomization and drug masking using closed envelope randomization)||f|t|f|t
33707177|NCT03408483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this randomized controlled study we aim to compare QLB (intervention) with control (no intervention) group in patients undergoing THA with regard to the VAS pain scores (at PACU arrival \& dischage,12, 24 \& 36 hours), duration of analgesia, time to first opioid medication, physical therapy evaluations, time to discharge, and surgeon and patient satisfaction scores.|t|f|t|f
33707178|NCT00934492|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33707179|NCT02087397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707180|NCT00560781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707181|NCT06052085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707182|NCT00631995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707183|NCT01340612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707184|NCT00851370|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33707185|NCT02983344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707186|NCT02658903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707187|NCT01319890|||CASE_ONLY||PROSPECTIVE|||||||
33707188|NCT01364649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790725|NCT01586299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790726|NCT05929911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790727|NCT00972504|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33790728|NCT05376930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707189|NCT03821649|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33707190|NCT00773656|||CASE_ONLY||CROSS_SECTIONAL|||||||
33707191|NCT05307068|||CASE_CONTROL||PROSPECTIVE|||||||
33707192|NCT03298815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707193|NCT02787096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707194|NCT04482374|||COHORT||PROSPECTIVE|||||||
33707195|NCT01311479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707196|NCT01405456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790729|NCT04586712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010418|NCT05553782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010419|NCT04669548|||CASE_ONLY||PROSPECTIVE|||||||
33790730|NCT00195975|||CASE_CONTROL||PROSPECTIVE|||||||
33790731|NCT00572000|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33790732|NCT03597841|||COHORT||PROSPECTIVE|||||||
33790733|NCT02918786|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790734|NCT00434018|RANDOMIZED|PARALLEL||||NONE||||||
33790735|NCT05600946|||COHORT||PROSPECTIVE|||||||
33790736|NCT01110850|||COHORT||PROSPECTIVE|||||||
33790737|NCT01838824|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33790738|NCT04178291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790739|NCT03639324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will start on dose level 1 of venetoclax in combination with rituximab and idelalisib, then escalate or de-escalate (if lower dose is available) based upon the estimated probabilities of toxicity from an extension of the continual reassessment method for 2 agents.||||
33790740|NCT01709266|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33790741|NCT00325858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33790742|NCT01018524|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33790743|NCT00018772|||||PROSPECTIVE|||||||
33790744|NCT00480519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33790745|NCT00802490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790746|NCT05305235|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will not be masked to their study conditions, as branding is visible in both RISE Guide and Breathe2Relax. Moreover, the UNC Research Coordinators will not be masked to condition, as they will be responsible for tracking RISE Guide progress and managing participant payments. The Principal Investigator, Biostatistician, Site Principal Investigators, Site Research Associates, and anyone involved in data analysis will remain masked to condition until data analysis is complete; masking will be maintained through reduced data viewing privileges in REDCap.|Randomization tables will be generated by the study Biostatistician and uploaded into the study REDCap database by a UNC Research Coordinator prior to launching data collection. Participants are randomized (1:1) to receive either the RISE Guide (experimental) condition or Breathe2Relax (control) condition after completing their 1-week survey. The list of assignments will be stored securely in REDCap.|f|t|t|t
33790747|NCT04619303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790748|NCT06477302|||COHORT||PROSPECTIVE|||||||
33932093|NCT05984628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The efficacy evaluation component is conducted in a blinded manner, meaning that the assessors of efficacy outcomes are composed of plastic surgeons who are not members of the research team, have not participated in the intervention, and are unaware of the group allocation of the patients.||f|f|f|t
33932094|NCT04282889|||COHORT||PROSPECTIVE|||||||
33932095|NCT05841953|NA|SINGLE_GROUP||OTHER||NONE||||||
33932096|NCT01116310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932097|NCT03006926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010420|NCT06415214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010421|NCT03804164|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010422|NCT00132054||||TREATMENT||||||||
34010423|NCT04855448|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010424|NCT00980889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010425|NCT06617442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, open label|f|f|f|t
33790749|NCT02787694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790750|NCT05505279|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|The patient is sedated and the investigators are blinded for the randomization. Only the care provider is aware of the randomisation.||t|f|t|t
34010426|NCT04924374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010427|NCT03804788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"PI Miller will be blind to participant assignment because the project manager will inform study therapists of participant assignment to conditions. PI Miller and study therapists will be blinded to assessment outcomes, and assessment RAs will be blinded to participant condition. All participants will be told that they are receiving treatment for insomnia in order to blind them to condition assignment (sleep hygiene will be described as brief insomnia treatment, and CBT-I will be described as the most intense treatment)."|Subjects will be randomized to receive sleep hygiene or to participate in sessions of individual Cognitive Behavioral Therapy for Insomnia (CBT-I).|t|f|f|t
33790751|NCT03615248|NA|SINGLE_GROUP||OTHER||NONE||||||
33790752|NCT02464956|||COHORT||PROSPECTIVE|||||||
33790753|NCT04599582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790754|NCT02674750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790755|NCT00046436|||||PROSPECTIVE|||||||
33790756|NCT04757103|||COHORT||RETROSPECTIVE|||||||
33790757|NCT01123083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790758|NCT06374784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932098|NCT01816542|NA|SINGLE_GROUP||SCREENING||NONE||||||
33932099|NCT01235507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932100|NCT04984928|||CASE_ONLY||RETROSPECTIVE|||||||
33932101|NCT04883697|||CASE_CONTROL||RETROSPECTIVE|||||||
33932102|NCT00441012|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33932103|NCT04067011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932104|NCT00300612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932105|NCT03623022|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The pharmacy will in charge of the randomization key, all others are blinded.|Subjects will undergo an exposure to inhaled endotoxin in a crossover fashion with normal saline inhalation.|t|t|t|t
33932106|NCT00052832||||TREATMENT||NONE||||||
33932107|NCT04635345|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932108|NCT05740891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707197|NCT05907876|||CASE_ONLY||PROSPECTIVE|||||||
33707198|NCT01774968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932109|NCT02152540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33932110|NCT06279975|||CASE_ONLY||PROSPECTIVE|||||||
33932111|NCT00410345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932112|NCT03713151|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study with a pre-post comparison||||
33932113|NCT05284656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932114|NCT05208450|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Stepped-wedge cluster RCT|f|f|f|t
33932115|NCT06338852|||OTHER||RETROSPECTIVE|||||||
33932116|NCT04348786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094480|NCT04919343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707199|NCT06505902|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Matched case-control study||||
33932117|NCT01481207|||COHORT||PROSPECTIVE|||||||
33707200|NCT02912117|||CASE_ONLY||PROSPECTIVE|||||||
33932118|NCT02977039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932119|NCT06213415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707201|NCT00033020|RANDOMIZED|||TREATMENT||||||||
33932120|NCT06246344|||COHORT||PROSPECTIVE|||||||
33707202|NCT00133328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932121|NCT03562520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707203|NCT05332665|||CASE_CROSSOVER||PROSPECTIVE|||||||
33707204|NCT04662125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|anesthetist not sharing in the study will assess patient|Analgesic management of post dural puncture headache: oral prednisolone vs oral pregabalin|t|f|f|t
33707205|NCT01517711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707206|NCT01628575|||COHORT||RETROSPECTIVE|||||||
33707207|NCT03673215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707208|NCT00115102|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33932122|NCT02823613|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|open label|||||
33932123|NCT03217318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33932124|NCT01890928|||COHORT||PROSPECTIVE|||||||
33932125|NCT00893828|||COHORT||PROSPECTIVE|||||||
33932126|NCT05153564|NA|SEQUENTIAL||TREATMENT||NONE||||||
33707209|NCT02279563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707210|NCT01807975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707211|NCT06556537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will only have codes but in the database but will not know which code corresponds to which group||f|f|f|t
33707212|NCT00009997||||TREATMENT||||||||
33932127|NCT06000215|||CASE_CONTROL||RETROSPECTIVE|||||||
33932128|NCT00513370|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932129|NCT02708004|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33932130|NCT03933072|NA|SINGLE_GROUP||TREATMENT||NONE||interventional study, parallel assessment, open label, non-randomized, safety-efficacy study; sponsored clinical trial;||||
33932131|NCT00744991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932132|NCT02277236|||COHORT||PROSPECTIVE|||||||
33932133|NCT00839436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932134|NCT04288297|||COHORT||RETROSPECTIVE|||||||
33932135|NCT04104841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932136|NCT04429074|||CASE_CONTROL||RETROSPECTIVE|||||||
33932137|NCT02724111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33932138|NCT03672552|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants may identify with the study receiving more oral care than previously but not know if they are in the intervention or control group. Clinicians performing swallowing and oral health assessments will not know which participants are randomly assigned to groups. Nursing staff will be performing daily care on all participants as specified in daily nursing protocols and may have more oral care but may not identify whether a participant is in the intervention or control group except some staff will be adding supervised brushing before plain (thin) water and between mealtimes.|All study participants will have assessments for swallowing and oral hygiene. The intervention group will have a dental hygiene cleaning and supervised tooth brushing before taking plain, thin (unmodified) water and between meals. The control group will continue with standard oral care and the agreed upon diet texture and fluid modifications.|t|f|f|f
33932139|NCT05942170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010428|NCT02166034|RANDOMIZED|PARALLEL||||NONE||||||
34010429|NCT04211519|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34010430|NCT02883517|||COHORT||PROSPECTIVE|||||||
34010431|NCT03399994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The members of the Event Adjudication Committee will be blinded to the patient assignment. All medical records, source documentation and event information collected for the adjudication process will be blinded to treatment assignment|Randomized multi-centre controlled clinical trial|f|f|f|t
34010432|NCT00882206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094481|NCT00380523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094482|NCT01257542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094483|NCT03017261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094484|NCT00534651|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34094485|NCT02350205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094486|NCT00540267|||CASE_CONTROL|||||||||
34094487|NCT05910398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094488|NCT01104012|||COHORT||CROSS_SECTIONAL|||||||
34094489|NCT03402087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094490|NCT00584623|||CASE_ONLY||CROSS_SECTIONAL|||||||
34094491|NCT03688737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded study. Blinding to the patient will be ensured by masking the instruments during the follow up. The patient will be informed of the steps of the follow up (as mentioned in the consent form) without getting into details of the method of follow up.|Participants will be randomly assigned to either control or study group in the ratio of 1:1 using random number table.|t|f|f|f
34094492|NCT05565547|||COHORT||PROSPECTIVE|||||||
34094493|NCT01447472|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34094494|NCT01501513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094495|NCT03632330|||OTHER||OTHER|||||||
34094496|NCT02451475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707213|NCT01702805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707214|NCT00005571||||TREATMENT||||||||
33707215|NCT01433705|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Subjects will have a PET scan after IV administration of a radio-labelled tracer, Rb-82 and N-13 or injection of F-18 FDG||||
33707216|NCT05450952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707217|NCT01651039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707218|NCT04029831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33707219|NCT01939652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094497|NCT01428128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707220|NCT04931407|NA|SINGLE_GROUP||OTHER||NONE||||||
33707221|NCT04505462|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Laboratory technicians who assess the study outcomes will be masked|A randomized, active-controlled trial with cross-over design|f|f|f|t
33707222|NCT01080001|||COHORT||PROSPECTIVE|||||||
33707223|NCT02126020|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707224|NCT01146418|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33707225|NCT03035370|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33707226|NCT04874298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled experimental study to determine the effect of ginger and peppermint after thyroid surgery on postoperative nausea and vomiting||||
33707227|NCT06105229|||OTHER||CROSS_SECTIONAL|||||||
33707228|NCT05719532|||COHORT||PROSPECTIVE|||||||
33707229|NCT04179708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707230|NCT03196102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707231|NCT03218904|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707232|NCT03543475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33707233|NCT02456441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707234|NCT06022939|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33707235|NCT05517915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor was kept blind to the allocation of participants.|Two group pretest-posttest parallel design.|f|f|f|t
33707236|NCT02048605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707237|NCT03461913|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707238|NCT05658120|||COHORT||RETROSPECTIVE|||||||
33707239|NCT02531204|RANDOMIZED|CROSSOVER||||NONE||||||
33707240|NCT00935363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33707241|NCT01412515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707242|NCT03266536|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33707243|NCT06394817|||COHORT||PROSPECTIVE|||||||
33707244|NCT01132430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707245|NCT00171353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707246|NCT05129215|||COHORT||CROSS_SECTIONAL|||||||
33932140|NCT04118062|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"To meet our objectives, the research team has developed a cross-sectional and mixed exploratory research according to three successive steps :~Step 1: Questionnaires and semi-structured individual interviews will : (a) to identify patients' needs and (b) to build the initial contents of the tool, items and issues. Four patients' populations will be recruited in this step : metastatic uveal melanoma, triple negative breast cancer, luminal B breast cancer, and pediatric cancer. This step will be conducted in parallel with these populations.~Step 2 : Focus groups : to evaluate the acceptability and applicability of the tool in this clinical context with expert patients, researchers and clinicians.~Step 3 : The DELPHI consensus method : to validate the contents of the booklet for patients with expert patients, researchers and clinicians."||||
33932141|NCT02705391|||CASE_ONLY||PROSPECTIVE|||||||
33932142|NCT03491280|||COHORT||OTHER|||||||
33932143|NCT00096551||||TREATMENT||||||||
33932144|NCT01455155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932145|NCT01473355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932146|NCT05942677|||COHORT||PROSPECTIVE|||||||
33932147|NCT03426449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932148|NCT02831283|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932149|NCT01921283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33932150|NCT06165718|||COHORT||PROSPECTIVE|||||||
33932151|NCT06135454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932152|NCT04928313|||CASE_ONLY||PROSPECTIVE|||||||
33932153|NCT04640753|||OTHER||OTHER|||||||
34010433|NCT05185258|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|As no blinding or randomization is instituted the investigator and sponsor will know the patient number and treatment. Some aspects of the analysis will be performed blinded were possible.|MEMPSOLAR is a phase 4, single-center, open-label, single-arm, self-controlled, split-body, interventional, vehicle-controlled, prospective cohort study evaluating the efficacy of Enstilar® foam in combination with NB-UVB in changing the number and/or type of TRM-cells in the skin in participants with moderate to severe psoriasis.||||
34010434|NCT05975177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a split-mouth study. STERIFY GEL will be administered into the periodontal pockets of one or two segments of patients undergoing whole-mouth extended SRP, with the contralateral segments serving as controls (split-mouth), in a single session.|t|f|f|f
34010435|NCT05983666|||OTHER||PROSPECTIVE|||||||
34010436|NCT01258101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010437|NCT02238561|||COHORT||PROSPECTIVE|||||||
34010438|NCT00920088|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34010439|NCT04734834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A double-blind placebo-controlled investigation in 150 subjects,|"A double-blind placebo-controlled investigation to evaluate the efficacy of Prodovite® VMP35 in Boosting Athletic Performance in Athletes"|t|t|t|t
34010440|NCT03297372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010441|NCT04661826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010442|NCT02332213|||COHORT||PROSPECTIVE|||||||
34010443|NCT02323165|||OTHER||PROSPECTIVE|||||||
34010444|NCT03291041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010445|NCT05724446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34010446|NCT05281978|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34010447|NCT01371084|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34010448|NCT00183586|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010449|NCT04514055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010450|NCT02215148|||COHORT||PROSPECTIVE|||||||
34010451|NCT06403072|||COHORT||PROSPECTIVE|||||||
34010452|NCT04206228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010453|NCT01884688|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010454|NCT05333224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34094498|NCT02298283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707247|NCT03699605|RANDOMIZED|PARALLEL||TREATMENT||NONE||The two groups were included for speech therapy. For any given subject, aphasia severity evaluations were completed on the same day.includes patients that are 40+ years old, and have three months of post stroke with diagnosis of chronic Broca's Aphasias, each patient received treatment for 4 months that includes 04 VESMP sessions per week with each session being 30-45 minutes long. The measurement will be taken at 0 week (baseline) after 16 weeks.||||
33790759|NCT04178941|NA|SINGLE_GROUP||OTHER||NONE||||||
33707248|NCT04180228|||COHORT||CROSS_SECTIONAL|||||||
33707249|NCT05036824|||CASE_ONLY||RETROSPECTIVE|||||||
33707250|NCT03024060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707251|NCT04244682|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707252|NCT05175053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707253|NCT04561466|NA|SINGLE_GROUP||TREATMENT||NONE||open||||
33790760|NCT04213534|||COHORT||PROSPECTIVE|||||||
33707254|NCT03773692|NA|SINGLE_GROUP||PREVENTION||NONE|Participants were aware of the phase of the study they were in.|Each individual will take part in the study for three phases, each with a duration of one month. The first month will involve collecting baseline PA levels. The second and third months of the study will provide the participants with passive PA level feedback and just-in-time persuasive feedback about their PA levels, respectively.||||
33707255|NCT04850937|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"esketamine 10ml (5mg/ml) and normal saline 10ml were respectively set as drug A or drug B.~Without the knowledge of the experimenter, the predetermined dose of drug A or B will be given to the experimenter before induction of anesthesia, with 0.05 mL /kg for each patient.~After all samples are collected, the third party will announce the grouping and medication."|180 patients will be divided into two groups according to the random number table method: control group (normal saline group),treatment group (esketamine group), 120 cases in each group.|t|f|t|f
33707256|NCT05494931|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33707257|NCT02981121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707258|NCT02959723|||COHORT||PROSPECTIVE|||||||
33707259|NCT05195671|||OTHER||RETROSPECTIVE|||||||
33707260|NCT02677532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707261|NCT06081868|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33707262|NCT03290092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707263|NCT04123314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707264|NCT05016999|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|"Each volunteer is assigned a participant number that is associated with the pot number that contains the product that the volunteer must take.~The pot number is the same as the participant number. The pot does not indicate what product it is carrying."||t|t|f|t
33707265|NCT03246893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707266|NCT04614220|||CASE_ONLY||PROSPECTIVE|||||||
33707267|NCT06220565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33707268|NCT06133205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking patients and statistician|two groups, randomized, pre-post intervention study|t|f|f|f
33790761|NCT03321539|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Cancer Center of Guangzhou Medical University~2. The Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital~3. The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital"||||
33790762|NCT02771938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790763|NCT00922675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932154|NCT04673240|||COHORT||PROSPECTIVE|||||||
33932155|NCT04440462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932156|NCT00902057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932157|NCT00004695|RANDOMIZED|||TREATMENT||NONE||||||
33932158|NCT05846269|||COHORT||PROSPECTIVE|||||||
33932159|NCT04655846|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33932160|NCT02622048|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33932161|NCT00559013|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932162|NCT02131389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932163|NCT01789749|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were blinded to the treatment allocation. The endoscopists performing the index and surveillance procedures were not blinded to the treatment.||t|f|f|f
33932164|NCT03144830|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33932165|NCT04530968|||COHORT||PROSPECTIVE|||||||
33932166|NCT00741104|||COHORT||PROSPECTIVE|||||||
33932167|NCT00606294|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932168|NCT04520919|||CASE_ONLY||PROSPECTIVE|||||||
33932169|NCT03809156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932170|NCT05124262|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomized controlled trial with direct or delayed treatment start||||
34010455|NCT05298787|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Each cohort will include 8 subjects randomized to receive either RLS-0071 (6 subjects) or placebo (2 subjects). Up to 7 cohorts (4 single-ascending dose \[SAD\] and 3 multiple-ascending dose \[MAD\]) enrolling up to 56 subjects are planned for the study. Subjects enrolled in a SAD cohort will receive a single infusion of RLS-0071. Subjects enrolled in a MAD cohort will receive a RLS-0071 infusion every (q) 8 hours for a total of 9 doses, with the ninth infusion occurring in the morning on Day 4. Dose escalation will depend on the Safety Review Committee (SRC) review of available blinded safety and PK data through the observation period of the previous cohort (ie, 48 hours after the last dose of study intervention).|t|t|t|t
34010456|NCT01541514|||COHORT||PROSPECTIVE|||||||
34010457|NCT03581188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010458|NCT02970552|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34010459|NCT04421092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010460|NCT00588328|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010461|NCT03405376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010462|NCT04217655|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34010463|NCT01426737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010464|NCT03009487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010465|NCT00206102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010466|NCT03658473|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34010467|NCT01096979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010468|NCT00616044|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34010469|NCT05857462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010470|NCT03469817|NON_RANDOMIZED|PARALLEL||OTHER||NONE||1 control group who have had been implanted with a Trident cup and have already had MRIs taken at their one year post-operative visit. This group's MRI's will be compared with MRI's from Tridend II patients who have had MRI's at 1 year post-operative visit.||||
34010471|NCT06290219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707269|NCT05184985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind, randomized, sham-controlled trial parallel arm study using TrueRelief as the experimental treatment and a TrueRelief device with sham capabilities as a placebo.|t|t|t|f
33707270|NCT01617018|||COHORT||PROSPECTIVE|||||||
33707271|NCT05022082|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|The researchers (are nurses) have roles of care provider and also investigator.||f|t|t|f
33707272|NCT05223244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigators, and outcomes assessors were blinded to treatment patients received|At each of the six weekly treatment visits, bladder capacity was determined, followed by the intravesical treatment of either DMSO or BTH.|t|f|t|t
33790764|NCT00877422|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33790765|NCT01910636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790766|NCT01007344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790767|NCT02178917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790768|NCT03329391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33790769|NCT03042520|||COHORT||PROSPECTIVE|||||||
34010472|NCT02170350|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010473|NCT04049916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blind randomised controlled trial. The treating physician and staff involved with assessing all laboratory outcomes of the study are blinded, but no placebo will be used. The study pharmacist will be unblinded and responsible for randomisation and treatment administration.||f|f|f|t
33790770|NCT06405867|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This was a single-center, with block randomisation \[1:1\], open-label, parallel group study.||||
33790771|NCT02919176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33790772|NCT00919763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790773|NCT00127179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010474|NCT03504761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790774|NCT00923676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790775|NCT05338996|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33790776|NCT01844544|||CASE_ONLY||PROSPECTIVE|||||||
33790777|NCT02364050|||OTHER||PROSPECTIVE|||||||
33932171|NCT04634019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This will be a two-arm parallel trial - control vs intervention.||||
33932172|NCT03665207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932173|NCT05837000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932174|NCT00474773|||COHORT||PROSPECTIVE|||||||
33932175|NCT02143141|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33932176|NCT04996524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932177|NCT00772811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932178|NCT01589692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010475|NCT05813379|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010476|NCT03447886|||OTHER||OTHER|||||||
33932179|NCT04903886|||COHORT||RETROSPECTIVE|||||||
33932180|NCT00649610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010477|NCT00563017|NON_RANDOMIZED|||TREATMENT||||||||
34010478|NCT00335335|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010479|NCT04814784|||CASE_CONTROL||RETROSPECTIVE|||||||
34010480|NCT04113824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blind, randomized controlled trial|f|f|t|t
34010481|NCT04099212|||CASE_ONLY||PROSPECTIVE|||||||
34010482|NCT03612739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This open-label Phase I study aims to define the recommended dose for further clinical development the NKR-2 treatment administered concurrently with AZA in treatment-naïve AML/MDS patients not candidates for intensive chemotherapy or hematopoietic stem cell transplantation.~This Phase I study is divided into three sequential cohorts evaluating three different dose-levels of NKR-2 (1x108, 3x108 and 1x109 NKR-2 per injection) using a 3+3 design evaluate. Further patients will be enrolled at the RecD to reach 9 evaluable patients in total at the RecD."||||
34010483|NCT03845413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit. The intervention arm consisted of 12-home visits by the Community Health Worker||||
34010484|NCT03964636|||CASE_CONTROL||PROSPECTIVE|||||||
34010485|NCT03024931|||COHORT||PROSPECTIVE|||||||
34010486|NCT01453621|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010487|NCT04886557|||COHORT||RETROSPECTIVE|||||||
34010488|NCT01629394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010489|NCT06614660|||COHORT||PROSPECTIVE|||||||
34010490|NCT04064736|||OTHER||CROSS_SECTIONAL|||||||
34010491|NCT00554320|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34010492|NCT05357859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A pharmacist will prepare the dosing of solubilized vitamin D3 and also identical appearance of placebo according to a randomized block schedule. Patients and researchers were blinded to treatment assignment.|double blinded RCT|t|t|f|f
34010493|NCT04067388|||COHORT||PROSPECTIVE|||||||
34010494|NCT04882982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010495|NCT00970255|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34010496|NCT04223778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010497|NCT03301818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010498|NCT03736187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two equal groups,140 women in each group|2 Groups of obese women under elective cesarean section|t|f|f|f
34010499|NCT06468748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790778|NCT04630457|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study is a Prospective Randomized crossover study. After randomization, the study is conducted by dividing group A (order of existing prosthesis-Meridium prosthesis-RoFT prosthesis) and B (order of existing prosthesis-RoFT prosthesis-Meridium prosthesis).||||
33790779|NCT01671241|RANDOMIZED|||PREVENTION||NONE||||||
33932181|NCT04420208|RANDOMIZED|PARALLEL||SCREENING||SINGLE|During the Pap test, there is a privacy curtain separating participants from the operators. Participants receiving the modified Pap test do not realize what is going on during the 15-second step because they are behind the privacy curtain. The operators performing the procedure are not informed whether to intervene or not by the assistants until a specimen is prepared for cervical cytology. The delayed disclosure of the group allocation until this step ensures the operators standardizing the insertion and opening phases of the Pap test.|Subjects are divided into two groups, one with traditional Pap smear and one with Pap smear adding a non-painful procedure at the end. The investigators will compare the real-time pain score and recalled pain to check whether the theory works.|t|f|f|f
33707273|NCT06505564|NA|SINGLE_GROUP||TREATMENT||NONE||This study aims to evaluate the efficacy of AVATAR therapy in patients with schizophrenia spectrum disorder using a single-group pre-post design with a waiting list control period. Initially, all patients will undergo a 12-week waiting list control period without treatment. Following this phase, participants will receive AVATAR therapy consisting of 7 sessions over 12 weeks. Comprehensive assessments will be conducted before and at the end of the waiting list period, with post-therapy assessments following the intervention. Evaluations by caregivers and therapists will also be included to provide comprehensive insights into the therapy's effectiveness and overall impact.||||
33707274|NCT04245852|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomly assigned to one of two groups: control group or experimental group. The control group will receive standard PT care and the experimental group will receive standard physical therapy care in addition to being provided a strength education video.||||
33707275|NCT03210246|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33707276|NCT05680883|||CASE_ONLY||CROSS_SECTIONAL|||||||
33707277|NCT03193203|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33707278|NCT03601975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33707279|NCT01723709|||COHORT||PROSPECTIVE|||||||
33707280|NCT03715530|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33707281|NCT06204601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Block randomization|Trial model with pretest posttest control group|t|f|f|f
33707282|NCT00256750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707283|NCT00925093|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707284|NCT06313775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Simple random sampling|f|f|f|t
33707285|NCT02194244|RANDOMIZED|CROSSOVER||||NONE||||||
33932182|NCT01477073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932183|NCT05711719|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind, placebo controlled trial|t|t|t|t
33932184|NCT04324268|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Subcutaneous cohorts will be assigned in a double-blind, randomized, placebo-controlled manner. IV cohorts will be open-label.||t|t|t|t
33932185|NCT02912962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932186|NCT02288442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932187|NCT01253967|||COHORT||PROSPECTIVE|||||||
33932188|NCT02365805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932189|NCT01619527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932190|NCT01306604|||COHORT||PROSPECTIVE|||||||
33932191|NCT00919568|||CASE_CONTROL||PROSPECTIVE|||||||
33932192|NCT03357211|||CASE_ONLY||PROSPECTIVE|||||||
33932193|NCT04031924|||CASE_CONTROL||PROSPECTIVE|||||||
33932194|NCT02945943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932195|NCT01720472|||COHORT||PROSPECTIVE|||||||
33932196|NCT04247321|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33932197|NCT04518592|||CASE_CONTROL||PROSPECTIVE|||||||
33932198|NCT06005038|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33932199|NCT04985513|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33932200|NCT01611311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932201|NCT01733524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932202|NCT01407289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932203|NCT00492518|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33932204|NCT04063865|RANDOMIZED|PARALLEL||PREVENTION||NONE||Tacrolimus as maintenance immunosuppression||||
33932205|NCT01210976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932206|NCT01402323|RANDOMIZED|||TREATMENT||SINGLE|||f|f|t|f
33932207|NCT01492816|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932208|NCT03596255|||COHORT||CROSS_SECTIONAL|||||||
33932209|NCT02796079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932210|NCT03375762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33932211|NCT04400227|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932212|NCT02930811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932213|NCT02359136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33932214|NCT00407641|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33932215|NCT06419790|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010500|NCT03746002|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, active control pilot study||||
34010501|NCT02588547|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34010502|NCT01865929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010503|NCT04660955|||COHORT||CROSS_SECTIONAL|||||||
34010504|NCT03382249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010505|NCT04486495|||COHORT||PROSPECTIVE|||||||
34010506|NCT00690482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010507|NCT03964519|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34010508|NCT02453633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34010509|NCT00427674|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010510|NCT05519657|||CASE_CONTROL||PROSPECTIVE|||||||
34010511|NCT06617702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33707286|NCT02100514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33707287|NCT05607901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|• A randomized, controlled, and parallel study will comprise 100 patients with AD|t|f|t|f
33707288|NCT02098967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010512|NCT01058551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707289|NCT05712759|||OTHER||PROSPECTIVE|||||||
34010513|NCT06617052|||COHORT||PROSPECTIVE|||||||
33707290|NCT06505044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind masking the patient was not be informed about the training group or the other group; they will be evaluated and trained at different places and times.||t|f|t|f
33707291|NCT04563351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707292|NCT04603456|RANDOMIZED|PARALLEL||OTHER||NONE||Group I included 15 cases who received probiotics only. Group II included 15 children who received SLIT. Group III included 15 children who received probiotics and SLIT.||||
34010514|NCT00004810|RANDOMIZED|||TREATMENT||||||||
33707293|NCT06312345|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33707294|NCT05728905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessing physiotherapist did not know to which group the patient belongs|A randomized single blind clinical trial|f|f|f|t
33707295|NCT02157987|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34010515|NCT04685694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010516|NCT02562417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010517|NCT04130178|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34010518|NCT00213057|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34010519|NCT06353737|||OTHER||PROSPECTIVE|||||||
34010520|NCT04963387|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, parallel group randomized controlled trial||||
34010521|NCT06322459|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Employing a Cluster randomized controlled experiment design, the experimental and control groups were randomly assigned to two different schools. Students participated in the Sport Education Model (experimental group) and traditional teaching (control group).|t|f|t|t
34010522|NCT06364332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research team will be kept blind to randomization. A safety procedure is drawn up in which a senior researcher is appointed who will be unblinded if absolutely necessary. Principally, this will not be needed, since the study psychologists are independently alerted when a subject wants to get in touch.|Participants are randomized to the intervention or the control group using block randomization with varying block sizes (block sizes vary from 2 to 16). The distribution key will be 1:1. The randomization schedule is computer generated by a researcher who will not be part of the analysing researchers.|f|f|t|f
34010523|NCT02070926|||COHORT||PROSPECTIVE|||||||
34010524|NCT01397617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707296|NCT04765956|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm clinical trial||||
33707297|NCT03187275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33707298|NCT04590222|||CASE_CONTROL||PROSPECTIVE|||||||
33707299|NCT02049424|||COHORT||RETROSPECTIVE|||||||
33707300|NCT03484091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind, placebo controlled RCT|t|t|t|t
33707301|NCT04437186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707302|NCT00288054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707303|NCT05045014|||CASE_CONTROL||PROSPECTIVE|||||||
33932216|NCT03216395|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients are randomized in a 1:1 ratio to receive; endoscopic treatment using OTSC or standard therapies Stratified randomization according to size of ulcers and non-ulcer lesions~1. size smaller than10mm in diameter~2. size equal to 10mm and less than 20mm in diameter~3. size equal or greater than 20mm in diameter~4. non-ulcer lesions"||||
33932217|NCT00707486|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932218|NCT00728728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33707304|NCT01550289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33707305|NCT04389853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Study comparing two standard of care treatments.|f|f|f|t
33932219|NCT01060124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932220|NCT02157662|||CASE_CONTROL||PROSPECTIVE|||||||
33932221|NCT06139939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932222|NCT06387004|||COHORT||PROSPECTIVE|||||||
33932223|NCT02620124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932224|NCT06353867|NA|SINGLE_GROUP||OTHER||NONE||||||
33932225|NCT00284336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932226|NCT00943410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932227|NCT01229410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33932228|NCT05829811|||CASE_CONTROL||PROSPECTIVE|||||||
33932229|NCT06156462|||COHORT||PROSPECTIVE|||||||
34010525|NCT00604201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010526|NCT03176368|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010527|NCT05032326|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34010528|NCT05752916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, open label, blinded-endpoint (PROBE)|f|f|f|t
34010529|NCT00999063|||||PROSPECTIVE|||||||
33707306|NCT04103658|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Patients will be randomly assigned to the group of excision without or with near-infrared heat. Both the patient and investigator will be aware of the group allocation prior to the definitive excision.|||||
33707307|NCT03268369|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33707308|NCT00999089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707309|NCT05160493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Parallel Assignment|t|t|t|t
33932230|NCT06263790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932231|NCT04738240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932232|NCT05875012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010530|NCT00036647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34010531|NCT02326974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010532|NCT01368627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010533|NCT03399617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010534|NCT02485821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010535|NCT00465049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707310|NCT00647881|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33707311|NCT05191771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707312|NCT02527005|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33707313|NCT05789160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707314|NCT05999929|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707315|NCT04365296|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33707316|NCT06159660|||OTHER||PROSPECTIVE|||||||
33707317|NCT05379738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707318|NCT03078049|||COHORT||RETROSPECTIVE|||||||
33790780|NCT06331871|RANDOMIZED|PARALLEL||TREATMENT||NONE||70 patients with shoulder pain undergoing arthroscopic surgery were recruited. They were divided into two groups at random; physiotherapy protocol group (n=35) and experimental group to which the same protocol was practiced and two sessions of ultrasound-guided percutaneous nerve stimulation (US-PENS) were added (n=35).||||
33790781|NCT03404154|||COHORT||PROSPECTIVE|||||||
33790782|NCT03155490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790783|NCT01516788|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33790784|NCT04857346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33790785|NCT02309580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707319|NCT00192361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34010536|NCT01000363|||COHORT||PROSPECTIVE|||||||
33707320|NCT02140086|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790786|NCT02866214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34010537|NCT01328912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790787|NCT05241119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790788|NCT03694678|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33790789|NCT00610688|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34010538|NCT03440424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707321|NCT02059395|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33707322|NCT05789810|RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional||||
33707323|NCT06075862|||CASE_CROSSOVER||PROSPECTIVE|||||||
33707324|NCT00714441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707325|NCT01507298|||OTHER||PROSPECTIVE|||||||
33707326|NCT03292562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707327|NCT03339908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707328|NCT03931161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790790|NCT01133132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33790791|NCT03244696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33790792|NCT04683263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomly assigned, using the Excel (Microsoft) RAND function, into 2 groups: treatment group and placebo group, a topical cream with similar characteristics and aspect, without active ingredients. Allocation was concealed from the recruiter and participants.|Prospective, randomized, double-blinded and placebo-controlled clinical trial|t|t|t|f
33790793|NCT06324734|||OTHER||RETROSPECTIVE|||||||
33790794|NCT04860258|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33790795|NCT02467296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33790796|NCT05358197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790797|NCT04760119|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding is not possible due to the completely different natures of the treatments allocated.|The treatment will consist of two treatment modalities: 1) Vein bypass surgery first strategy; 2) Endovascular treatment first (drug coated balloon angioplasty) strategy||||
33707329|NCT03222336|||CASE_ONLY||RETROSPECTIVE|||||||
33707330|NCT01682109|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707331|NCT01734356||||||NONE||||||
33707332|NCT01920321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707333|NCT03721744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707334|NCT01783262|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|f|t
33707335|NCT02229370|||COHORT||PROSPECTIVE|||||||
33707336|NCT00842608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707337|NCT01965301|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33707338|NCT02872207|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33707339|NCT01617200|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707340|NCT02862171|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707341|NCT03482544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707342|NCT04229784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790798|NCT06476002|NA|SINGLE_GROUP||OTHER||NONE||||||
33790799|NCT01507948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33790800|NCT02867046|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33790801|NCT00243399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790802|NCT01714557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790803|NCT02721225|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790804|NCT03643042|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Two modalities of threshold for transfusion:~* Restrictive group: Hb \< 80g/L and Hb maintain between 80 and 100g/L~* Liberal group: Hb \< 100g/L and Hb maintain between 100 and 120g/L"||||
33790805|NCT01191463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33790806|NCT05802602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790807|NCT02619266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010539|NCT06296524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010540|NCT02025231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010541|NCT01978808|||CASE_ONLY||PROSPECTIVE|||||||
34010542|NCT01923194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010543|NCT00845052|||COHORT||PROSPECTIVE|||||||
34025275|NCT03294720|NA|SINGLE_GROUP||TREATMENT||NONE||Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.||||
34010544|NCT05511220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome will be coded by raters who are trained to 80% reliability on a coding scheme with operational definitions, and naive to treatment condition and study phase|Hierarchical modelling will be used to examine aggregated data from multiple single case experimental design (SCED) series (n = 5 per series), with participants randomized to 1 of 2 treatment conditions. Target is 4 SCED series per treatment condition, therefore N of 20 per condition. See Jaksic et al. (2018) for information on this method.|f|f|f|t
34010545|NCT04435002|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomized Controlled Clinical Trial||||
34010546|NCT03392740|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective, 1:1 randomized, double-blinded and placebo-controlled clinical trial we plan to enroll patients who are to be treated with anthracycline chemotherapy to either lisinopril or placebo group.|t|t|f|f
34010547|NCT05800145|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The objective of this study is to conduct a pilot sequential multiple assignment randomized trial (SMART) addressing food insecurity in patients with uncontrolled Hypertension (HTN) to determine the feasibility of recruitment/retention and the potential impact on blood pressure in anticipation of a larger more definitive trial.||||
34010548|NCT05188183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010549|NCT01491308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010550|NCT01470196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790808|NCT05880732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34010551|NCT02750735|||CASE_ONLY|||||||||
34010552|NCT05414084|NA|SINGLE_GROUP||SCREENING||NONE||||||
33707343|NCT03228264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is designed as a randomized, controlled, evaluator-blinded multi-center superiority trial with two parallel groups and with word finding ability as primary endpoint at the end of the intervention. Aphasia outpatients will be recruited and randomly assigned to the experimental or control group. The randomization will be stratified by the study centre (Bern, Luzern) and the severity of aphasia (mild with a raw value/T-value smaller than 5/52, severe with a raw value/T-value greater or equal to 5/52 for the Token Test). Both groups will do a four weeks intensive tablet-delivered telerehabilitation training (2 hours a day).|f|f|f|t
33790809|NCT03807557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790810|NCT05307666|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"PARTICIPANT / PROVIDER / INVESTIGATOR: Alberta Health Services identifies eligible participants, randomizes them to intervention/control, and advises providers who is in the intervention group. Investigators are unaware who the participants are. Patients themselves are unaware they are in a trial, as MinMed has a waiver of consent (given the intervention is recommended care). Participants are only told their primary care provider is participating in an initiative to minimize medications.~OUTCOME ASSESSOR: All outcomes are derived from administrative claims data, including death, reason for hospitalization, community physician diagnoses, medications dispensed, and cost of care. All diagnoses are provided during routine care and the majority will come from physicians (e.g. emergency room physicians and hospitalists / specialists) who will be unaware their patient was enrolled in a community trial that minimized medications. Adjudicators of the claims data will be fully blinded."|PROBE: Prospective Randomized (patient-level) Open-label Blinded Endpoint-evaluation|f|f|t|t
33790811|NCT02486588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33790812|NCT04666818|||OTHER||PROSPECTIVE|||||||
33790813|NCT00560014|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33707344|NCT02131207|||COHORT||PROSPECTIVE|||||||
33707345|NCT04102787|RANDOMIZED|PARALLEL||OTHER||NONE||pre and post true experimental with two groups control and experimental||||
33707346|NCT03013738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707347|NCT00066885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707348|NCT06201741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707349|NCT04158297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707350|NCT00228384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707351|NCT01178957|||COHORT||PROSPECTIVE|||||||
33707352|NCT00569881|||CASE_CONTROL||RETROSPECTIVE|||||||
33707353|NCT05776615|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||randomized controlled experimental study|f|t|f|f
33707354|NCT00199680|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707355|NCT05466656|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental, uncontrolled, before-and-after study||||
33707356|NCT01919593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707357|NCT03862222|||COHORT||PROSPECTIVE|||||||
33790814|NCT04555265|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with hepatocellular carcinoma treated by thermal ablation||||
33790815|NCT02887196|||COHORT||PROSPECTIVE|||||||
33790816|NCT06080373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33707358|NCT01944605|||COHORT||PROSPECTIVE|||||||
33707359|NCT03915821|NA|SINGLE_GROUP||SCREENING||NONE||||||
33707360|NCT02468232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790817|NCT01985906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790818|NCT04472871|||COHORT||RETROSPECTIVE|||||||
33790819|NCT06469892|||OTHER||OTHER|||||||
33790820|NCT05452980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790821|NCT03775369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790822|NCT02727764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790823|NCT05907850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be masked to which intervention they receive, active study drug or placebo.|A phase I randomized, 2 arm single blinded feasibility study|t|f|f|f
34010553|NCT03341000|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||prospective, multi-center, open-label, feasibility study||||
34010554|NCT03740620|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34010555|NCT02712437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707361|NCT02215187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707362|NCT04092582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707363|NCT03821883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707364|NCT02057731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33707365|NCT03708081|||CASE_ONLY||PROSPECTIVE|||||||
33707366|NCT01015898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707367|NCT05865262|||COHORT||PROSPECTIVE|||||||
34010556|NCT00792519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010557|NCT00165230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010558|NCT00222963|||||PROSPECTIVE|||||||
34010559|NCT03244124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010560|NCT04671537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind|Study group - Control group|t|f|f|f
34010561|NCT03077529|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34010562|NCT04892121|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34010563|NCT05693818|||COHORT||PROSPECTIVE|||||||
34010564|NCT02493205|||CASE_ONLY||PROSPECTIVE|||||||
34010565|NCT02619682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010566|NCT00152191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010567|NCT06207123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094499|NCT03554109|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment will be administered in 2 phases, a neoadjuvant phase and a postoperative phase. For the experimental arm, subjects will receive treatment in the neoadjuvant phase for six 3-week cycles (ie, 18 weeks total). For the control arm, subjects will receive neoadjuvant treatment for a total of 16 weeks.||||
34094500|NCT02882984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094501|NCT01559623|||||RETROSPECTIVE|||||||
34094502|NCT02043860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094503|NCT03267589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Part 1: single cohorts of novel agents Part 2: randomized phase 2 against standard of care.||||
34094504|NCT04064307|||CASE_ONLY||PROSPECTIVE|||||||
33707368|NCT05050539|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Trained and field-reliable staff blinded to the study condition will collect data.|An enhanced non-responder trial design will be used to determine the effectiveness (Aim 1) and incremental cost-effectiveness (Aim 3) of an adaptive implementation strategy for WISE, while examining moderators and mediators of the strategy effect (Aim 2). In this trial, sites that do not respond to low-intensity strategies will be randomized to either (a) continue receiving low-intensity strategies or (b) receive high-intensity strategies. This design will determine the effect of an adaptive implementation strategy that adds high intensity versus one that continues with low intensity among non-responder sites.|t|f|f|t
33707369|NCT00900965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707370|NCT06239766|||COHORT||PROSPECTIVE|||||||
34010568|NCT04789395|||COHORT||PROSPECTIVE|||||||
34010569|NCT00468429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34010570|NCT06159309|||COHORT||PROSPECTIVE|||||||
33707371|NCT00367900|||COHORT||PROSPECTIVE|||||||
33707372|NCT04729868|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33707373|NCT00936559|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33707374|NCT01371916|||CASE_CONTROL||PROSPECTIVE|||||||
33707375|NCT04180046|||CASE_CONTROL||PROSPECTIVE|||||||
34010571|NCT01048502|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33707376|NCT02407860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707377|NCT02129998|||COHORT||PROSPECTIVE|||||||
33707378|NCT01007266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932233|NCT00534560|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34010572|NCT03554252|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34010573|NCT03748394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010574|NCT03708159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34094505|NCT03228576|||COHORT||PROSPECTIVE|||||||
34094506|NCT05796973|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients are randomized equally into three groups: 1/3 into guided exercise group, 1/3 into guided exercise and statin-treatment group and 1/3 into non-guided exercise group||||
34094507|NCT01295892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094508|NCT02289378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094509|NCT00999206|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34094510|NCT05000437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094511|NCT05611736|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33707379|NCT04524546|||COHORT||PROSPECTIVE|||||||
33932234|NCT01615692|||COHORT||PROSPECTIVE|||||||
33932235|NCT01011595|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932236|NCT00427375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932237|NCT03597789|NA|SINGLE_GROUP||TREATMENT||NONE||All families get the evidence-based treatment, Helping the Noncompliant Child (HNC)||||
33932238|NCT01307410|||COHORT||PROSPECTIVE|||||||
33932239|NCT00000768|RANDOMIZED|||TREATMENT||||||||
33932240|NCT02454452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932241|NCT02823236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932242|NCT06031181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932243|NCT00486512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33932244|NCT00664157|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33932245|NCT05793424|||CASE_CONTROL||OTHER|||||||
33932246|NCT02545972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932247|NCT03797885|||COHORT||CROSS_SECTIONAL|||||||
33932248|NCT05184972|||OTHER||RETROSPECTIVE|||||||
33932249|NCT00591396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932250|NCT01952613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932251|NCT05468580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients are randomized in a 1:1 fashion (stratified on preoperative abdominal pain VAS, psychiatric comorbidities and gender) for either endoscopic Coeliac Artery Release (eCAR) or a sham operation.The randomization takes place in the operating room by a randomization program. Except for the surgical team, all care providers are blinded. To maintain the blinding, there will be no (substantive) contact between the members of the operating team and the patient postoperatively (or in follow up).~In the event of an emergency in a patient included in the CARoSO study envelopes will be 24/7 available to break the blind. Furthermore the study will be unblinded when the difference in effectiveness as described in the hypothesis is achieved for the primary outcome after the analyses on the 6 months outcomes (both primary and secondary) have been completed for all included subjects. This decision will be made by the Data Safety and Monotoring Board."|A nationwide randomized placebo-controlled patient and observer blinded clinical superiority trial.|t|f|t|t
33932252|NCT03426761|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Since it's a pilot study, the sample size is fixed (n = 50). The sample size were not selected based on statistical criteria. However, we would need to know what would be the detectable effect size.~∆\^2=((z_(α/2)+z_β )\^2 (σ_1\^2+σ_2\^2 ))/n"||||
34010575|NCT02713815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010576|NCT02443584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34010577|NCT03192852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|We will use a gel with no effect only in the fourth session of group 3 to match the number of sessions in relation to the other groups||t|f|t|t
34010578|NCT04596306|||CASE_CONTROL||RETROSPECTIVE|||||||
34010579|NCT00379223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010580|NCT01771315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010581|NCT03508869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010582|NCT05752292|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33707380|NCT04564937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33707381|NCT05476198|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
33707382|NCT04360629|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33932253|NCT06009861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932254|NCT06446895|||COHORT||PROSPECTIVE|||||||
33932255|NCT01977157|||||PROSPECTIVE|||||||
33932256|NCT00776191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932257|NCT03024229|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Metabolic assessment in Urine and perfusion liquids||||
34010583|NCT05681754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Operators for endodontic - periodontal treatment will be different from the assessors for the initial assessments and subsequent review appointments.~The Treatment will be masked for the patient and assessor. As the blood samples will be collected from the patients at T6 for biomarker analysis, therefore the patient can be masked about the treatment as these blood can be used for the LPRF treatment for those patient who are randomised in the LPRF group.~The statistician will also be blinded to the allocations and will only conduct the analysis in a semi-blinded way (group 1 vs group 2 vs group 3 vs group 4) without knowing the corresponding groups until the analysis is complete."||t|f|t|t
34010584|NCT04640506|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34010585|NCT04977037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|active or sham tDCS|Double-blind, randomized controlled trial|t|f|f|t
34010586|NCT03063424|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34010587|NCT00682617|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34010588|NCT01174355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010589|NCT00093002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010590|NCT02531594|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010591|NCT00444821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010592|NCT03736928|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34010593|NCT01514825|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34010594|NCT05704972|||OTHER||CROSS_SECTIONAL|||||||
34010595|NCT05686148|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|All of the outcomes results were obtained by another researcher blinded to group allocation||f|f|f|t
34010596|NCT06147531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a blinded randomized trial, with clinical personnel, patients, family members, and outcome assessors blinded to group allocation. Given that the platelets will be different temperatures (but identical in appearance), an unblinded blood bank technologist, who will not have access to the collected study data, will blind the platelets by placing them in an insulated tamper-proof container accompanied by a pair of disposable insulated gloves. The clinician(s) directly handling the product at the time of transfusion will wear the insulated gloves to prevent unblinding (simulations have shown this to be an effective strategy). The platelets will also have blinded study labels and come prepared in identical collection bags.|PLTS-1 is a multicentre, randomized, controlled, pilot trial, using a conventional, parallel group, two-armed design at 2 cardiac surgery centres in Canada.|t|t|t|t
34025276|NCT01696058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707383|NCT03194230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707384|NCT02231944||||TREATMENT||||||||
33707385|NCT02530060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025277|NCT05279313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025278|NCT01535092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025279|NCT01404923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094512|NCT00456612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094513|NCT05331937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||multi-center placebo-controlled double-blind randomized controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months|t|t|t|t
34094514|NCT05145894|||COHORT||PROSPECTIVE|||||||
34094515|NCT05330377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094516|NCT04439409|||OTHER||PROSPECTIVE|||||||
34094517|NCT00910741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094518|NCT02094235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707386|NCT02981420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707387|NCT01105728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707388|NCT06495827|||COHORT||RETROSPECTIVE|||||||
33707389|NCT03331367|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study involves four arms consisting of patients who have undergone either total cryotherapy, focal cryotherapy, Cyberknife SBRT or radical prostatectomy.||||
33707390|NCT02200211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707391|NCT01429415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707392|NCT00232973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707393|NCT06491940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707394|NCT02528396|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33707395|NCT05887414|||CASE_ONLY||PROSPECTIVE|||||||
33932258|NCT06115824|||CASE_CONTROL||RETROSPECTIVE|||||||
33932259|NCT00486889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932260|NCT02253394|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33932261|NCT01761942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932262|NCT03694067|||CASE_CONTROL||RETROSPECTIVE|||||||
34094519|NCT02474706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707396|NCT02430012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessor and data extractors were blind to the results of randomization|The study was a cluster randomized controlled trial to test the effectiveness of a smartphone-based multifaceted intervention. Sixty hospitals were randomized to the intervention group (n=30) or control group (n=30). Clinicians at intervention hospitals received multifaceted interventions (i.e., centralized training, evidenced-based checklists, and performance monitoring and feedback report) aimed at improving discharge prescription adherence, while those at control hospitals maintained routine practice.|f|f|f|t
33707397|NCT04575116|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33707398|NCT01916720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707399|NCT00530946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707400|NCT00158834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707401|NCT05759247|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707402|NCT01417442|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790824|NCT05989412|RANDOMIZED|PARALLEL||SCREENING||NONE||The investigators will randomize 1786 eligible respondents across three arms, in a 2:1:1 fashion. The three arms comprise a control arm, a screening arm with limited participant referral for treatment (after three positive test scores on Patient Health questionnaire-9 (PHQ-9) or suicidal ideation), and a screening arm with standard referral for participants with moderate-severe symptoms of major depression (single positive test score on PHQ-9 questionnaire).||||
33707403|NCT05256329|||COHORT||PROSPECTIVE|||||||
33707404|NCT05566743|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33707405|NCT05810883|||COHORT||PROSPECTIVE|||||||
33707406|NCT03591835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The radiologist who will determine endotracheal tube placement in the X-ray||f|f|t|f
33707407|NCT00580684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707408|NCT02702154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33707409|NCT03646318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo medication|Randomised controlled trial (blinded)|t|t|t|t
33707410|NCT01389635|||COHORT||RETROSPECTIVE|||||||
33707411|NCT00283400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707412|NCT04637230|||COHORT||PROSPECTIVE|||||||
33707413|NCT02042677|||COHORT||PROSPECTIVE|||||||
33707414|NCT01483755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707415|NCT04427566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707416|NCT02153034|||CASE_CONTROL||PROSPECTIVE|||||||
33707417|NCT00057278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707418|NCT05787275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707419|NCT04193098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707420|NCT02562131|||CASE_ONLY||PROSPECTIVE|||||||
33707421|NCT00745836||PARALLEL||TREATMENT||||||||
33707422|NCT01805154|||COHORT||PROSPECTIVE|||||||
33707423|NCT01600469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790825|NCT03503630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790826|NCT02885311|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33790827|NCT03080038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094520|NCT00741949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34094521|NCT05807503|||COHORT||RETROSPECTIVE|||||||
34094522|NCT06158880|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33707424|NCT04138121|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707425|NCT04673422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a randomized, prospective, 2-arm, parallel-group, double-blind, placebo-controlled superiority trial|t|t|t|f
33707426|NCT02256631|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707427|NCT04353271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded to subject and investigators|Randomized placebo verses medication clinical trial|t|t|t|t
33707428|NCT01994447|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33707429|NCT05598541|||COHORT||PROSPECTIVE|||||||
33707430|NCT01615068|||COHORT||PROSPECTIVE|||||||
33707431|NCT01754701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707432|NCT01411007|||COHORT||PROSPECTIVE|||||||
33790828|NCT04544761|||COHORT||RETROSPECTIVE|||||||
33790829|NCT01935869|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
33790830|NCT04983745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932263|NCT05844774|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label clinical trial|1 control group, 1 intervention group without cross-over||||
33932264|NCT02089867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010597|NCT03857672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators will conceal treatment group assignment from staff that conduct outcome assessments by: using a permuted blocked randomization with random block sizes, using secure email to inform the interventionist about group assignment, keeping the interventionist and outcome assessor physically separate and sound isolated in research spaces, and training staff in other day-to-day measures designed to maintain the blind. Research staff will be educated about the importance of maintaining the blinded conditions of the study and strategies to engage participants in maintaining the blinding as well (being clear about who participants contact regarding study questions, reminding participants about maintaining the secrecy of their condition at the beginning of all outcome related calls, having the therapist remind participants to keep their condition secret from staff assessing outcomes).||f|f|f|t
34010598|NCT00128934|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34094523|NCT01419925|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094524|NCT00350506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094525|NCT04987970|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094526|NCT00106561|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34094527|NCT00940459|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34094528|NCT02949427|||COHORT||PROSPECTIVE|||||||
33707433|NCT03414060|NA|SINGLE_GROUP||TREATMENT||NONE||repeated measures||||
33707434|NCT02280304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707435|NCT03725475|||COHORT||RETROSPECTIVE|||||||
33707436|NCT05454098|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707437|NCT02971254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33707438|NCT06505304|||COHORT||PROSPECTIVE|||||||
33707439|NCT04173988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010599|NCT00311350|RANDOMIZED|||||DOUBLE||||||
34010600|NCT06218745|||COHORT||RETROSPECTIVE|||||||
34010601|NCT05171764|||COHORT||PROSPECTIVE|||||||
33707440|NCT01437462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010602|NCT03116061|||COHORT||PROSPECTIVE|||||||
34010603|NCT05251506|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each group use lancet (or laser) for first 2 months, take wash out period for 1month, then use laser (or lancet) for another 2 months.|f|f|t|f
34010604|NCT03382431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094529|NCT03753477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094530|NCT02714738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094531|NCT05244837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study consists includes two groups, one is the treatment of patients with resectable lung cancer and the other is the treatment of patients with unresectable lung cancer.||||
34094532|NCT05771623|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Control group: (38 patients with hypertrophic scar) receive traditional PT for postburn scar.~Study group: (38 patients with hypertrophic scar) receive botulinum toxin type a iontophoresis plus traditional PT."||||
34094533|NCT00360854|NON_RANDOMIZED|||TREATMENT||NONE||||||
33707441|NCT04453371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33707442|NCT01658462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707443|NCT00455078|||COHORT||PROSPECTIVE|||||||
33707444|NCT02099708|||COHORT||PROSPECTIVE|||||||
33707445|NCT04805541|||CASE_ONLY||PROSPECTIVE|||||||
33707446|NCT06438458|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Blood samples are taken before and after the interventions||||
33707447|NCT05032664|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33707448|NCT03845985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned to one of two conditions: (1) Seeking Safety + Signs of Safety toolkit, or (2) assessment-only waitlist control. Randomization will occur within each study site and stratified by gender. The Biostatistician will generate a computerized random number series and place numbers in individual sealed opaque envelopes. The RC will open an envelope to randomly assign a treatment condition to the participant. Both the PI and Co-I/Outcomes Assessor will be blind to study condition. (Note: the Co-I/Outcomes Assessor will remain blind to study condition until the end of the post-treatment assessment, at which point she will administer a client satisfaction measure that will unblind the Co-I to which subjects are in the waitlist control group.)||f|f|t|t
33707449|NCT04546061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707450|NCT00361569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707451|NCT01258582|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33707452|NCT01333254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707453|NCT03112395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707454|NCT00523562|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33707455|NCT00743483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707456|NCT02614092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707457|NCT02192138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707458|NCT02746796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707459|NCT03572062|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer blind|Parallel|t|t|t|t
33707460|NCT05120778|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized clinical trial||||
33707461|NCT00826943|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33707462|NCT04966624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33707463|NCT00039975||||TREATMENT||NONE||||||
33707464|NCT00750815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707465|NCT00204815|||CASE_ONLY||PROSPECTIVE|||||||
33707466|NCT01059084|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707467|NCT06492317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707468|NCT05697315|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor)||f|f|t|t
33707469|NCT00807378|||CASE_ONLY||PROSPECTIVE|||||||
33707470|NCT01698372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33707471|NCT00000869||||TREATMENT||DOUBLE||||||
33707472|NCT02738593|||COHORT||PROSPECTIVE|||||||
33707473|NCT05993377|||COHORT||PROSPECTIVE|||||||
33707474|NCT05495490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer-generated randomization table|Parallel single-blind masking randomized controlled clinical trial|t|f|f|f
33707475|NCT01267760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707476|NCT01890291|||OTHER||PROSPECTIVE|||||||
33707477|NCT02795832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707478|NCT04920019|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomized group of patient is identified and sealed in envelope. Postoperative outcomes are assessed by Acute Pain Service nurse or resident.|Group A: continuous epidural analgesia, Group B: no continuous epidural analsesia||||
33707479|NCT00418457|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010605|NCT01949714|||CASE_ONLY||CROSS_SECTIONAL|||||||
34010606|NCT06366945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010607|NCT06412042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34010608|NCT02752841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010609|NCT02112721|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34010610|NCT04372290|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34010611|NCT04306640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010612|NCT01239472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010613|NCT01191528|||COHORT||CROSS_SECTIONAL|||||||
34010614|NCT01001260|||CASE_ONLY||CROSS_SECTIONAL|||||||
34010615|NCT05550220|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34010616|NCT02556307|||CASE_ONLY||PROSPECTIVE|||||||
34010617|NCT00378950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34010618|NCT05688397|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34010619|NCT02477241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010620|NCT01754818|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34010621|NCT02839486|||COHORT||PROSPECTIVE|||||||
34010622|NCT00857259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010623|NCT05887219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010624|NCT05788575|||COHORT||PROSPECTIVE|||||||
33707480|NCT01427257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707481|NCT01685905|||COHORT||RETROSPECTIVE|||||||
33790831|NCT03324152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physical therapist performing assessments of muscle function (primary outcome), distributes questionnaires and who is present at maximal oxygen uptake tests and who plan all other assessments logistically is blinded to group allocation. The rheumatologists performing assessment of disease activity and the personell analysing biopsy data are also blinded to group allocation. The care provider is the only one who is not masked.|Patients are dandomized to either a high-intensity interval group (HIIT) or a control group performing standard low-intensity home exercise.|f|f|f|t
33707482|NCT03326466|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33707483|NCT03668860|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707484|NCT00760097|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33790832|NCT05982613|||COHORT||RETROSPECTIVE|||||||
33707485|NCT00065689|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33790833|NCT00356317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790834|NCT03804632|||CASE_ONLY||PROSPECTIVE|||||||
33790835|NCT04079335|||COHORT||PROSPECTIVE|||||||
33790836|NCT02299336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790837|NCT04589780|||OTHER||CROSS_SECTIONAL|||||||
33790838|NCT02498769|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790839|NCT02301221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790840|NCT05156450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790841|NCT03398811|||CASE_ONLY||CROSS_SECTIONAL|||||||
33790842|NCT01311180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790843|NCT01549496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790844|NCT00355914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790845|NCT06424977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790846|NCT01638884|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33790847|NCT04866823|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33790848|NCT01315899|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33790849|NCT01335165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790850|NCT06111937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33790851|NCT06221618|||COHORT||PROSPECTIVE|||||||
33790852|NCT00367692|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33790853|NCT05571436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707486|NCT00634374|RANDOMIZED|PARALLEL||||NONE||||||
33707487|NCT06158373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design with pretest posttest control group||||
33707488|NCT02478996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707489|NCT04229420|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Study will be conducted on 60 adults aged from 18 to 60 years presented for major abdominal surgeries (open colorectal resections or major ventral hernia repair) at general surgery operating theatres, Cairo university hospitals.~Patients will be divided into two equal groups; rectus sheath block group RSB (n=30) and erector spinae plane block group ESPB (n=30)."|t|t|f|t
33790854|NCT05171998|||COHORT||PROSPECTIVE|||||||
33790855|NCT04072822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801774|NCT04056624|RANDOMIZED|PARALLEL||PREVENTION||NONE||First, investigators will examine the association (RS Device Validity) between RS-assessed skin carotenoids and the primary outcomes of objectively-measured plasma carotenoids and self-reported F\&V consumption across four diverse groups: African-American/Black, Asian, White, and Hispanic/Latino. Then investigators will conduct a randomized controlled trial to define the relative skin carotenoid responses (RS Device Sensitivity) across racial-ethnic groups, in comparison with plasma carotenoid responses. Investigators will conduct a 6-week randomized controlled trial of a carotenoid-containing juice intervention \[placebo control, low and high dose juice across 4 genetically-stratified racial-ethnic groups (n = 156).||||
33932265|NCT03966092|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|During the assess period, the participant and the research staff involved in the data collection will be blinded to the randomization group|"Randomization in 2 groups~* Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations.~* Experimental group: patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen and morphine. Antimicrobial prophylaxis is performed according to recommendations. In this group, a bilateral quadratus lumborum block, using 20 ml of ropivacaine 3, 75 mg/ml is performed at the end of surgery, using ultrasound guidance."|t|f|f|f
34010625|NCT05134194|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in a 1:1 ratio to Arm A (Camrelizumab+Capecitabine or Eribulin or Gemcitabine or Vinorelbine), Arm B (Capecitabine or Eribulin or Gemcitabine or Vinorelbine)||||
34010626|NCT03054831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010627|NCT03544151|||COHORT||PROSPECTIVE|||||||
34010628|NCT04611984|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The investigators performing the clinical and surgical procedures, and patients were not blinded. Data assessment was performed by a blinded researcher. Gingival crevicular fluid samples were collected and numbered by another blinded researcher.||f|f|t|t
34010629|NCT03808870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707490|NCT01176838|||OTHER||PROSPECTIVE|||||||
33707491|NCT03834597|||COHORT||PROSPECTIVE|||||||
33707492|NCT02955602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707493|NCT02590367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33707494|NCT01392274|||||PROSPECTIVE|||||||
33707495|NCT01728909|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33707496|NCT05929664|NA|SINGLE_GROUP||TREATMENT||NONE|No Data Available|No Data Available||||
33707497|NCT00008203|RANDOMIZED|||TREATMENT||||||||
34010630|NCT00021060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010631|NCT02283450|||CASE_CONTROL||PROSPECTIVE|||||||
34010632|NCT03902002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010633|NCT01714050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33801775|NCT03752151||SEQUENTIAL||TREATMENT||NONE|Echocardiogram core lab will be masked to the individual patient subjects and MARVEL 2 algorithm mode.|Subjects enrolled in the MARVEL 2 study. Enrolled subjects will have the MARVEL 2 algorithm downloaded into their implanted market released Micra device. Each subject will be tested during when the MARVEL 2 algorithm is in monitor mode (VVI pacing) and in adaptive mode (VDD pacing).||||
33801776|NCT04159779|||COHORT||PROSPECTIVE|||||||
33801777|NCT01761487|NA|SINGLE_GROUP||||NONE||||||
33801778|NCT04454879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932266|NCT04692233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|An independent statistician will generate the randomization list using computer and keep a secure copy of the randomization codes assignments. The group assignment will be sealed in separate opaque envelopes and centrally controlled. The BQ master and exercise trainer will not have knowledge about the aims of the study. The RAs responsible for assessing the outcomes and entering the data will be blinded to the group allocation.||f|f|f|t
33932267|NCT01908049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932268|NCT04396327|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study will be double-blind. Neither study subjects nor study personnel will have knowledge of the treatments administered.||t|f|t|f
33932269|NCT02493335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932270|NCT06482255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932271|NCT00846352|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932272|NCT02092168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932273|NCT02219672|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34010634|NCT05608135|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34010635|NCT05342207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010636|NCT03362996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707498|NCT03831399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Administration of Leucine or placebo (microcrystalline cellulose) will be done twice/day in the morning and in the afternoon for 13 weeks measuring spoon of placebo. Both products will be delivered in white jars, without label, and will carry the patient number on the outside. Randomization of numbers to either placebo or verum product will take place by Bonusan and will be revealed to the researchers at the end of final phase.~The administration of prebiotics or placebo will last 13 weeks except for appearance of side-effects related to the study. The side-effects will be recorded and consulted with Bonusan Research Staff.~The researcher enrolled in the geriatric, psychological or analytical measurements will be blind to the drug treatment.~After finishing the study period, the study the Director of the Research group (Dr. Omar Cauli) will ask Bonusan to reveal who participants received Leucine and those who received placebo."|Study of phase I, pilot, prospective, multicentric, randomized, double blind and placebo-controlled|t|t|t|f
33707499|NCT06310317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707500|NCT06506344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707501|NCT05254821|||COHORT||PROSPECTIVE|||||||
33707502|NCT00747760|||COHORT||PROSPECTIVE|||||||
33707503|NCT04642443|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33707504|NCT04146233|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Ultrasound images will be saved and reviewed by blinded investigator||f|f|f|t
33707505|NCT04992676|||CASE_ONLY||PROSPECTIVE|||||||
33707506|NCT01619696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707507|NCT03557047|||OTHER||PROSPECTIVE|||||||
33707508|NCT00608621|||||PROSPECTIVE|||||||
33707509|NCT01256931|||CASE_CONTROL||PROSPECTIVE|||||||
33707510|NCT02145780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707511|NCT02119364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33801779|NCT01188655|||CASE_ONLY||PROSPECTIVE|||||||
33801780|NCT01409824|NON_RANDOMIZED|PARALLEL||||NONE||||||
33801781|NCT05382754|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The investigators will be masked as to the order of the two sleep tests|Participants will be randomized to the initial test (home sleep apnea test or polysomnography) and then complete the alternate test within one week.|f|f|t|t
34010637|NCT02336516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010638|NCT06064734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators involved in the clinical evaluation of the patients remained blinded to treatment grouping.||f|f|f|t
34010639|NCT00101842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010640|NCT05026931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010641|NCT01639950|||COHORT||PROSPECTIVE|||||||
34010642|NCT03432988||SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34010643|NCT04880720|||OTHER||PROSPECTIVE|||||||
34010644|NCT06090682|||COHORT||PROSPECTIVE|||||||
34010645|NCT00789113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010646|NCT03629028|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective Randomised Trial||||
34010647|NCT03163433|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention takes place at a highly specialized university hospital i Denmark. Two other higly specialized Danish hospitals recruit patients for the control group.||||
34010648|NCT04786977|||COHORT||PROSPECTIVE|||||||
34094534|NCT04318418|||COHORT||RETROSPECTIVE|||||||
34094535|NCT02184247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094536|NCT00864513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094537|NCT05124860|||COHORT||PROSPECTIVE|||||||
34094538|NCT06225752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094539|NCT01642316|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34094540|NCT06000384|||OTHER||PROSPECTIVE|||||||
34094541|NCT00376506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34094542|NCT05703776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||open randomized controlled trial||||
34094543|NCT02000037|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094544|NCT03640182|NA|SINGLE_GROUP||OTHER||NONE||||||
34094545|NCT03605056|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients involved in this study will receive a 3-drug regimen (chindamide, lenalidomide and dexamethasone)||||
34094546|NCT04292886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34094547|NCT00604383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094548|NCT01053052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094549|NCT05265676|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33707512|NCT03775629|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A: Tramadol hydrochloride +Polmacoxib Group B: Polmacoxib Group C: Tramadol hydrochloride||||
33707513|NCT04234750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707514|NCT01970215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707515|NCT03369093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was an unblinded intervention trial. Blinding could not be justified by the ethical review committee as the schedule of administration of the drugs was different and drug dispensing-related side effects were investigators' other concern.|Investigators have completed the enrollment of 308 participants by the study endline. All the Serious adverse events have been reported appropriately to the Ethical Review Committee and the Data Safety and Monitoring Board (DSMB)|t|f|f|f
33707516|NCT04997434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707517|NCT02084654|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34094550|NCT04947280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094551|NCT01599962|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34094552|NCT01442636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094553|NCT00768859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707518|NCT02829697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707519|NCT00713323|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707520|NCT02171377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707521|NCT05404776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707522|NCT03606499|||COHORT||PROSPECTIVE|||||||
33707523|NCT02211040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707524|NCT05036759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||68Ga-FAPI PET/MR||||
34094554|NCT00549328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094555|NCT05333744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094556|NCT01941056|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094557|NCT01668537|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094558|NCT00559715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094559|NCT00680173|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094560|NCT03819699|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34094561|NCT00051506||||TREATMENT||||||||
34094562|NCT05737732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094563|NCT01108055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707525|NCT00571012|||CASE_ONLY||PROSPECTIVE|||||||
33707526|NCT05515081|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33707527|NCT00394368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932274|NCT00809510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932275|NCT05923151|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33707528|NCT02803632|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707529|NCT02151383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707530|NCT05179798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33932276|NCT00923624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932277|NCT01780324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010649|NCT03443518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Physicians giving intraoperative care and recording data were blind to group type. Meanwhile, the anesthesiologist caring for the patient was aware to group type||t|t|f|t
34010650|NCT01015092|||COHORT||CROSS_SECTIONAL|||||||
34094564|NCT03188705|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The investigators will enroll up to 50 healthy Amish participants who have been identified through existing whole genome and exome sequencing along with bioinformatic approaches that have genetic variants that are predicted to significantly impact CES1 expression or catalytic function. Enrolled participants will undergo a two-stage intervention with clopidogrel (300 mg loading dose then 75 mg per day for the next 6 days), followed by clopidogrel (75 mg) plus aspirin 324 mg for 1 day. Platelet aggregation studies and other measures of platelet function will be performed before and after each intervention. In combination with previously collected data as part of the PAPI Study, the investigators will then characterize the impact of genetic variation in CES1 on clopidogrel and dual antiplatelet therapy response through single- and multi-variant association modeling.||||
34094565|NCT03059342|||COHORT||PROSPECTIVE|||||||
34094566|NCT01098578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094567|NCT00872157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094568|NCT03188029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The aim of this study is to investigate the effect of repeated doses of etomidate on the adrenocortical synthesis of corticosteroids in patients scheduled to electroconvulsive therapy every 2 days for 3 to 4 weeks.~Anesthesia protocol is standardized with 0.5 mg/kg propofol, 0.3 mg/kg etomidate and 0.5 mg/kg succinylcholine.~Blood samples for cortisol dosage are performed immediately before the first session, 24 hours after the first session, 24 hours after the third session and 24 hours after the sixth session. All blood samples are performed at 9 AM.~Samples were analyzed at the end of the recruitment, using the Electrochimiluminescence ECLIA -Cobas - Roche. The normal value are between 6.2-19.4 µg/dL."||||
34094569|NCT02396797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094570|NCT01896986|||COHORT||PROSPECTIVE|||||||
34094571|NCT02381327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094572|NCT01194700|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094573|NCT04078399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707531|NCT02378961|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33932278|NCT03021928|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33932279|NCT01957085|||COHORT||RETROSPECTIVE|||||||
34010651|NCT01322971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010652|NCT00641784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010653|NCT05487365|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Eligible patients are consecutive patients that are hospitalised for HF decompensation. All eligible patients will be offered to participate. At the time of inclusion, patients must be in NYHA class II to IV with a LVEF of ≤50%. A total of 330 patients will be included over 6 month. 11 hospitals in Belgium with an HF clinic employing at least one certified HF nurse will be participating in patient recruitment. Patients are not randomised and will all be participating in the smartphone digital support intervention.~165 patients will be included to use Comunicare app. Patients refusing use Comunicare app will be asked to complete a quality of life (QOL)-questionnaire at 0, 6, and 12 months. A total of 165 patients (who do not want to use the app) will be asked to answer this questionnaire.~So the app will be made available to 165 patients for home monitoring and another group of 165 patients without an application will be asked to answer quality of life questionnaires."||||
34010654|NCT03609281|||COHORT||CROSS_SECTIONAL|||||||
34010655|NCT05854459|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34010656|NCT04286919|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants do not know that there is another group getting a different exercise prescription. At the end of their participation, all participants will be offered the other exercise prescription.|Randomized Controlled Trial with 1 control group and 1 intervention group. The control group is getting the standard of care exercise prescription based on the 2018 physical activity guidelines for Americans and the intervention group is getting a new method of prescribing exercise based on new research informing the 2018 Move Your Way initiative where all physical activity across all types and intensities is advised.|t|f|f|f
34010657|NCT01685658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010658|NCT05813938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010659|NCT00854373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010660|NCT02976259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010661|NCT06616922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, parallel-group, blinded-assessor study|f|f|t|f
34010662|NCT05175924|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||It is a randomized controlled trial consisting of an experiment and a control group.||||
34010663|NCT03729154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010664|NCT01613664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707532|NCT04755569|||OTHER||PROSPECTIVE|||||||
33707533|NCT04003012|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33707534|NCT04070430|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707535|NCT04948710|||COHORT||PROSPECTIVE|||||||
33707536|NCT05613478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707537|NCT02473432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707538|NCT01725503|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707539|NCT01721655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33707540|NCT00885846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932280|NCT06281314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707541|NCT04546438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010665|NCT03902899|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The investigator personally delivers the training and can thus not be blinded for the endoscopists allocated to the intervention-arm.|This is a non-randomized controlled trial with two arms. The intervention-arm consists of all endoscopists employed by 9 semi-randomly chosen Dutch hospitals hospitals who receive an educational training. The control-arm consists of a specific number of randomly chosen endoscopists.||||
33707542|NCT01244269|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33707543|NCT00870441|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33707544|NCT05281211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707545|NCT02661893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707546|NCT06008821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study observes blinding of the patients, anesthesiologists, surgeons, nurses, outcome collectors, and data analysts. Only the regional anesthesiologist performing the intervention will be unblinded. To maintain the quality and legitimacy of the trial, unblinding may only occur if knowledge of the actual intervention is essential to treat and manage the patient. In events such as acute and limited episode of hypotension or bradycardia from a vasovagal event, blinding will be maintained as knowledge of intervention is not required for management. All code breaks with reason will be documented and reported. A protocol description of conditions and procedures for emergency unblinding will be drafted, but the ultimate decision at the time of the block will be at the discretion of the regional anesthesiologist.|This will be a triple-blinded (patient, outcomes assessor and all clinicians except the regional anesthesiologist), individually-randomized, placebo-controlled trial in which patients will be randomly allocated to two study groups in a 1:1 ratio. We will randomize patients in blocks of 4 or 6.|t|t|t|t
33707547|NCT01937416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707548|NCT05218551|||COHORT||PROSPECTIVE|||||||
33707549|NCT02848040|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707550|NCT03164135|NA|SINGLE_GROUP||TREATMENT||NONE||CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.||||
33707551|NCT00927602|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707552|NCT00545662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707553|NCT06504784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization and Concealed allocation will be assured by the distribution of investigational products by a nurse/researcher at the unit, otherwise not involved in the conduct of the study. The randomization schedule will be kept in a locked cabinet until the completion of the trial and all data had been entered into a computer database. Both the investigators and the participants will be blinded to treatment arm assignments.|Randomized, double-blind, placebo-controlled study|t|f|t|f
33707554|NCT00040482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707555|NCT01219569|||||PROSPECTIVE|||||||
33707556|NCT02250781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707557|NCT01606800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707558|NCT01256008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707559|NCT04096729|||COHORT||PROSPECTIVE|||||||
33707560|NCT03839979|||OTHER||RETROSPECTIVE|||||||
33707561|NCT00636272|||COHORT||PROSPECTIVE|||||||
33707562|NCT05706532|||COHORT||PROSPECTIVE|||||||
33707563|NCT04655638|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded parallel-group randomized multicenter clinical trial||||
33707564|NCT00884871|||COHORT||PROSPECTIVE|||||||
33707565|NCT00717197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707566|NCT06095947|||COHORT||PROSPECTIVE|||||||
33707567|NCT00457925|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707568|NCT00006237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932281|NCT03527303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will be blind to condition throughout data accrual.|Randomization to either digital meditation condition or wait-list control.|f|f|t|f
33932282|NCT02044822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932283|NCT02737605|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34010666|NCT02502734|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33932284|NCT00446797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010667|NCT05833152|||COHORT||PROSPECTIVE|||||||
33707569|NCT00528788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707570|NCT05892926|||COHORT||RETROSPECTIVE|||||||
33932285|NCT02331472|||COHORT||CROSS_SECTIONAL|||||||
33932286|NCT03649386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33932287|NCT00005640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932288|NCT05229588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932289|NCT06243289|||COHORT||PROSPECTIVE|||||||
33932290|NCT06100107|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Specifically, the study employs a half cross-over design. Group A begins with the intervention, while Group B starts with a control period of equal length, followed by the intervention. This design facilitates comparisons both between the groups and within Group B across the two periods.||||
33932291|NCT05892536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932292|NCT01375439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010668|NCT03179449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010669|NCT06127017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010670|NCT05045313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707571|NCT00354536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801782|NCT03849352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801783|NCT05284565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The study will prospectively include patients attending the Allergology Department, after signing an informed consent form and a data protection clause.||||
34010671|NCT03115528|||CASE_CONTROL||PROSPECTIVE|||||||
34010672|NCT04684524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010673|NCT00021489||||TREATMENT||DOUBLE||||||
34010674|NCT03861663|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Device evaluation - feasibility||||
34010675|NCT05089929|||COHORT||PROSPECTIVE|||||||
34010676|NCT01221090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010677|NCT01468376|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010678|NCT06504498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094574|NCT05708664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010679|NCT04394338|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized control trail comparing the duration of mesh placement and surgeon satisfaction of self-gripping mesh with plastic sheath and with non-plastic sheath covering mesh. Patients with groin hernia who planned for elective laparoscopically repair hernia with self-gripping mesh at Ramathibodi Hospital, Faculty of Medicine, Mahidol University will are informed of the details of research at the outpatient department before admission. 1:1 open label randomization trail was designed dividing the patients into two groups by the study number. The operation will be done with the standard laparoscopic hernia repair technique by experienced surgeons.||||
34094575|NCT00899457|||COHORT||PROSPECTIVE|||||||
34094576|NCT00448032|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
34094577|NCT00005271|||COHORT||CROSS_SECTIONAL|||||||
34094578|NCT05308693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled||||
34094579|NCT01797185|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707572|NCT04213079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In this project, 50 motion triggered MdDS patients with otherwise normal vestibular and neurological functions will be randomly assigned into two groups, one to be treated by velocity storage habituation and the other by readaptation. Patients will be followed up for 6 months. Based on the preliminary data, we expect both groups to yield similar initial success rates for symptom improvement.|t|f|f|f
33932293|NCT05320536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The group randomization method was adopted according to the central stratification, and a total of 240 cases were randomly assigned equally to the experimental group and the control group by SAS 9.2 statistical system programming to generate a random allocation sequence table. Sequence table according to the distribution of drugs for blind packaging, medicine make blind by the personnel not to participate in clinical trials according to the generated random distribution plans and standard operating procedures for blind of experimental drugs allocation coding, coding procedure shall monitor, after completion of blind plait blind bottom seal should be in duplicate, respectively by the eastern theatre, head of the general hospital drug clinical trial institution and subject to save. SAS programs that generate randomization and related parameters are saved together with the blind end.|Blind-wrapped drugs and corresponding emergency envelopes will be distributed to each centre in serial numbers based on the number of patients assigned to each centre. Each center shall sign a drug acceptance form, signed by two people in duplicate, with the group leader and each center holding one copy. The experimental drugs are stored at room temperature, away from light and dry, and are in the charge of special personnel. Each center will distribute drugs to eligible patients starting with the minimum number.|t|f|t|f
33932294|NCT06396130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932295|NCT01863706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33932296|NCT04576416|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"Participating doctors are either given access to an AI augmented digital educational platform or not. During the study period, both doctors of the intervention and control arm are registering skin lesions they encounter in their daily practice.~The expert dermatologists that evaluate the registered skin lesions are unaware of the registering doctors allocation."|A randomized superiority clinical trial. Participating doctors are stratified and randomized to either intervention or control in a 3:1 allocation ratio.|f|f|f|t
33932297|NCT01600105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932298|NCT04827940|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||This single-blind, pre-test-post-test with control group design quasi-experimental study|t|f|f|f
33932299|NCT02688725|NA|SINGLE_GROUP||SCREENING||NONE||||||
34010680|NCT05384886|||CASE_CONTROL||RETROSPECTIVE|||||||
34010681|NCT06242743|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34010682|NCT04788446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010683|NCT05022134|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34010684|NCT02346682|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010685|NCT01845402|||COHORT||PROSPECTIVE|||||||
34010686|NCT04681651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010687|NCT02180698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010688|NCT05002686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932300|NCT00345956|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34010689|NCT03448614|||COHORT||PROSPECTIVE|||||||
34010690|NCT02839668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34010691|NCT05434858|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094580|NCT04764539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Six children with ASD, between the ages of 4 and 8, were recruited to participate in a 12-sessions-long study that utilized the Video-Assisted Speech Therapy (VAST) application. The participants were divided into two groups: one which received the VR-integrated prototype, and one that received a 2D application on a tablet. Each session was approximately 15 minutes long (+/- 5 minutes), occurring twice per week.||||
34094581|NCT03291015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932301|NCT03398252|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33932302|NCT00289614|RANDOMIZED|PARALLEL||||DOUBLE||||||
33932303|NCT05609136|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Patients participating in the study will be blinded to which treatment group they will be included in. Patients' characteristics and all outcome measures before and after treatment will be evaluated by the blinded physiotherapist. Neurorehabilitation of the patients will be performed by another physiotherapist who did not participate in the evaluation of the patients. Physiotherapists will be instructed not to communicate with patients about possible goals or rationale for either treatment.|The patients will be divided into two groups as scapular exercise group and control group using the simple randomization method. Scapular stabilization exercises will be applied in combination with neurorehabilitation to the first group, while only neurorehabilitation will be applied to the control group. A 6-week (30 sessions) neurorehabilitation program specially planned for the patient will be applied to all groups.|t|t|t|t
34010692|NCT05672927|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Vials submitted for assay will be de-identified and labeled only with the study ID number.||f|f|f|t
34010693|NCT02940678|||COHORT||RETROSPECTIVE|||||||
34010694|NCT00298740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010695|NCT02396277|||CASE_ONLY||PROSPECTIVE|||||||
34094582|NCT00292994|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34094583|NCT01954173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010696|NCT02823730|||OTHER||RETROSPECTIVE|||||||
34010697|NCT04390802|||CASE_ONLY||PROSPECTIVE|||||||
34010698|NCT02450526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010699|NCT02815202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010700|NCT03969199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34094584|NCT06433063|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Metastatic castration resistant prostate cancer patients who will receive Lu-177 PSMA radionuclide treatment||||
34094585|NCT04732585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study on PFPS patients:~Non-randomized Controlled clinical trial~Study on ACL patients:~Non-randomized Controlled clinical trial"||||
34094586|NCT03869021|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single blinding|Case control trial|t|t|f|f
34094587|NCT01029821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094588|NCT06398639|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34094589|NCT04504760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094590|NCT06431659|||CASE_CONTROL||RETROSPECTIVE|||||||
34094591|NCT04249739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Assigned to 1 group according to the result of HER2. \<Cohort A\>: HER2 negative patients CapeOx+Pembrolizumab therapy (N=78)~* Cycle 1 CapeOX~* Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy~* Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy~  * CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~    1. Cycle: Day 1 through Day 21)~\<Cohort B\>: HER2 positive patients Cape/Cis+Trastuzumab+Pembrolizumab therapy (N=15)~* Cycle 1 Capecitabine + cisplatin (Cape/Cis)~* Cycle 2 up to Cycle 8 Cape/Cis + Trastuzumab + pembrolizumab therapy~* Cycle 9 up to Cycle 35 Capecitabine + Trastuzumab + pembrolizumab therapy~  * Cape/Cis + Trastuzumab + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~    1. Cycle: Day 1 through Day 21)"||||
33707573|NCT04978961|RANDOMIZED|PARALLEL||TREATMENT||NONE|PI was masked to assessment outcomes during intervention phase|||||
33707574|NCT03806790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707575|NCT04017078|||OTHER||CROSS_SECTIONAL|||||||
33707576|NCT03047057|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707577|NCT00972868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707578|NCT03648983|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33707579|NCT03311633|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three week percutaneous pinning group versus Six week percutaneous pinning group||||
33707580|NCT02056496||CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33790856|NCT05819541|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|We will use randomly-permuted 1:1 blocks of 10 to minimize seasonal bias of exacerbation precipitants that may have independent associations with treatment-response. The study biostatistician will use the randomizeR package in R statistical software to provide the randomization schedule. A Research Electronic Data Capture (REDCap) database will be built that will incorporate the randomization sequence. When the investigators place an electronic medical record order (eStar) order for drug, the randomization database will designate randomized treatment allocation to the pharmacy. Pharmacy will prepare appropriate drug. The REDCap database will email and text the study pharmacist performing plasma assays, pharmacy staff, and the investigators 24 hours after the 5th participant is randomized to MK within each dose group. This will alert the investigators to pause enrollment until MK assays are completed and the mg/kg MK dose is determined for the next dose group.|The aim is to perform an adaptive, double-masked, 2-arm RCT of high-dose oral montelukast, with 3 sequential, escalating dose-levels determined by PK-guided dose modeling, added to standard treatment versus standard treatment alone, in children with asthma exacerbations that are moderate or severe after initial treatment with inhaled albuterol.|t|t|t|t
33790857|NCT05398965|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into 2 study groups before starting their medication. The first group was only given standard COVID-19 therapy. While the treated group will be given standard COVID-19 along with adjuvant therapy (Eucalyptus oil on external use)||||
33790858|NCT03107962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790859|NCT03137966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The drugs (active or placebo) will be supplied by the supervision of Medigelium AB and will have the same appearance.|prospective, randomised, double-blind and placebo-controlled study with parallel groups, multiple centre trial.|t|f|f|f
33707581|NCT04578639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The investigators as well as the study participants, are blinded to the treatment allocation status. To assure this double-blinding, a dedicated treating nurse will be appointed at each study centre. Information about randomization (treatment arm) will be given directly through electronic communication (automatic generated email) from Viedoc™ to the treating nurse as soon as the randomization procedure has been performed. Only the treating nurse will have access to information concerning which treatment arm the patient is allocated to.~The treating nurse will order the medicine from the pharmacy and perform the dilution in NaCl (in an infusion bag).~An evaluating nurse and evaluating neurologist (blinded to study drug) will perform the clinical evaluation of the patient while the patient receives the medication and as part of registration of study information. The evaluating neurologist and evaluating nurse will not be able to access the randomization procedure in Viedoc™."|A prospective randomized double blinded multicenter non-inferiority study designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.|t|f|t|t
33932304|NCT05455840|NA|SINGLE_GROUP||TREATMENT||NONE||thymothmectomy or extended thymectomy through Da Vinci SP platform||||
33707582|NCT06367478|||COHORT||PROSPECTIVE|||||||
33707583|NCT04790422|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33932305|NCT04709094|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Part 1, Part 2, and Part 3 could be conducted concurrently or separately.||||
33932306|NCT02913833|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932307|NCT00995813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932308|NCT02315417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932309|NCT01737138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932310|NCT04843150|||COHORT||OTHER|||||||
33932311|NCT02531503|||COHORT||PROSPECTIVE|||||||
33932312|NCT02278224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33932313|NCT04005755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932314|NCT00877734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932315|NCT01976585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932316|NCT02807714|||CASE_ONLY||PROSPECTIVE|||||||
33932317|NCT06047860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932318|NCT00073034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932319|NCT03648411|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33707584|NCT01628978|||||PROSPECTIVE|||||||
33707585|NCT02988843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707586|NCT06084234|RANDOMIZED|PARALLEL||SCREENING||NONE||This is a randomized open-label study comparing US ± AFP vs. GALAD-based surveillance every 6 (± 3-month window) months starting at randomization.||||
33707587|NCT06310538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707588|NCT04826991|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, device installers, investigators, and outcomes assessor will all be blinded.|A whole-home UV water treatment system will be installed and operated at a minimum of 50 millijoules per square centimeter.|t|f|t|t
33707589|NCT05438394|NA|SINGLE_GROUP||TREATMENT||NONE||"Four dose groups. Using the 3 + 3 dose escalation principle, 3-6 subjects per dose group, according to the dose limiting toxicity (DLT) observed in the first cycle of chemotherapy for each subject. After completing the 21-day assessment of the first cycle of chemotherapy, if there was no DLT, the study started for the next dose group."||||
33707590|NCT02704273|||COHORT||PROSPECTIVE|||||||
33707591|NCT00358683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707592|NCT05823129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A project manager will randomize the participants to the intervention or standard-care group, and the outcome assessor will not be informed||f|f|f|t
33707593|NCT05606627|||COHORT||PROSPECTIVE|||||||
33707594|NCT03424863|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33707595|NCT00985569|||COHORT||PROSPECTIVE|||||||
33707596|NCT02458040|||OTHER||OTHER|||||||
33707597|NCT00798980|||COHORT||PROSPECTIVE|||||||
33707598|NCT04527705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707599|NCT04260152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Outcomes Examiner, Subject)|Split-mouth, randomized|t|f|f|t
33707600|NCT00730145|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33707601|NCT00291577|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707602|NCT02853422|||COHORT||CROSS_SECTIONAL|||||||
33790860|NCT00762463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790861|NCT04680013|||OTHER||RETROSPECTIVE|||||||
33790862|NCT00765752|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790863|NCT00199589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790864|NCT00618540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790865|NCT00271700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790866|NCT04021667|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||"The pregnant women and partners who came to the hospital were evaluated in terms of sample criteria and randomized sampling was divided into three groups.~In order to be able to perform randomized sampling, the selection of the groups to the individual breastfeeding education, group breastfeeding education and control group was determined by throwing a coin.~After the first group was identified, a research group was taken for each day."|t|f|f|f
33790867|NCT04839796|||COHORT||PROSPECTIVE|||||||
33932320|NCT04506385|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932321|NCT01499212|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33932322|NCT02180568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932323|NCT05935813|||COHORT||RETROSPECTIVE|||||||
33932324|NCT00230295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932325|NCT03801798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707603|NCT01781143|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33707604|NCT00319553|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707605|NCT01073033|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707606|NCT03447704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33707607|NCT04014816|||COHORT||PROSPECTIVE|||||||
33707608|NCT03178903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707609|NCT00113620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707610|NCT05282862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707611|NCT00259649|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33790868|NCT06466070|||CASE_CONTROL||RETROSPECTIVE|||||||
33932326|NCT00510107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932327|NCT00460525|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33932328|NCT05151562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932329|NCT02789072|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33932330|NCT00196261|||||PROSPECTIVE|||||||
33932331|NCT03278925|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932332|NCT05844657|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34010701|NCT05987735|RANDOMIZED|PARALLEL||TREATMENT||NONE||a two-arm randomized controlled trial (RCT). . Participants will be randomized into either the intervention group or waiting-list control group. If allocated to the intervention group, participants will have direct access to the online intervention for two weeks after allocation. When a participant is assigned to the waiting-list control group, he or she has a two-week waiting period, after which the participant will have access to the intervention. Assessments take place after screening (T0), at baseline (T1), and two weeks after allocation (T2). Participants in the waiting-list group will also be assessed two weeks after they have gained access to the intervention (T3).||||
34010702|NCT00483587|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010703|NCT00127517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34010704|NCT06241859|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34010705|NCT05556343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010706|NCT01891812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010707|NCT04056052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010708|NCT01800435|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010709|NCT00918463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010710|NCT04948294|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Patients requiring tracheal intubation for general anesthesia|t|f|f|t
34010711|NCT02144974|||CASE_ONLY||RETROSPECTIVE|||||||
33790869|NCT01697319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932333|NCT02635867|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33932334|NCT01341236|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707612|NCT00339521|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33707613|NCT05090007|||COHORT||PROSPECTIVE|||||||
33707614|NCT03800797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707615|NCT04660877|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants take part in an experiment in which they consume cheese then at another time consume milk||||
33707616|NCT03677362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707617|NCT00433121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707618|NCT03261973|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707619|NCT01337232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707620|NCT03064984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The products under study are prepared, standardized, controlled and sealed in anonymous frozen vials in the Transfusional Service of the S.Orsola-Malpighi Hospital, our partner and collaborator in the study. The products have same physical and colour characteristics and cannot be visually recognized. Boxes containing the vials report a code of assignement only known by the Transfusion service personnel.|"This is a double-blind, interventional clinical study, randomized, multicenter. The treatments under study comprise topical products prepared from two different sources: umbilical cord blood collected at birth and adult subject donor peripheral blood. The products are prepared, standardized, controlled and sealed in anonymous frozen vials in the Transfusional Service, partner in the study.~The study consists of two phases: Phase 1 is runned for one month treatment. The assignment of the treatment in Phase 1 is performed through a computer based randomization process, blind to the patient and the clinician, only known to the Transfusion Service personnel. The patient enter Phase 2 only in case of a corneal epithelial damage relapse taking place within two months after the end of Phase 1, and the treatment assigned belongs to the remaining arm. In this case also, the treatment is only known to the Transfusion Service personnel, trained to keep data aside."|t|t|t|t
33707621|NCT05856032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded as they won't be knowing in which intervention group they are allocated.||t|f|f|f
33707622|NCT06053996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||radiation to hepatic and pulmonary metastases||||
33707623|NCT01704378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707624|NCT06261502|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The randomization and participant code allocation process will be carried out by the Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS) pharmacy. The pharmacy will dispense the medication or placebo based on the randomization. The principal investigators, Drs. Lepage and Corbin and the research, as well as the participants and their caregivers, will never be aware of the randomization. To avoid any suspicions on the part of the investigators, Dr. Artuela Çaku, who is not part of the research team, will have access to the laboratory results. In the event of an adverse drug effect, Dr. Çaku may break the code to make a more informed decision for the patient's well-being, such as discontinuing participation or reducing the dose, etc.|Randomized, Double-blind, placebo-controlled, single center, cross-over trial|t|t|t|t
33707625|NCT01346449|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33707626|NCT04380415|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33707627|NCT00515346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707628|NCT01475994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33707629|NCT01233531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707630|NCT05229237|||CASE_ONLY||PROSPECTIVE|||||||
33707631|NCT05032859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator, study center staff, subject, and sponsor will be blinded to treatment assignment.|Following a 30-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily treatment with tapinarof cream, 1% or vehicle cream.|t|t|t|t
33707632|NCT04442867|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33707633|NCT01232517|||||PROSPECTIVE|||||||
33707634|NCT03217630|||COHORT||PROSPECTIVE|||||||
33707635|NCT00794378|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33707636|NCT00257101|RANDOMIZED|||TREATMENT||||||||
33707637|NCT02770560|||COHORT||RETROSPECTIVE|||||||
33707638|NCT05751902|||OTHER||CROSS_SECTIONAL|||||||
33707639|NCT03943147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Study||t|t|t|t
33790870|NCT02876471|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790871|NCT05830604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790872|NCT00345852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790873|NCT00979056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33790874|NCT02108743|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33790875|NCT02482233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33932335|NCT01974440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932336|NCT01137227|||||RETROSPECTIVE|||||||
33932337|NCT04432324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707640|NCT04899869|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind|Each study subject will undergo two pairs of faecal microbiota transplantation eight weeks apart (a total of four enemas for each patient). Our study design has several specific features: (a) Two consecutive transfers were designed to improve study microbiota engraftment. Before the first of every transfer pairs, the subjects will receive a reduced dose of oral polyethylene glycol for partial bowel preparation. (b) To help discern potential carry-over effects, a placebo-only group was included; this also enables us to assess long-term effects of the intervention. (c) The transferred microbiota is identical throughout the study, having been mixed beforehand, aliquoted and deep frozen. Its alpha diversity was artificially increased by mixing stools from several donors. (d) Placebo is made of the same mixture by careful autoclaving.|t|t|t|f
33707641|NCT04038684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||During the open trial, all participants will receive Mindfulness-Based Behavioral Weight Control (MBWC). During the RCT, participants will be randomly assigned to either MBWC or Standard Behavioral Weight Control.|f|f|f|t
33707642|NCT01007097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932338|NCT00275041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932339|NCT06141499|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Enrolled providers and enrolled patients will receive different interventions; outcomes assessed for these two groups will be different.||||
33932340|NCT01715090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932341|NCT02289833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932342|NCT04743401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||COVID-19 patients or PUI (persons under investigation) admitted to the MEDVAMC (n=60), with an anticipated length of stay of at least 3 days will be recruited. Participants will be randomized (n=1:1) to either intervention (IG) or control (CG) groups. Both groups will receive standard of care. IG will additionally receive Tele-Exergame MP therapy. Tele-Exergame sessions will range from 3-10 minutes based on patient ability and completed twice daily. They will complete assessments at baseline and at one-month post-hospital discharge.||||
33932343|NCT00176878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932344|NCT04668014|||COHORT||PROSPECTIVE|||||||
33932345|NCT06039280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932346|NCT03587727|||COHORT||PROSPECTIVE|||||||
33932347|NCT01167088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932348|NCT05122013|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be recruited to the study and randomized to intervention or control group. Medical and demographic data collection as well as measurements and validated questionnaires will be conducted at baseline (T0) and after the intervention (3 months after T0). In addition, at 3- and 6-months post intervention patients will be contacted via phone calls and asked about their weight, physical activity, sleeping and nutritional habits, and adherence to bariatric surgery recommendations. At T0, the intervention group will be scheduled for remote meetings and the the control group will receive a single meeting with the study's registered dietitian at the end of data collection of T0, along with a recommendation to continue follow-up and lifestyle changes.||||
33932349|NCT00003282|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932350|NCT04019236|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||Researcher will provide patients with suitable care for relieving dyspnea and record the outcomes|t|f|f|f
33932351|NCT03050307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932352|NCT00564265|||CASE_ONLY||RETROSPECTIVE|||||||
33932353|NCT04741087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932354|NCT03650049|||CASE_ONLY||RETROSPECTIVE|||||||
33932355|NCT02598700|||CASE_ONLY||CROSS_SECTIONAL|||||||
33932356|NCT02822352|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932357|NCT01962389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932358|NCT01849562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932359|NCT00957190|NA|SINGLE_GROUP||OTHER||NONE||||||
33932360|NCT03228849|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned to surgical or conservative groups. After 6 weeks patients in both groups were started on the same rehabilitation protocol.||||
33932361|NCT01785290|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33932362|NCT04998292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||split mouth study|t|t|t|t
33932363|NCT00981292|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33932364|NCT03794011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932365|NCT04603274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932366|NCT03904004|||COHORT||PROSPECTIVE|||||||
33932367|NCT01462045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932368|NCT04816370|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33932369|NCT04745247|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double Blind||t|t|t|t
33932370|NCT06336681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932371|NCT05580185|||COHORT||PROSPECTIVE|||||||
33932372|NCT05589012|||COHORT||PROSPECTIVE|||||||
33932373|NCT05695404|||COHORT||PROSPECTIVE|||||||
33932374|NCT05195515|||COHORT||PROSPECTIVE|||||||
33932375|NCT01755104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932376|NCT05963555|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33707643|NCT02550990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707644|NCT01265368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707645|NCT04858243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707646|NCT05841485|||OTHER||CROSS_SECTIONAL|||||||
33707647|NCT00251485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707648|NCT04935320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707649|NCT03140943|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will continue treatment for 18 cycles (12 induction cycles, 6 maintenance cycles) unless development of adverse events that require early cessation of treatment. Patients will be followed up for progression and survival until 1 year following the completion of the last patient's final cycle of induction therapy.||||
33707650|NCT01930266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790876|NCT01646775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33790877|NCT00000878||||TREATMENT||||||||
33790878|NCT02247258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790879|NCT03723512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790880|NCT01400750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790881|NCT03038503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932377|NCT02488356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790882|NCT05299333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932378|NCT04864327|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33932379|NCT03868475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932380|NCT04306302|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33932381|NCT03455634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932382|NCT04001660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932383|NCT02692560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33932384|NCT05469880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The creams are packaged in white tubes with specific labelling that does not allow to identify them. The 5% benzoyl peroxide tubes are delivered in commercial form.||t|t|t|t
33932385|NCT01364142|||CASE_ONLY||PROSPECTIVE|||||||
33932386|NCT01462591|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33932387|NCT02768389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932388|NCT00663689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932389|NCT00954824|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33932390|NCT02071329|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33932391|NCT03580525|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Participant will not know nicotine dose or rate of infusion.|Single blind, placebo-controlled, mixed-design with nicotine delivery as a within-subjects factor.|t|f|t|f
33932392|NCT03288727|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932393|NCT01723176|||COHORT||PROSPECTIVE|||||||
33932394|NCT04027036|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707651|NCT03811028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707652|NCT02537119|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33707653|NCT03214939|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with colorectal cancer receive a cellular preparation consisting of dendritic cells loaded with tumor lysate antigens and activated mononuclear cells.||||
33707654|NCT03732235|||CASE_CONTROL||PROSPECTIVE|||||||
33707655|NCT05446805|||COHORT||PROSPECTIVE|||||||
33707656|NCT04832867|||COHORT||RETROSPECTIVE|||||||
33707657|NCT00654680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707658|NCT06049238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707659|NCT02515825|||COHORT||PROSPECTIVE|||||||
33707660|NCT02096731|||COHORT||RETROSPECTIVE|||||||
33707661|NCT05943015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33707662|NCT02230592|||||PROSPECTIVE|||||||
33707663|NCT00585143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790883|NCT04593719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790884|NCT03418324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Bayesian design||||
33790885|NCT05285514|||COHORT||PROSPECTIVE|||||||
33790886|NCT02196818|||COHORT||PROSPECTIVE|||||||
33790887|NCT02215044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932395|NCT04646083|||COHORT||PROSPECTIVE|||||||
33932396|NCT06433024|||CASE_CONTROL||PROSPECTIVE|||||||
33932397|NCT01023373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932398|NCT00673218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33932399|NCT03939676|||OTHER||CROSS_SECTIONAL|||||||
33932400|NCT02118636|||COHORT||PROSPECTIVE|||||||
33932401|NCT02310360|||COHORT||CROSS_SECTIONAL|||||||
33932402|NCT00700349|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33932403|NCT06387277|||OTHER||OTHER|||||||
34010712|NCT03050034|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot perspective controlled randomized open-label single-center study to evaluate the management of critically ill patients hospitalized comparing vital signs wireless monitoring versus conventional monitoring in the first 72 h of hospitalization extendable to 5 days if the MEWS after 72 h is even greater than or equal to 3 and/or the NEWS is greater than or equal to 5.||||
34010713|NCT05068960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be blinded. Surgeon, nurses, and other clinical care providers will be blinded. Research staff will be blinded. The only staff who knows study group assignment is the pharmacist and the anesthesiologist and preoperative nurse who will administer the interscalene block.|Double Blinded Randomized Controlled Trial|t|t|t|t
34010714|NCT00093184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010715|NCT04162353|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation phase: BCMA-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of BCMA and CD19 CARs on a T cell with an escalation approach, 2e6 to 10e6 CAR-T cells/kg||||
33707664|NCT02893670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707665|NCT01292746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707666|NCT03533764|RANDOMIZED|PARALLEL||OTHER||SINGLE|The research assistants who will interview study participants will be blind to study condition.||f|f|f|t
33707667|NCT03973164|||COHORT||PROSPECTIVE|||||||
33707668|NCT02130232|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34010716|NCT00006333|||CASE_ONLY||PROSPECTIVE|||||||
34010717|NCT06614959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010718|NCT00643214|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34010719|NCT01365702|||COHORT||PROSPECTIVE|||||||
34010720|NCT00103402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010721|NCT02480426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010722|NCT00897949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010723|NCT05154552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010724|NCT03021213|||COHORT||PROSPECTIVE|||||||
34010725|NCT02924376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010726|NCT03629613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cardiovascular disease condition; healthy, age-matched control||||
34010727|NCT02396173|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34010728|NCT05009368|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010729|NCT01976455|||CASE_CROSSOVER||OTHER|||||||
34010730|NCT04817215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blinded||t|t|f|f
34010731|NCT03466541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010732|NCT05150418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Oxygen or room air administered.|Double-blind, randomized, crossover design.|t|f|t|t
34010733|NCT02057445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010734|NCT04600024|||CASE_CONTROL||PROSPECTIVE|||||||
34010735|NCT04920903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010736|NCT01021267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010737|NCT04593212|||COHORT||PROSPECTIVE|||||||
34010738|NCT04610060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For each participant were blinded till allocation of treatment. Investigator was also blinded.|A 4-Week, Single-Blind, Parallel-Group Study|t|f|t|f
33707669|NCT05588908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707670|NCT01599767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707671|NCT03567304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707672|NCT05719766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33707673|NCT00083863|||COHORT|||||||||
33707674|NCT05180084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707675|NCT04154735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707676|NCT03478930|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Although this is an open-label study and all participants will be receiving omalizumab, in order to minimize bias in this study participants and the evaluating physicians will be blinded to treatment assignment of the previous studies (GA39688/GA39855) until all participants have either completed the study through the follow-up period (Week 76) or discontinued early from the study, the database is locked, and the study analyses are final.||t|f|t|t
33707677|NCT06124833|||COHORT||PROSPECTIVE|||||||
33707678|NCT04316065|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707679|NCT04546230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33707680|NCT00999232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707681|NCT01497158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707682|NCT03910374|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants stay masked during the trial, care provider and investigators are unblinded at the surgical procedure and from thereon|Randomized controlled clinical trial|t|f|f|f
33707683|NCT05115903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707684|NCT02756013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707685|NCT00496470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707686|NCT05914805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Pivotal, Double-Blind - Part 1: multicenter, prospective, randomized, Double Blind, vehicle-controlled interventional study.~Extension, Single-Blind - Part 2: subjects who will have completed Pivotal, Double-Blind - Part I of the trial and have been defined as Part 1 responders, will be randomized to be treated, in Single-Blind, for additional 6 months with IMP or vehicle solution."|t|f|t|f
33707687|NCT02197520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33707688|NCT02221947|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33707689|NCT02837328|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33707690|NCT00935571|||CASE_CONTROL||PROSPECTIVE|||||||
33707691|NCT04904328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707692|NCT03037775|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707693|NCT00571948|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707694|NCT03212924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707695|NCT06094595|||OTHER||OTHER|||||||
33707696|NCT04633018|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707697|NCT04534959|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707698|NCT02052531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707699|NCT02325037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707700|NCT01925534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707701|NCT06373107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707702|NCT03717818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707703|NCT06015685|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33707704|NCT00541931|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707705|NCT01324843|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33707706|NCT04960501|||CASE_CONTROL||RETROSPECTIVE|||||||
33707707|NCT04178564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707708|NCT04786990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707709|NCT01955096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33707710|NCT02606019|||COHORT||PROSPECTIVE|||||||
33707711|NCT01230632|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707712|NCT06393829|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The proposed project will follow the steps of the Knowledge-to-Action framework (KTA) \[7\]. The KTA is a process model that provides practical guidance in planning and implementing research evidence into practice \[8\]. It is comprised of a Knowledge Creation Funnel and an Action Cycle. Our project will follow the steps of the Action Cycle from adapting to the local context through evaluating outcomes with a concern for sustaining knowledge use.||||
33790888|NCT05084755|||COHORT||PROSPECTIVE|||||||
33790889|NCT02422992|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790890|NCT04090190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790891|NCT04590924|||COHORT||PROSPECTIVE|||||||
33790892|NCT04629118|||CASE_ONLY||PROSPECTIVE|||||||
33790893|NCT05519969|||COHORT||PROSPECTIVE|||||||
33790894|NCT00800488|||CASE_CONTROL||PROSPECTIVE|||||||
33790895|NCT02050724|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33790896|NCT03457246|RANDOMIZED|PARALLEL||TREATMENT||NONE||intra-individual hand controlled trial (left/ right comparison)||||
33932404|NCT00168168|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33932405|NCT03949127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be two groups, one will be the exercise group and one will be used as a control group.|f|f|f|t
33932406|NCT04192318|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33932407|NCT04516941|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2 factorial design||||
33932408|NCT01125904|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33932409|NCT06417268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33932410|NCT05315024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932411|NCT04480749|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932412|NCT03622216|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33932413|NCT02550093|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33932414|NCT03878043|||COHORT||RETROSPECTIVE|||||||
33932415|NCT04672031|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible women will be randomized at a 1:1 ratio (using block randomization) into either the control arm or the intervention arm. It is understood that study participants, physicians, and nurse-educators cannot be blinded to group allocation. The randomization process will proceed as follows. A primary randomization model assigning patients to the New Target versus the Standard Target will be created for the one center (LAC+USC), and permuted-block randomization with random allocation will be used. The investigators will be blinded to the block size. The generation of randomization codes will be performed using SAS statistical software, v. 9.3, Cary, NC. A validation test will be performed to assure that treatment balance is achieved within the entire study."||||
33932416|NCT04847141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932417|NCT03669744|||CASE_ONLY||RETROSPECTIVE|||||||
33932418|NCT00794404|||COHORT||PROSPECTIVE|||||||
33932419|NCT01013090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33707713|NCT04986423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707714|NCT06279143|||COHORT||PROSPECTIVE|||||||
33707715|NCT04826575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Caretaking provider and investigators gathering data will be blinded.|Eligible patients will be randomized to control and intervention (pre-habilitation) group|f|t|t|f
33707716|NCT01776112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790897|NCT06382558|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790898|NCT00215345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790899|NCT06069986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790900|NCT00939042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790901|NCT04399525|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, cross-over study|t|f|f|t
33790902|NCT00015236||||PREVENTION||NONE||||||
33932420|NCT05724381|||OTHER||CROSS_SECTIONAL|||||||
33932421|NCT02402881|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34010739|NCT02521077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34010740|NCT00972907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010741|NCT00638794|||||PROSPECTIVE|||||||
34010742|NCT00725621|||COHORT||PROSPECTIVE|||||||
33707717|NCT01691339|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33707718|NCT00224042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707719|NCT03449797|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33932422|NCT03477669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|The study will be performed as a 4 week, placebo controlled, pilot trial with a one week run in period. Thirty subjects will be randomly assigned to each group for a total enrollment of 60 infants.|t|t|t|f
33932423|NCT00783549|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33932424|NCT04534049|RANDOMIZED|PARALLEL||BASIC_SCIENCE||||||||
33932425|NCT00757081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932426|NCT04969458|||CASE_ONLY||PROSPECTIVE|||||||
34010743|NCT02212340|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34010744|NCT03574311|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinding, study drug administration by separate staff blinded from participant and investigators|Randomized controlled 1:1|t|f|t|t
34010745|NCT02315547|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010746|NCT00504049|||CASE_CONTROL||PROSPECTIVE|||||||
34010747|NCT05260723|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010748|NCT02029781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010749|NCT04703621|NA|SEQUENTIAL||TREATMENT||NONE||The first 3 patients will be included in the safety run-in phase. The next 9 patients will be included in cohort 1 to receive 8 weekly injections. If the response rate is less than 100%, the next 9 patients will be included in cohort 2 to receive 8 weekly injections followed by 2 bi-weekly injections.||||
34010750|NCT04641247|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open-label study.|Participants will receive niraparib once a day, continuously throughout each 90-day cycle.||||
34010751|NCT06308172|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|"Patients are recruited and randomly assigned to either the single-layer or double-layer arm of the study. The randomization process occurs on the day of the cesarean section. Following randomization, patients are informed about their assigned group, and the cesarean section procedure is then carried out."|||||
34010752|NCT02155374|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34010753|NCT05129254|RANDOMIZED|PARALLEL||TREATMENT||NONE||"To compare the efficacy of laser to improve delivery of topical platelet rich plasma (PRP) to promote hair growth, the investigators will employ a randomized, unblinded, baseline-controlled study design. There will be two parallel treatment arms in the study. The first arm will enroll six participants to receive thulium laser and topical PRP. The second arm will enroll six participants to receive PRP injection alone. Total participants enrolled will be twelve (12). There will be a total of 8 study visits (4 treatment and 4 follow-up) lasting 16 months.~Each participant will receive an initial series of 4 treatments, either laser + topical PRP or PRP injection alone once a month for the first 4 months (month 1, 2, 3, 4). Thereafter, patients will be followed at 3-month intervals at month 7, 10, 13, and 16."||||
34094592|NCT06470724|NA|SINGLE_GROUP||TREATMENT||NONE|Participants did not know about the intervention and neither did a research assistant as an assessor who only provided assessments without involving the intervention.|"Intervention Day of Intervention Structural Intervention~1. st visit :Successive approaches,T-S-F-D,visual pedagogy~2. nd visitSuccessive approaches,T-S-F-D, visual pedagogy, audio-visual modelling~3. nd visit: Successive approaches, T-S-F-D, visual pedagogy, in vivo modelling~4. h visit: Successive approaches, T-S-F-D, visual pedagogy, behavioral trials~5. th visit:T-S-F-D, auto-modeling, behavioral trial~The intervention in the process of dental examination lasted within 5 times of dental visit. During the pre-intervention test, the dentist asked the child to submit to the 10 steps of the dental examination but did not force the child to comply and cooperativity was measured by Frankl Behavior Scale, and the assessment/post-test was conducted 3 times. dentist explained the steps using photographs and images, and the assistant filmed this activity."||||
34094593|NCT03936127|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094594|NCT01163656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932427|NCT05193929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932428|NCT04202432|||OTHER||PROSPECTIVE|||||||
33707720|NCT06444971|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a quasi pre test post test study with a single group. Participants will be recruited according to inclusion criteria .Each participant will receive same treatment .||||
33707721|NCT01910025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707722|NCT04646837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010754|NCT06239961|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The Brief Behavioral Activation (BA) Coaching will involve having lay coaches work with participants remotely (i.e., by phone or videoconference) to identify and schedule values-based, rewarding social engagement and activities and to use strategies to reduce and problem-solve barriers to social connectedness. Participants first review their daily activity patterns, and then chose activity goals, worked on specific implementation plans, and reviewed their successes and areas for improvement. The behavioral activation coach program will be modified to address the needs of people aging with HIV (PAWH) by working with those in the community to tailor the content and mode of delivery. There will be additional modules on physical activity and nutrition.||||
34010755|NCT03235869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010756|NCT02575339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010757|NCT05520606|||COHORT||RETROSPECTIVE|||||||
34103581|NCT06521736|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical trial employs a Single Group Assignment model to evaluate the commercial readiness of an Augmentative and Alternative Communication Brain-Computer Interface (AAC-BCI) device for individuals with minimal movement capabilities. The study involves up to 8 AAC-BCI users diagnosed with conditions such as late-stage amyotrophic lateral sclerosis (ALS), brainstem stroke, or severe quadriplegic cerebral palsy, supported by an industry partner's consultant, a speech language pathologist (SLP), and the user's in-home support person. Participants will be trained on the device, using it at least 10 hours per week at home. The primary objective is to achieve 80% stakeholder agreement on the device's readiness for product release. Secondary objectives focus on safety, performance, and user satisfaction. The study's design ensures comprehensive data collection on the AAC-BCI system's usability and performance, providing critical insights for future development and larger-scale trials.||||
34103582|NCT04839926|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33932429|NCT00171002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932430|NCT01117181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932431|NCT03951441|||COHORT||CROSS_SECTIONAL|||||||
33932432|NCT03573804|NA|SINGLE_GROUP||OTHER||NONE||||||
33932433|NCT04769336|||OTHER||PROSPECTIVE|||||||
33932434|NCT00880100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932435|NCT04024735|||COHORT||PROSPECTIVE|||||||
33932436|NCT05648123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932437|NCT03961893|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single-phase, two-stage, randomized phase II study||||
33932438|NCT01736163|||CASE_CONTROL||RETROSPECTIVE|||||||
33932439|NCT05739331|||CASE_ONLY||PROSPECTIVE|||||||
33932440|NCT02147691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932441|NCT06234085|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigators are blinded; participants can not be blinded to the intervention.|Randomized trial of an educational intervention or control.|f|f|t|f
33932442|NCT03993301|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33932443|NCT03515616|||COHORT||PROSPECTIVE|||||||
33932444|NCT01161927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932445|NCT00922038|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932446|NCT02683460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932447|NCT02304640|||COHORT||PROSPECTIVE|||||||
33932448|NCT01291511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932449|NCT02748278|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33932450|NCT06015841|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33932451|NCT03000621|||COHORT||PROSPECTIVE|||||||
33932452|NCT04944927|||CASE_ONLY||RETROSPECTIVE|||||||
33932453|NCT04438200|||OTHER||CROSS_SECTIONAL|||||||
33790903|NCT03861169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932454|NCT03156725|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|When 57Fe was added to a meal an empy capsule was consumed by the subjects. 58Fe and natutal abundace iron associated with A. oryzae was consumed in capsule form.|Subjects were two meals on two consecutive days with the stable isotopes.|t|f|f|f
33932455|NCT06236763|||COHORT||PROSPECTIVE|||||||
33932456|NCT03130504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932457|NCT00492895|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33932458|NCT00312741|||||PROSPECTIVE|||||||
33932459|NCT06066190|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33932460|NCT03645915|||CASE_ONLY||RETROSPECTIVE|||||||
33932461|NCT02347254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010758|NCT01606059|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34010759|NCT01959906|||COHORT||RETROSPECTIVE|||||||
34010760|NCT04711720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34010761|NCT01202617|||COHORT||PROSPECTIVE|||||||
34010762|NCT02322788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34010763|NCT05365152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34010764|NCT06227702|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized 1:1||||
34010765|NCT01941888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34103275|NCT06361446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either zonisamide and acetaminophen or propranolol and acetaminophen from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included zonisamide and acetaminophen, and Drug B included propranolol and acetaminophen. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will assess The number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.|f|f|t|t
33790904|NCT00810225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33790905|NCT00738075|||CASE_CONTROL|||||||||
33790906|NCT06416202|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A multi-center, randomized controlled trial will be conducted at King Fahad Medical City \& Prince Sultan Military Medical City. The study will involve two intervention groups and one control group: one receiving open-loop insulin delivery (OLID) and the others receiving Advanced Hybrid Closed Loop (AHCL) Therapy.~Participants will be randomly assigned to either the control group (OLID) or one of the intervention groups (AHCL). Stratified randomization will be used according to age (\<18 and ≥18 years) and HbA1c (\<8.5% and ≥8.5%) to avoid overrepresentation of certain age or glycemic control groups."||||
33790907|NCT01693614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790908|NCT01981850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790909|NCT03463135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790910|NCT04886180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790911|NCT05013606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Pills for both conditions look very similar and each group sees only the pill assigned to that group (H2 or placebo) and not the pill assigned to the other group. Also neither the outcome assessor nor the investigator know which condition that specific individual subjects are assigned to. This is because a blocked randomization schedule of numbers (1s and 2s) is used to assign each consecutive subject enrolled in the study to one of the study conditions. The code that links each subject to an identifiable condition assignment is known only by the PI and not the staff who selects the pills to be sent out to each subject or by the outcomes assessor. Also the subject fills out online outcome forms that involve no interaction with study staff, thus avoiding any staff-specific influence on online outcome forms.|This clinical study involves two groups, one group receiving only the active treatment, hydrogen pills mixed with water, and the other group receiving only a placebo pill mixed with water.|t|f|t|t
33790912|NCT06156319|||COHORT||PROSPECTIVE|||||||
33790913|NCT02605434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010766|NCT04357613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010767|NCT04417582|||COHORT||PROSPECTIVE|||||||
34010768|NCT03020784|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34103276|NCT05353751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103277|NCT06543381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010769|NCT00768118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010770|NCT01046630|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34010771|NCT04186559|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34010772|NCT00810888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094595|NCT04450875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Balanced groups are produced on the computer-generated random numbers based on the sex of the study subjects, that is, men and women were proportionally assigned in both groups. An investigator from outside the allocation of exposure generated the random numbers in four blocks: 1) men assigned to the experimental group, 2) women assigned to the experimental group, 3) men assigned to the control group and 4) women assigned to the control group. A second investigator, blindly assigned subjects to experimental and control group. Although concealment of allocation to interest groups could be confirmed, masking of difficulties was not possible once the follow-up began.|Experimental group: It consisted of a nutritional therapy administration of foods with a high content of methionine according to the National Nutrient Database For Standard Reference (USDA) and adapted to the consumption and usual cost in the Mexican diet. The supervision of the nutritional therapy was carried out through 24-hour reminders, where each patient wrote down the amount and food consumed described in the diet during a 3-month follow-up period. Because the daily requirement for methionine for adults is 260 to 700 mg 98, patients were instructed to combine the foods until they reached a daily intake of at least 700 mg of methionine. Two nutritionists performed both diet instruction and 24-hour reminder monitoring monthly. At the end of the three-month follow-up, the 24-hour reminder data such as food consumed, daily rations, and the monthly average of milligrams of consumed methionine contained in the food, were recorded in a database for subsequent analysis.|t|f|f|t
34094596|NCT05122715|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094597|NCT05987280|||OTHER||PROSPECTIVE|||||||
34094598|NCT05328544|RANDOMIZED|PARALLEL||TREATMENT||NONE||A- stabilization of the tibial attachment with a bioabsorbable screw (Arthrex) with simultaneous application to the tibial canal of autogenous cancellous bone grafts taken during the drilling of this canal; B- stabilization of the tibial insertion with a bioabsorbable screw (Arthrex) without simultaneous application of autogenous cancellous bone grafts to the tibial canal.||||
34094599|NCT05535335|||COHORT||PROSPECTIVE|||||||
34094600|NCT05301777|||COHORT||PROSPECTIVE|||||||
34094601|NCT05742750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094602|NCT02890888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094603|NCT04831554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094604|NCT04545138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094605|NCT05177263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The opaque envelopes are stored in a locked cabinet by the researcher who performed the randomization. The group including the eligible premature infants will not be shared care provider and assessors. Parents will be masked to the groups. Data entries will be performed using the codes A, B, C, and D. Codes will be shared with the researchers after statistical analyses are conducted and the research report is written.||t|t|t|t
34094606|NCT00852878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094607|NCT02083211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094608|NCT04393428|||COHORT||RETROSPECTIVE|||||||
33707723|NCT03798405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The primary investigators will be blinded, as will the computer programmers who collect the data.|Consecutive patients with IBD admitted to the hospital will be screened, and eligible patients will be consented. Patients who have a pain score \> 0 and require pain control will randomly receive the reactive traditional prescribing or the proactive standard-of-care orderset guideline - all patients will receive a FitBit exercise tracker.|f|f|t|t
34094609|NCT04312854|||COHORT||PROSPECTIVE|||||||
34094610|NCT03010956|||CASE_CROSSOVER||PROSPECTIVE|||||||
34094611|NCT04631978|||CASE_CONTROL||PROSPECTIVE|||||||
34094612|NCT02912377|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34094613|NCT00120874|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33707724|NCT05026255|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective multicentre open-label study of mechanically ventilated intensive care patients.||||
33707725|NCT06047483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707726|NCT01299740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707727|NCT02892578|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707728|NCT05776498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707729|NCT05473390|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790914|NCT02010619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094614|NCT06544395|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34094615|NCT00780039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094616|NCT04510753|||COHORT||PROSPECTIVE|||||||
34094617|NCT03170921|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33707730|NCT02097004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094618|NCT05132452|||COHORT||PROSPECTIVE|||||||
34094619|NCT02705157|||COHORT||PROSPECTIVE|||||||
33707731|NCT02898883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094620|NCT01623752|||COHORT||PROSPECTIVE|||||||
34094621|NCT06473428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094622|NCT03985995|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34094623|NCT03306121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094624|NCT00597675|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34094625|NCT00837330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094626|NCT04794998|||COHORT||RETROSPECTIVE|||||||
34094627|NCT06261957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094628|NCT05957120|||COHORT||CROSS_SECTIONAL|||||||
34094629|NCT02326090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094630|NCT00508300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094631|NCT05403073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094632|NCT03083379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707732|NCT03616600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
33707733|NCT05851066|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33707734|NCT02794883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707735|NCT01450995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707736|NCT02781831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707737|NCT05590130|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33707738|NCT05862415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707739|NCT01979887|||COHORT||PROSPECTIVE|||||||
33707740|NCT00970060|NA|SINGLE_GROUP||||NONE||||||
33707741|NCT04700371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707742|NCT05116618|||COHORT||PROSPECTIVE|||||||
33707743|NCT00941785|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790915|NCT00696618|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33790916|NCT00024531|RANDOMIZED|||TREATMENT||DOUBLE||||||
33932462|NCT05526625|||CASE_ONLY||CROSS_SECTIONAL|||||||
33932463|NCT00003304||||TREATMENT||||||||
33932464|NCT03838601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932465|NCT03531710|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932466|NCT02561676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932467|NCT00938093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932468|NCT03529175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932469|NCT02078089|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33932470|NCT00657930|||CASE_CONTROL||PROSPECTIVE|||||||
33932471|NCT01237223|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33932472|NCT03420157|||OTHER||PROSPECTIVE|||||||
33932473|NCT05249803|||OTHER||RETROSPECTIVE|||||||
33932474|NCT00057928|RANDOMIZED|||TREATMENT||||||||
33932475|NCT03152188|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single-blind study in which subjects will not be aware whether they will be on placebo or FMT capsulres|Placebo-controlled single-blind randomized trial|t|f|f|t
33932476|NCT03607149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932477|NCT03923504|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932478|NCT04872504|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932479|NCT01442090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932480|NCT01191957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932481|NCT05490381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932482|NCT03058263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932483|NCT03651128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932484|NCT00257504|||CASE_CONTROL||OTHER|||||||
33932485|NCT01670708|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932486|NCT02389218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932487|NCT00125892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932488|NCT03677544|||COHORT||RETROSPECTIVE|||||||
33707744|NCT03914378|||COHORT||PROSPECTIVE|||||||
33707745|NCT06524284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707746|NCT01284829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707747|NCT03090802|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707748|NCT02671175|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707749|NCT06111807|||COHORT||PROSPECTIVE|||||||
33707750|NCT02321878|||COHORT||PROSPECTIVE|||||||
33707751|NCT03284398|||OTHER||RETROSPECTIVE|||||||
33707752|NCT04207775|||COHORT||PROSPECTIVE|||||||
33707753|NCT02794038|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33707754|NCT05654220|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33707755|NCT01687998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932489|NCT02396004|||COHORT||PROSPECTIVE|||||||
33932490|NCT05764811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932491|NCT06137989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Except the investigator, the participants and the two clinical examiners were blinded to the type of bulk-fill resin composite applied in each tooth (a double-blinded clinical trial).|Each patient received three Class ӀӀ restorations with the three tested bulk-fill resin composites.|t|f|f|t
33932492|NCT03192800|||COHORT||PROSPECTIVE|||||||
33932493|NCT01928953|||COHORT||PROSPECTIVE|||||||
33932494|NCT03822546|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33932495|NCT03253185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932496|NCT06247449|NA|SINGLE_GROUP||SCREENING||NONE||||||
33932497|NCT00826384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094633|NCT05260632|||COHORT||CROSS_SECTIONAL|||||||
34094634|NCT02455180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094635|NCT02201576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094636|NCT02451319|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34103278|NCT05904548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103279|NCT04250402|||COHORT||RETROSPECTIVE|||||||
33707756|NCT00547482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707757|NCT04108065|||CASE_CONTROL||PROSPECTIVE|||||||
33707758|NCT02355457|||COHORT||PROSPECTIVE|||||||
33790917|NCT02370563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790918|NCT01559519|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33790919|NCT00795990|||COHORT||RETROSPECTIVE|||||||
34094637|NCT03223194|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Up to four subjects will be enrolled at each dose level including up to1 subject at each dose level randomized to control with delayed initiation of treatment. One of the dose levels will be chosen for dose expansion and all control subjects will then be treated at the chosen dose level.||||
34094638|NCT04398914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094639|NCT02369250|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094640|NCT03729479|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2x2 full factorial|f|f|f|t
34094641|NCT05162911|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||randomized control trial||||
34094642|NCT02907827|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34094643|NCT04550403|||COHORT||RETROSPECTIVE|||||||
33707759|NCT01938456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707760|NCT04152278|||CASE_CONTROL||PROSPECTIVE|||||||
33707761|NCT03495219|||OTHER||PROSPECTIVE|||||||
33707762|NCT02650674|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33707763|NCT01416064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707764|NCT00788567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707765|NCT00118677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707766|NCT05262608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707767|NCT03205332|RANDOMIZED|PARALLEL||TREATMENT||NONE|Eligibility Assessor|||||
33707768|NCT00816530|||||PROSPECTIVE|||||||
33707769|NCT05769829|||COHORT||PROSPECTIVE|||||||
33707770|NCT06451601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707771|NCT02376231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707772|NCT00653055|RANDOMIZED|CROSSOVER||||NONE||||||
33707773|NCT01699906|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707774|NCT01927653|||CASE_CONTROL||PROSPECTIVE|||||||
33707775|NCT00564772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707776|NCT00299104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707777|NCT05899036|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, open-label, single-arm study to assess the initial technical (performance), effectiveness, and safety of the RapidPulseTM Aspiration System. As such, no formal statistical hypothesis will be tested in this study.||||
33707778|NCT03994224|||COHORT||PROSPECTIVE|||||||
33790920|NCT06031194|||COHORT||PROSPECTIVE|||||||
33932498|NCT05258981|NA|SINGLE_GROUP||OTHER||NONE||||||
33932499|NCT01816373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932500|NCT05031806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932501|NCT00691977|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33932502|NCT01609569|||||PROSPECTIVE|||||||
33932503|NCT01154907|||COHORT||PROSPECTIVE|||||||
33932504|NCT05588713|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Masking is not possible. The assessors that will review the material for reliability and validity purposes will be blind to diagnostic status of the participants.|Group A will receive a brief assessment protocol and Group B will receive a comprehensive assessment protocol.||||
33932505|NCT03905525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, investigator staff, persons performing the assessments, will remain blind to the identity of the treatment within each cohort from the time of randomization until end of the study visit (week 60)|"Patients will be screened and enrolled into one of the 2 study Cohorts:~Cohort 1: At baseline subjects will be randomized in ratio 1:1:1:1 into one of three CFZ533 (iscalimab) arms (A, B or C) or to placebo (Arm D). After completion of 24 weeks of treatment (Period 1) placebo patients (Arm D) will be switched to active treatment (Arm D1) for the subsequent 24 weeks (Period 2).~Cohort 2: At baseline subjects will be randomized in ratio 1:1 to iscalimab (Arm E) or to placebo (Arm F). After completion of 24 weeks of treatment (Period 1), placebo patients (Arm F) will be switched to iscalimab active treatment (Arm F1) for the subsequent 24 weeks (Period 2).~All patients treated with iscalimab (Arms A,B,C,and E) in Period 1 will continue the same study treatment in Period 2."|t|t|t|t
33932506|NCT01666353|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932507|NCT00949845||||BASIC_SCIENCE||||||||
33932508|NCT05540210|NA|SINGLE_GROUP||OTHER||NONE||||||
33932509|NCT03458988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707779|NCT02284984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707780|NCT03486548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707781|NCT03570073|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33707782|NCT01099605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33707783|NCT03500354|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot feasibility open-label study||||
33707784|NCT02213367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707785|NCT02798133|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707786|NCT04962178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707787|NCT01022229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707788|NCT04563611|RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy recreational people aged between 18-25 will assign to this study. The participants will randomly be allocated four groups (Nordic protocol group, Supine sliding leg curls group, Turkish Get Up (TGU) and control group).||||
33790921|NCT05738226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790922|NCT04183530|||COHORT||PROSPECTIVE|||||||
33790923|NCT02905968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790924|NCT02148133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790925|NCT04355702|||COHORT||RETROSPECTIVE|||||||
33790926|NCT00906035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790927|NCT02716649|||COHORT||RETROSPECTIVE|||||||
33790928|NCT01260298|||COHORT||PROSPECTIVE|||||||
33790929|NCT01030497|||CASE_ONLY||PROSPECTIVE|||||||
33790930|NCT00128193|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33790931|NCT00018525|RANDOMIZED|||TREATMENT||||||||
33790932|NCT02135172|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33790933|NCT04008394|NA|SINGLE_GROUP||TREATMENT||NONE||Single-center,Open,One-arm Clinical Study||||
33790934|NCT02914522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790935|NCT03857334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33790936|NCT05028712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33790937|NCT05566587|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33790938|NCT00105794|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33790939|NCT00964119|||CASE_ONLY||PROSPECTIVE|||||||
33790940|NCT00385801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790941|NCT06426303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33790942|NCT00829855|||CASE_CROSSOVER||PROSPECTIVE|||||||
33790943|NCT01210157|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34094644|NCT01264471|||CASE_ONLY||CROSS_SECTIONAL|||||||
34094645|NCT01677065|||CASE_CROSSOVER||PROSPECTIVE|||||||
34094646|NCT02639026|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094647|NCT01447771|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34094648|NCT00601107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094649|NCT05399342|||COHORT||PROSPECTIVE|||||||
34094650|NCT02473874|||CASE_CONTROL||PROSPECTIVE|||||||
34094651|NCT05349500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094652|NCT04077606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double blind (trial participants and outcome assessors). Each participant included in this study will be blinded (without knowing type of intervention received).~Blinded assessors :blinding to the laboratory assessors is done by not involving them in sequence generation or allocation concealment or treatment options."||t|f|f|t
34094653|NCT01139372|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707789|NCT05813951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|. At the beginning of the study, simple randomization will be used to assign patients using the random numbers set offered by the ICU coordinator. Each patient will be assigned a randomized code consisting of two letters that indicate the intensive care unit and two digits indicating the randomization sequence.|Prospective randomized controlled study|t|t|f|f
33790944|NCT05395949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707790|NCT02803255|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790945|NCT03646331|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790946|NCT01336283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33707791|NCT01910857|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33790947|NCT04935749|||CASE_ONLY||CROSS_SECTIONAL|||||||
33790948|NCT05621811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010773|NCT00478452|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients will be randomized to cyclophosphamide 300 mg/m2 (arm 2) or no cyclophosphamide (arm 1). All subjects will receive intradermal injections of DC on day 2 and on week 3, 6, and 9 (+ 3 days). All subjects will undergo leukocyte apheresis at study enrollment and at week 10, which is the end of active study intervention. All study arm patients (1 and 2) will receive a single dose of trivalent killed influenza vaccine, and a single dose of Prevnar pneumococcal vaccine on the day they receive their first intradermal injections of DC on day 2.||||
34010774|NCT04478045|||CASE_ONLY||PROSPECTIVE|||||||
34010775|NCT04026373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010776|NCT05466279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010777|NCT06388837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010778|NCT06389513|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010779|NCT03968497|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Half of the patients were first evaluated by the female and then by the male investigator, and the other half the other way around, according to a cross-over study design but with a single group of subjects.||||
34094654|NCT04352530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103280|NCT01575548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707792|NCT05963594|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33707793|NCT05041205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study, participants and outcomes assessors are masked.|Participants are assigned to four group during the study: a placebo control group, a beauty drink powder group, a cosmetic apparatus group, and a beauty drink powder + cosmetic apparatus group|t|f|f|t
33707794|NCT06065943|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33707795|NCT05638568|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|It is not possible to blind LS-guided surfactant treatment in the interventional group, but the actual result of the LS-test will remain blinded for both groups until completion of the study except for as detailed above.|"all participating infants will have a gastric aspirate (GAS) sampled at birth within 45 minutes of life.~The GAS will be analyzed bedside by a LS-test POC device. For infants allocated to the interventional group the LS-result will be displayed as treat with surfactant or  do not treat with surfactant depending on wether the LS-ratio is under or above the cut-off ratio for treatment.~Those with LS-ratio above the cut-off ratio will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)~Infants allocated to the control group will be treated with surfactant as per routine in accordance with the European RDS guidelines based on oxygen requirement (FiO2 \> 0.30). The LS-ratio for those infants will remain blinded"||||
33707796|NCT02494297|||OTHER||CROSS_SECTIONAL|||||||
33707797|NCT02901314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||usual care education versus education with a pre-recorded card with heart failure instructions|f|f|t|f
33707798|NCT04602988|||COHORT||PROSPECTIVE|||||||
33707799|NCT04063930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707800|NCT01966159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707801|NCT06234917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33707802|NCT00134238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707803|NCT00092989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707804|NCT03280498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790949|NCT00005732|||NATURAL_HISTORY|||||||||
33790950|NCT02411942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790951|NCT04392713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790952|NCT04618458|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33790953|NCT02039713|||COHORT||PROSPECTIVE|||||||
33790954|NCT02709343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33790955|NCT04008836|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Subjects will be assigned to use the T-PLUS meter||||
33790956|NCT03659201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790957|NCT04138771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33790958|NCT01320072|||CASE_CONTROL||PROSPECTIVE|||||||
33790959|NCT05817318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790960|NCT04137874|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||ParaNASPP is a stepped wedge cluster randomized controlled intervention trial (SW-RCT).||||
33790961|NCT01591616|NA|SINGLE_GROUP||OTHER||NONE||||||
33790962|NCT05183906|||COHORT||PROSPECTIVE|||||||
33790963|NCT04867018|||CASE_CONTROL||PROSPECTIVE|||||||
34010780|NCT01695096|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34010781|NCT04719741|||CASE_CONTROL||PROSPECTIVE|||||||
34010782|NCT03509714|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Oxaloacetate/Vitamin C capsules were bottled in 30 count HDPE bottles. Placebo capsules (rice flour) were manufactured to similar size capsules and bottles. Bottles were labeled either Group A or Group 1. Code was broken at the end of Phase 1 of the study.|Baseline measurement of all participants. Randomized double-blinded placebo controlled crossover study for Phase 1. Due to carry-over effects, Phase 2 of the study started each participant with placebo.|t|t|t|f
34010783|NCT04186598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Standard CPAP systems and control CPAP systems that provide high flow oxygen without PEEP||t|t|f|f
34010784|NCT02237742|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34010785|NCT05248984|||COHORT||PROSPECTIVE|||||||
34010786|NCT01123317|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||||||
34103281|NCT05940649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34103282|NCT02006836|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707805|NCT06270667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010787|NCT03416114|||COHORT||OTHER|||||||
33707806|NCT02256020|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34010788|NCT05881642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707807|NCT00020904||||TREATMENT||||||||
33790964|NCT00812136||||PREVENTION||||||||
33790965|NCT05566080|||COHORT||CROSS_SECTIONAL|||||||
33790966|NCT04327882|||COHORT||PROSPECTIVE|||||||
33790967|NCT00038103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010789|NCT02898103|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Treatment group assignments were unmasked after the leads were removed 2 weeks after surgery.||t|t|t|t
33790968|NCT05861388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010790|NCT01226251|||COHORT||PROSPECTIVE|||||||
34010791|NCT05173870|||OTHER||PROSPECTIVE|||||||
34010792|NCT03971578|||CASE_CONTROL||OTHER|||||||
34010793|NCT03476317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707808|NCT02654340|||COHORT||PROSPECTIVE|||||||
33707809|NCT00277498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707810|NCT03758209|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigators and assessors will be blinded regarding preoperative preparation. Both randomization process and rehabilitation process will be carried out by a trained nurse, physiotherapist and psychotherapist, neither of them will be involved in outcome assessment.|"Patients planned for elective, curative operations for colorectal cancer will be randomized into two groups: experimental group will take part in a dedicated 4-week multimodal preparation program followed by ERAS preoperative management, while control group will just participate in the ERAS program without specific physical and mental preparation.~1:1 randomization will be performed."|f|t|t|t
33790969|NCT04726813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707811|NCT02900339|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707812|NCT03949361|||COHORT||PROSPECTIVE|||||||
33790970|NCT00201695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010794|NCT02946216|||CASE_ONLY||PROSPECTIVE|||||||
34010795|NCT03879096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010796|NCT05365659|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103283|NCT06690463|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34103284|NCT06542289|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label study|A single-arm study for subjects diagnosed with facial nerve palsy.||||
34103285|NCT01704989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707813|NCT04568070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707814|NCT04218825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707815|NCT05113017|||COHORT||PROSPECTIVE|||||||
33707816|NCT04578431|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|All participants are given the same intervention and are aware of this|"60 women will be divided into three groups (n=20 each) based on pre-pregnancy BMI and metabolic status.~The groups are~1. Normal weight (BMI \< 25),~2. Over weight (BMI \> 27),~3. Diabetic"||||
33790971|NCT06321913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790972|NCT04048304|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33790973|NCT01219218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33790974|NCT00028093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790975|NCT01620372|||COHORT||RETROSPECTIVE|||||||
33790976|NCT02167646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790977|NCT00099619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33790978|NCT02303444|||COHORT||PROSPECTIVE|||||||
33790979|NCT01444235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33790980|NCT02613364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33790981|NCT01557998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33790982|NCT01040741|||COHORT||PROSPECTIVE|||||||
33790983|NCT02176096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790984|NCT01078246|||COHORT||RETROSPECTIVE|||||||
33790985|NCT06123585|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33790986|NCT04580199|RANDOMIZED|PARALLEL||TREATMENT||NONE||age above 18 male or female manifested thyroid nodule||||
33790987|NCT04025606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33790988|NCT06189391|NA|SEQUENTIAL||TREATMENT||NONE||||||
33790989|NCT02459899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010797|NCT04737850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel assignment|t|t|t|t
34103286|NCT06689904|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103287|NCT03397641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790990|NCT00500500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33790991|NCT00060099|RANDOMIZED|||TREATMENT||DOUBLE||||||
33790992|NCT06260696|||COHORT||CROSS_SECTIONAL|||||||
33790993|NCT06421688|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33790994|NCT05068167|||OTHER||PROSPECTIVE|||||||
33790995|NCT00771849|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33790996|NCT01402271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33790997|NCT03531853|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33790998|NCT04148417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33790999|NCT02599844|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33791000|NCT05573711|||COHORT||PROSPECTIVE|||||||
33791001|NCT04132440|||COHORT||PROSPECTIVE|||||||
33791002|NCT04227990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010798|NCT03721302|||COHORT||PROSPECTIVE|||||||
34025280|NCT04837924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be blinded by sham procedure (disinfection, sting with blunt needle, (without piercing the skin), in the groin area, same place where actual FICB is given and covered with same gauze/patch). It will not be revealed to care providers and outcome measurement associate in which group participant is. After the data collection statistical analyst will not know is A group experimental or control.|80 participants, stratified randomization will be used, men/women, age 65-75 years/older then 75 years, The American Society of Anesthesiologists physical status classification, (ASA status) I-II/ ASA III and IV, and type of hip fracture intra/extracapsular|t|t|f|t
34025281|NCT05506150|||COHORT||PROSPECTIVE|||||||
34025282|NCT01446328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707817|NCT03267706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients and caregivers are blinded as to whether their clinician received training and access to the newly introduced comprehensive palliative care tool. Clinicians delivering care are not blinded to use of the tool, outcome assessors are not blinded to the data|Pilot prospective randomized controlled trial|t|f|f|f
33707818|NCT02541019|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33707819|NCT02080949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707820|NCT00003105||||TREATMENT||||||||
33707821|NCT00763100|||CASE_CROSSOVER||PROSPECTIVE|||||||
33707822|NCT03992001|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The patients will not be informed on the blood components sequence that they will receive. However, the units exterior appearance of the two types of preparations is different. For this reason, patients and care providers will most probably notice it.|Patients will be divided into two groups of approximately equal number. The first group will receive the blood component A for a period of 6 months and then the blood component B for the next 6 months. The second group will receive the blood components in inverted order||||
33707823|NCT03442205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707824|NCT00870792|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33707825|NCT05626985|||COHORT||PROSPECTIVE|||||||
33791003|NCT05407142|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791004|NCT05393336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791005|NCT02331043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791006|NCT02869620|||COHORT||PROSPECTIVE|||||||
33791007|NCT03851237|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791008|NCT01694628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791009|NCT05757076|||COHORT||PROSPECTIVE|||||||
33791010|NCT05156359|||CASE_ONLY||RETROSPECTIVE|||||||
33791011|NCT03813706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707826|NCT04564573|||CASE_ONLY||CROSS_SECTIONAL|||||||
33707827|NCT05729646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791012|NCT05735444|||COHORT||PROSPECTIVE|||||||
33791013|NCT03101618|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33791014|NCT06460948|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study Model description: In this open-labeled, interventional pilot trial, 16 adults with arginine-vasopressin deficiency and 16 healthy controls balanced for age, sex, and body mass index will be recruited||||
33791015|NCT02515682|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33791016|NCT02650596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33791017|NCT00559949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791018|NCT02485041|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791019|NCT02546219|||OTHER||PROSPECTIVE|||||||
33791020|NCT03537651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791021|NCT04687085|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33791022|NCT02685033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932510|NCT04571736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932511|NCT02047409|||COHORT||PROSPECTIVE|||||||
33932512|NCT04106180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932513|NCT04852952|||OTHER||CROSS_SECTIONAL|||||||
33932514|NCT02762760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932515|NCT05265390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33932516|NCT00971568|||CASE_CONTROL||RETROSPECTIVE|||||||
33932517|NCT01010776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932518|NCT00852761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932519|NCT05298163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932520|NCT04312789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932521|NCT02974660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33932522|NCT02603172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932523|NCT03260283|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Double blind randomized control trial|t|t|t|f
33932524|NCT04126460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932525|NCT05561634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932526|NCT00832689||||TREATMENT||||||||
33932527|NCT03122652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932528|NCT00959699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932529|NCT04712669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Following screening assessments, Patients will be enrolled into 1 of 3 treatment arms in a 1:1:1 randomization.|t|t|t|t
33932530|NCT00903994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33932531|NCT00758251|||CASE_ONLY||PROSPECTIVE|||||||
33932532|NCT04105322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932533|NCT06254846|NA|SINGLE_GROUP||OTHER||NONE||Prospective, single-centre study to assess the diagnostic performance (sensitivity and specificity) of HPV PCR on 1st-draft urine compared with cervico-vaginal sampling (= gold standard).||||
33932534|NCT00215189|||||PROSPECTIVE|||||||
33932535|NCT00706056|||COHORT||PROSPECTIVE|||||||
33932536|NCT03482336|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants were handled differently in the methods. For the first block of participants, the FOP was not pointed out. For the second block, researchers merely pointed to the FOP and indicated that it might be helpful in decision making.|Two blocks of participants were recruited. One block received no information regarding the FOP; for the second block, researchers pointed to an FOP and suggested that the information might be helpful in deciding which product was healthier.||||
33932537|NCT01451567|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33932538|NCT02090673|||CASE_ONLY||PROSPECTIVE|||||||
33932539|NCT02387073|||COHORT||CROSS_SECTIONAL|||||||
33932540|NCT02931747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932541|NCT05578560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025283|NCT06060678|||OTHER||PROSPECTIVE|||||||
34025284|NCT04127630|||COHORT||PROSPECTIVE|||||||
34025285|NCT00351533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025286|NCT06489626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025287|NCT00869336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707828|NCT05317182|RANDOMIZED|FACTORIAL||OTHER||NONE||"This clinical study has three arms of equal size: occlusal splints made by conventional impression and conventional fabrication (Group 1), occlusal splints made by conventional impression and digital design and fabrication (Group 2), and occlusal splints performed by intra-oral scanner and digital design and fabrication (Group 3).~Otherwise, the allocation of each subject to each group will be done at random by a list made with specialized software until the sample will be fulfilled when the patient is recruited."||||
33707829|NCT02801396|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707830|NCT01947582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707831|NCT00796198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707832|NCT03207854|||CASE_CONTROL||RETROSPECTIVE|||||||
33707833|NCT05282758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791023|NCT05288348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791024|NCT01981330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791025|NCT02852863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791026|NCT04658849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||We plan to conduct a prospective, randomized, double-blind, placebo-controlled trial in 44 men with nonmetastatic prostate cancer who will receive ADT with long acting GnRH agonist.|t|t|t|t
33791027|NCT04990219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791028|NCT04246619|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Treatment is started at Visit 2 with Pregabalin Krka or Dulsevia - according to randomisation.||||
33791029|NCT04628442|||COHORT||CROSS_SECTIONAL|||||||
33791030|NCT06420713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791031|NCT01717794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791032|NCT06631976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791033|NCT02220491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791034|NCT03432780|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, multicenter, multidisciplinary, parallel-group, open-label study with randomized group assignment||||
33791035|NCT03728595|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791036|NCT01490580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791037|NCT06435260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791038|NCT00673543|||CASE_CONTROL||PROSPECTIVE|||||||
33791039|NCT01198340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791040|NCT00161018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791041|NCT00117871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33932542|NCT04888182|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, parellel, not blinded||||
33932543|NCT02962505|||COHORT||PROSPECTIVE|||||||
33932544|NCT05498025|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective single arm interventional pilot study.||||
33932545|NCT02250391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932546|NCT04488549|||OTHER||PROSPECTIVE|||||||
33932547|NCT00937508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932548|NCT00438490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33932549|NCT04691531|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33932550|NCT04339725|||COHORT||PROSPECTIVE|||||||
33932551|NCT04094545|||OTHER||PROSPECTIVE|||||||
33932552|NCT04453605|||COHORT||PROSPECTIVE|||||||
33932553|NCT02276794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932554|NCT04705428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932555|NCT04506281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932556|NCT01449344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932557|NCT04737161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932558|NCT01355497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932559|NCT00096304||||TREATMENT||||||||
33932560|NCT02382289|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33932561|NCT06322108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932562|NCT00285649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932563|NCT04976478|||COHORT||PROSPECTIVE|||||||
33932564|NCT01329068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932565|NCT05848336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932566|NCT04114045|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One member of the research team whom did not have direct contact with participant during performance testing, matched participants for age, sex and body mass into one of three groups (protein, carbohydrate or placebo/water). This member of the research team also prepared and distributed all the research supplements in a sealed black opaque containers|Participants were divided into three groups: PRO (0.3g/kg - whey protein isolate), CHO (0.3g/kg - maltodextrin) or placebo control (H2O), matched for age, sex and body mass|t|f|t|f
33932567|NCT01804647|||COHORT||PROSPECTIVE|||||||
33932568|NCT00728195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932569|NCT00937001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932570|NCT01576224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33932571|NCT00099567|||NATURAL_HISTORY||PROSPECTIVE|||||||
33932572|NCT02544698|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33932573|NCT05756205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be a two-arm prospective, randomized, parallel-controlled clinical trial. 150 women will be recruited and screened during their pregnancy|t|f|f|f
34103583|NCT04535661|||COHORT||RETROSPECTIVE|||||||
34103584|NCT05669352|NA|SEQUENTIAL||TREATMENT||NONE||||||
34103585|NCT04314973|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791042|NCT00256243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791043|NCT02787109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791044|NCT03855709|||COHORT||PROSPECTIVE|||||||
33791045|NCT03970590|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The investigators will conduct an RCT testing the CTC intervention (video viewing, selection of preferred narrative, narrative-aligned text messages) compared to assessment text messages alone.|t|f|f|f
33791046|NCT04436055|||OTHER||PROSPECTIVE|||||||
33791047|NCT03814395|||COHORT||PROSPECTIVE|||||||
33801784|NCT01152398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932574|NCT06183268|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33932575|NCT05432895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094655|NCT04401293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Due to the pragmatic nature of this study open-label multi-center randomized active control trial with pseudo-blinding mechanisms at the time of randomization the study subject and corresponding Site PIs will be blinded (unaware of specific treatment arm the patient is assigned to i.e. Arm 0 or Arm 1). The study pharmacists as well as data extractors and designated randomization personnel (i.e. research coordinators and/or research nurses performing the randomization process) will be un-blinded (aware of specific treatment arm the patient is assigned to i.e. Arm 0 or Arm 1). At the time of subject randomization study subjects will be stratified to either ICU level of care vs. Non-ICU level of care."||t|t|t|f
34094656|NCT06248528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094657|NCT03429205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34094658|NCT03986268|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||The patients had measured a total of 25 OH vit D3 levels, previously treated with neoadjuvant therapy without replacement treatment with vitamine D3, as a control group, were planned to be compared with 30-50 patient in study groups at baseline and / or at the end of the treatment period. The pathological response rates of both groups were planned to be evaluated according to the molecular subtypes.||||
34094659|NCT03268187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094660|NCT00550004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34094661|NCT04097223|||COHORT||RETROSPECTIVE|||||||
34094662|NCT03120572|||COHORT||PROSPECTIVE|||||||
34094663|NCT03083041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094664|NCT04482790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34094665|NCT02663440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094666|NCT02200627|||COHORT||RETROSPECTIVE|||||||
34094667|NCT05900245|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|Due to the fact that anesthesiologists need to determine the timing of electrical stimulation based on the level of consciousness index during the treatment of electric shock, this study is a randomized controlled, single blind study. The subjects were not aware of their grouping, consciousness index level, and the anesthesiologist was aware of the subjects' consciousness index level, but did not participate in data analysis. The data analyst is not clear about the specific content of the grouping.|Due to the fact that anesthesiologists need to determine the timing of electrical stimulation based on the level of consciousness index during the treatment of electric shock, this study is a randomized controlled, single blind study.Due to the varying frequency of electroconvulsive therapy performed by each subject, with an average of 6-12 times and varying duration of each electroconvulsive treatment, this study uses a mixed effects model to analyze the relationship between different consciousness indices and patient factors on the duration of EEG seizures.|t|f|t|t
34094668|NCT03885388|RANDOMIZED|PARALLEL||TREATMENT||NONE||treatment by combination of methotrexate and actinomycin||||
34094669|NCT00855478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094670|NCT04574505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a two-arm randomized, placebo-controlled, double-blind, monocentric parallel-groups clinical study conducted in Italy.|t|t|t|f
34094671|NCT00901498|RANDOMIZED|CROSSOVER||||NONE||||||
34094672|NCT02337946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094673|NCT05406895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be masked to which technique they are receiving.|Parallel model for either CBCT guided or intra-oral technique. If the patients receive a two-stage implant placement technique then a cross-over model will be used.|t|f|f|f
34094674|NCT05788198|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Investigators, care providers, and participants will know treatment arm allocation.|Pre/Posttest implementation study.||||
34094675|NCT00169325|||COHORT||PROSPECTIVE|||||||
34094676|NCT00132483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34094677|NCT05362539|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103586|NCT05106374|||COHORT||PROSPECTIVE|||||||
34103587|NCT06630390|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomized to either the daridorexant or placebo arm.|t|t|t|t
33707834|NCT04008576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707835|NCT02555683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707836|NCT00039130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707837|NCT02847832|||COHORT||PROSPECTIVE|||||||
33707838|NCT06558032|RANDOMIZED|CROSSOVER||OTHER||NONE||This was a bioequivalence study||||
33707839|NCT03791489|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, feasibility study of multi-treatment locations||||
34103588|NCT00324545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707840|NCT04081974|||COHORT||PROSPECTIVE|||||||
33707841|NCT06103123|||COHORT||PROSPECTIVE|||||||
34103589|NCT05168592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707842|NCT02637284|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707843|NCT02325960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707844|NCT03515876|||CASE_CONTROL||PROSPECTIVE|||||||
33707845|NCT00126191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932576|NCT05526092|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33932577|NCT01704976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932578|NCT02966236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707846|NCT00266734|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33707847|NCT00827502|||||PROSPECTIVE|||||||
33707848|NCT05866172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33707849|NCT06461364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707850|NCT04800354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707851|NCT04145557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33707852|NCT05572320|||COHORT||PROSPECTIVE|||||||
33707853|NCT06051227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33707854|NCT04859361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33707855|NCT00520936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932579|NCT02793804|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932580|NCT00995189|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33932581|NCT00060151||||TREATMENT||NONE||||||
33932582|NCT03398824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010799|NCT04410575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Stratified randomization of participants via blocking factor to either pharmacist intervention or standard pharmacist care groups.~Participants will be assigned a unique identifier number \& group allocation for the duration of their participation in the study (also recorded by the pharmacy partner to ensure consistency in the delivery of pharmacist interventions described by the participant's group allocation.~The participant is sent a secured electronic link (to the contact number or email they provided in the written consent form) of the electronic version of the PHQ-9/GAD-7 questionnaire tool to complete.~The study data (from the participant's electronic questionnaire tool results) will be sent directly to a centralized \& secured website/spreadsheet to ensure allocation concealment for the investigational team. The participant will report their score to the pharmacist participant through an electronic recording platform"|Multi-center randomized control trial evaluating the mean difference in depression and anxiety score with patients with major depressive disorder (MDD) and/or generalized anxiety disorder (GAD) by pharmacists with prescribing \& management interventions in comparison to pharmacist management per standard pharmacist care.|f|f|t|t
34010800|NCT01345318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103590|NCT05125172|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be aware of their group allocation compared to the other group.|Randomized cross-over study. Participants will be randomized into the internal or external focus of attention group and one week later they will complete the opposite protocol.|t|f|f|f
34103591|NCT01518036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707856|NCT00289991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707857|NCT02643680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707858|NCT00244465|||COHORT||PROSPECTIVE|||||||
33707859|NCT05492344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707860|NCT06413563|||CASE_CONTROL||RETROSPECTIVE|||||||
33707861|NCT04401085|||COHORT||CROSS_SECTIONAL|||||||
33707862|NCT03680105|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33707863|NCT01785927|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707864|NCT00078442|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707865|NCT01024452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707866|NCT00804674|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33707867|NCT00920712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707868|NCT03290872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707869|NCT05433324|||CASE_CONTROL||PROSPECTIVE|||||||
33707870|NCT02124330|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33707871|NCT04945005|||COHORT||PROSPECTIVE|||||||
33801785|NCT02825641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932583|NCT00137293|RANDOMIZED|PARALLEL||||DOUBLE||||||
33932584|NCT02490904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932585|NCT00033059|RANDOMIZED|||TREATMENT||DOUBLE||||||
33932586|NCT05001581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 different groups. Differences in type of surgery Comparison of two ways of treatment||||
33932587|NCT04689217|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33932588|NCT06165016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double blinded study where both the participant and the people collecting data will be blinded.|Investigators will randomize 32 participants age 50 and older with PAD to one of two groups: far red light therapy or sham therapy. Participants will be followed for four months.|t|t|f|t
33932589|NCT00533299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932590|NCT00000767||||PREVENTION||DOUBLE||||||
33932591|NCT00126425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932592|NCT02037204|NA|SINGLE_GROUP||TREATMENT||NONE||First in man surgery: autologous chondrons are mixed with allogeneic MSCs and implanted in a fibrin glue carrier in a one-stage surgical procedure.||||
33932593|NCT00024206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932594|NCT04884997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932595|NCT00572312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932596|NCT00320190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932597|NCT02195947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932598|NCT02625467|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932599|NCT00588380|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33932600|NCT03998241|||CASE_ONLY||CROSS_SECTIONAL|||||||
33932601|NCT03051217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932602|NCT03710694|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932603|NCT01701856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932604|NCT02001922|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33932605|NCT06231004|||OTHER||OTHER|||||||
33932606|NCT00655122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33932607|NCT05180604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33932608|NCT01467089|||CASE_ONLY||CROSS_SECTIONAL|||||||
33932609|NCT04151719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932610|NCT01547962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932611|NCT01938560|||||PROSPECTIVE|||||||
33932612|NCT02599441|||CASE_ONLY||CROSS_SECTIONAL|||||||
33932613|NCT05326204|||OTHER||PROSPECTIVE|||||||
33932614|NCT04705350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a participant- and Investigator-blind study.||t|f|t|f
33707872|NCT02165215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707873|NCT02949869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707874|NCT04861389|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707875|NCT01384526|||CASE_CONTROL||RETROSPECTIVE|||||||
33707876|NCT05827510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects will be enrolled and assigned into two study groups, according to their indication; group A (acne scars) and B (facial wrinkles), each study group will receive treatment of different conditions.||||
33707877|NCT02080234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707878|NCT05384093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801786|NCT01039155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932615|NCT00959894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932616|NCT01510028|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707879|NCT06264375|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Data is collected and afterwards anonymized during the pre- and post measurement and during the intervention using a weekly questionnaire (activity level, gaming time)|8 weeks of intervention, where Group 1 does a specific physical training, Group 2 a general physical training and Group 3 who does not train.||||
33707880|NCT03019575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707881|NCT01846234|||COHORT||PROSPECTIVE|||||||
33707882|NCT01343420|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33707883|NCT02733432|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor blinded|||||
33707884|NCT03045315|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34010801|NCT06106451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be masked.|Patients will be randomized to one of the 3 arms of the study.|f|f|f|t
34010802|NCT01876849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010803|NCT05420779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010804|NCT02128555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025288|NCT00925366|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025289|NCT05177302|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34025290|NCT06132932|NA|SINGLE_GROUP||TREATMENT||NONE||WX390 continuous oral dosing (1.1 mg once a day).||||
34094678|NCT03052673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient and the attending anaesthesiologist will be blinded to the intraoperative infusions used. Postoperative patient recovery profile will also be evaluated by an independent assess or blinded to the intraoperative anaesthesia technique.|"76 patients belonging to ASA physical patients status II and III of either sex, scheduled to undergo laparoscopic bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass) under general anaesthesia. The patients will be randomly allocated by computer generated numbers to one of the following two groups of 38 patients each.~Group 1\[Ketamine + Fentanyl Group, n=38\]: Pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Group 2\[Fentanyl Group, n=38\]:Pre-induction fentanyl 1-mcg/kg, saline after induction followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + saline infusion.~Both the groups will receive intravenous PCA of fentanyl post-operatively"|t|t|t|t
34094679|NCT04806425|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094680|NCT01058824|RANDOMIZED|CROSSOVER||||NONE||||||
34094681|NCT01640561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094682|NCT02487485|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34094683|NCT01993758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34094684|NCT06532916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants will be informed about the nature and objectives of the study; however, they will not be informed about the material they are going to receive. The evaluator will not be aware of the treatment groups.|The design of the study will be a double blinded (Evaluator and Patient) split-mouth randomized clinical study with two study groups.|t|f|f|t
34094685|NCT04230239|NA|SINGLE_GROUP||OTHER||NONE||"This protocol corresponds to a prospective, multicenter, open-label, phase II study to assess efficacy of CPX-351 in elderly patients (60 to 75 years of age) with newly diagnosed high risk AML. In the context of this protocol, a treatment cycle is defined as the first day of study drug administration (Day 1) up to and including the day before the first day of the treatment cycle immediately afterwards. The treatment cycles will begin after Day 42 but no later than Day 80, counting from Day 1 of the treatment cycle immediately before.~Treatment cycles may be administered while the patient is hospitalized. Patients will receive a maximum of 4 treatment cycles (up to 2 inductions and 2 consolidations) and 6 maintenance cycles. Clinical conditions in the care of patients with acute leukemia require the need for flexibility. However, deviations from the study treatment defined in this section must be prospectively discussed with the coordinator."||||
34094686|NCT06283875|||COHORT||PROSPECTIVE|||||||
34094687|NCT04808453|NA|SINGLE_GROUP||TREATMENT||NONE||accelerated titration method followed by a conventional 3 + 3 dose escalation study design||||
34094688|NCT03443544|||COHORT||RETROSPECTIVE|||||||
34094689|NCT05501405|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Brain and eyetracking markers of deficits in recognition of emotional facial expression and associated autistic and/or psychotic disorders|t|f|f|f
34094690|NCT00247793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34094691|NCT05708378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and outcome assessors will be kept blinded about the intervention which the patients will be going to receive||t|f|f|t
33707885|NCT00003931|||CASE_ONLY||PROSPECTIVE|||||||
33707886|NCT00002105||PARALLEL||TREATMENT||||||||
33707887|NCT02018185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707888|NCT02746744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33707889|NCT00987675||||TREATMENT||||||||
33707890|NCT02464020|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33707891|NCT01382212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707892|NCT03522389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707893|NCT01372462|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33707894|NCT03298165|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|outcome assessor the assessor will not be blind about the type of intervention/control assessment methods. however it will not be allowed amongst the examiners to exchange any information throughout the entire study period||f|f|f|t
33707895|NCT05636059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707896|NCT05937542|||CASE_ONLY||RETROSPECTIVE|||||||
33707897|NCT00444912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707898|NCT05690373|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707899|NCT06111820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707900|NCT01620671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707901|NCT02740881|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707902|NCT02217267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707903|NCT04848597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707904|NCT00376727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707905|NCT03167190|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Participants will be enrolled into the control group (Landmark-based palpation and skin marking) vs the experimental group (ultrasound assisted identification of bony landmarks and skin marking).|t|f|f|f
33707906|NCT02862444|||||PROSPECTIVE|||||||
33707907|NCT06024590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707908|NCT00007865||||TREATMENT||||||||
33707909|NCT00709930|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33707910|NCT02460627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33707911|NCT03715881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33707912|NCT03148132|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The principal investigator and the outcomes assesor will be blinded, the assignation of the treatment will be randomized. The parents or tutor of the participant will be blinded|Group 1: Patients that fullfil type 1 ROP criteria that will be treated with Bevacizumab Group 2: Patients that fullfil type 1 ROP criteria that will be treated with Ranibizumab|t|f|t|t
33707913|NCT03198247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33707914|NCT04950998|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33932617|NCT06225804|NA|SEQUENTIAL||TREATMENT||NONE||||||
34094692|NCT00745160|||COHORT||PROSPECTIVE|||||||
33707915|NCT00160290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932618|NCT02373566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and assessor are both unaware of location of dermal template|part of wound treated with /without dermal template|t|f|f|t
33932619|NCT01102140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will either receive POMx or matching placebo (sugar pill)||t|f|f|f
33932620|NCT05265104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932621|NCT03077789|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932622|NCT04520867|||CASE_ONLY||RETROSPECTIVE|||||||
33932623|NCT05055037|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33932624|NCT06195566|||COHORT||PROSPECTIVE|||||||
33932625|NCT01909986|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33932626|NCT03749850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932627|NCT02805894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932628|NCT03170908|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33932629|NCT01899768|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33932630|NCT03839056|||OTHER||PROSPECTIVE|||||||
33932631|NCT05078307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932632|NCT06214923|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the VR and Sham-VR conditions|"This is a 2 (high- vs. low-impact pain) by 3 (3-week Active VR vs. 3-week Sham VR vs. 3-week NH) conditions mixed experimental design. TMD participants will be clinically phenotype into high-impact or low-impact pain groups according to Graded Chronic Pain Scale (GCPS). All participants will go through Active VR, Sham VR and NH phases (3-week each).~There will be 4 in-person visits where participants will be monitored for changes in cortical excitability via PAF oscillations and clinical benefit via Ecological Momentary Assessments (EMA) during the 3-week conditions.~Crossover Study Model was chosen because each participant will receive VR, Sham-VR, and No-VR in random order"|t|f|f|f
33932633|NCT00392951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932634|NCT01238952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932635|NCT05528328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is a double-blind study. Each product, CACIPLIQ20® or placebo, will be supplied in vials having the same appearance.|This is a prospective double-blinded placebo self-controlled trial. 50 female patients undergoing bilateral mammoplasty for breast hypertrophy will be included.CACIPLIQ20® will be administered topically on the vertical and peri-areolar incisions of one breast for 5 minutes, after subcutaneous plans suture and just before final skin suture. The placebo will be administered in the same manner on the contralateral breast. As a result, each patient will receive both CACIPLIQ20® and placebo, thus reducing the interpersonal variability with a self-controlled design.The treatment assignment for each breast will be randomized.The patient, investigator and adjudication committee will be blinded during the whole study, until all assessments have been performed.|t|t|t|t
33932636|NCT03053401|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33932637|NCT03570190|||CASE_ONLY||PROSPECTIVE|||||||
33932638|NCT01279967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932639|NCT02789189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932640|NCT04926792|||COHORT||OTHER|||||||
33932641|NCT00948285|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932642|NCT03424044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932643|NCT01319045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932644|NCT02253940|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932645|NCT01948518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932646|NCT02813590|||COHORT||PROSPECTIVE|||||||
33932647|NCT03924427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932648|NCT02091193|||COHORT||PROSPECTIVE|||||||
33932649|NCT01843205|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33932650|NCT02812108|||COHORT||PROSPECTIVE|||||||
33932651|NCT05303025|||OTHER||PROSPECTIVE|||||||
33932652|NCT00003549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932653|NCT05896410|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||In this study, participants act as their controls; traditional orthosis and 3D-printed orthoses. The order of intervention and testing conditions will be determined by drawing a concealed envelope from a bag . The testing protocol will be started after the fitting of orthoses. Participants will use the first orthosis for three weeks, be given a week for washout, and then cross over to the second orthosis. The participants should use the second orthosis for three weeks. All participants will be informed about the research details, and the measurements will be explained and demonstrated to the participant and provided signed informed consent before participation. Patients will receive identical orthotic-wearing instructions. Patients will be asked to use the orthosis during the daytime functional activities and ADLs for at least half of their waking hours. All patients will be asked to report any pain, discomfort, or skin irritations when using the orthosis.|f|f|f|t
33932654|NCT05861557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707916|NCT02179242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707917|NCT01849198|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33801787|NCT02313649|||CASE_ONLY||CROSS_SECTIONAL|||||||
33801788|NCT01837875|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33932655|NCT04045691|||COHORT||PROSPECTIVE|||||||
33932656|NCT03587467|||COHORT||RETROSPECTIVE|||||||
33932657|NCT05821491|||COHORT||RETROSPECTIVE|||||||
34094693|NCT02301091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103592|NCT05381753|||COHORT||OTHER|||||||
34094694|NCT04041518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094695|NCT01192698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094696|NCT04081571|||COHORT||PROSPECTIVE|||||||
34094697|NCT00968968|RANDOMIZED|||TREATMENT||NONE||||||
34094698|NCT04856618|||COHORT||RETROSPECTIVE|||||||
34094699|NCT05007444|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"This study is a design based on adaptive randomized simulations (BOIN12) (Zhou, Lee, \& Yuan, 2019). Each of the patients included in the different groups will undergo the analysis of the immune response parameters described in Annex 1.~With the optimal biological dose calculated in stage 1, it will go to stage 2 where 40 randomized breast cancer patients will be enrolled in treatment with the P2Et extract or placebo. In these patients, parameters related to the immune response, progression-free survival, quality of life and tumor reduction will be evaluated."|t|t|t|t
33707918|NCT04475991|RANDOMIZED|PARALLEL||TREATMENT||NONE||100 participants will be included and allocated in 4 groups of 25 each \[Currently used therapy (CT), Maraviroc+CT, Favipiravir+CT and Maraviroc+Favipiravir+CT\]. Subjects will be randomized using EPIDAT 4.2||||
33707919|NCT05683964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33707920|NCT01394432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707921|NCT02927730|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33707922|NCT01600638|NA|SINGLE_GROUP||OTHER||NONE||||||
33707923|NCT02235909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind masking in the Double Blind Phase and Withdrawal Phase.|There are 3 phases in this study. Double-blind, withdrawal phase, and open-label phase.|t|t|t|f
33707924|NCT00459628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707925|NCT03874637|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Subjects will be treated at 2 different device settings (one of which is Off) in random sequence during two 6-hour periods at least one week apart.|t|f|t|t
33707926|NCT03552731|||COHORT||PROSPECTIVE|||||||
33707927|NCT03815942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707928|NCT04557878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707929|NCT03572764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707930|NCT00603668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707931|NCT01974804|||COHORT||PROSPECTIVE|||||||
33707932|NCT00701675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707933|NCT02197247||||OTHER||NONE||||||
33707934|NCT03435484|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33707935|NCT00706212|||COHORT||PROSPECTIVE|||||||
33707936|NCT01256801|||COHORT||PROSPECTIVE|||||||
33707937|NCT03197597|||COHORT||RETROSPECTIVE|||||||
33707938|NCT02788812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707939|NCT04455113|||CASE_ONLY||PROSPECTIVE|||||||
33707940|NCT03704467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791048|NCT05112354|NA|SINGLE_GROUP||OTHER||NONE|both the invistigator and care provider donot know the detailes of audiological evalution of the patient nor the comobidities of the patient|"-If the patient come at first two weeks of onset of hearing loss the patient will be manged by oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.~2-Patient will be manged by 5 sessions of intratympanic steroid after failure of systemic steroid and patient who come after 2 weeks of onset of hearing loss , each session will be 3 days apart. The injectable material will be 1ml of hydrocortisone 8ml. The injection will be done under local anesthesia and microscope magnification. A pack of lidocaine gel will be applied in the external canal for 10 minutes in EAC to induce anesthesia by using insulin syringe 1ml bore.~An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM All patients will receive antiviral therapy in the form of acyclovir,valcyclovir All the patient will receive vasodilator."||||
33791049|NCT03150563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The randomization process of the sample will be carried out through the electronic website http://www.randomization.com, carried out by a subject external to the experimental and evaluation procedures. With this data, the site will generate a specific coding for each group and will randomly distribute the subjects into four groups: Control Group (GC), Experiment Group 1 (GE1), Experiment Group (GE2) and Experiment Group 3 (GE3).~The distribution will be kept in an opaque and sealed envelope, being revealed only to P2 only at the time of intervention. The P1, who will carry out the measurements, will not know to which group the individual belongs. To maintain the blinding procedure of the study, each individual at the time of intervention will spend 10 minutes in the intervention room (being 4 minutes for preparation and 6 minutes for intervention) and each group will have a corresponding color for the convenience of P2 White, blue, green and yellow)."||f|f|t|f
33791050|NCT03367494|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791051|NCT04059237|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791052|NCT03317535|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33791053|NCT05218408|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will contain two phases for the following objectives •The Phase 1 Dose Escalation will utilize a 3+3 dose escalation design and will evaluate safety, feasibility, and preliminary efficacy of four cohort dose levels of CYNK-001 administered after a 6M IU subcutaneous dose of rhIL-2 for both IV and IC cycles. Up to 21 patients will be enrolled over 4 dosing cohorts in Phase1 and 45 patients enrolled for phase IIa. Cohort 4 will be the safety run for Phase IIa. Cohort 4 in its entirety will be reviewed by the DMC prior to starting Phase 2a portion of this study. Phase 2a will continue to explore efficacy and safety of CYNK-001 in combination with rhIL2 in patients with recurrent resection eligible IDH1 wild-type glioblastoma.||||
33791054|NCT01711047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791055|NCT04874571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791056|NCT04707417|||COHORT||PROSPECTIVE|||||||
33791057|NCT04133974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791058|NCT02188758|||COHORT||PROSPECTIVE|||||||
33791059|NCT02791750|||COHORT||PROSPECTIVE|||||||
33791060|NCT05127499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33791061|NCT03887546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator doesn´t know the group of the patients until the study ends.|Patients are assigned randomly to the two working groups, each patient only receives one of the two protocols.|f|f|t|f
33932658|NCT01660997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094700|NCT00852982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094701|NCT05409638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33707941|NCT03663998|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|There will be no blinding|Groups A-F will be recruited sequentially, groups G and H once the optimal dose for IM has been determined, and group I selecting the optimal doses for IM and ID form groups A-F for combined administration. This will represent a divided dose group across two different anatomical sites. Each group will receive four vaccinations (at 0, 4, 8 and 12 weeks). The choice of four vaccinations is based on the observation that antibody responses to DNA vaccination in mice plateau after the fourth vaccination, while in rabbits after the third. Hence it is unclear where they may plateau in humans.||||
33707942|NCT04600128|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33707943|NCT00332007|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33707944|NCT02046161|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33707945|NCT00727493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33707946|NCT06259721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707947|NCT00603616|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33707948|NCT02439138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707949|NCT03630861|||COHORT||PROSPECTIVE|||||||
33932659|NCT04249284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707950|NCT00530244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707951|NCT02971397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791062|NCT00762606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791063|NCT01242150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791064|NCT05737238|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The target behavior (i.e. performance on an untrained shopping task) will be measured repeatedly, on a minimum of six occasions in each phase where possible, in accordance with the recommendations of the What Works Clearinghouse and RoBiNT criteria (Tate et al., 2013). Repeated measures of target behavior will be assessed via the OxMET-NL task and is scored automatically: no assessor input is required to either save or score the main outcome data. The secondary outcome measure(s) are scored by an outcome assessor who is blind to the order in which the secondary outcome measure(s) were taken.|"A randomized Single-case Experimental Design (SCED) with a follow-up period of 1 month. Participants will be first assigned to a baseline phase (phase A). The start of the treatment phase (phase B) is determined randomly for each participant, given the restriction that the baseline phase (phase A) should last for at least three weeks (21 days) and at most five weeks (30 days). This means that the treatment phase can start on any day between the 21th and the 30th days. So, in the first three weeks, all participants are in the baseline condition. The duration of baseline will thus be different for each subject. Nonspecific effects, such as linear trends, retesting or non-specific recovery, can be controlled by this approach, since expected changes in level of performance due to treatment should parallel this stepwise onset of therapy procedure.~Phase A acts as a control and is therefore compared with phase B."|f|f|f|t
33791065|NCT01215019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791066|NCT05987540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791067|NCT04602936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind, placebo-controlled|This is a 1-site, randomized, parallel group, double-blind, placebo-controlled, flexible-dose study in which solriamfetol 37.5-150 mg/day will be administered for 12 weeks to 64 outpatient adults with BED by DSM-5 criteria|t|t|t|t
33791068|NCT02001714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization schedule will be concealed so that investigators and staff at the sites will not be able to anticipate experimental group assignments. Evaluators at each site will be blind to group assignment throughout all assessments.||f|f|t|t
33791069|NCT05214235|||COHORT||PROSPECTIVE|||||||
33791070|NCT01611376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791071|NCT03193619|||COHORT||PROSPECTIVE|||||||
33791072|NCT04612894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791073|NCT06202599|||COHORT||RETROSPECTIVE|||||||
33791074|NCT04302519|NA|SINGLE_GROUP||TREATMENT||NONE||Dental pulp mesenchymal stem cells were injected intravenously||||
33791075|NCT05900297|||COHORT||CROSS_SECTIONAL|||||||
33791076|NCT02000999|||COHORT||RETROSPECTIVE|||||||
33791077|NCT04461236|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33791078|NCT01762072|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791079|NCT02447263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791080|NCT02009735|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33932660|NCT02858713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33932661|NCT03552289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932662|NCT05525286|NA|SINGLE_GROUP||TREATMENT||NONE||SN201 is a multi-modular clinical trial in patients with pancreatic adenocarcinoma.||||
33932663|NCT06161688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded||t|t|t|t
33932664|NCT04551560|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33932665|NCT00831857|||COHORT||PROSPECTIVE|||||||
33932666|NCT04036513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Evaluator different to care provider|Split mouth - experimental and control side in the same individual Side selection will be randomized|t|f|t|t
33932667|NCT04131244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932668|NCT05557136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34094702|NCT03097315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094703|NCT00311168|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34094704|NCT06153121|||COHORT||PROSPECTIVE|||||||
34094705|NCT06075290|||COHORT||PROSPECTIVE|||||||
33707952|NCT05012332|NA|SINGLE_GROUP||TREATMENT||NONE||We aim to enroll 10 healthy volunteers. All volunteers receive the same intervention.||||
33707953|NCT04714957|||OTHER||PROSPECTIVE|||||||
33707954|NCT05353283|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707955|NCT02664844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707956|NCT02023567|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33932669|NCT02769195|||COHORT||RETROSPECTIVE|||||||
33932670|NCT04540783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|sham device (by code)||t|f|f|t
33932671|NCT06455423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator will be blind|The study will consist of two groups.|f|f|t|f
33932672|NCT04247529|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33932673|NCT01425320|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33932674|NCT04889690|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34010805|NCT06111079|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pregnant women with normal NT scan who meet at least one high-risk factor or at least two medium-risk factors are included. Initiating aspirin 100mg qn during 12-16 weeks of gestation. At 24-27+6 weeks of gestation, the patients were 1:1 randomly divided into two groups. The experimental group discontinue aspirin at 28 weeks of gestation, and the control group receive aspirin until 36 weeks of gestation.||||
34010806|NCT04715776|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33707957|NCT05758298|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Consenting research team members will not know the order of the randomization schedule or what numbers correspond to treatment options. Blinded members of the research team will receive the participants chew logs for analysis||f|f|f|t
34010807|NCT01862419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34094706|NCT01721239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34094707|NCT02962557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34094708|NCT01010620|||OTHER||PROSPECTIVE|||||||
34094709|NCT01137812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33707958|NCT01603498|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34094710|NCT01774370|||OTHER||PROSPECTIVE|||||||
34094711|NCT05649774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study was a parallel group, four arm superiority trial with 1:1 allocation ratio and balanced randomization|t|f|f|f
34094712|NCT02038426|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33707959|NCT03676010|||OTHER||OTHER|||||||
34094713|NCT02346916|NA|SINGLE_GROUP||OTHER||NONE||||||
34094714|NCT03447795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled clinical trial (RCT) with parallel group, two arm, with 1:1 allocation ratio.|t|f|f|t
34094715|NCT03096353|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33707960|NCT05173662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to avoid bias in the evaluation of the data, the analysis of the coded data in terms of groups was done by an independent statistician. After the statistical analyzes were completed and the research report was written, the researcher explained the coding of the intervention and control groups. In this way, single blindness was achieved.|"Intervention Group Education was given about non-pharmacological methods that can be applied during the heel blood collection procedure in newborns and a brochure was given.~Control group: no intervention was made."|f|f|f|t
33707961|NCT05176730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The data were collected by three research assistants with at least 10 years nursing experiences who were not involved in any other parts of the study.~Also, the participants were randomly assigned equally to the study groups using a computerized random numbers procedure carried out by a research assistant who was not involved in any other parts of the study"|A repeated-measure, two-group, randomized design|f|f|f|t
33707962|NCT02303366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707963|NCT04946747|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Participants will be randomized into 2 groups -- Trained group and Control group.|t|f|f|f
33932675|NCT05116683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094716|NCT02980653|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094717|NCT00294788|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34094718|NCT05019053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094719|NCT01701648|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34094720|NCT02810327|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34094721|NCT01953237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34094722|NCT05639205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34094723|NCT03514537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707964|NCT03817788|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33707965|NCT05775874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801789|NCT00091650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932676|NCT04915872|||COHORT||PROSPECTIVE|||||||
33932677|NCT01858506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932678|NCT04878289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932679|NCT01047436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801790|NCT01645033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932680|NCT03195686|||CASE_ONLY||PROSPECTIVE|||||||
33932681|NCT05625815|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33932682|NCT01117805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33932683|NCT02602704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932684|NCT01718119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932685|NCT00836524|||COHORT||PROSPECTIVE|||||||
33932686|NCT03834480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33932687|NCT05352321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932688|NCT00117572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010808|NCT00792623|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34010809|NCT06247501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010810|NCT02645344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103593|NCT06517511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103594|NCT06688695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33932689|NCT01347840|||CASE_ONLY||PROSPECTIVE|||||||
33932690|NCT01560104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932691|NCT00183261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33932692|NCT02262013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932693|NCT04986891|||OTHER||CROSS_SECTIONAL|||||||
33932694|NCT04352881|||COHORT||PROSPECTIVE|||||||
33932695|NCT04068038|||COHORT||PROSPECTIVE|||||||
33932696|NCT01795261|||CASE_CONTROL||PROSPECTIVE|||||||
33932697|NCT02903966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932698|NCT06144567|||CASE_ONLY||PROSPECTIVE|||||||
33932699|NCT03138291|NA|SINGLE_GROUP||OTHER||NONE||||||
34010811|NCT05306951|||COHORT||RETROSPECTIVE|||||||
34010812|NCT01360827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010813|NCT03497832|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34010814|NCT01247779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025291|NCT05753995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103595|NCT06610240|||COHORT||RETROSPECTIVE|||||||
34094724|NCT03902990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||In this prospective, randomized, controlled, double-blinded study the patients were randomized to three groups as; dual-task group, single-task group and control group. All of the patients were scheduled on standard exercise programme. The patients in dual-task group received treadmill training with cognitive tasks and the patients in single-task group received treadmill training alone in addition to standard exercise programme. The training was scheduled as 30 minute sessions under supervision of a specialist, three times in a week for four weeks.|f|t|t|t
34094725|NCT04099420|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34094726|NCT04567485|||COHORT||RETROSPECTIVE|||||||
34094727|NCT02422901|||OTHER||PROSPECTIVE|||||||
34094728|NCT01604031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707966|NCT04023435|NA|SINGLE_GROUP||TREATMENT||NONE|No other parties will be masked.|This will be a pre- and post-intervention convenience sample of consecutive patients with chronic LBP (pain \> 6 months) meeting the inclusion criteria, attending outpatient PT. On initial examination, intake data and information will be collected prior to PNE and immediately following PNE.||||
34094729|NCT02971904|||CASE_ONLY||PROSPECTIVE|||||||
33707967|NCT04027244|||COHORT||PROSPECTIVE|||||||
33707968|NCT05342194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel|t|t|t|t
33707969|NCT04002713|||CASE_CONTROL||RETROSPECTIVE|||||||
34094730|NCT05005143|||COHORT||PROSPECTIVE|||||||
34094731|NCT00582452|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34094732|NCT00000975||||TREATMENT||||||||
34094733|NCT02457286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094734|NCT01198015|||||CROSS_SECTIONAL|||||||
34094735|NCT06050993|||CASE_CONTROL||PROSPECTIVE|||||||
34094736|NCT00454402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094737|NCT02154659|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094738|NCT00197483|||DEFINED_POPULATION||OTHER|||||||
34094739|NCT05364489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707970|NCT05834075|||COHORT||RETROSPECTIVE|||||||
34094740|NCT05242744|||CASE_ONLY||PROSPECTIVE|||||||
34094741|NCT06519149|||COHORT||RETROSPECTIVE|||||||
34094742|NCT00102167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094743|NCT02842996|||||PROSPECTIVE|||||||
34094744|NCT01109381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707971|NCT00864331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33707972|NCT04243798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707973|NCT04386252|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33707974|NCT00747448|||CASE_ONLY|||||||||
33707975|NCT00749645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33707976|NCT05458843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33791081|NCT06165185|RANDOMIZED|CROSSOVER||PREVENTION||NONE||All subjects will be exposed to three different intervention procedures; water and coffee loads (acutely and chronically), or no change from usual fluid intake (as a time-control), respectively in randomized order. The daily intake of coffee or water will amount to 3 L of water and 1 L of coffee, respectively for one week each. 3 weeks of wash-out between each intervention week.||||
33791082|NCT01443416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791083|NCT01192542|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33791084|NCT02770430|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791085|NCT02846194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33791086|NCT03395353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791087|NCT03393117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Medication utilized will be blinded in the chart per inpatient pharmacy.||t|f|f|f
33791088|NCT02975934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791089|NCT00537563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094745|NCT00875667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791090|NCT00778739|RANDOMIZED|CROSSOVER||||NONE||||||
33791091|NCT04674332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791092|NCT01312337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791093|NCT04639349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932700|NCT01786434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932701|NCT05313360|||CASE_ONLY||CROSS_SECTIONAL|||||||
33932702|NCT05726643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932703|NCT00776373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932704|NCT03119922|||COHORT||RETROSPECTIVE|||||||
33932705|NCT00130494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932706|NCT04179604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Researches will use a computer-generated permuted block randomization established by an independent Statistician. Pharmacy of each hospital will prepare randomized treatment, without being involved in the trial. Patients and physicians will be blind to the randomized therapeutic strategy that each patient will receive. The data will be entered into a specific electronic database in an anonymized and dissociated manner.|SPARTANS is a phase II-III, prospective, randomized, triple-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy of levosimendan in decrease perioperative low cardiac output Syndrome in patients with preoperatively severe left ventricular dysfunction (LVEF ≤ 35%) who will be scheduled for cardiac surgery on cardipulmonary bypass. Follow-up duration will be one year.|t|t|t|f
33932707|NCT02985684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932708|NCT02795065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932709|NCT02532413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932710|NCT00227968|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932711|NCT01892241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932712|NCT03534713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094746|NCT03103347|||COHORT||PROSPECTIVE|||||||
34094747|NCT05478746|RANDOMIZED|PARALLEL||TREATMENT||NONE||Longitudinal open-label randomized controlled trial. Patients enrolled for 3 months in one of two concurrently enrolling groups.||||
34103596|NCT01414647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103597|NCT06476535|||COHORT||RETROSPECTIVE|||||||
33707977|NCT05853068|||COHORT||RETROSPECTIVE|||||||
33707978|NCT05575531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized-controlled clinical trial|t|f|f|f
34094748|NCT04171999|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-Blind randomized controlled trial where the data collectors are blinded to the condition to which the subject has been assigned. The subject is also blinded to the condition they are assigned.||t|f|f|t
34094749|NCT03835897|||COHORT||PROSPECTIVE|||||||
34094750|NCT00347945|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34094751|NCT03451968|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094752|NCT05603221|||COHORT||PROSPECTIVE|||||||
34094753|NCT05967910|||COHORT||PROSPECTIVE|||||||
34094754|NCT06169085|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34094755|NCT06460909|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094756|NCT00476541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094757|NCT06500715|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|he treating oncologist will be blinded as to the patient's allocation and study intervention during each cycle of chemotherapy.|"Participating patients will be treated with one of the following doxorubicin-based protocols, for between 4 and 6 cycles: Doxorubicin and Dacarbazine (AD regimen); Doxorubicin and Ifosfamide (AI regimen); or Doxorubicin and Cisplatin (AC regimen). Subcutaneous 6mg of pegylated G-CSF (pegfilgrastim-jmdb, Fulphila) will be administered at 24h following chemotherapy.~Allocation to study groups: Study patients will be randomly allocated (1:1) to one of the two study treatment arms: Group A, undergoing the acupuncture intervention at the 1st chemotherapy cycle; no acupuncture at the 2nd cycle; intervention at the 3rd; and so on. Group B: No intervention at the 1st cycle; acupuncture intervention at the 2nd cycle; and so on. T"|f|t|f|f
34094758|NCT02236767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094759|NCT03279419|||CASE_CONTROL||PROSPECTIVE|||||||
34094760|NCT06082765|||OTHER||CROSS_SECTIONAL|||||||
34094761|NCT04834115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)|This is a double blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing hospitalization in outpatients with COVID-19.|t|f|t|t
34094762|NCT00498485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094763|NCT02234180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34094764|NCT00962650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094765|NCT06512233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094766|NCT06282289|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094767|NCT00611156|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34094768|NCT01995435|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34094769|NCT04205825|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34094770|NCT02993341|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34094771|NCT03219736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094772|NCT00013325|||||PROSPECTIVE|||||||
34094773|NCT02087592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094774|NCT05269277|||COHORT||CROSS_SECTIONAL|||||||
33707979|NCT02158403|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33707980|NCT03166384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33707981|NCT00004730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33707982|NCT00386048|||CASE_CONTROL||PROSPECTIVE|||||||
33707983|NCT03962842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707984|NCT03557099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707985|NCT00407797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33707986|NCT01166581|||COHORT||RETROSPECTIVE|||||||
33791094|NCT00860717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791095|NCT04479540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Determination of incidence of occurrence of pulmonary embolism in hospitalized patients with SARS-CoV-2 pneumonitis, first by performing systematic thoracic angiography scanner in all hospitalized patients and then to explore hemostasis profile||||
33791096|NCT00965952|||CASE_ONLY||PROSPECTIVE|||||||
33791097|NCT04680702|NA|SINGLE_GROUP||SCREENING||NONE||||||
33791098|NCT04066738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791099|NCT03014596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791100|NCT01944410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094775|NCT02776787|||COHORT||PROSPECTIVE|||||||
34094776|NCT03558672|||COHORT||PROSPECTIVE|||||||
34094777|NCT00213707|||COHORT||PROSPECTIVE|||||||
34094778|NCT05698212|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The lab associates conducting the diagnosis tests are blinded.|Two cohorts defined by confirmed diagnosis of endometriosis and further grouping by staging of endometriosis A third cohort of control participants who have not been suspected or diagnosed with endometriosis|f|f|f|t
34094779|NCT04261166|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34094780|NCT01903044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094781|NCT04836130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094782|NCT03134638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707987|NCT00160628|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33707988|NCT01957722|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33707989|NCT01421004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33707990|NCT03291730|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33707991|NCT01774604|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33707992|NCT04889079|||COHORT||PROSPECTIVE|||||||
33707993|NCT01746745|NA|SINGLE_GROUP||OTHER||NONE||||||
33707994|NCT01257087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33707995|NCT02124577|||CASE_CONTROL||PROSPECTIVE|||||||
33707996|NCT05091047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707997|NCT03991572|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33791101|NCT04307043|||COHORT||PROSPECTIVE|||||||
33791102|NCT00857142|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791103|NCT00250562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791104|NCT03255642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Mask treatment arm when analyzing polysomnography.|Prospective Randomized Open-label study|f|f|f|t
33791105|NCT00596167|NA|SINGLE_GROUP||||NONE||||||
33791106|NCT05193318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791107|NCT06076434|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33791108|NCT05206890|||CASE_ONLY||OTHER|||||||
33791109|NCT00544440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33707998|NCT06436365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The authors performed a prospective randomized controlled trial by including 42 patients to compare expert IMN with poller screws (Group One including 21 patients) versus distal tibial locked plate (Group Two including 21 patients) in fixation of extra-articular distal tibial fractures. The study was conducted after obtaining clearance from the Scientific Board and the Ethical Committee and all patients signed informed consents before starting the study.|t|f|f|f
33707999|NCT06275698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Intervention (Manuka honey) and placebo will be supplied in identical opaque jars with identical labels apart from individual unique ID numbers to facilitate un-blinding in the case of adverse events.~Neither the patient nor the researcher collecting data will be aware of which arm the patient has been enrolled onto."|"Intervention arm - Manuka honey, to be taken per-oral 15ml TDS for 14 days post-tonsillectomy.~Placebo - sugar-based syrup, thickened with sodium alginate and with honey flavouring, to be taken per-oral 15ml TDS for 14 days post-tonsillectomy."|t|t|f|t
33708000|NCT03757325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33708001|NCT00691860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708002|NCT05126589|||CASE_ONLY||PROSPECTIVE|||||||
33708003|NCT00246155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708004|NCT01445561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708005|NCT00843024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708006|NCT00779285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708007|NCT04678245|RANDOMIZED|PARALLEL||PREVENTION||NONE||Immediate intervention and delayed intervention groups - by school over 2 cohorts||||
33708008|NCT01125605|||COHORT||PROSPECTIVE|||||||
33708009|NCT00541593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708010|NCT01114256|||COHORT||PROSPECTIVE|||||||
33708011|NCT02159417|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708012|NCT04109183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This experiment used a block randomization method, and each research center competed for inclusion. The SAS software (9.3 or above) was used to generate a random table and the corresponding treatment group for the random table. The clinical trial electronic central stochastic system (DAS for IWRS) was used to assign random numbers.Blind bottom sealed preservation, respectively sealed by the sponsor and clinical research unit.|a multicenter, randomized, double-blind, double-simulation, positive control trial.|t|t|f|t
33708013|NCT02469298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708014|NCT01556711|||CASE_CONTROL||PROSPECTIVE|||||||
33708015|NCT05433493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|Parallel Assignment|t|f|f|t
33708016|NCT05820178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708017|NCT00837642|||COHORT||PROSPECTIVE|||||||
33708018|NCT01832974|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708019|NCT04546945|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33708020|NCT03675100|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33708021|NCT03198572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791110|NCT06479733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791111|NCT03963128|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||Recruited cohort divided into two groups: (i) a vitamin-D3 supplementation (50,000 IU administred every two months); and (ii) a placebo supplementation (administered orally every two months) control group.|t|f|t|f
33791112|NCT02561923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791113|NCT03505099|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm||||
33791114|NCT04182087|||CASE_ONLY||PROSPECTIVE|||||||
34010815|NCT06367036|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Two researchers do not know which site was injected.|There is no control group in this research design. The participants themselves are also the control group. Intervention was applied to one injection site of the participants 2 hours before the injection and not to the other. Post-injection pain and ecchymosis were evaluated for both sites. The two researchers who analyzed the results do not know the region where the intervention was applied.|f|f|t|f
34010816|NCT04080609||SEQUENTIAL||TREATMENT||NONE||||||
34010817|NCT06424717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708022|NCT05232396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708023|NCT02083783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708024|NCT04933877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|It is double-blinded study. it is blinded to the participants and medical staff who record medical data for the patients.||t|t|t|t
33708025|NCT06050278|||COHORT||PROSPECTIVE|||||||
33708026|NCT05492838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708027|NCT03200860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind, placebo controlled|randomized, placebo-controlled, double-blind, parallel group, multicenter study|t|t|t|t
33708028|NCT00048321|RANDOMIZED|||TREATMENT||DOUBLE||||||
33708029|NCT04974840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708030|NCT05504031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|We intend to blind all possible trial personal. Participants and care providers can not be blinded due to obvious scaring on the patient and the ward that is responsible for patient care.|1:1 randomization to Hybrid coronary revascularization or CABG|f|f|t|t
33708031|NCT03504657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33708032|NCT03121638|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708033|NCT00488462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708034|NCT03050554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708035|NCT03859505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The mode of intervention (active or placebo PBMT) will be coded by an independent researcher. The randomization schedule will contain only codes (not the actual intervention). The output from the PBMT device is exactly the same from either the active or the placebo interventions. These features will guarantee that participants, therapists and outcomes assessor will be blinded to the treatment arms.||t|t|t|t
33708036|NCT00418015|||COHORT||PROSPECTIVE|||||||
33708037|NCT03274024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708038|NCT06382259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708039|NCT02828696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103598|NCT05148663|||CASE_CONTROL||PROSPECTIVE|||||||
34103599|NCT03258229|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||2×2 cross-over Assignment|t|f|t|f
34010818|NCT06260826|RANDOMIZED|PARALLEL||TREATMENT||NONE|the treatment allocation was unblinded to both the patient and the staffs|Patients were randomly assigned in a 1:1 ratio to either the O2-Max Trio or JPAP group through a computer-generated randomization list .||||
34010819|NCT02681484|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34094783|NCT06377085|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"For this Phase 1 trial, we will conduct a dose-escalation study in children having CP who receive 5-Azacytidine (AZA) via a single subcutaneous (SQ) injection two weeks before their surgery, already scheduled to release their contractures. We will use a 3 + 3 dose-escalation design where decisions are based on the rate of toxicity at the current dose level independently from prior dose levels. The primary goal of this study is to determine a Maximum Tolerated Dose (MTD), which will be the highest dose level at which less or equal of 33% of patients experience Dose-Limiting Toxicity (DLT)."|t|t|f|t
34010820|NCT04702347|||COHORT||PROSPECTIVE|||||||
34094784|NCT06348212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization were performed by the provider of probiotic and placebo. The participant will never know their group. The study Investigator and Outcome assessor will not know the groups of participants until they finish recruiting and data processing.||t|f|t|t
34010821|NCT06284447|||COHORT||CROSS_SECTIONAL|||||||
34010822|NCT04149028|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patient will recieve the treatment with PRP||||
34010823|NCT02533284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34010824|NCT02787317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010825|NCT03113526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34094785|NCT05935488|||CASE_ONLY||CROSS_SECTIONAL|||||||
34094786|NCT03736096|||CASE_ONLY||PROSPECTIVE|||||||
34094787|NCT02617290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094788|NCT06355349|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34094789|NCT01006408|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34094790|NCT02508207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094791|NCT06154473|||COHORT||PROSPECTIVE|||||||
34094792|NCT02708173|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34094793|NCT03595891|||COHORT||RETROSPECTIVE|||||||
34094794|NCT00599313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094795|NCT00739219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094796|NCT02957825|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094797|NCT00645931|||CASE_CONTROL||PROSPECTIVE|||||||
34094798|NCT02472093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094799|NCT03115970|||COHORT||PROSPECTIVE|||||||
34094800|NCT02686255|||CASE_ONLY||PROSPECTIVE|||||||
34094801|NCT04135001|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Assignment to each condition (active vs. placebo) will be done by block assignment (by company) using the two versions of the HBMT program start code by study staff running participants||||
34094802|NCT00371449|||COHORT||PROSPECTIVE|||||||
34094803|NCT01281306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094804|NCT00004032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094805|NCT03418675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34094806|NCT01149551|||CASE_CONTROL|||||||||
34094807|NCT03289312|||CASE_CONTROL||PROSPECTIVE|||||||
34094808|NCT03238469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized intra-patient controlled trial.|f|f|f|t
34094809|NCT04379180|||COHORT||PROSPECTIVE|||||||
34010826|NCT05037773|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The outcome assessors (i.e., in charge of the baseline and post-intervention assessments) do not know to which group the participants belong.|"All participants receive the same intervention. However, Group 1 receives the intervention immediately after the baseline and Group 2 (i.e., the waiting-list group - acting as the control group -) receives the intervention after a second baseline assessment which is held after the completion of the Group 1 (i.e., approximatively 10 weeks later). Parent-child dyads were assigned to one of the 2 groups using a stratified randomization on children's age and when possible on children's gender.~This design was chosen to check the specific efficiency of the intervention (i.e., which would result in no evolution for the Group 2 between the 2 baselines)."|f|f|f|t
34010827|NCT00094458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010828|NCT04940702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010829|NCT00956787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010830|NCT02591212|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34010831|NCT00038831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094810|NCT03727581|||CASE_ONLY||PROSPECTIVE|||||||
34094811|NCT05720247|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research collecting outcome data is blinded to the study allocation|Randomised Controlled Trial|f|f|f|t
34094812|NCT02580552|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094813|NCT01101555|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34094814|NCT03264950|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients (\<18 years) will be recruited from from the Children's Hospital Winnipeg CF clinic. Charts will be reviewed for demographic and clinical data including blood work. Each patient will undergo shear wave elastography by a trained operator.||||
34094815|NCT00246961|||||PROSPECTIVE|||||||
34094816|NCT01098695|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708040|NCT05200091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708041|NCT00425295|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33708042|NCT03143413|||OTHER||PROSPECTIVE|||||||
33708043|NCT01605162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708044|NCT05984615|||COHORT||RETROSPECTIVE|||||||
33708045|NCT02940535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708046|NCT04073069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33708047|NCT01217359|NA|SINGLE_GROUP||||NONE||||||
33708048|NCT02616406|||COHORT||PROSPECTIVE|||||||
33708049|NCT03304548|||COHORT||CROSS_SECTIONAL|||||||
33708050|NCT00607971|NA|SINGLE_GROUP||||NONE||||||
33708051|NCT05006196|||COHORT||PROSPECTIVE|||||||
33708052|NCT00621153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708053|NCT02215512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094817|NCT01609192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708054|NCT04784377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708055|NCT04893538|||COHORT||PROSPECTIVE|||||||
33708056|NCT00296881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33708057|NCT00119106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33708058|NCT03119831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33708059|NCT03628820|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708060|NCT04534361|||OTHER||RETROSPECTIVE|||||||
33708061|NCT00170482|||||PROSPECTIVE|||||||
33708062|NCT05357313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects will be explained that the study aims to test the efficacy of the different modalities of non-pharmacological treatments for depression including bright light therapy and the negative ion generator, without mentioning which one is the placebo. An independent outcome assessor will be blinded to the treatment allocation throughout the study.|Randomized placebo-controlled trial|t|f|f|t
33708063|NCT01925937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33708064|NCT05801874|||COHORT||CROSS_SECTIONAL|||||||
34010832|NCT03779152|||COHORT||PROSPECTIVE|||||||
34010833|NCT00567476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010834|NCT06234774|||COHORT||PROSPECTIVE|||||||
34010835|NCT01857648|NON_RANDOMIZED|PARALLEL||||NONE||||||
34010836|NCT04375709|||COHORT||PROSPECTIVE|||||||
34010837|NCT04273282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the participants will be masked.|"Each study subject will be randomized by a table in the possession of investigators to receive one of 2 treatment groups, either experimental or control in the first eye. The second eye will undergo cataract surgery approximately 2 weeks later and will be treated with the other treatment group:~Dexycu Group:A total of 30 study subjects will have Dexycu intracameral dexamethasone placed in their scheduled surgical eye at the time of surgery and will receive 50 micrograms of intracameral moxifloxacin at the conclusion of the procedure. They will take Prolensa each day after surgery for 4 weeks.~Control Group:A total of 30 study subjects will receive topical moxifloxacin 0.5% 4 times per day 1 day prior to surgery and for 10 days postoperatively, Prolensa every day 1 day prior to surgery and for 4 weeks postoperatively, and prednisolone acetate 1% four times per day starting at the conclusion of cataract surgery for 2 weeks and twice per day for 2 weeks in their scheduled surgical eye."|t|f|f|f
34010838|NCT03069677|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1||||
34010839|NCT05125731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researcher evaluating child's behavior by watching video recordings taken during dental treatment and biostatistician will be blinded.||f|f|t|t
34010840|NCT01679197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010841|NCT04065568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Baseline and outcome will be assessed by blinded physiotherapists not involved in the intervention, who will be trained to be synchronized in the assessment procedures and to follow the same standardised protocol to assure consistency both at the Danderyd Hospital and Stockholm Sjukhem site.|A randomized controlled intervention study.|f|f|f|t
34010842|NCT04250831|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, prospective, open label pilot human intervention study||||
34010843|NCT02779751|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010844|NCT03767699|||COHORT||PROSPECTIVE|||||||
34010845|NCT01702779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010846|NCT04813016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34010847|NCT05015374|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34010848|NCT04423159|NA|SINGLE_GROUP||PREVENTION||NONE||A pre/post-vaccine study involving a cohort of individuals receiving an oral cholera vaccine in response to a cholera outbreak in the Lukanga Swamps.||||
34010849|NCT04628936|NA|SINGLE_GROUP||TREATMENT||NONE||All patients received a SC injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 up to a maximum of 96 weeks. Study drug administration ended for all patients when the last patient enrolled completed 48 weeks of dosing.||||
34010850|NCT03104348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010851|NCT05472116|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34094818|NCT03599466|RANDOMIZED|CROSSOVER||OTHER||NONE|Open label|||||
33708065|NCT01963585|||COHORT||PROSPECTIVE|||||||
33708066|NCT02326129|||CASE_CONTROL||PROSPECTIVE|||||||
34010852|NCT06198530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Radiologists, statisticians, and neuropsychologists who measure the outcomes will be blinded to the randomization status. Blinding will also be maintained for data management, outcome assessment, and data analysis. Participants and therapists cannot be blinded to the intervention they receive or provide.||f|f|t|f
34094819|NCT02945046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094820|NCT05535088|NA|SINGLE_GROUP||TREATMENT||NONE||The virtual reality will be applied by using a head mounted display. A minute of immersion was repited 6 times||||
34094821|NCT06140641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094822|NCT01160900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708067|NCT03699098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708068|NCT03324308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708069|NCT00318630|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33708070|NCT06064643|||COHORT||CROSS_SECTIONAL|||||||
33708071|NCT05043129|||COHORT||PROSPECTIVE|||||||
33708072|NCT02362061|||COHORT||PROSPECTIVE|||||||
33708073|NCT03208244|NA|SINGLE_GROUP||PREVENTION||NONE||Received heart transplant from HCV+ donor||||
33708074|NCT06385600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33720559|NCT03038633|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Individuals will receive 300 mg capsules of the novel medical food. The iron content of these capsules is 7.4mg. Our initial dose is set at 22.2 mg of iron. This dose was chosen as the initial starting dose because it is within the range of the RDA for iron for adult women (18mg). Thus this dose is considered the minimum that would be utilized in any setting for maintenance of a healthy iron status. The dosing increases to a maximum of 88.8mg of iron per day which is significantly below the standard amount of iron (165-195mg per day) recommended for an iron deficient individual or the amount of iron given intravenously (1000 mg) for some iron deficient conditions. As mentioned, the total element iron given a patient treated with FAS is up to 190mg of iron. Assuming a 10% absorption rate these patients get 19mg of iron. So if our goal is approximately 19mg of iron absorbed per day and we assume a 50% absorption rate then our target dose is 6-9 capsules per day (44.4-66.6 mg iron).||||
33720560|NCT04020393|||CASE_CONTROL||RETROSPECTIVE|||||||
33932713|NCT04629365|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Outcome assessor treated anonymus data||f|f|f|t
33932714|NCT02485067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932715|NCT04567953|NA|SINGLE_GROUP||SCREENING||NONE||||||
33932716|NCT00379873|RANDOMIZED|PARALLEL||||NONE||||||
33932717|NCT00702936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094823|NCT01433588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33932718|NCT05274009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants will be informed of the study interventions before providing informed consent but will be blinded to the specific trial condition at each of the 3 laboratory visits (control, recommended cooling, hybrid cooling). Data will be blinded prior to analysis.|Participant will complete 3 simulated extreme heat event exposures in random order: i) no cooling center intervention (control); ii) recommended cooling center intervention (1 x 2-hours of brief air-conditioning); and iii) hybrid cooling center intervention (2 x 1-hour interspersed brief air-conditioning)|t|f|f|t
33932719|NCT03073200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932720|NCT01899001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010853|NCT00149526|RANDOMIZED|||TREATMENT||||||||
34010854|NCT05122221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010855|NCT00452608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010856|NCT04303702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010857|NCT00002351||||TREATMENT||||||||
34010858|NCT02544542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34010859|NCT05235659|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Study staff at University of Bremen will not view the allocation sequence. The database will not reveal participants' treatment condition to study staff until after the family´s eligibility was verified (after pre-assessment). Families will be informed of their allocation status after baseline data collection is completed to assure that participants are blind to allocation during the initial assessment.|2 x 2 x 2 x 2 full factorial design||||
34010860|NCT03321994|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34010861|NCT06468306|||COHORT||PROSPECTIVE|||||||
34010862|NCT06449872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010863|NCT06301087|||COHORT||CROSS_SECTIONAL|||||||
34010864|NCT03885219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010865|NCT03525054|||COHORT||PROSPECTIVE|||||||
34094824|NCT04393844|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094825|NCT00401115|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010866|NCT03944681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34010867|NCT03380520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010868|NCT03870477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010869|NCT00873119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094826|NCT01270685|||COHORT||CROSS_SECTIONAL|||||||
34010870|NCT02906865|||COHORT||PROSPECTIVE|||||||
34010871|NCT01045707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010872|NCT02950142|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34010873|NCT04894071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010874|NCT05060731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators plan to recruit 285 patients on each arm.|f|f|f|t
34010875|NCT01330667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34010876|NCT03015714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010877|NCT01418677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010878|NCT06214611|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010879|NCT00826033|||||PROSPECTIVE|||||||
34010880|NCT00192673|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010881|NCT04047537|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34010882|NCT00316394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010883|NCT05669807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010884|NCT01872052|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010885|NCT00906373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010886|NCT06212050|||COHORT||RETROSPECTIVE|||||||
34010887|NCT05558449|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open|Prospective Randomized Clinical Trial||||
34010888|NCT04998422|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34094827|NCT04027946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094828|NCT06174701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The data collectors on our team will be masked.||f|t|f|t
34094829|NCT03833258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094830|NCT05176574|||OTHER||CROSS_SECTIONAL|||||||
34094831|NCT04371835|||COHORT||PROSPECTIVE|||||||
34094832|NCT01673945|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34094833|NCT02625740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34094834|NCT04330898|||OTHER||PROSPECTIVE|||||||
34094835|NCT00508508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708075|NCT06485167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group 2: Control group (CG): Non-active HIFEM® (sham-treatment) includes six 28-minute treatments with non-active HIFEM®, one treatment/week for a six-week continuous period with setting below therapeutic level (\<10% effect). The control group will be placed on the intervention chair in the same way as the active treatment group. The sham treatment will provide some sensation but without active HIFEM technology. The programming for the sham treatment will be amplitude limited, with the setting below the therapeutic level (\<10% effect).|"The intervention treatment consists pelvic floor training with high-intensity electromagnetic energy treatment (HIFEM®). HIFEM® is approval and permission of Food and Drug Administration (FDA) and CE of European Union (EU) to treat UI. One HIFEM® treatment includes 12 000 Kegel exercises over 28 minutes on an intervention-chair. The intervention includes six HIFEM® treatments of 28 minutes with one session per week for six weeks. The woman sits fully clothed on the intervention BLT Emsella chair. Before the first treatment, the woman answers questions about the degree of urinary leakage and records the frequency of urinary leakage before treatment and to next treatment.~Group 1: Active group (AG): Pelvic floor training with electromagnetic energy HIFEM®. Active treatment group (AG): Includes six HIFEM® treatments of 28 minutes at a frequency of one session/week for six consecutive weeks at program level 1 of 2."|t|f|f|f
33708076|NCT00514111|||COHORT||RETROSPECTIVE|||||||
33708077|NCT00569608|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33708078|NCT02301000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708079|NCT00950105|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33708080|NCT04552847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708081|NCT02804672|||COHORT||PROSPECTIVE|||||||
33708082|NCT03266965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708083|NCT01785693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708084|NCT00303784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708085|NCT06096753|||CASE_CONTROL||PROSPECTIVE|||||||
33708086|NCT02261155|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708087|NCT03218644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33708088|NCT04556513|||COHORT||PROSPECTIVE|||||||
33708089|NCT02705469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708090|NCT00602797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708091|NCT02216734|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708092|NCT00456014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708093|NCT06504095|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This research is a randomized controlled experimental study. It was planned to divide the students into two groups as experimental and control groups. Simple random sampling method will be used to determine the experimental and control groups. To ensure randomization, each student will be numbered and data sets (experiment and control) will be created.||||
33708094|NCT01983813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708095|NCT04849546|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33708096|NCT02517983|||||CROSS_SECTIONAL|||||||
33708097|NCT06009705|||COHORT||PROSPECTIVE|||||||
33708098|NCT00172952|||CASE_CONTROL||OTHER|||||||
33708099|NCT06304129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708100|NCT02959320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708101|NCT02908360|||CASE_ONLY||PROSPECTIVE|||||||
33708102|NCT05147025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708103|NCT03267758|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33708104|NCT06478485|||CASE_ONLY||RETROSPECTIVE|||||||
33708105|NCT00189982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708106|NCT00273832|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33708107|NCT00307411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708108|NCT01152697|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708109|NCT04027062|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708110|NCT06218641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator does not know to which group the patient who sent in the questionnaire belongs|Single-blind randomized controlled clinical trial|f|f|f|t
33708111|NCT02019329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708112|NCT00373152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708113|NCT03649360|||OTHER||CROSS_SECTIONAL|||||||
33708114|NCT00168896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708115|NCT06400862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708116|NCT01880801|||COHORT||PROSPECTIVE|||||||
33708117|NCT04187729|||OTHER||PROSPECTIVE|||||||
33708118|NCT00969917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708119|NCT00052481|||CASE_ONLY||PROSPECTIVE|||||||
33708120|NCT05111171|||COHORT||PROSPECTIVE|||||||
33708121|NCT00531323|RANDOMIZED|PARALLEL||||NONE||||||
33708122|NCT06504680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708123|NCT00217620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708124|NCT01644565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708125|NCT04447456|||COHORT||RETROSPECTIVE|||||||
33708126|NCT05572450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33708127|NCT00404846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708128|NCT01631981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708129|NCT05913492|||COHORT||PROSPECTIVE|||||||
33708130|NCT01866293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708131|NCT03198897|||COHORT||PROSPECTIVE|||||||
33708132|NCT00462618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708133|NCT04893278|||CASE_ONLY||PROSPECTIVE|||||||
33708134|NCT04645082|||COHORT||PROSPECTIVE|||||||
33708135|NCT00016185||||TREATMENT||||||||
34094836|NCT02817204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094837|NCT06494956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094838|NCT01041079|||COHORT||RETROSPECTIVE|||||||
34094839|NCT00653757||||TREATMENT||NONE||||||
34094840|NCT02732730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708136|NCT05191524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708137|NCT00908713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708138|NCT04639375|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708139|NCT00345839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708140|NCT06556316|||COHORT||CROSS_SECTIONAL|||||||
33708141|NCT03725930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708142|NCT04232995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708143|NCT00993070|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33708144|NCT00279305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708145|NCT05738954|||COHORT||PROSPECTIVE|||||||
33708146|NCT05999032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791115|NCT02703740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791116|NCT02216929|||||RETROSPECTIVE|||||||
33932721|NCT04594668|RANDOMIZED|PARALLEL||TREATMENT||NONE|Senicapoc-treated patients compared to standard treatment|A Randomized, Open-Label, Phase II Trial||||
33932722|NCT01718366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932723|NCT01336595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010889|NCT02177006|||COHORT||PROSPECTIVE|||||||
33932724|NCT04914195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010890|NCT04491357|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34010891|NCT03739138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010892|NCT05536037|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34010893|NCT01507090|||COHORT||PROSPECTIVE|||||||
34010894|NCT05019482|RANDOMIZED|PARALLEL||PREVENTION||NONE||"During the, baseline assessments were carried out in two groups (Experimental group, control group): measures of PA, ST, anthropometric data, sleep, physical condition and psychological variables (motivation, body appreciation, perceived control, well-being, ...) These assessments were performed in October 2021 (First Time - T1) and December 2021 (Second time - T2).~During the first academic semester, a university-based intervention to increase PA and reduce ST was realised in Experimental group."||||
34010895|NCT03512184|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34010896|NCT03588052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010897|NCT03341546|||CASE_ONLY||CROSS_SECTIONAL|||||||
34010898|NCT06132347|||COHORT||PROSPECTIVE|||||||
34010899|NCT00285519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010900|NCT02611011|||OTHER||PROSPECTIVE|||||||
34010901|NCT05374005|||COHORT||PROSPECTIVE|||||||
34010902|NCT05616403|||COHORT||RETROSPECTIVE|||||||
34010903|NCT02276768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010904|NCT04159519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010905|NCT00256776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094841|NCT01793935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932725|NCT05321589|RANDOMIZED|CROSSOVER||OTHER||NONE||the conventional open tray splinted impression technique and the digital intraoral impression technique were done for each patient||||
33932726|NCT06329713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932727|NCT03674294|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34010906|NCT04727684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010907|NCT03859128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010908|NCT01329224|||COHORT||CROSS_SECTIONAL|||||||
34010909|NCT01084382|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34010910|NCT01014624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34010911|NCT00093951|RANDOMIZED|||TREATMENT||DOUBLE||||||
34010912|NCT02581072|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34094842|NCT00513630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34094843|NCT00477724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34094844|NCT03172468|||COHORT||PROSPECTIVE|||||||
33708147|NCT04503785|||COHORT||OTHER|||||||
33708148|NCT03380403|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||non-randomized clinical trial||||
33708149|NCT04343963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Participants will receive pyridostigmine at a dose of 60 mg / day (or matching placebo), P.O. during a period of up to 14 days, until hospital discharge, death, mechanical ventilation, or increase in the SOFA scale ≥2 points.~The proposed dose is a safe dose according to the experience in myasthenia gravis and healthy people, as well as in at least three clinical studies in people living with HIV.~Participants will be double-blind 1: 1 randomized to receive pyridostigmine or placebo for up to 14 days."|t|t|t|t
33708150|NCT01090271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33708151|NCT04893044|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized pilot trial of video intervention||||
33708152|NCT04927260|||COHORT||OTHER|||||||
33708153|NCT01081678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791117|NCT04963569|||CASE_CONTROL||PROSPECTIVE|||||||
33791118|NCT02517411|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33791119|NCT00690248|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33791120|NCT02784327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791121|NCT01289119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791122|NCT01345604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791123|NCT05869318|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33791124|NCT01547741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791125|NCT00518726|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33791126|NCT02457702|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801791|NCT02541461|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932728|NCT02736929|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33932729|NCT01305941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932730|NCT05090098|||CASE_CONTROL||PROSPECTIVE|||||||
33932731|NCT04124224|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34094845|NCT01877954|||COHORT||RETROSPECTIVE|||||||
34094846|NCT02999321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34094847|NCT01050842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094848|NCT02512159|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33932732|NCT00383266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791127|NCT04189900|NA|SINGLE_GROUP||OTHER||NONE||The study model consists on a single group of subjects who receive the treatment condition (triptorelin)||||
33932733|NCT03035422|NA|SINGLE_GROUP||OTHER||NONE||||||
33932734|NCT01644981|||COHORT||PROSPECTIVE|||||||
33932735|NCT05604066|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a two-phase NIH-awarded study. The first R61 phase (currently awarded) is an observational study with one control group and one patient group. The second R33 phase is a pilot clinical trial, which will be awarded by the end of the R61 phase. The study design provided here is for R61 only.||||
33932736|NCT02325440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932737|NCT05242809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The principal researcher as the outcome assessor will be blinded when analyzing quantitative data, for example, the demographic data and scores of ICIQ-SF, but will not be blinded to the qualitative interview data, as these interviews will be conducted by the principal researcher.|The participants will be randomly allocated to two arms: intervention group and control group.|f|f|f|t
33932738|NCT01886352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932739|NCT01937403|||COHORT||PROSPECTIVE|||||||
33932740|NCT02581267|||COHORT||RETROSPECTIVE|||||||
33932741|NCT03119441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33932742|NCT04583670|||COHORT||CROSS_SECTIONAL|||||||
33932743|NCT05211973|||COHORT||PROSPECTIVE|||||||
33932744|NCT04350918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects for this study were patients diagnosed of mechanical neck pain in Physiotherapy Outpatient Department of Obafemi Awolowo University Teaching Hospital Complex (OAUTHC), Ile-Ife. Individuals who meet the inclusion criteria were randomly allocated to Muscle Energy Techniques Group and Static Stretching Group using the simple random assignment method without replacement (Fish Bowl).||||
34010913|NCT01298778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34010914|NCT03844789|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34010915|NCT05054894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010916|NCT04290286|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34010917|NCT04977609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010918|NCT01705860|||||PROSPECTIVE|||||||
34010919|NCT01415050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010920|NCT01594047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010921|NCT05274672|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study to be multi-institutional, double armed, randomized controlled trial between Baylor Scott and White medical center in Temple, Texas and Albert Einstein Medical Center in Philadelphia.~The study will include 100 patients who will have HoLEP in the 2 centers within almost one year, between March 2022 and March 2023. Patients will be randomized in to 2 groups:~* Group I: Experimental Group (not receiving antibiotics).~* Group II: Control Group (receiving 3 days of antibiotics after surgery)~Each center will have a study coordinator (resident and/or fellow) that will be responsible for randomization using closed envelope technique."||||
34010922|NCT06164028|||COHORT||OTHER|||||||
34010923|NCT05194449|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Two iPad tablets used in the study will be labeled A and B and will be preloaded with the app or white noise by the Hypnalgesics, LLC in randomized sequence. Personnel at CHA will not be aware which tablet presents test or control content. The opening screen and option screen of the white noise control app will use the same color scheme and lay-out as the one of the test Comfort Talk app. The statistical team will receive the encoded data entries and will not be informed about the content of the tablets until all analyses are completed. Since they also will not have direct contact with the study patients they are also not at risk of becoming unblinded during app use by the patients|This is a single-blind placebo-controlled trial comparing a Comfort Talk® calmative app (Cft Group) with a white noise app (WN, Control Group).|f|t|t|t
34010924|NCT01720420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010925|NCT02516384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010926|NCT04062617|||COHORT||PROSPECTIVE|||||||
34010927|NCT03601624|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional phase 2, multicentric, open label||||
34010928|NCT01161394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010929|NCT04143295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010930|NCT03488030|||COHORT||RETROSPECTIVE|||||||
34010931|NCT03658187|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34010932|NCT01519102|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010933|NCT01618682|||CASE_ONLY||RETROSPECTIVE|||||||
34010934|NCT05476263|||COHORT||PROSPECTIVE|||||||
34010935|NCT05992948|||CASE_ONLY||PROSPECTIVE|||||||
34010936|NCT02239198|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34010937|NCT02340494|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34010938|NCT06096714|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34010939|NCT01668121|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34010940|NCT02858648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010941|NCT00752284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791128|NCT05844748|NA|SINGLE_GROUP||OTHER||NONE|39 participants are in the intervention group and 39 participants are in the control group.|Motivational Interviewing Technique||||
33791129|NCT05905913|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33791130|NCT03719391|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, Open-Label, Cross-Over||||
33791131|NCT01149681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932745|NCT02966899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932746|NCT00906334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932747|NCT03447067|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34010942|NCT01526460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010943|NCT06384729|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|A randomized, double-blind clinical trial is proposed, in which two researchers will conduct the intervention, and a third researcher will be responsible for programming the suits and attaching the belt to the suit. The data will be analyzed by a fourth researcher.||t|t|t|f
34010944|NCT02148913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010945|NCT04659551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010946|NCT01726790|||CASE_ONLY||PROSPECTIVE|||||||
34094849|NCT04595019|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre, randomised phase II trial||||
34010947|NCT03918941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigator does not know the identity of the patients neither which group uses the app|group 1 will use the mobile application (Carey) throughout their pre- and postoperative journey group 2 will follow the conventional pre- and postoperative care sequence (control group).|f|f|t|f
33708154|NCT03711110|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, multicenter, open-label clinical trial comparing, in elderly patient with cancer under anti-tumoral treatment, two different cardiotoxicity prevention strategies||||
34010948|NCT02252523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010949|NCT03100890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34010950|NCT05127694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708155|NCT04753983|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708156|NCT04774328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708157|NCT01867437|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33708158|NCT01115101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708159|NCT03144947|RANDOMIZED|PARALLEL||OTHER||NONE||Non comparative, multi-center, open-label, neoadjuvant, randomized study, the purpose of randomization is to reduce bias owing to patient selection into treatments groups.||||
33708160|NCT01758432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This study has four modules with a total of 21 cohorts, each module was reported and submitted separately.~Module 1, NCT01758432 (54 subjects with 7cohorts including placebo); Module 2, NCT03578146 (48 subjects with 6 cohorts including placebo); Module 3, NCT03551730 (27 subjects with 4 cohorts including placebo); Module 4, NCT03551743 (28 subjects with 4 cohorts including placebo)"|t|t|t|t
33708161|NCT00873197|NA|SINGLE_GROUP||OTHER||NONE||||||
33708162|NCT02385500|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33708163|NCT05014789|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, Single Center, Prospective Clinical Study||||
33708164|NCT03873831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791132|NCT06563375|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010951|NCT03928535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34010952|NCT02287324|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34010953|NCT00865631|RANDOMIZED|CROSSOVER||||NONE||||||
34010954|NCT01264640|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34010955|NCT01917968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010956|NCT06269809|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentric non-blinded randomized controlled trial||||
34010957|NCT00488813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010958|NCT00688428|RANDOMIZED|CROSSOVER||||NONE||||||
34010959|NCT01602016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34010960|NCT03191708|||COHORT||PROSPECTIVE|||||||
34010961|NCT06061783|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Label randomized trial||||
34010962|NCT01008384|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34010963|NCT03552419|||COHORT||RETROSPECTIVE|||||||
34010964|NCT02667678|NA|SINGLE_GROUP||OTHER||NONE||||||
34010965|NCT00603863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010966|NCT02168140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010967|NCT00155233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34010968|NCT04086641|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34010969|NCT02438982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010970|NCT02331693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010971|NCT05828121|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||MRC framework for a complex intervention||||
34010972|NCT06445218|||COHORT||RETROSPECTIVE|||||||
34010973|NCT00396461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34010974|NCT04557176|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|"Masking will be maintained by administering finger prick tests to all participants, irrespective of trial arm. Intervention arm participants will have CRP levels measured from blood obtained by finger prick. Control arm participants will have beta-human chorionic gonadotropin (beta-hCG) levels measured from blood obtained by finger prick.~Only participants, study investigators and routine clinical care providers will be masked. Study staff performing TB screening in accordance with the participant's randomization assignment and activities downstream of TB screening (i.e., confirmatory TB testing, TPT eligibility assessment) will not be masked. The database administrator will have access to the randomized assignments."||t|f|t|f
34010975|NCT00303667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010976|NCT04418375|||COHORT||PROSPECTIVE|||||||
34010977|NCT03352752|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|It's a randomized controlled study, there were 218 cases, the ratio of the control group to the experimental group was one to one，109 cases per group.||||
34010978|NCT01216098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010979|NCT01841216|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34010980|NCT01534078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010981|NCT04072549|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||We will compare changes in weight status and obesogenic behaviors of children from low-income households randomized to one of two conditions: free summer programming or comparison/control.|f|f|t|t
34010982|NCT03512002|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study will compare acoustic stimulation linked to brainwave activity (HIRREM, along with continued current care, HCC), with continued current clinical care alone (CCC). Both groups will continue their other current care throughout, including non-pharmacological, and lifestyle modification therapies. The participants in the CCC group will be offered the opportunity to crossover and receive a course of HCC.||||
34010983|NCT01758822|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34010984|NCT03594409|||COHORT||CROSS_SECTIONAL|||||||
34010985|NCT01245036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34010986|NCT06276686|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34010987|NCT05442203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34010988|NCT05073120|||OTHER||PROSPECTIVE|||||||
34010989|NCT01051713|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34010990|NCT04344197|||OTHER||CROSS_SECTIONAL|||||||
34010991|NCT03491137|||COHORT||PROSPECTIVE|||||||
34010992|NCT03349827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34010993|NCT00168090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34010994|NCT00270933|||||PROSPECTIVE|||||||
33708165|NCT03131778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708166|NCT02781597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708167|NCT03655509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708168|NCT02318147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708169|NCT05482412|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Anonymity of participants is allowed for by using a participant computed platform assigning random visual stimulation sequences, thereby mixing Visual Inducer Test Media (T3, 4 \& 5 (Young Adult)). The laboratory observer, software identification of participants, investigators, assessors \& care providers are blinded in the software testing phase of the study.~The taVNS intervention is also triple blinded (participant sham intervention, observer, care provider, investigators \& assessors)."|The sequential study is involved in a translational study.|t|t|t|t
33708170|NCT02617381|NA|SINGLE_GROUP||OTHER||NONE||||||
33708171|NCT01758562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708172|NCT03722966|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33708173|NCT05699031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708174|NCT00810030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708175|NCT00788736|||COHORT||PROSPECTIVE|||||||
33708176|NCT02798874|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708177|NCT02883270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708178|NCT02547844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708179|NCT04191031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708180|NCT02123121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33708181|NCT01386827|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708182|NCT00718952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708183|NCT03673449|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Monocentre Study||||
33708184|NCT01587820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708185|NCT01741597|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708186|NCT03138954|||COHORT||PROSPECTIVE|||||||
33708187|NCT01378637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708188|NCT02978430|NON_RANDOMIZED|||PREVENTION||NONE||||||
33708189|NCT00841646|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33708190|NCT00005639|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33708191|NCT05544604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|serially numbered opaque closed envelopes. Each patient will be placed in the appropriate group after opening the corresponding sealed envelope|"twenty patients will be randomly allocated into one of the study designed groups using serially numbered opaque closed envelopes. Each patient will be placed in the appropriate group after opening the corresponding sealed envelope. The patient will receive one of the following interventions either:~* active tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day),~* sham tDCS over the primary motor cortex in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds ,~* active tDCS (2mA) targeting the insula of the contralateral side of the pain for 20 minute duration for five sessions in five consecutive days (one session /day),~* sham tDCS over the insula in the same stimulation parameters will be used but the device will be turned off without patient knowledge after 30 seconds."|t|f|f|t
33708192|NCT04702061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33708193|NCT04661735|||COHORT||RETROSPECTIVE|||||||
33708194|NCT00844831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708195|NCT00187577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708196|NCT00388960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708197|NCT00756756|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33708198|NCT06383078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708199|NCT03589872|||CASE_CROSSOVER||PROSPECTIVE|||||||
33708200|NCT03965039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33708201|NCT03338998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized, patient- and investigator-blinded, placebo-controlled, parallel group study of BAF312 on top of standard-of-care for ICH, consisting of 3 epochs: Screening/Baseline, Treatment (Day 1-14), and Follow-Up (to Day 90)|t|f|t|t
33708202|NCT00653575|||CASE_CONTROL||RETROSPECTIVE|||||||
33708203|NCT03205748|||COHORT||PROSPECTIVE|||||||
33708204|NCT01634633|||||CROSS_SECTIONAL|||||||
33791133|NCT04376385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791134|NCT04242732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791135|NCT05351372|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33708205|NCT00036712||||SUPPORTIVE_CARE||||||||
33708206|NCT01335191|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33708207|NCT00957970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33708208|NCT02578316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708209|NCT00238004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791136|NCT06350045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|closed envelop||t|t|t|t
33791137|NCT02026219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791138|NCT04463524|||COHORT||PROSPECTIVE|||||||
33791139|NCT00079664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791140|NCT04265378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791141|NCT01843491|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34010995|NCT00710749|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34010996|NCT03471208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigation of the post-op images included anonymized patient names providing unbiased analysis.|Dental implant surgery assisted by a stereotaxic surgical instrument|f|f|t|f
34010997|NCT03353298|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791142|NCT02883088|||COHORT||PROSPECTIVE|||||||
34010998|NCT05772884|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive the same (single) intervention.||||
34010999|NCT04119219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011000|NCT06503107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011001|NCT02907099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011002|NCT00356824|||COHORT||PROSPECTIVE|||||||
34011003|NCT02329119|NON_RANDOMIZED|PARALLEL||||NONE||||||
34011004|NCT02994251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094850|NCT01328626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094851|NCT03888690|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Interventional monocentric regional study opened in crossover test with randomization of sequence (sequence 1 with then without Virtual Reality, sequence 2 without then with Virtual reality)."||||
34094852|NCT03349047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708210|NCT06014203|||COHORT||PROSPECTIVE|||||||
33708211|NCT00680017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708212|NCT02077920|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708213|NCT05751265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708214|NCT02204878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33708215|NCT04141488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Study||||
33708216|NCT05007392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708217|NCT06237829|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Groups of participants will proceed with tactile aids in increasingly higher levels of complexity. The primary evaluation of participant outcome is the success rate with which they can correctly distinguish between multiple surfaces. In the first intervention, participants will be asked to categorize two different coated materials into their respective categories by touch. Participants who score 65% or higher, will be asked to continue. In the second intervention, participants will be asked to categorize four different coated materials into their respective categories. Participants who statistically significantly above chance can identify coated materials successfully will be asked to continue. In the last intervention, participants will be asked to identify between multiple categories on a tactile chart made from a combination of traditional physical features denoting categories and the coatings under investigation denoting another category.||||
33708218|NCT03207230|NA|SINGLE_GROUP||OTHER||NONE||All participants enrolled in the study will receive the wearables and will be evaluated for the relationship between daily physical activity levels and functional capacity (VO2 peak).||||
33708219|NCT03039283|||COHORT||RETROSPECTIVE|||||||
33708220|NCT06041867|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708221|NCT04420143|||COHORT||RETROSPECTIVE|||||||
33708222|NCT00270868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33708223|NCT02446483|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33708224|NCT06498492|||CASE_ONLY||PROSPECTIVE|||||||
33708225|NCT01495117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33708226|NCT01004913|||COHORT||PROSPECTIVE|||||||
33708227|NCT03524898|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm phase Ib/IIa multi-center study in patients with locally advanced or metastatic soft tissue sarcoma who have received first line or second line chemotherapy with no response or with evidence of disease progression.||||
33708228|NCT01818232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708229|NCT05902455|||CASE_ONLY||PROSPECTIVE|||||||
33708230|NCT00289965|RANDOMIZED|PARALLEL||||NONE||||||
33708231|NCT02650856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708232|NCT05240313|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33708233|NCT01007773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33708234|NCT06120387|||COHORT||OTHER|||||||
33708235|NCT02172768|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708236|NCT03335098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708237|NCT03491371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708238|NCT05251571|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
33708239|NCT02109380|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708240|NCT03222960|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33708241|NCT04770129|||COHORT||RETROSPECTIVE|||||||
33708242|NCT02068183|||COHORT||CROSS_SECTIONAL|||||||
33708243|NCT06084663|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33932748|NCT04644965|||CASE_CONTROL||PROSPECTIVE|||||||
33932749|NCT03050892|||COHORT||PROSPECTIVE|||||||
33932750|NCT05675618|||COHORT||PROSPECTIVE|||||||
33932751|NCT00537771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33932752|NCT05104086|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single investigator|Parallel Assignment|f|f|t|f
34011005|NCT03492970|NA|SINGLE_GROUP||SCREENING||NONE||To specify the evolution of the nycthéméral cycle of the secretion of melatonin in 10 adult subjects carrying a SMS||||
34011006|NCT05081336|||COHORT||PROSPECTIVE|||||||
34094853|NCT01566825|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34094854|NCT00428077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094855|NCT02073617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094856|NCT01068912|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34094857|NCT00785941|NA|SINGLE_GROUP||||NONE||||||
33708244|NCT02826902|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33708245|NCT02438332|||COHORT||RETROSPECTIVE|||||||
33708246|NCT03019315|||COHORT|||||||||
33708247|NCT00681083|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33708248|NCT05343845|||OTHER||PROSPECTIVE|||||||
33708249|NCT05270343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932753|NCT02077036|RANDOMIZED|PARALLEL||||DOUBLE||||||
33932754|NCT02245230|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33932755|NCT00085358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932756|NCT03827980|||OTHER||CROSS_SECTIONAL|||||||
33932757|NCT02650167|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932758|NCT00940849|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33932759|NCT05859867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932760|NCT01807611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932761|NCT00152789|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932762|NCT03296072|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Laboratory sample analyst will be blinded to treatment received. All study products will be overwrapped to conceal any labelling.~The dispensing staff will not be involved in any clinical assessments or laboratory analysis during the study. Dental examiner will also be blinded to the treatment received."||f|f|t|t
33932763|NCT03458403|NA|SINGLE_GROUP||OTHER||NONE||||||
33932764|NCT01708915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34094858|NCT00407030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708250|NCT00158990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708251|NCT04638933|||COHORT||PROSPECTIVE|||||||
33708252|NCT00527501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708253|NCT01509950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708254|NCT01006096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708255|NCT01875770|||COHORT||PROSPECTIVE|||||||
33708256|NCT04091594|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33708257|NCT00555971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708258|NCT05561049|||COHORT||PROSPECTIVE|||||||
33708259|NCT02174250|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33708260|NCT01120002|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33708261|NCT05889377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708262|NCT03748758|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33708263|NCT05773482|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants who do not receive BAT will be asked to perform deep breathing without mindfulness.|This parallel study will be age \& sex matched, and randomized.|t|f|f|f
33708264|NCT06448897|||OTHER||RETROSPECTIVE|||||||
33708265|NCT01018316|||COHORT||CROSS_SECTIONAL|||||||
33708266|NCT03719885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708267|NCT04847011|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33708268|NCT04071561|||OTHER||RETROSPECTIVE|||||||
33708269|NCT00820560|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708270|NCT00819806|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33708271|NCT03681405|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33708272|NCT04130620|||CASE_ONLY||CROSS_SECTIONAL|||||||
33708273|NCT00592696|||COHORT||CROSS_SECTIONAL|||||||
33708274|NCT02859168|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33708275|NCT05314751|||COHORT||PROSPECTIVE|||||||
33708276|NCT01996852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708277|NCT01830478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708278|NCT03800329|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708279|NCT02348905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708280|NCT00823095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708281|NCT05459272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|"This is a single-center, randomized, double-blind, placebo-controlled clinical trial with a dietary supplement with melatonin and herbal products, with two parallel group of subjects.~Once the informed consent is signed, the patient will be assigned a patient code. The study treatment will be provided in white boxes with trial and patient identification labels, which will be identical for both products (dietary supplement and placebo), and the administration regimen will be the same for both products, thereby maintaining the double blind.~Treatment intake will begin on study day 7 and end on day 14.~The investigator will have an encrypted randomization list, so that, if necessary, he/she can determine the treatment group assigned to a patient.~Treatment compliance will be recorded by the investigator at the 14-day visit.~No other pharmacological or non-pharmacological treatment for insomnia will be allowed during the study."|t|t|t|f
33708282|NCT03385460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708283|NCT02077244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Those who give their written informed consent will fill out the Post Traumatic Stress Scale 10 Intensive care screen (PTSS 10-I) Patients with a score equal or above 25 (indicating suffering from PTS symptoms) will be randomized to intervention or control group. Randomization will be performed using the computer program WebCRFNTNU. Patients who score below 25 will be included in an observation group and receive questionnaires at the same time points as the intervention and control group.~To be able to detect a difference of 10 between the groups as significant with 80% power and allow for 20% dropout, a total of 250 patients with PTS-10 score like or above 25 have to be included in the randomized part of the study. In the autum 2016 a new statistician in the procject recalculated the power and found the need for 134 randomized patients. The inclusion was then terminated."||||
33708284|NCT05523752|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33708285|NCT05532761|||COHORT||PROSPECTIVE|||||||
33708286|NCT01316796|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708287|NCT05754931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708288|NCT02891733|||COHORT||RETROSPECTIVE|||||||
33708289|NCT06289270|||COHORT||PROSPECTIVE|||||||
33708290|NCT02502578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708291|NCT05367401|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Safety run in (1L higher risk MDS + 1L unfit AML) followed by parallel expansion cohorts (1L higher risk MDS, 1L unfit AML, relapsed/refractory AML)||||
33708292|NCT03231605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33932765|NCT01476553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932766|NCT03415672|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33932767|NCT02942693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932768|NCT04557995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932769|NCT00225667|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33932770|NCT01946568|NA|SINGLE_GROUP||||NONE||||||
33932771|NCT05203328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33932772|NCT02728206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932773|NCT03535090|||COHORT||PROSPECTIVE|||||||
33708293|NCT00772291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708294|NCT04194398|||COHORT||PROSPECTIVE|||||||
33708295|NCT03796793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33708296|NCT01486732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708297|NCT04614064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33932774|NCT04383964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932775|NCT05004389|||COHORT||PROSPECTIVE|||||||
33932776|NCT05205928|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33932777|NCT04709250|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33932778|NCT05823649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Oral feeding|t|f|f|f
33932779|NCT01586962|NA|SINGLE_GROUP||||NONE||||||
33932780|NCT03649139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||experiment:placebo=2:1|t|f|t|f
33932781|NCT01003340|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932782|NCT00470977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932783|NCT01046968|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33932784|NCT00421590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33932785|NCT05570357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932786|NCT01456728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932787|NCT02565862|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33932788|NCT00489502|||DEFINED_POPULATION||PROSPECTIVE|||||||
33932789|NCT05748236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932790|NCT02702167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33932791|NCT00872781|RANDOMIZED|CROSSOVER||||NONE||||||
33932792|NCT04964804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932793|NCT04008667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intervention arm：receiving acupoint application and regular therapy; Placebo arm: receiving fake acupoint application and regular therapy; control arm: receiving regular therapy.|t|t|t|t
33932794|NCT02409264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932795|NCT05513092|||COHORT||PROSPECTIVE|||||||
33932796|NCT05578326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932797|NCT04994145|||COHORT||RETROSPECTIVE|||||||
33932798|NCT00938197|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34011007|NCT05062915|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|Bloc randomisation done by a physical therapist: only for the part of the study with vestibular rehabilitation|"Step 1:A prospective cohort of patients with acute Vestibular Syndrome (AVS) is compared to a baseline (historical) cohort. For a period of 1 year all patients with AVS are registred (baseline population 1) after 1 year their chart is reviewed and those with peripheral AVS (baseline population 2) are invited for a follow up. Those patients in the baseline population 2 who still has a balancedeficit are offered late onset vestibular rehabilitation.~Step 2: all patients admitted with AVS are enrolled as Study population 1, all have balancetesting (V-HIT, HINTS, Posturography and MRI) done upfront. From study population 1, the patients with peripheral AVS (study population 2) are offered (besides the workup with V-Hit and MRI) a vestibular rehabilitation programme (early onset rehabilitation)."||||
34011008|NCT06077734|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34011009|NCT06292494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011010|NCT01976728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011011|NCT03827018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Upon successful completion of the screening procedures, diagnosis criteria will be entered into an interactive web response system, and eligible subjects will be stratified for randomized study treatment into two cohorts according to whether subjects have new-onset or relapsing/refractory disease.|t|t|t|t
34011012|NCT02843659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011013|NCT00747292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708298|NCT01322269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708299|NCT04598230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708300|NCT03547583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708301|NCT01363674|||COHORT||OTHER|||||||
34011014|NCT04142242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011015|NCT01157715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011016|NCT00502801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011017|NCT01677013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011018|NCT02503475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011019|NCT02954159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708302|NCT04051866|RANDOMIZED|PARALLEL||TREATMENT||NONE|Intervention can't be masked. Statistician conducting the analysis will not know to which study arm a given patient has been assigned.|"The sample size has been calculated to estimate a difference of at least 0.4% units between groups in the change of HbA1c at 12 months.~By means of a list of the patients assigned in the usual practice to each participating dentist, who meets the inclusion criteria, and they will be contacted in the resulting order after carrying out a randomization of each list.~Once it has been confirmed that it meets the inclusion criteria and accepted the participation in it, a simple random assignment, with balanced groups, will be used, automatically implemented in the electronic data collection notebook.~The intervention can not be masked, however the main result is measured through an analytical parameter (HbA1c), minimizing the possibility of information bias.~To reduce the possible variability due to the different observers, a training and calibration session will be developed."||||
33708303|NCT01255917|||CASE_CONTROL||PROSPECTIVE|||||||
33708304|NCT04185428|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In this feasibility pilot and qualitative interview mixed methods study, quantitative data will be used to describe the distribution of changes over time for anxiety, pain and other common symptoms among intervention and standard care groups as well as measures of feasibility and acceptability for the study design and methods.||||
33708305|NCT01944397|||COHORT||RETROSPECTIVE|||||||
33708306|NCT03689348|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33708307|NCT01539005|||COHORT||PROSPECTIVE|||||||
33708308|NCT01032837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708309|NCT02047396|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33708310|NCT00847379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708311|NCT05417139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791143|NCT06189469|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33791144|NCT01590953|||CASE_CONTROL||PROSPECTIVE|||||||
33932799|NCT00108836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932800|NCT00384449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932801|NCT05305625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932802|NCT00395616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932803|NCT06107790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932804|NCT00453323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932805|NCT04110444|||OTHER||OTHER|||||||
33932806|NCT01456520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33932807|NCT02432690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932808|NCT04897594|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Triple||t|t|t|f
34011020|NCT03027921|NA|SINGLE_GROUP||SCREENING||NONE||||||
34011021|NCT06504147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011022|NCT01189526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011023|NCT05440331|||CASE_CONTROL||PROSPECTIVE|||||||
33791145|NCT04475224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791146|NCT00272935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791147|NCT00807924|||CASE_ONLY||PROSPECTIVE|||||||
33932809|NCT01474889|NA|SINGLE_GROUP||OTHER||NONE||Hypoglycemia Unaware T1 Diabetics \& 2 Control Groups. Non-Diabetics \& T1Ds With Intact Awareness.||||
33932810|NCT00926263|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33932811|NCT03498989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33932812|NCT01730001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932813|NCT00711412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708312|NCT05869266|RANDOMIZED|CROSSOVER||OTHER||NONE||Prospective, randomized crossover clinical study comparing two methods of fitting subjects with mild to moderate sensorineural hearing loss with hearing aids. Subjects will receive hearing aids and be assigned to professional-fitting arm or self-fitting arm, use the hearing aids for two weeks then switch to the other arm and use the hearing aids for another two weeks.||||
33708313|NCT04875182|||CASE_CONTROL||PROSPECTIVE|||||||
33708314|NCT02680080|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33708315|NCT01350297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708316|NCT04444388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33708317|NCT01375244|RANDOMIZED|CROSSOVER||||NONE||||||
33708318|NCT05338593|||COHORT||RETROSPECTIVE|||||||
33708319|NCT01095731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708320|NCT03821155|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients randomized to two different treatments:~1. corticosteroid treatment (prednisolone)~2. combined corticosteroid treatment (prednisolone) and vestibular rehabilitation"||||
33708321|NCT03903068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is blind to participant, care provider, investigator, outcomes assessor. If a serious adverse event occurs, stop treatment immediately.|Experiment Group: (NEXALIN ADI AC stimulators) vs Mock Group(pseudo-stimulators). Both require the same appearance, all kinds of buttons, buttons, lights, switches, settings, etc. are the same, but the pseudo-stimulator can not release current.|t|t|t|t
33708322|NCT00465348|||CASE_ONLY||PROSPECTIVE|||||||
33708323|NCT04464629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791148|NCT05074732|||COHORT||PROSPECTIVE|||||||
33791149|NCT04844957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791150|NCT00893373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791151|NCT04460573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, comparative randomized trial|f|f|f|t
33791152|NCT03355495|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized Controlled Trial||||
33791153|NCT05506098|||OTHER||CROSS_SECTIONAL|||||||
33791154|NCT01228448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932814|NCT00878306|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33932815|NCT02306941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932816|NCT03645811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Students who arrived on the day of the exam were assigned to the music therapy (M1 and M2), and EFT (E1 and E2) groups, and the control group (K1 and K2).||t|f|f|f
33932817|NCT04434833|||COHORT||PROSPECTIVE|||||||
33932818|NCT04827173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932819|NCT05165108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932820|NCT00645203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708324|NCT00135096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708325|NCT01202292|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33708326|NCT04271969|||COHORT||PROSPECTIVE|||||||
33708327|NCT03913312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708328|NCT00896571|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33708329|NCT02072018|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33708330|NCT01065285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708331|NCT02673138|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791155|NCT02562911|||COHORT||PROSPECTIVE|||||||
33791156|NCT00092833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791157|NCT01677104|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33791158|NCT01927835|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791159|NCT03165149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791160|NCT02618317|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33791161|NCT00075491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791162|NCT00132119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791163|NCT00573235|||OTHER||RETROSPECTIVE|||||||
33791164|NCT04056923|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791165|NCT06239948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The participants were categorized into two groups: stroke survivors and healthy individuals and randomized into control group (without music) and experimental group (with music).|t|f|t|t
33932821|NCT01605890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011024|NCT04951414|||COHORT||PROSPECTIVE|||||||
34011025|NCT01552967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011026|NCT01368926|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34011027|NCT00622115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011028|NCT02607423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011029|NCT06076369|||COHORT||PROSPECTIVE|||||||
34011030|NCT06013917|||OTHER||PROSPECTIVE|||||||
34011031|NCT04702724|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011032|NCT04254640|NA|SINGLE_GROUP||TREATMENT||NONE||cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle.||||
34011033|NCT03443817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective randomized controlled trial comparing the effects of a follow-up tele-rehabilitation program and conventional follow-up rehabilitation in patients with severe COPD. 54 patients fulfilling the inclusion criteria will be randomized in two groups to either an 8 week follow-up tele-rehabilitation program or to standard follow up after rehabilitation. Participants will be tested at baseline, after 8 weeks and 6 months after cessation of the training programs. In the intervention group, a real- and a virtual physiotherapist agent will facilitate the rehabilitation.|t|t|f|t
34011034|NCT01407224|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34011035|NCT01355718|||COHORT||PROSPECTIVE|||||||
33791166|NCT05923008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791167|NCT02175043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791168|NCT04890821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011036|NCT01419587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011037|NCT02303314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708332|NCT04974697|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects will be masked to the study lens to help reduce potential bias. Subjects will be unaware of the identity of the investigational product.|||||
33708333|NCT01218373|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708334|NCT06507813|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33708335|NCT04317469|||CASE_ONLY||PROSPECTIVE|||||||
33708336|NCT02654743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708337|NCT06004999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33708338|NCT02252783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708339|NCT03940040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708340|NCT04052347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708341|NCT06284746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708342|NCT03734276|RANDOMIZED|PARALLEL||TREATMENT||NONE||feasibility Study with randomized control trial||||
33708343|NCT05053100|||COHORT||PROSPECTIVE|||||||
33708344|NCT02074644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708345|NCT01396798|||COHORT||PROSPECTIVE|||||||
33708346|NCT05541770|||COHORT||CROSS_SECTIONAL|||||||
33708347|NCT06504823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33708348|NCT04488146|||COHORT||PROSPECTIVE|||||||
33708349|NCT02149498|||CASE_CONTROL||PROSPECTIVE|||||||
33708350|NCT06099197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The primary investigator and outcome assessor will be masked to the app assignment (Brain CareNotes vs Attention Control App).|Participants will be randomized to receive the Brain CareNotes app or an attention control app.|f|f|t|t
33708351|NCT03777774|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomized only after the closing stage of decompressive craniectomy to avoid surgeon bias||t|t|f|f
33708352|NCT03928119|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33708353|NCT00138580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708354|NCT00776308|||CASE_ONLY||PROSPECTIVE|||||||
33708355|NCT02914470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791169|NCT04371536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791170|NCT00003604||||TREATMENT||||||||
33791171|NCT06165172|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33791172|NCT01701713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33791173|NCT02709174|||COHORT||PROSPECTIVE|||||||
33791174|NCT02107378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791175|NCT00261053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791176|NCT01519362|||CASE_ONLY||RETROSPECTIVE|||||||
33791177|NCT01382342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791178|NCT06152484|||CASE_CONTROL||PROSPECTIVE|||||||
33791179|NCT05136443|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33791180|NCT00567515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791181|NCT03721432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|sealed opaque numbered envelopes indicating the group of each patient, carried out by an independent anesthesiologist and given to the ward nurse||t|t|t|t
33791182|NCT00931983|||CASE_ONLY||PROSPECTIVE|||||||
33791183|NCT03568799|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791184|NCT00140972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011038|NCT02737592|NA|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34011039|NCT02521181|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34011040|NCT06615791|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two parallel arms||||
33708356|NCT01459471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791185|NCT03748433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised open-label parallel group study||||
33791186|NCT04189107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1:1 Randomization to either experimental or control treatment|t|f|t|f
33791187|NCT02937792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791188|NCT05949125|NA|SEQUENTIAL||TREATMENT||NONE||"Dose escalation follows a BOIN comb design with 3 dose levels of 100, 250, and 500 million Allo-RevCAR01-T and 3 dose levels of R-TM123 resulting in a maximum of 9 dose levels.~Given 1 participant dose level cohorts, there will be an inherent stagger between each participant equivalent to the DLT window of 28 days"||||
33791189|NCT04985058|||COHORT||PROSPECTIVE|||||||
33791190|NCT03782558|||CASE_CONTROL||PROSPECTIVE|||||||
33801792|NCT02866968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801793|NCT02319434|||COHORT||PROSPECTIVE|||||||
33801794|NCT03202199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801795|NCT02551536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011041|NCT05786001|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34011042|NCT06063096|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Acute, randomised, double-blind, placebo-controlled, cross-over|t|f|t|f
34011043|NCT03694808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A non-inferiority randomized clinical trial to enroll 500 long term care (LTC) dwellers from at least one of 40 nursing homes sites in northern Ohio.~Age 65 and older to receive either Fluad or HD vaccine at 1:1 ratio.~Blood will be sampled pre- and post-vaccine and post-influenza season and coded for blinded laboratory analysis.~Randomization by from randomizer.org software./RedCAP"|f|f|f|t
34011044|NCT00622999|||COHORT||PROSPECTIVE|||||||
33708357|NCT06497621|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33708358|NCT00523016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708359|NCT05645575|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label Transcranial Magnetic Stimulation Treatment||||
33708360|NCT01309594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720561|NCT03414619|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The current study has two diagnostic arms (the Intrusive Thoughts group and the Non-Psychiatric Control group) all receiving a single interventional protocol.||||
33720562|NCT04814758|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708361|NCT05829304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the blinding is not possible (unfortunately) due to the nature of the trial. Trial participants, outcome assessors and statistician will be blinded.|Teeth that will be included in the current trial will be randomly assigned one of the experimental groups using closed white envelopes (simple randomization 1:1 ratio).|t|f|f|t
33708362|NCT06028139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708363|NCT00016887|RANDOMIZED|||TREATMENT||||||||
33708364|NCT03384238|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33708365|NCT06468566|||CASE_CONTROL||PROSPECTIVE|||||||
33708366|NCT01494571|||CASE_ONLY||PROSPECTIVE|||||||
33708367|NCT00844896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33708368|NCT01962896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708369|NCT04028921|||COHORT||CROSS_SECTIONAL|||||||
33708370|NCT00071097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708371|NCT01773811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708372|NCT02710396|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708373|NCT02503657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708374|NCT05384574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33708375|NCT04733014|||OTHER||PROSPECTIVE|||||||
33708376|NCT02695329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33708377|NCT01475357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932822|NCT03634293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the study drug and placebo will be identical arriving from the manufacturing company as a clear fluid for subcutaneous injection of 2 ml'. both arms, the control and intervention, will receive identical subcutaneous injections. the randomization will be prior to recruitment in the pharmacy. At the end of the study the outcomes assessor will be exposed to the data unblended.|the study is a randomized placebo controlled double blinded study. the control group will be receiving placebo and the treatment group will be receiving the study drug.|t|t|t|f
33708378|NCT01116583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33708379|NCT02956239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708380|NCT05478785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708381|NCT04678661|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708382|NCT00814164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708383|NCT01235143|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708384|NCT04059783|||COHORT||PROSPECTIVE|||||||
33708385|NCT05069532|||OTHER||CROSS_SECTIONAL|||||||
33708386|NCT03391037|||COHORT||PROSPECTIVE|||||||
33708387|NCT03256643|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33708388|NCT00993200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932823|NCT04724213|NA|SINGLE_GROUP||OTHER||NONE||||||
33932824|NCT03021590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932825|NCT01666015|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33932826|NCT02296229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932827|NCT04514406|||COHORT||PROSPECTIVE|||||||
33932828|NCT03616249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The elderly are initially distributed into two groups. Sarcopenic Group and Non-Sarcopenic Group and . 1) Training group - who will carry out the resistance training for 12 weeks or; 2) control group - who did not participate in the training in the same period.|t|t|t|t
33932829|NCT06430814|||COHORT||PROSPECTIVE|||||||
33932830|NCT03250130|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932831|NCT02918721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932832|NCT06104891|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth, then randomized to one of the study arms|t|f|t|f
33932833|NCT04168905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932834|NCT00674024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932835|NCT03152968|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33932836|NCT02448095|||COHORT||RETROSPECTIVE|||||||
33932837|NCT03419507|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The doctors will be informed about the research, but they will be blind to the specific purposes of the study|Equal numbers 1 and 2 will be written on the same sized papers. After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with No. 3 Macintosh laryngoscopy and doctors that drawed envelop number 2 will be asked to intubate with endotracheal tube introducer. Than groups will be changed.|t|f|f|f
34011045|NCT05262192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not know which group.|Nutrition education will be given to the experimental group. No intervention will be applied to the control group.|t|f|f|f
34011046|NCT06405542|NA|SINGLE_GROUP||OTHER||NONE||||||
34011047|NCT04959383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Assignment|t|f|f|t
33708389|NCT01678430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708390|NCT00109083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708391|NCT04170816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708392|NCT01304316|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708393|NCT02848872|||COHORT||PROSPECTIVE|||||||
33708394|NCT02277145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708395|NCT00519831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708396|NCT04332146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33708397|NCT00000883||||TREATMENT||DOUBLE||||||
33708398|NCT05119517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708399|NCT02406716|||CASE_CONTROL||PROSPECTIVE|||||||
33708400|NCT04640285|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33708401|NCT02499783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708402|NCT00967590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708403|NCT05661799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33708404|NCT03886805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708405|NCT04998786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708406|NCT05873309|||COHORT||PROSPECTIVE|||||||
33708407|NCT05449652|||COHORT||PROSPECTIVE|||||||
33708408|NCT02745444|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708409|NCT00956020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011048|NCT01028911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011049|NCT02378441|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011050|NCT05283603|||CASE_ONLY||PROSPECTIVE|||||||
34011051|NCT01039194|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34011052|NCT04851275|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34011053|NCT01787279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011054|NCT02560779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011055|NCT04917081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708410|NCT01354678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33708411|NCT04525378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708412|NCT00000329||||TREATMENT||DOUBLE||||||
33708413|NCT05566912|||OTHER||CROSS_SECTIONAL|||||||
33708414|NCT03627143|NA|SINGLE_GROUP||OTHER||NONE||Multicentre Behaviour Intervention Trial using a Stepped Wedge Cluster Randomized Design||||
33708415|NCT02627937|||CASE_ONLY||RETROSPECTIVE|||||||
33708416|NCT01501175|||CASE_ONLY||CROSS_SECTIONAL|||||||
33708417|NCT01595997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708418|NCT04533373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33708419|NCT03108183|||OTHER||CROSS_SECTIONAL|||||||
33708420|NCT00502047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708421|NCT02728609|||COHORT||PROSPECTIVE|||||||
33708422|NCT06457880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708423|NCT04290780|||COHORT||PROSPECTIVE|||||||
33708424|NCT03730571|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33708425|NCT01502930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708426|NCT05777850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708427|NCT05438264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708428|NCT01410201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708429|NCT06266078|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||"Firstly, a minimum of 14 experts will validate the content, using the Delphi technique of two tools (A) The innovative PPE assessment tool; and B) the simulation scenario script.~After reaching consensus among the experts, the protocol will be piloted. Two identical sessions will be conducted using the cross-over method with all participants, so that the same participant performs the tasks using the innovative PPE and the comparative PPE, allowing the participants compare characteristics of both PPE. The PPE use sequence and the PPE type will be randomized to minimize biases. Between both sessions there will a 30-minute break for the participants.~For the purpose of the development and piloting of this simulation protocol, the innovative PPE were selected according to compliance with the specifications required by the World Health Organization. It will enrolled 36 healthcare workers in piloting test."||||
33708430|NCT02846311|||COHORT||PROSPECTIVE|||||||
33708431|NCT02968771|||CASE_ONLY||PROSPECTIVE|||||||
33708432|NCT02920372|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708433|NCT02462460|||COHORT||PROSPECTIVE|||||||
33708434|NCT00596375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33708435|NCT04486105|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||RCT|t|f|f|f
33708436|NCT04112784|NA|SINGLE_GROUP||OTHER||NONE||||||
33708437|NCT00669929|||COHORT||RETROSPECTIVE|||||||
33708438|NCT03978000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33708439|NCT03783364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708440|NCT02453178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33708441|NCT00454896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708442|NCT01796561|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33708443|NCT02197130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708444|NCT01523353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33708445|NCT02837445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708446|NCT00253227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708447|NCT05394961|||COHORT||RETROSPECTIVE|||||||
33708448|NCT03841669|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Neither the investigator, nor outcomes assessors will know participants' group assignment. Participants will be instructed to refrain from speaking about their group's activities when visiting the lab for 6 month (if applicable) and follow-up assessments.In addition, special care was taken to ensure that non-blinded laboratory staff (i.e. staff member notifying participants of their group assignments, staff monitoring the intervention) are not located in the same proximity in the laboratory, further preventing accidental unblinding.|130 individuals between the ages of 26 and 58 will be randomly assigned to one of two groups; Aerobic Exercise group or Physical Activity and Health Information group. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week over a 12-month period. Both groups will be asked to wear activity monitors every 6 weeks. Both groups will have fitness testing and cardiovascular assessments completed at baseline, 6 months (optional) and following the completion of the 12-month intervention.|f|f|t|t
33708449|NCT06185283|RANDOMIZED|PARALLEL||OTHER||SINGLE||"A convenience sample of 18 completely edentulous participants were selected for this retrospective study from patients originally available at the start of the trial .~The patients were equally divided into two groups at the start of the trial. The patients (average age 45-60 years) were selected for this study from outpatient clinic of Removable Prosthodontics Department, Faculty of Dentistry, Mansoura University"|f|f|t|f
33708450|NCT04987346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708451|NCT01471470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720563|NCT04475679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720564|NCT04881708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720565|NCT05773820|NA|SEQUENTIAL||TREATMENT||NONE||Sequential||||
33720566|NCT03325075|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double Blind||t|f|t|f
33720567|NCT00917709|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34011056|NCT02194010|||COHORT||PROSPECTIVE|||||||
34011057|NCT06155773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34094859|NCT05872919|RANDOMIZED|PARALLEL||OTHER||DOUBLE|MA will provide randomization AD will assess participant at baseline and follow-up EH will deliver the intervention.|Eligible patients will be offered to participate. Willing patients will be randomly assigned to one of two groups: Two arms study design: first arm (control group)won't receive intervention while the second arm (intervention group) will receive telenursing intervention through SMS; Is a text messages will be sent to the intervention group comprised of a reminder on when, how to take lipid lowering medication, benefits, and adverse effect of not taken the drug as prescribed for three months duration. SMS (Short Messaging Service) will be sent three times per week in the first six weeks and twice per week in the second six weeks.|f|t|f|t
34094860|NCT01111292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34094861|NCT02090595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094862|NCT00104260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094863|NCT02287519|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34094864|NCT01117545|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34094865|NCT06414018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34094866|NCT04617327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094867|NCT03448029|||COHORT||PROSPECTIVE|||||||
34094868|NCT01767389|||COHORT||RETROSPECTIVE|||||||
33708452|NCT03746457|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Participants in the three experimental ART Centers received three cycles of intervention, while two ART Centers served as the controls. In the first cycle, participants in the three experimental Centers each received individual counseling, group intervention (GI) and collective advocacy (CA). In Cycle 2, participants in each experimental center received a second intervention (e.g. GI + CA) and in the third cycle, participants in each experimental Center received a third intervention (GI + CA + IC). In addition, in Cycle 3, the participants in one of the Control Centers received an integrated package of IC-GI-CI.||||
33708453|NCT01626391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708454|NCT00451659|||DEFINED_POPULATION||OTHER|||||||
33708455|NCT00873574|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33708456|NCT00247897|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33708457|NCT02521545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708458|NCT01209559|||COHORT||PROSPECTIVE|||||||
33708459|NCT03072992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|t|t|f
33791191|NCT06405555|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is open label and neither the study participant, research team, or members within the circle of care of the patient will be blinded to the randomization/treatment.|Participants are randomized in a 1:1 fashion to either the treatment arm (midodrine + standard of care) or control (no-midodrine, standard of care).||||
33791192|NCT04067960|NA|SINGLE_GROUP||SCREENING||NONE||||||
33791193|NCT00956306|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791194|NCT02422121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791195|NCT04722094|||COHORT||CROSS_SECTIONAL|||||||
33791196|NCT05163418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791197|NCT01787994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791198|NCT05391724|NA|SINGLE_GROUP||OTHER||NONE||||||
33791199|NCT06070324|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The type of suture used to close the periareolar incision will be determined by drawing the name of the suture from a random, sealed envelope at the start of the procedure in the operating room. The patient will not be informed of the suture type and they are unable to see the suture type due to postoperative dressings being placed overtop, until they see the surgeon at their 2-week followup appointment.|All patients will receive the surgical treatment they consented for, the only difference among them being the type of suture material used to close their perioareolar incisions (3 different types are investigated in this study).|t|f|f|f
34011058|NCT03727737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind study until trial is complete|The proposed study will evaluate the safety, durability and efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as a promising non-invasive therapeutic treatment for improving memory in older adults with mild or moderate Traumatic Brain Injury (TBI) who have been experiencing residual memory or cognitive problems that affect daily functioning.|t|t|t|t
34011059|NCT00149149|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Zinc carnosine or placebo for 7 days with 5 days of indomethacin from days 2-7. It was a cross over protocol with 2 week washout inbetween.||||
34011060|NCT02758860|||COHORT||PROSPECTIVE|||||||
34011061|NCT01430819|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708460|NCT06558552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011062|NCT01183117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094869|NCT01484366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094870|NCT01399294|||CASE_ONLY||CROSS_SECTIONAL|||||||
34094871|NCT05732545|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33708461|NCT01148472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094872|NCT01951066|RANDOMIZED|CROSSOVER||||NONE||||||
33708462|NCT00639678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33708463|NCT05160103|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Products Codes A-G|Single site, randomized, seven treatments, split face, efficacy study|t|f|t|f
33708464|NCT04556162|||COHORT||PROSPECTIVE|||||||
33708465|NCT04510012|||COHORT||PROSPECTIVE|||||||
33708466|NCT05713175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant understands he is being part of a clinical trial but unknowns the treatment group he has been allocated.|Parallel Groups Open Randomised Clinical Trial|t|f|f|f
33708467|NCT03481907|NA|SINGLE_GROUP||TREATMENT||NONE||This is a self-controlled trial in which subjects will receive punch biopsies at sites on each leg, and will receive a different treatment on each of the 2 sites.||||
33708468|NCT04317131|||OTHER||CROSS_SECTIONAL|||||||
33708469|NCT04550208|||COHORT||CROSS_SECTIONAL|||||||
33708470|NCT05410691|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33708471|NCT00573612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33708472|NCT05947825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708473|NCT06483464|||CASE_ONLY||RETROSPECTIVE|||||||
33708474|NCT01915082|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33708475|NCT00966329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708476|NCT02646137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708477|NCT00426790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708478|NCT01371175|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33708479|NCT04742985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33708480|NCT04483141|||COHORT||PROSPECTIVE|||||||
33708481|NCT00495365|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708482|NCT01986283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33708483|NCT01149187|||CASE_ONLY||PROSPECTIVE|||||||
33708484|NCT04957004|||CASE_CONTROL||PROSPECTIVE|||||||
33708485|NCT03953937|||COHORT||RETROSPECTIVE|||||||
33708486|NCT01435369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708487|NCT03228927|||COHORT||CROSS_SECTIONAL|||||||
33708488|NCT01088997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791200|NCT04201327|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and the assessment staff are blind to the assignment of participants throughout the data collection phase of the study.|4 arm randomized controlled trial|f|f|t|t
33791201|NCT01513213|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791202|NCT03451435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708489|NCT03626883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33708490|NCT06120998|||COHORT||PROSPECTIVE|||||||
33791203|NCT03419156|NA|SINGLE_GROUP||SCREENING||NONE||All patients with SBS on TPN at Cardinal Glennon will receive text messages inquiring about their symptoms instead of weekly phone calls from a nurse. There will be no randomization. All patients will be sent text-messages from the automated system for 6 months to assess response rates and the amount of time saved by the nurse staff. If the patient does not respond to the text messages or the text message responses suggest that the patient may be presenting with potentially harmful symptoms, the nurse will call the patient to inquire about more information.The text messages are designed to help target calls made by the nursing staff.||||
33791204|NCT00424762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791205|NCT04351646|||COHORT||PROSPECTIVE|||||||
33791206|NCT04852146|||COHORT||PROSPECTIVE|||||||
33708491|NCT02937883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708492|NCT04660669|RANDOMIZED|PARALLEL||OTHER||NONE||Group 1 receives 15 hours per week of ESDM intervention from ESDM therapists. The parents benefit from a 20 hour parent training program delivered in the participating center. Group 2 receives 8 hours per week of ESDM intervention from ESDM therapists in addition to whatever community service the parents choose. The parents benefit from a training program remotely delivered via a MOOC platform as well as parental supervision of sessions delivered at home 1 hour per week for the duration of the study.||||
33708493|NCT04729270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind researcher|RANDOMIZED CLINICAL TRIAL WITH BLIND EVALUATION BY THIRD PARTIES, LONGITUDINAL AND PROSPECTIVE.|f|f|t|f
33708494|NCT03720093|||COHORT||PROSPECTIVE|||||||
33708495|NCT06337266|||COHORT||RETROSPECTIVE|||||||
33720568|NCT04778579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720569|NCT00208039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720570|NCT00507754|||CASE_ONLY||PROSPECTIVE|||||||
33720571|NCT01988103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720572|NCT02570906|||CASE_ONLY||PROSPECTIVE|||||||
33791207|NCT01549730|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791208|NCT00553189|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34011063|NCT01980160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34011064|NCT06334419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Quadruple masking (participant, care provider, investigator and outcomes assessor)|This study was designed as a 2-intervention crossover, with all study participants receiving all possible interventions. These are placebo and Gaboxadol.||||
33720573|NCT02545790|||CASE_CONTROL||PROSPECTIVE|||||||
34011065|NCT01694017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011066|NCT05356182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011067|NCT04639297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34011068|NCT05349578|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34011069|NCT03995017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1 - Safety Lead In - Enroll 6-9 molecularly unselected participants to determine the safety of the triplet combination of Rucaparib plus Ramucirumab and Nivolumab. One level dose de-escalation of Rucaparib will be planned based on dose limiting toxicity (DLT) signal of the first 6 participants run in phase.~Phase 2 - Parallel - Enroll 52 participants (26 in each cohort), open label, two treatment cohorts design evaluating Rucaparib plus Ramucirumab with or without Nivolumab. 50 percent (%) of participants enrollment to each treatment cohort will represent molecularly unselected population and the remaining 50% will be selected based on integrated screening tumor Homologous Recombination Deficiency (HRD) gene panel. The primary objective is efficacy by measuring the Overall Response Rate (ORR)."||||
34011070|NCT06245759|||COHORT||RETROSPECTIVE|||||||
34011071|NCT01502124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011072|NCT05048641|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34011073|NCT03848247|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34011074|NCT05510115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011075|NCT05571072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011076|NCT00085306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011077|NCT00072072||||TREATMENT||||||||
34011078|NCT05665959|||OTHER||PROSPECTIVE|||||||
34011079|NCT00433277|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34011080|NCT01844531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011081|NCT05449782|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Placebo and cocoa flavanols will be delivered in same number of identical appearing capsules|2 group (healthy and type 2 diabetes) randomised controlled cross-over (2-period, 2-sequence) study|t|f|t|t
34011082|NCT01713179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34011083|NCT00146029|||||RETROSPECTIVE|||||||
33708496|NCT04770181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blocked randomization method will be used to assign participants to active and sham groups. Participants will be assigned to CES treatment or sham CES using a 1:1 ratio. Electromedical Products International, Inc. (EPI) will randomize the assignment of appropriate devices to active or sham groups by using a random list of computer generated numbers (1 for active and 2 for sham) in randomly selected block sizes. The PI and participants are blinded to which participants have Alpha-Stim® CES active or sham devices until data analysis is complete. After the completion of data analysis, blinding will be broken.|The design for the proposed study is a matched-pair, quasi-experimental, 1:1 randomized, double-blind, sham-controlled clinical trial with a longitudinal component. The analytic technique employed to answer the research questions will be repeated measures analysis of covariance.|t|t|t|t
33708497|NCT04390191|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, single-center, parallel group, open-label, randomized clinical trial, where the study team will investigate the efficacy of continuous positive airway pressure therapy (CPAP) in COVID suspected or confirmed patients who are sent home from the emergency room with mild pneumonia or respiratory illness but who do not require hospital admission. The study team proposes a randomized controlled trial of CPAP (n=100) vs. control (n=100) in COVID-19 suspected or confirmed patients with pneumonia or respiratory illness.||||
33791209|NCT03702400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||In a randomized, double-blinded study, 76 healthy patients having cesarean delivery under spinal anesthesia will be randomized, using an electronic system (the Randomizer App®, Version 3.2 Wisse Keizer program), to have systolic blood pressure maintained with bolus of phenylephrine at a dose of 100 mcg bolus (at a dilution containing 20 mcg / mL), or with norepinephrine at a dose of 5 mcg (at a dilution containing 1 mcg / mL).|t|t|t|f
33791210|NCT03584646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigator will conduct a patient-randomized, two-arm pilot study of 38 participants with a predicted attrition rate of 20% resulting in 30 total participants; n=10 in Arm 1 and n=20 in Arm 2. Arm 1 will serve as the control arm and Arm 2 will serve as the intervention arm.|f|f|t|f
33791211|NCT02955069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791212|NCT01767259|RANDOMIZED|CROSSOVER||||NONE||||||
33791213|NCT03055416|NA|SINGLE_GROUP||OTHER||NONE||||||
33791214|NCT00623506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791215|NCT05969236|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"This study consists of two parts:~* Part A: Single ascending dose in healthy volunteers~* Part B: Multiple ascending doses in healthy volunteers~The randomization code and the randomization list will be generated using SAS version 9.4 or the latest available version at time of randomization."|t|f|t|f
34103600|NCT04957082|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|Participants will be unaware of their assignment to a general versus culturally targeted condition.|Design is partial factorial. All white participants and half of African American participants will receive general video education/messaging. Half of African American participants will be assigned to an intervention condition that includes culturally-targeted information about SARS-CoV-2 antibody testing.|t|f|f|f
34103601|NCT06500689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103602|NCT06670313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791216|NCT00461799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33791217|NCT01934829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791218|NCT04588337|||COHORT||PROSPECTIVE|||||||
33791219|NCT02899585|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791220|NCT05922215|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33791221|NCT01419717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791222|NCT00307450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791223|NCT00984087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791224|NCT00414206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791225|NCT06351787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A 2-armed randomized cross-sectional experimental study with 20 healthy participants who hold yoga experience.||||
34011084|NCT01436565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011085|NCT00964288|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34011086|NCT04351841|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34011087|NCT04172519|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Stratified randomization was ensured by allocating the subjects using a simple method. One person picked envelopes with group allocation numbers from a computer generated random number table. It should be noted that the main investigator was blinded during the group allocation process. The randomized control trials (RCT) reporting quality has been improved using the CONSORT statement (Consolidated Standards of Reporting Trials).|Parallel crossover study|t|f|f|t
34011088|NCT05815082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011089|NCT00457210|||DEFINED_POPULATION||OTHER|||||||
34011090|NCT03360175|||COHORT||PROSPECTIVE|||||||
34011091|NCT02358850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011092|NCT02492841|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011093|NCT03245034|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34011094|NCT02305342|||CASE_ONLY||CROSS_SECTIONAL|||||||
34011095|NCT00809237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011096|NCT01682148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011097|NCT04161183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind, placebo control study. Eligible patients will be assigned a randomization number in sequential order and each of the randomization will determine the allocation of one of the two treatment groups (ESWT and Placebo) in 1: 1 ratio as shown below. The ESWT and placebo will be controlled by a research assistance who will not evaluate the therapeutic outcome to ensure the double-blind method.|t|f|t|f
34011098|NCT05883033|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011099|NCT06331520|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011100|NCT06473506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011101|NCT05098457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011102|NCT03637335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Phase-3 study, randomized, controlled, multi-center, double blind|t|f|t|t
34011103|NCT02253602|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34011104|NCT04353024|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Double-blind, placebo-controlled, 5-period cross-over design with 4 different doses of DMT and placebo|t|t|t|t
34011105|NCT06161142|||COHORT||PROSPECTIVE|||||||
34011106|NCT04689347|NA|SEQUENTIAL||TREATMENT||NONE||A 3 + 3 design will be used to assess the maximum tolerated dose (MTD) or maximum tested dose of the combination FLIRT-bevacizumab. The MTD will be defined as the dose level at which ≥2/3 or ≥2/6 subjects experience a dose-limiting toxicity (DLT). When the MTD or maximum tested dose has been determined or reached, the RP2D to be tested in a future phase II trial will be one dose level below the MTD or the maximum tested dose if MTD will not be reached. At least 6 patients should be treated at the RD during the dose escalation.||||
34011107|NCT02847208|||COHORT||CROSS_SECTIONAL|||||||
34011108|NCT02188082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011109|NCT00227266|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34011110|NCT01569347|||COHORT||RETROSPECTIVE|||||||
34011111|NCT02456649|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011112|NCT02744599|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34011113|NCT03496883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded study medication||t|t|t|t
34011114|NCT06177002|||COHORT||PROSPECTIVE|||||||
34011115|NCT01972347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011116|NCT01521078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34011117|NCT06240689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011118|NCT00706355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011119|NCT03039348|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34011120|NCT04025138|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34011121|NCT05627817|||COHORT||PROSPECTIVE|||||||
34011122|NCT04995757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011123|NCT02975037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34011124|NCT02409186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011125|NCT03033719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011126|NCT02365948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011127|NCT04474782|||OTHER||PROSPECTIVE|||||||
34011128|NCT01194102|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34011129|NCT06443359|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011130|NCT01269450|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33708498|NCT04430218|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The assessments will be analyzed by a blinded assessor.|This study is designed as a randomized clinical trial in a small population of subjects to answer the primary question of whether use of a sensory-enabled, high degree-of-freedom (SE-ihDOF) prosthesis with the iSens system improves the subject's quality of life compared to use of their prescribed state-of-art (SOA) prosthesis|f|f|f|t
33708499|NCT01318993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708500|NCT00497718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708501|NCT02042183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While the care provider and outcomes assessor were also blinded, this was classified as a double-blind trial|Placebo controlled|t|f|t|f
33708502|NCT05117788|||COHORT||RETROSPECTIVE|||||||
33708503|NCT01793896|RANDOMIZED|PARALLEL||PREVENTION||NONE||After a placebo phase with no intervention in the first 25 subjects recruited, overweight or obese patients were randomly assigned to one of 3 treatments: hypocaloric diet, high intensity interval training or both interventions simultaneously, for 3 months.||||
34011131|NCT01843686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34011132|NCT03445299|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subject design||||
34011133|NCT02032355|||CASE_ONLY||PROSPECTIVE|||||||
34011134|NCT01393730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011135|NCT05997719|||COHORT||PROSPECTIVE|||||||
34011136|NCT05345626|||COHORT||PROSPECTIVE|||||||
34011137|NCT00251641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011138|NCT04633655|||COHORT||PROSPECTIVE|||||||
34011139|NCT06293326|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34011140|NCT00850681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011141|NCT00001662||||TREATMENT||||||||
34011142|NCT04897113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011143|NCT05947526|||COHORT||PROSPECTIVE|||||||
34011144|NCT05680870|RANDOMIZED|PARALLEL||PREVENTION||NONE||46 participants will be classified into 2 arms : intervention arm will receive omeprazole plus chemotherapy Control arm will receive chemotherapy only||||
34011145|NCT03005067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011146|NCT06177314|||COHORT||PROSPECTIVE|||||||
34011147|NCT03883282|||COHORT||CROSS_SECTIONAL|||||||
34011148|NCT02540499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011149|NCT01176019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34011150|NCT04344457|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Open label, single arm study||||
34011151|NCT04197128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The subjects are randomly divided into 2 groups i.e., Control and Test group each consisting of equal number of participants who are age and sex matched.|t|t|t|f
34011152|NCT00071084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011153|NCT02197026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011154|NCT04800341|||COHORT||PROSPECTIVE|||||||
34011155|NCT01417819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34011156|NCT04953078|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34011157|NCT00838942|||CASE_ONLY||PROSPECTIVE|||||||
34011158|NCT03865537|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Randomization 1 (Cold vs. hot snare group): Masking only of participants Randomization 2 (Eleview vs Placebo): Masking of all checked above|"2 x 2 randomized trial.~First randomization: Among half of patients with a large polyp will be removed by electrocautery (hot) snare resection, and the other half will have their polyp removed by snare resection without electrocautery (cold).~Second randomization: Among half of patients the large polyp will by lifted (submucosal injection before resection) with Eleview; among the other by Placebo (Normal Saline with Methylene Blue)."|t|t|t|t
34011159|NCT00549016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011160|NCT02857231|||COHORT||PROSPECTIVE|||||||
34011161|NCT00706992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708504|NCT02621060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33708505|NCT00303732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708506|NCT01154582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
33708507|NCT02454491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708508|NCT02548780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708509|NCT01131754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708510|NCT02805101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708511|NCT02749071|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33708512|NCT00825578|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708513|NCT02349321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708514|NCT00512005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791226|NCT06375824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791227|NCT03045419|||COHORT||PROSPECTIVE|||||||
33791228|NCT03068611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011162|NCT05430945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011163|NCT03224247|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094873|NCT03191201|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"To ensure that patients are unaware of the study drug they are receiving, the infusion pouch will be prepared in a separate room by members of the pharmacy unit and opaque bags will cover the infusion kits and infusions will be done via dark coloured infusion sets. Finally, a curtain will be used to shield the injection site from the patient's view.~To ensure that Outcomes Assessors are unaware of the study drug the patient is receiving, a seperate team of care providers will supervise the infusion of the investigation product and collect and/or manage adverse events (AEs) and serious adverse events (SAEs). The Outcome Assessor will not have access to participant related data during the randomised part of the study."|"Double blind randomised placebo-controlled, parallel group comparative inferiority study with open-label extension divided in two parts:~* A first randomised and double-blind part in which FCM or placebo will be administered at baseline and post-baseline parameters assessed.~* A second non-randomised, non-blinded open-label extension part starting at the end of part 1, in which participants randomised to the placebo group will receive a FCM injection and post-baseline parameters assessed."|t|f|f|t
34094874|NCT03597555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34094875|NCT01356810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34094876|NCT01675700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094877|NCT03556176|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34094878|NCT01366105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094879|NCT01339182|RANDOMIZED|CROSSOVER||||NONE||||||
34094880|NCT02852434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094881|NCT05312060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094882|NCT01363076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708515|NCT04982809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708516|NCT05979870|||COHORT||PROSPECTIVE|||||||
33708517|NCT04483622|||CASE_ONLY||PROSPECTIVE|||||||
33708518|NCT05899205|||COHORT||PROSPECTIVE|||||||
33708519|NCT03303365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708520|NCT06242158|||COHORT||PROSPECTIVE|||||||
33708521|NCT05214495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708522|NCT01434030|NA|SINGLE_GROUP||||NONE||||||
33708523|NCT01599845|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791229|NCT03329742|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a longitudinal randomized parallel groups design of n=30 subjects randomized in a 1:1 ratio to either sipuleucel-T plus control diet arm (20% protein content) or sipuleucel-T plus intervention low-protein content diet (10% protein diet).||||
33791230|NCT05102266|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708524|NCT02025764|||CASE_ONLY||PROSPECTIVE|||||||
33708525|NCT04742010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708526|NCT03597776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708527|NCT01402414|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33708528|NCT05410483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708529|NCT00953901|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33791231|NCT04556435|||COHORT||PROSPECTIVE|||||||
33791232|NCT04531488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups that practiced powered mobility via different modes.||||
33791233|NCT00159354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791234|NCT06087432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791235|NCT06553833|||COHORT||RETROSPECTIVE|||||||
33791236|NCT02773160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791237|NCT03035045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791238|NCT02962674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011164|NCT03173170|NA|SINGLE_GROUP||OTHER||NONE||||||
34011165|NCT06423157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Three assessments will be made throughout the study: before the intervention (T0), after the experimental phase (T1) and after a 6-week follow-up period (T2). All variables will be assessed by an evaluator blinded to the assignment of the athletes to the study groups.||f|f|f|t
34011166|NCT01655524|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34011167|NCT04637633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011168|NCT04904016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011169|NCT01597479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094883|NCT02384460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094884|NCT04545697|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34094885|NCT06432426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094886|NCT02495675|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34094887|NCT00169403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094888|NCT04650035|||OTHER||RETROSPECTIVE|||||||
34094889|NCT03458091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094890|NCT06195605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094891|NCT04033913|||COHORT||PROSPECTIVE|||||||
34094892|NCT02663505|||COHORT||PROSPECTIVE|||||||
34094893|NCT06081062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094894|NCT03345004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial.|t|t|t|t
33932838|NCT05457400|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The study medication will be provided in identical looking bottles. Because of the completely identical appearance and smell (white, powdery substance and sweet smell), no difference can be perceived by the investigators or subjects. The bottles will be labelled with the respective labels as shown in chapter 8.1.6. Unblinding will be performed after the database lock (e.g. all pseudonymized data for statistical analysis entered into an Excel and/or SPSS sheet). Emergency envelopes will be provided from the sponsor to the Department of Clinical Pharmacology if emergency unblinding is necessary.|"The objective of this study is to evaluate differences in glucose metabolism parameters after oral administration of 30g glucose or 30g ENSO16. Blood samples will be be collected from 15 male or female subjects at defined time points (0 - 15 - 30 - 45 - 60 - 90 - 120~- 180 minutes; 3 min at each time point). Individual plasma glucose, insulin and C-peptide concentrations are going to be evaluated and statistically assessed. Subjects will also be asked to complete a questionnaire regarding their digestion after oral intake of ENSO 16 or glucose defined timepoints."|f|f|t|f
33932839|NCT04112953|||COHORT||PROSPECTIVE|||||||
33932840|NCT05693649|RANDOMIZED|FACTORIAL||SCREENING||QUADRUPLE|||t|t|t|t
34011170|NCT06069869|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The trial is quadruple blind with all trial participants, outcome assessors (research staff and care providers), investigators, and trials statistician and data analysts being unable to determine the allocated trial arm for any trial participant or identify trial participants who are on the same trial regimen.|Each participant will be randomized to one of 6 sequence orders to receive the three MMS regimens first, second or third in order (e.g., 30, 45, then 60 mg; or 45, 30, then 60 mg; or 45, 60 then 30 mg etc.).|t|t|t|t
34011171|NCT02651142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708530|NCT06298383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708531|NCT05185193|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33708532|NCT01269463|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||All subjects entered the Open-Label Dose optimization phase and were titrated until an optimized dose of Methylphenidate hydrochloride Extended Release capsule was achieved. Completing subjects then entered the randomized Double-blind Phase (crossover).|t|t|t|t
33708533|NCT03220178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011172|NCT02066337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708534|NCT00001190||||TREATMENT||||||||
33708535|NCT00867724|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708536|NCT01412320|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708537|NCT06557460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial|t|f|f|t
33708538|NCT00000789||PARALLEL||TREATMENT||||||||
33708539|NCT04195087|||COHORT||PROSPECTIVE|||||||
33708540|NCT02359760|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708541|NCT05975892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708542|NCT04180670|||COHORT||PROSPECTIVE|||||||
33708543|NCT05190159|||CASE_ONLY||RETROSPECTIVE|||||||
33708544|NCT00672243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708545|NCT00880009|RANDOMIZED|||TREATMENT||NONE||||||
33791239|NCT06631872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a two-arm, multicentre, comparative, assessor-blinded, randomised, controlled, hybrid (Type 1; examining both efficacy and feasibility) superiority trial that includes one sub-study.|f|f|f|t
33791240|NCT02803606|||CASE_ONLY||PROSPECTIVE|||||||
33791241|NCT06114329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33791242|NCT03841019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791243|NCT05609448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791244|NCT05726292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791245|NCT05676736|||CASE_CONTROL||PROSPECTIVE|||||||
33791246|NCT01367561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791247|NCT03665298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791248|NCT02023125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791249|NCT02981186|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011173|NCT03416491|RANDOMIZED|PARALLEL||TREATMENT||NONE|The centralized laboratory was blinded to treatment assignment.|parallel, stratified assignment||||
33708546|NCT01691209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33708547|NCT04309539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind study||f|f|f|t
33708548|NCT00541255|||COHORT||PROSPECTIVE|||||||
33708549|NCT02403492|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33708550|NCT03550456|||OTHER||PROSPECTIVE|||||||
33708551|NCT01351922|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33708552|NCT06241833|||COHORT||RETROSPECTIVE|||||||
33708553|NCT04177797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708554|NCT06066983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708555|NCT00003097||||PREVENTION||||||||
33708556|NCT05288244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomization controlled study||||
33708557|NCT04610723|||COHORT||PROSPECTIVE|||||||
33708558|NCT05175183|||COHORT||RETROSPECTIVE|||||||
33708559|NCT05989750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The examiner, the biostatistician and people working in the laboratory for the analyses, will be blinded for allocation group. Only the operator and the participant will be aware of the type of treatment based on the computer-generated allocation table that will be kept at the Trial Master File (TMF) of the study.|Randomized, examiner-masked clinical trial|f|f|t|f
33708560|NCT00489346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708561|NCT05647655|||OTHER||CROSS_SECTIONAL|||||||
33708562|NCT00919919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708563|NCT00811369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708564|NCT02850965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708565|NCT02801383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708566|NCT02121730|||COHORT||RETROSPECTIVE|||||||
33791250|NCT06186739|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33791251|NCT05829096|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|N/A, study does not involve pharmaceutical products or medical devices. There is no randomisation involved in this study.|Single arm feasibility study||||
33791252|NCT02915055|||CASE_CONTROL||PROSPECTIVE|||||||
33791253|NCT04680871|||COHORT||PROSPECTIVE|||||||
33791254|NCT00939991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791255|NCT00798096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791256|NCT00098280||||TREATMENT||||||||
33791257|NCT01499654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791258|NCT06409949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, randomized, placebo-controlled trial with two parallel arms.|Patients with peripheral artery disease and claudication will participate in a double-blind, randomized, placebo-controlled trial with two parallel arms. Patients will be randomized 2:1 to receive either a daily oral dose of 40 mg MitoQ or matched placebo for six months.|t|t|t|t
33791259|NCT04948151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011174|NCT01852734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708567|NCT03602144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33708568|NCT05641519|RANDOMIZED|PARALLEL||PREVENTION||NONE||SERVE OC is a randomized controlled trial that utilizes block randomization, and the family/household will be the unit of randomization (participants in the same household will be randomized to the same intervention arm). We will prospectively enroll 150-200 households with school-age children from the SAC cohort and randomize the Hispanic/Latinx, Vietnamese, and non-Hispanic/ Vietnamese households to the SERVE OC intervention or enhanced standard intervention (ESI) to ensure balance between intervention arms within each race and ethnic group. Participant follow-up will occur at 12, 24, and 36 months.||||
33708569|NCT03955744|NA|SINGLE_GROUP||OTHER||NONE||||||
33708570|NCT03602183|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708571|NCT05639426|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33708572|NCT06164678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blinded member of the research team will complete all follow-up assessments|Participants are randomized 1:1|f|f|t|t
33708573|NCT01861964|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33708574|NCT01191229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708575|NCT00040573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708576|NCT00519402|||COHORT||OTHER|||||||
33791260|NCT02644174|||COHORT||PROSPECTIVE|||||||
34011175|NCT03987347|||COHORT||PROSPECTIVE|||||||
33708577|NCT03323541|||COHORT||RETROSPECTIVE|||||||
33708578|NCT02004210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708579|NCT01129817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708580|NCT03558178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708581|NCT03692130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants don't know in which of the both arms they are, the outcome assessor don't know which participant of which study-arm he/she calculate|One group with new treatment, one group with known and defined treatment|t|f|f|t
33708582|NCT04903990|||CASE_CONTROL||PROSPECTIVE|||||||
33708583|NCT04396678|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33708584|NCT04160195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33791261|NCT01412034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791262|NCT06266858|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791263|NCT06006091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791264|NCT00394381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791265|NCT00235040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011176|NCT04598334|||COHORT||PROSPECTIVE|||||||
34094895|NCT01009697|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094896|NCT03695094|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33708585|NCT00764647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708586|NCT01370356|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33708587|NCT06111157|||COHORT||PROSPECTIVE|||||||
33708588|NCT00315172||||TREATMENT||||||||
33708589|NCT04397107|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||One group patients were treated with IL-2 and another group patients were treated with routine therapy.||||
33791266|NCT03031444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791267|NCT03119363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Potentially eligible ASCT survivors will be identified by HSCT physicians and nurses at each medical center. A research assistant (RA) will be introduced to survivors who express an interest in the research. An RA will explain the study and consent those who are eligible. Once informed consent is obtained, an RA will conduct the screening interview (including the FACIT-Fatigue scale and a psychiatric and sleep disorder screening). An RA will review a checklist of inclusion and exclusion criteria. This information will also be verified by a review of participants' medical charts before participation begins. Eligible study participants will be randomly assigned condition using a block randomization table prepared by our statistician. Participants who do not meet eligibility criteria or who decline participation will be informed that they have completed their participation.|t|f|f|f
33791268|NCT03138109|||OTHER||RETROSPECTIVE|||||||
33791269|NCT00185016|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33791270|NCT06432569|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind|"The study has two arms: Group 1: n=25 Treatment A e Group 2: n=25 Treatment B (with - Treatment A: 3 capsules/day of butyrate (625 mg) + 3 capsules/day PEA (200 mg) at a ratio of dosage of 3/1 - Treatment B: Placebo (3+3/day capsules of starch).~Eligible subjects with IBS will be randomized in a 1:1 ratio to the treatment A or treatment B for six weeks. After the first treatment period, there is a 14-day washout period.~Hence, individuals will be treated with B/A treatment for additional six weeks, according to the crossover design."|t|t|t|t
33791271|NCT03148990|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Two intervention groups (MR vaccine and MMR vaccine), with 1 dose of vaccine in each group.|t|t|t|t
33791272|NCT01552018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791273|NCT02158481|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33791274|NCT03001804|||COHORT||PROSPECTIVE|||||||
33791275|NCT01835899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33708590|NCT00481130|||FAMILY_BASED||OTHER|||||||
33708591|NCT03209596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All assignments and group randomization were performed by a research team member who was not directly involved in the study. The masking of the volunteers was performed by the control drink. For statistical analysis of the results, the masking was maintained by conferring fictitious names to the groups.||t|f|t|t
33708592|NCT00656383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708593|NCT03461497|||COHORT||PROSPECTIVE|||||||
33708594|NCT03560232|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open-label||||
33708595|NCT01270412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708596|NCT03194607|||OTHER||PROSPECTIVE|||||||
33708597|NCT02088710|||COHORT||PROSPECTIVE|||||||
33708598|NCT03702972|||COHORT||PROSPECTIVE|||||||
33708599|NCT04108793|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study is an open label trial where patients, orthopedic surgeons, Nurses, and physical therapist will be aware of the intervention group. Therefore, no blinding or allocation concealment will be performed. However, the research assistant who will assess incidence of fall on telephone call will be kept blinded to ensure blinded data assessing.||f|f|f|t
33708600|NCT04589806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708601|NCT03472183|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"3 types of patients will be included:~* 10 patients with Alzheimer's disease and as controls:~* 10 patients with Parkinson's disease~* 10 patients without neurodegenerative disease.~During the course of the colonoscopy that these 30 patients should have in the context of their medical usual care, additionnal biopsies of colon will be removed to perform in vitro analysis for this study."||||
33708602|NCT00649324|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33708603|NCT05329610|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All participants, data collectors, and outcome assessors will be blind to the group allocation.|A double-blinded, randomised, placebo-controlled, parallel group, feasibility trial. The allocation ratio of treatment to placebo will be 1:1.|t|t|f|t
33708604|NCT06247020|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33708605|NCT04329533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two arms including Arm 1 who receives a 30 day free trial of the app at the start of the study and Arm 2 who receives a 30 day free trial at the conclusion of the study. All participants will complete a baseline survey on perceived stress, anxiety, and sleep, a survey on stress at 2 weeks, and all three surveys again one month later.||||
33708606|NCT04080128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708607|NCT05391516|||COHORT||OTHER|||||||
33708608|NCT01308554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33708609|NCT01758003|||COHORT||CROSS_SECTIONAL|||||||
33708610|NCT02971657|||CASE_ONLY||PROSPECTIVE|||||||
33708611|NCT01425281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708612|NCT06394297|NA|SINGLE_GROUP||TREATMENT||NONE||Patients enrolled in this study must have received or planned to receive 45 to 50 Gray in 25 fractions to pelvis with a simultaneous integrated boost (SIB) of 55 Gray in 25 fractions to metabolic active primary lesion and of 55 Gray in 25 fractions to 62.5 Gray in 25 fractions suspicious nodes of prior external beam radiation therapy. Following completion, patients will receive a boost of 28 Gray in 4 fractions using Image Guided Stereotactic Body Radiation Therapy techniques.||||
33708613|NCT00306618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708614|NCT05063604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708615|NCT03478020||SEQUENTIAL||TREATMENT||NONE||||||
33708616|NCT03380208|||COHORT||PROSPECTIVE|||||||
33708617|NCT03047915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708618|NCT01215383|||COHORT||PROSPECTIVE|||||||
33791276|NCT04459988|||COHORT||PROSPECTIVE|||||||
33791277|NCT01952795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791278|NCT03094767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791279|NCT00497562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094897|NCT00315575|||COHORT||CROSS_SECTIONAL|||||||
33791280|NCT03083405|||COHORT||PROSPECTIVE|||||||
33791281|NCT00954707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791282|NCT00546871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791283|NCT01204528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791284|NCT05453955|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33791285|NCT04604054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791286|NCT01377623|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791287|NCT00537706|||||PROSPECTIVE|||||||
33791288|NCT06388941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791289|NCT00587106|||COHORT||PROSPECTIVE|||||||
33791290|NCT04009226|||COHORT||PROSPECTIVE|||||||
33791291|NCT03256812|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791292|NCT02864095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791293|NCT05875155|||CASE_ONLY||PROSPECTIVE|||||||
34094898|NCT06203795|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094899|NCT06208579|||COHORT||PROSPECTIVE|||||||
34094900|NCT02063269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34094901|NCT03928327|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34094902|NCT03650075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34094903|NCT00575302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791294|NCT05674370|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791295|NCT03749590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33791296|NCT03241654|||CASE_CROSSOVER||PROSPECTIVE|||||||
33791297|NCT03828162|||COHORT||PROSPECTIVE|||||||
33791298|NCT06553989|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34094904|NCT02365129|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34094905|NCT03608085|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34094906|NCT03723486|||COHORT||PROSPECTIVE|||||||
34094907|NCT05345314|||COHORT||PROSPECTIVE|||||||
34011177|NCT04625452|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The data will be collected under investigator's supervision, documented by nurses ( counselors), clinical officers ( doing routine consultations), lab technicians ( analyzing blood) and the clerk doing the measurements. Data sent to the investigators and statisticians for entry and analysis will be blinded beforehand by removing the identifiers' information. After completing the analysis, results will be again allocated to their respective arms.|"Intervention group will be administered at 3, 12 and 24 weeks. The intervention consists in addition to normal care and distribution of printed education pamphlets, of an individual counseling based on lifestyle risk factors of diabetic or hypertensive participants themed around 5 points (ask, advice or alert, assess , assist and arrange). It will use a guiding style from motivational interviewing consisting of asking opened questions, summarizing patients, reflecting him his statements, and capture change words, and requesting for permission to introduce any new point.~Normal care Participants allocated to normal care (control group) will receive standard care for diabetes or hypertension as per Malawi- government's NCD's guidelines: drugs, inconsistent unstructured advises regarding lifestyle behavior, opportunistic biological tests as per clinician's judgement."|f|f|t|t
34011178|NCT02333487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011179|NCT04916496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors and researchers(and health care providers of the study hospital) are blinded to the group assignment and intervention undertaken and concealed to the participant list.|Parallel Assignment; repeated-measures 2-arm randomized controlled trial|f|f|t|t
34011180|NCT04432675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34011181|NCT04825717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patients and the treating physicians and nurses will be blind to patient's nutritional plan (Intervention VS Control group)|"A randomized controlled double-blinded clinical trial. Intervention group: patients in this group will be administered nutrition and fluid plans prepared by the department dietitian using calorimetry-based measurements.~Control group: The nutrition plans of patients in this group will be calculated by the department dietitian using the standard, currently accepted RDI (recommended dietary intake) formula. Nutrition will be administered according to these calculations.~All patients included in this trial will receive a multivitamin supplement to prevent possible vitamin deficiencies."|t|t|t|f
34011182|NCT01049412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011183|NCT02131623|||CASE_ONLY||PROSPECTIVE|||||||
34011184|NCT01974882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34011185|NCT01793818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34011186|NCT05842304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011187|NCT01188265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011188|NCT04339426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011189|NCT04945772|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Treatment assignment will be unknown (or masked) to the study participants, the evaluating physician (non-injecting), outcomes assessor, the sponsor and its agents.|Following a 1:1:1 block randomization schema, 9 subjects will be enrolled in each MCO-010 treatment group, and 9 subjects will be enrolled in the sham-controlled group.|t|f|t|t
34011190|NCT00958867|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34011191|NCT01037582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011192|NCT00431782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011193|NCT03617627|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34011194|NCT01300624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011195|NCT04624152|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34011196|NCT00388895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011197|NCT00027742||||TREATMENT||||||||
34011198|NCT00938145|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011199|NCT02477852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011200|NCT04507035|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib treatment plus chemoradiotherapy||||
34011201|NCT05606588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All assessors will be blinded and participants will only be told the result of their randomization after the baseline assessment. For the following assessments patients and guardians will be instructed prior to the assessment not to reveal the arm they are in. Assessors are instructed to converse as little as possible outside the friendly instructions. Assessors and trainers will participate in separate study meetings and cannot speak to each other regarding patient matters.|This study will follow a prospective, multicenter, two-armed, randomised, controlled, assessor-blinded trial trial (RCT with follow-up).|f|f|f|t
34011202|NCT01663727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011203|NCT04768894|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||This is a clinical study. Patients with high grade non-muscle invasive bladder canser divided three groups according to time lapse.||||
34011204|NCT00839059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011205|NCT03135652|RANDOMIZED|PARALLEL||TREATMENT||NONE||adjuvant radiotherapy:SBRT chemotherapy:mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab||||
34011206|NCT02075606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011207|NCT00110188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011208|NCT06297655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011209|NCT03413384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011210|NCT00955552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011211|NCT05839327|||COHORT||RETROSPECTIVE|||||||
34011212|NCT03104933|||COHORT||PROSPECTIVE|||||||
34011213|NCT01613378|||COHORT||PROSPECTIVE|||||||
34011214|NCT02855619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011215|NCT04571892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011216|NCT06451718|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with keratoconus||||
34011217|NCT01839370|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011218|NCT01582919|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011219|NCT00401284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34011220|NCT00107042|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34011221|NCT03037034|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34011222|NCT00648024|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34011223|NCT02808208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011224|NCT06273787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment group a : Diaphragmatic Release in addition to positioning instruction group b: positioning instruction|t|f|f|f
34094908|NCT06407440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094909|NCT04534946|||COHORT||PROSPECTIVE|||||||
34094910|NCT03418480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094911|NCT05404841|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34094912|NCT01738178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094913|NCT03485456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094914|NCT03832088|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094915|NCT05934253|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34094916|NCT04488094|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients suspected of having acute allograft rejection after heart transplantation (HT, n = 10) or liver transplantation (LT, n = 10)||||
34094917|NCT01716156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094918|NCT01608204|||||PROSPECTIVE|||||||
34094919|NCT05586087|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094920|NCT01311583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34094921|NCT05406999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094922|NCT05520047|||COHORT||PROSPECTIVE|||||||
34094923|NCT04667169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34094924|NCT04231006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094925|NCT00006215||||TREATMENT||||||||
33932841|NCT00674687|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33932842|NCT04152668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Forty patients diagnosed with peri-implantitis on at least one implant will be randomly allocated by tossing a coin into test or control group. Two different operators will participate in the study (ML and AS). ML masked to the treatment assignment, will collect the data, and AS will perform the treatment.|Randomized, single-masked controlled trial (RCT)|f|f|t|t
33932843|NCT03876704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932844|NCT01634100|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932845|NCT03938636|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, open-label, multicenter, single and repeated-dose study designed to evaluate the reliability and sensitivity of TUV assessments in healthy controls and subjects with active RA.||||
33932846|NCT04461613|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|Study participants will receive an unmarked envelope consisting of all study material. The order of the study questionnaires inside the unmarked envelope will be randomized and sealed by the first researcher. The first researcher will give them to the second researcher who will again shuffle the envelopes order (without the first researcher present) before giving them to the care provider. The care provider will give the study envelope to the study participants. Therefore, investigators and care provider will be masked to the contents of the unmarked study envelope and cannot selectively assign the participants to a certain group. However, the study participants might recognize the original IPAQ if she/he received this questionnaire in the past.|Two groups of people with CMT will compare an original International Physical Activity Questionnaire short form (IPAQ-sf) and a revised one with a 7-days physical activity diary. The first group will begin with the original version and end with a revised one. The second group will begin with a revised IPAQ-sf and end with the original one. Both groups will also need to complete a 7-days activity diary two times.|f|t|t|f
33932847|NCT01373125|||COHORT||CROSS_SECTIONAL|||||||
33932848|NCT02469584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932849|NCT02681640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932850|NCT00706758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011225|NCT04008693|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34011226|NCT01506908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011227|NCT04704349|NA|SINGLE_GROUP||OTHER||NONE||All patients will undergo scintigraphy on 2 distinct devices and the images obtained will be compared.||||
34011228|NCT00578071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011229|NCT01854086|||CASE_ONLY||PROSPECTIVE|||||||
34011230|NCT04882319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011231|NCT01974128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011232|NCT04447937|||COHORT||RETROSPECTIVE|||||||
34011233|NCT05156424|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pilot randomised control trial||||
34011234|NCT01652729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011235|NCT04882917|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34011236|NCT02914249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011237|NCT02613078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011238|NCT02553278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011239|NCT04909541|||CASE_ONLY||PROSPECTIVE|||||||
34011240|NCT05481359|||COHORT||PROSPECTIVE|||||||
34011241|NCT06098287|RANDOMIZED|PARALLEL||TREATMENT||NONE||A quasi-randomized, within-subjects, parallel-group, pre-post intervention study||||
34011242|NCT02777684|||||CROSS_SECTIONAL|||||||
34011243|NCT03744221|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Proteins will be packed in non-transparent sealed sachets/jars and labeled with 'protein A/B/C'. Proteins will be flavored to mask taste|double blind, randomised, cross-over, short-term trial in which 36 study subject will participate. Study subjects will receive three protein interventions of 1 week with a washout period of 1 week between interventions. 12 subjects will also receive an acute postprandial digestibility test at the start of the intervention.|t|f|t|t
34094926|NCT04331405|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 patients having acute contusion spinal cord injury (3 days post-trauma max) and ASIA A/B neurological deficit were divided into 2 groups: pilot group (n = 10) receiving hUCBMC treatment in addition to standard therapy and control group (n = 10) receiving standard treatment.||||
34094927|NCT01431846|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34094928|NCT03854032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094929|NCT03709589|||CASE_CONTROL||PROSPECTIVE|||||||
34094930|NCT00127933|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34094931|NCT04137315|||COHORT||RETROSPECTIVE|||||||
34094932|NCT01981928|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34094933|NCT01824004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094934|NCT00943202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791299|NCT01159249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791300|NCT05127551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34094935|NCT04049565|||CASE_CONTROL||PROSPECTIVE|||||||
33791301|NCT03915613|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Single-dose, randomized, double-blinded, cross-over study (150 participants) wherein study participants will receive a total of two doses (i.e., one insulin, one placebo) with a washout period of 1 week.|t|t|t|t
33791302|NCT02763124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791303|NCT05069935|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33791304|NCT02275325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791305|NCT04168619|||CASE_ONLY||PROSPECTIVE|||||||
33791306|NCT02850055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791307|NCT03147911|||COHORT||RETROSPECTIVE|||||||
33791308|NCT00982033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791309|NCT05899335|NA|SINGLE_GROUP||OTHER||NONE||||||
33791310|NCT00853827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791311|NCT00327665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33791312|NCT00415389|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33791313|NCT00003435||||TREATMENT||||||||
33791314|NCT02426320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33791315|NCT00541606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33932851|NCT06020768|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33932852|NCT00790218|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Study Arms: CF102 (1, 5, and 25 mg BID) in 28-day cycles.||||
33932853|NCT02159989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932854|NCT03993119|||OTHER||CROSS_SECTIONAL|||||||
33932855|NCT03536936|||COHORT||RETROSPECTIVE|||||||
33932856|NCT00509938|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33932857|NCT03140657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33932858|NCT05880160|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Two centre open label randomised control trial to evaluate the phased withdrawal versus continuation of heart failure treatment for 'recovered' human epidermal growth factor receptor 2 (HER2) therapy-related cardiac dysfunction in non-high risk patients following completion of HER2 therapy.||||
33932859|NCT00197340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33932860|NCT01432704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932861|NCT02756741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33932862|NCT02972736|||COHORT||RETROSPECTIVE|||||||
33932863|NCT03809195|RANDOMIZED|PARALLEL||TREATMENT||NONE||intervention group versus control group||||
33932864|NCT04409496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932865|NCT01076374|||COHORT||PROSPECTIVE|||||||
33932866|NCT06302868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932867|NCT00608244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932868|NCT03334656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932869|NCT04918836|||OTHER||PROSPECTIVE|||||||
33932870|NCT03823898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor are masked|A clinical trial with three-arm|f|f|f|t
33932871|NCT03665493|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE||"Both groups of patients will perform the stop-signal task and the go-only task under two conditions: a) ON Levodopa medication state calculated after the first-morning dose which normally allowed the patient to attain the best control of symptoms (4) b) OFF Levodopa medication state. i.e patients did not take medications overnight prior to the study (19). Experimental conditions will be counterbalanced across patients and administered in two different experimental sessions occurring on different days.~Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced."|t|t|f|t
33932872|NCT05726955|RANDOMIZED|PARALLEL||TREATMENT||NONE|The evaluations of pain, proprioception, mobility, balance, functionality and quality of life were performed by a physiotherapist, while treatment programs were performed by the other physiotherapist in this study. Physiotherapists were blind to each other. Face to face interview method was used for the data collection. A consultation was provided by the researchers when the patients had questions. It took about 30 min to complete all assessments.|||||
33932873|NCT02637167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932874|NCT06313749|NA|SINGLE_GROUP||TREATMENT||NONE|This clinical study is observer masked only when measuring intraocular pressure (using Goldmann Applanation Tonometry). Intraocular pressure measurements will be determined using the 2-person method to reduce bias. Observer 1 (masked to real time reading) will look through the slit lamp and turn the Goldmann Tonometer dial, and Observer 2 will read and record the intraocular pressure readings. Observer 1 will be unable to see the readings with the use of a masking card.|||||
33932875|NCT06118944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932876|NCT01998113|||||RETROSPECTIVE|||||||
33932877|NCT02030860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011244|NCT05711342|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because an internet-based intervention is used, patients, therapists and researchers cannot be blinded to the condition to which the participant is allocated.|Randomized controlled trial (RCT) with a control condition that receives treatment as usual in forensic outpatient clinics, and an experimental condition that receives treatment as ususal plus the 10-week internet-based intervention 'Aggression'.||||
34011245|NCT03406182|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34011246|NCT02698865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011247|NCT04610177|||COHORT||PROSPECTIVE|||||||
34011248|NCT02257619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011249|NCT01370486|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34011250|NCT06451393|||COHORT||RETROSPECTIVE|||||||
34011251|NCT06347432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011252|NCT01932814|||COHORT||RETROSPECTIVE|||||||
34011253|NCT00764231|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011254|NCT00932282|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011255|NCT05712642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708619|NCT03493594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33708620|NCT02282579|||CASE_ONLY||RETROSPECTIVE|||||||
33708621|NCT02198066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708622|NCT01727297|NA|SINGLE_GROUP||SCREENING||NONE||||||
33708623|NCT01195558|||CASE_ONLY||CROSS_SECTIONAL|||||||
33708624|NCT06505668|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708625|NCT01367210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708626|NCT01486667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708627|NCT02295488|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708628|NCT01003288|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708629|NCT03743623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708630|NCT02632981|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33708631|NCT01683383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708632|NCT01657669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708633|NCT04978727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants receive the same intervention/treatment in disease specific or age stratified fashion.||||
33708634|NCT06506747|||COHORT||RETROSPECTIVE|||||||
33791316|NCT03469154|RANDOMIZED|PARALLEL||OTHER||SINGLE|After training participants demonstrate skills in a standardised scenario test with children resuscitation manikins. All tests are video recorded. Participants in videos identified by a unique id number. Training method is not mentioned in videos. Assessors have no knowledge on the relation between group and unique id (are blinded for the interventions). Assessors assess videos of all participants in a randomised order .|"Two parallel groups. Participants randomised to either dyad training or instructor led training.~Dyad training in pairs guided by instructional videos Instructor led training with maximum 6 participants per instructor."|f|f|f|t
33708635|NCT00592215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791317|NCT02207075|||COHORT||PROSPECTIVE|||||||
33791318|NCT02834182|NON_RANDOMIZED|PARALLEL||||NONE||||||
33791319|NCT02435199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791320|NCT05911750|||COHORT||CROSS_SECTIONAL|||||||
33791321|NCT05907720|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791322|NCT04680741|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Primary Care provider (PI) will be blinded during the active enrollment and study phase of the trial. PI will continue to be the treating physician for these patients.|This is a prospective cohort pilot study to test the feasibility of a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.||||
33791323|NCT01949740|||COHORT||PROSPECTIVE|||||||
33791324|NCT03179787|||COHORT||PROSPECTIVE|||||||
34011256|NCT00052416||||TREATMENT||NONE||||||
33708636|NCT01587001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708637|NCT05965492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791325|NCT06432842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791326|NCT00374699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791327|NCT02865733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791328|NCT03864055|||CASE_ONLY||RETROSPECTIVE|||||||
33791329|NCT04296513|||COHORT||CROSS_SECTIONAL|||||||
33791330|NCT00911430|||||PROSPECTIVE|||||||
34011257|NCT00822393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011258|NCT01471899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708638|NCT01957930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708639|NCT02609269|||CASE_ONLY||PROSPECTIVE|||||||
33708640|NCT05644353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33708641|NCT00834171|||CASE_ONLY||RETROSPECTIVE|||||||
33708642|NCT04753060|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33708643|NCT03602482|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33708644|NCT03978338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708645|NCT05993130|||OTHER||RETROSPECTIVE|||||||
33708646|NCT04333797|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708647|NCT01443260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708648|NCT01824641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708649|NCT02516163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094936|NCT04764604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a feasibility study using a 'before and after' design to test the immediate effects of exercising with Acapella Choice in comparison to the immediate effects of exercising with Tube-in-water resistance exercises (current treatment norm). Participants will be assigned groups according to their diagnosis (i.e. muscle tension group, vocal fold palsy group and presbylaryngis group). All participants will exercise with both techniques (i.e. Acapella and tube-in-water).||||
34094937|NCT01696968|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34094938|NCT04700462|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34094939|NCT05673655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34094940|NCT02993302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708650|NCT05477056|||COHORT||RETROSPECTIVE|||||||
33708651|NCT04540029|||CASE_CONTROL||PROSPECTIVE|||||||
33708652|NCT00450281|||CASE_ONLY||PROSPECTIVE|||||||
33708653|NCT04344509|||CASE_CONTROL||RETROSPECTIVE|||||||
33708654|NCT01354990|||COHORT||RETROSPECTIVE|||||||
33708655|NCT00872456|||COHORT||PROSPECTIVE|||||||
33708656|NCT01898806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708657|NCT05131698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708658|NCT04653961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708659|NCT03439553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33708660|NCT02444520|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Patients and GPs will not be blind to treatment allocation due to the nature of the trial (i.e. therapy trial). The trial team member responsible for treatment allocation will be unblind. All outcome data are based on self-report and will be collected either by post or email. The research assistant(s) responsible for contacting participants who have not returned or completed follow-up questionnaires will be unblind. Moreover, the Data Monitoring and Ethics Committee (DMEC), research workers and trial statisticians will remain blind to treatment allocation.|PRINCE Primary is a cluster randomised waiting list controlled trial to evaluate the acceptability and feasibility of an integrated approach to care in general practice for adults with PPS.|f|f|f|t
33708661|NCT02398175|||||RETROSPECTIVE|||||||
33708662|NCT03362008|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708663|NCT00404261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708664|NCT01925105|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708665|NCT06248801|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33708666|NCT02140372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708667|NCT01831050|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33708668|NCT04837261|||COHORT||PROSPECTIVE|||||||
33708669|NCT06515743|||COHORT||PROSPECTIVE|||||||
33708670|NCT06110611|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.||||
33708671|NCT04766515|||COHORT||PROSPECTIVE|||||||
33708672|NCT05230290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708673|NCT03054441|||CASE_CONTROL||PROSPECTIVE|||||||
33708674|NCT01804283|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33708675|NCT03921944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708676|NCT03809052|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||Part A: 56 subjects will be studied in 7 cohorts (Cohorts A1 to A7) Part B: 22 subjects will be studied in 2 cohorts (Cohorts B1 to B2)|t|t|t|t
33708677|NCT04946188|NA|SINGLE_GROUP||OTHER||NONE||||||
33708678|NCT02521870|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791331|NCT02758652|||CASE_ONLY||PROSPECTIVE|||||||
33791332|NCT00206258|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791333|NCT03276117|||COHORT||PROSPECTIVE|||||||
33791334|NCT00276250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791335|NCT05230875|||CASE_CONTROL||PROSPECTIVE|||||||
34011259|NCT01014416|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34011260|NCT01304420|||COHORT||CROSS_SECTIONAL|||||||
34011261|NCT01774825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094941|NCT03045094|||COHORT||PROSPECTIVE|||||||
33791336|NCT00633854|||COHORT||CROSS_SECTIONAL|||||||
34094942|NCT01824147|||COHORT||PROSPECTIVE|||||||
34094943|NCT02838238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791337|NCT04889664|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot study||||
33791338|NCT05158361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791339|NCT01774994|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
33791340|NCT01726140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932878|NCT01285414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932879|NCT00991367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33932880|NCT05936372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932881|NCT03144089|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Anesthesia facemasks will be opacified so that the clinical provider will be blinded to which oral airway (Guedel vs AOA) is being used and in what order. The patient will be anesthetized and thus blinded. The Investigator and Outcomes Assessor will only see video of the data on the anesthesia monitor (not the patient/device/etc) and will thus be blinded. The only individuals who will not be blinded are the Research Assistants who will not be involved in data analysis.|Prospective, randomized, crossover design. All patients will receive both interventions during a single anesthetic, with the order of intervention being randomized.|t|t|t|t
33932882|NCT04212403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized, controlled trial.|t|f|f|f
33932883|NCT01975376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011262|NCT02430805|NA|SINGLE_GROUP||||NONE||||||
34011263|NCT01464554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011264|NCT00010413||||TREATMENT||||||||
34011265|NCT06612203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094944|NCT01641432|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
34094945|NCT02321722|||COHORT||PROSPECTIVE|||||||
34094946|NCT01297790|||COHORT||PROSPECTIVE|||||||
34094947|NCT01428141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708679|NCT05204238|||COHORT||PROSPECTIVE|||||||
33708680|NCT00684346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708681|NCT04587232|||CASE_ONLY||PROSPECTIVE|||||||
33708682|NCT02170597|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791341|NCT03181958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding towards the caregivers is impossible and blinding towards the patients makes no sense. However, outcomes' assessors will be blinded, as endpoints will be recorded by investigators not involved in patients' care. An assessor per each participating NICU will be nominated. Moreover, investigators performing the final statistical analyses will be blinded to the treatment allocation, as data collected by assessors will be inserted in the dedicated website and the arms' allocation will be re-coded.|"When the neonate had fulfilled the extubation criteria, extubation will took place with a gentle intratracheal suction. Upper airways will then be suctioned and intervention will be started immediately as follows:~Ventilators~* CPAP: CPAP will be provided by either variable flow or continuous flow devices, as there is no evidence that one type of CPAP generator would be better than any other.~* NIPPV: NIPPV will be provided by any type of neonatal ventilator. Synchronization will not be applied, as many currently marketed neonatal ventilators usually do not provide it for NIPPV.~* NHFOV: NHFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase (that is, Acutronic FABIAN-III, SLE 5000, Loweinstein Med LEONI+, Sensormedics 3100A). Other machines providing high frequency ventilations will not be used.~Importantly, the randomization should be done within one hour from the extubation to avoid bias."|f|f|t|t
33791342|NCT00134511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791343|NCT00625937||||TREATMENT||NONE||||||
33791344|NCT02573818|||CASE_ONLY||PROSPECTIVE|||||||
33791345|NCT05719818|||OTHER||RETROSPECTIVE|||||||
33791346|NCT01921543|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33791347|NCT02332369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791348|NCT01233050|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33791349|NCT06051500|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Random allocation to one of two sequence of meditation practice.||||
33791350|NCT04158999|||COHORT||PROSPECTIVE|||||||
33791351|NCT04761718|||COHORT||CROSS_SECTIONAL|||||||
33791352|NCT00869037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791353|NCT05035199|||COHORT||PROSPECTIVE|||||||
33791354|NCT01778712|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33791355|NCT06113406|RANDOMIZED|PARALLEL||OTHER||SINGLE|The person who will make the statistical analysis does not know which group the participants in our study belong to and does not know the participants.|An experimental and a pretest-posttest control group design method were applied in this regard.|f|f|f|t
33791356|NCT02935218|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791357|NCT03617406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791358|NCT01833507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791359|NCT06278025|||COHORT||CROSS_SECTIONAL|||||||
33791360|NCT01955668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791361|NCT00361517|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791362|NCT03208062|||COHORT||PROSPECTIVE|||||||
33791363|NCT02550626|||CASE_CONTROL||PROSPECTIVE|||||||
33791364|NCT01048788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791365|NCT01603810|||CASE_ONLY||PROSPECTIVE|||||||
33791366|NCT00921076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791367|NCT03357549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33791368|NCT03643029|NA|SINGLE_GROUP||OTHER||NONE||||||
33791369|NCT04039971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791370|NCT01544062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791371|NCT05983484|||COHORT||PROSPECTIVE|||||||
33791372|NCT01545544|||CASE_ONLY|||||||||
33791373|NCT03911245|||COHORT||RETROSPECTIVE|||||||
33791374|NCT01771900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33791375|NCT02560818|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791376|NCT01152190|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33791377|NCT04117191|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All the participants would be introduced to receive 2g tryptophan loading for exploring serum and urine indoxyl sulfate concentration.||||
33791378|NCT04352452|||CASE_CONTROL||PROSPECTIVE|||||||
33791379|NCT00707590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708683|NCT02644135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33708684|NCT02241629|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708685|NCT02849678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708686|NCT04451850|||COHORT||PROSPECTIVE|||||||
33708687|NCT01405742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708688|NCT05880680|||COHORT||PROSPECTIVE|||||||
33708689|NCT06218485|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33708690|NCT05349916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33708691|NCT06557447|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Exploratory study||||
33708692|NCT00541710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708693|NCT01666574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33708694|NCT04686071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were randomly divided into two groups which differed in the type of a 10-day treatment model used after the operation.Specifying the group was done by drawing a sealed, opaque envelope: an envelope with an even number ment PNF treatment, while an odd number ment traditional therapy.||t|f|f|f
33708695|NCT00025493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708696|NCT05276193|||OTHER||PROSPECTIVE|||||||
33708697|NCT03338374|NA|SINGLE_GROUP||TREATMENT||NONE||Exploratory single-centre, open label, non-randomised, prospective cohort study||||
33708698|NCT06119945|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708699|NCT06085612|||CASE_CONTROL||PROSPECTIVE|||||||
33708700|NCT02613975|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708701|NCT02469753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708702|NCT01372267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33708703|NCT04533581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708704|NCT00176228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708705|NCT00640601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708706|NCT03890081|||CASE_ONLY||PROSPECTIVE|||||||
34011266|NCT06616350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a two-arm randomized controlled trial with measurements taken at two time points: pre-intervention and post-intervention. Participants who met the inclusion criteria were automatically randomized within the app into either the experimental or control group using a 1:1 allocation ratio. The experimental group received the intervention through the esTOCma app, and completed the assessment questionnaires before and after the intervention. Participants in the control group did not receive the intervention and completed the assessment questionnaires again 10 days after the pre-assessment (post-intervention).|t|f|f|f
33708707|NCT05087277|||COHORT||PROSPECTIVE|||||||
33708708|NCT05496062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708709|NCT04397783|RANDOMIZED|PARALLEL||PREVENTION||NONE|computer based aleatoric numbers|||||
33708710|NCT05199129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708711|NCT06505889|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be assigned to one of three study groups (A, B, or C) to receive different local anesthesia methods prior to arterial blood sampling:~Group A (Ice pack), Group B (10% lidocaine spray), Group C (Control)"||||
34011267|NCT00726102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011268|NCT03827928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708712|NCT05574790|||COHORT||PROSPECTIVE|||||||
33708713|NCT00959231|NON_RANDOMIZED|||TREATMENT||NONE||||||
34011269|NCT03104621|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigators, patients and other study participants were blinded to treatment assignment throughout the study. Evaluator of IOP was also masked to treatment assignment.||t|t|t|t
34011270|NCT05264961|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708714|NCT01499056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011271|NCT02172352|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33708715|NCT04566679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708716|NCT02336971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708717|NCT01496612|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33708718|NCT02703662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708719|NCT00705198|||COHORT||PROSPECTIVE|||||||
33708720|NCT03499704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708721|NCT05682898|||COHORT||PROSPECTIVE|||||||
33708722|NCT04269447|||COHORT||PROSPECTIVE|||||||
33708723|NCT01893164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708724|NCT01322139|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33708725|NCT03539471|||CASE_ONLY||PROSPECTIVE|||||||
33708726|NCT01866696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708727|NCT01619423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is a three arm study, however, we changed the high dose in the secord part of the study, from 10 micromol/kg (part 2a) to 5 mictomol/kg (part 2b)|t|t|t|f
33708728|NCT00795860|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33791380|NCT04178109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011272|NCT02556892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708729|NCT02295384|||COHORT||RETROSPECTIVE|||||||
33708730|NCT00952575|RANDOMIZED|PARALLEL||||NONE||||||
33708731|NCT00558558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708732|NCT05904197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A quasi-experimental (one-group pretest-posttest)||||
33708733|NCT05694845|||CASE_CROSSOVER||PROSPECTIVE|||||||
34011273|NCT01404117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011274|NCT00767520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011275|NCT04744454|||CASE_ONLY||PROSPECTIVE|||||||
34011276|NCT00110344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011277|NCT04614987|||COHORT||PROSPECTIVE|||||||
33708734|NCT06324539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33708735|NCT00838578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708736|NCT03543566|||COHORT||PROSPECTIVE|||||||
33708737|NCT01292434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708738|NCT04696315|||CASE_CONTROL||PROSPECTIVE|||||||
33708739|NCT00810238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708740|NCT01008592|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33708741|NCT00833794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708742|NCT00598988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33708743|NCT02575937|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33708744|NCT02250378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708745|NCT02966262|||CASE_ONLY||CROSS_SECTIONAL|||||||
33708746|NCT02073760|||OTHER||CROSS_SECTIONAL|||||||
33708747|NCT02672865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708748|NCT01560364|||||PROSPECTIVE|||||||
33708749|NCT01227434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708750|NCT03688204|||COHORT||PROSPECTIVE|||||||
33708751|NCT03718832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33708752|NCT05649397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791381|NCT02714127|||CASE_CONTROL||PROSPECTIVE|||||||
33791382|NCT00324506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708753|NCT05096897|||CASE_CONTROL||PROSPECTIVE|||||||
33708754|NCT03118648|||COHORT||PROSPECTIVE|||||||
33708755|NCT05307146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791383|NCT04761237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are prevented from having knowledge of the interventions assigned to individual participants.||t|f|f|f
33791384|NCT03099824|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33708756|NCT05081141|||COHORT||PROSPECTIVE|||||||
33708757|NCT01297712|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33708758|NCT01245660|NA|SINGLE_GROUP||||NONE||||||
33708759|NCT04269096|||COHORT||RETROSPECTIVE|||||||
33708760|NCT00192556|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33708761|NCT00019097||||TREATMENT||||||||
33708762|NCT01341145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708763|NCT04434898|||CASE_CONTROL||PROSPECTIVE|||||||
33708764|NCT05970562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708765|NCT01169493|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33708766|NCT03005314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708767|NCT04391647|||CASE_CONTROL||PROSPECTIVE|||||||
33708768|NCT03230097|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33708769|NCT00410111|||COHORT||PROSPECTIVE|||||||
33708770|NCT00395304|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33708771|NCT03644212|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708772|NCT04664712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708773|NCT00545610|||CASE_CONTROL||PROSPECTIVE|||||||
33708774|NCT02523248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708775|NCT05747820|||COHORT||PROSPECTIVE|||||||
33708776|NCT04945954|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708777|NCT06497998|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708778|NCT05535699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708779|NCT03623815|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Double blinding was carried out using a blinding code randomly assigned to each participant by a separate party. This code was entered into the transcranial direct current stimulation device by the investigator to deliver the stimulation. The investigator was not unblinded until initial analysis was complete.|Placebo controlled crossover design|f|f|f|t
33708780|NCT01634724|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708781|NCT03486223|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Arms 1/2 are placebo controlled and blinded to investigator and participant|Arm 1 and 2 are crossover arms|t|f|t|f
33708782|NCT02830698|||COHORT||PROSPECTIVE|||||||
33708783|NCT03365830|||COHORT||PROSPECTIVE|||||||
33708784|NCT03253276|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Codes (OCA or placebo) will be opened after final examination of final patient|Double blind placebo-controlled crossover|t|f|t|f
33708785|NCT02416921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791385|NCT02047851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791386|NCT00169780|||COHORT||PROSPECTIVE|||||||
33791387|NCT04267250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33791388|NCT01278433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708786|NCT03393130|||COHORT||PROSPECTIVE|||||||
33708787|NCT00687323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708788|NCT05202652|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708789|NCT02057679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33791389|NCT02952755|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791390|NCT04346888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|for double-blind period||t|t|t|t
33708790|NCT04250220|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33791391|NCT05073718|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study tablets will be identically packaged in small boxes. All study personnel, investigators and the participants will remain blinded throughout the trial.|Randomized double-blind placebo-controlled multicentre clinical trial|t|t|t|t
33791392|NCT05092412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791393|NCT04354610|NA|SINGLE_GROUP||OTHER||NONE||||||
33791394|NCT04933136|||COHORT||PROSPECTIVE|||||||
33791395|NCT01138215|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932884|NCT02640755|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932885|NCT04028024|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932886|NCT00844415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932887|NCT04816786|||COHORT||RETROSPECTIVE|||||||
33708791|NCT06163729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708792|NCT03778762|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708793|NCT02643381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708794|NCT05236049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708795|NCT05651997|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms: AMT and MACT||||
33708796|NCT05239247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708797|NCT03641274|||COHORT||PROSPECTIVE|||||||
33708798|NCT04906291|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708799|NCT01782222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708800|NCT00952978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708801|NCT04953091|||COHORT||PROSPECTIVE|||||||
33708802|NCT03310775|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33708803|NCT00189150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708804|NCT01755078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33708805|NCT05805904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708806|NCT00680706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708807|NCT00586001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Treatment with the Unified Protocol (Arm 1) compared to a 16-week wait list control condition (Arm 2).|f|f|f|t
33708808|NCT05045248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708809|NCT01023620|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932888|NCT05982444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932889|NCT04175431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932890|NCT03404219|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33932891|NCT05467605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33791396|NCT03961152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Patients were randomised to the PainCoach-app group or control group. Both groups received usual care. In the PainCoach-app group, in addition to receiving the aforementioned usual care, patients could use the PainCoach app whenever they wanted. In response to the patient's input of the pain experienced, the app gave advice on pain medication use, exercises/rest and when to call the clinic. This advice was the same as patients also received during usual care.|f|f|f|t
34011278|NCT05893446|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patient enrollment and data collection will begin in year two. In year one, sites will have been randomized to the intervention condition within four sequence blocks on a staggered schedule. The stepped wedge cluster-randomized trial design will go through 5 periods with each period lasting for 7 months for a total of 35 months (year 2 through year 4). The goal of year two is for all sites to initiate the schedule to which they are randomly assigned. All participating sites will start in the control condition (usual process/care) in period 1. By the end of year two, we aim for sites to be within period 2. At this time, two sites will be implementing the intervention. Patients will be recruited and enrolled from acute care hospital sites in a rolling fashion across the entire study period (year 2 to year 4).||||
33708810|NCT04166175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant don't know the procedure|two groups of patients randomly allocated group1 the botox group received 80 IU botox injection and group 2 under went lateral internal sphincterotomy|t|f|f|f
33708811|NCT02956421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011279|NCT04797442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708812|NCT00766311|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33708813|NCT06341868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33708814|NCT02660502|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33708815|NCT03823001|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708816|NCT02232165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708817|NCT06321783|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708818|NCT00339534|||CASE_CONTROL||RETROSPECTIVE|||||||
33708819|NCT04395443|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33708820|NCT01623583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708821|NCT03895385|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33708822|NCT01486537|||OTHER||PROSPECTIVE|||||||
33708823|NCT05288920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||To compare the effect of transforaminal injection of Steroids alone versus Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection on TNF-α level in lumbar disc related radicular pain|t|f|t|f
33708824|NCT05388331|||COHORT||PROSPECTIVE|||||||
33708825|NCT01458938|||CASE_CONTROL||PROSPECTIVE|||||||
33708826|NCT04944069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708827|NCT05012683|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708828|NCT01119417|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33708829|NCT05724563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708830|NCT03308734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised Control Trial||||
33708831|NCT01632488|||CASE_CONTROL||PROSPECTIVE|||||||
33791397|NCT05851768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||f|t|t|f
34011280|NCT06175936|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34011281|NCT06093087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011282|NCT02673879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011283|NCT05754229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011284|NCT01882582|||COHORT||PROSPECTIVE|||||||
34011285|NCT04316130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Range of motion||f|f|f|t
34011286|NCT04410484|||CASE_CONTROL||RETROSPECTIVE|||||||
34011287|NCT02689999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011288|NCT03919448|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34011289|NCT02171767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011290|NCT02667821|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011291|NCT00347113|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34011292|NCT06013059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011293|NCT00878696|||CASE_ONLY||RETROSPECTIVE|||||||
34011294|NCT01284855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011295|NCT01754506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011296|NCT03232099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Forty two men with established atherosclerotic disease will be studied:after a 2 week washout period, each subject receives both treatments, intervention and control||||
34011297|NCT06211413|||COHORT||PROSPECTIVE|||||||
33708832|NCT03233360|||COHORT||OTHER|||||||
33708833|NCT01145443|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33708834|NCT00844714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708835|NCT03990454|NA|SEQUENTIAL||TREATMENT||NONE||The study will employ a 3+3 dose-escalation design. Cohorts (same dose level) of 3 to 6 evaluable subjects will participate in a dose-escalation scheme in which the dose of SLC-391 will be increased in each consecutive cohort. Evaluation of a cohort of ≥ 3 subjects that have completed a 21-day cycle (cycle 1) is required prior to defining a new SLC-391 dose and schedule for the next cohort. Dose-escalation decisions by the Data Review Committee will take into account all available data including PK/pharmacodynamic data and the safety profile of prior cohorts. Based on all available emerging data, alternative dosing schedules, frequency, or dose reductions may be considered.||||
33708836|NCT04700761|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33708837|NCT04459533|||CASE_CONTROL||RETROSPECTIVE|||||||
33708838|NCT01352858|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791398|NCT00744393|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33791399|NCT00444431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708839|NCT03465306|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This study is been designed to have pre, post, and follow-up phases.|t|f|f|f
34011298|NCT05273931|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34011299|NCT06456879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011300|NCT03875014|||COHORT||RETROSPECTIVE|||||||
34011301|NCT05310799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011302|NCT02988934|||COHORT||PROSPECTIVE|||||||
34011303|NCT01150552|||COHORT||PROSPECTIVE|||||||
33708840|NCT06497413|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The investigators will use a randomizer to assign the participant with either the experimental or sham treatment condition.|Individuals will be randomly assigned either an experimental or a control condition|f|f|t|f
33708841|NCT05180279|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||40 human subjects will be recruited into this proposed study: 20 Healthy Controls and 20 UC subjects with left sided inactive disease. Patients will be matched with Health Controls. Patients will have two study visits: the first is the initial in-clinic screening and the second is the 7-day sleep lab intervention. There will be no follow-up after the lab.||||
33791400|NCT05666180|||OTHER||CROSS_SECTIONAL|||||||
33791401|NCT04136496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study A: 10-20 patients Study B: 25-50 patients~Study B will incorporate more patients as this is the population which we are more interested in, and will benefit the greatest from this technique. Study A is to determine if it is technically feasible and obtain feedback from the surgeons"||||
33708842|NCT01445262|||||PROSPECTIVE|||||||
33708843|NCT05840991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708844|NCT00006161|RANDOMIZED|PARALLEL||TREATMENT||||||||
33791402|NCT04806256|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33791403|NCT06443060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33791404|NCT04337775|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791405|NCT01523249|||COHORT||PROSPECTIVE|||||||
33708845|NCT01209260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708846|NCT03293290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708847|NCT05881928|NA|SINGLE_GROUP||OTHER||NONE||||||
33708848|NCT03732157|||COHORT||PROSPECTIVE|||||||
33791406|NCT00957658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791407|NCT00486330|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791408|NCT00476060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791409|NCT00057382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791410|NCT00076986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791411|NCT04604873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791412|NCT06333080|||COHORT||PROSPECTIVE|||||||
33791413|NCT00872417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791414|NCT00762099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791415|NCT06414382|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Koebner phenomena will be induced using tape-stripping or tape-stripping and micro needling. Koebner development will be assessed.||||
33791416|NCT04241224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791417|NCT06553287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791418|NCT01092806|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33791419|NCT05808439|||COHORT||PROSPECTIVE|||||||
33791420|NCT03546608|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708849|NCT05489510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be assigned randomly to either pulsed or continuous lighting.|Prospective, double-arm, randomized single-site study|f|f|t|f
33708850|NCT02321800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791421|NCT00852618|||CASE_ONLY||PROSPECTIVE|||||||
33791422|NCT03769233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932892|NCT01173822|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33932893|NCT04457661|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33932894|NCT04383106|||COHORT||PROSPECTIVE|||||||
33932895|NCT04609215|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single-arm design.||||
33932896|NCT05915104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All qualified participants will be randomly assigned in a 1:1 ratio to receive budesonide MMX® or budesonide CR. Blocked randomization (block size of 8) will be stratified on disease subtype (collagenous colitis vs. lymphocytic colitis). Randomization will be conducted through the REDCap® clinical trials randomization module, which will generate a random, blinded allocation sequence that will be concealed to both investigators and participants.~An independent pharmacist will prepare all treatment packages. Budesonide will be packaged into 4-week increments (two packages per 8-week treatment course). These treatment packages will be identical in appearance and size and labelled with a randomly generated study identification number. Investigators will not know the contents of each treatment package.~At the randomization visit, eligible participants will be randomized and be given the corresponding treatment package. Participants will not be blinded to treatment."|This phase 2a trial is a prospective, randomized, single-blinded (investigator-blinded), active comparator clinical study. Eligible participants with active Microscopic Colitis will be randomized 1:1 to receive either budesonide MMX® or budesonide CR 9 mg daily for 8 weeks.|f|f|t|t
33932897|NCT00320294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932898|NCT03890497|RANDOMIZED|PARALLEL||PREVENTION||NONE||• To assess the seroconversion to PV2 after one and two doses of fIPV and IPV when first dose is administered to children aged between 9 and 13 months with second dose administered 2 months later.||||
33932899|NCT01983046|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33932900|NCT03592394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932901|NCT00488059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932902|NCT01995422|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33932903|NCT02308306|||COHORT||PROSPECTIVE|||||||
33932904|NCT03625960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized to receive treatment with trichloroacetic acid or cantharidine.|Patients will be randomized to receive either trichloroacetic acid or cantharidine treatment.|f|f|t|f
33932905|NCT03139435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932906|NCT01365091|RANDOMIZED|CROSSOVER||||NONE||||||
33932907|NCT01636167|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33708851|NCT04404361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708852|NCT04659161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33708853|NCT04505189|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will receive 3 doses of psilocybin. The maximum dose a participant will receive in a single session is 25 mg.|||||
33708854|NCT02231775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708855|NCT00365482|||CASE_ONLY||PROSPECTIVE|||||||
33791423|NCT04761562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patient and the outcomes assessors of the tympanic membrane healing, hearing and questionnaires will not know in which group the patient was placed. The patient group will be known only to the doctoral student, the surgeon and the person who will prepare the PVRP. None of them will be included in the process randomisation and final assessment 3 and 6 months after surgery.||t|f|f|t
33791424|NCT04694248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932908|NCT04716712|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|This will be a quadruple blinded study. Only one biostatistician and one analyst at UCSF will have the unmasking information.|"The study will be a double-blind, placebo-controlled, cluster-randomized trial in which health centers (CSPS) in the 3 intervention regions will be randomized to either CHD combined with placebo (33%) or CHD combined with Azithromycin (67%), an allocation of 1:2 that favors active treatment. The allocation sequence and treatment labels will be masked to all but one biostatistician and one analyst at UCSF. The placebo will be indistinguishable from the active azithromycin.~Antimicrobial resistance will be monitored in a parallel study of communities from the target study area. 60 communities will be randomly selected among eligible communities, and randomized in a 1 : 1 fashion to CHD+placebo or CHD+azithromycin"|t|t|t|t
33932909|NCT05408052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708856|NCT06266572|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33708857|NCT04634734|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33708858|NCT00716534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708859|NCT06116760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The tDCS device has a built-in function for double blind studies, i.e., the experimenters are not aware whether they are applying real or sham tDCS.|"Three groups of participants were allocated to three different experimental treatments:~Group 1: audio-visual training + ipsilesional occipital tDCS Group 2: audio-visual training + ipsilesional posterior parietal tDCS Group 3: audio-visual training + sham, placebo tDCS"|t|f|t|f
33708860|NCT01246271|||COHORT||RETROSPECTIVE|||||||
33708861|NCT06295289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708862|NCT06455644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708863|NCT06506136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, placebo-controlled study to evaluate the efficacy and safety of fluoxetine in treating patients with refractory constipation.|t|t|t|t
33708864|NCT04100265|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||"Non-randomized investigation in three panels with different eligibility criteria and study procedures.~The target population in each arm consists of 10 'completers'. Completers are defined as: Panel 1: A successful gastric motility recording of at least 6 hours~Panel 2: Patients who develop POI (estimated to be 10% of enrolled subjects) and in who gastric motility was recorded successfully for at least 6 hours~Panel 3: Patients who develop POI, who completed questionnaires for at least 2 days (with a questionnaire completion rate ≥50%)."||||
33708865|NCT04736030|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Delayed abbreviated intervention|t|f|t|t
33708866|NCT05074667|NA|SINGLE_GROUP||OTHER||NONE||||||
33708867|NCT02400632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708868|NCT02927665|||CASE_ONLY||PROSPECTIVE|||||||
33708869|NCT05298631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor will be blinded to the treatment provided to both treatment groups.|it is a randomized clinical trial. total 60 patients will be recruited 30 in each group. both groups are treatment group. treatment of group 1 is stabilization exercises and group 2 is dynamic exercises. patients are allocated randomly randomization is done by computer generated software sheet|f|f|f|t
33708870|NCT04010149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|A computer programme will generate a random list assigning group allocation to participant numbers. The participant numbers will be given out in order of attendance in the laboratory. The study design is double blind: participants and the researchers who are conducting the behavioural testing will not know until the end of the intervention if the participant received brain stimulation. A researcher from the University of Birmingham (Dr Assecondi) will setup the blind protocol on the brain stimulation device and will keep a record of this.|"Eligible participants will begin the administration of the baseline measures (T0), and outcome measures (T1). On the first training day, participants will receive active or sham brain stimulation, concurrent with one session of their training routine (20 minutes). Before each training session, participants will also be asked to answer short questions (level of alertness, engagement, etc.). Participants will complete 10 additional consecutive training sessions (2 weeks), at home. Each session should take about 45 minutes.~When the first training phase is complete, the participant will undergo time 2 (T2) assessment, as in T1.~Participants will then start the second training phase, involving 3 weeks of training only (no brain stimulation), at home. When the second training phase is completed, participants will undergo time 3 (T3) assessment, as in T2.~A last follow-up assessment, as T3, will be carried out at T4, a month after the completion of the intervention."|t|t|f|t
33708871|NCT02900196|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33708872|NCT01057446|||CASE_CONTROL||PROSPECTIVE|||||||
33708873|NCT04694742|||COHORT||PROSPECTIVE|||||||
33708874|NCT02591290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33708875|NCT06263205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708876|NCT06332911|||OTHER||PROSPECTIVE|||||||
33932910|NCT02691468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33932911|NCT06353425|||OTHER||CROSS_SECTIONAL|||||||
33932912|NCT00360672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932913|NCT02048852|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33932914|NCT01848795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
12805241|NCT05996224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708877|NCT05075122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708878|NCT04771039|||CASE_ONLY||RETROSPECTIVE|||||||
33708879|NCT03989271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization codes will be generated by a study statistician at the begnining of the study and is provided to research pharmacist who will be dispensing the study drugs. The study drug bottles will be numbered with no information about the study drug. The randomization codes will not be revealed until all the data is collected and analyzed. Both placebo and quercetin will be similarly packaged and will have similar color, taste and texture.|Double blinded placebo controlled study|t|t|t|t
33708880|NCT05122832|||OTHER||CROSS_SECTIONAL|||||||
33708881|NCT05375370|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708882|NCT03678129|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and investigators are blinded to the drug condition|Case-control comparison. Repeated-measures cross-over design. Prepandemic, each subject received each one of the three pharmacological probes in separate visits (i.e., placebo, AZD7325 low dose and AZD7325 high dose), with the order of capsule administration being pseudorandomized. Post pandemic, each participant receives either placebo or 5mg clobazam with the order pseudorandomized.|t|f|t|f
33708883|NCT05154591|NA|SINGLE_GROUP||TREATMENT||NONE|"* Open label for surgeons and radiologists~* Closed label for pathologists and nephrologists"|||||
33708884|NCT04032860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708885|NCT00454012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708886|NCT05011565|||CASE_CONTROL||PROSPECTIVE|||||||
33708887|NCT05193370|RANDOMIZED|PARALLEL||TREATMENT||NONE||single-center, open-label pragmatic randomized controlled pilot trial using block randomization||||
33708888|NCT02312102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791425|NCT02513238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791426|NCT06000618|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791427|NCT02947568|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791428|NCT05292599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791429|NCT00151606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791430|NCT00502372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791431|NCT01345838|||CASE_CONTROL||PROSPECTIVE|||||||
33791432|NCT03050788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791433|NCT00809120|NA|SINGLE_GROUP||SCREENING||NONE||||||
33791434|NCT05998096|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Conditions will be packaged into non-descript, identical cans with identical flavoring.|Randomized, double-blind, placebo-controlled, parallel study design|t|f|t|f
33791435|NCT05379881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791436|NCT03168204|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791437|NCT00732368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791438|NCT00366353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791439|NCT02909751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791440|NCT05207137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized trial||||
33791441|NCT01229839|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33791442|NCT02276820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791443|NCT05315336|NA|SINGLE_GROUP||TREATMENT||NONE||All patients with R/R EBV- HLH receive DEP combine with PD-1 antibody as an treatment.||||
33791444|NCT04479254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791445|NCT02125825|||COHORT||CROSS_SECTIONAL|||||||
33791446|NCT01988233|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791447|NCT00817635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791448|NCT01132872|||||PROSPECTIVE|||||||
33791449|NCT03311568|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective observational study. Validation of a new non-invasive ultrasound device in four controlled categories of study participants.||||
33791450|NCT00662636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791451|NCT02819336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791452|NCT06504563|||OTHER||CROSS_SECTIONAL|||||||
33791453|NCT02993510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791454|NCT06252506|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33791455|NCT00739102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791456|NCT01414842|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791457|NCT02093533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791458|NCT06480123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791459|NCT01908634|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33791460|NCT03037502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791461|NCT01685528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801796|NCT04746833|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"We will conduct a 9-month, randomized, two-arm, parallel, open-label, feasibility trial. Eligible participants will be randomized to LIMIT versus a pain monitoring app. Outcome measures will be collected over 9 months.~To ensure rigor and successful future implementation, we will: 1) develop an evidence based program with features proven to maximize engagement and retention; 2) ensure that the program includes mechanisms to address the diverse obstacles veterans report when consider opioid tapering (e.g. fear of pain flares and abandonment by the system); 3) employ a User Centered Design - with meaningful input from veterans and primary care providers throughout the development and testing phases; and 4) adhere to recently published guidelines for mobile health interventions."||||
33801797|NCT05143996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801798|NCT06423534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33932915|NCT00744692|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932916|NCT02270489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33932917|NCT00744731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932918|NCT06245824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932919|NCT00002675||||TREATMENT||||||||
33932920|NCT04813289|||COHORT||RETROSPECTIVE|||||||
33932921|NCT00314054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932922|NCT00182013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932923|NCT04649190|||COHORT||RETROSPECTIVE|||||||
33932924|NCT06398093|NA|SINGLE_GROUP||OTHER||NONE||||||
33932925|NCT01124513|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33932926|NCT06186024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011304|NCT06469177|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized, parallel group prospective interventional study. Patient participants will be consented and then randomized to either the treatment group and a control group."||||
34011305|NCT01891305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011306|NCT04729465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participant|Drug: Propofol Device : Bispectral Index Monitor|t|f|f|f
34011307|NCT00343434||||SUPPORTIVE_CARE||||||||
34011308|NCT04196816|||COHORT||RETROSPECTIVE|||||||
34011309|NCT04001257|||COHORT||RETROSPECTIVE|||||||
34011310|NCT00877552|||CASE_CONTROL||PROSPECTIVE|||||||
34011311|NCT05788952|||CASE_ONLY||CROSS_SECTIONAL|||||||
34011312|NCT00963079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011313|NCT04794387|||COHORT||PROSPECTIVE|||||||
34011314|NCT01207440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011315|NCT05514795|||COHORT||PROSPECTIVE|||||||
34011316|NCT03041168|||CASE_ONLY||PROSPECTIVE|||||||
34094948|NCT06144801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study was designed as a single-blind, randomized, controlled clinical trial, with measures taken to minimize bias. Different individuals collected the data using the data collection form and tools, ensuring that the patients in the CoolSense and control groups remained confidential from the co-investigator and nurse responsible for administering the data collection tools, thereby implementing blinding.|To determine the sample, power analysis was utilized. With an effect size of 0.80 and a targeted test power of 0.80 (80%), the sample size was computed as 42 patients in total (21 for each group) for both the CoolSense group and the control group. This calculation was performed using the G\*Power 3.1.9.6 software, with a significance level of α=0.05, considering the absence of prior experimental studies investigating pain scores in this context. Accounting for potential issues such as participant withdrawal or study-related mortality, each group was increased by 20%, resulting in a total of 50 patients, with 25 patients in each group.|t|f|f|f
34011317|NCT04567576|||COHORT||PROSPECTIVE|||||||
34011318|NCT03030716|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34011319|NCT02582918|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34011320|NCT00393536|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34094949|NCT01458145|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34094950|NCT02473601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094951|NCT02122523|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708889|NCT00865696|RANDOMIZED|CROSSOVER||||NONE||||||
33708890|NCT02968797|||CASE_ONLY||RETROSPECTIVE|||||||
33708891|NCT02563223|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708892|NCT01247909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708893|NCT01969968|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33708894|NCT03046004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33708895|NCT01666496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708896|NCT05530421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708897|NCT04238702|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study|t|t|t|t
33708898|NCT04661839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33708899|NCT02109783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33708900|NCT02258698|||COHORT||PROSPECTIVE|||||||
33801799|NCT04141514|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801800|NCT05703646|||COHORT||PROSPECTIVE|||||||
34094952|NCT06545799|||COHORT||PROSPECTIVE|||||||
34094953|NCT02112552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094954|NCT04257669|||COHORT||CROSS_SECTIONAL|||||||
33708901|NCT04487392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708902|NCT05228171|||CASE_CROSSOVER||PROSPECTIVE|||||||
33708903|NCT00294437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708904|NCT02825056|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34011321|NCT01427166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011322|NCT00869986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011323|NCT00144833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801801|NCT02187887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011324|NCT00817947|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34011325|NCT03123887|||COHORT||RETROSPECTIVE|||||||
34011326|NCT01609621|||CASE_ONLY||PROSPECTIVE|||||||
34011327|NCT04948957|||COHORT||PROSPECTIVE|||||||
34011328|NCT05518448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Ketone vs placebo crossover|t|f|t|f
34011329|NCT06082297|NA|SEQUENTIAL||BASIC_SCIENCE||NONE|Participants did not receive information about what parameter-settings that were used for the different tests.|Repeated measures tests on on each of the 15 participants, comparing outcomes for no intervention and 10 different interventions in the form of variations in parameter-settings of neuromuscular electrical stimulation, with gradually increasing current amplitude until induction of ankle plantar flexion.||||
34011330|NCT04349631|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34011331|NCT01932099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708905|NCT04456608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||In this study we will recruit individuals who have previously been determined to have low or high RBC n-3 PUFA content and test platelet function at baseline and after 2-day aspirin treatment.||||
33708906|NCT02195583|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33708907|NCT02114216|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33801802|NCT01646749|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33801803|NCT06287489|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Mediterranean diet phase X regular diet phase|f|f|f|t
33801804|NCT04914442|||CASE_ONLY||RETROSPECTIVE|||||||
34011332|NCT04577573|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE||"At each visit, prototype cognitive prosthetic devices will be tested under 3 conditions:~No feedback, simple feedback, and enhanced feedback. Outcomes will include time taken for successful movements; and accuracy of movements."|f|f|f|t
34011333|NCT04203160|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase II: 2:1 Randomization with Bayesian Design Control Arm||||
34011334|NCT01807117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011335|NCT06401967|NA|SINGLE_GROUP||OTHER||NONE||||||
33708908|NCT04805424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33708909|NCT04070885|||COHORT||PROSPECTIVE|||||||
33708910|NCT00458211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708911|NCT04068870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801805|NCT02996136|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801806|NCT01411631|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33801807|NCT03282526|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33801808|NCT04079244|RANDOMIZED|PARALLEL||OTHER||NONE||"The attribution to the game-video or cartoon group is carried out according to a randomization by block  week ."||||
34011336|NCT03647631|||CASE_ONLY||RETROSPECTIVE|||||||
34011337|NCT06067451|RANDOMIZED|PARALLEL||PREVENTION||NONE||"We'll enroll 60 pediatric subjects diagnosed with prediabetes within three months at the Pediatric Diabetes Clinic. These subjects will be randomly assigned to two arms. All participants will receive standardized medical nutrition therapy protocol and visit frequency from RD. Study group participants will get the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT). SGSG will outline three SMART goal domains (exercise, diet, behavior) with a primary goal and example goals. Participants will personalize 2-3 SMART goals, those in standard of care group will just be asked what changes they plan to make."||||
34011338|NCT05057052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011339|NCT05556395|||COHORT||PROSPECTIVE|||||||
34011340|NCT00971984|||CASE_ONLY||RETROSPECTIVE|||||||
33708912|NCT05675397|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33708913|NCT03931538|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|t|f|f
33708914|NCT02560571|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801809|NCT02476409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801810|NCT06140732|NA|SINGLE_GROUP||TREATMENT||NONE||camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd||||
34011341|NCT01885702|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011342|NCT05206422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011343|NCT06175429|||COHORT||PROSPECTIVE|||||||
34011344|NCT03352895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34011345|NCT03716934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011346|NCT00255255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011347|NCT01443559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34011348|NCT02601274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011349|NCT04392557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single center single blind study|f|f|t|f
34011350|NCT01563926|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011351|NCT03353402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011352|NCT02373995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011353|NCT05336110|||COHORT||PROSPECTIVE|||||||
34011354|NCT03686020|||CASE_CONTROL||PROSPECTIVE|||||||
34011355|NCT04574128|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The person that controle the heart- and lung mashine is not masked. Other members of the surgical team is masked.|Randomised controlled non-inferiority trial|t|t|f|f
34011356|NCT03996720|||CASE_CONTROL||PROSPECTIVE|||||||
34011357|NCT03357887|||COHORT||RETROSPECTIVE|||||||
34011358|NCT00894114|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34011359|NCT02167542|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011360|NCT04523402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011361|NCT00347529|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34011362|NCT00121160|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34011363|NCT00456495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011364|NCT00746902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011365|NCT03103074|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Partcipant and investigator/outcomes assessor are blinded. Treatment will be given after randomization by a secondary investigator.|First treatment - one placebo and one active substance group Thereafter - all patients receive active substance|t|f|t|t
34011366|NCT02039752|||COHORT||OTHER|||||||
34011367|NCT04526392|||CASE_ONLY||PROSPECTIVE|||||||
34011368|NCT04467359|RANDOMIZED|PARALLEL||OTHER||NONE||The subjects were randomly divided into the experimental group and the control group. The control group received conventional rehabilitation nursing during the perioperative period, while the experimental group received ERAS intervention. The differences between the two groups in postoperative pain degree (NRS0-10) comfort level (Likert 1-5) and rehabilitation completion Range of motion(ROM) score were compared. The safety index was the occurrence of postoperative complications such as nausea, vomiting, dizziness, headache and urinary retention, and the occurrence of postoperative complications such as hypothermia after lower extremity deep venous thrombosis (preoperative and postoperative comparison of ESR CRP and procalcitonin indexes in blood routine)||||
34011369|NCT05695495|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||In the randomized arm, subjects will be administered intravenous DMT in 4 different bolus doses (5, 10, 15, 20mg) or placebo in randomized, counter-balanced order. In the dose escalation arm, subjects will be administered a placebo and a maximum of 5 DMT bolus doses (5, 10, 15, 20, 25mg) in an escalating dose order. In both arms, the bolus applications will be separated by one hour.|t|t|t|f
34011370|NCT01394848|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34011371|NCT01546324|||||CROSS_SECTIONAL|||||||
34011372|NCT00450983||||TREATMENT||NONE||||||
34011373|NCT05356936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094955|NCT04772131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Adult female subjects, who in the opinion of their physician require surgical treatment or who have already been diagnosed with stress urinary incontinence, will be eligible for study participation. Subjects who provide informed consent will undergo screening and baseline assessments. Subjects who successfully meet the study's inclusion and exclusion criteria will be eligible to undergo a Desara SIS or Desara Blue implant procedure, with subsequent follow-up assessments. The choice of implant, Desara One or Desara Blue, will be determined by the investigator based upon patient pathology and surgical preference.||||
34094956|NCT03290729|NA|SINGLE_GROUP||TREATMENT||NONE||multicenter single cohort prospective study||||
34094957|NCT02263690|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34094958|NCT00869596|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34094959|NCT05995366|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708915|NCT00858130|NA|SINGLE_GROUP||TREATMENT||NONE||Patients were told to use different voltages and numbers of treatment periods, and experiment with pad placement, to find intensity, frequency of use, and pad position for optimal PTS symptom relief. Assessments (Villalta score, QOL questionnaire, calf circumference) were obtained at study entry and after 8 weeks of device use.||||
34094960|NCT00896233|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708916|NCT04148053|||COHORT||PROSPECTIVE|||||||
34094961|NCT03995082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34094962|NCT01460771|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33708917|NCT04555083|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33708918|NCT05004025|NA|SINGLE_GROUP||TREATMENT||NONE||Tumor-Treating Fields in Combination with Immunotherapy||||
33708919|NCT03794297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708920|NCT01201018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708921|NCT03889444|||OTHER||RETROSPECTIVE|||||||
33708922|NCT03053960|||COHORT||PROSPECTIVE|||||||
33708923|NCT01648647|||CASE_ONLY||PROSPECTIVE|||||||
33708924|NCT06279091|RANDOMIZED|PARALLEL||OTHER||NONE||"Selected children will be divided randomly into 3 groups:~Control group (Group I). Diaphragmatic Breathing group (Group II). Bubble Blower Breathing group (Group III)."||||
33708925|NCT03519217|||CASE_ONLY||CROSS_SECTIONAL|||||||
33708926|NCT06055010|||COHORT||RETROSPECTIVE|||||||
33708927|NCT00297830|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33708928|NCT04551755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33708929|NCT01896102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708930|NCT02380781|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33708931|NCT04923191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708932|NCT02949037|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33708933|NCT01419678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708934|NCT00175994|||DEFINED_POPULATION||OTHER|||||||
33801811|NCT01957969|||COHORT||PROSPECTIVE|||||||
33801812|NCT01609218|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33932927|NCT06026423|||COHORT||PROSPECTIVE|||||||
33932928|NCT03122249|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive the intervention delivered via the internet||||
33932929|NCT00767299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932930|NCT02364661|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33932931|NCT03127462|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"In the first phase of the study 30 patients will receive standard treatment (control group) and in the following phase 30 patients will receive the individualized conversational/educational intervention (intervention group).The rationale for using a historical control group instead of a randomised control group is that it inreal-life setting is unpractical to realize a communicative intervention, because clinicians unintentional can intervene against the control group."||||
33932932|NCT01060722|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33932933|NCT02876484|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932934|NCT04584944|||OTHER||CROSS_SECTIONAL|||||||
33932935|NCT03436745|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33932936|NCT01905514|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33932937|NCT02283346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932938|NCT00108615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33932939|NCT00874224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33932940|NCT00873704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33932941|NCT04662645|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33932942|NCT00171613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932943|NCT01099761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932944|NCT04500223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932945|NCT01524926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932946|NCT01866306|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932947|NCT01679340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33932948|NCT00757367|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33932949|NCT02924272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932950|NCT02055729|||COHORT||PROSPECTIVE|||||||
33932951|NCT02058251|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33932952|NCT01386190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33932953|NCT03449706|||COHORT||PROSPECTIVE|||||||
33932954|NCT01709604|||COHORT||PROSPECTIVE|||||||
33932955|NCT02252328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33932956|NCT02897076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932957|NCT03066310|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33932958|NCT00175422|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33932959|NCT01711580|||COHORT||PROSPECTIVE|||||||
33932960|NCT05551910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|t|f|f|f
33932961|NCT02384785|||COHORT||PROSPECTIVE|||||||
33932962|NCT03928340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932963|NCT00858975||PARALLEL||TREATMENT||NONE||||||
33932964|NCT03367611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33932965|NCT05355324|||COHORT||RETROSPECTIVE|||||||
33791462|NCT05553613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive either loading doses of ticagrelor and aspirin or clopidogrel and aspirin by a specially trained and qualified nurse. We prepared sequentially numbered opaque sealed envelopes and 900 labels for each drug labelled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 900. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included ticagrelor, and Drug B included clopidogrel. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will conduct our randomized controlled trial, which will contain 2 arms; the ticagrelor arm (group A) will receive (a 180 mg loading dose during the first 24 hours of stroke onset, followed by 90 mg b.i.d from the 2nd to the 90th day), and the Clopidogrel arm will receive (300 mg loading dose during the first 24 hours of stroke onset followed by 75 mg once daily from the 2nd day to the 90th day).|f|f|t|t
33791463|NCT03652207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791464|NCT04954040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791465|NCT02002819|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33791466|NCT01194258|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33791467|NCT03787706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33791468|NCT01357044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791469|NCT00386204|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33791470|NCT01956669|NA|SINGLE_GROUP||TREATMENT||NONE||"The study design included a hierarchical 2-stage tumor response assessment with each cohort independent from one other.~* Cohort 1: rhabdomyosarcoma (RMS)~* Cohort 2: non-rhabdomyosarcomatous soft tissue sarcoma (NRSTS)~* Cohort 3: Ewing sarcoma/pPNET~* Cohort 4: osteosarcoma~* Cohort 5: measurable neuroblastoma (mNeuroblastoma)~* Cohort 6: evaluable neuroblastoma (eNeuroblastma)~* Cohort 7: hepatoblastoma"||||
33791471|NCT05716373|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Single (Participant) pain,tiredness,sleep quality|reiki|t|f|f|f
33791472|NCT00227032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791473|NCT03582618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791474|NCT05997199|||CASE_CONTROL||PROSPECTIVE|||||||
33791475|NCT00624312|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33791476|NCT01080599|RANDOMIZED|PARALLEL||||||||||
33791477|NCT03758950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple blind||t|t|t|t
33791478|NCT04635488|||COHORT||PROSPECTIVE|||||||
33791479|NCT02931123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791480|NCT00608673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33791481|NCT02940561|RANDOMIZED|CROSSOVER||||NONE||||||
33791482|NCT00002415||||TREATMENT||DOUBLE||||||
33791483|NCT00241930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791484|NCT02655380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33791485|NCT00357396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791486|NCT03070106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison between the functional medicine (FM) group and the usual care group||||
33791487|NCT02375048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791488|NCT06027112|||OTHER||PROSPECTIVE|||||||
33791489|NCT02265731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791490|NCT03958500|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791491|NCT02029664|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33791492|NCT05458141|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33791493|NCT00940992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791494|NCT04118699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791495|NCT00328523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791496|NCT00481234|||DEFINED_POPULATION||OTHER|||||||
33791497|NCT00449813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791498|NCT00435799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791499|NCT06537089|||COHORT||PROSPECTIVE|||||||
33932966|NCT06347692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly assigned to either the antigravity treadmill group (n = 20) or the control group (n = 20 ) using an online randomization website (www.randomization.com). The control group received a conventional physical therapy program. The therapists responsible for measuring and assessing the outcomes remained blinded to the group assignments.|The study included 40 patients with knee osteoarthritis who were randomly assigned to one of two groups: the antigravity treadmill group (n=20) or the control group (n=20). For 12 weeks, the antigravity treadmill group received training on the Alter G treadmill (75% weight-bearing, 30 minutes per session, three times per week) combined with traditional physical therapy. During the same period, the control group received only traditional physical therapy. The Visual Analogue Scale, Walkway System, and the Western Ontario and McMaster Universities Arthritis Index were used to assess pain, spatiotemporal gait parameters, and patient function, respectively. All outcome measures were obtained pretreatment, post-treatment|t|f|f|t
33932967|NCT03903536|||COHORT||PROSPECTIVE|||||||
33932968|NCT00853060|||||CROSS_SECTIONAL|||||||
33932969|NCT02021708|||COHORT||PROSPECTIVE|||||||
33932970|NCT04528394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932971|NCT00805818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33932972|NCT04311437|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33932973|NCT01819194|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33932974|NCT05953272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded study where the participant is unaware of the group allocation.|This is a randomized, parallel group, active controlled trial.|t|f|f|f
33932975|NCT00835276|RANDOMIZED|CROSSOVER||||NONE||||||
34011374|NCT01418716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011375|NCT01757899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011376|NCT01795079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011377|NCT04658316|||OTHER||CROSS_SECTIONAL|||||||
34011378|NCT06128694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33791500|NCT02174562|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33791501|NCT00698191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791502|NCT03671525|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33791503|NCT00760708|||CASE_CONTROL||PROSPECTIVE|||||||
33791504|NCT01199237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791505|NCT06074380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surfactant will be sent from Investigational Pharmacy|Comparison of the efficacy of calfactant compared to poractant alfa administered with a minimally invasive method for the treatment of respiratory distress syndrome in 28-36 week infants|t|f|t|f
33791506|NCT00927667|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33791507|NCT03008499|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791508|NCT04952129|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791509|NCT05921526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791510|NCT02488252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791511|NCT04884737|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"In months 1-3 Pre-Intervention participants will have 6 skin assessments at face (chin, cheeks, forehead), chest, and iliac crest: preoperative, Post Anesthesia Recovery Unit, transfer to floor, and post-operative days 1, 3 and 5.~In months 4-6 Intervention participants will have the same skin assessments at the same times and will have the dressings placed pre-operatively and removed following surgery."||||
33791512|NCT00285688|||CASE_CONTROL||PROSPECTIVE|||||||
33791513|NCT00876044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791514|NCT04894318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791515|NCT05788146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791516|NCT02179281|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791517|NCT01879371|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791518|NCT04561037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791519|NCT04861610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791520|NCT00006391||||TREATMENT||||||||
33791521|NCT02857491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791522|NCT00680472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791523|NCT01817036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791524|NCT01604447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791525|NCT04872829|||CASE_CONTROL||RETROSPECTIVE|||||||
33791526|NCT02496793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33791527|NCT04173962|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Midazolam has similar acute anesthetic effects compared to ketamine. This makes midazolam an appropriate substance to gauge whether ketamine can affect stress response thereby acting as an active control.|Participants are assigned to one of two groups in parallel during the duration of the study: the ketamine arm or the midazolam arm.|t|t|t|t
33791528|NCT04910932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33932976|NCT06127472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The effects of the adapted PE program will be evaluated in a Stepped Wedge Trial Design (SWTD), with the intervention sequentially rolled-out in ten (specialised) mental healthcare organisations. Furthermore, a pre-post design will be used to compare the situation before the roll-out period with the situation after the roll-out period.~A second intervention, training and education in detection and diagnosis of ASD in older adults, is rolled out in de same SWTD. The effects of this intervention will also be assessed further in pre-post design."||||
33932977|NCT05893836|||COHORT||RETROSPECTIVE|||||||
33932978|NCT04264494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932979|NCT02544490|||COHORT||PROSPECTIVE|||||||
33932980|NCT02231489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33932981|NCT02668692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791529|NCT02765373|||COHORT||PROSPECTIVE|||||||
33791530|NCT04042519|||CASE_CONTROL||RETROSPECTIVE|||||||
33791531|NCT03578640|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|An interventional, single-center, single-arm study among 30 patients who are treatment naïve, have no advanced fibrosis and mono-infected with HCV-GT4.||||
33932982|NCT00209092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33932983|NCT06189625|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the intervention, it will not be feasible to mask the received treatment at the time of care. Additionally, masking of the treatment group during clinical reviews will not be attainable, as some collected variables will be inherently related to the intervention itself. The data analyst specialist will also be unblinded to the group assignments.|Randomization sequence was created using the Epidat 4.2 software, ensuring allocation concealment, with a single, constant 1:1 allocation ratio||||
33932984|NCT06248944|||OTHER||OTHER|||||||
33932985|NCT04601181|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential Assignment||||
33932986|NCT00433927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791532|NCT00753168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33791533|NCT03958513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791534|NCT05114044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791535|NCT05010304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011379|NCT03675334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical parameters were screened by one single examiner that was not aware of the procedures|Randomized Controlled Split-mouth clinical trial|f|f|t|t
34011380|NCT00183885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011381|NCT03390348|||CASE_ONLY||PROSPECTIVE|||||||
34011382|NCT01659164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011383|NCT04301245|||COHORT||RETROSPECTIVE|||||||
34011384|NCT03614494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011385|NCT03348748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011386|NCT02879110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011387|NCT04458493|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34011388|NCT02555293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011389|NCT01937247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34011390|NCT01774279|||CASE_ONLY||PROSPECTIVE|||||||
34011391|NCT04908202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011392|NCT02946684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011393|NCT01875471|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33708935|NCT03558698|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The study is double-blinded but a few people in the research team are not blinded because of security reasons (they need to be able to control the concentrations of CO2).|The 36 children are divided into 6 groups of 6 children. Every group is exposed to all possible conditions (3) in a randomized order.|t|t|t|t
33932987|NCT03684525|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Two investigators unaware of the group to which the patients belong will carry out all the measurements on CBCT scan. One investigator will crop the view of the extraction site to ensure blinding of the other investigator.|"Randomized controlled clinical trial following CONSORT guidelines. Patients to be allocated equally to two groups: one treatment group and one control group as follows:~* Group 1: Extraction of primary maxillary canines group (EG)~* Group 2: Control group - no extraction (CG)"|f|f|t|f
34094963|NCT02783859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094964|NCT03228407|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Investigator in the lab performing Ussing's chamber analysis will be blinded to the diagnosis of the patient||f|f|t|f
34094965|NCT05838170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind, Vehicle-Controlled|"The investigational product (Lotilaner Gel, 2.0% \[TP-04\]) or vehicle control gel will be applied topically on the face twice daily (BID) during the study.~Participants will be randomized to a 2:1 ratio at baseline to apply Lotilaner Gel, 2.0% (TP-04) or vehicle control gel on the face BID for 12 weeks."|t|t|t|t
34094966|NCT03927716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094967|NCT00430612|||OTHER||PROSPECTIVE|||||||
34094968|NCT03123588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34094969|NCT01453647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708936|NCT06341842|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Investigator initiated Phase II proof of concept, multicentre, randomized 1:1, open label, parallel-groups study, designed to evaluate if dapagliflozin reduces chemotherapy induced cardiotoxicity in participants with breast cancer treated with (neo-) adjuvant Anthracycline-based chemotherapy +/- trastuzumab."||||
33708937|NCT00747500|||CASE_CONTROL||PROSPECTIVE|||||||
33708938|NCT04507737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33708939|NCT05972876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33708940|NCT06499597|||COHORT||PROSPECTIVE|||||||
33708941|NCT03699657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33708942|NCT03213522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708943|NCT06083662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708944|NCT04851834|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation to determine MTD/RP2D, then dose expansion||||
33708945|NCT01674296|||COHORT||PROSPECTIVE|||||||
33708946|NCT06304376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708947|NCT02995538|||OTHER||OTHER|||||||
33708948|NCT01413529|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33708949|NCT02366052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708950|NCT05251974|||COHORT||PROSPECTIVE|||||||
33708951|NCT06557005|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
33708952|NCT03432702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome measurements will be recorded by an examiner, who will not participate in any study procedure, and will be blind to the allocated treatment. This blinded examiner will be trained and calibrated to perform measurements. A dentist who is blinded to the treatment protocol will performe all radiographic measurements.|Single center, prospective, controlled, parallel-armed, randomized clinical trial.|t|f|f|t
33708953|NCT06083285|||COHORT||RETROSPECTIVE|||||||
33708954|NCT01699204|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33708955|NCT01537393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33708956|NCT02685085|RANDOMIZED|PARALLEL||||NONE||||||
33708957|NCT05019352|RANDOMIZED|PARALLEL||TREATMENT||NONE|open-label trial without masking|In a prallel design participants will be randomly assigned to three different trial groups||||
33708958|NCT04856189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708959|NCT01686815|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33708960|NCT05505682|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel, two-arm, non-blinded cluster-randomised controlled trial||||
33708961|NCT03937011|||COHORT||PROSPECTIVE|||||||
33708962|NCT03421665|||CASE_ONLY||PROSPECTIVE|||||||
33708963|NCT05015244|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33708964|NCT06166667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708965|NCT03129750|||COHORT||PROSPECTIVE|||||||
33708966|NCT04991909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HRS4800 Tablet compared with placebo|t|t|t|t
33708967|NCT05812196|||CASE_CONTROL||PROSPECTIVE|||||||
33708968|NCT03641443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708969|NCT03392701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33708970|NCT01023932|||COHORT||PROSPECTIVE|||||||
33708971|NCT02164500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33708972|NCT00721500|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34011394|NCT00911755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011395|NCT01449045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011396|NCT02707926|||COHORT||PROSPECTIVE|||||||
34011397|NCT05604937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011398|NCT05009836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This study plans to enroll 320 patients, and eligible patients will be randomized in a ratio of 1:1 into the following treatment groups using central randomization system (IWRS): • Study group: Savolitinib 600 mg or 400 mg QD orally + Osimertinib 80 mg QD orally~• Control group: placebo 600 mg or 400 mg QD orally + Osimertinib 80 mg QD orally"|t|t|t|t
34011399|NCT03720769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708973|NCT00287885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708974|NCT00004983|NON_RANDOMIZED|||PREVENTION||||||||
33708975|NCT02877381|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33708976|NCT04056078|||OTHER||CROSS_SECTIONAL|||||||
33708977|NCT03164720|||CASE_CONTROL||PROSPECTIVE|||||||
33708978|NCT00816764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33708979|NCT03130257|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34011400|NCT05616078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932988|NCT05589766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both participants and all investigators are blinded during the trial and during data analysis.|Randomized double-blinded placebo-controlled study. 80 participants randomized in 1:1:2 ratio to either: 1. Placebo (n=20), 2. NR 1000mg for 3 months (n=20), 3. Dose escalation group: NR 1000mg 1st month, NR 2000mg 2nd month, NR 3000mg 3rd month (n=40).|t|t|t|f
33932989|NCT00000895||||TREATMENT||||||||
33932990|NCT01186315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33932991|NCT05105854|||COHORT||PROSPECTIVE|||||||
33932992|NCT00469040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33932993|NCT01207804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33932994|NCT01660646|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33932995|NCT02656524|||COHORT||RETROSPECTIVE|||||||
33932996|NCT02314286|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33932997|NCT05006391|NA|SINGLE_GROUP||OTHER||NONE||||||
33932998|NCT03675594|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|the participants will not be told which type they received till obtaining the final results of both types.Outcomes will be collected only by the supervisor.||t|f|f|t
33932999|NCT03394118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933000|NCT02264652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933001|NCT01066650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933002|NCT00693420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933003|NCT02456571|||COHORT||PROSPECTIVE|||||||
33933004|NCT03418376|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All parties are blinded regarding the dietary supplement (beta-alanine) or placebo.|Twenty multiple sclerosis (MS) patients and twenty healthy controls (HC), aged \>18y will be included following written informed consent. Subjects will be excluded if they experience contraindications to participate in moderate to high intensity exercise or have an EDSS score \>3. First, exercise capacity (maximal graded exercise test) will be evaluated. Heart function will be assessed by an experienced medical doctor, followed by measurement of body composition (DEXA). Maximal strength of the back- and abdominal muscles will be assessed to evaluate core stability. MS patients and HC will be randomly allocated to one of four intervention groups following 6 months of moderate-to-high-intensity cardiovascular exercise therapy with (MSβ, n=10; HCβ, n=10) or without (MSpla, n=10; HCplac, n=10) β-alanine supplementation. Groups not receiving β-alanine supplements, will receive placebo tablets. Following 6 months of exercise training (POST) measurements will be performed similar to baseline.|t|t|t|t
33933005|NCT00419835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933006|NCT02384928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33933007|NCT05379192|||COHORT||PROSPECTIVE|||||||
33933008|NCT00486590|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933009|NCT00475072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933010|NCT00782106||PARALLEL||TREATMENT||NONE||||||
33708980|NCT00185939|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33933011|NCT06331273|||COHORT||PROSPECTIVE|||||||
33933012|NCT05537272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933013|NCT01875692|||COHORT||PROSPECTIVE|||||||
33933014|NCT05295940|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33933015|NCT05821374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933016|NCT00891449|||COHORT||PROSPECTIVE|||||||
33933017|NCT00576368|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011401|NCT05568979|||OTHER||PROSPECTIVE|||||||
34011402|NCT03333499|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34011403|NCT01061944|||COHORT||PROSPECTIVE|||||||
34011404|NCT00164034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011405|NCT02484313|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34011406|NCT00027508||||TREATMENT||||||||
34011407|NCT02988479|||COHORT||PROSPECTIVE|||||||
34011408|NCT04798482|NA|SINGLE_GROUP||OTHER||NONE||||||
34011409|NCT02135406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011410|NCT01111214|||||RETROSPECTIVE|||||||
33933018|NCT05708560|||COHORT||RETROSPECTIVE|||||||
33933019|NCT04454749|||COHORT||PROSPECTIVE|||||||
34011411|NCT04837027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will know that the participant has received balance or aerobic training, but will not be aware of which group the participant belonged.|Single blinded randomized controlled trial|f|f|f|t
34011412|NCT06364878|||CASE_CONTROL||PROSPECTIVE|||||||
34011413|NCT02249221|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011414|NCT05271136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization occurred by assignment to either Cell 1 or Cell 2 using a randomization list, prepared by Stephens prior to the start of the study. The list was first created by concatenating blocks of size of 4 subjects, 2 for Cell 1 and 2 for Cell 2. The list was then randomized by variables from 2 independent uniform distributions: one to randomize subjects within a block and one to randomized blocks. After the randomized list was created, treatment was assigned to each subject number accordingly.|Randomized, double-blind, controlled, single-center|t|f|t|f
34011415|NCT04269733|||COHORT||RETROSPECTIVE|||||||
34011416|NCT05587972|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34011417|NCT03537157|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Active drug will be masked with a placebo identical to the active drug. Patients will be identified by a code and central readers will not have access to the administered treatments|The study is a multicentre, randomised, double-blind, placebo controlled trial to assess the efficacy and safety of Rifaximin delayed release 400 mg tablet (800 mg BID daily) administered for 26 weeks in the prevention of endoscopic Crohn's disease recurrence following ileocolonic resection, in patients who had undergone curative ileocolonic resection, with ileocolonic anastomosis for Crohn's disease.|t|t|t|t
34011418|NCT01797926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011419|NCT00025129||||TREATMENT||||||||
34011420|NCT04914624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34011421|NCT05845294|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011422|NCT05859399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistical analysis of the data will be done by an expert independent of the research.|Prospective, parallel, two arm, randomized controlled clinical trial|f|f|f|t
34011423|NCT04652284|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, non-blinded||||
34094970|NCT04843904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094971|NCT02887586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094972|NCT01750281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933020|NCT03193944|RANDOMIZED|PARALLEL||TREATMENT||NONE||A detailed explanation on research design, location and population, sampling technique, sample size, instrument, data collection, data analysis and potential limitations of the study are outlined in the following sections. This study aims to find relationships between food insecurity, vitamin D intakes and its impact on metabolic syndrome among older adults in a city in Alborz province in Iran, known as Karaj. This study has 2 parts; the first part is to determine the prevalence of food insecurity and vitamin D deficiency among older adults in Karaj city. The second part is an intervention study examining effects of vitamin D supplementation on metabolic syndrome (diabetes, obesity, hypertension, and dyslipidaemia) among older adults who has at least have risk factors of metabolic syndrome, food insecure and vitamin D deficient. The intervention group will receive vitamin D supplementation 50000 IU for 8 weeks.||||
33933021|NCT05247060|||COHORT||PROSPECTIVE|||||||
34094973|NCT05838872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33708981|NCT01516437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34094974|NCT00607594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094975|NCT05361759|||COHORT||PROSPECTIVE|||||||
33933022|NCT00497159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933023|NCT00763607|||COHORT||RETROSPECTIVE|||||||
33933024|NCT00665691|||OTHER||OTHER|||||||
33933025|NCT04743869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and study nurse will be blinded to treatment allocation; however, surgeons cannot be blinded due to different techniques of bone cement application. A centralized and automated internet-based randomization system will ensure concealed randomization of study participants. Participants will be the unit of randomization. Randomization will be carried out with randomizer.at and will occur prior to the surgical procedure.||t|f|f|f
33933026|NCT01387074|||COHORT||PROSPECTIVE|||||||
33933027|NCT00952770|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011424|NCT01042535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011425|NCT06233357|||OTHER||RETROSPECTIVE|||||||
34011426|NCT05905016|||COHORT||PROSPECTIVE|||||||
34011427|NCT01922219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933028|NCT04426292|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33933029|NCT03906591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933030|NCT03873428|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933031|NCT04925830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933032|NCT03696628|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Open : no masking us used. All involved know the identity of the intervention assignment.|"All participants receive the same intervention throughout the protocol, no matter if they are healthy children or cardiomyopathic children."||||
33933033|NCT05103995|||COHORT||PROSPECTIVE|||||||
33933034|NCT01976975|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933035|NCT02941406|||COHORT||PROSPECTIVE|||||||
33933036|NCT00592176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933037|NCT01154322|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933038|NCT05813860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933039|NCT02035241|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33933040|NCT04101370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|Crossover Assignment two-way crossover||||
33933041|NCT01936597|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34094976|NCT03051009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"One dose level (25 μg desmopressin OCD) is included for female subjects and will be open-labelled for all female subjects.~Two different dose levels (25 μg desmopressin and 50 μg desmopressin ODT are included for male subjects in a double-blinded manner. Male subjects continuing from trial 000130 will continue their randomised treatment and subjects who received placebo will be randomised to one of the 2 dose levels (25 μg desmopressin or 50 μg desmopressin ODT).~New male subjects will be allocated to receive 50 μg desmopressin ODT in an open-labelled manner."|The trial is designed as partly an extension trial for subjects completing trial 000129 (female subjects) and 000130 (male subjects) and partly as a trial for new female and male subjects.|t|f|t|f
34094977|NCT00378859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34094978|NCT02528136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34094979|NCT04625972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34094980|NCT03019588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094981|NCT03524144||SEQUENTIAL||OTHER||NONE||||||
34094982|NCT04656431|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34094983|NCT06485180|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The pregnancy outcomes and contraceptive methods were all reviewed through telephone follow-up. All outcomes Assessor were provided patients' name and telephone without surgery methods.|This retrospective study screened 1027 CSP individuals from the multiple center Medical Record Data System (MRDS) from three large hospitals in China, recorded between Jan 1, 2019, and Dec 31, 2022. 606 patients underwent surgical treatment. The pregnancy outcomes and contraceptive methods were all reviewed through telephone follow-up. Conservative surgeries included dilatation and curettage (D\&C) and hysteroscopy and resection surgeries included CSP excision plus hysterotomy closure.|f|f|f|t
33708982|NCT04786145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Outcomes Assessors, physiotherapists and participants are blinded to the intervention.|The study is a single-center, blinded randomized controlled trial with two intervention arms and one placebo arm with allocation ratio of 1:1:1. One group receives one treatment of cryoneurolysis, the second group receives radiofrequency ablation and the third group receives placebo (control group).|t|t|f|t
33933042|NCT05081089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single blind randomised controlled trial. The treating physician and staff involved with assessing all laboratory outcomes of the study are blinded, but no placebo will be used. The study pharmacist will be unblinded and responsible for randomisation and treatment administration.||f|f|f|t
33933043|NCT01147367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33708983|NCT01007084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933044|NCT02984891|||COHORT||PROSPECTIVE|||||||
33933045|NCT02224937|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34094984|NCT04088253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094985|NCT00527345|||||PROSPECTIVE|||||||
34094986|NCT00182637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094987|NCT00117000|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34094988|NCT01635179|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33708984|NCT03470441|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This is a double-blind study where all study staff and participants are blinded to whether the patient receives active drug or placebo.|All subjects who fulfill all study eligibility criteria will be randomized to receive one of the 4 treatments.|t|t|t|f
33708985|NCT01472302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33708986|NCT02697864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33708987|NCT02481232|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33708988|NCT03026400|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33708989|NCT05004870|NA|SINGLE_GROUP||OTHER||NONE||||||
33708990|NCT00993083|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33708991|NCT00197639|||COHORT||PROSPECTIVE|||||||
33708992|NCT01911078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708993|NCT05277181|||COHORT||RETROSPECTIVE|||||||
33708994|NCT05199662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933046|NCT00031135|RANDOMIZED|||PREVENTION||DOUBLE||||||
33933047|NCT02766972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933048|NCT03865849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, multicentre, double blind, randomised controlled, non-inferiority, pilot study.|t|t|t|f
33708995|NCT05139238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33708996|NCT02642328|RANDOMIZED|PARALLEL||||NONE||||||
33708997|NCT06237998|||CASE_CONTROL||PROSPECTIVE|||||||
33708998|NCT04234191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33708999|NCT01737697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33709000|NCT00394147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709001|NCT00289783|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33709002|NCT01760460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709003|NCT06383221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709004|NCT04481854|RANDOMIZED|PARALLEL||OTHER||DOUBLE||patients will be randomized to recieve cricoid pressure or left paratracheal pressure|t|f|t|f
33709005|NCT00851747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind||t|t|t|f
33709006|NCT03613545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking only Participant|Parallel Assignment|t|f|f|f
33709007|NCT05325671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709008|NCT04717791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709009|NCT04465474|||OTHER||OTHER|||||||
33709010|NCT02094677|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33709011|NCT04905485|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants all received diet and supplement recommendations based on their microbiome results.||||
33709012|NCT00542334|||CASE_ONLY||CROSS_SECTIONAL|||||||
33709013|NCT02871297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709014|NCT03426813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709015|NCT01627600|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33709016|NCT00689234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709017|NCT00169598|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33709018|NCT04881370|||OTHER||CROSS_SECTIONAL|||||||
33709019|NCT02549937|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33709020|NCT04532944|NON_RANDOMIZED|PARALLEL||OTHER||NONE||40 patients with MS and 15 healthy controls||||
33709021|NCT00589251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709022|NCT02031068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933049|NCT05905679|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33933050|NCT00255983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933051|NCT03820206|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933052|NCT04143490|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single experimental trial with a UC patient group and an age and gender matched healthy control group||||
33933053|NCT02853786|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933054|NCT00043004|RANDOMIZED|||TREATMENT||NONE||||||
33933055|NCT04341584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933056|NCT05817422|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomized 4:1 to receive the cAd3-Marburg vaccine at 1.0 × 10\^11 PU dose or placebo at Day 1.|t|t|t|t
33933057|NCT03446313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933058|NCT01914939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011428|NCT04845906|||OTHER||PROSPECTIVE|||||||
34011429|NCT05563818|||COHORT||PROSPECTIVE|||||||
34011430|NCT05506878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|3 researchers have been appointed to randomization and are not participating in any part of the study other than treatment allocation. The researcher applying the device will not know the treatment allocation, and everyone else (participant, care provider, investigator and outcomes assessor) will be blinded to treatment allocation as well.|Active device versus Sham Device|t|t|t|t
34011431|NCT02332408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011432|NCT06304909|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34011433|NCT01095419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011434|NCT01923584|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011435|NCT00933959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011436|NCT02667002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011437|NCT02921503|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34011438|NCT03261479|||COHORT||PROSPECTIVE|||||||
34011439|NCT01731249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011440|NCT05680779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34011441|NCT04974034|||COHORT||RETROSPECTIVE|||||||
34011442|NCT01820858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011443|NCT03064321|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two group design||||
34011444|NCT00987649|||CASE_ONLY||PROSPECTIVE|||||||
34011445|NCT05372276|||OTHER||CROSS_SECTIONAL|||||||
34011446|NCT01784354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011447|NCT00008749|||CASE_CONTROL|||||||||
34011448|NCT04523324|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Open-label trial. Eligible HCP who report already having been vaccinated with Vaxigrip at the time they are approached to join the study will be eligible to participate.||t|f|f|f
34094989|NCT00335621|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34094990|NCT02200575|||COHORT||PROSPECTIVE|||||||
34094991|NCT00882388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709023|NCT02528929|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709024|NCT03925974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709025|NCT00228683|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33709026|NCT03728790|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized Control Trial with 2 arms||||
33709027|NCT01979445|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709028|NCT02627105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709029|NCT04528108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In our research, participants and outcome assessor are are prevented from having knowledge of the interventions assigned to individual participants.|In our research, 160 children are randomly divided into a Chinese medication periodic therapy group and a Gong Xue Ning control group, and they receive different treatment for 3 month.|t|f|f|t
33709030|NCT01616667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709031|NCT05453604|NA|SINGLE_GROUP||OTHER||NONE||||||
33709032|NCT04162639|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709033|NCT03523897|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34011449|NCT06471920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Follow-up assessments will be performed by a Researcher who will be blind to participants' treatment group assignment(s). Participants will be reminded by the Researcher not to discuss aspects of treatment during assessments.|A pragmatic randomized clinical trial used a Type I Hybrid effectiveness-implementation design|f|f|f|t
34011450|NCT01978899|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33933059|NCT02568852|RANDOMIZED|PARALLEL||||NONE||||||
33933060|NCT05928624|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33933061|NCT04487418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34011451|NCT06022367|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34011452|NCT00484419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011453|NCT01909128|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34011454|NCT06491069|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933062|NCT04686240|||COHORT||PROSPECTIVE|||||||
34094992|NCT04469283|||COHORT||RETROSPECTIVE|||||||
34094993|NCT00588276|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34094994|NCT03537430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a prospective randomized controlled clinical trial. Participants, care provider, and investigator all know the grouping situation. The Investigator collect the information and observation indicators of the two groups of participants and send to the Outcomes Assessor . The Outcomes Assessor does not know the grouping situation of each participant.|This is a single-center prospective randomized controlled trial. 98 patients aged between 18 and 75 years with clinically mediastinal tumors were randomly assigned to two groups, 50 patients received TNT uniportal VATS mediastinal tumor resection (TNT group) and 48 patients underwent traditional uniportal VATS mediastinal tumor resection (control group), the short-term perioperative outcomes would be reported here.|f|t|f|t
34094995|NCT06309758|NA|SINGLE_GROUP||PREVENTION||NONE||mixed-method study with a single-arm pre-post design with a duration of 3 months and extended follow-up after 6 months.||||
34094996|NCT01799278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933063|NCT04369872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34094997|NCT00705822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34094998|NCT02635490|||CASE_CROSSOVER||PROSPECTIVE|||||||
34094999|NCT06418165|||COHORT||PROSPECTIVE|||||||
34095000|NCT03881800|||COHORT||PROSPECTIVE|||||||
34095001|NCT00026338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095002|NCT05818787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Statistical analysis at the conclusion of the trial will be completed using de-identified data, masking the outcomes assessor from the identity and group assignment of each individual.|Four training paradigms will be evaluated in 4 cohorts of older 10 adults; each subject will complete only one training task. In addition to the active perceptual learning task, each subject will complete a control (i.e., placebo) intervention. Half of each cohort will begin with the perceptual learning protocol, and half will begin with the placebo; assignment will be randomized. One of the training protocols will be a roll tilt training protocol previously shown to reduce roll tilt thresholds. The remaining three training protocols will include the parameters found most effective following a series of basic science human subject experiments that will be completed prior to enrollment begins in the present clinical trial.|f|f|f|t
34095003|NCT00038246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095004|NCT01320566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095005|NCT01120197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095006|NCT01371682|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34095007|NCT05290298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011455|NCT00389779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011456|NCT01202071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011457|NCT03544398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33709034|NCT01448486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709035|NCT03078660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34011458|NCT02938520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011459|NCT01671982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709036|NCT01722084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709037|NCT05391698|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709038|NCT03409835|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33709039|NCT00005794||||TREATMENT||||||||
33933064|NCT02149186|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933065|NCT01572636|||COHORT||PROSPECTIVE|||||||
33933066|NCT01723202|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933067|NCT01528436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933068|NCT00713284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933069|NCT04694157|||CASE_ONLY||PROSPECTIVE|||||||
33933070|NCT01547676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933071|NCT02374073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933072|NCT04484038|NA|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized prospective multicenter study of hypofractionated postoperative radiotherapy in patients diagnosed with prostate carcinoma.||||
33933073|NCT02864706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933074|NCT03327363|RANDOMIZED|PARALLEL||OTHER||NONE||a prospective, randomized controlled, multicenter study||||
33933075|NCT02474628|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33933076|NCT02920879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011460|NCT04399265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients with SCA 3 will be randomised into the active treatment group and placebo group to which they are blinded from their group allocation. Likewise, the outcome assessor will be blinded from the patient's group status. A partial unblinding will be made with Group A vs. Group B (rather than the actual grouping) for preliminary analysis on Visit 1 and Visit 2.|This study will employ a double-blind randomised controlled trial (RCT) with two arms. Patients with SCA3 will be randomly allocated to oral trehalose group and a maltose placebo group. A total of 20 participants will be allocated to each group. There is a possibility of including other types of SCA at later stage of the study.|t|f|f|t
34011461|NCT03339505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded until the end of the trial. Unmasking will take place once all patients are included and the trial is concluded.|Randomized, double blinded and prospective.|t|t|t|t
34011462|NCT01739725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933077|NCT00613210|||CASE_CONTROL||PROSPECTIVE|||||||
33933078|NCT04225312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective national phase IV natalizumab cohort study||||
33933079|NCT03878160|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Approximately 20 individual interviews of ACS patients with elevated depression symptoms stratified by time since ACS (e.g. within the past 2 years or greater than 2 years ago), with 10 participants per strata. There will be approximately 10 individual interviews with ACS patients who are interested in treatment but not currently depressed.||||
33933080|NCT02165072|||||PROSPECTIVE|||||||
33933081|NCT02936362|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33933082|NCT03624790|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33933083|NCT04737954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||IVD Performance Evaluation Study||||
33933084|NCT04489940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933085|NCT01877031|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33933086|NCT03674307|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33933087|NCT04237636|||COHORT||RETROSPECTIVE|||||||
33933088|NCT03152110|NA|SINGLE_GROUP||OTHER||NONE||||||
34011463|NCT01201759|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34011464|NCT00416026|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34011465|NCT05470933|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
34011466|NCT04952831|||CASE_CONTROL||PROSPECTIVE|||||||
34011467|NCT03256422|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized trial in 2 parallel groups||||
33801813|NCT06407882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be Randomized control trial in which non probabilty convenient sampling will be used. Two groups of 6-12 age will be formed in which participants will be randomly divided. Group A will only receive Conductive education and group B will receive conventional physical therapy.|t|f|f|f
33801814|NCT01189942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933089|NCT04574869|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This study is a double-blinded and randomized study. Pharmacy staff will mask infusion bags and lines to maintain the study blind.|"Study intervention, RLS-0071 or placebo, will be administered as an IV infusion over 30 minutes (± 10 minutes).~The following dose groups are planned:~Part A (Single-Ascending Dose):~* Cohort 1: low dose (single infusion) vs. placebo~* Cohort 2: high dose (single infusion) vs. placebo~Part B (Multiple-Ascending Dose):~* Cohort 3: low dose administered q8 hours (± 1 hour) vs. placebo for 3 days (9 doses)~* Cohort 4: high dose administered q8 hours (± 1 hour) vs. placebo for 3 days (9 doses)"|t|f|t|f
33933090|NCT02561104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095008|NCT06456268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded data will be provided to the statistician w/o reference to specific treatment arms||f|f|f|t
33933091|NCT04564690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33933092|NCT02128919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933093|NCT02625389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933094|NCT05688540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34095009|NCT01011283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933095|NCT06315686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933096|NCT02433691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33933097|NCT00256906|||COHORT||RETROSPECTIVE|||||||
33933098|NCT06337760|||CASE_ONLY||OTHER|||||||
33933099|NCT05821192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095010|NCT01297114|||COHORT||CROSS_SECTIONAL|||||||
34095011|NCT06060886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933100|NCT01625611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095012|NCT02643199|||COHORT||PROSPECTIVE|||||||
34095013|NCT05898373|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34095014|NCT00557102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933101|NCT06434090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095015|NCT02662920|||COHORT||RETROSPECTIVE|||||||
34095016|NCT01334853|||COHORT||PROSPECTIVE|||||||
34095017|NCT04107051|||COHORT||PROSPECTIVE|||||||
34095018|NCT02836106|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34095019|NCT03321032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34095020|NCT03828383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Identical system is installed in all homes regardless of treatment arm. The member of research team who does the installation will now know which treatment arm has been assigned. Initiating the features of the system appropriate to the assigned treatment arm is done remotely by a member of the People Power staff (who has no contact with the participants) following the installation.||f|f|t|f
34095021|NCT02313597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933102|NCT00353340|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33933103|NCT03216668|RANDOMIZED|PARALLEL||TREATMENT||NONE||Block randomization||||
33933104|NCT04407286|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label treatment study for people with COVID 19 and low levels of vitamin D||||
33933105|NCT06317506|||OTHER||CROSS_SECTIONAL|||||||
33933106|NCT01656018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933107|NCT01066169|||COHORT||PROSPECTIVE|||||||
33709040|NCT04618068|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33933108|NCT03327246|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Matched intervention - control group study||||
33933109|NCT02210455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011468|NCT05275959|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011469|NCT02504723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011470|NCT05410054|||COHORT||PROSPECTIVE|||||||
34011471|NCT04711967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011472|NCT06417333|NA|SEQUENTIAL||PREVENTION||NONE||2 15 people groups were distributes wristbands during a 6 month span||||
34011473|NCT03360357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011474|NCT02776813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011475|NCT03336242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011476|NCT03301103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All researchers of the project team will be kept blind to assignment of treatment, and so will be the study subjects.The placebo will be matched in appearance and flavour to PTM202.|The APA12/PANTER study is a randomized, double-blind, placebo-controlled, parallel intervention study of 3 weeks in 72 healthy adults. Subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14). At study day 14, 15 and 16 subjects will receive either placebo or PTM202, a dietary formula containing dried bovine colostrum and dried whole egg.|t|f|t|t
34011477|NCT05734131|||COHORT||PROSPECTIVE|||||||
34011478|NCT03409991|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34011479|NCT03629600|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized open-label parallel-group non-inferiority controlled clinical trial||||
34011480|NCT06417164|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"1. Participants do not know which group they have been assigned to (treatment or control). This can be done by providing all participants with the same information after grouping, without revealing which group they are in, to ensure that they do not know which intervention they are receiving.~2. Trainer blinding is when the trainer does not know which group the participant is in. This can be done by assigning participants to groups by another researcher or by a randomization system to avoid the trainer knowing the participant's group.~3. Outcome assessment is performed by a researcher who does not know the group the participant is in, hiding information about the participant's group, and using a researcher who is independent of the intervention assignment to perform the outcome assessment."|A randomized controlled clinical trial|t|t|f|t
34011481|NCT01949116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011482|NCT01967693|||CASE_ONLY||RETROSPECTIVE|||||||
34011483|NCT02150759|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34011484|NCT04705116|||COHORT||PROSPECTIVE|||||||
34011485|NCT05209828|||COHORT||PROSPECTIVE|||||||
34011486|NCT03026907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011487|NCT03282006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933110|NCT00441727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933111|NCT05476757|NA|SINGLE_GROUP||OTHER||NONE||5 flavivirus naïve participants||||
33933112|NCT02853123|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33933113|NCT05535270|||COHORT||CROSS_SECTIONAL|||||||
33933114|NCT01977807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933115|NCT06071923|||OTHER||CROSS_SECTIONAL|||||||
33933116|NCT00944957|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33933117|NCT02978170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933118|NCT02597972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933119|NCT04031157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34011488|NCT04787952|||OTHER||PROSPECTIVE|||||||
34011489|NCT06027138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011490|NCT02340221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011491|NCT00733031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011492|NCT05189236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34011493|NCT04272203|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933120|NCT03369704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933121|NCT00064623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933122|NCT06102928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933123|NCT05627791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011494|NCT04546932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An anesthesiologist who did not involve in the study set the ventilator in accordance with the protocol in the envelopes. Another anesthetist who was in charge of the patient collected data during surgery. The surgeons taking part in the procedures and patients were not informed of the ventilator setting. Physicians in post-anesthesia care unit who were not responsible for intraoperative care carried out the postoperative evaluation. The analysis of the postoperative chest X-ray was completed by a radiologist who was not involved in the study.|Participants were randomly assigned to receive either lung-protective ventilation (LPV group) or conventional ventilation (CV group) at a ratio of 1:1.|t|f|t|t
34011495|NCT03438539|RANDOMIZED|PARALLEL||TREATMENT||NONE||An Internet survey hosted by Amazon.com's Mechanical Turk and Qualtrics: Online Survey Software will be used in this protocol. Cognitive tasks will be coded using PsyToolKit, an open-source tool for programming and running cognitive-psychological experiments and surveys online (Stoet, 2017). A mixed-model design will be used such that subjects are randomly assigned to one of three cognitive training conditions and two information feedback conditions (i.e., between-subjects variables). The same subjects will be sampled at each time point in the study (i.e., repeated/longitudinal variables).||||
34011496|NCT00403182|RANDOMIZED|||TREATMENT||NONE||||||
34011497|NCT00561314||||TREATMENT||||||||
34011498|NCT02540447|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34011499|NCT04551820|||CASE_ONLY||RETROSPECTIVE|||||||
34011500|NCT04216420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Permuted block randomization method was used to randomly allocate participants and maintain a balance of the number of participants assigned to each arm. The study investigators who were responsible for assessing study outcomes and writing the report were blinded to group allocation until the manuscript was completed. A statistician masked to group allocation performed the analyses.|A multicenter, randomized, controlled, open-label, non-inferiority, effectiveness-implementation type 2 hybrid trial.|f|f|f|t
34095022|NCT04899128|||COHORT||RETROSPECTIVE|||||||
34095023|NCT00299754|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34095024|NCT00792389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095025|NCT06005155|||COHORT||RETROSPECTIVE|||||||
34095026|NCT02546141|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34095027|NCT04612621|NA|SINGLE_GROUP||OTHER||NONE||All enrolled patients will undergo similar interventions||||
33709041|NCT01560793|NA|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33709042|NCT02216591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709043|NCT00005814||||TREATMENT||||||||
33709044|NCT01481376|||COHORT||RETROSPECTIVE|||||||
33709045|NCT03288129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709046|NCT01509378|||COHORT||PROSPECTIVE|||||||
33709047|NCT02131194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33709048|NCT01154790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709049|NCT05969145|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participant will not know that there is a control or experimental group. The result evaluator is an independent statistical expert, and the data analysis will be performed by a statistical specialist.|a single-blind randomized controlled trial to determine the effect of hot-cold application to the bladder on postoperative urinary retention in orthopedic surgery patients.|t|f|f|f
33709050|NCT03760783|NA|SINGLE_GROUP||OTHER||NONE||||||
33709051|NCT00492583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33709052|NCT03853408|||OTHER||RETROSPECTIVE|||||||
33709053|NCT01182675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709054|NCT01970046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709055|NCT05830591|||OTHER||CROSS_SECTIONAL|||||||
33709056|NCT03548259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Randomized Controlled Trial (Parallel Assignment)|t|t|t|t
33709057|NCT02249585|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33709058|NCT03217331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709059|NCT04352504|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be a randomized, parallel group comparison of almonds vs. isocaloric pretzels.||||
33709060|NCT05860478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33709061|NCT00587210|||COHORT||PROSPECTIVE|||||||
33709062|NCT02973698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709063|NCT01606007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709064|NCT03569033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709065|NCT01460888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709066|NCT05902780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33709067|NCT02352402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709068|NCT00468195|||COHORT||PROSPECTIVE|||||||
33709069|NCT04783584|||COHORT||PROSPECTIVE|||||||
33709070|NCT01505400|||COHORT||RETROSPECTIVE|||||||
33709071|NCT00004132|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33709072|NCT00277836|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33933124|NCT04527666|||CASE_CONTROL||PROSPECTIVE|||||||
33933125|NCT05135091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a two-stage study. Stage 1 is open-label and unmasked. Stage 2 is masked with participant, part of investigator team, and outcomes assessor masked to treatment assignment.|This is a two-stage study. Stage 1 is an open-label, single arm, sequential dose escalation. Stage 2 is a parallel, randomized, 2-arm, sham controlled study.|t|f|t|t
33933126|NCT02682576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933127|NCT03638518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neither the participants nor their therapists were blind to the treatment allocation. However, the assessor was independent to the study and was not aware of the treatments applied or the objective of the therapy.|Participants were randomized to a core stability training physiotherapy programme group, an acupuncture treatment group and control group for a 13 week study.|f|f|f|t
33933128|NCT01681836|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34011501|NCT00506506|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33791536|NCT05538455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients will be randomized on a 1: 1 ratio to intervention (use the PC4L system) and control group (no intervention) by an independent non-clinical partner of the consortium.~The control group will be assessed at baseline and will receive general written recommendations on the main areas (physical activity, sleep, cognitive, nutrition; social support and stress management for caregivers). At the follow-up, after three months, the same group will be assessed on quality of life using specific scales (EuroQoL53L).~The platform will be installed by one of the project's clinical partners in different scenarios.~Two different versions of the PC4L system will be tested. A fully equipped version, used in the previous 2 pilots, as well as a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). Of those patients using the PC4L system, 25% will use the full system, the remaining (75%) will use the cloud-based system."||||
33791537|NCT02250716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011502|NCT02979093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34011503|NCT03907514|RANDOMIZED|PARALLEL||OTHER||NONE|Blindness will be possible to the psychologist, who will evaluates the patient's cooperation, and the statistician responsible for the data analysis.|||||
33933129|NCT01476020|||COHORT||PROSPECTIVE|||||||
34095028|NCT03300336|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Trial - a form of crossover design with unidirectional crossover (from control to experimental) but with randomization of when each cluster undertakes the transition. In the stepped wedge design, there is a staggered roll-out of the intervention, where the time and sequence of clusters that will start the intervention at each period determined by random allocation.||||
34095029|NCT01279993|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
34095030|NCT02988557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095031|NCT02622022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095032|NCT00315315|||COHORT||PROSPECTIVE|||||||
33933130|NCT04063228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933131|NCT01381224|||CASE_ONLY||PROSPECTIVE|||||||
33933132|NCT03978572|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33933133|NCT01061840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933134|NCT00504192|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011504|NCT02529306|||OTHER||PROSPECTIVE|||||||
34011505|NCT02190448|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34011506|NCT03490474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34011507|NCT00328133|||COHORT||CROSS_SECTIONAL|||||||
34011508|NCT04429529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are assigned to either treatment or placebo|t|f|t|f
34011509|NCT05540821|||OTHER||PROSPECTIVE|||||||
33709073|NCT04819568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011510|NCT01587794|||CASE_ONLY||CROSS_SECTIONAL|||||||
34011511|NCT04528199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011512|NCT02497794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011513|NCT03329534|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709074|NCT02100085|||COHORT||PROSPECTIVE|||||||
33709075|NCT04764903|||COHORT||RETROSPECTIVE|||||||
33709076|NCT03118115|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.||||
33709077|NCT02164825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709078|NCT04394286|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33709079|NCT06255106|||COHORT||RETROSPECTIVE|||||||
34011514|NCT01401387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011515|NCT03418857|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34011516|NCT02116699|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34011517|NCT00722631|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011518|NCT02458092|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34095033|NCT03873688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095034|NCT05381870|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33709080|NCT05878145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709081|NCT04904562|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study medication and matching placebo (saline) administered by IV infusion|1:1 randomization to receive either study drug or placebo|t|t|t|f
33709082|NCT04015336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709083|NCT03727529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33709084|NCT02780310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709085|NCT01830270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709086|NCT03723941|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, stratified, nation-based multi-center, phase III trial for patients with ACC and Ki67≥10% after resection with curative intent||||
33709087|NCT06072846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||There is an initiative and control group. Reiki therapy will be provided to the intervention group. Monitoring will be performed on the control group.|f|t|t|f
33709088|NCT01958333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709089|NCT00675493|||COHORT||PROSPECTIVE|||||||
33709090|NCT01546207|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709091|NCT01090986|||CASE_ONLY||PROSPECTIVE|||||||
34095035|NCT01905683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095036|NCT00714272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33709092|NCT01799967|||COHORT||PROSPECTIVE|||||||
33709093|NCT02784275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709094|NCT01666782|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33709095|NCT06260085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The clinical nurse collected the data||f|f|f|t
33709096|NCT03192111|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33709097|NCT00380952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709098|NCT00923338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709099|NCT01484847|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709100|NCT02289417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709101|NCT05061732|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791538|NCT03178994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791539|NCT00719628|||COHORT||PROSPECTIVE|||||||
33791540|NCT06629675|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33791541|NCT00315120|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34011519|NCT02501551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011520|NCT06132633|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a cross-sectional study design. All participants receive the same intervention of our Neospot vitals measurements.||||
34011521|NCT02985879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011522|NCT05424614|||COHORT||PROSPECTIVE|||||||
34011523|NCT03974165|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Foods do not differ in shape or color. Participants are blinded to the treatments.|"1. Healthy subjects with normal body weight receive different cereal-based products fortified with legumes or reference food in a randomized crossover design. Postprandial glycemic and hormonal responses are evaluated.~2. Overweight subjects receive different cereal-based products fortified with legumes or reference food in a randomized crossover design. Postprandial glycemic and hormonal responses are evaluated."|t|f|f|f
34095037|NCT00923702|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095038|NCT01590615|||COHORT||PROSPECTIVE|||||||
34095039|NCT03983005|||COHORT||PROSPECTIVE|||||||
34095040|NCT04215575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A clinical trial design strategy in which parties involved in the trial, the investigator and participants, do not know which participants have been assigned which interventions. Type of masking include: double-blind masking.|Participants were randomized to BGI model 101-350 placement (BGI group) or an AGV model FP7or S2 placement (AGV group). Follow-up visits were scheduled 1 day, 1 week, 1 month, 3 months, 6 months, 1 year postoperatively. The primary outcome measure was failure that defined as IOP \>16 mmHg or less than a 20% reduction below baseline on 2 consecutive study visits.The IOP, the use of glaucoma medications, visual acuity (VA), visual fields, bleb morphology and rates of surgical complications were secondary outcome measures.|t|f|t|f
33791542|NCT02490176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33709102|NCT05650905|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33709103|NCT05329701|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a nationwide multicenter open label non-inferiority pragmatic randomized controlled trial. Patients will be randomized 1:1 to experimental treatment duration or standard care. Patients will be stratified based on if maximum CRP level is above or below 90 mg/l.||||
33709104|NCT03208205|||CASE_ONLY||RETROSPECTIVE|||||||
33709105|NCT03009981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709106|NCT04178486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants were not informed in which group they are.|Participants were randomized in one of the four groups.|t|f|f|f
33709107|NCT03537560|||CASE_ONLY||PROSPECTIVE|||||||
33709108|NCT02872194|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34011524|NCT06483256|NA|SINGLE_GROUP||OTHER||NONE||||||
34011525|NCT03264820|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Monocentric, prospective, non-randomized study 11 healthy volonteer 33 patients||||
34011526|NCT03936179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011527|NCT05385848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791543|NCT03557658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011528|NCT03594357|||CASE_CONTROL||PROSPECTIVE|||||||
34011529|NCT03232255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011530|NCT05628558|||COHORT||RETROSPECTIVE|||||||
33791544|NCT02932358|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The following interventions will be evaluated in the present study: restrictive family visitation model (intermittent visits according to local ICU regulation) and flexible family visitation model (12 consecutive hours per day). The unit of of concealed randomization is the ICU to minimize the risk of contamination, given that we intend to apply the intervention to the whole ICU multidisciplinary team. We will randomize ICUs to either an RFVM or to an FFVM as the initial intervention (T1). After enrollment of 25 ICU patients, there will be a 30-day period without recruitment to avoid contamination bias. After this period, each ICU will be assigned to an intervention contrary to that which initially receive (T2) until the enrollment of more 25 ICU patients.||||
33791545|NCT05624619|||COHORT||PROSPECTIVE|||||||
33791546|NCT05677178|||OTHER||PROSPECTIVE|||||||
33791547|NCT01057758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791548|NCT00208078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791549|NCT02284308|||COHORT||PROSPECTIVE|||||||
33791550|NCT01876511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791551|NCT01115049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33791552|NCT05493462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791553|NCT04900142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33791554|NCT02305082|||CASE_CONTROL||PROSPECTIVE|||||||
33791555|NCT06116058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double ( participant ,outcomes assessor)|"1. integrated neuromuscular inhibition technique and conventional physical therapy~2. instrument assisted soft tissue mobilization technique and conventional physical therapy~3. conventional physical therapy only"|t|f|f|t
33791556|NCT04154137|||CASE_CONTROL||PROSPECTIVE|||||||
33791557|NCT04204720|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33791558|NCT05667480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791559|NCT02117401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791560|NCT01640821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791561|NCT00005840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791562|NCT00314496|||||RETROSPECTIVE|||||||
33791563|NCT04899284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791564|NCT04329663|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"The inclusion criteria was child with ADHD age 5 to 12 years old that never taken medication prior to the study and willing to undergo training with computer based game which developed from phase one of the study for about 20 sessions with approximately 30 minutes per each session for 4 weeks consecutively. The training was conducted at school where the sample attended school so it would not disturb the learning and teaching process at school. The training would be guided and supervised directly by the researcher team.~The diagnosis of ADHD was conducted by trained child and adolescent psychiatrist guided by Mini-Kids which was structured interview guide built based on ICD-X. Children which included on the study were child with ADHD without any other mental disorder comorbidity and does not has chronic physical illness during the interview with the parents. Child which does not complete 90% of the numbers of the training that planned will not included in data analysis."||||
33933135|NCT05001308|||CASE_ONLY||RETROSPECTIVE|||||||
33933136|NCT02381067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933137|NCT05306262|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933138|NCT05758974|||COHORT||PROSPECTIVE|||||||
33933139|NCT00508469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933140|NCT01084473|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33933141|NCT00911222|||COHORT||PROSPECTIVE|||||||
33933142|NCT03527940|||COHORT||RETROSPECTIVE|||||||
33933143|NCT03908463|||COHORT||PROSPECTIVE|||||||
33933144|NCT05260190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Several devices (helmets) were available for the active and sham intervention. An investigator outside the study intervention labeled the active and sham helmets with an alphabetic code (A or B). The investigator applying the stimulation did not know which type of intervention was applying (A or B). Neither the investigator performing the intervention, nor the participant knew which intervention corresponded to each group. The data were analyzed by another researcher who was not involved in the assignment and intervention.||t|t|t|t
34011531|NCT02165306|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34011532|NCT01233843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011533|NCT01880788|||CASE_CONTROL||PROSPECTIVE|||||||
34011534|NCT00304707|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34011535|NCT02623452|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34011536|NCT05592249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34011537|NCT01072786|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34011538|NCT04701034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|None of the personnel with patient contact will have knowledge to the patient's allocation to active treatment or placebo group. Medicine will be handled at another location and sent to the RPL center masked with universal labels with only name of the patient and study ID number.||t|t|t|t
33933145|NCT00850265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933146|NCT03484689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933147|NCT02090218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933148|NCT05310760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933149|NCT02702284|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011539|NCT03515902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011540|NCT03013881|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34011541|NCT05992428|NA|SINGLE_GROUP||TREATMENT||NONE||2-part||||
34011542|NCT04127955|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34095041|NCT04694638|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility study||||
34095042|NCT01784185|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33791565|NCT05097469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33791566|NCT05097781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933150|NCT03756870|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 parallel design||||
33933151|NCT00164099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933152|NCT04185740|NA|SINGLE_GROUP||OTHER||NONE||||||
33933153|NCT05759481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933154|NCT01706120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933155|NCT05299151|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33933156|NCT04459442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|None (Open Label)|Parallel Assignment The investigators conducted a randomized controlled trial (parallel group study with 1:1 randomization), comparing early cord clamping (at 60 seconds) and delayed cord clamping (at 180 seconds) in 90 cases of 'normal', two-step vaginal births.|f|f|t|f
33933157|NCT00155831|||COHORT||PROSPECTIVE|||||||
33933158|NCT00864123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933159|NCT06287931|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33933160|NCT00013949|||DEFINED_POPULATION||PROSPECTIVE|||||||
33933161|NCT03906201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized double-blind clinical trial plus control group|cohort populations with diagnostic metabolic syndrome treatment base with ecdysterone for 90 days|f|t|f|t
33933162|NCT01431521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933163|NCT05094570|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
33933164|NCT03718923|||COHORT||CROSS_SECTIONAL|||||||
33933165|NCT06141889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933166|NCT05501457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933167|NCT00000281||||TREATMENT||||||||
34011543|NCT03330236|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients, care providers (excluding the anesthesia team taking care of the patient in the operative room), and outcome assessors are blinded to the results of randomization or group assignment.|The study is a prospective, pragmatic, patient and outcome assessor blinded, randomized 1:1 and controlled parallel trial.|t|t|f|t
34011544|NCT03016338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011545|NCT01818518|||COHORT||PROSPECTIVE|||||||
34011546|NCT03557359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011547|NCT04686513|||OTHER||CROSS_SECTIONAL|||||||
34011548|NCT02382549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011549|NCT04520776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will not be told their treatment group prior to surgery||t|f|f|f
34011550|NCT05473000|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Air quality (ozone and room air) will be double-blinded; neither participants nor the primary researcher will know the randomized order of the condition.||t|t|f|t
34011551|NCT01640873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011552|NCT03599167|||COHORT||RETROSPECTIVE|||||||
34011553|NCT03922074|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34011554|NCT01466322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011555|NCT02269644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011556|NCT03099629|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34011557|NCT04579315|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms, one intervention group and one control group||||
34011558|NCT06227624|RANDOMIZED|PARALLEL||TREATMENT||NONE|Investigators (research staff) and parents of the patients were aware of the treatment|This randomized clinical trial was carried out on 192 neonates with indirect hyperbilirubinemia, at neonatal intensive care unit (NICU) of Pediatric Department, National Liver Institute (NLI), Menoufia University from (June 2018- June 2019). Research Ethics Committee of NLI approved the study, NLI- Institutional Review Board (IRB) protocol number is (00136/2018). Neonates enrolled in the study were randomly assigned into two groups. Group (1) (zinc and phototherapy group) included 95 neonates receiving phototherapy and oral zinc sulfate with a dose of 5 mg every 12 hours using a calibrated dropper provided with the bottle, during the period of NICU admission on phototherapy. Group (2) (phototherapy group) included 97 neonates receiving phototherapy alone. Both groups receiving phototherapy based on the guidelines of American Academy of Pediatrics for the treatment of neonatal indirect hyperbilirubinemia. Any adverse effect were noted and recorded.||||
34095043|NCT02930720|||COHORT||CROSS_SECTIONAL|||||||
34095044|NCT04354571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|closed envelope technique||t|f|t|t
34095045|NCT00328809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095046|NCT05236751|||COHORT||RETROSPECTIVE|||||||
34095047|NCT03288831|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Subjects will be block randomized to either gluten-containing or placebo challenge.|Randomized, double-blinded, placebo-controlled oral gluten challenge|t|t|t|f
33709109|NCT01051323|||COHORT||PROSPECTIVE|||||||
33709110|NCT05570500|RANDOMIZED|PARALLEL||OTHER||SINGLE|"the participants will know the group they are assigned to since they need to access the online oral health education sessions in case of being assigned to that group. The participants in conventional method will receive their oral health education sessions in their classrooms directly, thus making it impossible to mask both participant groups.~the care provider is the primary investigator, and he is the person responsible of delivering the oral health education sessions which makes it impossible to mask the intervention details.~Only the outcomes assessor (which is the statistician) will be blinded from the groups involved, names of participants and study details."||f|f|f|t
33791567|NCT03014050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791568|NCT05626504|||COHORT||OTHER|||||||
33791569|NCT06613074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33791570|NCT05773612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791571|NCT00057850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791572|NCT05045703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791573|NCT01114919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791574|NCT06553391|||COHORT||RETROSPECTIVE|||||||
33933168|NCT02094625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933169|NCT02136316|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33933170|NCT00388375|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933171|NCT03743298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933172|NCT03942549|||COHORT||PROSPECTIVE|||||||
33933173|NCT04281823|||COHORT||PROSPECTIVE|||||||
33709111|NCT02854631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709112|NCT06140992|||COHORT||CROSS_SECTIONAL|||||||
33709113|NCT05166824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709114|NCT03378115|||OTHER||OTHER|||||||
33709115|NCT02034201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709116|NCT02974517|||COHORT||PROSPECTIVE|||||||
33709117|NCT01977794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709118|NCT00848471|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33709119|NCT06266169|RANDOMIZED|PARALLEL||OTHER||SINGLE||"For the retrospective (observational) stage of the study:~Embryos: 424 samples of the culture medium used from individually cultured blastocysts that were fresh and frozen before transferring a single embryo from the institution's internal biobank. Each sample is attributed based on the presence or absence of progressing pregnancy after transfer at 12-14 weeks.~Semen: 340 samples of sperm from the internal biobank of couples undergoing ICSI, each sample is attributed based on the success or failure of the embryological stage.~Endometrium: 300 samples of luminescent and visible spectra of patients' endometrium undergoing embryo transfer, each sample is attributed based on the presence or absence of ongoing pregnancy after transfer.~For the prospective (interventional) stage of the study:~For each object of study, the size of the dataset for prospective testing can only be determined after passing the observational part of the study."|t|f|f|f
33709120|NCT05698797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709121|NCT04853212|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33709122|NCT05423145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and analyst conducting the main analysis will be masked. The participants and project staff will not be masked.|two groups, intervention and wait list control|f|f|t|t
33709123|NCT05259670|||COHORT||PROSPECTIVE|||||||
33709124|NCT01446289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33709125|NCT03355040|||COHORT||PROSPECTIVE|||||||
33709126|NCT01819831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709127|NCT00257543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709128|NCT01795209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709129|NCT01031927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709130|NCT00594438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709131|NCT04467060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791575|NCT03649165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791576|NCT06040333|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791577|NCT04176458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933174|NCT00551967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933175|NCT01782885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933176|NCT00444834|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34011559|NCT02404519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34011560|NCT05660031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011561|NCT04787770|||OTHER||PROSPECTIVE|||||||
33933177|NCT05148559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33933178|NCT00789724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933179|NCT06124352|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33933180|NCT03356405|||COHORT||PROSPECTIVE|||||||
33933181|NCT04067440|||COHORT||RETROSPECTIVE|||||||
33933182|NCT00389129|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933183|NCT03971292|||COHORT||PROSPECTIVE|||||||
33933184|NCT01948323|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33933185|NCT04847739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933186|NCT00427167|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33933187|NCT05905705|||COHORT||PROSPECTIVE|||||||
33933188|NCT00430027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933189|NCT02278380|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33933190|NCT01657227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participating FCUs were not told about their intervention assignment (groups 1-4) until the last patient agreed to participate at every FCU. To warrant patient participation and cooperation, interventions could neither be blinded to patients nor to healthcare professionals. Data analysis is blinded to the intervention assignment.||f|f|f|t
33933191|NCT01040728|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34011562|NCT02499224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011563|NCT03311152|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The index test (mSEPT9) will be reported at the final step of the research, at time of data analysis.|Cross-sectional biomarker Phase II design|t|t|t|f
34011564|NCT00305552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011565|NCT05369013|||COHORT||OTHER|||||||
34011566|NCT00650988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709132|NCT01350492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709133|NCT04284670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34011567|NCT05449093|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34011568|NCT03651726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo controlled, proof of concept study, followed by an open uncontrolled treatment phase|t|f|t|t
33709134|NCT05866796|||COHORT||PROSPECTIVE|||||||
34095048|NCT05929586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Allocation: cluster randomised; intervention model: parallel assignment; arms: 2; allocation ratio: 1:1; restricted or stratified randomisation. Masking: none||||
34095049|NCT04769362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709135|NCT05968391|||CASE_ONLY||PROSPECTIVE|||||||
33709136|NCT01496807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709137|NCT03868020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791578|NCT03354169|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized within subjects, cross-over design||||
33709138|NCT01391559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709139|NCT01172431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709140|NCT01348503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709141|NCT02130570|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||This is a stepped-wedge design, where each primary care practice starts in usual care, and then at a randomly selected point in time switches to the intervention arm.|f|f|f|t
33709142|NCT03182478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be evaluated through scales applied before and after intervention by investigators that will be blinded about the intervention arm of the patient (individual or group format)|Intervention with Rothbaum protocol adapted to skin picking disorder, in individual or group format, consisting of eight weekly sessions, each session during 45 minutes in individual format and 90 minutes in group format|f|f|f|t
33709143|NCT04007978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709144|NCT03184831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709145|NCT04379024|RANDOMIZED|PARALLEL||PREVENTION||NONE|Randomization assignment is masked to all roles prior to randomization. Subsequent to randomization, agent is dispensed open-label.|Randomized to active agent or wait-list control.||||
33709146|NCT02066805|||COHORT||RETROSPECTIVE|||||||
33709147|NCT06293001|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33709148|NCT03384095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33791579|NCT04980261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791580|NCT02774538|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33791581|NCT05956600|NA|SINGLE_GROUP||TREATMENT||NONE||Single-Arm Administration of Amisulpride||||
33791582|NCT00002819|RANDOMIZED|||TREATMENT||||||||
33791583|NCT01396291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791584|NCT00719017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791585|NCT02955524|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33791586|NCT00332436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791587|NCT00177736|||||PROSPECTIVE|||||||
33791588|NCT01645917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791589|NCT03910517|||COHORT||CROSS_SECTIONAL|||||||
33791590|NCT06321809|||CASE_CROSSOVER||PROSPECTIVE|||||||
33791591|NCT05507463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791592|NCT03705299|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791593|NCT00382135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791594|NCT00662324|||COHORT||PROSPECTIVE|||||||
33791595|NCT05100199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791596|NCT04572217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot feasibility study||||
33791597|NCT03600935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791598|NCT06425068|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The study population comprises 26 patients being exposed to the conventional foam mattress (active comparator) and the novel air mattress (experimental) for one hour each in a random order. Interface pressure and contact are will be measured by means of a pressure mattress applied on top of the support systems. The patient comfort will be assessed objectively based on vital sign readings and subjectively based on questionnaire filled by professional care personnel and parents.||||
33791599|NCT00083044|||COHORT||PROSPECTIVE|||||||
33791600|NCT02531568||CROSSOVER||SCREENING||NONE||||||
33791601|NCT01337869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791602|NCT04630912|NA|SINGLE_GROUP||TREATMENT||NONE||Hermeneutic single case efficacy design (HSCED) series||||
33791603|NCT04851561|||CASE_CONTROL||RETROSPECTIVE|||||||
33791604|NCT06348849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791605|NCT05571358|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791606|NCT05561803|||CASE_ONLY||PROSPECTIVE|||||||
33791607|NCT05213715|||CASE_CONTROL||PROSPECTIVE|||||||
33801815|NCT00822367|NA|SINGLE_GROUP||||NONE||||||
33801816|NCT05746715|||COHORT||PROSPECTIVE|||||||
33801817|NCT00558506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801818|NCT01472900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33801819|NCT05756335|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933192|NCT03038516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933193|NCT01700647|||OTHER||PROSPECTIVE|||||||
33933194|NCT01744041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933195|NCT02267902|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33933196|NCT01104688|||||CROSS_SECTIONAL|||||||
33933197|NCT01833390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933198|NCT01413867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933199|NCT04127643|||COHORT||PROSPECTIVE|||||||
33933200|NCT01955785|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33933201|NCT04336007|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33933202|NCT01673425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933203|NCT05589623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33933204|NCT02950441|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33933205|NCT03693352|||CASE_ONLY||PROSPECTIVE|||||||
33933206|NCT02541500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933207|NCT00149890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933208|NCT02768844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933209|NCT04774913|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, international, multicenter study||||
33933210|NCT01990651|||COHORT||PROSPECTIVE|||||||
33933211|NCT00000908|||NATURAL_HISTORY|||||||||
33933212|NCT00250029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933213|NCT02967640|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33933214|NCT00985738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933215|NCT00431223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933216|NCT00417833|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33933217|NCT01372813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933218|NCT00211055|||||PROSPECTIVE|||||||
33709149|NCT03944915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933219|NCT00224497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34103288|NCT06420063|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group.|Patients enrolled in this clinical trial will receive a carefully designed treatment regimen. Before the infusion of CD33 and CD123 CAR-T cells, participants will undergo preconditioning chemotherapy. This chemotherapy serves to create an optimal environment for CAR-T cell therapy to effectively target and eliminate malignant B cells. Following chemotherapy, participants will receive the infusion of CD33 and CD123 CAR-T cells.||||
33933220|NCT03248024|||COHORT||RETROSPECTIVE|||||||
33709150|NCT03333447|||OTHER||CROSS_SECTIONAL|||||||
33709151|NCT02591069|NA|SINGLE_GROUP||OTHER||NONE||||||
33709152|NCT01866930|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709153|NCT03622944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709154|NCT01469195|||CASE_CONTROL||PROSPECTIVE|||||||
33709155|NCT00793091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709156|NCT00456560|RANDOMIZED|PARALLEL||||NONE||||||
33709157|NCT03797014|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study|This is an open-label phase 4 switch study to evaluate the efficacy, safety, and tolerability of FDC B/F/TAF in adults with HIV-1 and HBV coinfection.||||
33709158|NCT05448183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709159|NCT01103648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709160|NCT04092439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33709161|NCT04449900|||CASE_CONTROL||PROSPECTIVE|||||||
33709162|NCT04503902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709163|NCT02912910|||CASE_ONLY||PROSPECTIVE|||||||
33709164|NCT03474770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709165|NCT02560597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709166|NCT01752374|||COHORT||PROSPECTIVE|||||||
33709167|NCT06147739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709168|NCT04690491|||COHORT||PROSPECTIVE|||||||
33709169|NCT01776892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709170|NCT03936985|||OTHER||CROSS_SECTIONAL|||||||
33709171|NCT03702985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791608|NCT04235283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study proposed 1:1 randomization into pinless navigation and conventional technique. Each patient who enrolled in this study will be given sequence study number, and the chief surgeon will draw lots to decide which group will be assigned in. The patient and the independent reviewer are kept blinded|Enroll 100 patients who plan to undergo unilateral primary MIS-TKA and will be randomly assigned into two groups. The first group (50 patients) will be treated by pinless-navigation (Stryker, OrthoMap Express Knee Navigation) MIS-TKA, and the second group (50 patients) will undergo traditional MIS-TKA.|t|f|f|t
33791609|NCT00719823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791610|NCT00199108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709172|NCT01784159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo||t|t|t|t
33709173|NCT05230303|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33709174|NCT05365178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709175|NCT02716428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791611|NCT00305695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791612|NCT02378116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791613|NCT05363358|||COHORT||RETROSPECTIVE|||||||
33791614|NCT01450124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791615|NCT00002932||||TREATMENT||||||||
33801820|NCT05512052|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|t|t|f
33801821|NCT06515678|||OTHER||RETROSPECTIVE|||||||
33801822|NCT01149707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801823|NCT03785405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801824|NCT06136351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801825|NCT02559349|||COHORT||PROSPECTIVE|||||||
33933221|NCT04563104|||COHORT||PROSPECTIVE|||||||
33933222|NCT03253029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933223|NCT01866813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933224|NCT06287658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933225|NCT01069809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933226|NCT03339830|||COHORT||PROSPECTIVE|||||||
33933227|NCT03635606|||COHORT||PROSPECTIVE|||||||
33933228|NCT04140682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095050|NCT03948386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The anesthesiologist and certified registered nurse anesthetist or resident performing the spinal will be aware of group allocation and will perform spinal anesthesia according to standard operating procedures with the assigned local anesthetic.~Patients will remain blinded and surgeons and those performing postoperative assessments will remain blinded as well."|"Patients who agree to participate will then be randomized by a computer-generated sequence to one of the three study groups.~Dosing will be as follows: isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for \> 74 height; hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for \> 74 height; and isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for \> 74 height."|t|f|f|t
34095051|NCT05447832|||COHORT||CROSS_SECTIONAL|||||||
34095052|NCT05103592|||CASE_CONTROL||RETROSPECTIVE|||||||
34095053|NCT00932802|||COHORT||PROSPECTIVE|||||||
34095054|NCT06130202|||COHORT||PROSPECTIVE|||||||
34095055|NCT01996540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095056|NCT01958684|||COHORT||PROSPECTIVE|||||||
34095057|NCT03516500|NA|SINGLE_GROUP||TREATMENT||NONE||After the investigators cut the pulmonary vessels and ligate the segmental bronchus. The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.||||
34095058|NCT01381588|||OTHER||CROSS_SECTIONAL|||||||
33933229|NCT00510770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095059|NCT04234542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709176|NCT06409871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33709177|NCT03064997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709178|NCT03085381|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33709179|NCT03761160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709180|NCT01523171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709181|NCT03712072|||COHORT||PROSPECTIVE|||||||
33709182|NCT00942253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33709183|NCT03598530|||CASE_CONTROL||PROSPECTIVE|||||||
33709184|NCT03945578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933230|NCT04548479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Los evaluadores de los resultados y el investigador que realiza la aleatorización|aleatorizado 1:1|f|f|f|t
33933231|NCT02415595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933232|NCT00096824|||COHORT||PROSPECTIVE|||||||
33933233|NCT04480515|||COHORT||OTHER|||||||
33933234|NCT05312268|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933235|NCT02056756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933236|NCT00760890|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933237|NCT03751072|||CASE_ONLY||RETROSPECTIVE|||||||
33933238|NCT03726541|NA|SINGLE_GROUP||SCREENING||NONE||||||
33933239|NCT03116841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933240|NCT01855490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933241|NCT01770119|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33933242|NCT05307523|RANDOMIZED|CROSSOVER||OTHER||NONE||This pilot study uses a randomized, crossover design with children serving as their own controls. Study activities for each child will take place over 9 weeks. Children and their families will come to one of the research labs to participate, one family at a time. On the first visit, parents will be asked to review and sign an informed consent document to participate and baseline assessments will be completed. The intervention will take place during weeks 2-4 and weeks 6-8, with a washout and reassessment period during week 5 prior to crossover. A final reassessment session will take place during week 9.||||
33933243|NCT02608294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933244|NCT04639505|||OTHER||PROSPECTIVE|||||||
33933245|NCT05723874|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933246|NCT04430868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933247|NCT02745041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933248|NCT06000761|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|All de-identified saliva and breast milk samples will be conducted at a UF lab outside of Shands. ETT culture samples will also be de-identified before sending to Shands CoreLab. Investigators determining clinical outcomes will be blinded to group allocation|The proposed study will prospectively follow 168 VLBW infants and 168 mothers (dyad) for 4 weeks following birth. Infants will be randomized into 1 of 3 groups. Standardized oral care will be performed every 3-4 hours using human milk (Group 1), every 3-4 hours using sterile water (Group 2) or every 12 hours using sterile water (Group 3).|f|f|f|t
33933249|NCT02513394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933250|NCT01720693|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33933251|NCT01951872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933252|NCT03134469|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33933253|NCT00058006|RANDOMIZED|||TREATMENT||DOUBLE||||||
33933254|NCT00125697|||COHORT||PROSPECTIVE|||||||
33933255|NCT00628134|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33933256|NCT01318421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933257|NCT00017927||||TREATMENT||||||||
33709185|NCT03570021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709186|NCT06352489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709187|NCT00596284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709188|NCT03191994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||MDD exercise group, MDD control group, Healthy exercise group, Healthy control group||||
33709189|NCT01958931|||CASE_ONLY||PROSPECTIVE|||||||
33933258|NCT06167772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33933259|NCT03929406|NA|SINGLE_GROUP||OTHER||NONE||||||
33933260|NCT00003804|RANDOMIZED|||TREATMENT||||||||
33933261|NCT05108961|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33933262|NCT06376435|||COHORT||PROSPECTIVE|||||||
33933263|NCT03315858|||COHORT||PROSPECTIVE|||||||
33933264|NCT05069389|||COHORT||RETROSPECTIVE|||||||
33933265|NCT03185923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933266|NCT06030804|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933267|NCT01074840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933268|NCT00481689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791616|NCT06419933|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Cross-assignment. Participants who meet the inclusion criteria and undergo the full baseline assessment will be assigned to the intervention group condition or to the WLC group. Children assigned to the intervention condition will receive the eight-week intervention. Participants in the WLC group will not receive any psychological intervention during the eight-week program. Children and parents in all groups will complete the same set of measures at approximately the same time (pre-test and post-eight weeks). Children in the WLC group will receive the intervention after the follow-up visit is completed.|f|f|f|t
33791617|NCT05355415|||CASE_CONTROL||PROSPECTIVE|||||||
33791618|NCT05470894|||COHORT||PROSPECTIVE|||||||
33791619|NCT00021437|||DEFINED_POPULATION||OTHER|||||||
33791620|NCT04143919|NA|SINGLE_GROUP||SCREENING||NONE||A recent Cochrane analysis reported a high burden of HF in Latin America (Ciapponi et al 2016), reporting an incidence of HF of 199 cases per 100 000 person-years. A cross-sectional study of 633 individuals aged ≥ 45 years, randomly selected and registered in a primary care program in Brazil (Jorge et al 2016) reported 36.6% of patients with Stage A HF, 42.7% with Stage B, and and 9.3% with symptomatic HF (Stage C). In real world settings primary care physician may attend to up to 40 patients per day, which rose to as many as 70 patients per day during high season demand, meaning in some circunstances physicians may only have up to 12 minutes per patient so patients with HF may go unnoticed. The aim of this study is to assess the practicality of an algorithm to identify new cases of HF Stage C in subjects who are at risk of CV disease in real world high-volume ambulatory primary care settings in Central America.||||
33791621|NCT05857319|||COHORT||PROSPECTIVE|||||||
33791622|NCT06140745|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33933269|NCT03746145|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||During the entire winter over (WO) period, from arrival at COCORDIA until departure (1 year), participants receive 2g nutritional supplement powder (sachet, containing 10e11 CFU Bifidobacterium longum 1714 or placebo) once every day, to be taken in the morning with breakfast throughout the year.|t|t|t|t
33933270|NCT00863317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933271|NCT00333931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933272|NCT04130100|RANDOMIZED|PARALLEL||TREATMENT||NONE||low dose of dental pulp mesenchymal stem cells high dose of dental pulp mesenchymal stem cells Sodium hyaluronate||||
33933273|NCT01905904|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34095060|NCT03637374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095061|NCT00064454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095062|NCT02729168|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33933274|NCT03965806|||OTHER||CROSS_SECTIONAL|||||||
33933275|NCT03080532|||OTHER||PROSPECTIVE|||||||
33933276|NCT04930172|||COHORT||PROSPECTIVE|||||||
33933277|NCT00382655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933278|NCT00964639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791623|NCT02496806|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791624|NCT05303155|||CASE_CONTROL||PROSPECTIVE|||||||
33791625|NCT02313090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33791626|NCT03261596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study drug will be maintained and dispensed to the participant by a qualified un-blinded study staff member and witnessed by another un-blinded study staff member. The blinding of laboratory staff will be maintained throughout the trial until data entry and processing are complete and the data have been verified.|The study will be a single site Phase 4, open-label, randomized controlled study. Subjects will be randomized 1:1 to one of two treatment allocations: 150 to receive a single dose of 500 mg mebendazole and 150 to receive a multi-dose of 100 mg mebendazole twice a day for three days.|t|f|f|f
33791627|NCT06107166|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791628|NCT03991481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Platelets will be allocated to participant by unblinded blood bank staff. The platelets will be supplied by the blood bank with an opaque cover that obscures their method of storage (cryopreserved or liquid-stored), but that retain the original Blood Service information for checking.|Participants will be allocated to either: cryopreserved or standard liquid-stored platelets|t|t|t|t
33791629|NCT00242853|||||PROSPECTIVE|||||||
33791630|NCT04143555|||COHORT||PROSPECTIVE|||||||
33933279|NCT05493436|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933280|NCT03687476|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33933281|NCT02029391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933282|NCT02907411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933283|NCT01966276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933284|NCT01085162|||||PROSPECTIVE|||||||
33933285|NCT01748006|||COHORT||PROSPECTIVE|||||||
33933286|NCT01665898|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33933287|NCT04705168|||COHORT||PROSPECTIVE|||||||
33933288|NCT03016039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933289|NCT04171167|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33933290|NCT04259034|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933291|NCT00554528|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33933292|NCT02630485|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33933293|NCT00826709|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933294|NCT00797706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933295|NCT06004193|||COHORT||PROSPECTIVE|||||||
33933296|NCT00357786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933297|NCT04708340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking the dose administered|"In Part 1, RJX will be administered daily for 7 days (1 cycle). In Part 2, Placebo or RJX will be administered daily for 7 days for 1 cycle but may receive 2 cycles.~Each Cohort is comprised of Part 1, a single site, and Part 2, multiple sites. The 2 Cohorts are:~Cohort 1:~* Hospitalized COVID-19 patients ≥18 years without hypoxemia and either not receiving any oxygen therapy OR are receiving supplemental oxygen via mask or nasal prongs (clinical status score 4 or 5 on 8-point ordinal scale).~* Patients are required to have the following high-risk characteristics~  * Age ≥65 years AND type 2 diabetes or hypertension OR~ * Age ≥18 years with abnormal blood tests AND CRP \>50 mg/L PLUS at least 1 of the following biomarkers abnormal: a. D-dimer, b. Ferritin, c. High sensitivity cardiac troponin, d. LDH~Cohort 2:~• Hospitalized COVID-19 patients with hypoxemia and without ARDS who are receiving either non-invasive positive pressure ventilation (NIPPV) OR high flow oxygen"|t|f|t|f
33933298|NCT05166486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33933299|NCT02829606|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933300|NCT01038180|||COHORT||PROSPECTIVE|||||||
33933301|NCT04916015|||CASE_ONLY||RETROSPECTIVE|||||||
33933302|NCT03536273|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33933303|NCT05829564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933304|NCT03846089|||CASE_CONTROL||RETROSPECTIVE|||||||
33933305|NCT01922986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933306|NCT02929381|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33933307|NCT01995786|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33933308|NCT03521401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933309|NCT06174116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized, double-blind, placebo-controlled trial.|t|f|t|f
33933310|NCT03642275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to patients' randomization assignment||f|f|f|t
33709190|NCT03793660|||COHORT||PROSPECTIVE|||||||
33709191|NCT00582166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709192|NCT04286243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Model 1 involves: 1) cervico-vaginal self-sampling for high-risk HPV (hr-HPV) while waiting for appointments at the VFP clinic or other clinics, 2) same-day VIA for those women found to be hr-HPV-positive by rapid GeneXpert HPV testing, and 3) same-day thermocoagulation treatment for HPV-positive women who are eligible for ablative therapy by VIA.~Model 2 will offer women the same services as in Model 1, but they will also be given the option to perform cervico-vaginal self-sampling in the community, via Heath Surveillance Assistants (HSAs) who will bring their HPV sample to the clinic and notify them to return to the clinic for VIA and possible same-day thermocoagulation if their hr-HPV test is positive."||||
33709193|NCT00708968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709194|NCT02279537|||COHORT||OTHER|||||||
33709195|NCT02845505|||COHORT||RETROSPECTIVE|||||||
33933311|NCT03537183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33933312|NCT03064165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933313|NCT02422563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933314|NCT02014545|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33933315|NCT00609167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933316|NCT01836367|NA|SINGLE_GROUP||||NONE||||||
33933317|NCT01394211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933318|NCT00521118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933319|NCT02159768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933320|NCT03745989|NA|SEQUENTIAL||TREATMENT||NONE||Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies.||||
33933321|NCT05142176|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients unaware and care giver were unaware about what is injected inthe catheters|Bilateral erector spinae block|t|t|f|f
33933322|NCT06302608|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33933323|NCT00732706|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33933324|NCT01362972|||COHORT||RETROSPECTIVE|||||||
33933325|NCT05734014|NA|SINGLE_GROUP||PREVENTION||NONE||The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.||||
33933326|NCT03131011|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933327|NCT05037955|||COHORT||RETROSPECTIVE|||||||
33933328|NCT01877811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933329|NCT03607604|||COHORT||CROSS_SECTIONAL|||||||
33933330|NCT05386004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two groups of primiparous pregnant women who met the inclusion criteria and agreed to participate in the study were included in the study. Pregnant women were randomly assigned to experimental and control groups. The experimental group was treated with BSSC.|t|f|t|f
33933331|NCT02466204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933332|NCT02252588|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33933333|NCT02725749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933334|NCT01712191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933335|NCT00471315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933336|NCT00641459|||COHORT||PROSPECTIVE|||||||
33933337|NCT03846622|||COHORT||RETROSPECTIVE|||||||
33933338|NCT03688893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It was single blind; as the evaluator did not know what intervention the patient was assigned.|The investigators conducted a Randomized controlled trial (RCT) to study the effect of LASER in dental bleaching in 24 patients in Paraguay in 2015.|f|f|f|t
33933339|NCT03644381|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933340|NCT04308408|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33933341|NCT03976193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933342|NCT00365742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933343|NCT04685655|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Therapeutic plasma exchange in patients with severe COVID 19||||
33933344|NCT00409396|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933345|NCT05305053|||CASE_ONLY||PROSPECTIVE|||||||
33933346|NCT01603472|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933347|NCT05125991|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933348|NCT05800613|||FAMILY_BASED||PROSPECTIVE|||||||
33933349|NCT02331654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933350|NCT04562038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33933351|NCT03421262|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33933352|NCT00871676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933353|NCT00732654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011569|NCT04710537|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"At the time of surgery, the surgeon will be blinded to which acellular dermal matrix product he or she is utilizing in each breast, and the technical steps of the procedure will proceed identically on each side. This can be done through the help of circulators and scrub techs during the surgery, who can randomly prepare either AlloDerm or DermACELL to be placed in either the right or left breast, without informing the surgeon. Other items, like the selection of suture and number of drains placed will be at the discretion of the surgeon but will proceed identically in the two breasts.~Patients will also be blinded as to what product is in each breast. On the day of surgery, the circulator/operating room assistants will record what product is placed in each breast in the surgery electronic medical note."|"At the time of surgery, the assignment of AlloDerm vs. DermACELL to the patient's left and right breasts will be randomized. The surgical assistant, scrub tech, and circulators can randomly choose which acellular dermal matrix product will be used first or second. The ADM product that will be used first will be placed in either the left or right breast, depending on what breast the surgeon decided to perform the surgery on first. Then, the second breast that is operated on will receive whichever ADM product was not used on the first breast."|t|t|f|f
34011570|NCT02997657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011571|NCT01712919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011572|NCT04572139|||OTHER||CROSS_SECTIONAL|||||||
33709196|NCT05378880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The intervention consists of behavioural interventions, therefore masking of participants or care providers is not possible.|Cluster randomized controlled trial|f|f|f|t
33709197|NCT02706691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709198|NCT03201835|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33709199|NCT01025804|||CASE_ONLY||PROSPECTIVE|||||||
33709200|NCT05277324|||CASE_ONLY||PROSPECTIVE|||||||
33709201|NCT00967668|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709202|NCT05422196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709203|NCT06131567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized clinical trials with paired number of subjects|t|f|f|t
33709204|NCT01567124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709205|NCT00194571|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33709206|NCT05771376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709207|NCT05148598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo is visually indistinguishable from active treatment.|"* Prospective~* Randomized Parallel Group~* Placebo-Controlled~* Safety and Efficacy Trial"|t|t|t|t
33709208|NCT01306942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709209|NCT02994212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709210|NCT01927510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709211|NCT01312272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709212|NCT05608798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709213|NCT03384212|RANDOMIZED|PARALLEL||TREATMENT||NONE||open labled randomized controlled study||||
33709214|NCT02871700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709215|NCT05609006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709216|NCT00509015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33709217|NCT02871414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709218|NCT00971594|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33709219|NCT04698460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709220|NCT01752127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709221|NCT04579757|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33709222|NCT05216185|||OTHER||RETROSPECTIVE|||||||
33709223|NCT05654337|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33709224|NCT03312101|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel asigmanet||||
33709225|NCT02505867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709226|NCT05772832|||CASE_CONTROL||PROSPECTIVE|||||||
33709227|NCT02535117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709228|NCT01324908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709229|NCT01369095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34011573|NCT04176588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011574|NCT02836301|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34011575|NCT03421704|||COHORT||PROSPECTIVE|||||||
34011576|NCT02401477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011577|NCT04425889|||COHORT||CROSS_SECTIONAL|||||||
33709230|NCT00866385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33709231|NCT06259747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated into two groups; group (A) will receive acutaping in addition to traditional medical treatment (Doxylamine and Pyridoxine) while group (B) will receive traditional medical treatment(Doxylamine and Pyridoxine) only.||||
33709232|NCT04112056|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33709233|NCT01686529|RANDOMIZED|PARALLEL||||NONE||||||
34011578|NCT02740920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709234|NCT04056910|NA|SINGLE_GROUP||TREATMENT||NONE||Concurrent dosing of ivosidenib and nivolumab.||||
33709235|NCT02200562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709236|NCT00786500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709237|NCT01095445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709238|NCT00667069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709239|NCT01278979|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33709240|NCT00753415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720574|NCT05008250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Prior to the start of the study, the sponsor (or contract research organization) and statistician will make masking of the research drugs. The statistician in this study used statistical software to generate random coding table according to the method of stratified block randomization. Personnel who have no involvement in this study will paste the corresponding drug number on the drug packaging according to the random coding.||t|f|t|f
33720575|NCT00730912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720576|NCT01540656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720577|NCT01763424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095063|NCT05389839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34011579|NCT06051604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding for this study will be applied to the Principal Investigator (PI) and the study team. The team members who are directly involved in the analysis of the study results, including the biostatistician, will also be blinded. Only the designated group of team members directly involved in overseeing the logistical and distribution aspects of the study products will be unblinded. As needed, the PI may be unblinded in case of an AE/SAE that may impact participant safety. If the unblinding occurs inadvertently or through PI's need due to an AE/SAE impacting participant safety, that event will be noted as a protocol deviation.||t|f|t|t
34011580|NCT04932941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011581|NCT04574115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|subject masked to treatment|"This study is a prospective, interventional, randomized, controlled, paired eye, subject-masked design.~Subjects will be randomly assigned to which eye will receive the Omega Refractive capsule VI with an FDA approved intraocular lens. Fellow eyes will serve as controls and receive an FDA approved IOL (no Omega capsule)."|t|f|f|f
34011582|NCT03329976|||COHORT||PROSPECTIVE|||||||
34011583|NCT03235479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Participant|Randomized Controlled Trial|t|t|t|f
34011584|NCT04681625|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34011585|NCT06552104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011586|NCT01931527|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34011587|NCT00850226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011588|NCT01401894|||CASE_ONLY||CROSS_SECTIONAL|||||||
34011589|NCT01413282|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34011590|NCT01163084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011591|NCT06180408|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34011592|NCT03313882|||COHORT||RETROSPECTIVE|||||||
34011593|NCT03738527|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomized on the REDCap system. Their assignment will be made available to pharmacy, which will be prepare syringes with either TXA or placebo.|"Pilot Randomized Controlled Trial (RCT) with 2 arms: the interventional arm (receiving topical TXA) and the control arm (receiving placebo).~Intervention: Topical application of 20 mL of TXA (100 mg/mL injection solution) to the mastectomy cavity~Placebo: Topical application of 20 mL of 0.9% NaCl (normal saline) to the mastectomy cavity"|t|t|f|f
34011594|NCT02382926|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011595|NCT05287152|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Using the titanium tacks in free gingival graft fixation instead of conventional suturing.||||
34011596|NCT00002006||||TREATMENT||||||||
34011597|NCT04385524|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34011598|NCT00766155|RANDOMIZED|||TREATMENT||NONE||||||
34011599|NCT00697606|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011600|NCT03813693|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention group (GI) received two packs, each containing six towels impregnated with 2% chlorhexidine gluconate and an instruction manual on how to use them.~Two bottles of chlorhexidine gluconate 2% liquid (100 ml) were given to the control group (CG), the patients were instructed to perform the bath using one vial the night before surgery and the other on the morning of surgery."||||
34011601|NCT02234752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011602|NCT05002114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind, randomized, placebo-controlled.|double-blind, randomized, placebo-controlled.|t|t|t|t
34011603|NCT02948790|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34011604|NCT06218121|||COHORT||PROSPECTIVE|||||||
34011605|NCT04953416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011606|NCT06023849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011607|NCT06342024|RANDOMIZED|PARALLEL||OTHER||NONE|Not apply|Eligible participants will be randomized to one of two groups (pistachio vs. control) using permuted block randomization with stratification to balance assignment by sex. Randomization allocation tables will be created by a biostatistician not involved in the clinical trial using SAS software, version 9.4 (SAS Institute, Cary, NC, USA). The tables will be stored within the REDCap system at Virginia Tech, in such a way that only the biostatistician will be able to view them. Study outcomes will be analyzed blind to allocation status.||||
34011608|NCT00609284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011609|NCT00078507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34011610|NCT01709994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011611|NCT04928534|||COHORT||CROSS_SECTIONAL|||||||
33720578|NCT00487747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720579|NCT03318354|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720580|NCT01137045|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34011612|NCT03812991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34011613|NCT03781024|||COHORT||PROSPECTIVE|||||||
34011614|NCT00888784|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34011615|NCT03119493|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011616|NCT00272506||CROSSOVER||TREATMENT||||||||
34011617|NCT06406439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011618|NCT04683757|||COHORT||PROSPECTIVE|||||||
34095064|NCT06345820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34095065|NCT04926662|||COHORT||PROSPECTIVE|||||||
34095066|NCT05469308|NA|SINGLE_GROUP||OTHER||NONE||||||
34011619|NCT01283815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095067|NCT05571488|||COHORT||PROSPECTIVE|||||||
34095068|NCT02669537|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34103289|NCT06686771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103290|NCT06056102|NA|SEQUENTIAL||TREATMENT||NONE||||||
34103291|NCT06669715|||OTHER||CROSS_SECTIONAL|||||||
33720581|NCT06343194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||bruxism patients and non-bruxism patients||||
33720582|NCT00082355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720583|NCT02441608|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33933354|NCT05221489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33933355|NCT03428295|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental: Single Cohort in CRC This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting. Intervention: Device: Dose Safety Artificial Pancreas (AP) System||||
33933356|NCT02040298|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33933357|NCT00564200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933358|NCT04358991|||OTHER||PROSPECTIVE|||||||
33933359|NCT05934890|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Active-controlled|t|f|t|f
33933360|NCT04935567|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||PRECISE is a prospective multicentre study for prediction VNS efficacy based on pre-implantation EEG data. The patients with drug-resistant epilepsy will undergo standard VNS implantation based on a clinical decision. Before implantation, the scalp EEG, according to the study protocol, will be recorded. The EEG will be mathematically processed, and the patient´s predicted outcome in terms of predicted responder vs. predicted non-responders will be statistically determined. The stimulation parameters and AEDs therapy will be modified according to the best clinical practice. The real-life outcome will be determined by percent seizure reduction. Subsequently, the real-life and predicted outcome will be compared in terms of accuracy, sensitivity, and specificity. The main goal is to validate Pre-X-Stim in a real-life prospective study.||||
33933361|NCT02034864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933362|NCT03772704|||CASE_ONLY||PROSPECTIVE|||||||
33933363|NCT02727504|||COHORT||PROSPECTIVE|||||||
33933364|NCT00954473|||CASE_CONTROL||RETROSPECTIVE|||||||
33933365|NCT00367705|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33933366|NCT00169767|||COHORT||PROSPECTIVE|||||||
33933367|NCT03667794|||COHORT||CROSS_SECTIONAL|||||||
33933368|NCT00952952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933369|NCT00112567||||TREATMENT||NONE||||||
33933370|NCT05211492|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are 3 groups. 1 chronic pain, 2 acute pain, 3 no pain||||
33933371|NCT05580757|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933372|NCT02038790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933373|NCT05195424|||COHORT||PROSPECTIVE|||||||
33933374|NCT02287805|||COHORT||PROSPECTIVE|||||||
33933375|NCT03685929|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933376|NCT03743376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011620|NCT04199884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34011621|NCT05177159|||COHORT||PROSPECTIVE|||||||
34011622|NCT03123783|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1b dose escalation with up to 4 sequential dose levels. Followed by Phase 2 dose expansion at Recommended Phase 2 Dose in 3 parallel disease cohorts.||||
34011623|NCT01522950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011624|NCT05684146|RANDOMIZED|PARALLEL||TREATMENT||NONE||G4: Model Description\* Subjects will be randomized (1:1) to either the Emboliner (ARM 1) or Sentinel CPS (ARM 2). Device randomization will be stratified by (a) site and (b) TAVR device type (Edwards or Medtronic) to ensure that each study arm represents an equivalent patient population.||||
34011625|NCT06196593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011626|NCT06074302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011627|NCT01448356|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011628|NCT04038086|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34011629|NCT01727349|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011630|NCT05618145|||COHORT||PROSPECTIVE|||||||
34011631|NCT04517929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011632|NCT04441645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34011633|NCT01473576|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34011634|NCT03417791|||COHORT||RETROSPECTIVE|||||||
34011635|NCT04747314|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|t|f|t
34011636|NCT03501537|NA|SINGLE_GROUP||TREATMENT||NONE||Single-prospective one-arm study||||
34011637|NCT02282202||CROSSOVER||TREATMENT||NONE||||||
34011638|NCT04075552|NA|SINGLE_GROUP||TREATMENT||NONE||Single subject research methodology||||
34011639|NCT01084434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011640|NCT00836719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011641|NCT02355756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011642|NCT06502587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011643|NCT02610920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011644|NCT01342978|||COHORT||PROSPECTIVE|||||||
34011645|NCT00536484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011646|NCT01699529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011647|NCT02207335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011648|NCT02691832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011649|NCT01908894|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34011650|NCT03811132|||COHORT||PROSPECTIVE|||||||
34011651|NCT00411398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011652|NCT03351231|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34011653|NCT02056470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011654|NCT05850052|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34011655|NCT00978913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011656|NCT03606720|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|If low level laser therapy 810nm and pelvic stabilization exercises can reduce pain and improve function there will be a new treatment option for this condition|The study were to determine whether the combination of low level laser therapy and pelvic stabilization exercises is more efficient, and possibly effective, treatment protocol in the treatment of pelvic girdle pain,and study and compare the effectiveness of specific stabilizing exercises with low level laser therapy in PGP subjects in terms of pain intensity, functional status and health-related quality of life following delivery|t|t|t|t
33933377|NCT00952419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933378|NCT01547806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933379|NCT01044056|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933380|NCT02244125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933381|NCT01251094|||CASE_CONTROL||PROSPECTIVE|||||||
33720584|NCT01207765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720585|NCT02432534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933382|NCT05104788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933383|NCT01339104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933384|NCT01537289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933385|NCT01425307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933386|NCT00307944|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33933387|NCT06183554|||CASE_ONLY||PROSPECTIVE|||||||
33933388|NCT04437810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933389|NCT05333536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups , comparison group a control and b experimental|t|f|t|f
33933390|NCT02240992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933391|NCT03973749|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33933392|NCT01471938|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933393|NCT05765214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933394|NCT04525560|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33933395|NCT00063986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933396|NCT00005065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933397|NCT00622570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933398|NCT00373464|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33933399|NCT03930667|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33933400|NCT06099028|||COHORT||RETROSPECTIVE|||||||
33933401|NCT02744781|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34011657|NCT03409094|||COHORT||PROSPECTIVE|||||||
34011658|NCT05918822|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011659|NCT03585959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011660|NCT05407506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011661|NCT05871086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo will be given to patients in the control group||t|f|f|f
34011662|NCT01971866|||CASE_ONLY||PROSPECTIVE|||||||
34011663|NCT02486913|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011664|NCT05904249|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Study groups will be randomized by Researcher 3 using the Research Randomizer (https://www.randomizer.org). Researcher 1 will be blinded when selecting a treatment group.~Rehabilitation practices for both groups will be conducted by the Researcher 1 and outcome evaluation will be conducted by the Researcher 2. The Researcher 2 will not know which group the data of the patient he/she is evaluating belongs to."||f|f|t|t
34011665|NCT03560921|||COHORT||PROSPECTIVE|||||||
34011666|NCT04954378|||CASE_CONTROL||RETROSPECTIVE|||||||
34011667|NCT01508819|||COHORT||PROSPECTIVE|||||||
34011668|NCT04008537|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34011669|NCT04915690|||OTHER||OTHER|||||||
34011670|NCT04885192|||COHORT||PROSPECTIVE|||||||
34011671|NCT00724373|||COHORT||RETROSPECTIVE|||||||
34095069|NCT03166956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This is a prospective double-blind randomized study for surgical ICU patients whom can sustain enteral feeding. The test group was provided with glutamine and vitamin C (the GA group); the control (C) group was provided with maltodextrin of equivalent calories as that provided in the GA group.|Randomized controlled trial|t|t|t|t
34095070|NCT05168982|||OTHER||PROSPECTIVE|||||||
34095071|NCT00977561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095072|NCT04920734|||COHORT||PROSPECTIVE|||||||
33933402|NCT04851327|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Two similar tasting drinks will be used in random order, one low and one high energy After a standardised meal, the weight of food consumed will be measured by an observer blind to which supplement has been used|cross-over energy compensation study, participants acting as their own controls|t|f|f|t
33933403|NCT02454894|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33933404|NCT06242106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011672|NCT04882137|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34011673|NCT02589158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011674|NCT04660305|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33791631|NCT02379546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791632|NCT04580303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709241|NCT06139029|RANDOMIZED|PARALLEL||OTHER||NONE||"This randomized controlled trial was conducted at the Department of Pediatrics, Mardan Medical Complex, Mardan over a period of 4 months from 15th of November 2022 to 15th of March 2023.~Sample size was calculated with OpenEpi calculator using 95% confidence level and power 80%.~Estimated sample size 60, n1 (Patients in Group-A) =30, n2 (Patients in Group-B) =30.~A total of 60 infants from both the genders between the ages of 3 to 12 months admitted in the pediatric unit with bronchiolitis were included in this study through non-probability consecutive sampling and equally randomized into 2 groups.~Exclusion Criteria was set as infants having some underlying disease (e.g. Cystic fibrosis, bronchopulmonary dysplasia and cardiac or renal disease), prior history of wheezing, family history of asthma, pneumonia, TB, allergic history and progressive respira"||||
33709242|NCT01193868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709243|NCT03415035|||COHORT||PROSPECTIVE|||||||
33791633|NCT02909049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709244|NCT02215291|||COHORT||PROSPECTIVE|||||||
34095073|NCT05863416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33791634|NCT04866069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded||t|f|t|f
33709245|NCT06354595|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33709246|NCT03060629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Sponsor will be also blinded||t|f|t|f
33709247|NCT00042289|||COHORT||PROSPECTIVE|||||||
33791635|NCT04013646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Group 1: UCB infusion and EPO injection group Group 2: UCB infusion and placebo EPO injection group Group 3: Placebo UCB infusion and placebo EPO injection group|t|t|t|t
33709248|NCT02442518|||CASE_ONLY||PROSPECTIVE|||||||
33709249|NCT01581645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709250|NCT01594762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709251|NCT03159195|||COHORT||RETROSPECTIVE|||||||
33709252|NCT00826904|||COHORT||PROSPECTIVE|||||||
33709253|NCT04752397|||CASE_ONLY||PROSPECTIVE|||||||
33709254|NCT00241215|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33709255|NCT01155271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709256|NCT03438669|||COHORT||CROSS_SECTIONAL|||||||
33709257|NCT01796080|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33709258|NCT04447300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33709259|NCT04999176|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study aims to evaluate the efficacy and safety of oral rivaroxaban 10 mg for 30 days in thromboprophylaxis after gynecological pelvic cancer surgery compared to subcutaneous enoxaparin 40 mg. The primary efficacy outcome is a combination of symptomatic VTE and VTE-related death or VTE detected by mandatory Doppler ultrasound on day 30±4 post-operative. The primary safety outcome is the incidence of major and clinically relevant non-major bleeding according to ISTH criteria.||||
33709260|NCT00232609|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33709261|NCT05464069|||COHORT||RETROSPECTIVE|||||||
33709262|NCT02658305|||CASE_CONTROL||RETROSPECTIVE|||||||
33791636|NCT05581654|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33791637|NCT04289610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33791638|NCT00521937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791639|NCT03510637|||COHORT||PROSPECTIVE|||||||
33791640|NCT03326648|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects and testers will not be blinded. All analyses of muscle samples will be performed blinded.||f|f|f|t
33791641|NCT06053242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791642|NCT03266302|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Participant will not be informed about group allocation|two-arm randomized-controlled group sequential (Pocock) design for assessing superiority and safety|t|f|f|f
33791643|NCT04606069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791644|NCT05622188|||OTHER||CROSS_SECTIONAL|||||||
33791645|NCT04055766|||CASE_CROSSOVER||PROSPECTIVE|||||||
34095074|NCT05849753|||COHORT||PROSPECTIVE|||||||
34095075|NCT04757584|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34095076|NCT04599218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095077|NCT02713841|RANDOMIZED|CROSSOVER||||NONE||||||
34095078|NCT02388789|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095079|NCT00127010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095080|NCT01435915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095081|NCT06386549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34095082|NCT01018953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791646|NCT01667354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33791647|NCT05776446|||CASE_ONLY||RETROSPECTIVE|||||||
33791648|NCT06233812|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Patients will serve as their own controls -- one half of the full-thickness skin graft will be sutured with simple running sutures and the other half with simple interrupted sutures.|t|t|t|f
33791649|NCT01830842|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33791650|NCT00915330|RANDOMIZED|||DIAGNOSTIC||NONE||||||
34095083|NCT04954820|RANDOMIZED|PARALLEL||TREATMENT||NONE||"It's a prospective, national, multicenter, open-label, randomized, phase II study, to compare 2 additional cycles of Lutathera® versus active surveillance in patients who already received two cycles of Second PRRT (already retreated with two cycles).~Written informed consent will be collected before any study related procedures take place.~Patients previously treated with 4 cycles of Lutathera® will be registered after a first progression (clinic, biologic and/or radiologic) of their neuroendocrine tumor."||||
34095084|NCT06413407|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33709263|NCT02223897|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33709264|NCT02936830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33709265|NCT05604352|NA|SINGLE_GROUP||TREATMENT||NONE||Single sample, no randomisation, no blinding.||||
33709266|NCT01411202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791651|NCT01606553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33791652|NCT03556137|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791653|NCT00999843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709267|NCT05009121|||COHORT||PROSPECTIVE|||||||
33709268|NCT05366946|||CASE_CONTROL||PROSPECTIVE|||||||
33709269|NCT04963335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709270|NCT01752998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709271|NCT02478632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709272|NCT03197701|||OTHER||CROSS_SECTIONAL|||||||
33709273|NCT05059600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709274|NCT04897815|||COHORT||PROSPECTIVE|||||||
33709275|NCT00133471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33709276|NCT02667054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709277|NCT06211166|||COHORT||PROSPECTIVE|||||||
33709278|NCT03736447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|2:1 randomization|t|t|t|f
33709279|NCT01090843|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33709280|NCT04193332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791654|NCT03752385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801826|NCT00650104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801827|NCT04099875|||CASE_ONLY||PROSPECTIVE|||||||
33801828|NCT05557006|||CASE_ONLY||PROSPECTIVE|||||||
33933405|NCT05659004|||OTHER||RETROSPECTIVE|||||||
33933406|NCT01864486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933407|NCT04993755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933408|NCT02462122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933409|NCT04552067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933410|NCT05639829|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33933411|NCT03207724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933412|NCT04304404|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33933413|NCT01500265|||CASE_CONTROL||PROSPECTIVE|||||||
33933414|NCT02081911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933415|NCT00067444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933416|NCT04962880|||OTHER||CROSS_SECTIONAL|||||||
33933417|NCT01936428|NA|SINGLE_GROUP||||NONE||||||
33933418|NCT02171039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933419|NCT03612544|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation.|||||
33933420|NCT03456414|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A team of assessors, different to the researchers implementing the exercise, will record all dependent variables|All participants will receive during hemodialysis the conditions 'virtual reality exercise' for 12 weeks and 'control period-no exercise' for 12 more weeks|f|f|t|t
33933421|NCT01261494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933422|NCT03027869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33933423|NCT02431793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011675|NCT04399642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Because of the nature of the intervention, it is impossible for the surgeon to be blinded. However, postoperative infection will be diagnosed by an independent co-worker, not involved in the surgery. Patients will be blind as they will not be aware if they had intra-articular vancomycin powder or not||t|f|f|t
34011676|NCT06317948|||COHORT||RETROSPECTIVE|||||||
34011677|NCT01005329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011678|NCT04608799|||CASE_ONLY||RETROSPECTIVE|||||||
34011679|NCT01421199|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34011680|NCT05985382|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011681|NCT00280878|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709281|NCT05089942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709282|NCT03799081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Women who have undergone a missed abortion in the first trimester who want a surgical treatment option||||
33709283|NCT00612040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709284|NCT03530878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709285|NCT03443375|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34011682|NCT02168725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011683|NCT06014528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized, double-blind clinical study, therefore, investigator, site staff, subject, and sponsor involved in study will not know the treatment administered. In addition, the central imaging reviewer conducting the BICR evaluation will also be blinded to study treatment allocation.|"Treatment allocation/randomization will be stratified according to the following factors:~1. Prior bevacizumab use (yes or no).~2. Platinum free interval (PFI, \< 3 months or 3-6 months), 3 months is defined as 90 days."|t|t|t|t
34011684|NCT05735964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Consecutive patients||||
34011685|NCT02208115|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34095085|NCT05141747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095086|NCT03061019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095087|NCT01873885|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33791655|NCT04135378|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental randomized placebo trial study approach was designed to meet the previously mentioned objectives of the current study. The period of the study is from 1st November 2018 to 20th April 2019. A random sample of (90) students was taken in this study .||||
33791656|NCT02041104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34011686|NCT04528888|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study in conceived as open-label: the patients and all the health-care personnel will be aware of the assigned group.|The study is designed as a multicenter, national, interventional, randomized, investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned to one of the three treatment groups in a ratio 1:1:1. A block randomisation will be used with variable block sizes (block size 4-6-8), stratified by centre. Central randomisation will be performed using a secure, web-based, randomisation system. The allocation sequence will be generated by the study statistician using computer generated random numbers.||||
34011687|NCT01020799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011688|NCT05676255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be informed of their group assignment only after completion of the baseline (T1) assessment, and data collectors will be blinded to study group assignment for all future assessments. Participants will be asked to not discuss their group assignment with anyone other than the study coordinator. The PI and other investigators will be blinded to arm assignment.|randomized clinical trial design|f|f|t|t
34011689|NCT04594915|||COHORT||PROSPECTIVE|||||||
34011690|NCT05114759|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of SHR-A2009||||
34011691|NCT04147819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33791657|NCT02400151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791658|NCT01785004|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33791659|NCT03433950|||COHORT||PROSPECTIVE|||||||
33933424|NCT03547349|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Incidence and severity of atelectasis will be radiographically assessed on a 5 point scale (no apparent disease, subsegmental atelectasis, segmental atelectasis, lobar atelectasis, or pneumonia) by a chest radiologist and two pulmonary physicians blinded to study group assignment.|Patients will be enrolled sequentially in Group 1 until the desired group enrollment number is met (N=25) at which point participants will be randomized into groups 2 and 3, stratified by surgery type (open or laproscopic)|f|f|f|t
33791660|NCT05216653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791661|NCT01254019|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33791662|NCT03206671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791663|NCT01977612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791664|NCT00901069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791665|NCT03031262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791666|NCT06554197|||COHORT||PROSPECTIVE|||||||
33791667|NCT02462551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791668|NCT06116162|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Two dermatologists evaluating the severity of acne scars were blinded to the assignment. At patients' each evaluation visit, photographic assessments by dermatologists, VISIA and Antera 3D analysis and patients' subjective assessments were conducted.|Seventeen patients with moderate to severe acne scars were treated with SVF-gel filling and CO2 fractional laser through a 24-week, randomized split-face study. One randomly assigned half side of each patient's received one SVF-gel filling treatment and the other side by two CO2 fractional laser treatment once one months.|f|f|f|t
33791669|NCT05377346|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33791670|NCT03818178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933425|NCT00002394||PARALLEL||TREATMENT||||||||
33933426|NCT00546936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933427|NCT02182999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933428|NCT02410590|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33933429|NCT02174328|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33933430|NCT05431738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The stent is placed under endoscopy during general anesthesia. The type of stent is not specified in the endoscopy report. The patient is not informed of the type of esophageal stent placed.|This is a prospective, controlled, randomized, multicentre, single-blind study.|t|f|f|f
34011692|NCT04923711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011693|NCT00165386|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011694|NCT02440516|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34011695|NCT01706016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011696|NCT02708888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011697|NCT04150822|||COHORT||PROSPECTIVE|||||||
34095088|NCT02763995|NA|SINGLE_GROUP||||NONE||||||
33933431|NCT03832816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|placebo controlled, double-blind||t|f|f|t
33709286|NCT01142349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709287|NCT03619954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709288|NCT04240769|||COHORT||PROSPECTIVE|||||||
33709289|NCT04583475|||OTHER||PROSPECTIVE|||||||
33709290|NCT02730429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, double-blind, placebo-controlled|t|f|t|f
33709291|NCT01516346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791671|NCT04676984|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33791672|NCT00309088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791673|NCT03008018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791674|NCT02582437|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791675|NCT00506181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33791676|NCT02918071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933432|NCT04940741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|different phases: open-label treatment and randomised, double-blind, placebo-controlled treatment|Phase A: randomised, double-blind, placebo-controlled (Efficacy and safety) Phase B: Open-label treatment (long-term safety) Phase C: Open-label treatment (long-term safety) Phase D: randomised, double-blind, placebo-controlled (maintenance of efficacy)|t|t|t|t
33933433|NCT04341311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933434|NCT01986517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933435|NCT03780985|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933436|NCT06249880|||CASE_ONLY||CROSS_SECTIONAL|||||||
34095089|NCT00922051|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34095090|NCT06380608|||CASE_ONLY||PROSPECTIVE|||||||
33709292|NCT01061177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709293|NCT02789202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709294|NCT06374901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709295|NCT04433403|||CASE_ONLY||PROSPECTIVE|||||||
33709296|NCT03234933|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709297|NCT02333201|||||PROSPECTIVE|||||||
33709298|NCT00131118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933437|NCT00862524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709299|NCT03093883|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33709300|NCT01346228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709301|NCT02657291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33709302|NCT02815683|||COHORT||PROSPECTIVE|||||||
33709303|NCT04101877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Prospective, controlled, randomized, double-blind|t|t|t|t
33709304|NCT01044771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709305|NCT03546660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791677|NCT01881542|||COHORT||PROSPECTIVE|||||||
33791678|NCT05639699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33791679|NCT04881136|NA|SINGLE_GROUP||PREVENTION||NONE||"The study will take place at St James's Hospital, in the Falls and Syncope Unit at MISA.~Clinical data collection, processing, and data analysis will be conducted on-site by the study nurse and doctor and the on-site data manager recruited to the study team. The data collected by the investigational Falls Predictor software will be transmitted via CareLink™ and will be processed and analysed by Medtronic."||||
33791680|NCT00993850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791681|NCT02378714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791682|NCT02491749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791683|NCT00364286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791684|NCT00456274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791685|NCT00714558|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791686|NCT02786771|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791687|NCT03987542|||COHORT||OTHER|||||||
33791688|NCT00667745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791689|NCT03126656|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791690|NCT00362726|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33933438|NCT02743975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||phase I/II safety and dose-finding study||||
33933439|NCT02705755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933440|NCT01814189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933441|NCT03640520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|All participants on each team at each site will be blinded as to treatment condition and to the study goal of evaluating family centered care. Study staff who rate team performance of FCC from videotaped simulated pediatric resuscitations will also be blinded as to treatment condition.|Investigators will conduct an RCT of the FACETS online skills training module (intervention) vs. an online training module reviewing pediatric readiness standards for all EDs (control).|t|f|f|t
33933442|NCT00574366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933443|NCT03714789|||COHORT||PROSPECTIVE|||||||
34095091|NCT04008186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095092|NCT01865682|||CASE_ONLY||PROSPECTIVE|||||||
34095093|NCT05842291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709306|NCT01941121|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33709307|NCT00580021|||COHORT||RETROSPECTIVE|||||||
33709308|NCT02433730|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33709309|NCT04077827|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709310|NCT01150136|||CASE_ONLY||CROSS_SECTIONAL|||||||
33709311|NCT04384211|||COHORT||RETROSPECTIVE|||||||
33791691|NCT06464172|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The research team will conduct the randomization and participant code allocation process using REDCap and will dispense the medication or placebo based on the randomization. The placebo will be visibly identical to that of the active medication (i.e. white powder in a gel capsule of the same size and colour as the active medication)|Randomized, crossover, single-blind, placebo-controlled design|t|f|f|t
33791692|NCT00018226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791693|NCT06131047|RANDOMIZED|PARALLEL||OTHER||SINGLE|Asessor who will take readings is blind|Randomized Clinical trial|f|f|f|t
33933444|NCT00141622|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34095094|NCT03589053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933445|NCT03099304|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33933446|NCT04818489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The radiologist who will assess the CT scans will be blinded||f|f|f|t
33933447|NCT00493844|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33933448|NCT02023541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933449|NCT04720560|||CASE_ONLY||PROSPECTIVE|||||||
33933450|NCT06446050|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive infusion of MSC-L every 21 days.||||
33933451|NCT03874104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33933452|NCT00655239|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33933453|NCT01942304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933454|NCT02174809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933455|NCT01365442|||ECOLOGIC_OR_COMMUNITY|||||||||
33933456|NCT01131078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933457|NCT00927576|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33933458|NCT02996110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933459|NCT00492570|||COHORT||PROSPECTIVE|||||||
33933460|NCT01550614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933461|NCT00712270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933462|NCT03073369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933463|NCT02076243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933464|NCT03125655|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933465|NCT00505518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933466|NCT01675856|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Patients are randomized in a 1:1 ratio. The patient is randomized to receive;~1. Urgent endoscopy (defined by endoscopy within 6 hours from first consultation by GI specialists at PWH) or~2. Early endoscopy (defined by endoscopy next morning and within 24 hours from first consultation by GI specialists at PWH)"||||
33933467|NCT00141206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933468|NCT06398665|NA|SINGLE_GROUP||TREATMENT||NONE||This open-label pilot study aims to investigate the potential of a non-invasive brain stimulation technique, accelerated intermittent theta-burst stimulation (iTBS) repetitive transcranial magnetic stimulation (rTMS), for treating post- concussive syndrome (PCS) in persons with mild traumatic brain injury (mTBI).||||
33933469|NCT06096389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, controlled trial|t|f|t|f
33933470|NCT01537523|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33933471|NCT01501162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933472|NCT05822960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The dialysis day was W 1.3.5 as the control group and W 2.4.6 as the experimental group.||||
33933473|NCT01171742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933474|NCT00164567|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33933475|NCT00424840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933476|NCT02333136|||CASE_ONLY||PROSPECTIVE|||||||
33933477|NCT00102804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933478|NCT06367049|||CASE_CONTROL||PROSPECTIVE|||||||
33933479|NCT01153568|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933480|NCT00967876|||COHORT||PROSPECTIVE|||||||
33933481|NCT04655690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33933482|NCT04255368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, controlled crossover design where participants consume 3 meals containing (i) free choline; (ii) phosphatidylcholine; or (iii) no choline in a random order separated by a 1-week washout period|t|f|f|t
33933483|NCT01432938|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933484|NCT04490265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33933485|NCT00189436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933486|NCT00928304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011698|NCT03441295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Also the treating physiotherapist is blinded to the treatment the participant received.|Study 1 comparing Ligamys (DIS) and Internal Bracing (N=48). Study 2 comparing Internal Bracing and ACL Reconstruction (N=48).|t|f|f|f
34011699|NCT05636995|||COHORT||PROSPECTIVE|||||||
34011700|NCT03083626|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34011701|NCT02694549|NA|SINGLE_GROUP||OTHER||||||||
34011702|NCT00921037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095095|NCT04373070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We will perform a 2:1 randomised, two-arm, single (assessor)-blind, monocentric trial.|f|f|f|t
33933487|NCT01921699|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933488|NCT02209168|||COHORT||PROSPECTIVE|||||||
33933489|NCT00442130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933490|NCT02628899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933491|NCT04929691|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will occur in 4 stages: 1) Convene a Steering Committee of key stakeholders and recruit implementation sites; 2) Use the integrated Promoting Action on Research Implementation in Health Services (i-PARiHS) framework to guide a needs assessment of treatment centers' capacity to use high-flow oxygen therapy to treat COVID-19 patients, and utilize the findings to develop an implementation strategy for use of CPAP/ O2 helmet solution; 3) Build infrastructure to support training and data monitoring processes and to develop implementation protocols to evaluate the adaptability of the strategy for the use of the CPAP/O2 helmet; and 4) Train health workers, distribute a CPAP/O2 helmet solution for non-invasive ventilation, pilot test the implementation strategy, and assess feasibility of its use and acceptability that includes monitoring altered risk of SARS-CoV-2 infection among healthcare workers.||||
33933492|NCT00732238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095096|NCT02755090|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34095097|NCT02342951|NA|SINGLE_GROUP||SCREENING||NONE||||||
34095098|NCT00323544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095099|NCT05847400|||COHORT||CROSS_SECTIONAL|||||||
34095100|NCT04915300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled study|t|f|t|f
34095101|NCT00729001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34095102|NCT05332795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791694|NCT01850017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791695|NCT06554548|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791696|NCT06248788|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34011703|NCT03547726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physician will not know if the patient is receiving at home physical therapy or seeing a physical therapist in clinic.|There will be two groups of patients randomized either to receive formal physical therapy in clinic or a self-led at home rehabilitation regimen.|f|t|t|f
33791697|NCT02321813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791698|NCT05329454|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open label, randomized, single and multiple-dose, test-versus-reference drug, fed-versus-fasted, 3-way crossover study.||||
34011704|NCT02417194|||COHORT||PROSPECTIVE|||||||
34011705|NCT03044236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011706|NCT04792879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011707|NCT00166764|||DEFINED_POPULATION||OTHER|||||||
34011708|NCT05841147|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinding all personnel who may interfere with the trial results, such as Participant, Care Provider, Investigator and Outcomes Assessor|"The intervention group: An intravenous bolus (6µg/kg) over a 3 min period and a maintenance dose of 0.1µg/kg/min for 18 hour were used in this group.~The control group: The same dose of normal saline was used instead of tirofiban."|t|t|t|t
34011709|NCT02747004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011710|NCT00556101|||||PROSPECTIVE|||||||
34011711|NCT03335579|||COHORT||RETROSPECTIVE|||||||
34011712|NCT05123729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011713|NCT05602402|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Sealed envelop, double-blind randomized|CAEP-01, Placebo Dose: 44 mg/day Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)|t|f|t|f
34011714|NCT05918757|RANDOMIZED|PARALLEL||OTHER||NONE||Within 48 hours, intensive care patients on expected invasive mechanical ventilation of at least three days are allocated into two groups receiving enteral/parenteral nutrition with 1.5 g of protein/kg/day or 1.0 g of protein/kg/day as an active comparator.||||
34011715|NCT02303886|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34095103|NCT04114370|NA|SINGLE_GROUP||OTHER||NONE||||||
34095104|NCT01746160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|open label|||||
34095105|NCT04928586|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791699|NCT02667535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011716|NCT04208269|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011717|NCT04577885|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011718|NCT01980342|NA|SINGLE_GROUP||OTHER||NONE||||||
34011719|NCT03710590|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the power level and nicotine concentration used in each session.|The purpose of this study is to determine differences in nicotine delivery, use behavior (puff topography), carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers and experienced electronic cigarette users use an electronic cigarette with different settings (different voltage and resistance settings, which together determine power levels) and different e-liquid concentrations.|t|f|f|f
34011720|NCT03752554|||OTHER||PROSPECTIVE|||||||
34011721|NCT01969474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011722|NCT03684031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095106|NCT01182584|||COHORT||PROSPECTIVE|||||||
34095107|NCT01609140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095108|NCT00372320||||TREATMENT||||||||
34095109|NCT02569983|||COHORT||PROSPECTIVE|||||||
34095110|NCT05313464|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34095111|NCT06431958|||CASE_ONLY||RETROSPECTIVE|||||||
34095112|NCT02499315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095113|NCT04777903|||CASE_CONTROL||PROSPECTIVE|||||||
34095114|NCT03770975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095115|NCT05954689|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34095116|NCT03642054|||OTHER||PROSPECTIVE|||||||
34011723|NCT00517543|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709312|NCT04535700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709313|NCT02427893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709314|NCT05056545|RANDOMIZED|PARALLEL||PREVENTION||NONE||This step-wedge clinical trial will train all nurse/midwives working in antenatal care (ANC), labor and delivery (L\&D), infant vaccination (IV), or postpartum services at one of the study facilities in PPFP promotions or provision. The study team will train 'Happy Clients' (postpartum women who received promotions and selected a PPFP method) and community health workers affiliated with the intervention facilities as PPFP promotional agents. Women eligible for PPFP services in this study will be at any stage of pregnancy or up to 14 weeks postpartum, and receiving ANC, L\&D, IV, or postpartum services at one of the intervention facilities.||||
33709315|NCT00044278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709316|NCT04977752|||COHORT||RETROSPECTIVE|||||||
33709317|NCT04664062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709318|NCT01063452|RANDOMIZED|PARALLEL||||NONE||||||
33709319|NCT03311724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709320|NCT02607033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709321|NCT04736836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709322|NCT06410612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|patients will not know which group they are in|patients will be randomized into 2 groups.|t|f|f|f
33709323|NCT03810560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709324|NCT00356473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709325|NCT02873000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709326|NCT05364125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomly assigned by computer into treatment group and control group||f|f|t|f
33709327|NCT02649998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709328|NCT02223832|NA|SINGLE_GROUP||||NONE||||||
33709329|NCT00536562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709330|NCT02139631|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33709331|NCT01297660|||CASE_ONLY||RETROSPECTIVE|||||||
33709332|NCT02711397|||CASE_CONTROL||PROSPECTIVE|||||||
33709333|NCT03899571|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709334|NCT04971408|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||passive heat stress with water perfused heat suits and electrical heating blankets||||
33709335|NCT00164775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709336|NCT03206528|||COHORT||PROSPECTIVE|||||||
33709337|NCT04382339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709338|NCT02092493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709339|NCT04589078|||COHORT||PROSPECTIVE|||||||
33709340|NCT05836246|||OTHER||PROSPECTIVE|||||||
33933493|NCT01505140|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33933494|NCT04889755|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Parent Pre-session: Webinar on Supporting Siblings Session 1 (Sibling Group): Program Introduction Session 2 (Sibling Group): Understanding Emotions Session 3 (Sibling Group): Adaptive Thinking Session 4 (Sibling Group): Sitting with Emotions Session 5 (Sibling Group): Avoidance vs. Sitting with Emotions Sessions 6 (Sibling Individual): Telling Your Story Session 7 (Sibling Group): Keeping up with Skills Session 8 (Parent Individual): Parent/caregiver Check-In Session 9 (Sibling Group): Wrap-Up||||
33933495|NCT03675919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|f|f|f|t
33933496|NCT06105372|||OTHER||CROSS_SECTIONAL|||||||
33933497|NCT00026975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933498|NCT03766113|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33933499|NCT01880203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933500|NCT03022604|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33933501|NCT01163695|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33933502|NCT01387594|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933503|NCT02406339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33933504|NCT00039091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933505|NCT01525420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933506|NCT02365506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011724|NCT00017394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709341|NCT04051073|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Before-and-after|f|f|f|t
33709342|NCT02932670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33709343|NCT02598544|NON_RANDOMIZED|PARALLEL||||NONE||||||
33709344|NCT04762784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709345|NCT02461498|||COHORT||PROSPECTIVE|||||||
33709346|NCT04397224|||COHORT||PROSPECTIVE|||||||
33709347|NCT02087605|||COHORT||PROSPECTIVE|||||||
33709348|NCT04603690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot, randomized, controlled, open-label and pragmatic trial, comparing the treatment benefits of combination of curcumin, quercetin and vitamin D3 supplements as add-on to standard treatment vs. standard therapy, in mild to moderate symptomatic COVID-19 outpatients, within 48 hours, for testing Positive for SARS-CoV-2.||||
33709349|NCT00764738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709350|NCT05955105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709351|NCT00739791||||TREATMENT||||||||
33709352|NCT05117437|||COHORT||CROSS_SECTIONAL|||||||
33709353|NCT03167411|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933507|NCT04223206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933508|NCT01801774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933509|NCT02158195|||CASE_CONTROL||PROSPECTIVE|||||||
33933510|NCT04927351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2 arm parallel, cluster-randomized trial||||
33933511|NCT05409092|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Investigators and study participants will be blind to treatment allocation, with the astaxanthin and placebo supplements contained in identical looking capsules.|Randomized treatment, double blinded procedures, crossover|t|f|t|f
33933512|NCT00005577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933513|NCT03012360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933514|NCT01268514|||OTHER||PROSPECTIVE|||||||
33933515|NCT02616536|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33709354|NCT00629707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709355|NCT05175872|||COHORT||PROSPECTIVE|||||||
33709356|NCT02144012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709357|NCT06340373|||COHORT||CROSS_SECTIONAL|||||||
33709358|NCT01745133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33709359|NCT03660540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33709360|NCT03174834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709361|NCT05683769|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33709362|NCT04725461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709363|NCT00745823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709364|NCT04388202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709365|NCT02482285|||COHORT||PROSPECTIVE|||||||
33709366|NCT02389361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33709367|NCT03881566|||COHORT||PROSPECTIVE|||||||
33791700|NCT02311907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33791701|NCT00620217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933516|NCT00428103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933517|NCT01877005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933518|NCT03135262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933519|NCT04524091|||COHORT||PROSPECTIVE|||||||
33933520|NCT03386006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933521|NCT04329559|||COHORT||CROSS_SECTIONAL|||||||
33933522|NCT00911066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933523|NCT05935475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomly assigned using an internet-based computer program (http://www.randomizer.org) either to the anatomical landmark group or to the ECG group|"150 children and adolescents with end stage renal disease or any cause for urgent hemodialysis at our nephrology Unit at TUH during the period of the study and classified into two equal groups: Group A (control): insertion of dialysis catheter using the anatomical landmark-guided technique.~Group B: insertion of dialysis catheter using the ECG-guided technique."|t|f|f|t
33933524|NCT05596474|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33933525|NCT02256345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933526|NCT03399786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933527|NCT05789914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933528|NCT00654368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933529|NCT05810376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933530|NCT03238079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933531|NCT02280096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933532|NCT04570228|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Subjects will be randomized 2:1 with a sham controlled arm, with subjects and all follow up staff blinded to the subject treatment. Subjects will be unblinded at 6M, and sham control group will be offered treatment at this time if they meet the inclusion/ exclusion criteria. The primary effectiveness endpoint is measured at 6 months. The safety endpoint for blinded patients is at 6 months, and for treated patients again at 12 months.|t|t|t|t
33933533|NCT00820313|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33933534|NCT05746000|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933535|NCT03692312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933536|NCT02763267|||COHORT||PROSPECTIVE|||||||
33933537|NCT00467948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33709368|NCT00005045||||TREATMENT||||||||
33709369|NCT01050712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709370|NCT00133952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709371|NCT04510584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709372|NCT06392620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709373|NCT02723214|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33709374|NCT06485765|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This clinical trial is a single-group, pre-post design. In this model, quality of life and cardiac parameters were assessed before and after individualised DASH diet.||||
33933538|NCT00935324|||COHORT||PROSPECTIVE|||||||
33709375|NCT06498154|NA|SINGLE_GROUP||TREATMENT||NONE|Masking Description|Chemotherapy combined with radiotherapy||||
33709376|NCT04789460|||COHORT||RETROSPECTIVE|||||||
33709377|NCT01651247|||||RETROSPECTIVE|||||||
33720586|NCT04990414|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
33791702|NCT04633980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791703|NCT06211829|||COHORT||RETROSPECTIVE|||||||
33791704|NCT03835390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791705|NCT05823350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental - Randomised Controlled||||
33791706|NCT03448757|NA|SINGLE_GROUP||TREATMENT||NONE||measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure||||
33933539|NCT05607160|||COHORT||PROSPECTIVE|||||||
33933540|NCT03810053|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33933541|NCT05168436|||COHORT||CROSS_SECTIONAL|||||||
33933542|NCT01381809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933543|NCT02289521|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33933544|NCT00979472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933545|NCT05458869|||CASE_ONLY||PROSPECTIVE|||||||
33709378|NCT03645798|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"A randomized, controlled trial was conducted for 73 nurses from The Second Xiangya Hospitcal of Central South University (33 in the experimental group, 40 in the control group). The experimental group received a Wechat-based six-month three good things positive psychotherapy from August 2015 to January 2016, while the control group only received normal psychological instruction from the hospital."|f|f|t|f
33709379|NCT04165200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither patients, nor investigators are allowed to know about which group of patients is going to receive placebo and which one faecal microbiota capsules. The laboratory that provide us the capsules is going to divide and randomize our sample of patients, and also register the information in a data base.|Prospective controlled study experimental comparative|t|t|t|f
33709380|NCT05780918|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"Stepped wedge cluster randomized trial, sites randomized to start time.~The intervention will be administered as a quality improvement activity because its primary purpose is to increase behaviors recommended by professional societies, e.g., timely communication with families and emotional support."||||
33709381|NCT03072147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Researchers, providers, and subjects will be blinded to treatment group so that outcomes will not be influenced by expectations about the experimental treatment.|This is a prospective, randomized, placebo controlled, double blinded study. Interim results will determine if there is a crossover.|t|t|t|t
33709382|NCT02337660|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709383|NCT04565106|||COHORT||PROSPECTIVE|||||||
33709384|NCT03951571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709385|NCT03012165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709386|NCT01375556|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33709387|NCT03402568|||COHORT||CROSS_SECTIONAL|||||||
33709388|NCT04339439|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients who agree to participate will be enrolled and randomized to one of two study groups:~* Group 1: Incision closure without a vessel loop.~* Group 2: Incision closure with a vessel loop."||||
33709389|NCT05884905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709390|NCT05012488|||COHORT||CROSS_SECTIONAL|||||||
33709391|NCT02574468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709392|NCT03987217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709393|NCT00517998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709394|NCT05395715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind randomized controlled study|t|f|t|f
33709395|NCT00255398|||COHORT||PROSPECTIVE|||||||
33709396|NCT04866225|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33791707|NCT02040935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791708|NCT04256876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are blinded for the given treatment ( Active TTNS vs. Sham TTNS) by the care provider ( Physiotherapist).~The outcomes assessor (the pediatric urologist) isn't aware of the treatment neither."|"Prospective randomized-controlled superiority trial:~TTNS(Active treatment) vs. Sham TTNS (placebo)"|t|f|f|t
33791709|NCT00194623|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33791710|NCT01844141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791711|NCT03551067|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33791712|NCT00148291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791713|NCT06237868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791714|NCT01429233|||||PROSPECTIVE|||||||
33791715|NCT00234442|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791716|NCT03812952|||OTHER||RETROSPECTIVE|||||||
33791717|NCT03008915|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33791718|NCT05356819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791719|NCT00440973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791720|NCT02854761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791721|NCT04710017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791722|NCT03940417|||COHORT||PROSPECTIVE|||||||
33791723|NCT04250285|||OTHER||CROSS_SECTIONAL|||||||
33791724|NCT02131324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791725|NCT00130741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791726|NCT02049697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791727|NCT02390258|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33791728|NCT04333589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791729|NCT05154955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791730|NCT03750942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled trial|t|f|f|f
33791731|NCT01913119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791732|NCT01738802|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33791733|NCT01421654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791734|NCT02813252|||COHORT||PROSPECTIVE|||||||
33791735|NCT00681252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791736|NCT00432458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791737|NCT03869918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A pilot randomized comparative effectiveness trial of integrated exercise and urge suppression versus usual care in older women with UUI.||||
33791738|NCT03163186|||COHORT||PROSPECTIVE|||||||
33791739|NCT03441763|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791740|NCT02674646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33791741|NCT02864628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791742|NCT04731051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791743|NCT03068858|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33791744|NCT02187900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791745|NCT03187782|||CASE_ONLY||CROSS_SECTIONAL|||||||
33791746|NCT05633368|||COHORT||PROSPECTIVE|||||||
33791747|NCT02734628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933546|NCT05759104|||COHORT||RETROSPECTIVE|||||||
33933547|NCT02773472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933548|NCT05832060|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33933549|NCT03780088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933550|NCT00187044|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33933551|NCT00050336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33709397|NCT00415831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791748|NCT05498363|||CASE_ONLY||RETROSPECTIVE|||||||
33791749|NCT01977404|||COHORT||PROSPECTIVE|||||||
33791750|NCT04643236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A total of 50 sealed envelopes were prepared in which the group names were written. Following, they were separated in two plastic boxes equally. The group of each participant was recorded by the first author whom the educational intervention was performed (SG). The examiner who performed the clinical process (BM) was unaware of the groups|A Single-Centre, Randomised, Parallel Design Controlled Clinical Study|f|f|t|t
33791751|NCT03140735|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791752|NCT05739929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791753|NCT05257798|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33791754|NCT04652817|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33791755|NCT00579189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791756|NCT02433795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791757|NCT02090062|||CASE_ONLY||PROSPECTIVE|||||||
33791758|NCT02665130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791759|NCT01998555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791760|NCT05037344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791761|NCT06002542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||open-label randomized control trial||||
33791762|NCT00296907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33791763|NCT05729451|||COHORT||PROSPECTIVE|||||||
33791764|NCT01505101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791765|NCT04538755|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33791766|NCT02982265|||COHORT||OTHER|||||||
33791767|NCT00703625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791768|NCT05427058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Participant and Investigator masking:~The random order of the groups will be written on paper and hidden by using a sealed envelope with consecutive numbers. This envelope will be retained by personnel who are not involved in the care or evaluation of the patient, or the analysis of the data.~During the action, doctors and nurses are prohibited from communicating with participants regarding the actions given.~Outcomes assessor masking:~All data collection will be carried out by residents as research assistants who are trained for data collection. The assistant was not told what intervention was given to the patient, data collection was done directly by asking the patient without looking at the patient's status. The data that has been collected will be entered and processed by personnel outside the research team to ensure blinding."|"Patients were assigned to two groups.~Group 1: Patients with pelvic floor pain due to cervical and endometrial cancer who were treated with superior hypogastric plexus block.~Group 2: Patients with pelvic floor pain due to cervical and endometrial cancer who were given ganglion impar block."|t|f|t|t
33791769|NCT00298649|RANDOMIZED|PARALLEL||||NONE||||||
33709398|NCT04441814|||COHORT||RETROSPECTIVE|||||||
33791770|NCT05046132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791771|NCT03892954|||COHORT||CROSS_SECTIONAL|||||||
33791772|NCT01393119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791773|NCT04852432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33791774|NCT03390569|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791775|NCT06015581|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Stepped Wedged Design with a second randomization|f|f|f|t
33709399|NCT05984966|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33709400|NCT06268002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study was a multicenter randomized, paralleled, double-blind, controlled trial at 5 hospitals and 2 community pharmacies in Thailand|t|t|t|f
33791776|NCT01181375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791777|NCT01802632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791778|NCT05014516|||COHORT||PROSPECTIVE|||||||
33791779|NCT02248025|||COHORT||PROSPECTIVE|||||||
33791780|NCT03590288|||COHORT||PROSPECTIVE|||||||
33791781|NCT01555684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791782|NCT01597154|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791783|NCT02485236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791784|NCT05596630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933552|NCT05265936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933553|NCT00432354|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933554|NCT01756833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709401|NCT05780385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709402|NCT04841460|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participant identities were coded and treatments were blinded.|The study design is a two-period, randomized crossover design.|t|t|f|t
33709403|NCT05944757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Both models participated in this study.Models aged were from 20 up to 70|t|t|t|t
33709404|NCT06506331|||COHORT||RETROSPECTIVE|||||||
33709405|NCT05662631|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33709406|NCT04189081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720587|NCT05482633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent assessor who is unaware of the group of participants going to perform all evaluations.||f|f|f|t
33720588|NCT02223273|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33720589|NCT00494832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720590|NCT05479682|||COHORT||CROSS_SECTIONAL|||||||
33720591|NCT00350636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791785|NCT04069182|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients will be assigned to the treatment.||||
33709407|NCT03506282|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The participants and the research assistant operator who will deliver the experimental conditions will not be masked to the condition whilst the outcome assessor, the statistician and the principal investigator will be blinded.|"The experimental conditions to be tested in each subject will be: 0, running with no music; 1, running and listening to audio track resembling normal outdoor noise (70 dB); 2, running with music at moderate volume (80 dB); 3, running with music at moderate to high volume (85 dB). The experimental conditions will be carried out in random order, with a wash-out period of 10 minutes, to ensure the return to the auditory and vestibular baseline.~Depending on the random sequence generated, the subject will undergo the four conditions in the specified order. Each condition will be completed with the three steps lasting 2 mins each (A, running at 6 km/h; B, running at 8 km/h; C, running at 10 km/h) and carried out at 1-min time interval in between, before proceeding to the next one. A complete rest of 10 minutes will be allowed among the conditions to restore the physiological state of the auditory and vestibular systems and to recover from the submaximal running effort."|f|f|t|t
33709408|NCT06506149|NA|SINGLE_GROUP||TREATMENT||NONE||Consecutive patients with relapsed Graves' disease will be considered for microwave ablation treatment||||
33791786|NCT00562679|||COHORT||PROSPECTIVE|||||||
33791787|NCT05875350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791788|NCT03145246|||OTHER||RETROSPECTIVE|||||||
33791789|NCT04672772|||CASE_ONLY||RETROSPECTIVE|||||||
33791790|NCT03781206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791791|NCT05879588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33791792|NCT00384436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791793|NCT05924438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791794|NCT03768856|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791795|NCT04401358|||OTHER||PROSPECTIVE|||||||
33791796|NCT05135013|||CASE_CONTROL||RETROSPECTIVE|||||||
33791797|NCT06674122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33791798|NCT02194933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33791799|NCT06313125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluator researcher and participants will be blinded to group allocation.|There will be three groups in the study. Short-foot exercise for the control group; short-foot and 3-dimensional foot-ankle exercise for the foot-ankle group; short-foot and clam exercise will be applied for the hip group.|t|f|f|t
33791800|NCT04126330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||proof-of-concept, randomized double-blinded placebo-controlled parallel study|t|t|t|t
33933555|NCT05565794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933556|NCT03180021|||CASE_CONTROL||PROSPECTIVE|||||||
33933557|NCT02237365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933558|NCT04533516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33933559|NCT02897154|||OTHER||PROSPECTIVE|||||||
33933560|NCT05519124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709409|NCT05132387|||COHORT||PROSPECTIVE|||||||
33709410|NCT03902288|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A Patient with type 2 diabetes ( \< 15.8 FSG) and healthy individual ingested fresh pomegranate at 1.5 mL per kg of body weight after approximately 12 hours fasting. Blood samples were collected before (- 5 min) and after 1 and 3 hours of ingesting pomegranate juice.||||
33709411|NCT04460404|||CASE_ONLY||PROSPECTIVE|||||||
33709412|NCT05743569|||CASE_ONLY||PROSPECTIVE|||||||
33791801|NCT04090762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33791802|NCT05632731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933561|NCT00176072|||DEFINED_POPULATION||OTHER|||||||
33933562|NCT04402385|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33933563|NCT00233181|RANDOMIZED|||TREATMENT||||||||
34011725|NCT06598293|||CASE_CONTROL||PROSPECTIVE|||||||
34011726|NCT00604903|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No masking|||||
34011727|NCT04496128|||COHORT||PROSPECTIVE|||||||
33791803|NCT01927952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791804|NCT00341523|||COHORT||CROSS_SECTIONAL|||||||
33933564|NCT06503133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participant blinding is planned to prevent bias in the research. At the beginning of the study, all participants will be informed that prenatal yoga-supported online birth preparation training will be applied, but the start times of prenatal yoga practice may vary depending on the groups to which they will be randomly assigned, and they will be assigned to the experimental and control groups by randomization by an independent researcher. After the final measurements are taken, the participants in the control group will also undergo prenatal yoga practice. In addition, the independent researcher will make the post-test measurements. Data collected by the independent researcher will be ambiguously coded as A and B. The data will be analyzed and reported by an independent statistician. The groups will be unclear during the analysis and reporting phase.|The research is a single-centre parallel randomized controlled experimental study.|t|f|f|t
33933565|NCT01401101|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33933566|NCT04403841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933567|NCT06263725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933568|NCT00748332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933569|NCT01112904|||COHORT||PROSPECTIVE|||||||
33933570|NCT00982748|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33933571|NCT02868151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33933572|NCT00246285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933573|NCT06335160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933574|NCT04135664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933575|NCT01128452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933576|NCT01876472|||COHORT||PROSPECTIVE|||||||
33933577|NCT00179998|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33933578|NCT05316350|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933579|NCT05049642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will either be randomized to group 1 (instillation of 1 drop of C-NAC) or group 2 (no instillation of C-NAC) in a 1:1 fashion.||||
34011728|NCT02021253|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34011729|NCT04415684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011730|NCT04289454|NA|SINGLE_GROUP||OTHER||NONE|"Samples presented will not be identified (there will be no codes or visual cues regarding whether a model drink does or does not contain a flavor modifier). However, true blinding is impossible since flavor will differ between samples.~Investigators will not be blind to sample contents. However, responses will be collected and recorded using an automated computer program, which offers some protection against possible experimenter bias."|Within-subjects design (the same group of subjects will taste model KE drinks with vs. without added flavors), with order counter-balanced.||||
34011731|NCT00606502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011732|NCT02116517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095117|NCT04705571|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible subjects will receive 1 treatment with the MorpheusV Applicator according to the study protocol.||||
34095118|NCT03461861|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||This is a randomized, double-blind, placebo-controlled crossover study in which a low dose of AGB101 (220mg QD) or placebo will be administered to 50 healthy 55-75-year-old subjects, with the order of treatments counterbalanced in a within-subject crossover design.|t|t|t|t
34095119|NCT00696150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34095120|NCT00327171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095121|NCT01215812|||CASE_ONLY||RETROSPECTIVE|||||||
34095122|NCT00139035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095123|NCT00993889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34095124|NCT03821532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Packet of information containing Standard of Care education materials and {Action Plan or No Action Plan} are prepared prior to enrollment; all participants get unlabeled packet without prior knowledge of participant or investigator or care provider.|Control group (standard of care) compared to Intervention group (standard of care plus constipation action plan)|t|t|t|f
34095125|NCT02112175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095126|NCT02643784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709413|NCT02485600|||COHORT||PROSPECTIVE|||||||
33709414|NCT06504641|||CASE_ONLY||PROSPECTIVE|||||||
33709415|NCT00600652|||||PROSPECTIVE|||||||
33709416|NCT04380116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709417|NCT00980057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709418|NCT01731990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709419|NCT04119921|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33709420|NCT00057317|RANDOMIZED|||TREATMENT||DOUBLE||||||
33709421|NCT02418702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709422|NCT00612365|||COHORT||RETROSPECTIVE|||||||
33709423|NCT00640991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791805|NCT01720563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791806|NCT00003900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933580|NCT00636155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933581|NCT00978133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933582|NCT05394181|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33933583|NCT02652546|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33933584|NCT04574765|||COHORT||PROSPECTIVE|||||||
33933585|NCT03045640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933586|NCT02283840|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33933587|NCT03518580|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33933588|NCT01149525|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33933589|NCT04245657|||COHORT||CROSS_SECTIONAL|||||||
34095127|NCT03632447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments of pelvic floor muscle function accomplished by testing at baseline, 4-weeks (mid-study) and 8-weeks will be performed by blinded assessor||f|f|f|t
33791807|NCT05079269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized intervention cohort study of two preoperative fluid management strategies|t|t|f|f
33791808|NCT00800904|||||RETROSPECTIVE|||||||
33709424|NCT02044016|||COHORT||PROSPECTIVE|||||||
33709425|NCT01157260|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791809|NCT01141322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791810|NCT02241668|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709426|NCT05317832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All participants will be provided with the same WI program and mobile health technology. Furthermore, the participants in the WI + JITAI arm will receive randomized prompts of various types of tailored feedback and physical activity recommendations.|The proposed study is a 24-week longitudinal study that will comprise of 2 weeks of baseline physical activity monitoring, 14 weeks of physical activity monitoring and intervention, and 8 weeks of physical activity monitoring to assess physical activity level sustainability. Individuals with SCI will be randomized to a web-based physical activity intervention (WI) program or a WI program combined with the JITAI (WI + JITAI). Within the WI + JITAI arm, a micro-randomized trial - a clinical trial design for optimizing mobile-Health interventions - will be used to randomize participants several times a day to various types of tailored feedback and physical activity recommendations.|t|f|f|f
33709427|NCT02393170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791811|NCT05268042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a dietary intervention. As such, participants will likely know what diet prescription they are randomized to during the intervention. All investigators and individuals responsible for data analysis will be blinded to participant group assignment.|The objective of this parallel arm, randomized clinical trial is to use a 6-month family-based intervention with 2 phases, a 12-week controlled feeding and 12-week free-living phase, to examine the effects of weight maintaining, moderately carbohydrate-restricted vs fat-restricted diets in adolescents with NAFLD on depletion of hepatic lipid, improvement in hepatic insulin sensitivity, and changes in the plasma metabolome.|f|f|t|t
33791812|NCT00418912|||FAMILY_BASED||PROSPECTIVE|||||||
33933590|NCT02336880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933591|NCT00182234|RANDOMIZED|PARALLEL||||NONE||||||
33933592|NCT05566327|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|This is a health services intervention so the intervention and control group will know their allocation. The study team will know the allocation.|Randomized intervention trial|f|f|f|t
33933593|NCT01716949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933594|NCT00232050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933595|NCT01994278|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33933596|NCT03424616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Stagger-on design|t|t|t|t
33933597|NCT03395860|RANDOMIZED|PARALLEL||TREATMENT||NONE||drug: rATG drug: PTCy||||
33933598|NCT05654662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33933599|NCT00152841|RANDOMIZED|CROSSOVER||||NONE||||||
33933600|NCT01644019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933601|NCT01776502|||COHORT||PROSPECTIVE|||||||
33933602|NCT02861118|||COHORT||RETROSPECTIVE|||||||
33933603|NCT03745404|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Open-label enriched enrolment followed by double-blind treatment for 2 weeks.|"An enriched enrolment, randomized-withdrawal, parallel-group design was applied. Only participants responding to open-label active treatment were included into the Double-blind Phase.~The study comprised:~* A non-controlled, open-label enrichment phase with Lido-Patch treatment (Run-in Phase).~* A double-blind, randomized-withdrawal phase (Double-blind Phase).~* Upon request of the participant, treatment could be continued in the clinical study KF10004/02.~* A Follow-up Phase without treatment for participants not continuing in KF10004/02."|t|t|t|t
33933604|NCT00749528|||CASE_CONTROL||PROSPECTIVE|||||||
33933605|NCT05734404|||COHORT||PROSPECTIVE|||||||
33933606|NCT05544006|||CASE_CONTROL||PROSPECTIVE|||||||
33933607|NCT06404229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933608|NCT00446641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933609|NCT05068076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933610|NCT05590104|RANDOMIZED|PARALLEL||TREATMENT||NONE|The allocated groups will be concealed in serially-numbered sealed opaque envelops that was only opened just after recruitment. Women in any of the groups will receive the allocated treatment after their approval to participate in the study.|||||
33933611|NCT05049018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors who performed all assessments throughout the study were not involved in the intervention program. They were not informed about which group; each evaluated patient was belong (blind assessors).||f|f|f|t
33933612|NCT00576147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933613|NCT01924195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933614|NCT05480631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011733|NCT02979457|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34011734|NCT04321798|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34011735|NCT00986453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011736|NCT05279508|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator and assessor are blinded to randomization||f|f|t|t
34011737|NCT01189500|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011738|NCT01996059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011739|NCT00645424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011740|NCT02904668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011741|NCT01476228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011742|NCT02521818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011743|NCT01345526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Randomized Phase II Trial assessing the prevention of acne like Skin rash|Randomized Phase II trial|t|t|t|t
33933615|NCT01352767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933616|NCT00090766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011744|NCT05082363|||OTHER||CROSS_SECTIONAL|||||||
34011745|NCT06085573|||COHORT||PROSPECTIVE|||||||
34011746|NCT03939988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the Placebo group, participants will receive the simulated application with the laser set off, only using the beep to play the application. Therefore, they not know to which group they belong.||t|f|f|f
34011747|NCT02335515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34011748|NCT02490306|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011749|NCT00591331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933617|NCT06145217|NA|SINGLE_GROUP||TREATMENT||NONE||An open-label, non-randomized, two-treatment, single-period, single dose, drug-drug interaction study, which allows for independent establishment of the true intrasubject variability for dasatinib||||
33933618|NCT00854061|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33933619|NCT04944758|NA|SINGLE_GROUP||PREVENTION||NONE||Open-label feasibility study||||
33933620|NCT01095328|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34095128|NCT04224051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933621|NCT02209259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095129|NCT03465605|||COHORT||PROSPECTIVE|||||||
34095130|NCT06373939|NA|SINGLE_GROUP||OTHER||NONE||This single center, open, non-controlled investigation will be conducted at one site; the University Hospitals of Geneva, Switzerland. This will be a non-inferiority study between Pneumoscope and CE marked comparable medical devices in children and adults.||||
34011750|NCT01017419|||COHORT||PROSPECTIVE|||||||
34011751|NCT03180801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011752|NCT04569513|||COHORT||RETROSPECTIVE|||||||
34011753|NCT00619359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34011754|NCT03517254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011755|NCT00773682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011756|NCT01168570|||CASE_CONTROL||PROSPECTIVE|||||||
34011757|NCT06616207|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The manufacturer of Povi-One will provide the placebo. The products will be identical in appearance. Povi-One and placebo will be supplied every 6 months and stored at room temperature in locked storage in the orthodontics clinic. Povi-One and placebo will be delivered to the clinic site by the manufacturer marked with the different treatment codes. The study biostatistician will assign the codes and keep the key. The manufacturer will retain treatment codes until after analysis.|In triple blind parallel interventional study model, two or more groups of participants are treated simultaneously but separately, with an intervention group (10% povidone-iodine) and placebo (double distilled water colored to match the Povidone-Iodine solution in color and taste)and will be randomly assigned at the recruitment. The researchers compare the results between the groups to see if the intervention has a preventive effect. All three parties, participants, researcher, and data analyst are unaware of who is receiving which treatment between intervention and placebo to produce the most unbiased and reliable results.|t|t|t|t
34011758|NCT05557903|NA|SEQUENTIAL||TREATMENT||NONE||||||
34011759|NCT00002360|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011760|NCT05171959|||COHORT||PROSPECTIVE|||||||
34011761|NCT04825041|||COHORT||PROSPECTIVE|||||||
34011762|NCT01477814|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33933622|NCT05705206|||CASE_CONTROL||PROSPECTIVE|||||||
33709428|NCT00698698|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933623|NCT03955120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933624|NCT01968304|NA|SINGLE_GROUP||||NONE||||||
33933625|NCT02481791|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33933626|NCT01045551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933627|NCT00914719||FACTORIAL||PREVENTION||||||||
33933628|NCT00848289|||OTHER||PROSPECTIVE|||||||
33933629|NCT00992914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33933630|NCT06507215|||OTHER||PROSPECTIVE|||||||
33709429|NCT05315544|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33709430|NCT03641430|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709431|NCT06244732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709432|NCT06534554|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33709433|NCT01087138|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709434|NCT02139332|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33709435|NCT04357132|RANDOMIZED|PARALLEL||OTHER||NONE||60 participants assigned to one of two groups. VR- Distraction and VR-Biofeedback||||
33709436|NCT03663816|NA|SINGLE_GROUP||OTHER||NONE||||||
33709437|NCT05015465|||COHORT||PROSPECTIVE|||||||
33933631|NCT04451304|||COHORT||PROSPECTIVE|||||||
33933632|NCT00679380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933633|NCT01724775|||COHORT||PROSPECTIVE|||||||
34011763|NCT03456024|||COHORT||PROSPECTIVE|||||||
34011764|NCT04683237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933634|NCT00896350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933635|NCT04506879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933636|NCT01126567|||COHORT||PROSPECTIVE|||||||
33933637|NCT06113172|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933638|NCT03600220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933639|NCT04185662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709438|NCT02168634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709439|NCT01525810|||COHORT||PROSPECTIVE|||||||
33791813|NCT00168662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791814|NCT01405924|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33791815|NCT03040661|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791816|NCT04375449|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||The study will be performed as a multicentric, randomized, double-blind, and placebo-controlled in a 3-way cross-over design.|t|t|t|t
33791817|NCT01456819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791818|NCT02104648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791819|NCT05319288|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33791820|NCT00319436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791821|NCT02018224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791822|NCT03397381|||COHORT||PROSPECTIVE|||||||
33933640|NCT01966991|||COHORT||PROSPECTIVE|||||||
33791823|NCT03937843|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, open label phase II trial with two cohorts||||
33709440|NCT02285803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33791824|NCT04247204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791825|NCT05795946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The labels for the vitamins will only have the participant ID on them|"3 groups: 1 for B vitamins only, 1 with B vitamins in addition of D vitamins, and one is diet only.~This pilot study aims to explore the modulation of TMAO response in healthy adults after supplementation with a whole food matrix-based B vitamins formulation alone, and in combination with vitamin D. The assessments will be compared to the diet only control group."|t|t|f|f
33791826|NCT01510912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791827|NCT06077019|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33933641|NCT00764608|||CASE_ONLY||PROSPECTIVE|||||||
33933642|NCT00071214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33933643|NCT00731952|NA|SINGLE_GROUP||OTHER||NONE||||||
33933644|NCT01228149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933645|NCT02283372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709441|NCT03000140|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33709442|NCT01558271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709443|NCT04976660|NA|SEQUENTIAL||TREATMENT||NONE||3+3 Design||||
33709444|NCT04804969|||COHORT||PROSPECTIVE|||||||
33801829|NCT04508972|||COHORT||PROSPECTIVE|||||||
33933646|NCT02206191|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933647|NCT00122070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933648|NCT02339376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933649|NCT03860844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933650|NCT04146402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933651|NCT03749668|||COHORT||PROSPECTIVE|||||||
33933652|NCT01384188|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33933653|NCT02675595|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933654|NCT03931889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933655|NCT03285490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All Central Vendors and the sponsor were masked. The sponsor was unblind at the end of Day 57.|This study tested KX2-391 Ointment 1% against a placebo.|t|t|t|t
33933656|NCT05616052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709445|NCT04444102|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and yoga-based stretching instructor are not blinded. Nurses and lab technicians are blinded during blood draws. Laboratory analysts are blinded during sample analyses. Statisticians will be unblinded once all laboratory analyses are completed.|The present study is a pilot randomized clinical trial (RCT) with 3 arms. These arms are: Control Group, Mild Stretching Group, and Intense Stretching Group. Ten participants will be allocated in each arm.|f|f|t|t
33709446|NCT00306215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720592|NCT02631850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933657|NCT04333875|||COHORT||PROSPECTIVE|||||||
33933658|NCT03502941|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"Arm 1 and 2: Crossover design for two different doses of the product (\~6.3 and 12.6 g of active components).~Arm 3: Parallel comparison equal to the double dose of whey protein isolate (12.6 g)"|t|f|f|t
34011765|NCT04740931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34011766|NCT05563181|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34011767|NCT04958122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011768|NCT03718741|NA|SINGLE_GROUP||TREATMENT||NONE||Adiuvant Radiotherapy +/- CT||||
34011769|NCT05423470|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34011770|NCT00374582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709447|NCT05371691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding to treatment allocation is possible only for the outcomes assessor because the clinicians could know the intervention. All the trial documents will be labeled with the study ID number, which be used for participant identification and data collection without unmasking the allocation group.||f|f|f|t
33709448|NCT00139698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709449|NCT04843293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||In this study, stratified sampling was used according to postmenstrual week (PW) and type of nutrition. In order to ensure homogeneity in the intervention and control groups, according to PW \[28-(33+6)\] and \[34-35+6)\], according to the type of nutrition \[mixed nutrition (breast milk + formula milk)\] and \[breast milk\] 4 layers were formed. Firstly, 56 preterm newborns were divided as random into intervention (group A) and control (group B). Groups A and B were stratified first to the PW, then according to the type of feeding. Permutation was also used to strike a balance between the strata. Block sets were generated for each combination of the prognostic factors (PW and type of nutrition). The intervention and control groups were then randomized into the strata using a random numbers table.|f|f|f|t
33709450|NCT02519036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709451|NCT02646072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33709452|NCT00915213|||COHORT||PROSPECTIVE|||||||
33709453|NCT02535988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709454|NCT02299830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709455|NCT03851705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33791828|NCT02577198|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33709456|NCT03060538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709457|NCT02349087|||COHORT||PROSPECTIVE|||||||
33709458|NCT03952104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessor Blinded||f|f|f|t
33709459|NCT05482724|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants who met the inclusion criteria and underwent thorough the baseline assessment were randomly allocated to the conditions of the intervention group and the wait-list control group. Participants in the wait-list group (WLC) received no phycological (public or private) intervention during the eight-week duration of the program. Children and parents in both groups would complete the same series of measures at about the same time (pre-test and after eight weeks). Children in WLC group will receive the intervention once the follow-up visit is completed.|f|f|f|t
33709460|NCT01408485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709461|NCT05687383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33709462|NCT01740947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791829|NCT01348191|||COHORT||PROSPECTIVE|||||||
33791830|NCT05884918|||CASE_CONTROL||PROSPECTIVE|||||||
33791831|NCT01940003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791832|NCT03206736|NA|SINGLE_GROUP||OTHER||NONE||||||
33801830|NCT05076942|NA|SINGLE_GROUP||TREATMENT||NONE||phase II treatment trial||||
33801831|NCT05003778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933659|NCT03037112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Providers will be randomly assigned to the education or communication skills intervention study arms. Both groups will receive identical training on the appropriate prescribing of antibiotics for ARTIs, but only those in the communication intervention will receive additional training on communication skills. Once providers have been randomized and trained, eligible patients will be enrolled and exposed to one of the interventions based on the provider they see for their visit. Patients will not be informed of their provider's study arm.||t|f|f|f
33933660|NCT01908855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933661|NCT04684160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933662|NCT03072368|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933663|NCT00003761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933664|NCT00338013|||||PROSPECTIVE|||||||
33933665|NCT00583830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933666|NCT01611662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933667|NCT00704392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933668|NCT06417398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933669|NCT00004056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933670|NCT02332798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933671|NCT02897258|||COHORT||RETROSPECTIVE|||||||
33933672|NCT05546749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933673|NCT00296166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933674|NCT00741767|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33933675|NCT03277794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933676|NCT03321890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933677|NCT00484367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933678|NCT02244658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933679|NCT03202368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933680|NCT06386536|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A single-subject reversal study design (A-B) will be used. During the A and B phases, the participants will undergo training with either the VI-TRIVEL or a conventional stationary bike.|f|f|f|t
33933681|NCT00834925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933682|NCT02718625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933683|NCT01259921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||EEG Biofeedback versus wait list control condition.|f|f|f|t
33933684|NCT05732597|||COHORT||RETROSPECTIVE|||||||
33933685|NCT00155467|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933686|NCT01522118|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34011771|NCT03716531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011772|NCT04984421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researchers and school personnel will not be blinded to group allocation, but parents and children will be blinded.|Cluster randomized controlled trial with a hybrid type 3 evaluation design|t|f|f|f
34011773|NCT03937349|||COHORT||PROSPECTIVE|||||||
34011774|NCT03138122|||COHORT||PROSPECTIVE|||||||
34011775|NCT00254020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011776|NCT02575508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095131|NCT02826499|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34095132|NCT06367179|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34095133|NCT00005795||||TREATMENT||||||||
34095134|NCT05991479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095135|NCT06024265|NA|SINGLE_GROUP||TREATMENT||NONE||As designed, the single group will be divided into four cohorts. The first cohort of 1-6 participants will receive an initial dose, followed by a safety review of the included participants. If the safety is confirmed and decision made to proceed to the next higher dose, the next cohort of 3-6 participants will receive a higher dose. The planned increasing doses are 0.04, 0.08, 0.16, and 0.32 mg/kg, respectively in subsequent.||||
34095136|NCT02980536|||COHORT||PROSPECTIVE|||||||
34095137|NCT03183440|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34095138|NCT02196545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095139|NCT04322045|NA|SINGLE_GROUP||SCREENING||NONE||||||
34095140|NCT00748930|||COHORT||RETROSPECTIVE|||||||
34095141|NCT05789342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095142|NCT04063020|||COHORT||PROSPECTIVE|||||||
34095143|NCT04503200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095144|NCT03403517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095145|NCT05112588|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34095146|NCT03925714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095147|NCT03808857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095148|NCT00193986|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34095149|NCT05124678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095150|NCT02794779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34095151|NCT00668408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095152|NCT01643187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095153|NCT01997255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095154|NCT01175720|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34095155|NCT02685865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095156|NCT01114477|||CASE_ONLY||PROSPECTIVE|||||||
34095157|NCT01155323|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34095158|NCT06386120|||COHORT||PROSPECTIVE|||||||
34095159|NCT02513082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095160|NCT01446653|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34095161|NCT01846871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095162|NCT00404300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095163|NCT02505971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095164|NCT01302171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095165|NCT02843555|||COHORT||PROSPECTIVE|||||||
34095166|NCT02811978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095167|NCT00366561|||||RETROSPECTIVE|||||||
34095168|NCT03111732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095169|NCT01765621|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34095170|NCT04106037|||COHORT||RETROSPECTIVE|||||||
33709463|NCT03678298|||COHORT||PROSPECTIVE|||||||
33709464|NCT02714582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709465|NCT00476697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709466|NCT02459210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709467|NCT05142891|||CASE_ONLY||RETROSPECTIVE|||||||
33709468|NCT06318182|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33709469|NCT01068132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709470|NCT00155025|||DEFINED_POPULATION||OTHER|||||||
33709471|NCT06498245|||CASE_CONTROL||RETROSPECTIVE|||||||
33709472|NCT00963937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709473|NCT05527340|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095171|NCT06447896|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34095172|NCT01879657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095173|NCT01433770|NA|SINGLE_GROUP||||NONE||||||
34095174|NCT00868270|||COHORT||PROSPECTIVE|||||||
34095175|NCT05639868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095176|NCT00168532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095177|NCT02134028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095178|NCT01675336|||CASE_CONTROL||RETROSPECTIVE|||||||
34095179|NCT05120232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095180|NCT02271802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34095181|NCT06548243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095182|NCT00629239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095183|NCT05181657|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Neither study participants or principal investigator will know which group participants have been assigned to.|The four OnPoint syringe exchange locations will be randomized to deliver either the active (intervention) or didactic (control) version of the LinkUP intervention. The randomization scheme will be developed using an algorithm by La Frontera's statistician. Half way into enrollment, there will be a one-week 'washout' period, after which time the two original intervention syringe exchange sites will become control sites and the two original control sites will become intervention sites. This cluster randomization scheme will help ensure that no neighborhood in San Diego County is denied access to the LinkUP intervention. By the end of the study, 75 LinkUP participants will have been randomized to an intervention site and 75 will have been randomized to a control site.|t|f|t|f
34095184|NCT06163274|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participants, care providers, and investigators may be able to tell the difference in the hardness/flexibility of the two rings after handling them.|Participants will randomized to sequence of using 2 placebo intravaginal rings; Ring A followed by Ring B or Ring B followed by Ring A|f|f|f|t
34095185|NCT01509105|||CASE_ONLY||PROSPECTIVE|||||||
34095186|NCT00178906|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33709474|NCT06320002|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709475|NCT04606030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Partially Blinded: Patients will be informed which group they are randomized into and given the option to opt out of the study. Investigators (other than surgeons conducting surgery) and study personnel involved in patient measurements will be unaware of the patient treatment option.|Prospective, randomized, control arm|f|f|f|t
34011777|NCT00742599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095187|NCT05480098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be blinded to the surgeon grading the severity of bleeding and the patient will be unaware which side would receive the intervention.|A randomized, prospective clinical trial will be performed with IRB approval to compare intraoperative application of ophthalmic brimonidine solution to standard methods of hemostasis control. This study will be blinded to the surgeon grading the severity of bleeding and the patient unaware which side would receive the intervention. Topical brimonidine ophthalmic solution will be placed intraoperatively to the open surgical wound of one eyelid and we will assess the severity of bleeding via a surgeon's grading scale. The fellow eye's surgical wound will be used as the control. The laterality of intervention is randomized. Reduction of bleeding severity is the primary outcome as graded by a subjective surgeon's grading scale. A secondary outcome may be severity of postoperative bruising in the study eye versus the fellow control eye, as graded by post-operative bruising severity.|t|t|f|f
34095188|NCT02553070|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34095189|NCT00476788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095190|NCT03238872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095191|NCT01339013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095192|NCT00397930|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34095193|NCT03094299|||COHORT||PROSPECTIVE|||||||
34095194|NCT00129558|NON_RANDOMIZED|||TREATMENT||NONE||||||
34095195|NCT02762604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095196|NCT02781194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34095197|NCT00311805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095198|NCT04033536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095199|NCT00762177|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34095200|NCT04832308|RANDOMIZED|PARALLEL||PREVENTION||NONE||Block randomization stratified by site.||||
34095201|NCT05599425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095202|NCT01952678|||COHORT||RETROSPECTIVE|||||||
34095203|NCT04947787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095204|NCT03679884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension study|t|t|t|t
34095205|NCT01491165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095206|NCT05808621|||OTHER||CROSS_SECTIONAL|||||||
34095207|NCT04723069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and investigator both are blind|randomized, double-blind, positive control|t|f|t|f
34095208|NCT04419974|||COHORT||PROSPECTIVE|||||||
34095209|NCT02087683|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34095210|NCT05635864|||COHORT||PROSPECTIVE|||||||
34095211|NCT02541903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709476|NCT06505421|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33709477|NCT03502980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709478|NCT00970567|RANDOMIZED|CROSSOVER||||NONE||||||
33709479|NCT05490511|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects participate in a 3-phase fixed sequence pharmacokinetic study to evaluate the interaction between tacrolimus, cannabidiol, and genotype on tacrolimus AUC and immune system pharmacodynamic outcomes. Subjects with and without CKD will be enrolled in parallel arms.||||
34095212|NCT00267319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095213|NCT04281719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095214|NCT00358800|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34095215|NCT00907114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34095216|NCT04914000|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34095217|NCT03630887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be carried out by a collaborator investigator using a computer program (Excel 2016) when a new patient is included into the clinical trial. This collaborator investigator will call by phone the nurse in charge of receiving the patient in the preanesthetic room, telling this nurse how long prewarming has to be given to the patient: 0 minutes (no prewarming), 15 minutes, 30 minutes or 45 minutes, according to the group given by the computer program. This collaborator investigator will not provide clinical care to the patient. Thus, principal investigator will not be able to know how long prewarming will be given by the nurse to the patient (chosen by the computer program and organized by a collaborator investigator)|"We will compare different time periods: 0 minutes (control group), 15 minutes, 30 minutes and 45 minutes.~Sample size was authorized by IRB to be changed from 144 to 244 (61 patients per group) due to possible missing data."|f|t|t|f
34011778|NCT01376310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011779|NCT05514236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011780|NCT03707041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo capsules matched to the drug product with regard to appearance and taste|In each of the three treatment cohorts, subjects will be randomly allocated to receive either P218 or placebo.|t|t|t|t
34011781|NCT05424575|||CASE_CONTROL||PROSPECTIVE|||||||
34011782|NCT03794518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Random process|Pioglitazone (15 mg) and dapagliflozin (10mg) vs Placebo|t|f|f|f
34011783|NCT03155737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011784|NCT04365179|NA|SEQUENTIAL||TREATMENT||NONE||traditional 3+3 design||||
34011785|NCT02857829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34011786|NCT05510024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who were involved in outcome measurements will be masked.||f|f|f|t
34011787|NCT06326177|||COHORT||CROSS_SECTIONAL|||||||
34011788|NCT02083926|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34011789|NCT02408328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011790|NCT06617585|||CASE_CONTROL||RETROSPECTIVE|||||||
34011791|NCT02823314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933687|NCT04483128|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Randomization process will be masked by opaques envelopes with numbers. Participants choose one random envelope, unaware the number and group relation. Later, a researcher will associate participants, groups and numbers.|"Participants diagnosed with chronic low back pain will be divided into two different groups with 28 patients each:~* Experimental group: Participants in this group will receive electrical stimulation with interferential current. They will get also instructions to perform core strengthening exercises at home, after variable collection.~* Control group: Participants in this group will recieve the same electrical stimulation than in the experimental group but with no intensity. This group will get too instructions to perform core strengthening exercises at home (after variable collection) and follow General Practitioner indications about pharmacology."|t|f|f|f
33933688|NCT01208818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933689|NCT01329172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33933690|NCT04124406|||COHORT||PROSPECTIVE|||||||
33933691|NCT01144741|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933692|NCT01495260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933693|NCT05934708|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33933694|NCT00871195|||COHORT||PROSPECTIVE|||||||
33933695|NCT05677854|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33933696|NCT01751789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933697|NCT03304392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933698|NCT04432376|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Clinical Investigators, study staff and subjects randomized to the initial phase of the study are blinded to active drug and placebo.|Two phases; initial is randomized double-blind active vs placebo on a pre-determined number of subjects with otomycosis, to finish before starting second phase. Second phase is open-label use on diseased or healthy subjects to evaluate safety. Subjects from initial phase may crossover to second phase open-label if they meet the requirements, and new diseased or healthy subjects meeting requirements may enroll in this open-label phase.|t|t|t|f
33933699|NCT02797470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933700|NCT00134342|||COHORT||PROSPECTIVE|||||||
33933701|NCT00324272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933702|NCT00002981|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933703|NCT02903745|||||CROSS_SECTIONAL|||||||
33933704|NCT00729560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33933705|NCT04819724|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Blinding to the experimental condition is not possible because of the obvious differences between conditions (additional load). However, the person processing the data will be blinded to the condition.|cross-sectional experimental multimodal (clinical, biomechanical, radiological) data collection with multiple conditions and a control group||||
33933706|NCT01366534|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33933707|NCT00515554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933708|NCT02762136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933709|NCT01614275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33933710|NCT00000199||||TREATMENT||||||||
33933711|NCT01599819|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933712|NCT03966352|||FAMILY_BASED||OTHER|||||||
34011792|NCT02211014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011793|NCT00573170|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34011794|NCT01401374|||OTHER||OTHER|||||||
34011795|NCT01546649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011796|NCT04764630|RANDOMIZED|CROSSOVER||OTHER||NONE|The study will be unblinded as the product is administered intranasally and different arms will have a different number of administrations at different times.|This is a three-way crossover study where subjects will be randomized to one of six possible treatment sequences.||||
34011797|NCT05208658|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34095218|NCT06028373|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose levels are 0.03 mg/kg、 0.1 mg/kg、0.3 mg/kg 、1.0 mg/kg 、2.0 mg/kg、4.0 mg/kg 、6.0 mg/kg 、9.0 mg/kg||||
34095219|NCT00236678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933713|NCT03748420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33933714|NCT00479349|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33933715|NCT02866903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933716|NCT04007367|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33933717|NCT01571167|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33933718|NCT05732493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933719|NCT03510403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933720|NCT02084875|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34011798|NCT02035020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011799|NCT06199713|||COHORT||PROSPECTIVE|||||||
34011800|NCT00213720|||COHORT||PROSPECTIVE|||||||
34011801|NCT01758146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011802|NCT04508920|||COHORT||PROSPECTIVE|||||||
34095220|NCT04668963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial will be performed following a de facto masking.|Forty subjects will be divided in two groups depending they were submitted to intensive or a more spaced over time therapy|t|t|f|f
34095221|NCT04429594|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709480|NCT00067600|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33709481|NCT05780658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709482|NCT03200405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709483|NCT01389817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709484|NCT01949558|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709485|NCT06385899|||COHORT||PROSPECTIVE|||||||
33709486|NCT01402778|||COHORT||PROSPECTIVE|||||||
33709487|NCT02611219|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709488|NCT06499311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each participant will have one identification number that will be used to assign participants into two equal groups in number (n=27), sequentially numbered index cards will be secured in opaque envelopes. Another assistant for the researcher will open the sealed envelope and will allocated the participants according to their groups.|A prospective, randomized, controlled trial.|t|t|t|t
33709489|NCT04456660|||COHORT||PROSPECTIVE|||||||
33709490|NCT03315624||SEQUENTIAL||TREATMENT||NONE||Prospective, open, controlled, cross-over (with randomized treatment sequences), interventional, multi-center||||
33709491|NCT01858298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709492|NCT01646723|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720593|NCT01517269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933721|NCT05580237|||COHORT||CROSS_SECTIONAL|||||||
33933722|NCT04984070|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33933723|NCT02490241|||COHORT||PROSPECTIVE|||||||
33933724|NCT00740428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33933725|NCT01327573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933726|NCT00380406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933727|NCT01788111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933728|NCT04202796|||COHORT||PROSPECTIVE|||||||
33933729|NCT00118040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095222|NCT01531153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33933730|NCT03167827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind (Participant, Care Provider)|Parallel Assignment|t|t|f|f
34095223|NCT03490383|||CASE_CONTROL||PROSPECTIVE|||||||
34095224|NCT00442156|||COHORT||PROSPECTIVE|||||||
34095225|NCT03924297|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty subjects with PTSD will use the Chilipad nightly for 5 weeks. The subjects will be given an OURA ring to measure sleep duration and quality during the 5 weeks. Subjects will also be given questionnaires before and after the sleep study part of the study to measure changes||||
34095226|NCT05146765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessor|Pilot trial|t|f|f|f
34095227|NCT01895647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095228|NCT04954235|||COHORT||RETROSPECTIVE|||||||
34095229|NCT06135545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double-blinded non-inferiority clinical trial.|t|f|f|t
34095230|NCT06135909|||COHORT||PROSPECTIVE|||||||
34095231|NCT06210633|||COHORT||PROSPECTIVE|||||||
34095232|NCT02092428|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34095233|NCT02760511|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34095234|NCT01719302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095235|NCT03467945|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33933731|NCT03023319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933732|NCT01318928|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33933733|NCT02826655|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33933734|NCT02617706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933735|NCT01102946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33933736|NCT00824395|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33933737|NCT02827981|||COHORT||RETROSPECTIVE|||||||
33933738|NCT05135468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Drug:0.25% (2.275mg/mL) Finasteride Spray Placebo for CU-40102 Spray|t|t|t|t
33933739|NCT03252262|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34011803|NCT05683210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34011804|NCT00982891|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34011805|NCT00070616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011806|NCT06617338|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective, randomized cohort analysis study||||
34011807|NCT01472107|||CASE_ONLY||RETROSPECTIVE|||||||
34011808|NCT02128529|||COHORT||CROSS_SECTIONAL|||||||
34011809|NCT04109859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011810|NCT05213260|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34011811|NCT03595163|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34011812|NCT00266240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011813|NCT02384850|NA|SEQUENTIAL||TREATMENT||NONE||Dose level 1: Oxaliplatin at a dose of 85 mg/m2 IV over two hours (Day 1) 5-FU 400 mg/m2 IV bolus (Day 1) Leucovorin 400 mg/m2 IV over two hours (Day 1) 5-FU 2400 mg/m2 IV over 46 hours (Day 1-3) Selinexor 40 mg, PO (Day 1, 3 and 8) Dose level 2: Oxaliplatin at a dose of 85 mg/m2 IV over two hours (Day 1) 5-FU 400 mg/m2 IV bolus (Day 1) Leucovorin 400 mg/m2 IV over two hours (Day 1) 5-FU 2400 mg/m2 iv over 46 hours (Day 1-3) Selinexor 60 mg, PO (Day 1, 3 and 8) Dose level 3: Oxaliplatin at a dose of 85 mg/m2 iv over two hours (Day 1) 5-FU 400 mg/m2 iv bolus (Day 1) Leucovorin 400 mg/m2 iv over two hours (Day 1) 5-FU 2400 mg/m2 iv over 46 hours (Day 1-3) Selinexor 80 mg, PO (Day 1, 3 and 8) Dose level -1: Oxaliplatin at a dose of 85 mg/m2 IV over two hours (Day 1) 5-FU 400 mg/m2 IV bolus (Day 1) Leucovorin 400 mg/m2 IV over two hours (Day 1) 5-FU 2400 mg/m2 IV over 46 hours (Day 1-3) Selinexor 20 mg, PO (Day 1, 3 and 8)||||
34011814|NCT06617273|RANDOMIZED|PARALLEL||TREATMENT||NONE||controlled randomized, comparative||||
34011815|NCT06132620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011816|NCT01373879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34011817|NCT06193824|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Crossover Assignment|f|f|f|t
34011818|NCT01280617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011819|NCT04579276|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34011820|NCT06363253|||COHORT||PROSPECTIVE|||||||
34011821|NCT06188130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011822|NCT01293552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011823|NCT06226948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34011824|NCT01514994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011825|NCT03243929|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011826|NCT00903552|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011827|NCT04352465|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study will be divided in 3 phases:~Phase A: subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).~Phase B: will only start after 2nd or 3rd administration of phase A. Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).~Phase C: will only start after 2nd or 3rd administration of phase B. Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses)."||||
34011828|NCT05530070|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the nature of the study, the blinding of the participants is not possible, however bias is unlikely due to objective data collection. The blinding of the physicians, data managers and statisticians will be secured.|This trial is a series of three multicentric studies. It includes 1) a case-control study, which compares newly diagnosed CD patients (n=37) and CD patients on a GFD (n=99) to matched non-coeliac control subjects (n=136); 2) a prospective cohort study, which investigates how the outcomes change during a 1-year GFD started after diagnosis of CD (n=236); 3) an RCT, which investigates how a dietetic intervention (n=95) influences the outcomes, compared to standard of care (n=95), in CD patients following a strict GFD for at least 1 year. There will be no intervention for the sake of the study in the case-control and the cohort study. Parameters of interest will be assessed only once in the case-control study and twice in the cohort study. In the RCT, randomization will be carried out after the baseline dietary education and interview, in 1:1 allocation ratio. Parameters will be recorded at baseline and the end of the study.|f|t|f|t
34011829|NCT04702763|||COHORT||CROSS_SECTIONAL|||||||
34011830|NCT03528473|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, controlled, double-group assignment, open label study with intermediate crossover||||
34011831|NCT05319613|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Convenience sample of baseline community survey participants who elect to enter clinical PrEP care||||
34011832|NCT03803033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A prospective single-blind randomized control trial (RCT) for evaluating the economic impact of a clinical pharmacist's identifying and managing of TRPs as part of an home medication management review|Chronic diseases patients were initially assigned to either 3 months of routine care service (control group) or to an experimental clinical pharmacy-based HMMR service (intervention group) in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan.|t|f|f|f
34011833|NCT03463993|RANDOMIZED|PARALLEL||PREVENTION||NONE|Trial is an open label randomized control trial|Randomized control trial with two arms. Participants receive either 10mg/kg of TXA 10 minutes prior to elective caesarean section with prophylactic oxytocin administration after delivery of the baby, versus prophylactic oxytocin alone after delivery of the baby.||||
34011834|NCT02385201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011835|NCT00295139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011836|NCT03570450|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"* Dose escalation from 1.10\^6 cells/kg to 3.10\^6 cells/kg (phase 1a, non randomized, open-label);~* Effect-dose: 3.10\^6 cells/kg + placebo (phase 1b, randomized, double blind);~Phase Ia: n = 15 patients; Phase Ib: n = 80 patients"|t|f|t|f
34011837|NCT02883478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709493|NCT03323710|NA|SINGLE_GROUP||TREATMENT||NONE||Two-stage optimal Simon design||||
33709494|NCT05582525|||COHORT||RETROSPECTIVE|||||||
33709495|NCT02957305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, operators and statistical analysis were performed blindly.||t|t|t|f
33709496|NCT06218693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33709497|NCT05403281|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709498|NCT00804544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709499|NCT01980394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791833|NCT06549517|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multisite, prospective, and open-label study involving two arms. Subjects from the general adult population were randomly assigned to either a cognitive intervention group or a no-intervention control group. The intervention consisted of in-person cognitive training over 12 weeks, with baseline and final cognitive evaluations. A sub-study will investigate neuroimaging changes in brain volume and activation as parameters of neuroplasticity stimulation||||
33709500|NCT05686811|RANDOMIZED|PARALLEL||TREATMENT||NONE||To compare the effects of myofascial release therapy and post isometric relaxation technique on pain and functional disability in patients with tension type headache||||
33709501|NCT02430311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709502|NCT04105101|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Blinding is not possible in this testing set-up, participants however are not informed about the exact purpose of the tests and which exoskeleton is a prototype and which exoskeleton is a commercially available exoskeleton.|Randomized counterbalanced cross-over design|t|f|f|f
33709503|NCT00172471|||DEFINED_POPULATION||OTHER|||||||
33709504|NCT00027261||||PREVENTION||DOUBLE||||||
33709505|NCT00027898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709506|NCT05862480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709507|NCT05055362|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33709508|NCT03440268|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participant of the study won't know what is he receiving (placebo or NAC) and the assessor will not have any contact with the participants|There will be one group placebo/control and one group intervention. The group intervention will receive the medication N AcetylCysteyn (NAC), while the control will receive a placebo|t|f|f|t
33709509|NCT06169696|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33709510|NCT01651377|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33709511|NCT04281810|RANDOMIZED|PARALLEL||OTHER||SINGLE|Subjects were not informed of the results of allocation||t|f|f|f
33720594|NCT01133054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791834|NCT04628650|||CASE_ONLY||PROSPECTIVE|||||||
33791835|NCT03720613|||COHORT||PROSPECTIVE|||||||
33791836|NCT05260502|||OTHER||CROSS_SECTIONAL|||||||
33791837|NCT03557788|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791838|NCT00573833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791839|NCT04362215|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33791840|NCT04420195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791841|NCT03589651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791842|NCT01153750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011838|NCT02592759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011839|NCT00064584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791843|NCT03504072|RANDOMIZED|PARALLEL||PREVENTION||NONE||Follow up period will be 9 months (visits 0, 1, 3, 6 and 9). Study subjects (87) will receive toficitinib (5 mg 12 hourly). Control patients will get eternacept (50 mg subcutaneously every 7 days interval for 1st month then 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval till final visit.||||
34011840|NCT00685802|RANDOMIZED|CROSSOVER||||NONE||||||
34011841|NCT02172482|||COHORT||PROSPECTIVE|||||||
34011842|NCT01435447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011843|NCT01583517|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34011844|NCT03170388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group|t|t|t|f
34011845|NCT01766791|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34011846|NCT03004859|||COHORT||PROSPECTIVE|||||||
34011847|NCT04987255|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34011848|NCT03046719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34011849|NCT03327714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Children in classes that perform regular mindfulness are compared to children in classes that do not.||||
34011850|NCT00977548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011851|NCT04158817|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011852|NCT04617392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011853|NCT04222114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011854|NCT03410043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011855|NCT04693338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34011856|NCT02263820|||COHORT||PROSPECTIVE|||||||
33709512|NCT01594281|RANDOMIZED|PARALLEL||TREATMENT||NONE|An open-label design was chosen in which the evaluation of the primary objective was performed by a reading center. The reading center that evaluated the primary and several secondary objectives was blinded to randomization and therefore assessed these objectives uninfluenced by treatment information. However, laser burns were visible on the images, and no full blinding regarding panretinal laser photocoagulation (PRP) was possible for the reading center.|||||
33709513|NCT02973217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709514|NCT01294631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709515|NCT04922775|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be categorized into two (A\&B) groups randomly for cross-over study. A group will accept conventional taping before muscle fatigue exercise for the first course then accept Chinese medicine technique taping before muscle fatigue exercise for the second course. B group will accept Chinese medicine technique taping before muscle fatigue exercise for the first course then accept conventional technique taping before muscle fatigue exercise for the second course.||||
33791844|NCT00952718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33791845|NCT05608343|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33791846|NCT02054455|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33791847|NCT01420718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791848|NCT03842618|||OTHER||PROSPECTIVE|||||||
33709516|NCT03521934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791849|NCT01750463|||COHORT||PROSPECTIVE|||||||
33791850|NCT04141917|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33709517|NCT05249374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
33709518|NCT05018130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluator doctor will not have access to the protocol test applied to each patient and the surgeries will be conducted by different physicians.|Randomized, investigator-blinded, in parallel groups, two-arms, single-center, non-inferiority, clinical trial.|f|f|t|t
33709519|NCT01344434|||||RETROSPECTIVE|||||||
33709520|NCT00000297||||TREATMENT||DOUBLE||||||
33709521|NCT00720538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709522|NCT01889004|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709523|NCT05388409|||CASE_CONTROL||RETROSPECTIVE|||||||
33709524|NCT00003594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709525|NCT05988099|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33709526|NCT04053101|||COHORT||RETROSPECTIVE|||||||
33709527|NCT02859454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709528|NCT05095545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study was double-blinded. The staff of the clinical sites and the patients were unaware of the treatment and its doses assigned to each specific patient. Blinding was provided by a placebo mask (each patient received capsules containing either 80 mg of AV5080 or placebo), and drug distribution was controlled by the IWRS. Each patient was given two bottles containing the capsules, a bottle A and a bottle B. The two bottles had the same number and differed in lettering and label color: the bottle A had a white label and the bottle B had a yellow label. Patients were to take one capsule in the morning - from bottle A, and one capsule in the evening - from the bottle B.||f|f|f|t
33709529|NCT01832649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709530|NCT01810874|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33709531|NCT04668625|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants will be screened for a rapid Ag SARS-CoV-2 test detection. All negative subjects will be randomized to an experimental arm (participate in a massive musical event) or to a control arm (not participate in a massive musical event).||||
33709532|NCT01650844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33709533|NCT05801276|||COHORT||PROSPECTIVE|||||||
33709534|NCT01161862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709535|NCT00496808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709536|NCT02211937|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709537|NCT04674930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709538|NCT01756898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709539|NCT04774315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709540|NCT01880229|||CASE_CONTROL||PROSPECTIVE|||||||
33709541|NCT02161731|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709542|NCT01337739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709543|NCT03792698|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post intervention study design||||
33709544|NCT01542125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34011857|NCT01131299|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33709545|NCT05559138|||COHORT||RETROSPECTIVE|||||||
33709546|NCT01523990|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33709547|NCT04195698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709548|NCT00724360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791851|NCT02243813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33791852|NCT00193518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791853|NCT04991974|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011858|NCT02610816|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011859|NCT00597116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011860|NCT00627471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011861|NCT00685490|||CASE_ONLY||RETROSPECTIVE|||||||
34011862|NCT00248170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011863|NCT04762940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will be made by researches blinded for the patient´s group|Randomized controlled trial|f|f|f|t
34011864|NCT02358967|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34011865|NCT01372124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011866|NCT00802282|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34011867|NCT02791386|||COHORT||RETROSPECTIVE|||||||
33791854|NCT00009646|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33709549|NCT02385162|||COHORT||PROSPECTIVE|||||||
33709550|NCT04031937|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33709551|NCT02575495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709552|NCT02423876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709553|NCT00002014||||TREATMENT||||||||
33791855|NCT00541125|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791856|NCT02542852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791857|NCT05093712|||COHORT||PROSPECTIVE|||||||
33791858|NCT01326988|||COHORT||PROSPECTIVE|||||||
33791859|NCT01885845|RANDOMIZED|PARALLEL||||NONE||||||
33791860|NCT02523391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791861|NCT03565224|||COHORT||PROSPECTIVE|||||||
33791862|NCT00612586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791863|NCT06156306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33791864|NCT06367517|||COHORT||PROSPECTIVE|||||||
33791865|NCT04577625|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33791866|NCT00752817|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33791867|NCT04404972|||COHORT||RETROSPECTIVE|||||||
33709554|NCT03001531|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791868|NCT06326437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33791869|NCT04050631|||CASE_ONLY||PROSPECTIVE|||||||
33791870|NCT03215251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011868|NCT01025674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011869|NCT04239118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011870|NCT04618978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011871|NCT05472441|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"The LINK pragmatic randomized controlled trial (pRCT) uses a 2x2 factorial design to prospectively enroll study participants with type 2 diabetes and food insecurity into one of four study arms. The four study arms are: 1) Mid-Ohio Farmacy (receiving weekly produce through a consortium of local food banks); 2) Mid-Ohio Farmacy + Cooking for Diabetes (Cooking for Diabetes is a 6-week diabetes and culinary education intervention); 3) Mid-Ohio Farmacy + Health Impact Ohio Pathways Hub (The Pathways Hub uses a community health worker model to meet with participants, evaluate and address non-medical, health-related social needs); and 4) Mid-Ohio Farmacy + Cooking for Diabetes + Health Impact Ohio Pathways Hub).~Participants will be randomized using a 1:1:1:1 stratified randomization scheme built into Research Electronic Data Capture (REDCap) at the participant level."|f|f|f|t
34011872|NCT00375492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011873|NCT06616168|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33791871|NCT04379349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011874|NCT00290251|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|study agents were formulated in identical looking capsules|Subjects were studied during a single baseline menstrual cycle followed by a cross-over into three arms (active treatment at one of two doses, or placebo) given for three menstrual cycles|t|f|t|f
34011875|NCT00911599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011876|NCT03919487|||COHORT||PROSPECTIVE|||||||
34011877|NCT06615843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095236|NCT04680143|NA|SINGLE_GROUP||TREATMENT||NONE||The study included 10 patients diagnosed as post papilledemic optic atrophy that were attending Alexandria main university hospital. All patients underwent initially assessment of visual acuity, color vision, pupil reaction ,funduscopy and electrophysiological tests ( pattern visual evoked potential and pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control). Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies.||||
33791872|NCT06238154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinician collecting data from patients was blinded. The researcher who analyzed the results was blinded.||f|f|t|t
33709555|NCT03153371|||CASE_CONTROL||PROSPECTIVE|||||||
33709556|NCT01340885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709557|NCT04012983|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33709558|NCT01603056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709559|NCT04239144|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy. The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy.||||
33791873|NCT01546155|NA|SINGLE_GROUP||OTHER||NONE||||||
33791874|NCT00065052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791875|NCT01897233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791876|NCT00309452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791877|NCT05817409|||COHORT||PROSPECTIVE|||||||
33791878|NCT02925000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791879|NCT06231277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791880|NCT06102369|||CASE_ONLY||PROSPECTIVE|||||||
33791881|NCT05273242|RANDOMIZED|PARALLEL||TREATMENT||NONE||Same as that of WHO solidarity Trial Plus , Please refer to the ISRCTN18066414||||
33791882|NCT00415272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791883|NCT05714735|||COHORT||PROSPECTIVE|||||||
33791884|NCT04342338|||COHORT||PROSPECTIVE|||||||
34011878|NCT05403710|||CASE_ONLY||PROSPECTIVE|||||||
34011879|NCT02635581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011880|NCT04920526|||COHORT||PROSPECTIVE|||||||
34011881|NCT00896194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933740|NCT01581905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933741|NCT01251315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791885|NCT00092599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791886|NCT01405872|||COHORT||PROSPECTIVE|||||||
33933742|NCT01725295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34011882|NCT01583257|NA|SINGLE_GROUP||||||||||
34011883|NCT02459418|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34011884|NCT05472402|RANDOMIZED|PARALLEL||OTHER||NONE||"The R21 phase will use 4 focus groups with 48 black women, and feedback from 12 expert advisors to modify content from our existing evidence-based PA curriculum for online implementation. - This phase has been completed.~The R33 phase will use a randomized controlled trial design to implement a pilot study to evaluate the feasibility, acceptability, and impact on PA of the online PA curriculum."||||
33791887|NCT00831415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011885|NCT04684173|||COHORT||PROSPECTIVE|||||||
34011886|NCT02049021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34011887|NCT01135628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933743|NCT06177015|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two independent arms||||
33933744|NCT05097976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator (surgeon) and participant (patient) will be blinded to whether they are discharged with a placebo or treatment (oral corticosteroid).||t|f|t|f
33933745|NCT06076239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Supraspinatus tendon thickness and effusion of the cases included in the study were evaluated by ultrasonography before and after the study by the same specialist physician who was blind to the groups.|The participants in the Experimental Group were given Extra Corporeal Shockwave therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatments , while Control group received only conventional treatments for five days per week for 3 consecutive weeks|f|f|f|t
33933746|NCT06108466|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34011888|NCT04438590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011889|NCT00860691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34011890|NCT05646628|||COHORT||PROSPECTIVE|||||||
34011891|NCT04736108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011892|NCT01120769|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34011893|NCT04070287|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention Pilot~This study protocol will involve undertaking a prospective one-year assessment of five youth participatory interventions. These interventions are focused on promoting HIV self-testing and referrals to health facilities for other sexually transmitted infections test."||||
34011894|NCT04531670|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34011895|NCT05216588|||COHORT||PROSPECTIVE|||||||
34095237|NCT03158311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The free triple combination of salmeterol/fluticasone + tiotropium was open label, for which investigators and patients had full knowledge that the patient had been assigned free triple combination comparator treatment. Within the two QVM149 treatment arms patients, investigator staff, and persons performing the assessments, remained blind to the identity of the actual QVM149 treatment dose but had full knowledge that the patient had been assigned QVM149 as study treatment. The data analysts and sponsor team were blinded to Case Report Forms that reveal the treatment arm. Randomization data and treatment codes were kept strictly confidential until the time of unblinding, and was not accessible by anyone else involved in the study.|Parallel Assignment|f|f|f|t
33709560|NCT00130598|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709561|NCT04053114|||OTHER||RETROSPECTIVE|||||||
33709562|NCT00000489|RANDOMIZED|||TREATMENT||||||||
33709563|NCT03365583|||COHORT||CROSS_SECTIONAL|||||||
33709564|NCT04489563|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"A group of aged persons and their supervisors in day care facilities or nursing homes participated in this study to investigate the feasibility of the i-ACT system for use to engage and motivate aged persons in institutional facilities to perform physical activity. The aged persons received a 20-30 minutes test period with the self-developed programme of the i-ACT (based on hard- and software of the Microsoft Kinect). During and after the test, the feedback of the participants was noted by the supervisor (using the thinking aloud method). After the test, 3 questionnaires were conducted, i.e. the Intrinsic Motivation Inventory (IMI), System Usability Scale (SUS), and Credibility/Expectancy Questionnaire (CEQ).~The feedback from the supervisors was also noted as part of the thinking aloud method to gather as much information as needed to adapt the prototype of the i-ACT system towards the wishes and needs from aged persons."||||
33791888|NCT00161057|||COHORT||PROSPECTIVE|||||||
33791889|NCT02064660|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33791890|NCT03312335|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791891|NCT00817830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33791892|NCT00000313||||TREATMENT||||||||
33791893|NCT01533519|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33791894|NCT01795144|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791895|NCT06163586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors evaluating neurodevelopmental outcomes will be masked from knowing which intervention was assigned to individual participants.|Randomized controlled trial|f|f|f|t
33791896|NCT03696407|||COHORT||RETROSPECTIVE|||||||
33791897|NCT00405951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791898|NCT00794118|||COHORT||PROSPECTIVE|||||||
33791899|NCT00563537|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791900|NCT03561610|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33791901|NCT04879082|||CASE_ONLY||RETROSPECTIVE|||||||
33791902|NCT01764451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791903|NCT04301986|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791904|NCT02491723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791905|NCT03588845|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The primary objective of this randomized trial is to determine if a structured, treat-to-target algorithm based on treatment response and relapse performs better than standard care for the treatment of symptoms SSc-SIBO.|f|f|t|f
33791906|NCT01125306|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33791907|NCT00793286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33791908|NCT05576181|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33791909|NCT03182959|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be randomized to receive either 50 mg glucoraphanin (GR) in Cycle 1 and 100 mg GR in cycle 2, or 100 mg GR in Cycle 1 and 50 mg GR in Cycle 2, but all participants will receive both doses.||||
33791910|NCT00686023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791911|NCT06301035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791912|NCT02969954|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33791913|NCT01064804|||COHORT||PROSPECTIVE|||||||
33933747|NCT02545452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34011896|NCT04815382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011897|NCT04637126|||OTHER||PROSPECTIVE|||||||
34011898|NCT04995120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011899|NCT02992626|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34011900|NCT06058221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34011901|NCT00809965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720595|NCT00768300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720596|NCT06290713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to receive interventions based on their completion and results of Aim 1 (responsiveness to study drug). If participants are found to be Tadalafil-responsive after one dose, they will be included in Aim 2 of the study and will be asked to participate in the double-blinded, randomized, placebo-controlled longitudinal medication \& exercise 6-month study program.|t|t|t|t
33720597|NCT03680950|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720598|NCT00412763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33720599|NCT06209151|||COHORT||PROSPECTIVE|||||||
33720600|NCT05240560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo tablets will be identical in appearance to the BP1.3656 tablets.||t|t|t|t
33720601|NCT00868075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720602|NCT02139527|||CASE_ONLY||PROSPECTIVE|||||||
33720603|NCT03566823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720604|NCT05862207|||OTHER||CROSS_SECTIONAL|||||||
33720605|NCT01482039|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34011902|NCT02790034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011903|NCT01576302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011904|NCT06205706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase 1/2a, open-label, dose-escalation, multicenter, FIH, consecutive-cohort, clinical trial of BI-1910, as a single agent and in combination with pembrolizumab.||||
34011905|NCT06438926|||OTHER||CROSS_SECTIONAL|||||||
34011906|NCT05904275|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011907|NCT03696355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011908|NCT00480623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011909|NCT04442724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011910|NCT01538836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011911|NCT04363749|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34011912|NCT01352728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011913|NCT05418075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011914|NCT00556491|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34011915|NCT03239236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34011916|NCT02545647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011917|NCT05113459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011918|NCT06427902|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34011919|NCT01098994|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34011920|NCT01276717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011921|NCT04414475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011922|NCT02019082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34011923|NCT00720226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011924|NCT02489591|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34011925|NCT02790541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011926|NCT02113176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011927|NCT06237387|||OTHER||CROSS_SECTIONAL|||||||
34011928|NCT02758249|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34011929|NCT06583850|||CASE_CROSSOVER||PROSPECTIVE|||||||
34011930|NCT05828355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011931|NCT02857556|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791914|NCT01731665|||COHORT||OTHER|||||||
33791915|NCT02931383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709565|NCT03608098|RANDOMIZED|PARALLEL||TREATMENT||NONE||All subjects enrolled in the study will be randomized to either short pulse or long pulse for treatment of their stones. The date of treatment will be decided between the subject and the treating surgeon. All treatments will be performed using the standard of care and will be performed in the same fashion as procedures for patients not enrolled in the study. There is no modification of the techniques used to remove the stones. Post operatively, we plan to discharge all subjects home from the recovery unit. All subjects will be seen one week to one month after surgery for stent removal and a low dose CT of the abdomen and pelvis to assess stone free rates which is standard for all stone patients.||||
33709566|NCT02035930|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33709567|NCT02744014|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011932|NCT03424850|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33709568|NCT00000445|RANDOMIZED|||TREATMENT||NONE||||||
33709569|NCT03612505|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33791916|NCT03906968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791917|NCT02816632|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791918|NCT06076382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791919|NCT05876130|NA|SINGLE_GROUP||TREATMENT||NONE||hypofractionated IMRT (2.5 Gy x 16 fractions)||||
34011933|NCT03398148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011934|NCT00281476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709570|NCT00592943|RANDOMIZED|PARALLEL||||NONE||||||
33709571|NCT01427686|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33709572|NCT02590081|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33709573|NCT04833881|||CASE_CONTROL||OTHER|||||||
33709574|NCT04993248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single masking|Randomized clinical trial|t|f|f|f
33709575|NCT00134095||||TREATMENT||NONE||||||
33709576|NCT01965587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33791920|NCT05975983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791921|NCT02860884|||COHORT||RETROSPECTIVE|||||||
33791922|NCT06206330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33791923|NCT04664049|||CASE_ONLY||PROSPECTIVE|||||||
33791924|NCT00676533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791925|NCT06465498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"To reduce the risk of bias several levels of blinding are introduced:~1. Patients are blinded to their study arm allocation.~2. Treating physicians are blinded to the patient's study arm (both PE and POCUS arms will benefit from recommendations for decongestive therapy based on a generic congestion score).~3. Both sonographers and clinical investigators are reciprocally blinded and masked to the patient's study arm and clinical data files.~4. Outcomes adjudicators are blinded the patient's study arm~5. The biostatistician is blinded to the patients' study arm"|Multicentric blinded randomized controlled trial (RCT)|t|t|t|t
33791926|NCT05197699|||COHORT||PROSPECTIVE|||||||
33791927|NCT00722670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33791928|NCT00221637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801832|NCT03242148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801833|NCT02200094|||COHORT||PROSPECTIVE|||||||
33801834|NCT04619290|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single group comparison with contemporaneous conventionally treated patients.||||
33801835|NCT05205798|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33801836|NCT00182975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933748|NCT06198894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were blindfolded and earmuffed during the baseline procedure and follow-up endoscopic examinations. Implants were biodegradation at Week 4 to allow blinded assessment of bilateral edema score grade.|Stent-001 is a randomized (1:1), sham-controlled, parallel group, single-blind, non-inferiority, multicenter study|t|f|f|f
33933749|NCT06350877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Following completion of the baseline assessment (T1), students will be randomly assigned to an experimental arm or the control arm by a program coordinator for the study. To prevent care provider bias, the physical activity coaches will remain blind to the purpose of group allocation and hypotheses of the study. Research Randomizer (www.randomizer.org) will be used to allocate participants into three equal groups using a blocked design (with an allocation ratio of 1:1:1).|A 3-arm parallel Randomized Controlled Trial (RCT) assessing the immediate (post-intervention) and short-term (1-month) impact of the experimental arms (1:1 physical activity delivery and group-based physical activity delivery) compared to a 10-week control arm (wait-list control) will be conducted. A parallel arm design will be implemented, whereby participants will be randomized to a study arm and each study arm will be allocated a different intervention. The protocol adheres to CONSORT guidelines and SPIRIT recommendations for reporting of clinical trial protocols.|f|t|f|f
33933750|NCT04258449|||CASE_ONLY||PROSPECTIVE|||||||
33933751|NCT05533073|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933752|NCT00349024||||SUPPORTIVE_CARE||NONE||||||
33933753|NCT06507228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Propspective real world implementation and health economic study; historical control group for comparison||||
33933754|NCT01466062|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33933755|NCT04685369|||COHORT||RETROSPECTIVE|||||||
33933756|NCT01831011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933757|NCT00247806|||||PROSPECTIVE|||||||
33933758|NCT04140474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933759|NCT05177224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933760|NCT06274775|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33933761|NCT04668547|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Feasibility Study||||
34011935|NCT01021228|||COHORT||RETROSPECTIVE|||||||
34011936|NCT01709734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011937|NCT00116519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34011938|NCT02917408|||COHORT||RETROSPECTIVE|||||||
34011939|NCT04795388|||COHORT||RETROSPECTIVE|||||||
34011940|NCT00749502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011941|NCT06264791|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34011942|NCT02083419|||CASE_ONLY||PROSPECTIVE|||||||
33801837|NCT01833416|||COHORT||PROSPECTIVE|||||||
34095238|NCT04663672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34095239|NCT06296693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095240|NCT04992286|NA|SINGLE_GROUP||SCREENING||NONE||all participants receive the same intervention||||
34095241|NCT01873833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095242|NCT01112007|||COHORT||CROSS_SECTIONAL|||||||
34095243|NCT00746720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095244|NCT03356522|||CASE_ONLY||PROSPECTIVE|||||||
34095245|NCT01197027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095246|NCT00574899|||CASE_CONTROL||PROSPECTIVE|||||||
34095247|NCT02830633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095248|NCT00601237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095249|NCT02037074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095250|NCT06495281|||COHORT||PROSPECTIVE|||||||
34095251|NCT04135651|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The group assignments were sealed in opaque envelopes by a research assistant not involved in the study.~The interventional process covers opaque clothes."|Randomized double blinded clinical trial|t|f|t|t
34095252|NCT00158457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095253|NCT05135325|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The patients in the study will not know that other messages are being sent to other patients, although they will see the text of their own message. Providers will be blind to patient conditions.||t|t|f|f
34095254|NCT01363271|||COHORT||RETROSPECTIVE|||||||
34095255|NCT02113215|||COHORT||PROSPECTIVE|||||||
34095256|NCT02867826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095257|NCT03280680|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095258|NCT03849989|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095259|NCT02534480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095260|NCT02079870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095261|NCT05076929|||COHORT||PROSPECTIVE|||||||
34095262|NCT03428204|RANDOMIZED|PARALLEL||TREATMENT||NONE||The effect of two balloon inflation times will be evaluated in peripheral balloon angioplasty||||
34095263|NCT06387225|||OTHER||PROSPECTIVE|||||||
34095264|NCT00574561|||CASE_CONTROL||PROSPECTIVE|||||||
34095265|NCT04755725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34095266|NCT03738748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095267|NCT03413917|||OTHER||OTHER|||||||
33801838|NCT00823472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933762|NCT00011466|||DEFINED_POPULATION||OTHER|||||||
34095268|NCT02357485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095269|NCT01708525|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34095270|NCT03072875|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34095271|NCT06377163|||COHORT||RETROSPECTIVE|||||||
34095272|NCT03837275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double ( participant- outcome assessor) single blinded|it is randomized clinical trial.|t|f|f|t
33709577|NCT06411197|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33709578|NCT04478539|||COHORT||RETROSPECTIVE|||||||
34095273|NCT01509924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095274|NCT03281915|||CASE_ONLY||PROSPECTIVE|||||||
34095275|NCT00285675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095276|NCT02916329|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34095277|NCT04947267|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|2 % MEPIVACAINE WITH 1:100,000 EPINEPHRINE AND 3% MEPIVACAINE BOTH WERE MASKED BY DENTAL ASSISTANT WITH PINK AND BLUE COLOR RESPECTIVELY.||t|t|t|t
34095278|NCT02158507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095279|NCT03546231|||COHORT||RETROSPECTIVE|||||||
34095280|NCT04706403|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095281|NCT04193215|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34095282|NCT06421766|||COHORT||RETROSPECTIVE|||||||
34095283|NCT02211157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095284|NCT02264041|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709579|NCT04711044|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709580|NCT01844518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709581|NCT06505655|||COHORT||PROSPECTIVE|||||||
33709582|NCT06111300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|control group will take placebo|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery.Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.|t|f|f|f
33709583|NCT03123718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709584|NCT02601378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709585|NCT04466462|||CASE_CROSSOVER||OTHER|||||||
33709586|NCT03925883|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33709587|NCT04902794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709588|NCT02259881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33709589|NCT05878860|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Cohort 3 will be partially masked.|||||
33709590|NCT05108155|||COHORT||PROSPECTIVE|||||||
33709591|NCT02429544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33709592|NCT04329871|||CASE_ONLY||PROSPECTIVE|||||||
33933763|NCT02764086|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective non-randomised Phase I/II study with patients recruited to escalated dose cohorts. Escalated dose to the iGTV (internal gross tumour volume), with 60 Gy to the conventional PTV (planning target volume), will be delivered to successive cohorts of participants (6-12 participants/cohort) until the maximum tolerated oesophageal dose is determined. The minimum dose delivered to the iGTV will be 65 Gy, with 60 Gy to the PTV, delivered via intensity modulated radiation therapy (IMRT) or volume modulated arc therapy (VMAT), planned on an Average Intensity Projection (AVIP) dataset.||||
33709593|NCT06062511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33709594|NCT02298920|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709595|NCT00679315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709596|NCT03448783|||CASE_ONLY||PROSPECTIVE|||||||
33709597|NCT03435445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3 arms: Experimental group 1 receives diet, physical change and behavior change recommendations via an online platform for 24 weeks; Experimental Group 2 receives recommendations via an online platform plus a dietitian coaching via the online platform for 24 weeks; Control groups receives a minimal intervention with access to diet and physical change recommendations videos. After 24 weeks, the control group will gain access to the online platform.|f|f|f|t
33709598|NCT05042843|||OTHER||RETROSPECTIVE|||||||
33709599|NCT03969446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709600|NCT04976751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33709601|NCT03260309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33709602|NCT04007718|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33709603|NCT05139589|||COHORT||OTHER|||||||
33709604|NCT03258437|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33709605|NCT05965505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709606|NCT01749397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709607|NCT00002136||||TREATMENT||||||||
33709608|NCT06011044|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709609|NCT05747209|||OTHER||OTHER|||||||
33709610|NCT02454998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709611|NCT02412605|||CASE_CONTROL||RETROSPECTIVE|||||||
33709612|NCT02967744|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709613|NCT02034383|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33709614|NCT00864383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709615|NCT02716454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709616|NCT03638297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709617|NCT03986502|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33709618|NCT01369758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801839|NCT01507038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801840|NCT01647581|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33801841|NCT01098344|NON_RANDOMIZED|||TREATMENT||NONE||||||
33801842|NCT00484055|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33801843|NCT03771352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801844|NCT06429943|||COHORT||OTHER|||||||
33801845|NCT02306096|||COHORT||PROSPECTIVE|||||||
33801846|NCT04373434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33801847|NCT02704507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801848|NCT03368768|||CASE_ONLY||PROSPECTIVE|||||||
33801849|NCT01605773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801850|NCT01970813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933764|NCT03557229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933765|NCT00086385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011943|NCT03913182|NA|SINGLE_GROUP||TREATMENT||NONE|no special|no special||||
34011944|NCT01297816|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34011945|NCT04331964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34011946|NCT04310306|||COHORT||PROSPECTIVE|||||||
34011947|NCT00668720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34011948|NCT03940482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011949|NCT00733369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709619|NCT05382624|||CASE_ONLY||PROSPECTIVE|||||||
33709620|NCT02725710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709621|NCT00074152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709622|NCT02364739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709623|NCT00054145||||TREATMENT||NONE||||||
33709624|NCT05393258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709625|NCT06184932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709626|NCT06379412|||COHORT||CROSS_SECTIONAL|||||||
33709627|NCT01806298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709628|NCT03105895|||COHORT||PROSPECTIVE|||||||
33709629|NCT02414997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709630|NCT04524390|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709631|NCT06293495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, prospective trial with a CE-marked medical devices||||
33709632|NCT02088281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709633|NCT00730405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709634|NCT04040114|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Teledermatologist will be blinded to the Artificial Intelligence algorithm diagnosis.|Controlled before-and-after intervention study|f|f|f|t
33709635|NCT01378949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33709636|NCT05847920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709637|NCT04664166|||OTHER||PROSPECTIVE|||||||
33709638|NCT05705596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33709639|NCT02277756|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33709640|NCT00961233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709641|NCT00786149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709642|NCT00440713|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33709643|NCT03462303|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33709644|NCT01734863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709645|NCT01010061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709646|NCT02082275|RANDOMIZED|PARALLEL||||NONE||||||
33709647|NCT02614586|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33709648|NCT01564381|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33709649|NCT05704361|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33709650|NCT06506786|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33709651|NCT03379168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not feasible to blind patients who are randomized to receive Lipogems, as adipose tissue must be obtained from the participant. However, patients randomized to receive intra-articular corticosteroids or placebo injections will be blinded.|This study will be conducted as a randomized, placebo-controlled clinical trial. Patients will be randomized to receive either Lipogems, intra-articular corticosteroids, or a placebo injection of saline. Lipogems is cleared for use by the FDA in orthopaedics and arthroscopy and is offered as a treatment option for knee osteoarthritis. This study will be evaluating the effectiveness (not safety) of Lipogems when compared to corticosteroids and placebo. Thus, no information will be submitted to the FDA.|t|f|f|f
33709652|NCT03773991|||COHORT||PROSPECTIVE|||||||
33709653|NCT04713462|||COHORT||RETROSPECTIVE|||||||
33709654|NCT01583491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33709655|NCT05460845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709656|NCT01918774|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33709657|NCT03641638|||CASE_CONTROL||PROSPECTIVE|||||||
33709658|NCT02837783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709659|NCT05541952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709660|NCT01507597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33709661|NCT03706456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709662|NCT00549705|||COHORT||RETROSPECTIVE|||||||
33709663|NCT02697825|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709664|NCT03939260|||CASE_ONLY||PROSPECTIVE|||||||
33709665|NCT02639143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709666|NCT05120128|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|The participant will be masked to the identity of the study lens even though only one arm has been specified.|||||
33709667|NCT02067338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33709668|NCT02742610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709669|NCT02952781|||CASE_ONLY||PROSPECTIVE|||||||
33709670|NCT01996293|||CASE_ONLY||PROSPECTIVE|||||||
33709671|NCT01052350|||CASE_CONTROL||PROSPECTIVE|||||||
33709672|NCT06366620|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720606|NCT04899414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801851|NCT02703558|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801852|NCT02988089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801853|NCT03722316|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933766|NCT03374891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Step-wedge design. 6 groups will begin recruiting participants as control participants. Throughout the study, at 5 month intervals, 1 randomly selected site at a time will begin intervention.~Due to the impact of COVID-19 on sites and patient visits from March-April 2020, we moved back the implementation of intervention dates for the 5th site (UCH/DH) by 2 months and the 6th site (Beth Israel) by 1 month."||||
33933767|NCT01894776|NA|SINGLE_GROUP||OTHER||NONE||||||
33933768|NCT00726310|||CASE_ONLY||PROSPECTIVE|||||||
33933769|NCT04878276|||OTHER||PROSPECTIVE|||||||
33933770|NCT02839044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933771|NCT05094882|||COHORT||PROSPECTIVE|||||||
33933772|NCT03364062|||COHORT||PROSPECTIVE|||||||
33933773|NCT03884127|||CASE_CONTROL||PROSPECTIVE|||||||
33933774|NCT04026646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933775|NCT04346004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither participants, all care providers, investigators nor outcomes assessors know the treatment allocations.|Patients are divided into 2 groups, who are administered Iron isomaltoside \& Vitamin B12 or who are administered Normal saline (N/S).|t|t|t|t
33933776|NCT04835441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933777|NCT03335306|||COHORT||PROSPECTIVE|||||||
33933778|NCT02373891|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933779|NCT05993572|||COHORT||PROSPECTIVE|||||||
33933780|NCT03151538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental, Randomized Controlled Study||||
33933781|NCT04241120|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33933782|NCT01017692|||COHORT||PROSPECTIVE|||||||
33933783|NCT00785005|||COHORT||PROSPECTIVE|||||||
33933784|NCT01992328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933785|NCT06204510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933786|NCT04154995|||COHORT||PROSPECTIVE|||||||
33933787|NCT01680991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933788|NCT03206983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011950|NCT05122767|NA|SINGLE_GROUP||OTHER||NONE||Single-arm, multi-center, Phase I/II clinical trial, in two groups. Individuals with HIV infection taking Efavirenz (EFV), nevirapine (NVP) or lopinavir/ritonavir (LPV/r) and two nucleoside reverse transcriptase inhibitors (NRTI) who have undetectable HIV viral load (\< 50 copies/mL) and an indication for TPT, will be switched to DTG with tenofovir/emtricitabine (TDF/FTC), tenofovir/lamivudine (TDF/3TC), abacavir/lamivudine (ABC/3TC) or zidovudine/lamivudine (AZT/3TC) in accordance with South African National HIV Guidelines. Groups 1 and 2 will receive weekly HP for 12 total doses starting 4 weeks after initiating DTG. Individuals who are on an existing DTG-based plus two NRTI ART regimen for at least four weeks (and have not received efavirenz, or nevirapine or lopinavir/ritonavir for at least four weeks) who have an undetectable HIV viral load may also participate.||||
33801854|NCT06221059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011951|NCT06437106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Intervention group one includes premature babies who receive a blanket impregnated with the mother's smell.~The second intervention group includes premature babies who receive a blanket without the smell of the mother.~The control group includes premature babies who do not receive any intervention and receive routine care."|t|f|t|t
34011952|NCT04539626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcome Assessor will be an external member of the Gynecology Service, which will be blinded to the intervention.||f|f|f|t
34011953|NCT02947724|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34095285|NCT05016336|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE||The study included 32 subjects, 20 in the experimental group and 12 in the control group. The experimental group received 12 sessions of strategy-based cognitive training combined with a socially interactive learning method. The control group received the same number of meetings but without the strategy training. Participants were recruited from designated active groups in the community.|t|f|f|t
34095286|NCT02147080|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34095287|NCT05311163|||COHORT||OTHER|||||||
34095288|NCT04696770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095289|NCT01086475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095290|NCT00009555||||TREATMENT||DOUBLE||||||
34095291|NCT01392196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095292|NCT06468020|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33801855|NCT00354653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801856|NCT06197217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801857|NCT05789953|||COHORT||PROSPECTIVE|||||||
33801858|NCT02236793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801859|NCT00387452|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801860|NCT02596113|||CASE_CONTROL||PROSPECTIVE|||||||
33801861|NCT00871130|||COHORT||RETROSPECTIVE|||||||
33801862|NCT01040689|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33801863|NCT03035994|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33801864|NCT04002622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801865|NCT02660970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095293|NCT00668083|||CASE_ONLY||RETROSPECTIVE|||||||
34095294|NCT00902525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801866|NCT06331494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095295|NCT05472298|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34095296|NCT00661219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095297|NCT05955833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095298|NCT03698916|||COHORT||PROSPECTIVE|||||||
34095299|NCT06195215|RANDOMIZED|PARALLEL||OTHER||SINGLE||The research will be conducted in a single-centre, parallel group, randomised controlled pretest-posttest design.|f|f|f|t
34095300|NCT01922609|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095301|NCT02664883|||CASE_CONTROL||PROSPECTIVE|||||||
34095302|NCT00354211|||COHORT||PROSPECTIVE|||||||
33801867|NCT01548170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095303|NCT05349370|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801868|NCT06326931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinician evaluating MGS score was masked to subject treatment assignment|Prospective, randomized, controlled clinical trial|f|f|f|t
33801869|NCT01101594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801870|NCT00830934|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933789|NCT01326676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933790|NCT05743725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33933791|NCT00859573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933792|NCT03634228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933793|NCT03275519|RANDOMIZED|PARALLEL||TREATMENT||NONE||Using the block randomization procedures, a subject was assigned to a study group by computer using the REDCap randomization module. Subjects were randomized to receive post operative antibiotics or to not receive any antibiotics postoperative.||||
33933794|NCT06030076|||COHORT||PROSPECTIVE|||||||
33933795|NCT02740894|||CASE_ONLY||RETROSPECTIVE|||||||
33933796|NCT01979042|||COHORT||PROSPECTIVE|||||||
33933797|NCT02425969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933798|NCT03922711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933799|NCT01633528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933800|NCT06391970|NA|CROSSOVER||OTHER||NONE||"DigiCog is a crossover interventional study, involving participants selected both with and without the specific condition of long COVID. The intervention in this study is the use of a new digital device, which is being evaluated in comparison to the gold standard method.~Each participant receives both interventions in a predetermined sequence. This crossover design enables within-subject comparisons, as each participant acts as their own control. By comparing outcomes within the same participant under different interventions, this design helps to reduce variability and increase the statistical power of the study.~NB: Although a crossover design may typically imply multiple arms, in this specific study, participants serve as their own controls, resulting in only one arm."||||
33933801|NCT00004690|RANDOMIZED|||TREATMENT||DOUBLE||||||
33933802|NCT04844372|||OTHER||RETROSPECTIVE|||||||
33933803|NCT03987867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933804|NCT05533086|||OTHER||PROSPECTIVE|||||||
33933805|NCT04476615|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933806|NCT02505269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933807|NCT02852291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33933808|NCT02591836|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33933809|NCT02296905|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933810|NCT00005792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933811|NCT02747329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933812|NCT02943668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933813|NCT00614042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933814|NCT04162912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33933815|NCT04409340|||OTHER||CROSS_SECTIONAL|||||||
33933816|NCT00564603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933817|NCT01307228|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33933818|NCT00644241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933819|NCT00781404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933820|NCT03922269|||COHORT||PROSPECTIVE|||||||
33933821|NCT05533164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933822|NCT00947089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933823|NCT03746990|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33933824|NCT06003452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933825|NCT03649815|NA|SINGLE_GROUP||OTHER||NONE||||||
33933826|NCT02220530|||CASE_CONTROL||PROSPECTIVE|||||||
33933827|NCT03442595|||CASE_CONTROL||RETROSPECTIVE|||||||
33933828|NCT01314144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933829|NCT06234306|||COHORT||PROSPECTIVE|||||||
33933830|NCT01713257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34011954|NCT06317584|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The process of keeping the study group assignment hidden after the allocation to participant, care provider, investigator, outcomes assessor|Randomized trail method|t|t|t|t
34011955|NCT02904499|||COHORT||RETROSPECTIVE|||||||
34011956|NCT01643226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011957|NCT01103479|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33933831|NCT02703649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933832|NCT05495776|||COHORT||PROSPECTIVE|||||||
33933833|NCT01041040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933834|NCT00411970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33933835|NCT00641745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933836|NCT02777164|NA|SINGLE_GROUP||SCREENING||NONE||||||
33933837|NCT02749786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933838|NCT04561284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933839|NCT04970433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33933840|NCT00472043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933841|NCT04539665|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933842|NCT01964027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933843|NCT04258904|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933844|NCT02194452|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933845|NCT06198504|NA|SINGLE_GROUP||OTHER||NONE||||||
33933846|NCT00438776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933847|NCT00994760|||COHORT||PROSPECTIVE|||||||
33933848|NCT04493944|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933849|NCT02382614|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933850|NCT01085773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33933851|NCT05105529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Air quality condition (Ozone and filtered air) will be double-blinded; Participants will not be told at any time before the study completion to which group they are assigned (intervention or sham)||t|t|f|t
33933852|NCT02750501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933853|NCT00662727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33933854|NCT04838639|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33933855|NCT00658866|NA|SINGLE_GROUP||||NONE||||||
33933856|NCT00736606|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933857|NCT05953103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011958|NCT03998436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subject will be masked from the treatment by the Study Nurse (care giver) by using blinder during each treatment application. The site has two separate teams (blinded and unblinded) for masking. The unblinded investigator performs application of treatment during each treatment visit of subject to the site.|Prospective, Multicenter, Randomized, Double-Blind, Parallel groups|t|f|t|t
34011959|NCT00026871||||TREATMENT||||||||
34011960|NCT01316419|||||PROSPECTIVE|||||||
34011961|NCT01597219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34011962|NCT02291692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011963|NCT05820386|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34011964|NCT04822376|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"Efficacy trial : Exploratory, non-comparative, unblinded trial with Mab at D0 and vaccine at W6.~Immunological ancillary study : Exploratory, controlled, comparative, non-randomized, 2-group, unblinded study comparing Mab at D0 and vaccine at W6 for high-risk contacts with vaccine at D0 for vaccinated contacts."||||
34011965|NCT04265950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011966|NCT06324058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011967|NCT05295654|NA|SINGLE_GROUP||OTHER||NONE||||||
34011968|NCT05391711|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to a cultural humility and social justice training and support intervention or to a control group for a period of one year.||||
34011969|NCT03421041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011970|NCT02743728|||OTHER||CROSS_SECTIONAL|||||||
34011971|NCT01145924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34011972|NCT02276898|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095304|NCT05946772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators, care providers, and outcomes assessors are masked from study arm affiliation.|Double-blind multicentre RCT|t|t|t|t
34095305|NCT03463447|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709673|NCT05038436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The trial product (verum and placebo) is labelled and packaged by an authorised body according to randomisation, so that there is only specific numbering according to randomisation on the otherwise identical-looking packs. An emergency envelope, located at the study centre, can be used to unblind in an emergency by the principal investigator or investigator.|prospective, randomised, double blind, placebo controlled, 2 period crossover, monocenter|t|t|t|t
33709674|NCT03947320|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33709675|NCT00147446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33709676|NCT03056885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709677|NCT05930977|||CASE_ONLY||PROSPECTIVE|||||||
33709678|NCT06063824|NA|SINGLE_GROUP||OTHER||NONE||||||
33709679|NCT06332235|||OTHER||PROSPECTIVE|||||||
33709680|NCT04022993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709681|NCT05214456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709682|NCT00065403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33709683|NCT06014268|||OTHER||PROSPECTIVE|||||||
33709684|NCT02906618|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709685|NCT00669227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709686|NCT06177327|||COHORT||RETROSPECTIVE|||||||
33709687|NCT02824952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709688|NCT02251184|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709689|NCT05243836|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33709690|NCT01163045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33709691|NCT02880059|||CASE_CONTROL||PROSPECTIVE|||||||
33709692|NCT06298994|||CASE_CONTROL||PROSPECTIVE|||||||
33709693|NCT02550106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33709694|NCT01751178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33709695|NCT05776589|||COHORT||PROSPECTIVE|||||||
33709696|NCT02480114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709697|NCT05006911|NA|SINGLE_GROUP||TREATMENT||NONE||To determine safety and efficacy of a Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac compound to improve near uncorrected vision in healthy presbyopic patients||||
33709698|NCT00370032|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33709699|NCT01615185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709700|NCT02176499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33709701|NCT00878423|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709702|NCT03839901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709703|NCT00096070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709704|NCT06342414|||CASE_ONLY||RETROSPECTIVE|||||||
33709705|NCT02139228|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801871|NCT04038736|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|3 independent reviewers, licensed physicians, trained with reviewing and analyzing C-Scan System scans, will evaluate all study subjects original scans for potential findings, including type, location and size. All reviewers will be blinded to the subject groups (symptoms, classification etc.)|Evaluation of the performance of the C-Scan System in providing structural information on colonic polypoid lesions and masses in average risk vs. high risk subjects.|f|f|f|t
33933858|NCT02031510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933859|NCT03188302|NA|SINGLE_GROUP||OTHER||NONE||||||
33933860|NCT00216749|||COHORT||PROSPECTIVE|||||||
33933861|NCT03965546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933862|NCT01116349|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933863|NCT03623906|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33933864|NCT00809575|||COHORT||PROSPECTIVE|||||||
33933865|NCT02507050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933866|NCT02146768|||COHORT||RETROSPECTIVE|||||||
33933867|NCT03793894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33933868|NCT05118568|||OTHER||PROSPECTIVE|||||||
33933869|NCT02467660|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33933870|NCT04024202|||COHORT||PROSPECTIVE|||||||
33933871|NCT03658967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Double-blind, placebo-controlled, randomized|t|t|t|t
33933872|NCT00498368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933873|NCT02253160|RANDOMIZED|CROSSOVER||||NONE||||||
33933874|NCT02654041|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33933875|NCT04063176|||COHORT||PROSPECTIVE|||||||
33933876|NCT05427864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||47 male patients who will be evaluated with both imaging studies will be included in the study.||||
33933877|NCT02832817|||CASE_CROSSOVER||PROSPECTIVE|||||||
33933878|NCT04942522|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33933879|NCT00509028|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933880|NCT01343849|||COHORT||PROSPECTIVE|||||||
33933881|NCT06193980|||CASE_CONTROL||PROSPECTIVE|||||||
33933882|NCT04915105|NA|SINGLE_GROUP||SCREENING||NONE||||||
33933883|NCT00882362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933884|NCT06201403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095306|NCT05930470|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||Sham-controlled crossover trial|t|t|t|t
34095307|NCT03780062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095308|NCT03041870|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095309|NCT02726295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709706|NCT00011076||||TREATMENT||||||||
34095310|NCT00720200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095311|NCT03739554|NA|SINGLE_GROUP||TREATMENT||NONE||Three to 6 patients will be entered at a given CYC065 dose level. Dose escalation will be 33% until one out of 3 patients experienced a DLT at a given dose level. Dose escalation will continue at 25% if no additional DLT is observed; otherwise, dose escalation will be stopped. At least 6 patients will be treated at RD.||||
34095312|NCT03808454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011973|NCT03988517|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients were block randomized into two groups according to the time they are going to take the leovthyroxine tablet||||
33709707|NCT05778097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011974|NCT03686150|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized, parallel arm clinical trial 4 arms in part 1 2 arms in part 2||||
34011975|NCT03116321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011976|NCT06274866|RANDOMIZED|PARALLEL||TREATMENT||NONE|no blinding|Randomize controlled two groups||||
34011977|NCT05990504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34011978|NCT01560507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011979|NCT00396331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34011980|NCT04224727|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Respondents who meet the inclusion/exclusion criteria will be randomized into one of the following arms:~1. Control Arm (No Intervention)~2. Group Contract Arm~3. Individual Monetary Rewards Arm~4. Individual Commitment Contract Arm~To understand the effect that knowledge about the effectiveness of commitment contracts has on uptake, smoking quit rates, and weight loss, we will be cross-randomizing those assigned to Arms #2-4 into further subgroups:~Subgroup A. In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates. In other words, we aim to provide information that will encourage present-biased or loss-averse individuals to participate in the programs that offer the greatest chance at success.~Subgroup B. Participants will not receive any information about commitment contracts."||||
34011981|NCT03914118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34011982|NCT05759117|||COHORT||PROSPECTIVE|||||||
34011983|NCT05814991|||COHORT||PROSPECTIVE|||||||
33709708|NCT00380822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34011984|NCT00669981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34011985|NCT04913207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011986|NCT01481870|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34011987|NCT04146831|NA|SINGLE_GROUP||TREATMENT||NONE||Sintilimab||||
34011988|NCT03754751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34011989|NCT02199535|||||PROSPECTIVE|||||||
34011990|NCT03678779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34011991|NCT04364737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34011992|NCT01964443|||COHORT||PROSPECTIVE|||||||
34095313|NCT04661228|||COHORT||OTHER|||||||
33709709|NCT03785808|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Participants will be randomized to the low-carbohydrate diet (Diet A), the low-fat diet (Diet B), or the USDA control diet (Diet C). Participants will not be informed about the nature of the intervention diets or the hypotheses we aim to test. The participants will know the diets only as Diet A, Diet B, and Diet C. They will be de-briefed about the nature of the diets and our hypotheses by mail after the study has been completed. At that time, we will also offer them a folder with the dietary guidelines and recipes for the diets they had not been randomized to. The reason participants will be blinded about the diets is that knowing the details may create a placebo effect and/or opting into another intervention diet."||t|f|f|f
33709710|NCT03870698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709711|NCT05916014|||OTHER||PROSPECTIVE|||||||
33709712|NCT02818400|NA|SINGLE_GROUP||OTHER||NONE||||||
33709713|NCT00501670|||CASE_ONLY||PROSPECTIVE|||||||
33709714|NCT01725178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33709715|NCT03566147|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709716|NCT02836730|||COHORT||PROSPECTIVE|||||||
33709717|NCT04970797|||COHORT||PROSPECTIVE|||||||
33709718|NCT01561170|||CASE_ONLY||RETROSPECTIVE|||||||
33709719|NCT05938972|||COHORT||PROSPECTIVE|||||||
33709720|NCT04026997|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33709721|NCT02338141|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33709722|NCT04635462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This clinical trial is a single-blinded study. Research personnel performing the outcome assessments at baseline, three, six and twelve months will be blinded to group allocation. Participants will be aware of the type of training they receive.||f|f|f|t
33709723|NCT00630396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709724|NCT04613960|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33709725|NCT01184300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709726|NCT00205881|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709727|NCT00750932|||CASE_CONTROL||PROSPECTIVE|||||||
33801872|NCT00533910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34011993|NCT03720574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34011994|NCT02471079|||COHORT||RETROSPECTIVE|||||||
34011995|NCT05479422|||OTHER||PROSPECTIVE|||||||
34011996|NCT05382520|NA|SINGLE_GROUP||OTHER||NONE||Prospective Pilot and Feasibility study||||
34011997|NCT01014962|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34011998|NCT03977259|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Parents, clinical, and research staff apart from the study milk technician will be unaware of the treatment group.||t|t|t|t
34011999|NCT00805155|||COHORT||PROSPECTIVE|||||||
34012000|NCT00307931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095314|NCT05028088|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34095315|NCT06122064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34095316|NCT06433726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095317|NCT02930447|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34095318|NCT04889651|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095319|NCT01529216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095320|NCT00837460||CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34095321|NCT03428854|||COHORT||PROSPECTIVE|||||||
34095322|NCT01271972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095323|NCT04833608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095324|NCT05192876|||COHORT||PROSPECTIVE|||||||
34095325|NCT03400553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095326|NCT04243837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|Consists of 1 cohort with 2 arms: active treatment or placebo patients|t|t|t|f
34095327|NCT05037383|NA|SINGLE_GROUP||OTHER||NONE||||||
34095328|NCT02547987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095329|NCT05186298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095330|NCT06122493|NA|SINGLE_GROUP||TREATMENT||NONE||Chemotherapy includes carboplatin (AUC = 5, d1) and nab-paclitaxel (175 mg/m², day1) every 3 weeks for four cycles. Simultaneously, immunotherapy with tislelizumab (200 mg) is integrated into the treatment plan for these cycles. After the initial four cycles, patients have physical exams and imaging. Those with SD, PR, or CR receive radiotherapy targeting esophageal lesions and positive lymph nodes, with a total dose of 50.4 Gy over 28 fractions. During radiotherapy, two additional cycles of immunotherapy with tislelizumab are given at three-week intervals. After radiotherapy, patients continue with maintenance treatment, taking tislelizumab every three weeks. This maintenance therapy lasts up to a year, or until disease progression or intolerance develops.||||
34095331|NCT01090206|NA|SINGLE_GROUP||SCREENING||NONE||||||
34095332|NCT06298409|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709728|NCT04603443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both participants and study team members will be double blinded to intervention. The biostatistician and Research Pharmacist dispensing drug will be the only ones with the key to unblinding.|Randomized, double-blinded, placebo-controlled feasibility study|t|f|t|t
34095333|NCT03472677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095334|NCT03786575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709729|NCT00779701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709730|NCT00120094|||DEFINED_POPULATION||PROSPECTIVE|||||||
33709731|NCT03334903|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm parallel design.||||
33709732|NCT02414984|||COHORT||PROSPECTIVE|||||||
33709733|NCT02309684|||CASE_ONLY||PROSPECTIVE|||||||
33709734|NCT00918827|||COHORT||PROSPECTIVE|||||||
33709735|NCT01084369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709736|NCT00787891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709737|NCT01816282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709738|NCT04554979|||COHORT||RETROSPECTIVE|||||||
33709739|NCT03214965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned to participate into one of two groups (control group or intervention group) in parallel for the duration of the study. The control group receives no form of intervention or education. The intervention group participates into a closed facebook group.||||
33709740|NCT01797653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709741|NCT03604380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709742|NCT02713347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Statistician|Parallel|f|f|t|t
33709743|NCT03598621|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33933885|NCT01828567|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33933886|NCT01589575|||COHORT||PROSPECTIVE|||||||
33933887|NCT05849064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||One group receives basic behavioral management strategies. The second group gets targeted treatment strategies dependent on the concussion symptoms they are expressing.|t|f|t|f
33709744|NCT04481867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded|randomized control trail|f|f|f|t
33709745|NCT03982407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709746|NCT00635596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801873|NCT04677192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801874|NCT04999917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801875|NCT03406936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801876|NCT05237752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801877|NCT00276601||||TREATMENT||||||||
33801878|NCT04946487|||COHORT||RETROSPECTIVE|||||||
33801879|NCT02255877|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801880|NCT00257049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933888|NCT05984511|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, open-label trial, randomized controlled trial to evaluate the efficacy and safety of TACE-AB-I compared with TACE-AB for the treatment of HCC with branch PVTT.||||
33933889|NCT04447625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933890|NCT01174940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933891|NCT05354973|||COHORT||PROSPECTIVE|||||||
33933892|NCT01250301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933893|NCT01678560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33933894|NCT01575249|||CASE_CONTROL||PROSPECTIVE|||||||
33933895|NCT00169013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933896|NCT01576991|||COHORT||PROSPECTIVE|||||||
33933897|NCT01525524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933898|NCT04574674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Members of the research team that perform measurements are blinded to group allocation.|Randomised controlled trial with two groups, flexibility exercise group and resistance exercise group.|f|f|f|t
33933899|NCT05469152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33933900|NCT03908931|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933901|NCT00177008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933902|NCT01395966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933903|NCT02437721|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33933904|NCT02443051|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33933905|NCT00122317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933906|NCT00467012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33933907|NCT00113906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33933908|NCT01328769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33933909|NCT01787045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34095335|NCT00465868|||CASE_ONLY||PROSPECTIVE|||||||
34095336|NCT03380741|||OTHER||PROSPECTIVE|||||||
34095337|NCT02715752|||COHORT||RETROSPECTIVE|||||||
34095338|NCT03461809|||COHORT||RETROSPECTIVE|||||||
34095339|NCT04453254|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34095340|NCT06094829|||OTHER||CROSS_SECTIONAL|||||||
34095341|NCT00807404||||DIAGNOSTIC||NONE||||||
34095342|NCT03159949|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will know what exercise group they are assigned to.|||||
33709747|NCT06183424|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33709748|NCT01238471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33709749|NCT03651245|||COHORT||PROSPECTIVE|||||||
33709750|NCT02144428|||COHORT||PROSPECTIVE|||||||
33709751|NCT00714181||||TREATMENT||NONE||||||
33801881|NCT02172872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801882|NCT04135040|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933910|NCT03363789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will analyze the data as group 1 and 2, not knowing which group received what treatment.|Randomized Control Trial|f|f|f|t
33933911|NCT05605704|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Active Comparator: atherolive group Placebo Comparator: placebo group|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.|t|f|f|f
33933912|NCT02863861|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33933913|NCT05128604|||COHORT||PROSPECTIVE|||||||
33933914|NCT05121428|||COHORT||CROSS_SECTIONAL|||||||
33933915|NCT04839679|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33933916|NCT03352869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933917|NCT06239701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to either a Fitbit Only Condition, or a Fitbit + A Lifestyle Physical Activity Intervention.|f|f|f|t
33933918|NCT04281108|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33933919|NCT02647372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933920|NCT01653756|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33933921|NCT03765177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933922|NCT00002968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933923|NCT03175250|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|"Participants were randomly assigned by computer algorithm to three different conditions, and the intervention took place over individually assigned computers with screens that were not observable by the care provider, investigator, or outcome assessor. The two control groups were designed to be active, that is, designed to have some effects. Thus, there was no indication of which intervention might be more effective."|Participants were randomly assigned at the individual level to one of three different conditions within each drug diversion class.|t|t|t|t
33933924|NCT06343129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933925|NCT02614261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33933926|NCT05074394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933927|NCT05769907|NA|SINGLE_GROUP||OTHER||NONE||"Study setting The study was carried on by the Laboratory of Molecular Psychiatry at Hospital Clinic of Porto Alegre (HCPA), Brazil. The study will consist of face-to-face sessions performed in the Clinical Research Center (CPC) of the HCPA and online sessions performed through the platform Teams.~This project complies with the guidelines presented in SPIRIT 2013 Standard protocol items: Recommendations for Interventional Trials, an international protocol that aims to improve the completeness of studies, producing recommendations for a minimum set of items to be addressed. The 2013 SPIRIT Statement includes a 33-item checklist ."||||
33933928|NCT04471168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33933929|NCT01585168|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||All subjects received both the study drug and placebo. Family history was the main variable of interest, and randomization was stratified by this variable.|t|t|f|f
33933930|NCT00895908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Comparison of social skill training intervention with active attention control group (academic tutoring)|t|f|f|t
33709752|NCT03387332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709753|NCT04649060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent Review Committee was planned to be blinded to treatment assignment. Due to the early termination, the response assessments were only done by investigators, not by an independent review committee.||f|f|f|t
33709754|NCT02006719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709755|NCT03293589|||COHORT||RETROSPECTIVE|||||||
33709756|NCT00317356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33709757|NCT03088982|||COHORT||PROSPECTIVE|||||||
33709758|NCT01179568|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33709759|NCT05320120|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33709760|NCT01563302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709761|NCT05199012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33801883|NCT03698084|||COHORT||PROSPECTIVE|||||||
33801884|NCT01141959|||CASE_ONLY||PROSPECTIVE|||||||
33801885|NCT00634075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801886|NCT01118754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801887|NCT01953692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801888|NCT03759236|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two clinics are randomized to receive the health messaging via SMS and the third clinic is randomized to receive standard CDC health education materials.||||
33933931|NCT05385913|||COHORT||RETROSPECTIVE|||||||
33933932|NCT04236531|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Three groups of participants will be recruited: individuals at ultra-high risk for psychosis, first-episode psychosis patients and healthy controls.||||
33933933|NCT01542294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933934|NCT05451602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012001|NCT04745208|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Outcome assessor will be masked in the clinical trial. One of the investigators will enter the data by giving a for control group and b for intervention group. So that, the outcome assessor will not have knowledge which group is exposed to intervention."|Simulation-based education will be performed after the standard discharge training with the intervention group. The control group will receive only the standard discharge education|f|f|f|t
34012002|NCT00177463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709762|NCT06106178|RANDOMIZED|PARALLEL||OTHER||SINGLE|The POCUS examinations are videotaped without the possibility of identifying the participant. A camera visually records the movements of the ultrasound probe and the participant's hand, while a pen is used to mark the appropriate structures on the frozen ultrasound images. The audio recordings of these videos are transcribed and presented to the evaluators in written form only. After all participants have completed the baseline assessment, these two videos from each participant will be edited together and can be presented to the experts for evaluation as a compact video along with the transcribed audio recordings. In addition, the videos and audio transcripts presented to the experts will be labeled with randomly generated numbers for scoring.|Participants will attend a 90-minute workshop to learn the basics of point-of-care echocardiography. They will then be required to perform standardized transthoracic echocardiography before and after a two-week training period, which will be scored by blinded experts. During the training phase, one group will practice the hand-eye coordination required for echocardiography using an ultrasound simulator, while the second group will practice the same content using a serious video game. In addition, questionnaires will be used to collect additional data from the participants.|f|f|f|t
33709763|NCT04517812|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE|masking not considered for this feasibility investigation|||||
33709764|NCT04348773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709765|NCT00136799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33709766|NCT05096767|||CASE_ONLY||CROSS_SECTIONAL|||||||
33709767|NCT01578460|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33801889|NCT02803476|||CASE_CONTROL||PROSPECTIVE|||||||
33801890|NCT03107624|||COHORT||PROSPECTIVE|||||||
33801891|NCT06392412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33801892|NCT05927896|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801893|NCT04319432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective Study. In this study, patients will be placed into one of two different groups of voice rest duration. The voice rest durations will last either 3 or 7 days. Voice recording results of the different groups will be examined and analyzed. At the conclusion of this study, we hope to provide some clarity as to the optimal duration of voice rest following phonosurgery.|f|f|t|f
33801894|NCT04945135|||OTHER||RETROSPECTIVE|||||||
33801895|NCT00043966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801896|NCT03717506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801897|NCT01230450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933935|NCT00726492|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33933936|NCT04172376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933937|NCT06185062|||COHORT||PROSPECTIVE|||||||
33933938|NCT01637857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933939|NCT03605836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33933940|NCT02659137|||||PROSPECTIVE|||||||
33933941|NCT04673461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The test and reference IMPs will be identical in appearance. The kits will not contain any other information about treatment. Therefore, all site staff and patients will be blinded at treatment administration.|"Three treatment groups:~* STA363 60 mg/mL~* STA363 120 mg/mL~* Placebo"|t|t|t|t
33933942|NCT02325804|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33933943|NCT01969305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33933944|NCT03609710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012003|NCT00865098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012004|NCT04785157|||COHORT||PROSPECTIVE|||||||
34012005|NCT01264549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012006|NCT05862272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012007|NCT04704141|||CASE_CONTROL||PROSPECTIVE|||||||
34012008|NCT00296491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012009|NCT06326502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012010|NCT03365544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One group has their eating window between 6am-2pm and the other has their eating window between 2pm-10pm.||||
34012011|NCT05723419|||COHORT||CROSS_SECTIONAL|||||||
34012012|NCT02678442|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
34095343|NCT00800384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33709768|NCT06281106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Lab personnel|"During 4 weeks the patients of the 2 arms receive either Deucravacitinib 6mg 1x/day or an identically looking placebo.~At Week 4, Patients with underlying disease of Crohn's disease, colitis ulcerosa, uveitis will stop the study, to avoid that they are too long without efficient treatment for their underlying disease.~Patients with underlying disease of psoriasis or psoriatic arthritis will have the possiblity to continue in Part 2, where they all will receive Deucravacitinib 6mg 1x/day, open label for 3 months"|t|t|t|t
33709769|NCT00390468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709770|NCT04720898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012013|NCT04265690|NA|SINGLE_GROUP||PREVENTION||NONE||For this proof of concept/pilot trial, we will assess the feasibility and impact of this multi-component nutrition program on improving healthy eating behaviors and eating competence. However, because we are proposing a proof of concept pilot and feasibility study, in our experience and that of others, our proposed sample size generally provides sufficient data to estimate subject retention, distribution of variables and feasibility as we plan for a larger-multi-site RCT of the proposed study. We expect our intervention to demonstrate the feasibility of the intervention in a clinic setting.||||
34012014|NCT02695940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012015|NCT02716350|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34012016|NCT02655055|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34012017|NCT05380323|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012018|NCT01443910|||OTHER||CROSS_SECTIONAL|||||||
33801898|NCT00063713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801899|NCT00339131|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801900|NCT00746343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801901|NCT04095715|||COHORT||PROSPECTIVE|||||||
33709771|NCT01255202|||COHORT||PROSPECTIVE|||||||
33709772|NCT00346112|RANDOMIZED|PARALLEL||||NONE||||||
33709773|NCT01130012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709774|NCT00168220|||CASE_CONTROL||RETROSPECTIVE|||||||
33709775|NCT01845493|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33801902|NCT05150912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801903|NCT04828590|||CASE_ONLY||RETROSPECTIVE|||||||
33801904|NCT04542733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012019|NCT02695719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012020|NCT04834739|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|study and control group|30 volunteer healthcare workers who had Covid-19 and stayed in hospital or at home were included. In control group, 30 volunteer healthcare workers who were matched for age and gender with study group were included and these persons had not have Covid-19. Healthcare workers who have had Covid-19 disease will be evaluated for the first time within 1 month after their diagnosis with RT-PCR test for SARS-CoV-2 (The condition of completing isolation process of the patients will be sought).|f|f|f|t
34012021|NCT01981824|||CASE_CONTROL||PROSPECTIVE|||||||
34012022|NCT00951184|||COHORT||PROSPECTIVE|||||||
34012023|NCT01983514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33791929|NCT06183918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research products, saline and tranexamic acid ampoules containing 250 mg/2.5 ml of injectable solution, both in colorless, odorless, clean, and clear liquid form. The medications and medical supplies (gauze soaked with saline and TXA) to be used in the treatment according to the randomization number were prepared by a physician and a nurse working in the emergency room that were informed about the research priorly. Blindness was ensured by filling all groups to a 10 cc volume with saline. The prepared anterior nasal packing and medication administration were performed blindly by another emergency physician. Pressure was applied to both sides of the nose wings during the application for 10 minutes. Another researcher, who was not responsible for the preparation and administration of the medication, recorded the data in the Case Report Form.|"This randomized, double-blinded, phase-4 study. 3 different materials used to soak the gauze in nasal packing with gauze application, which is a treatment method for anterior epistaxis, were compared in terms of their superiority. First, those who met the study criteria and accepted to participate in the study and whose written consent was obtained were assigned to one of the treatment groups according to the next randomization number. Treatment groups were determined as;~1. Group: Gauze soaked with 1000 mg TXA-topical~2. Group: Gauze soaked with 500 mg TXA + 5 cc saline -topical~3. Group: Gauze soaked with 10 cc of saline-topical."|t|f|t|t
33709776|NCT03326102|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned to DHP107 or IV paclitaxel in a ratio of 2:1 (n=48 to DHP107 and n=24 to IV paclitaxel)||||
33709777|NCT03753529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709778|NCT03808532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33709779|NCT05777577|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801905|NCT00206986|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33709780|NCT00500669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33709781|NCT04229563|||COHORT||PROSPECTIVE|||||||
33709782|NCT04316923|||COHORT||PROSPECTIVE|||||||
33709783|NCT04971122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709784|NCT02309502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709785|NCT04734015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An Independent Evaluation team will conduct assessments and be blinded to participant randomization status. The investigators will also be blinded to randomization status during data collection and initial analyses.|"Randomized Waitlist Control Design. Adult/youth participant dyads will be randomized to either the intervention group or the wait-list control group after eligibility screening, enrollment and completion of the baseline assessment.~The intervention group will receive the 6-month intervention and 6-month maintenance phase immediately; the wait-list will receive standard care for 24 months and will then receive the intervention."|f|f|t|t
33709786|NCT00977899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709787|NCT02817100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33709788|NCT04335461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will occur at time of enrollment using unmarked envelopes. After consent, patients will be assigned a study ID that will be transcribed on the opaque envelope. The envelope will be unsealed in the operating room at time of surgery to determine the planned intervention, and it's contents will not be made available to the study personnel gathering postoperative pain data. The envelopes and randomization assignments will be kept in a locked, secured location. The only study personnel who will be unblinded are the operating surgeon and residents and physican assistants assisting in the operating room.||t|f|f|t
33709789|NCT02665520|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709790|NCT06060782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709791|NCT00736684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709792|NCT01332500|||COHORT||RETROSPECTIVE|||||||
33709793|NCT04072497|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33709794|NCT05548569|||COHORT||PROSPECTIVE|||||||
33801906|NCT04979715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants do not know which group they belong to|intervention (Group 1), control (Group 2) and routine follow-up (Group 3) groups|t|f|f|f
33801907|NCT00180934|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33801908|NCT01497704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012024|NCT02159937|||CASE_ONLY||PROSPECTIVE|||||||
34012025|NCT01819324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012026|NCT00485030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012027|NCT02235220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012028|NCT01421121|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34012029|NCT05767203|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34012030|NCT02036450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012031|NCT06489834|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Assessor would be blinded to which arm the participants is in. Investigator will also be blinded to the treatment.|Waitlist control group study with control group undergoing intervention 8 weeks after intervention group has ceased|f|f|t|t
34012032|NCT05605873|||COHORT||RETROSPECTIVE|||||||
34012033|NCT05962502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012034|NCT01477502|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012035|NCT02281331|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34012036|NCT04732988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012037|NCT03050697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012038|NCT03661606|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34012039|NCT01386502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012040|NCT01425255|||CASE_CROSSOVER||PROSPECTIVE|||||||
34012041|NCT02291471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012042|NCT05896969|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"This is a Phase 1, multi-center, randomized, double-blind, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C. The study will be divided into two parts:~* SAD cohorts;~* MAD cohorts. The two parts will be completed sequentially. The MAD part may be initiated when safety, tolerability, and PK data are known and deemed acceptable for single doses of at least the 5 planned dose levels of the SAD cohorts."|t|f|t|f
34012043|NCT06465732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012044|NCT02232750|||COHORT||PROSPECTIVE|||||||
33709795|NCT03971097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be made aware of their status in either the control group or experimental group.|The purpose of this study is to examine differences between two groups of individuals receiving treatment at a residential drug and alcohol rehabilitation facility located at UPMC's McKeesport campus. The control group will receive treatment as usual (TAU) which includes group therapy, 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), medical care, and individual needs assessment with recommendations for aftercare. The experimental group will receive TAU plus six additional individual counseling sessions that include integration of a self-forgiveness model developed by Worthington (2013). Differences between the groups will be measured by analyzing pre-test and post-test data on the Self-Forgiveness Dual Process Scale (SFDPS) (Griffin, Worthington, Davis, Hook, \& Maguen, 2018) and the Substance Abuse Self-Stigma Scale (SASSS) (Luoma et al., 2013).|t|f|f|f
33709796|NCT04425694|||COHORT||PROSPECTIVE|||||||
33709797|NCT01940874|||COHORT||PROSPECTIVE|||||||
33709798|NCT02137174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709799|NCT00726778|||COHORT||CROSS_SECTIONAL|||||||
33709800|NCT06411678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709801|NCT04298801|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33709802|NCT02288897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded review by independent review committee (IRC) for primary and key secondary endpoints.||f|f|f|t
33709803|NCT02681562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709804|NCT03799770|||COHORT||PROSPECTIVE|||||||
33709805|NCT01101984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33709806|NCT05979558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Children were randomly assigned to two groups having 31 children in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesiologist who were not involved in the study.|Children were randomly assigned to two groups having 31 children in each, by using a computer-generated table of random numbers which was enclosed in a sealed envelope and was opened by an anesthesiologist who were not involved in the study.|t|t|f|f
33709807|NCT05475132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33709808|NCT00080808|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709809|NCT03164902|NA|SINGLE_GROUP||TREATMENT||NONE|Sponsor will be blinded from any interim analysis results (except for safety outcomes) until the final analysis. A data monitoring committee has been formed to review interim analyses for study futility and safety.|||||
33709810|NCT05634434|||COHORT||PROSPECTIVE|||||||
33709811|NCT05985577|||CASE_ONLY||OTHER|||||||
33709812|NCT04124276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709813|NCT01452828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709814|NCT00885430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709815|NCT01332955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709816|NCT05013684|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33709817|NCT01388764|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33709818|NCT01784978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709819|NCT03262909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709820|NCT03556072|||COHORT||RETROSPECTIVE|||||||
33709821|NCT03727347|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled subjects will be treated with the InSeca Stylus||||
33709822|NCT03676257|||COHORT||RETROSPECTIVE|||||||
33709823|NCT03098953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709824|NCT04873804|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33709825|NCT02984709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709826|NCT01812174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in one arm are recipients of the 17mm On-X Aortic Valve. Patients in the second arm are recipients of the 23mm On-X Mitral Valve. Since double valve cases are exclusionary, these two arms are mutually exclusive and non-randomized.||||
33709827|NCT05238090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomised, single-blind, multicentre, randomised study.|f|f|f|t
33709828|NCT04454268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709829|NCT03143439|||CASE_CONTROL||RETROSPECTIVE|||||||
33791930|NCT06552494|RANDOMIZED|PARALLEL||OTHER||SINGLE||Women were randomized either to the intervention group (n=60) receiving the L-mHealth program plus care as usual or the control group (n=60) receiving care as usual alone. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention. Co-creation is a user-involved process that can create a useful and customized product for the WGC target population. As such, this process is a beneficial process to utilize when addressing the specific needs of WGC. Through the study of the L-mHealth program, it is expected to improve women's use of ICT and demonstrate its potential as an effective and easily accessible intervention to promote women's symptom interference and quality of life for WGC.|t|f|f|f
33791931|NCT04344613|NA|SINGLE_GROUP||OTHER||NONE||||||
33791932|NCT02087644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791933|NCT04176367|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33801909|NCT02779634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33933945|NCT02645136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933946|NCT00004127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933947|NCT01239329|||||CROSS_SECTIONAL|||||||
33933948|NCT03365440|||OTHER||PROSPECTIVE|||||||
33933949|NCT00962481|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33933950|NCT00669513|RANDOMIZED|CROSSOVER||||NONE||||||
33933951|NCT04591873|||CASE_CONTROL||PROSPECTIVE|||||||
33933952|NCT01488188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33933953|NCT02552823|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933954|NCT03893851|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33933955|NCT02160327|||||PROSPECTIVE|||||||
33933956|NCT06078306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933957|NCT02001493|||COHORT||PROSPECTIVE|||||||
33933958|NCT06016335|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||For all participants the same research activities will be performed (namely CT and MRI). The resulting paired MRI and CT scans will then be divided into a training set and a test set.||||
33933959|NCT00632515|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33933960|NCT01512108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709830|NCT04173468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|There will be two groups of participant. One group will receive MWM along with conventional therapy and the second group group will receive Mulligan knee taping along with conventional therapy.|t|f|f|f
33709831|NCT01031355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33709832|NCT05495516|||COHORT||PROSPECTIVE|||||||
33709833|NCT00960778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709834|NCT03782792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709835|NCT02129400|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33709836|NCT05516394|||COHORT||OTHER|||||||
33709837|NCT00828659|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33709838|NCT05664971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709839|NCT02512588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33709840|NCT00933972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709841|NCT04318795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709842|NCT05135117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover assignment||||
33709843|NCT00566371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709844|NCT03700775|NA|SINGLE_GROUP||TREATMENT||NONE||Singe center prospective cohort study||||
33709845|NCT05201703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709846|NCT04991415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33709847|NCT04165785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects in the study arm will receive a series of OPT IPL pulses using the M22 IPL handpiece. In subjects of the control arm, the device will be disabled. The subject will feel the lightguide on the skin, will hear clicking sounds, but no light will be actually produced by the M22 device. Since during treatment both eyes of the subject will be fully occluded, no subject will be able to see if the treatment is actual or sham. There is no way to completely mask the subjects, since the IPL generally causes slight redness of the skin, and in some patients is may also cause some discomfort|Subjects will be randomized 1:1 to a study arm and a control arm. Subjects in the study arm will be treated with OPT IPL and meibomian gland expression. Subjects in the control arm will be treated with sham OPT IPL and meibomian gland expression.|t|f|f|f
33709848|NCT02619552|||COHORT||PROSPECTIVE|||||||
33709849|NCT03249883|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33709850|NCT05806281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709851|NCT01747044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709852|NCT05060302|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709853|NCT00506662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709854|NCT05824793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Each participant was assigned a unique identifier number which does not inform the group they are in. The outcome assessor was not aware of which group the participants were allocated in.|"Each patient enrolled in the research was encoded using a code from 001 to n, in blocks of 10 numbers, compared to the number on the sealed envelope with the random number pre-selected via the function RAND() on Microsoft Excel by the data collector. Number in the patient's envelope: odd number of group 1, even number of group 2. In case the patient has two IMTM that need to be extracted, meeting the inclusion and exclusion criteria of the study; after random: if the first time in the odd group, be operated on according to the standard procedure, the remaining opposite teeth would be surgically operated on using A-PRF+, the second time after the first surgery at least five weeks. And similarly, if randomly selecting the number is an even.~* Control group (group 1 = odd number): no use of A-PRF+ after tooth extraction.~* Study group (group 2 = even number): use A-PRF+ after tooth extraction."|f|f|f|t
33709855|NCT04946006|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biased coin up-and-down design.|t|t|t|t
33709856|NCT02289339|||COHORT||OTHER|||||||
33709857|NCT02765295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709858|NCT02627144|||COHORT||CROSS_SECTIONAL|||||||
33709859|NCT00748501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709860|NCT04890769|||COHORT||PROSPECTIVE|||||||
33709861|NCT03558854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709862|NCT03066804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709863|NCT01271062|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709864|NCT03031678|NA|SINGLE_GROUP||OTHER||NONE||||||
33709865|NCT02279004|||COHORT||PROSPECTIVE|||||||
33709866|NCT00002098||PARALLEL||TREATMENT||||||||
33709867|NCT00000350||||TREATMENT||NONE||||||
33709868|NCT05742594|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33791934|NCT05826275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I, dose escalation/dose expansion study. Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.||||
33791935|NCT01251354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791936|NCT03302741|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33933961|NCT04871386|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33933962|NCT04722263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933963|NCT02907801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933964|NCT04443868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933965|NCT06061367|||COHORT||PROSPECTIVE|||||||
33933966|NCT06384300|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33933967|NCT02967562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933968|NCT02958033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933969|NCT06340776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Acupressure groupThose who received acupressure application were called the experimental group, and patients who received routine post-operative care were called the control group. Acupressure application was applied to the experimental group at the third and twenty-fourth hours after surgery.~Control group:The control group was evaluated for two days without any application."|t|t|f|t
33933970|NCT05442125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933971|NCT00925236|||COHORT|||||||||
33933972|NCT02257112|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933973|NCT02828995|||CASE_ONLY||CROSS_SECTIONAL|||||||
33933974|NCT01058057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012045|NCT00614822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933975|NCT01869452|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33933976|NCT02752425|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33933977|NCT04602013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33933978|NCT03049085|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33933979|NCT01891604||PARALLEL||||||||||
33933980|NCT05011331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933981|NCT02062970|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33933982|NCT00935662|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33933983|NCT02812329|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33933984|NCT00929422|||CASE_CONTROL||PROSPECTIVE|||||||
33933985|NCT02095249|NA|SINGLE_GROUP||OTHER||NONE||||||
34012046|NCT00591435|||COHORT||RETROSPECTIVE|||||||
34012047|NCT01633294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012048|NCT04039919|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34095344|NCT04760457|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The assessment of longitudinal outcomes will be performed by an assessor blinded to the surgical/loading protocols|"A factorial experiment of two factors is planned, each with two possible values or levels, and whose experimental units take on all possible combinations of these levels across all such factors (2×2 factorial design), allowing the study to determine the effect of each factor on the response variable, as well as the effects of interactions between factors on the response variable. The tested factors will be: loading protocol (immediate or delayed), and surgical approach (flapped or flapless), resulting in a factorial experiment with four treatment combinations in total. Hence, the design is denoted a 2² factorial, which identifies the number of factors (n=2) and how many levels each factor has (n=2) there are in the design (2²=4)."|f|f|f|t
33933986|NCT01751373|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33933987|NCT01174589|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33933988|NCT03588104|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomised trial||||
33933989|NCT02834494|NA|SINGLE_GROUP||OTHER||NONE||||||
33933990|NCT01711437|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33933991|NCT02124928|||CASE_ONLY||PROSPECTIVE|||||||
33933992|NCT02772835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933993|NCT05537506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933994|NCT05399602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33933995|NCT01191424|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33933996|NCT01945788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33933997|NCT00832091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33933998|NCT02669446|||CASE_ONLY||PROSPECTIVE|||||||
33933999|NCT03476928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012049|NCT05672953|||COHORT||CROSS_SECTIONAL|||||||
34012050|NCT01382745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012051|NCT03163849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012052|NCT01587131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012053|NCT03758482|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012054|NCT00617370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012055|NCT01051180|||CASE_CONTROL||PROSPECTIVE|||||||
34012056|NCT00214331|||COHORT||PROSPECTIVE|||||||
34012057|NCT04062682|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34012058|NCT05107882|||COHORT||CROSS_SECTIONAL|||||||
34012059|NCT00006108||||TREATMENT||||||||
34012060|NCT05526859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants were blinded to the allocation in the experimental treatment groups.|Two group were taken and given treatment with the concern study protocols.|t|f|f|f
34012061|NCT05007184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34012062|NCT01494441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012063|NCT05877391|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33709869|NCT05471791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial comparing treatment (use of mobile App) to usual care||||
33709870|NCT04482881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709871|NCT04672993|NA|SINGLE_GROUP||OTHER||NONE||||||
33709872|NCT06352801|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention Group: In Phase 1, children participants receive a 6-session self-compassion intervention training, plus parents of the participants receive a 3-session parent group. once to twice a week, 90 minutes per session.~Wait-list Control: receives the same intervention in Phase 2"||||
33709873|NCT03146013|||COHORT||PROSPECTIVE|||||||
33709874|NCT05949398|||CASE_ONLY||CROSS_SECTIONAL|||||||
33709875|NCT00190697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934000|NCT04748822|NA|SINGLE_GROUP||OTHER||NONE||Prospective cohort study||||
33934001|NCT04358913|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33934002|NCT03506204|||COHORT||PROSPECTIVE|||||||
33934003|NCT04459923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934004|NCT05620485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934005|NCT03669146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A provider other than the investigator(s) will be masked to the primary outcome of the study.||f|t|f|f
33934006|NCT01251991|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33934007|NCT02596841|||CASE_ONLY||RETROSPECTIVE|||||||
33934008|NCT02630394|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33934009|NCT00174889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934010|NCT05364112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934011|NCT06147336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934012|NCT00389805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934013|NCT02165592|||COHORT||CROSS_SECTIONAL|||||||
33934014|NCT01512693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934015|NCT06139198|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The randomization list will be computer-generated by personnel within the biostatistics core of the CWRU Neurological and Behavioral Outcomes Center who are not members of the study staff. the study team will train and follow up each study group independently from the other group.|prospective non-inferiority randomized clinical trial|f|f|t|t
33934016|NCT03368079|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33934017|NCT01440504|||||PROSPECTIVE|||||||
33934018|NCT05415865|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Region Hovedstadens Apotek, Herlev Hospital produces the Lidocaine solution and the matching placebo solution, performs the randomization, and packages the blinded dosing kits with the order of Lidocaine and placebo in a balanced design (50% Lidocaine at the first treatment). Participants will get consecutive randomization numbers, which specify the dosing kit. Neither the participant, the operator, or the healthcare professional interviewing the participant about her pain score know what solution the participant gets administered.|The study is a randomized, controlled, double-blinded, crossover study. The participants are their own control in the evaluation of the effect of intravesical alkalinized Lidocaine solution versus placebo as anesthesia prior to intravesical injection of onabotulinum toxin A. The chosen model is advantageous as a smaller sample size is needed, and error variance is reduced.|t|t|t|t
33934019|NCT03288311|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33934020|NCT04280081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934021|NCT00085644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934022|NCT00998985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934023|NCT01815905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33934024|NCT00013104|||||PROSPECTIVE|||||||
33934025|NCT01507441|||CASE_ONLY||RETROSPECTIVE|||||||
33934026|NCT05478967|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33934027|NCT05885906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33934028|NCT05482594|||COHORT||PROSPECTIVE|||||||
33709876|NCT02447042|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33709877|NCT05106283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709878|NCT02762357|||COHORT||PROSPECTIVE|||||||
33709879|NCT04952493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709880|NCT00477243|||COHORT||PROSPECTIVE|||||||
33709881|NCT03627247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Staff completing assessments were blind to participants' study condition|prospective, pre-test post-test, experimental control group design|f|f|f|t
33709882|NCT02997020|||CASE_CONTROL||PROSPECTIVE|||||||
33934029|NCT03595189|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|f|t
33934030|NCT06070727|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33934031|NCT00184067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934032|NCT03463109|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Every participant will recive stimulation on his back in a pre-defined random order.|The same procedure will be used for people with chronic low back pain and for healthy volunteers.|t|f|f|f
33934033|NCT03631394|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33934034|NCT01415973|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34012064|NCT06422338|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012065|NCT05840094|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012066|NCT03475134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012067|NCT01575717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012068|NCT02054013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012069|NCT02135120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34012070|NCT04598178|||COHORT||PROSPECTIVE|||||||
34012071|NCT03965637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012072|NCT05077228|||CASE_ONLY||RETROSPECTIVE|||||||
33791937|NCT06356116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33791938|NCT03285191|||COHORT||CROSS_SECTIONAL|||||||
34095345|NCT05257044|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The vials of CBG and placebo will be color-coded and only the PI will know what the color codes mean. Participants and the research assistant will be blinded.|Participants will be randomly assigned to ingest either CBG or a placebo in the first session. Those who ingest CBG in session 1 will ingest placebo in session 2. Those who ingest placebo in session 1 will ingest CBG in session 2.|t|f|f|t
34095346|NCT05787223|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34095347|NCT04630262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||ATTUNE Cementless Fixed Bearing||||
34095348|NCT01898130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709883|NCT06056037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PIs nor the individual conducting outcome assessments will know the status of the participants' randomization.|Pilot randomized controlled trial|f|f|t|t
33709884|NCT02154243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709885|NCT04096963|||CASE_ONLY||PROSPECTIVE|||||||
33709886|NCT04644081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709887|NCT05731778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33709888|NCT06446700|||OTHER||CROSS_SECTIONAL|||||||
33709889|NCT02418598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709890|NCT01757743|||CASE_ONLY||PROSPECTIVE|||||||
33791939|NCT01792830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791940|NCT04156724|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33791941|NCT01581736|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791942|NCT06264648|NON_RANDOMIZED|PARALLEL||OTHER||NONE||2 groups of physiotherapists with different fields of experience were attended to study.||||
33791943|NCT01984554|||COHORT||PROSPECTIVE|||||||
33934035|NCT03628391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo and haloperidol (verum) will have the same appearance|Randomised controlled double-blind placebo controlled clinical trial|t|t|t|t
33934036|NCT05312385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934037|NCT00454350|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934038|NCT02661256|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33934039|NCT03637894|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||RCT double blind study|t|t|t|f
33934040|NCT00821054|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33934041|NCT04829006|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934042|NCT02233491|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33934043|NCT01770093|||CASE_ONLY||PROSPECTIVE|||||||
33934044|NCT02573506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934045|NCT02111707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934046|NCT02941042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934047|NCT03068052|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33934048|NCT06169644|||COHORT||RETROSPECTIVE|||||||
33934049|NCT00613340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934050|NCT05329714|||COHORT||OTHER|||||||
33934051|NCT00833612|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934052|NCT01654393|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34095349|NCT00027443|RANDOMIZED|||TREATMENT||NONE||||||
34095350|NCT01321645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095351|NCT06403501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095352|NCT05957341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095353|NCT05119465|||OTHER||RETROSPECTIVE|||||||
34095354|NCT00200083|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33709891|NCT00393393|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33709892|NCT03466008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||between (two groups: WBC and control), and within subjects (two repeated measures: pre and post intervention)||||
33709893|NCT05830721|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|There will be no masking.|This study will be an open-label prospective randomized controlled trial with 3 parallel groups.||||
33709894|NCT01101087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33791944|NCT01130558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791945|NCT02696707|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33791946|NCT02614560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791947|NCT04911049|||COHORT||CROSS_SECTIONAL|||||||
33791948|NCT02698241|NA|SINGLE_GROUP||OTHER||NONE||||||
33791949|NCT04178954|||CASE_ONLY||RETROSPECTIVE|||||||
33791950|NCT02614118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791951|NCT03125382|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934053|NCT01594086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934054|NCT03800433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934055|NCT02698566|NA|SINGLE_GROUP||OTHER||NONE||||||
33934056|NCT06228781|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934057|NCT05367362|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial.|t|f|f|t
33934058|NCT04835688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care providers, data collectors, outcome assessors, research personnel, and data analysts will be blinded to treatment allocation. However, the ENT-specialist performing the insertion of the ventilation tube or placebo-treatment will inevitably be aware of treatment allocation.|A pro-spective, double-blinded, sham-controlled, randomized, clinical trial|t|t|t|t
33934059|NCT04230590|||CASE_ONLY||PROSPECTIVE|||||||
33934060|NCT02216292|||COHORT||PROSPECTIVE|||||||
33934061|NCT03814460|||CASE_CONTROL||PROSPECTIVE|||||||
33934062|NCT05300958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934063|NCT04531397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934064|NCT00861094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934065|NCT02460172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095355|NCT01140139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791952|NCT02623868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33791953|NCT00851240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791954|NCT03259932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095356|NCT02487706|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095357|NCT02096536|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709895|NCT04387032|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|blinded patient blinded researcher and person evaluating results|Experimental group - HVLA manipulations on blocked sacroiliac joints (SIJs) Control group (people without hypomobile SIJs), in which we performed sham manipulation|t|f|f|t
34095358|NCT03837730|||COHORT||PROSPECTIVE|||||||
34095359|NCT05756907|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34095360|NCT00746161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095361|NCT02769052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791955|NCT01351272|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33791956|NCT02498158|||COHORT||PROSPECTIVE|||||||
34095362|NCT04094636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791957|NCT03322332|||COHORT||CROSS_SECTIONAL|||||||
33709896|NCT03996252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709897|NCT05957575|||COHORT||PROSPECTIVE|||||||
33709898|NCT06297161|||COHORT||PROSPECTIVE|||||||
33709899|NCT01709513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709900|NCT04113005|NA|SINGLE_GROUP||TREATMENT||NONE||Safety and Tolerability Analysis||||
33709901|NCT01393691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33709902|NCT04401098|||OTHER||PROSPECTIVE|||||||
33709903|NCT04933994|||COHORT||OTHER|||||||
33709904|NCT01991691|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709905|NCT01868854|||COHORT||PROSPECTIVE|||||||
33709906|NCT00316849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709907|NCT03169556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33709908|NCT05228132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709909|NCT04678271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709910|NCT04615481|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33709911|NCT03152071|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33709912|NCT01877265|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33709913|NCT00071474|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709914|NCT02513953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709915|NCT01328509|||CASE_CONTROL||PROSPECTIVE|||||||
33791958|NCT00574743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33791959|NCT02156609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709916|NCT00300391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33791960|NCT05758558|||COHORT||CROSS_SECTIONAL|||||||
33791961|NCT03680391|||CASE_CONTROL||PROSPECTIVE|||||||
33791962|NCT00480766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791963|NCT04286529|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33791964|NCT04696341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments were done by the same physiotherapist (FU) before therapy and at the end of treatment sessions. The physiotherapist who did the assessments did not know to which group the subjects were belonged. Another physiotherapist who was not informed about the results of the evaluation treated the patients.||f|f|t|f
33934066|NCT00236106|RANDOMIZED|CROSSOVER||||SINGLE||||||
33934067|NCT03882866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934068|NCT04224987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In the mortality/resistance trial, we will use a matching placebo to mask study arm allocation. Placebo will be identical to azithromycin in appearance, smell, and packaging. Treatment assignment will be masked by assigning a series of upper- and lower-case letters to each trial, age group, and treatment arm. Those masked to study arm allocation include participants, investigators, most study personnel including study personnel administering treatment and collecting data on mortality outcomes, and laboratory personnel processing samples for resistance outcomes. Unmasked personnel include the trial biostatistician and data analyst responsible for implementing the randomization sequence and key members of Pfizer staff.~In a subset of 80 communities, open-label azithromycin will be distributed with no masking of participants, implementors, or outcome assessors."|The AVENIR mortality/resistance trial is a large simple double-masked cluster-randomized trial with response-adaptive allocation in Niger.|t|t|t|t
33934069|NCT01326390|||COHORT||PROSPECTIVE|||||||
33934070|NCT06392867|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Prior to the treatment, each participant will visit The Hong Kong Polytechnic University on a separate day. During the first visit, the researcher will also measure each participant's rMT. The PI will randomly assign the participant to different groups, such as sham group, 75% group, and 120% group, and calculate the maximum intensity of treatment based on the respective groups of the participant. To provide individualized treatment intensity to each participant, the TMS operator will receive the information from the PI and perform the treatment according to the determined intensity. The operator does not know the participant's rMT and sham coil is used. Furthermore, the participants have never received TMS treatment before taking part in this study, so they do not understand the difference between a placebo and a real treatment.|"Patients with Major Depressive Disorder will undergo daily intermittent theta-burst stimulation (iTBS) at left DLPFC, 20 sessions in 4 weeks. It is to investigate the potential antidepressant effects of iTBS treatment at a much lower stimulation intensity than the one currently employed by most centers in the United States and approved in these centers.~The current study proposes a randomized, triple-arm, controlled trial to compare the efficacy of iTBS at 75% (iTBS75) and 120% (iTBS120) rMT with sham iTBS (SiTBS). Based on the following considerations, SiTBS was selected to be compared with iTBS75 and iTBS120: SiTBS will reveal placebo antidepressant effects and serve as a control."|t|t|f|t
33934071|NCT05509491|NA|SINGLE_GROUP||TREATMENT||NONE||12-week physiotherapist delivered a postural awareness program with exercises||||
33934072|NCT04233957|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33934073|NCT04323098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934074|NCT03166657|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934075|NCT02758561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934076|NCT04174872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934077|NCT02940028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34095363|NCT03432689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34095364|NCT01507389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095365|NCT02037113|||COHORT||PROSPECTIVE|||||||
34095366|NCT04184908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709917|NCT04302298|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Medical students will be recruited via an email which asks them to participate in the trial. Those who respond will be randomly assigned into the virtual reality or technique guide group, and thus know which group they are a part of. They will be randomly assigned into these groups using a number generator of 1 or 2 for the virtual reality and technique guide group, respectively. An equal amount of participants will be allocated to each group.~Following completion of the experiment, the attending physician evaluating their performance will be blinded to which group they were in as well as the gender of the participant to eliminate any bias."||f|f|f|t
33709918|NCT04592315|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33709919|NCT03949504|||CASE_ONLY||CROSS_SECTIONAL|||||||
33709920|NCT04220320|||CASE_CONTROL||PROSPECTIVE|||||||
33709921|NCT06385639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33709922|NCT05238402|||COHORT||OTHER|||||||
33709923|NCT06261203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The The study's findings have the potential to clarify aspirin's role in preventing adverse pregnancy outcomes related to placental dysfunction and improve the management of women at risk of placental-mediated complications.|t|f|f|t
33709924|NCT02418364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33709925|NCT01013376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709926|NCT03040102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709927|NCT00920283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709928|NCT01004705|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33709929|NCT00728871|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709930|NCT00585247|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33709931|NCT05693558|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, multi-country, multi-center study in pediatric patients, suffering from congenital pseudarthrosis of the tibia (CPT), treated during the primary surgical intervention with NVD-003, an autologous 3D scaffold free osteogenic graft.||||
33791965|NCT02675920|||COHORT||PROSPECTIVE|||||||
33791966|NCT02196051|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33791967|NCT02562404|||COHORT||PROSPECTIVE|||||||
33791968|NCT05928364|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with inclusion criteria of uretral stricture will be treated with open uretroplasty with buccal graft and omental wrapping||||
33791969|NCT06537544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791970|NCT05804604|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33791971|NCT03259919|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33791972|NCT01983306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791973|NCT03488056|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The division of the control and experimental groups was done by center and for neither group are revealed to the patient nor responsible for the type of intervention they are undergoing.~After a certain time of the study, a blind investor will examine the children's centers and evaluate the outcome of the study. This researcher will not know which center is a control or experimental group."|The randomization was made by centers of the SESC (Social Service of the Commerce) of São Paulo state. Four centers will follow the ICCMS criteria and four other centers will follow criteria for diagnosis and treatment of SESC. The randomization will be stratified by sociodemographical conditions. The minimization will be used to equate preexisting oral health-related activities. According to allocated strategy, dentists in the center will guide their conduct with children attended to the CURUMIM project.|t|f|f|t
33791974|NCT04575285|||COHORT||PROSPECTIVE|||||||
33791975|NCT00774436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934078|NCT01545414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934079|NCT05651074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934080|NCT05925829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934081|NCT05354869|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive usual care or usual care and hi frequency transvaginal electrical stimulation administered by either a specialized urogynecology provider or licensed vocational nurse(LVN) using a secure online randomization system.||||
33934082|NCT04914468|||COHORT||PROSPECTIVE|||||||
33934083|NCT04298749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934084|NCT05224752|||COHORT||PROSPECTIVE|||||||
33934085|NCT04819191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934086|NCT05908929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012073|NCT00752674|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012074|NCT03032822|||COHORT||PROSPECTIVE|||||||
34012075|NCT01320020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012076|NCT04588441|NA|SINGLE_GROUP||TREATMENT||NONE||Testing will be applied to patients with deteriorating pulmonary function and who are newly intubated (within 24 hours) with rising oxygen requirements.||||
34012077|NCT05674214|||CASE_CONTROL||RETROSPECTIVE|||||||
34012078|NCT01155778|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012079|NCT05393063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012080|NCT05161819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34012081|NCT01690975|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34012082|NCT05612282|||CASE_CROSSOVER||PROSPECTIVE|||||||
34012083|NCT00350155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012084|NCT04589702|||CASE_CONTROL||RETROSPECTIVE|||||||
34012085|NCT00856505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012086|NCT06160414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012087|NCT02631876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012088|NCT00379990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012089|NCT04911465|||COHORT||PROSPECTIVE|||||||
34012090|NCT01749748|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34012091|NCT04818996|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34012092|NCT00965445|||CASE_CONTROL||PROSPECTIVE|||||||
34012093|NCT03250975|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34012094|NCT02045004|||COHORT||PROSPECTIVE|||||||
34012095|NCT05256472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095367|NCT04568772|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34012096|NCT05768659|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34012097|NCT02610764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012098|NCT03897478|||COHORT||PROSPECTIVE|||||||
34012099|NCT04997655|||CASE_CONTROL||PROSPECTIVE|||||||
34012100|NCT02668822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012101|NCT02171390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095368|NCT01975480|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label.|||||
34095369|NCT02164188|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34012102|NCT05440630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34095370|NCT06139458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095371|NCT01967875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095372|NCT01371760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095373|NCT03235414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012103|NCT04154826|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two dose level parallel groups||||
34012104|NCT00374075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012105|NCT01497626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012106|NCT02536235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012107|NCT03213431|||COHORT||PROSPECTIVE|||||||
34095374|NCT03827642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095375|NCT01946802|||COHORT||PROSPECTIVE|||||||
34095376|NCT00179179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095377|NCT05932030|NA|SINGLE_GROUP||OTHER||NONE||||||
34095378|NCT04259242|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34095379|NCT00884065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709932|NCT01897454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709933|NCT01165437|||COHORT||CROSS_SECTIONAL|||||||
33709934|NCT05416398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the patients were selected from the relevant population with the improbable random sampling method, the patients who accepted to participate in the study and met the inclusion criteria will be assigned to one of the aerobic exercise group, high-intensity interval training training group or control group with the closed-envelope method.|Randomized controlled experimental model|t|f|f|f
33709935|NCT01095783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709936|NCT01950741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709937|NCT05550805|||COHORT||PROSPECTIVE|||||||
33709938|NCT03374397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709939|NCT00038220|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709940|NCT02792972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33709941|NCT04489680|NA|SINGLE_GROUP||OTHER||NONE||||||
33709942|NCT06072391|||COHORT||PROSPECTIVE|||||||
33709943|NCT00929799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33709944|NCT03535610|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, open label study||||
33709945|NCT03003390|RANDOMIZED|PARALLEL||PREVENTION||NONE||Eligible subjects will be randomized 1:1 to treatment or control.||||
33709946|NCT04483271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709947|NCT05363644|NA|SINGLE_GROUP||PREVENTION||NONE||"All of the patients will be recruited from patients seen in the principal investigator's (PI's) hospital and practice. The offer to participate will be extended to all eligible subjects for the importance of a representative sample.~No women, children or prisoners will be enrolled in this study."||||
33709948|NCT06074367|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study was double blinded were Participant (patients), Care Provider (nurses, cardiac surgeons, and ICU physicians) were blinded but the outcome assessors (clinical pharmacist) who collect data were not blinded||t|t|f|f
33709949|NCT06172322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709950|NCT03954145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33709951|NCT03621397|RANDOMIZED|PARALLEL||TREATMENT||NONE||40 Spanish-speaking research participants who have sustained a subarachnoid hemorrhage in the last 6 months will participate in the research study. Participants will be randomly assigned to one of two groups: 1) Cognitive intervention group (n = 20) or 2) Control group (n = 20). The Cognitive Intervention group will receive the cognitive intervention, while the Control group will not receive any intervention.||||
33709952|NCT01565512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709953|NCT00702611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709954|NCT06086470|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, non-randomized study. All participants are enrolled into a single group to be treated with the experimental device.||||
33709955|NCT00159406|||COHORT||PROSPECTIVE|||||||
33709956|NCT01738373|||||PROSPECTIVE|||||||
33709957|NCT05280782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709958|NCT04067544|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33709959|NCT06077318|||COHORT||RETROSPECTIVE|||||||
33709960|NCT02161081|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33709961|NCT02275468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709962|NCT03930797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33709963|NCT00798499|||CASE_ONLY|||||||||
34095380|NCT02555098|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095381|NCT00326495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095382|NCT00581997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709964|NCT02864498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709965|NCT03775655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709966|NCT01372137|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33709967|NCT00289445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709968|NCT06296966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791976|NCT02289625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34012108|NCT01236157|||COHORT||PROSPECTIVE|||||||
34012109|NCT01817192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Results of 14-Gene prognostic assay will not be revealed to the patient. Low risk patients will be observed, intermediate and high risk patients will be randomized to observation or four cycles of a platinum-based doublet therapy.||t|f|f|f
34095383|NCT02487355|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095384|NCT01346553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709969|NCT04502693|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blinded study. Recipients \& study evaluators will be unaware of vaccine administered.||t|t|t|t
33791977|NCT00202969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791978|NCT00002995||||TREATMENT||NONE||||||
33791979|NCT06121830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33791980|NCT05161507|||CASE_ONLY||PROSPECTIVE|||||||
33791981|NCT06440824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791982|NCT00002527|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33934087|NCT04724291|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934088|NCT02098928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33934089|NCT04285294|||OTHER||OTHER|||||||
33934090|NCT03864627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934091|NCT05232292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934092|NCT00534924|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934093|NCT03189810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The rTMS technicians, participants, research analysts and investigators involved in the study will be blind to the rTMS treatment assignment.|Double-blind, placebo-controlled trial|t|t|t|t
33934094|NCT05013099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934095|NCT02899104|||CASE_ONLY||RETROSPECTIVE|||||||
33709970|NCT03431428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934096|NCT04583228|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|A total of 32 subjects were randomized in a double blind fashion with 24 subjects receiving active drug and 8 subjects receiving placebo. Eight subjects were randomized in each dose cohort at a 3:1 ratio, with 6 subjects receiving active drug and 2 subjects receiving placebo.|The investigators plan to enroll 8 subjects in each sequence, of which 2 receive intravenous injection of placebo and 6 receive intravenous injection of IP. Subjects are allocated in two groups randomly.|t|t|t|t
33934097|NCT05399589|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33934098|NCT00262353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934099|NCT02114398|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934100|NCT02257060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934101|NCT05799911|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Visually indistinguishable packages of hydrogen-rich water and placebo.||t|f|t|f
33934102|NCT06259604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One-sided blinding method will be applied in the research. Only one of the researchers has a PIOMI practitioner certificate and interventions will be carried out only by this researcher. The PIOMI practitioner researcher will perform all interventions of PIOMI and combined methods himself and will not tell other researchers which group the babies are in. All measurements of the babies, except PIOMI, will be carried out by a single researcher in the research group.||f|f|t|f
34012110|NCT01921491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012111|NCT01602471|NA|SINGLE_GROUP||||NONE||||||
34012112|NCT00809315|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34012113|NCT01612884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012114|NCT01788124|||COHORT||PROSPECTIVE|||||||
34012115|NCT03494114|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The radiologist who evaluates the PET scan will be blinded to the to patient groups (COPD versus control)|Testing whether folate-based imaging using 68 Ga-EC2115 can be used to identify macrophages expressing the high affinity folate receptor (folate receptor beta).|f|f|f|t
34012116|NCT05098002|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34012117|NCT05732181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012118|NCT02715219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34012119|NCT01166555|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34012120|NCT05189314|||COHORT||PROSPECTIVE|||||||
34012121|NCT01562054|||COHORT||PROSPECTIVE|||||||
34012122|NCT04109313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012123|NCT00604227|NA|SINGLE_GROUP||||NONE||||||
34012124|NCT04009889|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||N=162 pregnant women were randomly assigned to one of the 2 interventions: verum (Lactobacilli) or placebo|t|f|t|f
34012125|NCT03168321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012126|NCT05516459|||COHORT||PROSPECTIVE|||||||
34012127|NCT02994355|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34012128|NCT00455416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012129|NCT01430975|||COHORT||PROSPECTIVE|||||||
34012130|NCT01352182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34012131|NCT04623021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012132|NCT00736918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34012133|NCT02442271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709971|NCT02936570|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33709972|NCT05063487|||COHORT||PROSPECTIVE|||||||
33709973|NCT04404296|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional case series||||
33709974|NCT02853604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33709975|NCT03755297|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33709976|NCT03131765|NA|SINGLE_GROUP||TREATMENT||NONE||YS-ON-001 is a single agent used for this study||||
33709977|NCT05628532|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional single-arm open-label before/after multicentric national study||||
33709978|NCT04305262|||COHORT||PROSPECTIVE|||||||
33709979|NCT05292443|||COHORT||PROSPECTIVE|||||||
33709980|NCT00216632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33709981|NCT00695487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33709982|NCT02590614|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33709983|NCT03942263|||COHORT||OTHER|||||||
33709984|NCT02244606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709985|NCT01754623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709986|NCT02304172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709987|NCT01305902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33709988|NCT05564429|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012134|NCT03608852|||OTHER||PROSPECTIVE|||||||
34012135|NCT03531008|||COHORT||PROSPECTIVE|||||||
34012136|NCT05727475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095385|NCT03243890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The randomization-list is available to the data and safety monitoring board, but patients, nurses, physicians and other data collectors are kept blinded to the allocation during the study.|Subjects will be randomized 1:1 after stratiﬁcation for site, AVC score (300-599 or ≥600) and statin-use. Each site will be provided with sequentially numbered, opaque and sealed envelopes containing randomly generated treatment allocations. Four different types of envelopes are provided; 1) AVC 300-599, no statin-use; 2) AVC 300-599, statin-use; 3) AVC ≥600, no statin-use; and 4) AVC ≥600, statin-use.|t|t|t|t
34095386|NCT03030209|||COHORT||PROSPECTIVE|||||||
34095387|NCT00583804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095388|NCT04218851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095389|NCT01049672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095390|NCT01527981|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34095391|NCT02271542|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33709989|NCT03879226|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A researcher will program the device (placebo or PMBT) and will be instructed not to inform the volunteers or other researchers as to the type of treatment (PMBT or placebo). Therefore, the researcher responsible for the treatment will be blinded to the type of treatment being administered to the volunteers. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or PBMT).||t|t|t|t
33709990|NCT05449795|||COHORT||PROSPECTIVE|||||||
33709991|NCT06507982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization process of the patients participating in the study into groups was carried out by two endodontists (M.U. and S.E.) working in the unit where the research was conducted. Patients who met the inclusion criteria were randomly assigned to one of 3 groups. Additionally, patients requiring RCT for more than one tooth were randomly assigned to groups to ensure objectivity and maintain equal sample size.||t|f|t|t
33709992|NCT04289675|||COHORT||PROSPECTIVE|||||||
33709993|NCT04397731|||COHORT||PROSPECTIVE|||||||
33709994|NCT00871260|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33709995|NCT00724022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33709996|NCT04773860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients shall be randomly assigned to the intervention and control group.|Patients diagnosed with COPD|t|f|f|f
33709997|NCT06147804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33709998|NCT04786015|||OTHER||PROSPECTIVE|||||||
33934103|NCT01080625|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33934104|NCT04282369|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34095392|NCT00152230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095393|NCT03648970|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The diagnosis is made by resident unaware of the medication patients received|Multicenter Randomized Non Blinded Trial comparing low dose aspirin versus low dose aspirin and pravastatin in patients with high risk developing preeclampsia|f|f|f|t
34095394|NCT04049422|||COHORT||PROSPECTIVE|||||||
34095395|NCT04037956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095396|NCT00793611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095397|NCT02674087|||COHORT||PROSPECTIVE|||||||
34095398|NCT06203964|||COHORT||RETROSPECTIVE|||||||
34095399|NCT01084564|||COHORT||RETROSPECTIVE|||||||
34095400|NCT04764253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095401|NCT00358280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095402|NCT01145222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095403|NCT02370394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095404|NCT05683626|||COHORT||PROSPECTIVE|||||||
34095405|NCT04190095|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34095406|NCT04040673|||CASE_ONLY||RETROSPECTIVE|||||||
34095407|NCT03319121|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Participants will be randomly allocated into either the empirical group or guided group for 8 weeks.||||
34095408|NCT01535066|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34095409|NCT03723239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095410|NCT06163638|NA|SINGLE_GROUP||TREATMENT||NONE||We will work with a single-case design (ABAB), where all participants will receive the intervention||||
33709999|NCT05127668|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The investigator and reviewer were masked to the results|Prospective cross-sectional comparative study|f|f|t|t
33710000|NCT02417831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710001|NCT02581514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33791983|NCT05200247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33791984|NCT00501358|||CASE_CONTROL||OTHER|||||||
33791985|NCT04094155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934105|NCT00596895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934106|NCT01776372|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33934107|NCT06432491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"All the participants will only get access to their own group and will not get access to other group members.~The investigator who take charge of MRI test for participants' body composition will not have any idea about grouping."|Participants will be randomly divided into intervention group and control group. Intervention group will drink 4℃ water while control group will drink 37℃ water for 6 months.|t|f|t|f
33934108|NCT01654328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934109|NCT06015191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|f|f|f|t
33934110|NCT02729402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934111|NCT02892058|||CASE_ONLY||PROSPECTIVE|||||||
33934112|NCT03377829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33934113|NCT02418728|||COHORT||RETROSPECTIVE|||||||
33934114|NCT00045045|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33934115|NCT02502955|||CASE_ONLY||PROSPECTIVE|||||||
33934116|NCT00044694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934117|NCT06198218|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will get separate treatment protocol as and possible efforts will be put to mask the both groups about their treatment||t|f|f|f
33710002|NCT06321887|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an adaptive, open label study to compare the efficacy and tolerability of 8 weeks of low dose oral iron, in the treatment of iron deficiency anaemia in patients with inflammatory bowel disease (IBD).||||
33710003|NCT00901316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710004|NCT01480050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710005|NCT00335868||||TREATMENT||NONE||||||
33710006|NCT03802669|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710007|NCT04964375|NA|SEQUENTIAL||TREATMENT||NONE||||||
33710008|NCT02417597|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710009|NCT05165901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 different chronic pain classification||||
33710010|NCT01535547|NA|SINGLE_GROUP||||NONE||||||
33710011|NCT05746949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710012|NCT01912365|||COHORT||PROSPECTIVE|||||||
33710013|NCT00542555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710014|NCT04955197|||CASE_CONTROL||PROSPECTIVE|||||||
33710015|NCT02197000|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33710016|NCT04511169|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The assessor do not know if the participant is randomized to remainders or not||t|f|f|f
33710017|NCT06233981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710018|NCT04336085|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33710019|NCT00226707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710020|NCT05489198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, comparative, single-arm, randomised, and single-centre study||||
33710021|NCT01246700|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33710022|NCT03542474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710023|NCT04243681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710024|NCT03159767|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Each physiotherapist rater will have to independently attach the sensors to the participant's spine before testing, and no positioning marks will be left on the patient in between tests or between visits. They will work in different rooms and will not have access to earlier results.|Clinimetric study comparing repeated standardised spinal mobility test protocols by two independent raters on two occasions|f|f|f|t
33710025|NCT04332562|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791986|NCT04106141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33791987|NCT02834871|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33791988|NCT00217672|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33791989|NCT02200341|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33791990|NCT04662840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The referring surgeons, nursing staff, and the patient will all be blinded to outcome. Interventional radiologists and anesthetists performing the procedure itself cannot be blinded.|three-arm prospective double-blinded randomized comparative trial|t|t|f|f
33791991|NCT00233519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33791992|NCT02297880|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33791993|NCT00819442||PARALLEL||DIAGNOSTIC||NONE||||||
33791994|NCT04012853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791995|NCT00909363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"1. group of 11 WAS patients treated with eltrombopag~2. WAS patients who had their blood drawn once but did not receive eltrombopag treatment~3. healthy children as controls for testing only~3) healthy volunteers who had their blood drawn once"||||
33791996|NCT05691660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33791997|NCT00392418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33791998|NCT01135849|||COHORT||PROSPECTIVE|||||||
33710026|NCT05528354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710027|NCT03137290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710028|NCT01685281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710029|NCT00130936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710030|NCT02432729|||OTHER||PROSPECTIVE|||||||
33791999|NCT04897737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792000|NCT04307316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934118|NCT02096471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934119|NCT00041535||||TREATMENT||||||||
33710031|NCT02106936|||OTHER||PROSPECTIVE|||||||
33710032|NCT06099756|||COHORT||PROSPECTIVE|||||||
33710033|NCT02809937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792001|NCT06556186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792002|NCT00156117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792003|NCT05442463|||CASE_CONTROL||PROSPECTIVE|||||||
33792004|NCT01091298|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33792005|NCT02026258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33792006|NCT03806751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy volunteers||||
33792007|NCT06409988|||COHORT||RETROSPECTIVE|||||||
33792008|NCT05563246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792009|NCT02740530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33792010|NCT01692054|||CASE_CONTROL||RETROSPECTIVE|||||||
33792011|NCT02016131|||CASE_CONTROL||PROSPECTIVE|||||||
33792012|NCT02315391|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33792013|NCT04637152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Investigator)|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)|f|f|t|f
33792014|NCT05074615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934120|NCT00747708|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33934121|NCT01875068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33934122|NCT02904135|||COHORT||PROSPECTIVE|||||||
33934123|NCT01963962|||COHORT||PROSPECTIVE|||||||
33934124|NCT01759693|||CASE_CONTROL||PROSPECTIVE|||||||
33934125|NCT03201484|||COHORT||PROSPECTIVE|||||||
33710034|NCT06446167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation of outcomes was performed by an assessor blinded to the treatment allocation.|60 patients met the eligibility criteria and were enrolled in the study. The eligible participants were randomized into three distinct groups each comprising 20 individuals: an exercise alone group (Exercise group), an exercise combined with MLS laser therapy group (Laser group), and an exercise combined with ESWT group (ESWT group). Randomization was conducted using a computer-assisted program|f|f|f|t
33710035|NCT01750671|||COHORT|||||||||
33710036|NCT00427843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710037|NCT00944905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012137|NCT04441099|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33710038|NCT04194034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710039|NCT00779714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710040|NCT03025477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710041|NCT04785976|||COHORT||PROSPECTIVE|||||||
33710042|NCT00673803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710043|NCT05948020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking to the investigation sites and subjects (including subjects' guardians)||t|f|t|t
33710044|NCT00674245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710045|NCT00598104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710046|NCT01049308|||COHORT||PROSPECTIVE|||||||
33710047|NCT01738321|||COHORT||PROSPECTIVE|||||||
33710048|NCT00525330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710049|NCT02567916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710050|NCT04476069|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"a professional research coordinator is hired to develop blinded materials. A list of identification numbers will be created, and each number will randomly be assigned to either Group A (receive ibuprofen prior to extraction) or Group B (receive placebo prior to extraction, as a control). Only the RC will know the assignment of the numbers to groups. Blinded medications will be developed and labelled according to the identification (ID) numbers.~Once participants undergo consent, they will be assigned an ID number which placed them in a randomized group. The clinician will the medication associated with the participant's ID number prior to extraction."|Randomized, double-blind, placebo-controlled clinical trial|t|t|t|f
33710051|NCT01811654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710052|NCT04144244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710053|NCT04915430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were blindly assigned to one of the training regimens.|Patients were randomized to either a supervised training regimen (STR) or a home training regimen|f|f|t|f
33792015|NCT03073499|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012138|NCT05307159|NA|SINGLE_GROUP||OTHER||NONE||||||
34012139|NCT00430950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012140|NCT00350402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012141|NCT00336115|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34012142|NCT04128202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012143|NCT01780779|||CASE_ONLY||PROSPECTIVE|||||||
34012144|NCT03652987|||COHORT||PROSPECTIVE|||||||
34012145|NCT01680783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012146|NCT02098421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012147|NCT00905788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012148|NCT00419549|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34012149|NCT04588688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012150|NCT00788593|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34012151|NCT01564459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012152|NCT06273020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"There are 3 groups in this clinical trial~Group 1: 20 patients with previous intravenous thrombolysis (IVT) in the qualifying stroke and who agreed to receive and got selected (through randomization) cerebrolysin.~Group 2 : 20 patients with previous IVT in the qualifying stroke and who agreed to receive cerebrolysin but they were not choose through randomization.~Group 3: 20 patients that they were not candidates to receive IVT (out of therapeutic window) but agreed to receive cerebrolysin (randomization not used)"||||
34012153|NCT00384007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012154|NCT00253981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012155|NCT02612454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710054|NCT01277263|||CASE_ONLY||PROSPECTIVE|||||||
33792016|NCT03885596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792017|NCT00576888|||OTHER||OTHER|||||||
33792018|NCT05839938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792019|NCT01425437|||CASE_ONLY||PROSPECTIVE|||||||
33792020|NCT06381895|||COHORT||RETROSPECTIVE|||||||
33792021|NCT03522519|||COHORT||PROSPECTIVE|||||||
33792022|NCT05587309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792023|NCT01335932|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33792024|NCT06555146|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, double-blinded, placebo-controlled crossover with around 4 weeks between study periods.|t|f|t|f
33792025|NCT00775242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792026|NCT06294704|||COHORT||RETROSPECTIVE|||||||
33792027|NCT00001063||||TREATMENT||||||||
33792028|NCT02401919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34012156|NCT01733147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012157|NCT00654654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012158|NCT03354455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Sham stimulation||t|f|f|f
34012159|NCT00458666|||||PROSPECTIVE|||||||
34012160|NCT01333072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34012161|NCT00204022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012162|NCT03091413|||CASE_ONLY||PROSPECTIVE|||||||
34012163|NCT06030349|||COHORT||PROSPECTIVE|||||||
34012164|NCT05205018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34012165|NCT00751738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710055|NCT01609374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|since the study is concurrently controlled, masking is not possible|non-randomized, concurrent ACDF control||||
33710056|NCT06301685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710057|NCT03434275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710058|NCT00929318|RANDOMIZED|||BASIC_SCIENCE||NONE||||||
33710059|NCT03528772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012166|NCT01783002|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710060|NCT05923437|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The study will be conducted with a total of 40 newborns (intervention group=20, control group= 20). In order to prevent selection bias in the study, participants will be randomly assigned to the intervention and control groups and the block randomization method, one of the fixed probability randomization methods, will be used in randomization. Each of the intervention and control groups will be represented by one of the letters A and B. In the creation of the 4-block (2A, 2B); the assignment of 10 blocks from the total number of options determined using the permutation method will be carried out with the random numbers table tool on the www.random.org website."|t|f|f|f
33710061|NCT01506713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710062|NCT00101595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710063|NCT00948701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33710064|NCT03346278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33934126|NCT04917731|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33934127|NCT01898000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934128|NCT00578890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934129|NCT01216215|||COHORT||PROSPECTIVE|||||||
33934130|NCT03105375|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||SAD and MAD study||||
33934131|NCT06041191|||COHORT||CROSS_SECTIONAL|||||||
33934132|NCT03821350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was designed as prospective, single blinded, randomized controlled study. Patients were randomized into two groups. The enrollment of the participants was carried out by an independent researcher. Pre and post-injection evaluation was performed by the investigators who had no knowledge about the groups|Parallel group|f|f|t|f
33934133|NCT03593564|NA|SINGLE_GROUP||PREVENTION||NONE||The investigators will evaluate the KINDER program using pre- and post-test analysis. Eligible and consented subjects enrolled on a rolling basis. After enrollment, all caregivers will complete a baseline assessment. Caregivers will receive the intervention (8 lessons, delivered once per week) and will be asked to complete a reassessment after 10 weeks. Two months later, participants will be asked to complete a second reassessment.||||
33934134|NCT01310374|||COHORT||PROSPECTIVE|||||||
33934135|NCT04179760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase I: Multicenter in Korea, Randomized, Open-label, Parallel arm Phase II: Multicenter in Korea, Double-blind, Placebo-controlled, Parallel arm|t|t|t|t
33934136|NCT06168981|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934137|NCT04168151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934138|NCT05155839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934139|NCT05974891|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33934140|NCT03424213|||COHORT||RETROSPECTIVE|||||||
33934141|NCT03017833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934142|NCT03894267|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||This study is a prospective, randomized control design.||||
33934143|NCT01358006|NA|SINGLE_GROUP||||NONE||||||
33934144|NCT01832389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934145|NCT06063837|NA|SINGLE_GROUP||OTHER||NONE||||||
33934146|NCT03236506|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, un-blinded trial||||
33934147|NCT00503555|||DEFINED_POPULATION||OTHER|||||||
33934148|NCT03880123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012167|NCT04445064|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentric||||
34012168|NCT05302921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012169|NCT04088266|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012170|NCT01584531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012171|NCT03676166|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012172|NCT04762459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710065|NCT01506674|||COHORT||PROSPECTIVE|||||||
33710066|NCT03711812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33710067|NCT03435861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Our mono-centric project will consist in a double-blinded randomized placebo-controlled study, assessing the effect of neflamapimod on brain inflammation in patients suffering of AD by using \[18F\]-DPA714|t|t|t|t
33934149|NCT04941976|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomised, active-controlled, open label, parallel-group, international study.||||
33934150|NCT01221168|||COHORT||PROSPECTIVE|||||||
33934151|NCT03947099|||COHORT||PROSPECTIVE|||||||
33934152|NCT03655418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934153|NCT04682912|||COHORT||RETROSPECTIVE|||||||
33934154|NCT02072733|NA|SINGLE_GROUP||OTHER||NONE||||||
33934155|NCT00149110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934156|NCT03975517|||COHORT||PROSPECTIVE|||||||
34012173|NCT06229821|NA|SINGLE_GROUP||TREATMENT||NONE||Application of Intrapulmonary Percussive Ventilation (IPV) in preterm neonates, older than 14 days, who require mechanical ventilation. IPV will be administered in increasing intervals, for 15 minutes, starting every 6 hours, and ending every 24 hours; for a total of 7 days.||||
34012174|NCT00302302|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34012175|NCT01005706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012176|NCT04062994|||COHORT||PROSPECTIVE|||||||
34012177|NCT01434576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012178|NCT04760392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34012179|NCT01465282|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34012180|NCT02854059|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34012181|NCT04746599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012182|NCT05329493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012183|NCT05513716|||OTHER||RETROSPECTIVE|||||||
33710068|NCT04869891|||COHORT||PROSPECTIVE|||||||
33710069|NCT04947449|||COHORT||PROSPECTIVE|||||||
33934157|NCT05909462|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|double blind randomized controlled|randomized, controlled trial|t|f|t|f
33710070|NCT06021145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934158|NCT00671476|RANDOMIZED|||TREATMENT||SINGLE||||||
33934159|NCT04246268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934160|NCT01430949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934161|NCT03432936|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33934162|NCT04063397|||CASE_CONTROL||PROSPECTIVE|||||||
33710071|NCT03275454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710072|NCT01775085|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710073|NCT02684916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710074|NCT00003993||||TREATMENT||||||||
33710075|NCT02551978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710076|NCT06342466|NA|SINGLE_GROUP||TREATMENT||NONE||Bortezomib, pomalidomide, dexamethasone||||
33710077|NCT06124560|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33710078|NCT01331915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710079|NCT05746871|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33710080|NCT04176978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710081|NCT05808972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Independant groups included by randomisation|t|f|f|f
33710082|NCT06300372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor and participants will be blinded to the study|Fifty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II, scheduled for living liver donation surgery for liver transplantation will be included in the study. Patients will be randomly divided into two groups (Group A=M-TAPA block group, Group B = control group) including 25 patients each, before entering the operating room.|t|f|f|t
33710083|NCT02885012|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710084|NCT00079898|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33710085|NCT06110780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33710086|NCT03064451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710087|NCT00877253|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710088|NCT00795314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710089|NCT01604837|||CASE_CONTROL|||||||||
33710090|NCT01130142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710091|NCT06557070|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To ensure blinding in the study, randomization will be carried out by someone other than the researchers. A total of 8 sessions of Emotional Freedom Technique (EFT) will be applied to the experimental group, once a week. No application other than the scales will planned for the control group. Only, the control group will be taught the EFT technique at the end of the experiment.|A single-blind randomized controlled experimental study|t|f|f|f
33710092|NCT05362097|||COHORT||PROSPECTIVE|||||||
33710093|NCT00323921|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
33710094|NCT01175252|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33710095|NCT01663532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710096|NCT03594721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710097|NCT03454776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups with same problem of osteoarthritis in knee|f|f|t|f
33710098|NCT02868775|||COHORT||PROSPECTIVE|||||||
33710099|NCT03478332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710100|NCT00899054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710101|NCT05704452|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710102|NCT04812145|||COHORT||RETROSPECTIVE|||||||
33710103|NCT03303924|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710104|NCT04036344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33934163|NCT02717676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934164|NCT00410514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934165|NCT05057468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012184|NCT05859321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012185|NCT06236776|||COHORT||PROSPECTIVE|||||||
33710105|NCT03118258|RANDOMIZED|PARALLEL||SCREENING||NONE||"The two strategies consist of a preventive consultation followed by:~1. Direct patient referral for Pap smear testing in a partner health facility ('Pap smear' study arm)~2. An invitation to perform a self-collected vaginal swab for HPV-HR testing followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive\* \* A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason.~('self-collected vaginal swab for HPV-HR testing + Pap smear' triage study arm)"||||
33710106|NCT03187106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded||t|t|t|t
33801910|NCT00006349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33934166|NCT05957328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012186|NCT03523247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012187|NCT05690074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012188|NCT05580952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934167|NCT04892394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33934168|NCT00364832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934169|NCT01231672|||COHORT||PROSPECTIVE|||||||
33934170|NCT05116033|||OTHER||RETROSPECTIVE|||||||
34012189|NCT02389101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012190|NCT06314516|||COHORT||RETROSPECTIVE|||||||
34012191|NCT05215093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012192|NCT00836147|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34012193|NCT00775606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012194|NCT06309316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012195|NCT03516136|||COHORT||RETROSPECTIVE|||||||
34012196|NCT01589861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710107|NCT05457764|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Balanced and randomized controlled cross-over within-subjects design||||
33710108|NCT00000208||||TREATMENT||NONE||||||
33710109|NCT00188669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012197|NCT05069155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||This is a 2-arm, randomized, controlled trial over 12 weeks with 6 weeks of follow-up (18 weeks total) that compares a control group that uses a wearable device to track physical activity to an intervention group that uses the same wearable devices and receives a supportive social incentive-based gamification intervention to adhere to a step goal program.|t|f|t|t
34012198|NCT00854802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012199|NCT03046498|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34012200|NCT01347658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012201|NCT00953472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012202|NCT02477774|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33710110|NCT02155062|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34012203|NCT06166784|||COHORT||PROSPECTIVE|||||||
34012204|NCT00594113|RANDOMIZED|PARALLEL||||NONE||||||
33710111|NCT05125757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710112|NCT00232232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710113|NCT02878746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710114|NCT02079220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801911|NCT03005925|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33801912|NCT03825575|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of concept||||
33934171|NCT06358976|RANDOMIZED|FACTORIAL||OTHER||SINGLE|In this clinical trial, due to the nature of the interventions, it may not be possible to mask or blind the participants or therapists to the treatment received. However, efforts will be made to blind the outcome assessors who will be responsible for evaluating the participants' hand function, spasticity, and other outcome measures. Blinding the outcome assessors helps minimize potential bias and ensures the objective assessment of the intervention's effectiveness. By keeping the assessors unaware of the participants' group allocations, the integrity and reliability of the study findings can be enhanced.|The interventional study model for this clinical study is a pilot randomized controlled trial. Participants will be randomly assigned to one of three arms: Group A (vibrating splint intervention), Group B (standard splint intervention), or Group C (control group receiving no splint intervention). This model allows for the comparison of different interventions and the evaluation of their effectiveness in improving hand function and reducing spasticity after stroke. Randomization helps ensure that each group is comparable in terms of baseline characteristics, minimizing bias and increasing the validity of the study results.|f|f|t|f
33934172|NCT06004089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934173|NCT05868460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934174|NCT05615155|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33934175|NCT03170804|||COHORT||PROSPECTIVE|||||||
33934176|NCT00584987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934177|NCT03537937|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Observer bias will be minimized by use of objective endpoints collected in duplicate by \[1\] study personnel blinded to group assignment and \[2\] automated data extraction from the electronic health record.|In the PILOT trial, the entire study ICU will be assigned to a single SpO2 target (cluster-randomized) and the ICU will switch between lower, intermediate, and higher SpO2 targets every two months in a randomly generated sequence (cluster-crossover).|f|f|f|t
33934178|NCT00881023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934179|NCT01188811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934180|NCT04472819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934181|NCT04732780|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934182|NCT04164849|NA|SINGLE_GROUP||TREATMENT||NONE|all patients will receive active treatment|A combined phase 1/2 pilot study with emphasize on safety/tolerability but also clinical efficacy/effect||||
33710115|NCT02491203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710116|NCT04115839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710117|NCT03153969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710118|NCT04394260|||CASE_ONLY||CROSS_SECTIONAL|||||||
33710119|NCT01439269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710120|NCT00662012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710121|NCT06265012|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Single-blind||t|t|t|t
33710122|NCT01833013|NA|SINGLE_GROUP||||NONE||||||
33792029|NCT03109704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants were made aware of the 3 different interventions being investigated but were not told which technique they were assigned to receive|randomized controlled trial, 3 groups which includes a sham comparator|t|f|f|f
33792030|NCT04018508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33934183|NCT01699776|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33934184|NCT01518309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934185|NCT00154921|||DEFINED_POPULATION||OTHER|||||||
33934186|NCT01661504|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33934187|NCT03458234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934188|NCT00592072|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33934189|NCT03775603|||CASE_ONLY||PROSPECTIVE|||||||
33934190|NCT00262639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934191|NCT00554346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934192|NCT05960786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934193|NCT00998036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934194|NCT02909582|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934195|NCT03872336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principle investigator and outcomes assessor are masked to group assignment.||f|f|t|t
33934196|NCT02415829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934197|NCT04729595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, Double-blind, Placebo-Controlled|Randomized, Double-blind, placebo-controlled enrolling high risk subjects with early COVID19 infection.|t|t|t|t
34012205|NCT00962988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012206|NCT00868296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012207|NCT04111588|||CASE_ONLY||PROSPECTIVE|||||||
34012208|NCT05678855|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|students were given information about the study, but not in which group they are included. Thus, blinding was ensured.|Randomized controlled trial|t|f|f|f
34012209|NCT02972177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012210|NCT01915420|||COHORT||PROSPECTIVE|||||||
34012211|NCT06389006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012212|NCT00965770|||COHORT||RETROSPECTIVE|||||||
34012213|NCT03499119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34012214|NCT04933786|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34012215|NCT04754802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012216|NCT00140413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012217|NCT00040430|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095411|NCT06001307|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All research staff conducting participant assessments will remain blinded to group assignment. Randomization procedures will be conducted by a high level researcher (co-investigator responsible for clinical supervision).|The methodological approach includes a 2-arm trial of Project STARS vs. a time matched, attention-controlled comparison group, with up to n=20 per arm (total Phase 3 sample size = up to 40 participants enrolled and randomized). The study is intended to evaluate the impacts of STARS on the specified outcomes.|f|f|f|t
33934198|NCT05141344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The drugs will be given by an anesthetist who is not one of the observers to ensure blindness|50 patients will be divided into 2 equal groups|t|t|t|f
33934199|NCT02515773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934200|NCT01880879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934201|NCT03187210|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The BAL trial consists in two parts:~* single arm prospective phase I part;~* randomized two-arm open-label prospective phase II part."||||
34025292|NCT05326243|NA|SINGLE_GROUP||TREATMENT||NONE||"This study is a multiple-center, non-randomized, open-label, phase 1/2 study. Lymphodepletion chemotherapy (intravenous infusion of fludarabine plus cyclophosphamide will be administered for 3 consecutive days before the day of PL001 dosing (Day 0) and should take place within Day -5 to Day -3 (a safe window for a small subset of patients will be D -7 to D -3). This study will test two dose levels of PL001, dose level 1 and dose level 2. In Phase 1, doses will be tested in the modified 3 + 3 design initiating with dose level 1. The primary objective of Phase 1 is to assess the safety of PL001 and find the recommended phase 2 dose. Phase 2 expansion cohort will receive PL001 at the recommended dose determined in Phase 1. Efficacy evaluations using computed tomography (CT) and positron emission tomography (PET) will be performed at 1, 3, 6, 9, and 12 months."||||
34025293|NCT03478527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double blind|"1 Verum group, receiving the probiotic Vivomixx® powder~1 Placebo group, receiving a placebo powder (similar taste and consistency as Vivomixx® powder)"|t|f|t|f
34095412|NCT06150443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095413|NCT02077647|||CASE_CONTROL||PROSPECTIVE|||||||
33934202|NCT03942172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934203|NCT04021628|||COHORT||PROSPECTIVE|||||||
33934204|NCT03887052|NA|SINGLE_GROUP||OTHER||NONE||Multicenter single arm open label evaluation||||
33934205|NCT03353441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Partly double-blind (Glycine (MSG), Placebo, control without treatment)||t|f|t|f
33934206|NCT05563259|||COHORT||CROSS_SECTIONAL|||||||
33934207|NCT05013385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934208|NCT04669509|||COHORT||RETROSPECTIVE|||||||
33934209|NCT01322529|||COHORT||PROSPECTIVE|||||||
33934210|NCT00786461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934211|NCT00193128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934212|NCT01480791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934213|NCT03571867|||OTHER||PROSPECTIVE|||||||
33934214|NCT04880460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions. The type of masking was double-blind masking.|"A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A in parallel to participants in the other group, who receive drug B."|t|f|t|f
33934215|NCT05939076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomised treatment is open but the outcomes are blinded.|Multicentre, prospective 1:1 randomized open blinded for evaluation of end point (PROBE) controlled parallel-group superiority trial comparing first-line pulmonary vein isolation (PVI) using the cryoballoon (Arctic Front AdvanceR, Medtronic) and first-line antiarrhythmic drug (AAD) therapy.|t|t|t|t
33934216|NCT03734770|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized trial||||
33934217|NCT00249912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934218|NCT02168660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934219|NCT05762965|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study applies a randomized, parallel, double-blind design of 6 weeks|t|f|t|f
33934220|NCT01498770|||COHORT||RETROSPECTIVE|||||||
33934221|NCT01758640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934222|NCT02788825|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934223|NCT05525065|||COHORT||PROSPECTIVE|||||||
33934224|NCT05263011|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33934225|NCT03948594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation sequence is according computer generated random number list, it was prepared by an investigator with no clinical involvement in the trial. Allocation sequence was concealed from researcher enrolling and assessing participants. Allocation sequence will be sealed in sequentially numbered and opaque envelopes. A manila card will be placed inside envelop to render it impermeable to intense light. To prevent subversion of the allocation sequence, the name and I/C of the participant will be written on a book together with the series number on envelopes. The details in the book will be kept confidentially. After enrolled subject complete all baseline assessment, corresponding envelope will be enclosed by staff (who not involve in study) who prepare the drink. The staff need to ensure that the envelop still sealed when receive it. The staff will prepare the drink into identical container according to the assignment.|Subjects are randomised into 2 group: group A with 250cc plain water and group B with 1 packet resource(237ml)|f|t|f|t
33934226|NCT03822780|NA|SINGLE_GROUP||TREATMENT||NONE||cross-control||||
33934227|NCT04197206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934228|NCT01623856|||CASE_CONTROL||RETROSPECTIVE|||||||
33934229|NCT05987514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934230|NCT06424041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Double-Blinded, Randomized Placebo-Controlled Trial|t|t|t|t
33934231|NCT04759898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the first and second arms, prior to placement of electrodes, subjects will be randomized to either treatment or sham. This will occur using a random number generator with a binary choice determination (1 = stimulation; 2 = sham). Patients will be blinded to this choice.|In the first arm, Parkinson's disease and chronic stroke subjects will be investigated using noninvasive methods, including EEG and tDCS, respectively. In the second arm, a separate cohort of Parkinson's disease and chronic stroke subjects will be investigated using noninvasive methods, including EEG and sham tDCS, respectively. In the third arm, patients with Parkinson's disease will be investigated using electrocorticography (while undergoing surgery for deep brain stimulation) combined with tDCS.|t|f|f|f
33934232|NCT03712995|NA|SINGLE_GROUP||TREATMENT||NONE||Retrospective review of charts of the patients enrolled||||
33934233|NCT00682760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33934234|NCT05642793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095414|NCT02700256|||COHORT||PROSPECTIVE|||||||
34095415|NCT06156267|NA|SEQUENTIAL||TREATMENT||NONE||||||
34095416|NCT03712852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||parallel assignment|t|t|t|f
34095417|NCT03331562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled|This is a double-blind, randomized, placebo-controlled phase II trial with the identity of the treatment unknown to the patients, investigators, and the Sponsor.|t|t|t|t
34095418|NCT03522168|||COHORT||PROSPECTIVE|||||||
34095419|NCT04126668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095420|NCT05937282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095421|NCT02504736|||COHORT||PROSPECTIVE|||||||
34095422|NCT03246854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095423|NCT05895500|||COHORT||PROSPECTIVE|||||||
34095424|NCT00676052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095425|NCT04048083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34095426|NCT04501575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095427|NCT02958527|||CASE_ONLY||PROSPECTIVE|||||||
33934235|NCT04722380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||10 patients, twenty sites with, localized aggressive periodontitis, with CAL ≥ 5 will be included in the present study. Sites will be allocated randomly to be surgically treated with, Nigella Sativa oil extract Mixed with xenograft or xenograft alone.|t|f|t|t
33934236|NCT00993980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934237|NCT01131130|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33934238|NCT02918422|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33934239|NCT02587728|||COHORT||PROSPECTIVE|||||||
33934240|NCT01289561|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34095428|NCT05194488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095429|NCT03968627|||OTHER||PROSPECTIVE|||||||
34095430|NCT00727337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095431|NCT02588755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095432|NCT00309244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095433|NCT02127515|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34095434|NCT02740010|||COHORT||RETROSPECTIVE|||||||
34095435|NCT06500728|||COHORT||PROSPECTIVE|||||||
34095436|NCT05539508|||CASE_CONTROL||PROSPECTIVE|||||||
34095437|NCT02971189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934241|NCT02282488|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33934242|NCT02865928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095438|NCT01945242|||COHORT||PROSPECTIVE|||||||
34095439|NCT03745469|||CASE_ONLY||CROSS_SECTIONAL|||||||
34095440|NCT02410876|||CASE_CONTROL||PROSPECTIVE|||||||
34095441|NCT06251427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Three armed double blinded intervention.~1. Low dose of multiple micronutrient fortification~2. Moderate dose of multiple micronutrient fortification~3. High dose of multiple micronutrient fortification"|t|t|t|t
33934243|NCT06344039|||CASE_ONLY||RETROSPECTIVE|||||||
33934244|NCT02233582|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33934245|NCT04987424|||COHORT||PROSPECTIVE|||||||
33934246|NCT03014245|||CASE_CONTROL||PROSPECTIVE|||||||
33934247|NCT02579863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934248|NCT04324476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934249|NCT01440972|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33934250|NCT03001414|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33934251|NCT00236210|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934252|NCT00382551|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33934253|NCT01518673|||COHORT||PROSPECTIVE|||||||
33934254|NCT06507371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934255|NCT01915290|||||CROSS_SECTIONAL|||||||
33934256|NCT01641224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934257|NCT06267716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants under general anaesthesia and the orthopaedic surgeon responsible for the study will be blinded to the study groups and the specific block procedures. This surgeon will serve as the sole evaluator of postoperative outcomes. Intraoperative results will be recorded by the anaesthesia technician, who is present in the operating room and unaware of the block procedures. Moreover, the data analysis will be conducted before the data are unblinded.|prospective randomized standardized triple-blind|t|f|f|t
33934258|NCT00796549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095442|NCT06459973|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34095443|NCT02242110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710123|NCT03547180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710124|NCT03185767|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33710125|NCT04362982|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned to one of two or more groups in parallel for the duration of the study||||
33710126|NCT01701557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710127|NCT02654730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095444|NCT02345577|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34095445|NCT05299450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095446|NCT01893619|||COHORT||PROSPECTIVE|||||||
33710128|NCT05044390|||COHORT||RETROSPECTIVE|||||||
33710129|NCT00263601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710130|NCT01099982|||COHORT||PROSPECTIVE|||||||
33710131|NCT04654117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34095447|NCT05858229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710132|NCT06266234|||CASE_ONLY||RETROSPECTIVE|||||||
33710133|NCT03633695|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner masked||f|f|f|t
33710134|NCT00217295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710135|NCT02091934|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095448|NCT04411407|RANDOMIZED|CROSSOVER||OTHER||NONE||A randomised, within-participants, open, cross-over trial||||
33792031|NCT04788433|||CASE_ONLY||PROSPECTIVE|||||||
34095449|NCT00188838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710136|NCT00490360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710137|NCT01126853|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33710138|NCT04004715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|All participants and investigators will be blinded to the the beverage treatments. The meal treatment is not blinded.|Randomized, partially-blind, cross-over controlled trial|t|f|t|f
33710139|NCT03967652|||OTHER||PROSPECTIVE|||||||
33710140|NCT03859752|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, multiple dose, dose-escalation||||
33710141|NCT05142943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Clinical Trail|t|f|f|t
33710142|NCT05367648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33710143|NCT04985097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental group vs control group|t|t|f|f
33710144|NCT00975650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710145|NCT04255108|||COHORT||RETROSPECTIVE|||||||
33792032|NCT02657629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33934259|NCT06120192|NA|SINGLE_GROUP||TREATMENT||NONE||Open label feasibility study||||
33934260|NCT01339780|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934261|NCT01519336|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34095450|NCT06177353|||COHORT||PROSPECTIVE|||||||
34012218|NCT05613751|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Blinding is considered desirable; however, it will depend on the type of nudge and will be determined after the nudge is developed. Endpoint measurements will involve low level contact of study staff, however when contact is required (such as AIR/ confirmation of influenza/COVID-19 vaccine receipt etc), this will be carried out by trial staff shielded from information that might reveal trial group assignment. The study statistician undertaking the analysis and study investigators will remain blinded to trial intervention assignment.|"Four multi-centre, parallel group, superiority, randomized control trials (with 1:1 allocation) of nudge interventions to improve influenza and COVID-19 vaccine uptake among pregnant women and medically at risk children. Each RCT will enroll 1038 participants (n = 519 each in intervention and control groups), with a total of 4154 participants in the four RCTs:~* pregnant women's RCTs~  * COVID-19 vaccine (n= 1038): Arm #1 (Standard care, n=519); Arm #2 (Nudge intervention, n=519)~ * Influenza vaccine (n= 1038): Arm #1 (Standard care, n=519); Arm #2 (Nudge intervention, n=519)~* medically at-risk children's RCTs~  * COVID-19 vaccine (n= 1038): Arm #1 (Standard care, n=519); Arm #2 (Nudge intervention, n=519)~ * Influenza vaccine (n= 1038): Arm #1 (Standard care, n=519); Arm #2 (Nudge intervention, n=519)~There are eight arms in total for four RCTs."|t|f|f|t
34012219|NCT05466175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012220|NCT00002352||||TREATMENT||||||||
34012221|NCT01100879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012222|NCT02973321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012223|NCT03204474|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34012224|NCT01928303|||CASE_CONTROL||PROSPECTIVE|||||||
34012225|NCT06204419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012226|NCT05336305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012227|NCT05386524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012228|NCT05667636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012229|NCT04841330|||OTHER||PROSPECTIVE|||||||
34095451|NCT00541775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095452|NCT05756478|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"In order to investigate if implementing routine pharmacist-led medication reviews in the outpatient clinics of public hospitals for older adults with multi-morbidity, we are conducting a single-arm study at 2 sites to understand how the implementation strategies could be best carried out to facilitate the aim to reduce inappropriate prescribing. Pre- and post-medication review data on potentially inappropriate medications and other issues flagged will also be collected for a future scale up study. Each site is expected to recruit 30 patients.~An evaluation will also be conducted with the doctors and pharmacists delivering and implementing the study."||||
34095453|NCT04855669|||COHORT||PROSPECTIVE|||||||
34095454|NCT05315258|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34095455|NCT00837447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095456|NCT00448357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095457|NCT01051167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095458|NCT03478995||SEQUENTIAL||TREATMENT||NONE||||||
34095459|NCT05582603|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I: An open-label prospective Phase I dose-escalation study following a standard 3+3 rule-based up-and-down design without dose de-escalation will be followed.~Phase II: An open-label prospective clinical trial to validate the minimum dosage and appropriate safety using the training time obtained in Phase I for the CCT along a 15-day training period with a 24-hour rest between sessions."||||
34095460|NCT04599257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095461|NCT05009550|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|single||t|f|f|f
34095462|NCT04286958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095463|NCT02507999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34095464|NCT01851304|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34095465|NCT00663351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095466|NCT04374552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study medication will be tablets containing either active drug or placebo||t|t|t|t
34095467|NCT02955927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095468|NCT00471107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012230|NCT04812639|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|not showing the anesthetic procedure in the video tape||f|f|f|t
34012231|NCT06226701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant,outcomes assessed random generator|Impact of cryolipolsis on hormonal Profile in obese women with Pcps|t|t|f|f
34012232|NCT00003598|RANDOMIZED|||PREVENTION||||||||
34012233|NCT05424484|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34012234|NCT04062149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know if thy have been allocated to the control or experimental group|Exploratory pre-test - post-test experimental design|t|f|f|f
34012235|NCT03128684|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34012236|NCT03913260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Part A is a crossover design. Part B is a parallel design.|t|f|t|f
33801913|NCT00991497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934262|NCT05976906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934263|NCT03731910|NA|SINGLE_GROUP||OTHER||NONE||||||
33934264|NCT02269904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934265|NCT04287205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934266|NCT00515099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33934267|NCT06002997|||COHORT||PROSPECTIVE|||||||
33934268|NCT03336203|RANDOMIZED|PARALLEL||TREATMENT||NONE||180 participants in parallel groups. These patients with high SUA level (\>8 mg/dL; 480 µmol/L) are going to be divided into 2 arms (90+90) 1) with gout (EULAR's criteria) and 2) without gout but with presence of CKD 1-4)||||
33934269|NCT00666055|||CASE_CONTROL||PROSPECTIVE|||||||
33934270|NCT03050606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934271|NCT04557007|||COHORT||PROSPECTIVE|||||||
33934272|NCT06019390|NA|SINGLE_GROUP||SCREENING||NONE||||||
33934273|NCT05980611|||OTHER||CROSS_SECTIONAL|||||||
33934274|NCT04371549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012237|NCT01795248|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34012238|NCT05369078|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study includes 2 parts: Single does part and multiple dose part. Single does part and multiple dose part are started same time.||||
34012239|NCT04117737|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assessor was blinded to outcomes values between sessions and to the adherence of participants to the intervention.|||||
34012240|NCT03465748|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012241|NCT04760600|||CASE_CONTROL||RETROSPECTIVE|||||||
34012242|NCT04965389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012243|NCT03159286|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not know which intervention they are in during the course of the study. They will be debriefed at the end of the study and informed which condition they were a part of.||t|f|f|f
34012244|NCT05286840|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective, non-randomized, single arm, single center, open-label study .||||
34012245|NCT01244373|||CASE_ONLY||PROSPECTIVE|||||||
34012246|NCT05901259|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710146|NCT04445311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710147|NCT01753271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710148|NCT00025272||||TREATMENT||NONE||||||
33710149|NCT05504564|||COHORT||PROSPECTIVE|||||||
33710150|NCT00386178|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33801914|NCT02075736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934275|NCT03366974|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||An open-label, one-sequence, three-period study||||
33934276|NCT02034656|||COHORT||RETROSPECTIVE|||||||
33934277|NCT04233840|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I : Dose escalation study with Anti-PD1 dossages 4 cohorts Phase II : 3 parallel arms||||
33710151|NCT03478202|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710152|NCT04200664|||CASE_CONTROL||PROSPECTIVE|||||||
33710153|NCT04985864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710154|NCT01270776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710155|NCT04829396|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Double-blind|Placebo or intervention, wash-out, intervention or placebo|t|t|t|f
33710156|NCT01581255|||COHORT||PROSPECTIVE|||||||
33710157|NCT00982137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934278|NCT03452995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934279|NCT05017168|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33934280|NCT00505544|||CASE_CONTROL||PROSPECTIVE|||||||
33934281|NCT02227290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934282|NCT03960385|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934283|NCT02098148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934284|NCT00357240|RANDOMIZED|PARALLEL||||NONE||||||
34095469|NCT01660685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095470|NCT01446588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095471|NCT01857154|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33934285|NCT00741741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934286|NCT00854867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934287|NCT00194415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934288|NCT05202002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33934289|NCT02481323|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33710158|NCT00766337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710159|NCT02206048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710160|NCT01224860|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710161|NCT05636683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710162|NCT02755519|||CASE_CONTROL||PROSPECTIVE|||||||
33710163|NCT01633853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710164|NCT00006097||||TREATMENT||||||||
33710165|NCT01310621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710166|NCT00003499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710167|NCT01303107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33710168|NCT04073654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Implants have same macro design.|Randomized controlled trial, split-mouth design|t|f|f|t
33710169|NCT06201702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710170|NCT02034669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934290|NCT01962467|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934291|NCT03908086|||COHORT||RETROSPECTIVE|||||||
33934292|NCT01435122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934293|NCT02446028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934294|NCT04464473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33934295|NCT05388734|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Quasi-experimental, before-and-after, comparative, prospective, single-center, open-label study.||||
33934296|NCT01531686|||CASE_ONLY||PROSPECTIVE|||||||
33934297|NCT04453891|||COHORT||PROSPECTIVE|||||||
33934298|NCT03094494|||CASE_CONTROL||RETROSPECTIVE|||||||
33934299|NCT02100410|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33934300|NCT04313673|||CASE_ONLY||RETROSPECTIVE|||||||
33934301|NCT00125229|||CASE_ONLY||PROSPECTIVE|||||||
33934302|NCT01929512|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934303|NCT04018105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934304|NCT01957215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934305|NCT04996277|RANDOMIZED|PARALLEL||OTHER||NONE|During the study, it is difficult for researchers, operators and patients to blind the method due to objective reasons.|In this study, 300 subjects with target vessel stenosis of 50%-90% confirmed to be suitable for stent implantation by angiographic evaluation will be recruited and randomly assigned to FFR, OCT or Angio group according to 1:1:1. FFR group: Patients with FFR ≤0.8 were treated with PCI; FFR \&gt; 0.8 patients will receive drug therapy; All patients will undergo OCT examination. OCT group: if MLA\&lt; 4.5mm2 patients will receive PCI; Other patients will be treated with medication; All patients will be examined for FFR. Angio group: The appropriate treatment (stent implantation) will be given according to the evaluation of the doctor.||||
33934306|NCT03996889|||OTHER||PROSPECTIVE|||||||
33934307|NCT02142972|||COHORT||PROSPECTIVE|||||||
33710171|NCT00299910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710172|NCT00089154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710173|NCT03059602|||OTHER||PROSPECTIVE|||||||
33710174|NCT02587715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710175|NCT03031314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33710176|NCT01748669|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934308|NCT02484040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934309|NCT01581606|||CASE_ONLY||PROSPECTIVE|||||||
33934310|NCT01886495|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33934311|NCT03518775|||COHORT||PROSPECTIVE|||||||
33934312|NCT04151524|||COHORT||RETROSPECTIVE|||||||
33934313|NCT00564915|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934314|NCT03170492|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33934315|NCT02719210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934316|NCT05541250|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33934317|NCT02204059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934318|NCT00287755|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33934319|NCT02259764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934320|NCT00482365|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934321|NCT04431141|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934322|NCT02951728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934323|NCT05326906|||COHORT||RETROSPECTIVE|||||||
33934324|NCT04052412|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Physicians responsible for care are blinded to detailed study results to prevent any potential alterations to patient treatment. All treatment decisions are based on standard of care without regard for the biodistribution data collected from this study.|"This is a biodistribution and kinetics study looking at the uptake of 18F-AraG in non-small cell lung cancer patients in 3 different arms as follows:~1. Non-small cell lung cancer undergoing immunotherapy without radiation therapy~2. Non-small cell lung cancer undergoing immunotherapy with adjuvant radiation therapy"|f|t|f|f
33934325|NCT04251195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934326|NCT06393413|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934327|NCT05120453|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33934328|NCT00257322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934329|NCT05226572|||OTHER||RETROSPECTIVE|||||||
33934330|NCT05118750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934331|NCT00620737|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934332|NCT00650364|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33934333|NCT05455255|RANDOMIZED|PARALLEL||OTHER||NONE||"This research was planned to examine the effect of flipped learning on students' problem solving and critical thinking skills in nursing process teaching and their views on this model. In the quantitative part of this research, pretest-posttest randomized controlled experimental design, and in the qualitative part case study and phenomenological design will be used.~Intervention and control groups will be determined by stratified randomization in line with the pre-test. In the quantitative design, flipped learning will be applied to the intervention group, while the traditional method will be applied to the control group. A focus group discussion will be held with the intervention group after the post-tests are administered."||||
33934334|NCT02401776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33934335|NCT03077711|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients diagnosed with recurrent urinary tract infections are recruited into this study.||||
33934336|NCT00909883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934337|NCT04450004|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Partially-blinded|||||
33934338|NCT02382770|||COHORT||PROSPECTIVE|||||||
33934339|NCT01525108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934340|NCT00673816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934341|NCT04071808|||CASE_CONTROL||PROSPECTIVE|||||||
33934342|NCT00675129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934343|NCT05213676|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In this multi-center study, centers will use iNO per their usual protocol, and centers will then crossover to iNO deimplementation (that is, at the time of crossover, centers will stop using iNO in the initial resuscitation period). A stepped-wedge crossover study design will be used, and the timing of crossover will be cluster randomized at the level of the center.||||
33934344|NCT01557127|||COHORT||PROSPECTIVE|||||||
33934345|NCT03149497|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934346|NCT00053014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934347|NCT00374101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934348|NCT05431036|||COHORT||PROSPECTIVE|||||||
33710177|NCT06364098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33710178|NCT02268344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection|t|f|t|t
33710179|NCT01435200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710180|NCT04344392|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Outcome assessor will be blinded to ultrasonographic measurements. Statistical analysis will be performed by an independent consultant.|Single group|f|f|f|t
33934349|NCT02145754|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33934350|NCT03933306|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|For dexmedetomidine infusion, all the participants, care providers, investigators, outcomes assessors are masked. For blood pressure management, care providers, namely anesthesiologists, are not masked.|This is a 2x2 factorial trial|t|f|t|t
33934351|NCT02812394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934352|NCT00827125|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33934353|NCT00976963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934354|NCT01820845|||COHORT||PROSPECTIVE|||||||
33934355|NCT02203942|||CASE_ONLY|||||||||
33934356|NCT00223613|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33934357|NCT03718468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934358|NCT02021474|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934359|NCT06377436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934360|NCT02187133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012247|NCT01615263|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
34095472|NCT01926639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095473|NCT02982109|||COHORT||PROSPECTIVE|||||||
33710181|NCT04730284|NA|SINGLE_GROUP||OTHER||NONE||||||
34012248|NCT01000610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012249|NCT05671172|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34012250|NCT05001464|||COHORT||CROSS_SECTIONAL|||||||
34012251|NCT04085536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012252|NCT06104631|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|At V1, all enrolled patients will be randomly allocated to either BK003 or placebo using computerised block-randomisation with a 1:1 ratio. The randomisation list has been generated before study product packaging and each product has a number which will be consecutively allocated to patients in the eCRF.|"This is a randomised, double-blind, placebo controlled, multicentre, crossover study of BK003 in adult patients with Crohn's disease in remission without treatment or with stable maintenance therapy and having IBS-like symptoms. Patients will be recruited in the university hospitals of Liège (Belgium) and Lille (France). The recruitment period will last 1 year.~This study will consist of a 2 to 3-week run-in period. Then, patients will take either placebo or BK003 for 4 weeks, stop for 2 to 3 weeks (washout) and then switch products for 4 additional weeks.~Patients will undergo 5 visits: V0 (screening visit), V1 (randomization visit, 2 to 3 weeks ± 4 days after V0), V2 (washout, 4 weeks ± 4 days after V1), V3 (crossover, 18 days ± 3 days after V2) and V4 (end of study visit, 4 weeks ± 4 days after V3)."|t|f|t|f
34012253|NCT00876018|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34012254|NCT03272282|||CASE_CROSSOVER||PROSPECTIVE|||||||
34012255|NCT00002702|RANDOMIZED|||TREATMENT||||||||
34012256|NCT00308126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012257|NCT05322902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012258|NCT00775788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012259|NCT01173913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012260|NCT03554603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34012261|NCT05870371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012262|NCT01321281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33710182|NCT03305575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The anesthesia provider responsible for the clinical care of the patient will be given an envelope prepared during randomization and instructed to open it and prepare the medication in a separate room, such that the investigator and patient cannot see which vial is being used to prepare the medication. The anesthesia provider will also be instructed not to reveal the allocation group to the investigator or the patient.~Both bupivacaine and chloroprocaine are clear liquids, and the intended doses of both medications are the same volume, to insure complete blinding."|Prospective, randomized, double blinded clinical trial.|t|f|t|t
33710183|NCT06131177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934361|NCT05479136|NA|SINGLE_GROUP||OTHER||NONE|All participants will receive the same imaging.|Up to 30 eligible patients will be recruited from out-patient clinic visits at Barrow Neurological Institute.||||
33934362|NCT01446991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934363|NCT02188862|||CASE_CONTROL||RETROSPECTIVE|||||||
33934364|NCT06149741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934365|NCT00623766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934366|NCT00290303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934367|NCT03482193|||COHORT||CROSS_SECTIONAL|||||||
33934368|NCT03567590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934369|NCT04207125|RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective randomized controlled trial||||
33934370|NCT00432263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934371|NCT01805674|||CASE_ONLY||PROSPECTIVE|||||||
33934372|NCT05399329|||COHORT||RETROSPECTIVE|||||||
33934373|NCT02561364|||CASE_ONLY||PROSPECTIVE|||||||
33934374|NCT04814706|||CASE_ONLY||PROSPECTIVE|||||||
33934375|NCT02663947|||CASE_ONLY||PROSPECTIVE|||||||
33934376|NCT02613338|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934377|NCT02077972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934378|NCT01251081||||TREATMENT||||||||
33934379|NCT02583360|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Eligible consented subjects (study) from a single center will undergo standard of care diagnostic VFSS in combination with the research intervention of utilizing manometry procedures to measure pharyngo-esophageal motility to aid with precise diagnosis, either concurrent or sequential. They will then have parental choice of preferred feeding therapy based on combined testing methods rather than therapy being prescribed by the VFSS results. The controls are those who had VFSS alone (standard of care) with treatment based solely on VFSS guided provider recommendations from the same single center.||||
33934380|NCT00086242|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33934381|NCT06394960|||COHORT||PROSPECTIVE|||||||
33934382|NCT03605225|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33934383|NCT00498641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33934384|NCT01609036|||COHORT||PROSPECTIVE|||||||
33934385|NCT04002258|||COHORT||RETROSPECTIVE|||||||
33934386|NCT05336019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors will be masked not be aware of the random assignment of study participants. Trained outcome assessors who are working in health facilities where participants are not selected will be recruited and involved in the data collection once either in baseline or end line evaluation.|A single-blinded, parallel-group feasibility Randomized Controlled Trial design.|f|f|f|t
33934387|NCT01522196|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33934388|NCT04840394|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33934389|NCT02980991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934390|NCT03304912|||COHORT||PROSPECTIVE|||||||
33934391|NCT03199131|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33934392|NCT01971736|||CASE_CONTROL||PROSPECTIVE|||||||
33934393|NCT01428557|||COHORT||PROSPECTIVE|||||||
33934394|NCT05942872|||COHORT||RETROSPECTIVE|||||||
33934395|NCT04255992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The double-blind model is applied to the study. Only the adjudicator, responsible for the distribution of medication knew the different regimes. Calcium and Vitamin D/Calcium were packaged in boxes of identical appearance and labeled for each participant by name and number of the randomization program. The randomization and packaging of the drugs was done by an investigator who had no clinical involvement.|This study is a double blind, randomized, controlled parallel clinical trial conducted at the Yaounde central hospital, Cameroon|t|f|t|f
33934396|NCT05080504|||COHORT||PROSPECTIVE|||||||
33934397|NCT03061149|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33934398|NCT04790734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934399|NCT01638676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934400|NCT05562700|||CASE_ONLY||PROSPECTIVE|||||||
33934401|NCT05283499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Analgesic is formulate in capsules. Both OPIOID and NON-OPIOID analgesic formulas are packaged in the same capsules|A double-blind stratified randomized clinical trial is being conduct on the management of post-surgical pain after extraction of impacted third mandibular molars Subjects will be randomly assigned to either the OPIOID or NON-OPIOID group.|t|t|t|t
34012263|NCT06193447|||OTHER||CROSS_SECTIONAL|||||||
34012264|NCT04121117|||CASE_ONLY||OTHER|||||||
34012265|NCT03356886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once the patient has accepted the invitation to participate, the same researcher (FAGT) will gather the clinical assessment and determine eligibility. After this initial assessment, participants will be randomly assigned following simple computerized randomisation procedures to one of the two treatment groups through the use of cards previously placed in opaque sealed envelopes. The allocation sequence will be generated by a researcher (TCC) not involved in the assessment and interventions, and another research assistant will assign participants to interventions.|The recruited subjects will be randomized through the use of randomizer software in two groups of 52 individuals: SMT group which will receive PNE + SMT interventions or SMT alone. Both groups will be assessed at baseline (before the initial treatment session) by a blinded investigator. Immediately after the end of the last session and after the one-month follow-up, the primary outcomes and secondary outcomes will be re assessed. A single blinded investigator for the interventions administered will accomplish the assessment protocol. Another trained researcher (physiotherapist trained in SMT - 8 years of clinical experience) will administer the SMT maneuvers and a third researcher will be involved in the administration of the PNE. The treatment will last at least 8 sessions. The treatment will last at least 8 sessions lasting between 20 and 30 minutes each.|f|f|t|f
34012266|NCT04070339|||COHORT||PROSPECTIVE|||||||
34012267|NCT02880748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012268|NCT01612039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012269|NCT04332016|||CASE_ONLY||PROSPECTIVE|||||||
34012270|NCT01947478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095474|NCT03934307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095475|NCT04763408|||COHORT||PROSPECTIVE|||||||
34095476|NCT03242733|||COHORT||PROSPECTIVE|||||||
34095477|NCT00373087|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095478|NCT03366415|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stratified by stage||||
34095479|NCT02130011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792033|NCT03631537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Study group: receive nutritional intervention from the nutritional support team; Control group: receive routine nutritional support from clinicians||||
33792034|NCT01752465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792035|NCT03061474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind-Randomized||t|t|t|f
33792036|NCT03439124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792037|NCT04397900|||OTHER||RETROSPECTIVE|||||||
33792038|NCT05493124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792039|NCT06486987|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with hemiplegic cerebral palsy will be treated with constraint induced movement therapy with the therapist participating by televideo||||
33792040|NCT03987763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792041|NCT02739035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792042|NCT02987933|||CASE_CONTROL||PROSPECTIVE|||||||
33792043|NCT05663099|||CASE_CONTROL||RETROSPECTIVE|||||||
33792044|NCT01025999|||COHORT||PROSPECTIVE|||||||
33792045|NCT04795050|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized trial||||
33792046|NCT00740155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792047|NCT02618239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33792048|NCT01241292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792049|NCT05147389|||CASE_CONTROL||PROSPECTIVE|||||||
33792050|NCT04340284|NA|SINGLE_GROUP||TREATMENT||NONE||"retrospective study to report the outcome in patients treated with fluoroscopic guided per cutaneous injection of Adipose tissue derived stromal vascular fraction (SVF) at the site of fracture as an outpatient procedure between November 2012 to August 2018.~The indication for this procedure was established atrophic non-union with no evidence of infection with maximum gap between the fragments to be\<5 mm and duration not later than one year between the fracture and the procedure.~Healing at the injury site was evaluated using clinical and radio logical examination at 1,2,6, and 12 months post-treatment.Anterior-posterior radio graphs"||||
34012271|NCT02537873|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34012272|NCT00946049||||TREATMENT||||||||
34012273|NCT01057927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095480|NCT00472381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095481|NCT03492112|NA|SINGLE_GROUP||SCREENING||NONE||||||
34095482|NCT04743596|||OTHER||PROSPECTIVE|||||||
34095483|NCT01051752|||COHORT||PROSPECTIVE|||||||
34095484|NCT03277274|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34095485|NCT00363467|NA|SINGLE_GROUP||OTHER||NONE||||||
34095486|NCT06420908|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095487|NCT04799873|||COHORT||PROSPECTIVE|||||||
34095488|NCT02919631|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34095489|NCT05565404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34095490|NCT00554580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095491|NCT06305546|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The trial was a double blinded (patients and investigators). We were helped from a member of our department who is not a part of the study, to transfer the gels from commercial tubes to blank containers. The randomization codes remained unknown until data analysis was completed. Randomization was done by computer-generated software.||t|t|t|f
34095492|NCT04259489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a prospective, randomization, parallel, controlled study.||||
34095493|NCT00593437|||||RETROSPECTIVE|||||||
34095494|NCT03313193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Pragmatic Randomized Controlled Trial|f|t|f|t
34095495|NCT03880890|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group (A): sphenoidotomy. Group (B): Endoscopic sphenoid nasalization with posterior septectomy||||
34095496|NCT04422873|||COHORT||CROSS_SECTIONAL|||||||
34095497|NCT01732432|||||RETROSPECTIVE|||||||
34095498|NCT03989570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34095499|NCT02285309|||COHORT||PROSPECTIVE|||||||
34095500|NCT06194994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers and outcomes assessors will be blind to emotion regulation status.|Randomisation to two different treatments which will be compared.|t|t|f|t
34095501|NCT02036723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095502|NCT05978258|||CASE_CROSSOVER||PROSPECTIVE|||||||
34095503|NCT05250154|||COHORT||PROSPECTIVE|||||||
34095504|NCT03879109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095505|NCT02694250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095506|NCT04027387|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind placebo controlled. Study pharmacist unblinded.|Single dose escalation|t|t|t|t
34095507|NCT00356590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095508|NCT00625378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095509|NCT05415111|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not possible for the intended interventions, as the harvest of the SCTG requires an additional surgical site at the palate, which will be recognized by the patient. The investigators will also be aware of the type of procedure, as both follow different operation procedures.|Study specific intervention is the placement of a soft tissue autogenous graft (SCTG) or soft tissue substitute (VCMX) in addition to bone grafting of periimplantitis-affected implants. Study specific control intervention is the placement of a bone graft at periimplantitis-affected implants. No soft tissue grafts will be placed. The bone graft will remain permanently in the patients.||||
34095510|NCT06413771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were divided into two study arms based on the initial digits of their national IDs by ART nurses. Importantly, the IVF clinicians remained blinded to the patients' grouping throughout the study.||f|f|t|f
34095511|NCT01522547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095512|NCT01312675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095513|NCT00281801|||CASE_CONTROL||PROSPECTIVE|||||||
33710184|NCT03473977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant/care providers, investigators, and outcome assessor (pathology) were blinded to assignment. Randomization performed by external investigational pharmacy staff (dispenses the drug/placebo).|Participants will receive doses of drug or placebo. Optional open label extensions available following the double blind period.|t|t|t|t
33710185|NCT01882491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710186|NCT00887978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710187|NCT00282594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710188|NCT02367183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710189|NCT03890601|||COHORT||PROSPECTIVE|||||||
33710190|NCT00496821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710191|NCT04673162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled|Randomized, multicentric, double blind|t|t|t|t
33792051|NCT00148434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33792052|NCT01406028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33792053|NCT01436838|||COHORT||PROSPECTIVE|||||||
33792054|NCT05117372|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33792055|NCT04991233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The grouping was blind to the investigators performing the follow-up and the statistical analysis||f|f|f|t
33792056|NCT05039723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792057|NCT03884244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33792058|NCT00305591|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792059|NCT02710149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792060|NCT00391833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792061|NCT04644185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095514|NCT04761354|||COHORT||RETROSPECTIVE|||||||
34095515|NCT02246985|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34095516|NCT03324009|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cohort||||
34095517|NCT06352879|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095518|NCT00578058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710192|NCT04264091|||COHORT||RETROSPECTIVE|||||||
33792062|NCT06107738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934402|NCT04396106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded||t|t|t|f
33934403|NCT03369210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34095519|NCT02904356|NA|SINGLE_GROUP||OTHER||NONE||||||
33710193|NCT05415839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710194|NCT01952405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710195|NCT06464068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710196|NCT05832398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792063|NCT01121549|||||PROSPECTIVE|||||||
33792064|NCT02673788|||CASE_ONLY||PROSPECTIVE|||||||
33792065|NCT01510418|||COHORT||PROSPECTIVE|||||||
33792066|NCT04468490|||OTHER||PROSPECTIVE|||||||
33792067|NCT05059730|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||men are exposed to four conditions (3 cold conditions at 0, 8, 10C and 40C heat) women are exposed to four conditions (2 cold conditions- follicular and luteal phase; 2 heat conditions follicular and luteal phase)||||
33792068|NCT01105143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792069|NCT00427752|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33934404|NCT00765830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934405|NCT03614702|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934406|NCT04765176|||COHORT||PROSPECTIVE|||||||
33934407|NCT04299256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33934408|NCT02352090|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934409|NCT04884386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934410|NCT03199014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934411|NCT00834392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934412|NCT04716842|||COHORT||PROSPECTIVE|||||||
33934413|NCT02111070|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33934414|NCT00256646|||COHORT|||||||||
33934415|NCT02705352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934416|NCT04376424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012274|NCT00241683|||COHORT||RETROSPECTIVE|||||||
34012275|NCT00098228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012276|NCT03142035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012277|NCT03384706|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The assessors will remain blind to treatment condition throughout the study.|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) as compared to Accelerated Resolution Therapy (ART) and a Waitlist (WL) control using a Randomized, Cross-Over Design. 280 participants will be randomly assigned to ART, CPT or WL. Upon completion of the WL condition, participants will be re-randomized to ART or CPT.|f|f|f|t
34012278|NCT01764243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012279|NCT02860182|||||PROSPECTIVE|||||||
34012280|NCT00692224|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012281|NCT06083402|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Neither the participants nor the investigators will know the group assignment. Supplements will be prepared by the sponsor and marked with unidentifiable ID numbers before being sent to study site.|Healthy men and women with mild to moderate signs of skin aging will be randomly assigned to either receive a Ritual HyaCera or placebo for 12 weeks|t|f|t|f
34012282|NCT00419887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012283|NCT00983918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34012284|NCT03598361|||COHORT||PROSPECTIVE|||||||
34012285|NCT04986852|NA|SINGLE_GROUP||TREATMENT||NONE|It is open label study, so investigator and participant can know what is treated.|Patient will be assigned as sequentially with serial screening/ enrollment number.||||
34012286|NCT00543452|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34012287|NCT06233019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012288|NCT02876367|||COHORT||PROSPECTIVE|||||||
34012289|NCT04317313|||OTHER||RETROSPECTIVE|||||||
34012290|NCT02206620|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34012291|NCT00373191|||COHORT||PROSPECTIVE|||||||
34012292|NCT03451240|NA|SINGLE_GROUP||OTHER||NONE||To determine the impact of the Corporate Athlete® Resilience product through recalibrating mindset and changing resilience supportive behavior.||||
34012293|NCT02619136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012294|NCT02903238|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34012295|NCT06044194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot, monocentric, national, non-pharmacological, prospective, double-blind randomized trial|t|f|t|f
34012296|NCT01011075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012297|NCT01749670|||CASE_CONTROL||PROSPECTIVE|||||||
34012298|NCT03357081|||COHORT||PROSPECTIVE|||||||
34012299|NCT03421756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012300|NCT06231394|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012301|NCT01905709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012302|NCT04461132|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled trial||||
34012303|NCT06260579|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors are blinded to the group allocation of the patients. Due to the nature of the intervention, blinding of the patients is not possible. However, a sham training intervention is provided to the control group.|Parallel group randomized controlled trial|f|f|f|t
34012304|NCT05946174|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Set A comprises of outpatient clinic/ community participants, who will be randomized in a 1:1 ratio into Group A1 (receiving Intervention Set A- exercise sessions and meals over approximately 12 weeks) or Group A2 (control/ usual care)~Set B comprises of step-down community hospital participants, who will be randomized in a 1:1 ratio into Group B1 (receiving Intervention Set B- exercise sessions and meals over approximately 3 weeks) or Group B2 (control/ usual care)~Set C comprises of acute community hospital participants, who will be randomized in a 1:1 ratio into Group C1 (receiving Intervention Set C- meals over approximately 3 weeks) or Group C2 (control/ usual care)"||||
34012305|NCT02350582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34012306|NCT03765086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012307|NCT04636593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012308|NCT05365841|||COHORT||PROSPECTIVE|||||||
34012309|NCT00537108|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Motivational intervention and support|f|f|f|t
34025294|NCT01932723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025295|NCT05354739|||CASE_ONLY||PROSPECTIVE|||||||
34095520|NCT03883854|||OTHER||CROSS_SECTIONAL|||||||
34095521|NCT02568254|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34025296|NCT03678285|NA|SINGLE_GROUP||SCREENING||NONE|No other parties besides the participants will be masked.|All participants will take part in the same, single bout, exercise intervention||||
34025297|NCT02276950|||COHORT||PROSPECTIVE|||||||
33710197|NCT03539081|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Subjects are assigned to one of two groups based on whether they have Restless Leg Syndrome to undergo experimental measurements that are made at each of the five measurement time points.||||
33710198|NCT01243892|||COHORT||PROSPECTIVE|||||||
33710199|NCT05630209|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33710200|NCT02344277|||COHORT||PROSPECTIVE|||||||
33710201|NCT06501833|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33710202|NCT01694472|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33710203|NCT00026663|||COHORT||PROSPECTIVE|||||||
33710204|NCT02320110|||COHORT||CROSS_SECTIONAL|||||||
33710205|NCT00814970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792070|NCT06465563|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized, open-label, multicenter, Phase II clinical trial aimed at evaluating the efficacy and safety of Adebrelimab in combination with Cisplatin Plus Gemcitabine, with or without SHR-8068, as first-line treatment for advanced biliary tract cancer. The primary endpoint of the study is the Objective Response Rate (ORR), assessed by investigators based on RECISTv1.1 criteria||||
33934417|NCT04247828|NA|SINGLE_GROUP||OTHER||NONE||||||
33934418|NCT06353204|RANDOMIZED|PARALLEL||TREATMENT||NONE||A comparison between two groups will be made. One half of the participants will be randomly assigned to a group that receives the Halt-intervention, while the other group receives no Halt-intervention.||||
33934419|NCT01926704|||COHORT||PROSPECTIVE|||||||
33934420|NCT05891470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934421|NCT02019004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934422|NCT00338429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934423|NCT03566992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934424|NCT03104829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934425|NCT03336476|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomised||||
33934426|NCT03338881|NA|SINGLE_GROUP||OTHER||NONE||||||
33934427|NCT06386367|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33934428|NCT01685372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33934429|NCT03935685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934430|NCT00544505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934431|NCT04227119|NA|SINGLE_GROUP||OTHER||NONE||||||
33934432|NCT04103203|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Quasi-experimental intervention||||
33934433|NCT06188728|RANDOMIZED|PARALLEL||OTHER||SINGLE||comparing the intervention group with the control (intervention include either lifestyle modification, psyllium husk fiber or combined intervention of lifestyle modification and psyllium husk fiber.|t|f|f|f
34025298|NCT00737763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025299|NCT03759210|||COHORT||PROSPECTIVE|||||||
34025300|NCT05093361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025301|NCT00364936|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025302|NCT05395390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025303|NCT04083131|||COHORT||PROSPECTIVE|||||||
34025304|NCT04237935|||COHORT||RETROSPECTIVE|||||||
34025305|NCT02114385|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025306|NCT04919018|||COHORT||PROSPECTIVE|||||||
34095522|NCT03850587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|The purpose of this study is to investigate the efficacy and safety after administration of YYC301(Experimental) or Celecoxib(Comparator) in subjects with knee osteoarthritis in a state of uncontrolled pain who took Celecoxib(Cox-2 inhibitor).|t|f|t|f
33710206|NCT01154764|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792071|NCT05535530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934434|NCT06206772|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934435|NCT00135993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934436|NCT02647892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934437|NCT01711476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934438|NCT05687253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, active controlled||t|t|t|t
33934439|NCT04024449|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934440|NCT04432168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934441|NCT02651376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934442|NCT03683095|||COHORT||PROSPECTIVE|||||||
33934443|NCT04484506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934444|NCT00566332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012310|NCT03433755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The dose frequencies of Q2W and QM will not be blinded but the identity of investigational product (evolocumab or matching SC placebo) will be blinded. In order to protect the blinding of the double-blind treatment period the following labs will be blinded post-investigational product treatment until unblinding of the clinical database and not reported to sites as noted below:~• Blinded to the Amgen study team and site staff: lipid panel, Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), lipoprotein(a), high-sensitivity C-reactive protein (hs-CRP), and Proprotein convertase subtilisin/kexin type 9 (PCSK9)."|"Participants will be screened for this study and if found eligible as described by the study protocol may be randomized into 1 of 4 groups. Randomized means that you are put into a group by chance. It is like drawing numbers out of a hat. Randomization will be done using a 2:2:1:1 ratio. This means for every 6 participants randomized:~* 2 participants will be randomized to evolocumab 140 mg every 2 weeks~* 2 participants will be randomized to evolocumab 420 mg once a month~* 1 participant will be randomized to placebo every 2 weeks~* 1 participant will be randomized to placebo once a month."|t|t|t|t
34012311|NCT01046552|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34012312|NCT04252482|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012313|NCT04291807|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012314|NCT00001007||||TREATMENT||NONE||||||
34012315|NCT03097588|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34012316|NCT03201354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012317|NCT03442881|||COHORT||PROSPECTIVE|||||||
34012318|NCT05052242|||OTHER||PROSPECTIVE|||||||
33710207|NCT05083572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a randomized controlled, partially-blinded study with four study arms to (i) examine the effect of Vivomixx on the gut microbiome with and without colonic lavage, (ii) with and without antibiotic treatment, (iii) compare the gut microbiome after natural recovery and with Vivomixx treatment following colonic lavage, and (iv) evaluate the efficacy of Vivomixx in reducing bacterial translocation and oxidative stress. The subjects will not be informed of the identity of the study product (Vivomixx or placebo) given. However, it is not possible to blind the subjects of the colonic lavage and rifaximin interventions. The investigators and outcomes assessors involved in the data analysis will be blinded to the study group allocation.||t|f|t|t
33710208|NCT04175483|||CASE_ONLY||PROSPECTIVE|||||||
33710209|NCT03867292|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33710210|NCT06046391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710211|NCT02220205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33792072|NCT04925739|||OTHER||PROSPECTIVE|||||||
33792073|NCT00511537|||CASE_ONLY||PROSPECTIVE|||||||
34012319|NCT04744324|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34012320|NCT04638439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012321|NCT00686582|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792074|NCT03907098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792075|NCT04352582|||OTHER||PROSPECTIVE|||||||
33792076|NCT04424836|||CASE_CONTROL||RETROSPECTIVE|||||||
33792077|NCT02927132|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33934445|NCT02483065|||COHORT||PROSPECTIVE|||||||
33934446|NCT00722475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934447|NCT04410913|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Parallel assignment||||
33934448|NCT03594461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934449|NCT06442085|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All assessments of the student performances were recorded either by video camera (mannequin based simulation) or screen capture (virtual reality simulation). All videos were assessed by two blinded raters independently. In order to maintain consistency, virtual reality recordings were also scored manually by the raters, instead of the automated Trauma Simulator built-in tool. The video data were stored for the reviews and deleted afterwards.|This was a prospective, single-center, randomized, controlled, non-inferiority, simulation-based trial comparing the use of virtual reality simulation vs. mannequin based simulation in a simulated trauma scenario.|f|f|f|t
33934450|NCT03052465|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934451|NCT01810822|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934452|NCT04761575|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934453|NCT05637073|||COHORT||PROSPECTIVE|||||||
33934454|NCT03083106|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective Safety \& Efficacy Study||||
33934455|NCT05736042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934456|NCT04130880|||COHORT||PROSPECTIVE|||||||
33934457|NCT00191386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934458|NCT02052908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33934459|NCT02840734|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934460|NCT03898323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934461|NCT04120350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934462|NCT04713644|||COHORT||PROSPECTIVE|||||||
33934463|NCT00617162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012322|NCT05402982|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will done on 50 patients divided equally into two groups. Group A Fluid administration in the form of lactated ringer will be managed by Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2(10). Rohrich formula represents fluid maintinance,deficit and replacement fluid ( 0.25 ml crystalloid given for each 1 ml above 4 litre of lipoaspirate).~Group B Patients will receive fluid maintenance of lactated ringer 2 ml/kg/h, cardiometry guided SVV will be measured before and after induction then every 30 min ,it ranges between 5-15%, fluid bolus of lactated ringer 4 ml /kg over 15 min will be administered if SVV ˃ 15% ."||||
33710212|NCT00064337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934464|NCT03044743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934465|NCT04410835|||COHORT||PROSPECTIVE|||||||
33934466|NCT02982642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934467|NCT03272880|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This will be a pre-post intervention observational study utilizing a mixed methods approach||||
33934468|NCT03174808|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33934469|NCT00108277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012323|NCT04686656|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34012324|NCT05444322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012325|NCT00210899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095523|NCT04516200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind masking|Group 1: transcranial direct current stimulation and traditional physical therapy program Group 2: the same traditional physical therapy program|t|f|f|f
34012326|NCT03432065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012327|NCT04998578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the data of the participants will be collected by evaluators blind to the study and who will not know the allocation of the patients|Group A will only perform microneedling; group B will perform microneedling associated with the use of cosmetic in the office; group C will perform microneedling associated with the cosmetology of office and home use; and group D will perform non-ablative radiofrequency. Due to the application characteristics of the microneedle technique, there is no way to use a placebo group.|f|f|t|f
34012328|NCT03507413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||prospective, randomized, double blind, placebo-controlled, safety and efficacy study|t|t|t|t
34012329|NCT01120652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012330|NCT05151575|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34012331|NCT00695357|||CASE_ONLY||CROSS_SECTIONAL|||||||
34012332|NCT03432234|||COHORT||PROSPECTIVE|||||||
34095524|NCT04717583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012333|NCT03418168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012334|NCT03589248|||OTHER||PROSPECTIVE|||||||
34012335|NCT00195013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095525|NCT04775134|||COHORT||PROSPECTIVE|||||||
34095526|NCT00103753|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34095527|NCT06301152|RANDOMIZED|PARALLEL||TREATMENT||NONE||two different treatment modalities were applied in two groups||||
34095528|NCT02440399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095529|NCT04715100|||COHORT||PROSPECTIVE|||||||
34095530|NCT00647023||||BASIC_SCIENCE||||||||
34012336|NCT02194569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012337|NCT00793741|||CASE_CONTROL||PROSPECTIVE|||||||
34012338|NCT04960319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Core Lab is blinded|Prospective, 1:1 randomized, controlled, multicenter trial to assess effectiveness and safety of Intravascular Lithotripsy (IVL) compared to Rotational Atherectomy (RA) treatment in calcified coronary lesions. An interim analysis after enrollment of 50 patients randomized will be performed. Based on the result the sample size will be calculated.|f|f|f|t
34012339|NCT01349101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012340|NCT03060759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012341|NCT02400086|||CASE_ONLY||PROSPECTIVE|||||||
34012342|NCT00109837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012343|NCT00302549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012344|NCT04115709|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012345|NCT01493349|||||CROSS_SECTIONAL|||||||
34012346|NCT02135965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012347|NCT03036774|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34012348|NCT05666947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34012349|NCT05732259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012350|NCT02839421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012351|NCT05364008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind masking.|Two-arm parallel assignment (with 3:1 ratio)|t|t|t|t
34012352|NCT04835649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups as exercise group and control group|t|f|f|t
34012353|NCT06460441|||OTHER||PROSPECTIVE|||||||
34012354|NCT00892281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012355|NCT00472875|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34012356|NCT01524302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012357|NCT02406638|||CASE_ONLY||CROSS_SECTIONAL|||||||
34012358|NCT03936049|||COHORT||RETROSPECTIVE|||||||
34012359|NCT02710682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012360|NCT05466344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Participants will be selected based on the following inclusion criteria:~1. Skeletal class 2 malocclusion due to mandibular retrusion with increased overjet (SNA= 82±4, ANB=≥4°). With agefrom 18 to 25 years.~2. Mandibular arch with minimum (up to 4mm) or no crowding.~3. All permanent teeth are erupted (3rd molar not included).~4. Good oral and general health.~5. No systemic disease or regular medication that could interfere and/or affect orthodontic teeth movement.~6. No previous orthodontic treatment."|t|f|t|t
34012361|NCT05915286|NA|SINGLE_GROUP||TREATMENT||NONE||All participants enrolled in this proof-of-concept study will be treated with the intervention (diuretic medications) in escalating doses over the study period. Each participant will act as their own control with 2 weeks of no treatment followed by the intervention for 3 weeks.||||
34012362|NCT03513042|||COHORT||PROSPECTIVE|||||||
34012363|NCT02463799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012364|NCT00489281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095531|NCT04039438|||COHORT||CROSS_SECTIONAL|||||||
34095532|NCT04971824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710213|NCT04925362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012365|NCT05787002|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be randomized, in a 1:1 ratio into each of the treatment arms prior to the study commencing. Each participant will receive 2 treatments in total throughout the study.||||
34095533|NCT00682838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33710214|NCT03391180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710215|NCT03295812|||COHORT||PROSPECTIVE|||||||
33710216|NCT05392244|||CASE_CONTROL||RETROSPECTIVE|||||||
33710217|NCT02033616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710218|NCT00526513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710219|NCT01465997|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710220|NCT02641808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012366|NCT02677259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012367|NCT06470360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012368|NCT02941510|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34012369|NCT05017259|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34012370|NCT05623631|NA|SINGLE_GROUP||OTHER||NONE||||||
34012371|NCT01997021|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012372|NCT01197157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012373|NCT05973682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012374|NCT06403683|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34012375|NCT05116488|||COHORT||PROSPECTIVE|||||||
34012376|NCT00453817|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012377|NCT00958126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012378|NCT04136418|RANDOMIZED|PARALLEL||PREVENTION||NONE||A phase III, 2 arm, multi-centre, open label, parallel-group randomised designed clinical investigation||||
34012379|NCT02418117|NA|SINGLE_GROUP||||NONE||||||
34012380|NCT03902652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012381|NCT00112294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095534|NCT03581747|||CASE_CONTROL||PROSPECTIVE|||||||
34095535|NCT02218268|||COHORT||PROSPECTIVE|||||||
34095536|NCT04999748|||CASE_ONLY||CROSS_SECTIONAL|||||||
34095537|NCT05864014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095538|NCT02102828|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012382|NCT00913198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012383|NCT00345059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012384|NCT02773199|||COHORT||PROSPECTIVE|||||||
34025307|NCT02874885|||COHORT||PROSPECTIVE|||||||
34025308|NCT05523024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
34095539|NCT01272778|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34095540|NCT02990143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095541|NCT03421080|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34095542|NCT01438944|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34012385|NCT03329079|RANDOMIZED|PARALLEL||PREVENTION||NONE|The assessor will know which group assignment the subject has been given as is required for him to download the appropriate app and provide training on the technology to the subject.|||||
33934470|NCT03774836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934471|NCT04134377|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934472|NCT05260125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934473|NCT02892305|||COHORT||PROSPECTIVE|||||||
33934474|NCT01905306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934475|NCT04129190|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934476|NCT03192514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization||t|t|f|f
33934477|NCT01111721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33934478|NCT04189640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the patient, the investigators and the pain nurse who performs postoperative pain evaluation will blind to the data collection.|There are three models for this study. The first group is 20 ml volume group, the second one is 30 ml group, the third one is 40 ml group.|t|f|t|t
33934479|NCT01045876|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33934480|NCT02236650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934481|NCT03447041|||OTHER||PROSPECTIVE|||||||
33934482|NCT01377324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012386|NCT02122718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012387|NCT00111358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710221|NCT03707782|||FAMILY_BASED||PROSPECTIVE|||||||
33710222|NCT05089721|||OTHER||CROSS_SECTIONAL|||||||
33710223|NCT04968301|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710224|NCT00743340|NA|SINGLE_GROUP||OTHER||NONE||||||
33710225|NCT05278299|||OTHER||RETROSPECTIVE|||||||
33934483|NCT02821988|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934484|NCT05363618|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A remote, randomized, blinded, un-controlled trial to evaluate the tolerability of MHS-1031 and separately the tolerability of the formulated placebo in two similar subject groups with heartburn.|t|t|t|t
33934485|NCT01606332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934486|NCT03705468|||CASE_ONLY||RETROSPECTIVE|||||||
34095543|NCT03654079|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Group assignment will be removed from the data set prior to analysis.|Women in Centering Pregnancy groups at Wake Forest School of Medicine's Obstetrics (OB) and Gynecology (GYN) department will be recruited and sequentially assigned to participate in simulations or serve as controls.|f|f|f|t
34095544|NCT00907088|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095545|NCT04807296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each arm will consist of 50 patients: one undergoing Thulium Fiber Laser Enucleation of the Prostate (TFLEP) and the other undergoing Holmium:YAG Laser Enucleation of the Prostate with Moses Technology (m-HoLEP).Two surgeons will be involved in this study. One surgeon with experience with TFLEP will perform all 50 TFLEP procedures and one surgeon with experience with m-HoLEP will perform all 50 m-HoLEP procedures.||||
34095546|NCT05981807|||COHORT||PROSPECTIVE|||||||
34095547|NCT01021917|||CASE_CONTROL||PROSPECTIVE|||||||
34095548|NCT02794805|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34095549|NCT04131192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095550|NCT05758792|||COHORT||RETROSPECTIVE|||||||
34095551|NCT03769974|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|An independent blind assessor will perform the measurements and recorded the data. Finally, the participants will also be blinded.||t|f|t|f
34095552|NCT03237091|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a a randomized, sham-controlled crossover study in which all participants will participate in a single session of each type of intervention.|t|f|f|t
33710226|NCT02947503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710227|NCT01415284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33710228|NCT05416593|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33934487|NCT05894889|NA|SINGLE_GROUP||TREATMENT||NONE|None(Open Label)|Single Group Assignment||||
33934488|NCT00267657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710229|NCT01530061|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33710230|NCT04776200|||CASE_CONTROL||PROSPECTIVE|||||||
33710231|NCT05884996|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33710232|NCT05217147|||CASE_CONTROL||PROSPECTIVE|||||||
33710233|NCT03539536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710234|NCT04010487|||CASE_CONTROL||RETROSPECTIVE|||||||
33710235|NCT05914298|||COHORT||PROSPECTIVE|||||||
33934489|NCT04422197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934490|NCT04696172|||OTHER||PROSPECTIVE|||||||
33934491|NCT03422016|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934492|NCT01451957|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934493|NCT00332046|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33934494|NCT00291746|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33934495|NCT00000703||||TREATMENT||||||||
33934496|NCT04330989|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a parallel pilot randomized trial in which participants randomly assigned to the control arm will receive antiretroviral adherence support about HIV treatment and prevention. Those randomized to the intervention arm will additionally receive a multi-component support strategy comprising integrated next-step counseling (iNSC) and adherence supporter training.||||
33934497|NCT02117791|||COHORT||PROSPECTIVE|||||||
33934498|NCT04383171|||COHORT||PROSPECTIVE|||||||
34012388|NCT00530543|RANDOMIZED|PARALLEL||||NONE||||||
34012389|NCT04778293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessment will be performed by a blinded evaluator at the baseline, immediately after the technique application and 30 minutes after.|Randomized Control Trial|f|f|f|t
34012390|NCT01321021|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34012391|NCT03856593|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012392|NCT04445220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012393|NCT03695705|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34012394|NCT00003293|RANDOMIZED|||TREATMENT||||||||
34012395|NCT01810094|||CASE_ONLY||PROSPECTIVE|||||||
34012396|NCT05196360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710236|NCT06091267|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710237|NCT01850875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012397|NCT05265819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012398|NCT02032251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012399|NCT03762707|||COHORT||RETROSPECTIVE|||||||
34012400|NCT06338735|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012401|NCT01481740|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34012402|NCT06374966|||CASE_ONLY||PROSPECTIVE|||||||
34012403|NCT01369017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012404|NCT05351814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals will be divided into two groups by computerized randomization.|Individuals will be divided into two groups by computerized randomization. Control group; Traditional patellofemoral pain syndrome exercises, (n=20) Core stability group; Core stabilization and hip exercises will be given in addition to traditional patellofemoral pain syndrome exercises. (n=20)|t|f|f|f
34012405|NCT01922752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012406|NCT02324673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34012407|NCT04821388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095553|NCT03507283|||COHORT||RETROSPECTIVE|||||||
34095554|NCT02245373|||CASE_CONTROL||PROSPECTIVE|||||||
34095555|NCT01651598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095556|NCT03594370|||CASE_ONLY||CROSS_SECTIONAL|||||||
34095557|NCT05904366|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cross-sectional pilot study in which MRS and MRE measurements of ASMD patients will be compared to measurements in healthy subjects.||||
33710238|NCT00662805|||||PROSPECTIVE|||||||
34095558|NCT02679092|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095559|NCT00167947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095560|NCT01657500|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34095561|NCT02470377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||This was an N-of-1 pilot study in which all participants received one session of each of 3 targets and chose which of the 3 led to the most acute reduction in intensity of rocking. The participants were treated with the target that they chose and then completed post stimulation diaries.|t|f|t|f
34095562|NCT03269006|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized control trial will be performed with Inesfly 5AIGRNG TM, commercial available durable wall lining (DWL), impregnated of existing bed-net with insecticide tablet, KO TAB 123, indoor residual spraying (IRS) with Delthamethrin vs a control group (study with 5 arms). The study will be carried out in villages located in Mymensingh District. Four high endemic villages will be selected for the study. As per sample size calculation we need minimum 31 households to see the efficacy of the interventions. We will include 50 households for each intervention and 50 for control (No intervention). 18 households from each cluster will be selected randomly for entomological analysis which includes sand fly density measurement at base line and 1, 3, 6, 9, 12, 15, 18, 21 and 24 months after intervention, and WHO Cone bio-assay on the intervention surfaces and the control surfaces at 1, 3, 6, 9, 12, 15, 18, 21 and 24 months after intervention.||||
33710239|NCT04819074|||COHORT||RETROSPECTIVE|||||||
33710240|NCT04061213|||COHORT||PROSPECTIVE|||||||
33710241|NCT01352910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710242|NCT04779775|||OTHER||CROSS_SECTIONAL|||||||
33710243|NCT00934310|||CASE_CONTROL||PROSPECTIVE|||||||
34012408|NCT00411957|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012409|NCT03996551|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34012410|NCT02447926|NA|SINGLE_GROUP||OTHER||NONE||||||
34095563|NCT00265291|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34095564|NCT05015179|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34095565|NCT04116047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095566|NCT00025311||||TREATMENT||||||||
34095567|NCT02194686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095568|NCT02520440|||COHORT||PROSPECTIVE|||||||
34095569|NCT01495728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095570|NCT02697422|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|N/A; No masking will occur in this clinical trial.|Parallel: Participants are assigned to one of two groups--the control or intervention group- in parallel for the duration of the study.||||
33710244|NCT04031391|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, multi-center, clinical trial composed of two groups response variables and a twelve weeks follow up.||||
33710245|NCT01235351|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710246|NCT01929460|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33710247|NCT03119584|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710248|NCT02102906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710249|NCT05769439|||OTHER||PROSPECTIVE|||||||
33710250|NCT04080401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710251|NCT05680896|||COHORT||PROSPECTIVE|||||||
33710252|NCT05501301|||COHORT||PROSPECTIVE|||||||
33710253|NCT01749137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710254|NCT02467868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012411|NCT01815112|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34012412|NCT03967340|||CASE_ONLY||PROSPECTIVE|||||||
34012413|NCT05442242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34012414|NCT00006091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012415|NCT06172413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012416|NCT01888341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012417|NCT00393120|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34012418|NCT01289951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012419|NCT03196674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34095571|NCT06367114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095572|NCT04079725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095573|NCT04240847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095574|NCT02857920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095575|NCT03780725|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The trial is divided in 2 Parts and will be conducted in a staggered approach, i.e. Part 2 follows Part 1. Part 2 will be initiated following a positive decision of the Study Monitoring Committee (SMC) after reviewing of all available data from Part 1 in order to assess whether a blockade of \[89Zr\]Zr-BI 754111 will be demonstrated.||||
34095576|NCT01684592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095577|NCT02372084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095578|NCT02347007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095579|NCT02096224|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34095580|NCT05428228|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34095581|NCT05080270|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed study will assess primary safety and secondary efficacy endpoints of allogeneic tolerogenic fibroblasts administered through Intravenous infusion at a single dose of 100 million cells to 5 patients with relapsing remitting MS resistant to interferon.||||
34095582|NCT02979470|||COHORT||PROSPECTIVE|||||||
34095583|NCT04011709|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This open-label, non-drug methodology trial consists of a screening assessment, familiarization session and a nebulization assessment at one visit and a second nebulization assessment at a second visit.||||
34095584|NCT02468700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095585|NCT03794323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095586|NCT05488353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095587|NCT02584296|NON_RANDOMIZED|PARALLEL||||NONE||||||
34095588|NCT06025383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Cross-Over Assignment Double (Participant, Investigator) randomized, double-blind, placebo-controlled, cross-over study design|t|f|t|f
34095589|NCT00189384|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095590|NCT02524678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095591|NCT06177717|||COHORT||PROSPECTIVE|||||||
34095592|NCT00997815|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34095593|NCT02818062|||CASE_CONTROL||PROSPECTIVE|||||||
34095594|NCT00232154|RANDOMIZED|PARALLEL||||NONE||||||
34095595|NCT00787488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095596|NCT04338997|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095597|NCT05291481|RANDOMIZED|PARALLEL||PREVENTION||NONE|There is no masking in this study as participants are informed of the condition to which they are allocated|CAPAS-Youth is a culturally adapted version of the evidence-based intervention known as GenerationPMTO, which was originally adapted with a majority of Euro-American populations. The initial efficacy of CAPAS-Youth has already been demonstrated in a previous study. The current investigation is focused on tailoring CAPAS-Youth for Hispanic immigrants in Texas.||||
34095598|NCT03175458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095599|NCT00893295|RANDOMIZED|||SCREENING||NONE||||||
34095600|NCT06450561|||CASE_ONLY||RETROSPECTIVE|||||||
34095601|NCT00006457|RANDOMIZED|||PREVENTION||DOUBLE||||||
34095602|NCT03017287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095603|NCT00443326|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34095604|NCT00804479|||COHORT||PROSPECTIVE|||||||
34095605|NCT04132466|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter single arm open label||||
34095606|NCT02391584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095607|NCT01034696|||COHORT||PROSPECTIVE|||||||
34095608|NCT04835753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095609|NCT03752801|||COHORT||PROSPECTIVE|||||||
34095610|NCT04137887|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind: the participants, the outcome assessors in the hospitals and outpatient care, the Investigators, and the Sponsor will remain blinded to the vaccine assignment in order to avoid any bias in reporting and evaluating illnesses or SAEs. An unblinded qualified trial staff member will administer the appropriate vaccine.||t|t|t|t
34095611|NCT00954655|||CASE_ONLY||PROSPECTIVE|||||||
34095612|NCT01699685|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095613|NCT01617967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095614|NCT01558570|||CASE_ONLY||PROSPECTIVE|||||||
34095615|NCT04626336|||COHORT||RETROSPECTIVE|||||||
34095616|NCT00870155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095617|NCT01495273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095618|NCT01717859|NA|SINGLE_GROUP||OTHER||NONE||||||
34095619|NCT00002051||||TREATMENT||DOUBLE||||||
34095620|NCT03128060|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33934499|NCT03084432|||CASE_CONTROL||PROSPECTIVE|||||||
33934500|NCT00464620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934501|NCT00945269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934502|NCT01165294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33934503|NCT03733106|RANDOMIZED|PARALLEL||SCREENING||SINGLE|participants blinded to type of screening scan|Prospective randomized controlled study|t|f|f|f
33934504|NCT01464398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33934505|NCT02307604|||COHORT||PROSPECTIVE|||||||
33934506|NCT02169960|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33934507|NCT00675311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934508|NCT03052699|||COHORT||RETROSPECTIVE|||||||
33934509|NCT06245304|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33934510|NCT06465355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||In healthy adults, determine the correlation between the transmission of a bolus from the pharynx into the proximal esophagus and activating primary esophageal peristalsis.||||
33934511|NCT01958268|||||PROSPECTIVE|||||||
34012420|NCT01638858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012421|NCT03014193|||CASE_ONLY||PROSPECTIVE|||||||
34012422|NCT01566019|NA|SINGLE_GROUP||OTHER||NONE||||||
34012423|NCT05206487|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34012424|NCT00012428|||||PROSPECTIVE|||||||
34012425|NCT01931228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012426|NCT01047579|NA|SINGLE_GROUP||OTHER||NONE||||||
34012427|NCT05104099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012428|NCT02072551|||||PROSPECTIVE|||||||
34012429|NCT02065713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012430|NCT01334684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095621|NCT03990688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095622|NCT04268212|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34095623|NCT04562701|||COHORT||CROSS_SECTIONAL|||||||
34012431|NCT05406024|||COHORT||PROSPECTIVE|||||||
34012432|NCT00002262||||TREATMENT||||||||
34012433|NCT00603291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012434|NCT02894866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012435|NCT03664050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012436|NCT03527251||SEQUENTIAL||TREATMENT||NONE||Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.||||
34095624|NCT01667614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095625|NCT02428153|NA|SINGLE_GROUP||SCREENING||NONE||||||
33934512|NCT02279160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934513|NCT00691054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934514|NCT04157751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934515|NCT01517828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095626|NCT05309889|||COHORT||PROSPECTIVE|||||||
34095627|NCT02580344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095628|NCT04645056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Patients will be recruited for this randomized controlled clinical study the day after surgery. Participants are randomized into two groups using a randomization scheme according to whether the surgery is performed in a week with an even or uneven number (e.g. week number 42 or 43 within a given year). A designated person with no impact on the decision of surgical procedure will handle the randomization and recruitment (the project owner).~The patients are randomized to either intervention with nine specific and carefully selected neck stretching exercises or to the control group without any intervention.~Before discharge, both groups are instructed to perform either stretching exercises or to no intervention, respectively, the four postoperative weeks. A follow-up phone call will be made approximately one week after discharge to ensure patient adherence."|t|f|f|f
34095629|NCT05877612|||CASE_ONLY||PROSPECTIVE|||||||
34095630|NCT01316900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095631|NCT04216004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934516|NCT05969262|||COHORT||OTHER|||||||
33934517|NCT04064944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934518|NCT04660006|||COHORT||PROSPECTIVE|||||||
33934519|NCT01789710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934520|NCT01160224|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33934521|NCT05104749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both study medication and placebo are identical in appearance, odor, and taste. Statistician will be blinded as to treatment group.|Randomized, double-blind, placebo-controlled clinical trial|t|t|t|t
33934522|NCT03239262|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of patients undergoing standard treatment have been compared retrospectively.||||
33934523|NCT05272410|||CASE_CONTROL||RETROSPECTIVE|||||||
34012437|NCT00279955|||COHORT||PROSPECTIVE|||||||
34012438|NCT01252849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||iStent 1, 2, or 3 stents|f|f|f|t
34012439|NCT05893511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012440|NCT04852159|||OTHER||CROSS_SECTIONAL|||||||
34012441|NCT06481098|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Part A: single-ascending dose Part B: multiple-ascending dose|t|f|t|t
34012442|NCT03734887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention will enroll 70 patients over a 6-month period. Investigators will provide each patient with a smart pill bottle to sync medication use data with their phones and provide real-time data about adherence to study staff. After completing a baseline survey, investigators will confirm eligibility (including confirmation of loved ones' willingness to receive text messages), and randomize eligible patients to one of the two study arms. With synced data from the smart pill box, investigators will provide biweekly feedback about adherence in the form of a brief text message, including a comparison to the patient's adherence in the preceding week. Biweekly feedback will be provided for 12 weeks and semi-structured interviews will be performed among a random subsample of participants afterward.||||
34025309|NCT05090488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025310|NCT02905747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710255|NCT00653744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710256|NCT06431087|NA|SINGLE_GROUP||PREVENTION||NONE||Single-Center, an Arm, prospective intervention study.||||
33710257|NCT03429153|||COHORT||RETROSPECTIVE|||||||
33710258|NCT00471328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710259|NCT04177160|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710260|NCT03240302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710261|NCT02559921|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33710262|NCT04254705|NA|SINGLE_GROUP||OTHER||NONE||For stratification of subjects in the subsequent clinical trial||||
33710263|NCT02837601|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934524|NCT06009406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934525|NCT01253941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33934526|NCT00268476|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-arm Multi-Stage||||
33934527|NCT01137448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934528|NCT00456924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934529|NCT02737371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934530|NCT01478581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934531|NCT01466439|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33934532|NCT03797157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934533|NCT03930277|||COHORT||PROSPECTIVE|||||||
33934534|NCT04570982|||CASE_CROSSOVER||PROSPECTIVE|||||||
33934535|NCT01822249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934536|NCT05067114|||COHORT||PROSPECTIVE|||||||
33934537|NCT05382806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and outcome assessors are blinded to which group participants are allocated.|Participants are administered either flumazenil (group flumazenil) or 0.9% normal saline (group control).|t|f|f|t
33934538|NCT00411840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934539|NCT06064552|||COHORT||PROSPECTIVE|||||||
33934540|NCT02558452|||COHORT||PROSPECTIVE|||||||
33934541|NCT00372294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934542|NCT00807443|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934543|NCT03779906|NA|SINGLE_GROUP||OTHER||NONE||||||
33934544|NCT04630444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934545|NCT01404806|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33934546|NCT05628987|||CASE_CONTROL||PROSPECTIVE|||||||
33934547|NCT02439554|||COHORT||PROSPECTIVE|||||||
33934548|NCT03671642|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33934549|NCT00597532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33934550|NCT01703715|||COHORT||PROSPECTIVE|||||||
33934551|NCT05046236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934552|NCT03273699|RANDOMIZED|PARALLEL||TREATMENT||NONE||A repeated measures multivariate analysis of variance (MANOVA) will be conducted with the two groups (guided mindfulness meditation or control wait list group) as the between-group variable and OCD symptom scores as the dependent variables. A mediation analysis will examine whether obsessive beliefs, engagement in thought control strategies, psychological flexibility, and mind wandering mediates treatment related changes in OCD symptom scores (YBOCS, OCI). Daily practice data from the EEG headsets will be automatically uploaded to an encrypted server. These data will be made anonymous from the start of the study; subjects will be identified using their subject I.D. EEG data will be preprocessed and analyzed using EEG Lab (Delorme \& Makeig, 2004).||||
33934553|NCT02324036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934554|NCT04921176|||COHORT||CROSS_SECTIONAL|||||||
33710264|NCT00041990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710265|NCT03640130|NA|SINGLE_GROUP||OTHER||NONE||||||
33710266|NCT05767645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710267|NCT02008201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710268|NCT06098560|||COHORT||PROSPECTIVE|||||||
34095632|NCT02296801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095633|NCT02857959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710269|NCT02356601|||COHORT||PROSPECTIVE|||||||
33710270|NCT06088732|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33710271|NCT01385566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33710272|NCT04388189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710273|NCT03922503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the type of intervention only the outcome assessor and the statistician will be blinded.||f|f|f|t
33710274|NCT01788202|||CASE_ONLY||PROSPECTIVE|||||||
33710275|NCT02031354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710276|NCT04370405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710277|NCT03669172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710278|NCT02600572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33710279|NCT01827605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792078|NCT01967654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934555|NCT01987752|||COHORT||PROSPECTIVE|||||||
33934556|NCT05622968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934557|NCT02915692|||COHORT||RETROSPECTIVE|||||||
33934558|NCT01105468|||CASE_CONTROL||PROSPECTIVE|||||||
33934559|NCT03875833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934560|NCT05322083|||COHORT||PROSPECTIVE|||||||
33710280|NCT04770662|NA|SINGLE_GROUP||OTHER||NONE||A national, academic, interventional study. The data will be acquired through questionnaires.||||
33710281|NCT05953493|||CASE_CONTROL||PROSPECTIVE|||||||
33710282|NCT01694368|||OTHER||PROSPECTIVE|||||||
33710283|NCT03894553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710284|NCT03599999|||COHORT||PROSPECTIVE|||||||
33710285|NCT01998529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710286|NCT01815593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with erectile dysfunction are assigned to two groups in parallel for the duration of the study||||
33710287|NCT03618498||SEQUENTIAL||TREATMENT||NONE||A 25-gauged blunt-tipped needle connected with Viscoat® (Alcon laboratories, Fort Worth, TX, USA) containing syringe was placed within the macular hole just below the level of the macular hole. A small amount of Viscoat® was injected into and around the hole. An ICG solution (25 mg ICG in 15 ml 5% glucose-water solution, final concentration = 1.7 mg/ml) was then carefully applied around the macular hole within the arcade.Excessive ICG was immediately removed by suction. ILM at the parafoveal area was peeled in a circular fashion. Care was taken not to peel the ILM flap across the hole edge. If possible, at least 1.5 to 2 disc area of partially detached ILM around the hole was left in place with central part remained attached to the edge of the hole.||||
33792079|NCT00226148|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792080|NCT04203264|||COHORT||PROSPECTIVE|||||||
33792081|NCT06410963|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Data is collected using a secure digital platform. Outcome assessors will be blinded to baseline length allocations.|This study employs a sequential single-case experimental AB design with randomized waiting period lengths (7, 14 or 21 days). Included in the design is also standardized pre-post and 6-month follow up measurement allowing for single group analysis of change. In addition, we collect qualitative data from participating adolescents.|f|f|f|t
33792082|NCT02724085|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33792083|NCT01377519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792084|NCT01685788|||CASE_ONLY||PROSPECTIVE|||||||
33792085|NCT05058469|||COHORT||RETROSPECTIVE|||||||
33792086|NCT00165451|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792087|NCT01852019|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33792088|NCT02747732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792089|NCT00413179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012443|NCT04251091|NA|SINGLE_GROUP||TREATMENT||NONE||Previous work has demonstrated that the tuning of the exosuit technology is important for each patient post stroke to be able to maximally utilize the technology. These modulations include when the plantarflexion force is delivered, and how to deliver the assistance within a training session however it is still unclear how to implement this into a training protocol. During a part of this study, we will explore which timing: early timing (10-20%), mid timing (50%) and late timing (90%) may be optimal for an individual and then carry out a training protocol||||
34012444|NCT06094049|||OTHER||CROSS_SECTIONAL|||||||
34012445|NCT01059721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025311|NCT04483206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025312|NCT04034407|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization to damage control surgery or control group||||
34025313|NCT05129605|||COHORT||PROSPECTIVE|||||||
34095634|NCT01030575|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095635|NCT02360501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095636|NCT03024164|||CASE_ONLY||PROSPECTIVE|||||||
34095637|NCT00218894|||CASE_ONLY||PROSPECTIVE|||||||
34095638|NCT04391907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095639|NCT04935515|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710288|NCT03120416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710289|NCT04597788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710290|NCT05512845|||COHORT||PROSPECTIVE|||||||
33710291|NCT03319914|||COHORT||PROSPECTIVE|||||||
33710292|NCT02420392|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710293|NCT01874613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710294|NCT02335866|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792090|NCT06554262|||COHORT||PROSPECTIVE|||||||
33792091|NCT05783804|||COHORT||PROSPECTIVE|||||||
33792092|NCT01013441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792093|NCT03068468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792094|NCT02806518|||||PROSPECTIVE|||||||
33792095|NCT02184325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33792096|NCT04514419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792097|NCT03795428|NA|SEQUENTIAL||TREATMENT||NONE|Subjects entering the 0006 trial prior to the implementation of this protocol amendment will remain blinded until such time that open label dosing will not unblind the 0004 study.|To protect the blind of the parent study (PB1046-PT-CL-0004), all subjects entering PB1046-PT-CL-0006 will commence dosing at Week 1 on 0.4 mg/kg and will be up-titrated in 0.2 mg/kg increments in an open label fashion for 9 weeks.||||
33792098|NCT01986686|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792099|NCT00995150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792100|NCT05473871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple||t|f|t|t
33792101|NCT00694681|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33792102|NCT00758602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792103|NCT01118338|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34025314|NCT03550001|RANDOMIZED|PARALLEL||OTHER||NONE|Open label|Parallel||||
34025315|NCT04952909|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025316|NCT00863018|||CASE_CONTROL||PROSPECTIVE|||||||
34025317|NCT01243437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095640|NCT05815927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095641|NCT01598220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095642|NCT00608738||||HEALTH_SERVICES_RESEARCH||NONE||||||
34095643|NCT05695430|NA|SEQUENTIAL||TREATMENT||NONE||||||
34095644|NCT05236426|||COHORT||PROSPECTIVE|||||||
34095645|NCT03157882|||OTHER||PROSPECTIVE|||||||
34095646|NCT03018938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095647|NCT03434366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710295|NCT01559597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33710296|NCT02968901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095648|NCT02565472|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33710297|NCT03918122|||COHORT||PROSPECTIVE|||||||
33710298|NCT02319993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33710299|NCT04629352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|A computer-generated randomization sequence will be used for random assignment of treatment condition. A tDCS device equipped to deliver verum or sham stimulation upon entering manufacturer-assigned codes will be used for the study. Allocation concealment will be maintained by off-site bio-statistician.|In this prospective longitudinal study, add-on tDCS will be administered to SCZ patients in a double-blind, randomized, parallel-arm sham-controlled design for 5 days. Patients who show ≥20% reduction in AVH severity will be followed up at one-month and three-month after completion of tDCS-RCT, and other patients will be offered clinician-determined treatment.|t|t|t|t
33710300|NCT00495183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710301|NCT00787852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710302|NCT03346785|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710303|NCT01474824|||COHORT||PROSPECTIVE|||||||
33710304|NCT05113420|||COHORT||PROSPECTIVE|||||||
33710305|NCT03132220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710306|NCT01603355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792104|NCT05116839|RANDOMIZED|CROSSOVER||OTHER||SINGLE||a prospective cross_over study|t|f|f|f
33792105|NCT06343896|||OTHER||PROSPECTIVE|||||||
33792106|NCT04285762|||CASE_CONTROL||RETROSPECTIVE|||||||
33792107|NCT03833102|||COHORT||PROSPECTIVE|||||||
33792108|NCT03914170|||CASE_ONLY||RETROSPECTIVE|||||||
33792109|NCT04267744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Device: Myia Health platform and in-home suite of devices®||||
33792110|NCT01390402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792111|NCT00836797|||CASE_CONTROL||PROSPECTIVE|||||||
33792112|NCT06549933|NA|SINGLE_GROUP||OTHER||NONE||Athletes undergoing regular training were divided into two groups. One of them was subjected to cryotherapy treatments, the other was a control group, not subjected to any treatments at that time.||||
33792113|NCT02070315|||COHORT||PROSPECTIVE|||||||
33792114|NCT00202865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792115|NCT01460290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792116|NCT05499637|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792117|NCT01306513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792118|NCT01063686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792119|NCT00059241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792120|NCT01783977|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792121|NCT02057692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934561|NCT04655768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934562|NCT01951911|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33934563|NCT00242710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33934564|NCT05609162|||CASE_CONTROL||RETROSPECTIVE|||||||
33934565|NCT00951119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934566|NCT00610714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934567|NCT02343952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934568|NCT00251186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934569|NCT02748785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934570|NCT03345173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934571|NCT06379880|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934572|NCT02668055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934573|NCT05333289|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934574|NCT02444806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934575|NCT00095810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934576|NCT01461798|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934577|NCT02855086|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33934578|NCT01396031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33934579|NCT04062006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934580|NCT04576260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Members of the research team that perform measurements are blinded to group allocation.|A randomised controlled trial with two groups CBT intervention group and control group.|f|f|f|t
33934581|NCT00378534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934582|NCT01092949|||CASE_ONLY||PROSPECTIVE|||||||
33934583|NCT05591430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934584|NCT04868331|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33934585|NCT00131534|||OTHER||PROSPECTIVE|||||||
33934586|NCT05708729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding for rTMS (active stimulation vs sham stimulation)||t|f|t|f
33934587|NCT00415246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934588|NCT00529412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934589|NCT00987727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33934590|NCT00644813|||COHORT||PROSPECTIVE|||||||
34095649|NCT02385357|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33934591|NCT02793206|||COHORT||PROSPECTIVE|||||||
33934592|NCT02663115|||COHORT||PROSPECTIVE|||||||
33934593|NCT06409507|||COHORT||RETROSPECTIVE|||||||
33934594|NCT03175952|||COHORT||PROSPECTIVE|||||||
33934595|NCT04868162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934596|NCT04144062|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
34095650|NCT04656080|||CASE_ONLY||PROSPECTIVE|||||||
34095651|NCT05845190|RANDOMIZED|PARALLEL||OTHER||NONE||simple randomization using a randomization table created by a computer software program||||
33934597|NCT02291328|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33934598|NCT04946760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34095652|NCT06455254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095653|NCT00517062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095654|NCT00129896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934599|NCT04722289|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"A multi-method case study approach was used to identify mechanisms generating improved diabetes self-management and use of healthcare services (outcome) Thus, using this method, it enabled to investigate similarities and differences in how the mechanisms operated depending on peers' context.~All peers and peer supporters included and matched in the intervention from February 2018 to July 2019 were invited by the project manager to participate in this study. In total, 9 out of 12 pairs who completed the intervention during this period accepted the invitation, and were thereby selected as cases. The peers were recruited through CfD (N=7), their GP (N=1), and the home care (N=2). The peer supporters were recruited among people who had completed a patient education in CFD (N=5), by members from the DDA (N=2), their GP (N=1), or by people who applied via 'Together on Diabetes' webpage (N=2)."||||
33934600|NCT04343391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34012446|NCT05010733|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|"After assignment to interventions (Exeter V40 cemented femoral stem or Müller THA), participant and surgeon team will be aware of the type of cemented stem prosthesis allocated. Since after randomization this is an open-label study, emergency unblinding does not apply. Data analysts will be blinded.~Personal patient data will be coded and dissociated, so that the patient to whom they correspond is not recognizable. Consecutive numbers will be assigned as they are enrolled in the study, and these numbers (or codes) will be used in the eCRF, rather than personal data."|An anonymized list will be provided to the Biostatistics Department, who will randomly assign patients to a type of surgical intervention using a computer-generated randomization sequence. The randomization will be carried out previously to the surgery based on REDCap systems.||||
34012447|NCT00933283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012448|NCT02079168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012449|NCT03687879|||COHORT||PROSPECTIVE|||||||
34012450|NCT03544359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Eligible volunteers will be randomly assigned to receive either 5 consecutive days of active tES or 5 consecutive days of sham/inactive tES. This part of the study is optional. All eligible volunteers will receive active and sham/inactive tES during MRI.|t|f|f|f
34012451|NCT04867421|||COHORT||PROSPECTIVE|||||||
34012452|NCT00052026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012453|NCT01359176|||COHORT||PROSPECTIVE|||||||
34012454|NCT02359201|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34012455|NCT03482167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34012456|NCT04462484|RANDOMIZED|PARALLEL||PREVENTION||NONE||MAGO is a parallel, two-armed randomized controlled trial with three assessment points (baseline, post-intervention, and six-month follow-up). Participants will be randomized for the program or a no-treatment group.||||
34012457|NCT01060475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012458|NCT03465319|||CASE_ONLY||PROSPECTIVE|||||||
34012459|NCT00842530|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The observer-blind design was chosen since the products have different appearances and could be recognized. The person who performed vaccinations knew which product was administered while neither the participant nor the Investigator in charge of safety evaluation knew which product was injected. To maintain the blind and minimize the potential bias, the control group used the same route and schedule as the study vaccine.||t|f|t|f
34012460|NCT02006537|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012461|NCT02242721|||COHORT||PROSPECTIVE|||||||
33710307|NCT06505317|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"A stepped wedge cluster randomization design was chosen as a pragmatic way to evaluate the real world impact of AI-based PAD screening. The stepped wedge design has been used to evaluate a variety of interventions, including digital health-based studies. This particular design allows for analysis within and between clusters and can reduce the total number of clusters needed to see an effect, helping increase statistical power compared to parallel cluster randomization. A stepped wedge design, like other cluster randomization designs, also helps reduce possible contamination effects. By using institutions as the basis for clustering, we minimize the possibility that physicians increase their PAD diagnosis rates based on knowledge of the screening tool from adjacent clinics rather than direct use."||||
33792122|NCT04181307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792123|NCT06010888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792124|NCT06248359|||COHORT||RETROSPECTIVE|||||||
33792125|NCT03709628|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label||||
33792126|NCT04681768|||CASE_ONLY||PROSPECTIVE|||||||
33792127|NCT03899480|NA|SINGLE_GROUP||TREATMENT||NONE||Non-controlled intervention groups||||
33792128|NCT04835987|||OTHER||PROSPECTIVE|||||||
33792129|NCT05232630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||4 Group Assignment||||
33792130|NCT02887768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792131|NCT02524288|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33792132|NCT03728816|||COHORT||PROSPECTIVE|||||||
33792133|NCT03709693|||COHORT||PROSPECTIVE|||||||
33792134|NCT05574530|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Supplements are labeled A and B by a scientist who is not involved in this trial.||t|t|t|t
33792135|NCT06424964|||COHORT||RETROSPECTIVE|||||||
33792136|NCT02882230|||COHORT||PROSPECTIVE|||||||
33792137|NCT01296425|||COHORT||OTHER|||||||
33792138|NCT00947596|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792139|NCT04151550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012462|NCT00017459||||TREATMENT||||||||
34012463|NCT03896282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012464|NCT06076551|||COHORT||PROSPECTIVE|||||||
34012465|NCT01242761|||CASE_ONLY||PROSPECTIVE|||||||
33792140|NCT02008253|||CASE_ONLY||RETROSPECTIVE|||||||
33792141|NCT00032799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33792142|NCT02156687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792143|NCT04994054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792144|NCT04972591|||COHORT||PROSPECTIVE|||||||
33792145|NCT04948593|||COHORT||PROSPECTIVE|||||||
33710308|NCT03325283|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Human patients indicated for transcatheter aortic valve replacement||||
33710309|NCT03837197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710310|NCT00209469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710311|NCT03759574|||COHORT||PROSPECTIVE|||||||
33792146|NCT04120051|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The randomization sequence will be done by an investigator without contact to the participants. The personnel conducting the study will allocate participants to the sequence of intervention using a list of participant identification numbers matched with allocated sequences. The participants will be blinded to the intervention and blinding of the allocation sequence will be present for investigators during sample analysis and initial data analysis|The participants will be randomized to the Fermented Canola-Seaweed supplement or control and are expected to consume one sachet (5 grams) of either every day for 6 weeks|t|t|t|t
33792147|NCT00203580|RANDOMIZED|||TREATMENT||NONE||||||
33792148|NCT04670835|||CASE_ONLY||RETROSPECTIVE|||||||
33792149|NCT01717677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792150|NCT01081340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792151|NCT04615299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Sham acupuncture covers will be placed on control participants|The treatment group (Group 1) will receive postoperative auricular battlefield acupuncture. The control group (Group 2) will receive sham (placebo) postoperative auricular battlefield acupuncture.|t|f|f|t
33792152|NCT02533713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792153|NCT06133036|||COHORT||RETROSPECTIVE|||||||
33792154|NCT02780245|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33792155|NCT04407325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||outcomes of individual smell prints and digital ChestXrays will be compared with sputum sampling for GenXpert and Mycobacterial culture||||
33792156|NCT05460936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792157|NCT03586596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792158|NCT05619107|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants and investigators are blinded to treatment allocations throughout data collection and analysis. Participants and investigators are also masked to the outcomes data, which will be analysed offline by an independent trial statistician not involved with patient recruitment/device application who is masked to the treatment allocations.|Double-blind, open crossover, randomised sham-controlled trial|t|t|t|t
33792159|NCT04047966|||CASE_CONTROL||PROSPECTIVE|||||||
33792160|NCT00511160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33792161|NCT01931813|||CASE_ONLY||RETROSPECTIVE|||||||
33792162|NCT03566186|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33792163|NCT00578656|NON_RANDOMIZED|||DIAGNOSTIC||NONE||||||
33792164|NCT03334019|||COHORT||PROSPECTIVE|||||||
33792165|NCT00206024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33792166|NCT05764655|||COHORT||PROSPECTIVE|||||||
33792167|NCT00174434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934601|NCT03660280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intervention will be add-on specific probiotic to ongoing treatment with antidepressant medication or Cognitive Behavioral Therapy (CBT). Subjects will be randomized to placebo or probiotic. To assure a balanced subject recruitment, block randomization within strata (ongoing treatment with CBT, antidepressant or both) will be performed. Blood sampling and symptom rating scales will be completed at baseline, at weeks 4 and 8 (end of study). Feces will be collected at baseline and end of study. Biomarkers (from baseline, week 4 and week 8) will be analyzed after the study. Subjects will be recruited from outpatient or inpatient settings, Psychiatry Skåne or primary care clinics in Skåne, Sweden. Subjects will be recruited via clinical referrals, but also via ads.|t|t|t|t
33934602|NCT05579795|||COHORT||PROSPECTIVE|||||||
33934603|NCT01899040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934604|NCT00804128|||COHORT||PROSPECTIVE|||||||
33934605|NCT05165004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33934606|NCT05155410|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33934607|NCT03744598|||COHORT||PROSPECTIVE|||||||
33934608|NCT05804071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934609|NCT05474768|||COHORT||PROSPECTIVE|||||||
33934610|NCT04272762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934611|NCT01652222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33934612|NCT04634318|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934613|NCT01686347|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33710312|NCT03808545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710313|NCT00710346|||||PROSPECTIVE|||||||
33710314|NCT01033968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710315|NCT02335892|||OTHER||PROSPECTIVE|||||||
33710316|NCT01308060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710317|NCT03273595|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710318|NCT02036294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710319|NCT00381485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710320|NCT02933047|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33710321|NCT00790985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710322|NCT02363816|||COHORT||CROSS_SECTIONAL|||||||
33710323|NCT02656784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33710324|NCT00946699|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33710325|NCT02316431|||CASE_ONLY||PROSPECTIVE|||||||
33710326|NCT03801486|||CASE_CROSSOVER||PROSPECTIVE|||||||
33710327|NCT01881360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710328|NCT02628652|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33710329|NCT01317160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33710330|NCT02204397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710331|NCT00317005|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33710332|NCT01572558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710333|NCT01835587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012466|NCT02201290||||TREATMENT||NONE||"AEs were graded using the common toxicity criteria for adverse events (CTCAE) Version 4.03. If a patient reported more than one AE with the same preferred term (PT), the AE with the greatest severity was presented. If a patient reported more than one AE within the same primary system organ class (SOC), the patient was counted only once with the greatest severity at the SOC level, where applicable. An AE with missing CTCAE grade was included in the 'All grades' column of the summary tables.~In AE summaries, the primary SOC was presented alphabetically and the PTs were sorted within the primary SOC in descending frequency."||||
34012467|NCT02059720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012468|NCT06617767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were told that there were intervention and control groups in the study, but it was not explained which group they were in.|Single-blind randomized controlled trial|t|f|f|f
34012469|NCT01751542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012470|NCT05698706|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34012471|NCT05451732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012472|NCT02668848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012473|NCT02402075|||CASE_ONLY||PROSPECTIVE|||||||
34012474|NCT02027870|||CASE_ONLY||PROSPECTIVE|||||||
34012475|NCT06001723|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34095655|NCT03637829|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"treatments are in individual packages labelled A, B and C. Study participants and investigators are blinded to the composition of the test treatments."|A random and within subject, repeated measures experiment to study the effect of chocolate on cognitive performance, subjective appetite, food intake, and glycemic response in normal weight adults.|t|f|t|f
34012476|NCT04705870|||COHORT||PROSPECTIVE|||||||
34012477|NCT05322629|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In a randomized control trial of 750 women, the study team will evaluate: (1) PrEP continuation (missing \<1 PrEP collections) and (2) PrEP adherence per drug levels of TFV-DP at 6m follow up.~Pregnant women who are on PrEP or initiate PrEP at baseline visit will be recruited and screened for eligibility during their routine antenatal services at gestational \>25 weeks using a set script for screening and a brief description of the study. Study staff will obtain written informed consent immediately following screening."||||
34012478|NCT01920542|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34012479|NCT00500552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012480|NCT05603052|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012481|NCT02129647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095656|NCT05560906|||COHORT||PROSPECTIVE|||||||
34095657|NCT02782468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095658|NCT02845427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095659|NCT03368430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095660|NCT00308828|||COHORT||CROSS_SECTIONAL|||||||
34095661|NCT00118794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934614|NCT03739099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934615|NCT06425406|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33934616|NCT05829915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33934617|NCT05601518|||OTHER||PROSPECTIVE|||||||
33934618|NCT05859581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934619|NCT05384990|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The SR stimulation will be provided to the participant in a randomized order using a computer based program. Participants will be unaware of the test condition.|Cross sectional study in children with CP and age matched TD (typical developing). Each group will undergo two stimulation conditions, stochastic resonance (SR) stimulation and a no stochastic resonance (noSR) condition while performing postural Transitions.|t|f|f|f
33934620|NCT05462691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients will be blinded to the assignment group. outcomes assessors will be blinded to the assignment group|prospective randomized trial|t|f|f|t
33934621|NCT05291741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934622|NCT05299502|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934623|NCT06263400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In randomization, among the patients who volunteered to participate in the study, the odd number of patients and their caregivers in the list made according to the order of hospitalization constituted the study group, and the even number of patients and their caregivers formed the control group.||||
33934624|NCT00823186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934625|NCT04971980|NA|SEQUENTIAL||TREATMENT||NONE||||||
33934626|NCT03908268|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33934627|NCT03564327|||COHORT||PROSPECTIVE|||||||
33934628|NCT04587973|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934629|NCT00852098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934630|NCT03402360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934631|NCT05399836|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33934632|NCT05841069|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is expected due to the nature of interventions|Multicenter controlled randomized prospective study||||
33934633|NCT05147597|||CASE_ONLY||CROSS_SECTIONAL|||||||
33934634|NCT03019172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial, double blind allocation concealment|t|f|t|f
33934635|NCT01541982|||COHORT||PROSPECTIVE|||||||
33934636|NCT01273220|||||RETROSPECTIVE|||||||
33934637|NCT05411224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934638|NCT00020449||||TREATMENT||NONE||||||
33934639|NCT03440892|||COHORT||PROSPECTIVE|||||||
33934640|NCT01784250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934641|NCT05865756|NA|SINGLE_GROUP||SCREENING||NONE||40HNC patients in complete clinical remission (10 male/10 female adults \& 10 male/10 female elderly) diagnosed with dysphagia treated with radiochemotherapy and selected three months after the end of treatment will be submitted to cough and voice analysis.||||
33934642|NCT05570708|NA|SINGLE_GROUP||OTHER||NONE||||||
33934643|NCT01116674|||CASE_ONLY|||||||||
33710334|NCT05886829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multi-center, Phase 2/3 Study to evaluate the efficacy and safety of nasally administered CPM in subjects with symptomatic COVID-19 with a positive PCR test.|t|f|t|f
33710335|NCT02364479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710336|NCT05782491|NA|SINGLE_GROUP||TREATMENT||NONE|No blinding in this study|10 patients in cardiogenic shock listed for Impella 5.5 placement||||
33710337|NCT03149198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710338|NCT06558565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||each patient will receive single session of SVF in one half of the frontal scalp \& single session of PRP in the other half of the scalp to compare the effectiveness of them in AGA treatment|t|f|f|t
33710339|NCT00848874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710340|NCT01200602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710341|NCT05466877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Phase II Study of the Safety, Pharmacokinetics, Dose-Ranging and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Patients with Moderate-to-Severe Atopic Dermatitis|t|t|t|t
33710342|NCT05686850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710343|NCT00052689|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710344|NCT03168854|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710345|NCT02122250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33710346|NCT03268902|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Both participants and investigators will be blinded to the treatments allocated to each participant. The members of the DSMB will also be blinded.|Each intervention will be assigned independently. Intervention domains will be randomized separately on an individual basis. This will provide 4 different combinations of interventions: 1). Nicotinamide, azithromycin and nitazoxanide 2). Azithromycin and nitazoxanide 3). Nicotinamide only 4). No active treatment.|t|t|t|t
33710347|NCT00171392|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33710348|NCT06214338|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33710349|NCT04390178|NA|SINGLE_GROUP||TREATMENT||NONE||An open, non-randomised controlled, clinical trial||||
33710350|NCT04934397|NA|SINGLE_GROUP||OTHER||NONE||||||
33710351|NCT00230256|||COHORT||PROSPECTIVE|||||||
33710352|NCT05925660|NA|SINGLE_GROUP||SCREENING||NONE||||||
33710353|NCT02771093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710354|NCT04521153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710355|NCT04655898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710356|NCT02314702|||COHORT||PROSPECTIVE|||||||
33710357|NCT02800681|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710358|NCT02032121|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710359|NCT03949374|RANDOMIZED|PARALLEL||TREATMENT||NONE||10mg of the generic formulation (rosuvastatin, ROVASRO®) versus 10mg of the reference formulation (rosuvastatin, CRESTOR®)||||
33710360|NCT01815515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710361|NCT00769470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710362|NCT04942444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710363|NCT05833854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710364|NCT06178939|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33710365|NCT00986557|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33710366|NCT02568800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710367|NCT01991769|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33710368|NCT06279962|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33710369|NCT05009615|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Nutraceutical was provided in aluminum foil sachets marked A, B or C for blinding to participants. Aroma and flavor compounds were added to ensure similar organoleptic properties of the 3 nutraceuticals tested.|After a run-in period, participants were randomly allocated to one of each arm. Each intervention stage (8 weeks) was separated by a 4-week wash-out.|t|f|f|f
33710370|NCT02401438|||COHORT||PROSPECTIVE|||||||
33710371|NCT06506708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710372|NCT00000793||||TREATMENT||DOUBLE||||||
33710373|NCT00579228|||COHORT||PROSPECTIVE|||||||
33710374|NCT05641324|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33710375|NCT04051008|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33710376|NCT03284944|||COHORT||PROSPECTIVE|||||||
33710377|NCT02941198|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934644|NCT05819502|NA|SINGLE_GROUP||OTHER||NONE||This study will consist of an open-label, prospective, cohort trial design. Eighteen subjects will be recruited. Subjects will be recruited based on their primary deficit, where all subjects must have a mild or greater deficit of the midface and each of three subsets of 6 subjects will have a primary deficit/deformity of the nose, lips, and chin. All subjects will receive active treatment with hyaluronic acid at Baseline, with an optional touch at week two. There will be no placebo or no-treatment control groups. Subjects will be followed for five months.||||
33934645|NCT02559115|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934646|NCT03409575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33934647|NCT06437639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934648|NCT06106685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934649|NCT03317912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012482|NCT03560687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomization of 1000 consecutive patients undergoing heart surgery to either Iron supplementation or Control|f|f|f|t
34012483|NCT04462016|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34012484|NCT02322619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012485|NCT01906359|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34012486|NCT02214420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012487|NCT02986035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012488|NCT06021678|NA|SEQUENTIAL||TREATMENT||NONE||||||
34012489|NCT04283916|||CASE_CONTROL||PROSPECTIVE|||||||
34012490|NCT04647383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34012491|NCT00455442|RANDOMIZED|PARALLEL||||DOUBLE||||||
34012492|NCT04684693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710378|NCT01780818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710379|NCT05466682|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33934650|NCT02455843|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were divided into two groups: The microwave ablation plus chemotherapy group and the chemotherapy group.The former will be treated with microwave, followed by chemotherapy.The latter will be treated with chemotherapy alone.||||
33934651|NCT03687827|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934652|NCT01902836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934653|NCT04901390|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will be blinded to the ingredient (sugar) added to the yogurt.|Controlled single-group trial with a 4-week lead-in period and a 2-week treatment period. The treatment will consist of yogurt with sugar.||||
33934654|NCT05539924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934655|NCT06139094|||CASE_CONTROL||OTHER|||||||
33934656|NCT04961502|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||3 blood samples taken to compare the immunization response of the elderly with that of younger adults (priority caregivers)||||
33934657|NCT04958525|||COHORT||PROSPECTIVE|||||||
33934658|NCT04093206|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33934659|NCT01510561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934660|NCT00955344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934661|NCT05298410|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33934662|NCT02421640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934663|NCT04687436|||COHORT||PROSPECTIVE|||||||
33934664|NCT01529827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934665|NCT05498792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934666|NCT05576415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934667|NCT00307892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934668|NCT03288623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33934669|NCT02308904|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934670|NCT04594889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934671|NCT05505539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934672|NCT05389306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934673|NCT01287988|||||CROSS_SECTIONAL|||||||
33934674|NCT03053973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel groups non-blinded randomised controlled trial||||
33934675|NCT03505957|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||SafeBreak Vascular works with all IVs. The study participants will have SafeBreak Vasculars installed in all of their existing IV lines or new IV lines that are installed during their enrollment in the study.||||
33934676|NCT04724772|NA|SINGLE_GROUP||PREVENTION||NONE|The patient does not know which side receives the TXA in addition to the LA. They then personally assess pain and bruising. The provider is blinded to which syringe has both TXA and LA, and which only has LA.|Each patient is blinded to which eye receives TXA. All patients have both eyes injected with LA, and one eye injected with TXA.||||
33934677|NCT01917591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934678|NCT06186622|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33934679|NCT04543630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to which arm the individual participant was treated under|Well-controlled diabetic patients with indication of sinus floor augmentation to allow placement of a dental implant in the posterior maxilla will be randomized to one of two sinus augmentation protocols: particulated autogenous bone or advanced platelet-rich fibrin|f|f|f|t
33934680|NCT00275106|RANDOMIZED|||TREATMENT||||||||
33934681|NCT04485936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934682|NCT00205946|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934683|NCT05387135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33934684|NCT03371589|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who cannot receive the oral treatment due to a prior condition e.g. diabetes, high blood pressure, pregnancy.||||
33934685|NCT02949687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934686|NCT01071291|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934687|NCT02249260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934688|NCT04427410|||COHORT||PROSPECTIVE|||||||
33934689|NCT00520091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934690|NCT02455440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934691|NCT02022891|||COHORT||RETROSPECTIVE|||||||
33934692|NCT01703429|||COHORT||PROSPECTIVE|||||||
33934693|NCT03563586|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||f|t|t|t
34012493|NCT05915793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012494|NCT05608681|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012495|NCT02428179|||CASE_CONTROL||PROSPECTIVE|||||||
34012496|NCT04209010|||COHORT||PROSPECTIVE|||||||
34095662|NCT04941911|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Blinding (masking) will be achieved through the use of identical active drug product and control study drug syringes that are allocated by centrally-controlled and administered randomisation such that no clinical, research or statistical support staff are aware of allocation.|Patients will be randomised in a 2:1 ratio to either octreotide or placebo groups. Stratified randomisation of patients by source of liver graft (brain death or cardiac death) will be performed.|t|t|t|t
34095663|NCT01475500|||COHORT||PROSPECTIVE|||||||
34095664|NCT00298857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095665|NCT01210443|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095666|NCT00532857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095667|NCT03464981|||COHORT||PROSPECTIVE|||||||
34095668|NCT03132883|||COHORT||RETROSPECTIVE|||||||
34095669|NCT02002208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095670|NCT02893631|||CASE_ONLY||CROSS_SECTIONAL|||||||
34095671|NCT06499480|||COHORT||PROSPECTIVE|||||||
33710380|NCT02454296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710381|NCT03564314|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33710382|NCT02640014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710383|NCT00655044|||CASE_CONTROL|||||||||
33710384|NCT01102959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710385|NCT02172924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710386|NCT03751111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not be informed whether the drug they received is naloxone or placebo. The investigators will remove the package of the drugs and use the unified package for both of the drugs.|Participants will be randomly assigned to two arms using a computer-generalized sequence of random numbers.|t|f|f|f
33710387|NCT06254430|||CASE_ONLY||PROSPECTIVE|||||||
33710388|NCT01983436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710389|NCT04750330|||CASE_CONTROL||RETROSPECTIVE|||||||
33710390|NCT04330170|||COHORT||RETROSPECTIVE|||||||
33792168|NCT01967186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792169|NCT04048018|||COHORT||CROSS_SECTIONAL|||||||
33792170|NCT04128423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792171|NCT04946045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The stratified block randomization method was used to determine which group the preterm infants to be included in the study would be in.~Stratification was based on gestational age. The phase of inclusion in the study and control groups was carried out by another investigator in order to avoid study bias with block randomization."|This research is a randomized controlled study with a control group design with pre-test and post-test measurements from experimental research designs.|t|f|f|t
33792172|NCT01125761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33792173|NCT01713530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792174|NCT01157182|RANDOMIZED|CROSSOVER||||NONE||||||
33792175|NCT04670419|||COHORT||RETROSPECTIVE|||||||
33792176|NCT00365638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934694|NCT05679440|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In the intervention group, arterial blood gases, heart rate, blood pressure, finger pulse oxygen saturation and inhaled oxygen concentration were collected 30 minutes before ventilation in different positions according to pulmonary imaging data (Time 1). Patients are ventilated in prone position (for patients with bilateral lung lesions), left/right lateral position, semi-prone position (for patients with unilateral lung lesions or those who cannot tolerate prone ventilation, so that the diseased lung is above and the healthy lung is below), supine position (for patients who cannot tolerate prone ventilation or lateral ventilation, etc.) according to the pulmonary imaging data. Arterial blood gases, heart rate, blood pressure, finger pulse oxygen saturation, and inhaled oxygen concentration were collected again when the patient was ventilated in the different positions for 2 hours (Time 2).|f|f|f|t
33934695|NCT02447068|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33934696|NCT03858686|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33934697|NCT05126654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934698|NCT04246489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934699|NCT03583112|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33934700|NCT00383981|||||OTHER|||||||
33934701|NCT00776581|||||RETROSPECTIVE|||||||
33934702|NCT03250819|||COHORT||OTHER|||||||
33934703|NCT04694794|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm interventional study||||
33934704|NCT06179355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710391|NCT06272760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinding|Randomized Controlled Trial|f|f|f|t
33710392|NCT01186510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710393|NCT00958750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33710394|NCT02392143|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33792177|NCT06320119|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33792178|NCT05982353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded envelopes selected by operator|patients with dental sockets requiring immediate implantation with Gelatin Sponge vs polytetrafluoroethylene membrane|t|f|f|f
33792179|NCT06438406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792180|NCT04210765|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33792181|NCT05262803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792182|NCT02278848|NA|SINGLE_GROUP||OTHER||NONE||||||
33792183|NCT06427252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792184|NCT00143936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792185|NCT06097429|||CASE_CONTROL||PROSPECTIVE|||||||
33792186|NCT02823548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792187|NCT06406972|||OTHER||OTHER|||||||
34012497|NCT04092920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012498|NCT04816747|NA|SINGLE_GROUP||TREATMENT||NONE||All participants fulfilling the predetermined inclusion criteria will be considered eligible to be subjected to treatment with PRP. Injection of PRP will be conducted intradiscally and/or intra-articularly, in cases of lumbar DDD and/or FJS, as defined by clinical and radiologic assessment. Hence, all participants will be assigned to the same intervention.||||
34012499|NCT01716650|||CASE_ONLY||PROSPECTIVE|||||||
34012500|NCT02447159|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012501|NCT00678626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012502|NCT03100734|||COHORT||PROSPECTIVE|||||||
34012503|NCT00485927|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
33792188|NCT04300816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research manager will be blinded for this trial. Research coordinator and investigator will not.|3- arm randomized clinical trial. Arms: (1) CBT for uncertainty tolerance, (2) traditional CBT, (3) treatment as usual|f|f|f|t
33792189|NCT02248480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792190|NCT05647044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a triple blinded study with participants, investigators and outcomes assessors all masked until study completion.|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P and Magpro C-B60|t|t|t|t
33792191|NCT04224181|||COHORT||CROSS_SECTIONAL|||||||
33792192|NCT02268630|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33792193|NCT01144182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792194|NCT06245200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33792195|NCT02873754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792196|NCT05061342|||COHORT||PROSPECTIVE|||||||
33792197|NCT05318573|RANDOMIZED|PARALLEL||TREATMENT||NONE||FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle||||
33792198|NCT00837980|||COHORT||PROSPECTIVE|||||||
33934705|NCT01619995|||COHORT||PROSPECTIVE|||||||
33934706|NCT05127356|||OTHER||CROSS_SECTIONAL|||||||
33934707|NCT05399160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33934708|NCT02543606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934709|NCT06305819|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33934710|NCT00528840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934711|NCT01378091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934712|NCT06099808|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012504|NCT03529643|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34012505|NCT00000486|RANDOMIZED|||TREATMENT||||||||
34012506|NCT04533126|||COHORT||CROSS_SECTIONAL|||||||
34012507|NCT02662088|||COHORT||CROSS_SECTIONAL|||||||
34012508|NCT01343095|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012509|NCT02896777|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34012510|NCT00362830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012511|NCT03546803|||COHORT||PROSPECTIVE|||||||
34012512|NCT06427525|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012513|NCT05978739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792199|NCT02824159|||COHORT||PROSPECTIVE|||||||
33792200|NCT03278028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792201|NCT03829917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792202|NCT05404893|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33792203|NCT05387837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792204|NCT02452242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792205|NCT01463046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792206|NCT03003988|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33934713|NCT01335438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934714|NCT00004205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012514|NCT04449536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012515|NCT02631837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012516|NCT04012372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All participants will be allocated in an open-label manner to two randomly assigned ad libitum hydration regimens: first group will receive ROSA water for daily hydration, and second (control) group will receive other water of personal choice (including tap water)||||
34012517|NCT00780260|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012518|NCT03581513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012519|NCT02229565|||COHORT||PROSPECTIVE|||||||
33792207|NCT05679830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792208|NCT05262270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, placebo-controlled study.|The study intervention is three doses of 380mg XR-NTX (Weeks 0, 3 and 6) and two doses of 300mg XR-BUP (Weeks 0, 4). XR-NTX is delivered via intramuscular (IM) injection in the gluteus; XR-BUP is delivered via subcutaneous (SQ) injection in the abdomen.|t|t|t|t
33792209|NCT03896841|||CASE_CONTROL||PROSPECTIVE|||||||
33792210|NCT02052648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792211|NCT02767219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792212|NCT00515450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33792213|NCT00966017|||CASE_CONTROL||RETROSPECTIVE|||||||
33792214|NCT02961127|||||PROSPECTIVE|||||||
33792215|NCT02375581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792216|NCT03890263|NA|SINGLE_GROUP||TREATMENT||NONE||"This study will use parallel mixed methods including:~1. An interrupted time series design to evaluate outcomes of an evidence-based self-management intervention and opioid deprescribing. This time series will include 18 assessments over 36-weeks from 12 weeks prior to implementation of the combined intervention to 24 weeks after implementation of the combined intervention.~2. Qualitative semi-structured interviews informed by an interpretive description approach with patients and health care providers to understand their perspectives and experiences.~3. A nested cross sectional evaluation to determine the characteristics of people who are identified on high doses of opioids in primary care in South Eastern Ontario. Characteristics collected will include: age, sex, gender, education, household income, postal code/geographic location, work status, caregiver status, early childhood trauma, depression, post-traumatic stress, health-related quality of life, and comorbidities."||||
33792217|NCT02397317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792218|NCT03192319|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792219|NCT04770935|NA|SINGLE_GROUP||OTHER||NONE||||||
33792220|NCT04861012|NA|SINGLE_GROUP||SCREENING||NONE||||||
33792221|NCT03946813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792222|NCT02719769|||OTHER||PROSPECTIVE|||||||
33792223|NCT06354738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792224|NCT05991063|||COHORT||PROSPECTIVE|||||||
33792225|NCT02087358|||COHORT||PROSPECTIVE|||||||
33792226|NCT06025019|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This study is a two parallel-group, single-blinded randomized controlled trial designed to promote preschoolers' PA, and DB, and reduce sleep problems by providing parents with relevant health information through the eHealth modality. The two arms comprise (1) eHealth intervention and (2) control group.|t|t|f|f
33792227|NCT04965467|||OTHER||CROSS_SECTIONAL|||||||
33792228|NCT06461637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792229|NCT05066113|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be enrolled to test for the tolerability, safety, and histometric changes in skin-RF interactions in axillary skin. RF-based selective electrothermolysis will be administered to skin of healthy volunteers and Hidradenitis Suppurativa (HS) patients at varying depth, intensity, and time.||||
33792230|NCT01038349|||CASE_ONLY||PROSPECTIVE|||||||
33792231|NCT04027426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to randomization. Participants and providers will be blinded to study hypothesis.||f|f|f|t
33792232|NCT04589130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Masking during first 6 month phase (treatment or placebo control).~All participants receive treatment (Contrave) during second 6 months."|"Parallel - 2 arms during first 6 month phase (treatment and placebo control)~Crossover - placebo control group crosses over to treatment arm during second 6 months of the study"|t|t|t|t
33792233|NCT06358066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792234|NCT06084117|RANDOMIZED|PARALLEL||OTHER||NONE||pilot randomized unblinded controlled trial||||
33792235|NCT03103971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792236|NCT00510601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792237|NCT05762419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792238|NCT00038714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792239|NCT04678830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792240|NCT05593146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792241|NCT05165888|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33792242|NCT03684213|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject has one control site and three experimental sites concurrently tested within the same study using intradermal microdialysis on the dorsal forearm.||||
33934715|NCT05379933|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33934716|NCT02652572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934717|NCT04949776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934718|NCT06444997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934719|NCT05947695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33934720|NCT04990531|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33934721|NCT01397513|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934722|NCT00487994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934723|NCT00369889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934724|NCT06251544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934725|NCT04881110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792243|NCT02519699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934726|NCT01847872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934727|NCT04273568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934728|NCT05843344|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934729|NCT04362852|||FAMILY_BASED||PROSPECTIVE|||||||
33934730|NCT00934713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934731|NCT03316508|||OTHER||PROSPECTIVE|||||||
33934732|NCT00820963|RANDOMIZED|||TREATMENT||||||||
33934733|NCT06261840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012520|NCT00028535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792244|NCT03199235|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33792245|NCT02736799|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33792246|NCT01624168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792247|NCT03890016|||OTHER||PROSPECTIVE|||||||
33792248|NCT01301196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33792249|NCT01810263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33792250|NCT02523651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792251|NCT03773120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33792252|NCT02667249|||CASE_CONTROL||RETROSPECTIVE|||||||
33792253|NCT04410055|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792254|NCT01256034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792255|NCT00290849|||COHORT||RETROSPECTIVE|||||||
33792256|NCT01786564|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33792257|NCT01568749|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33792258|NCT04184804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33792259|NCT05218837|||COHORT||PROSPECTIVE|||||||
33792260|NCT00350675|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33792261|NCT03097016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792262|NCT03571191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792263|NCT04411446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will use a placebo identical to the active medication. The members of research team assessing the outcomes will not be aware of the treatment assignment.|Two parallel arms randomized controlled trial. A sequential design will be used with the first primary outcome being the primary outcome for the first step. This step will include 200 patients. After reach this point, a review of the primary outcome (change in respiratory SOFA) will be done. According to these results, the Executive committee will decide to proceed the second step of the study and include the remaining 1064 patients to evaluate the second primary outcome (need for high dose of oxygen supplementation or mechanical ventilation).|t|t|t|t
33792264|NCT03498170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792265|NCT00542087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792266|NCT05179837|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012521|NCT04267263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33792267|NCT00000871||||PREVENTION||DOUBLE||||||
33792268|NCT01376336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792269|NCT04261855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792270|NCT03014830|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33792271|NCT06070207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792272|NCT01499134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792273|NCT00184925|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34012522|NCT05246033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There are 2 cohorts enrolling 24 subjects who will be randomized to receive either TransCon CNP or Placebo in a 3:1 ratio|t|t|t|t
34012523|NCT05146349|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012524|NCT01312181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors blind to randomization outcomes||f|f|f|t
33792274|NCT01526642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792275|NCT02499419|||CASE_CONTROL||PROSPECTIVE|||||||
33934734|NCT03961139|RANDOMIZED|PARALLEL||PREVENTION||NONE|na. Open label|"Randomised-controlled trial with 2 parallel groups (1:1 ratio). Control group: intermittent bolus intra-gastric tube feeding (BF), Intervention group: continuous intra-gastric tube feeding (CF). Not blinded.~Stratified randomization along following birth weight groups:~1. \</=750 g~2. 751 - 1000 g~3. 1001 -1250 g Method of randomisation: Computer generated randomization codes stored in sealed opaque envelopes.~Intervention started by 72 hours of life (more than trophic feed volume achieved) and continued until an infant reaches a weight of 1.6 kg and is determined by the attending Neonatologist to be ready to commence oral feeding by breast or bottle, or when an infant attains a post-conceptional age of 36 weeks, whichever is earlier.~Continuous fed is delivered through a nasogastric tube by a syringe pump over 3hrs with 1 hour of break - 6 cycles a day. Feed volume, type of feed, feed increment regulated by the clinical team.~Intention to treat analysis."||||
33934735|NCT05961397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934736|NCT05678504|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934737|NCT05937490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934738|NCT03935594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to which halves of their scar are in either arm of the study. On each visit, before the patient is able to see the contents of syringes used for injection of either normal saline or platelet rich plasma, the syringes will be covered with a white sticker and labeled such that the provider knows which syringe has PRP vs normal saline but the patient does not (PRP is yellow and normal saline is clear). Depending on which side (left vs right) was assigned PRP vs normal saline, the appropriate area will be injected with 1mL/1sq-cm of PRP or normal saline.|All patients meeting inclusion/exclusion criteria will be offered enrollment. Using a coin flip, patients will have a 50% chance of receiving PRP injection on the right half of the scar (as opposed to the left half). Multiple scar sites may be enrolled per patient, without limit.|t|f|f|f
33934739|NCT05833061|||CASE_ONLY||PROSPECTIVE|||||||
34012525|NCT04731584|||CASE_CONTROL||PROSPECTIVE|||||||
34012526|NCT02459665|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33792276|NCT01953757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792277|NCT05032937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792278|NCT02668263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792279|NCT04856748|||CASE_ONLY||PROSPECTIVE|||||||
33792280|NCT05380869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic study||||
33792281|NCT04800016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792282|NCT01810250|||OTHER||PROSPECTIVE|||||||
33792283|NCT02487316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792284|NCT02900326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792285|NCT02106442|||COHORT||PROSPECTIVE|||||||
33934740|NCT04618549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934741|NCT03592173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Thirty chronic SCI participants will given the SAS intervention and a control intervention in a randomized cross-over study, with at least one week between interventions. Each patient will be required to attend the Burke Medical Research Institute on three occasions. We will use a within-subjects design, to test changes in neurophysiologic and voluntary measures after intervention with respect to baseline.||||
33934742|NCT00713557|||COHORT||PROSPECTIVE|||||||
33934743|NCT01782612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33934744|NCT03177954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934745|NCT02183610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934746|NCT02411006|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33934747|NCT01364116|||CASE_ONLY||PROSPECTIVE|||||||
33934748|NCT02979340|||COHORT||PROSPECTIVE|||||||
33934749|NCT03603574|RANDOMIZED|PARALLEL||OTHER||SINGLE|The outcome assessment will not be present during the performance of the epidural block and waveform analysis.|Randomized trial|f|f|f|t
33934750|NCT02158962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934751|NCT04853056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33934752|NCT05742789|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33934753|NCT05194215|||COHORT||PROSPECTIVE|||||||
33934754|NCT02118402|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33934755|NCT03209986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind to the randomization results of the participants.||f|f|f|t
33934756|NCT04415762|||COHORT||RETROSPECTIVE|||||||
33934757|NCT02170558|||CASE_ONLY||PROSPECTIVE|||||||
33934758|NCT02916199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934759|NCT04460300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33934760|NCT04683133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, multicenter, international, no-randomized, single-arm, investigator-initiated study||||
33934761|NCT01382667|||COHORT||PROSPECTIVE|||||||
33934762|NCT04731194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934763|NCT03632304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
34095672|NCT06319443|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Liquid and pill vinegar will be the treatments. The pill is the 'control' as the level of acetic acid is below the amount needed for an antiglycemic effect (a fact not realized by the participant).|This is a 9-day trial. Participants will be fitted with a continuous glucose monitor and follow their typical diet and activity patterns. Participants will be randomized to ingest 2 tablespoons of vinegar twice daily (diluted in water) or a vinegar pill for the first 4 days on the trial. On day 5 of the trial participants will consume the alternate treatment for trial days 5-8. Dietary intake will be recorded daily using a fitness app. Physical activity will be assessed at baseline and on study day 4 and 8. On day 9, participants will return to the test site for device removal.|t|f|f|f
34095673|NCT03338686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095674|NCT05911386|||CASE_ONLY||RETROSPECTIVE|||||||
34095675|NCT02025036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095676|NCT02353663|||COHORT||CROSS_SECTIONAL|||||||
34095677|NCT00430859|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|t|f
34095678|NCT03122366|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095679|NCT03512886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095680|NCT00669331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095681|NCT02506036|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095682|NCT02727959|||COHORT||PROSPECTIVE|||||||
34095683|NCT05189197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095684|NCT01260753|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710395|NCT04023604|RANDOMIZED|CROSSOVER||OTHER||SINGLE||This is a 16-week randomized, cross-over, controlled, blinded study. During weeks 2 and 9, participants usual, unrestricted dietary intakes will be assessed. At week 3 the participants will be randomized and assigned to consume either the controlled U.S. Healthy Eating Pattern with beef produced in conventional systems or to an identical controlled U.S. Healthy Eating Patter with beef produced in RWA (raised without antibiotics) systems. Week 10 will be the second 3- week long dietary intervention period. A total of 14 stool samples will be collected during the study (two after baseline, washout 1 and washout 2, and 4 during the two dietary interventions). Two fasting state serum samples and a psychological questionnaire will be collected during study weeks 2, 5, 9, and 12.|f|f|f|t
33710396|NCT01001377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710397|NCT04803370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710398|NCT00002169||||TREATMENT||||||||
33710399|NCT02248103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710400|NCT01528904|||CASE_CONTROL||PROSPECTIVE|||||||
33792286|NCT05022147|NA|SINGLE_GROUP||TREATMENT||NONE|There is only one arm in the study. Participants will be masked to which device intervention is active, but they will not be masked to the medication state.|On a single day, participants will switch between six DBS frequency conditions. Gait and body kinematics will be monitored during these conditions. The order that participants experience the six conditions will be randomized, and participants will be blinded to the condition. In addition, the assessments will be performed OFF and then repeated ON medication.||||
33792287|NCT01838200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792288|NCT01231113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710401|NCT01948947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710402|NCT04737083|||CASE_ONLY||RETROSPECTIVE|||||||
33710403|NCT06177730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710404|NCT02256189|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33710405|NCT05011539|||CASE_CONTROL||PROSPECTIVE|||||||
33710406|NCT02706340|||COHORT||PROSPECTIVE|||||||
33710407|NCT01320904|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33710408|NCT03067961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33710409|NCT06557837|||CASE_CONTROL||PROSPECTIVE|||||||
33710410|NCT01816204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710411|NCT04849143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710412|NCT03385902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710413|NCT01008488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710414|NCT03673033|||COHORT||PROSPECTIVE|||||||
33710415|NCT02587260|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Latin square design|f|f|f|t
33792289|NCT06037187|||COHORT||PROSPECTIVE|||||||
33792290|NCT02355158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792291|NCT03510949|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Group N: Patients' nasal mucosa will be anaesthetized and vasoconstricted. The NPA will then be advanced into the dominant nostril along the septum horizontally.~Group L: K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt."|t|t|f|t
33934764|NCT01834638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934765|NCT04178434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934766|NCT06111404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33934767|NCT05471024|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All conventional and digital mounting procedures will be performed with all trial participants and the allocation will occur as to which mounting procedure will be utilized in the designing of the crown. Sequence allocation will be performed using a random sequence generated by an impartial third party who will assign an equal number of participants to each mounting condition. This allocation will be shared with the laboratory technician but not the main investigator as he will be performing the outcomes assessments.|Triple blind (participant, investigator and outcomes assessor), randomized, clinical superiority trial with 1:1:1 allocation ratio.|t|f|t|t
34095685|NCT00115531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34095686|NCT00973973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095687|NCT05924230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934768|NCT04043351|||COHORT||PROSPECTIVE|||||||
33934769|NCT05089188|||COHORT||RETROSPECTIVE|||||||
33934770|NCT02870244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934771|NCT06407336|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33934772|NCT01223690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934773|NCT02723019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33934774|NCT02048657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095688|NCT05130983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012527|NCT04595266|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized in a 1: 1 ratio in the 2 arms:~Control Arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimental Arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4."||||
34012528|NCT01930175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012529|NCT05368441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The patients will be unaware of the group assignments and monitored in the reception area by a blinded anesthesiologist who will be in charge of the intervention and the evaluation of anxiety and sedation levels.|t|f|t|t
34012530|NCT02327507|||COHORT||PROSPECTIVE|||||||
33792292|NCT04498754|RANDOMIZED|PARALLEL||OTHER||NONE||Participants who are originally assigned to the minimal contact control condition will be invited to receive the active condition treatment after their study involvement has been completed, but no additional data will be collected from them.||||
33792293|NCT01437358|||||CROSS_SECTIONAL|||||||
33792294|NCT05347199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792295|NCT00398606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792296|NCT05165849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792297|NCT00253058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33792298|NCT02493933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792299|NCT00457236|||DEFINED_POPULATION||PROSPECTIVE|||||||
33792300|NCT03009513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792301|NCT01270633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792302|NCT05344300|||COHORT||PROSPECTIVE|||||||
33792303|NCT03368833|||CASE_CONTROL||PROSPECTIVE|||||||
33792304|NCT04602052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792305|NCT00517933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792306|NCT05402735|||CASE_ONLY||CROSS_SECTIONAL|||||||
33792307|NCT01980641|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33792308|NCT04552886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Patients, clinicians, investigators and support staff will be aware of the enrollment status of patients in this phase I trial.|The study will be constructed in a 3+3 algorithm for three steps of dose escalation for a novel GBM-targeting dendritic cell vaccine with rigorous and mandatory safety monitoring.||||
33792309|NCT04781218|||OTHER||PROSPECTIVE|||||||
33792310|NCT03316794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792311|NCT02779608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792312|NCT04922658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792313|NCT02328352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33792314|NCT05714358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"* Being chronic renal failure (stage 3)~* Being between the ages of 18-65~* Knowing how to read and write~* Being able to use a smart phone~* Volunteering to participate in the study~* Not having a mental problem~* Not having a communication problem"|The study, the experimental and control groups were determined as 110 individuals, 55 each.|t|f|f|f
33792315|NCT04789798|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33792316|NCT01919697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792317|NCT06391619|||COHORT||PROSPECTIVE|||||||
33792318|NCT05586113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792319|NCT04286256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33792320|NCT00811057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792321|NCT05172778|||CASE_ONLY||RETROSPECTIVE|||||||
33792322|NCT03067350|||COHORT||PROSPECTIVE|||||||
33792323|NCT02892968|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33792324|NCT04915885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33792325|NCT02861937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 34 patients with 19 males and 15 females in the age group of 20-60 years were included. Patients were divided into 3 groups to collect Gingival Crevicular Fluid (GCF) samples for the study.|f|f|t|t
33934775|NCT02259127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934776|NCT02339441|||COHORT||PROSPECTIVE|||||||
33934777|NCT05931068|||COHORT||PROSPECTIVE|||||||
34012531|NCT00963651|||CASE_ONLY||CROSS_SECTIONAL|||||||
34012532|NCT05576623|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012533|NCT06490575|RANDOMIZED|PARALLEL||PREVENTION||NONE||The educational intervention was a randomized controlled trial in which participants were randomly divided into control and intervention groups.||||
34012534|NCT05917028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934778|NCT01492738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934779|NCT03616470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934780|NCT03669107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33934781|NCT00004889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934782|NCT05990140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33934783|NCT02111954|||CASE_ONLY||PROSPECTIVE|||||||
33934784|NCT05135182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934785|NCT00794859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934786|NCT03973567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012535|NCT02121561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012536|NCT00780923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012537|NCT00608595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012538|NCT00589849|||COHORT||PROSPECTIVE|||||||
34012539|NCT03407118|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012540|NCT04715997|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34012541|NCT05294419|NA|SINGLE_GROUP||OTHER||NONE||||||
34012542|NCT03866018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012543|NCT02826291|||CASE_ONLY||PROSPECTIVE|||||||
34012544|NCT05614206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095689|NCT05372939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095690|NCT02606539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34095691|NCT04849052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|While participants and study trainers will be aware of group assignment, a blinded study team member will perform outcome assessments.|Randomized, controlled, single-blinded study|f|f|f|t
34095692|NCT02368236|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34095693|NCT01982227|||||PROSPECTIVE|||||||
33710416|NCT01251601|||OTHER||PROSPECTIVE|||||||
33710417|NCT00803725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710418|NCT00088478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710419|NCT00768157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710420|NCT04293120|NA|SINGLE_GROUP||TREATMENT||NONE||Case control, matched on gender, age, and BMI||||
33710421|NCT05876598|||COHORT||PROSPECTIVE|||||||
33710422|NCT05540353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792326|NCT04351113|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Double blind placebo controlled design|Randomized double blind parallel 3 group study|t|f|t|f
33792327|NCT02045719|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33792328|NCT00878462|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33792329|NCT04083833|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33792330|NCT05033509|||COHORT||RETROSPECTIVE|||||||
33792331|NCT06261450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Randomization and dispensing of active and control will be conducted by the research center pharmacy.|This study is a double-blind-crossover placebo control comparing the acute effect of oral CBD in patients with FXS to controls.|t|f|t|t
33792332|NCT05649878|RANDOMIZED|CROSSOVER||OTHER||NONE||"A single dose design was used, with 8 subjects under fasting conditions, two periods, two sequences, open, crossed with blocks scheme A-B and B-A, randomized, longitudinal, comparative and prospective, with a washout period of seven days between the two study sessions. The treatment groups were balanced, having an equal number of subjects who were randomly assigned to the administration sequences of the drug under study.~MEP sodium succinate was administered intravenously (1 mL, equivalent to 62.5 mg of Methylprednisolone) or the same dose intranasally by 2 using a Mucosal Atomization Device (MAD Nasal).~The nominal doses were similar, allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration at different times. Plasma was separated and frozen at -70 °C for further analysis."||||
33792333|NCT02592954|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33792334|NCT05429424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study, the participants, assessor, and statistician are all blinded to the treatment assignments except for the acupuncturist and study coordinator.||t|f|f|t
33792335|NCT01832506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792336|NCT04671719|||CASE_CONTROL||PROSPECTIVE|||||||
33792337|NCT00074633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792338|NCT02114749|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33792339|NCT04441593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Three and six month assessments will be conducted by RA who is masked to intervention condition|Compare Intervention to Control Condition in a Between Subjects Design|f|f|f|t
33792340|NCT02558218|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33934787|NCT06361706|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The statisticians and researchers involved in data analysis will be masked to the identity of participants, using a random code for each participant.|The REDOCVR study utilizes a Single-Group Interventional Model, where all participants receive the same VR-enhanced psychoeducational intervention for chronic pain management. This model facilitates a focused evaluation of VR's effectiveness and usability within a structured psychoeducational framework, allowing for direct assessment of participant experiences and outcomes.||||
33934788|NCT02662868|||CASE_ONLY||RETROSPECTIVE|||||||
33934789|NCT02587104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934790|NCT06388356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups, intervention and control group. Only intervention group is receiveing the intervention.||||
33934791|NCT03266367|||CASE_CONTROL||PROSPECTIVE|||||||
33934792|NCT03824457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will perform the assessment of primary, secondary efficasy and safety parameters|Assignment|f|f|f|t
34095694|NCT00584285|||CASE_ONLY||PROSPECTIVE|||||||
34095695|NCT05752890|||COHORT||OTHER|||||||
34095696|NCT02456558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095697|NCT05523739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095698|NCT06028737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095699|NCT05065827|||COHORT||RETROSPECTIVE|||||||
34095700|NCT02278237|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34095701|NCT00848315|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33710423|NCT02541682|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33710424|NCT00465205|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33710425|NCT00996307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33710426|NCT00620867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710427|NCT01824953|||CASE_CONTROL||PROSPECTIVE|||||||
33710428|NCT01481727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33710429|NCT02025621|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33710430|NCT03498027|||CASE_ONLY||PROSPECTIVE|||||||
33710431|NCT06364943|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33710432|NCT04531943|||COHORT||OTHER|||||||
33710433|NCT00729651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710434|NCT01444560|||COHORT||PROSPECTIVE|||||||
33710435|NCT00382252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710436|NCT00954070|||CASE_CONTROL||PROSPECTIVE|||||||
33710437|NCT01295801|||CASE_CONTROL||PROSPECTIVE|||||||
33710438|NCT01101503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710439|NCT01307397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710440|NCT05392296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095702|NCT03033043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095703|NCT04517058|||COHORT||PROSPECTIVE|||||||
34095704|NCT05895669|||COHORT||RETROSPECTIVE|||||||
34012545|NCT02531607|||CASE_CONTROL||PROSPECTIVE|||||||
34012546|NCT05438355|||COHORT||CROSS_SECTIONAL|||||||
34012547|NCT00109759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012548|NCT03916042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012549|NCT05681312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|metronidazol 500 mg 1bythree amoxicillin 500 mg 1by three doulprane 1000 mg one by one|Tibrolin combination of (Trypsin 48 mg, Bromelain 90 mgand a bioflavonoid (Rutoside 100 mg) .one by one for five day|t|f|f|f
34012550|NCT00004876|RANDOMIZED|||TREATMENT||||||||
34012551|NCT00646620|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34012552|NCT04104555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792341|NCT04416971|||COHORT||PROSPECTIVE|||||||
33792342|NCT06343103|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792343|NCT04402320|||COHORT||PROSPECTIVE|||||||
33792344|NCT05826951|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33792345|NCT04089488|||CASE_ONLY||PROSPECTIVE|||||||
33792346|NCT04551781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded|single-blinded randomized controlled trial|f|f|f|t
33792347|NCT02072213|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33792348|NCT03394027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792349|NCT06553014|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33792350|NCT01597752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792351|NCT00820079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934793|NCT05203744|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The 200 healthy participants will be divided into two cohorts (A and B) of 100 participants to fully cover the three tafenoquine regimens (i.e. weekly, low monthly and high monthly) in obtaining study information (e.g. AEs) and biospecimens for monitoring the safety, tolerability and PK of tafenoquine.||||
33934794|NCT03676465|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects (child/parent dyad, with child and parent counted as separate subjects randomized together) will be randomized to either a Control Group or an Experimental Group. Both groups will use a study CGM and activity tracker. MDI users will use an inPen to dispense their insulin treatment with their personal insulin. Subjects who use an insulin pump to care for their diabetes will use their personal pump and their personal insulin during the study. All subjects will be asked to download their equipment each week. The study team will communicate with both the subject and their parent(s) each week to discuss their diabetes management. Subjects will complete questionnaires at the beginning and end of the study.||||
33934795|NCT04781725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934796|NCT00997828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934797|NCT03827967|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Treatment cohorts (each n=6 total of n=24):~1. 1 x 10\^8 particles of PalloV-CC~2. 2 x 10\^8 particles of PalloV-CC~3. 4 x 10\^8 particles of PalloV-CC~4. 8 x 10\^8 particles of PalloV-CC PalloV-CC is inoculated weekly via intradermal injection. There will be sequential enrollment of dose-escalation cohorts, each patient treatment period is 4 weeks. Patients will conclude treatment with colectomy."||||
33934798|NCT03363568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Children were randomly assigned to adaptive treatment (n=20) or non-adaptive control (n=20) with identical tasks, stimuli, and goals. Children were instructed to train for 5 days a week (25m/day) for 4-weeks. All participants had between 10-20 training sessions at study completion.|t|f|t|f
33934799|NCT02485860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012553|NCT03975413|||CASE_ONLY||PROSPECTIVE|||||||
34012554|NCT02801552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012555|NCT02549794|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34012556|NCT02963402|||COHORT||PROSPECTIVE|||||||
34012557|NCT00794482|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012558|NCT02926781|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34012559|NCT01366443|||CASE_ONLY||PROSPECTIVE|||||||
34012560|NCT05664282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012561|NCT00865514|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34012562|NCT05416463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012563|NCT00057486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012564|NCT04918160|||CASE_CONTROL||PROSPECTIVE|||||||
34012565|NCT02356991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012566|NCT00143429|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34012567|NCT00613834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34012568|NCT01615887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012569|NCT01520636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012570|NCT01825135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012571|NCT00522444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012572|NCT01791153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012573|NCT04825015|||COHORT||PROSPECTIVE|||||||
34012574|NCT03051139|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012575|NCT00867841|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34012576|NCT03078582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012577|NCT01319786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012578|NCT05187611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The first 70 patients have been recruited in the context of the LEVELAT study (ClinicalTrials.gov Identifier: NCT04054895)|t|f|f|f
34012579|NCT03512496|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Randomized, double blind, crossover design|Randomized, double blind, crossover design|t|f|t|t
34012580|NCT01700478|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33710441|NCT00401453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710442|NCT05776147|||COHORT||RETROSPECTIVE|||||||
33710443|NCT00036452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710444|NCT00441714|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33710445|NCT06505434|||CASE_ONLY||OTHER|||||||
33710446|NCT00714649||PARALLEL||TREATMENT||NONE||||||
33710447|NCT04448574|||FAMILY_BASED||RETROSPECTIVE|||||||
33710448|NCT03756844|NA|SINGLE_GROUP||TREATMENT||NONE|There was no masking. This was a single subject study. Participants allowed us to use their clinical data for research purposes.|This was a single-subject (time series design).||||
33710449|NCT00215332|||||PROSPECTIVE|||||||
33710450|NCT02505204|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33710451|NCT06045897|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33710452|NCT00070174||||TREATMENT||NONE||||||
33710453|NCT00894660|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33710454|NCT05424367|||COHORT||PROSPECTIVE|||||||
33710455|NCT00357968|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710456|NCT04717609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710457|NCT00030121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710458|NCT00838396|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710459|NCT00605111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792352|NCT03398837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792353|NCT05456386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792354|NCT03949335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Only the surgeon and the operative staff will know which lens type is implanted and will be unmasked throughout the study. There may also be site coordinators and other site study staff, such as those performing slit-lamp exams, who will be unmasked. Unmasked study staff and study subjects will be instructed not to disclose the lens type the subject received or to talk about the lens to any subjects or masked evaluators.~The subjects and the study technicians performing the postoperative vision tests are to be masked through study completion. To maintain subject/technician-masking through the 6-month study exams, a masking plan will be tailored for each site to detail how lens assignment information will be concealed from masked technicians."||t|t|f|t
33792355|NCT01456078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792356|NCT00786942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33792357|NCT01958099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33792358|NCT00432029|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33710460|NCT05052762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710461|NCT06280170|RANDOMIZED|SEQUENTIAL||OTHER||NONE|The masking in this study involves a differential approach between providers and clients. Providers will be aware of whether they are in the Services-As-Usual (SAU) or Artificial Intelligence (AI) phase. However, participating clients will not be informed about the platform their provider is using to document their therapy sessions.|This study will follow a stepped-wedge, randomized controlled design, where each provider team will undergo two phases: SAU and the AI platform phase. All teams will initially start with SAU, and the AI platform will be sequentially introduced to teams over time. Teams will be randomly assigned to different time periods for the AI platform phase using simple randomization. The order of implementation will be determined by randomly selecting the number of the team from sealed envelopes every two months. In both phases, the study will enroll new and existing clients. At the end of the trial all teams would have used Eleos for a few months||||
33710462|NCT00791960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710463|NCT00341406|||COHORT||PROSPECTIVE|||||||
33710464|NCT01652612|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33710465|NCT05230550|||CASE_ONLY||PROSPECTIVE|||||||
34012581|NCT03827941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710466|NCT01356108|||COHORT||PROSPECTIVE|||||||
33710467|NCT00735410|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34012582|NCT02365259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012583|NCT02240563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012584|NCT05439811|||CASE_CONTROL||RETROSPECTIVE|||||||
34012585|NCT03603938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012586|NCT03935022|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34012587|NCT03282734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710468|NCT02818569|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Patients will receive both the oral dexmedetomidine intervention and placebo comparator in a randomized order.|t|t|t|f
33710469|NCT03103737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710470|NCT02272062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710471|NCT02923960|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33710472|NCT02615145|||COHORT||PROSPECTIVE|||||||
33710473|NCT00943059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33710474|NCT01488929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710475|NCT01538043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33710476|NCT05954806|||CASE_CONTROL||OTHER|||||||
33710477|NCT01162512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710478|NCT02577510|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33710479|NCT03225183|||COHORT||RETROSPECTIVE|||||||
33710480|NCT05479071|||COHORT||CROSS_SECTIONAL|||||||
33710481|NCT05926102|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Enrolled participants will be randomly allocated to receive either the precision screening intervention or usual care. The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.|f|f|f|t
33710482|NCT03033394|||COHORT||PROSPECTIVE|||||||
33710483|NCT01239004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33710484|NCT03122769|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|All 6 subjects allocated to the study will receive 11C-metformin intravenously.||||
33710485|NCT01314573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710486|NCT00081068||||TREATMENT||NONE||||||
33710487|NCT01186354|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33710488|NCT02732119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710489|NCT02228460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710490|NCT01794884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710491|NCT02744690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710492|NCT05188911|||COHORT||PROSPECTIVE|||||||
33710493|NCT04645875|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33710494|NCT01943578|||COHORT||PROSPECTIVE|||||||
33710495|NCT05557981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710496|NCT04472195|RANDOMIZED|PARALLEL||OTHER||NONE||Non-crossover, Prospective Randomized Controlled Trial||||
33710497|NCT04856371|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33710498|NCT01482000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710499|NCT05680597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical pre- and post-testing will be carried out by a researcher who is blinded to group assignment. Scientists analyzing daily life monitoring data will also be blinded to pre-post status.|We will randomize the 80 participants into two groups: 1) unsupervised home Agility Boot Camp (ABC) exercises (standard of care), 2) supervised balance (ABC) with therapist tele-rehabilitation.|f|f|f|t
33710500|NCT01728064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710501|NCT03646734|||CASE_CONTROL||PROSPECTIVE|||||||
33710502|NCT01201382|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33710503|NCT02381288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710504|NCT02600143|||COHORT||PROSPECTIVE|||||||
33710505|NCT01473836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710506|NCT05081154|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33710507|NCT00114946||||TREATMENT||||||||
33710508|NCT03921671|NA|SINGLE_GROUP||TREATMENT||NONE||Green-Dahlberg 2-stage design||||
33710509|NCT04176757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710510|NCT05467280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33710511|NCT02160574|NA|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33710512|NCT02760069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710513|NCT02626546|||COHORT||PROSPECTIVE|||||||
33710514|NCT03129100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801915|NCT06060119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"SAMPLING TECHNIQUE Purposive Sampling technique will be done. All the patients meeting the criteria will be screened and then 12 patients will be randomly allotted into either of the two groups. The treatment allocation to the test and control group will be assigned by means of a sealed envelope containing a code derived from a computer generated randomized list to receive either -~1. TEST GROUP (n = 12) - Microneedling on the selected area.~2. CONTROL GROUP (n = 12) - Subepithelial connective tissue grafting at the contralateral site"|f|f|f|t
34012588|NCT03914768|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with DIPG or GBM will be treated with immunomodulatory DC vaccine||||
34012589|NCT05824117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012590|NCT00273234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012591|NCT05877079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34012592|NCT01872247|||COHORT||PROSPECTIVE|||||||
34012593|NCT05443100|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34012594|NCT05528640|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study is a prospective 2-arm parallel controlled trial.||||
34012595|NCT03138902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710515|NCT01087645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710516|NCT03733002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33710517|NCT04956367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Used a computer-generated software to randomize the area to be treated.||t|f|f|t
33710518|NCT00904644|||COHORT||OTHER|||||||
33710519|NCT02469922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710520|NCT05533684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double-blinded study both participant and investigator are blind to the study drug|2 groups are included in the study|t|f|t|f
33710521|NCT04449575|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710522|NCT00313157|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33710523|NCT05863832|RANDOMIZED|PARALLEL||TREATMENT||NONE||They will be randomized by computer, into 2 treatment groups; Ciprodiazole ® tablets (Ciprofloxacin/Metronidazole) versus currently used Ciprofloxacin Tablets \& Metronidazole tablets||||
33710524|NCT01716767|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710525|NCT02893943|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710526|NCT05949008|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a randomized, single-blind, controlled trial. All eligible participants will be randomly assigned to placebo or Metformin.|t|f|t|f
33710527|NCT00646009|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33710528|NCT02901990|||COHORT||PROSPECTIVE|||||||
33710529|NCT02688205|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34012596|NCT02555020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34012597|NCT01782482|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34095705|NCT02220556|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095706|NCT04464083|||CASE_ONLY||PROSPECTIVE|||||||
34095707|NCT00888849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792359|NCT04911439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participant does not know what the other participants are doing, the researcher knows which study and group the subject is in, but only sets up the computerized presentations for each group and assigns folders within the computer that collects the data, thus avoiding a possible information bias, and finally, another researcher blind to the intervention will analyse the data to obtain the results.|As participants complete the State-Trait Anxiety Inventory, and are found to be free of trait anxiety, and state anxiety, they will be randomised in parallel to one of the three intervention groups.|t|f|f|t
33792360|NCT01301469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33792361|NCT00817817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792362|NCT06401174|RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE||Step wedge trial with 5 six-month steps, three clinics at a time, for a total of 15 clinics.|f|f|f|t
33792363|NCT01319435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792364|NCT03419208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095708|NCT06134414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095709|NCT02931500|||COHORT||RETROSPECTIVE|||||||
33710530|NCT04030611|||CASE_CONTROL||PROSPECTIVE|||||||
33710531|NCT06243263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants with bifocal mandibular fractures will be enrolled in the study (a fracture should be located on the dentate portion of the right hemi-mandible, and a second fracture located on the dentate portion of the left hemi-mandible). Each patient will receive either a right or left inferior alveolar nerve block with bupivacaine.|t|f|t|f
33710532|NCT02071121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710533|NCT00120835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710534|NCT06091631|RANDOMIZED|PARALLEL||OTHER||SINGLE|the participant will not know whither a magnesium sulfate inhalation or distilled water in the vaporizer|2 groups are investigated. Each group consists of 50 patients. First group will receive magnesium sulfate inhalation . The other group will receive distilled water inhation|t|f|f|f
33710535|NCT01528670|||OTHER||PROSPECTIVE|||||||
33710536|NCT03456050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome provider masked about the outcomes||t|t|f|f
33710537|NCT01839045|||CASE_ONLY||PROSPECTIVE|||||||
33710538|NCT00279591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710539|NCT02786797|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33710540|NCT00963196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33710541|NCT01581814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710542|NCT02881437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710543|NCT00567294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710544|NCT05956496|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a split-mouth design randomized, prospective trial designed to compare two standard of care techniques.||||
33710545|NCT05741632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant will be masked receiving treatment, post operative eye drops of both arms is the same. Subject allocation is blinded to investigator and outcomes assessor.|First group will receive Moxifloxacin intracameral during surgery Second group will receive Levofloxacin intracameral during surgery|t|f|t|t
33710546|NCT03947372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710547|NCT03087669|NA|SINGLE_GROUP||TREATMENT||NONE||"1. LVAD will have a setting of 4800 rounds per minute (RPM). Hemodynamic, echocardiographic and cerebral blood flow measurements will be performed: CO, PCWP, CVP, PAP, MAP, Peripheral and central hemoglobine oxygen saturation (SaO2 and SvO2), Heart Rate (HR), RV outflow tract Velocity Time Integral (RVOT VTI), RV and LV diameter, VTI of LVAD outflow. CBFV of right and left medial cerebral artery (RMCA and LMCA)~2. The above mentioned measurements will be repeated with LVAD settings of 5200 RPM, 5600 RPM, and 6000 RPM.~3. With the LVAD fixed to an optimized setting detected by the previous interventions, the blood pressure will be adjusted to MAP 60 mmHg. The above mentioned measurements will be repeated.~4. Using Noradrenaline the MAP will be adjusted to 70mmHg, 80 mmHg and 90 mmHg. At steady state for each level of MAP with a fixed LVAD flow, all the above mentioned measurements will be repeatedly performed."||||
33710548|NCT03204903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham laser acupuncture: laser acupuncture without laser output.|Subjects with dry eye are enrolled at two ophthalmic centers and randomly assigned to a laser acupuncture group and control group under conventional treatment with artificial tears. The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using verum or sham laser acupuncture during 3 sessions per week. After 4 and 12 weeks of treatment, the differences in the Tear film break-up time, Schirmer test, visual analogue scale, Ocular Surface Disease Index of the patients are analyzed, and compared between the laser acupuncture and control groups using paired t-test and one way ANOVA.|t|f|f|t
33710549|NCT04736420|||COHORT||RETROSPECTIVE|||||||
33710550|NCT04966715|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710551|NCT04403477|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm-A: Standard supportive treatment; Arm-B: Standard supportive treatment + CP 200 ml; Arm C: Standard supportive treatment + CP 400 ml||||
33710552|NCT01842776|||COHORT||PROSPECTIVE|||||||
33710553|NCT02923934|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study, all patients receive the same treatment as per the protocol.|||||
33710554|NCT05315128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded||t|t|f|f
33710555|NCT01296620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710556|NCT04370574|||CASE_ONLY||PROSPECTIVE|||||||
33792365|NCT02205086|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792366|NCT04671641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792367|NCT02692742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33792368|NCT05236491|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801916|NCT03697707|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||First 10 patients will get the lowest dose and next 10 patients will receive the highest dose||||
33801917|NCT00731237|||COHORT||PROSPECTIVE|||||||
34095710|NCT03177850|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095711|NCT01158768|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34095712|NCT05486702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095713|NCT04937530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095714|NCT01149785|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34095715|NCT01926392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095716|NCT03017664|||COHORT||PROSPECTIVE|||||||
33792369|NCT04840862|NA|SINGLE_GROUP||OTHER||NONE||A single group of subjects will receive a single dose of trikafta (orange tablet) in period 1. After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on day 1 through 17 and a single dose of trikafta (orange tablet) on day 15 in period 2.||||
33792370|NCT01726530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792371|NCT06256211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates|Neonates with PDA|f|f|f|t
33792372|NCT01413594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792373|NCT06212167|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33710557|NCT00902915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710558|NCT04748120|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be informed regarding the treatment they receive at the time of randomization.|This will be a prospective, non-blinded, pilot randomized controlled trial comparing operative to non-operative management of acute appendicitis and acute cholecystitis in patients with mild to moderate COVID-19 infection. This will be a two-arm trial with intervention 1: intervention 2 allocation ratio of 1:1.||||
33710559|NCT00222794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710560|NCT04833010|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33710561|NCT01276132|||COHORT||PROSPECTIVE|||||||
33710562|NCT03281577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710563|NCT01927237|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33710564|NCT05244785|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33710565|NCT04991285|||CASE_ONLY||CROSS_SECTIONAL|||||||
33710566|NCT03244215|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710567|NCT05832385|||COHORT||PROSPECTIVE|||||||
33710568|NCT01192516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710569|NCT02079545|RANDOMIZED|PARALLEL||||NONE||||||
33710570|NCT05027100|NA|SINGLE_GROUP||TREATMENT||NONE||Safety and effectiveness of tislelizumab combined with anlotinib and 2-cycle irinotecan monotherapy as second line treatment of small cell lung cancer||||
33710571|NCT02075710|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33710572|NCT01002027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710573|NCT05279443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710574|NCT00522197|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33710575|NCT01756547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33710576|NCT00590005|||COHORT||PROSPECTIVE|||||||
33710577|NCT02069717|||CASE_ONLY||PROSPECTIVE|||||||
33710578|NCT03425747|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710579|NCT02737293|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33710580|NCT05048784|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33710581|NCT05973500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710582|NCT06451094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710583|NCT03217175|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The study will be performed in single-blind fashion in that the participant will not know whether the bionic pancreas glucagon pump is filled with glucagon or placebo during the exercise visits. Study staff will fill the tandem t:slim glucagon pump with either glucagon or placebo according to the subject's randomization order. The subject will not be aware of their randomization. New infusion sets for both the glucagon/placebo and insulin pumps will be placed using an FDA approved steel cannula infusion set.|Once the subject has been enrolled and eligibility of subjects has been established, subjects will be randomized to one of the possible two visit-orders. In random order, subjects will complete an insulin only exercise visit and a bi-hormonal exercise visit. The outpatient run-in period for both exercise visits will use the bi-hormonal bionic pancreas.|t|f|f|f
33710584|NCT04047745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33710585|NCT05948397|||CASE_ONLY||PROSPECTIVE|||||||
33710586|NCT03662490|||COHORT||RETROSPECTIVE|||||||
33710587|NCT05907512|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33710588|NCT04039698|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33710589|NCT02457260|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy Controls vs Heart Failure with reduced Ejection Fraction (HFrEF) vs Heart Failure with preserved Ejection Fraction (HFpEF) on four weeks of nitrite treatment tid.||||
33792374|NCT00031512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792375|NCT01021865|||CASE_CONTROL||PROSPECTIVE|||||||
33792376|NCT03119636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792377|NCT02466672|||COHORT||PROSPECTIVE|||||||
33792378|NCT03140579|||COHORT||PROSPECTIVE|||||||
33792379|NCT00800163|NA|SINGLE_GROUP||||NONE||||||
33801918|NCT00434304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801919|NCT02680457|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33792380|NCT05482854|NA|SINGLE_GROUP||OTHER||NONE||"The trial will be a pilot proof of concept, one arm, multicenter, nested in the ANRS CO6 PRIMO Cohort, in which the intervention is treatment interruption (of at least 6 months)."||||
33792381|NCT03479736|||OTHER||RETROSPECTIVE|||||||
33792382|NCT02067026|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33792383|NCT04742842|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Non-blind staff preparing and administering vaccine or placebo do not participate in any other aspects of the study. Remaining trial staff and participant are blinded.||t|f|t|t
33792384|NCT04704037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33792385|NCT02221219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792386|NCT04128436|NA|SINGLE_GROUP||OTHER||NONE||||||
33792387|NCT02251613|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33792388|NCT06044545|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A total of 84 people, 42 in the experimental group and 42 in the control group, will be included in the study.|t|f|t|t
33792389|NCT04960176|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33792390|NCT05692947|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each athlete will be asked to exercise for 45 minutes in a hot/dry condition (38 degrees Celsius and 10-20% relative humidity) and a hot/humid condition (28 degrees Celsius and 80-100% relative humidity). Experimental sessions will occur at least seven days apart and participants will be randomly assigned to which condition they experience first.||||
33792391|NCT02770196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792392|NCT06378528|NA|SINGLE_GROUP||TREATMENT||NONE||single group, open label, pilot study||||
33792393|NCT00162331|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792394|NCT01957319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792395|NCT03665701|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33792396|NCT06281431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792397|NCT01777893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792398|NCT05672797|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33792399|NCT05924074|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792400|NCT00005786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792401|NCT06553521|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33792402|NCT05744206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792403|NCT04651244|||COHORT||PROSPECTIVE|||||||
33792404|NCT06182917|||CASE_ONLY||PROSPECTIVE|||||||
33792405|NCT05438537|||COHORT||PROSPECTIVE|||||||
33792406|NCT02008084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792407|NCT02188199|||COHORT||PROSPECTIVE|||||||
33792408|NCT02378155|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792409|NCT05923762|||COHORT||CROSS_SECTIONAL|||||||
33792410|NCT02168751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792411|NCT01787266|||COHORT||PROSPECTIVE|||||||
33792412|NCT00179335|||CASE_ONLY||PROSPECTIVE|||||||
33792413|NCT02423135|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33792414|NCT05582057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The current study is a two-wave randomized controlled trial that employs a 2 (group - between participants) by 2 (time - within participants) mixed measures design to assess a brief online strength-based parenting program.||||
33792415|NCT03342872|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a cluster randomized trial testing two additive implementation strategies for installing FBS quality improvement procedures in ASU outpatient treatment. Nine ASU treatment sites will be yoked and randomized into three conditions to enhance ecological validity; 1) Core Training Only; 2) Core Training and Facilitation; and 3) Control (no intervention). The implementation strategies (i.e., Core Training Only, Core + Facilitation), are system-level strategies for translating evidence-based interventions into multi-site service settings.||||
33792416|NCT00402155|||CASE_CONTROL||PROSPECTIVE|||||||
33792417|NCT02964780|||CASE_CONTROL||PROSPECTIVE|||||||
33792418|NCT06039852|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33792419|NCT04484402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095717|NCT02352142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095718|NCT02919345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095719|NCT01968785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095720|NCT00005940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095721|NCT05573360|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095722|NCT04483947|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The study will be blinded for all study site personal including the principal investigator during the clinical conduct of a given cohort. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study.||t|f|t|f
34095723|NCT06354088|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34095724|NCT00420836|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792420|NCT05259683|||COHORT||PROSPECTIVE|||||||
33792421|NCT00602264|||CASE_CONTROL||PROSPECTIVE|||||||
33792422|NCT01606163|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33792423|NCT01845467|||COHORT||PROSPECTIVE|||||||
33792424|NCT03900819|||CASE_ONLY||CROSS_SECTIONAL|||||||
33792425|NCT05647967|||COHORT||PROSPECTIVE|||||||
33792426|NCT01819493|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33792427|NCT03145935|||COHORT||PROSPECTIVE|||||||
33801920|NCT00003834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801921|NCT00785915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095725|NCT02056132|||COHORT||PROSPECTIVE|||||||
34095726|NCT00003685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710590|NCT05174897|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The aim of this study is to evaluate the effect of emotional liberation technique (EFT) in reducing fear and pain during intravenous catheterization in children aged 10-14 years who applied to the emergency department.|The research was planned as a randomized controlled study to examine the effect of the emotional freedom technique used in intravenous catheter applications in the pediatric emergency on fear and pain in children aged 10-14 years. The entire sample was numbered from 1 to 70, and odd numbers were assigned to the control group and even numbers to the intervention group. Randomization was performed by an independent nurse other than the researcher.|f|f|f|t
33710591|NCT02774525|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33710592|NCT03695120|RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects will be randomized into a control group or variable group with an approximate 50/50 randomization. The control group will consist of subjects receiving ACEIs/ARBs. The variable group will consist of subjects that will not receive ACEI/ARBs during the first 72 hours of admission.||||
33710593|NCT05812456|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|"this is a double-blinded study (investigator-outcome assessor) this is a double-blinded study, for both the investigator and outcome assessor, as the investigator will be responsible for collecting the sample and preparing the sample for the experiment.~The outcome assessors will be blinded during the intervention application. as he/she will be responsible for analyzing the results of each group in the experiment."||f|f|t|t
33710594|NCT04802291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|concurrent treatments different in subject matter but equal in nonspecific treatment effects|experimental group and an attention control group|t|f|f|f
33710595|NCT05742100|||COHORT||RETROSPECTIVE|||||||
33710596|NCT00187369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710597|NCT02517567|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33710598|NCT03274128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710599|NCT00777608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710600|NCT03102372|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blinded|Randomized single blinded, controlled intervention trial|t|f|f|f
33710601|NCT02352350|||OTHER||PROSPECTIVE|||||||
33710602|NCT05378204|NA|SINGLE_GROUP||OTHER||NONE||||||
33710603|NCT04849598|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710604|NCT03888456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|participants will be blindly assigned to study or control arm using a computer-based random sequence generation and seal envelop|randomised placebo controlled crossover study|t|f|f|t
33710605|NCT05613595|RANDOMIZED|PARALLEL||TREATMENT||NONE||Present study will be conducted on caregivers of Cerebral palsy children. It will be conducted in four phases. In phase I, Urdu translation \& adaptation of Caregiver Difficulties Scale (CDS) and Positive Psychotherapy (PPT) manual will be done. .||||
33710606|NCT04670848|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33710607|NCT01455259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710608|NCT03009578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710609|NCT05961085|||COHORT||PROSPECTIVE|||||||
33710610|NCT01872377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710611|NCT03379805|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710612|NCT01604174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710613|NCT05288530|||OTHER||CROSS_SECTIONAL|||||||
33710614|NCT05850546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710615|NCT06242951|||CASE_CONTROL||RETROSPECTIVE|||||||
33710616|NCT02937909|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33710617|NCT01294267|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33710618|NCT03415217|NA|SINGLE_GROUP||OTHER||NONE||||||
33710619|NCT05368571|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Unique client ID numbers will be assigned to each program e.g. 2000 series, 3000 series, etc. Using RedCAP, each program's ID numbers will be randomly assigned to an intervention condition in advance. The condition assigned to each client ID number will be placed into an opaque envelope and these envelopes will be included in the intake packets for each new participant. The envelope with the condition assignment will be opened by the assessor after the conclusion of the assessment. Therefore, assessor, CHOICES-TEEN interventionist and study staff delivering the attention control condition will all be blind to condition during the intake assessment. Follow-up assessments will be done by study staff who are not providing the intervention.|Young women recruited from the four programs administered by HCJP will be randomized to the CHOICES-TEEN (CT) condition or the Attention Control (AC) condition. Randomization will be stratified by program such that women within each program will have an equal probability of being assigned to the CT or the AC condition.|t|f|f|t
33710620|NCT05657834|NA|SINGLE_GROUP||OTHER||NONE||||||
33792428|NCT03408925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Test assessors and data collectors will be blinded to treatment allocation. The randomized phase will be unblinded after 14 weeks of data collection and the long-term follow-up (4 months) will be conducted by test assessors blinded to treatment allocation.|RCT, two groups (intervention/control)|f|f|t|t
34095727|NCT01028053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095728|NCT02015715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095729|NCT03298100|||COHORT||PROSPECTIVE|||||||
34095730|NCT04180878|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095731|NCT04324697|NA|SINGLE_GROUP||TREATMENT||NONE||Reconstruction of the localized deficient anterior maxilla using an allograft cortical bone plate, which was fixed at a distance from the alveolar ridge using two micro-screws, and the created gap between the allograft plate and the alveolar ridge was filled with autogenous cortical bone chips harvested intraorally using a bone scrapper.||||
34095732|NCT02510482|||OTHER||PROSPECTIVE|||||||
34095733|NCT00294567|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095734|NCT05079087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095735|NCT05376748|||COHORT||PROSPECTIVE|||||||
34095736|NCT01727154|||CASE_ONLY||PROSPECTIVE|||||||
34095737|NCT04935619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095738|NCT05687565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095739|NCT02413346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095740|NCT01486394|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34095741|NCT00999011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34095742|NCT01298466|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095743|NCT02717962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095744|NCT06389162|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind||t|f|t|t
34095745|NCT01420978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095746|NCT04257617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095747|NCT01854112|||CASE_ONLY||RETROSPECTIVE|||||||
34095748|NCT02614027|||COHORT||CROSS_SECTIONAL|||||||
34095749|NCT02006446|||COHORT||PROSPECTIVE|||||||
34095750|NCT05738889|||COHORT||PROSPECTIVE|||||||
34095751|NCT04942210|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be performed in a modified double-blind fashion: Investigators, Sponsor, and study staff who conduct the safety assessment and the participant will not know which vaccine is administered.||t|t|t|t
34095752|NCT05378542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Stratified block randomization will be used to avoid selection bias. In this study on application bias, researcher and participant blinding will not be done. Because the researcher will make the application himself and placebo cannot be used in the intervention.~Data collection forms to prevent detection bias will be applied online through Google Forms® independently of the researcher.~The data obtained from the research aimed at preventing reporting bias will be coded as A and B by an independent researcher and transferred to the SPSS program. Analysis of the data will also be done by an independent statistician.~In order to prevent attrition bias, Intention to Treat Test will be used in the sample group in case of missing/subtracting or not completing the post-tests."|The research is a single center, parallel group, stratified block randomized controlled experimental study.|t|f|f|t
34095753|NCT00731536|||CASE_ONLY||RETROSPECTIVE|||||||
34095754|NCT02242006|||COHORT||PROSPECTIVE|||||||
34095755|NCT00586547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095756|NCT00303628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095757|NCT00945620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095758|NCT01374789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095759|NCT00189514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095760|NCT01646216|NA|SINGLE_GROUP||TREATMENT||NONE||Split belt treadmill||||
34095761|NCT03338023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095762|NCT01155609|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34095763|NCT03123107|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095764|NCT05142085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The treatments are made in an independent laboratory that has a white area for packaging the placebos and the treatments with a label that is kept in a database on this site and, in its printed version, in another center.~Boxes are prepared with a content of 5 treatments (2 placebos for 3 active ingredients)"|Double-blind, placebo-controlled clinical trial|t|t|t|t
34095765|NCT05554055|||COHORT||PROSPECTIVE|||||||
34095766|NCT05241210|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple successive arms testing new feedback options||||
34095767|NCT04111783|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Volunteers and data collectors was masked||t|f|t|t
34095768|NCT02369926|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34095769|NCT04854590|||COHORT||PROSPECTIVE|||||||
33934800|NCT06409104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients will be randomly assigned into two equal comparable groups using computer- generated random numbers in opaque closed envelopes, each of which will include 101 patients. Randomization will be done by statistician and each group of the patient will revealed only when the included patient is transferred to preanesthetic room.|"* To compare hemodynamic profile of dexmedetomidine and Propfol during sedation in patients undergoing ERCP.~* To study both agents effect on respiratory complications.~* To demonstrate the effect of both drugs on cognitive functions.~* To assess the effect of both drugs on duration of procedure and number of interruptions."|t|f|t|f
33934801|NCT04146129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934802|NCT01003067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934803|NCT04383535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacist will be unblinded. The study intervention will be covered with an opaque development in order to ensure blinding of the intervention arm.|Multicenter randomized (2:1, 222 plasma 111 placebo), double-blind, placebo-controlled clinical trial|t|t|t|t
33934804|NCT05440344|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33934805|NCT03520894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934806|NCT05395728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A single person blinded in the study will draw the groups.|"Randomized clinical trial. Group 1: deflate the cuff at the beginning of the weaning protocol from mechanical ventilation.~Group 2: deflate after complete weaning from mechanical ventilation."|f|f|t|f
33934807|NCT02044367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934808|NCT02721654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934809|NCT03946644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The blinding of the patients is facilitated by the same mode schedule and the same treatment performance for both allocations.~The patients will not be informed of their treatment allocation. The clinical investigator who will prepare the follow-up investigations will not have information about treatment allocation too. The blinded investigator will not have access to the full documentation of the study and to randomizing data."|"At day 0 (day of EVLA), 7-14 days after inclusion of the patients, patients will be randomized with the online randomization program Randomizer (https://www.meduniwien.ac.at/randomizer/web/login.php).Patients will be randomized to one of the following two groups:~* EVLA with keeping of security distance of 2cm to the SFJ~* EVLA without keeping a distance tot he SFJ"|t|f|t|f
34012598|NCT05842967|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Substudy A is double blind therefore all parties (participant, site staff and sponsor) will be blinded to study intervention.~Substudy B is open-label therefore no blinding requirements are in place since all participants will receive RSVpreF."|"Substudy A: Phase 3, multicenter, randomized, double-blinded, placebo-controlled study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to \<60 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions. Approximately 675 participants ≥18 to \<60 years of age considered at high risk of RSV disease due to certain chronic medical conditions, excluding immunocompromising conditions, will be randomized to receive a single 120-µg dose of RSVpreF or placebo in a 2:1 ratio.~Substudy B: Phase 3, single-arm, open-label, multicenter study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in immunocompromised adults. Approximately 200 immunocompromised adults ≥18 years of age will receive 2 120-µg doses of RSVpreF with an interval of 1 month. Approximately 100 participants will be ≥60 years of age and approximately 100 participants will be ≥18 to 60 years of age."|t|t|t|f
34012599|NCT01557842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012600|NCT02930291|||COHORT||PROSPECTIVE|||||||
34012601|NCT00164749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012602|NCT05557448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|placebo|test drug|t|f|t|f
34012603|NCT05811026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012604|NCT06468423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012605|NCT06304649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012606|NCT00431158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012607|NCT04854252|NA|SINGLE_GROUP||PREVENTION||NONE||Patients were randomly assigned to two anesthesia groups: opioid-containing (n=20) or opioid-free (n=20). The opioid used in the opioid-containing anesthesia group was fentanyl.||||
34012608|NCT00602134|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095770|NCT04767412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095771|NCT01787903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095772|NCT04002557|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34095773|NCT00756834|||COHORT||RETROSPECTIVE|||||||
34095774|NCT01293877|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095775|NCT06376227|||COHORT||RETROSPECTIVE|||||||
34095776|NCT03529149|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095777|NCT03661580|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a pragmatic, parallel group, randomised controlled trial assessing the efficacy of BA compared to treatment as usual (TAU) for patients with depression who are accessing Community Drugs and Alcohol Treatment.||||
34095778|NCT06341283|||COHORT||RETROSPECTIVE|||||||
34095779|NCT00003720||||TREATMENT||||||||
34095780|NCT04869930|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095781|NCT01556100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095782|NCT00057070|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34095783|NCT01594268|NA|SINGLE_GROUP||OTHER||NONE||||||
34095784|NCT05193396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34095785|NCT05166642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710621|NCT01169207|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801922|NCT03847259|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095786|NCT03705611|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||1:1:1 randomization of primary health clinics (cluster randomized trial)||||
34095787|NCT00806026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095788|NCT00425139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095789|NCT04753177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095790|NCT06103682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710622|NCT03313791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||2 groups of 10 subjects both receive a different set of 6 different dairy products. Each subject within a group will receive all treatments on the same day of the week with a 1 week washout period between treatments. Results of the two groups will be analyzed separately, and products will only be compared within the same group of subjects, treating the data as two independent studies.|f|f|t|t
33792429|NCT03502278|RANDOMIZED|PARALLEL||TREATMENT||NONE||A small RCT (N = 60) will be conducted comparing Islamic Trauma Healing in an U.S. Somali refugee sample to a waitlist control||||
34095791|NCT02869139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095792|NCT01008540|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33792430|NCT05300399|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792431|NCT05081310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934810|NCT06250504|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The statistician and clinical team will not participate in the public randomisation. The statistician will remain blinded until the analysis plan has been finalised and the database is locked. Investigators remain blinded to allocation throughout. The participants and intervention delivery teams are not blinded|A hybrid phase 3B effectiveness implementation type 1a cluster randomised control trial (cRCT)|f|f|t|t
33934811|NCT02921906|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33710623|NCT00836485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710624|NCT01063868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710625|NCT00682162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33710626|NCT00486200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710627|NCT03833245|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33792432|NCT01596504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792433|NCT03484585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934812|NCT01739374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934813|NCT02698852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934814|NCT05126017|||COHORT||PROSPECTIVE|||||||
33934815|NCT05077280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934816|NCT01446549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934817|NCT02419586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33934818|NCT03276260|||COHORT||CROSS_SECTIONAL|||||||
33934819|NCT00593541|||CASE_CONTROL||PROSPECTIVE|||||||
33934820|NCT01029665|||COHORT||PROSPECTIVE|||||||
33934821|NCT05988086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934822|NCT04474392|||COHORT||PROSPECTIVE|||||||
33934823|NCT04513106|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessors will be blinded to group assignment of participants, and the research question.|Participated elderly community centres will be assigned to intervention group or control group at a 1:1 ratio|f|f|f|t
33934824|NCT01979380|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33934825|NCT02092324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934826|NCT01069094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934827|NCT02971072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934828|NCT05752461|RANDOMIZED|PARALLEL||PREVENTION||NONE||SHR-2004 injection compared with Enoxaparin sodium injection||||
33934829|NCT03930927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934830|NCT00777257|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33934831|NCT06305923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33934832|NCT05238558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934833|NCT03414268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934834|NCT01818765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934835|NCT03824964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934836|NCT06143228|||COHORT||PROSPECTIVE|||||||
33934837|NCT01595308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934838|NCT02845440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934839|NCT01183481|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33934840|NCT02374359|||COHORT||RETROSPECTIVE|||||||
34095793|NCT03752931|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34095794|NCT00352014|||||PROSPECTIVE|||||||
33710628|NCT03170401|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33710629|NCT02264197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710630|NCT05318170|||COHORT||RETROSPECTIVE|||||||
33710631|NCT04593225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment Single-blind, parallel-group, randomized controlled trial|f|f|f|t
33710632|NCT04555291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710633|NCT01397084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095795|NCT01127061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Investigator who randomized participants was blinded to participant PHI. Investigators who interpreted all data and assessed outcomes were masked to randomization status.||f|t|t|t
33710634|NCT05443789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized placebo controlled study||||
33710635|NCT00105469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710636|NCT02495298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710637|NCT00127660|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33710638|NCT02007109|||COHORT||PROSPECTIVE|||||||
33710639|NCT03600545|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710640|NCT02498314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710641|NCT01699282|RANDOMIZED|PARALLEL||||NONE||||||
33710642|NCT02171520|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33710643|NCT05256953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients were randomly divided into two groups of 30 patients each. In the system where computer generated random numbers (SPSS v23.0, IBM, NewYork, USA) were used, ESP and GA groups were determined at a ratio of 1:1. Sealed and sequentially numbered envelopes were created. One hour before the operation, an experienced anesthesiologist, who was not involved in the intraoperative and postoperative follow-up of the patient and would only perform the block procedure, opened a sealed opaque sealed envelope to learn the group that the patient would be included in. There were two different physicians who performed intraoperative and postoperative follow-up. Both of the follow-up physicians were blind to the patient group. The care provider and investigator were also blinded to the participant.|Our study is a single center, prospective, randomized controlled, single-blinded, parallel group.|f|t|t|t
33710644|NCT05799066|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Group 1 will consist of individuals with known RAPD Group 2 will consist of individuals with no known RAPD||||
33710645|NCT02551965|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33710646|NCT04189159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We plan a randomized trial using a wait-list control group.|f|f|f|t
33710647|NCT05657444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720607|NCT03752112|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a Phase 1/2 trial to evaluate the efficacy and safety of cefixime for use in treating women with acute syphilis.~This is a randomized, non-comparative, open label study assessing the efficacy and safety of cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.To benchmark the performance of benzathine penicillin in the study population being used for cefixime, The investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin."||||
33934841|NCT00608491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934842|NCT05187494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720608|NCT01488721|||CASE_ONLY||PROSPECTIVE|||||||
33720609|NCT02547610|||CASE_ONLY||PROSPECTIVE|||||||
33934843|NCT00906828|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33934844|NCT01675323|||CASE_CONTROL||PROSPECTIVE|||||||
33934845|NCT02391298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934846|NCT02214446|||COHORT||PROSPECTIVE|||||||
33934847|NCT04990102|NA|SEQUENTIAL||TREATMENT||NONE||Dose de-escalation of CPX-351||||
33934848|NCT00878644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934849|NCT03632551|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33934850|NCT04137055|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33934851|NCT03698929|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomized, double-blind, crossover|t|f|t|f
33934852|NCT05297383|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33934853|NCT03712670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934854|NCT04498390|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33934855|NCT01100658|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33934856|NCT01930981|||OTHER||PROSPECTIVE|||||||
33934857|NCT06250933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Following recruitment, the women were divided into a study and a control group by randomization (1:2 randomization)|t|f|t|t
33934858|NCT00260936|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934859|NCT01565460|||COHORT||PROSPECTIVE|||||||
33934860|NCT04672317|NA|SINGLE_GROUP||TREATMENT||NONE||Before surgery, patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy||||
33934861|NCT02020304|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33934862|NCT06325527|||COHORT||PROSPECTIVE|||||||
33934863|NCT04285177|||COHORT||PROSPECTIVE|||||||
33934864|NCT03247218|NA|SINGLE_GROUP||TREATMENT||NONE||a single center and open label study||||
33934865|NCT05774574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind||t|f|t|f
33934866|NCT00329459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934867|NCT05071911|||OTHER||PROSPECTIVE|||||||
33934868|NCT05375240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934869|NCT05157256|||OTHER||PROSPECTIVE|||||||
33934870|NCT05554744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934871|NCT00926185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33934872|NCT03722992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934873|NCT01602744|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33934874|NCT02827487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095796|NCT04995107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statisticians and outcome assessors will be blinded to the allocation.||f|f|t|t
34095797|NCT05998499|||COHORT||PROSPECTIVE|||||||
34095798|NCT02636491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934875|NCT03971019|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open, blank controlled, single-center clinical trial. The control group used dietary intervention instead of statins.||||
33934876|NCT00991536|||CASE_ONLY||RETROSPECTIVE|||||||
33934877|NCT04468828|||COHORT||PROSPECTIVE|||||||
33934878|NCT02353325|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33934879|NCT05191381|||COHORT||PROSPECTIVE|||||||
33934880|NCT01518140|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33934881|NCT02436915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934882|NCT05391295|||OTHER||PROSPECTIVE|||||||
33934883|NCT03667573|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be masked to the dosage of transcutaneous spinal direct current stimulation (tsDCS)|Participants will be randomized to one of four different parallel groups|t|f|f|f
33934884|NCT00273806|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934885|NCT03155880|||COHORT||CROSS_SECTIONAL|||||||
33934886|NCT01165463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33934887|NCT03644316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934888|NCT03954184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934889|NCT01665040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934890|NCT00883649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934891|NCT00474136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934892|NCT05051527|||COHORT||PROSPECTIVE|||||||
33934893|NCT06286267|||COHORT||OTHER|||||||
33934894|NCT06388460|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934895|NCT01281774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792434|NCT06073158|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33792435|NCT03020108|||COHORT||PROSPECTIVE|||||||
33792436|NCT02053363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792437|NCT02469467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792438|NCT02939469|NA|SINGLE_GROUP||OTHER||NONE||||||
33792439|NCT05322824|||COHORT||PROSPECTIVE|||||||
33792440|NCT03425630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792441|NCT00479206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792442|NCT00702806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792443|NCT00109785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934896|NCT01855204|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33934897|NCT00939055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33934898|NCT04797494|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is a Randomized Controlled Trial (RCT)||||
33934899|NCT05766267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934900|NCT03844139|||COHORT||PROSPECTIVE|||||||
33934901|NCT03846076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934902|NCT02410746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934903|NCT01601873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934904|NCT00886691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934905|NCT03991468|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Adjudicators are blinded to the imaging modality.|Cases are assessed using both glass slide light microscopy and NanoZoomer digital whole slide imaging in a random order|f|f|f|t
33934906|NCT02886338|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934907|NCT03705741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Opaque sealed envelopes, which are randomly picked out before the meeting with each participant||f|f|f|t
33934908|NCT03581045|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33934909|NCT00444951|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33934910|NCT03973502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934911|NCT04017624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33934912|NCT01706068|||CASE_ONLY||RETROSPECTIVE|||||||
33934913|NCT06435494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|It is not possible to perform any blinding during collection and use of PRO data as part of the evaluation and treatment of the shoulder condition. However, following the end of PRO collection (and use), the following data collection and evaluation of the use of healthcare services and satisfaction with the treatment given will be performed with information of randomization blinded to the evaluators (VIVE).|Patients evaluated and treated for a degenerative shoulder disorder will be randomised into two groups before first evaluation. For the intervention group, Patient reported outcomes (PRO) will be a part of the evaluation and follow-up of treatment. In the control group, it will not. Evaluation with PRO will be conducted every 3 months for 2 years follow-up.|f|f|f|t
33934914|NCT03178175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012609|NCT06484322|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The feasibility study has been designed as a pilot randomized control trial embedded in a mixed method approach. Using a predefined block randomization the participants will be randomly distributed to either the experimental/ intervention group or the control group. The experimental group will receive the internet-based occupational therapy intervention 'SEE' and the control group will receive care as usual.~Data from the participants will be collected at baseline (0) and 4- and 12 months post baseline. If the intervention indicates positive benefits for the participants, the intervention will be offered for the control group at the end of the study."||||
34012610|NCT05941273|NA|SINGLE_GROUP||TREATMENT||NONE|As the IMT has a unique appearance in the eye, it cannot be masked to the Investigator or to the patient|Single site case series||||
34012611|NCT04380675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012612|NCT03927924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012613|NCT05198882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792444|NCT06491212|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Our study was planned to evaluate healthy controls and cases with pes planus.||||
33792445|NCT01036113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012614|NCT02480231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012615|NCT00316069|||COHORT||PROSPECTIVE|||||||
34012616|NCT03923699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Anesthesia practitioner un-blinded to intervention, subject blinded to intervention, data analyst blinded to intervention, ACT Clinicians un-blinded to intervention|Randomized Parallel assignment|t|f|f|f
34012617|NCT00767338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012618|NCT00349726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012619|NCT02342249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012620|NCT01019707|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34012621|NCT05497141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012622|NCT05320848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34012623|NCT00701974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012624|NCT01319201|||COHORT||PROSPECTIVE|||||||
33792446|NCT03349736|NA|SINGLE_GROUP||OTHER||NONE||A feasibility study including 250 women to assess the feasibility of performing PFMT in pregnant Nepalese women. The PFMT programme consisted of attending a minimum of four supervised PFMT follow-up visits after inclusion to the programme and to perform PFMT daily at home.||||
33792447|NCT04521192|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No Masking|Single dose of oral administration of fluzoparib capsules||||
33792448|NCT00924534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792449|NCT04935489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792450|NCT00588419|||CASE_ONLY||CROSS_SECTIONAL|||||||
33792451|NCT02371746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792452|NCT04842604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792453|NCT00114699|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33792454|NCT01556958|||CASE_CONTROL||PROSPECTIVE|||||||
33801923|NCT03251222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801924|NCT05104840|||COHORT||CROSS_SECTIONAL|||||||
33801925|NCT01261052|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33934915|NCT04739995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized controlled trial|t|t|t|t
33934916|NCT04009824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33710648|NCT03558776|RANDOMIZED|PARALLEL||TREATMENT||NONE||Blood samples will be taken at the beginning and regularly every four weeks during the 12-weeks intervention period. For all groups, the consumption of additional n-3 PUFA sources is not permitted during the entire intervention period. The study intervention will consist of a daily dose of linseed oil (LO, 10 En%) and prepared daily menu plans determining the background diet, except for the control group D. The fat composition of the developed daily menu plans (fat content 20 En%) will differ between the groups A to C. For groups A to C, the daily menu plans will ensure an adequate intake of energy and nutrients according to the guidelines of the German Society of Nutrition. Group D serves as control because in this group the background diet is not fixed by menu plans. Participants of group D must follow their normal dietary habits, i.e. a typical Western diet (LA intake is about 15 g/d (5-7 En%) / SFA intake ranges from 10 to 15 En%).||||
34095799|NCT02544724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095800|NCT00069745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095801|NCT05363800|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of HRS-3738||||
34095802|NCT06093659|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34095803|NCT05474677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095804|NCT02785705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095805|NCT02500355|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33710649|NCT06229990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710650|NCT03779802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710651|NCT02741024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710652|NCT04186520|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33710653|NCT06025097|NA|SINGLE_GROUP||TREATMENT||NONE|Care giver and patient both are known to the treatment being offered under investigation.|Single group study, to show the therapeutic effects of Combination solution on diseases in fixed time.||||
33710654|NCT03012802|||OTHER||PROSPECTIVE|||||||
34095806|NCT01802671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095807|NCT03061851|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The enrolled patients will be randomly divided into two groups: the trial group and the control group. The estimated sample size was 200 patients for each group.||||
34095808|NCT06302361|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center cohort study||||
34095809|NCT01168180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710655|NCT00752232|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33710656|NCT02634320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710657|NCT01010490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710658|NCT02305056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33710659|NCT01362985|||COHORT|||||||||
33710660|NCT02891759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33792455|NCT05998525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blinding will be double blind, since neither the patient, the responsible investigator, the radiologists and the one who will perform the statistical analysis will know to which group each patient was assigned.|Any patient presenting with a diagnosis of acute myocardial infarction with and without ST segment elevation will be explained the objective of the study and after performing percutaneous coronary intervention they will be randomized using an excel sheet to one of two groups, the intervention group will receive Dapagliflozin 10 mg every 24 hours and the control group will receive placebo. In both groups, a simple cardiotomography was performed to evaluate the calcium score and epicardial fat at baseline and after 12 months of intervention.|t|t|t|t
33792456|NCT00887835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934917|NCT06154759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The caregivers did not know which group they were assigned to.||t|f|f|f
33934918|NCT01599949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934919|NCT05233423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding was provided that included inclusion criteria and agreement to participate in the study.|This study is a parallel group randomized controlled study|t|f|f|f
33934920|NCT01846208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012625|NCT02430415|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
34012626|NCT00065455||||TREATMENT||||||||
34012627|NCT06454396|||COHORT||PROSPECTIVE|||||||
34012628|NCT03024047|||||RETROSPECTIVE|||||||
33710661|NCT05421624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomly assigned to either intervention of (1) Amped-PD, or (2) Active-Control.|f|f|f|t
33710662|NCT04343547|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720610|NCT04025307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720611|NCT03541018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012629|NCT00466973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012630|NCT04429334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012631|NCT00118378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012632|NCT06231459|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, non-controlled, before-after comparison, quasiexperimental, single-center study.||||
34012633|NCT01792960|||COHORT||PROSPECTIVE|||||||
34012634|NCT02152735|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34012635|NCT02494050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012636|NCT04531657|||COHORT||PROSPECTIVE|||||||
34012637|NCT06209801|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34012638|NCT06142370|NA|SINGLE_GROUP||SCREENING||NONE||||||
34012639|NCT04053413|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012640|NCT01435031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012641|NCT01770431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33934921|NCT03638362|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Placebo beverage was selected from commercially available, artificially flavored and colored fruit punches (Great Value fruit punch, Bentonville, AR) to match a closely as possible the color (red) of the TCJ.|Crossover Assignment In this study, the investigators recruited at-risk individuals who were overweight (25.0-29.9 kg/m2) and obese (\> 30.0 kg/m2) and likely to exhibit one or more conditions associated with MetS. In this 10-week placebo-controlled 2 x 2 crossover dietary intervention, the investigators randomized participants to consume 240 mL (8 ounces) daily of either placebo (artificial cherry-flavored, anthocyanin-free beverage) or authentic TCJ for 4 weeks, followed by a 2-week washout period, then consumption of the alternate beverage for 4 weeks. Subsequently, the investigators determined the effect of TCJ in at-risk participants on markers of inflammation, glycemia, and lipidemia.|t|f|f|f
33934922|NCT01940380|||OTHER||RETROSPECTIVE|||||||
33934923|NCT01878175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934924|NCT03219554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934925|NCT00515944|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33934926|NCT06119568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012642|NCT00513175|||COHORT||PROSPECTIVE|||||||
34012643|NCT03433365|||OTHER||PROSPECTIVE|||||||
33934927|NCT02074397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33934928|NCT01536938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934929|NCT03461705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934930|NCT04366128|NA|SINGLE_GROUP||TREATMENT||NONE|Camrelizumab, apatinib and pegaspargase indution immunotherapy|Camrelizumab, apatinib and pegaspargase||||
33934931|NCT00604357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934932|NCT06423001|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33934933|NCT00062595|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33934934|NCT03700086|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 randomized controlled trial||||
33934935|NCT00251849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33934936|NCT05949463|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33934937|NCT01834469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33934938|NCT02809391|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33934939|NCT01341860|||CASE_CONTROL||PROSPECTIVE|||||||
33934940|NCT04849676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934941|NCT05747664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934942|NCT00408772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934943|NCT00139633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934944|NCT04372979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012644|NCT03624179|||COHORT||PROSPECTIVE|||||||
34012645|NCT00576641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012646|NCT03478228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34012647|NCT03519984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012648|NCT05785689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012649|NCT04792814|||CASE_CONTROL||RETROSPECTIVE|||||||
34012650|NCT03674502|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
34012651|NCT02794155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012652|NCT04303650|||COHORT||PROSPECTIVE|||||||
34012653|NCT02740829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012654|NCT01012557|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34012655|NCT06414239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized 1:1||||
34012656|NCT03858426|||COHORT||PROSPECTIVE|||||||
34012657|NCT04781114|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34012658|NCT00644384|RANDOMIZED|||PREVENTION||DOUBLE||||||
34012659|NCT06400108|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||pre-post pilot feasibility study||||
34012660|NCT02239107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012661|NCT00359632|NON_RANDOMIZED|PARALLEL||||NONE||||||
34012662|NCT02046668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012663|NCT04119999|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34012664|NCT06265207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Since the researcher will be conducting the research, blinding will not be possible, and separate consent forms were prepared for the experimental and control groups, without specifying which group they were in, and it was planned to blind the participants in this way. In addition, in order to prevent statistical bias, it is planned to prevent bias in data analysis by coding the data as first group and second group, rather than experimental and control group, when entering the data into SPSS, and by not giving information about which group is the experiment and which is the control group.|Single Blind Parallel Group Randomized Controlled Trial|t|f|f|t
34012665|NCT02907541|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012666|NCT00969124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Open Label|||||
34012667|NCT02591576|||COHORT||RETROSPECTIVE|||||||
33934945|NCT03787901|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33934946|NCT06077136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Concealed allocation will be performed by a researcher who will not be involved in the treatment or assessment. Permuted blocks will be used to ensure an equal 1:1 allocation ratio. Due to the nature of the study, the assessor and the data analyzer will be blinded|the model of this study will be 2 parallel arms where one arm will receive regular physical therapy including exercises to the upper limb and the experimental group will receive the same physical therapy plus upper limb exercises applied using the whole body vibration device|f|f|f|t
33934947|NCT01160042|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012668|NCT00974064|||CASE_CONTROL||PROSPECTIVE|||||||
34012669|NCT03978091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012670|NCT02547402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012671|NCT01409590|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34012672|NCT01094028|RANDOMIZED|||PREVENTION||QUADRUPLE|||t|t|t|t
34012673|NCT05547334|NA|SINGLE_GROUP||TREATMENT||NONE||A non-concurrent multiple baseline design||||
34012674|NCT06446310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012675|NCT04108559|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34012676|NCT05234528|||COHORT||PROSPECTIVE|||||||
34012677|NCT00188227|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34012678|NCT02999594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012679|NCT01826461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720612|NCT03091114|||COHORT||PROSPECTIVE|||||||
34012680|NCT05636566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Sixty patients were randomized and assigned into 3 groups (n=20) each, using sealed envelope technique:~* Group (S): received sevoflurane- oxygen for induction and sevoflurane with fentanyl (Fentanyl, Janssen-Cilag, Germany) infusion for maintenance of anaesthesia.~* Group (P): received propofol (Diprivan, Astra Zeneca, Wedel, Germany) for induction followed by propofol-fentanyl infusions for maintenance of anaesthesia.~* Group (D): received dexmedetomedine (Precedex, Dexmedetomedine HCL inj.,Hospira, Inc.,Lacke Forest, USA) infusion for induction followed by dexmedetomedine-fentanyl infusions for maintenance of anaesthesia. All solutions were prepared by a team member not participating in data recording of the study."|t|f|f|f
34012681|NCT04233086|||CASE_ONLY||RETROSPECTIVE|||||||
34012682|NCT06397820|||COHORT||RETROSPECTIVE|||||||
34012683|NCT03941353|||COHORT||RETROSPECTIVE|||||||
34012684|NCT00791141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012685|NCT02980250|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34012686|NCT05946902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012687|NCT06454942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012688|NCT01129453|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012689|NCT05692284|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients in the control and intervention groups did not know which group they belonged to, only the researcher knew who was in which group, and the study was continued single-blindly by providing blinding in this way.|In the study, 60 individuals, including 1 experimental and 1 control group, were included in the study.|t|f|f|f
34012690|NCT01447134|||||PROSPECTIVE|||||||
34012691|NCT00777127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720613|NCT03471195|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33720614|NCT03540966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012692|NCT05470764|RANDOMIZED|CROSSOVER||OTHER||NONE||Two-period, two-sequence, cross-over single dose study||||
34012693|NCT03023657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012694|NCT00019643|||||PROSPECTIVE|||||||
34012695|NCT01154959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012696|NCT06496074|||COHORT||CROSS_SECTIONAL|||||||
34012697|NCT04694612|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomly assigned (1:1) to either Favipiravir or Placebo among mild cases; and Favipiravir or Remdesivir among moderate cases. Randomization will be stratified by age group (18 to 40 years, 40 to 60 years and 60 to 80 years) and comorbidity (presence or absence of self-reported diabetes, hypertension, Coronary Artery Disease, Coronary Heart Failure, Cancer or auto-immune disease). The permuted block (30 patients per block) randomization sequence, including stratification, will be prepared by a statistician using STATA-15 software. Once an eligible patient is enrolled in the participating center, the physician will call the central hotline that will inform the physician about the allocation based on the sequence. Eligible patients allocated to the respective arm will receive individually numbered packs, according to the sequence order as informed by the hotline.||||
34012698|NCT01792414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012699|NCT05991596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012700|NCT03643263|||CASE_CONTROL||PROSPECTIVE|||||||
34012701|NCT05590156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012702|NCT01164306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012703|NCT06250036|RANDOMIZED|PARALLEL||TREATMENT||NONE||A UK multicentre, prospective, randomised open label phase II proof of concept study with screen selection design. There will be two cohorts with a 1:1 randomisation||||
34012704|NCT00474435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012705|NCT00937651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095810|NCT03519607|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Participant assignment will be masked for data analysis|Comparison of distress scores between the intervention group and the control group|f|f|f|t
34095811|NCT05133570|||COHORT||PROSPECTIVE|||||||
34095812|NCT06326918|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095813|NCT04687397|||COHORT||RETROSPECTIVE|||||||
34095814|NCT01666600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095815|NCT02503930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095816|NCT03751787|RANDOMIZED|PARALLEL||TREATMENT||||||||
34095817|NCT01828684|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34095818|NCT01604200|||||PROSPECTIVE|||||||
34095819|NCT06444100|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Selected schools will be divided into two groups: an intervention group, where teachers of selected schools will receive training on child abuse, and a control group without training. A comparative analysis will then evaluate the effectiveness of the intervention by assessing teachers' knowledge and attitudes towards child abuse. A pretest will be conducted to assess the existing knowledge level and attitude of the teachers toward child abuse. A 5-hour training session, led by an expert team, will follow the pretest questionnaire administration to all participants. The training will cover the introduction, definition, risk factors, signs, symptoms, and management of child abuse. Teachers will also be educated on how to report instances of child abuse.~The training will incorporate interactive lectures, group discussions, and role-playing to effectively convey the management of child abuse. A post-test will be administered using the same questionnaires two weeks after the training"|t|f|f|f
34095820|NCT00689988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095821|NCT02571231|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095822|NCT02569242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095823|NCT03362593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095824|NCT03364010|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095825|NCT03930108|||COHORT||RETROSPECTIVE|||||||
34095826|NCT02684045|||COHORT||RETROSPECTIVE|||||||
34095827|NCT05872399|||COHORT||CROSS_SECTIONAL|||||||
33720615|NCT02677922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720616|NCT03376854|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since it will be obvious to observers of the subjects whether they are in the treatment (TH+NMB) or control groups, the study is not masked but all treatments that determine outcome are protocolized.|Randomized (1:1) control (non-blinded) trial||||
33720617|NCT04639609|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720618|NCT04739631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720619|NCT00323518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33720620|NCT02689401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720621|NCT00886392|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33720622|NCT05405192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720623|NCT03893422|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Study product was provided for each arm in identical capsules|Balanced randomization across 3 arms: formulation WB-010, formulation WB-011 and placebo|t|t|t|t
33720624|NCT04123288|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33720625|NCT05594914|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720626|NCT03736291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720627|NCT03925740|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33720628|NCT00811473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720629|NCT02755766|||COHORT||PROSPECTIVE|||||||
33720630|NCT03849859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720631|NCT02684266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720632|NCT02254928|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720633|NCT01578395|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33720634|NCT00571987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710663|NCT03164252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Surgical procedures were always performed by the same surgeon and assistant, who were unaware of the surrogate group that belonged to the patient, as well as the patient himself. This randomization was performed involving numbers and envelopes, being only the investigator's knowledge.|"The sample of this study will be composed of 60 patients between 16 and 40 years old, who need to undergo the extraction of third molars included and / or impacted. The patients will be those who voluntarily seek the Discipline of Buccomaxillofacial Surgery and Traumatology, at the State University of São Paulo Júlio de Mesquita Filho - Unesp, to perform the procedure.~This study will be a randomized, double-blind, prospective clinical trial with the following groups:~Group I (with 20 patients) - laser therapy used in the immediate postoperative period will be intraoral irradiation with 660 nm red diode laser, 30 mW power and 10 J / cm2 fluency.~Group II (with 20 patients) - laser therapy used in the immediate postoperative period will be intraoral irradiation with 660 nm red diode laser, 30 mW power and 30 J / cm2 fluency.~Group III (with 20 patients) - Control Group - Application of laser sham."|t|t|t|t
33934948|NCT03832023|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Clusters were selected among facilities participating in the first phase of the CAP-TB project following an initial facility assessment for participating in the CAP-TB project. Facilities with diagnostic and treatment capacity and detecting and minimum of 50 bacteriologically confirmed pulmonary TB cases per year in a rural/semi-rural or semi-urban setting were selected. The facilities correspond to district hospitals in Cameroon and health center IV or district hospitals in Uganda.~Twenty clusters will be randomized between the intervention and the facility-based model. The randomization unit (cluster) will be the facility where TB cases (index cases) are diagnosed and its catchment area."||||
33934949|NCT01401985|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33934950|NCT00542217|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33934951|NCT00941707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934952|NCT02736474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934953|NCT00939094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934954|NCT01728766|||COHORT||PROSPECTIVE|||||||
33934955|NCT05754372|||COHORT||PROSPECTIVE|||||||
33710664|NCT01720121|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
33710665|NCT05349994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design was a before and after study. A control group was included for three months and received standard care. An intervention group was then included for six months and received extended amount of physical therapy.||||
33710666|NCT00365729|||CASE_CROSSOVER||PROSPECTIVE|||||||
33710667|NCT01236599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710668|NCT04764578|||COHORT||PROSPECTIVE|||||||
33710669|NCT05157230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33710670|NCT05038189|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33710671|NCT02950532|||COHORT||RETROSPECTIVE|||||||
33710672|NCT04006574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single Blind Randomized Control Trial|t|f|f|f
33710673|NCT02132091|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33710674|NCT02408315|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33710675|NCT00574132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710676|NCT00637338|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33710677|NCT06217198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial||||
33710678|NCT03833115|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot descriptive study||||
33710679|NCT01032005|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33710680|NCT01211327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710681|NCT00630981|||||PROSPECTIVE|||||||
33710682|NCT03143894|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind|Randomized, sham-controlled, double-blind, cross-over|t|t|t|t
33710683|NCT01180946|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33710684|NCT00122668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710685|NCT03938168|||COHORT||PROSPECTIVE|||||||
33710686|NCT05581420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710687|NCT00453297|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33710688|NCT04206501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710689|NCT04654676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710690|NCT03129698|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with untreated extensive-stage small-cell lung cancer||||
33710691|NCT05779995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720635|NCT05157490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720636|NCT03303079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720637|NCT05487326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720638|NCT01982747|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34012706|NCT03452072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded physician will assess outcomes from pictures|"The protocol will begin post-surgery. Eligible subjects will be assigned by computer-based randomization to case (0.25% timolol gel) or control (standard of care \[SOC\]) group and treated as follows:~Case group:~1. Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied~2. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing~3. Daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed)~SOC group:~1. Vaseline will be applied to wound bed immediately after surgery before dressing is applied~2. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing~3. This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed)"|f|f|f|t
34012707|NCT03204071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012708|NCT04713540|||COHORT||RETROSPECTIVE|||||||
34012709|NCT03738176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||sesame oil in orabase(80 gm CMC -20 gm sesame oil)|f|f|f|t
34012710|NCT01578668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792457|NCT03574844|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, double-blind, placebo-controlled, 3 parallel-arms, pilot clinical study|t|t|t|t
33792458|NCT02460952|||CASE_CONTROL||RETROSPECTIVE|||||||
33792459|NCT02118740|||OTHER||PROSPECTIVE|||||||
33934956|NCT03857464|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|Not possible as integrating diagnostics into the hospital system.|"Study design is a two-period, two-intervention, cluster randomized crossover (CRXO) design, in which each cluster (ward) receives each of the two interventions in a separate 6-month period of time leading to two cluster-periods. The order in which the interventions are delivered to each cluster (ward) is randomized to control for potential period effects. Within Foothills Hospital there are 40 wards which will be observed over a 12-month period. Each ward is randomly assigned to administer one of the two interventions for the first 6-month period (Period 1). In the second 6-month period (Period 2), the ward will administer the other intervention. Within each ward (cluster) there are two cluster-periods."||||
33934957|NCT04739540|||COHORT||PROSPECTIVE|||||||
33934958|NCT05529862|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33934959|NCT04671095|||COHORT||PROSPECTIVE|||||||
33934960|NCT05008549|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||A randomized, double-blinded, placebo-controlled, crossover study, to assess the synergistic effects of a cranberry beverage on cognitive function in healthy adults aged 18-45.|t|t|t|f
34012711|NCT03903159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012712|NCT00252174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012713|NCT06415617|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34012714|NCT04821765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012715|NCT00303875|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34012716|NCT04153448|||CASE_CONTROL||PROSPECTIVE|||||||
33934961|NCT03807128|||COHORT||PROSPECTIVE|||||||
33934962|NCT01961999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934963|NCT02927535|||COHORT||PROSPECTIVE|||||||
33934964|NCT02325128|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33934965|NCT02369211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934966|NCT00376675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33934967|NCT05823376|||COHORT||PROSPECTIVE|||||||
33934968|NCT01679704|NA|SINGLE_GROUP||||NONE||||||
33934969|NCT04760691|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33934970|NCT00058773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934971|NCT02578095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934972|NCT04684849|||CASE_CONTROL||PROSPECTIVE|||||||
34012717|NCT02960438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012718|NCT04840784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012719|NCT03654664|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34012720|NCT06027541|||COHORT||PROSPECTIVE|||||||
34012721|NCT00951626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34012722|NCT06533462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is blinded and neither participants nor the study team physicians know who is receiving multiallergen powder or placebo. Only few persons outside the study has this knowledge.||t|t|t|f
34012723|NCT01630174|||COHORT||PROSPECTIVE|||||||
34012724|NCT02692482|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012725|NCT01312311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710692|NCT03975608|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The design of this project will be a non-randomised and non-controlled before-and-after study in which observations will be made only in a patient group that receives the intervention. No control group will be recruited. Assessments will be conducted at three measurement points: T0 (before the intervention), T1 (at the end of the intervention), T2 (3 months after T1).||||
33710693|NCT01850771|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33710694|NCT00496054|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33710695|NCT01312701|||COHORT||PROSPECTIVE|||||||
33710696|NCT02095574|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710697|NCT04614740|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm clinical study||||
33710698|NCT03636061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792460|NCT00711919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33934973|NCT06336447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to study randomization|Randomized controlled trail.|f|f|f|t
34012726|NCT03623464|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012727|NCT00957619|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34012728|NCT06330519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34012729|NCT06004778|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34012730|NCT02704234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34012731|NCT03274622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessors and coders are blind to treatment assignment. This will be achieved by using different people to conduct the treatment vs assessment and coding. Additionally, these different staff members have offices on different floors.||f|f|t|t
34012732|NCT04910516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||"It was aimed to measure the anxiety and covid-19 fears of the Emergency Department nurses. The number of people to be included in the study was determined to be working with 44 nurses in the experimental group and 44 nurses in the control group in the calculation made for a maximum 5% type I error and at least 80% power. The determination of the sample size and the creation of the Randomization Table was calculated using the www.e-picos.com, NY New York, program."|t|t|f|f
34095828|NCT04086459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Either the participants, care providers, or outcomes assessors did not know which repetitive transcranial magnetic stimulation is active or sham.|Three groups (two groups of heroin addiction during methadone maintenance treatment and one healthy control group) were included in this study design. One heroin addiction group was administered active repetitive transcranial magnetic stimulation (rTMS) while another heroin addiction group was administered sham. The healthy control group was not given rTMS, just as control.|t|t|f|t
34095829|NCT05157763|NA|SEQUENTIAL||TREATMENT||NONE||||||
34095830|NCT06235541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095831|NCT01243125|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34095832|NCT03688113|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095833|NCT01087450|||OTHER||PROSPECTIVE|||||||
34095834|NCT02923180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095835|NCT05018559|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095836|NCT03899597|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095837|NCT03682081|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33710699|NCT03429686|NA|SINGLE_GROUP||TREATMENT||NONE||A single group pre-post intervention feasibility study with process evaluation. Data will be collected from residents and staff in Jordanian care homes through questionnaires, from care home records, and qualitative interviews.||||
34095838|NCT04319536|||COHORT||PROSPECTIVE|||||||
34095839|NCT05399355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigational Drug Service will create the randomization tables and provide the investigators with the appropriate device (active or sham), leaving all participants, investigators, and the statistician masked to treatment group assignment.|Parallel Assignment: Randomized, Triple-Masked, Placebo-Controlled, Parallel-Arm Human Subjects Clinical Trial|t|t|t|t
33710700|NCT06037395|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|A Randomized, Double-blind|Two-arm, Parallel group|t|t|t|t
33710701|NCT04258722|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors will be masked to group allocation.||f|f|f|t
33710702|NCT03125317|||OTHER||PROSPECTIVE|||||||
33710703|NCT03067168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will not know if they received an injection of bupivacaine or placebo, i.e., normal saline after completion of surgery. The surgeon, as well as any investigator or study personnel, will be blinded to injection type.||t|t|t|t
33710704|NCT04932551|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33710705|NCT05832359|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33710706|NCT02427022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33710707|NCT05070299|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33710708|NCT03438344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33710709|NCT00883805|||COHORT||PROSPECTIVE|||||||
33710710|NCT03951402|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This study was a randomized, double-blind, double-dummy, placebo- and moxifloxacin-controlled, 4-way cross-over study. The randomization was in the ratio 1:1:1:1. In all treatments the amount of administered tablets and capsules were the same. At the lower dose step the amount of tablets/capsules was adjusted with matching placebos. All study procedures were the same, irrespective of whether active compound, positive control or placebo was administered.|t|f|t|f
33710711|NCT04584645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"A set of existing Achievement members who have previously self-reported to meeting the inclusion criteria will be tagged for study inclusion, termed participants. Since participants will be blinded to their study participation status, participants will not be asked to take any action to enroll in the study. In order to identify a target list of participants, Evidation Health will leverage already permissioned information from Achievement members, including data on their cardiovascular diagnoses, age, sex/gender, race/ethnicity, and country of residence."||t|f|f|f
33710712|NCT01520012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710713|NCT04469036|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge||||
33710714|NCT01829373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710715|NCT01084785|||COHORT||PROSPECTIVE|||||||
33710716|NCT05010421|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized open single center study||||
33710717|NCT06036212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded to study participant. The study participants will not be aware of the treatment received. For those not being put under general anesthetic during the procedure, a screen will be put up between the subjects face and the ongoing procedure and associated platforms/instrumentation so that they are unable to see any of the procedure and are unable to guess whether they are having robotics assisted surgery or conventional surgery. Extra incisions (maximum of 4 based on approach that the operating surgeon uses) are required to conduct robotic assisted surgery, those subjects receiving conventional surgery will receive sham incisions.||t|f|f|f
33710718|NCT05273918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710719|NCT06361485|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Prospective, open label, non-controlled Pilot study||||
33720639|NCT04039412|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled (interventional) study conducted at Zagazig University Hospital, internal medicine department clinic||||
33720640|NCT03070379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33720641|NCT03192943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095840|NCT03192020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors who measured index, middle, ring and small fingers' flexion and extension degrees were blinded. Patients had opaque gloves in their hand when visiting the blinded outcome assessor. Due to the nature of the treatments it was not possible to blind patients, leading investigators or research assistants. To minimize any bias in interpreting the findings, we blinded treatment allocation in the draft results manuscript with groups labelled as A, B and C. The writing committee reached consensus on the interpretation of the findings prior to being unblinded to group assignments.|This is a multicenter, randomized, outcome assessor blinded, three parallel armed (1:1:1), superiority trial comparing needle fasciotomy, collagenase injection and surgery as primary intervention for people with treatment-naïve Dupuytren's contracture with a five-year follow-up.|f|f|t|t
34095841|NCT04813458|||COHORT||CROSS_SECTIONAL|||||||
34095842|NCT01574521|||CASE_CONTROL||PROSPECTIVE|||||||
34095843|NCT01793922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095844|NCT02663167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095845|NCT01839266|||COHORT||RETROSPECTIVE|||||||
34095846|NCT01263379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095847|NCT05025371|||COHORT||RETROSPECTIVE|||||||
34095848|NCT04359615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.|t|t|t|f
34095849|NCT04920994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095850|NCT01023464|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095851|NCT04831385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34095852|NCT02247856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095853|NCT03297827|||COHORT||PROSPECTIVE|||||||
34095854|NCT01304667|||COHORT||RETROSPECTIVE|||||||
34095855|NCT05860530|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095856|NCT02846727|||CASE_CONTROL||PROSPECTIVE|||||||
34095857|NCT02056522|||CASE_ONLY||PROSPECTIVE|||||||
34095858|NCT04626778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A blinded randomized controlled parallel group design trial|Each subject will be randomized to receive one of the two possible study products.|t|f|t|f
34095859|NCT00971503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095860|NCT01196234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095861|NCT01827943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095862|NCT03150797|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34095863|NCT00509600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095864|NCT01762007|||CASE_CONTROL||PROSPECTIVE|||||||
34095865|NCT04797728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095866|NCT05105932|||CASE_CONTROL||PROSPECTIVE|||||||
34095867|NCT01653262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095868|NCT01362270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34095869|NCT01183286|RANDOMIZED|PARALLEL||||NONE||||||
34095870|NCT06388213|||COHORT||PROSPECTIVE|||||||
34095871|NCT01981993|||COHORT||PROSPECTIVE|||||||
34095872|NCT00394472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095873|NCT01229553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095874|NCT05036460|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34095875|NCT05838313|NA|SINGLE_GROUP||OTHER||NONE||||||
34095876|NCT01959971||CROSSOVER||BASIC_SCIENCE||SINGLE||Single-sequence crossover|t|f|f|f
34095877|NCT05427916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095878|NCT06520423|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Eligible hospitals were randomly assigned in a 1:1 ratio to two intervention groups. Two treatment protocols were implemented in two groups of hospitals. When one group reaches a predetermined number of enrollees, hospitals in both groups will cross over to implement the alternate intervention.|f|f|t|t
34095879|NCT00693303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095880|NCT04591132|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095881|NCT01956942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095882|NCT01177488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095883|NCT00559351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095884|NCT00351104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095885|NCT04242602|NA|SINGLE_GROUP||OTHER||NONE||||||
34095886|NCT02774720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095887|NCT03168087|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095888|NCT06194669|||CASE_CONTROL||PROSPECTIVE|||||||
33934974|NCT05011409|||CASE_ONLY||PROSPECTIVE|||||||
33934975|NCT00230373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934976|NCT03986476|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33934977|NCT04573491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934978|NCT05661175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind trial in which participants were unaware of the study group and the intervention.|Participants are randomly assigned to an experimental or control group in parallel.|t|f|f|f
33934979|NCT05310942|||CASE_CONTROL||PROSPECTIVE|||||||
33934980|NCT00996541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33934981|NCT00481377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934982|NCT02932072|||CASE_ONLY||PROSPECTIVE|||||||
33934983|NCT02109549|||COHORT||RETROSPECTIVE|||||||
33934984|NCT02329860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33934985|NCT03774706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used|double-blind placebo randomized controlled trial|t|t|t|t
33934986|NCT04699240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934987|NCT05162833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934988|NCT00658450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934989|NCT01222416|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33710720|NCT03748797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research assistant who was blinded for the participants grouping was responsible for data collection.|"Exercise group: Performed an 8-week, 2 times/week exercise training (moderate intensity) under physiotherapist supervision.~Control group: No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have."|f|f|f|t
33934990|NCT00391495|||CASE_CONTROL||OTHER|||||||
33934991|NCT06153628|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-subject quasi-experimental research||||
33710721|NCT02119481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33934992|NCT03086148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934993|NCT03140722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33934994|NCT00036231|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33934995|NCT05477251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710722|NCT03677505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710723|NCT01625702|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33934996|NCT03189563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33934997|NCT00606229|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33934998|NCT01662128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33934999|NCT00398086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935000|NCT04105595|||COHORT||OTHER|||||||
33935001|NCT03477344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935002|NCT03827070|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|Single Group Assignment||||
33935003|NCT04778865|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE||Patients will randomly receive the experimental condition or the active comparator for 3 months. After 3 months of washout, the groups will be crossed to receive the opposite treatment.|t|t|t|f
33935004|NCT02945852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935005|NCT02000544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935006|NCT02820480|||COHORT||CROSS_SECTIONAL|||||||
33935007|NCT03145506|||OTHER||PROSPECTIVE|||||||
33935008|NCT02870348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935009|NCT01321658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935010|NCT04111185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33935011|NCT01307046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935012|NCT00721357|||COHORT||CROSS_SECTIONAL|||||||
33935013|NCT00902512|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33935014|NCT01800162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935015|NCT03486769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012733|NCT01927354|||COHORT|||||||||
33710724|NCT02820753|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33710725|NCT04313218|||OTHER||RETROSPECTIVE|||||||
33710726|NCT06502717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once enrolled, participants are randomized into one of the two arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.|Randomized, blinded, cohort study divided into two study arms: 1) control group (placebo), 2) precision-supplement|t|f|f|f
33710727|NCT03767816|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33710728|NCT03962920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710729|NCT02835404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710730|NCT06441994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710731|NCT05892471|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33710732|NCT00107471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710733|NCT01780636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710734|NCT03674801|||CASE_ONLY||PROSPECTIVE|||||||
33710735|NCT00138996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710736|NCT03695250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710737|NCT04690998|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710738|NCT02624908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710739|NCT04433377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710740|NCT06229197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710741|NCT00840450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710742|NCT04235114|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a single center, open-label, phase I/II diagnostic imaging study to assess the diagnostic quality of 89Zr-DFO-nimotuzumab with PET.||||
33710743|NCT05339568|||COHORT||PROSPECTIVE|||||||
33710744|NCT02671552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935016|NCT04270565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator assessing laboratory-based outcome measures will be blinded to group allocation. Additionally, the investigator designing the home exercise program and making progression decisions will be blinded to group allocation.|"There will be two groups:~1. real-time gait-training interventions along with a home exercise program (intervention group)~2. only home exercise program (control group)."|f|t|f|t
33935017|NCT04075955|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935018|NCT05418140|||COHORT||PROSPECTIVE|||||||
33935019|NCT05130489|||COHORT||PROSPECTIVE|||||||
33935020|NCT04440085|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Randomized, double-blind, single-center, placebo-controlled study|t|t|t|f
33935021|NCT04574141|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33935022|NCT04845815|||CASE_ONLY||OTHER|||||||
33935023|NCT05078086|||OTHER||PROSPECTIVE|||||||
33935024|NCT02762123|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935025|NCT06442176|||COHORT||OTHER|||||||
33935026|NCT04363723|||COHORT||RETROSPECTIVE|||||||
33710745|NCT00160693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710746|NCT05872841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710747|NCT01755013|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33710748|NCT00801632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710749|NCT00009698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710750|NCT04284410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710751|NCT02534870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710752|NCT03586180|||CASE_ONLY||CROSS_SECTIONAL|||||||
33710753|NCT04451239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710754|NCT01691781|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
33710755|NCT02407353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33710756|NCT03473860|||COHORT||PROSPECTIVE|||||||
33710757|NCT02898337|||COHORT||OTHER|||||||
33935027|NCT00002041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935028|NCT05302804|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each Subject acts as their own control in a repeated measures design||||
33935029|NCT03157999|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The Research Assistant who will be collecting the outcome measures will be blinded to group allocation (intervention vs. control) for the duration of data collection.|The proposed study design is a pragmatic randomized controlled trial (RCT). A pragmatic design applies RCT methodology in actual care settings to better inform decisions on the likely benefits, harms, and costs of real world implementation. The design is further classified as a Type II hybrid effectiveness-implementation study, which assigns equal weight to assessing program effectiveness and implementation.|t|f|f|t
33935030|NCT05687292|||COHORT||PROSPECTIVE|||||||
34012734|NCT01202877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012735|NCT04281394|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with full or virtually full thickness involvement of \>50% on the body surface area of the lower extremity||||
34012736|NCT04470531|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm A :control group will receive standard treatment, Arm B: experimental group will receive standard care and oral co-triamoxazole||||
34012737|NCT01731717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710758|NCT02954731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710759|NCT05503394|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33710760|NCT04740788|||CASE_ONLY||PROSPECTIVE|||||||
33710761|NCT06190691|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33710762|NCT05770856|||COHORT||RETROSPECTIVE|||||||
33710763|NCT00718835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710764|NCT00121745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710765|NCT03012438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935031|NCT04037462|NA|SINGLE_GROUP||TREATMENT||NONE||In the first stage, three Dex escalation cohorts will be evaluated sequentially from Cohort A to Cohort C until \> 2 patients exhibit FLT-PET response (i.e., 30% reduction in FLT-PET uptake in at least one target lesion); otherwise, the trial will be terminated due to futility. The secondary objective is to assess the effect of Dex on pembrolizumab in terms of overall response rate (ORR).||||
33935032|NCT04416191|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be tested before a 2-week limb immobilization period||||
34095889|NCT06368973|||COHORT||RETROSPECTIVE|||||||
34095890|NCT02492776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095891|NCT04279600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Supplement capsule packages were labeled as Supplement A and Supplement B and the nutrient (taurine or placebo- starch) was revealed after the end of the intervention."|Double-blind placebo controlled study|t|f|t|f
34095892|NCT03024632|||COHORT||RETROSPECTIVE|||||||
33792461|NCT03467555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792462|NCT06055114|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935033|NCT02300506|||COHORT||PROSPECTIVE|||||||
33935034|NCT00686699|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33792463|NCT05307614|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Cross Over||||
33792464|NCT00810680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792465|NCT01789489|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792466|NCT00561743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792467|NCT04505813|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792468|NCT01768676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792469|NCT04292054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatments will be conditioned by the Contract manufacturing organization (central pharmacy of Assistance-Publique Hôpitaux de Paris) according to a list provided by an independent person and assigning a treatment arm to each treatment number|"Double-blind, randomized controlled study with two arms (1:1)~Arm 1 : With antibiotic prophylaxis strategy, (cefazolin) if absence of colonization to Pseudomonas aeruginosa; or (piperacilline-tazobactam) if the burn is colonized with Pseudomonas aeruginosa.~Arm 2 : Without antibiotic prophylaxis strategy (placebo)"|t|f|t|f
33792470|NCT00987961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792471|NCT03298919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3-group design|f|f|f|t
33792472|NCT04154241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792473|NCT00168467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33792474|NCT01712113|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935035|NCT02489851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935036|NCT02557815|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33792475|NCT04700930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792476|NCT04266080|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-arm pilot study.||||
33935037|NCT06175104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33935038|NCT00596349|||COHORT||PROSPECTIVE|||||||
33935039|NCT03592589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935040|NCT03462030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled||t|t|t|t
33935041|NCT04861506|||CASE_ONLY||PROSPECTIVE|||||||
33935042|NCT02909920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935043|NCT03025516|||COHORT||PROSPECTIVE|||||||
33935044|NCT01561872|||CASE_ONLY||PROSPECTIVE|||||||
33935045|NCT05437692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095893|NCT05492903|RANDOMIZED|CROSSOVER||PREVENTION||NONE||cluster-randomized waitlist control design||||
34095894|NCT04719923|||COHORT||PROSPECTIVE|||||||
34095895|NCT03097159|||CASE_CONTROL||PROSPECTIVE|||||||
33935046|NCT01608555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935047|NCT04114773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935048|NCT01564485|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33935049|NCT03017040|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935050|NCT02465762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935051|NCT00611416|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33935052|NCT05393544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935053|NCT03100006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935054|NCT00561301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935055|NCT03227094|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33935056|NCT03256006|||COHORT||PROSPECTIVE|||||||
33935057|NCT03885076|||CASE_ONLY||PROSPECTIVE|||||||
33935058|NCT02482389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935059|NCT04327895|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33935060|NCT04226144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two-arm, parallel (1:1), superiority, blinded-assessor randomized controlled trial|f|f|f|t
33792477|NCT00002810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792478|NCT04379713|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792479|NCT04400006|||CASE_ONLY||PROSPECTIVE|||||||
33792480|NCT02777099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33935061|NCT02894788|||CASE_CONTROL||RETROSPECTIVE|||||||
33935062|NCT06246136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935063|NCT02587481|||CASE_ONLY||PROSPECTIVE|||||||
33935064|NCT03699527|||COHORT||PROSPECTIVE|||||||
33935065|NCT03643198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 arms|t|f|t|t
33935066|NCT03566498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935067|NCT01047462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935068|NCT00343395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935069|NCT02269982|||COHORT||PROSPECTIVE|||||||
33935070|NCT03531762|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34095896|NCT02011997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095897|NCT01181765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710766|NCT03406572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710767|NCT02944968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710768|NCT01765088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710769|NCT04692571|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Transradial limb-absent vs able-bodied subjects tested in sequence.||||
33710770|NCT06081257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792481|NCT05126004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Arm1: Control Arm2:AZA+NAC|t|t|t|f
33792482|NCT01623349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792483|NCT02893813|||COHORT||RETROSPECTIVE|||||||
33935071|NCT00853112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935072|NCT00822640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935073|NCT03080701|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The randomization sequence will be concealed to everyone except the study biostatistician.||f|f|f|t
33935074|NCT02968966|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment A - if no positive response: Treatment B||||
33935075|NCT05017727|||OTHER||PROSPECTIVE|||||||
33710771|NCT01830972|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935076|NCT03298048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935077|NCT04111926|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935078|NCT04741204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Breast cancer tumor response rate to metformin treatment prior to surgery in black vs. white women.||||
33935079|NCT04347252|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Within-subject design with each subject receiving 3 separate single day interventions.||||
33935080|NCT00372489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710772|NCT04255602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935081|NCT02213081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935082|NCT01531933|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935083|NCT01089751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935084|NCT04344015|NA|SINGLE_GROUP||OTHER||NONE||||||
33935085|NCT03793270|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935086|NCT05444829|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710773|NCT00755092|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33710774|NCT02555072|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33710775|NCT02058667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710776|NCT01154855|||CASE_CONTROL||PROSPECTIVE|||||||
33710777|NCT05318053|||COHORT||PROSPECTIVE|||||||
33710778|NCT05114798|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Subjects will be randomized by the data manager, by way of a stratified random sample in 1:1:1 ratio. The sample frame will be divided into strata based on BMI, sex, and age. Subjects from each stratum, will then be randomized to 1 of 3 groups: 1) TRE, 2) Cal-R, or 3) Control.|f|f|f|t
33710779|NCT03565744|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators will conduct a quasi-experimental trial of B'N Fit POWER in two middle schools that have both an onsite MSHP and MMCC service.||||
33792484|NCT02309398|||CASE_CONTROL||RETROSPECTIVE|||||||
33792485|NCT05129124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935087|NCT01437059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935088|NCT02196090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935089|NCT04120480|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935090|NCT03279146|RANDOMIZED|CROSSOVER||OTHER||NONE||Drug: Tenofovir Exalidex (TXL) oral formulations Other names: Lipid conjugateTFV||||
33935091|NCT03257306|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized, single-blinded, multi-institutional, non-inferiority study||||
33935092|NCT06098794|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33935093|NCT01512329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33935094|NCT04446494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935095|NCT00446225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710780|NCT06327347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) assessed at 80 cm in photopic conditions at minimum 1-month post-operative is perforemd by a blinded evaluator.|Parallel Assignement|f|f|f|t
33792486|NCT03502317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33710781|NCT03551639|||CASE_ONLY||PROSPECTIVE|||||||
33710782|NCT01471236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710783|NCT02071914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710784|NCT02793934|||COHORT||CROSS_SECTIONAL|||||||
33710785|NCT06418100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants under general anaesthesia and the cardiovascular surgeon responsible for the study were blinded to the study groups. This surgeon served as the sole evaluator of postoperative outcomes. Intraoperative results were recorded by the anaesthesia technician, who was present in the operating room and unaware of the block procedures performed. Moreover, the data analysis was conducted before the unblinding of the data.|prospective, randomized, triple-blind, controlled|t|f|f|t
33710786|NCT06293404|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33710787|NCT06239454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization is done by computer-generated pairwise according to order of enrolment, so that similar numbers of patients are recruited to each study group. The chief investigator generates the randomization sequence. The randomization scheme is kept in sealed envelopes. The randomization sequence was revealed only to the unmasked clinician responsible for the stimulation programming, but not to the rater. Patients were masked to randomisation group.|"50 Patients will be randomly assigned to either the interleaving stimulation modes group (ISG) or the empirical stimulation modes group (ESG).~ISG: empirical stimulation for the first 3 months, followed by interleaving programming period for 6 months, and any stimulation decided by the neurologists/neurosurgeons for the final 3 months.~ESG: empirical programming for the first 9 months' period, followed by any stimulation decided by the neurologists/neurosurgeons for the final 3 months."|t|t|f|t
33710788|NCT06158126|||COHORT||PROSPECTIVE|||||||
33710789|NCT06313229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The present clinical trial was single-blinded one as the evaluator and the statistician were both blinded. While both the implantologist or the participant were not blinded as the interventions were dissimilar.|single-center, prospective, single-blinded, randomized parallel two-arm controlled clinical trial|t|f|f|t
33710790|NCT03950115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710791|NCT05386069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Control Trial|t|f|f|f
33710792|NCT02340975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710793|NCT00309114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Active intervention that includes bacterial interference using E. coli 83972 is compared with a placebo intervention.|t|t|t|f
33710794|NCT05831020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The dressing is opened by principal investigator and then the supervising consultant is called for outcome assessment.|A two arm parallel assignment, where group A will be VAC group and group B will be bolster dressing group.|f|f|f|t
33710795|NCT05605795|||COHORT||CROSS_SECTIONAL|||||||
33710796|NCT05798832|RANDOMIZED|PARALLEL||OTHER||SINGLE|The person who will make the statistical analysis; He does not know which group the participants in our study belong to and he does not know the participants.|An experimental and a pretest-posttest control group design method were applied in this regard.|f|f|f|t
33710797|NCT03748888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The present study will involve two study groups.~1. Exercise group (EG). Pregnant women allocated in the EG will receive and intervention based on a supervised antenatal physical activity programme during 20-24 weeks. They must be enrolled in the study between their 12-16 weeks of gestation.~2. Control group (CG). Pregnant women allocated in CG will not receive any intervention. They will maintain standard health care during pregnancy."||||
33710798|NCT01804465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710799|NCT02142101|||COHORT||CROSS_SECTIONAL|||||||
33710800|NCT03428360|NA|SINGLE_GROUP||TREATMENT||NONE||The study population was male or female pediatric, adolescent, and adult subjects with a clinical diagnosis of epilepsy and with bouts of increased seizure activity, frequent breakthrough seizures, seizure clusters, or cluster seizures and who were on chronic, intermittent use of rescue medication (eg, Diastat AcuDial or other benzodiazepine).||||
33710801|NCT05037734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be randomized into one of the two available study arms, and will be blinded from treatment until surgery has occurred.||t|f|f|f
33710802|NCT05809284|||COHORT||PROSPECTIVE|||||||
33792487|NCT00770965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792488|NCT03411239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792489|NCT00937846|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33792490|NCT00294905|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33792491|NCT00193297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792492|NCT01586780|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33792493|NCT00234091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792494|NCT05907551|||COHORT||PROSPECTIVE|||||||
33792495|NCT01784146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792496|NCT01184235|||COHORT||PROSPECTIVE|||||||
33935096|NCT01487928|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935097|NCT01424865|||CASE_CONTROL||RETROSPECTIVE|||||||
33935098|NCT01528618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935099|NCT00662285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935100|NCT05454241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935101|NCT05346380|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The treatment arms are separated by type of surgery. Arm 1 is esophagectomy, Arm 2 is segmentectomy.||||
33935102|NCT00865202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935103|NCT01879475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935104|NCT06049628|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33935105|NCT06218628|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33935106|NCT01212120|||COHORT||PROSPECTIVE|||||||
33935107|NCT02142712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935108|NCT00006272|||NATURAL_HISTORY|||||||||
33935109|NCT01017666|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34012738|NCT01025219|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095898|NCT00560638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710803|NCT04817813|||COHORT||RETROSPECTIVE|||||||
33710804|NCT01959815|||COHORT||PROSPECTIVE|||||||
33710805|NCT01206660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792497|NCT05235789|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized clinical trial with control group, in people diagnosed with major depression attached to the PC.~This study is carried out in 9 primary care centers in Catalonia."||||
33792498|NCT00480012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33792499|NCT02808039|||COHORT||PROSPECTIVE|||||||
33792500|NCT01990937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33792501|NCT01537133|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33792502|NCT05113355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710806|NCT02468115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792503|NCT05888155|||OTHER||OTHER|||||||
33792504|NCT03772379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792505|NCT05434650|||COHORT||PROSPECTIVE|||||||
33792506|NCT03245593|||CASE_ONLY||PROSPECTIVE|||||||
33792507|NCT01378065|||COHORT||PROSPECTIVE|||||||
33935110|NCT06200870|||COHORT||CROSS_SECTIONAL|||||||
33935111|NCT02572089|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935112|NCT02954861|||COHORT||PROSPECTIVE|||||||
33935113|NCT05780229|||COHORT||PROSPECTIVE|||||||
33710807|NCT05739097|||COHORT||PROSPECTIVE|||||||
33710808|NCT02486432|NA|SINGLE_GROUP||||NONE||||||
33710809|NCT01257997|||OTHER||PROSPECTIVE|||||||
33710810|NCT05787457|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33710811|NCT00492908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935114|NCT03653585|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935115|NCT06411106|NA|SINGLE_GROUP||OTHER||NONE||Part A of the study is observational and Part B has an intervention. In Part B, the intervention is a challenge with imiquimod. All patients and healthy volunteers will receive the same challenge.||||
33935116|NCT03152175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Repeated measures parallel design.|t|f|t|f
33935117|NCT00912639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935118|NCT02798640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33935119|NCT04916301|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33935120|NCT00005555||||PREVENTION||||||||
33935121|NCT00024544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935122|NCT00440102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33935123|NCT00854568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935124|NCT04602611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935125|NCT00198731|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33935126|NCT03209791|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935127|NCT00579462|||CASE_CONTROL||PROSPECTIVE|||||||
33935128|NCT00339950|||COHORT||RETROSPECTIVE|||||||
33935129|NCT01925482|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33935130|NCT02033291|||CASE_ONLY||PROSPECTIVE|||||||
33935131|NCT05522543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935132|NCT06355206|||COHORT||PROSPECTIVE|||||||
33935133|NCT00038142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935134|NCT02110472|NA|SINGLE_GROUP||||NONE||||||
33935135|NCT04851223|||COHORT||RETROSPECTIVE|||||||
33935136|NCT03304769|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Selected from a single-site level one pediatric emergency department. Pediatric patients aged 4-17 years requiring an IV. Random number generator used to decide which patients will be using VR and which will have standard IV placement||||
33935137|NCT02204111|||CASE_CONTROL||PROSPECTIVE|||||||
33935138|NCT06371209|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935139|NCT00029341||||TREATMENT||NONE||||||
33935140|NCT04950933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935141|NCT04488991|||COHORT||PROSPECTIVE|||||||
33710812|NCT04981769|||COHORT||PROSPECTIVE|||||||
33710813|NCT05701527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710814|NCT01073553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710815|NCT00413452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710816|NCT04256798|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33710817|NCT00378820|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33710818|NCT03844646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710819|NCT05677581|||COHORT||PROSPECTIVE|||||||
33710820|NCT04830774|NA|SINGLE_GROUP||SCREENING||NONE||Single Group Assignment||||
33710821|NCT01379040|||COHORT||PROSPECTIVE|||||||
33710822|NCT03310021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (Participant, Care Provider, Investigator, Sponsor)||t|t|t|f
33710823|NCT04750148|||COHORT||CROSS_SECTIONAL|||||||
33792508|NCT04010448|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|To maintain the blind, infants allocated to the TV P2-VP8 vaccine arm will receive both TV P2-VP8 IM as well as oral placebo vaccine, and infants allocated to receive Rotarix® will receive both Rotarix® PO and placebo IM.|Participating infants will be randomized 1:1 to receive either: 1) 90 µg of the TV P2-VP8 vaccine IM plus oral placebo, or 2) Rotarix® PO plus IM placebo.|t|t|t|t
33792509|NCT02892162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792510|NCT03889678|||OTHER||CROSS_SECTIONAL|||||||
33792511|NCT01230619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792512|NCT01194154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792513|NCT01123928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792514|NCT04652076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792515|NCT00135135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792516|NCT00549536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792517|NCT00796068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935142|NCT02777034|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33935143|NCT01228786|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935144|NCT00921570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935145|NCT05190757|||CASE_CONTROL||PROSPECTIVE|||||||
33935146|NCT03973632|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935147|NCT00420212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095899|NCT04362150|||COHORT||PROSPECTIVE|||||||
34095900|NCT01320098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095901|NCT04846257|||COHORT||PROSPECTIVE|||||||
34095902|NCT01573793|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34095903|NCT00776997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095904|NCT06193967|RANDOMIZED|FACTORIAL||OTHER||NONE||2 x 2 factorial design||||
33710824|NCT05803005|||CASE_CONTROL||RETROSPECTIVE|||||||
34095905|NCT00856102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710825|NCT04847492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935148|NCT04770025|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double (Participant, Providers/Research Assistants)|Double-blind proof-of-concept randomized clinical trial|t|t|f|f
33935149|NCT00233324|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33935150|NCT00017524||||TREATMENT||NONE||||||
33935151|NCT03592927|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath through a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia.|t|f|f|f
34095906|NCT03168997|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095907|NCT01899703|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34095908|NCT00290238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095909|NCT01411371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095910|NCT02765971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34095911|NCT02636283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34095912|NCT01280500|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34095913|NCT00812097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935152|NCT03988790|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignement||||
34095914|NCT05621980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34095915|NCT04120675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|t|f
34095916|NCT04949295|||CASE_ONLY||PROSPECTIVE|||||||
33710826|NCT02848651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710827|NCT05450731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710828|NCT02012075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710829|NCT03500952|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710830|NCT05123261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33710831|NCT00576927|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710832|NCT02256852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710833|NCT03202498|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||QUADRUPLE|Placebo|"Cohort 1 (1:1 randomization):~Standard medical treatment + Yaq-001 (4 g/ day) - n= 14.~Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day) - n= 14.~Cohort 2 (1:1 randomization):~Standard medical treatment + Yaq-001 (8 g/ day) - n= 14.~Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day) - n= 14."|t|t|t|t
33710834|NCT02115893|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33710835|NCT04949048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710836|NCT03504475|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33710837|NCT01422317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792518|NCT05227066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33935153|NCT06362928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935154|NCT01245127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935155|NCT04801355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients with colon adenomas|Laparo-endoscopic full-thickness colon resection|t|f|t|f
33935156|NCT00011492|||COHORT||PROSPECTIVE|||||||
33935157|NCT00171067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935158|NCT00792857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935159|NCT01829867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935160|NCT00536354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33935161|NCT04330040|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective, Multicentre, Phase-IV Clinical Trial||||
33935162|NCT02272244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935163|NCT01344304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935164|NCT03339089|||COHORT||PROSPECTIVE|||||||
33935165|NCT00068822|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33935166|NCT00678249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935167|NCT03828864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active medical device and and identical dummy device (placebo) that does not emit the pulsed shortwave signal.||t|t|t|t
33935168|NCT05375786|||COHORT||PROSPECTIVE|||||||
33935169|NCT05148429|||COHORT||PROSPECTIVE|||||||
33935170|NCT00290355|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33935171|NCT03160066|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33710838|NCT05209958|||OTHER||OTHER|||||||
33710839|NCT01393704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710840|NCT00000443|RANDOMIZED|||TREATMENT||DOUBLE||||||
33710841|NCT00158158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710842|NCT03797599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Participants will be masked to the extent that they will not be told which group they have been allocated to nor the exact nature of the the three groups. However, they will be aware of the exercises they are asked to undertake.|||||
33792519|NCT05496816|||COHORT||RETROSPECTIVE|||||||
33935172|NCT03262064|||COHORT||PROSPECTIVE|||||||
33935173|NCT06092840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095917|NCT04863807|||COHORT||RETROSPECTIVE|||||||
34095918|NCT01451788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095919|NCT02455011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34095920|NCT04607616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095921|NCT00483392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095922|NCT05008770|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095923|NCT04898465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34095924|NCT06308445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095925|NCT01078428|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34095926|NCT00350220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095927|NCT04456283|||CASE_CONTROL||PROSPECTIVE|||||||
33935174|NCT05400811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.~The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.~Neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance."|Prospective, randomized, placebo-controlled, double-blind, double-dummy, multi-center trial|t|f|t|t
33935175|NCT03413228|||OTHER||PROSPECTIVE|||||||
33935176|NCT03870893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935177|NCT00093158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935178|NCT04691349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935179|NCT03316742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935180|NCT04426240|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935181|NCT01983683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935182|NCT04070092|||CASE_CONTROL||PROSPECTIVE|||||||
33935183|NCT03606707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935184|NCT00648492|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33935185|NCT00011375||||TREATMENT||||||||
33935186|NCT03210467|||COHORT||PROSPECTIVE|||||||
33935187|NCT04054219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935188|NCT02812615|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33935189|NCT03302624|||COHORT||PROSPECTIVE|||||||
33935190|NCT01508793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935191|NCT03769389|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33935192|NCT02138162|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935193|NCT01199198|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33935194|NCT04487795|||CASE_ONLY||RETROSPECTIVE|||||||
33935195|NCT06238089|||COHORT||CROSS_SECTIONAL|||||||
33935196|NCT03665987|||COHORT||PROSPECTIVE|||||||
33935197|NCT01135004|||COHORT||PROSPECTIVE|||||||
33935198|NCT05874947|||OTHER||PROSPECTIVE|||||||
33935199|NCT05903391|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34095928|NCT05581888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095929|NCT02655809|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34095930|NCT03973593|||COHORT||PROSPECTIVE|||||||
34095931|NCT04061499|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935200|NCT02158728|||COHORT||PROSPECTIVE|||||||
33935201|NCT01585909|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935202|NCT01347073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935203|NCT01092364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935204|NCT05746689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095932|NCT02489773|||OTHER||PROSPECTIVE|||||||
33710843|NCT05475795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710844|NCT04782427|||COHORT||RETROSPECTIVE|||||||
33710845|NCT05553249|||COHORT||PROSPECTIVE|||||||
33710846|NCT00447460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710847|NCT02188251|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33935205|NCT06001892|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be masked during consent and baseline data collection. They will know the intervention once it begins.||t|f|f|f
34095933|NCT00409760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34095934|NCT03367585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized prospective clinical trial, double-blind, placebo-controlled intervention|t|f|t|f
34095935|NCT01841853|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34095936|NCT00996177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095937|NCT02778802|||COHORT||PROSPECTIVE|||||||
34095938|NCT03211832|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34095939|NCT05354258|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34095940|NCT01971593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34095941|NCT05431907|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34095942|NCT00608036|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34095943|NCT06144086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095944|NCT01560130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095945|NCT03640026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34095946|NCT00523783|||||PROSPECTIVE|||||||
34095947|NCT05436912|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34095948|NCT05343429|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A pharmacist not part of the study will prepare two solutions, one of Benzydamine hydrochloride (BH) 0.15 % 15 ml diluted to 30 ml by adding plain water and another of Aspirin (AS) 600 mg dissolved in 30 ml plain water. The randomized patients will gargle with either BH and AS solution five minutes before conduct of General Anesthesia. The unique identification will be known only to principal investigator.|Parallel Assignment The study design is prospective double-blinded randomized controlled parallel trial with allocation ratio of 1:1.|f|t|f|t
34095949|NCT03517007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095950|NCT01716195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095951|NCT02673450|||COHORT||PROSPECTIVE|||||||
34095952|NCT05434676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710848|NCT05786391|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33710849|NCT00536198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33710850|NCT04034485|RANDOMIZED|CROSSOVER||TREATMENT||NONE|treatment is open label but lipid results are masked to participant, investigator and sponsor|open label, randomized, cross-over||||
33710851|NCT04606082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710852|NCT03645369|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study was conducted on receiving treatment patients in the Orthopedics and Traumatology wards of a university hospital.||t|f|f|f
33710853|NCT00657527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710854|NCT02449655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710855|NCT04873505|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33710856|NCT01405248|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33710857|NCT04673864|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710858|NCT06127953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710859|NCT00217594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710860|NCT02268084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Sham controlled|t|t|f|f
33710861|NCT05777876|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33710862|NCT05062798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935206|NCT04162262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random group allocation into Groups 1 and 2 will be performed using a 1:1 allocation ratio with permuted block sizes of 2 to 6. The investigators responsible for the weekly progression of the stretching and strengthening exercise protocol and the outcome assessor will be masked to the participants' assigned groups. The investigators providing instrument-assisted soft tissue mobilization will not be blinded to group assignment.|This study is divided into two parts. Part I is a parallel-group, pre-test post-test randomized controlled superiority trial comparing the effects of stretching and strengthening exercises (SS) (Group 1) versus SS plus IASTM (SS+IASTM, Group 2) in subjects with PF. Outcomes will be assessed by a blinded investigator after one visit and 4, 8, and 12 weeks of treatment. Part II is a pre-test, posttest comparison of the short-term effects of IASTM on PF (Group 2) and control (Group 3) groups.|f|t|f|t
33935207|NCT01023516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935208|NCT06147232|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||randomized, double-blinded, placebo-controlled, cross-over intervention study|t|t|t|f
33935209|NCT01424306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33710863|NCT00971698|||COHORT||RETROSPECTIVE|||||||
33710864|NCT00382577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33710865|NCT00732017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33710866|NCT04804475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33710867|NCT01118221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710868|NCT03660267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710869|NCT00502645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710870|NCT00123396|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33710871|NCT04882540|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710872|NCT02380677|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation study followed by phase 2a expansion cohort||||
33935210|NCT02039128|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33935211|NCT00949104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935212|NCT04856215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935213|NCT02252068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935214|NCT04739917|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935215|NCT02516891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33935216|NCT06118190|NA|SINGLE_GROUP||TREATMENT||NONE|open label|Retrospective analysis of the group that received treatment||||
33935217|NCT04115891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Investigator, Outcomes Assessor)||f|f|t|t
33710873|NCT00388778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33710874|NCT00660023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710875|NCT00001006||||TREATMENT||NONE||||||
34095953|NCT03713788|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A sample of convenience was recruited for this cross-sectional study. Participants were randomly assigned to a pain group or a control group using counterbalanced block randomization. Passive knee extension range of motion was measured three consecutive times with five-minute intervals between measurements. Both groups underwent a static stretch protocol consisting of two bouts of thirty-second constant-angle static stretching of the knee flexors with a one-minute rest between bouts. Subjects were instructed to keep the limb relaxed as the lower leg was passively moved towards extension. Following stretching, the post-stretch measurement was performed. Finally, subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. A Biodex system 4 pro dynamometer was used to quantify range of motion and passive resistive torque. Muscle activity was recorded as surface electromyography.||||
33935218|NCT00026039|RANDOMIZED|||||DOUBLE||||||
34095954|NCT00651807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935219|NCT04955652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and providers will not know that alerts were randomized. Participants will not know the arm to which they were assigned. Providers might notice that a given participant did or did not receive a certain alert, but this is expected to be unlikely, given the volume of alerts to which providers are exposed constantly.|1 x 2 factorial design, with randomization happening at the patient level|t|t|f|f
34095955|NCT02722135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095956|NCT03061500|||CASE_ONLY||PROSPECTIVE|||||||
33935220|NCT03234075|||OTHER||OTHER|||||||
34095957|NCT01011296|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34095958|NCT04891653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095959|NCT04623060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095960|NCT00527878|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34095961|NCT04561531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095962|NCT03074643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All participants will undergo a 6-month weight loss intervention of caloric restriction and supervised exercise followed by 12 months of follow-up with randomization to one of three groups (n=75/group): 1) Lower protein / higher CHO diet for the 6-month weight loss phase only (RecProt); 2) Higher protein / lower CHO diet for the 6-month weight loss phase only (6-mo HiProt); or 3) Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases (18-mo HiProt).|t|f|t|t
34095963|NCT04529798|||COHORT||OTHER|||||||
34095964|NCT02767245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34095965|NCT05926193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34095966|NCT02305459|||OTHER||PROSPECTIVE|||||||
34095967|NCT00157625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095968|NCT02521194|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34095969|NCT06210295|||COHORT||PROSPECTIVE|||||||
34095970|NCT03748563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic accuracy study||||
34095971|NCT01846143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095972|NCT00007501|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34095973|NCT05797090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095974|NCT01932580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095975|NCT01307735|||CASE_CONTROL||PROSPECTIVE|||||||
34095976|NCT00593255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095977|NCT02423720|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34095978|NCT00289900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34095979|NCT01732211|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34095980|NCT01898091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34095981|NCT00478140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34095982|NCT06311812|||COHORT||RETROSPECTIVE|||||||
34095983|NCT05698628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34095984|NCT05903742|||COHORT||PROSPECTIVE|||||||
34095985|NCT04299321|||COHORT||RETROSPECTIVE|||||||
34095986|NCT01272687|||COHORT||PROSPECTIVE|||||||
34095987|NCT04506710|||COHORT||PROSPECTIVE|||||||
34095988|NCT02441114|NA|SINGLE_GROUP||SCREENING||NONE||||||
34095989|NCT02898389|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34095990|NCT05644964|||CASE_CONTROL||PROSPECTIVE|||||||
34095991|NCT04948632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a single-center, randomized, controlled study comparing, in patients undergoing outpatient surgery at the CHUM, a group of patients benefiting from optimized support and follow-up using the LeoMed telecare platform (Group A) with a group benefiting from the current standard of care (Group B).|f|f|f|t
33710876|NCT00612781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710877|NCT02439840|||||PROSPECTIVE|||||||
33710878|NCT00403234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720642|NCT06459843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792520|NCT02404233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792521|NCT03018041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792522|NCT01976910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792523|NCT01299974|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33792524|NCT05816837|||COHORT||PROSPECTIVE|||||||
33792525|NCT00652301|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33792526|NCT00680342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792527|NCT00839540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792528|NCT00913913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792529|NCT00039455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792530|NCT01595321|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34012739|NCT05535439|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Cytologist and Histopathologist evaluating Diagnostic Yield and Specimen Accuracy will be blinded for type of needle used to minimize the potential of bias||f|f|f|t
34012740|NCT02794857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012741|NCT06420830|||COHORT||PROSPECTIVE|||||||
33792531|NCT05272046|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patient will not know which electrocautery tool will be used in their procedure.|Two groups with patients randomized into receiving either the standard of care bipolar electrocautery tool or monopolar electrocautery tool.|t|f|f|f
33792532|NCT00389246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792533|NCT05566418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded. Patients will be assessed by a senior Physiotherapist then divided into two groups for treatments. The assessor will be unaware of the treatment given to both groups|Parallel designed randomised controlled trial|f|f|f|t
33792534|NCT02925195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792535|NCT05061953|||COHORT||PROSPECTIVE|||||||
33792536|NCT06028451|||COHORT||PROSPECTIVE|||||||
33792537|NCT00192400|RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
33792538|NCT01286155|||COHORT||PROSPECTIVE|||||||
33792539|NCT05407480|||COHORT||PROSPECTIVE|||||||
33792540|NCT04109534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|LCPUVAS and Placebo are provided in sealed bags|Placebo-controlled prospective study|t|f|t|f
33792541|NCT01291563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792542|NCT05796440|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33792543|NCT04801329|||COHORT||OTHER|||||||
33792544|NCT05769517|||OTHER||OTHER|||||||
33792545|NCT04304859|||CASE_CONTROL||PROSPECTIVE|||||||
33792546|NCT03216135|||CASE_CONTROL||PROSPECTIVE|||||||
33792547|NCT01148719|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33935221|NCT01129414|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33935222|NCT04966806|NA|SINGLE_GROUP||OTHER||NONE||||||
33935223|NCT01998906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935224|NCT05553652|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33935225|NCT02778425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935226|NCT03542890|||COHORT||PROSPECTIVE|||||||
33935227|NCT02233608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33935228|NCT01392014|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935229|NCT04905836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935230|NCT03833349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935231|NCT03164122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935232|NCT02144090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935233|NCT04865224|||OTHER||CROSS_SECTIONAL|||||||
33935234|NCT02574520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935235|NCT02098044|||CASE_CONTROL||RETROSPECTIVE|||||||
33935236|NCT02430389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33935237|NCT04733664|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935238|NCT00302055|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935239|NCT00000662||||TREATMENT||||||||
33935240|NCT05518136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935241|NCT05306795|||COHORT||PROSPECTIVE|||||||
33935242|NCT05564754|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Participants will be blinded. Assessors of neurological prognosis will be blinded. Outcome assessors and investigators will be blinded. Health-care personnel will not be blinded.|2x2x2 factorial, with all patients taking part in each factor.|t|f|t|t
33935243|NCT05802290|NA|SINGLE_GROUP||TREATMENT||NONE||A Single-Arm, Open-Label||||
33935244|NCT03231228|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|n/a, this is an open label study|Approximately 110 subjects will be enrolled and assigned to 1 of the 2 dose groups in a 1:1 ratio (55 subjects in each group). Subjects with a weight of at least 25 kg but less than 60 kg will receive a single IV dose of 1 g cefazolin. Subjects with a weight of at least 60 kg will receive a single IV dose of 2 g cefazolin. Dose groups will not be balanced by age or gender.||||
33935245|NCT03541590|||COHORT||RETROSPECTIVE|||||||
34012742|NCT00049699||||TREATMENT||||||||
34012743|NCT03596619|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33792548|NCT01358136|||COHORT||PROSPECTIVE|||||||
33792549|NCT06476028|||OTHER||PROSPECTIVE|||||||
33792550|NCT01325246|||COHORT||RETROSPECTIVE|||||||
33792551|NCT05964231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33792552|NCT05323682|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, experimental, randomized||||
33792553|NCT02065050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792554|NCT00436644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792555|NCT03273348|NA|SINGLE_GROUP||TREATMENT||NONE||"This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .~.~The obtained results may contribute to the formulation of guidelines achieving low morbidity, high levels of patient satisfaction and oncological safety in breast cancer patients."||||
33935246|NCT05575583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935247|NCT05981755|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935248|NCT00002749||||TREATMENT||||||||
33935249|NCT00000405|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33935250|NCT01118585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710879|NCT03340532|RANDOMIZED|PARALLEL||OTHER||NONE||Participants are randomized to view one of two SunSmart educational videos or a control video on sleep hygiene. In the three months following the video intervention, participants' sun protection attitudes and behaviors are assessed. An additional measure of sun protection behaviors 12-months later will be provided by participants who participate in the optional 1-year follow-up.||||
33710880|NCT05502757|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710881|NCT02742480|||CASE_CONTROL||PROSPECTIVE|||||||
33710882|NCT01900704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33710883|NCT04053556|||OTHER||PROSPECTIVE|||||||
33710884|NCT00521014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710885|NCT02785432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33710886|NCT02193867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710887|NCT03251300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710888|NCT06136793|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|concurrent treatments different in subject matter but equal in nonspecific treatment effects|RCT|t|f|f|f
33710889|NCT02817256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710890|NCT05168527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710891|NCT01678911|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710892|NCT00959764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710893|NCT01024634|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33710894|NCT05295511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33710895|NCT01772108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710896|NCT04370938|RANDOMIZED|PARALLEL||OTHER||SINGLE|Individuals responsible for analyzing survey data (including that which was administered after the intervention), will be masked with regard to whether the participant received the intervention.|A longitudinal survey-based research study investigating the domains of perceived organizational support, anxiety, and burnout will take place. Healthcare providers with patient-care contact will be asked to fill out these surveys once every 30 days over a period of 6 months. After the first survey is complete, 20% of participants will be randomized to watch a 1-hour long video discussing coping strategies for stress related to the COVID-19 pandemic.|f|f|f|t
33710897|NCT00598832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710898|NCT00094744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710899|NCT02294591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710900|NCT01927874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710901|NCT00056524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710902|NCT00886899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710903|NCT06040060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33935251|NCT04224350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935252|NCT02515851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935253|NCT00067249|||NATURAL_HISTORY||OTHER|||||||
33935254|NCT00762528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935255|NCT02721290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34012744|NCT00156715|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34012745|NCT02664857|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34012746|NCT05339646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935256|NCT04725604|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All participants will take part in pH probe monitoring. Results from the monitoring system will not be available until results are reviewed. No clinical decisions will be made using the new pH probes.|Blinded diagnostic field study||||
33935257|NCT00026195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935258|NCT02462889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33935259|NCT05084768|||COHORT||PROSPECTIVE|||||||
33935260|NCT00634751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935261|NCT03330093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935262|NCT01803529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935263|NCT00216229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935264|NCT02449512|||COHORT||CROSS_SECTIONAL|||||||
34012747|NCT06264479|||COHORT||PROSPECTIVE|||||||
34012748|NCT01358552|||COHORT||PROSPECTIVE|||||||
34012749|NCT05355038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|control group were in the first 3 day of week (saturday ,sunday ,monday) study group were in the 2nd three day of week(tuesday, wednsday,thursday)|control and study group|t|f|f|f
34012750|NCT03399240|NA|SINGLE_GROUP||OTHER||NONE||||||
34012751|NCT04192123|NA|SINGLE_GROUP||OTHER||NONE||||||
34012752|NCT01673698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012753|NCT03801421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012754|NCT01010126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012755|NCT06357949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34012756|NCT04273919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012757|NCT00317642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012758|NCT03971487|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized placebo-controlled therapeutic trial|t|t|t|f
34012759|NCT04535752|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012760|NCT04386928|||COHORT||RETROSPECTIVE|||||||
34012761|NCT04030494|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012762|NCT03201406|||CASE_ONLY||RETROSPECTIVE|||||||
34012763|NCT03220126|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Open|Treatments 2 and 3 of LY900021 will be administered in parallel with LY3074828. Treatments 2, 3, and 4 of LY900021 will be administered sequentially pending a safety review after administration of Treatments 2 and 3.||||
34012764|NCT01056094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012765|NCT02920463|||COHORT||PROSPECTIVE|||||||
33935265|NCT00784459|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33935266|NCT02458352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935267|NCT02611934|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935268|NCT02132689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935269|NCT02807155|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935270|NCT01197495|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33935271|NCT05699044|||COHORT||PROSPECTIVE|||||||
33935272|NCT02147106|||COHORT||PROSPECTIVE|||||||
33935273|NCT02162264|||COHORT||PROSPECTIVE|||||||
33935274|NCT04933253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935275|NCT06412640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935276|NCT02327728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935277|NCT03749343|||COHORT||PROSPECTIVE|||||||
33935278|NCT04488601|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, Double-Blind, Placebo-Controlled Trial|t|t|t|t
33935279|NCT04680104|||COHORT||PROSPECTIVE|||||||
33935280|NCT05756894|NA|SINGLE_GROUP||TREATMENT||NONE||Participants with high cervical spinal cord injury will receive 40 treatment sessions (STDP stimulation and respiratory training) and will be asked to complete pre-, Post-20, and Post-40 assessment sessions.||||
33935281|NCT05345704|||COHORT||PROSPECTIVE|||||||
33935282|NCT05622656|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33935283|NCT04555811|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients are enrolled in cohorts of 3 starting at Dose Level 1. There are three dose escalating doses of FT596. A minimum of 28 days will separate each cohort. For Dose Level 1 a minimum of 28 days will separate each patient to assess for dose limiting toxicity (DLT). In subsequent cohorts, the 1st and 2nd patient will be separated by at least 28 days and at least 14 days will separate the 2nd and 3rd patient.~Each new cohort of three patients will be sequentially assigned to the most appropriate dose based on the updated toxicity probabilities under the continuous reassessment method (CRM), and the MTD will be identified when the total sample size of 18 is exhausted or 6 patients are sequentially enrolled at the same dose."||||
34095992|NCT00871000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34095993|NCT02227264|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33710904|NCT00125294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34095994|NCT04886609|||COHORT||PROSPECTIVE|||||||
34095995|NCT00284648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34095996|NCT04302259|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34095997|NCT06035198|||COHORT||OTHER|||||||
34095998|NCT04874441|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012766|NCT06137157|NA|SINGLE_GROUP||TREATMENT||NONE|Patients, investigators, and assessors will be masked as to whether patients received ATR12-351 on the right or left side of the body.|Intrapatient, randomized controlled study: ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks. Each patient is randomized to receive ATR12-351 on either the left or right side.||||
34095999|NCT03439514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the randomized, double-blind period, patients, Investigators, site personnel and the sponsor personnel directly involved with the conduct of the study will remain blinded to assigned treatment, except for regulatory reporting requirements.|The study will be conducted in 2 parts: a randomized, double-blind treatment period for at least 24 weeks, followed by an ARRY-371797 (PF-07265803) open-label treatment period.|t|f|t|f
34096000|NCT05320588|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple ascending dose and dose-expansion of BIO-106 administered as a single agent or in combination with pembrolizumab.||||
34096001|NCT00083707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096002|NCT02856373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096003|NCT02449447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096004|NCT00560599|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34012767|NCT00731549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710905|NCT03636932|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33710906|NCT03657511|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33710907|NCT00552916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710908|NCT05136768|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single center, single arm, phase II clinical study||||
33710909|NCT00214708|||DEFINED_POPULATION||PROSPECTIVE|||||||
34012768|NCT00000374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096005|NCT06091605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710910|NCT01684007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710911|NCT01361152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33710912|NCT05911516|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind, matched-pair study design|Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference.|t|f|t|f
34012769|NCT03832738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34012770|NCT06316713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34096006|NCT05515640|||COHORT||PROSPECTIVE|||||||
34012771|NCT06304935|NA|SINGLE_GROUP||OTHER||NONE||||||
34012772|NCT06139718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096007|NCT03912805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||vehicle controlled, parallel group|t|t|t|t
34096008|NCT06162234|||COHORT||PROSPECTIVE|||||||
33710913|NCT05114720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710914|NCT00095901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710915|NCT02379871|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33710916|NCT02414750|NA|SINGLE_GROUP||OTHER||NONE||||||
33710917|NCT03042624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each treatment is numbered consecutively without any reference to the underlying randomization scheme, which is known only to the statistician who generated the list and to the technician who prepared the packages. The packages and their contents are indistinguishable.|Parallel-arm, Randomized, Double-blind Controlled Trial|t|t|f|t
33710918|NCT05071469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Randomized Controlled Trial|f|f|f|t
33710919|NCT00280098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710920|NCT05013073|NA|SINGLE_GROUP||OTHER||NONE|Open Label.|Single arm prospective open label study||||
33710921|NCT01953068|||CASE_CONTROL||PROSPECTIVE|||||||
33710922|NCT05881447|||COHORT||PROSPECTIVE|||||||
33710923|NCT03620240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33710924|NCT01694030|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33710925|NCT01841983|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33710926|NCT03912155|||COHORT||PROSPECTIVE|||||||
33710927|NCT01804621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33710928|NCT06238050|||COHORT||PROSPECTIVE|||||||
33710929|NCT05490641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33710930|NCT04657120|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012773|NCT00922558|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34012774|NCT04890080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012775|NCT02011919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096009|NCT05391074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096010|NCT06131593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and assessing study outcomes will be blinded to the study group allocation.|Patients will be divided in to two groups; TAPB with dexamethasone as an adjuvant to local anesthetic Gr A(n=25) and TAPB with methyl prednisolone as an adjuvant to local anesthetic Gr B(n=25).|t|f|f|t
33710931|NCT00578812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710932|NCT02530593|||COHORT||PROSPECTIVE|||||||
34096011|NCT02261142|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34096012|NCT04993911|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34096013|NCT04855812|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized Clinical Trial|t|t|t|t
33710933|NCT03743389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710934|NCT00112060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012776|NCT01995721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012777|NCT05329298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34012778|NCT06288191|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, single centre, clinical trial||||
34012779|NCT04415008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012780|NCT04641793|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34012781|NCT03338842|NA|SINGLE_GROUP||TREATMENT||NONE||In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.||||
34012782|NCT02265341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012783|NCT02732691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012784|NCT01921465|||COHORT||PROSPECTIVE|||||||
34012785|NCT03325985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34012786|NCT02256579|||COHORT||PROSPECTIVE|||||||
34012787|NCT04925713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012788|NCT02470091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012789|NCT01638650|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096014|NCT00371631|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34096015|NCT02361684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34096016|NCT05564923|||COHORT||PROSPECTIVE|||||||
33710935|NCT05738668|||COHORT||RETROSPECTIVE|||||||
34096017|NCT04802915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096018|NCT02793778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096019|NCT00454142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096020|NCT00501085|||CASE_ONLY||PROSPECTIVE|||||||
33710936|NCT02173327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33710937|NCT00950703|||||PROSPECTIVE|||||||
34096021|NCT05942989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096022|NCT03767894|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects are assessed by an independent therapist. The therapist is not blinded to the control mechanism used during treatment.|||||
34096023|NCT03583866|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34096024|NCT04819620|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34096025|NCT02825537|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34096026|NCT06523946|||COHORT||PROSPECTIVE|||||||
33710938|NCT02648776|||COHORT||PROSPECTIVE|||||||
34012790|NCT05783661|RANDOMIZED|PARALLEL||TREATMENT||NONE|"The study treatment is not blinded, however the rectal and nasal swabs of the control group will be blinded to the investigator and the participant.~In all participants, microbiology department will immediately process the samples (swabs) in order to identify a potential colonization by MDR bacteria. Results will be available in the SAP system in patients randomized to the surveillance group but will remained blinded for the clinical investigators in the control group. Blinding will be broken when the patient completes the follow-up period (28 days)."|"Patients will recieve:~1. Antibiotic regimens guided by colonization/epidemiological surveillance.~2. Conventional antibiotic regimens."||||
34012791|NCT00449982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012792|NCT00684567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012793|NCT03150355|||CASE_ONLY||RETROSPECTIVE|||||||
34096027|NCT05643144|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34096028|NCT00369863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34096029|NCT00327132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096030|NCT01304719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710939|NCT03012308|||COHORT||RETROSPECTIVE|||||||
33710940|NCT05342545|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|double-blind|1:1 allocation ratio, randomized controlled trial|t|t|t|t
33710941|NCT03617445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a phase 2, double blind, doubly placebo-controlled, randomized trial assessing the treatment effects of FMT compared to oral Vancomycin for recurrent CDI in solid organ transplant recipients.|t|t|t|t
33710942|NCT02902198|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33710943|NCT01192854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710944|NCT01854710|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Single-center, randomized, double-blind, double-dummy, 2-dose, 3-period, active- and placebo-controlled, crossover QT/QTc and pharmacokinetic (PK) study of ADASUVE in healthy volunteers. All dosing and treatment-day follow-up in the study was conducted in the clinical research unit (CRU)|t|t|t|t
33710945|NCT06421493|||CASE_CONTROL||PROSPECTIVE|||||||
33710946|NCT01786044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33710947|NCT05506891|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710948|NCT03740945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710949|NCT04374721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||patients will undergo circadian genes evaluation in peripheral blood mononuclear cells||||
33710950|NCT05235672|||COHORT||RETROSPECTIVE|||||||
33710951|NCT00000534||||PREVENTION||DOUBLE||||||
33710952|NCT02771002|||COHORT||PROSPECTIVE|||||||
33710953|NCT00273871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710954|NCT04234178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710955|NCT05043506|||COHORT||RETROSPECTIVE|||||||
33710956|NCT01292616|||CASE_ONLY||PROSPECTIVE|||||||
33710957|NCT02967835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710958|NCT01433614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710959|NCT02370160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710960|NCT00889460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33710961|NCT01282892|||COHORT||PROSPECTIVE|||||||
33710962|NCT04157439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33710963|NCT02798575|||OTHER||PROSPECTIVE|||||||
33710964|NCT05622084|||COHORT||RETROSPECTIVE|||||||
33710965|NCT04585386|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33792556|NCT02618278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792557|NCT05263960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792558|NCT00373269|||COHORT||PROSPECTIVE|||||||
33792559|NCT00628719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792560|NCT03601351|||COHORT||RETROSPECTIVE|||||||
33792561|NCT02582710|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792562|NCT04292093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33792563|NCT03538210|||COHORT||PROSPECTIVE|||||||
33792564|NCT01250548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710966|NCT01804075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33710967|NCT00850564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710968|NCT05065632|||COHORT||CROSS_SECTIONAL|||||||
33710969|NCT02198274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710970|NCT03534557|||COHORT||PROSPECTIVE|||||||
33710971|NCT00913497|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33710972|NCT06021730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33710973|NCT00790023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33710974|NCT05740397|RANDOMIZED|PARALLEL||OTHER||NONE||The present study is a randomized controlled three parallel groups trial. The patient allocation is 1:1:1. The outcome of patients undergoing cardiac surgery and treated with a MAP standard during CPB is compared to patients treated with high MAP and patient-tailored MAP during CPB||||
33710975|NCT04964531|||COHORT||PROSPECTIVE|||||||
33710976|NCT02634671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33710977|NCT01343498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710978|NCT04809688|NA|SINGLE_GROUP||TREATMENT||NONE||Healthy subject (n=20) will be enrolled in a single group for oral administration of dried Saskatoon berry as snack.||||
33710979|NCT01126450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710980|NCT01367002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710981|NCT02616055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Extension Study, participants to be followed at the dose of tesevatinib they were receiving in Study KD019-101.||||
33710982|NCT00394732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33710983|NCT04745429|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is impossible to conduct a masked trial as the intervention is collection of exercises that have to be taught by an instructor.|"Two groups, intervention and control, 10 weeks of intervention. Study visits, blood, saliva collection twice: before and after."||||
33710984|NCT00670683|||||PROSPECTIVE|||||||
33710985|NCT01111097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33710986|NCT01427504|RANDOMIZED|CROSSOVER||||NONE||||||
33792565|NCT03853655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801926|NCT05736133|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the new model of care and comparison, it is not possible to blind the patient participants or health care providers. Since the primary outcomes are self-reported outcome measures, the assessor is also not blind to the intervention.|This is a pilot cluster randomized controlled trial randomizing 14 sites to the PT-led primary care model for hip/knee pain or to the usual care model||||
33801927|NCT00937183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801928|NCT00419341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801929|NCT04700189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801930|NCT02226536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801931|NCT03813498|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801932|NCT04255290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801933|NCT00074646|RANDOMIZED|||TREATMENT||NONE||||||
33801934|NCT04806529|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participant and observer-blinded|Observer-blind design, 2-arm, parallel group with 1:1 randomization between aCoV2 and placebo, equally stratified by age in two age subgroups, 18-55 years and 56 years and older|t|t|t|f
33801935|NCT01363492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801936|NCT05342233|||COHORT||PROSPECTIVE|||||||
33710987|NCT02061982|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33710988|NCT03331003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33710989|NCT03485547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33710990|NCT02387398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710991|NCT06204146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33710992|NCT04901468|||OTHER||PROSPECTIVE|||||||
33710993|NCT02704117|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33710994|NCT04413396|||CASE_ONLY||PROSPECTIVE|||||||
33710995|NCT01721278|||COHORT||PROSPECTIVE|||||||
33710996|NCT02688140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33710997|NCT03459547|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|double-blind|Patients of more than 18 years old without systemic disease/ disorders, smokers of less 5 cigarettes per day, periodontally healthy or treated with full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤ 15% at baseline with edentulous space needing an all on four or all on six treatment with overdenture width of the keratinized gingiva ≥ 2 at the level of the crest|t|f|t|f
33710998|NCT04029948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33710999|NCT04694417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants assigned to the two tablet groups will be blinded to the intervention. The magnesium and placebo tablets that are used in the trial will be identical in terms of packaging and appearance. The compression stocking group cannot be blinded, but the participants will not know their allotted intervention until they have received it by mail delivery. The statisticians will be blinded to the group allocation by using codes to label the three groups and will randomly assign outcome assessors to the follow-up. The allocation sequence will be concealed until the end of the study. The allocation code will be stored in a separate file.||t|f|t|f
33711000|NCT04964310|||CASE_CONTROL||RETROSPECTIVE|||||||
33711001|NCT02164760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711002|NCT00284583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33711003|NCT06066944|RANDOMIZED|PARALLEL||OTHER||NONE|A senior physiotherapist will be hired to assess the outcome measures.|Participants will be assigned to the intervention and control group randomly.||||
33711004|NCT01437072|||||CROSS_SECTIONAL|||||||
33711005|NCT03598556|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
33711006|NCT02539121|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33711007|NCT05950932|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participants and the evaluators enrolling the participants will be blinded to the treatment conditions. The verum and placebo products will be packaged in indistinguishable separate containers, labeled with alphanumeric codes, and placed inside a dedicated kit. The alphanumeric keys related to the classification of products as treated/placebo will only be made available to the researchers after the data processing has been completed.|The treatment order (Melissa phytosome or placebo) will be randomly assigned using a binary random sequence generated through appropriate programming on an electronic spreadsheet. The order of phytosome/placebo administration will be achieved through block randomization (block size = 4), with participant stratification based on gender.|t|f|t|f
33711008|NCT01718275|||CASE_CONTROL||PROSPECTIVE|||||||
33711009|NCT00179114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711010|NCT00084721||||TREATMENT||||||||
33801937|NCT04092205|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, active-treatment controlled once daily oral administration for 28 days and 28 days follow up||||
33801938|NCT04867824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33935284|NCT04507490|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind. Only the interventionist will be allowed to access the vibration condition. In this way, the patient and the investigator will be blind for the type of vibration that the patient will receive.|After confirming the eligibility criteria, patients will be asked to sign the informed consent form. Subsequently, they will be randomly allocated to three groups: (i) group 6 Hz: full body vibration (frequency 6 Hz, amplitude 4 mm, five cycles lasting 1 minutes and interval between cycles of 1 minute) , (ii) 25 Hz group: full body vibration (25 Hz frequency, 4 mm amplitude, five cycles lasting 1 minute and interval between 1 minute cycles) and (iii) sham group: The sham vibration will be performed with the platform disconnected. Additionally, a sound device will be connected producing a noise similar to that of the connected platform for a time equivalent to that of the treatment protocol. The patient will be instructed to position himself standing on the platform, with a semi knee flexion in order that the vibration wave does not propagate to the head. There will be a washout time of at least one week between one intervention and another|t|f|t|f
33935285|NCT04060433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935286|NCT02726204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33935287|NCT03028532|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935288|NCT05130229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935289|NCT03270618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012794|NCT05698927|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33711011|NCT05211882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935290|NCT04449718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012795|NCT00365287||||TREATMENT||NONE||||||
34012796|NCT00126126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34012797|NCT00923884|||COHORT||PROSPECTIVE|||||||
34012798|NCT05114382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective, single center, open-label, single arm study to evaluate the safety and technical performance of the CathVision Cube® system.||||
34012799|NCT04108247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012800|NCT06546007|||COHORT||PROSPECTIVE|||||||
34012801|NCT06226194|||COHORT||PROSPECTIVE|||||||
34012802|NCT04747704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711012|NCT01131663|||CASE_ONLY||PROSPECTIVE|||||||
33711013|NCT00144053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711014|NCT04506372|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled clinical trial||||
33720643|NCT04124289|||COHORT||PROSPECTIVE|||||||
33720644|NCT05962294|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33935291|NCT05371132|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935292|NCT01677676|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34012803|NCT03313648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two different treatments are conducted on the participant base on the randomized choices|f|f|t|t
34012804|NCT00725478|||||PROSPECTIVE|||||||
34012805|NCT01981499|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34012806|NCT04297995|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Part 1: open label.~Part 2: Matters related to the blinding of study treatment will be carried out by the statistics department. The subjects, the INV, the sponsor, and designees are not aware of the randomized allocation. This study will be unblinded overall approximately 3 months after the first administration in the last subject. Unblinding is allowed unless there is an emergency medical condition (emergency treatment is only possible when being informed of the randomized medication) or unblinding is requested by the regulatory authorities. Otherwise, the study should remain blinded. Only when all data have been input into the database, all data queries have been resolved, and subjects have been allocated into analysis sets, can the randomization codes be unblinded."||t|f|t|f
34096031|NCT04574700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096032|NCT01029483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34096033|NCT03970343|||OTHER||PROSPECTIVE|||||||
34096034|NCT00710554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34096035|NCT00260390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096036|NCT00875459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096037|NCT04294238|NA|SINGLE_GROUP||PREVENTION||NONE||Self-control study||||
34096038|NCT02027194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096039|NCT06423027|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34096040|NCT01986751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096041|NCT01703221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096042|NCT01663831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096043|NCT04453007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention is an online program, not an individual administering it, so masking is not necessary. Similarly, the same online survey is deployed in all follow-up assessments regardless of condition, and data are not collected by individuals, so masking of investigators is not necessary.||t|f|f|f
34096044|NCT00003812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096045|NCT06235970|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The investigators will use a single-group design in which 72 healthy young adults receive different stimulation protocols, randomized within-subject during either resting state or cognitive task conditions, while brain activity is monitored with electroencephalography (EEG).||||
34096046|NCT06548958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096047|NCT01129895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720645|NCT00445159|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096048|NCT01002391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34096049|NCT05351034|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33720646|NCT00680745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012807|NCT04294342|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||An intervention group which will be training the 10-week judo4 balance|f|f|f|t
34012808|NCT00322647|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34012809|NCT01185028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012810|NCT00614926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012811|NCT01863693|||COHORT||PROSPECTIVE|||||||
34012812|NCT04553224|NA|SINGLE_GROUP||OTHER||NONE||||||
34012813|NCT03897647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012814|NCT00363402|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34012815|NCT02554734|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34012816|NCT06409650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012817|NCT03311308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012818|NCT03018379|||COHORT||CROSS_SECTIONAL|||||||
34012819|NCT02712801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711015|NCT06117657|NA|SEQUENTIAL||TREATMENT||NONE||Low dose group will be administrated with 2.4×10\^11 vg/kg; Middle dose group will be administrated with 8.0×10\^11 vg/kg; High dose group will be administrated with 2.4×10\^12 vg/kg;||||
33711016|NCT01669616|||COHORT||CROSS_SECTIONAL|||||||
33711017|NCT04425915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711018|NCT00738595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711019|NCT04951999|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711020|NCT00959309|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33711021|NCT03141476|RANDOMIZED|PARALLEL||PREVENTION||NONE||BMI: \<30kg/m\*m: 1,5g, 31-50kg/m\*m: 3,0g, \>50kg/m\*m: 4,5g||||
33711022|NCT02672878|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33711023|NCT04726605|||COHORT||PROSPECTIVE|||||||
33711024|NCT04592601|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Single Group Clinical Trial||||
33711025|NCT05184244|||OTHER||CROSS_SECTIONAL|||||||
33711026|NCT04278638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711027|NCT00819611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711028|NCT01906502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711029|NCT00784498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711030|NCT03972332|||COHORT||PROSPECTIVE|||||||
33711031|NCT05033860|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"1. Intervention group: leaflets containing knowledge of COVID-19 and vaccination were distributed, and questionnaire surveys were conducted afterwards.~2. Control group: questionnaire surveys were conducted without leaflets distribution."|t|f|f|f
33711032|NCT06058676|||COHORT||PROSPECTIVE|||||||
33711033|NCT04000490|||COHORT||PROSPECTIVE|||||||
33711034|NCT05221515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711035|NCT03736616|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711036|NCT00980382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711037|NCT04356950|||OTHER||PROSPECTIVE|||||||
33711038|NCT01102504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33711039|NCT05412745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711040|NCT00645008|||OTHER||OTHER|||||||
33711041|NCT05281887|||COHORT||PROSPECTIVE|||||||
33711042|NCT04091854|||COHORT||PROSPECTIVE|||||||
33711043|NCT03987529|||CASE_ONLY||PROSPECTIVE|||||||
33711044|NCT01288105|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711045|NCT04445545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33711046|NCT05290415|||COHORT||CROSS_SECTIONAL|||||||
33711047|NCT02601469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711048|NCT00587054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711049|NCT05369637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33711050|NCT04481932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711051|NCT00521235|||COHORT||PROSPECTIVE|||||||
33711052|NCT02531906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711053|NCT03555955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711054|NCT01738360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711055|NCT02063620|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33711056|NCT04718051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711057|NCT05468827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||all study participants are allocated to intraoperative ICG mapping of locoregional lymphatic collector||||
33711058|NCT05845151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711059|NCT01595932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711060|NCT06076265|||COHORT||PROSPECTIVE|||||||
33711061|NCT06037447|||COHORT||PROSPECTIVE|||||||
33711062|NCT05374434|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33711063|NCT01055171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711064|NCT02297373|||COHORT||PROSPECTIVE|||||||
33711065|NCT04020965|RANDOMIZED|PARALLEL||PREVENTION||NONE|Outcome collectors were not informed of intervention status, but could have inferred status from observing intervention hardware during household visits.|||||
33711066|NCT04334031|NA|SINGLE_GROUP||OTHER||NONE||||||
33711067|NCT03394326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012820|NCT05043259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012821|NCT05012202|||COHORT||PROSPECTIVE|||||||
34012822|NCT03271606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34012823|NCT01993602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012824|NCT01878721|||CASE_ONLY||PROSPECTIVE|||||||
34012825|NCT01805726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012826|NCT06305520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Medical Device|t|f|t|f
34012827|NCT03811626|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34012828|NCT04292366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012829|NCT05015335|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective, single-center,open-lablel, interventional, randomizedcontrolled clinical trial that will be performed at the Ophthalmology Department, Peking Union Medical College Hospital.||||
34012830|NCT06337214|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34012831|NCT03966859|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The atorvastatin drug and the placebo will be encapsulated in identical capsules. Participants will not be aware of the treatment that they will be receiving; neither will the researcher. Allocation of treatments will be recorded on a Randomisation List, which will be updated when each new participant enters the randomised phase. The list will be held by a scientist uninvolved in the study.|Participants will be randomised, in a double-blind fashion, to either placebo or atorvastatin. The randomisation code will be drawn up by a researcher not involved in the study using an online randomisation tool (https://www.sealedenvelope.com/simple-randomiser/v1/lists).|t|t|t|f
34012832|NCT00834899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012833|NCT00705120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012834|NCT02804555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34012835|NCT05571267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012836|NCT01965184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012837|NCT04799613|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34012838|NCT06063668|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34012839|NCT00207194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012840|NCT06233578|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012841|NCT02584088|||CASE_ONLY||PROSPECTIVE|||||||
34012842|NCT02693431|||COHORT||PROSPECTIVE|||||||
34012843|NCT06207487|||COHORT||RETROSPECTIVE|||||||
34012844|NCT05876728|||CASE_CONTROL||PROSPECTIVE|||||||
34012845|NCT01084018|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34012846|NCT02493920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012847|NCT03262727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012848|NCT03138824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711068|NCT02771912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711069|NCT04226001|||COHORT||PROSPECTIVE|||||||
33711070|NCT05746312|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||We recruited 8 Black American adults to participate in this multiple baseline study. In a multiple-baseline design, one takes repeated measurements of one's outcomes of interest across time, and subsequently compares these outcomes of interest between an initial baseline control period with no intervention and a subsequent intervention period. This is a within-subjects study design for which participants serve as their own control.||||
33711071|NCT03414814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711072|NCT04352647|||COHORT||CROSS_SECTIONAL|||||||
33711073|NCT01365910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711074|NCT03570645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine or dexamethasone|f|f|t|t
33711075|NCT02067871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711076|NCT03128554|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33711077|NCT04817865|||COHORT||RETROSPECTIVE|||||||
33711078|NCT02764515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711079|NCT03980002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711080|NCT00700661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711081|NCT00492037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33711082|NCT03933345|||COHORT||PROSPECTIVE|||||||
33711083|NCT05130320|||CASE_CONTROL||PROSPECTIVE|||||||
34012849|NCT02705833|||COHORT||RETROSPECTIVE|||||||
34012850|NCT03269799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012851|NCT05574894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012852|NCT02519621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012853|NCT02130167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012854|NCT04844021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will randomize clinics to the active implementation conditions (Nudge \[k = 15\] or Nudge+ \[k = 15\]). Clinicians in clinics assigned to both conditions will deliver the S.A.F.E. Firearm storage program to patients during well-child visits.~Clinicians from all participating clinics, regardless of study arm, will be invited to participate in surveys and interviews."||||
34012855|NCT03267420|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012856|NCT04838028|||COHORT||PROSPECTIVE|||||||
34012857|NCT01007474|||COHORT||PROSPECTIVE|||||||
34012858|NCT01524328|||COHORT||CROSS_SECTIONAL|||||||
34012859|NCT00210613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012860|NCT06308835|||COHORT||PROSPECTIVE|||||||
34012861|NCT00167128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012862|NCT04142619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012863|NCT04387734|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012864|NCT06053762|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012865|NCT01926275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012866|NCT06110247|||CASE_CONTROL||PROSPECTIVE|||||||
34012867|NCT00369382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012868|NCT05519709|||COHORT||CROSS_SECTIONAL|||||||
34012869|NCT06425952|||COHORT||PROSPECTIVE|||||||
34012870|NCT01774175|||CASE_CONTROL||PROSPECTIVE|||||||
34012871|NCT05990842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012872|NCT06389916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012873|NCT01763918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012874|NCT04685551|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34012875|NCT03347513|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34012876|NCT01435226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012877|NCT04828798|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blinded crossover design|t|f|t|t
34012878|NCT00799916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012879|NCT01208428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012880|NCT04555278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will be masked to rTMS intervention (real or sham) but cannot be blinded to the exercise intervention. However, participants will not be aware of the study design (other arms).~Therapist delivering the exercise intervention will be masked to rTMS intervention (active vs. sham) but cannot be blinded to exercise intervention (yes vs. no).~Experimenter delivering the rTMS intervention will be masked to exercise intervention but not to rTMS intervention (real or sham).~Outcomes assessor will be completely masked to all interventions as all outcomes are questionnaires that will be completed online. Data will be de-identified and the data analyst will be masked to participants and group allocation."|"Pseudo-factorial design (rTMS: Active/Sham \| Exercises: Yes/No)"|f|f|f|t
34012881|NCT03420768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012882|NCT05829759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012883|NCT02770105||CROSSOVER||||SINGLE|||t|f|f|f
34012884|NCT02217696|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34012885|NCT02816502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34012886|NCT04216615|||COHORT||PROSPECTIVE|||||||
34012887|NCT05500573|NA|SINGLE_GROUP||TREATMENT||NONE||Sperm ejaculates are processed by an in-house protocol that utilized a multilayer density gradient comprised of four concentrations: 20%, 40%, 60%, and 90% to attempt selection of gender specific spermatozoa.||||
34012888|NCT02777918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34012889|NCT04259255|||OTHER||PROSPECTIVE|||||||
34012890|NCT00384384|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34012891|NCT00922259|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34012892|NCT05385809|||COHORT||RETROSPECTIVE|||||||
34012893|NCT05855616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Group A: Haemodialysis catheter exit site dressing with 2% chlorhexidine gluconate self-adhesive semi-permeable polyurethane dressings~Group B: Haemodialysis catheter exit site dressing with 2% chlorhexidine aqueous solution and covered with a dressing of self-adhesive semi-permeable polyurethane dressings."|f|f|f|t
34012894|NCT01020513|||CASE_ONLY||PROSPECTIVE|||||||
34012895|NCT02315066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
34012896|NCT00164541|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012897|NCT02602834|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34012898|NCT00005119||PARALLEL||DIAGNOSTIC||||||||
34012899|NCT01045421|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012900|NCT05750147|||COHORT||PROSPECTIVE|||||||
34012901|NCT02505152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012902|NCT03728023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34012903|NCT00494624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34012904|NCT00016276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012905|NCT03383419|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34012906|NCT03580564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012907|NCT04645979|||OTHER||RETROSPECTIVE|||||||
34012908|NCT02199678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34012909|NCT04036149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012910|NCT00412737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34012911|NCT02617524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012912|NCT04803188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34012913|NCT03319095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The main investigators and assessor will be blinded in relation to the allocation of participants in the groups||f|f|t|t
34012914|NCT02606526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012915|NCT03679273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012916|NCT03964610|||COHORT||PROSPECTIVE|||||||
34012917|NCT00095433||||TREATMENT||NONE||||||
34012918|NCT03864042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34012919|NCT05503251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012920|NCT06037278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012921|NCT01271179|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34096050|NCT03676725|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The scoring of the lidocaine test is masked, using the coded identity of the tastes. The tastes will be assessed in random order. The subjects and other study personnel will be told not to discuss what the subject could or couldn't taste. Scoring will not be shared with the testing site until all testing is complete.|A group of 100 subjects will be assessed.||||
34096051|NCT05474976|||OTHER||CROSS_SECTIONAL|||||||
34096052|NCT03897192|||CASE_ONLY||RETROSPECTIVE|||||||
34096053|NCT01678690|NA|SINGLE_GROUP||||NONE||||||
34096054|NCT05505890|||COHORT||PROSPECTIVE|||||||
34096055|NCT05431179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801939|NCT06516107|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34012922|NCT00512837||PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34012923|NCT04818437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012924|NCT05888324|||COHORT||PROSPECTIVE|||||||
34012925|NCT02150772|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012926|NCT01509482|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34012927|NCT04966364|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|participants and care provider and outcome assessor are blinded|using hypotension prediction index guided in the operation|t|t|f|t
33711084|NCT01104350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012928|NCT02348502|||COHORT||PROSPECTIVE|||||||
34012929|NCT01944787|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096056|NCT04902144|NA|SINGLE_GROUP||SCREENING||NONE||||||
34096057|NCT06494982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096058|NCT00615316|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33711085|NCT04838613|NA|SEQUENTIAL||DIAGNOSTIC||NONE||"Once eligibility is confirmed, the participants will be randomized in IRT to be assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio:~* Sequence 1: \[18F\]CTT1057 on Day 1 (investigational imaging agent of interest) followed by \[68Ga\]Ga-PSMA-11 at least 14 days apart (as part of CTS if required, and for secondary endpoint)~* Sequence 2: \[68Ga\]Ga-PSMA-11 (as part of CTS if required, and for secondary endpoint) on Day 1 followed by \[18F\]CTT1057 (investigational imaging agent of interest) at least 14 days apart"||||
33711086|NCT04250883|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE||Randomized|t|t|f|t
33711087|NCT05871645|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33711088|NCT04908878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711089|NCT00439244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711090|NCT03801291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711091|NCT05092724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33711092|NCT03322878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33711093|NCT01057342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711094|NCT04869644|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33711095|NCT02480439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711096|NCT05577442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711097|NCT02804932|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33711098|NCT03719521|RANDOMIZED|PARALLEL||OTHER||SINGLE|Staff conducting the outcome survey will be masked to the arm allocation|Community Based Interventions to improve HIV outcomes in youth: a cluster randomised trial|f|f|f|t
33711099|NCT01876160|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33711100|NCT03935204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33711101|NCT02452489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711102|NCT06175910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711103|NCT03032705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711104|NCT05669495|||COHORT||PROSPECTIVE|||||||
33711105|NCT05032560|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part A: single-ascending-dose Part B: escalating multiple-dose|t|t|t|t
33711106|NCT04767932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711107|NCT02007694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34012930|NCT03393455|||OTHER||RETROSPECTIVE|||||||
34096059|NCT03813251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096060|NCT01885234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34096061|NCT02018887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096062|NCT04756284|||CASE_ONLY||OTHER|||||||
34096063|NCT04258098|||CASE_CONTROL||RETROSPECTIVE|||||||
34096064|NCT01215240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects randomized to peritoneal dialysis catheter (PDC) or no PDC and standard care.||||
34096065|NCT01659541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096066|NCT05838040|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33711108|NCT02268604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33711109|NCT06153329|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711110|NCT05502601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33711111|NCT01233440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711112|NCT04569266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711113|NCT01074112|||COHORT||CROSS_SECTIONAL|||||||
33711114|NCT04502589|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 subjects with AUD will be randomized 1:1 to one of two groups; perampanel by itself, and perampanel combined with disulfiram.||||
33711115|NCT03766581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711116|NCT01308775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711117|NCT06498999|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized control trial design will be used in this study. It will be a three-arm study with the following groups: (1) an experimental group receiving the intervention in a group setting, (2) an experimental group receiving the intervention in an individual setting, and (3) a waitlist control group. In this research, a parallel group design will be used, with treatment given to all participants in a parallel manner. The allocation ratio and framework will be equivalence, meaning that each of the three groups will have an equal number of participants.||||
33711118|NCT00628784|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711119|NCT04443270|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Outcome Assessor will be an external member of the Internal Medicine Service, which will be blinded to the intervention.|Controlled Clinical Trial|f|f|f|t
33711120|NCT05770791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33711121|NCT02315001|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33711122|NCT04344925|||COHORT||PROSPECTIVE|||||||
33711123|NCT01606436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33711124|NCT05693896|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33711125|NCT06259266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711126|NCT05948696|||OTHER||PROSPECTIVE|||||||
33711127|NCT05544916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33711128|NCT00292266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711129|NCT06472063|||OTHER||RETROSPECTIVE|||||||
33711130|NCT01190774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33711131|NCT03009188|||FAMILY_BASED|||||||||
33711132|NCT01080534|RANDOMIZED|CROSSOVER||||NONE||||||
33711133|NCT03598283|||COHORT||PROSPECTIVE|||||||
33711134|NCT00359060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33711135|NCT01717261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711136|NCT01299792|||COHORT||PROSPECTIVE|||||||
33711137|NCT01238432|||CASE_CONTROL||PROSPECTIVE|||||||
33711138|NCT00386945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711139|NCT04580667|||COHORT||PROSPECTIVE|||||||
33711140|NCT01331447|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711141|NCT00808977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711142|NCT01467167|||CASE_CONTROL||PROSPECTIVE|||||||
33935293|NCT04022291|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind||t|f|t|f
33711143|NCT04547569|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711144|NCT02761278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711145|NCT01207869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33711146|NCT00789022|||||PROSPECTIVE|||||||
33711147|NCT04089384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||All patients selected for the research will be interviewed by the same Nutritionist, responsible for the anthropometric assessment, who will use a specific questionnaire to record the personal, socioeconomic and lifestyle information of the patients. A. Control Group: Patients in this group will receive an individualized eating plan every 15 days and a marked micropore. B. Auriculotherapy group: will receive individualized eating plan every 15 days and will undergo 12 auriculotherapy sessions, 1 per week, lasting 5 to 10 minutes for each session, will be compressed by mustard seed in the following points; mouth, stomach, anxiety, hunger and Shen Men. C. Placebo group: will receive individualized eating plan every 15 days and will undergo 12 auriculotherapy sessions, similar to the auriculotherapy group, but the applications will be in sham points, points not indicative for the proposed treatment, wrist and outer ear points.|t|f|f|f
33711148|NCT05452070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711149|NCT04813198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and co-Is will be blinded to group status. Survey and cognitive assessments will be delivered online without any reference to group. Interventionists have been trained to deliver program content but they are blinded to the primary outcomes of the study. Interviewers who gather qualitative data will be blinded to group status and primary outcomes of the study.|Participants will be randomly assigned to either the intervention or a wait-list control condition.|f|f|t|t
33935294|NCT03741140|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935295|NCT00842972|||COHORT||PROSPECTIVE|||||||
33935296|NCT01453686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935297|NCT03227601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935298|NCT00777686|||CASE_ONLY||PROSPECTIVE|||||||
33935299|NCT04759612|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33935300|NCT04371913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935301|NCT05870397|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The investigators will conduct a single-center, open-label, randomized controlled study in Zhejiang, China. Treatment-naive H. pylori-positive participants (n = 900) were randomly assigned to three groups in a 1:1:1 ratio with the same eradication regimen: amoxicillin 1000 mg, clarithromycin 500mg, rabeprazole 10mg, and colloidal bismuth 200 mg each given twice a day for 14 days. Urea breath tests were administered at different times after treatment: 4 to 6 weeks, 6 to 8 weeks, and 8 to 10 weeks, respectively, for different groups.||||
34012931|NCT05906199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012932|NCT05603455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Blinding of both the investigator (except for the investigator responsible for blinded product allocation) and the subject|a multicenter, double-blind, randomized, controlled study|t|t|t|f
34012933|NCT04774341|||COHORT||RETROSPECTIVE|||||||
33935302|NCT03089034|||COHORT||PROSPECTIVE|||||||
33935303|NCT04773964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935304|NCT02349776|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33711150|NCT02028065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711151|NCT00499577||||TREATMENT||||||||
33711152|NCT03254836|||COHORT||PROSPECTIVE|||||||
33711153|NCT00601458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711154|NCT06368544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711155|NCT00286403|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33711156|NCT01144286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711157|NCT02421432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711158|NCT02426437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711159|NCT01747798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711160|NCT00221585|||DEFINED_POPULATION||PROSPECTIVE|||||||
33711161|NCT06349031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One member of the research group will do the treatment allocation and will not be involved in clinical evaluation and collection of outcome data. Both study medications will be provided by him/her in opaque bottles with identical packaging and labeling. Neither the participants nor the rest of the study personnel will be aware of the treatment allocation.|DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL|t|t|t|t
33711162|NCT00380497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711163|NCT03803397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711164|NCT01928017|||||PROSPECTIVE|||||||
33711165|NCT01007812|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33711166|NCT04703335|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711167|NCT03203304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711168|NCT02649465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711169|NCT02039492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711170|NCT05447715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711171|NCT04258384|||CASE_ONLY||PROSPECTIVE|||||||
33711172|NCT03177694|||CASE_ONLY||PROSPECTIVE|||||||
33711173|NCT05517044|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two independent randomized-controlled trials with each an intervention and a control group.||||
33711174|NCT04073589|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33711175|NCT04922437|||COHORT||RETROSPECTIVE|||||||
34012934|NCT05794724|||COHORT||PROSPECTIVE|||||||
34012935|NCT05215613|||COHORT||OTHER|||||||
34012936|NCT06330532|||COHORT||RETROSPECTIVE|||||||
34012937|NCT03881345|||OTHER||PROSPECTIVE|||||||
34012938|NCT04440449|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Group A - Mobile Health + group intervention~* Group B (control arm)"||||
34012939|NCT03511274|RANDOMIZED|PARALLEL||PREVENTION||NONE||CMV seronegative pregnant women will be randomised to one of two study arms: treatment as usual or the education intervention||||
34012940|NCT01988168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012941|NCT00655850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012942|NCT00782028|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012943|NCT00000334||||TREATMENT||||||||
34012944|NCT02786719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096067|NCT00592826|||CASE_CONTROL||PROSPECTIVE|||||||
33935305|NCT03938558|RANDOMIZED|PARALLEL||OTHER||NONE||"This study distinguish two groups contributing to a dance and art production. The experimental group will perform 10 weeks of dance training, while the other group will contribute to the production in various ways (e.g. word art, photography, painting, ...).~Measures will be taken before and after the training or assistance in the production."||||
33935306|NCT04412668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Investigator, Sponsor, and participant will be blinded to treatment assignment; study center pharmacy personnel will be unblinded.|Participants will be randomized 1:1:1 to a single intravenous (IV) dose of efzofitimod 1 mg/kg, efzofitimod 3 mg/kg, or placebo matched to efzofitimod.|t|t|t|t
33935307|NCT03793790|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A double-blind randomization list (stratified for gender) was created by an independent statistician. Complete blinding of the researchers during the experiment is not possible due to the nature of conditioning paradigms. However, in this study blinding is optimized: the researchers are informed of the (conditioning) group to which participants are allocated after their final inclusion to the study, and after all questionnaires and pain calibration procedures have been completed on the testing day.|This study employs a 2-by-2 design (i.e.,2 conditioning induction groups and 2 attenuation groups), with an additional control group (i.e., sham conditioning). Participants are thus allocated in 1 out of 5 groups.|t|f|t|f
33935308|NCT00510575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935309|NCT02332876|RANDOMIZED|PARALLEL||TREATMENT||||||||
33935310|NCT01674972|||CASE_CONTROL||PROSPECTIVE|||||||
33935311|NCT00028964|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33935312|NCT03968211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935313|NCT01919086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935314|NCT01336257|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935315|NCT03729908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012945|NCT05064748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012946|NCT00567437||PARALLEL||DIAGNOSTIC||NONE||||||
34012947|NCT00825552|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33711176|NCT01932112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711177|NCT01512277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33711178|NCT03529851|NA|SINGLE_GROUP||OTHER||NONE||Feasibility pilot study||||
33711179|NCT02879305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711180|NCT00186030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711181|NCT03848117|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned into two groups: Cyriax Approach group and Mulligan approach group. A coin was flipped at start of data collection for the first patient to be assigned odd number and included in cyriax group. Later on odd and even numbered patients were included in specific group. Additionally, data was collected from lateral epicondylitis patients visiting the DHQ Hospital Bahawalnagar.||||
33711182|NCT03706105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711183|NCT01611649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33711184|NCT04007081|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711185|NCT02536196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33711186|NCT04101461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711187|NCT00965042|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711188|NCT03798496|||COHORT||OTHER|||||||
33711189|NCT05868200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The products will be packaged in such a way that they are not recognizable neither by the operator, nor by the patient. Each package will be assigned a number that in turn will refer to the type of the product. The association between the number and type of the product will be collected by another operator according to the association carried out by a dedicated software. The operator who will deliver the product will be informed about the type only at the end of the treatment.|80 subjects with plaque induced gingivitis, caused by accumulation of plaque, will be selected and enrolled in this study. Subsequently, subjects will be equally divided and randomly allocated for two groups, each group received a similar number of subjects (n=40) with a 1:1 allocation.|t|f|t|f
33711190|NCT04932278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||For this study, participants will be randomly assigned to 1. Usual care, or 2. Usual care and OMT.|f|f|f|t
33711191|NCT00706823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711192|NCT06177587|||COHORT||PROSPECTIVE|||||||
33711193|NCT04418453|||COHORT||PROSPECTIVE|||||||
33711194|NCT04847362|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized controlled trial|f|f|f|t
33711195|NCT02487602|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33711196|NCT03665805|||COHORT||PROSPECTIVE|||||||
33711197|NCT03416530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801940|NCT03122158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Adolescents with major depressive disorder or anxiety disorders will be recruited into 2 different diagnostic groups. Each group will include 30 participants. The total scores of the relevant assessment tools (Clinical Global Impression scale, Hamilton Rating Scale for Depression and Anxiety Disorders) at the starting point, 2nd and 6th month of the treatment will be compared.||||
33711198|NCT02435784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801941|NCT01168544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801942|NCT03067948|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33935316|NCT00638274|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33935317|NCT02015104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935318|NCT04956237|||COHORT||PROSPECTIVE|||||||
33935319|NCT05379764|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The principal investigator and outcome assessor will have no idea who is in what arm. It will be another investigator who is randomising the participant.|Parallel single blind randomised controlled trial|f|f|t|t
33935320|NCT03773601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012948|NCT01323452|||COHORT||RETROSPECTIVE|||||||
34012949|NCT04063982|||OTHER||PROSPECTIVE|||||||
34012950|NCT04628104|||COHORT||CROSS_SECTIONAL|||||||
34012951|NCT00344214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34012952|NCT03178916|||COHORT||PROSPECTIVE|||||||
34012953|NCT01124708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012954|NCT05697367|||COHORT||CROSS_SECTIONAL|||||||
34012955|NCT05899322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Mixed methods (qualitative and quantitative) randomized pilot feasibility trial (n=10 to treatment and 10 to waitlist control)||||
34096068|NCT04165980|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||The current studies have a randomized, parallel, sham-controlled and double-blinded design.|t|f|t|t
33711199|NCT04966598|||OTHER||RETROSPECTIVE|||||||
34096069|NCT02633657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096070|NCT05225168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096071|NCT00672269|||CASE_CONTROL||PROSPECTIVE|||||||
34096072|NCT03295448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34096073|NCT04867330|NA|SEQUENTIAL||TREATMENT||NONE||||||
34096074|NCT00221923|||COHORT||PROSPECTIVE|||||||
34096075|NCT03471949|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33935321|NCT03692195|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will either wear the WHOOP strap 2.0 one week before their sleep study (as well as the night of the sleep study) or one week after their sleep study (as well as the night of the sleep study). This is a within subjects design to compare sleep patterns the week subjects are wearing the Whoop strap 2.0 with the week subjects do not wear the Whoop Strap 2.0. Participants either wear the WHOOP strap 2.0 one week before or one week after their sleep study in order to counterbalance for ordering effects.||||
33935322|NCT02381262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935323|NCT01840280|||OTHER||PROSPECTIVE|||||||
33935324|NCT04849195|||OTHER||RETROSPECTIVE|||||||
33935325|NCT00127816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096076|NCT02383485|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096077|NCT03139630|||COHORT||PROSPECTIVE|||||||
34096078|NCT02737059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096079|NCT01513928|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711200|NCT00004915||||TREATMENT||||||||
34096080|NCT03591536|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|only principle investigator knew the drug from placebo|double blind randomized clinical trial|t|t|f|t
34096081|NCT05349266|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34096082|NCT00981175|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33711201|NCT01888679|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711202|NCT01217814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711203|NCT00438984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711204|NCT01028144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33711205|NCT00833885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711206|NCT02134795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711207|NCT00495339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711208|NCT05341193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935326|NCT02583464|RANDOMIZED|CROSSOVER||||NONE||||||
33935327|NCT01269827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935328|NCT02255955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935329|NCT05855421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935330|NCT01833026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935331|NCT01213511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935332|NCT02453139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935333|NCT00374127|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33935334|NCT03714256|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935335|NCT00824967|RANDOMIZED|PARALLEL||||NONE||||||
33935336|NCT02385591|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935337|NCT04132128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|no masking - open label|described in above section||||
33935338|NCT03552900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be masked to their mobile app however investigators conducting data analysis will be blinded to which participants were assigned to which app|Participants will be randomly assigned to one of two study groups and assigned to one of two different mobile apps|f|f|t|f
33935339|NCT05405855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935340|NCT00290680||||TREATMENT||||||||
33935341|NCT04331210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935342|NCT00645190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935343|NCT00948194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012956|NCT03418987|||COHORT||RETROSPECTIVE|||||||
34012957|NCT00971737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012958|NCT04375839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34012959|NCT05485220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012960|NCT03693534|||COHORT||PROSPECTIVE|||||||
34012961|NCT03794791|||COHORT||PROSPECTIVE|||||||
33711209|NCT01342302|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33711210|NCT03385005|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||The study will involve 3-10 eligible healthy volunteers and 2-5 eligible individuals with a stable cervical spinal cord injury. The study will first enroll healthy volunteers into the study in order to determine the feasibility of evoking refined hand movements through electrical stimulation, and determine the electrical stimulation parameters and electrode spatial configurations responsible for various hand movements. After this is done, the study will proceed with the enrollment of individuals with spinal cord injuries. This enrollment process is being done to reduce the participation time required for participants with a spinal cord injury, and thus lower the likelihood of risks that are more prevalent among individuals with a spinal cord injury.||||
33711211|NCT01310101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711212|NCT03615703|||OTHER||OTHER|||||||
33711213|NCT02509247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711214|NCT02399826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711215|NCT00725569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711216|NCT03478358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711217|NCT03958851|||OTHER||CROSS_SECTIONAL|||||||
33711218|NCT05229380|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34012962|NCT03093272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012963|NCT04873531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|For participant, they will be blind to the group which they will be assigned. The surgeon, who will evaluate the quality of the signal, will be blinded to patient's group.|a randomized controlled trial|t|f|t|f
34096083|NCT00319891|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096084|NCT04958590|||CASE_CONTROL||OTHER|||||||
34096085|NCT01016015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096086|NCT01886157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34096087|NCT04664088|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34096088|NCT04549428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096089|NCT02492919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096090|NCT03889262|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33935344|NCT06019091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be single blinding. Study participants/caretakers will not know which frequency has been assigned.|The participants will be randomized into three groups of 25 participants each for a total of 75 participants. The randomization will occur in blocks so that if the investigators need to terminate the study early there will be an equal number of participants in each group. The size of the blocks will also be kept secret for allocation concealment purposes. The randomization will be stratified by gender so that there is an equal number of participants from each gender in each group, reducing potential for gender as a confounding variable. Group 1 will be the low frequency set at 20 Hz. Group 2 will be the medium frequency set at 50 Hz. Group 3 will be the high frequency set 100 Hz. There is no sham group in this study as it has previously been found that posterior tibial TENS is effective and lasting. As such, all participants will be treated as a matter of routine medical care for pelvic pain.|t|f|f|f
34096091|NCT05210946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711219|NCT00036738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711220|NCT02925494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096092|NCT01552889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096093|NCT03362957|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This will be a single-blinded randomized-controlled study of GAE versus placebo in a small population with knee pain secondary to arthritis to determine safety and efficacy. The placebo procedure will be a diagnostic angiogram of the knee, without embolization. Appropriate measures will be taken to ensure patients and nursing staff caring for the patient are blinded to assignment. Each patient will be told at the time of recruitment that they may be randomly assigned to sham, but if after 1 month they have not had symptom improvement, their assigned procedure would be revealed and, if they had undergone a sham procedure, they will be allowed to proceed with embolization.|t|f|f|t
34096094|NCT03536377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096095|NCT01183637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096096|NCT05099445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096097|NCT02499536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096098|NCT04242134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will remain blinded until the final study results are released.|Patients will undergo 1:1 randomization to either PS-DCB which will be the treatment group or PS-NCB which will be the control group based on an online Clinical Research Data Management Platform provided by King Yee, Beijing CN. The initiation of the trial is defined as the time of randomization. After study subjects' enrollment and randomization, the study intervention will take place immediately. The follow-up visits for the primary endpoint are scheduled at 1, 6, and 12 months after the index procedure. Angiographic follow-up is scheduled at 13 months.|f|f|f|t
33711221|NCT03275012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711222|NCT03607162|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||"This is an open cluster randomized clinical trial with random and sequential crossover of clusters from control to intervention until all clusters are exposed. Clusters are defined as EDs.~2 periods will be considered, one when all children will receive usual care, whatever the cluster, and a second one when, in half of the clusters, the DIAFEVER algorithm will be applied, and in the remaining clusters, children will still receive usual care."|t|f|f|f
33711223|NCT02720471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711224|NCT03689478|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm study||||
33711225|NCT01182987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33711226|NCT06162936|||CASE_CONTROL||PROSPECTIVE|||||||
33801943|NCT03873896|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Photos of blocked digits will be taken and presented to blinded assessors to rate on a pre-determined scale of wrinkling|Blinded control trial assessing aquagenic skin wrinkling after digital nerve blockade in healthy volunteers. Digital nerve blocks to be performed on the left or right ring fingers of volunteers (to be randomized with coin toss) with the unblocked finger of each volunteer acting as its own control|f|f|f|t
33801944|NCT06203873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935345|NCT01885104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33935346|NCT05648006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935347|NCT02144376|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33935348|NCT00239668|||COHORT||PROSPECTIVE|||||||
33935349|NCT03508245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935350|NCT03285061|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33935351|NCT03445611|RANDOMIZED|PARALLEL||PREVENTION||NONE|randomized into either Group1 or Group 2 medication with or without presevatives.|||||
33935352|NCT03105869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||test and retest in a single group of patient||||
33935353|NCT02866773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935354|NCT03862586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935355|NCT01429155|||COHORT||RETROSPECTIVE|||||||
33935356|NCT01490333|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33935357|NCT01511640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33935358|NCT05939193|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33935359|NCT03934489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935360|NCT05002582|||COHORT||PROSPECTIVE|||||||
33935361|NCT01378676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935362|NCT05692986|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33935363|NCT02961400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935364|NCT00311090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935365|NCT01758172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096099|NCT04573530|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Participants are randomized to the intervention or control group||||
34096100|NCT02400580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34096101|NCT04934072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096102|NCT04085003|||OTHER||RETROSPECTIVE|||||||
34096103|NCT03904186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34096104|NCT00977184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096105|NCT05516095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The randomization will be performed in MatLab (https://se.mathworks.com/products/matlab.html), with the randperm command that perform randomization in four permuted blocks to groups and gender in a single operation. The randomization procedure in MatLab will be performed by the Research Department at the University Hospital North-Norway, and they will produce numbered colored envelopes (e.g. pink = female, blue = male) containing number of the coil (e.g. 1= active, 2 = sham) that will be opened by the research assistant who mount the coil before the clinician start the treatment procedure. Thus, neither the clinician nor the patient will know which treatment that is provided, but the patient will be asked to guess their group allocation at the follow-up four weeks after the treatment end, as recommended in recent repetitive transcranial magnetic stimulation (rTMS) guidelines."|Randomized placebo controlled clinical trial|t|t|t|t
34096106|NCT05515263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34096107|NCT05593640|||COHORT||PROSPECTIVE|||||||
34096108|NCT04151498|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34096109|NCT03116269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096110|NCT04772547|NA|SINGLE_GROUP||TREATMENT||NONE|Participants are unconscious, thus, inherently blinded to the intervention. All the endpoints are objective and will be assessed by a blinded investigator to the timing of vigabatrin administration.|pilot feasibility trial of pharmacokinetics of drug absorption||||
34096111|NCT00976391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096112|NCT01794975|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33711227|NCT05311618|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33711228|NCT01869270|||COHORT||RETROSPECTIVE|||||||
33711229|NCT01836770|||COHORT||PROSPECTIVE|||||||
33711230|NCT06488235|||COHORT||CROSS_SECTIONAL|||||||
33711231|NCT05538702|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711232|NCT04167644|||CASE_ONLY||CROSS_SECTIONAL|||||||
34096113|NCT04692051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096114|NCT01058005|RANDOMIZED|PARALLEL||||NONE||||||
34096115|NCT03780387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34096116|NCT01077895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096117|NCT02042001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096118|NCT01696214|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34096119|NCT02549378|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34096120|NCT03869788|||CASE_ONLY||CROSS_SECTIONAL|||||||
34096121|NCT04055662|||CASE_CONTROL||PROSPECTIVE|||||||
34096122|NCT00142597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096123|NCT04055389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34103292|NCT06690632|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The exams and distension scores will be determined by two radiologists (one expert and one trainee) blinded on patient allocation group. In case of disagreement, a third radiologist (expert) will be required.|"Prospective monocentric interventional single-blinded study. Randomization with 1:1 ratio between water preparation and standard preparation after stratification on past bowel resection and structuring phenotype.~The exams and distension scores will be determined by two radiologists (one expert and one trainee) blinded on patient allocation group. In case of disagreement, a third radiologist (expert) will be required."|f|f|f|t
33711233|NCT00824239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711234|NCT04525417|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Monocentric, open-label, prospective, non-randomized study||||
33711235|NCT04997161|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Parallel: Participants are assigned to two groups in parallel for the duration of the study.~Following 7-day screening, all participants who are enrolled will begin an up to 1-month HK Treatment Phase with SZC as per local label. Participants will receive dietary advice consistent with SoC at that site, including K+ restriction. A 4-month Diet Comparison Phase will begin next with participants being randomised to either continue taking SZC, which can be titrated as needed to maintain target S-K+ , and receive enhanced nutritional advice to consume fruit and vegetables (SZC arm), or SZC will be withdrawn and participants will receive SoC, including dietary K+ restriction (SoC arm)."||||
33711236|NCT01009632|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33711237|NCT04495348|||COHORT||PROSPECTIVE|||||||
33711238|NCT04700709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801945|NCT05401513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34012964|NCT00135382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711239|NCT06281990|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The researcher (YY) provided education in the outpatient clinic. The nurses and surgical team members working in the surgical ward were blinded (FÇ in the research group was blinded).|There are two groups in the research: control and intervention groups.|f|t|t|f
33711240|NCT05510180|||COHORT||PROSPECTIVE|||||||
33801946|NCT03572075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801947|NCT04522466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801948|NCT01388361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801949|NCT04695483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711241|NCT03971214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711242|NCT01562418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711243|NCT00230607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711244|NCT00542854|||CASE_CROSSOVER||PROSPECTIVE|||||||
33711245|NCT02790528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711246|NCT03917914|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711247|NCT04009343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and clinical trial nurses and pharmacists will be aware of the treatment assignment.||f|f|t|t
33711248|NCT01163175|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33711249|NCT04675645|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33711250|NCT03772691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711251|NCT00802139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711252|NCT00002581|RANDOMIZED|||TREATMENT||||||||
33711253|NCT05858710|NA|SINGLE_GROUP||TREATMENT||NONE||an adapted 3+3 multiple ascending dose (MAD) design with sentinel dosing||||
33711254|NCT01654029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711255|NCT00385983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33711256|NCT03018821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711257|NCT01612481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711258|NCT06113744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711259|NCT04464889|NA|SINGLE_GROUP||TREATMENT||NONE||"The aim of the study is to determine the recommended phase II dose (RP2D) of MDG1021 that will be determined on the basis of safety and ability to manufacture a cohort specific MDG1021 dose. The dose-escalation part of the study is designed to assess the safety and the MTD of MDG1021, using a standard 3+3 cohort design, with up to 3 additional subjects to be enrolled in case of dose limiting toxicity (DLT).~Upon completion of the dose-escalation part of the study, 20 eligible patients will be treated in the expansion part of the study with MDG1021 at the RP2D to further evaluate safety, feasibility and preliminary efficacy."||||
33711260|NCT00757887|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711261|NCT03450746|||COHORT||PROSPECTIVE|||||||
33801950|NCT01359631|||CASE_ONLY||PROSPECTIVE|||||||
33801951|NCT04045938|||OTHER||RETROSPECTIVE|||||||
33801952|NCT02331745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801953|NCT03215823|||COHORT||PROSPECTIVE|||||||
33801954|NCT01755936|||COHORT||PROSPECTIVE|||||||
33801955|NCT03125785|||COHORT||PROSPECTIVE|||||||
33801956|NCT04019405|||COHORT||PROSPECTIVE|||||||
33801957|NCT00294840|||CASE_ONLY||PROSPECTIVE|||||||
33935366|NCT00944476|||COHORT||PROSPECTIVE|||||||
33935367|NCT04574076|||COHORT||PROSPECTIVE|||||||
33935368|NCT03060590|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33935369|NCT00726167|||CASE_CONTROL||PROSPECTIVE|||||||
34012965|NCT06294379|||OTHER||RETROSPECTIVE|||||||
34012966|NCT01091103||PARALLEL||TREATMENT||NONE||||||
33935370|NCT03640728|||COHORT||PROSPECTIVE|||||||
33935371|NCT01563406|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33935372|NCT05178680|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33935373|NCT01001143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935374|NCT01122823|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33935375|NCT00050570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935376|NCT01018251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935377|NCT00032305|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935378|NCT03350802|||COHORT||PROSPECTIVE|||||||
33935379|NCT02463227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012967|NCT06310265|||CASE_CONTROL||RETROSPECTIVE|||||||
34012968|NCT01800526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012969|NCT06126666|NA|SEQUENTIAL||TREATMENT||NONE||||||
34012970|NCT01360866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012971|NCT01491035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34012972|NCT04171713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34012973|NCT01606852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012974|NCT01351350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012975|NCT01823276|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33711262|NCT00650260|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34012976|NCT03821363|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies||||
34012977|NCT01834781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096124|NCT04345432|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"As each patient is consented, the PI will go to the randomization log which is numbered 1 through 12 and record the subject's study identification number and initials and date in the next available space on the form. He will then remove the large manila envelope in sequence corresponding to the subject's randomization number on the form, open the envelope, and remove the sub-envelope labeled Week 1 Medication. He will remove the packet for Week 1 day 7 and return it to the large envelope. He will then dispense the envelope Week 1 Medication containing packets for days 1-6 to the subject. The large manila envelope will then be placed in the subject's study chart until the next visit on Day 7.~The PI will provide a photocopy of the randomization log to the independent observer after each patient is randomized. Only the independent observer will have the unblinding code in the event that an emergency situation arises and the code must be broken."|"Consented patients are randomized into one of two groups using balanced permutations generated randomization.com. Subject numbers will be ordered and placed in individually numbered, nontransparent envelopes by an independent observer. Trial medication is administered based on the randomization scheme.~Baseline data will be collected followed by a 7-day trial phase of either gabapentin or placebo on a gradually increasing dosing schedule. Post-trial data will be collected on day 7 followed by 1-week washout period and Week 3 crossover medication."|t|f|t|f
34012978|NCT01490866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096125|NCT03081923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, parallel arm, phase 2 trial||||
34096126|NCT01482728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34096127|NCT03949231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711263|NCT01461603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33711264|NCT04755127|RANDOMIZED|PARALLEL||TREATMENT||NONE||non-blinded randomized controlled trial||||
33711265|NCT04954703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711266|NCT02085317|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711267|NCT00272467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711268|NCT04073498|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Part 1a: Open label for intravenous (IV) doses and single blinded for SC doses (subjects are blinded) Part 1b: Single blinded (patients are blinded) Part 2: Open label Part 3: Open label Part 4: Open label Part 5: Open label Part 6: Open label|"The study will be conducted in 7 parts (Part 1a, Part 1b, Part 2, Part 3, Part 4, Part 5 and Part 6).~Part 1a will be a single ascending dose study in 15 healthy male subjects. Part 1b will be a single ascending dose study in a minimum of 12 male patients with severe hemophilia A or B with or without inhibitors.~Part 2 will involve subcutaneous doses not exceeding 1.2 mg/kg SerpinPC every 4 weeks in patients with severe hemophilia A or B with or without inhibitors.~Part 3 will involve subcutaneous doses of SerpinPC in patients who have completed Week 24 of Part 2.~Part 4 will involve subcutaneous doses of 1.2 mg/kg SerpinPC every 2 weeks for 24 weeks in patients who have completed Week 48 of Part 3.~Part 5 will involve subcutaneous doses of 1.2 mg/kg SerpinPC every 2 weeks for 52 weeks for patients who have completed Week 24 of Part 4.~Part 6 will involve a subcutaneous flat dose of 60mg SerpinPC every 2 weeks for 52 weeks for patients who have completed Week 52 of Part 5."|t|f|f|f
33711269|NCT02579720|||OTHER||PROSPECTIVE|||||||
33711270|NCT03142087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711271|NCT04215289|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33711272|NCT00280631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711273|NCT02028013|||CASE_CONTROL||PROSPECTIVE|||||||
33711274|NCT05950490|||COHORT||PROSPECTIVE|||||||
33711275|NCT02063360|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33711276|NCT03188874|||CASE_ONLY||PROSPECTIVE|||||||
33711277|NCT03910062|||COHORT||PROSPECTIVE|||||||
33711278|NCT01802931|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33711279|NCT03802136|||COHORT||PROSPECTIVE|||||||
33711280|NCT02503735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711281|NCT03487068|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711282|NCT01362205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711283|NCT02250170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711284|NCT04884477|||COHORT||RETROSPECTIVE|||||||
34012979|NCT00892788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012980|NCT02619448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012981|NCT04180176|NA|SINGLE_GROUP||OTHER||NONE||||||
34012982|NCT03351530|||CASE_CONTROL||PROSPECTIVE|||||||
33935380|NCT03988894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A pilot two-group (1:1) randomized controlled trial with a sample size of 60 (block of 20) in a Chinese Canadian community in the Greater Toronto Area, Ontario, Canada.||||
33935381|NCT02330601|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33935382|NCT03286634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||risk stratification-directed chemotherapy||||
33935383|NCT03659708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935384|NCT06006143|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
33935385|NCT00102336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935386|NCT00005629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935387|NCT03309241|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|Double-blind (sponsor open)||t|t|t|f
33935388|NCT01942395|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33935389|NCT05219006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935390|NCT05528562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935391|NCT02587975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935392|NCT05581927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||one group was allocated to standard Whole-Body Hypothermia, another group was allocated to modified Whole-Body Hypothermia|t|t|t|t
33935393|NCT04188210|||CASE_ONLY||PROSPECTIVE|||||||
33935394|NCT04764305|||COHORT||PROSPECTIVE|||||||
33935395|NCT02518568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935396|NCT02017067|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012983|NCT00755768|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34012984|NCT05621382|||OTHER||OTHER|||||||
34012985|NCT04142008|NA|SINGLE_GROUP||OTHER||NONE||||||
34012986|NCT05376618|||OTHER||PROSPECTIVE|||||||
34012987|NCT05210452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012988|NCT04178031|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34012989|NCT00269542|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34012990|NCT02605798|RANDOMIZED|CROSSOVER||||NONE||||||
34012991|NCT03307564|NA|SINGLE_GROUP||TREATMENT||NONE||marking the interface between the pancreas and duodenum with TraceIT Tissue Marker in patients undergoing image-guided radiotherapy||||
34012992|NCT04352608|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34012993|NCT04328519|||OTHER||PROSPECTIVE|||||||
34096128|NCT01770730|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34096129|NCT04786925|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants are randomly assigned to Control or NUTRIPRECISION strategy.||||
34096130|NCT01129973|||||PROSPECTIVE|||||||
34103293|NCT06689358|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1: General anesthesia with TPVB; Type: Experimental Intervention: 0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space.~Arm 2: General anesthesia alone (control group). Type: No intervention (control) Intervention: No intervention"||||
33935397|NCT01339676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935398|NCT03644589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935399|NCT02798445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935400|NCT02626806|||COHORT||PROSPECTIVE|||||||
33935401|NCT01847560|||COHORT||RETROSPECTIVE|||||||
33935402|NCT04080349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935403|NCT04461145|NA|SINGLE_GROUP||OTHER||NONE||||||
33935404|NCT00213967|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33935405|NCT02928081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935406|NCT02839590|||COHORT||PROSPECTIVE|||||||
33935407|NCT05906914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34012994|NCT04718129|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors of outcomes will be masked to intervention condition|Mindfulness vs. No intervention control|f|f|f|t
34012995|NCT06341049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34012996|NCT00062751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34012997|NCT02826941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34012998|NCT05025579|NA|SINGLE_GROUP||TREATMENT||NONE||The study, 65-75 years of age a in range, geriatric depression diagnosed with and willing to participate in the study is when individuals were included in the study. Geriatrics psychiatric disorders other than depression who, for any reason unable to ride a bike, that static man, to exercise contraindications u found my show compliance with the exercise program and to the individuals who were excluded from the study .||||
34012999|NCT03665948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013000|NCT05793814|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A Randomized, Double -Blind, Placebo-Controlled Study|t|t|t|t
34013001|NCT02370914|||COHORT||PROSPECTIVE|||||||
33711285|NCT02139111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711286|NCT03036696|||COHORT||PROSPECTIVE|||||||
33711287|NCT00763672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935408|NCT02709941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||the subjects were randomly allocated to either the sham training group or the inspiratory muscle training group using randomization lists for 4 strata (male/female X young/old)|t|f|t|f
33935409|NCT06245395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935410|NCT05488106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind placebo controlled parallel design|t|f|t|t
33935411|NCT00141167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935412|NCT00653406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935413|NCT02079415|||COHORT||PROSPECTIVE|||||||
33935414|NCT02956031|||COHORT||CROSS_SECTIONAL|||||||
33935415|NCT01079208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935416|NCT05681052|||COHORT||PROSPECTIVE|||||||
34096131|NCT05099406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Portable devices for applying the transcranial electrical stimulation are equipped with a software which allows a double-blinded procedure. The same computer program is in charge of randomly allocating patients to one of the three treatment groups. Thus, nor the researchers neither the participants will know what kind of stimulation is receiving each of them.|Participants will be randomly assigned to one of three treatment groups (40% active tDCS; 40% Active tACS; 20% Sham). Patients receiving sham stimulation will act as the control group.|t|t|t|t
34096132|NCT03233685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be blind regarding the aim of the study|Randomized control trial.|t|f|f|f
33801958|NCT03487172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Enrolled subjects will be randomized to 2 treatment groups: Right side treated and Left side treated. All subjects will receive three, single-sided injections of PLLA, performed 1 month apart. Treatments will be provided to one randomly assigned knee. The non-treatment knee will receive bacteriostatic water, injected in the same manner as PLLA. Up to one (1) syringe of PLLA, diluted at 16 mL, will be used per session"|t|f|f|t
33801959|NCT02416115|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33935417|NCT03518463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Mothers delivering by emergency CS were randomly assigned to either ERAS or routine care arms in a ratio of 1:1. We did simple randomization to either ERAS or routine care arm without any blocks. We generated patient group assignments using the computer algorithm (computer-generated list of random numbers) and placed in identical sealed opaque envelopes. A statistician not involved in the research generated the random number list. The envelopes were opened sequentially by the anesthetist when an eligible patient was encountered. Mothers were recruited into the study by the two research assistants implementing ERAS elements. Single blinding of PI and the two research assistants assessing outcomes was done to minimize bias.|The ERAS arm was exposed to modified ERAS elements including preoperative counseling and education, prophylaxis against nausea and vomiting (PONV), individualized goal directed fluid therapy, early mobilization at 6-8 hours postoperative, early feeding within 1 hour postoperative,urethral catheter removal at 6 hours, oral fixed combination non opioid analgesia, oral antibiotics and anti-emetics. PONV included intravenous metoclopromide and dexametasone, no ondansetron given. Patients in the control arm recovered with routine care.|f|f|t|t
33935418|NCT05529134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935419|NCT01748903|||COHORT||PROSPECTIVE|||||||
33935420|NCT06488014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935421|NCT00241657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33935422|NCT01312285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935423|NCT04453618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935424|NCT06256094|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935425|NCT04511429|||COHORT||PROSPECTIVE|||||||
33935426|NCT04347902|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled, clinical trial||||
33935427|NCT04451395|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935428|NCT01438775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096133|NCT02614014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096134|NCT01559285|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34096135|NCT03830411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096136|NCT05007509|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34096137|NCT05983406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096138|NCT04803435|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34096139|NCT01724190|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34096140|NCT02843386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096141|NCT05821595|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33711288|NCT05329974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711289|NCT00830362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013002|NCT01355354|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711290|NCT02373852|||COHORT||RETROSPECTIVE|||||||
33711291|NCT01839851|||COHORT||PROSPECTIVE|||||||
33711292|NCT06145061|||CASE_CONTROL||RETROSPECTIVE|||||||
33711293|NCT05251090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711294|NCT01167894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711295|NCT04528381|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective \& retrospective||||
33711296|NCT06378476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research coordinators collecting baseline and outcomes data from participants will be blinded to arm.||f|f|f|t
33711297|NCT04815161|NA|SINGLE_GROUP||OTHER||NONE||||||
33711298|NCT02205112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711299|NCT02052583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711300|NCT03765905|||CASE_CONTROL||PROSPECTIVE|||||||
33711301|NCT05349175|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33711302|NCT04211623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711303|NCT04462445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711304|NCT04277416|||COHORT||PROSPECTIVE|||||||
33711305|NCT05715034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33711306|NCT03771677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"Active Comparator:nucleotide analogues(NAs) patients continue to use NAs~Experimental: peg-interferon alfa-2a patients switch to sequential peg-interferon α-2a"|"Drug: nucleotide analogues(NAs)~Drug: Peginterferon alfa-2a and nucleotide analogues(NAs)"||||
33711307|NCT00996645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33711308|NCT05529303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The evaluation of the data will be carried out by an independent researcher who will be blinded to the intervention and control groups.|The Prolonged Grief Disorder-Patient Form will be administered to all gynecological cancer patients who meet the inclusion criteria. The patients with the highest prolonged grief reaction as much as the number of samples determined will be included in the study by dividing them into groups through block randomization.|f|f|f|t
33711309|NCT02272595|||CASE_CONTROL||PROSPECTIVE|||||||
33711310|NCT00627120|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33711311|NCT02662296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711312|NCT00064116|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711313|NCT06083272|||CASE_ONLY||PROSPECTIVE|||||||
33711314|NCT04191720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801960|NCT05748730|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be masked to the intervention condition at follow-up assessment time points.|"This study uses an effectiveness-implementation hybrid type 1 randomized clinical trial (RCT) design.~A qualitative, descriptive design will be used to analyze qualitative aims of this study."|f|f|f|t
33801961|NCT03097679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013003|NCT00521274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34013004|NCT05443269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013005|NCT02782091|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013006|NCT04529226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013007|NCT05101993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013008|NCT02225665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013009|NCT00382629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013010|NCT05123313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34013011|NCT05483582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34013012|NCT06132230|||OTHER||RETROSPECTIVE|||||||
34013013|NCT00488930|||CASE_ONLY||PROSPECTIVE|||||||
34013014|NCT03352141|NA|SINGLE_GROUP||OTHER||NONE||||||
34013015|NCT00765011|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34013016|NCT03740906|||COHORT||PROSPECTIVE|||||||
34013017|NCT03632967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013018|NCT03894241|RANDOMIZED|CROSSOVER||OTHER||SINGLE||"The Cogni-Action project presents a two-fold design with a cross-sectional investigation and a crossover-randomized trial. The aim of the first part is to establish the associations of physical activity (PA), sedentarism, and physical fitness with brain structure and function, cognitive performance and academic achievement in 797 Chilean schoolchildren. The aim of the second part is to determinate the acute effects of three different training sessions consisting in (i) Moderate-Intensity Continuous Training (MICT), (ii) Cooperative High-Intensity Interval Training (C-HIIT), and (iii) sedentary activity on spontaneous brain activity and neuroelectric indices of cognitive performance during a working memory and a reading task, as measured by electroencephalography (EEG) and eye-tracker. In an energy expenditure counterbalanced fashion, 32 adolescents will randomly undergo each training session, two weeks apart."|f|f|f|t
34013019|NCT03186703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34013020|NCT04133246|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34013021|NCT03715322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the investigators and the participants will be masked to the study allocation. The randonmization codes will be generated by a blinded medical statistician with the use of computerized program. Randomization will be achieved based on the permuted block design.|Patients will be randomized into the treatment group and control group. No cross-over of the study group will be made.|t|f|t|f
34013022|NCT03815968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096142|NCT00295243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711315|NCT05013593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Double-blinded, randomized, placebo-controlled three-month trial|t|t|t|t
33711316|NCT00461045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711317|NCT06280937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Interventions and assessment will be performed by separate researchers.|Control group will go on their routine daily activities. Study group will wear a tie during one office working day.|f|f|f|t
33711318|NCT00719420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711319|NCT04271137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711320|NCT00353262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711321|NCT01085747|||CASE_CONTROL||PROSPECTIVE|||||||
33711322|NCT02888886|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711323|NCT03910023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this prospective, evaluator-blinded, multi-centre, 2-parallel-arm, Zelen randomized (1:1), controlled trial, UCHE alone will be compared to spa therapy in addition to UCHE for the treatment of chronic low back pain.|f|f|t|t
33711324|NCT04953000|||COHORT||OTHER|||||||
33711325|NCT05536986|||COHORT||PROSPECTIVE|||||||
33711326|NCT03304743|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33711327|NCT04765124|||COHORT||RETROSPECTIVE|||||||
33711328|NCT05037708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Therefore, a randomized, blinded, crossover clinical trial is suggested to assess the effect of an intensive physiotherapy intervention on the treatment of lymphedema in its maintenance phase, in comparison with a control group without physiotherapy treatment.|f|f|t|t
33935429|NCT06178458|||COHORT||RETROSPECTIVE|||||||
33935430|NCT06380556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Using the block randomization technique, participants were divided into three groups. A web-based randomization list generation tool was used to assign participants to groups. Control and intervention groups were coded as A, B and C using the sealed envelope method. Randomization information was withheld from the researcher involved in data collection until data was collected. The researcher determines which group each baby is in. The researcher found out during the painful procedure. (investigator blinding).~Within the scope of the research, parents knew which group the baby was in. However, due to the nature of the sample group, the babies were blind.~To avoid statistical bias, study groups were coded as A, B and C; statistical blinding was performed (statistician blinding)."|In the study, participants were assigned to groups by block randomization. Type of delivery (vaginal and cesarean section), gender (male and female) and birth weight (2500-3000 g, 3001-3500 g, 3501 and above) variables were used for block randomization. Blocks were repeated three times in each group and 36 participants were assigned to each. A randomization list with 2 X 2 X 3 X 3 blocks was developed using an online randomization tool. In the study, the group to which the first participant was assigned was determined by a sealed envelope method.|t|f|f|t
33935431|NCT01841086|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935432|NCT04295668|||CASE_CONTROL||PROSPECTIVE|||||||
33935433|NCT02100813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935434|NCT02521168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935435|NCT05822284|||COHORT||PROSPECTIVE|||||||
34096143|NCT02579122|||CASE_ONLY||PROSPECTIVE|||||||
34096144|NCT02974426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103294|NCT06268730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will follow the same procedures.||||
34103295|NCT01396785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711329|NCT06451978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33711330|NCT03053544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711331|NCT00254449|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711332|NCT05174377|||COHORT||RETROSPECTIVE|||||||
34013023|NCT05112419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two cohorts (patients and matched healthy subjects) to be enrolled for this study.~Approximately 12 participants will be enrolled into each one of the 2 cohorts and receive the study intervention:~* Cohort 1 will enroll participants with moderate hepatic impairment and moderate renal impairment as assessed at screening.~* Cohort 2 will enroll healthy participants"||||
34013024|NCT04107142||SEQUENTIAL||OTHER||NONE||"The study consisT of 3 + 3 dose escalation study design with 3 distinct dose level.~The first dose level will be at 3 x 10\^8 chimeric antigen receptor (CAR) grafted γδ T cells per infusion.~The second dose level will be at 1 x 10\^9 CAR-γδT cells per infusion. The third dose level will be increased to 3 x 10\^9 cells CAR-γδT cells.~Each cycle of therapy will consist of 4 intravenous infusions, given 7 days apart."||||
34013025|NCT03744078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013026|NCT01378741|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34013027|NCT00004135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013028|NCT04428099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013029|NCT03914235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013030|NCT04830436|||COHORT||RETROSPECTIVE|||||||
34013031|NCT03508687|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34013032|NCT05329506|||OTHER||CROSS_SECTIONAL|||||||
34013033|NCT00821002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013034|NCT06181747|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34013035|NCT02549573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013036|NCT01727687|NA|SINGLE_GROUP||||NONE||||||
34013037|NCT02246868||||TREATMENT||||||||
34013038|NCT05457517|NA|SINGLE_GROUP||TREATMENT||NONE||YL-13027 combined with Sintilimab was used as a cycle for 21 days.||||
34013039|NCT03639974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blind: allocation concealment and outcome assessor|This is a randomized clinical trial that will be performed according to the CONSORT Statement (Consolidated Standards of ReportingTrials).|f|f|f|t
34096145|NCT04484181|RANDOMIZED|PARALLEL||OTHER||TRIPLE||In the two arms, embryos were cultured and selected for fresh transfer. For the standard incubation group, the selection for transfer was based on morphological criteria. In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm).|t|t|t|f
34096146|NCT00313898|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34096147|NCT04935294|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34096148|NCT02774174|||CASE_CONTROL||RETROSPECTIVE|||||||
34096149|NCT05331482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be a randomized controlled trial with 3 different groups|f|f|f|t
34096150|NCT02148770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096151|NCT01127477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096152|NCT00332098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096153|NCT04280315|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096154|NCT01890005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096155|NCT01925820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096156|NCT06449248|||CASE_CONTROL||RETROSPECTIVE|||||||
34096157|NCT01769365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096158|NCT05414773|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34096159|NCT01324180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711333|NCT02835924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711334|NCT02026739|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33711335|NCT04767373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33711336|NCT05226715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33711337|NCT00491075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711338|NCT03642405|||COHORT||PROSPECTIVE|||||||
33711339|NCT03889002|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33711340|NCT01468012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711341|NCT03497208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711342|NCT01730469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711343|NCT00838890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711344|NCT03995121|||CASE_CONTROL||PROSPECTIVE|||||||
33711345|NCT00552721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711346|NCT03962010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711347|NCT00174278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711348|NCT02704871|||OTHER||PROSPECTIVE|||||||
33711349|NCT05059210|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic, stepped-wedge cluster randomized controlled trial||||
33711350|NCT01808989|||COHORT||PROSPECTIVE|||||||
33711351|NCT05725967|||COHORT||PROSPECTIVE|||||||
33711352|NCT03167840|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33711353|NCT02339272|||CASE_CONTROL||PROSPECTIVE|||||||
33711354|NCT05090059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711355|NCT05512572|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711356|NCT03978520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013040|NCT06302972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were informed that they would receive treatment either from group 1 or group 2 without indicating which group should undergo IASTM and comprehensive corrective exercise program and which group undergo only comprehensive corrective exercise program|Participants were randomly assigned to the experimental group or control group after a baseline assessment with sealed enveloped method. Each participant took a envelope that identified their group and gave it to the researchers without seeing what was written. Participants were not notified which group was assigned to.|t|f|f|f
33711357|NCT05473702|||OTHER||PROSPECTIVE|||||||
33801962|NCT02032940|||COHORT||PROSPECTIVE|||||||
33801963|NCT04131153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801964|NCT02396602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801965|NCT04146324|||COHORT||PROSPECTIVE|||||||
33801966|NCT00264342|||CASE_CONTROL||PROSPECTIVE|||||||
33801967|NCT05035966|||CASE_CONTROL||RETROSPECTIVE|||||||
33801968|NCT00281554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801969|NCT00869011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33801970|NCT04659018|||COHORT||PROSPECTIVE|||||||
33801971|NCT02637011|||COHORT||PROSPECTIVE|||||||
34013041|NCT03507348|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34013042|NCT05982821|||COHORT||PROSPECTIVE|||||||
34013043|NCT02459041|||COHORT||PROSPECTIVE|||||||
34013044|NCT05778955|||COHORT||PROSPECTIVE|||||||
34013045|NCT05338021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711358|NCT01709916|||CASE_ONLY||PROSPECTIVE|||||||
33711359|NCT04199481|||COHORT||RETROSPECTIVE|||||||
33711360|NCT03608449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|not relevant|Parallel, randomized by order, open study, assignment (matching/rematching) supported by monitoring data.||||
33711361|NCT02221193||CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33711362|NCT02737098|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33711363|NCT00428311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711364|NCT03677531|NA|SINGLE_GROUP||OTHER||NONE||||||
33711365|NCT05433792|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an open label, 3 arms, Multicenter, randomized study to evaluate the effectiveness of new specially designed Fitlens soft central near and central far contact lens, Myolens CN/CF Compared with MiSight® for the control of progressive juvenile onset Myopia in children ages 8-12. with no prior contact lens experience. Subjects will be allocated to either of the study arms - CN / CF or MiSight in a 1:1:1 ratio. The randomization for each arm will be done regardless the Myopia categories.||||
33711366|NCT00828347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711367|NCT01984177|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33711368|NCT00002876||||TREATMENT||||||||
33711369|NCT03809143|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33711370|NCT01525485|||CASE_CONTROL||PROSPECTIVE|||||||
33711371|NCT06358365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711372|NCT00590720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711373|NCT05658146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711374|NCT04743297|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33711375|NCT05272020|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720647|NCT04814225|RANDOMIZED|PARALLEL||OTHER||TRIPLE||A randomized, triple-blind, comparator controlled, parallel clinical trial|t|f|t|t
33720648|NCT04615923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720649|NCT01305850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33720650|NCT05254457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720651|NCT04829565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801972|NCT04279366|||COHORT||PROSPECTIVE|||||||
33801973|NCT00004243||||TREATMENT||||||||
33801974|NCT06301204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33801975|NCT03484988|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The all details of groups assignment are arranged and controlled by the research designers. The color, shape, and external packaging of the n-3 polyunsaturated fatty acid and placebo are consistent (faint yellow to yellow oil in transparent soft capsules). Each bottle of capsules will be marked with the name (or identify number) of the participants by research designers. Thus, the grouping of participants is blind to the rest of the researchers (like outcomes assessors).||t|f|f|t
33801976|NCT00989066|||COHORT||PROSPECTIVE|||||||
33935436|NCT05740267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization assignment is performed by the statisticians of the clinical trial center to generate random codes.|Randomization will be performed in the operating room at the Colorectal division, Linkou Chang Gung Memorial Hospital. Following the induction of minimally invasive surgery, an independent research assistant randomly assigned patients to undergo either NOSE surgery or conventional laparoscopic mini-laparotomy resection by sealed-envelope randomization.|f|f|t|f
33935437|NCT05181215|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935438|NCT01786278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935439|NCT01944254|RANDOMIZED|CROSSOVER||||NONE||||||
33935440|NCT00032110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096160|NCT01835756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096161|NCT00411541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013046|NCT06493903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals collecting and processing sensor-based outcomes will be blinded to group assignment|Parallel-arm randomized Controlled trial|f|f|f|t
34013047|NCT05865977|||CASE_CONTROL||PROSPECTIVE|||||||
34013048|NCT01487382|||COHORT||PROSPECTIVE|||||||
34096162|NCT04299620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096163|NCT03336866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013049|NCT03895931|||COHORT||PROSPECTIVE|||||||
34096164|NCT00894920|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34096165|NCT02848352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34096166|NCT02746380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096167|NCT00453128|||CASE_CONTROL||PROSPECTIVE|||||||
33720652|NCT05400954|||COHORT||PROSPECTIVE|||||||
34013050|NCT01644136|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34013051|NCT00988689|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34013052|NCT04975321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013053|NCT05198388|||CASE_CONTROL||PROSPECTIVE|||||||
34096168|NCT00016302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096169|NCT03590327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096170|NCT03631121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096171|NCT03203512|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34096172|NCT05337748|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group will undergo the self-test and fitting (Lexie STF) intervention and the experimental group will undergo the professional test and fit (Lexie PTF) intervention.||||
34096173|NCT01713127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34096174|NCT02595554|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720653|NCT02173912|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33720654|NCT00014677||||TREATMENT||||||||
33935441|NCT04090515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||If participant meets eligibility criteria, the participant will be block randomized to one of two conditions: either (1) active (n = 12) or (2) educational video control (n = 6)|t|f|f|f
33935442|NCT03786276|RANDOMIZED|CROSSOVER||OTHER||NONE||We will use an 8-week, randomized cross--over design trial of active VR-WMR.||||
33935443|NCT01314404|||CASE_ONLY||PROSPECTIVE|||||||
33935444|NCT01376505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935445|NCT05835167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935446|NCT01314456|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935447|NCT05393895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935448|NCT04770428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is double-blinded with regard to treatment (MEDI7352 or placebo) for all placebo-controlled dose groups (groups where placebo and active substance is given in a cohort, ie, the Sponsor, the Investigator, all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding).||t|t|t|f
33935449|NCT05813405|||COHORT||PROSPECTIVE|||||||
34096175|NCT00811109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096176|NCT05907499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096177|NCT05628272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096178|NCT03331406|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34096179|NCT04524117|||CASE_CONTROL||PROSPECTIVE|||||||
34096180|NCT00487630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096181|NCT00530075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096182|NCT04034680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked for the study arm they are randomised to. Staff in the home care service are aware of the study arm their patients are in, while assessors that will interview home care staff by telephone are masked for study randomisation.|Cluster randomized trial|t|f|f|f
33935450|NCT00599222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720655|NCT00179400|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33720656|NCT02794103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720657|NCT03448822|||COHORT||PROSPECTIVE|||||||
33935451|NCT06169891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935452|NCT03031990|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935453|NCT01228695|||CASE_ONLY||PROSPECTIVE|||||||
34013054|NCT02760264|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34013055|NCT06147726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the physiotherapist administering the treatment and the physiotherapist performing the assessments will be different people|2 groups, conventional physiotherapy to the control group|f|f|f|t
34013056|NCT01612416|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34013057|NCT01570816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013058|NCT06236568|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013059|NCT03878888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|no masking; will provide qualified patients the opportunity to receive Exparel (liposomal bupivacaine) in Bilateral TAP blocks for open abdomen surgery|experimental group: patients having open abdominal surgery that will receive a bilateral TAP block with Exparel control group: patients having open abdominal surgery that will not receive a bilateral TAP block with Exparel||||
34013060|NCT04997395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013061|NCT05895721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801977|NCT04137497|||COHORT||CROSS_SECTIONAL|||||||
33801978|NCT00901901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013062|NCT02030314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013063|NCT02614313|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34013064|NCT03260075|||COHORT||CROSS_SECTIONAL|||||||
34013065|NCT01456091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096183|NCT01309191|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096184|NCT06494813|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33711376|NCT04435132|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Patients will undergo prone PCNL under fluoroscopic guidance and with the aid of the robotic device. They will then be admitted to inpatient ward as per standard of care for PCNL.|"Recruitment was carried out in University Malaya Medical Centre (UMMC) Hospital clinics and impatient wards. 5 patients were recruited with no preferred selection for gender or race. Patients recruited were set to be between 21 to 75 years of age.~Patients presenting to to clinic or admitted to ward for renal stone disease were assessed for indications of PCNL. Patients were assessed for renal stone disease as per standard of care - imaging study with CT scan, renal function, clinical assessment of fitness and suitability for prone PCNL.~Once patients were planned for prone PCNL, they will be informed about this study, the use of robotic device, potential benefits and complications by study investigators. If they are agreeable to informed consent, they will be recruited into the study."||||
33711377|NCT00350909|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711378|NCT00850668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711379|NCT02302820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33711380|NCT01502098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33711381|NCT06505291|||CASE_ONLY||OTHER|||||||
33711382|NCT01410786|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711383|NCT00694785|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711384|NCT04071132|||CASE_CONTROL||PROSPECTIVE|||||||
33711385|NCT05540405|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711386|NCT04564729|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Investigators not involved in administering the SDA and data collection will be blinded. The study subject and investigator(s) involved in administering the SDA and collecting outcomes data will be unblinded.|Randomized Controlled Trial|f|f|t|f
34013066|NCT02881164|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34013067|NCT02136849|||FAMILY_BASED||PROSPECTIVE|||||||
34013068|NCT05415020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013069|NCT03465436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34013070|NCT05116748|||COHORT||PROSPECTIVE|||||||
34013071|NCT01045915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013072|NCT00680186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013073|NCT04631887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013074|NCT03331237|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013075|NCT04209335|NA|SINGLE_GROUP||SCREENING||NONE||||||
34013076|NCT03648034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34096185|NCT03174275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096186|NCT05507684|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34096187|NCT04893031|||COHORT||OTHER|||||||
34013077|NCT02406430|||CASE_ONLY||RETROSPECTIVE|||||||
34013078|NCT04375930|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients with an ostomy were blinded.|This two-group, single-blind, quasi-experimental study enrolled 68 patients with ostomy recruited to a university affiliated hospital.|t|f|f|f
34013079|NCT04831086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pregnant women with singleton pregnancies admitted with a diagnosis of preterm labor and intact membranes between 23.0 and 34.6 weeks, not in labor at randomization and who do not meet exclusion criteria.||||
34013080|NCT01056640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013081|NCT05195866|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Individually randomized clinical trial~The children will be randomized into two groups. Randomization will be stratified by male/female as well as age \<5 years and \>5 years."||||
34013082|NCT04305379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The surgeon will be masked until the time of bladder neck reconstruction during the radical prostatectomy.||t|f|f|t
34013083|NCT01334710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711387|NCT02840097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711388|NCT05228808|||OTHER||PROSPECTIVE|||||||
33711389|NCT03181334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33711390|NCT01246401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711391|NCT05416502|||COHORT||PROSPECTIVE|||||||
33711392|NCT03961581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33711393|NCT06318195|NA|SINGLE_GROUP||TREATMENT||NONE||Prolonged exposure will be offered in a brief digital format with therapist support for three weeks. Treatment comprises of psychoeducation, rationales, in vivo exposure, imaginal exposure and relapse prevention.||||
33711394|NCT03216889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33711395|NCT02532491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711396|NCT03775811|||COHORT||PROSPECTIVE|||||||
34013084|NCT01812135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34013085|NCT04248348|||COHORT||PROSPECTIVE|||||||
34013086|NCT02612220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096188|NCT05357079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A. Specific aims~a. To conduct a multi-center study to prospectively evaluate the use of topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY) on pre-operative and post-operative hemoglobin (Hb)/hematocrit (Hct) in patients undergoing operative repair of isolated posterior wall (PW) acetabular fractures."|f|f|t|f
34096189|NCT01913470|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34096190|NCT03372915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711397|NCT05119452|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"After checking the inclusion- and exclusion criteria and after the patients´ consent the study investigator contacts the administrative office of the coordinating center. The online computerised randomisation algorithm Randomizer for Clinical Trials by the Medical University of Vienna (MUW) will be used for randomisation for all centres."|"At baseline, patients will be randomised in a 1:1 ratio in an Assisted monitoring (arm A) or a Clinical monitoring (arm B) arm respectively."|t|f|t|f
33711398|NCT02810197|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33711399|NCT00880828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711400|NCT04719871|||COHORT||RETROSPECTIVE|||||||
33711401|NCT01888237|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34096191|NCT03753542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34096192|NCT05654207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096193|NCT03409458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096194|NCT02898831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096195|NCT01294072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||curcumin alone in capsule form (Arm 1) curcumin combined with plant exosomes (Arm 2) will not take curcumin or plant exosomes (Arm 3)||||
34096196|NCT04453527|||COHORT||PROSPECTIVE|||||||
34096197|NCT03389750|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Intravenous Challenge Drug|t|f|f|t
34096198|NCT03248804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are assigned either to the soy group or the non-soy group.||||
34096199|NCT05659420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096200|NCT03961035|||COHORT||RETROSPECTIVE|||||||
33711402|NCT00177814|||OTHER||RETROSPECTIVE|||||||
33711403|NCT00713050|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33711404|NCT04460638|||COHORT||PROSPECTIVE|||||||
33711405|NCT02310568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801979|NCT04019509|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33801980|NCT05298813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801981|NCT01840748|||COHORT||PROSPECTIVE|||||||
34013087|NCT03898102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013088|NCT03359824|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013089|NCT05819671|||OTHER||CROSS_SECTIONAL|||||||
34013090|NCT02655159|||CASE_CONTROL||RETROSPECTIVE|||||||
34013091|NCT04086771|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention group- Tailored Navigation Delivered by Community Health Advisor (CHA+TN)~Control Group- Information and Reminder Only"||||
34013092|NCT02572349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013093|NCT03165955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013094|NCT01778153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013095|NCT02783430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013096|NCT01918631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013097|NCT02164734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013098|NCT04147988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||adult patients without intellectual disability (IQ\> 70 or college-level equivalent) and being on the waiting list for a diagnosis of ASD at the former Donald-T unit.||||
34096201|NCT06243159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096202|NCT04799665|||COHORT||PROSPECTIVE|||||||
34096203|NCT03684057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096204|NCT01641783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711406|NCT01622504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711407|NCT00442078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711408|NCT02787668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711409|NCT03378232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant as well as student investigators were blinded to the treatment randomization.||t|f|t|f
33711410|NCT05574699|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33711411|NCT03937297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor would not be told if the participant is in the intervention or control group||f|f|f|t
33711412|NCT04433221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711413|NCT05935293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711414|NCT06071130|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711415|NCT03103568|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33711416|NCT04303832|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33711417|NCT01384136|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33711418|NCT06074068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711419|NCT00923247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711420|NCT02073552|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33711421|NCT03346915|NA|SINGLE_GROUP||PREVENTION||NONE||"We are proposing a single arm proof of concept. We will recruit 30 parents/guardians and their age-eligible child for the single arm proof of concept.~For this proof of concept/pilot trial, we will assess the feasibility and impact of WOW to improve provider communication about HPV vaccination and increase the initial and complete vaccination rates for both boys and girls aged 9-17 and to enhance knowledge and awareness about risks and benefits of HPV vaccine among dyads. The power of our proposed pilot for determining intervention effects is limited. However, because we are proposing a proof of concept pilot and feasibility study, in our experience and that of others, our proposed sample size generally provides sufficient data to estimate subject retention, distribution of variables and feasibility as we plan for a larger-multi-site RCT of the proposed study. We expect our intervention to demonstrate feasibility of the intervention in a clinic setting."||||
33711422|NCT03294902|||COHORT||PROSPECTIVE|||||||
33711423|NCT01908374|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33711424|NCT02101060|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33711425|NCT04936256|||COHORT||PROSPECTIVE|||||||
33711426|NCT00461162|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711427|NCT00198939|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33711428|NCT00453622|||COHORT||PROSPECTIVE|||||||
33711429|NCT01234298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711430|NCT04943315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711431|NCT06504849|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33711432|NCT06044428|||COHORT||PROSPECTIVE|||||||
33711433|NCT01083368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711434|NCT00490295|||COHORT||PROSPECTIVE|||||||
33711435|NCT01752738|||COHORT||PROSPECTIVE|||||||
33711436|NCT03101683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711437|NCT06011057|||CASE_CONTROL||PROSPECTIVE|||||||
33711438|NCT01122277|||COHORT||PROSPECTIVE|||||||
33801982|NCT05952258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blinded RCT|t|f|t|t
33801983|NCT04695197|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking: blinding of primary outcome assessor (off-site laboratory-based staff)|Permuted block randomization||||
33801984|NCT01477268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801985|NCT02125110|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33801986|NCT05344807|||CASE_ONLY||CROSS_SECTIONAL|||||||
33801987|NCT04106869|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Patients will be blinded to the group, as well as the outcomes assessor and the investigator.~The anesthesiologist responsible for the patient's anesthesia will not be blinded."||t|f|t|t
33801988|NCT04513314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|study rater/outcomes assessor and participant will be ignorant of the treatment arm pharmacist and investigator will be aware of the treatment arm||t|f|f|t
33801989|NCT05769764|||COHORT||RETROSPECTIVE|||||||
33801990|NCT00495976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801991|NCT00996229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34096205|NCT00412451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096206|NCT00481104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103296|NCT04621279|||OTHER||PROSPECTIVE|||||||
33711439|NCT03761524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because the two interventions used in this trial are easily recognized by the participants and the investigator, neither the investigator nor the participant can be blinded. But, assessor and the statistician will be blinded.||f|f|f|t
33711440|NCT03948698|||OTHER||CROSS_SECTIONAL|||||||
33711441|NCT00712127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711442|NCT00430690|||COHORT||PROSPECTIVE|||||||
33711443|NCT02599129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096207|NCT04253860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, clinical trial|t|t|f|f
34096208|NCT01172301|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33711444|NCT01138553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096209|NCT00875901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096210|NCT04270786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096211|NCT02961725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711445|NCT00000752||||TREATMENT||DOUBLE||||||
33711446|NCT01064713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711447|NCT02812160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711448|NCT05503524|||CASE_CROSSOVER||PROSPECTIVE|||||||
33711449|NCT05621785|||CASE_ONLY||PROSPECTIVE|||||||
33711450|NCT03585257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized into receiving IV albumin vs placebo|t|t|t|t
33711451|NCT04077268|||OTHER||PROSPECTIVE|||||||
33711452|NCT00075959|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33711453|NCT00818818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711454|NCT03793933|||COHORT||RETROSPECTIVE|||||||
33711455|NCT05798091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33711456|NCT04763304|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|In a specific area, the blinded outcome assessor (researcher #2) performed standardized scanning of participants' skin and base clothing using ultraviolet light in a dark room, revealing the presence of any fluorescent traces. The seven body zones assessed were face, anterior and posterior neck, arms, hands, clothing (anterior/posterior, upper, and lower clothing), and foot covers. Fluorescent traces were measured (small traces, ≤1 cm; large traces, \>1 cm) and quantified for statistical analyses.|We designed a prospective, randomized, controlled crossover trial with a total of 60 healthy anesthesia personnel volunteers. A two-period/two-intervention (AB/BA) design was chosen for this trial in order to estimate differences between both PPE suits with greater precision, given there is no participant variation between groups. The primary outcome was within-participant variability. A potential carryover effect was not expected considering the combination of an active (wet wipe cleansing) and passive (15 minute interval) washout period between interventions. All participants were randomly allocated to either intervention sequence: PPE-G (personal protective equipment including a gown for body protection) followed by PPE-C (personal protective equipment including a coverall for body protection) or PPE-C followed by PPE-G. Both interventions took place on the same day.|f|f|f|t
33711457|NCT05199402|||COHORT||RETROSPECTIVE|||||||
33711458|NCT00621985|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711459|NCT02482506|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33711460|NCT01200966|||COHORT||OTHER|||||||
33711461|NCT02990910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33801992|NCT05137834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801993|NCT02909192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801994|NCT00448734|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801995|NCT01639235|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801996|NCT06340100|||OTHER||OTHER|||||||
33801997|NCT02352909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801998|NCT00764023|||CASE_ONLY||PROSPECTIVE|||||||
34013099|NCT03153618|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||In a two section clinic, the plan is to invite one section of newly enrolled patients coming to clinic for first visit to participate in interacting with VALIDATE while maintaining the standard of care within the other section for similarly matched patients. Parallel allocation design.||||
34013100|NCT01064531|||COHORT||PROSPECTIVE|||||||
34013101|NCT03766490|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib Hydrochloride Combined With gefitinib or Icotinib||||
34013102|NCT03662906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34013103|NCT01996384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34013104|NCT00190242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801999|NCT03676582|||COHORT||PROSPECTIVE|||||||
33802000|NCT00194610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013105|NCT04689100|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34013106|NCT05147441|||COHORT||PROSPECTIVE|||||||
34096212|NCT00515593|||CASE_ONLY||PROSPECTIVE|||||||
34013107|NCT02307214|NON_RANDOMIZED|PARALLEL||||NONE||||||
34013108|NCT03201679|||CASE_CONTROL||RETROSPECTIVE|||||||
34013109|NCT05223491|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34096213|NCT02813720|||COHORT||PROSPECTIVE|||||||
34096214|NCT03579485|||COHORT||RETROSPECTIVE|||||||
34096215|NCT03492268|NA|SINGLE_GROUP||TREATMENT||NONE||Patients undergo leukapheresis to separate their lymphocytes, from which CART cells are produced. Patients will receive a conditioning therapy with cyclophosphamide and fludarabine before CART therapy. BCMA-CART cells will be injected intravenously (IV) into patients on day 0.||||
34096216|NCT02781701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096217|NCT05448131|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096218|NCT03398382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The selection of anaesthesia combination with oral placebo or magnesium for each side will be determined by random selection, which will not be known to either the patient or the examiner until the trial is completed.|The study will be a double-blind, randomized, split mouth, placebo controlled trial.|t|t|t|f
34096219|NCT06415123|||COHORT||PROSPECTIVE|||||||
34096220|NCT02827708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096221|NCT03250195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096222|NCT01390935|||||RETROSPECTIVE|||||||
34096223|NCT03662971|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34096224|NCT01718990|||COHORT||PROSPECTIVE|||||||
34103297|NCT04014192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013110|NCT05042934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013111|NCT00926016|RANDOMIZED|PARALLEL||||NONE||||||
34013112|NCT01473121|||OTHER||PROSPECTIVE|||||||
34013113|NCT02046525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34013114|NCT00493246|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013115|NCT01045031|||COHORT||PROSPECTIVE|||||||
34013116|NCT00571194|NA|SINGLE_GROUP||OTHER||NONE||||||
34013117|NCT05221424|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was conducted as a single-blind randomized controlled study with pretest-posttest|t|f|f|f
34013118|NCT05106543|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34013119|NCT03643679|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013120|NCT05023577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013121|NCT05955495|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The participants were randomized (1:1 computerized block randomization) into two groups. One group is early feeding and another is delayed feeding.|t|f|f|t
34013122|NCT05907330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013123|NCT04551742|||COHORT||PROSPECTIVE|||||||
34096225|NCT03175588|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||There will be three groups in this study. Two intervention and one control gruop to be compared after the intervention.||||
34096226|NCT03540940|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096227|NCT01116843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34096228|NCT03865251|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34096229|NCT03161847|||COHORT||PROSPECTIVE|||||||
34096230|NCT01333566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34096231|NCT04288557|||COHORT||CROSS_SECTIONAL|||||||
34096232|NCT03868566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: SNP-612 dose1 Experimental: SNP-612 dose2||||
34096233|NCT04095936|NA|SINGLE_GROUP||TREATMENT||NONE||multi-national, open-label, phase 2/3 study||||
34096234|NCT05520177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096235|NCT03745456|||CASE_ONLY||PROSPECTIVE|||||||
33711462|NCT03919799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded for the first 28 Weeks|"Three groups (1:1:1) to receive orally administered belumosudil 200 mg QD, belumosudil 200 mg BID, or matched placebo for 28 weeks. The study was double-blinded for the first 28 weeks followed by an open-label extension of 24 weeks.~After unblinding, the participants in the belumosudil groups continued on the same belumosudil dose whereas the participants in the placebo group were re-randomized to one of the belumosudil doses (200 mg QD or 200 BID) in 1:1 fashion."|t|t|t|t
33711463|NCT03849196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, and observer-blind study|f|f|f|t
33711464|NCT04299490|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33711465|NCT03229278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802001|NCT03498768|||COHORT||PROSPECTIVE|||||||
33802002|NCT01185561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802003|NCT00227994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802004|NCT03567941|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33802005|NCT03488745|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34013124|NCT06126965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013125|NCT05964790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013126|NCT02282995|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096236|NCT04837742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013127|NCT02593227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013128|NCT01431352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013129|NCT04090970|||COHORT||PROSPECTIVE|||||||
34013130|NCT02513836|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34013131|NCT02987803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34013132|NCT04293549|||CASE_CONTROL||PROSPECTIVE|||||||
34013133|NCT05998551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Computer generated number lists and use of sealed opaque envelopes , double blinded trial|The eligible parturients will be randomly allocated into three groups according to the additive added to a fixed dose of local anesthetic (1ml=5mg of 0.5% hyperbaric bupivacaine).Total volume of 2 ml will be given to each patient|t|t|t|t
34013134|NCT03521648|||CASE_CONTROL||PROSPECTIVE|||||||
34013135|NCT00986570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096237|NCT03215615|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34096238|NCT03197155|||COHORT||RETROSPECTIVE|||||||
34096239|NCT03004456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096240|NCT01370642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096241|NCT03664141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711466|NCT04869332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711467|NCT03923712|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33802006|NCT02118064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802007|NCT04530149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802008|NCT00345150|RANDOMIZED|CROSSOVER||||SINGLE||||||
33802009|NCT02097069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802010|NCT04497766|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33802011|NCT06361953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013136|NCT01452048|||COHORT||CROSS_SECTIONAL|||||||
34013137|NCT03384017|NA|SINGLE_GROUP||TREATMENT||SINGLE|All assessors will be blind to intervention||f|f|f|t
34013138|NCT03290287|||CASE_CONTROL||PROSPECTIVE|||||||
34013139|NCT05491239|RANDOMIZED|PARALLEL||TREATMENT||NONE|As the analgesic strategies highly differ in nature (with or without percutaneous catheter) and/or postoperative care (mobility with or without prerequisites, urinary catheter placement), blinding for the randomised strategy is unfeasible.|This is a multi-centre randomised three-arm trial comparing continuous PVB, single-shot ICNB and TEA in a 1:1:1 ratio in patients who will undergo a VATS anatomic lung resection. We use a non-inferiority design with respect to the outcome measure 'pain' and a concomitant superiority design regarding 'quality of recovery'.||||
34096242|NCT00835978|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34096243|NCT06155214|||COHORT||PROSPECTIVE|||||||
34103298|NCT06603012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34013140|NCT05037786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||In the control group, there will be a face-to-face intervention of 15 minutes of education on pain explained by Verbal form with supporting Powerpoint presentation. In the intervention group, the same pain education will be carried out, explained verbally but with the support of an infographic instead of a Powerpoint. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.|f|f|t|t
34013141|NCT03938129|||OTHER||PROSPECTIVE|||||||
33711468|NCT01354756|||COHORT||PROSPECTIVE|||||||
34013142|NCT00514969|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711469|NCT01867424|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33711470|NCT03090178|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Investigators will first enroll patients, then healthy volunters. Healthy volunters will be matched to patients on age, sexe and wake up at a programmed time||||
33792566|NCT05214287|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The administration and sequence of intervention(s) will not be disclosed to the participant. However, due to the n-of-1 design, all participants will be exposed to all treatment modalities as well as the control condition arm, which makes concealed allocation not applicable other than the unconcealed intervention sequence. The investigators will assess success of masking by asking a participant in what sequence the different treatments were probably administered.~For safety and monitoring purposes, the intervention is not blinded for the lab technician, who will administer and monitor the intervention.~All outcomes will be assessed directly before and after the stimulus by an independent and blinded assessor."|The investigators will deploy an N-of-1 trial design (also known as single participant cross-over trial) in which multiple treatment pairs of active treatment and placebo are offered to an individual participant in a randomized, double-blind fashion. In an N-of-1 trial, random variation within the treatment effect at the individual level can be better accounted for and methodological power is optimized due to repeated treatment-pairs and the fact that the individual participant acts as their own control. Thanks to this design, in which each treatment-pair should be exchangeable in time, N-of-1 trials are especially suitable to investigate treatments in chronic, symptomatic conditions, where period effects (i.e. changes in disease state) and carry over effects (i.e. lingering hypoxia effects) are small. Given the slowly progressive nature of PD with relative stable symptoms, several N-of-1 trials have already been successfully performed to study symptomatic treatments in PD.|t|f|t|t
34013143|NCT00769626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792567|NCT01247337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792568|NCT03058991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792569|NCT05774717|RANDOMIZED|PARALLEL||PREVENTION||NONE|Provider will order tranexamic acid based based on even versus odd last digit of medical record number (MRN). Patient will be blinded, as will all personnel analyzing postoperative photographs and other data.|One group receives tranexamic acid prior to surgery, one group receives nothing (routine care).||||
33792570|NCT03954015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792571|NCT05139706|||COHORT||PROSPECTIVE|||||||
33792572|NCT02540551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792573|NCT02655367|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33792574|NCT04298606|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34013144|NCT06146439|||COHORT||CROSS_SECTIONAL|||||||
34013145|NCT05962450|RANDOMIZED|PARALLEL||TREATMENT||NONE|Block randomization was performed by the independent masked statistician. Two independent masked radiologist who are blinded to patients' clinical information will review the imaging examinations.|||||
34013146|NCT00567736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34013147|NCT02448849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013148|NCT02582372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096244|NCT04066244|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is an exploratory, adaptive, open-label study of single or multiple cycles of BLZ945 in participants with ALS. Cohorts 1-4 are not randomized, while Cohort 5 is randomized in open label two treatment arms. Cohorts 1-4 have single group design and Cohort 5 has parallel design.||||
33711471|NCT03984253|||COHORT||PROSPECTIVE|||||||
33711472|NCT04826432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Single-blinded, multicentric, placebo controlled phase II comparative trial|t|f|f|f
33711473|NCT03694821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711474|NCT00304993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711475|NCT02301572|||COHORT||RETROSPECTIVE|||||||
33711476|NCT01211002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711477|NCT01923493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013149|NCT01978210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013150|NCT02970435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013151|NCT05020249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013152|NCT01083017|||COHORT||PROSPECTIVE|||||||
34013153|NCT04877171|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34096245|NCT06257121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096246|NCT02287025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096247|NCT01528774|||CASE_CONTROL||PROSPECTIVE|||||||
34096248|NCT03518437|||COHORT||PROSPECTIVE|||||||
33711478|NCT00539136|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33711479|NCT03444961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711480|NCT03781596|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33711481|NCT03798483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711482|NCT00256191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096249|NCT05474820|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792575|NCT04477538|||COHORT||PROSPECTIVE|||||||
33792576|NCT02710929|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33792577|NCT03936348|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients were randomized to 3 groups. The first one performed a supervised RP using the Feelbreathe® device (FB group), the second group developed the same RP with oronasal breathing without FB (ONB group) and the third was the control group (CG). The RP was conducted during 8 weeks, 3 days per week, and includes a combined training of endurance and strength exercises.||||
33792578|NCT05131386|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, multicohort, single arm, open-label, multicenter, international clinical trial||||
33792579|NCT03815396|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792580|NCT02928757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792581|NCT03814668|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33792582|NCT03301454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792583|NCT00932022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792584|NCT03279718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096250|NCT01972984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792585|NCT05523076|||COHORT||CROSS_SECTIONAL|||||||
33792586|NCT02525510|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Enrolled donors will be divided into two populations based on local Organ Procurement Organization criteria:Pump Eligible and Not Pump Eligible.~Pump Eligible will include three arms. Not Pump Eligible will include two arms."|t|f|t|t
34013154|NCT03265067|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Before and after phase study||||
34013155|NCT00845975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013156|NCT06026852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013157|NCT03142516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013158|NCT05495113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013159|NCT02848066|||CASE_CONTROL||PROSPECTIVE|||||||
34013160|NCT04851431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled trial||||
34013161|NCT01492972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013162|NCT03494543|||COHORT||RETROSPECTIVE|||||||
34013163|NCT00608192|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34013164|NCT00979381|||COHORT||PROSPECTIVE|||||||
34013165|NCT01626963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013166|NCT03201211|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013167|NCT00261131|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34013168|NCT02110017|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34013169|NCT00266526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096251|NCT04162275|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33792587|NCT03496649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802012|NCT00296868|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33802013|NCT03113630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013170|NCT00002829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013171|NCT00932230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013172|NCT04317599|||COHORT||RETROSPECTIVE|||||||
33711483|NCT06261385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors at the telephone follow-up are blinded to the group allocation.||f|f|f|t
33711484|NCT02421523|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34013173|NCT02277704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711485|NCT02459353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711486|NCT03648541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711487|NCT05867745|||OTHER||OTHER|||||||
33711488|NCT03250845|||COHORT||PROSPECTIVE|||||||
33711489|NCT02651922|||COHORT||PROSPECTIVE|||||||
33711490|NCT01308671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711491|NCT00717132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711492|NCT06334783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711493|NCT04828252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711494|NCT05353023|||COHORT||RETROSPECTIVE|||||||
33711495|NCT00003746|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33711496|NCT03716089|||CASE_CONTROL||PROSPECTIVE|||||||
33711497|NCT01280175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711498|NCT06333145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33711499|NCT03918083|NA|SINGLE_GROUP||TREATMENT||NONE||WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.||||
33711500|NCT01357733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711501|NCT01966900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711502|NCT00657098|||COHORT||PROSPECTIVE|||||||
33711503|NCT04458974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel, randomized, controlled and triple blind experimental study|t|t|f|t
33711504|NCT02737657|||COHORT||PROSPECTIVE|||||||
33711505|NCT01132092|||COHORT||PROSPECTIVE|||||||
33711506|NCT06170723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711507|NCT06379178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013174|NCT04300829|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, multicentric Phase III study evaluating the Cicaderma ointment efficacy versus standard practice of each site in the prevention of radiodermatitis in patients presenting a non metastatic breast cancer||||
34013175|NCT06525922|NA|SINGLE_GROUP||PREVENTION||NONE||One group was compared between pre-intervention and post-intervention time points.||||
33711508|NCT04781998|NA|SINGLE_GROUP||TREATMENT||NONE||An open-label, multi-centre, 26-weeks clinical feasibility study||||
33711509|NCT04250103|||COHORT||PROSPECTIVE|||||||
33711510|NCT05109156|||CASE_ONLY||RETROSPECTIVE|||||||
33711511|NCT02777801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711512|NCT04488068|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention to prevent prostate cancer surgery related urological issues||||
33711513|NCT00663169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013176|NCT06327802|||COHORT||PROSPECTIVE|||||||
34013177|NCT02769884|NA|SINGLE_GROUP||TREATMENT||NONE||Use the MMPPC system for 72 hours in a hotel setting||||
34013178|NCT00770692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013179|NCT01715896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013180|NCT06615882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013181|NCT04758663|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Within-subject; participants/experimenters are aware of conditions|Within subject comparison of nap/overnight and wake/overnight conditions in habitual and non-habitual nappers||||
34013182|NCT02228993|||COHORT||PROSPECTIVE|||||||
34013183|NCT04199650|||CASE_ONLY||OTHER|||||||
34013184|NCT06224621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013185|NCT02728011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013186|NCT05051111|||CASE_ONLY||CROSS_SECTIONAL|||||||
34013187|NCT01300923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013188|NCT01004042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013189|NCT00002869|RANDOMIZED|||TREATMENT||||||||
33711514|NCT02550249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711515|NCT02906059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711516|NCT05477810|RANDOMIZED|CROSSOVER||OTHER||NONE||open-label, randomized, two-period, two-way crossover, single-dose bioequivalence study||||
33711517|NCT03609632|NA|SINGLE_GROUP||OTHER||NONE||||||
33711518|NCT00895167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935454|NCT03709940|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|The first part of the study (DAY 1 and DAY 2) is conceived as a single-blind placebo-controlled cross-over experiment. Participants are blind to the order of the tablets (placebo and MPH). After the two scanning sessions, all 60 participants are started on a long-acting formulation of MPH used routinely at the Adult ADHD Clinic (open trial phase).|30 participants with Attention Deficit Hyperactivity Disorder (ADHD) undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of methylphenidate (MPH). The order of the tablets is inverted for the second half of the sample, thus the last 30 participants undergo behavioural tests and brain scanning twice, once under an acute dose of MPH and once under placebo. All 60 participants are then treated with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.|t|f|f|f
33935455|NCT05544214|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34013190|NCT03511170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711519|NCT01126476|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33711520|NCT03055793|||OTHER||PROSPECTIVE|||||||
33711521|NCT01354977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711522|NCT03824613|||CASE_CONTROL||PROSPECTIVE|||||||
34096252|NCT00126737|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34096253|NCT01975584|NA|SINGLE_GROUP||OTHER||NONE||||||
34013191|NCT03604341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013192|NCT05582252|||CASE_CONTROL||OTHER|||||||
34013193|NCT00781521|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013194|NCT03777904|||COHORT||PROSPECTIVE|||||||
34013195|NCT01404871|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34013196|NCT05542979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013197|NCT03951584|||COHORT||PROSPECTIVE|||||||
34013198|NCT05559112|RANDOMIZED|PARALLEL||SCREENING||SINGLE||For this investigator-blinded, randomized, parallel design study, 50 participants (40 to finish; n=20/group) will complete a 12-week study period in which participants consume 84 g of vitamin-D enriched mushrooms containing 800 IU/serving or study powder (control) in the context of their usual diet. To assess the effects of including vitamin D-enriched mushrooms as part of participants' usual eating pattern on serum vitamin D status and indices of immune function and inflammatory status, we will measure circulating concentrations of 25-hydroxy-vitamin D2, pro- and anti-inflammatory cytokines, and immunoglobulins, among other immunity/inflammation outcomes. Health questionnaires related to perceived anxiety/depression and wellbeing are included to complement the currently funded longitudinal feeding study which includes these exploratory outcomes.|f|f|t|f
34013199|NCT00887328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013200|NCT00998972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096254|NCT03528850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096255|NCT05290974|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34096256|NCT00924482|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34096257|NCT04479384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096258|NCT04508985|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The patient and the treating doctor will be informed of the assigned treatment.|Open-label, randomized, study of approximately 40 adults. The following groups of participants will be considered: i) within 48 hours of diagnosis of COVID-19; ii) who have received a diagnosis of COVID-19 from another facility and are within 48 hours of transfer to a study recruitment site (Royal Victoria Hospital, Montreal General Hospital, and Jewish General Hospital \[all in Montreal, Quebec, Canada\])). Participants will be randomized 1:1 to an upfront temporary discontinuation) of RAAS inhibition for the duration of the hospitalization (and to consider re-initiate on discharge) versus a strategy continuation of RAAS inhibition.||||
34096259|NCT06469853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935456|NCT04089293|||CASE_ONLY||RETROSPECTIVE|||||||
33935457|NCT05725161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33935458|NCT01500421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935459|NCT04839328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935460|NCT00608803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935461|NCT01315080|||CASE_CONTROL||PROSPECTIVE|||||||
33935462|NCT01336231|||COHORT||PROSPECTIVE|||||||
33935463|NCT01388491|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935464|NCT03283891|RANDOMIZED|PARALLEL||OTHER||SINGLE||Mixed methods cluster randomised controlled trial|f|f|f|t
33935465|NCT05937399|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33935466|NCT06505681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935467|NCT02936115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935468|NCT01601990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935469|NCT04856969|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||2 Intervention group, open, single-sequence, multiple oral administration crossover design||||
34096260|NCT03246204|||COHORT||PROSPECTIVE|||||||
34096261|NCT05231941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096262|NCT04076137|NA|SINGLE_GROUP||TREATMENT||NONE|targeted activated T-cell|This is a single-center, open, single-arm controlled prospective clinical study to investigate the efficacy and safety of targeted T-cell therapy in solid tumors.||||
34096263|NCT04599985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-arm, parallel groups randomized comparative Trial.|t|f|f|t
34096264|NCT05845593|||CASE_ONLY||PROSPECTIVE|||||||
34103299|NCT04543253|||COHORT||PROSPECTIVE|||||||
34103300|NCT06688409|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33935470|NCT02525809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935471|NCT03610867|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33935472|NCT00683774|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935473|NCT05565066|||CASE_ONLY||RETROSPECTIVE|||||||
33935474|NCT04161313|||CASE_CONTROL||PROSPECTIVE|||||||
33935475|NCT06014021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The design of this study does not allow to mask participants or care providers. Investigators or outcomes assessors will not know which group athletes belong.||f|f|t|t
33935476|NCT00192465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935477|NCT03011528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935478|NCT04173481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935479|NCT00271128|||||PROSPECTIVE|||||||
33935480|NCT02074761|||COHORT||PROSPECTIVE|||||||
33935481|NCT00001685||||TREATMENT||||||||
33935482|NCT03148899|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|All members of the research team except the IP dispensing staff will be blinded for the duration of the research study. Once all the subjects have finished in the research study, and all data is data-locked, the outcomes assessor will then unblind the research data for the statistical analysis.||t|t|t|f
33935483|NCT02946151|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33935484|NCT03943940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935485|NCT01541540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33935486|NCT02387450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935487|NCT00478595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103301|NCT06536530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This experiment is a single-blind design, where participants will be blind to the intervention, but researchers will not be blind to intervention allocation.|This project consists in a three-arms parallel-group randomized study to measure the benefits of exergames on cognition, in adults suffering from depression. Researchers will compare three different interventions (training with an exergame, which combines cognitive and physical stimulation, training with a cognitive game, and a wait-list condition), by randomizing participants to each group with equal probability.|t|f|f|f
34013201|NCT03676751|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple: (Participant, Care Provider, Investigator, Outcomes Assessor)|Individually randomized placebo-controlled trail of azithromycin vs. placebo to establish the efficacy and safety of azithromycin.|t|t|t|t
33711523|NCT01152710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013202|NCT05936164|||COHORT||PROSPECTIVE|||||||
34013203|NCT03077321|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The therapists and the parents will not be blinded to group because they will be providing and receiving the intervention. The investigators who are collecting the data will be blinded to arm.|RCT 1:1:1|f|f|t|t
34013204|NCT00635830|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34013205|NCT06115226|||CASE_ONLY||RETROSPECTIVE|||||||
34013206|NCT04241367|||COHORT||PROSPECTIVE|||||||
34013207|NCT05306171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013208|NCT06125119|||COHORT||PROSPECTIVE|||||||
34013209|NCT05861635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013210|NCT03921151|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34013211|NCT01665924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013212|NCT02162355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013213|NCT00350649|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013214|NCT00453778|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34013215|NCT02676713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013216|NCT01400620|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013217|NCT05275972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013218|NCT02691741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34013219|NCT02632734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013220|NCT03957187|||CASE_ONLY||PROSPECTIVE|||||||
34103302|NCT03556384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103303|NCT03464552|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33711524|NCT05655962|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||9 centers implement the STARS framwork, and are compared to control centers that do not work according to STARS.||||
33711525|NCT05084521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711526|NCT01230905|NA|SINGLE_GROUP||SCREENING||NONE||||||
33711527|NCT05888766|||COHORT||PROSPECTIVE|||||||
33711528|NCT06370650|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711529|NCT03792581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Manual versus automated management of MAP|t|f|f|f
33711530|NCT03761277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711531|NCT01194180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711532|NCT01164982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33711533|NCT03467191|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33711534|NCT04847947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711535|NCT06237660|||COHORT||PROSPECTIVE|||||||
33711536|NCT03940404|||CASE_ONLY||PROSPECTIVE|||||||
33711537|NCT00660309|RANDOMIZED|PARALLEL||||NONE||||||
33711538|NCT03296358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711539|NCT02554357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711540|NCT03320954|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1 participants will include people with and without acquired brain injuries. This phase does not involve any intervention.~Phase 2 participants will include only people with acquired brain injuries. This portion of the research involves an intervention procedure. All participants will receive the same intervention.~Phase 3 participants will be limited to those people with acquired brain injuries who completed Phases 1 and 2. Phase 3 does not involved any intervention."||||
33711541|NCT03847662|||COHORT||PROSPECTIVE|||||||
33711542|NCT01803373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711543|NCT04188327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* The patients will be blind through the use of closed sealed envelops.~* The investigator will be blind through the use of sham block in the control group.~* The measurement will be collected by anesthesiologist not participating in the study and blinded to its group"|Prospective randomized controlled study|t|f|t|t
33711544|NCT02495168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711545|NCT04359654|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of nebulised dornase alfa \[2.5 mg BID\] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure||||
33711546|NCT00681005|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013221|NCT03349528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013222|NCT01425021|||CASE_ONLY||PROSPECTIVE|||||||
34013223|NCT05162651|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34013224|NCT03657108|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation study to determine MTD||||
34013225|NCT05981248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013226|NCT03892213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013227|NCT03984045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy sends down drug and placebo in study preparations for administration.||t|t|t|t
34013228|NCT02710513|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013229|NCT02213913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013230|NCT02709486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013231|NCT05179694|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013232|NCT04984941|||OTHER||CROSS_SECTIONAL|||||||
34013233|NCT06139224|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013234|NCT00507546|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34013235|NCT01510652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013236|NCT03177382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013237|NCT04332848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013238|NCT05009966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013239|NCT06104748|||COHORT||PROSPECTIVE|||||||
34013240|NCT02191475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34013241|NCT05506358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All the participants and study team members will be informed of the tests and devices used in the study.|"Around 90 participants will be recruited in Canada - 30 with SCD (HbSS), 30 with SCT (HbAS), and 30 healthy participants (HbAA).~Around 120 participants will be recruited in Nepal - 20 with SCD (HbSS), 20 with SCT (HbAS), 20 with sickle cell / β-thalassaemia compound heterozygous form (HbS/β-thalassemia), 20 with β-thalassaemia (Hbβ/ β-thalassemia), 20 with β-thalassaemia trait or carrier form (HbA/β-thalassemia), and 20 healthy participants (HbAA).~3-4 mL of blood will be drawn using standard phlebotomy practices. The following tests will be performed:~a. Low-cost tests i. Sickling test with low-cost microscope and automated screening with machine learning ii. Sickling test with traditional microscope (conventional manual screening used in Nepal) iii. HbS solubility test iv. Commercial point-of-care assays (HemoTypeSC and Sickle SCAN) v. Gazelle Hb variant test~b. Gold standard test: HPLC, for determining the accuracies of low-cost screening techniques"||||
34096265|NCT06274021|NA|SEQUENTIAL||OTHER||NONE|The participants and assessors are kept unaware of which intervention is being administered. For this, the study drugs are designed to be visually identical for all participants, and the intervention and sham stimulation configuration is set without the assessor being present in the room.|This study employs a crossover design, wherein each participant is systematically administered a sequence of five distinct interventions randomly. This approach ensures that every participant receives each intervention in a unique sequence. The design facilitates within-subject comparisons by minimizing inter-individual variability, as each participant effectively serves as their own control across the study phases. The random assignment of intervention sequences aims to balance potential carryover effects and period effects.||||
34096266|NCT05919056|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34096267|NCT01763411|||COHORT||RETROSPECTIVE|||||||
33711547|NCT03752294|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The first phase of the study is 9-month, double-blind, randomized-control treatment. All participants participants will cross-over to phase II (open label) for an additional 12 months of treatment with a 3-month non-treatment follow-up|Randomized-control, Double-blind, Multicenter, Delayed-start, Pilot|t|t|t|t
33711548|NCT00436683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013242|NCT00426010|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34013243|NCT04529330|||CASE_CONTROL||PROSPECTIVE|||||||
34013244|NCT02139917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013245|NCT00257920|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34013246|NCT04958382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34013247|NCT01706848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013248|NCT00359788||PARALLEL||TREATMENT||||||||
34013249|NCT01554826|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34013250|NCT01569776|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34013251|NCT01106521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013252|NCT01674647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711549|NCT02350153|||COHORT||RETROSPECTIVE|||||||
34013253|NCT04546893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013254|NCT03252327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33711550|NCT05184218|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blinded study|Subjects will be randomized to receive intranasal and intraoral administration of IGM-6268 or placebo at the assigned doses. Cohorts will be enrolled sequentially. Cohorts 1-3 and Sentinel will enroll healthy volunteers and Cohorts 4-5 and Ph1b Expansion will enroll mild-moderate COVID-19 patients.|t|f|t|f
34013255|NCT01859767|NA|SINGLE_GROUP||||NONE||||||
34096268|NCT01496443|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34096269|NCT03149861|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33711551|NCT01914198|||COHORT||PROSPECTIVE|||||||
33711552|NCT03223597|||COHORT||PROSPECTIVE|||||||
33711553|NCT04043260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013256|NCT04754334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Approximately 450 US- and Europe-based adult male and female subjects with T2DM will be randomized in a 1:1 ratio to receive either ORMD-0801 8 mg QD (one 8 mg capsule, dosed at night), or placebo dosed QD (dosed at night). It is anticipated that 225 subjects will be randomized to each arm of the study to complete approximately 200 subjects in each arm.|Approximately 450 US- and Europe-based adult male and female subjects with T2DM will be randomized in a 1:1 ratio to receive either ORMD-0801 8 mg QD (one 8 mg capsule, dosed at night), or placebo dosed QD (dosed at night). It is anticipated that 225 subjects will be randomized to each arm of the study to complete approximately 200 subjects in each arm.|t|t|t|t
34013257|NCT06271902|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized controlled trial with an intervention group and a control group to evaluate the effects of the YoSO-IPP. The intervention group will perform the exercises and attend the online educational workshop. The control group will only perform lower body stretching exercises which is considered as a sham program.||||
34013258|NCT04688580|NA|SINGLE_GROUP||OTHER||NONE||||||
34013259|NCT03443193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013260|NCT02726919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013261|NCT01092078|RANDOMIZED|PARALLEL||||NONE||||||
34013262|NCT06102408|||COHORT||RETROSPECTIVE|||||||
34013263|NCT03091621|||COHORT||PROSPECTIVE|||||||
34013264|NCT00952276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013265|NCT03297671|||COHORT||PROSPECTIVE|||||||
34013266|NCT02827890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34013267|NCT04209673|||CASE_CONTROL||PROSPECTIVE|||||||
34013268|NCT03106558|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34013269|NCT05495373|||CASE_ONLY||PROSPECTIVE|||||||
34013270|NCT02370225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013271|NCT03642782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013272|NCT06226922|||COHORT||RETROSPECTIVE|||||||
34013273|NCT04299659|||COHORT||PROSPECTIVE|||||||
34013274|NCT06140121|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33792588|NCT06454734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, outcome assessors and investigators will not know if received treatment was placebo or therapeutic. The physiotherapist will apply the treatment according to a list of random numbers generated to make 2 treatment groups|Double blind randomized clinical trial|t|f|t|t
34096270|NCT00096408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096271|NCT06302283|||CASE_ONLY||RETROSPECTIVE|||||||
34096272|NCT00679601||||TREATMENT||NONE||||||
33792589|NCT00339989|||COHORT||CROSS_SECTIONAL|||||||
33792590|NCT01946035|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34096273|NCT05481281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the drugs will be prepared by anesthesiologist who will not be the part of the study and these drugs will be injected by another anesthesiologist who will be blinded to the drugs and will be participating into the study.|"Patients will be randomly assigned to either group Dexmedetomidine (receiving I/V bolus of dexmedetomidine 0.1 mg/kg as a 20 ml solution, followed by 0.04mg/kg/hr infusion till surgery completion) OR group Ketamine (receiving 0.2 mg/kg iv of ketamine diluted to 20 ml followed by 0.1 mg/kg/hr infusion till surgery completion) through sequentially numbered opaque sealed envelope. Anesthesiologist and patients both will be blinded to the administered drug in two groups. Either of the drugs will be injected after giving spinal anesthesia and confirmation of achievement of desired level of block.~In the recovery room Shivering grade, and vitals of patients will be evaluated every 15 minutes interval after giving the drug till 1hour postoperatively. 1st reading taken 15minutes after giving the drug will be labelled as Zero time."|t|f|t|t
34096274|NCT01601977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096275|NCT05125939|||COHORT||PROSPECTIVE|||||||
34096276|NCT05866328|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Experimental: ET and IPS Control: IPS|Cognitive rehabilitation with a cognitive training program|f|t|f|t
34096277|NCT03667729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The rater did not know what interventions the participants belonged to.|"This study applied a randomized parallel case-controlled design.~Hospital-based randomized control trial . Subjects were chronic schizophrenia who were recruited from a psychotic ward complex and randomized into PMR, or control groups."|f|f|f|t
34096278|NCT03302663|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will be assigned to appropriate arm depending on outcome of routine obstetric screening||||
34096279|NCT00985790|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34096280|NCT06501937|RANDOMIZED|FACTORIAL||OTHER||NONE||Videos featuring influencers promoting e-cigarettes alongside healthy lifestyle activities||||
33792591|NCT02508896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792592|NCT00182936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34013275|NCT02059330|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34013276|NCT01139918|||COHORT||PROSPECTIVE|||||||
34013277|NCT04016337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Beverages were provided by manufacturer with codes and no one, up to now, knows the sweetener added on each type.|The chronic study consisted on a 60 days consumption of a beverage (330 mL) made with lemon and maqui and added a particular sweetener.|t|t|t|t
34013278|NCT03912402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013279|NCT03829358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34013280|NCT03431974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Over-encapsulated||t|t|t|t
34013281|NCT01010022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013282|NCT03250299|NA|SEQUENTIAL||TREATMENT||NONE||||||
34013283|NCT05739968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study was not fully blinded; however, the group allocation was concealed from the patient and primary researcher until after baseline assessments were completed. A primary researcher obtained patient consent, collected self-reported assessments, and if the patients were randomized to intervention group, the intervention trainer explained the MAP program to participants. The study statistician and data managers remained blinded at all times.|"This is a randomized controlled clinical trial which to compare the effects of the OCM care only (control) vs. MAP+OCM program (experimental group) on non-muscle invasive bladder cancer (NMIBC) patients.~For both groups, we assessed patients' outcomes (including baseline data) for 5 times (T1=baseline/during hospitalization of receiving surgery \& before their hospital; T2 to T5 = 6±2 weeks, 3, 6, 12 months after operation)."|t|t|t|f
34096281|NCT04981561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind|Double blind placebo controlled|t|f|t|t
34013284|NCT06392204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34013285|NCT00466726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013286|NCT00513552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013287|NCT05319834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All participants and investigators|To detect the efficacy and safety of vaginal progesterone alone or combined with aspirin in prevention of recurrent PTB.|t|t|t|t
34096282|NCT05484167|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-Blind|The patient crosses over at 90 days|t|f|t|f
34096283|NCT03158597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013288|NCT01574664|||COHORT||PROSPECTIVE|||||||
34096284|NCT00066924|||DEFINED_POPULATION||OTHER|||||||
34096285|NCT04678310|||CASE_CONTROL||PROSPECTIVE|||||||
34096286|NCT02712242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34096287|NCT02874131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013289|NCT04275726|RANDOMIZED|PARALLEL||TREATMENT||NONE||The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series).||||
34096288|NCT00950092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013290|NCT02114957|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34096289|NCT01414829|||CASE_CONTROL||PROSPECTIVE|||||||
34013291|NCT00107718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096290|NCT01532375|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34096291|NCT04294849|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34096292|NCT02383173|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34096293|NCT01283386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096294|NCT02541487|||COHORT||PROSPECTIVE|||||||
33792593|NCT01615835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096295|NCT02476682|||COHORT||PROSPECTIVE|||||||
34096296|NCT01623154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096297|NCT04268966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096298|NCT01027416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096299|NCT02313272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792594|NCT01362920|||CASE_CONTROL||PROSPECTIVE|||||||
33792595|NCT05647980|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Incomplete stepped wedge cluster randomised trial||||
34096300|NCT03323320|||COHORT||RETROSPECTIVE|||||||
33792596|NCT04333329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792597|NCT05206630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33802014|NCT05469841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935488|NCT03875872|||OTHER||RETROSPECTIVE|||||||
33935489|NCT01271127|NA|SINGLE_GROUP||SCREENING||NONE||||||
33935490|NCT04189380|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33935491|NCT01902927|NA|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33935492|NCT03455504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study run-in and phase II||||
33935493|NCT01877291|||COHORT||CROSS_SECTIONAL|||||||
33935494|NCT02969213|||||RETROSPECTIVE|||||||
33935495|NCT03284151|||COHORT||PROSPECTIVE|||||||
33935496|NCT05010863|||COHORT||PROSPECTIVE|||||||
33935497|NCT03782467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935498|NCT02002728|||CASE_ONLY||PROSPECTIVE|||||||
34096301|NCT01979094|||OTHER||PROSPECTIVE|||||||
34096302|NCT00160810|||CASE_ONLY|||||||||
34096303|NCT03514225|NA|SINGLE_GROUP||OTHER||NONE||||||
34096304|NCT04264962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096305|NCT02902315|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34096306|NCT01960842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096307|NCT02171208|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34096308|NCT05396781|NA|SINGLE_GROUP||OTHER||NONE||||||
34096309|NCT01713738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096310|NCT04613869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096311|NCT06211790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with renal cell carcinoma will be divided into three types, FuDan-GP1 subtype (targeted sensitive type), FuDan-GP2 subtype (Cold tumor) and FuDan-GP3 subtype (progenitor infiltrating type) in accordance with the condition of response to TKIs and the infiltration of immune cells, which dates from previous protein genomics study published by Nature Communications.||||
34096312|NCT00097565|||COHORT||PROSPECTIVE|||||||
34103304|NCT04733482|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802015|NCT02262468|||COHORT||RETROSPECTIVE|||||||
33802016|NCT05042375|RANDOMIZED|PARALLEL||TREATMENT||NONE||Camrelizumab Combined with Famitinib Malate versus Pembrolizumab||||
33802017|NCT05180851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802018|NCT00623987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802019|NCT02361918|||CASE_CONTROL||PROSPECTIVE|||||||
33935499|NCT03344562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935500|NCT00053105||||TREATMENT||||||||
33935501|NCT05405569|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33935502|NCT02681068|||CASE_ONLY||RETROSPECTIVE|||||||
33935503|NCT04692896|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935504|NCT01731756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935505|NCT00342667|||COHORT||PROSPECTIVE|||||||
33935506|NCT05186363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33711554|NCT02670837|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711555|NCT03332654|||COHORT||RETROSPECTIVE|||||||
33802020|NCT01973816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802021|NCT00663624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935507|NCT00667940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096313|NCT04665791|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A prospective dose-ranging human challenge study. Nasal inoculation with reconstituted, previously lyophilised Neisseria lactamica with dose escalation.||||
34096314|NCT02371252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096315|NCT00090402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34096316|NCT03950388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096317|NCT03832452|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Prospective, single-center, randomized, double-blind, placebo-controlled, two-part Phase 1 study (Part A: parallel, 2 treatments; Part B: crossover, 4 treatments)|t|t|t|t
34096318|NCT03997201|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective clinical trial||||
34096319|NCT01083472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096320|NCT05103735|||COHORT||RETROSPECTIVE|||||||
34096321|NCT02273466|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34096322|NCT01763957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096323|NCT03650608|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34096324|NCT04881721|||COHORT||PROSPECTIVE|||||||
34096325|NCT02117817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096326|NCT00469027|NA|SINGLE_GROUP||||NONE||||||
34096327|NCT02792946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34096328|NCT03978377|||COHORT||PROSPECTIVE|||||||
34096329|NCT00494884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096330|NCT06258291|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial: treatment in addition to standard of care versus standard of care alone||||
33711556|NCT01484197|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33711557|NCT01953263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711558|NCT02637739|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711559|NCT02866552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935508|NCT02311140|||COHORT||PROSPECTIVE|||||||
33935509|NCT04166955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33711560|NCT04019574|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33711561|NCT03878628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711562|NCT00139009|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33711563|NCT00023504|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720658|NCT04090645|NA|SINGLE_GROUP||TREATMENT||NONE||TheraSphere® consists of insoluble glass microspheres where Y-90 is an integral constituent of the glass. The mean sphere diameter ranges from 20 to 30 µm. Each milligram contains between 22,000 and 73,000 microspheres. TheraSphere® is supplied in 0.6 mL of sterile, pyrogen-free water contained in a 1.0 mL vee-bottom vial secured within a 12 mm clear acrylic vial shield. TheraSphere® is available in six activity sizes: 3 GBq (81 mCi), 5 GBq (135 mCi), 7 GBq (189 mCi), 10 GBq (270 mCi), 15 GBq (405 mCi) and 20 GBq (540 mCi).||||
33720659|NCT01537029|NA|SINGLE_GROUP||OTHER||NONE||||||
33935510|NCT01573286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935511|NCT05319886|||COHORT||PROSPECTIVE|||||||
33935512|NCT03062670|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935513|NCT05592444|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Acquired CT images are identical for all participants. The study arm is unknown to all, except the radiographers (radiology technicians) performing the examination.|Patients are randomly assigned to one of three injection methods: low concentration, low-volume and saline-dilution.|t|f|t|t
33935514|NCT02585635|||OTHER||CROSS_SECTIONAL|||||||
33935515|NCT05254925|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Subjects will be blinded to the name of the investigational products|The potential of BEMT 6% to produce a phototoxic response will be assessed using a preestablished grading scale for erythema and dermal response following the application of approximately 0.15 g or 0.15 ml of each product (4 investigational treatments) on the skin of human subjects, which will then be exposed to UV radiation. Each study arm will include one of the following investigational treatments: a sunscreen oil with 6% BEMT and 10% ethanol as penetration enhancer (SU E 101413 85) as compared to a Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT (SU E 101413 91); a dispersion of 6% BEMT in petrolatum (SU E 101413 82); and petrolatum vehicle (SU E 101413 83).|t|f|f|f
33935516|NCT04542395|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33935517|NCT04830657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Two groups (n = 31) will be determined by randomization created in computer environment by an independent researcher who is not involved in the study, and patients will be assigned to groups A or B created in computer environment. In determining the groups, lots were made with coins and group A was determined as the control group and group B as the remote reiki group. The information showing that the patients included in the study sample were assigned to the A and B groups according to the randomization table was put in an opaque envelope. This envelope will be kept by the coordinator researcher (MG) and when the researcher (MYB), who has a certificate of reiki application, goes to the patient for the application, he will fill in the Informed Consent Form and open the envelope to find out which group the patient is in. If the reiki group far from weakness comes out, the questionnaires will be filled out after verbal consent is obtained from the patient."|Prospective, parallel, two arm, randomized controlled clinical trial, single masking|t|f|f|f
33935518|NCT00198289|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34096331|NCT01186419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096332|NCT01121575|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096333|NCT03826004|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34096334|NCT02000271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096335|NCT05424809|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34096336|NCT00202995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096337|NCT00066937|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34096338|NCT01349621|||||PROSPECTIVE|||||||
33720660|NCT01996826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720661|NCT04447079|||COHORT||PROSPECTIVE|||||||
33720662|NCT00196716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096339|NCT02446938|||CASE_ONLY||PROSPECTIVE|||||||
34013292|NCT02037165|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34096340|NCT00947388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013293|NCT05539976|||COHORT||PROSPECTIVE|||||||
34013294|NCT03512951|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013295|NCT00717184|NON_RANDOMIZED|||TREATMENT||NONE||||||
34013296|NCT01170910|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34013297|NCT05101226|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE|The participants know in which group they are, as does the yoga instructor and the investigator|The participants will be randomly assigned either to the waiting list control group or the intervention group. The intervention group will be evenly split into the attending the yoga classes in person and attending them online.||||
34013298|NCT00522340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013299|NCT00027079|RANDOMIZED|||TREATMENT||DOUBLE||||||
34013300|NCT01414049|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34013301|NCT01252264|||CASE_CONTROL||RETROSPECTIVE|||||||
34013302|NCT05378919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013303|NCT04669054|||COHORT||PROSPECTIVE|||||||
34013304|NCT04989777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013305|NCT05723718|||COHORT||PROSPECTIVE|||||||
34013306|NCT00094081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013307|NCT02794259|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34013308|NCT01091272|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34096341|NCT05003999|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Two-by-two cross-over assignment||||
34096342|NCT02460380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096343|NCT06354569|||CASE_ONLY||CROSS_SECTIONAL|||||||
34096344|NCT01457430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096345|NCT05873621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096346|NCT06136234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All outcome measures are completed by the participant via online survey.|Randomized Controlled Trial|f|f|t|t
34096347|NCT06049277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096348|NCT00850655|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34096349|NCT04686409|||CASE_ONLY||PROSPECTIVE|||||||
34096350|NCT03055195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096351|NCT03750669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096352|NCT01452789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096353|NCT02237274|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096354|NCT05017636|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|N/D|experimental study||||
34096355|NCT01936974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792598|NCT04238000|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The patient and the examiner who administered the clinical scales were blind to the type of rTMS delivered, which was applied by another blinded experimenter.|Each patient received both rTMS and sham cerebellar stimulation in randomized order in two different sessions, separated by at least 2 weeks. In each session, motor tasks, clinical scales and wearing sensor assessments were tested twice in all patients: at baseline (pre-stimulation) and after rTMS (post-stimulation)|t|f|t|f
33792599|NCT04353830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013309|NCT03870113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013310|NCT00196131|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34013311|NCT00338052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013312|NCT00517959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013313|NCT01094249|NA|SINGLE_GROUP||||NONE||||||
34013314|NCT03632317|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be divided into two stratums; newly diagnosed high-grade glioma or DIPG after radiation (stratum A) and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).||||
34013315|NCT05240131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|PART A open label PART B \& C will be double blind until the primary analysis.|Part A is an open label dose ascending design. PART B is a randomised, double-blind, placebo-controlled, parallel group design PART C is an extension study to assess long-term safety and tolerability|t|t|t|t
34013316|NCT03946020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split mouth|t|f|f|t
34013317|NCT03131622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013318|NCT01068379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013319|NCT03353454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013320|NCT04906317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013321|NCT00916136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013322|NCT04677855|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 dose escalation followed by a dose expansion||||
34013323|NCT01129934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34096356|NCT06107673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096357|NCT04852653|||COHORT||PROSPECTIVE|||||||
34096358|NCT04129801|||COHORT||PROSPECTIVE|||||||
34096359|NCT05998239|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"Our study is a semi-randomized, non-blinded single case experimental design with alternating treatments. The comparison period will consist of Bootle Boot Camp exercise sessions offered with movement tracking feedback alternating with exercise sessions offered without this feedback (4 sessions per week x 4 week). Children will be randomized to 1 of 16 alternating treatment schedules. The version of the App providing the most therapeutic data pattern will be used for an additional two weeks.~We will also use a mixed methods sequential explanatory approach, with quantitative data collected in weeks 1-6 and qualitative data in weeks 7-8."||||
34103305|NCT06557343|||CASE_ONLY||PROSPECTIVE|||||||
34103306|NCT06690957|||COHORT||PROSPECTIVE|||||||
34103307|NCT06538350|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, single-centre, randomized, with parallel assignment, controlled trial, with a 1:1 allocation across two treatment arms: telemedicine consultations versus face-to-face consultations||||
34103308|NCT06691477|||COHORT||PROSPECTIVE|||||||
34103309|NCT00544726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103310|NCT05869604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792600|NCT00547118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792601|NCT02203630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792602|NCT02311972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792603|NCT01486550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792604|NCT03856541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792605|NCT00199342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792606|NCT00873691|||COHORT||PROSPECTIVE|||||||
33792607|NCT05721612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792608|NCT04584450|||OTHER||PROSPECTIVE|||||||
33792609|NCT02833272|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34013324|NCT00988936|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34013325|NCT01221246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013326|NCT02317679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013327|NCT05874817|||COHORT||RETROSPECTIVE|||||||
34013328|NCT06406660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013329|NCT02794935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013330|NCT04688476|||COHORT||PROSPECTIVE|||||||
34013331|NCT00682214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34013332|NCT01580657|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34013333|NCT04403217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013334|NCT02743143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013335|NCT04457453|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34013336|NCT06108258|||COHORT||PROSPECTIVE|||||||
34013337|NCT02486094|||COHORT||RETROSPECTIVE|||||||
34013338|NCT05992376|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Data will be collected through household surveys, mama mboga surveys, in-depth interviews (IDIs), and focus group discussions (FGDs). The protocol team has selected a subset of intervention FFZs for the evaluation and identified an equal number of geographic areas of similar size and level of urbanicity to serve as the controls.||||
34013339|NCT02772094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013340|NCT00555802|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34013341|NCT02377635|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34013342|NCT04810442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802022|NCT02867059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802023|NCT02195297|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34013343|NCT00005823|RANDOMIZED|||TREATMENT||||||||
34013344|NCT06426173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher responsible for conducting the functional assessment will be blinded to the randomization and allocation groups.|Randomized controlled trial|f|f|f|t
34013345|NCT04977661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|(single blind study) : Participants did not know the treatment which was given|prospective, randomized, and single blind study|t|f|f|f
34013346|NCT04272723|||OTHER||PROSPECTIVE|||||||
34096360|NCT04261595|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Dates and their constituents show a role in disease prevention through anti-oxidant, anti-inflammatory, anti-bacterial activity. Dates are considered a staple food item in the Middle East and North Africa and are also imported in Europe, the UK, and the USA. (12).~Dates' therapeutic effect in the management of the disease via its anti-oxidant, anti-inflammatory effect and for the sake of autistic children, is worthy to point and essential to evaluate Dates as a good remedy for autistic children because it is inexpensive and easy to access."||||
33711564|NCT00869154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The baseline data were collected before randomization. The data collection at 12 months was conducted by postal self-report questionnaires, and for GOSE, an assistant who was blinded to the group allocation performed a telephone interview. Two independent persons, who were blinded for the groups and were unfamiliar with the aim and content of the study, entered the data into the SPSS database. A statistician, who did not participate in the treatment program and was blinded to the group allocation when the data were analyzed, controlled the data and performed the statistical analyses for RTW and the secondary outcomes.|Randomized controlled trial. Multidisciplinary outpatient rehabilitation with individual contacts and a psycho-educational group intervention at two outpatient rehabilitation clinics compared to follow-up by a general practitioner after a multidisciplinary examination.|f|f|t|f
34096361|NCT04582643|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm pilot test of lifestyle intervention using newly developed tool||||
34096362|NCT00483509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711565|NCT00041483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711566|NCT04648553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711567|NCT00043914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935519|NCT01234311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935520|NCT01067573|||CASE_CROSSOVER||PROSPECTIVE|||||||
34096363|NCT05023005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant will not know the true positioning for strain counterstrain treatment of piriformis muscle versus hamstring muscle.|There are two arms to the study: treatment and sham. The treatment group will receive strain-counterstrain for the piriformis muscle. The sham group will receive strain-counterstrain treatment for the hamstring muscle.|t|f|f|t
34096364|NCT02623270|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34096365|NCT01751841|||CASE_ONLY||RETROSPECTIVE|||||||
34096366|NCT00279331|||||PROSPECTIVE|||||||
34096367|NCT02663570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096368|NCT02744547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34096369|NCT01684033|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34096370|NCT01546298|||COHORT||PROSPECTIVE|||||||
34096371|NCT05111769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096372|NCT04616352|||COHORT||RETROSPECTIVE|||||||
34096373|NCT02797535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096374|NCT00881244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096375|NCT04108260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096376|NCT03993678|NA|SINGLE_GROUP||TREATMENT||NONE||"Multicenter single arm, phase Ib/IIa with 2 Parts:~* Part 1 (referring to the phase Ib part of the trial) consists of a safety run-in cohort with 1 dose level (DL) of IP-001 and a de-escalation safety step with a reduced dose of IP-001, if needed. This 'all-comers' cohort will enroll patients with laser ablation-accessible advanced solid tumors.~* Part 2~  * Cohort 1: Dose expansion cohort consisting of 9 patients with advanced STS treated at the tentative recommended phase 2 dose (RP2D), as established in Part 1;~ * Cohort 2: Phase IIa part consisting of 18 patients with advanced melanoma treated at the tentative RP2D, as established in Part 1."||||
34096377|NCT02216162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935521|NCT06101680|||CASE_ONLY||RETROSPECTIVE|||||||
33935522|NCT02960308|||CASE_CONTROL||PROSPECTIVE|||||||
33935523|NCT03826992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935524|NCT04112745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33935525|NCT02828189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935526|NCT01755260|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33711568|NCT04381598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both stevia gel and placebo syringes are masked from participants and investigators.|one group of subjects receives intervention where as other group of subjects receive placebo.|t|f|t|f
33711569|NCT01603004|||COHORT||PROSPECTIVE|||||||
33711570|NCT04383405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711571|NCT05801250|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33711572|NCT02314416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711573|NCT06241534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711574|NCT04604223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711575|NCT02233647|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33711576|NCT01114425||CROSSOVER||TREATMENT||NONE||||||
33935527|NCT05714254|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind|Protocol designed to evaluate safety, tolerability and pharmacokinetic profile of an intervention for treating chronic pain|t|f|t|f
33935528|NCT03615664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935529|NCT03931590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935530|NCT00161746|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33935531|NCT02165644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935532|NCT01228838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935533|NCT01938768|||COHORT||PROSPECTIVE|||||||
33935534|NCT00164060|||||RETROSPECTIVE|||||||
34013347|NCT03582761|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34013348|NCT01752231|||COHORT||PROSPECTIVE|||||||
34013349|NCT03022669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013350|NCT04628260|||COHORT||CROSS_SECTIONAL|||||||
34013351|NCT04904159|||COHORT||PROSPECTIVE|||||||
34013352|NCT05987917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013353|NCT00959270|||COHORT||CROSS_SECTIONAL|||||||
34096378|NCT05830643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A Prospective Randomized Open, Blinded End-point (PROBE) design will occur. The end-points are evaluated by a blinded end-point clinical coordinator therefore there should be no different between the two types of trials in this regard.|Intervention group (social skills focused psychotherapy) and control group (adult interest focused psychotherapy)|f|f|f|t
34096379|NCT01082055|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34096380|NCT02708706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096381|NCT04870970|||COHORT||PROSPECTIVE|||||||
34096382|NCT05415787|||CASE_ONLY||PROSPECTIVE|||||||
34096383|NCT02468375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096384|NCT03315559|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|This will be an open-label study. Hence, masking will not be provided to the subjects.|This will be a 2-period, single-sequence crossover study. Subjects will receive IV and inhaled doses of GSK2269557 in treatment period 1 and oral dose of GSK2269557 in treatment period 2.||||
34096385|NCT05038956|||COHORT||PROSPECTIVE|||||||
34096386|NCT01232907|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096387|NCT05714397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096388|NCT05916066|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34096389|NCT05592288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind (participant)|This study protocol was drawn up for a single center, single-blind (participant), pretest-posttest, follow-up, parallel group (1:1 ratio) randomized controlled trial.|t|f|f|f
34096390|NCT00114478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096391|NCT04029051|||COHORT||PROSPECTIVE|||||||
34096392|NCT00595751|||COHORT||PROSPECTIVE|||||||
34096393|NCT02438085|||COHORT||PROSPECTIVE|||||||
34096394|NCT06543290|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Pharmacy will have data set with participants idea and placebo vs study drug. All others will be blinded.|We propose a double blinded randomized control trial of patients scheduled to undergo induction of labor at our institution. Enrolled patients will be randomized to receive a single dose of 2 grams Azithromycin or placebo. Induction will proceed per hospital protocols and the primary and secondary outcomes will be obtained from chart review after delivery and will end 6 weeks postpartum|t|f|t|f
34096395|NCT06178913|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34096396|NCT05803512|||OTHER||PROSPECTIVE|||||||
34096397|NCT00943904|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33711577|NCT05809401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711578|NCT02090244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711579|NCT01897402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711580|NCT03226938|||COHORT||PROSPECTIVE|||||||
33711581|NCT02612727|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|Non-inferiority trial comparing the two methods of phototherapy||||
33711582|NCT02709733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711583|NCT00727025|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33711584|NCT06159530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33711585|NCT00349440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711586|NCT03836794|||OTHER||PROSPECTIVE|||||||
33711587|NCT00957775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711588|NCT05685966|||COHORT||RETROSPECTIVE|||||||
33711589|NCT01510691|||OTHER||PROSPECTIVE|||||||
33711590|NCT00765050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711591|NCT00257478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711592|NCT01878838|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33711593|NCT03766932|||COHORT||PROSPECTIVE|||||||
33711594|NCT05169047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711595|NCT00580190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711596|NCT04943497|||COHORT||PROSPECTIVE|||||||
33711597|NCT03370601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720663|NCT05390944|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33792610|NCT04028336|NA|SINGLE_GROUP||OTHER||NONE||"All patients in intensive care and severe, moderate ARDS will be included in this study. All patients will benefit from Lung ultrasound (LUS) with a mapping of each lung looking for normal or pathological lung profiles, as well as a measurement of esophageal pressure (Peso) at rest. A PEP titration pulmonary opening (PEP-OP) test using a recruitment maneuver was then performed in all patients followed by a new LUS and Peso measurement."||||
33792611|NCT00630188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33792612|NCT05250895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013354|NCT05057026|||COHORT||PROSPECTIVE|||||||
34013355|NCT02547766|NA|SINGLE_GROUP||OTHER||NONE||||||
34013356|NCT05013177|||COHORT||PROSPECTIVE|||||||
34013357|NCT00658931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013358|NCT06208826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013359|NCT02714231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34013360|NCT04032158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013361|NCT02459145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013362|NCT02813421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013363|NCT00804141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013364|NCT01040884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013365|NCT04936776|||COHORT||PROSPECTIVE|||||||
34013366|NCT01953822|||COHORT||RETROSPECTIVE|||||||
34013367|NCT05920564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013368|NCT03261882|||OTHER||CROSS_SECTIONAL|||||||
34013369|NCT03634345||PARALLEL||BASIC_SCIENCE||NONE||||||
34013370|NCT00609388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013371|NCT04948229|||CASE_CONTROL||PROSPECTIVE|||||||
34096398|NCT05803993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The collected data will be analyzed in blind, as only one person not involved in the activities related to all the procedures of the study will know if faeces will be infused from a healthy donor or if an autologous FMT will be performed|Recruited subjects will be randomized with 1:1 ratio to receive FMT from healthy donors or autologous FMT (placebo). Patients will be evaluated before FMT and after 30, 60, 90 and 365 days|t|f|t|f
33935535|NCT03733132|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Study will be a double-blind, placebo-controlled, randomized design.||t|t|t|t
33792613|NCT00814346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792614|NCT04589000|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Single Blind. Investigator know which participant have been assigned which group but participant don't know||t|f|f|f
33792615|NCT05566145|||COHORT||RETROSPECTIVE|||||||
33792616|NCT05786456|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33792617|NCT04640363|||COHORT||PROSPECTIVE|||||||
33792618|NCT05773326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792619|NCT04926571|||COHORT||RETROSPECTIVE|||||||
33792620|NCT04613479|||COHORT||PROSPECTIVE|||||||
33792621|NCT00829348|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33792622|NCT04357236|||COHORT||RETROSPECTIVE|||||||
33935536|NCT02177786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935537|NCT00402285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935538|NCT04904640|||COHORT||OTHER|||||||
33935539|NCT02530827|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935540|NCT01947868|||CASE_ONLY||PROSPECTIVE|||||||
33935541|NCT06491992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935542|NCT03520426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935543|NCT00432289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935544|NCT03261037|NA|SINGLE_GROUP||OTHER||NONE||||||
33935545|NCT02049294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013372|NCT03697330|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.|comparing the effect of two different protocols of fluid therapy (liberal versus restrictive) in adult patients undergoing unilateral orthopedic lower limb surgery under spinal anesthesia|t|t|t|t
34013373|NCT00320567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013374|NCT03874494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013375|NCT01991665|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013376|NCT02332980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096399|NCT02105870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096400|NCT03580187|NA|SINGLE_GROUP||TREATMENT||NONE||Were included all patients aged 18 years and over, victims of isolated chest trauma, who were admitted to the intensive care unit. We excluded patients with any of the following criteria: not consent, pregnant woman, polytrauma, hemodynamic instability with systolic blood pressure less than 100 mmHg, treatment with morphine during transport or in the emergency room, need for initial ventilatory support, bradypnea (respiratory rate less than 12 cycles per minute), allergy to opiods, initial pain Visual Analog Scale (VAS) ≤ 4. Pain level was assessed by the pain VAS. We collected demographic, epidemiological, initial clinical examination data, explorations, lesions and we monitored the evolution of the VAS and the vital signs. Informed consent was obtained from all patients||||
34096401|NCT06318286|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open-label study to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma. Patients 18 years of age or older will be eligible for enrollment if they had histologically confirmed unresectable malignant pleural mesothelioma.||||
33792623|NCT00111722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792624|NCT02219919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792625|NCT04645069|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792626|NCT04009642|||CASE_CONTROL||PROSPECTIVE|||||||
33792627|NCT03895034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792628|NCT04076202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792629|NCT03709719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792630|NCT00422019|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792631|NCT00015990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792632|NCT05047341|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single-arm and open-label drug interaction study.||||
33792633|NCT06553040|||CASE_CONTROL||RETROSPECTIVE|||||||
33792634|NCT04306354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"On the eve of the eighth day of hospitalization, a person in charge of the research team performed a randomization of the participants exchanged in blocks, according to the methods of Schulz and collaborators (SCHULZ; GRIMES, 2002). The responsible person did not have contact with the participants. The blocks were made up of 12 participants each, and the ratio was maintained at 4: 4: 4, in order to reduce the chances of the groups getting mixed amounts. The members of the research team responsible for data collection, the technical team of the inpatient unit and the participants did not know to what condition each patient had been allocated.~These procedures guaranteed the randomization and double blinding of the study."||t|t|t|t
33792635|NCT06056908|||COHORT||PROSPECTIVE|||||||
34013377|NCT04477551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096402|NCT04382079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103311|NCT01974479|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the feasibility, safety and efficacy of anti-CD19 redirected NK cells infusion in research participants with B-Lineage Acute Lymphoblastic Leukemia (B-ALL) who have persistent disease as determined by MRD methods after intensive chemotherapy.||||
34013378|NCT00775684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013379|NCT02596386|||CASE_CONTROL||PROSPECTIVE|||||||
34013380|NCT05473819|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Split Mouth Design|f|t|t|t
34013381|NCT03036839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013382|NCT05159817|||COHORT||PROSPECTIVE|||||||
34013383|NCT04668976|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot non- randomized safety study||||
34013384|NCT01635062|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34013385|NCT02136563|||COHORT||PROSPECTIVE|||||||
34013386|NCT01399944|||CASE_ONLY||CROSS_SECTIONAL|||||||
34013387|NCT02443545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013388|NCT03182894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013389|NCT04068974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013390|NCT04576182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (participants, outcome assessor)|A randomized controlled trial|t|f|t|t
34013391|NCT02784782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013392|NCT01302730|||||PROSPECTIVE|||||||
34013393|NCT01066949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711598|NCT06460220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators, masked to condition, will conduct outcome assessments with parents and youth at baseline,1-month (the typical length of TAU in CATC prior to linking youth patients to ongoing outpatient care), and 3-month follow-up.|"Phase 2 will include pilot testing of the SAFETY-P asynchronous parent intervention module with a nonrandomized case series of 10 families receiving services in CATC.~Phase 3 will include an RCT with N = 30 youth and parents, who will be randomized either to SAFETY-P + treatment as usual (TAU) or to TAU alone."|f|f|f|t
33711599|NCT02083952|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33711600|NCT02537197|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post design, single treatment group||||
33711601|NCT04972695|||COHORT||PROSPECTIVE|||||||
33711602|NCT02034214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33711603|NCT04059978|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33711604|NCT03328312|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711605|NCT05992116|||CASE_ONLY||PROSPECTIVE|||||||
33711606|NCT03759847|NA|SINGLE_GROUP||PREVENTION||NONE||Comparison of interdialytic weight gain with fluid intake as recorded by fluid app||||
33711607|NCT03081065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33711608|NCT04021940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711609|NCT06417294|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33711610|NCT06384768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711611|NCT00739674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711612|NCT06402110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935546|NCT04366739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The evaluator of the primary endpoint and secondary endpoints relating to the clinical efficacy of CPZ and the evaluator of the biological and radiological effects of the CPZ will be maintained blindly throughout their duration of inclusion. This evaluator will collect clinical data, biological data, and imaging data without knowing the drug treatments delivered to patients.~The radiologists responsible for calculating the parenchymal damage score on the thoracic CT scan will be blind to the patient delivered drugs.~The biologists responsible for carrying out the analyzes on the biobank will be blind to the patient delivered drugs.~The biostatistician responsible for statistical study analysis will be kept blind to the drugs delivered to the subjects."|"Allocation: Randomized Intervention Model: Parallel Assignment~Intervention Model Description:~reCoVery is a multi-center, randomized, single-blind, standard care-controlled (1:1) pilot clinical study to explore the efficacy and safety of chlorpromazine (CPZ) in the treatment of adult subjects with COVID-19-moderate type (WHO-OSCI 3-5)."|f|f|f|t
33711613|NCT03780907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711614|NCT01950507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711615|NCT04374032|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment||||
33711616|NCT01895569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711617|NCT02014597|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33935547|NCT04081051|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33935548|NCT01958710|||COHORT||RETROSPECTIVE|||||||
33935549|NCT04096404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013394|NCT03974750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Evaluation of bimanual motor skill learning Motor skill learning with a rehabilitation robot|t|f|f|f
34013395|NCT02164630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103312|NCT02349828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711618|NCT03744611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711619|NCT04832360|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33711620|NCT06201559|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33711621|NCT03393637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Following consent, the participants will randomized to either the treatment or control groups using a computer-generated randomization table developed prior to study start. They will be randomized to either the MOMS intervention or prenatal care without the MOMS. Women randomized to the MOMS program will be assigned to a MOMS group in the first trimester.||||
33711622|NCT03004027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711623|NCT05593393|||COHORT||PROSPECTIVE|||||||
33711624|NCT01379755|||COHORT||PROSPECTIVE|||||||
34103313|NCT05208957|||COHORT||OTHER|||||||
34103314|NCT05639439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103315|NCT06691204|||CASE_ONLY||PROSPECTIVE|||||||
34103316|NCT06238037|||COHORT||PROSPECTIVE|||||||
34013396|NCT03822221|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Volunteers will be blinded to the study hypothesis and the reason for positioning changes during the study. One researcher will be blinded for outcomes statistics analysis.|After a familiarization session, there will be four sessions for testing the electrical stimulation at four different combinations of hip and knee angles for isometric contractions. The order of the combinations will be randomized, and a washout period of seven days will be reacquired between each session.|t|f|f|t
34013397|NCT06358287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013398|NCT06020001|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33711625|NCT04448483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711626|NCT00458198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711627|NCT04656691|NA|SINGLE_GROUP||TREATMENT||NONE||Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab.||||
34013399|NCT05212064|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34013400|NCT01387763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013401|NCT05863624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized follow-up study|f|f|f|t
34013402|NCT03394755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34013403|NCT02768038|||COHORT||PROSPECTIVE|||||||
34013404|NCT03708965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013405|NCT03010982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013406|NCT06314919|||COHORT||PROSPECTIVE|||||||
34013407|NCT01862393|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34013408|NCT06437418|||COHORT||CROSS_SECTIONAL|||||||
34013409|NCT00812422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013410|NCT03564301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It will not be possible to know which patient will correspond the prescription of the antibiotic or the placebo until the end of treatment. One of the researchers will be masked and will deliver the boxes with the placebo or the antibiotic according to the result of randomization. He will be different from the researcher who perform the treatment. This means that the treatment group will be masked to patients and dentists.|PLACEBO-CONTROLLED CLINICAL TRIAL IN HUMAN|t|t|t|f
34013411|NCT05607251|||OTHER||CROSS_SECTIONAL|||||||
34013412|NCT02689245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013413|NCT03346252|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label.||||
34013414|NCT04943159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013415|NCT06133803|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial comparing treatment to controls.||||
34013416|NCT01348984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013417|NCT06345144|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34013418|NCT06446141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"I- Postural correction through correction of:~* Forward head~* Protracted shoulders~* Depressed shoulder.~II- Strengthen ex to:~* Shoulder girdle elevators and retractors.~* Cervical and dorsal extensors~* raising arms to reach full flexion and elevation.~III- Restoration of normal mobility~o Inhibition of muscle spasm especially scaleni and pectoral ms. by source of heat\& slow, sustain and self-stretching ex.~IV- Breathing ex: diaphragmatic breathing."|"The Osteopathic technique included:~Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed."|t|f|f|f
34013419|NCT06278038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013420|NCT04236583|NA|SINGLE_GROUP||OTHER||NONE||||||
34013421|NCT06051084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013422|NCT02588066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013423|NCT02133001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013424|NCT01631526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103317|NCT05137054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33711628|NCT00851500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711629|NCT05132920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711630|NCT03942848|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33711631|NCT03566316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096403|NCT04179149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will not be blinded because the two arms are receiving different interventions. However, data will be coded such that data entry and initial analysis can be done in a blinded fashion as to intervention group until ad hoc analysis are conducted.|In this RCT study, subjects randomized to the intervention condition will receive the EE intervention as an adjuvant to standard gynecological care consisting of hormonal, analgesic or surgical treatment as necessary according to their symptoms during the study period. Participants randomized to the control condition will receive only standard care as necessary according to their symptoms during the study period in addition to an online patient training webinar.|f|f|f|t
34096404|NCT00120250|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34096405|NCT05548777|||COHORT||RETROSPECTIVE|||||||
34096406|NCT04945863|||COHORT||RETROSPECTIVE|||||||
33711632|NCT01937559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711633|NCT05195814|||COHORT||RETROSPECTIVE|||||||
33711634|NCT02834507|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33711635|NCT01546181|||CASE_CONTROL||PROSPECTIVE|||||||
33711636|NCT02364752|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33711637|NCT04633694|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The project leader are responsible for the masking while all other persons involved in the project do not know the protein source given.|A parallel 3 armed study, each arm with a different protein type|t|t|f|f
33711638|NCT02644733|||CASE_CONTROL||PROSPECTIVE|||||||
33711639|NCT00114036|RANDOMIZED|PARALLEL||ECT||NONE||||||
33711640|NCT04234698|||COHORT||RETROSPECTIVE|||||||
33711641|NCT05348070|||CASE_CONTROL||RETROSPECTIVE|||||||
33711642|NCT01619982|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711643|NCT04910802|NA|SINGLE_GROUP||PREVENTION||NONE||All women in the targeted age-range will be offered vaccination in conjunction with screening.||||
33711644|NCT04243967|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33711645|NCT06033794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711646|NCT04813445|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33711647|NCT05890846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792636|NCT05266599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792637|NCT05022251|||COHORT||PROSPECTIVE|||||||
33792638|NCT04752735|||COHORT||RETROSPECTIVE|||||||
33792639|NCT00978237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792640|NCT01830010|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792641|NCT04438668|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||Randomised Controlled Trial|t|t|t|t
33792642|NCT01569919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792643|NCT01671124|||COHORT||PROSPECTIVE|||||||
33792644|NCT01623336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792645|NCT06383546|||CASE_CONTROL||RETROSPECTIVE|||||||
33792646|NCT04875130|||CASE_ONLY||PROSPECTIVE|||||||
33792647|NCT05983107|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935550|NCT04700228|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Factorial Assignment Anesthesia will be induced with 100% oxygen and sevoflurane 8%. Once achieving the desired depth of anesthesia, I/V access will be taken. Propofol 3mg/kg and Nalbuphine 0.1mg/kg will be given. LMA of desirable size will be placed. After this, patient would be placed in lateral position for caudal Block. After all aseptic measures, Caudal Block procedure will be done with help of 23G needle by anatomical landmarks. On negative aspiration of the syringe, one of the drug combinations as explained under 'arms and intervention' will be used for the caudal block. First surgical incision will be given 10 mins after the application of caudal block. After the completion of surgery, LMA will be removed once the patient is awake and the patient will be shifted to PACU. IV paracetamol 15mg/kg will be given if FLACC score is more than 4 at any point during the surgery.|t|t|f|f
33935551|NCT00621244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935552|NCT03450486|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study will include one intervention arm and one control arm. The intervention arm will include balance measurements from the affected side of individuals with unilateral knee osteoarthritis. The control arm will will include balance measurements from the unaffected side of individuals with unilateral knee osteoarthritis.||||
33935553|NCT03333512|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935554|NCT02896751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935555|NCT04481880|||CASE_ONLY||PROSPECTIVE|||||||
33935556|NCT03338452|NA|SINGLE_GROUP||TREATMENT||NONE||"Longitudinal intervention study with repeated measurements. Participants will be subjected to a 12-week low energy ketogenic diet (LEKD) and requested not to change their physical activity levels throughout the study.~The participants will underwent a series of tests and consultations at baseline (prior to the start of the intervention), and after 1, 2, 4, 8 , and 12 weeks of LEKD intervention. At the end of each time points, body weight and composition will be measured in the fasting state, food and exercise diaries checked by a dietitian and a kinesiologist and discussed with the participants, psychological and cognitive tests will be performed by a psychologist. At the same time-points, different serum analyses will be performed."||||
33935557|NCT00547989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935558|NCT03797144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935559|NCT02663245|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935560|NCT06164743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked drug product|Double-masked, parallel, randomized|t|t|t|t
33935561|NCT03042195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935562|NCT00369408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935563|NCT00081263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33935564|NCT05126550|||CASE_ONLY||PROSPECTIVE|||||||
33935565|NCT00218452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935566|NCT04721275|||COHORT||PROSPECTIVE|||||||
33935567|NCT01940549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935568|NCT03817749|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33935569|NCT05465967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935570|NCT01551485|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33935571|NCT02844322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096407|NCT05130021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096408|NCT02475057|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34096409|NCT00318864|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34096410|NCT05456217|||COHORT||PROSPECTIVE|||||||
33711648|NCT04232384|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34096411|NCT04677036|||COHORT||PROSPECTIVE|||||||
34096412|NCT01928576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096413|NCT01243424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096414|NCT02661373|NA|SINGLE_GROUP||OTHER||NONE||||||
33711649|NCT00165776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33711650|NCT02113475|||COHORT||PROSPECTIVE|||||||
33711651|NCT00528658|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33711652|NCT05519410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792648|NCT01230840|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33792649|NCT03614611|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants who accept to take part in this study will be assigned to the intervention group. There will be no randomisation or controlled group.~This study will be taking place in Canada, with the intervention device being approved by Health Canada (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"||||
33792650|NCT02310295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792651|NCT02624219|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33711653|NCT02755558|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33792652|NCT00542113|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792653|NCT04882449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Patients and clinicians will be blinded to the results other than data readily available from other devices such as body weight. There will be no attempt to influence clinical practice.|All subjects will be given the Bodyport scale to use||||
33792654|NCT01607372|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33792655|NCT02692105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792656|NCT01725854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096415|NCT00337961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792657|NCT04645394|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Acute 4-arm crossover intervention.|t|f|t|t
33792658|NCT06465680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792659|NCT02845050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792660|NCT04838210|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34013425|NCT05234320|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The study will begin with recruitment for the single 25 mg dose arm /vehicle arm, and once all subjects have been treated and attended their first follow-up visit with no significant safety issues, recruitment of participants for the single 50 mg dose arm/vehicle arm and the multiple 25 mg dose arm/vehicle arm. Once subjects from the multi 25 mg dose Cohort have attended their follow-up visit with no significant safety issues, recruitment for the final multiple 50 mg dose arm/vehicle arm may commence.|A Phase 1, Randomized, Double-blinded, Vehicle-controlled, Single and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics|f|f|f|t
34096416|NCT03434509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096417|NCT02311166|||COHORT||PROSPECTIVE|||||||
34096418|NCT04527250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34096419|NCT01783782|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34096420|NCT02879890|||CASE_ONLY||PROSPECTIVE|||||||
34096421|NCT02792634|||||PROSPECTIVE|||||||
34096422|NCT01163877|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34096423|NCT02759523|||COHORT||OTHER|||||||
34096424|NCT02167360||||TREATMENT||||||||
34096425|NCT03699800|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34096426|NCT06255587|||OTHER||CROSS_SECTIONAL|||||||
34096427|NCT06461559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34096428|NCT01953354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792661|NCT02976818|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33792662|NCT02318381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792663|NCT02278393|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33792664|NCT05270551|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34096429|NCT00341939|||CASE_ONLY||RETROSPECTIVE|||||||
34096430|NCT03396458|||CASE_ONLY||PROSPECTIVE|||||||
34096431|NCT04055298|NA|SINGLE_GROUP||OTHER||NONE||||||
34096432|NCT00002390||||TREATMENT||DOUBLE||||||
34096433|NCT00800150||||TREATMENT||||||||
34096434|NCT02917499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34096435|NCT02518425|||COHORT||RETROSPECTIVE|||||||
34096436|NCT05018819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711654|NCT06506201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711655|NCT01065090|||CASE_CONTROL||PROSPECTIVE|||||||
33711656|NCT03876444|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label Randomized Control Trial||||
33711657|NCT00434330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711658|NCT02150317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33711659|NCT06432920|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants undergo constant-work rate cardiopulmonary exercise testing 2 times: once while wearing the active prototype device (intervention) and once wearing the inactive prototype device (control). Order of intervention/control is randomised.||||
33711660|NCT00763568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792665|NCT00664911|NA|SINGLE_GROUP||||NONE||||||
33792666|NCT04876573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792667|NCT05004272|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33792668|NCT00878722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802024|NCT04781790|||OTHER||PROSPECTIVE|||||||
34096437|NCT04584983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096438|NCT02924116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects will complete the first arm of the study. Upon completion, the subjects will be offered enrollment into the next long term arm of the study (Sustained Efficacy).||||
34096439|NCT05282407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096440|NCT00155571|||DEFINED_POPULATION||OTHER|||||||
34096441|NCT00513448|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
33711661|NCT03715010|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Placebo|BCAA|t|t|t|f
33711662|NCT02223091|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33711663|NCT02617745|NA|SINGLE_GROUP||OTHER||NONE||||||
33711664|NCT01441206|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711665|NCT06052605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802025|NCT03921580|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34096442|NCT03058016|NA|SINGLE_GROUP||PREVENTION||NONE||Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month.||||
34096443|NCT05496738|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"Investigators and other site staff will be blinded to participants' assigned study intervention.~Participants will be assigned to receive study intervention according to the assigned treatment group from the randomization scheme. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study.~In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded study intervention records at the site(s) to verify that randomization/dispensing has been done accurately.~Sponsor staff not directly involved in the conduct of the study will be unblinded to participants' assigned study intervention."||t|t|t|f
33802026|NCT02545738|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33802027|NCT02624258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096444|NCT00005021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802028|NCT01972724|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096445|NCT03159780|||CASE_ONLY||CROSS_SECTIONAL|||||||
34096446|NCT01065155|||OTHER||PROSPECTIVE|||||||
34096447|NCT00394537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096448|NCT02737787|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, non-randomized phase I trial of a vaccine combined with anti-PD-1 (nivolumab) in patients with recurrent ovarian cancer who are in second or third clinical remission following additional chemotherapy.||||
34096449|NCT05788354|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34096450|NCT00132912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34096451|NCT02491450|RANDOMIZED|CROSSOVER||||NONE||||||
34096452|NCT01111188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711666|NCT00327249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096453|NCT05319405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel 2-arm study in which participants will be randomly assigned to either Sana plus Treatment as Usual (Sana+TAU) or Treatment as Usual (TAU)|t|t|t|f
34096454|NCT02003027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096455|NCT03399123|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Two different tidal volume are conducted on the participant base on the randomized choices|t|t|f|t
34096456|NCT02547207|||COHORT||PROSPECTIVE|||||||
33711667|NCT04579705|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|It is the blind that makes microbiological and statistical analysis||f|f|f|t
33711668|NCT00783003|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33935572|NCT06282302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The RCT will involve thirty-six elderly volunteers (≥ 60 years of age) with systemic arterial hypertension, aiming to compare two types of physical exercise sessions, isometric wall squats and an aerobic exercise session on an exercise bike, on the 24-hour blood pressure levels.|f|f|f|t
33935573|NCT05704595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935574|NCT05613491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33935575|NCT00381108|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33935576|NCT02181504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935577|NCT04248556|NA|SINGLE_GROUP||SCREENING||NONE||Clinical trial, single-arm||||
33935578|NCT05997173|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33935579|NCT02238236|||COHORT||PROSPECTIVE|||||||
33935580|NCT00750672|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33935581|NCT01408732|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935582|NCT03540641|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33935583|NCT00537459|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33935584|NCT04742621|||COHORT||PROSPECTIVE|||||||
33935585|NCT01200563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935586|NCT00705380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935587|NCT06220188|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-center one-arm phase II study||||
33935588|NCT06225141|||COHORT||RETROSPECTIVE|||||||
33935589|NCT04116619|||COHORT||PROSPECTIVE|||||||
33935590|NCT02361073|||COHORT||PROSPECTIVE|||||||
33935591|NCT03163940|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935592|NCT03735017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and key research staff assessing outcomes will be blind to condition allocation.|Participants will be randomly assigned to one of two intervention arms. Both groups receive the same number of sessions, duration of sessions, and measures procured.|t|f|f|t
33935593|NCT04191252|||COHORT||PROSPECTIVE|||||||
33711669|NCT00990236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33711670|NCT06014034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711671|NCT02716571|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33711672|NCT05410561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33711673|NCT01525537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711674|NCT01286298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711675|NCT05930912|||CASE_ONLY||CROSS_SECTIONAL|||||||
33711676|NCT01206608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711677|NCT01022632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711678|NCT05061771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711679|NCT03242057|RANDOMIZED|PARALLEL||TREATMENT||NONE|provider and PI is masked for randomization but then no masking once treatment (mode of ventilation) is applied|||||
33711680|NCT04717115|||CASE_CONTROL||RETROSPECTIVE|||||||
33711681|NCT01700777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802029|NCT05519202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802030|NCT02488720|||COHORT||PROSPECTIVE|||||||
34013426|NCT06233110|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|In the subsequent safety expansion cohort, patients will be randomized to one of the two selected candidate doses.|"Initial dose escalation cohort:~Subjects enrolled in the initial dose escalation cohort will begin combination therapy with ruxolitinib 10mg twice daily and fostamatinib 100mg daily (dose level 1). As dictated by the 3+3 design, the dose of fostamatinib for subsequent patients will be 150mg daily (dose level 2) or 100mg twice daily (dose level 3). A dose level 0 of fostamatinib at 50mg daily will be evaluated if the frequency of dose-limiting toxicities at dose level 1 prevents the selection of a biologically optimal dose.~Safety expansion cohort:~Fostamatinib will be given at one of two identified candidate doses from the dose escalation cohort. Subjects will be randomized to one of these two doses. A total of 12 subjects will be accrued for each candidate dose level, including those who received the candidate doses in the dose escalation phase. Subjects will receive ruxolitinib at a dose of 10mg twice daily."|t|f|f|f
34013427|NCT00334256|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34013428|NCT00856713|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33711682|NCT02300688|RANDOMIZED|CROSSOVER||||NONE||||||
33711683|NCT02892071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711684|NCT03462264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised control trial||||
33711685|NCT02198742|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33711686|NCT02893514|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711687|NCT03793738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711688|NCT01121237|||COHORT||PROSPECTIVE|||||||
33711689|NCT01325298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711690|NCT06501638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711691|NCT04773483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711692|NCT01218568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711693|NCT02634229|||FAMILY_BASED||PROSPECTIVE|||||||
33711694|NCT00480298|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33711695|NCT03556150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711696|NCT00869453|||||PROSPECTIVE|||||||
33711697|NCT03630952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711698|NCT03818828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711699|NCT02275221|||OTHER||PROSPECTIVE|||||||
33711700|NCT04804878|||OTHER||PROSPECTIVE|||||||
33711701|NCT01532414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711702|NCT02563444|NA|SINGLE_GROUP||||NONE||||||
33711703|NCT00837811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711704|NCT03692442|||COHORT||RETROSPECTIVE|||||||
33711705|NCT03971058|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.||||
33711706|NCT03253497|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33711707|NCT03808493|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33711708|NCT01129648|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33711709|NCT01931124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711710|NCT04938232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711711|NCT01120678|||COHORT||PROSPECTIVE|||||||
33711712|NCT00855920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711713|NCT04049396|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study was conducted as an open-label, randomized controlled trial .|In this study , samples were randomly divided into two groups receiving and not receiving supplement||||
33711714|NCT01109043|||COHORT||PROSPECTIVE|||||||
33711715|NCT03527277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All outcomes will be analyzed/assessed by subject identity number, which are assigned prior to randomization to experimental arm.|Randomized controlled trial|f|f|f|t
33711716|NCT02984748|||COHORT||PROSPECTIVE|||||||
33711717|NCT05740644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711718|NCT02383277|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33711719|NCT04522362|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
33711720|NCT00484874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711721|NCT03340701|NA|SINGLE_GROUP||OTHER||NONE||Pharmacokinetic study to assess plasma concentration time profile of vaginal progesterone in pregnant women.||||
33711722|NCT04165447|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33711723|NCT03089450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711724|NCT00772343|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33711725|NCT00153075|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711726|NCT00415662|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33711727|NCT03751488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711728|NCT02557750|||COHORT||RETROSPECTIVE|||||||
33711729|NCT05545696|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33711730|NCT02823431|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33711731|NCT04412720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All the measurements will be performed by a professional blinded to the groups. The same assessor will be maintained to perform the evaluations before and after the intervention. The professionals involved with the evaluations will be different from the professionals involved on the intervention.||f|f|f|t
33711732|NCT04013334|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label||||
33711733|NCT04922008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711734|NCT01574131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33711735|NCT04231357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blocks of four, using EPIDAT3.1 statistical program, and created aluminum paper blinded envelopes with the numbered treatment allocation. The numbered envelopes will be opened on the treatment day by the researcher who is in charge of the PRP preparation. All physicians (including orthopaedists involved in clinical outcome assessments and radiologists involved in ultrasound assessments), except one radiologist who performed the procedures, will be unaware of treatment allocation. All patients will be blinded to the treatment. Peripheral blood will be drawn from all patients, and the syringe containing the treatment will be wrapped with gauze hindering treatment visualization.|Single center, superiority type, double blinded, randomised controlled study|t|f|f|t
33711736|NCT04426968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013429|NCT01304758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013430|NCT05500040|||CASE_ONLY||PROSPECTIVE|||||||
34013431|NCT01272115|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34013432|NCT00161798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34013433|NCT05462730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Investigator-initiated, 1:1 randomized, multicenter, double-blind, placebo-controlled clinical trial. A minimum of 378 patients with STEMI will be randomized 1:1 to an infusion of 250 mg (4 mL) methylprednisolone in the pre-hospital setting prior to primary PCI. The methylprednisolone will be given as a bolus infusion of 1 x 250 mg (1 x 4 mL) over a period of 5 minutes. Patients allocated to placebo will receive 4 mL of isotonic saline (NaCl 0.9%).|t|t|t|t
34096457|NCT03445273|||OTHER||PROSPECTIVE|||||||
34096458|NCT04275414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013434|NCT06167954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013435|NCT03712241|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34013436|NCT05736536|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34013437|NCT03249740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking is relevant to Phase 2 only|Phase 1: open-label GB-102 dose cohorts are initiated sequentially Phase 2: assignment to and initiation of cohorts occur in parallel - not completed in this study. Separate protocol (GBV-102-002) implemented for Phase 2.|t|t|f|t
34013438|NCT05237440|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013439|NCT00147849|RANDOMIZED|PARALLEL||ECT||NONE||||||
34096459|NCT03607058|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34096460|NCT06262373|||COHORT||PROSPECTIVE|||||||
34096461|NCT00622063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096462|NCT01260792|||||PROSPECTIVE|||||||
34096463|NCT00000987||||TREATMENT||||||||
34013440|NCT04054284|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34096464|NCT05628415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the Patient is blinded to the study. Patients do not know which stapler they are being treated with on which side because they are under anesthesia in the operating room and also do not have access to information regarding the stapler being used afterwards.|prospective randomized single-blinded monocentric study|t|f|f|f
34013441|NCT01490320|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34013442|NCT00209586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096465|NCT02344095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096466|NCT01796444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096467|NCT02619656|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34096468|NCT04200209|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34096469|NCT04546620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096470|NCT01975649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096471|NCT05182892|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Speech ratings in part 3 will be performed by speech therapists. They are blinded towards stimulator setting and visit number.||f|f|f|t
34096472|NCT00739570|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34096473|NCT03701087|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Effect of Vitamin D intake in pregnancy to prevent recurrence of gestational Diabetes||||
34096474|NCT01590966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096475|NCT01647685|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34096476|NCT05316987|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096477|NCT03938155|||COHORT||PROSPECTIVE|||||||
34096478|NCT00890721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711737|NCT03469375|||CASE_CONTROL||PROSPECTIVE|||||||
33711738|NCT03858114|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33935594|NCT03114462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935595|NCT03596320|||OTHER||CROSS_SECTIONAL|||||||
33935596|NCT04576663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935597|NCT04707027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33935598|NCT01369069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935599|NCT04250610|||COHORT||PROSPECTIVE|||||||
33935600|NCT04942769|NA|SINGLE_GROUP||TREATMENT||NONE||patients with Autoimmune thyroiditis||||
33935601|NCT04717167|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|A double-blinded study was achieved by giving no information about the assigned intervention to the executive researchers; and only the same general explanation about the intervention type to the subjects (Appendix A). Moreover, subjects were prohibited to see the needling-intervention. The group allocation was solely known by the treating therapists and the independent researcher (IB).|One group will receive dry needling session and one group will receive placebo treatment. A simple randomization on a website (www.randomizer.org) performed by a researcher (IB), independent from the executive researchers.|t|f|f|t
33935602|NCT01555541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935603|NCT05212467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients are randomized to one of the three treatment groups|f|f|t|t
33935604|NCT03075930|||COHORT||PROSPECTIVE|||||||
33935605|NCT05608200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935606|NCT04532281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935607|NCT03479658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935608|NCT06217640|||COHORT||CROSS_SECTIONAL|||||||
34013443|NCT01710436|||CASE_CONTROL||PROSPECTIVE|||||||
34013444|NCT03736759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34013445|NCT03109119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a double blinded study, where the participants are randomly selected using a computer - generated number and allocated to any one of the two groups. Both the patient and the outcome assessor will be blinded.|"All children will be randomly allocated into two groups - group S and P. Children in group S will be anaesthetised with sevoflurane, whereas children in group P will be anaesthetised with propofol.~Peripheral blood samples of 1.5 ml each will be taken immediately after extubation (S-2) , after 48 hours (S-3)and after 120 hours (S-4).A fifth blood sample (S-5) will be taken on the 14th postoperative day.~These blood samples will be evaluated for genomic instability using Alkaline Comet Assay and micronucleus test by the Genetics Lab of our hospital."|t|f|f|t
34013446|NCT05016622|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34013447|NCT02972502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013448|NCT05715814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013449|NCT03966391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Students will not be aware of whether they are in the intervention or control group. Care providers who are trained in the intervention are aware of the group allocation. They will not communicate with care providers not trained in the intervention. Care providers that are trained in the intervention will not deliver care to participants in the control group and care providers that are not trained in the intervention will not deliver care to participants in the intervention group|Cluster trial involving 8 community health centres. They will be randomized to CARD or control (standard care) groups in a 1:1 ratio. Eligible schools (approximately 13/community health centre) will be included.|t|f|f|f
34013450|NCT03580291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013451|NCT05408182|||COHORT||PROSPECTIVE|||||||
34013452|NCT04627077|||COHORT||CROSS_SECTIONAL|||||||
34013453|NCT03244423|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34013454|NCT03095898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34096479|NCT03868800|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34096480|NCT04197960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013455|NCT06331858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Before and after the treatment, all patients were evaluated by a blind evaluator in terms of physical examination, pain and functionality, physical performance, quality of life and gait parameters.|"1. STUDY GROUP~2. CONTROL GROUP"|f|f|t|t
34013456|NCT03284879|||CASE_ONLY||PROSPECTIVE|||||||
34013457|NCT01510249|||CASE_CONTROL||RETROSPECTIVE|||||||
34013458|NCT06015477|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients meeting the enrollment criteria will be randomly assigned to one of the two treatment groups (1:1) and will be followed up for 1 year. All patients received oral clopidogrel 75 mg + aspirin 100 mg for 3-5 days preoperatively.||||
34013459|NCT03887728|||COHORT||PROSPECTIVE|||||||
34096481|NCT03694652|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34096482|NCT01901588|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34096483|NCT05371197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711739|NCT05368688|||OTHER||RETROSPECTIVE|||||||
33711740|NCT04921371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33711741|NCT03571815|RANDOMIZED|PARALLEL||PREVENTION||NONE|interventional group-fluoride varnish application. control group-water|||||
33711742|NCT04974385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711743|NCT02720991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711744|NCT03495362|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The all details of groups assignment are arranged and controlled by the research designers. The color, shape, and external packaging of the yeast beta-glucan and placebo are consistent. Each bottle of capsules will be marked with the name (or identify number) of the participants by research designers. Thus, the grouping of participants is blind to the rest of the researchers (like outcomes assessors).||t|f|f|t
33711745|NCT04775875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711746|NCT05516602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711747|NCT05004766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711748|NCT06140784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33792669|NCT03906942|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Participants, center staff, and research staff will be blinded to participant group assignment.|Participants will be randomly assigned to either the Fun For Wellness (FFW) group or the Usual Care (i.e., UC) group by the code programmed within the FFW website that is specified to achieve a 1:1 group (i.e., nFFW = 15, nUC = 15) assignment. Participants assigned to the UC group (i.e., UC participants) will proceed through the pre-operative weight management program provided by the center. Participants assigned to the FFW group (i.e., FFW participants) will proceed through the pre-operative program provided by the center and will be given 4 weeks (i.e., Week 3 through Week 6) of 24 hr access to the FFW online intervention during data collection for this study.|t|t|t|t
33711749|NCT05989984|RANDOMIZED|PARALLEL||OTHER||NONE|No masking procedure will be applied|Monocentric, prospective, randomized study||||
33711750|NCT04343261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711751|NCT04416178|||COHORT||PROSPECTIVE|||||||
33711752|NCT00806390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711753|NCT01216306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711754|NCT02860013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711755|NCT00692081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711756|NCT05614830|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711757|NCT01801891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711758|NCT06201377|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|"Participant: Initially, the subject will not know which suture he/she has received, full information regarding the suture used, as well as the results obtained in his/her case, will be given at the last visit of the study.~Observer: (R.E. Another periodontist, external to the intervention, will be in charge of recording the clinical parameters.) Analyst: (X. M. The statistician does not know to which treatment each variable corresponds."|We will perform the experimental (periodontal surgery where the suture of the flap will be an absorbable suture with clorhexidine) control technique (periodontal surgery where the suture of the flap will be an absorbable suture without clorhexidine) according to the randomization sequence.|t|f|t|t
33711759|NCT06376279|||COHORT||CROSS_SECTIONAL|||||||
33792670|NCT01979393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792671|NCT02675348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096484|NCT03863301|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm interventional cohort study||||
34096485|NCT00520715|||COHORT||PROSPECTIVE|||||||
34096486|NCT03494192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096487|NCT04978831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096488|NCT06101407|||COHORT||PROSPECTIVE|||||||
34096489|NCT04331379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096490|NCT04688944|||COHORT||PROSPECTIVE|||||||
34096491|NCT05834153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096492|NCT06530095|||CASE_CONTROL||RETROSPECTIVE|||||||
34096493|NCT03604627|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34096494|NCT06121232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096495|NCT00140114|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096496|NCT02024009|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34096497|NCT05338580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096498|NCT01676350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096499|NCT02282384|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34096500|NCT06132750|||COHORT||PROSPECTIVE|||||||
34096501|NCT02968394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096502|NCT03363438|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34096503|NCT02659228|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935609|NCT01172990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935610|NCT04323917|||CASE_CONTROL||PROSPECTIVE|||||||
33935611|NCT03450824|||CASE_CONTROL||RETROSPECTIVE|||||||
34096504|NCT01034527|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935612|NCT00736450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935613|NCT00910936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33935614|NCT06097975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935615|NCT01910649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935616|NCT05017987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open, Randomization, single oral administration, 2 Intervention group, crossover design||||
34096505|NCT01307618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711760|NCT01158300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096506|NCT00662701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096507|NCT06141681|||OTHER||CROSS_SECTIONAL|||||||
34096508|NCT05711407|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096509|NCT04675281|||COHORT||PROSPECTIVE|||||||
34096510|NCT06550453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096511|NCT01482286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34096512|NCT04375592|||CASE_ONLY||PROSPECTIVE|||||||
34096513|NCT05366647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711761|NCT00375804|||COHORT||OTHER|||||||
34096514|NCT02545127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096515|NCT01119222|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33711762|NCT02927431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711763|NCT00813735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711764|NCT00281255|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33711765|NCT03849898|||CASE_CONTROL||PROSPECTIVE|||||||
33711766|NCT01385215|RANDOMIZED|PARALLEL||||NONE||||||
33711767|NCT00309569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711768|NCT05927493|||COHORT||RETROSPECTIVE|||||||
33711769|NCT03100032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711770|NCT01539850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711771|NCT00118001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711772|NCT00140595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711773|NCT01115634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711774|NCT03911804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, care providers and investigators are blinded to group assignment.|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are given 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.|t|t|t|f
33711775|NCT02175147|||COHORT||PROSPECTIVE|||||||
33711776|NCT01880840|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711777|NCT00599924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711778|NCT04127864|||COHORT||PROSPECTIVE|||||||
33711779|NCT01464099|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33711780|NCT00533195|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34013460|NCT06357663|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"The study will be performed as a Pilot follow-up study, should the 0 Hypothesis be successfully rejected, this study will be followed by a formal Double Blind Randomized Crossover Study.~We plan subjects may enter the study as a group and will have measurements done within short time frame from each other at beginning and at the end of 3 and 9 months.~As this is a pilot study, there will be no randomization into treatment and control group, as a control we will use the Normal values of telomere from general population. All subjects will receive a transmission and then will be practicing Tao Calligraphy mindfulness daily during the 9 months.~Every subject who is accepted into the study, will have blood sample taken for analysis and will fill Rand SF 36 Questionnaire. Afterwards, will receive transmission of subtle energy by Zhi Gang Sha (or his designee) and will be instructed on how to practice mindfulness with Tao Calligraphy."||||
34013461|NCT06063759|NA|SEQUENTIAL||OTHER||NONE||3 groups with the same study procedures in sequential timely series.||||
33711781|NCT01500694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711782|NCT02664753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711783|NCT00062374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711784|NCT04429139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711785|NCT04512404|||COHORT||PROSPECTIVE|||||||
33711786|NCT01288066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711787|NCT01803204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33711788|NCT04047940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33711789|NCT06382792|||COHORT||RETROSPECTIVE|||||||
33711790|NCT05979701|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33711791|NCT01350414|||COHORT||PROSPECTIVE|||||||
33711792|NCT03490097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711793|NCT03116893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711794|NCT04658498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, three arms parallel group randomized controlled trial with 1:1:1 allocation ratio|t|f|f|t
33711795|NCT05764759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33711796|NCT00595530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711797|NCT03239288|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||"Randomized, controlled, double-blind, crossover trial that includes one screening visit and two test visits separated by a washout period of 4-7 days. At Visit 1 (day -7), subjects will provide informed consent and undergo screening assessments. Test day instructions will also be provided.~At Visit 2 (day 0), subjects will arrive at the clinic fasted (10-14 h, water only, anchored to the t = -15 min blood draw), to undergo clinic visit procedures. Eligible subjects will be randomly assigned to a randomization sequence and will undergo the glycemic and insulinemic response test with blood glucose concentrations assessed via capillary measurement and insulin concentrations assessed via venous measurement.~At Visit 3 (day 7), subjects will return to the clinic for clinic visit procedures. Subjects will then crossover to the next study product in their test sequence and repeat the glycemic/insulinemic response test described above for Visit 2."|t|t|t|t
33711798|NCT02333877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792672|NCT04783610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792673|NCT01312441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711799|NCT06093698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792674|NCT05543837|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33792675|NCT02485379|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792676|NCT03487042||SEQUENTIAL||TREATMENT||NONE||||||
33792677|NCT04641000|||COHORT||PROSPECTIVE|||||||
33792678|NCT02884544|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792679|NCT02533635|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33792680|NCT06181812|||CASE_ONLY||OTHER|||||||
33792681|NCT04650048|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|"The participants are pseudo-randomly allocated to either the intervention or the control group so as the two groups are equally weighted on gender.~Using the build in double-blind software of the HD-tDCS device, the participant as well as investigator is blinded to the protocol that is administered."||t|t|t|t
33792682|NCT00541749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792683|NCT03510091|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33792684|NCT00647530|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pre- plus Post-operative chemotherapy (+/- Panitumumab) vs standard post-operative chemotherapy.||||
33792685|NCT04670159|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33792686|NCT06513234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792687|NCT04988048|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open, multicenter, collaborative and adaptive non-inferiority trial||||
33792688|NCT02888249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33792689|NCT05286762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blinded|Subjects are randomized in 1:1:1:1 order|t|t|t|t
34013462|NCT05083039|||COHORT||CROSS_SECTIONAL|||||||
34013463|NCT03719508|||COHORT||PROSPECTIVE|||||||
34013464|NCT05874440|||COHORT||CROSS_SECTIONAL|||||||
34013465|NCT05175976|||COHORT||RETROSPECTIVE|||||||
34013466|NCT02314572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013467|NCT01956019|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34013468|NCT05695872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096516|NCT02368509|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33711800|NCT05134012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study. All participants will receive two doses of \[15-O\]-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).||||
33711801|NCT06497933|||COHORT||PROSPECTIVE|||||||
33711802|NCT02941978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711803|NCT03763214|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, two arms||||
33711804|NCT00510120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711805|NCT06505616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||prospective, multicenter, randomized, crossover, non-masked study||||
33711806|NCT04280133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792690|NCT02091336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792691|NCT04569318|NA|SINGLE_GROUP||TREATMENT||NONE|Unmasked|Single arm interventional study||||
33711807|NCT00029614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711808|NCT00035516||||TREATMENT||||||||
33711809|NCT04822454|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33711810|NCT02331914|||CASE_ONLY||PROSPECTIVE|||||||
33711811|NCT04147130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33711812|NCT01375647|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33711813|NCT00048555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711814|NCT05000476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33711815|NCT05246761|||COHORT||PROSPECTIVE|||||||
33711816|NCT04659304|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||sequential dose escalation using a 3+3 design||||
33711817|NCT06505369|NA|SEQUENTIAL||TREATMENT||NONE||||||
33792692|NCT01669148|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792693|NCT03967886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33792694|NCT03812354|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33792695|NCT02612818|||COHORT||PROSPECTIVE|||||||
33792696|NCT02633423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33792697|NCT04801836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792698|NCT04741451|||COHORT||PROSPECTIVE|||||||
33792699|NCT00863824|||CASE_ONLY||PROSPECTIVE|||||||
33792700|NCT03316768|||CASE_CONTROL||PROSPECTIVE|||||||
33711818|NCT01831193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792701|NCT00004878|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33711819|NCT05239923|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||People were not vaccinated with SARS-COV2 vaccine were recruited for the administration of Bacillus subtilis oral vaccine||||
33711820|NCT00325728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711821|NCT00786682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711822|NCT00208091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711823|NCT05169749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711824|NCT00018200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711825|NCT00333814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711826|NCT00002418||||TREATMENT||||||||
33711827|NCT00705653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711828|NCT00897104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935617|NCT03737396|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|In the validation phase of the study, patients, nurses and investigators are aware of participating patients' allocation in the cross over validation study. However, nurses would be blinded to the electronic responses of patients. In the randomized phase of the study, patient, nurses and investigators will be aware of group allocation and no blinding is involved.|Participating patients performs self-administered preanaesthesia health screening on an electronic tablet, before receiving nurse-administered health screening by nurses blinded to their electronic responses. This cross over study design aims to validate the electronic patient responses. In another phase, a randomized controlled trial design will be adopted to compare nurse processing time between patients who are assessed by self-administration of PATCH vs patients who undergo standard nurse-led health assessment interview.||||
33935618|NCT02689544|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935619|NCT03194204|RANDOMIZED|PARALLEL||TREATMENT||NONE||A group of patients will receive methotrexate only, another group will receive methotrexate plus doxycycline||||
33935620|NCT00348075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33935621|NCT00809614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935622|NCT05225792|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33935623|NCT06220240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator administering the treatment and the investigator performing the evaluations will be different. The evaluator will not know about the interventions that the participants received.||f|f|f|t
33935624|NCT00532064|||COHORT||PROSPECTIVE|||||||
33935625|NCT00004141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935626|NCT03442933|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||A cross-over study with a single group (n = 40) of amateur cyclists subjected to each 2 different intervention conditions: a road bike time trial (CA) and a mountain bike time trial (MT).|t|t|t|t
33935627|NCT02057276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935628|NCT01245972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935629|NCT02299206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33935630|NCT06338813|NON_RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||f|t|t|t
33935631|NCT05973240|||OTHER||CROSS_SECTIONAL|||||||
33935632|NCT05685849|||COHORT||PROSPECTIVE|||||||
33935633|NCT01538433|||||RETROSPECTIVE|||||||
33935634|NCT02706795||SEQUENTIAL||TREATMENT||NONE||||||
33935635|NCT05483764|||OTHER||CROSS_SECTIONAL|||||||
33935636|NCT05847387|||COHORT||PROSPECTIVE|||||||
34096517|NCT00656812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711829|NCT03641924|||CASE_ONLY||PROSPECTIVE|||||||
33711830|NCT02556814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711831|NCT02697812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33711832|NCT03269383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study drugs will be randomized and prepared by the institutional pharmacy. The research coordinator will maintain the log tracking which patients received treatment vs placebo.|Randomized Controlled Trial with 2 arms, treatment and placebo|t|t|t|t
33711833|NCT03069807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomised trial evaluating treatment completion (the primary outcome), uptake, acceptability, safety and cost-effectiveness of treating latent tuberculosis infection (LTBI) in migrants in primary care, compared with secondary care.||||
33792702|NCT01975311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792703|NCT01215695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33792704|NCT05237258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792705|NCT03114553|||COHORT||PROSPECTIVE|||||||
33792706|NCT02770599|||OTHER||RETROSPECTIVE|||||||
33792707|NCT00854906|||CASE_ONLY||PROSPECTIVE|||||||
33792708|NCT02261337|||COHORT||PROSPECTIVE|||||||
33792709|NCT02867566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792710|NCT00552552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34013469|NCT06348056|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The two zinc supplements will have the same appearance, and will be in coded bottles, such that the participant, care provider, investigator, and outcomes assessor may be kept unaware of the order of the supplements for each participant until the data analysis is complete.|Participants will take the first zinc supplement for two weeks, followed by a two-week washout period, and then take the second zinc supplement for two weeks. The order of whether the first supplement is the zinc amino acid complex, or zinc gluconate, will be randomized.|t|t|t|t
34013470|NCT02416011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013471|NCT00949689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013472|NCT01747122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013473|NCT03992417|||CASE_ONLY||PROSPECTIVE|||||||
34013474|NCT04999033|||OTHER||CROSS_SECTIONAL|||||||
34013475|NCT06441461|||COHORT||PROSPECTIVE|||||||
34013476|NCT04542850|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label pilot study involving 40 patients with COVID-19 disease. Patients that are hospitalized due to confirmed SARS-CoV-2 infection will be assigned to two groups according o their severity grade (moderate or severe).||||
34013477|NCT04801667|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34013478|NCT02936687|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34013479|NCT05560789|NA|SINGLE_GROUP||OTHER||NONE||This study will assess glucose and hormone responses (insulin, glucagon, GLP-1) during structured exercise on a stationary bicycle ergometer or on a treadmill, up to a duration of 60 minutes, in individuals with a history of post-bariatric hypoglycemia.||||
34013480|NCT03167593|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013481|NCT03806842|NA|SINGLE_GROUP||TREATMENT||NONE|no masking due to being a single arm study|single arm, historically controlled, multi-center||||
34013482|NCT03169920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013483|NCT06443788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013484|NCT04013113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013485|NCT04667702|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34013486|NCT01200940|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34013487|NCT04158336|RANDOMIZED|PARALLEL||TREATMENT||NONE||USC Cohort is Parallel Assignment and MOI Cohort is Single Group||||
34013488|NCT03078452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013489|NCT02919826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096518|NCT06166823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711834|NCT02031107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33711835|NCT00245115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711836|NCT00000938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33711837|NCT01191398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33711838|NCT00482612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711839|NCT01118702|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33711840|NCT02496611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Individuals who consented to the project were enrolled in a screening phase of the study where they received meal replacement therapy in attempt to achieve a \>/= 5% body mass reduction. Individuals who did not meet this goal were considered screen failures. Individuals who met this goal were allowed to remain in the study and be randomized to one of the treatment arms (placebo or GLP-1 RA).~A total of 100 participants consented and were enrolled and 66 participants achieved the required BMI reduction with MRT and were randomized to study treatment (33 to GLP-1 RA (exenatide) and 33 to placebo)."|t|t|t|t
33711841|NCT05564936|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33711842|NCT04446520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711843|NCT02332850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711844|NCT02270957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711845|NCT04098198|||COHORT||PROSPECTIVE|||||||
33711846|NCT05951673|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomized using computer-generated randomization; Outcome assessors blinded against treatment assignment.|Enrolled participants are randomized to Treatment 1 (Life skills only) Treatment 2 (Life skills + digital skills) and control group (No intervention).|f|f|f|t
33711847|NCT04229485|||COHORT||PROSPECTIVE|||||||
33711848|NCT00352560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711849|NCT05017766|||COHORT||PROSPECTIVE|||||||
34096519|NCT01837888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711850|NCT00386789|||||OTHER|||||||
33711851|NCT03068481|RANDOMIZED|PARALLEL||OTHER||SINGLE|Healthy volunteer part -Multiple dose: Participant, Healthy volunteer part -Single dose and Patient part: No Masking|Healthy volunteer part -Multiple dose: Parallel, Healthy volunteer part -Single dose and Patient part: Single Group|t|f|f|f
33711852|NCT06066658|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Non randomised intervention and control both with standard care for breathlessness and anxiety||||
33792711|NCT01299753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792712|NCT02298140|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34013490|NCT03893734|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Clinicians will be provided with two blinded syringes containing either saline and hydromorphone or methadone and saline.|Patients will be randomized to receive either methadone at the start of anesthesia or hydromorphone at the end of surgery|t|t|t|t
34013491|NCT00821366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013492|NCT03496857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistic evaluation|RANDOMIZED CLINICAL TRIAL|f|f|f|t
34013493|NCT06490003|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013494|NCT00283413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013495|NCT06203912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013496|NCT01973023|||||RETROSPECTIVE|||||||
34096520|NCT02801708|||CASE_ONLY||PROSPECTIVE|||||||
34096521|NCT00598767|||COHORT||PROSPECTIVE|||||||
34096522|NCT04621786|NA|SINGLE_GROUP||TREATMENT||NONE|Subject and outcomes assessor were blinded to amplitude titration|||||
34096523|NCT00874809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096524|NCT01891838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34096525|NCT06197516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096526|NCT06199999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096527|NCT06151938|||COHORT||PROSPECTIVE|||||||
34096528|NCT01494974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33711853|NCT06077591|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.||||
33711854|NCT04876924|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33711855|NCT00728598|||CASE_CONTROL||PROSPECTIVE|||||||
33711856|NCT02759432|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711857|NCT00795106|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33711858|NCT02672657|||COHORT||PROSPECTIVE|||||||
33711859|NCT01489488|RANDOMIZED|CROSSOVER||||NONE||||||
33711860|NCT03637114|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The allocated gas mixture will not be disclosed to the patient since he will breath through a facemask during both interventions.|Including a baseline assessment and assessments under simulated altitude and normoxia.|t|f|f|f
33711861|NCT01369797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711862|NCT02573350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711863|NCT05471778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This study was conducted as a randomized controlled trial.|t|f|t|f
33711864|NCT00262574|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33711865|NCT02529345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711866|NCT00826215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711867|NCT03555591|||COHORT||PROSPECTIVE|||||||
33711868|NCT00413127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711869|NCT02430844|||COHORT||PROSPECTIVE|||||||
33711870|NCT03487276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711871|NCT05864872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711872|NCT05350111|NA|SINGLE_GROUP||OTHER||NONE||||||
33711873|NCT00928603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711874|NCT05924620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711875|NCT03675698|||COHORT||PROSPECTIVE|||||||
33711876|NCT02376088|||COHORT||PROSPECTIVE|||||||
33711877|NCT03006497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711878|NCT02195440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711879|NCT00622245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935637|NCT03851224|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Immediate implant placement in maxillary esthetic zone without augmenting the jumping gap versus the use of autogenous bone particulates or demineralized bovine bone graft.|Immediate implant placement in maxillary esthetic zone without augmenting the jumping gap versus the use of autogenous bone particulates or demineralized bovine bone graft.|t|f|f|f
33935638|NCT01189838|||CASE_ONLY||RETROSPECTIVE|||||||
33935639|NCT05010395|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935640|NCT03067064|||OTHER||CROSS_SECTIONAL|||||||
33935641|NCT02551328|||CASE_CONTROL||PROSPECTIVE|||||||
33935642|NCT01731808|RANDOMIZED|PARALLEL||||NONE||||||
33935643|NCT03381352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935644|NCT04547491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33935645|NCT04325919|||CASE_CONTROL||PROSPECTIVE|||||||
33935646|NCT00518336|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34013497|NCT02527018|||CASE_ONLY||PROSPECTIVE|||||||
34013498|NCT02463305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013499|NCT01588236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013500|NCT00795808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711880|NCT04219943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711881|NCT00028405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792713|NCT05242653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33792714|NCT02558244|||COHORT||RETROSPECTIVE|||||||
33792715|NCT01114945|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33792716|NCT06677411|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33792717|NCT01145248|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792718|NCT02894749|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792719|NCT00307463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013501|NCT02033304|||COHORT||PROSPECTIVE|||||||
34013502|NCT01994694|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013503|NCT04399876|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013504|NCT00594646|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34013505|NCT03816813|||COHORT||CROSS_SECTIONAL|||||||
34013506|NCT00027794||||TREATMENT||NONE||||||
34013507|NCT01090375||PARALLEL||BASIC_SCIENCE||||||||
34013508|NCT02918747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013509|NCT05123677|||CASE_CONTROL||PROSPECTIVE|||||||
34013510|NCT02560441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013511|NCT02546843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013512|NCT03393871|||COHORT||PROSPECTIVE|||||||
34013513|NCT06468293|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34013514|NCT00572117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013515|NCT00966043|||COHORT||PROSPECTIVE|||||||
34013516|NCT02893995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013517|NCT00215449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013518|NCT03757780|||COHORT||RETROSPECTIVE|||||||
34013519|NCT00679913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013520|NCT01568866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013521|NCT02818387|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
34013522|NCT02851550|||COHORT||PROSPECTIVE|||||||
34013523|NCT04572282|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34013524|NCT03695848|||CASE_CONTROL||PROSPECTIVE|||||||
34013525|NCT03476343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013526|NCT01088282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013527|NCT00975962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34013528|NCT05513287|||CASE_CONTROL||RETROSPECTIVE|||||||
34096529|NCT01993368|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34096530|NCT04064671|||COHORT||PROSPECTIVE|||||||
34096531|NCT03483090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Treatment arm and Placebo arm|t|t|t|t
33711882|NCT05086406|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients undergoing a laparoscopic hysterectomy for benign gynecologic etiologies with Drs. Arnolds, Frazzini Padilla, or Sprague at Cleveland Clinic Florida Section of Minimally Invasive Gynecologic Surgery will be recruited at the visit where decision is made to proceed with surgery. Enrolled subjects will be randomized using a computer generator into either the control group or the study group. Subjects will be notified of which group they have been selected to at the time of scheduling for their pre-operative visit. The control group will undergo standard in-office pre-operative counseling visit. The study group will receive pre-operative counseling via video followed by a virtual visit with a gynecologic surgery provider, using standard and secure communications that are currently approved by Cleveland Clinic. The link to the video and instructions for the virtual visit will be sent to the subject either via email and/or through a message on the electronic medical record platform.||||
33711883|NCT02148198|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33792720|NCT04573803|RANDOMIZED|PARALLEL||PREVENTION||NONE||The MAST trial consists of two pragmatic, open-label, multi-centre, independent, parallel, randomised trials. MAST-DURATION consists of two arms and MAST-PROPHYLAXIS consists of three arms.||||
33792721|NCT03610958|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single center, open-labeled single arm study.||||
33792722|NCT02079155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792723|NCT05392179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792724|NCT03465345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792725|NCT01930045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792726|NCT00333060|RANDOMIZED|PARALLEL||||DOUBLE||||||
33792727|NCT01517542|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792728|NCT01672619|||COHORT||PROSPECTIVE|||||||
33792729|NCT03575819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Following completion of the dose escalation phase of the study and determination of a recommended phase 2 dose, patients will be enrolled into a dose expansion cohort.||||
33935647|NCT04065815|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment parallel-group, randomized-controlled study||||
33935648|NCT01675817|||OTHER||PROSPECTIVE|||||||
33935649|NCT03740139|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Subjects will not know the arm that they are randomized to.|"Participants will be randomized either to the intervention (the Linkage System) or to no additional intervention."|t|f|f|f
33792730|NCT06630338|||CASE_ONLY||CROSS_SECTIONAL|||||||
33792731|NCT00696280|||||PROSPECTIVE|||||||
33792732|NCT05787964|||COHORT||PROSPECTIVE|||||||
33792733|NCT03730428|||COHORT||RETROSPECTIVE|||||||
33792734|NCT01169363|||OTHER||RETROSPECTIVE|||||||
33792735|NCT00383513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792736|NCT06677515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792737|NCT05676190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935650|NCT03727776|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935651|NCT01337791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935652|NCT00164788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935653|NCT01316835|||||RETROSPECTIVE|||||||
33935654|NCT00802880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935655|NCT00284167|RANDOMIZED|FACTORIAL||||SINGLE||||||
33935656|NCT01700140||PARALLEL||||DOUBLE||||||
33935657|NCT02240524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935658|NCT03344874|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33935659|NCT02190422|||CASE_CONTROL||PROSPECTIVE|||||||
33935660|NCT00794469|||COHORT||PROSPECTIVE|||||||
33935661|NCT03140488|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"This portion of the study will be carried out by the research pharmacy. Single (low dose) and triple (high dose) concentration of oxytocin will be premixed in the intravenous fluid bag in the pharmacy. Sequence generation for randomization will be created with 1:1 ratio in both the obese and lean group by the Department of Statistics. After the sequence is generated, ths list will be given to the research pharmacy. The premixed oxytocin medication will be sequentially labelled as OPS drug, patient #1, 2, 3 etc. per the allocation. Allocation concealment will also be carried out by pharmacy as these bags will completely appear identical after they are labelled numerically. Once a patient is randomized, the pharmacy will send up the appropriate concentration of oxytocin already premixed in the intravenous fluid bag, labelled as OPS drug, patient #. Lean group will be assigned at # 1-70 and obese group will be assigned at #71-140."|"4 Comparison groups:~1. Control group: Lean cohort: BMI ≤25, at \<20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol~2. Intervention group: Lean cohort: BMI ≤25, at \<20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol~3. Control group: Obese cohort: BMI ≥30, at \<20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol~4. Intervention group: Obese cohort: BMI ≥30, at \<20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol"|t|t|t|t
33935662|NCT04316286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33935663|NCT02411669|||OTHER||CROSS_SECTIONAL|||||||
33935664|NCT01127516|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33935665|NCT00369928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935666|NCT03952689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Observational, single arm test, self-controlled.||||
33792738|NCT05664100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792739|NCT04157530|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33792740|NCT02674451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33792741|NCT05737095|||COHORT||PROSPECTIVE|||||||
33792742|NCT02263508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase 1b was an open-label, single-arm study. Phase 3 was a randomized, double-blind, placebo-controlled study design.|t|f|t|f
33792743|NCT00868192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792744|NCT01113333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792745|NCT05785494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792746|NCT03996746|||CASE_ONLY||PROSPECTIVE|||||||
34013529|NCT05315622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of their group assignment|Single-blinded Randomized Controlled Trial|t|f|f|f
34013530|NCT02516423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792747|NCT05544578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data collection site will be the unit of randomization. The participants will be blinded to group assignment.|This is a phase 1 feasibility study via a cluster randomized controlled trial.|t|f|f|f
33792748|NCT02200159|||COHORT|||||||||
33792749|NCT06444386|||COHORT||PROSPECTIVE|||||||
33792750|NCT05688761|||CASE_CONTROL||PROSPECTIVE|||||||
33792751|NCT04956146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792752|NCT01112618|||COHORT||PROSPECTIVE|||||||
34013531|NCT01817465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013532|NCT01421342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013533|NCT01224028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013534|NCT05678231|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients electing to undergo primary TKA will be recruited into the study and randomized to receive and follow the ZDK protocol post-operatively or standard of care rehabilitation instructions.||||
34013535|NCT02780167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013536|NCT03959215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013537|NCT04766541|||CASE_ONLY||RETROSPECTIVE|||||||
34013538|NCT05154058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013539|NCT06354491|||COHORT||PROSPECTIVE|||||||
34013540|NCT00703508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013541|NCT04832490|||OTHER||RETROSPECTIVE|||||||
34013542|NCT01478282|NON_RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34013543|NCT03347760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013544|NCT05916521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34013545|NCT04614493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013546|NCT01745341|||COHORT||PROSPECTIVE|||||||
34013547|NCT01913236|RANDOMIZED|PARALLEL||||NONE||||||
34013548|NCT01842126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013549|NCT02725775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34013550|NCT05749679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013551|NCT01742559|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34013552|NCT01356784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34013553|NCT00000963||||TREATMENT||||||||
34013554|NCT04636242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013555|NCT01112813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013556|NCT05543330|RANDOMIZED|PARALLEL||TREATMENT||NONE||For Phase 2 study, the patients are enrolled into 2 arm parallelly.||||
34013557|NCT03197558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013558|NCT03415984|||COHORT||PROSPECTIVE|||||||
34013559|NCT03627234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013560|NCT02072824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013561|NCT03896984|||COHORT||RETROSPECTIVE|||||||
34013562|NCT02596321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013563|NCT00944112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013564|NCT05011630|||COHORT||RETROSPECTIVE|||||||
34013565|NCT05897268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013566|NCT00234455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013567|NCT01145131|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34013568|NCT04478461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013569|NCT05512520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013570|NCT05796063|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34013571|NCT02403921|||||PROSPECTIVE|||||||
34013572|NCT01641133|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34013573|NCT00287300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013574|NCT04368611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013575|NCT01795742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013576|NCT00209989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013577|NCT02350374|NA|SINGLE_GROUP||OTHER||NONE||||||
34013578|NCT01701830|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013579|NCT05715554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013580|NCT00192855|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34013581|NCT05676060|||OTHER||OTHER|||||||
34013582|NCT04392284|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Multiple Assignment Randomized Trial (SMART)||||
34013583|NCT01675024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013584|NCT02328950|||COHORT||PROSPECTIVE|||||||
34013585|NCT00097045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013586|NCT04414436|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|study participants will be identified with an anonymous ID|active intervention group vs waiting list group. Waitling list group crossing over to active group after 6 weeks|t|f|f|f
34013587|NCT02159781|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013588|NCT04307121|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34013589|NCT03399318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013590|NCT00156494|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013591|NCT02293291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013592|NCT06525272|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double (Participant,Investigator)|The study comprises two parts: Single Ascending Dose (SAD)，There are six dose groups (2000U, 4000U, 8000U, 12000U, 16000U, 20000U) and Multiple Ascending Dose (MAD),There are three dose groups (Low (TBD),Medium (TBD),High (TBD) ) both employing a multicenter, randomized, double-blind, and placebo-controlled design. Per dose group (6 receiving intrathoracic injection of OsrhCT and 2 receiving intrathoracic injection of placebo).|t|t|t|t
34013593|NCT00925301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor and Assessor were also blinded||t|f|t|f
34013594|NCT05009732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013595|NCT01227655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013596|NCT05852808|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective non-inferiority double-arm randomized controlled single centre trial||||
34013597|NCT04083586|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34013598|NCT03458247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34013599|NCT02199015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013600|NCT03642522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013601|NCT04698772|||COHORT||PROSPECTIVE|||||||
34013602|NCT00621920|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013603|NCT03326674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013604|NCT04444947|||CASE_CONTROL||OTHER|||||||
34013605|NCT00732420|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34013606|NCT01322126|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013607|NCT00300326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013608|NCT02226731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013609|NCT06390202|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013610|NCT03380559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Ratio 1:1:1|t|t|t|t
34013611|NCT01370213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013612|NCT02776514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34013613|NCT00542763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792753|NCT01601223|||COHORT||PROSPECTIVE|||||||
33935667|NCT03416517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935668|NCT05565599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935669|NCT01166386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33935670|NCT01875666|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33935671|NCT01351714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935672|NCT03351491|||OTHER||CROSS_SECTIONAL|||||||
34013614|NCT00586482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935673|NCT04451694|||COHORT||PROSPECTIVE|||||||
33935674|NCT04989595|||COHORT||PROSPECTIVE|||||||
33935675|NCT05776355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935676|NCT03401216|RANDOMIZED|PARALLEL||TREATMENT||NONE||80 patients, that underwent PCI with Synergy 48 mm stent implantation, will be randomized into 2 groups of follow-up OCT-visualization - 3 and 6 month.||||
33935677|NCT05102344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Lab assistants responsible for processing biological samples of interest and the principal statistician are blind to identifying participant information and group assignment.||f|f|f|t
33935678|NCT01271595|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33935679|NCT03053713|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Using a randomized, parallel treatment design, the effects of the Mediterranean diet pattern on symptoms, clinical disease activity, gut microbiome and fecal biomarkers in stable UC patients in remission will be examined. Using this design, we will compare the habitual diet (taken as a control diet) to the Mediterranean diet pattern taken by UC patients over a 12-week period."||||
34013615|NCT00140660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013616|NCT00355472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013617|NCT00390130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013618|NCT03910660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013619|NCT00387920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013620|NCT04808882|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research is a multicenter, parallel group, open-label, randomized controlled superiority trial, aiming at comparing three usual strategies of anticoagulation. The primary hierarchical criterion assessed at Day-28, includes all-cause mortality followed by the time to clinical improvement. The three strategies are LD-PA, HD-PA, and TA, with a 1:1:1 ratio||||
34013621|NCT05110807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013622|NCT01861483|||CASE_ONLY||RETROSPECTIVE|||||||
34013623|NCT03540394|||COHORT||PROSPECTIVE|||||||
34013624|NCT02594371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013625|NCT01956448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013626|NCT02024373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935680|NCT04065295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935681|NCT02789800|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935682|NCT04317898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33935683|NCT01256606|||CASE_CONTROL||PROSPECTIVE|||||||
33935684|NCT01572480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935685|NCT00656994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935686|NCT04844892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935687|NCT01930669|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935688|NCT00732472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935689|NCT04974411|||COHORT||PROSPECTIVE|||||||
33935690|NCT03488706|||COHORT||PROSPECTIVE|||||||
34013627|NCT03545191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935691|NCT06102291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935692|NCT01178190|||COHORT||PROSPECTIVE|||||||
34096532|NCT04692688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked|"This is a placebo-controlled, double-masked, randomized, Phase 2 study in approximately 100 subjects with moderately severe to severe non-proliferative diabetic retinopathy (NPDR), or mild proliferative diabetic retinopathy (PDR), evaluating safety and efficacy following administration of APX3330 twice daily for 24 weeks.~The study will have a 1:1 randomization (placebo: APX3330). Randomization will be stratified by level of disease severity (NPDR or PDR). Subjects with mild PDR will be capped at 20% for each arm."|t|t|t|t
34096533|NCT00626860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096534|NCT03022630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096535|NCT06391515|||COHORT||PROSPECTIVE|||||||
34096536|NCT05233059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 arm randomized controlled trial.||||
33711884|NCT03871712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In the written consent, the three groups will be described. Thus the participants will understand which group they are in after the first telephone call, and consequently not be blinded. The interventions are:~1. Motivational interview by 2 meetings between participant and the NAV case-worker. Both the NAV case-workers and the participants will know that the intervention is motivational interviewing because it is only in this arm a NAV case-worker will do the intervention.~2. Stratified vocational advice intervention (SVAI): a physiotherapist will call the study participants, and both the physiotherapist and the participants will know that they are in the SVAI intervention group from the informed consent.~The researchers will be blinded to group allocation throughout the study recruitment and assessment up to the 6-month follow-up."|"A multi-arm randomised controlled trial with two intervention groups and one control group doing as usual (ordinary NAV practice).~The allocation will be prepared with block randomisation for risk of long term sick leave as predicted by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. Preliminary data suggests a low/medium risk group (80% of the recruited participants) and a high risk group (20%). These numbers were calculated in another study of individuals on sick leave in Norway."|f|f|t|t
33711885|NCT04829903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711886|NCT03679936|||CASE_CONTROL||PROSPECTIVE|||||||
33711887|NCT05846945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33711888|NCT01506128|||CASE_ONLY||PROSPECTIVE|||||||
33711889|NCT02122562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711890|NCT00313378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711891|NCT02490228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711892|NCT02683161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711893|NCT05112744|||COHORT||PROSPECTIVE|||||||
33711894|NCT01221571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711895|NCT02638545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711896|NCT04286321|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33711897|NCT04897308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33711898|NCT01576263|||COHORT||RETROSPECTIVE|||||||
33711899|NCT01728831|||COHORT||PROSPECTIVE|||||||
33711900|NCT00822991|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33711901|NCT05420077|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33711902|NCT03903705|NA|SEQUENTIAL||TREATMENT||NONE||Open-Label Phase 1b/II Study of Fruquintinib in Combination with Sintilimab to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumor.||||
33711903|NCT03944460|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, multi-cohort trial.|t|f|t|f
33711904|NCT03393624|||CASE_CONTROL||PROSPECTIVE|||||||
33711905|NCT00187486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711906|NCT00471068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33711907|NCT03013478|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33711908|NCT00554073|||||PROSPECTIVE|||||||
33711909|NCT04812964|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935693|NCT00471276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33711910|NCT05623098|||COHORT||PROSPECTIVE|||||||
33711911|NCT00664872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711912|NCT02466178|||COHORT||PROSPECTIVE|||||||
33935694|NCT01697189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935695|NCT01897259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935696|NCT03542292|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33935697|NCT00128362|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935698|NCT06277609|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33935699|NCT01030991|||COHORT||PROSPECTIVE|||||||
33935700|NCT04027140|||COHORT||PROSPECTIVE|||||||
33935701|NCT03185325|||OTHER||CROSS_SECTIONAL|||||||
33935702|NCT04222257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935703|NCT02094612|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935704|NCT04519476|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study examining selinexor's ability to overcome resistance in multiple myeloma patients who are refractory to lenalidomide-containing therapy.||||
33935705|NCT04841681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study utilized the quasi-experimental design with a pre-test-post-test and without a control group.||||
33935706|NCT01814449|||CASE_CONTROL||PROSPECTIVE|||||||
33935707|NCT03808844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935708|NCT02596425|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33935709|NCT01855139|||COHORT||PROSPECTIVE|||||||
33935710|NCT03237390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935711|NCT03517735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935712|NCT04883099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935713|NCT01370772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935714|NCT05956028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935715|NCT03128255|||CASE_CONTROL||PROSPECTIVE|||||||
33935716|NCT00004580||||TREATMENT||||||||
33935717|NCT01315340|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935718|NCT01808365|||CASE_ONLY||CROSS_SECTIONAL|||||||
33935719|NCT02136329|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33935720|NCT00002590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711913|NCT04738396|||CASE_ONLY||PROSPECTIVE|||||||
33711914|NCT01991210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711915|NCT01828281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711916|NCT03812094|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trail||||
33711917|NCT06024356|||CASE_CONTROL||RETROSPECTIVE|||||||
33711918|NCT02835820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711919|NCT05579821|||COHORT||RETROSPECTIVE|||||||
33711920|NCT01676766|||CASE_ONLY||PROSPECTIVE|||||||
33711921|NCT05945524|NA|SINGLE_GROUP||OTHER||NONE||||||
33711922|NCT02312661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711923|NCT00540826|||COHORT||PROSPECTIVE|||||||
33711924|NCT03032146|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.||||
33711925|NCT05099874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711926|NCT01655472|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33711927|NCT03075540|NA|SINGLE_GROUP||SCREENING||NONE||Single arm trial||||
33711928|NCT05494333|||COHORT||CROSS_SECTIONAL|||||||
33711929|NCT04144205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792754|NCT04128839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Placebo (PLA) was flavor, color, and carbohydrate matched to intervention treatment of Aronia juice. PLA consisted of 28.8 g black cherry Koolaid mix (no sugar added), 128.5 g sorbitol, 74.5 g glucose, 77.9 g fructose, 4 oz lemon juice, 16 drops of blue food coloring, and enough water to create 1 L of solution. Participants consumed 100 mL/ day.||t|f|f|f
34096537|NCT05082155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The randomization list will be created by the University of California San Diego Investigational Drug Service. Investigational pharmacists will prepare all study solutions as determined by the randomization list. Bupivacaine and normal saline are indistinguishable in appearance, and therefore investigators, participants, and all clinical staff will be masked to treatment group assignment for the duration of the enrollment and data collection period. Unmasking will not occur until statistical analysis is complete (termed triple masking)."|This is a split-body study in which each study subject receives both treatments: one on each side of the body. Which treatment is applied to which side of the body is randomized (and masked).|t|t|t|t
33792755|NCT03698708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013628|NCT00594620|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34013629|NCT04289506|||COHORT||PROSPECTIVE|||||||
33711930|NCT01177592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013630|NCT01725919|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33711931|NCT01942330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711932|NCT01822431|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33711933|NCT04450225|||OTHER||PROSPECTIVE|||||||
33711934|NCT01513473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711935|NCT02299700|||COHORT||PROSPECTIVE|||||||
33711936|NCT00232024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33711937|NCT02074111|||CASE_CONTROL||OTHER|||||||
34096538|NCT00055965|RANDOMIZED|||TREATMENT||||||||
34096539|NCT05328895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096540|NCT04784403|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34096541|NCT05970211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711938|NCT06115213|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33711939|NCT06104670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study staff responsible for distributing SynaquellTM will not be blinded to the intervention, but all subjects and other study staff will be blinded.||t|f|t|f
33711940|NCT05130398|RANDOMIZED|PARALLEL||PREVENTION||NONE|"The vaccine doses of ≥7.8 x 107 pfu will be evaluated and compared to vaccination with varicella vaccine as a control. In addition, the closest contact persons of the vaccinees will be monitored for possible transmission of the viral vaccine vector.~The study will enroll children of two age groups living in Lambaréné, Gabon. Children will be followed-up for 12 months post vaccination.~The 1-2 closest contact persons of each participant will be involved in the monitoring of rVSV transmission."|A Phase 1/2, randomized, controlled, open label clinical trial.||||
33711941|NCT01262053|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
33792756|NCT02032719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792757|NCT00978406|||OTHER||CROSS_SECTIONAL|||||||
33792758|NCT00726999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013631|NCT00734201|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34013632|NCT04471402|||COHORT||PROSPECTIVE|||||||
34013633|NCT05517161|||CASE_ONLY||PROSPECTIVE|||||||
34013634|NCT01955655|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33711942|NCT05276401|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blind|Randomized|t|t|t|t
33711943|NCT03673332|NA|SINGLE_GROUP||TREATMENT||NONE||This is a national prospective phase 4, multi-centre, single arm, open-label cohort study to evaluate the safety and efficacy of immune checkpoint inhibitors-based therapies in elderly patients with advanced or metastatic melanoma or NSCLC.||||
33711944|NCT01864811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711945|NCT02253251|||COHORT||PROSPECTIVE|||||||
33711946|NCT04212650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Block Randomization|t|t|t|t
33711947|NCT04249583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711948|NCT03984097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013635|NCT00912093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711949|NCT03241251|||COHORT||PROSPECTIVE|||||||
33711950|NCT02654522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33792759|NCT00292383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792760|NCT02841553|||COHORT||CROSS_SECTIONAL|||||||
33792761|NCT04635358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013636|NCT04320979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013637|NCT05158218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Cerebral Palsy participants will undergo baseline mobility/brain imaging/cognitive testing, receive traditional gait therapy, and then repeat mobility/brain imaging testing.~Cerebral Palsy participants will undergo baseline mobility/brain imaging/cognitive testing, receive gait therapy utilizing robotic exoskeleton, and then repeat mobility/brain imaging testing."|f|f|f|t
33711951|NCT02516345|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33711952|NCT01293357|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
33711953|NCT05000060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded assessment and adjudication of endpoints|Prospective Randomized Open Label Blinded Endpoint pilot trial of 100 patients|f|f|f|t
33711954|NCT00328757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33711955|NCT02015871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711956|NCT06005779|||COHORT||OTHER|||||||
33792762|NCT01065636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33711957|NCT02204800|||OTHER||PROSPECTIVE|||||||
33711958|NCT04806724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33711959|NCT05995743|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33711960|NCT02784808|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33711961|NCT03247530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711962|NCT06294860|||COHORT||PROSPECTIVE|||||||
33711963|NCT03323931|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Principal investigator, the research team, and data analyst are all blind to the treatment conditions.|Random allocation to one of two intervention conditions: (1) standard therapy, derived from applied behavior analysis (ABA) and (2) a robot-enhanced intervention in which the same intervention is delivered by a semi-autonomous robotic mediator agent (the robot acts as a mediator while the therapist is supervising the session).|f|f|t|f
33711964|NCT00935597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711965|NCT03752632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711966|NCT04834076|||CASE_CONTROL||RETROSPECTIVE|||||||
33711967|NCT00456001|||COHORT||RETROSPECTIVE|||||||
33711968|NCT00000688||||TREATMENT||||||||
33711969|NCT03762421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Fidelity of masking will be ensured by having assessors guess the condition of each participant at the end of each assessment to assess the contamination across intervention and control arm.||f|f|t|f
33711970|NCT03535844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33792763|NCT05674006|||COHORT||RETROSPECTIVE|||||||
33792764|NCT03499236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In the randomized cohort, participants, the clinical team, and research staff managing the patient after randomization will be blinded to study assignment.|Randomized treatment versus control (1:1). Control patients will be allowed to cross-over at the completion of the blinded phase. A parallel roll-in arm will enroll up to 2 patients per site in an open-label study.|t|t|t|t
33792765|NCT00843193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792766|NCT05862454|||COHORT||PROSPECTIVE|||||||
33792767|NCT05132686|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be provided with healthful dietary information but will not be told what diets their diet plans are based on. Participants in the IER+MED diet group will be told they are on diet plan 1 and participants in the MED/DER diet group will be told they are on diet plan A. The dietitians will know which diet plan each participant is on, however; all other clinic staff who assess outcome measures will be blinded to each participant's diet group.|Randomized controlled trail. Participants will be randomized to either intermittent energy restriction (IER) and Mediterranean diet (MED) / IER+MED or the daily energy restriction (DER) and the Mediterranean diet / (MED/DER).|t|f|t|t
33792768|NCT01137799|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33792769|NCT04126239|||CASE_CONTROL||PROSPECTIVE|||||||
33792770|NCT00649935|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33792771|NCT02881944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792772|NCT05837390|||COHORT||PROSPECTIVE|||||||
33792773|NCT04328649|||COHORT||PROSPECTIVE|||||||
33792774|NCT04955119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792775|NCT03884855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792776|NCT03305003|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33711971|NCT00331682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792777|NCT03969472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792778|NCT01180153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792779|NCT05426863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33711972|NCT01259908|||COHORT||PROSPECTIVE|||||||
33792780|NCT03284411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792781|NCT00920244|||COHORT||PROSPECTIVE|||||||
33711973|NCT02385513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33711974|NCT02498184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33711975|NCT02926365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711976|NCT05021991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711977|NCT03916120|||CASE_CONTROL||PROSPECTIVE|||||||
33711978|NCT06217055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792782|NCT02771171|||COHORT||RETROSPECTIVE|||||||
33792783|NCT05928819|||COHORT||PROSPECTIVE|||||||
33792784|NCT06498895|||COHORT||PROSPECTIVE|||||||
33792785|NCT03824080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935721|NCT03248817|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33935722|NCT05098808|||CASE_CONTROL||PROSPECTIVE|||||||
33711979|NCT02591589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33711980|NCT00313391|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33711981|NCT05399056|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes will be collected by a member of the research staff blinded to participant treatment arm||f|f|f|t
33711982|NCT05227027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33935723|NCT00654576|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33711983|NCT02980601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33711984|NCT02927522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33711985|NCT05412511|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33711986|NCT03890172|||OTHER||PROSPECTIVE|||||||
33711987|NCT06508632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Outcomes Assessor)|Experimental, randomised controlled, single-blind study|t|f|f|t
33711988|NCT01679860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935724|NCT00355615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33711989|NCT02852538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711990|NCT05339737|||COHORT||PROSPECTIVE|||||||
33711991|NCT03296241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are unaware of the assignment. Both groups were treated according to the IncontiLaseTM clinical treatment protocol for SUI with non-ablative thermal-only Er:YAG laser, except that there was no energy output when treating the sham group.|Patients assigned randomly to two groups: laser-treatment group and sham (control) group|t|f|f|t
34103318|NCT05825742|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants, care providers, and investigators shall be masked before the first measurements. The randomization will be conducted after the first measurements.|Participants in two groups (Study group and Control group) shall receive instructions for standard oral hygiene. The same assessments are done for participants in both groups, and within the same time periods. The Study group will also be using the Lumoral Treatment device.||||
33711992|NCT04937491|||COHORT||PROSPECTIVE|||||||
33711993|NCT01778218|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33711994|NCT05665478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33711995|NCT01139073|||CASE_ONLY||CROSS_SECTIONAL|||||||
33711996|NCT06281600|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Every individual involved in undertaking this trial will be blinded.|This is a 16-week, randomised, placebo-controlled, double-blinded crossover trial. We aim to recruit 44 participants with IBS. These participants will be screened and classified into a particular IBS subtype. After a 14-day baseline period, participants will be randomised to orally consume either 5g of HMO for 28 days, or a placebo for 28 days. This will be administered at the University of Reading. All participants will then stop taking the product for 28 days (wash out period) and then swap treatment type and have 28 days of either placebo or HMO. This is then followed by another 14 days without any product. During the study, participants will be asked to complete a 24-hour food recall weeks 0 and 16. Additionally, participants will complete validated questionnaires (IBS-Symptom Severity Score, anxiety and depression score and Pittsburgh Sleep Quality Index (PSQI) every time they provide urine and faecal samples at each visit.|t|t|t|t
33711997|NCT01890356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103319|NCT00223379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33711998|NCT04810312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33711999|NCT04834284|||CASE_CONTROL||PROSPECTIVE|||||||
33712000|NCT04381403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33792786|NCT01183871|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34103320|NCT06691724|||OTHER||PROSPECTIVE|||||||
33712001|NCT02396485|RANDOMIZED|PARALLEL||||NONE||||||
33712002|NCT05077722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33712003|NCT04147208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712004|NCT05765604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33712005|NCT00888368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712006|NCT02619955|||COHORT||PROSPECTIVE|||||||
33712007|NCT00696722|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712008|NCT00820690|||COHORT||PROSPECTIVE|||||||
33712009|NCT05459675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three groups of patients will be recruited at obesity clinic, Ramathibodi Hospital Mahidol University, Bangkok, Thailand. One group will take part in the very low-calorie diet (VLCD). One group will be undergone bariatric surgery (LRYGB or LSG)||||
33712010|NCT05240053|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators included all patients who were subjected to laparoscopic colorectal surgery at our center between ( December 2019 to December 2021) for benign \& malignant conditions. sample size was 50 patients , divided into 2 equal groups . Group 1: included 25 patients who were subjected to enhance recovery program after laparoscopic colorectal surgery . Group 2: included 25 patients who were subjected to traditional way - nothing by mouth until the resolution of ileus, then a fluid diet, followed by a regular diet after laparoscopic colorectal surgery.||||
33712011|NCT00109798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712012|NCT02374801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712013|NCT00462267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792787|NCT01941277|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792788|NCT03662048|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|2 month photographs will be evaluated by study team members blinded to the study group.||f|t|f|f
33792789|NCT01989910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013638|NCT00059787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013639|NCT02941120|||CASE_ONLY||RETROSPECTIVE|||||||
34013640|NCT03351387|||COHORT||PROSPECTIVE|||||||
34013641|NCT00949455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013642|NCT01704430|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Glutamine|t|t|t|t
34013643|NCT03737318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All perceptual ratings will be obtained from blinded, naive listeners recruited through online crowdsourcing. Following protocols refined in previous published research, binary rating responses will be aggregated over at least 9 unique listeners per token.|All participants will complete a Dynamic Assessment session (Phase 0) consisting of 2 hours of traditional (non-biofeedback) instruction. Participants will be categorized into high, moderate, and low response groups based on performance in Phase 0, and the response groups will be block randomized to traditional or biofeedback speech treatment. Within the biofeedback condition, individuals will be sub-randomized in equal numbers to receive visual-acoustic or ultrasound treatment. Participants will then complete two phases of speech treatment in their randomly assigned condition. Phase 1 (Acquisition) will consist of high-intensity, highly interactive practice delivered in three 90-minute sessions over one week. Phase 2 (Generalization) will elicit structured practice of /r/ in 16 semiweekly 45-minute sessions over 8 weeks.|f|f|f|t
34013644|NCT03396237|||CASE_CONTROL||PROSPECTIVE|||||||
34013645|NCT05768126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013646|NCT06276088|||COHORT||PROSPECTIVE|||||||
34013647|NCT00976794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013648|NCT04731311|NA|SINGLE_GROUP||OTHER||NONE|No Masking|All participants will perform same protocol consisting of 4 evaluation sessions of the BrightGo device||||
34013649|NCT03656874|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34013650|NCT05266079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013651|NCT06437665|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Masking, also known as blinding, refers to the practice of concealing information about the intervention assignment from certain parties involved in a study to reduce bias. In the described study, the masking applies to the Outcomes Assessor, who is an independent blinded occupational therapist responsible for evaluating the driving performance of participants. This means that the Outcomes Assessor will not be aware of which group (ADAS-integrated driver simulation training or driving-simulator training alone) each participant belongs to during the assessment process, helping to ensure an unbiased evaluation of the study outcomes.|The parallel model involves comparing two distinct groups, in this case, older drivers (≥65 years of age), who are randomly assigned to either receive ADAS-integrated driver simulation training or driving-simulator training alone. This model allows for a direct comparison between the two groups regarding the effectiveness of the targeted ADAS intervention on driving performance.||||
34013652|NCT04107155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34096542|NCT03186924|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will perform a 4-month parallel-group randomised controlled trial, in which rheumatoid arthritis patients will be assessed at baseline (PRE) and after 4 months (POST). Moreover, a sub-sample (n=18) of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 8-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.||||
34013653|NCT02407171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013654|NCT04208126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This trial is a prospective randomized multicenter trial that assigns patients to either a treatment for ARDS with an ECMO immediately after admission to the intensive care unit or conservative treatment.|f|f|t|f
34013655|NCT04223999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Skullremodeling surgery prevents the participant, careprovider and investigator to be blinded to the randomization.~The outcome assessors (statisticians) will be blinded when analysing the data."|Patients will be randomized 1:1 to one of two study arms to receive either, 1) skullremodeling-surgery, TTFields and best practice medical oncological therapy (interventional arm), or 2) TTFields and best practice medical oncological therapy alone (control arm).|f|f|f|t
34013656|NCT04772391|NA|SINGLE_GROUP||OTHER||NONE||||||
34013657|NCT05673213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013658|NCT03282968|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34013659|NCT06322394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013660|NCT03255512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013661|NCT02485002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096543|NCT01052142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096544|NCT06484465|||OTHER||CROSS_SECTIONAL|||||||
34096545|NCT02981693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096546|NCT05301699|||COHORT||PROSPECTIVE|||||||
34096547|NCT03803579|||COHORT||PROSPECTIVE|||||||
34096548|NCT04578977|||CASE_ONLY||PROSPECTIVE|||||||
34096549|NCT02834897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096550|NCT04573283|||COHORT||PROSPECTIVE|||||||
34096551|NCT00047268||||DIAGNOSTIC||NONE||||||
34096552|NCT04641039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be informed if the anterior annulus is removed or replaced|Two groups. In one the anterior annulus will be removed to insert a lumbar disc prosthesis and in the other this section of the anterior annulus will be opened up in two flaps hinged lateraly and replaced once the complete lumbar disc prosthesis is implanted|t|f|f|f
34096553|NCT03251105|RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants, who were scheduled to undergo lower abdominal surgery and to receive anaesthesia||||
33712014|NCT04650360|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33712015|NCT05260788|||COHORT||PROSPECTIVE|||||||
33712016|NCT02161367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096554|NCT02942407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096555|NCT04783727|RANDOMIZED|PARALLEL||TREATMENT||NONE|During the treatment, both Participant and Care Provider will be masked but once the treatment end is achieved, they will be unmasked, and study participation is continued.|||||
33712017|NCT05502185|||OTHER||PROSPECTIVE|||||||
34096556|NCT00326040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096557|NCT06438952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096558|NCT01619449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096559|NCT04267328|||COHORT||PROSPECTIVE|||||||
33712018|NCT01818921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712019|NCT03186560|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Geko device will be provided||||
33712020|NCT02292602|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33712021|NCT04249674|||COHORT||PROSPECTIVE|||||||
33712022|NCT04360915|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712023|NCT04119882|||COHORT||PROSPECTIVE|||||||
33712024|NCT06372223|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712025|NCT04047394|NA|SEQUENTIAL||TREATMENT||NONE||||||
33712026|NCT01709162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712027|NCT03937310|||COHORT||PROSPECTIVE|||||||
34013662|NCT00488670|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712028|NCT00119626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712029|NCT06123845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Sealed opaque envelopes randomization|t|f|f|f
33712030|NCT05641753|NA|SINGLE_GROUP||OTHER||NONE||||||
33712031|NCT03982368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double masked|Parallel groups|t|t|t|t
33712032|NCT01575769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712033|NCT02379039|||CASE_ONLY||PROSPECTIVE|||||||
33712034|NCT03464305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712035|NCT03010514|||COHORT||RETROSPECTIVE|||||||
33792790|NCT00299741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013663|NCT03394313|||COHORT||PROSPECTIVE|||||||
34013664|NCT05260164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013665|NCT01795105|||CASE_ONLY||PROSPECTIVE|||||||
34013666|NCT02165618|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34013667|NCT03257150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013668|NCT00653484|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013669|NCT03487848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013670|NCT06273202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013671|NCT05361291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013672|NCT05628779|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomized controlled trial with open-label extension|A total of 150 patients will be randomly assigned with a 2:1 allocation to either interventional (n=100) or control group (n=50).||||
34013673|NCT05887349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trials|f|f|t|f
34013674|NCT04075019|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||"This study examined four separate groups, a full intervention group exposed to the interventions in grades 1 through 6, a late intervention group exposed to the interventions only in grades 5 and 6, a minimal parent-training only group (grades 5 and 6), and a control group that received no special intervention."||||
34013675|NCT05714566|||COHORT||PROSPECTIVE|||||||
34013676|NCT05811702|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34013677|NCT00287859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013678|NCT04487743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013679|NCT00110695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013680|NCT01882920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013681|NCT03438227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research team will be blinded to the patients' treatment arm. A team of resident physicians who are unfamiliar with the study aims will provide standard obstetric care to all participants.|All participants at less than 28 weeks gestation will have an anemia evaluation and work up per standard prenatal care. Those who meet a clinical diagnosis of iron-deficiency anemia will initiate oral iron and have their Complete Blood Count rechecked between 24 and 28 weeks gestation. If their hemoglobin is less than 10 mg/dL, they will be randomized to either continue their oral iron supplementation or receive a single intravenous dextran iron transfusion. If the patient is enrolled after 28 weeks and receives a diagnosis of iron deficiency anemia, she will be randomized at that time.|f|f|t|t
34013682|NCT01701037|NA|SINGLE_GROUP||OTHER||NONE||||||
34013683|NCT02464826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720664|NCT03582020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group design (4 groups), non-randomized Run in (14 d): Food frequency protocol (FFP, 7 d), questionnaires for lifestyle/nutrition/socio-economic status Screening: Fasting blood sample taking, health check Intervention: Four groups differing in their eating habits (pre-condition: stable since at least one year) Intervention - group A: Menu plans for persons who consume a traditional Western diet Intervention - group B: Menu plans for persons who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians Intervention - group C: Menu plans for vegetarians Intervention - group D: Menu plans for vegans||||
34013684|NCT01901874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013685|NCT00859001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013686|NCT06157606|||COHORT||OTHER|||||||
34013687|NCT05790954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34013688|NCT00197522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013689|NCT04155359|||COHORT||PROSPECTIVE|||||||
34013690|NCT00592202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013691|NCT02495181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013692|NCT03505814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34013693|NCT04734119|||CASE_CONTROL||PROSPECTIVE|||||||
34096560|NCT01776203|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096561|NCT03096990|||COHORT||PROSPECTIVE|||||||
33720665|NCT04830787|||CASE_CONTROL||RETROSPECTIVE|||||||
33720666|NCT06064474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720667|NCT02621411|||COHORT||PROSPECTIVE|||||||
34013694|NCT01835704|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34013695|NCT02409394|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34013696|NCT05407727|||COHORT||PROSPECTIVE|||||||
34013697|NCT01559987|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
34013698|NCT02048839|||COHORT||PROSPECTIVE|||||||
34013699|NCT04336839|||COHORT||RETROSPECTIVE|||||||
34013700|NCT05748327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-Mouth Design|t|f|f|t
34013701|NCT04854564|||OTHER||PROSPECTIVE|||||||
34013702|NCT01252875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013703|NCT06489938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34013704|NCT01194973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096562|NCT02040064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096563|NCT06535737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096564|NCT00565760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096565|NCT00924651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34096566|NCT02102737|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096567|NCT05690191|||CASE_ONLY||PROSPECTIVE|||||||
34096568|NCT00899847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096569|NCT02205138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096570|NCT01415115|||COHORT||PROSPECTIVE|||||||
34096571|NCT04419350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"* The area to be treated will be specified and split into two halves then randomized using sealed envelope into one of both arms: treatment or no treatment.~* One session of microneedling using derma roller 1.5 mm will be done."|f|f|t|t
34096572|NCT06235957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded evaluation of the trial patients functional status, radiographs and range of motion will be performed by a research assistant by use of the PRWE and qDASH scores|This study will be conducted as a single-blinded multicentre randomised clinical trial in three hospitals. In this study, three weeks of cast immobilisation is compared to one week of brace immobilisation.|f|f|f|t
34096573|NCT05880030|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Both groups took drops from the same dark bottles, 20 drops per day for two weeks.||f|f|f|t
34096574|NCT01718262|||COHORT||PROSPECTIVE|||||||
34096575|NCT03994120|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33712036|NCT04410211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Patients are randomized to either the Sevoflurane sedation arm or the Midazolam sedation arm based on a randomizer application and the selections are placed in a non-transparent envelope. Once a patient fulfills the eligibility to be recruited in the study, one envelope will be taken to see which arm will the patient be recruited into. Neither the patient nor the investigator will know.~Two investigators will be selected to participate in this study, whereby one of the investigators who will be providing the care will not be masked. The other investigator who assess the pre and post procedure outcome will be masked from knowing which method is used."|Patients are randomized to either the Sevoflurane sedation arm or the Midazolam sedation arm based on a randomizer application and the selections are placed in a non-transparent envelope. Once a patient fulfills the eligibility to be recruited in the study, one envelope will be taken to see which arm will the patient be recruited into. Neither the patient nor the investigator will know.|t|f|t|t
33712037|NCT04579185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013705|NCT04463498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All eligible participants will be informed that there may be a waitlist (length not specified) and receive a start-date without being informed that thay are in a waitlist group or not a waitlist group.|Randomized controlled trial|t|f|f|f
34096576|NCT04394221|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013706|NCT01820351||||BASIC_SCIENCE||||||||
34096577|NCT03942055|||COHORT||PROSPECTIVE|||||||
34096578|NCT01850940|||COHORT||PROSPECTIVE|||||||
34096579|NCT05253235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessment staff will be blind to families' experimental assignment at pretest.|Participants are randomly assigned to a preventive intervention or a no treatment control|f|f|f|t
34096580|NCT00948935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096581|NCT04147741|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||One week training (3 days Resistance Training and 2 Endurance Training in alternate days) with a Pre-Workout Supplement or Maltodextrin. 2 Weeks wash out period and then change supplement.|t|t|t|t
34096582|NCT02027493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096583|NCT00393380|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34096584|NCT02823561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096585|NCT05428917|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||60 healthy subjects (30 left handed and 30 right handed) will be recruited and will carry out the acquisition.||||
34096586|NCT03093168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096587|NCT00760071|||CASE_CROSSOVER||PROSPECTIVE|||||||
34096588|NCT01178411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096589|NCT00083447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096590|NCT04601909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive FX-322 or placebo randomized 4:1.|t|t|t|t
34096591|NCT02739646|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34096592|NCT00564070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096593|NCT03180502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096594|NCT04000711|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter, noninferiority randomized clinical trial was conducted in three public hospitals in Mexico City. A complete medical history, physical examination and review of laboratory tests and cultures were performed on all subjects with FN events who were considered low risk. All subjects began receiving intravenous inpatient treatment with cefepime. Subjects were followed-up daily, and those who met the inclusion/exclusion criteria after 48 to 72 hours of in-hospital intravenous treatment were randomly assigned to receive outpatient treatment with oral cefixime or to continue in-hospital intravenous treatment. The treatment was administered by the researchers.||||
34096595|NCT04342585|RANDOMIZED|PARALLEL||PREVENTION||NONE||All women with twin pregnancies will be screened for suitability via measurement of the cervical length at 20 to 24 weeks gestation. Those with a cervical length of 30mm or less will be recruited into the study.||||
34096596|NCT03099083|||COHORT||PROSPECTIVE|||||||
34096597|NCT01991535|NA|||OTHER||SINGLE|||t|f|f|f
34096598|NCT01477047|||COHORT||PROSPECTIVE|||||||
34096599|NCT01184118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096600|NCT06417411|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096601|NCT02875600|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096602|NCT01359384|||CASE_CONTROL||PROSPECTIVE|||||||
33712038|NCT04711447|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33712039|NCT03041597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33712040|NCT00016016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712041|NCT00597181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712042|NCT01421108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33712043|NCT06313814|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720668|NCT01974583|||CASE_CONTROL||PROSPECTIVE|||||||
34013707|NCT00908921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013708|NCT00280072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013709|NCT03144817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103321|NCT06690008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are assigned to two groups in parallel for the duration of the study|t|f|t|f
34013710|NCT01534637|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103322|NCT02534155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013711|NCT02100319|||COHORT||PROSPECTIVE|||||||
34013712|NCT00446199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013713|NCT02489604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013714|NCT04131231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013715|NCT00765141|||COHORT||PROSPECTIVE|||||||
34013716|NCT00750022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013717|NCT00289003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013718|NCT02573935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013719|NCT00000674||||TREATMENT||NONE||||||
34013720|NCT04918303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013721|NCT04695756|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34013722|NCT05897918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935725|NCT01675141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013723|NCT02441582|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34013724|NCT02055443|||CASE_ONLY||PROSPECTIVE|||||||
34013725|NCT03227224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013726|NCT06052488|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34013727|NCT02396784|||COHORT||PROSPECTIVE|||||||
34013728|NCT05802108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013729|NCT00906113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013730|NCT03064438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013731|NCT02087124|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34013732|NCT05396664|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013733|NCT00005586|RANDOMIZED|||TREATMENT||NONE||||||
34013734|NCT03338179|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|no masking|||||
34013735|NCT04076488|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34013736|NCT02307643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013737|NCT01475253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013738|NCT04773717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013739|NCT05160467|||COHORT||PROSPECTIVE|||||||
34013740|NCT01912638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013741|NCT04130659|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither the patients nor the Investigator will be blinded to the treatment to which the patients will be allocated.|Randomized, open-label, comparative, multicenter trial with two parallel groups of patients. At the end of the 28-day (± 1) 1st study period, patients will be included in an open-label, non-comparative follow-up (2nd study period) and treated with MARIAL® for additional 5 months from baseline.||||
34013742|NCT00002199||PARALLEL||TREATMENT||||||||
34013743|NCT06122233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, blinding will not be possible for participants and care providers (i.e. healthcare professionals making phone calls to participants). Where practicable, members of the investigative team will be blinded. Outcome assessors will also be blinded.||f|f|f|t
34013744|NCT01047020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096603|NCT04730375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope|The study include 2 equal groups, each group is 35 patients: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery and Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.|t|t|f|f
34096604|NCT01984060|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34096605|NCT01536327|||COHORT||PROSPECTIVE|||||||
34096606|NCT02974231|||CASE_ONLY||RETROSPECTIVE|||||||
34096607|NCT02407977|||CASE_ONLY||PROSPECTIVE|||||||
34096608|NCT02227966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096609|NCT02573467|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792791|NCT02794350|||COHORT||PROSPECTIVE|||||||
33792792|NCT00748410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792793|NCT04911842|||CASE_CONTROL||RETROSPECTIVE|||||||
33792794|NCT05763290|||OTHER||PROSPECTIVE|||||||
33792795|NCT04047784|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a single center, pilot study to evaluate critically ill patients diagnosed with acute pulmonary embolism using endobronchial ultrasound (EBUS). The investigators anticipate to enroll 60 subjects at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica. The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.||||
33792796|NCT02457507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33935726|NCT00676728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935727|NCT03727386|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be a pilot study with an internal feasibility study that aims at evaluating the acceptance and adherence of participants to the intervention. Participants will be randomized into an intervention (coconut oil) and control group (sunflower oil) using an online randomisation software; Sealed envelope.||||
34096610|NCT06100835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096611|NCT03478787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096612|NCT05248243|||COHORT||PROSPECTIVE|||||||
34096613|NCT02229292|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935728|NCT01620801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935729|NCT05307965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the interventional nature of the trial, masking is not feasible for operators, the clinical care team and participants. However, analysis of the OCT-derived primary and secondary end-points will be conducted offline in a blinded fashion.|The study will consist of 3 arms. Eligible participants will be 1:1:1 randomised to receive either standalone percutaneous coronary intervention (PCI) (Arm 1), thrombus aspiration + PCI (Arm 2) or retriever thrombectomy + PCI (Arm 3).|f|f|f|t
33935730|NCT04218513|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|Three-cycle crossover study||||
33935731|NCT03476824|||COHORT||RETROSPECTIVE|||||||
33935732|NCT04994275|||COHORT||PROSPECTIVE|||||||
33935733|NCT02315833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013745|NCT05130138|NA|SINGLE_GROUP||OTHER||NONE||||||
34013746|NCT05343052|||COHORT||PROSPECTIVE|||||||
34013747|NCT04818749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trial medication will be prepared by unmasked personnel who are not otherwise involved in the trial. The participant, personnel, caregivers, investigators, outcome assessors, and data analysts will be masked to treatment allocation.|Randomised, blinded, placebo-controlled, parallel clinical trial|t|t|t|t
34013748|NCT02680418|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34013749|NCT02170948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013750|NCT00227331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013751|NCT04150198|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Nombre de participants 45 sujets répartis dans 3 groupes:~1. Groupe MA-J (Maladie d'Alzheimer précoce)= 15 patients avec un diagnostic de MA-J~2. Groupe ACP (Atrophie Corticale Posterieure)= 15 patients avec un diagnostic d'ACP~3. Groupe sujets contrôles= 15 sujets contrôles"||||
34013752|NCT01843348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935734|NCT04683952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013753|NCT04413136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013754|NCT02009748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013755|NCT03144102|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34013756|NCT06382311|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner in Phase 1 and Phase 2.||t|t|t|t
34096614|NCT03946410|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomised||||
34096615|NCT05753475|||COHORT||PROSPECTIVE|||||||
34096616|NCT00215553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935735|NCT04631016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigational product only will be prepared and administrated by unmasked personnel.|Participants will be randomised to recieve either MEDI3506 or placebo.|t|t|t|t
34096617|NCT00640432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096618|NCT05220995|||OTHER||PROSPECTIVE|||||||
34096619|NCT05467137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096620|NCT06236997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802031|NCT03403478|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|To acute session, the participant will not be informed about what aquatic exercise session (light-, moderate-, high-intensity or control) intensity will be performed.||t|f|f|f
33802032|NCT02711436|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802033|NCT02128711|||COHORT||PROSPECTIVE|||||||
33935736|NCT05724147|NA|SINGLE_GROUP||OTHER||NONE||in a single group pretest-posttest research design||||
33935737|NCT04693312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935738|NCT05027776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935739|NCT01238705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013757|NCT00106938|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935740|NCT00706264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935741|NCT02407665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935742|NCT00166621|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33935743|NCT02443233|||COHORT||PROSPECTIVE|||||||
34013758|NCT02213952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013759|NCT03655236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013760|NCT05790421|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34013761|NCT00836329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013762|NCT02234206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013763|NCT01757574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013764|NCT00000824||||TREATMENT||||||||
34013765|NCT01264159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935744|NCT05091918|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935745|NCT04835051|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935746|NCT06146140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935747|NCT01935570|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33935748|NCT01204632|||COHORT||PROSPECTIVE|||||||
34013766|NCT04544020|||CASE_ONLY||PROSPECTIVE|||||||
34013767|NCT05609916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013768|NCT01364324|||CASE_CONTROL||PROSPECTIVE|||||||
34013769|NCT03184220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind researcher|RANDOMIZED CLINICAL TRIAL WITH BLIND EVALUATION BY THIRD PARTIES, LONGITUDINAL AND PROSPECTIVE.|f|f|t|f
34013770|NCT05302570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013771|NCT00056745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013772|NCT04400760|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be of a prospective, open-label trial design over a 2-year period. Patients at the Eric Williams Medical Sciences Complex (EWMSC), Mt. Hope, Trinidad and Tobago will be screened for potential eligibility.||||
34013773|NCT00784524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013774|NCT04356118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013775|NCT01685593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34013776|NCT05797584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096621|NCT03855371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096622|NCT05257213|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be under general anaesthesia during surgical procedure when the allocated treatment will be administered.|Comparison between two active intrauterine treatments administered immediately post surgery|t|f|f|f
34096623|NCT00511290|||||RETROSPECTIVE|||||||
34096624|NCT02919605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096625|NCT05067244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712044|NCT06348602|RANDOMIZED|PARALLEL||PREVENTION||NONE||Experimental, prospective, randomized, unblinded.||||
33712045|NCT00981734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712046|NCT06284174|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Patients will be randomly assigned by computer to one of three groups: a control group (soaked with 0.9% normal saline), an iodine group (soaked with 3.5% povidone-iodine solution), and a CHG group (soaked with 0.05% chlorhexidine gluconate). All groups will receive the same surgical pre-care, preoperative disinfection, and prophylactic antibiotics.~All patients understood the experimental process and signed the consent form. The patients did not know the group they were assigned to during the whole process. The bacterial culturers, examiners and clinical outcome assessors did not know the patient group."|This research will include patients diagnosed with lumbar spinal stenosis causing nerve compression, who are scheduled for open spinal decompression and fusion surgery. Patients will be randomly assigned to one of three groups: a control group (soaked with 0.9% normal saline), an iodine group (soaked with 3.5% povidone-iodine solution), and a CHG group (soaked with 0.05% chlorhexidine gluconate). All groups will receive the same surgical pre-care, preoperative disinfection, and prophylactic antibiotics. Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline. Samples from deep and superficial tissues and implants will be taken for bacterial culture and molecular biochip analysis.|t|f|f|t
33712047|NCT05576870|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33712048|NCT01990404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33712049|NCT03845725|||CASE_ONLY||RETROSPECTIVE|||||||
33712050|NCT01462097|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33712051|NCT00426907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712052|NCT00301665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33712053|NCT06295250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Interventionists and outcome assessors will not be informed regarding the study design and research question.||f|t|f|t
33712054|NCT02155608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, sham-controlled.||t|t|t|t
33712055|NCT04026308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935749|NCT00298311|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33935750|NCT03086746|||COHORT||PROSPECTIVE|||||||
33935751|NCT04395989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935752|NCT02268760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935753|NCT02514213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935754|NCT02233140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935755|NCT00549354|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935756|NCT03602638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935757|NCT01343576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33935758|NCT02937129|||COHORT||RETROSPECTIVE|||||||
33935759|NCT02837055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935760|NCT01738074|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33935761|NCT04682795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935762|NCT06134076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Subjects will receive both interventions labeled only as 1 or 2. The study team assessing inflammation and microbiome will not know the identity of intervention 1 or 2. The preparer of the meals will also conduct dietary recall interviews with subjects and will know the identities of the interventions.|2 week run-in period with no pulse consumption. Randomly assigned to order of receiving interventions. Blood sample, fecal sample, dietary recall. 2 week intervention 1. Blood sample, fecal sample, dietary recall. 2 week washout. 2 week intervention 2. Blood sample, fecal sample, dietary recall.|t|f|f|t
33935763|NCT01637844|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935764|NCT02148952|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935765|NCT04854785|||OTHER||PROSPECTIVE|||||||
33935766|NCT00789659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935767|NCT06135142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935768|NCT01551628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935769|NCT00006062||||TREATMENT||||||||
33935770|NCT04468464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Radiologist who evaluates the MRI results was blinded about the group of participants and also blinded about the diagnosis of the dentist.|Both groups receive splint treatment, but study group also receives osteopathic manual treatment|f|f|t|t
33935771|NCT02407691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33935772|NCT01140464|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33935773|NCT01487863|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33935774|NCT04563624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935775|NCT01359527|||CASE_CONTROL||PROSPECTIVE|||||||
33935776|NCT06435117|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33935777|NCT06101355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935778|NCT02835235|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33935779|NCT01557140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935780|NCT03463044|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33935781|NCT00113555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935782|NCT03258450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34013777|NCT01254682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013778|NCT00040248||||TREATMENT||||||||
34013779|NCT00327613|||CASE_ONLY||PROSPECTIVE|||||||
34013780|NCT02707133|||COHORT||PROSPECTIVE|||||||
34013781|NCT00003014|RANDOMIZED|||TREATMENT||||||||
34013782|NCT04010019|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interested adults will be screened, and eligible participants will be randomly assigned to one of two conditions: a Facebook group for individuals in pain similar to the groups that are occurring naturally (control condition) or an enhanced Facebook group for individuals in pain that is moderated by clinicians and offers psychosocial pain intervention techniques (experimental condition).||||
34013783|NCT04133766|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013784|NCT01393457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013785|NCT03293173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Stratification into group A (standard) or group B (experimental) based on biological risk factors||||
34013786|NCT00428779|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712056|NCT02622308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712057|NCT04743739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935783|NCT05032287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712058|NCT04324073|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bayesian open labelled randomized clinical trial||||
33712059|NCT02647203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712060|NCT04497688|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33712061|NCT02810860|NA|SINGLE_GROUP||OTHER||NONE||||||
33712062|NCT03312270|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Examination of comprehension differences when information is presented under different conditions: (a) written only, (b) auditory only or (c) combined written and auditory.||||
33712063|NCT04019483|||COHORT||PROSPECTIVE|||||||
33712064|NCT02754245|||COHORT||PROSPECTIVE|||||||
33712065|NCT03672747|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded|Full crossover; all participants complete all conditions|t|f|t|f
33712066|NCT00646776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712067|NCT00001265|||COHORT||PROSPECTIVE|||||||
33712068|NCT02055716|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33712069|NCT05758051|NA|SINGLE_GROUP||TREATMENT||NONE||subtrochanteric valgus osteotomy||||
33712070|NCT00166478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712071|NCT00823368|||COHORT||PROSPECTIVE|||||||
33712072|NCT04937673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712073|NCT04383795|||CASE_ONLY||PROSPECTIVE|||||||
33712074|NCT03667924|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Enrollment: Number of participants: 44 (33 senior volunteers; 7 clients (PWML); 4 caregivers)||||
33935784|NCT04076813|||CASE_ONLY||RETROSPECTIVE|||||||
33935785|NCT03582839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935786|NCT06330766|||COHORT||PROSPECTIVE|||||||
34013787|NCT00211965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013788|NCT02777515|NA|SINGLE_GROUP||OTHER||NONE||||||
34013789|NCT00270049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013790|NCT00750646|||COHORT||PROSPECTIVE|||||||
34013791|NCT04339920|||OTHER||PROSPECTIVE|||||||
34013792|NCT01405131|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34013793|NCT05397548|||COHORT||PROSPECTIVE|||||||
34013794|NCT01397708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013795|NCT01838928|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34013796|NCT02242318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34013797|NCT01634282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013798|NCT01192984|NA|SINGLE_GROUP||TREATMENT||||||||
34013799|NCT01543555|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013800|NCT04656730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Experimental group: Study 1: STW5 20 drops TID; Study 2: STW5-II 20 drops TID Control group: Placebo 20 drops TID|To determine the independent effects of STW5 and STW5-II on transit and evacuation of intestinal gas in subjects with functional dyspepsia and irritable bowel syndrome according to Rome IV criteria, measured as ml of gas recovered by a rectal cannula|t|f|t|f
34013801|NCT05520593|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34013802|NCT00065013|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34013803|NCT03257475|||CASE_ONLY||PROSPECTIVE|||||||
34013804|NCT01615042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013805|NCT02385331|||CASE_ONLY||CROSS_SECTIONAL|||||||
34013806|NCT04647669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013807|NCT00217269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013808|NCT05397743|NA|SINGLE_GROUP||OTHER||NONE||||||
34013809|NCT00293202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind Study|This is a double blind study- one group received 25mg Etanercept twice per week; the other is control - receiving saline twice per week|t|t|t|f
34013810|NCT01453413|NA|SINGLE_GROUP||||NONE||||||
34013811|NCT05506722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|By mixing the devices together and giving them to the participants blindly.|Double blinded two groups, one is the treated group and the other is the placebo group.|t|t|t|t
34013812|NCT00325208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013813|NCT02573753|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Crossover; Single group||||
34013814|NCT05070702|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Active and Placebo capsules are identical in appearance.|Ascending Single Doses followed by Ascending Multiple Doses of Study Intervention|t|t|t|t
34013815|NCT01184248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013816|NCT03697265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013817|NCT05195749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, neither the participants nor the investigator is aware of the assigned treatment.|19 eligible patients will be enrolled to receive '005 + Standard of Care (SOC) and 10 patients will be enrolled to a control group receiving the SOC + placebo. The 1st open-label stage a 3+3+3 design will be implemented. 3 patients will receive 10mg '005 + SOC, 3 patients will receive 20mg '005 + SOC, and 3 patients will receive 30mg '005 + SOC. If no safety concerns are identified the 2nd stage will be initiated. All dose-escalation decisions will be based on previous cohort safety data, and doses will not be escalated unless 2 patients receiving the highest current dose have been observed for 24 hours post the 3rd dose. At the 2nd double blind stage neither the participants nor the investigator will know which treatment participants are receiving until the clinical trial is over. 20 patients will be enrolled and randomly allocated in a 1:1 ratio to the treatment (SOC + '005) or placebo group (SOC + placebo). The treatment dose will be chosen based on the 1st stage safety results.|t|t|t|t
34013818|NCT04714970|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||60 participants are randomized, through the predetermined random number list, into intervention group or sham stimulation group in equal.|t|t|t|t
34013819|NCT01144728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013820|NCT00263614|||||RETROSPECTIVE|||||||
34013821|NCT01752114|||COHORT||PROSPECTIVE|||||||
34013822|NCT01079832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013823|NCT00512694|||COHORT||PROSPECTIVE|||||||
34013824|NCT00331071|||CASE_CONTROL||RETROSPECTIVE|||||||
34013825|NCT02480582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34013826|NCT00728442|RANDOMIZED|PARALLEL||||NONE||||||
34103323|NCT06513416|||CASE_CONTROL||OTHER|||||||
34013827|NCT04387682|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Oral squamous cell carcinoma (OSCC) subject and healthy donors (HDs) subject|t|f|f|f
34013828|NCT03344978|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized crossover. Participant will be randomly assigned initially to care in one of two devices for 24 hours, then crossed over to other device for 24 hours. This will be repeated once more for a total of 96 hours study time. Patterns may be A-B-A-B or B-A-B-A.||||
34013829|NCT01382251|||||PROSPECTIVE|||||||
34013830|NCT05758220|||COHORT||PROSPECTIVE|||||||
34013831|NCT05670782|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-Blinded||t|f|t|f
34013832|NCT05485519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013833|NCT01102569|||COHORT||PROSPECTIVE|||||||
34013834|NCT01846273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013835|NCT01484418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013836|NCT02969772|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013837|NCT05717582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096626|NCT03520569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each subject is studied 4 times in a randomized sequential order||||
34096627|NCT01454557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712075|NCT01437722|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33712076|NCT01153347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712077|NCT02460302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712078|NCT04314336|||COHORT||RETROSPECTIVE|||||||
33712079|NCT01264497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712080|NCT02474459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712081|NCT00253045|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33712082|NCT04487301|||CASE_ONLY||CROSS_SECTIONAL|||||||
34013838|NCT04085471|||COHORT||PROSPECTIVE|||||||
34013839|NCT05703035|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Computer-assisted 4-block-based randomization via random.org|Two equal groups with equal comorbid conditions will be compared|t|t|f|t
34013840|NCT03621319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013841|NCT01947231|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34013842|NCT03353623|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The study was masked only for the medical doctor who performed the motor assessments with clinical scales: she did not follow the rehabilitation sessions.|The investigators adopted a 2x2 crossover design (2-sequence, 2-period, 2-treatment crossover design, with sequences AB and BA): each participant received both conventional and VR-aided therapy for a period of 4 weeks per treatment (2 sessions per week of 45 minutes) assigned in a different order. A wash out period of 4 weeks was included before the second period of intervention started.|f|f|f|t
34013843|NCT04133649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013844|NCT05364996|||COHORT||PROSPECTIVE|||||||
34096628|NCT03087357|||COHORT||PROSPECTIVE|||||||
34096629|NCT00205608|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096630|NCT03986541|||COHORT||OTHER|||||||
34096631|NCT04617223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712083|NCT03625414|||CASE_CONTROL||PROSPECTIVE|||||||
33712084|NCT00704054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712085|NCT02412475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712086|NCT00905697|||COHORT||PROSPECTIVE|||||||
33712087|NCT04061291|||COHORT||PROSPECTIVE|||||||
33712088|NCT01504035|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712089|NCT01876030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712090|NCT05144321|||COHORT||PROSPECTIVE|||||||
33712091|NCT03358121|||COHORT||CROSS_SECTIONAL|||||||
33712092|NCT04106960|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712093|NCT05992532|||COHORT||CROSS_SECTIONAL|||||||
33712094|NCT02324062|||COHORT||PROSPECTIVE|||||||
33712095|NCT05221528|||COHORT||RETROSPECTIVE|||||||
33712096|NCT05279274|||COHORT||PROSPECTIVE|||||||
34013845|NCT03452774|||COHORT||PROSPECTIVE|||||||
33712097|NCT06408025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712098|NCT05732688|NA|SINGLE_GROUP||SCREENING||NONE||||||
33712099|NCT00788021|||COHORT||PROSPECTIVE|||||||
33712100|NCT04366102|RANDOMIZED|PARALLEL||TREATMENT||NONE||Neonates admitted in the Neonatal intensive care unit will be divided randomly into 2 groups.||||
33712101|NCT04758169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33712102|NCT06361030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013846|NCT04900909|||COHORT||RETROSPECTIVE|||||||
34096632|NCT01543503|||COHORT||PROSPECTIVE|||||||
34096633|NCT01444170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33712103|NCT02205632|NON_RANDOMIZED|||||NONE||||||
34096634|NCT04424680|RANDOMIZED|PARALLEL||OTHER||NONE||Once patients have been included in the study, the assignment process will be carried out by random sampling to the study groups. In the First Group (control group), patients will be followed in HF outpatients units according to the usual established protocol. In the Second Group (intervention group), patients will participate in the ACP program. Treatment for HF will be the same in both groups. The research team has developed the ACP program based on the published bibliography on ACP and advanced HF. The four hospitals mentioned will start recruiting at the beginning of the study. The principal investigator will be responsible for interrupting recruitment once the sample size has been reached.||||
34096635|NCT00333307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096636|NCT00156130|||||PROSPECTIVE|||||||
33712104|NCT03229850|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|During one euglycemic clamp study, insulin lispro will be injected subcutaneously into an area of subclinical lipohypertrophy of the abdomen identified by ultrasound, during the other insulin lispro will be injected to an area with no subclinical lipohypertrophy.||f|f|t|t
33712105|NCT06229340|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33712106|NCT03057431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33712107|NCT04688853|NA|SINGLE_GROUP||OTHER||NONE||||||
33712108|NCT00569478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712109|NCT05848960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712110|NCT05612789|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712111|NCT01761890|||CASE_ONLY||PROSPECTIVE|||||||
34096637|NCT01441414|RANDOMIZED|||TREATMENT||NONE||||||
33712112|NCT05304273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712113|NCT04669600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013847|NCT03814941|||COHORT||RETROSPECTIVE|||||||
34013848|NCT05881902|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The collected data will be analyzed by an independent statistician. The fact that the intervention 1 and intervention 2 groups of the study are known by the researcher and the women with physical disabilities do not know, makes it a double-blind randomized controlled study.|Randomized controlled experimental design|t|f|f|t
34013849|NCT04669717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The examiner, the biostatistician and people working in the laboratory for the analyses, will be blinded for the allocation group. Only the two operators and the participants will be aware of the type of treatment based on the computer-generated allocation table that will be kept at the Trial Master File (TMF) of the study.|Randomized, 3-arm parallel group, single-blind, comparative superiority and exploratory clinical trial with 1:1 allocation ratio.|f|f|t|f
34013850|NCT01525472|||COHORT||CROSS_SECTIONAL|||||||
34013851|NCT01183325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013852|NCT00207948|||COHORT||PROSPECTIVE|||||||
34013853|NCT05575635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013854|NCT01157897|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013855|NCT00534794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013856|NCT03130114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active drug (azithromycin) will be delivered as dry powder, in opaque glass bottles. Control children with receive placebo powder that will appear, smell, and taste similar to the active drug. All drug bottles will be coded with participant numbers only, so that no-one will know the contents of the bottle.||t|t|t|t
34013857|NCT05839535|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Clinical mechanism study|f|f|t|t
34013858|NCT05880121|||CASE_CONTROL||PROSPECTIVE|||||||
34013859|NCT03500042|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013860|NCT03913897|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34013861|NCT06194006|NA|SINGLE_GROUP||OTHER||NONE||||||
34013862|NCT04463290|||CASE_CONTROL||PROSPECTIVE|||||||
34013863|NCT06453512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013864|NCT02276079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013865|NCT03141879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096638|NCT04648241|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096639|NCT04557761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712114|NCT02222974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33712115|NCT04617509|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is divided in two parts. Part I will evaluate PK, safety and tolerability of a single oral dose of two different formulations of GS-248 in fasting conditions. Part II will evaluate PK, safety and tolerability of one of the two different formulations of GS-248 in fed conditions. Subjects are expected to participate in both Part I and Part II.||||
33712116|NCT00319865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792797|NCT06423742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The participants were randomly allocated with three different arms (control, single-session, and dual session) using block to balance the size of each group. . Participants who assigned to the control group underwent dual sham stimulation per day, twice a week for 1 month. Patients were received sham and true stimulation once alternately in the single session group and two true stimulation per day in the dual session group for the same period as the control group. All subjects who enrolled this study were given a conventional treatment such as tinnitus retraining therapy, sound therapy using sound generator, and medications like clonazepam, selective serotonin reuptake inhibitors for patients who wanted to take for relief of symptoms.|t|f|f|f
33792798|NCT04537065|||CASE_CONTROL||OTHER|||||||
33792799|NCT02403219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33792800|NCT04021381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792801|NCT01273844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013866|NCT03532633|||COHORT||PROSPECTIVE|||||||
34096640|NCT01691092|NA|SINGLE_GROUP||OTHER||NONE||||||
34096641|NCT02387879|||COHORT||PROSPECTIVE|||||||
34096642|NCT04781985|NA|SINGLE_GROUP||TREATMENT||NONE||surgical treatment for bladder stone||||
34096643|NCT01354535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792802|NCT04476745|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33792803|NCT05149313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096644|NCT03807167|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103324|NCT03193437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103325|NCT05021042|||CASE_CONTROL||PROSPECTIVE|||||||
33720669|NCT03109574|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33792804|NCT06268262|||CASE_CONTROL||PROSPECTIVE|||||||
33792805|NCT03579368|NA|SINGLE_GROUP||TREATMENT||NONE||Single group study||||
33792806|NCT01687452|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33792807|NCT02082158|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33792808|NCT02881749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792809|NCT00240916|||COHORT||PROSPECTIVE|||||||
33792810|NCT06312943|||COHORT||PROSPECTIVE|||||||
33792811|NCT04932707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792812|NCT05967338|||COHORT||PROSPECTIVE|||||||
33792813|NCT03988504|||COHORT||PROSPECTIVE|||||||
33792814|NCT04714502|||COHORT||PROSPECTIVE|||||||
33792815|NCT00130780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013867|NCT03481413|||COHORT||PROSPECTIVE|||||||
34013868|NCT03827564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34013869|NCT00753220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013870|NCT01555827|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34013871|NCT00256711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013872|NCT00352235|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34013873|NCT02038231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013874|NCT01301508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013875|NCT05100173|||CASE_ONLY||CROSS_SECTIONAL|||||||
34013876|NCT04922684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34013877|NCT06415266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013878|NCT03235661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||BiPAP and nCPAP are used as primary mode of ventilation in preterm twins infants with RDS|t|t|t|t
34103326|NCT06385834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, outcome measurement personnel and intervention personnel were separated during the whole process of the experiment, outcome measurement personnel did not know the grouping status, intervention personnel and rehabilitation therapists did not participate in the outcome measurement work.|The study was divided into three groups: morning intervention group (8:00-9:00AM), evening intervention group (16:00-17:00AM) and control group|f|f|f|t
34103327|NCT04949087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded, randomized||t|t|t|f
33712117|NCT06485882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Teachers fullfilled the scales and so they were not known about children who are intervention group|Social Learning Theory is used for fostering positive health habits for children between 5-6 age.|f|t|f|f
33712118|NCT02279420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712119|NCT04347044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712120|NCT02300532|||COHORT||PROSPECTIVE|||||||
33712121|NCT01833520|NA|SEQUENTIAL||TREATMENT||NONE||||||
33792816|NCT02845856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792817|NCT02589002|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33792818|NCT00395928|||DEFINED_POPULATION||OTHER|||||||
33792819|NCT01654588|||CASE_ONLY||PROSPECTIVE|||||||
33792820|NCT04002973|NA|SINGLE_GROUP||OTHER||NONE||||||
33792821|NCT01966055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792822|NCT03808883|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792823|NCT03624140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Blood measurement||||
33792824|NCT03200587|NA|SINGLE_GROUP||TREATMENT||NONE||A phase 1B, open label, dose-finding study||||
33792825|NCT06512649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792826|NCT04956224|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33792827|NCT06555198|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33792828|NCT05605834|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33792829|NCT01948804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34013879|NCT04337684|||CASE_CONTROL||PROSPECTIVE|||||||
34013880|NCT00472797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34013881|NCT02865395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013882|NCT05460559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013883|NCT03746548|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34013884|NCT02646449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013885|NCT00003517||||TREATMENT||||||||
34013886|NCT05638841|||COHORT||PROSPECTIVE|||||||
34013887|NCT04624347|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Controlled, bicentric, single-blind, cross-over study with randomization of the sequence order (with and without caregivers' access to videos and movement curves).|f|f|f|t
34013888|NCT02306057|||CASE_ONLY||PROSPECTIVE|||||||
34013889|NCT02224573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013890|NCT04450849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In a parallel design, 22 patients with mandibular class II furcation defects were recruited. Each defect was randomly assigned to the control group (CG - Bio-Gide® Perio, n=11) or test group (TG - Bio-Oss® Collagen + Bio-Gide® Perio, n=11). Tomographic and clinical evaluations were conducted at baseline and 12 months post-surgery.|t|t|t|t
34013891|NCT01000493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013892|NCT05618535|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34013893|NCT03914079|||COHORT||PROSPECTIVE|||||||
34013894|NCT02264093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712122|NCT01743053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712123|NCT06231160|||COHORT||PROSPECTIVE|||||||
33712124|NCT01949506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712125|NCT05699239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712126|NCT05813015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712127|NCT04023851|||COHORT||PROSPECTIVE|||||||
33712128|NCT06072729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712129|NCT03582540|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with a difficult biliary cannulation are included in the study if the guidewire is inserted in the pancreatic duct. At that point, patients are randomized in two arms: early versus delayed DGT. The early arm attempts biliary cannulation using the DGT immediately and the delayed arm uses the DGT only if 10 more minutes of conventional cannulation technique does not allow biliary cannulation.||||
33712130|NCT05288231|||COHORT||PROSPECTIVE|||||||
33712131|NCT05990114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Randomized Controlled Trial|t|t|f|f
33712132|NCT05062382|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors were masked to the intervention.|Cross-sectional pre- post-evaluation of intervention and comparison group|f|f|f|t
33712133|NCT04766398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712134|NCT01846416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712135|NCT00138203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712136|NCT05447637|||COHORT||PROSPECTIVE|||||||
33712137|NCT00395369|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33712138|NCT02397278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Arm 1- Conservative Treatment Arm 2- PRP Injections|f|f|f|t
33712139|NCT04658277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792830|NCT04397198|||COHORT||PROSPECTIVE|||||||
33792831|NCT01669382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792832|NCT01641913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792833|NCT00003717||||TREATMENT||||||||
33792834|NCT03915769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792835|NCT05416450|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013895|NCT02759770|||OTHER||OTHER|||||||
34013896|NCT04263428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34013897|NCT03314818|||COHORT||PROSPECTIVE|||||||
34013898|NCT04024293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096645|NCT03757676|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomly assigned into one of three experimental groups: a control group and two play groups. The two play groups consisted of a group that was asked to play Pokémon Go ad libitum (at will play) and the other group was asked to achieve a specific level within the game during the study period (goal oriented play). Participants were measured for baseline physical activity levels (2 weeks) followed by randomization to one of the three groups. The intervention period lasted 4 weeks. All participants completed a brief questionnaire and were measured for height and weight, and daily physical activity levels using a FitBit accelerometer. Locations of where individual engaged in physical activity were recorded using a GPS tracking application. During the 5th week of the study period, participants completed five (5) short surveys per day using Ecological Momentary Assessment (EMA) software to assess level of play and engagement of play.|t|f|f|f
33712140|NCT04160897|||COHORT||RETROSPECTIVE|||||||
33712141|NCT03926169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712142|NCT03269864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||two arms, one will be managed by pedicled perforator flaps the other will be managed by free perforator flaps||||
33712143|NCT02323113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712144|NCT05753423|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712145|NCT02254252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712146|NCT01140243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33712147|NCT05109689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized into either ACT-P or T4C, two group programs that will run simultaneously.|f|f|f|t
33712148|NCT04083053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712149|NCT05745584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792836|NCT03414736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792837|NCT04822948|||COHORT||PROSPECTIVE|||||||
33792838|NCT00293865|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792839|NCT00967512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792840|NCT00918957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792841|NCT05503212|||COHORT||RETROSPECTIVE|||||||
33792842|NCT01305434|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33792843|NCT05134025|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792844|NCT02713048|||CASE_ONLY||PROSPECTIVE|||||||
33792845|NCT04291586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712150|NCT03647033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Shuffled envelope system. Patient will be blinded to the procedure. The intraocular pressure (IOP) measure and reader will be blinded to the procedure.~There will be no planned breaking of randomization. Unplanned breaking will happen if any envelopes are damaged or lost. Unmasking will take place after 1 year post operation by the study team to inform the patient of the procedure."|"Single centre, randomised prospective trial, the patient and the intraocular pressure (IOP)checking staff will be blinded. Randomised by random envelope shuffle technique.~1:1 ratio allocation 2 arms: phacoemulsification alone and phacoemulsification and iStent. 16 patients in each arm, 32 patients in total. The post-operative management is the same for both arms After operation the patient will be followed up at day 1, week 1, week 2, months 1, 3, 6 and 12.~At each visit the patient will have the following tests: Tonometry (IOP check) - Not to be taken by the operating surgeon, to be taken by 2 people, one IOP checker and one reader."|t|f|f|t
34013899|NCT00970008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013900|NCT06316128|||COHORT||PROSPECTIVE|||||||
34013901|NCT01633502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013902|NCT03804398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34013903|NCT05530616|||CASE_ONLY||RETROSPECTIVE|||||||
34013904|NCT00010166||||TREATMENT||||||||
34013905|NCT01299805|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34013906|NCT03223948|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients recruited will be divided into 3 groups according to their oxygen (O2) requirements at recruitment (low, medium and high).~All recruited patients will then be given supplementary O2 using the Optiflow system. Patients from all three recruitment oxygen requirements (low, medium and high) will be randomised to 30 litres, 45 litres or 60 litres per minute with initial a fractional inspired O2 concentration(FiO2) of 0.90 (90% oxygen). The FiO2 is then decreased in 0.05 increments every 5 minutes and the minimum oxygen saturation recorded until it reaches 94%."||||
34013907|NCT05626699|NA|SINGLE_GROUP||OTHER||NONE||RTs will be observed during patient care without the use of the RT Assistant during the non-interventional phase and with the use of the RT Assistant during the interventional phase. RTs will be observed by highly trained RTs during both phases. RTs will answer a likert scale questionnaire about the use of the RT Assistant used to make clinical decisions.||||
34096646|NCT05226689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712151|NCT05975944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712152|NCT06304194|NA|SINGLE_GROUP||SCREENING||NONE||||||
33712153|NCT02301052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712154|NCT02301494|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33712155|NCT00871702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712156|NCT01104506|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33712157|NCT00299975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792846|NCT06467253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Comparative, double-blind, randomized controlled clinical trial.|t|t|t|f
33792847|NCT05345561|||COHORT||PROSPECTIVE|||||||
33792848|NCT04680260|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open label 1:1 randomized phase II exploratory study||||
33792849|NCT02823106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792850|NCT02707913|RANDOMIZED|CROSSOVER||||NONE||||||
33792851|NCT01524523|||||PROSPECTIVE|||||||
33792852|NCT02806869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This is a parallel study design that allocated subjects into a fasted or fed group. Subject were asked to complete the same study procedures on two occasions.~Subjects assigned to the fasted or fed group were not crossed-over from one group to the other."||||
33792853|NCT05923567|||COHORT||RETROSPECTIVE|||||||
33792854|NCT04989725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized screening phase II trial|f|f|f|t
33792855|NCT01101152|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34096647|NCT00008333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096648|NCT01160744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096649|NCT04757857|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, open-label, controlled randomized trial||||
34096650|NCT02516111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096651|NCT06124677|||COHORT||RETROSPECTIVE|||||||
34096652|NCT02585167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712158|NCT01929798|RANDOMIZED|CROSSOVER||||NONE||||||
33712159|NCT04079101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33712160|NCT03098550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792856|NCT04418323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792857|NCT05125133|RANDOMIZED|PARALLEL||PREVENTION||NONE||Households allocated into Two arms to receive ITENs+ITWS installed or none with a 1:1 ratio at sub-village level.||||
33712161|NCT01673867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712162|NCT00577681|||CASE_CONTROL||RETROSPECTIVE|||||||
33712163|NCT01053416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33712164|NCT04779840|||COHORT||RETROSPECTIVE|||||||
33712165|NCT02052674|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712166|NCT05083962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712167|NCT05228288|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Patients and data analysts will be blinded regarding the assignment of interventions.~The randomization result will be communicated to the care providers non-verbally without revealing the result to the patient. Before data evaluation, the identifying variables will be made illegible. Investigators and care providers carrying out the intervention cannot be blinded due to the nature of the study. In the follow-up period two hours after the end of anesthesia, the outcome survey should be performed, if possible, by an investigator who was not involved in the intervention to ensure blinding. It will be documented whether blinding could be accomplished at this point. Un-blinding of the patient is only intended if an unexpected difficult airway situation occurred and the patient is issued a personal anaesthesia problem card. However, even in such cases, blinding can usually be ensured until after the last study visit."|In this randomized, controlled, three-armed parallel group design, multi-center trial, a total of more than 2500 adult patients scheduled for perioperative endotracheal intubation will be randomized. In equally large arms, video-assisted laryngoscopy with a Macintosh-shaped or a hyperangulated blade will be compared to the standard of care (direct laryngoscopy with Macintosh blade).|t|f|f|t
33712168|NCT02704715|NA|SINGLE_GROUP||||NONE||||||
33712169|NCT03729089|RANDOMIZED|PARALLEL||OTHER||NONE||Eligible pregnant women at 34 to 40 weeks gestation will be randomized to interventional group (Biophysical profile scanning) or to a control group receiving the current standard of care||||
33712170|NCT00336687|||||PROSPECTIVE|||||||
33792858|NCT03197337|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The participants will not be informed prior to the experiment if they will first undergo the control manipulation or the study manipulation.||t|f|f|f
33792859|NCT02572141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720670|NCT06228040|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Before - After study||||
33720671|NCT03747432|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33720672|NCT02391155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33792860|NCT05903833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802034|NCT05381233|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33802035|NCT00198315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935787|NCT04143789||SEQUENTIAL||TREATMENT||NONE||"Review of safety and pharmacokinetic (PK) parameters by the Clinical Trial Review Committee (CTRC) at the completion of each dose level in the Phase 1 will determine if escalation to the next dose level may occur.~Anticipated Dose Levels in the Phase 1 Portion of the Study Cohort Anticipated Dose Anticipated Sample Size Level 1 8 mg QD PO × 14 days\* (1 patient) Level 2 16 mg QD PO × 14 day\* (1 patient) Level 3 32 mg QD PO × 14 days\* (1 patient) Level 4 64 mg QD PO × 14 days\* (1 patient) Level 5 84 mg QD PO × 14 days\* (3 patients) Level 6 108 mg QD PO × 14 days\* (3 patients) Level 7 140 mg QD PO × 14 days\* (3 patients) Level 8 180 mg QD PO × 14 days\* (3 patients)~\* Note: 21-day schedule with 2 weeks on, one week off. The actual sample size will be guided by the CRM; sample size may be larger for dose levels that require expansion. Interim meetings may occur when relevant new data becomes available between scheduled CTRC meetings"||||
33935788|NCT03352167|||COHORT||CROSS_SECTIONAL|||||||
33935789|NCT02935595|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
33935790|NCT01243203|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33935791|NCT05790915|||COHORT||RETROSPECTIVE|||||||
33935792|NCT04023344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935793|NCT04576390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33935794|NCT01432665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935795|NCT03233672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935796|NCT02766049|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935797|NCT00654394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935798|NCT05281549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935799|NCT02473016||CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33935800|NCT03419351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935801|NCT00935961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935802|NCT03659240|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34013908|NCT03088618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013909|NCT02621801|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34013910|NCT04051684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34013911|NCT03982576|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-arm semi-pragmatic randomized design among recently quit smokers (N = 100). Random assignment (1:1 ratio, stratified by building and sex).||||
34013912|NCT05530746|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013913|NCT06331000|||COHORT||RETROSPECTIVE|||||||
34013914|NCT06405698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013915|NCT01117337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33935803|NCT03662828|||COHORT||RETROSPECTIVE|||||||
34013916|NCT04807751|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE||All subjects will receive all treatments with treatments randomised over test fields.|t|f|t|f
33792861|NCT04405713|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were divided into three groups according to the timing of the surgery: from the onset of symptoms within the first 3 days (group 1), between 4 and 7 days (group 2) and beyond 7 days (group 3).|Patients with ACC were divided into three groups according to the timing of the surgery: from the onset of symptoms within the first 3 days (group 1), between 4 and 7 days (group 2) and beyond 7 days (group 3).|t|f|t|t
33712171|NCT06502535|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This study will be conducted under a double-blind setup, which implies that neither the participants nor the researcher will be aware of whether the participants are being given inulin or a combination of inulin and nitrate. The supplements will be labelled A and B by an independent party otherwise not involved in the study, and the investigator and participants will not know which supplement is which letter during the study period.|Participants will be assigned randomly to receive either A) a combination of inulin and nitrate, or B) inulin alone. This will be done following a crossover and counterbalanced design, ensuring that all participants will receive both treatments in a randomised order.|t|f|t|f
33712172|NCT04244721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To make the comparison between the two groups on autism symptoms outcome measured with ADOS-2, with a power of 80% and an improvement of 0.6 points, we need 198 children (99 per group). After taking into account of a 20% consensual withdrawals and poor compliance with PACT, 238 children (119 per group) will be required. Each center will therefore have to include 50 children during the inclusion period.|To make the comparison between the two groups on autism symptoms outcome measured with ADOS-2, with a power of 80% and an improvement of 0.6 points, we need 198 children (99 per group). After taking into account of a 20% consensual withdrawals and poor compliance with PACT, 238 children (119 per group) will be required. Each center will therefore have to include 50 children during the inclusion period.|t|f|f|f
33712173|NCT06049940|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33712174|NCT01837615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712175|NCT01874054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712176|NCT03667261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded as well as the data analysis|cases with with hopeless mandibular molars followed by immediate implant placement|f|f|f|t
33712177|NCT05806788|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a beta-testing of a new behavioral intervention treatment - all participants will be assigned to the treatment and give feedback on the treatment throughout the study.||||
33712178|NCT06433869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712179|NCT05085652|||COHORT||RETROSPECTIVE|||||||
33712180|NCT05173402|||CASE_CONTROL||PROSPECTIVE|||||||
33712181|NCT02353104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33712182|NCT03903848|NA|SINGLE_GROUP||OTHER||NONE||||||
33712183|NCT05127473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712184|NCT05333978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712185|NCT03002766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712186|NCT00160485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712187|NCT01995032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712188|NCT04783480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712189|NCT05334888|||COHORT||PROSPECTIVE|||||||
33712190|NCT03817307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712191|NCT02947997|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712192|NCT06270498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712193|NCT00006361||||TREATMENT||||||||
33712194|NCT04388800|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33712195|NCT01377090|||COHORT||PROSPECTIVE|||||||
33712196|NCT06258356|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||One patients receiving Remimazolam, the other patients receiving placebo|t|t|t|t
33712197|NCT02559193|||CASE_ONLY||OTHER|||||||
33712198|NCT01261104|||COHORT||RETROSPECTIVE|||||||
33712199|NCT04068714|||COHORT||RETROSPECTIVE|||||||
33712200|NCT01433991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712201|NCT03879707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33712202|NCT01938677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792862|NCT01943799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792863|NCT00442117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792864|NCT06296056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792865|NCT00138138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33792866|NCT00301990||||TREATMENT||NONE||||||
33792867|NCT01794936|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33792868|NCT05576844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792869|NCT05112861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792870|NCT04776993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935804|NCT00397631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935805|NCT00169338|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33935806|NCT06380036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935807|NCT02900599|||COHORT||PROSPECTIVE|||||||
33935808|NCT02992912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935809|NCT01594411|||COHORT||PROSPECTIVE|||||||
33935810|NCT02676050|NA|SINGLE_GROUP||OTHER||NONE||||||
33935811|NCT02477540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935812|NCT04275492|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33935813|NCT00723086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935814|NCT00002274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935815|NCT02058706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935816|NCT05844254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33935817|NCT01762592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935818|NCT02186535|RANDOMIZED|PARALLEL||||NONE||||||
34013917|NCT00169351|||DEFINED_POPULATION||PROSPECTIVE|||||||
34013918|NCT04004117|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"All research staff, treating clinicians, analysts and patients will remain blinded to the treatment allocation.~Unbinding will only occur in emergency situations following consultation with the principal investigator and at the conclusion of collecting the last data point for the last participant in the entire study."|Single centre randomized clinical trial, double-blinded, cross-over design, comparing fentanyl sublingual at a dose 12,5 mcg to placebo.|t|t|t|t
34013919|NCT03340753|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34013920|NCT05115526|||COHORT||PROSPECTIVE|||||||
34013921|NCT00306163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34013922|NCT00368095|||COHORT||PROSPECTIVE|||||||
34096653|NCT03811873|NA|SINGLE_GROUP||PREVENTION||NONE||Testing a single group of participants who are first time liver transplant candidates.||||
33712203|NCT03909256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The investigator will be blinded when performing the data analyses. Hence, data will be anonymised before analysis and the investigator will not know whether the group of subjects were allocated to the control or the intervention group.~Results from blinded data analyses will be interpreted by project group before unblinding."||f|f|t|f
33712204|NCT04412369|||CASE_ONLY||PROSPECTIVE|||||||
33712205|NCT00469183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712206|NCT03628404|||OTHER||OTHER|||||||
33712207|NCT00673569||||TREATMENT||NONE||||||
33712208|NCT02870582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712209|NCT04342897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712210|NCT05731895|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792871|NCT03825133|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to 3 groups: LR-PRP group, the BMAC group or HA group. Functional scores and outcomes will be compared to determine clinical efficacy of all groups and which treatment is more effective in treating knee OA||||
33792872|NCT01941563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34013923|NCT05393505|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-center, pragmatic, open-labelled, randomized, controlled trial with 1:1 parallel-group assignment, which aims to establish superiority in antibiotic stewardship.||||
34013924|NCT00995085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013925|NCT06248268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013926|NCT06048289|||COHORT||PROSPECTIVE|||||||
34013927|NCT06616012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013928|NCT02261909|||CASE_CONTROL||PROSPECTIVE|||||||
34013929|NCT00621036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013930|NCT03459352|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34013931|NCT05990582|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Outcomes of a group of preterm born children are compared to a group of children born at term.||||
34096654|NCT02149160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096655|NCT02466581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096656|NCT05331833|||CASE_CONTROL||PROSPECTIVE|||||||
34096657|NCT00834587|RANDOMIZED|CROSSOVER||||NONE||||||
34096658|NCT03343886|||COHORT||PROSPECTIVE|||||||
34096659|NCT03544164|||COHORT||PROSPECTIVE|||||||
34096660|NCT01879852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712211|NCT04757870|||OTHER||OTHER|||||||
33712212|NCT03150615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712213|NCT01783301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712214|NCT00030810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712215|NCT01931904|||COHORT||PROSPECTIVE|||||||
33712216|NCT03047694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096661|NCT02228122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096662|NCT02887326|||CASE_ONLY||RETROSPECTIVE|||||||
34096663|NCT04489056|||CASE_CONTROL||PROSPECTIVE|||||||
34096664|NCT03148925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096665|NCT03796130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096666|NCT01707121|||COHORT||PROSPECTIVE|||||||
34096667|NCT04828733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096668|NCT01426451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712217|NCT01936103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712218|NCT03730246|||COHORT||PROSPECTIVE|||||||
33712219|NCT04655391|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712220|NCT05252117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be allocated, according to randomization into one of two groups, after gynecological evaluation at the Gynecology Outpatient Clinic of Hospital das Clínicas Samuel Libânio, in Pouso Alegre. They will be informed about the study and invited to participate and, accepting, signing the Informed Consent Form. Randomization will be followed to define which drug will be used in the patient who will undergo the procedure determined by the study, in a modified lithotomy position, always by the same examiner.|t|f|f|f
33792873|NCT03608618|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33792874|NCT01566708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792875|NCT06386562|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792876|NCT04616053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792877|NCT04628026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind with open label dose-finding run-in part||t|t|t|t
33792878|NCT05417893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013932|NCT00043537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34013933|NCT01218984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013934|NCT01976013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013935|NCT05043064|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|All tasks will be recorded and evaluated blinded using the modified Global Evaluative Assessment of Robotic Skills (mGEARS) score by two not participating raters||f|f|f|t
34013936|NCT04757181|NA|SINGLE_GROUP||TREATMENT||NONE||The study design is a single-arm, prospective, pre-post intervention trial.||||
34013937|NCT01088919|RANDOMIZED|CROSSOVER||||NONE||||||
34013938|NCT01092260|||COHORT||CROSS_SECTIONAL|||||||
34096669|NCT02815956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096670|NCT00673114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096671|NCT02822287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096672|NCT04598659|||COHORT||RETROSPECTIVE|||||||
34096673|NCT04361045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096674|NCT05586360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096675|NCT01395537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096676|NCT02866266|||COHORT||RETROSPECTIVE|||||||
33935819|NCT02528799|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33935820|NCT04605458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935821|NCT02626299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935822|NCT00854685|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34013939|NCT01369602|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34013940|NCT05339269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013941|NCT03993249|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled||||
34096677|NCT05372900|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This is a double-blind, controlled, randomized, 2-arm, cross-over, group sequential design clinical trial. Subjects will receive the two different interventions in a randomized order.|t|f|t|f
34096678|NCT00964678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096679|NCT04695626|||COHORT||PROSPECTIVE|||||||
34096680|NCT05144282|||COHORT||PROSPECTIVE|||||||
34096681|NCT03422718|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34096682|NCT02901795|||CASE_CONTROL||PROSPECTIVE|||||||
34096683|NCT03148639|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Partial crossover design||||
34096684|NCT02285972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33935823|NCT05817591|||COHORT||PROSPECTIVE|||||||
34096685|NCT03750227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096686|NCT01889563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34096687|NCT04311580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096688|NCT04106765|||COHORT||RETROSPECTIVE|||||||
34096689|NCT05045599|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096690|NCT02170012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096691|NCT01111370|NA|SINGLE_GROUP||OTHER||NONE||||||
34096692|NCT03941886|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This is a stepped wedge cluster-randomized trial. There are total of 7 clusters across Asia. This study involves a period where no intervention will take place at all recruiting units, i.e. routine prenatal care, and then at regular intervals (every 6 weekly), one cluster will be randomized to transit from non-intervention group to intervention group in which first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis for high-risk women.||||
34096693|NCT02747225|||CASE_ONLY||CROSS_SECTIONAL|||||||
34096694|NCT04322695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34096695|NCT02082483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096696|NCT00652613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935824|NCT02668328|NA|SINGLE_GROUP||||NONE||||||
33935825|NCT01941212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935826|NCT05956236|||COHORT||PROSPECTIVE|||||||
33935827|NCT00976261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935828|NCT00901394|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33935829|NCT05743413|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in the study.|The study participants will be enrolled into two parallel groups.||||
33935830|NCT02274766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935831|NCT01487694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935832|NCT05585983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The following are masked in the study: Participant, Care Provider, Investigator, Outcomes Assessor.~The following are not masked: unblinded study nurses at participating sites randomizing participants in the eCRF system. The unblinded study nurses are not otherwise involved or participating in the study."|In this double blind, placebo-controlled clinical trial participants are allocated to either influanza vaccination (active) or to placebo (control).|t|t|t|t
33935833|NCT04771390|RANDOMIZED|CROSSOVER||OTHER||NONE||Part 1: sequential and non-randomized design Part 2: cross-over and randomized design||||
33935834|NCT02447952|NA|SINGLE_GROUP||OTHER||NONE||||||
33935835|NCT01359111|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33935836|NCT03245944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935837|NCT00957034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935838|NCT01640067|NA|SINGLE_GROUP||||NONE||||||
33935839|NCT03750344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935840|NCT00540163|||||PROSPECTIVE|||||||
33935841|NCT00603876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935842|NCT06508697|||COHORT||PROSPECTIVE|||||||
34013942|NCT00016718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|open-label|||||
34013943|NCT05656079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013944|NCT03021694|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34013945|NCT00847106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013946|NCT02506608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013947|NCT05760352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34013948|NCT02795637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096697|NCT01164969|||CASE_ONLY||PROSPECTIVE|||||||
34096698|NCT03880409|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34013949|NCT05253274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The researchers will involve in the data analysis and statistics stages will blind to the group assignment. Patients in study can not be blinded. Also, the person who performed the measurements cannot be blinded due to the nature of VR application. A statistician will analyze the data, and the findings will be reported.|prospective, parallel, two arm, randomized controlled clinical trial||||
34096699|NCT05039385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Investigator: The persons who make the data analysis and decide whether a patient has experienced an outcome of interest will be masked.~Outcome assessors: The persons who assess patients and provide outcome data will be masked."|"This project is based on an, longitudinal, prospective, controlled, randomized, intervention study and blind for the researchers responsible for the study. Thus, the subjects participating in the study will be divided into 2 groups, one of which will perform the exercise program (intervention group, IG), and another that will follow their daily routine treatment without added exercise (control group, CG).~Each group will have 4 measurements in which the corresponding variables will be evaluated: A) before the start of the intervention, B) at 3 months (12 weeks), C) at 6 months (at the end of the intervention, 24 weeks), D) at 9 months (3 months post-intervention, 36 weeks)."|f|f|t|t
34096700|NCT01529151|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
34096701|NCT04992741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The two high schools included in the research will be determined as experimental and control groups by lottery method. By an independent researcher who was not involved in the study, 27 mothers from both schools who agreed to participate in the study will be selected by lottery method. Selected mothers will be called one by one by phone to be informed about the research, and the Informed Consent Form will be filled in via whatsapp and survey/scale forms will be applied. Participants will be blinded. The researcher (YA) cannot be blinded due to the nature of the research. When the research is completed, the data will be transferred to the computer environment by an independent researcher who does not know the A and B groups and the data will be analyzed by a statistician and the findings will be reported"||t|f|f|f
34096702|NCT03031769|||COHORT||CROSS_SECTIONAL|||||||
34096703|NCT00302666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096704|NCT00280189|||CASE_ONLY||PROSPECTIVE|||||||
34096705|NCT03818932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34096706|NCT06106373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096707|NCT01935505|||||PROSPECTIVE|||||||
34096708|NCT02665455|NA|SINGLE_GROUP||OTHER||NONE||||||
34096709|NCT04320082|||COHORT||PROSPECTIVE|||||||
34096710|NCT04228653|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34096711|NCT02072993|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34096712|NCT06114966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33712221|NCT02734940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33712222|NCT01384760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33712223|NCT01325636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712224|NCT03725098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712225|NCT01328925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712226|NCT06278467|||CASE_ONLY||PROSPECTIVE|||||||
34013950|NCT04719104|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study population will include 200 newborns of 35 weeks' gestation or greater who are over 24 hours old. Each baby will be studied only once.~In addition to the routine SBR (capillary blood sample to measure serum bilirubin (jaundice), a paired TcB measurement will be taken 10-14 hours after stopping phototherapy. Taking a TcB measurement will involve using a 'biliflash'. This is a non-invasive measurement that flashes a light against the baby's ear and can be done at the cotside. The test takes less than a minute and does not cause the baby discomfort."||||
34013951|NCT02856009|NA|SINGLE_GROUP||OTHER||NONE||||||
34013952|NCT05852795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34096713|NCT00855582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103328|NCT06688890|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants ignore which product is being used in each intervention.|clinical trial, randomized, crossover.|t|f|f|f
34103329|NCT05806372|||OTHER||CROSS_SECTIONAL|||||||
33712227|NCT02817191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712228|NCT05849389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712229|NCT04799431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712230|NCT04605315|||COHORT||RETROSPECTIVE|||||||
33712231|NCT03982628|||COHORT||RETROSPECTIVE|||||||
33712232|NCT02343627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712233|NCT00081640|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33712234|NCT01456247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33712235|NCT04889456|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A prospective interventional sequential cohort study with a transition period||||
33712236|NCT02695498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712237|NCT01382823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712238|NCT00023764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712239|NCT04074460|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients are blinded to the anaesthetic type given. Statistician also blinded.||t|f|f|t
33712240|NCT00056316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712241|NCT04172506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712242|NCT04813406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792879|NCT06345560|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pre-bariatric surgery pharmacokinetics study of Drospirenone compare with post-bariatric surgery||||
33935843|NCT02449915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33935844|NCT00740818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935845|NCT03817931|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization using a random number system will be performed by the compounding pharmacy. Records linking subject number to their allocation will be kept by the pharmacy, inaccessible to the investigator, patient, care providers.|Permuted block stratified by recruitment site|t|t|t|t
33935846|NCT04340687|||COHORT||RETROSPECTIVE|||||||
33935847|NCT02906098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935848|NCT05481944|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935849|NCT06415916|||COHORT||PROSPECTIVE|||||||
33935850|NCT01960556|||COHORT||PROSPECTIVE|||||||
33935851|NCT04063540|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34013953|NCT04888676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participants Participants will be blinded to the technique used, since the patient will attend the same number of visits and he can not differentiate between different restorative materials.~Blinding of the operator The operator cannot be blinded because of the use of different restorative materials applied in each group.~The outcome assessor The outcome assessor will be blinded to the material used. This will be performed by M.A. and Y.H. Therefore it is necessary that the assessors won't be included in the preclinical assessment."|Randomized Parallel Controlled Trial. Trial type: Two, Parallel arm design. Trial framework: Equivalence frame Allocation ratio: 1:1.|t|f|t|t
34013954|NCT02373670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013955|NCT03166813|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34013956|NCT02948920|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34013957|NCT00754013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013958|NCT04194684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013959|NCT02677181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013960|NCT04555304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34013961|NCT01124695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013962|NCT02766426|NA|SINGLE_GROUP||||NONE||||||
34013963|NCT00692146|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34013964|NCT02039414|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013965|NCT04674397|||COHORT||PROSPECTIVE|||||||
34013966|NCT00283322|||COHORT||PROSPECTIVE|||||||
34013967|NCT00553449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013968|NCT01974024|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34013969|NCT06028503|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The RC will have a shuffled stack of envelopes with a group assignment in each. As participants meet inclusion into the study, their information, including Study ID, will be placed in one of the shuffled envelopes. The envelope will be placed in another envelope and sealed. Once approximately 10 participants are randomized to each group, the RC will contact all participants who have been randomized to share the date and time of the intervention and ask them to complete the 30-minute baseline surveys comprised of self-report measures (located in measures section) that they will receive by email. If recruitment slows down, we will do the randomization once 5 participants express interest in the study. The RC will then send a unique Qualtrics link to each participant (to prevent participants from needing to enter identifying information on the survey). The baseline self-report survey is described below in the Measures section.|his study will compare the efficacy of ACT+CGM+LE to CGM+LE, or LE alone, on hemoglobin HbA1c in 60 people with T2D recruited from a rural population.|t|f|f|f
34013970|NCT05730504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34013971|NCT00336128|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34013972|NCT00841360|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34013973|NCT00831623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013974|NCT01829919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013975|NCT04031612|||OTHER||PROSPECTIVE|||||||
34013976|NCT01408563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096714|NCT02346370||SEQUENTIAL||TREATMENT||NONE||The study was planned to include a Dose Escalation portion utilizing a standard 3 + 3 dose escalation design. Participants were enrolled sequentially into their assigned dose cohort. The Treatment Period consisted of 21-day treatment cycles with administration of PEGPH20 on Day 1 (doses tested were 1.6, 3.0, and 2.2 ug/kg) and docetaxel (standard dosing 75 mg/m\^2 for all participants) on Day 2 of each cycle.||||
34096715|NCT03742544|||COHORT||PROSPECTIVE|||||||
34096716|NCT01330524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34096717|NCT01903200|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34096718|NCT04607447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096719|NCT05099276|RANDOMIZED|PARALLEL||OTHER||SINGLE|Both oral TXA and oral placebo will be distributed to subjects in bottle marked with subject name and instructions for use following discharge from PACU.||t|f|f|f
34096720|NCT02054195|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34096721|NCT03408145|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33935852|NCT01513629|||COHORT||RETROSPECTIVE|||||||
33935853|NCT00669591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935854|NCT03042585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose-Escalated Total Body Irradiation (TBI) of 4 levels. Palifermin (Kepivance) is being supplied by the sponsor and is FDA approved to decrease the incidence and duration of severe oral mucositis in participants with hematologic malignancies who receive high doses of chemotherapy and radiation therapy followed by stem cell rescue.||||
33935855|NCT00449995|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33935856|NCT02117492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935857|NCT05042570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33935858|NCT02054663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935859|NCT03790267|||COHORT||PROSPECTIVE|||||||
33935860|NCT01381731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935861|NCT04299750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33935862|NCT01855191|||COHORT||PROSPECTIVE|||||||
33935863|NCT00958191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013977|NCT03477955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34013978|NCT02760706|||CASE_ONLY||PROSPECTIVE|||||||
33935864|NCT00912496|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33935865|NCT06136910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935866|NCT02726607|RANDOMIZED|PARALLEL||PREVENTION||NONE||We employed a matched randomized pilot study design in two government hospitals; one randomized to receive the HITSystem 2.0 intervention while the other maintained standard of care PMTCT services.||||
33935867|NCT04884633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935868|NCT01670825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935869|NCT01430689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33935870|NCT05008367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935871|NCT04813549|||COHORT||PROSPECTIVE|||||||
33935872|NCT02483611|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33935873|NCT00985140|||COHORT||PROSPECTIVE|||||||
33935874|NCT02510976|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33935875|NCT00860704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935876|NCT00054860|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33935877|NCT02098655|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33935878|NCT04170491|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33935879|NCT05295836|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A randomized crossover study will be conducted, in which 4 international walkers will perform 3 different conditions: CON) water intake of 26 mL/kg/weight at 16°C; PLA) 26 mL/kg/weight + placebo at 28°C and GLY) intake of 1.2 g glycerol + 26 mL/kg/weight at 28°C.|t|f|f|f
33935880|NCT04696328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712243|NCT04134013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Project manager, participants, and investigator will be blinded to study. The registered dietitian will not be blinded.|Participants will be randomized into one of two arms: 1) nutrition+chiropractic or 2) chiropractic only|t|f|t|t
33935881|NCT06138392|||COHORT||PROSPECTIVE|||||||
33935882|NCT03034109|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712244|NCT03861975|NA|SINGLE_GROUP||SCREENING||NONE||This is an interventional, non-therapeutic screening trial comparing two measurement devices cross-sectionally.||||
33935883|NCT02339454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935884|NCT00262561|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34013979|NCT03202901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34013980|NCT02097602|||||PROSPECTIVE|||||||
33712245|NCT03836937|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized clinical control trial study||||
33712246|NCT00002916||||TREATMENT||||||||
33712247|NCT04980040|||COHORT||PROSPECTIVE|||||||
33712248|NCT01779401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712249|NCT02945683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33712250|NCT00050518|RANDOMIZED|PARALLEL||PREVENTION||||||||
33712251|NCT05933395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study has a non-randomized umbrella design. Participants will be assigned to a treatment arm based on tumor/plasma genetic profiling and treatment history using the primary treatment phase algorithm.||||
33712252|NCT01740193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33712253|NCT06245135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single: Outcomes Assessor|Parallel assignment|f|f|f|t
33712254|NCT01548651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712255|NCT00572702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712256|NCT05786820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The experimental pine bark dietary supplement is packaged in neutral capsules, which are dispensed to the study patients in bottles with code labels.|randomized, double-blind, placebo-controlled 2-arm, parallel group clinical trial|t|t|t|t
33935885|NCT00756821|||COHORT||CROSS_SECTIONAL|||||||
33935886|NCT03826316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935887|NCT04491292|||COHORT||CROSS_SECTIONAL|||||||
33935888|NCT01657214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935889|NCT01646151|||COHORT||PROSPECTIVE|||||||
33935890|NCT04840849|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33935891|NCT04085991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935892|NCT00411879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935893|NCT00035412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935894|NCT01594463|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33935895|NCT06249646|||COHORT||RETROSPECTIVE|||||||
33935896|NCT01138293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935897|NCT00470873|||COHORT||PROSPECTIVE|||||||
34013981|NCT01772264|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34013982|NCT04946565|||CASE_ONLY||PROSPECTIVE|||||||
34013983|NCT02140307|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34013984|NCT00560027|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34013985|NCT06411340|||COHORT||PROSPECTIVE|||||||
34013986|NCT06051383|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33935898|NCT02461849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935899|NCT03061227|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33935900|NCT04307589|||OTHER||PROSPECTIVE|||||||
33935901|NCT05749874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935902|NCT03011073|||CASE_ONLY||PROSPECTIVE|||||||
33935903|NCT03832166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Prospective, randomized two group study|f|f|f|t
33935904|NCT02788851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935905|NCT05337735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935906|NCT02721446|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33935907|NCT01266421|||COHORT||PROSPECTIVE|||||||
33935908|NCT05098249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33935909|NCT03731975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935910|NCT02828462|||CASE_CONTROL||PROSPECTIVE|||||||
33935911|NCT00884936|||CASE_CONTROL||PROSPECTIVE|||||||
33935912|NCT01486940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935913|NCT01061827|||CASE_ONLY||PROSPECTIVE|||||||
33935914|NCT05680090|||COHORT||PROSPECTIVE|||||||
34096722|NCT05471661|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients from Hematology Department- Hematopoietic Stem Cell Transplantation Unit, George Papanikolaou Hospital and Bone Marrow Transplantation Unit of the University Hospital of Patras will be eligible to receive penta-STs as treatment for infection of one or more of the target-pathogens or for increasing pathogen load in two consecutive timepoints, following any type of allogeneic transplant.~If patients are receiving steroids for treatment of GVHD or for other reasons, dosage must have been tapered to ≤0.5mg/kg prednisone (or equivalent) prior to study enrollment. Patients may not have received ATG, or Campath or other immunosuppressive monoclonal antibodies in the last 28 days."||||
33792880|NCT03967795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A bolus of Dipeptiven (Glutamine-Alanine) administered intravenously over 30 minute (20 gramme of N2-L-Alanyl-L-Glutamine solution, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes).||||
33792881|NCT00816049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792882|NCT00269516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792883|NCT05831917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792884|NCT05664880|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935915|NCT02846766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096723|NCT03536962|||COHORT||PROSPECTIVE|||||||
33935916|NCT03196973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096724|NCT04726488|RANDOMIZED|PARALLEL||TREATMENT||NONE|All investigators will be blinded (i.e., closed envelop open in the OR to choose which approach will be performed either periareolar Vs infra-mammary approach in minimally invasive cardiac surgery)|||||
34096725|NCT04718389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study.|This is randomized, double-blind, parallel group, multi-center and non-inferiority study.|t|f|t|f
34096726|NCT01095874|||COHORT||PROSPECTIVE|||||||
34096727|NCT01133106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096728|NCT01814332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096729|NCT01845415|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34096730|NCT06353516|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This study is a double-blinded randomized controlled trial. The group assignment is conducted by the pre-generated random number table. The participant, investigator and the outcome assessor are blinded to the group assignment.|The participants are randomly assigned to total intravenous anesthesia group or inhaled gas anesthesia group|t|f|t|t
34096731|NCT05708222|||OTHER||PROSPECTIVE|||||||
34096732|NCT04071483|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34096733|NCT00552058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096734|NCT04411095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096735|NCT06265805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34096736|NCT04465149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The subjects were children undergoing orthodontic treatment in whom early extraction was indicated to facilitate their treatment in some specific conditions (i.e. posterior crowding, altered second molar eruption, non-extraction approach). For each subject, the first germectomy was scheduled 15 days apart. The same senior operator, assisted by the same practitioner, completed all the surgical procedures. All interventions made with mepivacaine were performed with the same anaesthetic technique routinely used in Oral surgery (IANB). The technique was complemented with anaesthesia of the buccal nerve, as routine for this technique, administering another 1.8 ml of the same anaesthetic used in each intervention. On the other hand, the surgical procedures in articaine cases were made practising a plexus technique, performing a deep buccal injection distally to the second mandibular molar.||||
34096737|NCT05172336|||COHORT||PROSPECTIVE|||||||
34096738|NCT04333654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096739|NCT02636322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096740|NCT00177489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096741|NCT02372032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34096742|NCT01104272|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34096743|NCT02746731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34096744|NCT05365464|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34096745|NCT06021444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. Blind: Investigator~2. Un-blind: Investigator(or CRC)."|1:1 Parallel.|f|t|f|t
34096746|NCT02594878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103330|NCT05498220|NA|SINGLE_GROUP||TREATMENT||NONE||The study will use a Simon two-stage design. In the first stage 27 evaluable subjects will be recruited. If there are at least 13 (≥ 13) subjects with a partial or complete response after 4 cycles, another 17 subjects will be enrolled and treated in the second stage of the trial, for a total of 44 evaluable subjects.||||
34103331|NCT06499909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103332|NCT00214526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792885|NCT03419325|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||After being consented, patients will undergo rapid ex vivo platelet functional testing (i.e., residual platelet reactivity units, PRU, measured using the VerifyNow P2R12 assay for Clopidogrel response) and CYP2C19 genotyping. Patients will then be categorized into 4 groups based on tests results: 1) high on-treatment platelet reactivity (HTPR)/ CYP2C19 loss-of-function (LOF) alleles (i.e., presence of both HTPR and CYP2C19 LOF alleles); 2) HTPR/No-LOF (presence of HTPR, but no CYP2C19 LOF allele); 3) No-HTPR/LOF (presence of a CYP2C19 LOF allele, but no HTPR); 4) No-HTPR/No-LOF (absence of both HTPR and CYP2C19 LOF alleles).||||
33792886|NCT02783755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792887|NCT06553794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33792888|NCT04465734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792889|NCT00839046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33792890|NCT00000635||||TREATMENT||NONE||||||
33792891|NCT00332644|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33792892|NCT01377259|||CASE_CONTROL||PROSPECTIVE|||||||
33792893|NCT00075972|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33792894|NCT02469337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33792895|NCT06372912|||COHORT||RETROSPECTIVE|||||||
33792896|NCT00755118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935917|NCT00004833|RANDOMIZED|||TREATMENT||||||||
33935918|NCT04583267|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34013987|NCT02844517|NA|SINGLE_GROUP||OTHER||NONE||The objective of the study is for clinical staff to gain experience using the proposed artificial pancreas system named inControl and the inControl Cloud and assess 24/7 in-home usability prior to initiating a large randomized controlled trial. Study subjects will wear the study insulin pump and CGM for approximately 2-4 weeks.||||
34013988|NCT01231750|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34013989|NCT00886041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712257|NCT04984720|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The participant, investigator and care provider will be aware of the intervention and the sequence in which it is administered.~The outcomes will be assessed by an outcome assessor who will not be aware of the arm into which the participant was randomized prior to the assessment."|"* A run-in period of 4 weeks prior to randomization to optimize therapy and to document the baseline frequency and severity of headaches.~* At the end of run-in period, the patients will be randomly allocated into the smartphone based digital App first arm or the paper diary first arm. The digital app and paper diary- are available in Hindi as well as English.~* Randomization will be done by computer generated random number table.~* Concealment: The sequence of allocation will be held concealed by opaque sealed envelopes.~* Participant and investigator both will be aware of the allocated group - it is an open label study.~* Participants will be followed up at 4 weeks and the headache characteristics and outcome parameters would be captured from the app and paper diary respectively.~* Subsequently patients would be crossed over to the other arm and 4 weeks after the cross over, parameters would again be assessed."|f|f|f|t
33792897|NCT06070415|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The interventor providing the education sessions will be blinded to group allocation The outcome assessor will be blinded to the interventions|Two arms study, experimental vs control|f|t|f|t
33792898|NCT04533464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792899|NCT02785718|NA|SINGLE_GROUP||||NONE||||||
33792900|NCT01831791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792901|NCT03939819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792902|NCT03321344|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized||||
33792903|NCT02319122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792904|NCT04658212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792905|NCT04330950|||COHORT||PROSPECTIVE|||||||
33792906|NCT05696977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open labelled, prospective,non-randomized, two-arms,parallel groups, non-placebo controlled clinical trial||||
34013990|NCT04969861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34013991|NCT01452594|||COHORT||PROSPECTIVE|||||||
34013992|NCT04072276|||COHORT||PROSPECTIVE|||||||
34013993|NCT00761449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34013994|NCT02902718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34013995|NCT01949753|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34013996|NCT06394726|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Randomized Controlled Study|f|f|f|t
34013997|NCT03065595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, randomized controlled trial|t|t|t|f
34013998|NCT04815330|||COHORT||PROSPECTIVE|||||||
34013999|NCT00192270|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34014000|NCT04189731|||CASE_ONLY||PROSPECTIVE|||||||
34014001|NCT02522403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014002|NCT01405287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014003|NCT01478737|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34014004|NCT02931045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||f|t|t|t
34014005|NCT02080832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014006|NCT01685541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34014007|NCT06321003|||CASE_CONTROL||PROSPECTIVE|||||||
33935919|NCT06267495|||OTHER||RETROSPECTIVE|||||||
33935920|NCT05422833|||COHORT||RETROSPECTIVE|||||||
33935921|NCT01836029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935922|NCT01728649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935923|NCT00491751|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33935924|NCT02159365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935925|NCT01642004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935926|NCT03607240|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33935927|NCT02061163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33935928|NCT04272814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||compression therapy vs standard therapy||||
33935929|NCT03307473|||COHORT||PROSPECTIVE|||||||
33935930|NCT03184766|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33935931|NCT05085327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes (erythema) assessor is blinded to treatment allocation||f|f|f|t
33935932|NCT02393989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935933|NCT01961128|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33935934|NCT03249441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clients are randomly assigned to one of two groups, Treatment as Usual (TAU) or Compassion-focused therapy plus Treatment as Usual (CFT). The outcomes assessor is blind to which of the two groups participants are assigned to.|This study utilised a randomised controlled trial (RCT) research design to investigate the efficacy of a group based CFT intervention programme. Participants were randomly allocated to one of the two groups, CFT plus Treatment as Usual (CFT) or Treatment As Usual (TAU), and psychological measures were administered at three time points (pre-intervention, post-intervention and follow-up assessment at three months follow up). The primary outcomes included self-compassion, shame and self-criticism. Emotional eating and depressive symptoms were assessed as secondary outcomes.|f|f|f|t
34014008|NCT02041091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792907|NCT05288868|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33792908|NCT03009006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792909|NCT02773017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712258|NCT00373347|||COHORT||PROSPECTIVE|||||||
33712259|NCT01528488|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33712260|NCT06241872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33712261|NCT00824512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33712262|NCT03954925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712263|NCT02066246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712264|NCT06390800|||COHORT||PROSPECTIVE|||||||
33712265|NCT04388709|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort A: Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once Cohort B: Best supportive care||||
33712266|NCT05312723|||OTHER||CROSS_SECTIONAL|||||||
33792910|NCT01799148|||COHORT||PROSPECTIVE|||||||
33792911|NCT02854319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935935|NCT06186895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
34014009|NCT04334655|||CASE_ONLY||PROSPECTIVE|||||||
33935936|NCT06235229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935937|NCT01266070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014010|NCT04556552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|sham stimulation|nVNS versus sham stimulation|t|t|t|t
34014011|NCT01389934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34014012|NCT04799652|||COHORT||PROSPECTIVE|||||||
34014013|NCT01148641|||CASE_CROSSOVER||PROSPECTIVE|||||||
34014014|NCT00681759|||||PROSPECTIVE|||||||
34014015|NCT01269281|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014016|NCT02425215|||COHORT||PROSPECTIVE|||||||
34014017|NCT02974036|||COHORT||PROSPECTIVE|||||||
34014018|NCT00247299|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014019|NCT05692076|RANDOMIZED|PARALLEL||PREVENTION||NONE||"• we sought statistical advice regarding the sample size needed for the study~sample size was calculated using G power program to detect significant difference.~* To detect the incidence of atelectasis in these patients we performed a pilot study included 15 patients using simple mask as oxygen therapy, the results showed an incidence of 50% rate of atelectasis according to the inclusion and exclusion criteria~* To be able to detect 30% reduction in the incidence of atelectasis we need to include 43 patients in each group~* Alpha error=.05, 80 % power of the study with equal group assignment~Group (A) :43 patients (control group):~• Patient will receive conventional oxygen therapy via nasal prongs , normal oxygen mask or venturi mask~Group (B) 43 patients ( HVNI group):~• Patient will receive HVNI therapy"||||
34014020|NCT04732364|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014021|NCT01816815|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34014022|NCT01651546|NA|SINGLE_GROUP||||NONE||||||
34014023|NCT00003621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014024|NCT05555394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the patients don't know what intervention of study. Investigator don't know the allocation of patients outcomes assessor don't know the allocation of patients.|clinical trial randomized allocated controlled|t|f|t|t
34014025|NCT03716076|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34014026|NCT00793026|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014027|NCT03050918|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a single center, pragmatic, randomized, controlled clinical trial.||||
34014028|NCT05333237|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||3 interventions will be administered in fasted healthy volunteers in a random sequence on 3 different days.|t|f|t|t
34014029|NCT06392763|||COHORT||RETROSPECTIVE|||||||
34014030|NCT03574922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34014031|NCT04252222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014032|NCT01360502|||||PROSPECTIVE|||||||
34014033|NCT01021241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014034|NCT03601546|||COHORT||PROSPECTIVE|||||||
34014035|NCT03650959|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014036|NCT06082674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study Blinded the investigator and outcome assesors||f|f|t|t
34014037|NCT00673933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014038|NCT02932020|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34014039|NCT03329807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014040|NCT03563846|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014041|NCT04860596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34014042|NCT02526095|||COHORT||PROSPECTIVE|||||||
33712267|NCT06175091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712268|NCT06007885|NA|SINGLE_GROUP||TREATMENT||NONE||A 26-week individual-based convergent mixed methods design||||
33712269|NCT00004760||||ECT||||||||
33712270|NCT03475537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712271|NCT00479076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712272|NCT03210818|||COHORT||PROSPECTIVE|||||||
33712273|NCT01649661|||CASE_CROSSOVER||PROSPECTIVE|||||||
33712274|NCT03608592|NA|SINGLE_GROUP||TREATMENT||NONE||A package of 100ml normal saline with 10\^6/kg umbilical cord derived MSCs suspension will infused from central venous catheter.||||
33712275|NCT05174260|||COHORT||PROSPECTIVE|||||||
33720673|NCT05397665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|AT-007 and its matching placebo will have the same presentation, the same aspect and taste in order to be indistinguishable, and they will be supplied and used in the same conditions.|Randomized, double blind study|t|t|t|t
33720674|NCT00922831|||COHORT||PROSPECTIVE|||||||
33720675|NCT02529618|||CASE_CONTROL||PROSPECTIVE|||||||
33720676|NCT05195463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which group they belongs to.||t|f|f|f
33720677|NCT03195088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792912|NCT06158048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33792913|NCT05679713|||OTHER||CROSS_SECTIONAL|||||||
33792914|NCT02101190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792915|NCT00545077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935938|NCT03439722|||CASE_CONTROL||PROSPECTIVE|||||||
33935939|NCT02564562|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33935940|NCT06367335|||COHORT||RETROSPECTIVE|||||||
34014043|NCT02357342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096747|NCT04957524|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants will be masked to which treatment they are receiving in which order. They will be randomly assigned to one of two groups. The randomization assignments will be generated by the principal statistician in the UCLA Department of Urology with a random number generator algorithm in Microsoft Excel so that the proposed recruited patients will be randomly assigned to control or intervention group in an equal amount per group. This will be stored in a central location on a password protected system on the UCLA Health Box for the research staff to access and as each patient is randomized they will use the next available group assignment on the sheet and cross them off. This will be closely monitored to maintain appropriate use. The randomization will occur at the time of enrollment.|Patient will then be randomized to treatment A followed by treamtent B (Group 1) or treatment B followed by treatment A (Group 2).|t|t|f|t
33712276|NCT03779724|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective randomized controlled trial aimed to recruit 50 patients with MS from the physical medicine and rehabilitation clinic of Ankara Training and Research Hospital, Health Sciences University, Ankara, Turkey. Fifty patients who met the inclusion criteria were enrolled in the study. Fifty patients were randomized to two groups: isokinetic exercise (Group 1) (n=25) and home exercise (Group 2) (n=25). Randomization was completed using sequentially numbered, opaque envelopes by the investigator. All patients gave informed consent before the assessment. The outcome measures were assessed initially and at eighth week after the treatment. Group 1 performed isokinetic concentric quadriceps and hamstring strengthening exercises under supervision and Group 2 performed lower extremity muscle strengthening and balance exercises at home.||||
33712277|NCT01118650|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712278|NCT05667545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To study the effect of self assembling-peptide P11-4 treatment on dentine remineralization, after removal of all infected dentine (Remineralization of caries affected dentin),|t|f|f|f
33712279|NCT01121822|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712280|NCT01635946|NA|SINGLE_GROUP||||NONE||||||
33712281|NCT06150313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, outcomes assessor)|Single-blind, parallel group, randomized controlled trial|t|f|f|t
33712282|NCT01025791|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33712283|NCT00825591|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33712284|NCT04235478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712285|NCT04654130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is an effectiveness trial investigating neurofeedback as an intervention for both symptoms of PTSD, and the commonly associated cognitive impairment/dysfunction (e.g., attention, executive function, processing speed). Participants will be randomized to one of two conditions: NFB or Wait List.|f|f|f|t
33712286|NCT02596308|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33712287|NCT05238441|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33712288|NCT02016053|||COHORT||PROSPECTIVE|||||||
33712289|NCT00911053|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33712290|NCT02088047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712291|NCT03233503|||OTHER||CROSS_SECTIONAL|||||||
33712292|NCT00420966|||OTHER||PROSPECTIVE|||||||
33712293|NCT01927367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712294|NCT03733834|||CASE_CONTROL||PROSPECTIVE|||||||
33712295|NCT02658929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712296|NCT05695898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The Phase 2 portion of the study will not be initiated.||||
33712297|NCT05858554|||CASE_ONLY||RETROSPECTIVE|||||||
33712298|NCT01441505|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33712299|NCT01423058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712300|NCT01654536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712301|NCT03183076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|MD María Ingrid Alanis Guevara. Neurologist Hospital of the Western National Medical Center. Guadalajara. Mexico|Clinical trial, Parallel, controled|f|f|t|f
33712302|NCT00064194|RANDOMIZED|||PREVENTION||TRIPLE|||t|t|t|f
33712303|NCT00751270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712304|NCT00089245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712305|NCT02319889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712306|NCT04022902|||OTHER||OTHER|||||||
33712307|NCT06012825|||COHORT||PROSPECTIVE|||||||
33712308|NCT03379532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33712309|NCT03647397|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33712310|NCT01288495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712311|NCT04691505|||COHORT||RETROSPECTIVE|||||||
33712312|NCT04450368|||OTHER||PROSPECTIVE|||||||
33712313|NCT05015608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935941|NCT06011785|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking required.|"The study design is a controlled non-blinded clinical study without randomization to test the effectiveness of an intervention among individuals with symptoms of Silicosis as a result of working as quartzite miners. The intervention to be studied is a homeopathic preparation of Silica 12CH on a sample of clients with Silicosis already receiving ongoing conventional medical care. The intervention is Silica 12CH given over one year: a single dose at intervals of three months (three times in the study period).~Participants will be recruited locally through the clinic where they already receive ongoing medical attention. The local secretary of health authorizes the release of the patient files. Potential participants will be given printed information about the study details along with information about how to participate and the associated deadlines for joining the study. Interested individuals will be given the informed consent form."||||
33935942|NCT00294229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935943|NCT01726504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935944|NCT04142762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935945|NCT01938391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935946|NCT02943044|||COHORT||PROSPECTIVE|||||||
33935947|NCT00689910|||COHORT||PROSPECTIVE|||||||
33935948|NCT03551392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Research assistants who administer pre and post measures will be masked, as well as participants who receive the intervention.|This is a blinded parallel group sham controlled pilot trial, with half the participants in each group randomized to the real NIR treatment and half to the sham treatment condition.|t|t|f|t
33935949|NCT05472376|||CASE_CONTROL||RETROSPECTIVE|||||||
33935950|NCT00342472|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33935951|NCT02734849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33935952|NCT04684706|NA|SINGLE_GROUP||OTHER||NONE||||||
33935953|NCT03842761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935954|NCT00767494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935955|NCT04419597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935956|NCT00600249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935957|NCT05939700|||COHORT||PROSPECTIVE|||||||
33935958|NCT03491852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33935959|NCT00821756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935960|NCT02074475|||COHORT||PROSPECTIVE|||||||
33935961|NCT01222936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935962|NCT05204108|||COHORT||PROSPECTIVE|||||||
34014044|NCT00006387|NA|SINGLE_GROUP||TREATMENT||||||||
34014045|NCT06107478|||OTHER||PROSPECTIVE|||||||
34014046|NCT04419623|NA|SINGLE_GROUP||TREATMENT||NONE||Up to 18 subjects will participate in a dose-finding safety lead-in to determine the recommended TL-895 dose.||||
34014047|NCT06221878|||COHORT||RETROSPECTIVE|||||||
34014048|NCT04247919|||COHORT||RETROSPECTIVE|||||||
34014049|NCT03840252|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014050|NCT04587102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||vibration Group (A) will receive low vibrational training in the form of whole body vibration for 8 weeks , while group B is the control, both groups will receive their routine medical care and physical therapy rehabilitation.|f|f|f|t
34014051|NCT00136578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014052|NCT05818748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomised|f|f|f|t
34014053|NCT02446834|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
34014054|NCT06130319|||CASE_ONLY||CROSS_SECTIONAL|||||||
34025318|NCT04855578|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|"It is impossible to blind physicians or study participants. However, medical staff on study units will not be told that gabapentinoids are being targeted by the trial until after the control period has ended. The rationale is that prior knowledge of the goal may bias medical staff in favour of gabapentinoid deprescription. Similarly, participants recruited during the control period will not be told that gabapentinoids are targeted. Since medical staff work in multiple study units in a given year, all units will transition from the control phase to the intervention phase simultaneously to prevent contamination between the control and intervention group.~It is impossible to blind outcome assessors at the time of follow-up. Undue influence on the investigator by outcome assessors will be mitigated through the use of a standardized survey that do not depend on the judgement of outcome assessors. Additionally, patient data will be anonymized with a unique identifier prior to analysis."|Prospective before-and-after study involving five medical wards at two health centres. All wards will start in the control phase and enrolled participants will receive standard therapy. Once the pre-specified target of a 80 participants have been enrolled, all five wards will simultaneously transition into the intervention phase. All subsequently enrolled participants will receive the intervention until another 80 participants are enrolled. The control and intervention phases are expected to take approximately 5 months each.|f|f|t|f
34025319|NCT02051062|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34025320|NCT00856375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025321|NCT05686226|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm phase II clinical trial.||||
34025322|NCT02851693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025323|NCT04665466|||CASE_CONTROL||PROSPECTIVE|||||||
33935963|NCT06161324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization list will remain hidden from the responsible physical therapist who will implement the treatment in the groups (he/she will be informed on the first day of the intervention for each patient). Due to the nature of the treatment, the intervention is not blinded between participants and clinicians. However, the analysis of the data will be 'blind' to all both parties, assessor and investigator.||f|t|t|t
33935964|NCT04535258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Stepped-wedge cluster randomized (18 institutions, 4 waves)||||
33935965|NCT02021149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935966|NCT03186040|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after comparison||||
33935967|NCT01620658|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33935968|NCT02382692|||COHORT||PROSPECTIVE|||||||
33935969|NCT06408987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712314|NCT01440660|||COHORT||PROSPECTIVE|||||||
33935970|NCT00893763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33935971|NCT02334137|||COHORT||PROSPECTIVE|||||||
33935972|NCT01326910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33935973|NCT01076270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935974|NCT00133185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33935975|NCT00859716|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025324|NCT06378398|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025325|NCT06634082|||COHORT||RETROSPECTIVE|||||||
34025326|NCT00577395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33935976|NCT02672644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33935977|NCT02084316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935978|NCT02910349|||COHORT||PROSPECTIVE|||||||
33935979|NCT01994109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935980|NCT01614522|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33712315|NCT05123768|||COHORT||CROSS_SECTIONAL|||||||
33712316|NCT02943278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712317|NCT05908513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|We will use double blind for this study. Neither the participants nor the researcher knows which treatment or intervention participants are receiving until the clinical trial is over.||t|t|t|t
33712318|NCT03902574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712319|NCT04772911|||CASE_CONTROL||PROSPECTIVE|||||||
33712320|NCT03506178|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34014055|NCT00677079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014056|NCT02984774|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34014057|NCT05862194|||COHORT||RETROSPECTIVE|||||||
34014058|NCT00038649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014059|NCT02603978|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34014060|NCT00908518|||COHORT||PROSPECTIVE|||||||
34014061|NCT05182619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014062|NCT05177562|||COHORT||CROSS_SECTIONAL|||||||
34014063|NCT02422914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014064|NCT06158074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33935981|NCT02797288|||CASE_ONLY||PROSPECTIVE|||||||
33935982|NCT02711410|||COHORT||PROSPECTIVE|||||||
34014065|NCT04798235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935983|NCT02820831|||COHORT||PROSPECTIVE|||||||
33935984|NCT03380169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients do not know which group they belongs to, and all wounds (for both experimental and control group) will be covered by gauze dressing at the top.|This is a single-blind two-arm parallel randomized controlled trial on occlusive ionic silver-containing dressing conducted in Princess Margaret Hospital (PMH). PMH is a major acute general hospital in Kowloon West Cluster in Hong Kong, providing 1,542 beds to maintain a wide range of specialist care. There are around 150 abdominal colorectal surgery provided every year in our department. Both the subjects, data collectors and outcome assessors will be blinded to the type of dressing being used. Eligible inpatients receiving colorectal surgery from the department of surgery will be consecutively recruited in each surgical ward (namely, A4 ward, B4 ward and CD4 ward).|t|f|f|f
33935985|NCT00031915||||TREATMENT||NONE||||||
33935986|NCT02052154|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33935987|NCT01308489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33935988|NCT04198311|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will participate in sessions individual Cognitive Behavioral Therapy for Insomnia (CBT-I).||||
33935989|NCT00118924|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34014066|NCT03237533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014067|NCT03216694|||COHORT||RETROSPECTIVE|||||||
34014068|NCT04221607|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility of intervention||||
34014069|NCT05709483|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34014070|NCT03367325|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34014071|NCT02595008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014072|NCT06178159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014073|NCT04397952|||CASE_CONTROL||PROSPECTIVE|||||||
34014074|NCT00384878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014075|NCT00106470|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34014076|NCT03832699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014077|NCT03425279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014078|NCT00033904|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014079|NCT04462471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014080|NCT02629913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014081|NCT03605251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014082|NCT01425723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014083|NCT01034787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014084|NCT02516904|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34014085|NCT00877357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014086|NCT00788502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014087|NCT02191007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014088|NCT04153019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014089|NCT04808830|||OTHER||PROSPECTIVE|||||||
34014090|NCT03026972|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014091|NCT04792359|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Exploratory, interventional, prospective, uncontrolled, single arm, monocentric study||||
34014092|NCT01524913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014093|NCT04390906|||COHORT||PROSPECTIVE|||||||
34014094|NCT02855606|||OTHER||PROSPECTIVE|||||||
34014095|NCT00999180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33935990|NCT01740765|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33935991|NCT01818128|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33935992|NCT02336191|||COHORT||PROSPECTIVE|||||||
34014096|NCT00076713|||COHORT||PROSPECTIVE|||||||
34014097|NCT03786133|||CASE_CONTROL||RETROSPECTIVE|||||||
34014098|NCT04882566|||COHORT||PROSPECTIVE|||||||
34014099|NCT00037102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014100|NCT04793074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014101|NCT03345394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|researchers had no contact with participants during the 12 week trial|Single-blind randomized controlled trial|f|f|t|f
34014102|NCT06455436|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34014103|NCT02050425|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34014104|NCT03962582|NA|SINGLE_GROUP||OTHER||NONE||comparing two different back support to access if there are postural and functional differences.||||
34014105|NCT03602040|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This feasibility study will be using mixed methods and will be conducted in 2 phases.Phase 1 of the study is an uncontrolled clinical trial of the psychoeducational education. Phase 2 is a nested qualitative component of the feasibility study and will be comprise of at least 7 semi-structured interviews lasting up to 30 minutes with patients who participated in the trial.||||
34014106|NCT06383871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014107|NCT05775822|NA|SINGLE_GROUP||SCREENING||NONE||||||
34014108|NCT06071819|||CASE_CONTROL||RETROSPECTIVE|||||||
34014109|NCT01229657|||COHORT||RETROSPECTIVE|||||||
34014110|NCT06181799|||CASE_CONTROL||PROSPECTIVE|||||||
34014111|NCT01839513|||COHORT||PROSPECTIVE|||||||
34014112|NCT03780946|||CASE_CONTROL||PROSPECTIVE|||||||
34014113|NCT02939014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014114|NCT02053129|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014115|NCT02867475|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014116|NCT04061642|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33712321|NCT02612324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712322|NCT02299297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712323|NCT06373627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712324|NCT01240720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712325|NCT00489021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792916|NCT03816124|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with knee osteoarthritis with Kellgren-Lawrance scale stage 3-4 will receive radiofrequency ablation to their genicular nerves and will be evaluated before treatment, 3 weeks and 3 months after treatment.||||
33935993|NCT03595982|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Depending on the group the person gets randomized into they will receive 60 mg of nifedipine at 0h vs 30 mg of nifedipine at 0h followed by 30 mg extra at 12h, These medications will be administered by a nurse or physician on the floor.~After 12h and at the end of the 24h (plus or minus 30 min) a blood sample (2cc) with be obtained and sent to Mount Sinai Hospital to determine serum Procardia levels. This blood samples will be stored until this research study is finished and will be disposed after. A total of 20cc of blood will be obtained from each patient.~Also the patient will take a survey of side effects of the BP medication. BPs will be measured Q 4h and documented at 0h, 4h, 8h, 12h, 16h, 20h and 24h (plus or minus 30 min)"||||
33935994|NCT03185091|NA|SINGLE_GROUP||OTHER||NONE||||||
33935995|NCT06296043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Double (Participant, Outcomes Assessor) Since the application will be performed by the researcher, participant will be blinded in this study. The statistician will be blinded in the evaluation of the data.|Three groups with su-jok group, progressive muscle relaxation exercise group and control group|t|f|f|f
33935996|NCT03474237|||COHORT||PROSPECTIVE|||||||
33935997|NCT03942640|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33935998|NCT03088332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33935999|NCT00693563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33936000|NCT06099678|RANDOMIZED|PARALLEL||OTHER||SINGLE|The mental effort aspect of the study will be concealed from subjects, so they will not be aware of any difference between training groups.|Two intervention groups will perform different types of elastic band training, and a control group will not perform any elastic band training.|t|f|f|f
33936001|NCT03148249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936002|NCT03092622|NA|SINGLE_GROUP||OTHER||NONE||||||
33936003|NCT05610436|||COHORT||PROSPECTIVE|||||||
33936004|NCT00638898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936005|NCT03898752|NA|SINGLE_GROUP||PREVENTION||NONE||All men with DFI \>15 (SCSA method) are assigned to life-style intervention.||||
33936006|NCT05315973|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936007|NCT01085695|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936008|NCT03720106|NA|SINGLE_GROUP||OTHER||NONE||feasibility study||||
33936009|NCT00803296|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936010|NCT05592145|NA|SINGLE_GROUP||OTHER||NONE||The ViOptix machine will be used to measure the oxygenation of composite tissue.||||
33936011|NCT04714554|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||In each study part (Part 1 and Part 2), study treatments will be administered in a fixed (single) sequence, crossover manner in two sequential treatment periods (Treatment Period 1 and Treatment Period 2).||||
33936012|NCT04481711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936013|NCT06216769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936014|NCT05277298|||COHORT||PROSPECTIVE|||||||
33936015|NCT03079518|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014117|NCT01713426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014118|NCT01164410|||COHORT||PROSPECTIVE|||||||
34014119|NCT00398931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014120|NCT05513586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014121|NCT02494934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014122|NCT06300788|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33712326|NCT05541172|||CASE_ONLY||PROSPECTIVE|||||||
33712327|NCT03403660|RANDOMIZED|PARALLEL||OTHER||NONE||Women are randomly assigned to having their postpartum physician team wear a white coat (WC) or not (no-WC) during rounds.||||
33712328|NCT01485237|||CASE_CONTROL||RETROSPECTIVE|||||||
33712329|NCT05104229|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-armed open-labeled clinical trial||||
33712330|NCT04084665|NA|SINGLE_GROUP||OTHER||NONE||Single Arm Open Label||||
33712331|NCT02837016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712332|NCT00812864|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712333|NCT02771054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096748|NCT05712382|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34096749|NCT01472835|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33792917|NCT03570827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792918|NCT01203618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792919|NCT02217644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33792920|NCT05383313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33792921|NCT05185830|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Non-Randomized study with control group||||
33792922|NCT03145337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|3-4 independent breast surgeons using predefined criteria will assess the aesthetic outcomes of each subject using photographs of their pre-mastectomy and 12 month post-reconstructions. The surgeons will not be apprised of the ADM type or post-mastectomy site/surgeon|Prospective, randomized, controlled|f|f|f|t
34096750|NCT01060111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33792923|NCT05372380|NA|SEQUENTIAL||TREATMENT||NONE||||||
34096751|NCT00295776|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34096752|NCT00937911|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34096753|NCT04787458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096754|NCT02502071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096755|NCT02150382|||COHORT||PROSPECTIVE|||||||
34096756|NCT00686738|||CASE_ONLY||PROSPECTIVE|||||||
34096757|NCT01665378|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096758|NCT01035307|||COHORT||RETROSPECTIVE|||||||
34096759|NCT03055507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096760|NCT04449809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096761|NCT02830087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34096762|NCT05311410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096763|NCT01123564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096764|NCT05539170|RANDOMIZED|PARALLEL||OTHER||SINGLE||"micro parenting intervention vs. care-as-usual control condition"|t|f|f|f
34096765|NCT01220063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096766|NCT05023655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096767|NCT02975453|||COHORT||PROSPECTIVE|||||||
34096768|NCT04690647|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096769|NCT03786055|NA|SINGLE_GROUP||TREATMENT||NONE||Criteria for enrollment included cancer survivors age 18 or older; any type or stage of cancer, currently completed all treatment with no current evidence of disease; at least mild peripheral neuropathy symptoms (either sensory or motor) as rated on the Patient Neurotoxicity Questionnaire (PNQ), attributable to chemotherapy intervention as a component of cancer treatment. Exclusion criteria included active cancer disease or current cancer treatment; co-morbidities such a diabetes or prior history of peripheral neuropathy from any cause. All participants will be screened with the physical activity readiness questionnaire (PAR-Q) to determine the safety or possible risk of exercising based on health history, current symptoms and risk factors. Somatic yoga and meditation (SYM) will be provided during 16 sessions/8 weeks for 1.5 hours and participants will complete home-based SYM and journal entries.||||
34096770|NCT03251599|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The randomization will be via enclosed envelope technique. The anesthetic management of the patient will be provided by an anesthesiologist other than the investigator. This anesthesiologist will not be blinded to the dose of the study drug, and will be responsible from the administration of the appropriate dose of the study drug.~The perfusionist, who is the main care provider during the rewarming period of the cardiopulmonary bypass, will be blinded to the dose of the study drug.~The investigator will be blinded, and will be responsible from the collection, and validation of the data."|Intervention type is drug dosage. Patients will be assigned to 2 arms, where they will receive different doses of the same drug. The study will end when both of the arms will have at least 48 patients each.|t|t|t|t
34096771|NCT01538407|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34096772|NCT00770094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096773|NCT01551823|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34096774|NCT04251936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096775|NCT03279965|||CASE_ONLY||PROSPECTIVE|||||||
34096776|NCT00245570|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33792924|NCT05641363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double dummy design||t|t|t|t
33792925|NCT04195516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33792926|NCT02967588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792927|NCT04492189|||OTHER||PROSPECTIVE|||||||
34014123|NCT02546362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014124|NCT00361114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014125|NCT05203666|||COHORT||RETROSPECTIVE|||||||
34014126|NCT00635115|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33792928|NCT00319566|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33792929|NCT05638620|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single-site, non-randomized, open-label, prospective study to evaluate the effects of bilateral Dual Sympathetic Blocks (DSB) on the dysautonomic symptomatology of Post-Acute Sequelae of SARS-CoV-2 (PASC). Patients will be evaluated for pain interference and dysautonomic symptomatology by the PROMIS-29 and COMPASS-31 scores at 0,1, and 4 weeks.||||
34096777|NCT03996460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be randomized by a Biostatistician by an internet based randomization module into three groups. The researchers include : Primary investigator , Sub-Investigators ,Clinical Coordinators, Nurse Practitioners, and Clinical Research unit (CRU) staff.~The investigators will be blinded to the dosage. Medications for any patient will be labeled by the CRU with a package medical identification number (Med. Id). A patient specific patient identification number (Pat. Id.) will be assigned to each patient. The investigator will have to note the Pat.Id on the designated medication package number after randomization."|The effects of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) versus 384 mg powder of K0706 (equivalent to 192 mg capsule of K0706) versus matching placebo powder taken daily by mouth for 12 weeks, followed by a 4 week wash-out period in individuals diagnosed with DLB will be evaluated.|t|t|t|t
33792930|NCT04277299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33792931|NCT05005065|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, open-label, multiple dosing, crossover study||||
34014127|NCT02381626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014128|NCT03126357|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34014129|NCT05970419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014130|NCT03624803|||OTHER||OTHER|||||||
34014131|NCT02002000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014132|NCT04226235|NA|SINGLE_GROUP||OTHER||NONE||||||
34096778|NCT04405388|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34096779|NCT04697992|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded investigators that assess grade of improvement at end of the study compared to baseline|clinical trial, patients were divided into two groups, 30 each.|f|f|f|t
34096780|NCT01168440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014133|NCT01516866|||CASE_CONTROL||PROSPECTIVE|||||||
34096781|NCT06106438|||OTHER||CROSS_SECTIONAL|||||||
34096782|NCT02159404|||CASE_CONTROL||PROSPECTIVE|||||||
34096783|NCT04821011|||COHORT||PROSPECTIVE|||||||
34096784|NCT05713370|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Subjects will complete all arms of the study in a counterbalanced design||||
34096785|NCT01131650|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34096786|NCT02828085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096787|NCT05017402|||COHORT||OTHER|||||||
34096788|NCT04225520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096789|NCT01408498|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34096790|NCT05688709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is an open-assessor blinded study-we will not blind study participants and staff to treatment arms after the point of randomization except for the outcome assessors.||f|f|f|t
34096791|NCT04624997|||COHORT||PROSPECTIVE|||||||
34096792|NCT00817102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096793|NCT06457932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096794|NCT01786109|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34096795|NCT00138970|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096796|NCT05877209|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34014134|NCT01970865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014135|NCT01211704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096797|NCT03006575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096798|NCT00408447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096799|NCT05696158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096800|NCT06342349|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a single center, randomized, double-blind, controlled phase I clinical trial.|t|t|t|t
34096801|NCT03304587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096802|NCT04080934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096803|NCT01978574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34096804|NCT04356443|||COHORT||PROSPECTIVE|||||||
34096805|NCT00385229|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096806|NCT04249635|||COHORT||PROSPECTIVE|||||||
34096807|NCT05285150|||OTHER||CROSS_SECTIONAL|||||||
33792932|NCT05719038|||COHORT||PROSPECTIVE|||||||
33792933|NCT05729724|||COHORT||PROSPECTIVE|||||||
33792934|NCT06533878|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33792935|NCT01027299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792936|NCT00243854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792937|NCT06552884|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"After the pre-test was applied to the mother and father candidates included in the experimental group, Maternity Identity Development Training was given in the prenatal and postnatal period. This training program, based on Ramona T. Mercer's model of mothering role ability and covering four stages, was given to parents in their own homes."||||
34014136|NCT05223257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It will be a parallel RCT|f|f|f|t
34014137|NCT03485638|||COHORT||PROSPECTIVE|||||||
34014138|NCT03052413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014139|NCT03325972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014140|NCT00312676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014141|NCT00378651|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014142|NCT05334355|||CASE_CONTROL||RETROSPECTIVE|||||||
34014143|NCT04439084|||COHORT||PROSPECTIVE|||||||
34014144|NCT02964819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096808|NCT03400189|NA|SINGLE_GROUP||OTHER||NONE||Phase I, single centre, prospective, ascending single oral doses, open-label, 3-period clinical trial||||
34014145|NCT04700280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014146|NCT00750126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014147|NCT02562482|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34014148|NCT04471038|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34096809|NCT02985281|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34096810|NCT00163735|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34096811|NCT04995926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096812|NCT00312962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34096813|NCT05374993|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-arm prospective study||||
34096814|NCT00406237|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34096815|NCT05855642|||CASE_ONLY||PROSPECTIVE|||||||
34096816|NCT06482424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||karma desen kullanılacaktır.|t|f|t|f
34096817|NCT05152095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096818|NCT01784536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096819|NCT01037465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096820|NCT05916924|||COHORT||PROSPECTIVE|||||||
34096821|NCT02692612|||COHORT||CROSS_SECTIONAL|||||||
33712334|NCT00723983|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34014149|NCT03364166|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34014150|NCT06310928|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study is a single center randomized controlled clinical trial.The sample consisted of a total of 60 patients who would undergo interventional peripheral arterial surgery, met the study criteria and agreed to participate in this study. They will be divided into two groups as 30 experimental group and 30 control group by randomization method.|f|f|f|t
34014151|NCT00819975|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34014152|NCT02432079|||FAMILY_BASED||PROSPECTIVE|||||||
34014153|NCT00652028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014154|NCT04722601|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34014155|NCT04232241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014156|NCT00653991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014157|NCT02664818|||COHORT||PROSPECTIVE|||||||
34014158|NCT05609123|||COHORT||PROSPECTIVE|||||||
34014159|NCT02217631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014160|NCT06242561|||COHORT||RETROSPECTIVE|||||||
34014161|NCT04395651|||OTHER||PROSPECTIVE|||||||
34014162|NCT00364806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014163|NCT03401450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014164|NCT03898713|||COHORT||PROSPECTIVE|||||||
34014165|NCT03017118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014166|NCT02158611|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014167|NCT00695435|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34014168|NCT05102136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014169|NCT03639259|||COHORT||PROSPECTIVE|||||||
34014170|NCT02620215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712335|NCT01191801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712336|NCT03116971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712337|NCT01220375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712338|NCT00775424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712339|NCT04008615|||COHORT||PROSPECTIVE|||||||
33712340|NCT06230887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessor will not have access to shared files, and will not be at any team meetings in which individual participants are discussed, so she will not know to what condition the participants have been assigned.|Participants will be randomized to either the experimental condition (Building Spiritual Strength, an evidence-based, manualized, spiritually integrated group counseling program for moral injury/spiritual distress/values related distress associated with trauma) or the control condition (Present Centered Group Therapy, an evidence-based, manualized group treatment for PTSD.)|f|f|f|t
34014171|NCT04481178|||OTHER||RETROSPECTIVE|||||||
34014172|NCT01832675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014173|NCT02269878|||COHORT||PROSPECTIVE|||||||
34014174|NCT05053347|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34014175|NCT05417360|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be randomized pasteurized A. muciniphila or placebo using variable block randomization with stratification for gender and age following the weight-loss period. The procedure will be done by an independent researcher using a validated variable block randomization model in the Castor database management system (DBMS). The same independent researcher will provide the participants with the supplements, and the product (pasteurized A. muciniphila or placebo). The supplement packages will not contain information about the content. Blinding will be maintained until the analysis has been completed.|A double-blind, placebo-controlled randomised intervention study|t|t|t|t
34014176|NCT01539993|||||PROSPECTIVE|||||||
34096822|NCT02197988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096823|NCT03517826|||OTHER||PROSPECTIVE|||||||
34096824|NCT05900310|||OTHER||RETROSPECTIVE|||||||
34096825|NCT02714959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792938|NCT01505946|||COHORT||PROSPECTIVE|||||||
34014177|NCT02867657|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34014178|NCT05068375|||COHORT||OTHER|||||||
34014179|NCT06457737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients who participated in the study and the assessor of the treatment outcome do not know the type of treatment procedure received.|Split mouth study design, patients will be assigned to two different treatment protocols.|t|f|f|t
34014180|NCT04918641|||COHORT||PROSPECTIVE|||||||
34014181|NCT00563680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014182|NCT03376542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients included in the study will perform cardiopulmonary exercise testing prior to surgery||||
34014183|NCT05993715|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Supplements were allocated in a randomised order and double-blind design by an independent technician who had no further involvement in this study. The randomization and blinding were held until the end of the study.||t|f|t|f
34014184|NCT01939041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014185|NCT01403753|||COHORT||CROSS_SECTIONAL|||||||
34014186|NCT04073628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||In a single-arm, randomized, placebo-controlled (non-active comparison lighting intervention), between-subjects study, we will investigate the effect of long-term exposure (6 months) to a lighting intervention, which is designed to promote circadian entrainment.|t|t|f|t
34014187|NCT05765136|||COHORT||RETROSPECTIVE|||||||
34014188|NCT02442583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014189|NCT02553902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014190|NCT01933464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014191|NCT02771795|||CASE_CONTROL||PROSPECTIVE|||||||
34014192|NCT02933762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014193|NCT03660436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014194|NCT00788229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014195|NCT04346966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34014196|NCT01938404|||COHORT||PROSPECTIVE|||||||
34014197|NCT04686838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will all agree to the dynamic tailoring phase with remote monitoring and surveys, and will not know whether the phone calls are related to anomaly detection or are a control condition phone call.|Dyads will be randomized (assigned by chance) to one of two groups: 1) READyR A or 2) READyR B|t|f|f|f
34014198|NCT04816630|||COHORT||PROSPECTIVE|||||||
34014199|NCT00530686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096826|NCT01346241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096827|NCT00901563|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096828|NCT04626362|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)|Experimental: Cranberry juice consumption participants will be provided cranberry juice to consume for 21 days Intervention: Other: Cranberry juice Placebo Comparator: Placebo juice consumption participants will be provided placebo juice to consume for 21 days Intervention: Other: Placebo juice|t|f|t|t
34096829|NCT00523666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096830|NCT00832962|||||PROSPECTIVE|||||||
34096831|NCT03068520|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"to use the combined data obtained by PET-MRI scanning regarding amino acid metabolic profile, functional and morphological details in order to:~1. Distinguish between progressive tumor and treatment related effects~2. To identify pseudoresponse to antiangiogenic therapy from tumor progression~3. To optimize the study protocol of PET-MRI for future routine clinical application."||||
34096832|NCT04759755|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34096833|NCT05583058|||COHORT||PROSPECTIVE|||||||
34096834|NCT06329336|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34096835|NCT04599335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096836|NCT00120848|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096837|NCT03879577|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34096838|NCT01618708|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34096839|NCT02217007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096840|NCT05298501|||OTHER||CROSS_SECTIONAL|||||||
33792939|NCT03368378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33792940|NCT06109831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study|t|t|t|t
34014200|NCT02011074|||COHORT||PROSPECTIVE|||||||
34014201|NCT01739296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34014202|NCT03045471|||COHORT||PROSPECTIVE|||||||
34014203|NCT06097793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014204|NCT00657228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014205|NCT01857960|||CASE_ONLY||CROSS_SECTIONAL|||||||
34014206|NCT02375919|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34014207|NCT01289444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34014208|NCT04455178|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomly divided into two groups, taking spironolactone (20mg/tablet) once a day or indapamide (1.5mg/tablet) once a day.||||
34014209|NCT02943967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014210|NCT02058082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014211|NCT02823483|NA|SINGLE_GROUP||||NONE||||||
34014212|NCT01174082|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34014213|NCT06206083|||COHORT||RETROSPECTIVE|||||||
34014214|NCT02777567|||CASE_ONLY||PROSPECTIVE|||||||
34014215|NCT03867955|||COHORT||PROSPECTIVE|||||||
34096841|NCT03828669|||COHORT||PROSPECTIVE|||||||
34096842|NCT01666314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096843|NCT04107363|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34096844|NCT04060745|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be screened for active brown adipose tissue (BAT) using FDG PET/CT. Only BAT-positive participants will enter the two-phased randomized crossover trial using DMI under cold or thermoneutral conditions||||
34096845|NCT05706285|||COHORT||PROSPECTIVE|||||||
34096846|NCT02496429|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34096847|NCT02201082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096848|NCT02706548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096849|NCT04688996|||COHORT||PROSPECTIVE|||||||
34096850|NCT03777176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096851|NCT03883451|NA|SINGLE_GROUP||PREVENTION||NONE||single group of football athletes||||
33712341|NCT06194565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712342|NCT05360381|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33712343|NCT04391127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Two non-transparent bottles The first bottle will contain the initial treatment: Two ivermectin tablets, two hydroxychloroquine tablets, or two placebo tablets.~The second bottle will contain the follow-up treatment (10 tablets): Two tablets will be indicated, which will be take 12 hours after ingestion of the initial bottle and then one tablet every 12 hours for 4 more days. This bottle will contain placebo and hydroxychloroquine according to the corresponding group."||t|t|f|f
33712344|NCT02860169|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33792941|NCT01788930|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33792942|NCT01736098|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33792943|NCT04851379|||COHORT||RETROSPECTIVE|||||||
33792944|NCT04385355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|None of the participants or the outcomes assessor will know the device (transmucosal abutment) received. The care provider will connect the transmucosal abutment while the surgery, after opening the randomization envelope; and the investigator will identify the participant's group while analysing the radiographs.|For each participant on the test group will be another participant on the control group|t|f|f|t
33792945|NCT04998903|||COHORT||PROSPECTIVE|||||||
33792946|NCT06374732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792947|NCT02015741|||COHORT||PROSPECTIVE|||||||
33792948|NCT02511197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792949|NCT01293604|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33792950|NCT03728036|||COHORT||PROSPECTIVE|||||||
34096852|NCT03707080|||COHORT||OTHER|||||||
33792951|NCT03391635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33792952|NCT06676111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096853|NCT02216877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096854|NCT05839509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096855|NCT02266862|||CASE_ONLY||PROSPECTIVE|||||||
34096856|NCT02968290|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34096857|NCT02014454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096858|NCT03917264|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34096859|NCT02453191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096860|NCT01093885|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm open label study.||||
34096861|NCT00600782|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34096862|NCT06328231|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34096863|NCT01359280|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34096864|NCT02773628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712345|NCT01004627|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34096865|NCT00831207|||||CROSS_SECTIONAL|||||||
34096866|NCT02105142|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34096867|NCT02882516|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34096868|NCT06093503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096869|NCT02645708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712346|NCT03827733|||OTHER||CROSS_SECTIONAL|||||||
33712347|NCT01402544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712348|NCT06204913|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33712349|NCT04983654|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33792953|NCT06070688|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Statistician assessing financial and resource utilization between study arms (primary and secondary outcomes) will be blinded as to which cohort had the results of the Memed diagnostic test (experimental vs standard groups)||f|t|f|t
33792954|NCT02839369|||||CROSS_SECTIONAL|||||||
33792955|NCT03946241|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33792956|NCT00981630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792957|NCT02035735|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792958|NCT02723929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||tDCS and tUS|t|f|t|t
33792959|NCT03945942|NA|SINGLE_GROUP||OTHER||NONE||||||
33792960|NCT05590650|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33936016|NCT02811081|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936017|NCT04697108|NA|SINGLE_GROUP||OTHER||NONE||||||
33936018|NCT00438724|RANDOMIZED|PARALLEL||||NONE||||||
33936019|NCT06325644|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936020|NCT04051489|||OTHER||PROSPECTIVE|||||||
33936021|NCT05119790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936022|NCT05547594|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936023|NCT06053281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind|t|f|t|f
33936024|NCT04501965|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible consenting symptom-free patients with COVID-19 confirmed by a positive Polymerase Chain Reaction test were subjected to the 10 days of treatment allocated to each of the 3 arms of the trial. Virological clearance is assessed on days 3, 6 and 14. Side effects are noted throughout the trial period. Clinical, paraclinical and laboratory examinations are occasionally provided. Viral clearance, side effects, and the onset of COVID symptoms are evaluated and the data is statistically processed.||||
33936025|NCT02672150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Pairs of sites were optimally randomize based on 10,000 trials to the two conditions by the coordinating center. The assignment (to core or core+enhanced) was not revealed to the local research center or site until after completion of the core. Thus it is double blind.|Staff from 34 juvenile community supervision agencies were observed for a 6 month baseline period than trained over 4 months on using a behavioral health service cascade model to screen, identify, and refer youth to substance use treatment. Half the sites were randomized to 12 additional months of facilitation. Sites were then monitored for an additional 4 month maintenance phase.|t|f|t|t
33936026|NCT02404909|||COHORT||RETROSPECTIVE|||||||
33792961|NCT04036630|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|single-blind|The current study includes 4 different experiments (i.e., arms) including different experimental designs. See separate design description for each arm of the study|t|f|f|f
33792962|NCT04566042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792963|NCT03110458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33792964|NCT02497092|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33792965|NCT04340362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792966|NCT01219699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792967|NCT01987154|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34014216|NCT02221037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014217|NCT02439671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014218|NCT02192008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34014219|NCT02071953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014220|NCT02527499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014221|NCT04431882|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm clinical trial for patients presenting with severe sight threatening papilledema due increased intracranial pressure following leukemia treatment meeting the criteria of idiopathic intracranial hypertension not responding to maximal medical treatment.||||
34014222|NCT05450328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014223|NCT01078129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34014224|NCT03799991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014225|NCT04048941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|t|f|t
34014226|NCT03334721|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34014227|NCT03748355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014228|NCT01332578|RANDOMIZED|CROSSOVER||||NONE||||||
33792968|NCT02516644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792969|NCT04483063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33792970|NCT00480662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792971|NCT05948358|||CASE_ONLY||PROSPECTIVE|||||||
33792972|NCT01693419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792973|NCT05455424|RANDOMIZED|PARALLEL||TREATMENT||NONE||NERO is a multicentre, 2 arm, open-label UK randomised phase II trial comparing Niraparib versus ASC in patients with previously treated mesothelioma.||||
33792974|NCT06167265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33792975|NCT04155151|NA|SINGLE_GROUP||SCREENING||NONE||Prospective observational||||
33792976|NCT01771666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33792977|NCT00397358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33792978|NCT06400446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33792979|NCT05620303|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomized controlled trial||||
33712350|NCT00954434|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33712351|NCT02498860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712352|NCT03192254|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33712353|NCT01250405|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33712354|NCT04802460|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712355|NCT05288075|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Bioanalytical laboratory will be blinded with regard to the sequence of the product administration.|||||
33712356|NCT02847156|NA|SINGLE_GROUP||||NONE||||||
33712357|NCT00982878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712358|NCT04105153|||COHORT||RETROSPECTIVE|||||||
33712359|NCT03780855|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33712360|NCT00878774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712361|NCT05765240|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33712362|NCT01482884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792980|NCT04323358|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|Which eye as well as the order of devices and observer will be randomized. Randomization information will be put in a sealed envelope on screening date and opened right before measurements start.||t|t|t|t
33792981|NCT04347954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792982|NCT01696578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792983|NCT03514251|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33792984|NCT00130819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792985|NCT01126307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33792986|NCT00338858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33792987|NCT00873899|||COHORT||PROSPECTIVE|||||||
33792988|NCT01034943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712363|NCT05444192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33792989|NCT04608955|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33792990|NCT06125106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792991|NCT05304546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792992|NCT00158054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792993|NCT02026778|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33936027|NCT00150150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936028|NCT02814812|NA|SINGLE_GROUP||OTHER||NONE||||||
33936029|NCT00436722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936030|NCT01960192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936031|NCT03628040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The randomization sequence will be computer-generated. Allocation concealment will be carried out via concealed assignments in opaque, sealed, and consecutively numbered envelopes. Blinding will be achieved by sham blocks. After patient allocation, a research assistant not participating in the clinical care and outcome assessment will prepare a syringe of 30 mL 0.5% ropivacaine or normal saline labeled study drug which will then be passed on to one of the investigators (CL or KK) who are blinded to patient allocation. Patients who are allocated to the block group (group B) will receive 0.5 ropivacaine with the ESPB while the control group (group C) will receive normal saline. In addition to ESPB, both group will receive multimodal systemic analgesia including acetaminophen, non-steroidal anti-inflammatory medication and an intravenous (IV) opioid patient-controlled analgesia (PCA) that provides IV opioids on patient-demand."|The study will be a single center (Victoria Hospital), prospective randomized, patient and assessor blinded randomized controlled trial.|t|t|t|t
33936032|NCT02114918|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33936033|NCT05619432|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936034|NCT03881644|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33936035|NCT00914095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936036|NCT00348192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936037|NCT05711511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936038|NCT05129111|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The central idea of the device resides in transmitting the vibration generated by two vibrating modules to the two parotid glands through the superficial contact established between each vibrating module and the respective parotid gland, achieving the stimulation of both parotid glands simultaneously.||||
33936039|NCT06316375|||COHORT||PROSPECTIVE|||||||
33936040|NCT04784546|||COHORT||PROSPECTIVE|||||||
33936041|NCT04989140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936042|NCT01462422|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936043|NCT00004654|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34014229|NCT01834430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014230|NCT01570348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014231|NCT00292188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014232|NCT03145831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014233|NCT05651555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014234|NCT00663832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014235|NCT01713231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34014236|NCT01829087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014237|NCT01649466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014238|NCT05841290|RANDOMIZED|PARALLEL||SCREENING||NONE||Root Canal Treatment (RCT) with 2 parallel groups, two arms, superiority trial with 1:1 allocation ratio||||
34025327|NCT03071939|NA|SINGLE_GROUP||OTHER||NONE||One arm in this study comprising 119 patients and one of their relatives||||
33712364|NCT04422470|||COHORT||PROSPECTIVE|||||||
33792994|NCT05661162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33792995|NCT04653935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33792996|NCT06357819|||OTHER||CROSS_SECTIONAL|||||||
33792997|NCT00270803|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34025328|NCT04049136|||COHORT||PROSPECTIVE|||||||
34025329|NCT01769560|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34025330|NCT03871296|||COHORT||PROSPECTIVE|||||||
34025331|NCT03674255|||COHORT||PROSPECTIVE|||||||
34025332|NCT01873183|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014239|NCT05147038|RANDOMIZED|PARALLEL||SCREENING||NONE|Neither patients nor investigators will be blinded for the allocation.|The study group is divided into the intervention and control group. A randomisation was stratified according to the disease (Idiopathic Pulmonary Fibrosis (IPF) and non-IPF). At first, the participants undergo an initial assessment including a respiratory muscle function and strength testing, physical activity measurement, fatigue, depression status, overall quality of life, disease status, exercise capacity and isometric quadriceps muscle strength testing. Both groups will receive information about the importance of being physically active and the PA recommendations provided by the World Health Organization (leaflet discussed in an education session (one-to-one) of 10-15 minutes). The intervention and control periods are followed by a final assessment (exactly the same as the initial one).||||
34096870|NCT04984408|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The PI, study staff, and participants will be blinded as to receipt of study vaccine or comparator. The pharmacy staff preparing the vaccine syringes and the study nurse who is administering the vaccine will not be involved in the safety assessment of participants and will be instructed not to comment on the experimental agent to study staff. Enrollment numbers will be assigned sequentially by the study nurse/pharmacist upon confirmation of eligibility and enrollment into the study according to their Human Immunodeficiency Virus (HIV) stratification by the Investigator. All case report forms (CRFs) and source documents will be labeled with the enrollment number and study visit number. Personal identifying information linking the study number to an individual volunteer will not be captured on case report form (CRF) as study data.|A randomized, observer-blind, controlled, phase 3 trial will be conducted to assess the safety, immunogenicity and efficacy of two doses of intramuscular BBIBP-CorV vaccine, followed by a booster dose, in adults 18 years of age and older.|t|t|t|f
34096871|NCT01557816|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33792998|NCT01205620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34096872|NCT05020522|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Paired, non-randomised, comparative study||||
34096873|NCT01305343|||CASE_ONLY||PROSPECTIVE|||||||
34096874|NCT02585102|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34096875|NCT03592992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation concealment will be achieved through central pharmacy randomization with the use of a master randomization list of computer-generated random numbers prior to initiation of recruitment.|Institutional Research Ethics Board Approval was obtained (Western Research Ethics Board 111264). Term pregnant women presenting to the Obstetric Care Unit at Victoria Hospital for an elective cesarean delivery will be approached for recruitment. Consenting participants will be randomly assigned to receive either 75 mcg of hydromorphone or 150 mcg of morphine at the time of their spinal anesthetic. Randomization will be achieved through a simple computerized randomization technique (use of random numbers list for allocation).|t|t|f|t
34096876|NCT02887599|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34096877|NCT03685240|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34096878|NCT00842036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096879|NCT01691742|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096880|NCT06468475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096881|NCT05963919|||CASE_CONTROL||PROSPECTIVE|||||||
33792999|NCT01637662|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33793000|NCT02361437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793001|NCT05636852|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33793002|NCT02211898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793003|NCT01607619|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33793004|NCT04010955|||COHORT||PROSPECTIVE|||||||
33793005|NCT01252316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33793006|NCT04201249|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33793007|NCT06556251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This study will be a randomised, prospective and single-centre clinical trial in which one group (EG) will have access to the PIPPEP platform in addition TAU, while the other group (CG) will receive TAU without using the platform.~The study will be carried out in all 9 community mental health centres of the Sanitary Parc Sant Joan de Déu. Patients will be randomly assigned to the EG or CG using a list of random numbers. The evaluation will be based on variables of the clinical history of the patients in both conditions (EG and CG) at the beginning of the study, after 6 months and after 12 months."||||
33793008|NCT05026086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793009|NCT00745446|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33793010|NCT06100705|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single-arm phase II study||||
33936044|NCT00952744|||COHORT||PROSPECTIVE|||||||
33936045|NCT01254786|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33936046|NCT02254304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936047|NCT04949308|||CASE_CONTROL||RETROSPECTIVE|||||||
33936048|NCT04048057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936049|NCT04807244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Every patient has to give informed consent for participating in one of both study arms. To avoid clustering, only one tooth per patient can be included. Arm A is designed as a randomized-controlled and arm B as a non-controlled intervention trial.~The intervention in study arm B will be conducted adapted to the clinical findings after entering slightly the pulp chamber. Depending on the pulpal bleeding time, either a partial pulpotomy or a full pulpotomy will be conducted, according to the predefined protocol mentioned in treatment protocol for arm A. Due to the experimental design, only single blinding of the patient is feasible."|Randomized Controlled Trial and Prospective Non-controlled Intervention Trial|t|f|t|t
33936050|NCT02996240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936051|NCT01563952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33936052|NCT02884193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33936053|NCT05312099|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936054|NCT02871791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014240|NCT05628519|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Randomized control Trial, double blind|f|t|f|t
34014241|NCT00228241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712365|NCT05955729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712366|NCT02048891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712367|NCT04885361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712368|NCT05145530|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33712369|NCT02010775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712370|NCT03907358|||CASE_CONTROL||PROSPECTIVE|||||||
33712371|NCT06055647|||CASE_ONLY||RETROSPECTIVE|||||||
34014242|NCT04171557|||COHORT||PROSPECTIVE|||||||
34014243|NCT01701869|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33712372|NCT05546645|||OTHER||PROSPECTIVE|||||||
33712373|NCT03906123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind, randomized, placebo controlled study|t|t|t|t
33712374|NCT00618072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712375|NCT06040125|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712376|NCT05501730|||OTHER||RETROSPECTIVE|||||||
33712377|NCT00563979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712378|NCT01847794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33712379|NCT01695902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712380|NCT00615498|||COHORT||PROSPECTIVE|||||||
33712381|NCT05376124|||COHORT||PROSPECTIVE|||||||
33712382|NCT01203605|||COHORT||PROSPECTIVE|||||||
33712383|NCT05023772|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label one arm. Unblinded.||||
33712384|NCT03767504|NA|SINGLE_GROUP||OTHER||NONE||Open label, single arm, ascending dose||||
33712385|NCT02948972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712386|NCT01876797|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712387|NCT05539495|||OTHER||CROSS_SECTIONAL|||||||
33712388|NCT05511909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712389|NCT05268900|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33712390|NCT00607009|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712391|NCT05018299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712392|NCT01304654|||CASE_ONLY||PROSPECTIVE|||||||
33712393|NCT01993485|||COHORT||PROSPECTIVE|||||||
33712394|NCT03501316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patients and clinicians will remain blinded to the intervention until the intervention is carried out. Research personnel will remain blinded to specific patient allocation throughout the process through the means of patient barcodes. The key linking the barcodes to the patients will be available to the Chief Investigator. The intervention codes will only be available once the key analyses have taken place.|"Analysis: the effect of treatment group (Manual vs ultrasonic) on changes in CRP levels (and other secondary outcomes):~* Appropriate generalised linear models~* Binary logistic models (for dichotomous outcomes)"|f|f|t|t
33712395|NCT05181683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712396|NCT03519646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712397|NCT00785668|NA|SINGLE_GROUP||TREATMENT||||||||
33712398|NCT06365398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||All patients enrolled are randomly divided into three groups according to the random number principle, which includes conventional systemic heparinization group, micro-dose systemic heparinization, and heparin-free angiography. It is carried out with a 1:1:1 ratio and variable block sizes.|t|t|f|t
33712399|NCT05699499|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33712400|NCT04993092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712401|NCT02170298|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33712402|NCT05373368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33712403|NCT01515709|||COHORT||PROSPECTIVE|||||||
33712404|NCT04473924|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33712405|NCT01003912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712406|NCT01038050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712407|NCT04070274|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34014244|NCT05841446|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014245|NCT03977831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33712408|NCT05346471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712409|NCT01516554|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712410|NCT04128176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712411|NCT04388618|||CASE_CONTROL||PROSPECTIVE|||||||
33712412|NCT00817024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712413|NCT03639298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712414|NCT01380275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712415|NCT01836510|||COHORT||PROSPECTIVE|||||||
33712416|NCT02811445|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33712417|NCT03259776|||OTHER||OTHER|||||||
33712418|NCT05711953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712419|NCT02151591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712420|NCT01412047|||OTHER||PROSPECTIVE|||||||
33712421|NCT06227845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712422|NCT05237531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720678|NCT02169739|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34014246|NCT06205472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014247|NCT00102830||||TREATMENT||||||||
34014248|NCT01769274|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34014249|NCT00441350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014250|NCT03521063|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34014251|NCT03132194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014252|NCT01764295|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34014253|NCT02834806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014254|NCT06502197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014255|NCT02701231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014256|NCT00949611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34014257|NCT00358293|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34014258|NCT00149188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014259|NCT04013945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomization will be carried out by computer-generated block-randomization lists. Subjects will be randomized to one of the two treatment groups, in blocks of 6. The randomization will be seeded, with the seed only available to the statistician generating the randomization list.|Subjects who successfully meet the eligibility criteria will be randomized on a 1:1 basis, to receive Superba Boost or Placebo.|t|f|t|t
34014260|NCT00000813||||PREVENTION||DOUBLE||||||
33712423|NCT03069547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Investigators, study coordinators, outcome assessors, clinical staff, study staff, and other personnel directly involved in the clinical activities of the study, will be blinded to the group allocation.~Participants and providers of the exercise delivery are not blinded to the group allocation."|"Eligible participants will be randomly assigned (1:1) to one of the two following groups:~* QE - quadriceps exercise program~* HE - hip exercise program"|f|f|t|t
33712424|NCT00545194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712425|NCT04866030|||OTHER||RETROSPECTIVE|||||||
33712426|NCT01874132|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33712427|NCT04802278|||COHORT||PROSPECTIVE|||||||
33712428|NCT04556695|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33712429|NCT02635945|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33712430|NCT01300598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712431|NCT02024815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712432|NCT06029478|||CASE_CROSSOVER||PROSPECTIVE|||||||
33712433|NCT03489824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712434|NCT01993654|||COHORT||PROSPECTIVE|||||||
33712435|NCT06304220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomized, and controlled clinical study with two different progestogens: desogestrel 75 mg and medroxyprogesterone acetate 10 mg.||||
33712436|NCT06074939|||COHORT||CROSS_SECTIONAL|||||||
33712437|NCT01302093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33712438|NCT02495441|||CASE_ONLY||PROSPECTIVE|||||||
33793011|NCT05189340|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients in the standard of care arm will be enrolled through a specified date (currently targeting late February 2022, at which time enrolled patients will be included in the intervention group until data collection ceases in late April||||
33712439|NCT01183156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712440|NCT00111345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712441|NCT00847860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793012|NCT05380791|||COHORT||PROSPECTIVE|||||||
33793013|NCT00431431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793014|NCT03646123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793015|NCT00078533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793016|NCT06532435|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793017|NCT03684265|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793018|NCT00709644|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33793019|NCT01291290|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33936055|NCT04050475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients were advised that they would have received a psychological treatment and a nutritional consultation in order to evaluate the possibility of the prescription of a diet, investigating on their diet habits The investigator wasn't informed about the randomization procedures of the two groups.~A clinical psychologist administered the psychological tests separately in the same treatment centre were the patients received the protocol and he wasn't aware about the randomization arm."|After a psychiatric, psychological and anthropometric assessment, depressed patients were randomly assigned to psychotherapy and diet (PSY-FMD) or only psychotherapy (PSY) groups. PSY-FMD participants received 20 individual sessions of Functional Psychotherapy. Each session attended twice a week for the first 8 weeks and once a week for the remaining 4. Furthermore, they received a nutritional consultation and prescription of a Fasting Mimicking Diet. PSY group received just the psychotherapy protocol and the nutritionist prescribed to keep a food diary without changing their habitual diet style. All patients were retested at the end of the treatment (3 months later) and at follow-up 3 months after the last session.|t|f|t|t
33936056|NCT04752631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes will be performed by a blinded assessor.||f|f|f|t
33936057|NCT02253680|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936058|NCT01578525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936059|NCT04918069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34014261|NCT02947074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34014262|NCT02109536|||OTHER||PROSPECTIVE|||||||
34014263|NCT00234182|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014264|NCT05695755|||OTHER||CROSS_SECTIONAL|||||||
34014265|NCT00038987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34014266|NCT04102631|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34014267|NCT02147249|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014268|NCT03396666|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014269|NCT02013375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014270|NCT04294420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014271|NCT01861444|||COHORT||PROSPECTIVE|||||||
34096882|NCT03374904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Interview analysis, for ascertaining the level of PRF will be done by an encoder highly trained in said techniques. Transcriptions will be anonymous in order to mask the identity of the caregiver. Whether the caregiver belongs to a control or intervened group will also be masked when working in transcriptions.~Due to the characteristics of the intervention, the main researcher will not be masked regarding who receives the intervention and who is in the control group."|Participants will be randomized to intervention or control group at a 2:1 ratio|f|f|f|t
33793020|NCT04102371|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, open-label, randomized pragmatic comparative effectiveness trial.||||
34014272|NCT01660334|||CASE_ONLY||RETROSPECTIVE|||||||
34014273|NCT00015028||||TREATMENT||||||||
34014274|NCT00556023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014275|NCT01917864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014276|NCT00632086|RANDOMIZED|CROSSOVER||||NONE||||||
34096883|NCT03975114|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative Randomized Phase 2 Design||||
34014277|NCT03504280|RANDOMIZED|PARALLEL||TREATMENT||NONE||single center, interventional, open labelled study||||
34014278|NCT05143151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793021|NCT01196429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793022|NCT05815342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096884|NCT02732145|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||We performed the same interventions: Three Rings Vulvoscopy, Vulvar Biopsy and Histopathologically Evaluation in four groups of patients with and without vulvar discomfort, with the aim to detect vulvar dermatosis.||||
34014279|NCT05435339|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential assignment||||
34014280|NCT00313456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014281|NCT03817801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will remain blinded until the final study results are released.|Patients will undergo 1:1 randomization to either non-slip element (NSE) predilation which will be the treatment group or non-compliant (NC) balloon predilation which will be the control group. The initiation of the trial is defined as the time of randomization. After study subjects' enrollment and randomization, the study intervention will take place immediately. The follow-up visits for the primary endpoint are scheduled at 1and 6 months after the index procedure.|f|f|f|t
34014282|NCT05262036|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014283|NCT00787579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014284|NCT01222390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014285|NCT06371144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blinded|To compare intravenous paracetamol versus intramuscular tramadol as labour analgesia and to evaluate the incidence of side effects on mother and baby of both drugs|t|f|f|f
34014286|NCT00309764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014287|NCT00506818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34014288|NCT03992794|||COHORT||PROSPECTIVE|||||||
34014289|NCT04091958|NA|SINGLE_GROUP||TREATMENT||NONE||This is a cohort study.||||
34014290|NCT06000735|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot Study (uncontrolled)||||
34014291|NCT01934738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096885|NCT04508959|||COHORT||PROSPECTIVE|||||||
34014292|NCT03677791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||RCT (Randomized controlled trial)|f|t|f|f
34025333|NCT04234932|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34025334|NCT00613886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34096886|NCT00001082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34096887|NCT03115658|NA|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34096888|NCT04162314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34096889|NCT03744975|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Placebo-controlled study comparing Oral Placebo with Oral LCZ 696 (Entresto)|t|t|t|f
34096890|NCT02277860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096891|NCT00337194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096892|NCT02994277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096893|NCT00863460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096894|NCT02998099|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34096895|NCT03092843|||COHORT||PROSPECTIVE|||||||
34096896|NCT02347956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096897|NCT04604093|||COHORT||PROSPECTIVE|||||||
34096898|NCT02056288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096899|NCT03115632|||CASE_CONTROL||PROSPECTIVE|||||||
34096900|NCT00574951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096901|NCT05187637|||COHORT||PROSPECTIVE|||||||
34096902|NCT02614768|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793023|NCT00845832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793024|NCT04710225|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33793025|NCT01492218|||COHORT||PROSPECTIVE|||||||
33793026|NCT00665379||PARALLEL||TREATMENT||NONE||||||
33793027|NCT04931446|||CASE_ONLY||RETROSPECTIVE|||||||
33793028|NCT00242190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025335|NCT03552068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712442|NCT03671460|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, open-label, nonrandomized, no control, prospective clinical trial||||
33712443|NCT01224431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33712444|NCT05119205|||OTHER||CROSS_SECTIONAL|||||||
34014293|NCT06354855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assignment of people to groups will be done by a statistician, apart from the research using a computer program. Randomization will be determined by entering the total number of cases through the program whose URL address is https://www.randomizer.org.|Two groups with a conventional therapy control group|f|f|f|t
34014294|NCT04259138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will be trained on the treatment algorithms and target groups. Study participants will be blinded to target group assignment, whereas investigators will be unblinded.|"In this study, participants with active UC will be randomized in a 5:4:1 ratio (initially 2:3:5) to 1 of 3 treatment target groups. Participants will be assigned a treatment algorithm based on their existing UC treatment at time of entry. Treatment algorithms may include the use of vedolizumab. A key premise is that vedolizumab has a favorable safety profile and can be used to treat participants who are in symptomatic remission but who have not attained endoscopic or histopathologic remission.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm."|t|f|f|f
34014295|NCT03955471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014296|NCT00789763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014297|NCT00207779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014298|NCT01402180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014299|NCT00216645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014300|NCT03363399|||COHORT||CROSS_SECTIONAL|||||||
34014301|NCT03531801|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34014302|NCT02254018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096903|NCT02959606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096904|NCT03435406|||COHORT||CROSS_SECTIONAL|||||||
34096905|NCT02548364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096906|NCT00193947|||COHORT||PROSPECTIVE|||||||
34096907|NCT05747547|||COHORT||PROSPECTIVE|||||||
34096908|NCT00283569|||CASE_CONTROL||PROSPECTIVE|||||||
34096909|NCT03799120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34096910|NCT01758081|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34096911|NCT00962455|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34096912|NCT02585492|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34096913|NCT05823077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096914|NCT02053584|NA|SINGLE_GROUP||OTHER||NONE||||||
34096915|NCT02948075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096916|NCT00153920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096917|NCT06252337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34096918|NCT04225832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor does not randomize participant until after the baseline assessment||f|f|f|t
34096919|NCT00500929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096920|NCT01735799|||||PROSPECTIVE|||||||
34096921|NCT01663987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096922|NCT04867590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096923|NCT01834651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096924|NCT04394832|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline case-series design (AB), with a randomised duration of baseline length.||||
34096925|NCT03756935|||OTHER||PROSPECTIVE|||||||
34096926|NCT05028595|||CASE_ONLY||CROSS_SECTIONAL|||||||
34096927|NCT01261377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096928|NCT05102838|||COHORT||PROSPECTIVE|||||||
34096929|NCT00353015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34096930|NCT01347957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096931|NCT04228315|RANDOMIZED|PARALLEL||TREATMENT||NONE||The clinical study is a two arm, randomized, open-label treatment study of Thai adults with acute infection with P. vivax. All subjects will be treated with a short acting oral antimalarial, artesunate, to eradicate P. vivax malaria from the bloodstream. Radical cure with primaquine (15 mg/ day for 14 days) to eliminate the relapsing hypnozoite of P. vivax will be given at different times, depending on this study arm. Ten healthy controls will also be enrolled for 1 day to provide baseline samples.||||
33712445|NCT03777878|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A Double-Blind Randomized Clinical Trial|A Double-Blind Randomized Clinical Trial|t|t|t|t
34096932|NCT01975285|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096933|NCT05551221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks.~Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks."|t|t|t|t
33712446|NCT03462082|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712447|NCT03292588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712448|NCT03674749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33712449|NCT06504901|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33712450|NCT02038023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712451|NCT03550898|NA|SINGLE_GROUP||DIAGNOSTIC|||Dynamic ultrasonography was performed during the filling phase of the urodynamic study. The radiologist and the urodynamicist had no verbal or visual contact during the examinations, with use of a siding.|Dynamic ultrasonography was performed in all patients during the urodynamic study.||||
33712452|NCT01943890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712453|NCT00808366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712454|NCT04216771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712455|NCT00902408|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33712456|NCT01658072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33712457|NCT04897932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712458|NCT00948129|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712459|NCT01129609|||COHORT||OTHER|||||||
33712460|NCT01675414|||COHORT|||||||||
33712461|NCT02116907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096934|NCT01327365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793029|NCT02888080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793030|NCT03219645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793031|NCT06550102|||COHORT||PROSPECTIVE|||||||
33793032|NCT01441453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793033|NCT03636867|||COHORT||PROSPECTIVE|||||||
33793034|NCT03092713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Particpant are blinded to Group allocation, and all assessments are blinded to Group allocation.|Randomized controlled trial with active treatment group compared to treatment as usual|t|f|f|t
33793035|NCT02984319|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33793036|NCT04983537|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All personnel involved in antibody determination shall remain blinded to the assigned strategy.||f|f|f|t
33793037|NCT00641654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793038|NCT02412774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793039|NCT01080950|||CASE_CONTROL||PROSPECTIVE|||||||
33793040|NCT03181464|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled cross-over trial|t|f|t|f
33793041|NCT05300919|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm parallel assignment.||||
33793042|NCT04190342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33793043|NCT02071979|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33793044|NCT03986424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793045|NCT04028635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014303|NCT04497675|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34014304|NCT01083810|||CASE_ONLY||PROSPECTIVE|||||||
34014305|NCT05683327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014306|NCT04729647|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients without axillary metastases and who did not receive neoadjuvant treatment were examined by dividing them into two groups as pathologically non-metastatic (Group NM) and metastasized (Group M) in axillary lymph node sampling.||||
34014307|NCT02030483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014308|NCT01432574|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014309|NCT03031665|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34014310|NCT03627741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014311|NCT04788160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014312|NCT04126616|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014313|NCT02650401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014314|NCT06105320|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Assessors of disease monitoring outcomes (defined as Secondary outcomes below) are blinded. One of the primary outcomes (Adherence) assessed by dietitian which cannot be blinded.||f|f|f|t
34014315|NCT04741399|||OTHER||PROSPECTIVE|||||||
34014316|NCT03175289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014317|NCT00161382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014318|NCT01311557|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014319|NCT00429520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014320|NCT06127914|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014321|NCT01187121|||COHORT||PROSPECTIVE|||||||
34014322|NCT03795831|||COHORT||PROSPECTIVE|||||||
34014323|NCT02427295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014324|NCT05033912|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blind|This is a phase1, randomized sequence of placebo, low-, mid- and high-dose CST-2032 after a pre-administered dose of 3 mg CST-107.|t|t|t|t
34014325|NCT04154150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014326|NCT04750135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014327|NCT03376620|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Label number coded by manufacturer and released after blinding period|Double-Blind Randomized Controlled Trial; Patient as their own control|t|f|t|f
34014328|NCT03648242|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34014329|NCT06333223|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Arm 1: Mixture of (Poly)phenols and a probiotic supplement Arm 2: (Poly)phenols and maltodextrin (placebo)|t|f|t|t
34014330|NCT03755479|||COHORT||PROSPECTIVE|||||||
34014331|NCT04586153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014332|NCT05636163|||COHORT||RETROSPECTIVE|||||||
34014333|NCT06091748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014334|NCT05212883|||COHORT||PROSPECTIVE|||||||
34014335|NCT00464074|||CASE_ONLY||PROSPECTIVE|||||||
34096935|NCT06279403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096936|NCT03830970|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34096937|NCT01787968|||COHORT||PROSPECTIVE|||||||
34096938|NCT06288178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34096939|NCT06548464|||COHORT||RETROSPECTIVE|||||||
34096940|NCT04771871|NA|SINGLE_GROUP||TREATMENT||NONE||This is a one-stage phase II study with a single arm design. All patients will receive 4 cycles of epirubicin + cyclophosphamide followed by paclitaxel +carboplatin for four cycles in the neo-adjuvant setting. Those with clinical response (assessed via breast ultrasound), will undergo surgery. After surgery, all patients who achieve pCR will undergo radiotherapy. Patients with pathological incomplete response or stable disease may have additional chemotherapy at the discretion of the managing physician.||||
34096941|NCT00266981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34096942|NCT02677285|||CASE_ONLY||OTHER|||||||
34096943|NCT04776876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096944|NCT02552654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34096945|NCT00674232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096946|NCT04853290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers and investigators responsible for data collection will be blinded for collection and analysis of data.|It is a PROBE (Prospective Randomized Open Blinded End Point), parallel, controlled, and single center randomized clinical trial (RCT).|f|f|t|t
34096947|NCT05937100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the observer and the recipients will be blinded to the study group to avoid bias (double blind randomized controlled trial)||t|f|t|f
34096948|NCT06473818|||COHORT||PROSPECTIVE|||||||
34096949|NCT03693508|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, phase 4 study. The naive patients will be treated with elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide as a first-line treatment||||
34096950|NCT04289298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096951|NCT00666471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096952|NCT00884598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096953|NCT00728182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34096954|NCT03295357|||OTHER||RETROSPECTIVE|||||||
34096955|NCT04333459|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Double-blind Study||t|f|t|f
34096956|NCT01968408|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096957|NCT06195111|||OTHER||PROSPECTIVE|||||||
34096958|NCT05038371|||CASE_CONTROL||PROSPECTIVE|||||||
34096959|NCT02588534|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34096960|NCT04614779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096961|NCT04679818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33712462|NCT02132130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712463|NCT00271583|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33712464|NCT03519425|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||A pragmatic open, three-arm individually-randomised controlled trial and economic evaluation|f|f|t|t
33712465|NCT00275184|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33712466|NCT05405205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All three products are identical in smell, flavour, color, texture, appearance, packaging (sachets) and labelling.|Randomised, controlled, double-blind|t|t|t|t
33712467|NCT05409456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|assessor is blind|two groups group A is assign mild aerobic group b is assign moderate aerobic|f|f|f|t
33712468|NCT06289998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712469|NCT03795987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096962|NCT06337409|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34096963|NCT03888482|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34096964|NCT00451984|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34096965|NCT03811405|NA|SINGLE_GROUP||TREATMENT||NONE|Each of the 3 interventions will be videotaped for blinded motor score assessment by an independent rater.|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time.||||
34096966|NCT00222261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096967|NCT02172599|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33712470|NCT04011267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single|Assignment|f|f|t|t
33712471|NCT05677724|||COHORT||RETROSPECTIVE|||||||
33712472|NCT00203996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33712473|NCT00090480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712474|NCT04967443|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33712475|NCT01099254|||OTHER||PROSPECTIVE|||||||
33712476|NCT00812578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33712477|NCT02868320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33712478|NCT05837819|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33712479|NCT06541652|||COHORT||OTHER|||||||
33712480|NCT06171763|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34096968|NCT03572114|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096969|NCT03874403|RANDOMIZED|PARALLEL||OTHER||TRIPLE||compare the DSA monitoring between the patients receiving intubated or NIVATS|f|t|t|t
34096970|NCT05240885|||COHORT||PROSPECTIVE|||||||
34096971|NCT00300495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096972|NCT05695482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096973|NCT05391087|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34096974|NCT02141724|||COHORT||RETROSPECTIVE|||||||
34096975|NCT02852733|||COHORT|||||||||
34096976|NCT05931900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096977|NCT01666652|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34096978|NCT00675454|||COHORT||PROSPECTIVE|||||||
34096979|NCT03819205|NA|SINGLE_GROUP||TREATMENT||NONE||self-controlled study||||
34096980|NCT00732693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34096981|NCT01153282|||OTHER||OTHER|||||||
34096982|NCT00002226||||TREATMENT||||||||
34096983|NCT05786755|||COHORT||RETROSPECTIVE|||||||
34096984|NCT01972971|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34096985|NCT01391949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34096986|NCT03600428|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34096987|NCT06021964|||COHORT||PROSPECTIVE|||||||
34014336|NCT00166153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014337|NCT01520974|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34014338|NCT03937128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712481|NCT00740831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014339|NCT04054128|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, open label, clinical trial in chronic hemodialysis patients with a catheter as a vascular access, randomized to bicarbonate lock or heparin lock (control) as standard treatment.||||
34014340|NCT05577650|||CASE_ONLY||CROSS_SECTIONAL|||||||
34014341|NCT00773942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014342|NCT01071447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014343|NCT01565265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014344|NCT02287129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34096988|NCT05769595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
34096989|NCT01216280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34096990|NCT01208051|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 was dose finding. Phase 2 parallel group comparison.||||
34096991|NCT05438420|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34096992|NCT03220555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34096993|NCT00071331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34096994|NCT03889795|NA|SEQUENTIAL||TREATMENT||NONE||3 Subjects per Cohort + 3 additional subjects in Expansion Cohort.||||
34096995|NCT04093700|||COHORT||OTHER|||||||
34096996|NCT01248390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34096997|NCT02164721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34096998|NCT06040450|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34096999|NCT03436420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097000|NCT05395780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097001|NCT01694394|||COHORT||PROSPECTIVE|||||||
34097002|NCT04387214|||OTHER||CROSS_SECTIONAL|||||||
34097003|NCT01691313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097004|NCT04877639|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34097005|NCT03612700|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097006|NCT00257855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097007|NCT02217384|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34014345|NCT03112980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025336|NCT02064985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025337|NCT00587028|||COHORT||PROSPECTIVE|||||||
34025338|NCT03133338|||COHORT||CROSS_SECTIONAL|||||||
34025339|NCT03115216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025340|NCT03904589|||COHORT||PROSPECTIVE|||||||
34025341|NCT00096603||||TREATMENT||NONE||||||
34097008|NCT05223712|||COHORT||OTHER|||||||
34097009|NCT04784975|||OTHER||CROSS_SECTIONAL|||||||
34097010|NCT05691985|||CASE_CONTROL||PROSPECTIVE|||||||
34097011|NCT01960478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097012|NCT00133211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097013|NCT03281538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097014|NCT03426007|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097015|NCT06017375|||COHORT||PROSPECTIVE|||||||
34097016|NCT01574404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097017|NCT06516731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712482|NCT00433095|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712483|NCT05554094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712484|NCT04997811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712485|NCT05545215|||COHORT||PROSPECTIVE|||||||
33712486|NCT02601690|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34014346|NCT06094452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since it will not be possible to blind the participants because the experimental and control interventions have to be explained to them and their caregivers before randomization. The single blinding will be applied to researchers who conducted the measurements to minimize the potential assessor biases. Blinding will be also maintained for data management, outcome assessment, and data analysis.|After recruitment and baseline assessments, pairs of participants with MCI and mild AD will be randomly allocated into either the CCT group and the control group. Participants in CCT group will receive a multidomain adaptive computerized cognitive training program (www.66nao.com) for 24 weeks. Patients in control group will receive treatment as usual (TAU) for 24 weeks.|f|f|t|t
34014347|NCT05050695|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34097018|NCT05666856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will know what group they are in. When data is sent to the statistician for analysis we will code the groups (e.g., 123) without informing which is which. This masks (or blinds) him to the condition.|Conduct a fully-powered RCT comparing two groups. One group will receive digital delivery of the optimized top performing adapted CRAFT intervention from Phase I (CRAFT-A), which consists of a digitally automated curriculum and weekly group coaching sessions, and the second will receive WTV peer support only (PEER).|f|f|f|t
34097019|NCT03008096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097020|NCT01192360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097021|NCT00620035|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014348|NCT06032455|||CASE_CONTROL||PROSPECTIVE|||||||
34014349|NCT02265172|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014350|NCT03977701|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097022|NCT00249041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097023|NCT05267002|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The primary outcome will be the Scar Cosmesis Assessment and Rating scale (SCAR) score, with photographic assessment by three blinded fellowship-trained board-certified Mohs surgeons who were not involved with the original surgery or wound repair.|Split Scar Study|f|f|f|t
34097024|NCT06469268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Enrolled patients who received cisplatin or oxaliplatin were randomly assigned to one of two groups. Group A was the routine observation group, 50 patients were enrolled in the group. After receiving antineoplastic drug treatment, they were discharged home, and the treatment-related adverse reactions were observed and intervention according to the routine process. Group B was the ePRO study group: A total of 50 patients were enrolled in this group. After receiving anti-tumor drug treatment, the ePRO system was installed through the mobile phone. After training, the patients could skillfully use the ePRO system.|f|f|t|f
34097025|NCT03787160|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34097026|NCT03896360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097027|NCT05033535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34097028|NCT01578720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097029|NCT03406052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Psychiatrists providing psychiatric care will be blinded to the group allocation of subjects under their treatment. One outcome assessor (who will conduct the 24-item Hamilton Rating Scale for Depression (HRSD-24) will be blinded. Investigators will be blinded.||f|t|t|t
34097030|NCT02738697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097031|NCT00581789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097032|NCT00362323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097033|NCT02783989|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34097034|NCT04588363|||COHORT||PROSPECTIVE|||||||
34097035|NCT04918797|NA|SINGLE_GROUP||PREVENTION||NONE||Open label||||
34097036|NCT05381168|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The volunteers are divided into 2 groups which are calcium from fish bone treatment group and calcium carbonate treatment group. Both groups receive the calciums every day for 6 months.|t|t|t|t
34097037|NCT01907178|||CASE_ONLY||PROSPECTIVE|||||||
34097038|NCT02874352|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34097039|NCT00862901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097040|NCT01197274|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712487|NCT06254404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34014351|NCT02545855|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025342|NCT00519688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025343|NCT00001028||||TREATMENT||||||||
34097041|NCT02726269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097042|NCT01135056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097043|NCT02587364|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34097044|NCT00053742||||TREATMENT||||||||
34025344|NCT04854889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097045|NCT00474968|||CASE_CONTROL||PROSPECTIVE|||||||
33712488|NCT00907777|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712489|NCT06139432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014352|NCT05880836|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||HFNC with trans-nasal aerosol delivery is a multi-center trial comparing nebulization of medications via trans-nasal delivery with vibrating mesh nebulizer to standard jet nebulization in patients with mild or moderate hypoxemic respiratory failure (with or without acute hypercapnic respiratory failure) treated with HFNC. The crossover nature of the study is reflected in the universal application of bronchodilators via both study interventions (HFNC/VMN and FM/SJN) in all subjects but in variable order depending on the randomization of subjects into Path A or Path B||||
34014353|NCT03074396||SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34014354|NCT05587335|RANDOMIZED|PARALLEL||PREVENTION||NONE||In person and online arms||||
33712490|NCT03932110|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34014355|NCT01310673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014356|NCT06331741|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Main group for ACL: 5 patients with ACL injury, who undergo ACL reconstruction with collagen membrane augmentation; Reference group for ACL: 5 patients with ACL injury, who undergo ACL reconstruction without collagen membrane augmentation; Main group for HR (Hallux Rigidus): 5 patients with Hallux Rigidus, who undergo resection arthroplasty with introduction of collagen membrane Reference group: none|t|f|t|f
34014357|NCT02778503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014358|NCT01207999|||CASE_ONLY||CROSS_SECTIONAL|||||||
34014359|NCT02434224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014360|NCT01147978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097046|NCT03865680|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Participants and the statistician are blinded to the treatment groups. The operator will not be blinded to the treatment as the test group will receive MI varnish while the control group will receive Duraphat varnish.|The study is a double blind randomized controlled clinical trial, with a 1:1 allocation ratio. Subjects are randomly assigned using a computer -generated list of random numbers to one of the two arms (MI varnish, Duraphat fluoride varnish).|t|f|f|t
34097047|NCT03197688|||COHORT||RETROSPECTIVE|||||||
34097048|NCT03476512|||OTHER||CROSS_SECTIONAL|||||||
34097049|NCT02965976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34097050|NCT01622335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34014361|NCT00474942|||COHORT||PROSPECTIVE|||||||
34014362|NCT06346002|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized cluster trial with a wait-list control||||
34014363|NCT03174106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The cardiologist, physical therapist and the physiologist at NIMI and Feiring will be masked.|Randomization to two different arms, intervention- or control-group|f|t|f|t
34014364|NCT02247219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34014365|NCT02251119||PARALLEL||TREATMENT||NONE||||||
34014366|NCT05404074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097051|NCT00499538|RANDOMIZED|CROSSOVER||||NONE||||||
34097052|NCT05025917|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33712491|NCT05806814|NA|SINGLE_GROUP||TREATMENT||NONE||The primary objective is to evaluate the feasibility and immune response of an extended course of Sipuleucel-T immunotherapy given at week 0, 2, and 12-14 in patients with metastatic castration-resistant prostate cancer.||||
33712492|NCT02885753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712493|NCT02279381|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712494|NCT05079139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Descriptive study||||
33712495|NCT06056713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33712496|NCT02563405|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33720679|NCT03446742|||COHORT||PROSPECTIVE|||||||
34014367|NCT03575871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014368|NCT04451603|||COHORT||PROSPECTIVE|||||||
34014369|NCT00134173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014370|NCT00449319|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34014371|NCT03023514|RANDOMIZED|||||||||||
34014372|NCT05335993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014373|NCT05044884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014374|NCT00855803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014375|NCT03477019|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two liver metastases in every patient are preselected on baseline computer tomography. These will be randomized to either 1) target lesion to be treated or 2) control lesion. Difference in response (pre- and post-treatment measure) between treated lesions and control lesions will be the primary outcome of the trial.||||
34014376|NCT02192164|||OTHER||PROSPECTIVE|||||||
34014377|NCT05028231|||COHORT||PROSPECTIVE|||||||
34014378|NCT05622136|NA|SEQUENTIAL||TREATMENT||NONE||||||
33793046|NCT04476095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (placebo PBMT or active PMBT) and will be instructed not to inform the patients or other researchers as to the type of treatment (PMBT or placebo). Therefore, the researcher responsible for the treatment, the investigator and the outcome assessor will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or PBMT).||t|t|t|t
34097053|NCT04785807|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793047|NCT01367548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33793048|NCT00587925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793049|NCT02786602|||COHORT||RETROSPECTIVE|||||||
33793050|NCT05917249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793051|NCT03023280|||COHORT||PROSPECTIVE|||||||
33793052|NCT00457691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793053|NCT04502511|||COHORT||PROSPECTIVE|||||||
33793054|NCT02127333|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33793055|NCT02401633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793056|NCT06368349|||COHORT||OTHER|||||||
33793057|NCT04152616|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097054|NCT05451888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33793058|NCT00002436||||TREATMENT||||||||
33793059|NCT02135341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was designed in this study|Patients with urodynamically proven DHIC and age-matched controlled OAB patients with urodynamic DO selected from our previous clinical trials were compared for the treatment outcome of onabotulinumtoxinA injection||||
33793060|NCT04074577|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33793061|NCT05635604|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, placebo-controlled design in migraine without aura patients.|t|t|t|t
33793062|NCT04421391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793063|NCT01043263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793064|NCT02522000|||COHORT||PROSPECTIVE|||||||
33793065|NCT03429062|||COHORT||PROSPECTIVE|||||||
34014379|NCT05613517|||OTHER||PROSPECTIVE|||||||
34014380|NCT03673319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014381|NCT02919241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014382|NCT00145639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014383|NCT03218891|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Optimized clinical treatment group + physical training for 12 weeks (TF);~2. optimized clinical treatment group (CT);~3. Group with coronary insufficiency without angina (CD);~4. Group normal healthy subjects"||||
34014384|NCT02101242|||COHORT||PROSPECTIVE|||||||
34097055|NCT04199039|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study only the patient was blinded. Investigators involved with the running of the study were not blinded.|prospective, single-blind non-randomized clinical trial study|t|f|f|f
34097056|NCT00919490|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34097057|NCT02269488|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34097058|NCT06417307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097059|NCT01073514|||CASE_ONLY||PROSPECTIVE|||||||
34097060|NCT02113566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793066|NCT04736849|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793067|NCT02939378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097061|NCT00291226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097062|NCT00612768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097063|NCT00587262|||COHORT||PROSPECTIVE|||||||
34097064|NCT00580294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793068|NCT00708032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793069|NCT00688948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793070|NCT02214693|NON_RANDOMIZED|PARALLEL||||NONE||||||
33793071|NCT03382080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014385|NCT05637437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014386|NCT02384252|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34014387|NCT05784116|||COHORT||PROSPECTIVE|||||||
34014388|NCT04936828|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34014389|NCT02296684|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33712497|NCT05984160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization was performed by a general surgeon who would not be present during the block procedure. Patients were numbered sequentially according to the randomization scheme. Patient numbers were recorded in the follow-up files. Evaluation of the postoperative results was done by a general surgeon who was unaware of the group distributions. Since both the patients and the general surgeon who will make the evaluation did not know whether the block procedure was applied or not, the study was performed as double-blind.|The patients were divided into two groups as perigastric neural block and control group.|t|t|t|t
33712498|NCT05784350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712499|NCT06141395|||COHORT||PROSPECTIVE|||||||
33720680|NCT02135146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793072|NCT00740415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793073|NCT00155558|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793074|NCT06229717|||COHORT||PROSPECTIVE|||||||
33793075|NCT01395225|||||PROSPECTIVE|||||||
33793076|NCT00481390|||COHORT||PROSPECTIVE|||||||
33793077|NCT02001623|NA|SEQUENTIAL||TREATMENT||NONE||Escalation phase for dose finding followed by expansion phase||||
33793078|NCT01466881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793079|NCT05039606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793080|NCT01563991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793081|NCT02005094|||COHORT||PROSPECTIVE|||||||
33793082|NCT06339489|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793083|NCT01909778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793084|NCT01806454|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793085|NCT01597258|||CASE_ONLY||PROSPECTIVE|||||||
33793086|NCT04590287|||CASE_ONLY||PROSPECTIVE|||||||
33793087|NCT05774119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover randomized clinical trial. Premenopausal women with overweight or with obesity will be included. The participants attend 3 sessions: in the first, a clinical history is applied, and anthropometric measurements are taken; in the second and third sessions they consume a standard breakfast (519 kcal) together with 240 ml of coffee with 6 mg/caffeine/kg of weight or the same breakfast but accompanied by 240 ml of water. The sequence of the type of intervention is randomly assign with a period of 1 week wash. Fasting and every 30 minutes during the 3 hours following breakfast consumption, sensations of appetite are recorded using visual analog scales. Fasting, 30 and 180 min after breakfast consumption, ghrelin and cholecystokinin levels are measured. Dietary intake is recorded on the day before the two interventions and on the day of intervention, after breakfast consumption.||||
33793088|NCT01521624|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33793089|NCT03959241|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized at a ratio of 1:1 between the treatment arms using permuted blocks of random sizes.||||
33793090|NCT04941924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33793091|NCT01174199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793092|NCT00571818|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33793093|NCT02422095|||COHORT||PROSPECTIVE|||||||
33793094|NCT03801551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793095|NCT02066441|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33793096|NCT06060002|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33793097|NCT04536441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34014390|NCT06360068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014391|NCT01741779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34014392|NCT03666481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014393|NCT06482671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigators and gastroenterologists involved in the trial are blinded for the intervention arm (rikkunshito or placebo).|Double blind intervention with Rikkunshito (herbal preparation) or Placebo|t|t|t|f
34014394|NCT02030548|||COHORT||PROSPECTIVE|||||||
34014395|NCT02939950|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34025345|NCT00307918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025346|NCT00274118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34025347|NCT05256719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793098|NCT02798718||PARALLEL||PREVENTION||NONE||||||
34025348|NCT05162508|||COHORT||PROSPECTIVE|||||||
34025349|NCT00000812||||TREATMENT||DOUBLE||||||
34025350|NCT02669030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025351|NCT02437435|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34025352|NCT01822366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025353|NCT00591981|||COHORT||PROSPECTIVE|||||||
33793099|NCT05307991|||COHORT||PROSPECTIVE|||||||
33793100|NCT06545994|||COHORT||PROSPECTIVE|||||||
34014396|NCT04476628|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Patients will be randomly divided to either start with 5MR or 1MR administration methods. They will undergo a 2 week washout period before starting their respective administration method. The first administration methods will be once daily for 8 weeks in duration. This is then followed by an additional washout period of 2 weeks. Finally, patients will switch to the other administration method for an additional treatment duration of daily application for 8 weeks. We will assess which administration method is more effective. Patients will be asked to administer budesonide daily with a minimum requirement of at least five days a week to ensure changes seen are related to the appropriate treatment arm. The washout period will involve standard of care daily non-medicated intranasal saline irrigation. Data will be collected at baseline, 2 weeks, 10 weeks, 12 weeks, and lastly 20 weeks follow-up visit."|f|f|t|f
33793101|NCT03998280|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793102|NCT02519452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793103|NCT06429852|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization will be conducted by a research assistant using an internet-based program following the pre-test. The pre-test and post-tests will be administered by a different researcher who is blinded to the study. The therapy program will be conducted by independent therapists who are also blinded to the study.|The study will be a quantitative, randomized controlled trial with two groups, including a pre-test and repeated post-tests.||||
34014397|NCT03587155|||CASE_CONTROL||PROSPECTIVE|||||||
34014398|NCT05032313|||COHORT||CROSS_SECTIONAL|||||||
34014399|NCT05702879|||CASE_CONTROL||PROSPECTIVE|||||||
34014400|NCT03324321|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-centre, prospective, before and after study||||
34014401|NCT00103038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014402|NCT04793035|NA|SINGLE_GROUP||TREATMENT||NONE||The study is an observational, prospective, non-randomized, open-label, feasibility study of patients receiving the Ω-Cuff device. The study is intended to evaluate the safety of the Ω-Cuff device and its ability to reduce the symptoms of GERD by augmenting the function of the LES. The study will be performed at up to three (3) investigational centers in the US with a maximum of 15 subjects who will be implanted with the device.||||
34014403|NCT02243293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014404|NCT01438255|||||PROSPECTIVE|||||||
34014405|NCT05579379|||COHORT||PROSPECTIVE|||||||
34014406|NCT04274023|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
34014407|NCT00209846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014408|NCT06398613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014409|NCT05160753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. The group of laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area.~2. Patients in the control group will undergo standard laparoscopic gastrectomy (laparoscopic distal gastrectomy with simultaneous D1+ lymph node dissection)."|t|t|f|f
34014410|NCT03274713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014411|NCT02221908|||COHORT||PROSPECTIVE|||||||
34014412|NCT00198653|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34014413|NCT00393224|||COHORT||OTHER|||||||
34014414|NCT01274806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34014415|NCT00344851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014416|NCT04135521|||COHORT||RETROSPECTIVE|||||||
34014417|NCT03035552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessors and the investigator are masked to the group assignment|Randomized to Pacifier Activated Lullaby (mother's voice contingent on suck, 15 minutes, 5 sessions) before surgery or and Sounds of Love (mother's voice playing freely, 15 minutes, 5 sessions). Arm 2: Sounds of love before surgery, Pacifier activated lullaby after the surgery.|f|f|t|t
34014418|NCT02980302|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014419|NCT02749292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014420|NCT01277718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014421|NCT00992368|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34014422|NCT02156141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014423|NCT02467608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014424|NCT02575612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014425|NCT05978908|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Each dose cohort will enroll 8 healthy adults participants, participants will be randomly assigned to receive a single subcutaneous (SC) injection of FC-12738 or placebo in a ratio of 6:2, respectively.|Each dose cohort will enroll 8 healthy adults participants, partipants will be randomly assigned to receive a single subcutaneous (SC) injection of FC-12738 or placebo in a ratio of 6:2, respectively.|t|t|t|t
34014426|NCT02916693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014427|NCT04870723|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34014428|NCT02775136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014429|NCT00000651||||TREATMENT||DOUBLE||||||
34014430|NCT05529472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014431|NCT03823235|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33720681|NCT04139187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistical analyzer will be masking.|Two groups design where one randomized group receive treatment and the other not in the same period of time.|f|f|t|t
34014432|NCT01904006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014433|NCT00004748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014434|NCT02274207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802036|NCT04719858|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants in the intervention condition will be explained that the aim of #LIFEGOALS is to help them adopt a healthy lifestyle. The link between a healthy lifestyle and mental health may come clear when using the #LIFEGOALS app, but this will not be explained to the participants at the start of the study.|Group-Randomized Control Trial with Intervention and Control group. Randomization will occur at group level (school) to avoid spillover effects between the two conditions.||||
34014435|NCT05449509|||OTHER||CROSS_SECTIONAL|||||||
34014436|NCT04464993|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Outcomes assessor will not have access to study arm assignment and participants will be encouraged not to divulge their study arm assignment during assessments.|Investigators will use the multiphase optimization (MOST) framework to conduct a highly efficient full-factorial experimental study to simultaneously test the main effects for each of three intervention components (LOCKOUT, TEXT, EARN) and their interactions (e.g., TEXT+EARN; LOCKOUT+EARN+TEXT) over 16 weeks.|f|f|f|t
33802037|NCT06366984|RANDOMIZED|PARALLEL||OTHER||SINGLE|outcome assessor is unaware of group allocated|Randomized controll trial|f|f|f|t
34014437|NCT04691180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014438|NCT04231734|NA|SINGLE_GROUP||OTHER||NONE||||||
34014439|NCT00584441|||CASE_CONTROL||PROSPECTIVE|||||||
33720682|NCT00746642|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014440|NCT01099059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014441|NCT05120323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will have a follow up appointment at 3 months and the respiratory therapists will be blinded to the study treatment to assess the participant's inhaler technique.|They will be randomized to the intervention arm or standard of care arm.|f|f|f|t
34014442|NCT02426047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014443|NCT03277209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014444|NCT02316249|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34014445|NCT02621034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014446|NCT02969993|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014447|NCT01748331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014448|NCT02384694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014449|NCT01546935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097065|NCT01992471|||COHORT||PROSPECTIVE|||||||
34097066|NCT00138294|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097067|NCT01511237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097068|NCT02331121|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34097069|NCT04968145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097070|NCT02717715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097071|NCT06419309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097072|NCT04209842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097073|NCT02569905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097074|NCT04366583|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention device: argon plasma coagulation ( (PSD-60/Endoplasma, Olympus Corp., Tokyo,Japan) ; hemoclipping (Olympus HX 110/610) Intervention drug: distilled water design setting: argon plasma coagulation plus distilled water injection vs hemoclipping plus distilled water||||
34097075|NCT00468000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097076|NCT01732523|||COHORT||PROSPECTIVE|||||||
34097077|NCT05001503|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34097078|NCT00741221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097079|NCT01259024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097080|NCT02425488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34097081|NCT04249193|||COHORT||PROSPECTIVE|||||||
34097082|NCT02126202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097083|NCT04213638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097084|NCT01867476|||CASE_ONLY||PROSPECTIVE|||||||
34097085|NCT05268120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097086|NCT05053776|||OTHER||CROSS_SECTIONAL|||||||
34097087|NCT00768638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097088|NCT02269449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34097089|NCT02493855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097090|NCT06553469|||CASE_ONLY||RETROSPECTIVE|||||||
34097091|NCT05658211|||COHORT||RETROSPECTIVE|||||||
34097092|NCT05089175|||COHORT||PROSPECTIVE|||||||
34097093|NCT04786574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097094|NCT02614664|||COHORT||PROSPECTIVE|||||||
34097095|NCT00842374|||COHORT||PROSPECTIVE|||||||
34014450|NCT02014077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720683|NCT00434655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014451|NCT04235452|||CASE_CONTROL||RETROSPECTIVE|||||||
34014452|NCT01138111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097096|NCT01447147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097097|NCT05154162|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34097098|NCT00169390|||CASE_CONTROL||PROSPECTIVE|||||||
34097099|NCT03720171|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, uncontrolled study.||||
34097100|NCT03428555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are not blinded.|Intervention Arm (n=30 over 17 months at, CAMH): The intervention is an integrated care pathway and Comparison Arm- Treatment As Usual (n=30 over 17 months at SHSC):||||
33720684|NCT06182826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a single blinded randomized controlled trial having two groups. One group will be given Core Stabilization Protocol along with Routine exercise therapy whereas other group will only receive Routine Exercise therapy protocol. Both groups will be recruited concurrently.|t|f|f|f
33720685|NCT01953341|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34014453|NCT02218619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097101|NCT05752331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802038|NCT01236560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014454|NCT04449757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802039|NCT05758649|||COHORT||PROSPECTIVE|||||||
33802040|NCT03988842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014455|NCT04919941|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Test feasibility and acceptability of a patient decision aid|f|f|t|t
34014456|NCT01366378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014457|NCT03715998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014458|NCT00206492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014459|NCT03883750|||CASE_ONLY||PROSPECTIVE|||||||
34014460|NCT02216019|||COHORT||PROSPECTIVE|||||||
34014461|NCT05441995|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34097102|NCT01774539|||COHORT||PROSPECTIVE|||||||
34014462|NCT03176459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind Study||t|t|f|t
34097103|NCT01718106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097104|NCT04785885|||COHORT||PROSPECTIVE|||||||
34097105|NCT01795560|||CASE_ONLY||PROSPECTIVE|||||||
34097106|NCT00025233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097107|NCT01249443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097108|NCT00349076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097109|NCT05202431|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34097110|NCT00063037|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34097111|NCT02415803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097112|NCT00567151|||COHORT||PROSPECTIVE|||||||
34097113|NCT04614272|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|while assessing for endogenous pain inhibition and pain intensity the assessor will be blind and will not know to which group the participant belong. Participants will be blinded by being blind to the study hypothesis.||t|f|f|t
34097114|NCT03164174|||COHORT||PROSPECTIVE|||||||
34097115|NCT00738517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097116|NCT05655897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097117|NCT00415259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33802041|NCT00310635|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014463|NCT01032772|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34014464|NCT02810821|||COHORT||PROSPECTIVE|||||||
34014465|NCT02658513|||COHORT||PROSPECTIVE|||||||
34014466|NCT00650442|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34014467|NCT01583218|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014468|NCT04337619|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34014469|NCT03664895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014470|NCT04476966|RANDOMIZED|CROSSOVER||OTHER||NONE||three way three sequence two treatment partial replicate crossover bioequivalence study||||
34014471|NCT01030341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014472|NCT05410158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097118|NCT06157125|||COHORT||PROSPECTIVE|||||||
34097119|NCT05178979|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Clinics will be randomly assigned to intervention or control via coin toss. Two cohorts of participants will be recruited from both the intervention arm and control arm. The total number of participants (N=240) represents the patient cohort, for which change in patient HIV engagement outcomes are the primary outcomes of the study. A second cohort of HIV providers will also be recruited (n\~80-140) depending on the number of HIV providers per clinic, who will provide secondary outcomes related to change in provider knowledge, attitudes, and skills.|t|f|f|t
34097120|NCT04214236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Analysis of data and statistical analysis will be blinded to groups.|Case-control Experimental/Interventional Group: post-operative ciNPT (first 7 days) Control Group: post-operative standard wound care|f|f|f|t
34097121|NCT03815604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"As the preference issue makes RCTs in housing research difficult the investigators will use a specific time window in Zurich that allows conducting an RCT due to a scarcity of IHS settings and will combine the RCT with a comparative observational study in Berne where IHS is already well-established.~The investigators intend to directly compare the outcomes of a randomized controlled trial (RCT) with a study in an observational study design (OSD). Here, the investigators utilize the hypothesis that the OSD will provide similar results as the RCT."||||
34097122|NCT00576342|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34097123|NCT03475043|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Examiners who conduct pre, post, and retention tests with participants do not know to which group a participant is assigned (experimental group, active control group, passive control group).|Experimental group Active control group Passive control group|f|f|f|t
34097124|NCT03696667|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34097125|NCT01276418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097126|NCT06070532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097127|NCT02985710|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802042|NCT03664960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802043|NCT05161585|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Postoperative adjuvant therapy (chemotherapy and radiotherapy) and specific implementation scheme shall be determined by the clinical physician blinded to ctDNA status and randomized group. Other parts are open-label.|||||
33802044|NCT00304031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014473|NCT02431819|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014474|NCT00463320|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34014475|NCT03032861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014476|NCT05495984|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All participants (n=15) will complete Study Visit 1 for the Primary Objective, and Study Visits 2-14 for the Secondary Objective.||||
34014477|NCT01672970|||COHORT||PROSPECTIVE|||||||
34014478|NCT01069952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014479|NCT06491160|||CASE_ONLY||CROSS_SECTIONAL|||||||
34014480|NCT02469779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014481|NCT00366041|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34014482|NCT06223217|||COHORT||PROSPECTIVE|||||||
34014483|NCT00649727|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34097128|NCT03356561|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34097129|NCT05033600|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot study has one arm only: PEMF therapy treatment. This pilot study does not make use of a placebo, no double-blind, and no control group.||||
34097130|NCT00239980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097131|NCT06375720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097132|NCT00504231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097133|NCT01791296|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinding for participants, care providers, investigator and outcomes assessor|RCT|t|t|t|t
34097134|NCT04555369|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097135|NCT00705276|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34097136|NCT05452512|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097137|NCT00270075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097138|NCT01666613|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34097139|NCT05249400|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34097140|NCT05137145|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34097141|NCT06190665|RANDOMIZED|PARALLEL||TREATMENT||NONE||DEB-TACE with visualable microspheres or PVA microspheres||||
34097142|NCT03189433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802045|NCT00000936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097143|NCT00311233|||COHORT||PROSPECTIVE|||||||
34097144|NCT00552500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097145|NCT00185900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097146|NCT02355470|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802046|NCT05771350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097147|NCT01766089|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802047|NCT02639286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802048|NCT01895699|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33802049|NCT04126707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802050|NCT03470376|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients names and allocation to arms was masked for outcomes assessors|NC vs noNC|f|f|f|t
33802051|NCT00150241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014484|NCT00773695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014485|NCT03911921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a randomized Phase II trial|t|f|t|f
34014486|NCT03071328|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014487|NCT01375595|||||PROSPECTIVE|||||||
34014488|NCT04979273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097148|NCT00929097|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34097149|NCT01530256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097150|NCT06006221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34097151|NCT06523816|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097152|NCT02142621|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097153|NCT00912730|||CASE_CONTROL||PROSPECTIVE|||||||
34097154|NCT03513146|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Microbiological assessment of bacterial colonization of the oropharyngeal cavity and the GIT will be masked|Oropharyngeal Administration of mother's milk (OPAMM)|f|f|f|t
33802052|NCT04406792|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The participant and the outcome assessor will be masked to the allocation groups.|"1. Online DPP only: Participants will not be led by a doula diva; they will merely be in small groups led by the dietitian and lifestyle coach. Group members will consist of all people at risk for T2DM.~2. Online DPP+ Doula divas: Online DPP where a doula diva leads the teams."|t|f|f|t
33802053|NCT00152087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802054|NCT01418794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802055|NCT01014273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014489|NCT00500175|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34014490|NCT03392493|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single Blind (Outcomes Assessor)|AB or BA|f|f|f|t
34014491|NCT04004143|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34014492|NCT05077436|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34014493|NCT03257605|||COHORT||RETROSPECTIVE|||||||
34014494|NCT03642470|||COHORT||CROSS_SECTIONAL|||||||
34014495|NCT03166553|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group treated with the Elemene Injection/Elemene Oral Emulusion in Combination with Systematic Chemotherapy including Oxaliplatin , another group treated with Systematic Chemotherapy including Oxaliplatin.||||
34014496|NCT01499680|||CASE_CONTROL||PROSPECTIVE|||||||
34014497|NCT00374608|||CASE_ONLY||PROSPECTIVE|||||||
34097155|NCT01169961|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097156|NCT00500110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097157|NCT01245049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097158|NCT04633304|NA|SINGLE_GROUP||OTHER||NONE||primary end point||||
34097159|NCT03532490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097160|NCT01634750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097161|NCT03607695|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The intervention is a 10-week gait, treadmill-training program. The sessions are 1 hour long, twice a week.||||
34097162|NCT00887588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097163|NCT06358677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will apply topical tretinoin to one half of the face and topical moisturizer (placebo) to the other half of the face daily starting the day that anti-EGFR treatment is initiated. The sides of the face tretinoin and moisturizer are applied to will be randomized. Standardized photographs of the face will be obtained at screening and every two weeks from Week 1 Day 1 until after six weeks of treatment. Photographs will be graded by a dermatologist who will be blinded to treatment sidedness. Facial rash severity will be graded using a modified Investigators Global Assessment (IGA) score.|This is a randomized, double-blind, split-face, phase II study of topical tretinoin prophylaxis for anti-EGFR treatment-induced skin toxicity in metastatic colorectal cancer.|t|t|t|f
34097164|NCT01291875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014498|NCT00254852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014499|NCT00222352|||COHORT||PROSPECTIVE|||||||
34014500|NCT06073535|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The investigator will be unaware of their treatment allocation before surgery. One clinician, not involved in patient treatment and not aware of what therapeutic approach, performed clinical measurement of face swelling on the surgery, 3th and 7th days.||f|f|t|t
34014501|NCT01237353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097165|NCT06293950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097166|NCT05054582|||COHORT||PROSPECTIVE|||||||
34097167|NCT00177632|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097168|NCT05509374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097169|NCT03360487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097170|NCT04621760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||HIV Prevention Decision Support Tool (DST) - An interactive, tablet-based decision support tool that is designed to help women consider options to reduce their risk of HIV, with emphasis on PrEP as an emerging HIV prevention tool for women.||||
34097171|NCT03422471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097172|NCT01031615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097173|NCT02427217|||COHORT||OTHER|||||||
34097174|NCT01691482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097175|NCT05740384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The order of the assessment measurements is batch-wise randomised but there is no masking. Both the participant and investigator know what sort of measurements is being performed.|This is a validation study in 28 ears with Eustachian tube dysfunction.||||
34097176|NCT04279678|||COHORT||PROSPECTIVE|||||||
33712500|NCT05170841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||2 study phases: a single-dose phase (first 8 hours) and a multiple-dose phase starting after the single-dose phase (from 8h until Day 5).In the single-dose phase the patients will receive a single dose treatment, consisting of 1 film-coated tablet and 2 capsules which must be orally administered together at the same time (Day 1). The multiple-dose phase will begin 8 hours after the first dose. The patients assigned to DKP.TRIS/TRAM.HCl fixed combination or TRAM.HCL 100 mg during the single-dose phase will continue to receive the same treatment during the multiple-dose phase; however, the patients assigned to receive placebo during the single-dose phase will either receive DKP.TRIS/TRAM.HCl fixed combination or TRAM.HCL 100 mg during the multiple-dose phase.|t|t|t|t
33712501|NCT03308877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33712502|NCT02918175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33712503|NCT04402931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712504|NCT02775162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712505|NCT05590013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014502|NCT02071849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014503|NCT06131827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014504|NCT02609412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014505|NCT03971149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014506|NCT04724434|||COHORT||PROSPECTIVE|||||||
34097177|NCT01506375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097178|NCT01390584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097179|NCT03958487|NA|SINGLE_GROUP||TREATMENT||NONE|Patients will not be informed about the phases of the study they are in (baseline, treatment, post-treatment, follow-up)|Patients with acquired brain damage and with cognitive deficits on executive/monitoring and self awareness,previously measured through neuropsychological screening||||
34097180|NCT02731859|||COHORT||PROSPECTIVE|||||||
34097181|NCT05897554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097182|NCT01902303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097183|NCT00166894|||NATURAL_HISTORY||OTHER|||||||
34097184|NCT02211742|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34097185|NCT06328894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34097186|NCT05760677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097187|NCT03331588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the operating room a dressing will be placed so that it covers the entire hemithorax whereby the incision is hidden. This is done identically regardless of surgical technique. This dressing is left in place until discharge. If changing of the dressing is needed, either the project-nurse or a nurse for another team will assist.|Parallel Assignment|t|t|f|f
34097188|NCT03410537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097189|NCT04723368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712506|NCT00897260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712507|NCT03767530|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not blinded study.|All subjects will be ophthalmologically evaluated before treatment and at weeks 8, 16 and 24. Subjects will be randomly assigned into 2 study groups. Mibo group will have 3 sessions (basal, week 2, week 4) of thermal therapy with Mibo Thermoflo in both eyes. The control group will use warm compresses and eyelid massage 2 times per day in both eyes. At the week 16 control group will also have 3 sessions of Mibo therapy at 2 weeks interval.||||
33712508|NCT05776420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33712509|NCT02532972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014507|NCT03785535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014508|NCT04690036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014509|NCT02701413|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014510|NCT02998450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014511|NCT00003972|RANDOMIZED|||TREATMENT||||||||
34014512|NCT04715360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014513|NCT03322384|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will begin epacadostat on day 1 of radiotherapy, which will consist of three threatments over one week. Epacadostat will continue until disease progression or intolerance occurs. On days 1, 8, 15, 22, 29, intralesional injectinons of SD101 will be given to patients.||||
34014514|NCT02604472|||COHORT||RETROSPECTIVE|||||||
34014515|NCT02334865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014516|NCT00674401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025354|NCT01609712|||COHORT||PROSPECTIVE|||||||
34097190|NCT01507727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097191|NCT00062959|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34014517|NCT04802707|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, One Site, Open label study in the pediatric and adult population||||
34014518|NCT02978924|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34014519|NCT02429141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014520|NCT03692143|||COHORT||PROSPECTIVE|||||||
34014521|NCT01485250|||||PROSPECTIVE|||||||
34014522|NCT06036888|||CASE_ONLY||PROSPECTIVE|||||||
34014523|NCT03347552|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blind assessor will administer follow up measures. In order to keep the assessor blind to participant status (active vs. control), research staff will facilitate phone calls. To monitor blinding, the blind assessor will record if participants inadvertently un-blind themselves during the assessment and also record their guess to which treatment condition (active versus E-CARE)participants were allocated.||f|f|f|t
34014524|NCT01824134|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34014525|NCT00952549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014526|NCT04595916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014527|NCT04029987|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients, parents and data analysts will be blinded to group assignments.|"age:5-12, American Society of Anesthesia I-III, abdominal laparoscopies, randomly allocated into one of the study groups, randomization sequence will be concealed in sealed envelopes with alphabetic codes. The identifiers will be attached to the opened envelopes and secured by dedicated person independent of randomization proceedings. Patients, parents and data analysts will be blinded to group assignments.~The groups:~* group A → Trans muscular quadrous lamborum block (n=22)~* group B → Intra muscular quadrous lamborum block (n=22)~* group c → control (n=22) will receive conventional analgesia. Sample size Starting number of 22 patients for each group, Recalculation of the sample size will be carried out after studying 10 patients per group.~The alpha error is set at 0.05 and the study power is 0.95."|t|f|f|t
34014528|NCT02882685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014529|NCT05940623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||iCare Home2 tonometer||||
34014530|NCT00290394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014531|NCT02017990|||COHORT||PROSPECTIVE|||||||
34014532|NCT04887233|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34014533|NCT00833352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014534|NCT02149121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014535|NCT04277871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014536|NCT05624827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097192|NCT02216851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097193|NCT05202496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097194|NCT01712464|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34097195|NCT04922762|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34097196|NCT01232842|||CASE_ONLY||RETROSPECTIVE|||||||
34097197|NCT03864549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097198|NCT00992394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097199|NCT00472641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097200|NCT02696577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097201|NCT02443129|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34097202|NCT00250861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097203|NCT01778985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34097204|NCT03548792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34097205|NCT04015687|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34097206|NCT03614988|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34097207|NCT04100187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097208|NCT00665886|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712510|NCT03633682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712511|NCT03205033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33712512|NCT00314093|NA|SINGLE_GROUP||TREATMENT||SINGLE||||||
33712513|NCT00831168|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33712514|NCT01129479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712515|NCT03793777|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|block randomization|Cross-over study with 2 intervention conditions|t|f|t|t
33712516|NCT02027896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712517|NCT00553644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712518|NCT04846621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|all cases in both groups will not know which drug they receive||t|f|f|f
33712519|NCT01842074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712520|NCT05989763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712521|NCT00560859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33793104|NCT04332666|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be performed using sealed envelopes with a ratio of 1:1 including information on treatment assignment and a five-digit number, which will be open by the person responsible for drug constitution. Each vial or syringe will be then labeled with the randomly allocated number it will be assigned to the nursing personnel. The doctors and nurses administering the drugs, as well as the local investigators and research personnel who collected data, were unaware of the treatment assignments.|Randomized, controlled, investigator initiated, phase II/phase III seamless, adaptive, single blinded, interventional trial to evaluate the efficacy, safety and clinical impact of intravenous Ang-(1-7) infusion compared to standard treatment in ICU patients with severe respiratory failure associated with COVID-19. This study will be conducted initially in one center (Erasme Hospital, Belgium), but other sites will be allowed to join if: Number of expected patients with COVID related ARF ≥ 10, experience in treatment of ARDS patients (\> 25/year), including prone positioning ,availability of the equipment required to provide the blood sample processing and storage. We planned a first phase of the study where 30 patients will be randomly receiving Ang-(1-7) or placebo to confirm the safety. The Final power calculation will be reassessed after 30 included patients (i.e. 15 in each arm), in line with a preplanned expected total number of patients needed of 60.|t|f|t|t
33793105|NCT00223119|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33793106|NCT03799380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793107|NCT01926002|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33793108|NCT01779999|||COHORT||PROSPECTIVE|||||||
34014537|NCT04842500|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be randomized to one of four baseline reinforcement conditions. They will not be informed of which condition they have been assigned to, or why they have been assigned to it.|The investigators will enroll 80 adults with developmental disabilities in a low-stakes translational investigation employing a 2x2 factorial, crossed, and randomized matched blocks design, with batched randomization logic. Procedures will include: (a) matching participants within batches according to progressive ratio reinforcer analysis results, and (b) randomly assigning participants to one of four experimental conditions to determine whether information about reinforcer value can be used to set baseline parameters that either promote or eliminate bursts during extinction.|t|f|f|f
34097209|NCT06493942|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Blinding to participants : will not know either the intervention or the comparator will be applied to their teeth Blinding to investigator: covering the 2 syringes with opaque seal to avoid performance bias Blinding to outcomes assessor: to overcome detection bias|Randomized control trial|t|f|t|t
34014538|NCT04135196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|all data were blinded for analysis||f|f|f|t
34014539|NCT03245957|||CASE_ONLY||PROSPECTIVE|||||||
34014540|NCT02957188|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34097210|NCT01309880|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34097211|NCT05664815|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization 3:1||||
34014541|NCT02132754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014542|NCT04912882|||COHORT||PROSPECTIVE|||||||
34014543|NCT04019184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014544|NCT03776292|||OTHER||PROSPECTIVE|||||||
34014545|NCT03221348||SEQUENTIAL||TREATMENT||NONE||3+3 sequential cohort design||||
34014546|NCT06067321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014547|NCT04111848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study medications were prepared by a pharmacist who was not involved in the patient management or the data collection. Both the patients and the stuff involved in their management were unaware of the group assignment. Equal rates of the drug infusion and equal volumes of the administered drugs were applied to all patients to ensure double blinding of the study.|90 female patients scheduled for cancer breast surgeries will be assigned to 2 groups, each of 45. Group (K) will receive a bolus of 0.5 mg/kg ketamine with induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. Group (KM) will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery.|t|t|t|t
34014548|NCT03016221|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34014549|NCT00393471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014550|NCT05684471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014551|NCT02756247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014552|NCT03631082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The two groups will be Slump stretching group and Lumbar mobilization group. All physical therapy techniques in both groups will be applied 3 times in a week up to 2 weeks with each session consisting of 25-40 minutes.~Group 1 will receive slump stretching along with standardized exercises while group 2 will recieve lumbar mobilization along with standardized exercises.~Demographic details of the patients will be collected at baseline (1st Visit) while Modified Oswestry Low Back Pain Disability Questionnaire,Numeric pain rating scale,Fear-Avoidance Beliefs Questionnaire,Active range of motion (AROM) of lumbar spine and Short-Form Health Survey (SF-36) will be measured at baseline, 1st week, and final week."|t|f|f|f
34014553|NCT03192865|||COHORT||PROSPECTIVE|||||||
34014554|NCT04801953|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34014555|NCT02881060|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34014556|NCT02623049|||COHORT||CROSS_SECTIONAL|||||||
33712522|NCT05825521|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34097212|NCT05038514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple-blind (i.e., triple-masking) studies are randomized experiments in which the treatment or intervention is unknown to (a) the research participant, (b) the individual(s) who administer the treatment or intervention, and (c) the individual(s) who assess the outcomes|A triple-blind randomized controlled clinical trial|t|f|t|t
34097213|NCT03665168|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097214|NCT03640377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Tablets will be crushed and given with orange juice|Children ages 12-48 months who are infected with S. japonicum (Philippines) or S. mansoni (Uganda) will be randomized to receive either 40 or 60 mg/kg of praziquantel at baseline. Six months later, half of each group will receive second treatment at same dose or placebo.|t|f|t|t
34097215|NCT03545841|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34097216|NCT02205359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097217|NCT06327854|||COHORT||PROSPECTIVE|||||||
34097218|NCT00076609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712523|NCT02292277|||CASE_CONTROL||PROSPECTIVE|||||||
33712524|NCT05531760|||COHORT||RETROSPECTIVE|||||||
33712525|NCT02384889|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33712526|NCT00963547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712527|NCT02888444|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33712528|NCT02013739|||COHORT||PROSPECTIVE|||||||
33712529|NCT02689388|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33712530|NCT05508581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712531|NCT01918085|RANDOMIZED|CROSSOVER||||NONE||||||
33712532|NCT00355693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712533|NCT02197845|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33793109|NCT03404583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793110|NCT02049866|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014557|NCT01426035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014558|NCT00208117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34097219|NCT02255695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793111|NCT06002360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793112|NCT06122896|NA|SINGLE_GROUP||SCREENING||NONE||||||
34097220|NCT05832814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097221|NCT01089543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097222|NCT00038415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097223|NCT05750082|||CASE_ONLY||PROSPECTIVE|||||||
34097224|NCT05020912|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will serve as their own control - one tumor will be PDT-treated and other left as untreated control||||
34097225|NCT06468917|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a randomized, controlled, open-label study. The Study will be registered in the International Standard Randomized Controlled Trial Registry.~All patients encountering inclusion criteria will be randomized on POD1, using computer-generated randomization codes.~Group A: Drain removal on POD 1 (in case of POD 1 DFA\< 300 U/L) Group B: Drain removal on POD 3 (in case of POD 1 DFA\< 300 U/L)"||||
34097226|NCT03004092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097227|NCT00430664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097228|NCT05915169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||topical haemoglobin spray care group and standart gas dressing with saline solution care group||||
34097229|NCT00069329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097230|NCT01521364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097231|NCT00164866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097232|NCT00400205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097233|NCT03593447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097234|NCT02369692|||OTHER||PROSPECTIVE|||||||
34014559|NCT00225537|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34014560|NCT06139393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014561|NCT03510182|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible participants with aphasia will receive the tDCS||||
34014562|NCT04219735|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo capsules looking identical to minocycline capsules|Placebo vs minocycline|t|t|t|t
34097235|NCT03065738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097236|NCT05302232|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Treatment allocation will be single blinded, in that the researcher will know what intervention the patient is receiving but the patient will not.|Patients will be randomised to receive joint injection of either lidocaine plus steroid or, as a control, just steroid injection|t|f|f|f
33712534|NCT00320411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712535|NCT03710538|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|snack beverage or flavored placebo will be not recognizable|"1. Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study \[condition control\]~2. Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study \[snack effect on PPG excursion\]~3. Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5); \[exercise effect on the PPG excursion\]~4. Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5). \[Combined snack and exercise effect on the PPG excursion\]"|t|f|f|f
33712536|NCT00018837||PARALLEL||||||||||
33712537|NCT05316142|RANDOMIZED|PARALLEL||OTHER||NONE||Clinical trial study with two parallel groups, randomized using computer permuted block randomization, 35 patients in each group are included and followed up for at least 6 months.||||
33712538|NCT05773963|NA|SINGLE_GROUP||OTHER||NONE||||||
33712539|NCT04229394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subjects and study site personnel (other than the study site pharmacists) are all blinded to the treatment assignment. An un-blind pharmacist is necessary for study drug preparation.||t|t|t|t
33712540|NCT02321644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712541|NCT00059982||||TREATMENT||NONE||||||
33712542|NCT03805321|||COHORT||PROSPECTIVE|||||||
33793113|NCT04628572|||OTHER||RETROSPECTIVE|||||||
33793114|NCT00974025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793115|NCT03483662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793116|NCT05712018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712543|NCT04072302|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33793117|NCT03400462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793118|NCT03002246|||COHORT||PROSPECTIVE|||||||
33793119|NCT02142348|||COHORT||PROSPECTIVE|||||||
33712544|NCT01695265|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793120|NCT06462963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793121|NCT02020824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793122|NCT04060537|||COHORT||RETROSPECTIVE|||||||
33793123|NCT05922124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled clinical study with historical controls||||
33793124|NCT02534350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793125|NCT02837497|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33793126|NCT03185819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793127|NCT06232629|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The subject will be blind to stimulation conditions (sham/active TUS). The assessor will be blind to the stimulation condition (sham/active TUS) while analyzing LFPs.||t|f|f|t
33793128|NCT01760837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793129|NCT01370694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793130|NCT03774914|||COHORT||PROSPECTIVE|||||||
33793131|NCT03043638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014563|NCT02733081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793132|NCT05899179|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34014564|NCT03767855|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34014565|NCT01363804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793133|NCT05969665|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||single-centre, randomized controlled, open-label trial||||
33793134|NCT00780663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793135|NCT04423328|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33793136|NCT03336450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793137|NCT06600425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793138|NCT00980135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33793139|NCT05818904|||COHORT||PROSPECTIVE|||||||
33793140|NCT05733936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33793141|NCT03356444|RANDOMIZED|PARALLEL||TREATMENT||NONE|The administration methods of the two groups are different, therefore, the investigators decide not to use masking.|||||
33793142|NCT00754936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793143|NCT03426683|RANDOMIZED|PARALLEL||TREATMENT||NONE||an open label, parallel study||||
33793144|NCT04455399|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intravitreal Injection Guide (Malosa, Beaver Visitec International, Waltham, MA)||||
33793145|NCT01134354|||||PROSPECTIVE|||||||
33793146|NCT01287052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014566|NCT00125411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014567|NCT04870450|||COHORT||PROSPECTIVE|||||||
34014568|NCT02872792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014569|NCT01936519|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014570|NCT03475264|||CASE_CONTROL||PROSPECTIVE|||||||
34014571|NCT04790123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014572|NCT04079127|||COHORT||OTHER|||||||
34014573|NCT05002413|||OTHER||PROSPECTIVE|||||||
34014574|NCT03852459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|active gel and matching vehicle control gel||t|t|t|t
34097237|NCT00539214|||||PROSPECTIVE|||||||
34097238|NCT05326100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097239|NCT04102111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014575|NCT05077371|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34014576|NCT01706874|||CASE_CONTROL||PROSPECTIVE|||||||
34014577|NCT00569790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014578|NCT04435106|||CASE_CONTROL||RETROSPECTIVE|||||||
34097240|NCT06272682|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomised, controlled, non-inferiority analytical study||||
34097241|NCT02979054|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34097242|NCT04332185|NA|SINGLE_GROUP||TREATMENT||NONE||(VST) included the following steps. a-traumatic tooth extractio. One-cm long vestibular access incision was made 3-4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators . implant was placed. A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel then stabilized using a micro screw to the alveolar bone. The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft. A chairside-fabricated anatomical healing abutment was used to seal the socket orifice . restorative phase then took place 45 days post-surgery till the final restoration finally cemented at 2 months post-surgery and followed up for 1 and 2 years using CBCT.||||
34097243|NCT00801268|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34097244|NCT05417256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34097245|NCT00003456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097246|NCT02070991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097247|NCT02421965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014579|NCT01197417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014580|NCT02387593|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34014581|NCT04439773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Participants are randomly assigned to controll group or lidocaine group. Participants of control group are given placebo while participants of lidocaine group are given lidocaine.|t|t|f|t
34014582|NCT01057381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014583|NCT05752565|NA|SINGLE_GROUP||OTHER||NONE||||||
34014584|NCT01681966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025355|NCT05612672|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants will get the intervention and outcomes will be measured pre- and post-implementation||||
34014585|NCT03093818|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"A 10% random sample will be re-assessed for causality and severity of recorded ADE will by a second independent, blinded (unaware of patient allocation) assessor.~Drug-genotype association of the ADE as per the Dutch Pharmacogenomics Working Group guideline will be assessed by a blinded review committee"||f|f|f|t
34014586|NCT04612517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double-blind, placebo-controlled, single ascending dose trial in healthy subjects, randomized to ZP7570 or placebo|t|f|t|t
34014587|NCT03867799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014588|NCT01882179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014589|NCT02496819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34014590|NCT01762124|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34014591|NCT04731402|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|t|f|f|f
34014592|NCT03074539|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014593|NCT03828448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014594|NCT00273741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014595|NCT04027374|||CASE_CONTROL||PROSPECTIVE|||||||
34014596|NCT05959434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014597|NCT06125496|||OTHER||OTHER|||||||
34014598|NCT06196021|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34014599|NCT05960474|||OTHER||CROSS_SECTIONAL|||||||
34014600|NCT04121650|||CASE_ONLY||PROSPECTIVE|||||||
34014601|NCT00560937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097248|NCT01795755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014602|NCT05099484|||COHORT||PROSPECTIVE|||||||
34097249|NCT01864096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097250|NCT04091308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097251|NCT00747071|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34014603|NCT04917718|NA|SINGLE_GROUP||OTHER||NONE||||||
34014604|NCT02268266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014605|NCT01414751|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34014606|NCT04211142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014607|NCT02577341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014608|NCT02138942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014609|NCT04160845|||COHORT||CROSS_SECTIONAL|||||||
34014610|NCT00390702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014611|NCT05695092|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|One group is taking actual intervention and other is taking sham interventioin||t|f|f|f
34014612|NCT00287313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014613|NCT02957266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014614|NCT04971213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097252|NCT03276481|||COHORT||PROSPECTIVE|||||||
33712545|NCT06504043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33712546|NCT02028624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33712547|NCT05079529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study is randomized control double-blinded true experimental study. So the only party that acknowledge whom is given Polysaccharide Peptide capsule or Placebo is the collaborator who provides the adjuvant therapy agent. There is an exception for Outcomes Assessor. They might ask for detail description of the intervention that have been given to the participant if there is any serious adverse event going on.|"This study conducted cardiometabolic syndrome patients based on NCEP-ATPIII criteria with modification of obesity classification to Asian population criteria. All of the participant would be divided into 2 groups/arms in which one group will be given Polysaccharide Peptide capsule 3 times daily for 90 days and the other one will be given Placebo in the same duration of time.~Before Polysaccharide Peptide is given, there will be a sequence of pre-test examination, include: blood pressure measurement, body weight and body height measurement to determine Body Mass Index status, waist circumference measurement, blood glucose profile, lipid profile, renal function profile, parameter of inflammation status, parameter of oxidative stress, parameter of endothelial function, and completion of SF 36 questionnaire in which all of them will be done as post-test after intervention completed."|t|t|t|t
34097253|NCT06488001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33712548|NCT00002210||||TREATMENT||||||||
33712549|NCT02618889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712550|NCT03631472|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with RheOx||||
33712551|NCT00686192|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33712552|NCT04819646|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33712553|NCT04770012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, clinical care providers and research staff will be blinded to treatment allocation.|2:2:1 randomization to placebo-control, aspirin 81 mg daily or clopidogrel 75 mg daily|t|t|t|f
34014615|NCT04921124|NA|SINGLE_GROUP||OTHER||NONE||This is an open-label, parallel, clinical trial in two separate groups, men and women.||||
34014616|NCT03314662|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial is designed as a double-blind study||t|t|t|t
34014617|NCT00442000|||||RETROSPECTIVE|||||||
34014618|NCT04785508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34014619|NCT00930254|RANDOMIZED|PARALLEL||||NONE||||||
34097254|NCT02051283|||||RETROSPECTIVE|||||||
34097255|NCT06295146|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE||For trainees, we will use a randomized, single-blinded, two-period cross-over study design for Groups 1 and 2. Participants will complete baseline assessments and then be randomized to either Group 1 or Group 2. After we have completed enrollment for Groups 1 and 2 (N=40 per group) we will enroll participants into Group 3 ( N=40 per group).|t|f|f|f
34097256|NCT00499941|||OTHER||OTHER|||||||
34014620|NCT06221267|||OTHER||PROSPECTIVE|||||||
34014621|NCT02033330|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34014622|NCT03295695|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014623|NCT01435187|||COHORT||PROSPECTIVE|||||||
34014624|NCT05895734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34097257|NCT04303403|NA|SEQUENTIAL||TREATMENT||NONE||The first part of this study will be a standard 3+3 dose-escalating||||
34097258|NCT02483273|||CASE_CONTROL||PROSPECTIVE|||||||
34097259|NCT06328621|||COHORT||PROSPECTIVE|||||||
34097260|NCT02603627|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34097261|NCT02458300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097262|NCT04657692|||CASE_ONLY||RETROSPECTIVE|||||||
34097263|NCT03169972|||COHORT||PROSPECTIVE|||||||
34097264|NCT06499220|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34097265|NCT04739436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097266|NCT00265642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097267|NCT00425854|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33712554|NCT02554448|NA|SINGLE_GROUP||SCREENING||NONE||||||
33712555|NCT02479178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712556|NCT02692703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793147|NCT02787161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793148|NCT04628286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793149|NCT05489406|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33712557|NCT00553514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712558|NCT03056898|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33793150|NCT03444506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793151|NCT02690090|||CASE_ONLY||PROSPECTIVE|||||||
34097268|NCT00754286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33793152|NCT04874415|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34097269|NCT03967314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|The patients were aged 18-65 years, American Society of Anesthesiologists classification I-II, and scheduled for lumbar disc surgery under general anesthesia. The patients were randomly divided into two groups using a randomizing computer program: a TLIP block group (group T) and a wound infiltration group (group W), with 30 patients in each group).|t|f|f|t
33793153|NCT06316206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793154|NCT03123172|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097270|NCT03222609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936060|NCT03612674|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will not be informed about diagnostic procedure in order to evaluate the acceptability of the exam with or without the studied device (in fact at the end of the examination care provider will ask participant about perceived pain during the procedure through the VAS score).|Subjects will be randomized in two arms: a control-arm and an experimental-arm. Then arms data will be compared.|t|f|f|f
33936061|NCT00590941|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33936062|NCT01138462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014625|NCT03516084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014626|NCT03994549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, double-blind, placebo-controlled, single ascending dose trial in healthy subjects, randomized to ZP7570 or placebo|t|f|t|t
34014627|NCT04214717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014628|NCT03212521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014629|NCT00400894|||DEFINED_POPULATION||OTHER|||||||
34014630|NCT02870400|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34014631|NCT04572594|||CASE_ONLY||RETROSPECTIVE|||||||
34014632|NCT04781036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34025356|NCT05898165|||COHORT||PROSPECTIVE|||||||
34025357|NCT00656266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097271|NCT00927186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097272|NCT06636591|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097273|NCT04999293|||COHORT||RETROSPECTIVE|||||||
34097274|NCT03802929|||COHORT||PROSPECTIVE|||||||
33712559|NCT02521610|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33712560|NCT02931968|||COHORT||RETROSPECTIVE|||||||
33712561|NCT03623802|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a randomized clinical trial with parallel-group design including two intervention groups: integral movement therapy and conventional local movement therapy.||||
33793155|NCT01374893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33793156|NCT04282304|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled, open-label study||||
33793157|NCT00831935|||COHORT||PROSPECTIVE|||||||
33793158|NCT00232635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793159|NCT02940704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793160|NCT06552676|||COHORT||PROSPECTIVE|||||||
33793161|NCT02682537|||OTHER||PROSPECTIVE|||||||
33793162|NCT05316805|||COHORT||PROSPECTIVE|||||||
33793163|NCT05617586|||CASE_ONLY||RETROSPECTIVE|||||||
33793164|NCT04747392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793165|NCT03636919|||COHORT||PROSPECTIVE|||||||
33793166|NCT02079324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793167|NCT04039984|NA|SINGLE_GROUP||TREATMENT||NONE||This study design will be a prospective cohort with a retrospective control group.||||
33793168|NCT06122857|||OTHER||RETROSPECTIVE|||||||
33793169|NCT01069341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793170|NCT04273412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793171|NCT00354640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793172|NCT01018212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793173|NCT01610479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936063|NCT06074133|||COHORT||PROSPECTIVE|||||||
33936064|NCT05597111|||CASE_CONTROL||PROSPECTIVE|||||||
33936065|NCT03391336|||CASE_ONLY||RETROSPECTIVE|||||||
33936066|NCT03656146|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33936067|NCT00261378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936068|NCT06348862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blinded||t|f|t|f
33936069|NCT01632553|||CASE_CONTROL||PROSPECTIVE|||||||
33936070|NCT05815862|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936071|NCT02520141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936072|NCT02902692|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33936073|NCT04829864|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936074|NCT02060903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936075|NCT03885674|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to one of three intervention groups; video call reminders, automated text messages, or no intervention (standard care).||||
33936076|NCT02080494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936077|NCT05223686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936078|NCT05655416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936079|NCT05637541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936080|NCT02300844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936081|NCT00857116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33936082|NCT04443257|||COHORT||PROSPECTIVE|||||||
33936083|NCT00205374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936084|NCT04154761|||CASE_ONLY||CROSS_SECTIONAL|||||||
33936085|NCT02208505|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936086|NCT05700760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants will randomize participants to a study arm. The participant will be assigned to a new research assistant for the follow-up assessment, who is masked from the study arm.|ROSE vs Enhanced Care as Usual (CAU)|f|f|f|t
33936087|NCT01427127|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33936088|NCT02371694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33936089|NCT05659940|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936090|NCT04212611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936091|NCT05124067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936092|NCT02802657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936093|NCT03537001|||COHORT||PROSPECTIVE|||||||
33936094|NCT01126281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936095|NCT02950311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936096|NCT01018615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936097|NCT00781183|NA|SINGLE_GROUP||||NONE||||||
33936098|NCT03998995|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33936099|NCT05265585|||CASE_ONLY||PROSPECTIVE|||||||
33936100|NCT05000866|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||This study utilizes a randomized controlled trial design to evaluate the efficacy of two intervention components for couples HIV testing and counseling (CHTC): a communication skills training video and a substance use module. Participants are randomized in a full-factorial design to one of 4 conditions: CHTC as usual; CHTC + communication skills training videos; CHTC + substance use module; or CHTC plus both adjunct components.||||
33936101|NCT03733249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936102|NCT02074436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936103|NCT04722692|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will have been injected with SPIO during the breast procedure. Those who have invasive breast cancer on final pathology will receive radioisotope and undergo SLND. Patients will be randomly allocated to one of two arms: Experimental arm (SLND will be SPIO-guided and the isotope activity will be controlled as background) and control arm (SLND will be isotope-guided and SPIO activity will be controlled as background).||||
33936104|NCT01428414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936105|NCT05609500|||CASE_ONLY||CROSS_SECTIONAL|||||||
33936106|NCT05616572|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33936107|NCT04196049|||CASE_ONLY||PROSPECTIVE|||||||
33936108|NCT00766181|||COHORT||CROSS_SECTIONAL|||||||
33936109|NCT04448340|||COHORT||PROSPECTIVE|||||||
33936110|NCT06084065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936111|NCT02981173|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33936112|NCT01579526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33936113|NCT02462811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936114|NCT01203111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936115|NCT03305913|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||According to the standard 3+3 dose finding strategy, a safety assessment will be performed after the test of each dose level (patient cohorts of n=3) and the frequency of DLTs determined. Based on the results the dose for the consecutive patient cohort will either be escalated (0/3 DLTs), repeated (1/3 DLTs) or deescalated (\>1/3 DLTs).||||
33936116|NCT02496390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936117|NCT01037140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936118|NCT01950364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936119|NCT01183104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936120|NCT02685449|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33936121|NCT03032523|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33936122|NCT02983851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097275|NCT05039593|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Before starting the practice in this study, the purpose of the research will be explained to all nurses working in the unit by the researchers and an information meeting about oral care will be held. After the operability of the guide in the intensive care unit is ensured, the data collection phase will begin. Randomization of patients will be done by the nurse in charge of the service.~The frequency of oral care of the patients will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses."||||
34097276|NCT02783937|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33936123|NCT06379672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936124|NCT02234024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936125|NCT05550857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936126|NCT04176328|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, exploratory, open-label, dose-escalation study evaluating the pharmacokinetics of inhaled Teicoplanin in Cystic Fibrosis patients.||||
33936127|NCT05347563|||COHORT||PROSPECTIVE|||||||
33712562|NCT02554266|||OTHER||PROSPECTIVE|||||||
33712563|NCT02798185|||COHORT||PROSPECTIVE|||||||
33936128|NCT02825238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936129|NCT00600236|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34097277|NCT01666080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097278|NCT06569264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple|A randomized clinical trial|t|f|t|t
34097279|NCT05803343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097280|NCT06579248|NA|SINGLE_GROUP||OTHER||NONE||||||
34097281|NCT03934879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One school will receive FitClub intervention. Second school will receive regular school activities.||||
34097282|NCT02182700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097283|NCT02405065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097284|NCT03120039|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34097285|NCT01801527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34097286|NCT04568512|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33712564|NCT03790488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712565|NCT03750604|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33712566|NCT00070278|RANDOMIZED|||TREATMENT||||||||
33712567|NCT05679232|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study requires a blinded evaluator for the assessment of the primary outcome (i.e. radiological signs of failed osseointegration). The investigators and the participating patients are not blinded to treatment allocation.||f|f|f|t
33712568|NCT02164812|NA|SINGLE_GROUP||||NONE||||||
33712569|NCT04201002|||CASE_ONLY||RETROSPECTIVE|||||||
33712570|NCT04412824|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33712571|NCT04425161|||COHORT||PROSPECTIVE|||||||
33712572|NCT02697032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712573|NCT00002942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712574|NCT05861921|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The participants and recruiters will not know the study group to which the next participant will be assigned.~The trial participants, outcome assessors, and data analysis will be blinded after assignment to interventions.~Emergency un-blinding: In cases of emergency to decrease or prevent any harms for the participants."||t|f|f|t
33712575|NCT01224067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712576|NCT03810898|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Huntington's disease gene expansion carriers (HDGEC) compared to healthy controls (HC)||||
33712577|NCT04756024|||COHORT||CROSS_SECTIONAL|||||||
33712578|NCT04255524|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33712579|NCT01923220|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712580|NCT04605484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712581|NCT01903187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936130|NCT01060527|||CASE_CONTROL|||||||||
33936131|NCT01655641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936132|NCT05977374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|one of my groups is experimental and the other one is controlled.||t|f|f|f
33936133|NCT03245294|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33936134|NCT06485661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936135|NCT01659489|||COHORT||PROSPECTIVE|||||||
33936136|NCT05719415|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33712582|NCT03769454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712583|NCT04608526|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33712584|NCT04475653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This prospective, randomized clinical trial included 54 sarcoidosis patients who received an AT (Group Ia: 27 with coaching and Group Ib: 27 without). Exercise capacity and fatigue scores (Fatigue Assessment Scale) were evaluated at baseline and after three months. A historical group of sarcoidosis patients (Group II; n=41) from an earlier study who did not follow a physical activity program served as controls.|f|f|t|t
33712585|NCT00368355|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712586|NCT05325554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712587|NCT00217386||||TREATMENT||NONE||||||
33712588|NCT05035953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712589|NCT05205005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Dietary supplement vs placebo|t|t|t|t
33712590|NCT03036046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients in group low dose fluconazole will be enrolled ahead of group high dose fluconazole. Group posaconazole will be enrolled in parallel according to prevaling practice in the institutions involved in the study||||
33712591|NCT05192681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936137|NCT03619902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936138|NCT06166251|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participants were not informed that there were different intensity and timing groups. In addition, the participant did not know whether he/she was exercising at moderate or low intensity because the speed of the treadmill during the exercise was adjusted by the therapist according to a predetermined target heart rate.~The participant's heart rate was monitored with a polar heart rate monitor."|75 young adults were divided into five groups: two groups that did low or moderate intensity aerobic exercise before motor practice (LOW-MP, MOD-MP), two groups that did aerobic exercise after motor practice (MP-LOW, MP-MOD), and non-exercise control group.|t|f|f|f
33936139|NCT04268706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097287|NCT05951842|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33936140|NCT02871570|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33936141|NCT00005187|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33936142|NCT02772991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936143|NCT03201744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936144|NCT02159001|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33936145|NCT04034069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936146|NCT06237608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936147|NCT03968588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097288|NCT01301001|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34097289|NCT01498666|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34097290|NCT04716309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097291|NCT03660982|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34097292|NCT05628974|||CASE_ONLY||PROSPECTIVE|||||||
34097293|NCT02223130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097294|NCT04105660|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34097295|NCT01429935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097296|NCT02285244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097297|NCT03473158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097298|NCT03391323|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34097299|NCT00331149|RANDOMIZED|PARALLEL||TREATMENT||||||||
34097300|NCT04122495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097301|NCT03286075|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||3 arms will take part in the study: Anode tDCS Cathode tDCS Placebo tDCS These 3 types of tDCS stimulation will enable us to study the different modulations possible for the DLPFC and the impact on all the variables previously mentioned|t|t|t|t
34097302|NCT05633446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"* This trial is double-blinded (blinded to investigators and participants)~* Blinding will be maintained for the duration of the study."||t|f|t|f
33936148|NCT02591251|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34097303|NCT04317846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multi-center randomised controlled trial|t|t|f|f
34097304|NCT06504732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097305|NCT01429623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097306|NCT05493345|||CASE_ONLY||PROSPECTIVE|||||||
34097307|NCT04885010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097308|NCT06070051|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34097309|NCT00857051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097310|NCT02526394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097311|NCT05268237|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The study is being conducted in 2 parts. Part 1 is an open-label study with no requirements for randomisation or blinding. Part 2 is a placebo-controlled, observer blinded, partially randomised, repeated treatment double-blinded controlled trial with active comparator.||t|f|t|f
34097312|NCT03476252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Stemi group undergoing primary pci||||
34097313|NCT06203665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097314|NCT03380988|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34097315|NCT02567292|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34097316|NCT04250038|||COHORT||PROSPECTIVE|||||||
34097317|NCT04612127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097318|NCT00819832|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097319|NCT03092037|||OTHER||CROSS_SECTIONAL|||||||
34097320|NCT01576393|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097321|NCT02503865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097322|NCT00172666|||CASE_CONTROL||OTHER|||||||
34097323|NCT04062604|||COHORT||PROSPECTIVE|||||||
34097324|NCT05470725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097325|NCT04383015|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients with type 1 diabetes on insulin pump therapy will remain on their usual insulin regimen. However, we are testing percent basal rate reductions during exercise (50 percent reduction) with or without carbohydrate feeding.||||
34097326|NCT01580332|||COHORT||PROSPECTIVE|||||||
34097327|NCT01560988|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34097328|NCT06185530|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34097329|NCT04772430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34097330|NCT02722603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097331|NCT00593645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936149|NCT02411266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936150|NCT04527536|||CASE_CONTROL||PROSPECTIVE|||||||
34097332|NCT02137356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793174|NCT04892290|||COHORT||RETROSPECTIVE|||||||
33793175|NCT05790616|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33793176|NCT01918163|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33793177|NCT04061902|||COHORT||PROSPECTIVE|||||||
33936151|NCT04668365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936152|NCT04589832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936153|NCT01006915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936154|NCT03373279|||CASE_ONLY||PROSPECTIVE|||||||
33936155|NCT05830240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936156|NCT04624529|||COHORT||CROSS_SECTIONAL|||||||
33936157|NCT05690711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936158|NCT02892734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936159|NCT06359886|NA|SINGLE_GROUP||PREVENTION||NONE||A Pilot Study||||
33936160|NCT02396264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936161|NCT01191138|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936162|NCT03215745|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33936163|NCT04145193|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is designed to evaluate the efficacy and safety of standard-of-care adjuvant mFOLFOX6 chemotherapy alone or in combination with novel oncology therapies. The study will be conducted in subjects who have undergone radical surgical resection for Stage II or III MSS-CRC, are eligible for mFOLFOX6 adjuvant therapy, and are confirmed as ctDNA positive post-surgery.||||
33936164|NCT02243306|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33936165|NCT03710291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936166|NCT04376736|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33936167|NCT01966406|RANDOMIZED|PARALLEL||||NONE||||||
33936168|NCT03930810|||COHORT||RETROSPECTIVE|||||||
33936169|NCT05560074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33936170|NCT05022706|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33936171|NCT06463106|||CASE_CONTROL||RETROSPECTIVE|||||||
33936172|NCT02325089|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33936173|NCT01145404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936174|NCT05018052|||OTHER||OTHER|||||||
33936175|NCT02483351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936176|NCT02094664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936177|NCT04300842|||COHORT||CROSS_SECTIONAL|||||||
33936178|NCT01855867|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936179|NCT06049251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936180|NCT01731275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936181|NCT06352502|||COHORT||PROSPECTIVE|||||||
34097333|NCT04942509|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were allocated into the experimental and wait-list control groups. The experimental group colored for at least 5 days during a 10-day period while the control group did not.||||
34097334|NCT05925855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097335|NCT00437775|||DEFINED_POPULATION||PROSPECTIVE|||||||
34097336|NCT02376335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097337|NCT03831555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097338|NCT04280861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097339|NCT03569007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|f|t|t
34097340|NCT01292473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097341|NCT01426646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097342|NCT00272558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712592|NCT00759031|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33712593|NCT05067036|||COHORT||CROSS_SECTIONAL|||||||
33712594|NCT02076698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712595|NCT01380171|||CASE_ONLY||RETROSPECTIVE|||||||
33712596|NCT02146898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712597|NCT00327678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712598|NCT03825315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded|Subjects will be randomly assigned to 1 of 3 treatment groups: DAXI for injection LOW dose, DAXI for injection HIGH dose, Placebo|t|t|t|t
33712599|NCT02135302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712600|NCT00854477|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936182|NCT03565926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936183|NCT05570136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The treatment group will receive functional exercise intervention, and the sham control group will receive weekly newsletters and phone calls.|f|f|f|t
33936184|NCT04193605|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33936185|NCT01197872|||||PROSPECTIVE|||||||
33936186|NCT01736930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936187|NCT01241890|||COHORT||PROSPECTIVE|||||||
33936188|NCT02458742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936189|NCT01221662|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33936190|NCT02184390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936191|NCT02758106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33936192|NCT05002036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936193|NCT06364306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients are blinded to their treatment allocation until hospital discharge criteria according to the primary endpoint are fulfilled. After discharge, blinding is difficult to be ensured because there is no control, if dressing have been removed or modified. To ensure patient blinding during hospital stay, patients from both treatment arms will receive identical dressings as if an open and minimal-invasive access had been performed. In case the dressing must be changed during the hospital stay, this will be performed while the patient is blinded using a cover.~In case for any reason the patient has been unblinded to his treatment allocation (accidental or intentional dressing removal, bed-side wound opening, other) all outcome data are assessed regardless and unblinding is documented and reported in the final report."||t|f|f|t
33936194|NCT05705687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936195|NCT05111184|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936196|NCT04993430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||HRS8807 monotherapy and in combination with SHR6390||||
33936197|NCT02378610|||COHORT||RETROSPECTIVE|||||||
33936198|NCT03453346|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, historical control||||
33936199|NCT03745391|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|A blinded neurologist investigator (M. Gomis) will perform the clinical assesment of included patients at 90 days in outpatient clinics|Patients will be included consecutively and randomized (1:1) to Multimodal MR or Multimodal CT stratifying by age (\<70, ≥70), stroke severity (NIHSS\<18, ≥18) and time from onset to hospital (\<8 hours, ≥8 hours)|f|f|f|t
33936200|NCT03489538|||CASE_ONLY||RETROSPECTIVE|||||||
33936201|NCT04124952|||COHORT||PROSPECTIVE|||||||
33936202|NCT00159653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097343|NCT00621322|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34097344|NCT06064201|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34097345|NCT03954730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed envelope method is used to randomly assign participants into two groups. The therapist will know about the treatment but patient is not aware of treatment type.|There will be two treatment groups of participants, One group will be trained on eccentric graded protocol whereas the other will receive active release technique of quadriceps.|t|f|f|f
34097346|NCT00452400||PARALLEL||TREATMENT||||||||
34097347|NCT06146400|||CASE_CONTROL||PROSPECTIVE|||||||
34097348|NCT03521336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A 2:1 ratio of randomization (intervention group:control group) was used.|t|f|f|f
34097349|NCT00676637|||COHORT||PROSPECTIVE|||||||
33712601|NCT05503615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33712602|NCT02397785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712603|NCT04669639|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The care provider and outcome assessor will be unaware of the study design|There has been a recent renewed interest in using the suprascapular nerve block (SSNB) as a phrenic nerve sparing approach for analgesia after shoulder surgery. The suprascapular nerve provides 70% of the sensory input to the glenohumeral joint and also innervates the infraspinatus and supraspinatus muscles. However, some researchers suggest that SSNB alone cannot provide a sufficient analgesia.The high-thoracic erector spinae plane block (HT-ESPB) has been described in several case reports as an effective analgesic modality for the shoulder region without causing motor or phrenic nerve block|f|t|f|t
33712604|NCT05490329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712605|NCT01922128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712606|NCT01101646|RANDOMIZED|CROSSOVER||||NONE||||||
33712607|NCT04011761|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel assignment||||
33712608|NCT03918720|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33712609|NCT01083745|||COHORT||PROSPECTIVE|||||||
33712610|NCT05611398|||COHORT||RETROSPECTIVE|||||||
33936203|NCT05807191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Single blinding (to mothers) was performed in this study. Care provider blinding was performed because the mothers did not know whether kangaroo care was carried out in accordance with a guide. In addition, because the premature babies in the study would not know which group they were in, participant blinding was performed.~In order to prevent bias in the analysis phase of the data; Analysis was done by an independent statistician. After the statistical analysis was completed and the report of the research was prepared, it was explained how the intervention and control groups were coded. The intervention group was coded with '1' while the control group was coded with the number '2'."|parallel group (experimental-control)|t|t|f|t
33936204|NCT03239769|RANDOMIZED|PARALLEL||TREATMENT||NONE||These patients were individually randomly assigned (1:1:1 ratio) into the conventional access group (CA), the aesthetic principles access group (APA) or the minimally invasive access group (MIA).||||
33936205|NCT05458492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936206|NCT02833610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936207|NCT00995215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936208|NCT03755167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936209|NCT05455645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Team members collecting outcomes data will not know participant allocation|Randomized controlled trial with one intervention arm and one control arm|t|f|f|t
33936210|NCT04812665|||COHORT||PROSPECTIVE|||||||
33936211|NCT03990922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33936212|NCT01086267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014633|NCT06129344|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Typically, participants are unaware whether they are receiving experimental treatment or a control (e.g., standard care). The researchers and medical staff are aware of the treatment allocation.~Due to medical ethics, if there is related breast pain and discomfort, the medical staff will still relieve the patient's breast pain."|This study assesses the effectiveness of manual lymphatic drainage and therapeutic ultrasound on postpartum breast engorgement, pain, and hardness. It explores these interventions' impact on psychosocial support for breastfeeding mothers and medical attention. The goal is to identify the most effective treatment and examine its acceptability among postpartum women. The research will evaluate the processes of participant recruitment, randomization, and outcome assessment to ensure proper implementation and anticipate challenges. Additionally, it will consider whether these interventions should be included in Taiwan's National Health Insurance benefits, focusing on their cost-effectiveness and potential clinical benefits to enhance maternal care quality.|t|f|f|f
34014634|NCT00792727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014635|NCT00194155|||CASE_ONLY|||||||||
34014636|NCT02227654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014637|NCT01299649|||CASE_CONTROL||RETROSPECTIVE|||||||
34097350|NCT00977873|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34097351|NCT04725981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Compare two surgical techniques Prospective randomized, controlled, single-blind inversion study|t|f|f|f
34097352|NCT00429455|||CASE_ONLY||RETROSPECTIVE|||||||
34097353|NCT02794311|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34097354|NCT01104298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097355|NCT03280030|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33712611|NCT00102726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712612|NCT06049498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712613|NCT01828957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097356|NCT02403778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793178|NCT04024631|NA|SINGLE_GROUP||OTHER||NONE|Data analyses (including by outcomes assessors and investigators) will be de-identified, and individuals performing laboratory analyses and DXA interpretation will be blinded to polygenic risk score for type 2 diabetes. Participants and nursing staff will not be informed of polygenic risk score at the time of the study.|cross sectional||||
33793179|NCT02953080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097357|NCT01346709|||COHORT||PROSPECTIVE|||||||
34097358|NCT03683901|NA|SINGLE_GROUP||TREATMENT||NONE|Participant, Investigator, and Outcomes Assessor were masked to the particular stimulation during each range of motion assessment|Cohort study; single group but with random serial allocation of treatment type||||
34097359|NCT01823887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097360|NCT00710957|||COHORT||PROSPECTIVE|||||||
33712614|NCT04849455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33712615|NCT06436508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712616|NCT05627960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||For dose escalation, model is an accelerated titration design-1-(3+3)||||
33712617|NCT04121377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712618|NCT00148018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712619|NCT02063022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712620|NCT02875756|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33793180|NCT02717299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793181|NCT05237921|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793182|NCT04033432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014638|NCT01797484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014639|NCT02510014|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097361|NCT04941365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a multi-centric prospective observational study, testing whether the blood level of MDSC-related immunosuppression does correlate with clinical outcome (clinical response by RECIST criteria, PFS, DFS) and thus may help predicting sensitivity or resistance to therapy in cancer patients. In addition, blood samples will be extensively studied to gain insights into the molecular and metabolic pathways regulating myeloid-mediated immunosuppression, with the goal of defining novel targets of immunomodulation.||||
34097362|NCT04933058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33712621|NCT01661296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712622|NCT01125384|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33712623|NCT00404677|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33712624|NCT06359470|NA|SEQUENTIAL||TREATMENT||NONE||This study was conducted on ninety male patients (30 in each group), ages ranged from 20 - 40 years old, and were diagnosed with unilateral lumbar disc prolapse (group1: L3-L4), (group 2: L4- L5) and (group 3: L5-S1) for at least three months in a radiology center specialized in the spine (Egyscan center). Each group was imaged three times (from the supine position, then from the oblique position after 10 minutes, and finally from the oblique position again after 48 hours). The oblique image was taken during a specific trunk position the modified reversed contralateral rotation (side-lying with side bending to the non-affected side and rotation to non affected side).The CSA of LIVF and SLR test was assessed at the three times of testing||||
33712625|NCT04548570|||CASE_CONTROL||PROSPECTIVE|||||||
33712626|NCT00691015|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793183|NCT04807322|||COHORT||RETROSPECTIVE|||||||
33793184|NCT02768272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793185|NCT03301376|||COHORT||PROSPECTIVE|||||||
34097363|NCT02669108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097364|NCT02822755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097365|NCT02525731|||COHORT||PROSPECTIVE|||||||
33712627|NCT06044155|||COHORT||RETROSPECTIVE|||||||
33712628|NCT02097576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712629|NCT00160251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712630|NCT00002378||||TREATMENT||||||||
33712631|NCT00888862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712632|NCT01717560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712633|NCT03740061|||COHORT||PROSPECTIVE|||||||
33793186|NCT02060019|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793187|NCT02391207|||COHORT||PROSPECTIVE|||||||
33793188|NCT04665661|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33793189|NCT04825184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data analysts will be blinded to condition allocation (dummy coded) when conducting statistical analyses on primary and secondary trait outcomes; however, blind analyses cannot be conducted on primary and secondary state measures due to the within-group design. Two datasets will be created one for between group analyses with dummy coding, and a second dataset for within group analyses without dummy coding.||f|f|f|t
33793190|NCT06484803|||COHORT||PROSPECTIVE|||||||
33793191|NCT06554145|||CASE_ONLY||PROSPECTIVE|||||||
33793192|NCT04505943|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomized controlled trial|randomized controlled trial|t|f|f|f
33793193|NCT00920881|||COHORT||PROSPECTIVE|||||||
33936213|NCT00057265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936214|NCT00865358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936215|NCT01985204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33936216|NCT02132416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936217|NCT06117956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936218|NCT00561067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936219|NCT00952588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936220|NCT02176005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936221|NCT06279052|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33936222|NCT05869175|||CASE_ONLY||CROSS_SECTIONAL|||||||
33936223|NCT05060081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936224|NCT03117699|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33936225|NCT04653727|||OTHER||CROSS_SECTIONAL|||||||
33936226|NCT00490126|||OTHER||OTHER|||||||
33936227|NCT00846027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936228|NCT00112554|RANDOMIZED|||TREATMENT||DOUBLE||||||
33936229|NCT06138704|||COHORT||CROSS_SECTIONAL|||||||
33936230|NCT06279845|||COHORT||PROSPECTIVE|||||||
33936231|NCT01661231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936232|NCT05465668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936233|NCT05790967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33936234|NCT01875874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936235|NCT04626570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936236|NCT06327568|||CASE_CONTROL||PROSPECTIVE|||||||
33936237|NCT06185686|||COHORT||PROSPECTIVE|||||||
33936238|NCT03756142|||CASE_CONTROL||PROSPECTIVE|||||||
33936239|NCT04315298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936240|NCT01426009|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33936241|NCT00381992|||OTHER||CROSS_SECTIONAL|||||||
33936242|NCT01732133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936243|NCT02022592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936244|NCT01020929|||COHORT||PROSPECTIVE|||||||
33936245|NCT02355925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936246|NCT06232187|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The ultrasound images will receive quality scoring from an experienced fetal medicin consultant. Theese are blinded for which intervention the participant received.|"The participants are allocated to one of three groups:~control group, feedback group 1 with black box AI or feedback group 2 with explainable AI feedback."|f|f|f|t
33936247|NCT03190681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34097366|NCT03940092|||COHORT||PROSPECTIVE|||||||
34097367|NCT00682435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097368|NCT05865249|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34097369|NCT04595812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized clinical trial|t|f|f|f
33793194|NCT04440124|||COHORT||PROSPECTIVE|||||||
33793195|NCT05599256|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936248|NCT04476108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936249|NCT04145505|||CASE_ONLY||PROSPECTIVE|||||||
33936250|NCT02309216|||COHORT||PROSPECTIVE|||||||
33936251|NCT02845284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936252|NCT04690556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936253|NCT04893395|NA|SINGLE_GROUP||SCREENING||NONE||||||
33936254|NCT06096012|||OTHER||RETROSPECTIVE|||||||
34014640|NCT04420338|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014641|NCT02399098|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34097370|NCT00795405|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34097371|NCT00464529|||||PROSPECTIVE|||||||
34097372|NCT03028922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712634|NCT02959931|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33712635|NCT01651195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33712636|NCT04943185|RANDOMIZED|PARALLEL||TREATMENT||NONE||The XEN gel stent (Allergan inc.) is a gelatin stent that has been developed for the surgical treatment of medically uncontrolled glaucoma and allows the filtration of aqueous humour from the anterior chamber to the subconjunctival space. The ab interno placement and outcomes of the XEN implant has been described (1,2,3). We describe an ab externo approach to implant the XEN microstent; ab externo closed conjunctiva implantation. This approach has many potential advantages over the ab interno technique, notably a quicker procedure, a potentially better subconjunctival placement of the implant and cost effectiveness due to absent need to rely on an operating room to perform the procedure as it can be done in an office setting.||||
33712637|NCT06350825|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control||||
33712638|NCT02789150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712639|NCT06131034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712640|NCT04294576|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|no masking is used. All involved know the identity of the intervention assignment.|||||
33712641|NCT01020227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33712642|NCT00909051|||COHORT||PROSPECTIVE|||||||
33712643|NCT02715674|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33712644|NCT03817177|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33712645|NCT01927224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712646|NCT02687945||||SUPPORTIVE_CARE||||||||
33712647|NCT00000105|||CASE_CONTROL||PROSPECTIVE|||||||
33712648|NCT06112262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712649|NCT00205582|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712650|NCT05538221|||OTHER||CROSS_SECTIONAL|||||||
33712651|NCT06373991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793196|NCT01165658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793197|NCT02266641|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793198|NCT03766711|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant intervention arm will be randomized and they will not be told which whether the treatment is being applied in the current set. However, they will be instructed of the task goal at the beginning of the session and will be told that we will be modifying visual feedback to help improve reaching symmetry in some manner.||t|f|f|f
33793199|NCT03320096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936255|NCT02935907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936256|NCT02368730|||COHORT||PROSPECTIVE|||||||
33936257|NCT02139280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014642|NCT04132401|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014643|NCT01917955|||COHORT||PROSPECTIVE|||||||
34014644|NCT00350376|||DEFINED_POPULATION||OTHER|||||||
34014645|NCT05160714|NA|SINGLE_GROUP||TREATMENT||NONE||Dose-finding phase 1 trial with four dose levels and 3+3 design: 12 patients if no DLT occurs up to 24 patients if 1 DLT per dose-level occurs.||||
34097373|NCT05264584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097374|NCT06539663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097375|NCT02849223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097376|NCT04033757|||COHORT||PROSPECTIVE|||||||
34097377|NCT01939275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097378|NCT03055221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097379|NCT06426576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097380|NCT00803907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097381|NCT06433011|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Pulse Spray and Infusion of r-tPA||||
34097382|NCT01047397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712652|NCT01872988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712653|NCT02387060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712654|NCT04758780|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, open prospective study||||
33712655|NCT04821921|||OTHER||PROSPECTIVE|||||||
33712656|NCT04608591|||COHORT||PROSPECTIVE|||||||
33712657|NCT00767637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712658|NCT05733754|||CASE_ONLY||RETROSPECTIVE|||||||
33712659|NCT02116296||||PREVENTION||||||||
33712660|NCT05743946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712661|NCT01322178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720686|NCT00067366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720687|NCT03621852|||COHORT||PROSPECTIVE|||||||
33793200|NCT01640678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793201|NCT03795558|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||This is a single-center, prospective, dose-escalation, pilot study. Starting dose 2.5 mg thrice weekly dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly.||||
33793202|NCT02508844|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936258|NCT00003992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936259|NCT04142840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936260|NCT05099718|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34014646|NCT00852566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014647|NCT00027859|RANDOMIZED|||TREATMENT||||||||
33793203|NCT00025987||||TREATMENT||||||||
33936261|NCT01071941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936262|NCT00005054||||TREATMENT||||||||
33936263|NCT04135391|NA|SINGLE_GROUP||PREVENTION||NONE||A randomized controlled trial was performed in stroke patients adequate for exercise trainings. Different exercise regimens were prescribed and was blind to the assessors. The study was conducted from August 2016 to June 2018. Participants were randomly allocated to the moderate-intensity continuous training (MICT) or high-intensity interval training (HIIT) groups using a computer-generated, concealed allocation schedule. All included stroke patients received traditional rehabilitation programs, including balance, range of motion, or therapeutic exercise, and additional in-hospital supervised 30 min of MICT or HIIT for 36 times. Data were collected by a blinded assessor prior to randomization after completing the exercise trainings.||||
33936264|NCT01832844|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33936265|NCT03003013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712662|NCT05182489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to their group status for the duration of the study assessments and procedures (24 months post-operatively).|All subjects will be randomized in the trial to receive either the Medtronic titanium or the PEEK cage supplemented with a pedicle screw system and milled local autograft bone supplemented with GRAFTON™ DBM DBF. Subject randomization will be stratified according to smoking status. Subjects will be blinded to their group status for the duration of the study assessments and procedures (24 months post-operatively).|t|f|f|f
34014648|NCT04718194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34014649|NCT04300413|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study but will use two historical cohorts as comparison groups to assess outcomes: 1) usual care and 2) high-intensity, functionally based resistance training alone. The historical cohorts were included in a previous study (Clinical Trials Registry identifier: E2193-P). This design will include independent cohorts of patients within a single SNF, using the facility as its own control. This design optimally controls for facility-level variables that vary widely between SNFs and may influence care delivery, such as staffing levels, staff experience, and productivity standards.||||
33712663|NCT05931861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712664|NCT05163444|RANDOMIZED|CROSSOVER||OTHER||NONE||Clinical trial, randomized, crossover||||
33712665|NCT02837575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014650|NCT05477160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014651|NCT01521065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014652|NCT02349620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014653|NCT00841906|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34014654|NCT01385306|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34014655|NCT02106650|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014656|NCT04891965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014657|NCT03236142|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34014658|NCT01861236|||COHORT||PROSPECTIVE|||||||
34097383|NCT04817579|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each patient will try in three crowns with different methods for shade matching.|t|f|f|t
34097384|NCT05192083|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Self-management education and support||||
34097385|NCT04076111|||COHORT||CROSS_SECTIONAL|||||||
34097386|NCT03270241|NA|SINGLE_GROUP||TREATMENT||NONE||Participants diagnosed with Vitiligo who are enrolled in the study will receive phototherapy (NB-UVB), with the starting dose of 250 mJ/cm2. The dose will be increased by 10% with each treatment. Small skin samples will be collected before and after NB-UVB treatment.||||
33712666|NCT03158116|NA|SINGLE_GROUP||TREATMENT||NONE||two-center, prospective, case control clinical trial||||
33712667|NCT06381882|||COHORT||PROSPECTIVE|||||||
33793204|NCT05752136|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The 54 enrolled patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery).~The other 54 patients with MSS-type advanced middle-low rectal cancer will receive a combined regimen of neoadjuvant chemoradiotherapy combined with immunotherapy and total mesorectal excision (TME surgery)."||||
33793205|NCT01026064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33793206|NCT06089954|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized non-inferiority trial||||
33793207|NCT05247034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793208|NCT01426750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712668|NCT02396615|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33712669|NCT05562128|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33793209|NCT04630080|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793210|NCT03920215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793211|NCT03897348|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind, placebo-controlled||t|f|t|t
33793212|NCT05175989|||COHORT||PROSPECTIVE|||||||
33712670|NCT00717691|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712671|NCT00116467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712672|NCT00645060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712673|NCT00254904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712674|NCT02837198|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33712675|NCT05392010|||COHORT||PROSPECTIVE|||||||
33712676|NCT04870593|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33712677|NCT01152242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712678|NCT06229353|||OTHER||PROSPECTIVE|||||||
33712679|NCT03276156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793213|NCT03899675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The research will be divided into two moments, in which subjects will participate in the same experiment on two different and non sequential days, and on the first day, the measurement of data will occur without the ingestion of caffeine or placebo. Participants will be randomized at the end of the first evaluation.~The randomization of the volunteers to define the groups will be performed using random numbers obtained at www.randomized.com. Subjects will be allocated to one of two groups: I) strength training and caffeine; II): strength training and placebo."|It is a randomized, single-blind clinical trial|t|f|f|f
33936266|NCT03333434|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33936267|NCT06139445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33936268|NCT02986165|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33936269|NCT02633917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936270|NCT03698214|||OTHER||RETROSPECTIVE|||||||
34014659|NCT00004175||||TREATMENT||||||||
34014660|NCT04177563|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34014661|NCT06359860|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34014662|NCT04560465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|two groups comprising of cases and control|t|t|t|f
34014663|NCT05086718|NA|SINGLE_GROUP||TREATMENT||NONE||300 cases of dry perforation CSOM||||
34014664|NCT04999930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014665|NCT06337825|||COHORT||PROSPECTIVE|||||||
34014666|NCT05094752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014667|NCT05290324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label|Radomized Controlled Trial|t|f|f|f
34014668|NCT05536726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014669|NCT00965055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014670|NCT01983319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34014671|NCT03276780|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||In vivo or standard of care||||
33712680|NCT02673437|||COHORT||PROSPECTIVE|||||||
33712681|NCT03130868|||COHORT||PROSPECTIVE|||||||
33712682|NCT05404295|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33712683|NCT02157467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33712684|NCT01145040|||COHORT||CROSS_SECTIONAL|||||||
33712685|NCT00003170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33712686|NCT02603614|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712687|NCT01880398|||CASE_ONLY||PROSPECTIVE|||||||
33712688|NCT03541304|||CASE_ONLY||RETROSPECTIVE|||||||
33712689|NCT05895747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712690|NCT03576924|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a single-centre, 3-arm parallel-group randomized trial.||||
33712691|NCT02114814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712692|NCT06476262|||COHORT||PROSPECTIVE|||||||
33712693|NCT05557799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participant nor the outcome assessor will know to which group the participant belongs, seeing as laser application will be simulated in the placebo group.||t|f|f|t
33712694|NCT05898698|||OTHER||PROSPECTIVE|||||||
33712695|NCT02260700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712696|NCT04432896|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712697|NCT00229905|||||RETROSPECTIVE|||||||
33712698|NCT03910842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712699|NCT02617628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712700|NCT01113983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936271|NCT00636506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936272|NCT02400840|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33936273|NCT05728424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936274|NCT06378606|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The aim of study is to find the effects of screen based cognitive therapy on mild dementia in elderly .|The aim of study is to find the effects of screen based cognitive therapy on mild dementia in elderly .|t|f|t|t
33936275|NCT00468624|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34097387|NCT03073109|||COHORT||PROSPECTIVE|||||||
34097388|NCT03384485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097389|NCT06329297|||COHORT||PROSPECTIVE|||||||
33712701|NCT03258021|||OTHER||PROSPECTIVE|||||||
33712702|NCT01530568|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33720688|NCT04130126|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014672|NCT03082664|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720689|NCT05973383|||OTHER||PROSPECTIVE|||||||
33720690|NCT04899804|||COHORT||CROSS_SECTIONAL|||||||
33720691|NCT01463319|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33720692|NCT00116532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720693|NCT02671591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014673|NCT03967587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720694|NCT06027853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720695|NCT06317155|||CASE_ONLY||PROSPECTIVE|||||||
34014674|NCT02006368|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014675|NCT04390321|NA|SINGLE_GROUP||OTHER||NONE||Participants are assigned to a single group following the same intervention||||
34014676|NCT00676325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34014677|NCT02872363|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|t|f|f
34014678|NCT03891017|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34014679|NCT01458106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014680|NCT03134521|||COHORT||RETROSPECTIVE|||||||
34014681|NCT01855048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014682|NCT03361384|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double (Participant, Outcomes Assessor)|Participants are randomly assigned to a beverage condition: alcohol, placebo, or control (water).|t|f|f|t
34014683|NCT00772720|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34014684|NCT00043758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33720696|NCT03477227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720697|NCT04349670|||COHORT||PROSPECTIVE|||||||
33720698|NCT02792556|||COHORT||PROSPECTIVE|||||||
33720699|NCT01519960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720700|NCT00000586|RANDOMIZED|||TREATMENT||DOUBLE||||||
33720701|NCT04015245|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control trial||||
33720702|NCT01608659|||CASE_ONLY||RETROSPECTIVE|||||||
34014685|NCT02252653|||COHORT||PROSPECTIVE|||||||
34014686|NCT05934617|||COHORT||RETROSPECTIVE|||||||
34014687|NCT05089695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014688|NCT04313049|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097390|NCT00004485||||TREATMENT||||||||
34097391|NCT05099211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097392|NCT00502515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097393|NCT05853159|||CASE_ONLY||RETROSPECTIVE|||||||
34014689|NCT03347136|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to type of intervention masking was not possible.|The neonates with mild to moderate respiratory distress were randomly allocated to tratment with NIPPV and CPAP.||||
34014690|NCT03757273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because the two interventions used in this trial are easily recognized by the participant and the investigators, neither the investigator nor the participant can be blinded. But, the assessor and the statistician will be blinded.||f|f|f|t
34014691|NCT00492765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014692|NCT05729919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014693|NCT05652959|||COHORT||PROSPECTIVE|||||||
34097394|NCT04791852|||COHORT||CROSS_SECTIONAL|||||||
34014694|NCT01261741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097395|NCT00211900|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34097396|NCT03324958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Assessment of the mean local pain during brachytherapy applicator'setting up, with and without virtual reality helmet use.||||
34097397|NCT01708837|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34097398|NCT00178542|||CASE_CONTROL||PROSPECTIVE|||||||
34097399|NCT00686218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793214|NCT04805073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Stratified randomization design||t|t|t|f
33793215|NCT06513442|||COHORT||RETROSPECTIVE|||||||
34097400|NCT02979600|||CASE_ONLY||RETROSPECTIVE|||||||
33712703|NCT04540601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The allocation of the patients is not known to the clinical investigator, the surgeon or the outcome assessor but to the patient's oncologic doctor and nurse, who are in charge of drug delivery, and a supervisor (Klaus Gotfredsen) not involved in any registrations or surgeries.~The participating patients will not be blinded. The patients do know which group they are randomized to and therefore do know if they are treated with or without drug holiday during the trial period (1+3 months). The patients are carefully instructed not to reveal which group they belong during the trial to the assessor.~Klaus Gotfredsen will make sure that the patients randomized to the intervention group will continue their antiresorptive therapy and the patients randomized to the control group will be treated with drug holiday this in close collaboration with the oncological departments. The medicine will be giving to the patient by the department's nurse."|This trial is designed as an investigator-initiated, parallel-group, randomized, clinical, single-blinded, trial investigating no antiresorptive drug holiday starting before tooth extraction with primary closure versus antiresorptive drug holiday starting before tooth extraction with primary closure in cancer patients|f|f|t|t
33793216|NCT06544161|NA|SINGLE_GROUP||OTHER||NONE||||||
33793217|NCT04584489|||COHORT||PROSPECTIVE|||||||
33793218|NCT03272113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Behaviour change||||
33793219|NCT06121310|||CASE_ONLY||PROSPECTIVE|||||||
33793220|NCT00258037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33793221|NCT02994654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793222|NCT04017169|||CASE_CONTROL||PROSPECTIVE|||||||
33793223|NCT03224299|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33793224|NCT00391755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793225|NCT04117724|||COHORT||PROSPECTIVE|||||||
34097401|NCT05001412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We divide them into two cohorts based on the extent of tumor invasion to the mediastinum or hilar large vessels||||
34097402|NCT02978768|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34014695|NCT05101369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014696|NCT01311752|||COHORT||PROSPECTIVE|||||||
34097403|NCT04586972|||CASE_ONLY||PROSPECTIVE|||||||
34097404|NCT02590510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014697|NCT04799678|||COHORT||PROSPECTIVE|||||||
34014698|NCT03043560|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind||t|f|t|f
34014699|NCT03444272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014700|NCT02780427|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34014701|NCT04527328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014702|NCT05335213|||COHORT||PROSPECTIVE|||||||
34014703|NCT04322149|NA|SEQUENTIAL||TREATMENT||NONE||||||
33793226|NCT04668742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|masking of the intervention and control groups in the statistical analysis of the data, which will be represented as group 0 and 1, without identifying whether they are control or intervention||f|f|t|f
33793227|NCT04714450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Saliva samples will be identified by participant identification number only. Technicians assessing levels of biological measures in these samples will be blind to condition.|The investigators propose a parallel experimental trial examining physiological and psychological responses to a socio-evaluative stress task (The Mannheim Multicomponent Stress Test; MMST) under laboratory conditions. Participants will be tested on three occasions in a randomised order, with each trial separated by 7 days. On two occasions, participants will be complete a socially evaluated math-based serial addition task whilst simultaneously viewing a series of positive and negative images and in the presence of white noise (duration \~ 5 minutes). On the other occasion, participants will rest quietly and will be exposed to a short film and some images that are not designed to induce anxiety or stress for the same duration as the stress test in the stress induction room. The non-stress control condition, will occur either 1-week preceding or 1-week following both MMST trials, thereby controlling for order effects influencing baseline physiological and psychological outcome measures.|f|f|f|t
33793228|NCT00319397|||||PROSPECTIVE|||||||
33793229|NCT00852150|||||PROSPECTIVE|||||||
33793230|NCT05938387|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33793231|NCT03794180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793232|NCT03812003|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Breast cancer patient|t|t|f|f
33793233|NCT04330768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793234|NCT06496958|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33793235|NCT01221142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793236|NCT06345417|||COHORT||RETROSPECTIVE|||||||
33793237|NCT03443934|||COHORT||PROSPECTIVE|||||||
33793238|NCT05358119|||COHORT||PROSPECTIVE|||||||
33793239|NCT05951218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793240|NCT06129370|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33793241|NCT03993613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793242|NCT05121506|NA|SINGLE_GROUP||OTHER||NONE||||||
33793243|NCT02984124|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793244|NCT06677268|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigators analyzing the polysomnography and total sleep time (primary endpoint) will be blinded of the group in which the patient is randomized.|randomized, controled, interventional, multi center|f|f|t|f
33793245|NCT04467788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33793246|NCT06134466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793247|NCT02916836|||COHORT||PROSPECTIVE|||||||
33936276|NCT05182294|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients will be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula and receive HFNT for 2 hours during the first session. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session.Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered. At the end of this second session the patient will be discharged from the study and receive usual medical care for the COPD exacerbation and other medical conditions as clinically indicated.||||
33936277|NCT05064943|||CASE_ONLY||PROSPECTIVE|||||||
33936278|NCT01836549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936279|NCT03185169|NA|SINGLE_GROUP||TREATMENT||NONE||Observational, prospective open label trial||||
33936280|NCT00921908|||CASE_ONLY||PROSPECTIVE|||||||
33936281|NCT03960372|||COHORT||PROSPECTIVE|||||||
33936282|NCT02098629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33936283|NCT04966611|||OTHER||PROSPECTIVE|||||||
33936284|NCT05245695|||CASE_CONTROL||PROSPECTIVE|||||||
33936285|NCT03260062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936286|NCT05723276|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936287|NCT00883792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014704|NCT01906086|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34014705|NCT01626521|||COHORT||PROSPECTIVE|||||||
34014706|NCT01598519|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34014707|NCT05166681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014708|NCT02790307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014709|NCT04551911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014710|NCT05703243|||CASE_CONTROL||PROSPECTIVE|||||||
34014711|NCT00922987|||COHORT||PROSPECTIVE|||||||
34014712|NCT00117403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014713|NCT00321386|||COHORT||PROSPECTIVE|||||||
34014714|NCT05532579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014715|NCT03352336|||COHORT||PROSPECTIVE|||||||
34014716|NCT00313443|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014717|NCT05402462|||COHORT||CROSS_SECTIONAL|||||||
34097405|NCT03446573|RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study and therefore no blinding is required. No summaries of the study data according to actual randomized treatment groups will be available to sponsor staff prior to the planned Week 24 preliminary analysis.|This is a randomized study with parallel group assignment where participants will be randomized into one of the two treatment groups. Participants randomized to DTG + 3TC will receive DTG + 3TC up to Week 200. Participants randomized to TBR will continue to take their current regimen up to Week 148, at which time and if HIV-1 RNA \<50 c/mL at Week 144, these participants will switch to DTG + 3TC up to Week 200. Randomization will be stratified by Baseline third agent class (protease inhibitor \[PI\], integrase inhibitor \[INI\], or non-nucleoside reverse transcriptase inhibitor \[NNRTI\]).||||
34097406|NCT02065583|||COHORT||PROSPECTIVE|||||||
34097407|NCT06222047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Breast milk and dextrose video recording It was applied just before starting. It is not clear which intervention was made before the procedure.|Breast Milk Dextrose Control|f|f|f|t
34097408|NCT03528577|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34097409|NCT01117558|||COHORT||PROSPECTIVE|||||||
34097410|NCT05737498|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34097411|NCT05034354|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective multi-methods observational study||||
34097412|NCT04124510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097413|NCT05075681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097414|NCT01421134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712704|NCT04217876|||COHORT||RETROSPECTIVE|||||||
33712705|NCT05283668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712706|NCT00612690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33712707|NCT04310501|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712708|NCT02622321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712709|NCT02495805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712710|NCT04522960|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33936288|NCT05202184|||COHORT||RETROSPECTIVE|||||||
33936289|NCT00374062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936290|NCT04409990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936291|NCT01209117|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33936292|NCT02039089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936293|NCT00461604|||||PROSPECTIVE|||||||
33936294|NCT01550770|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936295|NCT03362216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33936296|NCT01989936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936297|NCT06219876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33936298|NCT02573012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936299|NCT04853264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers and investigators responsible for data collection will be blinded for collection and analysis of data.|It's a randomized, parallel, controlled, blinded for data collection and analysis, single-center clinical trial; this study will follow the guidelines of the Consolidated Standards of Reporting Trials (CONSORT).|f|f|t|t
34097415|NCT03426488|||COHORT||PROSPECTIVE|||||||
34097416|NCT00191152|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097417|NCT02113046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097418|NCT02922660|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34097419|NCT00279513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097420|NCT00270166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712711|NCT05144360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712712|NCT01682057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712713|NCT00869674|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33712714|NCT05510804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT with 2:1 allocation either to Intervention or TAU (low-frequency unstructured contacts with therapist)|f|f|t|f
33712715|NCT00600483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33712716|NCT04380792|||OTHER||RETROSPECTIVE|||||||
33712717|NCT03468153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712718|NCT02877420|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33712719|NCT05448053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712720|NCT01526798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712721|NCT02573298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712722|NCT05024591|||COHORT||PROSPECTIVE|||||||
33712723|NCT01000389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712724|NCT03501069|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33712725|NCT01550302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712726|NCT03129984|||CASE_ONLY||RETROSPECTIVE|||||||
33712727|NCT02338661|||COHORT||PROSPECTIVE|||||||
33712728|NCT00023634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712729|NCT03158376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712730|NCT01479699|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33712731|NCT02820272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712732|NCT02302027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712733|NCT01335984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712734|NCT03492346|||COHORT||OTHER|||||||
33712735|NCT04077645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33712736|NCT06076616|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pilot study||||
33712737|NCT01985867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097421|NCT03719937|NA|SEQUENTIAL||TREATMENT||NONE||pilot-feasibility study||||
34097422|NCT03225222|||COHORT||PROSPECTIVE|||||||
34097423|NCT02409901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097424|NCT00950924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097425|NCT05161156|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double-blind, double-dummy, placebo controlled|t|f|t|f
34097426|NCT01605058|||COHORT||RETROSPECTIVE|||||||
34014718|NCT05476614|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be grouped at random into social robot-instructed yoga or human-instructed yoga.||||
34014719|NCT00278187||||TREATMENT||NONE||||||
34014720|NCT03022474|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014721|NCT01900496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014722|NCT03188718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Blinded to the subject's diagnosis|||||
34014723|NCT05192759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014724|NCT00869024|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33712738|NCT03048968|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34014725|NCT03822364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A 3 part study including: A) Single Dose Crossover in Healthy Volunteers, B) Single Ascending Dose with placebo control in Healthy Volunteers, and C) Single Ascending Dose with placebo control in Subjects with Established Parkinson's Disease|t|t|t|t
34097427|NCT05196646|||COHORT||PROSPECTIVE|||||||
34097428|NCT06193629|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
34097429|NCT06403696|||COHORT||PROSPECTIVE|||||||
34097430|NCT02517138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097431|NCT05213351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097432|NCT06483555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097433|NCT05952193|||COHORT||PROSPECTIVE|||||||
33712739|NCT01574625|||CASE_CONTROL||PROSPECTIVE|||||||
34097434|NCT00104715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097435|NCT04527731|||COHORT||PROSPECTIVE|||||||
34097436|NCT02623439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097437|NCT05940038|||COHORT||RETROSPECTIVE|||||||
34097438|NCT01951027|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34097439|NCT00449007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097440|NCT05030701|||CASE_ONLY||RETROSPECTIVE|||||||
34097441|NCT02241915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097442|NCT02388100|||COHORT||PROSPECTIVE|||||||
34097443|NCT06213805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097444|NCT01386320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097445|NCT01706380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097446|NCT02885922|||COHORT||PROSPECTIVE|||||||
34097447|NCT05196139|||COHORT||RETROSPECTIVE|||||||
34097448|NCT00689286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097449|NCT03274349|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients will be coded by a consecutive numbering. Data will be saved only with this number. Access to the data will only be provided to authorized personnel (study nurses) and will be retained in inaccessable and locked rooms.|Prospective, controlled pilot study|f|f|f|t
33712740|NCT02152033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712741|NCT04857905|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712742|NCT00992576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712743|NCT04138654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33712744|NCT00005589|RANDOMIZED|||TREATMENT||NONE||||||
33712745|NCT00297375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712746|NCT01340898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712747|NCT02393508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712748|NCT03789344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712749|NCT03928574|||COHORT||RETROSPECTIVE|||||||
33712750|NCT03092609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712751|NCT04440202|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712752|NCT00878085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712753|NCT00666627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712754|NCT00563381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712755|NCT02322034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33712756|NCT05924204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33712757|NCT04016285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33712758|NCT03063567|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective crossover trial. All patients will undergo a one month trial of each of the 3 interfaces (nasal masks, oronasal masks, nasal cushions) in a randomised order.||||
33712759|NCT04610840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33712760|NCT06236178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A Randomized Clinical Trial|f|f|t|f
33712761|NCT02364973|||CASE_ONLY||PROSPECTIVE|||||||
33712762|NCT06094569|||COHORT||PROSPECTIVE|||||||
33712763|NCT01125683|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33712764|NCT00940225|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33712765|NCT01213745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33712766|NCT02759328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712767|NCT01461902|||COHORT||PROSPECTIVE|||||||
33712768|NCT01725334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712769|NCT03928600|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33712770|NCT02824874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712771|NCT05137106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participants and Outcomes Assessor)|Active Dry Needling Sham Dry Needling|t|f|f|t
33712772|NCT01217840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712773|NCT00700960|||COHORT||PROSPECTIVE|||||||
33712774|NCT02454400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33712775|NCT02254993|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712776|NCT04658953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720703|NCT00878527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014726|NCT01698775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014727|NCT00024648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014728|NCT02581878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014729|NCT00831636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014730|NCT02919813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014731|NCT04944134|||COHORT||PROSPECTIVE|||||||
34014732|NCT01828944|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34014733|NCT00242125|||DEFINED_POPULATION||OTHER|||||||
34014734|NCT00541164|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34014735|NCT00551382|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34014736|NCT03764046|||COHORT||PROSPECTIVE|||||||
34097450|NCT05961384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097451|NCT01382407|||CASE_CONTROL||PROSPECTIVE|||||||
34097452|NCT03996421|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34097453|NCT00999570|||CASE_CONTROL||PROSPECTIVE|||||||
34097454|NCT06211270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data collectors are blinded to participant's study arm.|Randomized wait-list controlled pilot study using a convergent mixed methods approach|f|f|f|t
34097455|NCT02687165|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34097456|NCT05198310|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34097457|NCT03126734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34097458|NCT01356056|||COHORT||PROSPECTIVE|||||||
34097459|NCT01533909|||||CROSS_SECTIONAL|||||||
33712777|NCT06244472|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"In healthy subjects, we will test our hypotheses in three independent experiments (20 subjects per experiment), covering an important part of the current field of use of MEG in auditory, visual, motor and somaesthetic modalities. Subjects will have the opportunity to participate in one, two or all three experiments, as they wish.~In adults with mild traumatic brain injury, we will test our hypotheses using resting-state recording (20 subjects).~For all the tasks, we will carry out an acquisition with the 275-sensor SQUID (Superconducting Quantum Interference Devices) MEG system from the MEG department at CERMEP (Centre d'Etude et de Recherche Multimodal Et Pluridisciplinaire) in Lyon, and a similar acquisition with the FYNA Research system.~If the subject has no anatomical MRI (Magnetic resonance imaging), a 3D anatomical MRI (15-minute acquisition time) on a 1.5 Tesla MRI will be performed after the last MEG examination."||||
33712778|NCT02183194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712779|NCT01008007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712780|NCT02030392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33712781|NCT02322398|||CASE_CONTROL||RETROSPECTIVE|||||||
33712782|NCT01929915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712783|NCT06387095|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||randomized controlled|f|f|t|f
33793248|NCT00506727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33793249|NCT01630564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014737|NCT03036553|||COHORT||PROSPECTIVE|||||||
34014738|NCT02884323|NA|SINGLE_GROUP||OTHER||NONE||||||
34014739|NCT00832221|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014740|NCT05362721|||CASE_ONLY||PROSPECTIVE|||||||
34097460|NCT02919150|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097461|NCT03286803|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a four arms randomized controlled trial. Arms 1 and 2 will randomize children aged 14 weeks old into either full dose or fractional dose IPV and arms 3 and 4 will randomize children aged 9 months old into either full dose or fractional dose IPV||||
34097462|NCT01831713|||COHORT||PROSPECTIVE|||||||
33793250|NCT01071993|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33793251|NCT01838070|||COHORT||PROSPECTIVE|||||||
34014741|NCT00073775|||COHORT||PROSPECTIVE|||||||
34014742|NCT00711841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014743|NCT02290275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014744|NCT06339320|NA|SINGLE_GROUP||TREATMENT||NONE||Retrospective Registry Study||||
34014745|NCT03814330|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Prospective Randomized Clinical Trial|t|f|f|f
34014746|NCT01782508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014747|NCT01888575|||COHORT||RETROSPECTIVE|||||||
34014748|NCT02504346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097463|NCT06503393|||CASE_ONLY||RETROSPECTIVE|||||||
34097464|NCT01404260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097465|NCT01297244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097466|NCT04590183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097467|NCT01838889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712784|NCT00276744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712785|NCT00267384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712786|NCT00261664|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34014749|NCT06236945|||COHORT||RETROSPECTIVE|||||||
34014750|NCT00513682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014751|NCT04597489|||COHORT||RETROSPECTIVE|||||||
34014752|NCT06157762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34014753|NCT04681040|||COHORT||PROSPECTIVE|||||||
34014754|NCT03181321|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The investigators will conduct a 6 month, two-arm, CRCT: TF20 vs. Control (which will receive delayed treatment after 6 months). Eligible fire departments volunteering for the trial will be randomized to one of the two study treatment arms. Treatment outcomes will be assessed at baseline and 6 months by our staff.||||
34014755|NCT00325832|RANDOMIZED|FACTORIAL||||NONE||||||
34014756|NCT05957419|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Beating-heart myectomy device||||
34014757|NCT04212533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the patients dont know what they received before the operation|two parallel groups each one 43 patients undergoing total thyroidectomy one received prophylactic vitamin d and calcium before surgery the other received nothing , calcium level, vit d levels measured preand postoperative , clinical assessment of patients postoperatie for development of tetany|t|f|f|f
34097468|NCT03278145|||COHORT||PROSPECTIVE|||||||
34097469|NCT00563212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097470|NCT02926612|||COHORT||PROSPECTIVE|||||||
34014758|NCT03082170|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigators would appreciate the quality of swallowing of participants suffering from sleep apnea that had half a year ago or more robotic resection of tongue base or soft palate surgery. The investigators will use the SDQ self reported questionnaire and the FEES test as tools for assessing the participant's swallowing.||||
34014759|NCT02130076|||CASE_CONTROL||PROSPECTIVE|||||||
34014760|NCT01362465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014761|NCT04516408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple|Herpes Zoster|t|t|t|t
34014762|NCT05144347|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation followed by Cohort-expansion in NHL-specific expansion cohorts||||
34014763|NCT05226559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Physiotherapists are blinded toward the diagnosis and outcome measures.|Prospective, parallel group, randomized clinical trial.|f|t|t|f
34014764|NCT02206373|||COHORT||CROSS_SECTIONAL|||||||
34014765|NCT02615171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014766|NCT05372874|||COHORT||CROSS_SECTIONAL|||||||
34014767|NCT03045237|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014768|NCT04625322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Models of Care||||
34014769|NCT05404412|||COHORT||PROSPECTIVE|||||||
34014770|NCT00614809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014771|NCT04486755|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A modified 3+3 study design will be employed to determine the dose-fractionation schedule that results in less than 33% dose limiting toxicity. One de-escalation will be allowed if the initial dose-fractionation schedule results in too high a frequency of dose limiting toxicities. A total of 6 patients will be treated following the dose-fractionation schedule that is recommended for further study.||||
34014772|NCT02566993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014773|NCT02782494|||COHORT||PROSPECTIVE|||||||
34014774|NCT01176643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34097471|NCT05605080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34097472|NCT03687697|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097473|NCT01158404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097474|NCT03657407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Opaque sealed envelopes generated by biostatistician used to determine intervention A or B. Drug dictionary entries created within the Pyxis system by the Mercy Medical Center Department of Pharmacy, as Protocol Drug A and Protocol Drug B, recorded in medical record in this way. Identity of Protocol Drug A and Protocol Drug B revealed by pharmacist at conclusion of data analysis."|Randomization to one-time intervention A (medicated suppository) or intervention B (placebo), allocation was sealed in consecutively numbered opaque envelopes generated by biostatistician using blocked randomized technique.|t|t|t|t
34097475|NCT02249793|||COHORT||PROSPECTIVE|||||||
34097476|NCT03184675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097477|NCT04889911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be kept blind to participant assignment.|Randomize controlled trial with random assignment to intervention being studied (NECT-YA) or treatment as usual (Coordinated Specialty Care).|f|f|f|t
34097478|NCT00170755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097479|NCT05824676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It insures unbiased patient reported outcomes in data collection, the participants are blinded to what arm they are put in.||t|f|f|f
34097480|NCT02530073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097481|NCT02931539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097482|NCT01122212|||CASE_ONLY||PROSPECTIVE|||||||
34097483|NCT02609906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097484|NCT03506308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097485|NCT01112267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097486|NCT06433544|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097487|NCT05569889|||OTHER||PROSPECTIVE|||||||
34097488|NCT03275272|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE|Measurment of blood level of IGF-1 and Maternal BMI|Measurment of maternal BMI and serum level if IGF-1 in infant||||
34097489|NCT02820103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34097490|NCT05316051|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34097491|NCT05534607|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study uses a wait list control design, where the wait-list control group is offered the intervention at the completion of the intervention group's 12-month intervention and assessment period.||||
34097492|NCT04557137|||COHORT||PROSPECTIVE|||||||
34097493|NCT06066515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097494|NCT06434779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097495|NCT03358706|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097496|NCT04201405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097497|NCT02021604|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097498|NCT01520662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097499|NCT00823888||CROSSOVER||TREATMENT||NONE||||||
34097500|NCT01219075|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33712787|NCT03738267|||COHORT||RETROSPECTIVE|||||||
33712788|NCT01034865|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34014775|NCT06216743|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014776|NCT02199054|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34014777|NCT04988152|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34014778|NCT00974948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34014779|NCT04102241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014780|NCT03398629|||COHORT||PROSPECTIVE|||||||
34014781|NCT01727986||||TREATMENT||NONE||||||
34014782|NCT00157859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014783|NCT00438477|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014784|NCT02350634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014785|NCT01801683|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34014786|NCT04375852|NA|SINGLE_GROUP||SCREENING||NONE||||||
34014787|NCT06461481|||COHORT||PROSPECTIVE|||||||
34014788|NCT01314378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014789|NCT05747521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097501|NCT03000751|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712789|NCT01384253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712790|NCT04358120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712791|NCT00688753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712792|NCT02579408|||COHORT||PROSPECTIVE|||||||
33712793|NCT05642208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712794|NCT00688974|||COHORT||PROSPECTIVE|||||||
33712795|NCT04094363|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33712796|NCT03981263|RANDOMIZED|CROSSOVER||OTHER||NONE||Cross-over (2 periods), prospective, open and monocentric study. The wash-out period will be 15 days||||
33712797|NCT04221009|NA|SINGLE_GROUP||OTHER||NONE||Participants will be asked to participate in four treatment sessions. The 4-session intervention is derived from evidence-based Motivational Interviewing and Cognitive Behavior Therapy. Participants will complete study measures pre- and post-intervention. Then, they will participate in a post-intervention interview to gather information of acceptability.||||
33712798|NCT02499302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712799|NCT04253184|||COHORT||PROSPECTIVE|||||||
33712800|NCT03537105|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Sclerodermic patients||||
33712801|NCT00400751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712802|NCT05261256|||CASE_CONTROL||PROSPECTIVE|||||||
34097502|NCT00092469|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34097503|NCT05214950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33712803|NCT04490538|||CASE_ONLY||PROSPECTIVE|||||||
33712804|NCT02171923|||CASE_CONTROL|||||||||
33712805|NCT01336764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Physical separation of Care Provider during self-administration of intervention||t|t|f|f
33712806|NCT03908697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Anonymized demographic data|Prospective cohort analysis of three menstrual cycles of hormone data, comparing two fertility monitors that analyze urine hormones. Satisfaction and ease of use will be assessed using surveys. Individual data will be anonymized.||||
33712807|NCT00035334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712808|NCT00959621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712809|NCT04478955|||COHORT||CROSS_SECTIONAL|||||||
33712810|NCT06298110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712811|NCT04394767|||CASE_ONLY||PROSPECTIVE|||||||
33712812|NCT05518539|||COHORT||PROSPECTIVE|||||||
33712813|NCT04261348|||OTHER||PROSPECTIVE|||||||
33712814|NCT06498401|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712815|NCT03940495|||COHORT||PROSPECTIVE|||||||
33712816|NCT06373302|||COHORT||OTHER|||||||
33712817|NCT01202474|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712818|NCT04109794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014790|NCT00553592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014791|NCT00454519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014792|NCT01683890|||COHORT||PROSPECTIVE|||||||
34014793|NCT05032521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712819|NCT03321123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712820|NCT06501066|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33712821|NCT01293721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712822|NCT04763798|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A single-blind (evaluator) randomized controlled trial|Cross sectional study. Randomized controlled trial|f|f|f|t
33712823|NCT02966028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014794|NCT00358748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014795|NCT00444457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34014796|NCT03528785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014797|NCT00997139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014798|NCT01827124|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34014799|NCT04627480|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Sham Device||t|t|t|f
34014800|NCT03236948|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individual level randomised trial, with intervention and control group||||
34014801|NCT05253924|||CASE_CONTROL||PROSPECTIVE|||||||
34014802|NCT04963595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014803|NCT01940328|||CASE_CONTROL||PROSPECTIVE|||||||
34014804|NCT03721731|||COHORT||PROSPECTIVE|||||||
34014805|NCT00004402||||TREATMENT||||||||
34014806|NCT00969319|||COHORT||PROSPECTIVE|||||||
34014807|NCT05346783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014808|NCT03966482|NA|SINGLE_GROUP||TREATMENT||NONE||Uncompared before-after clinical trial||||
34014809|NCT01293760|RANDOMIZED|PARALLEL||||NONE||||||
33712824|NCT04885972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712825|NCT05300620|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33712826|NCT03547869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33712827|NCT00848081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712828|NCT00664391|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33712829|NCT00075010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712830|NCT03254004|NA|SINGLE_GROUP||TREATMENT||NONE||Pembrolizumab 200mg injection||||
33712831|NCT02781493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712832|NCT03032315|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712833|NCT04112290|||COHORT||PROSPECTIVE|||||||
33712834|NCT00694993|RANDOMIZED|SEQUENTIAL||TREATMENT||||||||
33712835|NCT02992106|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33712836|NCT05131646|||COHORT||PROSPECTIVE|||||||
33712837|NCT00228059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712838|NCT01919723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712839|NCT04236830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of examiners is impossible to be done during intervention and follow up due to different natures of the materials. However, participants and outcome assessors could be blinded (double blinding).|This is a 3 arm clinical trial. All selected first permanent molars will be randomly equally allocated into three groups according to capping material used.|t|f|f|t
33712840|NCT01513161|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33712841|NCT00205790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33712842|NCT02108353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33712843|NCT01009125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712844|NCT00285454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33712845|NCT05577481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33712846|NCT01265277|||COHORT||PROSPECTIVE|||||||
33712847|NCT01958008|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33712848|NCT00488176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712849|NCT01980368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712850|NCT00622791|||COHORT||PROSPECTIVE|||||||
33712851|NCT02509156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712852|NCT02266121|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712853|NCT04580953|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33712854|NCT00449020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712855|NCT00321945|||CASE_ONLY||RETROSPECTIVE|||||||
33712856|NCT05833191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In our study, which is planned as a single-blind evaluation, different physiotherapists will perform the evaluation and application.|The study will be included in a 12-session treatment program over four weeks.|f|f|t|f
33712857|NCT04620993|||OTHER||CROSS_SECTIONAL|||||||
33712858|NCT05240456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712859|NCT06054698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712860|NCT00844389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712861|NCT03971370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33712862|NCT03789318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712863|NCT00468182|||||PROSPECTIVE|||||||
33712864|NCT06347835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712865|NCT05578391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712866|NCT01606514|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33712867|NCT01748032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33712868|NCT00804791|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33712869|NCT01353326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712870|NCT04104945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712871|NCT03861351|NA|SINGLE_GROUP||TREATMENT||NONE||Men and women aged ≥ 18 years old suffering from bilateral cataract and astigmatism||||
33712872|NCT02037269|||||PROSPECTIVE|||||||
34014810|NCT03043118|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014811|NCT01706029|||COHORT||PROSPECTIVE|||||||
34014812|NCT02104336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014813|NCT00371306|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34014814|NCT05173038|||COHORT||PROSPECTIVE|||||||
34014815|NCT00121147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014816|NCT03824990|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34014817|NCT03184259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014818|NCT01750619|||COHORT||PROSPECTIVE|||||||
34014819|NCT02314039|||COHORT||CROSS_SECTIONAL|||||||
34014820|NCT03095573|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The videos will be reviewed by three experts operators blinded about the sequence of capsule examination administration|Each enrolled patients will undergo examination of the small bowel by means of both endoscopic capsule devices (the axial-view PillCam SB3 and the lateral-view CapsoCam) on the same day at approximately 3 hours interval from one another. The order of administration of the two different capsules will be determined by a specific randomization sequence.|f|f|f|t
34014821|NCT05875922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind masking; Patient will not be informed which IOL model was implanted until end of the study. Outcomes assessors will not be informed which IOL model was implanted until end of the study.||t|f|f|t
34014822|NCT00377507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014823|NCT05012865|||COHORT||RETROSPECTIVE|||||||
34014824|NCT00351598|||COHORT||PROSPECTIVE|||||||
34014825|NCT01393184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014826|NCT01530594|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014827|NCT05672693|||OTHER||RETROSPECTIVE|||||||
34014828|NCT05748119|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double Blind||t|t|f|f
34097504|NCT05890586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
34097505|NCT01801605|RANDOMIZED|CROSSOVER||||DOUBLE|||t|t|f|f
34097506|NCT04174820|||CASE_CONTROL||OTHER|||||||
34097507|NCT05339061|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, single-center, non-randomized, single-arm study.||||
34097508|NCT01837095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097509|NCT00366535|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34097510|NCT04250363|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34097511|NCT00805220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712873|NCT00088517||||TREATMENT||||||||
33712874|NCT04949477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014829|NCT06205433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34014830|NCT03501836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014831|NCT05222542|||COHORT||PROSPECTIVE|||||||
34014832|NCT04284514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014833|NCT04178265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712875|NCT01276353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097512|NCT03275610|||COHORT||PROSPECTIVE|||||||
34097513|NCT02330263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34097514|NCT02821000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097515|NCT00108537|RANDOMIZED|||TREATMENT||NONE||||||
34097516|NCT03462563|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33712876|NCT01332474|||OTHER||RETROSPECTIVE|||||||
33712877|NCT02584673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33712878|NCT04237194|||COHORT||PROSPECTIVE|||||||
33712879|NCT04203238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigator and care providers will be blinded to randomization and treatment allocation.|Randomized parallel design|f|t|t|t
33712880|NCT05209984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712881|NCT02324569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712882|NCT01516385|||COHORT||PROSPECTIVE|||||||
33712883|NCT01327898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014834|NCT05574231|||COHORT||OTHER|||||||
34014835|NCT02439203|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34014836|NCT04960306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34014837|NCT00013494|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34014838|NCT01720199|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014839|NCT01846117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014840|NCT01543659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097517|NCT03016403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34014841|NCT00704613|||CASE_ONLY||PROSPECTIVE|||||||
34014842|NCT06153654|||CASE_CONTROL||PROSPECTIVE|||||||
34014843|NCT03114696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34014844|NCT00073021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014845|NCT00181259|||OTHER||PROSPECTIVE|||||||
34097518|NCT02196909|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34097519|NCT02245386|||||CROSS_SECTIONAL|||||||
34097520|NCT00112307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097521|NCT01176994|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097522|NCT04708054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097523|NCT00438412|||CASE_CONTROL||PROSPECTIVE|||||||
34097524|NCT00290758|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33793252|NCT01026636|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793253|NCT02570191|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014846|NCT06070987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be a research code representing patients' identity, this code will not show patients' name, social security number, and home address. For the results of patients' visit and the diagnosis, the study moderator will maintain a confidential attitude and be careful to maintain patients' privacy.||t|f|f|f
34014847|NCT01144364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793254|NCT01321606|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33793255|NCT00540202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793256|NCT03229707|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33793257|NCT04136912|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Acoustic angiography is a new type of contrast enhanced ultrasound imaging which is specifically sensitive to microvascular structure and density.||||
33793258|NCT03825419|||COHORT||PROSPECTIVE|||||||
33793259|NCT02897622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793260|NCT00005772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014848|NCT05015920|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014849|NCT03621007|||COHORT||PROSPECTIVE|||||||
34014850|NCT06436352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective research was carried out between January 2021 and February 2023. Patients were randomized into two groups: Group I: cases with capsulotomy and Group II: cases without capsulotomy. The study was conducted after an ethical approval was obtained.|t|f|f|f
34014851|NCT01565772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014852|NCT01893645|||CASE_ONLY||CROSS_SECTIONAL|||||||
34014853|NCT03647046|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014854|NCT01974908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014855|NCT00932945|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34014856|NCT00896324|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Pre-chemotherapy participants are randomized between active neurofeedback, and a sham (placebo) neurofeedback.|t|t|t|t
34014857|NCT02182128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014858|NCT04629859|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014859|NCT00077584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014860|NCT05905263|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34014861|NCT02921126|||COHORT||RETROSPECTIVE|||||||
34014862|NCT03896464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Autograft donation incisions will be covered with adhesive bandages for clinical outcome assessment by the attending physician. The assessor will perform a physical assessment of the patient's knees, including range of motion and laxity.||f|f|f|t
34014863|NCT05675241|||COHORT||CROSS_SECTIONAL|||||||
34014864|NCT02480218|||COHORT||PROSPECTIVE|||||||
34014865|NCT06425107|||COHORT||PROSPECTIVE|||||||
34014866|NCT00618202|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014867|NCT03653494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Volunteers and data collectors was masked|"1. Put 80 patients divided into group S（non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block） and group D（non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block）randomly.~2. Compare the volume of anesthetic drugs between the two groups.~3. If the date of group S greater than group D，it shows that the effect of anesthetic effect of group D is better than group S."|t|f|t|t
34014868|NCT03596736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014869|NCT00809159|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34014870|NCT04755257|||OTHER||PROSPECTIVE|||||||
34014871|NCT02044549|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34014872|NCT03149458|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled study||||
34097525|NCT01727427|||COHORT||PROSPECTIVE|||||||
34097526|NCT06476691|||CASE_ONLY||OTHER|||||||
33793261|NCT01637506|||CASE_CONTROL||PROSPECTIVE|||||||
33793262|NCT01269736|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33793263|NCT01365637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793264|NCT06028282|||CASE_CONTROL||PROSPECTIVE|||||||
34014873|NCT03866915|||COHORT||CROSS_SECTIONAL|||||||
34014874|NCT03946254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After the random assignment of the groups, the coaches will be oblivious to the investigation, so there is no bias.Furthermore, the principal investigator will not know where the data of each group comes from.||f|f|t|t
34014875|NCT03968198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014876|NCT04529447|||OTHER||RETROSPECTIVE|||||||
34014877|NCT05518630|||COHORT||OTHER|||||||
34014878|NCT03022058|NA|SINGLE_GROUP||OTHER||NONE||||||
34014879|NCT01700426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014880|NCT03858218|||COHORT||CROSS_SECTIONAL|||||||
34014881|NCT02003911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014882|NCT02744131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014883|NCT00356980||||TREATMENT||NONE||||||
34014884|NCT00911807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014885|NCT01089621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014886|NCT00389831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34014887|NCT05173246|NA|SINGLE_GROUP||TREATMENT||NONE||JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Esophageal Small Cell Carcinoma||||
34097527|NCT02454582|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34097528|NCT04745988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097529|NCT01491932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097530|NCT04056637|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34097531|NCT02846454|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34097532|NCT05634928|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097533|NCT02982200|||COHORT||PROSPECTIVE|||||||
34097534|NCT06072261|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097535|NCT03357705|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097536|NCT04947904|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34097537|NCT00826293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097538|NCT03053830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014888|NCT01239979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34097539|NCT04220281|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34097540|NCT03099356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097541|NCT03156452|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre, open label randomised clinical trial of MMF with steroid as a first line treatment for patients with ITP against the standard care pathway involving steroids alone as first line treatment.||||
34097542|NCT05378607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097543|NCT00324194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097544|NCT04347759|NA|SINGLE_GROUP||OTHER||NONE||||||
34097545|NCT03181009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded labeling (Individual dosing cups will mention a choice of two doses the participant could be assigned to). Oat flour is used as the filler to create equal volumes for all doses|This is a phase 2 multi site study that will be conducted at two centers in the U.S. All subjects will receive oral immunotherapy for their specific food allergies (peanut, egg, milk, wheat, soy, cashew, walnut, almond, hazelnut, sesame seed, cod, salmon and shrimp). All participants will receive three doses of Omalizumab 4 weeks apart over 8 weeks. The subject's allergens will be introduced after receiving the third omalizumab dose. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B.|t|f|t|f
34097546|NCT04432584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097547|NCT02040220|||COHORT||PROSPECTIVE|||||||
34097548|NCT01096186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097549|NCT05280808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097550|NCT00972257|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34097551|NCT00270569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097552|NCT00305279|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34097553|NCT03926598|||COHORT||PROSPECTIVE|||||||
34097554|NCT05219344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The kinesiologist (care provider), investigator and assessors will be blind for group allocation of the participants|Randomized controlled trial|f|t|t|t
34097555|NCT01899287|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34097556|NCT03722030|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot/Feasibility trial - 2 arms, one strength-training intervention vs. waitlist control group||||
34097557|NCT03193307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097558|NCT03073057|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33712884|NCT02314897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712885|NCT00935753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014889|NCT01530763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014890|NCT03316378|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||In this mechanistic study, the Achilles tendinopathy group receives an anesthetic injection. The healthy control group does not receive an injection.||||
34014891|NCT06357793|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34014892|NCT06011616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the subjects would be masked about the group they belong too.|2 group parallel randomized control trial; both groups will be recruited and provided with interventions in parallel|t|f|f|f
34014893|NCT02280226|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34014894|NCT03626506|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, controlled, open-label trial||||
34014895|NCT05690893|||COHORT||RETROSPECTIVE|||||||
34014896|NCT01674413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014897|NCT00433316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014898|NCT03405558|||COHORT||PROSPECTIVE|||||||
34014899|NCT05367414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34014900|NCT02599259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014901|NCT05461118|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is an interventional clinical trial, in which prospectively enrolled subjects will be compared with the historical control arm.||||
34014902|NCT02899949|||COHORT||RETROSPECTIVE|||||||
34014903|NCT03907800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097559|NCT06314035|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to their group assignment. The personnel administering the interventions will not be blinded||t|f|f|f
34097560|NCT03178942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study product will be randomized, packaged and blinded so that the packaging for both treatments look identical.|Patients will be assigned to the test or reference permethrin to treat scabies.|t|t|t|t
34097561|NCT00908687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097562|NCT01762462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097563|NCT00009633|||COHORT||PROSPECTIVE|||||||
34014904|NCT04764955|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014905|NCT01957228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014906|NCT02099604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014907|NCT05613725|||CASE_ONLY||PROSPECTIVE|||||||
33712886|NCT00988611|||OTHER||PROSPECTIVE|||||||
33712887|NCT00615758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720704|NCT00484211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720705|NCT04022447|||OTHER||RETROSPECTIVE|||||||
33720706|NCT00000976||||TREATMENT||||||||
33720707|NCT05217329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793265|NCT03993392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712888|NCT03445104|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Randomization allocation will be performed by personnel not involved in data collection to maintain participant and investigator blinding.|The participants will be randomized to receive huperzine A or placebo during the first session. They will then receive the other treatment during the second session.|t|f|t|t
33793266|NCT03122704|NA|SINGLE_GROUP||SCREENING||NONE||||||
34014908|NCT02516410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34014909|NCT05278572|NA|SINGLE_GROUP||TREATMENT||NONE|N/A: Study only has one arm.|This clinical trial involves a single treatment arm, consisting of 10 women enrolled in a pilot group. The group will meet weekly for 8 weeks. The intervention consists of cognitive-behavioral stress management/expressive supportive therapy (CBSM+) targeting depression among older women with HIV. The group will be co-facilitated by a Psychologist and a Peer.||||
34014910|NCT05518266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014911|NCT00569413|||COHORT||CROSS_SECTIONAL|||||||
34014912|NCT05974917|||CASE_CONTROL||PROSPECTIVE|||||||
34014913|NCT03344926|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study of treatment delivery in a new format.||||
34014914|NCT03588442|||COHORT||PROSPECTIVE|||||||
34014915|NCT01138826|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34014916|NCT05649735|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33793267|NCT04565691|NA|SINGLE_GROUP||TREATMENT||NONE|No masking.|We study the impact of bacteremia. The subjects will be their own controls at the different time-points.||||
33793268|NCT04704739|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33793269|NCT05146817|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparison of 2 patients' groups to assess the efficiency of the method of ventilator-associated infections prevention||||
34014917|NCT01829113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34014918|NCT00102245|||COHORT||PROSPECTIVE|||||||
34014919|NCT04293978|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, with immediate effects of interest. Varying number of intervention uses across participants.||||
34014920|NCT02591121|||COHORT||PROSPECTIVE|||||||
33793270|NCT04848441|||COHORT||RETROSPECTIVE|||||||
33793271|NCT05607108|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm phase 2 study of ZEN003694 in patients with advanced NSD3- amplified squamous cell lung cancer.||||
33793272|NCT02044523|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793273|NCT02616861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712889|NCT03124875|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center pilot study||||
33793274|NCT02061228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793275|NCT03657017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793276|NCT00064506|||COHORT||PROSPECTIVE|||||||
33793277|NCT00962117|||||CROSS_SECTIONAL|||||||
34097564|NCT02458495|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33793278|NCT01698255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793279|NCT01510041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014921|NCT06186102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double (Participant, Investigator)|Randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.|t|t|t|t
34014922|NCT03507478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014923|NCT03010566|||OTHER||PROSPECTIVE|||||||
34014924|NCT01631513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014925|NCT04968860|||CASE_CONTROL||PROSPECTIVE|||||||
34014926|NCT05732896|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34014927|NCT05036395|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34014928|NCT00639145|||COHORT||PROSPECTIVE|||||||
34014929|NCT03970265|||COHORT||PROSPECTIVE|||||||
33712890|NCT01137500|||COHORT||PROSPECTIVE|||||||
33712891|NCT00561236|||CASE_ONLY||PROSPECTIVE|||||||
33712892|NCT05284149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712893|NCT04623138|||COHORT||PROSPECTIVE|||||||
33712894|NCT04862000|||COHORT||PROSPECTIVE|||||||
33793280|NCT04558112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793281|NCT01290224|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33793282|NCT02796092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793283|NCT06282744|||OTHER||CROSS_SECTIONAL|||||||
33793284|NCT05110391|||COHORT||RETROSPECTIVE|||||||
33793285|NCT02866435|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34097565|NCT02046187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097566|NCT00736476|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34097567|NCT04759170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936300|NCT04043416|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All outcome measures will be collected by the physiotherapy team at The Glebe Centre. The physiotherapy team will be blinded to the group allocation of each participant.|This study has 2 six week campaigns with a six week washout in between the 2 campaigns. During the first campaign half of the participants will use the motivating reminiscence technology while receiving the standard fall prevention programming, while the second half will receive just the standard fall prevention programming. During the 6 week washout period all participants will just receive the standard fall prevention programming. After the washout period, there will be the second campaign where the other half of the participants will use the motivating reminiscence technology while receiving the standard fall prevention programming, whereas the remaining participants will just receive the standard fall prevention programming.|f|f|f|t
34097568|NCT01250314|NON_RANDOMIZED|PARALLEL||||NONE||||||
34097569|NCT04983498|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34097570|NCT00003327||||TREATMENT||||||||
34097571|NCT04725643|||OTHER||PROSPECTIVE|||||||
34097572|NCT02318277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936301|NCT01627041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936302|NCT01704144|||COHORT||PROSPECTIVE|||||||
33936303|NCT02033252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936304|NCT05675475|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097573|NCT03212469|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is an open label, multicentric, Phase I/II trial||||
34097574|NCT03561740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097575|NCT05979077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34097576|NCT03197935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097577|NCT03167398|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097578|NCT00201773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097579|NCT01991574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34097580|NCT06440759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|single-blinding (patient)||t|t|t|f
34097581|NCT03536065|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Pre-Post Study Design with Non-Pharmacologic Intervention||||
34097582|NCT00000839||||TREATMENT||||||||
34097583|NCT05607758|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34097584|NCT05254210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097585|NCT06344377|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34097586|NCT06285695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097587|NCT03167710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097588|NCT04252118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097589|NCT05662943|||CASE_ONLY||RETROSPECTIVE|||||||
33936305|NCT05431335|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel design randomized clinical trial||||
33936306|NCT02050828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936307|NCT04225936|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34097590|NCT00520442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097591|NCT06413394|||COHORT||PROSPECTIVE|||||||
34097592|NCT01524458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936308|NCT04469556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 150 patients will be randomized in a 1:1 ratio to receive one of the two standard of care regimens in patients with confirmed metastatic PDAC||||
33936309|NCT04290767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cohort study in a single center||||
34097593|NCT00537082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097594|NCT03120923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097595|NCT02379897|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34097596|NCT03309605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"* Cohort 1: ELX-02 0.1 mg/kg or placebo SC twice a week for 9 doses;~* Cohort 2: ELX-02 0.3 mg/kg or placebo SC twice a week for 9 doses;~* Cohort 3: ELX-02 1.0 mg/kg or placebo SC twice a week for 9 doses;~* Cohort 4: ELX-02 2.5 mg/kg or placebo SC twice a week for 9 doses;~* Cohort 5: ELX-02 up to 2.5 mg/kg (50 mg/mL per injection) or placebo SC twice a week for 9 doses;~* Cohort 6: ELX-02 2.5 to 5.0 mg/kg or placebo SC twice a week for 9 doses. Optional Cohort~* Cohort 7: ELX-02 up to 5.0 mg/kg or placebo SC twice a week for 9 doses. Optional Cohort"|t|t|t|t
33712895|NCT03627624|||COHORT||RETROSPECTIVE|||||||
33936310|NCT03884556|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33936311|NCT01345825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33936312|NCT04068220|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097597|NCT05342688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking description: The outcome assessor will be blind to the group assignment of the participants. Participants and the investigator who deliver the intervention will be aware of group assignment because it is inherent to the type of practice they receive and deliver respectively.|The study will be a randomized controlled trial with a pre-post design.|f|f|f|t
34097598|NCT00726427|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34097599|NCT06532071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097600|NCT05763316|||COHORT||PROSPECTIVE|||||||
34097601|NCT04014088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097602|NCT03793452|||COHORT||PROSPECTIVE|||||||
34097603|NCT00000446|RANDOMIZED|||TREATMENT||DOUBLE||||||
34097604|NCT03573765|||COHORT||RETROSPECTIVE|||||||
34097605|NCT03002909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34097606|NCT01765881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097607|NCT05163535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097608|NCT03246594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097609|NCT05311462|||COHORT||PROSPECTIVE|||||||
34097610|NCT06192212|||COHORT||RETROSPECTIVE|||||||
34097611|NCT03479346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097612|NCT05162391|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097613|NCT02474901|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open label|||||
34097614|NCT05469061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097615|NCT00754039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097616|NCT02319083|||COHORT||PROSPECTIVE|||||||
34097617|NCT04447066|||COHORT||CROSS_SECTIONAL|||||||
34097618|NCT04389671|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single treatment of reconstituted Lucinactant, delivered as an intratracheal liquid.||||
34097619|NCT03450135|||COHORT||PROSPECTIVE|||||||
34097620|NCT03048279|||CASE_CONTROL||PROSPECTIVE|||||||
34097621|NCT01804907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097622|NCT04538898|||COHORT||RETROSPECTIVE|||||||
33712896|NCT00543556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712897|NCT01764321|||COHORT||PROSPECTIVE|||||||
33712898|NCT02954237|||CASE_ONLY||PROSPECTIVE|||||||
33712899|NCT00525083|||CASE_ONLY||CROSS_SECTIONAL|||||||
33712900|NCT03548103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo|double blind placebo-controlled trial|t|t|t|f
33712901|NCT05549570|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33712902|NCT00358124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712903|NCT01417273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712904|NCT03748147|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Both arms will receive identical appearing drug made by the Investigational Drug Unit of the Pharmacy.|Parallel design randomized trial. Two study groups: control (25 mcg) intervention (50 mcg)|t|t|t|f
33793286|NCT05802264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793287|NCT00886145|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936313|NCT01362049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33936314|NCT04207944|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33936315|NCT00717951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936316|NCT04348136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936317|NCT02812290|||COHORT||PROSPECTIVE|||||||
33936318|NCT00364468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936319|NCT03422744|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936320|NCT04444323|NA|SINGLE_GROUP||OTHER||NONE|Data analysis will be masked|Single cohort patients seen face-to-face and then by 3D telemedicine||||
33936321|NCT02397772|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936322|NCT01965028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936323|NCT03378973|RANDOMIZED|PARALLEL||OTHER||SINGLE|The anesthesiologist administering anesthetic agents will have knowledge of their doses. The technologist performing motor evoked potential testing and other participants will not.||f|f|t|f
33936324|NCT05917392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34014930|NCT00324311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014931|NCT04324710|||COHORT||PROSPECTIVE|||||||
34014932|NCT04056975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014933|NCT04325152|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34014934|NCT03998579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014935|NCT01095679|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34014936|NCT01899365|||COHORT||PROSPECTIVE|||||||
34014937|NCT03592342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All 4 interventions will be similar in appearance and be allocated by use of a blinded kit number (each kit contains drug for 1 week).|Randomization will be 1:1:1:1 to 1 of the 4 parallel arms (3 active and 1 placebo) and patients will be stratified according to number of patches needed (1-3 and 4-6).|t|t|t|t
34014938|NCT03520868|||CASE_ONLY||PROSPECTIVE|||||||
34014939|NCT04335175|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34097623|NCT03962816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34097624|NCT03378388|||COHORT||PROSPECTIVE|||||||
34097625|NCT06096948|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097626|NCT03033212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34097627|NCT04956965|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patient who needs electro-mapping in routine care.||||
34097628|NCT02734914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34097629|NCT06494514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097630|NCT00356421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097631|NCT00335192|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014940|NCT03407521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014941|NCT00376974|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34014942|NCT04665206|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 dose escalation: 3 + 3 design Part 2 dose expansion: up to 6 cohorts||||
34097632|NCT01855568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712905|NCT04367636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33712906|NCT04913402|||COHORT||PROSPECTIVE|||||||
34014943|NCT03500497|||COHORT||PROSPECTIVE|||||||
33712907|NCT00119054|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34014944|NCT01582984|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712908|NCT02662491|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Double blind|Calcium 600mg, vitamin D 2000IU, both or placebo|t|t|t|t
33712909|NCT01654341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712910|NCT06290726|||COHORT||RETROSPECTIVE|||||||
33712911|NCT02851758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712912|NCT02603094|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34097633|NCT05064800|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a Phase1, open-label,3-treatment, 6-sequence, 3-period crossover study to estimate the effect of PF-07321332/ritonavir and ritonavir on the Pharmacokinetics of dabigatran in healthy participants||||
33793288|NCT02999048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793289|NCT02013830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014945|NCT01155401|||CASE_ONLY||PROSPECTIVE|||||||
34014946|NCT04320550|||COHORT||PROSPECTIVE|||||||
34014947|NCT01509521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014948|NCT01946074|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34014949|NCT00845234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014950|NCT00046449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34014951|NCT03338348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936325|NCT04600427|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, single centre study||||
33936326|NCT02308553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936327|NCT01616641|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936328|NCT00975442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936329|NCT04305665|||COHORT||PROSPECTIVE|||||||
33936330|NCT05103501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936331|NCT01792492|||COHORT||PROSPECTIVE|||||||
33936332|NCT03130465|||COHORT||OTHER|||||||
33936333|NCT01620437|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33936334|NCT04904991|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study randomized controlled trial with four repeated measurements was conducted between Apply 2016 and October 2017. Participants in the Qigong group were given a structured program about Chan-Chung qigong for 3 months; those in the control group received usual care for cognitive impairment during the same study period. The intervention effects were measured by muscular strength, muscular endurance, and 6-min walk distance at baseline, Month 1, Month 2, and Month 3. In addition, QoL was measured at baseline and Month 3.||||
33936335|NCT02064829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936336|NCT02261402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936337|NCT01376908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936338|NCT04838340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936339|NCT04369586|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33936340|NCT04317794|||CASE_ONLY||PROSPECTIVE|||||||
33936341|NCT00255606|RANDOMIZED|||TREATMENT||||||||
33936342|NCT01623089|||CASE_ONLY||PROSPECTIVE|||||||
33936343|NCT03731169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33936344|NCT05499689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936345|NCT04139629|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33936346|NCT03059511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936347|NCT01981096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936348|NCT05847556|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pathway 1: pilot study of non-medical device Pathway 2: observational cohort study of medical device Pathway 3: randomised pilot study of non-medical device||||
33936349|NCT00022906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936350|NCT01646346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014952|NCT00775541|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33712913|NCT02904330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712914|NCT06208644|||OTHER||PROSPECTIVE|||||||
33712915|NCT04014712|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33712916|NCT00751751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712917|NCT04851314|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33720708|NCT05526612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment (Outcomes Assessor)|f|f|f|t
33720709|NCT03179995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33720710|NCT01541774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720711|NCT01165554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720712|NCT01525043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936351|NCT01949792|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34014953|NCT02714933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014954|NCT00407758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014955|NCT05515016|NA|SINGLE_GROUP||TREATMENT||NONE||The same surgical procedure was performed on 10 participants. These participants had a double chin with skin redundancy and a receding chin. The result was evaluated with photos and chin advancement was measured with a Vernier caliper.||||
34014956|NCT00990587|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34014957|NCT02593513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014958|NCT01121341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014959|NCT04037930|||CASE_CONTROL||PROSPECTIVE|||||||
34014960|NCT03421366|||COHORT||PROSPECTIVE|||||||
34014961|NCT04979884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014962|NCT00749281|||CASE_CONTROL||PROSPECTIVE|||||||
34014963|NCT03722355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014964|NCT03581071|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34014965|NCT02630836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936352|NCT04830176|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Both the participant and the care provider were masked. They were unaware of the paste they were using as it was marked alphanumerically|sample size of 30- First group of 15 subjects recording of plaque and gingival scores were recorded. Patients were given first dentifrice and asked to brush for 72 hours and then asked to report. A washout period of 2 weeks followed. The next round, the subjects were given the second dentifrice and asked to brush for 72 hrs and then after a period of 3days asked to report|t|t|f|f
33936353|NCT01711606|||COHORT||PROSPECTIVE|||||||
33936354|NCT03180294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33936355|NCT04493489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936356|NCT04800484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the heel wedge conditions.|Participants will be evaluated in their clinically configured AFO and without an AFO if able. They will also complete evaluation with four provided heel wedge conditions in randomized order: tall soft, tall firm, short soft, short firm.|t|f|f|f
33936357|NCT00336466|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33936358|NCT03426644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936359|NCT00562536|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097634|NCT05803954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936360|NCT01913015|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936361|NCT02416765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936362|NCT03378128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936363|NCT03356795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936364|NCT05272306|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Prospective Randomized Clinical Trial|t|f|f|f
33936365|NCT01626755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33936366|NCT00885729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936367|NCT00075660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936368|NCT04012762|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33936369|NCT00881686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936370|NCT02331316|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33936371|NCT02179827|||CASE_ONLY||RETROSPECTIVE|||||||
33936372|NCT05972122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesiologist who performs postoperative pain evaluation and the patient will not know the group.|There are two models for this study. The first group is the SPSIPB group. The second one is the control group.|t|f|f|t
33936373|NCT04751123|||OTHER||PROSPECTIVE|||||||
33936374|NCT03052634|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936375|NCT02550860|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33936376|NCT04098016|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936377|NCT00278967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33936378|NCT03613168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936379|NCT03463213|NA|SINGLE_GROUP||PREVENTION||NONE||This is a feasibility study with a single group pre/post outcome design.||||
33936380|NCT03166228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936381|NCT00291460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33936382|NCT03227692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Persona TKA with iASSIST Knee system (Investigational group) or Persona TKA with conventional instrumentation (Control group). The randomization scheme is based on equal numbers per group. The randomization will occur via a random number generator (computer) using blocked randomization procedure. The PI or his/her team does not have influence on the randomization scheme. Sealed opaque envelopes, which will be prepared based on predetermined randomization assignment, will be provided to each study site before study initiation.|At surgery, intervention group using iASSIST Knee system. At surgery, conventional group not using iASSIST Knee system.|t|t|t|t
33936383|NCT06177223|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial design would be used in this study. it would be two arm study and there would be two groups an experimental and wait-list control group. Experimental group will receive intervention and another group would be placed in waitlist. In this research , parallel group design would be used. We will give treatment to all participants in a parallel way. Allocation ratio and framework would be equivalence i.e., treatment group and control group would be equal number of participants.||||
33936384|NCT01722214|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936385|NCT02993783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936386|NCT00166244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936387|NCT04277052|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33936388|NCT04076904|||OTHER||CROSS_SECTIONAL|||||||
33936389|NCT01935674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014966|NCT06616948|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The proposed pilot study will utilize the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation and Maintenance) to focus on the reach and effectiveness of a 6-month triweekly in-home cycling program and then pilot a health coach model to promote maintenance for the subsequent 3-month period.||||
34014967|NCT02914236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014968|NCT02343757|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34014969|NCT04039386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34014970|NCT05344651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014971|NCT05720975|||CASE_ONLY||PROSPECTIVE|||||||
34014972|NCT03342599|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34014973|NCT00851643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34014974|NCT04343703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34014975|NCT03113448|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized controlled trial, double blind|t|t|t|t
34014976|NCT03542084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014977|NCT01744119|||COHORT||PROSPECTIVE|||||||
34014978|NCT04184661|||CASE_CONTROL||PROSPECTIVE|||||||
34014979|NCT03143478|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34014980|NCT06138119|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||It will be a 2x2 between-subject factorial design. Simulation FOE (Fiberoptic Intubation) scores will be the dependent variable. Being male or female and stereotype threat will be the study's independent variables. There will be four groups to be compared: Male anesthesiologists in the experimental group (1), male anesthesiologists in the control group (2), female anesthesiologists in the experimental group (3), female anesthesiologists in the control group (4).|t|t|t|f
34014981|NCT06222541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34014982|NCT02514161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014983|NCT00705692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34014984|NCT03336957|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014985|NCT01940497|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34014986|NCT01528020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34014987|NCT01929031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097635|NCT00635180|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097636|NCT00632970|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33936390|NCT03623204|||CASE_ONLY||PROSPECTIVE|||||||
33936391|NCT04576273|||CASE_ONLY||RETROSPECTIVE|||||||
33936392|NCT06357429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33936393|NCT01671605|||CASE_ONLY||RETROSPECTIVE|||||||
33936394|NCT01017549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014988|NCT05121844|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm study||||
34014989|NCT04093869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097637|NCT04233580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097638|NCT01427452|||COHORT||PROSPECTIVE|||||||
34097639|NCT00093223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097640|NCT04464902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and investigator all don't know which group they participated in.||t|f|t|f
34097641|NCT02329275|||CASE_CONTROL||PROSPECTIVE|||||||
34097642|NCT06034652|||COHORT||PROSPECTIVE|||||||
34097643|NCT04309448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097644|NCT06214962|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097645|NCT06088628|||COHORT||CROSS_SECTIONAL|||||||
34097646|NCT06274437|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34097647|NCT01593111|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34097648|NCT05538468|||OTHER||CROSS_SECTIONAL|||||||
34097649|NCT02032212|RANDOMIZED|CROSSOVER||||NONE||||||
34097650|NCT04113486|||OTHER||CROSS_SECTIONAL|||||||
34097651|NCT02832947|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097652|NCT01576965|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34097653|NCT06404554|||COHORT||RETROSPECTIVE|||||||
34097654|NCT03553888|||OTHER||CROSS_SECTIONAL|||||||
34097655|NCT06110182|||COHORT||RETROSPECTIVE|||||||
33936395|NCT03271411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720713|NCT03649685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720714|NCT00016146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720715|NCT05089227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720716|NCT03407534|||COHORT||PROSPECTIVE|||||||
33720717|NCT06096220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720718|NCT02935322|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33720719|NCT04634747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720720|NCT04859712|||COHORT||PROSPECTIVE|||||||
33720721|NCT01982084|||OTHER||OTHER|||||||
33720722|NCT02985229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793290|NCT02050308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793291|NCT03794193|||COHORT||RETROSPECTIVE|||||||
33793292|NCT02461615|||OTHER||PROSPECTIVE|||||||
33793293|NCT03804086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936396|NCT04037059|||OTHER||PROSPECTIVE|||||||
33936397|NCT01718015|||CASE_ONLY||PROSPECTIVE|||||||
33936398|NCT06366854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936399|NCT04394013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33720723|NCT02478801|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720724|NCT03973840|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720725|NCT00297908|||||PROSPECTIVE|||||||
33720726|NCT03611790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720727|NCT00438087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720728|NCT04111679|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"This will be a 4-period 4-sequence 2-treatment crossover study, participants will be exposed to both control group (A), the silent group, and intervention group (B), the music group, whilst performing a laparoscopic task in a box trainer.~Participants will be randomly assigned to a sequence that determines in which order they are being exposed to both auditory environments"|f|f|t|t
33720729|NCT02732509|||COHORT||CROSS_SECTIONAL|||||||
33720730|NCT01963403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720731|NCT02400502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936400|NCT00688389|||CASE_CONTROL||OTHER|||||||
33936401|NCT03547765|||CASE_ONLY||PROSPECTIVE|||||||
33720732|NCT01106898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720733|NCT01857466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720734|NCT05022784|||COHORT||RETROSPECTIVE|||||||
33936402|NCT01263470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936403|NCT03726749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936404|NCT03238040|||COHORT||PROSPECTIVE|||||||
33936405|NCT04785144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936406|NCT01269489|||COHORT||PROSPECTIVE|||||||
33936407|NCT02393612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936408|NCT04802395|||COHORT||PROSPECTIVE|||||||
33936409|NCT02280109|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33936410|NCT04210232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936411|NCT05705674|||CASE_ONLY||PROSPECTIVE|||||||
33936412|NCT01680146|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936413|NCT05727631|RANDOMIZED|PARALLEL||PREVENTION||NONE||Preterm babies who apply to the blood collection room to draw blood, will be included in the experimental and control group. Randomization was done at www.randomizer.org.||||
33936414|NCT03109444|||COHORT||PROSPECTIVE|||||||
33936415|NCT04261218|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"All patients will be initially treated with tomivosertib monotherapy for 14 ± 2 days (the run-in period). Once the on-treatment samples for pharmacodynamic (PD) assessments are obtained, weekly paclitaxel will be added to the treatment regimen.~The first 3 to 9 patients will be part of Group 1. The first 3 patients enrolled in this group will receive tomivosertib at a dose of 100 mg orally twice daily (BID), in fasting conditions, and will be assessed for dose-limiting toxicities (DLTs) during the first cycle of tomivosertib in combination with paclitaxel. Depending on the occurrence/absence of DLTs, this first group of 3 patients may need to be expanded (up to 9 patients) or the trial may proceed to start enrollment in Group 2. Group 2 patients will receive tomivosertib at a dose of 100 mg orally BID during the 'run-in' period, as well as weekly paclitaxel in combination with tomivosertib during the 'post run-in' period."||||
33936416|NCT03307213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomised to one of the treatment arms to receive either the BioFreedom™ SS or the BioFreedom™ CoCr stent.|t|f|f|f
33936417|NCT02557048|||COHORT||RETROSPECTIVE|||||||
33936418|NCT02324413|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33936419|NCT04241536|NA|SINGLE_GROUP||OTHER||NONE||||||
33936420|NCT03303872|||COHORT||PROSPECTIVE|||||||
33936421|NCT00931190|||COHORT||PROSPECTIVE|||||||
33936422|NCT04844567|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Participants are naïve to the difference in interventions. Allocation was concealed to the care provider screening participants.|Participants perform both conditions. Condition order was randomised across participants using a script prior to data collection.|t|t|f|f
34097656|NCT04452838|RANDOMIZED|CROSSOVER||OTHER||NONE||"This is a Phase 1 randomized, open-label, single-dose crossover study in healthy participants. A two stage approach outlined below will be followed:~Part A (Cohort 1): This part of the study is a 2 sequence, 4 period, crossover design.~Part B (Cohort 2): This part of the study is a 4 sequence, 4 period, crossover design. Participants will be randomized to 1 of 4 possible treatment sequences. If bioequivalence (BE) criteria for the comparison of the BIC SR7 formulation with the BIC SR4 formulation administered in the fasted state are met in Part A, the formulations will be considered bioequivalent in the fasted state and only the first two periods of Part B will be conducted. Part B (all periods) may not be conducted if the AUCinf or Cmax Percent Geometric Mean Ratio GMR is less than 90% and greater than 111% and/or if variability suggest a highly variable drug (e.g., greater than 30%) because BE demonstration may not be possible with a reasonably sized 4 sequence 4 period study."||||
34097657|NCT00567112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097658|NCT01032278|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34097659|NCT00560404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097660|NCT01922414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097661|NCT06503458|||COHORT||PROSPECTIVE|||||||
34097662|NCT00585585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097663|NCT01356485|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34097664|NCT03548415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097665|NCT04201210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who fulfill inclusion criteria will be stratified according to donor availability. Patients with a matched sibling donor (MSD; defined as 8/( or 10/10 allelic match) will be stratified into the control arm.||||
34097666|NCT00723944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097667|NCT05881356|||CASE_CROSSOVER||PROSPECTIVE|||||||
34097668|NCT05139940|||COHORT||PROSPECTIVE|||||||
34097669|NCT06130137|||COHORT||PROSPECTIVE|||||||
34097670|NCT04903509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Within the central electrocardiogram (ECG) lab, the staff involved with interval measurements will be blinded with respect to the treatment and also with regard to the recording date and time as well as planned time points of the ECGs. The interval measurements for a given subject will be performed in a random and blinded sequence by a single technician.||t|f|f|f
34097671|NCT04757844|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097672|NCT02217553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34097673|NCT05733533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097674|NCT02326246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097675|NCT01658735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097676|NCT02787798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097677|NCT03708770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097678|NCT05952479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34097679|NCT02175758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097680|NCT03611465|NON_RANDOMIZED|PARALLEL||OTHER||NONE||There is no randomization. Patients are provided into 3 groups according to their pathology.||||
33712918|NCT05385731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind (Investigator, Outcomes Assessor, Care Provider)|Study Type: Interventional, Randomized controlled multicenter clinical trial In this research, four groups of patients with Parkinson's disease will receive intervention during 4 months of different physical therapy programs (Nordic walking) and free walking, who will receive telephone guidance for performing home-based exercises. The training programs will have a duration of 4 months and will be periodized so that the duration of the sessions is matched between them. The intensity of the interval training will be manipulated by the subjective effort scale (Borg) and by the heart rate, with predetermined series durations. All training programs will have a frequency of two sessions per week and a duration of 60 minutes. In order to evaluate the effects of the training, evaluations will be performed before and after the training period: 1) Basal (month 0): initial pre-training evaluation; 2) month 4: Evaluation 48h after the last training session.|f|t|t|t
34097681|NCT00753142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712919|NCT01089062|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33712920|NCT05407402|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33712921|NCT05385536|||COHORT||PROSPECTIVE|||||||
33712922|NCT01664533|||COHORT||PROSPECTIVE|||||||
33712923|NCT03954236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a prospective, randomized double-blinded, vehicle- and comparator controlled pilot study followed by an open label extension for all patients who wish to continue on study.|t|f|t|f
33712924|NCT02108470|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33712925|NCT01975753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712926|NCT03920579|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025358|NCT05667675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It will not be possible to blind participants to their group allocation. However, study information materials and the consent form will indicate that after consenting they will be randomly allocated to one of two approaches to providing support, without a detailed description of the interventions. This approach will provide some degree of blinding of participants. Additionally, RAs conducting outcomes assessment visits, the biostatistician and investigators will remain blind to each child's group allocation. Blinding will be achieved by having the group allocation coded as A and B in the database; group allocation will be concealed until the final data analysis is performed.|A pragmatic, 1:1 allocation, parallel-group superiority pilot randomized controlled trial will be conducted.|f|f|t|t
33712927|NCT01564420|||CASE_CONTROL||PROSPECTIVE|||||||
34025359|NCT02525237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097682|NCT03144635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097683|NCT06190015|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34097684|NCT01091532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34097685|NCT01137721|||CASE_CONTROL||PROSPECTIVE|||||||
34097686|NCT03132259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097687|NCT01117350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793294|NCT04586881|||COHORT||PROSPECTIVE|||||||
34097688|NCT05233540|||COHORT||PROSPECTIVE|||||||
34097689|NCT03051230|||COHORT||PROSPECTIVE|||||||
34097690|NCT03518203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097691|NCT02222181|NA|SINGLE_GROUP||||NONE||||||
33712928|NCT06531057|||OTHER||CROSS_SECTIONAL|||||||
33936423|NCT02237144|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34025360|NCT03854682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding to treatment allocation of patients, physiotherapists (health care providers) will not be possible due to the nature of the interventions. However, independent data collectors will be responsible for baseline and follow-up assessments, while all self-reported outcome measures will be made available to the patients electronically, and responses entered into a database identified by identification numbers only. The data analyst will be unaware of the treatment allocation as data will be analyzed using recoded identification numbers. The recoding will be performed by an independent person.|A prospective, blinded, parallel-group trial with balanced randomization \[1:1\], in accordance with CONSORT|f|f|t|t
34025361|NCT02474056|||||PROSPECTIVE|||||||
34097692|NCT04652843|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34097693|NCT04853537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097694|NCT05128344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097695|NCT02407015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34097696|NCT00298519|||COHORT||PROSPECTIVE|||||||
33712929|NCT03956732|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|D-pro will be double-blinded in respect to D vitamin supplementation or placebo, whereas the allocation of yoghurt with high versus medium milk protein content will not be blinded.||t|t|t|t
33712930|NCT04561193|||COHORT||RETROSPECTIVE|||||||
33936424|NCT04945304|||COHORT||PROSPECTIVE|||||||
33936425|NCT01012037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936426|NCT00175318|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33936427|NCT03686462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936428|NCT00733473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936429|NCT00964769||PARALLEL||||NONE||||||
33936430|NCT06283303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025362|NCT05908292|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34025363|NCT00338455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025364|NCT04798131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097697|NCT01400633|||CASE_ONLY||PROSPECTIVE|||||||
34097698|NCT04113980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025365|NCT05597748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient and care provider can't be masked as it is obvious what appliance modification is being used.|Four parallel arms all under treatment|f|f|f|t
34025366|NCT05443568|||COHORT||PROSPECTIVE|||||||
34025367|NCT06633458|||COHORT||PROSPECTIVE|||||||
34097699|NCT00372515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097700|NCT05615961|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The study has been blinded by an impartial third party from the company that has provided both the probiotic supplements and the placebo capsules.|Participants are assigned into either supplement or placebo intervention groups, in a pair-matched, double-blind, placebo controlled manner.|t|t|t|t
34097701|NCT01436292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097702|NCT02307500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097703|NCT00585169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097704|NCT01270867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712931|NCT02970422|||OTHER||CROSS_SECTIONAL|||||||
33712932|NCT01850524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712933|NCT05551039|||COHORT||RETROSPECTIVE|||||||
34097705|NCT05003336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712934|NCT04812691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712935|NCT01344005|RANDOMIZED|||DIAGNOSTIC||NONE||||||
33712936|NCT00001830||||TREATMENT||||||||
33712937|NCT00821353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712938|NCT05870020|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33712939|NCT02034110|NA|SINGLE_GROUP||TREATMENT||NONE||9 indications: anaplastic thyroid cancer (ATC), biliary tract cancer (BTC), gastrointestinal stromal tumor (GIST), low grade (WHO G1/G2) glioma (LGG), high grade (WHO G3/G4) glioma (HGG), non-seminomatous germ cell tumors (NSGCT)/non-germinomatous germ cell tumors (NGGCT), adenocarcinoma of the small intestine (ASI), hairy cell leukemia (HCL) and multiple myeloma (MM).||||
33712940|NCT03530098|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A hand radiograph will be randomly assigned to one of two groups - control and experiment. In the control group, participating radiologists will diagnose the exam using the current standard of care (no intervention). In the experiment group, the radiologists will factor in the output of the Artificial Intelligence algorithm in their skeletal age estimation. In all cases, the decision of the radiologist will be considered final.||||
33712941|NCT03846596|||COHORT||PROSPECTIVE|||||||
33712942|NCT00952679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712943|NCT04143321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33712944|NCT00709683|||COHORT||PROSPECTIVE|||||||
33712945|NCT00634894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793295|NCT05831007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793296|NCT01465724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712946|NCT02956577|||COHORT||PROSPECTIVE|||||||
34097706|NCT04795362|||COHORT||PROSPECTIVE|||||||
33793297|NCT00688519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793298|NCT06346769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097707|NCT00441740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793299|NCT00043082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793300|NCT04456348|||COHORT||PROSPECTIVE|||||||
33793301|NCT01320280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097708|NCT03927755|||COHORT||PROSPECTIVE|||||||
33793302|NCT06304636|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Study consists of two parts. Part 1 is a single-arm dose escalation study. Part 2 is a dose-expansion study with 2 arms.||||
34097709|NCT04989738|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34097710|NCT00729807|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label Phase II trial that will utilize a Simon two stage acquisition of patients with evaluable relapsed and/or refractory melanoma.||||
34097711|NCT06109753|||CASE_CONTROL||PROSPECTIVE|||||||
34097712|NCT00514917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097713|NCT04002427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097714|NCT06082544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097715|NCT03043469|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34097716|NCT00791882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712947|NCT06382584|||COHORT||RETROSPECTIVE|||||||
33712948|NCT02020330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712949|NCT00003325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793303|NCT03870191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793304|NCT04365400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936431|NCT04337528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the assessor of pre-post-biomechanical measurements will be blinded to which manipulation the participant has been assigned to. The manipulation intervention will be performed by a separate physical therapist who is not involved with the biomechanical measurements.|Group 1: Thrust technique Group 2: Muscle-energy technique Group 3: Placebo|t|f|f|t
33936432|NCT01802294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936433|NCT02649075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33936434|NCT02251028|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33936435|NCT00791011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936436|NCT02597686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936437|NCT02045225|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936438|NCT02045979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097717|NCT05052307|||CASE_CONTROL||PROSPECTIVE|||||||
34097718|NCT03116087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097719|NCT05645185|||COHORT||RETROSPECTIVE|||||||
34097720|NCT00195052|||CASE_ONLY||PROSPECTIVE|||||||
34097721|NCT04938674|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33712950|NCT03585998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712951|NCT04166916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||we forecast the enrollment of 70 participants which includes the conduction of pilot assessments and the collection of 18 complete participant datasets for the main clinical trial (described here).|t|f|f|t
33936439|NCT03887325|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33936440|NCT01215786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097722|NCT05004298|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33712952|NCT05333146|||COHORT||RETROSPECTIVE|||||||
33712953|NCT00387023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712954|NCT00949520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33712955|NCT01103791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712956|NCT04860453|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33712957|NCT00964860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712958|NCT00171730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712959|NCT00494078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712960|NCT04254471|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33712961|NCT01785550|||CASE_CONTROL||PROSPECTIVE|||||||
33712962|NCT04479423|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33793305|NCT02052219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793306|NCT01221779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793307|NCT03156712|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both investigators and participants were blinded to the iron treatment in this double-blinded, crossover study. Three different iron supplements were given, whereby participants were either administered 10 mg FeSO4, 10 mg ASP Fe, or 20 mg ASP Fe.|Double-blinded, cross-over experimental design, whereby subjects were randomly given three different iron supplements with a meal in three different visits. All three visits (iron treatments) were each separated by two weeks time.|t|f|t|f
33793308|NCT04986683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793309|NCT05685095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The researchers involved in data collection and in data analysis will be blinded with regard to the patients' group allocation. Randomization will be performed by an operator not otherwise involved in the study, under the RED-Cap application.||f|f|t|t
33793310|NCT00637234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097723|NCT06059079|||COHORT||RETROSPECTIVE|||||||
34097724|NCT02449928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097725|NCT04607590|||COHORT||PROSPECTIVE|||||||
34097726|NCT06405425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097727|NCT00051350|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Outcome assessors were unaware of diet sequence.|Individuals were randomized to a sequence of 3 diets (CARB, UNSAT, PROTEIN)|f|f|f|t
34097728|NCT00194090|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34097729|NCT05456841|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34097730|NCT03008330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097731|NCT02082093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097732|NCT03646188|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Placebo|3+3 Design||||
34097733|NCT02525432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33936441|NCT05320224|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33936442|NCT05307081|||COHORT||PROSPECTIVE|||||||
33936443|NCT02542189|||||RETROSPECTIVE|||||||
33936444|NCT03607994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This study will compare acoustic stimulation linked to brainwave activity (HIRREM-SOP, along with continued current care, BCC) with acoustic stimulation not linked to brainwave activity (NCC, along with continued current care). The participants in the NCC group with will offered the opportunity to crossover and receive a course of BCC at the end of their original participation.|t|f|t|t
33936445|NCT00269620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025368|NCT05076019|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"A unique identifier (code) will be generated for all patients to allow for data management.~The list of patients enrolled in the study is available to the data and safety monitoring board. Patients, physicians, nurses, and other data collectors are kept blinded to the allocation during the study.~The study medication is allocated in identical non-transparent containers. The placebo resembles the study drug for taste, smell, color, and shape.~Hospital pharmacy will be responsible for packaging the medicine, blinding and create sealed code envelopes in case of urgent need for unblinding.~The unblinding of study 2 is planned to take place when the last patients has been followed for at least 30 days and early data analysis have been statistically treated while data is still blinded"|"Intervention: Atorvastatin, n = 133 Dose: 80 mg/daily P.O. Length of preoperative statin exposure: 7 to 14 days prior to surgery Length of postoperative exposure: 30 days Control group: Placebo, n = 133~Study parameters Incidence, placebo group: 36% Incidence, Atorvastatin group: 20% Alpha: 0.05 Beta: 0.2 Power: 0.8 Enrolment ratio: 1:1~Sample size Placebo: 133 Atorvastatin: 133"|t|t|t|t
34025369|NCT01384955|||CASE_CONTROL||RETROSPECTIVE|||||||
34025370|NCT02002286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025371|NCT00644852|||COHORT||RETROSPECTIVE|||||||
34097734|NCT00567801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097735|NCT04967703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097736|NCT01084863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34097737|NCT04291833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33936446|NCT02292888|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||f|t|f|t
33936447|NCT03059524|||COHORT||PROSPECTIVE|||||||
33936448|NCT05924503|||CASE_ONLY||PROSPECTIVE|||||||
33936449|NCT06048913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936450|NCT03371303|||COHORT||PROSPECTIVE|||||||
33936451|NCT00017225||||TREATMENT||||||||
33936452|NCT04177186|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study will follow double-blinding/ masking. As the outcome assessor and the participant will be blinded.||t|f|f|t
33936453|NCT00003991|RANDOMIZED|||TREATMENT||||||||
33936454|NCT03500536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33936455|NCT03888976|||COHORT||RETROSPECTIVE|||||||
33936456|NCT00396968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936457|NCT02148601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097738|NCT05456893|||CASE_ONLY||PROSPECTIVE|||||||
34097739|NCT00529581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097740|NCT05866276|||OTHER||PROSPECTIVE|||||||
34097741|NCT00373711|||COHORT||PROSPECTIVE|||||||
34097742|NCT02571244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097743|NCT03849456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34014990|NCT03805308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patient and the treating physician will be aware of the treatment assignment. Assessment of outcome on NIHSS and mRS will be performed by a certified rater blinded to the treatment allocation. Each site must designate one or more individual(s) to perform these blinded assessments at 24 (16-36) hours, 6 ± 1 days or discharge (whichever is earlier), 30 days ± 7 days, and 90 days ± 30 days from randomization.~Neuroimaging core lab evaluation will also be assessed in a blinded manner, except for angiographic revascularization grading which will only be performed for the intra-arterial treatment arm.~Information on treatment allocation will be stored separately from the main study database. An unblinded independent statistician will combine treatment allocation data with the clinical data in order to report to the DSMB. A second blinded statistician will be part of the steering committee."|TESLA is a pragmatic, phase III, prospective, randomized, open-label, blinded endpoint, multicenter trial. Patients with moderate-large infarcts will be assigned to either best medical management alone (including intravenous recombinant tissue-type plasminogen activator (IV rtPA)) or intra-arterial treatment (IAT) with mechanical thrombectomy added to best medical management. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the instructions for use (IFU). Patients will be enrolled at up to 25 centers over an anticipated three-year period, with an additional year for trial closeout.|f|f|f|t
34097744|NCT04250675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34014991|NCT04859036|||CASE_CONTROL||PROSPECTIVE|||||||
34014992|NCT03008239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34014993|NCT01949948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34014994|NCT03544879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34014995|NCT02337049|||||RETROSPECTIVE|||||||
34014996|NCT01255735|||COHORT||PROSPECTIVE|||||||
34014997|NCT02311920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34014998|NCT04745715|||COHORT||RETROSPECTIVE|||||||
34014999|NCT03425487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015000|NCT02397005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015001|NCT04097171|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34015002|NCT05507762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015003|NCT04694326|||COHORT||CROSS_SECTIONAL|||||||
34015004|NCT02138292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015005|NCT02524587|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34015006|NCT00667082|NA|SINGLE_GROUP||OTHER||NONE||||||
34015007|NCT03924011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34097745|NCT00505362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097746|NCT04986969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Active therapy is delivered to patients, thus it is impossible to mask the participant or care provider. The investigators are blinded.|The investigators will use a longitudinal, 2-arm randomized, comparative effectiveness trial, stratified by sex. Patients will be randomized to one of two study arms: 1) real-time, face-to-face, video-conferenced CBT (vcCBT) with a trained CBT therapist; or 2) self-administered internet-based CBT (iCBT) via a well-tested online CBT program, MoodGym. Patients will be followed for 12 months from baseline and depressive symptom data collected at 3, 6, and 12 months to characterize intervention response. Participants will be randomized to either vcCBT (n = 150) or iCBT (n = 150) arm.|f|f|t|f
34097747|NCT01454063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097748|NCT04844346|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34097749|NCT06123559|||COHORT||PROSPECTIVE|||||||
34097750|NCT00122187|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097751|NCT03296345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097752|NCT05651737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097753|NCT03923842|RANDOMIZED|PARALLEL||TREATMENT||NONE|NN|This is a phase II, 2:1 randomized, open label, and multicentre proof of principle trial with denosumab in patients with recurrent/metastatic (RM) NPC at first line systemic therapy.||||
34097754|NCT00629213|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34097755|NCT05474209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention study will include treated patients with relapsing-remitting MS who meet the 2010 MR McDonald criteria for dissemination in time and space, last month before enrollment without relapse, no severe cognitive impairment, and according to the Kurtz Disability Scale (EDSS). 4.5 for 12 months and exercise intensity three times a week.||||
34097756|NCT01821053|||COHORT||PROSPECTIVE|||||||
34097757|NCT03335566|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34097758|NCT04354688|RANDOMIZED|PARALLEL||TREATMENT||NONE||Test implant- T3 Certain Tapered implant with DCD Active Comparator- T3 Certain Tapered implant without DCD||||
34097759|NCT02269605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097760|NCT00417729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712963|NCT01906008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712964|NCT00112320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712965|NCT02699645|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015008|NCT00836017|||CASE_ONLY||PROSPECTIVE|||||||
34015009|NCT05312242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||To examine differences in acceptability and adherence across three different approaches to antenatal micronutrient supplementation within the context of ANC||||
34097761|NCT05316727|||CASE_CONTROL||PROSPECTIVE|||||||
34097762|NCT04236466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097763|NCT01759641|||CASE_ONLY||PROSPECTIVE|||||||
34097764|NCT04063904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097765|NCT05648916|||COHORT||RETROSPECTIVE|||||||
34097766|NCT01266928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015010|NCT02677649|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33712966|NCT04648956|||COHORT||PROSPECTIVE|||||||
34025372|NCT02112487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712967|NCT06428669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33712968|NCT01202396|||CASE_CONTROL||PROSPECTIVE|||||||
33793311|NCT02083991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793312|NCT01391130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793313|NCT05859971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793314|NCT05262478|||COHORT||RETROSPECTIVE|||||||
33793315|NCT01335542|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33936458|NCT03351062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936459|NCT04205474|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33936460|NCT01960764|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33936461|NCT03797794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective, randomized, dubbel blind, placebo-controlled parallel study|t|t|t|f
33936462|NCT01921959|||COHORT||PROSPECTIVE|||||||
33936463|NCT01142791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936464|NCT03384472|||COHORT||PROSPECTIVE|||||||
33936465|NCT01902654|||COHORT||RETROSPECTIVE|||||||
33936466|NCT03990051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized double-masked parallel treatment assignment will be made using a block design at the ratio of 2:1, study drug:placebo, (22 subjects:11 subjects). This 70-day double-masked phase will be followed by 6 weeks open-label active drug treatment of the subjects previously on placebo.|The double-masked phase involves placebo controlled administration of study drug for 70 days or 10 weeks. Subsequently the placebo group will receive the active study drug of 42 days or 6 weeks. Long term open label phase to 27 months.|t|t|t|t
33936467|NCT02230787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936468|NCT04582162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936469|NCT04585113|||OTHER||CROSS_SECTIONAL|||||||
33936470|NCT02098915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936471|NCT05751252|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936472|NCT01579162|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33936473|NCT02531919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936474|NCT00720720|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33936475|NCT02233894|||COHORT||PROSPECTIVE|||||||
33936476|NCT01646736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936477|NCT00190606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936478|NCT05535790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33936479|NCT00269958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936480|NCT01859884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33936481|NCT04368741|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33936482|NCT03686527|||CASE_ONLY||PROSPECTIVE|||||||
33936483|NCT05601765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33936484|NCT02590406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33936485|NCT02931955|||COHORT||PROSPECTIVE|||||||
33936486|NCT01646255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936487|NCT01250392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33936488|NCT00589602|NA|SINGLE_GROUP||TREATMENT||NONE||Allogeneic Hematopoietic Stem Cell Transplantation||||
33936489|NCT05682326|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label single arm trial, where all participants are on active treatment with daprodustat.||||
33936490|NCT00718991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936491|NCT06375694|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not know which group they are in. The lozenges will be distributed in unmarked bottles|Participants will be randomized into two groups with one group receiving the oral probiotic and the other receiving the placebo. Each group will take their intervention 2X a day for 7 days.|t|f|f|f
33936492|NCT05574712|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an evolutionary double bind, open-label, multi-site, Phase II neoadjuvant study in men with regional prostate cancer planning to undergo prostatectomy. This study will assess the rate of near pathological complete response (pCR) after 3 months (12 weeks) of neoadjuvant treatment with leuprolide acetate, abiraterone acetate, and belzutifan as assessed on prostatectomy specimens.~Participants will be treated with neoadjuvant therapy for a total of 3 months (12 weeks) prior to prostatectomy. Therapy will consist of leuprolide acetate, abiraterone acetate, and belzutifan. Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects."||||
33936493|NCT03232502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936494|NCT04619381|||CASE_ONLY||CROSS_SECTIONAL|||||||
33936495|NCT03095157|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936496|NCT00408785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936497|NCT04454840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Lable|||||
33936498|NCT00381524|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33936499|NCT01680562|||CASE_ONLY||PROSPECTIVE|||||||
33936500|NCT03526692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Comparison between three groups : two experimental groups and a control group|t|f|f|t
33936501|NCT01195857|||COHORT||PROSPECTIVE|||||||
33936502|NCT02658149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936503|NCT03978286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936504|NCT02482415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34097767|NCT06138080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The radiologist and the isotope specialist are not aware of the results of previous VUR investigations.|||||
34097768|NCT00664040|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936505|NCT04252391|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant will be masked to which treatment arm they are in. The outcome assessor will be masked to which treatment arm the participant was in.|Randomized controlled cross-over study|t|f|f|t
33936506|NCT01755390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936507|NCT02738294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936508|NCT05402111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936509|NCT05841277|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33936510|NCT01438216|||COHORT||PROSPECTIVE|||||||
33936511|NCT03662789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Opaque envelopes, infusion administered by third party, concealed infusion|Randomized, placebo controlled, parallel group, double blind design|t|t|t|t
33936512|NCT04118673|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"The study is an interventional controlled observational study based in the Secondary care setting. Control groups will be utilized through the mechanism of wait-listing the enrolment of recruitment centres into the study.~Mixed methods will be used for both data collection and analysis. Historical clinical participant data (pre-intervention) will be collected by the PI. data will be collected immediately after the consultation and at 3 months post intervention."||||
33936513|NCT05371795|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33936514|NCT02949414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936515|NCT00684463|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936516|NCT05373810|||COHORT||CROSS_SECTIONAL|||||||
33720735|NCT03300479|RANDOMIZED|PARALLEL||TREATMENT||NONE||After admission to the ICU the patients presenting with primary intracerebral hemorrhage are evaluated for enrollment. If systolic blood pressure is higher than 160 mmHg or \<160 mmHg under intravenous antihypertensive drug, started less than 3 h before randomizsation, the patient will be randomized in one of the two study groups and intravenous therapy with Cleviprex® or Ebrantil® will start immediately. Data of systemic haemodynamics will be collected continuously by online monitoring, starting at baseline and ending after 24h. If the target values are not attained within 30 minutes, the investigators can add or switch to alternative antihypertensive drugs of their choice. 24h after initiation of Cleviprex® or Ebrantil®, all patients receive Cardene® (standard care in daily clinical routine) for another 24h followed by orally administered antihypertensive medication.||||
33720736|NCT01894854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793316|NCT00758433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33720737|NCT05749445|||COHORT||RETROSPECTIVE|||||||
33793317|NCT00959413|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793318|NCT05023512|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33793319|NCT03253913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793320|NCT01802866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793321|NCT05826678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33793322|NCT04640064|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33793323|NCT00739518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793324|NCT01727128|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793325|NCT00761930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793326|NCT04035291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All of the interventions will be shown to the infants' (participants') parents by the investigator physiotherapist.|Infants will be divided into two groups according to prenatal risk factors (maternal age, intrauterine growth retardation, chronic diseases etc.) by random minimization method and taken into 2 different physiotherapy programs. As the control group, the group participating in the evaluations stating that they cannot participate in the treatment without any intervention will be taken.|t|t|t|f
33793327|NCT00564967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793328|NCT04246762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793329|NCT02662530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936517|NCT01960452|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936518|NCT00146224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936519|NCT00381836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936520|NCT01830322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936521|NCT02576093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936522|NCT00877227|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936523|NCT00175838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936524|NCT00997607|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33936525|NCT00196833|||OTHER||OTHER|||||||
33936526|NCT03039907|||COHORT||PROSPECTIVE|||||||
33936527|NCT04742140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33936528|NCT05789706|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study will employ a case-crossover design where patients will undergo both a standard of care arm as well as an intervention arm. Half of the study participants will be randomized and enrolled in the standard of care arm for the initial 3 months and then transition to the intervention arm for 3 months. The remaining patients will be enrolled in the intervention arm for the initial 3 months and then transitioned to the standard of care arm.||||
33936529|NCT05793372|||COHORT||OTHER|||||||
33936530|NCT01590446|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33936531|NCT05500391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936532|NCT05989815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936533|NCT00354484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936534|NCT05914233|NA|SINGLE_GROUP||TREATMENT||NONE||Tremendous development has been achieved in the matrix ultrasound transducer. The investigators build the signal element ultrasound transducer to provide a stable energy release to stimulate a particular area. The investigators can limit the ultrasound focus to a minor point. The neuron activities induced by the focused 3 Megahertz (MHz) transducers have shown a spatial resolution of 250±50 µm. According to previous study, the Intensity Spatial-Peak Pulse-Average (ISPPA.3) is 26 (Under FDA suggestion of 28).||||
33936535|NCT00758004|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33936536|NCT00112840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936537|NCT01008436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097769|NCT00419432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793330|NCT01424332|RANDOMIZED|CROSSOVER||||NONE||||||
33793331|NCT06620406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793332|NCT04619914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936538|NCT03932591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||intervention group: inhibitory kinesio taping application in spastic hemiplegic patients controlled group: sham kinesio taping application in spastic hemiplegic patients|t|f|f|f
33936539|NCT02639754|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936540|NCT05413356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936541|NCT04099225|||COHORT||CROSS_SECTIONAL|||||||
33936542|NCT02618512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936543|NCT04361721|||CASE_ONLY||PROSPECTIVE|||||||
33936544|NCT04471532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"All outcome assessors will be blinded to group allocation and previous results and the participants are requested not to disclose their allocation when outcomes are assessed 6 and 12 months after surgery.~The biostatistician who perform the data analyses and validate the results will also be blinded to group allocation."|This is a pragmatic, randomized, controlled, assessor- and statistician- blinded trial with two parallel groups; an intervention group receiving a behavior change intervention and a control group receiving no intervention.|f|f|f|t
33936545|NCT01723124|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33936546|NCT02558972|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33936547|NCT04955574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015011|NCT04633421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study feeds will be blinded. Dosing of intervention will be volume based, with the same volume targets for both groups. Differences in composition of study feeds will result in differences in protein intake at similar volume administration.||t|t|t|t
34015012|NCT01023295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015013|NCT02707861|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015014|NCT00206830|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34015015|NCT05622292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This study is a single-blind, randomized, controlled clinical trial|f|t|f|t
34097770|NCT00366613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097771|NCT05363085|||COHORT||PROSPECTIVE|||||||
34097772|NCT03368560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study will recruit 30 patients with treatment-resistant late life depression, and 7 age-matched controls.||||
33720738|NCT00531154|||DEFINED_POPULATION||OTHER|||||||
33936548|NCT05393661|||COHORT||OTHER|||||||
33936549|NCT01469637|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936550|NCT02937090|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936551|NCT05257915|||COHORT||PROSPECTIVE|||||||
34015016|NCT02836834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015017|NCT03653052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015018|NCT05183295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097773|NCT00652652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097774|NCT02914223|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33720739|NCT02029833|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33720740|NCT02875860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936552|NCT03979495|RANDOMIZED|PARALLEL||SCREENING||NONE|The intervention is not masked to the providers or the participants. Randomization status is masked to the participants but not the providers. Masking is not feasible because randomization will take place at the level of the practice and practices will need to be informed about intervention components that will be made available to patients in their practice and the health care team|All individuals in this study will receive the current standard of care at Massachusetts General Hospital, Brigham and Women's Hospital, and Dartmouth Hitchcock for the follow-up of abnormal cancer screening tests (Arms 1-4). In addition to this standard of care, we will test 3 additional arms of increasing intensity of intervention: Arm 2-access to an IT platform to facilitate updates to HM modifiers and problem lists for visit-based reminders; Arm 3- the IT platform in addition to automated reminders to patients between visits and the care team; Arm 4-the IT platform, automated reminders, and administrative outreach and navigation to help with scheduling and to address social barriers to care.||||
33936553|NCT04334044|NA|SINGLE_GROUP||TREATMENT||NONE||Use of ruxolitinib on patients with respiratory distress and pneumonia changes on chest computed tomography||||
33936554|NCT02513355|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936555|NCT01688986|||COHORT||RETROSPECTIVE|||||||
33936556|NCT00537810|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34015019|NCT03462355|||COHORT||PROSPECTIVE|||||||
34097775|NCT00377806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34097776|NCT05442892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34097777|NCT00710788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097778|NCT01927289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097779|NCT03281720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097780|NCT02307435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097781|NCT06549764|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two-armed, cluster, randomized feasibility trial (unstratified, blinded analyses, 1:1 allocation|f|f|t|t
34097782|NCT00552838|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33720741|NCT03696914|||CASE_CONTROL||RETROSPECTIVE|||||||
33720742|NCT00288847|||||RETROSPECTIVE|||||||
34015020|NCT04407078|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34097783|NCT05702619|||COHORT||PROSPECTIVE|||||||
34097784|NCT00908661|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33720743|NCT00602147|||COHORT||PROSPECTIVE|||||||
33720744|NCT01053819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720745|NCT03945474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Parents, infants and lactation consultants are not made aware of in which group the patient is placed, OMT or sham. Physicians are the only people aware of treatment/sham status.|Patients are randomized to either arm, OMT or sham.|t|t|f|f
33720746|NCT04109755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720747|NCT03092531|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Block randomization||f|f|f|t
33720748|NCT00468416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720749|NCT02601950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720750|NCT06313970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720751|NCT00605670|||COHORT||PROSPECTIVE|||||||
33936557|NCT01945190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33936558|NCT02894294|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33936559|NCT04770259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled, longitudinal.|f|t|f|t
33936560|NCT02540655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936561|NCT05993585|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single centre trial - observational cohort study||||
33936562|NCT03231592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33936563|NCT05411263|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936564|NCT01886092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33936565|NCT06399068|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936566|NCT00865995|||CASE_CONTROL||PROSPECTIVE|||||||
33936567|NCT03701061|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective, Exploratory study with up to 50 subjects total, who previously participated in the HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with and without AS03 Adjuvant study||||
33936568|NCT02432911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936569|NCT04224909|||COHORT||PROSPECTIVE|||||||
33936570|NCT03248960|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936571|NCT02604628|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936572|NCT04216511|||CASE_CONTROL||PROSPECTIVE|||||||
34015021|NCT06091852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Young vs. old||||
34015022|NCT02736682|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015023|NCT04235699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015024|NCT05953857|||COHORT||PROSPECTIVE|||||||
34015025|NCT03238976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936573|NCT01416532|||COHORT||PROSPECTIVE|||||||
33936574|NCT01110486|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936575|NCT01247012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936576|NCT06396689|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33936577|NCT05565209|||COHORT||PROSPECTIVE|||||||
33936578|NCT06147206|||COHORT||PROSPECTIVE|||||||
33936579|NCT02966106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936580|NCT04728880|||COHORT||RETROSPECTIVE|||||||
33936581|NCT04330456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936582|NCT03083470|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Phase 2, randomized, dose-rising, double-blind trial. Subjects will enroll in four dose-escalating cohorts of eight subjects each. Each cohort will be randomized to SOR007 or Ointment vehicle in a ratio of 3:1. Safety will be assessed in an ongoing manner and formal safety reviews will be conducted four times for each cohort: at Day 8, Day 15, Day 21, and Day 28 for the last subject enrolled in each cohort. The next dose level cohort will enroll upon a finding of safety and tolerability at the previous cohort's second safety review. Once the last cohort has completed the study, all available data, including safety, pharmacokinetics, and preliminary efficacy will be analyzed. The PK blood samples will be analyzed per cohort when the last subject of each cohort completes Day 28.|t|t|t|f
33936583|NCT05834179|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936584|NCT00003606|RANDOMIZED|||TREATMENT||||||||
34015026|NCT04761705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015027|NCT05600205|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental with a mixed-method matched design||||
33936585|NCT04220658|||CASE_ONLY||PROSPECTIVE|||||||
33936586|NCT00293319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936587|NCT02034539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936588|NCT06326164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936589|NCT05320640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015028|NCT01664221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015029|NCT04219683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720752|NCT02350881|||COHORT|||||||||
33720753|NCT02533037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720754|NCT04465851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Participants (and supplements) will be coded and randomly allocated (applied randomly by software \[gender balanced\[) to treatment arms to eliminate order effects and maintain research staff blinding.|Allocation: Randomisation (block) Intervention Model: Parallel, Randomised placebo-controlled design Masking: Double-blind|t|t|t|t
33936590|NCT00242944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015030|NCT02349971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015031|NCT03668821|||COHORT||PROSPECTIVE|||||||
33936591|NCT02660060|RANDOMIZED|CROSSOVER||||NONE||||||
33936592|NCT02791477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936593|NCT05575024|||CASE_CONTROL||PROSPECTIVE|||||||
33936594|NCT06041230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33936595|NCT02319564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936596|NCT05174351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936597|NCT00240929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33936598|NCT01763632|||COHORT||PROSPECTIVE|||||||
33936599|NCT00036946||||TREATMENT||||||||
33936600|NCT01300000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936601|NCT02582151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936602|NCT01213849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33936603|NCT02542566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936604|NCT03607292|RANDOMIZED|PARALLEL||TREATMENT||NONE|A single blinded anesthesiologist performed posterior or anterior sciatic nerve block and femoral block and left the operating room 'after the nerve block was completed.|Randomize, single blind, prospective||||
33936605|NCT01768702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936606|NCT04272372|||COHORT||PROSPECTIVE|||||||
33936607|NCT01807494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936608|NCT00890136|||CASE_ONLY||PROSPECTIVE|||||||
33936609|NCT00407251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936610|NCT04331808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936611|NCT02239562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936612|NCT02868801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936613|NCT05637567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936614|NCT06049706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Duble (Participant, Investigator) All examiners will be blinded to the type of treatment the patient received (active stimulation or sham) and other assessments. Thus, all guidelines established by CONSORT 2010 (Consolidated Standards of Reporting Trials) will be complied with variable control following systematized and countersigned procedures: random sequence generation, allocation concealment, blinding of participants and professionals, blinding of outcome evaluators and attrition bias (loss analysis using the last observation carried forward method)|Parallel Assignment Participants will be divided into 02 groups, each with 16 patients, totaling 32 volunteers: Active - participants who will receive real priming stimulation; Sham - participants who will receive simulated priming stimulation. Participants entered into the study through the eligibility criteria will be randomly allocated in a simple way, at a rate of 1:1.|t|f|t|f
33936615|NCT00698139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936616|NCT01020994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936617|NCT01968915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936618|NCT03398174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to participants' treatment allocation||f|f|f|t
33936619|NCT00364611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936620|NCT01592942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936621|NCT04316780|||COHORT||RETROSPECTIVE|||||||
33936622|NCT01087229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936623|NCT04591704|||CASE_CONTROL||RETROSPECTIVE|||||||
33936624|NCT06108440|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided into Group A (n = 20) and Group B (n = 20) using a randomization through computer generated numbers program. Patients in Group A will receive action observation training with conventional treatment. All participants will undergo the training for 25 minutes per session, 5 days per week for 8 weeks. Patients in Group B will receive motor imagery with conventional treatment. All participants will receive interventions for twenty-five minutes per session, five times a week, for eight weeks.||||
33936625|NCT05255497|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34015032|NCT06428435|||OTHER||PROSPECTIVE|||||||
34015033|NCT04026685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and participant cannot see to which study group the participant belongs. The person performing randomisation and fluid application will not be involved in the data collection and Analysis.|double-blind, randomised controlled non-inferiority trial|t|f|t|f
34015034|NCT02944942|||COHORT||RETROSPECTIVE|||||||
33712969|NCT06372002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The technician in charge of the evaluation of those participating in the study must be blinded throughout the CST intervention, i.e., he/she will not know whether the users being evaluated belong to the intervention or the control group.~The CRE Alzheimer professional responsible for randomization and data analysis will also be blinded.~The participants and the technician performing the intervention cannot be blinded due to the nature of the intervention."|"A pragmatic, multicenter, randomized, controlled clinical trial is proposed to compare treatment with CST-ES followed by maintenance treatment with CST-ES with treatment as usual:~* First Phase: Participants who meet the inclusion criteria will be randomized to the CST-ES intervention group or a treatment-as-usual control group. Participants assigned to the intervention group will receive two sessions of CST-ES per week for 7 weeks, also they will continue their usual treatment. Participants in the control group will receive their usual treatment during the development of the study.~* Second Phase: After the first phase is completed, participants assigned to the intervention group will receive one session of maintenance CST-ES per week for 24 weeks besides continuing their usual treatment, whereas participants in the control group will continue their usual treatment during this second phase."|f|f|t|t
33712970|NCT04541862|||COHORT||PROSPECTIVE|||||||
33712971|NCT02418026|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33936626|NCT04509297|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33936627|NCT05424744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||enroll up to 10 patients/clinic||||
34015035|NCT02072148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097785|NCT06137547|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33936628|NCT00697255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936629|NCT02217449|||COHORT||PROSPECTIVE|||||||
33936630|NCT02809846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33936631|NCT01749865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936632|NCT02954952|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33936633|NCT01914991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015036|NCT05045352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participant will be anesthetized and asleep Outcome assessor will not be in the operating theater during the procedure|Two arms Venous access either with echogenic needles or with non-echogenic needles|t|f|f|t
34015037|NCT01458821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015038|NCT06296654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34015039|NCT05017974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34015040|NCT02413931|||COHORT||PROSPECTIVE|||||||
34015041|NCT02988869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015042|NCT02523196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015043|NCT04810520|||CASE_CONTROL||PROSPECTIVE|||||||
34015044|NCT01684436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015045|NCT00304226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34015046|NCT04897152|||COHORT||RETROSPECTIVE|||||||
34015047|NCT02031016|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34015048|NCT01071148|||COHORT||PROSPECTIVE|||||||
34015049|NCT05987462|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34015050|NCT03077906|||COHORT||RETROSPECTIVE|||||||
34015051|NCT01254474|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015052|NCT05579574|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34097786|NCT04714580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34097787|NCT03307850|NA|SINGLE_GROUP||OTHER||NONE||||||
34097788|NCT05756309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097789|NCT00398905|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34097790|NCT06310109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097791|NCT06377527|||COHORT||OTHER|||||||
33712972|NCT03516994|RANDOMIZED|PARALLEL||OTHER||NONE||Mixed-methods, longitudinal, multi-site study, cluster randomized trial||||
33712973|NCT02385552|||COHORT||PROSPECTIVE|||||||
33712974|NCT04448288|NA|SINGLE_GROUP||OTHER||NONE||||||
33936634|NCT05007301|||COHORT||PROSPECTIVE|||||||
33936635|NCT01481714|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33936636|NCT06305169|||COHORT||PROSPECTIVE|||||||
34097792|NCT03307070|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is a randomized, waitlist controlled trial. All participants randomized to waitlist were offered the opportunity to receive the intervention after completion of the waitlist.||||
34097793|NCT01494142|||CASE_CONTROL||PROSPECTIVE|||||||
34097794|NCT00513864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34097795|NCT05689515|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized in a 2:1 ratio to intervention (PL4Y use) or standard of care||||
34097796|NCT03708289|||COHORT||PROSPECTIVE|||||||
34097797|NCT04006457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097798|NCT05100147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712975|NCT02047890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712976|NCT01584102|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33712977|NCT01087190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712978|NCT00697762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712979|NCT00673465|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33712980|NCT00716885|||COHORT||PROSPECTIVE|||||||
33712981|NCT05231395|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.~Evaluations and interventions will be performed different physiotherapist. In addition, before statistical analysis patients' groups will be coded."|Parallel Assignment|t|f|t|t
33712982|NCT02362217|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33712983|NCT04953780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||4 parallel-arm study of the different dose of Calaspargase Pegol-mknl with combination with High Dose Cytarabine and /or Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia||||
33712984|NCT01491334|||CASE_CONTROL||PROSPECTIVE|||||||
33712985|NCT03764501|RANDOMIZED|PARALLEL||TREATMENT||NONE||Image fusion group will utilize 3D preoperative planning and image fusion system. Control group will utilize only 3D preoperative planning.||||
33712986|NCT06166303|||CASE_CONTROL||PROSPECTIVE|||||||
33712987|NCT06166355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936637|NCT00730249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936638|NCT00436891|||||PROSPECTIVE|||||||
34015053|NCT05834530|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34015054|NCT00232271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015055|NCT05334264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015056|NCT01869478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015057|NCT05161650|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34015058|NCT03801941|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34015059|NCT02286219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015060|NCT02126930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015061|NCT03898674|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study - single arm||||
34015062|NCT05857826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936639|NCT03138798|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will give consent in the first stage of labor. Randomization will then be performed using sealed envelopes at the time of pushing in the second stage of labor. Duration of the second stage and time spent pushing will be recorded for both groups.||||
33936640|NCT05801016|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015063|NCT01251978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015064|NCT00762931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015065|NCT02608970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015066|NCT00000476|RANDOMIZED|||TREATMENT||DOUBLE||||||
34015067|NCT00973765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015068|NCT04511052|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34015069|NCT04171024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015070|NCT02287493|||COHORT||PROSPECTIVE|||||||
34015071|NCT00304720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015072|NCT01957566|NA|SINGLE_GROUP||SCREENING||NONE||||||
34097799|NCT04636944|||OTHER||OTHER|||||||
34015073|NCT05545761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33936641|NCT06257615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients were included in the study and blinded without being informed about whether they were divided into groups or which groups they were in. Data of the research; They were coded as groups A and B by someone else under the control of the consultant researcher, who had no role in the intervention and measurements and did not know which group the patients were in, and transferred them to the SPSS program.||t|f|f|t
33936642|NCT02952430|||COHORT||PROSPECTIVE|||||||
33936643|NCT00435929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015074|NCT02196740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097800|NCT04739774|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||one sequence cross-over design||||
34097801|NCT03394846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097802|NCT01169337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097803|NCT04808895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Use of placebo tablets of the same shape, colour of the investigational drug. Identical time and route of administration.|Experimental phase 3 drug trial, randomized 1:1, double-blind, multicentre in patients treated with acetylsalicylic acid vs placebo.|t|t|t|t
34097804|NCT03574714|||OTHER||OTHER|||||||
33936644|NCT01635244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097805|NCT01734928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097806|NCT04566380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097807|NCT02213991|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluate the safety of intraoperative radiotherapy using Intrabeam in Korean patients with early breast cancer.||||
34097808|NCT00799864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097809|NCT02537743|||COHORT||PROSPECTIVE|||||||
34097810|NCT01629862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097811|NCT03043820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33712988|NCT00651794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33936645|NCT06147180|||COHORT||RETROSPECTIVE|||||||
34015075|NCT02667288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015076|NCT01408095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015077|NCT05058534|||COHORT||PROSPECTIVE|||||||
34015078|NCT05299736|||COHORT||PROSPECTIVE|||||||
34015079|NCT03458637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Staff involved in anthropometric measurements will be masked to group allocation.|One arm will be randomised to usual care The experimental arm group will be randomised to usual care and LITE program|f|f|f|t
34097812|NCT05759455|||CASE_CROSSOVER||PROSPECTIVE|||||||
34015080|NCT02697773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097813|NCT06122051|||OTHER||PROSPECTIVE|||||||
34097814|NCT01363830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097815|NCT04455295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34097816|NCT05032105|NA|SINGLE_GROUP||OTHER||NONE||Single arm, open-label, prospective intervention study of MRgFUSA for adults with refractory, partial-onset epilepsy with moderate-severe anxiety||||
34097817|NCT01795937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097818|NCT06291207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097819|NCT01572688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097820|NCT03318055|||CASE_ONLY||PROSPECTIVE|||||||
34097821|NCT01829165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34097822|NCT00003474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097823|NCT00709345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097824|NCT05901831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097825|NCT00003501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097826|NCT04875273|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34015081|NCT00626717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33712989|NCT06204744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33712990|NCT03146715|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33712991|NCT06219512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33712992|NCT04742296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936646|NCT02749552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015082|NCT01566864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015083|NCT06000917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015084|NCT06138470|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34015085|NCT02312713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097827|NCT04082676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097828|NCT05062369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34097829|NCT03587103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015086|NCT01648504|NA|SINGLE_GROUP||||NONE||||||
34015087|NCT01797835|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015088|NCT06307782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|randomize clinical study|randomize control trials|t|f|f|f
34015089|NCT00004153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015090|NCT02232464|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015091|NCT06026111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015092|NCT06312514|RANDOMIZED|FACTORIAL||PREVENTION||NONE|None (Open Label)|intervention and waitlist control groups||||
34015093|NCT03092739|||COHORT||PROSPECTIVE|||||||
34015094|NCT06045819|||COHORT||PROSPECTIVE|||||||
34015095|NCT02963311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015096|NCT05255965|||OTHER||PROSPECTIVE|||||||
34015097|NCT05645770|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015098|NCT00552383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015099|NCT03110601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015100|NCT03848169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015101|NCT04056546|||COHORT||OTHER|||||||
34015102|NCT01784666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015103|NCT01908218|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34015104|NCT01112657|||COHORT||PROSPECTIVE|||||||
34097830|NCT04090749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research assistant collecting data will be blinded to group assignment for each participant.||f|f|f|t
34097831|NCT00655746|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34097832|NCT00754559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097833|NCT05560633|||COHORT||RETROSPECTIVE|||||||
34097834|NCT00720811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097835|NCT04419142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and physiatrists performing isokinetic measurements were blinded to group allocation.|Patients were randomized in a 1:1 ratio via computer-generated randomization using Microsoft Excel 2016 (Microsoft Corporation, Seattle, WA, USA) to be allocated in the total or partial infrapatellar fat pad excision group before the TKA operation (Figure 1). Unblinded senior resident implemented the randomization. Patients and physiatrists performing isokinetic measurements were blinded to group allocation.|t|f|t|f
34097836|NCT05369156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||research|t|f|t|t
34097837|NCT01623284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097838|NCT02563210|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097839|NCT05446155|||COHORT||PROSPECTIVE|||||||
34097840|NCT01526746|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34097841|NCT01745302|||CASE_CONTROL||PROSPECTIVE|||||||
34097842|NCT01132690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097843|NCT04026516|NA|SINGLE_GROUP||OTHER||NONE||||||
34097844|NCT04359680|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34097845|NCT02405208|||COHORT||PROSPECTIVE|||||||
34097846|NCT03555097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097847|NCT05575427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, Placebo Controlled|A Phase 4 Randomized, Double blind, Placebo Controlled|t|f|t|f
34097848|NCT03341221|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097849|NCT02725606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097850|NCT04953260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researcher B is responsible for including the subjects and assigning the number of the subjects according to the order of treatment. During the operation, researcher B will give the sealed envelope to the surgeon L according to the number, then leave, and will not participate in surgery, measurement and other studies. Researcher C is responsible for measuring various indicators on a regular basis. Until the end of the experiment, C did not know the grouping of the subjects.|This study is a single-center, simple, randomized parallel group design clinical trial in which each random group is allocated according to the proportion of 1:1:1|f|f|t|t
34097851|NCT02367768|||COHORT||PROSPECTIVE|||||||
34097852|NCT02410174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097853|NCT06131463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34097854|NCT04346238|||CASE_ONLY||RETROSPECTIVE|||||||
34097855|NCT04541342|NA|SINGLE_GROUP||TREATMENT||NONE||quasi experimental one group pretest posttest study design||||
34097856|NCT04928404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097857|NCT01631929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097858|NCT05142644|||COHORT||RETROSPECTIVE|||||||
34097859|NCT03691870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097860|NCT03563612|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||prospective randomized controlled crossover study|t|f|f|t
34015105|NCT06072495|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34015106|NCT02811263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015107|NCT03274882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015108|NCT00818129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015109|NCT06224712|RANDOMIZED|PARALLEL||OTHER||SINGLE||The study team will use a 2 arm(intervention and control), pre and post, mixed-methods quasi experimental design comparing the intervention to the standard interventions in the area. It will be implemented in two PHC-HWCs in the Devadurga and Kollegal blocks of Raichur and Chamrajanagar districts; Two additional PHC- HWCs from these blocks similar in characteristics as the intervention PHC-HWCs will be identified as control.|f|f|t|f
34015110|NCT06221553|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation study||||
34015111|NCT00899470|RANDOMIZED|CROSSOVER||||NONE||||||
34015112|NCT05033366|||COHORT||PROSPECTIVE|||||||
34097861|NCT05823883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097862|NCT04132180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097863|NCT00163852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097864|NCT01142687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34097865|NCT01104337|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34097866|NCT04891861|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Central blinded assessment of endpoints|Randomized trial of 1 versus 4 week DOAC restart after TICrH|f|f|f|t
34097867|NCT02322515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097868|NCT01053065|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34097869|NCT05888779|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097870|NCT03632720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097871|NCT03391154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097872|NCT05113602|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34097873|NCT01442285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34097874|NCT00990379|||COHORT|||||||||
34097875|NCT01531803|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097876|NCT05540275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097877|NCT04630730|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm open-label multicenter phase II trial||||
34097878|NCT03084679|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial in a 2:1 (intervention:control) proportion and in blocks of 6 participants.||||
34097879|NCT05922735|||COHORT||RETROSPECTIVE|||||||
34097880|NCT05163405|||OTHER||PROSPECTIVE|||||||
34097881|NCT00642265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097882|NCT02366130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097883|NCT02559960|||COHORT||PROSPECTIVE|||||||
34097884|NCT04197323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097885|NCT04556097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33712993|NCT02990598|||OTHER||PROSPECTIVE|||||||
33712994|NCT01487551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712995|NCT06507891|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33712996|NCT02727751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712997|NCT02573311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712998|NCT03517956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33712999|NCT03287661|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33713000|NCT00791245|||CASE_ONLY||PROSPECTIVE|||||||
33713001|NCT04572932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713002|NCT03700671|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants were randomised to either high or moderate intensity exercise||||
33713003|NCT05506085|||COHORT||PROSPECTIVE|||||||
33713004|NCT02461303|||CASE_ONLY||OTHER|||||||
33713005|NCT01244425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713006|NCT00076284||||TREATMENT||||||||
33713007|NCT01773785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015113|NCT03605654|RANDOMIZED|PARALLEL||PREVENTION||NONE||A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102||||
34015114|NCT00531141|||COHORT||PROSPECTIVE|||||||
34015115|NCT03792360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015116|NCT00666848|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34015117|NCT05215080|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34015118|NCT02824471|||CASE_CONTROL||PROSPECTIVE|||||||
34015119|NCT02859948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015120|NCT06367595|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34015121|NCT02610387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015122|NCT05456711|||OTHER||PROSPECTIVE|||||||
34097886|NCT03202550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant, provider, and nursing staff will be blinded to the intervention. The pharmacy will prepare the treatment drugs and placebos.. Randomization will be stratified by gestational age (\>= 20 weeks or \<20 weeks) and the randomization allocation sequence will be computer-generated with a random number generator by a statistician. The pharmacist will be aware of the randomization sequence and will dispense the drugs as appropriate, while keeping track of which arms participants were randomized to.|Randomized controlled trial|t|t|t|t
34097887|NCT01060969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097888|NCT04462250|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|Participants will enter all data using a numeric identifier assigned by a third-party recruiter||t|f|t|f
34097889|NCT01221766|||CASE_ONLY||PROSPECTIVE|||||||
33793333|NCT00860353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33793334|NCT05717114|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective randomized study|f|f|t|t
33793335|NCT06512246|||COHORT||RETROSPECTIVE|||||||
33793336|NCT01807858|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33793337|NCT03070938|||CASE_ONLY||PROSPECTIVE|||||||
33793338|NCT02830750|||OTHER||PROSPECTIVE|||||||
33793339|NCT02201173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793340|NCT04123132|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33793341|NCT05103748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793342|NCT02182414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793343|NCT03727854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33793344|NCT06555354|||COHORT||OTHER|||||||
33793345|NCT00947986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793346|NCT02960542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793347|NCT00538213|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793348|NCT02117440|||CASE_ONLY||PROSPECTIVE|||||||
33793349|NCT02162420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936647|NCT03289494|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"Each diet will be labelled Diet A or Diet B"|Each subject will receive two independant weeks of diet intervention, in a crossover design|t|f|f|f
33936648|NCT04443205|||COHORT||PROSPECTIVE|||||||
33936649|NCT01582191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936650|NCT02980263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936651|NCT03035058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936652|NCT01389076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936653|NCT05910983|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a randomized clinical trial. The study team is interested in approaching and recruiting patients who were referred for Bipolar enucleation of the prostate surgery for their urinary symptoms and also eligible for intravesical Botox injections. This cohort of patients will be recruited and randomized into two groups: a control group that would undergo BipolEP procedure only, and an experimental group that will undergo BipolEP procedure combined with an intravesical Botox injection.This study will utilize a 1:1 randomization scheme to assign participants to either the control group or the experimental group. Participants will not be blinded to the procedure they are receiving. No one on the study team including those involved in data analysis will be blinded to the study arm assignment. The investigators plan to recruit a maximum of 50 participants in each arm. The study's intervention is whether Botox injections are added during the surgery or not.||||
33793350|NCT02616835|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33793351|NCT00298597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936654|NCT00846911|||COHORT||PROSPECTIVE|||||||
33936655|NCT05435092|||COHORT||PROSPECTIVE|||||||
33936656|NCT02112149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33936657|NCT04211857|||COHORT||OTHER|||||||
33936658|NCT02508506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936659|NCT03330106|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33936660|NCT05412693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking is not possible during the first 6 weeks of treatment due to the nature of the interventions. Investigators and outcome assessors will be masked for follow-up after 6 weeks.||f|f|t|t
33936661|NCT03530059|||COHORT||PROSPECTIVE|||||||
33936662|NCT05863806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single (Outcomes Assessor) no||t|f|t|f
33936663|NCT06193837|||COHORT||RETROSPECTIVE|||||||
33936664|NCT03049514|||COHORT||PROSPECTIVE|||||||
33936665|NCT03445962|||CASE_CONTROL||PROSPECTIVE|||||||
33936666|NCT04474366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33936667|NCT02069327|||CASE_ONLY||PROSPECTIVE|||||||
33936668|NCT03030157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936669|NCT04791644|||COHORT||OTHER|||||||
33936670|NCT01430364|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936671|NCT04176562|||COHORT||PROSPECTIVE|||||||
33936672|NCT00692393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936673|NCT05270265|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936674|NCT00948714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33936675|NCT05848752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936676|NCT04214106|||CASE_CONTROL||RETROSPECTIVE|||||||
33936677|NCT05600556|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936678|NCT00328952|||CASE_CONTROL||PROSPECTIVE|||||||
33936679|NCT04445766|||COHORT||PROSPECTIVE|||||||
33936680|NCT02382952|RANDOMIZED|PARALLEL||||NONE||||||
33713008|NCT01366690|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713009|NCT03707860|||COHORT||PROSPECTIVE|||||||
33713010|NCT02445092|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33713011|NCT04220684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793352|NCT05632432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients are randomized to CABG or AAMs groups using block randomization via the online tool at www.sealedenvelope.com with block sizes 2 and 4, and stratification to sex (female, male). Randomization is carried out by the study nurse, who texts the Sealed Envelope service phone number 'AAMS2' and a command 'randomise', and the participant pseudonym. The allocation is received by a text message. The study nurse oversees the allocation in a double-blinded manner, where the patient and the evaluating cardiologist and radiologists remain blinded. Given the nature of the treatment (AAMs-processing vs. no processing) it is impossible to blind the operating surgeon or the study nurse to the allocations intraoperatively. However, the surgeon is blinded when planning the anastomoses. All LGE-CMRI and TTE measurements as well as laboratory analyses are done by those blinded to the allocations.|The trial enrolls 50 patients in a 1:1 group allocation ratio to the two study groups: 1.) collagen-based patch + AAMs + CABG (treatment arm) and 2.) collagen-based patch + CABG (control arm). Autologous RAA tissue is harvested from the RAA during CABG from all participants. Based on randomization, the piece of RAA tissue is either processed to AAMs perioperatively or stored for biochemical analyses. The AAMs, embedded in fibrin matrix gel, are placed on an collagen-based patch sheet, which is epicardially adhered in place. The epicardial transplantation site is pinpointed to ischemic scar area by preoperative LGE-CMRI.|t|t|f|t
33713012|NCT03725280|||CASE_CONTROL||PROSPECTIVE|||||||
33793353|NCT01334320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793354|NCT05723510|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-arm, two-period crossover||||
33793355|NCT00414999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33793356|NCT04679519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised control study with four groups, one control and three protein supplements.|t|f|f|f
33793357|NCT06530264|NA|SEQUENTIAL||TREATMENT||NONE|"1. Patients with chronic dacryocystits,~2. primary nasolacrimal duct obstruction~3. Lacrimal mucocele~4. Lacrimal fistula"|All patients included in this study will be verbally briefed about the details and the nature of the study \& will sign a written consent according to the local Ethics Committee of Minia University Faculty of Medicine. The study will be conducted in Ophthalmology department, Minia university Hospital, Egypt.||||
33713013|NCT00302250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33793358|NCT02576340|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33793359|NCT03375255|NA|SEQUENTIAL||TREATMENT||NONE||||||
33802056|NCT03295747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants randomized to one of three prospective arms as reflected by three treatment doses for the duration of the study.||||
33936681|NCT01355224|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33936682|NCT03357328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Although the placebo effect might not be an issue in those with severe dementia, the treatment may affect staff, creating bias such as the Hawthorne effect. Potential changes in staff routines and behaviours in response to the treatment may affect outcome, making a control condition necessary. In this controlled trial, we will compare patients receiving the intervention (therapy light rooms) with control units receiving placebo light (standard light). The researchers will install the same standard light solution (100 lux at eye level, 3000K) in all control units. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."|"4 nursing home units will receive the intervention (ceiling mounted LED-light in the living room) and 4 will receive the control condition (standard light). The trial lasts for 24 weeks. Data will be collected at baseline and after 8, 16 and 24 weeks."|t|t|f|f
33936683|NCT00949949|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936684|NCT01654406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936685|NCT02178592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936686|NCT05857215|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Subjects were assigned to a treatment using a computer-generated randomization schedule.|Part 1 of the study was a double-blind, randomised, placebo-controlled assessment of single subcutaneous (SC) ascending doses of amilo-5MER in healthy young adult male subjects. Subjects were enrolled sequentially into 1 of up to 5 cohorts, each containing 8 subjects|t|t|t|t
33936687|NCT05385172|||COHORT||PROSPECTIVE|||||||
34015123|NCT02639052|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34015124|NCT04629261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial: 2 intervention groups and 1 control group.|t|f|f|f
34015125|NCT01915719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713014|NCT03376022|||OTHER||CROSS_SECTIONAL|||||||
34015126|NCT04568031|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015127|NCT05291455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713015|NCT03425123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713016|NCT02760199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713017|NCT04758039|||COHORT||PROSPECTIVE|||||||
33713018|NCT00284050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33713019|NCT00674544|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33713020|NCT02098759|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33713021|NCT00811798|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713022|NCT05403905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients who were diagnosed with complete rupture of the ACL in the outpatient department of Peking University Third Hospital, the sports medicine doctor explained in detail (1) the way of conservative treatment, (2) the ruptured anterior cruciate ligament has the possibility of healing after fixation and (3) Willing to join the cohort study after enrollment. There were 60 subjects in the non-surgical treatment group and 60 in the surgical treatment group, for a total of 120 subjects.||||
33713023|NCT03624894|||OTHER||PROSPECTIVE|||||||
33713024|NCT06140927|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will serve as their own control and baseline measurements will be made before the administration of study drug. After baseline measurements, increasing doses of the study drug will be administered and effects measured.||||
33713025|NCT00157534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713026|NCT02376361|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33713027|NCT04208789|||CASE_CONTROL||RETROSPECTIVE|||||||
33713028|NCT00475358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33713029|NCT03577691|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Prospective, randomized,controlled, unblinded study||||
33793360|NCT05304663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open label phase I study in subjects with glioblastoma at first progression to explore two different administration schedules of lomustine for the combination with L19TNF (ARM 1 and ARM 2).~Patients will be assigned in an alternating fashion to ARM 1 or ARM 2 as long as both treatment arms are open. Should one treatment arm be stopped as more or equal to two dose limiting toxicities occur in this treatment arm, then all remaining patients will be assigned to the treatment arm that is still open until also this treatment arm will be stopped."||||
34097890|NCT01168479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793361|NCT02388139|||COHORT||PROSPECTIVE|||||||
33793362|NCT01818401|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33713030|NCT04080414|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793363|NCT00157014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097891|NCT03209583|||COHORT||OTHER|||||||
33793364|NCT05065320|||COHORT||PROSPECTIVE|||||||
33793365|NCT02551055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793366|NCT00822055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33793367|NCT01866566|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793368|NCT00410124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015128|NCT00532935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015129|NCT05977972|||OTHER||PROSPECTIVE|||||||
34015130|NCT02993770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015131|NCT04445779|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34015132|NCT06264245|||COHORT||PROSPECTIVE|||||||
34015133|NCT01700049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015134|NCT04281979|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|In each of the two conditions, participants will be asked to consume a drink and pill. They will be informed that the drink and pill may contain a variety of over the counter substances but they will not be informed about the contents of the drinks and pills until they have completed both the active and placebo visits.|This study will examine the acute effects of a substance (e.g. stimulant, sedative, analgesic) on a single group of nondaily smokers. All participants will complete 2 experimental sessions under the influence of a substance or placebo. The order of the active and placebo sessions will be randomized.|t|f|f|f
34015135|NCT04719234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015136|NCT03083236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015137|NCT03297528|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015138|NCT02478320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015139|NCT03272620|||COHORT||PROSPECTIVE|||||||
34015140|NCT04531995|||COHORT||PROSPECTIVE|||||||
34015141|NCT00302120|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34015142|NCT01828710|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34015143|NCT01484184|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34015144|NCT05687487|||COHORT||PROSPECTIVE|||||||
34015145|NCT04798365|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34015146|NCT00002473|RANDOMIZED|||TREATMENT||||||||
34015147|NCT01301235|||CASE_ONLY||CROSS_SECTIONAL|||||||
34015148|NCT01264042|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34015149|NCT00825136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015150|NCT04306237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015151|NCT03052322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015152|NCT02340845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015153|NCT03735134|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015154|NCT00443768|||CASE_CONTROL||PROSPECTIVE|||||||
34015155|NCT02238626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015156|NCT00243464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34015157|NCT04906252|||COHORT||PROSPECTIVE|||||||
34015158|NCT03533257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-Controlled, Double-Blind, Parallel-Group|t|t|t|t
33713031|NCT03640845|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33713032|NCT01745172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713033|NCT04350489|||CASE_CONTROL||PROSPECTIVE|||||||
33713034|NCT00691418|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713035|NCT01259505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713036|NCT01050426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713037|NCT00468325|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720755|NCT05846906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793369|NCT04962074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793370|NCT01883492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793371|NCT01278888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793372|NCT02878915|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33793373|NCT02607384|NA|SINGLE_GROUP||OTHER||NONE||||||
33793374|NCT04951518|||COHORT||OTHER|||||||
34015159|NCT01918826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015160|NCT03983694|||COHORT||PROSPECTIVE|||||||
34015161|NCT03015727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015162|NCT04324593|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34015163|NCT06033365|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015164|NCT04597398|||CASE_ONLY||RETROSPECTIVE|||||||
34015165|NCT05060432|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34015166|NCT00709436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015167|NCT03828266|||COHORT||PROSPECTIVE|||||||
34015168|NCT03578237|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only the investigator/physician applying the cryoneurolysis will be aware of the treatment group assignment.||t|t|f|t
34015169|NCT04094948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015170|NCT05373121|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015171|NCT01746264|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34015172|NCT03508414|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34015173|NCT00629265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34097892|NCT00003008||||TREATMENT||||||||
33793375|NCT05340244|NA|SINGLE_GROUP||OTHER||NONE||This is a pre-market, open label, prospective, non-randomized clinical research study conducted at one site in the United States.||||
33793376|NCT00957307|||CASE_ONLY||PROSPECTIVE|||||||
33793377|NCT00036036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793378|NCT04853017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33713038|NCT06093295|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The researchers will employ a single-blinded cross-over study design. The participant will not know which day the participant receives the true (experimental) or control (placebo) repetitive transcranial magnetic stimulation condition.|The researchers will employ a single-blinded cross-over study design.|t|f|f|f
33713039|NCT06334510|||COHORT||PROSPECTIVE|||||||
33793379|NCT00354406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097893|NCT05848375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Interventional study, randomized in two parallel groups, multicenter (trial of superiority) :~The research procedure for arthroscopic rotator cuff repair is performed under local regional anesthesia alone without general anesthesia. LRA is performed by injecting anesthetic into the interscalene nerve block under ultrasound guidance. This LRA can be accompanied by hypnotic or morphine sedation. The comparison procedure is arthroscopic rotator cuff repair performed under LRA and GA"|f|f|f|t
33793380|NCT00189202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793381|NCT01233713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097894|NCT00310479|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793382|NCT06261775|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33793383|NCT04570631|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34097895|NCT02542579|||CASE_ONLY||PROSPECTIVE|||||||
33793384|NCT00042198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793385|NCT04609618|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, self-controlled, feasibility study.||||
34097896|NCT04806126|||COHORT||PROSPECTIVE|||||||
34097897|NCT05058638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097898|NCT05938010|||COHORT||PROSPECTIVE|||||||
34097899|NCT01983904|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33713040|NCT02468414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713041|NCT01652898|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713042|NCT01705639|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713043|NCT02740764|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713044|NCT02807532|||CASE_CONTROL||RETROSPECTIVE|||||||
33713045|NCT05589922|||COHORT||CROSS_SECTIONAL|||||||
33713046|NCT03763253|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Three-arm unblinded randomised controlled trial using a positive control||||
33713047|NCT06406283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization sequence is concealed (blinded) from research personnel, so that the investigators are not aware of whether a particular subject has been randomized to one of the intervention groups or to the active control group.|"In Study 1: 174 participants, all of them university students aged 18 to 25 years old, are randomly assigned to one of three arms: The first group (n=58) receives HIFT. The second group (n=58) receives Qigong. Finally, the third group (n=58) receives MBSR.~In Study 1: 45 participants, all of them university students aged 18 to 25 years old, are randomly assigned to one of three arms: The first group (n=15) receives HIFT-VR. The second group (n=15) receives Qigong-VR. Finally, the third group (n=15) receives MBSR-VR."|f|f|t|t
33713048|NCT05453656|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713049|NCT03053323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713050|NCT04090450|||COHORT||RETROSPECTIVE|||||||
33713051|NCT05666492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomized into test or control groups.|This is a placebo-controlled randomized control trial|t|f|f|f
33713052|NCT05870540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Quadruple masking: participant, Investigator, therapist, outcomes assessor and Sponsor||t|f|t|t
33713053|NCT00718224|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713054|NCT06355154|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomized controlled trial||||
34097900|NCT01368731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33713055|NCT01463553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713056|NCT04152161|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33713057|NCT00161083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33713058|NCT00151268|||||PROSPECTIVE|||||||
33713059|NCT04567225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713060|NCT01291173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793386|NCT00044148||||TREATMENT||||||||
34097901|NCT05105971|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33793387|NCT01842724|RANDOMIZED|||TREATMENT||||||||
33793388|NCT00940537|||COHORT||CROSS_SECTIONAL|||||||
33802057|NCT05280275|NA|SEQUENTIAL||TREATMENT||NONE||||||
34097902|NCT00936039|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713061|NCT01953198|||COHORT||PROSPECTIVE|||||||
33802058|NCT06383793|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33802059|NCT06499558|RANDOMIZED|PARALLEL||OTHER||NONE|In the study, participants are divided into two groups: the laboratory training group (the group receiving standard training) and the group receiving standard patient training. For this reason, blinding was not possible among the participants.|In the study, participants are divided into two groups: the laboratory training group (the group receiving standard training) and the group receiving standard patient training.||||
33802060|NCT04834141|||CASE_CONTROL||PROSPECTIVE|||||||
33802061|NCT02117752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713062|NCT03466697|NA|SINGLE_GROUP||OTHER||NONE||||||
34097903|NCT00631644|||||PROSPECTIVE|||||||
33713063|NCT01631578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713064|NCT02224040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713065|NCT01456468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713066|NCT02269241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720756|NCT02159690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097904|NCT01431547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097905|NCT04644757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097906|NCT06286046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720757|NCT04416464|||COHORT||PROSPECTIVE|||||||
34015174|NCT00644449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097907|NCT04759092|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment study, open label||||
34097908|NCT02405858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097909|NCT02728726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015175|NCT02733562|||COHORT||RETROSPECTIVE|||||||
34015176|NCT02613325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793389|NCT06427486|RANDOMIZED|PARALLEL||TREATMENT||NONE|The trial author responsible for enrolling participants will not have access to the concealed random allocation sequence. However, due to the nature of the intervention, blinding the treatment assigned to participants will not be feasible.|This is a mixed-method pilot randomized waitlist-controlled trial with two parallel groups: the telecoaching intervention group and the waitlist control group, and semi-structured interviews with intervention participants. The utilization of a waitlist control group enables the comparison of the potential effects of the intervention group with those of a control group while ensuring that parents in the wait-listed control group can have access to telecoaching intervention after the completion of the study. After completing telecoaching sessions, participants from the intervention group will be invited to participate in semi-structured interviews to explore their perceptions about the intervention. The reason for using a mixed method is to achieve a comprehensive understanding of telecoaching intervention (its feasibility, acceptability, and potential efficacy) and to explain findings by connecting information obtained from both designs.||||
34097910|NCT02444377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097911|NCT04017910|||COHORT||PROSPECTIVE|||||||
34015177|NCT03504995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097912|NCT01038466|||COHORT||RETROSPECTIVE|||||||
34097913|NCT05610267|||COHORT||RETROSPECTIVE|||||||
34097914|NCT03112187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097915|NCT02528305|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking, this was not possible with this study design.|||||
34097916|NCT02681432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097917|NCT05457387|||COHORT||PROSPECTIVE|||||||
34097918|NCT06450704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097919|NCT06091371|||OTHER||PROSPECTIVE|||||||
34097920|NCT01842178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34097921|NCT01237405|||COHORT||CROSS_SECTIONAL|||||||
34097922|NCT01433003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097923|NCT01014156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097924|NCT01951456|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097925|NCT06358989|||OTHER||CROSS_SECTIONAL|||||||
34097926|NCT02979158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097927|NCT05236127|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The primary investigator will be blinded to the study participants' study group status. Additionally, the statistician will be blinded from group assignment.||f|f|t|t
34097928|NCT03112850|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a randomised crossover trial with participants randomized into two equal groups to carry out separate crossover experiments. All participants will undergo an individualised auditory training for a period of 6 months, and will be randomly allocated to one of the following groups.~1. Participants who will be fitted with hearing aids for the first 3 months of auditory training program - Group A~2. Participants who will be fitted with hearing aids for the last 3 months of auditory training program - Group B Groups will be matched in terms of the degree of hearing loss with one member from each matched pair randomly assigned to Group A and the other member of each matched pair assigned to Group B. A random sequence of binary digits will be used for this purpose."||||
34015178|NCT06362382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015179|NCT01194336|||COHORT||PROSPECTIVE|||||||
34015180|NCT05166954|||COHORT||RETROSPECTIVE|||||||
33793390|NCT02886754|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and outcome assessors were unaware of which intervention group subjects were allocated|The study design is a parallel group, double-blind, randomized trial|t|f|f|t
33802062|NCT01637246|||COHORT||RETROSPECTIVE|||||||
34015181|NCT01916746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015182|NCT06182904|||CASE_CONTROL||PROSPECTIVE|||||||
34015183|NCT04473521|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34015184|NCT05690087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015185|NCT04859842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Conventional therapy group will receive sham electrotherapy sessions and outcome assessments will be performed by a investigator who was blinded to group allocation.|Three groups with a conventional therapy control group.|t|f|f|t
34015186|NCT06288022|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"All eligible patients will be provided with an explanation of the research and invited to participate.~Patient will participate or not depends on whether they not meet the surgical exclusion criteria. If they meet the criteria, they will not participate in the research. If they not meet the criteria, they will be randomly assigned to one of the groups.~Patients will not be informed of the treatment intervention in advance"|"Randomized Controlled Trial in 2 group~1. total tubeless mini-PCNL~2. tubeless mini-PCNL"|t|t|f|f
34015187|NCT02799030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015188|NCT02453906|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34015189|NCT02043613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015190|NCT03734211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015191|NCT05060133|||COHORT||PROSPECTIVE|||||||
34015192|NCT03424512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015193|NCT01286389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34097929|NCT05611424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Neovascular Age-related Macular Degeneration||||
34097930|NCT05199038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097931|NCT05449873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097932|NCT04474379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and outcomes assessor will be blind to which cognitive training a participant will be randomized.|Participants will be randomized to treatment arm (1:1 ratio, stratified by sex and Clinical Dementia Rating (CDR) Score 0 or 0.5): the strategy training or the process training.|t|f|f|t
34097933|NCT04728464|||COHORT||PROSPECTIVE|||||||
34097934|NCT01151462|||OTHER||OTHER|||||||
34097935|NCT04151641|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33793391|NCT03775551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015194|NCT04722159|||CASE_CONTROL||PROSPECTIVE|||||||
34015195|NCT03124862|NA|SINGLE_GROUP||OTHER||NONE||||||
34015196|NCT01799317|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34015197|NCT02816866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34015198|NCT05800899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research staff conducting the initial assessment prior to randomizations to brief interventions or culturally informed intervention and those conducting follow-up assessments will be blind to participant assignment.||t|f|f|t
34015199|NCT03026855|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34015200|NCT02304991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097936|NCT01413646|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34097937|NCT04162483|||COHORT||RETROSPECTIVE|||||||
34015201|NCT02828059|||CASE_ONLY||PROSPECTIVE|||||||
34015202|NCT05479799|||COHORT||CROSS_SECTIONAL|||||||
34015203|NCT05465642|||COHORT||PROSPECTIVE|||||||
34015204|NCT05869214|||COHORT||PROSPECTIVE|||||||
34015205|NCT00599898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015206|NCT02922101|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34015207|NCT05562908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After randomisation, the attending consultant informed the patient of the harvesting method. Data collector and outcome adjudicator were blinded.|Randomised trial|f|f|t|t
34015208|NCT05499780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097938|NCT04920123|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34097939|NCT00744419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097940|NCT00795795|RANDOMIZED|PARALLEL||||NONE||||||
34097941|NCT05328232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097942|NCT04744532|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097943|NCT03957057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097944|NCT03376009|||CASE_ONLY||PROSPECTIVE|||||||
33793392|NCT04023916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097945|NCT00440570|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34097946|NCT02434614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097947|NCT00821821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34097948|NCT04119336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097949|NCT02358395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097950|NCT03342859|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097951|NCT01489358|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097952|NCT05234333|||CASE_ONLY||CROSS_SECTIONAL|||||||
34097953|NCT01665105|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34097954|NCT03322891|NA|SINGLE_GROUP||OTHER||NONE||||||
34097955|NCT05560321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Triple blind - exception of the study team member applying the disinfectant product (intervention)|Each participant's inpatient room was enrolled in both the intervention and control arms at the same time.|t|t|t|t
34097956|NCT03927430|||CASE_ONLY||RETROSPECTIVE|||||||
34097957|NCT05875077|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34097958|NCT02866448|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34097959|NCT03090035|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial||||
34097960|NCT03907423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be divided into two group (one arm is DM-type 2 patients who will receive rosuvastatin -metformin-glimepiride combination (40 patients) and another arm is DM-type 2 patient who will receive glimepiride-metformin combination (30 patients).|t|f|t|f
34097961|NCT03153293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097962|NCT00776425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097963|NCT06289881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793393|NCT06501586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793394|NCT01826695|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33793395|NCT00281996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793396|NCT03547752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793397|NCT05001750|RANDOMIZED|PARALLEL||OTHER||NONE||The patients will be randomized into one of two groups, either continuous antibiotic usage until the EVD is removed or antibiotics for a total of twenty-four hours; in both cases antibiotics will begin no more than sixty minutes pre-procedure.||||
33793398|NCT02732314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793399|NCT01568736|||CASE_ONLY||PROSPECTIVE|||||||
33793400|NCT02886793|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793401|NCT06069726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793402|NCT03441360|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793403|NCT00950404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793404|NCT02171663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793405|NCT05061615|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793406|NCT00112983|RANDOMIZED|||PREVENTION||DOUBLE||||||
33793407|NCT03183999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"1. Participant masking:~   To intervention arm, capsules including 160mg of fermented ginseng(GINST) ingredients will be provided. To control arm, capsules of the same shape and weight as GINST capsules will be provided. These apsules are made of a cellulose component.~2. Care provider masking The care providers will be unaware which participant belonged to the experimental group or control group during stuty period."|Randomized, double-blind, placebo-controlled trial for evaluation of sperm motility improvement effect of fermented ginseng|t|t|f|f
33793408|NCT03630939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793409|NCT00097513|||COHORT||PROSPECTIVE|||||||
34015209|NCT00975286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015210|NCT00862017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||||||||
34015211|NCT01802749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015212|NCT04610463|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34097964|NCT04097184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients will then be randomized and assigned to one of the 2 groups: the first group will receive a series of 10 effective stimulation sessions (experimental group active tDCS) and the second group will receive a series of 10 placebo stimulation sessions (control group sham tDCS)."|Prospective multicentre controlled randomized, double-blind, two-arm study|t|t|t|t
33713067|NCT03410550|NA|SINGLE_GROUP||TREATMENT||NONE||Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10) SCI.||||
33713068|NCT03579732|||COHORT||RETROSPECTIVE|||||||
33793410|NCT05607186|||COHORT||RETROSPECTIVE|||||||
33713069|NCT03532334|NA|SINGLE_GROUP||OTHER||NONE||||||
33713070|NCT00922181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793411|NCT03611530|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind study||t|f|t|f
33793412|NCT03710564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||multicenter, randomized, double-masked|t|t|t|f
34097965|NCT04518423|||COHORT||PROSPECTIVE|||||||
34015213|NCT05211999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33713071|NCT00692341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713072|NCT02254486|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33793413|NCT03786263|||COHORT||PROSPECTIVE|||||||
33793414|NCT05148780|NA|SINGLE_GROUP||OTHER||NONE||||||
33793415|NCT03637634|||COHORT||OTHER|||||||
33793416|NCT05646745|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous fascia lata is utilized via transobturator approach||||
33793417|NCT05401227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|Subjects will be randomized to one of three ketamine arms. with in each ketamine arm, subjects will be randomized to TS-134 or placebo for 6 total arms.|t|f|t|t
33793418|NCT02414204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793419|NCT01676090|||OTHER||CROSS_SECTIONAL|||||||
33793420|NCT06009120|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients who met the sample selection criteria were randomly divided into two groups, an intervention (education) group and a CG, using a computer-based program (www.random.org). The assignment to the intervention and CG was performed by an independent statistician. Thus, by implementing randomized allocation and concealing the randomization, selection bias was controlled. In the study, participant blinding was carried out, but researcher blinding was not possible due to the researcher's awareness of the intervention being administered. In a 1:1 ratio, the women were separated into intervention and CGs (Figure 1).|t|f|f|t
33793421|NCT02792374|||CASE_CONTROL||RETROSPECTIVE|||||||
33936688|NCT03427528|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We will conduct an uncontrolled pilot study examining acceptability and feasibility of the Fathers and Babies (FAB) curriculum.||||
33936689|NCT05715840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936690|NCT01549028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936691|NCT03140046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936692|NCT02890940|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
33936693|NCT05634837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33936694|NCT01860131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936695|NCT05849740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936696|NCT02306148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33936697|NCT00715949|||CASE_ONLY||PROSPECTIVE|||||||
34015214|NCT01758055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015215|NCT02941276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015216|NCT01366092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015217|NCT03647683|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to one of three experimental groups in parallel for the duration of the study||||
33713073|NCT06221293|||CASE_CROSSOVER||PROSPECTIVE|||||||
33713074|NCT03440021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||High-dosage (60mg), Low-dosage (10mg), Placebo|t|f|t|f
33713075|NCT05036902|||COHORT||PROSPECTIVE|||||||
33713076|NCT02707874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713077|NCT02128178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33713078|NCT02280785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713079|NCT01535053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713080|NCT01947205|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33713081|NCT05380804|||CASE_CONTROL||PROSPECTIVE|||||||
33713082|NCT00412659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713083|NCT01965275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713084|NCT03742934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33713085|NCT05763550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713086|NCT02980445|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713087|NCT00793598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713088|NCT02562053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713089|NCT04648631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793422|NCT02959658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793423|NCT00878618|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793424|NCT01609517|||COHORT||PROSPECTIVE|||||||
33793425|NCT03668249|||COHORT||RETROSPECTIVE|||||||
33793426|NCT01924884|||CASE_CONTROL||OTHER|||||||
33793427|NCT01045655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015218|NCT05541991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized double-blind clinical study versus placebo|t|t|t|f
33793428|NCT05390099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015219|NCT02009683|||COHORT||PROSPECTIVE|||||||
33793429|NCT04623658|||COHORT||RETROSPECTIVE|||||||
34015220|NCT00055133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015221|NCT04796779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713090|NCT01931852|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33713091|NCT06306040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"* Group C (Control group n=35 ): 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery~* Group M (Magnesium sulfate group n=35 ): 30 mg/kg Magnesium sulphate diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery~* Group N (Nalbuphine group n=35 ): 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery"|"* Group C (Control group n=35 ): 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery~* Group M (Magnesium sulfate group n=35 ): 30 mg/kg Magnesium sulphate diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery~* Group N (Nalbuphine group n=35 ): 0.1 mg/kg nalbuphine diluted to 10 ml isotonic saline will be injected intravenously before 30 min from end of surgery"|t|f|f|f
33713092|NCT02966990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793430|NCT04430426|NA|SINGLE_GROUP||OTHER||NONE||||||
33793431|NCT04812951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793432|NCT00877513|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793433|NCT01534910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015222|NCT01923623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34015223|NCT00337441|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34015224|NCT01101204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33713093|NCT02887885|||CASE_ONLY||PROSPECTIVE|||||||
33713094|NCT01327105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713095|NCT05387031|||COHORT||PROSPECTIVE|||||||
33713096|NCT04891874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Adjuvant SBRT after surgery group vs. surgery alone group.|f|f|f|t
33713097|NCT01414855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713098|NCT02505997|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713099|NCT05755048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713100|NCT03342105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713101|NCT02889965|||COHORT||PROSPECTIVE|||||||
33713102|NCT01934114|||COHORT||PROSPECTIVE|||||||
33713103|NCT01594879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713104|NCT00585728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713105|NCT02546804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33713106|NCT03330730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015225|NCT03161964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015226|NCT04813315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713107|NCT01634360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713108|NCT02516683|||CASE_CONTROL||PROSPECTIVE|||||||
33713109|NCT01466855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713110|NCT01204853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713111|NCT03875885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33713112|NCT00173277|||DEFINED_POPULATION||OTHER|||||||
33713113|NCT01096901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33713114|NCT04851249|||CASE_CONTROL||PROSPECTIVE|||||||
33713115|NCT01073891|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33713116|NCT03553667|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33713117|NCT02033694|||CASE_CONTROL||PROSPECTIVE|||||||
33713118|NCT05524155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793434|NCT05570019|||COHORT||PROSPECTIVE|||||||
33793435|NCT00092664|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33793436|NCT01828320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33793437|NCT06555887|||COHORT||RETROSPECTIVE|||||||
33793438|NCT00781196|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33793439|NCT05781555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793440|NCT00609700|||COHORT|||||||||
33793441|NCT02559518|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33793442|NCT00764920|||OTHER||OTHER|||||||
33793443|NCT03990272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793444|NCT01513135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793445|NCT01185899|||COHORT||PROSPECTIVE|||||||
33793446|NCT06553560|NA|SINGLE_GROUP||OTHER||NONE||||||
33793447|NCT03751150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793448|NCT04672590|||CASE_CONTROL||PROSPECTIVE|||||||
33793449|NCT04878081|||CASE_ONLY||PROSPECTIVE|||||||
33793450|NCT02616237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793451|NCT03230396|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33793452|NCT01494246|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33793453|NCT00346151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793454|NCT00258635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793455|NCT01456936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793456|NCT02177318|||COHORT||PROSPECTIVE|||||||
34015227|NCT02019212|||COHORT||OTHER|||||||
34015228|NCT04732936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015229|NCT03330782|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015230|NCT00732433|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713119|NCT00000383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33713120|NCT00137748|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33713121|NCT03388879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher doing the statistical analyses will be masked for treatment Group (i.e. Group 1 or 2) in a databse blinded for treatment grioups and without variables indirectly revealing treatmnet arm. These will be analyzed later.|Prospective randomized two-group clinical trial with block randomization.|f|f|f|t
33713122|NCT02554487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097966|NCT03164356|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
34097967|NCT03522259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097968|NCT02477046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34097969|NCT05174507|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants, investigators and study nurses will be blinded to the study drug.|Placebo controlled, double-blind, randomized, cross-over proof-of-concept study. Subjects will be randomized to either group 1-6 (ratio 1:1, in blocks of 4 participants).|t|t|t|f
34097970|NCT02441699|||COHORT||PROSPECTIVE|||||||
34097971|NCT05749185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34097972|NCT05206331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||eligible participants will have contrast enhanced mammography before their scheduled biopsy||||
34097973|NCT05812495|RANDOMIZED|PARALLEL||TREATMENT||NONE|Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis|||||
34015231|NCT03493776|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33713123|NCT03081260|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33713124|NCT02786446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33713125|NCT03405129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713126|NCT02200120|||COHORT||PROSPECTIVE|||||||
33713127|NCT02551757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015232|NCT04422119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015233|NCT02701166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015234|NCT03801538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015235|NCT01684163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015236|NCT06127368|RANDOMIZED|PARALLEL||TREATMENT||NONE||sequential||||
34015237|NCT02631018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015238|NCT02563717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015239|NCT03273491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015240|NCT01333345|||CASE_ONLY||CROSS_SECTIONAL|||||||
33713128|NCT06135350|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33713129|NCT02033785|||COHORT||PROSPECTIVE|||||||
33720758|NCT06135233|||COHORT||RETROSPECTIVE|||||||
33793457|NCT06184854|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomised Controlled Trial|t|f|f|f
33793458|NCT02709863|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33793459|NCT05767099|||OTHER||PROSPECTIVE|||||||
33793460|NCT03827512|||OTHER||CROSS_SECTIONAL|||||||
33793461|NCT04827654|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Individuals collecting data will be blinded to the participant randomization status.|Randomized controlled trial, outcomes on reference child and reference caregiver; In the intervention arm, fruits and vegetables and vouchers cover more than 1 cup a day increase for families, using an average of 5 people as family size.|f|f|t|t
33793462|NCT03720990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793463|NCT00092755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015241|NCT05882916|NA|SINGLE_GROUP||PREVENTION||NONE||randomized stepped wedge trial||||
34015242|NCT00578981|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
34015243|NCT02244918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015244|NCT01717430|||COHORT||PROSPECTIVE|||||||
34015245|NCT04703582|||COHORT||PROSPECTIVE|||||||
34015246|NCT03150823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34015247|NCT04460196|||COHORT||PROSPECTIVE|||||||
33793464|NCT02306343|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793465|NCT00929721|NA|SINGLE_GROUP||||NONE||||||
33793466|NCT04347499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793467|NCT01576133|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor did not know which study group the person they visited was in and told participant not to reveal it.|"Time limited home based intervention of a Nurse, Occupational Therapist, and a handyman to work with low income older adults to assess, prioritize and meet their functional goals."|f|f|f|t
33793468|NCT02863380|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34015248|NCT03704402|||COHORT||PROSPECTIVE|||||||
33720759|NCT04905095|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793469|NCT00238446|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33793470|NCT00414648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unlabeled sirolimus tablets were provided by Pfizer. Identical appearing placebo tablets were obtained from a commercial source. Sirolimus levels were reported only to the medical monitor. To maintain the blind, when dose adjustments were made in the sirolimus group, a sham adjustment was also made in the placebo group||t|t|t|t
34097974|NCT02692261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793471|NCT04870060|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||prospective, single centre, pilot pharmacokinetic and pharmacodynamic study with an adaptive design||||
33793472|NCT06043128|||COHORT||CROSS_SECTIONAL|||||||
33793473|NCT04405063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793474|NCT00904956|||CASE_ONLY||PROSPECTIVE|||||||
33793475|NCT06015750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015249|NCT05767606|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34097975|NCT02347865|||CASE_ONLY||PROSPECTIVE|||||||
33793476|NCT00042224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015250|NCT03683524|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Experimental group: bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)~* Control group: continuation of their current stable ART."||||
34015251|NCT01027741|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015252|NCT01946360|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015253|NCT02613312|||CASE_ONLY||PROSPECTIVE|||||||
34015254|NCT06453239|||COHORT||PROSPECTIVE|||||||
34015255|NCT03606421|||COHORT||PROSPECTIVE|||||||
34015256|NCT01576874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015257|NCT02218112|||COHORT||PROSPECTIVE|||||||
34015258|NCT01469702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015259|NCT03667014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015260|NCT01252719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015261|NCT01235702|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34015262|NCT06231719|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Two intervention ,one control group||||
34015263|NCT03421808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects will get EEGS and TMS, but in one group the TMS pulses are synchronized to the EEG, and in the other not. There is no way for the subject or treater or anyone to detect who is in which arm.|In a double blind, randomized (1:1) trial enrolling only at MUSC over three years in 60 treatment resistant depressed patients, we hypothesize that daily prefrontal rTMS over 4-6 weeks with the initial TMS pulse of each train synchronized to the subject's alpha phase (SYNC TMS), will result in improvement in depression, and that these improvements will be greater than the improvements seen using the same form of treatment but not with the initial pulse synchronized (NON-SYNC TMS).|t|t|t|t
34015264|NCT06417138|||COHORT||RETROSPECTIVE|||||||
34015265|NCT03214341|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34015266|NCT00496535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015267|NCT04124666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015268|NCT03721536|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34015269|NCT03639519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713130|NCT04107194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators performing urea breath test 30 days after the end of the treatment (assessment of the primary outcome: eradication rate) will not be aware of participants' allocation and received therapy. Moreover, two independent investigators will perform RT-PCR on stool samples and gastric biopsy specimens, blinded to the other test results.|Open-label, multicenter, parallel-arm randomized controlled trial|f|f|f|t
34015270|NCT03234894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015271|NCT01703936|RANDOMIZED|PARALLEL||||NONE||||||
34097976|NCT01426659|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34097977|NCT03049800|||COHORT||PROSPECTIVE|||||||
34097978|NCT00908388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097979|NCT03833843|||COHORT||RETROSPECTIVE|||||||
34097980|NCT01794169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097981|NCT01283425|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015272|NCT03385941|||CASE_CONTROL||PROSPECTIVE|||||||
33713131|NCT05182138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computer-based randomisation system|3 arms in parallel|t|t|t|f
33713132|NCT00050934||||TREATMENT||||||||
33793477|NCT04136639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34015273|NCT04355663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015274|NCT03001219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015275|NCT02443415|||CASE_CONTROL||PROSPECTIVE|||||||
34015276|NCT03762499|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34015277|NCT00006235||||TREATMENT||||||||
34015278|NCT00511992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015279|NCT04333472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015280|NCT00687310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015281|NCT05332782|||COHORT||RETROSPECTIVE|||||||
34015282|NCT03885882|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort 1 and Cohort 2 will receive treatment as parallel assignment. Cohort 3 will receive treatment in cross-over manner.||||
34015283|NCT00865618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015284|NCT01382082|||CASE_CONTROL||PROSPECTIVE|||||||
34015285|NCT03880799|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||non-randomized feasibility study||||
34015286|NCT04910659|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blind|prospective randomized controlled study|t|f|f|t
34015287|NCT01699763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015288|NCT00054041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015289|NCT00104091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015290|NCT04712149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015291|NCT05801653|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34015292|NCT05288036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015293|NCT05499013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 1 is an open-label, dose-finding study. Phase 2 is a randomized, double-blind, placebo-controlled study.|t|t|t|t
34015294|NCT04414839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34015295|NCT00017823||||TREATMENT||NONE||||||
34097982|NCT00212355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097983|NCT04418479|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, two-arm, randomized controlled trial||||
34097984|NCT03075436|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34097985|NCT00445120|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34097986|NCT02465047|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34097987|NCT00684138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34097988|NCT05055336|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34097989|NCT01730976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097990|NCT00002370||||TREATMENT||||||||
34097991|NCT03020888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34097992|NCT00315029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34097993|NCT01033227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34097994|NCT03703986|||CASE_CONTROL||RETROSPECTIVE|||||||
33713133|NCT03020160|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713134|NCT01851616|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33713135|NCT01250275|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34015296|NCT00560430|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34015297|NCT02341950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015298|NCT04146363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Randomized, double-blind, parallel group, placebo controlled|t|t|t|t
34097995|NCT01272856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34097996|NCT03468946|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34097997|NCT01433874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34097998|NCT03488485|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Real Life Efficacy Study||||
34097999|NCT04743895|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participant is blinded to study treatment and radiographers that assess CT scans are also blinded.|Randomized, Single Blinded Study|t|f|f|t
33713136|NCT02346630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713137|NCT02350790|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33713138|NCT05571540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713139|NCT01853761|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33793478|NCT04930588|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33793479|NCT03942341|||COHORT||CROSS_SECTIONAL|||||||
34098000|NCT01263028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793480|NCT03731936|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713140|NCT06364449|||COHORT||RETROSPECTIVE|||||||
33713141|NCT06410820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Allocation: Randomized Intervention Model: Parallel Assignment|f|f|t|t
33793481|NCT03630224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793482|NCT02932163|||COHORT||PROSPECTIVE|||||||
34015299|NCT04309552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center, prospective, non-randomized trial of 30 newly diagnosed patients with suspected HGG undergoing surgical planning will be enrolled to undergo combined FMISO/FLT PET at baseline. Blood samples will be drawn during PET acquisition. Preoperatively FMISO/FLT PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization. Longitudinal clinical data will be collected from the medical record for standard of care visits to the oncology and surgical clinics. Imaging data from research scans will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year post baseline assessment.||||
34015300|NCT00683982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34015301|NCT04689763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015302|NCT00407693|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015303|NCT03631095|||COHORT||PROSPECTIVE|||||||
34015304|NCT00952536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015305|NCT02091323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34015306|NCT01563419|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015307|NCT01687582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015308|NCT01408628|NA|SINGLE_GROUP||||NONE||||||
34015309|NCT03872882|||COHORT||CROSS_SECTIONAL|||||||
34015310|NCT00148330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015311|NCT02672202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015312|NCT03304028|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, multicenter, longitudinal pilot study on cohort, in 3 phases||||
34015313|NCT02182791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015314|NCT00262041|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34015315|NCT02328742|||COHORT||PROSPECTIVE|||||||
34015316|NCT03499002|RANDOMIZED|PARALLEL||OTHER||SINGLE|Research assistant will be present when student randomly chooses which environment they will learn how to suture in. The principal investigator will be unaware of this randomization.||f|f|t|f
34015317|NCT00590278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015318|NCT00607152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015319|NCT01437033|||OTHER||PROSPECTIVE|||||||
34015320|NCT00225121||||TREATMENT||NONE||||||
34015321|NCT04866277|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Due to the nature of the study, there will be no blinding of pregnant women, health professionals or members of the research team after assignment of the intervention. However, those involved in the outcome assessment and data analysis will be blinded as there will be no identification of the intervention and control group.|Parallel superiority pragmatic clinical trial randomized by clusters (Primary Health Care Units)|f|f|f|t
34015322|NCT00618930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34015323|NCT05640518|||COHORT||PROSPECTIVE|||||||
34015324|NCT02548312|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34015325|NCT02083237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34015326|NCT06309446|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34015327|NCT05019820|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34015328|NCT02070302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015329|NCT04508036|||COHORT||PROSPECTIVE|||||||
34015330|NCT05445726|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Cardiologist that interpret ECG strips to not know which strip is from the reference device and which is from the test device.|Comparison of test device ECG to reverence device ECG.|f|f|f|t
33713142|NCT04472130|||COHORT||PROSPECTIVE|||||||
33713143|NCT03972553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713144|NCT02021240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713145|NCT02911753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713146|NCT04831723|||OTHER||PROSPECTIVE|||||||
33713147|NCT01943331|||CASE_CROSSOVER||PROSPECTIVE|||||||
33713148|NCT04943094|||OTHER||PROSPECTIVE|||||||
33713149|NCT01929434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793483|NCT06089694|||COHORT||PROSPECTIVE|||||||
34015331|NCT05391334|||COHORT||PROSPECTIVE|||||||
34015332|NCT01427842|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34015333|NCT03096847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015334|NCT05731622|||COHORT||PROSPECTIVE|||||||
34015335|NCT02334111|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34015336|NCT01095042|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015337|NCT06038708|||COHORT||PROSPECTIVE|||||||
34015338|NCT00562770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015339|NCT02470793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098001|NCT00699166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015340|NCT01714375|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015341|NCT05415774|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||"Single center, randomized, three one-month periods, six sequences, cross-over, double blind, study to evaluate the effect of 2 innovative settings of DBS combining the stimulation of STN and SNr, vs. a standard (S) stimulation, on FoG, in PD patients with DBS with severe FoG.~the sequence of different stimulation parameters will be randomized and not the treatment Each patient receives the three treatments (S, C1 and C2)"|t|f|t|f
34098002|NCT03486639|||COHORT||PROSPECTIVE|||||||
33713150|NCT01324765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713151|NCT06211478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713152|NCT01777100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713153|NCT00479609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713154|NCT01760707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713155|NCT01880385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713156|NCT00767533|||COHORT||PROSPECTIVE|||||||
33713157|NCT01448278|RANDOMIZED|PARALLEL||||NONE||||||
33713158|NCT03932227|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Monocentric, cross study, randomized|f|f|f|t
33713159|NCT00003128|RANDOMIZED|||TREATMENT||||||||
33713160|NCT03198117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713161|NCT01997632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33713162|NCT03423381|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Crossover randomised|t|f|f|f
33713163|NCT02994979|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33793484|NCT00491517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793485|NCT03162978|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33793486|NCT01979354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793487|NCT03121131|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34015342|NCT01591889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015343|NCT02138136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015344|NCT02979236|||COHORT||PROSPECTIVE|||||||
34015345|NCT02017730|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33793488|NCT04821336|||OTHER||RETROSPECTIVE|||||||
33793489|NCT03329144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793490|NCT05417542|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34015346|NCT04948580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015347|NCT02409602|||CASE_CONTROL||PROSPECTIVE|||||||
34015348|NCT03977974|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34015349|NCT05199766|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open-label, single-arm, single-stage phase II trial in patients treated with Voxelotor 1500 mg daily for 48 weeks.~Assessments will be done during the study at week 0, week 6, week 12, week 24, week 36 and week 48."||||
34015350|NCT03797820|||COHORT||PROSPECTIVE|||||||
34015351|NCT04323020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participant will be comatose cardiac arrest|||||
34015352|NCT06088849|NA|SINGLE_GROUP||OTHER||NONE||We will enroll mothers who have been prescribed ACE-inhibitors for medical reasons and are breastfeeding their infant while taking this medication. The mother will be asked to collect milk samples and donate 2 blood samples during a 24h period. Furthermore, we will ask the parents if we can collect a blood sample of the child. In addition, clinical maternal and infant variables will be collected, as well as medication intake, sampling information and general infant health.||||
34015353|NCT02537847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098003|NCT03346512|||COHORT||RETROSPECTIVE|||||||
34098004|NCT05303974|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34098005|NCT01220154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103333|NCT06690216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This study is open-label, with no masking of any parties involved in the clinical trial. All participants, care providers, investigators, and outcomes assessors are aware of the interventions.|This is a Phase I/II, single-center, interventional clinical trial assessing the safety, efficacy, and prognostic value of \[18F\]AlF-NOTA-PCP2 PET/CT in evaluating PD-L1 expression in patients with malignant tumors. The study involves pre-treatment imaging with \[18F\]AlF-NOTA-PCP2 PET/CT, followed by correlation with PD-L1 expression in tumor samples and clinical outcomes.||||
34103334|NCT06121284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793491|NCT01537003|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793492|NCT03900637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793493|NCT03289611|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015354|NCT06141824|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713164|NCT04800705|||CASE_CONTROL||PROSPECTIVE|||||||
34015355|NCT05018520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015356|NCT02405949|||CASE_CONTROL||RETROSPECTIVE|||||||
34015357|NCT06492200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015358|NCT03915665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015359|NCT02025751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098006|NCT05358535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding plan: Either the investigational drug service with the CUH central pharmacy will prepare the admixture syringes or a separate anesthesia staff not involved in subject's case will prepare admixture syringes thus preventing any case personnel involved with subject's case or subject from knowing which admixture is present within syringes for subject's case.|This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.|t|t|f|f
34098007|NCT05224648|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34098008|NCT00422461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098009|NCT06435845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098010|NCT00395512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098011|NCT03919266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098012|NCT04991987|||OTHER||PROSPECTIVE|||||||
34098013|NCT01582256|||OTHER||OTHER|||||||
34098014|NCT04127929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098015|NCT03556878|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 'treatment development' pilot study in which we intended to continue to develop and adapted 'Fitted TranS-C' as we gain experience. At the outset of the study, it involves 4 x 20-30 minute sessions. It utilizes four cross-cutting, 3 core and 1 optional modules from Standard TranS-C. All participants will get the same Fitted Trans-C.||||
34098016|NCT00330278|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34098017|NCT01570192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is an open-label study with 1:1 randomization between two active treatment groups.||t|f|t|f
34098018|NCT02829957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098019|NCT06355687|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34098020|NCT03701178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098021|NCT00028288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098022|NCT06009497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098023|NCT06244251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098024|NCT00005596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098025|NCT00000665||||TREATMENT||||||||
34098026|NCT04432298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Proof-of-concept|t|t|t|t
33713165|NCT00193154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098027|NCT00961012|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34098028|NCT06671184|||COHORT||RETROSPECTIVE|||||||
34098029|NCT04846478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098030|NCT06119412|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34098031|NCT06309797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator carrying out the measurements was not aware of which patients were assigned to the test group.|single-center, single-blinded, randomized controlled trial|f|f|t|f
34098032|NCT06053450|NA|SINGLE_GROUP||OTHER||NONE||||||
34098033|NCT06300905|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33713166|NCT03863249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinding: The researchers who performed the measurements and treatment will be different from those who performed the microbial analysis; the examiner will be blinded during the entire duration of the study about the type of analysis subgingival dental plaque has been undergone.|Double blinded, randomized clinical trial.|t|t|f|f
33713167|NCT00666029|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33713168|NCT01554553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33713169|NCT00584506|||||RETROSPECTIVE|||||||
33713170|NCT03591198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713171|NCT06506383|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33713172|NCT03471650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713173|NCT04647578|||CASE_CONTROL||PROSPECTIVE|||||||
33713174|NCT01083576|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713175|NCT02650362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713176|NCT01447602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713177|NCT03181581|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33713178|NCT04464369|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33793494|NCT02140138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793495|NCT05516654|||OTHER||CROSS_SECTIONAL|||||||
33793496|NCT01846754|||COHORT||PROSPECTIVE|||||||
33793497|NCT02545751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793498|NCT02104765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33713179|NCT04632108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713180|NCT00592384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713181|NCT01750450|||COHORT||PROSPECTIVE|||||||
33713182|NCT03352622|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||CASES AND CONTROLS||||
33713183|NCT01283360|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713184|NCT05118503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33713185|NCT03198234|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34015360|NCT04736563|NA|SINGLE_GROUP||TREATMENT||NONE||open single arm study||||
34015361|NCT03248453|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34015362|NCT05855486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025373|NCT06552156|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The group assignment was only known by the principal investigator. All other people involved (participants and investigators) were blinded.|Double Blind, placebo-controlled, randomised controlled trial.|t|t|t|t
34025374|NCT03279692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015363|NCT05689593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be randomly divided into 3 groups. (They will be selected by simple random sampling using the closed envelope method.) They will be divided into Group A (Low-intensity eswt, hot pack and exercise) and Group B (low intensity laser, hot pack and exercise) Group C (hot pack and exercise).~Outcome evaluations in the study will be carried out by a researcher who is blind to group allocation."|Three groups with a conventional therapy control group|f|f|t|f
34015364|NCT02249676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015365|NCT00288717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34015366|NCT03185403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34098034|NCT04656548|||CASE_CONTROL||RETROSPECTIVE|||||||
34098035|NCT01783015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098036|NCT04942873|||COHORT||RETROSPECTIVE|||||||
34098037|NCT06304727|||COHORT||RETROSPECTIVE|||||||
34098038|NCT00320580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098039|NCT04334811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098040|NCT04787120|||COHORT||PROSPECTIVE|||||||
34098041|NCT04336800|||COHORT||PROSPECTIVE|||||||
34098042|NCT05819788|||COHORT||RETROSPECTIVE|||||||
34098043|NCT04986813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The random allocation of the patients to either group was done by one of the investigators using a random number table.|This was a single centre, parallel group, prospective randomized control study.|t|f|f|f
34098044|NCT01630811|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34098045|NCT00558493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098046|NCT01964313|||COHORT||PROSPECTIVE|||||||
34098047|NCT00121953|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34098048|NCT05675696|NA|SINGLE_GROUP||OTHER||NONE||||||
34098049|NCT02662465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098050|NCT01412983|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34098051|NCT01197898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098052|NCT00676962|RANDOMIZED|PARALLEL||||NONE||||||
34098053|NCT03057327|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||sequential single group||||
33713186|NCT00439660|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomised double blind placebo controlled tri|Randomised double blind placebo controlled tri|t|f|t|t
34098054|NCT04867070|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||After the application of the ESPB was explained to the volunteers, a block was applied if the patients provided their consent. The donors were randomly assigned to Group B (ESPB group) or Group C (control group) using computer-generated random numbers placed in separate closed envelopes that the study investigator opened before performing the block in the operation room.|t|f|f|f
33713187|NCT02710565|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713188|NCT02557620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713189|NCT04847505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Neuroendocrine cancer patients, regardless of the primary tumor origin, are eligible. Recruitment is across all Canada but the examination is performed at the primary site of the study. The safety profile of the procedure will be assessed, and integration of 68Ga-DOTA-TATE will be integrated in the routine clinical practice.||||
33713190|NCT05834660|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015367|NCT02719106|||COHORT||PROSPECTIVE|||||||
34015368|NCT05200962|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33713191|NCT01525368|||CASE_CONTROL||PROSPECTIVE|||||||
33720760|NCT00830843|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720761|NCT01116297|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015369|NCT03325400|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34015370|NCT01181271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015371|NCT05713552|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34015372|NCT02792959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015373|NCT00996931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015374|NCT04131049|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34015375|NCT01159782|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098055|NCT00732459|||COHORT||PROSPECTIVE|||||||
34098056|NCT03922971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34098057|NCT00202852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098058|NCT05639712|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Randomization sequences will be generated prior to the first enrolment of the amended protocol by an independent group (Clinical trails unit- OUS) not affiliated with the present study.~The drug will be prepared after opening an opaque envelope on the day of surgery by a nurse not participating in the study. The syringe with the drug will be labeled with a code number and handed to the study nurse or doctor."|The patient will be randomized to 1 of 10 arms: Placebo (saline 0.9%), morphine 2.5 - 5 - 10 mg, oxycodone 2.5 - 5 -10 mg, or fentanyl 0.025 - 0.05 - 0.1 mg iv.|t|f|t|f
34098059|NCT00965094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098060|NCT03914014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098061|NCT03512158|RANDOMIZED|PARALLEL||TREATMENT||NONE||This pilot study will be an open-label, parallel arm, multi-centre randomized controlled trial with a 1:1 allocation ratio of individual patients in randomly varying blocks of 4, 6, or 8 stratified by centre and gestational age (\<26 weeks vs. ≥26 weeks GA). Neither investigators, nor bedside clinicians will be blinded due to the nature of the investigation, but allocation will be concealed by way of using an electronic randomization system (REDCap). This study will be conducted at 3 NICUs in North America and Australia: McMaster Children's Hospital (McMaster University, lead site), Royal Alexandra Hospital (University of Alberta), and Westmead Hospital (University of Sydney) with the possibility of additional centres joining. Moreover, outcome assessments will also not be blinded.||||
33720762|NCT05805982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33720763|NCT05126784|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double Blind|Arm 1: AVT03 Arm 2: US-Prolia|t|t|t|t
33720764|NCT05503147|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713192|NCT05071456|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"This study will include sixty subjects separate into three groups of twenty subjects based on the skin disease: acne, atopic dermatitis and a group control.~This is a study validating the feasibility of a measure collected by a tool at the prototype stage with a view to pre-industrialization. The following process is:~Measurement by patches and sensors of substances of interest on 2 areas of the face separated by the midline (forehead / cheek).~Collection on the skin surface by 2 swabs repeated on 2 areas"||||
33793499|NCT01392872|NA|SINGLE_GROUP||||NONE||||||
33936698|NCT04490499|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713193|NCT02782975|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098062|NCT03377127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and physicians will not be blinded to the intervention. However, the data collectors and the data analysts will be unaware of the patients allocation. The outcome assessors will also not be aware of the allocation. The biostatistician will also be blinded.|This is a randomized open-label, controlled parallel group trial of a pharmacist managed diabetes clinic in high-risk diabetes patients, with a 1:1 allocation to either standard of care (SOC) or SOC and PMDC and a 6-month and 12-month follow-up.|f|f|t|t
33713194|NCT01458652|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33936699|NCT02554201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713195|NCT01432080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713196|NCT01448811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33713197|NCT02829515|||COHORT||PROSPECTIVE|||||||
34098063|NCT05682469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713198|NCT04988646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, single blind, single dose, 2-periods, cross-over design study with one week washout period between each treatment in 28 healthy subjects under fasting condition|t|f|t|f
33713199|NCT04376372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713200|NCT03682445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants wil be making exercise. It is not possible to make participants blinded to the study.|The study has 3 arms.|f|f|t|t
33713201|NCT01925053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33713202|NCT03766633|||COHORT||RETROSPECTIVE|||||||
33713203|NCT03224572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|Parallel Assignment Randomized double-blinded controlled trial|t|t|f|f
33793500|NCT00707135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802063|NCT00000969||PARALLEL||TREATMENT||||||||
33713204|NCT01572220|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33713205|NCT06436872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analysed by a independent researcher||f|f|f|t
33936700|NCT02258191|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33713206|NCT01411904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936701|NCT05057884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936702|NCT03643276|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"pB-ALL/MR: 2 parallel groups (R-MR) or 2x2 factorial design (R-eHR, R-MR) depending on early risk group assignment.~pB-ALL/HR: 2 parallel groups (R-HR) or 2x2 factorial design (R-eHR, R-HR) depending on early risk group assignment.~T-ALL/early non-SR: 2 parallel groups (R-T).~pB-ALL/SR: Single group.~T-ALL/early SR: Single group."||||
33936703|NCT00909194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936704|NCT05136209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936705|NCT00476515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936706|NCT01108224|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33936707|NCT04686929|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936708|NCT04891510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713207|NCT04199611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936709|NCT05138289|||OTHER||PROSPECTIVE|||||||
34015376|NCT05356143|RANDOMIZED|CROSSOVER||OTHER||NONE||This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study.||||
34015377|NCT04698148|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015378|NCT03418506|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34015379|NCT03421782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015380|NCT00608517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015381|NCT01021982|||CASE_CONTROL||PROSPECTIVE|||||||
34015382|NCT02799238|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|||||
34015383|NCT00321737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015384|NCT06180317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34015385|NCT06414460|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34015386|NCT04397445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing. Subjects and staff will be blinded to treatment assignment. The blind will be maintained through a randomization schedule held by the dispensing pharmacist. Subjects will be blindfolded during oral study drug administration. All subjects will be provided low nitrite/NDMA meals for the first two periods of the study and high nitrite/NDMA meals for the last two periods of the study. This ordering of meals will allow purchasing a single lot of perishable items for different meals and to simplify meal preparation and serving at the study site.|This is a randomized, placebo-controlled, single-dose, 4-period crossover study with 18 healthy subjects|t|t|t|t
34015387|NCT00061217|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34015388|NCT03918109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled, multicenter|t|f|t|t
34015389|NCT03987594|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 allocation with Permuted block randomization||||
34015390|NCT05814003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025375|NCT03456453|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34025376|NCT04462887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025377|NCT01547130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025378|NCT03671616|NA|SINGLE_GROUP||OTHER||NONE||||||
34025379|NCT04792762|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34025380|NCT01667835|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34015391|NCT05742698|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Participants will be randomized using variable block sizes concealed from participating sites. Central randomization will be done with the database and project manager software, REDCap.~After consent and screening, study staff will enter disease severity into the electronic data capture system randomization module so the research pharmacist will be notified via email of study ID and disease severity. Participants will be randomly assigned to receive either Nabilone or placebo for the first treatment phase."|This is a multi-centre double blind, placebo-controlled randomized cross-over study comparing 6 weeks of nabilone treatment to 6 weeks of placebo with a 3-week washout between periods. The study will involve an established network of up to 8 FTD centres in Canada.|t|t|t|t
34015392|NCT04899193|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34015393|NCT03346070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015394|NCT00177502|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34015395|NCT04440319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individual with T2DM in both of groups will not know their groups (single blind), but the researcher knows|The study has a DM nutrition education module that will be determined to intervention group (individual with T2DM). While control group follow the conventional DM counseling.|t|f|f|f
34015396|NCT01475084|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34015397|NCT03971266|NA|SINGLE_GROUP||OTHER||NONE||||||
34015398|NCT01386684|||CASE_ONLY||PROSPECTIVE|||||||
34015399|NCT05697055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015400|NCT01851018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Radiation (hypo fractionation)||||
34015401|NCT00405613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098064|NCT04193527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098065|NCT01864694|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098066|NCT05852249|||COHORT||PROSPECTIVE|||||||
34098067|NCT06132997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Intercostal chest tube group|Medical thoracoscopy group|t|f|f|f
34098068|NCT03041480|||CASE_CONTROL||OTHER|||||||
34098069|NCT05834335|||OTHER||OTHER|||||||
34098070|NCT04576949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098071|NCT00365963|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33713208|NCT01790256|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33936710|NCT05617248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessors are blind to individuals' reports of perceived stress prior to and following the intervention, i.e. at all assessment times.|Randomised controlled trial testing a brief digital intervention (SeApp) against a control group receiving only EMA|t|f|f|t
33713209|NCT01640223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098072|NCT05960123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713210|NCT05516290|||CASE_CROSSOVER||PROSPECTIVE|||||||
34098073|NCT02316132|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34098074|NCT03428269|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel assignment, not blinded, randomized study||||
34098075|NCT05504421|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34098076|NCT01524705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34098077|NCT00477217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098078|NCT00388141|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098079|NCT01245933|||COHORT||PROSPECTIVE|||||||
34098080|NCT00069550|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34098081|NCT01161121|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098082|NCT05553210|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated either to the intervention or control groups. The intervention group will use the intervention with an intervention plan and the control - without an intervention plan. Both groups will participate in the program at the same time.||||
33713211|NCT04346602|||COHORT||PROSPECTIVE|||||||
33713212|NCT04933656|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Double blinding: Participant and person collecting data measurement.|Dietary intervention consisting of four 24-hour feeding periods (1 feeding period per week for 4 weeks).|t|t|f|f
33936711|NCT03608462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this research,we combine a cross-sectional case control study and a randomized controlled study.|t|f|f|t
33936712|NCT00362297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936713|NCT03837301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098083|NCT02619812|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33936714|NCT04533360|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33936715|NCT02106845|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098084|NCT03977610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098085|NCT04212065|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is a randomized, non-blinded single center clinical trial conducted at Ohio State University (OSU) Wexner Medical Center of 139 women with diagnosed Opioid Use Disorder. These women will be randomized between 14 and 27 weeks to one of two groups:~* Sublingual Suboxone® 8mg twice daily~* Subcutaneous SublocadeTM of 300mg monthly"||||
34098086|NCT01236807|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34098087|NCT05510973|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Non-randomized controlled clustered study||||
34098088|NCT05995418|||COHORT||RETROSPECTIVE|||||||
34098089|NCT01932424|NA|SINGLE_GROUP||||DOUBLE|||t|t|f|f
34098090|NCT03799367|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34098091|NCT05356611|NA|SINGLE_GROUP||TREATMENT||NONE||The trial will be a single-arm feasibility trial of Engage for treatment of late-life depression in older adults with comorbid executive/cognitive dysfunction.||||
34098092|NCT01654250|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34098093|NCT05266950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098094|NCT00785447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098095|NCT04038658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Statistical analysis undertaken by researcher blinded to group allocation.|Cluster randomised control trial|f|f|f|t
34098096|NCT03820947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713213|NCT01474057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713214|NCT04412408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713215|NCT03471130|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Double blind, placebo controlled|t|f|t|t
33720765|NCT02834533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33936716|NCT03527836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"Patients, the operating team, nurses, and observers involved in the assessment of the follow-up data collection were unaware of group allocation. The labor analyst is unaware of group allocation.~The list of cases will be provided in spreadsheet program by an observer-blinded assistant and was statistically evaluated by an independent analyst."|Study participants n=10 in the L group, n=10 in the B group and n=10 in the mixture group|t|f|t|t
34098097|NCT06270394|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936717|NCT00879788|RANDOMIZED|CROSSOVER||||NONE||||||
33936718|NCT04296721|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controled Trial||||
33936719|NCT01332851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936720|NCT04661891|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The purpose of this study is to develop a real-time controller for exoskeletons using neural information embedded in human musculature. This controller will consist of an online interface that anticipates human movement based on high-density electromyography (HD-EMG) recordings, and then translates it into functional assistance. This study will be carried out in both healthy participants and participants post-stroke.||||
33936721|NCT00002336||||TREATMENT||DOUBLE||||||
33936722|NCT01960179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015402|NCT03642626|||CASE_CONTROL||PROSPECTIVE|||||||
34015403|NCT04603911|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34015404|NCT06425770|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015405|NCT04487002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015406|NCT03413137|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Using the NaviGo™ system each patient will undergo a biopsy using the transperineal followed by transrectal approach.||||
34015407|NCT00408564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015408|NCT00378716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015409|NCT03541863|||COHORT||RETROSPECTIVE|||||||
34015410|NCT02119117|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34015411|NCT03218163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015412|NCT06303713|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34015413|NCT00025636|RANDOMIZED|||TREATMENT||||||||
34015414|NCT01669473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015415|NCT03533374|||CASE_CONTROL||RETROSPECTIVE|||||||
34015416|NCT03118570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor will be masked until the primary analysis of the study except for open-label substudy treatment arm. The study site pharmacist will be unmasked to treatment allocation throughout. Study treatment will be monitored by a separate unmasked monitoring team.|Double-blind, Dose-finding Study, incorporating an open-label substudy|t|f|t|f
34015417|NCT04901013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015418|NCT02664233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015419|NCT03725865||SEQUENTIAL||TREATMENT||NONE||||||
34015420|NCT01298713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015421|NCT00725114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015422|NCT01617694|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34015423|NCT02692729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015424|NCT03649412|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|There will be no masking as this is an open-label study.|Part A will be a 6-period, 6-way fixed sequence design, in which up to 4 MR tablet prototype coated formulation will be evaluated, following single dose administration (240 mg) in fasted or fed state. There will be a minimum 7-day washout between doses. Part B of the study is optional. Following the final period of Part A, there will be an interim review to determine whether to proceed with optional Part B, and if so, the formulations and tablet strengths to be investigated in Part B. The Part B of the study will be a 7-period fixed sequence which will evaluate the selected MR prototype coated tablet formulation(s) at different tablet strengths or as multiple unit doses.||||
34015425|NCT02310282|||COHORT||PROSPECTIVE|||||||
34015426|NCT03336320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015427|NCT05418231|||COHORT||PROSPECTIVE|||||||
34015428|NCT03667079|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Villages were allocated to one of three treatment arms: in Arm 1 villages people received deworming treatment and dogs rabies vaccination through an integrated delivery; in Arm 2 villages only deworming of people occurred; in Arm 3 only dog vaccination occurred. After the study, Arm 2 and 3 villages received rabies vaccination and deworming, respectively.||||
34015429|NCT04583020|NA|SINGLE_GROUP||TREATMENT||NONE||Neoadjuvant PD-1 inhibitor will be administered to patients with newly diagnosed glioblastomas, followed by surgical resection, standard radiochemotherapy, and further PD-1 inhibitor treatment||||
33793501|NCT06017167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double (Participant, Outcomes Assessor)~* The participants will be kept blind in both groups.~* Outcome assessors will be blinded as they will be anesthesia resident and nurse not participating in the study."|"Patients will be randomly classified with computer generated random numbers into two equal groups (each group 35 patients) Group I: will receive Ondansetron 4mg + dexmedetomidine 0.5 ug/kg + normal saline to complete 10 ml. volume IV infusion over 10 minutes.~Group II: will receive Ondansetron 4mg + dexamethasone 8mg + normal saline to complete 10 ml volume IV ifusion over 10 minutes."|t|f|f|t
33793502|NCT00002450||||TREATMENT||DOUBLE||||||
33793503|NCT06127888|||OTHER||CROSS_SECTIONAL|||||||
34098098|NCT06499649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793504|NCT01564199|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793505|NCT05535491|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33793506|NCT02032329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793507|NCT05685173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015430|NCT03525418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Phase 1: no masking. Phase 2: HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio|"Phase 1: 10 patient safety run-in: all patients treated with LMSCs during Stage II surgery.~Phase 2: 20 patients randomized 1:1 to receive either LMSCs or no cells (controls) during Stage II surgery."|t|f|t|f
34015431|NCT04975074|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34015432|NCT03412812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015433|NCT01086501|||||PROSPECTIVE|||||||
34015434|NCT04158960|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Therapists were blinded to the outcome measures and assessments used to obtain those outcome measures in this study||f|t|f|f
34015435|NCT02448121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015436|NCT03195036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study utilizes a cluster-randomized trial (CRT) design in order to evaluate the impact of the KIDSS ECD program delivered by Catholic Relief Services, specifically the home visiting component, on child development outcomes and utilization of HIV testing services. The main reason for including randomization is to reduce the risk of selection bias. The unit of inference for this CRT is at the individual level but the unit of randomization is the health facility (cluster) level due to issues of program feasibility.||||
34015437|NCT04209205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This was a double-blind, randomized treatment trial.~Subjects, investigator staff, persons performing the assessments remained blinded to the identity of the treatment from the time of randomization until Week 60 database lock, using the following methods:~1. Randomization data were kept strictly confidential until the time of unblinding and were not accessible by anyone else involved in the study with the exception of the bioanalyst.~2. The identity of the treatments were concealed by the use of study treatments in the form of i.v. injection, filled with secukinumab or placebo that were identical in appearance."||t|t|t|t
34015438|NCT05943119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793508|NCT01050569|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34098099|NCT05610761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793509|NCT01140048|||COHORT||PROSPECTIVE|||||||
33793510|NCT06513559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793511|NCT00227682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793512|NCT06005220|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33793513|NCT02698891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793514|NCT01239563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793515|NCT06535958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936723|NCT05564715|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The subjects will be informed that sham and active HD-tDCS will be used in the study, but they will be masked to condition in Phase 1. Aside from the PI, other study team members who perform assessments will be masked to HD-tDCS condition. Questionnaires will be completed examining how well the participants and outcomes assessors were blinded in Phase 1. During Phase 2, individuals who were assigned to the sham condition will be unblinded following all assessments as they will be given the option to return for the active condition. Study team members will become unblinded as a result.|In Phase 1, there will be two treatment arms (active and sham). All subjects will have the option to complete active stimulation of HD-tDCS. Those assigned to the sham condition group will have the option to return for active treatment in Phase 2. Each HD-tDCS condition is comprised of 10 days of active or sham stimulation targeting the pre-SMA (supplemental motor area)/sACC (subgenual anterior cingulate cortex) followed by neuropsychological testing after completion of the last session.|t|f|f|t
33936724|NCT00000368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936725|NCT03663972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Young children (age 4-5) and Old children (age 7-8) will be enrolled in either a Motoric behavioral treatment arm or phonological treatment arm.||||
33936726|NCT00984152|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936727|NCT02640924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936728|NCT02010931|||COHORT||RETROSPECTIVE|||||||
33936729|NCT02010567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936730|NCT04803916|||COHORT||PROSPECTIVE|||||||
33936731|NCT04043221|||OTHER||RETROSPECTIVE|||||||
33936732|NCT03631849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015439|NCT01956695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015440|NCT04831372|RANDOMIZED|PARALLEL||TREATMENT||NONE|"BLINDING: none It is impossible to blind the surgeon to the arm as the techniques and instruments required for on-table vs off-table are substantially different. All subjects will be patients of Dr. Owen and he is the only operating surgeon for this study.~The patient will see the beds when they are rolled into the operating room and are positioned. Thorough informed consent will make it apparent which table they are using."|"Primary Objectives- Determine whether there is a difference in operating room efficiency when preparing for, positioning, performing and turning over an operating room after a total hip arthroplasty (THA) via the direct anterior approach (DAA) when using a purpose built traction table (On-Table) vs a standard operating table (Off-Table)?~Secondary Objective- Examine whether there is a difference in early post-operative pain, mobilization, complication rates and clinical outcomes when comparing patients who underwent a THA via the DAA when using an On-Table vs Off-Table technique."||||
34015441|NCT05417503|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34015442|NCT05467046|||COHORT||PROSPECTIVE|||||||
34015443|NCT04779541|||COHORT||RETROSPECTIVE|||||||
34015444|NCT05255926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015445|NCT03160157|||COHORT||PROSPECTIVE|||||||
34015446|NCT06240715|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Cluster Randomized Crossover|f|f|f|t
34015447|NCT01215513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015448|NCT04312269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessors and participant are blinded to groups.||t|f|f|t
34015449|NCT06434922|RANDOMIZED|PARALLEL||PREVENTION||NONE|The investigators known the groups.|"Intervention group: patient education covered various aspects, including regular monitoring of blood glucose levels, effective dietary management, consistent physical activity, routine foot inspections, adherence to prescribed medications, and appropriate footwear selection based on plantar foot pressure measurements.~During the intervention procedure, data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.~Control group: Patients were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets."||||
34015450|NCT03604107|||COHORT||PROSPECTIVE|||||||
34015451|NCT05820867|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015452|NCT03251274|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||machine bathing group traditional bathing group||||
34015453|NCT03533127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The subjects will receive the treatment with LY01008 or bevacizumab combined with paclitaxel and carboplatin for 4-6 cycles, and then both groups of subjects will receive the maintenance monotherapy with LY01008|t|f|t|f
34015454|NCT05307887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015455|NCT05619055|||CASE_CONTROL||RETROSPECTIVE|||||||
34015456|NCT05369468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|both investigator and outcome assessor do not know in which group is the patient||f|f|t|t
34015457|NCT00206765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34098100|NCT03921437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Adopting the method of unnamed, the analysis uses de-named coding, who will not know who the respondent is.|A random 1:1 assignment was made using a random number table to generate a sequence, and the participants were randomly divided into an experimental group and a control group.|f|f|f|t
34098101|NCT05560529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098102|NCT01217515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098103|NCT00274794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098104|NCT03693378|||COHORT||PROSPECTIVE|||||||
33713216|NCT05438056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled interventional research||||
33713217|NCT00885391|||COHORT||PROSPECTIVE|||||||
33713218|NCT04404374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098105|NCT00072579||||TREATMENT||NONE||||||
34098106|NCT03749863|NA|SINGLE_GROUP||TREATMENT||NONE||Serial monthly vocal fold injections with PRP for total of 4 injections.||||
34098107|NCT05783050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|computer-assisted randomization method||t|f|f|f
34098108|NCT04102982|RANDOMIZED|PARALLEL||OTHER||NONE||"Arm 1：Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days.~Arm 2：Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days."||||
34098109|NCT00841074|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098110|NCT00851136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098111|NCT04171310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098112|NCT06237127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098113|NCT01185366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33713219|NCT00002416||||TREATMENT||||||||
33713220|NCT00989378|||COHORT|||||||||
33713221|NCT03983291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||For six weeks one arm receives the FaReWell Depression intervention and one arm receives a control resting intervention. The former arm continues on the FaReWell Depression intervention while the latter arm is switched to the FaReWell Depression intervention for another six weeks.|f|f|f|t
33713222|NCT03856164|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33713223|NCT04027712|||CASE_ONLY||PROSPECTIVE|||||||
33713224|NCT02235480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713225|NCT04691453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713226|NCT02850029|||COHORT||PROSPECTIVE|||||||
33793516|NCT04517318|||COHORT||RETROSPECTIVE|||||||
33793517|NCT05027178|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Data analysis - single blinded||f|f|f|t
33793518|NCT02899286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793519|NCT05272124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study is single blinded Randomized control Trials.patients are randomly allocated into two groups through lottery method.|Two groups are formed. Control group and Experimental group.|t|f|f|f
34098114|NCT02131493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098115|NCT02272010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793520|NCT05209880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793521|NCT00476333|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793522|NCT00612937|||||PROSPECTIVE|||||||
33793523|NCT00325013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098116|NCT03730701|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936733|NCT03429166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The current study proposes a blending of design components of clinical effectiveness and implementation research for the purposes increasing translational gains and providing useful information to inform future implementation that would otherwise not be available or take much longer to obtain. This Hybrid Type 1 design combines a randomized clinical effectiveness trial with a mixed-method, multi-stakeholder process evaluation of the delivery of the intervention.|f|f|f|t
33936734|NCT00397449|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33936735|NCT01970735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936736|NCT02141529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936737|NCT00926562|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936738|NCT05594667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936739|NCT00381706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936740|NCT02094196|||COHORT||RETROSPECTIVE|||||||
33936741|NCT00896662|||CASE_ONLY||PROSPECTIVE|||||||
34098117|NCT06401109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098118|NCT01567020|||CASE_CONTROL||PROSPECTIVE|||||||
33713227|NCT05499312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713228|NCT04978740|NA|SINGLE_GROUP||SCREENING||NONE||||||
33713229|NCT03347877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713230|NCT01033591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713231|NCT03256877|||COHORT||PROSPECTIVE|||||||
33713232|NCT05284214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713233|NCT03364023|||COHORT||PROSPECTIVE|||||||
33793524|NCT01500395|||CASE_ONLY||PROSPECTIVE|||||||
34098119|NCT03295279|||COHORT||RETROSPECTIVE|||||||
34098120|NCT04285684|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||4 subjects receiving 0.5mg/kg and 1.0mg/kg of ketamine at least 5 days apart with collection of breast milk by pumping at 3 hour intervals||||
34098121|NCT06334315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098122|NCT02798952|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098123|NCT00160615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).||||
33793525|NCT05675956|RANDOMIZED|CROSSOVER||OTHER||SINGLE|This will be a single-blind study, the investigators will know which condition subjects are assigned at which visit.|Participants will participate in both arms of the intervention.|t|f|f|f
34098124|NCT02740582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34098125|NCT05540067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded raters will conduct interviewer-rated assessments of anxiety and depression (primary outcomes)|This is a 2-arm RCT.|f|f|f|t
33793526|NCT03101436|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Phase I: Intervention with Diet (Extra Virgin Olive Oil) Washout Period Phase I: Intervention with Diet (Red Wine)||||
34098126|NCT06369051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33793527|NCT00221234|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33793528|NCT01326130|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098127|NCT03292978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33936742|NCT06246864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized control experimental trial|t|f|f|f
34098128|NCT05616780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936743|NCT02502240|||CASE_ONLY||OTHER|||||||
33936744|NCT00004064|RANDOMIZED|||TREATMENT||||||||
34098129|NCT06279988|||COHORT||PROSPECTIVE|||||||
33936745|NCT02310724|||COHORT||PROSPECTIVE|||||||
33936746|NCT00088595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936747|NCT02309268|||CASE_ONLY||PROSPECTIVE|||||||
33936748|NCT05275127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936749|NCT05124600|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33936750|NCT05061758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blinded, randomized, placebo controlled, multi center efficacy phase 2 study|t|t|t|t
33936751|NCT02901106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936752|NCT02545049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936753|NCT00424099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33936754|NCT06037265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936755|NCT05392101|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Phase II open label interventional pilot study. It is a mono-center cohort study||||
33936756|NCT01849328|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936757|NCT03667391|||COHORT||PROSPECTIVE|||||||
33936758|NCT05898854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Twenty consecutive patients newly diagnosed with gastric or gastro-esophageal junction cancer are recruited.||||
33936759|NCT04239573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936760|NCT04809649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936761|NCT00394277|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33936762|NCT03685643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936763|NCT04921969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936764|NCT00646191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936765|NCT02822924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936766|NCT03644173|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33936767|NCT05773716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936768|NCT05703490|||COHORT||PROSPECTIVE|||||||
34015458|NCT05289128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
34015459|NCT01372241|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33793529|NCT00842257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793530|NCT06251193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098130|NCT05250440|||COHORT||PROSPECTIVE|||||||
33793531|NCT04382365|NA|SINGLE_GROUP||OTHER||NONE||||||
34098131|NCT05397405|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793532|NCT00255437|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793533|NCT02336776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793534|NCT01257074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015460|NCT02053675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936769|NCT00106366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936770|NCT05299216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936771|NCT01785914|||CASE_ONLY||RETROSPECTIVE|||||||
33936772|NCT00428285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015461|NCT05314894|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34015462|NCT00435396|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34015463|NCT04764136|||COHORT||PROSPECTIVE|||||||
34015464|NCT00267345|||CASE_CONTROL||PROSPECTIVE|||||||
34015465|NCT01193738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34015466|NCT03795714|||CASE_ONLY||RETROSPECTIVE|||||||
34015467|NCT05492370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015468|NCT00105573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015469|NCT04125121|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participants will not be present during randomisation. The participants will be anaesthetised when the investigational drug (maintenance anaesthetic) is administered, and will thus not be aware what type of anaesthesia is administered in which (otherwise identical) session.|Randomisation to one of two options in session 1: sevoflurane or propofol. In session 2, the remaining option is administered.|t|f|f|t
34015470|NCT03928314|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Standard 3+3 dose escalation design, followed by dose expansion||||
34015471|NCT04570397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015472|NCT04158661|||CASE_CONTROL||OTHER|||||||
34015473|NCT03185013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015474|NCT01298401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015475|NCT03301532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015476|NCT03375294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015477|NCT03165877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34015478|NCT00534014|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34015479|NCT02691793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015480|NCT00311311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015481|NCT04149886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015482|NCT00838708|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34015483|NCT05889234|||COHORT||PROSPECTIVE|||||||
34015484|NCT01152866|||COHORT||PROSPECTIVE|||||||
34015485|NCT05531188|||COHORT||PROSPECTIVE|||||||
34015486|NCT02088190|||COHORT||PROSPECTIVE|||||||
34015487|NCT01153230|||||CROSS_SECTIONAL|||||||
34015488|NCT01616953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793535|NCT06368089|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomization||||
33793536|NCT00612391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793537|NCT00968448|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33793538|NCT05452681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33793539|NCT01412619|||||PROSPECTIVE|||||||
33793540|NCT04925492|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Population of adult Sickle Cell patients.||||
33936773|NCT00536094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33936774|NCT04837690|||CASE_ONLY||PROSPECTIVE|||||||
33936775|NCT05143736|||COHORT||PROSPECTIVE|||||||
34015489|NCT03119506|||COHORT||CROSS_SECTIONAL|||||||
34015490|NCT04993677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015491|NCT06148571|||COHORT||OTHER|||||||
34015492|NCT05824741|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot study is being conducted to inform feasibility of the next phase of this research project.||||
34015493|NCT00794391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34015494|NCT05964192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015495|NCT01462318|NA|SINGLE_GROUP||OTHER||NONE||||||
34015496|NCT02801084|NA|SINGLE_GROUP||OTHER||NONE||||||
34015497|NCT04078438|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015498|NCT00631852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015499|NCT05372783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015500|NCT03256084|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793541|NCT04258358|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"The factorial model examines the effect of using technology (telehealth) and learning and development resources on the cost of delivering dementia care and the well being of people living with dementia, family carers and staff delivering care.~The learning and development resources hosted in an accessible repository will comprise three modular training modules at three different levels of healthcare professionals, carers and the public. The training modules include principles of CASCADE, person centred leadership and learning climate (giving and receiving feedback).~Technology"||||
34015501|NCT05051202|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34015502|NCT00046631|||COHORT||PROSPECTIVE|||||||
34015503|NCT03138447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The design of this protocol involves a prospective and retrospective cohort. The prospective cohort includes 30 participants. In the retrospective chart review, participants will be matched to the prospective group for age, gender, and baseline A1C. (For this study, the use of the word 'matched' means that the retrospective patient charts will be matched as close as possible from available patient data within the Bay West Endocrinology medical record database and may not always be an exact match to the prospective group for age, gender, and baseline A1c.) The chart review will thus be conducted after the last subject is enrolled in the prospective arm of the study.||||
34015504|NCT00000607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793542|NCT04519671|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single||t|f|f|f
33793543|NCT04928053|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793544|NCT01229358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793545|NCT03330418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793546|NCT01025843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015505|NCT01131572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015506|NCT03074747|||CASE_ONLY||PROSPECTIVE|||||||
34015507|NCT01472328|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34098132|NCT03466164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||discordant twin design||||
34098133|NCT06281002|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34098134|NCT05508594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098135|NCT05012969|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33793547|NCT02021799|NON_RANDOMIZED|PARALLEL||||NONE||||||
33793548|NCT01418391|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33793549|NCT00732381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793550|NCT03353116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793551|NCT02874430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793552|NCT02639013|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793553|NCT06676644|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33793554|NCT00929617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793555|NCT03747354|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793556|NCT00636064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793557|NCT00000919||||TREATMENT||DOUBLE||||||
34015508|NCT05701644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015509|NCT06214533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015510|NCT03054259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015511|NCT02214368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015512|NCT04262661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|Part 1: Single ascending dose, placebo control. Part 2: Multiple ascending dose design, active control.|t|t|t|t
34015513|NCT00114621||||TREATMENT||||||||
34015514|NCT02485730|||COHORT||PROSPECTIVE|||||||
34015515|NCT00004734|RANDOMIZED|||PREVENTION||DOUBLE||||||
34015516|NCT00973518|||COHORT||PROSPECTIVE|||||||
34015517|NCT04076670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34015518|NCT01457261|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015519|NCT02140866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015520|NCT01997229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015521|NCT05422430|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34015522|NCT03841890|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Sore throat and mucosa injury are documented by a blinded observer on the next day.||t|f|f|f
34015523|NCT00564226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015524|NCT03633448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098136|NCT05703412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098137|NCT01047176|||CASE_ONLY||PROSPECTIVE|||||||
33793558|NCT01521013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793559|NCT02813486|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33793560|NCT05245825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793561|NCT03922412|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33793562|NCT02572219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793563|NCT02734056|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was possible.|||||
33793564|NCT06289348|||COHORT||PROSPECTIVE|||||||
33793565|NCT04812938|||COHORT||RETROSPECTIVE|||||||
33793566|NCT00842049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793567|NCT03091010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098138|NCT05154929|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicenter 6 month randomized controlled clinical trial. This study will investigate the efficacy of two just-in-time adaptive interventions (JITAIs) delivered via a mobile app for patients with hypertension. Eligible participants will be randomized to the two JITAIs or control in a 1:1 manner stratified by site. There will be two sites: the University of Michigan Health System in Ann Arbor and the Hamilton Community Health Network Clinic in Flint.||||
34015525|NCT05968534|NA|SINGLE_GROUP||OTHER||NONE||"Mother AdvocateS In the Community (MOSAIC) Plus intervention to reduce depressive and PTSD symptoms and prevent additional IPV among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate IPT principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."||||
34015526|NCT06213714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015527|NCT01856036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098139|NCT01115010|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34098140|NCT05414747|RANDOMIZED|PARALLEL||TREATMENT||NONE||ABV-1701 Ocular Endotamponade||||
34098141|NCT01041105|||COHORT||RETROSPECTIVE|||||||
34098142|NCT05655572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098143|NCT05460988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098144|NCT00491023|||||RETROSPECTIVE|||||||
34098145|NCT03508453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy preparation of identical-appearing placebo|Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
34098146|NCT06293859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098147|NCT02303938|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34015528|NCT05777759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015529|NCT05953766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The surgeon, research team, participants and data analysts will be blinded to treatment group. Our clinic nurse, who works 5 days per week in our ambulatory office and who will have no other role in this study, will prepare the active and placebo syringes and label the syringes according to the randomization list. Each syringe will be prepared individually and provided to the surgeon on the day of surgery. Study participants will be randomized on the day of surgery. The surgeon will instill the drug/placebo from the labeled syringe into the presacral space as the first step prior to starting the hysterectomy.|We will create a randomization list using a computer-generated allocation sequence in equal ratio with study numbers 1 to 60.|t|t|t|t
34098148|NCT06465901|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants should be randomised by a member of the research team who will not be performing the any aftercare, including trial-specific follow-up assessment(s). The follow-up assessor at 30 days will therefore be blinded to treatment allocation until after the completion of follow-up. Unless otherwise instructed by a research ethics committee, the operative notes should not include details of the specific intervention used.|Pragmatic, outcome assessor blinded, stratified, international multi-centre, multi-arm multi-stage 2x2x2 factorial randomised controlled trial, with internal pilots. Strata are defined according to the anticipated category of wound contamination: (1) clean-contaminated and (2) contaminated or dirty.|f|f|f|t
34098149|NCT00284934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098150|NCT03682393|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study is double blinded, neither the patients or investigators or nurses managing the drugs do not know whether the patient receives placebo (isotonic saline) or active drug (corticosteroid). In case of emergency the codes can be cracked.|half of the recruited patients will receive intravenous corticosteroid and the other half will receive intravenous isotonic saline as placebo|t|t|t|f
34098151|NCT03766698|||OTHER||CROSS_SECTIONAL|||||||
34098152|NCT01128920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098153|NCT05538650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34098154|NCT01554852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098155|NCT05507216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098156|NCT02882178|||OTHER||OTHER|||||||
34098157|NCT02920567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098158|NCT05414942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098159|NCT06430762|||OTHER||PROSPECTIVE|||||||
34098160|NCT02334410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098161|NCT05085405|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||"Assignment to one of two clinician-level implementation strategies will be done at the cluster level according to the identity of the clinician to be contacted. Clinicians will be randomized 1:1 to receive either clinician notification (CN) or clinician notification + nurse facilitation (CN+NF). Patients within each clinician cluster will also be individually randomized to receive a patient activation guide or to a usual care arm.~There are 2 arms for each group (patients and clinicians)."||||
34098162|NCT00378560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34098163|NCT04168138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793568|NCT05502458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|By statistical professionals using SAS software on the computer, according to the propofol group and halothane group the proportion of 1:1, to patients by ASA classification, disease category, coexist, the condition of the body after stratified according to stratified random methods such as random coding, in this study, each participant will be according to the center of the random number sequence into the propofol group and halothane group|"Propofol general anesthesia group (P group) : intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained at 4-8 mg/kg/h.~In the general anesthesia group with desflurane (group D), intravenous propofol infusion was slowly pushed until consciousness disappeared, and then anesthesia was maintained with 4-6% desflurane"|t|t|f|f
33793569|NCT05936671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, medical staff who measure outcome variables, surgeons and nurses in the recovery room and wards are blinded so that medical staff and patients do not know the patient's assigned group.|Prospective, single-blinded, parallel-group, randomized clinical study|t|f|t|t
34098164|NCT01166945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34098165|NCT01805570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098166|NCT00854854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098167|NCT00928005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793570|NCT05250141|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098168|NCT03622931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||74 patients (about 37 in the experimental and 37 in the placebo arm), evaluable for the principal efficacy endpoint, are required. These will be recruited from an expected number of 15 sites.|t|f|t|f
33793571|NCT00143234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793572|NCT01872403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793573|NCT04266951|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE||Pilot study: Pre and post intervention with a single patient cohort.|t|f|f|t
33793574|NCT00920257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793575|NCT04325048|||COHORT||PROSPECTIVE|||||||
33793576|NCT02997280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793577|NCT01918644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793578|NCT00535977|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33793579|NCT02110056|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33793580|NCT05657041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, experimental study||||
34015530|NCT03330912|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single subject - participants will be compared to themselves. STROBE guidelines will be followed.||||
34015531|NCT04243408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization will be done by external source and the assignment will disclosed to cord bank bank only. They will produce either a cord blood or placebo unit which will be completely covered. Each unit will have its own index number that will be documented by the research coordinator. Neither the researcher or the family will know the nature of the unit.|"This study is a phase II, prospective, double blind, placebo-control study of the efficacy of autologous umbilical cord blood infusion.~The study population will consist of 72 children ages 2 months to 12 years with cerebral palsy. The population will be randomly assigned to 2 groups, the study group be treated by cord blood in the beginning of the study and the control group by placebo product.~The study population will be stratified to reduce variance 3 groups by age: 2-12 months / 1-6 years / 6-12 years The study will consist of 4 stages Stage 1: initial assessment by physiotherapist and occupational therapist / treatment by cord blood or placebo / blood work before and after treatment Stage 2: at stage 1 + 3 months assessment by physiotherapist and occupational therapist Stage 3: at stage 1 + 6 months assessment by physiotherapist and occupational therapist"|t|t|t|t
34015532|NCT03407430|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Double-blind|placebo-controlled, double blind, randomized crossover trial|t|t|t|t
33793581|NCT02708199|||COHORT||PROSPECTIVE|||||||
34015533|NCT00423995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793582|NCT06431516|||COHORT||PROSPECTIVE|||||||
34015534|NCT03046134|||COHORT||PROSPECTIVE|||||||
33793583|NCT06325761|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793584|NCT04091152|||COHORT||PROSPECTIVE|||||||
34015535|NCT01690221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015536|NCT03831763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015537|NCT02724865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025381|NCT04504123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Over encapsulation with opaque purple capsule|Doxycycline Hyclate 50 mg versus placebo capsule|t|t|t|t
34098169|NCT02425176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098170|NCT03335267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098171|NCT00743262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098172|NCT05706402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a double-blind randomised controlled trial on NAC as an adjunctive treatment for acute COPD exacerbation. The randomization will be done via computer software with half of the patients randomized to received oral NAC (600 mg twice daily) and half receive placebo, with randomization ratio being 1 to 1. Patients in the two randomised group will be asked to participate in the study for a maximum of 1 week.|t|f|t|f
34098173|NCT02965131|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34098174|NCT04557345|||COHORT||OTHER|||||||
34098175|NCT02386579|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34098176|NCT02039570|||CASE_ONLY||PROSPECTIVE|||||||
34098177|NCT02145611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098178|NCT01108796|||COHORT||PROSPECTIVE|||||||
34098179|NCT03607136|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098180|NCT05357170|||COHORT||PROSPECTIVE|||||||
34098181|NCT06502080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793585|NCT01392313|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33793586|NCT04577014|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33793587|NCT00662480|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34098182|NCT02106559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793588|NCT01325142|||CASE_CONTROL||RETROSPECTIVE|||||||
33793589|NCT03417492|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-placebo controlled||||
33793590|NCT01288326|||COHORT||PROSPECTIVE|||||||
33793591|NCT03047083|||COHORT||RETROSPECTIVE|||||||
33793592|NCT06636929|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015538|NCT05500716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed about which treatment was given in the other group.|All groups will be involved physical therapy and both groups will have traditional rehabilitation program for TMD. Only the group 1 will also have auricular non-invasive vagus nerve stimulation.|t|f|f|f
34015539|NCT03660241|NA|PARALLEL||BASIC_SCIENCE||NONE||Part 1 will be conducted. The 8 subjects from the renal impaired group will be recruited before recruiting the 8 subjects without renal impairment function in Part 1. After statistical evaluation of results from Part 1, Part 2 may be conducted.||||
34015540|NCT05780021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098183|NCT05192785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34015541|NCT02494817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34015542|NCT01140490|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098184|NCT00147537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015543|NCT02907788|||COHORT||PROSPECTIVE|||||||
34015544|NCT00683267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015545|NCT05983913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, parallel-group randomized study|f|f|f|t
34015546|NCT05396131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants diagnosed as either Collateral Ventilation (CV) Negative or CV Positive.~CV Negative participants will only receive the endobronchial valves (EBV). CV Positive participants will receive both the lung sealant and the EBV."||||
34015547|NCT01131793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015548|NCT06332001|||COHORT||PROSPECTIVE|||||||
34015549|NCT05120102|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34015550|NCT03690882|||CASE_ONLY||RETROSPECTIVE|||||||
34098185|NCT01428973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098186|NCT01603511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015551|NCT00014625||||TREATMENT||||||||
34098187|NCT00901095|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34098188|NCT05335265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"Envelope method was used in randomization.~-Each clinic prepared 12 envelopes, 6 of them have a paper with the words VIRTUAL EDUCATION and 6 of them CLASSIC EDUCATION. The patient was asked to draw one of these mixed envelopes. The form of education in the envelope was applied to the patient."|"Patients randomized according to a simple random numbers table, half of the patients received video-mediated virtual inhaler training (which is published on the Turkish Thoracic Society's official site and with permission for use obtained) and the other half received classical face-to-face inhaler training.~Envelope method was used in randomization.~-Each clinic prepared 12 envelopes, 6 of them have a paper with the words VIRTUAL EDUCATION and 6 of them CLASSIC EDUCATION. The patient was asked to draw one of these mixed envelopes. The form of education in the envelope was applied to the patient."||||
34098189|NCT04799639|NA|SINGLE_GROUP||TREATMENT||NONE||patients will receive intravenous drip of standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles||||
34098190|NCT05146258|||COHORT||PROSPECTIVE|||||||
33936776|NCT03678506|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The patients included in the study will receive a serial determination of D-dimer assay (a maximum of four determinations in case of negative results).The D-dimer measurements should be performed at the moment of patient screening, when patients still assume their anticoagulant treatment (T0), at 15±2 days (T1), 30±4 days (T2), and 60±5 (T3) days after their anticoagulant treatment has been stopped. At the first positive D-dimer result patients resume anticoagulation with apixaban 2.5 mg bis in die for the next 18 months. Patients with negative D-Dimer results at all determinations stop anticoagulation definitely and will followed up for the next 18 months.||||
33936777|NCT03483012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015552|NCT03762551|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34015553|NCT00399971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015554|NCT03196414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015555|NCT01742780|RANDOMIZED|PARALLEL||||NONE||||||
34015556|NCT06213870|||COHORT||RETROSPECTIVE|||||||
34015557|NCT02254369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015558|NCT01908790|||COHORT||PROSPECTIVE|||||||
34015559|NCT00401297|||OTHER||PROSPECTIVE|||||||
34015560|NCT06202924|||COHORT||CROSS_SECTIONAL|||||||
34015561|NCT01338987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015562|NCT03970486|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned into two dry needling treatment groups.||||
34098191|NCT05586100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098192|NCT02801227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098193|NCT03348397|||COHORT||RETROSPECTIVE|||||||
33936778|NCT04367649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713234|NCT04081168|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stereotactic Body Radiotherapy vs. Microwave Ablation||||
33936779|NCT02599324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713235|NCT02101476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936780|NCT04647695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936781|NCT06194721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936782|NCT03704090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients were randomized in 16 blocks of 10 patients and only one investigator has the randomized information. This researcher will not have any role in the recruitment, intervention, and diagnosis of postoperative delirium. Also, the analysis of data will be performed by researchers who will be masked to the randomization information.|"Elderly patients who will undergo major surgery will be randomized to 2 prevention groups of postoperative delirium:~1. Control: standard non-pharmacological prevention measures for 5 days after surgery.~2. Intervention: occupational therapist plus standard non-pharmacological prevention measures for 5 days after surgery."|f|t|t|f
33936783|NCT02468804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33936784|NCT01641341|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33713236|NCT03851068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936785|NCT05557240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936786|NCT02875366|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33936787|NCT00906932|||||PROSPECTIVE|||||||
33936788|NCT04387591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936789|NCT01609491|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33936790|NCT01353066||||TREATMENT||||||||
33936791|NCT06355466|||CASE_ONLY||PROSPECTIVE|||||||
33936792|NCT04262557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936793|NCT05823428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015563|NCT00466908|||CASE_CONTROL||RETROSPECTIVE|||||||
34015564|NCT02880657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34015565|NCT04208074|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34015566|NCT03012672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015567|NCT03096626|||CASE_ONLY||RETROSPECTIVE|||||||
34015568|NCT02466230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025382|NCT04611633|||COHORT||PROSPECTIVE|||||||
34098194|NCT01159184|||CASE_ONLY||PROSPECTIVE|||||||
34098195|NCT00118859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098196|NCT00281580|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34098197|NCT03008577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098198|NCT06354543|||COHORT||OTHER|||||||
34098199|NCT03854448|||COHORT||PROSPECTIVE|||||||
34098200|NCT06208163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098201|NCT06505642|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713237|NCT00660998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713238|NCT01661621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713239|NCT03234686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33713240|NCT00039832||||TREATMENT||||||||
33713241|NCT03778125|||COHORT||PROSPECTIVE|||||||
33713242|NCT01856413|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713243|NCT01355341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713244|NCT03571152|NA|SINGLE_GROUP||OTHER||NONE|No masking.|Pre-experimental study design The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.||||
33713245|NCT02693925|||COHORT||CROSS_SECTIONAL|||||||
33713246|NCT03554746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713247|NCT04140591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713248|NCT01492244|||COHORT||PROSPECTIVE|||||||
33713249|NCT04155060|||COHORT||RETROSPECTIVE|||||||
33713250|NCT01235247||||HEALTH_SERVICES_RESEARCH||||||||
33713251|NCT01260636|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33713252|NCT01612936|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713253|NCT04048694|||COHORT||PROSPECTIVE|||||||
33713254|NCT05798169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713255|NCT03095014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cesarean Myomectomy||||
34015569|NCT06124274|RANDOMIZED|CROSSOVER||OTHER||NONE||This study uses a 4-way counterbalanced crossover design. A total 10 young women (Ages: 18-35 years old; 5 per OC and non-OC group) will be recruited and randomized to begin in either the mid-follicular (7-11 days after the onset of menses) or mid-luteal phase (5-9 days after ovulation) if part of non-OC group; and active pill (10-20 days within starting their new pill cycle) or withdrawal phase (at least 48hrs after their last pill) if part of the OC group. Participants of each group will take part in two metabolic trials, one in each phase of their menstrual cycle or pill cycle.||||
34015570|NCT01474902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015571|NCT03602443|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The study is a randomized, wait-list, cross-over design pilot feasibility trial.|f|f|f|t
34098202|NCT04874207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098203|NCT04822909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098204|NCT06081465|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Eligible subjects will be sequentially enrolled cohort by cohort. In each cohort, subjects will be randomized to receive VG290131 or matching placebo, respectively.|"The study consists of three parts: a single ascending dose (SAD) part, a multiple ascending dose (MAD) part and a food effect (FE) part. The FE study is incorporated as part of the SAD study. Approximately 86 subjects will be enrolled in the study.~SAD+FE study: 6 cohorts (1, 5, 25, 50, 100, and 200 mg), 8 subjects in each cohort, except that there are 14 subjects in the 5 mg cohort, which is the FE study cohort.~MAD study: 4 cohorts (1, 5, 25, and 100 mg), 8 subjects in each cohort."|t|f|t|f
34098205|NCT06056570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098206|NCT04674904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098207|NCT06128226|||COHORT||PROSPECTIVE|||||||
34098208|NCT03254147|||COHORT||RETROSPECTIVE|||||||
34098209|NCT02099591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098210|NCT06484517|||CASE_CONTROL||PROSPECTIVE|||||||
34098211|NCT05029362|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098212|NCT04329806|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34098213|NCT06539377|NA|SINGLE_GROUP||TREATMENT||NONE||Curative treatment of unresectable intrahepatic cholangiocarcinoma via living donor donation and one- or two-staged hepatectomy||||
34098214|NCT03556280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34098215|NCT02173366|NA|SINGLE_GROUP||PREVENTION||||||||
34098216|NCT04135443|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Participants are randomly assigned to their condition without being made aware of their assigned condition as attention control or intervention. Each condition accesses materials online."|This is a two arm randomized controlled trial. Upon completing a baseline survey participants will be randomized into the intervention or an attention control condition. After randomization, participants will be granted access to their assigned mobile app (3T app or a general health website).||||
34098217|NCT05816473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34098218|NCT05948982|NA|SEQUENTIAL||TREATMENT||NONE||||||
34098219|NCT03967665|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098220|NCT02111356|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098221|NCT05629338|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|For Cohorts 1 and 2, blinding is not necessary because subjects will only receive a single infusion of FrontlineODP. Cohort 3 subjects will be randomly assigned to a treatment sequence and will remain blinded to the study product they receive at each visit. Study participants, the Principal Investigators, the Independent Medical Monitor, and the Data Monitoring Committee will be blinded to the randomization treatment assignments throughout the study.|This study in healthy volunteers (n=24) is designed to assess the safety of infusing ascending doses of reconstituted autologous FrontlineODP in 1, 2, and 4 fixed-dose units. Subjects in Cohort 1 (n = 6) will receive 1 unit of FrontlineODP (Arm 1), which is approximately 200 mL. Subjects in Cohort 2 (n = 6) will receive 2 FrontlineODP units (Arm 2) (total volume of approximately 400 mL). Cohort 3 is a crossover design where subjects (n = 12) will be randomly assigned to receive either 4 units of FrontlineODP followed 14 days later by 4 units of PF24 (Arm 3 - ODPxPF24), or 4 units of PF24 followed 14 days later by 4 units of FrontlineODP (Arm 4 - PF24xODP), where each infusion has a total volume of approximately 800 mL.|t|t|t|t
34098222|NCT03325257|||COHORT||RETROSPECTIVE|||||||
34098223|NCT00756444|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098224|NCT06265610|||CASE_CONTROL||PROSPECTIVE|||||||
34098225|NCT04885712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098226|NCT05994534|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098227|NCT03315689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098228|NCT00001215|||COHORT||PROSPECTIVE|||||||
34103335|NCT04804007|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients who completed HDCT+PBSCT within the past 16 weeks will enroll and randomize in 1:1 fashion in blocks of 8 to maintenance daily oral etoposide 50mg vs. observation only.~Randomization will be stratified based on:~-Presence of platinum refractory disease status defined by radiographic or serologic progression within 4 weeks of first-line cisplatin-based combination chemotherapy: yes vs. no"||||
34103336|NCT03049397|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103337|NCT00421408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103338|NCT03655639|||COHORT||PROSPECTIVE|||||||
34103339|NCT04486885|||COHORT||RETROSPECTIVE|||||||
34015572|NCT01401257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015573|NCT05324826|||CASE_ONLY||PROSPECTIVE|||||||
33713256|NCT03006991|||COHORT||RETROSPECTIVE|||||||
33713257|NCT03907553|||COHORT||RETROSPECTIVE|||||||
33713258|NCT01479517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713259|NCT01502059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713260|NCT01554150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713261|NCT01823185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936794|NCT03581565|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936795|NCT05546086|||COHORT||PROSPECTIVE|||||||
33936796|NCT02807194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936797|NCT06414616|||COHORT||CROSS_SECTIONAL|||||||
33936798|NCT01742039|||COHORT||PROSPECTIVE|||||||
33936799|NCT01742663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936800|NCT00218569|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33936801|NCT03013426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936802|NCT00608894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936803|NCT05714852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936804|NCT02105168|NA|SINGLE_GROUP||SCREENING||NONE||||||
33936805|NCT02463331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936806|NCT04614194|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33936807|NCT00263406|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936808|NCT04420065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and assessor unaware of chosen programming mode and activated algorithms. The standard of care that is biventricular pacing will be provided to all participants.|Patients randomized after enrollment to receive either standard biventricular pacing, or preferential left ventricular pacing (left ventricle will be resynchronized, but right ventricle will be activated through the intrinsic conduction system)|t|f|f|t
33936809|NCT00836316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936810|NCT04507516|||COHORT||PROSPECTIVE|||||||
33936811|NCT02640430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936812|NCT05063760|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|lab technicians and statistician are blinded.|controled trial with exercise intervention|f|f|t|t
33936813|NCT03564210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936814|NCT04605068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masking (Participant, Investigator)|144 patients will be randomly divided (using the computer-generated randomization table) into two equal groups, each will include 72 patients; Group I will undergo transverse preputial island flap (Duckett's technique) and Group II will undergo double-faced preputial flap (DFPF).|t|f|t|f
33936815|NCT04959786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936816|NCT04957745|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants in the group will see all three interventions (peripheral targets in three visual confusion conditions) in a randomized order. In this study design, each participant will serve as their own control, and the order of the interventions will be randomized to account for potential carryover or ordering effects. There will be no comparison or control group. The outcome will be compared through a within-subject analysis.||||
33936817|NCT01628458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936818|NCT03896087|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33936819|NCT04139603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936820|NCT05237414|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||BDs will be randomly distributed for one of three training conditions: Combined Training (i.e, active tDCS and active CT), Cognitive Training (i.e., sham tDCS and active CT), and Control (i.e., sham tDCS and sham CT).|t|t|f|t
33936821|NCT04249791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936822|NCT01808040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936823|NCT04995731|||CASE_ONLY||CROSS_SECTIONAL|||||||
33936824|NCT05116111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936825|NCT04786639|||COHORT||CROSS_SECTIONAL|||||||
33936826|NCT04428762|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"This is a multi-center,2 parts study:~the first part: randomized crossover study second part: prospective follow-up study"||||
33936827|NCT03324867|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33936828|NCT01469299|||COHORT||PROSPECTIVE|||||||
33936829|NCT03431623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, multi-center, phase 3 clinical trial|t|t|t|t
33936830|NCT01406366|||COHORT||CROSS_SECTIONAL|||||||
33936831|NCT00417391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936832|NCT04021706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double blind randomized controlled clinical trial|t|f|t|t
33936833|NCT04976309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936834|NCT00403390|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936835|NCT03887975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Completely edentulous patients|t|t|t|t
34015574|NCT06225557|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||follow ERAS society guidelines recommendations in elective CESAREAN SECTION|t|f|t|f
34015575|NCT03265613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015576|NCT06289803|NA|SINGLE_GROUP||TREATMENT||NONE||Patients diagnosed with pancreatic tumours will undergo surgical resection, and PCLE will be used for identifying the behaviour of tumours (benign or malignant neoplasms) and predicting the status of resection margin.||||
34015577|NCT06411587|||CASE_CONTROL||OTHER|||||||
34015578|NCT05080647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015579|NCT00286819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015580|NCT06412588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713262|NCT05028920|||COHORT||CROSS_SECTIONAL|||||||
33713263|NCT02227758|||CASE_ONLY||PROSPECTIVE|||||||
33713264|NCT02057406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713265|NCT02602496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713266|NCT04235985|NA|SINGLE_GROUP||OTHER||NONE|This is a cross-over design study where it will only be possible to mask the Outcomes Assessor|Volunteer forearms will be marked with 6 test sites which will be randomly assigned a time point for the application.||||
33713267|NCT05127434|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713268|NCT04962204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Interventional group Control group||||
33713269|NCT03284827|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713270|NCT00958152|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33713271|NCT05885204|||COHORT||RETROSPECTIVE|||||||
33713272|NCT02056340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936836|NCT00648544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33936837|NCT02813434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33936838|NCT00933387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936839|NCT03359551|||COHORT||PROSPECTIVE|||||||
34015581|NCT05106088|||COHORT||PROSPECTIVE|||||||
34015582|NCT03722095|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34015583|NCT02857738|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34015584|NCT00793936|||CASE_CONTROL||PROSPECTIVE|||||||
33936840|NCT02355665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936841|NCT04095962|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936842|NCT01393665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936843|NCT03113799|NA|SINGLE_GROUP||TREATMENT||NONE||In this study the subject will act as their own control and will be treated on day one with the standard of care EVD and then on Day 2 treated with the SED.||||
33936844|NCT01662986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33936845|NCT04825106|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33936846|NCT03746340|||OTHER||OTHER|||||||
33936847|NCT01110928|||COHORT||PROSPECTIVE|||||||
34015585|NCT00888459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015586|NCT02900963|NA|SINGLE_GROUP||OTHER||NONE||||||
34015587|NCT05266820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015588|NCT05733520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The primary investigator and outcome assessor will be masked to the App assignment (Brain CareNotes vs Attention Control App)|Participants will be randomized to receive the Brain CareNotes app or an attention control app.|f|f|t|t
34015589|NCT04872972|NA|SINGLE_GROUP||OTHER||NONE||Before and After approach||||
34015590|NCT06052865|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34015591|NCT03480438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015592|NCT00953108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015593|NCT04860765|||COHORT||PROSPECTIVE|||||||
34015594|NCT05125380|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||The whole cohort is offered an HPV self-sample. The HPV high risk positive women gets randomised into two arms VIA or VIA/VILI at the triage step.|t|f|f|f
34015595|NCT05476107|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-blinded (Part 1), Open Label (Part 2)|Study participants will be randomized to either receive AMT-126 or placebo (Part 1), Radiolabeled tablet (Part 2)|t|t|t|f
34015596|NCT00312819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098229|NCT04746183|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|CST-2: Phase I, open-label EIDD-2801 vs standard of care. Phase II, blinded controlled parallel group of EIDD-2801 vs placebo CST-3A: Phase Ia, open-label nitazoxanide CST-3B: Phase Ib, II, open label nitazoxanide vs standard of care CST-5: Phase I, blinded VIR-7832 vs placebo, Phase II, blinded VIR-7832 vs VIR-7831 vs placebo CST-6: Open label IV favipiravir vs standard of care CST-8: Open label Molnupiravir and Paxlovid® versus standard of care CST-9: Open label ALG-097558 versus ALG-097558 + remdesivir versus standard of care|CST2:Open-label 2:1 randomised controlled phaseI of EIDD-2801 VS standard of care followed by a 1:1 blinded controlled parallel group PhaseII trial of EIDD-2801 VS placebo CST3A:single arm, open-label phase Ia to confirm the optimum dose, safety and tolerability of Nitazoxanide in healthy volunteers CST3B:Openlabel 1:1 randomised controlled phase Ib of Nitazoxanide VS SOC to confirm the safety and tolerability of Nitazoxanide in participants with COVID-19 followed by a 1:1 blinded parallel group Phase II trial of Nitzaoxanide VS SOC CST5:3:1 randomised, blinded, placebo-controlled phase I of VIR-7832, followed by a 2:2:1 blinded, parallel group Phase II trial of VIR-7832 versus VIR-7831 VS placebo CST6:2:1 randomised open-label standard of care controlled phase I IV favipiravir CST8:Open-label 2:1 randomised controlled Phase I de-escalation study of molnupiravir + Paxlovid versus SOC alone CST9:1:1:1 randomised openlabel Phase II of ALG-097558 versus ALG-097558+ remdesivir VS SOC|t|t|t|t
34015597|NCT02895815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015598|NCT03262506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015599|NCT02717559|||COHORT||PROSPECTIVE|||||||
34015600|NCT02824718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098230|NCT04217057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713273|NCT01754610|||COHORT||PROSPECTIVE|||||||
33713274|NCT02547649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33713275|NCT05157984|||OTHER||OTHER|||||||
33713276|NCT05954013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant and care provider (PD_Pal nurse) will not be blinded. The outcome assessor will be blinded.||f|f|f|t
33713277|NCT00671697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713278|NCT02582502|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33713279|NCT05096104|||CASE_ONLY||RETROSPECTIVE|||||||
33713280|NCT03768960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713281|NCT00602342|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33713282|NCT01444118||||||NONE||||||
33713283|NCT03583489|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33936848|NCT02717429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936849|NCT04913792|||COHORT||PROSPECTIVE|||||||
33936850|NCT02664740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936851|NCT01416506|||COHORT||PROSPECTIVE|||||||
34015601|NCT05799027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015602|NCT00558909||||TREATMENT||||||||
34015603|NCT01122290|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34015604|NCT01687348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015605|NCT04554797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33713284|NCT03724955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded|Prospective, double-blinded, randomized, placebo-controlled, interventional|t|f|f|t
33713285|NCT05028478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713286|NCT02187185|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33713287|NCT00440219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713288|NCT01658670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33713289|NCT05104320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936852|NCT05790902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936853|NCT06258265|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34098231|NCT05358912|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be blind to their designated groups.|"Patients in different groups will be subjected to different monitoring protocols.~All will be treated according to designated target values."|t|f|f|f
34098232|NCT06547801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||This study was conducted as a randomized, double-blind, placebo-controlled, parallel arm study. The Human Protection Institutional Review Board (IRB2022-1559F) approved the study following ethical standards for the conduct of human participant research as described in the Declaration of Helsinki.|t|f|f|f
34098233|NCT04792970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098234|NCT03843970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793593|NCT06469684|RANDOMIZED|PARALLEL||SCREENING||SINGLE|"Randomisation done at mosque level. Allocation was not masked from individuals recruiting and delivering the interventions in the mosque.~All participants within the same mosque receive the same intervention. Thus participants are only notified of the session conducted in the mosque they were recruited in.All participants are masked from the sessions conducted in other mosques."|This is a matched pair cluster randomised controlled trial. Mosques in intervention and control arm are matched based on the region. Sessions within the same region (one intervention mosque and one control mosque) run parallel.|t|f|f|f
33793594|NCT02307565|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33793595|NCT03083119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793596|NCT06175572|||COHORT||PROSPECTIVE|||||||
33713290|NCT05937204|NA|SINGLE_GROUP||OTHER||NONE||||||
33713291|NCT04103853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793597|NCT00382161|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33793598|NCT04153435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793599|NCT06677281|||COHORT||RETROSPECTIVE|||||||
33793600|NCT03420209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098235|NCT04796220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098236|NCT06125379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103340|NCT06690346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Intervention group: Systematic oral health education Control group: Routine oral health education|f|f|t|t
33793601|NCT04391283|||CASE_ONLY||PROSPECTIVE|||||||
33793602|NCT04415086|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1 into 3 treatment groups: A- standard (control); B- standard and convalescent plasma in a volume of 200ml (150-300ml); C- standard and convalescent plasma in a volume of 400ml (300-600ml)||||
33793603|NCT00014599||||TREATMENT||NONE||||||
33713292|NCT03421028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713293|NCT06440395|||COHORT||PROSPECTIVE|||||||
33713294|NCT02853110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713295|NCT05264935|||CASE_ONLY||PROSPECTIVE|||||||
33713296|NCT02677467|||COHORT||PROSPECTIVE|||||||
33713297|NCT04771260|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33713298|NCT01139619|||COHORT||RETROSPECTIVE|||||||
33713299|NCT05776199|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33713300|NCT05858762|||OTHER||PROSPECTIVE|||||||
33713301|NCT03383198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only anesthesiologist performing injection will be aware of which side is injected with each drug.||t|t|f|t
33713302|NCT01784458|||COHORT||PROSPECTIVE|||||||
33713303|NCT04338698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Adaptive design (sample size given below is indicative)|f|f|t|t
33713304|NCT04119492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The occupational therapist administering the pre- and post-assessments will be blinded to group assignment|Participants will be randomized to the CO-OP treatment group or the waitlist control group|f|f|f|t
33793604|NCT01353963|||||PROSPECTIVE|||||||
33793605|NCT00910754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793606|NCT02000817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793607|NCT02331004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793608|NCT04014933|||CASE_CONTROL||PROSPECTIVE|||||||
33793609|NCT01750307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793610|NCT02017665|||COHORT||PROSPECTIVE|||||||
33793611|NCT03087084|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33713305|NCT01786798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713306|NCT01925677|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713307|NCT01532778|||COHORT||PROSPECTIVE|||||||
33713308|NCT05371743|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713309|NCT05042167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793612|NCT06454721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793613|NCT05671263|||CASE_CONTROL||PROSPECTIVE|||||||
33793614|NCT00197886|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33793615|NCT01801449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936854|NCT04503473|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Baseline characteristics and training parameters (steps, intensity parameters) will be compared between treatment groups using independent group comparisons. (ANOVA, Kruskal-Wallis, or Chi-squared tests as appropriate).||||
33936855|NCT04008095|||COHORT||PROSPECTIVE|||||||
33936856|NCT05091073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936857|NCT02782364|||COHORT||PROSPECTIVE|||||||
33936858|NCT04849260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936859|NCT01389895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33936860|NCT05206682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936861|NCT03752840|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33936862|NCT00394654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936863|NCT00177606|||||PROSPECTIVE|||||||
33936864|NCT00442611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936865|NCT00104273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936866|NCT01252992|||OTHER||PROSPECTIVE|||||||
33936867|NCT03501381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936868|NCT00716040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936869|NCT01965444|||COHORT||PROSPECTIVE|||||||
33936870|NCT02894892|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34098237|NCT05524909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Group allocation will be concealed from study staff until the 7-day pre-intervention period begins (for preparation of corresponding e-leaflets, genetic risk estimates and/or baseline Fitbit step goal calculations), and from participants until the interventions are delivered. Given the nature of the interventions delivered, it will be impossible for participants to be blinded to the specific intervention they receive once the initial interventions are provided; however, study staff analyzing participants' de-identified data will remain blinded to participant randomization assignment.|parallel-group, open randomized controlled trial|f|f|t|t
34098238|NCT02091830|||COHORT||RETROSPECTIVE|||||||
33713310|NCT06113809|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib||||
33713311|NCT05786885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713312|NCT04625309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713313|NCT00247091|||DEFINED_POPULATION||PROSPECTIVE|||||||
33713314|NCT00465374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713315|NCT02471430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713316|NCT01410032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713317|NCT05601284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713318|NCT01939743|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713319|NCT00302835|||CASE_CONTROL||RETROSPECTIVE|||||||
33936871|NCT03894202|||COHORT||PROSPECTIVE|||||||
33936872|NCT03748875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936873|NCT04615429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936874|NCT04341025|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will take part in a 6-session MBPST group for treatment of situational ED. Each session will be 2 hours in length and will be spaced one week apart, for a total of 12 hours of treatment time. Participants will also take part in supportive group follow-up sessions at 1- and 4-months following group completion. Treatment endpoints will be assessed at four time-points (pre-treatment, immediate post-treatment, 1-month post-treatment, and 4-months post-treatment).||||
33936875|NCT02239029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936876|NCT01982669|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33936877|NCT01172561|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||f|t|t|t
33936878|NCT05452187|||COHORT||RETROSPECTIVE|||||||
33936879|NCT01784211|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33936880|NCT00000995||||TREATMENT||NONE||||||
33936881|NCT02701569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936882|NCT04089228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|this study is randomized control trail, participants are randomly allocated through sealed envelope method||t|f|f|f
33936883|NCT03739060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936884|NCT03607461|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group will consist of those who meet the inclusion criteria and have received traditional home health services following total knee arthroplasty (TKA). Intervention group participants who meet the inclusion criteria will receive a smartphone app instead of traditional home health services to aid in knee mobility recovery following TKA||||
33936885|NCT02087241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936886|NCT02804685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33936887|NCT04844450|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33936888|NCT02912741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936889|NCT03249480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936890|NCT03656536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936891|NCT03042494|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Crossover design with 4 week washout period.|t|f|t|t
33936892|NCT03639688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936893|NCT05791773|||COHORT||RETROSPECTIVE|||||||
33936894|NCT04688827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936895|NCT01681706|||||PROSPECTIVE|||||||
33936896|NCT00754299|||CASE_ONLY||PROSPECTIVE|||||||
33936897|NCT03140033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936898|NCT05474924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33936899|NCT04128072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936900|NCT01661725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33936901|NCT02005211|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33936902|NCT05867706|||COHORT||PROSPECTIVE|||||||
33936903|NCT01481428|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33936904|NCT02445352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33936905|NCT04691011|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"3 groups :~* muscle~* brain~* spinal cord"||||
33936906|NCT04837781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding to treatment allocation was possible only for the investigator and data analyst because the clinicians could know the intervention as osteo-perforation can be obviously seen clearly. Masking the intervention for the participants were not possible because micro-osteoperforation is a surgical procedure. All the trial documents were labeled with the study ID number, which was used for participant identification and data collection without unmasking the allocation group. This allowed the investigator to complete data collection and measurements blindly.||f|f|t|t
33936907|NCT00302575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936908|NCT04502199|||COHORT||RETROSPECTIVE|||||||
33936909|NCT03011424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936910|NCT05489718|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33936911|NCT03869489|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33936912|NCT02274311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936913|NCT04808492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participating subjects will be blinded to group assignment. Also, the outcomes assessor analyzing the data will be blinded to group assignment|Randomized Clinical Trial|t|f|f|t
34098239|NCT04134312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098240|NCT06355921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103341|NCT00226044|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was an open-label randomized intervention trial to study the efficacy of a single oral or rectal administered omeprazole dose of 1 mg/kg in infants with GERD due to EA or CDH.||||
34103342|NCT04442750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713320|NCT05760833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33713321|NCT00289471|||||CROSS_SECTIONAL|||||||
33713322|NCT00873223|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33713323|NCT02905552|||CASE_CONTROL||PROSPECTIVE|||||||
33713324|NCT03649750|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33713325|NCT01029626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713326|NCT02863029|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713327|NCT00408356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713328|NCT05485376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713329|NCT03232021|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, double-blind,randomized, placebo controlled trial|t|t|t|t
33713330|NCT05343351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713331|NCT02231723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713332|NCT03867006|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713333|NCT02341885|||COHORT||PROSPECTIVE|||||||
33713334|NCT05496257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720766|NCT05878054|RANDOMIZED|CROSSOVER||OTHER||NONE||Stepped wedge cluster randomized controlled trial||||
33936914|NCT01830829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936915|NCT03630185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936916|NCT00854984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936917|NCT01922518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936918|NCT02845115|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33936919|NCT02828644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33936920|NCT00994890|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33720767|NCT00656409||||BASIC_SCIENCE||||||||
33936921|NCT04154111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34015606|NCT03298295|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The only person blinded in this study is the pathologist analyzing the tissue sections.|Non-diabetic patients scheduled for selective plastic surgery (abdominoplasty).||||
33936922|NCT03309293|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936923|NCT04456803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936924|NCT03934515|||OTHER||PROSPECTIVE|||||||
34015607|NCT05291832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Conditions are randomly assigned by computer and coded ('A' vs 'B'), where the condition identity is unknown until after data analysis is complete||t|t|t|f
34015608|NCT04878614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized 1:1 to either continue current management with the same dose or to dose equivalent liquid levothyroxine|This will be a randomized controlled trial.|t|f|f|f
34015609|NCT04472247|||COHORT||PROSPECTIVE|||||||
34015610|NCT02954926|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34015611|NCT01081314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015612|NCT02662231|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34015613|NCT01229644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015614|NCT02450708|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34015615|NCT02501434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015616|NCT01300052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015617|NCT02686203|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34015618|NCT04082728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This trial is designed as a mono-center, prospective, double-blind, randomized placebo controlled superiority trial comparing 2 groups of patients|t|t|t|t
34015619|NCT02581163|||CASE_ONLY||PROSPECTIVE|||||||
34015620|NCT01679587|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34015621|NCT04099979|||CASE_ONLY||PROSPECTIVE|||||||
34015622|NCT01302613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015623|NCT04271696|||COHORT||PROSPECTIVE|||||||
34015624|NCT06490952|||COHORT||PROSPECTIVE|||||||
34015625|NCT06277141|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized controlled trial||||
34015626|NCT03880760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Probiotics or placebo group|t|f|t|f
34015627|NCT00301847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015628|NCT05834166|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015629|NCT04498741|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||4-Part Single Group study||||
34015630|NCT01835379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015631|NCT03021252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015632|NCT05544565|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, multicentric, parallel group non-inferiority clinical trial with 1:1 randomization||||
34015633|NCT01621191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015634|NCT06231953|||COHORT||PROSPECTIVE|||||||
34015635|NCT04515082|||CASE_ONLY||PROSPECTIVE|||||||
34015636|NCT04254835|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015637|NCT03483207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Diagnosis of acute MVT will be based on clinical presentation \&positive CT scan.(9) .patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively .(11)In addition to usual care ,intravenous heparin will be started and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. (12) followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. All patients will be critically monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be perfomed .The mortality and all complications associated with surgery will be recorded."||||
34015638|NCT05991830|||COHORT||PROSPECTIVE|||||||
34015639|NCT01825122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015640|NCT00857792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015641|NCT02103270|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34098241|NCT05476718|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In a randomized, placebo-controlled experimental trial, the participants and data analyzer will be blinded, and the researcher will be blinded to group assignments. Randomizer org site will be used for random assignment of groups as Kinesio or placebo (httpp://www.random.org/lists/). Index cards prepared by simple randomization by the researcher who did not participate in the clinical part of the study will be placed in closed opaque envelopes and sequence numbers will be written on the envelopes. Envelopes will be retained by the clinical secretary who did not participate in the study. The research data will be entered into the computer database by the researcher as coded as A and B, statistical analyzes will be carried out by the researcher who did not participate in the data collection phase according to this code, and the research report will be written in coded form.|In this study, which was designed as a randomized controlled study (pretest-posttest control group design), Kinesio and placebo groups were formed as the experimental and control groups.|t|f|f|t
34098242|NCT05592730|||COHORT||PROSPECTIVE|||||||
34098243|NCT01492803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34098244|NCT01663805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103343|NCT04718441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103344|NCT05990465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713335|NCT04745754|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Embedded primary care providers (PCPs) will provide comprehensive care for survivors, including cancer surveillance services, preventive care, and management of long-term therapy and associated side effects (e.g., endocrine therapy in breast survivors). A comprehensive multilevel approach will prepare survivors and PCPs (physicians and/or advance practice providers). Eligible patients in the embedded PCP model will be provided with tailored education regarding the planned transition and, after cessation of active treatment, printed information on the planned course of care, expectations for embedded PCP care, transition timing, and reassurance that the oncology team will be available via telephone and email, and that PCPs will refer back to the oncologist for any concerning signs or symptoms. Tailored alerts will also be added to the electronic medical record (EMR) for recommended cancer surveillance and preventive care services that will fire for visits with embedded PCPs.||||
34103345|NCT06687044|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34103346|NCT06686940|||COHORT||PROSPECTIVE|||||||
34103347|NCT00964522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713336|NCT02533739|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33713337|NCT05739955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Triple blind - exception of the study team member applying the disinfectant products (intervention 1 or 2)|Each participant's inpatient room are enrolled in one of the interventions and control arms at the same time.|t|t|t|f
33713338|NCT04571138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713339|NCT05730751|||CASE_CONTROL||PROSPECTIVE|||||||
33713340|NCT02373215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713341|NCT03951844|NA|SINGLE_GROUP||OTHER||NONE||||||
33936925|NCT06227416|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"one group of patients undergoing mohs surgery from which ex-vivo cryosections will be used for the study.~one group of patients with actinic keratoses which will have taken a punch biopsy from which ex-vivo cryosections will be included in the study."||||
33936926|NCT05441436|||COHORT||PROSPECTIVE|||||||
33936927|NCT01935167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936928|NCT01603615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936929|NCT03849014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936930|NCT05056272|||OTHER||CROSS_SECTIONAL|||||||
33936931|NCT03781154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|PI and study staff conducting assessments at study visits will be blinded to study arm assignment.|Patients will be prospectively assigned or allocated to either the group-based exercise intervention or control group for 12 weeks.|f|f|t|t
34015642|NCT00238849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015643|NCT04795908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015644|NCT06213467|NA|SINGLE_GROUP||TREATMENT||NONE||15 patients that have at least two dental implants in jaws.||||
33793616|NCT03257813|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Masking will be carried out using identical boxes in the primary package in both groups.~Blinding for the research subject and the investigator will be carried out by using labels containing the assignation number, which will replace the original labels in the case of the comparator. Due to the nature of the primary containers of the research products, single-dose vials and multidose bottle, it is not possible to use identical labels."|"60 subjects with diagnosis of open angle primary glaucoma with mild, moderate or severe damage and / or with intraocular hypertension users of Krytantek Ofteno® at least two previous months and are under control Of the corresponding IOP target.~a study group A or B will be randomly assigned, in group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be evaluated again and switched from therapy to solution PRO-122 which will be used for 30 days until the 60th day, date of the final visit.~In the case of those assigned to group B on day 1, the change to PRO-122 solution will be made for 30 continuous days until the date of revision on day 30, the day on which treatment with Krytantek Ofteno® will be restored to continue until the Day 60 for the final evaluation.~The selected subjects will be observed for 60 days."|t|f|t|f
33793617|NCT06491888|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33793618|NCT04835870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936932|NCT03700931|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"The experimental aim is concealed presenting it as a study on memory of daily activities"|The participants are allocated to one of the two conditions (experimental or control condition) of the study in a randomised sequence.|t|f|f|f
33936933|NCT03529734|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33713342|NCT02698839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936934|NCT00965744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33936935|NCT00221533|||||PROSPECTIVE|||||||
33936936|NCT03506113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713343|NCT00133614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936937|NCT00312728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936938|NCT01774227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936939|NCT02516306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936940|NCT01913652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713344|NCT05976750|||COHORT||RETROSPECTIVE|||||||
33936941|NCT00935467|NA|SINGLE_GROUP||||NONE||||||
33936942|NCT05939219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015645|NCT02205502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015646|NCT01692314|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34015647|NCT01467206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015648|NCT04128475|||COHORT||RETROSPECTIVE|||||||
34015649|NCT01007747|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713345|NCT04631081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||open-label, randomized controlled trial||||
33713346|NCT01044862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713347|NCT03097094|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33713348|NCT03063372|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Phase 1 is not masked, but in phase 2 the participants and investigator will be masked (double blind).|Phase 1 is a single group feasibility pilot in 10 participants, all of whom will receive the nutritional supplement. Phase 2 is a parallel double blinded trial in 40 participants, half of whom will receive the supplement and half of whom will receive a placebo.|t|f|t|f
33713349|NCT05231902|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33713350|NCT00557960|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713351|NCT03902821|||CASE_ONLY||PROSPECTIVE|||||||
33713352|NCT04252456|NA|SINGLE_GROUP||TREATMENT||NONE|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.|Biologically enriched phase II clinical trial. All patients will receive aflibercept in combination with FOLFIRI according to the Italian label.||||
33713353|NCT06431490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713354|NCT02490332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33713355|NCT05205044|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713356|NCT02465216|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33713357|NCT01676844|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33713358|NCT02589756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33713359|NCT06146452|||CASE_ONLY||RETROSPECTIVE|||||||
33713360|NCT04953377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713361|NCT04221841|||OTHER||CROSS_SECTIONAL|||||||
33713362|NCT04395469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713363|NCT02747095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713364|NCT04983264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713365|NCT01598324|||COHORT||PROSPECTIVE|||||||
33713366|NCT06167512|||CASE_CONTROL||PROSPECTIVE|||||||
33713367|NCT03578861|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713368|NCT01218230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713369|NCT00965718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713370|NCT01849224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713371|NCT01948622|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713372|NCT06020378|||COHORT||RETROSPECTIVE|||||||
33713373|NCT06268626|||CASE_CONTROL||PROSPECTIVE|||||||
33713374|NCT04887051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713375|NCT06240975|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33713376|NCT00203125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713377|NCT06463327|NA|SEQUENTIAL||TREATMENT||NONE||||||
33713378|NCT01114178|||COHORT||PROSPECTIVE|||||||
33713379|NCT03348033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713380|NCT05846932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant that rates goal attainment at the conclusion of therapy will be asked to participants' intervention assignment (OTEE HORS v OT Clinic).|Youth with be randomized to either receive occupational therapy integrating horses (OTEE HORS) or occupational therapy in a clinic (OT Clinic)|f|f|f|t
33713381|NCT04323787|||COHORT||OTHER|||||||
33713382|NCT00938639|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015650|NCT01594450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015651|NCT06041841|NA|SINGLE_GROUP||TREATMENT||NONE||This is a study where each participant participates for up to 56 weeks. The study consists up to 7 visits to study center which include a Screening period, treatment period, and a follow-up period. Eligible participants who are willing to enter the long-term extension period and who are judged by the study doctor to have no safety concerns, will continue to receive LB54640 at the same dose level from the treatment period. The long-term extension period will be followed by a follow-up period||||
33713383|NCT05588232|RANDOMIZED|PARALLEL||OTHER||NONE||Monocentric, prospective, comparative, randomized, open-label study.||||
33793619|NCT02510534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793620|NCT03698396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103348|NCT03139266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793621|NCT02529696|||COHORT||PROSPECTIVE|||||||
33793622|NCT02095899|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33793623|NCT05862363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be randomly assigned either RUSF or MDCF-2 (as dietary supplements). The participants will be made unaware of the supplement they are receiving; however, the field staff and investigators will be made aware of the dietary supplement allocation.|All the activities in both Aim 1A and 1B are divided into two parallel arms. In 1A, EGD will be performed for both women within reproductive age with low-BMI and with normal-BMI. The interventions are designed in two arms. The first arm will enroll women from ages 18-35years with low BMI. They will be subdivided into two groups, each of which will receive either RUSF-BEP or MD-BEP. There will be cohort of healthy women with normal BMI for comparison. The second arm will consist of pregnant women from ages 18-35 years with low BMI. They will also be subdivided into two groups, each of which will receive either RUSF-BEP or MD-BEP. There will be cohort of healthy pregnant women with normal BMI for comparison.|t|f|f|f
34103349|NCT05029999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793624|NCT00182845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33793625|NCT05388565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33793626|NCT02393716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713384|NCT00679302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936943|NCT05677828|||COHORT||RETROSPECTIVE|||||||
33936944|NCT01111175|||COHORT||PROSPECTIVE|||||||
33936945|NCT03523715|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33936946|NCT04144933|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33713385|NCT02669433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713386|NCT05779098|||COHORT||PROSPECTIVE|||||||
33713387|NCT04091568|||COHORT||PROSPECTIVE|||||||
33713388|NCT04441021|||CASE_ONLY||PROSPECTIVE|||||||
33713389|NCT05234151|||OTHER||PROSPECTIVE|||||||
33713390|NCT02589184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713391|NCT03598985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713392|NCT03648268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The subjects, care providers, investigators and outcome assessors will all be blinded as to the randomization sequence, and thus will be blinded as to sham vs active TMS status. Blinding codes are used to determine which side of an active/passive Magpro coil (cool B65 A/P, Magventure A/S, Denmark) is used for stimulation.|There will be four groups: an active DLPFC TMS group, an active TMS cerebellum group, a sham DLPFC group, and a sham cerebellum group. Participants will be randomized to one of these group groups, and they will receive that type of stimulation for the entire study.|t|t|t|t
33713393|NCT01793649|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713394|NCT06141109|NA|SEQUENTIAL||TREATMENT||NONE||MB07133 600mg/m2/day+Sintilimab 200mg、 MB07133 1200mg/m2/day+Sintilimab 200mg、 MB07133 1800mg/m2/day+Sintilimab 200mg||||
33713395|NCT01813591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713396|NCT02743559|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33713397|NCT04134468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713398|NCT02922556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713399|NCT01442493|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33793627|NCT03329066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistants who interview the teenager and their parents/caregivers will not know to which arm the participants are randomized.||f|f|f|t
33793628|NCT04755530|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Until the statistical analyses are performed, principal investigator and statistician are blinded|16-week parallel randomized controlled trial|f|f|t|t
33793629|NCT03413748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33793630|NCT02356549|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33793631|NCT06182462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793632|NCT00519129|RANDOMIZED|PARALLEL||||NONE||||||
33793633|NCT00328393|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33793634|NCT04225780|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We distribute the patients with CMV infection into two groups, one group will be treated with low-dose IL-2 and ganciclovir, another group will be only treated with ganciclovir.||||
33936947|NCT06269406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33936948|NCT00083616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936949|NCT04602299|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33936950|NCT03323086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33936951|NCT04251377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936952|NCT01693289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936953|NCT04916106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015652|NCT05958706|||COHORT||PROSPECTIVE|||||||
34015653|NCT04706923|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34015654|NCT00669071|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34015655|NCT04310839|||COHORT||PROSPECTIVE|||||||
34103350|NCT03017911|||COHORT||PROSPECTIVE|||||||
34103351|NCT01669889|||COHORT||PROSPECTIVE|||||||
34103352|NCT03810495|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936954|NCT05412160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936955|NCT05683158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34103353|NCT05671861|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103354|NCT05118438|NA|SINGLE_GROUP||OTHER||NONE||||||
33713400|NCT03018704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015656|NCT04188314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The patient will be blinded (masked) to the group they have been randomised to, as the vapour will only be started after induction of anaesthesia. The research assistant administering the post-operative QoR-15 will be blinded (masked) to the intervention.~The treating anaesthetist, the Chief Researcher and theatre staff will not be blinded to the intervention, as this would not be practical. All treating anaesthetists and theatre staff will be strongly inculcated not to disclose the allocation status of the participant at any time prior or after the general anaesthetic.~The piece of paper indicating the group will be attached to the Case Report Form. The Case Report Form will be collected by the Chief Researcher and will not be in the patient's file where it may unblind the patient or research assistant.~There are no circumstances under which unblinding will be permissible."|This study will be conducted as a randomised, controlled, patient and observer blinded, single-centre trial with two parallel groups and a primary end-point of 15-point Quality of Recovery Score on day 1 after surgery. Randomization will be performed as block randomization with a 1:1 allocation.|t|f|f|t
34015657|NCT05712525|||COHORT||PROSPECTIVE|||||||
34015658|NCT01423136|||CASE_CONTROL||PROSPECTIVE|||||||
33713401|NCT01693653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713402|NCT01950650|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33713403|NCT05230771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713404|NCT03954756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713405|NCT04693884|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33713406|NCT01082991|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33713407|NCT01115725|||COHORT||PROSPECTIVE|||||||
33713408|NCT01539694|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33713409|NCT05607277|||CASE_ONLY||RETROSPECTIVE|||||||
33713410|NCT06042452|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713411|NCT03383172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713412|NCT01911871|||COHORT||PROSPECTIVE|||||||
33793635|NCT02670525|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793636|NCT01170299|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33793637|NCT03416465|||COHORT||PROSPECTIVE|||||||
33793638|NCT00521833||PARALLEL||TREATMENT||NONE||||||
33793639|NCT03738111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793640|NCT03071848|||COHORT||RETROSPECTIVE|||||||
33793641|NCT04516564|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
33793642|NCT00903019|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33793643|NCT04132024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793644|NCT03768843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793645|NCT00801983|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33793646|NCT05018754|||CASE_ONLY||RETROSPECTIVE|||||||
34103355|NCT00940511|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33793647|NCT01596751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33793648|NCT05428319|||OTHER||RETROSPECTIVE|||||||
33793649|NCT06237751|NA|SINGLE_GROUP||PREVENTION||NONE||The investigators planned a study to evaluate the feasibility and efficacy of sildenafil citrate by comparing 2 groups of patients, the first without the drug and the second with 25 mg of sildenafil citrate.1) Feasibility and efficacy were assessed by comparing the amount of intraoperative bleeding, the effect of CVP, and the surgeon's operative field grading.2) Liver and renal function indexes, length of hospitalization, hospitalization costs, and postoperative complications were assessed by comparing patients' preoperative, 1d postoperative, 3d postoperative, and 7d postoperative occurrence, to assess the safety of its clinical application.||||
33793650|NCT02995096|||COHORT||PROSPECTIVE|||||||
33793651|NCT02239796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713413|NCT06129071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793652|NCT00154791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793653|NCT04378062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793654|NCT02715258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793655|NCT01116180|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33713414|NCT03634462|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects with lipedema or secondary leg lymphedema will receive standard manual lymphatic drainage therapy with negative pressure.||||
34015659|NCT01470612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713415|NCT02329353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713416|NCT01749345|||COHORT||CROSS_SECTIONAL|||||||
33713417|NCT05466526|NA|SINGLE_GROUP||TREATMENT||NONE||All participants in the arm were suffering from chronic open-angle glaucoma and were indicated for surgery due to either progression of field defect and raised intraocular pressure above 21 mmHg in spite of maximum medical treatment or for patients who were not compliant patient to their medical treatment.||||
33713418|NCT02316808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713419|NCT05408949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double (participant, investigators) blinded|Randomized control trial 13-weeks parallel non-inferiority study|t|t|t|t
33713420|NCT01102400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713421|NCT05924295|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713422|NCT02035878|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33713423|NCT02246660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713424|NCT02433483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713425|NCT04899921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713426|NCT03975790|||COHORT||RETROSPECTIVE|||||||
33713427|NCT03503955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793656|NCT00212784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793657|NCT00478335|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33793658|NCT01807546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793659|NCT01265134|||CASE_CONTROL||PROSPECTIVE|||||||
33793660|NCT00922207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793661|NCT05254171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||1:1 randomization to Experimental Arm vs. Control Arm|t|t|t|t
33793662|NCT03346018|||COHORT||PROSPECTIVE|||||||
33793663|NCT04215471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713428|NCT03873233|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients undergoing craniotomy will be ventilated during surgery using both conventional VCV and FVC modes. Standard baseline VCV is used for induction and stabilization of anesthesia. The order of ventilation mode is randomly assigned.||||
33713429|NCT05029440|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34015660|NCT01224938|||COHORT||CROSS_SECTIONAL|||||||
34015661|NCT03985787|NA|SINGLE_GROUP||OTHER||NONE||||||
34015662|NCT01859806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713430|NCT04532164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713431|NCT01530867|||COHORT||CROSS_SECTIONAL|||||||
33713432|NCT03893799|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34015663|NCT00283491|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33713433|NCT01622790|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33713434|NCT00856154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713435|NCT00684307|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33713436|NCT05092620|||COHORT||PROSPECTIVE|||||||
34015664|NCT05723068|||COHORT||PROSPECTIVE|||||||
34015665|NCT01006941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015666|NCT02814435|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015667|NCT06163599|NA|SINGLE_GROUP||OTHER||NONE||||||
34015668|NCT06259136|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"For this study a cross-sectional stepped wedge clustered clinical trial will be conducted.~The design will start by an initial period in which all clusters e.g. different hospital sites, are part of the control group in which the patients receive care as usual. Subsequently, groups of clusters are exposed to the intervention at regular intervals (steps) until all clusters patients in all clusters have received care as defined in the intervention. The decision about which group of clusters will receive the intervention at which point in time is decided by randomization"|t|f|f|f
34015669|NCT01805830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015670|NCT02793570|||COHORT||PROSPECTIVE|||||||
34015671|NCT01948570|||CASE_CONTROL||PROSPECTIVE|||||||
34015672|NCT04815421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two persons of our protocol who was unknown of the patients' treatment method and period estimated the VAS of every patient freely and evaluated the clinical effects and outcomes according to the criteria of diagnostic and therapeutic effect of orthopaedic and traumatologic diseases and syndromes in traditional Chinese medicine|Patients who were diagnosed with stiff-neck syndrome according to the diagnostic criteria（Acute onset of severe pain and stiffness in one-sided neck after sleep; Mostly because of bad sleep posture or cold in neck, shoulder or head; Pain or discomfort can radiate to head, arm and back; Any attempt to move neck can obviously exacerbate the pain; The head slants to the affected side; Without neck injury history or other relative systematic diseases.; Neck X-ray film has no positive signs such as degenerative lesions of cervical spine; Trachelismus and rhomboideus major/ minor, levator scapulae accessible lumps or streak in muscle. All criteria conformed to the prescription in criteria of diagnostic and therapeutic effect of orthopaedic and traumatologic diseases and syndromes in traditional Chinese medicine）. They were randomly enrolled in meridian group or paste group according to the visiting time (with digital random table).|f|f|f|t
34015673|NCT04515537|||COHORT||CROSS_SECTIONAL|||||||
34015674|NCT03200691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015675|NCT00944268|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34015676|NCT02624726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015677|NCT00940836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015678|NCT01048216||||TREATMENT||||||||
34015679|NCT05142371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34015680|NCT03982563|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34015681|NCT01806038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015682|NCT01946776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015683|NCT04765527|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Coded, capsules|Randomized, parallel group|t|f|t|f
34015684|NCT03185234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015685|NCT00102687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015686|NCT01151956|||COHORT||PROSPECTIVE|||||||
34015687|NCT03659474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015688|NCT03053336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015689|NCT02888977|||COHORT||PROSPECTIVE|||||||
34015690|NCT04754126|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized controlled trail will be conducted to ascertain the effectiveness of the Amazing Me intervention in 9-11 year old children. The randomized controlled trial will consist of an intervention and control group. Between 100 to 180 classrooms will be randomized to control or intervention condition. Randomization distribution will be 50%; thus, half of the educators/classrooms will be in the intervention and half in the control. We estimate about 30 students per teacher, yielding a maximum of 2,700 students randomized to intervention and 2,700 students randomized to control. Educators and school districts will be recruited to participate. Educators and students will complete an online baseline survey and another survey after the intervention. Finally, a 6-month and 12-month follow-up survey will be conducted for students.||||
34015691|NCT02809170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015692|NCT02674230|||COHORT||PROSPECTIVE|||||||
34015693|NCT02127775|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34103356|NCT01445483|||COHORT||PROSPECTIVE|||||||
34103357|NCT04131894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103358|NCT01872182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103359|NCT02431520|RANDOMIZED|PARALLEL||||NONE||||||
33713437|NCT05010577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713438|NCT03291054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713439|NCT03973385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713440|NCT06102759|||COHORT||PROSPECTIVE|||||||
33713441|NCT02908555|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793664|NCT04116203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|This is a randomized open-label parallel study in overweight/obese young women with PCOS, in which the participant will be randomly assigned to one of three treatment arms|Outcomes at 6 and 12 weeks will be compared to baseline values to determine the efficacy of interventions. Participants will act as their own control in each intervention||||
34015694|NCT06055036|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistical analyst is blinded to the intervention group.|randomized, wait-list controlled trial with 2 arms|f|f|f|t
33713442|NCT05083442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be set up by a statistician through REDCap, the data collection system utilized for the study.|Randomized clinical trial where subjects are placed into 2 different study arms. Subjects randomized to 2 groups that either receive Low Level Laser therapy with lifestyle modifications or Sham (placebo) with Lifestyle Modifications.|t|f|f|f
33713443|NCT06173921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713444|NCT05798429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33713445|NCT00466778|||CASE_CONTROL||PROSPECTIVE|||||||
33713446|NCT04258397|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33713447|NCT05479084|||OTHER||PROSPECTIVE|||||||
33793665|NCT01990924|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33793666|NCT00212056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713448|NCT06102239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713449|NCT00136617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713450|NCT05271695|||CASE_CONTROL||PROSPECTIVE|||||||
33713451|NCT03905603|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking is involved in this study.|This is a cross-sectional physiological observational study.||||
33713452|NCT01962805|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33713453|NCT01533025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33793667|NCT01884636|NA|SINGLE_GROUP||||NONE||||||
33713454|NCT06232811|||COHORT||CROSS_SECTIONAL|||||||
33793668|NCT02281318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713455|NCT01624389|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33713456|NCT03498300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793669|NCT05471414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793670|NCT00395603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793671|NCT04689425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34015695|NCT01304693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015696|NCT06285968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015697|NCT01064323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015698|NCT03763760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All intervention drugs will be blinded by a nurse who is not a participant in the study or in the treatment of the patient in any way.~The Patient, the administrator of the drug(nurse or doctor), the assessor, the investigator and the care team will all be blinded."|A randomized double blinded controlled trial.|t|t|t|t
34015699|NCT00941057|RANDOMIZED|CROSSOVER||||NONE||||||
34015700|NCT03286478|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking not possible within design.|Parallel 4-arm cluster randomised controlled trial.||||
34098245|NCT05477576|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \[HA\]-DOTATATE.||||
34098246|NCT00884000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098247|NCT04245904|||CASE_CONTROL||PROSPECTIVE|||||||
34098248|NCT05174702|||COHORT||PROSPECTIVE|||||||
34098249|NCT01163500|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098250|NCT05996705|||CASE_ONLY||CROSS_SECTIONAL|||||||
34098251|NCT02207179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103360|NCT00684554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713457|NCT02233816|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713458|NCT06040372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, there will be unblinded pharmacist for investigational product distribution.|This was a randomized, double-blind, placebo-controlled study conducted in two parts. Study Part 1 had a SAD design to investigate the safety, tolerability, and PK of LB54640 administered orally in healthy overweight and obese subjects. Study Part 1 included a cohort (Cohort S3) to assess the effect of food on LB54640, which was conducted with a blinded, placebo-controlled, two-way crossover design. Study Part 2 had a MAD design to investigate the safety, tolerability, PK, and PD of LB54640 administered orally in healthy overweight and obese subjects|t|f|t|f
33713459|NCT01788332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713460|NCT02432014|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713461|NCT01327521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793672|NCT06466902|||COHORT||PROSPECTIVE|||||||
34103361|NCT02988674|||COHORT||PROSPECTIVE|||||||
33793673|NCT01585558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793674|NCT04807725|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33793675|NCT04978935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"80 patients by randomization will be divided into groups A and B. Group A will be determined as the study group and group B as the control group. The information showing the nurses included in the research sample is assigned to the A and B groups will be put in an opaque envelope. This envelope will be kept by the coordinator researcher (GAU). When the researcher (DS) goes to the patient for the application, after filling the Informed Consent Form, she will open the envelope and find out which group the patient is in. The participants will be blinded. The researcher (DS), on the other hand, cannot be blinded due to the nature of the research. When the research is completed, the data will be transferred to the computer environment by a statistician who does not know the A and B groups, and the data will be analyzed by a statistician independent of the research and the findings will be reported."|Prospective, parallel, two arm, randomized controlled,single blind|t|f|f|f
33793676|NCT06024369|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793677|NCT03522467|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm cohort||||
33793678|NCT04327180|||COHORT||PROSPECTIVE|||||||
33793679|NCT02312336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713462|NCT01636804|||COHORT||PROSPECTIVE|||||||
33720768|NCT02278250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015701|NCT05487079|||COHORT||PROSPECTIVE|||||||
34015702|NCT03433716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015703|NCT04309214|NA|SINGLE_GROUP||OTHER||NONE||||||
34015704|NCT01222286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015705|NCT03970837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Participants will be randomized to one of six intervention arms in ratio of 6:6:3:1:1:1|t|f|t|f
34015706|NCT05270200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098252|NCT06406478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking will occur in this study, as the groups will be aware of which schedule they are working, and the researchers will be examining differences between intervention and control groups.|Participants will be stratified by study site and race, and then randomized into either the control or intervention group. The allocation sequences will be generated by a research team member using a random number table assigning groups 1:1, with equal numbers of participants in each intervention and control group.||||
34098253|NCT00051142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098254|NCT05257980|NA|SINGLE_GROUP||OTHER||NONE||||||
34098255|NCT00986895||||TREATMENT||NONE||||||
34098256|NCT04289272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|masking not possible for participants within design, but outcome assessors do not know which condition participants are in|Parallel 2-arm cluster randomised controlled trial|f|f|f|t
34098257|NCT00084279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098258|NCT05151965|||COHORT||PROSPECTIVE|||||||
34098259|NCT04468009|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098260|NCT04865978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open-label, prospective, randomized, 1:1 intervention arm versus control||||
34098261|NCT04724200|||COHORT||PROSPECTIVE|||||||
34098262|NCT06465368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720769|NCT01372501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720770|NCT02900287|||COHORT||RETROSPECTIVE|||||||
33720771|NCT05364723|||CASE_ONLY||OTHER|||||||
33720772|NCT04557657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||36 volunteer assigned randomly into 2 equal groups of 18|t|t|t|t
33720773|NCT00483379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720774|NCT03028831|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|similar packets, similar appearing supplements|dietary supplementation|t|t|t|t
33720775|NCT00674661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720776|NCT04367688|||COHORT||PROSPECTIVE|||||||
33720777|NCT01481233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720778|NCT00351260|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720779|NCT01852942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793680|NCT04162119|NA|SINGLE_GROUP||TREATMENT||NONE||This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.||||
34098263|NCT03397758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793681|NCT04779333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793682|NCT03967717|||CASE_ONLY||PROSPECTIVE|||||||
33793683|NCT00468910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33793684|NCT04970810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This will be a single-blind study, and subjects will blinded to the different group assignment.||t|f|f|f
33793685|NCT04873336|||COHORT||PROSPECTIVE|||||||
33793686|NCT04402957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793687|NCT01084954|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793688|NCT01070888|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33793689|NCT02621424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793690|NCT05092139|||COHORT||PROSPECTIVE|||||||
33793691|NCT00746330|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33793692|NCT00246012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793693|NCT06676826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34015707|NCT00384176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015708|NCT05884879|||COHORT||PROSPECTIVE|||||||
34098264|NCT05213390|NA|SINGLE_GROUP||SCREENING||NONE|No masking is possible, because all participants receive the same intervention.|The study will be a multi-centre, mixed-methods clinical investigation to develop evidence regarding the feasibility, acceptability and potential effectiveness of Dora.||||
33720780|NCT00489398|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33720781|NCT03583138|||COHORT||PROSPECTIVE|||||||
33720782|NCT01462084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33720783|NCT05507255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random generator||t|f|f|t
33720784|NCT01403246|NA|SINGLE_GROUP||OTHER||NONE||||||
33720785|NCT03512314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720786|NCT03799497|||CASE_CONTROL||PROSPECTIVE|||||||
33793694|NCT00188461|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793695|NCT03308461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793696|NCT02337569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793697|NCT02783235|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34015709|NCT04594174|||COHORT||PROSPECTIVE|||||||
34015710|NCT05161806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015711|NCT06299852|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34015712|NCT04376528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015713|NCT02363608|||COHORT||PROSPECTIVE|||||||
34015714|NCT02758522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015715|NCT03772431|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomized to one of four narrator/introduction combinations: 1) male voice, informational content; 2) male voice, motivational content; 3) female voice, informational content; 4) female voice, motivational content.|f|f|f|t
34015716|NCT00010608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34015717|NCT04691310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34015718|NCT04158349|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is a prospective, multi-center, open-label phase I trial designed to determine the MTD of IP oxaliplatin when given in combination with mFOLFIRI. This will be conducted according to a traditional 3+3 dose-escalation schedule and halted once MTD is established.||||
34015719|NCT02219971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015720|NCT04912336|||COHORT||PROSPECTIVE|||||||
34015721|NCT00307034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015722|NCT05665920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015723|NCT00112346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015724|NCT00982449|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34015725|NCT00759902|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34015726|NCT00306423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015727|NCT03695861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The interpretation of the PET-CT will be performed by a nuclear medicine expert who is expert in cardiac imaging and infectious pathology, blinded to other imaging tests.|"Diagnostic study, prospective, delayed-type cross-sectional study (the result of the reference test is defined at 3 months of follow-up), monocentric, blinded, including consecutive patients."||||
34015728|NCT04063488|||CASE_ONLY||PROSPECTIVE|||||||
34015729|NCT05726175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015730|NCT03680287|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34015731|NCT03875937|NA|SINGLE_GROUP||OTHER||NONE||Prospective, open-label, multicentre, pharmacokinetic study.||||
34015732|NCT03764436|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||This study uses a cluster-randomized stepped-wedge design with three steps to evaluate the impact of LEAPS-NCHD program. Ninety-nine clusters (villages) are enrolled. Thirty-three clusters per step are randomly selected to cross-over from receipt of standard services (comparison) to receipt of the LEAPS-NCHD program (intervention). Unit of randomization is at the village (cluster) level. A process evaluation will assess program rollout for fidelity, adherence, quality, and cost.|f|f|t|t
34015733|NCT00008151||||TREATMENT||||||||
34015734|NCT01479257|||COHORT||PROSPECTIVE|||||||
34015735|NCT05046665|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
34015736|NCT01908413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015737|NCT03927417|||COHORT||PROSPECTIVE|||||||
34015738|NCT04670666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098265|NCT00004931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098266|NCT00365820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098267|NCT05004246|||COHORT||PROSPECTIVE|||||||
34098268|NCT00057577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098269|NCT03364686|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098270|NCT03943992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34098271|NCT00416754|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34098272|NCT06324578|||OTHER||CROSS_SECTIONAL|||||||
34098273|NCT01134614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098274|NCT06609148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled study of probiotic combination versus placebo in patients with bile acid diarrhea|t|f|t|f
34098275|NCT06104306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098276|NCT00004015||||TREATMENT||||||||
34098277|NCT02074137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098278|NCT03043937|||OTHER||PROSPECTIVE|||||||
34098279|NCT06375876|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33720787|NCT01912287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720788|NCT05505357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720789|NCT02044744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793698|NCT01026233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793699|NCT04676568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793700|NCT05695833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015739|NCT01576094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015740|NCT02592109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015741|NCT05726760|||COHORT||PROSPECTIVE|||||||
34015742|NCT02377063|NA|SINGLE_GROUP||OTHER||NONE||||||
34015743|NCT03102593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition.|t|t|t|t
34015744|NCT05927831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34015745|NCT02776579|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34015746|NCT04378517|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot-study||||
34015747|NCT01359644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098280|NCT02920554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098281|NCT03044288|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098282|NCT01377311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098283|NCT02268487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793701|NCT01649180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793702|NCT01793441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098284|NCT06288711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098285|NCT06479057|||OTHER||PROSPECTIVE|||||||
34098286|NCT03517293|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of an exercise study, the participant cannot be blinded to the group. However, those assessing outcomes are blinded to group assignment.|women were randomly assigned to either aerobic exercise intervention or no exercise.|f|f|f|t
34098287|NCT00775515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098288|NCT05978362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomized single-blind study|prospective, comparative, longitudinal, randomized single-blind study|t|f|f|f
34098289|NCT05171335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098290|NCT01851226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720790|NCT03314155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Images' analysis will be done by an INSERM engineer without the knowledge of the group to which the subjects belong.|||||
33720791|NCT04028206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33720792|NCT04818281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded||t|f|t|f
34015748|NCT04857463|RANDOMIZED|PARALLEL||OTHER||NONE||This study was a clustered, randomized, parallel, multicenter clinical trial.||||
33713463|NCT03432754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was conducted by the principle investigator (PI) and study coordinator using a computerized random number generator program (randomization.com). All experimenters (except the PI and study coordinator) were blinded to group assignments until study conclusion. To further reduce demand characteristics, participants were unaware of which group was considered the experimental intervention until debriefed by an experimenter after completing the study. Study binders were created to blind group assignment, and participants in each group were asked not to discuss the sessions with members of the other group or with the experimenter at their post-intervention assessment.|This randomized control trial compared a mindfulness-based attention training (MBAT) group with an active control lifestyle education group. A total of 147 individuals underwent eligibility screening over the phone and in-person at an initial assessment session. Of those eligible, 75 participants volunteered to participate and were randomly assigned to groups. However, one of these participants did not complete the first assessment session and was randomized in error. Thus, 74 participants who completed the first assessment session and met all eligibility criteria were randomly assigned to either the MBAT group or the active control group (lifestyle education). Randomization was conducted by a study author using a computerized random number generator program (randomization.com), applying a varying block size of two and four and stratifying participants by gender. A total of 37 participants were allocated to the each of the two groups.|t|f|f|t
34015749|NCT05019625|||COHORT||PROSPECTIVE|||||||
33713464|NCT00078637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793703|NCT01015404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793704|NCT01212991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713465|NCT04477902|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33793705|NCT05987878|||OTHER||PROSPECTIVE|||||||
33793706|NCT04275817|||COHORT||PROSPECTIVE|||||||
33793707|NCT04408898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793708|NCT06173258|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33793709|NCT06265636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects who participate in the study will receive, in the case of the experimental group, 10 minutes of manual therapy and exercises and 10 minutes of percutaneous electrical nerve stimulation (PENS) guided by ultrasound. In the case of the control group, they will receive 20 minutes of manual therapy and exercises. The treatment will consist of one session per week for three weeks (a total of 3 sessions). Each session will last 30 minutes, of which 10 minutes will be used for the initial evaluation and 20 minutes for the assigned treatment. Two weeks after the last session, a final evaluation without treatment will be performed.|f|f|f|t
33713466|NCT04366453|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33720793|NCT05505019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|A randomization schedule will be designed by the research coordinator (MJ) and only the research coordinator will know the group allocations. If any experimental condition is shown to be harmful to any participant and it is medically crucial for a participant to know which intervention group they are in, the research coordinator will break code and disclose this information to the participant.|Participants with Parkinson's Disease (PD) and apathy will be randomly assigned to one of two experimental groups: 1) A music-listening group, and 2) a podcast-listening group.|t|t|f|t
33720794|NCT01475331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720795|NCT01837979|||COHORT||PROSPECTIVE|||||||
33793710|NCT03587168|||CASE_CONTROL||PROSPECTIVE|||||||
33793711|NCT00069342|||COHORT||PROSPECTIVE|||||||
33793712|NCT05355116|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793713|NCT06513806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793714|NCT02847312|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33793715|NCT05495334|||COHORT||PROSPECTIVE|||||||
33793716|NCT03236064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793717|NCT00868569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793718|NCT05001945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793719|NCT00091624|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793720|NCT01263730|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793721|NCT06288932|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will comprise the newly diagnosed patients of Immune thrombocytopenia purpura aged 5-60 year. Patients will with a 1:1 ratio among the two group.||||
33793722|NCT05459740|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34015750|NCT04934150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham stimulation was provided by turning the TMS coil to the non-stimulating side.|The study was conducted in a single-blinded, randomized, placebo-controlled design|t|f|f|f
34015751|NCT04341376|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34015752|NCT01374139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015753|NCT02795377|||COHORT||PROSPECTIVE|||||||
34015754|NCT04606836|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The statistician will be masked to the groups the participants fall in (case vs control).|Cases will be recruited prospectively and controls will be taken retrospectively|t|f|f|t
34015755|NCT04883970|NA|SINGLE_GROUP||SCREENING||NONE||||||
34015756|NCT02244879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015757|NCT05558995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015758|NCT03903458|NA|SINGLE_GROUP||TREATMENT||NONE|open-label|this is an open label, non-randomized, Phase IB clinical trial studying a new anticancer drug combination||||
34015759|NCT02671240|||COHORT||RETROSPECTIVE|||||||
34015760|NCT02429934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015761|NCT03056261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||comaring combined general anesthesia and epidural technique to general anaesthsia alone or gastrointestinal recovery and pain managment||||
34015762|NCT06428630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Investigative group: Subjects with symptomatic oral lichen planus (OLP) or oral lichenoid reactions (OLR) Control Group: Those otherwise healthy~Both groups will receive the same intervention. 5 of the control subjects will swish for 5 minutes, 5 of the control subjects will swish for 2 minutes."||||
34015763|NCT02418143|||CASE_CONTROL||PROSPECTIVE|||||||
34015764|NCT03356028|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Interventional research involving the category 2 human person at minimal risk and constraint, excluding health product, multicentre||||
33713467|NCT04187014|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Prior to being included in the study, the patient will be mentioned the times when he will receive the medication as well as the dosage of administration. The patient will not know what medication is being administered to him / her. The pills will be given to the patient in a medicine cup without access to any information legend. In the same way, the medication will be administered by a doctor outside the research protocol and will not participate in any other phase of the study so that no member of the research team will know what medication was administered.|Two study groups will be generated, each consisting of 45 research subjects, randomly each recipient will receive 3 doses of one of the two study drugs (tranexamic acid or aminocaproic acid). The group to which the patient belongs will be assigned through a computer program, the patient will not know to which group he belongs or what medication he will receive. The patients will be extracted from the external traumatology clinic|t|f|t|f
33713468|NCT01573975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713469|NCT05850572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33713470|NCT02839070|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33713471|NCT04814134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be enrolled in CPNS treatment arm or to the control arm. Treatment with CPNS system includes endovascular stimulation of the cardiac autonomic nerves in addition to standard of care. Subjects in the control arm will receive the available standard treatment.||||
33793723|NCT03887624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This study is a double-blind and double-simulation design. In the course of clinical study, all subjects, researchers and evaluators are blind to grouping information. The results of the study are audited by blind state data. The placebos are administered in capsules with no difference in appearance, color, weight or odor from the positive drugs. Both subjects and drugs are coded blindly.~In the study, the coding system for research drugs have an emergency blindness detection procedure, so as to quickly identify the drugs in emergency medical condition, without destroying the blind design of clinical research."||t|t|t|t
33793724|NCT00176371|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793725|NCT01023490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793726|NCT05570994|NA|SEQUENTIAL||TREATMENT||NONE||This is a prospective phase I/II study 1-arm study of efficacy and safety of 177Lu HTK03170 for treatment of patients with mCRPC who are referred to BC Cancer - Vancouver for treatment of progressive tumours.||||
33793727|NCT00490685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793728|NCT04748185|||COHORT||PROSPECTIVE|||||||
33793729|NCT02427698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793730|NCT04407780|||COHORT||PROSPECTIVE|||||||
33793731|NCT00855465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793732|NCT03760627|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This is a stepped wedge cluster randomized trial design. The design involves random and sequential crossover of clusters from control to intervention until all clusters are exposed. The controls from the previous session who were available for the parallel portion of the study, will later become the treatment group while another control group is recruited for them, which in turn will become an intervention group and so forth.|t|f|f|f
33793733|NCT04558437|||COHORT||PROSPECTIVE|||||||
33793734|NCT02427633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793735|NCT05572801|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793736|NCT02838342|NA|SINGLE_GROUP||OTHER||NONE||||||
33793737|NCT02669524|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33793738|NCT03629444|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33793739|NCT05506943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded independent review committee will be used to assess the primary study endpoint.||f|f|f|t
33793740|NCT04880694|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to three cohorts in a 2:2:1 ratio to receive continuous infusion of STC3141 either at rate 58.3mg/hr or 87.5mg/hr up to 3 days (72hours), or to receive appropriate standard of care. All subjects in STC3141 treatment groups will also receive standard of care for their conditions as background treatment.||||
33793741|NCT06675539|||COHORT||PROSPECTIVE|||||||
33713472|NCT03176251|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized, two-arm, single-blinded|f|f|t|t
33793742|NCT00861458|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33793743|NCT05561036|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33793744|NCT03839095|||COHORT||RETROSPECTIVE|||||||
34015765|NCT06211153|||COHORT||RETROSPECTIVE|||||||
34015766|NCT02347371|||COHORT||PROSPECTIVE|||||||
34015767|NCT01046799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713473|NCT00525460|||CASE_ONLY||PROSPECTIVE|||||||
33713474|NCT04677374|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The intervention will be rolled-out in the implementation phase in a sequential and incremental manner called implementation blocks. Implementation blocks will be as follows: block 1: Intensified health education (I); block 2: Intensified health education and SMS/telephonic Tracing (IT) and finally, Block 3: Intensified health education, SMS/telephonic tracing and transport Reimbursement (RITe)||||
33713475|NCT03369405|||OTHER||RETROSPECTIVE|||||||
33720796|NCT03274726|||OTHER||CROSS_SECTIONAL|||||||
33720797|NCT00454610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720798|NCT00255047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720799|NCT05325450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two within-subject crossover experiments (short-term and long-term) where each subject will follow two phases of the protocol (training A and training B).||||
33720800|NCT00772772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015768|NCT01946191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015769|NCT02689063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015770|NCT05706194|||COHORT||PROSPECTIVE|||||||
34015771|NCT04920916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015772|NCT00974961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015773|NCT05865080|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34015774|NCT02726893|||COHORT||PROSPECTIVE|||||||
34015775|NCT03463486|||COHORT||PROSPECTIVE|||||||
34015776|NCT04204759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34015777|NCT02337140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015778|NCT02283164|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34015779|NCT03898921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713476|NCT04635943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Ivermectin presentation will be an oral drop solution in a flasks containing 5ml. The placebo presentation will also be an oral drop solution, undistinguishable from ivermectin, but without this device pharmaceutical ingredient. The pharmacist will prepare the treatment flasks (three 5ml flasks per participant), labelling them according to the randomization list in blocks of four (a, b) previously prepared by the epidemiologist, and according to the randomized treatment allocation previously notified by the principal investigator. The participant, investigator and outcomes assessor will be blinded to the study intervention.|SAINT-PERU is a triple-blinded, randomized, placebo-controlled trial with two parallel arms to evaluate the efficacy of one daily dose of ivermectin during three consecutive days, administered to patients with a positive PCR test for SARS-CoV-2 in a nasopharyngeal specimen, symptomatic for 96 hours or less, with non-severe COVID-19 disease at baseline, regardless of the presence of risk factors for progression to severity. The efficacy of the drug-based strategy to reduce or block transmission involves treating during early phases of infection, when viral replication is yet limited.|t|f|t|t
34015780|NCT00391079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098291|NCT00712075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713477|NCT02091544|||COHORT||PROSPECTIVE|||||||
34015781|NCT00774696|RANDOMIZED|CROSSOVER||||NONE||||||
33713478|NCT05606497|||COHORT||RETROSPECTIVE|||||||
33713479|NCT03780283|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015782|NCT05791682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713480|NCT02390895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713481|NCT01658891|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713482|NCT04118166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713483|NCT05078008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33713484|NCT05352334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.||||
33713485|NCT00235898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713486|NCT04818398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713487|NCT01675271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713488|NCT05229601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713489|NCT00634530|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33713490|NCT06508216|RANDOMIZED|PARALLEL||TREATMENT||NONE||COMPASS-TNBC is a single-center, open-label, modular phase 1b/2 trial assessing the safety and efficacy of innovative therapies and combinations in patients with early relapsed advanced TNBC. The study is of modular design allowing assessment of safety, tolerability, and antitumor activity of multiple modules combining a wide range of different compounds. New combination treatment modules could be added during the study, via a protocol amendment. The combination module will be composed of 2 parts: a dose-finding part (Part 1) based on study drugs dose escalation and de-escalation and a dose-expansion part (Part 2) based on the RP2D found in Part 1. Modules for which the RP2D is already determined will be composed only of a dose-expansion part (Part 2). Therefore, the first 2 modules (Module 1: Dato-DXd single agent and Module 2: Dato-DXd + Durvalumab) will be composed only of part 2.||||
33713491|NCT02048787|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33713492|NCT00892762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793745|NCT02950558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793746|NCT02982993|||COHORT||PROSPECTIVE|||||||
34015783|NCT04658836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015784|NCT00750308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34015785|NCT03846713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015786|NCT00453427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015787|NCT03438396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015788|NCT02362984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015789|NCT05886452|||COHORT||PROSPECTIVE|||||||
34015790|NCT02906241|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34015791|NCT00427713|RANDOMIZED|||TREATMENT||NONE||||||
34015792|NCT03679052|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34015793|NCT01534923|||COHORT||PROSPECTIVE|||||||
34015794|NCT05134896|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34015795|NCT01460901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015796|NCT00940797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015797|NCT04336124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015798|NCT02017860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015799|NCT01176214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015800|NCT03343613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015801|NCT01955213|||CASE_CONTROL||PROSPECTIVE|||||||
34015802|NCT05136118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098292|NCT05648357|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098293|NCT03307096|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||A total of 200 patients, aging between 18 and 60 years are enrolled into the study, patients will be prospectively randomized into group A and group B with a 1:1 ratio. Group A will receive the microperc surgery and group B will undergo FURS.|f|f|f|t
34098294|NCT06565156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To reduce bias in the determination of closure, an independent blinded reviewer will review the image obtained from the wound measurement device in each case where the Investigator determines the wound has achieved closure.||f|f|f|t
34098295|NCT04916665|||CASE_ONLY||RETROSPECTIVE|||||||
34098296|NCT06571032|||COHORT||PROSPECTIVE|||||||
34098297|NCT01578746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098298|NCT06299163|NA|SEQUENTIAL||TREATMENT||NONE||||||
33793747|NCT06489899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793748|NCT00509639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793749|NCT04486222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793750|NCT02507336|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793751|NCT01748318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793752|NCT06556199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793753|NCT06219187|||OTHER||PROSPECTIVE|||||||
33793754|NCT04557488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793755|NCT05181254|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793756|NCT00863993|||COHORT||PROSPECTIVE|||||||
33793757|NCT03504644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793758|NCT00420316|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793759|NCT01839903|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33713493|NCT05307419|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The pathologist is masked by 30 day delay and should be conducted by another pathologist than the first.|Prospective randomized blinded case-control study.|f|f|f|t
33793760|NCT05323838|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015803|NCT05625087|RANDOMIZED|PARALLEL||TREATMENT||NONE||After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was designed as a randomised, open-label, multicentre, phase II study, for comparison of alpelisib to ribociclib in combination with fulvestrant (as the continuation of the CDK4/6 inhibitor-fulvestrant strategy)||||
34015804|NCT01618188|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34098299|NCT03094273|||CASE_ONLY||PROSPECTIVE|||||||
34098300|NCT06410807|||COHORT||PROSPECTIVE|||||||
34098301|NCT02098538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098302|NCT04909411|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33713494|NCT03128944|||CASE_ONLY||CROSS_SECTIONAL|||||||
33713495|NCT00944489|||COHORT||PROSPECTIVE|||||||
33713496|NCT03940612|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Masking will be subjected to Participant, Care Provider, Investigator|Placebo and STP4 will be administered via a parallel design|t|t|t|f
33713497|NCT01307007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713498|NCT06386250|RANDOMIZED|PARALLEL||PREVENTION||NONE||Regional block group (Group A), wound infiltration group (Group B), caudal block group (Group C)||||
33713499|NCT02876354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713500|NCT01053884|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713501|NCT02152696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713502|NCT00890006|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793761|NCT04473586|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|Bi-directional sequencing results and Spartan results will not be shared with participants. The investigator will not see the bi-directional sequencing results.|"All subjects will experienced the same number of buccal and saliva samples collected. This means all subjects will participate in Arm 1 and have materials collected at the same time in the event they are enrolled in arm 2.~Based on enrollment numbers and their immediate genotype, it will be determined at that time if the subject will participate in the second arm of the study."|t|f|t|f
33793762|NCT03178110|NA|SINGLE_GROUP||TREATMENT||NONE||The methodology of a single subject design will be used with multiple baseline and during treatment measures to determine the effectiveness of the treatment protocol.||||
33793763|NCT03161990|||COHORT||RETROSPECTIVE|||||||
33793764|NCT03547804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793765|NCT01971788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793766|NCT02129049|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793767|NCT02554240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793768|NCT02929485|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33793769|NCT03988569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||the proposed study is to test the null hypothesis that there is no difference in surgical preparedness between women who receive a standard surgical consent for pelvic reconstructive surgery (control) and those who receive a standard surgical consent that is enhanced with an audiovisual decision aid (treatment) for the same surgery. Equivalently, the null hypothesis is that the odds ratio is 1.00.||||
33793770|NCT03299816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single center, randomized controlled trial with two parallel arms.|f|f|f|t
33793771|NCT04426045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34098303|NCT03240432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098304|NCT05705128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34098305|NCT00784927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713503|NCT00516438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713504|NCT05557604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Subjects who meet all study eligibility criteria will be randomly assigned in a 1:1 ratio.~Randomization is centralized at the promoter and takes place according to a specific procedure (in attachment).~The randomization schedule will be generated by an independent group of the promoter.~Patient study number and result of randomization will be given immediately by email."|prospective, open, randomized phase 2 trial|f|f|t|f
33713505|NCT04461678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713506|NCT02056314|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713507|NCT03608501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713508|NCT01516697|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33793772|NCT00982618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793773|NCT00457769|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793774|NCT01638039|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33793775|NCT02842424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793776|NCT00318253|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33793777|NCT01002768|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34015805|NCT01330420|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34015806|NCT01739920|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34015807|NCT06236932|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34098306|NCT02983942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098307|NCT01829503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098308|NCT05167058|||CASE_ONLY||PROSPECTIVE|||||||
34015808|NCT04126421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial (RCT). Randomized to either E1 semented cup or Marathon semented cup in total hip arthroplasty (THA).|t|t|f|f
34015809|NCT05403736|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open Label||||
34015810|NCT04322578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015811|NCT04166513|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Care provider, participant, and outcome assessor are masked for tDCS status.|Partial crossover design. Participants will maintain one of two speech therapy modalities throughout the study, but will crossover from targeted to active control stimulation (or vice versa).|t|t|f|t
34098309|NCT06232421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098310|NCT05306574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015812|NCT01698437|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098311|NCT06129682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015813|NCT02526511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015814|NCT02932228|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34015815|NCT03544541|||COHORT||PROSPECTIVE|||||||
34015816|NCT01524250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015817|NCT03096275|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned to two treatment arms and were treated for 12 months.||||
34015818|NCT04665375|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot intervention study||||
34098312|NCT05574400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a single-center, quadruple-blinded, randomized control trial at Michigan Medicine|This will be a three-arm parallel trial.|t|t|t|t
34098313|NCT05352594|||COHORT||PROSPECTIVE|||||||
34098314|NCT03182556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34098315|NCT06021223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098316|NCT04249648|||COHORT||PROSPECTIVE|||||||
34098317|NCT06256874|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098318|NCT06015334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will remain unaware of their specific study arm assignments until the completion of the study.|Patients with cataract will receive implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.|t|f|f|f
34098319|NCT00617903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098320|NCT04607785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34098321|NCT04873661|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098322|NCT02388256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34098323|NCT00060385|RANDOMIZED|||TREATMENT||||||||
34098324|NCT02950974|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34098325|NCT04933227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098326|NCT02083263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098327|NCT00756314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34098328|NCT00134498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33713509|NCT06507007|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713510|NCT05258175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
33713511|NCT02283697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713512|NCT04051723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33713513|NCT01652703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713514|NCT00338234|||COHORT||PROSPECTIVE|||||||
33713515|NCT00583778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713516|NCT06501482|RANDOMIZED|PARALLEL||TREATMENT||NONE||National, multicenter, open-label randomized, 2-arm, phase III superiority trial||||
33713517|NCT02829450|||COHORT||PROSPECTIVE|||||||
33713518|NCT00754260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33713519|NCT02528071|||COHORT||PROSPECTIVE|||||||
33713520|NCT05712928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713521|NCT01539057|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713522|NCT05577260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33713523|NCT02548650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713524|NCT06036771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|outcome assessors will be blinded to the group allocation.|60 PWP will be randomized into the intervention group (IG) and controlled group (CG). Block randomization is performed by an independent research team member who will not be in contact with participants via a free third-party website. Allocations will only be revealed upon the commencement of the intervention period and cannot be altered.|f|f|f|t
33713525|NCT02088255|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33713526|NCT00602706||||TREATMENT||||||||
33713527|NCT03426501|||COHORT||PROSPECTIVE|||||||
33713528|NCT03776383|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The data for the outcome are being provided from a third party with no involvement in the study|3:3:1 for intervention 1: intervention 2: control|f|f|f|t
33713529|NCT00314392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33713530|NCT01025752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713531|NCT00759811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713532|NCT04355845|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33713533|NCT02768012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713534|NCT05328193|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All study personnel that are in a position to change the study protocol or its implementation in study participants should be blinded to information that may allow them to do so, from when the study starts until the study ends, with specific exceptions. This means that all investigators and study staff should be blinded to study data aggregated by study arm that have the potential to impact the study's outcome.||f|f|t|t
33713535|NCT00637481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713536|NCT01338766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713537|NCT00107445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713538|NCT01868750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33713539|NCT01045720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713540|NCT02200289|||COHORT||PROSPECTIVE|||||||
33713541|NCT06158594|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713542|NCT00068471||||SUPPORTIVE_CARE||NONE||||||
33713543|NCT06507319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33936956|NCT06375811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For participants who agree to be randomized, a computer-generated randomization list will be created by the PREGnant Data Coordinating Center (DCC) and randomization will be performed prior to the first dose of elagolix. Randomization will have random sizes (2, 4, or 6) of blocks and be stratified by site, i.e. whole blocks are assigned to sites. The randomization list will not be available to any person involved in the conduct and evaluation of the trial until the trial is complete and database is declared clean and is released by the DCC. Likewise, treatment allocation information will not be accessible to investigators (except for serious safety concerns), trial staff at the site or central laboratory personnel during the trial.|Half of the subjects (200, randomized or not randomized) will receive elagolix 200mg twice a day (BID) and the other half of subjects will receive placebo BID or SOC IVF (200, placebo or SOC IVF). Elagolix or placebo will be taken for a minimum of 60 days before IVF cycle start. For convenience of IVF cycle scheduling, participants may receive up to an additional 14 days of intervention (elagolix or placebo) beyond the minimum 60 days of pre-IVF treatment, such that the last dose of study intervention (elagolix or placebo) is received no more than 24 hours before start of IVF treatment protocol.|t|t|t|f
33936957|NCT05664828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open-label, non-randomised and non-placebo-controlled study||||
33936958|NCT01051856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33936959|NCT01766986|||COHORT||RETROSPECTIVE|||||||
33936960|NCT02227901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33936961|NCT03904862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936962|NCT00362440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936963|NCT03224832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the cases which will come to general surgery outpatient clinic will be subjected to standard approach while the cases which will come to our EL Rajhi outpatient clinic will be subjected to artery-first approach|one group will be subjected to artery fgirst approach at EL Rajhi hospital and the other group will be subjected to standard approach at the main general surgery department at Assiut university hospital|t|f|f|f
33936964|NCT01227252|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33936965|NCT01321476|||||PROSPECTIVE|||||||
33936966|NCT04237610|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33936967|NCT01997892|||COHORT|||||||||
33936968|NCT03388554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA.|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.|t|f|f|t
33936969|NCT03037333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33936970|NCT00441194|||COHORT||PROSPECTIVE|||||||
33936971|NCT04388072|||COHORT||PROSPECTIVE|||||||
33936972|NCT02728310|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33936973|NCT04177394|||COHORT||PROSPECTIVE|||||||
33936974|NCT03760302|||CASE_ONLY||RETROSPECTIVE|||||||
33936975|NCT05115006|||COHORT||CROSS_SECTIONAL|||||||
33936976|NCT02765854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936977|NCT05983679|||COHORT||PROSPECTIVE|||||||
33936978|NCT04857606|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33936979|NCT00478530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33936980|NCT03923829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor and statistician will be blinded to the intervention||f|f|f|t
33936981|NCT01610414|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33936982|NCT00908050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33936983|NCT02655263|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33936984|NCT02696590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33936985|NCT04992000|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33936986|NCT01078779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33936987|NCT01276392|||COHORT||PROSPECTIVE|||||||
33936988|NCT00636038|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33936989|NCT06239649|||CASE_CONTROL||PROSPECTIVE|||||||
33936990|NCT04752228|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33936991|NCT04741867|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33936992|NCT04400669|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Surgeons and the assessor will be blind. The nurse working in the gynecology setting perform the intervention to the previously randomized patients. Patient will be told for not to reveal the intervention that she undergoes.||f|f|t|t
33936993|NCT02617199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713544|NCT03611764|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713545|NCT02458820|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33713546|NCT03281486|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33936994|NCT01910142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33936995|NCT03491254|||COHORT||PROSPECTIVE|||||||
33936996|NCT05546957|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33936997|NCT03262285|||CASE_ONLY||PROSPECTIVE|||||||
33713547|NCT00839150|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713548|NCT02326571|||COHORT||PROSPECTIVE|||||||
33713549|NCT01508650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713550|NCT06013670|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713551|NCT01935271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713552|NCT02045134|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33936998|NCT04019197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33936999|NCT01087073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937000|NCT01250899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937001|NCT00917540|||COHORT||PROSPECTIVE|||||||
33937002|NCT03953040|||COHORT||RETROSPECTIVE|||||||
33937003|NCT04825704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713553|NCT04887714|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34015819|NCT06091228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015820|NCT04701515|||COHORT||OTHER|||||||
34015821|NCT00570882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015822|NCT03209375|||COHORT||PROSPECTIVE|||||||
34015823|NCT04952077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015824|NCT03828136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 168 patients will be randomized in 7:2 ratio to Investigational (n=130) and Control arms (n=38).|t|f|f|f
34015825|NCT00181220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793778|NCT05244486|RANDOMIZED|PARALLEL||PREVENTION||NONE|Given the nature of the study, it is not possible to mask either the study participant or investigator.|Once enrolled, patients will be randomized 2:1 to receive either Restorex or control (no treatment) beginning at 1 month post-op until 6 months. They will then enter an open label phase for 3 additional months.||||
33793779|NCT00269880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098329|NCT04079764|||CASE_CONTROL||PROSPECTIVE|||||||
33793780|NCT00320502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33793781|NCT06552962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study was designed as a double-blind randomize-controlled study in which the participant and the evaluator were blinded.|Within the scope of the research, individuals with chronic non-specific low back pain will be randomized and divided into two separate groups. The control group will undergo lumbar stabilization exercises twice a week for 6 weeks. The experimental group will have the same lumbar stabilization exercises performed on the whole body vibration device twice a week for 6 weeks. The frequency of the device will be set to 30 Hz. Exercise duration, frequency, number and variety will be kept equal for the experimental and control groups. Demographic information of the patients, viscoelastic properties of the lumbar region, pain, function, quality of life, lower extremity muscle strength, endurance, balance and proprioception will be evaluated. Measurements will be made before treatment and at the end of 6 weeks of treatment.|t|f|f|t
33793782|NCT04097210|||OTHER||RETROSPECTIVE|||||||
33793783|NCT02824939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33793784|NCT02804516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793785|NCT03922867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937004|NCT01774838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937005|NCT00506740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33937006|NCT00469976||||TREATMENT||NONE||||||
33937007|NCT03109535|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937008|NCT04365491|||COHORT||PROSPECTIVE|||||||
33937009|NCT01172704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937010|NCT00534664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937011|NCT04520295|||COHORT||PROSPECTIVE|||||||
33937012|NCT03944551|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an unblinded, age-stratified, randomized trial with a 2:1 allocation ratio.||||
33937013|NCT00397644|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33937014|NCT05956990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||patients were randomly assigned to the rehabilitation group and control group by online randomization software|f|t|f|t
33937015|NCT05933993|||COHORT||PROSPECTIVE|||||||
33937016|NCT01878981|||CASE_CONTROL||PROSPECTIVE|||||||
33937017|NCT02413086|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33937018|NCT02959736|||COHORT||PROSPECTIVE|||||||
33937019|NCT00004256|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34015826|NCT01347866|NON_RANDOMIZED|||BASIC_SCIENCE||NONE||||||
34015827|NCT00074737|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098330|NCT05977530|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098331|NCT04123795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098332|NCT02824549|||COHORT||PROSPECTIVE|||||||
34098333|NCT00576394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098334|NCT03886324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098335|NCT02884180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098336|NCT05160285|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label, Single-arm, Phase II Study||||
34098337|NCT00045955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793786|NCT06242899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793787|NCT06677528|||COHORT||PROSPECTIVE|||||||
33937020|NCT06059274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937021|NCT00597857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937022|NCT00315523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937023|NCT01841164|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34015828|NCT03772366|||COHORT||PROSPECTIVE|||||||
34015829|NCT00326287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015830|NCT04328571|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Single coding|3-arms randomized-controlled, parallel group, single center, double-blinded study investigating 3 different formulations of the investigational product|t|f|t|t
34015831|NCT00211991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34015832|NCT02099695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015833|NCT01206621|||COHORT||PROSPECTIVE|||||||
34015834|NCT05000970|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Both participant and investigator will be blinded on the study assignment group.||t|f|t|f
34015835|NCT00141986|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015836|NCT02341833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015837|NCT05843799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34015838|NCT02680431|||CASE_CONTROL||PROSPECTIVE|||||||
34098338|NCT04241718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098339|NCT01312077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098340|NCT03118895|NA|SINGLE_GROUP||TREATMENT||NONE|370 high bleeding risk items|||||
34098341|NCT04718675|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098342|NCT01862029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098343|NCT03725059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098344|NCT06253208|||CASE_CROSSOVER||PROSPECTIVE|||||||
34098345|NCT03020082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098346|NCT02202720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098347|NCT03568786|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34015839|NCT01833533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015840|NCT03522571|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34015841|NCT04254939|NA|SEQUENTIAL||TREATMENT||NONE||||||
33713554|NCT02309697|||COHORT||PROSPECTIVE|||||||
34015842|NCT02145026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015843|NCT05701137|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015844|NCT02035839|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34015845|NCT01613950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015846|NCT02196519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015847|NCT04583748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the treatment hypothesis, while investigators and treating clinicians will be additionally blinded to the intervention.|Patients will undergo 1:1:1 randomization to Sahaj Samadhi Meditation or Health Enhancement Program or Treatment as Usual, stratified by gender. Twenty-five irreversible age-related vision loss patients and their 25 caregivers will be assigned, on a rolling basis, in the three groups.|f|f|t|t
34015848|NCT00862238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015849|NCT04016792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015850|NCT02353052|||COHORT||PROSPECTIVE|||||||
34015851|NCT00004997||||TREATMENT||||||||
34098348|NCT00512083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098349|NCT06029998|NA|SINGLE_GROUP||TREATMENT||NONE||A modified intent-to-treat data set will be used for both safety and efficacy endpoint analysis. All participants who have received one dose of study medication will be included in all efficacy and safety data sets. Participants who fail to begin study therapy will be replaced.||||
34098350|NCT03929055|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098351|NCT05420025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi Experimental||||
34098352|NCT01701635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098353|NCT03810794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098354|NCT00700089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34098355|NCT06085209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the use of SCT to prevent knowledge of their group assignment from biasing their subjective assessments. Adjudicators in the primary outcome measurements (quantitative CT) will be blinded to group assignment as well.|Participants will be randomly allocated in a 1:1 fashion to intervention standard of care (SOC) + SCT and control (SOC) groups. Participants will be blinded to the use of SCT to prevent knowledge of their group assignment from biasing their subjective assessments. Adjudicators in the primary outcome measurements (quantitative CT) will be blinded to group assignment as well.|t|f|f|t
34103362|NCT06673914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713555|NCT02564250|||COHORT||PROSPECTIVE|||||||
33713556|NCT03478267|||COHORT||PROSPECTIVE|||||||
33713557|NCT05653167|||OTHER||CROSS_SECTIONAL|||||||
33713558|NCT06376799|||OTHER||PROSPECTIVE|||||||
33713559|NCT03988985|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
33713560|NCT06476561|||COHORT||CROSS_SECTIONAL|||||||
33713561|NCT01681225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713562|NCT00144092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713563|NCT02234089|||COHORT||PROSPECTIVE|||||||
33713564|NCT04938804|NA|SINGLE_GROUP||SCREENING||NONE||||||
33713565|NCT05187715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713566|NCT02399501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713567|NCT06158789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713568|NCT02356614|||COHORT||PROSPECTIVE|||||||
33713569|NCT04233645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713570|NCT03576976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713571|NCT04540224|||CASE_CONTROL||PROSPECTIVE|||||||
33713572|NCT03355651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ACL parasagittal cuts were performed in T1 sequences and analyzed by a blinded musculoskeletal radiologist to improve the quality of the study||f|f|f|t
33713573|NCT02013791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713574|NCT02733939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713575|NCT05351125|||CASE_ONLY||PROSPECTIVE|||||||
33713576|NCT01116011|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33713577|NCT02455232|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713578|NCT00652405|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33713579|NCT02694510|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33713580|NCT04940351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713581|NCT00616395|||COHORT||PROSPECTIVE|||||||
33713582|NCT04939402|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713583|NCT00298051|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33713584|NCT03433521|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33713585|NCT00504933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713586|NCT03547687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713587|NCT00191789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713588|NCT03418415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713589|NCT00905398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713590|NCT04693234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713591|NCT00554411|||COHORT||PROSPECTIVE|||||||
33713592|NCT02475746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713593|NCT00382460|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33713594|NCT03655691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|different doses are packaged in identical containers|parallel dose groups|t|t|t|t
33713595|NCT04957693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713596|NCT01845207|||COHORT||PROSPECTIVE|||||||
34015852|NCT02826811|||COHORT|||||||||
34015853|NCT04432961|||CASE_ONLY||RETROSPECTIVE|||||||
34015854|NCT01709279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015855|NCT03356574|||COHORT||RETROSPECTIVE|||||||
33713597|NCT02382393|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33713598|NCT03716024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713599|NCT05650398|||CASE_CONTROL||PROSPECTIVE|||||||
33713600|NCT04150393|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||3+3 design dose escalation||||
34015856|NCT04696107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"After randomization and assignment to each arm, the masking will be triple ( researcher, evaluator of results, participant):~* Researchers: All the professionals who participate in the study will only do so in a single specific stage and will be blinded to the assignment and development of others.~* Evaluators of results: The results will be analyzed by an independent statistical professional and the evaluation of the response will be carried out by researchers who do not know the group to which each patient belongs.~* Participant: Patients will be blinded for up to six months of follow-up. Then they will know the group to which they belong and will be invited to do the workshop if they have belonged to the control group.~We don't believe that it is possible that a patient emergency unmasking will be required due to secondary effects, even so, the Patient Safety Committee will inform of any incident."|"A triple blinded, Randomized, Parallel-Group Clinical Trial.~1. Patients who meet the inclusion criteria are informed, voluntarily agree to participate and give signed consent at their Primary Care Center, will be included in the study. In the Investigation Unit of the Hospital San Juan De Dios del Aljarafe they will be anonymised using a table where their medical history number will be assigned an order number, which will serve as identification. They will also be randomized by permuted blocks.~2. Telephone surveys: A professional of the Hospital San Juan de Dios del Aljarafe will be responsible for taking all questionnaires by telephone at the beginning, per month, three months and six months of inclusion for each patient.~3. Psychoeducational intervention: The two professionals who teach the workshops are hospital workers with training in Pain Neuroscience and Coaching.~4. Data analysis: by a biostatistics expert. No professional can access the rest of the information of the study."|t|f|t|t
34015857|NCT01009671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015858|NCT06456944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double blinded randomized controlled trial (participants blinded to the intervention and statistician blinded to group assignment)||t|f|f|f
34015859|NCT00916435|||COHORT||PROSPECTIVE|||||||
34015860|NCT05879198|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025383|NCT03831165|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The patients will be treated at the Clinic of Gynecology, University of Sao Paulo during a total of 04 visits. In the first and fourth visits, patients will be sent to the laboratory of the University Hospital for collecting the cluster of differentiation 4 cells, interleukin-2 and serology for herpes.|The patients will be divided into three groups. One group (group A) will receive a bottle with 360 pills of acyclovir 200 mg. These individuals will be instructed to take 2 tablets of 200mg acyclovir (400 mg) twice daily for 90 days. Group B will receive 90 tablets of 30 mg of melatonin, the tablet will be used as 01 tablet daily for 90 days. Group C will receive 90 tablets of melatonin 3mg, and 360 tablets of acyclovir dose is 1 tablet per day for 90 days.|t|t|t|f
34025384|NCT01450527|||CASE_ONLY||PROSPECTIVE|||||||
34025385|NCT01121848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713601|NCT05299281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713602|NCT01580618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33713603|NCT04689633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33713604|NCT00639054|||COHORT||PROSPECTIVE|||||||
33713605|NCT02460614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713606|NCT06048445|||COHORT||PROSPECTIVE|||||||
33713607|NCT00691821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713608|NCT03115814|||OTHER||PROSPECTIVE|||||||
33713609|NCT03021122|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Blinding to the purpose of the study during recruitment will be maintained to minimize preparation bias. Nurses will be unblinded when the simulated scenario start."||t|f|f|f
33713610|NCT03272074|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713611|NCT03749070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Clinical trial, randomized, double-blind and controlled|t|t|t|t
33713612|NCT03052725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713613|NCT06311201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33713614|NCT04044235|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A non- randomized study design being implemented in 2 facilities in Lilongwe Urban. The first component is a cross-sectional study of AGYW in which HIV testing counselors will offer HIV tests and assess HIV risk. A sample of AGYW testing HIV-negative and established to be at high risk will be consented to enroll in the PrEP study. In the second component, AGYW who refuse PrEP will be consented to enroll in an HIV incidence cohort study and will be followed every 3 months for 12 months to determine HIV incidence. In the third component, AGYW who consent will be enrolled in a PrEP study. The PrEP study has two phases, which are, (i) a formative qualitative study involving AGYW and PrEP providers to understand factors and barriers to delivering PrEP to AGYW and (ii) a feasibility study of delivering PrEP to HIV negative AGYW. AGYW will be followed every 3 months for 12 months to determine incidence, assess factors and costs of delivering PrEP to AGYW.|f|t|f|f
33713615|NCT02144051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713616|NCT04827160|||COHORT||RETROSPECTIVE|||||||
33713617|NCT04061915|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33713618|NCT01499745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713619|NCT02407821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713620|NCT03171415|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double Blind, Randomized, Placebo Controlled|This is a consecutive 4 cohort, dose escalation placebo-controlled clinical trial|t|t|t|f
33713621|NCT00602953|||OTHER||CROSS_SECTIONAL|||||||
33713622|NCT02870296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33713623|NCT00063973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713624|NCT05743270|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33713625|NCT03483051|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||In this phase IIb, double-blind, cross-over trial, we will assign 22 subjects who are post-TAVR for severe AS to: (A) Potassium nitrate administered by mouth at a dose of 6 mEq three times daily for 4 weeks, or (B) Potassium chloride (KCl) at identical doses. The order of the interventions (AB-BA design) will be randomized, with a 1-week washout period separating each intervention. A crossover design will enable each subject to receive both treatments.|t|t|t|t
33713626|NCT02603419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713627|NCT04372030|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is an online survey completed by participants willing to take part||||
33713628|NCT04912050|||COHORT||PROSPECTIVE|||||||
33713629|NCT00680862|||COHORT||CROSS_SECTIONAL|||||||
33937024|NCT04481724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Participants will be randomized 3:1, GLA:placebo. Interim analyses of the primary outcome will be performed at 12 and 18 months; if greater weight loss is maintained in the GLA compared to placebo group, the study will be unblinded and placebo group participants will cross over to the GLA group for the remainder of the trial.|t|t|t|f
33937025|NCT02619929|||COHORT||PROSPECTIVE|||||||
33937026|NCT03390127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33937027|NCT03617471|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937028|NCT05614700|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Feasibility Study||||
33937029|NCT01159886|RANDOMIZED|PARALLEL||||NONE||||||
33937030|NCT00099840|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937031|NCT02735044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937032|NCT02460094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937033|NCT04409691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937034|NCT01607749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937035|NCT02092506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937036|NCT02628366|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937037|NCT01742182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937038|NCT02133261|||COHORT||PROSPECTIVE|||||||
33937039|NCT02289118|||COHORT||PROSPECTIVE|||||||
33937040|NCT00443534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937041|NCT00098865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937042|NCT05972577|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33937043|NCT00518739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937044|NCT05431972|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective, Multi-center, Open-label, Randomized, Controlled, Investigator-Initiated Trial||||
33937045|NCT05524363|||COHORT||PROSPECTIVE|||||||
33937046|NCT03208504|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, non-randomized, interventional clinical study. All subjects will be treated by implantation of the Single Branch Nexus™ Aortic Arch Stent graft System.||||
33937047|NCT03254849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937048|NCT02158000|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937049|NCT01524809|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33937050|NCT03844061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937051|NCT02916628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937052|NCT05894486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937053|NCT06028906|||COHORT||PROSPECTIVE|||||||
33937054|NCT01106313|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937055|NCT01713907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937056|NCT05598840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937057|NCT02563886|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33937058|NCT03795545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937059|NCT00836953|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33937060|NCT05391412|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937061|NCT03080441|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937062|NCT00533780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937063|NCT05340816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researcher who made the assessments and participants do not know which group participants belong to.|Participants will be assigned to manual lymph drainage, transcutaneous electrical nerve stimulation, or a control group.|t|f|f|t
33937064|NCT04949633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937065|NCT04170855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937066|NCT05375656|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The study will be blinded with respect to the genotype of the participants for everyone involved in the study except for the investigator. The dietary intervention will not be blinded.|"A cross-over design will be applied to the intervention. Participants will be randomized to first receive either a diet high in starch and relatively high in sucrose, resembling a western diet, or a diet low in carbohydrate with many marine foods, resembling a traditional Inuit diet. There will be a wash out period of 7 days between the two diets.~Each participant will throw a dice in order to randomize the order of which the participants receive the two intervention diets."|t|t|f|t
33937067|NCT03485404|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Central randomization. Groups are marked as A and B with no participants, care provider, investigator and outcome assessors know which group is the drug and which is the placebo. Placebo are made as tablets that mimics the color, shape and size of the drugs.||t|t|f|f
33937068|NCT02411877|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937069|NCT00572065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937070|NCT02450240|||CASE_CONTROL||PROSPECTIVE|||||||
33937071|NCT01030757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937072|NCT05840393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33713630|NCT02373202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713631|NCT00530764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33937073|NCT01576887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937074|NCT00597129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937075|NCT06450782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33937076|NCT01814228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713632|NCT02016560|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|Applies only to confirmatory phase: the independent readers are blinded to all clinical information.|All subjects in both the exploratory and confirmatory phases of the study, receive both florbetapir and florbetapir scans, regardless of subgroup assignment.|f|f|f|t
33713633|NCT06013865|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Observational Cohort Study||||
33937077|NCT03687931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937078|NCT03738774|||COHORT||PROSPECTIVE|||||||
33937079|NCT06054594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937080|NCT01511549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937081|NCT01701349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025386|NCT02244814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025387|NCT02849938|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34025388|NCT01663883|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098356|NCT03109925|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single group of patients undergoing prostate artery embolization with a new embolic which is radio-opaque and can give a better idea of embolization distribution (DC Lumi Beads by BTG)||||
34098357|NCT04741256|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34098358|NCT06539169|||COHORT||CROSS_SECTIONAL|||||||
34098359|NCT02975700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098360|NCT03834259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098361|NCT02852746|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34098362|NCT00153478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720801|NCT05413707|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial with to arms: Fixation of posterior malleolus fractures (PMFs) versus no fixation of the PMF.||||
33720802|NCT00819351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720803|NCT05366244|||COHORT||PROSPECTIVE|||||||
33720804|NCT01388608|||COHORT||PROSPECTIVE|||||||
33720805|NCT06196333|||OTHER||CROSS_SECTIONAL|||||||
33937082|NCT04559867|RANDOMIZED|PARALLEL||OTHER||NONE||During the procedure, the study doctor will evaluate the participant's anatomy to determine if both approaches are possible to safely perform. If both approaches are assessed as safe to perform, then the participant will be randomly assigned (like the toss of a coin) to one approach. If the study doctor is unable to gain access using the approach the patient is initially assigned to, then they will switch approaches and use the other approach.||||
33937083|NCT03389867|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33937084|NCT02680366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||BMSCs group (BMSCs-scaffold plus Foley catheter) or control group (only Foley catheter).|t|f|f|f
33937085|NCT02627196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937086|NCT00367627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937087|NCT03215849|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33937088|NCT01956331|||COHORT||PROSPECTIVE|||||||
33937089|NCT05749276|NA|SINGLE_GROUP||TREATMENT||NONE||Continual Reassessment Method for MTD||||
33937090|NCT00840385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937091|NCT03315702|||COHORT||PROSPECTIVE|||||||
33937092|NCT04511091|||COHORT||RETROSPECTIVE|||||||
33937093|NCT00249522|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937094|NCT01860794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937095|NCT02672306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33937096|NCT06152770|||CASE_ONLY||OTHER|||||||
33937097|NCT05518994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937098|NCT02302586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937099|NCT06397157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937100|NCT02245685|||COHORT||PROSPECTIVE|||||||
33937101|NCT06142162|||COHORT||PROSPECTIVE|||||||
33937102|NCT02203916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937103|NCT03192384|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33937104|NCT01445002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937105|NCT02286752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33937106|NCT02569645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937107|NCT06298838|||COHORT||PROSPECTIVE|||||||
33937108|NCT06500234|RANDOMIZED|PARALLEL||TREATMENT||NONE||Malnourished patients with megestrol acetate 160mg oral, olanzapine 2.5mg oral, everyday during the immunotherapy course or intolerable.||||
33937109|NCT00571051|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33937110|NCT05538585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937111|NCT00671515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937112|NCT00109239|RANDOMIZED|||TREATMENT||NONE||||||
33937113|NCT02089178|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33937114|NCT01657253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937115|NCT00103779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937116|NCT02840552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937117|NCT00425191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937118|NCT01440829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937119|NCT03001765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937120|NCT05820776|||COHORT||PROSPECTIVE|||||||
33937121|NCT04225806|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33937122|NCT02367859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937123|NCT04919694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937124|NCT04764838|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|Will not be shared with other researchers and statisticians related to the intervention and control group.|Randomized controlled single blind|f|f|t|t
33937125|NCT02429089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937126|NCT05297292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937127|NCT00826787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937128|NCT00942656|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33937129|NCT04545931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patient will be allocated to either arms of the study using concealed random allocation method.||t|f|t|f
33937130|NCT04530318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937131|NCT04818112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The video coders measuring mother-infant synchrony will be blinded to group assignment.|This randomized clinical trial uses group comparison of an intervention group and an education control group.|f|f|f|t
33937132|NCT04574791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937133|NCT03001791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937134|NCT05486689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective||||
33937135|NCT02837549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098363|NCT05045963|||COHORT||RETROSPECTIVE|||||||
34098364|NCT04010253|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098365|NCT03924076|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34098366|NCT04900857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|Prospective randomized controlled trial|t|f|f|t
34098367|NCT05738252|||COHORT||PROSPECTIVE|||||||
34098368|NCT06493383|NA|SINGLE_GROUP||OTHER||NONE||||||
34098369|NCT00263562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103363|NCT05591300|||CASE_CONTROL||PROSPECTIVE|||||||
33793788|NCT05722106|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793789|NCT00814047|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33793790|NCT04574635|||CASE_ONLY||PROSPECTIVE|||||||
33793791|NCT06554080|||COHORT||RETROSPECTIVE|||||||
33793792|NCT05686421|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33793793|NCT00509769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793794|NCT04143126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This proposed study consists of an 18-month randomized-controlled trial in which 90 outpatients with schizophrenia with moderate-to-severe persistent negative symptoms will be randomized to Cognitive Enhancement Therapy (CET) or Enriched Supportive Therapy (EST) and treated for 18 months. Comprehensive measures of cognition, negative symptoms, and functional outcome will be collected prior to treatment, every 6-months thereafter (6 and 12 months), at treatment completion (18 months), and 3-month (21 months) and one year (30 months) post-treatment follow-up to provide a rigorous confirmatory test of the efficacy of CET and EST for patients with persistent negative symptoms and the cognitive mechanisms of negative symptom improvement in the disorder.|f|f|f|t
33793795|NCT01134562|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33793796|NCT00597519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098370|NCT06445179|RANDOMIZED|PARALLEL||TREATMENT||NONE|The ENDO-RAS Trial is a multicenter, randomized, controlled, and open-label study.|Eligible patients will be randomized into two parallel groups.||||
34098371|NCT01407978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098372|NCT02157337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098373|NCT04102644|||COHORT||PROSPECTIVE|||||||
34098374|NCT01636544|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098375|NCT04086615|RANDOMIZED|PARALLEL||TREATMENT||NONE||"84 (anticipated) participants will be assigned to one of two parallel groups. Sample size was determined using 1) an alpha level of 0.05 and power of 0.80; 2) review of PFPS literature and data from pilot work; and 3) calculation of effect sizes for key variables from previous studies that addressed the Specific Aims.~For the primary outcome variable of strength, the sample size calculated was 35 subjects per groups (70 total subjects) with an effect size of 0.52. For the outcomes measures of function, mobility and pain, assuming that standard errors will be similar to those observed in our previous work, the sample size of 35 per group is sufficient to detect the expected mean changes. To account for dropouts, the investigators inflated the sample size by 20%, for a total of 42 subjects per group and a total sample size of 84."||||
34098376|NCT02255279|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33713634|NCT03804047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Randomization will done using concealed allocation with the use of opaque envelopes. Envelopes will be spread out over a table and participants will choose one to give it to the Physical Therapist (PT). The PT will open the envelope to check the type of tape (without showing or saying it to the participant) to be applied (kinesio or Sham tape). Participants are unaware about tape categorization treatment or placebo as the tapes are unlabeled."|Two arm randomized controlled trial (Pre; Post)|t|f|f|f
33713635|NCT05218460|NA|SINGLE_GROUP||OTHER||NONE||||||
33713636|NCT04697524|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713637|NCT02314611|||COHORT||PROSPECTIVE|||||||
33713638|NCT02272491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713639|NCT02285790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713640|NCT04998474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713641|NCT01408004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713642|NCT04276792|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Our design is a Hybrid Type 3 design with the primary aim to compare 2 implementation strategies, and a secondary aim to assess client-level outcomes associated with the trial; the design includes a cluster randomized parallel design with staggered starts||||
33713643|NCT02669732|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713644|NCT06302504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793797|NCT01418118|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793798|NCT06369922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33793799|NCT02520856|||CASE_ONLY||PROSPECTIVE|||||||
33793800|NCT03587363|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793801|NCT01801293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793802|NCT00588666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937136|NCT03201133|||CASE_CONTROL||RETROSPECTIVE|||||||
33937137|NCT03769857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Quadruple Blind|treatment versus placebo|t|t|t|t
33937138|NCT03708484|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33937139|NCT06461195|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group interventional study acquiring spirometry data, respiration sound and physiological data in patients suffering from pulmonary disease.||||
33937140|NCT05516264|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants from 2 nursing homes (25+25) are all receive three visit with a dog and three without a dog. It is randomised whter participents receive the dog visits first or last.||||
33937141|NCT04290000|||COHORT||PROSPECTIVE|||||||
33937142|NCT00661414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937143|NCT06339281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937144|NCT02390362|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937145|NCT00675844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937146|NCT03303625|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33937147|NCT06302699|||CASE_ONLY||RETROSPECTIVE|||||||
33937148|NCT01034709|||COHORT||PROSPECTIVE|||||||
33937149|NCT00780676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937150|NCT05272540|||COHORT||PROSPECTIVE|||||||
33937151|NCT04671745|||COHORT||PROSPECTIVE|||||||
33937152|NCT05794672|NA|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937153|NCT01962116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937154|NCT00832065|||CASE_ONLY||PROSPECTIVE|||||||
33937155|NCT00685308|||COHORT||PROSPECTIVE|||||||
33937156|NCT01624974|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33937157|NCT05885373|NA|SINGLE_GROUP||OTHER||NONE||All study subjects will receive the same study products.||||
33937158|NCT02079311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937159|NCT03085212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025389|NCT04473066|||CASE_CONTROL||PROSPECTIVE|||||||
34098377|NCT03437733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098378|NCT02892708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098379|NCT02369159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098380|NCT00195429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098381|NCT04375215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective randomized clinical study|t|f|f|t
34098382|NCT05352113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098383|NCT05940636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-center, randomized controlled trial|t|f|f|t
34098384|NCT03666702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098385|NCT05059080|||COHORT||PROSPECTIVE|||||||
34098386|NCT04325386|RANDOMIZED|PARALLEL||OTHER||NONE||The investigators will compare an educational intervention between participant prescribers located at the randomized clinic sites.||||
33713645|NCT03724760|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713646|NCT04554667|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm, safety and feasibility trial.||||
33713647|NCT03729960|NA|SINGLE_GROUP||OTHER||NONE||||||
33713648|NCT06384040|||CASE_CONTROL||PROSPECTIVE|||||||
33713649|NCT03329950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713650|NCT03145350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|PI,and research assistants undertaking measurements will be blinded to the dietary intervention the participant is undertaking.|Randomised crossover with washout period.|f|f|t|f
33713651|NCT02813564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713652|NCT05845684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793803|NCT04541901|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33793804|NCT04213599|||COHORT||PROSPECTIVE|||||||
33793805|NCT03635294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098387|NCT02688231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33793806|NCT04610008|||COHORT||RETROSPECTIVE|||||||
33793807|NCT05379491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A randomized grouping sequence by block randomization with a block size of 4 is generated using a web-based service. Linaclotide or placebo is allocated according to the sequence and labelled in numerial order (1 - 720) without labelling the allocation information. Therefore, patients, endoscopists, and other investigators at each center will be unaware of the drug allocation.||t|t|t|t
33793808|NCT04183959|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33793809|NCT00221208|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793810|NCT06041919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Microbiology staff will be blinded to treatment allocation.|Parallel control arm, randomised clinical study in two sequential stages, with no stratification|f|f|f|t
33793811|NCT04442919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793812|NCT03280017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937160|NCT01914510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937161|NCT00003687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33937162|NCT00422968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937163|NCT05283785|||OTHER||PROSPECTIVE|||||||
33937164|NCT04561050|||COHORT||RETROSPECTIVE|||||||
33937165|NCT03170089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025390|NCT06108076|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, pilot trial||||
34025391|NCT03047434|||CASE_ONLY||PROSPECTIVE|||||||
34025392|NCT05816538|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
34025393|NCT01892280|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34025394|NCT05965973|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Triple (Participant, Investigator, Outcomes Assessor)||t|f|f|f
34025395|NCT04819334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Double-blind, randomised, crossover design|t|f|t|f
34025396|NCT05365724|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025397|NCT05395286|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34098388|NCT03847090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098389|NCT01206270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098390|NCT02046200|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34098391|NCT01801969|||COHORT||RETROSPECTIVE|||||||
33713653|NCT03030508|||CASE_CONTROL||PROSPECTIVE|||||||
33713654|NCT04010708|||COHORT||PROSPECTIVE|||||||
33713655|NCT01525381|||COHORT||PROSPECTIVE|||||||
33713656|NCT00068497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713657|NCT01148784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713658|NCT01892293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713659|NCT00284271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713660|NCT05471622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33713661|NCT02170051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713662|NCT01605877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713663|NCT04013139|||COHORT||PROSPECTIVE|||||||
33793813|NCT03542630|||COHORT||PROSPECTIVE|||||||
33793814|NCT04782635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33793815|NCT02999581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33793816|NCT00835380|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33937166|NCT05015062|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33937167|NCT03153124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937168|NCT01786499|NA|SINGLE_GROUP||TREATMENT||||||||
33937169|NCT01365715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33937170|NCT03687710|||COHORT||PROSPECTIVE|||||||
33937171|NCT01560754|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937172|NCT00000244||||TREATMENT||DOUBLE||||||
33937173|NCT00717561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937174|NCT00619216|||CASE_ONLY||PROSPECTIVE|||||||
33937175|NCT02194192|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33937176|NCT03562689|||COHORT||RETROSPECTIVE|||||||
33937177|NCT00740090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33937178|NCT03493373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34025398|NCT04421300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937179|NCT06410794|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"This is a non-randomised controlled experiment where we aim to recruit 20 patients from each of the six clinics involved in ABM training and up 100 from each of the clinics involved in VR. That is, 10 receiving ABM training and 10 in the control group, and 60 receiving VR and 40 in the control group. The participants will complete the questionnaires and cognitive measures one the day of arrival and on the penultimate or ultimate day of the rehabilitation/treatment. The measures will take approximately one hour to complete at each measurement point and will not interfere with the participation in the rehabilitation/treatment.~In the qualitative part of this pilot, it is aimed to recruit 15 patients, five at each of the three clinics."||||
33937180|NCT05727527|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33937181|NCT03381703|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937182|NCT02035410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34015861|NCT06406517|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study investigator/postdoctoral researcher/research coordinator will randomize participants into a study arm based on the day the participant is scheduled to receive their MRI. Participants will not be told which study arm they are being randomized into. MRI techs will be told which arm patients are randomized in to so that the correct IV contrast drug and dose will be administered. All MRIs will be read by cardiac radiologists, who will also not be told which study arm a participant was in. The master list of randomized participants will be maintained by the study investigator/postdoctoral researcher/research coordinator.|This will be a prospective, single center, parallel group, double-blinded, randomized clinical trial. The study will be conducted at UC San Diego MRI suites. Study participants will be randomized into one of four study arms prior to their MRI: Gadopiclenol 0.075 mmol/kg, gadopiclenol 0.10 mmol/kg, gadopiclenol 0.15 mmol/kg, gadobenate dimeglumine 0.15 mmol/kg (standard of care).|t|t|f|t
34015862|NCT01045993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34015863|NCT01762826|||CASE_CONTROL||PROSPECTIVE|||||||
34015864|NCT00238875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015865|NCT05886439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015866|NCT01117766|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34015867|NCT00577434|||COHORT||PROSPECTIVE|||||||
34015868|NCT00375570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015869|NCT00937820|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34015870|NCT02041936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015871|NCT06309277|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34015872|NCT05763706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34015873|NCT04899817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015874|NCT00605865|||CASE_ONLY||PROSPECTIVE|||||||
34015875|NCT04892797|||COHORT||PROSPECTIVE|||||||
34015876|NCT05333484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was quasi-experimental design with a parallel control group and the participants were recruited with convenience sampling method.||||
34015877|NCT03024736|||COHORT||RETROSPECTIVE|||||||
34015878|NCT05296382|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34015879|NCT03083821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015880|NCT00136318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34015881|NCT03589235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34015882|NCT01727882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015883|NCT01669993|||CASE_ONLY||PROSPECTIVE|||||||
34015884|NCT02148861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015885|NCT02310646|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34015886|NCT05480592|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34015887|NCT00306865|||||OTHER|||||||
34015888|NCT01047930|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098392|NCT04919551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-center, randomized, open-label, single-dose, fasted/high-fat meal/low-fat meal, 3-cycle, 3-way crossover||||
34098393|NCT00088101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098394|NCT01348490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098395|NCT04632030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098396|NCT01803737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098397|NCT03050489|||COHORT||PROSPECTIVE|||||||
34098398|NCT02186171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098399|NCT02690740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098400|NCT03600727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes Assessor will be blinded to this study.|Patients receiving total hip and knee arthroplasty will be intraoperative sedated by propofol or dexmedetomidine.|f|f|f|t
34098401|NCT01867554|||COHORT||PROSPECTIVE|||||||
34098402|NCT06633419|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34098403|NCT01056055|||CASE_CONTROL||PROSPECTIVE|||||||
34098404|NCT04755478|||COHORT||PROSPECTIVE|||||||
34098405|NCT01529112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098406|NCT02382900|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098407|NCT02916433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713664|NCT03038997|||COHORT||PROSPECTIVE|||||||
33713665|NCT02375113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33713666|NCT01150864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713667|NCT04341389|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33713668|NCT00744003|||COHORT||PROSPECTIVE|||||||
33937183|NCT01213342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937184|NCT01241318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937185|NCT00060567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937186|NCT05076552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33937187|NCT02531633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937188|NCT01631006|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33937189|NCT00898950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33937190|NCT05193890|||COHORT||RETROSPECTIVE|||||||
33937191|NCT03094338|||COHORT||PROSPECTIVE|||||||
33937192|NCT06390293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098408|NCT05190887|||COHORT||PROSPECTIVE|||||||
34103364|NCT03720275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015889|NCT02796131|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34015890|NCT05954182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015891|NCT04714229|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33937193|NCT04139421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Deception will be necessary prior to and during the study to achieve blinding of participants for the prevention of expectation bias.|The randomization will be performed by an independent assessor using a computer-generated list of numbers. Participants in both groups will receive a 3-hour Shinrin-Yoku session in either natural forest or urban green area in Hong Kong.|t|f|f|f
34015892|NCT01714349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015893|NCT04601038|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34015894|NCT00085774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015895|NCT06251596|||COHORT||PROSPECTIVE|||||||
34015896|NCT02483832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015897|NCT04463303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015898|NCT04950959|||COHORT||PROSPECTIVE|||||||
34015899|NCT05056610|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||During confocal endomicroscopy food antigens are given on the duodenal mucosa. The response of the mucosa is evaluated by the entry of fluorescein into the intestinal lumen and cell shedding||||
34015900|NCT01862315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015901|NCT00588640|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33937194|NCT01864629|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33937195|NCT06257394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937196|NCT00467506|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33937197|NCT01114594|||OTHER||PROSPECTIVE|||||||
33937198|NCT03996525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937199|NCT00835757|||CASE_CONTROL||PROSPECTIVE|||||||
33937200|NCT02079506|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937201|NCT00407420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937202|NCT02705547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937203|NCT00011128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937204|NCT01809704|||COHORT||PROSPECTIVE|||||||
33937205|NCT02962193|||COHORT||PROSPECTIVE|||||||
33937206|NCT00601653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937207|NCT03996655|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34015902|NCT05468788|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will not know which group they are in, as they will not be familiar with the particular procedure of the intervention being studied|One group will receive a new behavioral intervention; the other group will receive improvisational theatre alone|t|f|f|f
34015903|NCT02524717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015904|NCT00725530|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34015905|NCT03602963|||COHORT||PROSPECTIVE|||||||
34015906|NCT02882672|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015907|NCT01753336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015908|NCT03947736|||COHORT||PROSPECTIVE|||||||
34015909|NCT00472836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015910|NCT03582280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015911|NCT03001752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The care provider could not be blinded because of the nature of the treatment. The patient was blinded and the investigator and outcome assessor as well (using a code to identify teeth and patients).||t|f|t|t
34015912|NCT02062554|||COHORT||PROSPECTIVE|||||||
34015913|NCT03263039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34015914|NCT04430855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015915|NCT03486054|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomized, controlled, open-label|Experimental Arm: INTERCEPT Treated Whole Blood Control Arm: Standard of Care (Red Blood Cells, Whole Blood)||||
34015916|NCT05228496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015917|NCT05366465|||COHORT||CROSS_SECTIONAL|||||||
34015918|NCT03143608|||COHORT||PROSPECTIVE|||||||
34015919|NCT02876926|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34015920|NCT01844999|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34015921|NCT02622113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015922|NCT01072266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015923|NCT01163448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015924|NCT05414292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participant will not know if they are taking Rapamune or placebo||t|f|f|f
34015925|NCT05337774|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an exploratory Phase 1, case-control study. Neuroimaging, neuropsychological tests, medical history reviews, and questionnaires will be collected for all eligible subjects.||||
34015926|NCT06218264|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34015927|NCT00891371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015928|NCT04566705|||OTHER||RETROSPECTIVE|||||||
34015929|NCT03613116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants receive identically appearing capsules which contain either 4,000 IU (high-dose) or 600 IU (standard-dose) of vitamin D3.|Parallel Randomized Double-Blind Intervention of high-dose versus standard-dose vitamin D3.|t|t|t|t
34015930|NCT02765217|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34015931|NCT03986450|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34015932|NCT00853086|||COHORT|||||||||
34015933|NCT04669470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34025399|NCT00561418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025400|NCT05142397|||COHORT||PROSPECTIVE|||||||
34025401|NCT03715504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713669|NCT03554824|||COHORT||CROSS_SECTIONAL|||||||
33937208|NCT05353907|||COHORT||PROSPECTIVE|||||||
33937209|NCT00003465||||TREATMENT||||||||
33937210|NCT02946008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937211|NCT01215877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937212|NCT01948791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937213|NCT01657149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937214|NCT04656717|||OTHER||RETROSPECTIVE|||||||
33937215|NCT03581396|||COHORT||RETROSPECTIVE|||||||
33937216|NCT03652090|||COHORT||CROSS_SECTIONAL|||||||
33937217|NCT05858437|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||randomized, double-blind, placebo-controlled|t|t|t|t
33713670|NCT04186039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937218|NCT05967728|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"For the study component involving patients with CSVD, we will aim to achieve double blinding of the patients, care providers, and the outcome assessors regarding the initial randomization to RIC treatment or sham for the first 30 days. This will be achieved in two important ways: (1) the same device can be randomized to sham or control, so it will appear identical to the patient and to the assessors, and (2) the device randomization to sham or control will be implemented remotely through a platform that can program the devices, which will be inaccessible to the outcome assessors.~The study components involving MSU patients and physicians/paramedics will not involve blinding."|"The randomized-controlled trial component of the study will involve 24 patients with CSVD, randomized 1:1 to either receive RIC for the full 60-days, or sham treatment (inflation to 30mmHg) for the first 30-days followed by cross-over to RIC.~The MSU-based component of the study, consisting of 10 patients with acute ischemic stroke, will not involve randomization and all participants will be receiving true RIC."|t|t|f|t
33937219|NCT00364624|||COHORT||PROSPECTIVE|||||||
33937220|NCT00405275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937221|NCT05353218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Prospective|f|t|t|t
33713671|NCT01443988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937222|NCT03042728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937223|NCT00366444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33713672|NCT03938389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Blinding|Randomized prospective controlled clinical trial with three parallel arms, no crossover.|t|f|t|t
33713673|NCT01965496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713674|NCT05261074|||COHORT||RETROSPECTIVE|||||||
33713675|NCT05853198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713676|NCT05495906|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33937224|NCT02836366|||COHORT||PROSPECTIVE|||||||
33937225|NCT03918213|NA|SINGLE_GROUP||OTHER||NONE|No masking is possible|"Normative values for the routine procedure of high-resolution anorectal manometry for Russian population has not been studied yet. Some factors allows to suggest that normative values may differ from those obtained in other countries. This pilot study is aimed to either support the null-hypothesis of the presence of the differences or decline it. It is expected to obtain primary data that could be used for further work and planning of the cohort studies. During the study, healthy volunteers are to be examined with a registered diagnostic tool (i.e. high-resolution anorectal manometry with solid-state catheter). This diagnostic procedure is not intended as one for routine examination, therefore the study type is interventional, though no pharmacological intervention or surgery is planned. The estimated sample size sufficient to reach the power of 80%, and type 1 error 0.05 was obtained with single-sample t-test of Statistica10 (StatSoft, USA)"||||
33937226|NCT01304927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937227|NCT03088410|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single blind - one party, either the investigator or participant, is unaware of the intervention assignment.||t|f|t|f
33937228|NCT05220293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713677|NCT02893878|||OTHER||OTHER|||||||
33937229|NCT04844970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double-blind. Neither the investigator nor the participant would know the assigned drug/placebo|One group receives Anamorelin, and the other group receives placebo.|t|f|t|f
33937230|NCT00289302|||DEFINED_POPULATION||PROSPECTIVE|||||||
33937231|NCT01881724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937232|NCT01289028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937233|NCT05846542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937234|NCT04960995|||CASE_ONLY||RETROSPECTIVE|||||||
33937235|NCT01282190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937236|NCT01140230|||CASE_ONLY||RETROSPECTIVE|||||||
33937237|NCT00252499|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33937238|NCT01731600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937239|NCT00962416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937240|NCT00000641||||TREATMENT||NONE||||||
33713678|NCT05604118|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33937241|NCT03551704|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to each of the two treatment conditions in accordance with a computer-generated randomization list. The treatment conditions will be actively running in parallel.||||
33937242|NCT04440306|||COHORT||RETROSPECTIVE|||||||
33937243|NCT02586116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025402|NCT01747746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025403|NCT04328298|||COHORT||OTHER|||||||
34025404|NCT03411135|||OTHER||PROSPECTIVE|||||||
34025405|NCT02227511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34025406|NCT03629756|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose escalation design.||||
34025407|NCT02154295|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34025408|NCT02187146|||COHORT||PROSPECTIVE|||||||
34025409|NCT01014793|||CASE_ONLY||PROSPECTIVE|||||||
34025410|NCT00428116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025411|NCT00516152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025412|NCT00985101|||CASE_CONTROL|||||||||
34025413|NCT03283384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713679|NCT02669381|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713680|NCT01497691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713681|NCT04488484|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The research is a prospective, follow-up cohort, non-randomized and interventional study that aims at following patients who presented a positive serology for the COVID-19||||
33713682|NCT01266954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713683|NCT03130361|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33713684|NCT04676282|||CASE_ONLY||CROSS_SECTIONAL|||||||
33713685|NCT06166160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713686|NCT00187876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713687|NCT04823650|||COHORT||PROSPECTIVE|||||||
33713688|NCT00859053|NON_RANDOMIZED|PARALLEL||||NONE||||||
33713689|NCT05918692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Accelerated Titration Design, Followed by Modified 3+3||||
33713690|NCT00849641|||CASE_CONTROL||PROSPECTIVE|||||||
33713691|NCT00863603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713692|NCT01117831|||COHORT||PROSPECTIVE|||||||
33713693|NCT01129960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713694|NCT03932721|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patients will be assigned to evolocumab (140 mg every two weeks) on top of the standard of care, SOC therapy ( SGLT2 inhibitors, maximal statin dose and ideal control of blood glucose (HbA1c 6.5% to 7%) and blood pressure (SBP \<140 mm Hg). Or to the exclusive use of the SOC therapy.|t|f|f|f
33793817|NCT01343342|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713695|NCT02165774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793818|NCT05861050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713696|NCT01648946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793819|NCT03445598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participant is masked to the intervention assigned to them. All outcome measures are self-reported by the participants through a computer program without any involvement of the experimenters.||t|f|f|t
33713697|NCT02273024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713698|NCT01414010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33713699|NCT04445324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33713700|NCT03673553|||OTHER||PROSPECTIVE|||||||
34103365|NCT05309746|||OTHER||PROSPECTIVE|||||||
33793820|NCT02576821|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33793821|NCT02853695|||OTHER||CROSS_SECTIONAL|||||||
33793822|NCT06552702|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33793823|NCT05006092|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793824|NCT06037824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33793825|NCT00586586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793826|NCT06072105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793827|NCT04108754|||COHORT||RETROSPECTIVE|||||||
33937244|NCT06423404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After schools agreed to participate, they were randomly assigned using a sequence generated by the IBM SPSS statistical package, with concealed allocation to one of two groups: 1) the Experimental Group (n=3), receiving a 12-week program of video-guided active breaks with curricular content in the school classroom; and 2) the Control Group (n=3), receiving the same intervention as the experimental group after the final data collection. A simple stratified randomization sequence by sex was used to achieve balance between males and females in both groups. The randomization sequence will be concealed through sequentially numbered, opaque, sealed envelopes, conduct by a project investigator with no contact with schools and participants. Significant differences in the quality of life, motor skills, and academic performance have been found in studies with similar samples.|The project involves public primary schools with similar indices of school vulnerability (SVI) and medium to low socioeconomic status in the Biobío province, Chile. This selection was made because students attending these schools spend approximately eight hours per day (from 8:00 AM to 4:00 PM) with two 30-minute breaks and a longer one-hour lunch break. The intervention will focus on 1st to 4th grade classes. Six schools (three treatments and three controls) were recruited, estimating a sample size of 700 students (six schools × eight classes, with each class having 30 to 40 students).|f|f|t|t
33713701|NCT06089525|||COHORT||PROSPECTIVE|||||||
33937245|NCT03844529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blinded( blinded evaluator and subject) clinical trial.|240 subjects will be recruited in total, and each hospital will recruit 60\~120 subjects.|t|f|t|f
33937246|NCT01832051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937247|NCT03626389|||COHORT||PROSPECTIVE|||||||
34103366|NCT02122185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33713702|NCT05999045|||COHORT||CROSS_SECTIONAL|||||||
33713703|NCT05960266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One arm of patients will be treated by subcutaneous immunotherapy (SCIT). A second arm of patients will be treated by intralymphatic immunotherapy (ILIT).||||
33713704|NCT04610268|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937248|NCT05120375|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33937249|NCT03083964|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The outcome assessor is blind to study assignment and investigators do not have access to randomization records.|The participants are randomized to one of two treatment arms, usual care or intervention.|f|f|t|t
33937250|NCT05707195|NA|SINGLE_GROUP||OTHER||NONE||||||
33937251|NCT05661838|||CASE_CONTROL||RETROSPECTIVE|||||||
33937252|NCT05759949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937253|NCT05684367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937254|NCT04458311|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33937255|NCT00586833|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937256|NCT03870789|||COHORT||OTHER|||||||
33937257|NCT00806611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33937258|NCT03441516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937259|NCT02505009|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33937260|NCT03742271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937261|NCT02363673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937262|NCT03164746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34025414|NCT06632470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025415|NCT06500611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single ( Outcome Assessor)||f|f|f|t
34025416|NCT03300843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103367|NCT02913573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713705|NCT00033215|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Four dose levels were evaluated sequentially in separate groups of 6 to 8 patients: 1,600 mg/d (800 mg BID, Dose Level1 (DL1)), 3,200 mg/d (1,600 mg BID, DL2), 4,800 mg/d (2,400 mg BID, DL3), and 6,400 mg/d (3,200 mg BID, DL4). There was no intrapatient dose escalation.||||
33713706|NCT00019578||||TREATMENT||||||||
33713707|NCT05014763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33713708|NCT01120301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713709|NCT02547454|||CASE_ONLY||PROSPECTIVE|||||||
33713710|NCT05723237|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34015934|NCT03731221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesiologists will not be blinded to the intervention, but all outcomes will be assessed by research personnel who are blinded to the group assignment.|Patients will be randomized the day of surgery upon presentation to the operating room to either a treatment group (PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine) or a control group (PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline) using secure web-based randomization.|t|f|f|t
34015935|NCT02546349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713711|NCT02632474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713712|NCT03806140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015936|NCT06073366|||COHORT||PROSPECTIVE|||||||
33713713|NCT01538420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015937|NCT01176110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015938|NCT03252418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|when measuring the gingival brightness and MAF of melanosomes|treating of gingival hyperpigmentation by two different methods|f|f|f|t
34015939|NCT00946348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34015940|NCT04969159|||COHORT||PROSPECTIVE|||||||
34015941|NCT00640536|||CASE_CONTROL||PROSPECTIVE|||||||
34015942|NCT03325465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015943|NCT05379855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015944|NCT06422390|||CASE_ONLY||CROSS_SECTIONAL|||||||
34015945|NCT04775420|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34015946|NCT05566964|||OTHER||PROSPECTIVE|||||||
34015947|NCT03122340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Single-center double-blind, randomized, placebo-controlled study|t|t|t|t
34015948|NCT02876380|||COHORT||OTHER|||||||
34015949|NCT05296486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015950|NCT03672305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34015951|NCT03961022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Single dose, Randomized, Double Blinded, Placebo-controlled Study|t|f|t|t
34015952|NCT02788149|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34015953|NCT02756936|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34015954|NCT00546572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34015955|NCT02721836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015956|NCT02860442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34015957|NCT01618136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015958|NCT02185313|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34015959|NCT00070538||||TREATMENT||NONE||||||
34015960|NCT04673513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015961|NCT06440798|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34015962|NCT04978064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Women in the intervention group will be blinded but not women in the control group.|A pilot randomised controlled trial (RCT), co-designed by patient input using a modified Zelen's design with additional qualitative evaluation, will be nested within a cohort study.|t|f|f|f
34015963|NCT03512262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment will be blinded to participants, investigators, outcome Assessor and care provider throughout the study except in a medical emergency where the identity of study medication is necessary to appropriately treat the participant.|Participants will be randomized in a 2:1 treatment ratio (abaloparatide:placebo).|t|t|t|t
34015964|NCT04765774|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34015965|NCT00486018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103368|NCT03795870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The randomization list will be generated using http://www.randomization.com and the investigator team will be blinded at enrollment using supplement codes. A designated study coordinator will hold the randomization codes and the codes will be revealed to the investigators only after the statistical analysis is complete.|Prospective Randomized Controlled|t|t|t|f
34103369|NCT02302833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103370|NCT03024411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103371|NCT05224726|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized control study|t|f|f|t
34103372|NCT05596240|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|The participant will not be told whether they are assigned to the interventional or sham group. The outcomes (blood flow, pain pressure threshold, and range of motion) will be assessed by an investigator blinded to the intervention assignment.|Pre-test Post-Test Design|t|f|f|t
34103373|NCT02887352|||OTHER||CROSS_SECTIONAL|||||||
34103374|NCT06689605|||CASE_ONLY||PROSPECTIVE|||||||
33713714|NCT02090569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713715|NCT05647954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713716|NCT00785733|||COHORT||PROSPECTIVE|||||||
33713717|NCT01439191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713718|NCT01569789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33713719|NCT00720434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713720|NCT05582746|NA|SINGLE_GROUP||SCREENING||NONE||||||
33713721|NCT00725023|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33713722|NCT01624454|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33713723|NCT03048565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713724|NCT01331798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713725|NCT06243809|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33713726|NCT05722483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713727|NCT00468689|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33713728|NCT01174303|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33713729|NCT01918930|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33713730|NCT03459248|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33713731|NCT02255604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713732|NCT05397821|||COHORT||RETROSPECTIVE|||||||
33720806|NCT01167647|||COHORT||PROSPECTIVE|||||||
34015966|NCT02199340|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34015967|NCT05115591|||CASE_ONLY||PROSPECTIVE|||||||
34015968|NCT03335605|||CASE_CONTROL||PROSPECTIVE|||||||
34015969|NCT02296853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015970|NCT03923530|NA|SINGLE_GROUP||TREATMENT||NONE||Enroll subjects who underwent TAVR and had documentation of abnormal invasive cardiac hemodynamics.||||
34098409|NCT03425370|RANDOMIZED|PARALLEL||OTHER||SINGLE|The efficacy of intervention methods will be assessed at the 3 month and 6 month follow-ups by having the patient and two blinded observers rate the healing progression of the wound using the POSAS. The observers will be either dermatology faculty or dermatology. The POSAS is a standard metric in measuring wound healing in cutaneous surgery studies since it does not require training but takes into account the scar assessment of the patient and observers. Subsequently, the height and width of the scar will be measured and compared to the surrounding unaffected skin. The assessments of the two blind observers will be averaged.|"Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures. The nurse will refer to the randomization list and inform the surgeon which side of the wound will receive tissue glue and which side will receive deep sutures. Following common practice of wound labeling, side A will always be left or superior from the surgeon's perspective, whereas side B will always be right or inferior from the surgeon's perspective.~Per randomization, half of the wound will be closed with deep absorbable sutures followed by superficial non-absorbable sutures. The other half of the wound will be closed with superficial non-absorbable sutures followed by tissue glue (Dermabond). Tissue glue will be spread to cover an area extending one cm from the wound margin on both sides."|f|f|f|t
34098410|NCT03954938|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33713733|NCT03415191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This was a single center, double-blind, placebo controlled, parallel-group, prospective study. Patients were randomly assigned to Ketamine or Placebo group in 1:1 ratio and no changes to methods after trial commencement as type of randomization or eligibility criteria were attended.|t|t|t|t
33713734|NCT02263989|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33713735|NCT02115789|||CASE_CONTROL||RETROSPECTIVE|||||||
33713736|NCT00144963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713737|NCT04720820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors are blinded to the patients' group|The trial consists of two arms; An Early Supported Discharge group and Conventional Rehabilitation group|f|f|f|t
33713738|NCT04446546|||CASE_ONLY||RETROSPECTIVE|||||||
33713739|NCT04770350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713740|NCT01197651|||COHORT||PROSPECTIVE|||||||
33713741|NCT05566132|||COHORT||RETROSPECTIVE|||||||
33713742|NCT04405947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|given the fact that the different approaches come with different scars, just the outcomes assessor can be blinded|prospective randomized study|f|f|f|t
33713743|NCT03341949|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713744|NCT04575922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793828|NCT04551794|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking was not necessary as the participants were automatically randomized within the baseline assessment.|"The study is a randomized controlled study with three conditions: Condition 1: Online intervention with therapeutic guidance (telephone contacts). Condition 2: Online intervention with additional peer support (online forum). Condition 3: Wait-list control group (access to the online intervention after completion of the post-assessment).~Two assessments-points, the intervention period (pre-post) is three months. At both assessments psychopathological data are obtained via the Internet survey Enterprise Feedback Suite survey by QuestBack Unipark®."||||
33793829|NCT00050375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33793830|NCT01829386|||COHORT||PROSPECTIVE|||||||
33793831|NCT03688659|NA|SINGLE_GROUP||TREATMENT||NONE|open|||||
33793832|NCT06178822|||COHORT||PROSPECTIVE|||||||
33793833|NCT03699293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Qualified patients will be treated with immediate release 81mg aspirin for 4 weeks in the run-in period followed by randomization to celecoxib (200 mg bid) vs. naproxen sodium (550 mg bid) for 4 weeks and then cross over to the other drug for another 4 weeks. Blood and urine samples will be collected before the aspirin run-in period (baseline), 24±4 hrs after the last dose of aspirin in the run-in period, 24±4 hr after the last dose of the study drug in the first period and 24±4 hr after the last dose of the study drug in the second period. Assays for platelet function, biomarkers of inflammation and endothelial function will be performed at these time points||||
33937263|NCT04003415|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants enrolled in the study will be in the intervention arm. Intervention consists of device feasibility and validation of heart rate and respiratory rate data collected.||||
33937264|NCT01804413|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33937265|NCT00319176|||CASE_ONLY||PROSPECTIVE|||||||
33937266|NCT02270190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937267|NCT02826083|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33937268|NCT04303247|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|||||
33937269|NCT03775473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional Research, at Risk and Minimal Constraints, Category 2||||
33937270|NCT03172013|||CASE_CONTROL||RETROSPECTIVE|||||||
33937271|NCT02180191|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937272|NCT02689141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937273|NCT00253422|RANDOMIZED|||TREATMENT||DOUBLE||||||
33937274|NCT04874350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized 1:1 to LPCN 1148 or placebo|t|t|t|t
33937275|NCT05692206|||COHORT||PROSPECTIVE|||||||
33937276|NCT03128606|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33937277|NCT06454565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34015971|NCT01986439|||COHORT||PROSPECTIVE|||||||
34015972|NCT01953939|NA|SINGLE_GROUP||||NONE||||||
34015973|NCT03499418|||COHORT||PROSPECTIVE|||||||
34015974|NCT01452711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015975|NCT03680859|||COHORT||PROSPECTIVE|||||||
34015976|NCT03055663|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-labelled|Prospective, randomized controlled trial||||
34015977|NCT04393766|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|after random generation sequence, the list of 152 were sealed with envelope which later opened by research assistance||t|f|f|t
34015978|NCT02960061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713745|NCT02059486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015979|NCT04944719|||COHORT||PROSPECTIVE|||||||
33713746|NCT01995825|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34098411|NCT00143143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098412|NCT06500221|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||patients with Type 2 diabetes combined with sarcopenia.||||
34098413|NCT02137681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713747|NCT04465331|||COHORT||PROSPECTIVE|||||||
33713748|NCT00487773|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33713749|NCT04082312|||COHORT||RETROSPECTIVE|||||||
33713750|NCT02311582|RANDOMIZED|PARALLEL||TREATMENT||NONE||As of Amendment 12, patients enrolled in the phase II portion of this trial will no longer be randomized. These patients will undergo MLA followed by MK-3475 treatment.||||
33713751|NCT05493527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713752|NCT04942691|RANDOMIZED|PARALLEL||PREVENTION||NONE||The control group not performed physical activity during the time of the study. In the exercise group SuperJump® training was performed for three times a week, each session lasting 60 minutes for a total of 20-weeks.||||
33793834|NCT05746247|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"For the pilots, for patients with a PCP within the healthcare system, we are testing 2 different centralized referral models to increase the # of patients that see a lipid specialist (active choice vs default).~For patients without a PCP within the health system, we are testing out health system mediated outreach vs Family Heart Foundation mediated outreach in order to increase the number of patients who make an appointment with a lipid specialist.~For Phase 3: There will be 2 arms. Arm 1) Penn PCP: For patients with a Penn PCP, we will use a default centralized referral model to engage PCPs to sign a referral for their patients to see a lipid specialist. Arm 2) Direct to Patient: For patients without a PCP at Penn, we will conduct direct outreach to the patients to invite them to schedule a free telehealth appointment with a lipid specialist."||||
33793835|NCT03567798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind|Single blind, randomized, multicentric placebo controlled study|t|f|f|f
33793836|NCT05404906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793837|NCT06673602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793838|NCT03856099|NA|SEQUENTIAL||TREATMENT||NONE||||||
33793839|NCT05175248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713753|NCT06249191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793840|NCT05206773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants enrolled in the open-label extension will be treated with venglustat only.||t|f|t|f
33937278|NCT02249351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937279|NCT04754906|||CASE_CONTROL||PROSPECTIVE|||||||
33937280|NCT00414973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937281|NCT00377468|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33937282|NCT01341925|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33937283|NCT01467024|||COHORT||RETROSPECTIVE|||||||
33937284|NCT05268601|||COHORT||OTHER|||||||
33937285|NCT02471586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For those subjects randomized to the IVUS or Angiography treatment arms, the operating investigator at the site was blinded to the final post-PCI OCT run for the subject.||f|f|t|t
33937286|NCT02612792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937287|NCT05067010|||COHORT||PROSPECTIVE|||||||
33937288|NCT00381784|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33937289|NCT06014476|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33937290|NCT02110550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937291|NCT00840528|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937292|NCT04366089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098414|NCT03105401|||OTHER||CROSS_SECTIONAL|||||||
34098415|NCT03061214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098416|NCT02635789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098417|NCT06237907|||CASE_CONTROL||PROSPECTIVE|||||||
33713754|NCT00241813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713755|NCT03782272|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This is a mixed-methods pilot study to assess the safety, acceptability, and feasible dosage of AA-ORS among children with mild to moderate stunting (LAZ between -1 and -3) who are at risk for EED and to assess the acceptability of this fluid supplementation for their caregivers. During the main study, up to 66 child participants will be randomized to receive 14 days of AA-ORS or placebo solution daily, dosing of up to 237 ml over a 3-hour period. Study staff and participants will be blinded to the study product allocation. Caregivers will store and return unused study product. Data collection methods to include direct observation of product consumption, structured surveys with caregivers, average daily volume consumed, and measurement of plasma/serum markers of metabolism, gut dysfunction, systemic inflammation, and micro-nutrient status pre- and post-administration of product.|t|t|t|f
33793841|NCT02631343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793842|NCT00255281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098418|NCT00002836|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793843|NCT00411996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793844|NCT03384069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793845|NCT00666094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793846|NCT02631148|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33793847|NCT03337568|||CASE_ONLY||PROSPECTIVE|||||||
33793848|NCT05650268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937293|NCT05651269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937294|NCT05686629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937295|NCT00850629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937296|NCT00631969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937297|NCT05012709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In total, 90 patients were randomly assigned to either the intervention or the control group. After a 2-week washout period, the intervention group was reassigned to the control and vice versa.||||
33937298|NCT05631730|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Separate endpoint adjudication committee blinded to randomized allocation of patients to treatment groups|Crossover prospective randomized open-label blinded-endpoint (PROBE) trial.|f|f|f|t
33937299|NCT01592110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098419|NCT06469775|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098420|NCT06035549|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713756|NCT05135897|||CASE_CONTROL||PROSPECTIVE|||||||
33713757|NCT01366521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713758|NCT03766555|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized study to be conducted in an academic hospital with a specialized hepato-biliary team. The principal investigator and other members within the team will perform patient selection and recruitment of this study according to the inclusion and exclusion criteria.||||
33793849|NCT00558363|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33713759|NCT01709890|||COHORT||PROSPECTIVE|||||||
33713760|NCT04876274|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33713761|NCT00617565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713762|NCT02503553|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33713763|NCT05798650|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||"After obtaining a written informed consent participants were divided into two groups, the experimental group and the control group. The experimental group had 60 Instagram user images of attractive smiles and the control group had 60 appearance- neutral Instagram images of nature.~The neutral images for the control group were chosen with a hashtag nature on Instagram. These images only had nature and no people in them.~A questionnaire was designed to investigate the effect of social networking site on facial and smile dissatisfaction, face related discrepancy and whether these effects differ from the use of appearance-neutral Instagram images. The questionnaire also assessed the use of social media and its effect on people."|t|t|t|t
33713764|NCT00524784|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33713765|NCT06074211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713766|NCT01085591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713767|NCT02248155|||COHORT||PROSPECTIVE|||||||
33713768|NCT02883153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713769|NCT05812898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||exercise plus myofascial release of the adductor and tipialis posterior muscles.|t|f|f|t
33793850|NCT01245452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793851|NCT01495936|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33793852|NCT06442345|||CASE_ONLY||RETROSPECTIVE|||||||
33793853|NCT06048991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793854|NCT02563613|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33793855|NCT03255096|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33793856|NCT01629186|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793857|NCT04727424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigational medical product will be packaged in similar bottles by a third party who will keep the allocation confidential until the end of the study. The bottles will be sealed and identified as Research Product with no commercial value and coded. They will be randomly allocated among the participants using a centralized randomization system The research subjects, medical assistance, administrative and health staff will not have access to the contents of the bottles. All arms will have a placebo counterpart with same dose schedule.~All planned Data and Safety Monitoring Board (DSMB) interim analysis will be blinded. If needed a unblinded statistician will be provided if DSMB decides to stop any arm. At the end of the study, or early termination as per DMSB interim analysis plan, the arms will then be identified."|"TOGETHER trial is a Multiplatform, adaptive trial started on 20 Jan 2021. This description is in allignment as per amendment seven with Brazilian National Ethics Committee final decision letter (letter# 5416996) issued on May 18, 2022.~Patients with mild disease will be screened at primary and secondary care public health services and randomly allocated to one of three treatment arms in a 1:1:1:1 ratio, as per described in detail in approved protocol version 8.0 dated 12 APR 2022.~1. Fluvoxamine + Budesonide~2. Fluoxetine + Budesonide~3. Spirulin Platensis~4. Placebo~We will use a centralized random allocation schedule, generated by computer and stratified by site and age."|t|t|t|t
33793858|NCT03774563|||COHORT||PROSPECTIVE|||||||
33793859|NCT05573035|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, dose-escalation and -expansion study||||
33793860|NCT03582410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793861|NCT01911169|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33937300|NCT03675685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937301|NCT00727350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937302|NCT06388915|||CASE_ONLY||RETROSPECTIVE|||||||
33937303|NCT02202161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937304|NCT01378494|||COHORT|||||||||
33937305|NCT04678349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937306|NCT05738928|||CASE_ONLY||PROSPECTIVE|||||||
33937307|NCT01711944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937308|NCT02022644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937309|NCT01265173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937310|NCT00764322|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937311|NCT05688176|||COHORT||PROSPECTIVE|||||||
33937312|NCT02067806|||COHORT||PROSPECTIVE|||||||
33937313|NCT06421467|||CASE_ONLY||CROSS_SECTIONAL|||||||
33937314|NCT01084811|||CASE_CONTROL||PROSPECTIVE|||||||
33937315|NCT02402049|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33937316|NCT02857205|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937317|NCT03926780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937318|NCT02520102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937319|NCT06471088|||CASE_ONLY||PROSPECTIVE|||||||
33937320|NCT04536350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and the investigator administering inhalation devices of drug or placebo are not aware of which group they have been randomized to (double-blinded). Someone not involved in the study (e.g. the hospital pharmacist or a nurse not involved in study) prepares the inhalation devices with either drug or placebo according to the randomization plan received by the CTU|Patients will be randomly allocated to receive either Aviptadil together with standard care or the placebo (NaCl 0.9%) together with standard care,|t|f|t|f
33713770|NCT02141243|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33713771|NCT01339429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713772|NCT05196165|||CASE_ONLY||PROSPECTIVE|||||||
33713773|NCT04661085|||COHORT||CROSS_SECTIONAL|||||||
33713774|NCT02067169|||COHORT||PROSPECTIVE|||||||
33937321|NCT03883295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937322|NCT02506907|||COHORT||PROSPECTIVE|||||||
33937323|NCT01785940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937324|NCT03371394|||COHORT||PROSPECTIVE|||||||
33937325|NCT05243940|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33937326|NCT03260673|||CASE_CONTROL||RETROSPECTIVE|||||||
33937327|NCT01035216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937328|NCT01693562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937329|NCT02869451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937330|NCT01585467|||||PROSPECTIVE|||||||
33937331|NCT02050672|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34098421|NCT05947955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo of normal saline is visibly indistinguishable from the study drug ans is to be at the same volume of administration.|1:1 randomization to rhu-pGSN or saline placebo arm|t|t|t|t
33937332|NCT02898792|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937333|NCT03754842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098422|NCT04951063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098423|NCT05719597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098424|NCT06088446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098425|NCT02845596|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34098426|NCT05808127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Clinicians treating Chronic Opioid Use Registry patients will be randomized to one of two conditions involving surveys completed by the patients: (1) Current Opioid Misuse Measure \[COMM\] \[standard clinical care\] or (2) COMM + PainTracker|f|f|f|t
34098427|NCT04520451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937334|NCT04002206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33937335|NCT02814591|||COHORT||OTHER|||||||
33937336|NCT02890511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937337|NCT03523806|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33937338|NCT01926652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937339|NCT04932694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098428|NCT05625971|||COHORT||PROSPECTIVE|||||||
34098429|NCT00190892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098430|NCT02644811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103375|NCT00690352|||CASE_CONTROL||RETROSPECTIVE|||||||
34103376|NCT06687720|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33713775|NCT05236010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713776|NCT04506021|||COHORT||PROSPECTIVE|||||||
33713777|NCT01108302|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713778|NCT00205738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713779|NCT02657174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713780|NCT01655615|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713781|NCT03923855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713782|NCT03938532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2 parallel arm|t|f|f|t
33713783|NCT03210168|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.||||
33713784|NCT02127879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33713785|NCT05884723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeons, surgical team, and data abstractors will be blinded to participant randomization|preoperative ketogenic diet group vs control standard of care preoperative diet|f|t|f|t
33713786|NCT02393768|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713787|NCT01353053|||COHORT||PROSPECTIVE|||||||
33713788|NCT03151837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713789|NCT01593215|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33713790|NCT00300937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713791|NCT02536040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713792|NCT03630172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Random assignment will occur using opaque envelopes. The primary investigator (who is also the care provider) will select an envelope when a subject arrives. The research assistant, who will be blinded to group allocation, will take the pre and post intervention measurements. The primary investigator will be blinded to the pre and post intervention measurements.|Subjects will be randomly assigned to one of two dry needling conditions: dry needling or placebo.|t|t|t|t
33713793|NCT05292846|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713794|NCT06287411|||CASE_ONLY||PROSPECTIVE|||||||
33713795|NCT04880525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|There was no masking in the study.|"For a period of 12 weeks, subjects in the Study Group (SG) and Control Group (CG) groups received three 45-minute sessions of Pilates exercises per week.~Study Group: In addition to Pilates, she followed a three-month weight-loss diet based on Turkey Dietary Guidelines, as prescribed by the dietician. These diet plans were designed to ensure that carbohydrates provided 45-60% of the energy, protein provided 10-20%, and fat provided 20-35 percent.~Control Group: The women in the control group did only reformer pilates for three months. They were followed up for not applying any diet."||||
33713796|NCT05944874|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|HD-TDCS applicator, six-minute walk test evaluator, and patient are blind|"This study is a clinical trial, and may also be called a before and after study, in which all subjects receive the same treatment and their condition is checked before beginning and after various moments of treatment"|t|t|t|f
33713797|NCT04755842|||COHORT||PROSPECTIVE|||||||
33713798|NCT03582124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713799|NCT00878033|||COHORT||CROSS_SECTIONAL|||||||
33713800|NCT06066554|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Thirty new patients with early stage mycosis fungoids will be allocated to proper treatment modality that differ according to the patient's clinical state following kasralainy phototherapy unit protocol||||
33713801|NCT06069284|||COHORT||PROSPECTIVE|||||||
33713802|NCT05673512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713803|NCT02790398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713804|NCT01053221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720807|NCT05941923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple blinding : Patients, respiratory critical care nurses, and data analyzers will be blinded to the allocation|A randomized controlled clinical superiority trial with two-arm parallel group design|t|t|f|t
33720808|NCT04572074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720809|NCT01073709|RANDOMIZED|CROSSOVER||||NONE||||||
33793862|NCT02825225|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33793863|NCT01692730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793864|NCT03409263|||CASE_ONLY||PROSPECTIVE|||||||
33793865|NCT00028678||||TREATMENT||||||||
33793866|NCT06376357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33793867|NCT00316316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793868|NCT02695290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793869|NCT00753012|NA|SINGLE_GROUP||||NONE||||||
33793870|NCT00903266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793871|NCT06676748|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study uses a randomized (1:1 allocation ratio) and single-blinded trial design. Block randomization will be used to randomly assign patients to no intervention i.e., usual practice (Control) and BH (Difflam) spray (study) groups in a 1:1 allocation ratio based on a computer-generated code that will be prepared at a remote site and sealed in opaque, sequentially numbered envelopes.||||
33793872|NCT02329613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33793873|NCT05105646|||COHORT||RETROSPECTIVE|||||||
33793874|NCT01370707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793875|NCT00413595|||COHORT||PROSPECTIVE|||||||
33793876|NCT00117663|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33793877|NCT04222959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793878|NCT02828423|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33793879|NCT00328055|RANDOMIZED|CROSSOVER||||SINGLE||||||
33793880|NCT00003339|RANDOMIZED|||TREATMENT||||||||
34015980|NCT05476653|NA|SINGLE_GROUP||OTHER||NONE||||||
34015981|NCT00871741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015982|NCT00000734||||TREATMENT||NONE||||||
34015983|NCT03532113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The experimenters are blind in the clinical trials. Participants know that there are different training programs but they ignore the purpose of each one.|"Older participants are randomly assigned to one of three intervention conditions (Inhibition ; Updating ; General knowledge).~Young participants only complete the initial assessment."|t|f|f|t
34098431|NCT04534725|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|double blinding from central system.|the study uses a SMART design. (sequential multiple arm randomised trial) meaning that participants can enter into the study and progress through the subsequent arms if they meet the additional eligibility criteria (for instance, pre-covid \> post exposure \> develop moderate infection \> infection becomes severe) it is important to note that participants can enter into the study at any point and do not have to transition into the other arms|t|t|t|t
34098432|NCT01966497|||COHORT||PROSPECTIVE|||||||
34098433|NCT05611892|||OTHER||PROSPECTIVE|||||||
34098434|NCT03095976|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Case Series||||
34098435|NCT04483232|||COHORT||PROSPECTIVE|||||||
33720810|NCT05938933|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33720811|NCT01168531|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33720812|NCT01649531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720813|NCT05793320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720814|NCT05048628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Multiple blinding (data collectors, participants, statistician, and reporters) was performed in the Randomized Controlled Experiment.|Four Groups. Group were comprised of control group, green tea Gargle Solution group, ice pieces impregnated group, arnica montana tea Gargle Solution group.|t|t|t|t
33720815|NCT06072950|||COHORT||PROSPECTIVE|||||||
33793881|NCT02485444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793882|NCT03105505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793883|NCT00092014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33793884|NCT04300426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking will apply for the whole duration of study until end of study defined as week 20 visit for the last participant.|The 20-week study period consists of a 12-week induction phase (Part A1), with randomized, double-blind parallel group interventions by endoscopic infusions at weeks 0 and 2, and an 8-week maintenance phase (Part A2) where all participants receive one single open label endoscopic infusion on week 12. Additionally, all participants who complete the 20-week study period are followed for a maximum 16 weeks monitoring period (Part B) to obtain longer-term data on safety and durability of intervention effects.|t|f|t|t
33793885|NCT02613871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793886|NCT03007836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793887|NCT04091425|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33793888|NCT02666742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793889|NCT05162144|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Cohort Study||||
33793890|NCT04104698|||OTHER||CROSS_SECTIONAL|||||||
33793891|NCT03359460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793892|NCT00846066|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33793893|NCT01035658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793894|NCT02071017|||COHORT||PROSPECTIVE|||||||
33793895|NCT02630719|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33793896|NCT01443117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33793897|NCT04172246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793898|NCT03208101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793899|NCT02500654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793900|NCT05739903|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015984|NCT03734666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015985|NCT02107326|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34015986|NCT03257904|||COHORT||PROSPECTIVE|||||||
34015987|NCT00317421|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34015988|NCT05566548|||COHORT||PROSPECTIVE|||||||
34015989|NCT05921513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will be masked to which mouth-rinse, gel and spray they are receiving.|Parallel model: Patient will receive either normal saline mouth-rinse to rinse, or Chlorhexidine mouth-rinse with placebo gel and placebo oral spray or Stellalife Oral Care Kit with mouthrinse, gel and oral spray.|t|f|f|f
34015990|NCT01297374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34015991|NCT04078880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34015992|NCT06469489|||COHORT||PROSPECTIVE|||||||
34015993|NCT05241717|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will be provided the intervention|Mixed methods, single-arm feasibility study||||
34015994|NCT00468728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34015995|NCT05727917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34015996|NCT01242930|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34015997|NCT04622397|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|surgeon will be blinded to type of injection|randomized comparative study|f|t|f|f
34015998|NCT03493542|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34015999|NCT01699386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016000|NCT05667350|||CASE_CONTROL||PROSPECTIVE|||||||
34016001|NCT04261205|||OTHER||PROSPECTIVE|||||||
34016002|NCT06164314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016003|NCT02304458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016004|NCT03979820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016005|NCT00878514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34016006|NCT04666519|||COHORT||PROSPECTIVE|||||||
34016007|NCT01168765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016008|NCT03856684|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33713805|NCT06072170|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|"The treatment assignment (active or placebo) will not be known by the study participants. Study participants will be informed of the dose range they could receive but will not be informed of the actual dose assigned to them.~Furthermore, the randomization code will not be available to the Investigator and clinical staff involved in the collection, monitoring, revision, or evaluation of AEs, as well as clinical staff who could have an impact on the outcome of the study including the pharmacokineticist (or delegate) and biostatistician, until all the case report form (CRFs) have been approved and signed and the bioanalytical phase of the study has been completed."||t|t|t|t
33713806|NCT02501473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713807|NCT03684395|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33713808|NCT06198868|||COHORT||PROSPECTIVE|||||||
33713809|NCT01479673|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33713810|NCT05894928|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33793901|NCT00552942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793902|NCT01970358|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793903|NCT00136058|RANDOMIZED|PARALLEL||||NONE||||||
33793904|NCT04155177|||COHORT||PROSPECTIVE|||||||
33937340|NCT02330471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937341|NCT05788562|||COHORT||PROSPECTIVE|||||||
33937342|NCT03899389|||COHORT||RETROSPECTIVE|||||||
33937343|NCT05006651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937344|NCT03165682|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937345|NCT02995811|||COHORT||PROSPECTIVE|||||||
33937346|NCT04849338|||COHORT||CROSS_SECTIONAL|||||||
33937347|NCT06456411|||CASE_CONTROL||PROSPECTIVE|||||||
33937348|NCT00646347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937349|NCT05907005|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33937350|NCT05789940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937351|NCT03640715|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33937352|NCT04029649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937353|NCT01308853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937354|NCT03316755|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomised|f|f|t|t
33937355|NCT01009333|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33937356|NCT03856749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind study. The outcomes assessor will be blind to group allocation. Because of the nature of the study, it will not be possible to blind participants or trainer.|A single-blind randomized controlled trial. Each participant in the study consists of a caregiver and wheelchair user dyad. 1 dyad = 1 manual wheelchair user + his/her caregiver.|f|f|f|t
33937357|NCT05150249|||COHORT||PROSPECTIVE|||||||
33937358|NCT02385864|||COHORT||PROSPECTIVE|||||||
33937359|NCT03330548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor for the imaging studies will be blinded to the study arms of the subjects.|Subjects will be randomized 2:1 into Culinary Rx or TeleMOVE! prior to baseline measures. We plan to enroll a subset of the 80 participants to undergo a PET-MRI sub-study (total of 21 participants). This cohort requires participants to have a pooled cohort risk score of ≥ 7.5%, be willing and able to undergo FDG-PET-MRI. \[The ACC/AHA pooled risk calculator utilizes information such as age, lipid profile, hypertension to estimate 10 year risk of ASCVD.|f|f|f|t
33937360|NCT02003430|||COHORT||PROSPECTIVE|||||||
33937361|NCT03525821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937362|NCT06212505|||OTHER||PROSPECTIVE|||||||
33937363|NCT04545086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants were assigned randomly to three groups|t|t|f|f
33937364|NCT05407376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937365|NCT04399304|||CASE_CONTROL||PROSPECTIVE|||||||
34016009|NCT05732974|||COHORT||PROSPECTIVE|||||||
34016010|NCT05402241|||COHORT||PROSPECTIVE|||||||
34016011|NCT02581007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098436|NCT05862441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016012|NCT04514965|||COHORT||PROSPECTIVE|||||||
34016013|NCT01475006|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016014|NCT02668926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34016015|NCT01859130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016016|NCT04707976|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016017|NCT03660358|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016018|NCT03308539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016019|NCT00298818|||CASE_ONLY||PROSPECTIVE|||||||
34016020|NCT03869203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098437|NCT00468637|||||PROSPECTIVE|||||||
34098438|NCT02633631|||COHORT||PROSPECTIVE|||||||
34098439|NCT02388958|||CASE_CONTROL||PROSPECTIVE|||||||
34098440|NCT02015936|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103377|NCT06641505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||f|f|f|t
34103378|NCT06549322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016021|NCT03525730|RANDOMIZED|PARALLEL||TREATMENT||NONE||6 week study, including 2 week intervention and 4 week post-treatment period.||||
34016022|NCT01880125|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34016023|NCT04167176|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34016024|NCT00002241||||TREATMENT||||||||
34016025|NCT02143583|||||PROSPECTIVE|||||||
34016026|NCT03610568|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||1,400 adolescents were enrolled in the intervention group - 1,000 in-school and 400 out-of-school 1,400 adolescents were enrolled in the control group - 1,000 in-school and 400 out-of-school||||
34016027|NCT01029158|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34098441|NCT05507892|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label non-randomized mechanistic trial. This trial will enroll 40 participants who will receive 100 mg of canagliflozin daily for six (6) months in addition to standard of care.||||
34098442|NCT06173843|||COHORT||PROSPECTIVE|||||||
34098443|NCT04674800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098444|NCT02325453|||OTHER||RETROSPECTIVE|||||||
34098445|NCT03142451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study, with limited access to the randomization code. The randomization code will be held in confidence until after the study database is locked and a memo documenting the database lock has been issued. Every effort will be made to retain the integrity of the blind. When issued to the sites, the study drug will be identical in appearance for all participants, regardless of treatment assignment.||t|f|t|f
33937366|NCT01893879|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937367|NCT06202677|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33937368|NCT01077310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937369|NCT03742687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937370|NCT04726566|||COHORT||PROSPECTIVE|||||||
33937371|NCT00486148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937372|NCT04131127|||CASE_ONLY||PROSPECTIVE|||||||
33937373|NCT02814734|||COHORT||PROSPECTIVE|||||||
33937374|NCT04863118|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33937375|NCT03593005|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low altitude and High altitude||||
33937376|NCT00648973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937377|NCT03858855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34016028|NCT02384941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793905|NCT06174662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial (RCT) with parallel arms: control and intervention group. Not blinded.||||
33793906|NCT03731312|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33937378|NCT03211104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937379|NCT01894685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937380|NCT01220596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937381|NCT04586322|||COHORT||PROSPECTIVE|||||||
33937382|NCT06065241|RANDOMIZED|PARALLEL||OTHER||DOUBLE||2 month, double blind placebo controlled study.|t|f|t|f
33937383|NCT00772889|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33937384|NCT00614367|||||PROSPECTIVE|||||||
33937385|NCT02846259|||COHORT||PROSPECTIVE|||||||
33937386|NCT03601091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|DOUBLE BLINDED|RANDOMISED- DOUBLE BLINDED|t|f|t|f
34016029|NCT05515393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016030|NCT01703884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016031|NCT01598350|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34016032|NCT03457649|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||SAD MAD|t|t|t|t
34016033|NCT04860050|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098446|NCT05199272|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016034|NCT01370135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016035|NCT03822507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016036|NCT00204165|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34016037|NCT05614557|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34016038|NCT04764656|||COHORT||PROSPECTIVE|||||||
34016039|NCT05149443|NA|SINGLE_GROUP||OTHER||NONE||The effectiveness of the 'Move it, Move ID'-intervention and its two different components (i.e. buddy and gamification) will be measured through an aggregated single case design, i.e. the ABAB reversal design. Rather than taking few measurements from a sample of many individuals, many measurements are taken repeatedly from the same individual(s) in ABAB reversal designs. Participants are serving as their own controls, leading to the fact that overall sample sizes are smaller than traditional RCTs without losing adequate power.||||
34016040|NCT05006872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Healthcare providers (doctors and nurses from the participants' health centres, do not know if their patients are participating in the study nor the group (intervention vs control) they are. Just if a patient ask them for more information related to the study or text messages, they will know about it. Also, the interviewers that evaluate and register participants data are masked until randomization. After 12 months of follow-up, the interviewers will be masked before post-intervention evaluation. The primary outcome HbA1c is an objective measure and assessors of this outcome will be blinded to treatment allocation.||f|t|f|t
34016041|NCT06034561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016042|NCT02073877|||CASE_CONTROL||PROSPECTIVE|||||||
34098447|NCT06253429|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34098448|NCT02537925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33793907|NCT02698007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098449|NCT06092580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098450|NCT06218433|NA|SINGLE_GROUP||SCREENING||NONE||||||
34098451|NCT04297267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098452|NCT02610257|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34098453|NCT04559672|||CASE_CONTROL||RETROSPECTIVE|||||||
34098454|NCT03724097|||CASE_CONTROL||PROSPECTIVE|||||||
34098455|NCT00894647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098456|NCT02417480|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098457|NCT02105857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098458|NCT04774354|||COHORT||PROSPECTIVE|||||||
34098459|NCT00949078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098460|NCT03907956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Assignment to groups. To the extent that the sample is recruited, subjects will be randomly distributed into two groups (intervention and control) using a software-generated randomization system. Each subject will be assigned a numbered, sealed and opaque envelope where their inclusion in the intervention or control group will be specified.~The evaluating staff will be blinded to the assignment to the groups."|The study is a randomized single-blind clinical trial (RCT).|f|t|f|t
34098461|NCT00400088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098462|NCT05667402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793908|NCT03833804|NA|SINGLE_GROUP||SCREENING||NONE|No masking as the manual screen is already part of usual care and the automated screen will become usual care in the post-period of the pre-post design.|Quasi-experimental design as an interrupted time series||||
33793909|NCT02342119|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33793910|NCT00361283|NA|SINGLE_GROUP||SCREENING||NONE||||||
33793911|NCT00460785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793912|NCT06167525|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793913|NCT04675944|NA|SEQUENTIAL||TREATMENT||NONE||||||
33793914|NCT04425408|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33793915|NCT04364789|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double (Paticipant, Investigator)||t|f|t|f
33793916|NCT02399696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793917|NCT00360451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33793918|NCT00097188||||TREATMENT||||||||
33793919|NCT05562050|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34098463|NCT06274476|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|double|maxillary and mandibular atrophic ridge|f|f|t|t
34098464|NCT01289587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34098465|NCT02716142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098466|NCT00370604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098467|NCT02802085|||COHORT||PROSPECTIVE|||||||
33793920|NCT02181660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793921|NCT02599142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre parallel group randomised controlled trial investigating the impact of using open-face thermoplastic immobilisation shells upon setup reproducibility in patients having cranial radiotherapy.||||
33793922|NCT04120597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793923|NCT02871999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793924|NCT03749044|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Control Trial||||
33937387|NCT02492542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937388|NCT04347434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of AMI in addition to standard therapy for the disease.||||
33937389|NCT04451486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937390|NCT02084394|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33793925|NCT05705700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793926|NCT02874326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937391|NCT01864304|||COHORT||CROSS_SECTIONAL|||||||
33937392|NCT02839655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937393|NCT01751269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937394|NCT03137173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937395|NCT05143645|||COHORT||PROSPECTIVE|||||||
33937396|NCT00485121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937397|NCT06410729|||COHORT||RETROSPECTIVE|||||||
33937398|NCT04437329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016043|NCT01295866|||COHORT|||||||||
34016044|NCT03657212|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34016045|NCT05982730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016046|NCT01562340|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34016047|NCT02920918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016048|NCT06387459|NA|SINGLE_GROUP||OTHER||NONE||||||
34098468|NCT04717180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098469|NCT04202783|NA|SINGLE_GROUP||TREATMENT||NONE||The present study is being undertaken as an open label study to evaluate the safety and feasibility of exosomes as an intervention for patients with craniofacial neuralgia. Baseline and outcome measures in this study utilize validated tests that are appropriate for repeated measures. The present study can be easily implemented because the neuropsychological testing instruments have been in routine clinical deployment providing for a high degree of availability and reliability. Quality assurance is tightly controlled. The study population is sufficiently broad and the conditions of interest are sufficiently prevalent so that recruitment of subjects is not a limiting factor.||||
34098470|NCT01289535|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098471|NCT04738669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098472|NCT01895179|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34098473|NCT00036465|RANDOMIZED|PARALLEL||TREATMENT||||||||
34098474|NCT01296113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098475|NCT01558375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098476|NCT02058407|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34098477|NCT03189511||SEQUENTIAL||BASIC_SCIENCE||NONE||Open-label non-randomized historic control (before-after) trial||||
34098478|NCT01187875|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34098479|NCT05431751|NA|CROSSOVER||BASIC_SCIENCE||NONE||Placebo-controlled, cross-over study design||||
34098480|NCT00655798|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34098481|NCT03261258|||COHORT||PROSPECTIVE|||||||
34098482|NCT05792254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098483|NCT03542357|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34098484|NCT01698008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group is standard of care. The other is given the opportunity to use a new mobile app for reporting blood sugars.||||
34098485|NCT06174506|||COHORT||PROSPECTIVE|||||||
34098486|NCT02194088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098487|NCT00492674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098488|NCT01760980|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098489|NCT03675555|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34098490|NCT01038895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937399|NCT02607865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937400|NCT01310192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937401|NCT02499172|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937402|NCT01695928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937403|NCT01369667|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33937404|NCT00204802|RANDOMIZED|PARALLEL||||SINGLE||||||
33937405|NCT04607291|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33937406|NCT04050891|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33937407|NCT01173328|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33937408|NCT04022304|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind study|Partially replicated design, crossover trial|t|f|t|f
33937409|NCT00786903|||CASE_CONTROL||PROSPECTIVE|||||||
33937410|NCT02169466|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33937411|NCT03999333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937412|NCT01865136|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33937413|NCT04652466|||OTHER||PROSPECTIVE|||||||
33937414|NCT03908866|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33937415|NCT06446830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the candidate will be masked, and Assessments regarding the primary outcome will be conducted by an assessor blind to treatment allocation. The assessor will go through a profound assessment training program|two parallel-group, randomized, double-blinded|t|f|f|t
33937416|NCT01263405|||CASE_ONLY||PROSPECTIVE|||||||
33937417|NCT04558385|||CASE_ONLY||RETROSPECTIVE|||||||
33937418|NCT01118884|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33937419|NCT03108742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937420|NCT05375838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937421|NCT03407027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In this randomized, double-blind trial, patients will be randomized into one of three groups. First group, infiltration of the quadratus lumborum muscle and fascia (with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%). Second group, gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%. The last group, namely the control group, infiltration of the quadratus lumborum muscle and fascia with 10ml of levobupivacaine 0,25%.|t|t|t|t
34016049|NCT03440541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016050|NCT02773459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016051|NCT02593448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098491|NCT01881295|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34098492|NCT06027892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098493|NCT01545466|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098494|NCT03876548|NA|SINGLE_GROUP||PREVENTION||NONE|Open label|Pilot study||||
34098495|NCT01522976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016052|NCT01256723|||CASE_ONLY||PROSPECTIVE|||||||
34016053|NCT03474432|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016054|NCT02038465|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016055|NCT02021370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016056|NCT00942695|RANDOMIZED|CROSSOVER||||NONE||||||
34016057|NCT03524183|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The unit of randomization (control vs. treatment) is at the school level. Participants at each school will be masked of the other schools' assigned condition.|The efficacy of the VFB Ecosystem will be tested using a cluster randomized trial with repeated measures at baseline, posttest (immediately after 3-month intervention), mid-term follow up (6 months post intervention), and a long-term follow up (12 months post intervention). A 3-month intervention period was selected to observe variance in engagement over the course of an academic semester in the afterschool programs. A cluster randomized design is indicated when outcomes are tracked at a group level (afterschool programs) instead of at the individual level (children) and is the preferred method to reduce the impact of dependency in the data. From a pool of 24 demographically matched afterschool programs, we will randomly assign pairs to either receive the Ecosystem or physical activity as usual. Outcomes will be modeled and expressed as changes occurring at the afterschool program level--the unit of randomization.|t|f|f|f
34016058|NCT02327741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34016059|NCT01884922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016060|NCT03182582|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The investigator is blinded to which patient is receiving sharp or laser debridement as his/her first treatment.|A portion of the patients will be randomized to sharp debridement first, then laser for the second debridement. The other portion will undergo this in the opposite order.|f|f|t|f
34016061|NCT04626752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016062|NCT00712738|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016063|NCT04058574|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention Group ACL: 30 patient, athletes, with ACL deficiency candidate to a surgical ACL reconstruction Control Group: 15 healthy volunteers, athletes."||||
34016064|NCT03134443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental group: Routine treatment for acute tonsillitis + Xiyanping injection Contral group: Routine treatment for acute tonsillitis + Xiyanping injection simulation(0.9% normal saline)|t|f|f|f
34016065|NCT03596931|||OTHER||RETROSPECTIVE|||||||
34016066|NCT00999648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016067|NCT06133075|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will receive mirabegron 50 mg or 25 mg orally for 8 weeks to determine their effects on blood pressure.||||
34016068|NCT00605735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016069|NCT04299451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713811|NCT03750799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All of the participants were told that the vibration stimulation was performed for muscle strengthening. However, participants had no knowledge about the characteristics of the vibration used for muscle-strength enhancement. Vibration was applied in the experimental group, whereas sham vibration was applied in the Control group. The WBV exercise was performed at different days for the Control and Experimental groups to make them blind to each other's applications.All measurements were made by an independent assessor (isokinetic test laboratory assistant) blinded to the trial allocation.|Experimental group was exposed WBV, Control group was exposed sham WBV|t|f|t|t
33713812|NCT05967156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713813|NCT03731611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713814|NCT05812612|||COHORT||PROSPECTIVE|||||||
34016070|NCT00960830|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34016071|NCT03485053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016072|NCT01565616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098496|NCT03944005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016073|NCT04331444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016074|NCT03358784|||OTHER||CROSS_SECTIONAL|||||||
34016075|NCT05980286|RANDOMIZED|PARALLEL||OTHER||SINGLE||We will conduct a 2-arm randomized pilot trial.|f|f|t|f
33713815|NCT05615012|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33713816|NCT01087398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713817|NCT03508921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713818|NCT00155350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33713819|NCT04401189|||CASE_CONTROL||PROSPECTIVE|||||||
33713820|NCT05650216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713821|NCT04039815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|as above|double blind, randomized-controlled trial|t|t|f|t
33713822|NCT03651921|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33713823|NCT00136656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713824|NCT01776333|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713825|NCT04097002|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I and Phase IIa.~Phase I/ Part A is a Single-escalated dose of ORCA-010 (3 dose cohorts) to determine the Maximum Tolerated Dose.~Phase IIa/ Part B is a two administration dose cohort at Maximum Tolerated Dose."||||
33713826|NCT02332278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33713827|NCT04298892|||COHORT||OTHER|||||||
33713828|NCT03740711|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled test||||
33713829|NCT00221728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713830|NCT05634304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single (Outcomes Assessor) The researcher who applied the intervention program and the researcher who collected the data was never the same.|In the third year, we will test a patient-needs mobile app SM program for OA by randomized controlled trial of 6 months' duration. The total 66 patients with OA will be recruited while the participant in orthopedics clinic of a hospital. The experimental group (N=33) will receive a mSM program, and the control group (N=33) will receive with the usual care only.|f|t|f|t
33713831|NCT00720837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713832|NCT04757064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Group (A) will receive the standard protocol of king Hussein hospital 6 weeks post-operative which is:~Start aggressive knee flexion exercises and increase the extensor strength. Consider CPM/dynasplint if flexion \<60_ MUA contraindicated.~Examination under anesthesia can be done to assess the cause of limited knee flexion. Surgical release is indicated if knee flexion is \< 60 degrees at six months after surgery.~Group (B) will receive supervised rehabilitation program 1 session / week for 45 minutes-1 hour."|t|t|t|t
33713833|NCT03038191|||OTHER||PROSPECTIVE|||||||
33713834|NCT04113304|||CASE_ONLY||PROSPECTIVE|||||||
33713835|NCT01414283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713836|NCT00378196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713837|NCT02670083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713838|NCT04403971|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
33713839|NCT05914714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713840|NCT00642941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713841|NCT04550390|||COHORT||PROSPECTIVE|||||||
33713842|NCT01442675|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713843|NCT02174120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713844|NCT04161989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713845|NCT04024020|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713846|NCT00881582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713847|NCT05037591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study was a 4-week, randomized, double-blind, placebo-controlled clinical trial. Evaluation during the initial visit includes physical examination in the form of Body Mass Index based on Asia-Pacific guidelines and blood parameter screening tests in the form of blood glucose, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol, and PGC-1α were performed on all participants within 1 week of the initial screening. A random number between 1 and 70 was generated for each subject and registered participants were scheduled for their first visit and randomly assigned to the sea grape extract group (n=35) or placebo (n=35). Sea grape extract/placebo tablets/capsules were given to participants every 1 week (1 day of consumption per oral) 15 Minutes before eating (According to the diabetes drug guidline consumtion).|t|t|f|f
33713848|NCT02275871|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713849|NCT02209389|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713850|NCT03145285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713851|NCT06304753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713852|NCT03668912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713853|NCT02319746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713854|NCT01255657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713855|NCT00173784|||DEFINED_POPULATION||PROSPECTIVE|||||||
33937422|NCT02710422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know their treatment arm assignment until after robotic assisted radical prostatectomy (RARP) surgery.||t|f|f|f
33937423|NCT04782492|RANDOMIZED|PARALLEL||TREATMENT||NONE||saphenous vein as Y-composite graft based on the left internal thoracic artery versus aortocoronary conduit||||
33937424|NCT02019992|||COHORT||PROSPECTIVE|||||||
33937425|NCT04321590|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blind sachets|Randomized, parallel, double blind study|t|f|t|f
33937426|NCT03928509|||COHORT||PROSPECTIVE|||||||
33937427|NCT00653692|||COHORT||PROSPECTIVE|||||||
33937428|NCT04719533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients' data recorded according to a coding system|prospective randomized-controlled trial|t|f|f|f
33937429|NCT00172003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937430|NCT01406730|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34016076|NCT05054218|||COHORT||PROSPECTIVE|||||||
34016077|NCT02512536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016078|NCT02151812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016079|NCT05258331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016080|NCT01093664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016081|NCT00261963|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34016082|NCT01075841|||CASE_ONLY||PROSPECTIVE|||||||
34016083|NCT01303705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713856|NCT02259868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937431|NCT04787835|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study will be open-label as both the patient and resident/surgeon will be aware of the type of block (forearm vs local) performed.|Patients who consent to participation will then be randomized using a random number generator to receive either a forearm nerve block or local anesthetic infiltration, there will be 20 patients assigned to each group.||||
34016084|NCT04572126|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomly assigned to either the mindfulness intervention group or control group.||||
34016085|NCT01389947|||CASE_CONTROL||PROSPECTIVE|||||||
34016086|NCT01016093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937432|NCT04882124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713857|NCT04728074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blind, randomized control study|f|f|f|t
33713858|NCT05695443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Prisoners are not informed whether they are in the treatment or control group and are therefore blind to treatment status. Dental staff is blind to prisoners' treatment status at the first oral examination and questionnaire. The prisoner's treatment status is revealed just after this. Hence, dental staff collects data prior to knowing the prisoners' treatment status, and only learns this when they start the MI-based conversation. When prisoners are back at T1 and T2 for follow-up oral examinations and questionnaires, dental staff might still remember whether the prisoner was treated or not. To partially account for potential bias in the oral examination (assessment of plaque and mucosal inflammation), there are two independent assessments of this at T1 and T2.|Following the initial oral examination and questionnaire, prisoners are randomly assigned into either a treatment or control group, blocking at prison level. The randomization tool at www.randomizer.org is used. Prisoners in the treatment group receive an up to 30 Motivational Interviewing conversation, aiming at improving oral health and oral health-related behavior. The intervention is carried out by dental staff in prison. Prisoners in the control group do not receive the MI intervention.|t|t|f|f
33713859|NCT00071513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713860|NCT03090113|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33713861|NCT00080977||||TREATMENT||||||||
33713862|NCT02156596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33937433|NCT05656131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713863|NCT01543698|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33713864|NCT01184794|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33713865|NCT00603889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713866|NCT01476371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713867|NCT03873571|||OTHER||PROSPECTIVE|||||||
33713868|NCT01133483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937434|NCT06317415|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33937435|NCT03228836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937436|NCT02526537|||CASE_CONTROL||PROSPECTIVE|||||||
33937437|NCT01807676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937438|NCT05744830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinding, the physician who does the audiogram||f|f|f|t
33937439|NCT04958551|||COHORT||PROSPECTIVE|||||||
33937440|NCT00517725|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33937441|NCT06161233|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33937442|NCT01521351|||COHORT||PROSPECTIVE|||||||
33937443|NCT03229876|NA|SEQUENTIAL||TREATMENT||NONE||||||
33937444|NCT05819424|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Placebo-controlled, randomized, double-blind, cross-over design.|t|t|t|t
33937445|NCT03611946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937446|NCT05883228|||OTHER||CROSS_SECTIONAL|||||||
33937447|NCT04022590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
33937448|NCT02347202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937449|NCT05604911|||COHORT||PROSPECTIVE|||||||
34016087|NCT00448136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016088|NCT00276952|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34016089|NCT00767065|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34016090|NCT06456437|||COHORT||PROSPECTIVE|||||||
34016091|NCT03780231|||COHORT||PROSPECTIVE|||||||
34016092|NCT03591939|||CASE_CONTROL||PROSPECTIVE|||||||
34016093|NCT01630681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016094|NCT05707143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016095|NCT06168435|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34016096|NCT03873636|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34016097|NCT02310243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016098|NCT03203135|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016099|NCT00885014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016100|NCT05771675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Drug: Simvastatin Drug: Placebo|t|t|t|t
34016101|NCT06341387|||CASE_CONTROL||PROSPECTIVE|||||||
34016102|NCT04116853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will be conducted by trained study staff members masked to maintenance condition.|All randomized participants will receive extended-care intervention delivered via phone; however, the frequency/timing of these calls will vary between the ADAPTIVE and STATIC conditions.|f|f|f|t
34016103|NCT01078337|||COHORT||PROSPECTIVE|||||||
34016104|NCT00289874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016105|NCT05964712|||COHORT||PROSPECTIVE|||||||
34016106|NCT01103622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016107|NCT00456430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016108|NCT00002321||||TREATMENT||||||||
34016109|NCT06165666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind, parallel, randomized controlled clinical trial, allocation ratio 1:1 and with third-party evaluation.|Participants are randomly assigned into 2 groups (intervention group (EG) and control group (CG)).|f|f|f|t
34016110|NCT00003093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016111|NCT04161014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective clinical pilot study||||
34098497|NCT00693732|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34016112|NCT03832881|||OTHER||OTHER|||||||
34098498|NCT05726279|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098499|NCT01260415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098500|NCT00499304|||CASE_CONTROL||PROSPECTIVE|||||||
34098501|NCT01383824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098502|NCT06354842|||OTHER||CROSS_SECTIONAL|||||||
34098503|NCT04890171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098504|NCT04731662|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098505|NCT00393146|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34098506|NCT03974490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098507|NCT03383133|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study will involve only a single individual.||||
34098508|NCT01733888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016113|NCT02451098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098509|NCT02198131|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34098510|NCT06209775|||COHORT||RETROSPECTIVE|||||||
34098511|NCT06209125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098512|NCT05736146|||CASE_CONTROL||PROSPECTIVE|||||||
34098513|NCT05001555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098514|NCT02872688|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098515|NCT05511480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34098516|NCT06500897|||COHORT||PROSPECTIVE|||||||
34098517|NCT00003107||||TREATMENT||||||||
33937450|NCT01633775|||COHORT||PROSPECTIVE|||||||
33937451|NCT00221689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937452|NCT03422757|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33937453|NCT00805649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016114|NCT02471261|||CASE_ONLY||PROSPECTIVE|||||||
34016115|NCT05483803|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Participants will be enrolled in two sub-studies. Participants in sub-study 1 will be enrolled in an intervention for 1 month. After sub-study 1 completion a new group of participants will be enrolled in the sub-study 2 for the intervention lasting 3 months.||||
34016116|NCT01759017|||COHORT||PROSPECTIVE|||||||
34016117|NCT03287973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant who scores the sleep study and the laboratory technician who does the blood test are blinded to the intervention arm.||f|f|f|t
34016118|NCT05410366|||COHORT||PROSPECTIVE|||||||
34098518|NCT01367756|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34098519|NCT00882765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098520|NCT05414253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098521|NCT01449994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34098522|NCT01714388|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098523|NCT05386836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098524|NCT05930353|||COHORT||PROSPECTIVE|||||||
33937454|NCT02258841|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937455|NCT03721549|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||A total of 16 eligible healthy young adults will be challenged with either the moderate or higher dose of norovirus inoculum||||
34016119|NCT04727437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016120|NCT01956617|NA|SINGLE_GROUP||||DOUBLE|||t|f|f|t
34016121|NCT02262793|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016122|NCT04511221|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Treatment capsules are provided by Deerland Enzymes in coded packaging. Participants, investigators, and data assessors will not be provided the key to the codes. Once all data is entered and analyzed, the keys will be provided by Deerland.|Randomized, double-blinded, placebo controlled, parallel arm|t|f|t|t
34016123|NCT00633516|||CASE_CONTROL||PROSPECTIVE|||||||
34098525|NCT04928638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098526|NCT02786511|||CASE_ONLY||PROSPECTIVE|||||||
34098527|NCT00441935|||OTHER||PROSPECTIVE|||||||
34098528|NCT01496703|||COHORT||RETROSPECTIVE|||||||
34098529|NCT00478894|||COHORT||PROSPECTIVE|||||||
34098530|NCT04246710|||COHORT||PROSPECTIVE|||||||
34098531|NCT05287100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098532|NCT02620111|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34098533|NCT06013085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098534|NCT02051855|||COHORT||PROSPECTIVE|||||||
34098535|NCT04319055|||CASE_ONLY||RETROSPECTIVE|||||||
34098536|NCT01633112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Fingolimod patients were dose blind.||t|f|f|t
34098537|NCT02813824|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098538|NCT03870971|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34098539|NCT01356888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098540|NCT05921123|||COHORT||RETROSPECTIVE|||||||
34098541|NCT03306290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098542|NCT01173926|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098543|NCT04858529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098544|NCT00933166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098545|NCT06009926|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Investigators and clinical research coordinators will avoid speculating with the participant regarding the participant's treatment group. The individual authorized to break the blind, if conditions are met, is the study principal investigator (PI) in consultation with the DCP medical monitor.||t|f|t|f
34098546|NCT03128086|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098547|NCT02192697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098548|NCT05281640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical research data will be gathered at baseline, post-intervention (week 8) and follow-up (week 12) by research assistants (RAs). RAs will be masked to group allocation to demonstrate to future funders this is achievable in an Umbrella trial. Blind-breaks will be recorded, and minimised using previously successful strategies (e.g., separate offices / diaries)|This study is a pilot/feasibility Umbrella trial, comprising of 3 'interventionist-causal' trials (IC-RCTs)|f|f|f|t
34098549|NCT01512537|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34098550|NCT06251830|||COHORT||PROSPECTIVE|||||||
34098551|NCT04341662|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel cluster randomised trial with a baseline control phase, along with mixed-methods and health economic evaluations||||
34098552|NCT03133780|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098553|NCT02560415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098554|NCT03782103|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098555|NCT05403515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34098556|NCT01922661|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34098557|NCT01655212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098558|NCT03588000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098559|NCT00276393|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34098560|NCT00098293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098561|NCT00523679|||CASE_ONLY||PROSPECTIVE|||||||
34098562|NCT01229670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098563|NCT03033693|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34098564|NCT01712074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098565|NCT06092983|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34098566|NCT03079583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098567|NCT04116697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098568|NCT00209638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098569|NCT06535321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098570|NCT01713140|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098571|NCT02898441|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33793927|NCT04460612|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Infrared wraps will be compared to non-infrared placebo wraps which are identical in appearance.|Double Blind Randomized Placebo Controlled using the patients as their own controls. Patients will be randomized to receive either placebo wraps or the infrared wraps and then crossover to the alternative wrap.|t|t|t|t
33793928|NCT05889195|||CASE_ONLY||PROSPECTIVE|||||||
34098572|NCT02077712|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34098573|NCT03822819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is going to be carried out with two groups in which participants are either administered with probiotic cocktail capsules or placebo capsules|t|t|t|t
34098574|NCT04584554|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||15 patient/family dyads will undergo intervention||||
34098575|NCT01217138|RANDOMIZED|PARALLEL||||NONE||||||
34098576|NCT04560114|NA|SINGLE_GROUP||TREATMENT||NONE||Open, prospective, single-center phase 2 study||||
34098577|NCT06477510|NA|SINGLE_GROUP||TREATMENT||NONE||"The study population will include consecutive subjects referred to the Department of Periodontics, PGIDS, Rohtak for clinical evaluation. The patients will be screened according to the inclusion and exclusion criteria for eligibility to participate in the study. All participants will be informed about the purpose of the study and only individuals who provide written informed consent prior to the start of the study will be included.~After validation of the PAPS scale, patients with Stage I/II/III Periodontitis will be selected, and PAPS score recorded at baseline, then at 4 weeks and 3 month post non-surgical periodontal treatment and clinical parameters recorded at baseline and 3 month post non-surgical periodontal treatment with ultrasonic scaler or hand instruments as required."||||
34098578|NCT03774472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793929|NCT04808505|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793930|NCT02954016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793931|NCT03016455|||CASE_CONTROL||PROSPECTIVE|||||||
33793932|NCT00631579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793933|NCT03471611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793934|NCT02785380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937456|NCT05613192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Study medications were given to the patients by an unblinded pharmacist to ensure the right treatment assignment, however this pharmacist was not included in the outcome assessment.~All patients were diagnosed with NAFLD depending on abdominal ultrasonography performed by a radiologist where the liver brightness and liver parenchyma with diffuse echogenicity in confirm the diagnosis."|"Group 1: patients received the standard conventional therapy in addition to placebo for 4 months.~Group 2: patients received the standard conventional therapy in addition to a single oral dose of cholecalciferol 300,000 IU followed by oral cholecalciferol 800 IU daily for 4 months."|t|f|t|t
33937457|NCT04011137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33937458|NCT02847000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937459|NCT02565576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937460|NCT01158885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937461|NCT03194672|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33937462|NCT03151772|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Bioavailability study with an adaptive design (evaluation after 5 patients up to a total maximum of 20 patients in each arm). Experimental therapy not to be combined and not any comparison between therapies||||
33937463|NCT01644812|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937464|NCT01511692|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33937465|NCT01700595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937466|NCT02380703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33937467|NCT03030794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937468|NCT02316379|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937469|NCT05544110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937470|NCT05357924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937471|NCT03158155|||COHORT||CROSS_SECTIONAL|||||||
33937472|NCT01081951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098579|NCT06150014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098580|NCT06519175|||COHORT||OTHER|||||||
34098581|NCT02400736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098582|NCT00008268||||TREATMENT||||||||
34098583|NCT04802785|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098584|NCT04476485|||COHORT||PROSPECTIVE|||||||
33713869|NCT01648101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713870|NCT05004701|||COHORT||PROSPECTIVE|||||||
33713871|NCT02823301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713872|NCT02480023|NA|SINGLE_GROUP||SCREENING||NONE||||||
33713873|NCT03974945|||COHORT||CROSS_SECTIONAL|||||||
33713874|NCT02593474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713875|NCT00366314|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34098585|NCT03547232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34098586|NCT05945758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098587|NCT01389284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098588|NCT03938415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713876|NCT01295502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713877|NCT03674996|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33713878|NCT01660698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33713879|NCT05737303|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33713880|NCT01871532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713881|NCT00121602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713882|NCT04988724|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pilot study without control group||||
33713883|NCT01733602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713884|NCT01247740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713885|NCT00493324|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33713886|NCT02236195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713887|NCT04842266|||COHORT||PROSPECTIVE|||||||
33713888|NCT04225611|NA|SINGLE_GROUP||TREATMENT||NONE|No masking in Phase A of this trial.|The study begins with phase A, which is an open label study in that will enroll up to 6 subjects. The goal of this phase is to have 3 subjects complete the study. The enrollment number is 6 in order to accommodate for withdraws and/or terminations (for reasons other than adverse event to the study intervention and include loss of the lens before 7 days). Subjects will wear the TCL-DDS in one eye for 3 days during which time they will be closely followed with examinations at 1 hour, 6 hours, 24 hours, 3 days, and 7 days. After the TCL-DDS is removed after 3 days of wear, the subjects will be followed with weekly examinations for 3 additional weeks for evaluation of safety.||||
33713889|NCT01899300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713890|NCT01993147|NA|SINGLE_GROUP||OTHER||NONE||||||
33713891|NCT04581161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Subjects in the active treatment group will receive ventilatory support with Life2000® Ventilator following the labeled instructions for the device.~POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."||||
33713892|NCT05286281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713893|NCT02637752|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33713894|NCT04606173|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33713895|NCT05232201|||COHORT||CROSS_SECTIONAL|||||||
33713896|NCT05243862|NA|SINGLE_GROUP||TREATMENT||NONE||Following the Simon's 2-stage design, 18 participants will be enrolled in the first stage. If no participant with a response is observed, the study will be terminated for futility. If ≥ 1 participants achieve a response, then the study can proceed to the second stage, and additional 10 participants will be enrolled to the second stage.||||
33713897|NCT02337257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33713898|NCT03809117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713899|NCT00258531|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713900|NCT06335914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713901|NCT00020475||||TREATMENT||||||||
33713902|NCT00643227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713903|NCT05833347|||COHORT||PROSPECTIVE|||||||
33713904|NCT01378078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33713905|NCT03079908|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33713906|NCT00177398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713907|NCT04907656|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participants will be randomly assigned to either the dCBT app or a waitlist (control) condition with a 1.5:1 allocation (dCBT:Control) using a blocked randomized sequence. If initially allocated to the control condition, participants will be given access to the dCBT app after week 10 (that is, after the post-treatment evaluation, participants in the control group will be provided (crossed over to) dCBT).|f|f|f|t
33713908|NCT01897220|||COHORT||PROSPECTIVE|||||||
33713909|NCT03998189|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||45 female/ 45 male participants||||
33713910|NCT05188690|||COHORT||RETROSPECTIVE|||||||
33713911|NCT00672867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713912|NCT04262284|||COHORT||PROSPECTIVE|||||||
33793935|NCT04063826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In the first part 3 patients will be imaged, 2 with severe biopsy proven SH and one with severe CASH. Thereafter, depending on the imaging results, the second part will include up to 7 patients with mild to moderate SH and those with mild to moderate CASH||||
33793936|NCT00168922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33793937|NCT00765973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793938|NCT05119023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793939|NCT03121586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793940|NCT02105064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34098589|NCT01057940|||COHORT||PROSPECTIVE|||||||
34098590|NCT04472208|NA|SINGLE_GROUP||OTHER||NONE||||||
34098591|NCT01893762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098592|NCT00145327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016124|NCT01193036|||COHORT||PROSPECTIVE|||||||
34016125|NCT06323486|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|We shall perform a double-blinding system where the participants, study investigators, transcranial magnetic stimulation (TMS) technicians (those who operate and administer TMS procedures), and research assistants (outcome assessors) are masked to the assignment of the enrolled participants.|We will enroll patients who are willing to be randomized to either the accelerated bilateral sequential theta burst stimulation (absTBS)-sham or sham-absTBS treatment sequence arms. In the absTBS-sham sequence, participants shall receive the active absTBS treatment at Week 1, followed by sham treatment at Week 3, while in the sham-absTBS sequence, participants shall receive sham treatment at Week 1, followed by the active absTBS treatment at Week 3. The primary rationale for employing this sequential treatment strategy for both arms in this trial is to ensure that those assigned to the sham-absTBS group do not have to wait for longer periods to begin receiving the active absTBS therapy and to maintain blinding continuity.|t|t|t|t
34016126|NCT01006564|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34016127|NCT05046639|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study pharmacy will prepare the study medication and it will be labeled as subject number for administration|Prospective Randomized Crossover Controlled Trial|t|t|t|t
34016128|NCT00107549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016129|NCT01112943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34098593|NCT00185055|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34098594|NCT04286503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098595|NCT01311011|||COHORT||PROSPECTIVE|||||||
34098596|NCT02583009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098597|NCT00573820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098598|NCT00493558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098599|NCT02030639|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098600|NCT05514899|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This will be a double-blind, randomized, 2-sequence crossover trial of CBD versus THC to reduce systemic and neuro-inflammation. This design was chosen to balance consideration of addressing the key scientific questions (effects of CBD versus THC on the microbiome, ECS and inflammation and their interaction with HIV infection), scientific rigor, power and feasibility.|t|t|t|t
33793941|NCT01550666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34098601|NCT05714228|||COHORT||RETROSPECTIVE|||||||
34098602|NCT05950126|||COHORT||PROSPECTIVE|||||||
34098603|NCT04049084|||OTHER||OTHER|||||||
34098604|NCT03979989|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants were randomized to 1 of 2 treatment sequences (AB or BA). There was a washout of at least 7 days between the CG5503 administrations.||||
34098605|NCT00858052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098606|NCT01300520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098607|NCT04626531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|They did not know if they were in the control and intervention group at the time of randomization.||t|f|f|f
34098608|NCT03087123|RANDOMIZED|SEQUENTIAL||OTHER||NONE||In accordance with a single case design approach, where each subject acts as his/her own control, families will be randomized to a 2, 4, or 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period.||||
34098609|NCT00375310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098610|NCT01740427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098611|NCT01259882|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33793942|NCT05654012|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793943|NCT00566904|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33793944|NCT05399394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793945|NCT04949607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Subjects will be administered 1-4 grams of Inulin twice daily for 3 months.||||
33793946|NCT03180450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793947|NCT04753099|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33793948|NCT00361946|||COHORT||CROSS_SECTIONAL|||||||
33793949|NCT04164680|||COHORT||PROSPECTIVE|||||||
33937473|NCT01911884|NA|SINGLE_GROUP||OTHER||NONE||||||
33937474|NCT02177604|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937475|NCT00772980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937476|NCT04211649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098612|NCT03044912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized open label study|t|f|f|f
34098613|NCT01141790|RANDOMIZED|||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34098614|NCT00700232|||COHORT||PROSPECTIVE|||||||
34098615|NCT01062295||CROSSOVER||SUPPORTIVE_CARE||||||||
34098616|NCT04772924|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|triple blind||t|t|t|t
34098617|NCT00086125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098618|NCT04887038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098619|NCT01707550|||COHORT||PROSPECTIVE|||||||
34098620|NCT02650349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793950|NCT04133740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A before-and-after study in which the first half to the planned patients are following the standard regime for oxygen therapy with a fixed amount and the other half of the patients receive oxygen therapy to achieve normal levels of partial pressure of arterial oxygen.||||
33793951|NCT05981534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937477|NCT00005623|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33937478|NCT05503966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study is a three-armed, double-blinded, pragmatic randomized controlled trial comparing the efficacy of ABM as add-on to treatment with antidepressants (SSRI ABM group) in primary care compared to standard antidepressant treatment (SSRI TAU group). The third group will in addition to TAU be engaged in answering all the questionnaires and perform all the tasks, but without ABM, thus controlling for being engaged in some cognitive activity (SSRI Active comparison group).|t|t|t|t
33937479|NCT04652102|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The randomized observer-blinded phases of this study are participant and investigator blinded. This is followed by an open-label phase.||t|f|t|f
33937480|NCT02506972|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33937481|NCT00494195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016130|NCT00777413|RANDOMIZED|CROSSOVER||||NONE||||||
33937482|NCT02710110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713913|NCT05732454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"PART 1 Double Blind portion (Day 1 through Week 16): all parties are blinded to treatment.~PART 1 Open Label Extension portion: All parties will be aware participant is taking etrasimod for up to an additional 52 weeks.~PART 2 Open Label All parties will be aware participant is taking etrasimod for 52 weeks."|"Part 1: Approximately 60 participants with moderate-to-severe AD with a history of prior systemic treatment failure will be randomized (1:1 ratio) in a double blind (DB) manner to receive etrasimod 2 mg or placebo orally, once daily, for 16 weeks. Randomization will be stratified by disease severity as measured by IGA score (3 \[moderate AD\], 4 \[severe AD\]) at baseline.~After DB period, participants may be given the option to continue in an open label extension (OLE) phase whereby they will receive etrasimod 2 mg (tablet) for up to an additional 52 weeks.~Part 2: Approximately 340 additional participants will be enrolled to receive etrasimod 2 mg orally, once daily, for 52 weeks in an open-label manner."|t|t|t|t
33713914|NCT02231060|||COHORT||PROSPECTIVE|||||||
33713915|NCT03258151|||COHORT||OTHER|||||||
33713916|NCT03180723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713917|NCT01491412|||CASE_ONLY||PROSPECTIVE|||||||
33713918|NCT02051608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33713919|NCT04078113|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33937483|NCT02557867|NON_RANDOMIZED|PARALLEL||||NONE||||||
33937484|NCT01004874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937485|NCT00320619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937486|NCT05686876|NA|SINGLE_GROUP||SCREENING||NONE||||||
34016131|NCT06048666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016132|NCT05657236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016133|NCT02647593|||COHORT||PROSPECTIVE|||||||
34016134|NCT03589521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016135|NCT04785859|||CASE_CONTROL||PROSPECTIVE|||||||
34016136|NCT05881226|||COHORT||PROSPECTIVE|||||||
34016137|NCT05655247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016138|NCT01481324|||CASE_ONLY||PROSPECTIVE|||||||
34016139|NCT01804218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016140|NCT01363427|||CASE_ONLY||RETROSPECTIVE|||||||
34016141|NCT02288390|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016142|NCT05696795|NA|SINGLE_GROUP||TREATMENT||NONE||Male and female subjects at least 18 years of age with moderate to severe cutaneous sarcoidosis.||||
34016143|NCT00239655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016144|NCT01108666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016145|NCT01642199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016146|NCT05579483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the investigator, the participants, nor the outcome assessor will know who received what. No Care Provider is included in this trial.|A randomized, placebo-controlled, parallel, double-blind trial with two intervention arms and two control (placebo) arms.|t|f|t|t
34016147|NCT04802902|||CASE_ONLY||PROSPECTIVE|||||||
34016148|NCT01769339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016149|NCT04001920|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016150|NCT01939925|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33937487|NCT02313506|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study used a delayed control design.||||
33937488|NCT04139772|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Comparative Randomized Phase 3 Design||||
33937489|NCT04572724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|it is a open label cohort study|The participants who met the inclusion and exclusion criteria will enrolled in the trial. Subjects will be divided into two groups (1:1 matching will be achieved after a screening of propensity score) to receive one of two interventions in addition to standard HF management: Sacubitril/Valsartan group or RAS inhibitor group.||||
33937490|NCT03165799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Observers collecting data were blinded to participant treatment/control randomization allocation.|Participating teams were randomized with a 1:1 ratio to receive the intervention.|f|f|f|t
33937491|NCT01119924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937492|NCT00381472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937493|NCT01311973|||COHORT||PROSPECTIVE|||||||
33937494|NCT01922466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937495|NCT03202589|||OTHER||PROSPECTIVE|||||||
33937496|NCT03044704|||COHORT||PROSPECTIVE|||||||
33937497|NCT04715659|||OTHER||CROSS_SECTIONAL|||||||
33937498|NCT01573611|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33937499|NCT00779818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937500|NCT05012514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|N/D|Participants received seven sessions of PBMT LED twice a week, the last session being about twenty minutes before the surgical procedure of bariatric surgery. The therapy was performed on the left side of the abdominal region following the linea alba of all research participants and the right side was considered as control, for application they will receive eye protection, using goggles for safety, the abdomen of the participants will be cleaned by using a neutral cleansing soap.||||
33937501|NCT01715376|||COHORT||PROSPECTIVE|||||||
33937502|NCT05705960|NA|SINGLE_GROUP||OTHER||NONE||||||
34016151|NCT06534528|NA|SEQUENTIAL||TREATMENT||NONE||Dose1 Group：6.0×10\^6 cells/person, single-dose Dose2 Group：3.0×10\^7 cells/person, single-dose Dose3 Group：6.0×10\^7 cells/person, single-dose Dose4 Group：9.0×10\^7 cells/person, single-dose||||
34016152|NCT01941940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937503|NCT04322266|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937504|NCT01132768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937505|NCT05327244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All CAI participants will be assigned to the intervention arm and will all receive the same treatment (6 sessions of RWVF gait retraining in 2-weeks). Posttest data from CAI participants in arm 1 will be compared to data from pre-collected de-identified healthy control data.||||
34016153|NCT04371328|||COHORT||PROSPECTIVE|||||||
34098621|NCT05897502|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The participant does not know who the intervention group is versus the control group|The research design explores the evaluation of intervention effectiveness through a parallel group and experimental research design. Intentionally select experimental and control groups. A single blinding design (participants). The experimental group used multi-media education, 20 minutes per session, total 8 courses. The control group received routine education. The Principal investigator explains the research purpose to eligible participant, and signs a consent form. The interviewer conducted data: basic information and nutritional status indicators (mini nutritional assessment scale, dietary knowledge, attitude, behavior scale, simple dietary intake frequency scale) of two groups of hemodialysis patients as the Baseline. After 8-week nutritional education by dialysis nursing staff. Post tests (dietary knowledge, attitude, behavior scale, mini nutritional assessment scale, simple dietary intake frequency scale) were conducted by interviewer at the 3rd, 4th, and 5th months.|t|f|f|f
34098622|NCT04163770|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34098623|NCT05545488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34098624|NCT05847335|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34098625|NCT05708235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098626|NCT06172049|||COHORT||RETROSPECTIVE|||||||
34098627|NCT04954443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single blind (Care provider, investigator)||f|t|t|f
34098628|NCT02622594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34098629|NCT01769118|||||PROSPECTIVE|||||||
34098630|NCT05224908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098631|NCT06397066|||COHORT||CROSS_SECTIONAL|||||||
34098632|NCT05280158|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Groups will be enrolled as follows:~1. Mid-dose - Sentinel group, n=2~2. Standard-dose - Initial group, n=2~3. Cohort 1: 2:1 Randomization into~   * Mid-dose group, n=18~  * Standard-dose group, n=9~4. High-dose - Sentinel group, n=2~5. Cohort 2: 2:1 Randomization into~   * High-dose group, n=18~  * Standard-dose group, n=9~We will perform stratified randomization for the two cohorts based on: 1) the number of prior doses, and 2) prior receipt of any BNT162b2 vaccines."||||
34098633|NCT06153459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34098634|NCT01032343|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33793952|NCT01188499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793953|NCT03700216|||COHORT||PROSPECTIVE|||||||
33793954|NCT01052454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937506|NCT03114670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937507|NCT01856179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937508|NCT05414669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Key envelope was kept by third party and will be opened once the data analysis is done.||t|t|t|t
33937509|NCT00992485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937510|NCT00652522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937511|NCT01984294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937512|NCT03637166|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low altitude and High altitude||||
33937513|NCT03016832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937514|NCT02495584|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33937515|NCT00959829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33937516|NCT03681873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937517|NCT01738594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937518|NCT03245840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937519|NCT02020213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937520|NCT03474939|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33937521|NCT03882736|||COHORT||PROSPECTIVE|||||||
33937522|NCT02783651|||OTHER||RETROSPECTIVE|||||||
33937523|NCT03174392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33937524|NCT00338806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098635|NCT02551809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098636|NCT05119907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098637|NCT02571855|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33793955|NCT01192633|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33793956|NCT00867191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793957|NCT05193188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937525|NCT02625363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33937526|NCT05162300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937527|NCT04340089|||COHORT||PROSPECTIVE|||||||
33937528|NCT03930394|||COHORT||PROSPECTIVE|||||||
33937529|NCT04952116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937530|NCT01085942|||CASE_ONLY||PROSPECTIVE|||||||
33937531|NCT01234337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937532|NCT05092867|||COHORT||PROSPECTIVE|||||||
33937533|NCT03648502|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||3 participants arms Diagnostic tools validation|f|f|f|t
33937534|NCT03950440|||COHORT||PROSPECTIVE|||||||
33937535|NCT04276831|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33937536|NCT03757299|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33937537|NCT01260038|||CASE_ONLY||PROSPECTIVE|||||||
33937538|NCT02499640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937539|NCT02621008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937540|NCT03436524|||COHORT||RETROSPECTIVE|||||||
33937541|NCT04754724|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33937542|NCT03507270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-center study||||
33937543|NCT00004147||||TREATMENT||||||||
34098638|NCT06121219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098639|NCT06582771|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a phase 2 study with a single cohort.||||
34098640|NCT01124266|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34098641|NCT05380570|||COHORT||PROSPECTIVE|||||||
34098642|NCT01514435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098643|NCT00657501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098644|NCT00711763|||OTHER||PROSPECTIVE|||||||
34098645|NCT01151631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098646|NCT02256800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098647|NCT05376306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098648|NCT02563431|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098649|NCT01843504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098650|NCT03545581|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34098651|NCT04403126|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Classrooms participating in this study will be randomly assigned to either an experimental group (with forgiveness intervention) or a control group (with regular instruction). The experimental group will receive the 1st forgiveness intervention for 12 weeks and then the control group will turn into an experimental group to receive a 2nd forgiveness intervention for 12 weeks.|t|t|t|t
34098652|NCT03299335|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098653|NCT05914259|||COHORT||RETROSPECTIVE|||||||
34098654|NCT03426852|||COHORT||PROSPECTIVE|||||||
33937544|NCT01641354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937545|NCT01402375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33937546|NCT03202667|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33937547|NCT03577444|||COHORT||PROSPECTIVE|||||||
33937548|NCT02132169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937549|NCT04768049|||OTHER||OTHER|||||||
33937550|NCT05757466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937551|NCT01876134|||COHORT||PROSPECTIVE|||||||
33937552|NCT05509556|||CASE_CONTROL||RETROSPECTIVE|||||||
33937553|NCT04101786||CROSSOVER||BASIC_SCIENCE||NONE||||||
33937554|NCT03810261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937555|NCT05823389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937556|NCT02679430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937557|NCT01903616|||COHORT||PROSPECTIVE|||||||
33937558|NCT00065351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937559|NCT04990999|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33937560|NCT05348564|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33937561|NCT00519571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937562|NCT02839512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937563|NCT02854501|||CASE_CONTROL||PROSPECTIVE|||||||
33937564|NCT00474539|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937565|NCT06439342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937566|NCT02417129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937567|NCT01097434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937568|NCT02150291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33937569|NCT02365376|||CASE_ONLY|||||||||
33937570|NCT03212209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants have never had contact with CPAP, therefore were not aware of PAP modality prescribed. Investigator were also naive, as well as sleep specialist responsible for Polysomnography reports. Only respiratory therapist who was assigned to CPAP clinic was aware of patient´s treatment condition.|This is a crossover study comparing different CPAP modalities in a group of patients with moderate to severe OSA.|t|f|t|f
33937571|NCT03170635|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The Refreshing Recess program was provided one day/week for 6 consecutive weeks.||||
33937572|NCT01910272|||COHORT||PROSPECTIVE|||||||
33937573|NCT02615561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937574|NCT02352428|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33937575|NCT05646160|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34098655|NCT03125356|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098656|NCT00176254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098657|NCT04860583|||COHORT||RETROSPECTIVE|||||||
34016154|NCT02934763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016155|NCT02706782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016156|NCT02115217|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34016157|NCT01415219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016158|NCT01672944|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016159|NCT01989338|||CASE_ONLY||PROSPECTIVE|||||||
34016160|NCT01439230|RANDOMIZED|CROSSOVER||||NONE||||||
34016161|NCT04671030|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subjects are not aware of the nature of the drug that they are receiving|Single group interventional study with brief crossover of subjects into the placebo group|t|f|f|f
34016162|NCT03916523|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All laboratory testing will be performed by investigators who are not aware of group assignment.||t|f|t|f
34016163|NCT03820934|NA|SINGLE_GROUP||SCREENING||NONE||||||
34016164|NCT01491230|||COHORT||PROSPECTIVE|||||||
34016165|NCT00074776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016166|NCT03335293|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34016167|NCT00045175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016168|NCT02681224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016169|NCT03754374|||COHORT||PROSPECTIVE|||||||
34016170|NCT01125020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34098658|NCT03526432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098659|NCT05612607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will be tested to determine SMB cell proportion/SMB cell levels for eligibility for IGRT discontinuation. If SMB cells are ≥ 2%, IGRT will be discontinued. If SMB cells are \< 2%, the patient will remain on IGRT and a maximum of 40 mL of blood will be drawn again in 3-6 months to reassess SMB levels and eligibility for IGRT discontinuation.||||
34098660|NCT01630603|||COHORT||CROSS_SECTIONAL|||||||
34098661|NCT04865458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098662|NCT01539889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098663|NCT03969758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|t|t|f
34098664|NCT00810186|||CASE_CONTROL||PROSPECTIVE|||||||
34098665|NCT02151604|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098666|NCT00170820|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34098667|NCT05598307|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34098668|NCT01783873|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34098669|NCT02576366|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33713920|NCT01954550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713921|NCT01596868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713922|NCT01975545|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33713923|NCT04848545|||CASE_CONTROL||PROSPECTIVE|||||||
33713924|NCT03737721|NA|SINGLE_GROUP||TREATMENT||NONE||This study has been designed as an open-label, non-randomized, single-arm phase II study to investigate the feasibility and efficacy of Avelumab in combination with radiation therapy in patients with unresectable cuSCC.||||
33713925|NCT06311968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713926|NCT03647982|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33713927|NCT00816985|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33713928|NCT03303534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||3:2 randomization to short-term protein calorie restriction diet versus regular meals prior to elective carotid artery endarterectomy||||
33713929|NCT05152589|||COHORT||PROSPECTIVE|||||||
33713930|NCT02006745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33713931|NCT03659812|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33713932|NCT01101295|||COHORT||PROSPECTIVE|||||||
34016171|NCT01544738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016172|NCT02995876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34016173|NCT01565850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016174|NCT05243186|RANDOMIZED|CROSSOVER||OTHER||NONE|There are no masking in the study. All parties have all the information regard the conditions of the study.|All participants will participate in four different sessions of the study that will be randomly crossed over.||||
34016175|NCT00084448||||TREATMENT||NONE||||||
34016176|NCT04015401|||CASE_ONLY||CROSS_SECTIONAL|||||||
34098670|NCT06466252|||OTHER||PROSPECTIVE|||||||
34098671|NCT06386042|||COHORT||PROSPECTIVE|||||||
34098672|NCT04619030|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|It is not possible to blind participants to visual information in the patient leaflet (augmented reality versus traditional). The data collected will be fully anonymised before statistical assessment by an independent statistical service|Randomised crossover|f|f|t|t
34098673|NCT03753503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098674|NCT05757700|NA|SEQUENTIAL||TREATMENT||NONE||||||
33937576|NCT06038968|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34016177|NCT01876550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937577|NCT00150514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937578|NCT00544193||||TREATMENT||||||||
34016178|NCT00921089|||||CROSS_SECTIONAL|||||||
34016179|NCT01200264|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016180|NCT01884428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016181|NCT03369743|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016182|NCT04327856|||COHORT||PROSPECTIVE|||||||
34016183|NCT05124197|||COHORT||RETROSPECTIVE|||||||
34016184|NCT05224284|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016185|NCT04660890|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016186|NCT04976998|||CASE_CONTROL||PROSPECTIVE|||||||
34016187|NCT00931268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016188|NCT04375865|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34016189|NCT00050232|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34016190|NCT04569448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016191|NCT03250949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34016192|NCT05730907|||COHORT||RETROSPECTIVE|||||||
34016193|NCT01903603|||COHORT||PROSPECTIVE|||||||
34098675|NCT06407778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome Assessor will be blind||f|f|f|t
33937579|NCT05362825|||COHORT||PROSPECTIVE|||||||
33937580|NCT00536640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937581|NCT03377452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be blinded to group assignment.|Individuals will be assigned to one of two programs simultaneously|t|f|f|t
33937582|NCT05257668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937583|NCT02638753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937584|NCT04099030|||COHORT||RETROSPECTIVE|||||||
33937585|NCT00861302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937586|NCT00850135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937587|NCT05335785|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled clinical trial||||
33937588|NCT04272996|RANDOMIZED|PARALLEL||TREATMENT||NONE||The control group (surgery) would only receive surgical evacuation of a hematoma using current standard of care. The treatment group (surgery plus) would receive surgical evacuation followed by endovascular embolization of the middle meningeal vessels using current standard of care. We will directly compare these two treatment modalities to obtain class I evidence on the efficacy of embolization for treatment of chronic subdural hematomas.||||
33937589|NCT00740194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937590|NCT03990324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of dependent variables was blinded to group assignment|Randomized controlled trial|f|f|f|t
33937591|NCT00002494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937592|NCT06028178|||CASE_CONTROL||PROSPECTIVE|||||||
33937593|NCT00806494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016194|NCT04549935|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33937594|NCT02150304|||CASE_CONTROL||RETROSPECTIVE|||||||
33937595|NCT02149628|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016195|NCT02643017|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34016196|NCT04111406|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Historical control study (Before and after study) Data in current practice was derived from acute pain record before Jan 2019|t|f|f|t
33937596|NCT02299128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33937597|NCT05905601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937598|NCT00075413||||TREATMENT||||||||
34016197|NCT01550744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016198|NCT01294475|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34016199|NCT02927977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016200|NCT06227156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016201|NCT01930318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34016202|NCT05444686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016203|NCT02993315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016204|NCT06301061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016205|NCT03880773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016206|NCT03876977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016207|NCT02901613|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016208|NCT04226573|||COHORT||PROSPECTIVE|||||||
34016209|NCT03736213|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All perceptual ratings will be obtained from blinded, naive listeners recruited through online crowdsourcing. Following protocols refined in previous published research, binary rating responses will be aggregated over at least 9 unique listeners per token.|In this single-case randomization design, each participant will receive an equal number of sessions of visual-acoustic and ultrasound biofeedback, with randomized allocation of treatment types to individual sessions. Treatment will last 20 hrs (10 days) over a 5 week period. Randomization will be blocked, with each day of treatment serving as a block; within each day, one hour of treatment will be randomly assigned to feature visual-acoustic and one to feature ultrasound treatment. A congruent condition and an incongruent condition will be defined for each participant based on their sensory profile, where the congruent condition is the biofeedback type that is expected to be more effective and the incongruent condition is the type expected to be less effective. Visual-acoustic biofeedback is defined as the congruent condition for individuals with a primary auditory deficit and ultrasound biofeedback is defined as congruent for individuals with a primary somatosensory deficit.|f|f|f|t
34016210|NCT05426304|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016211|NCT00537927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016212|NCT02246439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016213|NCT01914120|||CASE_ONLY||PROSPECTIVE|||||||
34016214|NCT01739621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016215|NCT00608153|||COHORT||PROSPECTIVE|||||||
34016216|NCT01892657|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33937599|NCT02712008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937600|NCT02261246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33937601|NCT01812395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33937602|NCT04058795|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33937603|NCT02819583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937604|NCT00423267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937605|NCT03484052|NA|SINGLE_GROUP||OTHER||NONE||||||
33937606|NCT00010244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937607|NCT02404038|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33937608|NCT04504474|||COHORT||OTHER|||||||
33937609|NCT05131035|RANDOMIZED|PARALLEL||OTHER||SINGLE||The R33 study design will utilize a randomized intervention model. All participants will participate in cognitive training with small group support.One group will complete speeded cognitive training tasks and the other group will complete non-speeded cognitive training tasks.|f|f|f|t
33937610|NCT00684073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937611|NCT04121052|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937612|NCT05467033|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33937613|NCT05246228|||COHORT||PROSPECTIVE|||||||
33937614|NCT03139773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33937615|NCT00930501|||CASE_ONLY||PROSPECTIVE|||||||
34016217|NCT02923882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34016218|NCT02599636|||COHORT||PROSPECTIVE|||||||
34016219|NCT05789719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016220|NCT02715206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016221|NCT01138865|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34016222|NCT03373136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016223|NCT02567318|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34016224|NCT02880020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016225|NCT01389466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34016226|NCT03729076|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016227|NCT05072197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34016228|NCT00003436|RANDOMIZED|||TREATMENT||||||||
34016229|NCT02666352|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016230|NCT05841082|||COHORT||RETROSPECTIVE|||||||
34016231|NCT02454803|||COHORT||PROSPECTIVE|||||||
34016232|NCT00005918||||TREATMENT||DOUBLE||||||
33937616|NCT06389773|||OTHER||OTHER|||||||
34016233|NCT00622466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016234|NCT05222503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016235|NCT01383421|||OTHER||OTHER|||||||
34016236|NCT02229448|||CASE_ONLY||RETROSPECTIVE|||||||
33937617|NCT04387695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937618|NCT01096615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33937619|NCT00879593|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33937620|NCT00184366|||CASE_ONLY||PROSPECTIVE|||||||
33937621|NCT00703781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937622|NCT06371326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937623|NCT02350192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34016237|NCT03698266|NA|SINGLE_GROUP||OTHER||NONE||All patients enrolled in the study will consent to a needle knife fistulotomy as a starting technique to gain access to the biliary system.||||
34016238|NCT03476122|||COHORT||PROSPECTIVE|||||||
34016239|NCT01969292|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34016240|NCT03983252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016241|NCT02058212|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34016242|NCT03514654|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither the patients nor the clinical team will be blinded to the trial arms of this study|To evaluate whether a sufficient number of eligible patients can be identified and are willing to accept randomisation of the interventions in question. Recruitment and compliance rates of which will inform the feasibility and design of a larger trial||||
34016243|NCT05376852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016244|NCT06166316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937624|NCT01339845|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33937625|NCT05372289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, the primary endpoint assessors, who are assessing parameters constituting the primary endpoints, will be masked to the treatment regimen. Any personnel involved with the statistical analysis and interpretation of the data and results will be masked to the treatment regimen until database lock.||f|f|f|t
33937626|NCT02640989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937627|NCT02591511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34016245|NCT02031952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016246|NCT04691050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016247|NCT01059266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016248|NCT03566264|||COHORT||RETROSPECTIVE|||||||
33937628|NCT04783961|||COHORT||PROSPECTIVE|||||||
33937629|NCT05890131|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016249|NCT01079884|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34016250|NCT00770536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016251|NCT01659736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016252|NCT02960919|||COHORT||PROSPECTIVE|||||||
34016253|NCT04751084|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double blinded to the randomization list|A prospective double blinded randomized controlled trial|t|t|t|f
34016254|NCT00031083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016255|NCT04593017|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|3rd party will be involved in labeling the test and placebo samples|Two groups matched in age and gender|t|f|t|f
34016256|NCT03997071|||COHORT||PROSPECTIVE|||||||
34016257|NCT00249691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016258|NCT05314114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016259|NCT04796636|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label phase 1 randomized controlled trial||||
33937630|NCT00000231||||TREATMENT||||||||
33937631|NCT03773016|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The intervention activity will consist of the cross-over use of two different visual art apps in touchscreen tablets with people with mild to moderate dementia that lives in care homes. The study will take place in a nursing home in Nottinghamshire and will involve 12 residents of the care home with dementia and up to 12 staff members that are involved in participants' care. Study data collection will take 8 weeks; four weeks will involve the execution of the intervention and four weeks for additional measurements (collect consent, screening and end measures). Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The data collection will consist of the observation of the activity and on the use of dementia-specific instruments and questionnaires.||||
33937632|NCT03508973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937633|NCT04833049|NA|SEQUENTIAL||OTHER||NONE||||||
33937634|NCT02346799|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33937635|NCT01066637|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34016260|NCT05873361|||CASE_ONLY||PROSPECTIVE|||||||
34016261|NCT02819141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016262|NCT03231319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016263|NCT03014336|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016264|NCT02405663|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34016265|NCT00166270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016266|NCT02658565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016267|NCT04977063|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Randomised control trial involving simultaneous ingestion of two medical devices - the Atmo gas capsule and SmartPill.||||
34016268|NCT01527617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016269|NCT05250674|||CASE_ONLY||PROSPECTIVE|||||||
34016270|NCT00003034|RANDOMIZED|||TREATMENT||NONE||||||
34016271|NCT00038337|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34016272|NCT01847820|||CASE_ONLY||PROSPECTIVE|||||||
34016273|NCT03564041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant enrolment will be masked from care provider, investigator, and the outcomes assessors through the use of third party randomization. This ensures that only participants, and those necessary in coordinating their participation in the study, are aware of whether or not they are part of the experimental or control group.|This study will be a blinded (rater, investigator, and clinician), 12-week randomized controlled trial (RCT) conducted at Western University, London, ON, Canada, and McGill University, Montreal, QC, Canada.|f|t|t|t
34016274|NCT02812979|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34016275|NCT04014855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34016276|NCT03081741|||COHORT||PROSPECTIVE|||||||
34016277|NCT00944749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016278|NCT00115297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016279|NCT06010459|||OTHER||CROSS_SECTIONAL|||||||
34016280|NCT04191798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All TUG and RoM assessments will be performed by trained physician assistants who will remain blinded to allocation throughout the study||f|f|f|t
34016281|NCT02011750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016282|NCT00557076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016283|NCT00620659|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34016284|NCT05925504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016285|NCT01447836|||COHORT||PROSPECTIVE|||||||
34016286|NCT00576264|||COHORT||PROSPECTIVE|||||||
34016287|NCT00115557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016288|NCT04416620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study is a single-blinded randomized controlled trial. The patients 'study groups were only known for the clinical pharmacist.|"Participants in the active group received the usual care delivered at the community pharmacies at both countries plus the pharmaceutical care service designed by the research group and provided by the clinical pharmacist, an experienced female with extensive knowledge on PCOS. The intervention was delivered via oral advice and recommendations, and written material, with a special focus on diet and exercise. Participants in the control group received the usual care only and did not receive the pharmaceutical care service.~Following the intervention, both groups were followed up for four months and re-interviewed at the community pharmacy."|t|f|f|f
34016289|NCT02410356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016290|NCT00571285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016291|NCT04787393|||CASE_ONLY||PROSPECTIVE|||||||
34016292|NCT02439749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016293|NCT02715934|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016294|NCT05550883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016295|NCT04982874|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||randomized, single blind, single dose, 2-period, cross-over design with one week washout period between each treatment in 24 healthy volunteers beneath fasting condition|t|f|t|f
34016296|NCT01346774|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016297|NCT05207566|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34016298|NCT03302312|||OTHER||RETROSPECTIVE|||||||
34016299|NCT04874636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016300|NCT05757882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34016301|NCT00299637|||CASE_CONTROL||OTHER|||||||
34016302|NCT04465630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016303|NCT01173471|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016304|NCT04993300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016305|NCT00054548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016306|NCT05697926|||COHORT||PROSPECTIVE|||||||
34016307|NCT02010788|||COHORT||PROSPECTIVE|||||||
34016308|NCT01745211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016309|NCT02243267|||CASE_CONTROL||PROSPECTIVE|||||||
34016310|NCT01791231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016311|NCT02043665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937636|NCT03755362|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will randomize 60 subjects ≥65 years old with asymptomatic carotid artery stenosis (ACAS), mild to moderate cognitive impairment and periodontitis. These 60 patients will be randomized to two groups (intensive vs. standardized periodontal treatment). As randomization will be computer generated, the likelihood of randomization to either group is 50:50.||||
33937637|NCT04168515|||CASE_ONLY||PROSPECTIVE|||||||
33937638|NCT03544385|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33937639|NCT05431231|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33937640|NCT02056249|||CASE_CROSSOVER||PROSPECTIVE|||||||
34098676|NCT05366842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a single center, randomized; singe blinded, two-arm trial comparing the effects of direct placement of lyopreservation placental tissue over the spared neurovascular bundles vs. standard care (no placement of tissue) on erectile recovery and quality of life in patients undergoing bilateral nerve sparing radical prostatectomy for prostate cancer. The sample size will be 30 patients randomized to each study arm (60 patients total).|t|f|f|f
34098677|NCT00063999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098678|NCT00638079|RANDOMIZED|CROSSOVER||||NONE||||||
34098679|NCT02560792|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34016312|NCT04659252|||COHORT||PROSPECTIVE|||||||
34016313|NCT01646047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34016314|NCT04746300|||COHORT||PROSPECTIVE|||||||
34016315|NCT03095313|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34016316|NCT00766935|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016317|NCT06148064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016318|NCT02551666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34016319|NCT02836626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016320|NCT01870882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016321|NCT00423319|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016322|NCT00040183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34016323|NCT02606175|NA|SINGLE_GROUP||SCREENING||NONE||||||
34016324|NCT05232084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and the anesthesiologist who will perform postoperative pain evaluation and opioid consumption will not know the group|There are two models for this study. The first group is 30 ml volume ESPB group. The second one is 20 ml volume ESPB group|t|f|f|t
34016325|NCT03593811|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34016326|NCT05937321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016327|NCT00939120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016328|NCT00752960|||COHORT||RETROSPECTIVE|||||||
34103379|NCT06255340|RANDOMIZED|CROSSOVER||TREATMENT||NONE|FE part of the trial is designed as open-label. SRD part is designed as blinded to subjects.|"The food effect (FE) part of the trial is designed as a randomised, two-sequence, open-label, two period, two-way cross-over trial.~The single rising dose (SRD) part is designed as blinded to subjects, randomised, and placebo-controlled within parallel dose groups."||||
34103380|NCT06537401|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Non-Randomized Crossover||||
34103381|NCT04845555|||COHORT||PROSPECTIVE|||||||
34103382|NCT06456541|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33713933|NCT01731392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33713934|NCT04416594|||COHORT||PROSPECTIVE|||||||
33713935|NCT03290898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blindet, randomization and training intervention by non-investigator. Open-label after primary follow up. After unblinding, blindet 3rd party performs tests (visit 9 and 12 months, e.g. spirometry)|A randomized, controlled parallel group, outcome assessor blinded, clinical trial|f|f|t|t
33713936|NCT05022108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713937|NCT03262818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713938|NCT04144946|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33713939|NCT05147116|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will undergo both the hypoxia and sham conditions and will be blinded to the conditions in which they are in.|Single blind, randomized, balanced, crossover design study|t|f|f|f
33713940|NCT05208255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713941|NCT00275990|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33713942|NCT04351321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713943|NCT00375076|RANDOMIZED|PARALLEL||||DOUBLE||||||
33713944|NCT02363517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713945|NCT01849380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713946|NCT02611557|NA|SINGLE_GROUP||SCREENING||NONE||||||
33713947|NCT01112241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33713948|NCT02133768|||COHORT||PROSPECTIVE|||||||
33713949|NCT04359550|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713950|NCT02525666|||COHORT||PROSPECTIVE|||||||
33713951|NCT04216095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||MST (Magstim Theta device, Magstim Company Limited, Whitfield, Wales, UK) versus ECT (Thymatron IV device, Somatics LLC, USA) assigned per the clinical decision making of the ECT psychiatrist as deemed best for the patient.||||
33713952|NCT03773081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713953|NCT01904591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713954|NCT04250870|RANDOMIZED|PARALLEL||OTHER||NONE||randomized clinical trial||||
33713955|NCT04803825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a prospective randomised controlled trial, feasibility trial.|f|f|t|t
33713956|NCT02395380|NA|SINGLE_GROUP||OTHER||NONE||||||
33713957|NCT03086889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713958|NCT05626257|||COHORT||PROSPECTIVE|||||||
33713959|NCT01411774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713960|NCT04918433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33713961|NCT01084746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33937641|NCT02685839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33937642|NCT04882826|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33937643|NCT03515265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098680|NCT04784871|RANDOMIZED|PARALLEL||PREVENTION||NONE||The design is a randomized controlled trial (RCT) with one intervention group and two wait-list control groups. The goal with this design is to demonstrate the initial efficacy and feasibility of the 5WaysA intervention. We have one active control group writing activity log and one inactive not getting any tasks while waiting. The effect analysis will involve a comparison of self-reported wellbeing at different measurement points, using a two-way mixed measures ANOVA. In addition, PI will run a longitudinal analysis using linear mixed (multilevel) models on the data from all 5-6 measurement time points. Mixed modelling is a flexible way to handle unbalanced data in case of non-registration and repeated observations. The models allow PI to investigate the effects of the intervention and test the hypotheses of group and individual development in wellbeing while controlling for both stable and time-varying covariates.||||
34098681|NCT02238327|||COHORT||PROSPECTIVE|||||||
34098682|NCT01856660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098683|NCT04457778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098684|NCT04661332|||COHORT||PROSPECTIVE|||||||
34098685|NCT00449969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098686|NCT00894725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098687|NCT00986583|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34098688|NCT00743080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098689|NCT00275899|||CASE_CONTROL||OTHER|||||||
34098690|NCT03160807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098691|NCT02362932|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34098692|NCT05098236|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098693|NCT02978508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098694|NCT05014542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor for taking the physiatrist's measure and the assessor in charge of helping fill WOMAC, VAS, KDSQ, drug dosage taken, and Lequesne index were blind to the fact to which group participant belong.|A randomized, controlled, open-label, interventional, prospective.|f|f|f|t
34098695|NCT03383081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098696|NCT02087878|||OTHER||OTHER|||||||
34098697|NCT04443777|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial.|t|f|t|t
34098698|NCT04169412|||COHORT||PROSPECTIVE|||||||
34098699|NCT03000959|||COHORT||PROSPECTIVE|||||||
34098700|NCT00553475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098701|NCT06134895|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33713962|NCT01104493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713963|NCT03621098|||CASE_CONTROL||PROSPECTIVE|||||||
33713964|NCT03935100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded to clipping, undergo same procedure||t|f|f|f
33713965|NCT03688165|||COHORT||PROSPECTIVE|||||||
33713966|NCT02176330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33713967|NCT02917304|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33713968|NCT02642289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33713969|NCT05377983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes.|f|f|f|t
33713970|NCT03731780|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The recruiter will be blinded. The operator cannot be blinded because of the different in the procedures of caries prevention applied in each group. However, the assessors will be kept unaware of the treatment assigned to the patient.||t|f|f|t
33713971|NCT00830596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33713972|NCT00467571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713973|NCT00875251|||COHORT||PROSPECTIVE|||||||
33713974|NCT03656328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blind|t|f|t|f
33713975|NCT05117320|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|Allocation of images was performed before inclusion of participants began. Allocation process ensured that is was unnecessary for the investigator to assess the randomization.|In a crossover and multi-reader multi-case study, physicians read CXRs from acute dyspnoic patients. Each physician retrospectively interprets each image twice in two sessions - once with and once without AI-support in random order.The wash-out period was a minimum four weeks. The images were randomly allocated to the physicians via block randomization. Each image was viewed by at least one physician once with and once without AI on trial day 1.||||
33713976|NCT05112432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713977|NCT05741320|||COHORT||PROSPECTIVE|||||||
33713978|NCT04368767|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will use a randomized controlled trial design to examine feasibility of the prolonged SSC intervention in the first week of life for late preterm infants and to provide preliminary data for future research to compare the effects of usual incubator care with prolonged SSC on biomarkers of stress in late preterm infants in the first week of life.||||
33713979|NCT05993468|||COHORT||PROSPECTIVE|||||||
33713980|NCT03274505|||COHORT||CROSS_SECTIONAL|||||||
33713981|NCT01102751|||CASE_CONTROL||PROSPECTIVE|||||||
33713982|NCT04459091|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33713983|NCT06340815|NA|SINGLE_GROUP||TREATMENT||NONE||a clinical study of prospective, single-arm objective performance criteria||||
33713984|NCT01189903||||TREATMENT||||||||
33713985|NCT01753791|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33713986|NCT02344485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937644|NCT03062644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind||t|t|t|f
33937645|NCT04510844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937646|NCT04061304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937647|NCT03960593|||COHORT||PROSPECTIVE|||||||
33937648|NCT04244773|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
33937649|NCT03928106|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33937650|NCT01566981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937651|NCT00320632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937652|NCT02073227|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33713987|NCT05608889|NA|SINGLE_GROUP||PREVENTION||NONE||This study will use a quasi-experimental pre-post design to compare values of outcome measures at the three times points: baseline, immediately post-intervention (3 months after baseline), and follow-up (9 months after baseline). Randomization of the intervention is not feasible at the individual level due to contamination effects within a site and no appropriate control condition. Furthermore, as each of the sites is unique, a randomized cluster design would not be able to account for confounders since there are only three sites, each with institutional differences. An advantage of the pre-post design is that each participant will act as their own control, increasing the power of the study.||||
33937653|NCT02729870|||COHORT||PROSPECTIVE|||||||
33937654|NCT02824315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937655|NCT02996175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33937656|NCT02491528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937657|NCT05663827|NA|SINGLE_GROUP||TREATMENT||NONE||Cases with steroid-refractory GVHD would be given an add-on therapy of age/weight adjusted dosage of Ruxolitinib||||
33937658|NCT00866606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937659|NCT01021293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937660|NCT04928521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937661|NCT05673382|RANDOMIZED|PARALLEL||TREATMENT||NONE||After recruitment finished, participants will be randomized to either intervention condition (treatment group) or control condition (wait-list). Participants in the control condition will receive the same treatment once the treatment group has finished the treatment and outcome measures has been collected from both groups.||||
33937662|NCT00003716||||TREATMENT||||||||
33937663|NCT00462488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937664|NCT01292850|||||PROSPECTIVE|||||||
33937665|NCT01357720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33937666|NCT03723811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937667|NCT01057394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937668|NCT01351233|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33937669|NCT01349842|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937670|NCT05096442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937671|NCT01738568|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937672|NCT01649752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937673|NCT04973722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937674|NCT05066802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937675|NCT02934061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937676|NCT04729010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937677|NCT02489656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937678|NCT03530189|||COHORT||PROSPECTIVE|||||||
33937679|NCT00958113|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937680|NCT06425224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937681|NCT03431415|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33937682|NCT01572844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33937683|NCT02603939|||COHORT||PROSPECTIVE|||||||
33937684|NCT01951326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937685|NCT02409628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937686|NCT06032429|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33937687|NCT02465541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33937688|NCT01562379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937689|NCT01023139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937690|NCT01660529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937691|NCT02773511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937692|NCT05161624|||OTHER||RETROSPECTIVE|||||||
33937693|NCT03003429|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937694|NCT05746572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937695|NCT03187795|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All study investigators, participants, and assessors will be blind to group assignment. Blinding code will only be broken in emergency situations for reasons of subject safety, where knowledge of the treatment administered is necessary for the treatment of the adverse event under Good Clinical Practices (GCPs), or when required by local regulatory authorities.|After a two-day washout period, participants will be randomly assigned to one of two treatment groups: 1) an escalating dose of mirabegron for 6 weeks (25 mg once daily plus two placebo pills for 2 weeks, followed by 50 mg once daily plus 2 placebo pills for 4 weeks); or 2) Oxybutynin IR (5 mg orally three times daily) for 6 weeks. All participants will then be switched to the opposite study treatment for 6 weeks. Assessments will be performed at Baseline, Week 6 (completion of first study medication and prior to administration of second study medication), and Week 12 (completion of second study medication).|t|t|t|t
33937696|NCT00945685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937697|NCT00742391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016329|NCT04969718|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34016330|NCT04060342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 - Dose Escalation of 3 different Regimens and Expansion, Phase 2 - Basket Expansion of 3 Cohorts||||
34016331|NCT03733210|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34016332|NCT04015726|||OTHER||CROSS_SECTIONAL|||||||
34016333|NCT04273581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016334|NCT02917330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016335|NCT02252159|||COHORT||PROSPECTIVE|||||||
34016336|NCT05056766|||COHORT||PROSPECTIVE|||||||
34016337|NCT04064814|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, open Label , active controlled study||||
34016338|NCT04064619|RANDOMIZED|PARALLEL||TREATMENT||NONE||60 patients with idiopathic OAB and treated with solifenacin 5mg twice daily for one month. After improvement of their condition, we divided the responders into 2 groups, group I stopped the drug suddenly, while group II underwent gradual weaning of the drug.||||
34016339|NCT01268605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016340|NCT05507593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016341|NCT05770765|||COHORT||PROSPECTIVE|||||||
34016342|NCT03362918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will be blind to the allocation of the study participants.||f|f|f|t
34016343|NCT06219590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34016344|NCT05770505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016345|NCT02442674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33713988|NCT06174493|||CASE_CROSSOVER||PROSPECTIVE|||||||
33713989|NCT03085420|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33793958|NCT03861741|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot study will recruit relatives of 16 patients with a diagnosis of non-syndromic thoracic aortic disease. As many FDR and SDR of the proband (index patient) as possible will be recruited into the study (family based analysis). They will be screened through complete clinical evaluations, genetic tests (whole exome sequencing) and imaging modalities (TTE and MRI) for the presence of newly NS-TADs.||||
33793959|NCT02061930|||COHORT||RETROSPECTIVE|||||||
33793960|NCT03909477|||COHORT||PROSPECTIVE|||||||
33937698|NCT05141565|||COHORT||PROSPECTIVE|||||||
33793961|NCT02547922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793962|NCT05987969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793963|NCT01595906|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793964|NCT00790790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937699|NCT00264511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeons initially operating were unaware of allocation. Outcomes arbitrations were conducted by surgeons blind to intervention allocation. Chief investigator masked until follow up data finally received and records locked.||f|f|t|t
33713990|NCT04744142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects were randomized by an external, independent researcher. Supplements were color and taste matched.|Subjects were pair-matched for body weight, % body fat and energy intake, where after they were randomly allocated to an experimental group|t|t|t|t
33937700|NCT04264182|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective. Randomized control trial.||||
34016346|NCT01593241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016347|NCT05520320|||COHORT||RETROSPECTIVE|||||||
34016348|NCT03359577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016349|NCT04149795|||CASE_ONLY||CROSS_SECTIONAL|||||||
34016350|NCT05676086|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34016351|NCT00222989|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34016352|NCT04137666|||COHORT||PROSPECTIVE|||||||
34016353|NCT03008486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33713991|NCT02986399|||COHORT||RETROSPECTIVE|||||||
33713992|NCT04661540|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33713993|NCT03859349|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Trial participants will remain blinded to their randomized treatment. Additionally, the biostatistician performing the analysis will be blinded as to which intervention arm participants were allocated to, as the group allocations will be coded as Group A and Group B. Provided this is an endoscopic trial, endoscopist blinding will not be feasible. Nonetheless, all patients deemed surgical candidates after EBUS will have their pathology compared to EBUS staging in order to ensure appropriate diagnosis. Pathologists performing such pathology report will be blinded to which intervention arm participants are allocated to.|All participants who provide consent for participation and who fulfil eligibility criteria will be randomized with a unique randomization sequence derived from the random permuted block design (with blocks of varying sizes) in a 1:1 ratio. Participants will randomized to either Systematic Sampling (Control) or Targeted Sampling (Experimental).|t|f|f|f
33713994|NCT05544357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33713995|NCT03806998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be no masking of the treatment arm for researchers|Participants will be randomly assgned to receive the ketoacid supplement or placebo|t|f|f|f
33713996|NCT02365792|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33713997|NCT00756860|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33713998|NCT06381050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33713999|NCT03758352|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient enrolment will be done by the on-call doctor and intervention will be performed by unblinded research personnel who won't be involved in sample collection or data analysis.|Patients will be allocated to an intervention group (rIC) and compared to a retrospective control group. Data assessment will be blinded to the assessor.|f|f|t|t
33714000|NCT02113592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33714001|NCT02049281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714002|NCT01127074|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714003|NCT03998033|NA|SEQUENTIAL||TREATMENT||NONE||||||
33714004|NCT01092104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714005|NCT01506206|||COHORT||CROSS_SECTIONAL|||||||
33714006|NCT03507894|||OTHER||PROSPECTIVE|||||||
33714007|NCT05138497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For the assignment to the groups, a random sampling will be carried out from the Epidat program. This classification will be hidden, therefore, those responsible for admitting patients to the intervention phase will not know which group each has been assigned to. Said assignment will be previously carried out by a researcher who will not intervene in the subsequent phases of evaluation, data recording intervention and database development. The assignment will be communicated by sealed and totally opaque envelopes. The analysis of the results will be carried out by a researcher outside the group assignment and the intervention.||f|t|t|t
33714008|NCT03920033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714009|NCT02708121|RANDOMIZED|PARALLEL||OTHER||SINGLE|Staff recruiting participants and doing outcomes assessment will remain blinded to treatment assignment||f|f|f|t
33714010|NCT00295841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937701|NCT06336876|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33937702|NCT06125626|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33937703|NCT03479203|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937704|NCT02912832|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33937705|NCT00333736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937706|NCT02543801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937707|NCT04045873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937708|NCT01699451|||OTHER||PROSPECTIVE|||||||
33937709|NCT00440232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937710|NCT01156012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33793965|NCT01199705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793966|NCT00158028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098702|NCT00991003|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33793967|NCT01356758|||CASE_CONTROL||PROSPECTIVE|||||||
33793968|NCT05813899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33793969|NCT00475319|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33793970|NCT00920725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793971|NCT01556971|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33793972|NCT02399358|||COHORT||PROSPECTIVE|||||||
34098703|NCT00620802|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098704|NCT02096497|||COHORT||RETROSPECTIVE|||||||
34098705|NCT01502072|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098706|NCT00602641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793973|NCT02905812|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34098707|NCT03442465|||COHORT||PROSPECTIVE|||||||
34098708|NCT04296682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098709|NCT03407911|||OTHER||OTHER|||||||
34098710|NCT04955093|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Feasibility study to test out methodology prior to any future large scale trial.~It involves a detailed follow up of a clinical sample of people with highfunctioning autism, using repeated measures in a randomized control experimental design. Intervention participants will be given a biofeedback device and training immediately, whilst the control group will wait 6 weeks and then receive the intervention. This will help to increase participation and maximize the detailed data collection that is required"||||
34098711|NCT00347087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098712|NCT06114550|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33793974|NCT02980718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793975|NCT04661150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793976|NCT06181318|||COHORT||PROSPECTIVE|||||||
34098713|NCT06232031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33793977|NCT06226636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793978|NCT03127995|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33793979|NCT01812733|||COHORT||PROSPECTIVE|||||||
33793980|NCT06054867|NA|SINGLE_GROUP||OTHER||NONE||||||
33793981|NCT00864786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33793982|NCT00419094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33793983|NCT03280836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants are randomized to the intervention or control arm.|f|t|f|t
33793984|NCT00367991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793985|NCT06185114|||COHORT||PROSPECTIVE|||||||
34098714|NCT02993432|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34098715|NCT05916287|NA|SINGLE_GROUP||OTHER||NONE||||||
34098716|NCT05198362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33793986|NCT05196438|||CASE_ONLY||CROSS_SECTIONAL|||||||
33793987|NCT05826457|||CASE_CONTROL||PROSPECTIVE|||||||
33793988|NCT01326715|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33793989|NCT05310136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33793990|NCT03407807|||COHORT||PROSPECTIVE|||||||
33793991|NCT04242264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33793992|NCT03512756|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33937711|NCT04540614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937712|NCT00550615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937713|NCT01744340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937714|NCT02442765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Sequential parallel comparison design|t|t|t|t
34098717|NCT03439878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and the researchers performing biochemical analyses will be blinded to the intervention.|Randomized, blinded crossover design.|t|f|f|t
34098718|NCT05063383|||OTHER||CROSS_SECTIONAL|||||||
34098719|NCT05129202|||COHORT||RETROSPECTIVE|||||||
34098720|NCT01986322|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33937715|NCT03393091|||OTHER||PROSPECTIVE|||||||
33937716|NCT04012294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937717|NCT05757791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937718|NCT01730625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33937719|NCT04048876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937720|NCT00058448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937721|NCT00819052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937722|NCT05068726|||COHORT||PROSPECTIVE|||||||
33937723|NCT03271944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098721|NCT02320825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098722|NCT06217900|||CASE_CONTROL||PROSPECTIVE|||||||
34098723|NCT00052715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098724|NCT05040464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098725|NCT01004393|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33793993|NCT03192046|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, repeated measures, matched group study.||||
33793994|NCT02129582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793995|NCT06513455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33793996|NCT04353037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For PATCH 2: participant and care provider are blinded. For PATCH 3: Health care worker is blinded.|Treatment and prevention study|t|t|f|f
33793997|NCT02298751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33793998|NCT01145170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33793999|NCT01328418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937724|NCT02743546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937725|NCT05905042|||CASE_ONLY||PROSPECTIVE|||||||
33937726|NCT00869375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937727|NCT04820946|||CASE_ONLY||RETROSPECTIVE|||||||
33937728|NCT04779476|||COHORT||PROSPECTIVE|||||||
34098726|NCT04682964|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Children aged 3 to 14 years with clinically diagnosed acute tonsillitis will receive bacteriophage therapy using a liquid pyobacteriophage complex (liquid pyobacteriophage complex - PCL).||||
34098727|NCT06323720|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34098728|NCT06453876|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1 randomized allocation||||
34098729|NCT01031654|||COHORT||CROSS_SECTIONAL|||||||
34098730|NCT05487495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098731|NCT03464448|||COHORT||PROSPECTIVE|||||||
33794000|NCT03318406|||COHORT||OTHER|||||||
34098732|NCT04032327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937729|NCT02425995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937730|NCT02070081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937731|NCT05278884|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||For each hospital, the intervention will be to pair a 2-day technical resuscitation skills training adapted from the ACLS/AHA and a 3-day VAST course for a multidisciplinary team of 20 participants (i.e., nurses, doctors, non-physician anesthesia providers). Participants' resuscitation skills will be tested at 4 time points: immediately before the ACLS course, immediately after the ACLS course, immediately after the VAST Course, and at 4 months post training.||||
34098733|NCT04256031|||CASE_CONTROL||PROSPECTIVE|||||||
33937732|NCT01310985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937733|NCT03192228|||COHORT||PROSPECTIVE|||||||
34098734|NCT04313439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098735|NCT00804557|||CASE_CROSSOVER||PROSPECTIVE|||||||
34098736|NCT04197505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098737|NCT04495478|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34098738|NCT04416685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Anatomical classification was established based on the relationship between portal confluence (PC) and tumor location . Those tumors located superior to the PC were classified as Level I, whereas tumors on the confluence inferiorly located to PC were classified as Level II and Level III.||||
34098739|NCT01829607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098740|NCT03305211|NA|SINGLE_GROUP||OTHER||NONE||patients requiring renal biopsy for medical reasons||||
34098741|NCT02473263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098742|NCT00512044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098743|NCT05892874|||COHORT||PROSPECTIVE|||||||
34098744|NCT04356001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098745|NCT05071833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33794001|NCT02707224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794002|NCT05486260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33937734|NCT03527290|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants are blinded to the nature of the other intervention so as not to contaminate the intervention. The clinical research staff taking the measurements is also blinded to the respective intervention the participant has been randomized to.||t|t|f|t
33937735|NCT00847691|||CASE_ONLY|||||||||
33937736|NCT01320527|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33937737|NCT00694434|||COHORT||RETROSPECTIVE|||||||
33937738|NCT03315676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937739|NCT02340936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937740|NCT05031494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937741|NCT05260450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937742|NCT01594749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937743|NCT01951976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33937744|NCT05696002|||COHORT||OTHER|||||||
33937745|NCT03583502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937746|NCT04101162|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937747|NCT01424267|||COHORT||PROSPECTIVE|||||||
33937748|NCT05466240|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"Eligible subjects will be randomized to receive either AT-752 or matching placebo orally 3 times a day (TID) for 5 days in Cohort 1 of the study.~Subsequent cohorts will receive AT-752/placebo either twice a day (BID) or TID"||t|t|t|f
33937749|NCT02492724|||CASE_ONLY||PROSPECTIVE|||||||
33937750|NCT01143844|||CASE_CONTROL||PROSPECTIVE|||||||
33937751|NCT04335357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind placebo controlled|Double blind placebo controlled|t|f|t|t
33937752|NCT04873895|NA|SINGLE_GROUP||TREATMENT||NONE||single-center open-label Phase 1B trial||||
33937753|NCT00335634|||CASE_ONLY||PROSPECTIVE|||||||
33937754|NCT03543449|||CASE_CONTROL||RETROSPECTIVE|||||||
33937755|NCT03732196|||COHORT||CROSS_SECTIONAL|||||||
34098746|NCT00224354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098747|NCT00398450||||TREATMENT||||||||
34098748|NCT03066557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098749|NCT05544955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33794003|NCT04493242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|Multi-center, double-blinded, placebo-controlled, randomized controlled trial.|t|t|t|f
33794004|NCT04942249|||COHORT||PROSPECTIVE|||||||
33794005|NCT01325558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937756|NCT01383551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33937757|NCT04828928|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937758|NCT01814891|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33937759|NCT06091202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33937760|NCT02678156|||COHORT||PROSPECTIVE|||||||
33937761|NCT03734133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937762|NCT03640104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937763|NCT02221570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33937764|NCT01265940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098750|NCT04605588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study medication will be tablets/capsules containing either active drug or placebo||t|t|t|t
34098751|NCT04807868|||OTHER||PROSPECTIVE|||||||
34098752|NCT01391871|||CASE_CONTROL||PROSPECTIVE|||||||
34098753|NCT02916771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098754|NCT05463666|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34098755|NCT01447030|||CASE_ONLY||RETROSPECTIVE|||||||
34098756|NCT00447369|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34098757|NCT05050838|||COHORT||PROSPECTIVE|||||||
33794006|NCT03131206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794007|NCT01544270|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33794008|NCT05968833|NA|SINGLE_GROUP||OTHER||NONE||Pre-post design||||
33794009|NCT06447987|NA|SEQUENTIAL||TREATMENT||NONE||||||
33794010|NCT04116515|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants will be informed of their group at the conclusion of the study.||t|f|f|f
33794011|NCT03444701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase 1 study of E7130 in participants with advanced solid tumors. This study will be conducted in 2 parts (Part 1 and Part 2). Part 1 will be the dose escalation portion of this study, conducted to assess dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) in participants with solid tumors. The dosage and the duration of the treatment cycle in Part 2 will be determined based on the data from Part 1. Part 2 will be comprised of cohort expansions to further characterize the safety and tolerability of E7130.||||
33794012|NCT03653013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016354|NCT04247152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016355|NCT03676517|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled patient receive 1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME). Short-term outcomes including complications, TME completeness, and tumor response will be investigated. EORTC-QLQ-C30 questionnaire scoring will be used to evaluate QoL during the treatment period and after surgery. Cost effectiveness will be assessed using cost-utility analysis.||||
34016356|NCT04898491|||COHORT||PROSPECTIVE|||||||
34016357|NCT05816369|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016358|NCT03161548|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, non-comparative phase II clinical trial to assess efficacy and safety of tongue conservation treatment with sequential doxcetaxel, cisplatin and tegafur/uracil plus leucovorin (DCU) induction chemotherapy, tongue conservation surgery and postoperative CCRT in patients with advanced oral tongue cancer.||||
34098758|NCT05180773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Once consent is obtained the screening sheet will be submitted to the data coordinating center. This will be reviewed to ensure the subject meets criteria for randomization. Subjects will be randomized by the Data Coordinating Center (DCC).|200 women meeting all inclusion and exclusion criterial will be randomized in a placebo controlled double blind investigation evaluating the impact of bromocriptine on outcomes for women newly diagnosed with peripartum cardiomyopathy. An additional 50 women in excluded from the trial due to an intent to continue breastfeeding but meeting all other criteria will be enrolled in an observational cohort. All women with receive standard medical care for peripartum cardiomyopathy and will be followed for up to three years.|t|t|t|t
34098759|NCT03598764|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098760|NCT04202588|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34098761|NCT06090721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098762|NCT04924452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomisation will be independent and the patients and parents/guardians will remain blinded to group status.|randomized parallel-group controlled clinical study|t|f|f|f
34098763|NCT04460794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34098764|NCT05610839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098765|NCT02883933|||CASE_ONLY||PROSPECTIVE|||||||
34098766|NCT06238700|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34098767|NCT03896932|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34098768|NCT00825175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098769|NCT01817452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098770|NCT04886037|||CASE_CONTROL||PROSPECTIVE|||||||
34098771|NCT02929121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098772|NCT00370136|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34098773|NCT02381574|||||PROSPECTIVE|||||||
34098774|NCT00781664|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34098775|NCT01319461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33794013|NCT06301841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794014|NCT04867291|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098776|NCT00361244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098777|NCT03845868|||COHORT||PROSPECTIVE|||||||
34098778|NCT05459610|||OTHER||RETROSPECTIVE|||||||
34098779|NCT00482469|||COHORT||PROSPECTIVE|||||||
34098780|NCT02676622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098781|NCT05595395|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, explorative, multicenter, randomized, parallel group, open-label study||||
34098782|NCT04492293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098783|NCT02408770|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098784|NCT00000538||||TREATMENT||||||||
34098785|NCT02583477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103383|NCT03803943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors and coders will be naive to experimental condition|Children will enroll in the study around 12 months of age and will be randomly assigned to either a parent-implemented communication intervention (PICT) or a control group.|f|f|f|t
34103384|NCT01140932|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794015|NCT00033163|RANDOMIZED|PARALLEL||TREATMENT||||||||
33794016|NCT00532220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794017|NCT04431388|||COHORT||PROSPECTIVE|||||||
33794018|NCT04396730|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double (Participant, Investigator)||t|f|t|f
33794019|NCT03883009|||OTHER||OTHER|||||||
33794020|NCT06392633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794021|NCT02314117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794022|NCT02507752|||COHORT||PROSPECTIVE|||||||
33794023|NCT00401323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794024|NCT04021615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Fifty general surgery patients who are difficult and prolonged weaning patients from both sexes (men \& women) with age ranged from 40 to 50 years old in surgical intensive care unit, Kasr Al Ainy Teaching Hospital, Cairo University and Beni- Suef Teaching Hospital , Beni -Suef University.|f|f|f|t
34016359|NCT01850095|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34016360|NCT00681707|||COHORT||RETROSPECTIVE|||||||
33794025|NCT01834248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794026|NCT03122574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794027|NCT04378361|||COHORT||PROSPECTIVE|||||||
33794028|NCT00509535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34103385|NCT01105832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794029|NCT05766189|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Difference-in-differences||||
33794030|NCT01140113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794031|NCT00597038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103386|NCT00655356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103387|NCT06151665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|an external pediatric Dentist will assess the radiographic and clinical follow-up of the enrolled patients|Primary molars with irreversible pulpitis|f|f|f|t
33794032|NCT05758727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33794033|NCT06676514|||COHORT||RETROSPECTIVE|||||||
33794034|NCT03196167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.|Patients will be enrolled using 1:1 randomization between active ingredient (intervention) and control arms, to be assigned randomly using a computer generated algorithm.|t|t|t|t
33794035|NCT01839578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794036|NCT01842763|||OTHER||CROSS_SECTIONAL|||||||
33794037|NCT03614546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794038|NCT04567888|RANDOMIZED|PARALLEL||OTHER||NONE||Users are randomly assigned between arms after completing baseline assessment and stay in that arm for the duration of the study.||||
33794039|NCT05992311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study group assignment will be determined by the research pharmacist using a random number generator within blocks of four participants. Participant group assignment will be disclosed only at time of data analysis or in case of emergency.|Double blind, placebo-controlled, randomized clinical trial|t|t|t|t
33794040|NCT01039142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794041|NCT00046995|RANDOMIZED|||TREATMENT||||||||
33794042|NCT02675309|NA|SINGLE_GROUP||||NONE||||||
33794043|NCT03498651|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participants will be aware whether they are completing the intervention by phone or computer, and will know if they are receiving coaching or not.||f|f|t|f
33794044|NCT03689699|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will include a total of approximately 30 patients per arm to achieve at least 23 evaluable patients per arm.||||
33794045|NCT02918032|||COHORT||OTHER|||||||
33794046|NCT00971906|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33794047|NCT04881318|RANDOMIZED|CROSSOVER||TREATMENT||NONE|It is not possible to mask participants to the compression garment intervention.|This study will investigate the effects waist high compression garments and medications compared to waist-high compression garments and medications held. Participants will cross-over and complete both arms. If participants participate in the abdominal compression sub-study, the order of waist-high compression - abdominal compression will also be randomized.||||
33794048|NCT03371966|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33794049|NCT05475106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794050|NCT01209546|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33794051|NCT06068699|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||"This was a stepped-wedge randomized controlled trial with two waves. In wave 1, Veterans who had sent at least 1 transmission within the past 2 years but had become non-adherent were randomly assigned to receive a postcard or no postcard. Those receiving postcards were randomized to 1 of 2 messages: 1) a warning postcard describing risks of non-adherence or 2) an encouraging postcard describing benefits of adherence. In wave 2, Veterans who had either not received a postcard in wave 1 or had since become non-adherent were mailed a postcard (again, randomized to 1 of 2 messages). Patients who did not send a RM transmission within 1 month were mailed a second, identical postcard."|f|f|t|f
33794052|NCT04918849|||COHORT||CROSS_SECTIONAL|||||||
33794053|NCT03312309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794054|NCT01808495|||||PROSPECTIVE|||||||
33794055|NCT02230358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794056|NCT01740063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794057|NCT05228691|||OTHER||CROSS_SECTIONAL|||||||
33794058|NCT03221569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Aside from primary investigator (B.Sin) and pharmacist procuring the study interventions, blinding will be applied to patient, physicians, nurses, research associates responsible for collect data and also the independent biostatistician responsible for evaluating the data. Patients will be randomized to receive study numbers that corresponds to treatment arms.|Arm A would include 0.3mg/kg intravenous piggyback ketamine and 1cc normal saline as placebo via intravenous push while Arm B would receive 50ml normal saline and ketorolac 30mg.|t|t|f|t
33794059|NCT00953836|||||PROSPECTIVE|||||||
33794060|NCT02801071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794061|NCT05601466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794062|NCT00281424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794063|NCT03823911|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794064|NCT06676579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794065|NCT03762213|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators propose a parallel-group pilot randomized controlled trial with a stratified block randomization and an equal allocation ratio of 1:1. The participants will be randomly allocated to Group A (VR/intervention group) or Group B (iPad/control group). The relaxation session will last for 10 minutes in each group using the same application Happy Place (© Mimerse) played on VR headsets (Oculus GO) versus iPad (Apple Inc. Cupertino CA). The randomization will be stratified on the basis of pain score on the day of intervention.||||
33794066|NCT02910635|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34016361|NCT05236920|RANDOMIZED|PARALLEL||TREATMENT||NONE|None. Masking is not possible.|A total of 40 subjects will be randomized to standard care, or standard care plus administration of the device.||||
34016362|NCT04684303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective observational clinical trial||||
34016363|NCT05847439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016364|NCT01963130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016365|NCT00797329|||||RETROSPECTIVE|||||||
34016366|NCT05757323|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34016367|NCT05777161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors were blind to condition. The integrity of the blind was evaluated||f|f|f|t
34016368|NCT00362921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016369|NCT03072199|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1/2 unblinded interventional dose escalation study||||
34016370|NCT05434377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34016371|NCT03179163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Investigator and Outcomes Assessor are masked according to treatment.|Subjects are grouped as normal (\<120/80 mmHg) and hypertensive (≥140/90 mmHg and \<160/110 mmHg). All subjects undergo one round of experiments. Hypertensive subjects received randomly-assigned antihypertension medication angiotensin converting enzyme inhibitor with a sulfahydrl donor (ACEi+SH), angiotensin converting enzyme inhibitor (ACEi), or diuretic for 16 weeks and then repeat experiments. Normotensive subjects receive no intervention and repeat experiments16 weeks after initial experiments as a time control.|f|f|t|t
34016372|NCT00000396|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34103388|NCT04343768|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the three arms of the study.~Patients will be allocated to three therapeutic arms (Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a group and Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b group and the Base Therapeutic Regiment Group, i.e., Hydropinchloroquine + / Ritonavir. For this purpose, we will use the method of Balance Block Randomization for three groups."||||
33794067|NCT06677099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794068|NCT00889694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794069|NCT06677216|||COHORT||PROSPECTIVE|||||||
33794070|NCT03300037|||COHORT||PROSPECTIVE|||||||
33794071|NCT01126112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794072|NCT04530513|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation Study||||
33794073|NCT06375291|||COHORT||RETROSPECTIVE|||||||
33794074|NCT00011726|||NATURAL_HISTORY||PROSPECTIVE|||||||
33794075|NCT00003880|RANDOMIZED|||TREATMENT||||||||
33794076|NCT01181180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714011|NCT02448420|RANDOMIZED|PARALLEL||TREATMENT||NONE||When the recruitment cohorts C begins, the recruitment in cohorts A and B will be closed.||||
33714012|NCT05577390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded study. Subjects will be randomly assigned to one of two treatment groups. Treating therapists will be informed of the study arm assignment. The physical therapist performing the pre and post evaluation measurements will be different than the treating therapists and blinded to the study arm assignment.|Two arms: One INF® Therapy Treatment group and One standard physical therapy treatment group|f|f|t|f
33714013|NCT00642876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794077|NCT06677489|||COHORT||RETROSPECTIVE|||||||
33794078|NCT00244855|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794079|NCT06676306|||CASE_ONLY||PROSPECTIVE|||||||
33794080|NCT04744402|NA|SINGLE_GROUP||TREATMENT||NONE||Investigational group: CartiLife® Extracellular matrix-associated autologous chondrocytes comprise CartiLife®, composed as pellets (1.1 to 1.8 mm in diameter) in suspension. One pre-filled syringe is implanted per 1 cm3 of defect volume, and fibrin adhesive is applied to fix pellets in place through minimal arthrotomy.||||
33794081|NCT00470938|RANDOMIZED|PARALLEL||||NONE||||||
33794082|NCT01336036|||COHORT||PROSPECTIVE|||||||
33794083|NCT05315180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794084|NCT01117584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794085|NCT03968666|||OTHER||RETROSPECTIVE|||||||
33794086|NCT01815450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33714014|NCT00809276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794087|NCT05239299|||OTHER||CROSS_SECTIONAL|||||||
33794088|NCT00006224||||TREATMENT||||||||
33794089|NCT01656096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794090|NCT01112644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794091|NCT00861549|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33794092|NCT03506373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794093|NCT00316836|||CASE_ONLY||PROSPECTIVE|||||||
33794094|NCT06249295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies ,and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth), while the control group received general routine care.||||
33794095|NCT00092937||||TREATMENT||||||||
33794096|NCT05609032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intervention assignment will be masked to participants only||t|f|f|f
33794097|NCT03251898|||COHORT||PROSPECTIVE|||||||
33794098|NCT04191434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind and double-dummy||t|f|t|f
33794099|NCT02891278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794100|NCT04689568|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a single-center, non-randomized, preferred assignment study.||||
33794101|NCT01029093|||||PROSPECTIVE|||||||
33794102|NCT02643940|||COHORT||PROSPECTIVE|||||||
33794103|NCT02620410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794104|NCT05097924|||OTHER||PROSPECTIVE|||||||
33794105|NCT03258619|||CASE_ONLY||PROSPECTIVE|||||||
33794106|NCT03150238|||COHORT||CROSS_SECTIONAL|||||||
33794107|NCT06676631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794108|NCT02660645|||CASE_ONLY||PROSPECTIVE|||||||
34016373|NCT00221611|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016374|NCT03906162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Primary investigator will be blinded for allocation before making the final analyses. No outcome assessments will be made by an assessor. Only objectively measured steps per day and participant reported outcome measures will be used for this study.|12 week intervention with two groups in a parallel design|f|f|t|t
34016375|NCT04560348|NA|SINGLE_GROUP||PREVENTION||NONE||Single group pre-posttest design||||
34016376|NCT03437915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016377|NCT04905849|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34016378|NCT04708639|||COHORT||PROSPECTIVE|||||||
33937765|NCT06464887|||CASE_CONTROL||RETROSPECTIVE|||||||
33937766|NCT00269685|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937767|NCT05390034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized to one of the two arms (i.e., ART program or active control group). Outcomes assessments will be performed with online questionnaires.|Treatment compared to an active control group (i.e., a relaxation program group)|t|f|f|f
33937768|NCT04084873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33937769|NCT03043300|||OTHER||PROSPECTIVE|||||||
33937770|NCT06030154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937771|NCT06187051|||COHORT||RETROSPECTIVE|||||||
33937772|NCT00006185||||DIAGNOSTIC||NONE||||||
33937773|NCT02608892|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33937774|NCT03871764|||CASE_ONLY||CROSS_SECTIONAL|||||||
33937775|NCT01833793|||COHORT||PROSPECTIVE|||||||
34016379|NCT05589519|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
34016380|NCT00692718|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016381|NCT03118388|RANDOMIZED|PARALLEL||TREATMENT||NONE||The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months). The eight IPS principles were implemented over 20 months by an employment specialist, clinician, and case manager.||||
34016382|NCT03063762|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016383|NCT03858166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016384|NCT00776165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016385|NCT05892146|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016386|NCT01775436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessor did not know which study arm the participant was randomized to.||f|f|f|t
34016387|NCT00168311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016388|NCT06150456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016389|NCT01736436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016390|NCT04434664|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|For blinding, tablets are placed into oral gelatin capsules with an inert filler (lactose monohydrate). Blinding is performed and maintained by the University of Pennsylvania Investigational Drug Service.||t|t|t|t
34016391|NCT02664363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016392|NCT04757701|||COHORT||CROSS_SECTIONAL|||||||
34016393|NCT03861793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016394|NCT00359242|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33714015|NCT01678677|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33714016|NCT03268720|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Participants consume a two week lasting low FODMAP diet, followed by 5 days washout, and subsequent two week gluten-free diet.||||
33714017|NCT05171595|||COHORT||PROSPECTIVE|||||||
33714018|NCT00230997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714019|NCT02407704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714020|NCT00945048|||COHORT||PROSPECTIVE|||||||
33714021|NCT05660551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33714022|NCT02240251|||CASE_ONLY||PROSPECTIVE|||||||
33714023|NCT01267734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714024|NCT04868890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714025|NCT01401283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714026|NCT03423095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714027|NCT04500002|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized parallel assign controlled trial|double blind randomized parallel assign controlled trial|t|t|t|t
33714028|NCT03234764|||COHORT||PROSPECTIVE|||||||
33714029|NCT04740502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714030|NCT05020717|||OTHER||RETROSPECTIVE|||||||
33714031|NCT05662228|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will use covariate-adaptive randomization to assign participants to one of three treatment arms while accounting for sex, age, and other medical history.||||
33714032|NCT04432857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714033|NCT04766801|||COHORT||RETROSPECTIVE|||||||
33714034|NCT05759676|||COHORT||PROSPECTIVE|||||||
33714035|NCT01514929|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33714036|NCT02338414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714037|NCT05179473|||COHORT||PROSPECTIVE|||||||
33714038|NCT05531084|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the same treatment modality (surgeon-modified fenestrated stent grafts).||||
33714039|NCT05130177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714040|NCT04616378|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33714041|NCT03369392|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33714042|NCT04068090|||CASE_CONTROL||PROSPECTIVE|||||||
33714043|NCT04069494|||CASE_ONLY||PROSPECTIVE|||||||
33714044|NCT02302001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714045|NCT03029065|||COHORT||PROSPECTIVE|||||||
33714046|NCT00214175|||CASE_CONTROL||PROSPECTIVE|||||||
33714047|NCT01185132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714048|NCT02317185|||COHORT||PROSPECTIVE|||||||
33714049|NCT02915276|NON_RANDOMIZED|PARALLEL||||NONE||||||
33714050|NCT01599234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714051|NCT04614831|||COHORT||CROSS_SECTIONAL|||||||
33714052|NCT00025766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016395|NCT03580122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016396|NCT04613674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016397|NCT02312063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016398|NCT01302522|RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
34016399|NCT04838236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098786|NCT04264195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Masking of Patients: patients are unaware if they are participating in a control or experimental group; groups didn't have contact Masking of investigator: Allocation of patients to treatment group and control group by using sealed envelopes.~Masking of Assessors: Four assessors (qualified occupational therapists) from both clinical and academic side of CRP were recruited for outcome measurement. Each group had an individual assessor and the same assessor was assigned in pretest, posttest and follow-up assessments. Assessors were not allowed to ask patients for details of the treatment.~Masking of Therapist: Therapists were randomly allocated into groups before they get (separated) group-specific training in application of the protocol and treatment modality. Therapists have no idea about which is the control group treatment and which is the experimental group treatment. Both groups have got a new, specific way of exercising by a peer regulated group treatment program."|The main element of this model is randomization where participants were randomly assigned into a control group and an experimental group. Both groups got their treatment at the same time for 2 hours for 4 days in a week. The experimental group practiced the tasks with the paretic hand only - the non-paretic hand being constrained by the use of a mitten - where the control group practiced the tasks bimanually.|t|t|t|t
34098787|NCT00398242|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34103389|NCT06680232|NA|SEQUENTIAL||TREATMENT||NONE||Part 1 is to identify a safe and well tolerated dose regimen of PBGENE-HBV Part 2 is an expansion cohort to aid in selecting a dosing regimen.||||
33794109|NCT04548830|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single center investigator initiated study for patients who display indeterminant pulmonary nodules and diffuse parenchymal lung disease on CT chest imaging who have been referred to the Pulmonary service.||||
33794110|NCT04531137|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study consists of intervention and control groups. The intervention group will receive CLA-fortified milk powder containing 3.4 gram CLA for one a day. The control group will receive milk powder for one a day. In each group, the intervention phase will be conducted in 12 weeks. Each group will also receive nutritional counseling and nutrition module|t|t|t|t
33794111|NCT05238194|||OTHER||PROSPECTIVE|||||||
33794112|NCT06488625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794113|NCT04613024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794114|NCT06153641|||COHORT||CROSS_SECTIONAL|||||||
33794115|NCT05150054|||COHORT||PROSPECTIVE|||||||
33794116|NCT01518829|||CASE_CONTROL||PROSPECTIVE|||||||
33794117|NCT05144412|||COHORT||RETROSPECTIVE|||||||
33794118|NCT01970748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794119|NCT01645098|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794120|NCT00078572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937776|NCT01027065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937777|NCT00731666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937778|NCT04589117|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33937779|NCT02938611|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33937780|NCT01979328|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33937781|NCT01323933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937782|NCT01425528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937783|NCT00542425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937784|NCT03840681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each patient will be given a code by the researcher ( T.A ) and the observer will be blind to which group this case belongs Patients,evaluators and statistican will be blinded||t|f|f|t
33937785|NCT03855618|||CASE_ONLY||PROSPECTIVE|||||||
34016400|NCT03827616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016401|NCT01362127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016402|NCT01601366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016403|NCT04739696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34016404|NCT06352229|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Evaluation is based on a parallel group study, with half of the participants receiving care as usual and half of the participants receiving care as usual along with the Playful Learning in Infancy Program.||||
34016405|NCT02993692|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34016406|NCT01764282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016407|NCT05253365|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016408|NCT05167604|||COHORT||PROSPECTIVE|||||||
34016409|NCT00367003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016410|NCT01207505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016411|NCT01553279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016412|NCT06456619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Observational clinical trial|t|f|f|f
34016413|NCT02355171|||COHORT||OTHER|||||||
34016414|NCT04205396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016415|NCT01787539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794121|NCT03484611|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937786|NCT04509635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937787|NCT02924766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937788|NCT05022693|NA|SINGLE_GROUP||OTHER||NONE||Open label, single dose, PK study||||
33937789|NCT03833336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937790|NCT01731197|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33937791|NCT04890730|||COHORT||PROSPECTIVE|||||||
33937792|NCT00155324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937793|NCT00685828|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937794|NCT01636739|||COHORT||PROSPECTIVE|||||||
33937795|NCT01719809|||OTHER||PROSPECTIVE|||||||
33937796|NCT01052675|||OTHER||PROSPECTIVE|||||||
33937797|NCT00421616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33937798|NCT04723303|NA|SEQUENTIAL||TREATMENT||NONE||"Study Participants will be assigned to one of 3 doses of stem cells depending on when the subject is enrolled. The first three patients will be assigned to the low dose group, the next three patients will be assigned the intermediate dose group and last three patients will receive the high dose of ULSC's. An independent review group will evaluate the response to therapy to each dose group before moving to the next dose. The groups and doses are described below:~A low dose group receives an IV infusion of 50 million stem cells.~An intermediate dose group receives an IV infusion of 100 million stem cells.~A high dose group receives an IV infusion of 200 million stem cells."||||
33937799|NCT03267576|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34016416|NCT05380076|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Interventions are standardized video tape. Information collected through standardized informatic questionnaires for blinded investigators.|4 parallel groups|f|f|t|t
34016417|NCT01376193|||||PROSPECTIVE|||||||
34016418|NCT01718470|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34016419|NCT02192749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016420|NCT03436914|NA|SINGLE_GROUP||TREATMENT||NONE||There is only one arm in this study. Patients diagnosed as NERD will take PPI (Esomezol) for 8 weeks.||||
34016421|NCT05970445|||COHORT||RETROSPECTIVE|||||||
33937800|NCT00040066||PARALLEL||TREATMENT||DOUBLE||||||
34016422|NCT04216758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016423|NCT03651466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016424|NCT02169349|||CASE_ONLY||PROSPECTIVE|||||||
34016425|NCT04009538|NA|SINGLE_GROUP||TREATMENT||NONE||COPD patient participated first and second rehabilitation program||||
33794122|NCT01547936|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794123|NCT00761436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098788|NCT03357445|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The two subgroups will have the medical device with the following objectives:~Subgroup 1 Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD.~Subgroup 2 Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner."||t|f|f|f
34016426|NCT02126774|||COHORT||PROSPECTIVE|||||||
34016427|NCT04805918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes Assessor: The individual who evaluates the video-based outcome(s) of interest|The study population will be randomly allocated in the ratio 1:1 to either VIPP-SD or CAU. The randomization is stratified by municipality. A computer-generated list of random numbers is used for the allocation of participants. The allocation list is created using block randomization with block sizes of 10. The allocation sequence is generated by an investigator with no clinical involvement in the project.|f|f|f|t
34098789|NCT03387774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794124|NCT05790408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937801|NCT05408403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The anesthesia doctor who will perform the interfascial plane block (TFPB, anterior QLB) will be informed with a sealed envelope by an independent assistant outside the study, and the patient will not know which block is performed.|Randomization of the study will be done by a doctor who will not participate in patient follow-up with closed envelopes using computer-generated randomization codes.|t|t|t|t
33937802|NCT04971759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937803|NCT04802928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937804|NCT03486951|||COHORT||PROSPECTIVE|||||||
33937805|NCT03140267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937806|NCT05230069|||CASE_ONLY||RETROSPECTIVE|||||||
33937807|NCT00122824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937808|NCT06231251|RANDOMIZED|PARALLEL||TREATMENT||NONE||"endoscopic reduction of ghrelin rich gastric mucosa either with~1. band ligation (group 1; n=16) and diet control~2. argon plasma mediated reduction and diet control (group 2; n=16)~3. control group exposed to low caloric diet and exercise (group 3; n=16)."||||
33937809|NCT05977569|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016428|NCT06248658|||COHORT||OTHER|||||||
34016429|NCT05611450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34016430|NCT02299817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937810|NCT06135506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34016431|NCT04231942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded outcome assessor has np information on the patients belonging to the Study Group|A multicenter, open, superiority randomized clinical trial with blinded outcome assessor.|f|f|f|t
34016432|NCT05430126|||CASE_ONLY||CROSS_SECTIONAL|||||||
34016433|NCT05813288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016434|NCT00034983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016435|NCT02400671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016436|NCT01917448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016437|NCT02497313|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016438|NCT01765582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937811|NCT05433064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937812|NCT04050228|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial design is a Phase II study to demonstrate the use of quantitative ultrasound to guide adaptive chemotherapy for patients with breast cancer. The primary endpoint will be measurement of improved response rate locally. Patients were randomly allocated in 1:1 ratio to a standard arm or experimental arm stratified by hormonal receptor status||||
33937813|NCT02972294|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34016439|NCT03178526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016440|NCT01409057|||COHORT||PROSPECTIVE|||||||
34016441|NCT05480826|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||"2 groups of subjects are enrolled in the study:~* patients with a mental disorder~* relatives of patients included"|f|f|f|t
34016442|NCT00110006|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016443|NCT02047175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016444|NCT02831959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016445|NCT02006628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016446|NCT00069186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34016447|NCT04978116|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The care provider (clinician in charge) will be also be the outcome assessor and will know the allocation arm.||t|f|f|f
34016448|NCT01558297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016449|NCT02133586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34016450|NCT01722565|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016451|NCT03403166|||COHORT||PROSPECTIVE|||||||
34016452|NCT02244736|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016453|NCT00598624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794125|NCT04058990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"SV study: A prospective, multicenter, 2:1 randomized, controlled, single-blind, non-inferiority trial.150 subjects are expected to be enrolled to support a 2:1 randomization. (Investigational test device: Agent DCB, N=100 subjects or Control device: SeQuent Please DCB, N=50 subjects)~ISR substudy: A prospective, multicenter, single-arm, open-label trial. 30 subjects are expected to be enrolled."||t|f|f|f
33794126|NCT02835768|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|f|f|f|t
34098790|NCT05377671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||40 patients (20 patients with a cognitive deficit at least 2 SD below the norm and 20 patients without cognitive impairment) will be explored by multimodal ultra-high field (7T) MRI||||
33794127|NCT05434611|||CASE_CONTROL||RETROSPECTIVE|||||||
33794128|NCT00590369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794129|NCT04177316|||COHORT||RETROSPECTIVE|||||||
33794130|NCT06076876|||CASE_ONLY||RETROSPECTIVE|||||||
33794131|NCT05651399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098791|NCT05854264|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|specialized nutrition and microbiota analysis|specialized nutrition group|t|f|f|f
33794132|NCT00367354|||CASE_CONTROL||PROSPECTIVE|||||||
33794133|NCT00573339|||COHORT||PROSPECTIVE|||||||
33794134|NCT01131494|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33794135|NCT00326924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794136|NCT03546634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794137|NCT01033058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794138|NCT01442935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794139|NCT03978468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016454|NCT01922167|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34016455|NCT03040323|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients will not be informed of diagnostic arm.|Two interventional arms, selected by day of month; 1) biopsy with Lumason, 2) biopsy with placebos|t|f|f|f
34016456|NCT01077882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34098792|NCT00676754|||COHORT||PROSPECTIVE|||||||
34098793|NCT02298569|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794140|NCT05356572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794141|NCT02590042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794142|NCT04913779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This is an adaptive phase 2/3, randomized, blinded, placebo-controlled study. 200 total patients (ratio 1:1) will be included with intermediate evaluations when reaching the initial 20 patients (initial analysis of safety and pharmacokinetics), 100 (analysis of safety and efficacy) and 200 (final analysis).|t|t|t|t
33937814|NCT06012266|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Order of drug intake will be balanced and randomized, with 6 patients starting with Dapagliflozin (Visits 1-2) and subsequently switching to Empagliflozin (Visits 3-4), and 6 patients starting with Empagliflozin (Visits 1-2) and subsequently switching to Dapagliflozin (Visits 3-4).||||
33937815|NCT04771936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to the three groups|Patients with a diagnosis of OA hip who are awaiting a total hip replacement will be recruited in this study. Both male and female subjects age 40 years and over will be included in the study.|t|f|f|f
33937816|NCT03394196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016457|NCT05632341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34016458|NCT03642353|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34016459|NCT00370357|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34016460|NCT01360684|||COHORT||PROSPECTIVE|||||||
34016461|NCT03045159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|outcomes assessor blinded to study condition||f|f|f|t
34016462|NCT04180553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded|Randomized controlled trial - 20 patients per arm. A permuted block randomization plan will be used with block sizes of 2 and 4|f|f|f|t
34016463|NCT01063166|||COHORT||PROSPECTIVE|||||||
34016464|NCT03594695|||OTHER||PROSPECTIVE|||||||
34016465|NCT05389982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016466|NCT00336765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016467|NCT03340571|||COHORT||PROSPECTIVE|||||||
34016468|NCT00817076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016469|NCT05318209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016470|NCT03912441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016471|NCT02379286|||COHORT||PROSPECTIVE|||||||
34016472|NCT04683419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016473|NCT05304611|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|t|t|f
34016474|NCT00577902|||||PROSPECTIVE|||||||
34098794|NCT03435315|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34098795|NCT05874011|||CASE_CONTROL||OTHER|||||||
34098796|NCT00268398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016475|NCT01124357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098797|NCT03685825|||COHORT||PROSPECTIVE|||||||
34098798|NCT05153187|||COHORT||RETROSPECTIVE|||||||
34098799|NCT01300065|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34098800|NCT00562107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016476|NCT00342836||||TREATMENT||||||||
34098801|NCT01602666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098802|NCT01916811|||CASE_CONTROL||RETROSPECTIVE|||||||
34098803|NCT02455089|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098804|NCT00355550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098805|NCT03385486|NA|SEQUENTIAL||TREATMENT||NONE||"The study will consist of a Dose Escalation Phase and a Dose Expansion Phase. TBX-3400 will be administered on Day 1 of each treatment cycle and can be repeated.~In the Dose Escalation Phase, a 3+3 design will be employed. Each dose cohort will initially enroll 3 patients. Enrollment and treatment of the first 3 patients in the first cohort will be staggered to allow for evaluation of safety. After each cohort has been enrolled and all patients in the cohort have completed Cycle 1, a Data Safety Monitoring Committee will review cumulative safety data to determine whether to proceed with further dose escalation.~Each cohort may be expanded in groups of 3 patients to a maximum of 12 patients. Up to six TBX 3400 dose levels will be evaluated during the Dose Escalation Phase of the study."||||
34098806|NCT02605694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098807|NCT02176525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098808|NCT01064284|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098809|NCT02903381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098810|NCT06532422|||COHORT||PROSPECTIVE|||||||
34098811|NCT01579305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098812|NCT02314247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098813|NCT06126380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794143|NCT04439799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016477|NCT05884242|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34016478|NCT05991128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098814|NCT04403893|||COHORT||PROSPECTIVE|||||||
34098815|NCT06501261|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34098816|NCT03152890|NA|SINGLE_GROUP||TREATMENT||NONE||The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.||||
34098817|NCT02834442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34098818|NCT04461535|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34016479|NCT04310956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016480|NCT05792124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016481|NCT01320748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34016482|NCT04680234|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided into two groups (randomly assigned and comparably cross matched for age and sex) Cryotherapy group (No.= 50): Superficial cryotherapy using dimethyl ether and propane (DMEP) at -57C Microneedling group (No. = 50): Microneedling||||
34016483|NCT04076384|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34016484|NCT04797520|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34098819|NCT05688423|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit patients at bedside in the hospital setting at approximately six hospitals and randomly assign approximately 480 inpatients in 1:1 ratio to the SIRI Team vs. TAU. Randomization will be stratified by 1) hospital site, 2) primary drug (opioid versus non-opioid), and 3) admission to intensive care unit (ICU) as part of the index hospitalization (ICU versus non-ICU) as a proxy for severity of infection.||||
34098820|NCT04023474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098821|NCT05706675|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34098822|NCT00689052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098823|NCT01819480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098824|NCT03987607|||COHORT||PROSPECTIVE|||||||
34098825|NCT03302936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098826|NCT00972894|||||PROSPECTIVE|||||||
34098827|NCT03779854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098828|NCT04699162|||COHORT||RETROSPECTIVE|||||||
34098829|NCT03237312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098830|NCT05777278|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm||||
34098831|NCT03615898|||OTHER||RETROSPECTIVE|||||||
33794144|NCT00190216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33794145|NCT02808585|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33794146|NCT05247749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794147|NCT02886741|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794148|NCT05843136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|only the participant was blinded|The research is a randomized clinical trial, was submitted and approved by the Human Ethics Committee (CEP) with opinion 5,175,882, CAEE: 52035721.9.0000.0171. Participants were chosen at random, with single-blind masking, Random Allocation ® software was used to generate random numbers for the intervention and control groups, non-probalistic convenience sample. There were three groups: interventional, control 01 and control 02|t|f|f|f
33794149|NCT00000760||||TREATMENT||||||||
34098832|NCT01081938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098833|NCT00721890|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34098834|NCT01624207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098835|NCT02203760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098836|NCT06016790|||CASE_CONTROL||PROSPECTIVE|||||||
34098837|NCT06696027|||CASE_CONTROL||PROSPECTIVE|||||||
33937817|NCT05087563|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Prospective randomized double masked two arm|Prospective randomized double masked two arm|t|t|t|f
34016485|NCT03659461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34016486|NCT01440439|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016487|NCT02575274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016488|NCT01868711|RANDOMIZED|PARALLEL||TREATMENT||NONE||Depressed patients will be randomized between cognitive behavor therapy and supportive therapy.||||
34016489|NCT02063243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016490|NCT06428318|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34016491|NCT04704635|||COHORT||PROSPECTIVE|||||||
34016492|NCT01403974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016493|NCT05783648|||COHORT||RETROSPECTIVE|||||||
34016494|NCT05087862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective randomized comparison between two analgesic techniques|f|f|f|t
34016495|NCT01951885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098838|NCT00362609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098839|NCT04633876|RANDOMIZED|FACTORIAL||PREVENTION||NONE||RCT, lifestyle coaching in two arms: individualised coaching and group coaching. No coaching as a control group.||||
33937818|NCT00536458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937819|NCT05825365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937820|NCT05238844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937821|NCT05297552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937822|NCT05673785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937823|NCT05624892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||In the study, 60 individuals, including 1 experimental and 1 control group, were included in the study.|t|f|t|f
33937824|NCT06267040|||COHORT||PROSPECTIVE|||||||
33937825|NCT01171872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937826|NCT00710151|||COHORT||PROSPECTIVE|||||||
33937827|NCT01002040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937828|NCT00396344|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33937829|NCT02951585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937830|NCT02924987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937831|NCT00329199|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34098840|NCT01570582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098841|NCT01935154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098842|NCT02872142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098843|NCT02333968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34098844|NCT00677378|||CASE_CONTROL||PROSPECTIVE|||||||
34098845|NCT02384343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794150|NCT05469802|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33794151|NCT02261467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016496|NCT04783974|||CASE_CONTROL||RETROSPECTIVE|||||||
33794152|NCT06360016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Investigator, Outcomes Assessor)|pre and post-test with the control group|f|f|t|t
33794153|NCT03996083|RANDOMIZED|PARALLEL||OTHER||DOUBLE|participants were randomized (in a 1:1 ratio) through sealed opaque envelopes by coin-tossing sequence generation into either the multicomponent or the walking group.||t|f|t|f
33937832|NCT06482138|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937833|NCT01608139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937834|NCT03523403|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||All 60 participants will participate in the Chronic phase of the study, which will follow a randomized, controlled, parallel-arm design to investigate the effects of consuming 3 apples per day for 6 weeks. 30 of those 60 participants will also participate in the Acute phase of the study, which will follow a randomized, crossover design to investigate the effects of eating 3 apples in addition to a high-fat meal in one sitting.|f|f|f|t
34016497|NCT06110728|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with a diagnosis of diabetes and depression, anxiety, and/or substance use disorder will be randomized to one of two treatment groups: (1) Habit Change and (2) TAU.||||
33937835|NCT04430036|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder cancer prior to radical cystectomy. We will begin with an initial safety run-in to establish the safety of the combination prior to expansion to the full planned phase II. The overall phase II will be an open-label, single arm study in two stages to evaluate the efficacy of the combination in pathologic downstaging of MIBC.||||
33937836|NCT01809327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016498|NCT02068521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016499|NCT01089114|||||OTHER|||||||
34016500|NCT03561441|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|t|t|f
34016501|NCT01668693|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34016502|NCT02980874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34016503|NCT05985733|||OTHER||PROSPECTIVE|||||||
34016504|NCT00474851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016505|NCT02198326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34016506|NCT04749836|||COHORT||PROSPECTIVE|||||||
34016507|NCT02685202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016508|NCT06394674|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34016509|NCT01524965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016510|NCT00003638|RANDOMIZED|||TREATMENT||||||||
34016511|NCT00535587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016512|NCT02660528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016513|NCT03272841|||COHORT||PROSPECTIVE|||||||
34016514|NCT01923441|||COHORT||PROSPECTIVE|||||||
34098846|NCT00997191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794154|NCT05516004|NA|SINGLE_GROUP||TREATMENT||NONE||"Single arm, non blinded study to determine the effectiveness of the PXL Platinum 330 system and Peschke TE (topical 0.25% riboflavin solution) for cornea thinning conditions (which is the drug or solution under investigation in combination with the specific UV light delivery system)"||||
33794155|NCT01435395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098847|NCT02197104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794156|NCT05727397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794157|NCT02245334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794158|NCT02590952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794159|NCT05552508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794160|NCT05777317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neurological exam assessors are blinded to treatment assignment||f|f|f|t
33794161|NCT03505619|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The older adults will be included if they fulfil the following inclusion criteria a) ≥65 years or older and live at home, b) home care has been granted and the user is deemed not to need home rehabilitation performed by rehabilitation staff, c) two or more identified challenges in everyday activities that can benefit from everyday rehabilitation, d) are able to understand and express themselves in Swedish. One or more of the reasons will result in exclusion from the study: have cognitive limitations that make reablement unappropriate, in need of care in institutional dwelling or are terminally ill ,the older adults have had home help services more than three years.~When the older person in either the intervention or control group agrees to be involved in the study, they will be asked if they could consider involving a significant other.~The home care providers delivering ASSIST 1.0 or the ordinary home care will be included consisting of 8-10 staff from each group."|A feasibility study with a pre-post-test design.|t|t|f|f
33794162|NCT03573258|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|single-blinded|Randomized, single-blinded cross-over trial in 24 morbidly obese human subjects undergoing RYGB.|t|f|f|f
33794163|NCT00036933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794164|NCT03745001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|EHP-101 Liquid or matching placebo.|Single center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study|t|f|t|f
33794165|NCT00947869|||COHORT||PROSPECTIVE|||||||
33794166|NCT06555042|||CASE_ONLY||PROSPECTIVE|||||||
33794167|NCT02277288|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33794168|NCT00102063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794169|NCT05394779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, multicenter, pragmatic, randomized, double-arm, placebo-controlled, parallel, single-blind study.||||
33794170|NCT01063036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794171|NCT03618134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794172|NCT00687622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794173|NCT02350842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794174|NCT05056753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will spend approx 30 min/day for 5 days/week in HWBV testing for the 4-week treatment period at the treatment clinic. Eligible participants who consent to the study are screened and randomized to either the active or control group, using the vibration device with controller that has 2 unmarked presets as to which treatment protocol they represent (HWBV or monotonic vibration). Neither the study coordinator, technician, nor site investigator will know which setting is the active or control. The device technician (blinded to the treatment hypothesis) will help participants set up the device and provide assistance. To avoid unblinding, device technician will be segregated from all study personnel and data. He/she will also be instructed not to comment to the patients on any aspects of the device and defer study related questions to the study staff. A blinded coordinator / staff member will conduct study assessments at baseline, weeks 1, 2, 3, and 4, visits.|This is a 4-week, randomized, double-blind, controlled, parallel group study with 5 visits; at screening/baseline, and weeks 1-4 and daily visits to the treatment clinic, with blinded evaluation of efficacy and safety assessments.|t|t|t|t
33794175|NCT05003570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794176|NCT03930823|NA|SINGLE_GROUP||OTHER||NONE||One to one Interviews||||
33794177|NCT05150613|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Single blinding method will be employed to limit possible participant influence on test results (anticipation bias)||t|f|f|f
33794178|NCT05949749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33794179|NCT06258031|NA|SINGLE_GROUP||OTHER||NONE|"Study is single group, but participants are blinded to the fixed doses received on both dosing days (Dose A and Dose B), and the outcomes assessor responsible for evaluating OCD and depression symptoms using the Y-BOCS and MADRS is also blinded. Assessors evaluating all other outcomes are unblinded.~Note to editor: I ticked 'None (Open Label)' as advised, to avoid this being flagged and to be able to release this protocol; it is impossible to accurately describe our study's design with these options available. Please may this 'None (Open Label)' description be removed once it is published?"|Two different, fixed doses of psilocybin (Dose A = 10mg - x, Dose B = 10mg - y) are given on two separate dosing days to all patients.||||
33794180|NCT01385436|||COHORT||CROSS_SECTIONAL|||||||
33794181|NCT05099939|||COHORT||OTHER|||||||
33794182|NCT03477149|NA|SINGLE_GROUP||TREATMENT||NONE||French multicenter, phase 2b (device), prospective study||||
33794183|NCT04139538|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33794184|NCT02749578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794185|NCT02205307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794186|NCT05799963|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective, multi-center, open-label single-arm study. Prospective, multi-center, open-label single-arm study designed to enroll 85 patients in up to 15 centers in up to 3 European countries.~All patients will be followed up for 9 months. The BMX Alpha Registry study will serve as reference and historic comparator."||||
33794187|NCT02562352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33794188|NCT03615924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794189|NCT02712099|||COHORT||PROSPECTIVE|||||||
33794190|NCT05715151|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794191|NCT01482013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794192|NCT05400707|||COHORT||PROSPECTIVE|||||||
33794193|NCT03501173|||COHORT||PROSPECTIVE|||||||
33794194|NCT01377129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794195|NCT04747756|NA|SINGLE_GROUP||OTHER||NONE||||||
33794196|NCT03655938|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33794197|NCT03174054|||COHORT||PROSPECTIVE|||||||
33794198|NCT00411138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016515|NCT04154306|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34016516|NCT04129320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel study model refers to concurrent enrollment of non-randomized Modules X and Y.||||
34016517|NCT00539357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016518|NCT05944120|NA|SINGLE_GROUP||TREATMENT||NONE||As noted in the background, resiliency-building activities appear to have a positive relationship with managing stress in the workplace. Additionally, offering a variety of strategies is anticipated to increase the sample size and encourage continued use of the strategies over time.||||
34016519|NCT00704730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714053|NCT05225766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33714054|NCT04953468|||CASE_CONTROL||RETROSPECTIVE|||||||
33714055|NCT03295578|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be assigned to the personalised feedback group or generic feedback group (control) by an independent researcher that is not involved in the study. Assignment will be random and balanced for gender and age. To avoid subjects being aware of the group they are in, both groups will receive some sort of feedback, either generic or personalised. Subjects will be informed that they should not discuss their feedback with other study participants.|Randomized controlled trial with two parallel arms.|t|f|t|f
33714056|NCT02023398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714057|NCT04944953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714058|NCT01880164|||COHORT||PROSPECTIVE|||||||
33714059|NCT03476694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714060|NCT02769455|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33714061|NCT02663674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714062|NCT04938193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714063|NCT05815940|NA|SINGLE_GROUP||OTHER||NONE||||||
33714064|NCT00924456|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33714065|NCT01574040|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714066|NCT00226161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33714067|NCT02982876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714068|NCT02176811|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714069|NCT04984083|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33714070|NCT01823523|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33714071|NCT02838303|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33714072|NCT03545165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714073|NCT02338440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714074|NCT00240162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714075|NCT05854082|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33714076|NCT06310720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714077|NCT02037698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714078|NCT02438098|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714079|NCT01446900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714080|NCT02538250|NA|SINGLE_GROUP||||NONE||||||
33714081|NCT04630171|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participant will be blinded to what procedure will be used to identify lumbar landmarks.~All devices will be in the room with the operator of the devices."|Prospective randomized controlled trial|t|f|f|f
33714082|NCT02733068|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714083|NCT06043089|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33714084|NCT02974166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714085|NCT00788476|||CASE_ONLY||PROSPECTIVE|||||||
33714086|NCT00349804|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714087|NCT00248014|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714088|NCT00580606|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33714089|NCT02585960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714090|NCT03305653|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33714091|NCT03352830|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Masking is not feasible for this intervention.|||||
33714092|NCT01315678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714093|NCT05177978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33714094|NCT00546637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714095|NCT01223001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714096|NCT03165656|||CASE_CONTROL||PROSPECTIVE|||||||
33714097|NCT03252834|||COHORT||PROSPECTIVE|||||||
33714098|NCT01803919|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33714099|NCT01110434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33714100|NCT01689701|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33714101|NCT05241496|NA|SEQUENTIAL||TREATMENT||NONE||||||
33714102|NCT04975685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714103|NCT03875586|||OTHER||CROSS_SECTIONAL|||||||
33714104|NCT02231541|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33714105|NCT04774640|||COHORT||PROSPECTIVE|||||||
33714106|NCT03187197|||COHORT||PROSPECTIVE|||||||
33714107|NCT01382953|||COHORT||PROSPECTIVE|||||||
33714108|NCT03876197|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Long-term follow-up of Randomized controlled trial MESRIX|t|f|t|t
33714109|NCT03513562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714110|NCT03356990|NA|SINGLE_GROUP||OTHER||NONE||||||
33714111|NCT05351762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714112|NCT00182377|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33714113|NCT06153576|||CASE_ONLY||RETROSPECTIVE|||||||
33714114|NCT05313594|||CASE_ONLY||CROSS_SECTIONAL|||||||
33714115|NCT02744235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714116|NCT06409572|||CASE_ONLY||CROSS_SECTIONAL|||||||
34016520|NCT04309253|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||A. Group A: Patients with vascular cognitive impairment (VCI), n=80. B. Group B: Alzheimer's disease/mild cognitive impairment (MCI), n=80. C. Group C: Fronto-temporal dementia (FTD), n=30. D. Group D: Normal control, n=30. E. Group E: progressive supranuclear palsy(PSP), n=80.|f|f|t|f
34016521|NCT01211782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016522|NCT04553861|||COHORT||PROSPECTIVE|||||||
34016523|NCT04669535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016524|NCT03483168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098848|NCT06479083|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The participants are randomized into two groups: Interventional and control group. Neither APN nor the patients know in which group they belong until the first visit.|Study design: mixed-method approach; randomized study design. Planned intervention period: 12 months.|t|t|f|f
34098849|NCT04425278|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34098850|NCT02417337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098851|NCT01494857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714117|NCT06499155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714118|NCT01135199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714119|NCT01215994|||||CROSS_SECTIONAL|||||||
33714120|NCT03249727|NA|SINGLE_GROUP||SCREENING||SINGLE|Endoscopist will not be provided the results of either the FIT or NK Vue tests performed as part of the trial; biochemist will not be provided the results of the colonoscopy|All subjects will have a FIT (OC FIT-CHEK, Polymedco) and NK Vue test prior to colonoscopy|f|f|f|t
33714121|NCT03697629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714122|NCT03957720|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33714123|NCT02345681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714124|NCT03383679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714125|NCT02655939|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33714126|NCT04906213|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Placebo-controlled, double-blind, randomized clinical trial|t|t|t|f
33714127|NCT03026010|||COHORT||PROSPECTIVE|||||||
33714128|NCT03291808|NA|SINGLE_GROUP||OTHER||NONE||||||
33714129|NCT02882009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714130|NCT01647620|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33714131|NCT04219553|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Pre-post intervention study model||||
33714132|NCT01610544|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714133|NCT00002862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714134|NCT02239978|||COHORT||CROSS_SECTIONAL|||||||
33714135|NCT00667368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714136|NCT02254187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714137|NCT04316715|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714138|NCT00003479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714139|NCT03853265|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Study is parallel design with control group having the option of receiving treatment after study data is collected from initial treatment group|f|f|f|t
33714140|NCT03073044|||COHORT||RETROSPECTIVE|||||||
33714141|NCT00007969||||TREATMENT||||||||
33714142|NCT01490229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714143|NCT03551054|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel randomized controlled trial||||
33714144|NCT00031863|RANDOMIZED|||TREATMENT||DOUBLE||||||
33714145|NCT06319508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714146|NCT00948987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714147|NCT01690208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714148|NCT05647434|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|lung ultrasound will be done by same doctor in both groups who is trained in lung ultrasound he will enter operating room only during ultrasound examination. not to know sustained inflations done in which cases||f|f|t|f
33714149|NCT02193568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33714150|NCT03683108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714151|NCT01244724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714152|NCT03019822|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33714153|NCT04153240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Devices are pre-programmed and by the central site by an unblinded researcher. Devices are allocated randomly by an online randomisation schedule. Researchers and participants, and the central Sleep Therapist remain blinded.|Prospective randomised, parallel, double-blinded trial|t|t|t|t
33714154|NCT05451368|||COHORT||PROSPECTIVE|||||||
33714155|NCT04274842|NA|SINGLE_GROUP||OTHER||NONE||prospective observational cohort||||
33714156|NCT01656473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714157|NCT04056689|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33714158|NCT04183595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The research center must assign an unblinded pharmacist or a designated person and a non-blinded CRO monitor, to monitor medication supply and other unblinded documentation of the study.~Masking through identical capsules and blister in the two arms of intervention."|"One hundred and sixteen (116) participants will be randomized in a 1:1 ratio, to either one of the two arms of this trial.~This study will consist of 2 time periods/4 visits~1. Screening~2. Day 1 (Treatment start day, 7 days after visit 0)~3. Day 14 ± 3 days (Treatment end day)~4. Day 28 ± 3 days (Treatment drug-free follow-up end day)"|t|t|t|t
33714159|NCT05657314|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Subjects will take a daily protein supplement (e.g., 15 g of pea protein or 15 g of pea protein + probiotic blend) for 4 weeks, have a 1-week washout period (i.e. meaning they will not take either supplement), and then take the alternate protein supplement for an additional 4 weeks.|f|f|t|f
33794199|NCT00228007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794200|NCT02212054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098852|NCT02292680|||COHORT||RETROSPECTIVE|||||||
34098853|NCT06195774|||CASE_ONLY||PROSPECTIVE|||||||
34098854|NCT00667589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098855|NCT02459925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098856|NCT06254690|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098857|NCT01477411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098858|NCT06535776|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
34016525|NCT04341649|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants may be aware partially or totally of the nature of the intervention. For instance Manual Head Massage or Helmet Massager cannot be blind. However, for LLT or sham LLT the participants will remain blind. Indeed, Relaxed reading time is known by the participants|It is a crossover randomized trial where each participant is exposed to one of the 7 types of intervention, allocated randomly. Up to 20 healthy volunteers will be recruited.||||
34016526|NCT01180439|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016527|NCT05225974|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34016528|NCT04941339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016529|NCT02559882|||COHORT||PROSPECTIVE|||||||
34016530|NCT04648124|||COHORT||PROSPECTIVE|||||||
34016531|NCT04232813|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Prospective, monocentric, open-label, randomized, parallel-group study.||||
34016532|NCT06363786|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy volunteers get patches carrying a low pH or control formula applied to the forearms. The patches are carried over two days and the skin parameters and skin microbiome is measured on day 3.||||
33794201|NCT02957539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016533|NCT05120206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective cohort study||||
34016534|NCT01377675|||COHORT||CROSS_SECTIONAL|||||||
34016535|NCT05663450|||COHORT||OTHER|||||||
34016536|NCT02428686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016537|NCT00361335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794202|NCT06676189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Arm 1: Total knee replacement with medial pivot polyethylene~Arm 2: Total knee replacement with ultra-congruent polyethylene"||t|f|f|f
34098859|NCT03010397|||COHORT||PROSPECTIVE|||||||
33937837|NCT05021666|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The Investigator and other members of staff involved with the study will remain blinded to the treatment randomization code during the assembly procedure. The placebo solution will be identical in appearance to the PB-718.|"In Part A, 48 subjects will be studied in 6 groups (Groups A1 to A6), with each group consisting of 8 subjects.~In Part B, 32 subjects will be studied in 4 groups (Groups B1 to B4), with each group consisting of 8 subjects Following review of the safety, tolerability, and PK data, additional dose groups may be added to the study. Up to 3 further groups of 8 subjects (6 PB-718: 2 placebo) may be included in each of Parts A and B."|t|t|t|f
33937838|NCT03756285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016538|NCT05855083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016539|NCT00106236|RANDOMIZED|PARALLEL||||NONE||||||
34016540|NCT01775969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34016541|NCT01344174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016542|NCT06360315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016543|NCT00532818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016544|NCT00203970|||COHORT||RETROSPECTIVE|||||||
34016545|NCT04542265|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34016546|NCT01693627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016547|NCT00803036|||COHORT||PROSPECTIVE|||||||
34016548|NCT00679536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016549|NCT00044980|RANDOMIZED|||OTHER||||||||
34016550|NCT01598441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098860|NCT04307355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098861|NCT04319276|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33937839|NCT02460120|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937840|NCT01002885|||||PROSPECTIVE|||||||
33937841|NCT03453528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937842|NCT05344859|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Statistician and the assessor will be blinded/masked to participant assignment. The health coach will not be blinded. It will not be possible to blind the participants.|We propose to use the multiphase optimization strategy (MOST) design, as an ideal approach for the study, that is based on the principle of resource management and continuous improvement. Our study aim aligns with the preparatory and optimization phases of MOST, and is structured to serve as the preparatory phase for a future large-scale MOST optimization phase.|f|f|t|t
33937843|NCT00123786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937844|NCT04191694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33937845|NCT05472051|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33937846|NCT05231928|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, longitudinal, prospective, uncontrolled case series||||
33937847|NCT00542139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33937848|NCT03823963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937849|NCT01235767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937850|NCT00231972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016551|NCT02511899|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34016552|NCT01157780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016553|NCT02989168|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34016554|NCT03481062|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34016555|NCT01031953|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016556|NCT05682846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33794203|NCT04669925|||COHORT||RETROSPECTIVE|||||||
33794204|NCT06049732|||CASE_ONLY||PROSPECTIVE|||||||
33794205|NCT03616639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33794206|NCT05256641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794207|NCT06677333|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomized to consume 50 g of whey or pea protein for seven days.||||
33794208|NCT03691428|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33794209|NCT05153551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||30 families (30 children and 30 parents/legal guardians) to be enrolled||||
33794210|NCT00030888||||TREATMENT||||||||
33794211|NCT06632379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither participants, providers, investigators or outcome assessors will know to which of these groups participants are assigned. In case of an emergency, however, the study doctor can get this information.|a double-blinded randomized controlled trial|t|t|t|t
33794212|NCT06556160|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34016557|NCT06395779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will be divided into two parallel groups: The neuromuscular exercise group and the Dance therapy group. Both groups will participate in exercise programs for 12 weeks.||||
34016558|NCT05787054|RANDOMIZED|PARALLEL||SCREENING||SINGLE||1:1|f|f|t|f
34016559|NCT01429051|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34016560|NCT01742520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34016561|NCT00251719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016562|NCT02662166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016563|NCT02996760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016564|NCT03022708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016565|NCT04887246|||OTHER||PROSPECTIVE|||||||
34016566|NCT01969448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016567|NCT05994820|NON_RANDOMIZED|PARALLEL||OTHER||NONE|All parties are aware of assignment|||||
34016568|NCT00031122|||FAMILY_BASED||RETROSPECTIVE|||||||
34098862|NCT06378255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794213|NCT03572023|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937851|NCT06189027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33937852|NCT06022497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937853|NCT04815915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937854|NCT05246644|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|blinded medication with codes kept in the pharmacy|randomized double blind double dummy|t|t|t|t
33937855|NCT03323372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The design of this randomized, double blind, intervention study was structured based on the CONSORT (Consolidated Standards of Reporting Trials) standards.|t|f|t|t
33937856|NCT04360291|||OTHER||PROSPECTIVE|||||||
33937857|NCT05637294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multicentre, three-treatment, three-period, randomised, crossover superiority trial (3 x 6 crossover design)||||
33937858|NCT01856894|||CASE_CONTROL||PROSPECTIVE|||||||
33714160|NCT06049784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will collect the data from the files without knowing the participants' group assignment.|Parallel assignment Randomised Control Trial|f|f|f|t
33937859|NCT05084820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||each participant will be requested to draw either number one or two from a box.number one refers to group A and number two refers to group B. Group A patients will receive conventional treatment of 40 minutes in total. group B is experimental group , patients will watch videos of 5 common motor tasks that implicit the usage of items to be used for action observation treatment.|f|f|f|t
33937860|NCT04493229|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized, double-blind study of oxytocin (IM) or placebo given|t|f|t|t
33937861|NCT03299621|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33937862|NCT04491331|||COHORT||PROSPECTIVE|||||||
33937863|NCT00942422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937864|NCT04296929|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937865|NCT06039904|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized crossover trial||||
33937866|NCT02442375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016569|NCT02139124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016570|NCT00345735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34016571|NCT00004313|RANDOMIZED|||TREATMENT||DOUBLE||||||
34016572|NCT00186043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098863|NCT01943825|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714161|NCT01325415|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33714162|NCT02573857|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714163|NCT02709785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714164|NCT04165434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714165|NCT01000272|||CASE_CONTROL||PROSPECTIVE|||||||
33714166|NCT04362787|||COHORT||PROSPECTIVE|||||||
33714167|NCT05350553|||COHORT||CROSS_SECTIONAL|||||||
33714168|NCT01214629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714169|NCT01987505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714170|NCT04173078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were blind to whether they were in the experimental (Distress Intolerance Intervention) or control (Healthy Behaviors Intervention) condition. All outcome measures were self-report except for the four-month follow-up Cannabis Use Diagnostic interview which was conducted by an interviewer blind to the participant's treatment condition.|At the end of the baseline assessment, the participant was randomized to the Computerized Distress Intolerance Intervention condition or the Computerized Healthy Behaviors condition. Participants in each condition attended two 1-hour intervention sessions followed by a post-treatment assessment. Follow-up assessments were conducted one-month and four-months after the post-treatment assessment.|t|f|f|t
33714171|NCT02811250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714172|NCT03406455|||COHORT||PROSPECTIVE|||||||
34016573|NCT01775865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016574|NCT00675636|||OTHER||PROSPECTIVE|||||||
34016575|NCT02494102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Computer generated randomization list, subject, clinical team and research team blinded to intervention|double blind randomized placebo controlled trial|t|f|t|f
34016576|NCT02925806|||COHORT||RETROSPECTIVE|||||||
34016577|NCT03119974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016578|NCT03597360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016579|NCT01691820|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34016580|NCT00772135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34016581|NCT02160093|||COHORT||PROSPECTIVE|||||||
34016582|NCT06332287|NA|SINGLE_GROUP||TREATMENT||NONE||Trilaciclib||||
34098864|NCT05945732|||CASE_CONTROL||PROSPECTIVE|||||||
34098865|NCT02441816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098866|NCT01594372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937867|NCT05320211|NA|SINGLE_GROUP||TREATMENT||NONE||within-subjects design||||
33937868|NCT01040416|||COHORT||RETROSPECTIVE|||||||
33937869|NCT01571973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937870|NCT03795051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937871|NCT03511924|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33937872|NCT04016506|||COHORT||PROSPECTIVE|||||||
33937873|NCT00939341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937874|NCT02354690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937875|NCT04697589|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33937876|NCT01526967|||COHORT||PROSPECTIVE|||||||
33937877|NCT01824524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016583|NCT06197958|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33937878|NCT04306770|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33937879|NCT01377038|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33937880|NCT02865681|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33937881|NCT00199368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937882|NCT00078455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937883|NCT00180206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937884|NCT01104922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937885|NCT02884440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016584|NCT00531349|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016585|NCT02556372||SEQUENTIAL||TREATMENT||NONE|This is an open label study|The patient takes 5mg up to 40mg depending on the monthly response.||||
34016586|NCT00204958|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34016587|NCT02756026|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016588|NCT03748849|||CASE_CONTROL||PROSPECTIVE|||||||
34016589|NCT06219993|||CASE_CONTROL||PROSPECTIVE|||||||
34016590|NCT02777957|||COHORT||PROSPECTIVE|||||||
34016591|NCT05876455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098867|NCT03686722|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||"Twenty Eligible Adult Subjects Will be Randomized Equally into two Groups: A and B To Receive Either:~Group (A):10 subjects will receive 500 mg Metformin twice daily on day 1-4 then 1000mg metformin twice on day 5-7 Group (B):10 subjects will receive 500 mg co-administered daily with Daclatasvir 60 mg once daily on day 1-4 then 1000mg Metformin co-administered twice daily with Daclatasvir 60 mg once daily on day 5-7"|f|f|t|t
33937886|NCT01149044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937887|NCT05496855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled non-inferiority trial|f|f|f|t
33937888|NCT01586286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937889|NCT00523172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937890|NCT03041493|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, non-randomized case controlled study of the effects of electronic cigarettes on vascular health. The study population will comprise the three groups based on the criteria EC users (experimental group), (TC) smokers (positive control) and nonsmokers (negative control).||||
33937891|NCT01913509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016592|NCT03055442|||CASE_ONLY||PROSPECTIVE|||||||
33937892|NCT03620292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33937893|NCT00097240|||COHORT||PROSPECTIVE|||||||
33937894|NCT04957810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33937895|NCT02125812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937896|NCT05956327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33937897|NCT02556346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937898|NCT03198728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label||t|f|f|f
33937899|NCT05719259|||COHORT||PROSPECTIVE|||||||
34016593|NCT00362479|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34016594|NCT01195272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016595|NCT02440568|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016596|NCT02676362|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34016597|NCT00326560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34016598|NCT06414278|||COHORT||PROSPECTIVE|||||||
34025417|NCT05227963|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Non-probability convenient sampling technique was used to recruit the sample through lottery method into two groups.|The randomized control study was conducted in two groups,one was experimental group received soft tissue mobilization and other was control group received strengthening exercises with supportive treatment for both groups.|f|f|t|f
34098868|NCT06016660|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098869|NCT05229367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants were randomly divided into two groups.|t|f|f|t
34098870|NCT03114644|NA|SINGLE_GROUP||OTHER||NONE||||||
34098871|NCT02642276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098872|NCT01215162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714173|NCT03919214|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33714174|NCT05311540|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|An independent physician not involved in the study conducted the random assignment process. The investigators who were blinded to the randomisation process closely followed up the enrolled infants for any evidence of feeding intolerance and/or NEC, late-onset sepsis (LOS), bronchopulmonary dysplasia (BPD), hemodynamically significant patent ductus arteriosus (hsPDA), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP) along with other possible neonatal morbidities and signs of toxicity or side effects (adverse events)||t|f|t|f
33714175|NCT00164554|RANDOMIZED|PARALLEL||||SINGLE||||||
33714176|NCT01356472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714177|NCT04238598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||test, active, control|t|t|t|f
33714178|NCT03326765|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"2 groups:~* 30 Children(0-18y) withTSC without epilepsy~* 30 Adults(\>18y) withTSC without epilepsy"||||
33714179|NCT06454383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714180|NCT01293175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714181|NCT02674529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714182|NCT02032810|NA|SEQUENTIAL||TREATMENT||NONE||||||
33714183|NCT04931745|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled trial||||
33714184|NCT06374160|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||BREATH is a prospective 3-arm 2:1:1 randomized controlled trial (RCT). The first arm represents the control group, which will receive the standard treatment for the first 12 weeks (recommendations for physical activity during cancer treatment). The other two arms represent the exercise groups, one group will receive individualized endurance training and the other group a combination of individualized endurance and strength training. All arms will be treated for 12 weeks. Afterwards, the patients in the control group are randomized to one of the other two study arms and then also treated twice for 12 weeks.||||
33714185|NCT03275662|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33714186|NCT04519710|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714187|NCT02018588|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33714188|NCT05614128|||CASE_ONLY||PROSPECTIVE|||||||
33714189|NCT02236832|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34098873|NCT02285959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098874|NCT01687205|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33714190|NCT02256904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714191|NCT00159471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714192|NCT04982887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714193|NCT05935852|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Four Arms with different disease activity and duration||||
33714194|NCT01596400|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714195|NCT00001105||||TREATMENT||||||||
33714196|NCT02728076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714197|NCT03178877|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33714198|NCT06001099|||CASE_CONTROL||PROSPECTIVE|||||||
33714199|NCT00543140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714200|NCT06150560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33714201|NCT05385393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714202|NCT05896475|||COHORT||PROSPECTIVE|||||||
33714203|NCT03481322|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33714204|NCT05101005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714205|NCT04952402|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33714206|NCT01907815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714207|NCT00719134|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33714208|NCT02354989|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34098875|NCT05632900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098876|NCT04878926|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34098877|NCT03409146|||COHORT||PROSPECTIVE|||||||
33794214|NCT05573854|NON_RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Investigator will not participate of the 3 MRI sessions. Outcome Assessor will receive the data for statistical analysis blinded|The data will be collected in three phases. Firstly, after a fasting period of eight hours, the participants will attend the Radiology Service of the Hospital de Cancer, Cuiaba, Brazil to perform MRI images of the upper abdomen with the objective of measuring the fasting GRV (phase 1). In this phase, adequate stomach motility will be observed to exclude cases of possible gastroparesis. GRV (cmˆ3) will be measured in the fasting state by MRI tracking the region of interest (ROI) in each slice, forming a volume by the sum of all ROIs. In phase 2, each participant while still inside the MRI exam room will ingest 200 mL of the study drink described below. The individual will be immediately positioned in the supine position and another MRI scan will be carried out. Finally, phase 3 will be performed after a 3-hour pause and a third MRI scan will be done to measure again the GRV.|f|f|t|t
33794215|NCT04470986|||COHORT||PROSPECTIVE|||||||
33794216|NCT01883908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33794217|NCT02571816|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794218|NCT05761834|||COHORT||PROSPECTIVE|||||||
33794219|NCT04097418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The computerized randomization software will generate personal codes to allocate every patient to a treatment arm. These codes will be placed in opaque envelopes and delivered to the patient by an operator external to the study.|"This study is a monocentric, non-pharmacological, longitudinal, randomized, blind, controlled study.~Subjects The Investigators will study 40 MS patients and 40 HC. Subjects will then be randomized through a sequence generated by the computer to determine their assignment to the conventional motor rehabilitation therapy group (control group) or to the aerobic training (experimental group). The computerized randomization software will generate personal codes to allocate every patient to a treatment arm.~Participants will be split into 4 groups of 20 subjects per group:~1. Group of aerobic training of healthy subjects: aerobic training by treadmill at moderate intensity;~2. Group of conventional motor training of healthy subjects: training of passive mobility, stretching and balance;~3. Group of aerobic training of MS patients: aerobic training by treadmill at moderate intensity;~4. Treatment group control of MS patients: training of passive mobility, stretching and balance."|f|t|t|t
34098878|NCT03238157|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized to either observation (2:1) (standard of care) or intravitreal Fluocinolone Acetonide (FA) implant||||
33794220|NCT06677112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794221|NCT03309579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|open-label blinded-endpoint|Multicentre pragmatic, open-label blinded-endpoint|f|f|f|t
33794222|NCT05875285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33794223|NCT03951207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794224|NCT06245746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098879|NCT00246766|||||PROSPECTIVE|||||||
34098880|NCT01018056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098881|NCT01426555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794225|NCT00390728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794226|NCT03385967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|This is a prospective, randomized, double blind study of adding dexmedetomidine 0.25mcg/kg body weight to standard dose (25ml) of 0.5%ropivacaine for Brachial plexus block and assessing the analgesia with VAS pain scales (0-10), Satisfaction scale by VAS scale (0-10) and time to first analgesic consumption.|t|t|f|f
33794227|NCT06677138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794228|NCT03941912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794229|NCT04520880|||OTHER||PROSPECTIVE|||||||
33794230|NCT02279017|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794231|NCT00034463||||TREATMENT||||||||
33794232|NCT03597100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794233|NCT02636855|||CASE_ONLY||PROSPECTIVE|||||||
33937900|NCT02994927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study was double-blind, double-dummy, i.e., placebo capsules were identical in appearance to the avacopan capsules, and prednisone capsules also had matching placebo capsules. To maintain the blind, multiple measures were taken (i.e., randomization code was not accessible to study personnel who had contact with study centers or who were involved in data management and analysis for the duration of the study).||t|t|t|t
33937901|NCT04978922|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only data entry people and biostatisticians were masking||f|f|f|t
33937902|NCT00129376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937903|NCT01116128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33937904|NCT00457093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937905|NCT05010434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937906|NCT03112499|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33937907|NCT03223740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33937908|NCT02881918|||CASE_ONLY||PROSPECTIVE|||||||
33937909|NCT02422160|||COHORT||PROSPECTIVE|||||||
33937910|NCT03089008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937911|NCT05713513|||OTHER||PROSPECTIVE|||||||
33937912|NCT00284258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937913|NCT05734703|NA|SINGLE_GROUP||TREATMENT||NONE||One group of 25 adults aged 50 or over.||||
34098882|NCT04682314|||COHORT||PROSPECTIVE|||||||
34098883|NCT00383851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098884|NCT05676567|||COHORT||PROSPECTIVE|||||||
34098885|NCT05301231|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34098886|NCT03780712|||COHORT||PROSPECTIVE|||||||
34098887|NCT01213771|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098888|NCT01450267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098889|NCT01200134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098890|NCT01407133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34016599|NCT04436978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The study is designed as a multicentre open label randomized controlled superiority trial with regards to safety and non-inferiority trial with regards to efficacy.~Participating study centres will enrol patients undergoing PCI who have previously or newly diagnosed AF and indication for NOAC. As soon as possible, but within 72 hours after PCI, patients will be randomized 1:1 to either~* 30 days DAPT (asprin + P2Y12 inhibitor), followed by guideline-directed therapy (edoxaban + P2Y12 inhibitor)~* Standard guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)"|f|f|f|t
34016600|NCT01258166|||CASE_ONLY||RETROSPECTIVE|||||||
34016601|NCT05438407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016602|NCT02245061|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016603|NCT02806258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016604|NCT01087671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016605|NCT04597294|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization 1:1||||
34016606|NCT01311349|||||PROSPECTIVE|||||||
34016607|NCT06242002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016608|NCT03760614|NA|SEQUENTIAL||TREATMENT||NONE||"This will be a modified 3+3 dose-escalation design with a primary endpoint of dose-limiting toxicity. All cohorts will receive the same dose of FOLFOX, once every 2 weeks. All cohorts will receive entinostat on days 1,8, 15, and 22 of 28 day cycles. Cohorts will vary in their dose of entinostat as follows:~* Cohort 0: 2mg~* Cohort 1: 3mg~* Cohort 2: 4mg~* Cohort 3: 5mg~Dosing will start with cohort 1. If no dose limiting toxicities (DLTs) are observed, the dose will be escalated directly to cohort 3. If any DLTs are experienced in cohort 1, three additional subjects will be enrolled in cohort 1. If no DLTs are experience by the additional subjects, the dose will be escalated to cohort 2. If a DLT occurs in two subjects in any dose cohort, dose escalation will be halted, and the next three subjects will be enrolled at the next lower dose cohort."||||
34016609|NCT03732261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025418|NCT00006348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34098891|NCT04868903|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||2,000-person two-arm, double-blinded randomized controlled trial, with half the subjects randomized to low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day).|t|t|t|t
34098892|NCT04875845|||COHORT||PROSPECTIVE|||||||
33714209|NCT04498013|RANDOMIZED|PARALLEL||TREATMENT||NONE||Female patients aged 40 to 52 years (inclusive) with mastodynia and BI-RADS category 3, who meet the requirements of inclusion/exclusion criteria will be randomized in 2 groups. The main group will be treated with Cyclodynon 1 tab per day - 6 month in addition to lifestyle modification. The control group lifestyle modification only. Dynamics of mammographic breast density (changing in BI-RADS score of category 3).||||
33714210|NCT02737189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098893|NCT05263245|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multicenter open label randomized cross-over design. Patients will be randomized to start with the experimental or standard regimen. In the experimental regimen, patients will take cabozantinib with a light breakfast. In the standard regimen, patients will take cabozantinib in fasted state. After all pharmacokinetic samples have been completed, patients will switch to the other regimen.||||
34098894|NCT03221296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714211|NCT01385553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714212|NCT05480085|NA|SINGLE_GROUP||OTHER||NONE||||||
33714213|NCT00353210|||OTHER||OTHER|||||||
33714214|NCT04214054|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was designed as a randomized controlled clinical trial and the participants were allocated randomly into two equal groups.||||
33714215|NCT01929278|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33714216|NCT04397653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714217|NCT04441606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714218|NCT01633333|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33714219|NCT05228262|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Population of postmenopausal women ≥50 years of age with osteoporosis requiring the initiation of antiosteoporotic therapy.||||
33714220|NCT02027389|||OTHER||RETROSPECTIVE|||||||
33714221|NCT02185833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714222|NCT06471452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714223|NCT02803489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714224|NCT03535116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|drug vs placebo(saline). Identification is in a sealed envelope. The anesthetist gives the medication without telling the surgeon or the patient what medication is given(patient will be under a general anesthetic). Neither patient or surgeon will know what the patient gets until the follow up period(6 weeks) is completed.|Double Blind Randomized Control Trial of breast reduction patients and their postoperative hematoma rates with the use of ketorolac|t|t|f|f
33714225|NCT04675840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714226|NCT04244331|||COHORT||PROSPECTIVE|||||||
33714227|NCT02310061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714228|NCT05035550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group was blinded to their condition. The intervention group was not blinded.||t|f|f|f
33714229|NCT04470440|||COHORT||RETROSPECTIVE|||||||
33714230|NCT02799511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714231|NCT03362476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33714232|NCT06295224|||CASE_ONLY||RETROSPECTIVE|||||||
33714233|NCT05303636|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||Two cohorts: Cohort 1 (adolescents); Cohort 2 (adults)||||
33714234|NCT02054091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single group for first 12 infants RCT for next 40 infants|f|f|f|t
33714235|NCT01767155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714236|NCT00406445|||CASE_CONTROL||PROSPECTIVE|||||||
33714237|NCT01901497|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33714238|NCT01811160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714239|NCT05219214|||OTHER||PROSPECTIVE|||||||
33714240|NCT05117528|||COHORT||PROSPECTIVE|||||||
33714241|NCT03829982|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment||||
33714242|NCT05133453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937914|NCT01686048|||CASE_ONLY||PROSPECTIVE|||||||
33937915|NCT00027404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937916|NCT06095024|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34016610|NCT05723679|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The order of the room air and HeO2 tests will be randomized and the subjects will not be told what gas mixture they will be breathing.|Mechanistic Clinical Trial|t|f|f|f
34016611|NCT00173537|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34016612|NCT01080573|||COHORT||PROSPECTIVE|||||||
33714243|NCT00869895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794234|NCT04988841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|At week 27, unblinding will be performed on patients who progressed. For those who received Placebo, Maat 013 will be administrated in open label.|Multi-center, prospective, randomized, double blinded, pilot, proof-of concept, clinical trial|t|t|t|t
33714244|NCT03729505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33794235|NCT03445130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33794236|NCT03656094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794237|NCT06676696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794238|NCT05295134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33794239|NCT05128019|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Cluster Randomized Controlled Trial with an intervention group and a control group||||
33937917|NCT00370825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937918|NCT02913885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33937919|NCT04711395|||COHORT||PROSPECTIVE|||||||
33937920|NCT01166776|||CASE_ONLY||PROSPECTIVE|||||||
33937921|NCT00813774|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33937922|NCT04954976|||COHORT||PROSPECTIVE|||||||
33937923|NCT02394366|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34016613|NCT03036241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016614|NCT03898830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016615|NCT01507974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937924|NCT00073515|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33937925|NCT05761262|||COHORT||PROSPECTIVE|||||||
33937926|NCT02276690|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33937927|NCT02784184|||COHORT||PROSPECTIVE|||||||
33937928|NCT00906555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937929|NCT04174534|||COHORT||PROSPECTIVE|||||||
33937930|NCT00003899||||TREATMENT||||||||
34016616|NCT04746911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016617|NCT04002505|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34016618|NCT01411865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34016619|NCT02214784|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34016620|NCT00402454|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016621|NCT01244061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016622|NCT04134923|||OTHER||PROSPECTIVE|||||||
33714245|NCT02916108|||CASE_CONTROL||PROSPECTIVE|||||||
33714246|NCT05466162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The interventions assigned to individual participants will be kept hidden from the outcome assessors in the clinical trial.|It is a randomized controlled trial. Total 60 patients will be recruited, 30 in each group that includes There will be one interventional group and one control group. Treatment will be allocated by using a random number sheet generated by SPSS software version 21. Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33714247|NCT02214524|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714248|NCT06508424|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be told which arm of the trial they are taking part in. PulseOn crackers and the wheat flour control crackers have been matched as closely as possible for energy content and sensory characteristics. Participants will be asked to rate the acceptability of the crackers to determine whether there are any discernible differences, however they are required to consume a set amount.|Participants will be randomly assigned to either the treatment (PulseOn) or control group at the outset of their participation. Following a minimum of a one-week washout period, participants will then participate in the alternative arm.|t|f|f|f
33714249|NCT01170858|RANDOMIZED|PARALLEL||||NONE||||||
33714250|NCT03629132|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33714251|NCT03529916|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714252|NCT03099421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714253|NCT06221540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33714254|NCT04928040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714255|NCT00677508|||CASE_ONLY||PROSPECTIVE|||||||
33714256|NCT02397759|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33714257|NCT03266094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714258|NCT01916213|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33714259|NCT00549965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016623|NCT01586403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016624|NCT00545207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016625|NCT05227612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016626|NCT01587937|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34016627|NCT03439852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators blinded to outcome follow-up data reported by study condition until completion of intervention period. Outcomes assessor blinded to participant identity - data entered only with ID number|cluster randomized controlled trial comparing physical activity/sedentary time intervention to delayed treatment condition|f|f|t|t
33714260|NCT00671892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33714261|NCT02356068|||COHORT||PROSPECTIVE|||||||
33714262|NCT00303277|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714263|NCT03071770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714264|NCT02552199|||COHORT||PROSPECTIVE|||||||
33714265|NCT01032642|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34016628|NCT00231257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016629|NCT03138226|||COHORT||PROSPECTIVE|||||||
34016630|NCT04862611|||CASE_ONLY||PROSPECTIVE|||||||
34016631|NCT02273336|||CASE_ONLY||PROSPECTIVE|||||||
33794240|NCT00778362|||CASE_ONLY||RETROSPECTIVE|||||||
33794241|NCT04962906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All personnel involved in antibody determination shall remain blinded to the assigned strategy.||f|f|f|t
33794242|NCT06677541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794243|NCT05286632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is an interventional, multicentric, randomized, double arm, comparative, parallel, open-label study.||||
33794244|NCT02620618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794245|NCT04707313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794246|NCT02765438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794247|NCT01591928|||COHORT||PROSPECTIVE|||||||
33794248|NCT01685606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016632|NCT02802618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34016633|NCT01179126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016634|NCT02575976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016635|NCT01679106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33794249|NCT06089824|||COHORT||RETROSPECTIVE|||||||
33794250|NCT01615432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794251|NCT02348658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794252|NCT04025359|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The study medication will be prepared by research pharmacy using over-encapsulation.|Double-blind, randomized, placebo-controlled cross-over human laboratory study. Participants will be asked to come to the testing site for a total of four times: one initial screening session (\~ 3 hours) and three test days (\~ 6 hours each) where study medication will be administered, separated by at least 72 hours to limit carryover effects for dronabinol administration.|t|f|t|f
33794253|NCT01750333|||COHORT||RETROSPECTIVE|||||||
33937931|NCT06094686|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33937932|NCT04857840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random allocation of the double blinded 2 Arms : Double-blind placebo controlled during Period 1 of 12 weeks|2 Arms : Double-blind placebo controlled during Period 1 of 12 weeks followed by open-label periods 2 (24 weeks) and 3 (12 weeks)|t|t|f|f
33937933|NCT02510989|||FAMILY_BASED||OTHER|||||||
33937934|NCT04735211|||COHORT||PROSPECTIVE|||||||
33937935|NCT01468844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937936|NCT04772404|||COHORT||PROSPECTIVE|||||||
33937937|NCT04726436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33937938|NCT01738724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937939|NCT02353806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937940|NCT01970540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937941|NCT01873196|RANDOMIZED|PARALLEL||||NONE||||||
33937942|NCT02411773|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34016636|NCT02823860|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34016637|NCT00741936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016638|NCT05673681|||COHORT||PROSPECTIVE|||||||
34016639|NCT00229736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016640|NCT04132895|||COHORT||PROSPECTIVE|||||||
34098895|NCT04652882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098896|NCT04287556|||COHORT||OTHER|||||||
34016641|NCT06447337|||CASE_CONTROL||PROSPECTIVE|||||||
34016642|NCT02804230|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, single-cohort study with no control group to evaluate initial safety, feasibility, and effectiveness of the Exablate 4000 Type 1 or 1.1 System.||||
34016643|NCT01509742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34016644|NCT00400621|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
34016645|NCT01508754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016646|NCT04601298|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34016647|NCT03340870|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016648|NCT02273687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016649|NCT02251873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016650|NCT02123212|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34098897|NCT05811975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098898|NCT05320757|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34098899|NCT02200666|||COHORT||PROSPECTIVE|||||||
33794254|NCT05925686|NA|SINGLE_GROUP||SCREENING||NONE||||||
33794255|NCT03874299|||COHORT||PROSPECTIVE|||||||
33794256|NCT01901276|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794257|NCT05985356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794258|NCT02560896|||FAMILY_BASED||PROSPECTIVE|||||||
33794259|NCT03774459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794260|NCT00444990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794261|NCT03776890|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34016651|NCT05055895|||COHORT||RETROSPECTIVE|||||||
33937943|NCT04885075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937944|NCT01925014|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33937945|NCT00071604|RANDOMIZED|PARALLEL||||DOUBLE||||||
34016652|NCT04114565|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34016653|NCT03146182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016654|NCT01272362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016655|NCT03893474|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016656|NCT00914459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016657|NCT03173053|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, randomized controlled, open label superiority trial||||
34016658|NCT04631523|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016659|NCT05104463|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34016660|NCT05717855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016661|NCT02302859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016662|NCT01959035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016663|NCT01599130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016664|NCT01369563|||||PROSPECTIVE|||||||
34098900|NCT05496699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 group, intervention|t|f|f|f
34098901|NCT03012945|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098902|NCT03981393|||COHORT||RETROSPECTIVE|||||||
34098903|NCT02501785|||COHORT||PROSPECTIVE|||||||
33794262|NCT06271304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are instructed not to discuss the appearance of their designated eyewear with their care providers or the investigator or outcome assessor. Participants are not informed of the exact filtration level of their eyewear.|Outcome assessors will be blinded to the treatment assignment. At the beginning of each assessment, participants will be instructed not to describe or discuss their glasses with the assessor. Because the two types of glasses are of different color (clear (LF) and orange (BB)), we cannot guarantee a full blinding of the participants. Participants will be informed that we are studying the effects of two different types of light filters without more detail so they will not be provided with certain knowledge of which condition is expected to yield the largest effect. We will assess the integrity of the blind by asking participants whether they think they received glasses with high or low filtration lenses at the end of the study. Participants will be discouraged from actively seeking information about sleep glasses during the study|f|f|t|t
33794263|NCT03802266|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33794264|NCT05204615|||COHORT||PROSPECTIVE|||||||
33794265|NCT00172185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794266|NCT01321411|||COHORT||PROSPECTIVE|||||||
34016665|NCT02479373|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||Control and participant groups.||||
34016666|NCT03187366|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016667|NCT04461119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016668|NCT00759239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016669|NCT00856973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016670|NCT02838511|||COHORT||PROSPECTIVE|||||||
34016671|NCT03261765|||OTHER||CROSS_SECTIONAL|||||||
34016672|NCT03490448|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34016673|NCT02635217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016674|NCT02441244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016675|NCT05384717|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016676|NCT01732484|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34098904|NCT02470767|||COHORT||CROSS_SECTIONAL|||||||
33794267|NCT05966779|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33794268|NCT00943735|||OTHER||PROSPECTIVE|||||||
33794269|NCT06319586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794270|NCT04957225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Block randomized sealed envelopes handled by external coordinator.|Cluster randomized clinical trial with two parallel arms.|f|f|t|t
33794271|NCT00309595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794272|NCT01340079|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34098905|NCT05450120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794273|NCT00661648|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33794274|NCT03302546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794275|NCT04033042|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE|One group will receive the instructions for use and the other will not.|||||
33794276|NCT02031471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794277|NCT05838495|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, single arm, non-randomized, open-label, observational study||||
33794278|NCT01523405|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794279|NCT01622075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794280|NCT01131624|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794281|NCT02662855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794282|NCT00027820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794283|NCT03961633|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants are assigned to a single intervention (treatment) group. Intervention at the two sites are not concurrent; the Boston University site intervention takes place in March - May 2018, and the Harvard University site intervention takes place in October - December 2018."||||
34016677|NCT02647736|NA|SINGLE_GROUP||||NONE||||||
34098906|NCT06633406|||COHORT||OTHER|||||||
34016678|NCT02791893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016679|NCT05875220|||COHORT||PROSPECTIVE|||||||
34016680|NCT03465917|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016681|NCT01150617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016682|NCT00548158|||COHORT||PROSPECTIVE|||||||
34016683|NCT05355714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Treatments will be split-body with subjects receiving treatment from one device on their right side and one on their left.|f|f|f|t
33794284|NCT02682446|||COHORT||PROSPECTIVE|||||||
33794285|NCT04261842|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794286|NCT01688089|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33794287|NCT06027372|||CASE_ONLY||PROSPECTIVE|||||||
33794288|NCT01606631|||CASE_CONTROL||PROSPECTIVE|||||||
33794289|NCT04846491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794290|NCT00970307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794291|NCT00282971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794292|NCT04263480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794293|NCT05746325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794294|NCT01845532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016684|NCT00548938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016685|NCT00001713||||TREATMENT||||||||
34016686|NCT02093221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016687|NCT01684137|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34025419|NCT01192607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025420|NCT00115427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025421|NCT03167463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025422|NCT06634225|||CASE_CONTROL||PROSPECTIVE|||||||
34025423|NCT04778488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Observational cohort study.||||
34025424|NCT01753557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025425|NCT05113433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098907|NCT04961203|||CASE_CONTROL||RETROSPECTIVE|||||||
34098908|NCT06427174|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients and anesthesiologist won't know which group is patients will selected||t|t|f|f
33794295|NCT06032364|||CASE_ONLY||RETROSPECTIVE|||||||
33794296|NCT06281704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016688|NCT04599127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participant will be blinded by unknowing the randomization of the group allocation using a sealed envelope.~The physical therapy (S) who treats the participants using mobilization with movement will be blinded by unknowing the group allocation of the participants.~The physical therapy (E) who treats the participants using conventional physical therapy will be blinded by unknowing the group allocation because all of the participants will be treated using conventional physical therapy.~The examiner (AH) and (FN) will be blinded by unknowing the participant group and the sequence of assessments will be randomized."|All of the eligible participants will be divided into two groups; conventional physical therapy and conventional physical therapy plus mobilization with movement|t|t|f|t
34016689|NCT04519034|||OTHER||RETROSPECTIVE|||||||
34098909|NCT06284837|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34098910|NCT00496327|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34098911|NCT03418207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098912|NCT04315142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098913|NCT00592722|||COHORT||PROSPECTIVE|||||||
34098914|NCT05520450|||CASE_ONLY||PROSPECTIVE|||||||
34098915|NCT02691377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098916|NCT06307444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34098917|NCT01457456|||COHORT||PROSPECTIVE|||||||
34098918|NCT00005922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34098919|NCT01287429|||COHORT||PROSPECTIVE|||||||
34098920|NCT05215847|NA|SINGLE_GROUP||TREATMENT||NONE||This study includes one intervention arm.||||
33794297|NCT02981706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794298|NCT04013555|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|All raters, investigators and other staff will be blind to treatment assignment except for the research pharmacist. The research pharmacist does not participate in assessing any of the primary symptom or side effect dependent variables and conveys no information about treatment assignment to participants or staff except in a medical emergency.|This will be a double-blind, placebo-controlled, randomized cross-over challenge study. Participant randomization will use a permuted block randomization system (block sizes 2 or 4), in which treatment assignment order is random within each block, with an equal number of participants assigned to each treatment, to generate a list of treatment assignments. Thus, it will be difficult to ascertain the next treatment assignment, even if a participant becomes unblinded, while any imbalance in the number of participants between the treatment groups will be kept within tight limits.|t|t|t|t
33794299|NCT02163954|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34098921|NCT03499665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants didn't know taking which exercise treatment methods|Experimental, Randomized Controlled Study|t|f|f|f
34098922|NCT02608346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794300|NCT03516604|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants will be randomly allocated to one of three groups (PF-04995264, citalopram or placebo) and receive their allocated study medication for 7 days.|t|t|t|t
33794301|NCT05274217|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||A randomized waitlist stepped wedge design with study participants recruited in staggered cohorts, with those in each annual recruitment wave receiving individual-level random assignment to either immediate intervention or waitlist control.|f|t|t|t
33794302|NCT02169492|||OTHER||PROSPECTIVE|||||||
33794303|NCT00003728|RANDOMIZED|||TREATMENT||||||||
33794304|NCT00670020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794305|NCT01942707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patient will not know if the Scarpa´s fascia has been removed or preserved.||t|f|f|f
33794306|NCT06211907|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority Trial||||
33937946|NCT00215228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937947|NCT02048774|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33937948|NCT02670187|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33937949|NCT05292456|||COHORT||PROSPECTIVE|||||||
33937950|NCT04673630|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking is used. All involved know the identity of the intervention assignment.|||||
33937951|NCT02330640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single center prospective randomized controlled study|f|f|t|f
33937952|NCT03944811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33937953|NCT05991440|||CASE_CONTROL||PROSPECTIVE|||||||
33937954|NCT03432208|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937955|NCT04486404|||COHORT||PROSPECTIVE|||||||
34098923|NCT03555045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34098924|NCT01749566|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098925|NCT00930332|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34098926|NCT00137280|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|research assessors had minimal contact with staff involved in implementation||f|f|f|t
34098927|NCT03947021|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098928|NCT03997838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098929|NCT04579419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937956|NCT04742764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|No masking is applied in this study, as it is impossible to blind the medical personnel and participants. Statisticians will be blinded to allocation|Prospective, randomized, controlled, three-arm, open-label, international, multi-centre, phase III study|f|f|f|t
33937957|NCT01460849|||COHORT||RETROSPECTIVE|||||||
33937958|NCT02650193||PARALLEL||OTHER||NONE||||||
33937959|NCT04106011|||COHORT||PROSPECTIVE|||||||
33937960|NCT00443365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937961|NCT02358928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098930|NCT05459714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098931|NCT03041337|||OTHER||PROSPECTIVE|||||||
34098932|NCT06436521|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were assigned to one approach: Positive CBT or Traditional CBT, through simple randomization.||||
34098933|NCT03848351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor will not be present during explanation of oral hygiene maneuvers. Moreover, participants will be asked not to mention about techniques and group participation to the outcome assessors.|Single-centre randomized, parallel design, clinical trial with a 1-month follow-up|f|f|t|t
33794307|NCT03988036|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, interventional, prospective, single arm, open label, neoadjuvant phase II trial evaluating the pathological complete response (pCR) rate induced by pembrolizumab in combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.||||
34016690|NCT00303394|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34098934|NCT00888082|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098935|NCT00002835|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098936|NCT05511688|||COHORT||PROSPECTIVE|||||||
34098937|NCT04400955|||COHORT||CROSS_SECTIONAL|||||||
34098938|NCT00711204|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34098939|NCT03148782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098940|NCT05013086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098941|NCT00636974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937962|NCT01278810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794308|NCT01628237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794309|NCT04803630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794310|NCT04832542|||COHORT||PROSPECTIVE|||||||
33794311|NCT02744521|RANDOMIZED|PARALLEL||DIAGNOSTIC||||||||
33794312|NCT05921708|||OTHER||CROSS_SECTIONAL|||||||
33794313|NCT01434134|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33794314|NCT02846480|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33794315|NCT02130128|NA|SINGLE_GROUP||||NONE||||||
33794316|NCT01763892|||COHORT||PROSPECTIVE|||||||
33794317|NCT03624166|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794318|NCT04206215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794319|NCT06028984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794320|NCT01101685|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33937963|NCT03983304|NA|SINGLE_GROUP||OTHER||NONE||||||
33937964|NCT05696613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937965|NCT01172340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016691|NCT04049617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016692|NCT00794976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016693|NCT05862636|||COHORT||PROSPECTIVE|||||||
34016694|NCT01031966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016695|NCT00621049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016696|NCT01197430|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33794321|NCT05271188|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups of people who are undergoing open wedge high tibeal osteotomy aged between 40 and 60 yrs old not diabetic and neurologically free||||
33794322|NCT03103295|NA|SINGLE_GROUP||TREATMENT||NONE|Open|||||
33794323|NCT05016713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Blinding of the operator: Blinding will not be possible for the operator during the application interventions and during the follow up visits as he will be responsible for recruitment of sample, giving instruction about different hygiene measures that will be used by intervention/control group and follow up of patients collecting samples for that will be used in analysis.~Blinding of the outcome assessors: It is a single blinded study, the outcome assessors only will be blind. The patients name will be sealed from pre and post samples. Then assessor will carry on, blindly and independently, the measurements and analysis of the study."||t|f|f|t
33794324|NCT02805439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016697|NCT03285789|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016698|NCT00397306|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016699|NCT02991430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016700|NCT00197392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016701|NCT05320341|||CASE_CONTROL||PROSPECTIVE|||||||
34016702|NCT00727948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016703|NCT00593788|||CASE_ONLY||PROSPECTIVE|||||||
34098942|NCT01210209|||FAMILY_BASED||RETROSPECTIVE|||||||
34098943|NCT03412890|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Extension||||
34098944|NCT03706352|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34098945|NCT01571609|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794325|NCT06113692|||OTHER||RETROSPECTIVE|||||||
33794326|NCT05345119|||COHORT||RETROSPECTIVE|||||||
33794327|NCT01287286|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33794328|NCT04480827|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794329|NCT00176813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794330|NCT01944319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794331|NCT01097343|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33794332|NCT03691168|||COHORT||PROSPECTIVE|||||||
33794333|NCT01071733|||COHORT||PROSPECTIVE|||||||
33794334|NCT03847116|||COHORT||PROSPECTIVE|||||||
33794335|NCT00199459|||CASE_CONTROL||PROSPECTIVE|||||||
33794336|NCT02116543|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33794337|NCT00687388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794338|NCT04191265|||CASE_ONLY||PROSPECTIVE|||||||
33794339|NCT00568542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794340|NCT02441036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33794341|NCT03903900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937966|NCT00003736||||SCREENING||||||||
33937967|NCT06059521|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33937968|NCT03894306|||COHORT||PROSPECTIVE|||||||
33937969|NCT03815955|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937970|NCT04961125|||COHORT||PROSPECTIVE|||||||
33937971|NCT02171806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33937972|NCT03000764|NA|SINGLE_GROUP||OTHER||NONE||||||
33937973|NCT01899729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33937974|NCT01355094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016704|NCT00523965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016705|NCT01610739|NA|SINGLE_GROUP||OTHER||NONE||||||
34016706|NCT02579161|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34098946|NCT00624078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937975|NCT05698160|||OTHER||PROSPECTIVE|||||||
33937976|NCT03575780|NA|SINGLE_GROUP||TREATMENT||NONE||This study will test KX2-391 Ointment 1%.||||
33937977|NCT01137006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33937978|NCT04030819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33937979|NCT00004236||||TREATMENT||||||||
33937980|NCT02983695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937981|NCT03595176|NA|SINGLE_GROUP||TREATMENT||NONE||The Coronary IVL System is a proprietary balloon catheter system designed to enhance stent outcomes by enabling delivery of the calcium disrupting capability of lithotripsy prior to balloon dilatation at low pressures. The Coronary IVL System consists of an IVL Balloon Catheter with two integrated pairs of lithotripsy emitters, a Lithotripsy Generator, and Connector Cable.||||
33937982|NCT06210165|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33937983|NCT00806533|||COHORT||PROSPECTIVE|||||||
33937984|NCT06184165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Informants (caregivers)||t|t|t|t
34016707|NCT04315870|||COHORT||OTHER|||||||
34016708|NCT02775474|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794342|NCT03629730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Principal Investigator and Research Coordinators conducting participant assessments will be masked as to participant group assignment.|Three intervention dose groups and one active control group will be compared.|f|f|t|t
33794343|NCT02950896|||OTHER||PROSPECTIVE|||||||
33794344|NCT04978571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Concussion: After study completion, a designated member of the study will disclose study group. This designated member will not have direct contact with study participants during their participation.~COVID: open label"|Concussion: prospective, randomized-controlled treatment trial. COVID: prospective, open label, non-randomized-controlled treatment trial.|t|t|t|t
33794345|NCT05865379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794346|NCT03175913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33794347|NCT00779545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794348|NCT03761108|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33794349|NCT01183780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794350|NCT05612048|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients will complete a questionnaire and undergo imaging by the intra-oral camera of their teeth.||||
33794351|NCT03060642|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33794352|NCT00174317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794353|NCT05757310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794354|NCT01382030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794355|NCT02083029|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794356|NCT01039688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794357|NCT00880048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794358|NCT04219137|||COHORT||PROSPECTIVE|||||||
33794359|NCT06357910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794360|NCT05393180|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, open-label, single arm (Hybrid Convergent only) post-approval study||||
33794361|NCT05565859|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Crossover randomized control trial with two phases: a Planetary Health Plate intervention phase where signage promoting the planetary health diet was posted and a control phase with signage as usual.||||
33937985|NCT01110889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794362|NCT00617812|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33937986|NCT05277194|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants will be grouped into teams (child with autism, their teacher, and 1:1/aide) and teams will be randomized to one of the two arms. Teams (n = 10) randomized to the intervention will be given the KeepCalm application to use for 3 months. Teams randomized to the waitlist control condition (n = 10) will be given access to the app following the study's completion.||||
33937987|NCT02981238|||CASE_ONLY||PROSPECTIVE|||||||
33937988|NCT00094640||||TREATMENT||||||||
34016709|NCT05690126|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34016710|NCT04338217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016711|NCT03073395|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34016712|NCT04053465|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016713|NCT02479542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016714|NCT04453098|RANDOMIZED|PARALLEL||PREVENTION||NONE||participants receive an intervention throughout the protocol||||
33794363|NCT05977634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor and investigator that assesses the patients will be blind to the study groups||f|f|t|t
33794364|NCT02472782|||COHORT||PROSPECTIVE|||||||
33794365|NCT04743765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794366|NCT02737878|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33794367|NCT04440046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794368|NCT01692938|||CASE_ONLY||PROSPECTIVE|||||||
33794369|NCT00317226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937989|NCT00413777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794370|NCT01471392|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33794371|NCT01086917|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33794372|NCT00487305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937990|NCT04051944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937991|NCT00131131|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34016715|NCT01629966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016716|NCT05753761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34098947|NCT01515111|||||CROSS_SECTIONAL|||||||
34098948|NCT01471574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098949|NCT02382263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098950|NCT04378088|||OTHER||CROSS_SECTIONAL|||||||
34098951|NCT02656342|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34098952|NCT00635583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098953|NCT01599676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34098954|NCT03695601|||COHORT||PROSPECTIVE|||||||
34098955|NCT01398475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098956|NCT06694038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098957|NCT01766843|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34098958|NCT04640987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34098959|NCT02178189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098960|NCT03156621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34098961|NCT02239484|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34098962|NCT00676689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098963|NCT02116062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098964|NCT00609973|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34098965|NCT05417386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098966|NCT01691807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098967|NCT04738162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098968|NCT04826614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34098969|NCT04295265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34098970|NCT05236465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention group vs. waiting list control group status will be known to the participants and the personnel delivering the 3-day course. However, the investigator and outcome assessor will be masked to the conditions.|Randomized Controlled Trial, in which participants are randomly allocated to either the intervention group or to the waiting list control group.|f|f|t|t
34098971|NCT03861507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34098972|NCT05509673|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Digital analysis of wound area is masked||f|f|f|t
34098973|NCT02306785|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34098974|NCT01777529|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33937992|NCT03399331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Pain scores of the oral mucosa will be conducted twice a daily for study purposes. The patients will be assessed by their RNs for pain which is documented in the patient charts twice per day in the morign and in the evening (even in the absence of pain), the nurses will have no knowlegde of group assignment.|three groups randomized using a computer generted number sequence|f|f|t|t
34098975|NCT06471166|||COHORT||PROSPECTIVE|||||||
33937993|NCT04543565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937994|NCT05283122|NA|SINGLE_GROUP||PREVENTION||NONE||primigravida pregnant patients with placenta previa conditions||||
33937995|NCT02440828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33937996|NCT04815291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937997|NCT02655315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33937998|NCT05229575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33937999|NCT03295331|||CASE_ONLY||RETROSPECTIVE|||||||
33938000|NCT02093741|||CASE_ONLY||PROSPECTIVE|||||||
33938001|NCT02489877|||CASE_CONTROL||PROSPECTIVE|||||||
33938002|NCT00639808|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33938003|NCT00161720|||COHORT||RETROSPECTIVE|||||||
33938004|NCT04062513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938005|NCT06378164|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33938006|NCT01172054|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33938007|NCT01635387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938008|NCT00294528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938009|NCT00245635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938010|NCT04411225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be assigned by study statisticians.|This is a between-group, double blind, placebo controlled design.|t|t|t|t
33938011|NCT04102696|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, investigators, physicians, and outcomes assessors will be blinded to treatment allocation. The sticks of aromatherapy and placebo are the same, and the smell of them is similar. In order to achieve allocation concealment, a web-based central system will automatically assign a random code for each participant. Each stick of aromatherapy or placebo will be labeled according to the pre-determined random code by an independent agency that does not involve any persons associated with the trial.|Randomized (two arms), double-blind, placebo-controlled intervention is proposed in this study. 460 participants undergoing CABG for the first time are anticipated to be enrolled from the Beijing Anzhen Hospital. Before hospital discharge, participants will be randomly assigned to receive aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol) after CABG for 6 months.|t|t|t|t
34098976|NCT01052428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34098977|NCT03854981|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34098978|NCT03256656|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||||||||
34098979|NCT03666793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34098980|NCT05990738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34098981|NCT02636036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098982|NCT04835428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study subjects will not be informed of their treatment group assignment at the time of randomization or at any time before the subject's last office visit. The blind will be broken only if it is necessary to protect the safety or welfare of the subject as determined by the Investigator.|Four hundred eight (408) eligible subjects at up to twenty-five (25) study sites will be randomized 1:1 for treatment using the AGN1 LOEP SV Kit (Intervention Group) or PMMA bone cement (Active Control Group).|t|f|f|f
34098983|NCT00850187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098984|NCT06069271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor was blinded to group assignment|Randomized Control Trial|f|f|f|t
34098985|NCT03728231|||CASE_CONTROL||OTHER|||||||
34098986|NCT00490412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34098987|NCT01423890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016717|NCT03095118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016718|NCT01764230|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016719|NCT01466452|RANDOMIZED|PARALLEL||||NONE||||||
33794373|NCT03861767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794374|NCT05062577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794375|NCT05871346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34016720|NCT01602965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016721|NCT02278419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016722|NCT04957420|||COHORT||PROSPECTIVE|||||||
34098988|NCT04169659|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||Prospective Rondomized Open Blinded End Point|t|f|f|f
33794376|NCT06643507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016723|NCT02991170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016724|NCT01763749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016725|NCT03293381|||COHORT||PROSPECTIVE|||||||
34016726|NCT00798187|||CASE_CONTROL||RETROSPECTIVE|||||||
34016727|NCT01077466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794377|NCT03213249|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34016728|NCT00001026||||PREVENTION||DOUBLE||||||
34016729|NCT01962181|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34016730|NCT03557528|||CASE_CONTROL||RETROSPECTIVE|||||||
34016731|NCT03278002|||OTHER||PROSPECTIVE|||||||
33794378|NCT06656715|||COHORT||PROSPECTIVE|||||||
34016732|NCT04834843|||COHORT||RETROSPECTIVE|||||||
34016733|NCT00212576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34098989|NCT00983957|NA|SINGLE_GROUP||||NONE||||||
33794379|NCT04940117|NA|SINGLE_GROUP||TREATMENT||NONE|Patients with renal failure with Eefooton oral solution for six months and blood test to check the changes in eGFR values|Chronic Kidney Disease before dialysis||||
34098990|NCT05023889|NA|SINGLE_GROUP||TREATMENT||NONE||This protocol is a single center pilot study designed to evaluate the efficacy and safety of patisiran in adult patients with wtATTR amyloidosis and symptomatic polyneuropathy as assessed with Neuropathy Impairment Score (NIS).||||
34098991|NCT03313765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34098992|NCT06663293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"50 patients aged 1-14 years in the pediatric burn unit were divided into two groups as Group HFO: High flow oxygen (n: 25) and Group NC: nasal cannula oxygen (n: 25).~The high flow group received nasal high flow therapy delivered by AIRVO™ 2 (Fisher and Paykel Healthcare Systems, New Zealand) along with single-use nasal oxygen cannulas. The HFNCO device was set to a temperature of 36°C and an FiO2 of 0.4. The initial oxygen flow rate for the high flow group was determined according to the age and weight of the patients, based on our pediatric intensive care team's guidelines and the reference from the Slain NK (10) study. When SpO2 fell below 94%, it was considered hypoxia, and the flow rate was increased by 2 to 4 L/min.~For the low flow group, the initial flow rate for nasal cannula oxygen was set at 3 L/min. In cases of hypoxia, the oxygen concentration was adjusted by increasing the flow rate by 1 to 2 L/min."|t|f|t|f
34098993|NCT02321150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34098994|NCT05371223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098995|NCT01720602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794380|NCT05702996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794381|NCT06629155|||COHORT||CROSS_SECTIONAL|||||||
33794382|NCT01948999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34098996|NCT03951415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34098997|NCT01167712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794383|NCT04131114|||COHORT||PROSPECTIVE|||||||
33794384|NCT05617378|||OTHER||CROSS_SECTIONAL|||||||
33794385|NCT02537769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016734|NCT03854786|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34016735|NCT03703648|||COHORT||PROSPECTIVE|||||||
34016736|NCT04866849|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016737|NCT03145402|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016738|NCT05963191|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33794386|NCT02346006|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33794387|NCT03760419|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Effectiveness of the EHR-based antibiotic decision support application for promoting guideline-concordant antibiotic prescribing in children presenting for emergency care will be evaluated in a pragmatic, cluster-randomized study conducted over a period of 18 months that includes two respiratory seasons. Randomization will occur monthly at each hospital. To ensure balanced representation of each arm in periods of both low and high pneumonia prevalence, randomization will occur in 3 permuted blocks (size=6).||||
33794388|NCT05847842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794389|NCT01491399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794390|NCT00793754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794391|NCT00396851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794392|NCT03580798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016739|NCT01700166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016740|NCT00003144||||SUPPORTIVE_CARE||||||||
34016741|NCT04190030|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016742|NCT04238832|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the staff nor the participants will be told whether the e-liquid is free base or salt based.||t|f|t|f
34016743|NCT00435565|||DEFINED_POPULATION||PROSPECTIVE|||||||
34016744|NCT00467636|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794393|NCT04433429|||CASE_ONLY||PROSPECTIVE|||||||
33794394|NCT06676423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794395|NCT03311113|||COHORT||PROSPECTIVE|||||||
33794396|NCT02008019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016745|NCT05054322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016746|NCT00094237|||COHORT||PROSPECTIVE|||||||
34016747|NCT01651143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016748|NCT00713999|NA|SINGLE_GROUP||||NONE||||||
34016749|NCT04957836|||COHORT||RETROSPECTIVE|||||||
34016750|NCT03380533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|t|t|f
34098998|NCT02763748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34098999|NCT05409612|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099000|NCT04981756|||COHORT||RETROSPECTIVE|||||||
33794397|NCT02052375|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34099001|NCT06139796|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, multi-centre, single-arm, phase I/II study||||
34099002|NCT02256878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099003|NCT04662632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to their randomization arm assignment until the completion of Stage 1 surgery.||t|f|f|f
34099004|NCT04213339|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinded||t|f|f|f
34099005|NCT04530695|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099006|NCT02282033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099007|NCT02816970|RANDOMIZED|CROSSOVER||||NONE||||||
33794398|NCT05739474|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34099008|NCT05343507|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|One investigator not involved in the data acquisition and analysis, and the pharmacist who will prepare the syringe for the TCI will not be blind.|Double-blind, placebo-controlled, cross-over RCT|t|f|t|t
33794399|NCT01393353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099009|NCT04918628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794400|NCT05211544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"three group~1. exercise group~2. exercise and kinesiotape~3. exercise and physical therapy modalities"||||
33794401|NCT06466564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794402|NCT03139084|||OTHER||PROSPECTIVE|||||||
33794403|NCT01056835|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794404|NCT03949348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients who undergo a transobturator sling placement using autologous rectus fascia|f|f|f|t
33794405|NCT06554093|RANDOMIZED|PARALLEL||TREATMENT||NONE||"• Experimental arm: PathKeeper System (PKS) One to ten-level posterior, open, instrumented spine surgery using unilateral or bilateral pedicle screw instrumentation under PKS intraoperative navigation guidance.~Intervention: Medical Device - PKS. The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.~• Control arm: Standard of care - free-hand technique guided by intra-operative 2D Fluoroscopy One to ten-level posterior, open, instrumented spine surgery using unilateral or bilateral pedicle screw instrumentation under free-hand technique guided by intra-operative 2D fluoroscopy."||||
33794406|NCT06243588|||COHORT||RETROSPECTIVE|||||||
34099010|NCT03686111|||COHORT||PROSPECTIVE|||||||
33794407|NCT05831202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794408|NCT02914951|NA|SINGLE_GROUP||TREATMENT||NONE||Behavior therapy for irritability and disruptive behavior for children with autism and intellectual disability||||
34099011|NCT06493071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible participants who consent to study participation will be randomized to one of two groups: active taVNS, or sham taVNS. Each group will undergo 30 days of the respective treatment.|t|f|f|f
33794409|NCT05221736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794410|NCT04275778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Hydroxychloroquine and placebo will be provided by AGEPS which outsources these drugs fabrication. The AGEPS outsources operations which are technically non-feasible locally, or if the volume or logistical constraints are inconsistent with the balance of its human and material resources."|"Group 1 : Hydroxychloroquine Group 2 : Placebo d'hydroxychloroquine Hydroxychloroquine or placebo will be performed at 2 pills (400 mg) per day, during the pregnancy, and stopped at delivery.~The conventional treatment will be the same in the 2 groups:~* aspirin 100 mg/day will begin , the preference at the preconception, and continued during pregnancy and will be stopped at 35 weeks of gestation.~LMWH enoxaparin 4000 UI/day will begin as soon as possible after confirmation of the pregnancy, and will be continued during 6 weeks postpartum."|t|f|t|f
33794411|NCT04877834|RANDOMIZED|CROSSOVER||OTHER||NONE||A single center, open-label, randomized, single-dose, two-period, two-way, cross-over study.||||
33794412|NCT01738308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794413|NCT03292315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794414|NCT01182116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794415|NCT01811108|||COHORT|||||||||
33794416|NCT00717626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794417|NCT02890368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794418|NCT00891176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794419|NCT02296619|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33794420|NCT04998318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794421|NCT01932450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099012|NCT04583826|NA|SINGLE_GROUP||OTHER||NONE||||||
34099013|NCT00106535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099014|NCT00610038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099015|NCT01401205|||CASE_ONLY||PROSPECTIVE|||||||
34099016|NCT03080714|||COHORT||PROSPECTIVE|||||||
34099017|NCT01466231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099018|NCT05265637|||COHORT||PROSPECTIVE|||||||
34099019|NCT02102386|||CASE_ONLY||PROSPECTIVE|||||||
34099020|NCT02884960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099021|NCT03765021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Method of randomization: using closed envelopes containing cards with fractional CO2 Rt and fractional CO2 Lt and the patient will draw one of them blindly.||t|f|t|f
34099022|NCT00777673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099023|NCT06108336|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cerebellar and Occipital stimulation groups will be tested under sequence-demanding and non-sequence demanding tasks (in counterbalanced order)||||
34099024|NCT05812599|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33794422|NCT00644709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794423|NCT02251080|||COHORT||PROSPECTIVE|||||||
33794424|NCT00154648|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33794425|NCT05211063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33794426|NCT03493269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind|t|t|t|t
33794427|NCT00002632||||TREATMENT||||||||
33794428|NCT00003292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794429|NCT06226714|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794430|NCT00958386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794431|NCT05785988|||COHORT||RETROSPECTIVE|||||||
33794432|NCT03646279|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-subject A-B design||||
33794433|NCT01424969|||COHORT||PROSPECTIVE|||||||
33794434|NCT01511172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794435|NCT04683718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794436|NCT02961179|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33794437|NCT00711958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794438|NCT00323752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794439|NCT03837028|||COHORT||PROSPECTIVE|||||||
33794440|NCT05790928|||COHORT||RETROSPECTIVE|||||||
33794441|NCT06257693|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33794442|NCT00057837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099025|NCT00032331|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794443|NCT06518798|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33794444|NCT01595854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794445|NCT01811407|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794446|NCT04320186|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||two groups design with approximately equal allocation, but assignment based on respondent drive sampling||||
33794447|NCT00074568|||CASE_CONTROL||PROSPECTIVE|||||||
33794448|NCT06223113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794449|NCT01490086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794450|NCT04260750|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Factor one: Regular therapist support by a therapist/On-demand guidance by a health care team (the participants themselves can choose to contact a physician, a nurse, a clinical psychologist, an IT-technician and/or the principal investigator of the study).~Factor two: The content (the modules) is chosen by the participants themselves/The content is chosen by the therapist conducting the intake interview."||||
33794451|NCT03902236|||CASE_CONTROL||PROSPECTIVE|||||||
33794452|NCT04288219|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|No masking will be done, as the CPAP device will be visible to both participants and investigators|||||
33794453|NCT03726268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016751|NCT03531190|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized to intervention. Control is the present treatment in the department + protein supplementation||||
34016752|NCT02420418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016753|NCT01463436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025426|NCT04974203|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Outcome assessors are blinded to the PCR test result|Patients who undertake PCR test are asked to provide saliva sample|f|f|f|t
34025427|NCT04484259|RANDOMIZED|PARALLEL||TREATMENT||NONE|Staff performing PK/PD assessments will remain blinded to treatment assignment.|Prospective randomized||||
34025428|NCT00183911|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794454|NCT03062137|||CASE_ONLY||PROSPECTIVE|||||||
33794455|NCT04771234|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Pragmatic, within-group pilot study||||
33794456|NCT06677320|||CASE_ONLY||PROSPECTIVE|||||||
33794457|NCT04372394|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Subjects will be randomly assigned to 1 of the 2 possible treatment sequences as follows:~* Fed/Fasted: surufatinib with food on Day 1 and surufatinib without food on Day 8~* Fasting/Fed: surufatinib without food on Day 1 and surufatinib with food on Day 8"||||
33794458|NCT01500954|||CASE_CONTROL||PROSPECTIVE|||||||
33794459|NCT02965248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794460|NCT04244604|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The experimenter will be blinded to what sodium condition the participant is in, and all data analysis will be conducted blinded to the condition as well.|The intervention is to provide subjects with either a low sodium meal (140 mg sodium) and a high sodium meal (2500 mg sodium), in a randomized order.|f|f|t|f
33794461|NCT06201819|NA|SINGLE_GROUP||TREATMENT||NONE||quasi-experimental prospective before-and-after study.||||
33794462|NCT00572078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794463|NCT04485156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794464|NCT03983889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794465|NCT02171104|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794466|NCT02253719|||COHORT||PROSPECTIVE|||||||
33794467|NCT01830946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794468|NCT06249204|RANDOMIZED|PARALLEL||OTHER||NONE||The study design is a cluster, randomized, no blinded, controlled study.||||
33938012|NCT04979338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938013|NCT01889615|||COHORT||PROSPECTIVE|||||||
33938014|NCT05261594|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind|"The study entails two sessions and uses a crossover design. Participants will be randomized to start with either the caffeine condition or the placebo condition. Participants will complete the second session with the other condition (the condition not allocated to in session 1).~The study includes two arms: (a) participants with Panic disorder (estimated n=50; actual n=30) and (b) healthy controls (estimated n=50; actual n=53). Both arms (Panic disorder and healthy controls) will complete both conditions (caffeine and placebo condition) in randomized order."|t|f|t|f
33938015|NCT03504384|||OTHER||PROSPECTIVE|||||||
33938016|NCT04404244|||CASE_ONLY||PROSPECTIVE|||||||
33938017|NCT06336694|||COHORT||RETROSPECTIVE|||||||
34025429|NCT04546880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099026|NCT01353885|||COHORT||PROSPECTIVE|||||||
34099027|NCT05683080|||COHORT||PROSPECTIVE|||||||
33794469|NCT03476070|||COHORT||PROSPECTIVE|||||||
33794470|NCT00001384||||TREATMENT||||||||
33794471|NCT04414098|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental, open-label, prospective, single center, add-on (added to the standard treatment) study, compared with an historical control arm.||||
34099028|NCT02294019||||||NONE||||||
34016754|NCT04298645|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|"Masking to the study arm is not possible for participants since the study involves consumption of real food to which the participants cannot be blinded. Similarly, the researchers cannot be blinded to the food provided to the participants."|"60 participants will be invited of which 20 participants with an earlier and 20 participants with a later chronotype are expected to finish the study. Participants will consume a meal rich in carbohydrates with a high GI on two separate days at different times. Hence, participants are randomly assigned to one group stratified by chronotype: intake of a meal with a high GI on day 5 either in the morning or in the evening. On day 7, meal timing of the high GI meal is switched. Following a 3 - day observational part on free days, the controlled nutrition trial will last 4 days: run - in (day 4), high GI meal for breakfast/dinner (days 5 / 7), and wash - out (day 6). The trial is a two-arm cross-over study in which each participant serves as his / her own control to account for inter-individual variations in diurnal glycaemic responses."||||
34016755|NCT02702713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016756|NCT04524052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016757|NCT02654171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016758|NCT06292884|||CASE_CONTROL||PROSPECTIVE|||||||
34016759|NCT02416024|||COHORT||PROSPECTIVE|||||||
34016760|NCT06074484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016761|NCT02728752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025430|NCT04635527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099029|NCT05358782|||CASE_CONTROL||RETROSPECTIVE|||||||
34025431|NCT02810379|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34099030|NCT06384703|||CASE_CONTROL||PROSPECTIVE|||||||
34099031|NCT06092957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099032|NCT02697929|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938018|NCT00000756||||TREATMENT||NONE||||||
34099033|NCT03318419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099034|NCT03204747|||COHORT||PROSPECTIVE|||||||
34099035|NCT05761483|||COHORT||PROSPECTIVE|||||||
34099036|NCT01639976|||COHORT||PROSPECTIVE|||||||
34099037|NCT06249477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099038|NCT03932383|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study of intervention||||
34099039|NCT04250974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099040|NCT00974233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099041|NCT04926493|||OTHER||RETROSPECTIVE|||||||
34099042|NCT05296655|||CASE_ONLY||PROSPECTIVE|||||||
33938019|NCT02062099|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938020|NCT01796106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33938021|NCT01392040|||COHORT||PROSPECTIVE|||||||
33938022|NCT04914806|||CASE_CONTROL||PROSPECTIVE|||||||
33938023|NCT02084472|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33938024|NCT04995666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938025|NCT04202029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"The participants will be randomely assigend by a computer based algorithm to either the standard monitoring group as defined by the German S3 guidline Sedierung in der gastrointestinalen Endoskopie containing pulsoxymetry and non-invasive blood preassure monitoring versus the standard and additionally the thoracic impedance monitoring using an extra ECG"|t|f|f|f
33938026|NCT02139176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938027|NCT03381612|||OTHER||CROSS_SECTIONAL|||||||
33938028|NCT06360510|||OTHER||PROSPECTIVE|||||||
33938029|NCT04653558|||COHORT||RETROSPECTIVE|||||||
33938030|NCT01007318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938031|NCT00886587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33938032|NCT04035473|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938033|NCT03410602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938034|NCT01906814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938035|NCT04972890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938036|NCT04525911|||COHORT||PROSPECTIVE|||||||
33938037|NCT05439629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938038|NCT00250094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938039|NCT05569356|||COHORT||PROSPECTIVE|||||||
33938040|NCT03155776|||CASE_ONLY||PROSPECTIVE|||||||
33938041|NCT01097733|||COHORT||PROSPECTIVE|||||||
33938042|NCT00827112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938043|NCT03592134|||CASE_CONTROL||PROSPECTIVE|||||||
33938044|NCT02251366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33938045|NCT00811395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025432|NCT04492657|||OTHER||CROSS_SECTIONAL|||||||
34099043|NCT05359757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099044|NCT04997421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099045|NCT04555733|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34099046|NCT01242046|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34099047|NCT02111980|NA|SINGLE_GROUP||OTHER||NONE||||||
34099048|NCT01857115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099049|NCT05362136|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34099050|NCT03683498|NA|SEQUENTIAL||TREATMENT||NONE||Initial enrollment will be at Dose-level A. Subsequent cohorts will be dose escalated.||||
34099051|NCT04449978|||COHORT||PROSPECTIVE|||||||
34099052|NCT01881633|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34099053|NCT01953276|||COHORT||PROSPECTIVE|||||||
34099054|NCT01558414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099055|NCT02923622|||COHORT||PROSPECTIVE|||||||
34099056|NCT02187081|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099057|NCT04773977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099058|NCT01336972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099059|NCT06309329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34099060|NCT05553288|||OTHER||PROSPECTIVE|||||||
34099061|NCT01708746|||CASE_CONTROL||PROSPECTIVE|||||||
34099062|NCT04642066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016762|NCT05965531|NA|SINGLE_GROUP||TREATMENT||NONE||This study adopts the Simon's optimal two-stage design and uses the objective response rate (ORR) as the primary endpoint. The first stage will enroll 19 eligible patients. If the observed ORR \> 70%, the study will enter the second stage and continue to enroll 40 eligible patients. The final sample size is 65 when a drop-out rate of 10% is considered.||||
34016763|NCT05387707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Part A includes 4 arms and Part B includes 2 arms.|t|f|t|f
34016764|NCT03195777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigators who are analyzing images will be blinded to all clinical data, including clinical follow-up data to determine PTS|This study is a one-center observational study examining DVT with FDG- PET/CT. 80 individuals with DVT will be imaged with PET/CT and followed for development of PTS||||
34016765|NCT00642694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016766|NCT03562741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016767|NCT00555035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34016768|NCT02622451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016769|NCT00002922||||TREATMENT||||||||
34016770|NCT00816361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016771|NCT03936673|NA|SINGLE_GROUP||TREATMENT||NONE||Patients diagnosed with unilateral obstructed kidney with RRF 10% or less underwent application of percutaneous nephrostomy tube on affected side.||||
34016772|NCT01744093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016773|NCT05966220|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34016774|NCT03819621|NA|SINGLE_GROUP||OTHER||NONE|Non-masked study.|Pilot study to evaluate the mediGrid App against the gold standard rule as a measuring device.||||
34016775|NCT03120533|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34016776|NCT01785121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34016777|NCT06136637|||COHORT||PROSPECTIVE|||||||
34016778|NCT03776253|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016779|NCT04971265|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not know that there are 3 other scenarios within the Family Supports and Beliefs survey.|Participants are randomized to see one of four scenarios at the start of the study, while taking the Family Supports and Beliefs Survey \[#1: LowSES, High Societal Supports; #2, Low SES, Low Societal Supports; #3 High SES, High Societal Supports; or #4 High SES, Low Societal Supports\]|t|f|f|f
34016780|NCT00343239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016781|NCT03265366|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34099063|NCT00930176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099064|NCT02182453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099065|NCT03272165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are randomized to one of two groups within a cohort of 8 participants (N=6 MEDI1341; N=2 placebo)|t|t|t|t
34016782|NCT05741541|||OTHER||PROSPECTIVE|||||||
34016783|NCT04003584|||COHORT||RETROSPECTIVE|||||||
34099066|NCT01807104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099067|NCT00083109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099068|NCT03636269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016784|NCT00363753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099069|NCT03255590|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016785|NCT02983136|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34016786|NCT00251225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016787|NCT02583893|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016788|NCT02928133|||COHORT||PROSPECTIVE|||||||
34016789|NCT01036490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016790|NCT03003273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099070|NCT02968875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099071|NCT01852214|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34099072|NCT05004168|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099073|NCT01148420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099074|NCT02454764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099075|NCT02609451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099076|NCT01905267|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34099077|NCT05936853|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"It will not be possible to mask the participant's anaesthetist for the case, or the member of the research team. The participant, their Legal Representatives, and the members of the investigation team that are not present for the case, will all remain blinded for the duration of the trial.~To ensure blinding to arm allocation at the time of outcome analysis/assessment, each participant will also be given a separate 'unique sample identifier code' directly linked to their 'unique participant ID'. This link will not be known by members of the research team."|Participants will be randomised to receive maintenance of anaesthesia through either an intravenous approach (TIVA) or inhalational approach (using volatile agents). As is routine anaesthetic practice for this age-group, a gas/inhalational induction will be performed for all participants. After induction a baseline sample of blood will be taken. For participants in the inhalational maintenance group the volatile-based anaesthetic agent (in an air and oxygen mixture) will be continued after induction for the duration of the case. For participants in the TIVA maintenance group, once induction of anaesthesia has been successfully completed, at the earliest appropriate opportunity, the volatile-based anaesthetic will be switched to TIVA which will then be continued for the duration of the case. After the surgical procedure has been completed, and prior to emergence from general anaesthesia, a further blood sample will be taken for analysis.|t|f|f|t
34099078|NCT03093870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Treatment: protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition|t|f|t|f
34016791|NCT05627167|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016792|NCT03250676|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016793|NCT03795896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking|prospective observational study||||
34016794|NCT02996045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
34016795|NCT06224322|||COHORT||PROSPECTIVE|||||||
34016796|NCT00003851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016797|NCT00033813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016798|NCT01398943|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34016799|NCT05259878|||COHORT||PROSPECTIVE|||||||
34025433|NCT02365116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794472|NCT06676605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this double-blind study, rigorous masking procedures were implemented to ensure the integrity of the results. None of the participants knew or met each other, and they had no prior information about the researcher conducting the study. Participants were instructed not to discuss their experiences, feelings, or outcomes with each other throughout the study duration. Furthermore, the researchers who processed the data were blinded to the participants' identities; they only analyzed the biochemical and anthropometric parameters without knowing which patient each set of data belonged to or any personal background information. This ensured that the analysis remained unbiased and confidential.|This clinical trial was a double-blind, randomized, placebo-controlled study conducted in the Nutrition department with the Clinical Analysis Laboratory at University of Monterrey. It aimed to evaluate ashwagandha's effect on serum lipid concentrations and body composition in Mexican adults with overweight and obesity. Eligible participants were adults with a BMI of 25 kg/m\^2 or higher, glucose levels around 100 mg/dL, LDL-C levels of 160 mg/dL or higher, total cholesterol levels of 200 mg/dL or higher, HDL-C levels lower than 40 mg/dL, and triglyceride levels exceeding 150 mg/dL. Participants provided informed consent per NOM-012-SSA3-2012 guidelines. They followed a prescribed dietary plan including 500 mg daily ashwagandha (Withania somnifera), authorized for use by the FDA. The supplementation period lasted 40 days. Participants were randomly assigned to the intervention group (W. somnifera, n=17) or placebo group (starch rice capsule/tablet, n=17).|t|f|t|t
33794473|NCT02847117|NA|SINGLE_GROUP||OTHER||NONE||||||
33794474|NCT01511471|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33794475|NCT04920032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794476|NCT02947217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794477|NCT00988637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794478|NCT06227468|||OTHER||PROSPECTIVE|||||||
33794479|NCT01641172|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33794480|NCT00346593|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33794481|NCT03393377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794482|NCT00475501|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33794483|NCT01063517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794484|NCT01965119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794485|NCT06404710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled (experimental and control group)|t|f|f|f
33794486|NCT06510348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33794487|NCT04703920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794488|NCT06466980|||COHORT||OTHER|||||||
33794489|NCT01441934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794490|NCT04490369|||COHORT||PROSPECTIVE|||||||
33794491|NCT06554886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794492|NCT03624413|RANDOMIZED|PARALLEL||OTHER||NONE||A pilot randomized controlled trial with 40 adolescents receiving a social media intervention and 40 adolescents receiving standard of care.||||
33794493|NCT03118804|||COHORT||PROSPECTIVE|||||||
33794494|NCT02421081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794495|NCT00570219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794496|NCT04243304|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Longitudinal study design (2 years follow up) where results of SV2A PET/CT, PE2I PET/MR and clinical rating scales are compared between PD patients and healthy controls.||||
33794497|NCT01807663|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794498|NCT05799261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients in supportive periodontal therapy will be treated according to standard protocols of the Department of Periodontology. The test group patient will undergo treatment by the concept of Guided Biofilm Management consisting of removal of soft supra- and subgingival bacterial deposits by means of erythritol powder air-polishing, followed by the local precise removal of hard deposits and a subsequent use of another sub- and supragingival erythritol powder air-polishing. The study duration will be 3 years.|f|f|f|t
33794499|NCT06675968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794500|NCT02249988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794501|NCT01241435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794502|NCT04305574|||COHORT||CROSS_SECTIONAL|||||||
33794503|NCT03276104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of research optometrists to group affiliation at the postoperative examinations will be endeavored. A physician will perform slit lamp examinations at the postoperative visits, hence he/she cannot be masked, nor can the surgeon. The investigator will be masked during the image analysis.|Randomized clinical trial|f|f|f|t
33794504|NCT02009839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33794505|NCT05857267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794506|NCT02834884|||COHORT||PROSPECTIVE|||||||
33794507|NCT01430858|NA|SINGLE_GROUP||OTHER||NONE||||||
33794508|NCT03521037|NA|SINGLE_GROUP||OTHER||NONE||||||
33794509|NCT01787240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794510|NCT05076435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794511|NCT04655131|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33794512|NCT02602106|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794513|NCT03618849|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dosage-escalation study||||
34016800|NCT02929446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The interventions were not possible to mask for patients or healthcare professionals at the recovery unit. The research nurses and the physiotherapists, who performed the postoperative spirometry, were blinded to the group randomization. All data were coded, and group assignment was blinded for outcome analyses|Randomized controlled trial|f|f|t|t
34016801|NCT04190849|||COHORT||PROSPECTIVE|||||||
34016802|NCT00386126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34016803|NCT03181698|||CASE_CONTROL||PROSPECTIVE|||||||
34016804|NCT02914093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025434|NCT04482673|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025435|NCT01279720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025436|NCT03957070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025437|NCT04880473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025438|NCT06354452|||COHORT||OTHER|||||||
34025439|NCT04279236|||COHORT||PROSPECTIVE|||||||
34016805|NCT04646486|NA|SINGLE_GROUP||TREATMENT||NONE|Videos from baseline period and intervention period will be mixed and assessed at the end of the study. The raters will be blinded to which period the video originates from|"Data - videos of team performance - will be included as follows:~Year 1) Baseline. Video inclusion, before introducing real-life video debriefings of team performance (n=200).~Year 2) During the start-up of the debriefings (n=20) which will be evaluated in a feasibility study.~Year 2-3) Intervention. After real-life video debriefings have been introduced as standard procedure (n=200)."||||
34016806|NCT05372133|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34016807|NCT06141161|||COHORT||PROSPECTIVE|||||||
34016808|NCT05568693|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34016809|NCT01870245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016810|NCT03340064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016811|NCT03560349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34016812|NCT02161120|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34016813|NCT02681146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016814|NCT00131872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016815|NCT06051565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016816|NCT00771082|||CASE_CONTROL||RETROSPECTIVE|||||||
34016817|NCT01459055|||COHORT||PROSPECTIVE|||||||
34016818|NCT00735917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016819|NCT05079386|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34016820|NCT01547364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016821|NCT03242460|NA|SINGLE_GROUP||TREATMENT||NONE||the transplant-ineligible patients with Relapsed and/or refractorY multiple myeloma (MM) who had lenalidomide+dexamethasone (LD) following frontline bortezomib combined chemotherapy||||
34016822|NCT00072020|RANDOMIZED|||TREATMENT||NONE||||||
34025440|NCT00912613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099079|NCT06466772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Consolidation arm: hyper-personalized feedback-based motor rehabilitation with targeted auditory stimulation during sleep (HPF intervention, TASS intervention)|t|t|t|t
34099080|NCT04088357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099081|NCT01113814||||DIAGNOSTIC||||||||
33714266|NCT03107754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"A statistician not involved with the conduct of the study will use a computer random number generator to generate random permuted blocks. This statistician will place allocation assignment cards in sequentially numbered, sealed, opaque envelopes. A different randomization scheme will be used for each location, one at the Kapi'olani office and one at the Queen's office.~A clinic staff member not involved with the conduct of the study will be trained specifically in the opening of the allocation envelopes. The staff member will be trained to open the envelope and remove the study card to read the allocation group: buffered lidocaine or plain lidocaine. The clinic staff member will then prepare the buffered lidocaine or plain lidocaine in an unlabeled syringe, and place it on the surgical tray."|Randomized controlled trial|t|t|t|t
34025441|NCT03597464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099082|NCT03808909|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099083|NCT00713180|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34099084|NCT03664778|||OTHER||PROSPECTIVE|||||||
34099085|NCT04351893|||CASE_ONLY||PROSPECTIVE|||||||
34099086|NCT04920825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34099087|NCT02334254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099088|NCT00797901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34099089|NCT04242654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099090|NCT03780322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34099091|NCT05112068|||COHORT||PROSPECTIVE|||||||
34099092|NCT02232321|NA|SINGLE_GROUP||OTHER||NONE||||||
34099093|NCT00463775|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34099094|NCT01362530|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34099095|NCT00485849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099096|NCT03733483|NA|SINGLE_GROUP||OTHER||NONE||Subjects are their own controls, with baseline measurements serving as the control values prior to intervention.||||
34099097|NCT05922098|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34099098|NCT01009242|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34099099|NCT04980794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blind to condition assignments during their involvement in the program.|Participants are randomly assigned to one of two conditions.|t|f|f|f
34099100|NCT04348578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099101|NCT04167436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the interventions neither participant, care provider or investigator is blinded. Outcome assessor of primary outcomes are blinded.|Randomized Clinical Trial with an intervention arm and a standard of care arm.|f|f|f|t
34099102|NCT02452658|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099103|NCT01894360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099104|NCT02541201|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34099105|NCT01439334|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34099106|NCT01878916|||COHORT||PROSPECTIVE|||||||
34099107|NCT01593358|||CASE_ONLY||RETROSPECTIVE|||||||
34099108|NCT04727827|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This will be a prospective, pre/post interventional, single arm study||||
34099109|NCT03053999|||CASE_CONTROL||RETROSPECTIVE|||||||
33794514|NCT00551876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016823|NCT05387174|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As blinding is an unavoidable condition in this type of study, the surveyors in the data collection will not have knowledge about the experimental group and comparison group, so they will be given as group A and B, both at the beginning and at the end of the study in the pre- and post-tests, with the aim of preventing certain biases in some of the stages of the trial and thus protect the sequence after the allocation for convenience.|Parallel: participants are assigned to one of two or more groups in parallel for the duration of the study.|f|t|f|f
34016824|NCT05533398|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34016825|NCT05090228|||COHORT||PROSPECTIVE|||||||
34016826|NCT01296659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016827|NCT02158312|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34016828|NCT00406042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34016829|NCT03075319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016830|NCT02121275|||CASE_ONLY||PROSPECTIVE|||||||
34016831|NCT02302521|||CASE_CONTROL||PROSPECTIVE|||||||
34016832|NCT05717504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016833|NCT05565339|||OTHER||RETROSPECTIVE|||||||
34016834|NCT01350843|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34016835|NCT06290518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Triple (Participant, Care Provider, Investigator) Only one person of the collaborator that provides the capsules (Biosearch Life) know the correspondecs between each reference (one reference per each subject) and the arm (probiotic or placebo). The codes are blinded for the participant, the care provider and the investigator.|Parallel Assignment Volunteers are classified into 2 groups. All women in the probiotic group consume (oral route) a daily capsule with \~50 mg of freeze-dried probiotic (9.5 log10 CFU of L. salivarius CECT5713; excipient: maltodextrin). All women in the placebo group consume (oral route) a daily capsule with \~50 mg of maltodextrin.|t|t|t|f
34016836|NCT01019473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016837|NCT06024083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016838|NCT01649271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099110|NCT04359706|||COHORT||PROSPECTIVE|||||||
34099111|NCT03401580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34099112|NCT05051358|||COHORT||RETROSPECTIVE|||||||
34099113|NCT03368521|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34099114|NCT06262997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researcher who will do the pilates training and taping and the other researcher who will do the pre-test and post-test are blinded.|One group will receive only pilates training. Other group participants will receive kinesiobant application in addition to pilates training.|f|f|t|t
33794515|NCT02212522|||CASE_CONTROL|||||||||
34016839|NCT02015689|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34016840|NCT04555681|||COHORT||PROSPECTIVE|||||||
34016841|NCT01388166|||COHORT||PROSPECTIVE|||||||
34099115|NCT03279068|||COHORT||PROSPECTIVE|||||||
34099116|NCT00625729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099117|NCT04456270|||COHORT||PROSPECTIVE|||||||
34099118|NCT01197677|||CASE_ONLY||PROSPECTIVE|||||||
34099119|NCT00002482||||TREATMENT||||||||
34099120|NCT03342794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099121|NCT04459637|||COHORT||PROSPECTIVE|||||||
34099122|NCT00618566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099123|NCT04617938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099124|NCT03511066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794516|NCT05390736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794517|NCT00776451|||CASE_CONTROL||PROSPECTIVE|||||||
33794518|NCT04313543|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33794519|NCT05509842|NA|SINGLE_GROUP||OTHER||NONE||The proposed study is for an open-label trial in which participants will undergo up to 11 separate sessions, including a 6-day noninvasive brain stimulation intervention and basic neurological testing, neuroimaging, gait assessment, and cognitive/motor testing over a period of 4-6 weeks.||||
33794520|NCT05283616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794521|NCT03400124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099125|NCT06480812|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomised Controlled||||
34103390|NCT05287685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Teachers rating behavior and independent coders assessing parent-child interactions will be masked to condition.||f|f|f|t
34103391|NCT06017115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Each patient will be randomly allocated in one of the two groups: test group (n=36) or control group (n=12)|t|f|f|t
33794522|NCT01285830|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794523|NCT04642794|||OTHER||PROSPECTIVE|||||||
34103392|NCT05295953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant will not know whether they receive active or sham TMS|Active group and sham group|t|t|f|f
33714267|NCT02228629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794524|NCT04333758|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective open label study.||||
33794525|NCT05426057|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794526|NCT05996588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794527|NCT05339477|||COHORT||PROSPECTIVE|||||||
34016842|NCT04163978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Investigators, and Assessors/Adjudicators will be blinded to assignment. One unblinded research coordinator at the site to complete the initial and interim dose administration and IMP reconciliation.|Prospective double-blind, randomized, controlled, parallel group|t|t|t|t
33794528|NCT04030767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Single blinded:~Blinding of the participants is not applicable. Blinding of the operator is not applicable. Outcome assessor (primary and secondary outcomes) \& biostatistician will be blinded."|Randomized Controlled Clinical Trial: Parallel group, two arm, non-inferiority trial with 1:1 allocation ratio.|f|f|t|f
33794529|NCT01080872|||CASE_CONTROL||PROSPECTIVE|||||||
33794530|NCT01964469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794531|NCT03426839|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients will be randomly assigned to each of two treatment groups using sealed envelopes:~* Patient group 1: haemostasis strategy guided by conventional coagulation tests.~* Patient group 2: transfusion algorithm guided by viscoelastic POC tests and algorithms."||||
33794532|NCT05686434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016843|NCT02890836|||COHORT||PROSPECTIVE|||||||
34016844|NCT00431275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016845|NCT05342415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The pre-and-post measurements will be performed by researchers who do not know the group allocation.||f|f|f|t
34016846|NCT00062010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016847|NCT02916017|||COHORT||PROSPECTIVE|||||||
34016848|NCT00468078|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34016849|NCT05215717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double|Participants will be randomized and enrolled into one of two study groups, self-administered hypnosis (treatment group) or sham white noise hypnosis (control group).|f|f|t|t
34016850|NCT03676699|||COHORT||PROSPECTIVE|||||||
34016851|NCT01303536|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34016852|NCT05865808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016853|NCT04841018|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients enrolled are allocated into one of the following two groups: control group (group C) who receive a higher dose of dexamethasone known to enhance the effect of caudal block from previous study (0.5mg/kg) and dexamethasone group (group D) who receive a lower, antiemetic dose of dexamethasone (0.15mg/kg)|t|t|f|t
34016854|NCT05986812|||CASE_CONTROL||RETROSPECTIVE|||||||
34016855|NCT05369286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016856|NCT04738682|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"Modified crossover study model, containing two similar patient groups, exposed to identical diet registration methods, but in opposite sequence.~Group 1: 3 days of digital dietary registration using mobile devices, followed by 3 days of conventional paper based dietary registration.~Group 2: 3 days of conventional paper based dietary registration, followed by 3 days of digital dietary registration, using mobile devices.~Each individual patient acts as his/her own control, with regards to the primary endpoint; precision. However patients are divided into two groups, in order to accommodate the study secondary endpoint; progression of nutritional condition, which is evaluated with regards to the registration method used. This requires two arms, where each arm experiences opposite registration method sequences"||||
34016857|NCT02772549|||COHORT||OTHER|||||||
34016858|NCT03898895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016859|NCT01902628|||COHORT||PROSPECTIVE|||||||
34103393|NCT05254860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794533|NCT04906278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794534|NCT04719377|RANDOMIZED|PARALLEL||TREATMENT||NONE||PowerMe Midline||||
33794535|NCT05603520|||COHORT||PROSPECTIVE|||||||
33794536|NCT00630786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714268|NCT02931487|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33794537|NCT04077632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794538|NCT03168048|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-center prospective exploratory study||||
33794539|NCT04911933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794540|NCT01596946|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34016860|NCT05772806|||COHORT||PROSPECTIVE|||||||
34016861|NCT05986331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016862|NCT00723645|||COHORT||PROSPECTIVE|||||||
33714269|NCT01097447|||COHORT||PROSPECTIVE|||||||
33714270|NCT02600702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714271|NCT06417476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714272|NCT02311296|||CASE_CONTROL||PROSPECTIVE|||||||
33714273|NCT03283852|||COHORT||CROSS_SECTIONAL|||||||
33714274|NCT01415310|||COHORT||PROSPECTIVE|||||||
33714275|NCT02438202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714276|NCT02957422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720816|NCT06231212|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||A randomized, double-blind, placebo- and active-controlled clinical trial was performed on 18 to 50-year-old participants with acute TMD. These were randomly assigned to four treatment groups for 14 days: placebo, ibuprofen, ECa 233 250mg and 500 mg. At baseline, subjects reported 5 to 8 (out of 10) of pain intensity on a numerical rating scale (NRS). No medications were self-reported 24 hours before and during the trial and no systemic conditions were diagnosed. Degenerative joint disease was screened before treatment. Pain intensity levels, mandibular range of motion including pain-free, unassisted and assisted mouth opening, were recorded at baseline and 7 and 14 days post-treatment. Masticatory muscle and jaw joint tenderness were evaluated upon palpation according to the Diagnostic Criteria for TMD (DC/TMD).|t|t|t|f
34016863|NCT05743231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly divided into two groups. The physician who will collect data in the cardiac surgery intensive care unit and cardiac surgery clinic will not know which group the participant is in.||t|t|f|f
34016864|NCT02772952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34016865|NCT00826579|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016866|NCT02487381|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34016867|NCT01487070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016868|NCT06395376|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016869|NCT03687658|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34016870|NCT00515931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016871|NCT03564418|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Controlled, Open trial.||||
34016872|NCT04175743|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Subjects will be assigned a randomization number prior to dosing on Day 1 in the order in which they are enrolled into the study to receive their allocated treatment according to a computer-generated randomization schedule prepared by the unblinded study statistician prior to the start of the study.|The study is planned to have 3 dose levels (3 study cohorts); the actual dose level cohorts will be decided by the SRC after review of the data from each cohort that was successfully completed in the SAD study. Each dose cohort will include 8 subjects randomized to placebo (2 subjects) or active drug (6 subjects).|t|f|t|f
34016873|NCT04642859|NA|SINGLE_GROUP||TREATMENT||NONE||compare scores before and after the intervention||||
34016874|NCT06444932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Double arm parallel design RCT|f|f|t|f
34099126|NCT04678960|RANDOMIZED|PARALLEL||PREVENTION||NONE||An effectiveness-Implementation Hybrid Design - Type 1; Randomized controlled trial and delayed-start study testing the effectiveness of Trust-based Relational Intervention and three different support formats (no coaching/structured coaching/adaptive coaching) among Juvenile Justice (JJ)-involved youth transitioning to their communities and a safe adult (e.g. parent/guardian, extended family member). In the delayed-start design, JJ agencies are randomly assigned to four different starting points with two months apart for starting the project. The last 18-months of the delayed-start design will provide a naturalistic investigation of sustainment of the intervention within the facilities after responsibility for intervention delivery has been transferred from TCU to the JJ agencies (TCU provide trainings to foster in-house TBRI expertise and assistance for implementation).||||
34099127|NCT04626596|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099128|NCT01205737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016875|NCT01781520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016876|NCT03949244|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Patients will have baseline NFC blood flow measurements after application of cedar oil. Then the study team will use NF application of either normal saline, latanoprost 0.005% or LTB 0.024% in random sequence. The patient and imager will know which study article is applied. NFC blood flow will be remeasured after 15 minutes. Preliminary data on controls suggests that 15 minutes is sufficient time to see a change in blood flow. NF article application will occur on a specially designed well applied to the 4th digit of the non-dominant hand. Two masked observers will evaluate NFC blood flow.||f|f|f|t
34016877|NCT00430495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016878|NCT05442671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016879|NCT03835221|NA|SINGLE_GROUP||OTHER||NONE|Study lenses will be transferred, by an assistant, out of their packaging to unmarked new contact lens cases filled with unpreserved sterile saline just prior to dispensing to maintain subject masking of the study lenses|||||
34016880|NCT06006000|||COHORT||PROSPECTIVE|||||||
34016881|NCT05656820|||COHORT||PROSPECTIVE|||||||
34016882|NCT04998019|RANDOMIZED|PARALLEL||OTHER||NONE||cluster randomized trial||||
34016883|NCT06095141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016884|NCT04580121|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34016885|NCT02109510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016886|NCT03159130|||COHORT||PROSPECTIVE|||||||
34099129|NCT03983070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded researcher will perform preliminary and outcomes measures.|Randomized clinical trial with parallel groups|f|f|f|t
34099130|NCT03193385|||COHORT||PROSPECTIVE|||||||
34099131|NCT00538265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099132|NCT06260839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099133|NCT05877664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099134|NCT00465283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099135|NCT00250575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099136|NCT05562635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double masking|two groups parallel study: experimental and control group|t|t|t|f
34099137|NCT04210245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099138|NCT03066375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099139|NCT05285163|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients were distributed with the minimization method of covariate-oriented randomization. According to NYHA (class III, IV), sex (male and female), and the number of hospitalizations (≤3 and ≥4) within one year, the patients were randomly appointed to the control and intervention groups. Thus, the patients in the intervention and control groups were distributed as homogeneous.|The control group took usual care and the intervention group took both usual care and palliative care.|t|f|f|f
34099140|NCT01512173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099141|NCT03570138|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34099142|NCT01204281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099143|NCT04849000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1209 monotherapy|t|t|t|t
34099144|NCT01126398|||CASE_ONLY||PROSPECTIVE|||||||
34103394|NCT02336555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34016887|NCT00907127|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34016888|NCT04156620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, randomized treatment trial. Subjects, investigators, investigator staff and persons performing the assessments, will remain blind to the identity of the treatment from the time of randomization until database lock, using the following methods: (1) Randomization data are kept strictly confidential until the time of unblinding and will not be accessible by anyone else involved in the study with the exception of the bioanalyst, (2) the identity of the treatments will be concealed by the use of study treatment in form of vials, filled with secukinumab or placebo that are identical in appearance.||t|t|t|t
33794541|NCT03617978|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|participants will not be able to see the device measuring the hemodynamic parameters||t|f|f|f
33794542|NCT06555757|||COHORT||PROSPECTIVE|||||||
33794543|NCT03319706|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794544|NCT06240663|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794545|NCT02027558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794546|NCT06170593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794547|NCT00200135|||CASE_CONTROL||PROSPECTIVE|||||||
33794548|NCT04784364|||COHORT||PROSPECTIVE|||||||
33794549|NCT05603338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794550|NCT00933088|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794551|NCT04014803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794552|NCT03789786|||CASE_CONTROL||OTHER|||||||
33794553|NCT00210509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794554|NCT05677633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025442|NCT05422625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be blinded to treatment group. Only the clinician providing the treatment will be aware of the treatment group assignment.|Randomized, single-blind, sham controlled.|t|f|f|f
34025443|NCT05296135|||COHORT||PROSPECTIVE|||||||
34025444|NCT01192867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025445|NCT02437903|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34099145|NCT04428593|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Blinding was carried out by using Placebo equivalent to Treamid tablets without active substance and the corresponding labeling of the study drug.|The dose cohorts were included into the study subsequently based on preliminary safety results evaluation performed by the Data Safety Monitoring Committee. 3 doses of Treamid/placebo (5 mg, 15 mg and 50 mg) were used in the study.The duration of exposure to the study drug was 6 days in each cohort: Day 1, once, at the step of single administration, and then in 6 days, daily, 1 time a day for 14 days at the step of multiple administration.|t|f|t|f
34099146|NCT03473301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Every attempt will be made to blind the outcomes assessor.||f|f|f|t
34099147|NCT01078740|||COHORT||PROSPECTIVE|||||||
34099148|NCT04950907|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34099149|NCT06042660|||COHORT||RETROSPECTIVE|||||||
34099150|NCT02302326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099151|NCT02491060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34099152|NCT02472951|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34099153|NCT01810107|||COHORT||PROSPECTIVE|||||||
34099154|NCT02626351|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Masking was only until randomisation status identified at the start of each intervention step.|Stepped wedge trial: therefore all clusters receive intervention, in randomised sequence.|f|t|f|f
34099155|NCT05298969|NA|SINGLE_GROUP||TREATMENT||NONE||Assessment of temporalis myofascial flap effectiveness in reconstruction of cranio-maxillofacial defects||||
34099156|NCT05238103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34099157|NCT06298864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099158|NCT04448080|RANDOMIZED|PARALLEL||TREATMENT||NONE|non|This is a randomised, non-blinded, controlled clinical study comparing two types of anesthesia for MicroPulse Transscleral Laser Treatment for Glaucoma||||
34099159|NCT04044287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind Randomised Control Trial|Prospective cohort|t|t|t|t
34099160|NCT01875276|||COHORT||RETROSPECTIVE|||||||
34099161|NCT03380481|||COHORT||PROSPECTIVE|||||||
34099162|NCT05364346|||COHORT||PROSPECTIVE|||||||
34099163|NCT00000544|RANDOMIZED|||TREATMENT||||||||
33794555|NCT06656377|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||In this interventional study, we will include prediabetic patients who will undergo three sequential exercise protocols to optimize exercise timing, intensity, and duration. Each protocol is designed to explore a unique combination of these exercise parameters, allowing us to assess the effects on health outcomes relevant to prediabetes management. By using a randomized, cross-over design, participants will experience different exercise regimens, enabling us to compare the impact of each combination on glucose control, cardiovascular health, and overall metabolic function. This study aims to develop evidence-based exercise guidelines specifically tailored to prediabetic individuals.||||
33794556|NCT00583167|||COHORT||PROSPECTIVE|||||||
33794557|NCT05184946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794558|NCT00000646||||TREATMENT||||||||
33794559|NCT05567822|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794560|NCT06549673|||COHORT||PROSPECTIVE|||||||
33794561|NCT03804918|NA|SINGLE_GROUP||OTHER||NONE||A pre-post mixed methods pilot educational study||||
33794562|NCT01052246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794563|NCT01714193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794564|NCT02916758|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33794565|NCT00103025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794566|NCT05274334|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||One arm, Proof of Concept Study assessing metabolites in exhaled breath of healthy adults.||||
33794567|NCT01787760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33794568|NCT05221073|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33794569|NCT03201224|||COHORT||PROSPECTIVE|||||||
33794570|NCT01812148|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33794571|NCT03098810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794572|NCT03380390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025446|NCT02593253|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34025447|NCT02863055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794573|NCT04713371|NA|SINGLE_GROUP||TREATMENT||NONE||Male or female subjects greater than 18 years of age with histologically- proven metastatic cancer with at least one imaging- or histologically- proven metastases to lymph nodes, bone, or soft tissue.||||
33794574|NCT04093908|||COHORT||RETROSPECTIVE|||||||
33794575|NCT04933123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794576|NCT04262440|||CASE_CONTROL||PROSPECTIVE|||||||
33794577|NCT00888108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794578|NCT02799706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794579|NCT01490541|||||PROSPECTIVE|||||||
33794580|NCT00644475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794581|NCT02353988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794582|NCT02541916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099164|NCT03595722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794583|NCT02878330|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025448|NCT04648696|RANDOMIZED|PARALLEL||TREATMENT||NONE||To assess the risk of vancomycin-associated nephrotoxicity and outcomes associated with continuous infusions (CI) versus II dosing in the outpatient parenteral antibiotic therapy (OPAT) setting||||
34099165|NCT05329883|||COHORT||PROSPECTIVE|||||||
34099166|NCT05597891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099167|NCT03751748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicenter, randomized, sham controlled, single blind with objective end points.|t|t|f|t
33794584|NCT03400969|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|A Block randomisation is made by a person, other than the one who applies the product. Neither the patient nor the person who records the product or the person who registers data knows which product is used for the intervention. The product is not labeled with name|The different moisturizers will be compared in a double blind, cross-over design. Patient responses will be collected at baseline, immediately after exposure and after 2 hours.|t|t|t|t
33794585|NCT04367415|||COHORT||PROSPECTIVE|||||||
33720817|NCT01077804|||COHORT||PROSPECTIVE|||||||
33794586|NCT03703037|||OTHER||PROSPECTIVE|||||||
33794587|NCT05949255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794588|NCT04497727|||COHORT||PROSPECTIVE|||||||
33794589|NCT05870241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|random generator|Ga-As Laser and Microcurrent|f|f|f|t
33794590|NCT04051255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794591|NCT04686942|||CASE_ONLY||PROSPECTIVE|||||||
33794592|NCT02762006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794593|NCT01603784|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33794594|NCT04792554|||COHORT||PROSPECTIVE|||||||
34025449|NCT06632795|||OTHER||CROSS_SECTIONAL|||||||
34025450|NCT00059397|||||PROSPECTIVE|||||||
34025451|NCT04622319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025452|NCT02996487|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34025453|NCT05946616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34025454|NCT06353542|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
34025455|NCT03939715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099168|NCT01528852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099169|NCT02035228|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34099170|NCT02209909|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|f|t
34099171|NCT00186992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099172|NCT06154447|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34099173|NCT00107289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720818|NCT04216654|||CASE_CONTROL||PROSPECTIVE|||||||
33720819|NCT04052269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Healthy vs affected eyes (glaucoma)||||
33720820|NCT05394441|||COHORT||CROSS_SECTIONAL|||||||
33720821|NCT00292864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794595|NCT03425058|||COHORT||PROSPECTIVE|||||||
33794596|NCT06228846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794597|NCT02122445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794598|NCT00657943|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33794599|NCT02323529||CROSSOVER||TREATMENT||NONE||||||
33794600|NCT02705937|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938046|NCT05466591|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The clinical events are blindly adjudicated by an independent Clinical Events Committee|The patients are randomised to 1) pre-hospital rule-out with POC troponin measurement (intervention group) and 2) direct transfer to the ED (standard care group).|f|f|t|t
33938047|NCT01873599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938048|NCT00327210|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938049|NCT01132391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938050|NCT01066611|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33720822|NCT05114785|||CASE_CONTROL||PROSPECTIVE|||||||
33720823|NCT03604640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720824|NCT05485766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720825|NCT01550796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720826|NCT04099927|NA|SINGLE_GROUP||TREATMENT||NONE||SHR0410 monotherapy||||
33720827|NCT01035203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33938051|NCT03681808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be dispensed product according to the treatment arm corresponding to their randomization and will be unmasked. The Investigator will be masked.|Investigator/Sponsor masked, randomized, open-label, parallel-group, multicenter study|f|f|t|f
33938052|NCT04831892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938053|NCT06307210|||COHORT||RETROSPECTIVE|||||||
34099174|NCT05932680|NA|SINGLE_GROUP||OTHER||NONE||||||
34099175|NCT05573737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099176|NCT05159011|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Investigator masked from randomization until results analysis.|Interventional chat bot|f|f|t|f
34099177|NCT03607786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016889|NCT05029401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Stage 1 (phase 1) of the study is single-blind (participant blinded); patients receive one initial dose of placebo, followed by one dose of IMP on the next day, and thereby serve as their own controls.~Stage 2 (phase 2a) is double-blinded. Patients will be randomized to receive either the IMP or placebo as a single dose"|"The initial Stage 1 (phase 1) design was an open label study. Following review of data from the first cohort in Stage 1, an additional 6 subjects will be recruited into Cohort 1 and the protocol has been amended to implement a multi-centre, single-blind placebo-controlled assessment of QTcF and individualized heart rate correction modeling of QTcI.~Following baseline evaluations each subject receives placebo (Day 1) followed by ibogaine (Day 2), serving as his or her own control. In addition, data is collected from the baseline assessments (Day -1) to assess QT/RR diurnal variability under normal conditions and in response to autonomic stimulus (i.e. postural changes).~Stage 2 (phase 2a) is a double-blind, placebo-controlled, parallel group design targeting opioid-dependent patients to receive a single dose of the DMX-1002 or placebo for medically supervised opioid withdrawal."|t|f|t|f
34016890|NCT02212912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016891|NCT01088321|||COHORT||PROSPECTIVE|||||||
34016892|NCT03365167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34016893|NCT04650113|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|"All participants will be randomly assigned to know which one of the right or left side will be allocated randomly in either the control or the intervention group.~Sequence Generation Eligible consented participants will be randomly assigned to know which one of the participants will be control or intervention group according to a sequence generated on a Microsoft Excel sheet where the intervention (I) and the control (C) are simply randomized. The table of sequence generation will be kept with the co-supervisor."||t|t|t|t
34016894|NCT00999765|||COHORT||PROSPECTIVE|||||||
34016895|NCT03605511|||COHORT||PROSPECTIVE|||||||
34016896|NCT00377936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016897|NCT05089474|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, open label||||
34016898|NCT01588886|||COHORT||RETROSPECTIVE|||||||
34016899|NCT00626314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016900|NCT01558336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016901|NCT02823652|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34016902|NCT06406946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099178|NCT04521166|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The participant will be blinded to the hearing aid features being adjusted. The order of presentation of the hearing aid features will be randomized across participants, using a Latin-Square design. The outcomes assessor(s) (who score speech intelligibility) will also be blinded to the conditions.|Settings in a wearable hearing aid will be adjusted within a clinically-relevant range for two features. The features include wide dynamic range compression and microphone directionality.|t|f|f|t
34099179|NCT03294655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|only the post test assessor will be blinded to condition, as participants will know which condition they are assigned to|pre-post experimental design, 60 adults aged 50+ will be randomized to either a no-contact control or intervention condition|f|f|f|t
34099180|NCT04985656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099181|NCT00563563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099182|NCT03376087|||COHORT||PROSPECTIVE|||||||
34099183|NCT00043784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099184|NCT03892915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomized controlled trial with 4 sites randomly assigned to implement evidence-based depression care in addition to usual care and 4 sites randomly assigned to implement usual care only||||
34099185|NCT00018798|||COHORT||PROSPECTIVE|||||||
34099186|NCT03154112|||COHORT||PROSPECTIVE|||||||
34099187|NCT01926067|||||PROSPECTIVE|||||||
34099188|NCT01509209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099189|NCT06115564|||COHORT||PROSPECTIVE|||||||
34099190|NCT01179620|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099191|NCT02614066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099192|NCT06106295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099193|NCT00985192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099194|NCT04017975|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Subjects and the physician reading ECGs will be blinded.|Subjects will be randomized into two groups using permuted block and stratified according to type of surgical repair.|t|f|f|t
34099195|NCT03767231|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33720828|NCT04716387|||COHORT||PROSPECTIVE|||||||
33720829|NCT03099447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099196|NCT05521282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Based on basic treatment, Qianglidingxuan mimetics were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.|Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.|t|f|f|f
34099197|NCT01063673|||COHORT||PROSPECTIVE|||||||
34099198|NCT02531711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099199|NCT04634175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Volunteers, health care professionals and researchers will not have access to randomization and will also not know which intervention group they were assigned to.|Pre-test-post-test.|t|t|t|f
34099200|NCT04140344|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be told they will receive appropriate information about their spine surgery (including instructions on proper wound care, mobility, and signs and symptoms of infection) in general, either through phone calls, text messages and/or handouts, without specifying the difference between the control and the intervention group.|Following baseline assessments, subjects will be randomized with equal probability to one of two arms: 1). The experimental arm, which will receive automated standardized text messages at predetermined intervals, occurring daily the first week post-operatively and gradually tapering over the second week; 2). The control arm - where subjects will not receive any scheduled contact (outside of standard of care phone interactions). All subjects will receive a phone call 30 days (up to 37 days) post-discharge in order to complete the study questionnaires.|t|f|f|f
34099201|NCT03938324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Five year randomized controlled trial to test efficacy of behavioral intervention versus attention control group on primary and secondary outcomes across 12 months.||||
34099202|NCT06350513|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel Group (Experiment-Control) Randomized Controlled Experimental|f|f|f|t
34099203|NCT04076579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099204|NCT06019819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34099205|NCT00773110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099206|NCT04455750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099207|NCT01793909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099208|NCT01530997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099209|NCT05181631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099210|NCT01920464|||||RETROSPECTIVE|||||||
34099211|NCT04367935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099212|NCT05507229|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind Study||t|t|t|f
34099213|NCT02927314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34099214|NCT04761588|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099215|NCT06450470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33938054|NCT03097497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938055|NCT04528693|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The qualifying physician does not know which of the examined persons will be allocated in the intervention or in the control group.|The study is designed as a prospective randomized clinical trial where subjects are randomally allocated to intervention group (study) or non-intervention group (control).|f|t|f|f
33720830|NCT03652844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized cohorts|t|f|f|f
33938056|NCT01628718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluator is blind to treatment assignment.||f|f|f|t
33938057|NCT01204489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938058|NCT04118140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This study can perform a partial blind design for participants in the true and sham intervention groups. Blind of outcome assessment will be also achieved in the true and sham intervention groups as all the questionnaires are patient-reported and the participants themselves will be the outcome assessors. Data analysis will be conducted by an independent statistician who are blinded to the group allocation.||t|f|f|t
33938059|NCT06238349|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938060|NCT03177473|||COHORT||PROSPECTIVE|||||||
33938061|NCT02646891|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938062|NCT00832533|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33938063|NCT03661983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938064|NCT00439309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938065|NCT00782756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720831|NCT02451839|||COHORT||PROSPECTIVE|||||||
33720832|NCT05783362|RANDOMIZED|PARALLEL||OTHER||NONE||Individuals will be randomized to one of three groups: High Exposure (HE), Low Exposure (LE), No Exposure (NE).||||
33720833|NCT02619292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720834|NCT03978429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants and health providers in the control clinics are unaware of the intervention and the investigators and outcome assessors are completely blinded from assignment of the intervention to the participants.||t|f|t|t
33720835|NCT02734381|||COHORT||RETROSPECTIVE|||||||
33720836|NCT04532866|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720837|NCT03296254|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||It is a 2-sequence, 2-period, 2-treatment crossover design with sequences AB and BA|f|f|t|t
33720838|NCT06415409|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Unidentified bottles.|Randomized Cross over design.|t|f|f|f
33720839|NCT01013701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33720840|NCT00956904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938066|NCT02881892|||CASE_ONLY||CROSS_SECTIONAL|||||||
33938067|NCT05709587|NA|SINGLE_GROUP||TREATMENT||NONE||The subjects that received virtual reality functional gait training for 12 sessions. During the virtual reality intervention, they also received routine conventional rehabilitation therapy for twice a week, and training lasted for one hour. The 6-minute walking test (6MWT), 10-meter walk test (10MWT), Berg balance scale (BBS) and Chinese version of the Activities specific Balance Confidence scale were assessed pre- and post-intervention.||||
33938068|NCT03838666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938069|NCT04709406|||COHORT||PROSPECTIVE|||||||
33938070|NCT02160639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33938071|NCT00231491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938072|NCT00939146|RANDOMIZED|PARALLEL||||NONE||||||
33938073|NCT04495322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||single-center, randomized, double-blind, placebo-controlled, single-dose|t|t|t|t
33938074|NCT02967172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938075|NCT06193161|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinded assessors|Participants are randomized to I-PE for eight weeks or to a waitlist. Participants in the control arm will be crossed over to I-PE treatment after completion of the 1 month follow up (primary endpoint).|f|f|f|t
33938076|NCT01773616|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938077|NCT02933411|||OTHER||PROSPECTIVE|||||||
34099216|NCT06695949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099217|NCT00976300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099218|NCT05999552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099219|NCT05800015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099220|NCT02743754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099221|NCT01189227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099222|NCT04784780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099223|NCT05511844|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099224|NCT04841876|||CASE_CONTROL||PROSPECTIVE|||||||
33714277|NCT03477877|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a community randomised controlled trial, randomized at the level of sector (Rwandan geographic administrative units are: Province \> District \> Sector \> Cell \> Village). 28 sectors spread across 7 districts are participating; randomisation as intervention or control was stratified across districts to ensure adequate geographical spread of program delivery. Within each randomised sector are two separate assessments of impact: (1) A Couple Cohort comprised of heterosexual couples who enrol together in a couples training program or similarly situated couples in control communities, surveyed at enrolment, 12 months post-baseline, and 24 months post-baseline. (2) A Community Survey designed to measure community diffusion which comprises a repeat cross-sectional population-based household survey of married/cohabiting adults in intervention/control communities who are NOT direct participants in the couples cohort, surveyed at baseline and 24 months."||||
33714278|NCT02788357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714279|NCT00573469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714280|NCT03274440|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33714281|NCT05898477|||COHORT||RETROSPECTIVE|||||||
33714282|NCT00774644|RANDOMIZED|CROSSOVER||||NONE||||||
33714283|NCT01083394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714284|NCT06026761|||COHORT||PROSPECTIVE|||||||
33714285|NCT04160091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714286|NCT03733795|||OTHER||PROSPECTIVE|||||||
33714287|NCT00275769|RANDOMIZED|FACTORIAL||||NONE||||||
33714288|NCT01954602|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33714289|NCT03275376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714290|NCT01220843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714291|NCT00797472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714292|NCT03007576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714293|NCT05953220|||COHORT||PROSPECTIVE|||||||
33714294|NCT00905073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714295|NCT01655706|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33714296|NCT00218465|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714297|NCT00790855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714298|NCT03959358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714299|NCT04282434|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714300|NCT03256565|||CASE_CONTROL||RETROSPECTIVE|||||||
33714301|NCT00125801|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33714302|NCT00366288|||COHORT|||||||||
33714303|NCT04518150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind randomized controlled trial|A Randomized Controlled Trial|t|f|f|f
33714304|NCT04287244|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33714305|NCT00585819|NON_RANDOMIZED|PARALLEL||||NONE||||||
33714306|NCT05710536|NA|SINGLE_GROUP||OTHER||NONE||||||
33714307|NCT02857543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714308|NCT00572585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714309|NCT01962207|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714310|NCT03785002|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33714311|NCT00231075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714312|NCT04168385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714313|NCT05071989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714314|NCT03053804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714315|NCT04099134|||CASE_ONLY||PROSPECTIVE|||||||
33714316|NCT00022308||||TREATMENT||||||||
33938078|NCT05370560|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33938079|NCT06237361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938080|NCT01984359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938081|NCT04072796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33938082|NCT02016586|RANDOMIZED|PARALLEL||||NONE||||||
33938083|NCT02532075|RANDOMIZED|FACTORIAL||||NONE||||||
33938084|NCT00888316|||COHORT||PROSPECTIVE|||||||
33938085|NCT01096966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938086|NCT06016595|||CASE_ONLY||RETROSPECTIVE|||||||
33938087|NCT03593720|||CASE_CONTROL||PROSPECTIVE|||||||
33938088|NCT02018276|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33938089|NCT03588949|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33938090|NCT05621876|||COHORT||PROSPECTIVE|||||||
33938091|NCT02745795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938092|NCT01633372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938093|NCT05232461|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938094|NCT03416972|||COHORT||PROSPECTIVE|||||||
33938095|NCT04951479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938096|NCT00656799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938097|NCT00983242|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016903|NCT03412786|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Not a randomized study. The first 10 patients included will be treated in arm A - the last 10 will be treated in arm B.|||||
34016904|NCT04048343|NA|SINGLE_GROUP||TREATMENT||NONE||All subject will be dosed tezepelumab administered subcutaneously||||
34016905|NCT03829137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34016906|NCT01660464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099225|NCT04029038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099226|NCT06052397|||COHORT||PROSPECTIVE|||||||
34099227|NCT06553820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099228|NCT01638299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099229|NCT04619082|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099230|NCT02405637|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34099231|NCT01260324|||CASE_CONTROL||RETROSPECTIVE|||||||
34099232|NCT06067971|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099233|NCT02742974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099234|NCT05993325|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34099235|NCT00147797|||||PROSPECTIVE|||||||
34099236|NCT01990352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099237|NCT00893581|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34099238|NCT00151463|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099239|NCT01277731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099240|NCT03796975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099241|NCT04679025|||COHORT||CROSS_SECTIONAL|||||||
34099242|NCT04576221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||use of two manner of breathing for patients with pneumonia.||||
34099243|NCT04851015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo||t|t|t|t
34099244|NCT05847543|||COHORT||CROSS_SECTIONAL|||||||
34099245|NCT06380530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099246|NCT05986058|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34099247|NCT06568536|||COHORT||PROSPECTIVE|||||||
34099248|NCT01266083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099249|NCT02936271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099250|NCT00888966|||COHORT||PROSPECTIVE|||||||
34099251|NCT06290024|||OTHER||OTHER|||||||
34099252|NCT02831036|RANDOMIZED|PARALLEL||||NONE||||||
34099253|NCT02539407|||COHORT||PROSPECTIVE|||||||
33794601|NCT04969172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|155 patients will be randomized in a 2:1 ratio to receive either 1010 exosome particles -103 patients, or placebo- 52 patients.|A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study population will include patients with moderate or severe COVID-19 infection and laboratory markers predictive of the cytokine storm from the Corona department of each site, who have provided an informed consent.|t|f|t|f
33794602|NCT04043364|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Mixed method, stepped wedge randomized controlled trial||||
33794603|NCT03034681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients were recruited as follows: the rehabilitation doctor evaluated and diagnosed the patient and referred them to the Physiotherapy Unit (PTU) with a prescription for TENS or Vojta treatment. It was at the PTU of the health centre where the patient was informed of the possibility of taking part in the study. Patients who agree were allocated alternately in order of arrival to the PTU, in such a way that half of the sample was treated using TENS and the other half with Vojta therapy ."||||
33794604|NCT00476255|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33794605|NCT00035841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794606|NCT03058965|NA|SINGLE_GROUP||OTHER||NONE||||||
33794607|NCT05054764|||CASE_ONLY||PROSPECTIVE|||||||
34016907|NCT04731870|||COHORT||CROSS_SECTIONAL|||||||
34016908|NCT00132249|||CASE_CONTROL||OTHER|||||||
34016909|NCT02598258|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34016910|NCT05906420|||COHORT||RETROSPECTIVE|||||||
34016911|NCT02251691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016912|NCT00833742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016913|NCT03801382|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34016914|NCT05935566|||COHORT||RETROSPECTIVE|||||||
34016915|NCT00834652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016916|NCT00727727|||||PROSPECTIVE|||||||
34016917|NCT02139371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016918|NCT03714360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34016919|NCT03516214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025456|NCT03585634|NA|SINGLE_GROUP||OTHER||NONE||Prospective, non-comparative design||||
34025457|NCT03200912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099254|NCT02226783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34099255|NCT04972175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099256|NCT02557165|||CASE_CROSSOVER||PROSPECTIVE|||||||
34099257|NCT01420003|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099258|NCT04491383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind clinical trial.|Experimental (Tocovid Suprabio (HOV-12020)) vs Control (Placebo)|t|t|t|t
34099259|NCT05663593|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34099260|NCT05783323|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an open label, non-randomized study to evaluate the efficacy and safety of the combination of larotrectinib followed by 131I therapy for patients with NTRK fusion differentiated thyroid cancer.||||
34099261|NCT06686719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099262|NCT06074523|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-subjects measures, correlational analysis||||
34099263|NCT06469580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099264|NCT06319287|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Multi-center, Open Label, Randomized Controlled Clinical Trial Evaluating the Effect of PEP/TISSEEL in the Treatment of Diabetic Foot Ulcers||||
34099265|NCT05524532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34099266|NCT06694207|||COHORT||PROSPECTIVE|||||||
34099267|NCT06565078|||COHORT||RETROSPECTIVE|||||||
34099268|NCT04483219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794608|NCT02655835|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33794609|NCT04567043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33794610|NCT03663842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016920|NCT05758480|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Two groups:~1. Patients with Long COVID~2. Control group composed of patients who recovered from COVID-19 without persistent symptoms.~Each patient with Long COVID is paired with a matched control, based on age, sex, and date of COVID-19."||||
34016921|NCT04929938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will be blind to the condition that owns the patients included|This is a randomized clinical trial in wich a group will receive inmediate UP plus standard intervention and the other one will be in a waiting list plus standard care at PIPPEP.|f|f|f|t
34016922|NCT01055132|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34016923|NCT04205370|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34016924|NCT00365937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016925|NCT03805100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016926|NCT04213976|||COHORT||RETROSPECTIVE|||||||
34016927|NCT04250948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016928|NCT01568320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016929|NCT01881113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016930|NCT00782821|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34016931|NCT00861198|||||PROSPECTIVE|||||||
34016932|NCT04604743|RANDOMIZED|PARALLEL||PREVENTION||NONE||2) Cluster randomized controlled trial design (N=4 clinics). This design minimizes risk of contamination between participants in different arms and is ideal when settings are similar in population characteristics. Cluster randomized controlled trials are frequently used when interventions are to be carried out at the level of whole groups (clinic populations).||||
34025458|NCT06632223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794611|NCT02839018|||OTHER||PROSPECTIVE|||||||
33794612|NCT04105868|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794613|NCT06079840|RANDOMIZED|PARALLEL||PREVENTION||NONE||The evaluation will involve a two-group RCT in which 100 African American informal caregivers of PLWHA, who previously participated in a caregiver study will be randomly assigned to one of two conditions: (1) MBSR-AAC app (n=50): Participants will receive the MBSR-AAC app for 8-weeks; or (2) Comparison (n=50): Participants will receive information regarding caregiver services and resources for 8-weeks. Assessments will be conducted with all participants at baseline and 4-, 8-, and 12-weeks post-baseline.||||
33794614|NCT04296019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794615|NCT02010372|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794616|NCT02852681|RANDOMIZED|CROSSOVER||||NONE||||||
33794617|NCT04009577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794618|NCT03102710|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33794619|NCT01125319|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794620|NCT06677593|||COHORT||PROSPECTIVE|||||||
33794621|NCT03302819|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33794622|NCT05371288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794623|NCT04871750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Healthy postmenopausal women aged 50 to 70, with Fitzpatrick skin type I or II.|t|t|t|t
33794624|NCT01243619|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794625|NCT06676956|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33794626|NCT01839981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794627|NCT05165082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794628|NCT06405880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33794629|NCT04492631|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33794630|NCT03161327|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33794631|NCT03105219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Urinary albumin excretion at 3 month||f|f|f|t
33794632|NCT03686891|NA|SINGLE_GROUP||SCREENING||NONE||||||
33794633|NCT04016870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be a randomized, multi-center, single-blinded non-inferiority study of 260 patients (all outside of United States) with Class I indications for pacemaker implantation.|t|f|f|f
33794634|NCT00444769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938098|NCT05839002|||CASE_ONLY||RETROSPECTIVE|||||||
33938099|NCT00002986||||TREATMENT||||||||
33938100|NCT04062240|||CASE_CONTROL||PROSPECTIVE|||||||
33938101|NCT00004885|RANDOMIZED|||TREATMENT||||||||
33938102|NCT06010992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938103|NCT03570528|||CASE_CONTROL||RETROSPECTIVE|||||||
33938104|NCT01320033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938105|NCT01199692|||CASE_CONTROL||PROSPECTIVE|||||||
33938106|NCT02169726|||CASE_CONTROL||PROSPECTIVE|||||||
33938107|NCT04780191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938108|NCT01041885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938109|NCT01112189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938110|NCT06191991|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33938111|NCT00006463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938112|NCT00783263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938113|NCT03887286|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938114|NCT02332694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938115|NCT05882435|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33938116|NCT00971191|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938117|NCT03698695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938118|NCT04748250|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33938119|NCT05963165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33938120|NCT02815072|||CASE_ONLY||PROSPECTIVE|||||||
33938121|NCT01011764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938122|NCT00514592|||||PROSPECTIVE|||||||
33938123|NCT03911284|||OTHER||RETROSPECTIVE|||||||
33938124|NCT04599660|||COHORT||RETROSPECTIVE|||||||
33938125|NCT00957723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938126|NCT05488327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938127|NCT02297204|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34016933|NCT04043936|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Participant will be in the Cognitive Bias Modification Intervention for Help-Seeking Stigma (CBM-HS) condition (intervention condition), the Cognitive Bias Modification (CBM-Placebo) condition (placebo condition), or the Self-Directed Psychoeducation condition (comparison condition).|Participants will be placed in one of three groups (Cognitive Bias Modification Intervention for Help-Seeking Stigma (CBM-HS) condition, the Cognitive Bias Modification (CBM-Placebo) condition, or the Self-Directed Psychoeducation condition \[comparison condition\]). Participants will then complete 5 additional virtual study visits (3 intervention weeks, 1 post-treatment, 1 two-month follow-up); these study visits will occur through a web-based platform. Self-report measures will be administered at enrollment/baseline, mid-intervention, post-intervention, and two-month follow-up.|t|f|f|f
33794635|NCT05657795|RANDOMIZED|PARALLEL||OTHER||NONE||Participating infants will be randomised either to manual oxygen control or closed-loop automated oxygen control, adjusted by clinical staff as necessary.||||
33794636|NCT05232669|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33794637|NCT00969371|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794638|NCT00626418|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33794639|NCT06112977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to their surgical allocation (mesh or no mesh) and will be unblinded after completion of their post-operative questionnaire at day 90.|"Restore-B is a prospective, multicentre parallel 2-armed single-blinded randomised controlled feasibility trial comparing no-mesh to mesh- assisted immediate implant-based prepectoral breast reconstruction surgery.~Patients will be randomised 1:1 to either the intervention surgery (no- mesh) arm or the control arm surgery (mesh-assisted)."|t|f|f|f
33794640|NCT03460756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794641|NCT01970618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794642|NCT06547164|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33794643|NCT02798835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016934|NCT04744350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016935|NCT02075671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34016936|NCT00714129|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016937|NCT05810558|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34016938|NCT01328236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016939|NCT00127036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016940|NCT04359576|||CASE_CONTROL||PROSPECTIVE|||||||
34016941|NCT01372514|||COHORT||PROSPECTIVE|||||||
34016942|NCT03142815|||COHORT||PROSPECTIVE|||||||
34016943|NCT05746065|||COHORT||PROSPECTIVE|||||||
34016944|NCT05976841|||COHORT||OTHER|||||||
34016945|NCT00233506|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016946|NCT01121666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34016947|NCT01102062|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34016948|NCT00003592|RANDOMIZED|||TREATMENT||||||||
34016949|NCT02637375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016950|NCT01150890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34016951|NCT01836406|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34016952|NCT05294939|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34016953|NCT06284577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34016954|NCT02608138|||||CROSS_SECTIONAL|||||||
34016955|NCT02122120|||CASE_CONTROL||PROSPECTIVE|||||||
34016956|NCT02885649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099269|NCT04813874|||CASE_CONTROL||PROSPECTIVE|||||||
34099270|NCT05635721|||OTHER||PROSPECTIVE|||||||
34099271|NCT03784300|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.|t|f|t|t
33794644|NCT04878991|||COHORT||PROSPECTIVE|||||||
33794645|NCT06676800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794646|NCT04276402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33794647|NCT02098382|||COHORT||PROSPECTIVE|||||||
33794648|NCT01924767|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33794649|NCT06261996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794650|NCT06328985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33794651|NCT05095246|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33794652|NCT00372450|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33794653|NCT05588193|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33794654|NCT02599818|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938128|NCT06127108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Study staff will collect two (2) anterior nasal swabs from each Participant.~One anterior nasal swab will be collected by a study staff member and tested immediately on the Panbio™ COVID-19/Flu A\&B Panel by an untrained test operator. The other anterior nasal swab will be eluted in VTM within 10 minutes of sample collection. The swab will be rotated vigorously in the VTM, and the swab head will be left in the VTM, by snapping the shaft or clipping the base of the swab if necessary. VTM samples will be stored, handled and tested with comparator assays according to the manufacturers' product instructions. VTM specimens can be stored for up to 48 hours at 2-8°C. If delivery and processing of samples exceeds specified time periods, specimens should be transported in dry ice and once in laboratory frozen at -70°C or colder."||||
33938129|NCT04367740|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794655|NCT06376513|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794656|NCT02550808|||COHORT||PROSPECTIVE|||||||
33794657|NCT05786898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794658|NCT05570188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794659|NCT05078424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794660|NCT06676865|||COHORT||PROSPECTIVE|||||||
33794661|NCT02398565|||COHORT||RETROSPECTIVE|||||||
33794662|NCT01694823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794663|NCT06105710|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33794664|NCT01185769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33794665|NCT05824546|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938130|NCT02610894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33938131|NCT04624581|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Exploratory case control pathophysiology study of psychophysical (central sensitization assessment) and genetic (candidate gene panel) characteristics.||||
33938132|NCT06001294|||CASE_ONLY||PROSPECTIVE|||||||
33938133|NCT02653989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794666|NCT01691963|RANDOMIZED|PARALLEL||||NONE||||||
33938134|NCT04423224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Control group Management of the hemodynamic status in the control group versus a goal directed group based on stroke volume variation protocol (with Nexfin monitor) in patients undergoing hip fracture fixation under spinal anesthesia|t|f|f|t
33938135|NCT05707520|||COHORT||RETROSPECTIVE|||||||
33938136|NCT05039411|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive a total of 60 million cells per visit for 5 consecutive visits, with a 4-week interval between the injections. If the patient is completely healed during any course of stem cell injections, subsequent stem cell treatments can be discontinued. However, patients will still be required to undergo regular follow-up examinations, including physical examinations and other medical tests, until the study is completed.||||
33938137|NCT02675582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33938138|NCT01948089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016957|NCT05007314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34016958|NCT00787020|||CASE_CONTROL||PROSPECTIVE|||||||
34016959|NCT00974974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016960|NCT06467773|||COHORT||PROSPECTIVE|||||||
34016961|NCT05585476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to mask the patients from the treatment group to which they have been assigned, a simulated laser treatment session will be carried out in the case of patients belonging to the topical regenerative treatment group, which will consist of keeping the device turned off during it but faithfully reproducing both the duration as the sounds emitted by the device through recording previously made. In the case of patients assigned to laser treatment exclusively, they will be provided with a topical placebo (water-based), which must be applied with the same regimen as the emollient treatment under study.|A single-blind, randomized, controlled clinical trial is proposed, in which the patients included will be assigned to one of the three treatment arms.|t|f|f|t
34016962|NCT05594303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794667|NCT00355940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794668|NCT05756010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794669|NCT05731466|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective study||||
33794670|NCT00035542||||TREATMENT||||||||
33794671|NCT00002972|NON_RANDOMIZED|||TREATMENT||NONE||||||
33794672|NCT03958734|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794673|NCT01230047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794674|NCT04870645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794675|NCT01804751|||COHORT||PROSPECTIVE|||||||
33794676|NCT02208258|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33794677|NCT02326649|||COHORT||PROSPECTIVE|||||||
33794678|NCT06062212|||COHORT||PROSPECTIVE|||||||
33794679|NCT04720014|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single-arm, pre-test/post-test pilot study||||
33794680|NCT00588809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794681|NCT01576523|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34016963|NCT00354250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016964|NCT05484453|||OTHER||PROSPECTIVE|||||||
34025459|NCT02935621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34025460|NCT02103504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025461|NCT05260580|NA|SINGLE_GROUP||OTHER||NONE||one group (Experiment group)||||
34025462|NCT00424918|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34025463|NCT01269931|||CASE_CONTROL||PROSPECTIVE|||||||
33794682|NCT06241989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794683|NCT00297674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794684|NCT05218733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33794685|NCT00748150|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33794686|NCT03951649|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled Trail||||
33794687|NCT05339763|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33938139|NCT05835518|||COHORT||PROSPECTIVE|||||||
34025464|NCT04667286|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised trial||||
34025465|NCT01548118|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33938140|NCT03309722|||COHORT||PROSPECTIVE|||||||
33938141|NCT01041586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938142|NCT06482801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938143|NCT01858337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33938144|NCT04313309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938145|NCT06117072|NA|SINGLE_GROUP||PREVENTION||NONE||This randomized controlled intervention study aimed to compare the effects of a Dietary Approaches to Stop Hypertension (DASH) diet and a salt-free diet on blood pressure in hypertension patients. Methods: This study was conducted with 60 patients with primary hypertension. One group (n=30) was given an individualized DASH diet, the other group was given a salt-free diet (n=30), and the participants were followed for two months.||||
33938146|NCT05989152|NA|SINGLE_GROUP||OTHER||NONE||||||
33938147|NCT04328181|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938148|NCT00779116|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33938149|NCT02444689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938150|NCT00439699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938151|NCT04489602|||CASE_ONLY||PROSPECTIVE|||||||
33938152|NCT06247475|||OTHER||PROSPECTIVE|||||||
33938153|NCT00807989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938154|NCT02310984|||COHORT||CROSS_SECTIONAL|||||||
33938155|NCT00026624||||TREATMENT||NONE||||||
33938156|NCT02301728|||CASE_ONLY||PROSPECTIVE|||||||
33938157|NCT05454709|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Investigational Medicinal Product dasiglucagon and control GlucaGen are masked as either treatment A or B. Only the assistant researcher who does the preparation and allocation of the drugs has this key.|Three days treatment A, four days wash out period (standard treatment), three days treatment B.|t|t|t|t
33938158|NCT05314699|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomly assigned to three group, namely the resistance-aerobic exercise group (RA), the aerobic-resistance exercise group (AR), and the reading control group (RC). Participants in RA groups were asked to finish 5 min warm-up, 13 min resistance exercise, 12 min aerobic exercise, and 5 min cool down. Participants in AR groups were asked to finish 5 min warm-up, 12 min aerobic exercise, 13 min resistance exercise, and 5 min cool down. Participants in RC group were required to finish 35 min reading. All groups took a 30 min cognitive test before and after the intervention.The blood lactate were collected before, 17 minutes after, and after the intervention.||||
33938159|NCT00005533|||OTHER||PROSPECTIVE|||||||
33938160|NCT01196091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938161|NCT00934726|||COHORT||PROSPECTIVE|||||||
33938162|NCT02978911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025466|NCT03244683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025467|NCT01069874|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099272|NCT06375772|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33794688|NCT04795128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794689|NCT06448364|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33938163|NCT05786976|RANDOMIZED|PARALLEL||OTHER||SINGLE||intra-individual comparison|t|f|f|f
33794690|NCT04663464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In each of 2 study periods, subjects received receive either a transdermal patch containing 300 μg abaloparatide for 5 minutes or an injection of abaloparatide SC 80 μg.||||
33794691|NCT03571711|||COHORT||PROSPECTIVE|||||||
33794692|NCT04594759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|The study member assessing change in acne using the Comprehensive Acne Severity Scale does not know the medication the participants are taking.|||||
33794693|NCT01849055|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33794694|NCT05422651|||COHORT||PROSPECTIVE|||||||
33794695|NCT04974008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794696|NCT00959946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794697|NCT03769506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794698|NCT03781336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants are allocated into the mindfulness-based self-care group or a wait list group for 5 weeks. Since the group is offered during work hours, the waitlist group could be best described as life as usual. After group allocation, all participants completed demographic and self report clinical assessments at baseline, and self report clinical assessments at follow-up."||||
33794699|NCT00785863|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33938164|NCT01659528|||COHORT||PROSPECTIVE|||||||
33938165|NCT03362658|||CASE_CONTROL||PROSPECTIVE|||||||
33938166|NCT03642327|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT||||
33938167|NCT02293265|NA|SINGLE_GROUP||||NONE||||||
34025468|NCT00014352||||TREATMENT||||||||
34025469|NCT06633276|||CASE_ONLY||PROSPECTIVE|||||||
34025470|NCT06634290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938168|NCT05791669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938169|NCT05248100|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be told during the consent process that as part of the study there are intervention and control clinics. Laboratory staff analyzing viral load samples will be blind to intervention/control attribution.||f|f|f|t
34025471|NCT00754715|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34025472|NCT05135403|||COHORT||PROSPECTIVE|||||||
34025473|NCT04563546|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34025474|NCT02796794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099273|NCT02944825|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34099274|NCT01652274|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34099275|NCT04140929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster-randomized controlled trial|t|f|f|f
34099276|NCT05376553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099277|NCT04606966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Speech therapist evaluator will be blinded to participants' intervention condition assignment|"Randomized Controlled Trial assigned to one of 3 groups:~Therapeutic Horseback Riding group Barn Activity group (no-horse control) Waitlist Hybrid group"|f|f|f|t
34099278|NCT05537857|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Dietary salt will be varied. Kitchen staff will not be blinded. Foods/diet will be coded so blind to investigators interacting with participants and analytical staff although participants may be able to perceive salty foods.||t|f|f|f
34099279|NCT03034876|||COHORT||PROSPECTIVE|||||||
34016965|NCT05854888|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomization envelope was opened by the midwife when the participant entered the second stage of labor and was destroyed thereafter. The allocation was only shown to the midwife and if necessary, the obstetrician. The trial intervention took place during the second stage of the spontaneous vaginal birth. Participants were randomized to one of the two groups, perineal massage and warm compresses on second stage of labor or control group (hands-on). The participants were blinded to their allocation. After the placenta delivery, a blinded midwife not otherwise involved in the birth but trained, assessed the perineum (graded the perineal tears). The data about the variables included in the study were registered by the midwife responsible for the birth. Midwives who assess the primary outcomes and the principal investigator were blinded to the randomization.|The present study was a single-centre, prospective, randomized controlled trial. Eligibility and informed consent to participate were checked once the woman was in established labor. All participants signed an informed consent form and received a copy wherein the study was described in detail.Eligible participants were randomized at the second stage of labor.The trial intervention took place during the second stage of the spontaneous vaginal birth. Participants were randomized to one of the two groups, perineal massage and warm compresses on second stage of labor or control group (hands-on). The participants could adopt the birth position they preferred.|t|f|t|t
34016966|NCT04694183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016967|NCT00786994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099280|NCT00944021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099281|NCT05697003|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33794700|NCT01538719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794701|NCT00001637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794702|NCT04783246|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A two-period cross over design will be implemented to compare between groups in a self-paired manner to minimize the effects of confounding covariates. Participants will agree to either immediate randomization to the non-intervention period or the intervention period at the time of consent. Participants will be randomized utilizing conceal block randomization.||||
33794703|NCT01885806|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33794704|NCT05692908|NA|SEQUENTIAL||TREATMENT||NONE||||||
33794705|NCT01234844|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33794706|NCT05223205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794707|NCT01147380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794708|NCT01833364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794709|NCT06174337|||COHORT||PROSPECTIVE|||||||
33794710|NCT04828642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The provider will produce the supplementation and the placebo with the same aspect, marked with numbers|A randomized, double-blind, placebo-control, parallel controlled trial will be conducted.|t|f|t|f
33794711|NCT01282944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794712|NCT06675370|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794713|NCT01179334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794714|NCT03919864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33794715|NCT00459758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794716|NCT04566458|||COHORT||RETROSPECTIVE|||||||
33794717|NCT05819099|||CASE_CONTROL||RETROSPECTIVE|||||||
33794718|NCT00992173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794719|NCT04677322|||CASE_ONLY||PROSPECTIVE|||||||
33794720|NCT03538912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794721|NCT00735384|||CASE_CONTROL||PROSPECTIVE|||||||
33794722|NCT00628862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794723|NCT03491696|NA|SINGLE_GROUP||TREATMENT||NONE||It is an exploratory open label study with a single group, considered as a population of interest. Datas will be reported to existing knowledges and could not be a evidence of an effect but a suggestion for eventual future studies which have to be controlled versus placebo.||||
33794724|NCT02808338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794725|NCT02910388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34016968|NCT02279693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34099282|NCT02802865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099283|NCT02080130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34099284|NCT04982822|||OTHER||PROSPECTIVE|||||||
34099285|NCT05295290|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE|This is a low-interventional cohort study to determine cardiac and non-cardiac long-term outcomes of persons less than 21 years of age with myocarditis/pericarditis after the administration of COMIRNATY, compared with similarly aged persons with myocarditis/pericarditis associated with COVID-19, including MIS-C, without exposure to COMIRNATY.|||||
34099286|NCT03077308|||COHORT||PROSPECTIVE|||||||
34099287|NCT05232305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will not know which type of bread to eat.|The study will conduct by using a prospective randomized double-blind clinical trial model.|t|t|f|f
33794726|NCT00001354||||TREATMENT||||||||
33794727|NCT06318624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There are 2 different groups in the study. One of them is the intervention group and the other is the sham group.||t|f|f|f
33794728|NCT05056051|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||All patients enrolled will have neo-squamous segment tested with WATS-3D and biopsy forceps|f|f|f|t
33794729|NCT06398912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33794730|NCT06647641|||COHORT||CROSS_SECTIONAL|||||||
33794731|NCT03189316|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33794732|NCT03938428|||COHORT||PROSPECTIVE|||||||
33794733|NCT03335969|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each patient will serve as their own control by comparing their bowel habits in a diary 4 weeks prior to colon irrigation to the bowel habits in their diary 4 weeks post colon irrigation.||||
33794734|NCT05558020|||CASE_ONLY||PROSPECTIVE|||||||
33794735|NCT00888979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794736|NCT03754218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794737|NCT04016025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator of the study will not know in which vehicle the enrolled patient will receive the standard therapeutical drug|Randomized single-blind|f|t|t|f
33794738|NCT04979988|||CASE_ONLY||RETROSPECTIVE|||||||
33794739|NCT01185782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794740|NCT01315314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794741|NCT00992238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794742|NCT06015542|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, phase two, prospective, non-randomized, sponsor-initiated explorative trial||||
33794743|NCT01208311|||COHORT||PROSPECTIVE|||||||
33794744|NCT04864275|||COHORT||PROSPECTIVE|||||||
33794745|NCT06549582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794746|NCT02740140|||COHORT||PROSPECTIVE|||||||
33794747|NCT05147688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794748|NCT04501276|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33794749|NCT03784768|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 stroke patients will be included in this study. The patients who meet the inclusion criteria will be divided randomly into 2 groups as study (n=15) and control (n=15). Patients in study group received 45-min conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion and strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy. Patients in the control group received 60-min conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion and strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.||||
33794750|NCT05677438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794751|NCT02711293|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33794752|NCT05697081|||OTHER||CROSS_SECTIONAL|||||||
33794753|NCT03697876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the partial and final analysis.~The masking will be done by means of identical labels. Which, in accordance with current and applicable regulations, must contain at least:~* Name, address and telephone number of the sponsor~* Pharmaceutical form and route of administration~* Lot Number~* Legend Exclusively for clinical studies~* Date of Expiry"|controlled, of parallel groups, double blind, randomized, exploratory|t|f|t|f
33794754|NCT06674304|||COHORT||PROSPECTIVE|||||||
33794755|NCT04151407|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33794756|NCT03730922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study started as a randomized trial but was november 2023 changed for a prospective single arm tieal||||
33794757|NCT00138619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794758|NCT03697616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794759|NCT02867670|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794760|NCT00012506||||TREATMENT||||||||
33794761|NCT00012935|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33794762|NCT03003845|||OTHER||PROSPECTIVE|||||||
33794763|NCT05168553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794764|NCT05370430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794765|NCT06225882|||COHORT||CROSS_SECTIONAL|||||||
33794766|NCT06323902|||COHORT||PROSPECTIVE|||||||
33794767|NCT06001242|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794768|NCT00188604|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33794769|NCT03702673|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33794770|NCT03336424|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel study, where group A receives non-invasive investigations and group B receives Invasive investigations.||||
33794771|NCT03620214|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33794772|NCT05041491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A study research assistant that is not involved in the study participants' allocation process will create opaque, sealed envelopes with allocation sequences based on the randomization table created by the study statistician. The assignment of intervention to study participants will be based on the study allocation sequence generated by the statistician and the study team will enroll study participants and assign them to the interventions. The study team will be blinded until study participants' allocation (the day before visit G). After this, the study team will not be blinded to study participants' allocation as they will be responsible for assigning study participants, and for applying and monitoring the interventions. The study statistician will always be blinded.|Participants will be randomized to either the BREAK condition (5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/wk) or the ONE condition (45-min of brisk walking performed as a single continuous bout, 5 days/wk) for 3 months. Participants will complete all study visits in only one group.|f|f|f|t
34016969|NCT04588714|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot study, one arm, pre-test, post-test trial||||
34016970|NCT01718548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34016971|NCT04882423|RANDOMIZED|CROSSOVER||PREVENTION||NONE||In a randomized crossover design, each participant will undergo four study phases with a different test meal at the end of each phase. Every phase will consist of subjects consuming for six days their normal diet excluding cruciferous and apiaceous vegetables, alcohol, and caffeine. Furthermore, participants will refrain from meat products for 24 hours prior to the test meal, given that HAA are generally excreted in the urine by 12 hours post ingestion (18, 80). Compliance will be assessed with a questionnaire and the analysis of baseline levels of phytochemicals in spot urine samples that are to be collected prior to the test meal. On day seven of each phase and after an overnight fast, subjects will be randomly assigned to eat (in a private room near Dr. Truda's lab) one of four meals (prepared in a food grade lab also near Dr. Truda's lab)||||
34016972|NCT03477552|RANDOMIZED|PARALLEL||OTHER||NONE||Adult sickle cell patients who need of a new peripheral intravenous catheter placement (for fluid or porphine therapy) will be randomized between two arms : usual technique or use of the AccuveinV400® device). The randomization list (ratio 1: 1) will be made by the statistician of the study using the SAS software and balanced by random blocks of small size (2, 4, 6) to make it unpredictable. The randomization will be stratified on the center and the number of hospitalizations in the previous year (\>3, \<3).||||
34016973|NCT03738514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016974|NCT05755152|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants will be randomized to their first intervention and cross over to the second intervention.|t|f|f|f
33794773|NCT01587755|RANDOMIZED|PARALLEL||||NONE||||||
33794774|NCT05485402|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Randomized, controlled, parallel and double-blind intervention study. The total duration of the study will be 24 weeks (12-weeks of intervention and 12-weeks of follow-up). The study will have three arms of intervention. The intervention products will be prebiotic supplement based on FOS and inulin or virgin olive oil rich in phenolic compounds with 156 mg hydroxytyrosol and tyrosol/kg oil. The placebo will be refined olive oil (38.6 mg hydroxytyrosol and tyrosol/kg oil) or maltodextrin. Both with the same format and appearance, to ensure the double-blind intervention.~All the volunteers will receive NFOC-diet and physical activity recommendations co-created during the co-creation study. The nutritional recommendations are based on DASH diet and foods rich in protein (in particular, leucine), vitamin D, polyunsaturated acids, phosphorus and iron. The physical activity recommendations are 150 min/week of physical activity, with at least two sessions focused on motor strength."|t|f|t|t
34016975|NCT02945605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34016976|NCT00485628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34016977|NCT01822574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34016978|NCT02415569|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34016979|NCT02242565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794775|NCT03343938|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33794776|NCT03737682|||COHORT||PROSPECTIVE|||||||
33794777|NCT03608839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All the patients were masked. They didn't have acess to the group they belonged.~The care provider didn't know the quantity of the drug injected. The outcome assessor was masked as well."|At the baseline study visit, patients were randomized with a 1:1:1 allocation to receive dexamethasone solution 4 mg/ml: 0,01 ml (40 µg); or 0,03 ml (120 µg); or 0,05 ml (200 µg). In follow up visits (1, 3, 7, 14, 21, 28 days after) were performed BCVA, slit-lamp biomicroscopy, applanation tonometry, fundus biomicroscopy, SD- OCT (Spectralis; Heidelberg Engineering, Heidelberg, Germany). The randomization schedule was computer generated and stored in a locked cabinet until the study ended. Both patients and the study personnel who collected BCVA, OCT data were masked to the patient study assignment.|t|t|t|t
33938170|NCT03653286|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigations of the peak muscle torque, analysis of ventilatory anaerobic thresholds, running economy and maximal oxygen consumption will be performed by a blind investigator. Data analysis will be performed by a blind investigator in the control and intervention groups.|The runners will be randomized into two groups, being: control group (CG) - will perform only run and intervention group (GI) - using the medium-frequency alternating current and run.|f|f|t|t
33938171|NCT06376812|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938172|NCT01637792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938173|NCT04749368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938174|NCT00816894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794778|NCT02538263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794779|NCT05989646|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Cross-sectional and interventional cohort study||||
33794780|NCT05908942|||CASE_CONTROL||PROSPECTIVE|||||||
33794781|NCT02006940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794782|NCT03035123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33794783|NCT00959582|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794784|NCT04191486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794785|NCT06676397|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33794786|NCT06234644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794787|NCT05261815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study would be double blinded as participants and assessors of the study would be kept blind of the treatment group to which the participant will be allocated.||t|f|f|t
33794788|NCT04705922|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33794789|NCT04464421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794790|NCT05483335|||OTHER||CROSS_SECTIONAL|||||||
33794791|NCT03540667|||COHORT||PROSPECTIVE|||||||
33794792|NCT03768869|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Because inpatient management and outpatient management use different treatment methods, blinding is not possible.|Patients will be stratified as high risk, where they will receive inpatient management, or low risk, where they will then be randomize to receive inpatient or outpatient management.||||
33794793|NCT01454661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33794794|NCT01169311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794795|NCT05704751|||CASE_CONTROL||PROSPECTIVE|||||||
33794796|NCT05245786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938175|NCT04185844|||COHORT||PROSPECTIVE|||||||
33938176|NCT03702166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938177|NCT00508820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938178|NCT02309372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938179|NCT04297124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938180|NCT02371980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938181|NCT01429376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34016980|NCT01551641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34016981|NCT00860366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016982|NCT05813366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34016983|NCT06104241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016984|NCT01329575|||COHORT||PROSPECTIVE|||||||
34016985|NCT03706170|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34016986|NCT01521039|||COHORT||PROSPECTIVE|||||||
34016987|NCT06253819|||COHORT||PROSPECTIVE|||||||
34016988|NCT04798118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34016989|NCT00392236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34016990|NCT00773734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016991|NCT05355766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016992|NCT03054558|||CASE_CONTROL||PROSPECTIVE|||||||
34016993|NCT02082821|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34016994|NCT02448706|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34099288|NCT03508570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794797|NCT02158091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34016995|NCT05284396|||CASE_CONTROL||RETROSPECTIVE|||||||
34016996|NCT04436861|||COHORT||OTHER|||||||
34016997|NCT05056883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34016998|NCT00281606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34016999|NCT00220987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714317|NCT04682015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017000|NCT01059539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017001|NCT04094376|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34017002|NCT01745705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33714318|NCT05604092|||CASE_ONLY||CROSS_SECTIONAL|||||||
33714319|NCT02544230|||COHORT||RETROSPECTIVE|||||||
33714320|NCT00247689|||||PROSPECTIVE|||||||
33714321|NCT01417234|||COHORT||PROSPECTIVE|||||||
33714322|NCT05573789|||OTHER||RETROSPECTIVE|||||||
33714323|NCT03446469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017003|NCT04530240|||COHORT||RETROSPECTIVE|||||||
34017004|NCT02909738|||COHORT||PROSPECTIVE|||||||
34017005|NCT02704780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099289|NCT05669066|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients were randomized to 2 groups. The Meditation group or the Control group. The meditation group was asked to meditate 2 times a day, for 2 weeks preoperatively and for 30 days post operatively||||
33714324|NCT05512611|||CASE_ONLY||PROSPECTIVE|||||||
33714325|NCT02903550|||OTHER||PROSPECTIVE|||||||
33714326|NCT03714867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, care providers, and investigators will all be blinded to patient group identity.|Intervention is single dose. Patients will be assigned to either treatment or placebo arms. No opportunity for crossing over will be present.|t|t|t|f
33714327|NCT04894773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Our study will be single-blinded, outcome assessor-blinded. The assessor will be blinded to avoid being biased during the outcome assessment.||f|f|f|t
33714328|NCT01161147|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714329|NCT03125343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All patients with complete response defined as described above will be offered to enter the study||||
33714330|NCT03018171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714331|NCT02521636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714332|NCT05773508|||CASE_CONTROL||PROSPECTIVE|||||||
33714333|NCT00821977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714334|NCT05822713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714335|NCT00211809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714336|NCT04762433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and the assessor will be blinded as to the recruitment and allocation via the electronic consent format and the intervention via the mobile application.|This study will use a single-blind, single-centre, parallel, randomized controlled trial (RCT) design which will incorporate individualised treatment flexibility, as in a real-world setting, and provide a realistic estimation in future KEPT-app RCT study (Sidik et al., 2021).|f|f|t|t
33714337|NCT04462549|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial 100 subjects who will participate in this study will be randomly assigned to the Resource Facilitation Group. These subjects will receive resource facilitation services in addition to their regular rehabilitation follow-up services, and 50 subjects who will participate in this study will be randomly assigned to the Regular Follow-up Group, who will only receive their regular rehabilitation follow-up services/standard of care. Randomization will be generated within RedCap.||||
33714338|NCT00784992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714339|NCT00399776|||CASE_CONTROL||RETROSPECTIVE|||||||
33714340|NCT03240614|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Interventions will be labeled using a Letter key so the analysis of the dataset by our statistician will be blinded|Will test preoxygenation using High Flow Nasal Cannulae, Non-rebreather mask and Bag-Valve-Mask|f|f|f|t
33714341|NCT02329730|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33714342|NCT05255068|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Because this study is a single-group design, all participants were recruited from the nursing home site that was assigned as the intervention group. no one is blinded to the intervention assignment, but all participants and outcome assessors were blinded for the research questions/aims.|||||
33714343|NCT06208033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714344|NCT04925037|||COHORT||CROSS_SECTIONAL|||||||
33714345|NCT00256893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33794798|NCT05732701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind||t|f|f|t
33714346|NCT01306591|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33714347|NCT02206334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714348|NCT01438424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714349|NCT05324553|||OTHER||PROSPECTIVE|||||||
33714350|NCT03297970|||COHORT||PROSPECTIVE|||||||
33714351|NCT04325581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Interventional , Placebo Control|t|t|t|t
33714352|NCT03715764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33714353|NCT04853511|||COHORT||PROSPECTIVE|||||||
33714354|NCT03021408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714355|NCT06352281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794799|NCT01012453|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33794800|NCT04145492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794801|NCT02458911|||COHORT||PROSPECTIVE|||||||
33794802|NCT04905225|||COHORT||RETROSPECTIVE|||||||
33794803|NCT01461655|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34017006|NCT04340817|||COHORT||PROSPECTIVE|||||||
34017007|NCT00417404|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34017008|NCT04724044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a prospective, 1:1 randomized, double-blind, placebo-controlled trial|t|t|t|t
34017009|NCT04314232|||COHORT||PROSPECTIVE|||||||
34017010|NCT02856880|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34017011|NCT03426566|||OTHER||RETROSPECTIVE|||||||
34017012|NCT06490237|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34017013|NCT00336076|||COHORT||PROSPECTIVE|||||||
34017014|NCT04987242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects, Investigators and laboratories involved in the conduct of the study will be blinded to subject treatment assignment.|Study population includes generally healthy subjects with hyperuricemia without CKD, and those with eGFR of mild-moderate CKD. The maximal tolerated dose from the MAD study in normal healthy volunteers (Study 102) will be administered. The study is comprised of two Parts. Under optional Part 2, only subjects with eGFR of CKD Stages 2- 3a.|t|f|t|f
33794804|NCT05082714|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority trial||||
33794805|NCT01124188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794806|NCT06353282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794807|NCT01424540|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33794808|NCT04628715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"There are two intervention phases, a supervised intervention and a feasibility study for a non-supervised intervention (during the follow-up phase after the supervised intervention).~During the supervised intervention (5weeks), participant will be randomly allocated to the RSA biofeedback intervention (1) or a sham-control intervention (2). Then a 5-week follow-up phase is included during which the feasibility study of a non-supervised RSA biofeedback intervention will take place. The two groups from the supervised intervention will each be split into two (a and b) where groups 1a and 2a will receive a non-supervised biofeedback intervention and groups 1b and 2b will receive no intervention. Allocation to groups a and b is also ad random. Important to note: only during the supervised intervention, blinding of participants is possible whereas during the non-supervised intervention, this is not feasible."|t|f|f|f
33794809|NCT00497991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017015|NCT02520752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794810|NCT05591144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794811|NCT03943459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
33794812|NCT06676020|||CASE_CONTROL||PROSPECTIVE|||||||
33794813|NCT01027624|||COHORT||PROSPECTIVE|||||||
33794814|NCT02387099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794815|NCT00295074|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794816|NCT00001304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794817|NCT06354283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The progressive relaxation intervention and follow-up was conducted by the researcher who was not blinded to the interventions (PSI). Randomization was performed by another academic who was not an investigator in the study. In order to avoid bias, the researcher who conducted the intervention did not participate in any step of the pre-test, post-test and statistical evaluation process. Group information was not shared with the statistician who performed the analysis.|Intervention Group and Control Group|f|f|t|t
33794818|NCT05036746|||COHORT||PROSPECTIVE|||||||
33794819|NCT04189770|||COHORT||PROSPECTIVE|||||||
33794820|NCT01964937|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33794821|NCT00815750|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33938182|NCT00498706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938183|NCT04744766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the assessment of the results as regard the complication and long term follow up is done by a person who is blind as regard the study group of the patient examined||f|f|f|t
33938184|NCT00875966|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938185|NCT02278159|||COHORT||PROSPECTIVE|||||||
33938186|NCT01521637|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33938187|NCT01308528|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938188|NCT01318291|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33938189|NCT01584427|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33938190|NCT00728572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017016|NCT05190653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It will not be possible to blind participants or researchers (PC clinicians who will be involved in delivery the intervention) to the intervention but the individual doing the data collection, the research assistant, will be blinded to the randomization allocation.||f|f|f|t
34017017|NCT01431859|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34017018|NCT00240942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017019|NCT05340777|||CASE_ONLY||PROSPECTIVE|||||||
34017020|NCT03859141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The phase Ⅰ clinical trial was a single arm.The phase Ⅲ was 3 parallel arms.|t|f|t|f
34017021|NCT00968292|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017022|NCT02991027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714356|NCT05511051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714357|NCT00928681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714358|NCT03551860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to nature of intervention (one single injection vs a second single injection in different anatomical location) the participant and the care provider cannot be blinded.The investigator will use an already filled data collection sheet and enter randomised data into a master file. The data will be analysed by an individual blinded to the which group the participant was in.||f|f|t|t
33714359|NCT06023823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714360|NCT00314912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714361|NCT01791569|||||PROSPECTIVE|||||||
33714362|NCT02950025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714363|NCT01261689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714364|NCT00719121|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33714365|NCT02743871|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33714366|NCT05748756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714367|NCT05289180|||CASE_ONLY||PROSPECTIVE|||||||
33714368|NCT01629160|||COHORT||PROSPECTIVE|||||||
33714369|NCT02615366|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714370|NCT05792891|||CASE_CONTROL||PROSPECTIVE|||||||
33714371|NCT02840370|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33714372|NCT05050604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Participant, Investigator)||t|t|t|t
33938191|NCT01609673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938192|NCT04681573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Arm study including patients with NAFLD||||
33938193|NCT00369564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34099290|NCT02827370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099291|NCT01141543|||COHORT||PROSPECTIVE|||||||
33714373|NCT04085809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Upon enrollment, each subject received a randomization code, indicating which leg the study product had to be applied (the other leg received no study product). Each subject in this study served as her own control.|f|f|t|t
33714374|NCT04061356|||COHORT||PROSPECTIVE|||||||
33714375|NCT00644995|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714376|NCT00001598||||TREATMENT||||||||
33714377|NCT02652520|NA|SINGLE_GROUP||OTHER||NONE||||||
33714378|NCT04831983|||COHORT||PROSPECTIVE|||||||
33714379|NCT00435214|||COHORT||OTHER|||||||
33714380|NCT02075450|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|f|t
33714381|NCT02753023|||COHORT||PROSPECTIVE|||||||
33714382|NCT00004978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714383|NCT04425174|||CASE_CONTROL||PROSPECTIVE|||||||
33714384|NCT04862364|||CASE_CONTROL||PROSPECTIVE|||||||
33714385|NCT00499876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33714386|NCT04959344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|observer-blind||t|t|t|f
33714387|NCT02526745|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33714388|NCT03059823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714389|NCT02507505|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33714390|NCT01240447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714391|NCT01842698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714392|NCT05145452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blind, randomized controlled trial in men and women||t|f|f|f
33714393|NCT02775721|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714394|NCT05565651|||COHORT||RETROSPECTIVE|||||||
33714395|NCT02104713|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33714396|NCT03336853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single center, participants and data analyst blind, two-arm, randomized, placebo controlled clinical trial study|t|f|f|f
33714397|NCT06066684|||COHORT||PROSPECTIVE|||||||
33714398|NCT06248632|||COHORT||PROSPECTIVE|||||||
33714399|NCT00635960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714400|NCT01536847|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33714401|NCT03064360|||COHORT||PROSPECTIVE|||||||
33714402|NCT01010386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714403|NCT01813578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714404|NCT05601817|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Single-blind|A 2 by 2 factorial design|f|f|t|t
33714405|NCT05673278|||COHORT||PROSPECTIVE|||||||
33714406|NCT01380873|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33714407|NCT06175260|||COHORT||PROSPECTIVE|||||||
33714408|NCT04380168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33714409|NCT06331416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Open-label randomized controlled trial, allocation ratio 1:1||||
33714410|NCT00892853|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794822|NCT04632368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligible participants, on enrollment in the study, would be randomly assigned to meditation intervention group vs control group. Control group will be offered intervention at the end of the study||||
33794823|NCT06068244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794824|NCT01772420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794825|NCT04429230|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33938194|NCT04101227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938195|NCT01693666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938196|NCT00645229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938197|NCT00040911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33938198|NCT04837768|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Patients undergoing frozen cycles following ICSI will receive artificial endometrial preparation from day 2/3 of their cycle in the form of 2mg Estradiol Valerate pills thrice daily for 7-10 days. After confirming endometrial thickness \> 7mm via TVS, progesterone supplementation will start via Prontogest® 400mg vaginal pessaries twice daily for 5 days, ending with the day of embryo transfer (ET).~On the morning of ET, serum progesterone will be measured and if the value is over 9.2ng/ml, only the traditional twice daily vaginal progesterone will be resumed until 12 weeks gestation. If the value is under 9.2 ng/ml, intramuscular progesterone supplementation with Prontogest® 100mg will be added in twice-weekly doses (every 3 days) to the vaginal supplementation.~Quantitative β-hcg 2 weeks after ET to detect chemical pregnancies. Ultrasound 4 weeks after ET to detect clinical pregnancies. Ultrasound repeated at 12 weeks to confirm ongoing pregnancy rates."||||
33938199|NCT00001925||||TREATMENT||||||||
33938200|NCT04652349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938201|NCT02734472|||COHORT||PROSPECTIVE|||||||
33938202|NCT02177942|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33938203|NCT02295254|||COHORT||PROSPECTIVE|||||||
33938204|NCT04052594|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33938205|NCT04091451|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938206|NCT03814161|||COHORT||PROSPECTIVE|||||||
33938207|NCT04838587|||COHORT||PROSPECTIVE|||||||
33938208|NCT04585633|||OTHER||PROSPECTIVE|||||||
33938209|NCT05074160|||OTHER||OTHER|||||||
33938210|NCT04310267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938211|NCT02773849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938212|NCT05762224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938213|NCT01271049|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33938214|NCT05675124|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33938215|NCT01336114|||CASE_ONLY||PROSPECTIVE|||||||
33938216|NCT06246162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938217|NCT02620631|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33938218|NCT04726124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938219|NCT01842191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938220|NCT02364999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099292|NCT05020119|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study aims to investigate the safety profile and therapeutic potential of neoantigen-expanded autologous immune cell for treating solid tumors. The safety evaluation will be performed by a traditional 3+3 dose escalation scheme. The three cohorts will be established in the trial, and the dose level of each cohort will be enrolling 3\~6 subjects.||||
34099293|NCT01210911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938221|NCT00218283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017023|NCT04402775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients eligible for the trial were randomly allocated to the tourniquet group (intervention) or vascular clamp group (control)|t|f|f|t
34017024|NCT03050008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017025|NCT00097877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017026|NCT04244201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017027|NCT02148341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34099294|NCT01439295|||COHORT||PROSPECTIVE|||||||
34099295|NCT06694103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34099296|NCT05047887|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A single group in a split-mouth design, right and left sides are randomly allocated to the intervention group (16 sides in 8 patients)||||
34099297|NCT05811637|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized and trial||||
34099298|NCT01310114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099299|NCT00414609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099300|NCT00276380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099301|NCT01506336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714411|NCT04671407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomized controlled double-blind|Randomized controlled double-blind|t|t|t|f
33714412|NCT03731988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714413|NCT03296930|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017028|NCT02737332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714414|NCT03092154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two groups: with or without lipid-lowering agents|t|f|t|t
33714415|NCT02707991|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33714416|NCT02206568|NA|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33714417|NCT02241174|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017029|NCT02564419|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Participants will be undergoing a unilateral implantation of the Medtronic Active PC+S with unilateral subdural strip electrodes over the motor cortex. They will receive 24 sessions over a 3-6 month period which consists of external stimulation.|Medtronic Activa PC + S is a multi-programmable primary cell neurostimulator that records bioelectric data and deliver electrical stimulation through leads implanted in the brain.||||
33714418|NCT05592964|||CASE_CONTROL||PROSPECTIVE|||||||
33714419|NCT06337188|NA|SINGLE_GROUP||OTHER||NONE||||||
33714420|NCT05893173|||CASE_ONLY||CROSS_SECTIONAL|||||||
33714421|NCT03066089|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017030|NCT06285630|||COHORT||PROSPECTIVE|||||||
34017031|NCT05370755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017032|NCT05485935|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34017033|NCT04072016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017034|NCT00486564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017035|NCT03850951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099302|NCT03656575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099303|NCT02080728|RANDOMIZED|PARALLEL||||DOUBLE||||||
34099304|NCT01716559|||COHORT||PROSPECTIVE|||||||
34099305|NCT00664677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099306|NCT05422222|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099307|NCT00360100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099308|NCT03931512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714422|NCT04133220|||COHORT||PROSPECTIVE|||||||
33714423|NCT00006080||||TREATMENT||||||||
33714424|NCT03872167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714425|NCT00869349|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33714426|NCT00550706|||CASE_ONLY||PROSPECTIVE|||||||
33714427|NCT03454893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714428|NCT00359008|||COHORT||PROSPECTIVE|||||||
33714429|NCT05573607|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33714430|NCT00435292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714431|NCT06065995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open-label randomized controlled trial||||
33714432|NCT03916276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized 3-group, 90-subject clinical trial to test the mediators and moderators of cognitive therapy, mindfulness meditation, and activation skills on individuals with heterogeneous chronic pain conditions who are at risk for opioid misuse.|f|f|f|t
33714433|NCT05799729|||COHORT||PROSPECTIVE|||||||
33714434|NCT02029625|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33714435|NCT00587639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714436|NCT04182360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biased coin up-and-down design.|t|t|t|t
33938222|NCT01843933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938223|NCT02615808|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33938224|NCT04793243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938225|NCT01815866|||CASE_CONTROL||PROSPECTIVE|||||||
33938226|NCT03561844|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33938227|NCT03087110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938228|NCT00735072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938229|NCT00171327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938230|NCT04775485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single intervention across 3 arms - - no comparator||||
33938231|NCT00606710|||COHORT||PROSPECTIVE|||||||
33938232|NCT03082768|NA|SINGLE_GROUP||OTHER||NONE||||||
34099309|NCT01146444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099310|NCT05539911|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34099311|NCT05121922|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34017036|NCT00606359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017037|NCT04323241|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator will not know the interventional group.|The operative procedures are similar in all patients and followed the same technical steps. All patients are randomized according to the removal of placenta from the uterus after childbirth; manually removing placenta and control of endometrial cavity by fingers (Group 1) or controlled cord traction without putting fingers inside the uterus (Group 2).|f|f|t|f
34017038|NCT01025479|||CASE_ONLY||RETROSPECTIVE|||||||
34017039|NCT02438852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34017040|NCT03002662|||CASE_CONTROL||PROSPECTIVE|||||||
34017041|NCT05865821|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator|Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure.|f|f|t|f
34017042|NCT03895723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor was masking for patients treatment arms|Arm A: minimally invasive surgery Arm B: open|f|f|f|t
34017043|NCT04008966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017044|NCT02218970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017045|NCT01412372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017046|NCT02890407|||FAMILY_BASED||RETROSPECTIVE|||||||
34017047|NCT02925585|||CASE_CONTROL||PROSPECTIVE|||||||
34017048|NCT06019520|RANDOMIZED|PARALLEL||PREVENTION||NONE||It will be a two-arm study with 35 patients in each arm. After taking informed consent, a total of 70 patients will be enrolled. The patients will be enrolled by convenience nonprobability sampling technique. Then they will be randomized to the N-Acetylcysteine plus chemotherapy and chemotherapy-alone arms.||||
34017049|NCT02541162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017050|NCT04055051|||COHORT||PROSPECTIVE|||||||
34017051|NCT00554775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017052|NCT04757038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017053|NCT00929331|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099312|NCT05791149|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34099313|NCT03118271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099314|NCT00000738||||TREATMENT||DOUBLE||||||
34099315|NCT04776252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099316|NCT06278298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099317|NCT06548347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34099318|NCT03702374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099319|NCT05835557|RANDOMIZED|PARALLEL||OTHER||SINGLE|Sham treatment of altitude exposure in an environmental chamber.|Two groups exposed to 9 sessions of high intensity short interval training with or without blood flow restriction between sets of exercise.|t|f|f|f
34099320|NCT00180700|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blinded||t|f|f|f
34099321|NCT02617212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099322|NCT06038032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099323|NCT06149013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099324|NCT02639559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099325|NCT00158431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099326|NCT05038826|||COHORT||RETROSPECTIVE|||||||
34099327|NCT02048813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714437|NCT01266512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714438|NCT01943903|||COHORT||PROSPECTIVE|||||||
33714439|NCT01078012|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33714440|NCT02692716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714441|NCT04030754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33714442|NCT01650623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714443|NCT00836290|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33714444|NCT03605459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714445|NCT01514812|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33714446|NCT01549860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714447|NCT02417701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714448|NCT04224649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714449|NCT02425657|||COHORT||OTHER|||||||
33714450|NCT01887873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714451|NCT03043131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714452|NCT01581931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714453|NCT01411228|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714454|NCT02852408|||CASE_CONTROL||PROSPECTIVE|||||||
33714455|NCT01090960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714456|NCT05195970|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714457|NCT00867009|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714458|NCT01155232|||COHORT||PROSPECTIVE|||||||
33714459|NCT03453710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be evaluated by a blinded study nurse, unaware of treatment allocation, for administration of baseline questionnaires, as well as subsequent post-operative questionnaires.|Prospective, randomized controlled trial|f|f|f|t
33714460|NCT05195125|NA|SINGLE_GROUP||PREVENTION||NONE||All study subjects will be enrolled to the treatment arm||||
33714461|NCT04053205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714462|NCT01352299|RANDOMIZED|PARALLEL||||NONE||||||
33714463|NCT04086147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714464|NCT01680705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714465|NCT03552315|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33714466|NCT00642460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794826|NCT00411099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794827|NCT01078688|||COHORT||CROSS_SECTIONAL|||||||
34017054|NCT04188301|RANDOMIZED|PARALLEL||TREATMENT||NONE|While this is an open label study and there is no placebo treatment group, all efforts will be made to ensure that that medical/technical staff assessing skin Mf, adverse events (AEs) and ophthalmological findings will be unaware of initial baseline skin and ocular Mf findings and treatment arm as best as possible.|"Participants will be split into two strata - those without ocular Mf detected six months after ivermectin pretreatment in the Part I preceding study AND without ocular Mf detected at baseline in the part II study will be in stratum 1. Those participants with ocular Mf detected 6 months after ivermectin pretreatment in the preceding study OR with ocular Mf detected at the baseline exam for this study will be in stratum 2. Stratum 1 will be enrolled first, followed by stratum 2. Members of each stratum will be evenly randomized into one of three treatment arms:~1. IVM + ALB - Single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)~2. IDA x 1 dose - Single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)~3. IDA x 3 doses -Once daily for 3 days oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)"||||
34017055|NCT05065983|NA|SINGLE_GROUP||PREVENTION||NONE|Open Label|Open Label Safety and Immunogenicity||||
33794828|NCT02753413|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34017056|NCT05154812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017057|NCT00696579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794829|NCT00131144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794830|NCT06556225|||OTHER||RETROSPECTIVE|||||||
33794831|NCT05061641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the treating physicians were not informed of the grouping|Prospective cohort study|t|t|f|f
33938233|NCT01553695|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33938234|NCT01281722|||CASE_CONTROL||PROSPECTIVE|||||||
33938235|NCT03519776|||CASE_ONLY||PROSPECTIVE|||||||
33938236|NCT01235494|NA|SINGLE_GROUP||OTHER||NONE||||||
33938237|NCT04525287|||CASE_CONTROL||RETROSPECTIVE|||||||
33938238|NCT03166189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938239|NCT03004833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938240|NCT00702741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938241|NCT00676806|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938242|NCT01664585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938243|NCT05344235|||COHORT||PROSPECTIVE|||||||
33938244|NCT04819711|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The main outcomes will be recorded by outcome assessors blinded to treatment allocation. It will not be possible to blind antenatal nurses delivering the intervention in participating centres or the participants themselves to intervention allocation.|two-arm pilot individual randomised controlled trial|f|f|f|t
33938245|NCT02655211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938246|NCT03277651|||COHORT||PROSPECTIVE|||||||
33938247|NCT03432585|||COHORT||PROSPECTIVE|||||||
33938248|NCT02630381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938249|NCT06460935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938250|NCT04762550|||COHORT||PROSPECTIVE|||||||
33938251|NCT00003958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938252|NCT02466906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938253|NCT03110757|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33938254|NCT03441399|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33938255|NCT03345849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938256|NCT01810289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Clinic level stepped wedge design where each clinic has an amount of time in the pre-intervention or standard of care condition and then crosses over in the intervention condition||||
33938257|NCT06115512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938258|NCT04888195|||CASE_ONLY||PROSPECTIVE|||||||
33938259|NCT02438670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794832|NCT01240837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33794833|NCT01530698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794834|NCT03443037|||COHORT||PROSPECTIVE|||||||
33794835|NCT02081274|||COHORT||RETROSPECTIVE|||||||
33794836|NCT06500962|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE||2x2 Factorial Randomization|t|f|t|t
33794837|NCT06186791|||OTHER||CROSS_SECTIONAL|||||||
33794838|NCT01931254|||CASE_CONTROL||PROSPECTIVE|||||||
33794839|NCT02817724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33794840|NCT02578108|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33794841|NCT06512961|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33794842|NCT04956757|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33794843|NCT06017193|||COHORT||PROSPECTIVE|||||||
33794844|NCT00805571|||COHORT||PROSPECTIVE|||||||
33794845|NCT04783454|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All investigators and outcome assessors are blind to the subjects' allocation||f|f|t|t
33794846|NCT05559346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794847|NCT05857813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099328|NCT05858151|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Data will be collected through household surveys, market actor surveys and observations, in-depth interviews (IDIs), and focus group discussions (FGDs). The protocol team has selected a subset of the intervention districts for the evaluation and identify an equal number of districts outside the program coverage area with similar characteristics to serve as the control.||||
34099329|NCT00033475|RANDOMIZED|||TREATMENT||||||||
34099330|NCT05783765|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099331|NCT06517316|NA|SINGLE_GROUP||OTHER||NONE||||||
34099332|NCT03531567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099333|NCT02645162|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34099334|NCT05304962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be two study arms opened sequentially to the same patient population. Arm A is RGT-419B alone (singlet). Arm B is RGT-419B + Hormonal Therapy (doublet) and will follow completion of Arm A.||||
34099335|NCT04165486|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34099336|NCT01401075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714467|NCT02324894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714468|NCT01797601|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33714469|NCT00380757|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33714470|NCT01134783|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33714471|NCT03008681|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33714472|NCT04207970|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33714473|NCT02308085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714474|NCT02782780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714475|NCT05711173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714476|NCT01989078|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will all receive the study medication in addition to the standard of care treatment. There is no control group for this pilot study.||||
33714477|NCT05841394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714478|NCT05087212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714479|NCT04967833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714480|NCT04769440|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714481|NCT00872534|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33794848|NCT06604871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794849|NCT02960269|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33794850|NCT03015454|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33794851|NCT03617653|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33794852|NCT03264235|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into one of two groups. Group 1 will wear the exoskeleton device while completing all training sessions and will participate in 30 minutes of stair training in the device. Group 2 will not wear the exoskeleton device during training sessions and will be participate in 30 minutes of stair training without the device.||||
33714482|NCT03823352|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.||||
33794853|NCT00675246|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938260|NCT00605228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33938261|NCT02085486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938262|NCT05071391|||COHORT||PROSPECTIVE|||||||
33938263|NCT03160872|||COHORT||RETROSPECTIVE|||||||
33938264|NCT06053086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"* COHORTE A = Treatment ETHOS RT :46 evaluable patients with high risk of LRR and bf+ risk~* COHORT B = Conventional IMRT : 454 others patients with high risk of LRR and bf- risk"||||
33938265|NCT02006394|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33938266|NCT03089749|||COHORT||PROSPECTIVE|||||||
33938267|NCT03391375|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938268|NCT03481296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33938269|NCT05626465|||CASE_CONTROL||PROSPECTIVE|||||||
33938270|NCT04648995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Low energy:~Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ~High energy:~Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ"|t|f|f|t
33938271|NCT01327924|||COHORT||PROSPECTIVE|||||||
33938272|NCT01881906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33938273|NCT02616328|||COHORT||PROSPECTIVE|||||||
33938274|NCT01430598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938275|NCT04297176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938276|NCT02453828|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33938277|NCT05027711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938278|NCT00858949|||COHORT||PROSPECTIVE|||||||
33938279|NCT05155540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, non-randomized, prospective, double-arm clinical trial||||
33938280|NCT02161224|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938281|NCT01702402|RANDOMIZED|PARALLEL||||NONE||||||
33938282|NCT01228435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099337|NCT02845180|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34099338|NCT04204642|||OTHER||CROSS_SECTIONAL|||||||
34099339|NCT06389695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099340|NCT06395636|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34099341|NCT02739828|||COHORT||PROSPECTIVE|||||||
34099342|NCT03142334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099343|NCT02564770|||CASE_ONLY||RETROSPECTIVE|||||||
34099344|NCT03839680|||COHORT||PROSPECTIVE|||||||
34099345|NCT04414202|||COHORT||PROSPECTIVE|||||||
34099346|NCT02719860|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34099347|NCT02261532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099348|NCT01115621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714483|NCT01779102|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33714484|NCT03026452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017058|NCT02171676|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099349|NCT02718612|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34099350|NCT05138822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a randomized double-blind study with both participants and site staff blinded.|This will be a randomized double-blind study and participants will be randomized to receive either GSK3882347 or nitrofurantoin in a 3:1 allocation ratio using an interactive response technology (IRT).|t|f|t|f
34099351|NCT03323476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714485|NCT04900220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blinded randomized trial enrolling patients into one of the two treatment groups. The volume of the doses of steroid to be given will be standardized to 1 cc of either methylprednisolone (40 mg) or betamethasone (6 mg). We will instruct patients who meet the inclusion criteria to complete a visual analog scale (VAS) of their pain (1-10) prior to the injection, immediately after the injection, five minutes after the injection, and once a day for a minimum of 7 days after the injection. The incidence, intensity, time to peak and time to resolution of the flare reactions (defined as a 2-point increase from pre-injection pain) will be assessed and compared between the two groups.|t|t|t|t
33714486|NCT01036841|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714487|NCT01598012|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33714488|NCT03592199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714489|NCT00039364||||TREATMENT||||||||
33714490|NCT00318110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714491|NCT06293755|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33714492|NCT03123653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714493|NCT01090336|||||PROSPECTIVE|||||||
33714494|NCT04811989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomisation will be performed through an online random number generator, by a researcher external to the team of this study, to ensure the concealment of the allocation of participants by the several groups (Pandis, 2012). It will not be possible to conceal the group to which the patient was allocated to the medical and nursing team, since they have to administer the intervention or the researcher who will have to inform the respective team and administer the intervention in the Reading Group. Only the participants will be blind to the group to which they have been allocated.|Participants will be randomized at a ratio of 1:1 for the two conditions - Video Watching Group or Real-time Leaflet Reading Group versus Standard Care Group - into blocks of variable size, multiples of two. This randomization will be stratified according to the hospital (hospital 1 versus hospital 2) and the presence or absence of active diabetic foot ulcer.|t|f|f|f
33714495|NCT00007657|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33714496|NCT05563233|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33714497|NCT02326324|||COHORT||PROSPECTIVE|||||||
33714498|NCT01010516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714499|NCT02345694|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33714500|NCT05692934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be two independent cohorts of subjects who will each receive two treatments (high dose strength and low dose strength), and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability. In each cohort approximately 40 healthy subjects will be randomized to receive treatment with IP to complete at least 32 evaluable subjects.||||
33714501|NCT00969202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714502|NCT06215248|||COHORT||PROSPECTIVE|||||||
33714503|NCT04443725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714504|NCT01860651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714505|NCT05140798|||COHORT||PROSPECTIVE|||||||
33714506|NCT03676595|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33714507|NCT00661882|||OTHER||PROSPECTIVE|||||||
33714508|NCT01265290|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33714509|NCT06000514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both arms will use the same active standard medication (Sbv) and both arms will use a topical cream (one arm - placebo; the other Sm29).|Randomized and controlled|t|f|f|t
33714510|NCT02558140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714511|NCT06190223|||COHORT||PROSPECTIVE|||||||
33714512|NCT02684760|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34017059|NCT03233425|||CASE_ONLY||PROSPECTIVE|||||||
34017060|NCT00001253||||TREATMENT||||||||
34017061|NCT01614145|||COHORT||PROSPECTIVE|||||||
34017062|NCT03365011|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34017063|NCT02395965|||COHORT||PROSPECTIVE|||||||
34017064|NCT02849327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017065|NCT00400361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017066|NCT02287207|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34017067|NCT00242736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017068|NCT05229653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017069|NCT00040053|RANDOMIZED|||TREATMENT||DOUBLE||||||
34017070|NCT02688426|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34017071|NCT03291353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017072|NCT04132336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017073|NCT03077035|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34017074|NCT02978820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017075|NCT05615181|||COHORT||PROSPECTIVE|||||||
33714513|NCT02303288|||COHORT||PROSPECTIVE|||||||
33714514|NCT02342327|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33714515|NCT04358380|||COHORT||PROSPECTIVE|||||||
34017076|NCT01383798|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34017077|NCT00986180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017078|NCT03144011|||COHORT||PROSPECTIVE|||||||
34017079|NCT00003079|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34017080|NCT00573157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017081|NCT02930486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017082|NCT00270257|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017083|NCT01507155|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34017084|NCT01387581|||CASE_CONTROL||PROSPECTIVE|||||||
34017085|NCT06076850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017086|NCT03734406|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"We designed a multicentric, pragmatic, parallel groups trial, with 1:1 randomization, that will involve patients discharged from EDs with a diagnosis of atrial fibrillation (AF) or deep vein thrombosis (DVT).~The study aims to demonstrate the superiority of the intervention in terms of patients' comprehension of their medical condition, assessed with a telephone interview that will be conducted within 48 hours from patients' discharge."|f|f|t|t
34017087|NCT03769883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Upon completion of the study and prior to breaking the allocation code, a data-collection form is generated by a statistician and the principal investigator. The data-analyst breaks the allocation code and labels the participants according to the assigned treatment and analyzes the outcomes. Following the analyses, group allocation will be concealed in all data outputs and the N per group and present the data to the writing committee in a blinded fashion. Then the writing committee will provide their blinded interpretations.||f|f|f|t
34017088|NCT00376194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017089|NCT02357329|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34017090|NCT02397642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017091|NCT03039179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017092|NCT06446466|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794854|NCT01385384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017093|NCT00971958|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34017094|NCT00276549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099352|NCT03710733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099353|NCT06335979|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099354|NCT03502772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099355|NCT04633720|NA|SINGLE_GROUP||OTHER||NONE||||||
33714516|NCT04845789|||OTHER||PROSPECTIVE|||||||
33714517|NCT02079181|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714518|NCT01250834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714519|NCT06179797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|concealed allocations and blinded laboratory personnel.|randomized|t|f|f|t
33714520|NCT00194064||PARALLEL||TREATMENT||NONE||||||
33714521|NCT03826407|||COHORT||PROSPECTIVE|||||||
33714522|NCT03755492|||CASE_CONTROL||PROSPECTIVE|||||||
33714523|NCT00429273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714524|NCT02377245|||COHORT||PROSPECTIVE|||||||
33714525|NCT04167202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714526|NCT02272920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714527|NCT00447161|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714528|NCT03950167|||COHORT||PROSPECTIVE|||||||
33938283|NCT05998603|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33938284|NCT00021281||||TREATMENT||||||||
33938285|NCT04549675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938286|NCT03659695|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33938287|NCT04123340|NA|SINGLE_GROUP||TREATMENT||NONE|post-procedural an assessment will be done of the ablation completeness using registration software. The actual ablation verification will be done qualitatively by the treating physician.|prospective, single blind, single-arm, phase II stud||||
33938288|NCT00670813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33938289|NCT03408457|||CASE_ONLY||PROSPECTIVE|||||||
33938290|NCT00849173|||||PROSPECTIVE|||||||
33938291|NCT00545740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938292|NCT00578396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938293|NCT05131659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938294|NCT01400204|||CASE_CONTROL||PROSPECTIVE|||||||
33938295|NCT04395521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Access to a diabetic foot self-management support program via a Facebook group platform for 3 months.||||
33938296|NCT03568513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938297|NCT00590031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938298|NCT02541994|NA|SINGLE_GROUP||SCREENING||NONE||||||
34017095|NCT05745792|||COHORT||CROSS_SECTIONAL|||||||
34017096|NCT04725448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017097|NCT05224934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017098|NCT01841775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017099|NCT06423638|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34017100|NCT05685901|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34017101|NCT05038332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017102|NCT05981820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017103|NCT02434432|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34017104|NCT02754466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017105|NCT03660293|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34017106|NCT01988506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017107|NCT04426279|||COHORT||RETROSPECTIVE|||||||
34099356|NCT03302611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to participants' intervention condition.|Consenting active duty service members with major depressive disorder will be randomized to receive 6 weeks of either surf or hike therapy. Participants will be allowed to receive the other intervention (i.e., the condition that they were not originally randomized to) if interested after the initial intervention period.|f|f|f|t
34099357|NCT03382860|||COHORT||PROSPECTIVE|||||||
34099358|NCT00601016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099359|NCT05922033|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714529|NCT01171339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714530|NCT00754819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714531|NCT01595698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33714532|NCT01919125|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714533|NCT06112444|||OTHER||RETROSPECTIVE|||||||
33714534|NCT03074591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714535|NCT04712305|||COHORT||PROSPECTIVE|||||||
33714536|NCT05532839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714537|NCT04878588|||CASE_ONLY||CROSS_SECTIONAL|||||||
33714538|NCT02671396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099360|NCT05610150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938299|NCT06182215|||COHORT||PROSPECTIVE|||||||
33938300|NCT05532462|||CASE_ONLY||PROSPECTIVE|||||||
34099361|NCT01210599|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34099362|NCT02545166|||CASE_CONTROL||PROSPECTIVE|||||||
34099363|NCT03014388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099364|NCT05987137|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34099365|NCT04433026|||CASE_ONLY||RETROSPECTIVE|||||||
34099366|NCT00482456|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099367|NCT05954988|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|The Sponsor, Investigator, and study personnel working on behalf of the Investigator and Sponsor will remain blinded.||t|t|t|t
34099368|NCT02037880|||COHORT||PROSPECTIVE|||||||
34099369|NCT04630886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The surgeon performing the Mohs surgery will be aware of which group the participant is in. The participant will be masked.|Once a participant has provided informed consent to participate in the study, he/she will be randomly assigned to either the TXA experimental group or the control group. A randomized list will be created prior to the start of the study with the help of a biostatistician. The provider will be aware of which study arm the participant is in, however the participant will be blinded.|t|f|f|f
34099370|NCT05552495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099371|NCT05542901|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||Parallel Assignment|t|f|t|t
34099372|NCT02403037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34099373|NCT02455323|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33714539|NCT05156853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the taste and nature of the intervention foods, blinding of study staff and participants is not possible during this study.||f|f|f|t
33938301|NCT03549585|||COHORT||PROSPECTIVE|||||||
33938302|NCT04778228|||COHORT||PROSPECTIVE|||||||
33938303|NCT04473495|||OTHER||PROSPECTIVE|||||||
33938304|NCT04234399|||CASE_ONLY||PROSPECTIVE|||||||
33938305|NCT04799340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714540|NCT06474052|||COHORT||PROSPECTIVE|||||||
33714541|NCT03752580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714542|NCT04012775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714543|NCT01691001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714544|NCT06043440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33714545|NCT04369521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714546|NCT00735956|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33714547|NCT03510884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938306|NCT01888965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938307|NCT03194256|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will be blind to the nicotine content of their assigned study cigarette and the nicotine dose of the e-liquid in the study vaping device. Investigators, research staff, and biostatisticians will also be blind to the conditions. E-liquid flavors will not be blinded.|Mixed between subjects and within-subjects design. Random assignment to the between subjects factor (nicotine content in cigarettes), within-subjects manipulation of nicotine concentration and flavors in e-liquid in the electronic cigarettes|t|f|t|t
33938308|NCT06369584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938309|NCT04543656|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33938310|NCT04678193|||COHORT||OTHER|||||||
33938311|NCT01042912|||CASE_ONLY||PROSPECTIVE|||||||
33938312|NCT03411356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938313|NCT04003064|||OTHER||PROSPECTIVE|||||||
33938314|NCT04271202|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938315|NCT04098029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"In total, the study will involve 150 patients in three groups. The first and second groups will receive infusions of umbilical cord blood hematopoietic cells, with varying degrees of selection for the genes of the HLA system.~The third group will be the control group. In the control group, 50 patients with similar pathology will be examined, comparable in age, sex and degree of disorder of the type of paracopies against the background of standard therapy."||||
33938316|NCT03261739|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blind, placebo controlled|Randomized, placebo controlled, with 3 sequential cohorts|t|t|t|t
33938317|NCT05970146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938318|NCT05761405|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The pharmacy prepares a randomization list with an additional 20% to account for drop-outs. Based on this, the pharmacy prepares labels (study ID, local center ID, subject ID) and a randomization list (subject ID, open-label treatment (i.e. AMK, AMK+MAN, CRO)). These are delivered to the blinded to the patient awaiting surgery with anonymized subject IDs (consecutive numbering). The investigator has no access to this list.|Randomized, multicentre, double-blind|t|t|t|f
33938319|NCT00142818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938320|NCT02176434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938321|NCT05704140|||OTHER||PROSPECTIVE|||||||
33938322|NCT00403689|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33938323|NCT02583828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938324|NCT05920109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938325|NCT00236574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938326|NCT04233775|||COHORT||PROSPECTIVE|||||||
33938327|NCT01252576|||COHORT||PROSPECTIVE|||||||
33938328|NCT05839899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794855|NCT06676410|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization~Forty participants with a recent diagnosis of HIV infection, without previous antiretroviral treatment and indication to start antiretroviral treatment, will be randomized as follows:~* 20 participants will receive Standard Antiretroviral Treatment + Codivir~* 20 participants will only receive Standard Antiretroviral Treatment A randomization will be balanced by sex and age."||||
33794856|NCT04393142|||OTHER||CROSS_SECTIONAL|||||||
33794857|NCT00588302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794858|NCT01111526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794859|NCT03532711|||CASE_ONLY||RETROSPECTIVE|||||||
33794860|NCT06047522|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34017108|NCT01839630|||CASE_CONTROL||PROSPECTIVE|||||||
33794861|NCT05585775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794862|NCT00043264||PARALLEL||TREATMENT||DOUBLE||||||
33794863|NCT06257888|||COHORT||PROSPECTIVE|||||||
34017109|NCT01391741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017110|NCT00191633|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017111|NCT01418482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017112|NCT05001711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099374|NCT01067911|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34099375|NCT01282138|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34099376|NCT06247215|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33714548|NCT05213650|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|It will be shared with the participants of the study that when their treatment is finished, the plaques will be requested back and a study will be carried out on these plaques to affect the plaques from the process. However, the information that the study is on the effects of the cleaning agent they use will not be shared. Therefore, the participants do not have information about being in a group related to plaque cleaning efficiency.|controlled clinical trial|t|f|f|f
33714549|NCT04376710|||OTHER||PROSPECTIVE|||||||
33714550|NCT02093832|||CASE_ONLY||RETROSPECTIVE|||||||
33714551|NCT04348734|||COHORT||PROSPECTIVE|||||||
33714552|NCT01348945|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33714553|NCT05945914|||CASE_ONLY||RETROSPECTIVE|||||||
33714554|NCT02846779|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33714555|NCT03091634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714556|NCT05495256|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients are screened, consented, and all go through the inhaler training.||||
33714557|NCT06095453|||COHORT||RETROSPECTIVE|||||||
33714558|NCT00543504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714559|NCT00081484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714560|NCT02674152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714561|NCT02106091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714562|NCT03053284|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33714563|NCT00225173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714564|NCT05246501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33714565|NCT02402127|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33714566|NCT03764865|RANDOMIZED|PARALLEL||TREATMENT||NONE||non-inferiority||||
33714567|NCT03591471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714568|NCT01755351|||COHORT||CROSS_SECTIONAL|||||||
33714569|NCT00263133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794864|NCT04668391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794865|NCT01061424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794866|NCT02272959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794867|NCT00367107|||COHORT||PROSPECTIVE|||||||
33794868|NCT00113971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794869|NCT05343832|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794870|NCT01951508||CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33794871|NCT00396084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794872|NCT02694978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794873|NCT06375265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794874|NCT01576484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794875|NCT04759066|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single group descriptive pilot study||||
33794876|NCT05408559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|These potential subjects will be recruited in a randomized, controlled, double blinded pilot study comparing SFN to placebo.|Well trained Nurses of Clinical Research Institute, TTUHSC will receive placebo and test compound from supplier and will dispense them to test subjects.|t|f|f|f
33794877|NCT06071624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017113|NCT03932123|||COHORT||PROSPECTIVE|||||||
34017114|NCT00219583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017115|NCT03792724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017116|NCT03842579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not be informed about allocation of the participants prior to the assessment of outcomes. The participants will be informed not to give any information to outcome assessors about the result of their randomization||f|f|f|t
34017117|NCT01678053|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017118|NCT00601666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017119|NCT02876575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017120|NCT02253030|||CASE_CONTROL||PROSPECTIVE|||||||
34017121|NCT00212121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017122|NCT05388240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial; pilot study|f|f|t|f
34017123|NCT04309318|||CASE_CONTROL||PROSPECTIVE|||||||
34099377|NCT02441257|NA|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34099378|NCT00433511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099379|NCT04817800|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34099380|NCT06235905|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34099381|NCT03727061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099382|NCT05306015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099383|NCT06012695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017124|NCT05489237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017125|NCT01485666|||COHORT||PROSPECTIVE|||||||
34017126|NCT00787397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017127|NCT04794192|||COHORT||PROSPECTIVE|||||||
34099384|NCT05549453|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The purpose of the investigation is to assess the usability of the new device user interface in a feasibility study conducted with a prototype device utilizing the new interface in an open label use of the device.||||
33714570|NCT02151253|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33714571|NCT05430737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017128|NCT02757976|RANDOMIZED|PARALLEL||TREATMENT||NONE||This trial will compare two management strategies for patients with Heart Failure, left ventricular systolic dysfunction, and intermediate prolonged QRS duration (120-149ms). The control group is conventional Cardiac Resynchronization Therapy (CRT). The experimental group is LV endocardial CRT.||||
34017129|NCT04146506|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017130|NCT00349557|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017131|NCT05496543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017132|NCT00273481|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34017133|NCT00169819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017134|NCT05662735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were blinded for repair with sutures alone or sutures with mesh augmentation|randomised controlled trial|t|f|f|f
34017135|NCT04420221|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34017136|NCT04650152|||COHORT||PROSPECTIVE|||||||
34017137|NCT04781387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017138|NCT01443936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017139|NCT01574482|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34017140|NCT05223296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34017141|NCT05824247|||COHORT||PROSPECTIVE|||||||
34017142|NCT00859066|||CASE_CONTROL||PROSPECTIVE|||||||
34017143|NCT00469768|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34017144|NCT06044532|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017145|NCT05807516|||COHORT||PROSPECTIVE|||||||
34017146|NCT03326609|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34017147|NCT03166683|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized (1:1) study of 2 treatment groups (hemopatch versus standard of care) in liver resection surgery. Non-inferiority study||||
34017148|NCT03905564|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, single-dose with two periods, two sequences (AB, BA; A = Reference and B = Test) crossover study in healthy participants under fasting conditions. Washout period between the two study periods will be at least 20 days.||||
34017149|NCT04528030|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The investigator analyzing the 4 cycles will not know whether it's an ON of OFF cycle during the 24 hour treatment period.|"Sequential Assignment~In the same subject there were 2 periods:~OFF cycles (6 hours x 2): 'No intervention' period (no vibrations) - two 6 hour epochs - total of 12 hours of 'No intervention' ON cycles (6hours x 2). Experimental period (with vibrations) - two 6 hour epochs - total of 12 hours of 'vibration intervention'~In the same subjects cardio-respiratory parameters will be continuously monitored through the 24 hour treatment period of 4 cycles- heart rate, respiratory rate and oxygen saturation were compared during the experimental period (vibration) and during the no intervention period (no vibration)."|f|f|t|t
34017150|NCT02969941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017151|NCT00726154|RANDOMIZED|PARALLEL||||NONE||||||
34017152|NCT04930757|||COHORT||PROSPECTIVE|||||||
34099385|NCT05275244|||CASE_ONLY||PROSPECTIVE|||||||
34099386|NCT00000483|RANDOMIZED|||PREVENTION||||||||
34099387|NCT05243316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomizing will be masked, as well as data analysis.|Randomized controlled trial|f|f|f|t
34099388|NCT01830673|||CASE_CONTROL||PROSPECTIVE|||||||
34099389|NCT04707183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099390|NCT02061956|||COHORT||PROSPECTIVE|||||||
33714572|NCT00483223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714573|NCT04666051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714574|NCT05433805|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714575|NCT02192931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714576|NCT03107936|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714577|NCT03900351|RANDOMIZED|PARALLEL||TREATMENT||NONE||"There are two group of subjects:~1. Group A (study group).~2. Group B:(Control group)."||||
33714578|NCT01264588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33714579|NCT01488682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714580|NCT00085631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714581|NCT04953546|||COHORT||PROSPECTIVE|||||||
33714582|NCT00294268|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714583|NCT04108533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714584|NCT06323278|||COHORT||PROSPECTIVE|||||||
33714585|NCT04095845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714586|NCT02421276|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33714587|NCT02743520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714588|NCT02852785|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714589|NCT02518750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714590|NCT02533427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714591|NCT00569699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714592|NCT02839109|||COHORT||PROSPECTIVE|||||||
33714593|NCT02465801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714594|NCT05785871|||COHORT||PROSPECTIVE|||||||
33714595|NCT05390281|||COHORT||PROSPECTIVE|||||||
33714596|NCT02207166|||CASE_ONLY||PROSPECTIVE|||||||
33714597|NCT01574326|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33714598|NCT04353076|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33714599|NCT02291198|NA|SINGLE_GROUP||SCREENING||NONE||||||
33714600|NCT01906203|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714601|NCT03898154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714602|NCT01402791|||COHORT||PROSPECTIVE|||||||
33714603|NCT06285981|||COHORT||RETROSPECTIVE|||||||
34017153|NCT04191655|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|"In this study, we will randomize a total of 500 participants into two arms: A. high definition white light colonoscopy with biopsy (n=250) or B. chromocolonoscopy (n=250).~The randomization schedule was created by using GraphPad website. Then sealed opaque envelopes which numbered from 1 to 500 for all subjects were created based on the randomization schedules by one of the study co-investigators (Mohammed El-Dallal MD). These envelopes will be opened only by the endoscopy provider once the subject agrees and sings the informed consent. Of note, the randomization schedules will be saved in a separate document that only Mohammed El-Dallal MD has access to it. Neither the participants nor the study members (other than Mohammed El-Dallal MD) know about the assignment before opening the envelopes."|After patients consent to participate to the study, they will be randomized 1:1 by one of the study members who is blinded to the patient's history to either High Definition White Light Colonoscopy with biopsies every 10 cm or Dye Spraying Chromocolonoscopy. The gastroenterologist will be informed about the randomization result and s/he will conduct the procedure.|t|t|t|f
34017154|NCT01550276|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34017155|NCT06217484|||COHORT||CROSS_SECTIONAL|||||||
34017156|NCT04038268|||COHORT||RETROSPECTIVE|||||||
34017157|NCT01533766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017158|NCT02982031|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34017159|NCT04361227|||COHORT||PROSPECTIVE|||||||
34017160|NCT01567748|||CASE_ONLY||PROSPECTIVE|||||||
34017161|NCT06429319|NA|SINGLE_GROUP||TREATMENT||NONE||This is open-label MD NOLTREX™ safety assessment study includes eligible and non-eligible patients who received study MD as part of the IA/PAAG-SI/OA/2019 study. It was planned that 72 patients would take part in the study. In fact, 67 patients were screened into the study because not all patients from CS1 progressed to CS2; 2 of these patients failed screening measures, so the final population included 65 patients.||||
34017162|NCT00266357|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34017163|NCT01394952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017164|NCT00771745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017165|NCT03566576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017166|NCT01552811|||CASE_CONTROL||PROSPECTIVE|||||||
34017167|NCT05389683|NA|SINGLE_GROUP||OTHER||NONE||It is a single group study in which a single group of subjects will receive a single intervention and the outcomes will be assessed over time.||||
34017168|NCT02468492|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34017169|NCT02016261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017170|NCT03529578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017171|NCT00755859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017172|NCT03982472|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Difference of group was compared between groups|t|f|t|f
34017173|NCT01950234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017174|NCT06007131|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There is a study group that uses the device \& the data is monitored and sent to the physician. The second group is a control group that will not use the device and will continue with normal standard of care.|f|f|f|t
34017175|NCT03219931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is a triple blind study in which the treatment or intervention is unknown to the research participant, the individuals who administer the treatment or intervention, and the researchers who assess the outcomes.|During the 90 days of the study, parents were asked to give 5 drops of active product (108 viable cells/strain) or placebo and to daily take note of minutes of crying, number, color, and consistency of evacuations, and number of regurgitations or vomits.|t|t|t|t
34017176|NCT00545675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017177|NCT01158573|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017178|NCT00474474|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
34017179|NCT00724490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099391|NCT05800847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34099392|NCT03681600|||COHORT||PROSPECTIVE|||||||
34099393|NCT03685435|||CASE_ONLY||PROSPECTIVE|||||||
34099394|NCT06126744|NA|SEQUENTIAL||TREATMENT||NONE||||||
34099395|NCT03915054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099396|NCT01192477|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34099397|NCT00948207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34099398|NCT03142204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714604|NCT06363851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714605|NCT03862820|||COHORT||PROSPECTIVE|||||||
33714606|NCT01294657|||COHORT||PROSPECTIVE|||||||
33714607|NCT00753610|||CASE_CONTROL||PROSPECTIVE|||||||
33714608|NCT04010357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714609|NCT02309879|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714610|NCT02204163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714611|NCT01021540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714612|NCT04461730|||COHORT||PROSPECTIVE|||||||
33714613|NCT04666584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Offline data analysis will be performed without knowing the allocated intervention group.|Eligible patients randomized to predilatation with ScoreFlex balloon or a standard non-compliant balloon before percutaneous coronary intervention with implantation of a Magmaris bioresorbable scaffold.|f|f|t|t
33714614|NCT04305483|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33714615|NCT02487693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099399|NCT04983511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with deactivated epidural/CSE catheters will be given electrical epidural stimulation test to detect its ability to be reactivated.||||
34099400|NCT02443077|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34099401|NCT00629642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099402|NCT05694208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The women included in the study sample will be divided into two groups as experimental and control groups according to randomization. Experimental group; the group to be trained. control group; This is the group in which no attempt will be made other than data collection.||||
34099403|NCT05340660|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099404|NCT01515527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099405|NCT02544087|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34017180|NCT04874675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34017181|NCT01524614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34017182|NCT05435716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017183|NCT01921621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34017184|NCT00298779|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017185|NCT01519986|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34017186|NCT01832207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017187|NCT00118131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017188|NCT00896155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017189|NCT01338649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017190|NCT01081535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34099406|NCT03099863|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34099407|NCT05299970|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34099408|NCT05415527|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017191|NCT04178161|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study involves a single group of patients with Hyperhidrosis. Left and right palms are randomized for treatment versus control (untreated).||||
34017192|NCT06077331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017193|NCT02175836|||COHORT||PROSPECTIVE|||||||
34017194|NCT00968760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017195|NCT05649449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research interviewers are blinded to study condition.|Self-directed care is a recovery-oriented model of community mental health service delivery in which participants manage a personal budget from which they purchase goods and services, including specific types of mental health care, social supports, and items that allow them to recover their health and emotional wellness and live independently.|f|f|f|t
34017196|NCT04870138|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34017197|NCT03606876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017198|NCT00729274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017199|NCT01570283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017200|NCT04875611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099409|NCT04874779|||COHORT||OTHER|||||||
34099410|NCT06662422|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34099411|NCT00049309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099412|NCT06695286|||COHORT||RETROSPECTIVE|||||||
34099413|NCT00666341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099414|NCT06089798|||CASE_CONTROL||PROSPECTIVE|||||||
33794878|NCT05004935|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33794879|NCT06297135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794880|NCT05085990|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive 6 weekly doses of TARA-002 at the recommended Phase 2 dose (R2PD)||||
33794881|NCT06122727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794882|NCT00592813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794883|NCT00092885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794884|NCT06068439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794885|NCT00386516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794886|NCT00922649|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34099415|NCT03903770|NA|SINGLE_GROUP||TREATMENT||NONE|Assessor blinded to intervention and study's objectives|single-subject with multiple baselines (AAAB)||||
33794887|NCT02932709|||COHORT||PROSPECTIVE|||||||
33794888|NCT03854253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794889|NCT06291233|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33794890|NCT01191892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794891|NCT02749968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33794892|NCT00118066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794893|NCT00892593|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33794894|NCT02078804|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33794895|NCT02474147|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33794896|NCT02068430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794897|NCT03612882|||COHORT||CROSS_SECTIONAL|||||||
33794898|NCT01733238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017201|NCT05647226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the lifestyle programme, participants, clinicians and data collectors will not be able to be masked, however allocation will be concealed from the statistician in charge of performing the analysis.|A multicentre, open-label, parallel design, randomised controlled trial.|f|f|f|t
34017202|NCT03811496|||COHORT||PROSPECTIVE|||||||
34017203|NCT03044041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017204|NCT05124561|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017205|NCT02884973|||COHORT||RETROSPECTIVE|||||||
34017206|NCT02351544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017207|NCT03737565|||CASE_ONLY||PROSPECTIVE|||||||
34017208|NCT06250049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34017209|NCT01915693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017210|NCT04614623|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34017211|NCT05028049|||COHORT||PROSPECTIVE|||||||
34017212|NCT04174976|||COHORT||PROSPECTIVE|||||||
34017213|NCT06062849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017214|NCT01988961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017215|NCT00584844|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017216|NCT05050890|||COHORT||PROSPECTIVE|||||||
34099416|NCT00113126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099417|NCT02250573||||TREATMENT||||||||
34099418|NCT02191397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099419|NCT02096965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34099420|NCT05738291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|MRD: single blinded to subject DDI: open-label|"The multiple-rising dose (MRD) part of this trial is designed as single blinded to subject, randomised, and placebo-controlled within parallel dose groups.~The Drug-Drug Interaction (DDI) part of this trial is designed as open-label, within-group comparison interaction trial."|t|f|f|f
34099421|NCT01946100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099422|NCT03765918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099423|NCT06644417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099424|NCT02957123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099425|NCT05373836|||COHORT||RETROSPECTIVE|||||||
34099426|NCT05249855|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||General Trust mediates the relation between the level of anxiety at the beginning of the treatment and the end of the treament.||||
34099427|NCT01129284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099428|NCT04007874|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-label randomized controlled trial||||
34099429|NCT06672575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099430|NCT00026403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099431|NCT03865498|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099432|NCT04643431|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099433|NCT06057428|||CASE_CROSSOVER||PROSPECTIVE|||||||
33714616|NCT04590365|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Allocation to each group, treatment or placebo administration and data analysis will be blinded to both participant and investigator. The sprays will be blinded at the site of manufacture. Trial sealed envelopes will be available in case of any adverse reactions.|The study design consists of a double blind, randomised placebo-controlled trial. Of the 480 participants recruited, 240 participants will be randomly allocated to each of either the treatment arm (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline) or placebo (Coldamaris sine i.e. 0.5% saline) arms.|t|t|t|t
33714617|NCT05178524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714618|NCT04205071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794899|NCT06336486|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups with a conventional therapy control group||||
33794900|NCT00223795|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794901|NCT06676358|||OTHER||CROSS_SECTIONAL|||||||
33794902|NCT02964195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794903|NCT05821322|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33794904|NCT02701855|||CASE_ONLY||PROSPECTIVE|||||||
33794905|NCT05454163|||CASE_CONTROL||PROSPECTIVE|||||||
33794906|NCT01590836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794907|NCT03264755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794908|NCT05093218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794909|NCT06390943|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33794910|NCT03207568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Relay Pro and Relay NBS Pro device||||
33794911|NCT00938535|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794912|NCT01305291|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33794913|NCT03199781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794914|NCT03833154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double- Blind||t|t|t|t
33794915|NCT06000072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794916|NCT04307407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938329|NCT00474552|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33938330|NCT05512195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938331|NCT01521260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938332|NCT00633425|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938333|NCT04009252|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938334|NCT05364658|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open-label, non-comparative clinical trial||||
33938335|NCT06048068|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized 2:1 to the informational intervention group or the control group (care as usual). Participants will remain in their assigned arm for the entirety of their study participation. Randomization will be performed using the REDCap randomization module by a study coordinator. This study will be unblinded.||||
33938336|NCT06308328|||COHORT||PROSPECTIVE|||||||
33938337|NCT06135766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938338|NCT00438191|||COHORT||PROSPECTIVE|||||||
33938339|NCT02875782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938340|NCT00315640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938341|NCT02020564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938342|NCT04377399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938343|NCT04379258|||COHORT||PROSPECTIVE|||||||
33938344|NCT02140762|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938345|NCT05869526|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Supplements will be identical in look and taste|1:1:1 basis|t|f|t|t
33938346|NCT03416036|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938347|NCT03511729|||COHORT||PROSPECTIVE|||||||
33938348|NCT03085342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938349|NCT06459856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938350|NCT05178511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938351|NCT04631757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938352|NCT04073472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938353|NCT06039540|||COHORT||PROSPECTIVE|||||||
33938354|NCT02294370|||CASE_ONLY||PROSPECTIVE|||||||
33938355|NCT03000413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33938356|NCT05571852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938357|NCT05487092|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33938358|NCT01845766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33938359|NCT05119998|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938360|NCT02282774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33938361|NCT04460391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33938362|NCT02858596|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938363|NCT01211366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938364|NCT00696540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938365|NCT05376241|||COHORT||PROSPECTIVE|||||||
33938366|NCT04341792|||COHORT||PROSPECTIVE|||||||
33938367|NCT03106857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938368|NCT04783740|||OTHER||PROSPECTIVE|||||||
33938369|NCT05528159|||COHORT||PROSPECTIVE|||||||
34017217|NCT01044654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017218|NCT05035342|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double-blinded placebo-controlled randomized multicentric controlled trial with a 1:1 randomization.|Double-blinded placebo-controlled randomized multicentric controlled trial with a 1:1 randomization.|t|t|t|t
34017219|NCT04493320|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double blind crossover study|t|t|t|t
34017220|NCT03456960|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34017221|NCT04840966|||COHORT||PROSPECTIVE|||||||
34017222|NCT03858738|||COHORT||CROSS_SECTIONAL|||||||
34017223|NCT03709459|||COHORT||PROSPECTIVE|||||||
34017224|NCT02289235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017225|NCT04735952|||COHORT||PROSPECTIVE|||||||
34017226|NCT04666714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017227|NCT05945576|||COHORT||OTHER|||||||
34017228|NCT01109563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017229|NCT05486455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017230|NCT03501121|||COHORT||PROSPECTIVE|||||||
34017231|NCT04588311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017232|NCT06030141|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||In this study, catheter application and follow-up will be carried out by the researcher Burcu Nal, and phlebitis evaluation will be made by a specialist nurse other than the researcher. Patients will be aware that they are included in the study, but they will be blinded as one of the oils applied in the care they will be given will be used by hiding the information of which group they are in. In order to prevent bias, patients will be included in the study groups according to the assignment made from the Randomizer.org program. Since the data will be transferred to the SPSS program and the analysis will be done by an independent statistician, the bias will also be controlled in the data evaluation process.|t|f|t|t
34017233|NCT00001045||||TREATMENT||||||||
34017234|NCT02808949|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017235|NCT06295328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Phase 1b study with two parallel treatment arms and placebo controls.|t|t|t|t
34017236|NCT04915014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099434|NCT03457597|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34099435|NCT04501445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017237|NCT05051501|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Participants with an odd identification number will receive substance A in the first three months and a complementary substance B in the following three months. Participants with an even identification number will receive substance B in the first three months and a complementary substance A in the following three months. Manufacturer of the new probiotics C2P will mark one set of substances as set A and a complementary set of substances as set B. If substance A/B is a probiotic or placebo will be known to a manufacturer only. Investigators and participants are blinded to this information.|First 3 months: group A on probiotics; group B on placebo Next 3 months: group A on placebo; group B on probiotics. Next 3 months: no intervention in either group|t|t|t|t
34017238|NCT04710511|||OTHER||CROSS_SECTIONAL|||||||
34017239|NCT03760250|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017240|NCT02067429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099436|NCT03055078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099437|NCT05881330|NA|SINGLE_GROUP||OTHER||NONE||||||
34099438|NCT03502590|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099439|NCT00002461|RANDOMIZED|PARALLEL||TREATMENT||||||||
34099440|NCT06686667|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label trial assessing a behavioral eating intervention||||
33714619|NCT03552263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial having three arms including T89 low-dose, T89 high-dose and a placebo controlled group. People will be screened against the inclusion/exclusion criteria after informed consent. Eligible subjects will be randomly assigned into one of three arms and instructed to use T89 orally twice daily for 14 days (Days 1-14) before ascending, and 5 days after ascending during the observation period (Days 15-19). Specifically, for subjects in the T89 high-dose group, they will take placebo instead of T89 from Day 1 to Day 12, and take T89 on Days 13-14. The primary efficacy parameter is Lake Louise Scoring System (LLSS) which will be evaluated by subject-self and principal investigator in clinic. Other efficacy parameters include Visual Analog Scales (VAS), exercise tolerance, blood lactate, and blood oxygen saturation that will be performed at altitude.|t|t|t|t
33714620|NCT05445986|||COHORT||PROSPECTIVE|||||||
33714621|NCT00326456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714622|NCT02708160|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33714623|NCT00197964|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33714624|NCT01119885|||COHORT||PROSPECTIVE|||||||
33714625|NCT01386554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714626|NCT05160220|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33714627|NCT05076903|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients don't know which group they belong to.||t|f|f|f
33714628|NCT01694589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714629|NCT00748683|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33714630|NCT05993260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33714631|NCT01342796|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33714632|NCT01832987|NA|SINGLE_GROUP||||NONE||||||
33714633|NCT04158440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|No Masking|Parallel|t|t|t|t
33714634|NCT06436482|||COHORT||CROSS_SECTIONAL|||||||
33714635|NCT02345850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714636|NCT03658655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714637|NCT00642577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714638|NCT02635555|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33714639|NCT03266107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714640|NCT04161560||SEQUENTIAL||DIAGNOSTIC||NONE|4 groups according to different doses|1， dose of drug 2, control group||||
33714641|NCT01429753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714642|NCT00309387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714643|NCT01749462|||COHORT||PROSPECTIVE|||||||
33714644|NCT03465202|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33714645|NCT03869346|||OTHER||OTHER|||||||
34017241|NCT05752682|||COHORT||PROSPECTIVE|||||||
34017242|NCT00712985|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017243|NCT03758404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017244|NCT00706381|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34017245|NCT00449826|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34017246|NCT06024200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017247|NCT00004421||||TREATMENT||||||||
34017248|NCT04271020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017249|NCT00002040||||TREATMENT||NONE||||||
34017250|NCT05502965|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34017251|NCT02289859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017252|NCT03952234|NA|SINGLE_GROUP||TREATMENT||NONE||L-Citrulline||||
34017253|NCT04316507|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34017254|NCT00885521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017255|NCT00973401|||||PROSPECTIVE|||||||
34017256|NCT04973553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017257|NCT03754465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind||t|f|t|f
34017258|NCT00011349|||COHORT||PROSPECTIVE|||||||
34017259|NCT05717530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017260|NCT00569621|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34017261|NCT00671138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017262|NCT06070974|||COHORT||PROSPECTIVE|||||||
34099441|NCT06024161|||COHORT||PROSPECTIVE|||||||
34099442|NCT05062772|||COHORT||OTHER|||||||
34099443|NCT03205943|||CASE_ONLY||PROSPECTIVE|||||||
34099444|NCT02618395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714646|NCT01804296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714647|NCT01101932|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33714648|NCT01579175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714649|NCT01195415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714650|NCT00971854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714651|NCT02322567|||||PROSPECTIVE|||||||
33714652|NCT01616524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714653|NCT00573911|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017263|NCT03957330|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants are told about the nature of their treatment but not about the exact nature of all the conditions.||t|f|f|f
34017264|NCT06166238|||COHORT||PROSPECTIVE|||||||
34017265|NCT00285948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017266|NCT01378455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017267|NCT02987023|||COHORT||PROSPECTIVE|||||||
34017268|NCT02570113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017269|NCT06032962|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34017270|NCT01330771|||COHORT||PROSPECTIVE|||||||
34017271|NCT02583386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099445|NCT05450718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714654|NCT00873756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714655|NCT06163170|||COHORT||RETROSPECTIVE|||||||
33714656|NCT00865774|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33714657|NCT00846430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714658|NCT00967772||PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33714659|NCT05551559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714660|NCT03854305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017272|NCT04730089|||CASE_CONTROL||PROSPECTIVE|||||||
34017273|NCT04050150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017274|NCT02751359|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34017275|NCT03386565|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34017276|NCT02229539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714661|NCT05426902|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33714662|NCT01877070|||FAMILY_BASED||PROSPECTIVE|||||||
33714663|NCT02123225|||CASE_ONLY||PROSPECTIVE|||||||
33714664|NCT00441883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714665|NCT00696696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017277|NCT03254602|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34017278|NCT02884349|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017279|NCT02833376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099446|NCT06027463|||OTHER||PROSPECTIVE|||||||
34099447|NCT02213107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099448|NCT02427672|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34099449|NCT02577380|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099450|NCT00070499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099451|NCT01279187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099452|NCT06349473|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34099453|NCT03114397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33714666|NCT01211054|||COHORT||PROSPECTIVE|||||||
33714667|NCT03194022|||COHORT||PROSPECTIVE|||||||
34017280|NCT03480126|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34017281|NCT01403064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017282|NCT01644110|NA|SINGLE_GROUP||TREATMENT||NONE||"Cohort 1 (Patient 1 - Patient 41): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.~Cohort 2 (Patient 42 - Patient 90): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be started at 0.5 mg once daily up to 2 mg once daily."||||
34017283|NCT05979363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017284|NCT02846688|||CASE_ONLY||PROSPECTIVE|||||||
34017285|NCT01708629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017286|NCT00470457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017287|NCT01130636|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099454|NCT06118281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099455|NCT05899816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34017288|NCT00673387|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34017289|NCT03090997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, care provider, investigator and outcomes assesor will be masking using placebo for resveratrol and vitamin C, the three groups will receive the same intervention with the use of placebo. The placebo will be prepared for the Pharmacology Department and packing and label for exclusive use into the protocol study. Any participant, care provider or investigator will know if package content vitamin C, resveratrol or placebo.|Randomized Clinical Trial|t|t|t|t
34017290|NCT03972267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017291|NCT02922881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017292|NCT05107531|||COHORT||PROSPECTIVE|||||||
34017293|NCT04407494|||COHORT||PROSPECTIVE|||||||
34017294|NCT02833545|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|the outcome assessor was not aware of the therapy administered|A sequential series of patients receiving steroid injections was compared to a sequential series of patients receiving ozone injections|f|f|t|t
34017295|NCT06062797|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34017296|NCT04819035|||CASE_CONTROL||PROSPECTIVE|||||||
34017297|NCT01216852|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017298|NCT03939325|||COHORT||PROSPECTIVE|||||||
34017299|NCT05061576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017300|NCT00003748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017301|NCT03028740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017302|NCT02375139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017303|NCT03185442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017304|NCT02733952|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34017305|NCT05335291|||CASE_ONLY||PROSPECTIVE|||||||
34017306|NCT02540317|RANDOMIZED|PARALLEL||TREATMENT||||||||
34017307|NCT02027181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017308|NCT05882279|||OTHER||PROSPECTIVE|||||||
34017309|NCT00004755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017310|NCT03453671|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will know their own condition (strategy) but not what the other conditions are. The primary investigator will be blind to participants' assignment to condition.||t|f|t|t
34017311|NCT01796158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099456|NCT05399134|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A within-subject crossover study design is used to assess the effectiveness of incorporating novel staple food into people's diet to improve their glycemic control. Subjects will undergo two study arms: Treatment and Control. The duration of each arm is 14-days, with a 1-week washout period in between.||||
34099457|NCT02070380|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34099458|NCT02565186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099459|NCT04518670|||CASE_ONLY||PROSPECTIVE|||||||
34099460|NCT05489159|||COHORT||PROSPECTIVE|||||||
34099461|NCT06454812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Using the block randomization technique, participants will be divided into 3 groups. A web-based randomization list creation tool will be used to create the blocked randomization list. Control and intervention groups will be coded as A, B and C using the sealed envelope method. Randomization information will be kept from the researcher involved in data collection until data collection begins. The researcher will learn which group each baby is in just before the application (researcher blinding).~Parents will know which group the baby is in within the scope of the research. By the nature of the sample group, babies are blind.~Research data will be entered into the computer database by coding the group name as A, B and C, and statistical analysis will be performed using this coding (statistician blinding)."|Participants will be assigned to experimental and control groups using block randomization method. Body weight and sex variables will be used for block randomization.|t|f|f|t
34099462|NCT05869825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099463|NCT04214899|||COHORT||PROSPECTIVE|||||||
34099464|NCT05879172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099465|NCT04097912|||COHORT||RETROSPECTIVE|||||||
34099466|NCT02540434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34099467|NCT06358703|||CASE_CONTROL||PROSPECTIVE|||||||
34099468|NCT04774146|||COHORT||PROSPECTIVE|||||||
34099469|NCT05465876|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective multi-centre open-label investigator-initiated single arm descriptive phase 2 clinical trial||||
34099470|NCT03270163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714668|NCT05384015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714669|NCT04481581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study providers cannot be masked, outcome assessors and investigators will be blinded|This will be a parallel design, unblinded, randomized (1:1) trial|f|f|t|t
33714670|NCT02606604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714671|NCT02559245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714672|NCT01035515|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33714673|NCT03445650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714674|NCT01852578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714675|NCT03383107|||OTHER||PROSPECTIVE|||||||
33714676|NCT03314402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"SAD: 8 cohorts, 8 subjects take jaktinib and 2 subjects take placebo;~MAD: 5 cohorts, 8 subjects take jaktinib and 2 subjects take placebo;~Postprandial Phamocokinetics:12 subjects, crossover designing"|t|t|t|t
34017312|NCT04206514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017313|NCT01430793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017314|NCT05709041|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017315|NCT05001932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34017316|NCT05211076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017317|NCT02848911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017318|NCT00374426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017319|NCT05686083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Bioanalytics and biostatistics services will be blinded to treatment identity until after the database has been locked and all analysis is complete.|Three way crossover in a random order|f|f|f|t
34017320|NCT04412148|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||f|f|t|t
34099471|NCT04202211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34099472|NCT05034978|||COHORT||PROSPECTIVE|||||||
34099473|NCT05016752|||COHORT||PROSPECTIVE|||||||
34099474|NCT03614585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099475|NCT02539394|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34099476|NCT05704829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a multicentre, interventional, prospective, two-arm, randomised, open-label, controlled (neo-)adjuvant, phase-II trial evaluating the efficacy and safety of trastuzumab-deruxtecan (T-DXd) vs. standard-of-care paclitaxel + trastuzumab + pertuzumab (PAC+T+P) in low- to intermediate-risk or docetaxel/paclitaxel + carboplatin + trastuzumab + pertuzumab in intermediate- to high-risk HER2+ early breast cancer in pre- and postmenopausal women.||||
34099477|NCT06200207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099478|NCT00198614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099479|NCT01197105|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34099480|NCT00576407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099481|NCT06445166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099482|NCT03517969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099483|NCT01694771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099484|NCT04281771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099485|NCT05554003|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34099486|NCT04139499|||CASE_CONTROL||PROSPECTIVE|||||||
34099487|NCT05129384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, randomized, placebo-controlled study|Infants will be randomized 1:1 to one of two study arms (treatment or placebo)|t|t|t|t
34099488|NCT02557893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34099489|NCT06581666|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34099490|NCT03480516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099491|NCT03952520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34099492|NCT04630626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099493|NCT06695377|||CASE_ONLY||RETROSPECTIVE|||||||
34099494|NCT06426888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099495|NCT05193149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Staff completing outcomes testing and study participants will be blinded to treatment assignment (IMT/SHAM). The IMT/SHAM devices are the same with ability to alter resistance; however, upon use at the lower intensity, the participant may be able to tell whether the device has resistance.||t|f|f|t
34099496|NCT01284088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34099497|NCT01459731|||COHORT||PROSPECTIVE|||||||
34099498|NCT03965299|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The only unmasked person involved in the trial is the operator who will be responsible for the daily application of the study intervention at the patient. The role of an operator can be occupied by a research assistant/study nurse or investigator not involved in the clinical management and assessment of clinical outcomes. Thus, patients and care providers involved with clinical assessments are blinded.||t|t|f|t
34099499|NCT05525715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099500|NCT01853085|||CASE_ONLY||PROSPECTIVE|||||||
34099501|NCT05061355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099502|NCT03834662|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Evaluation of the safety, tolerability, and dose-limiting toxicities (DLTs), to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of AVID200 when administered once every 3 weeks (Q3W) by IV infusion to patient cohorts (3)||||
34099503|NCT00002238||||TREATMENT||DOUBLE||||||
34099504|NCT00926705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34099505|NCT03995511|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099506|NCT02533674|NA|SINGLE_GROUP||OTHER||NONE||||||
34099507|NCT06009354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099508|NCT04153032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physician and the patient will not be blinded to the allocation, but the rest of the study team will be blinded. We will blind to allocation the physician who will assess for outcomes, and the research assistants who are collecting the data, data analysts.|1:1:1 randomized, controlled, parallel design|f|f|t|t
34099509|NCT06686095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Group A (n=30): Patients who underwent adductor canal block , group I (n=30): Patients who underwent infiltration block between popliteal artery and knee capsule block, group G (n=30): Patients who underwentgenicular nerve block|t|f|f|f
34099510|NCT02926196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099511|NCT02203786|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33714677|NCT01405599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714678|NCT02876263|||COHORT||PROSPECTIVE|||||||
33714679|NCT02290561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099512|NCT05259176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The present study will be conducted in 2 recruiting centers with a randomized double-blind design. Post-stroke patients with apraxia will be randomly allocated into two parallel groups (Group A and Group B) by creating two randomisation lists of 10 patients which will allow for random and balanced assignment of patient numbers to either Group A or Group B. Group A will undergo direct current transcranial stimulation (tDCS) for 10 consecutive days and online treatment with Smania training. Group B will undergo sham stimulation for 10 consecutive days and online treatment with Smania training.|t|f|f|t
34099513|NCT05627986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34099514|NCT03574779|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study|||||
34099515|NCT00862862|||OTHER||PROSPECTIVE|||||||
34099516|NCT05373966|||COHORT||PROSPECTIVE|||||||
34099517|NCT06623266|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized 1:1 to the experimental or control arm. Experimental arm: radical resection of the primary lesion only, with neck observation, the safety margins of the primary lesion are 1.0-1.5cm far away from the palpable margins of the lesion.~Control arm: radical resection of the primary lesion with 1.0-1.5cm safety margins, and elective neck dissection."||||
33714680|NCT00776958|||CASE_CONTROL||PROSPECTIVE|||||||
33714681|NCT01396148|NON_RANDOMIZED|||TREATMENT||NONE||||||
33938370|NCT02417935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938371|NCT02352181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938372|NCT05168189|||COHORT||PROSPECTIVE|||||||
33938373|NCT02946268|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017321|NCT05423444|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|An independent assessor will conduct interviews to quantify symptom severity during and after treatment. The participant will not be given specific information about treatment assignment or the differences between the two treatments.|Randomized controlled trial of Trauma-focused Cognitive Behavioral Therapy (TF-CBT) versus Treatment as Usual (TAU)|t|f|f|t
34017322|NCT05969379|||COHORT||RETROSPECTIVE|||||||
34017323|NCT04503395|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparision of two different procedure to repair abdominal aortic aneurysms with short necks||||
34017324|NCT00172536|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34017325|NCT06171607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017326|NCT01941355|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34017327|NCT01240317|||CASE_CROSSOVER||PROSPECTIVE|||||||
34017328|NCT00857584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017329|NCT01169532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017330|NCT02964949|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34017331|NCT02673996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017332|NCT04919863|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34017333|NCT01518049|||COHORT||PROSPECTIVE|||||||
34017334|NCT02963441|||CASE_ONLY||CROSS_SECTIONAL|||||||
34017335|NCT00891748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017336|NCT02435836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017337|NCT02944370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017338|NCT03596229|||COHORT||RETROSPECTIVE|||||||
34017339|NCT02394730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017340|NCT00725751|||COHORT||PROSPECTIVE|||||||
34017341|NCT01400386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34017342|NCT04030182|||CASE_ONLY||CROSS_SECTIONAL|||||||
34017343|NCT04525638|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single-arm||||
34017344|NCT04901637|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017345|NCT01884662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017346|NCT03762941|||COHORT||PROSPECTIVE|||||||
34017347|NCT02862496|||CASE_CONTROL||PROSPECTIVE|||||||
34099518|NCT04299425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only participants will be masked to the intervention.|"NIRAF detection technology is used as an adjunctive tool for intraoperative parathyroid identification in patients who undergo parathyroidectomy (PTx) in the interventional group.~Generic Name of Device: Parathyroid Autofluorescence Detection Device (NIRAF detection technology).~The Parathyroid Autofluorescence Detection Device consists of a disposable fiber-optic probe that emits non-ionizing radiation from a near infrared (NIR) 785 nanometer (nm) laser source, and also transmits the resulting tissue NIRAF to a photo-detector. The 785 nm laser source emits a maximum power of 20 milliwatts (mW). The device has an FDA clearance for clinical use in general surgeries and dermatological use (Class 2 device)."|t|f|f|f
33714682|NCT03879122|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multi-arm multi-stage (MAMS), multi-centre randomised controlled trial with 3 arms (2 experimental arms and a control arm) and 4 stages (three intermediate and a final stage). In all 3 intermediate stages of the trial, each experimental arm is compared in a pairwise manner with the control arm using an intermediate outcome measure. Experimental arms that do not reach a predefined critical value are discontinued. In the final stage, the remaining(s) arm(s) will be compared with the control arm in terms of overall survival (definitive outcome). The 3 arms included in this trial are the Control arm (ARM 1): ADT plus 6 cycles of DOCETAXEL and 2 experimental arms: ADT plus DOCETAXEL plus NIVOLUMAB (ARM 2) and ADT plus IPILIMUMAB alternating with DOCETAXEL and with NIVOLUMAB (ARM 3). Other experimental arms could be included later."||||
34099519|NCT00003151||||TREATMENT||||||||
34099520|NCT06544148|||CASE_CONTROL||PROSPECTIVE|||||||
34099521|NCT03568071|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34099522|NCT06557577|||OTHER||CROSS_SECTIONAL|||||||
33714683|NCT01971411|||COHORT||PROSPECTIVE|||||||
34017348|NCT02148679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34099523|NCT05874297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099524|NCT02668315|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34099525|NCT06081114|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099526|NCT04302168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099527|NCT05754775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017349|NCT02933021|||COHORT||PROSPECTIVE|||||||
34017350|NCT02377518|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017351|NCT03939299|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients received optical coherence tomography examination after successful stening at the chronic total occlusion lesion.||||
34017352|NCT01644552|||CASE_ONLY||RETROSPECTIVE|||||||
34017353|NCT04683666|||COHORT||PROSPECTIVE|||||||
34017354|NCT05162365|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34017355|NCT02302664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34017356|NCT03868462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017357|NCT01907126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017358|NCT00678041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714684|NCT04245332|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34017359|NCT02603302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017360|NCT02568566|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017361|NCT00845806|||CASE_ONLY|||||||||
34017362|NCT01374126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017363|NCT01461226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017364|NCT02195466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017365|NCT04890951|||COHORT||PROSPECTIVE|||||||
34017366|NCT04191837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017367|NCT03668561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017368|NCT01688076|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34017369|NCT03493386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study will be conducted in two parts. Part 1 is the bioequivalence part in which subjects will receive single dose of 2 tablets of 2 mg daprodustat and single dose of 1 tablet of 4 mg daprodustat in crossover manner. Part 2 is Food effect part. In this part, subjects will receive single dose of 4 mg daprodustat tablet in fasting and fed state in a crossover manner.||||
34017370|NCT06004219|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will assign 12 patients into peer support group (intervention) and 12 patients as control (usual care with no support group) group. Patients will be followed for 6 months.||||
34017371|NCT04375683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017372|NCT04884867|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants will use a wireless pill container to monitor their adherence passively. Participants, lay coaches, and clinicians will all be blinded to adherence monitoring.|||||
34017373|NCT02423356|||COHORT||PROSPECTIVE|||||||
34099528|NCT03091491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714685|NCT01088945|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714686|NCT03544190|||COHORT||CROSS_SECTIONAL|||||||
33714687|NCT04489823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714688|NCT02608710|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33714689|NCT05718128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714690|NCT03723759|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is asked according to company standard procedures||t|t|t|t
33714691|NCT02740777|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714692|NCT01737944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714693|NCT01166113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714694|NCT01877434|||CASE_ONLY||PROSPECTIVE|||||||
33714695|NCT02566434|NA|SINGLE_GROUP||OTHER||NONE||||||
33714696|NCT01730391|||CASE_ONLY||CROSS_SECTIONAL|||||||
33714697|NCT00698360|||CASE_ONLY||PROSPECTIVE|||||||
33714698|NCT03837106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33714699|NCT01082406|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33714700|NCT01619774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714701|NCT00260494|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714702|NCT00733408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714703|NCT01659775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714704|NCT00870571|RANDOMIZED|CROSSOVER||||NONE||||||
33714705|NCT01634971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714706|NCT01953588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714707|NCT05715593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33714708|NCT05527860|||CASE_ONLY||RETROSPECTIVE|||||||
33714709|NCT02412423|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714710|NCT01134978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33714711|NCT00450684|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33714712|NCT00147199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714713|NCT01092611|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33714714|NCT02927080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714715|NCT05791344|||COHORT||OTHER|||||||
34017374|NCT05215769|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34017375|NCT01345175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017376|NCT05255874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|statistician||t|f|f|f
34017377|NCT01520532|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017378|NCT00894738|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017379|NCT03744871|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34017380|NCT02754908|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34017381|NCT05397561|||CASE_ONLY||CROSS_SECTIONAL|||||||
34017382|NCT02613013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017383|NCT05075720|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Given the nature of the interventions, participants, and the investigators responsible for delivering the interventions will be unblinded throughout the trial. However, all researchers performing the laboratory analyses and data analyses will be blinded to the interventions that the participants received until after the data analysis has been performed.|prospective, mono-centre, randomised, controlled, crossover study|f|f|f|t
34017384|NCT00306943|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017385|NCT05705817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017386|NCT00910091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017387|NCT02733315|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34017388|NCT00700609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017389|NCT06056011|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34017390|NCT01661699|||CASE_ONLY||PROSPECTIVE|||||||
34017391|NCT01878487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017392|NCT02925819|||COHORT||PROSPECTIVE|||||||
34017393|NCT02372071|NA|SINGLE_GROUP||SCREENING||NONE||||||
34017394|NCT01878162|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017395|NCT03460769|||CASE_CONTROL||PROSPECTIVE|||||||
34017396|NCT00823121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017397|NCT02016313|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34017398|NCT00512382|||CASE_ONLY||PROSPECTIVE|||||||
34017399|NCT03916302|||COHORT||PROSPECTIVE|||||||
34017400|NCT04962984|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34017401|NCT02489019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017402|NCT05377593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"A Randomized Clinical Trial A Trial will be carried out in hospital of Oral and Maxillofacial Surgery department- Faculty of dentistry Cairo University.~Equal Randomization: Participants receiving treatment. Positive Controlled: Both groups receiving treatment. Parallel group study: each group of patients receives single treatment simultaneously."|t|f|f|t
34017403|NCT03254030|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants are randomised to undergo the flexible sigmoidoscopy screening examination either for control or intervention group. Control group is to undergo inspection of colonic mucosa only during withdrawal phase of the examination. Intervention group will undergo the examination during which the colonic mucosa will be inspected during inspection and withdrawal phase.||||
34017404|NCT01321008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017405|NCT02212002|||CASE_CONTROL||PROSPECTIVE|||||||
34017406|NCT04751292|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34017407|NCT02743234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017408|NCT03585465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017409|NCT05600504|||OTHER||PROSPECTIVE|||||||
34017410|NCT00327288|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017411|NCT02373748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017412|NCT05177172|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Four test products and one reference product (control). Participants are not aware of which product that is served at each visits|Randomised food study in healthy subjects|t|f|f|f
34017413|NCT04761458|NA|SINGLE_GROUP||SCREENING||NONE||||||
34017414|NCT04040153|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This is a cluster-randomized, pragmatic trial, with randomization at the pediatrician level and observation of intervention effects at the adolescent patient level. Using a constrained randomization approach, the study team will randomize 72 pediatricians, 24 in each healthcare system (36 intervention, 36 control), to either Intervention (GGC) or Control arms. Constraints (pediatrician panel size, pediatrician gender, and a pediatrician panel-level indicator of socioeconomic status) will ensure balance across intervention and control arms after randomization, reduce potential variability in effect sizes among pediatricians, and increase power. Patients and families are not aware of their pediatrician's assignment. Adolescents born between 6.1.2007 and 5.31.2009 and empaneled with the 72 pediatricians will participate in the study if their parent/legal guardian consents. GGC will be recommended to all parents/legal guardians of adolescents in the intervention arm.|t|f|t|f
34017415|NCT02005887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017416|NCT05367726|||COHORT||RETROSPECTIVE|||||||
34017417|NCT01912274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017418|NCT05931666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017419|NCT01712737|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34017420|NCT01183221|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both the participant and investigator are blind to drug condition.|Participants are randomized to receive 24IU intranasal oxytocin or placebo on days separated by a minimum of 3 weeks. Randomization order to drug condition is counter-balanced.|t|f|t|f
34017421|NCT00289757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017422|NCT04848311|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017423|NCT01725776|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017424|NCT03207841|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33938374|NCT00911144|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34017425|NCT05134246|||COHORT||PROSPECTIVE|||||||
34017426|NCT01335373|||COHORT||PROSPECTIVE|||||||
34017427|NCT03456895|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Three populations are being investigated in this trial; a healthy volunteer population, a patient population, and a staff population. Each population has the potential to participate in survey tools and/or physical environmental experiences.||||
34017428|NCT03018210|||COHORT||PROSPECTIVE|||||||
34017429|NCT01661179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017430|NCT03317665|||COHORT||PROSPECTIVE|||||||
34017431|NCT01587586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017432|NCT04593966|||COHORT||PROSPECTIVE|||||||
34017433|NCT02813057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017434|NCT03790579|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017435|NCT02815449|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34017436|NCT05181332|||COHORT||OTHER|||||||
34017437|NCT03952611|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Randomization will be done by computer allocation|Three Arm Randomized Control Trial|t|f|t|t
34017438|NCT01708590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017439|NCT06457399|||COHORT||PROSPECTIVE|||||||
34017440|NCT04414306|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants whose initial engagement with the study via online study arms 2 and 3 will not know that they are being randomly assigned to one of two educational interventions: a video and website module about colorectal cancer screening or a video about lung cancer screening, and will not be told about the in-person educational arm. Participants in the in-person educational arm may be told that others are participating online as part of the study, but will not be told about he lung cancer screening video specifically.||t|f|f|f
34017441|NCT04943978|||CASE_CONTROL||PROSPECTIVE|||||||
34017442|NCT00210236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938375|NCT01568983|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33938376|NCT00149006|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33938377|NCT03855358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017443|NCT05502523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017444|NCT00652249|||COHORT||CROSS_SECTIONAL|||||||
34017445|NCT01431911|||COHORT||RETROSPECTIVE|||||||
34017446|NCT03537274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017447|NCT01349582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017448|NCT03130218|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized by day of week||||
34017449|NCT04056871|||COHORT||PROSPECTIVE|||||||
34017450|NCT02651454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017451|NCT04021732|||CASE_CONTROL||PROSPECTIVE|||||||
34017452|NCT03763552|||CASE_ONLY||RETROSPECTIVE|||||||
34017453|NCT00804817|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34017454|NCT03525743|||COHORT||PROSPECTIVE|||||||
34017455|NCT03061682|NA|SINGLE_GROUP||OTHER||NONE||||||
33938378|NCT05580107|NA|SEQUENTIAL||TREATMENT||NONE||Dose finding (24 and 48 mg) based on dose limiting toxicity (DLT)||||
34017456|NCT06014918|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|As this is an observational study to assess feasibility, the participants, care providers, researchers, and outcome assessors cannot be masked by the nature of the design.|This study is designed to examine the feasibility of a smart device application to assess and manage postoperative pain in a single group of patients undergoing major surgery.||||
34017457|NCT01046266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017458|NCT03863483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017459|NCT00458926|||CASE_CONTROL||PROSPECTIVE|||||||
33938379|NCT05768568|RANDOMIZED|CROSSOVER||PREVENTION||NONE||CP children who will meet the inclusion criteria will be assigned into two groups. Baseline debris, calculus and gingival and plaque status will be recorded using Oral Hygiene Index Simplified (OHI-S) and gingival \& plaque index (PI, GI). The group I will receive a conventional manual toothbrush and group II will be given powered toothbrush. After 4 weeks will receive powered brush and group II will receive manual brush. After 4 weeks again the subjects will be assessed again for PI, GI, OHI-S. The scores will be compared and analyzed from baseline, after first phase and after second phase of interventions||||
33938380|NCT02394028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938381|NCT05659459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938382|NCT05761236|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33938383|NCT04588376|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Cluster Randomized Trial||||
33938384|NCT04319861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938385|NCT00517634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938386|NCT06259591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"Pedometer data collection and coaching text administration will be done by an unmasked team member.~30-day interview will be done by a masked team member."|||||
33938387|NCT02407236|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33938388|NCT05075434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938389|NCT01097564|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33938390|NCT01497665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938391|NCT03376776|||CASE_CONTROL||RETROSPECTIVE|||||||
33938392|NCT02133144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938393|NCT04257006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938394|NCT00541502|||||PROSPECTIVE|||||||
33938395|NCT02114359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938396|NCT00750867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938397|NCT00274352|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33938398|NCT04182165|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33938399|NCT01732861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938400|NCT00887913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938401|NCT02298699|||COHORT||PROSPECTIVE|||||||
33938402|NCT04184921|||COHORT||PROSPECTIVE|||||||
33938403|NCT02365324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938404|NCT03224936|||COHORT||PROSPECTIVE|||||||
33938405|NCT03709914|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|Subjects \<12 years of age, are assigned by age to one of five age based cohorts. Study is open label and not masked.|multiple-center, non-comparative, open-label, PK study||||
33938406|NCT00740688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33938407|NCT01509157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017460|NCT05218382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding of the participants is not possible due to the nature of the intervention.|Randomized controlled superiority trial|f|t|t|t
34017461|NCT05495035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099529|NCT06066931|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is planned to recruit patients over the age of 18, suffering from cancer of the lower ampullary rectum with T1-T4N0-2M0 (according to the classification of malignant tumors TNM in the 8th edition) who meet the inclusion criteria taking into account the exclusion criteria in the number of 150 people. Group 1 is a simple method (Plastic surgery with local tissues) n=50; Group 2 is plastic surgery with a mesh endoprosthesis n=50; group 3 is a new method of plastic surgery n=50.||||
33938408|NCT03884803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938409|NCT01879891|NON_RANDOMIZED|PARALLEL||||NONE||||||
33938410|NCT02600663|||COHORT||PROSPECTIVE|||||||
33938411|NCT03001726|||CASE_CONTROL||PROSPECTIVE|||||||
33938412|NCT05745506|||COHORT||PROSPECTIVE|||||||
33938413|NCT00476502|||COHORT||CROSS_SECTIONAL|||||||
34017462|NCT03762486|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"TENS was applied to around the insicion: Transcutaneous electrical nerve stimulation was applied to around the incision.~TAES was applied to acupuncture points: Transcutaneous electrical stimulation was applied to acupuncture points.~No intervention: No stimulation was performed to the patients.~A standard analgesia protocol for post-operative pain control was used in all patients included in the study. A standard antiemetic protocol was used for all patients after surgery."||||
34017463|NCT05707312|||COHORT||RETROSPECTIVE|||||||
34017464|NCT00953641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017465|NCT01689662|NA|SINGLE_GROUP||OTHER||NONE||||||
34017466|NCT05311917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017467|NCT00486317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017468|NCT01289665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099530|NCT06128343|||COHORT||PROSPECTIVE|||||||
34099531|NCT02551107|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34099532|NCT05449262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099533|NCT05035693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099534|NCT00421733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099535|NCT05718336|||COHORT||PROSPECTIVE|||||||
34099536|NCT06291961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938414|NCT02258516|RANDOMIZED|PARALLEL||||NONE||||||
33938415|NCT04554394|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938416|NCT04764591|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938417|NCT05059184|||OTHER||CROSS_SECTIONAL|||||||
33938418|NCT03198884|||CASE_CONTROL||RETROSPECTIVE|||||||
33938419|NCT02113644|||OTHER||CROSS_SECTIONAL|||||||
33938420|NCT01240772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938421|NCT00928733|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33938422|NCT03665233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938423|NCT03279991|||COHORT||CROSS_SECTIONAL|||||||
33938424|NCT01064986|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33938425|NCT05506306|||COHORT||PROSPECTIVE|||||||
33938426|NCT02485405|||COHORT||OTHER|||||||
33938427|NCT00188981|||DEFINED_POPULATION||OTHER|||||||
33938428|NCT06372405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938429|NCT02186886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099537|NCT04091438|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34099538|NCT02286791|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34099539|NCT05615350|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34099540|NCT03947827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, their families, referring clinicians, lab workers and research assistants carrying out assessments will be concealed from allocation. Once randomized, pharmacy at the Centre for Addiction and Mental Health (CAMH) will be informed by email and deliver medication to the patient. An independent study psychiatrist will manage any clinical concerns and will be blind to treatment allocation. To assess the integrity of blinding procedures, participants and independent raters will be asked to complete a conventional guess form asking whether they believe participants received Minocycline or placebo as a treatment after the final ratings have been completed.||t|t|t|t
34099541|NCT06007248|||CASE_CONTROL||PROSPECTIVE|||||||
34099542|NCT00964444|||||PROSPECTIVE|||||||
34099543|NCT05156125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will employ a double-blind design. Subjects, Investigators, study center staff, persons performing the assessments, central endoscopy readers and the Sponsor are to remain blinded to the identity of the Induction Period treatment from the time of randomization until the interim database lock for the study.||t|t|t|t
34099544|NCT00252473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099545|NCT03216291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Everyone is masked to the assignment of home or office biofeedback training. Once the subject makes it to their treatment session, then everyone will know which one the subject has been allocated to.||t|f|t|t
34099546|NCT04803903|||COHORT||RETROSPECTIVE|||||||
34099547|NCT05528666|||COHORT||RETROSPECTIVE|||||||
34099548|NCT05358938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099549|NCT04293965|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||SAD, MAD and FE study||||
33714716|NCT05448833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33714717|NCT04791904|||COHORT||RETROSPECTIVE|||||||
33714718|NCT02260921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714719|NCT03858764|||OTHER||OTHER|||||||
33714720|NCT02696473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33714721|NCT00903695|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33714722|NCT00251550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714723|NCT05659095|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33714724|NCT01959893|||||PROSPECTIVE|||||||
33714725|NCT00684593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714726|NCT01954004|||COHORT||PROSPECTIVE|||||||
33714727|NCT05713747|||COHORT||CROSS_SECTIONAL|||||||
33714728|NCT03102255|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33714729|NCT01661491|||CASE_CONTROL||PROSPECTIVE|||||||
33714730|NCT01722890|||COHORT||RETROSPECTIVE|||||||
33714731|NCT06321315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention group (Case-based instruction group) Control group||||
33714732|NCT05261360|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was planned as three arms. One arm will be the control group, and the other two arms will be the experimental group. The control group defines the group that did not receive treatment. Those in the experimental group, who are the participants other than the control group, will occur in both experimental groups. SF-MSC (synovial fluid-derived mesenchymal stem cells) will be applied intraarticularly to the experimental group's right knee, and the experimental group's right knee will be included in the SF-MSC treatment group. SF-MSC-EX (synovial fluid-derived mesenchymal stem cells-derived exosomes) will be applied intraarticularly to the experimental group's left knee, and the experimental group's left knee will be included in the SF-MSC-EX treatment group.||||
33714733|NCT06000098|||CASE_ONLY||PROSPECTIVE|||||||
33714734|NCT04246008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a mixed-design study. It includes a two-group parallel, randomized clinical trial with acute coronary syndrome patients.|f|f|f|t
33714735|NCT02809456|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714736|NCT04430543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||There will be 2 groups- treatment group and control group. Both groups will receive a web-based motivational intervention then will be randomized to Cognitive Bias Modification or Sham (control) training. Participants will complete a total of 5 sessions of CBM or Sham over the course of a week.|t|f|f|f
33714737|NCT04042337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33794917|NCT04977856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducting post- and follow-up assessments will be blind to treatment allocation, for the full duration of the trial. The outcome measures are identical for both groups, ensuring that the assessors remain blind. At each follow-up assessment, participants will be reminded by their assessor to not reveal their arm allocation. To measure blinding integrity, all assessors will record whether the participating families inadvertently reveal their group allocation, and subsequently guess each participant's treatment allocation at each assessment point and motivate their choice. The blinding will be broken after the trial's final participant has finished his/her 3-month follow-up assessment (primary endpoint). The trial will end when the trial's final participant has finished his/her 3-month follow-up assessment.|Single-blind parallel-group randomised controlled trial|f|f|f|t
33794918|NCT06300996|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-arm, open-label study performed to quantify variables that are predictive of the efficacy of spinal cord stimulation to improve motor control.||||
33794919|NCT02587130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938430|NCT01614366|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33938431|NCT05378893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099550|NCT05508165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33714738|NCT00859768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714739|NCT01120223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714740|NCT02123498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714741|NCT00379574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714742|NCT01077856|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33714743|NCT06034470|NA|SEQUENTIAL||TREATMENT||NONE||||||
34099551|NCT03485209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099552|NCT03438656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099553|NCT02916914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017469|NCT04385966|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|After randomization, only Interscalene Block performer staff will know which intervention group is assigned to the participants. Spirometry and ultrasound assessments will be conducted by only one blinded anesthesiologist of Assessment staff who will not be communicated to IBPB staff. Recruitment and Assessment staff and participants will not be allowed to receive any information about the group allocation. Study unblinding will occur when every ultrasound and Spirometry assessments have been completed after 24-hour follow-up postoperative closeout. After follow-up finished, every study data will figure in the patient medical record. Code breaks should occur only in exceptional circumstances when knowledge of the actual treatment is absolutely essential for further management of the patient as an allergy episode. The Research staff will be encouraged to maintain the blind as far as possible. Unblinded IBPB staff will manage the emergency.|The REDOLEV study is a randomized, comparative, prospective, unicenter, double-blind, two-arm and controlled Clinical trial (RCT).|t|f|t|t
34017470|NCT05066763|||COHORT||PROSPECTIVE|||||||
34017471|NCT06464432|NA|SINGLE_GROUP||TREATMENT||NONE||Un-randomized Pilot||||
34017472|NCT03230500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the trial only the outcome assessor will be masked from the intervention or control group|Assignment|f|f|f|t
34017473|NCT04405895|RANDOMIZED|PARALLEL||TREATMENT||NONE||The researcher will explore the effect of serum samples collected from T2D participants following either Breakfast Diet (3Mdiet) or Allday Diet (6Mdiet) schedule, on SIRT1 and Clock Gene circadian expression of cultured hepatocytes using the ex-vivo/in-vitro approach||||
34017474|NCT04717102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017475|NCT04817566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017476|NCT01721811|NON_RANDOMIZED|PARALLEL||||NONE||||||
34017477|NCT03997214|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34017478|NCT05094245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34017479|NCT06132217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017480|NCT03884374|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants will be block randomized with stratification for site, sex, and race in double blind fashion.|Adults (half AA, half NHW) with knee OA will be randomized to one of four conditions created by crossing Real tDCS vs. Sham tDCS with Focused BAT vs. Standard BAT|t|f|t|f
34017481|NCT03034655|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After the first screening visit, the patients who grant their consent will be included in the study and randomised to one of the following study arms. Randomisation will be performed by C.H.U de Santiago Clinical Epidemiology and Biostatistics Unit. Once the informed consent form is signed, the care provider will contact the unit, which will give him the code of the arm to which the patient is assigned. A n= 20 block balanced randomisation sequence will be used. The investigator will analyse results and evolution, being blind type and duration of vestibular rehabilitation.|Experimental study, single-center, open, randomized (balanced blocks of patients) in four branches in parallel, in 220 elderly patients (over 65 years) with high risk of falls; follow-up period: twelve months.|f|f|t|t
34017482|NCT00933517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017483|NCT04842136|||CASE_CONTROL||RETROSPECTIVE|||||||
34017484|NCT03518892|||CASE_CONTROL||PROSPECTIVE|||||||
34017485|NCT02803229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017486|NCT01250483|||CASE_CONTROL||RETROSPECTIVE|||||||
34017487|NCT01301586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017488|NCT02642796|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34017489|NCT06214169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017490|NCT03792087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017491|NCT03531398|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34017492|NCT04046796|||CASE_CONTROL||PROSPECTIVE|||||||
34017493|NCT05953753|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Data will be collected through household surveys, value chain actor semi-structured interviews, KIIs, and FGDs. The protocol team has selected a subset of the intervention local government areas for the evaluation and identified an equal number of local government areas outside the program coverage area with similar characteristics to serve as the control.||||
34017494|NCT00739986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017495|NCT02240342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017496|NCT05534308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34017497|NCT02053623|||COHORT||RETROSPECTIVE|||||||
34017498|NCT01747720|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099554|NCT06480110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099555|NCT02021734|||FAMILY_BASED||PROSPECTIVE|||||||
34099556|NCT00401830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099557|NCT03015779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017499|NCT00163670|||COHORT||PROSPECTIVE|||||||
34017500|NCT03416803|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34017501|NCT05406063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017502|NCT02453776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017503|NCT00838435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017504|NCT01833091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017505|NCT02548611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099558|NCT06557369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099559|NCT05667493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099560|NCT06239480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017506|NCT03201250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017507|NCT00063414||||TREATMENT||||||||
34099561|NCT04704921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The administration of RGX-314 requires an outpatient surgical procedure performed in an operating room, while the active control, ranibizumab, is administered via intravitreal injection in an office setting. This study will be partially masked which will include masking of key study assessors and study drug dose.|2 RGX-314 treatment arms, 1 control arm (ranibizumab)|t|t|t|t
34099562|NCT04595578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099563|NCT03990844|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The investigators will randomized the subjects to consume the noodles at different enrichment levels. Subjects will not know the level of enrichment.|This study is a within-subject cross-over trial to assess the glycemic and insulinemic responses of 0%, 10% and 20% okra-seed enriched noodles in healthy human subjects.|t|f|f|f
33714744|NCT04068662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All women are told that they are participating in a support group program for pregnant women who have experienced intimate partner violence, and do not receive any information about the content of either condition or their assignment.|Participants are assigned to either the Pregnant Moms' Empowerment Program or an active control group. Members of the active control group participate in a non-directive support group with contact equivalent time to the Pregnant Moms' Empowerment Program (10 hrs).|t|f|f|f
34017508|NCT06123442|NA|SEQUENTIAL||TREATMENT||NONE|After enrolling participants and conducting baseline assessments, individuals will be randomly assigned to one of two treatment conditions using a 1:1 allocation ratio following the guidelines already laid down guidelines. It's worth noting that this study will involve university students from various levels and programs, as long as they meet the criteria outlined in Table 1.2. While the facilitators will be aware of the treatment conditions, the research assistant responsible for conducting assessments after randomization will remain blind to these conditions. The process of characterizing the participants will follow the same approach as the three one-arm trials, with any necessary adjustments made based on lessons learned during the trial groups' execution.|This open-label, 2-year pilot study seeks to determine the feasibility and acceptability of CRI in students with psychological distress comorbid with suicide behavior. This study will employ three single-arm trials followed by a pilot randomized controlled trial with an experimental and control group. This university-based research will use a pretest-posttest design to collect data||||
33714745|NCT00429104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714746|NCT00967525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714747|NCT03880071|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714748|NCT04775459|||COHORT||OTHER|||||||
33714749|NCT05484739|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The investigators will conduct a randomized crossover design study. Older individuals will be exposed to one of two heat wave conditions (Very hot and dry or hot and humid). For each heat wave condition the individual will receive one of the following cooling strategies, with each cooling strategy applied on a different day: A) a control trial, B) skin wetting only trial, C) fan only trial, and D) a combination of skin wetting with a fan trial. Thus, to complete the trial for a selected heat wave condition (e.g., either very hot and dry or hot and humid) four experimental visits will be required - one visit for each cooling strategy.||||
33714750|NCT04867603|||COHORT||PROSPECTIVE|||||||
33714751|NCT01119612|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33714752|NCT02630498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714753|NCT05885607|||COHORT||PROSPECTIVE|||||||
33714754|NCT05255406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714755|NCT00002096||||TREATMENT||||||||
33714756|NCT01974349|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33714757|NCT06289491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714758|NCT01311570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714759|NCT03542981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33714760|NCT02483728|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33714761|NCT05146401|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714762|NCT01074450|RANDOMIZED|CROSSOVER||||NONE||||||
33714763|NCT03552198|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|To avoid bias participants were not told how the wording of the health advice had been changed.|This was a randomised control trail using a 2-way factorial design, with target population (2 levels: general population vs. individuals with a pre-existing health condition) and message format (2 levels: usual message format vs. alternative format) as between-factors.|t|f|f|f
33714764|NCT00656110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714765|NCT01661439|||COHORT||PROSPECTIVE|||||||
33714766|NCT04219631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33714767|NCT00246727|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33714768|NCT03236974|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not applicable, thisis an open-label study.|||||
33714769|NCT03939884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33714770|NCT01638065|||||PROSPECTIVE|||||||
33714771|NCT05377385|||CASE_ONLY||OTHER|||||||
33714772|NCT01080521|||COHORT||PROSPECTIVE|||||||
33938432|NCT04180475|NA|SEQUENTIAL||OTHER||NONE||"Phase 1 - determine the feasibility of the Apple Watch medication/exercise reminder system MedRem by deploying the system to control subjects.~Phase 2 of study- assess the subjects' adherence to medications, exercise and checking heart rate (and quality of the exercise), with the use of MedRem~• assess the acceptance and usability of the MedRem system."||||
33938433|NCT01688427|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33938434|NCT04651647|||CASE_CONTROL||RETROSPECTIVE|||||||
33938435|NCT01352624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33938436|NCT05373186|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Three-period crossover|t|f|t|f
33938437|NCT03990441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33938438|NCT00192712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938439|NCT04498585|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938440|NCT02292524|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33938441|NCT01050140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33938442|NCT05639361|||COHORT||PROSPECTIVE|||||||
33938443|NCT03652506|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participant, Outcomes Assessor|prospective,randomized|t|f|f|f
34099564|NCT05933876|||CASE_CONTROL||OTHER|||||||
34099565|NCT05034887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099566|NCT05970406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714773|NCT05420129|||CASE_CONTROL||PROSPECTIVE|||||||
33714774|NCT00380185|||CASE_CONTROL||PROSPECTIVE|||||||
33714775|NCT04432194|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33714776|NCT06044285|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and outcome assessors will be blinded to the participants' condition. The study coordinator will oversee the randomization protocol.|Multi-method, within subjects, perspectives, experimental design|t|f|f|t
33714777|NCT01602146|||COHORT||PROSPECTIVE|||||||
33714778|NCT01321424|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714779|NCT01944527|||COHORT|||||||||
33714780|NCT06501768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017509|NCT05354830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"It was planned as an open-label, blinded, randomized and controlled experimental study. A computer-assisted simple randomization method was used to distribute the groups homogeneously. For this purpose, 72 sets were created by using the functions available at the https://www.random.org/integer-sets internet address, and each of these sets included 8 participants, 4 participants from each study group. As the next operation, 72 sets were shown with 1 number each, and 9 numbers between 1 and 72 were generated using the RANDOMLY SEARCH function in Excel, and 9 sets to be used in randomization were randomly determined. In order to reach the sample number of 68 people, 4 participants, 2 from each study group, were selected in the final set. Thus, patients were randomly assigned to the experimental and control groups in order to reduce selection bias and control the variables that may affect the outcome parameters."|Randomized controlled parallel groups|f|f|t|f
34017510|NCT05023382|||COHORT||PROSPECTIVE|||||||
34017511|NCT03347422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017512|NCT02201238|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34017513|NCT02350244|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34017514|NCT03972449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017515|NCT03570086|||COHORT||PROSPECTIVE|||||||
34017516|NCT02679157|||COHORT||PROSPECTIVE|||||||
34017517|NCT01111019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017518|NCT01333280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017519|NCT05414032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794920|NCT04704778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blind observer:~A third party (statesman) is used, who does not know the treatment that each person is receiving.~patient, to assess the response."|The selected sample will be divided into three groups (GA = transcutaneous electrostimulation and splint, GB = percutaneous electrostimulation and splint, GC = splint); the allocation by group will be made by means of a randomization in balanced blocks. For this process, a series of blocks will be assembled made up of a certain number of cells in which the types of treatment are included. The number of blocks will be determined by the number of participants to be included in the study and the number of cells that it has been decided to include in each block. Each block will contain in each cell one of the treatment alternatives and within each block there must be a balanced number of possible treatments.|f|f|f|t
34017520|NCT02722148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017521|NCT03926481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714781|NCT03458273|||CASE_CONTROL||RETROSPECTIVE|||||||
34017522|NCT00120536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099567|NCT05111522|||COHORT||PROSPECTIVE|||||||
34099568|NCT05666960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099569|NCT01121354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099570|NCT03123562|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34099571|NCT00144508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099572|NCT06241482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099573|NCT06165653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099574|NCT02327247|RANDOMIZED|CROSSOVER||||NONE||||||
34099575|NCT01218256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099576|NCT01733693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099577|NCT05123105|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Each person participated in three tests with an interval of approximately one week between them. The following study protocol was followed; (short version)~1. cupping therapy;~   - a minimum interval of 7 days;~2. control test;~   - a minimum interval 7 days;~3. ischemic compression."||||
34099578|NCT06362642|NA|SEQUENTIAL||OTHER||NONE||The treatments will be: Day 1: single oral dose of PC14586, Day 20: oral dose of itraconazole BID, Day 21-22: single oral dose of itraconazole QD, Day 23: single oral dose of PC14586 and single oral dose of itraconazole, Day 24-27: single oral dose of itraconazole QD.||||
34099579|NCT01034657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099580|NCT00002480||||TREATMENT||||||||
34099581|NCT04103970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099582|NCT05670340|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|only the care provider knows the group asignement|The implant abutment height could be short (\<2mm) or long (\>2mm)|t|f|f|t
34099583|NCT06101862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714782|NCT00118963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714783|NCT05712616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794921|NCT00316641|RANDOMIZED|PARALLEL||||DOUBLE||||||
34017523|NCT03205930|NA|SINGLE_GROUP||TREATMENT||NONE|Open clinical study|Single center single arm clinical study||||
34017524|NCT03744702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017525|NCT05303376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017526|NCT02399735|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099584|NCT06493565|||COHORT||PROSPECTIVE|||||||
34099585|NCT05013229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099586|NCT05348915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099587|NCT03225989|NA|SEQUENTIAL||TREATMENT||NONE||Participants treated with LOAd703 at three dose levels (5x10e10 VP, 1x10e11 VP, 5x10e11 VP) and SOC tailored to the indication||||
34099588|NCT06688669|||CASE_CROSSOVER||PROSPECTIVE|||||||
34099589|NCT05569954|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34099590|NCT06254326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714784|NCT04541550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714785|NCT05485038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Dynamics of motor function before, within 10 days after surgery and in 3 months after surgery will be assessed by neurosurgeon blinded for the treatment arm||f|f|f|t
33714786|NCT04140799|||COHORT||PROSPECTIVE|||||||
34017527|NCT00771381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099591|NCT01596244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794922|NCT05790096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794923|NCT00569049|||COHORT||PROSPECTIVE|||||||
33794924|NCT06656689|||COHORT||PROSPECTIVE|||||||
34099592|NCT05362175|||COHORT||PROSPECTIVE|||||||
34099593|NCT00231465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099594|NCT06690268|||COHORT||PROSPECTIVE|||||||
34099595|NCT05441696|||COHORT||RETROSPECTIVE|||||||
34099596|NCT00684736|||COHORT||PROSPECTIVE|||||||
34017528|NCT06426108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Triple blind|Randomized placebo controlled triple blind clinical trial|f|f|f|t
34017529|NCT00846521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017530|NCT03989622|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017531|NCT02302313|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33794925|NCT00834834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34017532|NCT02000401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017533|NCT04093635|||COHORT||PROSPECTIVE|||||||
34017534|NCT06531369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34017535|NCT05043623|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"The study is organised sequentially into three phases due to research capacity~Phase 1: The first 250 participants (5-18 years) will be randomly assigned to Arm 1 and Arm 2 for the clinician collected/supervised phase.~Phase 2: 50 participants (5-18 years) will be allocated to Arm 3 for the self-collected Rhinoswab/saliva/combined nose+throat swab.~Phase 3: 50 subsequent participants (1m - 5 years) will be allocated to Arm 4 for the self-collect throat+nose/saliva/RAT"||||
34017536|NCT02899832|||CASE_ONLY||PROSPECTIVE|||||||
34017537|NCT02932514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017538|NCT06255301|||COHORT||PROSPECTIVE|||||||
34017539|NCT00409318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017540|NCT00884702|||COHORT||PROSPECTIVE|||||||
34017541|NCT04995692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research assistants conducting telephone follow-up assessments 2, 4, and 6 months after enrollment will be blinded to group allocation.|Pilot randomized controlled trial using a parallel design, in which subjects are randomized to one of two different arms|f|f|f|t
34017542|NCT03915730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017543|NCT03716245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017544|NCT03738852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded||t|f|f|f
34017545|NCT06271720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017546|NCT04278898|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34099597|NCT01399099|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099598|NCT05343650|NA|SINGLE_GROUP||OTHER||NONE||prospective interventional study||||
34099599|NCT04250389|||COHORT||PROSPECTIVE|||||||
34099600|NCT05130957|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups as experimental and control.||||
34099601|NCT05196724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded for allocation when coding story stem and video outcomes|This is a prospective cluster-randomized controlled trial with two conditions: (1) an intervention group who will receive MBT and (2) and a control group who receive usual care (UC).|f|f|f|t
33794926|NCT00258895|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794927|NCT06676228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Group leaders/care providers and investigators know the group assignments but the participants do not know which group they were assigned to.||t|t|t|f
33794928|NCT05510544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794929|NCT02735616|||CASE_CONTROL||PROSPECTIVE|||||||
33794930|NCT04810793|||COHORT||PROSPECTIVE|||||||
33794931|NCT05943171|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized to either Digital Avatar Assisted CBT or Human Administered CBT||||
33794932|NCT03599453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794933|NCT00605982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33794934|NCT03796247|||CASE_CONTROL||PROSPECTIVE|||||||
33794935|NCT02271971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794936|NCT04126109|||OTHER||RETROSPECTIVE|||||||
33794937|NCT04820933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794938|NCT06449300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a researcher blinded to the interventions||f|f|t|f
33794939|NCT04518748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794940|NCT04136470|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794941|NCT01281813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794942|NCT05939063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794943|NCT00664430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794944|NCT04819815|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33794945|NCT05265559|||COHORT||PROSPECTIVE|||||||
33794946|NCT06511817|||COHORT||OTHER|||||||
33794947|NCT05618236|||COHORT||PROSPECTIVE|||||||
33794948|NCT04177017|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|The lab that analyzed hair cortisol levels did not know to which group corresponded the samples|semi-randmized controlled intervention||||
33794949|NCT02886858|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794950|NCT01059877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Small placebo controlled randomized trial.|t|t|f|t
33794951|NCT03026036|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33794952|NCT00246714|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017547|NCT02273791|||COHORT||RETROSPECTIVE|||||||
34017548|NCT02257294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33794953|NCT05007678|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised||||
33794954|NCT03883542|||CASE_ONLY||RETROSPECTIVE|||||||
33794955|NCT06108271|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33794956|NCT00861510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33794957|NCT05250336|||CASE_CONTROL||OTHER|||||||
33794958|NCT00658996|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33794959|NCT03461575|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33794960|NCT00486759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794961|NCT03885817|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794962|NCT02118077|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
33794963|NCT04995445|||OTHER||RETROSPECTIVE|||||||
34017549|NCT04145583|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017550|NCT04120584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099602|NCT06260618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked: The people receiving the treatment/s, The people analysing the results/data Unmasked: The surgeon administering the treatment.|Single blinded randomised clinical trial|t|f|f|f
34099603|NCT06361810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099604|NCT01544075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34099605|NCT00317863|||COHORT||OTHER|||||||
33714787|NCT04624568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"clinical trial with 2 parallel groups :~1. Treatment arm : Use of the vaginal gel for the first 6 months, then absence of treatment for the next 6 months until follow-up.~   * First month : 1 cannula of Papilocare® per day except the last 7 days of the month.~  * The next five months : alternate days except the last 7 days of the month.~2. Control arm - Absence of treatment for 12 months.~Inclusion of 150 patients, balanced randomization meaning 75 patients in each arm.~Follow-up after 6 months : a cervical cytology and a HPV testing for each patient + listing how many patients suffer from vaginal discomfort for 6 months.~Follow-up after 12 months : a cervical cytology and a HPV testing for each patient."|f|f|f|t
33714788|NCT00266903|||||RETROSPECTIVE|||||||
33714789|NCT06151834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714790|NCT05281939|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Masking was performed for all participants, colposcopists, and outcome assessor.|Participants were randomly assigned to an Artificial intelligence (AI) group or a control group.|t|f|t|t
33714791|NCT03217487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794964|NCT06426602|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Single arm Phase 2 experimental device efficacy clinical trial~To facilitate interpretation of the data generated with this DoC cohort, we will also recruit subjects with locked in syndrome (LIS) receiving care from one or more of our collaborative team and who are not able to communicate via traditional methods but have cognition intact. These patients will follow the same inclusion criteria with the exception of DoC status."||||
33794965|NCT05667454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33794966|NCT03473522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|A randomized, double-blind, sham-controlled, clinical trial involving two types of intervention: (1) Physical therapy + active tDCS; (2) Physical therapy + sham tDCS.|t|f|f|t
33794967|NCT06677372|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33794968|NCT02994017|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33794969|NCT00002472||||TREATMENT||||||||
33794970|NCT04290117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33794971|NCT00617201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017551|NCT05210244|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34017552|NCT00503711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017553|NCT02893137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017554|NCT02232490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017555|NCT05483049|||COHORT||RETROSPECTIVE|||||||
34017556|NCT00395174|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34017557|NCT00112866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017558|NCT05484843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was in the experimental type and was conducted as a longitudinal, randomized controlled study according to the pretest-posttest trial model.||||
34017559|NCT02418377|||COHORT||CROSS_SECTIONAL|||||||
34017560|NCT05341297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017561|NCT06190535|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34017562|NCT01781819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017563|NCT03074253|||COHORT||PROSPECTIVE|||||||
34017564|NCT03535675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multicenter, double-blind, randomized study to evaluate the benefit of MPX supplementation in the subset of men who display the Alanine/Alanine SOD2 genotype of MnSOD. Based on a previous randomized phase II trial of MPX at Hopkins, PSA doubling time (PSA-DT) was prolonged in this subgroup of men.|t|t|t|t
34017565|NCT05129436|||COHORT||PROSPECTIVE|||||||
34017566|NCT01857765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34017567|NCT02713880|||COHORT||PROSPECTIVE|||||||
34017568|NCT03983174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017569|NCT00033124||||TREATMENT||||||||
34017570|NCT04095949|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33794972|NCT01663519|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33794973|NCT05598151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938444|NCT04104893|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients with either a mismatch repair deficiency or biallelic inactivation of CDK12 in their tumor are eligible for this study. Patients with these mutations will be identified primarily through standard of care genetic testing with either archival tissue or blood. Once enrolled the patient will undergo a biopsy of a metastatic lesion (baseline biopsy) to identify molecular correlates.~Pembrolizumab will be administered at a starting dose of 200 mg intravenously every 3 weeks until disease progression or unacceptable toxicity. During the treatment, patients will either simultaneously receive a GnRH analogue or undergo a bilateral orchiectomy prior to treatment to maintain a castrate level of testosterone ( 50 ng/dl). At progression, patients will undergo a second biopsy of the same metastatic lesion of the baseline biopsy. The baseline (pre-treatment) and at-progression biopsies will be used for correlative analyses to determine the efficacy of pembrolizumab."||||
33938445|NCT03481634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938446|NCT02782039|||COHORT||OTHER|||||||
33938447|NCT06069622|||COHORT||PROSPECTIVE|||||||
33938448|NCT05131815|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33938449|NCT05326932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938450|NCT04945499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938451|NCT01985412|||COHORT||PROSPECTIVE|||||||
33938452|NCT00499161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33938453|NCT00766272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938454|NCT05119244|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938455|NCT02299544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017571|NCT02369900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017572|NCT05042050|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of Concept Case Series Design||||
34017573|NCT05562193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34017574|NCT03664648|||OTHER||PROSPECTIVE|||||||
34017575|NCT04619992|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34017576|NCT01335997|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34017577|NCT06476366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Two arms of the study will be as follows:~Group A: Methotrexate 10mg/week Group B: Azathioprine 0.3mg/kg daily"|t|f|f|f
34017578|NCT00005965||||TREATMENT||||||||
34017579|NCT00554307|||COHORT||PROSPECTIVE|||||||
34099606|NCT03460964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099607|NCT06197711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All instruments and questions will be administered online.|"The RCT will inform about the effect of PRISMA. Of the projected 5'100 people entering pretrial detention during the enrollment window, it is expected that roughly 43% (or 2'194 individuals) will be eligible for PRISMA and roughly 65% (or 3'316 individuals) will be eligible for the proactive social services intervention, respectively. Thus, it is expected that 1'428 individuals to be eligible for both interventions and, hence, constitute randomization sample C. This means that 766 individuals will be eligible for PRISMA only and 1'888 individuals for proactive social services only. 1'018 individuals will not be eligible for any of the two interventions.~For the analysis, observations from the REGULAR PRETRIAL and the PRISMA group from randomization samples A and C, respectively, will pooled. This leaves N = 1480 participants who will be involved in the RCT (assigned to either receiving the PRISMA intervention (N=740) or control condition (N = 740))."|f|f|f|t
34099608|NCT06549127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099609|NCT05540600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099610|NCT06088563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099611|NCT03928704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099612|NCT06549114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099613|NCT04462393|||COHORT||RETROSPECTIVE|||||||
34099614|NCT04063137|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||This study is a within-subject cross-over trial design to assess the influence of black rice anthocyanin on postprandial blood glucose and insulinemic responses, and lipid profiles.|t|f|f|f
34099615|NCT05086172|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an early pilot study that will compare an interventional assignment group to an assessment only control. The focus is on feasibility and acceptance of such a short intervention. The intervention is an ultrabrief, single-session (90 minute) administration of UBA, a psychotherapy intervention derived from the evidence-based LETS ACT Behavioral Activation treatment for substance use disorder. However, the investigators will also measure the difference of change in alcohol use behavior between groups as an additional outcome to gain an initial understanding of the magnitude of the effect for the design of future controlled studies."||||
34099616|NCT04673695|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099617|NCT04146909|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099618|NCT05503732|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34099619|NCT05599581|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomized controlled trial||||
34099620|NCT02793414|||COHORT||PROSPECTIVE|||||||
34099621|NCT00392275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34099622|NCT01290354|NA|SINGLE_GROUP||OTHER||NONE||||||
34099623|NCT05257161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099624|NCT04798924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34099625|NCT05099588|||COHORT||PROSPECTIVE|||||||
34099626|NCT04619173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099627|NCT00649571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34099628|NCT05315583|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Collection of biological samples (Day 0, D3, D15, Month 1, M2, M3, M4, M5, M6, M9, M12, M18) with associated data for the study of the kinetics of antibodies against COVID-19. All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.||||
34099629|NCT04948333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099630|NCT04594083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized, controlled, and experimental design|t|f|f|f
34099631|NCT03103308|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33714792|NCT05398211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of the therapist and the participants will not be possible, due to the nature of the interventions. Additionally, the music therapist will need to be acquainted with the results of the randomization in order to tailor each individual intervention. Masking of the outcome assessors will be attempted, but is expected to be incomplete, since the assessors will have to related to both the patients directly and to the medical staff who are well-acquainted with the patients, and who both might accidentally reveal the treatment allocation. Outcome assessors will attempt to remind the medical staff to keep the allocation concealed at all times. In order to verify the masking, the assessors will be asked about their knowledge of the patients' allocation to the treatment groups upon the last completed assessment.|A randomized controlled repeated measures design.|f|f|f|t
33714793|NCT01447901|||CASE_CONTROL||PROSPECTIVE|||||||
33714794|NCT02279173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794974|NCT03760835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099632|NCT03309111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099633|NCT04901052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Randomized Parallel with placebo|t|t|f|f
34099634|NCT04376632|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are unaware that there are 2 pecan groups (with and without dietary substitution instructions)||t|f|f|f
33794975|NCT01036412|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33794976|NCT03085316|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All patients who meet eligibility will undergo device implantation surgery and follow up per protocol.||||
33794977|NCT00903227|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33794978|NCT05499559|||COHORT||PROSPECTIVE|||||||
33938456|NCT04477668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938457|NCT03748654|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33938458|NCT01884155|NA|SINGLE_GROUP||TREATMENT||NONE||allogeneic cord blood for stroke patients||||
33938459|NCT00004084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794979|NCT04424641|NA|SEQUENTIAL||TREATMENT||NONE||||||
34099635|NCT03309475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluators will not know the patients' assigned treatment arm until the end of the follow-up period. This information will only be delivered to investigators in charge of intervention groups, but not to those in charge of statistical analyses.|Pilot, multi-center, rater-blinded, prospective (48-weeks follow-up), randomized, controlled (versus active comparator \[psychoeducation\]), clinical trial. The experimental arm will receive treatment as usual (both drug and psychosocial therapy) and mindfulness-based social cognition group training, specifically designed for patients with first episode psychosis by the research team. The active comparator arm will receive treatment as usual (both drug and psychosocial therapy) and psychoeducation group training for psychosis.|f|f|t|t
34099636|NCT03098407|RANDOMIZED|PARALLEL||OTHER||NONE|Open Label|||||
34099637|NCT05984667|||COHORT||PROSPECTIVE|||||||
34099638|NCT03850431|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The intervention arms were assigned letters and the statistician was blinded for analysis.|The primary objective is to systematically develop and test the effectiveness of a series of changes to appointment letters in a cluster RCT with the goal of reducing no-shows and increasing access. First, the investigators will iteratively obtain feedback and refine messages in draft interventions (Aim 1). Then evaluate the effects of four enhanced appointment reminder interventions informed by BE and the Theory of Planned Behavior, and compare them to usual care and each other (Aims 2 and 3). Appointments will be randomly allocated to one of the four interventions or usual care at the provider-level, with providers blinded to allocation. The trial will be conducted at eight locations across VAPORHCS in both mental health and primary care. The investigators will also conduct a qualitative assessment with key informants (Aim 4) to provide data that will be useful for future implementation (if intervention is effective) or suggest modifications to the intervention (if ineffective).||||
34099639|NCT01221480|||COHORT||RETROSPECTIVE|||||||
34099640|NCT05939609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator administering the treatment and the investigator performing the evaluations will be different. The evaluator will not know about the interventions that the participants received.|Participants will be divided into three groups with equal numbers by computer randomization method.|f|f|f|t
34099641|NCT03978156|NA|CROSSOVER||TREATMENT||TRIPLE|double blinded|This is a randomized, double blind, cross-over study of dronabinol compared to placebo|t|t|t|f
34099642|NCT04364971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099643|NCT01163565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714795|NCT02933125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714796|NCT05759923|NA|SEQUENTIAL||TREATMENT||NONE||||||
33714797|NCT05950009|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714798|NCT04419584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714799|NCT05945043|||COHORT||PROSPECTIVE|||||||
33714800|NCT01533389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714801|NCT05562076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714802|NCT02563353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714803|NCT00189254|||||PROSPECTIVE|||||||
33714804|NCT03970798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714805|NCT02099357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33714806|NCT05898555|||COHORT||PROSPECTIVE|||||||
33714807|NCT00275054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714808|NCT02297477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714809|NCT00002904||||TREATMENT||||||||
33714810|NCT01613404|||COHORT||PROSPECTIVE|||||||
33714811|NCT04752514|||COHORT||CROSS_SECTIONAL|||||||
33938460|NCT05756933|||CASE_ONLY||PROSPECTIVE|||||||
33938461|NCT04526444|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938462|NCT03086954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938463|NCT05366374|||CASE_ONLY||PROSPECTIVE|||||||
33938464|NCT00114764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714812|NCT01093807|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33714813|NCT04497805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714814|NCT05433714|||OTHER||PROSPECTIVE|||||||
33714815|NCT06166849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714816|NCT01497132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714817|NCT05810142|||COHORT||RETROSPECTIVE|||||||
33714818|NCT01037647|||CASE_CONTROL||PROSPECTIVE|||||||
33714819|NCT03815331|NA|SINGLE_GROUP||TREATMENT||NONE||All 20 subjects will receive Xiaflex® plus T treatment (Aveed®). Data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD using Xiaflex® only.||||
33714820|NCT03981211|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33714821|NCT01156090|||CASE_ONLY||RETROSPECTIVE|||||||
33714822|NCT01082120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714823|NCT05659797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714824|NCT00002054||||TREATMENT||DOUBLE||||||
33714825|NCT05422703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714826|NCT03482375|||COHORT||PROSPECTIVE|||||||
33714827|NCT04398498|||COHORT||PROSPECTIVE|||||||
33714828|NCT03111602|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers were blinded to the allocation data of pregnant women in the groups|Clinical trial with a healthy group as comparator.|f|t|t|f
33714829|NCT03132207|||COHORT||PROSPECTIVE|||||||
33714830|NCT01765205|||CASE_CONTROL||PROSPECTIVE|||||||
33714831|NCT06508073|||CASE_CONTROL||RETROSPECTIVE|||||||
33714832|NCT02243332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714833|NCT01672697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33714834|NCT03632525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714835|NCT05154006|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assignment of groups to the villages will be random (drawing lots by a person not included in the research team). All participants from one village will receive the same intervention. Participants are blinded to condition. Enumerators cannot be blinded to condition, but the specific intervention assignment is concealed until the arrival at the intervention site. In a debriefing after the follow up interviews, the allocated intervention group will be revealed to the participants.|3-arm parallel non-randomized controlled trial|t|f|f|f
33714836|NCT01506167|||COHORT||PROSPECTIVE|||||||
34017580|NCT01904617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017581|NCT05993117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017582|NCT02177136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the open-label LTSE phase.||t|t|t|f
34099644|NCT03954873|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34099645|NCT03365908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Operating surgeon and outcome assessor will be blind to whether patient had nerve block prior to OR.||f|f|t|t
34099646|NCT06670521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded placebo controlled|Multicenter prospective randomized clinical trial|t|t|t|t
34099647|NCT04579211|||COHORT||PROSPECTIVE|||||||
34017583|NCT00523536|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34017584|NCT03914950|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All parties involved in the clinical trial have knowledge of the interventions assigned to the individual participants.|Prospective study with one single group with two kinds of PET/CT imaging (with TOF-reconstruction and without TOF-reconstruction) for each patient.||||
34017585|NCT04327713|||OTHER||PROSPECTIVE|||||||
34017586|NCT01019863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017587|NCT04850248|||COHORT||RETROSPECTIVE|||||||
34017588|NCT00444093|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparision between treatment with Tinctura Opii normata and Loperamid in patients with therapy-associated diarrhea during radiaton therapy of small pelvis||||
34017589|NCT05033574|||CASE_ONLY||PROSPECTIVE|||||||
34017590|NCT00602277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017591|NCT03374241|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34017592|NCT03863093|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34017593|NCT02963623|||OTHER||RETROSPECTIVE|||||||
34017594|NCT06167590|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33714837|NCT01426373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017595|NCT02159170|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017596|NCT01321619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017597|NCT00672165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017598|NCT03438825|||COHORT||PROSPECTIVE|||||||
34017599|NCT03245645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34099648|NCT05669599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099649|NCT02296359|||CASE_CONTROL||PROSPECTIVE|||||||
34099650|NCT04995003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be non-randomly assigned to one of two arms, Arm A or Arm B. Dose de-escalation will occur independently in each arm.~Arm A treatment will consist of autologous HER2 CAR T cells infused in combination with lymphodepletion and the PD-1 antibody pembrolizumab. Accrual will start at Dose Level 1. In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.~Arm B treatment will consist of autologous HER2 CAR T cells infused in combination with lymphodepletion and the PD-1 antibody nivolumab. Accrual will start at Dose Level 1. In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."||||
34099651|NCT06031051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099652|NCT03430570|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to complete a computerized intervention or a wait list control.||||
34099653|NCT06451926|RANDOMIZED|PARALLEL||OTHER||DOUBLE||experimental group|f|f|t|t
34099654|NCT01253356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099655|NCT01239745|||CASE_CONTROL||PROSPECTIVE|||||||
33714838|NCT03015389|||COHORT||CROSS_SECTIONAL|||||||
33714839|NCT05830851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33714840|NCT01708681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33714841|NCT01713686|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33714842|NCT04077983|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group Assignment||||
34099656|NCT02449577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34099657|NCT04065256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34099658|NCT05861453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099659|NCT06225531|NA|SINGLE_GROUP||OTHER||NONE||Experimental case series, with a non-concurrent multiple baseline design. This will involve a baseline period which varies in length between participants (3-5 sessions), followed by an intervention period (6 sessions for all)||||
34099660|NCT00067873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099661|NCT02123511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34099662|NCT00004163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099663|NCT00050427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099664|NCT01121458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714843|NCT04023786|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714844|NCT05167214|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33714845|NCT00002531||||TREATMENT||||||||
33714846|NCT02406976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714847|NCT04334551|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot, prospective, non-randomized study to evaluate the safety and efficacy of switches from etravirine to doravirine, in experienced patients with multiple class resistance including NNRTI resistance||||
34017600|NCT00593632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017601|NCT05690503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34017602|NCT03400072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017603|NCT05301530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two group: study drug and reference|t|t|t|t
34017604|NCT06014749|||CASE_CONTROL||PROSPECTIVE|||||||
34017605|NCT00368901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017606|NCT00005765|||NATURAL_HISTORY||CROSS_SECTIONAL|||||||
34017607|NCT02274844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017608|NCT01513564|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34017609|NCT05386082|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33714848|NCT05593120|||COHORT||PROSPECTIVE|||||||
33714849|NCT03568760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The results are assessed by independent assessors blinded to when the data is obtained and from which group.||f|f|f|t
33714850|NCT02483520|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33714851|NCT06028568|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34017610|NCT00541970|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34017611|NCT01676077|||COHORT||PROSPECTIVE|||||||
34017612|NCT03123861|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017613|NCT04713098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34017614|NCT03798665|||OTHER||PROSPECTIVE|||||||
34017615|NCT01584206|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017616|NCT05913466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017617|NCT01043120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017618|NCT01208220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017619|NCT02906930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017620|NCT04667260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded|Randomized controlled trial|t|f|f|f
34017621|NCT05777460|||COHORT||RETROSPECTIVE|||||||
34017622|NCT03580174|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"There will be two groups as Routine Physiotherapy group and Goal Directed Activity Based Physical Therapy (GDPT) group.~* Routine Physiotherapy (RPT) group: Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) .~* Goal Directed Activity Based Physical Therapy (GDPT) group: Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary."|f|f|f|t
34017623|NCT04002336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded to primary outcome measure||t|f|f|f
33714852|NCT06334471|||COHORT||OTHER|||||||
34017624|NCT04769687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, non-comparative 2: 1 phase 2 study (symbiotic vs placebo) aimed at evaluating the efficacy of the use of symbiotics in reducing chronic inflammation observed in chronic renal failure.|t|t|t|f
34017625|NCT04608825|||COHORT||RETROSPECTIVE|||||||
34017626|NCT04415736|||COHORT||PROSPECTIVE|||||||
34017627|NCT03485183|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be recruited for the intervention group and receive the intervention. Their data will be compared to baseline data--data without personal identifiers retrieved from chart review. These data will serve as the control group.||||
33714853|NCT00489541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714854|NCT04358133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol. The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm|Randomized, double-blind, placebo-controlled, parallel-group,single center, phase 2 pilot study|t|t|t|f
33714855|NCT06254586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714856|NCT01656785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938465|NCT01373099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938466|NCT04562233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938467|NCT05197985|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Data collectors will not know which families have received treatments. The investigators will be masked during analysis.|Longitudinal, randomized-control trial with stepped-wedge research design|f|f|t|t
33938468|NCT04780594|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33938469|NCT06449794|||CASE_ONLY||CROSS_SECTIONAL|||||||
33938470|NCT03196206|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938471|NCT05731362|||COHORT||PROSPECTIVE|||||||
33938472|NCT00553904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33938473|NCT00421460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938474|NCT01427829|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938475|NCT00957060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938476|NCT02455596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938477|NCT01890733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938478|NCT04562727|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938479|NCT05701085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33938480|NCT04090827|NA|SINGLE_GROUP||OTHER||NONE||||||
33938481|NCT05907083|||CASE_ONLY||CROSS_SECTIONAL|||||||
33938482|NCT01161433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938483|NCT00382044|||COHORT||PROSPECTIVE|||||||
33938484|NCT03322592|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33938485|NCT05649046|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938486|NCT05108311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938487|NCT01840215|||||PROSPECTIVE|||||||
33938488|NCT02346955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938489|NCT05822349|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938490|NCT02469597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938491|NCT03971227|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, multi-center, randomized concurrent-control study with the treatment duration of 90 days.||||
33938492|NCT00908895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938493|NCT01250782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938494|NCT04437602|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective Randomized Trial||||
33938495|NCT01225211|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33938496|NCT02227433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938497|NCT04745065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938498|NCT01751243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938499|NCT03796923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938500|NCT06409975|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938501|NCT00515905|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938502|NCT02559830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938503|NCT00337740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938504|NCT01590810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938505|NCT00284609|RANDOMIZED|PARALLEL||||NONE||||||
33938506|NCT01815099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938507|NCT05140486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017628|NCT05620602|||COHORT||PROSPECTIVE|||||||
34017629|NCT02724982|||||CROSS_SECTIONAL|||||||
34099665|NCT01061710|||CASE_ONLY||RETROSPECTIVE|||||||
34099666|NCT04315207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Primary endpoint is a patient-reported outcome. Statistician were blinded to intervention until all statistical analyses were conducted|Randomized (1:1), controlled trial|f|f|f|t
34099667|NCT00507507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099668|NCT03206385|||COHORT||PROSPECTIVE|||||||
34099669|NCT05863364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099670|NCT02298504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099671|NCT03495440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099672|NCT04895280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099673|NCT00562861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099674|NCT06545955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099675|NCT06686966|||COHORT||RETROSPECTIVE|||||||
34099676|NCT04998149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There will be a standard group and an intervention group selected by BRMS.||||
34099677|NCT02598999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099678|NCT05825131|||COHORT||CROSS_SECTIONAL|||||||
34099679|NCT04089826|||CASE_ONLY||PROSPECTIVE|||||||
34099680|NCT06524037|||COHORT||CROSS_SECTIONAL|||||||
34099681|NCT05116592|||CASE_ONLY||PROSPECTIVE|||||||
34099682|NCT01306994|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017630|NCT01436799|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34017631|NCT00307606|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34017632|NCT01155024|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34017633|NCT06204211|||CASE_CONTROL||RETROSPECTIVE|||||||
34017634|NCT01021826|||COHORT||PROSPECTIVE|||||||
33714857|NCT02519192|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34017635|NCT04732481|||COHORT||PROSPECTIVE|||||||
34017636|NCT00226421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017637|NCT04927026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34017638|NCT02288182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017639|NCT01949961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||PROBE: Prospective randomized open-label blinded-endpoint|t|f|f|t
34099683|NCT04548050|||COHORT||PROSPECTIVE|||||||
34099684|NCT02959892|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34099685|NCT06322862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099686|NCT04658147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099687|NCT05145439|NA|SINGLE_GROUP||TREATMENT||NONE|Though the treatment device will be known to all participants, the level of treatment will be randomized among 3 distinct sessions and the level of treatment will be masked for the subject (participant), care provider, investigator, and outcomes assessor.|Prospective, single arm, open-label, feasibility acute phase study||||
34099688|NCT02234986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099689|NCT05753969|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34099690|NCT06695559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099691|NCT01327781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099692|NCT01783145|||COHORT||PROSPECTIVE|||||||
34099693|NCT05922280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099694|NCT04952688|NA|SINGLE_GROUP||OTHER||NONE||||||
34099695|NCT01120444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34099696|NCT02882893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099697|NCT05655169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099698|NCT00344669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34099699|NCT00094666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099700|NCT02244528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099701|NCT04539431|||COHORT||PROSPECTIVE|||||||
34099702|NCT05916482|||OTHER||CROSS_SECTIONAL|||||||
34099703|NCT01589250|||||PROSPECTIVE|||||||
34017640|NCT02023736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017641|NCT01066091|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34017642|NCT05256134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017643|NCT01705236|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017644|NCT00195234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017645|NCT06198036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment.|The study will be Randomized Clinical Trial to compare between the immediate effects of hold-relax Proprioceptive Neuromuscular Facilitation and Muscle Energy Technique (RI) for hamstring flexibility in school. Participants meeting the pre-determind inclusion and exclusion criteria will be divided into two groups going children|t|f|f|f
34017646|NCT02674061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017647|NCT00675064|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34017648|NCT04470336|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34017649|NCT01578135|||COHORT||PROSPECTIVE|||||||
34017650|NCT02879253|||CASE_ONLY||RETROSPECTIVE|||||||
34017651|NCT04612569|||COHORT||PROSPECTIVE|||||||
34017652|NCT00017537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017653|NCT00971841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017654|NCT00018811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017655|NCT05425693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A cluster randomized study will be implemented among French vineyard workers. Four groups of 30 participants will be constituted; corresponding to four different conditions: (1) hybrid warm-up intervention (HWU); (2) dynamic warm-up intervention (DWU); (3) stretching warm-up intervention (SWU); (4) no warm-up intervention (NWU). A total of 120 vineyard-workers will be recruited to participate in the study.|t|f|f|t
34017656|NCT02700711|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34017657|NCT00061243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017658|NCT02196701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017659|NCT01031459|||COHORT||CROSS_SECTIONAL|||||||
34017660|NCT00960765|||COHORT||PROSPECTIVE|||||||
34017661|NCT03394911|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Identical packaging, identical labeling, identifying random numbers in key onsite with pharmaceuticals technician on site. Identical vehicle. Pheromone is odorless, colorless, tasteless. Placebo handled exactly as Pheromone/experimental, but without application of pheromone.|Double-blind, cross-over, placebo-controlled clinical trial in hospital setting overseen by attending physician, χ2 test for categorized data|t|t|t|t
34017662|NCT06526455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017663|NCT05007847|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The investigators propose a prospective, randomised controlled study to determine our hypothesis. This single-centre, investigator-initiated trial will be performed at Barts Health NHS Trust which provides tertiary cardiac electrophysiology services to 4 stroke units part of the London Stroke Care Network (SCN).~Participants will be randomised on day 0 to either the active or control study arm. Participants randomised to the active arm will be provided with an AW Series 4 on Day 0 for the duration of the study. All participants will be followed up for 12 months after enrolment."||||
34017664|NCT04860063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017665|NCT01856361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017666|NCT06483542|||COHORT||RETROSPECTIVE|||||||
34017667|NCT04559971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099704|NCT02824328|||CASE_ONLY||PROSPECTIVE|||||||
34099705|NCT02562040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099706|NCT05759364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant will be blinded to the type of therapy they recieved. Inverstiagators will be blinded. Outcome assessor, including the physican that will assess the bishop score will be blinded Only the nurse that gives the therapy won't be blinded.|Double blinded randomized placebo controlled trial Group 1: will get IV PAPAVERINE 80 mg in 100 ml saline Group 2: will get IV 100 ml saline|t|f|t|t
34017668|NCT04304365|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34099707|NCT03456297|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"The 10 clinical departments will be randomised into two clusters, experimental and controlled clusters. The participants will be randomised based on the department that they work in. The advantage of the cluster randomised controlled trial is the ability to control for contamination across individuals, for example, one individual's use of WCP may influence another individual in the same department (Kellar \& Kelvin, 2013)."|A prospective cluster randomisation trial will be used for this study. The Web-based Clinical Pedagogy Program will be provided to the participants in the experimental cluster, while the participants in the control cluster will receive the current preceptorship course.|t|f|f|f
34099708|NCT04635163|||COHORT||PROSPECTIVE|||||||
34017669|NCT02563821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017670|NCT05709977|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Randomized, Controlled, Interventional, Monocenter Trial||||
34017671|NCT04183647|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The study was planned as a single blind. Evaluations will be made by the blind evaluator.|Between the applications, a washout period of one week will be given to each patient to apply both local and whole body vibrations.|f|f|f|t
34017672|NCT05559775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017673|NCT04570540|||COHORT||PROSPECTIVE|||||||
34017674|NCT00158756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017675|NCT06278571|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are unaware of other intervention arms|Multicenter clinical trial|t|f|f|f
34017676|NCT00595686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017677|NCT03192241|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Enrollment will be of 60 mother-infant dyads.|f|f|t|t
34017678|NCT03476525|||CASE_ONLY||PROSPECTIVE|||||||
33714858|NCT04669782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714859|NCT05564689|||CASE_ONLY||OTHER|||||||
33714860|NCT00230230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099709|NCT05111964|NA|SINGLE_GROUP||TREATMENT||NONE||"No randomisation. Four recruitment cohorts, patients with:~1. Soft tissue sarcoma 1-5cm for resection~2. Soft tissue sarcoma \>1cm with infield recurrence for resection~3. Soft tissue sarcoma unsuitable for resection or further chemo- or radiotherapy~4. Small (1-8 cm) symptomatic intra-abdominal desmoid tumour unsuitable for surgery"||||
34099710|NCT06343597|||COHORT||RETROSPECTIVE|||||||
34099711|NCT04143438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099712|NCT00006135|RANDOMIZED|||TREATMENT||DOUBLE||||||
34099713|NCT05144581|||OTHER||RETROSPECTIVE|||||||
34099714|NCT02718482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099715|NCT06236009|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34099716|NCT05623085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099717|NCT01229111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099718|NCT05971888|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Data will be collected through household surveys, worker surveys, dairy value chain actor surveys, in-depth interviews (IDIs), and focus group discussions (FGDs). In Amhara Region, the protocol team has selected a subset of the intervention districts for the evaluation and identified an equal number of districts outside the program coverage area with similar characteristics to serve as the control.||||
34099719|NCT03815019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The drug will be dispensed by the investigational pharmacy at each site, who will be the only unblinded part of the team. They will receive the random codes prepared by the study statistician, and will dispense placebo/megestrol as appropriate.|This is a multi-center, randomized, placebo-controlled, double-blind clinical trial. The primary focus of the study is the evaluation of the effectiveness of treatment with megestrol as part of a 24 week behavioral feeding protocol in transitioning from tube to oral feedings in a pediatric population. Approximately 60 pediatric subjects matching the criteria for eligibility will be enrolled in the study and randomized to receive either megestrol (n=30) or placebo (n=30).|t|t|t|f
34099720|NCT03283995|||CASE_CONTROL||PROSPECTIVE|||||||
34099721|NCT03932409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099722|NCT05835687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099723|NCT04381377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33714861|NCT01980992|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33714862|NCT04231864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714863|NCT01749514|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33714864|NCT05575986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714865|NCT00192842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714866|NCT00680381|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33714867|NCT03381846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714868|NCT05033353|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|"Randomization was done by sealed envelope method and the patients were divided into two groups; group I (targeted EtCO2 32-38 mmHg) and group II (targeted EtCO2 39-45 mmHg).~only the anesthetist knows the group of the patient"||t|t|f|t
33714869|NCT05122520|||OTHER||PROSPECTIVE|||||||
33938508|NCT05763329|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The patients will be subsequently randomized 1:1 to one of the two treatment sequences. Participants will complete two overnight sleep studies and cross-over with 1-week wash-out period. Patients will receive either Lemborexant 5 mg per day or placebo prior 5 minutes before lights-out. Time of lights out was calculated from the median usual bedtime for each participant from the most recent 5 days (± 1 hour) and was kept constant between the two study nights. During this 2-night polysomnography, sleep parameters will be analyzed. The Stanford Sleepiness Scale Questionnaire to define sleepiness and OSLER test to define vigilance will be obtained on the following morning.|t|t|f|f
33938509|NCT01242072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938510|NCT02362256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938511|NCT02141854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938512|NCT01002196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938513|NCT01609686|||COHORT||PROSPECTIVE|||||||
33938514|NCT06183255|||CASE_CONTROL||PROSPECTIVE|||||||
33938515|NCT04040166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Carotid PET/MRI With DOTATATE in patients post head and neck radiation therapy||||
33938516|NCT04312815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938517|NCT01431456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33938518|NCT02071342|||COHORT||PROSPECTIVE|||||||
33938519|NCT04663828|RANDOMIZED|PARALLEL||TREATMENT||NONE||Four different types of interventions will be included in the RCT. Two of them mainly target on the auditory aspects of tinnitus (hearing aid fitting and sound therapy), whereas the other two mainly target the CNS (Structured Counselling and Cognitive Behavioral Therapy).||||
33938520|NCT05592600|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938521|NCT05965999|||COHORT||PROSPECTIVE|||||||
33938522|NCT04898088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938523|NCT03683238|||CASE_CONTROL||RETROSPECTIVE|||||||
33938524|NCT05763472|||COHORT||RETROSPECTIVE|||||||
33938525|NCT05684315|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The subjects will not be informed what activity awaits them and which leg will be subjected to intervention.|The study will be conducted in two rounds over 4 weeks. In the first round, subjects will have one leg threaded during the fatigue protocol, and after a four-week rest after full recovery, they will have the other leg threaded during the fatigue protocol.|t|f|t|f
33938526|NCT03671434|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"* Participants: Participants will not be informed of their status as part of an intervention or control group.~* Provider: No masking~* Investigator: No masking~* Outcome Assessor: Survey data will indicate intervention assignment; observational data will be masked such that document coders will not be aware of the condition associated with coded documents."|Participants will be randomly assigned to either a comprehensive intervention or a control group that receives minimal intervention.|t|f|f|t
34017679|NCT03113513|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is designed as a RCT.||||
34017680|NCT04565613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to enteral protein supplementation or standard care (no enteral protein supplementation) in a 1:1 ratio.||||
34017681|NCT00858962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017682|NCT03867461|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34099724|NCT03197272|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The participants are not aware which eye will receive the homogeneous zone treatment and which eye will receive the ring-shaped treatment.|"Prospective, single-masked intraindividually comparing randomized controlled trial. Participants will be randomized to receive ultraviolet (UV) light according to protocol A in one eye and protocol B in the other, which is masked to the participant. Both eyes will be treated during the same visit.~Protocol A: UV irradiation in a central 4 mm homogenous zone of the cornea. Protocol B: UV irradiation in a central ring-shaped 4 mm area of the cornea. Patients are randomized utilizing a computer list of unique random numbers between 1 and 23; an even number will be treated with a homogeneous zone in the right eye; an uneven number with a homogeneous zone in the left eye."|t|f|f|f
34017683|NCT00325195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017684|NCT05637320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a randomized controlled trial, consisting of an intervention arm and a control arm, which will occur concurrently. Participants will be continually enrolled in the study until 202 parent-child dyads are recruited.|f|f|t|t
34017685|NCT01239446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017686|NCT03519659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017687|NCT00199771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017688|NCT02129296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34017689|NCT03826498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017690|NCT00000569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017691|NCT01622374|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34017692|NCT00891839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099725|NCT05253833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017693|NCT01087632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099726|NCT00073047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099727|NCT06243926|||OTHER||PROSPECTIVE|||||||
34099728|NCT05371028|||OTHER||RETROSPECTIVE|||||||
34099729|NCT05684614|||COHORT||CROSS_SECTIONAL|||||||
34017694|NCT03230799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017695|NCT00576992|||COHORT||PROSPECTIVE|||||||
34017696|NCT04904263|||OTHER||OTHER|||||||
34017697|NCT00521417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017698|NCT02893592|||COHORT||RETROSPECTIVE|||||||
34017699|NCT03457155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017700|NCT00842478|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34099730|NCT06360341|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization to RC or Intervention group will not be masked to the Principal Investigator (PI), co-PI, or to participants.|Individuals in the pilot randomized controlled trial (RCT) intervention will be randomized to either the intervention or routine discharge care (RC) using REDCap randomizer and assigned to RC or Emergency Department Digital Pain Self-Management Intervention (EDPSI) + RC.||||
34099731|NCT04367454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Blinding of participants and researchers involved in the experiment is not possible. Only the outcome assessor and data analyst (SS) is kept blinded to the allocation of subjects.|single-center, randomized (1:1), parallel-group, manikin trial|f|f|f|t
34099732|NCT04765072|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099733|NCT04869124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|A double-blind randomized placebo-controlled phase IV clinical trial.|t|f|t|f
34099734|NCT01663142|||COHORT||PROSPECTIVE|||||||
34099735|NCT05810116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099736|NCT06424535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||1:1 randomized controlled crossover study||||
34099737|NCT02944461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099738|NCT00906750|RANDOMIZED|PARALLEL||||NONE||||||
33714870|NCT01409655|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33714871|NCT05008497|||OTHER||PROSPECTIVE|||||||
33714872|NCT03076398|||OTHER||PROSPECTIVE|||||||
33714873|NCT02180152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714874|NCT03112421|||OTHER||PROSPECTIVE|||||||
34017701|NCT02860065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017702|NCT05504590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33714875|NCT00004482|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714876|NCT02588807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714877|NCT01806545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714878|NCT00369993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714879|NCT00086320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33714880|NCT05433766|||COHORT||PROSPECTIVE|||||||
34017703|NCT04636359|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Two experimental groups with different condition receive identical intervention, with control group as baseline for comparison.|t|f|t|t
33714881|NCT00420927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714882|NCT01119391|||COHORT||PROSPECTIVE|||||||
33714883|NCT03208855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714884|NCT05759650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33714885|NCT06145776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly allocated, using an online generator (www.random.org), into two groups (1:1): CG) tDCS active + gait training; EG) tDCS active + gait training + dual-task. This sequence will be performed independently and remotely by a blinded investigator, who will have no knowledge of other study procedures. The concealed allocation process will be conducted using sequentially numbered sealed opaque envelopes. The outcome assessors and patients will be blinded to the procedures.|This study is a randomized, double-blind, group controlled clinical trial. Parallel study,|t|f|f|t
33714886|NCT00885105|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017704|NCT06224166|||OTHER||OTHER|||||||
34017705|NCT04461366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34017706|NCT00132093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017707|NCT04700163|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34017708|NCT03812705|NA|SINGLE_GROUP||TREATMENT||NONE||fecal microbiome transplantation for patients with steroid resistant/dependent acute gastroinstestinal graft versus host disease||||
34017709|NCT01240213|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34017710|NCT06002971|||COHORT||PROSPECTIVE|||||||
34017711|NCT06219486|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34017712|NCT04822233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017713|NCT01785706|||COHORT||PROSPECTIVE|||||||
34017714|NCT02356003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017715|NCT00609466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017716|NCT04567914|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017717|NCT00193427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017718|NCT03421158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017719|NCT00334061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017720|NCT01573026|||CASE_ONLY||PROSPECTIVE|||||||
34017721|NCT00306150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017722|NCT04427644|||COHORT||RETROSPECTIVE|||||||
34017723|NCT01527084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017724|NCT04629768|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017725|NCT01551888|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34017726|NCT04370951|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34017727|NCT03500653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017728|NCT00001993||||TREATMENT||||||||
34017729|NCT04070586|||COHORT||PROSPECTIVE|||||||
34017730|NCT02483143|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34017731|NCT03866720|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Where applicable (i.e. the two breakfast feeding trials) participants will be blinded to the breakfast that they receive.|"Participants will complete 3 breakfast feeding trials in a randomised order:~Typical high carbohydrate breakfast followed by an ad libitum lunch. Whey protein enriched carbohydrate followed by an ad libitum lunch. Extended morning fast followed by an ad libitum lunch."|t|f|f|f
34017732|NCT05581290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34017733|NCT01179698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017734|NCT01233921|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017735|NCT03309007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the study research pharmacy will have access to the randomization list.|This is a double-blind, approximate placebo-controlled trial of 12 weeks of metformin vs. CaCO3 (Placebo) among adult patients with prediabetes.|t|t|t|t
34017736|NCT00793494|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34017737|NCT05089318|||CASE_ONLY||PROSPECTIVE|||||||
34017738|NCT05174676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017739|NCT04023903|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34017740|NCT02558231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017741|NCT04213352|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34017742|NCT04566341|||CASE_ONLY||CROSS_SECTIONAL|||||||
34017743|NCT04238988|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm multicenter phase II trial||||
34017744|NCT03853018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017745|NCT00003138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017746|NCT05002426|||CASE_ONLY||RETROSPECTIVE|||||||
34017747|NCT00955136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017748|NCT01234792|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34099739|NCT05317455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34099740|NCT04331171|||COHORT||PROSPECTIVE|||||||
34099741|NCT06581692|||COHORT||CROSS_SECTIONAL|||||||
34099742|NCT03920020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33714887|NCT02257944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33714888|NCT02148692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33714889|NCT05641207|NA|SINGLE_GROUP||TREATMENT||NONE||An intervention of a device product||||
33714890|NCT00005094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33714891|NCT01937728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714892|NCT06030102|||OTHER||RETROSPECTIVE|||||||
33714893|NCT03157778|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Obese men versus normal-weight men||||
33714894|NCT02036021|||COHORT||PROSPECTIVE|||||||
33714895|NCT04267367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The source of the population of the study in both intervention and control group will be known cases of T2DM and newly diagnosed cases of T2DM patients who are within 20-64 years of age group attending the OPD of the hospital.||||
33714896|NCT05322876|NA|SINGLE_GROUP||PREVENTION||NONE||Sample||||
33714897|NCT04337125|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33714898|NCT00616954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714899|NCT04579731|||COHORT||RETROSPECTIVE|||||||
33714900|NCT01058109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714901|NCT00805103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714902|NCT02757846|||COHORT||RETROSPECTIVE|||||||
33714903|NCT00264329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794980|NCT00310154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017749|NCT05341882|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Study 2, we randomized 19 participants to either the Mindfulness or Educational Support condition. In Study 3, we randomized 56 participants to the Mindfulness or Educational Support condition.||||
34017750|NCT00792870|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34017751|NCT00692874|||COHORT||PROSPECTIVE|||||||
34017752|NCT02327117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017753|NCT02852642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017754|NCT06078917|||COHORT||PROSPECTIVE|||||||
34099743|NCT04615065|||COHORT||PROSPECTIVE|||||||
34099744|NCT02532946|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34099745|NCT01152385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099746|NCT03709095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were randomized to one of two groups: (A) sprint interval training (SIT) or (B) moderate intensity continuous training (MICT).||||
33714904|NCT04253145|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, uncontrolled and multicenter phase I-II study||||
33714905|NCT00166673|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33714906|NCT00715078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714907|NCT02972489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714908|NCT00934973|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33714909|NCT00594984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714910|NCT00135720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33714911|NCT00812656|||COHORT||PROSPECTIVE|||||||
33714912|NCT02322918|||COHORT|||||||||
33714913|NCT03718585|||OTHER||CROSS_SECTIONAL|||||||
33714914|NCT06060288|||OTHER||CROSS_SECTIONAL|||||||
33714915|NCT01826344|||COHORT||PROSPECTIVE|||||||
33714916|NCT01652560|||||PROSPECTIVE|||||||
33714917|NCT04357678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714918|NCT02520843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714919|NCT05513066|||OTHER||PROSPECTIVE|||||||
33714920|NCT00847704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714921|NCT03210376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714922|NCT06195163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714923|NCT01674270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938527|NCT05510791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||randomized, cross-over trial with water control.||||
33938528|NCT03200028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938529|NCT05165264|||COHORT||PROSPECTIVE|||||||
33938530|NCT03096691|RANDOMIZED|PARALLEL||PREVENTION||NONE||100 pregnant women with a preterm delivery history and / or a cervical length of less than 25 mm will be included among the pregnancies between 16 and 24 weeks of gestation referred to obstetric and perinatology clinics. Information about the use of disease pessaries and treatment success in preventing premature birth of the pessary will be provided. Urine culture and cervical culture samples will be taken from both groups of patients. In the presence of infection, the patient's treatment will be planned and out of work. If no infection is detected and the patient agrees to use the pessary, the pessary will be used to prevent premature birth.||||
34017755|NCT00390221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017756|NCT05567484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017757|NCT01527136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017758|NCT00755404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714924|NCT03705676|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|"Participants are aware that electrocutaneous stimulation might occur during the fear condition and never during the control condition. This is of paramount importance, as the expectancy of a painful stimulus is the main difference between both conditions.~The researcher that will perform the EMG-analysis, i.e. onset determination of the various muscles that were measured, will be blinded for participant, condition and muscle during that process. EEG-data does not have to be blinded as data processing is computer based and not subjectable to subjective bias of a researcher."|Each participant will perform both experimental conditions spread out over 2 test days in a randomized order. Between 2 test days a minimum of 5 days has to be present in order to ensure full recuperation from test day 1. Half of the participants will receive the control condition on test day 1 and the fear condition on day 2, the other half vice versa.|f|f|f|t
33714925|NCT04268810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33714926|NCT00381095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714927|NCT03470818|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33714928|NCT02431234|||COHORT||PROSPECTIVE|||||||
33714929|NCT04334161|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33714930|NCT04755803|||COHORT||PROSPECTIVE|||||||
33714931|NCT01735682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714932|NCT02245308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714933|NCT02637453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794981|NCT04141943|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33794982|NCT04215406|||COHORT||PROSPECTIVE|||||||
33794983|NCT02044588|||COHORT||PROSPECTIVE|||||||
33794984|NCT02165761|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33938531|NCT05247736|||OTHER||PROSPECTIVE|||||||
33938532|NCT01996228|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938533|NCT01228084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938534|NCT02306291|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33938535|NCT02130635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938536|NCT01780285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938537|NCT06231927|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33938538|NCT00645736|||COHORT||CROSS_SECTIONAL|||||||
33938539|NCT00572663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938540|NCT03018340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938541|NCT03479840|||COHORT||RETROSPECTIVE|||||||
33938542|NCT05421585|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Before coming to the operating room, the patients will be randomly divided into 2 groups (Group Q= QL2 block group, Group T= Classic TLIP group) each containing 26 patients, using a closed envelope method.|prospective randomized trial|t|f|f|f
33938543|NCT00795938|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33938544|NCT02579525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938545|NCT00362141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938546|NCT04238286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938547|NCT04525989|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized||||
33938548|NCT02717026|||CASE_CONTROL||PROSPECTIVE|||||||
33938549|NCT02029365|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33938550|NCT05868408|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Double-blind, randomized, controlled, multi-arm trial|t|t|t|t
33938551|NCT01569724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938552|NCT03263169|||COHORT||PROSPECTIVE|||||||
33938553|NCT01885962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938554|NCT00005736|||OTHER||PROSPECTIVE|||||||
33938555|NCT02878135|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33938556|NCT03128372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938557|NCT00134589|RANDOMIZED|FACTORIAL||||SINGLE||||||
34099747|NCT06063083|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099748|NCT05608668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only person who will know the arm of each participant will be the study team member in charge of randomization (the clinical research coordinator)||t|t|t|t
34099749|NCT01775709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099750|NCT06567327|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34099751|NCT02681042|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34099752|NCT00017186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099753|NCT01125644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099754|NCT05150886|||COHORT||PROSPECTIVE|||||||
34099755|NCT04323566|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The nurse(s) administering Rituximab or placebo (NaCl) infusions will be prevented from having insight into which of the infusions she/he is administering.|This is a placebo-controlled, interventional study of parallel groups with 40 participants, randomized to either treatment-first with 500 mg Rituximab i.v. at 0 (infusion 1) and at 4 months (infusion 2), or placebo-first, with NaCl-infusions at 0 and at 4 months. Main evaluation takes place at eight months. The study arms are then crossed over, i.e. those with treatment-first receive placebo at 8 (infusion 3) and 12 months (infusion 4), and those with placebo-first receive Rituximab at these time points. Final evaluation takes place at 16 months. Before each infusion, all patients are pre-treated with Solu-Medrol i.v., Paracetamol p.o. and Cetirizin p.o. Patients are monitored with psychiatric rating scales and blood samples at baseline (-1 month) and every four months. The evaluations at baseline, eight and 16 months also encompass collection of CSF (lumbar puncture), psychologic testing and extended blood samples.|t|t|t|t
34099756|NCT04359693|||COHORT||PROSPECTIVE|||||||
34099757|NCT00327431|||||PROSPECTIVE|||||||
34099758|NCT01435980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099759|NCT00225758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099760|NCT05813834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Genicular Nerves Block|t|t|f|f
34099761|NCT05187624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099762|NCT06501235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Between subjects design|t|f|f|f
34099763|NCT04396860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714934|NCT04644627|NA|SINGLE_GROUP||TREATMENT||NONE|Wound size calculations will be performed on digital photos, the outcome assessor will not know which wounds are treated and which are controls.|Each patient serve as its own control, study treatment is given to one half of the body, the other half receives regular wound treatment. Which side to be treated is determined with randomization.||||
33714935|NCT03441776|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single site, randomized, open label, pilot study to test the environment, resources and tools required to perform a comparative effectiveness trial assessing two different standard of care vestibular rehabilitation approaches.||||
33714936|NCT05633420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714937|NCT00949897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714938|NCT02003820|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33714939|NCT04716569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714940|NCT05619081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomised Control Trial (RCT)||||
33714941|NCT01618994|||CASE_CONTROL||PROSPECTIVE|||||||
33714942|NCT05708287|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33714943|NCT01031069|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33714944|NCT06503224|NA|SEQUENTIAL||TREATMENT||NONE||||||
33714945|NCT03334448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33714946|NCT00911820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714947|NCT05115734|||CASE_CONTROL||PROSPECTIVE|||||||
33714948|NCT05977582|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33714949|NCT03519932|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33714950|NCT01894191|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33714951|NCT01548521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714952|NCT00569569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714953|NCT05576714|||CASE_CONTROL||PROSPECTIVE|||||||
33714954|NCT03520803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33714955|NCT06243991|||CASE_CONTROL||PROSPECTIVE|||||||
33714956|NCT00162201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714957|NCT03580694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714958|NCT02902419|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33714959|NCT03601689|||COHORT||RETROSPECTIVE|||||||
33714960|NCT01138033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33714961|NCT02663232|||COHORT||CROSS_SECTIONAL|||||||
33714962|NCT02365090|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33714963|NCT02066870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714964|NCT00777478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714965|NCT05240118|||COHORT||RETROSPECTIVE|||||||
33714966|NCT05194592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714967|NCT02855333|||||RETROSPECTIVE|||||||
33938558|NCT01864668|||COHORT||PROSPECTIVE|||||||
33938559|NCT01070628|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938560|NCT06282952|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The research statistician performs the computer-generated randomization. The study nurse prepares the fecal transplant according to the randomization. Study participants or investigators are not aware of study group.|"The eligible women are randomized into two groups in which their newborns receive either fecal microbiota transplant from 1) their own mother (50 newborns) or 2) the Microbiome Biobank (50 newborns). The randomization 1:1 is done in blocks of 4 mothers. The study is double blinded. If mother has Group B streptococcus colonization or other infectious disease described in table 1, and microbiota transplant cannot be given or if mother will have non-elective-CS and the microbiome transplant is not available, the mother is included in 3) the observational cohort, which is open (not blinded)."|t|t|t|f
33938561|NCT02335567|||CASE_ONLY||CROSS_SECTIONAL|||||||
33938562|NCT01685060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938563|NCT03727802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938564|NCT06502509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33938565|NCT00794989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33714968|NCT06404216|NA|SINGLE_GROUP||TREATMENT||NONE|"The assessor will be external, not part of the training team, to avoid bias due to trainer/therapist- training participant subjective biases.~Therefore there is assessor blinding but not to allocation as there is one arm."|"One arm of treatment in a special displaced population during war. This is a pilot feasibility study, prior to a full RCT in order to evaluate this protocol.~Intervention of 2 weekly sessions for 8 weeks (total 16). Assessments will be conducted by a blinded assessor at baseline, end of training, 2+4 months post-intervention."||||
33714969|NCT06426121|||CASE_ONLY||PROSPECTIVE|||||||
33714970|NCT00295906|RANDOMIZED|||||||||||
33714971|NCT04203953|||COHORT||PROSPECTIVE|||||||
33714972|NCT05065762|||OTHER||CROSS_SECTIONAL|||||||
33714973|NCT02612974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714974|NCT06214182|||CASE_ONLY||PROSPECTIVE|||||||
33714975|NCT06346964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33714976|NCT03062683|||COHORT||PROSPECTIVE|||||||
33714977|NCT00459953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714978|NCT05966181|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled experimental study with pretest-posttest control group design|f|f|f|t
33714979|NCT01490957|||COHORT||PROSPECTIVE|||||||
33714980|NCT02899988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33714981|NCT00320892|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33714982|NCT04245787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33714983|NCT02050529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938566|NCT05456646|||COHORT||PROSPECTIVE|||||||
33938567|NCT05541159|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will be divided into 2 parts. Participants in the renal impairment groups will be staged by their respective degree of renal function (mild, moderate, or severe) according to the estimated glomerular filtration rate determined at the screening visit.~Healthy participants who were identified and enrolled as matching partners for a renal impairment group in Part I can serve as matching partners for participants in renal impairment group (Group 4) in Part II if they fulfilled the matching criteria. Otherwise, additional matched healthy participants will be enrolled.~Part I: will include participants with mild and moderate levels of renal impairment as well as healthy control participants Part II: will include participants with severe renal impairment, if allowed after results of interim analysis (IA) obtained for mild and moderate groups."||||
33938568|NCT04994886|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site, single-arm, non-blinded, non-randomized, interventional||||
33938569|NCT00002024||||TREATMENT||||||||
33938570|NCT04932681|||COHORT||PROSPECTIVE|||||||
33938571|NCT06065787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938572|NCT06258772|||COHORT||OTHER|||||||
33938573|NCT03124524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33938574|NCT02377440|||COHORT||PROSPECTIVE|||||||
33938575|NCT01252927|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33938576|NCT04474210|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938577|NCT02293200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938578|NCT00216086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938579|NCT00000952||||TREATMENT||||||||
33938580|NCT04830865|||COHORT||PROSPECTIVE|||||||
34017759|NCT06142123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017760|NCT05370820|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33714984|NCT01333644|||COHORT||PROSPECTIVE|||||||
33714985|NCT02516215|||COHORT||CROSS_SECTIONAL|||||||
33714986|NCT02968407|||OTHER||PROSPECTIVE|||||||
33714987|NCT02284594|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33714988|NCT00197132|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33714989|NCT02292979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714990|NCT03292094|||COHORT||PROSPECTIVE|||||||
33714991|NCT05331274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714992|NCT01176084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714993|NCT02240238|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34017761|NCT05070871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34017762|NCT02630056|||CASE_ONLY||PROSPECTIVE|||||||
34017763|NCT04607330|NA|SINGLE_GROUP||OTHER||NONE||Single-arm intervention study to evaluate the acceptability (compliance, gastrointestinal tolerance and palatability) of the high protein liquid feed in patients with elevated protein needs.||||
34017764|NCT03861481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017765|NCT01532479|||COHORT||PROSPECTIVE|||||||
34017766|NCT01924923|||CASE_ONLY||PROSPECTIVE|||||||
34017767|NCT00415194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017768|NCT04763018|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Sham device produces noise but no stimulation energy. Assessor does not know which device the subject received. The subject does not know which device he or she received|Day 14-30, all subjects receive therapy device|t|f|f|t
34017769|NCT02124941|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017770|NCT02926820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017771|NCT04199013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017772|NCT01799122||||TREATMENT||||||||
34017773|NCT02775708|NA|SINGLE_GROUP||OTHER||NONE||||||
34017774|NCT00937482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017775|NCT03761680|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, open-label, clinical trial||||
34017776|NCT05913271|||OTHER||OTHER|||||||
34017777|NCT01566357|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34017778|NCT06420791|||COHORT||RETROSPECTIVE|||||||
34017779|NCT01124344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017780|NCT03258853|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017781|NCT02681744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34017782|NCT01985074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34017783|NCT00044668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017784|NCT03784521|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34017785|NCT02116959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017786|NCT00063635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938581|NCT03819023|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Evaluation of the device on people with normal and suppressed respiration||||
33938582|NCT04080700|||COHORT||PROSPECTIVE|||||||
33938583|NCT05796024|||COHORT||RETROSPECTIVE|||||||
33938584|NCT04771650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized to one of two conditions. They will be unaware of their randomization condition. The Research assistant conducting follow-ups will be unaware of the participant's treatment condition.|Clinical effectiveness trial that tests two conditions (CAMI plus booster + standard care compared to assessment + standard care). Health outcomes are reduced drinking, related harms and improvement of mental health. Follow-up at 3,6, and 12 months.|t|f|f|t
34099764|NCT03416933|NA|SINGLE_GROUP||OTHER||NONE||||||
34099765|NCT00403065|RANDOMIZED|||TREATMENT||||||||
34099766|NCT03760068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938585|NCT02886442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938586|NCT03606889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33938587|NCT00256204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938588|NCT00527046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938589|NCT06000566|||COHORT||CROSS_SECTIONAL|||||||
33938590|NCT00051194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938591|NCT01816880|||COHORT||PROSPECTIVE|||||||
33938592|NCT03323385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938593|NCT01146262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938594|NCT01694667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938595|NCT03319329|||COHORT||CROSS_SECTIONAL|||||||
33938596|NCT05237024|||COHORT||PROSPECTIVE|||||||
33938597|NCT01430910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33938598|NCT05247515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938599|NCT04727411|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33938600|NCT04677803|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, individual dose titration-to-response, basket trial||||
33938601|NCT01040494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938602|NCT06089772|RANDOMIZED|PARALLEL||TREATMENT||NONE||The groups determined as randomly into the four groups. Group I (n=14) received HVLA spinal manipulation, Group II (n=14) underwent foam roller stretching, Group III (n=14) received a combination of HVLA spinal manipulation and foam roller stretching, and Group IV (n=14) underwent sham manipulation as the control group. Measures were measured before the acute intervention and right after the intervention.||||
33938603|NCT04397757|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 1:1 to receive either convalescent plasma on Study Day 1 in addition to standard care or standard care alone.||||
33938604|NCT02223949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938605|NCT01332006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938606|NCT01218061|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938607|NCT04651751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938608|NCT02331706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33714994|NCT04086862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The frequency setting on the ultrasound machine will be set and known only to the principal investigator.|Subjects will be randomized to double-blind treatment with 1 MHz or 3 MHz therapeutic ultrasound.|t|t|f|f
33714995|NCT00573534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33714996|NCT01463878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33714997|NCT03682666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33714998|NCT02421315|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938609|NCT02375529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938610|NCT04839211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938611|NCT03512028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are masked to group assignment (RLIC vs. Sham conditioning).|Single blinded, randomized controlled trial|t|f|f|f
33938612|NCT02532816|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33938613|NCT04625530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be blinded to participants and statistician conducting the data analysis. The physicians and nurses who will perform this infusion will not be blinded.||t|f|f|t
34017787|NCT02122406|||COHORT||CROSS_SECTIONAL|||||||
34017788|NCT02313636|||CASE_ONLY||PROSPECTIVE|||||||
34017789|NCT04853992|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Placebo-controlled|Each treatment period will last 7 days with a wash-out period of 7 days between treatments|t|f|t|f
34017790|NCT06412263|||COHORT||PROSPECTIVE|||||||
34017791|NCT04763694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017792|NCT01983709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017793|NCT03544996|||CASE_ONLY||PROSPECTIVE|||||||
34017794|NCT00197496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017795|NCT05476120|RANDOMIZED|PARALLEL||OTHER||SINGLE||single-blind, parallel-group, randomized-controlled intervention study|t|f|f|f
34017796|NCT06007547|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of prophylaxis compared to rescue surfactant, administered using a minimally invasive technique, in premature infants less that 30 weeks gestation||||
34017797|NCT01506544|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34017798|NCT02243839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017799|NCT03063879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017800|NCT00200759|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34017801|NCT02301767|||CASE_CONTROL||PROSPECTIVE|||||||
34017802|NCT06095336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the study did not know the group they belonged to.|In the study, which was planned as a randomized controlled study, participants were randomly divided into 3 groups.|t|f|f|f
34099767|NCT04031768|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34099768|NCT03159442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single-blind with regards to treatment (AZD8871 or placebo) at each dose level. However, the study centre staff are also blinded only during the clinical conduct of a given cohort prior to the respective safety review committee meeting (SRC).|Single center, randomized, single blind, placebo-controlled study.|t|f|f|f
34099769|NCT04057638|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective longitudinal observational analysis of functional and aesthetic outcomes after treatment of severe facial defects and upper extremity injuries with microvascular composite tissue allotransplantation. There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.||||
34099770|NCT06356597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099771|NCT04274465|||COHORT||PROSPECTIVE|||||||
34099772|NCT05694637|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a stepped wedge cluster randomization trial||||
33794985|NCT06677502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients enrolled to the intervention group (CER group) receive Cerebrolysin for 7 consecutive days at a dose of 50mL daily administrated in 250 mL 0.9% NaCl. Patients enrolled the control group (K group) receive 250 mL 0.9% NaCl.|f|f|f|t
33794986|NCT00716144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33794987|NCT06447675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33794988|NCT00311363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794989|NCT05159297|||CASE_ONLY||CROSS_SECTIONAL|||||||
33794990|NCT03399370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33794991|NCT02806557|||COHORT||PROSPECTIVE|||||||
33794992|NCT01175317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794993|NCT02602743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33794994|NCT01331863|NA|SINGLE_GROUP||OTHER||NONE||||||
33794995|NCT01980069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33794996|NCT05857436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33794997|NCT01535144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33794998|NCT06102525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33794999|NCT00375453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795000|NCT05516927|||CASE_CONTROL||PROSPECTIVE|||||||
33795001|NCT02571387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795002|NCT01897298|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33795003|NCT05440981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795004|NCT05967819|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33795005|NCT02667808|||CASE_ONLY||CROSS_SECTIONAL|||||||
34017803|NCT04882631|NA|SINGLE_GROUP||OTHER||NONE|The participant and evaluator are blinded to the identity of the test product (3 strengths of PBI-100), vehicle, negative control and positive control placed on each subject's forearm, upper arm or back|The order of test product patch placement is randomized.||||
34017804|NCT00173875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017805|NCT00396799|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017806|NCT01620619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34017807|NCT02503020|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34017808|NCT00080405|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017809|NCT00299845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017810|NCT05469217|||COHORT||CROSS_SECTIONAL|||||||
34017811|NCT01754116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099773|NCT05432960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795006|NCT05499351|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795007|NCT04297917|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The participants will be recruited in 6 cohorts as follows - Cohort 1 - Healthy Volunteers - Low dose Vaccine - 5 participants Cohort 2 - Healthy Volunteers - High dose Vaccine - 5 participants Cohort 3 - Participants with Chronic Hepatitis B infection - Low dose - 6 participants Cohort 4 - Participants with Chronic Hepatitis B infection - High dose - 6 participants Cohort 5 - Healthy Volunteers who have completed 2 doses of COVID-19 AZD1222 vaccine Cohort 6 - Healthy Volunteers who have completed 2 doses of either Pfizer or Moderna mRNA COVID 19 vaccine||||
33795008|NCT01013012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795009|NCT00949975|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33795010|NCT06188611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795011|NCT00158639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795012|NCT04722237|RANDOMIZED|PARALLEL||TREATMENT||NONE|As trial therapists will perform assessments, blinding is not possible.|This study is a two-arm, parallel group, randomised controlled trial comparing ACT with waitlist controls who will then receive ACT after the 3-month waiting period. Participants will be randomised on a 1:1 ratio to receive 12-weeks of treatment either immediately or following a 12-week wait. The treatment will be DNA-v which is a model of ACT adapted to those aged 11-24 years. The model will be further adapted for those who have undergone brain tumour treatment. As trial therapists will perform assessments, blinding is not possible. Follow-up assessments will be conducted at 12-, 24-, 36-, and 48-weeks post-randomisation with primary end point at 12-weeks.||||
33795013|NCT04658030|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795014|NCT00129948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795015|NCT03798080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795016|NCT05219617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study|This double-blind, randomized, placebo-controlled study will evaluate the efficacy of carisbamate 200 mg BID or the pediatric equivalent dose and 300 mg BID or the pediatric equivalent dose for the treatment of seizures associated with Lennox Gastaut syndrome in subjects 4 to 55 years of age.|t|t|f|f
34017812|NCT01201941|||CASE_CONTROL||PROSPECTIVE|||||||
34017813|NCT04832321|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Study participants are randomly assigned to be read vignettes with slight changes in wording. Neither study participants nor outcomes assessors are provided with information about treatment assignment."||t|f|f|t
34017814|NCT01066689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017815|NCT02254161|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34017816|NCT05209217|||COHORT||PROSPECTIVE|||||||
34017817|NCT06179836|||COHORT||PROSPECTIVE|||||||
34017818|NCT01515930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017819|NCT05656586|||COHORT||PROSPECTIVE|||||||
34017820|NCT03816215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017821|NCT04856124|||COHORT||RETROSPECTIVE|||||||
34017822|NCT00476632|||CASE_CONTROL||PROSPECTIVE|||||||
34017823|NCT04527653|NA|SINGLE_GROUP||TREATMENT||NONE|The mean of the improvement in actinic keratosis performed by two independent dermatologists using photograph images taken at baseline and at 4, 12-weeks follow-up visits.|Single-center, Prospective, Open Label, with Before-After Study Design||||
34017824|NCT00123955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017825|NCT01790035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017826|NCT01501136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017827|NCT01547949|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34025475|NCT06551779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Baseline: Adequate assembly with balanced groups through randomization and clinical stratification.~* Execution: Proper application of the experimental maneuver with established doses at each injection point.~* Outcome: Same number of evaluations in both groups and a 20% increase in sample size in case of losses.~* Masking: Triple-blind study."|"Experimental Group: Patients who meet the inclusion and exclusion criteria, to whom perineural injection with dextrose and conventional physical therapy will be applied for the treatment of Bell's palsy.~Control Group: Patients who meet the inclusion and exclusion criteria, to whom only conventional physical therapy will be applied for Bell's palsy."|t|t|t|t
34025476|NCT04972110|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation, expansion and Phase 2||||
34025477|NCT02782806|NA|SINGLE_GROUP||OTHER||NONE||||||
34025478|NCT04553874|||COHORT||PROSPECTIVE|||||||
34099774|NCT04401631|||COHORT||PROSPECTIVE|||||||
34099775|NCT03269786|||COHORT||CROSS_SECTIONAL|||||||
33714999|NCT01782495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715000|NCT00088985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715001|NCT00859404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715002|NCT02303301|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33715003|NCT02000973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715004|NCT04430114|NA|SINGLE_GROUP||OTHER||NONE||||||
33715005|NCT00001723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715006|NCT00022139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715007|NCT00120770|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33715008|NCT00488436|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715009|NCT00398892|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33715010|NCT05854732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715011|NCT03220516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715012|NCT03585504|RANDOMIZED|PARALLEL||PREVENTION||NONE||participants were randomized to receive a contraceptive implant before hospital discharge or at their six week postpartum visit||||
33715013|NCT05550402|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33715014|NCT02384408|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33715015|NCT01827397|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33715016|NCT03528993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|t|f|f|f
33715017|NCT05358951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715018|NCT03764189|RANDOMIZED|PARALLEL||TREATMENT||NONE|not possible as the subject will sign an informed consent and areas of microosteoperforation will be apparent|||||
33715019|NCT02563275|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33715020|NCT02822768|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715021|NCT03766308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715022|NCT04192734|||CASE_ONLY||RETROSPECTIVE|||||||
33715023|NCT03482609|||COHORT||PROSPECTIVE|||||||
33715024|NCT04884854|||CASE_ONLY||PROSPECTIVE|||||||
33715025|NCT01635972|NA|SINGLE_GROUP||||NONE||||||
33715026|NCT03758274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The University of Rochester based study team, led by MPI Conner, were masked to treatment assignment (which was performed at the Medical University of South Carolina), and the University of Rochester based team performed all follow-up assessments.||f|f|t|t
33715027|NCT05505214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prior to recruitment, the study statistician conducted randomization in a 1:1:1 model, which will divide patients into three arms: (a) bacterial decolonization regimen (b) topical corticosteroid use daily or (c) topical corticosteroid use daily with antibacterial decolonization regimen.|f|f|t|t
33715028|NCT04990154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor was blinded to the group assignment|A randomized, controlled trial with a two parallel-group design|f|f|f|t
33715029|NCT05602181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715030|NCT05637398|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All core-laboratory staff will be blind to the endpoints||f|f|f|t
33715031|NCT02229747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715032|NCT00615095|||COHORT||PROSPECTIVE|||||||
33715033|NCT00227435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33715034|NCT04557397|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33715035|NCT04208698|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33715036|NCT03950648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715037|NCT00203177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715038|NCT01995240|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715039|NCT00399854|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715040|NCT01818908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715041|NCT05790629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|children do not know which material used||t|f|f|f
33715042|NCT03847233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715043|NCT01955733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715044|NCT03590106|NA|SINGLE_GROUP||PREVENTION||NONE||All patients meeting the eligibility criteria will be approached about participation in the Peer Recovery Support Program. Those who agree will receive the intervention as designed. Those who receive will continue to receive standard of care.||||
34099776|NCT00271570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099777|NCT00001857||||TREATMENT||||||||
34099778|NCT05166928|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099779|NCT05416632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Blinded|||||
34099780|NCT05227430|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34099781|NCT05383950|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099782|NCT04318886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34099783|NCT04934215|||COHORT||RETROSPECTIVE|||||||
34099784|NCT05453357|||CASE_ONLY||PROSPECTIVE|||||||
34099785|NCT01848223|||||PROSPECTIVE|||||||
33938614|NCT03062605|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This was a single blind study. The participants knew which one time treatment they were receiving, but the person doing the saliva sampling and testing did not know which treatment the participant was assigned|Participants were randomly assigned to one of two treatment groups and continued in parallel for the three-month duration of the study.|f|f|t|f
33938615|NCT00864539|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33938616|NCT01056601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938617|NCT06278584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938618|NCT01188785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938619|NCT00375596||PARALLEL||||||||||
33938620|NCT05524259|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33938621|NCT05258565|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33938622|NCT04108598|||COHORT||PROSPECTIVE|||||||
33938623|NCT02638363|||CASE_ONLY||PROSPECTIVE|||||||
33938624|NCT04974944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938625|NCT06058338|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938626|NCT04681742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938627|NCT01882439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938628|NCT04229082|||COHORT||CROSS_SECTIONAL|||||||
33938629|NCT04479306|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938630|NCT04834258|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Outcomes Assessor (PFT, PImax, PEmax, SNIP, 6MWT, UPDRS III): Blind to group allocation Investigator: Blind to initial and final assessments Participant: Blind to training|Randomized controlled|t|f|t|t
33938631|NCT00681902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938632|NCT04850885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The blinding of this clinical study was done by confidential supporting staff. The supporting staff was hired for documentation and blinding. Details of role and responsibilities were described to him/her. The study materials ie 30 ml vial of lignocaine 2% (20 mg/ml Xylocaine, AstraZeneca, India); 2 ml in dexamethasone ( 4mg/ml Inj Dexona, Zydus Aliadac, India), in adrenaline 1mg/ml (Actiza, India), normal saline (NS) and identical 5ml syringe and file were given to supporting staff. On the day of surgery, he/she prepared drugs for IANB either the 4 ml Mixture B ( 2ml dexamethasone 4mg/ml + 2ml lignocaine 20mg/ml ) or 4ml Mixture A ( 2ml lignocaine 20mg/ml + 2ml adrenaline 0.01mg/ml, freshly prepared ) in 5 ml identical syringes as mentioned in block randomization chart. The patient name and age were documented the same in a file and a special code was generated and labelled on syringes.|The non-probability convenience sampling method was used to select the subjects for this study based on availability and willingness to take part. Total 406 patients presented in department oral and maxillofacial surgery were examined and screened for the study. Detailed history, examination and radiograph ( orthopantomogram) were taken to evaluate disease and mandibular foramina. The sixty subjects were assigned randomly into two groups; DXN or ADN. Subjects were received either Mixture A and Mixture B for IANB on side of surgery. Group ADN has received 4 ml Mixture A ( 2ml Lignocaine 2%+ 2ml freshly prepared solution of adrenaline 0.01mg/ml in normal saline) whereas Group DXN was received 4 ml Mixture B (2ml Lignocaine 2%+ 2ml dexamethasone 4mg/ml).|t|f|t|f
33938633|NCT01896466|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33938634|NCT05643170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938635|NCT06129006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938636|NCT02089191|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33715045|NCT04931108|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Half of patients will take nitrendipine/atenolol (5/10mg) once daily for 6 weeks first, and then evenly turn into nitrendipine (10mg) or atenolol (25mg) once daily for 6 weeks. Another half of patients will evenly take nitrendipine (10mg) or atenolol (25mg) first, and turn into nitrendipine/atenolol (5/10mg) next.||||
33715046|NCT01447095|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715047|NCT05660772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor, Investigator, Participant are blinded. Unblinded operator will perform procedure.||t|f|t|t
33715048|NCT01896440|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33715049|NCT03505307|||CASE_ONLY||PROSPECTIVE|||||||
33715050|NCT05651451|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33715051|NCT04982198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715052|NCT06391723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multicenter, randomized, double-blind, sham-controlled trial|t|f|t|t
33715053|NCT02389348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715054|NCT04648072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sealed envelopes.|Randomized control trial. Two arms of 30 participants will be included in this study. The experimental arm will receive both the periarticular injection and the adductor canal block with local anesthetic, while the control group will receive the periarticular injection and a sham adductor canal block with normal saline.|t|t|t|t
33715055|NCT03915496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715056|NCT01516931|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||rTMS intervention|t|t|f|t
33715057|NCT02317068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33715058|NCT04384328|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, interventionnal with minimal risks and constraints, multicentric, non-randomized, open study.||||
33715059|NCT04930016|||COHORT||CROSS_SECTIONAL|||||||
33715060|NCT03049280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715061|NCT02113501|||COHORT||PROSPECTIVE|||||||
33715062|NCT00721552|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33795017|NCT04809090|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"Subjects who will participate in the study voluntarily will be given some pre-intervention tests (T1) to assess their psychological well-being, to understand the main coping strategies they employ to manage stress, general stress, and the presence of cognitive impairment. Questionnaires will be used to collect data and exclude those subjects who do not meet the inclusion criteria.~Subjects included in the research will be randomly divided into 4 groups, one group will receive a standard 8 SMT (Stress Management Training) psychological interviews, one group will receive 8 (SMT) psychological interviews and subjects will use an APP together with a CA (Conversational Agent), one group will receive only the APP and the CA, one group will be placed in waiting-list.~After the closing of the pathway (T2) the subjects will receive the same questionnaires they received at the beginning and again after 3 months (T3)."|t|f|f|f
33795018|NCT01948960|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33795019|NCT02705183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795020|NCT01771588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33795021|NCT05235698|||COHORT||OTHER|||||||
33795022|NCT01234116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795023|NCT02787941|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33795024|NCT06170450|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33795025|NCT00826852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795026|NCT01773980|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33795027|NCT05751499|||COHORT||PROSPECTIVE|||||||
33795028|NCT06012331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33795029|NCT03657004|||CASE_CONTROL||RETROSPECTIVE|||||||
33795030|NCT02754479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795031|NCT02608528|||COHORT||PROSPECTIVE|||||||
33938637|NCT00663533|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938638|NCT05516615|||OTHER||CROSS_SECTIONAL|||||||
33938639|NCT02061540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938640|NCT02109939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33938641|NCT06365957|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33938642|NCT05487976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938643|NCT00193726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715063|NCT06506760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715064|NCT06502574|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715065|NCT04856774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715066|NCT03578159|||COHORT||PROSPECTIVE|||||||
33715067|NCT04047498|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants and the UPDRS examiner are blinded to the stimulation condition.|||||
33715068|NCT01255059|||CASE_CONTROL||RETROSPECTIVE|||||||
33715069|NCT04825418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715070|NCT03354611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects in this group will be enrolled from screening assigned BIRADS 0, patient complaint, or referral for second opinion. The enrolled patient will accept CE-CBBCT scans within 4 weeks of her diagnostic mammography and before breast biopsy if biopsy is needed.||||
33715071|NCT01524692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715072|NCT02976428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715073|NCT02208557|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33715074|NCT05285605|||CASE_ONLY||PROSPECTIVE|||||||
33715075|NCT00307294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715076|NCT00576121|||CASE_CONTROL||PROSPECTIVE|||||||
33715077|NCT06131697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants of both group will be informed about the possible risks and potential benefits but they won't know which group they are placed in. The participants must sign consent forms agreeing to the experiment. Concealment will be done via sealed opaque envelopes.||t|f|f|f
33715078|NCT01464489|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33715079|NCT01065623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715080|NCT02054221|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33715081|NCT04140292|NA|SINGLE_GROUP||TREATMENT||NONE||Study group will be compared to a baseline cohort of patients from a previous study (IRB 16-1615) who received the same regimen of PDT, but without any Vit D||||
33715082|NCT05779293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation and treatment will be carried out by different physiotherapists. In this way, it is aimed to provide an objective evaluation||f|f|t|f
33715083|NCT03147014|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33715084|NCT05909098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715085|NCT01450436|||COHORT||PROSPECTIVE|||||||
33715086|NCT05778916|||COHORT||OTHER|||||||
33715087|NCT01080352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715088|NCT04672928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795032|NCT01052233|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33795033|NCT04000269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot prospective double blinded randomized controlled trial|t|t|f|f
33795034|NCT06273891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795035|NCT04576858|||COHORT||PROSPECTIVE|||||||
33795036|NCT02888457|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795037|NCT06333132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938644|NCT02790450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938645|NCT05797727|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Parallel: Clinical trials with a two arms: A prospective, pre-post design will be employed, whereby the LifeChamps platform will be deployed for a total of 3 months||||
33938646|NCT02850276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938647|NCT01531764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938648|NCT03206606|||COHORT||PROSPECTIVE|||||||
33938649|NCT03598140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators associated with this study will not have access to the randomization schedule. The principal investigator, study team, and study subjects will be blinded in this study.|This study is a placebo-controlled, double-blinded clinical trial. Randomization will be 1:1 sildenafil:placebo, and will be in blocks of 10. In this study, 100 boxers and 80 controls will be enrolled and randomized.|t|f|t|f
33938650|NCT00352170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938651|NCT03494946|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized study were half of the subjects will be given standard chemo therapy and the other half will undergo liver transplantation.||||
33795038|NCT02886221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795039|NCT04063410|NA|SINGLE_GROUP||SCREENING||NONE||||||
33795040|NCT03394976|||CASE_CONTROL||PROSPECTIVE|||||||
33795041|NCT01740310|RANDOMIZED|FACTORIAL||||NONE||||||
33795042|NCT03981042|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33795043|NCT00311207|||CASE_CONTROL||OTHER|||||||
34025479|NCT03134092|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34025480|NCT03613727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025481|NCT00000378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025482|NCT04644601|||COHORT||CROSS_SECTIONAL|||||||
34025483|NCT01230112|||||PROSPECTIVE|||||||
34025484|NCT01827865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715089|NCT03898141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"As the employed study design necessitates the deception of participants about the true nature of the used intervention, i.e. placebo cream and the true aim of the dog's presence.~After the termination of the study, all the subjects are debriefed regarding the real experimental procedures."|randomized controlled parallel group within-subjects design|t|f|f|f
33715090|NCT00453882|NA|SINGLE_GROUP||||NONE||||||
33715091|NCT03592108|NA|SINGLE_GROUP||SCREENING||NONE||||||
33715092|NCT05922397|||COHORT||PROSPECTIVE|||||||
33715093|NCT01606930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33715094|NCT04340401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715095|NCT00004860||||TREATMENT||||||||
33715096|NCT00987220|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715097|NCT01228760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715098|NCT00126568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715099|NCT05558514|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Participants will be randomized into either the intervention group or the control group. In the intervention group, cochlear implants will be programmed according to a custom, place-based pitch map. In the control group, cochlear implants will be programmed according to the standard of care, generalized pitch map.~Participants will undergo repeated audiological and music and speech perception testing at baseline, initial activation (\~ 6 months post-operative), 1-month, 3-months, 6-months, 7-months, and 1-year post-activation. Each participant will listen to their assigned map during the first 6 months of cochlear implant use. After 6 months, participants will listen to the alternative map for 1 additional month. After the 7th month, participants will have the opportunity to choose their preferred map. Final assessment will take place at 1-year post-implantation. Performance will be compared between the groups and as a function of frequency-to-place mismatch."|t|f|f|t
33715100|NCT05532592|||CASE_CONTROL||RETROSPECTIVE|||||||
33715101|NCT05086991|||COHORT||PROSPECTIVE|||||||
33715102|NCT01896544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715103|NCT02056782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715104|NCT05163600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||monocenter||||
33715105|NCT05456464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Reiki and control group|The research will be conducted as a randomized, experimental study with a pretest-posttest control group.|t|f|f|f
33715106|NCT04003922|||OTHER||OTHER|||||||
33715107|NCT02122393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715108|NCT00883116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715109|NCT06215040|||CASE_CONTROL||PROSPECTIVE|||||||
33715110|NCT00371137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715111|NCT04542785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors will be blinded. Participants will not be informed of the heart rate target or actual heart rate. Treatment providers managing the heart rate target will not be blinded as the intervention requires information of the heart rate. Other treatment providers will not be informed of the heart rate target.||t|f|f|t
33715112|NCT05036551|||CASE_ONLY||CROSS_SECTIONAL|||||||
33715113|NCT05533281|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33715114|NCT00653250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715115|NCT01357187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715116|NCT00674700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715117|NCT00017498||||TREATMENT||||||||
33715118|NCT03077750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715119|NCT01812824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715120|NCT06001476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715121|NCT06058481|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715122|NCT06506734|||COHORT||RETROSPECTIVE|||||||
33715123|NCT04261751|||COHORT||PROSPECTIVE|||||||
33715124|NCT03957304|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Blinding of dose levels will not be possible so outcome assessors will be blinded by virtue of being remote from the clinical encounter. Furthermore, video segments will commence immediately after intranasal sprays are given so outcome assessors will not see what volume is administered. Two independent assessors will score each video and an interrater agreement (kappa) will be calculated.|Dose-escalation pilot study|t|t|t|t
33715125|NCT00310791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715126|NCT00936910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715127|NCT00173082|||||PROSPECTIVE|||||||
33715128|NCT00227214|||||PROSPECTIVE|||||||
33715129|NCT04756492|||CASE_ONLY||PROSPECTIVE|||||||
33715130|NCT01294293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795044|NCT02131181|||COHORT||PROSPECTIVE|||||||
33938652|NCT05824611|||OTHER||OTHER|||||||
33938653|NCT00743613|||COHORT||PROSPECTIVE|||||||
33938654|NCT00033293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938655|NCT02481986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938656|NCT00826540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938657|NCT00794235|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938658|NCT03704428|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33938659|NCT04835740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025485|NCT01272479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34025486|NCT02308566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025487|NCT05648188|||COHORT||PROSPECTIVE|||||||
34025488|NCT02425163|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025489|NCT03253055|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017828|NCT05753670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will occur by simple randomization with a computer-generated random number list. The patient will be randomized to one of the two groups (preoperative tamsulosin 0.4mg tablet versus placebo). This random number list will be sent directly from the statistician to the pharmacy. The clinician will place an order for the preoperative trial medication and the pharmacy will dispense either a single tablet of tamsulosin 0.4mg or placebo to the preoperative holding area according to the randomization list that the pharmacy has been provided by the statistician. The trial medication will be sent from the pharmacy to the preoperative area to be taken prior to surgery. The clinicians, preoperative and postoperative nursing staff, and the patients will be blinded to the trial group and medication.|"This is a prospective randomized, double-blinded, placebo- controlled trial of patients who are undergoing elective mid-urethral sling placement with the Center for Pelvic Health at the Northshore University Health System. Written consent will be obtained.~Patients who are undergoing a mid-urethral sling placement will be enrolled (after an informed consent discussion) to receive either a single tablet of tamsulosin 0.4mg or a placebo in the preoperative holding area on the day of their scheduled surgery."|t|t|t|t
34017829|NCT04823962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, placebo-controlled and double-blind, phase II clinical trial|t|t|t|t
34017830|NCT02963870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017831|NCT00849771|||COHORT||PROSPECTIVE|||||||
34017832|NCT03474250|||CASE_ONLY||PROSPECTIVE|||||||
34017833|NCT00418821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017834|NCT03894748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017835|NCT00041249||||TREATMENT||||||||
34017836|NCT01911663|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017837|NCT02283294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017838|NCT04469621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017839|NCT06092385|||COHORT||PROSPECTIVE|||||||
34017840|NCT02091141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017841|NCT03947424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham treatment consists of laser treatment according to the same protocol as active treatment but with no energy applied. Clinical measurements will be performed by an evaluator unaware of group assignment.|Three groups; laser (LP), laser (SMOOTH), control (sham)|t|f|f|t
34017842|NCT02059018|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34017843|NCT03787576|||CASE_ONLY||PROSPECTIVE|||||||
34017844|NCT00055614||||TREATMENT||||||||
34017845|NCT04516512|NA|SINGLE_GROUP||SCREENING||NONE||||||
34017846|NCT01593033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017847|NCT01206816|NON_RANDOMIZED|||TREATMENT||NONE||||||
33715131|NCT03409523|||OTHER||PROSPECTIVE|||||||
33715132|NCT00884312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715133|NCT01741701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715134|NCT00750204|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715135|NCT01116154|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715136|NCT00321802|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33715137|NCT04234581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33715138|NCT05118906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715139|NCT01463540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715140|NCT02756689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715141|NCT02949102|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33715142|NCT05454592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715143|NCT02061267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33715144|NCT01878058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715145|NCT03063554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715146|NCT01649687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715147|NCT05693779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715148|NCT02403154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715149|NCT01772238|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33715150|NCT01402492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715151|NCT02052284|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33715152|NCT03965962|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind: the participant (or legally acceptable representative) and the Investigator remain unaware of the treatment assignments throughout the study. An unblinded qualified trial staff member administered the appropriate vaccine but was not involved in the immunogenicity and safety evaluations.|The study was divided into 4 groups: groups 1 to 3 (VRVg-2 + HRIG; Verorab + HRIG; Imovax Rabies + HRIG) were modified double-blind and group 4 (VRVg-2 standalone) was open-label.|t|t|t|t
33715153|NCT05012839|||COHORT||RETROSPECTIVE|||||||
33715154|NCT01428544|||||RETROSPECTIVE|||||||
33715155|NCT01753856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715156|NCT02739204|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33715157|NCT02727023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715158|NCT05823961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715159|NCT05002010|||COHORT||CROSS_SECTIONAL|||||||
33715160|NCT00424671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017848|NCT00003179|RANDOMIZED|||PREVENTION||||||||
34017849|NCT03832309|RANDOMIZED|PARALLEL||OTHER||SINGLE|During the consent for the study, the physician will do the following depending on which group the patient has been randomized to: Packet 1: The physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel not pain, cause them to forget the procedure, and allow them to dream the dream of their choice. The resident will specifically ask the patient what he or she wants to dream about and the resident will then write the patient's answer on the instruction sheet. Packet #2: They physician will be asked to read a written statement about how the drug they will be given will cause analgesia, amnesia, and may cause hallucinations.|The study will be conducted in the emergency department at CHRISTUS Spohn Shoreline hospital is the region's primary acute care center. It houses the Chest Pain, Stroke, and Cancer Centers of CHRISTUS Spohn and is the only level II trauma center in south Texas. It is a major affiliate of Texas A\& M medical school, and serves an inner-city population|t|f|f|f
34099786|NCT06213636|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group.|"Patients enrolled in this clinical trial will receive a carefully designed treatment regimen. Prior to the infusion of CD19 and CD22 CAR-T cells, participants will undergo preconditioning chemotherapy. This chemotherapy serves to create an optimal environment for the CAR-T cell therapy to effectively target and eliminate malignant B cells. Following chemotherapy, participants will receive the infusion of CD19 and CD22 CAR-T cells.~Monitoring and Follow-up:~Following the CAR-T cell infusion, patients will be subjected to rigorous monitoring to assess safety and treatment response."||||
34099787|NCT06694844|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34099788|NCT05485350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099789|NCT04006756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34099790|NCT04570423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099791|NCT01534403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099792|NCT00135161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099793|NCT06447688|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099794|NCT04597333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099795|NCT02037984|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34099796|NCT03837535|||COHORT||PROSPECTIVE|||||||
34099797|NCT04269187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099798|NCT05467228|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099799|NCT03931785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017850|NCT05555368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099800|NCT02003209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099801|NCT01341548|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017851|NCT02505490|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34099802|NCT01758471|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34017852|NCT03466359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33715161|NCT00677612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715162|NCT00540514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715163|NCT04956497|||CASE_ONLY||PROSPECTIVE|||||||
33715164|NCT01081925|||CASE_ONLY||CROSS_SECTIONAL|||||||
33715165|NCT01411111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017853|NCT01914055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017854|NCT06306235|||OTHER||PROSPECTIVE|||||||
34017855|NCT00057213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017856|NCT02536326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099803|NCT03763266|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34099804|NCT06032975|||COHORT||PROSPECTIVE|||||||
34099805|NCT04465305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099806|NCT00614341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099807|NCT03600103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34099808|NCT02201628|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34099809|NCT01795131|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34099810|NCT04578054|||COHORT||PROSPECTIVE|||||||
34099811|NCT03158779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715166|NCT06452654|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715167|NCT06089928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both the participant and outcome assessor would not know to which group of study they belong investigator can not be masking|clinical and radiographical comparisons of newly formed bone following vertical ridge augmentation which is achieved by use sandwich osteotomy with Interpositional inlay graft (ramus block) without fixation (test group), and same procedure with using micro-plates and screws as a mean of fixation (control group).|t|f|f|t
33715168|NCT03627806|||COHORT||PROSPECTIVE|||||||
33715169|NCT02835508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715170|NCT03944954|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Functionality will be tested following combinations of THC and TMS will be tested in randomized, double-blind, placebo- and sham-controlled experiments.|Participants will be assigned to either excitatory or inhibitory TMS treatment arms. All individuals will receive multiple doses of oral THC (0, 10 and 30mg) and TMS (real or sham).|f|f|t|f
33715171|NCT06231615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluation of the patients was carried out by a blinded investigator, and the treatment was carried out by a different investigator.|dual parallel group design|f|f|f|t
34099812|NCT02526316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099813|NCT02813512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099814|NCT02301429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099815|NCT01155310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017857|NCT04736043|||COHORT||PROSPECTIVE|||||||
34017858|NCT03901859|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34017859|NCT02263235|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34099816|NCT01655069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099817|NCT04656028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The trial is a randomized prospective cohort study. The study will include patients 18 years of age and older with a probable or definite diagnosis of FH according to the Dutch criteria (6 points or more). A total of 180 patients will be included in the study. All patients will be randomly divided into 2 groups for genetic testing. Randomization will be performed as block randomization with a 2:1 allocation ratio (2 with genetic testing : 1 without genetic testing). The allocation ratio 2:1 was chosen because in the group with genetic testing there will be cases where mutation(s) associated with FH will be identified and cases where the mutation(s) will not be identified. A separate analysis is planned in patients with genetic testing and identified mutation(s) and in patients with genetic testing but no identified mutation(s).~Each study group will be randomized into 2 subgroups depending on the conduct of motivational counseling with an 1:1 allocation ratio."|f|f|f|t
34099818|NCT06512155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099819|NCT04266314|||CASE_ONLY||PROSPECTIVE|||||||
34099820|NCT00240773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34099821|NCT05439837|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017860|NCT03621059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible children were randomly assigned by sealed envelope to either intervention or control group. Several methods were used to maintain the treatment blindly, including segregation of assessment and treatment staff and instructions to children and parents to avoid discussions of treatment assignment with the independent evaluators.|A collection of behavioral skills named as Comprehensive Behavioral Intervention (CBIT) for Tics had been found to be effective (Piacentini et al., 2010).The major components of CBIT includes psychoeducation of tics, habit reversal training (HRT), function-based interventions, and relaxation training (Piacentini et al., 2010).The HRT consists of several therapeutic activities, including awareness training (i.e., observing the premonitory urge or other signs preceding the occurrence of a tic), competing response training (i.e., engaging in a voluntary behavior that is physically incompatible with the tic to manage the premonitory urge), self-monitoring of tics and relaxation training (Himle et al., 2006).|t|f|f|f
34017861|NCT03522610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This study is a two-group randomized controlled effectiveness trial with baseline and three follow-up assessment points|f|f|t|t
34017862|NCT04489758|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||4Dx XV Ventilation Analysis applied to fluoroscopic images||||
34017863|NCT01916590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017864|NCT05084664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34017865|NCT00874003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099822|NCT04970576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Transthoracic echocardiography assessment for the dissolution of LV thrombus will be blinded to the treatment group||f|f|f|t
34099823|NCT01888198|||COHORT||OTHER|||||||
34099824|NCT03073304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099825|NCT03823885|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Code|Crossover with 2 week washout|f|f|f|t
34017866|NCT00166036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017867|NCT06303973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34017868|NCT06429839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017869|NCT00786279|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34099826|NCT05606614|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099827|NCT04394559|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Other: 2 arms, before-after study and mixed methods analysis of implementation||||
34099828|NCT02500342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099829|NCT05172310|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Investigators select subjects that are scheduled for~* surgical removal of either a malignant lesion in the pancreas, bile ducts, or stomach (first arm)~* surgical removal of primary stage epithelial cancer of the ovary (EOC), interval debulking surgery (IDS) of EOC or surgical removal/tissue biopsy of recurrent EOC (first arm)~* surgical removal of a benign lesion in the pancreas (second arm)~All patients will undergo a PET/CT with the interventional drug/radiotracer 68Ga-FAPI-46 before surgery."||||
34099830|NCT03737032|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The content of each TBS condition will be unknown to participants and to the research staff member conducting assessment of change neural, behavioral, and subjective response with TBS.|All participants will receive intermittent Theta Burst Stimulation (TBS), continuous TBS, and sham TBS mimicking stimulation, in randomized, double-blind order across three sessions.|t|f|f|t
34099831|NCT00559117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099832|NCT01065766|||||PROSPECTIVE|||||||
34099833|NCT01406054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34099834|NCT03352180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34099835|NCT01818310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099836|NCT02059642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099837|NCT04129333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Multicenter prospective national, controlled, randomized, superiority study, open-label with blind evaluation, on 2 parallel groups|f|f|f|t
34099838|NCT06059001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715172|NCT03007160|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715173|NCT00314665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715174|NCT02464462|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715175|NCT04897360|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33715176|NCT05855252|||COHORT||PROSPECTIVE|||||||
33715177|NCT04771442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715178|NCT01092559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715179|NCT03344250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||EGFR BATs administered in combination with standard of care temozolomide and radiation||||
33715180|NCT00374790|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33938660|NCT04475029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomization and medication will be handled by hospital pharmacy. Randomisation list will be concealed until all statistical analyses are made.~* plan for data analysis was decided upon at a meeting with a statistician on September 7th, 2023. The plan was made before A and B lists were obtained from the hospital pharmacy. This study will be undertaken as an equivalence trial with the application of intention to treat analysis. Missing data are assumed to be missing at random. Primary outcome will be analyzed paired or unpaired t-test for difference, depending on distribution. Analysis of secondary outcome NRS will be reported as median(interquartile range) and compared between groups at the various times using the Mann-Whitney U test. If normal distributed multilevel mixed effects linear regression will be carried out. Analysis of other secondary outcomes will be dichotomized and presented for 3 and 24 hours with X2 test."|Randomized controlled trial.|t|t|t|t
33938661|NCT00138853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938662|NCT02912624|||COHORT||PROSPECTIVE|||||||
33938663|NCT06177210|||COHORT||PROSPECTIVE|||||||
33938664|NCT03770936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938665|NCT01920516|||COHORT||PROSPECTIVE|||||||
33938666|NCT01513694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938667|NCT03474627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715181|NCT02551276|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33938668|NCT02366715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33938669|NCT01279954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938670|NCT06128642|||CASE_CROSSOVER||PROSPECTIVE|||||||
33938671|NCT06324175|||COHORT||PROSPECTIVE|||||||
33938672|NCT02088736|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33938673|NCT02131571|||COHORT||PROSPECTIVE|||||||
33938674|NCT00748111|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938675|NCT04338542|||COHORT||RETROSPECTIVE|||||||
33938676|NCT01782976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938677|NCT04729699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were divided into intervention group and control group.||t|f|f|f
33938678|NCT06447935|||COHORT||RETROSPECTIVE|||||||
33938679|NCT00808028|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33715182|NCT01338792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715183|NCT01050868|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715184|NCT05255172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715185|NCT00360789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33715186|NCT01879332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715187|NCT01813097|||CASE_CONTROL||PROSPECTIVE|||||||
33715188|NCT00227695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715189|NCT04873791|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715190|NCT03128892|NA|SINGLE_GROUP||OTHER||NONE||||||
33715191|NCT02726646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715192|NCT00545168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33715193|NCT02579044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715194|NCT02940977|||CASE_ONLY||PROSPECTIVE|||||||
33715195|NCT03989453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assignment to the groups will be of simple random type and hidden. Those responsible for admitting patients to the intervention phase will not know what group has been assigned each. This assignment will be made in advance by a researcher who will not intervene in the later stages of evaluation, intervention, data recording and elaboration of database. The assignment will be communicated through sealed and totally opaque envelopes.|Randomized controlled trial|f|t|t|t
33715196|NCT05148754|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715197|NCT02877615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715198|NCT02998593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715199|NCT02075229|||CASE_CONTROL||PROSPECTIVE|||||||
33715200|NCT02005445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715201|NCT04069091|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33715202|NCT03461367|||COHORT||PROSPECTIVE|||||||
33715203|NCT02789709|||COHORT||PROSPECTIVE|||||||
33715204|NCT02958124|||CASE_ONLY||PROSPECTIVE|||||||
33715205|NCT04019665|NA|SINGLE_GROUP||OTHER||NONE||||||
33715206|NCT04531293|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33715207|NCT04346537|||COHORT||PROSPECTIVE|||||||
34017870|NCT01630213|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34017871|NCT05631834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single centered, open label, randomized controlled trial|This is a single centered, open label, randomized controlled trial|t|f|f|f
34017872|NCT03172247|||COHORT||PROSPECTIVE|||||||
34017873|NCT02446327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34017874|NCT00667810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017875|NCT03625518|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34017876|NCT02831218|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34017877|NCT02497118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017878|NCT00325377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017879|NCT06026774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017880|NCT03835143|||CASE_ONLY||PROSPECTIVE|||||||
34017881|NCT05589961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017882|NCT01685073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017883|NCT04393090|||COHORT||PROSPECTIVE|||||||
34017884|NCT02683265|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Blinded active capsules looked identical to the same strength placebo capsules|Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study|t|t|t|t
34017885|NCT00495547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017886|NCT03749629|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigators will prospectively randomize 400 participants with DSM-V major depressive disorder to best practice guidelines plus PGx- guided psychiatric treatment (n=200) or best practice guidelines alone (n=200) and follow them for one year.||||
34099839|NCT04810858|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be assigned to one of 4 study groups: HIV+ marijuana user, HIV+ non-drug user, HIV- marijuana users, and HIV- non-drug user||||
34099840|NCT00183391|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34099841|NCT04209803|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34099842|NCT00422929|||COHORT||PROSPECTIVE|||||||
34099843|NCT05652582|||CASE_ONLY||RETROSPECTIVE|||||||
34099844|NCT04653064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34099845|NCT05803499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be informed which arm they have been randomized into. Research assistants will also be blinded to randomization. Only the control and intervention session facilitators and Principal Investigator will be aware of participants' study arm.|This pilot will test the targeted intervention for feasibility, acceptability, and preliminary effects. Participants will be randomized to either 1) the targeted intervention for bereavement and sleep disturbance based on Cognitive Behavior Therapy for Insomnia (CBT-I), and 2) an information-only control. Participants will complete self-report measures and an in-person visit at baseline and post-treatment, and a 6-month follow-up (psychosocial measures only).|t|t|f|t
34099846|NCT06695520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099847|NCT05259540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938680|NCT00303329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099848|NCT02246036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099849|NCT04506775|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|None, patients are their own control.|Single group design, patients are their own control.||||
34099850|NCT03047213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099851|NCT04298112|||CASE_ONLY||PROSPECTIVE|||||||
34099852|NCT01063881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938681|NCT03602742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938682|NCT05322538|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33938683|NCT05289999|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33938684|NCT00928499|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938685|NCT04209491|||COHORT||RETROSPECTIVE|||||||
33938686|NCT00039546|RANDOMIZED|||TREATMENT||||||||
34017887|NCT03250494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34017888|NCT00110162|RANDOMIZED|||TREATMENT||||||||
34017889|NCT00220142|||||PROSPECTIVE|||||||
34017890|NCT03071094|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938687|NCT05086640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938688|NCT02622802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938689|NCT03869632|NA|SINGLE_GROUP||TREATMENT||NONE||dose escalation||||
33938690|NCT01044472|||COHORT||PROSPECTIVE|||||||
33938691|NCT03538899|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal study of autologous stem cell transplant of cells transduced with corrected DCLRE1C gene using a self-inactivating lentiviral vector (AProArt). The CliniMACS® CD34 Reagent System cell sorter device will be used to select CD 34 cells. Sub-ablative busulfan will be used for pre-transplant conditioning.||||
34017891|NCT01678001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017892|NCT01625130|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34017893|NCT01986621|||COHORT||PROSPECTIVE|||||||
34017894|NCT00000117|RANDOMIZED|||TREATMENT||DOUBLE||||||
34017895|NCT00653965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017896|NCT04060719|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795045|NCT01430611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33795046|NCT03506880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||1 group receives the MADD parent intervention; the second group receives parent materials from the Surgeon General; and the third group is TAU|t|f|f|f
33795047|NCT01820195|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33795048|NCT00767013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795049|NCT00079183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33795050|NCT06542133|||CASE_ONLY||PROSPECTIVE|||||||
33795051|NCT03921450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not know the stimulation protocol, neither will the outcome assessor or the mental health care provider know the protocol applied|3 week intervention with 15 sessions of add-on rTMS in 4 parallel arms, randomized, double-blind, placebo-controlled|t|t|f|t
33938692|NCT01829672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795052|NCT04781439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33938693|NCT00755521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938694|NCT01792024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795053|NCT03184623|||COHORT||PROSPECTIVE|||||||
33938695|NCT00829010|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938696|NCT04453345|NA|SINGLE_GROUP||TREATMENT||NONE||TPM treatment plan: thalidomide 50-100mg qn + prednisone 0.5-1mg / kg qod +methotrexate 10mg / m2 / week.||||
33938697|NCT03021707|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33938698|NCT03336281|||COHORT||PROSPECTIVE|||||||
34099853|NCT04179162|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I/II trial of intravesical gemcitabine given between doses of BCG in patients who have relapsing but BCG-responsiveNon-Muscle Invasive Bladder Cancer (NMIBC).||||
34099854|NCT05522972|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099855|NCT06305858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34099856|NCT01775410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099857|NCT01820104|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34099858|NCT05049499|||COHORT||PROSPECTIVE|||||||
33938699|NCT03841773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099859|NCT06415344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099860|NCT06272929|||CASE_CONTROL||RETROSPECTIVE|||||||
34099861|NCT00086463|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34099862|NCT03699995|NA|SINGLE_GROUP||SCREENING||NONE||||||
34099863|NCT03838328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The allocation is masked for the participant, care provider, investigator and outcomes assessor.||t|t|t|t
34099864|NCT05302518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099865|NCT04286386|||COHORT||PROSPECTIVE|||||||
34099866|NCT05492682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099867|NCT05541471|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34099868|NCT03531502|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized, controlled||||
34099869|NCT05718518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099870|NCT00931320|||COHORT||RETROSPECTIVE|||||||
34099871|NCT03255499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795054|NCT00028769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795055|NCT05216692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|f|t
33795056|NCT04148040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795057|NCT01834703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795058|NCT06241235|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795059|NCT01552980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795060|NCT04001517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795061|NCT06333717|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blinding||t|f|t|f
33795062|NCT00942123|||CASE_ONLY||PROSPECTIVE|||||||
33795063|NCT01818713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795064|NCT01018836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795065|NCT05988307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795066|NCT03709758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795067|NCT04100148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938700|NCT02986425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938701|NCT04321291|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938702|NCT05790499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938703|NCT00935701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938704|NCT00070837|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938705|NCT02108795|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33938706|NCT03008889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938707|NCT00114257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938708|NCT00309361|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33938709|NCT02220660|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33938710|NCT02065635|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33938711|NCT02933489|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33938712|NCT04622163|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938713|NCT03147495|||CASE_CONTROL||PROSPECTIVE|||||||
33938714|NCT01947127|||COHORT||PROSPECTIVE|||||||
33938715|NCT00989664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938716|NCT00207506|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33938717|NCT04754568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938718|NCT00957463|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33938719|NCT00547729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938720|NCT06230003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938721|NCT05008302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938722|NCT05008718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938723|NCT03089489|||COHORT||PROSPECTIVE|||||||
33938724|NCT04399993|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The volunteers will be allocated randomly using a website called radom.org, which ensures that neither neither the volunteer nor the assessor will know the final allocation.||t|f|f|t
33938725|NCT03125681|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33938726|NCT03310099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099872|NCT00890097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715208|NCT00000507|RANDOMIZED|||TREATMENT||||||||
33938727|NCT01804504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938728|NCT00890201|||CASE_CONTROL||PROSPECTIVE|||||||
33938729|NCT01551381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938730|NCT02994199|NA|SINGLE_GROUP||OTHER||NONE||||||
33938731|NCT02099292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099873|NCT06491576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099874|NCT03990337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blinded|prospective two-arm randomized controlled single blinded|f|t|f|f
34099875|NCT02809781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099876|NCT02458885|||COHORT||PROSPECTIVE|||||||
34099877|NCT02144818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099878|NCT01282554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715209|NCT00150982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715210|NCT04782024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33715211|NCT03012906|||COHORT||PROSPECTIVE|||||||
33715212|NCT02959944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715213|NCT02011737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715214|NCT01737151|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715215|NCT05951504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715216|NCT04850131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 82 patients with inguinal hernias were selected randomly to participate in this study. They were subjected to either Lichtenstein hernioplasty or Desarda herniorrhaphy. A follow-up was conducted to analyze the hospital stay, return to work, recurrence rate, chronic pain, postoperative complications, and cost-effectiveness.|t|f|t|f
33715217|NCT05871294|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715218|NCT01711970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715219|NCT03421119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715220|NCT00636142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715221|NCT03421392|||COHORT||PROSPECTIVE|||||||
33715222|NCT04233151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715223|NCT02856503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715224|NCT01033266|||CASE_ONLY||PROSPECTIVE|||||||
33715225|NCT06286904|||COHORT||PROSPECTIVE|||||||
33715226|NCT04563923|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a case-controlled, randomized, open-labelled, and multicenter phase II clinical trial. Four Dermatologic French centers (Nice, Marseille Nord, Marseille Timone and Montpellier university hospitals) specialized in the in the care of BP patients will be participating in the study. It is expected that forty subjects will be included in this trial.||||
33715227|NCT06399978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this study, 40 MCI participants will be randomly assigned to either an intervention group (digital cognitive training with a gamified DOT programme, N=20) or an active control group (digital cognitive training with a gamified non-DOT programme, N=20).|t|t|f|f
33715228|NCT03664557|NA|SINGLE_GROUP||OTHER||NONE||Open label feasibility study||||
33715229|NCT05963217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715230|NCT03839745|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33715231|NCT02221050|||COHORT||CROSS_SECTIONAL|||||||
33715232|NCT02733991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715233|NCT00678054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715234|NCT00864214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715235|NCT05209438|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|"Phase 1 - Participants will receive INT, there is no blinding.~Phase 2 - Participants will not be told which group they are assigned to until the end of the study."|"Prior to the start of the randomized Phase II for the trial, a limited intervention-only pilot will be carried out with up to 5 participants (Phase I). The purpose of this is to confirm feasibility of cohort and identify challenges, intervention, and outcome assessment procedures to ensure they are optimized by the start of the randomized phase, and allow additional time to work towards any obstacles that arise with the placebo.~Phase II will be a single-blind, randomized, pilot clinical trial that aims to enroll 20 participants who will be randomized to receive 6 sessions of CR intervention linked to brainwaves (INT) (n=10) or 6 sessions of sham control tones not linked to brainwaves (CON) (n=10). In this study, the tones not linked to brainwaves will be used as the control."|t|f|f|f
33715236|NCT06220682|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715237|NCT05245370|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33715238|NCT04501666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715239|NCT00672412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715240|NCT02890446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715241|NCT00005937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715242|NCT02916342|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33715243|NCT00002990|RANDOMIZED|||TREATMENT||||||||
33715244|NCT05735132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33715245|NCT05612984|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pregnant women will be individually randomized to daily CAMMS or IFA from recruitment (at 6\<20 weeks gestation) to delivery.||||
33715246|NCT03265275|||COHORT||PROSPECTIVE|||||||
33715247|NCT03146494|||COHORT||PROSPECTIVE|||||||
33715248|NCT03140553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715249|NCT04136860|||COHORT||PROSPECTIVE|||||||
33715250|NCT05186064|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715251|NCT03412487|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715252|NCT03027778|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715253|NCT04320446|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33715254|NCT03500627|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715255|NCT02706470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715256|NCT01979016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938732|NCT00519558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938733|NCT04631640|||COHORT||OTHER|||||||
33938734|NCT04497636|||COHORT||PROSPECTIVE|||||||
33938735|NCT02881151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938736|NCT02859480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938737|NCT02629887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938738|NCT05496166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938739|NCT05183594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33938740|NCT01293214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938741|NCT02477800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938742|NCT04804072|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, 1:1 study of 450 participants. Participants in the intervention arm will be provided integrated health services delivered in the mobile unit and peer navigation for 26 weeks. Participants in the active control arm will be provided 26 weeks of peer navigation to connect them to health services available at community-based agencies.||||
34017897|NCT05154032|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"All participants will complete the following design. Women who experience menstrual flow will be scheduled to ensure that flow occurs on weeks 4 and 8 for consistency.~Baseline block (weeks 1-4): At intake, participants will complete up to 13 surveys, which includes two baseline questionnaires, \& the first rendition of weekly and monthly surveys. Participants will complete daily surveys each morning \& night, \& wear wearable devices to monitor physiology during sleep. Additionally, a laboratory visit will occur once per week for completion of weekly surveys \& cognitive assessments; monthly surveys will also be completed during the fourth week.~Intervention block (weeks 5-8): Daily, weekly, \& monthly activities described for the baseline block will continue. Additionally, during weeks 5-7, participants will complete three 60-minute Float-REST sessions per week; The final week of this block will only involve the daily, weekly \& monthly activities plus an exit survey."||||
34017898|NCT01034072|||OTHER||CROSS_SECTIONAL|||||||
34017899|NCT01855074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017900|NCT01799863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017901|NCT00124995|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34017902|NCT00026221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017903|NCT01064141|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017904|NCT05114837|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg)||||
34017905|NCT00793780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017906|NCT00706095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017907|NCT04136691|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blind||f|f|t|f
34099879|NCT02245893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099880|NCT03517020|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099881|NCT04476680|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Observational study in two cohorts, matched for age and latitude. One group will be taking vitamin D supplements.||||
34099882|NCT05084885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study will be evaluated using a pre-test vs. post-test design.||||
34099883|NCT05051657|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking, product will be given open label|single group - all patients to receive relevant express plus product||||
34099884|NCT04394000|||COHORT||OTHER|||||||
34099885|NCT02758080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099886|NCT06631092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099887|NCT04191733|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 Block Randomization||||
34099888|NCT03898609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099889|NCT05517785|||OTHER||CROSS_SECTIONAL|||||||
34099890|NCT06450444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099891|NCT03363464|||COHORT||RETROSPECTIVE|||||||
34099892|NCT05292183|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||The researchers will use computerized randomization of electrical stimulation for each participant. The stimulation vs non stimulation are not discrete events and occur in random order within individual participants during each daily testing session.||||
34099893|NCT03593408|||COHORT||PROSPECTIVE|||||||
34099894|NCT02079285|||COHORT||PROSPECTIVE|||||||
34099895|NCT01856829|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34099896|NCT05977491|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The health care provider will know if informed about the POCT results (in groups 2,3) or not (group 1). He will not know if patient is in group 2 or 3.~The investigator will be present at various times during inclusion for quality control and therefore is not blinded.~The outcome assessor ( the PhD candidate and the statistician) will receive data files without specific group label."|"Three armed RCT.~1. Standard treatment~2. POCT result based treatment~3. POCT result based treatment plus patient education and addressing of anxiety, depression and domestic violence"|t|f|f|t
34099897|NCT04165902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099898|NCT05274035|||COHORT||PROSPECTIVE|||||||
34099899|NCT04140903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent blinded endpoint committee will assess the primary outcome.|Investigator-initiated, international, multi-centre, randomised, parallel groups, non-inferiority trial|f|f|f|t
34099900|NCT05879432|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33938743|NCT03273868|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33938744|NCT06045936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938745|NCT00215904|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33938746|NCT01021839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017908|NCT04729192|||CASE_ONLY||PROSPECTIVE|||||||
34017909|NCT00283790|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34017910|NCT05237518|NA|SINGLE_GROUP||OTHER||NONE||||||
34017911|NCT03334617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.~Within each module, there will be treatment cohorts."||||
34017912|NCT00872482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34017913|NCT02800213|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34025490|NCT05801471|||COHORT||PROSPECTIVE|||||||
33795068|NCT01909258|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795069|NCT02126878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33795070|NCT04612348|||CASE_CONTROL||PROSPECTIVE|||||||
33795071|NCT01336439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938747|NCT03094481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All parties will be blinded except for the specific anesthesiologist performing the nerve blocks. This person will not be involved in providing further care (administering anesthesia) nor data collection.||t|t|t|t
33938748|NCT04155190|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|As a double-blinded study, the Investigators, the site staff, PellePharm, and the Clinical Monitor(s) will be blinded to the treatment assigned to individual subjects. Delegated staff members at the study site will dispense the investigational product (IP) and will collect and weigh all used and unused IP tubes.|Participants will be randomized (1:1) to receive either Patidegib Topical Gel, 2%, or Vehicle for 9 months. Randomization will be stratified by gender.|t|t|t|f
33938749|NCT00796809|||COHORT||RETROSPECTIVE|||||||
33938750|NCT04610320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715257|NCT00369616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938751|NCT02198313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34017914|NCT04102852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients do not know if the LGG dose they a taking is the regular ot the double dose The investigator that assess the parameters at the end of the treatment is different from the investigator that examined the patient at the pre-treatment visit."||t|f|t|t
34017915|NCT02208674|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34017916|NCT02018926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017917|NCT01829841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017918|NCT01367652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017919|NCT01898325|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34017920|NCT05285670|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to 1) A digital counseling tool plus interactive two-way SMS dialogue or 2) Control (no SMS) at the clinic level, using 1:1 allocation at the clinic level.||||
34017921|NCT00616941|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34017922|NCT02431182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34017923|NCT02528747|||COHORT||PROSPECTIVE|||||||
34017924|NCT03047837|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34017925|NCT01573169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017926|NCT01284296|NA|SINGLE_GROUP||||NONE||||||
34017927|NCT03771937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinding was provided that included inclusion criteria and agreement to participate in the study||t|f|f|f
34017928|NCT04354519|||COHORT||PROSPECTIVE|||||||
34099901|NCT05572216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind|ACCURATE is a nation-wide, single-blind, multicentric, prospective randomized controlled trial enrolling patients with a single complex renal mass, defined as RENAL NS≥7. Randomization (1:1) between the experimental and the conventional group will take place on day of inclusion and will be stratified by center.|t|f|f|f
34099902|NCT00013299|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34099903|NCT04154488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099904|NCT05080543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a randomized controlled and double-blinded|f|f|t|f
34099905|NCT03586232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34099906|NCT00831896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099907|NCT06580925|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34099908|NCT03451305|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Patients eligible for the study were selected by an independent research assistant. The study was explained, and informed consent was obtained from patients before the surgery. Using a randomization sequence, the patients were assigned to the international or control group. The attending surgeons and patients were blinded before the surgery.|Patients with single level osteoporotic compression fracture|f|f|t|f
34099909|NCT05349773|||CASE_ONLY||PROSPECTIVE|||||||
33715258|NCT00737282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715259|NCT03028714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715260|NCT02659306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017929|NCT00697684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715261|NCT03580655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715262|NCT01714635|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715263|NCT02050776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715264|NCT03886974|||COHORT||CROSS_SECTIONAL|||||||
33715265|NCT02450903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715266|NCT06074315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study|t|f|t|f
33715267|NCT01320761|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33715268|NCT01647815|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33715269|NCT06395974|||OTHER||CROSS_SECTIONAL|||||||
33715270|NCT02942394|||OTHER||PROSPECTIVE|||||||
33715271|NCT00818233|||CASE_ONLY||PROSPECTIVE|||||||
33715272|NCT00241280|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33715273|NCT02151760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715274|NCT00933374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715275|NCT02289040|||CASE_CONTROL||PROSPECTIVE|||||||
33715276|NCT03626623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795072|NCT01806428|||COHORT||PROSPECTIVE|||||||
33795073|NCT00333658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795074|NCT02457117|||OTHER||OTHER|||||||
33795075|NCT04305405|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34017930|NCT01536990|||CASE_ONLY||PROSPECTIVE|||||||
34017931|NCT00472862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017932|NCT06174870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795076|NCT06262139|NA|SEQUENTIAL||DIAGNOSTIC||NONE||prostate cancer patients||||
33795077|NCT00723450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017933|NCT02684708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099910|NCT03681093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, double dummy study design.||t|f|t|f
34099911|NCT06383052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099912|NCT01628809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34099913|NCT06403267|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Potential bias will be reduced by the following steps:~* allocation concealment: via online central randomization~* trial participants will remain blinded to dose and treatment allocation and will not be informed until after database lock.~* blinded endpoint assessment, at Days 30 and 90 central blinded assessors will contact the participants for mRS and EQ-5D-5L assessments.~Clinical site staff, including the Principal Investigator (PI), sub-investigators, clinic site staff, and the Sponsor will not be blinded"|Prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial||||
34017934|NCT03030820|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33795078|NCT06676124|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study is double-blinded. Participants, care providers, investigators, and outcomes assessors are all masked to group assignments. Cookies for both the intervention and placebo groups are identical in appearance, taste, and packaging to prevent any indication of group allocation. The randomization and coding were handled by an independent party, and group assignments were concealed using sealed, opaque envelopes. All study personnel involved in data collection, analysis, and monitoring were also blinded to maintain the integrity of the results and minimize bias throughout the trial|Two parallel groups: one group receives Piper crocatum cookies, and the other group receives placebo cookies for 12 weeks|t|t|t|t
33795079|NCT06513546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind study||t|t|t|t
34017935|NCT01064154|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34017936|NCT03805503||SEQUENTIAL||TREATMENT||NONE||Prospective, up-down sequential allocation||||
34017937|NCT01983917|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34017938|NCT03098914|||COHORT||PROSPECTIVE|||||||
34017939|NCT03000218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017940|NCT00450619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017941|NCT05060354|||COHORT||PROSPECTIVE|||||||
34017942|NCT01021358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017943|NCT05012163|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Providers who prescribe vaccination and diagnose conditions will not be randomized to study arms or informed of patient assignment. Although patients will not be explicitly informed of which arm they were randomized to, they will be aware of the messages they receive.|"Eligible patients will be randomly assigned to one of four arms:~* Pennsylvania Lottery Scratch-Off Financial Incentive~* Certain Cash Payout Financial Incentive~* Reminder / Active Control Arm (No Financial Incentive)~* No Treatment Control Arm"|f|t|f|f
34017944|NCT04573517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025491|NCT03190213|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, non-randomized phase 2 study||||
34099914|NCT03612895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099915|NCT06312813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099916|NCT01230814|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34099917|NCT05317871|||COHORT||PROSPECTIVE|||||||
34099918|NCT00251966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34099919|NCT00440739|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34099920|NCT05807750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715277|NCT03171623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715278|NCT04785014|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715279|NCT04984798|NA|SINGLE_GROUP||TREATMENT||NONE||This single-group open-label dose-finding clinical study will use a before-and-after design, with repeated outpatient evaluations.||||
33715280|NCT05038423|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clustered randomised controlled trial||||
33715281|NCT03594084|||CASE_ONLY||RETROSPECTIVE|||||||
33715282|NCT00002602|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715283|NCT02656121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715284|NCT00398801|||COHORT||PROSPECTIVE|||||||
33715285|NCT06437860|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33715286|NCT03553134|||COHORT||PROSPECTIVE|||||||
33715287|NCT01186679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715288|NCT05304403|||OTHER||PROSPECTIVE|||||||
33715289|NCT05089760|||COHORT||PROSPECTIVE|||||||
33715290|NCT00352144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715291|NCT01885143|||COHORT||PROSPECTIVE|||||||
33715292|NCT01958320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Early routine, mandated PDA treatment versus Conservative treatment only if Rescue criteria are met|f|f|f|t
33715293|NCT03541720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"18F-DA scans will be performed within 4 weeks of standard imaging evaluations, such as CT (computed tomography) and I-123mIBG scanning.~18F-DA will be injected into a vein in the arm or leg, or via central venous access line."||||
33715294|NCT05552950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study and control sprays can only be distinguished by serial numbers, the content of which is not known by the study staff or the subjects.||t|t|f|f
33715295|NCT00850824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33715296|NCT02178228|||COHORT||PROSPECTIVE|||||||
33715297|NCT04358029|||COHORT||OTHER|||||||
33715298|NCT05796297|||CASE_CONTROL||PROSPECTIVE|||||||
33715299|NCT02859207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715300|NCT01366209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715301|NCT01220622|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715302|NCT04508478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715303|NCT00861276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715304|NCT06226753|RANDOMIZED|PARALLEL||TREATMENT||NONE||Allocation: Randomized. Intervention Model: Open labeled, Parallel Assignment, Superiority trial.||||
33715305|NCT01705184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715306|NCT02554669|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33715307|NCT00296478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795080|NCT01787773|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33795081|NCT04818255|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants and care partners who demonstrate intact decisional capacity to engage in PET biomarker disclosure, and who wish to receive the participant's PET results will be provided with education, results, and recommendations for next steps and supportive resources (the intervention). After this intervention, participants will complete follow-up evaluations of mood and anxiety within one week and at six weeks post disclosure.||||
33795082|NCT03934658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795083|NCT04381143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pragmatic designs|t|t|t|t
33795084|NCT02425111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795085|NCT01094405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795086|NCT03863834|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive the treatment and outcome will be followed||||
33795087|NCT00211913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795088|NCT04408937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795089|NCT02994719|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33795090|NCT04349150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795091|NCT06467279|||COHORT||PROSPECTIVE|||||||
33795092|NCT05089097|||COHORT||PROSPECTIVE|||||||
33795093|NCT01583712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715308|NCT03842124|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study is randomized such that the same operator can be doing the extraction with force gauge with or without the force information.||f|f|f|t
33795094|NCT04507945|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Intestinal dysfunction is defined as the damage of intestinal substance and/or function, which leads to digestion, absorption and/or mucosal barrier function.|t|f|t|f
33795095|NCT04911231|||COHORT||PROSPECTIVE|||||||
33795096|NCT02083575|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33795097|NCT04313868|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Dose Escalation Trial||||
33795098|NCT05496907|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795099|NCT00848627|||COHORT||PROSPECTIVE|||||||
33795100|NCT01755897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795101|NCT04071964|||OTHER||PROSPECTIVE|||||||
33795102|NCT03179969|||COHORT||PROSPECTIVE|||||||
34017945|NCT04001101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In an effort to minimize bias, the study will utilize a randomization. The randomization list will be generated by the study biostatistician and provided only to the study personnel who will be responsible for assigning each subject to a cohort of the study.||f|f|t|t
33795103|NCT00349583|RANDOMIZED|PARALLEL||||DOUBLE||||||
34017946|NCT04031781|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34017947|NCT01362166|||CASE_ONLY||CROSS_SECTIONAL|||||||
34017948|NCT03449836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715309|NCT03992859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715310|NCT01728701|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795104|NCT00711126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795105|NCT02566707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795106|NCT00716924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795107|NCT03720210|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single interventional series||||
33795108|NCT04669249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795109|NCT04169399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795110|NCT02491554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33795111|NCT01021410|||COHORT||PROSPECTIVE|||||||
33795112|NCT02512965|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795113|NCT06259058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795114|NCT05745376|NON_RANDOMIZED|PARALLEL||OTHER||NONE||intervention and comparison||||
33795115|NCT00533013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795116|NCT03529396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795117|NCT02173444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795118|NCT04631003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795119|NCT02345018|||COHORT||PROSPECTIVE|||||||
33795120|NCT05263037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, study statisticians and investigators will be blinded to treatment group assignment until after the last subject contributes their primary outcome at week 16. Prior to the primary analysis, the database will be officially locked and signed off by the Sponsor and key stakeholders. Study participants will remain blinded to treatment group assignment until study completion.|"Enrolled participants will be randomized 1:1:1:1 and assigned to one of four treatment arms:~* 56-day skills-based VR program (EaseVRx-8w)~* 56-day skills-based VR program followed by an extended 56-day on-demand period (EaseVRx-8w plus extended on-demand)~* 56-day control (Sham VR)~* 56-day control followed by an extended 56-day on-demand period (Sham VR plus 8w extended on-demand)"|t|f|t|t
33795121|NCT00922220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795122|NCT03347942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be blinded, as they will be instructed to perform the intervention in the control of meal time. This is a limitation of the study design, however, it is expected to minimize the bias by not explaining to the participants what is expected by the intervention of the research. The researcher, who will measure the outcomes, will not know to which group the individual belongs.|Randomized and controlled clinical trial in adults of both sexes, overweight and obese who accepted to participate in the research at the Hospital de Clínicas in the city of Porto Alegre. Individuals will be divided into two paired groups for age, gender and waist diameter. These two groups will be randomized by lottery.|f|f|f|t
33795123|NCT02383108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795124|NCT01371968|NA|SINGLE_GROUP||OTHER||NONE||||||
33795125|NCT02425449|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34017949|NCT05623943|||COHORT||PROSPECTIVE|||||||
34017950|NCT02293330|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
34017951|NCT02328235|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34017952|NCT06109337|||CASE_CONTROL||PROSPECTIVE|||||||
33938752|NCT01609361|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33938753|NCT00877890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795126|NCT03350542|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open label, single arm, multi-center||||
33938754|NCT00141544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938755|NCT06150352|||COHORT||PROSPECTIVE|||||||
33938756|NCT00001242|||COHORT||PROSPECTIVE|||||||
33938757|NCT01519180|||CASE_CONTROL||PROSPECTIVE|||||||
33938758|NCT00682292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017953|NCT01323049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017954|NCT02468622|||CASE_ONLY||PROSPECTIVE|||||||
34017955|NCT04941482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A total of registered 92 stroke patients in Vietnam National Geriatrics Hospital will be included in the study for 6 months. Included patients will be randomized to an intervention group and received the long-term follow-up program or to a control group receiving standard care.|f|f|f|t
33715311|NCT06076161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will use a randomized controlled trial triple blind study design with a pre-post design.|The number of respondents in this study amounted to 32 people. Respondents will be divided into 2 groups, namely the intervention group and the control group. The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.|t|t|t|t
33715312|NCT02891850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715313|NCT03924973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomization will follow that of the IDEA study|single blind|f|f|f|t
33715314|NCT04520737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The participant will be randomized (1:1) using seed, a Stata's random-number generated function. The subjects will be allocated into one of the two groups of the study.||||
33715315|NCT03041402|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33715316|NCT02061033|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715317|NCT01511315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795127|NCT03396692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795128|NCT04466904|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33795129|NCT00092105|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33795130|NCT06360744|NA|SINGLE_GROUP||OTHER||NONE||The design is an open-labelled, non-randomised, parallel group, phase IV study with historical controls.||||
33795131|NCT06374199|RANDOMIZED|PARALLEL||TREATMENT||NONE||Standard 2 group parallel randomized trial study design.||||
33795132|NCT06676345|||COHORT||PROSPECTIVE|||||||
33795133|NCT05800405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795134|NCT03546998|||COHORT||PROSPECTIVE|||||||
33795135|NCT06520345|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multinational, multicenter, prospective, randomized, controlled, open-label Phase 3 study designed to investigate and confirm the benefits and risks associated with 177Lu-TLX591 administered together with SOC compared to SOC alone, in participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have progressed after their first treatment with an ARPI (specifically abiraterone or enzalutamide) or docetaxel administered during either the metastatic castrate-sensitive prostate cancer (mCSPC) or first-line metastatic castrate-resistant prostate cancer (mCRPC) treatment stages.||||
33795136|NCT04864925|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33795137|NCT00590668|||COHORT||PROSPECTIVE|||||||
33795138|NCT00777244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715318|NCT01770626|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33938759|NCT03478592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33938760|NCT01823666|||COHORT||PROSPECTIVE|||||||
33938761|NCT01364948|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33715319|NCT06499077|||COHORT||PROSPECTIVE|||||||
33715320|NCT00326989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715321|NCT06397014|||CASE_CONTROL||RETROSPECTIVE|||||||
33715322|NCT01613729|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938762|NCT00058318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938763|NCT03497390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open label|||||
33938764|NCT05267899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938765|NCT04050540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938766|NCT00722410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938767|NCT00258596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33938768|NCT00967343|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938769|NCT01651676|NA|SINGLE_GROUP||SCREENING||NONE||||||
33938770|NCT05876949|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double Blind||t|t|t|t
33938771|NCT00812591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33938772|NCT01933399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938773|NCT02882451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34017956|NCT06140043|RANDOMIZED|PARALLEL||OTHER||NONE||patients are randomised to one of two groups, either consultation with models on a computer screen or with models shown in augmented reality||||
34017957|NCT05354570|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm Phase II single institution trial.||||
33938774|NCT01092572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017958|NCT04699526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017959|NCT00870649|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34017960|NCT01024686|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34017961|NCT03712982|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34017962|NCT01763814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34017963|NCT00814918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017964|NCT05553899|NA|SINGLE_GROUP||OTHER||NONE||||||
34017965|NCT01196078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017966|NCT00423683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34017967|NCT05020613|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34017968|NCT00231218|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34017969|NCT06305130|||COHORT||RETROSPECTIVE|||||||
34017970|NCT03907384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938775|NCT04704206|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomization will be carried out by means of a simple drawing where an independent researcher, not involved in the intervention or evaluation of the participants, will allocate the participants and it will be hidden using opaque and closed envelopes.|We propose an RCT with 128 children aged 24 to 36 months and their parents. Measures of cognitive, motor and language development through the Bayley III Scale and Auditory Vocabulary Test. For follow-up purposes, parents will be asked to complete the Daily Record Board. Children will be randomly randomized into two groups: Active Interactive Media Group: children will use the media actively (games) and Passive Interactive Media Group: children will use the media passively (content viewing). Both groups will participate in the intervention for 30 minutes, three times a week, for 16 weeks. After this period, children will be reassessed for cognitive, language and fine motor development, receptive vocabulary and analysis of the Daily Record Board.|t|f|f|f
33938776|NCT04011462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938777|NCT05209204|||COHORT||RETROSPECTIVE|||||||
33938778|NCT02029885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938779|NCT03928990|NA|SINGLE_GROUP||OTHER||NONE||||||
33938780|NCT05747768|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34099921|NCT03723525|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34099922|NCT00384150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099923|NCT06492720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099924|NCT02731768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099925|NCT03963622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is also a basket design, which examines a single intervention in multiple disease populations. This basket trial consists of an identical 2-arm mechanical ventilation protocol implemented in two different study populations (patients with COVID-19-induced ARDS, and patients with all ARDS not induced by COVID-19). The protocol and procedures are identical between the two study populations in this basket trial.|f|f|f|t
34099926|NCT06218784|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34099927|NCT06471517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099928|NCT04262427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099929|NCT01728961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099930|NCT05180656|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|N/A - single-arm study.|Participants will participate in two 60-minute virtual yoga classes each week, delivered through videoconferencing for 8 weeks.||||
34099931|NCT04463914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099932|NCT02143778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099933|NCT02775851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099934|NCT03847805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33795139|NCT05430334|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Each participant will attend the lab for five different visits that differ by nicotine flux and/or form in random order. All sessions will be double-blind (Participant / Investigator). The analytical chemist will be providing the investigator with e-liquid in a random order in each session for each participant.|Each participant will attend the lab for five different visits that differ by nicotine flux and/or form in random order.|t|f|t|f
34099935|NCT06140238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938781|NCT00017173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938782|NCT04889937|||OTHER||PROSPECTIVE|||||||
33938783|NCT05419284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Feasibility study||||
33938784|NCT05669573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33938785|NCT05192044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938786|NCT06025591|||CASE_ONLY||PROSPECTIVE|||||||
33938787|NCT01481259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938788|NCT04547127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938789|NCT05953129|||CASE_ONLY||PROSPECTIVE|||||||
33938790|NCT01729611|||COHORT||PROSPECTIVE|||||||
34099936|NCT05848232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099937|NCT00029900|NON_RANDOMIZED|||TREATMENT||NONE||||||
34099938|NCT02605538|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099939|NCT05574244|RANDOMIZED|PARALLEL||OTHER||SINGLE|"* The clinical research assistant will fill-out the electronic case report form (eCRF) randomisation page and perform the randomisation. The site will immediately provide the study identification number for the patient and the allocation group.~* The clinical research assistant will print the result of the randomisation. The printed document will be placed in a sealed envelope that will be stored in the patient's file.~* The surgeon will open the envelope in the operating theatre once the patient has been placed under general anaesthesia.~To prevent breaking the blinding post-operatively, the complete or partial aspect of endoscopic resection will not be mentioned in the surgical report (the patient will be specifically informed of that particular point before signing the informed consent). The complete or partial aspect of surgery will be revealed to patients at the end of follow-up, and in case of any surgical problem (e.g. need for re-intervention) or consent withdrawal."|"Non inferiority Comparative single-blinded (patient) multicentre randomised clinical trial in two parallel groups:~* Group 1: Conventional endoscopic prostatic surgery~* Group 2: Partial surgery preserving the prostatic apex"|t|f|f|f
34099940|NCT06087510|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099941|NCT04558853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099942|NCT00520572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795140|NCT05488366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795141|NCT05025267|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, single-arm, non-randomized, open-label observational study||||
33795142|NCT03903081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795143|NCT02894151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795144|NCT06666725|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33795145|NCT00148369|||||PROSPECTIVE|||||||
34017971|NCT06444945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel designed randomized control trial|f|f|t|f
34017972|NCT05233930|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, double-arms, parallel, open-label study.||||
34017973|NCT02161250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34017974|NCT01806818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34017975|NCT01247246|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34017976|NCT00057083|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34017977|NCT00044109||||TREATMENT||||||||
34017978|NCT05818618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes|The main aim of the study is to analyze the impact of topical clobetasol on gingival crevicular fluid miRNAs expression in subjects affected by oral lichen planus.|t|f|t|f
34017979|NCT04469010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants will receive either iron and vitamin C, iron alone or placebo for a period of 16 weeks to consume daily|t|f|t|t
34017980|NCT02951442|NA|SINGLE_GROUP||OTHER||NONE||||||
34017981|NCT04628520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715323|NCT05040321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind; the participants, care provider, investigators and outcome assessors are blinded.|"We will use an IRB approved structured telephone screen to ask about basic demographics, major study required inclusion/exclusion criteria, and questions regarding MR contraindications. Those who do not have major exclusionary conditions identified during the telephone screening and who are interested in participating will be invited for an in-person visit. During the in-person screening visit, informed consent will be obtained, and subjects will undergo screening neuropsychological testing and medical evaluation.~Subjects will come back after their initial screening visit for 2 more screening visits before they are found eligible and go through Baseline visits, also known as Day 0. Subjects will receive MIB-626 or placebo twice a day for 90 days. There will be one more visit, known as the washout period, at day 105. The total completion of all of the study visits will be 8 visits, for 150 days."|t|t|t|t
33715324|NCT04970888|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This clinical trial is a single-blinded study. Research personnel performing the outcome assessments and investigators will be blinded to group allocation.|parallel assignment (1:1:1)|f|f|t|t
33715325|NCT00231725|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33715326|NCT04348929|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33715327|NCT02187250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795146|NCT02032849|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33795147|NCT00813904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938791|NCT04102657|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33938792|NCT05093244|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 2:1 ratio to either the SeQuent Please ReX or POBA arms, stratified by the presence or absence of baseline diabetes mellitus and acute coronary syndrome (ACS) vs. non-ACS presentation.||||
33938793|NCT03634852|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938794|NCT02689089|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938795|NCT04775966|||COHORT||RETROSPECTIVE|||||||
33938796|NCT00761033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938797|NCT02434250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938798|NCT02774863|||CASE_CONTROL||PROSPECTIVE|||||||
33938799|NCT04583176|||COHORT||PROSPECTIVE|||||||
33938800|NCT03460665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33938801|NCT02117973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938802|NCT06481605|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot, single-center, interventional, prospective case-series study.||||
33938803|NCT05049122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938804|NCT02385292|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33938805|NCT01351415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938806|NCT03427762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938807|NCT01199640|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33938808|NCT05301140|||CASE_ONLY||PROSPECTIVE|||||||
33938809|NCT06147544|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33938810|NCT03491475|||COHORT||CROSS_SECTIONAL|||||||
33938811|NCT05801185|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will perform a 5-day unloading intervention using the ULLS model. Short-length crutches, aided by handgrip and forearm support distal to the elbow will be used to assist in any upright or ambulatory activity. One foot (randomized in a counterbalance manner) will be equipped with a shoe having a 10-cm thick sole, which permits the unloaded limb to move passively about the hip joint while adopting a near straight position.||||
33938812|NCT00003684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33938813|NCT03099512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938814|NCT05433233|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938815|NCT04383665|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33938816|NCT02281604|||COHORT||PROSPECTIVE|||||||
33938817|NCT06220227|||CASE_ONLY||RETROSPECTIVE|||||||
33938818|NCT02056665|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33938819|NCT01924260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938820|NCT02699840|||COHORT||PROSPECTIVE|||||||
33938821|NCT02365272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938822|NCT05788718|||COHORT||PROSPECTIVE|||||||
33938823|NCT00498927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938824|NCT01495689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938825|NCT00099606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938826|NCT03552809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938827|NCT04049344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938828|NCT01060150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938829|NCT02428387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33938830|NCT04906733|||COHORT||PROSPECTIVE|||||||
33938831|NCT02030457|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33938832|NCT00276224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938833|NCT01118039||||TREATMENT||NONE||||||
33938834|NCT01775995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938835|NCT03894501|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm randomized controlled trial.||||
34099943|NCT05882331|NA|SINGLE_GROUP||TREATMENT||NONE||ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.||||
34099944|NCT01133977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099945|NCT01249287|||CASE_CONTROL||PROSPECTIVE|||||||
34099946|NCT05826158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099947|NCT00597792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099948|NCT04391816|||OTHER||PROSPECTIVE|||||||
34099949|NCT02149797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099950|NCT06056024|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099951|NCT06010108|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||intervention pilot||||
34099952|NCT06580769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099953|NCT05978414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Women will be randomly assigned to a test and control group according to their disease. The person performing the visceral tests and techniques will not know which group the woman belongs to. The evaluator of the results will not know whether they are the group with or without visceral techniques.|Description of the study group: The study will qualify women, aged from 18 to 60 years old admitted to the Sredz Heart Hospital in Sroda Wielkopolska, gynecology and obstetrics department. The planned study group is 200 women after surgical treatment (100 with prolapse of reproductive organs and 100 with a diagnosis of endometriosis). Both conditions are planned to be randomly divided into: a subgroup undergoing physiotherapy intervention and a subgroup without physiotherapy intervention. Women who do not consent to physiotherapeutic intervention will be included in the control group.|t|f|t|t
34099954|NCT05623605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded|Randomized controlled trial|t|f|f|f
34099955|NCT06687512|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-Blind Study||t|f|t|f
34099956|NCT03076164|NA|SINGLE_GROUP||TREATMENT||NONE||Trametinib 1.5mg + Erlotinib 75mg||||
34099957|NCT03978208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Overencapsulation of study drug tablets||t|t|t|t
34099958|NCT03522246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
34099959|NCT06050512|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34099960|NCT05633667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099961|NCT01553500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34099962|NCT05092503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34099963|NCT05676944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099964|NCT01704560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34099965|NCT02801604|||OTHER||PROSPECTIVE|||||||
34099966|NCT05414812|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Interrupted time series design||||
33715328|NCT05236569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The allocation sequence was generated with a computer by an analyst. The allocation sequence was concealed from the investigators, care provider, outcomes assessor, and subjects.|Eligible subjects were randomized to receive either 10 mg of intradermal tranexamic acid injection or placebo on one side of the face with 1:1 ratio. The allocation sequence was generated with a computer by an analyst.|t|t|t|t
33715329|NCT03241342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, placebo-controlled, parallel design, randomized, multicenter, Phase 2 study consisting of the following periods: screening period, treatment period, and follow-up period.|t|f|t|f
33715330|NCT01782144|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715331|NCT06481332|||COHORT||RETROSPECTIVE|||||||
33715332|NCT05060055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The present study was designed as a prospective, controlled clinical trial with a parallel-group design and balanced randomization (ratio 1:1)|f|f|t|f
33715333|NCT01443650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715334|NCT05168488|NA|SINGLE_GROUP||OTHER||NONE||||||
33715335|NCT01503151|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33938836|NCT03316898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938837|NCT06371989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33938838|NCT02736942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938839|NCT00325949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938840|NCT00201058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938841|NCT03534466|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment All subjects were divided into two groups: intervention group A (treadmill intervention + routine physical rehabilitation therapy) and positive control group (receiving routine physical rehabilitation therapy only).||||
33938842|NCT03099018|||CASE_ONLY||PROSPECTIVE|||||||
33938843|NCT00065715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938844|NCT01108263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938845|NCT04697888|NA|SINGLE_GROUP||TREATMENT||NONE||This is a compassionate use protocol for patients with PNALD who have failed traditional treatment to receive Omegaven through an IND.||||
33938846|NCT05232344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938847|NCT01157585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938848|NCT00281528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938849|NCT02813317|||COHORT||PROSPECTIVE|||||||
33938850|NCT02798172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938851|NCT01795716|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938852|NCT04102410|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938853|NCT04728789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938854|NCT05904041|||OTHER||CROSS_SECTIONAL|||||||
33938855|NCT02002637|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33938856|NCT03847272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938857|NCT05750615|||OTHER||PROSPECTIVE|||||||
34099967|NCT06687954|||CASE_CONTROL||PROSPECTIVE|||||||
33938858|NCT00523744|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099968|NCT06686004|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||Active comparator: orange carrot 100g or 300g Placebo comparator: baseline - before ingestion|f|f|t|f
34099969|NCT01341938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099970|NCT01392495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099971|NCT06446362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This study employs a double-blind masking approach. Participants, care providers, and investigators are blinded to intervention allocation. The outcomes assessor, responsible for evaluating primary and secondary outcomes, is also blinded to group assignments. This minimizes bias and ensures objective assessment of breastfeeding self-efficacy, attitudes, and problems. Masking is maintained through coded intervention materials and separate teams for intervention delivery and outcome assessment.|This randomized controlled trial (RCT) evaluates the impact of a client health behavior interaction model-based breastfeeding support program on primipara mothers. Participants are randomly assigned to either the intervention group, which receives structured support including educational sessions, motivational interviews, and follow-up via WhatsApp, or the control group, which receives standard care. The study focuses on measuring changes in breastfeeding self-efficacy, attitudes, and problems in the first six months postpartum.|t|t|t|t
34099972|NCT02631694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34099973|NCT06362200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099974|NCT05280314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Multi-arm, Two indications, One Cohort SCCHN 2 Cohorts melanoma (1 cohort randomized and one cohort not randomized)||||
34099975|NCT02469961|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34099976|NCT03336658|||COHORT||PROSPECTIVE|||||||
34099977|NCT05765344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938859|NCT04184466|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This study was blinded for Sponsor, investigators and analytical laboratory|two-way crossover|f|f|f|t
33938860|NCT02462200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938861|NCT02143336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34099978|NCT00480311|||||CROSS_SECTIONAL|||||||
34099979|NCT05799950|||COHORT||CROSS_SECTIONAL|||||||
34099980|NCT05344274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34099981|NCT03180138|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Study team members are blinded to group assignments.|Single blinded prospective study|f|f|t|f
34099982|NCT01029197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099983|NCT06249672|||COHORT||PROSPECTIVE|||||||
34099984|NCT04187690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34099985|NCT06353932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33938862|NCT00278486|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938863|NCT03516227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33938864|NCT03131258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938865|NCT02990065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33938866|NCT00630318|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938867|NCT03698370|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33938868|NCT03272009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938869|NCT03281356|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33938870|NCT05159063|||COHORT||PROSPECTIVE|||||||
33938871|NCT01277666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938872|NCT03792412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|pseudonymity|randomised cohort study with control group|t|f|f|f
33938873|NCT02998931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938874|NCT00180349|||COHORT||PROSPECTIVE|||||||
33715336|NCT05090137|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33715337|NCT01723592|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33715338|NCT01214811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715339|NCT03402386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715340|NCT03283592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blind (outcome assessor)|2-arm, parallel assignment|f|f|f|t
33715341|NCT03182088|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715342|NCT01727453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715343|NCT06124144|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 design for ascending doses||||
33715344|NCT05486858|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715345|NCT02064868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715346|NCT01113801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715347|NCT03211416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715348|NCT01648205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Matching placebo and ranolazine pills were used. Patients were blinded regarding administration of medication. ECG Core Lab reading ECGs was blinded regarding drug assignment.|Patients will receive placebo for 1 month and subsequently ranolazine 1000mg twice a day for 5 months.|t|f|f|t
33715349|NCT06471816|RANDOMIZED|PARALLEL||PREVENTION||NONE||Kindergartens from three different organisations are involved. The kindergartens are randomized to the implementation or control condition within each organisation (block randomization).||||
33938875|NCT01739868|NA|SINGLE_GROUP||||NONE||||||
33938876|NCT00427739|||COHORT||PROSPECTIVE|||||||
33938877|NCT03123549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938878|NCT05591573|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|"To ensure blinding of participants and researchers, a randomisation list will be produced using Statistical Package for the Social Sciences (SPSS) software by an employee of Swansea University, who is not actively involved in the study.~Blinding will be maintained by the use of encoded beverages to ensure participants, researchers, and the data analysers are unaware of the intervention. The blind will be broken only after statistical analysis of the data is complete."|In a randomized, double-blind, and counterbalanced order (AB/BA), participants will receive either a high glycemic index or low glycemic index pre-bed drink. After a 1-week washout period, participants will consume the alternate drink.|t|f|t|t
33938879|NCT01396486|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33938880|NCT03619369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938881|NCT04312061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715350|NCT02525341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33715351|NCT04084301|RANDOMIZED|PARALLEL||PREVENTION||NONE||To compare normal (2.4 L/min/m2) and high (2.9 L/min/m2) cardiopulmonary bypass flow during cardiac surgery||||
33715352|NCT00632242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715353|NCT05717374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation|Prospective, randomized, double blind study|t|f|f|t
33715354|NCT00003081||||TREATMENT||||||||
33715355|NCT03627533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||electroacupuncture versus sham electroacupuncture|t|f|t|t
33715356|NCT04981743|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled Parallel Open label Randomized Clinical Trial .||||
33715357|NCT02289898|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715358|NCT01959789|||CASE_CONTROL||PROSPECTIVE|||||||
33938882|NCT01937949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938883|NCT03065166|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33938884|NCT05892302|RANDOMIZED|PARALLEL||OTHER||NONE|Only the statistician will be blinded to study group.|||||
33938885|NCT02263742|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33938886|NCT01315873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938887|NCT05051306|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938888|NCT04303091|NA|SINGLE_GROUP||OTHER||NONE||Single group feasibility study||||
33938889|NCT03287726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938890|NCT01542632|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33938891|NCT01431794|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938892|NCT04258761|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multi-center, open label, single ascending dose comparison.||||
33938893|NCT03278210|||CASE_CONTROL||PROSPECTIVE|||||||
33938894|NCT00388128|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33938895|NCT02289144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017982|NCT00754403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34017983|NCT04701112|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The patient is not aware of the pacing modality used for each measurement. The outcomes assessment will be performed blinded to pacing modality.||t|f|f|t
34017984|NCT02935166|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34017985|NCT02737982|||COHORT||PROSPECTIVE|||||||
34017986|NCT01713049|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34017987|NCT06263062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34017988|NCT04677296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized double blinded|t|t|t|f
34017989|NCT01681602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34017990|NCT00763438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017991|NCT02646930|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34017992|NCT01032018|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34017993|NCT00446745|||COHORT||PROSPECTIVE|||||||
34017994|NCT00943462|||CASE_ONLY||PROSPECTIVE|||||||
34017995|NCT00507286|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34017996|NCT03726281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34017997|NCT05402774|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|At this stage, the patients were divided into two groups: POCUS was applied to patients in the POCUS group after primary clinical evaluation. This procedure was performed in the first hour after the primary clinical evaluations of the patients by evaluating the predetermined parameters in the study form for hepatobiliary, renal, and upper and lower abdominal findings. All processes and results for patients in the control group were followed without any intervention and the results were recorded in the study form.|a randomized, prospective, controlled study|f|t|f|t
34017998|NCT04737070|||COHORT||RETROSPECTIVE|||||||
34017999|NCT04995705|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomised waitlist control model.||||
34018000|NCT02060474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018001|NCT01580813|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34018002|NCT04414761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018003|NCT01295294|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34018004|NCT04928274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two blinded operators have carried out the assessment of bone height changes in order to have accurate results.||f|f|f|t
34018005|NCT05084508|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Observer-blind study. Recipients and study evaluators will be unaware of vaccine administered.||t|f|t|t
34018006|NCT04171271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018007|NCT06116318|||COHORT||PROSPECTIVE|||||||
34018008|NCT03858595|RANDOMIZED|PARALLEL||PREVENTION||NONE|Neither the participants nor the investigators or the assessors of outcomes can be blinded to allocation because of the obvious nature and the delivery procedure of the interventions which investigators are going to provide and thus, investigators are obliged to make the RCT non-blinded/open. However, it is prudent to mention that the outcomes of the trial are of objective nature. Furthermore, the randomization, as well as statistical analysis, will be carried out by someone unconnected to the recruitment process.|This study is designed as a prospective, two-arm, parallel, and open-label randomized controlled external pilot trial. Eligible participants (high-risk pregnant women) will be individually randomized 1:1 to the intervention arm who will regularly monitor their nutritional status (rate of gestational weight gain) using a digital weighing scale and continuously self-monitor their blood pressure using a wearable device (Salu Health Gauge) from 20 weeks of gestation up to termination of to pregnancy alongside conventional antenatal and postnatal care or the control arm who will receive conventional antenatal and postnatal care only.||||
34018009|NCT04784910|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018010|NCT02459496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018011|NCT03227614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34018012|NCT04562480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018013|NCT01692444|||CASE_CONTROL||PROSPECTIVE|||||||
34025492|NCT03483363|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34099986|NCT01642849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34099987|NCT00432991|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025493|NCT03747510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025494|NCT02771535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34099988|NCT02385487|||CASE_CONTROL||PROSPECTIVE|||||||
34025495|NCT06350916|||CASE_CONTROL||PROSPECTIVE|||||||
34099989|NCT02168439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34025496|NCT00513591|||COHORT||PROSPECTIVE|||||||
34099990|NCT04525183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34099991|NCT06000904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715359|NCT03024450|||COHORT||PROSPECTIVE|||||||
34025497|NCT05096832|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025498|NCT06039345|||CASE_ONLY||PROSPECTIVE|||||||
34025499|NCT05772247|||COHORT||PROSPECTIVE|||||||
34025500|NCT05168683|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Subjects in each study Part participate in all treatment arms of that Part.||||
34025501|NCT04584762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, randomized, double-blind, parallel group, sham-controlled|t|t|t|f
34025502|NCT00695305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025503|NCT01649960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025504|NCT03580486|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34025505|NCT05365971|||COHORT||PROSPECTIVE|||||||
33715360|NCT03866005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After enrollment by the study Primary Investigator, a single retinal specialist from each site, masked to subjects' supplement status, will deliver all treatments per his/her usual protocol for treatment of CI-DME based on individual examination findings. Supplements and identically-appearing placebo will be provided by ZeaVision, LLC of Chesterfield, MO.|This will be an investigator initiated, single-clinic/two location, double-blinded prospective study of 150 adult subjects with newly diagnosed CI-DME receiving anti-VEGF injections, with add-on laser and/or steroid as required on follow-up examination (Standard Treatment) versus standard treatment plus adjunctive DiVFuSS supplementation in one of two doses (2 softgels per day - Supplement Treatment Group 1; and 4 softgels per day - Supplement Treatment Group 2). Subjects will be identified and enrolled with informed consent from two retinal specialty practice sites in Washington State (Sound Retina; Tacoma, WA and Olympia, WA). Subjects will be randomized to Standard Treatment; Supplement Treatment Group 1, or Supplement Treatment Group 2.|t|t|t|t
33715361|NCT04912947|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33715362|NCT03003936|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33715363|NCT06495047|||CASE_ONLY||CROSS_SECTIONAL|||||||
33715364|NCT02216188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715365|NCT01585194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715366|NCT00603993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715367|NCT01169974|||COHORT||PROSPECTIVE|||||||
33715368|NCT03918590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1: Placebo (Preservative free artificial tears) Group 2: Nepefanac 0.3% suspension Group 3: Patch for 2 hours|t|f|f|t
33715369|NCT06155409|||COHORT||OTHER|||||||
33715370|NCT02638727|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33715371|NCT03070782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715372|NCT05733104|||CASE_ONLY||PROSPECTIVE|||||||
33938896|NCT04835389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects and investigators (including outcomes assessment) will be blinded to the treatment arm that is assigned.|Randomized, Placebo-Controlled, Double-Blinded|t|f|t|t
33938897|NCT05350800|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33938898|NCT03962413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a prospective randomized comparative clinical study.|t|f|f|f
33938899|NCT03351140|||COHORT||PROSPECTIVE|||||||
33938900|NCT00644033|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33938901|NCT04236440|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Part A: Randomized, double-blind Part B: Open-label Part C: Open-label|Part A: placebo-controlled 2-way crossover Part B: fixed single sequence Part C: single group, single dose|t|t|t|t
33938902|NCT05010291|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34025506|NCT04604886|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33938903|NCT04848129|||CASE_ONLY||RETROSPECTIVE|||||||
33938904|NCT04383743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938905|NCT06272279|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant will be connected to the stimulation device(s) but will not know if it has been turned on during each trial. In addition, the person analyzing the outcome data will not be aware of the stimulation status of the participant.|Semi-blinded, randomized block entry design, crossover intervention study.|t|f|f|t
33938906|NCT00025090|RANDOMIZED|||TREATMENT||NONE||||||
34025507|NCT06552013|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025508|NCT01422187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025509|NCT02339662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025510|NCT05911880|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with established diagnosis of Rheumatoid Arthritis by the ACR 1987 or ACR/EULAR 2010 criteria, with mild to moderate disease activity measured by DAS-28 PCR (2.6-5.1), with personalized nutritional intervention, isocaloric and with modification of the percentage of proteins from plant origin (80%), for 14 days.||||
34025511|NCT01635283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025512|NCT00303459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025513|NCT04774848|RANDOMIZED|PARALLEL||TREATMENT||NONE||Infants stratified by presence of intrathoracic liver (yes/no) and are randomized to either high frequency jet ventilator or high frequency oscillating ventilator in a sequential 1:1 manner||||
34025514|NCT06168110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025515|NCT00782405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025516|NCT01406444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025517|NCT02305160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025518|NCT04502212|NA|SINGLE_GROUP||OTHER||NONE||||||
34025519|NCT01386983|||COHORT||RETROSPECTIVE|||||||
34025520|NCT00902317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025521|NCT06201156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018014|NCT04051463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The active drug and placebo will be provided in 2.5 ml bottles identical, in appearance. Only the designated dosing coordinator is unmasked.||t|f|t|t
34018015|NCT05634850|||COHORT||PROSPECTIVE|||||||
34018016|NCT00466453|RANDOMIZED|CROSSOVER||||NONE||||||
34018017|NCT02550730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34018018|NCT04641065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34018019|NCT00425334|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34018020|NCT02938403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018021|NCT04057469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018022|NCT01401049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018023|NCT01175031|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018024|NCT00140621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34099992|NCT04713046|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:1, 2-arm open-label trial||||
34018025|NCT03025490|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34018026|NCT04100174|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018027|NCT01584843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018028|NCT06167720|||COHORT||RETROSPECTIVE|||||||
34018029|NCT05808153|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Model description: Identification, evaluation and validation of new clinical, biological and imaging biomarkers (MRI without contrast product and PET with intravenous administration of a radiotracer) on a prospective cohort of carriers of the mutation responsible for Huntington's disease and healthy volunteers.||||
34018030|NCT00324480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018031|NCT04914858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34018032|NCT02865252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018033|NCT01956877|||COHORT||PROSPECTIVE|||||||
34018034|NCT00106340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018035|NCT00973375|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018036|NCT05376670|||OTHER||OTHER|||||||
34018037|NCT02528487|||CASE_CONTROL||PROSPECTIVE|||||||
34018038|NCT04192279|||COHORT||PROSPECTIVE|||||||
34018039|NCT01622686|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34018040|NCT04467268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blood samples outcome assessor was blinded to group allocation.|Randomized controlled trial.|f|f|f|t
34018041|NCT03899311|||COHORT||PROSPECTIVE|||||||
34018042|NCT05885191|NA|SINGLE_GROUP||OTHER||NONE||||||
34018043|NCT02833766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018044|NCT04383236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All clinical outcome variables are recorded by a single investigator whom is blinded to the treatment modalities|The study is a randomized, controlled, clinical trial|f|f|f|t
34018045|NCT05227300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A statistician will provide a two-product randomization scheme which will randomize each of the 40 subjects on the order of their entry into the study. The research assistants will be aware of and document this scheme, but the student researcher/PI will not know what type of anesthetic will be administered.|This study will be a single-center, controlled, randomized, double-blind (provider and subject), 2 treatment, 1 period, parallel study|t|t|t|f
34018046|NCT04072380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018047|NCT03169036|||COHORT||OTHER|||||||
34018048|NCT00749736|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34099993|NCT00969085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34099994|NCT00535899|||||PROSPECTIVE|||||||
34099995|NCT00452530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34099996|NCT05460000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34099997|NCT06438107|||COHORT||PROSPECTIVE|||||||
34099998|NCT01091415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34099999|NCT02573441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100000|NCT01431573|NA|SINGLE_GROUP||TREATMENT||NONE|"This is an open label study so all participants know what the treatment is."|||||
34100001|NCT01899378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34100002|NCT06100172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"On the day of surgery, subjects will be randomized 1:1 to either the active stimulation group or the sham group. In the sham group, the device looks like the active device, but it will not deliver any electrical stimulation to the vagus or trigeminal nerves.~Both groups will receive the SOC for post-operative pain management for lumbar fusion patients."|Randomized, double blind, sham controlled.|t|f|t|f
34100003|NCT05656976|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized Controlled Trial (RCT)||||
34100004|NCT02842281|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34100005|NCT00965991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100006|NCT04172064|||COHORT||PROSPECTIVE|||||||
33715373|NCT00647790|||COHORT||PROSPECTIVE|||||||
33715374|NCT03152851|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33715375|NCT04101825|NA|SINGLE_GROUP||OTHER||NONE||This trial is open label, multi-center, non-randomized single group.||||
33715376|NCT04565860|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor)||t|f|t|t
34018049|NCT06398821|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34018050|NCT05900557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm study performing subdural ECoG monitoring to assess for presence or absence of spreading depolarization.||||
34018051|NCT00630890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018052|NCT01660191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018053|NCT05031689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018054|NCT03274674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Blinded, Parallel group, Randomized Controlled Trial|f|f|t|t
34018055|NCT00129051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018056|NCT02056392|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34018057|NCT05832528|NA|SINGLE_GROUP||TREATMENT||NONE||Dietary intervention trial||||
34018058|NCT00567866|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34018059|NCT00977730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018060|NCT05532059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100007|NCT06558279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100008|NCT05042466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Participant, Providers|Phase 1, 8 week time frame, M/W/F 0.15 to 0.33G, tailored dose of non synthesized psilocybin. A Monthly dose of 1 gram to 1.5 grams psilocybin. QC, controllers, Psychiatrist, LCPC Therapist, Plant Medicine On Boarding Specialist.|t|t|f|t
34100009|NCT04628182|||COHORT||PROSPECTIVE|||||||
34100010|NCT00337688|||CASE_CONTROL||PROSPECTIVE|||||||
34100011|NCT03479684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100012|NCT05813483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100013|NCT06390371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100014|NCT03638271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective manner study will include 50 patients of both sex and different age with any type of cardiomyopathy diagnosed clinically or by Doppler echocardiography, will undergo cardiac magnetic resonance.||||
34100015|NCT03120507|||COHORT||PROSPECTIVE|||||||
34100016|NCT03199365|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100017|NCT03056430|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Repeated-measures, 2 groups \* 2 timepoints||||
34100018|NCT01950390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100019|NCT06148285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938907|NCT06481410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study implements blinding for the outcome assessor.|This is a prospective, randomized, controlled, single-blind study.|f|f|f|t
33938908|NCT06496789|NA|SINGLE_GROUP||TREATMENT||NONE||Drug：Serplulimab+Oxaliplatin+S-1||||
33938909|NCT01276795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33938910|NCT01109589|||COHORT||RETROSPECTIVE|||||||
33938911|NCT02692976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715377|NCT05077397|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33938912|NCT03042663|NA|SINGLE_GROUP||PREVENTION||NONE||The study will recruit septic shock patients with hemodynamic instability on vasopressor support and on direct arterial blood pressure monitoring through a radial arterial cannula that is not older than 12 hours.||||
33938913|NCT04839913|||CASE_ONLY||RETROSPECTIVE|||||||
33938914|NCT05972343|||COHORT||PROSPECTIVE|||||||
33715378|NCT04232124|NA|SINGLE_GROUP||TREATMENT||NONE||Execute a smaller version of the LA Barbershop BP Study through the new Nashville network as the test case for: A) recruiting regular patrons with uncontrolled HTN, B) conducting a research protocol and evaluating a HTN intervention; and C) creating a local registry of potential subjects as platform for enrolling black men in future research studies.||||
33715379|NCT03755102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715380|NCT04613063|||CASE_ONLY||RETROSPECTIVE|||||||
33715381|NCT03589443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715382|NCT03585608|||COHORT||PROSPECTIVE|||||||
33715383|NCT02965547|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33715384|NCT05044598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715385|NCT03023475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715386|NCT05426577|||CASE_ONLY||PROSPECTIVE|||||||
33715387|NCT03934931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33938915|NCT01696708|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33938916|NCT04071639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Case group use Deutetrabenazine，Risperidone，Zoloft and Idebenone(depending on demand and symptom).~Control group use Haloperidol，Risperidone，Zoloft and Idebenone(depending on demand and symptom)."||||
33938917|NCT02283229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33938918|NCT04270890|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33938919|NCT03225027|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||One experimental procedure proposed to three groups of participants||||
33938920|NCT01526928|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33938921|NCT02975206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938922|NCT04265027|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33938923|NCT03700424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study will be performed double-blind||t|t|t|t
33938924|NCT05072834|||COHORT||PROSPECTIVE|||||||
33938925|NCT00472823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938926|NCT02663206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938927|NCT02237573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938928|NCT04027842|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33938929|NCT04283773|||CASE_CONTROL||RETROSPECTIVE|||||||
33938930|NCT04026633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33938931|NCT00599144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938932|NCT01987609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938933|NCT01577927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938934|NCT02261311|||COHORT||PROSPECTIVE|||||||
33938935|NCT01641029|||CASE_ONLY||PROSPECTIVE|||||||
33938936|NCT04890782|||CASE_CONTROL||PROSPECTIVE|||||||
33938937|NCT04700891|NA|SINGLE_GROUP||SCREENING||NONE||||||
33938938|NCT03362723|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33938939|NCT02814799|||||PROSPECTIVE|||||||
33938940|NCT05701475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Since the disinfection protocol has to be performed by the patient and care provider, this can not be blinded. However, the laboratory staff will not know which treatment arm the patient was allocated to when assessing the bacterial cultures.|Randomised controlled trial|f|f|f|t
33938941|NCT05960656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects will be randomly assigned 2:1 active drug:placebo.|A randomized controlled 4 arm clinical trial comprised of 5 studies|t|f|f|f
33938942|NCT03267511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33938943|NCT02455544|||COHORT||PROSPECTIVE|||||||
33938944|NCT03703661|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled trial||||
33938945|NCT05505201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795148|NCT06182397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The operator performing the procedure will not be blinded. The treating physician during subsequent follow-up of the patient will be different from the Operator, and the treating physician will be blinded. The Study Coordinator will be unblinded.~The technologists performing follow-up ultrasound scans, the Clinical Events Committee, and core laboratories will be blinded, as will be the participants, and treating team. In cases of emergencies, the treating physician has the responsibility of determining if unblinding the participant's treatment is warranted, with the patient's safety as the first consideration in making such a decision. If the treating physician decides that unblinding is warranted, the investigator will contact Concept Medical to release information on the treatment allocation."||t|t|f|t
33938946|NCT04374526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938947|NCT06205979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938948|NCT01878786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938949|NCT04254575|||CASE_ONLY||PROSPECTIVE|||||||
33938950|NCT04563130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795149|NCT05674357|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|There will be two groups in this study- one is patient participants (n=100) and the other is therapist participants (n=15). Therapist participants will deliver evidence-based therapy treatments to patients participants. Outcomes in each group will not be compared to each other.|There will be two groups in this study- one is patient participants (n=100) and the other is therapist participants (n=15). Therapist participants will deliver evidence-based therapy treatments to patients participants. Outcomes in each group will not be compared to each other.||||
33938951|NCT02570581|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34100020|NCT05380596|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is an unblinded randomized clinical trial comparing the outcomes between a group that will receive a Pharmaceutical Telecare intervention (pharmaceutical consultation via telephone), and the control group that will receive only the usual care. All steps of this study will follow the recommendations of the CONSORT guideline for clinical trials (SCHULZ, 2010)||||
34100021|NCT03845673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100022|NCT02370693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100023|NCT04928066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100024|NCT04634903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized to the Behavioral Activation SSI (BA-SSI), Growth Mindset SSI (GM-SSI), or the Supportive Therapy SSI (ST-SSI; each 30 minutes in length).|t|f|t|f
34100025|NCT06478940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100026|NCT01275937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795150|NCT03201562|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33795151|NCT03690037|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not Blinded|A Phase IV, single centred, open label, parallel group, randomised controlled trial||||
33795152|NCT01936792|||CASE_CONTROL||PROSPECTIVE|||||||
33795153|NCT01304277|NA|SINGLE_GROUP||OTHER||NONE||||||
33795154|NCT02578615|||COHORT||PROSPECTIVE|||||||
33795155|NCT05318885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled study||||
33795156|NCT01048931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795157|NCT03703518|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||cross-over pilot study|f|f|f|t
33795158|NCT06612762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33795159|NCT05297864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795160|NCT05706168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors evaluating the cognitive and motor function will be blinded of the outcomes from duplex carotid ultrasound and transcranial Doppler ultrasound and vice versa.|The post-stroke chronic patients will be randomly assigned into three groups consisting of a non- interventional (control group) and two aerobic exercise interventional groups (treadmill and cycle ergometer). The enrollment for the three groups will be concurrent for the whole duration of the study. The quantitative data on the large extracranial and intracranial cerebral arteries haemodynamic and morphological features as determined by duplex carotid ultrasound and transcranial Doppler ultrasound, and the quantitative data on the cognitive and motor function of the patients will be collected and analysed at 3 time periods (baseline (before intervention), 6 weeks, and 12 weeks)|f|f|f|t
33795161|NCT01379014|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33795162|NCT00715494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This was a single-site, feasibility, pilot, randomized trial of 21 general medical/surgical intensive care unit survivors (8 controls and 13 intervention patients) with either cognitive or functional impairment at hospital discharge. After discharge, study controls received usual care (sporadic rehabilitation), whereas intervention patients received a combination of in-home cognitive, physical, and functional rehabilitation over a 3-month period via a social worker or master's level psychology technician utilizing telemedicine to allow specialized multidisciplinary treatment. Interventions over 12 wks included six in-person visits for cognitive rehabilitation and six televisits for physical/functional rehabilitation.|f|f|f|t
33795163|NCT03830736|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||a randomized blinded cross-over study|t|f|f|f
33795164|NCT06553911|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33795165|NCT00126997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33938952|NCT00626795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33938953|NCT05644639|||CASE_ONLY||PROSPECTIVE|||||||
34018061|NCT00048204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018062|NCT03035721|RANDOMIZED|PARALLEL||OTHER||SINGLE|Anthropometric and body composition measurements were performed by three medical investigators who were blinded to allocated treatment.||f|f|f|t
34018063|NCT02178280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018064|NCT04060316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018065|NCT02468063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018066|NCT00413686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018067|NCT04749472|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants wore different sling in a randomized order.||||
34100027|NCT03566550|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100028|NCT06406816|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100029|NCT03849612|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34100030|NCT05597761|||COHORT||PROSPECTIVE|||||||
34100031|NCT02628067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018068|NCT03776838|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization into group SoC + NOL vs SoC will be done prior to the entrance in the OR, the day of the surgery|2 groups of patients. Randomization into group SoC + NOL vs SoC according to randomization list for a total number of 70 patients|t|t|f|t
34018069|NCT02287909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795166|NCT01686906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795167|NCT00833365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100032|NCT00783848|||COHORT||PROSPECTIVE|||||||
33795168|NCT02139046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795169|NCT06092203|||CASE_CONTROL||PROSPECTIVE|||||||
33795170|NCT00977223|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33795171|NCT05174065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33938954|NCT03097562|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|"Consecutive patients who underwent cataract surgery using one of the following three types of surgical wound will be compared:~1. Catalys - Initial wound parameters~2. Catalys - Revised wound parameters~3. Standard manual technique (MT control group)"|Post market study (Phase IV)||||
33938955|NCT00062842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938956|NCT01524094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938957|NCT04638036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33938958|NCT03371004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938959|NCT03706144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"The primary outcomes are standardized, computerized assessments.~Please note that the primary outcome is on the individual student level, while the randomization and participant number below is per teacher.~Each teacher participates with 1-4 classes of on average 25 students"|"This is a randomized trial with two arms. Teachers (and their respective classes of students) have been randomized into one of two groups:~1. Participating in the adaptive, online Prodigy Math Training~2. treatment as usual (TAU) - classic math instruction in school"|f|f|f|t
33938960|NCT05980390|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33938961|NCT03436095|||COHORT||PROSPECTIVE|||||||
33938962|NCT02993289|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34018070|NCT04648332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018071|NCT05846867|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018072|NCT01280409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018073|NCT03253523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018074|NCT03583632|||CASE_CONTROL||OTHER|||||||
34018075|NCT00004800|RANDOMIZED|||PREVENTION||DOUBLE||||||
34018076|NCT02772848|||COHORT||PROSPECTIVE|||||||
34018077|NCT00548171|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018078|NCT02331368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018079|NCT00319982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018080|NCT00299936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018081|NCT04269564|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34018082|NCT06458842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018083|NCT01270737|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34018084|NCT06425315|||COHORT||RETROSPECTIVE|||||||
34018085|NCT02745886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018086|NCT03702361|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, open-label trial to assess the safety and efficacy of rapid administration of velaglucerase alfa (VPRIV) to treatment-naive patients with type I Gaucher disease.||||
34018087|NCT03850808|||CASE_CONTROL||RETROSPECTIVE|||||||
34018088|NCT06495515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018089|NCT01705132|||FAMILY_BASED||PROSPECTIVE|||||||
34018090|NCT06347601|||OTHER||CROSS_SECTIONAL|||||||
34018091|NCT06309927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100033|NCT01216085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938963|NCT01031108|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34018092|NCT05214963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind \[Participant\]|Randomized 1:1 between Active treatment and Sham control|t|f|f|f
34018093|NCT00658749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018094|NCT03976583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018095|NCT06026020|||CASE_CONTROL||PROSPECTIVE|||||||
34018096|NCT03838861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34018097|NCT03058419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018098|NCT01438528|||COHORT||PROSPECTIVE|||||||
34018099|NCT00005595||||TREATMENT||||||||
34018100|NCT03538119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100034|NCT04314180|||COHORT||PROSPECTIVE|||||||
34100035|NCT05864716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo powder was applied in the control group, and the powder was prepared in probiotics factory, which was blind to both patients and caregivers.||t|t|t|t
34100036|NCT04284436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100037|NCT00667836|||COHORT||PROSPECTIVE|||||||
34100038|NCT03516708|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100039|NCT03852693|||OTHER||OTHER|||||||
34100040|NCT05708599|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34100041|NCT01232361|||COHORT||PROSPECTIVE|||||||
34100042|NCT04431778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Placebo and ethosuximide will be indistinguishable.|Randomisation 1:1 placebo or ethosuximide|t|t|t|t
33795172|NCT06676930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795173|NCT01679951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795174|NCT05579366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants will receive PRO1184 in ascending dose levels to establish a maximum tolerated dose, if reached, and the recommended Phase 2 dose, followed by dose expansion at selected dose and schedule.||||
33795175|NCT06676332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795176|NCT04560855|||COHORT||PROSPECTIVE|||||||
33795177|NCT01189513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795178|NCT01292252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795179|NCT04584099|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795180|NCT04617652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34100043|NCT02841631|||COHORT||PROSPECTIVE|||||||
34018101|NCT02000661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018102|NCT06155058|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will be the robotic and the active comparator will be the conventional mirror therapy exercise group||||
34018103|NCT03514641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Study 603A: bexagliflozin tablets, 20 mg or placebo~* Study 603B week 1 to week 12: bexagliflozin tablets, 20 mg, open-labeled~* Study 603B week 13 to week 24: bexagliflozin tablets, 20 mg or placebo"|"The primary endpoint of study 603A is the change from baseline (Day 1) to week 12 in the 24-hour average SBP of the bexagliflozin group compared to the placebo group using a superiority testing at an overall two-sided 0.05 level of significance.~The primary endpoint of study 603B is the change from week 12 (cumulative week 24) to week 24 (cumulative week 36) in the 24-hour average SBP in the bexagliflozin group compared to the placebo group using a superiority testing at an overall two-sided 0.05 level of significance."|t|t|t|t
34018104|NCT05759936|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Active vs. placebo|t|f|t|t
34018105|NCT01074762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34018106|NCT03823495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34018107|NCT03868163|||COHORT||PROSPECTIVE|||||||
33795181|NCT05437783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|None (Open Label)|||||
33795182|NCT05347108|||CASE_ONLY||PROSPECTIVE|||||||
33795183|NCT00188136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795184|NCT05938894|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795185|NCT00004124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795186|NCT05283395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795187|NCT05058170|||COHORT||PROSPECTIVE|||||||
34018108|NCT06418685|||COHORT||PROSPECTIVE|||||||
34018109|NCT05677646|||COHORT||PROSPECTIVE|||||||
34018110|NCT03382314|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018111|NCT01172821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018112|NCT05407025|||CASE_CONTROL||PROSPECTIVE|||||||
34018113|NCT01484613|||CASE_ONLY||PROSPECTIVE|||||||
34018114|NCT02785224|||OTHER||RETROSPECTIVE|||||||
34018115|NCT00236067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018116|NCT05286723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018117|NCT05050006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All enrolled participants are assigned to be treated with a single dose of ITIL-168||||
34018118|NCT01175811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018119|NCT05778136|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel assignment. The participants will be randomized to either left or right leg resistance training.|f|f|f|t
34018120|NCT05348980|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Two color coded envelops containing drug doses for intervention.|The study design was prospective double-blinded randomized parallel with allocation ratio of 1:1.|t|t|f|t
34018121|NCT05418270|||COHORT||CROSS_SECTIONAL|||||||
34018122|NCT03294486||SEQUENTIAL||TREATMENT||NONE||"Phase 1 :~Dose-escalation trial using an accelerated titration 3+3 design. Eligible patients will first be consecutively enrolled in a one-patient cohort at lowest dose level and then in 3-patients cohorts up to a DLT observation. All patients within a given cohort will be treated with the same dose schedule of TG6002. Following the 1st and 2nd infusion of TG6002 patients will be given oral 5-FC for 3 days starting on Day 5 and 12 and ending on Day 7 and 14, respectively. Following the 3rd infusion of TG6002 on Day 15, patients will be given oral 5-FC for 21 days starting on Day 19 and ending on Day 39 (end of treatment).~Phase 2a Patients will be treated IV at the Recommended Phase 2 dose (RP2D)."||||
34018123|NCT01098864|NA|SINGLE_GROUP||||NONE||||||
34018124|NCT05863143|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018125|NCT05565092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018126|NCT06217861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018127|NCT06033638|||COHORT||PROSPECTIVE|||||||
34018128|NCT04499365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018129|NCT05935436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34018130|NCT00486616|||||PROSPECTIVE|||||||
34018131|NCT00260169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018132|NCT03222752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment device will deliver subsensory treatment while the sham device will deliver no treatment.|A single site, 6 week, randomized, double-blind, placebo controlled evaluation of efficacy and tolerability of cranial electrotherapy stimulation (CES) for the treatment of adults from 18-65 years of age with treatment resistant Major Depressive Disorder (MDD) with a 6 week open label extension phase.|t|t|t|f
34018133|NCT03355014|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018134|NCT03370874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018135|NCT04505293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018136|NCT03535779|||COHORT||PROSPECTIVE|||||||
34018137|NCT03168594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018138|NCT01531738|||CASE_CONTROL||PROSPECTIVE|||||||
34018139|NCT02593435|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34018140|NCT06049836|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34018141|NCT00039520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018142|NCT02908737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018143|NCT01948986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018144|NCT01002014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018145|NCT02074592|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34018146|NCT01710553|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33795188|NCT05521880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795189|NCT02738840|NA|SINGLE_GROUP||OTHER||NONE||International, multicenter, prospective, and single-arm design||||
33795190|NCT03626142|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795191|NCT01508507|||CASE_CONTROL||RETROSPECTIVE|||||||
33795192|NCT00732953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795193|NCT06512714|||CASE_ONLY||RETROSPECTIVE|||||||
33795194|NCT04052919|NA|SINGLE_GROUP||SCREENING||NONE||||||
33795195|NCT00369733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795196|NCT00516386|NA|SINGLE_GROUP||OTHER||NONE||||||
33795197|NCT02968472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795198|NCT02694666|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33795199|NCT06673277|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33795200|NCT03444649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795201|NCT01984086|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795202|NCT01994122|||CASE_CONTROL||PROSPECTIVE|||||||
33795203|NCT05569837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795204|NCT05133063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33795205|NCT02158754|||CASE_CONTROL||RETROSPECTIVE|||||||
33795206|NCT04533659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795207|NCT00114244|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795208|NCT01446068|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33795209|NCT02971488|||COHORT||PROSPECTIVE|||||||
33795210|NCT01239316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795211|NCT05501249|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795212|NCT06553209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795213|NCT00338299|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795214|NCT00428688|||CASE_ONLY||PROSPECTIVE|||||||
33795215|NCT02726490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795216|NCT04829539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33938964|NCT01707940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938965|NCT05830656|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33938966|NCT05150171|NA|SINGLE_GROUP||TREATMENT||NONE||An e-self-management intervention consisting of videos informing patients with hand osteoarthritis about recommended treatment (information, hand exercises, use of assistive devices and orthoses, information about pharmacological and surgical treatment).||||
33938967|NCT03717727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938968|NCT02814747||PARALLEL||||NONE||||||
33938969|NCT01587599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33938970|NCT00968929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938971|NCT01176864|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33938972|NCT03058276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded experiment regarding rTMS treatment is applied to both subjects and investigators. The only non-masked role is for the technician applying either Magstim Rapid or SAM coils to each group of subjects.||t|f|t|f
33938973|NCT02203006|NA|SINGLE_GROUP||OTHER||NONE||||||
33938974|NCT04898036|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33938975|NCT04125199|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33938976|NCT04778644|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||All subjects will receive both the study drug and placebo.|t|t|t|t
33938977|NCT04184752|||CASE_ONLY||RETROSPECTIVE|||||||
33938978|NCT01599585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33938979|NCT00869063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33938980|NCT01063361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938981|NCT02802735|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Part 1 was a randomized open-label crossover study. Part 2 was a randomized, double-blind study.|Part 1 of the study was a 3-treatment period, 3-sequence crossover study. Part 2 was a parallel-group, placebo-controlled, single-period study.||||
33938982|NCT00451074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938983|NCT00086489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33938984|NCT05875194|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|A person, who is not involved in the study procedure will assign the participants to the sham or treatement condition. The study members will only receive for each stimulation a new number which is necessary to start and encode the type of stimulation (placebo or verum).||t|f|t|t
33938985|NCT01665716|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33938986|NCT03626844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33938987|NCT05273294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33938988|NCT03560479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Part 1 (Main part): Patients are randomized to receive intravesical instillations of either alpha1H (7.4 mg/mL) or placebo. The randomization ratio is 1:1.~Part 2 (DE part): In this open part of the study, two groups of patients will receive escalating doses of alpha1H in a standard 3+3 design. One group will receive a dose of 37 mg/mL and, if tolerated, one group will receive a dose of 74 mg/mL."|t|t|t|t
33938989|NCT00304421|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33938990|NCT05349474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018147|NCT04404946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018148|NCT01206114|||COHORT||PROSPECTIVE|||||||
34018149|NCT02134743|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33795217|NCT04228536|||COHORT||PROSPECTIVE|||||||
33795218|NCT05377151|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33795219|NCT05863195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795220|NCT02455752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795221|NCT04184336|||COHORT||OTHER|||||||
33795222|NCT04756323|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795223|NCT03072953|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33795224|NCT05924958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Conventional treatment group Eprolidone group|t|f|t|f
33795225|NCT03900442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795226|NCT01801410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795227|NCT00771446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795228|NCT06677060|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo controlled||t|t|t|t
33795229|NCT02887625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795230|NCT06676098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795231|NCT06194734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795232|NCT06086080|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The investigator and outcomes assessor will not have access to the type of treatment a patient received.|Patients are randomized either to standard care or in the intervention group. Standard care patients are treated with knee brace (2 weeks) and physical therapy. In the intervention group: they receive knee taping with knee brace during 1-week.|f|f|t|t
33795233|NCT01228916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795234|NCT06524700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795235|NCT00787033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795236|NCT05038228|||COHORT||RETROSPECTIVE|||||||
33795237|NCT05432934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33795238|NCT02139748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795239|NCT00464399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795240|NCT03829813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Mixed methods study with pre and post intervention surveys and Visual analog scales, combined with focus groups/interviews of patients, family members and staff||||
33795241|NCT03106480|||COHORT||PROSPECTIVE|||||||
33795242|NCT02740686|||COHORT||PROSPECTIVE|||||||
33795243|NCT01856335|NA|SINGLE_GROUP||OTHER||NONE||||||
33795244|NCT03822650|||COHORT||OTHER|||||||
33795245|NCT05500664|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We hypothesized that the use of lavender aromatherapy before surgery would reduce preintervntion of radiofrequency anxiety as assessed by the Speilberger State-Trait Anxiety Inventory (STAI) questionnaire|f|f|f|t
33795246|NCT01104415|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795247|NCT04781595|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33795248|NCT06038617|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795249|NCT01948648|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33795250|NCT00539799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795251|NCT02274896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795252|NCT03923491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Intervention vs. Attention Control|f|f|t|t
33795253|NCT05817968|NA|SINGLE_GROUP||OTHER||NONE||Method comparison study; participants serve as their own control||||
33795254|NCT06302491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795255|NCT02537704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795256|NCT06088225|NA|SINGLE_GROUP||PREVENTION||NONE||Paired testing those ocular parameters before and after 12-month usage of distance-image screen||||
33795257|NCT04114968|||COHORT||PROSPECTIVE|||||||
33795258|NCT02950779|||COHORT||PROSPECTIVE|||||||
33795259|NCT05311319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795260|NCT00094575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795261|NCT05640791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795262|NCT03316521|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a prospective, single-center, open-label FIH study investigating the safety, tolerability, PK and PD after single and multiple doses of AMY-101 in healthy male volunteers. In the SAD part of the study, a single dose at ascending dose levels of AMY-101 will be administered to different cohorts, following a careful dose-escalation strategy. In the MD part of the study, multiple doses will be administered using different dosing intervals; the cohorts will include a minimum of four (4) subjects each. Additional subjects may be added in the cohorts if necessary.||||
33795263|NCT04707430|||COHORT||PROSPECTIVE|||||||
33795264|NCT02779517|||COHORT||CROSS_SECTIONAL|||||||
33795265|NCT04020718|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pilot sequential multiple assignment randomized trial||||
33795266|NCT00000699||||TREATMENT||NONE||||||
34100044|NCT04423367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100045|NCT03486470|||CASE_ONLY||CROSS_SECTIONAL|||||||
34100046|NCT03486106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33795267|NCT00947817|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795268|NCT00565110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795269|NCT05065684|||COHORT||PROSPECTIVE|||||||
33795270|NCT06461455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33795271|NCT03874650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given that this is a psychological assessment, it is not possible to mask the participant, care provider, or investigator. Hence, only the outcomes assessor will be masked.||f|f|f|t
33795272|NCT00086892||||TREATMENT||NONE||||||
33795273|NCT05051319|||OTHER||CROSS_SECTIONAL|||||||
33795274|NCT05573191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795275|NCT02376517|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33795276|NCT04580901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795277|NCT03354039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795278|NCT01268813|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33795279|NCT00082810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795280|NCT01348880|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33795281|NCT01793662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795282|NCT05148897|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795283|NCT02613676|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33795284|NCT04705376|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The investigators propose a randomized crossover trial involving the use cryotherapy machines as a means of pain control following arthroscopic rotator cuff repair surgery. Patients will be randomized into receiving one of two possible cryotherapy devices immediately after surgery: Breg Polarcare or Thermazone. Randomization will occur with the use of a randomization excel spreadsheet. On post-operative day 3, patients who were originally randomized to Breg will then use Thermazone and patients who were randomized to Thermazone will use Breg for post-operative days 3 and 4. Both groups will alternate between both cryotherapy devices every two days post-operatively for 8 days total. Both groups will maintain a pain journal during the 8 study days post-operatively to document VAS scores, number of narcotic pain medications taken, and any adverse reactions from the cryotherapy devices. At 2 and 6-weeks follow-up, both groups will complete a functional evaluation.||||
33795285|NCT06612879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795286|NCT02814643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33795287|NCT02186236|||COHORT||PROSPECTIVE|||||||
33795288|NCT02747602|RANDOMIZED|CROSSOVER||||NONE||||||
33938991|NCT03611179|NA|SINGLE_GROUP||TREATMENT||NONE||40 patients diagnosed with advanced epithelial ovarian cancer presenting to Assiut university hospitals ,,the aim of the study is evaluation of response, survival and toxicity of upfront chemotherapy with Bevacizumab in those patients.||||
33938992|NCT06186089|||COHORT||PROSPECTIVE|||||||
33938993|NCT00916994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33938994|NCT05874700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33938995|NCT00862329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33938996|NCT02709889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938997|NCT03421236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33938998|NCT01295632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715388|NCT05526430|NA|SEQUENTIAL||TREATMENT||NONE||This study will employ the continual reassessment method (CRM) to find an MTD of Harmine. It uses a statistical model to estimate the relationship between dose and DLT risk to inform decisions on dosing. It first starts with a selected target DLT rate and a mathematical model for the relationship between dose and toxicity, the prior dose-toxicity curve. After a patient experiences a DLT or not, the dose-toxicity curve is re-fit incorporating the latest outcome. The next dose assigned is that most likely to be associated with the target toxicity level (the MTD). At every step, the next patient is assigned the dose estimated to be nearest to the MTD.||||
33715389|NCT01125865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715390|NCT06087276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded randomization into either the Parallel Design or Randomized Withdrawal studies|"* Parallel Design: A 12-week parallel design (PD) randomized, double-blind, placebo-controlled study to evaluate the proportion of participants that respond to and the efficacy and safety of ulixacaltamide compared with placebo.~* Randomized Withdrawal: A 12-week randomized withdrawal (RW), double-blind, placebo-controlled study to evaluate the efficacy, maintenance of response, and durability of effect in participants who respond to ulixacaltamide and safety.~* Long-term Safety Study: A LTSS study to evaluate the long-term safety of ulixacaltamide for up to 1 approximately 1 year. The first 2 weeks of the LTSS will be double-blind."|t|t|t|f
33715391|NCT02375568|||CASE_ONLY||PROSPECTIVE|||||||
33715392|NCT06051929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715393|NCT00901264|||CASE_CONTROL||PROSPECTIVE|||||||
33715394|NCT00118365|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33715395|NCT04066673|||CASE_ONLY||CROSS_SECTIONAL|||||||
33715396|NCT05508191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator (who evaluated the skin aging status, or the outcomes assessor) will be blinded to the treatment allocation until the end of data collection. We cannot perform the masking to the participants as they will surely aware which side of their face receive microneedle or fractional CO₂ laser, even though they are required to close their eyes during treatment.|Each participant will receive fractional CO₂ laser treatment on one side of the face and microneedle treatment on the other half. The allocation of which side receive a particular treatment will be determined by a computer programme.|f|f|f|t
33715397|NCT04566991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All patients and investigators who will be directly involved in the care of these patients or in data analysis will be blinded to randomization status.This trial uses a Bayesian adaptive randomization protocol, where there are three groups that patients will be randomized into: placebo, DFO 32 mg/kg and DFO 48 mg/kg. The first 50 patients will be randomized evenly into each of these groups. The randomization ratio will be adjusted based on the design report after 50 subjects and then every 10 patients.||t|t|f|f
33715398|NCT05151146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715399|NCT04843345|||COHORT||PROSPECTIVE|||||||
33715400|NCT02964351|||COHORT||PROSPECTIVE|||||||
33938999|NCT01149161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33939000|NCT00125268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715401|NCT06292065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||45 patients on semaglutide therapy will be included together with 45 age, BMI and diabetes status matched controls.||||
33715402|NCT02515058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715403|NCT01331551|||CASE_CROSSOVER||PROSPECTIVE|||||||
33715404|NCT00531570|||CASE_ONLY||PROSPECTIVE|||||||
33715405|NCT05439226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715406|NCT04201860|||CASE_CONTROL||OTHER|||||||
33715407|NCT05015127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715408|NCT03053076|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33715409|NCT01920789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939001|NCT03770689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939002|NCT03814057|||COHORT||CROSS_SECTIONAL|||||||
33939003|NCT00979862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939004|NCT03773068|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939005|NCT04908319|||COHORT||OTHER|||||||
33939006|NCT05675202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939007|NCT04671576|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"A controlled, decentralized, double-blind trial of healthy, term, formula-fed infants randomized to one of two infant formulas:~Control Formula (a standard, commercially available infant formula) or Investigational Formula for 16 weeks."|t|t|t|t
33939008|NCT02581852|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939009|NCT03822286|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939010|NCT04056715|||COHORT||PROSPECTIVE|||||||
33939011|NCT00476190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939012|NCT02504957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939013|NCT03316599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939014|NCT03325933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33939015|NCT02605889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33939016|NCT02010229|||COHORT||PROSPECTIVE|||||||
33939017|NCT00285246|||COHORT||PROSPECTIVE|||||||
33939018|NCT02853903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939019|NCT01962909|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939020|NCT00031109||||PREVENTION||||||||
33939021|NCT05924997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939022|NCT02312375|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939023|NCT00904436||FACTORIAL||||NONE||||||
33939024|NCT04604028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939025|NCT04083521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33939026|NCT04249466|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939027|NCT03849092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939028|NCT04282967|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939029|NCT04735432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939030|NCT02730546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939031|NCT01334463|||COHORT||PROSPECTIVE|||||||
33939032|NCT00374491|||||PROSPECTIVE|||||||
33939033|NCT00656227|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33939034|NCT01195636|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33939035|NCT06351735|||CASE_CROSSOVER||PROSPECTIVE|||||||
34018150|NCT05770921|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-center, single-group||||
34018151|NCT02235038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34100047|NCT02913859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715410|NCT03807466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The team at Health Quality Ontario will be aware of the physicians' assignment to dynamic versus paginated reports so that they can send the correct audit-and-feedback document. However, the analytic team at ICES will be masked, and outcome data will be extracted by the analysis team from routinely collected administrative databases (Ontario drug benefits database).|Assess two interventional parallel study models consisting of two intervention arms each|t|f|t|t
33715411|NCT01761331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33715412|NCT03606733|NA|SINGLE_GROUP||TREATMENT||NONE||Injection of triamcinilone or/ and VEGF blockade agents in the Supra Choroidal Space||||
33715413|NCT01382056|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33715414|NCT04981951|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33715415|NCT05920291|||COHORT||PROSPECTIVE|||||||
33715416|NCT01596608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715417|NCT04492202|||OTHER||OTHER|||||||
33715418|NCT05821114|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715419|NCT01970449|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33715420|NCT01899690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715421|NCT03353493|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants are masked at baseline assessment to treatment allocation. Outcome assessors are masked to treatment allocation.|Randomised to Mindfulness-based cognitive therapy plus treatment as usual, or treatment as usual.|f|f|f|t
33715422|NCT02120534|||CASE_ONLY||PROSPECTIVE|||||||
33715423|NCT00806754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715424|NCT05768880|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715425|NCT00053053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33715426|NCT01282268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715427|NCT01890850|||CASE_CONTROL||RETROSPECTIVE|||||||
33715428|NCT04371991|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715429|NCT00097110|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33715430|NCT04653129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the assessment of outcome measures will be performed by a dedicated surgeon not involved in the surgery or preoperative patient evaluation||f|f|f|t
33715431|NCT02597894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715432|NCT01485770|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33715433|NCT02598154|||COHORT||PROSPECTIVE|||||||
33715434|NCT04667650|||COHORT||RETROSPECTIVE|||||||
33715435|NCT00220870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715436|NCT03628560|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33715437|NCT03735225|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Dose escalation|t|t|t|t
33715438|NCT00425360|RANDOMIZED|||TREATMENT||NONE||||||
33715439|NCT04893967|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33715440|NCT03728660|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Baseline AI administered prior to randomization, outcomes assessor masked on intervention assignment before and after crossover|Intention to treat design; crossover with 22 week washout period between interventions; primary outcome measure is patient-reported function|f|f|f|t
33715441|NCT06034236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blinded study, participants will be divided into two groups by simple random sampling technique.|The participants are divided into two groups, group A will be given Otago exercises and grouo B will be given Resistance training.|t|f|f|f
33715442|NCT05360576|RANDOMIZED|CROSSOVER||PREVENTION||NONE||All subjects will receive LSP-5415 (28 days) and NuvaRing (28 days) under fasted conditions. There will be a 28-day washout period after ring removal in Treatment Period 1 and ring insertion in Treatment Period 2.||||
33715443|NCT06008457|||COHORT||PROSPECTIVE|||||||
33715444|NCT00742534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715445|NCT04016753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715446|NCT03543579|||CASE_ONLY||PROSPECTIVE|||||||
33715447|NCT02034279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715448|NCT01029795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715449|NCT02117648|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939036|NCT03056209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939037|NCT04450862|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trial||||
33939038|NCT00945594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939039|NCT04588909|||COHORT||RETROSPECTIVE|||||||
33939040|NCT02873780|||COHORT||PROSPECTIVE|||||||
33939041|NCT03479541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blinded design.||f|f|t|t
33939042|NCT02962102|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939043|NCT01287858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939044|NCT00207636|RANDOMIZED|PARALLEL||ECT||NONE||||||
33939045|NCT00601510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939046|NCT05260476|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33939047|NCT01315457|||COHORT||RETROSPECTIVE|||||||
33939048|NCT02742155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939049|NCT00004728|RANDOMIZED|||PREVENTION||DOUBLE||||||
33939050|NCT00606931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018152|NCT01414595|||CASE_ONLY||RETROSPECTIVE|||||||
34018153|NCT00017719|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34018154|NCT02257463|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34018155|NCT05194878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018156|NCT02747862|||COHORT||RETROSPECTIVE|||||||
34018157|NCT02998970|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34018158|NCT04644094|||COHORT||PROSPECTIVE|||||||
34018159|NCT03865186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was of quasi-experimental (pretest-posttest, with a control group) design.||||
34018160|NCT05390918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||One hundred ninety youths aged 11 years, 0 months, to 18 years, 11 months, inclusive at time of consent, with sleep problems (within the past month) and suicidal ideation (within the past 90 days) will be randomized to either TAILOR (n=95) or to EUC (n=95).|f|f|f|t
34100048|NCT00484900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715450|NCT06088706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Clinician: injection interventions are performed under the supervision of a sports medicine specialist who does not know the dose of the injections and only injects the solution prepared by another assistant.~Assessor Clinician: Assessments before and after interventions will be done by a sports medicine resident who is not involved in running the trial.~Statistical analyzer: The analysis of the research data will be done by a statistical consultant who is not aware of the patient groups."|"In the randomized clinical trial study, Convenience Sampling will be done among the patients with knee osteoarthritis called to the sports medicine assessment clinic, at Hazrat Rasool Akram hospital.~Allocation of patients in treatment groups will be done randomly using blocks with blocks of six in one of the treatment groups as follows:~A: Control (CL) B: O3 20mg C: O3 40mg~The block randomization method is used to assign people to the three study groups. For this purpose, the length of the block will be equal to 6 houses (two houses for each treatment)."|t|t|t|t
33715451|NCT00822835|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33715452|NCT02049957|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715453|NCT02935088|||CASE_ONLY||PROSPECTIVE|||||||
33715454|NCT04998461|||COHORT||PROSPECTIVE|||||||
33715455|NCT01847417|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939051|NCT04650685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A research assistant will be responsible for randomisation and grouping hence the outcome assessor will not be aware of which group the participant belonged to. One outcome assessor will be responsible for the clinical evaluations, who will be masked to the intervention groups throughout the study. Individual participants will not be informed about the study hypothesis and will strictly be asked not to disclose to the outcome assessor which oral hygiene tool they are using. This is to ensure the outcome assossor is fully blinded in this study.|"Group 1: Salvadora persica toothbrush (under the brand of Al-Abyad) that is to be used without toothpaste application.~Group 2: Salvadora persica chewing sticks (under the brand of Al-Khair) with uniform diameter (1cm) and equal length of 15 cm. Three miswak chewing sticks will be distributed to each participant (one stick/week). Upon receiving, they will be sealed in air-tight plastic bags. This miswak chewing stick is also to be used without the application of any toothpaste.~Group 3: Participants will be given a regular, standard straight-handle soft-bristle Colgate toothbrush each to be used with the application of Colgate® fluoride toothpaste.~Professional cleaning of scaling and polishing will be performed if needed during the first visit."|f|f|f|t
33939052|NCT00000642||||PREVENTION||NONE||||||
33939053|NCT03813576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All women will undergo a clinical-collected cervical HPV swab and a self-collected vaginal HPV swab and the results of both swabs compared. The women will be randomised to the sequence of which they undergo the clinical-collected swab first or the self-collected swab first.||||
33939054|NCT00818636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939055|NCT01741584|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33939056|NCT05096533|||COHORT||PROSPECTIVE|||||||
33939057|NCT04262674|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33939058|NCT02537275|NA|SINGLE_GROUP||||NONE||||||
33939059|NCT03075865|||COHORT||PROSPECTIVE|||||||
33939060|NCT05608694|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33939061|NCT01594489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34018161|NCT05249530|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be masked to whether they are receiving an adjustment with force or a non-force stimulation||t|f|f|f
34018162|NCT00103818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018163|NCT01689818|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018164|NCT05555563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018165|NCT04190069|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34018166|NCT00073242|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34018167|NCT03572166|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Observational randomized cross-over diagnostic international multicenter study|f|f|f|t
34018168|NCT03681327|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34018169|NCT03107143|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, non-blinded, randomized trial. This cohort was divided into two groups: Control and Treatment.||||
34018170|NCT02385253|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34018171|NCT01632111|||COHORT||RETROSPECTIVE|||||||
34018172|NCT04650503|||COHORT||PROSPECTIVE|||||||
34018173|NCT04551430|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018174|NCT04979286|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34018175|NCT02603393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018176|NCT04310618|||OTHER||PROSPECTIVE|||||||
34018177|NCT04476719|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018178|NCT06324890|||OTHER||RETROSPECTIVE|||||||
34018179|NCT00422981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018180|NCT05530148|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessors will be masked to group allocation. Participants will not be masked from knowledge of the other group, but will only receive the training from one specific training group.|The study is a single-blind randomized trial with parallel groups design involving an experimental exercise and an exercise comparison.|f|f|f|t
34018181|NCT02379780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018182|NCT04585984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, investigator, assessing physician, embryologist and all site personnel with the exception of the trial nurse/coordinator and/or pharmacy assistant will remain blinded throughout the course of the trial as to which treatment each subject received.||t|f|t|t
34100049|NCT03268161|||COHORT||RETROSPECTIVE|||||||
34100050|NCT00758043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100051|NCT05775575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100052|NCT01684254|||COHORT||CROSS_SECTIONAL|||||||
34100053|NCT03725735|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot study||||
34100054|NCT06689891|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Study population will include patients who have an indication for referral for pelvic floor rehabilitation (PFR).||||
34100055|NCT00409227|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100056|NCT04288531|||COHORT||PROSPECTIVE|||||||
34100057|NCT04430621|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33715456|NCT00617773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715457|NCT01230944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715458|NCT02071251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715459|NCT04445922|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715460|NCT02856230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715461|NCT02266225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715462|NCT01892228|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33715463|NCT02386514|||COHORT||PROSPECTIVE|||||||
33715464|NCT01554384|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33715465|NCT04449198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715466|NCT02568085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33715467|NCT01634815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715468|NCT00053040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715469|NCT01366170|||COHORT||PROSPECTIVE|||||||
33715470|NCT04829708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715471|NCT02205814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715472|NCT01023230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715473|NCT00789139|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33715474|NCT02839707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715475|NCT00260351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715476|NCT00794131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715477|NCT00380614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33715478|NCT06429202|||OTHER||CROSS_SECTIONAL|||||||
33715479|NCT02975661|||OTHER||PROSPECTIVE|||||||
33939062|NCT05669144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"1. Intracoronary and intra-myocardial injection of exosomes (5 patients)~2. Intracoronary and intra-myocardial injection of mitochondria (5 patients)~3. Intracoronary and intra-myocardial injection of exosomes and mitochondria (5 patients)~4. Placebo (5 patients)"|t|t|t|t
33939063|NCT01349491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939064|NCT00654056|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33939065|NCT05859776|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33939066|NCT02197351|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33939067|NCT05779176|RANDOMIZED|PARALLEL||TREATMENT||NONE|This trial is open labeled, the treatment allocation is known to the treating physicians and the patients|Safety and efficacy of therapeutic hypothermia in acute ischemic stroke (AIS) patients treated with Intravascular thrombectomy is a prospective, multi-center, randomized, parallel-group interventional study.||||
33939068|NCT00748176|||||PROSPECTIVE|||||||
33939069|NCT06160362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939070|NCT01563224||CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33939071|NCT03737344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939072|NCT05993455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939073|NCT03898440|||COHORT||PROSPECTIVE|||||||
33939074|NCT00952471|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939075|NCT04173910|||COHORT||PROSPECTIVE|||||||
33939076|NCT04953663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||3 arms for phase 1, and 3 arms for pashe 2|t|t|t|f
33939077|NCT01676649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939078|NCT01035723|||||OTHER|||||||
33939079|NCT06228365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Prospective, randomised, open-label, single-centre study in two parallel groups of 200 patients.~Maximum duration of patient participation in the study = 2 days."||||
33939080|NCT03170765|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants are infants ranging from 6-9 months of age. They are expected to be unaware of the intervention. The laboratory personnel performing the antibody level measurements will be blinded by sending the samples with only a four digit code that does not reveal the intervention received.|THREE ARM RCT|t|f|f|t
33939081|NCT04919135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939082|NCT05310006|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33939083|NCT01202643|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33939084|NCT00089505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939085|NCT02439866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33939086|NCT00392210|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33939087|NCT05550272|||CASE_ONLY||RETROSPECTIVE|||||||
34018183|NCT05038579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018184|NCT02667171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All assessors are blinded to group allocation and previous test results. Due to the nature of the study the patients cannot be blinded, but prior to the assessments they are reminded not to disclose their group allocation to the assessors. In case of failure keeping the outcome assessor blinded (that is, if a participant reveals his/her allocation) a second assessor will be available to step in and conduct the assessment on another day.~To avoid investigators (subconscious) bias the biostatistician who perform the data analyses and validate the results will be blinded to group allocation.~The research group will interpret the results, and the conclusion will be prepared in two versions before the allocation code is broken (one assuming that arm A is the intervention, and one assuming that arm B is the intervention)."|This study is a randomized controlled, assessor- and statistician blinded, superiority, multicentre trial with two parallel-groups. Online COPD Rehab versus Coventional COPD rehab|f|f|t|t
34018185|NCT00134043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018186|NCT05190848|||CASE_CONTROL||PROSPECTIVE|||||||
34018187|NCT04399928|||COHORT||PROSPECTIVE|||||||
34018188|NCT05010044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018189|NCT00188487|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018190|NCT05492253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34018191|NCT05532930|||COHORT||PROSPECTIVE|||||||
34018192|NCT04600466|||COHORT||OTHER|||||||
34018193|NCT04583449|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34018194|NCT01659866|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939088|NCT00065221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33939089|NCT04787744|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy.||||
33939090|NCT01392079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018195|NCT01521416|||CASE_ONLY||RETROSPECTIVE|||||||
34018196|NCT04997941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018197|NCT00329472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018198|NCT01352130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018199|NCT06410170|||COHORT||PROSPECTIVE|||||||
34018200|NCT04218500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Both moisturizers have the same physical characteristics, with the same color and odor.~Randomization was carried out by other than researcher (statistical adviser)"|There were 46 subjects in the niacinamide 4% arm and 46 subjects in the VCO 30% arm|t|f|t|f
34018201|NCT02400424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018202|NCT02578264|||CASE_ONLY||PROSPECTIVE|||||||
34018203|NCT04403711|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018204|NCT05587114|||OTHER||RETROSPECTIVE|||||||
34018205|NCT04408599|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018206|NCT00660205|||COHORT||PROSPECTIVE|||||||
34018207|NCT01011244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100058|NCT06339762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34100059|NCT05725525|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will receive the same interventions|||||
34100060|NCT05746260|||COHORT||PROSPECTIVE|||||||
33715480|NCT05838105|RANDOMIZED|PARALLEL||TREATMENT||NONE||"All patients will be randomly divided into two groups, each will receive a different luteal treatment:~1. Study group - patients will receive luteal support with GNRH agonist and HCG according to departmental protocol (described later).~2. Control group - patients will receive luteal support with vaginal progesterone."||||
33715481|NCT01110954|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33715482|NCT00477282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715483|NCT03032731|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|||||
33715484|NCT03687489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715485|NCT01300039|||CASE_CONTROL||PROSPECTIVE|||||||
33715486|NCT06327451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715487|NCT04661657|||COHORT||PROSPECTIVE|||||||
33715488|NCT04170114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715489|NCT02167893|||COHORT||PROSPECTIVE|||||||
33715490|NCT03630627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715491|NCT04822064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715492|NCT03571269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715493|NCT02062918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715494|NCT02381249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33715495|NCT02155842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939091|NCT00147082|||COHORT||PROSPECTIVE|||||||
33715496|NCT01322360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715497|NCT01879150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715498|NCT05241106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715499|NCT04426981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939092|NCT02355860|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33939093|NCT00934791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939094|NCT00225628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939095|NCT05734144|RANDOMIZED|PARALLEL||OTHER||DOUBLE|both the participant patients and the surgeon had no knowledge about the chosen procedure and the choosen procedure were known by the investigator who told the surhgeon later which procedure to perform for the selected patient.|This study was carried out on 432 patients with gall bladder stones and with suspected or confirmed CBDS at two centers 264 patients at the Gastrointestinal Surgery Unit in the Zagazig University Hospitals and 168 patients at gastroenterology surgery unite at ALAHRAR hospitals from January 2010 till May 2022. Patients were randomized divided into two equally groups, the first group was treated by a single-step procedure combining LC and IOES while the second (control) group was treated by 2-stage (sequential treatment) POES followed by LC.|t|t|f|f
33939096|NCT06100367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||11C-metomidate synthesis will be done at Clinical Imaging Research Centre in compliance with good manufacturing practice using a General Electric Medical Systems PET trace 860 cyclotron. Non-contrast CT images will be acquired over the adrenal. After an intravenous injection of 11C-metomidate, PET images will be acquired. Attenuation and decay-corrected images will be converted to standardized uptake value (SUV) maps through division by (injected activity per patient weight). The maximum SUV values over regions of interest will be determined for 10-min static images starting 35 min after the injection.||||
33939097|NCT05495009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled experimental research||||
33939098|NCT03603340|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
33939099|NCT05070208|||COHORT||RETROSPECTIVE|||||||
33939100|NCT02865772|||COHORT||PROSPECTIVE|||||||
33939101|NCT05488028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-mouth model|t|t|f|t
33939102|NCT04516629|||CASE_CROSSOVER||PROSPECTIVE|||||||
33939103|NCT00554424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33939104|NCT00143728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939105|NCT02460042|||COHORT||PROSPECTIVE|||||||
33939106|NCT00886314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939107|NCT05950373|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33939108|NCT04411472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939109|NCT00748449|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33939110|NCT04081740|||CASE_ONLY||RETROSPECTIVE|||||||
33939111|NCT03696498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939112|NCT05193292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939113|NCT02532829|||COHORT||PROSPECTIVE|||||||
33939114|NCT01128855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939115|NCT02971449|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34100061|NCT06268717|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The principal investigator and clinical research coordinators will be blinded to the challenges during the course of the study. The metabolic kitchen and a delegated research staff member will be unblinded.|Double-blind crossover. Each participant will be randomized to undergo two double-blind food challenges with at least a 10-day washout period between the challenges. One food challenge will contain pork meat containing alpha-gal sugar; one challenge will contain pork meat without alpha-gal sugar.|t|t|t|t
34100062|NCT00862277|||CASE_CONTROL||RETROSPECTIVE|||||||
34100063|NCT03423953|||COHORT||PROSPECTIVE|||||||
34100064|NCT06514248|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34100065|NCT02627638|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939116|NCT00174876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100066|NCT03005574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100067|NCT01722734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34100068|NCT06446778|||COHORT||PROSPECTIVE|||||||
34100069|NCT04406519|||CASE_CONTROL||PROSPECTIVE|||||||
34100070|NCT02961582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100071|NCT01568229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939117|NCT04449614|||COHORT||RETROSPECTIVE|||||||
33939118|NCT04601779|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33939119|NCT01935284|||||PROSPECTIVE|||||||
33939120|NCT00779233|RANDOMIZED|CROSSOVER||||NONE||||||
33939121|NCT04502394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An Open-label, Phase 1b/2 Study of KRT-232 in combination with acalabrutinib in Subjects with B-cell Non-Hodgkin Lymphoma||||
33939122|NCT01371799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33939123|NCT05724654|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Study participants will receive in random order daily 60 g of skin roasted peanuts (peanut intervention) or no peanuts for a total of 16 weeks (control intervention), separated by a wash-out period of at least 8 weeks.|f|f|t|t
33939124|NCT02005718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939125|NCT01021553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939126|NCT01063114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939127|NCT00852124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939128|NCT00753025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939129|NCT06085040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939130|NCT04427904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939131|NCT04815226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939132|NCT04384991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939133|NCT01753843|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33939134|NCT04433936|||CASE_CONTROL||PROSPECTIVE|||||||
33939135|NCT00871468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939136|NCT04651699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Triple-blind criteria will be achieved by identic collocation of the electrodes in both groups and by activating the double-blind option in the Starstim tDCS® Software (Neuroelectrics Inc, Barcelona, Spain) that allows concealing the protocol by writing a neutral number. The evaluator, not allowed to stay in the same room while interventions, will conceal the protocols with the neutral number and the therapist will read it in the envelope, ignoring which number coincides with each intervention. At the end of the full treatment, patients will be asked whether they received active or sham stimulation, to assess the blinding success. Patients recruited will not meet in waiting rooms to avoid them to comment on their experience during the protocol. The statistician will be also blinded through the mentioned neutral numbers. Unblinding will be permissible when any event could suppose a risk for the patient's health."|"This study will be a triple-blinded experimental longitudinal prospective randomized controlled trial with a parallel design. The randomization will be realized through the GraphPad software by an independent investigator. All the participants who fulfill the inclusion criteria and have none of the exclusion ones will be randomly allocated into two groups: active-tDCS (a-tDCS) or sham-tDCS (s-tDCS). Allocation concealment will be ensured by the inclusion of the assigned group in closed opaque envelopes that will be opened at the time of the intervention."|t|t|t|t
33939137|NCT01738789|||COHORT||PROSPECTIVE|||||||
33939138|NCT04352686|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33939139|NCT04560179|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation trial.||||
33939140|NCT02897011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939141|NCT01745900|||COHORT||CROSS_SECTIONAL|||||||
33939142|NCT00984009|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939143|NCT01688479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939144|NCT03946189|||COHORT||PROSPECTIVE|||||||
33939145|NCT04905563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33939146|NCT04581057|NA|SINGLE_GROUP||OTHER||NONE||||||
33939147|NCT01992744|||COHORT||PROSPECTIVE|||||||
33939148|NCT01802242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939149|NCT02084940|||COHORT||PROSPECTIVE|||||||
33939150|NCT03449186|||CASE_CONTROL||PROSPECTIVE|||||||
33939151|NCT01054339|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33939152|NCT05357586|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, uncontrolled, pilot study||||
33939153|NCT00641979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33939154|NCT03234257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939155|NCT03669263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939156|NCT05651412|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33939157|NCT06250452|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33939158|NCT05124327|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33939159|NCT01272544|||COHORT||PROSPECTIVE|||||||
33939160|NCT05367921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigators will be blinded to the measurement results.|||||
33939161|NCT02509663|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34018208|NCT06300671|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||48 healthy individuals between the ages of 18-40 constitute the population of the study. Participants randomized into neutral, pronation, and hyperpronation groups.||||
34018209|NCT03751956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018210|NCT06018974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018211|NCT04205019|NA|SINGLE_GROUP||TREATMENT||NONE||TSCI patients are treated once at start of the study and followed up for 3 months to characterize and confirm safety of intrathecal administration of Neuro-Cells.||||
34018212|NCT03906396|RANDOMIZED|PARALLEL||OTHER||SINGLE|"i) A number of assessors from occupational therapy students will be recruited. This is to allow for randomization possibility on assessment responsibility.~1. Pre-evaluation is conducted randomly by accident by an independent assessor with an occupational therapy background without knowing which participant in which group. There is no specific client on specific assessor.~2. The post-evaluation is conducted randomly by accident by an independent assessor with an occupational therapy background. There is no specific client on specific assessor.~ii) Information among participants is kept confidential and blinding from each other. No cross-over is allowed to reduce bias."|Intervention group: Using the Xbox 360 Kinect Control Group: No intervention, continue with daily routine|f|f|f|t
34018213|NCT03501914|NA|SINGLE_GROUP||TREATMENT||NONE||Mindfulness based intervention||||
34018214|NCT02528123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018215|NCT05854017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018216|NCT00000212||||TREATMENT||||||||
34018217|NCT03293784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018218|NCT01767961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018219|NCT02642536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking was Double Blind||t|f|t|t
34018220|NCT02475941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018221|NCT00203086|||COHORT||PROSPECTIVE|||||||
34018222|NCT02870387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018223|NCT00630097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018224|NCT03724526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is a two-arm, parallel, randomized clinical trial. The primary outcome and secondary outcomes was measured by blinded assessors throughout the study period.|The eligible participants will be randomly allocated into intervention and control groups in a 1:1 ratio. The intervention group will receive text messages in addition to usual care for 12 months, while the control group will receive usual care.|f|f|t|t
34018225|NCT05195476|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018226|NCT00010192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018227|NCT02760524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018228|NCT05137470|||COHORT||PROSPECTIVE|||||||
34018229|NCT00093600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018230|NCT02893202|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018231|NCT05896930|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be a standard 14 day EBA design incorporating 2 groups with parallel treatment arms. This design allows comparison of the results of this study with similar prior studies of treatments for TB. No placebo treatment is included in this study - all participants will be given either active study treatment or Rifafour e275® control. The planned sample size is15 participants per treatment group.||||
34018232|NCT01633411|||COHORT||PROSPECTIVE|||||||
34018233|NCT01389583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018234|NCT01411527|||COHORT||PROSPECTIVE|||||||
34018235|NCT06074081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single blinded study in which participants will be allocated into 2 groups by using coin flip method.|Participants are divided into 2 groups Patients in experimental group will receive treatment through Motor-relearning program. Patient in controlled group will receive treatment through mirror therapy .|t|f|f|f
34018236|NCT05142566|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
34100072|NCT04900935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Masking of participants and care providers is not possible in this clinical intervention. However, we will mask the outcomes assessor to minimize bias.|There will be two phases of this research study: 1) an open pilot of 10 patients to refine the intervention and study protocol, in which all patients receive the POISE intervention; followed by 2) a randomized controlled trial in which patients are randomized to receive either the POISE intervention or usual care.|f|f|f|t
34100073|NCT05860400|||COHORT||PROSPECTIVE|||||||
33795289|NCT03763721|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The patient will be blinded in the study, to prevent detection bias in filling out the questionnaires|The design of the study is a prospective, international, multicenter, non-inferiority, randomized controlled interventional clinical trial to compare the outcomes after posterior lamellar surgery with an iOCT optimized surgical protocol, and current practice, where the eye is over-pressurized for a set period of time. These groups will be labelled iOCT optimized protocol (iOCT-p) and current practice protocol (CP-p). Eligible patients will be assigned to either one of the groups. The study will be conducted simultaneously at the University Medical Center Utrecht (UMCU), Maastricht University Medical Center (MUMC) and the University Hospitals Leuven (UZL, Belgium). The inclusion, preoperative and postoperative measurements and questionnaires will take place at the Ophthalmology department of the site were the surgery was conducted. The research activities will be coordinated by the UMCU.|t|f|f|f
33795290|NCT03999866|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||DOUBLE||We used these 4 video laryngoscopes ( c-mac, d-blade, macgrath mac x-blade and airtraq) on the same patient.|t|f|f|t
33795291|NCT06554353|||COHORT||PROSPECTIVE|||||||
33795292|NCT03812978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795293|NCT02557542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33795294|NCT00437346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795295|NCT04358354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795296|NCT02471755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018237|NCT03279211|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||3 groups, one for each protein sources (zein and whey) and one for determination of endogenous amino acid losses (protein-free meal)|f|f|f|t
34100074|NCT00443287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100075|NCT02953964|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100076|NCT04211155|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34100077|NCT03966118|NA|SINGLE_GROUP||TREATMENT||NONE||Avelumab + Paclitaxel / Ramucirumab||||
34018238|NCT00655876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018239|NCT02991677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34018240|NCT00211120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018241|NCT00045903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018242|NCT06356363|||CASE_ONLY||CROSS_SECTIONAL|||||||
34018243|NCT01781000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018244|NCT01207648|||COHORT||RETROSPECTIVE|||||||
34018245|NCT05578365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34018246|NCT01177059|NA|SINGLE_GROUP||OTHER||NONE||||||
34018247|NCT05726461|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018248|NCT00712426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018249|NCT01571076|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018250|NCT00578669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018251|NCT03058653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018252|NCT02075827|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34018253|NCT02655744|||COHORT||PROSPECTIVE|||||||
34018254|NCT03050203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018255|NCT03239886|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm study; all patients will discontinue imatinib (intervention)||||
34018256|NCT02923674|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34018257|NCT01732874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34018258|NCT01825343|||CASE_ONLY||RETROSPECTIVE|||||||
34018259|NCT00132171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018260|NCT06194032|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This study is double-blinded with regard to treatment (baxdrostat or placebo), for all placebo-controlled dose groups (groups where placebo and active substance is given in a cohort, ie, the sponsor, the investigator, all clinical staff involved in the clinical study (except for the unblinded pharmacist), the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding). Moxifloxacin will be administered as an open-label positive control in this study.||t|t|t|f
34018261|NCT04996563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are asked not to unmask themselves at their visit to any staff or their care provider.|Participants are randomly assigned prospectively to one of two interventions to evaluate the effect of the educational video intervention on their knowledge of prolapse and satisfaction in their healthcare decision making for management of prolapse.|f|t|f|f
34018262|NCT04067336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018263|NCT01844739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018264|NCT02180126|||CASE_ONLY||RETROSPECTIVE|||||||
34018265|NCT04418843|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized study (1:1), multicenter, non-blind of consecutive non-pedunculated lesions of serrated and adenomatous histology, homogeneous, with a size greater than or equal to 20 mm (no upper limit in size). Performing cold-EMR vs standard EMR. A non-inferiority study of cold-EMR versus standard EMR.||||
34018266|NCT03727659|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive SHADE therapy for drug use and depression for 10 weeks plus CONNECT FaceBook social support.||||
34018267|NCT02981303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018268|NCT01321463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018269|NCT02184559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018270|NCT03163004|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||One intervention and one control condition||||
34018271|NCT04340921|||COHORT||PROSPECTIVE|||||||
34100078|NCT03379493||SEQUENTIAL||TREATMENT||NONE||||||
34100079|NCT01415453|NA|SINGLE_GROUP||||NONE||||||
34100080|NCT01961011|||COHORT||PROSPECTIVE|||||||
34100081|NCT04380636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100082|NCT05893537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018272|NCT01783249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34018273|NCT01453894|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34018274|NCT04341857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018275|NCT03743792|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34018276|NCT06185335|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018277|NCT02187510|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018278|NCT00587600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018279|NCT00026364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018280|NCT04241666|||OTHER||CROSS_SECTIONAL|||||||
34018281|NCT01900483|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018282|NCT03285308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018283|NCT03073785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018284|NCT01736241|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34018285|NCT05703373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34018286|NCT03172663|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34018287|NCT03011190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34018288|NCT01434186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018289|NCT00701948|||COHORT||PROSPECTIVE|||||||
34018290|NCT04921020|||OTHER||CROSS_SECTIONAL|||||||
34018291|NCT03433144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be unaware of which group they have been randomized into|In this study, patients will be randomized into two groups: and intervention group and placebo. The intervention group will receive a single pre-operative dose of TXA IV (10mg/kg) and the placebo group will receive the same volume of fluid intravenously.|t|f|f|f
34018292|NCT05682690|||COHORT||RETROSPECTIVE|||||||
34018293|NCT02381951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939162|NCT00504452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939163|NCT03245099|||OTHER||CROSS_SECTIONAL|||||||
33939164|NCT00004166|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33939165|NCT02331173|||COHORT||PROSPECTIVE|||||||
33939166|NCT00324454|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939167|NCT03702452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33939168|NCT00790491|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33939169|NCT01714336|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939170|NCT00983944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939171|NCT05551234|||CASE_ONLY||PROSPECTIVE|||||||
33939172|NCT05864391|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This is a single-blind, randomised, placebo-controlled, MAD study with up to 3 study intervention cohorts that are participant- and investigator-blinded.|Each participant is expected to be in the study for approximately 24 weeks, including a screening period of up to 4 weeks, a 12-week study intervention period, and a follow-up visit at week 18 (10 weeks following the final dose). Participants will be randomly assigned in a 3:1 ratio to receive AZD7503 or placebo. Study intervention will be administered via subcutaneous injection.|t|t|t|f
33939173|NCT03678766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939174|NCT01276873|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939175|NCT00982267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939176|NCT05369572|||COHORT||PROSPECTIVE|||||||
33939177|NCT03933553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939178|NCT01943136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939179|NCT01675401|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33939180|NCT03340272|||COHORT||PROSPECTIVE|||||||
33939181|NCT01126385|||CASE_ONLY||PROSPECTIVE|||||||
33939182|NCT04033029|||OTHER||PROSPECTIVE|||||||
33939183|NCT04926870|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33939184|NCT01849549|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33939185|NCT01321333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939186|NCT01392391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939187|NCT05956080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939188|NCT01022918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939189|NCT03689270|||OTHER||PROSPECTIVE|||||||
34100083|NCT04496687|||COHORT||OTHER|||||||
33939190|NCT06307561|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939191|NCT05507515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939192|NCT01558791|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34100084|NCT04882215|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33939193|NCT06374316|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"We will select schools for participation in arm 1 and 2, respectively, based on the feasibility of installing ceiling-mounted and placing portable air purifiers in each relevant classroom. In arm 3, all three classrooms will be equipped with both ceiling-mounted and portable air purifiers, as well as indoor air quality sensors.~For this arm, we will randomize the three classrooms to each of three weekly programs for the air purifiers;~Program 1) Week 1, 4, and 7: Ceiling-mounted ON, Week 2, 5, and 8: No purifier on, Week 3, 6, and 9: Portable ON. Program 2) Week 1, 4, and 7: Portable ON, Week 2, 5, and 8: Ceiling-mounted ON, Week 3, 6, and 9: No purifier on. Program 3) Week 1, 4, and 7: No purifier on Week 2, 5, and 8: Portable ON, Week 3, 6, and 9: Ceiling-mounted ON.~Each classroom will be assigned a computer-generated random number and will based on the ascending order of the random numbers be allocated to the three predetermined sequences of programs."||||
33939194|NCT01681537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939195|NCT05882773|||COHORT||OTHER|||||||
33939196|NCT02182856|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33939197|NCT06319066|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Participants will be allocated to the control (CFO without wedge) or experimental (CFO with W1 or W2) groups according to the seal-envelop randomization technique. Then, they will be assessed all outcomes for the baseline including pain intensity, foot function, plantar fascia thickness, balance outcomes, and gait parameters by the 2nd physical therapist. And the participants will receive the assigned treatment by the 1st physical therapist.|The present study will use a randomized controlled trial (RCT) to determine the effectiveness of CFO for the treatment of patients with PHP. Three treatment groups including the CFO without wedge, the CFO with W1, and the CFO with W2 will be randomly assigned to each participant by a computer-generated randomization. The opaque-sealed envelopes will be used to allocate the groups of participant.|f|f|f|t
33939198|NCT06212518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939199|NCT06144411|||COHORT||PROSPECTIVE|||||||
33939200|NCT01550315|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33939201|NCT00039104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939202|NCT01749436|||COHORT||PROSPECTIVE|||||||
34100085|NCT05516966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||HRS9531 injection compared with placebo and open positive-controlled group|t|f|t|f
34100086|NCT01404065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100087|NCT04170075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34100088|NCT05136521|RANDOMIZED|CROSSOVER||OTHER||NONE||The study is single dose, open-label, randomised, two-period, two-sequence, cross-over, bioavailability and bioequivalence study||||
34100089|NCT00063232||||TREATMENT||NONE||||||
33939203|NCT02831894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939204|NCT00244803|||COHORT||PROSPECTIVE|||||||
33939205|NCT06264336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939206|NCT03506828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind (Investigator) study||f|f|t|f
33939207|NCT06319677|||COHORT||PROSPECTIVE|||||||
33939208|NCT05760651|||CASE_ONLY||PROSPECTIVE|||||||
33939209|NCT02879864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939210|NCT03500419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33939211|NCT04852666|||COHORT||PROSPECTIVE|||||||
33939212|NCT00260806|||COHORT||PROSPECTIVE|||||||
33939213|NCT04912297|||COHORT||PROSPECTIVE|||||||
33939214|NCT01813149|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is best thought of as a single-arm study because the primary purpose for recruiting control patients is to use their skin biopsies as controls when running immunohistochemistry tests for determining α1-adrenoceptors (α1-AR) expression in CRPS patients. The primary outcomes are concerned with making comparisons between subgroups of CRPS patients, and not between CRPS patients and control patients.||||
33939215|NCT00309192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939216|NCT03701932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939217|NCT05748366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939218|NCT05143853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939219|NCT03898856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939220|NCT03615690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939221|NCT02045615|||CASE_CONTROL||RETROSPECTIVE|||||||
33939222|NCT04104308|||COHORT||PROSPECTIVE|||||||
33939223|NCT05240781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized treatment will not be revealed to patient or data analyst at any time during procedure or afterwards until follow-up and analysis has been done.|"Randomized, double-blind, non-inferiority clinical trial enrolling eligible subjects with high bleeding risk and coronary artery disease to be treated by percutaneous coronary intervention at the National Institute of Cardiology Ignacio Chávez in México. Included patients will have follow-up at the outpatient clinic through 1 year, until death or study exit, whichever comes first."|t|f|f|t
34100090|NCT04612231|RANDOMIZED|PARALLEL||TREATMENT||NONE|Research assistants will be masked to control for biases while administering the objective measure at baseline and post- assessment.|The statistician will use a random number generator to assign participants to the T-STEP Intervention condition or the Counseling Only Intervention condition. Assignment will be made separately at each site and with equal numbers assigned to each condition. This will ensure that equal numbers of participants are assigned to each condition across sites per year.||||
34100091|NCT04920292|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33715500|NCT00038857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715501|NCT03012256|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715502|NCT00658593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715503|NCT01239654|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715504|NCT00512707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715505|NCT03982927|||COHORT||PROSPECTIVE|||||||
33715506|NCT05065177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33715507|NCT00937612|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort||||
33715508|NCT01598051|||CASE_ONLY||PROSPECTIVE|||||||
33715509|NCT03223246|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33715510|NCT05016921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715511|NCT04120545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715512|NCT02039622|||COHORT|||||||||
33715513|NCT02533154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33715514|NCT00237198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715515|NCT02356744|||CASE_CONTROL||PROSPECTIVE|||||||
33715516|NCT04378218|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-post trial, observational, feasibility study||||
33715517|NCT05940207|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715518|NCT05010031|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, phase II noninferiority, prospective trial||||
33715519|NCT00242489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33715520|NCT05693441|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715521|NCT02663323|NA|SINGLE_GROUP||TREATMENT||NONE||Single intervention with MeRes100 Device||||
33715522|NCT03054389|||OTHER||RETROSPECTIVE|||||||
33715523|NCT02188212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715524|NCT00662363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715525|NCT03684811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715526|NCT05699395|||COHORT||PROSPECTIVE|||||||
33715527|NCT04604821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of the primary outcome will be blind to treatment condition.|Feasibility Study (Small Randomized Control Trial)|f|f|f|t
33720841|NCT03375918|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The primary outcome is blood pressure (BP) change as recorded in the electronic medical record (EMR) of racial/ethnic minority patients and Medicaid recipients of any race/ethnicity with controlled and uncontrolled hypertension. Secondary outcomes are patient-reported quality of care and clinician communication, and patient adherence to medications, visits and diet changes. Patient participants are masked to the intervention status of their provider trainees.|Clusters of clinical trainees \[stratified by specialty (internal medicine (IM), family medicine (FM), NP students) and by training block\] will be randomly assigned to 1 of 5 start dates. Clinical outcomes will be assessed at the patient level.|f|f|f|t
33795297|NCT00653341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939224|NCT02315794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939225|NCT03008928|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34100092|NCT04168411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100093|NCT03721965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100094|NCT05885997|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data analysts will be blinded to group assignment when analyzing electronic health record data to determine the effectiveness of the program.||f|f|f|t
34100095|NCT01063803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795298|NCT02710708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795299|NCT00149838|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33795300|NCT03053388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795301|NCT03830866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018294|NCT01385982|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34018295|NCT03346486|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Open, fixed sequence diet-switch 4-week intervention||||
34018296|NCT01317355|||COHORT||CROSS_SECTIONAL|||||||
34018297|NCT00658645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018298|NCT01097525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018299|NCT05157867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, placebo-controlled, cross-over study|t|f|t|f
34018300|NCT06219226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33720842|NCT01404325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720843|NCT04028596|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The PROBE design will be used in this study, in which the principal investigator will be blinded to the administration of drugs until the end of the study. The other principal investigator will know about administration, but will not be involved in testing patients.|This study makes use of a 3 x 3 crossover design, in which patients receive a randomized sequence of interventions in pairs of 3 (acetaminophen, nimodipine, no intervention), with a maximum of 12 interventions/measurements.|f|f|t|f
33720844|NCT04142554|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720845|NCT03475966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33720846|NCT02140567|||COHORT||PROSPECTIVE|||||||
33720847|NCT03879382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720848|NCT03006159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720849|NCT02166554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33720850|NCT04336982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720851|NCT00358566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795302|NCT03148496|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33795303|NCT04778917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795304|NCT02964429|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795305|NCT04723706|||COHORT||PROSPECTIVE|||||||
33795306|NCT05741996|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33795307|NCT01591733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795308|NCT05857371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795309|NCT02896699|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33795310|NCT04660214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795311|NCT02045836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795312|NCT01613274|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795313|NCT01716858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795314|NCT05850091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795315|NCT01064817|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795316|NCT03093467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open randomized controlled trial in one mental health center.|f|f|f|t
33795317|NCT04906954|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Phase II||||
33795318|NCT06030713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Timing of umbilical cord clamping is different in the two arms. One gram of Cefazolin (once, intravenous) will be given to one group of women before skin incision compared to 1g cefazolin given to another group of women after umbilical cord clamping during an elective caesarean section.|t|f|f|f
33795319|NCT00281008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939226|NCT05998902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33939227|NCT04966091|||COHORT||PROSPECTIVE|||||||
33939228|NCT05290584|||OTHER||PROSPECTIVE|||||||
33939229|NCT05555914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939230|NCT06013033|||COHORT||PROSPECTIVE|||||||
33939231|NCT02357524|NA|SINGLE_GROUP||OTHER||NONE||||||
33939232|NCT06377215|||COHORT||PROSPECTIVE|||||||
33939233|NCT00519415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33939234|NCT05213689|RANDOMIZED|PARALLEL||PREVENTION||NONE||This cluster-randomized controlled trial (RCT) will evaluate the effectiveness of HIVST delivery approaches on HIV testing uptake among refugee youth in the Bidi Bidi Refugee Settlement. Participants from two villages within each of the two zones (i.e., four geographically different areas) will be randomized together to one of 4 study arms: Arm 1-HIVST, Arm 2- HIVST+ educational comic book, Arm 3-educational comic book, and Arm 4 - standard of care(control). Data collectors will administer tablet-based surveys (baseline and at 3 months).||||
33939235|NCT03500315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939236|NCT03040479|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This is a multicenter, open-label, non-randomized, parallel-group, single dose study.~This study will enroll up to 24 participants and will include 2 hepatic impaired participant groups and one group of control participants with normal hepatic function."||||
33939237|NCT05915429|||COHORT||PROSPECTIVE|||||||
33939238|NCT04327115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||stepped wedge cluster randomised trial||||
33939239|NCT02186340|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33939240|NCT01126372|||COHORT||PROSPECTIVE|||||||
33939241|NCT04143256|RANDOMIZED|CROSSOVER||OTHER||NONE||Four crossover groups and two single arm groups||||
33939242|NCT03864029|||COHORT||RETROSPECTIVE|||||||
33939243|NCT02366806|||CASE_CONTROL||PROSPECTIVE|||||||
33939244|NCT00447395|||||PROSPECTIVE|||||||
33939245|NCT03066687|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33939246|NCT03102424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33939247|NCT03735186|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33939248|NCT03195231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939249|NCT03338699|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In the pilot phase of the study, participating infants will be allocated to circumcision with either the ShangRing or Mogen clamp. Infants will be randomized in a 1:1 fashion. (Total enrollment: 1380)~In the second phase of the study, participating infants will receive circumcision with the ShangRing as part of our Field Study design. (Total enrollment: 1690)~(Total trial enrollment: 3070)"||||
34018301|NCT00468650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018302|NCT02138019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018303|NCT02182869|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34018304|NCT00393965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018305|NCT03241381|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018306|NCT02296021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018307|NCT02618408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018308|NCT02327416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018309|NCT03752463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34018310|NCT05325593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Randomized 1:1||||
34018311|NCT05034276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018312|NCT02839148|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34018313|NCT02889055|||CASE_ONLY||PROSPECTIVE|||||||
34018314|NCT06283576|||COHORT||PROSPECTIVE|||||||
34018315|NCT02632513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018316|NCT01272726|||CASE_ONLY||PROSPECTIVE|||||||
34018317|NCT03996161|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34018318|NCT02709252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018319|NCT05854823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018320|NCT04714320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018321|NCT02309775|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34018322|NCT01660399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018323|NCT01728402|||COHORT||PROSPECTIVE|||||||
34100096|NCT03918031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||If participant meets eligibility criteria, the participant will be randomly assigned to complete a one-session computer-delivered intervention: either (1) personalized feedback intervention on ability to handle discomfort and smoking or (2) personalized feedback intervention on smoking only.|t|f|f|f
34100097|NCT04616235|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"The IL-6R receptor blockade infusion will have bag concealment so that neither the scientific staff or the subject will know if Tocilizumab or saline (placebo) is given and we do not expect the subjects to feel the infusion or the results of the infusion.~All scientific staff will be blinded to group allocation using encryption. Only once all data have been obtained (histology, blood analysis, gene-expression, Western Blot, Flow cytometry, single cell RNA sequencing) concealment will be broken so that statistical analysis can be conducted."||t|f|t|t
34100098|NCT06695767|NA|SINGLE_GROUP||OTHER||NONE||||||
34100099|NCT04213274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100100|NCT05153486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100101|NCT04191096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100102|NCT01795339|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34100103|NCT04181463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939250|NCT05835544|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34100104|NCT00281853|||COHORT||PROSPECTIVE|||||||
34100105|NCT00160875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100106|NCT04026451|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34100107|NCT02002195|||COHORT||PROSPECTIVE|||||||
34100108|NCT05402085|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participant will be blinded as to which diet they are receiving for each day of the 14-day study.|A 120 single-subject trials (n-of-1 trials) is proposed to compare the glycaemic response of three common diets, i.e. a high carbohydrate-low glycemic index diet, a high protein diet, and a high fat diet. An n-of-1 trial is a clinical trial in which a single individual is the entire trial. Each individual serves as his/her own control, and different intervention are administered in a cross-over design.|t|f|f|f
34100109|NCT03701308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100110|NCT05072041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939251|NCT01409265|||CASE_ONLY||PROSPECTIVE|||||||
33939252|NCT05850962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939253|NCT05968794|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and investigators will not be blinded for the intervention.|International, multicenter randomized controlled trial||||
33939254|NCT05381194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939255|NCT06144333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939256|NCT06208410|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33939257|NCT01917136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939258|NCT01943396|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33939259|NCT04952233|||OTHER||RETROSPECTIVE|||||||
34018324|NCT02543619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018325|NCT03844958|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will apply the parallel method and volunteers will be randomized into two groups.||||
34018326|NCT04435821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Pediatric Chronic Pain Patients||||
34018327|NCT03710720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Urn randomization will be monitored by the Principal Investigator.||f|f|f|t
34018328|NCT02590835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018329|NCT06256913|||COHORT||RETROSPECTIVE|||||||
34018330|NCT00121316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018331|NCT01204450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018332|NCT01401621|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34018333|NCT02400242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018334|NCT03233230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018335|NCT00343343|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34018336|NCT03956836|||COHORT||PROSPECTIVE|||||||
34018337|NCT03940794|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment all participants will receive the same verbal instruction||||
34018338|NCT05376709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34018339|NCT02185651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018340|NCT03829696|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective cohort||||
34018341|NCT01882075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018342|NCT05135208|||CASE_CONTROL||RETROSPECTIVE|||||||
34018343|NCT01771471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018344|NCT00760565|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34018345|NCT01415765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018346|NCT02263781|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34018347|NCT01523223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018348|NCT05530343|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
34018349|NCT03479463|||CASE_CONTROL||OTHER|||||||
34018350|NCT04710966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Whereas patients and surgeons were aware of the group assignments, the outcome assessors and data analysts were remained blinded during the study period.|Before initiating the trial, an investigator who was not involved in the study generated a computer-generated randomization list (block length 10, ratio 1:1). Allocation concealment was achieved by using opaque, sealed, sequentially numbered envelopes containing details of group assignment. Assignment occurred after baseline information was recorded. According to preoperative allocation, the patients were given arthroscopic debridement or repair respectively.For the debridement group, only stump refreshing and surrounding soft tissue cleaning were performed. For the repair group, we converted partial tears into full-thickness tears and sutured them|f|f|f|t
34018351|NCT02860221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018352|NCT05813314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018353|NCT00146341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018354|NCT01297387|||COHORT||PROSPECTIVE|||||||
34100111|NCT05137613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100112|NCT06559150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100113|NCT01234987|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100114|NCT04444297|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Investigator and outcomes assessor will be blinded to method of telemedicine. It is not possible to blind participants.|Randomised to 2D then 3D, or 3D then 3D telemedicine consultations|f|f|t|t
34100115|NCT04566510|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster-randomised trial||||
34100116|NCT02992431|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34100117|NCT05382325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100118|NCT02615496|||OTHER||CROSS_SECTIONAL|||||||
34100119|NCT05682144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100120|NCT06674187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100121|NCT05140980|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939260|NCT01433328|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34100122|NCT04082442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939261|NCT02324049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100123|NCT00353574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100124|NCT06054464|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The treatment duration will be up to: 1 day for Treatment Period 1 (PC14586) and 4 days for Treatment Period 2 (PC14586 + ARA) for Parts 1 and 2.||||
34100125|NCT04667728|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A three-month quasi-experimental study with an intervention and control group and ex-ante and ex-post evaluations||||
34100126|NCT06532344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100127|NCT03075631|||COHORT||PROSPECTIVE|||||||
34100128|NCT01680055|||CASE_CONTROL||PROSPECTIVE|||||||
34100129|NCT06064695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100130|NCT05809154|||COHORT||PROSPECTIVE|||||||
34100131|NCT02520947|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34100132|NCT03293563|||COHORT||PROSPECTIVE|||||||
34100133|NCT02088580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939262|NCT02256150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939263|NCT06373224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939264|NCT02180464|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33939265|NCT05030662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sigle,were not involved in the study assessments beyond recording the timed-get-up-and-go test before and after the treatment intervention||t|f|f|f
33939266|NCT03200418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939267|NCT01599611|||CASE_CONTROL||PROSPECTIVE|||||||
33939268|NCT04286737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind will be done in the study. Only parents will be blinded. Two weeks follow up will be done in both groups. Since the researcher should implement the intervention, evaluate and manage the process, it will not be blinded.|The study will be conducted as a single-blind, randomized controlled trial.|t|f|f|f
33939269|NCT01236131|||||CROSS_SECTIONAL|||||||
34100134|NCT02326688|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34100135|NCT00158470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100136|NCT04928339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Each study participant and OR anesthesia team, cardiac surgery team, cardiothoracic ICU team, and nursing staff caring for the participant will be blinded to the study drug the patient received. However, the anesthesia provider performing the block (separate from the provider caring for the patient in the operating room) will not be blinded to the study drug injected and will have access to all monitors deemed appropriate by the primary team caring for the participant.|prospective, single-center, randomized, double-blind, controlled trial|t|t|f|f
34100137|NCT02618187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100138|NCT06047717|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34100139|NCT06563349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The drug or placebo (normal saline) will be placed in a syringe by the principal investigator. Only principal investigator will be aware of the participants allocation. The principal investigator will not be involved in the process of: recruitment, providing an intervention, or outcomes assessment.||t|t|t|t
34100140|NCT02267525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100141|NCT05618626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34100142|NCT04903288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100143|NCT03614780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34100144|NCT03445845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100145|NCT06567860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34100146|NCT02773537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100147|NCT06439082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Study||t|t|t|t
33939270|NCT02495714|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939271|NCT05753124|||CASE_CONTROL||PROSPECTIVE|||||||
33795320|NCT03181763|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Blinded, placebo between group; all participants undergo fear conditioning, with half randomized to receive 100 mg MDMA and half receiving inactive placebo|t|f|t|f
33939272|NCT01678794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795321|NCT03363802|||OTHER||CROSS_SECTIONAL|||||||
33795322|NCT03911479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Short-term, non-blinded, non-randomized longitudinal study comparing obese patients undergoing bariatric surgery with those on clinical treatment.||||
33795323|NCT00617019|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33795324|NCT02431663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795325|NCT00993369|||CASE_CONTROL||PROSPECTIVE|||||||
33795326|NCT06034665|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33795327|NCT06555991|NA|SINGLE_GROUP||OTHER||NONE||||||
33795328|NCT00568659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795329|NCT00492791|||COHORT||PROSPECTIVE|||||||
33795330|NCT03855891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795331|NCT05656846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"1. Recruitment of eligible patients. Patients will receive an explanation of the study protocol, purpose and methodology including the difference between the two study groups. Willing participants will sign an informed consent.~2. Initiation visit, the patient will be randomly assigned to one of the 2 study groups.~3. Following the random assignment, all participants will complete 3 validated questionnaires.~   Addendum 1. Questionnaire: Maternal Antenatal Attachment Scale-MAAS (female) Addendum 2. Revised Prenatal Distress Questionnaire. Addendum 3. After completion of the questionnaires, patients will be instructed on the mode of operation of home ultrasound device (pulsenmore), the frequency and means of communication with the study team.~4. At 20-22 weeks of gestation, completion of the three questionnaires.~5. Collected data~   1. Demographic characteristics~  2. Antenatal follow-up~  3. Results of the various questionnaires"||||
33795332|NCT05503446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessed by double-blind, placebo-controlled food challenge|Parallel arm, with cross-over for those allocated to control group only following determination of primary outcome|f|f|f|t
33795333|NCT04861454|||COHORT||PROSPECTIVE|||||||
33939273|NCT00053482|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939274|NCT03312127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939275|NCT05853640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessors, and participants will be blinded to group allocation. An independent statistician, blinded to treatment allocation, will perform the statistical analysis. Treatment providers will be blinded to study hypothesis and the content of the different treatment arms.|1:1 double blind randomized controlled trial, conforming to the CONSORT statement|t|f|f|t
33939276|NCT00743184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939277|NCT00868738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33939278|NCT02176226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939279|NCT05507086|||COHORT||RETROSPECTIVE|||||||
34018355|NCT00631449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018356|NCT04102813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects are advised that they are going to receive some kind of psychological support after a psychosocial stress. The investigator isn't informed about the randomisation procedures of the two groups.|After a psychiatric, psychological and anthropometric assessment, healthy volunteers will receive the Trier Social Stress Test (TSST) procedure and than they are randomly assigned to 30 min of deep diagrammatic breathing based on Functional therapy (FT) or attention control (AC). All subjects are tested at the baseline (T0), at the end of the TSST (T1), at the end of the treatment (T2) and 30 minutes after the treatment (T3)|t|f|t|t
34018357|NCT02876783|||CASE_ONLY||PROSPECTIVE|||||||
34100148|NCT05829317|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100149|NCT05876312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Masking is only applicable to Phase 1 in HP. Phase 2a is open label and there is no masking.|Model Description|t|t|t|f
34100150|NCT03788928|||CASE_ONLY||CROSS_SECTIONAL|||||||
34100151|NCT06375538|||COHORT||PROSPECTIVE|||||||
34100152|NCT06245603|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre open-label, controlled, randomized clinical trial||||
34100153|NCT01193231|||||PROSPECTIVE|||||||
34100154|NCT01064622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100155|NCT05215561|||COHORT||PROSPECTIVE|||||||
33939280|NCT02207738|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33939281|NCT03066505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects and clinicians will be blind to treatment condition.|Sixteen (16) subjects will receive active treatment with MeRT and the other 15 with sham. Subjects in each study group will be treated 30 min a day, 5 days a week for 4 weeks.|t|t|t|t
33939282|NCT01768039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939283|NCT00397891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33939284|NCT05961514|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33939285|NCT04646850|||CASE_CONTROL||OTHER|||||||
34018358|NCT03055702|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939286|NCT00279266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34100156|NCT06347744|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be stratified based on gender at birth then randomized to one of the study arms|Participants will be stratified based on gender at birth then randomized to one of the study arms.|t|f|t|f
34100157|NCT02957227|||CASE_CONTROL||PROSPECTIVE|||||||
34100158|NCT04883086|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100159|NCT00198744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100160|NCT05336721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100161|NCT00004083||||TREATMENT||||||||
34100162|NCT06077071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100163|NCT04138082|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were blindly assigned to the high dB or low dB group. They were also blinded to the purpose of the study until completion.||t|f|f|f
34100164|NCT05882006|||CASE_CONTROL||RETROSPECTIVE|||||||
34100165|NCT04530552|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100166|NCT00374985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720852|NCT01805024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018359|NCT00520286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100167|NCT05618847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100168|NCT04645693|||COHORT||PROSPECTIVE|||||||
34100169|NCT06034314|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34100170|NCT00358579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100171|NCT01204372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939287|NCT02910492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939288|NCT03720067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939289|NCT03853057|NA|SINGLE_GROUP||OTHER||NONE||||||
33939290|NCT03696576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Speech Language Pathologists (SLPs) will not know which group the participants have been randomized to.||f|t|f|f
33939291|NCT06430736|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, two arm, open-label, single-center trial.||||
33720853|NCT06482476|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33939292|NCT05265494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The intervention to which the subjects have been assigned, the specialist and the researcher who collects the information and carries out the follow-ups will be blinded. Data analysis will also be performed in a blinded way.|Randomized clinical trial with passive control, triple blind (for the patient, the physiotherapist applying the technique and evaluator), with a parallel and multicenter design. The study will have two arms or groups; the intervention group (G1) will undergo neuromodulation treatment with the NESA XSIGNAL® device and the control group (G2) will not carry out any intervention, but both will be evaluated for the same variables at the same times.|t|t|t|f
33939293|NCT03164031|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|"Participants will be trialling two different pairs of shorts, where one pair will be designed as an orthoses and the other will look similar but be looser and not designed to support the hips.~The investigator is also the main outcome assessor and they will be blinded to which pair of shorts will be worn at each stage of the study."||t|f|t|t
33939294|NCT05309499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720854|NCT01259154|||CASE_CONTROL||RETROSPECTIVE|||||||
33939295|NCT01601093|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34018360|NCT01926717|||CASE_CONTROL||RETROSPECTIVE|||||||
33939296|NCT00820014|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33939297|NCT05456516|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33939298|NCT01058395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939299|NCT04093544|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33939300|NCT00006037||||TREATMENT||||||||
34018361|NCT02328222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018362|NCT02875158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018363|NCT03306953|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34018364|NCT01365117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018365|NCT03847103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100172|NCT04595370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Participants who meet the eligibility criteria will be randomized to one of the following treatment group:~1. AZD9977 Dose A + dapagliflozin 10 mg~2. AZD9977 Dose B + dapagliflozin 10 mg~3. AZD9977 Dose C + dapagliflozin 10 mg~4. Dapagliflozin 10 mg"|t|t|t|t
34100173|NCT02455856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100174|NCT03468426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100175|NCT06253793|||OTHER||PROSPECTIVE|||||||
33720855|NCT03095391|||COHORT||PROSPECTIVE|||||||
34018366|NCT05187702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720856|NCT06318793|||COHORT||RETROSPECTIVE|||||||
34018367|NCT00290160|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34018368|NCT01914627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018369|NCT00334100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018370|NCT03731871|||COHORT||PROSPECTIVE|||||||
34018371|NCT01516307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018372|NCT00903448|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34100176|NCT03434301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100177|NCT06590558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100178|NCT05113732|||CASE_ONLY||PROSPECTIVE|||||||
34100179|NCT06419894|||COHORT||PROSPECTIVE|||||||
34100180|NCT01989585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100181|NCT03543020|||COHORT||PROSPECTIVE|||||||
34100182|NCT00984633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100183|NCT05980455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100184|NCT06531473|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34100185|NCT05061134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100186|NCT01399086|||COHORT||RETROSPECTIVE|||||||
33720857|NCT04429737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33720858|NCT00099554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720859|NCT03465592|NA|SINGLE_GROUP||TREATMENT||NONE||"Adults: 240 mg IV (in a vein) over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks. A maximum of 24 cycles will be given on study. Participants may continue to receive Nivolumab unless they develop serious side effects or the tumor worsens.~There were two parts to this study. The first part, Part A, was for patients who have relapsed or have progressive disease after their BMT. Part A is now closed. The second part, Part B, is for patients who have not yet relapsed or progressed after BMT."||||
33720860|NCT02409459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720861|NCT05683054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PASI and IGA score will be performed by a blinded and independent physician.|A prospective, single blinded, randomized, non-inferiority study|f|f|f|t
33720862|NCT03972280|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720863|NCT01505868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720864|NCT03441633|||COHORT||RETROSPECTIVE|||||||
33720865|NCT06346873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795334|NCT06676904|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|There will be no blinding/masking of the treatment group allocation to providers or parents to ensure providers are aware of treatment allocation to guide platelet transfusions. This is necessary to ensure adherence to the treatment arms. However, a standard tool will be used to assess bleeding as described below and grading of the severity of bleeding will be performed centrally. In addition, radiologists interpreting cranial ultrasound findings will be blinded to treatment arm allocation.|Randomized trial with 1:1 allocation to parallel arms within strata of Study Center and gestational age (23-24 weeks and 25-26 weeks PMA). Multiples will be randomized independently. Approximately 30% of enrolled participants are expected to meet the platelet count threshold for randomization. The target sample size for randomization is 730, or 365 per arm.|t|f|t|t
33795335|NCT06647017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and investigator will be blind to participant treatment group assignment. Only the research coordinator will know treatment group assignment.||t|f|t|f
34018373|NCT05617937|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34018374|NCT01324635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795336|NCT03912948|||COHORT||PROSPECTIVE|||||||
33795337|NCT03973944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795338|NCT05800977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018375|NCT03267875|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34018376|NCT01592305||PARALLEL||||NONE||||||
34018377|NCT00477295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018378|NCT03951896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The injection process was made with injectors coated with opaque adhesive tapes, and were prepared by another researcher who wasn't involved in injection or assessment. The statistical analyses were conducted without knowing the content of the groups.||t|f|t|t
34018379|NCT00075036|||COHORT||PROSPECTIVE|||||||
34100187|NCT04188626|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Monocentric preliminary study including an experimental driving session in a driving simulator.||||
34100188|NCT06694025|||COHORT||PROSPECTIVE|||||||
34100189|NCT05206435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100190|NCT06267508|||COHORT||PROSPECTIVE|||||||
34100191|NCT04540900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100192|NCT03623490|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34100193|NCT04929028|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100194|NCT05746884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind|Single-blind, controlled, comparative, randomized, multicentre, international post-marketing follow-up study of a CE marked medical device.|t|f|f|f
34100195|NCT03797326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795339|NCT00523237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795340|NCT04554082|||COHORT||PROSPECTIVE|||||||
33795341|NCT03009864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795342|NCT02430740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100196|NCT01790815|||COHORT||PROSPECTIVE|||||||
33795343|NCT00639002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795344|NCT00851708|RANDOMIZED|PARALLEL||PREVENTION||||||||
33795345|NCT00229268|||COHORT||PROSPECTIVE|||||||
33795346|NCT00356265|NON_RANDOMIZED|PARALLEL||OTHER||NONE||All three groups will have the same intervention||||
33795347|NCT06081686|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795348|NCT02108106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33795349|NCT04302844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent Evaluators are blind to treatment condition||f|f|f|t
33795350|NCT01001078|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34100197|NCT04681937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33795351|NCT03956641|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33795352|NCT04503356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||To prospectively assess the clinical effect of ab-interno transluminal viscodilation and trabeculotomy performed using the OMNI Surgical System as a standalone procedure or in combination with cataract extraction on intraocular pressure (IOP) and the use of ocular hypotensive medications in patients with open-angle glaucoma (OAG).||||
34100198|NCT01574495|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34018380|NCT01974336|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34018381|NCT03332238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018382|NCT00698542|||COHORT||PROSPECTIVE|||||||
34018383|NCT01717586|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018384|NCT00076804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018385|NCT05518084|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34018386|NCT02398357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018387|NCT00218166|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34018388|NCT00548093|NON_RANDOMIZED|||TREATMENT||NONE||||||
34018389|NCT00003174||||TREATMENT||||||||
34018390|NCT01776463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018391|NCT04918316|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018392|NCT00004890||||TREATMENT||||||||
34018393|NCT00666783|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34018394|NCT05633108|||COHORT||RETROSPECTIVE|||||||
34018395|NCT01957072|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34018396|NCT02636192|||COHORT||RETROSPECTIVE|||||||
34018397|NCT05102292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018398|NCT03567382|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34018399|NCT02390141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795353|NCT05516641|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33795354|NCT02539212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795355|NCT01551407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795356|NCT04299984|||COHORT||PROSPECTIVE|||||||
33795357|NCT00866866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018400|NCT03530176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939301|NCT04352244|||OTHER||CROSS_SECTIONAL|||||||
33939302|NCT06402149|||CASE_CONTROL||PROSPECTIVE|||||||
33939303|NCT01207921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939304|NCT05985616|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795358|NCT06385886|||CASE_ONLY||PROSPECTIVE|||||||
33939305|NCT02287363|||CASE_CONTROL||PROSPECTIVE|||||||
33795359|NCT06231355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33939306|NCT04081987|||CASE_ONLY||PROSPECTIVE|||||||
33939307|NCT03415607|||COHORT||PROSPECTIVE|||||||
33939308|NCT04875195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939309|NCT02478658|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939310|NCT01062516|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33939311|NCT00304681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939312|NCT03870646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Identical vials for the intervention and control group|Unicentre, randomized, two arm, double-blind, controlled trial.|t|t|f|f
33795360|NCT04905186|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33795361|NCT05482399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is open-label, with blinded outcome adjudication. Identification of potential outcome events is performed by blinded study team members. Participants, care providers, investigators and outcomes assessors are blinded to the baseline CAC scores.||f|f|f|t
33795362|NCT06676852|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm feasibility clinical trial||||
33795363|NCT00006276||||TREATMENT||||||||
33795364|NCT00483873|||CASE_CONTROL||PROSPECTIVE|||||||
33795365|NCT06199648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only pseudonymous, blinded data will be provided to statisticians for analysis.||f|f|f|t
33795366|NCT06677294|||COHORT||PROSPECTIVE|||||||
33795367|NCT06176716|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795368|NCT06552325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795369|NCT05523674|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33795370|NCT03848234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, add-on to anti-psychotics, double blind, placebo-controlled, parallel group clinical trial|t|t|t|f
33795371|NCT00530517|NA|SINGLE_GROUP||OTHER||NONE||||||
33795372|NCT06297070|||CASE_ONLY||PROSPECTIVE|||||||
33795373|NCT01091831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795374|NCT00576134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795375|NCT03694288|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicenter randomized clinical trial comparing implant retention (Retention) to scheduled removal of implants (Removal) in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.||||
33795376|NCT06280950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795377|NCT01041365|||COHORT||CROSS_SECTIONAL|||||||
33795378|NCT03324035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795379|NCT05241847|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single arm interventional trial with use of the RTC mobile application representing the intervention of interest||||
33795380|NCT03703297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33795381|NCT03599414|||COHORT||PROSPECTIVE|||||||
33795382|NCT05095051|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Healthy subjects will undergo cryocompression of the various temperature and pressure levels in the cryocompression device. One temperature will be tested on 3 subjects for 3 hours. Tolerability of the temperature will be determined through a visual analogue pain scale (VAS). Should 1 out of 3 subjects display intolerance to the temperature level, 3 more healthy subjects will be tested to ensure consistency.~Cancer patient limb cryocompression sessions will comprise of a pre-cooling period, continued with paclitaxel infusion and a post-cooling period. Overall, hypothermia will be administered for no longer than four hours.~Each patient will undergo maximum limb cooling. The initial device settings for the first cycle for each patient will be based on the optimal temperature determined to be safe and tolerable in healthy subjects. Safety and tolerance of the concomitant cryocompression will be measured using VAS."||||
33795383|NCT00000251|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33795384|NCT02894463|||COHORT||PROSPECTIVE|||||||
33795385|NCT06504368|NA|SEQUENTIAL||TREATMENT||NONE||||||
33795386|NCT00012740|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795387|NCT04795544|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33795388|NCT01505881|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939313|NCT00366106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939314|NCT05502120|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018401|NCT00639847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33795389|NCT06554769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split mouth randomized clinical trial|f|f|f|t
33795390|NCT01700400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795391|NCT06085755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795392|NCT05386680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795393|NCT02247713|||COHORT|||||||||
33795394|NCT02553460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795395|NCT05216120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795396|NCT04424303|||COHORT||PROSPECTIVE|||||||
33795397|NCT01701453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795398|NCT04603625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Physicians measuring Migration Percentage (Primary Outcome) will be blind||f|f|f|t
33795399|NCT01800513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795400|NCT05991908|RANDOMIZED|PARALLEL||TREATMENT||NONE||study group with fludarabine, busulfan and melphalan regimen versus control group with fludarabine and busulfan||||
33939315|NCT05569915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939316|NCT03210831|||COHORT||PROSPECTIVE|||||||
33939317|NCT02504424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939318|NCT01503294|||CASE_ONLY||PROSPECTIVE|||||||
33939319|NCT00355381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33939320|NCT00002852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939321|NCT04765839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization outcomes will not be disclosed to participants.||t|f|f|f
33939322|NCT00242814||||TREATMENT||||||||
33939323|NCT00775138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939324|NCT04143828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are randomly assigned to one of two conditions: The intervention group receives a mobile mindfulness programme (mMP). The participants in the control group are wait-listed. They will receive access to the mobile mindfulness programme after three months.||||
33939325|NCT04623281|||OTHER||PROSPECTIVE|||||||
33939326|NCT05365906|||OTHER||PROSPECTIVE|||||||
33939327|NCT01017640|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939328|NCT01931774|||CASE_CONTROL||PROSPECTIVE|||||||
34018402|NCT04780841|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This is a two part study; Part A is open label and Part B is blinded to study participants (all drug labels for treatment arm and placebo will be identical)|In Part A, treatment arms will be dosed based on the results from the previous arm. For Part B, one treatment arm from Part A will be selected|t|f|f|f
34018403|NCT03056820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The person measuring and recording the study data will be blinded.||f|f|f|t
34018404|NCT00700323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018405|NCT00982176|||COHORT||PROSPECTIVE|||||||
34018406|NCT05989113|||CASE_ONLY||PROSPECTIVE|||||||
34018407|NCT02945670|||COHORT||CROSS_SECTIONAL|||||||
34018408|NCT03370731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018409|NCT03081234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018410|NCT00006438|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018411|NCT05451186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Experimental group and control group|This research is a single-blind study with a pretest-posttest randomized control group.|t|f|f|f
34018412|NCT03340142|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018413|NCT03693573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018414|NCT00516009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720866|NCT06297109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The care provider and the investigator are blinded up to the selection of the device used for the surgery, as blinding is no longer possible from this state.||t|t|t|f
33720867|NCT03045081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720868|NCT02965274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720869|NCT05874076|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33720870|NCT04424017|||OTHER||CROSS_SECTIONAL|||||||
33720871|NCT00947479|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720872|NCT04946357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720873|NCT03145025|||COHORT||PROSPECTIVE|||||||
33720874|NCT01326767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720875|NCT01466348|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33939329|NCT01038544|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939330|NCT03013335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720876|NCT03876431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795401|NCT03247543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
33939331|NCT06093152|||CASE_CROSSOVER||PROSPECTIVE|||||||
33939332|NCT02367196|NA|PARALLEL||TREATMENT||NONE||||||
33939333|NCT05138224|||COHORT||PROSPECTIVE|||||||
33939334|NCT02053649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939335|NCT01402622|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33939336|NCT01208844|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33939337|NCT00951912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018415|NCT00215761|||||PROSPECTIVE|||||||
34018416|NCT00158600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018417|NCT00719849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795402|NCT03396848|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patient will have access to an online clinic after their prostate cancer treatment. This is a feasibility study to determine whether it would be feasible to implement SHAReClinic as a pan-Canadian sexual health and rehabilitation intervention||||
34018418|NCT06341634|||CASE_CONTROL||PROSPECTIVE|||||||
33795403|NCT04656886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both the participants and the investigator are blind.|A group of remitted depressed participants will receive an intravenous infusion of ketamine or an inactive placebo, in a double-blind, cross over design. A minimun of 1 week is required between the two study sessions.|t|f|t|f
33795404|NCT06164327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study sets up three cohorts of BEBT-908 combined with different drugs.The researchers decide whether to terminate the cohort study according to the safety and tolerability results of each cohort during the first cycle of medication. If the participants in the above three cohorts are unable to receive the treatment during the first cycle of medication, two alternative cohort studies will be conducted.||||
33795405|NCT00456209|||COHORT||PROSPECTIVE|||||||
33795406|NCT01814150|||COHORT||PROSPECTIVE|||||||
33795407|NCT02195713|||COHORT||PROSPECTIVE|||||||
33795408|NCT04187326|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study team will use a waitlist-control design. A subset of participants will return to complete visual training using the Micro Expression Training Tool (METT). Half of these participants will complete the task at their first follow up visit (approximately six months post scan), and half will complete the task at their second follow up visit (approximately twelve months post scan).~The METT presents videos of micro expressions; participants receive real-time feedback following forced choice emotional identification. The METT includes a brief pre-test, training, and then a post-test. We will collect performance accuracy data. This behavioral task will provide preliminary feasibility data for the development of interventions with visual system targets by helping the investigators determine if the METT is tolerable in individuals with high trait anxiety."||||
33795409|NCT05049538|||COHORT||PROSPECTIVE|||||||
33795410|NCT01420393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795411|NCT02327611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795412|NCT01259102|NON_RANDOMIZED|PARALLEL||||NONE||||||
33795413|NCT04761783|||CASE_CONTROL||PROSPECTIVE|||||||
33795414|NCT02508038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795415|NCT02613806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795416|NCT05846841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Clinicians will be randomized on a 1:1 basis to usual care or precision treatment. Patients will be assigned to the same arm as their clinician.|f|f|f|t
33795417|NCT05132348|||COHORT||PROSPECTIVE|||||||
33795418|NCT03081949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795419|NCT01207362|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33795420|NCT00727038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795421|NCT01366664|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33795422|NCT06393244|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33795423|NCT02470949|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33795424|NCT04785989|||CASE_CONTROL||PROSPECTIVE|||||||
33795425|NCT06079320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be assigned to receive study intervention according to the assigned treatment group from the randomization scheme. Investigators will remain blinded to each participant's assigned study intervention until all participants complete treatment.|This is a Phase 2/ Phase 3, superiority, adaptive, two parallel-arm, randomized, multi-center, placebo-controlled, double-blind study.|t|t|t|t
33795426|NCT03107403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795427|NCT02042898|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795428|NCT04459819|||CASE_ONLY||RETROSPECTIVE|||||||
33795429|NCT03959839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795430|NCT03706261|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795431|NCT00126308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795432|NCT02770495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939338|NCT03660566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33939339|NCT04984811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939340|NCT04059354|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple single subject baseline design||||
33939341|NCT02714894|||CASE_CONTROL||PROSPECTIVE|||||||
33939342|NCT01015066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939343|NCT01962272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939344|NCT06406829|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33939345|NCT02382276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939346|NCT05681533|||COHORT||OTHER|||||||
33939347|NCT02461576|||OTHER||CROSS_SECTIONAL|||||||
33939348|NCT02621281|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33939349|NCT02014285|||COHORT||PROSPECTIVE|||||||
33939350|NCT03480841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939351|NCT01560013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939352|NCT01363154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33939353|NCT05567679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939354|NCT02241356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939355|NCT03961529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939356|NCT04718883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939357|NCT00152997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33939358|NCT03513575|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|only primary investigator will know the intervention done by the subject. The outcome investigator(assessor) will be unaware (blinded) to which intervention the subject is undertaken.||f|f|f|t
33939359|NCT06356441|||COHORT||PROSPECTIVE|||||||
33939360|NCT03961724|||COHORT||PROSPECTIVE|||||||
33939361|NCT00346294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939362|NCT05071222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939363|NCT01566006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018419|NCT06449326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a prospective, randomized, parallel-design, sham-controlled clinical trial.|t|t|f|t
34018420|NCT04398264|||COHORT||OTHER|||||||
34100199|NCT04218682|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This is a waitlist randomized controlled study in which participants are randomly assigned to immediately begin to play the game (intervention) following enrollment versus wait 6 weeks to play the game following study enrollment. Participants will continue to receive all clinical care as usual throughout and following the study.|f|t|f|f
33715528|NCT06378463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomly assigned to CR + sham tDCS (group 1) or CR + active tDCS (group 2) with a 1:1 allocation as per a computer-generated randomization plan using permuted blocks of random sizes. The block sizes will not be disclosed to ensure concealment. As such, both the researcher as the participant can stay blind to the tDCS treatment condition. Also, the assessors who will do neuropsychological tests are blind to the condition the participant is in and are blind to the type and aim of the treatment. After finishing measurement T2, the participants can indicate if they suspect to have experienced either the real or the sham tDCS treatment. The patients will be informed about the type of treatment they have received when all participants completed measurement T3.|This is a pragmatic triple-blinded, randomized, sham-controlled trial, following a non-concurrent multiple baseline design, with the participants serving as their own control. Participants will be randomized over two groups: CIRCuiTS +sham tDCS (group 1), or CIRCuiTS + active tDCS (group 2). The trial will start with a first measurement (T0), followed by a waiting period of 16 weeks and a second measurement (T1). The waiting period serves as the control condition (service users are their own control). Next, the participants will be allocated to 16-20 weeks of either CIRCuiTS + sham tDCS or CIRCuiTS + active tDCS. This period of 16-20 weeks is not fixed as it depends upon how fast participants go through the program. This is followed by a third measurement after treatment (T2). There will be a fourth measurement six months after the end of the intervention (T3).|t|t|t|t
33715529|NCT00006344||PARALLEL||TREATMENT||||||||
33715530|NCT04973826|NA|SINGLE_GROUP||OTHER||NONE||||||
33720877|NCT06399588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This trial will have two groups: intervention and control. The unit of randomisation will be schools, where the adolescents enrolled in school years 8 and 9 in Dhaka, Bangladesh.|t|f|f|f
33720878|NCT03016286|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795433|NCT00756730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939364|NCT00566475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720879|NCT04299308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||2 arm, cross-sectional||||
33795434|NCT00841633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939365|NCT04492306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In our clinical trial double blinding will be performed, the participants and both assessors (H.M.\& N.H.) will be blinded to the type of the material used to reduce performance and ascertainment bias and also reduce biased estimates of treatment effects. The operator cannot be blinded in this trial because of the difference in the application procedures of each restorative material. Therefore, the operator (O.I.) will take care to treat the two allocation groups as equally as possible by standardizing the care of participants, frequency of follow-ups and management of complications.||t|f|f|t
33939366|NCT02393365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939367|NCT00372944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939368|NCT00002625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939369|NCT03420989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939370|NCT05786404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939371|NCT06185036|||OTHER||PROSPECTIVE|||||||
33939372|NCT01078974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939373|NCT05986006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939374|NCT02415582|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33939375|NCT04847167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939376|NCT01728610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33939377|NCT03869931|NA|SINGLE_GROUP||TREATMENT||NONE||In this single-centre, open label study, 300 adults with DN will be recruited over 3 years. Following screening and baseline metabolic evaluations, eligible subjects will be treated with fenofibrate for 30-days and re-assessed.||||
33939378|NCT02288793|||COHORT||RETROSPECTIVE|||||||
33939379|NCT02260791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939380|NCT00453453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939381|NCT00090844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939382|NCT03258762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795435|NCT03368937|NA|SINGLE_GROUP||OTHER||NONE||||||
33795436|NCT01886430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795437|NCT01340261|||CASE_ONLY||PROSPECTIVE|||||||
33795438|NCT04299230|||OTHER||PROSPECTIVE|||||||
33795439|NCT04255888|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795440|NCT00624026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939383|NCT04214470|||CASE_ONLY||PROSPECTIVE|||||||
33939384|NCT04787276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939385|NCT04038437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939386|NCT06214039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939387|NCT04034342|||COHORT||PROSPECTIVE|||||||
33939388|NCT05421416|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33939389|NCT03620500|||COHORT||PROSPECTIVE|||||||
33939390|NCT03444246|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939391|NCT04265859|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adults having mild-to-moderate levels of depression or who will serve as non-depressed/anxious controls. Participants in each of these study groups then will be randomized into two conditions, each of which will receive 2 assessment/MRI appointments along with 6 sessions of guided practice/training in either 1) Re-interpretation or 2) Mindfulness ER techniques. Immediately after the first and sixth practice sessions, participants also will undergo fMRI so that brain function relative to that stage of practice can be assessed.||||
33939392|NCT05713331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939393|NCT05610670|NA|SINGLE_GROUP||OTHER||NONE||||||
33939394|NCT01729806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939395|NCT00984919|||CASE_CONTROL||PROSPECTIVE|||||||
33939396|NCT00979004|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33939397|NCT02706535|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939398|NCT01301209|||COHORT||PROSPECTIVE|||||||
33939399|NCT00090246|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33939400|NCT02863406|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33939401|NCT03058809|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be their own controls||||
33939402|NCT01082042|||CASE_CONTROL||PROSPECTIVE|||||||
33939403|NCT02811640|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939404|NCT02638740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939405|NCT00722735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939406|NCT03590613|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|It is a double-blinded study, where the subjects, investigators and the site-staff will be blinded.|Study will comprise of four TPs, each of at least 7 days in duration with subjects in-house for 4 nights (through 72 hours after the first dose). During each TP, subjects will be admitted to the unit, day before dosing and will be discharged after completion of 72 hours post-dose assessments. dose will be administered TID, in an ascending manner. Every individual subject will receive placebo and GSK2982772 (60, 120,240 mg TID) as per assigned sequence. For TID dosing, GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hour (the second dosing) and 14 hour (the third dosing) on Day 1 in each period. On Day 1, subjects will fast 8hour overnight prior to first dose. breakfast will be served approximately 2hour after first dose. Lunch and dinner will be served between 2 to 3hour prior to second and third doses, respectively. A washout of atleast 7-days between the TP doses for each individual subject.|t|t|t|f
33939407|NCT04093401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33939408|NCT04541836|||CASE_CONTROL||PROSPECTIVE|||||||
33939409|NCT01943266|NA|SINGLE_GROUP||OTHER||NONE||||||
33939410|NCT01327586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939411|NCT06095999|NA|SINGLE_GROUP||PREVENTION||NONE|N/A due to single-arm study.|A mixed-method single-arm pre-post intervention study will be used. Baseline questionnaires (T0) measure demographic, PA and smoking-characteristics. Post-intervention questionnaires (T1) measuring feasibility of the study and Perfect Fit intervention, acceptability of the Perfect Fit intervention and virtual coach, and preliminary effectiveness of the Perfect Fit intervention will be administered 16 weeks after the start of the intervention (i.e., expected end of intervention). Participants who consent to take part in the semi-structured individual interview will be invited for this interview also around 16 weeks after the start of the intervention. Finally, follow-up questionnaires measuring preliminary effectiveness of the Perfect Fit intervention will be administered 24 (T2), 40 (T3), and 64 (T4) weeks after the start of the intervention (i.e., respectively 2, 6 and 12 months after expected end of the intervention).||||
33939412|NCT04659447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939413|NCT03998345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795441|NCT04549532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Design: The current study will employ a single blinded, two-group repeated measures (baseline, 2-week, 4-week, 3-month) design with permuted block random assignment to T-MD and usual care intervention groups.|f|f|t|f
33795442|NCT04010318|||OTHER||PROSPECTIVE|||||||
33795443|NCT05715268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Three month feasibility pilot with a standard of care control||||
33795444|NCT05803850|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Sequential Assignment|t|t|t|t
33795445|NCT00765934|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795446|NCT04271410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795447|NCT04586686|RANDOMIZED|PARALLEL||PREVENTION||NONE||All patients will undergo a laparoscopy for an ovarian biopsy (about 20% of the ovarian volume). The side of the ovarian biopsy will be randomized on the day of the laparoscopy either from the right side (group 1) or from the left side (group 2). All patients will then continue with a controlled ovarian stimulation, using corifollitropin alpha and follitropin beta in a GnRH antagonist protocol using ganirelix. The metaphase II oocyte yield will be evaluated between the biopsied versus non-biopsied ovary to proof a non-inferiority (assuming that a difference of 1 metaphase II oocyte yielded from the biopsied ovary compared to the non-biopsied ovary is not clinically relevant).||||
33939414|NCT00069251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33939415|NCT05490849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795448|NCT06258668|||COHORT||PROSPECTIVE|||||||
33795449|NCT03522558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795450|NCT05724472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is a single blind study. The participant will be unaware of the intervention.|This is a single-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of rVSVΔG-SEBOV-GP vaccine at 3 dose levels in adults in good general health.|t|f|f|f
34018421|NCT03713879|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. rectal indomethacin 100 mg to be administered before or after ERCP~2. a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire) or~3. a PD stent plus rectal indomethacin 100 mg before or after ERCP~In patients randomized to receive PD stenting, the number of attemtps is limited to 5."||||
34018422|NCT01642459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018423|NCT02944383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018424|NCT01219413|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34018425|NCT03743740|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34018426|NCT02445417|||COHORT||PROSPECTIVE|||||||
34018427|NCT01425333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100200|NCT06594159|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Part A and B-Double-blinded Part C-Open-label crossover Part D-Open-label||t|f|t|f
33795451|NCT03768310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795452|NCT06150053|||COHORT||RETROSPECTIVE|||||||
33795453|NCT04852302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795454|NCT05222087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795455|NCT06225427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939416|NCT05386641|||CASE_CONTROL||PROSPECTIVE|||||||
33939417|NCT00712764|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33939418|NCT01710904|||COHORT||PROSPECTIVE|||||||
33939419|NCT02306525|||COHORT||PROSPECTIVE|||||||
33939420|NCT00657748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939421|NCT02019121|||COHORT||RETROSPECTIVE|||||||
33939422|NCT03974711|||COHORT||PROSPECTIVE|||||||
34018428|NCT01339663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018429|NCT04712617|||CASE_CONTROL||PROSPECTIVE|||||||
34018430|NCT02798705|||COHORT||PROSPECTIVE|||||||
34018431|NCT04804865|||COHORT||RETROSPECTIVE|||||||
34018432|NCT05992818|||COHORT||PROSPECTIVE|||||||
34018433|NCT02546336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100201|NCT03449381|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100202|NCT06695403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939423|NCT05305742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939424|NCT01835236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939425|NCT06432361|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33939426|NCT05948722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33939427|NCT00856115|||CASE_CONTROL||RETROSPECTIVE|||||||
33939428|NCT04808167|RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33939429|NCT02939196|||CASE_CONTROL||PROSPECTIVE|||||||
33795456|NCT06113146|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"To cover the true aim of the study, participants will be told that the study is about different types of protein and body composition changes and that this is not a weight-loss study. Participants will be debriefed about the true study aim by email when the last participant finishes the study.~Equal numbers of participants will be randomly allocated to each treatment order. The allocation sequence will be concealed until participants are enrolled and assigned to the intervention orders. Meals will be given a 3 random-digit code to conceal treatment allocation. However, the diets cannot be administered in a fully blinded manner due to the nature of the study foods. Study participants and research staff involved in food provision might be able to identify differences between the diets based on the types of foods served.~Data is blinded by an independent researcher outside of the research project and unblinding will occur after the primary analyses have been conducted."|The study is a balanced-order, block randomized controlled cross-over trial with 2 treatment arms. The study will have a run-in period to determine dietary habits at baseline and a washout period (14 days) to prevent carry-over effects. All participants will receive both treatments and are their own control (within participant design).|t|f|f|t
33795457|NCT01664871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795458|NCT02999477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795459|NCT00373555|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33795460|NCT02206672|NA|SINGLE_GROUP||||NONE||||||
33795461|NCT02928874|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34100203|NCT04032431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physical therapists and bioengineers in charge of outcome assessment are not involved in study design|"This is a prospective, assessor blinded, parallel group pilot RCT that will be conducted at:~1. The Sardinian Center for Diagnosis and Treatment of Multiple Sclerosis, Cagliari, Italy.~2. The Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel.~Participants will be randomly assigned to one of the two intervention groups:~1. Telerehab VR training;~2. Conventional therapy~The two interventions will be comparable in length (8-weeks), frequency (twice weekly) and session duration (50-60 min).~Pre-intervention tests (T0) characterizing groups and obtaining baseline values of primary and secondary outcome measures will be performed one week±3 days prior to the intervention program.~Within one week after completion of the intervention, post-intervention tests will be performed (T1). The same tests will be repeated after 1-month of follow-up (T2). During the follow-up period (T1-T2), patients will be instructed to continue their regular activities."|f|f|f|t
34100204|NCT06689644|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34100205|NCT06694870|||CASE_ONLY||PROSPECTIVE|||||||
34100206|NCT01157429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100207|NCT05714501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100208|NCT05816317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100209|NCT06671665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100210|NCT04297761|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34100211|NCT03856177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Randomization will be based on the last digit (odd vs. even) of the participant's research identifier.|Participants will be randomly assigned into neutral or emotionally evocative conditions prior to assessing EEG brain signals of reward.|f|f|t|f
34100212|NCT03656562|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigator staff, persons performing the assessments, and the clinical trial team (CTT) will remain blind to the identity of the treatment within each cohort from the time of randomization until end of the Week 29 visit||t|f|t|t
34100213|NCT06366958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795462|NCT02393001|||CASE_CONTROL||PROSPECTIVE|||||||
33795463|NCT04838158|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795464|NCT02384070|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33795465|NCT02759965|||OTHER||PROSPECTIVE|||||||
33795466|NCT00004004||||TREATMENT||||||||
33795467|NCT05898152|||CASE_ONLY||PROSPECTIVE|||||||
33795468|NCT05026476|||OTHER||PROSPECTIVE|||||||
33795469|NCT05578053|||COHORT||PROSPECTIVE|||||||
33795470|NCT05530824|||COHORT||RETROSPECTIVE|||||||
33795471|NCT00016471|||DEFINED_POPULATION|||||||||
33795472|NCT05311137|||COHORT||PROSPECTIVE|||||||
33795473|NCT05814211|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33795474|NCT01464736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795475|NCT06478238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939430|NCT00477867||||HEALTH_SERVICES_RESEARCH||||||||
33939431|NCT01029899|||CASE_ONLY||PROSPECTIVE|||||||
33939432|NCT02136264|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33939433|NCT03928249|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33939434|NCT03049852|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33939435|NCT03779828|||OTHER||PROSPECTIVE|||||||
33939436|NCT05237609|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33939437|NCT05473442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, randomized at a 1:1:1 ratio to receive 20 mg of EQU-001, 60 mg of EQU-001 or a matched placebo|t|t|t|t
33939438|NCT04581291|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33939439|NCT04334902|||CASE_CONTROL||RETROSPECTIVE|||||||
33939440|NCT00056628|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33939441|NCT02672982|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33939442|NCT00018694|NON_RANDOMIZED|||||NONE||||||
33939443|NCT04016727|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33939444|NCT04096469|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention group received the motivational interviewing and the comparison group an orientation with a traditional educational approach. Both groups were followed for 8 months and the changes in the variables of interest were analyzed.||||
33939445|NCT03313752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33939446|NCT01113411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939447|NCT05540015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939448|NCT02746991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939449|NCT00692991|||COHORT||PROSPECTIVE|||||||
33939450|NCT00126386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939451|NCT00237081|||||OTHER|||||||
34018434|NCT03880435|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|None of the participants will be informed of the allocated treatment by the surgeon performing the operative hysteroscopy or the personnel present in the OR. The medical record will not reveal any information whether HYALOBARRIER® GEL ENDO was applied at the end of the procedure. The REDCap software will automatically document the allocation and store all the records and the randomisations. The gynaecologist doing the operative hysteroscopy should not be the same as the fertility physician and the gynaecologist doing the second look hysteroscopy. In the exceptional case that the surgeon doing the operative hysteroscopy is the same person as the fertility physician or the gynaecologist doing the second-look hysteroscopy, blinding is assured by notification of treatment allocation if the surgeon has left the operating room.||t|t|t|f
34018435|NCT04576052|||COHORT||RETROSPECTIVE|||||||
34018436|NCT00103311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018437|NCT00462059|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795476|NCT05926596|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be interfered with with a wearable robotic exoskeleton.||||
33795477|NCT04077151|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33795478|NCT02320123|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research staff conducting assessments for all participants was masked to patients receiving the intervention as well as those assigned to the control group.||f|f|f|t
33795479|NCT01029717|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018438|NCT01294826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018439|NCT03785392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795480|NCT03546907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795481|NCT05568264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinicians involved in clinical assessments are blinded to study group|Stratified randomized block design, two-arm, parallel assignment|f|f|f|t
33795482|NCT02033018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795483|NCT04847219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33795484|NCT06676176|||COHORT||PROSPECTIVE|||||||
33795485|NCT05550740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795486|NCT04045106|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33795487|NCT03601780|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795488|NCT04618224|||COHORT||PROSPECTIVE|||||||
33795489|NCT04271449|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33795490|NCT05657496|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Syringes will be prepared and masked with opaque tape by the clinic nurses, thus providing blinding for subjects.|The patient is randomized into one of two treatment arms. Randomization is employed using a computer-generated random assignment sequence and results kept in envelopes. The patient is blinded to the injection received. Subjects receive the injection indicated by study arm at initial visit with a synovial fluid aspiration, urine, and blood collection. At the 1-month visit, subjects provide blood, urine, and synovial fluid aspiration. After the 1-month visit if the patient is experiencing pain and wants an injection, they are instructed to schedule a visit with the PI. If an injection is indicated, the patient is unblinded to which injection they previously received and may choose which to receive. If subject received steroid injection at initial visit, they must wait 3 months before receiving another steroid injection per standard of care guidelines. Subjects is required to complete VAS, KOOS-JR, and UCLA activity surveys at baseline, 2, 4, 8, 12, 24 , 26 and 52 weeks.|t|f|f|f
33939452|NCT01969604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33939453|NCT06091306|||CASE_ONLY||PROSPECTIVE|||||||
33939454|NCT06077123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized in a 1:1 ratio using a permuted block method to receive one of the two intervention strategies.|f|t|t|t
33939455|NCT00302029|||COHORT||PROSPECTIVE|||||||
33939456|NCT06168929|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, Open, Single Dose, Two Sequences, Two Cycles, Self-Crossover Control||||
33939457|NCT04248972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33939458|NCT05497622|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Two groups will be used in the study to evaluate Quantitative Ultrasound Imaging (QUI) biomarkers and TART assessments.~1. Healthy participants. Non-invasive quantitative ultrasound (B-mode image, ultrasound elastography), EMG, and osteopathic assessment (TART assessments) will be performed on the upper trapezius muscle in healthy controls one time at the time of the enrollment.~2. Patients with chromic neck pain. Non-invasive quantitative ultrasound (B-mode ultrasound, ultrasound elastography), EMG, osteopathic assessment, and osteopathic manipulative treatment (OMT) of the upper trapezius muscle will be performed on participants with chronic neck pain 3 times. All ultrasound, EMG biomarkers and TART assessments will be collected before and after OMT."||||
33939459|NCT01183572|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939460|NCT00419029|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33939461|NCT00501930|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33939462|NCT05951374|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33939463|NCT00490477|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939464|NCT03566563|||COHORT||PROSPECTIVE|||||||
33939465|NCT04755699|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||The study will enroll a total of 28 participants. Of the 28 participants, 7 will be healthy volunteers having no disabilities, 7 will be individuals with paralysis or paresis from a spinal cord injury, 7 will be individuals with paralysis or paresis from a stroke, and 7 will be individuals with paralysis or paresis from other brain or nerve injuries.||||
33939466|NCT02733276|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33939467|NCT00443794|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939468|NCT05135507|NA|SINGLE_GROUP||TREATMENT||NONE||Within subject pre and posttest design||||
33939469|NCT03154918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939470|NCT02827084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018440|NCT04068636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018441|NCT00568815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939471|NCT00286156|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34018442|NCT01136993|||COHORT||PROSPECTIVE|||||||
34018443|NCT06195696|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34018444|NCT01019928|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34018445|NCT03738020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||IND approved from KFDA|t|f|f|t
34018446|NCT03277638|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because this is an open-label, safety and tolerability study in which all enrolled subjects will receive Pembrolizumab in Combination with LITT, this study is unblinded.|Three parallel groups given Pembrolizumab injections at different timepoints||||
34018447|NCT04852900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018448|NCT04571125|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018449|NCT00612430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018450|NCT00405886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018451|NCT01631175|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34018452|NCT02473783|NA|SINGLE_GROUP||OTHER||NONE||||||
34018453|NCT04198636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment|t|f|t|f
34018454|NCT00500747|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34018455|NCT01461564|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34018456|NCT06131749|||COHORT||PROSPECTIVE|||||||
34018457|NCT03984123|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34018458|NCT00453557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018459|NCT02807168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34018460|NCT03505879|||CASE_ONLY||PROSPECTIVE|||||||
34018461|NCT05080101|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 28 individual diagnosed with chronic low back pain will be included in this study. The patients who meet the inclusion criteria will be divided into 2 groups randomly as study (n=14) and control (n=14). Patients in control group will receive 40-mins conventional physiotherapy session for 3-days per week, over 6 weeks. Conventional physiotherapy will consist of stretching and strengthening exercises, postural alignment exercises, as well as electrotherapy such as transcutaneous electric magnetic stimulation. Patients in study group will receive Basic Body Awareness Therapy (BBAT) 3 days in a week, over 6 weeks in addition to conventional physiotherapy. BBAT will consist of flexibility exercises and cognitive exercises||||
34018462|NCT05805735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Blinding of sponsor label (de-branded product)|Intra-individual comparison||||
34018463|NCT01430663|||CASE_CONTROL||PROSPECTIVE|||||||
34018464|NCT00085423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018465|NCT00235196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018466|NCT00267943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720880|NCT00645073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018467|NCT05333991|||COHORT||PROSPECTIVE|||||||
34018468|NCT01529918|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34018469|NCT02054130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018470|NCT02488330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018471|NCT01557738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34018472|NCT01182558|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34018473|NCT01432418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34018474|NCT00105976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018475|NCT01763684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018476|NCT01677923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018477|NCT03481218|||CASE_ONLY||RETROSPECTIVE|||||||
33720881|NCT03623360|||COHORT||CROSS_SECTIONAL|||||||
33720882|NCT02042248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720883|NCT03959020|||COHORT||RETROSPECTIVE|||||||
33720884|NCT02692781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33720885|NCT03351179|||CASE_CONTROL||RETROSPECTIVE|||||||
33720886|NCT01829750|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720887|NCT01832870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720888|NCT03559946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients in both CP and SP groups will come to the clinic twice per week, and will not know their group assignment until the end of the study.~All the interventions will be performed by the sub-investigator. The care providing physician will not know the group assignment of the patients."|We will be recruiting 66 patients, who will be randomized (1:1) to either the Standard Protocol (SP) group or the Condensed Protocol (CP) group.|t|t|f|f
33720889|NCT01969240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33720890|NCT03571074|||COHORT||RETROSPECTIVE|||||||
33720891|NCT06144346|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33720892|NCT00957073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720893|NCT00247637|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33720894|NCT01274390|||COHORT||PROSPECTIVE|||||||
33720895|NCT06250985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720896|NCT05823623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720897|NCT04265781|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33720898|NCT06406192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33720899|NCT00130221|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33720900|NCT01754844|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33720901|NCT01341262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33720902|NCT05884047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Semi-experimental|f|f|t|t
33720903|NCT03219294|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The anesthesiologist will NOT be blinded, but the orthopedic surgeon performing the hip replacement surgery will be.||t|f|f|t
33720904|NCT05220163|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33720905|NCT00299013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720906|NCT04843644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33720907|NCT01897142|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33720908|NCT00713154|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33720909|NCT04880967|||COHORT||PROSPECTIVE|||||||
33720910|NCT00099385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720911|NCT01738854|RANDOMIZED|CROSSOVER||||SINGLE|||f|t|f|f
33720912|NCT03128346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded to the randomization|two groups: the nerve block group and the standard of care group|t|f|f|f
33720913|NCT02085733|||COHORT||PROSPECTIVE|||||||
33720914|NCT05573984|||COHORT||PROSPECTIVE|||||||
33720915|NCT03195543|||COHORT||PROSPECTIVE|||||||
33720916|NCT01619345|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33720917|NCT02655042|||COHORT||PROSPECTIVE|||||||
34018478|NCT00749541|||CASE_CONTROL||PROSPECTIVE|||||||
34018479|NCT02866526|||OTHER||CROSS_SECTIONAL|||||||
34100214|NCT04744129|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Quadruple||t|t|t|t
34100215|NCT03975829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795491|NCT00604019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939472|NCT03256123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this study, the subjects will be randomly assigned to two groups: a group receiving biscuits with red palm oil and a control group receiving biscuits with palm shortening with corresponding fatty acids.|t|t|f|f
33939473|NCT01927640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939474|NCT01162967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939475|NCT02967965|||COHORT||PROSPECTIVE|||||||
33939476|NCT05414578|||COHORT||PROSPECTIVE|||||||
33939477|NCT02967406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33939478|NCT06504433|||CASE_CONTROL||PROSPECTIVE|||||||
33939479|NCT05696652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939480|NCT00979264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939481|NCT00688194|RANDOMIZED|||TREATMENT||DOUBLE||||||
33939482|NCT03574987|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomised controlled trial with 3 arms. One arm is a typical diet (50% CHO, 20% SUG), one arm is low sugar (50% CHO, \<5% SUG), one arm is low carbohydrate (\<8% CHO, \<5% SUG). Stratified by sex and physical activity level (PAL).||||
33939483|NCT02938975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Placebo||t|t|t|t
33939484|NCT00162630|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33939485|NCT04429828|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|This is an evaluation of an educational learning package, which is a form of 'supportive intervention' for students provided during the coronavirus pandemic. Therefore the investigators will conduct interviews with people who have used the e-package. The investigators will interview up to 45 participants.|All students have access to the COVID-19 educational package to support psychological wellbeing in healthcare students (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.||||
33939486|NCT04759040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33939487|NCT01115114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939488|NCT01682759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939489|NCT04822090|||COHORT||PROSPECTIVE|||||||
33939490|NCT04999319|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33939491|NCT02880930|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33939492|NCT05022303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and investigator blinded, Pharmacy unblinded.|Placebo and drug arm (10 μg/kg/dose up to 500 μg/dose)|t|f|t|f
33939493|NCT00135408|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33939494|NCT04823858|||OTHER||PROSPECTIVE|||||||
33939495|NCT05299411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939496|NCT06092411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939497|NCT05733468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939498|NCT00001302||||TREATMENT||||||||
33939499|NCT05798702|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33939500|NCT01238757|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33939501|NCT01249521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939502|NCT06381310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939503|NCT01289873|||COHORT||PROSPECTIVE|||||||
33939504|NCT00457158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939505|NCT05723211|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research staff conducting the outcome assessments will be blinded to the participant intervention group assignment.||f|f|f|t
33939506|NCT06253624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939507|NCT04109066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939508|NCT05379621|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33939509|NCT04403074|||OTHER||PROSPECTIVE|||||||
34018480|NCT04442490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018481|NCT03678324|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||20 patients with Fabry and 20 unaffected||||
34018482|NCT04373044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018483|NCT06111274|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018484|NCT03911518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An investigator blinded to treatment assignment determine the cosmetic healing rate at 90 days||f|f|f|t
34018485|NCT04029441|||COHORT||PROSPECTIVE|||||||
34018486|NCT02753491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34018487|NCT06168877|||COHORT||PROSPECTIVE|||||||
34018488|NCT00580216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018489|NCT03050060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018490|NCT05502692|||COHORT||CROSS_SECTIONAL|||||||
34018491|NCT05042115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A simple randomized sequence will be created through the website www.randomization.com by a collaborator external to the researchers directly involved in the research. After the initial assessment, the researcher will access the randomization envelope and the participant will be allocated to 1 of the 2 treatment groups. The allocation will be hidden using opaque envelopes, sealed, and identified by number. The researcher/evaluator will be blinded to the allocation of intervention groups. Given the nature of the study, it is impossible to blind the researcher/therapist and volunteers|Education in Pain Neuroscience through Clinical Hypnosis associated with Osteopathic Manipulative Treatment|f|f|f|t
34018492|NCT04203875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018493|NCT02039466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34018494|NCT04404452|||CASE_ONLY||PROSPECTIVE|||||||
34018495|NCT04390659|||COHORT||PROSPECTIVE|||||||
34100216|NCT00510471|NA|SINGLE_GROUP||||NONE||||||
34100217|NCT05648214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part A: Sequential ascending dose Part B: Parallel|t|t|t|t
34100218|NCT04829214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled, multicenter|t|f|t|t
34100219|NCT05026385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100220|NCT01640535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100221|NCT06461273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100222|NCT00420056|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100223|NCT06688760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100224|NCT02104011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100225|NCT03574532|||COHORT||RETROSPECTIVE|||||||
34100226|NCT05698992|||COHORT||PROSPECTIVE|||||||
34100227|NCT06688812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100228|NCT05698563|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Outcome assessor is blinded to type of patient they are examining.|"This is a prospective diagnostic study, including a patient and a control group.~There is a treatment option with standard treatment for the patient group, if there is indication based on the diagnostic imaging."|f|f|f|t
34100229|NCT04645251|||COHORT||OTHER|||||||
34100230|NCT04385836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100231|NCT04429971|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Part 1 of study will enroll 30 participants. Part 2 of study will enroll 40 participants||||
34100232|NCT02520154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100233|NCT05894798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100234|NCT02373163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100235|NCT02495935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100236|NCT06695000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100237|NCT06685965|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind|Cross-over assignment: low dose, high dose and a placebo in randomized order|t|t|t|f
34100238|NCT06067230|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part A: double-blind Part B: open-label (no masking)|"Part A participants will be randomized into 2 treatment dose groups at a 1:1 ratio.~Part B is non-randomized."|t|t|t|t
34100239|NCT04096885|||COHORT||PROSPECTIVE|||||||
34100240|NCT05439863|||COHORT||PROSPECTIVE|||||||
34100241|NCT05394571|||COHORT||PROSPECTIVE|||||||
34100242|NCT04936269|||COHORT||PROSPECTIVE|||||||
34100243|NCT05100017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100244|NCT06561204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100245|NCT02502838|||COHORT||PROSPECTIVE|||||||
34100246|NCT03760666|NA|SEQUENTIAL||TREATMENT||NONE||Subjects start dosing with brequinar alone; Cohort 2 subjects may roll over into ribavirin dosing; Cohort 3 subjects started with brequinar monotherapy then added ribavirin dosing.||||
34100247|NCT04651296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome evaluator is blind to experimental condition|Experimental condition: manualized compassion meditation protocol, a 10-session group-based meditation training class led by a trained instructor Control condition: manualized health education protocol, a 10-session group-based health education and discussion led by a trained instructor|f|f|f|t
34100248|NCT01087619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100249|NCT05741710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100250|NCT06277830|||COHORT||CROSS_SECTIONAL|||||||
33795492|NCT05185921|RANDOMIZED|PARALLEL||TREATMENT||NONE||182 patients selected by simple randomization from a list of people at the Health Center who meet the eligibility criteria will be divided at study enrollment into an intervention group (n=91) and a control group (n=91). Assignment to each group will be 1:1.||||
33795493|NCT03598478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795494|NCT05881577|||CASE_CONTROL||OTHER|||||||
33795495|NCT00173914|||DEFINED_POPULATION||OTHER|||||||
33795496|NCT02703714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795497|NCT04257435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100251|NCT05199155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100252|NCT01791400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100253|NCT06694363|||COHORT||PROSPECTIVE|||||||
34100254|NCT02004275|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795498|NCT02716220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795499|NCT06676462|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33795500|NCT04287894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795501|NCT01531075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795502|NCT04352283|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled open trial||||
33795503|NCT00485940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795504|NCT02304913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33795505|NCT04135989|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2-by-2 randomization|f|f|f|t
34100255|NCT05038735|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33795506|NCT02845063|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33939510|NCT04955236|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34100256|NCT06105892|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Only the clinical coordinators and technicians (programming the therapy) will know the therapy type. Investigators, clinical examiners, and data analysts, will be masked to therapy type until performing group level analysis.|Each of these participant cohorts (Control and TBI with CI \[PTCI\]) will be randomly halved to generate a total of four cohorts for a semi-crossover study design: 1) BNC Active, 2) BNC Sham \[Placebo\], 3) PTCI Active, and 4) PTCI Sham \[control group\]. PTCI participants in Sham will later undergo active therapy.|t|f|t|t
34100257|NCT04634331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator performing the assessments will be blinded to group allocation.|50 individuals with Parkinson's disease will be randomized to either 1) traditional multi-modal training, or 2) augmented reality multi-modal training.|f|f|t|f
34100258|NCT06586164|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to Targeted Cognitive Training (TCT) + Treatment as Usual (TAU) or Treatment as Usual (TAU)||||
34100259|NCT05705804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100260|NCT04783168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100261|NCT03932786|||CASE_CONTROL||OTHER|||||||
34100262|NCT03055013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100263|NCT05737693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100264|NCT02255383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100265|NCT02057666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100266|NCT05925972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100267|NCT06467864|||COHORT||PROSPECTIVE|||||||
34100268|NCT06202989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All included patients, research personnel, healthcare providers and outcome assessors will be blinded to the treatment allocation.|2-arm parallel group randomized placebo-controlled trial|t|t|t|t
33939511|NCT00934752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939512|NCT02116192|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939513|NCT05138965|||COHORT||PROSPECTIVE|||||||
33939514|NCT01401127|||CASE_CONTROL||PROSPECTIVE|||||||
33939515|NCT03553264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33939516|NCT03719716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be randomised automatically by the local trials unit and allocated a study number. This will be used in all statistical analyses and other quantitative data analysis including the questionnaires. The study researcher will know the identity of the participants she interviews and the qualitative analysis cannot be blinded although all data generated will be anonymised.|Feasibility randomised controlled trial|t|f|f|t
33939517|NCT03318822|||COHORT||PROSPECTIVE|||||||
34100269|NCT06684353|||CASE_CONTROL||PROSPECTIVE|||||||
34100270|NCT06431646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Student|Randomized controlled study with a pretest-posttest design|t|f|f|f
34100271|NCT04166864|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will receive TMS treatment however, we will not disclose the frequency they will be treated at. Each Subject will receive 75 trains of 40 pulses every 26 secs however, the frequency may differ.|||||
34100272|NCT04328727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100273|NCT06694467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100274|NCT01011231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100275|NCT04991519|||CASE_CONTROL||PROSPECTIVE|||||||
34100276|NCT06658080|||COHORT||PROSPECTIVE|||||||
34100277|NCT06639503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The envelope will be opened in the operating room prior to beginning the procedure. This ensures subjects are blinded to their treatment modality.|Subgroups will be determined using equal block randomization. Blocks will be set to groups of 4 with each block of 4 comprising 2 peri-incisional local anesthesia and 2 genicular nerve blockade opaque envelopes in random order.|t|f|f|f
34100278|NCT03511209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the participants and the outcome assessors will be masked.||t|f|f|t
34100279|NCT06585423|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Intraocular pressure (IOP) measurements using 3 different prototype tips. All standard equipment used to perform Goldmann Applanation Tonometry will be used with the only difference being the applanator tip. The 3 different prototypes are as follows and would be tested in random order:~1. - Medical grade acrylic tip covered by a sterile commercially available bandage contact lens (Air Optix, Night and Day Contacts, Alcon). The bandage contact lens will be changed between subjects and the underlying acrylic tip sterilized per standard clinical procedure (bleach soak followed by soak and rinse in sterile water).~2. - Medical grade acrylic tip coated with medical grade silicone of a thickness \&lt; 100 µm. This tip will be sterilized per standard clinical procedure between subjects~3. - Medical grade acrylic tip coated with medical grade silicone of a thickness \&gt; 100 µm. This tip will be sterilized per standard clinical procedure between subjects."||||
34100280|NCT06465602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be assigned to either Nicotinamide or placebo through block allocation. One researcher will be responsible for patient recruitment via telephone and obtaining informed consent. Another researcher will perform patient randomization and drug dispensing. Physiotherapists conducting both the initial and final physical assessments and those conducting rehabilitation sessions will be blinded to the patient's assigned group.|Pilot randomized clinical trial, block allocation, double-blind|t|t|f|t
34100281|NCT04503122|||COHORT||PROSPECTIVE|||||||
33795507|NCT00971711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795508|NCT04563156|||COHORT||PROSPECTIVE|||||||
33795509|NCT00869323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939518|NCT06135558|||COHORT||RETROSPECTIVE|||||||
33939519|NCT04852484|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939520|NCT02426645|||COHORT||PROSPECTIVE|||||||
33939521|NCT05453929|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33939522|NCT00923806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939523|NCT06019351|||OTHER||CROSS_SECTIONAL|||||||
33939524|NCT02624024|||CASE_ONLY||PROSPECTIVE|||||||
33939525|NCT00532987|||COHORT||PROSPECTIVE|||||||
33939526|NCT03312075|||COHORT||PROSPECTIVE|||||||
33939527|NCT00528814|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33939528|NCT04772287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100282|NCT03072342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018496|NCT04761874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a pre-post interventional study following inpatient telestroke intervention for longitudinal treatment of acute ischemic stroke patients at a comprehensive stroke center.~The pre-treatment group is the conventional in-personcohort. The post-treatment group is the telestroke cohort.~The groups were non-randomly allocated. All acute ischemic stroke patients admitted during phase 1 were include in the in-person cohort and all acute ischemic stroke patients admitted during phase 2 were included in the telestroke cohort."||||
34018497|NCT06233084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34018498|NCT01816919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100283|NCT06097481|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will not know if they are in the intervention or sham control arm. Statisticians will not know arm when assessing outcomes.|Study will have two arms, intervention and sham control arms.|t|f|f|t
33939529|NCT06000462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To blind the investigators and participants,150 packs of medication labelled from 1 to 150 numbered randomly from 1-150 (but this depends on number of patients who did not respond to run in period intervention), 50 each containing either 10 mg dapagliflozin or 1000mg metformin or the placebo. The label on the pack only has the serial number but the pharmacist (who is not part of this study) has the code of what each bottle contains and that is kept safely and confidentially (Hard copy and multiple soft copies in safe custody). Participants are numbered serially according to recruitment, and each gets the correspondingly numbered bottle (which has been previously randomly assigned by the pharmacist).|Triple-blind, parallel groups, randomized, placebo control trial|t|f|t|t
34100284|NCT05828823|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized parallel-group type 1 hybrid study||||
34100285|NCT03094221|||COHORT||PROSPECTIVE|||||||
34100286|NCT05855551|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100287|NCT03024671|NA|SINGLE_GROUP||OTHER||NONE||||||
34100288|NCT00002135||||TREATMENT||||||||
34100289|NCT06169423|NA|SINGLE_GROUP||OTHER||NONE|The participants are nursing students. The questionnaire that they will carry out to find out their knowledge and satisfaction will be masked.|This is an activity for simulation-based learning.||||
34100290|NCT05638139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939530|NCT03287830|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The care provider, primary statistician and analyst will be blinded to participant status.||f|t|t|t
33939531|NCT01266876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939532|NCT02059174|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33939533|NCT00245869|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939534|NCT00172237|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33939535|NCT05542472|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939536|NCT03908749|||CASE_ONLY||PROSPECTIVE|||||||
33939537|NCT03181672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939538|NCT00928642|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939539|NCT05038111|||CASE_ONLY||RETROSPECTIVE|||||||
33939540|NCT03953690|||COHORT||PROSPECTIVE|||||||
33939541|NCT04025749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33939542|NCT06355024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939543|NCT00006493||||TREATMENT||NONE||||||
33939544|NCT04465240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939545|NCT04352049|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33939546|NCT02943863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34018499|NCT00437879|||CASE_ONLY||PROSPECTIVE|||||||
34018500|NCT03137927|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The study is dose-escalating, so there will be 3 groups. Group 1: 9 individuals will be vaccinated intranasally with 2,5\*108 bacteria (CFU), 3 individuals will get placebo.~Group 2: 9 individuals will be vaccinated intranasally with 109 bacteria cells(CFU), 3 individuals will get placebo.~Group 3: 9 individuals will be vaccinated intranasally with 4\*109 bacteria cells(CFU), 3 individuals will get placebo."|t|f|f|f
34018501|NCT03178032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018502|NCT05067530|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, multicenter, open, five-arm study with unequal allocation ratios of 1:1:2:1:2 (palbociclib : paclitaxel : palbociclib + paclitaxel : carboplatin : carboplatin + paclitaxel)||||
34100291|NCT03800628|||OTHER||OTHER|||||||
34100292|NCT06567873|||COHORT||CROSS_SECTIONAL|||||||
34100293|NCT05531461|||COHORT||PROSPECTIVE|||||||
34100294|NCT06450340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34100295|NCT04189757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100296|NCT06230055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100297|NCT03104517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018503|NCT04997226|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|"Participants are randomly assigned to one of the four groups and are not aware whether they receive sham or real stimulation.~Data analysis will be conducted with analysts blind to the study condition."|"The investigators will compare 4 intervention protocols aiming to improve memory performance:~tDCS over the left DLPFC with adaptive memory game; Sham-tDCS with adaptive memory game; tACS over the left DLPFC at theta-gamma coupling with adaptive memory game; Sham tACS over the left DLPFC at theta-gamma coupling with adaptive memory game"|t|f|f|t
34018504|NCT00321828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018505|NCT01860911|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34018506|NCT02533375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018507|NCT04275765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Interventional study design||||
34100298|NCT04220190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
34100299|NCT03355261|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100300|NCT03444688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The recruited subjects will be divided into 2 groups through a simple randomization scheme using Microsoft Excel (rand function); 1) Conventional gait training (CT, control group) and 2) Gait rehabilitation with the new walker modified after 1st stage (WT, experimental group). Each subject will undergo training programs consisting of 45 minutes training session (excluding rest periods), 3 days (alternate) a week for 6 consecutive weeks."|f|f|f|t
34100301|NCT06566365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100302|NCT03565588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34100303|NCT04286100|||CASE_CONTROL||RETROSPECTIVE|||||||
34100304|NCT04593329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100305|NCT06618534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100306|NCT05919823|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33720918|NCT05598775|||COHORT||PROSPECTIVE|||||||
33720919|NCT02964468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939547|NCT05202106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Outcome assessors will be blinded to treatment, and final data analysis will be conducted using de-identified and blinded data.|This study is designed as an open-label, 3-arm parallel trial|f|f|t|t
33939548|NCT01591642|||||CROSS_SECTIONAL|||||||
33939549|NCT00510406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939550|NCT01193361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720920|NCT05417945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939551|NCT01934166|NA|SINGLE_GROUP||||NONE||||||
33939552|NCT02129192|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939553|NCT01969227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018508|NCT00506129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018509|NCT03377764|||CASE_CONTROL||PROSPECTIVE|||||||
34018510|NCT04768166|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34018511|NCT00270348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018512|NCT03244943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||40 patients were allocated: periodontitis patients (P) (n=20) and breast cancer with periodontitis patients (CAN/P) (n=20). The clinical parameters: probing depth (PD), clinical attachment level (CAL), plaque index (PI), Bleeding of probing (BOP) and levels of IFN-γ, IL-4, IL-10, TGF-β, IL-17, IL-2, IL-6, IL-1β and TNF-α in gingival crevicular fluid (GCF) were evaluated at baseline, 45 and 180 days after therapy.||||
34018513|NCT01007565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018514|NCT05142098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720921|NCT01622361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939554|NCT01711333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939555|NCT06183060|||COHORT||PROSPECTIVE|||||||
33939556|NCT01713569|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33939557|NCT03386864|||COHORT||CROSS_SECTIONAL|||||||
33939558|NCT03098576|||COHORT||PROSPECTIVE|||||||
33939559|NCT03080506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33939560|NCT02454140|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939561|NCT00539825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34018515|NCT00752830|RANDOMIZED|CROSSOVER||||NONE||||||
34018516|NCT00653952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018517|NCT05276882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34018518|NCT05927272|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||monocentric, open-label study, and translational research.||||
34018519|NCT05980741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||High-quality nursing will be provided to the study group based on primary nursing|f|f|t|t
34018520|NCT05100979|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34018521|NCT03275766|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind||t|f|f|t
34018522|NCT01984203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018523|NCT04639713|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded assessed of the improvement would be done between Last FU images and baseline, following randomization of the images.|All participants will undergo treatment with Tixel 2 Device - 4 treatments, 4 weeks apart and 2 Follow Up visits||||
34018524|NCT02119286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018525|NCT04787874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018526|NCT02569736|||COHORT||PROSPECTIVE|||||||
34100307|NCT05956392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34100308|NCT06566196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100309|NCT02819544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100310|NCT03639051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject and assessor double-blinding will be maintained through 1 year post-procedure.|Subjects will be randomized with equal allocation (1:1) into two arms: TLD therapy plus optimal medical care (Active Treatment) and optimal medical care (Sham Control). Randomization of subjects will be stratified based on investigational site, participation in a pulmonary rehabilitation maintenance program and baseline use of an inhaled corticosteroid at the time of enrollment.|t|f|f|t
34100311|NCT02155855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34100312|NCT04189042|||COHORT||PROSPECTIVE|||||||
34100313|NCT03752073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100314|NCT00675233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100315|NCT05675293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715531|NCT03835585|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Participants are informed that the purpose of the study is to test the effects that providing gun locks as part of a psychological intervention has on gun safety behaviors and that there are two treatment groups and that one is a gun lock group and that one is standard intervention group."|Experimental group and comparison group measured immediately prior to intervention, immediately after intervention, 2 weeks after intervention, and one month after intervention. Analyses conducted will be Repeated Measures Analysis of Variance (RM-ANOVA).||||
33715532|NCT04841031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715533|NCT01124422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715534|NCT04007094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939562|NCT01341574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939563|NCT05422027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939564|NCT01476033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33939565|NCT04337879|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939566|NCT04789564|||COHORT||PROSPECTIVE|||||||
33939567|NCT00311012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33939568|NCT01089946|||COHORT||PROSPECTIVE|||||||
33939569|NCT05499091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In addition to the standard clinical care, blood samples and/or urine samples and/or skin biopsy will be proposed to the included patient to carry out further genetic analysis.||||
33939570|NCT04401072|||OTHER||PROSPECTIVE|||||||
33939571|NCT00278044|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939572|NCT06335589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical interviewers who assess primary outcomes will not be informed of participant's randomization assignment.|Massed PTSD treatment (e.g., cognitive processing therapy \[CPT\] or prolonged exposure \[PE\] therapy delivered at least 3 times per week) will be compared to CPT \& PE delivered as usual, which is usually once per week.|f|f|f|t
33939573|NCT04706715|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33939574|NCT04164264|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939575|NCT01038635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939576|NCT04343027|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33939577|NCT03475355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939578|NCT00643851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939579|NCT01414439|||COHORT||PROSPECTIVE|||||||
34018527|NCT06304025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental (pilot clinical study), randomized, blind, and parallel.|t|t|f|f
34018528|NCT05561530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715535|NCT02989194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715536|NCT03653650|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not blinded study.|Subjects will be randomly assigned to three groups. Demographic characteristics and underlying etiologies will be identified. Subjects will undergo a general ophthalmologic evaluation (baseline) and PED size will be measured. Treatments will be administered until complete defect healing is achieved and visits will be scheduled weekly or as needed for continued ophthalmologic evaluation. After complete closure, subjects will be followed for three months with visits every 2 to 4 weeks to evaluate progress and identify recurrences.||||
33939580|NCT00066716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939581|NCT01545089|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33939582|NCT05235802|||COHORT||PROSPECTIVE|||||||
33939583|NCT02485431|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33939584|NCT02785861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939585|NCT01778140|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939586|NCT02146885|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939587|NCT02065479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939588|NCT02995018|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33939589|NCT04494087|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33939590|NCT05603481|||CASE_ONLY||PROSPECTIVE|||||||
33939591|NCT03437811|||COHORT||CROSS_SECTIONAL|||||||
33939592|NCT05891301|||COHORT||CROSS_SECTIONAL|||||||
33939593|NCT04630561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939594|NCT03549637|NA|SINGLE_GROUP||OTHER||NONE||||||
33939595|NCT01930396|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33939596|NCT00653198|||CASE_CONTROL||PROSPECTIVE|||||||
33939597|NCT00305773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939598|NCT04313894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939599|NCT01997333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939600|NCT06326073|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study included systemic healthy smokers(SP)(n:11) and non-smokers(P)(n:11) with periodontitis, smokers (SH)(n:11) and non-smokers(H)(n:11) with periodontal healthy individuals||||
34018529|NCT00499174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018530|NCT01762930|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34018531|NCT00561704||PARALLEL||TREATMENT||NONE||||||
34018532|NCT01986010|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34018533|NCT03489161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018534|NCT03597685|||COHORT||RETROSPECTIVE|||||||
34018535|NCT03003949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34018536|NCT05000086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018537|NCT01529398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018538|NCT00801359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018539|NCT04334486|RANDOMIZED|PARALLEL||OTHER||NONE||Non-blinded parallel examination of training or non-training effect of video game participation prior to Eyesi surgical simulator evaluation.||||
34018540|NCT03091270|||CASE_CROSSOVER||PROSPECTIVE|||||||
34018541|NCT03164421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018542|NCT04293094|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018543|NCT01642992|||COHORT||RETROSPECTIVE|||||||
34018544|NCT00709839|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34018545|NCT05418166|||COHORT||PROSPECTIVE|||||||
34100316|NCT03876808|RANDOMIZED|PARALLEL||TREATMENT||NONE|At time of consent the randomization is masked for the participant, care provider, and investigator. Once randomization has occurred there is no masking as you clearly know what group has been assigned.|||||
34100317|NCT03958604|NA|SINGLE_GROUP||TREATMENT||NONE||Burst neurostimulation for discogenic low back pain. If this fails to provide pain relief of at least 50%, tonic stimulation targeting the DRG will be the second treatment potential. Follow-up during one year.||||
33715537|NCT04159844|RANDOMIZED|PARALLEL||OTHER||NONE||"3 separate sets :~* URGOBD001 SSI compared with the SSI of a short stretch bandage~* URGOBD001 SSI associated with wading bandage compared with the SSI of a short stretch bandage~* URGOBD001 SSI compared with the SSI of a multi component bandage."||||
33715538|NCT04224311|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715539|NCT01693926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715540|NCT00521378|||COHORT||PROSPECTIVE|||||||
33715541|NCT01454622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715542|NCT00268957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715543|NCT01867268|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33715544|NCT04076319|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Waitlist control design||||
33715545|NCT04208984|||COHORT||PROSPECTIVE|||||||
33715546|NCT00507962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715547|NCT02955485|||COHORT||PROSPECTIVE|||||||
33715548|NCT02514447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715549|NCT01285310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715550|NCT05604690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind. The Sponsor, Investigator, Medical Monitor, study personnel, and participants are not to make any effort to determine which study drug therapy is being received. Unblinded pharmacy (or other qualified site) personnel will be used in this study to prepare the study drug. Assigned unblinded clinical staff will be responsible for overseeing treatment administration.||t|f|t|f
33715551|NCT00456521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715552|NCT02875483|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715553|NCT03238508|||CASE_CONTROL||PROSPECTIVE|||||||
33715554|NCT03569540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715555|NCT05419700|||COHORT||RETROSPECTIVE|||||||
33795510|NCT04725305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not be aware of the arm that the participate will be placed in- i.e. whether the tonsillectomy was carried out by electrocautery or using the BiZact device|Two groups of participants will receive different interventions. One arm will receive the standard of care ( electrocautery) and the other group will receive the BIZACT method of tonsillectomy. The group allocation will be carried out by stratified randomization.|t|f|f|f
33795511|NCT01152970|||CASE_CONTROL||PROSPECTIVE|||||||
33795512|NCT05865314|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33795513|NCT06101992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized double-blind controlled clinical trial|f|f|t|f
33795514|NCT03264846|||OTHER||CROSS_SECTIONAL|||||||
33795515|NCT01102049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34018546|NCT05887895|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study was a single-center, randomized, open, six-sequence, three-cycle crossover phase I study in healthy subjects. The objective of this trial was to compare the PK/PD and safety of HR20014, INS068 and INS062 in a single subcutaneous injection of the same dose.||||
34018547|NCT05441839|||COHORT||PROSPECTIVE|||||||
34018548|NCT00587015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018549|NCT05188053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018550|NCT03153189|||OTHER||CROSS_SECTIONAL|||||||
34018551|NCT05163197|||COHORT||PROSPECTIVE|||||||
34018552|NCT03327636|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be arranged into either HIFU group or AS group randomly||||
34018553|NCT01199679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018554|NCT04690517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018555|NCT04214925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled parallel group|t|f|f|f
34018556|NCT02175576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018557|NCT05174117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018558|NCT05501366|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34018559|NCT05341440|||CASE_ONLY||PROSPECTIVE|||||||
34018560|NCT03814616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018561|NCT06484634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018562|NCT03121430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018563|NCT03967951|||OTHER||RETROSPECTIVE|||||||
34018564|NCT00969631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018565|NCT06079827|||COHORT||PROSPECTIVE|||||||
34018566|NCT02735850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018567|NCT00630019|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34018568|NCT00153608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018569|NCT06037226|||COHORT||CROSS_SECTIONAL|||||||
34100318|NCT04755062|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34100319|NCT02545400|||COHORT||RETROSPECTIVE|||||||
33715556|NCT04817371|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715557|NCT03144362|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33715558|NCT01580189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33715559|NCT01218204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715560|NCT06541600|||COHORT||RETROSPECTIVE|||||||
34100320|NCT05059860|||CASE_CONTROL||PROSPECTIVE|||||||
33715561|NCT06193720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715562|NCT00001995||||TREATMENT||DOUBLE||||||
33715563|NCT03316404|||COHORT||PROSPECTIVE|||||||
33715564|NCT03298594|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The cervicograph of all participants will be reviewed by two assessors blinded to the study group. In order to be blinded, lines will be added to the cervicographs of the control group by a third party not involved in the evaluation||f|f|f|t
33795516|NCT01168154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795517|NCT05919446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blinded (participants and statistician)||t|f|t|f
34100321|NCT04919590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are not explicitly told they are in the control group, although they may deduce their assignment from presence or lack of regular text message intervention.~Research staff doing data collection will not be aware of the random assignments and all participants will receive the same follow-up assessments regardless of assignment."||t|f|f|t
34018570|NCT00937378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018571|NCT05494645|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|patient is blinded to study||t|f|f|f
34018572|NCT03954314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The pharmacy will prepare 2 syringes of 50 ml of topical TxA (5 g) or placebo. They will also prepare for the same patient 2 syringes of 50 ml (5 g) for intravenous (i.v.) injection or placebo. TxA is similar in all aspects to normal saline. Blinding of both teams will be easy. The syringes will be prepared and randomized in pharmacy before the surgery.|Tranexamic Acid intravenous + Placebo topical versus Placebo intravenous + Tranexamic Acid topical|t|t|t|t
34018573|NCT06394843|||CASE_CONTROL||PROSPECTIVE|||||||
34018574|NCT04335318|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34018575|NCT06438536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Stratified block randomization with concealed randomization sequences will be conducted after baseline assessment. Independent assessors blinded to the treatment will evaluate outcomes. Analysis of outcomes will be carried out following the intention-to-treat principles.|The study is a high-quality randomized, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment. A total of 140 adults with ASD will be allocated to receive either 12 weeks of Virtual Reality-based Social Cognitive Training (VRSCT) + treatment as usual (TAU) or TAU. All participants will be assessed at baseline and at 3- and 6-months post-baseline.|f|f|t|t
34018576|NCT02319395|||CASE_CONTROL||PROSPECTIVE|||||||
34018577|NCT06064292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|. The professional that collected the data and the participants were unaware of group assignment.||t|t|t|t
34018578|NCT03933436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018579|NCT01003093|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018580|NCT04173299|||CASE_CONTROL||RETROSPECTIVE|||||||
34018581|NCT03349008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018582|NCT03318276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018583|NCT02843594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018584|NCT01155453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018585|NCT00712205|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34018586|NCT06205017|RANDOMIZED|PARALLEL||OTHER||NONE||"The sample size was calculated in order to identify differences significant in the increase of liking in the study group compared with the control. According to the PI's experience, the frequency of liking in the group control is 5% and this is expected to increase to 70% in the study group.~Considering using a Fisher's exact test with alpha level=0.05, to obtain a power of 95%, 14 patients per group are needed. This number is increased by 10% in case of possible dropouts, for a total of 16 subjects per group and 32 total."||||
34018587|NCT00006472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018588|NCT03576183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator)||t|f|t|f
34018589|NCT01490931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018590|NCT00432302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018591|NCT01779154|||COHORT||PROSPECTIVE|||||||
34018592|NCT02785536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018593|NCT04386174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018594|NCT01031563|||||OTHER|||||||
34018595|NCT04182048|||COHORT||PROSPECTIVE|||||||
34018596|NCT03217396|||CASE_CONTROL||OTHER|||||||
34018597|NCT04774887|NA|SINGLE_GROUP||PREVENTION||NONE||Children of mothers in the study will receive the HPV vaccine as per Kenya guidelines.||||
34018598|NCT06168565|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34018599|NCT02905214|||COHORT||PROSPECTIVE|||||||
34018600|NCT01305148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018601|NCT00001586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018602|NCT01390285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34018603|NCT03832036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100322|NCT04319198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795518|NCT01282346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795519|NCT00839241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795520|NCT04779892|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Biological: CMAB008 Biological: Remicade|t|f|t|f
33795521|NCT05254769|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm Pre and Post intervention Design||||
33795522|NCT04040413|||COHORT||PROSPECTIVE|||||||
33795523|NCT03272035|||OTHER||CROSS_SECTIONAL|||||||
33795524|NCT02425917|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33795525|NCT03949855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795526|NCT03814252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795527|NCT06075212|||CASE_CONTROL||PROSPECTIVE|||||||
33795528|NCT01899027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795529|NCT03160781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018604|NCT01449279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018605|NCT03487783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018606|NCT04099173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018607|NCT00808964|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34100323|NCT05094037|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33795530|NCT06110533|||CASE_ONLY||RETROSPECTIVE|||||||
33795531|NCT06668597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795532|NCT06450730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795533|NCT04064801|||COHORT||RETROSPECTIVE|||||||
33715565|NCT01169142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715566|NCT02562430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715567|NCT00060112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715568|NCT03030872|||CASE_ONLY||RETROSPECTIVE|||||||
33715569|NCT06422130|||COHORT||PROSPECTIVE|||||||
33715570|NCT04203784|||COHORT||PROSPECTIVE|||||||
33715571|NCT00280462|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33715572|NCT03320785|||COHORT||PROSPECTIVE|||||||
33715573|NCT02759471|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33715574|NCT03156543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939601|NCT05563441|||CASE_CONTROL||RETROSPECTIVE|||||||
33939602|NCT06116474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups with a conventional control group||||
33939603|NCT06178835|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33939604|NCT00095394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939605|NCT03180320|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given the nature of the intervention, it is not possible to blind the patients and personnel involved in conducting the programs.|||||
33939606|NCT02835391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939607|NCT00404326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939608|NCT01100203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939609|NCT02879435|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33939610|NCT05679076|||COHORT||CROSS_SECTIONAL|||||||
33939611|NCT05199558|||COHORT||PROSPECTIVE|||||||
33939612|NCT00238160||||TREATMENT||||||||
33939613|NCT03430726|NA|SINGLE_GROUP||OTHER||NONE||All eligible participants will be assigned to receive the commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.||||
33939614|NCT00170846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33401089|NCT05840419|||CASE_CONTROL||RETROSPECTIVE|||||||
33715575|NCT02401815|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715576|NCT00995826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715577|NCT02987920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715578|NCT05756946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33715579|NCT05846191|NA|SINGLE_GROUP||OTHER||NONE||Evaluation of serum pentraxin 3 and high sensitive CRP in female patients with gestational diabetes mellitus in second trimester of pregnancy.||||
33715580|NCT04752150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesiologist who performs postoperative pain evaluation and the patient will not know the group.|There are two models for this study. The first group is ESPB group. The second one is RIB group|t|f|f|t
33715581|NCT04386980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795534|NCT00001524||||TREATMENT||||||||
33795535|NCT04339374|||COHORT||PROSPECTIVE|||||||
33795536|NCT05774444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All supplements with be colour and flavour matched|Parallel 2x2 factorial design|t|t|t|t
33795537|NCT03107806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33795538|NCT00897546|||OTHER||RETROSPECTIVE|||||||
33795539|NCT04219930|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33795540|NCT00422617|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33795541|NCT01548846|NA|SINGLE_GROUP||||NONE||||||
33939615|NCT00299481|||||PROSPECTIVE|||||||
33939616|NCT01854957|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33795542|NCT06676592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939617|NCT00062972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33939618|NCT04693091|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A pilot stage, exploratory, First-In-Human and traditional feasibility, interventional study of the Senti V1.0 device (CE marked, Class I device), involving 10 patients attending A\&E, who are being discharged into the care of the community respiratory team. 5 devices will be used, to cover a range of sizes from extra-small to extra-large.||||
33939619|NCT01183611|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33939620|NCT01584128|||COHORT||PROSPECTIVE|||||||
33939621|NCT02940353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939622|NCT05312359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939623|NCT00529152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939624|NCT03397199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939625|NCT01246024|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939626|NCT03264027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the participant and the outcome assessor will be blinded to the study intervention.||t|f|f|t
33939627|NCT02853318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939628|NCT01089933|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939629|NCT02067546|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939630|NCT01309646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939631|NCT00757289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939632|NCT06354920|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental randomized controlled trial||||
33939633|NCT04039295|||CASE_ONLY||PROSPECTIVE|||||||
33939634|NCT04627233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939635|NCT03236935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939636|NCT06104709|||COHORT||PROSPECTIVE|||||||
33939637|NCT06071533|||COHORT||RETROSPECTIVE|||||||
33939638|NCT01183130|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939639|NCT02572869|||COHORT||RETROSPECTIVE|||||||
33939640|NCT00395720|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939641|NCT06330649|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Individuals will be randomly assigned to either an experimental or a control condition.|f|f|t|f
33939642|NCT03376360|||COHORT||RETROSPECTIVE|||||||
33939643|NCT00642122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33939644|NCT02842255|NA|SINGLE_GROUP||||NONE||||||
33939645|NCT01584115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939646|NCT02469506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939647|NCT03290586|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33939648|NCT04056962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939649|NCT03187626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939650|NCT03116633|||COHORT||PROSPECTIVE|||||||
33939651|NCT02429206|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33939652|NCT03884049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Double-blinded randomized placebo-controlled clinical trial|t|f|t|f
33939653|NCT01790763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939654|NCT03802201|NA|SEQUENTIAL||TREATMENT||NONE||"Multiple PTG-300 dose levels/regimens are planned to be tested for each subpopulation of β thalassemia (NTD and TD) on separate arms:~* Cohort 1: 3 mg subcutaneous (SC) weekly~* Cohort 2: 10 mg SC weekly~* Cohort 3: 20 mg SC weekly~* Cohort 4a: 40 mg SC weekly~* Cohort 4b: 40 mg SC every 2 weeks~* Cohort 7: 80 mg SC weekly~* Cohort 8: 40 mg SC twice a week~Additional Cohorts (Cohorts 5,6,9,10, and 11) will include subjects between 12 years of age and less than 18 years of age."||||
33939655|NCT02010073|||COHORT||PROSPECTIVE|||||||
33939656|NCT03725566||SEQUENTIAL||OTHER||NONE||||||
33795543|NCT03089840|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, open-label, single arm, prospective trial using retrospective matched controls||||
34100324|NCT03609944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In addition to the participant and the investigator assessing outcomes, study coordinators involved in collecting outcomes data will be masked to the treatment assignment.|Subjects will be randomized 1:1 to either EUS+sham or EUS+ERCP with miES.|t|f|f|t
34100325|NCT06077747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100326|NCT04488419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel-group study|t|t|t|t
34100327|NCT06081348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100328|NCT02096159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795544|NCT04102462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795545|NCT00230399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795546|NCT06246435|||OTHER||RETROSPECTIVE|||||||
33795547|NCT02073123|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795548|NCT05209386|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795549|NCT04414904|||CASE_CONTROL||PROSPECTIVE|||||||
33795550|NCT03996863|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The sponsor will be randomly assigning the Otoband or placebo device to participants. The investigator will not know which device is assigned.|"Patients who qualify for the study based on their response to the first round of chemotherapy will be randomly assigned to one of two groups for their second and third rounds of chemotherapy.~Half of the patients will be given a device set at working parameters believed to significantly mitigate nausea for their second round, and a placebo device for the third round of chemotherapy. The second half of the patients will receive the placebo device for the second round and the effective device for the third round."|t|f|t|f
33795551|NCT01633606|||COHORT||PROSPECTIVE|||||||
33795552|NCT00976937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795553|NCT01060137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795554|NCT04045977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795555|NCT04003805|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795556|NCT01563380|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33795557|NCT00261534|||DEFINED_POPULATION||PROSPECTIVE|||||||
33795558|NCT00004266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795559|NCT02076451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795560|NCT02741349|||COHORT||PROSPECTIVE|||||||
33795561|NCT03183518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33795562|NCT00724217|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795563|NCT03703219|||COHORT||PROSPECTIVE|||||||
33795564|NCT05817630|||COHORT||RETROSPECTIVE|||||||
33795565|NCT00448721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795566|NCT02043483|||CASE_CONTROL||PROSPECTIVE|||||||
33939657|NCT02827331|||COHORT||RETROSPECTIVE|||||||
33795567|NCT00908817|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33795568|NCT03185780|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients with high grade glioma undergoing adjuvant (post-surgical) chemo-radiation treatment will be treated with acupuncture and/or touch therapies, this in parallel to their conventional treatment regimen. The primary study outcome will be the scores on four Patient-Reported Outcome Measures (PROMs): the Measure Yourself Concerns and Wellbeing (MYCAW) study tool; the Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br) questionnaire; the Edmonton Symptom Assessment Scale (ESAS); and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30). Secondary study outcomes will include the safety of the complementary medicine treatments, and adherence to the planned oncology treatment regimen, as measured by the Relative Dose Intensity (RDI) calculation.||||
33795569|NCT06312618|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33795570|NCT05172752|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795571|NCT05752513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33795572|NCT04740164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795573|NCT01985269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795574|NCT01305733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795575|NCT00869817|||COHORT||PROSPECTIVE|||||||
33795576|NCT06247085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939658|NCT00151528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939659|NCT00045019|||CASE_ONLY||PROSPECTIVE|||||||
33939660|NCT05515653|||CASE_CONTROL||PROSPECTIVE|||||||
33939661|NCT05737004|||COHORT||PROSPECTIVE|||||||
33939662|NCT00997464|||COHORT||PROSPECTIVE|||||||
33939663|NCT01676428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939664|NCT03761628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939665|NCT02976090|||COHORT||RETROSPECTIVE|||||||
33939666|NCT03566849|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled trial (RCT) with two treatment groups, kinetic chain management approach (KC) and conventional training of scapula dyskinesis (CT).||||
33939667|NCT05647928|||COHORT||RETROSPECTIVE|||||||
33939668|NCT06002815|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939669|NCT03929614|||COHORT||CROSS_SECTIONAL|||||||
33939670|NCT03409640|||COHORT||PROSPECTIVE|||||||
33939671|NCT00326976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939672|NCT02926690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939673|NCT02894606|||CASE_CONTROL||PROSPECTIVE|||||||
33939674|NCT01177826|||CASE_CONTROL||PROSPECTIVE|||||||
33939675|NCT01157962|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34100329|NCT02594956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100330|NCT03491085|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34100331|NCT05804292|||COHORT||CROSS_SECTIONAL|||||||
34100332|NCT02221297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100333|NCT06072430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100334|NCT05645692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100335|NCT03003897|||COHORT||PROSPECTIVE|||||||
34100336|NCT01742052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100337|NCT05877365|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||diet only vs whole food supplement based intervention|t|t|f|f
34100338|NCT04560309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795577|NCT06013878|||COHORT||PROSPECTIVE|||||||
33795578|NCT00478738|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33795579|NCT05214924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795580|NCT02281838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795581|NCT01147341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018608|NCT03891186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Eligible participants will be recruited by the investigators in collaboration with the multidisciplinary team of each institution. A baseline assessment will be carried out and the instruments will be applied after informed consent by participants. Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). The control group will not participate in the MCT program. In both groups will be maintained the TAU. The variables for whom the participants are stratified are educational level, duration of mental disorder and type of treatment. All participants will be re-assessed at the end of the program and three months later. The program will be applied during four weeks (two session per week).|Metacognitive Training For Schizophrenia|f|f|t|t
34018609|NCT00317252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018610|NCT03097835|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This will be a longitudinal study in which patients will be initially treated with hyper-diluted Botox Cosmetic in the superficial dermis or they will be treated 0.9% saline. Then, on day 30 of the study patients initially treated with hyper diluted Botox Cosmetic will be treated with saline and patients initially treated with saline will be treated with hyper-diluted botox.|t|t|t|t
34018611|NCT05971654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018612|NCT02658825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34100339|NCT01723566|||COHORT||PROSPECTIVE|||||||
34100340|NCT00501943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34100341|NCT03787212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100342|NCT06694545|||COHORT||PROSPECTIVE|||||||
33795582|NCT04835181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795583|NCT06300489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795584|NCT01809392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795585|NCT01199575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795586|NCT01667302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795587|NCT01813812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795588|NCT05865938|||COHORT||PROSPECTIVE|||||||
33795589|NCT01092494|||COHORT||RETROSPECTIVE|||||||
33795590|NCT01976936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33795591|NCT02419261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795592|NCT03637231|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33795593|NCT05827393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939676|NCT01724164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939677|NCT02766309|||||CROSS_SECTIONAL|||||||
33939678|NCT02590172|||COHORT||PROSPECTIVE|||||||
34100343|NCT01520714|RANDOMIZED|PARALLEL||||NONE||||||
34100344|NCT04514549|||COHORT||PROSPECTIVE|||||||
34100345|NCT03149380|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34100346|NCT04257513|||COHORT||PROSPECTIVE|||||||
34100347|NCT00000810||||TREATMENT||||||||
34100348|NCT05865535|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100349|NCT06522529|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental, uncontrolled, before-and-after study||||
33795594|NCT03818204|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Masked/blinded clinical staff will apply the lid magnets polarized either through thickness or through height (counterbalanced) to the study subjects. Also, 10 magnets of different sizes will be placed inside a plastic housing in order to prevent bias (participant and clinical staff will not know the actual size of the magnets) and counterbalance to control for order effect.|This is a prospective cross-over study with some aims having double-blind methodology. Randomization and masking will be used in aims 1 and 2 experiments. Aim 1: The spectacle magnet will be rotated to 1 of 4 settings in an order which will be counterbalanced using a Latin Square approach. Patient and experimenters will be masked to the actual force setting. Aim 2: 17 participants were randomized to be fitted first with either through thickness or through height polarization of the lid magnets using an online randomizer by a study staff not involved in the data collection or analysis who will keep the code. Every other subject in the sequence will be balanced to receive the alternative order. Counterbalancing is being used because of the small sample size.|t|f|t|t
33939679|NCT06025656|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33939680|NCT04052906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33939681|NCT05606549|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33939682|NCT01216644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939683|NCT03186079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33939684|NCT03350724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939685|NCT05644613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939686|NCT04467866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939687|NCT05330429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939688|NCT05290441|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||cross-sectional interventional clinical research||||
34100350|NCT03718403|NA|SINGLE_GROUP||OTHER||NONE||Open label intervention study, off label use of theophylline||||
34100351|NCT05719389|||CASE_ONLY||PROSPECTIVE|||||||
34100352|NCT04581629|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100353|NCT00932503|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34100354|NCT03535519|||COHORT||PROSPECTIVE|||||||
34100355|NCT05655507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100356|NCT04973384|||COHORT||CROSS_SECTIONAL|||||||
34100357|NCT06631339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study is a double-blind, semi-randomised controlled trial in which neither the study participants, the investigators nor study personnel responsible for measuring and analysing the study outcomes will be aware of the treatment given.~Study team will document consent to participate and non-objection response to classroom lighting change. A 100% non-objection rate from the parents of students within one classroom will be required prior to changing the classroom lighting. Randomization: Classrooms randomly be assigned into technical or other arms (cluster). Students from classrooms not included in the technical arms will be randomized into control or digital intervention arm.~For the purpose of maintaining double-blind, all participants (parents) will be given LightUP application that will either be sham or interventional. Only a group of unmasked study personnel will know the treatment allocation and they will not be involved in data collection and analysis of results/data."|Primary School-based, 12-Month, semi-randomised, controlled, double-blinded, 3 study arm (n=132 per arm) trial.|t|t|t|t
34100358|NCT01123525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100359|NCT04422132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100360|NCT01649583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795595|NCT06271590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2:1 randomized trial (MagicTouchTM Sirolimus-Coated Balloon VS Drug eluting stent (ZES or EES)|t|f|f|t
33795596|NCT00288392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33795597|NCT04562636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795598|NCT04798248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795599|NCT02163876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795600|NCT02678091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795601|NCT02401646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33795602|NCT00465829|||COHORT||PROSPECTIVE|||||||
34018613|NCT04145453|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|lnvestigator is responsible for collecting the questionnaires and anonymizing the data|"To achieve the goals of the study, a group of healthy adults will be qualified. Genotype will be assed at the baseline. Consumption of fruit and vegetables will be assessed before and after intervention. The duration of the study will be 20 weeks. Blood results and body analyze will be assessed at the beginning and after the intervention. Overall food consumption will be assessed at the beginning. For the basic characteristics of study participants, their anthropometric and biochemical parameters will be analyzed twice at the baseline and after intervention. The intervention effect, including the TAS2R38 polymorphism, will be analyzed by statistical analysis.~In a randomized manner volunteers will be assigned to one of three groups: intervention and two control group."|f|f|t|f
34018614|NCT03569150|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||cluster-assigned pilot, wait-list control||||
34018615|NCT01483053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018616|NCT06414070|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster-randomized controlled trial; stratified randomization based on urban/rural location||||
34018617|NCT00704093|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34100361|NCT02852005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100362|NCT06168799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100363|NCT04572230|||COHORT||PROSPECTIVE|||||||
34100364|NCT05068830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blinded, randomized controlled clinical phase II trial|t|f|t|f
34100365|NCT01783236|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34100366|NCT06681220|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2, multicenter, randomized, clinical trial to assess the efficacy of Temozolomide with PARP inhibitor in biomarker selected relapsed SCLC patients. Participants will be stratified into biomarker-positive and biomarker-negative subgroups. Biomarker-positive participants will be randomized 2:1 to receive ARM 2 (experimental combination of TMZ+ PARP inhibitor or Lurbinectedin). Arm 1 (control, biomarker-negative) participants will be treated with the standard of care Lurbinectedin.||||
33795603|NCT06555159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants do not know if they belong to the control group or the experimental group Simple randomization will be performed using sealed envelopes, each containing a letter indicating group assignment that will not be seen by participants||t|f|f|f
33795604|NCT03097744|||CASE_ONLY||RETROSPECTIVE|||||||
33795605|NCT03151655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795606|NCT06315049|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33795607|NCT04352803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an Interventional, Prospective, Open label (Voluntary Assignment), single to multiple center expansion, unmatched controlled, Sequentially Interim analysis tested Trial||||
33795608|NCT00971789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939689|NCT02473380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939690|NCT03018028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939691|NCT03701373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939692|NCT03907943|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33795609|NCT00362869|RANDOMIZED|PARALLEL||||DOUBLE||||||
33795610|NCT01281371|||COHORT||PROSPECTIVE|||||||
33795611|NCT06107582|||COHORT||PROSPECTIVE|||||||
33795612|NCT02165748|||COHORT||PROSPECTIVE|||||||
33795613|NCT04496362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795614|NCT04638374|||CASE_ONLY||PROSPECTIVE|||||||
33795615|NCT00984737||||DIAGNOSTIC||||||||
33939693|NCT00694265|||COHORT||PROSPECTIVE|||||||
33939694|NCT01872273|||CASE_ONLY||PROSPECTIVE|||||||
33939695|NCT01977040|||COHORT||RETROSPECTIVE|||||||
33939696|NCT03348644|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, multiple crossover study||||
33939697|NCT01896648|||COHORT||OTHER|||||||
33939698|NCT00739440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939699|NCT03539900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939700|NCT00798733|||COHORT||PROSPECTIVE|||||||
33939701|NCT02580136|||COHORT||PROSPECTIVE|||||||
33795616|NCT00390299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939702|NCT04267939|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33939703|NCT01246921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939704|NCT04319835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939705|NCT02504606|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34100367|NCT05877287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||parallel group (experiment-control) randomized controlled experimental|t|f|f|f
34100368|NCT02597361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100369|NCT03741842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33939706|NCT02327182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939707|NCT01842334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939708|NCT04115605|||CASE_ONLY||PROSPECTIVE|||||||
33939709|NCT03188133|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939710|NCT00906542|||COHORT||PROSPECTIVE|||||||
33939711|NCT00187733|||COHORT||PROSPECTIVE|||||||
33939712|NCT05840627|NA|SINGLE_GROUP||OTHER||NONE||||||
33939713|NCT01197976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33939714|NCT02268942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939715|NCT00757354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018618|NCT06420544|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Acceptability, feasibility and efficacy of this intervention will be measured, including the measurement of outcomes (skill formation) compared with a 'placebo' control group among pre-school children from low socio-economic backgrounds in Santiago. A mixed-method design with a strong qualitative component to understand better the factors that might facilitate or interfere with the delivery and acceptability of this intervention will be conducted. At the start of the study there will be a mapping the structure of the schools, the locations, staff composition, characteristics of the children and families, and other contextual factors important for the successful implementation of the intervention.~Schools that fulfil the inclusion and exclusion criteria will be invited to participated. Six schools be selected and will be randomized and allocated in 1:1 proportion to intervention and control group."|f|f|t|t
34018619|NCT00168597|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34018620|NCT02572934|||COHORT||CROSS_SECTIONAL|||||||
34018621|NCT00228423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939716|NCT05096455|||COHORT||RETROSPECTIVE|||||||
34100370|NCT01497093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100371|NCT04861805|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, single arm, multicenter pivotal study in an expanding cohort of symptomatic patients with severe aortic stenosis (following the initial FIH feasibility study).||||
34100372|NCT06074185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a before-and-after study||||
34100373|NCT03177070|NA|SINGLE_GROUP||OTHER||NONE||||||
34100374|NCT04129970|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|All participants will receive active iTBS.|||||
33715582|NCT04850807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Principal investigator is blinded to allocation of nursing homes to treatment or control conditions|The investigator's primary outcome (staff report of resident agitated and aggressive behaviors) will be evaluated using a parallel design|f|f|t|f
33715583|NCT00511667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939717|NCT02941861|||COHORT||RETROSPECTIVE|||||||
33939718|NCT04001699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33939719|NCT05473728|||COHORT||PROSPECTIVE|||||||
34100375|NCT01358305|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34100376|NCT05257083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100377|NCT00544687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715584|NCT05552560|||COHORT||PROSPECTIVE|||||||
33715585|NCT00707824|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33715586|NCT01824394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715587|NCT00563511|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33715588|NCT03857191|||COHORT||PROSPECTIVE|||||||
33715589|NCT04798001|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"This study evaluates 3 dosages of MV-014-212 in healthy adults.~Cohort A (18-55 years, inclusive) enrolls first. 10 participants (Group 1) receive Dosage 1. 20 participants (Group 2) receive Dosage 2. 50 participants (Group 3) receive Dosage 3: (i) 20 participants (Group 3a) receive a single dose; (ii) 10 participants (Group 3a) receive a 1st dose followed 2nd dose approx. 35 days after the 1st dose; (iii) 20 participants (Group 3b) receive a single dose by nasal atomizer (spray).~After review of Cohort A safety data, Cohort B (56-69 years, inclusive) enrolls. Sequential enrollment into Group 4 (10 participants; Dosage 1), Group 5 (20 participants; Dosage 2), then Group 6 (20 participants; Dosage 3) is based in each case on the preceding safety data review, as for Cohort A.~Within each group, a sentinel dosing approach is implemented as an added safety measure."||||
33715590|NCT01176669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715591|NCT03066271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33715592|NCT06460857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715593|NCT00026351||||TREATMENT||NONE||||||
33715594|NCT01777256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715595|NCT03209687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715596|NCT01508858|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33715597|NCT04128267|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715598|NCT00612924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939720|NCT00807456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939721|NCT04247724|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33939722|NCT03683680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939723|NCT02036476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939724|NCT03268057|NA|SEQUENTIAL||TREATMENT||NONE||A dose escalation phase based on the use of a 3 + 3 design and treament of up to 6 subjects in each of three VX15/2503 dose levels; a fixed dose of avelumab will be employed. Once the recommended phase two dose is determined, subjects will receive that dose of VX15/205 combined with avelumab moving forward.||||
33939725|NCT05981872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Study group (A) which will include 18 patients who will receive cognitive rehabilitation (Rehacom ) and selected physical therapy program.~Control group (B) which will include 18 patients who will receive only selected physical therapy program"|t|t|t|t
33939726|NCT02525835|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33939727|NCT02021864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939728|NCT05570747|NA|SINGLE_GROUP||TREATMENT||NONE|Data collected will be deidentified upon collection - surveys and assessment forms will be labelled with a numerical identifier.|||||
33939729|NCT03552614|||COHORT||RETROSPECTIVE|||||||
33939730|NCT00216346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939731|NCT04041258|NA|SINGLE_GROUP||TREATMENT||NONE||interventional study||||
33939732|NCT00409149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33939733|NCT02777008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33939734|NCT00425594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33939735|NCT02219516|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939736|NCT03799523|NA|SINGLE_GROUP||OTHER||NONE||||||
33939737|NCT04087967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939738|NCT02895542|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939739|NCT05588011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939740|NCT00323479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939741|NCT01072656|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33939742|NCT06083428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33939743|NCT01173874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939744|NCT04793893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939745|NCT05138692|||COHORT||PROSPECTIVE|||||||
33939746|NCT03878420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Valeda Light Delivery System|t|t|t|t
33939747|NCT00434876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939748|NCT02984735|||COHORT||CROSS_SECTIONAL|||||||
33939749|NCT04374149|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33939750|NCT04598100|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33939751|NCT00919828|||CASE_ONLY||PROSPECTIVE|||||||
33939752|NCT02265445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939753|NCT02079701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939754|NCT05780164|||OTHER||PROSPECTIVE|||||||
33939755|NCT04036006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939756|NCT05288179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939757|NCT00068549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939758|NCT01696396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939759|NCT04129242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939760|NCT02405091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939761|NCT03729128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939762|NCT04619563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939763|NCT00050440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939764|NCT02297295|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939765|NCT05158244|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33939766|NCT01758367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939767|NCT05231694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33939768|NCT01185613|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33939769|NCT02783261|||COHORT||PROSPECTIVE|||||||
33939770|NCT02425813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939771|NCT03946592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939772|NCT03225833|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33939773|NCT05858567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939774|NCT01871909|||CASE_ONLY||PROSPECTIVE|||||||
33939775|NCT03831607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018622|NCT06445036|||COHORT||CROSS_SECTIONAL|||||||
34018623|NCT06162104|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018624|NCT02736877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018625|NCT00658658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018626|NCT02358343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018627|NCT05228821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018628|NCT02253836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018629|NCT02233166|||COHORT||PROSPECTIVE|||||||
34018630|NCT05549518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Interventional (Clinical Trial)|f|f|f|t
34018631|NCT05367479|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34018632|NCT06478264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018633|NCT01045174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018634|NCT00044421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018635|NCT03272464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018636|NCT02128217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018637|NCT04675853|||COHORT||PROSPECTIVE|||||||
34018638|NCT06053918|||COHORT||PROSPECTIVE|||||||
34018639|NCT06047392|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34018640|NCT05592392|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Investigator blinded to device programming, therapy imperceptible to patient|Partial crossover - initial randomized to therapy On/Off. Subsequent OFF converted to On after primary efficacy endpoint.|t|t|t|f
34018641|NCT01918540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018642|NCT01338948|NA|SINGLE_GROUP||TREATMENT||||||||
34018643|NCT00000660||||TREATMENT||||||||
34018644|NCT05549635|||COHORT||PROSPECTIVE|||||||
34018645|NCT01233648|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34018646|NCT03110068|||COHORT||PROSPECTIVE|||||||
34018647|NCT04666415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of the clinical and psychological outcomes (research psychologist) will be blinded to the treatment group and will use standardized research questionnaires. Assessors of the osteopathic outcomes will not perform the osteopathic sessions, to guarantee an independent evaluation.||f|f|f|t
34018648|NCT03018808|||OTHER||CROSS_SECTIONAL|||||||
33939776|NCT00413231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939777|NCT01058356|||CASE_CONTROL||PROSPECTIVE|||||||
33939778|NCT02642458|||COHORT||PROSPECTIVE|||||||
33939779|NCT03036956|||COHORT||PROSPECTIVE|||||||
33939780|NCT02067104|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018649|NCT04319159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018650|NCT02213120|||COHORT||PROSPECTIVE|||||||
34018651|NCT03106831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018652|NCT02216318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34018653|NCT02737527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018654|NCT00856830|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open-label, Phase I - II trial with an initial dose escalation component and an expansion cohort of patients treated at the recommended Phase II dose.||||
34018655|NCT04596228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018656|NCT03468595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34018657|NCT01995266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018658|NCT03750435|NA|SINGLE_GROUP||TREATMENT||NONE||prospective single arm||||
34018659|NCT03875534|||CASE_ONLY||PROSPECTIVE|||||||
34018660|NCT03986736|||CASE_ONLY||PROSPECTIVE|||||||
34018661|NCT05005871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018662|NCT02291770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018663|NCT06367855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939781|NCT03874208|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939782|NCT00460499|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33939783|NCT03686579|||COHORT||OTHER|||||||
33939784|NCT02733887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939785|NCT02431195|||COHORT||PROSPECTIVE|||||||
33939786|NCT00090324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018664|NCT01172483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Education \& exercise|f|t|t|t
34018665|NCT03688282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34018666|NCT06209021|||CASE_ONLY||PROSPECTIVE|||||||
34018667|NCT01749917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34018668|NCT00302081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018669|NCT02987959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018670|NCT00797537|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018671|NCT00649818|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018672|NCT05034341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018673|NCT02608151|RANDOMIZED|PARALLEL||||NONE||||||
34018674|NCT00208806|||COHORT||PROSPECTIVE|||||||
34018675|NCT02693093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715599|NCT02732704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795617|NCT05832086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939787|NCT05476094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A Randomized, Double-blind, Placebo-controlled, Single Center and Single Dose||t|t|t|t
33939788|NCT02527031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939789|NCT01959594|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33939790|NCT00552006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939791|NCT04134949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33939792|NCT01077193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939793|NCT01103895|||||PROSPECTIVE|||||||
33939794|NCT02338128|||COHORT||PROSPECTIVE|||||||
33939795|NCT03963076|NA|SINGLE_GROUP||TREATMENT||NONE||prospective multicentric study||||
33939796|NCT00672750|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33939797|NCT05936476|||COHORT||CROSS_SECTIONAL|||||||
33939798|NCT04882930|NA|SINGLE_GROUP||PREVENTION||NONE||Healthy subjects, acute stroke patients, subacute stroke patients||||
33939799|NCT02646332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018676|NCT03435718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each patient's treatment condition will be masked by a code assigned at randomization. The study pharmacist will know this assignment. A person other than the investigator will administer the drug as directed by the pharmacists.|This study will be conducted as a field trial. Patients will be randomly assigned to one of five treatment groups: 6 mg/kg, 15 mg/kg or 30 mg/kg oxfendazole as a single dose; 15 mg/kg oxfendazole on three consecutive days; or 400 mg albendazole as a single dose (50 patients per group). The main objective of this study is to assess the efficacy (Cure Rate) of oral oxfendazole. Secondary objectives are to assess the Egg Reduction Rate for Trichuris in those subjects not cured of infection, to assess the efficacy (Cure Rate and Egg Reduction Rate) of oxfendazole against other common intestinal helminth infections, and to assess the safety and tolerability of oxfendazole treatment in adult patients.|t|t|t|t
34018677|NCT04598048|||COHORT||PROSPECTIVE|||||||
34018678|NCT05968560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018679|NCT02254213|||COHORT||PROSPECTIVE|||||||
33715600|NCT00968994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018680|NCT03903926|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018681|NCT05953974|||COHORT||RETROSPECTIVE|||||||
33715601|NCT06080607|||OTHER||PROSPECTIVE|||||||
34018682|NCT00424775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018683|NCT00378404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715602|NCT02496273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715603|NCT03117907|||CASE_CONTROL||PROSPECTIVE|||||||
33715604|NCT05957484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715605|NCT00925912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715606|NCT01432860|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33715607|NCT02408640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715608|NCT00707707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715609|NCT03770442|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Ultrasound images will be labelled by their participant number, and not by intervention. Therefore, when image analysis takes place, the investigators will not know whether the images come from somebody who received cycling sessions or the control group.~Tissue samples will be treated in the same way.~In follow up sessions, participants will be asked not to reveal if they can remember whether they cycled or not."||f|f|f|t
33715610|NCT03415841|RANDOMIZED|PARALLEL||OTHER||NONE||"50 patients who are randomized to the intervention group (mHealth) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics. The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics"||||
33715611|NCT00681369|||COHORT||RETROSPECTIVE|||||||
33715612|NCT02670564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33715613|NCT02031666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715614|NCT03621488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715615|NCT01428089|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33715616|NCT01990989|||COHORT||PROSPECTIVE|||||||
33715617|NCT05615272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715618|NCT06098066|||COHORT||RETROSPECTIVE|||||||
33715619|NCT05486104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33939800|NCT00514241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33939801|NCT03824444|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single Group||||
33939802|NCT01058811|||CASE_ONLY||PROSPECTIVE|||||||
33939803|NCT00458601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939804|NCT00466986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939805|NCT05189535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blinded|A prospective, randomized, placebo controlled|t|f|f|f
33939806|NCT04610827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939807|NCT04896840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939808|NCT00171964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939809|NCT00397527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33939810|NCT01743066|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939811|NCT03480529|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939812|NCT01627379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939813|NCT00111176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939814|NCT02699047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939815|NCT03646812|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33939816|NCT03572699|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939817|NCT02660073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939818|NCT00418444|RANDOMIZED|PARALLEL||||NONE||||||
33795618|NCT00092027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795619|NCT02178020|||CASE_CONTROL||PROSPECTIVE|||||||
33939819|NCT01852591|NA|SINGLE_GROUP||||NONE||||||
33939820|NCT00609089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939821|NCT03091569|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33795620|NCT05952206|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|"Masking:~* Patient-observer blinded for the stent type allocation.~* Open-label for the antiplatelet regimen"|Phase III, prospective, randomized (1:1:1:1), factorial design 2x2, active control, patient-observer blinded and multicentre clinical trial.|t|f|f|t
33795621|NCT04631744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715620|NCT02366520|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33715621|NCT02301884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715622|NCT04156425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group1：escitalopram + golimumab (N = 60), group2：escitalopram + calcium tablet (N = 60) group3：escitalopram +placebo (N = 60).|f|f|f|t
33715623|NCT04211051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715624|NCT03455920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715625|NCT04044612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715626|NCT00881712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715627|NCT04693325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715628|NCT01550380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715629|NCT02197715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715630|NCT05800093|||COHORT||PROSPECTIVE|||||||
33715631|NCT02999854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715632|NCT01014650|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33715633|NCT03171129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715634|NCT02703584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715635|NCT01379547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715636|NCT03516591|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715637|NCT00736723|||COHORT||PROSPECTIVE|||||||
33715638|NCT00022009|RANDOMIZED|||TREATMENT||NONE||||||
33715639|NCT00469989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33715640|NCT05814978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715641|NCT04806854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715642|NCT03729856|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A Single Case Experimental Design (SCED) will be used to evaluate the intervention. Participants act as their own controls, and thus are exposed to both the treatment and control conditions. The study will be conducted and reported according to the Singe Case Reporting guidelines in BEhavioural Interventions (SCRIBE). A randomised, concurrent, multiple-baseline A1 (baseline control) - B (intervention)-A2 (follow-up withdrawal) design will be used to meet the methodological recommendations for SCEDs. Participants will be randomly allocated to a 5, 8 or 11 week baseline period during which they will undertake their usual activities. The baseline phase will be followed by a 16-week intervention period during which participants will participate in 12, one hour sessions with an accredited exercise physiologist. The intervention phase will be followed by a 5-week follow-up phase where participants will have no contact with the intervention personnel.||||
33715643|NCT04300114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715644|NCT05157854|||CASE_ONLY||PROSPECTIVE|||||||
33715645|NCT00162656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715646|NCT02523898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715647|NCT04772755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715648|NCT04334629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33715649|NCT00221273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715650|NCT04978389|||OTHER||OTHER|||||||
33715651|NCT00426855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715652|NCT01493570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33715653|NCT01027221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715654|NCT02419053|||COHORT||RETROSPECTIVE|||||||
33795622|NCT01426178|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33795623|NCT00493402|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33795624|NCT00005137|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
33795625|NCT03942835|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33795626|NCT03705442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33795627|NCT05678972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795628|NCT03314675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795629|NCT01972763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795630|NCT00855686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939822|NCT03480620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A stratified random sampling approach will be used for this study whereby graduates from the BPRP will first be identified as having weaned off opioid medications (weaners) or did not wean off opioid medication (non-weaners). Once stratified into these two groups, participants will then be randomly assigned to either the standard care group (control group) or the telerehabilitation group (intervention group) based on sequential enrollment into each study group. Participants will continue with there post-discharge exercise and self-management program for one year, completing follow up assessment using the online platform at 1, 3, 6, 9, and 12 months post discharge.||||
33939823|NCT02961348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33939824|NCT01492660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939825|NCT00329992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939826|NCT03218670|||COHORT||CROSS_SECTIONAL|||||||
33939827|NCT06370065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939828|NCT05384821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939829|NCT02630459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33939830|NCT01486992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939831|NCT05093842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research personnel conducting outcome assessments will be blinded to participant group assignment. As the participant will be receiving a behavioral intervention, both the participant and interventionist will be aware of group assignment.||f|f|f|t
33939832|NCT02992054|||CASE_CONTROL||PROSPECTIVE|||||||
33939833|NCT00191438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939834|NCT01706744|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939835|NCT03932292|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939836|NCT03435328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939837|NCT00207493|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33939838|NCT01816516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33939839|NCT03866239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939840|NCT03636009|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups receiving interventions||||
33939841|NCT04593173|||CASE_ONLY||OTHER|||||||
33939842|NCT00298792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939843|NCT03759444|||CASE_ONLY||RETROSPECTIVE|||||||
33939844|NCT01657903|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33939845|NCT03419741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham TMS|This is a randomized, double-blinded design of active rTMS and sham rTMS. The pilot will include a total of 20 nicotine-dependent patients with cancer. Subjects will be randomized to either sham rTMS or real rTMS over the left DLPFC. At the end of 7-day study, everyone can be referred to the Hollings Cancer Center (HCC) Tobacco Treatment Program for active treatment.|t|f|t|t
33939846|NCT03453593|||COHORT||PROSPECTIVE|||||||
33939847|NCT05654727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33939848|NCT04686539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33939849|NCT04079322|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33939850|NCT05132140|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939851|NCT01138605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939852|NCT01485185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33939853|NCT02552537|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34018684|NCT04229524|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018685|NCT00757848|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33715655|NCT01031732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715656|NCT00459667|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33715657|NCT00139399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715658|NCT00840710|||COHORT||CROSS_SECTIONAL|||||||
33715659|NCT01149824|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33715660|NCT01407640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715661|NCT01122836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715662|NCT01128257|||COHORT||PROSPECTIVE|||||||
33715663|NCT05491954|||COHORT||PROSPECTIVE|||||||
33715664|NCT02999945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939854|NCT02485340|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33939855|NCT04678973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomly assigned to one of two groups: self-compassion intervention or wait-list control group.|t|f|t|t
33939856|NCT00751335|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33939857|NCT03010059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33939858|NCT01185912|||CASE_CONTROL||PROSPECTIVE|||||||
33939859|NCT01072500|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33939860|NCT04251949|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939861|NCT02168816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939862|NCT04759729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33939863|NCT01728454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939864|NCT01008228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939865|NCT02498340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939866|NCT02142673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33939867|NCT03580902|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33939868|NCT02581098|||COHORT||PROSPECTIVE|||||||
33939869|NCT00343161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939870|NCT01603628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939871|NCT04087824|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33939872|NCT00671411|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939873|NCT04835935|||CASE_CONTROL||PROSPECTIVE|||||||
33939874|NCT04211740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939875|NCT02865278|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33939876|NCT01308151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939877|NCT05564364|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939878|NCT03377166|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33939879|NCT05844592|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33939880|NCT02055872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939881|NCT00089206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939882|NCT02668679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33939883|NCT05877495|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33939884|NCT02367157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939885|NCT03800758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33939886|NCT03378284|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33939887|NCT00000576|RANDOMIZED|||||||||||
33939888|NCT04613791|||COHORT||PROSPECTIVE|||||||
33939889|NCT02205177|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33939890|NCT01181336|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939891|NCT05520489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939892|NCT00072098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939893|NCT03830463|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33939894|NCT05504018|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33939895|NCT00005838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939896|NCT00120029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33939897|NCT00562081|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33939898|NCT04501419|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939899|NCT05743439|NA|SINGLE_GROUP||TREATMENT||NONE|Although this is a single-arm trial, outcome assessors will be masked to reduce potential for experimenter bias. We will also employ a technique for single-case experimental designs called masked visual analysis.|||||
33939900|NCT00859144|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33939901|NCT02487901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|ultrasonic bone osteotome||t|f|f|t
33939902|NCT01961518|||CASE_ONLY||RETROSPECTIVE|||||||
33939903|NCT06172829|||COHORT||PROSPECTIVE|||||||
33939904|NCT06435455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939905|NCT00564135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939906|NCT01264562|||CASE_CONTROL||PROSPECTIVE|||||||
33939907|NCT02603380|||||CROSS_SECTIONAL|||||||
33939908|NCT06503640|||COHORT||PROSPECTIVE|||||||
33939909|NCT06085768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34018686|NCT04421586|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34018687|NCT04062474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018688|NCT04603170|||OTHER||CROSS_SECTIONAL|||||||
34018689|NCT01126411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018690|NCT00714493|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018691|NCT00761865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715665|NCT04208620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939910|NCT02912793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939911|NCT01625364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33939912|NCT01888367|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33939913|NCT05940051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939914|NCT00266695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939915|NCT01957111|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33939916|NCT03943394|||OTHER||CROSS_SECTIONAL|||||||
33939917|NCT02363244|||OTHER||CROSS_SECTIONAL|||||||
33939918|NCT02422537|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33939919|NCT00086164|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33939920|NCT04185792|||COHORT||PROSPECTIVE|||||||
33939921|NCT03919760|||CASE_CONTROL||RETROSPECTIVE|||||||
33939922|NCT00784160|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939923|NCT05662488|||COHORT||PROSPECTIVE|||||||
34018692|NCT05626439|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34018693|NCT00364949|||CASE_CONTROL||PROSPECTIVE|||||||
34018694|NCT03591003|||COHORT||OTHER|||||||
34018695|NCT04391530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the analysis of the research will be done by the other researcher, not by the researcher who applied it.|Students who meet the inclusion criteria for the research will use the Random.org website to allocate students to the breath therapy, Emotional Freedom Technique and Control group with student numbers in the class list.|f|f|f|t
34018696|NCT03052959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018697|NCT02373033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34018698|NCT03717714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018699|NCT06002087|RANDOMIZED|PARALLEL||TREATMENT||NONE|To ensure blinding of participants and intervention facilitator, a randomizing researcher, who is different from the facilitator, will generate the sequences and assign an ID (1-50) to one of the groups based on the sequence. The sealed envelopes will be given to the facilitator, who will open the envelope in the interview and inform the participants about their allocated group. This will ensure that neither the participants nor the facilitator will know which group they are assigned to, which will help to minimize bias in the study.|"Experimental group: Participants in the experimental group will receive the Unified Protocol (UP) treatment.~Control group: Participants in the control group will be placed on a waitlist and will not receive any treatment until the end of the study."||||
34018700|NCT01249365|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34018701|NCT02030366|||COHORT||PROSPECTIVE|||||||
33715666|NCT01318304|||COHORT||PROSPECTIVE|||||||
33715667|NCT03272490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715668|NCT02872467|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33715669|NCT04450966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multi-site cluster-randomized parallel groups trial. \>30 pediatric primary care clinicians will be recruited from \~10 practices and will be allocated 1:1 to either deliver usual care or the cSBI intervention to their participating patients ages 14-17 years-old.|f|f|f|t
33715670|NCT05279898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Group 1: Control - receives standard of care anesthesia and blinded EEG and Cerebral Oximetry(CO) monitoring Group 2: Intervention - receives MMGA bundle, guided by EEG monitoring, blinded CO will be passively collected|t|f|f|f
33715671|NCT06463210|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of participants or care providers was not feasible to implement due to the nature of the intervention|2 randomized groups with 60 patients per arm||||
33715672|NCT01267318|||COHORT||PROSPECTIVE|||||||
33715673|NCT00528333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715674|NCT04809207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715675|NCT00005892||||TREATMENT||||||||
33715676|NCT00188149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715677|NCT02231333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715678|NCT00179634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715679|NCT00726661|||COHORT||PROSPECTIVE|||||||
33715680|NCT02633644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715681|NCT01705821|||CASE_ONLY||PROSPECTIVE|||||||
33715682|NCT04914104|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33715683|NCT04287491|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33715684|NCT01354951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715685|NCT03305822|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33715686|NCT06040112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715687|NCT02625259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715688|NCT00936585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715689|NCT05908695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715690|NCT05778123|||OTHER||PROSPECTIVE|||||||
33715691|NCT04687878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939924|NCT06037499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939925|NCT01219166|||COHORT||RETROSPECTIVE|||||||
33939926|NCT03977506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All the inclusive patients will benefit the first test of driving during 45minutes. The evaluation will be realized by a present occupational therapist and a neuropsychologist in the vehicle.~The second test on road will be for the part of included patients and will be made with the driving instructor and the therapist.~Then, the third test on road will be realized after sessions on driving simulator for the part of the patients requiring a re-entrainment."||||
34018702|NCT03275636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939927|NCT06154460|||OTHER||PROSPECTIVE|||||||
34018703|NCT04990596|||COHORT||PROSPECTIVE|||||||
33939928|NCT05165186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33939929|NCT01342627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939930|NCT05507190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939931|NCT04493736|||CASE_ONLY||PROSPECTIVE|||||||
33939932|NCT02576171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939933|NCT03847064|||COHORT||RETROSPECTIVE|||||||
33939934|NCT05841615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939935|NCT06173076|||COHORT||PROSPECTIVE|||||||
33939936|NCT02365740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939937|NCT02306928|||CASE_ONLY||PROSPECTIVE|||||||
34018704|NCT02777112|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34018705|NCT04967963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018706|NCT05829213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018707|NCT06081426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34018708|NCT03450395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||For each of the two periods, a hot breakfast cereal will be consumed once daily for a duration of 6 weeks each. There will be a 4 week washout period in between each test substance.|t|f|t|f
34018709|NCT05787470|||CASE_CONTROL||PROSPECTIVE|||||||
34018710|NCT03842813|||COHORT||PROSPECTIVE|||||||
33939938|NCT02367690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018711|NCT00397163|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34018712|NCT04354038|||COHORT||PROSPECTIVE|||||||
34018713|NCT03582826|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34018714|NCT03251963|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants enrolled in months 1-6 of the study will all receive a fixed dose of enoxaparin. Patients enrolled in months 7-12 of the study will all receive a variable dose of enoxaparin.||||
34018715|NCT01610453|||COHORT||PROSPECTIVE|||||||
34018716|NCT06280378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018717|NCT06176066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator is the surgeon and so cannot be blinded from the type of surgical procedure carried out (interventional or standard of care).|Randomized, non-blinded trial of intervention versus standard of care, with all further treatment and follow up in parallel|t|f|f|t
34018718|NCT00611481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34018719|NCT04547530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018720|NCT03547336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018721|NCT05322499|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018722|NCT05178433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018723|NCT02277678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018724|NCT00000723||||TREATMENT||||||||
34018725|NCT02252718|||CASE_ONLY||CROSS_SECTIONAL|||||||
34018726|NCT01873911|||COHORT||PROSPECTIVE|||||||
34018727|NCT03529461|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled trial|t|f|f|t
33939939|NCT00305266|||||PROSPECTIVE|||||||
33939940|NCT02543762|||COHORT||PROSPECTIVE|||||||
33939941|NCT01729065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018728|NCT01914068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34018729|NCT04244669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient will not informed about the treatment arm, but the presence of paresthesia is a factor that break the masking.~The care provider and investigators will not know the treatment arm and only collect the information in the forms."|Prospective, randomized, multicentre, parallel, controlled, and double-blind trial. It is a study with 2 groups with evaluation pre and post treatment with SCS implantation. The study has been designed to assess primarily non-inferiority and secondarily superiority of SCS DTM therapy|f|t|t|f
34100378|NCT06593665|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The primary investigator or his/her designee will inform the anesthesiology team caring for each subject of the arm of the study they are in for each case. Subjects and research staff doing post-operative assessments will be blinded to the randomization.|"A total of 142 subjects will be randomized by a computer program into two groups.~1. Intrathecal preservative free morphine (duramorph) 200mcg with 7.5 mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)~2. Intravenous methadone dose at 0.2mg/kg Ideal Body weight up to a maximum dose of 20 mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)"|t|t|f|f
33715692|NCT04859023|NA|SINGLE_GROUP||OTHER||NONE||||||
33715693|NCT06103357|||COHORT||CROSS_SECTIONAL|||||||
33715694|NCT00290888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715695|NCT04051762|||COHORT||PROSPECTIVE|||||||
33715696|NCT02299609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33715697|NCT02989675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715698|NCT02226055|||COHORT||RETROSPECTIVE|||||||
33715699|NCT00329381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715700|NCT06347614|||COHORT||RETROSPECTIVE|||||||
33715701|NCT05714813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715702|NCT00349284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33715703|NCT01949051|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33715704|NCT01713972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715705|NCT02664441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715706|NCT00003514||||TREATMENT||||||||
33715707|NCT00844688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715708|NCT02790060|||CASE_ONLY||PROSPECTIVE|||||||
33795631|NCT06277401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients will be kept blind to treatment allocation by being provided with minimal information about the content of the two exercise interventions and the study hypotheses; the patients will be informed that the study compares two different exercise protocols that both include safe exercises to reduce knee pain and increase knee function.~An independent biostatistician blinded to group allocation will perform the primary RCT analysis. To reduce the risk of interpretation bias, blinded results from the analyses (group A compared with group B) will be presented to all authors, who will agree on two alternative written interpretations before the data manager unblinds the randomisation code."||t|f|t|f
33795632|NCT00006505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795633|NCT01323777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795634|NCT03547479|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study design consists of (a) 4 qualitative focus groups (b) a pretest of 10 patient (c) a pilot randomised study of 60 patients and (d) interviews of stakeholders including healthcare professionals and policymakers||||
33795635|NCT01707758|||||PROSPECTIVE|||||||
33795636|NCT03285685|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33795637|NCT05251688|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A quasi-experimental research design||||
33795638|NCT01066923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33795639|NCT00446550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795640|NCT05249036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795641|NCT03446482|||COHORT||PROSPECTIVE|||||||
33795642|NCT03411278|RANDOMIZED|CROSSOVER||OTHER||SINGLE||A randomized, cross-over, repeated measures design is used to evaluate the effects of DO on recovery. At random in study phase I the half of the group performs a DO self-treatment twice daily (4 applications) for 15 minutes each, whereas the other half gets no intervention. After a washing out period in study phase II a crossover will be performed. The same protocol is performed again, whereas the other half of the participants carries out the DO intervention .|f|f|f|t
33795643|NCT06676202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The sample will not be selected from the universe and all patients who meet the inclusion criteria will constitute the sample. The minimum sample size of the study was determined by performing power analysis with the G-power 3.1.9.4 program. In the calculation made according to the two-way independent samples t-test, the effect size was taken as 0.80, with a margin of error of 0.05 and a power of 90%, the total sample number was calculated as 60 (Cohen, 1998). Considering the losses within the scope of the study, 66 patients who meet the inclusion criteria will be randomly divided into the experimental group (33 patients) and the control group (33). Finally, in order to minimize the risk of contamination, the first 33 patients who meet the inclusion criteria after being admitted to the clinic will constitute the control group, and the following 33 patients will constitute the experimental group.|t|f|t|f
33795644|NCT06214117|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33795645|NCT03281694|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The study will be double-blind. Only the statistician performing randomization and the dispensing pharmacist will know the sequence of test conditions.|||||
33795646|NCT02952768|NA|SINGLE_GROUP||OTHER||NONE||||||
33795647|NCT01091233|||COHORT||PROSPECTIVE|||||||
33795648|NCT04674449|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Patients and clinicians responsible for downstream (post-catheter laboratory) care are blinded to the randomisation allocation group (i.e. are blinded to whether the patient was in the intervention or blinded/control group).||t|t|f|t
33795649|NCT02240550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939942|NCT03161951|||CASE_CONTROL||PROSPECTIVE|||||||
33939943|NCT04145310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939944|NCT04205604|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939945|NCT03818399|NA|SINGLE_GROUP||TREATMENT||NONE||The study is designed to determine effect of SUBLOCADE on repeat overdose and death compared to historical control data.||||
33939946|NCT01606280|||COHORT||RETROSPECTIVE|||||||
33939947|NCT03677661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939948|NCT00911326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33939949|NCT06403358|||COHORT||PROSPECTIVE|||||||
33939950|NCT04187586|||CASE_CONTROL||RETROSPECTIVE|||||||
33939951|NCT06405256|||COHORT||OTHER|||||||
33939952|NCT02543879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939953|NCT02331927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939954|NCT03604094|||COHORT||PROSPECTIVE|||||||
33939955|NCT02013076|||COHORT||PROSPECTIVE|||||||
33939956|NCT03622268|||COHORT||PROSPECTIVE|||||||
33939957|NCT02576652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33939958|NCT02023515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939959|NCT01034384|||||PROSPECTIVE|||||||
33939960|NCT04864184|NA|SINGLE_GROUP||TREATMENT||NONE|Participants will be blinded to the respiratory rates being practiced during each study visit. Breathing patterns will be completed in random order.|Each participant will complete 2 different sessions in random order.||||
33939961|NCT05605691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939962|NCT05976061|||COHORT||RETROSPECTIVE|||||||
33939963|NCT05902533|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm prospective trial.||||
33939964|NCT02036983|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33939965|NCT04354701|||CASE_ONLY||PROSPECTIVE|||||||
33939966|NCT05439200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939967|NCT01849289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939968|NCT06389994|||COHORT||PROSPECTIVE|||||||
33939969|NCT02263924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to receive either placebo or investigational drug (mixed tocotrienols dietary supplement) for 6 months.|t|t|t|t
34018730|NCT04671186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be blindly randomized at baseline (Visit 1) into one of two groups: probiotic or placebo. Investigators are to be blinded as well|Participants will be blindly randomized at Visit 1 into one of two groups (probiotic or placebo). Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) and the other group receive placebo oral capsule daily throughout the study. All participants in either group will undergo: Life style modification as per NASPGHAN NAFLD guidelines. Fibroscan assessing CAP and TE score once every 3 month until the end of study. Monitoring ALT every 3 months until end of study as per standard of care guidelines.Collection of stool sample to be sent for microbiome analysis at the time of diagnosis, 3 months and 6 months (end of the study). Secondary variables collected, Age, Gender, Race, BMI, Fibroscan probe.|t|t|t|f
34018731|NCT02267668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018732|NCT05364060|||COHORT||PROSPECTIVE|||||||
33795650|NCT05817370|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The way a physician is trained on the detection of HSIL screening and treatment to prevent anal cancer will be modified so that the cancer prevention strategy is readily adopted for a low-to middle-income setting. An implementation science committee will guide the development of the modified training over 3 iterations every 4 months for up to a year. To test if the modified training improves implementation of anal cancer screening and treatment, the physician will first conduct screening after standard training for 12 months. Then the physician will conduct screening after the modified training for 12 months. Depending on the time of when the participants visit the clinic will determine which arm they are enrolled. There is no randomization and the arms are sequential.||||
34018733|NCT06125574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018734|NCT00523224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018735|NCT01819974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018736|NCT00376025|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34018737|NCT06192836|||CASE_CONTROL||PROSPECTIVE|||||||
34018738|NCT03565393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A placebo-controlled, randomized; double-blind 2 arm trial to assess the efficacy of fibersol-2 in children with acute watery diarrhea.|A placebo-controlled, randomized|t|t|t|t
34018739|NCT00429156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018740|NCT01680497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018741|NCT04319718|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34018742|NCT01935466|||COHORT||RETROSPECTIVE|||||||
34018743|NCT00482183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018744|NCT05998941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018745|NCT06157203|||COHORT||PROSPECTIVE|||||||
34018746|NCT01345435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34018747|NCT00757757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018748|NCT00784576|||COHORT||PROSPECTIVE|||||||
34018749|NCT04336514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018750|NCT02516527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34018751|NCT00026286|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34018752|NCT05500118|||CASE_CONTROL||PROSPECTIVE|||||||
34018753|NCT01874795|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33795651|NCT00534937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795652|NCT00777816|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33795653|NCT00917865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795654|NCT03973970|||COHORT||PROSPECTIVE|||||||
33795655|NCT02712658|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33795656|NCT00064714|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795657|NCT02632305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795658|NCT01790529|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33795659|NCT00600548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795660|NCT05491031|NA|SINGLE_GROUP||OTHER||NONE||||||
33795661|NCT03594396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795662|NCT06570473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795663|NCT00084903|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795664|NCT01483248|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795665|NCT01091454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795666|NCT01764815|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795667|NCT02368171|||CASE_CONTROL||PROSPECTIVE|||||||
34018754|NCT03247517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018755|NCT02249312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018756|NCT05757739|||OTHER||PROSPECTIVE|||||||
34018757|NCT05610592|||COHORT||RETROSPECTIVE|||||||
34018758|NCT00039962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018759|NCT03417193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018760|NCT00679926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018761|NCT00333879|NA|SINGLE_GROUP||||NONE||||||
34018762|NCT05382169|||COHORT||PROSPECTIVE|||||||
34018763|NCT00727766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018764|NCT05960240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018765|NCT00348088|||CASE_ONLY||PROSPECTIVE|||||||
34018766|NCT00263991|||CASE_CONTROL||OTHER|||||||
34018767|NCT01108406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018768|NCT03698448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo medication with identical appearance to the active drug|Randomised, double blind, dose-finding|t|t|t|t
34018769|NCT03947671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018770|NCT02961166|||COHORT||RETROSPECTIVE|||||||
34018771|NCT00839592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018772|NCT01334983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34018773|NCT03438214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018774|NCT03752944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Cards will have sequential numbers one number for each card then these cards will be placed within opaque sealed envelopes. Then these envelops will be placed in a container (box), each participant will grasp one envelope the day of procedure.|Randomized|t|f|f|f
34100379|NCT01098357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795668|NCT01917097|||COHORT||RETROSPECTIVE|||||||
33715709|NCT05502328|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender and endorsement of problems with energy and/or focus reported during enrollment, then randomized to one of the study arms|t|f|t|f
33715710|NCT04954274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||there will be two groups: one treated by supplementation of the culture medium with 1 Micromolar of the molecule, the other being the control group.|t|f|t|f
33715711|NCT05108831|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Masking is not possible|"The study involves two arms: intervention and control. Health facilities will serve as clusters, with half of the facilities (16) receiving the intervention and the other half serving as controls (16). Health facilities will be allocated to their respective study arm pragmatically with respect to geography. A parallel design (groups of matched intervention and control health facilities) will start the study in step-wedge manner. Every 2-4 months, a new group of 10-12 new facilities will be added to the study.~At the end of the Phase 1 of the study, the control facilities will also receive the intervention, along with additional facilities for a total of up to 40 health facilities."||||
33715712|NCT04190394|||COHORT||RETROSPECTIVE|||||||
33715713|NCT00560976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715714|NCT05679908|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715715|NCT04223570|||COHORT||PROSPECTIVE|||||||
33715716|NCT00477971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715717|NCT01168167|||CASE_CONTROL||PROSPECTIVE|||||||
33715718|NCT04464356|||CASE_ONLY||RETROSPECTIVE|||||||
33715719|NCT02228785|RANDOMIZED|||TREATMENT||NONE||||||
33715720|NCT05277740|||COHORT||PROSPECTIVE|||||||
33715721|NCT05188950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33715722|NCT01414114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715723|NCT05073991|||FAMILY_BASED||RETROSPECTIVE|||||||
33715724|NCT00848705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33715725|NCT03174236|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Metronidazole and its placebo will be masked. They will both be contained in similar bottles labelled with sequential study numbers according to a prepared blocked randomisation list before the trial begins. They will also be of similar appearance.~Ceftriaxone and penicillin + gentamicin will not be masked."|The trial will investigate two separate antimicrobial interventions in a 2x2 factorial design randomised controlled clinical trial. A factorial design allows more than one intervention to be tested and is useful in assessing a potential package of care. Two randomisations will be made. The two interventions will be analysed separately. Ceftriaxone and metronidazole is an effective and commonly used antibiotic combination, hence major interactions that interfere with efficacy are considered unlikely. However, evidence for interaction between the two interventions will be tested.|t|t|t|t
33715726|NCT00045123|RANDOMIZED|||TREATMENT||DOUBLE||||||
33715727|NCT00822250|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33715728|NCT05253053|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study will consist of three arms: Arm A (TT-00420 Tablet Monotherapy), Arm B (TT-00420 tablet in combination with atezolizumab(Tecentriq®)) and Arm C (TT-00420 tablet in combination with nab-paclitaxel (Abraxane®)).||||
33715729|NCT01059799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715730|NCT05048940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715731|NCT06415292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715732|NCT00035620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715733|NCT04646889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715734|NCT01759667||PARALLEL||DIAGNOSTIC||NONE||||||
33715735|NCT01443754|||CASE_ONLY||PROSPECTIVE|||||||
33715736|NCT05557461|||COHORT||PROSPECTIVE|||||||
33715737|NCT01265472|||||PROSPECTIVE|||||||
33715738|NCT05675943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715739|NCT04508244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomized, double-blinded, placebo-controlled trial|t|t|f|f
33715740|NCT03985449|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Data analysts will be blinded to the setting randomization.|Stepped wedge trial with randomization at the clinic level. Patient enrollment will occur at five gynecology clinics in the United States. The uterine fibroid Option Grid patient decision aid intervention will be implemented in the 'active' implementation phase of the trial following a brief initiation session at each clinic to introduce clinicians to the intervention.||||
33715741|NCT00894049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939970|NCT00887094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939971|NCT00942292|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33939972|NCT02659839|||COHORT||PROSPECTIVE|||||||
33939973|NCT02871024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33939974|NCT03700866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33939975|NCT00198510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33939976|NCT02023892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33939977|NCT02994576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939978|NCT00732199|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33939979|NCT02411994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33939980|NCT00424736|||DEFINED_POPULATION||PROSPECTIVE|||||||
33939981|NCT03691649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33939982|NCT01491711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33939983|NCT04375007|||COHORT||PROSPECTIVE|||||||
33939984|NCT01256957|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33939985|NCT03111810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33939986|NCT04565535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33939987|NCT04313595|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33939988|NCT01497002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33939989|NCT05348499|||COHORT||CROSS_SECTIONAL|||||||
33939990|NCT05914480|||CASE_ONLY||CROSS_SECTIONAL|||||||
33939991|NCT06481007|||COHORT||PROSPECTIVE|||||||
33939992|NCT03205111|||CASE_CROSSOVER||PROSPECTIVE|||||||
33939993|NCT04772586|||CASE_ONLY||PROSPECTIVE|||||||
33939994|NCT02594514|||COHORT||RETROSPECTIVE|||||||
33939995|NCT02512094|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795669|NCT06401551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Contralateral (split face) study design|t|f|f|t
33795670|NCT05942963|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33795671|NCT05375188|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study was conducted among 60 patients allocated randomly into two groups. In the study group (group D), dexmedetomidine was given as an infusion of 0.4 μg/kg/h from induction of anesthesia for 24 hours. In the control group (group C), the patients were receiving an equal volume of normal saline. The primary outcome of the study was Serum Creatinine (mg/dl) which was measured before the surgery as baseline and then at 48 hours after surgery.|t|t|t|t
34018775|NCT05754307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment is disclosed to the examiner after all data have been collected.|Randomised controlled clinical trial having 2 parallel intervention arms for surgical treatment (step 3) of interproximal residual defects (PPD≥6mm and BoP)|t|f|f|t
34018776|NCT05949671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients do not know which group they belong to and other groups|doctoral thesis including case and control groups|t|f|f|f
34018777|NCT05989724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a first-in-human and first-in-class, open-label, Phase I clinical trial including a Phase Ia dose escalation stage for the participants with all solid tumor types using seven dose levels of SON-DP to determine the RP2D, MTD and DLT; and a Phase Ib dose expansion stage for the participants of four arms including breast cancer, pancreatic cancer, ovary cancer or colorectal cancer using the RP2D of SON-DP obtained from Phase Ia.||||
34018778|NCT01374295|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
34018779|NCT05197218|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34018780|NCT03332927|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34018781|NCT05870137|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"To ensure masking in this clinical trial, the intervention sequence was randomized for each participant, and the assessors were kept blinded to the sequence. The assessors were not informed about which intervention was provided to each participant or which arm of the study each participant completed first.~The trial achieved masking by randomly allocating participants to either the control or intervention groups and further by anonymizing the data after capturing the sequence, prior to releasing it to the outcome assessors. This approach ensured that the assessors were not biased in their assessments and were unaware of which intervention was provided to each participant. By blinding the assessors, the study was able to reduce potential sources of bias and increase the validity and reliability of the results. Overall, the masking approach used in this trial was designed to minimize the risk of bias and ensure that the results were as objective and accurate as possible."|Randomised cross-over trial|f|f|f|t
34018782|NCT06258759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34018783|NCT00879892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018784|NCT04259983|||OTHER||CROSS_SECTIONAL|||||||
34018785|NCT05925673|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34018786|NCT01825889|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34018787|NCT02751970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100380|NCT02642679|NA|SINGLE_GROUP||TREATMENT||NONE||Opticell Ag dressing applied to STSG donor site||||
34100381|NCT05691439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34100382|NCT06689969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34100383|NCT06658249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100384|NCT03816826|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||60 athletes with hamstring injury distributed randomly into 3 group|f|f|t|f
34100385|NCT04094610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795672|NCT03328715|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33795673|NCT01796782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795674|NCT03573999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795675|NCT06676917|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, open-label, non-comparative, single-arm, phase II trial||||
33795676|NCT03603184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795677|NCT02689180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795678|NCT03462589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795679|NCT03626558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795680|NCT04570046|||COHORT||RETROSPECTIVE|||||||
33795681|NCT06396611|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Clinical evaluation is performed in invited hospitals, physical activity evaluation is performed by the outcomes assessor in Faculty of Sport of University of Porto. The investigator is the person who will conduct the intervention, and he's the one that will know what protocol is assigned to each patient, but without knowing the results from clinical and physical fitness evaluations.|"Eligible patients who fulfil criteria will be randomized into a controlled design (RCT) comparing the effects of 16 weeks intervention program with a maximum of 2 sessions per week ensuring a 24h rest period between similar sessions, for the same aims and muscular groups. All participants are assessed in primary and secondary outcome measures before and after the intervention period. The intervention is designed with: a) Resistance Exercise Training (REX); b) Control Group (CG).~We also expect to follow up those patients, after the intervention protocol terminus, using routine consultation on participating Hospitals, and acquiring data to support the long-term effects of the protocol. The follow-up will maintain the Onco-Hematology consultations routine and periodicity (6 months after last medical appointment), where all initial assessments will be undertaken."|t|t|f|t
33795682|NCT03470142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795683|NCT01924975|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33795684|NCT02245581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795685|NCT03429530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33795686|NCT03623997|||CASE_ONLY||PROSPECTIVE|||||||
33795687|NCT06063733|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33795688|NCT04529278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100386|NCT06343883|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|No masking, no sham. All subjects will receive all conditions, all of which are active.|Primary cohort (safety) will be collected prior to full study collection. Primary collection will involve highest pressure application and follow-up safety scans (MRI) to be reviewed by a Neuroradiologist. Once cleared - parallel design will be utilized for eeg and fMRI cohorts. Both cohorts will receive 3 LIFU pressures randomized over 3 study visits. Electrical stimulations will be applied pre and post LIFU administration to induce somatosensory evoked potentials (SEPs).||||
34100387|NCT06169579|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100388|NCT05960929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All study procedures will be performed behind a portable screen or curtain, or in a separate procedure room so that non-study personnel (including the primary care team) will be unaware of the subject's assigned study arm. Study personnel involved in the study procedure will not be masked. All other study personnel including the investigator and the outcomes accessor will be masked throughout the duration of the study.~The subject's family will remain blinded to treatment assignment throughout."|This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™.|t|t|t|t
34100389|NCT06691516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100390|NCT06368622|||COHORT||PROSPECTIVE|||||||
34100391|NCT04980872|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open-label)|Multicenter||||
34100392|NCT03334305|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795689|NCT06538558|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participant remains blinded. Investigator and study sponsor are unblinded.|Participants will be divided into four dose escalation cohorts. A DSMB safety review will be completed after each cohort (at a minimum) to determine appropriateness of continuing dose escalation.|t|f|f|f
33795690|NCT06554860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795691|NCT03783754|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||Main Study: Multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial|t|t|t|f
33795692|NCT03114904|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33939996|NCT04107935|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33939997|NCT00045006||||TREATMENT||||||||
33795693|NCT01576952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795694|NCT05593159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Clinical evaluation of restorations will be conducted by two trained and calibrated examiners. All examiners and patients are going to be blinded from group assignment. Allocation concealment will be done by using sequentially numbered, sealed/opaque envelopes.|Split mouth design; each patient will receive three restorations, one for each arm of this study.|t|f|t|t
33795695|NCT04738565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795696|NCT05596994|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33795697|NCT04393246|RANDOMIZED|PARALLEL||TREATMENT||NONE||TACTIC-E is a randomised, parallel arm, open-label platform trial||||
33939998|NCT06000826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795698|NCT06677398|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel group-randomized trial|t|f|f|f
33795699|NCT00117130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795700|NCT04920617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795701|NCT05627336|||COHORT||PROSPECTIVE|||||||
33939999|NCT02948244|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33795702|NCT04042545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795703|NCT05612399|||COHORT||PROSPECTIVE|||||||
33795704|NCT02899000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018788|NCT05174494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Though sealed envelopes both clinicians and patients were masked to the selected treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Scaling and Root Planing (SRP), while the control group undergo to standard oral hygiene treatment.|t|f|t|f
34018789|NCT03559621|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||RCT with a mobile based lifestyle intervention||||
34018790|NCT06483139|||CASE_CONTROL||RETROSPECTIVE|||||||
34018791|NCT00843375|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018792|NCT05648786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018793|NCT06314685|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018794|NCT00291980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018795|NCT01246622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018796|NCT02359747|||COHORT||RETROSPECTIVE|||||||
34018797|NCT03101982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018798|NCT05648461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018799|NCT00494039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100393|NCT04720833|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomly assign to one of the arms.||||
34100394|NCT03418350|||COHORT||PROSPECTIVE|||||||
34100395|NCT01433081|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34100396|NCT02142829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795705|NCT01320657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33940000|NCT03049839|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940001|NCT00000151|RANDOMIZED|||TREATMENT||||||||
33940002|NCT03958409|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33940003|NCT00543842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940004|NCT04385667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940005|NCT01901809|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33940006|NCT01523613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Although material allocation was masked to evaluators, at times a difference in appearance (translucency) of the restorations at recall may have given it away.||t|f|f|t
33940007|NCT02045823|||COHORT||PROSPECTIVE|||||||
33940008|NCT01597934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940009|NCT04789005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795706|NCT01573598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33795707|NCT00629941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795708|NCT00420654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940010|NCT04879511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795709|NCT04891458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesiologists who provide anesthesia for patients need to adjust the dose of sedative drugs according to the score of MOAA/S during operation, so blind method is not used for anesthesiologists.||t|f|f|t
33795710|NCT00346333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940011|NCT00606918|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940012|NCT06428175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33940013|NCT03527927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940014|NCT05071794|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized clinical trial|t|f|f|f
33940015|NCT01314261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940016|NCT04723342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940017|NCT02009501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018800|NCT06493149|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomised, controlled, parallel, two-arm trial||||
33795711|NCT01494896|||CASE_ONLY||PROSPECTIVE|||||||
34018801|NCT01191983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018802|NCT01465620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018803|NCT05607641|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, multicenter, randomized, open-label, parallel-group comparative clinical trial||||
34018804|NCT05946954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34018805|NCT00380692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018806|NCT01624441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018807|NCT00324766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018808|NCT00888823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018809|NCT02255682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33795712|NCT05979324|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention will take place over a maximum of 104 days, i.e. 15 weeks, a minimum of 13 weeks, i.e. 91 days. During this period, it is recommended to use the ABAstroke technology (app) for a maximum of 91 days along with standard therapy, including the possibility of using rehabilitation (as recommended by researchers or other physicians rehabilitating a patient after a stroke). The study is planned as a superiority study. Patients in the control group will be on standard stroke therapy.||||
33795713|NCT03365622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795714|NCT04125433|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||In this study a Medicaid Managed Care Plan will identify up to 400 plan members who have visited an emergency department greater than 6 time in a 12-month period. These individuals will receive enhanced integrated peer care services and will be tracked across health and social service venues using a single IT platform. This study will examine the impact of this intervention on total cost of care.||||
33795715|NCT01487148|||||PROSPECTIVE|||||||
33795716|NCT05944822|||CASE_CONTROL||RETROSPECTIVE|||||||
33940018|NCT04615728|||COHORT||PROSPECTIVE|||||||
33940019|NCT01444144|||CASE_ONLY||RETROSPECTIVE|||||||
33940020|NCT04337203|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33940021|NCT05122442|||COHORT||PROSPECTIVE|||||||
33940022|NCT02193685|||COHORT||PROSPECTIVE|||||||
33940023|NCT02062216|||COHORT||PROSPECTIVE|||||||
34018810|NCT06156345|RANDOMIZED|PARALLEL||TREATMENT||NONE||Permuted block randomization to ensure an equal number of allocations in each of the three groups (Conservative only and conservative with Denneroll cervical traction orthodontic). Each random block was stored in opaque sealed envelopes consecutively numbered with a third researcher. Once each participant officially joins the study the researcher will open the subsequent envelop.||||
34018811|NCT00285831|||||PROSPECTIVE|||||||
34018812|NCT03449927|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34018813|NCT03840616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34018814|NCT00183937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018815|NCT01270165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018816|NCT01494935|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34100397|NCT01835431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795717|NCT05297448|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33795718|NCT02620761|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940024|NCT04605341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34018817|NCT04222374|||CASE_ONLY||PROSPECTIVE|||||||
34018818|NCT03595631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018819|NCT06206382|||COHORT||PROSPECTIVE|||||||
34018820|NCT04941118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940025|NCT01183728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940026|NCT01968629|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940027|NCT04360889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940028|NCT01908335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940029|NCT02691078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940030|NCT03385629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33940031|NCT00001116||||TREATMENT||||||||
33940032|NCT01273506|RANDOMIZED|CROSSOVER||||NONE||||||
33940033|NCT02155712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940034|NCT04828304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940035|NCT02063932|||CASE_CONTROL||PROSPECTIVE|||||||
33940036|NCT00198042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018821|NCT04280705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018822|NCT02248038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018823|NCT02527928|||||CROSS_SECTIONAL|||||||
34018824|NCT04413864|NA|SINGLE_GROUP||OTHER||NONE||open-label monocentric cohort study, with intervention added||||
34018825|NCT02401620|||COHORT||CROSS_SECTIONAL|||||||
34018826|NCT01237925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100398|NCT06338670|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subject||||
34100399|NCT04852601|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33715742|NCT00230568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715743|NCT04921254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|DB and placebo controlled|Single escalation dose safety, tolerability and PK followed by multiple escalation dose for safety, tolerability and PK.|t|t|t|t
33715744|NCT03848650|NA|SINGLE_GROUP||OTHER||NONE||||||
34018827|NCT03337165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715745|NCT00345345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715746|NCT00004182||||TREATMENT||||||||
33715747|NCT03138889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715748|NCT06472765|||OTHER||CROSS_SECTIONAL|||||||
33715749|NCT05316753|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Interventional study, Alternating Assignment, Open Label||||
33715750|NCT02664454|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940037|NCT01548729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940038|NCT05450133|||COHORT||CROSS_SECTIONAL|||||||
33940039|NCT00556309|||CASE_ONLY||PROSPECTIVE|||||||
33940040|NCT03444831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33940041|NCT05914844|||CASE_CROSSOVER||PROSPECTIVE|||||||
33940042|NCT04885660|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34018828|NCT05234372|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants were informed at enrollment what arm they belonged to. Investigators could see what arm participants were assigned to. Outcome assessors/data analysts was blinded.|In collaboration with community partners, we designed mivacunaLA as an RCT with a wait-list control group to ensure that all participants could benefit from the educational intervention. The treatment group received the 1 month intervention upon enrollment and the wait-list control received the intervention at month 2 from enrollment. We propose to analyze baseline data for the primary outcomes related to adult caregiver behaviors regarding COVID-19 vaccination for children living in the household for 1 month outcomes, before the control group was exposed to the intervention.|f|f|f|t
34018829|NCT03308266|||CASE_CONTROL||RETROSPECTIVE|||||||
34018830|NCT01962480|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34018831|NCT05464043|NA|SINGLE_GROUP||SCREENING||NONE||||||
34018832|NCT02896582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018833|NCT05897385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018834|NCT01030744|||COHORT||PROSPECTIVE|||||||
34018835|NCT00615654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34018836|NCT04625595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018837|NCT04059224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Stratified dual-stratum open-label two-stage single-center phase 2 trial||||
33940043|NCT01593176|||COHORT||PROSPECTIVE|||||||
34018838|NCT01070459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018839|NCT00238706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34018840|NCT00469157|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34018841|NCT00297856|||COHORT||PROSPECTIVE|||||||
34018842|NCT03823014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot study to determine feasibility of device use for supportive care of transgender patients with erectile concerns post phalloplasty. Device is currently available in market.||||
34018843|NCT04221139|NA|SINGLE_GROUP||OTHER||NONE||||||
34018844|NCT02098096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018845|NCT00173550|||DEFINED_POPULATION||OTHER|||||||
33940044|NCT04834375|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a parallel fashion into either the standard dexamethasone dose of 6 mg or weight-based dexamethasone of 0.2 mg/kg (maximum dose of 20 mg)||||
33940045|NCT00975208|||CASE_CONTROL||PROSPECTIVE|||||||
33940046|NCT05506813|RANDOMIZED|PARALLEL||TREATMENT||NONE||total 20 Participants will be divided in two groups. In group A patients will receive cognitive training along with conventional therapy. while in Group B Participants will receive motor dual task training along with conventional therapy.||||
33940047|NCT04845581|||CASE_ONLY||PROSPECTIVE|||||||
33940048|NCT03161015|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Multiple-center, nonrandomized, open-label, parallel group study||||
33940049|NCT01591044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940050|NCT04566523|||CASE_CONTROL||PROSPECTIVE|||||||
33940051|NCT03799133|NA|SINGLE_GROUP||SCREENING||NONE||Eligible patients will be placed the Florence catheter.||||
33940052|NCT00953784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940053|NCT02765191|NA|SINGLE_GROUP||OTHER||NONE||||||
33940054|NCT00323804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33940055|NCT02750436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940056|NCT02781246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940057|NCT02368158|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940058|NCT04698954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940059|NCT03562728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940060|NCT05986890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940061|NCT00267267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940062|NCT06033495|||COHORT||PROSPECTIVE|||||||
33940063|NCT05585801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940064|NCT05245838|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33940065|NCT02253173|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940066|NCT01496560|||COHORT||PROSPECTIVE|||||||
33940067|NCT03862781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The patients, nursing staff and the perioperative care team (physician assistants, residents) will be blinded.|After the participants have been consented to the study, the study coordinator will refer to the randomization schedule, and alert the surgeon whether creation of the anastomosis will be done in either an intra-corporeal or extra-corporeal fashion.|t|f|f|f
33940068|NCT00554229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940069|NCT05754736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940070|NCT03210415|||COHORT||PROSPECTIVE|||||||
33940071|NCT01992900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018846|NCT02017548|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34018847|NCT00698880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018848|NCT05968443|||COHORT||RETROSPECTIVE|||||||
33795719|NCT01283750||PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795720|NCT02577419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795721|NCT02695381|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33795722|NCT00233337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795723|NCT04080258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The subjects will be randomly assigned to two groups, OMTh and LTT, and will be randomized from a computer-generated list prepared in advance by an external statistician. Allocation will be concealed with opaque sealed envelopes which will be opened after enrolment.~The paediatrician in charge of the outcome assessor will be blinded to allocation concealment. The nurse staff, and the osteopath in charge of collecting the data will be blinded to group assignment.~The two osteopaths in charge of Osteopathic Manipulative Therapy and Light Touch Therapy will be unblinded to group assignment.~Data export will be performed by the external statistician. The blind-to-treatment allocation was tested using a post-treatment single question survey conducted by the pediatrician."|A two arms randomized controlled trial. The experimental group will receive Osteopathic Manipulative Therapy and the Active Comparator will receive Light Touch Therapy.|t|f|t|t
33795724|NCT04893213|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33795725|NCT04045886|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33795726|NCT06261372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795727|NCT00812617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33795728|NCT00989183|||OTHER||PROSPECTIVE|||||||
33795729|NCT05691738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physician who will evaluate the metabolic parametres will not know which arm the individual is in. İn addition, the participants will not know which arm they are in.||t|f|f|t
33795730|NCT03379935|||COHORT||RETROSPECTIVE|||||||
33795731|NCT04390958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795732|NCT02731339|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33795733|NCT05700513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33795734|NCT00596648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795735|NCT00345761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795736|NCT02086370|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33795737|NCT04910555|||COHORT||PROSPECTIVE|||||||
33795738|NCT00080639|||COHORT||PROSPECTIVE|||||||
33795739|NCT00598208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795740|NCT04764448|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double blind||t|f|t|t
33795741|NCT06676215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795742|NCT05589506|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33795743|NCT01353170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795744|NCT05018325|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33795745|NCT03753594|||COHORT||PROSPECTIVE|||||||
33795746|NCT05278871|NA|SINGLE_GROUP||OTHER||NONE||||||
33795747|NCT02089698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795748|NCT03508310|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Quasi-experimental design, in which the intervention condition (i.e., video and posters) was implemented for 10 months and the historical comparison condition (i.e., standard waiting room environment) was the prior 10-month period.||||
33795749|NCT04778124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795750|NCT06334549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33795751|NCT02138006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795752|NCT04681079|||OTHER||OTHER|||||||
33795753|NCT04217850|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795754|NCT01560416|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized 2:1 B Fulvestrant+Ganetespib:A Fulvestrant||||
33795755|NCT06172517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical intervention by orthoses||||
33795756|NCT03696862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795757|NCT01354769|||COHORT||PROSPECTIVE|||||||
33795758|NCT04540497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795759|NCT02315469|||CASE_ONLY||PROSPECTIVE|||||||
33795760|NCT06042439|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33795761|NCT00928213|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33795762|NCT01180192|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795763|NCT01365208|||CASE_ONLY||PROSPECTIVE|||||||
33795764|NCT00479648|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33795765|NCT02708069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795766|NCT05593523|||COHORT||PROSPECTIVE|||||||
33795767|NCT06555380|||COHORT||RETROSPECTIVE|||||||
33795768|NCT06386627|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33795769|NCT03607708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
34018849|NCT05438498|NA|SINGLE_GROUP||PREVENTION||NONE||multi-center, prospective, open-label, pragmatic evaluation||||
34018850|NCT06456736|||COHORT||RETROSPECTIVE|||||||
34018851|NCT02570516|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34018852|NCT02307266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34018853|NCT02606214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018854|NCT00264368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018855|NCT03966248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are randomly divided into Chinese Tuina group and Physical Manual group at a ratio of 1:1, only knowing that they will receive the manual therapies. The assessor, data manager and statistician will not participate in the randomized process and the treatment and share any information with each other.|Two arms recruit and evaluate the participants at the same time, and the included participants have the equal opportunity to either the Chinese Tuina or physical manual therapy groups.|t|f|f|t
34018856|NCT00614783|||COHORT||PROSPECTIVE|||||||
34018857|NCT02731417|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34018858|NCT04648566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34018859|NCT02086136|||COHORT||PROSPECTIVE|||||||
34018860|NCT05240170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The 1st group: RIRS The 2nd group: SWL|f|f|f|t
34018861|NCT00167687|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34018862|NCT05649241|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2x2 factorial design||||
34018863|NCT04276844|||COHORT||PROSPECTIVE|||||||
34018864|NCT04016441|||OTHER||PROSPECTIVE|||||||
34018865|NCT04131543|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, ope label clinical trial||||
34018866|NCT05331157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomly assigned to 2 equal groups (ultrasonography and palpation; 55 subjects in each group) using the permuted block randomization method with randomly selected block sizes of 4 and 6. The group allocation codes were concealed in sequentially numbered, opaque, sealed envelopes that were opened only after assessing the eligibility and obtaining the consent from the parents||t|f|t|f
34018867|NCT04662138|||COHORT||PROSPECTIVE|||||||
34018868|NCT02582866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018869|NCT01990833|||CASE_CONTROL||PROSPECTIVE|||||||
34018870|NCT02619877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715751|NCT05931354|||COHORT||PROSPECTIVE|||||||
34018871|NCT05583136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34018872|NCT04561687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100400|NCT04065854|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multi-centre, pragmatic, parallel-group, randomised controlled trial, with internal pilot trial, and embedded process and economic evaluations.~Web-based randomisation, using a dynamic adaptive algorithm, stratified for centre and other variables to 1) active intervention or 2) standard brief falls assessment and advice. An internal pilot trial will recruit the first 50 participants."||||
34100401|NCT00449800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100402|NCT03935048|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34100403|NCT06695364|NA|SINGLE_GROUP||OTHER||NONE||||||
34100404|NCT04902066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Independent assessors blinded to the treatment will evaluate outcome. Investigator\&#39;s conduct assessment and/or supervise assessments and are masked.|A randomised, assessor-blinded parallel-groups superiority clinical trial.|f|f|t|t
34100405|NCT01044693|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33715752|NCT01588808|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33715753|NCT03686371|||COHORT||PROSPECTIVE|||||||
33715754|NCT03404557|||COHORT||PROSPECTIVE|||||||
33715755|NCT00279240|RANDOMIZED|||PREVENTION||NONE||||||
33715756|NCT05668455|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|re-labelling for clinical trials|"Prospective, single-centre, controlled, randomised, single-blind, cross-over clinical study with 2 treatments and an artificial tear.~(First treatment (14 days) and Wash out (1month) / Second treatment treatment (14 days) and Wash out (1month) /Third treatment (14 days) and Wash out (1month)"|t|f|f|f
33715757|NCT01500629|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33715758|NCT02387853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715759|NCT00290914||||TREATMENT||||||||
33715760|NCT00706407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715761|NCT04464512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blind to the treatment/group assignment.||t|f|f|f
33715762|NCT03140020|||CASE_CONTROL||PROSPECTIVE|||||||
33715763|NCT02642952|||COHORT||PROSPECTIVE|||||||
33715764|NCT05070533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33715765|NCT01622153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715766|NCT02212392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33715767|NCT06320028|NA|SINGLE_GROUP||TREATMENT||NONE|There is no masking.|All participants will receive the same treatment protocol.||||
33715768|NCT05211791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33715769|NCT05600491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715770|NCT05752201|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||"In phase 2, participants will receive one dose of vaccine and one dose of placebo 28 days apart, in a cross over design.~In phase 3, participants will be randomized to receive one of the three possible types of vaccines and all of them will receive one dose of the corresponding vaccine and 1 dose of placebo 28 days apart, in a cross over design."|t|t|t|t
33715771|NCT03281681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715772|NCT00754624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715773|NCT01671618|||COHORT||PROSPECTIVE|||||||
33715774|NCT04951284|||CASE_CONTROL||PROSPECTIVE|||||||
33715775|NCT02062723|||COHORT||PROSPECTIVE|||||||
33715776|NCT00751829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715777|NCT06023342|||COHORT||PROSPECTIVE|||||||
33715778|NCT04793685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715779|NCT03182101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715780|NCT01952275|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795770|NCT04086966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018873|NCT05604248|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34018874|NCT02053480|||COHORT||PROSPECTIVE|||||||
34018875|NCT04314414|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34018876|NCT05808075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34018877|NCT01342107|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34018878|NCT01515514|||COHORT||PROSPECTIVE|||||||
34018879|NCT02551432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018880|NCT03174262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33715781|NCT01572545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715782|NCT00568074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715783|NCT03398967|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715784|NCT01003730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795771|NCT04482400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795772|NCT02020616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33795773|NCT03778099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795774|NCT04758026|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795775|NCT04364594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100406|NCT03072849|||COHORT||PROSPECTIVE|||||||
33715785|NCT05693246|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33715786|NCT02961751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715787|NCT00931762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795776|NCT06390826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795777|NCT02957136|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33795778|NCT04645550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795779|NCT04587908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018881|NCT02774135|||COHORT||PROSPECTIVE|||||||
34018882|NCT00361062|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34018883|NCT02452996|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34018884|NCT04740814|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34018885|NCT00446836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795780|NCT03770507|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34018886|NCT03065426|||COHORT||PROSPECTIVE|||||||
33795781|NCT05000944|RANDOMIZED|CROSSOVER||PREVENTION||NONE||same participants will complete three breakfast conditions||||
33795782|NCT05517772|||OTHER||CROSS_SECTIONAL|||||||
33795783|NCT03534869|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was designed as a prospective interventional randomized parallel longitudinal single-center study to evaluate the effects of auricular acupuncture on pain relief after episiotomy conducted in the Department of Gynecology and Obstetrics, University Hospital Center Sestre milosrdnice, Zagreb, Croatia. Prospective data were collected from November 2016 to April 2017. The study included healthy pregnant women over 18 years of age, a minimum of 36 weeks gestation that underwent mediolateral episiotomy during vaginal delivery. Sixty patients were included in the study. The patients were allocated either of the groups by using a heads-tails binary result coin toss method. Twenty-nine patients were treated with auricular acupuncture for episiotomy pain relief combined with oral analgesic therapy per request, while 31 patients were treated with oral analgesics per request only. In both groups, administration of oral analgesics was recorded.||||
33795784|NCT00482378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940072|NCT05371249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940073|NCT04885205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940074|NCT02194634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940075|NCT03115164|||COHORT||RETROSPECTIVE|||||||
34018887|NCT04241991|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Participants and researchers used dark laser goggles for eye protection against irradiation, and participants were blinded by a blindfold on top of safety glasses.||t|f|t|f
34018888|NCT00084032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018889|NCT01102374|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018890|NCT04270136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018891|NCT02613741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018892|NCT03728634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018893|NCT00356174|||COHORT||PROSPECTIVE|||||||
34018894|NCT03889067|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Ambulatory outpatient human experimental infection||||
34018895|NCT05418530|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Patients who meet the inclusion criteria and after signing the informed consent by the guardian will be randomized to closed system aspiration with an expiratory pause and closed system aspiration without an expiratory pause. Randomization will be performed by blocks of sealed envelopes, allocating the patient to a first technique to be performed and, after 6 hours, to another technique. All patients will perform both forms of aspiration and will be aspirated 2 hours before the start of each technique to match the groups.||||
34018896|NCT01429116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018897|NCT00171301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018898|NCT02534844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While it is a double-blind trial, the participant and outcomes assessor will be blinded, as well as the Care Provider and Investigator.|In Parts A/B (see other registration for Part C description)|f|t|t|f
34018899|NCT05315635|||CASE_ONLY||PROSPECTIVE|||||||
34018900|NCT04645810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018901|NCT03305406|||COHORT||PROSPECTIVE|||||||
34018902|NCT06248541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018903|NCT01968694|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34018904|NCT03300544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018905|NCT04331561|NA|SINGLE_GROUP||TREATMENT||NONE|Masking is not practical for this pilot trial.|Non-randomized, single group design with 2 baseline and 1 post-treatment assessment time points||||
34018906|NCT00006199||||TREATMENT||||||||
34018907|NCT05569603|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33940076|NCT01134328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940077|NCT00679354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940078|NCT00812552|||CASE_CONTROL||RETROSPECTIVE|||||||
33940079|NCT06421194|RANDOMIZED|CROSSOVER||OTHER||NONE||A randomized controlled crossover trial, where participants will undergo four sessions, each followed by a six-day wash-out period.||||
33940080|NCT04691622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018908|NCT05097313|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Double blind trial. Research product blinding will be maintained using one label for both products (fiber and placebo) and the same capsules for both.~Subjects, who collect the data (eg, Investigator and coordinator) and those who evaluate the data (eg, Statistician) will be blinded. One or more pharmacists / vaccine administrators designated by the facility will not be blinded. These designated unblinded individuals will maintain investigational vaccine blindness and will not participate in the safety assessment of the subjects."|"This is an interventional, randomized, non-comparative, exploratory, three-arm, double-blind, randomized study, divided into three groups (2 intervention and placebo) using an allocation ratio of 1: 1: 1.~Treatment allocation will be made according to a random code."|t|t|t|t
34100407|NCT04253171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome will be assessed by a blinded clinical events adjudication committee and by a blinded OCT core laboratory analysis.|Investigator-initiated 1:1 randomized, controlled, multinational, superiority trial.|f|f|f|t
34100408|NCT06413134|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be told what therapy they will be using in either arm, and since they are naive to PAP therapy, they would be more blinded than adherent patients.|There will be two, 6-week arms where patients will breathe on standard APAP therapy and the test therapy, TheraPAP. Starting therapy will be randomly assigned, but all participants will sleep using both therapies.|t|f|f|f
34100409|NCT04635982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Thirty-seven subjects were randomly allocated to the different study groups using the software AleatorMetod.xls. Subjects were divided into three groups: 13 subjects were assigned to the experimental group with KT activation (KTact); 12 subjects, to the placebo group with a sham tape KT (KTst); and 12 subjects, to the control group (CG).|f|f|f|t
34100410|NCT05730660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100411|NCT02504385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018909|NCT00596037|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100412|NCT06284252|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participant blinding: In order to ensure participant blinding, all students will register to the site where virtual game simulations will be hosted.~Statistics blinding: In order to blind the statistics expert, at the end of data collection, the website expert will share the collected data with the statistics expert as group A and B data. The statistician will perform statistical analyzes without knowing which group is the control and which group is the experiment.~Researcher blinding: In order to ensure researcher blinding, the expert who designed the web page for virtual game simulations selected the students who registered on the website, using the A and B codes, according to the list he received from the statistics expert, on the website with a random group as control and one group as experiment. will assign it to the site."|Control group and intervention group|t|f|t|t
34100413|NCT04880590|||COHORT||PROSPECTIVE|||||||
34100414|NCT06578195|||COHORT||PROSPECTIVE|||||||
34100415|NCT06635889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100416|NCT00580203|||CASE_ONLY||PROSPECTIVE|||||||
34100417|NCT06694350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018910|NCT03090607|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34018911|NCT05571735|||COHORT||PROSPECTIVE|||||||
34100418|NCT01144351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100419|NCT04880356|||OTHER||OTHER|||||||
34100420|NCT00829478|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34018912|NCT00230074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018913|NCT05107102|||CASE_ONLY||PROSPECTIVE|||||||
34018914|NCT02044796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100421|NCT04739345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100422|NCT04410133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Positron Emission Tomography (PET) Imaging study||||
34100423|NCT03586453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100424|NCT03540485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100425|NCT02402231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100426|NCT03244254|||COHORT||PROSPECTIVE|||||||
34100427|NCT02297035|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34100428|NCT02262273|||COHORT||RETROSPECTIVE|||||||
33940081|NCT01970436|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940082|NCT02423733|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33940083|NCT02807376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940084|NCT00073541||||TREATMENT||NONE||||||
33940085|NCT02619461|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940086|NCT00417235|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33940087|NCT06119828|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|Since one researcher conducted the study, blinding was not possible.|It was conducted as a randomized controlled experimental study to determine the effect of breastfeeding education given to the family member who supports the mother in the postpartum period on breastfeeding parameters.||||
33940088|NCT00531310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940089|NCT00779597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33940090|NCT00138892|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940091|NCT04390360|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33940092|NCT03452397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940093|NCT01520675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940094|NCT04282499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are not aware to the study design.|clinical evaluating the effects of 2 exercise training modalities on blood pressure variability. Recruited subjects will be randomized in two interventional arms: 1) aerobic exercise; 2) combined exercise (aerobic+resistance training).|t|f|f|f
33940095|NCT02648867|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33940096|NCT00003368||||TREATMENT||||||||
34018915|NCT03195153|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34018916|NCT05597956|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018917|NCT04363840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018918|NCT04509882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100429|NCT00159874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100430|NCT02129010|||COHORT||PROSPECTIVE|||||||
34100431|NCT01410487|||CASE_ONLY||PROSPECTIVE|||||||
33940097|NCT00792324|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34018919|NCT05318274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018920|NCT05702671|||COHORT||CROSS_SECTIONAL|||||||
34018921|NCT00070057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018922|NCT06387485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018923|NCT03277482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018924|NCT00463242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018925|NCT02239341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018926|NCT05525793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100432|NCT04745806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100433|NCT05991466|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34018927|NCT03059004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not be appraised of treatment arm.|Four arm parallel randomized controlled trial.|f|f|f|t
34100434|NCT01033370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100435|NCT05135780|||OTHER||PROSPECTIVE|||||||
34100436|NCT03173508|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100437|NCT05467150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795785|NCT00317902|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940098|NCT02250586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018928|NCT06085118|||COHORT||PROSPECTIVE|||||||
33940099|NCT02698917|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The physician determining neurological outcome at six months after cardiac arrest is blinded to the study group allocations||f|f|f|t
34018929|NCT03000335|||CASE_CONTROL||OTHER|||||||
34018930|NCT00714961|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34018931|NCT02229123|NA|SINGLE_GROUP||TREATMENT||NONE||LEVNEONAT-1 is an open and sequential dose-finding study with 1 loading dose of 30, 40 and 50 mg/kg and 8 quarter-loading maintenance doses for a 3-day treatment. The optimal dose will be the one estimated to be associated with a toxicity not exceeding 10% and an efficacy higher than 60%. Efficacy has been defined by a seizure burden reduction of 80% after the loading dose. A 2-patient cohort will be necessary at each dose level to consider an upper dose level assignment with a dynamic consideration of each participant data. The maximal sample size expected is 30 participants patients.||||
34018932|NCT05738759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients were divided into two groups using computer-generated block-of-four randomization. The experimental group received epidural anesthetic cocktail following endoscopic discectomy, while the control group received placebo.|t|t|t|t
34018933|NCT01080443|RANDOMIZED|CROSSOVER||||NONE||||||
33940100|NCT04717856|NA|SINGLE_GROUP||SCREENING||NONE||||||
34018934|NCT00006466||||TREATMENT||||||||
34018935|NCT06514690|||COHORT||PROSPECTIVE|||||||
34018936|NCT02349243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018937|NCT00923000|RANDOMIZED|CROSSOVER||||NONE||||||
34018938|NCT03106649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34018939|NCT03178565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Mechanically ventilated patients will be randomized to receive respiratory physiotherapy using a mechanical insufflation-exsufflation device (intervention group) or to receive standard respiratory physiotherapy without the use of a mechanical insufflation-exsufflation device (control group).||||
34018940|NCT02095808|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940101|NCT04735289|||CASE_CONTROL||PROSPECTIVE|||||||
34018941|NCT03822832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018942|NCT01478243|||CASE_ONLY||CROSS_SECTIONAL|||||||
34018943|NCT00708786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34018944|NCT04532359|||COHORT||PROSPECTIVE|||||||
34018945|NCT04060043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795786|NCT04979299|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Participants included in the wheelchair group settle into a hospital wheelchair. The wheelchair comes from a batch of two, without specific brand, standard color.~The videos are showed to 10 different psychiatrists whom each proceed to 10 iCGI rating assessments, after receiving methodological informations.~The psychiatrists are blinded evaluators. They are not aware of the objective of the study focusing on the impact of the wheelchair. They will be decepted with the information that the study aim to evaluate the iCGI, as a new version of the CGI with elderly patients (we will procede to a feedback afterward)."|We procede in a randomization 1:1, stratified by site. In one group, patients will be seated in a wheelchair and in the second group, patients will be seated in an regular chair. Allocation concealment will be ensured by the use of sequentially numbered, opaque, sealed envelopes (SNOSE).|f|f|f|t
33795787|NCT06342063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measurement was blinded to participant intervention.|Patients were recruited and randomized to one of the two treatment arms.|f|f|f|t
33940102|NCT05224856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940103|NCT01540110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940104|NCT05577351|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective, multi-center, open-label, single-arm study to assess the initial technical effectiveness and safety of the RapidPulseTM (feasibility version). As such, no formal statistical hypothesis will be tested in this study.||||
33940105|NCT05949528|||COHORT||PROSPECTIVE|||||||
33940106|NCT00079157||||TREATMENT||||||||
33940107|NCT01148836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940108|NCT00276354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33940109|NCT05945563|||COHORT||OTHER|||||||
33940110|NCT05534594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100438|NCT06567691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature and means of access of the two interventions (one via peroral approach and one via abdominal incision) blinding of the subjects, study investigators, and treating clinicians will not be practicable short of subjecting patients to sham endoscopy and/or surgery, which we feel would be unethical.|||||
34100439|NCT05882903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100440|NCT03178890|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective study. Each patient is his/her own control.||||
34100441|NCT04743141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795788|NCT05622786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795789|NCT01477879|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33940111|NCT03557801|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33940112|NCT01927276|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33940113|NCT01886144|||COHORT||PROSPECTIVE|||||||
33940114|NCT04437589|||COHORT||RETROSPECTIVE|||||||
33940115|NCT01524900|||||PROSPECTIVE|||||||
33940116|NCT01931020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940117|NCT05850429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A three arm, acute randomised, double blind crossover design feeding study will be used to establish the impact and dose response to co-ingestion of BioDulse (a protein hydrolysate from Irish seaweed) with maltodextrin on postprandial blood glucose and insulin concentrations.|t|f|t|f
33940118|NCT05110495|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 0 'window of opportunity' study testing whether xentuzumab blocks IGF signalling and markers of growth in men with localised prostate cancer scheduled for radical prostatectomy||||
33940119|NCT03599284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018946|NCT02276014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34018947|NCT05280132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018948|NCT02264288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018949|NCT02858492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018950|NCT04146311|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33795790|NCT03601910|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795791|NCT05429346|||COHORT||PROSPECTIVE|||||||
33795792|NCT04581317|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795793|NCT03221023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both patient and surgeon will be blinded to the treatment.|The subjects meeting the inclusion criteria will be randomized to either the treatment arm or the control arm by site in a 1:1 ratio.|t|t|f|f
33795794|NCT04563117|||OTHER||CROSS_SECTIONAL|||||||
33795795|NCT03024606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795796|NCT01689272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795797|NCT03070483|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot study is a one arm study which will assess the safety and feasibility of supplementing 15 young adults with African ancestry and low vitamin D levels with 5,000 IU of Cholecalciferol (vitamin D3) combined with 1000 mg of elemental calcium daily for 3 months||||
33940120|NCT01630629|||COHORT||PROSPECTIVE|||||||
33940121|NCT03653039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised controlled||||
33940122|NCT05632705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor will not have information with regards to the intervention arms|Randomised trial|f|f|f|t
33940123|NCT03280186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940124|NCT02334813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940125|NCT01365468|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940126|NCT04464876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940127|NCT06303362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018951|NCT06035471|||COHORT||PROSPECTIVE|||||||
34018952|NCT01939496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018953|NCT03660163|||COHORT||PROSPECTIVE|||||||
34018954|NCT00105300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018955|NCT05640219|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34018956|NCT06434077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34018957|NCT04450576|||COHORT||RETROSPECTIVE|||||||
34018958|NCT00231647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34100442|NCT05649553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding was provided that included inclusion criteria and agreement to participate in the study.|This study is a parallel group randomized controlled study|t|f|f|f
34100443|NCT05156398|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34100444|NCT01569880|||CASE_ONLY||PROSPECTIVE|||||||
33795798|NCT03393078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33795799|NCT06127836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Surgeons will be blinded to the results of the lymphoscintigraphy and will perform SLN biopsy in the operating room using near-infrared imaging with ICG injection. And the results will not be released until the consenting surgeon contacts the Nuclear Medicine team after attempting to identify the SLN by use of near-infrared imaging with ICG injection.|This is a prospective study to evaluate the performance of near-infrared imaging with ICG injection, compared with lymphoscintigraphy, for the detection of the inguinofemoral SLN in patients with vulvar cancer.||||
33795800|NCT01166152|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33795801|NCT03458546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795802|NCT03209037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795803|NCT01331824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795804|NCT01832480|RANDOMIZED|PARALLEL||TREATMENT||NONE|This was an open label study|||||
33795805|NCT01159704|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33795806|NCT01886625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940128|NCT03436992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018959|NCT00706511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018960|NCT04505137|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (GMA301 Injection or placebo). Blinding will be maintained at least until the clinical phase of the study is completed (i.e., when reporting and evaluation of all AEs have been completed, for all cohorts).|Two sequential dosing cohorts, each with 6 subjects receiving GMA301 Injection and 2 subjects receiving placebo (total of 16 subjects). The doses to be administered will be 1500 mg and 2000 mg, or matching placebo, single dosing. Each cohort will include at least 2 participants of Chinese descent, if possible.|t|f|t|f
34100445|NCT06412198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100446|NCT03641677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100447|NCT01665794|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33940129|NCT04765306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a prospective, singled-blinded, randomized controlled study. Eligible patients who provide consent will be randomized into one of two arms either undergoing fascial closure with a fascial closure device or traditional direct closure on the day of surgery. Every patient will have equal probability of being assigned to either study arm. The patients will be blinded to which study arm they have been assigned to, but providers will be aware due to the nature of study topic.||t|f|f|f
33940130|NCT04065516|NA|SINGLE_GROUP||TREATMENT||NONE||A clinical trial will be carried out, including all patients with achalasia, treated by peroral myotomy older than 18 years old, with abnormal acid exposure in the pHmetry test 3 months or more after treatment, who accept the management of ablation with hybrid argon plasma. To whom the ablation will be performed with Hybrid Argon Plasma and its effectiveness will be evaluated by clinical questionnaires, endoscopy and pH measurement at the beginning, 2 months, 6 months and 12 months after the procedure.||||
33940131|NCT03506581|||COHORT||CROSS_SECTIONAL|||||||
33940132|NCT01739192|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33940133|NCT00582764|||CASE_ONLY||PROSPECTIVE|||||||
33940134|NCT04605133|||COHORT||PROSPECTIVE|||||||
33940135|NCT00400868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940136|NCT01306240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940137|NCT00758420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940138|NCT00307736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940139|NCT01880489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940140|NCT00554840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940141|NCT01372189|||||PROSPECTIVE|||||||
33940142|NCT04983004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940143|NCT05415631|||CASE_ONLY||PROSPECTIVE|||||||
33940144|NCT06320964|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100448|NCT04880889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-dummy|Study phase III, randomized, double-dummy, placebo controlled, single-center, of regarding the non-inferiority of the medication BL3000, when compared to Pantogar® treatment of telogen effluvium in women.|t|t|t|t
34100449|NCT06630676|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcome assessor will not be privy to the treatment group.|Patients will be randomized to a comprehensive educational program consisting of 27 slides and answering questions, or a control group (3 brief slides)|f|f|f|t
34100450|NCT06694142|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34100451|NCT06046651|||COHORT||PROSPECTIVE|||||||
34100452|NCT04191616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100453|NCT06681727|||COHORT||OTHER|||||||
34100454|NCT02166762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100455|NCT03983655|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|t|t|f
34100456|NCT06483828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34100457|NCT05112237|||OTHER||OTHER|||||||
34100458|NCT06694480|NA|SEQUENTIAL||TREATMENT||NONE||"FID-022 treatment Single arm study with 6 planned dose levels.~Intravenous Administration of FID-022, infusion on day 1 and 8 of each 21-day cycle:~Dose level 1: 20 mg/m2. Dose level 2: 40 mg/m2. Dose level 3: 60 mg/m2. Dose level 4: 80 mg/m2. Dose level 5: 100 mg/m2. Dose level 6: 120 mg/m2."||||
34100459|NCT03375307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715788|NCT01075945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715789|NCT01373372|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940145|NCT04383691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940146|NCT03230266|NA|SINGLE_GROUP||OTHER||NONE||||||
33940147|NCT06366685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33940148|NCT03960164|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|There will be no masking of the treatment for researchers|Single group to test safety of the treatment||||
33940149|NCT06295822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715790|NCT02455622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715791|NCT04101357|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715792|NCT02596191|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940150|NCT05528068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33940151|NCT00113035|||||PROSPECTIVE|||||||
33940152|NCT02147431|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33940153|NCT02557633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940154|NCT03137433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940155|NCT03513432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||"This is a three-arm parallel-group, randomized controlled study to evaluate the effect of consumption of beer with or without alcohol (5.20 %, 0.45 % and 0.00 %), during 4 weeks, on healthy individuals.~The study will focus on the effects of beer on microbiota and biochemical biomarkers in healthy human volunteers."|t|t|t|t
33940156|NCT00969735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940157|NCT06095349|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33940158|NCT01738672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940159|NCT01435564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940160|NCT01432236|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33940161|NCT04152538|||CASE_ONLY||PROSPECTIVE|||||||
33940162|NCT02865317|||COHORT||CROSS_SECTIONAL|||||||
33940163|NCT03020797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940164|NCT04340804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940165|NCT02054572|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940166|NCT00793715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940167|NCT01930487|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34100460|NCT06694064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100461|NCT00887133|||COHORT||PROSPECTIVE|||||||
33795807|NCT04635267|||COHORT||PROSPECTIVE|||||||
33795808|NCT04567407|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-arm intervention trial||||
33795809|NCT05352035|||COHORT||PROSPECTIVE|||||||
33795810|NCT02764307|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33795811|NCT01551433|||COHORT||PROSPECTIVE|||||||
33795812|NCT04462055|||COHORT||PROSPECTIVE|||||||
34018961|NCT03370809|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34018962|NCT00345657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715793|NCT03874247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33715794|NCT03151460|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"All PD patients were examined in two conditions: following the standard dopamineric medication (on) and following a 12-18 hours of treatment wash-out (off). Normal controls were examined twice with no drug assumption."||||
33715795|NCT02257788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715796|NCT06466122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795813|NCT05360043|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795814|NCT02202499|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795815|NCT05006729|||COHORT||PROSPECTIVE|||||||
33715797|NCT00390858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795816|NCT02418013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795817|NCT01084850|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33795818|NCT06676371|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial of two groups||||
33795819|NCT00483093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795820|NCT03897413|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795821|NCT04368858|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940168|NCT03076411|||COHORT||PROSPECTIVE|||||||
33940169|NCT01998854|||COHORT||PROSPECTIVE|||||||
33940170|NCT00219310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940171|NCT05676723|||COHORT||PROSPECTIVE|||||||
33940172|NCT02985385|||COHORT||PROSPECTIVE|||||||
33940173|NCT02409251|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33940174|NCT03322540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the implementation of Amendment 05 the study is no longer blinded.||t|t|t|t
33940175|NCT01615094|||COHORT||PROSPECTIVE|||||||
33940176|NCT00652964|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33940177|NCT01972295|||COHORT||PROSPECTIVE|||||||
33940178|NCT00959192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940179|NCT04972097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940180|NCT01098942|||COHORT||PROSPECTIVE|||||||
33940181|NCT04915937|NA|SINGLE_GROUP||OTHER||NONE||||||
33940182|NCT04121182|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Seven thousand residents will be recruited by 280 nursing home in 2 major regions in France and followed for 1 year. At the end of the randomization, half of the institutions will benefit from an on-line training on the prevention and management of pulmonary disease in residents. Other institutions will continue their usual practice (routine care) and will not benefit from training during the study period."||||
33940183|NCT01001884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33940184|NCT02939456|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940185|NCT03524586|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33940186|NCT01211067|||CASE_ONLY||PROSPECTIVE|||||||
33940187|NCT03356327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940188|NCT05743816|||CASE_CONTROL||PROSPECTIVE|||||||
33940189|NCT00243490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940190|NCT05902611|||CASE_ONLY||CROSS_SECTIONAL|||||||
33940191|NCT06083376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940192|NCT00620672|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33940193|NCT04524013|||COHORT||CROSS_SECTIONAL|||||||
33940194|NCT04531345|||CASE_CONTROL||PROSPECTIVE|||||||
33940195|NCT03699501|||COHORT||PROSPECTIVE|||||||
33940196|NCT02347124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940197|NCT03040180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715798|NCT03926273|||CASE_CONTROL||OTHER|||||||
33715799|NCT00877383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715800|NCT03557463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Supplements were coded based on protein type and both participants and researchers were blinded to the underlying code|Controlled, randomized, double blind pilot study|t|t|t|f
33940198|NCT05060003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940199|NCT01116726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940200|NCT04670042|NA|SINGLE_GROUP||TREATMENT||NONE||Case series of 15 subjects with chronic post-surgical pain (CPSP). Subjects will be recruited over 6 months (on average 1 subject per week)||||
33940201|NCT02275949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33940202|NCT01440231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940203|NCT02736149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940204|NCT05178329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33795822|NCT00222326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940205|NCT05231551|||OTHER||PROSPECTIVE|||||||
34018963|NCT01697566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018964|NCT01665300|||CASE_ONLY||PROSPECTIVE|||||||
34018965|NCT05134506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018966|NCT00600808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34018967|NCT04642937|NA|SEQUENTIAL||TREATMENT||NONE||||||
34018968|NCT02586142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018969|NCT01593696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34018970|NCT00960115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018971|NCT04549714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients enrolled in the study were randomly assigned to different surgical groups using random envelopes. All study personnel were blind to treatment allocation and had no way of influencing whether a participant would receive high or low AI ablation.||t|t|f|t
34018972|NCT01943721|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34018973|NCT04365114|||COHORT||RETROSPECTIVE|||||||
34018974|NCT00661141|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33795823|NCT06588257|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A pilot study of mixed quantitative and qualitative methodology is proposed. A prospective cohort of 100 men who have sex with men and transgender women, with and without HIV will be organized at Fundación Huésped to study acceptability of HPV vaccine and effect of HPV vaccine on anal HPV infection. Moreover, 20 people from the cohort along with 5 additional people who shall not agree to receive the HPV vaccine will participate in in depth interviews. (qualitative component).||||
33795824|NCT06392711|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795825|NCT04943770|||CASE_ONLY||PROSPECTIVE|||||||
33795826|NCT04838886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intervention and control groups|t|f|f|t
33795827|NCT00622531|||CASE_CONTROL||PROSPECTIVE|||||||
33795828|NCT03290248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double blind study.|Randomization will be 1:1:1 so that equal number of subjects will be treated in each arm of the study.|t|t|t|t
33795829|NCT03387319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Of the 100 participants recruited, 80 will have a diagnosis of chronic kidney disease (CKD) and 20 will not. Participants will be randomized such that half will recall the racial experience and half will recall the non-racialized stressful event. Each participant will have an equal chance of being placed in the racialized or non-racialized experience group.||||
33795830|NCT05695911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized by ratio of 1:2 in the CTL to EXP group.|f|f|t|t
33795831|NCT03399968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective randomized controlled double blinded clinical intervention study|t|f|t|t
33795832|NCT03227757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795833|NCT04525170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795834|NCT04484480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator an outcomes assessor were blinded for the information whether analyzed participant was in the interventional group or control one.||f|f|t|t
33795835|NCT01816958|||CASE_CONTROL||RETROSPECTIVE|||||||
33795836|NCT03179722|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel group intervention study. In a subset of 140 patients, a pre-post study design is used.||||
33940206|NCT03935893|NA|SINGLE_GROUP||TREATMENT||NONE||This study will follow the Bayesian basket design proposed by Simon et al (2016). Treatment will be considered active in a specific histology cohort if the response rate is over 20% (phi = 0.2) and not active if the response rate is less than 5% (plo = 0.05).||||
33940207|NCT04927611|||CASE_ONLY||PROSPECTIVE|||||||
33940208|NCT05761769|||COHORT||PROSPECTIVE|||||||
33940209|NCT00412295|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33940210|NCT03474172|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33940211|NCT02796495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940212|NCT01931189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940213|NCT06073431|||COHORT||PROSPECTIVE|||||||
33940214|NCT00103935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940215|NCT00640575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795837|NCT05137223|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795838|NCT02238418|NA|SINGLE_GROUP||OTHER||NONE||||||
33795839|NCT04275193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795840|NCT01852526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795841|NCT03779763|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33940216|NCT02243163|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33940217|NCT00198406|||||PROSPECTIVE|||||||
33940218|NCT04765449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940219|NCT04914091|||COHORT||PROSPECTIVE|||||||
33940220|NCT01114906|||||RETROSPECTIVE|||||||
33940221|NCT05190328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940222|NCT03903861|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33940223|NCT01700127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940224|NCT02435940|||OTHER||PROSPECTIVE|||||||
33940225|NCT01710215|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33940226|NCT00000980||||TREATMENT||||||||
33940227|NCT02425891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940228|NCT03684460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial with 2 cohorts|f|f|f|t
33940229|NCT00082238|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940230|NCT05860595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940231|NCT04772651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940232|NCT03459963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940233|NCT01612611|||COHORT||PROSPECTIVE|||||||
33940234|NCT05750901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940235|NCT00672139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940236|NCT00298285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940237|NCT03459105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940238|NCT04812236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940239|NCT03438591|NA|SINGLE_GROUP||TREATMENT||NONE||patients who meet the criteria of current CRT treatment||||
33940240|NCT03958461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940241|NCT01694459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34018975|NCT03253211|||COHORT||PROSPECTIVE|||||||
34018976|NCT05802251|||COHORT||PROSPECTIVE|||||||
34018977|NCT04432103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups depending on the stage of the disease according to the CDC of China classification severe and critical COVID-19 pneumonia||||
34018978|NCT02116426|||COHORT||PROSPECTIVE|||||||
33795842|NCT05448807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This research will be a double blinded study, where the patient (participant) and the statistician will be blind to the treatment groups (to avoid detection and reporting bias). Information bias, selection bias, and confounding will be avoided in this study. The operator will not be blinded to the treatment as the test group will receive a PM (Oraverse) injection while the control group will not receive a reversal agent.|"Intervention group: they receive phentolamine mesylate (Oraverse) injection after the completion of their dental procedures with ratio 1:1 to LA in children weighed 30 kg and more while in children less than 30 kg only half of the amount of the cartridge is administrated.~Control group: they don't receive any reversal agent or placebo after the completion of their dental procedures."|t|f|f|t
33795843|NCT00592241|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33795844|NCT02651480|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33795845|NCT04820361|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, CROSSOVER, MULTICENTER STUDY.||t|t|t|f
33795846|NCT01081145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34018979|NCT03320200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018980|NCT05577143|||CASE_CONTROL||PROSPECTIVE|||||||
34018981|NCT04161846|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized 2 group repeated measures design (Pre-Pandemic) \[Pandemic modification: Only Virtual world group\]|f|f|f|t
34018982|NCT01777360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018983|NCT02352545|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34018984|NCT01094418|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34018985|NCT00201955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34018986|NCT00698893|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34018987|NCT06156735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||participant will receive one passive music therapy session consisting of relaxation to music, one active music therapy session consisting of instrument-playing, and one control condition.|t|f|f|t
34018988|NCT02074748|||CASE_CONTROL||PROSPECTIVE|||||||
31537296|NCT06718166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34018989|NCT06295848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34018990|NCT06402370|||COHORT||PROSPECTIVE|||||||
34018991|NCT03009916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34018992|NCT00893737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018993|NCT01216696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34018994|NCT03214874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Fully Replicate double-crossover||||
34018995|NCT01604590|||CASE_ONLY||PROSPECTIVE|||||||
34018996|NCT01319773|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33795847|NCT02817984|NA|SINGLE_GROUP||OTHER||NONE||||||
34018997|NCT01753947|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34018998|NCT03422367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34018999|NCT02038907|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34019000|NCT05069337|||CASE_ONLY||PROSPECTIVE|||||||
34019001|NCT05739552|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34019002|NCT03330080|||COHORT||PROSPECTIVE|||||||
34019003|NCT05277623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34019004|NCT06281327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795848|NCT05850026|||CASE_ONLY||CROSS_SECTIONAL|||||||
33795849|NCT05110534|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants were randomly allocated to the test and control groups by a computer-generated random sequence prepared by a statistician, blinded to the recruiting person.The examiners were blinded regarding the group status of the children, as other practice personal had to perform the preventive sessions.|Randomized Controlled Trial|f|f|t|f
33795850|NCT06245863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33795851|NCT00736853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019005|NCT00784186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019006|NCT01642914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019007|NCT01053234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019008|NCT06404892|||COHORT||PROSPECTIVE|||||||
34019009|NCT02140723|||COHORT||PROSPECTIVE|||||||
34019010|NCT01905748|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019011|NCT02269163|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019012|NCT01211080|||COHORT||PROSPECTIVE|||||||
34019013|NCT05755503|||COHORT||CROSS_SECTIONAL|||||||
33795852|NCT03010553|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795853|NCT01901510|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33795854|NCT00092781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795855|NCT03244579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795856|NCT05641311|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33795857|NCT06673147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Out of 50 pregnant women who will be screened for their eligibility criteria, The participants will be randomized to either intervention group (Nordic Walking) or control group (standard prenatal care).|t|f|f|t
33795858|NCT03833648|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study participants will not know which version of the app they are instructed to install.|Patients will be randomized to one of two conditions: 1) usual care versus 2) provision of the provider-prescribed education/tool part of the consumer health informatics app (UControlPain) using a random electronic 1:1 allocation scheme.|t|f|f|f
33940242|NCT03345875|NA|SINGLE_GROUP||SCREENING||NONE||"This is a prospective cohort study of women in an HPV self-collection screen-and-treat strategy for cervical cancer prevention to assess collection, triage and treatment through a service delivery model using descriptive, quantitative methods, and formative, qualitative research with providers and women.~Methods to assess feasibility of the service model are electronic medical record (EMR) documentation of women's progression from eligibility for and receipt of services through each step of the HPV self-collection screen-and-treat strategy, from self-collection through test results to treatment of precancer, including referral for suspect cancer.~Acceptability will entail: a) in-depth interviews with health providers, community mobilizers, health facility staff and managers and b) in-depth interviews and surveys with women who receive services as well as women that are eligible and decline services."||||
33940243|NCT04537364|||COHORT||PROSPECTIVE|||||||
33940244|NCT03433391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940245|NCT00000970||||TREATMENT||||||||
33940246|NCT03755037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind randomisation|Women with unexplained infertility (n=150) were divided into 3 equal groups. Group 1 received estradiol and clomiphine citrate (cc), group 2 received sildenafil and cc and group 3 cc and placebo.|t|f|t|f
33940247|NCT04686110|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940248|NCT00193856|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33940249|NCT03163121|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Stage A is an open label study. Stage B of the clinical study will be double-blinded.||t|t|t|t
33940250|NCT06193733|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33940251|NCT03369340|RANDOMIZED|CROSSOVER||OTHER||NONE|Sponsor staff, Investigator, the subjects and the investigational site will be blinded to the randomization sequences until they are assigned. Subjects will not be informed of the complete sequence to which they have been assigned.|A single-center, open-label, randomized, crossover study.||||
33940252|NCT00917878|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33940253|NCT00209755|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940254|NCT00066443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940255|NCT03137524|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single Centre Pilot study using a randomised controlled crossover design (aka randomised A-B single-subject design).||||
33940256|NCT02192190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940257|NCT05670028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940258|NCT01334008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940259|NCT03132129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940260|NCT01137851|||COHORT||RETROSPECTIVE|||||||
33940261|NCT06110091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940262|NCT04173169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For participants who agree to be randomized, a computer-generated randomization list will be created by the PREGnant Data Coordinating Center (DCC) and randomization will be performed prior to the first dose of elagolix. Randomization will have random sizes (2, 4, or 6) of blocks and be stratified by site, i.e. whole blocks are assigned to sites. The randomization list will not be available to any person involved in the conduct and evaluation of the trial until the trial is complete and database is declared clean and is released by the DCC. Likewise, treatment allocation information will not be accessible to investigators (except for serious safety concerns), trial staff at the site or central laboratory personnel during the trial.|Half of the subjects (200, randomized or not randomized) will receive elagolix 200mg twice a day (BID) and the other half of subjects will receive placebo BID or SOC IVF (200, placebo or SOC IVF). Elagolix or placebo will be taken for a minimum of 60 days before IVF cycle start. For convenience of IVF cycle scheduling, participants may receive up to an additional 14 days of intervention (elagolix or placebo) beyond the minimum 60 days of pre-IVF treatment, such that the last dose of study intervention (elagolix or placebo) is received no more than 24 hours before start of IVF treatment protocol.|t|t|t|f
33940263|NCT04193137|||COHORT||PROSPECTIVE|||||||
33940264|NCT02356042|||CASE_CONTROL||PROSPECTIVE|||||||
33940265|NCT00724594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940266|NCT00581724|||CASE_ONLY||PROSPECTIVE|||||||
33940267|NCT02716532|NA|SINGLE_GROUP||OTHER||NONE||||||
33940268|NCT02607735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940269|NCT00391820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940270|NCT00000529|RANDOMIZED|||PREVENTION||||||||
33940271|NCT00195702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940272|NCT03784716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940273|NCT00144456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940274|NCT00833066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940275|NCT00411606|||CASE_ONLY||PROSPECTIVE|||||||
33795859|NCT04725227|||CASE_CONTROL||PROSPECTIVE|||||||
33795860|NCT02010138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795861|NCT03038217|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33795862|NCT00488657|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33795863|NCT01117480|||COHORT||PROSPECTIVE|||||||
33795864|NCT03870607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers will identify the patients through a unique number and through the initials of the name. Randomization will be simple and conducted independently by clinical trial support staff who are not participating in the study. The random sequence will be generated by computer program.|Eligible patients who consent to participate in this study will be randomized 1: 1 in two groups: Group A or experimental and Group B or control|f|f|t|t
33795865|NCT03005678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795866|NCT05368025|||OTHER||OTHER|||||||
33795867|NCT04233931|NA|SINGLE_GROUP||PREVENTION||NONE||pre-post test evaluation of the impact of a mobile app on PrEP treatment adherence||||
33795868|NCT04775290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33795869|NCT06677450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795870|NCT02744859|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795871|NCT04554628|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33795872|NCT02139943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33795873|NCT01271452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795874|NCT00518869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795875|NCT00964197|NA|SINGLE_GROUP||OTHER||NONE||||||
33795876|NCT06483308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795877|NCT04455516|||CASE_CONTROL||RETROSPECTIVE|||||||
33795878|NCT05246098|||COHORT||OTHER|||||||
33795879|NCT01720550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795880|NCT02452918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795881|NCT06677606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795882|NCT05647070|NA|SINGLE_GROUP||TREATMENT||NONE||"A sterile Foley catheter is placed to drain the bladder, following this, injectable normal saline is utilized using 10 cc syringe for hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through Pfannestiel incision, \~1 cm× \~5 cm rectus fascia strip is isolated from the anterior rectus sheath. Two stay sutures are secured to the corner of the fascial segment on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration"||||
33795883|NCT01075217|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33795884|NCT03107572|||COHORT||PROSPECTIVE|||||||
33795885|NCT00976625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795886|NCT04195568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019014|NCT04366427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants, Care Provider, and Investigators will not be masked. Only outcome assessors will only evaluate data without knowing the arm the patients were assigned to.|Five arms: one control without treatment; one at low pressure (1.45 ATA); one at standard pressure (2.5 ATA); one at atmospheric pressure (1 ATA) breathing air mixture with 30% O2; one at atmospheric pressure (1 ATA) breathing air mixture with 50% O2;|f|f|f|t
34019015|NCT02924727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795887|NCT01269853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019016|NCT05497193|||CASE_CONTROL||PROSPECTIVE|||||||
34019017|NCT00536263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019018|NCT05644470|||COHORT||PROSPECTIVE|||||||
34019019|NCT01020344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019020|NCT00365131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019021|NCT06462859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Information regarding the allocation of each group was not provided and outcome assessment was performed by an investigator blinded to group allocation|Two groups with a neurodevelopmental treatment control group|t|f|f|t
33795888|NCT06554158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795889|NCT04004468|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel groups participating in differing resistance training designs.||||
33795890|NCT03396146|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34019022|NCT01025544|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019023|NCT03310411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019024|NCT02399930|||||PROSPECTIVE|||||||
33795891|NCT05325853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study is single masked. Treatment assignments will be masked to the subjects and their parent/legal guardian only.|Subjects who provide informed consent and fulfill all the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to receive a single dose of AG-920 or proparacaine into one (study) eye (2 drops 30 seconds apart).|t|f|f|f
33795892|NCT05575869|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The lecturers at the nursing schools (x2) will have no access to the results of the surveys. A study number is assigned to the students and with the study number they enter their answers to the questionnaires||t|f|t|t
33795893|NCT03220425|RANDOMIZED|PARALLEL||||NONE||||||
33795894|NCT04202393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795895|NCT05261568|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34019025|NCT04971798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019026|NCT02145312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019027|NCT00440466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019028|NCT04819399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019029|NCT03958123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants were randomized to 1 of 4 treatment groups on Day -3: The study included a nested cross-over design for participants in treatment group 3 (A, B).|t|f|t|f
34019030|NCT04688931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019031|NCT03111914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019032|NCT00891852|||CASE_ONLY||CROSS_SECTIONAL|||||||
34019033|NCT04317209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019034|NCT04821531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind(outcome assessor)||f|f|f|t
34100462|NCT05675020|NA|SINGLE_GROUP||TREATMENT||NONE||"* This project utilizes a one-group pretest-posttest design study for 9 adolescents (aged 12-17 years) diagnosed with a mental health condition(s) and their parent/legal guardian.~* This educational program will be delivered via a 45-minute presentation via Zoom.~* Participants will have the option to select between multiple dates and times for educational presentation~* The educational presentation will be recorded and emailed to participants within 1 week of intervention to re-watch/review.~* The educational program will promote healthy lifestyle knowledge and behaviors through education evidenced by the Centers for Disease Control (CDC), World Health Organization (WHO), and the American Academy of Pediatrics.~* We will compare the effects of an educational program on healthy lifestyle knowledge and behaviors pre-and post-program (after one month) via a REDCap survey for the adolescent and their parent/legal guardian."||||
34100463|NCT02429167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100464|NCT01679665|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33795896|NCT03984617|||COHORT||RETROSPECTIVE|||||||
33795897|NCT03737097|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Both arms will take place in the same period.||||
33795898|NCT05571722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment scheme of the study does not allow for double-blinded manipulations. Postoperative evaluations and measurements will be performed in a blinded fashion by an investigator different from the physician who managed the patient in the operating room: SSI rates, adverse events, and length of stay. Statistical analyses will be performed in a blinded fashion.|Single-blind randomized controlled trial|f|f|f|t
33795899|NCT03197246|RANDOMIZED|PARALLEL||OTHER||SINGLE|The radiologist is masked/blinded in this clinical trial.|RCT, two groups|f|f|f|t
33795900|NCT06509841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33795901|NCT00971022|||CASE_ONLY||PROSPECTIVE|||||||
33795902|NCT05625334|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795903|NCT03919292|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33795904|NCT02894242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795905|NCT01742481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33795906|NCT05394896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795907|NCT03456336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795908|NCT02569866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795909|NCT00106054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795910|NCT05594576|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33795911|NCT06076980|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795912|NCT03581357|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be conducted as a randomized wait-list control design, such that participants will be randomized to either begin the intervention immediately or after 8 weeks.||||
33795913|NCT02219178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795914|NCT06461624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795915|NCT03950869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants are assigned to one of three arms in parallel for the duration of the study.|t|f|t|t
33795916|NCT04287114|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795917|NCT04997746|||COHORT||PROSPECTIVE|||||||
33795918|NCT05089084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795919|NCT01153451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33795920|NCT03956004|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33795921|NCT01050192|||COHORT||PROSPECTIVE|||||||
33795922|NCT06171464|||COHORT||RETROSPECTIVE|||||||
33795923|NCT02488980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33795924|NCT01523158|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795925|NCT06203639|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomly assigned to one of the three group conditions: 1) UR Caregiver; 2) active control group; and 2) control group.||||
33795926|NCT03995446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33795927|NCT00812526|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795928|NCT04797416|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795929|NCT06115993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795930|NCT05925985|||COHORT||PROSPECTIVE|||||||
33795931|NCT04777968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principle investigator \& co-investigator are masked before assessing the outcomes|Extracted Discarded Primary Molars divided into CONTROL Group \& INTERVENTIONAL Group|f|f|t|t
33795932|NCT02828254|||OTHER||PROSPECTIVE|||||||
33795933|NCT04762875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795934|NCT00595205|||||PROSPECTIVE|||||||
33795935|NCT04794959|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33795936|NCT02864238|||COHORT||RETROSPECTIVE|||||||
33795937|NCT00851669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795938|NCT02434107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795939|NCT00807144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33795940|NCT06359327|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33795941|NCT00831272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795942|NCT00616733|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795943|NCT03615495|||CASE_ONLY||RETROSPECTIVE|||||||
33795944|NCT00898846|||COHORT||PROSPECTIVE|||||||
33795945|NCT00502736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33795946|NCT01630772|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33795947|NCT06677008|||COHORT||RETROSPECTIVE|||||||
34100465|NCT05889000|||COHORT||RETROSPECTIVE|||||||
34100466|NCT05398627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795948|NCT02960659|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33795949|NCT00552097|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33795950|NCT01522092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795951|NCT00119951|||DEFINED_POPULATION||PROSPECTIVE|||||||
33795952|NCT00000152|RANDOMIZED|||PREVENTION||||||||
33795953|NCT05300061|RANDOMIZED|PARALLEL||OTHER||SINGLE||Three-arm randomised control trial including two values interventions: (a) a personal one, b) a prosocial one, and (c) a no-instructions control. Each participant is allocated to one of the three arms.|t|f|f|f
33795954|NCT00535678|||COHORT||PROSPECTIVE|||||||
33795955|NCT02377726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33795956|NCT02190006|||COHORT||PROSPECTIVE|||||||
33795957|NCT05679154|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The trial includes two groups: team-focused implementation and standard implementation (comparison group).||||
33795958|NCT02705586|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33795959|NCT03802032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blind|A randomised controlled trial|f|t|f|f
33795960|NCT00237770|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33795961|NCT03857971|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33795962|NCT05859542|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33795963|NCT06064357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Transverse friction massage at Rectus femoris, hip adductors, hamstring, and calf of both lower limbs.Applied time is 30 seconds, 3 sets with 10 seconds rest interval after that massage will be performed on next group of muscle.4 time / week for 6 weeks.~Conventional physical therapy program included application hot pack for 15 minutes, and Bobath treatment followed by stretching of calf muscles (10 repetitions with at least 8 seconds hold) 4 times / week for 6 weeks.~Tissue floss band will be applied on Rectus femoris, hip adductors, calf and hamstring of both lower limbs. Floss band will be wrap around the particular muscle from distal to proximal direction with 25 % stretch and 50% overlap and then 10 Reps of rom will be actively performed and then the rest interval is 2 mints. 4 sessions / week for 6 weeks."|f|f|f|t
33795964|NCT00116623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33795965|NCT03232463|||CASE_ONLY||PROSPECTIVE|||||||
33795966|NCT02128607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33795967|NCT02883764|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33795968|NCT00881842|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33795969|NCT02412748|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33795970|NCT00795054|||COHORT||PROSPECTIVE|||||||
33795971|NCT05370690|||CASE_CONTROL||RETROSPECTIVE|||||||
33795972|NCT01573130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795973|NCT06395870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795974|NCT02783014|||CASE_CONTROL||PROSPECTIVE|||||||
34019035|NCT04814030|NA|SINGLE_GROUP||TREATMENT||NONE||Trans hepatic arterial infusion of PD-1 antibody, chemoembolization and FOLFOX-based chemotherapy||||
34019036|NCT02669758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019037|NCT01540773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019038|NCT03373734|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Enjoy Your Bump is an online life skills course based on cognitive behavioural therapy principles. It has been designed to address issues pertinent to mood in pregnancy. The course compiles five modules delivered in the form of an online slideshow with audio. It can be accessed from a range of devices. There are a series of worksheets the user can access and download which accompany the modules.||||
34019039|NCT02408068|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019040|NCT04722822|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Investigator and data analysis team will be blinded to the arms during analysis. Practices (unit of randomization) cannot be blinded; however patients who are subjects of the intervention are not aware of the group allocation of the practice in the clinical trial.||f|f|t|f
34019041|NCT02716935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34019042|NCT00895947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019043|NCT03427502|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34019044|NCT05185401|||COHORT||RETROSPECTIVE|||||||
34019045|NCT03851926|||COHORT||PROSPECTIVE|||||||
34019046|NCT05975736|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|"Participants will not know the goals of the study but they will be fully informed about the conditions and asked to respond as quickly and accurately as possible."|One group of observers will get separate blocks of each of four conditions. The other group will see all conditions, intermixed.||||
34019047|NCT03416244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019048|NCT01186601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019049|NCT01484262|||COHORT||PROSPECTIVE|||||||
34019050|NCT05116462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019051|NCT02493413|||CASE_CONTROL||PROSPECTIVE|||||||
34019052|NCT03198975|||COHORT||PROSPECTIVE|||||||
34019053|NCT04727814|||CASE_CONTROL||PROSPECTIVE|||||||
34019054|NCT03145636|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100467|NCT01190371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795975|NCT00839371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33795976|NCT06673316|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33795977|NCT01065220|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33795978|NCT00527540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100468|NCT06490874|||COHORT||PROSPECTIVE|||||||
34100469|NCT06695351|||CASE_ONLY||CROSS_SECTIONAL|||||||
34100470|NCT04867408|||OTHER||CROSS_SECTIONAL|||||||
34100471|NCT06065540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34100472|NCT05415397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||12-week double-blind, randomized (1:1), placebo-controlled trial comparing celecoxib add-on (400 mg/d) versus placebo add-on to TAU in the treatment of 140 subjects with MDD and Immuno-metabolic Depression features|t|t|t|t
33795979|NCT04577612|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This is a double-blind study. Investigators, study personnel, and participants will be blinded to the group assignment during the study|Phase 2b, randomized, double-blind, placebo-controlled study|t|f|t|f
34100473|NCT04969107|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100474|NCT03506633|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||1:1 Randomized, cross-over, double-blinded design|t|f|t|f
34100475|NCT04094090|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||The study is a prospective, double-armed, randomized, single study.|f|f|t|f
34100476|NCT06688552|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study is a randomised controlled (parallel group) experimental study.||||
33795980|NCT06384547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, active controlled, safety and tolerability study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TED)|t|f|t|f
33795981|NCT03696771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33795982|NCT04128319|NA|SINGLE_GROUP||TREATMENT||NONE||A single group of patients will receive T-Guard for treatment of steroid-refractory acute GVHD.||||
33795983|NCT00190619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33795984|NCT02038868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33795985|NCT01532310|||COHORT||PROSPECTIVE|||||||
33795986|NCT01622413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795987|NCT03268577|||COHORT||PROSPECTIVE|||||||
33795988|NCT01895218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795989|NCT05905172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Before the clinical trial begins, the test drug and placebo are packaged in the same way, and the drug number is marked on the packaging according to the random table. The subjects take the drugs according to the randomly assigned drug number.|"Test group: hydronidone capsules, three times a day, 3 capsules each time，oral，daily therapeutic dose of 270 mg, half an hour before the meal~Control group: placebo capsules, three times a day, 3 capsules each time，oral，half an hour before the meal.~Basic treatment: Both test and control groups were treated with entecavir antiviral therapy, once daily, 0.5 mg per time, oral.~In case of drug resistance or other conditions requiring dose adjustment, the investigator may adjust the dose and type of basic treatment drug appropriately."|t|t|t|t
33795990|NCT03703856|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33795991|NCT05450016|||COHORT||RETROSPECTIVE|||||||
33795992|NCT01284907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34100477|NCT06219707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After a participant's eligibility is confirmed, a randomization number which corresponds to the group allocation will be provided to the acupuncturist. The clinical assessor and participants will be blinded to the allocation.|Each patient will be scheduled for a total of 12 treatment sessions, 30 minutes for each session, 2 times a week over 6-week period.|t|f|f|t
34100478|NCT06488222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100479|NCT03397719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100480|NCT05083364|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1, participants are randomized to receive either ARO-C3 or placebo. Participants,care providers, investigator and outcomes assessors are all blinded to treatment assignment. Part 2 in patients with C3G or IgAN is open-label and there is no masking.||t|t|t|t
34100481|NCT03166631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100482|NCT01272622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100483|NCT03807648|||CASE_CONTROL||PROSPECTIVE|||||||
33795993|NCT02599935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795994|NCT04226664|RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals who meet study eligibility criteria will be randomized in 1:1 fashion to bariatric surgery (intervention arm) or MWM (control arm).||||
33795995|NCT01962844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795996|NCT04970979|||OTHER||CROSS_SECTIONAL|||||||
34100484|NCT06687941|NA|SEQUENTIAL||TREATMENT||NONE||||||
34100485|NCT06548581|||COHORT||CROSS_SECTIONAL|||||||
34100486|NCT06342960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100487|NCT01478087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100488|NCT06009978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33795997|NCT05947305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33795998|NCT04694885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a monocentric randomized controlled trial with two parallel arms. All participants will be recruited in the University Hospital Basel (CH). They must be adult, female, diagnosed with first time breast cancer and undergoing adjuvant or neo-adjuvant chemotherapy. During chemotherapy, the control group as well as the intervention group will be offered the standard of psycho-oncological care. This means they can chose how much psychological support they want to use. Additionally, participants in the intervention group participate in 10 structured sessions of hypnotherapy aimed to alleviate quality of life. These therapeutic sessions will take place approximately every two to three weeks.||||
33795999|NCT05390047|||COHORT||RETROSPECTIVE|||||||
33940276|NCT02757651|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940277|NCT01326481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796000|NCT00623792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100489|NCT00130559|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34100490|NCT05463705|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34100491|NCT06642532|||OTHER||PROSPECTIVE|||||||
34100492|NCT05241834|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940278|NCT02532998|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33940279|NCT03820518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940280|NCT02094339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940281|NCT02217046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100493|NCT04960943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100494|NCT00948454|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100495|NCT01657942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100496|NCT05492994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796001|NCT04456218|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796002|NCT00494780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100497|NCT02991859|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34100498|NCT00790660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100499|NCT05837923|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
34100500|NCT06469372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100501|NCT03697408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100502|NCT06689345|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"First, we will test the savety and effects of neuromodulation using four different tecniques on autonomous system of healthy people.~Then, we will test the effect of neuromodulation through, vagal stimulation, on pain, fatigue, mental healthy and disautonomy of people with primary chronic pain and/or post-COVID syndrom. For this, active and sham stimulations will be compared."|t|f|t|f
34100503|NCT06184724|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants will be recruited from two surgery clinics in a pre-post trial. The comparison group is a historic baseline for routine care.||||
34100504|NCT05092516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100505|NCT05577065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||study consists of 2 arms, intervention and placebo.|t|t|t|t
34100506|NCT04667559|||CASE_ONLY||PROSPECTIVE|||||||
34100507|NCT04509011|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The participant is not informed of the assigned group, whereas the the care giver (surgeon) is informed due to the use (or not) of the Fluobeam®-LX.~Randomization is performed 1: 1 in blocks of 10 via the Eurocrine quality register platform."|Intervention group (intraoperative use of Fluobeam®-LX during thyroid surgery) Control group (clinical assessment and identification of parathyroid glands during thyroid surgery)|t|f|f|f
34100508|NCT03101670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100509|NCT06240143|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Simon's two-stage design||||
34100510|NCT03382561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100511|NCT05545306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34100512|NCT06223009|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34100513|NCT05577715|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100514|NCT02390635|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100515|NCT02340676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100516|NCT05947786|||COHORT||OTHER|||||||
34100517|NCT06551701|||COHORT||PROSPECTIVE|||||||
34100518|NCT00920270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100519|NCT06691386|RANDOMIZED|CROSSOVER||OTHER||SINGLE|This was a partial and single-blind study. During the in-clinic product use period, subjects knew whether the product was a pouch or MST product but were blinded to the strength of the oral TDN product they used on a given day.|This was a 6-way crossover design to evaluate plasma nicotine PK and subjective effects associated with the use of different nicotine levels (6, 9, and 12 mg) and different flavors of oral TDN products and subjects' OBMST product. A 6x6 Latin Square was used for the randomization, with the following sequences: Sequence 1 = ABFCED, Sequence 2 = BCADFE, Sequence 3 = CDBEAF, Sequence 4 = DECFBA, Sequence 5 = EFDACB, and Sequence 6 = FAEBDC. For pharmacokinetics analysis a linear mixed model for analysis of variance was performed on the natural log-transformed nicotine baseline-adjusted PK parameters Cmax(0-180) and AUC(0-180). For subjective effects measures a linear mixed model for analysis of variance was performed on each of the Emax-UC parameter values for the 2 items in the Smokeless Urge and Craving Questionnaire and for each of the Emax-PE parameter values for the 7 items in the Product Effects Questionnaire.|t|f|f|f
34100520|NCT01517776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100521|NCT06688825|NA|SINGLE_GROUP||TREATMENT||NONE|This project will be a single-arm feasibility study, with a treatment intervention that includes three interrelated components: (1) patient education using a proven weight loss curriculum, and (2) technology tools for making healthy lifestyle choices.|This project will be a single-arm feasibility study, with a treatment intervention that includes three interrelated components: (1) patient education using a proven weight loss curriculum, and (2) technology tools for making healthy lifestyle choices.||||
34100522|NCT04618965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100523|NCT04227522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100524|NCT04704128|||CASE_CONTROL||PROSPECTIVE|||||||
34100525|NCT03673722|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||RCT|f|f|f|t
33796003|NCT02704741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796004|NCT05929105|||CASE_CONTROL||PROSPECTIVE|||||||
33796005|NCT02891525|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33796006|NCT03505801|||COHORT||PROSPECTIVE|||||||
33796007|NCT00281489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33796008|NCT00160004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33796009|NCT06005246|||COHORT||PROSPECTIVE|||||||
33796010|NCT06677385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796011|NCT01385254|||CASE_CONTROL||PROSPECTIVE|||||||
33796012|NCT01518478|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796013|NCT04857502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796014|NCT00739765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial of three time-limited (14 week) psychotherapies for unmedicated patients with chronic posttraumatic stress disorder (PTSD)|f|f|f|t
33796015|NCT01755949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100526|NCT03914326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34100527|NCT04044248|||CASE_ONLY||PROSPECTIVE|||||||
33940282|NCT01272245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940283|NCT01662752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940284|NCT05538689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940285|NCT06282731|NA|SINGLE_GROUP||SCREENING||NONE||||||
33940286|NCT03909724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940287|NCT05944861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940288|NCT03586076|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33940289|NCT00029666||||TREATMENT||||||||
33940290|NCT02015624|||OTHER||CROSS_SECTIONAL|||||||
33940291|NCT00642824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940292|NCT00638989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940293|NCT01828463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940294|NCT05729165|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, randomized, parallel assigment||||
34019055|NCT03511443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||If P.f malaria case were detected, the responsible malaria worker or basic health staff will inform to survey team and blood samples for cRDT, hsRDT, Dried Blood Spot for PCR will be collected from index case and contacts (nearby 10-household members and peers). Then the results of cRDT and hsRDT will be confirmed by PCR for evaluating their performance. Then the applicability of hsRDT to detect low parasitaemia for enhancing malaria elimination activities will be evaluated.||||
33940295|NCT04151758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100528|NCT01234714|||COHORT||RETROSPECTIVE|||||||
34100529|NCT03981198|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single Group||||
34100530|NCT05937165|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33940296|NCT03099811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940297|NCT00043199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940298|NCT01250236|||CASE_CONTROL||PROSPECTIVE|||||||
33940299|NCT03235999|||COHORT||PROSPECTIVE|||||||
33940300|NCT01321736|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33940301|NCT03812224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940302|NCT00095134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940303|NCT00838968|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940304|NCT06280755|||OTHER||RETROSPECTIVE|||||||
33940305|NCT00621764|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33940306|NCT01690013|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940307|NCT04216628|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. For the early amniotomy group amniotomy will be performed as the exclusive primary intervention. Oxytocin infusion will begin as per local standard dose protocol no earlier than 2 hours following amniotomy.~2. For the late amniotomy group oxytocin infusion will begin as per local standard dose protocol. Amniotomy will be performed no earlier than 2 hours following the commence of oxytocin infusion"||||
33940308|NCT00354627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940309|NCT01874587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940310|NCT03914053|||COHORT||RETROSPECTIVE|||||||
33940311|NCT04734249|NA|SEQUENTIAL||TREATMENT||NONE||||||
33940312|NCT02800122|||COHORT||RETROSPECTIVE|||||||
33940313|NCT02308709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940314|NCT05200468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person who will perform the biochemical determinations, the gut microbiota sequencing and the statistical analysis will be blinded from the intervention group by assigning each patient|The groups will receive the treatment simultaneously|f|f|f|t
33940315|NCT05536544|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33940316|NCT01725724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940317|NCT03027180|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33940318|NCT03810781|||CASE_CONTROL||PROSPECTIVE|||||||
33940319|NCT01906489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940320|NCT02909504|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940321|NCT00955682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940322|NCT05044715|RANDOMIZED|PARALLEL||TREATMENT||NONE||Members will be randomized to treatment-as-usual (TAU) CAPS groups or CFT groups.||||
33940323|NCT05780099|||COHORT||PROSPECTIVE|||||||
33940324|NCT04284033|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940325|NCT03276494|NA|SINGLE_GROUP||TREATMENT||NONE||prospective case series||||
33940326|NCT05536934|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940327|NCT02290990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940328|NCT03952676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940329|NCT01501474|||COHORT||PROSPECTIVE|||||||
34019056|NCT02403453|||COHORT||PROSPECTIVE|||||||
34019057|NCT01327261|RANDOMIZED|CROSSOVER||||NONE||||||
34019058|NCT04871763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019059|NCT00574912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019060|NCT02161822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019061|NCT01781741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019062|NCT06113926|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Three independent groups|t|f|f|f
34100531|NCT03004131|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34100532|NCT03997734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100533|NCT03808467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100534|NCT04912531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100535|NCT05429502|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34100536|NCT05556967|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34100537|NCT03438032|||COHORT||CROSS_SECTIONAL|||||||
34100538|NCT03497286|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized control trial design that will compare the outcomes of randomly assigned treatment and control groups after participation in the NurturePA program.||||
33796016|NCT05723133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and treating dentist cannot be masked. The investigators and outcome assessors are masked|Randomized clinical trial with 3 treatment arms (control group: manual toothbrush; test group 1: electric toothbrush without digital visual feedback; test group 2: electric toothbrush with visual feedback). Every patient received the same initial treatment and oral hygiene instructions. Sealed envelops will determine in which group the patient will participate.|f|f|t|t
33796017|NCT02957006|||CASE_ONLY||PROSPECTIVE|||||||
33796018|NCT06353165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||blinded|t|f|t|f
33796019|NCT02473419|||OTHER||PROSPECTIVE|||||||
33796020|NCT06676527|||COHORT||OTHER|||||||
33796021|NCT01222910|RANDOMIZED|CROSSOVER||||NONE||||||
33796022|NCT00542035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33796023|NCT02999022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796024|NCT06188754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed by an interviewer who is unaware of treatment condition.|Participants will be randomly assigned to take part in either time-restricted eating or the Mediterranean diet.|f|f|f|t
33796025|NCT05874986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796026|NCT00936507|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33796027|NCT03925558|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34100539|NCT05445843|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100540|NCT06610019|||COHORT||PROSPECTIVE|||||||
34100541|NCT03387579|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective patients will be randomized to one of the two treatment arms, either composite lipid containing fish oil (Smoflipid) or soy-based lipid reduction. A third arm will include retrospective patients who will act as controls and received soy-based lipid at standard dosing.||||
34100542|NCT05151380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100543|NCT05571163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34100544|NCT06476821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100545|NCT03768674|||COHORT||CROSS_SECTIONAL|||||||
34100546|NCT05032599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796028|NCT05136092|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||"Prospective, pilot, feasibility, single-center, non-randomized, open-label, phase 1, investigator-initiated study to evaluate the specific uptake of fructose by human colorectal tumors with 12 subjects in 2 cohorts:~Cohort 1: fructose-fed with 6 subjects Cohort 2: xylose-fed with 6 subjects.~Eligible subjects scheduled to undergo colorectal resection for cancer treatment will be invited to participate in the study in consecutive order from the practice of colorectal surgeons at the time of their preoperative clinic visit. First, Cohort 1 subjects will be enrolled followed by the Cohort 2 subjects."||||
33796029|NCT00007956||||TREATMENT||||||||
33796030|NCT05031390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796031|NCT05072743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796032|NCT02685488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796033|NCT03100227|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33940330|NCT03844581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were assigned randomly used sealed envelope|A total of 40 volunteers women with a diagnosis of interstitial cystitis. Their ages ranged from 25 to 40 years old; their body mass index was \> 30 kg/m2 and were randomly assigned to a group (A) received interferential current at the lower abdomen, and also received traditional medicine or group (B) received traditional medicine for 8 successive weeks.|t|f|t|f
33940331|NCT05156697|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33940332|NCT01839760|||COHORT||PROSPECTIVE|||||||
33940333|NCT00680966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940334|NCT00155246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940335|NCT02624661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940336|NCT01032265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940337|NCT02561273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940338|NCT00632372|||CASE_ONLY||PROSPECTIVE|||||||
33940339|NCT01148433|||CASE_ONLY||PROSPECTIVE|||||||
33940340|NCT01416259|||COHORT||PROSPECTIVE|||||||
33940341|NCT05791357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940342|NCT00137267|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940343|NCT00696774||PARALLEL||TREATMENT||NONE||||||
33940344|NCT05365984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940345|NCT00688649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796034|NCT03013504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33796035|NCT05908799|||COHORT||RETROSPECTIVE|||||||
33940346|NCT01533285|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33940347|NCT00004844|RANDOMIZED|||TREATMENT||DOUBLE||||||
33940348|NCT00313742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940349|NCT05212623|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940350|NCT02545686|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33940351|NCT04417868|||COHORT||RETROSPECTIVE|||||||
33940352|NCT03845010|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized trial comparing catheter ablation with two different potent AADs with different engagement mechanisms in a 1:1:1 ratio with a crossover design in the AAD arm.||||
33940353|NCT04470349|||COHORT||RETROSPECTIVE|||||||
34100547|NCT00715897|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34100548|NCT06358651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100549|NCT01043029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100550|NCT05866601|||CASE_ONLY||OTHER|||||||
34100551|NCT05848050|NA|SINGLE_GROUP||PREVENTION||NONE||monocentric, prospective, interventional, exploratory study||||
33796036|NCT04512651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized clinical trial of quantitative character.|t|f|f|t
33940354|NCT01536418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940355|NCT00004842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940356|NCT06353529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940357|NCT04451369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940358|NCT00715039|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33940359|NCT05455723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796037|NCT06675942|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33796038|NCT01735019|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33796039|NCT03201549|NA|SINGLE_GROUP||OTHER||NONE||||||
33796040|NCT02969863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796041|NCT03922334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There will be two cohorts: One cohort will be provided intensive, individualized, one-on-one navigation services through 12 weeks postpartum and, based on individual needs, ongoing, tapered navigation through one year (11-13 months) postpartum. The second cohort will receive usual care.||||
33940360|NCT02571829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940361|NCT04146870|||COHORT||PROSPECTIVE|||||||
33940362|NCT03236649|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open, randomized controlled, multicenter||||
33940363|NCT02840903|||COHORT||PROSPECTIVE|||||||
33940364|NCT03968523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each patient will be included in one cohort of treatment by a randomized criteria.|Two randomized cohorts of treatment.|t|t|t|t
33940365|NCT04081142|||CASE_ONLY||PROSPECTIVE|||||||
33940366|NCT00333242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33940367|NCT02815475|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33940368|NCT04880642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940369|NCT06159049|||CASE_ONLY||PROSPECTIVE|||||||
33940370|NCT04854226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Doctors, nurses and parents are blinded to the intervention||t|t|t|t
33940371|NCT02286336|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940372|NCT04013633|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors are blinded for study groups|Randomized controlled trial|f|f|f|t
33940373|NCT00848172|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33940374|NCT05734040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind|"Subjects will be randomized (1:1:1:1:1:1) into 6 groups of 100 subjects to receive:~* First group: OVX836 480µg and Fluarix Tetra at commercial dose administered intramuscularly concomitantly into opposite arms.~* Second group: OVX836 480µg and Afluria Quad at commercial dose administered intramuscularly concomitantly into opposite arms.~* Third group: OVX836 480µg, concomitantly administered with placebo, intramuscularly into opposite arms.~* Fourth group: Fluarix Tetra at commercial dose, concomitantly administered with placebo, intramuscularly into opposite arms.~* Fifth group: Afluria Quad at commercial dose, concomitantly administered with placebo, intramuscularly into opposite arms.~* Sixth group: placebo administered intramuscularly as two concomitant injections into opposite arms."|t|f|t|f
33940375|NCT04389931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A double-blind, randomized controlled trial, where patients with a history of Moderate Periodontitis with moderate rate of progression (Stage II grade B) and Severe Periodontitis with potential for additional tooth loss and moderate rate of progression (Stage III grade B). The intervention group received nonsurgical periodontal therapy (SRP) plus Omega 3, and the control group received SRP plus placebo. The clinical variables were measured before the treatment, the first, third and six month of the end of the SRP, while the microbiological variables were measured before the treatment and in the third month after treatment.|t|t|f|t
33940376|NCT02027285|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33940377|NCT05504928|NA|SINGLE_GROUP||PREVENTION||NONE||Interrupted time series design||||
33940378|NCT06337942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940379|NCT06436170|||CASE_CONTROL||PROSPECTIVE|||||||
33940380|NCT05241470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940381|NCT03046069|||COHORT||PROSPECTIVE|||||||
33940382|NCT06381752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940383|NCT05248542|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940384|NCT02374944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940385|NCT00596713|||COHORT||CROSS_SECTIONAL|||||||
33940386|NCT01633567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940387|NCT06331806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940388|NCT04065464|||COHORT||PROSPECTIVE|||||||
33940389|NCT02875184|||COHORT||PROSPECTIVE|||||||
33940390|NCT01208025|||OTHER||PROSPECTIVE|||||||
33940391|NCT06042179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be designed as a randomized control trial with a 1:1:1:1 randomization. This study will utilize a permuted block design to randomly allocate a participate to a treatment group, while maintaining a balance across treatment groups.|f|f|f|t
33940392|NCT03406806|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940393|NCT05779501|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Two-armed randomized trial with waiting-list control and pre-, mid-, and post-intervention measurements.|f|f|f|t
33940394|NCT06283901|||COHORT||PROSPECTIVE|||||||
33940395|NCT01844414|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940396|NCT01567072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940397|NCT03082066|||COHORT||RETROSPECTIVE|||||||
33940398|NCT02883881|||COHORT||RETROSPECTIVE|||||||
33940399|NCT05170581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940400|NCT03088345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940401|NCT03865160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Code labelled eye drop containers Blinded investigators|Year one: arm A atropine 0.02% / arm B placebo Year two: arm A atropine 0.02% / arm B atropine 0.01% Year three: arm A placebo/ arm B atropine 0.01%|t|f|t|f
33940402|NCT04461457||SEQUENTIAL||TREATMENT||NONE||"To investigate the pharmacokinetics of the conjugate 211At-MX35 F(ab') 2.~Groups of 3 patients will be treated at increasing activity concentrations starting at 50 MBq/L"||||
34019063|NCT02086630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019064|NCT01751035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34019065|NCT03715075|||COHORT||PROSPECTIVE|||||||
33796042|NCT05845528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The researcher will receive equipment already programmed by a research assistant, so the researcher who will deliver the tDCS to perform stimulation will not know the programed stimulation. Patients will be instructed to discuss aspects of treatment with the respective investigator. Two independent evaluators who will not participate in the consultations where guidance on the use of tDCS will be provided will be trained to make outcome assessments in follow-up. Patients will not be aware of the type of intervention received, since the sham condition produces a stimulus, but no expected effects. In order to study the level of the blinding, at each moment of evaluation, the patient will be asked about the type of intervention that he / she believes to have received (active or simulated), and about the degree of safety in the response, using a standardized questionnaire. The blinding will be evaluated at the end of each treatment week by means of a standardized instrument.|Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial|t|t|t|t
33796043|NCT02749318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33796044|NCT04801563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796045|NCT05894317|||CASE_ONLY||RETROSPECTIVE|||||||
33796046|NCT01977638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796047|NCT06150287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||randomized, double-blinded, placebo-controlled, single-center pilot/exploratory trial|t|t|t|t
33796048|NCT02729701|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33796049|NCT02234739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796050|NCT04353674|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single centre, prospective, randomized controlled pilot study with approximately 40 patients to be included: 20 in the control group and 20 patients in the L-MOD-SLEDD group.||||
33796051|NCT04157855|||CASE_ONLY||PROSPECTIVE|||||||
33940403|NCT05248776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double- Blind. The identity of IMP and placebo will not be known to investigators, research staff and participants.|Double-blind, randomized, placebo- controlled, parallel-group study to explore the efficacy, safety, tolerability and PK of 4 different doses of CPL207280 administered for 14 days orally.|t|f|t|f
33940404|NCT00273169|||||PROSPECTIVE|||||||
33940405|NCT04306692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940406|NCT04343612|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Everyone is blinded, codes are selected by a third party not involved in any step of the study|4 groups, each group receives one of three treatments or the sham treatment. Double-blinded, sham controlled, crossover study|t|f|t|t
33940407|NCT00315692|||COHORT||PROSPECTIVE|||||||
33940408|NCT05272969|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100552|NCT03177915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Investigate if, and to what extent, hydro-dissection using Hyalase versus saline, under ultrasound guidance, can improve the clinical condition, change in nerve conduction parameters of patients with CTS and delay or avoid the surgical intervention.|t|f|f|t
34100553|NCT03247712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796052|NCT02570711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940409|NCT06127394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940410|NCT01070186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940411|NCT00494689|||CASE_CONTROL||PROSPECTIVE|||||||
33940412|NCT02929875|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940413|NCT00316212|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33940414|NCT02098733|||COHORT||PROSPECTIVE|||||||
33940415|NCT06099496|||COHORT||PROSPECTIVE|||||||
33940416|NCT03164213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940417|NCT05481190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a randomized controlled experimental study.||||
33940418|NCT06283615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940419|NCT01697371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940420|NCT04568629|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The research team and participants were blind to intervention allocation, whilst the database specialist was not blinded to allocation. Group allocation was only revealed once the database had been locked and analyses had been completed.|Participants were randomly assigned to one of two study arms and received advice reportedly from either a prognostic algorithm, or another clinician.|t|f|t|f
33940421|NCT02161614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940422|NCT06065410|NA|SINGLE_GROUP||OTHER||NONE||Between the ages of 50 and 75 years, who were admitted to the outpatient clinic of Gazi University Faculty of Medicine, Department of Physical Medicine and Rehabilitation or hospitalized in the ward and diagnosed with knee osteoarthritis according to ACR knee osteoarthritis criteria and had a Kellgren Lawrence staging of at least 2, were included.||||
33940423|NCT04522193|NA|SINGLE_GROUP||OTHER||NONE||||||
33940424|NCT00301236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940425|NCT05608265|NA|SINGLE_GROUP||OTHER||NONE||||||
33940426|NCT03446664|NA|SINGLE_GROUP||TREATMENT||NONE||Two cohorts of subjects with refractory epilepsy; (1) subjects with primary generalized tonic-clonic seizures and (2) subjects with partial onset seizures including complex partial seizures with or without secondary generalization.||||
33940427|NCT04492267|||CASE_ONLY||RETROSPECTIVE|||||||
33940428|NCT00682409|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940429|NCT05466604|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33940430|NCT00890396|||COHORT||OTHER|||||||
33940431|NCT02181335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940432|NCT01969565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940433|NCT02068261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100554|NCT05621044|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Behavioral|f|f|f|t
34100555|NCT05887661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100556|NCT05128032|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796053|NCT05601830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796054|NCT06179862|||OTHER||PROSPECTIVE|||||||
33796055|NCT06370572|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a interrupted time series intervention, which allows a pre- and post-intervention assessment of the effect of PAINAD scale.||||
33796056|NCT05542862|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will receive the same single intervention with analysis groups being based on the type of primary vaccine received||||
33796057|NCT05296811|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33796058|NCT06231069|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Following stratification (balanced by age, gender, dietary patterns, and PA levels), randomization into supplement vs. placebo groups will be done by an outside party. Thereafter, GCP (good clinical practice)-certified research coordinators will administer the supplements and collect the baseline/post data in a blinded fashion. These data will be locked and the code for randomization will not be broken until the study is completed. The integrity of the data and the quality of the data analyses will be verified by an outside source. Compliance to GCP will be checked regularly throughout the study period.|The present study is a randomized, double-blind, placebo-controlled 12-week mixed training and supplementation study (placebo vs. active supplement), with data collection occurring at several different time-points (pre, mid, and post) in young males and females (18-30 years of age).|t|t|t|t
33796059|NCT03239899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796060|NCT03216538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, caregivers and Investigators will be masked to the nature of the treatment until all patients completed participation in the study.|On day 1 patients will be randomly allocated to one of the two following study arms in a 1:1 ratio and in a masked manner: (1) AS101 1% oral solution (2) Placebo oral solution. Patients of both study arms will be instructed on how to administer orally the drug at home once daily for 24 weeks. Patients will stop taking the study oral solution at week 24 treatment visit.|t|t|t|f
33796061|NCT01482975|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33796062|NCT03416842|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33940434|NCT03184805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940435|NCT05241756|||CASE_ONLY||PROSPECTIVE|||||||
33940436|NCT06323863|||COHORT||RETROSPECTIVE|||||||
34019066|NCT03168971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patient-caregiver dyads will be randomly assigned to the intervention or a usual care control condition.|f|f|f|t
34019067|NCT02135653|||COHORT||PROSPECTIVE|||||||
34019068|NCT03929783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019069|NCT04167293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019070|NCT00278889|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940437|NCT02216630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940438|NCT04496336|||COHORT||PROSPECTIVE|||||||
33940439|NCT00718887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940440|NCT02246309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940441|NCT00082628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940442|NCT03845504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940443|NCT02397980|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33940444|NCT05516316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the study, study participants, investigators, the sponsor, and all other persons involved in the conduct of the study will be blinded to treatment.|The study is double-blind, placebo-controlled and parallel-group in design.|t|f|t|f
33940445|NCT04679896|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Intra-patient control. Each patient serves as their own control.||||
33940446|NCT01959269|||COHORT||PROSPECTIVE|||||||
33940447|NCT01412333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940448|NCT02469662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940449|NCT02320591|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940450|NCT03990155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940451|NCT03263767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940452|NCT05393778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940453|NCT01590524|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33940454|NCT05285397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940455|NCT04852809|||COHORT||PROSPECTIVE|||||||
33940456|NCT00268658|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33940457|NCT03265431|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940458|NCT04207216|||OTHER||PROSPECTIVE|||||||
33940459|NCT05504811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
33940460|NCT03037489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940461|NCT00204763|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940462|NCT00963469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940463|NCT04555876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The patients will randomly be divided into two equal groups in number:~1. Group A :~   Thirty patients will participate in physical therapy program in form of high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks plus supervised regular aerobic exercise program on stationary bicycle with moderate intensity, ( score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks .~2. Group B:~Thirty patients will participate in a supervised regular aerobic exercise program only on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks."|"The patients will randomly be divided into two equal groups in number:~1. Group A :~   Thirty patients will participate in physical therapy program in form of high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks plus supervised regular aerobic exercise program on stationary bicycle with moderate intensity, ( score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks .~2. Group B:~Thirty patients will participate in a supervised regular aerobic exercise program only on stationary bicycle with moderate intensity, (score 12-14 on Borg scale for rate of perceived exertion) 40 minutes per session, 3 times per week, for 10 weeks."|t|f|f|f
33940464|NCT00659009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33940465|NCT04380480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019071|NCT02032706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019072|NCT04360044|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Each participant will have an identification number and randomization of drug sequence allocation will be performed a priori using a random number generator by the study pharmacist. The 4 treatments will be identically encapsulated by the study pharmacist using Storz \& Bickel filling set. The study pharmacist will place the capsules in identical sealed plastic bags labeled Migraine 1 through Migraine 4."|Randomized, Double-blind, Placebo-controlled, Crossover Trial|t|t|t|t
33796063|NCT05518396|||COHORT||PROSPECTIVE|||||||
33796064|NCT02448446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796065|NCT01611467|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796066|NCT05766969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized at a 2:1 ratio.|There are 2 groups in this trial: interventional group (active drug) and control group (placebo).|t|f|t|f
33796067|NCT01786525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33796068|NCT05393726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796069|NCT03702647|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Patients will be randomized by an independent research pharmacist to receive either 30mL 0.2% ropivacaine or 30mL of placebo (saline), both being clear, colorless solutions. These samples will be prepared by the research pharmacist 2-3 weeks prior to the procedure and stored until the procedure date as per pharmacy standards. On the morning of the procedure, the study solution will be taken to the operating room with the patient. During the POEM procedure, prior to closure of the mucosotomy, the study solution is instilled into the tunnel. The investigator, patient, care provider, and research coordinator will be blinded to the group assignment.|Patients enrolled in the study will be randomized to receive either 30mL of normal saline (placebo), or 30mL of 0.2% ropivacaine in the POEM tunnel.|t|t|t|t
33796070|NCT02135042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796071|NCT00917241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796072|NCT01843569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796073|NCT02399865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796074|NCT01624844|NA|SINGLE_GROUP||||NONE||||||
33796075|NCT05845645|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Part A is open-label and Part B double-blind (Participants will be blinded to the treatment (ie, UCB0599 or Placebo), but not to the dosage).|Part A of the study is following a full crossover design and Part B is a parallel design with crossover character referring to the dose levels.|t|t|t|t
33796076|NCT01970891|NA|SINGLE_GROUP||TREATMENT||NONE||Sensory electrical stimulation for the amelioration of FoG through the continuous delivery of stimulation.||||
33796077|NCT05072171|||COHORT||PROSPECTIVE|||||||
33796078|NCT06213324|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind||t|t|t|t
33796079|NCT03143348|||OTHER||PROSPECTIVE|||||||
33796080|NCT05203861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796081|NCT02059980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796082|NCT02163252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796083|NCT04591067|||COHORT||CROSS_SECTIONAL|||||||
33796084|NCT01100125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796085|NCT01269749|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796086|NCT05985512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019073|NCT05593861|||OTHER||CROSS_SECTIONAL|||||||
34019074|NCT00128414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019075|NCT02746471|||COHORT||PROSPECTIVE|||||||
34019076|NCT03407235|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34019077|NCT01884311|NA|SINGLE_GROUP||OTHER||NONE||||||
34019078|NCT03023176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34019079|NCT00959361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019080|NCT02519335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019081|NCT02508090|||COHORT||PROSPECTIVE|||||||
34019082|NCT02356926|||CASE_CROSSOVER||PROSPECTIVE|||||||
34019083|NCT00207675|RANDOMIZED|||TREATMENT||DOUBLE||||||
34019084|NCT00822341|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33796087|NCT03030248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation status of patients within this study will be held in sealed envelopes by the unblinded research pharmacist on the team. Neither the main care provider, study physicians, or the patient will know of their group, until either the end of the study (after data analysis). We will also have a blinded pharmacist.|Patients will be divided into two groups, one receiving oral vancomycin capsules, the other receiving oral placebo capsules.|t|t|t|f
33796088|NCT02754999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796089|NCT00208663|||COHORT||PROSPECTIVE|||||||
33796090|NCT03759743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796091|NCT01325233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796092|NCT06364839|||COHORT||RETROSPECTIVE|||||||
33796093|NCT03799536|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The subjects and the investigator will not be blinded towards the identity of the study products. However, analysts will be blinded towards identity of the study products administered.||f|f|f|t
34019085|NCT02037035|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34019086|NCT01752543|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34019087|NCT03456154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019088|NCT03199430|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34019089|NCT03048149|||CASE_ONLY||RETROSPECTIVE|||||||
34019090|NCT06198608|||COHORT||PROSPECTIVE|||||||
34019091|NCT00114166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019092|NCT02874209|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34019093|NCT04989712|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomised cross over design. Participants act as own controls.||||
34019094|NCT06238596|NA|SINGLE_GROUP||OTHER||NONE||This is a drug-free, single arm, single center, superiority, interventional study aimed at treatment feasibility.||||
34019095|NCT01454271|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019096|NCT00069836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019097|NCT02912845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019098|NCT01991418|||||PROSPECTIVE|||||||
34019099|NCT05549908|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34019100|NCT00254228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796094|NCT05127226|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33796095|NCT03483519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33796096|NCT03097250|||CASE_CONTROL||PROSPECTIVE|||||||
34019101|NCT02897986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019102|NCT00324402|||COHORT||PROSPECTIVE|||||||
34019103|NCT05192694|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Exploratory prospective cohort study.||||
34019104|NCT05480163|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33715801|NCT04517474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The masking technique will be partially single-blinded-in that participants in either of the two active treatment groups will not know which version they work with. The two versions are neutrally described as two differently optimized variants to prevent participants from having a preference of one over the other possibly resulting in a disappointment when being allocated to the unwished version. However, subjects will know whether they have been assigned to treatment-as-usual (TAU). Any blinding of research and study personnel is not warranted.||t|f|f|f
33715802|NCT01840501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019105|NCT04263402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019106|NCT02306226|||COHORT||PROSPECTIVE|||||||
34019107|NCT04906083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019108|NCT03236415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019109|NCT01819116|||COHORT||PROSPECTIVE|||||||
34019110|NCT02095925|||COHORT||PROSPECTIVE|||||||
34019111|NCT01106664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019112|NCT05739344|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34019113|NCT03945669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study participants, care providers and investigator can not be blinded. The outcome assessor will be blinded with regards to the two treatment groups.|This study is a multicenter pragmatic assessor blinded randomized and prospective clinical trial.|f|f|f|t
34019114|NCT01288053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019115|NCT03915366|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34019116|NCT04896411|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33715803|NCT01113281|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715804|NCT04049968|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Patients were divided into two two groups. Control group was assessed with traditional routine healthcare and instruction. Experimental group was assessed with a mobile health application.|t|f|f|f
33715805|NCT03719976|NA|SINGLE_GROUP||OTHER||NONE||||||
33715806|NCT05109650|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715807|NCT03883620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For the Cohort 1 (Initial Safety Cohort), no placebo control will be used and hence, blinding is not applicable.For remaining cohorts, both participant and investigator will be unaware of treatment allocation as well as the laboratories analyzing the biochemistry and hematology parameters, pharmacokinetic and immunogenicity (ADA) samples will be blinded to treatment allocation. The drug administrator will be unblinded who will prepare and administer the study drugs. The 7 day safety data for each cohort will be reviewed by group-wise unblinding. Individual level unblinding will be done only in cases of suspected serious adverse reactions as per the judgement of investigator or medical monitor / sponsor representative.|"This is a Phase 1, randomized, partially-blind (observer-blind), placebo controlled, single dose ascending study in healthy adults. For the Cohort 1 (Initial Safety Cohort), no placebo control will be used and hence, blinding is not applicable.~There will be 4 dose levels. The proposed doses to be studied are; 1 mg/kg, 3 mg/kg, 12 mg/kg and 25 mg/kg. Total of 40 participants will be dosed and followed till Day 84 from dosing."|t|f|t|t
33715808|NCT06401395|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715809|NCT01045512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715810|NCT02747589|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33715811|NCT00649701|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33715812|NCT04472624|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715813|NCT02415660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715814|NCT02159495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715815|NCT00113217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715816|NCT04474704|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34019117|NCT04732273|||COHORT||PROSPECTIVE|||||||
34019118|NCT03269331|||COHORT||PROSPECTIVE|||||||
34019119|NCT02500641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The study physician, responsible for randomization and drug supply handling, was unblinded to study medications and therefore not involved in the main efficacy evaluations of each patient randomized in the study.~Conversely, the study physician/s responsible for the main efficacy evaluation (Pulse Wave Velocity) was blinded to study treatments."||f|f|f|t
34019120|NCT01584453|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34019121|NCT03891966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019122|NCT03802955|NA|SEQUENTIAL||TREATMENT||NONE||||||
34019123|NCT02344719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019124|NCT05876663|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34019125|NCT00275938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019126|NCT03663634|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34019127|NCT03584984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019128|NCT03123536|||COHORT||PROSPECTIVE|||||||
34019129|NCT02887300|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34019130|NCT03664518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019131|NCT04955535|||CASE_ONLY||RETROSPECTIVE|||||||
34019132|NCT02351583|||CASE_CONTROL||PROSPECTIVE|||||||
34019133|NCT03924206|||CASE_CONTROL||PROSPECTIVE|||||||
34019134|NCT01909830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019135|NCT03517696|RANDOMIZED|PARALLEL||TREATMENT||NONE|Intervention is not able to be blinded|Non-blinded Randomized Controlled Trial||||
34019136|NCT00376311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019137|NCT01145430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796097|NCT00946582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796098|NCT04484701|||COHORT||PROSPECTIVE|||||||
33796099|NCT05190419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Tablets will be packaged in the same type of blister and the active and placebo tablets will have the same appearance (in terms of size, form, weight, and color).|Participants will be assigned randomly in a 1:1:1:1 ratio to receive 1 of the 3 orismilast modified release doses (20 mg, 30 mg, or 40 mg) or placebo twice daily (BID)|t|t|t|t
33796100|NCT05474105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796101|NCT04456543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants are randomly devided into two groups. Outcome measurements and data analyses were performed by a trained and blinded outcome assessor who was not involved in the intervention.|patients with partial-/full-thickness burns, which spontaneously healed or required skin grafting, from the Department of Rehabilitation Medicine at the Hangang Sacred Heart Hospital of Korea|t|f|f|t
33796102|NCT04283552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796103|NCT03182010|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33796104|NCT02846389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796105|NCT01592448|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796106|NCT02641990|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33796107|NCT00153309|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796108|NCT03185156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||60 maternal aged 20-40 years will be collected|t|f|t|f
33796109|NCT05688592|||OTHER||PROSPECTIVE|||||||
33796110|NCT00006327||||PREVENTION||DOUBLE||||||
33796111|NCT01703897|||COHORT||PROSPECTIVE|||||||
33940466|NCT00312468|||COHORT||PROSPECTIVE|||||||
33796112|NCT05527717|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open-label, two-arm, randomized controlled trial||||
33940467|NCT02119494|||COHORT||CROSS_SECTIONAL|||||||
33940468|NCT01024946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940469|NCT00946829|||COHORT||PROSPECTIVE|||||||
33940470|NCT02008461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940471|NCT05742152|||COHORT||PROSPECTIVE|||||||
33940472|NCT00665249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940473|NCT02497599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940474|NCT01053806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940475|NCT01201291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940476|NCT02610231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940477|NCT03389594|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Each patient will be given a code by researcher (M.H) and the observers will be blind to which group this case belong||t|t|t|t
33940478|NCT01797367|||OTHER||PROSPECTIVE|||||||
33940479|NCT00901849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940480|NCT04997564|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940481|NCT01719042|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33940482|NCT03529162|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Controlled Trial||||
33940483|NCT00827060|||CASE_ONLY||PROSPECTIVE|||||||
33940484|NCT00529113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940485|NCT01869686|NA|SINGLE_GROUP||||NONE||||||
33940486|NCT05879380|||COHORT||PROSPECTIVE|||||||
33940487|NCT03819504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940488|NCT01292733|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33940489|NCT03594422|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized at 1:1:1 ratio into the three dose cohorts: 30 mg QOD, 40 mg QOD and 50 mg QOD.Non-randomized selected adult subjects will receive a 40 mg QOD dosing regimen. And the minor will be enrolled to the three dose cohorts: 20mg QOD, 30 mg QOD, 40 mg QOD according to the weight.||||
33940490|NCT04203290|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33940491|NCT05330806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33796113|NCT05776680|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796114|NCT06677463|NA|SINGLE_GROUP||OTHER||NONE|This study will be conducted to evaluate the effect of applying virtual reality among laboring women during first stage of labor|This study will be conducted to evaluate the effect of applying virtual reality among laboring women during first stage of labor||||
33796115|NCT05475405|RANDOMIZED|PARALLEL||TREATMENT||NONE||32 Participants were recruited in the study and divided into two groups. Group A was given intervention Scapulothoracic mobilization and Group B with IASTM.||||
33796116|NCT00300248|||COHORT||PROSPECTIVE|||||||
33940492|NCT04744311|||CASE_ONLY||PROSPECTIVE|||||||
33940493|NCT01643109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940494|NCT04754867|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Investigators will recruit participants planning to begin using nicotine patches in local smoking cessation programs, and randomly assign them to one of three conditions: 1) discontinued-smoker age-progressed future self virtual reality images vs. 2) discontinued-smoker + continued smoking age-progressed future self virtual reality images vs. 3) control - current self virtual reality images."|t|f|f|f
33940495|NCT01607996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940496|NCT02003586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33940497|NCT02896998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940498|NCT04075240|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|over-encapsulated rivaroxaban/ASA|randomized, controlled, double-blind|t|t|t|t
33940499|NCT02382887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940500|NCT03307395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940501|NCT01784900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940502|NCT04019860|RANDOMIZED|PARALLEL||PREVENTION||NONE||Four-armed randomised controlled trial||||
33940503|NCT04715958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940504|NCT03809403|||COHORT||PROSPECTIVE|||||||
33940505|NCT00596622|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940506|NCT02652286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940507|NCT01531244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940508|NCT01215461|||COHORT||PROSPECTIVE|||||||
33940509|NCT05345431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940510|NCT05871008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33940511|NCT01432756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34100557|NCT04717908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100558|NCT06190613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940512|NCT04851041|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Longer-term (12-weeks) well-controlled intervention trial with a parallel design including 56 overweight and obese (BMI25-35 kg/m2) men and women|f|f|t|f
33940513|NCT02392091|||COHORT||PROSPECTIVE|||||||
33940514|NCT04252924|||COHORT||CROSS_SECTIONAL|||||||
34019138|NCT00346463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019139|NCT00396435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019140|NCT02130882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019141|NCT00316147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019142|NCT00688376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019143|NCT01830218|||CASE_ONLY||PROSPECTIVE|||||||
34019144|NCT05490290|RANDOMIZED|PARALLEL||OTHER||SINGLE||"The study will be performed as a multi-center cluster randomized trial with departments acting as clusters combined with a before-after-revert design. Four hospitals with each 8 participating departments for a total of 32 clusters will be included in the study. All departments will start with the control condition. Subsequently, stratified per specialty (surgical vs. non-surgical), half of the departments - chosen at random - will switch to the active intervention while the other remain in the control condition.~Amendments November 2023:~I)see Study Description~II) We made an amendment to the applied sample size calculation. The original sample size for MERC review was calculated using clusterPower version 0.6.111 function crtpwr.2prop. The amended sample size calculation that in the online publication of the protocol applies a newer, more appropriate version of clusterPower version 0.7.0 using the function cpa.did.binary."|f|f|f|t
34019145|NCT04863222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019146|NCT03757975|||CASE_ONLY||CROSS_SECTIONAL|||||||
34019147|NCT05447000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019148|NCT01142479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34019149|NCT03728218|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a crossover study of two types of contact lenses (toric orthokeratology and soft multifocals).||||
34019150|NCT01468805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019151|NCT01633736|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34019152|NCT00673153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019153|NCT00005614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019154|NCT02158286|||CASE_ONLY|||||||||
34019155|NCT02631967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019156|NCT04602065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019157|NCT06072365|||CASE_ONLY||PROSPECTIVE|||||||
34019158|NCT04672486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A two-arm, individually randomized controlled trial with equal allocation of participants between arms.|f|f|t|t
34019159|NCT00117208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019160|NCT05922475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34019161|NCT04064853|||COHORT||CROSS_SECTIONAL|||||||
34019162|NCT02866045|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34019163|NCT04766736|||COHORT||RETROSPECTIVE|||||||
34019164|NCT03666559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019165|NCT02854111|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34019166|NCT02802631|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Model Description: Cohorts 1 and 2 were run concurrently as they were using the approved doses of intravenous minocycline in the United States. Cohorts 3, 4, 5 and 6 were run sequentially and only after review of data from the preceding cohorts by the data monitoring committee.|t|t|t|t
34100559|NCT05813093|NA|SINGLE_GROUP||TREATMENT||NONE||We propose a pilot study using state-of-the-art concurrent fMRI acquisition to identify circuits involved with mood, and to subsequently use concurrent interleaved iTBS-fMRI and neuronavigation to examine/dynamically probe, for the first time, how iTBS of the left DLPFC mediates target engagement/functional connectivity between the DLPFC-sgACC circuit and reward system in TRD versus UTRD across varying stimulation amplitude (i.e. doses). Our secondary objective is to identify subtypes of UTRD/TRD patients from pre-treatment iTBS-fMRI who demonstrate clinical improvement in depressive symptoms with a previously validated accelerated iTBS treatment protocol over 5 consecutive days \[6\].||||
33940515|NCT02997111|NA|SINGLE_GROUP||OTHER||NONE||||||
33940516|NCT02500706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940517|NCT05389865|||COHORT||RETROSPECTIVE|||||||
33940518|NCT02939326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940519|NCT00747942|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33940520|NCT04601194|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33940521|NCT03006276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796117|NCT06456970|||COHORT||CROSS_SECTIONAL|||||||
33940522|NCT05932160|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor)||t|t|f|t
33940523|NCT05869981|||OTHER||CROSS_SECTIONAL|||||||
33940524|NCT03820804|||COHORT||RETROSPECTIVE|||||||
33940525|NCT06204133|||COHORT||RETROSPECTIVE|||||||
33940526|NCT04974931|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled, open-label, multi-center superiority trial with 2 parallel groups and primary endpoint of surgical site infection at day 7 (after 7-day use of PREVENA) and day 30.||||
33940527|NCT03941327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be randomly assigned to a control group or intervention group using a computer based randomization tool. Patient's undergoing bilateral neck dissection will receive an implant on one side and act as self control.||t|f|f|f
34019167|NCT05991648|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Masking will not be applied due to the nature of the interventions. However, blinding of the intervention sequence will be maintained for the researchers responsible for data analysis.|"Once the newborn's enrollment in the study is confirmed, procedures for HRV recording will be initiated, following the procedure below. Randomization of the newborn to the intervention sequence will be performed accordingly: sequence AB as Kangaroo Care - incubator care, or sequence BA as incubator care - Kangaroo Care.~The HRV signal will be obtained using a Polar H10 chest strap connected via Bluetooth to the Polar RS800 monitor. In the RR function, the accuracy is less than 1 millisecond per beat. The chest strap will be placed on the anterior region of the newborn's chest (Figure 1). Before the start of data recording, a stabilization period of 30 minutes in the assigned intervention sequence will be allowed. After this period, HRV recording will begin using the Polar monitor for 60 minutes for each intervention. Before changing the intervention sequence, a washout period of three hours will be allowed"|f|f|t|f
34019168|NCT02757365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019169|NCT03984292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcome assessor shall not be aware of the type of training which has been given to the students.|"The students will be randomly distributed into two groups by using pre-designed envelopes:~Group I: Single teaching session of 3 hours at single encounter Group II: 3 teaching sessions of 1 hour each over a period of 3 weeks The study will be open to all the year 2, 3 and 4 medical students of Aga Khan University Medical College and recruitment shall be done on first come-first serve basis."|f|f|f|t
34019170|NCT00314223|||CASE_CONTROL||PROSPECTIVE|||||||
34019171|NCT06240520|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled trial.||||
34019172|NCT00152724|||COHORT||PROSPECTIVE|||||||
34019173|NCT00573781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019174|NCT01104909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34019175|NCT05041621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019176|NCT05296356|NA|SINGLE_GROUP||TREATMENT||NONE||Open study||||
34019177|NCT06358170|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019178|NCT02132637|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34019179|NCT00179816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019180|NCT04269538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019181|NCT00967044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019182|NCT05748613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent assessor (blind to treatment condition) will conduct pre-intervention and follow-up assessments. The assessor will have extensive training and experience in conducting the relevant assessments including clinical interviews and neuropsychological evaluations. A separate interventionist will assist in the delivery of the intervention.|Variable-sized permuted block randomization will be used to allocate participants to treatment condition, stratified by dementia severity (MCI vs. mild ADRD) and gender.|t|f|f|t
34019183|NCT05355649|NA|SINGLE_GROUP||PREVENTION||NONE||PREGNOLIA SYSTEM||||
34019184|NCT02045992|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34019185|NCT04972123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized 1:1 to CPC or placebo||t|t|t|f
34019186|NCT05341466|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34019187|NCT01549106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019188|NCT01297465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019189|NCT03290365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019190|NCT04178070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019191|NCT00883623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796118|NCT02825485|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33796119|NCT01549756|||CASE_ONLY||RETROSPECTIVE|||||||
33796120|NCT01347125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796121|NCT04065932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796122|NCT05528341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796123|NCT04973735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33796124|NCT02076958|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33796125|NCT05650125|||COHORT||PROSPECTIVE|||||||
34019192|NCT05638958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants ant the biostatician will be blinded on the assignment group|"Test: A customized PEEK abutment mimicking the subgingival emergence of the extracted tooth will be screw retained on top of the implant to seal the extraction site.~Control: A commercially available healing abutment will be screwed on top of the implant and a collagen sponge will be used to protect the graft."|t|f|f|f
33796126|NCT03284086|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796127|NCT00718939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796128|NCT03557008|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Longitudinal and Randomized||||
33796129|NCT05289466|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Non-randomized, Single-arm||||
33796130|NCT01266265|||COHORT||PROSPECTIVE|||||||
33796131|NCT03573284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796132|NCT03916835|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33796133|NCT03187860|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796134|NCT04470258|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34019193|NCT03956810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34019194|NCT03816514|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33796135|NCT06677047|||COHORT||PROSPECTIVE|||||||
33796136|NCT02488200|||COHORT||PROSPECTIVE|||||||
33796137|NCT03823534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patient and study investigators will be blinded. The hospital pharmacy will be unblinded.|This study is a prospective, randomized, double-blind, placebo-controlled trial.|t|f|t|f
33796138|NCT04395326|||COHORT||PROSPECTIVE|||||||
33796139|NCT06553547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796140|NCT02794480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796141|NCT02565069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796142|NCT02477670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796143|NCT02570542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019195|NCT00322504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019196|NCT04616547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019197|NCT04959318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician is external to the research team and has not been involved throughout the trial period. She will receive data upon completion of the trial and perform the outcomes assessment.|Subjects were enrolled, submitted fasting blood sample, and returned for initial measurements when lab results were available. At this visit, randomization based on a random number generator and concealed allocation with sequentially numbered opaque envelopes took place. This allowed the first treatment/professional counseling session to be held the same day depending on group assignment.|f|f|f|t
34019198|NCT01761370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019199|NCT03041324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019200|NCT01780987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019201|NCT01715064|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34019202|NCT00398996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019203|NCT00195637||||TREATMENT||||||||
34019204|NCT00821873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019205|NCT00430209|||CASE_ONLY||CROSS_SECTIONAL|||||||
34019206|NCT02202863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019207|NCT02711683|||COHORT||PROSPECTIVE|||||||
34019208|NCT00673244|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019209|NCT03493516|||COHORT||PROSPECTIVE|||||||
34019210|NCT00257218|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34019211|NCT00266071|||DEFINED_POPULATION||OTHER|||||||
34019212|NCT05631353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|data will be sent blinded for statistical analysis||t|f|f|t
34019213|NCT01996943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34019214|NCT00300625|||||PROSPECTIVE|||||||
34019215|NCT00006408|||||RETROSPECTIVE|||||||
34019216|NCT03668236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor- and analyst-blinded trial||f|f|f|t
34019217|NCT01965470|RANDOMIZED|PARALLEL||PREVENTION||||||||
34019218|NCT02770885|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34019219|NCT00148824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019220|NCT05643248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019221|NCT06489457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019222|NCT02502773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796144|NCT05183724|||COHORT||PROSPECTIVE|||||||
34019223|NCT03717857|||CASE_ONLY||CROSS_SECTIONAL|||||||
34019224|NCT06273839|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019225|NCT03996642|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study will use a one-group observational design to establish feasibility and acceptability of Avatar therapy intervention in patients with advanced cancer.||||
34019226|NCT03306524|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Neonates|Ten different interventions (with changing slope time or ventilation mode) will be compared in a crossover design. Each intervention will be given for 15 minutes. For details of the intervention see study design details.|t|f|f|f
34019227|NCT04149106|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Any|"A cluster randomized design will be used.~Year 1:~Arm 1: SPAQ for children less than 10 years old (Standard treatment) Arm2: SPAQ will be delivery to children 3 months to less than 10 years (extension of SMC to children 5-9 years with current drug) Arm 3: DHAPQ will be delivery to children 3 months to less than 10 years~Year 2:~Arm 1: SPAQ will be delivery to children 3 months to less than 10 years (extension of SMC to children 5-9 years with current drug) Arm2: DHAPQ will be delivery to children 3 months to less than 10 years Arm 3: Standard of care defined as SPAQ for children less than 5 years old according the NMCP national politic for malaria control"||||
34019228|NCT00130455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019229|NCT00077545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796145|NCT02776969|||COHORT||PROSPECTIVE|||||||
33796146|NCT06479668|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796147|NCT05020756|||OTHER||RETROSPECTIVE|||||||
34019230|NCT04303286|||COHORT||PROSPECTIVE|||||||
34019231|NCT04811365|||OTHER||PROSPECTIVE|||||||
34019232|NCT01246011|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34019233|NCT02834650|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34019234|NCT02910674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019235|NCT05145686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|observers were blinded|"Experimental: Biodentine Dental materials~Interventions:~Drug: Biodentine Drug: ProRoot (Aggregate) Experimental: ProRoot MTA Dental Materials~Interventions:~Drug: Biodentine Drug: ProRoot (Aggregate)"|f|f|f|t
34019236|NCT01090830|NA|SINGLE_GROUP||OTHER||NONE||||||
34019237|NCT03596151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019238|NCT03543241|||CASE_ONLY||PROSPECTIVE|||||||
34019239|NCT00002149||PARALLEL||TREATMENT||||||||
34019240|NCT03607526|||OTHER||OTHER|||||||
34100560|NCT05624957|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33796148|NCT01354795|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33796149|NCT03411291|||OTHER||PROSPECTIVE|||||||
33796150|NCT00065260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796151|NCT04908371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients in both study groups will not be able to see the ultrasound monitor during block placement and therefore will be blinded to group allocation. The outcome assessor (research nurse) will not be present in the procedure room during block placement and thus will also be blinded to group allocation. Dressings applied on the skin to cover the needle entry sites will also be identical in the two study groups. The anaesthesiologist (principal investigator) performing the allocated BPB will take no further part in the study after block placement."|Patients will be randomly assigned to receive either a SeTB (SeTB group) or hybrid interscalene-supraclavicular BPB (IS-SC group) under ultrasound guidance. The randomization sequence will be generated using an online randomization software (www.randomization.com). The randomization sequence will be assigned as 1 = selective trunk block (SeTB group) and 2 = interscalene-supraclavicular BPB (IS-SC group). The group allocation will be prepared by a computer officer (third party) in the Department of Anaesthesia \& Intensive Care, of the Chinese University of Hong Kong.|t|f|f|t
33796152|NCT00660439|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019241|NCT01364181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019242|NCT02649985|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34019243|NCT01490983|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33796153|NCT05707871|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will be blinded to content of nicotine in cigarettes|Within Subject|t|f|f|f
33796154|NCT00192491|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33796155|NCT05960695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The volunteers who met the inclusion criteria were divided into 2 groups. The patients have informed about 2 different groups, but they were not told which of them. Stretching exercises were taught regardless of which group the patients were in. In addition, relaxation exercises were taught to the patients in the stretching+relaxation group.|t|f|f|f
33796156|NCT05539755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796157|NCT06672042|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33796158|NCT05504941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|A person blinded to all clinical data will assess the primary endpoint.|Explorative, one-arm, open label trial||||
33796159|NCT01320215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796160|NCT03233633|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33796161|NCT02354885|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796162|NCT06555718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Intervation group (Peer support) Control group (Standart care)|The study will start after obtaining official institutional permissions. The researcher will examine the profile of patients receiving treatment at the dialysis center. After this stage, the following steps will be followed|t|f|f|f
33796163|NCT03623672|||COHORT||PROSPECTIVE|||||||
33796164|NCT00634452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796165|NCT05480358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a pilot, double arm randomized and prospective clinical trial assessing feasibility and safety of a 5-day low protein fasting-mimicking diet in pazients affected by Mild Cognitive Impairment or early Alzheimer disease.|t|f|f|f
33796166|NCT00470899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796167|NCT05952336|||COHORT||OTHER|||||||
34019244|NCT00121134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019245|NCT02562339|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019246|NCT01471119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019247|NCT02938754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34019248|NCT04689919|RANDOMIZED|CROSSOVER||OTHER||NONE||Two period Two way cross-over study||||
34019249|NCT02881138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019250|NCT02585934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019251|NCT00170794|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34019252|NCT02216513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715817|NCT04193657|||COHORT||PROSPECTIVE|||||||
33715818|NCT02624583|||CASE_ONLY||PROSPECTIVE|||||||
33715819|NCT00814398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715820|NCT06504602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33715821|NCT02468323|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715822|NCT01545284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715823|NCT00827424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715824|NCT01561365|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715825|NCT05738161|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective investigator-initiated single-arm, phase 1 clinical trial, risk category C||||
33715826|NCT00953446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715827|NCT01923701|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33715828|NCT02898246|||COHORT||CROSS_SECTIONAL|||||||
33715829|NCT03992742|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33715830|NCT05833295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized into 3 groups. Clinical and electrophysiological tests before and after walking sessions will be performed by an unannounced researcher.||f|f|f|t
33715831|NCT03382392|||COHORT||RETROSPECTIVE|||||||
33715832|NCT05729659|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33715833|NCT06085079|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm 1: Subjects will self-administer subcutaneous injection of ixekizumab during the baseline week (Week 0) using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q2 weeks for 24-weeks.~Arm 2: Subjects will self-administer subcutaneous injection of ixekizumab during the baseline week (Week 0) using a loading dose of 160 mg of subcutaneous ixekizumab (Taltz), followed by 80 mg of subcutaneous ixekizumab Q4 weeks for 24-weeks."||||
33715834|NCT02825992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33720922|NCT05435079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study is a single-blind study. The researcher clearly defines the treatment group, but index evaluation, data collection and data statistics are completed by different trained researchers, and they don't know the specific grouping.|Before the start of the study, all enrolled patients were required to sign an informed consent form. Patients who met the inclusion criteria were divided into NTHF (observation group) and AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand) group (control group) in a 1:1 ratio.|f|f|f|t
33940528|NCT05815576|NON_RANDOMIZED|SEQUENTIAL||SCREENING||SINGLE|"The data will be coded (pseudonymization). The subject's name or other identifiers will be stored separately from their research data and replaced with a unique code to create a new identity for the subject.~The outcomes assessor will be blind for participants' injury status for the following :~* while conducting kinematic and kinetic data processing,~* while performing muscle size measurements on the ultrasound images,~* while performing statistical analysis (for all outcomes)~There will be no blinding while scoring the following outcomes (because these scores are immediately determined in the presence of the participant) :~* Foot muscle strength,~* Foot posture index,~* Navicular drop,~* Modified Star Excursion Balance Test,"|"The intervention is a fatigue protocol of the intrinsic foot muscles. Only subjects with chronic ankle instability will undergo this fatigue protocol.~Participants with chronic ankle instability will perform the movement analysis first without and then with foot muscle fatigue."|f|f|f|t
33940529|NCT05178563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a double blind, CONSORT-based randomized, controlled clinical trial comparing the use of local use of photodynamic therapy (PDT) pretreatment on systemic inflammation, vascular dysfunction and patient discomfort following a single session of non surgical periodontal therapy (IPT) vs. IPT alone.||t|f|f|t
33940530|NCT05129917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940531|NCT01397331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940532|NCT01432002|||COHORT||PROSPECTIVE|||||||
33940533|NCT02275559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940534|NCT03132038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940535|NCT06164418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant and Investigator)|Each patient will receive one restoration in a posterior tooth on any side randomly selected from the 4 tested restorative systems groups, all materials will be used according to manufacturers' instructions|t|f|t|f
33940536|NCT06110962|||COHORT||RETROSPECTIVE|||||||
33940537|NCT05030506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940538|NCT05954273|||CASE_CONTROL||RETROSPECTIVE|||||||
33940539|NCT05510999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940540|NCT02871232|||COHORT|||||||||
33940541|NCT01080339|||CASE_CONTROL||PROSPECTIVE|||||||
34019253|NCT05806918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019254|NCT01342536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019255|NCT04333108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019256|NCT03127644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019257|NCT03150849|||CASE_CONTROL||PROSPECTIVE|||||||
34019258|NCT05465239|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34019259|NCT04007770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100561|NCT04778709|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|CBCT review, core biopsy evaluation and histomorphometry will be performed by a masked investigator.|Each subject will receive bilateral sinus augmentation. Right and left sinuses will be randomly assigned to Bone Graft A and Bone Graft B.|t|f|f|t
34100562|NCT06110689|||CASE_CONTROL||PROSPECTIVE|||||||
34100563|NCT02467881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100564|NCT05530707|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34100565|NCT01183182|NA|SINGLE_GROUP||||NONE||||||
33796168|NCT02574026|NA|SINGLE_GROUP||OTHER||NONE||||||
33796169|NCT05590273|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study has been designed in accordance with the NIH Science of Behavior Change ORBIT model for developing behavioral interventions and represents a Phase Ia Define Trial.||||
33940542|NCT03621111|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940543|NCT01229592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019260|NCT05617105|||CASE_ONLY||RETROSPECTIVE|||||||
34019261|NCT01673438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019262|NCT02538848|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34019263|NCT06218953|||COHORT||OTHER|||||||
34019264|NCT00556777|NON_RANDOMIZED|||TREATMENT||NONE||||||
34019265|NCT04407091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019266|NCT04619719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019267|NCT04567030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34019268|NCT00896909|||OTHER||RETROSPECTIVE|||||||
34019269|NCT02518919|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34019270|NCT04589416|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34019271|NCT01698827|||COHORT||PROSPECTIVE|||||||
34019272|NCT05145582|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants cannot be blinded to condition because ICBT (like other psychotherapies) cannot be both provided to and concealed from a participant. However, the difference between the two conditions (i.e., presence or absence of an online discussion forum) will be concealed from all participants. Because only participants assigned to the ICBT + Peer Support Forum condition will have access to the Peer Support Forum, it will not be possible to mask the forum moderator to those participants' condition. Because outcomes will be assessed via self-report questionnaire measures, outcomes assessor masking is not possible.|Participants will be randomly assigned to one of two treatment conditions (unguided ICBT only or unguided ICBT + online discussion forum)||||
34019273|NCT01254266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019274|NCT05803928|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100566|NCT05359718|||COHORT||PROSPECTIVE|||||||
34100567|NCT05753683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100568|NCT06119581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100569|NCT06035497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100570|NCT03159676|||CASE_ONLY||PROSPECTIVE|||||||
33940544|NCT05990257|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33940545|NCT03206190|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Two Arms are blinded (mutation carriers vs. non mutation carriers) the third arm is an open-arm for presymptomatic tested mutation carriers||t|t|t|f
33940546|NCT02751606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940547|NCT03720158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33796170|NCT06676839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants, physicians, and healthcare professionals will be informed of the allocation of the subjects' group membership after randomization. However, research nurses who will collect data on the primary and secondary outcomes during visits common to all subjects in the trial will be blinded to the subjects' group assignment. Participants and their caregivers will be asked to avoid mentioning the type of treatment they are receiving to the research nurse conducting the interview.||f|f|f|t
33796171|NCT06073769|||COHORT||PROSPECTIVE|||||||
33796172|NCT06010433|||CASE_ONLY||PROSPECTIVE|||||||
33796173|NCT04563559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796174|NCT06390852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796175|NCT03928912|||CASE_CONTROL||RETROSPECTIVE|||||||
33796176|NCT00024141||||TREATMENT||||||||
33796177|NCT04706078|||COHORT||RETROSPECTIVE|||||||
33796178|NCT00145743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796179|NCT04813419|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and outcomes assessor are blinded to laser therapy received at each side of face|adult patients with similar atrophic acne scar on both sides of face|t|f|f|t
33796180|NCT06073860|||COHORT||PROSPECTIVE|||||||
33796181|NCT06676254|||COHORT||RETROSPECTIVE|||||||
33796182|NCT02167906|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33796183|NCT02202824|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33940548|NCT03087474|||COHORT||RETROSPECTIVE|||||||
33940549|NCT03365401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019275|NCT04234984|||COHORT||RETROSPECTIVE|||||||
34019276|NCT04335526|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019277|NCT05613296|||CASE_ONLY||PROSPECTIVE|||||||
34019278|NCT01513837|||CASE_ONLY||PROSPECTIVE|||||||
34019279|NCT02621918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019280|NCT00894036|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34019281|NCT06276036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019282|NCT01259115|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34019283|NCT01099527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019284|NCT01305395|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019285|NCT03080753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019286|NCT04915482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019287|NCT00003916|RANDOMIZED|||TREATMENT||||||||
34019288|NCT04555850|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Dose Escalation for 3 Cohorts.|t|t|t|t
34019289|NCT04006223|||COHORT||PROSPECTIVE|||||||
34019290|NCT02841813|||CASE_CONTROL||RETROSPECTIVE|||||||
34019291|NCT04284995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019292|NCT03174951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019293|NCT02851329|||COHORT||RETROSPECTIVE|||||||
34019294|NCT05874583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019295|NCT01826786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019296|NCT01632761|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34019297|NCT00611273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019298|NCT02667015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019299|NCT05965115|||COHORT||PROSPECTIVE|||||||
34019300|NCT01161849|||||PROSPECTIVE|||||||
34019301|NCT00742924|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796184|NCT01474707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33796185|NCT03597113|||COHORT||PROSPECTIVE|||||||
33796186|NCT06220071|||COHORT||RETROSPECTIVE|||||||
33796187|NCT02740595|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33796188|NCT04949035|||COHORT||PROSPECTIVE|||||||
33796189|NCT06677125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796190|NCT04363996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796191|NCT02943629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796192|NCT00463788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796193|NCT01562925|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34019302|NCT01512706|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34019303|NCT04132583|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019304|NCT03599271|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The randomized cohort is double-blinded, which both participants and outcome assessor being masked to treatment assignment|A PK non-randomized cohort in 5 participants, followed by a randomized, intra-patient controlled double-blind cohort in 70 participants|t|f|f|t
34019305|NCT02335736|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019306|NCT02190474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019307|NCT04881630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019308|NCT00054600|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34019309|NCT03920176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34019310|NCT03674086|||CASE_ONLY||PROSPECTIVE|||||||
34019311|NCT06405282|||CASE_CONTROL||RETROSPECTIVE|||||||
34100571|NCT02799290|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34100572|NCT02289014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100573|NCT04449523|||COHORT||PROSPECTIVE|||||||
33796194|NCT06552624|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33940550|NCT03973775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Study Team consisted of blinded and unblinded teams. The blinded team consists of the Principal investigator(s) and their designee(s). This team includes trained study personnel who are experienced at finding scabies mites in skin lesions. Blinded team members completed informed consent/assent, screen for inclusion/exclusion criteria, enroll subjects, collect demographic information, perform the pre- and post-treatment evaluations and complete the Case Report Forms (CRFs). The unblinded team members consists of the dedicated study pharmacist and/or their designee(s).||t|t|t|f
33940551|NCT06376942|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940552|NCT01663298|||COHORT||PROSPECTIVE|||||||
33940553|NCT01174602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940554|NCT04746729|||COHORT||OTHER|||||||
33940555|NCT00863135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940556|NCT05240872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940557|NCT02840760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940558|NCT01164267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940559|NCT03356301|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940560|NCT05619939|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Subjects will be blinded as to which protein type they are receiving.|This study is designed as a single-blinded randomized crossover trial in which individuals will be assigned to 2 groups. One group will receive 10 days of pea protein isolate followed by 10 days of consuming egg white protein isolate, with the two treatment periods separated by a 14-day washout period. The second group will receive the isolates in the opposite order.|t|f|f|f
33940561|NCT02053597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940562|NCT01350466|||CASE_CONTROL||PROSPECTIVE|||||||
33940563|NCT04604015|NA|SEQUENTIAL||DIAGNOSTIC||NONE|All de-identified imaging data will be sent to a core laboratory which will provide independent quantitative and qualitative assessment of all NB-IS TCD and Standard of care (SOC) TCD, TTE, and TEE bubble study data. They will be blinded to the study and local diagnostic report data and provide independent review. The Core Lab interpretations will supersede all local interpretations and will be applied to all study endpoint analyses as applicable.|"The NeuralBot Investigational System is comprised of both the Lucid M1 System and the NeuralBot accessory. The NeuralBot accessory must be used with the Lucid M1 System and cannot operate independently. The NB-IS is a modification of a 510k cleared device called NeuralBot Guided Head mounted Accessory (K180455;22May2018). The NeuralBot Investigational System is the investigational study device used in this study.~The NeuralBot Investigational System (NB-IS) moves two ultrasound probes around the two temporal regions (Right and Left) of the head to find the transtemporal window and then optimizes cerebral blood flow velocity (CBFV) measurements. The system uses TCD data to systematically specify and evaluate probe positions. The NeuralBot Investigational System consists of a head-support structure that houses two probe positioning modules, a robotic controller unit and computer tablets. The NeuralBot Investigational System is non-invasive and does not deliver energy into a subject."||||
33940564|NCT02548091|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33940565|NCT03705156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940566|NCT02522091|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33940567|NCT00650715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940568|NCT05832866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There was no masking in the intervention|There were two groups, one with clinical based and the other with telemonitored home based. The two groups received thera band exercises of isometric contractions. The clinical based at the hospital, and the home based at home but being monitored by researcher with phone call.|t|f|f|f
33940569|NCT03297554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940570|NCT02838368|||CASE_ONLY||PROSPECTIVE|||||||
33940571|NCT03531918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940572|NCT05179291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940573|NCT02255162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940574|NCT04252560|||COHORT||PROSPECTIVE|||||||
33940575|NCT03665129|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33940576|NCT04524507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is double-blinded so neither the participant nor the study team/investigators will know which plasma treatment (CCP1 or CCP2) that the participant is receiving.|"This study has 2 treatment arms and participants will be assigned/randomized to one arm:~1. CCP1 - CCP tested for the presence of anti-SARS-CoV-2 antibodies and assigned high-titer~2. CCP2 - CCP tested for the presence of anti-SARS-CoV-2 antibodies and assigned standard-titer"|t|f|t|f
33940577|NCT02790749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940578|NCT05343962|||COHORT||CROSS_SECTIONAL|||||||
33940579|NCT02993640|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940580|NCT02068391|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33940581|NCT05386979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33940582|NCT06477523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940583|NCT02895971|||COHORT||PROSPECTIVE|||||||
33940584|NCT03445780|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33940585|NCT05057377|||COHORT||PROSPECTIVE|||||||
33940586|NCT02449629|||COHORT||CROSS_SECTIONAL|||||||
33940587|NCT01186133|||COHORT||PROSPECTIVE|||||||
33940588|NCT02447393|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34100574|NCT03192332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment of the primary outcome will be performed by an independent and blinded person.|Prospective, randomized, open label, blinded endpoint (PROBE)|f|f|f|t
34100575|NCT06057337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34100576|NCT01371565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796195|NCT03932188|||CASE_CONTROL||PROSPECTIVE|||||||
33796196|NCT03793998|||COHORT||PROSPECTIVE|||||||
33796197|NCT02962141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796198|NCT00412321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796199|NCT00092274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796200|NCT00844636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940589|NCT00808132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940590|NCT02932449|||COHORT||OTHER|||||||
33940591|NCT05633290|||COHORT||PROSPECTIVE|||||||
33940592|NCT00482209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33940593|NCT01206933|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940594|NCT04597424|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1 : doxycycline and Bexsero vaccine Arm 2 : doxycycline and no vaccine Arm 3 : No doxycycline and Bexsero vaccine Arm 3 : No doxycycline and No Bexsero vaccine||||
33940595|NCT02833727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940596|NCT01643889|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33940597|NCT05807815|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33940598|NCT00997906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940599|NCT02976194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940600|NCT02908841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940601|NCT00153452|||DEFINED_POPULATION||OTHER|||||||
33940602|NCT02841254|||OTHER||PROSPECTIVE|||||||
33940603|NCT01684085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33940604|NCT05895422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|one blind|randomized intervention study|t|f|f|f
33940605|NCT02288416|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940606|NCT01474993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940607|NCT06031064|||COHORT||PROSPECTIVE|||||||
34019312|NCT06275191|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|"Blinding to the intervention is not possible in this study, as the intervention requires provider engagement. Provider participants and any clinic personnel will be blinded to the allocation sequence, and those not yet receiving the intervention will not be aware of the time at which they will have the intervention implemented. The study biostatistician will be aware of the allocation sequence.~At the beginning of each period, the study biostatistician will inform the research coordinator, project manager, academic detailing pharmacist, and PIs which cluster will be transitioning to the intervention condition next. This information will be used to facilitate scheduling academic detailing visits and coordinate blister pack and patient instructions material assembly. The clinic will be informed of their allocation during Visit 4 to facilitate scheduling academic detailing visits."|Stepped wedge cluster randomized trial|t|f|t|f
34019313|NCT06477484|||COHORT||CROSS_SECTIONAL|||||||
33796201|NCT03443102|||CASE_CONTROL||PROSPECTIVE|||||||
33796202|NCT04898140|||COHORT||PROSPECTIVE|||||||
33796203|NCT02306616|||CASE_ONLY||RETROSPECTIVE|||||||
34019314|NCT02261844|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34019315|NCT02903992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019316|NCT05912907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019317|NCT04614246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind to placebo and open-label for active comparator||t|t|t|t
34019318|NCT03203486|NA|SINGLE_GROUP||OTHER||NONE||non-randomised, open-label study||||
34019319|NCT03206580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019320|NCT02368574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019321|NCT03728400|||COHORT||PROSPECTIVE|||||||
34019322|NCT03492827|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34019323|NCT04412265|||CASE_ONLY||RETROSPECTIVE|||||||
34019324|NCT02894281|||OTHER||PROSPECTIVE|||||||
34019325|NCT05335733|||CASE_CONTROL||PROSPECTIVE|||||||
34019326|NCT03249974|||CASE_ONLY||PROSPECTIVE|||||||
34019327|NCT01867944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019328|NCT02165865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019329|NCT01558180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019330|NCT03871868|||CASE_CONTROL||PROSPECTIVE|||||||
34019331|NCT04257552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Investigators are unaware of study arm.||f|f|t|f
33796204|NCT03897127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940608|NCT00182494|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33940609|NCT03115021|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33940610|NCT04286724|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pre-post study||||
34019332|NCT05769933|||COHORT||PROSPECTIVE|||||||
34019333|NCT05279365|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100577|NCT04471844|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomly assigned equally to one of two groups:~1. Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.~2. Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®."||||
33796205|NCT05153135|||COHORT||RETROSPECTIVE|||||||
33796206|NCT02937831|||COHORT||RETROSPECTIVE|||||||
33796207|NCT06040073|||COHORT||PROSPECTIVE|||||||
33796208|NCT01926977|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796209|NCT02464852|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33796210|NCT06376383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796211|NCT01359436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796212|NCT06182423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796213|NCT06666972|||OTHER||CROSS_SECTIONAL|||||||
33796214|NCT03092401|||CASE_CONTROL||RETROSPECTIVE|||||||
33796215|NCT06272162|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33796216|NCT00003017||||TREATMENT||||||||
33796217|NCT02789917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796218|NCT02014766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796219|NCT06216730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796220|NCT06335446|||COHORT||PROSPECTIVE|||||||
33796221|NCT01400776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796222|NCT04705623|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A single-center, randomized, controlled, open-labelled, two-armed, interventional clinical trial||||
33796223|NCT04081792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796224|NCT00306449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796225|NCT01385891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796226|NCT00346684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796227|NCT03881488|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33796228|NCT06306378|||OTHER||OTHER|||||||
33796229|NCT05598632|||COHORT||PROSPECTIVE|||||||
33796230|NCT02180945|||COHORT||PROSPECTIVE|||||||
33796231|NCT04019873|||COHORT||PROSPECTIVE|||||||
33796232|NCT01568918|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796233|NCT01711710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796234|NCT06073834|||CASE_CONTROL||PROSPECTIVE|||||||
33796235|NCT03229044|||CASE_ONLY||RETROSPECTIVE|||||||
33796236|NCT03901937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33796237|NCT04614636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796238|NCT03567369|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33796239|NCT02432131|||COHORT||PROSPECTIVE|||||||
33796240|NCT02427269|||COHORT||PROSPECTIVE|||||||
33796241|NCT03834792|||COHORT||RETROSPECTIVE|||||||
33796242|NCT05094050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796243|NCT01077934|||COHORT||PROSPECTIVE|||||||
33796244|NCT06345495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796245|NCT05500807|NA|SINGLE_GROUP||TREATMENT||NONE||40 patients who will receive emicizumab prophylactically||||
33796246|NCT06318104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796247|NCT05849233|||CASE_ONLY||CROSS_SECTIONAL|||||||
33796248|NCT02329457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796249|NCT02218502|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33796250|NCT00783354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796251|NCT05619016|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Treating clinicians will be blinded for the results of the HER2-PET|"Prospective, single-center, single-blinded, diagnostic explorative phase II basket trial.~Investigators select subjects that are scheduled for anti-HER2 treatment due to~* metastatic HER2 positive gastroesophageal cancer (GEAC)~* metastatic breast cancer with low HER2 expression (HER2low mBC).~All patients undergo a PET/CT with the interventional drug/radiotracer 68Ga-ABY-025 before starting treatment. GEAC patients will undergo an additional ABY-025-PET after 3 cycles of treatment. Results will be compared to HER2 analysis of tissue samples."||||
33796252|NCT02886637|||CASE_ONLY||PROSPECTIVE|||||||
33796253|NCT05956626|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"The following team members will be masked:~Bio-Statistician, Data Programmer, Imaging Reading Center Team, Head of Clinical Development and Medical Affairs."|"The study will be conducted in two phases.~Phase 1 is a multicenter, open-label, dose-ranging/dose escalation study. A 3+3 study design will be used for the sequential dose-escalation cohorts in which subjects will receive a single subretinal injection of OCU410ST.~Phase 2 is a dose-expansion phase of the study, where the subjects will be randomized in a 1:1:1 ratio to either one of two treatment groups (adult and pediatric subjects) or to an untreated (adult and pediatric subjects) control group."|f|f|f|t
33796254|NCT04510454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Nasopharyngeal and oropharyngeal samples will be analyzed by the standard RT-qPCR test and the ddPCR assay.||||
33796255|NCT06199323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All researchers were required to maintain isolation from participants beyond necessary contact and strictly keep confidentiality of research content. We used blind labels to identify participants' intervention or treatment allocation. These labels remained confidential during the research process and were accessible only to researchers and specific staff. In addition, all data collection and assessment were conducted by professionals who were not involved in the intervention and were not aware of the study design to ensure objectivity and independence. All medical staff responsible for the intervention received detailed training before the start of the study to ensure their understanding and proper implementation.||f|f|f|t
33796256|NCT05755100|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Uncontrolled pilot trial.||||
33796257|NCT06375668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796258|NCT03178292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796259|NCT02048592|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33796260|NCT05143658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33796261|NCT05579106|||CASE_CONTROL||PROSPECTIVE|||||||
33796262|NCT01535833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796263|NCT02541188|||COHORT||PROSPECTIVE|||||||
33796264|NCT02306577|||||PROSPECTIVE|||||||
33796265|NCT01870479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796266|NCT06675994|||COHORT||PROSPECTIVE|||||||
33796267|NCT00495417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796268|NCT05019417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796269|NCT02384577|||COHORT||PROSPECTIVE|||||||
33796270|NCT06212141|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|single-blind|Randomized split-mouth clinical trial|f|f|f|t
33796271|NCT06172699|||COHORT||PROSPECTIVE|||||||
33940611|NCT03175822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Teacher||t|f|f|t
33940612|NCT03347279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.|t|t|t|f
33940613|NCT02401945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100578|NCT06606405|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100579|NCT03390400|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Groups will be randomized. Randomization information will be put in a sealed envelope on screening date and opened in operating theatre right before procedure start.|Bilateral femtosecond-laser assisted cataract surgery will be performed in individuals with age-related cataract. Eyes will be randomized into two groups receiving either anterior capsulotomy before lens fragmentation or vice versa in the contralateral eye. After laser procedure samples of aqueous humor will be collected and when complete all samples will be analysed by ELISA for Prostaglandin.|t|t|t|f
34100580|NCT05381636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100581|NCT03760640|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34100582|NCT03112369|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34100583|NCT04702750|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34100584|NCT06567561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100585|NCT00779883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100586|NCT00043680||||TREATMENT||||||||
34100587|NCT01862965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796272|NCT06555627|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||2x2 factorial|f|f|t|t
33796273|NCT05630508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participant won't know if they got the full or sham or no intervention|Participants are assigned to one of three groups in parallel for the duration of the study|t|f|f|f
33796274|NCT05112146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796275|NCT05581745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796276|NCT01472003|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796277|NCT04461197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796278|NCT02550197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33796279|NCT00866203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796280|NCT05660993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796281|NCT00101010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796282|NCT05021211|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33796283|NCT03141333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33796284|NCT00870207|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796285|NCT01568073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796286|NCT05473260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796287|NCT00338559|||COHORT||PROSPECTIVE|||||||
33796288|NCT00707291|||CASE_ONLY||PROSPECTIVE|||||||
33796289|NCT00229346|||||RETROSPECTIVE|||||||
33796290|NCT05510245|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796291|NCT00507689|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33796292|NCT00401206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796293|NCT02735941|||COHORT||PROSPECTIVE|||||||
33796294|NCT00841035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940614|NCT03943004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940615|NCT03431467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All data will be masked as far as possible. For example, Echo data will be masked|Randomised controlled trial at three U Penn Sites|f|f|f|t
33940616|NCT03870139|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33940617|NCT02400593|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33940618|NCT06332274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blinded, randomized, placebo-controlled, multi-center, national, Phase 3 biology-driven trial designed to investigate the impact of systemic treatment with tislelizumab or placebo following detection of MRD minimum 3 months and maximum 4.5 months after completion of curative-intent therapy.|t|t|t|t
33940619|NCT00145379|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33940620|NCT00779181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940621|NCT01833351|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796295|NCT05507749|NA|SINGLE_GROUP||OTHER||NONE||||||
33940622|NCT05166031|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796296|NCT05463549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data regarding maternal characteristics, anxiety and pain levels as reported by the patients via the questioners will be stored according to random serial numbers without intervention type. The investigator handling the statistical analysis will be unaware of the patient's exposure.|"Women assigned to undergo amniocentesis during the trail time-period will be invited to participate in the study and will be signed a consent form.The randomization will be based on different days for each intervention - a day specified to women comprising of the research group while the following clinic day will be dedicated to women from the control group.~The study group will watch an informative video while waiting for amniocentesis, and the control group will not watch the video while waiting."|f|f|f|t
33796297|NCT01240941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796298|NCT04121858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The primary investigator and outcome assessor will be masked to the App assignment (Brain Safe vs Attention Control Medication list App)|Enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.|f|f|t|t
33796299|NCT03130439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796300|NCT00003516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796301|NCT04998799|||COHORT||CROSS_SECTIONAL|||||||
33796302|NCT00238212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796303|NCT05887180|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be randomly assigned to 1 of 2 possible treatment arms (standard of care vs. intervention)||||
33796304|NCT03297346|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33796305|NCT04529382|||COHORT||RETROSPECTIVE|||||||
33796306|NCT02341625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796307|NCT03145480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel assignment based on fitness of participants||||
33796308|NCT01118806|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796309|NCT05727202|||CASE_ONLY||PROSPECTIVE|||||||
33796310|NCT05590468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796311|NCT02115139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796312|NCT06110416|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33796313|NCT01460563|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33796314|NCT05475041|||COHORT||RETROSPECTIVE|||||||
33796315|NCT00000338||||TREATMENT||NONE||||||
33796316|NCT04410510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|100 patients will be randomized in a 1: 1 ratio (50 in each group)|This is a randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of P2Et (Caesalpinia spinosa extract) treatment in patients with a clinical diagnosis of Covid-19 infection when added to standard therapy.|t|t|t|f
33796317|NCT03087578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796318|NCT02957812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796319|NCT05099575|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33796320|NCT05971563|RANDOMIZED|CROSSOVER||OTHER||NONE||A three-way, randomized, controlled, open-label, crossover, single-dose clinical trial in healthy adult volunteers.||||
33796321|NCT00979537|RANDOMIZED|CROSSOVER||||NONE||||||
33796322|NCT01317446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33796323|NCT00389012|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33796324|NCT05499039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither the participant , care provider , the investigator nor the outcome assessor will select patients in both groups , see results of other patients till the end of the study or informed by literature opinion in this intervention|patients with will be randomly enrolled to either non invasive group or HFNC group and improvement and patient satisfaction will be assessed|t|t|t|t
33796325|NCT03470662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100588|NCT04702672|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Letter labeling of test products|Randomized, single-blinded, cross-over, acute, dietary intervention study|t|f|f|f
34100589|NCT04941898|||COHORT||PROSPECTIVE|||||||
33796326|NCT06545214|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Monocentric prospective non-randomized study comparing the arousal and respiratory responses to hypercapnia in adult patients with drug-resistant epilepsy and in healthy subjects||||
33796327|NCT06193850|||COHORT||PROSPECTIVE|||||||
33796328|NCT02050763|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33796329|NCT02494999|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796330|NCT03151590|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33796331|NCT06676137|||CASE_ONLY||PROSPECTIVE|||||||
33796332|NCT04957069|||COHORT||RETROSPECTIVE|||||||
33796333|NCT03127358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796334|NCT01703585|||COHORT||PROSPECTIVE|||||||
33796335|NCT01386138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33940623|NCT05116904|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940624|NCT01680835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796336|NCT02827617|||COHORT||PROSPECTIVE|||||||
33796337|NCT00860665|||COHORT||PROSPECTIVE|||||||
33796338|NCT06676267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796339|NCT06337955|||COHORT||PROSPECTIVE|||||||
33940625|NCT00095836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100590|NCT00579488|||CASE_ONLY||PROSPECTIVE|||||||
34100591|NCT06238921|NA|SEQUENTIAL||TREATMENT||NONE||||||
33796340|NCT00318019|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33796341|NCT00081250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33796342|NCT04612686|||COHORT||CROSS_SECTIONAL|||||||
33940626|NCT04874129|RANDOMIZED|CROSSOVER||TREATMENT||NONE||ramdomized, open-label, single-dose, two-way crossover study||||
33940627|NCT04098172|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940628|NCT04205188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940629|NCT03925493|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33940630|NCT06203028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940631|NCT00475579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940632|NCT05290935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940633|NCT01634867|||CASE_CONTROL||PROSPECTIVE|||||||
33940634|NCT01070654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940635|NCT04057313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be ensured by an outsider who will hold the coffee cups to nurses with the name of patients on the cups|A randomized multicenter trial: hemodialysis patients in three dialysis units will be randomized to two groups, group 1 will take coffee for 4 weeks, group 2 will take decaffeinated coffee for 4 weeks|t|t|t|t
33940636|NCT05529030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know that there are different versions of surveys||t|f|f|f
33940637|NCT00730665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940638|NCT03268395|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940639|NCT06133790|||COHORT||RETROSPECTIVE|||||||
33940640|NCT02764931|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33940641|NCT03364114|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940642|NCT05521542|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, single-arm, feasibility study||||
33940643|NCT00736385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019334|NCT02440022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019335|NCT04120090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019336|NCT00431314|||COHORT||CROSS_SECTIONAL|||||||
34019337|NCT04616339|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019338|NCT03149939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019339|NCT04551833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019340|NCT06345989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Due to the nature of the study, blinding to intervention will not be possible for the participants or clinicians during data acquisition. All data analysis will be carried out blinded using a coded data set.|Prospective single-centre parallel arm randomised controlled trial, with an allocation ratio of 1:1 to investigate the difference in chairside time and cost of alginate impressions vs intraoral scans.|f|f|f|t
34019341|NCT01056978|||COHORT||PROSPECTIVE|||||||
34019342|NCT04544501|RANDOMIZED|PARALLEL||PREVENTION||NONE||"28 Latina women at risk for HBOC will be randomly assigned to one arm after completing the baseline assessment.~We will conduct a Hybrid Type 1 design to (1) test the effectiveness of two intervention approaches (video vs. FORCE fact sheet) in enhancing GCRA uptake and psychosocial outcomes and to (2) collect data on implementation outcomes regarding the interventions (video vs. FORCE fact sheet) and the implementation of a short screening survey to identify at-risk women.~Given the hybrid design, we will also conduct focus groups with clinic staff, in which we estimate 32 staff to participate. Given their participation in the focus groups, clinic staff are also considered participants, but they are not part of the randomized trial."||||
34019343|NCT00505089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019344|NCT06404164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940644|NCT03663361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940645|NCT04045314|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, open label, randomized study with passive control.||||
33940646|NCT00000175||CROSSOVER||TREATMENT||DOUBLE||||||
33940647|NCT05474885|NA|SEQUENTIAL||TREATMENT||NONE||||||
33940648|NCT00847249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33940649|NCT01146691|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33940650|NCT02358876|||COHORT||PROSPECTIVE|||||||
33940651|NCT05458674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019345|NCT03837743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019346|NCT06314789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019347|NCT01150318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019348|NCT02636543|||||PROSPECTIVE|||||||
34019349|NCT06390644|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940652|NCT00015015|||DEFINED_POPULATION||PROSPECTIVE|||||||
33940653|NCT02876315|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940654|NCT02893332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33940655|NCT00003016|RANDOMIZED|||TREATMENT||||||||
33940656|NCT01882036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019350|NCT04748523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Mirtazapine and placebo containers of same appearance will be identified with a code, which will be uncovered at the end of the study. The codes assigned to Mirtazapine and placebo will be protected by the protocols coordination of the Functional Unit of Thoracic Oncology. The code will be assigned to patients in order of admission, according to a list pre-established by random numbers without knowing to which group the attending physician, the nutritionist, the psychiatrist or the patient belongs.|Randomized, double-blind clinical trial|t|t|t|t
34019351|NCT03272061|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Participants will follow in randomized order a tightly controlled, progressive, aerobic-based exercise program or control program for eight weeks, separated by a washout period of twelve weeks.|f|f|f|t
34019352|NCT05225532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019353|NCT00009009||||TREATMENT||||||||
34019354|NCT02889471|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34019355|NCT05704517|||CASE_ONLY||RETROSPECTIVE|||||||
33796343|NCT02962791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796344|NCT03250052|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796345|NCT01162876|NA|SINGLE_GROUP||OTHER||NONE||||||
34019356|NCT05304286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019357|NCT00662948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019358|NCT06160297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796346|NCT04614675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796347|NCT00568854|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796348|NCT05780788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796349|NCT04448158|||CASE_ONLY||RETROSPECTIVE|||||||
33796350|NCT00908830|||OTHER||PROSPECTIVE|||||||
33796351|NCT03802149|NA|SINGLE_GROUP||OTHER||NONE||||||
33796352|NCT01094613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796353|NCT04404881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796354|NCT00780299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796355|NCT03655626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796356|NCT02889718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796357|NCT01819883|||COHORT||PROSPECTIVE|||||||
34019359|NCT06156189|||COHORT||PROSPECTIVE|||||||
34019360|NCT02130583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019361|NCT01425918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019362|NCT01998672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019363|NCT06273826|||COHORT||PROSPECTIVE|||||||
34019364|NCT02493777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019365|NCT02796937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019366|NCT00006243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019367|NCT02563587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019368|NCT00968786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34019369|NCT01560481|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019370|NCT00415844|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019371|NCT03806712|||OTHER||PROSPECTIVE|||||||
34019372|NCT01536158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019373|NCT04213872|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single-group nonrandomized pilot study on the effects of 8 weeks of MM program on changes in cognitive function, anxiety, sleep quality, depression, and selected gene expression factors.||||
34019374|NCT03559166|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Randomized, double-blind, placebo controlled||t|t|t|t
34019375|NCT00821314|||COHORT||PROSPECTIVE|||||||
34019376|NCT03911050|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34019377|NCT01725321|||COHORT||PROSPECTIVE|||||||
34019378|NCT03707665|||COHORT||PROSPECTIVE|||||||
34019379|NCT00540293|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019380|NCT03830918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019381|NCT04361149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants were blinded by the cream treatment given. Both creams were in a concealed, blank, container|A randomized placebo controlled trial using 2 treatments: 1) placebo cream 2) capsaicin cream (0.075%) (Zostrix HP)|t|f|f|f
34019382|NCT03528083|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The investigators will conduct a quality improvement process for all children diagnosed with bronchiolitis at our hospital who meet inclusion criteria. Outcomes for these patients will be compared with retrospective controls.||||
34019383|NCT05340543|||COHORT||PROSPECTIVE|||||||
34019384|NCT04350320|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, prospective, randomized, controlled, open-label and pragmatic trial, comparing the administration of colchicine plus standard treatment vs. standard therapy, in hospitalized patients with COVID-19, within the first 48 hours, and no severity criteria||||
34019385|NCT04079920|||COHORT||PROSPECTIVE|||||||
34019386|NCT00455611|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34019387|NCT00437632|RANDOMIZED|PARALLEL||TREATMENT||||||||
34019388|NCT04006314||SEQUENTIAL||TREATMENT||NONE||Patients are divided into two groups. One group receiving PRP injections only. One group receiving PRP plus neural prolotherapy injections.||||
34019389|NCT01782586|||COHORT||PROSPECTIVE|||||||
34019390|NCT02957370|||CASE_CONTROL||PROSPECTIVE|||||||
34019391|NCT03540771|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), versus Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services)||||
34019392|NCT00004450|RANDOMIZED|||TREATMENT||DOUBLE||||||
34019393|NCT03861403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019394|NCT00324649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796358|NCT03204396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, placebo-controlled trial|t|t|t|t
33796359|NCT01831284|||COHORT||PROSPECTIVE|||||||
33796360|NCT01875744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796361|NCT03611712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796362|NCT03519737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding is achieved through operator entry of a randomization variable obtained from IWRS at the time of enrollment and randomization. This randomization variable (A or B), the meaning of which is blinded to the operator, is entered into the control box and determines the mode of the device as either active insonation or sham insonation.|Sham control and active insonation. During lead-in phase for the first 40 subjects, only active insonation will be programmed.|t|t|t|t
33796363|NCT05588453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796364|NCT03704935|||COHORT||PROSPECTIVE|||||||
33796365|NCT01184508|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33796366|NCT05001477|||CASE_ONLY||PROSPECTIVE|||||||
33796367|NCT05206266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33796368|NCT05457127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796369|NCT06285097|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33796370|NCT01960218|||CASE_ONLY||PROSPECTIVE|||||||
34019395|NCT06314880|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019396|NCT05213338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019397|NCT04792775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019398|NCT01371266|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019399|NCT03296384|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34019400|NCT04223531|NA|SINGLE_GROUP||OTHER||NONE||||||
34019401|NCT04636060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019402|NCT00604136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019403|NCT02257541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796371|NCT00980330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715835|NCT04702334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical operators were kept blind until the moment of adjunctive treatment application allocated by the randomizer. Patients remained blinded during the entire follow-up. Microbiological evaluation and statistical interpretation of the results were made blinded on the treatment performed.|"All patients underwent a full mouth debridement completed within 48h in two consecutive visits.~At reevaluation, a tooth entering the inclusion criteria was selected. After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group and local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket. Patients were advised not to drink or eat for 2 hours. This adjunctive treatment was performed at baseline and at the 3 months control. For both groups cleaning of supragingival tooth deposits and polishing was repeated at 3, 6, 9, and 12 months."|t|t|f|f
33715836|NCT01457521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715837|NCT03025503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715838|NCT05039645|NA|SINGLE_GROUP||OTHER||NONE||The study is a single-arm, open-label, multicentre, pilot/feasibility study evaluating the adherence and usability of daily use of remote thermovisual monitoring alongside standard of care in patients with a previous DFU.||||
33715839|NCT02050074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33715840|NCT02801292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715841|NCT02944474|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33796372|NCT06643728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796373|NCT02063321|||COHORT||PROSPECTIVE|||||||
33796374|NCT03691922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33940657|NCT04488406|||CASE_CONTROL||PROSPECTIVE|||||||
33940658|NCT06282081|||COHORT||PROSPECTIVE|||||||
33940659|NCT02200510|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940660|NCT04746027|||COHORT||PROSPECTIVE|||||||
33715842|NCT05546567|NA|SINGLE_GROUP||OTHER||NONE||Open label single group||||
33715843|NCT04833504|||CASE_ONLY||PROSPECTIVE|||||||
33715844|NCT04470674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715845|NCT02504008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715846|NCT04147221|NA|SINGLE_GROUP||OTHER||NONE||||||
33715847|NCT02093845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715848|NCT05295043|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796375|NCT06174636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796376|NCT01261234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796377|NCT06522295|||COHORT||PROSPECTIVE|||||||
33796378|NCT03655652|||COHORT||PROSPECTIVE|||||||
33796379|NCT01599897|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33796380|NCT02778958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796381|NCT00394615|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796382|NCT03166449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796383|NCT04559659|||OTHER||CROSS_SECTIONAL|||||||
33940661|NCT03233308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Paired comparison study|t|f|t|f
33940662|NCT00809627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940663|NCT02292615|||CASE_ONLY||PROSPECTIVE|||||||
33940664|NCT01512849|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940665|NCT01875731|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33940666|NCT03435289|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open-label study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer||||
33940667|NCT03730870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blinded as to study arm participation and outcome assessments.|Participants will be randomized to have their study clinician have access to their pharmacogenomics report prior to prescribing medications (experimental group) or no access (control group) until end of the study.|t|f|f|t
33940668|NCT00600665|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33796384|NCT04928248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796385|NCT02302300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796386|NCT03253848|||CASE_ONLY||PROSPECTIVE|||||||
33796387|NCT02562391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796388|NCT06676774|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Case-control trial with randomized, placebo-controlled, double-blind, cross-over design|t|f|t|f
33796389|NCT01716182|||||PROSPECTIVE|||||||
33796390|NCT00889499|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33796391|NCT02627183|||COHORT||PROSPECTIVE|||||||
33796392|NCT01684397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019404|NCT00117325|RANDOMIZED|PARALLEL||TREATMENT||||||||
34019405|NCT02512926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796393|NCT03915886|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
33796394|NCT02748590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796395|NCT00768235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796396|NCT04504916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796397|NCT01161498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796398|NCT00783419|||CASE_CONTROL||RETROSPECTIVE|||||||
33796399|NCT05888584|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940669|NCT00382382|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33940670|NCT02650804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940671|NCT05703789|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either oral rehabilitation or a waiting-list condition for 4-6 months. Patients receiving dental treatment will be allocated to one of two different treatment groups based on individual treatment need and proven experience. Patients in group 1 will be treated with minimal invasive treatment, with restorative composite fillings. Patients in group 2 will be treated with prosthetic rehabilitation, dental crowns. Patients that are randomized to no dental treatment will act as controls. The overall treatment results will be followed up after 4, 12 and 24 months. After the 4-6-month follow-up, the corresponding control patient from the waiting list will receive requisite dental treatment.||||
33940672|NCT00005066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940673|NCT03365531|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial of Caloric Restriction vs. Alternate-Day Fasting||||
33940674|NCT02987166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940675|NCT05976711|||COHORT||PROSPECTIVE|||||||
33940676|NCT01694966|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33940677|NCT05284604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators, study assessors, and participants will not be aware of the group assessments (double-blinded randomized controlled trial)|Participants are assigned to one of three groups in parallel for the duration of the study|t|t|t|t
33940678|NCT01914900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019406|NCT03993730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019407|NCT02494609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019408|NCT01197755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019409|NCT03053219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103395|NCT04857671|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"In this study, injections will follow a slightly modified FollowTheSutures injection protocol.~Study duration is 36 weeks long. A 4 weeks screening/baseline period with a daily electronic headache diary (eDiary) follows inclusion and informed consent. After completing the 4-week screening/baseline period, participants will be re-screened and eligible participants will enter the randomized phase of the study consisting of two treatment periods. The treatment periods is either injections with verum (onabotulinum toxin suspended in saline (Botox® and NaCl 0,9% Braun) or placebo (only NaCl 0,9% Braun). The participants are randomized to the order with which they enter the two periods, and a quadruple-blinding regime is implemented. Each treatment period lasts 12 weeks, separated by a 4 week washout period. Participants continue to keep a daily eDiary and register adverse events in the entire randomized period."|t|f|f|t
33796400|NCT04310072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|After the patients were evaluated for inclusion in the study and after signing the informed consent form, they were randomized using the website www.randomization.com (1 complete randomized block). Considering our intervention protocol, it was not possible to blind the patients and/or the investigator who performed the electrostimulation. However, the other investigators who conducted the 6MWT and performed the randomization were blinded.|The study team conducted a prospective randomized study to investigate the effects of NMES versus standard therapy on a hospitalized population with AHF. After the patients with AHF were stabilized they were included in the trial and were randomized by a blinded investigator to control group or NMES therapy. At the time of enrollment, patients were clinically evaluated and their associated comorbidities and drug therapy were noted. ECG, echocardiography, 6-minute walk test (6MWT) were performed and laboratory samples were collected including oxidized LDL, NT- proBNP, CK, uric acid, lipid profile and PCR. At the time of discharge, all patients underwent a 6MWT and laboratory samples such as oxidized LDL and NT-proBNP were collected again. During the hospitalization period we monitored any adverse events and tolerance to NMES therapy. At the time of inclusion in the study, patients signed an informed consent form in two copies, one remaining with the patient.|f|f|f|t
33796401|NCT00831675|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796402|NCT00239083|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33796403|NCT00002555|RANDOMIZED|||TREATMENT||||||||
33796404|NCT05430880|||COHORT||PROSPECTIVE|||||||
33796405|NCT05736497|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Comparison of pre and post testing of same cohort.||||
33796406|NCT02161172|||CASE_ONLY||CROSS_SECTIONAL|||||||
33796407|NCT05774951|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomised in a 1:1 ratio to one of the following arms:~* Arm A: Continue standard ET of investigator's choice (aromatase inhibitors \[AI; exemestane, letrozole, anastrozole\] or tamoxifen)~* Arm B: Camizestrant"||||
33796408|NCT05981547|||COHORT||PROSPECTIVE|||||||
33796409|NCT04737681|||CASE_CONTROL||PROSPECTIVE|||||||
33796410|NCT04830501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796411|NCT03165071|NA|SINGLE_GROUP||OTHER||NONE||||||
33796412|NCT03840486|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796413|NCT05287282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796414|NCT02462369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796415|NCT05404763|||COHORT||PROSPECTIVE|||||||
33796416|NCT00703911|||||PROSPECTIVE|||||||
33796417|NCT05251207|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796418|NCT01178632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796419|NCT04199728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796420|NCT06640387|||COHORT||PROSPECTIVE|||||||
33796421|NCT06676436|||COHORT||RETROSPECTIVE|||||||
33796422|NCT01083342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796423|NCT06355388|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|In order to maintain the 'double-blind,' at the end of the experimental protocol, the data acquired in each phase (baseline, active tVNS, placebo tVNS) will be saved in three different files, made unrecognizable by one of the investigators not involved in the tabulation and data analysis. A second investigator, unaware of the stimulation phases, will proceed with the tabulation of the data for each individual recording (three per patient). Only at the end of the study (or after recruiting 50% of patients for any interim analyses), will the investigators responsible for data analysis be revealed the corresponding phase for each recording.||t|f|t|f
33796424|NCT00704184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796425|NCT05880472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796426|NCT00599716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796427|NCT05284812|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796428|NCT06516042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796429|NCT06338241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796430|NCT00178386|||COHORT||RETROSPECTIVE|||||||
33940679|NCT02678702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940680|NCT03970967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940681|NCT02405676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940682|NCT02251574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940683|NCT00003572||||TREATMENT||||||||
33940684|NCT04829591|||COHORT||PROSPECTIVE|||||||
33940685|NCT04882839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940686|NCT01373294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796431|NCT01128790|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33796432|NCT02949583|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33940687|NCT01192334|||CASE_ONLY||PROSPECTIVE|||||||
33796433|NCT03712930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103396|NCT06124313|NA|SINGLE_GROUP||OTHER||NONE||||||
34103397|NCT00692237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715849|NCT04588948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is an exploratory investigation to evaluate the intraocular and systemic pharmacokinetics of intravitreal aflibercept. A sample size of 60 eyes was chosen to provide a sample of 30 non-vitrectomized eyes and 30 vitrectomized eyes to evaluate. This sample size will allow for an initial determination of the pharmacokinetics of intravitreal aflibercept injection inside the eye and in the systemic circulation of eyes with DME.One eye per patient may be eligible. In this research proposal, participants will be followed for 12-month period and have 17 study visits||||
33715850|NCT05887726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715851|NCT06420479|||COHORT||PROSPECTIVE|||||||
33715852|NCT01654731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715853|NCT00664976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33715854|NCT00531999|RANDOMIZED|PARALLEL||||NONE||||||
33715855|NCT05378490|||COHORT||OTHER|||||||
33715856|NCT05397756|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel assignment, not blinded, randomized study||||
33715857|NCT05436392|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33715858|NCT05953246|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715859|NCT02196558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715860|NCT04276597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715861|NCT04294472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33715862|NCT01504945|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33715863|NCT01680523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715864|NCT04245696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715865|NCT05533021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled experimental study||||
33715866|NCT06187727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33715867|NCT02432820|||CASE_ONLY||CROSS_SECTIONAL|||||||
33715868|NCT01829334|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715869|NCT04934384|||CASE_CONTROL||RETROSPECTIVE|||||||
33715870|NCT04304807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715871|NCT00397397|||||OTHER|||||||
33715872|NCT00137046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715873|NCT01732250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715874|NCT04070950|||COHORT||PROSPECTIVE|||||||
33715875|NCT04541940|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715876|NCT00547092|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715877|NCT03211689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715878|NCT00891254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33715879|NCT01896531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715880|NCT02269345|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33715881|NCT04169321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multiple center, open label, non-randomized, single dose study, in subjects with cancer undergoing or treatment with a checkpoint inhibitor either as a monotherapy or in combination. subjects. Eligible subjects will receive an injection of \[68Ga\]-NOTA-hGZP pre checkpoint inhibitor administration and a second dose between 5 and 42 days post initial checkpoint inhibitor administration. Upon dosing each subject will undergo PET scans at 40, 60 and 90 minutes post dosing. The images will be analyzed for the distribution of radioactivity. Subjects will be followed for adverse events for approximately 4-6 hours post injection or until pembrolizumab injection plus a follow up phone call to assess adverse events 1-3 days after injection.||||
34103398|NCT06078189|||OTHER||PROSPECTIVE|||||||
33715882|NCT01521208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715883|NCT03080311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715884|NCT03867981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715885|NCT02630433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715886|NCT03327883|||COHORT||RETROSPECTIVE|||||||
33715887|NCT02480842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715888|NCT02263794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715889|NCT03613012|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33715890|NCT02701439|||||CROSS_SECTIONAL|||||||
33715891|NCT03530904|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715892|NCT04356664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715893|NCT03666715|||COHORT||RETROSPECTIVE|||||||
33715894|NCT01302587|||COHORT||PROSPECTIVE|||||||
33715895|NCT00616200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715896|NCT04840615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715897|NCT02046356|||COHORT||PROSPECTIVE|||||||
33715898|NCT02018328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715899|NCT00003596|RANDOMIZED|||TREATMENT||||||||
33715900|NCT01412346|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33715901|NCT05295862|||COHORT||OTHER|||||||
33715902|NCT06289608|||COHORT||CROSS_SECTIONAL|||||||
33715903|NCT04240925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33715904|NCT05113472|||COHORT||CROSS_SECTIONAL|||||||
33715905|NCT04539847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two-arm parallel assignment|t|f|f|f
33715906|NCT02891083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715907|NCT02645110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715908|NCT05427253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The IMP, i.e., the C106 and the placebo oral solutions, are identical in appearance. Both solutions are colourless to yellow. Hence, it is expected that the subjects, Investigator and other site personnel will remain unaware of treatment allocation.|Part A, single ascending dose (SAD) including a food interaction cohort Part B, multiple ascending dose (MAD)|t|t|t|t
33715909|NCT05964244|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|NIV masks can not be masked during the treatments. Only the analysis will be masked.|Crossover study where each participant receives NIV on the Vela investigational mask and the Nivairo standard mask for one hour each in random order.|f|f|f|t
33796434|NCT01235884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796435|NCT01821612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796436|NCT05789472|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33796437|NCT06120699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a prospective double-blind randomized controlled study.|t|f|f|t
33796438|NCT04301596|||COHORT||PROSPECTIVE|||||||
33796439|NCT03644329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796440|NCT00457743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796441|NCT03019614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796442|NCT06677346|||COHORT||CROSS_SECTIONAL|||||||
33796443|NCT03126812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796444|NCT06554691|||COHORT||PROSPECTIVE|||||||
33796445|NCT03777696|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|a double-blinded randomized placebo-controlled trial|A Double-Blind Randomized Clinical Trial|t|t|t|t
33796446|NCT03895268|||COHORT||PROSPECTIVE|||||||
33796447|NCT02156050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796448|NCT06472206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796449|NCT06347640|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33796450|NCT04825366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796451|NCT02872753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796452|NCT04360057|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Subjects will be included from two oncology clinics, one in radiation oncology and one in chemotherapy oncology||||
33796453|NCT04949581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|bioelectric therapy and routine cardiac rehabilitation program|t|f|f|t
33796454|NCT03668288|||COHORT||PROSPECTIVE|||||||
34019410|NCT05326321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"According to the randomization table, the information showing the patients included in the research sample is assigned to the A and B groups will be put in an opaque envelope. This envelope will be kept by the coordinator researcher (DL) and when the researcher (HŞ) goes to the patient for application, after filling out the Informed Voluntary Consent Form, he will open the envelope and learn which group is in which group. Due to the nature of the study, patients and the researcher (HŞ) will not be blinded, since abdominal massage will be applied only to the patients included in the study. When the research is completed, the data will be transferred to the computer environment by a statistician who does not know the A and B groups, and the data will be analyzed by a statistician independent of the research and the findings will be reported. Thus, the data analysis and statistics phase will be blind to group assignment."|Prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
34019411|NCT02317614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019412|NCT04808466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the choice of HIPEC drugs is unknown to patients with advanced gastric cancer, but known to doctors, investigators and outcomes assessors.|We divide patients into 3 groups randomly. Test group 1: D2 Surgery + HIPEC (paclitaxel) + SOX/XELOX regimen Test group 2: D2 Surgery + HIPEC (lobaplatin) + SOX/XELOX regimen Control group: D2 Surgery + HIPEC (no drug) + SOX/XELOX regimen|t|f|f|f
34019413|NCT05387538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||patients will be randomized into two groups according to the surgical procedure performed as follows group (A )had pts who will undergo One-layer Duct-to-mucosa Pancreaticojejunostomy group(B) had pts who will undergo Two-layer Duct-to-mucosa Pancreaticojejunostomy|t|f|f|f
34019414|NCT00192244|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34019415|NCT03191110|||COHORT||PROSPECTIVE|||||||
33796455|NCT02949206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796456|NCT06676969|||COHORT||PROSPECTIVE|||||||
33796457|NCT05485389|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The nurses included in the study were named as participants.|pre-test and post-test semi-experimental design||||
33796458|NCT03994055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796459|NCT01714882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796460|NCT01350804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796461|NCT00381173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796462|NCT05505799|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Before and After study of a Checklist Intervention||||
33796463|NCT04618614|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled trial (RCT)|t|f|f|f
33796464|NCT02162446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796465|NCT04384250|||CASE_ONLY||PROSPECTIVE|||||||
33796466|NCT06306313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940688|NCT04833972|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Study participants are randomly assigned to be read survey questions with slight changes in the wording of the response options. Neither study participants nor outcomes assessors are provided with information about treatment assignment."||t|f|f|t
33940689|NCT03167866|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Randomization will be by study personell that is not in contact with participants||t|t|t|f
33940690|NCT04804111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940691|NCT05459519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33940692|NCT01170481|||CASE_CONTROL||PROSPECTIVE|||||||
33940693|NCT00126763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940694|NCT04062942|||COHORT||PROSPECTIVE|||||||
33940695|NCT01979003|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796467|NCT00590707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33796468|NCT00551980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796469|NCT01292681|NA|SINGLE_GROUP||||NONE||||||
33940696|NCT00003556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940697|NCT04922814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796470|NCT06676384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician/ outcome assessor will be blinded to the drug allocation and use coded data.|This is a Phase 4 multi-arm, multi-stage (MAMS) platform trial. It is a multicenter, randomised, single-blind (outcome assessor), active comparator trial. The participants will be randomised 1:1 to the comparator and each of the four interventional arms. The sample size of 585 participants is for five arms, including the active comparator. The sixth arm may begin after the planned interim analysis conditional to the availability of the generic drug in the Indian market and will recruit additional 117 participants with concurrent comparator arm.|f|f|f|t
33796471|NCT02634970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019416|NCT03776721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All patients undergo the same liposuction procedure. During general anesthesia, patients are randomized to either fat grafting or sham grafting with saline injection to the axilla. After stem cell suspension, patients receive either stem cell or saline injection depending on randomization using masked syringes.~Participants are blinded, care providers postoperatively are blinded, primary investigator is blinded and all outcome assessors are blinded. The surgeon performing the liposuction and the stem-cell staff are unblinded."||t|t|t|t
34019417|NCT01072474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34019418|NCT02953951|||COHORT||PROSPECTIVE|||||||
34019419|NCT04625426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cluster randomised trial|f|f|f|t
34019420|NCT01090921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019421|NCT02426853|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019422|NCT00640679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019423|NCT00569530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019424|NCT03389529|||COHORT||PROSPECTIVE|||||||
34019425|NCT04253496|||COHORT||OTHER|||||||
34019426|NCT04340609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019427|NCT04943484|||COHORT||PROSPECTIVE|||||||
34019428|NCT00613535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019429|NCT02508753|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34019430|NCT04896814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019431|NCT06432049|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34019432|NCT01716624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019433|NCT04917653|||COHORT||PROSPECTIVE|||||||
34019434|NCT01104792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019435|NCT00160641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019436|NCT03816566||SEQUENTIAL||DIAGNOSTIC||NONE|"The outcome assessor performing the automatic analysis of the patch data will be blinded to the PSG scores performed by the Sleep Lab Technicians.~The principal investigator responsible for the completion and closing of the study according to the protocol will be blinded to the patch AHI automatic analysis.~Similarly, the Sleep Lab Technicians scoring the PSG will be blinded to the patch automatic analysis.~By the end of recruiting the target sample size, the data will be un-blinded and statistical analysis will be performed."|||||
34019437|NCT04343326|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34019438|NCT02987101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019439|NCT03720379|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All participants,Care Providers, Investigators and Outcomes Assessor will be aware of the current subject's allocation and will be unconscious which product is fluoride varnish and which placebo. participants assigned to intervention(s) based on a protocol Patients will be distributed between Group A (Fluor Protector S) and group B (placebo) according to allocation for 2 types of intervention and blindness (codes for the type of intervention A and B will be assigned to patient numbers according to the reporting order and placed in opaque envelopes).|"We plan to include 168 subjects in this study.~1. Dental examination Qualified for the study will receive oral and written information on the causative factors of dental caries, hygienic and dietary recommendations.~2. Oral hygiene instruction will be provided.~3. Caries risk assesment~4. Application Fluor Protector S or Placebo~Dental examination will be performed before the intervention (preliminary), after 6 months and after 12 months. Dental exams will include an interview, a physical examination , radiological examination (bite- wing x-ray images) and Diagnodent assessment.~The applications of Fluor Protector S (intervention A) or placebo (intervention B) will be performed every three months during one year."|t|t|t|t
34019440|NCT01647672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796472|NCT03255720|||CASE_CONTROL||PROSPECTIVE|||||||
33796473|NCT02874118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33796474|NCT01306864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796475|NCT01109745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33796476|NCT00486005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796477|NCT06193005|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796478|NCT02849535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796479|NCT01038648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796480|NCT04558424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Immediately after randomization, random numbers of the two sets will assigned as patients code number. One set will be designated as intervention group and another group will placebo group. Two sets of code number that belongs to the intervention group and placebo group will be written with patient's id number. this total procedure will be conducted by the person unrelated to this research. Thus, the participants, caregiver, outcome assessor and the analyst, who require being blind for such study will effectively blind|"Criteria~Inclusion Criteria:~* ≥ 18 years presenting symptoms who test positive for COVID-19~* Moderate to severe patients obtained consent~* Hypoxic respiratory failure (saturation \<90% on air at rest or increasing oxygen requirement)~* Chest examination findings of bilateral crackles on auscultation or chest x-ray showing bilateral infiltrates~* C-Reactive Protein \> 50mg/L~* women of childbearing potential who meet the above and have a negative pregnancy test.~Exclusion Criteria:~* Pregnant women: Current known pregnancy positive pregnancy test.~* Lactating women.~* Documented history of mental illnesses~* Multi-organ failure~* Severe ARDS (requiring ventilator support on presentation in the form of invasive or non-invasive ventilation)~* Septic Shock~* Drug allergy/intolerance"|t|t|t|t
33796481|NCT06171425|||CASE_CONTROL||PROSPECTIVE|||||||
33796482|NCT05264012|||COHORT||PROSPECTIVE|||||||
33796483|NCT00010309||||TREATMENT||||||||
33796484|NCT04617353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patient enrollment according to the inclusion criteria. Carrying out medical manipulations according to the group inclusion criteria. Efficiency control based on the clinical course of the disease, instrumental and laboratory study methods.~After the patient is discharged from the hospital, a follow-up examination after 12 months, including an objective examination, a spiral computed tomography of the chest organs. Complete blood count, general urine test, biochemistry blood test.~Comparison of the main clinical and laboratory parameters between patients of both groups: the total number of bed-days spent, the time spent in the ICU, the duration of mechanical ventilation, laboratory parameters: red blood cell count, coagulation system, markers of infection and inflammation, state of sepsis, determination of how fast the bone tissue reparation is. CT scan of the chest, sternum, examination of the bacterial flora and bacterial contamination of the postoperative wound"||||
33796485|NCT00232895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796486|NCT03233919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796487|NCT03923946|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the active nature of the interventions it is not possible to mask participants.|Feasibility RCT||||
33796488|NCT00891930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796489|NCT05636332|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The qualified electrocardiogram reviewer will be blinded to the age of electrodes||f|f|f|t
33796490|NCT03047746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796491|NCT03270358|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796492|NCT05762549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940698|NCT03756636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940699|NCT05043194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940700|NCT02212249|NON_RANDOMIZED|PARALLEL||||NONE||||||
33940701|NCT00932399|||COHORT||RETROSPECTIVE|||||||
33940702|NCT01796795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33940703|NCT04441658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33940704|NCT05626959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation is concealed utilising central randomisation by computer.|"At the beginning of the study, participants will be randomised into either the active group or placebo group. Both groups will commence a double-blinded baseline dose of either 5mg/kg/day of NTI164 or Placebo that will be increased weekly by 5mg/kg for a period of 4 weeks until the maximum tolerated dose or 20/mg/kg/day is achieved.~At the end of the 8-week period, both study groups will be unblinded and all participants will begin or continue NTI164 for 8 weeks."|t|t|t|f
33940705|NCT04412226|||OTHER||PROSPECTIVE|||||||
33940706|NCT04715867|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33940707|NCT03109418|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33940708|NCT01861158|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33940709|NCT02111031|||CASE_ONLY||PROSPECTIVE|||||||
34019441|NCT03443388|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This is an open-label, randomized, 2-way crossover pilot safety study of the Hövding helmet device in patients with drug resistant epilepsy. Reference therapy is no head-protective device. Part 1 will test helmets on 4 normal controls falling from standing. If the helmet deploys in at least 3 out of 4 falls, we will proceed to Part 2. Part 2 will enroll up to 20 patients with Drug Resistant Epilepsy. Patients will be block randomized to first wear the helmet in their daily lives until helmet deployment or for up to 3 months, or to first not wear a helmet for up to 3 months. Patients in each group will complete self-administered questionnaires. We will compare circumstances, injuries, and post concussive scales in seizures resulting in falls occurring while the helmet was worn versus seizures resulting in falls occurring while the helmet was not being worn using daily seizure calendar, medical records review, the Rivermead Post Concussive Scale and other qualitative questionnaires.||||
34019442|NCT04557306|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019443|NCT05351554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019444|NCT00415766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796493|NCT03520413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Because participants will receive information on both study arms during the consent process, we will not attempt to blind participants to randomization assignment. However, in order to assure blinding of the staff that manage outcome data collection, randomization (including participant notification of group assignment by phone) will be managed by the project coordinator.|VA Home Telehealth (HT) nurses will deliver the 5 intervention components during telephone encounters. The standard encounter frequency will be every two weeks, but may be extended to every 4 weeks for participants achieving their HbA1c goal. Should Veterans relapse while receiving the lower encounter frequency, HT will return to every-two-week encounters until the next HbA1c assessment. The 5 intervention components are: Telemonitoring, Self-management support, Diet/activity support, Medication management, \& Depression support|f|f|f|t
33796494|NCT00695071|NA|SINGLE_GROUP||||NONE||||||
33796495|NCT00111709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796496|NCT04257136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796497|NCT02468388|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33940710|NCT00756223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940711|NCT01901679|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34019445|NCT00930371|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34019446|NCT06057441|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Patients will be recruited from Child and Adolescent Psychiatry in Lund. Typically developing children (TDC) will be recruited from schools.~All participants will perform a cross over control study. Participants will perform the entire test battery at one occasion, containing no noise, auditory white noise and visual white pixel noise (two levels). Participants in the ADHD group will perform the tests unmedicated. The order of the noise stimulation and no noise, as well as the order of the tasks, will be randomized over participants."||||
34019447|NCT00003521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019448|NCT01120041|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33940712|NCT05507294|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34019449|NCT01663935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019450|NCT04047524|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|There is no masking. Both the investigator and participant will be aware of which arm they have been randomised to.|Participants will be randomised sequentially i.e. 1:1 to receive either the Prehabilitation Programme or not||||
33796498|NCT02993588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34019451|NCT00354341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019452|NCT04408430|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||210 subjects: 110 in treatment arm and 100 in registry of medical treatment for patients who are not eligible for treatment.||||
34019453|NCT02731027|||COHORT||PROSPECTIVE|||||||
34019454|NCT00485420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34019455|NCT03158974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019456|NCT03246126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019457|NCT05583838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019458|NCT02093130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019459|NCT02671227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34019460|NCT03548649|NA|SINGLE_GROUP||TREATMENT||NONE||AIS A-D SCI patients with injury level C7-L5||||
34019461|NCT05596721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019462|NCT02070874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33940713|NCT01102816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019463|NCT04302558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33940714|NCT05256511|||COHORT||RETROSPECTIVE|||||||
34019464|NCT04101500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019465|NCT05301153|||CASE_CONTROL||PROSPECTIVE|||||||
34019466|NCT00852969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796499|NCT03769571|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33796500|NCT00661778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796501|NCT06357754|||COHORT||PROSPECTIVE|||||||
33940715|NCT01450566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33940716|NCT00735163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940717|NCT06421363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940718|NCT02005679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940719|NCT03793010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-blind, Placebo-controlled, Parallel-group|t|t|t|t
33940720|NCT04907942|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33940721|NCT05306860|||CASE_CONTROL||PROSPECTIVE|||||||
33940722|NCT01296464|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940723|NCT00000515|RANDOMIZED|PARALLEL||PREVENTION||||||||
33940724|NCT01462851|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33940725|NCT04229186|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33940726|NCT05883566|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33940727|NCT04810806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940728|NCT02582619|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33940729|NCT05511636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940730|NCT04591340|||OTHER||OTHER|||||||
33715910|NCT03619486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind, placebo control study. Eligible participants will be assigned a randomization number in sequential order and each of the randomization will determine the allocation of one of the two treatment groups (LESW and Placebo) in 1: 1 ratio as shown below. The LESW and placebo will be controlled by a research assistance who will not evaluate the therapeutic outcome to ensure the double blind method.|t|f|t|f
33715911|NCT03762824|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019467|NCT05178381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Because stimulation occurs at different locations on the scalp participants will be able to distinguish between the two conditions. However, because they will be unaware of our hypothesis, they will not know which condition is the control condition and which is the target condition.|"The main analyses in this study will ask whether cTBS applied to frontal pole and IFG changes explore-exploit behavior relative to the control condition where cTBS is applied to vertex within age group. Our main predictions are: (1) frontal pole will reduce directed exploration in both age groups, and (2) IFG stimulation will increase both directed and random exploration in both age groups.~To test these hypotheses we will perform separate repeated-measures ANOVAs for the different age groups (younger and older adults), for different types of exploration (directed vs random), and for the different target stimulation sites (frontal pole vs IFG), yielding 8 different analyses.~Each ANOVA will include TMS condition (vertex vs target) as a within subject factor and order (vertex first vs target first) as a between-subjects factor. The key question is whether there is a main effect of TMS condition on our measures of directed and random exploration."|t|f|f|f
34019468|NCT04031638|||COHORT||PROSPECTIVE|||||||
34019469|NCT02645396|||COHORT||PROSPECTIVE|||||||
34019470|NCT02955914|||OTHER||PROSPECTIVE|||||||
34019471|NCT05711836|||CASE_CONTROL||PROSPECTIVE|||||||
34019472|NCT00751907|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019473|NCT03621358|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double Blind (Participant and Investigator)||t|f|t|f
33715912|NCT03903445|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Pre-post evaluation of 2 separate interventions (no comparison)||||
33715913|NCT05911776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715914|NCT06285305|||CASE_CROSSOVER||PROSPECTIVE|||||||
33715915|NCT04688112|||COHORT||PROSPECTIVE|||||||
33796502|NCT00687011|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33796503|NCT03123198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796504|NCT00178399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019474|NCT03614897|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019475|NCT01076686|||COHORT||PROSPECTIVE|||||||
34019476|NCT03601364|||CASE_CONTROL||PROSPECTIVE|||||||
34019477|NCT01752686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019478|NCT03142906|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Outcomes assessor blinded to patient assignment.|Randomized parallel group controlled clinical trial|f|f|f|t
34019479|NCT04110938|||COHORT||PROSPECTIVE|||||||
34019480|NCT01157559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019481|NCT01190943|||CASE_ONLY||RETROSPECTIVE|||||||
34019482|NCT00290836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019483|NCT02682095|||COHORT||CROSS_SECTIONAL|||||||
34019484|NCT03376230|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34019485|NCT00992524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019486|NCT05321225|||COHORT||PROSPECTIVE|||||||
34019487|NCT00250900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019488|NCT00758680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019489|NCT04390542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019490|NCT04086836|||COHORT||PROSPECTIVE|||||||
33715916|NCT04880512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019491|NCT00675753|||CASE_CONTROL||RETROSPECTIVE|||||||
34019492|NCT04265339|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The data analysis will be conducted without knowledge of the group assignment|Three study groups: Smokers, non-smokers and smoking cessation group.|f|f|f|t
34019493|NCT06227013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||open-label, two-arm Randomized Control Trail (RCT)||||
34019494|NCT03213730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019495|NCT02752763|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34019496|NCT03709823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019497|NCT00002679||||TREATMENT||||||||
33715917|NCT01817998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715918|NCT03247855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715919|NCT00976092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715920|NCT03634449|RANDOMIZED|PARALLEL||OTHER||DOUBLE||one group using the endotracheal tube one group using the i-gel|t|t|f|f
33715921|NCT00875212|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33796505|NCT00187941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796506|NCT00364013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796507|NCT05322837|||COHORT||PROSPECTIVE|||||||
33796508|NCT00983593|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796509|NCT02154217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796510|NCT00223587|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33715922|NCT00132587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33715923|NCT00609492|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33715924|NCT04857242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019498|NCT04227236|RANDOMIZED|PARALLEL||OTHER||NONE|No masking was done as the assignment was evident based on the type of training offered. However, participants were unaware of the other options.|Participants were randomly assigned to one of two groups: in-person training or e-based virtual training.||||
34019499|NCT03590392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019500|NCT03796039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Investigator was masked at pre-testing. It was unknown which participants would be receiving the intervention. However, due to resources this was not repeated at post testing|Long term care (LTC) facilities will be recruited, with half of the LTC facilities randomized as the intervention (n=2) and half as the control group (n=2).|f|f|t|f
34019501|NCT03961048|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34019502|NCT03014180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940731|NCT01985035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940732|NCT05920655|||CASE_CONTROL||PROSPECTIVE|||||||
33940733|NCT02114099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940734|NCT01915355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940735|NCT00271076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940736|NCT06126289|||CASE_CONTROL||PROSPECTIVE|||||||
33940737|NCT02296528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940738|NCT06102993|||COHORT||OTHER|||||||
33940739|NCT02523742|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33940740|NCT01205646|NA|SINGLE_GROUP||SCREENING||NONE||||||
33940741|NCT05588076|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940742|NCT04296344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940743|NCT02828202|||COHORT||PROSPECTIVE|||||||
33940744|NCT06292429|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled trial|f|f|f|t
34019503|NCT02227147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019504|NCT03734783|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34019505|NCT04810403|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019506|NCT04168190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34019507|NCT01379001|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34019508|NCT01340105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019509|NCT06069778|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Radiologists that assess the CT scans will be blinded to the trial treatment.||f|f|f|t
34019510|NCT03123510|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Neither the volunteers nor the coaches will be aware|One group will receive a synbiotic supplement and the other placebo capsules.|t|t|f|f
34019511|NCT04406597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019512|NCT01846013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33715925|NCT06291025|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is prospective, non-comparative, non-inferiority, single-arm, multicentric, national.||||
33715926|NCT02234960|||COHORT||PROSPECTIVE|||||||
33715927|NCT01503944|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33715928|NCT03186521|||OTHER||PROSPECTIVE|||||||
33715929|NCT03566394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715930|NCT02638844|||CASE_ONLY||PROSPECTIVE|||||||
33715931|NCT02524795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715932|NCT00894569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715933|NCT01030939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715934|NCT01829191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715935|NCT03587012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715936|NCT03757897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a preliminary interventional trial in which participants will serve as their own controls.||||
33715937|NCT04920604|||COHORT||PROSPECTIVE|||||||
33715938|NCT01936688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715939|NCT06083116|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of drug-drug interaction between Henagliflozin Proline and Hydrochlorothiazide. A single-center, single-arm, open-label, multi-dose, three-period study was conducted in healthy Chinese volunteers.||||
33715940|NCT00847236|||CASE_CONTROL||PROSPECTIVE|||||||
33715941|NCT03240250|||COHORT||PROSPECTIVE|||||||
33715942|NCT06045767|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715943|NCT02814513|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33715944|NCT02728050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715945|NCT03134287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33715946|NCT04020679|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||Stepped Wedge Cluster Randomised Controlled Trial|t|f|f|f
33715947|NCT01655550|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796511|NCT00986466|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33940745|NCT05143294|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster RCT|f|f|f|t
33940746|NCT04005781|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33940747|NCT00266149|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34019513|NCT00788294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019514|NCT01268332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019515|NCT00452517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940748|NCT03618433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940749|NCT02092142|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33940750|NCT00117520|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33940751|NCT01729481|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940752|NCT03098667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33940753|NCT00992706|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33940754|NCT04918979|||COHORT||PROSPECTIVE|||||||
33940755|NCT05514093|||COHORT||PROSPECTIVE|||||||
33940756|NCT04557696|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33940757|NCT03742258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019516|NCT06009510|||CASE_CROSSOVER||PROSPECTIVE|||||||
34019517|NCT03694366|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34019518|NCT01700036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019519|NCT04557202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients were blinded to the type of intervention, as well as the data collector|We enrolled 120 patients with lower ureteric stones. They were randomly divided into two groups. Group A had 58 patients who underwent non-stented ureteroscopy using Ho-YAG laser for stone disintegration and received alpha1-blockers for one week preoperatively and another two weeks postoperatively, while Group B had 62 patients who underwent non-stented ureteroscopy and laser and received placebo.|t|f|f|t
34019520|NCT04392583|||COHORT||PROSPECTIVE|||||||
34019521|NCT05117983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019522|NCT02351960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019523|NCT03778658|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33940758|NCT00696644|||COHORT||PROSPECTIVE|||||||
33940759|NCT05454631|NA|SINGLE_GROUP||OTHER||NONE|not everyone involved in the research (patients, investigators, caregivers, and statistical analysis stakeholders) will know which mask the patient is using at which time.|||||
33940760|NCT00430924|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33940761|NCT01919749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940762|NCT00743041|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33940763|NCT01947166|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33940764|NCT03125902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Sponsor and its agents; the study site personnel, including the investigator; and the participant will be blinded to treatment assignment.||t|f|t|f
33940765|NCT00606021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940766|NCT00695318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940767|NCT00585104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940768|NCT02666118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33940769|NCT04937608|||CASE_CONTROL||PROSPECTIVE|||||||
33940770|NCT04101994|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33940771|NCT01494727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940772|NCT05978804|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects meeting eligibility criteria will be randomized to receive either tDCS + cognitive training or only tDCS. After 50 treatment sessions (approximately 10 weeks) participants will switch to the other condition.||||
33940773|NCT04791241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940774|NCT01766401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940775|NCT00087594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940776|NCT05425537|||COHORT||RETROSPECTIVE|||||||
33940777|NCT02981745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940778|NCT02589873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940779|NCT04498949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940780|NCT01271608|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33940781|NCT05709470|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34019524|NCT04181749|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients randomized to No treatment or Aspirin and Statin||||
34019525|NCT00511095|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019526|NCT03166423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019527|NCT03008876|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019528|NCT05211661|||CASE_CONTROL||PROSPECTIVE|||||||
33940782|NCT05979857|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is a phase 1, open-label, multicenter, dose escalation (part 1) and dose selection optimization (part 2) study of SP-3164 in patients with R/R B-cell NHL.||||
33940783|NCT00105833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940784|NCT05926895|RANDOMIZED|PARALLEL||OTHER||NONE||Patients will be followed up in two groups according to the presence of central sensitization before treatment.||||
33940785|NCT00925522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940786|NCT02830295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940787|NCT01078181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940788|NCT02510885|NA|SINGLE_GROUP||OTHER||NONE||||||
33940789|NCT05170516|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33940790|NCT01614951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940791|NCT04125290|||COHORT||RETROSPECTIVE|||||||
33940792|NCT03731065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33940793|NCT01428479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33940794|NCT03670056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796512|NCT04391101|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, parallel, randomized clinical trial with stratified (center and age) patient allocation in a 2 :1 ratio (plasma: standard management) for a superiority hypothesis||||
33796513|NCT00886951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940795|NCT04901286|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The PI will be blinded to the order of conditions for each participant.|||||
33940796|NCT00673140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940797|NCT00162799|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33940798|NCT04915209|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Narrative interviews||||
33940799|NCT06317298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33715948|NCT06121687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Surgery shall be performed for patients with VOD who are not responding to medical treatment and are candidate for penile prosthesis implantation. VOD will be documented by cavernosography to affect the deep system of veins; the internal pudendal vein, unilaterally.~Patients will be randomized into two groups: one to proceed to Penile Prosthesis Implantation (PPI Group), and another to be offered a choice between PPI or SHAEER-I. Patients opting for PPI will be assigned to the PPI group. Patients opting to SHAEER-I will be assigned to (SHAEER-I group)."|f|f|f|t
33715949|NCT04769544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind. Patients will be allocated into two groups based on randomized 20-block method by an independent assistant using computer generated randomization. Both patients and evaluators will be blinded with regard to the TKA design.|"Patients will be treated surgically with a TKA. The two patient groups will include: 1) Study group treated a medial pivot TKA; 2) Control group treated with a conventional TKA.~Patients will be followed at regular postoperative intervals by orthopaedic surgeons not involved in the surgeries or cares."|t|f|f|t
33715950|NCT04052893|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715951|NCT01252017|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33715952|NCT03016754|||COHORT||PROSPECTIVE|||||||
33715953|NCT02512237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715954|NCT05783778|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33715955|NCT03704207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715956|NCT03584711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715957|NCT02059460|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33796514|NCT02456506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796515|NCT00596609|||CASE_CONTROL||PROSPECTIVE|||||||
33796516|NCT03565523|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33796517|NCT05176964|||COHORT||PROSPECTIVE|||||||
33796518|NCT04528472|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33796519|NCT01842880|||COHORT||CROSS_SECTIONAL|||||||
33796520|NCT02972801|||CASE_ONLY||PROSPECTIVE|||||||
33796521|NCT03583125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796522|NCT05011734|||COHORT||PROSPECTIVE|||||||
33796523|NCT04815616|||COHORT||RETROSPECTIVE|||||||
33796524|NCT00310726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796525|NCT04767698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796526|NCT05570435|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33796527|NCT02675088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796528|NCT02338245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796529|NCT00523107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940800|NCT01218477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019529|NCT03986619|||COHORT||CROSS_SECTIONAL|||||||
34019530|NCT01832935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34019531|NCT02796118|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019532|NCT01376817|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34019533|NCT02890030|||CASE_CONTROL||PROSPECTIVE|||||||
34019534|NCT06060808|||COHORT||PROSPECTIVE|||||||
34019535|NCT02694471|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34019536|NCT02788253|||COHORT||PROSPECTIVE|||||||
34019537|NCT05153421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019538|NCT02537366|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34019539|NCT03908177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019540|NCT03108092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019541|NCT04940949|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33715958|NCT03982823|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stapled Sleeve Gastrectomy Group and Hand-Sewn Sleeve Gastrectomy Group||||
33715959|NCT00865124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33715960|NCT01285674|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019542|NCT00142233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33715961|NCT01486251|NA|SINGLE_GROUP||||NONE||||||
33715962|NCT00799240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019543|NCT05436717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019544|NCT00244530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019545|NCT02699684|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34019546|NCT06314347|||OTHER||CROSS_SECTIONAL|||||||
34019547|NCT04629417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019548|NCT05191303|RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistician, who is not involved in the study has done block-randomization with variable block-sizes (2,4,6) by StatsDirect program for two groups; an intervention and control group. Maternity care staff asks informed consent and then performs the randomization of primiparous women to the intervention or control group.|A single-blind randomized controlled trial with a two-arm design will be conducted among primiparous mothers. Participants are randomized to two groups, a intervention and a control group. Participants receive standard usual care of breastfeeding counselling in both groups. In addition, the intervention group members will use mobile intervention of breastfeeding counseling.|t|f|f|f
34019549|NCT01007942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019550|NCT00297726|NON_RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34019551|NCT00507481|||||PROSPECTIVE|||||||
34019552|NCT02321735|NA|SINGLE_GROUP||||NONE||||||
34019553|NCT05043844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34019554|NCT05590832|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|"The individuals included in the study were first stratified according to their BMI classes (normal, preobese, obese). Then, the BMI classes were included in the experimental and control groups in a balanced way by block randomisation method. Within each stratum, randomisation lists were generated with the help of The random sorting randomization algorithm (Maximum Allowable Deviation = 10%) PASS 11.0 software (NCSS LLC, Kaysville, UT). In total, participants were randomly assigned to experimental and control groups of 51 participants each.The study was completed with 96 pregnant women"||t|f|f|t
34019555|NCT02835781|||COHORT||PROSPECTIVE|||||||
34019556|NCT05898321|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019557|NCT04719520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|This study is a comparative study of the benefits of different ways of contacting patients' family members during surgery.|This study is a comparative study of the benefits of different ways of contacting patients' family members during surgery.||||
34019558|NCT01599065|||COHORT||PROSPECTIVE|||||||
34019559|NCT00210873|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34019560|NCT04258475|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34019561|NCT00378183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019562|NCT05916261|NA|SINGLE_GROUP||TREATMENT||NONE||The traditional 3+3 design will be used in dose escalation||||
34019563|NCT00001365||||TREATMENT||||||||
34019564|NCT00292487|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33715963|NCT06144489|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33715964|NCT05872646|NON_RANDOMIZED|PARALLEL||OTHER||NONE||patient and age-gender matched healthy groups||||
33715965|NCT01934530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019565|NCT04193306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded study with placebo||t|t|t|t
34019566|NCT02984618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019567|NCT04215848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019568|NCT04646551|||OTHER||OTHER|||||||
33715966|NCT00760578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715967|NCT03060876|||COHORT||PROSPECTIVE|||||||
33715968|NCT04537767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33715969|NCT02564289|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100592|NCT05671679|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will follow a randomized two-arm parallel design. Study visits will be done remotely via video calls or in-clinic when coinciding with usual care appointments. Following a baseline visit and before randomization, baseline characteristics and medical history of the participants will be collected (as detailed in section 4.3). Following randomization, the intervention group will use SNAQ app for the first 3 weeks while the control group will proceed without any modification/intervention by the study team. After the first 3 weeks, the control group will undergo 3 weeks of SNAQ app use (weeks 4-6). At the end of their respective SNAQ app periods (weeks 4-6 for the intervention group and weeks 7-9 for the control group), both groups will discontinue the use of SNAQ app for 3 weeks to assess sustainability of potential effects. Finally, both groups will be offered to use SNAQ app for 3 additional weeks as per their preference (follow-up period).||||
34019569|NCT02447796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34019570|NCT02907606|||CASE_ONLY||PROSPECTIVE|||||||
34019571|NCT04016961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019572|NCT00004151||||TREATMENT||||||||
34019573|NCT05213143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019574|NCT02390349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019575|NCT01753466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019576|NCT04352387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Two research assistants who conducted the observations were blinded to the group allocation.||f|f|f|t
34019577|NCT00517179|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34019578|NCT02982798|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019579|NCT03449550|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
34019580|NCT01738828|||CASE_CONTROL||PROSPECTIVE|||||||
34019581|NCT01921530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019582|NCT02357563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34019583|NCT05495828|||COHORT||PROSPECTIVE|||||||
34019584|NCT02721693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019585|NCT06367491|||COHORT||PROSPECTIVE|||||||
34019586|NCT04104854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019587|NCT00954330|RANDOMIZED|||TREATMENT||SINGLE|||f|f|f|t
34100593|NCT05521399|||COHORT||PROSPECTIVE|||||||
34100594|NCT05954962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100595|NCT03129607|||COHORT||PROSPECTIVE|||||||
34100596|NCT01355510|||COHORT||PROSPECTIVE|||||||
34019588|NCT00686530|||CASE_CONTROL||PROSPECTIVE|||||||
34019589|NCT06436040|||COHORT||RETROSPECTIVE|||||||
34019590|NCT06417736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019591|NCT05420974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019592|NCT04134806|||COHORT||PROSPECTIVE|||||||
34019593|NCT03429517|||CASE_CONTROL||PROSPECTIVE|||||||
34019594|NCT01595386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019595|NCT00548951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019596|NCT03397771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind placebo control||t|t|t|t
34019597|NCT01853930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940801|NCT04528433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The medical treatment of participants will be given by a doctor who does not know the study group of the patient. The investigator of the primary outcome and secondary outcome will also be unaware of the grouping of the patient. One psychiatrist blind of grouping will ask parents about the ADHD symptom of their children and rate it with SNAP-IV score.|The present study will be carried out using a parallel randomized study design. Each participant will be randomly assigned either to the collaborated intervention or to the routine clinical care control group.|f|f|t|t
33940802|NCT05095779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940803|NCT03883659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|one assessor who don't know the group will measure the range of motion by using goniometer|randomized controlled trial|f|f|f|t
33940804|NCT00845299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019598|NCT00703573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019599|NCT05641974|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Statistician analyzing outcomes is blinded to study arm assignment||f|f|f|t
34019600|NCT03525925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019601|NCT02716727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715970|NCT06245330|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33715971|NCT05586529|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33940805|NCT01957033|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33940806|NCT03714451|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double blinded|double blinded randomized|t|t|t|t
33940807|NCT04194086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940808|NCT02987205|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33940809|NCT03046329|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33940810|NCT02763605|||COHORT||RETROSPECTIVE|||||||
33940811|NCT01359813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940812|NCT00661362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940813|NCT04046666|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940814|NCT05042804|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33940815|NCT02390323|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33940816|NCT04770701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The group of HIV / AIDS uses drugs under study. The group of HIV / AIDS uses a placebo.|60 people were recruited HIV / AIDS positive between the ages of 20 and 60 and divided into 2 groups according to a random distribution.|f|f|f|t
33940817|NCT05830331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940818|NCT03839576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A single-blinded, randomized controlled trial is designed to compare the effects of social interaction, computerized cognitive training, lower extremity strengthening, and tai chi chuan on improving cognitive functions and gait/mobility and reducing falls.|t|f|f|f
33940819|NCT05720936|||COHORT||PROSPECTIVE|||||||
33940820|NCT00538486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940821|NCT00692159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940822|NCT04126187|||COHORT||PROSPECTIVE|||||||
33940823|NCT03469206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33715972|NCT02041468|||COHORT||PROSPECTIVE|||||||
33940824|NCT04657003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940825|NCT04018391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940826|NCT03395704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940827|NCT06250712|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||In the 588 patients who require additional testing due to arrhythmia symptoms, continuous single lead ECG or intermittent handheld ECG will be randomly assigned to the test for 1 month. If arrhythmia symptoms are not diagnosed after 1 month, cross over the device and use it for another month for evaluation.|f|f|f|t
33940828|NCT05288049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The experimental group will receive 12 weekly sessions (1 per week) of the intervention, which will be conducted by two psychologists blinded to the assessments.|An experimental randomized controlled clinical study is proposed, which will be rater-blinded and stratified by age, gender and socioeconomic status to assess the efficacy of a new intervention designed to increase CR in FEP and HR-SZBD subjects.|f|f|t|f
33940829|NCT05118893|||CASE_CONTROL||PROSPECTIVE|||||||
33940830|NCT00075634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940831|NCT01066546|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940832|NCT03524664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940833|NCT00003649||||TREATMENT||||||||
33940834|NCT01223560|NA|SINGLE_GROUP||PREVENTION||||||||
33940835|NCT04249076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||At least 210 participants Will be randomized in a 2:1 randomization ratio (140 to clobetasol arm, 70 to placebo arm) in order to have 202 evaluable participants (4% lost to follow-up rate expected)|t|f|t|f
33940836|NCT03030092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940837|NCT06462079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940838|NCT05146531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33940839|NCT04641013|||COHORT||PROSPECTIVE|||||||
34019602|NCT03791710|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups one will have the fat grafting and the other will be the control group treated with the conventional methods||||
34019603|NCT01945073|RANDOMIZED|FACTORIAL||||NONE||||||
33715973|NCT02543645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715974|NCT00064844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715975|NCT04080297|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||open-label, two dose study||||
33715976|NCT04057391|||CASE_ONLY||RETROSPECTIVE|||||||
33715977|NCT02598076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33715978|NCT01011634|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33715979|NCT00727181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715980|NCT05522101|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33715981|NCT02818686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715982|NCT02298803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33715983|NCT03991715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a pilot study. All participants receive the intervention.||||
33796530|NCT02502396|||COHORT||RETROSPECTIVE|||||||
33796531|NCT04374916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019604|NCT00589329|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019605|NCT06084962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019606|NCT00915928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33715984|NCT05939986|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not-blinded study protocol.|Participants will be assigned to one of three intervention arms, namely the VRET with multimodal feedback (visual, auditory, and vibrotactile; VRET-M), the VRET with bimodal feedback (visual and auditory; VRET-B), or the imagery exposure treatment (IET).||||
33715985|NCT05860803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study staff who administer clinical testing before and after LT-PR will be blinded to the patient's group allocation.||f|f|t|f
33715986|NCT05819515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33715987|NCT00004196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019607|NCT05068089|||CASE_CONTROL||RETROSPECTIVE|||||||
34019608|NCT01026181|||COHORT||PROSPECTIVE|||||||
34019609|NCT06289153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019610|NCT03810755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Active Comparator: Control group : PVS program, of proven effectiveness for the promotion of physical activity, diet and smoking cessation|Experimental: Supervision group= personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources|f|t|f|t
34019611|NCT04022928|NA|SINGLE_GROUP||TREATMENT||NONE||patients with symptomatic ankle OA for at least 6 months were recruited. Patients received a single injection of 3-ml of PRP into symptomatic ankles.||||
34019612|NCT01672112|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34019613|NCT04654663|||COHORT||RETROSPECTIVE|||||||
34019614|NCT04585165|||COHORT||PROSPECTIVE|||||||
34019615|NCT06030219|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34019616|NCT03484117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019617|NCT05103189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019618|NCT02838654|||COHORT||CROSS_SECTIONAL|||||||
34019619|NCT01020136|RANDOMIZED|CROSSOVER||||NONE||||||
34019620|NCT02831647|NA|SINGLE_GROUP||OTHER||NONE||||||
34019621|NCT05404607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019622|NCT01325181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019623|NCT01159197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019624|NCT00000386|RANDOMIZED|||TREATMENT||||||||
34019625|NCT05808218|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019626|NCT02799771|||COHORT||PROSPECTIVE|||||||
34019627|NCT02302547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019628|NCT04236726|||COHORT||CROSS_SECTIONAL|||||||
34019629|NCT00459121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019630|NCT02034058|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019631|NCT00146887|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34019632|NCT02516553|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019633|NCT04842565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019634|NCT02641197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100597|NCT03586609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100598|NCT06695871|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34019635|NCT02898753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019636|NCT03663439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|control group (modified shell technique) study group (onlay bone graft)|control group (modified shell technique) study group (onlay bone graft)|f|f|f|t
34100599|NCT00310180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100600|NCT03683199|NA|SINGLE_GROUP||TREATMENT||NONE||The total sample size will be 27 patients to study as calculated using G power version 3.1.3, in order to detect a significant difference in the mean of nasal ratios before and after surgery in the studied group (one of basic tools to measure the outcome). Assumed Effect size= 0.5, Power =0.80, Alpha error = 0.05.||||
34100601|NCT04621929|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 ratio block site of 6||||
33715988|NCT00766480||||TREATMENT||NONE||||||
33715989|NCT03548909|||COHORT||PROSPECTIVE|||||||
33715990|NCT00505531|||CASE_CONTROL||PROSPECTIVE|||||||
33715991|NCT05901168|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33715992|NCT00617123|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33715993|NCT02110290|||CASE_ONLY||PROSPECTIVE|||||||
33715994|NCT04348214|||COHORT||PROSPECTIVE|||||||
33715995|NCT01523860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33715996|NCT04625829|||CASE_ONLY||PROSPECTIVE|||||||
33715997|NCT02338284|||COHORT||PROSPECTIVE|||||||
33715998|NCT02043249|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33715999|NCT03668314|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Parts 1 and 3 are parallel designs with escalating doses within each part. Part 2 is a FE cross-over study|t|f|t|t
33716000|NCT05951062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33716001|NCT05292040|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33716002|NCT02683889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716003|NCT06163313|||COHORT||PROSPECTIVE|||||||
33716004|NCT02118051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716005|NCT03197259|||OTHER||PROSPECTIVE|||||||
33716006|NCT00002714||||TREATMENT||||||||
34019637|NCT05966675|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient will be blind to type of intervention. Due to a need of method-specific use of hardware and tailored programming of cardiac devices, medical staff is impossible to blind. The inability to blind affects also echocardiographists and anyone performing device interrogation as significant differences in number and localisation of pacing leads, their electrical parameters and pacemaker settings are inherently different in studied arms.|Patients will be randomized 1:1 to the intervention and control groups. In the control group, the type of ventricular pacing will depend on the left ventricular ejection fraction (LVEF): 1) RVP is planned in the group of patients with LVEF ≥40%, 2) BVP is planned in the group of patients with LVEF \<40%, following current ESC guidelines.|t|f|f|f
33940840|NCT04280185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33940841|NCT06016829|||CASE_ONLY||PROSPECTIVE|||||||
33940842|NCT03145857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940843|NCT02943577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019638|NCT02160275|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716007|NCT02597075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716008|NCT00667004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716009|NCT02981498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716010|NCT01529255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716011|NCT04026867|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33716012|NCT00031057||||TREATMENT||||||||
33716013|NCT00905151|||COHORT||OTHER|||||||
33716014|NCT02966587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716015|NCT04155112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716016|NCT04142853|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33716017|NCT04883190|||COHORT||PROSPECTIVE|||||||
33940844|NCT02411968|||COHORT||PROSPECTIVE|||||||
33940845|NCT05853926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33940846|NCT06117644|||COHORT||PROSPECTIVE|||||||
33940847|NCT02255240|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33940848|NCT06160531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940849|NCT01829542|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33940850|NCT04851769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940851|NCT05322759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940852|NCT01822912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940853|NCT04390217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple blinding including the sponsor and all sponsor agents, subjects, investigators, care providers, and family members.|All patients will be randomized into one of two treatment groups (LB1148 or Placebo) in a 1:1 ratio, and stratified by peripheral capillary oxygen saturation and by PF ratio at the time of Screening.|t|t|t|t
33940854|NCT02842333|NA|SINGLE_GROUP||OTHER||NONE||||||
33940855|NCT00741910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940856|NCT01362816|||COHORT||PROSPECTIVE|||||||
33940857|NCT02554916|||COHORT||PROSPECTIVE|||||||
33940858|NCT01650610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940859|NCT02760589|||COHORT||RETROSPECTIVE|||||||
33940860|NCT00143793|||COHORT||PROSPECTIVE|||||||
33940861|NCT03501394|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Single group with one arm and no masking.|Single group longitudinal study.||||
33940862|NCT06029465|||CASE_CROSSOVER||PROSPECTIVE|||||||
33940863|NCT02798809|||COHORT||PROSPECTIVE|||||||
33940864|NCT03157752|||COHORT||PROSPECTIVE|||||||
33940865|NCT04399434|||CASE_CONTROL||PROSPECTIVE|||||||
33940866|NCT00374764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940867|NCT04900714|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33940868|NCT00587340|||COHORT||PROSPECTIVE|||||||
33716018|NCT04359433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716019|NCT02648178|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33716020|NCT02555189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716021|NCT02601508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716022|NCT05030038|||COHORT||PROSPECTIVE|||||||
33716023|NCT01092754|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33716024|NCT06046339|||COHORT||RETROSPECTIVE|||||||
33716025|NCT06359067|||COHORT||RETROSPECTIVE|||||||
33716026|NCT01901237|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33940869|NCT04747028|||OTHER||CROSS_SECTIONAL|||||||
33940870|NCT05231291|||OTHER||CROSS_SECTIONAL|||||||
33940871|NCT03338335|||OTHER||OTHER|||||||
33940872|NCT00537251|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33940873|NCT00212667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940874|NCT04806334|NA|SINGLE_GROUP||OTHER||NONE||Not studying the MRI device; it is looking at feasibility of creating a radiogenomic workflow to learn about the correlation structure between the radiomic and genomic parameters of interest. The study is not an ACT but should be registered to meet ICMJE recommendations.||||
33940875|NCT00034697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940876|NCT00006242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019639|NCT01229735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019640|NCT00506649|||DEFINED_POPULATION||OTHER|||||||
34100602|NCT06481969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the particularity of the treatment plan, the evaluator, namely the follow-up personnel who collect the postoperative medical history and the ultrasound evaluator, will be blinded in this trial to hide the grouping results. Blinding of participants and researchers is not possible.|Eligible participants will be randomized to two groups at a ratio of 1:1- SVF protocol, and conventional protocol.|f|f|f|t
33716027|NCT01066533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34019641|NCT03589586|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, controlled, open-label trial comparing DermACELL AWM to conventional care||||
34019642|NCT01163630|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019643|NCT03982979|||COHORT||PROSPECTIVE|||||||
34019644|NCT01262742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019645|NCT01049711|||||PROSPECTIVE|||||||
34019646|NCT03659526|||COHORT||PROSPECTIVE|||||||
34019647|NCT00436904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019648|NCT04525235|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||each participants will receive phenotyping probe drugs with the standard dose of rifampicin and with a high dose rifampicin in a fixed oreder||||
34019649|NCT04751539|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34019650|NCT03446911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019651|NCT00967291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019652|NCT02637921|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019653|NCT01517659|NA|SINGLE_GROUP||TREATMENT||NONE|Panel of blinded physicians evaluated photos of pre-treatment and post-treatment images. Reviewers were blinded to the time point images were collected.|||||
34019654|NCT00057993||||TREATMENT||NONE||||||
34019655|NCT01608386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019656|NCT02237716|||CASE_CONTROL||PROSPECTIVE|||||||
34019657|NCT04175535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were unaware of the grouping process. The surgeons were unaware of the grouping process. The follow-up recorders were unaware of the grouping process.||t|t|f|t
34019658|NCT02620150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716028|NCT06076057|||COHORT||CROSS_SECTIONAL|||||||
34019659|NCT02188511|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019660|NCT04023643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019661|NCT06137690|||COHORT||PROSPECTIVE|||||||
34019662|NCT03601650|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34019663|NCT04573764|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized placebo-controlled double-blinded crossed-over acute intervention study.|t|t|t|f
34019664|NCT01166906|||CASE_ONLY||PROSPECTIVE|||||||
34019665|NCT03744663|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients admitted to the WFBMC Medication-Assisted-Therapy (MAT) clinic with a diagnosis of moderate/severe Opioid-Use Disorders (OUD) who are more than 18 years old will be approached for enrollment in this study. Because of the nature of a pilot study, it's proposed a total of 30 patients, 15 in each group. Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day, the subject will be started on the treatment to which they are randomized, either Suboxone® SL or Sublocade®. Control group -Suboxone®SL: Patients assigned to this group will continue with their already established dose of Suboxone ®SL films for 24 weeks along with weekly therapy. Study drug-Sublocade® group: Patients assigned to this group will receive the study drug (subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. At the end of the 24-weeks subjects will continue the medication of their choice within the constraints of their insurance provider.||||
34019666|NCT03627520|NA|SINGLE_GROUP||OTHER||NONE|open label|This is single centre, open label, single dose study||||
34019667|NCT03434912|||COHORT||PROSPECTIVE|||||||
34019668|NCT02331329|||COHORT||PROSPECTIVE|||||||
34019669|NCT06445634|NA|SINGLE_GROUP||TREATMENT||NONE||prospective cohort||||
34019670|NCT01058720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019671|NCT04164914|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34019672|NCT03954509|||OTHER||PROSPECTIVE|||||||
34019673|NCT01264731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019674|NCT00184353|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34019675|NCT02935205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716029|NCT05744154|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Local trauma committees will not be told explicitly what aspect of the intervention is randomised; they will only be aware that there are two variations of the intervention. Data extractors and analysts will be blinded to group allocation. Due to the nature of the intervention, it will not be possible to blind the investigators to allocation groups.|We will conduct a parallel arm, pragmatic cluster randomized trial (CRT) embedded in the provincial trauma quality assurance program. As the trial will be based on routinely collected data that are available at no extra cost, we will use a baseline observation period pre-randomization to increase study power. We will randomize at the hospital level because quality programs operate at the local trauma committee level in each hospital. A stepped wedge design will not be used as the minimum one-year roll-out period is unacceptably long for stakeholders and parallel arm CRTs have fewer risks of bias than stepped wedge CRTs. The trial is pragmatic as the intervention will be embedded in the 2023 evaluation cycle of the provincial quality assurance program.|t|t|f|t
33716030|NCT01407250|||||PROSPECTIVE|||||||
33716031|NCT00005970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716032|NCT04533438|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participant will be blinded to the study arm they are assigned to.|2:1 site-stratified randomization will be used to allocate participants to either the RhinAer procedure or treatment with the sham (control) procedure. Crossover within 30 days after 3- or 6-month follow-up visit.|t|f|f|f
33716033|NCT02566655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019676|NCT04310813|||COHORT||PROSPECTIVE|||||||
34019677|NCT06303037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34019678|NCT00000408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100603|NCT05389800|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34100604|NCT01111487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34100605|NCT04524000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1 of the study has a Single group design and the Part 2 has a Parallel design."||||
34100606|NCT03606590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019679|NCT05217706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The enroller, treating provider, and patient are masked. Only the pharmacist will be un-masked, as they are preparing the medication or placebo.|double-blinded randomized controlled trial|t|t|t|t
33716034|NCT02627781|||COHORT||PROSPECTIVE|||||||
34019680|NCT04461561|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34019681|NCT00039026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019682|NCT03822065|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019683|NCT02926430|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34019684|NCT01211418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019685|NCT05526261|||COHORT||PROSPECTIVE|||||||
34019686|NCT00030992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019687|NCT03255655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Investigator was blinded to the treated vs. control/sham treated patient identity and to the treated foot.~Researchers were blinded to the Investigators physical exam finding and patient outcome measure reports"|Adult Patients (age 18 - 85) of either gender diagnosed with chronic plantar fasciitis pain (\>90 days) where Standard of Care treatments had failed to reduce pain.|f|f|t|f
34019688|NCT05919121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019689|NCT03712839|||CASE_CONTROL||RETROSPECTIVE|||||||
34019690|NCT03340363|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34019691|NCT05899751|||CASE_ONLY||RETROSPECTIVE|||||||
34019692|NCT06262230|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||In this study, ordinary children will be paired with ASD children according to age, hobbies and other conditions||||
34019693|NCT05715983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double|assignment prospective, multi-centre.parallel-arm randomized controlled trial|t|f|f|t
34019694|NCT05556759|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blinded(participants and outcome assessors)|"The patients will be divided randomly by a computer-generated randomization table into three groups:~Group C :(Control group) patients will be operated on under general anesthesia. Group IPS: patients will receive anterior IPS block with 30 ml of bupivacaine 0.25% followed by general anesthesia.~Group Supra-iliac QL: patients will receive supra-iliac anterior QL block with 30 ml of bupivacaine 0.25% followed by general anesthesia."|t|f|f|t
34019695|NCT05133921|||COHORT||PROSPECTIVE|||||||
34100607|NCT05431127|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34100608|NCT06695468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A computer-generated database of random numbers will be used to randomly assign patients into two groups in a 1:1 ratio. The randomization will be carried out using a numbered, opaque, and sealed envelope.||t|t|t|t
34100609|NCT01708954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34100610|NCT06042855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
34100611|NCT00510562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34100612|NCT05647122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100613|NCT06338358|||CASE_CROSSOVER||PROSPECTIVE|||||||
34100614|NCT03643991|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrolled patients will be computer randomized in 1:1 ratio to either the intervention group or the control group.||||
34100615|NCT06396403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100616|NCT03075943|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100617|NCT05480046|||COHORT||PROSPECTIVE|||||||
34100618|NCT01029873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100619|NCT03081078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100620|NCT06570603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100621|NCT05447078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34100622|NCT00923507|||COHORT||PROSPECTIVE|||||||
34100623|NCT03971045|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II single center, open-label, non-randomized study||||
34100624|NCT00259701|||DEFINED_POPULATION||OTHER|||||||
34100625|NCT00972478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100626|NCT05290818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised control Trial (1:2 ratio: 53 in the rUKA arm and 106 in the mTKA)|f|f|t|t
34100627|NCT00930787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100628|NCT05935215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100629|NCT06034275|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
34100630|NCT06691763|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A one-group pretest-posttest design, incorporating two pretest measurements (i.e., a double pretest) to enhance the methodological rigor. Specifically, participants were assessed twice prior to the intervention (using both questionnaires and devices) and once after the intervention.||||
34100631|NCT00420407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100632|NCT03721107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind trial design||t|f|t|f
34100633|NCT00499434|||COHORT||PROSPECTIVE|||||||
34100634|NCT02145663|||CASE_ONLY||PROSPECTIVE|||||||
34100635|NCT05017948|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34100636|NCT02604667|||OTHER||PROSPECTIVE|||||||
34100637|NCT00148538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716035|NCT05803057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There are two stimulating colis with the same shape, color and touch. The one is able to stimulate, the other is able to sham-stimulate. All patients are randomly assigned to use one of the two coils for treatment. Except for the designer, all participant, care provider, investigator, and outcomes assessorthey don not know who used which coil to treatment.|There are two groups of this study. The one is that the patients receive nrTMS stimulation with high-frequency on the thumb-related motor cortex on the lesional hemisphere. The other is that the patients receive nrTMS sham-stimulation with high-frequency on the thumb-related motor cortex on the lesional hemisphere.|t|t|t|t
33716036|NCT05396560|||COHORT||PROSPECTIVE|||||||
33716037|NCT02226406|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940877|NCT01944462|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33940878|NCT04899167|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective, unblinded, Parallel, imaging study||||
33940879|NCT04114266|||COHORT||PROSPECTIVE|||||||
33940880|NCT06120023|||COHORT||PROSPECTIVE|||||||
33940881|NCT00651911|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940882|NCT03433599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33940883|NCT03466528|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a 3- arm randomised, open label, controlled study in a cohort of alcoholic patients admitted through A\&E. Patients will be randomised to concurrent infusion of one of the following:~* Arm 1: IV thiamine~* Arm 2: IV magnesium sulphate followed by delayed IV thiamine~* Arm 3: IV thiamine and IV magnesium sulphate Thiamine will be administered as IV Pabrinex, a compound preparation which also contains B vitamins and vitamin C. Administration of IV Pabrinex is standard care in this patient group and magnesium sulphate is routinely co-administered at Glasgow Royal Infirmary."||||
33940884|NCT00780533|||COHORT||CROSS_SECTIONAL|||||||
33940885|NCT02804581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940886|NCT02670395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019696|NCT01011179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716038|NCT01901198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019697|NCT01455363|NA|SINGLE_GROUP||||NONE||||||
34019698|NCT04346420|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34019699|NCT03512860|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34019700|NCT05177874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019701|NCT01359917|||CASE_CONTROL||PROSPECTIVE|||||||
34019702|NCT04864470|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33716039|NCT02622581|||COHORT||PROSPECTIVE|||||||
33716040|NCT06142045|||CASE_ONLY||CROSS_SECTIONAL|||||||
33716041|NCT03295045|||COHORT||PROSPECTIVE|||||||
33716042|NCT05699798|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33716043|NCT00004814|RANDOMIZED|||TREATMENT||||||||
33716044|NCT03546192|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were enrolled in two age groups: participants aged 18 to 60 years and participants aged 61 years or older.||||
33716045|NCT02181023|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33716046|NCT04037605|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|3 of the 4 conditions are masked by use of identical injections and pills. However one condition (adrenal testis) is not masked. Hence the study is partially masked.|Blood is sampled every 10 minutes from 4 pm to 9 pm for future mathematical deconvolution in order to determine hormone pulse characteristics in response to the clamp conditions.|t|f|t|t
33716047|NCT03140644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716048|NCT00438113|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Label|||||
33716049|NCT02758899|||COHORT||PROSPECTIVE|||||||
33716050|NCT01431560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716051|NCT02655562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716052|NCT04911530|||COHORT||PROSPECTIVE|||||||
33716053|NCT00742001|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33716054|NCT05989126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716055|NCT02354079|NA|SINGLE_GROUP||OTHER||NONE||||||
33716056|NCT01221883|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33716057|NCT01784640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716058|NCT03273374|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention: intraoperative radiotherapy||||
33716059|NCT01996982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716060|NCT00856284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716061|NCT05000177|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33716062|NCT04104412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716063|NCT04174833|||COHORT||PROSPECTIVE|||||||
33716064|NCT05816512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single (participant)||t|t|t|f
33716065|NCT03338855|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33716066|NCT05891314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716067|NCT05558163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who will undergo scrotal approach will be compared with a case-matched of patients who underwent PPI through peno-scrotal approach in our institution during the last 5 years.||||
33716068|NCT06255314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716069|NCT03577353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716070|NCT05423236|||CASE_ONLY||RETROSPECTIVE|||||||
33716071|NCT01643655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716072|NCT06197854|||COHORT||PROSPECTIVE|||||||
33716073|NCT03721601|||CASE_CONTROL||PROSPECTIVE|||||||
33716074|NCT03980106|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33716075|NCT04406233|||COHORT||PROSPECTIVE|||||||
33716076|NCT03398395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716077|NCT00371423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940887|NCT05167955|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomized controlled waitlist (N= 34 experimental and n=34 waitlist)||||
33940888|NCT02363699|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33940889|NCT02770872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33940890|NCT00522652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940891|NCT02908945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940892|NCT00396266|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940893|NCT00956046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940894|NCT02744963|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33940895|NCT00504595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019703|NCT05037214|||COHORT||CROSS_SECTIONAL|||||||
34019704|NCT06299124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019705|NCT02077439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019706|NCT06406270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019707|NCT03670264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34019708|NCT02565173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019709|NCT02114476|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34100638|NCT03967574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants and assessors were blind to the assignment of the treatment vs placebo group, while there was no feasible way to conceal the control group.~Participants from the treatment and placebo group received the tDCS intervention by a care provider not involved in the recruitment, data collection or outcome assessment. The tDCS apparatus was out of sight of the participant for the duration of the treatment. Treatment patients received tDCS treatment for the whole duration of the planned intervention (20 minutes), while the device was only turned on for 30 seconds, then gradually turned off for the participants in the placebo group. This was done in order to mimic the initial sensation of tingling felt by participants in the treatment group."|"All participants received a subacromial corticosteroid injection.~Two weeks following the injection, participants were randomized into 3 groups:~* Anodal transcranial direct current stimulation (treatment group)~* Placebo tDCS (placebo group)~* No further intervention (control group)"|t|f|t|t
34019710|NCT05182255|||COHORT||RETROSPECTIVE|||||||
34019711|NCT00003708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019712|NCT03551496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A review of the wound assessment data will be completed by independent reviewer(s) who will be blinded to the randomized therapy.|Approximately 201 subjects will be randomized in a 2:1 fashion for phase A RCT. Randomizations will be stratified by investigational center and lesion length with 2 subjects receiving the DES BTK for every 1 subject receiving treatment with standard PTA.|f|f|f|t
34019713|NCT01858974|||CASE_ONLY||PROSPECTIVE|||||||
34019714|NCT02452541|NA|SINGLE_GROUP||||NONE||||||
34019715|NCT00674557|RANDOMIZED|||TREATMENT||NONE||||||
33716078|NCT04242303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The evaluation of the results obtained will be carried out blindly by an examiner with adequate clinical skills to carry out the evaluation and who does not take part in the operational phases of the study.|The patients will be divided into 2 groups, based on the alignment technique used Total number of patients involved: 180 (90 Group A Patients: EM Technique), (90 Group B Patients: IM Technique) Total number of centers involved: 3 Patients per Center: 30 Group A Patients, 30 Group B Patients|f|f|f|t
33716079|NCT02957877|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716080|NCT05485597|NA|SINGLE_GROUP||OTHER||NONE||The proposed trial is designed as an open-label, non-randomized interventional study.||||
33716081|NCT01314443|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33716082|NCT02042885|NON_RANDOMIZED|||TREATMENT||NONE||||||
33716083|NCT00147888|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716084|NCT00793403|||COHORT||PROSPECTIVE|||||||
33716085|NCT02467010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716086|NCT00290368|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33716087|NCT06378567|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Parallel Assignment|t|f|t|t
33716088|NCT05127005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940896|NCT05228236|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33940897|NCT02381795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940898|NCT02145429|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33940899|NCT02008981|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33940900|NCT03188003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33940901|NCT00078715|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33940902|NCT00469443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940903|NCT05892406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940904|NCT01335659|||COHORT||RETROSPECTIVE|||||||
33940905|NCT00424463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940906|NCT03068182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|by a blinded and independent research assistant who opened sealed envelopes that contained a computer-generated randomization card|Parallel assignments|t|f|t|f
33940907|NCT00001658||||TREATMENT||||||||
33940908|NCT05934929|NA|SINGLE_GROUP||OTHER||NONE||||||
33940909|NCT01064973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940910|NCT00436085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940911|NCT01909635|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
33940912|NCT06218238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Using a cross-over experimental design, 20 unilateral, transfemoral amputee subjects (10 men and 10 women) will be evaluated in the Jesse Brown VAMC Motion Analysis Research Laboratory (MARL) while wearing the Ossur Power Knee and Ossur Rheo XC. Subjects will be provided a one-month accommodation period wearing each prosthetic knee prior to testing. Prosthetic foot type will be standardized for subjects so they will walk with the same foot while testing each prosthetic knee joint.||||
33940913|NCT02940158|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33940914|NCT02403089|||OTHER||PROSPECTIVE|||||||
34019716|NCT04112173|NA|SINGLE_GROUP||TREATMENT||NONE||single-group, observational study||||
34019717|NCT00845819|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34019718|NCT02245022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019719|NCT03107026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34019720|NCT02774096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019721|NCT01108211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716089|NCT05381116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33716090|NCT02643082|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33716091|NCT03108833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716092|NCT00680667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716093|NCT02050360|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33716094|NCT05879861|||COHORT||RETROSPECTIVE|||||||
33716095|NCT05798949|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Sequential replicated randomized single-case experimental-design|f|f|t|f
33716096|NCT02468544|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33716097|NCT01698801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716098|NCT03441854|||CASE_CONTROL||PROSPECTIVE|||||||
33716099|NCT01627522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716100|NCT02475720|||COHORT||RETROSPECTIVE|||||||
33716101|NCT05984732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33716102|NCT05687591|||CASE_ONLY||OTHER|||||||
33716103|NCT03599024|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither the investigators nor the patients were blinded in the study.|The patients were randomized into two groups with two distinct interventions - patient-controlled analgesia vs. conventional analgesia prescribed by the attending physician.||||
33716104|NCT01943292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716105|NCT04140851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||this study enrolled 12 patients with simple overweight or obesity, including 9 males and 3 females. In addition, 20 patients with simple overweight or obesity were randomly selected by comparable age and gender to the control group (excluding criteria), including 11 males and 9 females, and another 20 healthy people were recruited to the healthy control group.|f|t|t|t
33716106|NCT00491998|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33716107|NCT04488900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716108|NCT03942627|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33716109|NCT05526495|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Eligible hospitals (cluster) within the 26-100th centile for routine preoperative tests will be parallel randomized into two study arms.||||
33716110|NCT03117101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716111|NCT06101979|||COHORT||PROSPECTIVE|||||||
33716112|NCT06057168|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33716113|NCT01246414|||COHORT||CROSS_SECTIONAL|||||||
33716114|NCT00258245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716115|NCT04111484|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Study participants and investigator will be blinded.||t|f|t|f
33716116|NCT02064894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716117|NCT06036667|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34019722|NCT04790838|||OTHER||RETROSPECTIVE|||||||
34019723|NCT02715544|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019724|NCT03898518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||exercise intervention group, control group||||
34019725|NCT02384330|||CASE_ONLY||OTHER|||||||
34019726|NCT02433054|||CASE_ONLY||PROSPECTIVE|||||||
34019727|NCT06207214|NA|SINGLE_GROUP||OTHER||NONE||||||
34019728|NCT00367549|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019729|NCT00725205|||COHORT||PROSPECTIVE|||||||
34019730|NCT00759135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019731|NCT03830827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019732|NCT00920517|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34019733|NCT02008786|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33716118|NCT04285879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigators will compare the use of exercises augmented with BFR with quantitative measurements of strength and patient reported outcomes. A total of 20 youth and adolescent patients undergoing a surgical procedure for ACL reconstruction at Connecticut Children's Elite Sports Medicine and completing physical therapy at Connecticut Children's Sports Physical Therapy will be recruited for this study. A review of data from 20 previous patients, matched for age, sex, BMI and surgical procedure that completed physical therapy at Connecticut Children's Sports Physical Therapy will be used as a comparison.~As part of this pilot study, the investigators will additionally collect prospective controls. This population will be patients not participating in physical therapy at Connecticut Children's but underwent ACL reconstruction by Elite Sports Medicine."||||
33716119|NCT00592839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716120|NCT03757689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716121|NCT01733771|||COHORT||PROSPECTIVE|||||||
33716122|NCT01506427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716123|NCT01012960|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33716124|NCT04920370|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34019734|NCT03688438|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two study arms: (1) Standard of Care and (2) WoundVac||||
34019735|NCT03476369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019736|NCT00217126|||COHORT||PROSPECTIVE|||||||
34019737|NCT03336177|||OTHER||PROSPECTIVE|||||||
34019738|NCT00002639||||TREATMENT||||||||
34019739|NCT04677881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019740|NCT03276065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019741|NCT00276822|NA|SINGLE_GROUP||||NONE||||||
34019742|NCT05268263|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019743|NCT04902625|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trail||||
34019744|NCT00004218|RANDOMIZED|||TREATMENT||||||||
34019745|NCT02477163|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post design||||
34019746|NCT05889468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|1:1 fashion to aspirin 81 mg vs identical-appearing placebo to be continued for 6 weeks' postpartum. Patients will receive these medications prior to hospital discharge. Both the patient and provider will be blinded to their assigned group. NT-proBNP levels will be drawn at the 4-6-week postpartum visit. NT-proBNP levels will be compared between groups.|Treatment Arm vs Placebo Arm|t|f|t|f
34019747|NCT01475058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019748|NCT06300814|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34019749|NCT01409161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019750|NCT03542955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019751|NCT06050473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants blinded to the cohort they are randomized to (i.e., nerve-sparing group vs nerve-sacrificing group). Care providers were blinded to the randomization and made aware of the patient's cohort just prior to surgery.||t|f|f|f
33716125|NCT05205733|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are assigned to complete either a mail-in or in-clinic semen analysis.||||
33716126|NCT00518986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716127|NCT03374878|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross sectional study with 16 in each group.||||
33716128|NCT05066594|||CASE_ONLY||PROSPECTIVE|||||||
33716129|NCT01961388|||COHORT||PROSPECTIVE|||||||
33716130|NCT06395454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"In a parallel group design, participants are randomized to two groups (PCT guided versus Non PCT guided (standard of care).~Each group receives a different intervention (e.g., pct vs crp, tw, blood culture, temperature and clinical).~The groups are compared to assess the effectiveness of the interventions."|t|f|f|f
33716131|NCT02388204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716132|NCT00005610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716133|NCT05104892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716134|NCT00516204|||COHORT||PROSPECTIVE|||||||
33716135|NCT01331200|||CASE_CONTROL||PROSPECTIVE|||||||
33716136|NCT04907721|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33716137|NCT06494839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716138|NCT00446290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716139|NCT00150722|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33716140|NCT05001685|||CASE_ONLY||RETROSPECTIVE|||||||
33716141|NCT00296374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716142|NCT03111901|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33716143|NCT04542655|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Participants will be randomized to an order of exercise-intervention: cycling, running. This will be followed by a resting intervention. Interventions are planned 1 week apart.~Blood will be sampled before, immediately after and again at 1, 2, 3 and 24 hours after intervention start. Spot urine is sampled before, after and the next day."||||
33716144|NCT03853395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716145|NCT00711854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716146|NCT04035681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33716147|NCT04316754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33716148|NCT05864495|||COHORT||PROSPECTIVE|||||||
34019752|NCT01653561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019753|NCT05367518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A staff member not part of the study group will be assigned to distribute blinded samples. The participant or the investigators will not be aware of the dose groups.|"Participants will be randomly assigned to one of the 2 groups consuming Fast Melt powder containing two different doses of Streptococcus salivarius K12 :~Group A: Probiotic Streptococcus salivarius K12 Fast Melt Powder (Dose 1: 1 Billion colony forming unit/gram) Group B: Streptococcus salivarius K12 Fast Melt Powder (Dose 2: 100 Million colony forming unit/gram)"|t|f|t|f
34019754|NCT00682682|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34019755|NCT04243434|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019756|NCT02440113|||COHORT||RETROSPECTIVE|||||||
34019757|NCT03686449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019758|NCT05918224|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019759|NCT05344248|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34019760|NCT01331226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019761|NCT05873010|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34019762|NCT03401359||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33716149|NCT05855850|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|This is an open label trial. Only study staff processing and analyzing the data will be fully blinded.|This investigation is a one-way two-group between-subjects open-label design||||
33716150|NCT00010374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716151|NCT01094223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716152|NCT06154785|||COHORT||PROSPECTIVE|||||||
33716153|NCT06224101|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33716154|NCT00556712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716155|NCT06184815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|The standard educational and treatment program consists of outpatient management and education in the office and consultation referral to nutrition and psychology with a duration of 4 months.|The educational programme consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months. The multidisciplinary treatment consists of 4, each one every month, consultations of specialties of nutrition, endocinrology and psychology.||||
33716156|NCT04960150|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33716157|NCT04542772|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34019763|NCT00826449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019764|NCT03276221|RANDOMIZED|PARALLEL||OTHER||NONE||Cannabis users are randomized either to 30 days of cannabis abstinence or 30 days of monitoring with no abstinence requirement. Non-users are not randomized.||||
34019765|NCT01775852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019766|NCT04498403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019767|NCT01062997|||CASE_CONTROL||PROSPECTIVE|||||||
34019768|NCT04141475|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34019769|NCT02637635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019770|NCT02591732|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34019771|NCT04464590|||COHORT||RETROSPECTIVE|||||||
34019772|NCT00131378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019773|NCT01792219|NA|SINGLE_GROUP||||NONE||||||
34019774|NCT00476554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019775|NCT00000583|RANDOMIZED|||PREVENTION||DOUBLE||||||
34019776|NCT05935241|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34100639|NCT00572481|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.||||
34100640|NCT04769986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34019777|NCT05842421|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|participant and investigator, who does the clinical examination and planning of surgery are not blinded, but surgeons and pathologists are blinded to the groups|randomized, controlled, unicentric study||||
34019778|NCT01476735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019779|NCT05932992|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcomes assessor and investigator will be masked to intervention. In regards to the intervention, participants and care providers won't be masked.|Randomized controlled trial of mothers being trained to measure MUAC vs standard of care to prevent relapse|f|f|t|t
33940915|NCT03639064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double-blind study. The different cannabis oil formulations have the same colour, taste and smell. Study investigators will be blind to the dose/formulation of cannabis oil. Unblinding will only be performed in the event of a Serious AE. The site PI will maintain a randomization list kept in a locked secure 24h a day accessible location for emergency unblinding.|"This is an interventional, phase II, randomized, open-label, double-blind, two-centre study to evaluate the safety, tolerability, and dose-finding of Cannabis oil preparation for pain in Parkinson's disease.~Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20. A total of 15 patients will be block randomized to one of the three groups. Each patient will receive one formulation of CanniMed® Oil only, with 5 patients per group."|t|f|t|t
33716158|NCT01144923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716159|NCT06205004|||COHORT||CROSS_SECTIONAL|||||||
33716160|NCT02336711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716161|NCT03661632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940916|NCT03202641|NA|SINGLE_GROUP||TREATMENT||NONE||Physiologic crossover study. There is no randomization.||||
33940917|NCT05237713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940918|NCT02086760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100641|NCT01652105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33716162|NCT05736744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The dose of the administered muscle relaxants will be given by an investigator not included in the study.|To compare the effect of magnesium sulphate pretreatment on the onset and duration of intense and deep neuromuscular Block of rocuronium versus Cis-Atracurium and on the period of no response to nerve stimulation in children undergoing elective laparoscopic surgeries.|t|f|t|t
33716163|NCT03069053|||COHORT||OTHER|||||||
33716164|NCT03032094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716165|NCT02150798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716166|NCT03935529|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Multiple Single Case Experimental Design||||
33716167|NCT00439842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33716168|NCT04955522|||CASE_CONTROL||RETROSPECTIVE|||||||
33716169|NCT03339960|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33716170|NCT01385202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940919|NCT06356649|||CASE_ONLY||PROSPECTIVE|||||||
33940920|NCT02399189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940921|NCT02768636|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940922|NCT00840684|NON_RANDOMIZED|||TREATMENT||NONE||||||
33940923|NCT00592644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940924|NCT04880499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33940925|NCT04030806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940926|NCT00799370|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940927|NCT04378049|RANDOMIZED|PARALLEL||TREATMENT||NONE|Surgeons cannot be blinded to treatment group. It would not be feasible to blind the health care team and patients because the incisions and imaging are visually distinguishable. We will attempt to minimize bias in subjective measures by presenting patients with balanced information on each treatment group prior to the trial. All participants will receive a computed tomography (CT) scan prior to surgery to maintain blinding and to give surgeons additional information about 3 dimensional modelling for implant placement. Data analysts will be blinded to treatment allocation. An independent outcomes assessor will independently review radiographic alignment for each patient and review relatedness of adverse events and re-operations. The independent assessor cannot be blinded because imaging is visually distinguishable.|||||
34100642|NCT06549725|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The laboratory personnel performing the lipidomic testing and using the investigated medical device software will be blinded to the allocation of the participants/ samples.|Arm 1: Histologically confirmed diagnosis of resectable Pancreatic cancer Arm 2: Participants without PaC but at higher risk of Pancreatic cancer disease due to their predispositions|f|f|f|t
33716171|NCT05628454|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The operator knows which puncture technique to be used, but the subject and the outcomes assessor does not know the technique.||t|f|f|t
33716172|NCT06314542|||COHORT||RETROSPECTIVE|||||||
33716173|NCT03227029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716174|NCT01442233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716175|NCT05919433|||CASE_ONLY||OTHER|||||||
33716176|NCT04391244|||COHORT||PROSPECTIVE|||||||
33716177|NCT01329731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716178|NCT04342364|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|embryologist assessing oocyte survival (primary outcome) is blinded|Randomized Controlled Trial in a paired design|f|f|f|t
33716179|NCT04766580|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The participants think they are taking two medications (if not in the control group), but the care provider and investigators know that only placebos (a placebo and a nocebo) are given."|"All the participants will take two medications (which are all placebos). The order of the medications are randomized."|t|f|f|f
33716180|NCT05049551|||OTHER||RETROSPECTIVE|||||||
33716181|NCT04655274|||COHORT||PROSPECTIVE|||||||
33716182|NCT05567692|||COHORT||PROSPECTIVE|||||||
33940928|NCT01833299|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the radiologists who assessed the outcomes were blinded.||f|f|f|t
33940929|NCT00297284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940930|NCT04084444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940931|NCT05040867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33940932|NCT05774886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940933|NCT01904760|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33940934|NCT00882544|||COHORT||PROSPECTIVE|||||||
33940935|NCT03673631|||COHORT||PROSPECTIVE|||||||
33940936|NCT02905344|||||PROSPECTIVE|||||||
33940937|NCT02271620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33940938|NCT05179564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716183|NCT03398681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Because ferric carboxymaltose is a dark-brown solution that is easily distinguishable from the saline placebo, study personnel responsible for the preparation and administration of the study drug will aware of the group assignments and therefore, not involved in any study assessments. To ensure that patients will be unaware of the study drug, materials used in drug administration will be covered with aluminum foil or other opaque material and the injection site shield from the patient view. Once treatment is allocated, the investigators team will ensure that patients are blinded to the treatment received.|After providing informed consent, patients will be randomly assigned, with a remote, web-based computer-generated block randomization procedure in an allocation 1:1 ratio, to either receive intravenous ferric carboxymaltose (FCM) or placebo. Intramyocardial iron will be evaluated at 3 time points: before administration of CMF/placebo, and at 7 and 30 days. At 30 days, patients assigned to placebo will receive intravenous CMF if iron deficiency persists.|t|t|t|f
33940939|NCT01539720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940940|NCT04932915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940941|NCT04778696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be masked to treatment arm. Investigator performing statistical analysis and adjudicating outcomes will be masked to treatment arm|1:1 simple randomisation|t|f|t|f
33940942|NCT04646720|||COHORT||PROSPECTIVE|||||||
33940943|NCT00159146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33940944|NCT00681772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940945|NCT00973466|||COHORT||PROSPECTIVE|||||||
33940946|NCT04996342|||COHORT||PROSPECTIVE|||||||
33940947|NCT05472506|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study|Randomized 1:1 to Cohort 1 or Cohort 2||||
34019780|NCT04483635|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The Laboratoires Riva will provide the active vitamin D3 and placebo pills, identical in appearance, which will be pre-packaged in coded 60-pill bottles. A web-based randomisation system will allow the research personnel (RP) to log in, obtain a randomization number, and dispense study drugs, pre-prepared by the Central pharmacy, in masked kits.|Parallel-group, placebo controlled trial of vitamin D3 supplementation|t|t|t|t
34019781|NCT03587389|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33940948|NCT01632527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019782|NCT05154630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940949|NCT00363181|||||PROSPECTIVE|||||||
33940950|NCT00481949|||CASE_CONTROL||PROSPECTIVE|||||||
33940951|NCT00796172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33940952|NCT03704233|||CASE_ONLY||PROSPECTIVE|||||||
33940953|NCT01196793|||COHORT||PROSPECTIVE|||||||
33940954|NCT05278611|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33940955|NCT03708029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019783|NCT04713553|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34019784|NCT01752647|NA|SINGLE_GROUP||SCREENING||NONE||||||
34019785|NCT05778552|||COHORT||PROSPECTIVE|||||||
34100643|NCT01658878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940956|NCT05853172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940957|NCT02094781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33940958|NCT01978548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716184|NCT00823394|||CASE_CONTROL||PROSPECTIVE|||||||
33940959|NCT01192893|||COHORT||RETROSPECTIVE|||||||
33940960|NCT01066338|||CASE_ONLY||RETROSPECTIVE|||||||
33940961|NCT00497744|||CASE_ONLY||PROSPECTIVE|||||||
33940962|NCT06043895|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The care providers (conducting physicians) and the research assistants who observe and record the results will know the assignments, while the participants and data analysts will not know the assignments.||t|f|t|f
33940963|NCT00842504|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33940964|NCT00837889|||CASE_CONTROL||PROSPECTIVE|||||||
33940965|NCT03428230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The study will be double-blind. Neither the Investigator/co-investigators/study nurses involved in the clinical study procedures, nor will the patients be aware of the administered treatment. At the site, syringes for injection will then be prepared by a person not involved in any other study-related activities where a bias is possible.|Eligible patients will be randomised into four treatment groups (15 patients/group) to receive either one of the three single doses of Paracetamol 3% (30 mg, 60 mg, 90 mg) or placebo solution (1 mL, 2 mL, 3 mL) according to the randomised, parallel-group design.|t|f|t|t
33940966|NCT01521494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33940967|NCT04061018|||COHORT||CROSS_SECTIONAL|||||||
33940968|NCT02205229|||COHORT||PROSPECTIVE|||||||
33940969|NCT05926011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||An interventional, prospective, multicentric, randomized, comparative and double-blinded pivotal clinical investigation|t|t|t|t
33940970|NCT02752178|||CASE_CONTROL||PROSPECTIVE|||||||
33940971|NCT04346368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33940972|NCT04185194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sealed envelopes|randomized control trial|t|f|f|f
33940973|NCT00863031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940974|NCT06449456|||OTHER||PROSPECTIVE|||||||
33940975|NCT05869240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019786|NCT04043130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019787|NCT00239044|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33796532|NCT05658406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Patients will be prospectively and randomly assigned to one of the four groups (25 in each group). Random sequence generation and allocation concealment will be done using Computer-generated randomization. Supplemental crystalloid administration started after induction of anaesthesia (intraoperatively), in addition to standard fluid management. Patients will be divided into 4 groups:~1. Group A: intraoperative infusion of 15 mL/kg/hour Ringer's lactate.~2. Group B: intraoperative infusion of 10 mL/kg/hour Ringer's lactate.~3. Group C: intraoperative infusion of 6 mL/kg/hour Ringer's lactate.~4. Group D: standard fluid management alone."|t|f|f|f
34019788|NCT02908282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34019789|NCT00497952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019790|NCT00505375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33796533|NCT05702515|||CASE_ONLY||PROSPECTIVE|||||||
34019791|NCT00259168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019792|NCT05344430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34019793|NCT03476863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34019794|NCT05680935|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019795|NCT02955017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019796|NCT03972202|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33796534|NCT02186197|||CASE_ONLY||PROSPECTIVE|||||||
33796535|NCT06123208|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33796536|NCT01547403|||COHORT||PROSPECTIVE|||||||
33796537|NCT03995498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796538|NCT00190931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796539|NCT04393233|||COHORT||PROSPECTIVE|||||||
33796540|NCT05662917|||COHORT||PROSPECTIVE|||||||
33796541|NCT06676761|||COHORT||OTHER|||||||
33796542|NCT04959136|NA|SINGLE_GROUP||OTHER||NONE||||||
33796543|NCT02174393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796544|NCT02564757|||COHORT||RETROSPECTIVE|||||||
34019797|NCT00601874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34019798|NCT06291350|||OTHER||PROSPECTIVE|||||||
34019799|NCT01088802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019800|NCT01936623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019801|NCT01597466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019802|NCT00045669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019803|NCT05424874|||OTHER||RETROSPECTIVE|||||||
34019804|NCT03596892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796545|NCT03621826|||CASE_CONTROL||OTHER|||||||
33796546|NCT05033938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796547|NCT03339024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796548|NCT02971085|||COHORT||PROSPECTIVE|||||||
33796549|NCT05172388|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33796550|NCT02100371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019805|NCT05861336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019806|NCT02131597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019807|NCT06319937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796551|NCT05261061|||COHORT||RETROSPECTIVE|||||||
33796552|NCT02709655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796553|NCT01244113|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33796554|NCT05308381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and Researchers will be blinded to the interventions.||t|f|t|f
33796555|NCT06039046|||CASE_CROSSOVER||PROSPECTIVE|||||||
33796556|NCT03767907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796557|NCT02817334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796558|NCT06373744|||COHORT||RETROSPECTIVE|||||||
33796559|NCT04930718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33796560|NCT02343211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796561|NCT04711213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Masked randomized study|Randomized to 2 active dosing groups and 2 corresponding dosing groups|t|f|f|f
33796562|NCT05780827|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796563|NCT06131268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796564|NCT02986269|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33796565|NCT06006806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The goal of this study is to measure skin reactions during proton therapy for 100 patients over a period of three years.||||
33796566|NCT03982303|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|open-label|||||
33796567|NCT06397963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796568|NCT03516435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796569|NCT06324240|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019808|NCT00562575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019809|NCT01930955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019810|NCT03202979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The present study will be performed in double blind conditions. During the study, neither the Investigator nor the patient will be aware of the treatment assigned.|Double-blind, placebo controlled, double-dummy, dose finding, multicentre, international, prospective, pilot study.|t|f|t|f
33796570|NCT04395235||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33796571|NCT06676787|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking|The interventions for each arm were selected based on findings from a feasibility evaluation conducted with national and sub-national stakeholders. This evaluation considered the local context of immunisation challenges and identified incentives that have broad stakeholder support across the Expanded Programme on Immunization (EPI) and the community.||||
33796572|NCT03619616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple(Participant, Investigator, Clinical Research Associate)||t|t|t|t
33796573|NCT05004402|||COHORT||PROSPECTIVE|||||||
33796574|NCT00979992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796575|NCT01038011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796576|NCT03078634|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33796577|NCT05789771|||COHORT||RETROSPECTIVE|||||||
33796578|NCT01824030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796579|NCT06023186|||CASE_ONLY||PROSPECTIVE|||||||
33796580|NCT02006017|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33796581|NCT01759771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33796582|NCT00425152||||TREATMENT||||||||
33940976|NCT01302535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940977|NCT02321163|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33940978|NCT03185637|||COHORT||PROSPECTIVE|||||||
33940979|NCT01222767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940980|NCT00124384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33940981|NCT02046213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33940982|NCT04439708|||OTHER||PROSPECTIVE|||||||
33940983|NCT03906006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940984|NCT00201565|||DEFINED_POPULATION||OTHER|||||||
33940985|NCT05739890|||COHORT||OTHER|||||||
33940986|NCT01322711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940987|NCT01772017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940988|NCT01468389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33940989|NCT03958695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940990|NCT04477018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants will receive either iron and vitamin C, iron alone or placebo for a period of 16 weeks to consume daily|t|f|t|t
33940991|NCT01013636|||CASE_ONLY||PROSPECTIVE|||||||
33940992|NCT05972668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33940993|NCT02196389|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33940994|NCT02481440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33940995|NCT04529525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33940996|NCT01985152|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33940997|NCT02311634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33940998|NCT03715036|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33940999|NCT03523390|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subsequent cohorts of subjects treated at different dose levels in this study.||||
33941000|NCT05584072|||CASE_ONLY||PROSPECTIVE|||||||
33941001|NCT01853397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941002|NCT02583399|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, Open-label||||
33941003|NCT04417166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941004|NCT01574118|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33941005|NCT01602627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941006|NCT00352794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941007|NCT02963194|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941008|NCT02827773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941009|NCT03917576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power (i.e., load in Watts) achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively). The exercise session was supervised individually by exercise professionals, monitoring the heart rate with a continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland). During the single HIIT session, the HR pre each interval (HR-preINT) and the HR post each interval (HR-postINT) of cycling was recorded individually. In addition, we calculated and report the percentage of maximum heart rate in each interval, delta of HR increment and delta HR recovery for each 10-interval HIIT are reported.|We will compare a type 2 diabetes mellitus group during exercise, with another hyperglicaemic, and normoglicaemic group in the heart rate maxymum.|f|f|t|f
33941010|NCT02994511|||OTHER||PROSPECTIVE|||||||
33941011|NCT01402206|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33941012|NCT04779294|||COHORT||PROSPECTIVE|||||||
33941013|NCT03034746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941014|NCT02612168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941015|NCT05717413|||CASE_CONTROL||RETROSPECTIVE|||||||
33941016|NCT01496924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941017|NCT02220608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941018|NCT00516126|||COHORT||PROSPECTIVE|||||||
33941019|NCT04864197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Third professional person apply PRF membrane.||t|f|t|f
33941020|NCT01203566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941021|NCT02438111|||COHORT||PROSPECTIVE|||||||
33941022|NCT02429076|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33941023|NCT06148025|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and Investigator are blinded to BCG vaccine or placebo.|"Participants are allocated to Substudy 1 (BCG re-challenge) or Substudy 2 (Yellow Fever vaccine) Participants are randomised to receive~* antibiotics or comparator (unblinded) and~* BCG vaccine or placebo (blinded)~* BCG vaccine or Yellow Fever vaccine (unblinded)"|t|f|t|f
33941024|NCT00752518|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33941025|NCT02555527|||COHORT||RETROSPECTIVE|||||||
33941026|NCT01278966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941027|NCT03713242|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||prospective, single-center, open-label, single-dose||||
33941028|NCT05847140|||COHORT||RETROSPECTIVE|||||||
34019811|NCT01196676|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34019812|NCT02636426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019813|NCT00510289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019814|NCT05739214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient didn't know the types of modes of laser applied even in the control group i used light not laser to equalize the blindness|group A received laser therapy in sequential mode, group B received laser therapy in separate mode and the control group C receive conventional wound care treatment|t|f|f|t
34019815|NCT03692390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34019816|NCT06412718|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34019817|NCT02387983|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34019818|NCT04325035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Matching Placebo||t|t|t|f
34019819|NCT01521182|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34019820|NCT01454908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019821|NCT02633488|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34019822|NCT00242619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019823|NCT04752046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019824|NCT05030558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients participating in the study will know that they are in a randomized controlled study, but they will not know which group they are in until the study is completed.|Randomized controlled study|t|f|f|f
34019825|NCT04162132|||COHORT||PROSPECTIVE|||||||
34019826|NCT02053935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019827|NCT02393443|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019828|NCT04202809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019829|NCT02552056|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34019830|NCT03321162|||OTHER||OTHER|||||||
34019831|NCT05325073|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34019832|NCT03482349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019833|NCT00250796|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019834|NCT02731326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34019835|NCT02275130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019836|NCT00080938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019837|NCT05203718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019838|NCT05154435|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The patients who accepted to participate in the study and the doctor who measured the inferior vena cava did not know the groups of the patients.|A total of 60 patients over the age of 65, who were scheduled for proximal femoral surgery due to intertochanteric fracture, and operated with ASA1-3 risk will be included in the study. The patients will be randomized into two groups as Group K (n=30) and Group H (n=30) by the closed envelope method and the patients will not know their groups.|t|t|t|f
34019839|NCT04684004|||CASE_CONTROL||PROSPECTIVE|||||||
34019840|NCT01483469|NON_RANDOMIZED|PARALLEL||||NONE||||||
34019841|NCT03533738|RANDOMIZED|CROSSOVER||OTHER||NONE||randomized crossover design||||
34019842|NCT02648295|||CASE_ONLY||PROSPECTIVE|||||||
34019843|NCT02433262|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34019844|NCT00643136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100644|NCT05836987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Adjudication of safety events will be performed by a Clinical Endpoint Committee made up of blinded assessors. The Data Coordinating Center (DCC) blinded statistician(s) will also be blinded.|Participants randomized (1:1) to the experimental arm (AFSW-guided DOAC) will only take DOAC for 30 consecutive days following a qualifying AF episode (i.e., greater than 1 hour) detected by the participants AFSW if no further AF is detected. Participants randomized to the standard of care arm will remain on continuous DOAC throughout the study.|f|f|f|t
34019845|NCT00090610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019846|NCT06180265|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34019847|NCT04293328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent examiners will be responsible for the assessment of the primary outcomes, which are the axial length and surface coating.|All subjects will be prescribed with monthly replacement orthokeratology for a period of 12 months. They will be randomly assigned to normal cleaning and intensive cleaning groups on 1:1 basis. All subjects follow the same daily cleaning procedures and subjects in intensive cleaning group will be required to perform weekly protein removal in addition to the daily routine.|f|f|f|t
34019848|NCT06348706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019849|NCT02414438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34019850|NCT02524730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019851|NCT03183492|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100645|NCT06292299|||COHORT||PROSPECTIVE|||||||
34100646|NCT01333657|||CASE_ONLY||PROSPECTIVE|||||||
34100647|NCT05558670|||COHORT||PROSPECTIVE|||||||
34100648|NCT04895358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716185|NCT04327557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There is no mention of MBCP as an option for childbirth education classes in the consent form or recruitment materials, but participants who are randomized to the MBCP group do find out that they are in the MBCP group.|Participants are randomized to either MBCP childbirth education course or a non-MBCP childbirth course to look at effects of different types of childbirth education.|t|f|f|f
33716186|NCT02656979|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33716187|NCT03394807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded|Prospective, randomised, placebo controlled trial|t|t|t|t
33716188|NCT03763591|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716189|NCT05277714|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|sham procedure||t|f|f|f
33716190|NCT05713721|||OTHER||PROSPECTIVE|||||||
33716191|NCT04549506|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33716192|NCT03900078|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT with two therapy arms.||||
33716193|NCT03846011|||COHORT||PROSPECTIVE|||||||
33716194|NCT00940420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716195|NCT01279278|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33716196|NCT05398562|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33716197|NCT00398060|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33716198|NCT04271891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716199|NCT00286169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716200|NCT02159014|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33716201|NCT01960244|||COHORT||PROSPECTIVE|||||||
33716202|NCT02510859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716203|NCT01252108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716204|NCT02590848|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716205|NCT02814851|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716206|NCT04058145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716207|NCT00923598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716208|NCT05877833|||CASE_ONLY||PROSPECTIVE|||||||
33716209|NCT02281461|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716210|NCT01708733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33716211|NCT02024633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716212|NCT01948050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716213|NCT02921854|NA|SINGLE_GROUP||OTHER||NONE||||||
33716214|NCT05496387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigator did not collect pre-and post- neuromobilization techniques data and the patients were not aware of whether they had been allocated to tension or sliding group. Participants' evaluation and interventions were performed by different investigator. Participants were trained at different places.|A prospective, randomized, controlled, double-blinded study|t|f|t|t
33716215|NCT05948254|NA|SINGLE_GROUP||TREATMENT||NONE||Triple Function Scan Body||||
33716216|NCT01220323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716217|NCT06504225|||CASE_ONLY||RETROSPECTIVE|||||||
33716218|NCT02482623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33716219|NCT05151484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716220|NCT02485574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716221|NCT06190639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716222|NCT04776499|NA|SINGLE_GROUP||OTHER||NONE||Evaluation of a potential synergistic blood pressure effect after administration of propylthiouracil, riociguat, and perphenazine||||
33716223|NCT05652946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked/blinded outpatient therapists will perform outcome assessments.|One group receives inpatient rehabilitation with advanced rehabilitation technology and one group receives inpatient traditional rehabilitation without advanced rehabilitation technology.|f|f|f|t
33716224|NCT04171778|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The initial phase of the study will be a three month randomized clinical trial of a whole food plant based nutrition program vs. usual care in patients with chronic kidney disease. Subjects randomized to the intervention arm will start the nutrition program as soon as they are able.~Subjects assigned to the control arm will be placed on a 'wait-list' to start the nutrition program after they undergo three months of testing during their usual care, which consists of routine CKD care as directed by their primary nephrologist. After a 3 month 'wait', they will start the same plant-based nutrition program as the intervention arm subjects.~Both experimental and control group subjects will be followed for a total of 9 months after starting the plant-based dietary intervention. Thus, in addition to the 3-month randomized control trial, there will be data from a 9-month single arm clinical intervention."||||
33720923|NCT04922983|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Participants will understand they may receive placebo, and that they will not be told Investigators will know whether they give injections or not, but will not know if injection is placebo.~Outcomes assessors will be blinded to the entire procedure (radiologists reading X-rays)."|Three groups: Group I: Placebo isometric measure, no injection Group II True isometric exercise, placebo injection Group III: True isometric exercise, botulinum injection|t|t|t|t
33941029|NCT05220020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941030|NCT02424136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941031|NCT06070831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The professional that collected the data and the participants were unaware of group assignment.||t|t|t|f
33941032|NCT01143818|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33941033|NCT00028015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941034|NCT01281592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941035|NCT02798159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941036|NCT00496145|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941037|NCT03718728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100649|NCT01942980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716225|NCT04012385|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A specific alphanumeric code is assigned to each participant|"Primary purpose of the study is the improvement of semen quality in healthy young men living in highly polluted areas, operating on two specific lifestyle factors, that are nutrition and physical activity. Overall, 450 subjects will be enrolled (150 for single recruiting area) and they will be assigned by chance to one of the two arms of the study, named Control group and Intervention group. Every subject is identified by means of an individual alphanumeric code that does not specifies which group they belong to, in order to mask to all the outcomes assessors the membership to one arm or another."|f|f|f|t
33716226|NCT04067895|||COHORT||PROSPECTIVE|||||||
33716227|NCT04570150|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33716228|NCT04411875|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33716229|NCT00186381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716230|NCT04184869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials||||
33716231|NCT01964703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716232|NCT04062175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33716233|NCT00306605|||OTHER||PROSPECTIVE|||||||
33716234|NCT00003204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716235|NCT05894629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33716236|NCT06508125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716237|NCT05781607|||COHORT||RETROSPECTIVE|||||||
33716238|NCT00840346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716239|NCT00523003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716240|NCT00783250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716241|NCT04256070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33716242|NCT00110149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716243|NCT02520076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716244|NCT01437046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716245|NCT04602455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33716246|NCT01274754|||COHORT||PROSPECTIVE|||||||
33716247|NCT06472635|||CASE_CONTROL||RETROSPECTIVE|||||||
33716248|NCT01852110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716249|NCT01957553|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33716250|NCT00492661|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716251|NCT00192205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796583|NCT05389436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this study the patient, surgeon and care providers can not be blinded. The outcome assessor will be blinded with regards to the two treatment groups.|This study is a single center, prospective, assessor-blinded, randomized independent clinical trial|f|f|f|t
33796584|NCT00145314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796585|NCT00982098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796586|NCT02120599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796587|NCT02041039|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941038|NCT03010358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941039|NCT01442961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941040|NCT00171691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941041|NCT04997629|||COHORT||RETROSPECTIVE|||||||
33941042|NCT00982111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941043|NCT00710489|||OTHER||OTHER|||||||
33941044|NCT01196065|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33941045|NCT00758394|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33941046|NCT00377221|||||PROSPECTIVE|||||||
33941047|NCT03315416|||COHORT||OTHER|||||||
33941048|NCT03672721|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study of combined intraarterial carboplatin + radiotherapy. Total number of 6 arms, 5 patients per arms plus 5 patients in the arm determined as the NOAEL: arm 1 = 400 mg/m\^2 carbo + 15 Gy; arm 2 = 400 mg/m\^2 carbo + 18 Gy; arm 3 = 400 mg/m\^2 carbo + 20 Gy; arm 4 = 400 mg/m\^2 carbo + 25 Gy; arm 5 = 400 mg/m\^2 carbo + 30 Gy and arm 6 = 400 mg/m\^2 carbo + 35 Gy.||||
33941049|NCT02204267|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941050|NCT04695444|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33941051|NCT02576951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941052|NCT03098992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716252|NCT02507921|||COHORT||CROSS_SECTIONAL|||||||
33716253|NCT03163615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716254|NCT04282993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720924|NCT04718467|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33720925|NCT01910090|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33796588|NCT05500378|NA|SINGLE_GROUP||TREATMENT||NONE||One group design||||
33941053|NCT03163277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941054|NCT02581501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941055|NCT01825759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941056|NCT05327309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33941057|NCT03797742|||CASE_CONTROL||PROSPECTIVE|||||||
33941058|NCT05442827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase one：300mg/400mgSHR7280 tablets were compared with placebo Phase two：SHR7280 monotherapy group, SHR7280 reverse therapy group and placebo group were controlled|t|t|t|t
33941059|NCT02365311|NA|SINGLE_GROUP||||NONE||||||
33941060|NCT02150785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941061|NCT01917799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941062|NCT06464276|||CASE_ONLY||PROSPECTIVE|||||||
33941063|NCT05994664|RANDOMIZED|PARALLEL||OTHER||NONE||Trial will have two parallel groups and randomization will be performed at a 1:1 allocation.||||
33941064|NCT00303719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941065|NCT03212872|NA|SINGLE_GROUP||SCREENING||NONE||||||
33941066|NCT03965234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941067|NCT00114400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33941068|NCT01540890|||CASE_CONTROL||PROSPECTIVE|||||||
33941069|NCT02400281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941070|NCT05482958|||CASE_CONTROL||PROSPECTIVE|||||||
33941071|NCT04968327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split-mouth|f|f|f|t
33941072|NCT04703712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941073|NCT03782766|RANDOMIZED|PARALLEL||TREATMENT||||"Three models:-~* Split mouth design where piezocision will be performed on the right of left side of the patient in bilateral first molar extraction space subjects.~* comparison between 2 groups of subjects; one group where protraction is done with piezocision and the other group where protraction was done with no piezocision.~* third part where the same side of space receives the 2 interventions. Molar protraction started with no piezocision for 3 months followed by piezocision and protraction for another 3 months,"||||
33941074|NCT02795182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941075|NCT02195895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941076|NCT00115622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019852|NCT03627507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|. Since the test and comparator drugs used in this clinical study have different package of vial, a double blind design is not appropriate. Study investigators along with study staffs involved in safety evaluation and laboratory analysis will be blinded regarding the assigned treatment of the participant. The vaccine administration team will be unblinded to the treatment assignment list. The vaccine administrator team members will not be involved in the evaluation of vaccine safety and laboratory analysis.|Eligible participants will be assigned to receive the Hepa-B Vaccine and Engerix-B Vaccine, in a 1:1 ratio across the target population according to the randomization schedule. The study agents (Hepa B Vaccine or Engerix B Vaccine) will be labelled as per the randomization list.79 participant will receive locally produced Hepa-B Vaccine and 79 participant of comparator group will receive Engerix B Vaccine.|f|f|t|t
33716255|NCT05403125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Test and placebo drugs will be identical in appearance and labeled by the manufacturer as A and B. The biostatistician will generate an assignment list. Individual packets will be prepared, and the clinician will open the packet to determine which study drug to apply. The packets and the drug containers will be color coded to minimize error. In each case a second staff member will verify on site that the participant received the correct coded treatment. Blinding: Participants and the examiners will be blind to treatment.|Randomized Controlled Trial, Intention to Treat|t|t|t|t
33716256|NCT03569553|||COHORT||RETROSPECTIVE|||||||
33716257|NCT02036463|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33716258|NCT01824901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716259|NCT02801240|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34019853|NCT03514849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019854|NCT05352165|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective multicenter multi-arm umbrella clinical study.||||
34019855|NCT06013410|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34019856|NCT05430984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019857|NCT02068664|||COHORT||PROSPECTIVE|||||||
34019858|NCT04251286|||COHORT||CROSS_SECTIONAL|||||||
34019859|NCT04681066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo||t|t|t|t
34019860|NCT00914914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019861|NCT04492826|||CASE_ONLY||RETROSPECTIVE|||||||
34019862|NCT00088621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019863|NCT01305174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019864|NCT00144911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019865|NCT04889144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34019866|NCT02528513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019867|NCT01449097|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34019868|NCT05589532|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
34019869|NCT04166448|||COHORT||PROSPECTIVE|||||||
33716260|NCT03590379|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33716261|NCT03537898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716262|NCT01288469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716263|NCT00001596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716264|NCT02940145|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34019870|NCT03801889|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a multi-center, open-label, dose-escalation study designed to evaluate the safety, tolerability, and iron clearing efficacy of SP 420 administered three-times per week in subjects with transfusion-dependent beta-thalassemia or other rare anemias. Approximately 24 subjects are to be enrolled in 3 cohorts (doses of 28 mg/kg, 56 mg/kg and 84 mg/kg) of approximately 8 subjects each. Based upon the results from lower dose cohorts, if needed the size of latter cohorts may be increased to improve the power of the study to detect efficacy to approximately 74 subjects in total.||||
33716265|NCT02520050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716266|NCT03968484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716267|NCT06374706|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716268|NCT01798004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716269|NCT00740701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33941077|NCT02561026|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941078|NCT02609529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33941079|NCT04126876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Persons that are masked/ blinded for which medication the patient receives: participant, treating physician/ team (including the person giving the intradermal injection) and peron who collects the data.|A Randomized Controlled Phase II Multicenter Clinical Trial|t|t|t|f
33941080|NCT04327245|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|the participant has no knowledge of the intervention assignment|The experimental design was developed 3 times. Each intervention was performed separately for a minimum period of 7 days out and a maximum of 14 days, depending on the availability of the experimental subjects. Cross treatment design (crossover) each women serves as its own control The first intervention corresponded to the control group, in order to maintain the ignorance of the type of sweetener they were receiving, between day 7 or maximum 14 days post-intervention the order of the test of the NNS was reversed. Therefore, during the second or third intervention they were given to drink water with D-tagatose or stevia respectively|t|f|f|f
33941081|NCT04369742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Placebo-controlled, Randomized|t|t|f|f
33941082|NCT04306835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33716270|NCT02356224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941083|NCT01986049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941084|NCT05117580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33941085|NCT04005924|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33941086|NCT06286735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33941087|NCT04841928|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The study uses a 2\^3 factorial design, randomizing participants to 8 experimental conditions||||
33941088|NCT00758316|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941089|NCT06008522|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33941090|NCT06103266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941091|NCT02863003|||COHORT||OTHER|||||||
33941092|NCT04239781|||OTHER||PROSPECTIVE|||||||
33941093|NCT01443039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941094|NCT00381810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941095|NCT03908723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941096|NCT01479816|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33941097|NCT01719718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941098|NCT04131504|||COHORT||PROSPECTIVE|||||||
33941099|NCT05474131|||COHORT||RETROSPECTIVE|||||||
34019871|NCT02901964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34019872|NCT03277235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34019873|NCT00539227|||CASE_CONTROL||PROSPECTIVE|||||||
34019874|NCT03554213|||COHORT||PROSPECTIVE|||||||
34019875|NCT00054912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019876|NCT04791475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019877|NCT00813631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34019878|NCT01965392|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34019879|NCT00134693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019880|NCT04679610|||OTHER||PROSPECTIVE|||||||
34019881|NCT04229459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019882|NCT00246142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019883|NCT04175210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019884|NCT05934240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34019885|NCT04539886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Principal Investigator will select a sub investigator to be the blinded investigator to classify healing characteristics and aesthetic appearance of each subject's selected lesions at baseline and treated lesions post treatment and at 7-days, 30-days, and 60-days following the last CellFX treatment or Electrodessication. This sub investigator will be blinded to the treatment assignment. The subject may not be blinded to the treatment assignment.|Subjects will be randomized to receiving the two treatments in a split-face design with CellFX being used on only one side of the face and Electrodessication on the other side. The randomization assignment will include the type of treatment and which side of the face.|f|f|f|t
34019886|NCT03516396|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Randomized cluster design of households in rural Nepal. Groups will be randomized to receive either: (a) Training Only (livestock management and child nutrition), (b) Training plus enhanced community development activities, or (c) no inputs (Control). After 24 months, groups A and C will receive community development inputs||||
34019887|NCT01008852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100650|NCT01755156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100651|NCT00714363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100652|NCT06372483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Placebo controlled, single dose.|t|t|t|t
34100653|NCT02219451|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33716271|NCT03399591|||COHORT||PROSPECTIVE|||||||
33716272|NCT03153254|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Phase 1: Healthy persons Phase 2: Stroke patients||||
33716273|NCT00319644|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716274|NCT00292695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796589|NCT04426461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Interview-based assessments will be conducted by blinded clinical assessors and participants will be blinded until after completion of all baseline assessments.|Participants will be randomized to behavioral activation, exposure-based, or supportive therapy according to parallel assignment, stratified by sex (male, female) and symptom severity (mild, moderate, severe).|f|f|f|t
34100654|NCT06367894|||COHORT||RETROSPECTIVE|||||||
34100655|NCT05181475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100656|NCT04535479|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100657|NCT04236414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100658|NCT03235492|NA|SINGLE_GROUP||OTHER||NONE||||||
34100659|NCT06089980|||OTHER||PROSPECTIVE|||||||
34100660|NCT04556825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33716275|NCT02667574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716276|NCT04406727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716277|NCT03157258|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33716278|NCT03627429|||OTHER||PROSPECTIVE|||||||
33716279|NCT00229060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33716280|NCT00972569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716281|NCT04557371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluator-blind|The study is a randomized, 3-arm parallel group study.|f|f|t|t
33720926|NCT04718142|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34100661|NCT05265364|||COHORT||PROSPECTIVE|||||||
34100662|NCT05463055|NA|SINGLE_GROUP||TREATMENT||NONE||a clinical study of prospective, single-arm objective performance criteria||||
34100663|NCT06255938|||COHORT||PROSPECTIVE|||||||
34100664|NCT04098744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, study team, and sponsor are blinded to the treatment assignment.||t|f|t|f
34100665|NCT06338267|||COHORT||PROSPECTIVE|||||||
34100666|NCT05587998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100667|NCT06694922|||CASE_ONLY||CROSS_SECTIONAL|||||||
34100668|NCT04160221|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100669|NCT05747027|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study surgeon is providing clinical care to enrolled subjects, thus masking the surgeon to treatment allocation or subject symptoms is not practical or feasible, other than the allocation concealment prior to surgical randomization. Given the surgical procedure requires a transvaginal or abdominal incision, it is clinically not possible to mask the participant or other research personnel.|||||
34100670|NCT04721691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|All study personnel aside from the institution's pharmacist will remain blinded for the duration of this study.|This study aims to assess the efficacy of Epidiolex in patients with ESES. ESES is characterized by sleep potentiated spikes with a spike index greater than 85% (conventional definition) and 50% (new definition). Several drugs including: steroids, intravenous Gama globulin, Clobazam, other benzodiazepines, Valproic acid, and other anti-epileptic drugs have been tried with mixed benefits. Cannabidiol (CBD) would provide a novel mechanism of action to assess for its efficacy in this population4. This will be a double-blind placebo-controlled crossover clinical trial.|t|f|t|f
34100671|NCT02098681|||COHORT||PROSPECTIVE|||||||
34100672|NCT04287647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and other care providers are blinded to whether they receive a transpyloric stent vs sham||t|t|f|f
34100673|NCT02754037|||CASE_ONLY||PROSPECTIVE|||||||
34100674|NCT02907957|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34100675|NCT05235256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100676|NCT06642168|||COHORT||PROSPECTIVE|||||||
34100677|NCT02839733|||CASE_CONTROL||PROSPECTIVE|||||||
33716282|NCT02252094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysis will be blinded.||f|f|f|t
33716283|NCT05237154|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be randomly distributed into 3 groups: the intermittent fasting group (GIF) composed of individuals who will only perform the nutritional intervention for 8 weeks; the physical exercise group (GEX), composed of individuals who will perform only physical training for 8 weeks and the intermittent fasting group associated with physical exercise (GIF+EX), composed of individuals who will perform the nutritional intervention combined with physical training in the period of 8 weeks.|Randomized clinical trial.||||
33716284|NCT02175589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716285|NCT04117984|||OTHER||CROSS_SECTIONAL|||||||
33716286|NCT04300127|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33796590|NCT03472807|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||prospective multicenter study, not therapeutic,||||
33796591|NCT00371085|RANDOMIZED|PARALLEL||||NONE||||||
33716287|NCT01502449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33716288|NCT03506815|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Pilot Trial comparing two groups - Rivaroxaban 10mg po daily for 90 days vs standard of care (usual treatment)||||
33716289|NCT00604539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716290|NCT03852355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To our knowledge the effectiveness of 3rd occipital nerve blocks in managing chronic upper neck pain, headache in RA patients is not measured yet, so we aimed at assessing the the effectiveness of 3rd occipital nerve blocks in headache management in RA patients who used other medical agents and to compare the results with those of the patients who used only 3rd occipital nerve pulsed radiofrequancy on clinical and radiographic bases.|f|f|f|t
33716291|NCT00248989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796592|NCT03207672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796593|NCT01141010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33796594|NCT02852850|||COHORT||PROSPECTIVE|||||||
33796595|NCT02722070|||COHORT||CROSS_SECTIONAL|||||||
34100678|NCT05659251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100679|NCT06691399|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100680|NCT06694649|||CASE_CONTROL||RETROSPECTIVE|||||||
34100681|NCT01972919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100682|NCT02615691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100683|NCT06226415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34100684|NCT00322426|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34100685|NCT02511769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100686|NCT04892173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100687|NCT06695065|||CASE_CONTROL||PROSPECTIVE|||||||
34100688|NCT05748171|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized at 2:1 ratio, so that approximately 67 participants will receive InO and 33 participants will receive the comparator treatment regimen, ALLR3||||
34100689|NCT05256251|||COHORT||PROSPECTIVE|||||||
34100690|NCT06695052|||COHORT||PROSPECTIVE|||||||
34100691|NCT06678854|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34100692|NCT01743703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100693|NCT05980403|||COHORT||OTHER|||||||
34100694|NCT04561609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will not know to which group they belong. They will all receive treatment (study group with CO2, control group with air), the nurse who will prepare the gas for treatment will know the group belonging for the patient. The investigator, who will evaluate neuropathy before and after treatment will not know the group belonging of the patient. At the end, the person evaluating the results will compare results from 2 groups, not knowing which one was study and which control.|The use of transcutaneous application of gaseous CO2 for treatment of diabetic peripheral neuropathy. A double blind clinical trial. Control group receives placebo treatment.|t|f|t|t
34100695|NCT06215118|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100696|NCT05685069|||COHORT||PROSPECTIVE|||||||
34100697|NCT06021522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100698|NCT02955550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941100|NCT01287507|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33941101|NCT03205813|||COHORT||PROSPECTIVE|||||||
33941102|NCT00286234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019888|NCT04190810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know that there exists more than one condition.|Smokers, who just quitted smoking or start with smoking cessation, are randomly assigned to one of three conditions and are tested on three consecutive points in time.|t|f|f|f
34019889|NCT01992523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019890|NCT02836496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019891|NCT01167322|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019892|NCT01400919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019893|NCT04351048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716292|NCT05654753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34019894|NCT02488421|||COHORT||RETROSPECTIVE|||||||
33716293|NCT00084565||||TREATMENT||NONE||||||
33716294|NCT03732001|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716295|NCT01602874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716296|NCT00305305|||COHORT||PROSPECTIVE|||||||
33716297|NCT02532933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941103|NCT05416385|||COHORT||PROSPECTIVE|||||||
33716298|NCT02069301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716299|NCT05486676|NA|SINGLE_GROUP||TREATMENT||NONE||The study has a non-concurrent, multiple baseline, single-case, AB-design. Participants will first be randomly allocated to a 3 or 5-week baseline period. After baseline (A-phase), a trained therapist performs the 12 session VR-Moodboost (B-phase).||||
33716300|NCT06037291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716301|NCT03096054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33716302|NCT06362811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716303|NCT00402766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716304|NCT00779467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33716305|NCT01148823|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33716306|NCT04937829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716307|NCT02348541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716308|NCT01572454|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33716309|NCT00099853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716310|NCT04400240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33716311|NCT01781403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716312|NCT05502393|NA|SEQUENTIAL||TREATMENT||NONE||Sequential||||
33716313|NCT02766725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716314|NCT05001386|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33716315|NCT02373982|||COHORT||RETROSPECTIVE|||||||
33716316|NCT06043076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33716317|NCT05153239|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open-label, randomized, controlled||||
33716318|NCT05525143|||COHORT||RETROSPECTIVE|||||||
33716319|NCT00741637|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716320|NCT01586676|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33716321|NCT01694641|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33716322|NCT06462807|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33716323|NCT01550640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33716324|NCT06214104|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33716325|NCT02894918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716326|NCT01817621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716327|NCT00459108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716328|NCT03655197|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Healthy Subjects-No Intervention Ocular Rosacea Subjects-Mandatory Doxycycline Intervention Cutaneous Rosacea Subjects-Optional Doxycycline Intervention||||
33720927|NCT01041560|||CASE_ONLY||PROSPECTIVE|||||||
33796596|NCT01180088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796597|NCT01865890|||COHORT||PROSPECTIVE|||||||
33941104|NCT02215915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941105|NCT00808184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941106|NCT05594966|||COHORT||PROSPECTIVE|||||||
33941107|NCT03822689|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34019895|NCT01688570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34019896|NCT05211414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34019897|NCT05320601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34019898|NCT02573090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019899|NCT05433727|||CASE_CONTROL||PROSPECTIVE|||||||
34019900|NCT05009680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parts 1 \& 3 - Open Label, Single Dose Part 2 - Double-blind. The blinding will be maintained throughout the study.|Parts 1 \& 3 Open Label, Single Dose Part 2 Randomised to either GB1211 or Placebo|t|f|f|f
34019901|NCT03550105|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A) Study Subjects with Baseline Glucose of \> 150mg/dl, will have Gentle Jogger Only for 7 days B) Study Subjects with Baseline Glucose of \< 150 mg/dl will have basal oral glucose tolerance test (OGTT) and repeat OGTT after 7 days of Gentle Jogger||||
34019902|NCT05644015|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33796598|NCT06551909|NA|SINGLE_GROUP||TREATMENT||NONE||"This is study of feasibility in terms of toxicity of a dose escalation radiotherapy procedure, with 5 patients at each dose level, on 30 patients. The dose will be increased, moving to the next 5 patients, if no more than 1 acute toxicity of grade (G) 4 will be registered.~The assumption is that the percentage of patients free from cumulative acute toxicity G≥3 (Common Terminology Criteria of Adverse Events-CTCAE- v5.0 scale) at 1 month after the end of treatment should not exceed 30%. A sample size of 30 patients results in a two-sided 95% confidence interval with a width of 0.328 (0.136-0.464) when the sample proportion is 0.300.~Dropouts will be replaced by patients visited later, so as to reach the expected sample. Serum from 30 healthy volunteers, with sex and age characteristics comparable to the patients, will be collected to compare the level of immune biomarkers."||||
33796599|NCT04716855|||CASE_ONLY||OTHER|||||||
33796600|NCT00019747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716329|NCT05484518|NA|SINGLE_GROUP||TREATMENT||NONE|One group only, no masking required.|Case series||||
33941108|NCT03986671|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, cohort, pilot study with blinded data analysis and two physician testers to assess intertester reliability and device usability. Volunteers will include healthy adults, participants with documented neurologic pharyngeal muscle dysfunction (ALS and muscular dystrophy), and participants with severe OSA. For each participant diagnostic properties of EMG studies will be assessed using a conventional needle and TM-EMG sensor in pharyngeal muscles.||||
33941109|NCT00158275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716330|NCT01635101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796601|NCT05981157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796602|NCT02981888|||CASE_CONTROL||PROSPECTIVE|||||||
33796603|NCT03145649|||COHORT||PROSPECTIVE|||||||
33796604|NCT04460313|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||multicenter nationwide prospective cohort||||
33796605|NCT01120418|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33796606|NCT04094532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796607|NCT06377111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796608|NCT03401190|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33796609|NCT03281382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796610|NCT06371196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716331|NCT00704158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716332|NCT04931862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716333|NCT06036459|||COHORT||PROSPECTIVE|||||||
33716334|NCT03017651|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33716335|NCT02287272|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716336|NCT01723852|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716337|NCT02194205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33716338|NCT05856201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The 6-week examination and review will be performed by the surgeon with all study data and future visits completed by blinded co-authors (Different surgeon or Urogynecology fellows) who will be unaware of group allocation.|We will perform a interventional, no profit, prospective, randomized 1:1 multicentre, controlled trial with participating tertiary referral hospital centers in Italy, to compare the laparoscopic cervicosacropexy (CSP) and Shull technique via V-NOTES (VNS) in the management of apical prolapse.|f|f|t|t
33716339|NCT01280916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716340|NCT01601626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716341|NCT04945551|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Thirty obese patients with (n=15) and without (n=15) type 2 diabetes will be included in the study. Both groups will undergo a 12-week aerobic exercise training intervention.||||
33716342|NCT04506554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716343|NCT01740986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716344|NCT02423577|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716345|NCT04333823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blinded|1:1 ratio for treatment with Dapagliflozin or placebo|t|t|t|t
33716346|NCT04980690|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33716347|NCT02130973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716348|NCT00098085|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33716349|NCT02323477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716350|NCT01050972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716351|NCT03407105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716352|NCT02845544|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33716353|NCT04973124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each participant will be assigned an identifier that the research team will use from enrollment to follow-up.|Participants will be randomly assigned to any of the groups: Control Group and DEX Group|t|t|f|f
33716354|NCT02522195|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33720928|NCT00525174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796611|NCT00979563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796612|NCT03234088|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33941110|NCT05046418|||COHORT||PROSPECTIVE|||||||
33941111|NCT06268366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary investigators and statisticians will be blinded to the group allocation||f|f|f|t
33941112|NCT06308289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33941113|NCT03381144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941114|NCT03613766|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two groups (experimental and control). Chronological order of recruitment||||
33941115|NCT02935023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941116|NCT05818215|||COHORT||RETROSPECTIVE|||||||
33941117|NCT03117686|||OTHER||PROSPECTIVE|||||||
33941118|NCT03491527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941119|NCT06225830|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33941120|NCT04277429|||CASE_CONTROL||PROSPECTIVE|||||||
33941121|NCT02178215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941122|NCT03245372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33941123|NCT05718011|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941124|NCT03941041|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33941125|NCT05572489|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941126|NCT00106496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941127|NCT00050505|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33941128|NCT03531879|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941129|NCT04491045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All participants are offered depression care services at the CHS, therefore participants are not aware of the different implementation supports provided to the supervisors.||t|f|f|f
33941130|NCT03719144|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941131|NCT00151723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941132|NCT03309865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941133|NCT02473770|||COHORT||PROSPECTIVE|||||||
33941134|NCT02315859|||CASE_ONLY||PROSPECTIVE|||||||
34019903|NCT02802774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716355|NCT03985631|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group receiving the intevention, one evaluation before and 1 one after the intervention period.||||
33716356|NCT00418314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33716357|NCT04937621|||COHORT||OTHER|||||||
33716358|NCT01571427|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigators and assessors are blind to the group assignment|Experimental and control groups. The experimental group will have 30 minutes daily (5 times per week) video chat with standardized conversational staff for 6 weeks, while the control group will have phone check-in once per week for 10 minutes for increasing retention. Both groups will complete weekly web-based heath form using PC and internet.|f|f|f|t
33716359|NCT06028724|||COHORT||PROSPECTIVE|||||||
33716360|NCT00463333|||DEFINED_POPULATION||PROSPECTIVE|||||||
33716361|NCT04044716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician blinded to study arms during analysis phase.|Arm 1 Treatment group, Arm 2 Control group, Arm 3 Nurse Interventionist group|f|f|f|t
33716362|NCT03187262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716363|NCT01773382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716364|NCT01744054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716365|NCT06403995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals with social anxiety will either: 1) self-refer to the adapted intervention (self-referral, undirected iCBT); 2) be recommended the adapted intervention by a registered health professional and will complete the program without guidance (recommended, undirected iCBT); or 3) be recommended the adapted intervention by a registered health professional, with low-intensity guidance throughout the program (recommended, directed iCBT).||||
33716366|NCT03355521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor|Experimental: Nordic walking Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW or NW); (c) return to the calm and ultimate stretching. The participants were trained with individualized prescription according to their maximum distance. A heart rate monitor, Model FT4 attached to the chest of the xiphoid process, was used to control the progression of intensity for the training cycles ranging from 60% to 80% of heart rate reserve. Additionally, we used the Borg RPE for training intensity control, which ranged between 13 and 17 of that scale.|f|f|t|t
33716367|NCT02837094|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716368|NCT01450839|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33716369|NCT00919724|||CASE_CONTROL||PROSPECTIVE|||||||
33716370|NCT05084274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716371|NCT00629681|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716372|NCT06217289|||OTHER||RETROSPECTIVE|||||||
33716373|NCT03747328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716374|NCT03457129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716375|NCT05025761|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Stepped-wedge cluster-randomized controlled trial (one-way crossover) with nested mixed methods study||||
33716376|NCT02113605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716377|NCT00003623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33716378|NCT00939081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716379|NCT02282020|RANDOMIZED|||TREATMENT||NONE||||||
33716380|NCT03578601|||COHORT||PROSPECTIVE|||||||
33716381|NCT02734238|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716382|NCT05891262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716383|NCT05908370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716384|NCT06385223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33716385|NCT06434844|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Both acupuncture interventions will be carried out by a Hong Kong licenced Chinese medical practitioner (CMP) with no involvement in data collection and assessment. A research assistant will be responsible for the randomisation and inform the CMP regarding the group allocation. The acupuncture needles are kept in place for 20 minutes before the dental treatment.~The extractions of premolars will be performed by a licenced general dental practitioner who is blinded towards the types of acupuncture received, so as the patient and their parents or caretakers."||t|t|f|t
33716386|NCT01190878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716387|NCT03618992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Randomized control split body study|t|f|f|f
33716388|NCT03413566|||COHORT||CROSS_SECTIONAL|||||||
33716389|NCT04069611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716390|NCT01308346|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33941135|NCT00483600|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33941136|NCT02475564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941137|NCT01633398|||OTHER||PROSPECTIVE|||||||
33941138|NCT00642343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941139|NCT01813630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941140|NCT05198284|||COHORT||PROSPECTIVE|||||||
34019904|NCT01662349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019905|NCT05913778|RANDOMIZED|PARALLEL||TREATMENT||NONE||open, prospective, randomized, controlled in parallel groups||||
34019906|NCT01323465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019907|NCT04811586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941141|NCT03824704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941142|NCT06188403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941143|NCT01671176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941144|NCT03044730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941145|NCT05613933|RANDOMIZED|PARALLEL||PREVENTION||NONE||A 2-arm, registry-based, cluster RCT, to be conducted in all French Health Territories (Territoires de santé, TDS) of metropolitan France, which will serve as randomization clusters||||
33941146|NCT03575975|||COHORT||CROSS_SECTIONAL|||||||
33941147|NCT04930601|||COHORT||PROSPECTIVE|||||||
33941148|NCT03890029|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33941149|NCT03753867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941150|NCT03351660|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941151|NCT04998344|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33941152|NCT01108068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941153|NCT01520727|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33941154|NCT06333535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941155|NCT04561739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941156|NCT04427306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941157|NCT05637749|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941158|NCT02017366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33941159|NCT01808911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941160|NCT02950168|||COHORT||PROSPECTIVE|||||||
34100699|NCT01324466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100700|NCT02883049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100701|NCT06105463|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||An randomized crossover trial and single-blind.|f|f|f|t
33716391|NCT06374745|||COHORT||RETROSPECTIVE|||||||
33941161|NCT02679222|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33941162|NCT03647059|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941163|NCT00708344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941164|NCT00229242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941165|NCT03976882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Hetrombopag compared with placebo|t|t|t|t
33941166|NCT02505789|||COHORT||PROSPECTIVE|||||||
33941167|NCT04333628|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will compare three groups of treatment, identical of their size (by randomization table) group 1- 125mgx1 / d low dose chloroquine group for 7 days (or until the condition worsens, whichever comes first) group 2- Regular dose chloroquine dose at 500mgx2 / d for 7 days (or until the condition worsens, whichever comes first) 3. Standard treatment group.~We will monitor patients' clinical status and periodic PCR (Polymerase Chain Reaction) results from nasal and pharyngeal surfaces."||||
33941168|NCT03710460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941169|NCT03171142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941170|NCT01485003|||CASE_ONLY||PROSPECTIVE|||||||
33941171|NCT01711931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941172|NCT03281239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941173|NCT04868513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two groups were formed assigning 28 women to each intervention group. G-I received 0.1% silane fluoride applied as varnish in each visit. G-II women's teeth were coated with 0.1% silane fluoride and 1% chlorhexidine. For the primary culture, CRT Bacteria® system (Ivoclar-Vivadent™) was used for the growth and identification of cariogenic Streptococci.|Random clinical trial of parallel groups|f|f|t|f
34100702|NCT01965483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"ONCE-WEEKLY HYPOFRACTIONATED RADIOTHERAPY FOR BREAST CANCER:~PHASE II NON-RANDOMIZED CLINICAL TRIAL"||||
34100703|NCT05073757|||COHORT||PROSPECTIVE|||||||
34100704|NCT06673043|||COHORT||PROSPECTIVE|||||||
33941174|NCT05837429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941175|NCT05465785|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33941176|NCT04865016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941177|NCT01145833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941178|NCT00124696|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33941179|NCT00090623|RANDOMIZED|||TREATMENT||DOUBLE||||||
33941180|NCT02183792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941181|NCT01172795|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33941182|NCT04005885|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Subjects and investigators will be masked to the study lenses - lenses will be overlabelled.||t|f|t|f
33941183|NCT02808273|||CASE_CONTROL||PROSPECTIVE|||||||
33941184|NCT06148181|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941185|NCT04923958|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941186|NCT04627805|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will enroll the first 33 participants to the usual care group, to evaluate the baseline occurrence of family planning discussions and referrals. Following the completion of the usual care group, the investigators will then enroll 33 participants to the MyPath intervention. This allocation scheme was chosen so as to not contaminate the baseline group by rolling out the intervention simultaneously.~Providers will be recruited at the conclusion of the study to complete an exit survey if they interacted with at least one Phase 3 participant."||||
33941187|NCT00721136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796613|NCT06383442|RANDOMIZED|PARALLEL||OTHER||NONE||Participants were evenly distributed according to a counterbalanced design and divided into three different groups by the body fat percentage of subjects: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest), 3. Control group. Target intensities of each interval bout, exercise and rest (Ex./R.), were 85-90% VO2peak/65-70% VO2peak zones, respectively.||||
33796614|NCT05461417|||COHORT||PROSPECTIVE|||||||
33796615|NCT00502229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796616|NCT01250678|||COHORT||PROSPECTIVE|||||||
33796617|NCT04134143|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Cohort 2 will begin when the study starts, and after the safety monitoring board approves progression to the next cohort, Cohort 3 will begin.||||
33796618|NCT03443453|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33796619|NCT05188781|||CASE_ONLY||RETROSPECTIVE|||||||
33796620|NCT03933605|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33796621|NCT01697969|NA|SINGLE_GROUP||||NONE||||||
33796622|NCT03130231|||COHORT||PROSPECTIVE|||||||
33796623|NCT00018603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796624|NCT04598321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941188|NCT01547208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941189|NCT01309581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941190|NCT04995042|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, Multicenter, Singel Group||||
33941191|NCT00963820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941192|NCT02599727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33941193|NCT02114528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941194|NCT05314530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941195|NCT03708042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941196|NCT00917280|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941197|NCT03384394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019908|NCT04425538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019909|NCT01141244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019910|NCT05148390|||CASE_ONLY||PROSPECTIVE|||||||
33796625|NCT05863481|||COHORT||RETROSPECTIVE|||||||
33941198|NCT04157907|||COHORT||PROSPECTIVE|||||||
33796626|NCT00619294|||COHORT||PROSPECTIVE|||||||
33796627|NCT02779062|||OTHER||PROSPECTIVE|||||||
33796628|NCT04934904|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study adopted a randomized, open, blank control design, and did not blind researchers, patients or clinicians.|"Experimental Group:~On the basis of the clinical routine treatment of AGI in severe patients (gastrointestinal dynamic drugs, traditional Chinese drugs and physical rehabilitation therapy), the ultrasound-guided erector spinae plane block intervention is given.~Controlled Group:~Normal Treatment."||||
33796629|NCT05255224|||COHORT||OTHER|||||||
33796630|NCT04813952|RANDOMIZED|PARALLEL||TREATMENT||NONE||they will divided into two equal groups as Group M (minimal flow anesthesia group) with fresh gas flow 0,5 L.min-1 and Group C (high flow anesthesia/ control group) with fresh gas flow 4 L.min-1.||||
33796631|NCT00328835|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33941199|NCT00880958|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34019911|NCT00839514|||COHORT||CROSS_SECTIONAL|||||||
34019912|NCT01293838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019913|NCT01432379|||COHORT||PROSPECTIVE|||||||
34019914|NCT03296436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019915|NCT02398773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019916|NCT00796263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019917|NCT01910974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019918|NCT01199471|||CASE_ONLY||PROSPECTIVE|||||||
34019919|NCT00570895|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34019920|NCT03231644|||COHORT||CROSS_SECTIONAL|||||||
34019921|NCT02517073|||CASE_ONLY||CROSS_SECTIONAL|||||||
34019922|NCT02118090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019923|NCT02931006|RANDOMIZED|PARALLEL||||NONE||||||
34019924|NCT01164345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019925|NCT03287336|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Three doses of Tranexamic acid (5 mg/kg, 10 mg/kg, and 15 mg/kg) will be used in a dose escalation fashion by cohort with the lowest dose first.|f|f|f|t
34019926|NCT04141358|||COHORT||PROSPECTIVE|||||||
34019927|NCT03281863|||COHORT||PROSPECTIVE|||||||
34019928|NCT06633237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Cluster parallel randomized clinical trial|f|f|f|t
34100705|NCT06367153|NA|CROSSOVER||TREATMENT||NONE||Patients cross over from test treatment (T) to reference treatment (R) (two periods, fixed sequence).||||
33941200|NCT00352027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941201|NCT00208572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33941202|NCT03045497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941203|NCT00025194|RANDOMIZED|||TREATMENT||||||||
33941204|NCT02269709|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941205|NCT05779280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941206|NCT02243904|||COHORT||PROSPECTIVE|||||||
33941207|NCT02599740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941208|NCT00408031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34019929|NCT02788786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019930|NCT05872893|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The experimental group will receive intravenous push injections of 0.9% sodium chloride before each infusion, and the control group will receive a 4-hour infusion of sodium chloride after each dose of push injection.|"Each patient will serve as his or her own control. Study participants will be randomly assigned to the sequence of treatment. If the patient is assigned to the experimental arm during the first cycle of chemotherapy, he or she will receive the comparator treatment during the second cycle and vice versa. Treatment modalities will follow each other throughout the whole study period.~Mean nausea score during each chemotherapy cycle will be calculated. To achieve statistically significant results, 140 chemotherapy cycles must be included in the analysis."|t|f|f|f
34019931|NCT05476913|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The trial will be single blind for the primary outcome. Devices will be taken off before participants have Doppler imaging at 7 days and 14 days. Data on VTE will be taken by a blinded researcher using information available on hospital information systems.|Standard block randomisation|f|f|f|t
34019932|NCT03938714|RANDOMIZED|PARALLEL||TREATMENT||NONE||Coagulating Shears ® model||||
34019933|NCT00228514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019934|NCT00635063|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34019935|NCT03876418|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34019936|NCT01751763|||COHORT||PROSPECTIVE|||||||
34019937|NCT05416697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, care provider, and assessor will be blinded.|cannabinoid versus placebo|t|t|f|t
34019938|NCT06152406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019939|NCT02717858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019940|NCT03870867|||COHORT||PROSPECTIVE|||||||
34019941|NCT01157806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019942|NCT03239912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34019943|NCT01699035|||||CROSS_SECTIONAL|||||||
34019944|NCT04561375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019945|NCT04952636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019946|NCT03981653|||COHORT||PROSPECTIVE|||||||
34019947|NCT04452253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Sub-project 1 is a RCT study (Nurses) Sub-project 2 is an open label design (IT Employees)|f|f|f|t
34019948|NCT00574925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019949|NCT03265288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomly assigned to take either the active drug (fenretinide capsule) or a matching inactive placebo (inactive capsule).|Double-blind, randomized, parallel groups and placebo-controlled trial.|t|t|t|t
34100706|NCT01941628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34100707|NCT05040542|||COHORT||PROSPECTIVE|||||||
34100708|NCT04570280|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34100709|NCT02605616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100710|NCT06635109|||OTHER||PROSPECTIVE|||||||
34100711|NCT03083730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34100712|NCT04452370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100713|NCT02544815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33716392|NCT03244345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716393|NCT03687853|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Pancreatic cancer patients who received chemotherapy through peripheral vein after operation|Pancreatic cancer patients who received hepatic arterial perfusion chemotherapy after operation|t|f|f|f
33716394|NCT02742324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716395|NCT05554705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33716396|NCT04686981|||COHORT||PROSPECTIVE|||||||
33720929|NCT01646515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720930|NCT05540301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-group two-factor research design was used.|t|f|f|t
33720931|NCT01356745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720932|NCT02671994|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941209|NCT04235491|||COHORT||PROSPECTIVE|||||||
34019950|NCT03321838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019951|NCT04682730|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge. In addition to the vanguard clinic, there will be five steps, each with three clinics.||||
34019952|NCT04838548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019953|NCT05136300|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34019954|NCT02203214|||CASE_ONLY||PROSPECTIVE|||||||
34019955|NCT00690976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019956|NCT03311100|||COHORT||RETROSPECTIVE|||||||
34019957|NCT03452332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019958|NCT04298060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Stage 2, Ansun will know the dosage.||t|t|t|f
34019959|NCT01239875|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019960|NCT01879865|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34019961|NCT01476618|||COHORT||RETROSPECTIVE|||||||
34019962|NCT03062228|||COHORT||CROSS_SECTIONAL|||||||
34019963|NCT05695677|NA|SINGLE_GROUP||OTHER||NONE||||||
34019964|NCT01072955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34019965|NCT00003875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019966|NCT03296761|||COHORT||RETROSPECTIVE|||||||
34019967|NCT04714983|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34019968|NCT06182176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34100714|NCT05524948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100715|NCT00077012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796632|NCT01294033|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33796633|NCT03009136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100716|NCT02832505|||COHORT||CROSS_SECTIONAL|||||||
34100717|NCT01415323|||COHORT||PROSPECTIVE|||||||
33796634|NCT03802318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796635|NCT05001269|NA|SEQUENTIAL||TREATMENT||NONE||Children 2-11 years of age will begin enrolling prior to the under 2 year old age group's open.||||
33796636|NCT00643071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796637|NCT02329132|||CASE_ONLY||PROSPECTIVE|||||||
33796638|NCT05483452|||COHORT||PROSPECTIVE|||||||
33796639|NCT04889131|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to immediately begin a 12-week yoga class or complete a 12-week wait (wait-list control).||||
33796640|NCT03824262|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33796641|NCT03473340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796642|NCT04236973|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33796643|NCT06676501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796644|NCT00519389|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33796645|NCT02748486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796646|NCT05993052|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796647|NCT02496702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33796648|NCT04970342|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Study Site/National Advanced Driving Simulator: Triple (Participant, Investigator, Outcomes Assessor) blind|The study uses two treatments - alprazolam and cannabis - and placebo. Subjects are randomized to a study sequence where the order of treatments (study arm) is counter-balanced, but all treatments and placebo are received by all subjects. At a visit, you might receive placebo alprazolam and placebo cannabis, placebo alprazolam and active cannabis, or active alprazolam and placebo cannabis. There is not a visit where you receive both active alprazolam and active cannabis.|t|f|t|t
33796649|NCT01803139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796650|NCT05124847|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33796651|NCT06555510|||COHORT||PROSPECTIVE|||||||
33941210|NCT03727685|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The design is a stepped-wedge cluster design in which specific areas of the hospital will adopt the intervention, in sequence. All areas of the hospital will begin in the control phase. 12 weeks into the study period, the first wedge or area of the hospital will adopt the Our Care Wishes intervention, 4 weeks after, the next wedge will switch the control phase, the final wedge will adopt the intervention after that."||||
33941211|NCT04483999|||CASE_ONLY||PROSPECTIVE|||||||
33941212|NCT02993731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941213|NCT01835964|NA|SINGLE_GROUP||OTHER||NONE||||||
33941214|NCT01314885|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33941215|NCT04335552|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients will be initially randomized to one of two arms in a 1:1 ratio: 1) Standard of care treatment or 2) Standard of care treatment plus 5 days of hydroxychloroquine. Participants who meet eligibility criteria to receive azithromycin will undergo a second randomization in a 1:1 ratio to receive additional concurrent therapy.||||
33941216|NCT00468273|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33941217|NCT06042764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941218|NCT00574340|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33941219|NCT00153322|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33941220|NCT04451460|||COHORT||RETROSPECTIVE|||||||
33941221|NCT01028131|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33941222|NCT04822389|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33796652|NCT01135511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796653|NCT04528264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed Envelope will be used to conceal allocation. Patients will be unaware of their group allocation. Outcome assessor will be blinded to the group allocation.|Randomized double blind|t|f|f|t
33796654|NCT03204968|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33796655|NCT00257283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796656|NCT00939419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33941223|NCT00725387|||COHORT||PROSPECTIVE|||||||
33796657|NCT03806348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796658|NCT05984836|RANDOMIZED|PARALLEL||PREVENTION||NONE||Find out the impact of Early Childhood Home-Related Injuries education on the Mothers' Knowledge and Attitudes regarding First Aid in Matrouh.||||
33796659|NCT00051272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796660|NCT03753841|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796661|NCT02492048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796662|NCT05972915|||COHORT||PROSPECTIVE|||||||
33796663|NCT06674538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941224|NCT00281359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941225|NCT04313660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941226|NCT00515021|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33941227|NCT04301492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941228|NCT04134689|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is an open-label parallel pilot RCT where adult male and female patients with a new diagnosis of TB (N=144) will be randomized to DOT selfie (n=72) and standard in-person DOT (n=72). Patients in the DOT selfie arm will receive the intervention, which will comprise a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders. Patients receiving sin-person DOT will serve as the control arm.||||
33941229|NCT03112343|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized in a 1:1 ratio to either the information and communication technology(ICT)-based intervention group or the conventional intervention group||||
34100718|NCT01326897|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34100719|NCT05338450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796664|NCT05712941|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33941230|NCT02172820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941231|NCT04373616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100720|NCT04619147|||CASE_CONTROL||RETROSPECTIVE|||||||
34100721|NCT05702047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33941232|NCT00299091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941233|NCT03702023|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33941234|NCT03794531|||COHORT||PROSPECTIVE|||||||
33941235|NCT03011606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941236|NCT04840914|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941237|NCT02182505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33941238|NCT04152109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The investigators and outcome evaluators will be blind to interventions that participants receive (do not know participants' allocation) and participants will be blind to subgroups without laying on of hands, laying on of hands with and without Spiritual connection (Spirit passe), not knowing which group they were allocated to."||t|f|t|t
33941239|NCT03310476|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33941240|NCT05763836|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33941241|NCT03091920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind||t|t|t|f
33941242|NCT05275140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The assessments will be scheduled one week before and after the intervention with a team of evaluators who will not have information about the training groups, nor will the participants know their identities. That is, a double-blind shield|The study includes an experimental design (randomized controlled trial), double-blind, with repeated measures, parallel groups and a quantitative approach.|t|f|f|t
33941243|NCT06166394|||COHORT||PROSPECTIVE|||||||
33941244|NCT04280042|||OTHER||OTHER|||||||
33941245|NCT05315531|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm hydration water intake intervention with a baseline urine concentration threshold for eligibility||||
33941246|NCT00558961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941247|NCT03826641|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941248|NCT00529646|RANDOMIZED|||||QUADRUPLE|||t|t|t|t
33941249|NCT05263895|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33941250|NCT03086044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941251|NCT05818176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941252|NCT03853759|||CASE_CONTROL||PROSPECTIVE|||||||
33941253|NCT03059576|||COHORT||OTHER|||||||
33941254|NCT00852358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941255|NCT01444989|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941256|NCT00673075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941257|NCT04241627|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will randomly assign participants to cell phone support by voice, cell phone support by text message, or automated text reminders.||||
33941258|NCT00551681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941259|NCT00498784|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941260|NCT04689399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Citizens who have booked an appointment and shows up for a COVID-19 test at a Testcenter Denmark test center in the Capital Region are offered to participate in the project.||||
33941261|NCT00743639|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941262|NCT01117428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941263|NCT00495508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941264|NCT04902573|||COHORT||PROSPECTIVE|||||||
33941265|NCT01484522|||COHORT||PROSPECTIVE|||||||
33941266|NCT00183976|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796665|NCT06100458|||COHORT||RETROSPECTIVE|||||||
33941267|NCT02683135|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33796666|NCT02147535|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796667|NCT04749017|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33796668|NCT02244060|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33796669|NCT03426228|||COHORT||PROSPECTIVE|||||||
33796670|NCT06499246|NA|SINGLE_GROUP||TREATMENT||NONE|It is open label. No masking involved.|Parathyroid transplant from brain dead donors into patients with permanent hypoparathyroidism||||
33796671|NCT00156741|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33796672|NCT04520659|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34019969|NCT05284461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33796673|NCT04572191|||COHORT||PROSPECTIVE|||||||
33796674|NCT05317910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796675|NCT04782817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796676|NCT04034745|||COHORT||PROSPECTIVE|||||||
33796677|NCT02693730|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941268|NCT00998933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019970|NCT01906567|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34019971|NCT00097903|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34019972|NCT05206292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Adult patients with psychotic disorder without known organic cause.||||
34019973|NCT04465552|||CASE_CONTROL||RETROSPECTIVE|||||||
34019974|NCT02885597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796678|NCT03948997|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33796679|NCT03946046|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796680|NCT06400745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Contralateral (split face) study design|t|f|f|t
33796681|NCT01402830|||CASE_CONTROL||RETROSPECTIVE|||||||
33796682|NCT04191954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33796683|NCT02074488|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33796684|NCT06475508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Throughout the study neither the investigators nor the patients knew which drug was being administered until the end of the comparative treatment study period||t|f|t|f
33796685|NCT00478478|||COHORT||PROSPECTIVE|||||||
33796686|NCT04201041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941269|NCT05311358|NA|SINGLE_GROUP||TREATMENT||NONE||In the first phase, we will test our video-game based Kinect sensor in healthy children aged 10-12 years old. The healthy children and the occupational therapists have to reply the satisfaction form and comment our game for further improvement. The sample size of this phase is 10.||||
33941270|NCT03862729|||COHORT||PROSPECTIVE|||||||
34019975|NCT02547155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34019976|NCT05962580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34019977|NCT02951468|||CASE_ONLY||RETROSPECTIVE|||||||
33720933|NCT00969176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796687|NCT05468411|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The taste modifying function of miracle fruit as a sweetness enhancer is masked. Participants are told that they are participating in a study developing a dietary supplement for diabetic patients.|"This study is a randomized crossover trial that has two interventions (miracle fruit pill and placebo). This means that participants have a 100% chance of getting both applications.~Participants are asked to participate in a total of six sessions (Part 1: session 1, 2, \& 3, Part 2: session 4, 5, \& 6). Participants are randomly assigned to either of two interventions (miracle fruit and placebo) in part 1 and their assignment are switched from one application to another in part 2."|t|f|f|f
33796688|NCT01598636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941271|NCT05191615|RANDOMIZED|PARALLEL||OTHER||NONE||A Randomized Controlled Trial (RCT) design will be used to evaluate the effect of job-crafting, need crafting, and preventative health visits based on motivational underpinnings. As a basis for collecting data through the different time points and evaluate the intervention, the study will adopt a mixed method approach. That is, both qualitative (i.e., focus groups and interviews) and quantitative (i.e., questionnaires) methods will be applied to evaluate the interventions implemented.||||
33941272|NCT04667585|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants undergo either reduced radiation dose or standard radiation dose based on the metabolic signature from an Interim 18FDG-PET/CT|t|f|f|f
34100722|NCT03791697|RANDOMIZED|PARALLEL||OTHER||NONE||"Eligible patients will be randomized to Arm1 or Arm2 (Telephone follow up or clinic follow up). Permuted block randomization with randomly varying block sizes will be used. Generation of allocation sequences will be performed using a random-number table.~The allocation sequence will be generated by our statistician who is neither responsible for patient recruitment or outcome assessment. Sequentially numbered opaque sealed envelopes will be used for concealment of treatment allocation.~It is not possible to mask clinical staff or participants, as they will be aware of the follow-up care that is being delivered over the telephone or in clinic. As such this is not a blinded study."||||
33796689|NCT04674371|||COHORT||PROSPECTIVE|||||||
33796690|NCT04640259|||CASE_ONLY||OTHER|||||||
33941273|NCT00104299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941274|NCT00915226|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33941275|NCT00154895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941276|NCT00352833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720934|NCT03089606|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2, single-arm, open-label study.||||
33941277|NCT03108989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33941278|NCT00492739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941279|NCT01146158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941280|NCT00889031|||COHORT||PROSPECTIVE|||||||
34019978|NCT00470067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019979|NCT01483859|NA|SINGLE_GROUP||||NONE||||||
34019980|NCT03275818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34019981|NCT05472662|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34019982|NCT05591586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34019983|NCT04493632|||COHORT||PROSPECTIVE|||||||
34019984|NCT00998478|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34019985|NCT05244395|NA|SINGLE_GROUP||OTHER||NONE||||||
34019986|NCT05062902|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34019987|NCT06258603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single Blinded|The randomization of the study was achieved by the faculty member of the University's Faculty of Medicine, Department of Biostatistics and Medical Informatics, with the R version 3.1.3 program. First of all, the individuals included in the study were stratified according to two age groups (19-44 years and 45-70 years) in the computer environment. Then, individuals in each age group were included in the experimental and control groups in a balanced manner using the block randomization method. The randomization list was hidden from the researcher and the patient and was given to the researcher by a third party during the application. Eligibility and randomization assessment was performed by a critical care nurse independent of the study.|t|f|f|f
34019988|NCT04300140|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34019989|NCT01440036|||CASE_CONTROL||PROSPECTIVE|||||||
34019990|NCT03591393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34019991|NCT04342260|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34019992|NCT02422771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34019993|NCT04948164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34019994|NCT03131674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"We use a delayed treatment design, where both groups receive the same treatment.~One group receives the treatment immediately after the inclusion. The other group receives the treatment after a 9-weeks delay."|t|t|f|t
34019995|NCT06007066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34019996|NCT05578196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34019997|NCT00521040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34019998|NCT03524924|||COHORT||PROSPECTIVE|||||||
34019999|NCT04940260|||CASE_ONLY||PROSPECTIVE|||||||
34100723|NCT04011189|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34100724|NCT04480853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100725|NCT05494736|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720935|NCT02750592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720936|NCT00130416|RANDOMIZED|PARALLEL||||SINGLE||||||
33720937|NCT00982514|||COHORT||PROSPECTIVE|||||||
33720938|NCT01798199|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33720939|NCT05543122|||COHORT||CROSS_SECTIONAL|||||||
33720940|NCT04269980|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double (Participant, Care Provider)||t|t|f|f
33720941|NCT02420054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33720942|NCT03523975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720943|NCT00488163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33720944|NCT00536796|||COHORT||PROSPECTIVE|||||||
33720945|NCT02468869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33720946|NCT04407000|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33720947|NCT02838563|||COHORT||PROSPECTIVE|||||||
34100726|NCT01688401|NA|SINGLE_GROUP||OTHER||NONE||||||
33941281|NCT04371757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The allocation secrecy will be maintained until the time of the experiments, through a randomization list, in a remote place and without direct access by the researchers.|Randomization for exercise interventions, as well as placebo or α1-adrenergic, will be performed using a computer program containing the coded distribution. The randomization of the subjects will be characterized as simple and divided into two parts; (A) directed to the three arms of exercise (aerobica exercise, resistido exercise and combinade exercise) and (B) the order in relation to the placebo or α1-adrenergic block.|t|f|t|f
34100727|NCT00667979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100728|NCT06646042|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||open-label, 2-period, fixed sequence||||
33796691|NCT00731185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796692|NCT02768571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941282|NCT04330794|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33941283|NCT04842942|NA|SINGLE_GROUP||OTHER||NONE||The study intervention in this study is the TOETVA-procedure. This is an Transoral Endoscopic Thyroidectomy Vestibular Approach.||||
34100729|NCT01812941|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33796693|NCT05216510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796694|NCT05530577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized parallel group design.|t|f|t|t
33796695|NCT03876249|||COHORT||PROSPECTIVE|||||||
33796696|NCT03430414|||OTHER||RETROSPECTIVE|||||||
33796697|NCT00166166|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796698|NCT05689125|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will perform endotracheal intubation by four methods in a randomized order. The four methods are endotracheal intubations assisted by a railroaded bougie, assisted by a preloaded bougie, assisted by a stylet, and with no assistance.||||
33796699|NCT05702658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941284|NCT01386749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33941285|NCT04778722|NA|SINGLE_GROUP||TREATMENT||NONE||Receiving Oral Probiotics||||
33941286|NCT02776904|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33941287|NCT00327834|RANDOMIZED|PARALLEL||||DOUBLE||||||
33941288|NCT02194699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941289|NCT01226186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941290|NCT01749930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941291|NCT05818202|||COHORT||RETROSPECTIVE|||||||
33941292|NCT02530281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941293|NCT02698176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941294|NCT05869513|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All supplements will be matched for taste and look|1:1 parallel group design|t|f|t|t
33941295|NCT02443311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941296|NCT05713344|||COHORT||CROSS_SECTIONAL|||||||
34020000|NCT05914935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020001|NCT02424643|RANDOMIZED|PARALLEL||||NONE||||||
34020002|NCT01513382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020003|NCT00164814|||||PROSPECTIVE|||||||
34100730|NCT05370144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020004|NCT05841927|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34020005|NCT01041066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34020006|NCT05552079|||OTHER||PROSPECTIVE|||||||
34020007|NCT02669940|||COHORT||PROSPECTIVE|||||||
34020008|NCT00515541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020009|NCT00993486|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020010|NCT01267994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020011|NCT02747550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020012|NCT04015323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020013|NCT01682863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020014|NCT03254381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020015|NCT03462849|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34100731|NCT05918302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100732|NCT03084900|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Intervention Arm 1 versus standard care.||||
34100733|NCT04632381|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Matching placebo|Patients will be randomized 3:1 to receive zotatifin or placebo in 3 cohorts of 12 patients each. Cohorts will be sequentially enrolled at progressively higher zotatifin dose levels: 0.01, 0.02, or 0.035 mg/kg.|t|t|t|t
33796700|NCT02170324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796701|NCT00839995|||CASE_ONLY||PROSPECTIVE|||||||
33796702|NCT01648569|||COHORT||RETROSPECTIVE|||||||
33796703|NCT06090695|||COHORT||CROSS_SECTIONAL|||||||
33796704|NCT02694835|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33796705|NCT04709055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33796706|NCT01968226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796707|NCT05886491|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33796708|NCT03083197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796709|NCT04436393|||COHORT||PROSPECTIVE|||||||
33796710|NCT03014973|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796711|NCT01538914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100734|NCT06686732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100735|NCT06019832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100736|NCT06337097|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34100737|NCT03731585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100738|NCT03346746|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were not told what diet they were consuming each day.|All participants took part in both conditions.|t|f|f|f
34100739|NCT02738398|NA|SINGLE_GROUP||TREATMENT||||||||
33796712|NCT03560934|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are initially categorized as non-frequent or frequent cannabis users based on their cannabis use behavior and then receive the same treatment of 10-60mg dronabinol upon participation in the study.||||
33796713|NCT06328023|||OTHER||CROSS_SECTIONAL|||||||
33796714|NCT06676722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796715|NCT04734730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796716|NCT03950778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796717|NCT01616459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33796718|NCT02528188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796719|NCT05260086|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The investigators compare study outcomes using aiTBS in personalized stimulation targets vs conventional F3 stimulation targets in parallel arms, each arm controlled by its respective sham stimulation in a counterbalanced crossover design.|t|t|t|t
33796720|NCT01465516|||COHORT||PROSPECTIVE|||||||
33941297|NCT03097666|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with previously untreated (by means of ablation therapy) flat type Barrett's Esophagus (BE) (extent BE ≤C3) with Low-Grade Dysplasia (LGD) or High-Grade Dysplasia (HGD), or residual BE after removal of early adenocarcinoma||||
33941298|NCT03294343|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941299|NCT00461851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941300|NCT01749228|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941301|NCT01920061|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34020016|NCT05477498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each administration of the study drug will be carried out after completion of all applicable study related assessments. FCM is a dark brown solution and cannot be easily masked from placebo (0.9% saline). Therefore, unblinded study personnel (at least one study nurse) who will not be involved in any study procedures for efficacy or safety will be responsible for preparing the infusion and packing bag and tube in an opaque wrapping. Preparation and wrapping will take place in a different room to maintain subject blinding. Administration of the study drug will take place by blinded study personnel. The results of the central laboratory on iron deficiency status and Hb will be sent only to the unblinded study personnel, who will be responsible for evaluating these parameters for subsequent dosing and/or other intervention, if applicable.|Intervention group: Active treatment with ferric carboxymaltose, given as diluted solution by intravenous injection Control group: Placebo, administered as normal saline 0.9%|t|t|t|t
34020017|NCT03048253|||COHORT||PROSPECTIVE|||||||
34020018|NCT04771663|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participant undergoes two phases of the experiment and the participant does not know which one|Interventional single blinded randomized crossover prospective study|t|f|f|f
34100740|NCT03927846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study coordinator will be blinded to randomization|Participants (n=60) in the primary care and rheumatology clinics will be randomized to one of 2 arms: (1) 6 regular telephone contacts, vs. (2) 6 computer generated email reminders (control arm) over an 8-week period. To enhance participants' motivation to engage in the web-based CBT, nurses will use motivational interviewing technique.|f|f|f|t
33796721|NCT04054635|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to one of three application regimens of silver diamine fluoride (SDF) to cavitated caries lesions in primary teeth during the duration of the study. Regimen 1 will be two applications of SDF four months apart. Regimen 2 will be two applications of SDF six months apart. Regimen 3 will be two applications of SDF one month apart.||||
33796722|NCT03098966|||OTHER||RETROSPECTIVE|||||||
33796723|NCT04581850|||CASE_CONTROL||PROSPECTIVE|||||||
33796724|NCT01087762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796725|NCT00529659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796726|NCT06552663|||COHORT||PROSPECTIVE|||||||
33796727|NCT03920566|||COHORT||PROSPECTIVE|||||||
33796728|NCT03692117|||COHORT||PROSPECTIVE|||||||
33796729|NCT01399671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796730|NCT02748265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796731|NCT02080650|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33796732|NCT01195883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796733|NCT03942497|||COHORT||RETROSPECTIVE|||||||
33796734|NCT00006035||||TREATMENT||||||||
33796735|NCT05625282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941302|NCT01422395|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33941303|NCT00442429|||DEFINED_POPULATION||PROSPECTIVE|||||||
33941304|NCT00577564|||CASE_ONLY||RETROSPECTIVE|||||||
33941305|NCT02058186|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33941306|NCT03272672|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|A blinded investigator will segment all Ultrasound images.||f|f|f|t
33941307|NCT00512928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941308|NCT01489332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941309|NCT05299840|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33941310|NCT00207870|||||RETROSPECTIVE|||||||
33941311|NCT02243189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941312|NCT05706610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941313|NCT01048164|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941314|NCT00845533|NA|SINGLE_GROUP||||NONE||||||
33941315|NCT06092866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization 1:1||||
33941316|NCT03055806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941317|NCT06457529|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33941318|NCT02813681|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33941319|NCT02095444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941320|NCT04263129|||CASE_ONLY||PROSPECTIVE|||||||
33941321|NCT03640962|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941322|NCT04343937|||COHORT||RETROSPECTIVE|||||||
33941323|NCT00314028|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33941324|NCT03722901|||COHORT||PROSPECTIVE|||||||
33941325|NCT05488873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941326|NCT03969589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are blind to participant condition||f|f|f|t
33941327|NCT05785949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors will be blinded, i.e., the outcome assessors will not participate in the operation and do not know the subject grouping information. The outcome assessors will make efficacy judgment based on MRI results, so as to reduce study bias caused by subjective assessment error.|In this study, parallel-controlled design is adopted. The experimental group and the control group will complete the study under the same study conditions at basically synchronous study time.|f|f|f|t
33941328|NCT00462657||||DIAGNOSTIC||||||||
34020019|NCT05384639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34020020|NCT04644874|||COHORT||PROSPECTIVE|||||||
34020021|NCT03252912|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34020022|NCT06073210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020023|NCT00848107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020024|NCT03720327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Participants will be randomized to one of two groups for the study duration (3 months):~1. control group (Get FIT);~2. intervention group (Get FIT+)."|t|f|t|t
34020025|NCT02018783|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34020026|NCT06354010|||OTHER||OTHER|||||||
34020027|NCT03929341|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020028|NCT01568138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020029|NCT00281671|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34020030|NCT02584400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020031|NCT00997568|||CASE_ONLY||PROSPECTIVE|||||||
33716397|NCT06207994|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Subjects will be switched between the standard target range, the narrow target range, and the target range with a higher median every 12 hours. The sequence will be randomized differently for each subject, with a balanced block design such that every 3 days each range is evaluated twice.~Once enrolled, each subject will continue in the study with regular changes in averaging time through the course of their need for A-FiO2 or 30 days, whichever is shorter. All other elements of care will be as routinely used."||||
33716398|NCT02697786|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716399|NCT03916328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716400|NCT05463575|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33716401|NCT06234007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716402|NCT03259204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33716403|NCT02097810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716404|NCT00066950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33716405|NCT04719754|||COHORT||CROSS_SECTIONAL|||||||
33716406|NCT06367725|||COHORT||PROSPECTIVE|||||||
33716407|NCT03579160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded physician will assess outcomes from pictures|"The protocol will begin post-surgery. Eligible subjects will be assigned by computer-based randomization to case (0.25% timolol gel) or control (standard of care \[SOC\]) group and treated as follows:~Receiving site of FTSG/case group:~1. During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~2. During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~3. After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks~Receiving site of FTSG/control group:~1. FTSG surgery as per SOC~2. After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"|f|f|f|t
33716408|NCT01275391|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33716409|NCT05526820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716410|NCT03327649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|randomized controlled trial|t|t|t|t
33716411|NCT05691452|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716412|NCT04519684|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single||t|f|f|f
33716413|NCT00884247|||CASE_ONLY||PROSPECTIVE|||||||
33716414|NCT00340080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716415|NCT04525664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||We will use the lot quality assurance sampling (LQAS) method. Households will be selected through random sampling, and each household will be asked for a list of all people over eighteen years old. Then, a person in the household will be selected using random sampling methods and be asked if they wish to participate in the study. Willing participants will provide informed consent and will be given a questionnaire to identify common symptoms of dyspepsia . All participants who complete the questionnaire will also provide a stool specimen (if willing) for fecal antigen testing. Participants who underwent Hp eradication therapy or empiric omeprazole treatment will also be given the opportunity to complete a follow-up questionnaire following completion of their treatment regimen.||||
33716416|NCT05337007|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||all subjects are undergoing each intervention|t|f|f|f
33716417|NCT06001424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled trail|t|f|f|t
33716418|NCT01494194|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33716419|NCT02326961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716420|NCT02470234|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open-label, single-dose||||
33716421|NCT01286181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716422|NCT05954026|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, open label, single-arm multicenter study||||
33716423|NCT02530554|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716424|NCT02599272|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33720948|NCT05311332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720949|NCT01184625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720950|NCT03418298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720951|NCT03633487|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34020032|NCT04353765|||COHORT||RETROSPECTIVE|||||||
34020033|NCT03344861|NA|SINGLE_GROUP||OTHER||NONE||||||
34020034|NCT03652558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Investigators who evaluate the clinical and biochemical parameters did no know the groups.~And participants did not know ozone device work or not when holding the probe."|In this study the investigators select the split mouth study design to eleminate host effects on healing.|t|f|t|f
34020035|NCT00259272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020036|NCT02011113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020037|NCT02342106|||CASE_CONTROL||PROSPECTIVE|||||||
33796736|NCT04293705|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Outcomes assessors and participants are blinded with respect to group assignment, as both Group 1 and Group 2 use the TOPS program platform, even though with different contents.|Group 1 performs the regular TOPS intervention on problem-solving and executive function-related behaviors, while Group 2, serving as active control group, performs a modified version of the TOPS including only sessions on health and wellness but no contents on problem-solving and executive function-related behaviors.|f|t|f|t
33796737|NCT00376519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941329|NCT03975816|||CASE_ONLY||PROSPECTIVE|||||||
33941330|NCT01522599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941331|NCT01691937|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941332|NCT04720027|||COHORT||PROSPECTIVE|||||||
33941333|NCT05860166|NA|SINGLE_GROUP||OTHER||NONE||||||
33796738|NCT00235508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941334|NCT02907866|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941335|NCT03049891|||COHORT||RETROSPECTIVE|||||||
33941336|NCT02216539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941337|NCT01212666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941338|NCT00615420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study was blinded to all except necessary pharmacy staff until after the study was closed.||t|t|t|t
33941339|NCT06409442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Kinesio taping group (KTG), Local vibration therapy group (LVTG), and Control group (CG)|f|f|t|t
33941340|NCT05359029|||COHORT||RETROSPECTIVE|||||||
33941341|NCT05977777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941342|NCT03783221|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33941343|NCT00356434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941344|NCT01063699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941345|NCT00705627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941346|NCT01888380|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33941347|NCT01579383|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33941348|NCT04701801|||OTHER||PROSPECTIVE|||||||
33941349|NCT03103464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient's primary physical therapist will not be aware whether the patient is in the intervention or control group.||f|t|f|f
33941350|NCT00416572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941351|NCT01160458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941352|NCT01506232|||COHORT||PROSPECTIVE|||||||
33941353|NCT06201936|||OTHER||PROSPECTIVE|||||||
33941354|NCT00202267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941355|NCT01952041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded clinical assessors also conducted assessments with all participants at baseline and every 3 months post-randomization.||f|f|f|t
33941356|NCT03143855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941357|NCT05140694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33941358|NCT04950491|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33941359|NCT01787435|||COHORT||RETROSPECTIVE|||||||
33941360|NCT06318000|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020038|NCT00902720|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020039|NCT04098900|||OTHER||PROSPECTIVE|||||||
34020040|NCT01866059|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34020041|NCT02603718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020042|NCT00996775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716425|NCT03916198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|79 participants with rotator cuff tear will be randomly assigned to PDRN or CONTROL depending on the injection material. Randomization will be performed with a computerized random-sequence generator by an independent nurse.|79 participants with rotator cuff tear will be classified into two group. One group (PDRN) will be injected at the repaired cuff with 3cc polydeoxyribonucleotide just after surgery and be injected with another 3cc polydeoxyribonucleotide under ultrasound guidance 2 weeks after the surgery. The other group (CONTROL) will be injected with 3ml normal saline in the same manner.|t|t|t|t
33941361|NCT02363322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020043|NCT01168206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020044|NCT05676281|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34020045|NCT02928718|||COHORT||PROSPECTIVE|||||||
34020046|NCT04492020|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34020047|NCT01439750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716426|NCT03118778|||CASE_ONLY||RETROSPECTIVE|||||||
33716427|NCT05120297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716428|NCT05738005|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33716429|NCT00376662|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33941362|NCT05064449|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33720952|NCT01895855|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33720953|NCT02730325|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33941363|NCT01402999|||COHORT||OTHER|||||||
33941364|NCT01747733|||CASE_ONLY||PROSPECTIVE|||||||
33941365|NCT04572464|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One group pre test post test||||
33941366|NCT06119061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941367|NCT04569890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessor and data analyst blindness. To avoid bias, physicians who assess disease activity will be blinded. Participants are required not to discuss their treatment allocation with physicians at each visit. The success of the blind method will be judged by requiring the assessors to determine the treatment allocation of participants after each visit. When the database is locked, the statistician will carry on the data analysis in the hidden of allocation.|Central random. Statistical experts from a third-party company not involved in the study will generate a random number table by computer system. The patients will be numbered according to their visiting order, and 1:1 allocated according to the random data table.|f|f|t|t
33941368|NCT04768439|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33941369|NCT01329822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796739|NCT03522337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The randomised sequence will be generated by an investigator who does not participate in the outreach service. The allocation sequence will be sealed in an envelope, and opened at the Special Child Care Centres by an assistant. The assistant will be responsible for delivering the materials to children and their parents.|This study is designed as a 24-month randomised, controlled, blind, parallel clinical trial conducted in Special Child Care Centres, aiming to promote oral health among preschool children with special needs.|t|f|f|t
33796740|NCT05090930|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intervention team # 1 using an extracorporeal hemoperfusion device Jafron (Zhuhai Jafron Biomedical, China) (50 patients) in subgroups: A (n = 10) - patients on extracorporeal life support systems with heart failure; B (n = 10) - patients on extracorporeal life support systems with pulmonary failure; C (n = 5) - patients with implantation of a left ventricular accessory device; D (n = 25) - during operations with prolonged artificial circulation, hypothermia and circulatory arrest.~Intervention team # 2 using extracorporeal cytokine, CytoSorb (CytoSorbents Corporation, Monmouth Junction, NJ, USA) (50 patients) in subgroups: A (n = 10) - patients on extracorporeal life support systems in heart failure; B (n = 10) - patients on extracorporeal life support systems with pulmonary failure; C (n = 5) - patients with implantation of a left ventricular accessory device; D (n = 25) - during operations with prolonged artificial circulation, hypothermia and circulatory arrest."||||
33796741|NCT05668819|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Randomized, Controlled||||
33796742|NCT00788853|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33796743|NCT01729169|||CASE_CROSSOVER||PROSPECTIVE|||||||
33796744|NCT05892055|||CASE_CONTROL||OTHER|||||||
33796745|NCT04880408|||OTHER||CROSS_SECTIONAL|||||||
33796746|NCT04763044|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Fifth leg of the study will not be randomized, participants will remain blinded but all will use the same product.||t|f|t|f
33796747|NCT05471635|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33796748|NCT03596268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796749|NCT04996680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assignment to the BFR or control group was stratified by sex (male/female/X) and affected leg (right, left, both), and only visible for physiotherapists treating patients. The study was single-blinded, as the outcome assessors were blinded from randomization whereas masking of participants was not possible due to the nature of the intervention.||t|f|f|t
33796750|NCT06553261|||COHORT||RETROSPECTIVE|||||||
33796751|NCT00837278|||COHORT||PROSPECTIVE|||||||
33796752|NCT04233632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The three condoms in the trial are distinctly different and so condom specific training is required and so cannot be blinded. The statistician analysing the data will be blinded to female condom type.|This research study will be a parallel randomized controlled trial to assess the effectiveness of three female condoms (Cupid, Cupid 2 and FC2) for the prevention of pregnancy among women choosing the female condom as their method of fertility regulation|f|f|f|t
33796753|NCT02561039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796754|NCT05201976|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized, non-inferiority, Case vs. Control (1 to 1)|f|f|t|f
33796755|NCT00084045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796756|NCT05335798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796757|NCT04647786|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"3 phases:~1. Safety testing in sequential patients~2. 2x2 factorial design~3. Simple unblinded RCT using finalised device vs standard care"||||
33796758|NCT00232349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796759|NCT01662336|||CASE_ONLY||PROSPECTIVE|||||||
33796760|NCT01368016|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33796761|NCT03650855|||COHORT||PROSPECTIVE|||||||
33796762|NCT04962282|||FAMILY_BASED||RETROSPECTIVE|||||||
33796763|NCT00473811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796764|NCT05452720|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"The MASA Valve Early Feasibility Study (MVEFS) is a multi-center, non-randomized, prospective, interventional clinical study to determine the safety and probable benefit of MASA Valve pulmonary valved conduit in the indicated subset of patients requiring Right Ventricular Outflow Tract Reconstruction (RVOTR).~Each implanted subject will be consented to be followed for a total of 5 years with a post-op, 30 day (30+7), 180 day (180±30) and 1 year follow-up (365 ± 90 days) followed by an annual follow up until 5 years (annual visits with a window of ± 90 days per visit), or until trial closure. Total expected duration of the trial is approximately 5 year from the last enrolled patient. Intermediary results of the trial may be calculated prior to completion of the 1-year (365 ± 90 days) endpoint of all patients."||||
33796765|NCT00366873|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33796766|NCT03891927|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized clinicl trial||||
33796767|NCT03370796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33796768|NCT04297306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Case-controlled trial randomised, prospective trial||||
33796769|NCT02748954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796770|NCT05973812|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Only one person of the research team (statistician) knew the correspondence between each reference (one reference per each subject) and the arm (probiotic or control). The codes were blinded for the participant, the care provider and the investigator.|Infants were classified into 2 groups. All infants in the probiotic group consumed an infant formula containing a freeze-dried probiotic (7 log10 CFU of B. breve PS1 per gram of formula). All infants in the control group consumed the same formula but without probiotic supplementation.|t|t|t|f
33796771|NCT00566527|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796772|NCT00471627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796773|NCT03895346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assessors will be masked to the group assignment of participants (mindfulness or brain games and puzzles).||f|f|t|t
33941370|NCT05978063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Part A includes 4 arms and Part B includes 2 arms.|t|f|t|f
33941371|NCT00544674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941372|NCT03814876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33941373|NCT01641523|||COHORT||PROSPECTIVE|||||||
33941374|NCT01017991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33941375|NCT02095028|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33941376|NCT01791088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941377|NCT01711359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941378|NCT00917007|||COHORT||PROSPECTIVE|||||||
33941379|NCT05384509|||CASE_CONTROL||PROSPECTIVE|||||||
33941380|NCT05291429|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33941381|NCT03218943|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||A randomized controlled study with cross-over design.||||
33941382|NCT00146458|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941383|NCT01333020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33941384|NCT01740349|||CASE_CONTROL||PROSPECTIVE|||||||
33941385|NCT03687229|||CASE_CONTROL||PROSPECTIVE|||||||
33941386|NCT04657302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941387|NCT03851315|||COHORT||PROSPECTIVE|||||||
33941388|NCT04755751|||CASE_ONLY||OTHER|||||||
33941389|NCT00000528||FACTORIAL||PREVENTION||||||||
33941390|NCT04239807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Screening (day -21 until day -7): Subjects will be evaluated according to In- and Exclusion critera~Randomization (day -7): Subjects will be randomized to either Intervention Group (training on wbv platform) or non-Intervention Group (training without wbv).~Introduction Week -1(-7d-d1): All subjects will receive introduction in their training~Month 1:~Day 1: From this day subjects are supposed to start their training accoridng to protocol~Day 2: Telephone Visit~Day 5: Telephone Visit~Day 7: Telephone Visit~Day 10: Telephone Visit~Day 13: Telephone Visit~Day 20: Telephone Visit~Day 27: Telephone Visit~Week 4, Day 28: Study center Visit: 6MWD, QoL-Questionnaire, AEs, re-training~Month 2:~Week 5, Day 34:~Week 6, Day 41:~Week 7, Day 48:~Week 8, Day 55:~Month 3:~Week 9, Day 62:~Week 10, Day 69:~Week 11, Day 76:~Week 12, Day 83: Final Visit"||||
33941391|NCT05734586|NA|SINGLE_GROUP||OTHER||NONE||||||
33941392|NCT06173726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100741|NCT03393975|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a Phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 in the prophylactic and on-demand treatment of participants with severe congenital thrombotic thrombocytopenic purpura (cTTP).||||
34100742|NCT02440529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941393|NCT05862740|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Group A is the study group (completed laparoscopic debulking); Group B (conversion to laparotomy) is the control group in which laparoscopy could not be completed||||
33941394|NCT05103540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941395|NCT02216227|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33941396|NCT00557362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941397|NCT03604159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941398|NCT06496698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941399|NCT05523648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941400|NCT06107387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941401|NCT02555722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941402|NCT02369757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941403|NCT04763824|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized trial with delayed-start control arm||||
33941404|NCT01406509|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33941405|NCT06402240|NA|SINGLE_GROUP||TREATMENT||NONE||Pragmatic single-arm clinical trial.||||
33941406|NCT01335360|||COHORT||CROSS_SECTIONAL|||||||
33941407|NCT02343991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020048|NCT03860662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The purpose of this thesis is to research the effect of oral baclofen treatment and botulinum toxin injection treatments over the electromyographic nociceptive flexor reflex (NFR) threshold in hemiplegic patients with spasticity. The results of the study evaluated the Modified Ashworth Scale, joint range of motion, muscle strength, Brunnstrom stages, Barthel daily life activities index, electromyographic nociceptive flexor reflex (NFR) threshold.|f|f|t|t
34100743|NCT00098761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100744|NCT00348374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716430|NCT03210597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant: During the training period the subjects were not informed about the training modality they were performing and also were not informed about the modalities of the other subjects, only they were informed that hydrogymnastic sessions would be performed.~Outcomes assessor:The team evaluating the outcomes was blinded, not receiving information about the intervention received by the subjects participating in the study"||t|f|f|t
33716431|NCT00233103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716432|NCT04309188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Vision Center and balance assessor will be blinded to group allocation|The pilot study will use a pre-test post-test randomized controlled trial.|f|f|f|t
33716433|NCT05604222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33716434|NCT00106392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716435|NCT00367094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33941408|NCT05286034|RANDOMIZED|PARALLEL||SCREENING||NONE||"A cluster randomized controlled trial with two arms (one experimental arm and one active control arm) will be conducted in the Occitanie region, France to assess the effectiveness of a decision aid accessible via artificial intelligence-based Chatbot platforms to improve the return rate of HPV self-samples and the proportion of invited women well managed among disadvantaged women. A cluster is defined by aggregated units for statistical information (Ilots Regroupés pour l'Information Statistique, IRIS) and it refers to a target size of 2000 inhabitants per unit. Only IRIS classified as 4 and 5 according to the French version of the European Deprivation Index (EDI) will be included. The study will be conducted as a two-armed nested into the French cervical cancer screening programme in the Occitanie Region. Clusters will be randomly assigned by a computer-generated randomized schedule following simple randomization procedures in a 1:1 ratio."||||
33941409|NCT02727452|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33941410|NCT04736966|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941411|NCT03795324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941412|NCT04925466|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941413|NCT02743494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941414|NCT04205513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941415|NCT05853289|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33941416|NCT04417816|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33941417|NCT06218290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941418|NCT04465513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941419|NCT04162145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomly assigned to one of the 2 treatment groups in equal ratio. Randomization will be done centrally using a randomized block design, with blocks of 4 using the Pqantadosi Randomization software. There will be a randomization table provided to the person dispensing the devices. The unblinded, lead research coordinator will keep the data in a secure database and will not be involved in any of the patient recruitment or study procedures. All other research coordinators, investigators, and nurses involved will be blinded to group allocation. In general, the study biostatisticians and the person dispensing will be the only people un-blinded throughout the duration of the study.|Two groups will be studied: one group using active BRIDGE devices and one using sham or inactive devices.|t|t|t|t
33941420|NCT01126528|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33941421|NCT03572101|||COHORT||PROSPECTIVE|||||||
33941422|NCT03309215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941423|NCT02683031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020049|NCT04267107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participants cannot be masked to study groups in this study. The researcher who is responsible for data collection and data analysis will be masked to group allocation.~A research assistant will assign ID codes to each participant, manage the key to the ID codes. Feasibility questionnaire, only for experimental group, will be coded with participant ID codes.~Participants will be instructed not to share any information on group allocation with the researcher during the assessments. Masking of the assessor will be monitored by reports of the assessor receiving any information during the assessments on the allocation of the participant. If there are multiple occurrences of this, a sensitivity analysis will be used."|This feasibility study will use a mixed-methods approach, nested in a pilot 2-arm randomized control design (experimental and no intervention control). We will collect qualitative and quantitative data simultaneously which will expand our understanding of the feasibility of the program.|f|f|t|t
34020050|NCT03576482|||COHORT||PROSPECTIVE|||||||
34020051|NCT02821052|||COHORT||PROSPECTIVE|||||||
34020052|NCT01908816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020053|NCT02556983|||OTHER||PROSPECTIVE|||||||
34020054|NCT03387696|||COHORT||RETROSPECTIVE|||||||
34020055|NCT02832180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020056|NCT03139786|||COHORT||PROSPECTIVE|||||||
34020057|NCT04638335|||COHORT||CROSS_SECTIONAL|||||||
33716436|NCT03253250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716437|NCT04488289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716438|NCT02496897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716439|NCT02793141|||COHORT||PROSPECTIVE|||||||
33716440|NCT03489447|||COHORT||RETROSPECTIVE|||||||
33716441|NCT03504150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716442|NCT05985889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716443|NCT03958955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This was a phase 2a, within-subject trial design, where all subjects were treated with active treatment on one DLE target lesion and vehicle treatment on another DLE target lesion.|t|f|t|f
33716444|NCT05392998|||COHORT||PROSPECTIVE|||||||
33716445|NCT01519414|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33716446|NCT04455802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be a randomized, double-blind, double-dummy, intention-to-treat clinical trial. All clinical providers, research personnel and participants will be blinded to group assignment. Pharmacy personnel will be the only un-blinded individuals. The placebo medication will be identical in appearance and volume to a dose of the medication at the respective dose.|Infants will be randomly assigned to treatment arms of either morphine or buprenorphine|t|t|t|t
33716447|NCT00774618|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33716448|NCT03824327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941424|NCT00568399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941425|NCT03716206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020058|NCT03964064|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-randomized trial||||
34020059|NCT00894426|||COHORT||PROSPECTIVE|||||||
34020060|NCT04173624|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020061|NCT02988024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020062|NCT06388759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020063|NCT00623038|||COHORT||PROSPECTIVE|||||||
34020064|NCT05199519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020065|NCT01386151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020066|NCT00006267||||TREATMENT||||||||
34020067|NCT02141035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020068|NCT02868918|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34020069|NCT04832893|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34020070|NCT02109419|||CASE_CONTROL||PROSPECTIVE|||||||
34020071|NCT03052868|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020072|NCT02571192|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34020073|NCT03170427|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34020074|NCT06008366|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34020075|NCT00237913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100745|NCT03153202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-randomized trial. Patients will be allocated to appropriate cohort A-D per their disease type and time of enrollment to study.||||
34100746|NCT04518657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100747|NCT05857540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100748|NCT03891953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100749|NCT06695494|||COHORT||PROSPECTIVE|||||||
34100750|NCT05528588|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients will undergo stratified randomization based on BAN-ADHF score (0-11 vs. ≥ 12). Within each stratum, patients will be randomized in a 1:1 ratio (intervention: control).||||
33941426|NCT05353881|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941427|NCT01265628|||COHORT||PROSPECTIVE|||||||
33941428|NCT01482676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941429|NCT05613244|||COHORT||RETROSPECTIVE|||||||
33941430|NCT02602028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33941431|NCT05677906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941432|NCT00412360|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941433|NCT04255329|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33941434|NCT01482338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941435|NCT02500901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941436|NCT06287554|||CASE_CONTROL||OTHER|||||||
33941437|NCT04810429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|atients with inclusion criteria will be seen in an orofacial pain session and assessed for pain using the VAS scale, by scoring the degree of pain between 0 (absence of pain) and 10 (maximum pain). Then the patients are proposed for TMJ arthroscopy. The nurse enters the room with the patient and asks to the patient to choose an envelope. In this moment, the envelope is placed on a table and the patient writes his name. The nurse accompanies the patient to the doctor's office. Alone, the nurse opens the envelope and sees the code and the indication of PLACEBO or BTXA. Then, she will prepare in her room, isolated from the whole team, 2 syringes. She will put the envelope in a bag and deliver a tray with 2 syringes for treatment and a code to identify the patient in the treatment room. The doctor injects the syringes according to the protocol.|For this randomized clinical trial an appropriate number of sealed envelopes will be prepared: 15 for placebo and 15 for the treated group. Patients with inclusion criteria will be seen in an orofacial pain session and assessed for pain using the VAS scale, by scoring the degree of pain between 0 (absence of pain) and 10 (maximum pain). Then the patients are proposed for TMJ arthroscopy. The nurse enters the room with the patient and asks to the patient to choose an envelope. In this moment, the envelope is placed on a table and the patient writes his name. The nurse accompanies the patient to the doctor's office. Alone, the nurse opens the envelope and sees the code and the indication of PLACEBO or BTXA. Then, she will prepare in her room, isolated from the whole team, 2 syringes. She will put the envelope in a bag and deliver a tray with 2 syringes for treatment and a code to identify the patient in the treatment room. The doctor injects the syringes according to the protocol.|f|f|t|f
33941438|NCT04774029|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33941439|NCT03493204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941440|NCT03417999|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33941441|NCT05254964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941442|NCT01916733|||COHORT||PROSPECTIVE|||||||
33941443|NCT00036816|RANDOMIZED|||TREATMENT||||||||
33941444|NCT02358863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941445|NCT04342572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941446|NCT01747655|||||PROSPECTIVE|||||||
34020076|NCT04062656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020077|NCT00102518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020078|NCT03011736|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020079|NCT04081766|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020080|NCT00006055||||TREATMENT||||||||
34020081|NCT04605003|RANDOMIZED|PARALLEL||OTHER||SINGLE|The swabbing of the endoscopes are performed by a research assistant, and the end result is evaluated by the primary investigator||f|f|t|f
34020082|NCT03065218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Clinical evaluation of utility of the FDA approved radiopharmaceutical (i.e., 99mTc sestamibi) for differentiated thyroid cancer in a select patient populaton of patients with elevated serum thyroglobulin levels and negative diagnostic radioiodine scans with the objective of determining utility in identifying the site of metastasis(es) that is accounting for the elevated serum thyroglobulin level.||||
34100751|NCT05543382|||COHORT||PROSPECTIVE|||||||
34100752|NCT00860431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100753|NCT01748552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34020083|NCT03400943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be applied to Treatment Groups A1, B1, and B2; Treatment Group A2 will be open-label||t|t|t|t
34020084|NCT02589483|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34020085|NCT05656521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020086|NCT02027675|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34020087|NCT05763108|||COHORT||PROSPECTIVE|||||||
34020088|NCT00482651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020089|NCT02763371|RANDOMIZED|CROSSOVER||||NONE||||||
34020090|NCT02936180|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020091|NCT00918138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020092|NCT01118286|||COHORT||PROSPECTIVE|||||||
34020093|NCT00798421|||COHORT||PROSPECTIVE|||||||
34020094|NCT06408883|||COHORT||PROSPECTIVE|||||||
34020095|NCT01070771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020096|NCT02610036|||CASE_CONTROL||PROSPECTIVE|||||||
34020097|NCT03092063|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Raters are blind to treatment condition.|Diabetes Self-Management Education|f|f|f|t
34020098|NCT04905030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34020099|NCT05737316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patient blinding will be done by ensuring that patients are unaware of the content of either treatment group before participation, and will only be made aware of the content of their allocated programme after randomization. They will be instructed not to share the details of their exercise programme with their physicians or other study participants, and to only contact their assigned physiotherapist in case of any problems during the study. Intervention and control group participants will be assigned different dates for study site visits to avoid cross-contamination.~Study team members who will assess outcomes or perform data analyses will be masked to group allocation."||t|f|f|t
34020100|NCT02439931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020101|NCT03107312|||COHORT||CROSS_SECTIONAL|||||||
34020102|NCT01656538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020103|NCT00415441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020104|NCT04809935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020105|NCT03487952|||COHORT||PROSPECTIVE|||||||
34020106|NCT02197013|||COHORT||PROSPECTIVE|||||||
34020107|NCT04271553|RANDOMIZED|PARALLEL||OTHER||DOUBLE|prospective blinded (assessor) randomized controlled trial||f|t|f|t
34020108|NCT05973266|RANDOMIZED|CROSSOVER||OTHER||SINGLE|endoscopist blinded|Randomized controlled experimental design|f|f|f|t
34020109|NCT03942705|||COHORT||PROSPECTIVE|||||||
34020110|NCT05537194|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020111|NCT06187493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020112|NCT01675661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020113|NCT00423475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020114|NCT06008743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34020115|NCT05483725|||COHORT||PROSPECTIVE|||||||
34020116|NCT01041183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34020117|NCT05937828|||COHORT||PROSPECTIVE|||||||
34020118|NCT06311162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study team members who are conducting assessments on the participants remain blinded to the treatment allocation.|Single-blind randomized controlled parallel-group clinical trial|f|t|t|f
34020119|NCT04847349|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34020120|NCT04856150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020121|NCT02902536|||OTHER||OTHER|||||||
34020122|NCT00022542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020123|NCT00775905|RANDOMIZED|CROSSOVER||||NONE||||||
34020124|NCT01069991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33716449|NCT00061698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716450|NCT03232957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the anesthetic record, 0.5% isobaric bupivacaine with study drug is recorded.||t|f|f|t
33716451|NCT05340608|||COHORT||CROSS_SECTIONAL|||||||
33716452|NCT00811551|||COHORT||PROSPECTIVE|||||||
33716453|NCT05075304|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33716454|NCT00165243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716455|NCT06208228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716456|NCT06208891|||COHORT||RETROSPECTIVE|||||||
33716457|NCT03680573|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject has one control site and three experimental sites concurrently tested within the same study using intradermal microdialysis on the dorsal forearm.||||
33716458|NCT04367220|||COHORT||PROSPECTIVE|||||||
33716459|NCT00940251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716460|NCT00426491|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33716461|NCT01026467|||CASE_ONLY||PROSPECTIVE|||||||
33716462|NCT01883843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716463|NCT00686660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716464|NCT02267811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716465|NCT03746873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33716466|NCT04502953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716467|NCT01392508|||CASE_ONLY||PROSPECTIVE|||||||
33716468|NCT06186011|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center parallel randomized Clinical Trial with three arms: intraoperative Ultrasound vs. wire vs. radioactive seed||||
33716469|NCT00869531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716470|NCT01096524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716471|NCT02763189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716472|NCT02136524|RANDOMIZED|CROSSOVER||||NONE||||||
33716473|NCT05609461|||COHORT||PROSPECTIVE|||||||
33716474|NCT00711711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716475|NCT05782465|||COHORT||PROSPECTIVE|||||||
33796774|NCT05734924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients in control group will receive sham magnetic therapy in addition to, cervical stabilization exercise protocol.|The selected patients will be randomly assigned into two equal groups study group (GI), and control group (GII). The study group (GI) will receive low Frequency High Intensity magnetic therapy in addition to cervical stabilization exercise protocol . The control group (GII) will receive sham magnetic therapy in addition to, cervical stabilization exercise protocol.|t|f|f|f
33796775|NCT03441204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020125|NCT05860205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will not know if they are assigned to the multiple component mobile-aid pain reduction intervention and sham osteopathic manipulation treatment group or the multiple component mobile-aid pain reduction intervention and actual osteopathic manipulation treatment group. Additionally, the outcomes assessors will not know which groups the participants have been assigned to.|Group 1 (no treatment condition) will only receive educational materials through email and a weekly phone call from the Coordinator to reduce dropouts for 12 weeks. Group 2 will receive the new multiple component mobile-aid pain reduction intervention (MCMAPRI) and sham osteopathic manipulative treatment \[OMT\] for 12 weeks. Group 3 will receive both MCMAPRI and actual OMT for 12 weeks.|t|f|f|t
34020126|NCT00919152|||CASE_ONLY||RETROSPECTIVE|||||||
34020127|NCT00295295|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020128|NCT06506162|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34020129|NCT00658021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020130|NCT04713150|||COHORT||CROSS_SECTIONAL|||||||
34020131|NCT02468752|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34020132|NCT02782793|||COHORT||PROSPECTIVE|||||||
34020133|NCT06394349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34020134|NCT00664131|||||PROSPECTIVE|||||||
34020135|NCT03669939|||OTHER||PROSPECTIVE|||||||
34020136|NCT00107705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34020137|NCT03577483|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Exploratory comparative multicentric study.||||
34020138|NCT00188292|||COHORT||PROSPECTIVE|||||||
34020139|NCT04105426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020140|NCT00804713|NA|SINGLE_GROUP||SCREENING||DOUBLE|All study participants received 4 tests, including the use of two skin tests, one on each arm. However, the participant and outcomes assessors were blinded to which skin test was placed on which arm to avoid bias in assessment of the outcomes.||t|f|f|t
34020141|NCT03886987|NA|SINGLE_GROUP||SCREENING||NONE||"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml~Negative control: Blank patch Dose: Not applicable"||||
34020142|NCT00457899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020143|NCT01097941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020144|NCT04689555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020145|NCT00807677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020146|NCT02593682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34020147|NCT01023191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020148|NCT00000718||||TREATMENT||NONE||||||
34020149|NCT01050608|||COHORT||PROSPECTIVE|||||||
34020150|NCT02569112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Both investigator and independent reviewer to determine which side of the body the multi-polar radiofrequency, pulsed-electromagnetic fields and vacuum therapy was applied.|All participants to receive cryolipolysis treatment on one side of their body and cryolipolysis plus multipolar radiofrequency with varipulse technology treatment on the other side of their body.|f|f|t|t
34020151|NCT03122067|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34020152|NCT06490445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100754|NCT01534715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100755|NCT06097988|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34100756|NCT06615375|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100757|NCT04147234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100758|NCT06293287|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33716476|NCT05045001|||CASE_ONLY||RETROSPECTIVE|||||||
33716477|NCT02466360|||||CROSS_SECTIONAL|||||||
33716478|NCT05875090|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|Two physicians (unrelated to any recruiting center) will have access to pseudonymized data, masked to both screening and hospital decisions.|Two models of population-based glaucoma screening will be tested. Lisbon center will conduct screening using an Artificial-Intelligence software based on optic disc centered retinographies. The Minho center will conduct screening based on OCT-based findings on the retinal nerve fibre layer thickness (RNFL)|f|f|f|t
33716479|NCT00210002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716480|NCT06069245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double blind randomized placebo controlled crossover design|t|f|t|f
33716481|NCT03912285|NA|SINGLE_GROUP||TREATMENT||NONE||an open-label, three-period, fixed-sequence clinical trial||||
33716482|NCT00523354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100759|NCT04744831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716483|NCT01426880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100760|NCT05908656|NA|SINGLE_GROUP||SCREENING||NONE||||||
33716484|NCT01017614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716485|NCT00901446|||CASE_ONLY||CROSS_SECTIONAL|||||||
33716486|NCT06071091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716487|NCT02368431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716488|NCT03055260|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33716489|NCT03709771|||COHORT||PROSPECTIVE|||||||
33716490|NCT05235074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716491|NCT03630003|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33716492|NCT01614054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716493|NCT01847222|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33716494|NCT02886520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716495|NCT04059094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716496|NCT01438957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796776|NCT03481608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the intervention oil (single-blind).|Acute feeding study. Participants will arrive at our Human Metabolic Research Unit on 2 separate occasions. Participants will be randomized to consume 1 of 2 shake on each occasion. Shakes will be prepared with 2 tablespoons of either control (olive) or intervention (coconut) oils.|t|f|f|f
33796777|NCT01832467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796778|NCT02561871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33796779|NCT01872026|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796780|NCT00064012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796781|NCT03071185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33796782|NCT00751075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796783|NCT05659901|||COHORT||PROSPECTIVE|||||||
33796784|NCT01867216|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33796785|NCT00003005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796786|NCT05919017|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33796787|NCT05752006|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross-sectional study||||
33796788|NCT00899899|||CASE_ONLY||RETROSPECTIVE|||||||
33796789|NCT00161733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33796790|NCT06546384|RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding procedures in place|This is an exploratory, monocentric, randomized controlled clinical trial||||
33796791|NCT04756245|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomly assigned to one of two 4-week interventions: a virtual-reality or video conference-based group-mediated activity program||||
33796792|NCT02509585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796793|NCT04496830|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"1. For the MS diagnostic test, the investigators will select 50 patients with definite MS (CIS/RIS excluded) and 50 controls, including 25 non-inflammatory neurological diseases (NIND) that mimic MS (such as patients with vascular-ischemic changes, complex migraines, leukodystrophies, etc.) and 25 other inflammatory neurological diseases (OIND) such as NMO, Susac's syndrome, sarcoidosis, CNS vasculitis.~2. For validating the RRMS versus progressive MS classifier, the investigators will select CSF from 50 RRMS and 50 progressive MS patients (25 SPMS and 25 PPMS).~3. Cryopreserved CSF samples from these patients will be analyzed blindly using SOMAscan assay. Probability of MS diagnosis and progressive MS diagnosis will be calculated based on published models. Results will then be unblinded and analyzed for accuracy of diagnostic conclusion.~4. To evaluate the MS severity score, the investigators will select 50 RRMS and 50 progressive MS (25 PPMS and 25 SPMS)."||||
33796794|NCT05834946|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All participants will be blinded from the randomisation. An opaque envelope will be used to conceal the implant designation and will only be revealed to the operator after the site is ready for implant placement. A blinded researcher will be assigned as clinical assessor who will not be involved with the surgical procedure, subject recruitment nor consent taking. An assistant who is not involved with the research will also be asked to re-code the sample tubes to ensure blinding for data/sample analysis.|"Test group: Patient with history of periodontitis Control group: Patient without history of periodontitis~Patients in both groups will be randomised to receive one of two type of implants with different surface characteristics."|t|t|f|t
33796795|NCT00501618|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796796|NCT01458210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796797|NCT06448598|||OTHER||RETROSPECTIVE|||||||
33796798|NCT06178978|||COHORT||CROSS_SECTIONAL|||||||
33796799|NCT02640781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796800|NCT04561544|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33796801|NCT02618018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796802|NCT05290168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796803|NCT00481182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020153|NCT04793048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Maintenance of blinding in this study was facilitated by the fact that (1) treatment delivery (active or sham) was hard-coded into the device's firmware, making active devices physically indistinguishable from sham devices, (2) both the device serial code block sizes and the treatment allocation block sizes were not known by the clinical investigative staff and that the order of blocks in each sequence was random, (3) patients only received treatment with their assigned device (active or sham) at home and never came in contact with another enrolled patient or device other than their own. This scheme rendered deliberate and accidental breaking of the blind difficult for both the patients or the clinical investigator, as no comparisons could be made between two devices that delivered different treatments and no pattern linking the device serial code and assigned treatment could be deduced, since the size and the order of blocks were randomly shuffled."|This trial was a parallel-arm, sham-controlled, randomized, and double-blind pivotal trial. A total of 30 patients were randomly assigned to one of two groups: one group received an active intraoral electrotherapy device and a scaling and root planing (SRP) at baseline, another group received a sham device and a scaling and root planing (SRP) at baseline.|t|t|t|t
34020154|NCT01612026|||CASE_CONTROL||PROSPECTIVE|||||||
34020155|NCT04343404|||CASE_ONLY||RETROSPECTIVE|||||||
34020156|NCT05672823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The outcomes assessor, being the trial statistician, is blinded for the treatment groups.~Groups are defined as group A and B during the preparation of the statistical tests. Only after performing the required statistical tests the data will be unblinded."||f|f|f|t
34020157|NCT01674127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020158|NCT03312595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100761|NCT01095965|RANDOMIZED|PARALLEL||||NONE||||||
34100762|NCT02781285|||COHORT||PROSPECTIVE|||||||
34100763|NCT05857878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100764|NCT06578338|||OTHER||PROSPECTIVE|||||||
34100765|NCT03964909|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100766|NCT05463952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100767|NCT03855839|||OTHER||CROSS_SECTIONAL|||||||
34100768|NCT05203237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796804|NCT03061552|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34100769|NCT03528642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100770|NCT03422731|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34100771|NCT00527748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796805|NCT02442895|||COHORT||RETROSPECTIVE|||||||
33796806|NCT02506257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796807|NCT01426295|RANDOMIZED|PARALLEL||||NONE||||||
33796808|NCT01202955|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33796809|NCT04057196|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020159|NCT05282186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized cluster design with 19 service centers assigned to one of the two treatments.|f|f|f|t
34020160|NCT00975403|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34020161|NCT03757351|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34020162|NCT04582461|||COHORT||PROSPECTIVE|||||||
34020163|NCT04849065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|Phase II, prospective, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial|t|f|t|f
34020164|NCT02107820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020165|NCT02514850|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34020166|NCT01193127|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34020167|NCT00778024|RANDOMIZED|CROSSOVER||||NONE||||||
34020168|NCT04992429|||COHORT||PROSPECTIVE|||||||
34020169|NCT00005809||||DIAGNOSTIC||||||||
34020170|NCT03979781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020171|NCT03827746|||CASE_ONLY||PROSPECTIVE|||||||
34020172|NCT00831766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020173|NCT05850988|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34020174|NCT03258073|NA|SINGLE_GROUP||OTHER||NONE|No masking will be done|Investigators will conduct a cohort study among medical and nursing students and follow groups of students according to their rotation in the four major clinical disciplines. A cohort will represent a group of students who start a clinical rotation and complete their clinical year together. A total of 4 rotations exist concurrently every academic year in a year of study (Pediatrics, Internal medicine, Surgery and Obstetrics). During each rotation, a cohort will be exposed to at least 1 simulation scenario relevant to the discipline of the rotation. Investigators hypothesize that repeated exposure to simulation scenario execution will improve CTS scores. Therefore in this cohort study, investigators will measure CTS scores before and after exposure to simulation scenario training.||||
34020175|NCT03824496|||COHORT||PROSPECTIVE|||||||
34020176|NCT03121378|||CASE_CONTROL||PROSPECTIVE|||||||
34020177|NCT04126213|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data was collected in an observer-blind manner. The laboratory in charge of the sample testing was blinded to the intervention assignment, codes were used to link the subject and study (without any link to the intervention attributed to the subject) to each sample. Investigators remained blinded to each subject's assigned study intervention until the second analysis. After the second analysis, the study was not considered observer blind as the investigator brochure was updated to include safety information presented by treatment group. This led to inadvertent unblinding of investigators and site staff to some subjects' treatment assignments. The subjects themselves remained blinded throughout their participation in the study.||t|t|t|t
34100772|NCT01682603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100773|NCT02112916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100774|NCT02380872|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34100775|NCT01924065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34100776|NCT00290420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100777|NCT06174532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100778|NCT02043847|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Increasing doses of Total Marrow Irradiation (TMI), 3 Gy, 6 Gy, and 9 Gy.||||
34100779|NCT06688903|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34100780|NCT03347539|||CASE_ONLY||PROSPECTIVE|||||||
33716497|NCT05971810|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33716498|NCT01832376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716499|NCT06239376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716500|NCT03951792|||CASE_CONTROL||PROSPECTIVE|||||||
33796810|NCT04727125|||COHORT||PROSPECTIVE|||||||
33796811|NCT00710515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796812|NCT00073684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796813|NCT04925765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796814|NCT05552469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796815|NCT06142851|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020178|NCT00599378|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34020179|NCT01830491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020180|NCT05919316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33716501|NCT00748033|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Two different activation times for the wetting solution for a urinary catheter will be used in healthy volunteers, compared to the use of a registered urinary catheter.|t|f|f|f
33716502|NCT03365739|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33716503|NCT05216705|||COHORT||PROSPECTIVE|||||||
33716504|NCT02590653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796816|NCT05726604|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34100781|NCT03227627|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy. After the 24 sessions, participants will have a repeat MBSS and results will be scored using the Pen-Asp scale and FOIS scale. Both the control group and experimental group will answer the PSI-4 after the repeat MBSS.||||
34100782|NCT02369679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34100783|NCT04317534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100784|NCT04576481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be blinded to their treatment assignment. However, research staff will be blinded to treatment assignment when collecting study data.|The intervention consists of 3 intervention groups. Participants will be stratified by site and randomized 1:1:1 to receive one of the 3 AH interventions for an 8-week duration.|f|f|f|t
34100785|NCT06051292|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33796817|NCT04488783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796818|NCT03680703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33796819|NCT00734240|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33796820|NCT02817282|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33796821|NCT01563354|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796822|NCT02200770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796823|NCT04769765|NA|SINGLE_GROUP||PREVENTION||NONE||Establishment of a care pathway (basic and specific) discussed and validated via a tele-expertise pluridisciplinary meeting by the 8 centers, quarterly monitoring of the course and for one year.||||
33796824|NCT05220215|RANDOMIZED|PARALLEL||OTHER||SINGLE|According to Study|Two groups with randomization, Assignment: Nordic Hamstring exercise versus Hamstring Curl with Resistance band|t|f|f|f
34100786|NCT05324787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100787|NCT05498038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a four-year multicenter mechanistic treatment (Phase 3) RCT that recruits CSM and healthy service members as controls. CSM who have signed a consent form to participate in the trial will be randomly assigned to either exercise+PRA or to PRA alone by the research assistant using a computer-generated randomization scheme generated by the study statistician. CSM will be allocated to trial arm using a pre-determined block randomization procedure in a 1:1 ratio, in multiples of 3 and limited to a maximum of 9, to reduce potential for imbalance across study arms. We will stratify the sample by sex and site and attempt to recruit a M:F ratio similar to the military in general (80:20). Randomization will occur without knowledge of the clinician who diagnosed the concussion. Data is collected at the first visit and weekly until clinical recovery, or up to 4 weeks from injury, and at the final 3 month time point. Controls will complete the clinic visits twice, two weeks apart.|f|t|f|t
34100788|NCT06212323|||COHORT||PROSPECTIVE|||||||
34100789|NCT02218151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100790|NCT05058040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100791|NCT00002316||||TREATMENT||DOUBLE||||||
34100792|NCT01273675|||CASE_ONLY||PROSPECTIVE|||||||
33716505|NCT02662946|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33716506|NCT01662258|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716507|NCT04189211|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33716508|NCT00255827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716509|NCT06408532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716510|NCT01710254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716511|NCT00329654|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33716512|NCT01265732|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33716513|NCT05981417|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716514|NCT06038084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716515|NCT05599607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, with parallel-groups, and placebo-controlled|t|f|t|f
33716516|NCT00386776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716517|NCT06131307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33716518|NCT04328584|NA|SINGLE_GROUP||OTHER||NONE||||||
33716519|NCT04607850|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Lead in phase will be open label. Main phase and expansion phase will be blinded.||t|t|t|t
33716520|NCT00184691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716521|NCT01945957|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33716522|NCT03999372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither the participant nor the outcomes assessor know the assignment codes|Randomized controlled trial|t|f|f|t
33716523|NCT05951790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796825|NCT03929770|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33796826|NCT05692635|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716524|NCT04356131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"The study was done experimentally in pre-test and post-test design and randomized controlled model among students with PD.~The sample size was calculated with power analysis. According to calculations, it was found that 58 students were enough for sampling through 95% of power value, 0.05 of confidence interval and 0.88 of effect size. Students who were determined to meet sampling and inclusion criteria through questionnaire and accepted to participate in the study were assigned into the experimental and control groups through randomization.~During the follow-up of the three menstruation periods, the number of groups was increased in case of drop-out and 100 students were included. However, the study was completed with a total of 97 students -50 students for the experimental group and 47 students for the control group- because 3 students of the control group withdrew from the study in the second month."|t|t|f|t
33796827|NCT00477776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796828|NCT06227637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the treatment they will receive, and the statistics doctor will be blinded.|The sample will be randomly subdivided into 2 Groups: Group (A)- Muscle Energy Techniques and Group (B)- Local Muscle Vibration.|t|f|f|t
33796829|NCT06112899|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33796830|NCT05303753|NA|SINGLE_GROUP||OTHER||NONE||Modifying diet by adding a fermented dairy protein with prebiotic fiber||||
33796831|NCT04244214|||COHORT||PROSPECTIVE|||||||
33796832|NCT00461747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796833|NCT04833855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33796834|NCT01462058|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34100793|NCT03425188|||COHORT||PROSPECTIVE|||||||
33796835|NCT06554327|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796836|NCT03400488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is single-blind (in which the study centre staff will remain blinded during the clinical conduct of a given cohort) with regard to treatment (AZD5718 or placebo) at each dose level. In the event of a medical emergency when management of a subject's condition requires knowledge of the trial medication, the treatment received may be revealed by personnel authorized by the Principal Investigator (PI).||t|f|f|f
34100794|NCT05339659|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34100795|NCT05478707|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants randomized to dulaglutide or placebo and study personnel who analyze data and instruct patients regarding insulin adjustments will be blinded to treatment allocation.||t|t|f|t
34100796|NCT03737994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100797|NCT06695884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant) Participants will be blinded as to TMS condition||t|f|f|f
34100798|NCT02596893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100799|NCT03673228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100800|NCT01008527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100801|NCT03976323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100802|NCT06319274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The preparation will be done by an unblinded study nurse independent of the including ICU´s, who will be responsible for preparing the investigational drug to be administered in a blinded fashion. Iloprost is a colorless fluid that is to be diluted in 0.9% saline. The infusion pump containing diluted active drug and placebo will be identical in both looks and behavior.|Randomization active/placebo (1:1) parallel arms|t|t|t|t
34100803|NCT03021005|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34100804|NCT06582641|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100805|NCT05535244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716525|NCT02374554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33796837|NCT01959126|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796838|NCT05896319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||split-mouth|f|f|t|t
33796839|NCT02568683|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33796840|NCT06488079|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33796841|NCT05967533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796842|NCT03615417|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796843|NCT02615210|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33716526|NCT03015012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716527|NCT02389010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716528|NCT03936543|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33716529|NCT03068130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716530|NCT04919850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716531|NCT03836612|||COHORT||RETROSPECTIVE|||||||
33716532|NCT03393546|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716533|NCT01797692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796844|NCT06090786|NA|SINGLE_GROUP||OTHER||NONE||||||
33796845|NCT04944446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) external evaluator|Randomized controlled longitudinal experimental study|t|f|f|t
33796846|NCT02271789|||CASE_ONLY||PROSPECTIVE|||||||
33796847|NCT05873322|||COHORT||PROSPECTIVE|||||||
33796848|NCT02683811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796849|NCT04415528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study involves partial disclosure to prevent confirmation bias on the part the research assistant who will be administering assessments. The research assistant will be blinded to the study purpose throughout the study. Participants will be informed that there will be different phases of data collection, and provision of the intervention. The research assistant will not be informed of participant allocation to the intervention group or the wait list control group.|This will be a small pilot RCT study that will use a wait list control trial design. Participants will be randomly allocated to either the intervention or control group|f|f|f|t
33796850|NCT03410966|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796851|NCT03801499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796852|NCT05316220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796853|NCT04820439|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33796854|NCT05604885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multi-center, two-part, randomized, double-blind, placebo-controlled study 4 and 12 weeks study with repeated doses of AP1189|t|f|t|t
33796855|NCT06131359|||COHORT||PROSPECTIVE|||||||
33796856|NCT01527253|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33796857|NCT05433935|||COHORT||PROSPECTIVE|||||||
33796858|NCT05305846|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"Sample size calculation:~The sample size (n = 66) has been divided into three subgroups according to BMI: normal weight, overweight and obesity class I and class II; minimum 6 subjects each group.~Dropouts will be replaced."||||
33796859|NCT05698069|||CASE_ONLY||CROSS_SECTIONAL|||||||
33796860|NCT06673628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796861|NCT01152944|||COHORT||PROSPECTIVE|||||||
33796862|NCT00484614|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33796863|NCT00212745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796864|NCT02299375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796865|NCT03460067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796866|NCT02347436|||CASE_CONTROL||PROSPECTIVE|||||||
33796867|NCT03570957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796868|NCT06441539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796869|NCT00030238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796870|NCT05783726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796871|NCT04491032|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|Investigator, who will take and record the measurements, will not know about the volume of caudal injection. Another investigator will analyze the ultrasonography images without any knowledge of the patient or the intervention.|Patients will receive either a low or high volume of caudal injection.|f|t|t|t
33796872|NCT06203197|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||two groups with conventional care control groups||||
33796873|NCT00267462|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33796874|NCT00149864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796875|NCT00345007|||DEFINED_POPULATION||PROSPECTIVE|||||||
33796876|NCT04048135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part 1 was blinded, Part 2 was open label||t|f|t|f
33796877|NCT04540822|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The childcare assistant in charge of primary outcome assessment should not having taken care of the child before. In addition, the catheter-extension tube junction, with or without compress,will be secured by placing a crepe bandage. The nurse will call him to assess the primary outcome after the catheter ( and compress and crepe bandage) will have been removed.||f|f|f|t
33796878|NCT01784653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796879|NCT02888808|||CASE_CONTROL||PROSPECTIVE|||||||
33796880|NCT04788836|||OTHER||PROSPECTIVE|||||||
33796881|NCT02561949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33796882|NCT03001180|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34020181|NCT05080426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The current study employs a cluster randomization strategy to assign organizations to either Condition A (intervention group) or Condition B (control group). One organization will be randomly assigned to the intervention and the other organization to the control group.|f|f|t|f
34020182|NCT01616108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020183|NCT02422238|||COHORT||PROSPECTIVE|||||||
34020184|NCT00049582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020185|NCT04176406|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34020186|NCT03467880|||COHORT||CROSS_SECTIONAL|||||||
33796883|NCT00144144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796884|NCT03881449|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label 2-site (Durham and Houston Veterans Affairs (VA) Health Care Systems), provider randomized, prospective 2-arm (intervention vs. TAU) pragmatic trial. We will enroll 300 adult patients with schizophrenia, bipolar I disorder, or major depressive disorder currently being treated with oral Aripiprazole from either the Durham, North Carolina or Houston, Texas Veterans Affairs (VA) Health Care System.||||
33796885|NCT00172926|||DEFINED_POPULATION||OTHER|||||||
34020187|NCT03677076|||CASE_ONLY||PROSPECTIVE|||||||
34020188|NCT03086837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020189|NCT02853370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020190|NCT00440544|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020191|NCT03080415|NA|SINGLE_GROUP||TREATMENT||NONE||All of the participants will be receiving combined therapy of sofosbuvir and daclatasvir for 12 weeks.||||
34020192|NCT05508464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020193|NCT03599830|NA|SINGLE_GROUP||OTHER||NONE||||||
34020194|NCT00601809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796886|NCT05086159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33796887|NCT02921399|||CASE_CONTROL||PROSPECTIVE|||||||
34020195|NCT03251352|||COHORT||PROSPECTIVE|||||||
34020196|NCT05795738|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessors are blinded to the assigned group of participants||f|f|f|t
34020197|NCT02737748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020198|NCT02933268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020199|NCT06584890|||CASE_ONLY||PROSPECTIVE|||||||
34020200|NCT02218125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33796888|NCT04168801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the person who performed the statistical analysis did not know to which group each patient belonged|Prior authorization from the ethics committee in health research. Patients with diagnosis of mild acute biliary pancreatitis, were divided into: Group A (early oral refeeding) and Group B (usual oral refeeding). Outcome measures were lipase pancreatic, systemic inflammatory response (concentrations of leukocytes) were used as marker for it, feasibility evaluated by abdominal pain recurrence, presence and recurrence of gastrointestinal symptoms and length of hospital stay.|f|f|f|t
33796889|NCT05488080|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study design is a pragmatic clinical trial.||||
33716534|NCT02186912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716535|NCT01750242|||COHORT||RETROSPECTIVE|||||||
33796890|NCT04783012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796891|NCT02101905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796892|NCT06676566|||COHORT||PROSPECTIVE|||||||
33796893|NCT03746665|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory personnel assessing primary and secondary serological endpoints (Men A and Tetanus Toxoid) will be blinded to group allocation (i.e. MenAfriVac Group versus Control Group).|100 eligible mother-infant pairs randomized to the control group in the PROPEL trial (SCC1433, NCT02628886) who gave consent for their samples to be used for other ethically-approved research will be chosen at random and serve as controls for this study|f|f|f|t
33716536|NCT03491241|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33716537|NCT05091099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One arm accept on time zoledronic acid after long-tearm denosumab. Another arm accept alendronate for 4 months and then zoledronic acid after long-tearm denosumab.|f|f|f|t
33716538|NCT00003903||||SUPPORTIVE_CARE||||||||
33716539|NCT03149185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized experimental trial designed to evaluate the effects of a 10-week technology-based group cognitive-behavioral stress management intervention (T-CBSM) vs. a health promotion (T-HP) group-based attention matched control condition. This is a 2 x 3 design with group assignment (T-CBSM vs. T-HP) as the between group factor, and time (baseline \[T1\], 6-months post-T1 \[T2\], and 12-months post T1 \[T3\]) as the within-group factor.||||
33796894|NCT04440618|||OTHER||PROSPECTIVE|||||||
33796895|NCT03966508|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796896|NCT05076318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796897|NCT06491732|||COHORT||PROSPECTIVE|||||||
33716540|NCT03856840|||OTHER||PROSPECTIVE|||||||
33796898|NCT03737240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized in a 1 to 1 ratio to receive the study treatment or standard of care.||||
34020201|NCT05576766|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33716541|NCT04946838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|2 groups (TENS and sham)|t|f|t|f
34020202|NCT02902783|||COHORT||PROSPECTIVE|||||||
33716542|NCT03779204|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will employ a convergent mixed methods design (i.e., quantitative and qualitative data are collected concurrently, and the findings combined) embedded within a RCT and a CBPAR framework. 24 participants will be assessed for eligibility, and then randomized into 1 of 2 arms using covariate adaptive randomization. 12 are allocated to the intervention group (rent subsidies + mentoring), while 12 are allocated to the control group (rent subsidies only). Participants in the intervention group (n = 12) will be matched with an adult mentor recruited by one of the community partners. Mentors are selected and matched through one-on-one interviews with someone in a leadership role within the organization. A common mentoring guide will be used for all sites; these booklets cover information ranging from ideal mentor characteristics to mentor code of conduct.||||
34020203|NCT03568279|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33716543|NCT01288248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716544|NCT01706081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716545|NCT06277921|||COHORT||PROSPECTIVE|||||||
33716546|NCT05248412|||COHORT||RETROSPECTIVE|||||||
33716547|NCT02924779|||CASE_ONLY||RETROSPECTIVE|||||||
33716548|NCT02634684|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33716549|NCT02733588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720954|NCT00495170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796899|NCT05848583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single center, open-label||||
33796900|NCT06386237|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34020204|NCT04190719|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Paprika program will be proposed to all eligible patients.|Interventional group: Patients with Paprika program Historical group: Patients with same characteristics operated in 2018-2019||||
34020205|NCT00663767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020206|NCT05498402|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Data extraction will be fully automated and the statistician will not know the identity of the participants or the sequence they were allocated to.|Prospective, multicenter, crossover, simulation-based, randomized controlled trial|f|f|f|t
34020207|NCT00336245|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34020208|NCT06170437|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled groups||||
34020209|NCT02470390|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34020210|NCT05506410|||CASE_ONLY||PROSPECTIVE|||||||
34020211|NCT03216070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020212|NCT05960318|||CASE_ONLY||PROSPECTIVE|||||||
34020213|NCT03564444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020214|NCT03956121|||CASE_CONTROL||PROSPECTIVE|||||||
34020215|NCT03630237|||COHORT||PROSPECTIVE|||||||
34020216|NCT05135052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020217|NCT01406392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020218|NCT03441724|||CASE_CONTROL||PROSPECTIVE|||||||
34020219|NCT05323331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020220|NCT01176708|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34020221|NCT05791513|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stepped-wedge randomised trial||||
34020222|NCT03849287|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020223|NCT04872673|||OTHER||PROSPECTIVE|||||||
34020224|NCT05783518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941447|NCT01259388|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Each study participant agreed to a two-year enrollment commitment. Each subject was asked to take lithium for one year and to be observed for one year. Randomization was used to determine the sequence of lithium vs. observation (year 1 or year 2).|f|f|f|t
33941448|NCT05331547|||CASE_CONTROL||PROSPECTIVE|||||||
33941449|NCT01783223|||COHORT||PROSPECTIVE|||||||
33941450|NCT00339027|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941451|NCT01891539|||COHORT||PROSPECTIVE|||||||
33941452|NCT00824746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941453|NCT02176122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941454|NCT01849354|||CASE_CONTROL||PROSPECTIVE|||||||
33941455|NCT01976494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941456|NCT05190406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor will be blinded||f|f|f|t
33941457|NCT05312528|||CASE_CONTROL||PROSPECTIVE|||||||
33941458|NCT01963533|||CASE_ONLY||PROSPECTIVE|||||||
33941459|NCT01017289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941460|NCT05547828|NA|SINGLE_GROUP||TREATMENT||NONE|This study is a single-arm, prospective, open-label clinical study|||||
33941461|NCT03803176|||CASE_CONTROL||PROSPECTIVE|||||||
33941462|NCT05182034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941463|NCT00497939|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33941464|NCT04890028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941465|NCT02804386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941466|NCT02465957|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941467|NCT03933254|||OTHER||PROSPECTIVE|||||||
34020225|NCT01555008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716550|NCT03906903|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single|The aim of this study is to evaluate the clinical effects of 5Hz rTMS over Left Dorsolateral Prefrontal Cortex on an active versus placebo modality stimulation and Cognitive Stimulation.|t|f|f|f
33716551|NCT03363204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716552|NCT01671189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716553|NCT06364540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716554|NCT02744391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020226|NCT04068844|RANDOMIZED|FACTORIAL||TREATMENT||NONE||HFpEF patients with either central or peripheral limitations to exercise will be randomly assigned to either whole body or isolated single leg exercise.||||
34020227|NCT04100785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020228|NCT00266396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020229|NCT00561561|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34020230|NCT02478073|||CASE_ONLY||PROSPECTIVE|||||||
34020231|NCT05941689|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34020232|NCT00426712|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34020233|NCT02444793||||TREATMENT||NONE||||||
34020234|NCT05903456|NA|SINGLE_GROUP||TREATMENT||NONE|NO masking|||||
34020235|NCT03271450|||COHORT||OTHER|||||||
34020236|NCT05982717|||CASE_ONLY||RETROSPECTIVE|||||||
33716555|NCT03181568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator will be blinded to study Clinical staff that will evaluate wounds at baseline, 2, 4, 6, 8, 10 and 12 weeks after date of randomisation and therapy initiation will be blinded|This will be a single blinded randomised trial where the control group will be receiving a standard wound care whereas the treatment group would also be receiving standard wound care but under the guidance of the imaging device.|f|t|t|f
33716556|NCT00814190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33716557|NCT03408756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33716558|NCT03869866|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716559|NCT00718497|||CASE_ONLY||CROSS_SECTIONAL|||||||
33716560|NCT01170091|||||PROSPECTIVE|||||||
33716561|NCT03555201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716562|NCT01719523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716563|NCT05615389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33716564|NCT06128395|||COHORT||RETROSPECTIVE|||||||
33941468|NCT03525912|NA|SINGLE_GROUP||TREATMENT||NONE||single group assignment interventional||||
33941469|NCT00738322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941470|NCT06143995|||OTHER||CROSS_SECTIONAL|||||||
33941471|NCT00136461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941472|NCT04376905|||COHORT||PROSPECTIVE|||||||
33941473|NCT04506073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941474|NCT04803656|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||COPD patients: Respiratory muscle strength, peripheral muscle strength in both upper and lower extremity were evaluated. Pulmonary function tests obtained during routine controls of patients.||||
33941475|NCT03949816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33941476|NCT06234891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients in both groups were evaluated after treatment by a physiatrist blinded to the study.|Patients with VAS, ODI and SF-36 quality of life values before treatment, in addition to demographic data, who have applied to our Physical Medicine and Rehabilitation Policlinic in our hospital with chronic low back pain in the last 3 (three) months, are determined, and at least 30 above the age of 18 who received physiotherapy and who did not receive physiotherapy. By calling the patient on the phone and being called to our hospital; patient consents will be obtained and VAS, ODI and SF-36 quality of life values will be questioned.|f|f|f|t
33941477|NCT03481933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||left-excitatory tDCS ; right-inhibitory tDCS; sham tDCS (placebo)|t|f|t|t
33716565|NCT00384995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720955|NCT00671307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020237|NCT03682224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not be aware of the drug group. A study statistician will generate the randomization with two arms. Statistician will be blinded and will not be aware of the treatment allocation. Researchers and clinicians will be aware of the allocation and drugs will be dispensed by the hospital pharmacy based on the allocation sequence.|Participants will be randomly assigned to receive either Exparel or Marcaine during surgery. Based on the randomization they will receive one of the two drugs. Participants are assigned one of the two groups in parallel for the duration of the study|t|f|f|f
34020238|NCT04180163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020239|NCT04460859|||OTHER||PROSPECTIVE|||||||
34020240|NCT04275206|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Participants: Tap water and medicinal water have the same pH, colour, smell; in another study we proved that they could not differentiate them.~Care providers do not know if tap water or medicinal water was installed in the bath tub.~Investigator: Control and treated patients are encoded. Outcome assessor can see only the encoded measurement results."|"Psoriasis / RA (t=0) Control (t=1) ---\> (t=3) Medicinal water (t=4) (t=0) Medicinal water (t=1) ---\> (t=3) Control (t=4)~After 6 months, treatments will be repeated, but transposed, the previously control patients will receive medicinal water treatment, and tap water treatment will be performed on the previously treated group."|t|t|t|t
34020241|NCT03641391|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34020242|NCT05779423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020243|NCT00045539||||TREATMENT||NONE||||||
33716566|NCT03067649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluators were unaware of condition assignment|Experimental intervention vs. an information only control|f|f|f|t
33716567|NCT02042378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716568|NCT06199531|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation cohort study of GS-100 administered by intracerebroventricular (ICV) infusion; dose cohorts will be assigned in sequential or parallel order.||||
33716569|NCT04768231|NA|SINGLE_GROUP||TREATMENT||NONE||Single intervention group compared with historical controls||||
33716570|NCT05752903|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33716571|NCT00975481|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33716572|NCT05370222|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716573|NCT05752279|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33716574|NCT03937427|||COHORT||PROSPECTIVE|||||||
33716575|NCT04784949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||permanent molar with symptomatic irreversible pulpitis|t|f|f|t
33716576|NCT02074254|||OTHER||RETROSPECTIVE|||||||
33716577|NCT03181204|||OTHER||CROSS_SECTIONAL|||||||
33716578|NCT01152086|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33716579|NCT02493621|||CASE_CONTROL||RETROSPECTIVE|||||||
33716580|NCT02371551|||CASE_ONLY||PROSPECTIVE|||||||
33716581|NCT06346496|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33716582|NCT05515757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716583|NCT03713970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After examining the participant for eligibility,each participant will be given a number start from one by Shafeq(the main researcher )i.e. each participant will be assigned by numbers and allocated to different groups using these numbers.(for example, the odd numbers to the intervention and the even numbers to the control group)|two groups withe different laminate veneers restorations(celtra duo press and IPS e.max press)|t|t|t|f
33716584|NCT04925128|RANDOMIZED|PARALLEL||OTHER||SINGLE|single participant according to study|two groups with randomization. Assignment; treadmill walking|t|f|f|f
33716585|NCT05816551|||COHORT||PROSPECTIVE|||||||
33716586|NCT05734625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Research subjects will be informed that they are in a trial of nerve blocks in treatment and prevention of migraine headache and may receive up to 10 nerve blocks. The language of consenting will seek to minimize bias by seeking to avoid suggesting that more blocks are better than less as follows: There are small and large nerves all over the front, back and sides of your head that can contribute to a migraine headache. In this study, subjects will get nerve blocks in various combinations of one or two or up to 10 nerves at a time. The nerves blocked may or may not respond to the location of your pain."|Pragmatic randomized comparison trial|t|f|f|f
33716587|NCT04698902|||COHORT||PROSPECTIVE|||||||
33941478|NCT05573204|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study is randomized controlled, parallel and prospective 6-months duration study. Accepted patients will be randomized into 2 groups as the following:~* Group 1 (Obeticholic acid group): 30 patients will receive 10 mg/day OCA for 6 months.~* Group 2 (Control group): 30 patients will receive Vitamin E 400 mg twice daily for 6 months."||||
33941479|NCT00805142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941480|NCT06170359|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941481|NCT00840931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941482|NCT02918136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941483|NCT03102073|||COHORT||OTHER|||||||
33941484|NCT05340179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33941485|NCT04806165|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33941486|NCT00340938||||TREATMENT||||||||
33941487|NCT01087151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941488|NCT00001126||||TREATMENT||DOUBLE||||||
33941489|NCT01959087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33941490|NCT05113849|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33941491|NCT00935766|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33941492|NCT04372173|||COHORT||PROSPECTIVE|||||||
33941493|NCT01742013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941494|NCT02705339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941495|NCT02511691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941496|NCT01454973|||CASE_CROSSOVER||PROSPECTIVE|||||||
33941497|NCT01990339|||COHORT||PROSPECTIVE|||||||
33941498|NCT01811693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941499|NCT05909618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941500|NCT00598884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941501|NCT06075251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors responsible for coding the primary outcome will be masked to condition. Due to the nature of the intervention (behavioural program), participants and care providers cannot be masked to condition.|This study is a single-site, two-arm randomized clinical trial. Families will be randomized to receive care as usual or active I-InTERACT-North stepped-care treatment.|f|f|f|t
33941502|NCT02929836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020244|NCT02517437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020245|NCT00485680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34020246|NCT03994497|NA|SINGLE_GROUP||SCREENING||NONE||||||
34020247|NCT02915965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020248|NCT00658827|||COHORT||PROSPECTIVE|||||||
34020249|NCT00121472|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020250|NCT00687089|||CASE_ONLY||PROSPECTIVE|||||||
34020251|NCT03573505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941503|NCT01865344|||COHORT||PROSPECTIVE|||||||
33941504|NCT00329836|||COHORT||PROSPECTIVE|||||||
33941505|NCT01652027|||COHORT||PROSPECTIVE|||||||
33941506|NCT01160510|||OTHER||RETROSPECTIVE|||||||
33941507|NCT04460651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Simple, pragmatic, double-blind, placebo-controlled trial|t|t|t|f
33941508|NCT00423540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941509|NCT04952090|||COHORT||CROSS_SECTIONAL|||||||
33941510|NCT04680273|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33941511|NCT03066492|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020252|NCT03579966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020253|NCT05532124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020254|NCT02571166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020255|NCT05393843|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized, double-blind|t|t|t|t
34020256|NCT02562105|||COHORT||PROSPECTIVE|||||||
34020257|NCT02365870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33716588|NCT06192186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a double-blind design, which blinds both the researcher and the patient. Considering that adebrelimab is administered by injection and the solvent is a 5% glucose solution, therefore, the control group will use 5% glucose solution as placebo. They are not easily distinguishable in appearance, so patients can be blinded. During the research process, patient grouping information will be randomly extracted by Jialin Luo, and kept confidential to other researchers (other members who responsible for follow-up and analysis) until unblinding. Meanwhile, Jialin Luo did not participate in the follow-up and statistical analysis of patients after medication.||t|f|t|f
33716589|NCT02461563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716590|NCT02707250|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33716591|NCT03545919|||CASE_ONLY||PROSPECTIVE|||||||
33941512|NCT00856336|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33941513|NCT04228666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941514|NCT04436406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941515|NCT00212615|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34020258|NCT00144664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020259|NCT05808673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biological: Pre- and Post-change CMAB807X, Xgeva®|t|t|t|t
34020260|NCT00002353||||TREATMENT||||||||
34020261|NCT00267449|||DEFINED_POPULATION||PROSPECTIVE|||||||
34020262|NCT00722982|||CASE_CONTROL||PROSPECTIVE|||||||
33941516|NCT03733704|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Spontaneous ventilation via an obstructing plastic tube||||
33716592|NCT04063709|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This unblinded, open-label, exploratory study will be conducted in 60 patients with clinical indication for carotid endarterectomy (CEA). Among these 60 patients, N=20 will be symptomatic with 50-69% carotid artery stenosis, N=20 will be symptomatic with 70-99% stenosis, and N=20 will be asymptomatic with 70-99% stenosis. The study will also be conducted in N=20 additional patients without clinical indication for CEA. These patients will be asymptomatic with 50-60% stenosis.||||
33716593|NCT03199586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716594|NCT01141907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33941517|NCT02026193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020263|NCT05291039|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomized controlled|prospective study for IBD patients receiving either adalimumab (group 1) or infliximab (group 2).||||
34020264|NCT00593203|||OTHER||PROSPECTIVE|||||||
34020265|NCT01287039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716595|NCT06182189|||COHORT||PROSPECTIVE|||||||
33716596|NCT04386421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716597|NCT03186222|||CASE_CONTROL||PROSPECTIVE|||||||
33716598|NCT00372125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716599|NCT05296759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716600|NCT00433849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716601|NCT05183373|||COHORT||PROSPECTIVE|||||||
33716602|NCT03096210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716603|NCT03447132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716604|NCT02622516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33716605|NCT05843981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients, the outcome assessors (when possible) and the statistical advisors will be blind to the used implant|Split-mouth|t|f|f|t
33716606|NCT02988505|||COHORT||PROSPECTIVE|||||||
33716607|NCT02436889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716608|NCT04432662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716609|NCT05340868|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33716610|NCT03156673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716611|NCT00703989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716612|NCT00197041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716613|NCT00941473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33716614|NCT00344227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716615|NCT03440710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716616|NCT03498690|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized 1:1:1 to feedback that is integrative or role specific or presented consecutively||||
33716617|NCT03038334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716618|NCT00432471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716619|NCT02245490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33716620|NCT00105482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716621|NCT01053728|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33716622|NCT02526472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716623|NCT02392247|||||PROSPECTIVE|||||||
33716624|NCT00332033||||TREATMENT||||||||
33716625|NCT03194321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716626|NCT01179854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716627|NCT01324999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716628|NCT04497506|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Allocation will be concealed to the participants, researchers -who will be in class the assessment days if possible depending on the Covid-19 scenario- and teachers.|Participants will be randomized in a 1:1 ratio blocked by gender to one of two groups: experimental condition (SA+ITP) versus control condition (anti-stress condition) in parallel for the duration of the study.|t|f|f|t
33716629|NCT02422511|RANDOMIZED|PARALLEL||OTHER||SINGLE|Families are masked to randomization until disclosure sessions||t|f|f|f
33716630|NCT05627154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Due to the nature of the intervention, the study will be single blinded only to citalopram or placebo administration. As the primary researcher will be the one administering the behavioural activation (BA) training, both the participants and the primary researcher will be aware of who did or did not receive the psychological intervention. However, participants will not be aware that receiving BA means they are also taking citalopram. The primary researcher, on the other hand, will be aware of this and will only be blinded to drug administration in the BA-free groups. To compensate for the lack of complete blinding, post-treatment outcome data will be collected online and not directly by the primary researcher. Moreover, before the data is analysed, participant ID numbers will be re-allocated to avoid bias in the outlier detection and data exclusion process.|Participants are randomised into one of three groups, each undergoing two weeks of either: 1) placebo alone, 2) citalopram alone or 3) citalopram and behavioural activation training.|t|f|f|t
33716631|NCT00380107|||||PROSPECTIVE|||||||
33716632|NCT06372860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716633|NCT00607412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716634|NCT04496544|||COHORT||RETROSPECTIVE|||||||
33716635|NCT05971407|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are blinded to intervention. Assessors measuring outcomes are blinded to participant identity and intervention.|Participants complete a 6-week intervention period during which the participants receive either RIPC or sham. There is then a 6-week washout period, after which participants complete the other intervention|t|f|f|t
33716636|NCT05747781|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, longitudinal, non-randomized, open-label study with glaucoma patients and control group (healthy volunteers)||||
33716637|NCT06030557|||OTHER||PROSPECTIVE|||||||
33716638|NCT02978261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716639|NCT03176329|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Prospective randomized crossover study||||
33716640|NCT02177305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941518|NCT02565303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941519|NCT01773057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33941520|NCT01997827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020266|NCT04646941|||COHORT||RETROSPECTIVE|||||||
33716641|NCT00983021|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33716642|NCT01967121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716643|NCT00414362|||OTHER||RETROSPECTIVE|||||||
33716644|NCT01816633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716645|NCT00115050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716646|NCT02056704|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941521|NCT06118853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized into two groups: Group A (control): standard treatment /Group B (intervention): yoga + gentle massage + standard treatment. Group B (intervention) will receive 8 individual integrative practice sessions at the bedside, each lasting 15 to 20 minutes, with 2 sessions per week during the following periods: from admission until D+0 / until D+7 / until D+14 / until D+21 or discharge. The therapist will choose the integrative practices that best suit the patient for each session, based on their psychophysical state and symptoms, as there can be many variations during HSCT. Group A (control) will receive 8 visits from integrative therapists who will remain in the patient's room, able to interact but without offering integrative practices, during the same periods described above. After D+21, these patients will also receive 8 integrative practice sessions at the bedside or in the Integrative Medicine room.||||
33941522|NCT02083822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941523|NCT03782389|||COHORT||RETROSPECTIVE|||||||
33941524|NCT00699361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941525|NCT00723515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34020267|NCT04325763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020268|NCT00186758|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34020269|NCT00166907|NON_RANDOMIZED|PARALLEL||ECT||NONE||||||
34020270|NCT05967052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020271|NCT02314091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020272|NCT05262998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020273|NCT01884818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020274|NCT03589573|||OTHER||OTHER|||||||
34020275|NCT00798876|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020276|NCT00416702|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020277|NCT04669847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020278|NCT01271751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716647|NCT00168688|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716648|NCT02569723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716649|NCT01617174|||COHORT||PROSPECTIVE|||||||
33716650|NCT04638023|||COHORT||RETROSPECTIVE|||||||
33716651|NCT04334720|||CASE_CONTROL||RETROSPECTIVE|||||||
33716652|NCT05004753|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 to 1 ratio||||
33716653|NCT00425451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716654|NCT05368857|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716655|NCT00565344|||COHORT||RETROSPECTIVE|||||||
33716656|NCT00002925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716657|NCT05184140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Controlled, prospective, descriptive||||
33716658|NCT03852940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716659|NCT05609240|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|An anaesthetist will provide the intra-operative intervention and will the subsequently not be involved in the patients follow up or outcome assessment. alternatively, a research nurse not involved in participant follow up will provide the intra-operative intervention.||t|t|t|t
33716660|NCT03590236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716661|NCT03933189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will complete all the research outcome measures with a blinded independent examiner who will not be treating the participants and who will not know which treatment group participants are randomized to.|Blinded randomized controlled study.|f|f|f|t
33716662|NCT03495076|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|"Participants will not be informed about the hypotheses tested and will not be informed about the sham-injection condition. The fact that they received only one injection during the study period will be uncovered at the end of the project.~Examiner will be blinded towards conditions sequence. Between pre-test and post-test examiner will not be present in the research room to provide blinding towards the manipulation provided (control, saline injection, sham injection)."|Within-group designed study. All participants will be assessed in three different experimental conditions (control, saline injection, sham injection). The order of conditions will be counterbalanced across participants and randomly chosen.|t|f|f|t
33716663|NCT06495164|||COHORT||RETROSPECTIVE|||||||
33716664|NCT03793231|||COHORT||PROSPECTIVE|||||||
33716665|NCT04065906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716666|NCT03724084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716667|NCT03029377|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33716668|NCT05201560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716669|NCT00527007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716670|NCT05528679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716671|NCT04481750|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single Blind||t|f|f|f
33716672|NCT05124964|||COHORT||PROSPECTIVE|||||||
33716673|NCT04684498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716674|NCT02880189|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33716675|NCT03372811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33716676|NCT05424042|RANDOMIZED|PARALLEL||OTHER||SINGLE|Staff who will assess outcomes at follow up visits will be blinded to group assignment.|One-hundred participants (100) will be randomized to the three study arms in a 1:1:1 ratio. Recruitment will be stratified by sex. Once eligibility is established and baseline testing is completed, participants will be randomized using a permuted block scheme with blocks of varying size stratified by sex to one of the 3 intervention groups.|f|f|f|t
33716677|NCT04473014|||OTHER||OTHER|||||||
34020279|NCT06320808|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants will be randomized to receive either the one-page FDA-template PMI (FDA PMI), a modified template, which added information about drug benefits (Decision Critical PMI), or the existing drug information insert (standard drug information). Participants will complete the same survey questions measuring perceived usefulness and comprehension of the information.|f|f|t|f
33716678|NCT00342433|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020280|NCT03651258|||COHORT||PROSPECTIVE|||||||
34020281|NCT02908035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34020282|NCT01221012|||CASE_CONTROL|||||||||
34020283|NCT05561543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020284|NCT06160505|||COHORT||RETROSPECTIVE|||||||
34020285|NCT05033093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||After the final irrigation process root canals will be dried with sterile paper points and then randomly divided into three main groups according to the root canal sealer ; G1: AH Plus G2: iRoot SP G3: GuttaFlow Bioseal to be used in the obturation process (n: 28).|t|f|f|f
34020286|NCT02117700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled randomized double blind||t|t|t|t
34020287|NCT04067427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020288|NCT02454660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34020289|NCT05874739|||COHORT||PROSPECTIVE|||||||
34020290|NCT02650479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34020291|NCT02365558|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34020292|NCT00543608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020293|NCT02994940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020294|NCT02125162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716679|NCT05796050|||COHORT||RETROSPECTIVE|||||||
33716680|NCT00503802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716681|NCT04378751|RANDOMIZED|PARALLEL||SCREENING||SINGLE||"Computer-generated randomization (equal numbers in each arm), patients will be randomized to one of two arms:~1. Decision aid video~2. Genetic counseling informational brochure"|t|f|f|f
33716682|NCT02560233|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33716683|NCT06039826|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33716684|NCT06481514|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33716685|NCT05827523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Enrolled patients are unaware of which group they have been assigned to.|Randomized controlled, single-blinded, multicenter phase III trial|t|f|f|f
33716686|NCT03017950|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716687|NCT03055351|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716688|NCT06371053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716689|NCT00000233||||TREATMENT||||||||
33716690|NCT03628703|NA|SINGLE_GROUP||OTHER||NONE||||||
33716691|NCT00804830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716692|NCT05263323|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33716693|NCT04637789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716694|NCT03178864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716695|NCT00022451||||TREATMENT||NONE||||||
33716696|NCT01877499|||COHORT||PROSPECTIVE|||||||
33716697|NCT03409406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716698|NCT00759954|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33716699|NCT03229161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This open-label randomized controlled trial aims to enroll 20 patients randomized (1:1) to a control- (Con) or IWT-group. Patients in both the IWT- and Con-group follows the standardized GDM care program for GDM patients at OUH through the 6-week intervention period, which consists of instruction of self-monitoring of BG levels, dietary guidance, and in some cases, insulin treatment. Additionally, the program also consists of close obstetric control visits and exercise guidance. All patients are instructed not to start any new type of PA after inclusion and continue their lives without any changes.~Patients randomized to the IWT-group goes through a 6-week non-supervised IWT-program, where they are prescribed to conduct 3 IWT sessions per week of 40-50 minutes each.~Before and after the 6-week intervention, maternal blood glucose (BG) levels is measured by continuous glucose monitoring, PA level measured using accelerometers and physical fitness measured using two walking tests."||||
33716700|NCT00726804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716701|NCT00996216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716702|NCT00811538|||COHORT||PROSPECTIVE|||||||
33716703|NCT00876772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716704|NCT00001889||||TREATMENT||||||||
33716705|NCT03277105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716706|NCT00596570|||COHORT||PROSPECTIVE|||||||
33716707|NCT03348956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716708|NCT01431833|NON_RANDOMIZED|PARALLEL||||NONE||||||
34100806|NCT05912166|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The researchers will collect implementation feasibility and acceptability data of the 9-week Spanish-language Wakeful app in a mixed sample of young adult cancer survivors (n=30) between 18-39, using a single arm pre-post test design. Following consent, participants will be immediately directed to a secure Redcap assessment URL to complete the T1 assessment. Next, participants will be sent an email to access the Wakeful web app where they will watch a brief video orientation and begin the 9-week self-directed course. After 9 weeks, participants will be emailed a secure URL to complete the T2 assessment.||||
34100807|NCT06471998|NA|SINGLE_GROUP||TREATMENT||NONE||proof-of-concept, single-center, prospective, interventional, non-randomized Phase II study||||
34100808|NCT04428281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study||||
34100809|NCT05623020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100810|NCT01468961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100811|NCT03812172|||COHORT||PROSPECTIVE|||||||
34100812|NCT04103606|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34100813|NCT05379985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100814|NCT06121635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed whether the stimulations applied are active or sham.||t|t|f|f
34100815|NCT06689696|||COHORT||PROSPECTIVE|||||||
34100816|NCT01715545|||COHORT||RETROSPECTIVE|||||||
34100817|NCT06695676|||OTHER||PROSPECTIVE|||||||
34100818|NCT05243017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The first cohort will be treated with low dose, and a total of 6 enrolled participants is anticipated. The second cohort will be treated with high dose, and a total of 9 enrolled participants is anticipated.||||
34100819|NCT05556187|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The two different oxygen doses at home is randomised after the initial assessment. It is not possible to blind the patients nor the investigator in this feasibility design.|The study will be conducted as a multicentre pilot randomized crossover feasibility trial.||||
34100820|NCT00127543|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34100821|NCT03167424|||COHORT||PROSPECTIVE|||||||
33716709|NCT01640145|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34100822|NCT06658470|||OTHER||CROSS_SECTIONAL|||||||
34100823|NCT06233461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796901|NCT04409912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Dialysis centre staff and procedurist performing the intervention will also be masked|Participants will be randomly allocated in a 1:1 ratio into either the treatment (SCB) arm or control (PB) arm. As above-elbow AVFs generally have larger vessel size and better outcomes compared to below-elbow AVFs, randomisation will be stratified by location of AVF (above vs below elbow) to ensure a more even distribution of AVF by location between both groups.|t|t|t|t
33796902|NCT06677034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941526|NCT01483378|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33941527|NCT05911893|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants aged 1 to 3 years who are malnourished (underweight and wasting) are randomly divided into an experimental group and a control group. The experimental group is given nutritional education and high-energy total nutrition formula, while the control group is given nutritional education and dietary guidance. At the 1-month, 2-month, 3-month, and 6-month follow-ups of enrollment, children in the control group are transferred to the trial group if the assessment revealed that they are unable to achieve ≥75% of their predicted nutritional requirements through dietary modification or their rate of weight gain do not improve, according to the study design principles of the stepped wedge cluster trial.||||
33941528|NCT04981236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33941529|NCT00364351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941530|NCT00104429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941531|NCT05086549|||COHORT||PROSPECTIVE|||||||
34100824|NCT04818086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100825|NCT05630053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants should be masked until after the surgical procedure.||t|f|f|f
34100826|NCT04093882|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34100827|NCT04082689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The group allocation of the participating Children will be masked to the co-workers performing the ultrasound measurement of rectal diameter at 9 months and 4 years of age.|A randomized controlled trial (RCT) where one group of children who begin assisted infant toilet training at age 0-2 months (group A) is compared to a group of children who begin assisted infant toilet training at 10-11 months (group B).|f|f|f|t
34100828|NCT06393985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716710|NCT01548092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941532|NCT01939067|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941533|NCT06447831|||COHORT||PROSPECTIVE|||||||
34100829|NCT06209086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100830|NCT06694298|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
34100831|NCT03937947|||COHORT||PROSPECTIVE|||||||
33716711|NCT04326348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716712|NCT04087694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716713|NCT02402439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716714|NCT00589563|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33716715|NCT06369376|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716716|NCT04218305|||CASE_CONTROL||PROSPECTIVE|||||||
33716717|NCT04894903|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33716718|NCT02259582|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33716719|NCT03404791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716720|NCT03824912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study products are blinded and provided to the patients in the same packaging.|Randomized, double-blind, placebo-controlled, three-arm, parallel group, multiple-site bioequivalence study with clinical endpoints.|t|t|t|t
33716721|NCT03294057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel Assignment||||
33716722|NCT02554812|RANDOMIZED|||TREATMENT||NONE||||||
33716723|NCT03222050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716724|NCT05219084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716725|NCT01679977|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34020295|NCT02860338|||COHORT||RETROSPECTIVE|||||||
34020296|NCT02305953|||COHORT||RETROSPECTIVE|||||||
34020297|NCT05145881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020298|NCT02925507|||CASE_CONTROL||PROSPECTIVE|||||||
34020299|NCT06258798|||CASE_ONLY||RETROSPECTIVE|||||||
34100832|NCT00005133|||COHORT||PROSPECTIVE|||||||
34100833|NCT05975125|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100834|NCT02705820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796903|NCT02269280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796904|NCT04226703|||COHORT||CROSS_SECTIONAL|||||||
33796905|NCT00648011|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33796906|NCT05344001|||COHORT||PROSPECTIVE|||||||
33796907|NCT05317611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor (anesthesiologist not sharing in the study) will assess outcome parameters|Study the effect of intraperitoneal instillation vs intravenous ondansetron on PONV added to intraperitoneal bupivacaine for enhanced recovery and to decrease incidence of PONV after laparoscopic gynecological surgeries.|f|f|f|t
33796908|NCT04651881|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33796909|NCT00880477|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796910|NCT05226416|||COHORT||PROSPECTIVE|||||||
33796911|NCT03822572|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33796912|NCT06381999|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796913|NCT02296424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding was required in this open-label study|A two-part open-label study that collected long-term efficacy, safety, and tolerability data from SJIA patients receiving canakinumab treatment who had inactive disease at the last visit in Study CACZ885G2301E1 (Cohort 1), and from SJIA patients who were canakinumab treatment-naïve and had active disease at the time of screening for this study (Cohort 2)||||
33796914|NCT01374607|||COHORT||PROSPECTIVE|||||||
33796915|NCT01748565|||COHORT||PROSPECTIVE|||||||
33796916|NCT05064930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796917|NCT04616963|NA|SEQUENTIAL||PREVENTION||NONE||Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.||||
33796918|NCT03845114|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33796919|NCT03696966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33796920|NCT02018016|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33796921|NCT01396837|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous Blood Clot Product was applied to all patients||||
33796922|NCT01129232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796923|NCT03787537|||COHORT||PROSPECTIVE|||||||
33796924|NCT06530056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33796925|NCT05709431|||OTHER||PROSPECTIVE|||||||
33796926|NCT04178239|||COHORT||PROSPECTIVE|||||||
33796927|NCT03197090|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33796928|NCT03293056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment: highintensity interval training water versus aerobic continuous|f|f|t|t
33796929|NCT02800434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796930|NCT00001992||||PREVENTION||||||||
33796931|NCT00553683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796932|NCT06255795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796933|NCT04333355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796934|NCT00043654||||TREATMENT||||||||
33796935|NCT06307548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796936|NCT06676553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33796937|NCT00018785||PARALLEL||PREVENTION||NONE||||||
33796938|NCT01161563|RANDOMIZED|CROSSOVER||||NONE||||||
34020300|NCT02781337|||COHORT||PROSPECTIVE|||||||
34020301|NCT02819050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33796939|NCT02035969|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796940|NCT00177216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33796941|NCT03414658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796942|NCT04872621|||COHORT||PROSPECTIVE|||||||
33796943|NCT02552186|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796944|NCT02645006|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33796945|NCT06484504|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|t|t|f
33796946|NCT03565939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Double-blind randomised, placebo-controlled, 24 weeks, comparative, exploratory phase II proof of concept trial.|t|t|t|t
33796947|NCT05425433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796948|NCT02301442|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33796949|NCT02227771|||COHORT||PROSPECTIVE|||||||
34020302|NCT00654758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020303|NCT01782235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020304|NCT04568473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020305|NCT02312518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020306|NCT02210741|||CASE_ONLY||PROSPECTIVE|||||||
34020307|NCT03234725|||COHORT||PROSPECTIVE|||||||
34020308|NCT00000717||||TREATMENT||NONE||||||
34100835|NCT04669093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be aware of the type of suggestion (or the fact there are different types of suggestions) during the experiment. They will be debriefed upon the study's conclusion.|This is a within-participant design. Each participant will participate in two sessions. In both sessions, an over-the-counter hand cream will be applied to their skin, accompanied by a placebo suggestion that the cream is analgesic. In one session, the suggestion will match the participant's motivational style, and in the other session the suggestion will not match their motivational style. The order of sessions will be counterbalanced across participants. Each session will also include a control condition, in which participants will be told that the cream has no affect. The same over-the-counter hand cream will be used in all sessions.|t|f|f|f
33720956|NCT03688750|||OTHER||PROSPECTIVE|||||||
33720957|NCT00000381|RANDOMIZED|||TREATMENT||DOUBLE||||||
33720958|NCT06081127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot Randomized Controlled Trial||||
33720959|NCT03904433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33720960|NCT05302544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720961|NCT05757531|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720962|NCT06163261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33720963|NCT03644745|NA|SINGLE_GROUP||OTHER||NONE||The first 5 volunteers will be assigned for the preliminary in-home deployment to test the usability and provide feedback to potentially refine the system. Researchers will provide each participant with an activity tracker and download the required software on the participant's computer and smart phone. After 1 week, two researchers will conduct a home visit to provide the participant with a brief introduction to the system. Participants will interact with the system for 30 days while researchers use protocol analysis to record usability issues. All interactions with the system will be recorded. After 30 days, we will conduct an interview with the participant designed to uncover issues. The outcome measures described below will also be recorded. After necessary changes to the engagement and coaching system are made, we will deploy the system in an additional 15 homes for 3 months.||||
33720964|NCT01660607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720965|NCT05863910|||COHORT||PROSPECTIVE|||||||
33720966|NCT06237595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33720967|NCT03410940|||COHORT||PROSPECTIVE|||||||
33720968|NCT02375191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33720969|NCT00164190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720970|NCT05418192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720971|NCT05202418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33720972|NCT06363006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720973|NCT00002546|RANDOMIZED|||TREATMENT||||||||
33720974|NCT03573895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33720975|NCT05715008|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33720976|NCT04672447|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Randomized, placebo-controlled, double-blind, parallel-groups study.|Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator)|t|f|t|f
33720977|NCT02989740|||COHORT||PROSPECTIVE|||||||
33720978|NCT01817933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720979|NCT04251221|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33720980|NCT04511793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720981|NCT05985655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720982|NCT01033682|||COHORT||PROSPECTIVE|||||||
33720983|NCT01998737|||COHORT||CROSS_SECTIONAL|||||||
33720984|NCT02734446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33720985|NCT06350292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720986|NCT01042236|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33720987|NCT02625155|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33720988|NCT04976166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720989|NCT02418507|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33720990|NCT05901779|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720991|NCT05569200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720992|NCT03301038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33720993|NCT03233906|RANDOMIZED|PARALLEL||TREATMENT||NONE||Human subjects- females (18-45 y.o.) with a BMI greater than or equal to 26.||||
33720994|NCT04063956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33720995|NCT04602832|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33720996|NCT05915741|||COHORT||PROSPECTIVE|||||||
33720997|NCT01988259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33720998|NCT02724306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33720999|NCT03337074|||CASE_CONTROL||PROSPECTIVE|||||||
33721000|NCT04962009|NA|SINGLE_GROUP||TREATMENT||NONE||Travoprost Evolute (Travoprost Punctal Plug Delivery System), 166 ug||||
33721001|NCT01648907|||COHORT||PROSPECTIVE|||||||
33721002|NCT04798547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trial|t|f|f|f
33721003|NCT02333695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721004|NCT02588170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721005|NCT06403735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721006|NCT05972265|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33721007|NCT00604331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721008|NCT05304156|||COHORT||PROSPECTIVE|||||||
33721009|NCT05635240|||COHORT||PROSPECTIVE|||||||
33721010|NCT01873001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721011|NCT05009940|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33721012|NCT01876888|||COHORT||PROSPECTIVE|||||||
33721013|NCT02208947|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33721014|NCT00060476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33721015|NCT05657678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721016|NCT01710956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721017|NCT01831154|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33721018|NCT04696952|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33796950|NCT05030077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796951|NCT06273878|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796952|NCT03967626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"* experimental group: CCT (cerebral temperature target) performed by the external cooling device on the TC measured by the PIC/TC sensor (PIC:intracranial pressure)~* control group: CCT performed by the external cooling device on the TS, measured by a bladder sensor (coupled to the vesal probe, according to the standard service protocol)."|t|f|t|t
33716726|NCT06474585|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||"The patient included in the study will be provided with two pairs of insoles. Insole type A is molded in an unloaded condition (sitting), which is the standard method we routinely use (CONTROL). Insole type B is molded under load (standing), and this treatment is considered EXPERIMENTAL. Once we receive both treatments, they will be randomized using the random.org application. Therefore, one group will use insole type A, and another group will use insole type B."|t|f|f|f
33796953|NCT06148727|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The succession of complete denture insertion was randomized to diminish the effect of the order of complete denture use on the results.|Each patient received two prostheses; conventional and 3D-printed implant overdentures. The succession of complete denture insertion was randomized to diminish the effect of the order of complete denture use on the results. First, each denture was used for three months, followed by two weeks of rest; then, the other denture type was delivered to the patient and used for another three months.|f|f|t|f
33796954|NCT02711839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796955|NCT03196310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to therapy they receive||t|f|f|f
33796956|NCT01215552|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33796957|NCT02671344|||CASE_ONLY||RETROSPECTIVE|||||||
33796958|NCT02192606|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34020309|NCT03881956|NA|SINGLE_GROUP||OTHER||NONE||The study sample included 88 women (46 for the intervention and 42 for the control group) diagnosed with GDM. The control group received only usual care and they were followed according to the institution's diabetes follow-up protocol. In addition to the usual care, the intervention group was provided with an education program that consisted of three 45 min sessions.The women in the both group were administered the introductory information form, the Health-Promoting Lifestyle Profile II (HPLP-II), the Center for Epidemiologic Studies Depression Scale (CES-D) and the Short Form 36 Health Survey (SF-36) in the first assessment. After the education program, the HPLP-II, CES-D and SF-36 were re-administered to the intervention group four weeks after the first assessment. The HPLP-II, CES-D and SF-36 were re-administered to the both groups in the postpartum 6th week.||||
34020310|NCT06048965|||OTHER||PROSPECTIVE|||||||
34020311|NCT00562237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34020312|NCT05437926|||CASE_CONTROL||PROSPECTIVE|||||||
34020313|NCT00006239||||TREATMENT||||||||
34020314|NCT01788618|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020315|NCT01837524|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020316|NCT01671332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020317|NCT05765630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020318|NCT03735069|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a prospective case series study; VPT (IPT, partial or complete pulpotomies) will be done depending on the severity of the case (depth of caries/pulpal involvement, symptoms and response to vitality testing). The study will include about 150 hypomineralized first permanent molars, patients age will range from 6-16 years old. Sample will be divided into 3 groups according to the treatment that will be provided (IPT / Cvek pulpotomy / Cervical pulpotomy). Patients' teeth will be randomly allocated to different treatment procedures (IPT or pulpotomy) using random tables.||||
34020319|NCT05944601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020320|NCT02502279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34020321|NCT04390295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020322|NCT03696030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020323|NCT04635826|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.|2 X 2, within-subjects, balanced placebo design|t|f|t|f
34020324|NCT05933980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020325|NCT00938249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34020326|NCT05236283|||COHORT||RETROSPECTIVE|||||||
34020327|NCT05974436|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020328|NCT00587990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020329|NCT04735757|||CASE_CONTROL||PROSPECTIVE|||||||
34020330|NCT03537716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020331|NCT00912704|||CASE_ONLY||RETROSPECTIVE|||||||
33796959|NCT01012388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796960|NCT03814265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33796961|NCT00590551|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796962|NCT06588894|||COHORT||PROSPECTIVE|||||||
33796963|NCT04895475|||CASE_ONLY||PROSPECTIVE|||||||
33796964|NCT00997386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796965|NCT04432688|||CASE_ONLY||PROSPECTIVE|||||||
33796966|NCT04880434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796967|NCT01859416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796968|NCT02449070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796969|NCT02416076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716727|NCT02149004|||COHORT||PROSPECTIVE|||||||
33716728|NCT01170455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716729|NCT02707510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716730|NCT01891695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796970|NCT05961150|||COHORT||RETROSPECTIVE|||||||
33796971|NCT05549869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796972|NCT00902499|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33796973|NCT01422616|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33796974|NCT00988975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34020332|NCT01795274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020333|NCT05199168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941534|NCT01636050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34100836|NCT04967274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participants receives real and control interventions.||||
33941535|NCT05223478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941536|NCT01051414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941537|NCT01797302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941538|NCT00464126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020334|NCT05869461|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The intervention and assessment study staff do not overlap and all reasonable care is taken to keep assessment staff blinded to intervention allocation for the whole duration of the study. Investigators know intervention arm on a need to know basis but do not have contact with participants directly.|Randomized Control Trial|f|f|t|t
33941539|NCT01871428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941540|NCT03914924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly allocated to one of two interventions: Exercise Program (Ex) or Exercise and Lifestyle Education Program (ExLE).|f|f|t|t
33941541|NCT00412425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941542|NCT02041533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020335|NCT04134507|||COHORT||OTHER|||||||
34020336|NCT02014207||||PREVENTION||||||||
34020337|NCT04428112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34020338|NCT04941521|NA|SINGLE_GROUP||TREATMENT||NONE||Case series design run as a single-arm open-label pilot||||
34020339|NCT05036356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020340|NCT05913089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020341|NCT03082287|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34020342|NCT05841303|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Each site with thin gingival phenotype will be randomly allocated to either intervention group (vit. C with MN) or control group (I-PRF with MN). The allocation sequence will be concealed in opaque sealed envelopes, which will be identified with the initials of the patient's name. For each patient, the envelope will be opened immediately before the intervention. Patients will be blinded during the intervention and follow-up sessions.~* The patients will be blinded~* The operator will be blinded as investigator can give the operator the vial filled with either"|A Split-mouth Randomized Clinical Trial.|t|t|f|t
34020343|NCT03123432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020344|NCT05347381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020345|NCT03506984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the participant|Participants will randomely divided into two equal groups. Group (A) will receive a programe of high intensity interval training 30-40 minutes three times per week for one month.the participant will start cycling slowly for five minute without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down. The participant will be closely monitored by the handheld telemetry. Group (B) will receive a program of inspiratory muscle training by using the threshold based inspiratory muscle trainer for 10-15 minutesonce daily with frequency three times per week for four weeks.|t|f|f|f
34100837|NCT02470871|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34100838|NCT06041828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be collected using individual study codes for participants. Study codes do not reveal which group the participant has belonged to.|Randomized clinical study on a medical device.|f|f|f|t
33716731|NCT00147810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33716732|NCT00159536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716733|NCT03401424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33716734|NCT01504425|||COHORT||PROSPECTIVE|||||||
33716735|NCT06339723|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33716736|NCT02446990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716737|NCT03171792|||COHORT||CROSS_SECTIONAL|||||||
33716738|NCT05378815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this trial, the patient, the investigator performing the intra-articular injection and the investigator assessing the outcomes will be blinded|Randomised, double blinded, placebo-controlled trial comparing 3 intra-articular injections of PRP (Regenkit) and NaCl in patients with symptomatic knee osteoarthritis|t|f|t|t
33716739|NCT01721616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33716740|NCT00699621|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33716741|NCT01120912|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33716742|NCT04022044|||COHORT||PROSPECTIVE|||||||
33716743|NCT05899309|||COHORT||RETROSPECTIVE|||||||
33716744|NCT00901160|||COHORT||PROSPECTIVE|||||||
33716745|NCT04590261|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33716746|NCT05518643|||COHORT||PROSPECTIVE|||||||
33716747|NCT04646798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant and clinician will not be masked. Data outcomes will be assessed by the research team utilising unique study Identifiers only and group allocation.|To assess the feasibility of undertaking a randomised controlled trial of hemiarthroplasty versus total elbow arthroplasty for patients over the age of 65 who have an unreconstructible distal humeral fracture|f|f|f|t
33716748|NCT02699528|||COHORT||PROSPECTIVE|||||||
33716749|NCT04958005|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33716750|NCT02240160|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33716751|NCT03903731|||COHORT||RETROSPECTIVE|||||||
33716752|NCT02887521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33716753|NCT06391151|||COHORT||PROSPECTIVE|||||||
33716754|NCT05745350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716755|NCT01886040|||CASE_ONLY||RETROSPECTIVE|||||||
33716756|NCT00141076|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
33716757|NCT05529043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33716758|NCT01577056|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33716759|NCT04498611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716760|NCT01370174|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33716761|NCT00913003|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33716762|NCT02256228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716763|NCT01700725|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796975|NCT00773708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716764|NCT06087107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinding|Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial.|f|f|f|t
33796976|NCT05118581|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33796977|NCT06400394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|computerized block randomization using the website www.randomization.com with a block size of 8 and allocation ratio of 1:1|a randomised double blind placebo controlled parallel group study|t|t|t|t
33796978|NCT00226772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33796979|NCT02971176|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33796980|NCT05332366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796981|NCT00831259|||COHORT||PROSPECTIVE|||||||
33796982|NCT02514278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941543|NCT05011110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941544|NCT04094662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941545|NCT02737514|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33941546|NCT04628754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941547|NCT02439424|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33941548|NCT04328142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neither the participants nor their therapists were blind to the treatment allocation. However, the assessor was independent to the study and was not aware of the treatments applied or the objective of the therapy.|Participants were randomized to a Qigong exercise programme group, a Physiotherapy treatment group and control group for a 6 week study.|f|f|f|t
33941549|NCT00671190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941550|NCT03508206|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33941551|NCT02198911|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33941552|NCT02327949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941553|NCT05867849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716765|NCT01635192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33716766|NCT00213798|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33941554|NCT04129931|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Treatment sequence will be randomly assigned as either test treatment followed by matching placebo or vice-versa.|t|t|t|t
33941555|NCT02694562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941556|NCT00001343||||TREATMENT||||||||
33941557|NCT04636333|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33941558|NCT03770663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941559|NCT02492789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716767|NCT02678845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33716768|NCT01898611|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33716769|NCT04997993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716770|NCT04202692|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind, placebo controlled||t|t|t|f
33716771|NCT01392976|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716772|NCT04350840|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33716773|NCT00829946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33716774|NCT02192814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716775|NCT05701150|||COHORT||OTHER|||||||
33716776|NCT02242409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716777|NCT01223989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716778|NCT01551082|||COHORT||RETROSPECTIVE|||||||
33716779|NCT05913011|||OTHER||CROSS_SECTIONAL|||||||
33716780|NCT05205746|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|The first sentinel group (6 of each previous vaccine) will be without masked only to the subjects to ensure safety measurement in each group. The randomized double-mask placebo-controlled phase will begin when the safety committee, after evaluating the information from the sentinel group of the first three subjects (by vaccine and by specific route of administration), gives authorization to continue with the recruitment. It will be conducted through a computerized assignment system. Randomization for the double-masking phase of the study will be carried out using a computer assignment system.|Patients will be assigned according to their previous vaccine.|t|f|t|f
33716781|NCT02552563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716782|NCT04954053|||OTHER||PROSPECTIVE|||||||
33716783|NCT00438698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716784|NCT00815945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716785|NCT00797030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716786|NCT05830292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All adult patients (\>18years of age) undergoing GI cancer surgery will be included in the study.||||
33716787|NCT00459784|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
33941560|NCT00347685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941561|NCT00003159|RANDOMIZED|||TREATMENT||||||||
33941562|NCT05043493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34100839|NCT06425731|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants are prospectively assigned to participate in one of two study conditions that respectively seek to test different interventions and outcomes.||||
33716788|NCT04292860|||COHORT||PROSPECTIVE|||||||
33716789|NCT03481036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716790|NCT02626520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33796983|NCT00758810|||COHORT||PROSPECTIVE|||||||
33796984|NCT04227288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796985|NCT01118377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33796986|NCT04210505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33796987|NCT00818805|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33796988|NCT01030705|||||RETROSPECTIVE|||||||
33796989|NCT06457178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33796990|NCT05791812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796991|NCT01006824|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33796992|NCT01061203|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33796993|NCT04308330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941563|NCT02416466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33796994|NCT03782350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care provider, investigator and outcomes assessor will be blinded to treatment allocation.|The subject will be assigned to either high dose regimen group or low dose regimen group of tranexamic acid in a blinded fashion|t|t|t|t
33796995|NCT03264742|||COHORT||PROSPECTIVE|||||||
33796996|NCT01983371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33796997|NCT05957900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33796998|NCT01551056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33796999|NCT05997836|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This study will use a stepped wedge design, with participating medical centers assigned to one of four different waves. Wave 1 will begin the trial receiving implementation facilitation. Waves 2-4 will begin the trial receiving centralized technical assistance, and will then cross over to implementation facilitation.||||
33797000|NCT04901312|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|The Outcomes Assessor (data collection team) will not be aware of the participant's study arm when they collect survey data.|Sequential Multiple Assignment Randomized Trial|f|f|f|t
33797001|NCT02988817|NA|SEQUENTIAL||TREATMENT||NONE||||||
33797002|NCT03474822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797003|NCT00393848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34020346|NCT06169501|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional Study Model: This study employs a single-group assignment where participants are exposed to a mindfulness intervention for caregivers of children with autism spectrum disorders living in rural areas of Maine. The primary aim is to assess the intervention's impact on reducing caregiver stress and anxiety levels. Participants complete daily mindfulness lessons and report anxiety for up to 60 days.||||
34020347|NCT02926456|||COHORT||PROSPECTIVE|||||||
34020348|NCT04877886|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34020349|NCT00147602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34020350|NCT00062543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020351|NCT05041881|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||each group consist of patient receiving one type of intraocular lens- trifocal, accommodating or monofocal||||
34020352|NCT02078336|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34020353|NCT05673330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34020354|NCT04340349|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|DOUBLE BLINDED|Parallel Assignment|t|t|t|f
34020355|NCT05357092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34020356|NCT05979649|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34020357|NCT00532038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020358|NCT04436887|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Blinding Process~Patients, care providers, staff collecting data, and those assessing the endpoints were all blinded to treatment allocation. Patients were blinded to the surgical procedure performed until the final assessment of the study endpoints. Because the blinding of the operating surgeons was not feasible, they were not involved in the data collection and outcome assessment. Physicians in charge of patients' management were not involved in the operating room and were blinded to the intervention. The data were collected and analyzed by physicians who were not involved in the patient's management during the whole Randomized Controlled Trial."|Sample size: Considering a mean percentage of incidence of Incisional Hernia of 20% in the open middle line laparotomy in the clean-contemned setting. We hypothesized that Incisional Hernia rate in Group B (Experimental Group) would be superior to Group A (control group) if the difference in a mean percentage of incidence of Incisional Hernia was less than 15%. 194 patients are required to have a 90% chance of detecting, as significant at the 5% level, a decrease in the primary outcome measure from 20% in the control group to 5% in the experimental group. Baseline comparisons were performed using chi-square tests and T-tests. Continuous variables are expressed as mean ± standard deviation (SD). Differences between preoperative and postoperative parameters were compared by Wilcoxon paired rank test. For all tests, a two-sided p\<0.05 was considered statistically significant. The study designed with Sealed Envelope.|t|t|t|f
34020359|NCT04268316|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either BA in VR, BA in real-life, or a waitlist control group.||||
34020360|NCT06138236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients suffering from plantar fascitiis were randomized into three arms of treatment: Infiltration of collagen hydrolyzed peptides, ESWT and a combination of both treatments|t|f|f|f
34020361|NCT00375830|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34020362|NCT05731791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 3 two-armed randomized clinical trial for localized favorable breast cancer patients, randomizing to CT-based radiation treatment vs. MRI-based radiation treatment||||
34020363|NCT05944380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, placebo-controlled|t|t|t|f
34020364|NCT04175444|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020365|NCT05094492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020366|NCT05466006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34020367|NCT02062294|||COHORT||RETROSPECTIVE|||||||
34020368|NCT01480843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020369|NCT00498901||||TREATMENT||NONE||||||
34020370|NCT04798612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blinded placebo-controlled phase 2 study.|t|f|t|f
34020371|NCT01777620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020372|NCT01123837|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34020373|NCT04121754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020374|NCT00398255|RANDOMIZED|PARALLEL||||NONE||||||
34020375|NCT02588950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34020376|NCT01413516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020377|NCT03320421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020378|NCT03321435|||COHORT||PROSPECTIVE|||||||
34020379|NCT06273930|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020380|NCT01906892|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33797004|NCT06674486|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797005|NCT01177696|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797006|NCT01501188|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33797007|NCT03772457|||COHORT||PROSPECTIVE|||||||
33797008|NCT03071653|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Control Trial||||
34100840|NCT03495895|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|As the intervention is a home visiting intervention participants and care providers cannot be blinded. Outcome assessor and data analyst will be blinded.||f|f|f|t
34100841|NCT02065804|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34100842|NCT06450171|NA|SINGLE_GROUP||SCREENING||NONE||||||
33797009|NCT02549170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797010|NCT01304849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797011|NCT04301635|||COHORT||OTHER|||||||
33797012|NCT04688801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33797013|NCT03692013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797014|NCT06513936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer-generated permuted block randomization will be used to assign patients to one of two groups|Two arm groups will be included control group arm (receive standard care) study group arm (receive skin care bundle)|t|f|f|f
33797015|NCT01404416|||COHORT||PROSPECTIVE|||||||
33797016|NCT06671717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797017|NCT00220272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797018|NCT03799783|NA|SINGLE_GROUP||TREATMENT||NONE||Drug administration by a loading dose followed by continuous infusion during a procedure||||
33797019|NCT01525446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797020|NCT00711217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797021|NCT03276871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797022|NCT04561219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were randomly allocated into one of the two groups: A or B. Patients received labelled medication: A or B, by the pharmacist. Patients received an identification number, so care providers, outcomes assessors and investigators did not know anything regarding the patients' groups.|"Hospitalized patients with clinical signs of COVID-19, and either chest tomography scans suggestive of COVID-19 or confirmed by RT-PCR molecular tests, will be randomly divided into 2 groups: experimental and control groups.~Experimental group: 250 hospitalized patients diagnosed with COVID-19 derived pneumonia will receive nitazoxanide 500mg 8/8 hs for 5 days. Control group: 250 hospitalized patients diagnosed with COVID-19 derived pneumonia will receive placebo 8/8 hs for 5 days."|t|t|f|f
33797023|NCT06315777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797024|NCT02339779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797025|NCT06290297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797026|NCT02354105|||COHORT||PROSPECTIVE|||||||
33797027|NCT02841150|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33797028|NCT02389777|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33797029|NCT03584659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797030|NCT05817097|||COHORT||RETROSPECTIVE|||||||
33797031|NCT06259409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, randomized, controlled investigational study|t|t|t|t
33797032|NCT01996917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797033|NCT02220478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797034|NCT00153569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797035|NCT01535963|||COHORT||PROSPECTIVE|||||||
33797036|NCT06672484|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797037|NCT04912791|||COHORT||PROSPECTIVE|||||||
33797038|NCT04075942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797039|NCT04605406|||COHORT||PROSPECTIVE|||||||
33797040|NCT03293498|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33797041|NCT05612815|||COHORT||PROSPECTIVE|||||||
33797042|NCT04380350|||COHORT||PROSPECTIVE|||||||
33797043|NCT03997916|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33797044|NCT04481373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797045|NCT02272452|||COHORT||PROSPECTIVE|||||||
33797046|NCT04674436|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797047|NCT02731885|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797048|NCT01803555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797049|NCT05188430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797050|NCT05519813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797051|NCT00296751|RANDOMIZED|PARALLEL||||NONE||||||
34020381|NCT03694600|||OTHER||PROSPECTIVE|||||||
34020382|NCT03967496|||OTHER||PROSPECTIVE|||||||
34020383|NCT05940155|||COHORT||PROSPECTIVE|||||||
34020384|NCT05748249|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34020385|NCT04360096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the study pharmacist will be aware of treatment assignment|Multicenter Randomized Placebo-controlled Trial|t|t|t|t
33797052|NCT01499771|RANDOMIZED|CROSSOVER||||NONE||||||
33797053|NCT05844449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797054|NCT06269822|||CASE_CONTROL||OTHER|||||||
34020386|NCT03041649|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34020387|NCT05835739|||COHORT||PROSPECTIVE|||||||
34020388|NCT05295238|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020389|NCT00912483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020390|NCT06230718|NA|SINGLE_GROUP||TREATMENT||NONE|Patients will receive 3 interventions: placebo, motor imagery and action observation|||||
34020391|NCT01561430|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34020392|NCT02330315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020393|NCT02497651|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34020394|NCT01831765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020395|NCT02044406|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34020396|NCT00599521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020397|NCT00923273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020398|NCT02119819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020399|NCT05073952|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|surgical treatment will be conducted with surgeon-investigator and patient unblinded. the outcome assessor will be blinded as primary outcome measurements will be taken on a computer.|two groups will be compared with different treatment|f|f|f|t
34020400|NCT05340348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Monocentric interventional study with minimal risks and constraints||||
34020401|NCT04880824|||COHORT||PROSPECTIVE|||||||
34100843|NCT04484662|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This study will recruit 60 subjects, in sum of 30 families.|This study will recruit 60 subjects, in sum of 30 families.||||
34100844|NCT02243826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100845|NCT05785767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100846|NCT02660346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100847|NCT05647382|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33797055|NCT02057497|||COHORT||OTHER|||||||
33797056|NCT06335628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33797057|NCT03932981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797058|NCT05520086|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||2 consecutive cohorts will be included in order of recruitment. the first 10 patients will receive 1 single dose and the second 10 patients will receive 2 doses separated by 15 days||||
33797059|NCT00348322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797060|NCT01184664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797061|NCT01029587|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797062|NCT01377935|||COHORT|||||||||
33797063|NCT01884441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797064|NCT04861324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797065|NCT06455241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797066|NCT01512810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797067|NCT01352533|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797068|NCT04186546|||CASE_ONLY||PROSPECTIVE|||||||
33797069|NCT04735341|||CASE_ONLY||PROSPECTIVE|||||||
33797070|NCT02016352|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33797071|NCT05835219|||COHORT||PROSPECTIVE|||||||
33797072|NCT02351648|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33797073|NCT03426033|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33797074|NCT03914859|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||"The groups will be defined according to the urinary level of 1-hydroxypyrene, the most sensitive biomarker for PAH exposure. A threshold of 0.1 μmol / mol of creatinine was determined according to the INRS.~It corresponds to the 90th percentile value for non-smokers not occupationally and nutritionally exposed. The reference value in the general population is \<0.51 μg / g creatinine, and in smokers \<0.3 μmol / mol creatinine."|t|f|f|f
33797075|NCT06186245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797076|NCT05141149|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33797077|NCT00742300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797078|NCT05350527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only the clinical research associate (CRA) will know the patient's arm. The rest of the clinical team will be blinded. The self-questionnaires will be completed by the patients and then retrieved by the CRA who will enter the data into the eCRF, with no possible access to this data by the investigators.||f|f|t|f
33797079|NCT02244411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797080|NCT00551577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797081|NCT04655859|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797082|NCT04320771|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33797083|NCT01063140|||||PROSPECTIVE|||||||
33797084|NCT00904852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797085|NCT05871450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33797086|NCT01745016|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
33797087|NCT03282786|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33797088|NCT05925920|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
33797089|NCT05552443|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33797090|NCT01422044|||COHORT||PROSPECTIVE|||||||
33797091|NCT02769468|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020402|NCT05417035|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective open clinical study||||
34020403|NCT05727371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797092|NCT04996264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, Investigators, and study personnel involved in the conduct of the study, including data management, will be blinded to treatment assignment except for a specified unblinded statistician and programmer from the study contract research organization who will have access to the randomization code. The unblinded study personnel will not participate in study procedures or data analysis prior to unblinding of the study data to all study-related personnel upon database lock. If an interim analysis is conducted, then unblinded personnel who are not otherwise involved in the study will prepare the data for review.||t|t|t|t
33797093|NCT02890004|||COHORT||PROSPECTIVE|||||||
33797094|NCT03025802|||COHORT||PROSPECTIVE|||||||
33797095|NCT02868268|||COHORT||PROSPECTIVE|||||||
34020404|NCT00681512|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34020405|NCT05671016|||COHORT||PROSPECTIVE|||||||
34020406|NCT04312295|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020407|NCT04260867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100848|NCT04484441|||CASE_CONTROL||PROSPECTIVE|||||||
34020408|NCT00925080|||COHORT||PROSPECTIVE|||||||
34020409|NCT02804711|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34020410|NCT00236366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34020411|NCT01928706|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34020412|NCT00355810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020413|NCT05452135|||COHORT||PROSPECTIVE|||||||
34020414|NCT06252428|||COHORT||CROSS_SECTIONAL|||||||
34020415|NCT01212354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020416|NCT06148168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020417|NCT03410251|||OTHER||CROSS_SECTIONAL|||||||
34020418|NCT04579016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020419|NCT04063436|NA|SINGLE_GROUP||TREATMENT||NONE||After the baseline period, all participants will be trialed on the same new nasal pillows mask.||||
33797096|NCT01703923|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33941564|NCT05250999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34100849|NCT01682720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34100850|NCT04415710|||COHORT||PROSPECTIVE|||||||
34100851|NCT06585709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100852|NCT01964560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100853|NCT06508450|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34100854|NCT00047632|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34100855|NCT06687291|||COHORT||PROSPECTIVE|||||||
34100856|NCT05720520|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34100857|NCT05587543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||CAR-T、TCR-T||||
34100858|NCT04569097|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patients will be stratified into the following groups: Group A) Patient Group receiving Pharyngeal strengthening (n=150); and Group B) Healthy Controls (n=50). Participants' age may range from 18-99 years old, however, the investigators expect most study participants will be \>60 years old due to the age range typically affected by dysphagia.|f|f|f|t
34100859|NCT02363127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34100860|NCT05449132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100861|NCT03955185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100862|NCT05763862|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be randomised to genetic testing versus standard medical therapy in a 1:1 ratio, via a block randomisation process. The block randomisation sequence will be generated by a web-based randomisation service in blocks of four for each recruitment site. Blinding is not applicable for the treatment assigned.|This is a multicentre, prospective, randomised, open blinded endpoint trial.||||
34100863|NCT05704049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100864|NCT05754112|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941565|NCT03114709|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33941566|NCT01747928||PARALLEL||||NONE||||||
33941567|NCT02388750|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941568|NCT01086306|||COHORT|||||||||
33941569|NCT01192139|RANDOMIZED|CROSSOVER||||NONE||||||
33941570|NCT05897996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716791|NCT02355353|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33716792|NCT01244906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716793|NCT03931291|NA|SINGLE_GROUP||TREATMENT||NONE||APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.||||
33716794|NCT04339127|||COHORT||RETROSPECTIVE|||||||
33941571|NCT05205161|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941572|NCT02254694|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33941573|NCT01840566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941574|NCT03399227|||CASE_CONTROL||PROSPECTIVE|||||||
33716795|NCT04810845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941575|NCT04994015|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941576|NCT02616172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100865|NCT06328595|||OTHER||CROSS_SECTIONAL|||||||
34100866|NCT01637597|||||PROSPECTIVE|||||||
34100867|NCT03318874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716796|NCT01493206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716797|NCT04006197|||COHORT||PROSPECTIVE|||||||
33716798|NCT02111850|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33716799|NCT01778881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716800|NCT06030791|||COHORT||PROSPECTIVE|||||||
33716801|NCT00221598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716802|NCT01150981|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33716803|NCT01635413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33716804|NCT00208611|NA|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
33716805|NCT03330769|||COHORT||PROSPECTIVE|||||||
33716806|NCT01546740|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33716807|NCT02500888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716808|NCT01541124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716809|NCT00650624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716810|NCT00054314||||TREATMENT||NONE||||||
33716811|NCT02335294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716812|NCT00229853|||||RETROSPECTIVE|||||||
33716813|NCT00812890|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716814|NCT01320085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716815|NCT02154490|||CASE_ONLY||PROSPECTIVE|||||||
33716816|NCT01621620|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33716817|NCT03336047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716818|NCT01260285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716819|NCT00335673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716820|NCT06098391|||CASE_ONLY||RETROSPECTIVE|||||||
33721019|NCT01428453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721020|NCT01359449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941577|NCT03558503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941578|NCT04144257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020420|NCT04249544|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34020421|NCT03216018|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020422|NCT05219461|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34020423|NCT04321954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020424|NCT03595085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020425|NCT01889212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020426|NCT03865368|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The outcomes assessor was blinded.|Active Whole Body Vibration (aWBVT) group, performed ten dynamic standard exercises on a vibration platform. The vibration protocol lasted for 15 minutes, in a frequency of 30 Hz and amplitude of 2 mm. Control group performed only ten dynamic standard exercises with no vibration application. Blood Pressure, heart rate, saturated oxygen were measured for the hemodynamic response. Modified Borg Dyspnoea Scale (MBDS) and The Borg Rating of Perceived Exertion (BRPE) Scale were used in order to evaluate fatigue level. All evaluations were performed at the beginning of the study, at the end of the session and at the recovery period|f|f|f|t
34020427|NCT05439876|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34020428|NCT05107388|NA|SINGLE_GROUP||OTHER||NONE||||||
34020429|NCT03728855|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The subject, staff and investigators are aware of which method of medication administration the patient is given, SAM or standard care. Only the data analysis is blinded by anonymizing and coding all data. Furthermore, an independent person will perform the data analyses.|The intervention of this study is the implementation of self-administration of medication (SAM) by hospitalized patients. SAM will be compared to standard care.|f|f|f|t
33797097|NCT03646435|NA|SINGLE_GROUP||SCREENING||NONE|After all the study participants are recruited, they will be assigned a study ID which investigators will use to anonymize data and track patient health data that is collected via the Fitbit.|This study model will involve a single cohort of about 50 GIM patients. All patients will be asked to wear the Fitbit Charge 2 for the duration of their stay in the hospital and the health information (heart rate, sleep, physical activity) collected from the wearable will be compared to the nurses' vital sign assessment for accuracy. There will be no other comparison group in this study.||||
33797098|NCT01708499|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33797099|NCT03693651|||COHORT||PROSPECTIVE|||||||
33797100|NCT03860532|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33797101|NCT03480854|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a two-part prospective study to be conducted over 3 years with option to extend to 5 years. In Year 1, we will gather baseline performance data from participating MS clinics (microsystems), create a combined MSCQI systems-level database, and conduct analyses of performance variation and benchmarking. In the second part of the study (Years 2-3), we will investigate the effect of Continuous Quality Improvement interventions on primary endpoints and selected secondary measures.||||
33797102|NCT03540381|||COHORT||PROSPECTIVE|||||||
33797103|NCT03210129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Every patient will be given a person-specific code and every information collected will be pseudonymised.~The group assignment will be hidden to the investigator and to the scientific collaborators who will collect, record and analyse the data. However, both patients and the two motivational interviewing counsellors will be aware of the group assignment."|The patients will be randomly assigned to the experimental group with motivational interviewing or the control group. Group assignment will be done by a motivational interviewing counsellor using randomization lists generated by the Competence Center in Methodology and Statistics (Luxembourg Institute of Health). For each type of cancer, a separate randomisation list will be used.|f|f|t|t
33797104|NCT00523146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797105|NCT05495477|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33797106|NCT06499584|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33797107|NCT01197807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797108|NCT01593813|||COHORT||PROSPECTIVE|||||||
33797109|NCT00990730|||COHORT||CROSS_SECTIONAL|||||||
33797110|NCT01750866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797111|NCT04414683|||COHORT||RETROSPECTIVE|||||||
34020430|NCT04514536|NA|SINGLE_GROUP||OTHER||NONE||||||
34100868|NCT06695481|||CASE_CONTROL||RETROSPECTIVE|||||||
33797112|NCT02359370|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33797113|NCT04816487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797114|NCT01240330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797115|NCT00145392|||||PROSPECTIVE|||||||
33797116|NCT04149548|||COHORT||PROSPECTIVE|||||||
33797117|NCT03450096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797118|NCT02807467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797119|NCT02763033|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33797120|NCT00186186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797121|NCT06050109|||COHORT||PROSPECTIVE|||||||
33797122|NCT04666506|||OTHER||PROSPECTIVE|||||||
33797123|NCT05353517|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797124|NCT03114267|||COHORT||RETROSPECTIVE|||||||
33797125|NCT01060514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797126|NCT00705328|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33797127|NCT04961047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797128|NCT03319680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797129|NCT02975310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797130|NCT00666276|||CASE_ONLY||PROSPECTIVE|||||||
33797131|NCT03553212|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility trial||||
33797132|NCT06422650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797133|NCT01867632|||COHORT||OTHER|||||||
33797134|NCT05003219|||COHORT||PROSPECTIVE|||||||
33797135|NCT01638949|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33797136|NCT03503084|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Twenty-one TCC practitioners and nineteen normal controls were included in this study. The hemodynamics, serum insulin, indices of insulin resistance/sensitivity, serum endothelin-1 (ET-1), blood lipids and aldosterone before and 30 min after a rest or a session of classical Yang's TCC exercise were compared.||||
33797137|NCT02863900|NA|SINGLE_GROUP||||NONE||||||
33797138|NCT06555848|||COHORT||PROSPECTIVE|||||||
33797139|NCT01843101|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33797140|NCT01470040|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33797141|NCT03221777|||COHORT||PROSPECTIVE|||||||
33797142|NCT00206375|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797143|NCT02860910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797144|NCT04693130|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33797145|NCT03057639|||CASE_ONLY||PROSPECTIVE|||||||
33797146|NCT01199783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797147|NCT06575413|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797148|NCT01666704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797149|NCT01919645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797150|NCT04496050|||CASE_ONLY||PROSPECTIVE|||||||
33797151|NCT05574192|NA|SINGLE_GROUP||OTHER||NONE||Mixed-method participatory action research design||||
33797152|NCT04303156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797153|NCT02043054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797154|NCT05319366|||OTHER||PROSPECTIVE|||||||
33797155|NCT05682183|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33797156|NCT06392451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants are not provided investigational results and will only be provided with routine standard of care diagnostics results.|||||
33797157|NCT05276310|NA|SINGLE_GROUP||TREATMENT||NONE||Part 1: Dose Escalation Part 2: Expansion cohort||||
33797158|NCT01840930|||COHORT||PROSPECTIVE|||||||
33797159|NCT01764464|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33797160|NCT03020745|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33797161|NCT03085498|||COHORT||CROSS_SECTIONAL|||||||
33941579|NCT06481046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941580|NCT03894111|||OTHER||RETROSPECTIVE|||||||
33941581|NCT01231620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941582|NCT04647682|||CASE_ONLY||PROSPECTIVE|||||||
33941583|NCT03470272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941584|NCT03901742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941585|NCT05685537|||CASE_CONTROL||RETROSPECTIVE|||||||
33941586|NCT00664729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941587|NCT03581032|||CASE_CROSSOVER||PROSPECTIVE|||||||
33941588|NCT00591786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941589|NCT03832712|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Tremor is measured with the Essential tremor rating scale (ETRS) with focus on items 5/6 (hand tremor) \& 11-14 (hand function). ETRS is performed before surgery at baseline and at 6 months on/off med/stim. The evaluation is done blinded to the patients in the surgical group. The evaluation is documented on video (with the patient wearing a head cap) and segmented for blinded evaluation of two expert evaluators|"Study design:~* Step 1 is designed as a randomized controlled trial in order to compare the effect of DBS (Group A) and medical treatment (Group B) on ET (Aim 1).~* In step 2 - 4 the patients in group A are operated and group A and B joined into one single group.~  * Step 2 - all electrode contacts are individually analysed regarding chronic and acute stimulation effects in relation to their location in either the Vim or the cZi in order to decide which target is more effective (Aim 2).~ * Step 3 - Effects and side effects, with consideration to field of stimulation, are analyzed in relation to neighboring structures in order to map the whole area and delineate the optimal target points (Aim 3).~ * Step 4 - The long-term effect is evaluated in a non-randomized longitudinal study at 1, 3, 5, 10 years (Aim 4)."|f|f|f|t
33941590|NCT04517825|||COHORT||PROSPECTIVE|||||||
33941591|NCT03124329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941592|NCT01266811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941593|NCT02117362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941594|NCT04006821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941595|NCT01169233|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941596|NCT03464929|||OTHER||PROSPECTIVE|||||||
33941597|NCT03550040|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized study||||
33941598|NCT02918006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Oral vaccination followed by viral challenge at 3 months post vaccination|t|t|t|t
33941599|NCT05032391|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The present study was a double-blind, placebo-controlled study, i.e., neither the investigator nor the parent / adoptive parent of the child knew which particular drug was administered to a particular study participant.|Multicenter, prospective, randomized double-blind, placebo-controlled|t|f|t|f
33941600|NCT04022109|||COHORT||PROSPECTIVE|||||||
33941601|NCT01679964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941602|NCT04129138|||COHORT||PROSPECTIVE|||||||
33797162|NCT05016830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both sham and bilateral transcranial direct current stimulation were applied with the same electrode configuration, but the functioning of the stimulation device was blinded to the patient, the care provider, and the researcher performing measurements. The operator of the stimulation device selected the stimulation protocol. Sham stimulation protocol consisted of current ramp and delivery of current for 30 seconds and 19 minutes and 30 seconds with no current delivery. Actual stimulation consisted of a current ramp and 20 minutes of current delivery. There were no visual cues allowing to differentiate sham and stimulation protocols.|A randomized, controlled pilot trial, that consists in two groups: a control group that receives sham stimulation and ocular occlusion, and a second group that receives bilateral transcranial direct current stimulation and ocular occlusion.|t|t|f|t
34100869|NCT06244199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Key investigators and outcomes assessors at each site will remain blinded to participant group placement. Quantitative study endpoints are assessed by blinded study personnel (i.e., separate from the clinical and study exercise physiologists who treat the patients in the T2CR intervention or usual HBCR).|"This is a 4-year, 2-site, type 1 hybrid-effectiveness-implementation trial using a randomized controlled design to compare T2CR-facilitated HBCR to Usual Care, an option that can include Promising Practice HBCR (henceforth called usual HBCR) but without a transition to HBCR."|f|f|t|t
34100870|NCT06084286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797163|NCT04426786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33797164|NCT05816486|||COHORT||PROSPECTIVE|||||||
33797165|NCT05074836|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The two milk products have the same-looking package and similar taste.||f|f|f|t
33797166|NCT03040596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797167|NCT02961010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797168|NCT03639350|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be provided with healthful dietary information but will not be told what diets their diet plans are based on. Participants in the IER+MED diet group will be told they are on diet plan 1 and participants in the DASH diet group will be told they are on diet plan A. The research dietitians will know which diet plan each participant is on, however; all other clinic staff who assess outcomes measures will be blinded to each participant's diet group.|Randomized controlled trial. Participants will be randomized to either the IER+Med diet or the DASH diet for 12 weeks.|t|f|t|t
33797169|NCT05826379|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33797170|NCT02948114|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33941603|NCT00750360|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941604|NCT05610228|||COHORT||PROSPECTIVE|||||||
33941605|NCT01642420|||CASE_CONTROL||PROSPECTIVE|||||||
33941606|NCT01509066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941607|NCT05597592|NA|SINGLE_GROUP||OTHER||NONE||||||
33797171|NCT00554736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797172|NCT00005152|||COHORT||PROSPECTIVE|||||||
33797173|NCT05858073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941608|NCT01008098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941609|NCT00689611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941610|NCT01066624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941611|NCT03436576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941612|NCT01297621|RANDOMIZED|PARALLEL||||NONE||||||
33941613|NCT05486715|||CASE_CONTROL||PROSPECTIVE|||||||
33941614|NCT03491501|||CASE_ONLY||PROSPECTIVE|||||||
33941615|NCT00187148|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33941616|NCT01597921|||COHORT||CROSS_SECTIONAL|||||||
33941617|NCT05399823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941618|NCT02962973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941619|NCT01361724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941620|NCT04778215|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941621|NCT02825745|NA|SINGLE_GROUP||OTHER||NONE||||||
33941622|NCT04868929|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33941623|NCT02743689|||COHORT||PROSPECTIVE|||||||
33941624|NCT05883150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33941625|NCT04225104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Members of the investigative team will be blinded to the participant's group assignment until all testing is completed.||f|f|t|f
33941626|NCT06313658|||COHORT||RETROSPECTIVE|||||||
33941627|NCT02779621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941628|NCT05528965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33941629|NCT05608824|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All SWE and MFI images are evaluated for quality and analyzed by qualified study physicians that are blinded to the clinical data. The analysis includes but is not limited to reading images, identifying the regions of interest, and making measurements. Clinical data will then be reviewed to validate the clinical diagnosis.|||||
33941630|NCT05947968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941631|NCT00867061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941632|NCT03588234|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941633|NCT06477432|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33941634|NCT02545504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941635|NCT02238509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941636|NCT05199285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941637|NCT04812821|||OTHER||CROSS_SECTIONAL|||||||
33941638|NCT00515866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941639|NCT02791841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100871|NCT06380400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34100872|NCT06187935|||COHORT||PROSPECTIVE|||||||
34100873|NCT06254482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100874|NCT06429124|NA|SINGLE_GROUP||OTHER||NONE|This study will not use any masking.|We will execute the specific aims using a pre-post non-randomized study design in which all participants receive the intervention. Outcome assessments for specific aim 2 will include neuropsychological tests, blood biomarkers, and psychological well-being measured at baseline and after 3 months of intervention.||||
33797174|NCT06446726|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort (30 cases): Patients receive neoadjuvant low-dose radiotherapy (4 Gy/2f) combined with a domestic PD-1 inhibitor (tislelizumab) and chemotherapy as neoadjuvant treatment.||||
33797175|NCT03707691|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33797176|NCT03082846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797177|NCT02882698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797178|NCT05978037|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797179|NCT01814033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797180|NCT06479187|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797181|NCT01691326|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797182|NCT05201261|||COHORT||PROSPECTIVE|||||||
33797183|NCT05729672|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The course includes five online teaching and learning modules and two hours of offline teaching and learning, using MOOCs/SPOCs online teaching system and constructs on the Chinese Open Education platform. For this prospective, randomized controlled trial, 150 nurses working in a medical center in northern Taiwan were recruited and randomized into 2 groups. The experimental group (n=75) received the Nightingale in Gen-sEx course. The control group (n=75) received without course. Data were collected at baseline, 1month, and 3 months after the course.|t|f|t|f
33797184|NCT04811950|||OTHER||RETROSPECTIVE|||||||
33797185|NCT02651233|||||PROSPECTIVE|||||||
33797186|NCT00194974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797187|NCT00510887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797188|NCT02209415|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33797189|NCT06676007|||COHORT||PROSPECTIVE|||||||
33797190|NCT05706480|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33797191|NCT05208554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33797192|NCT02399670|||COHORT||PROSPECTIVE|||||||
33797193|NCT01908296|NA|SINGLE_GROUP||OTHER||NONE||||||
33797194|NCT06519253|RANDOMIZED|PARALLEL||OTHER||NONE||Our study proposes a feasibility open-label RCT of a novel VR based music intervention in an acute geriatric inpatient GAU setting to assess feasibility and efficacy in improving positive emotions, pain, mental wellbeing, symptoms of anxiety and depression in older adults.||||
33797195|NCT04583514|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33797196|NCT00014248||||SUPPORTIVE_CARE||||||||
33797197|NCT00712335|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33797198|NCT00827346|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33797199|NCT04505982|||COHORT||PROSPECTIVE|||||||
33797200|NCT03403998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients (reporting one of the main outcome for this study - pain) will be unaware of the hypothesis of this study and performance biases will be avoided by telling them that both treatment options have similar effectiveness. Assessors (measuring clinician assessed tests) and Statistician will be blinded to hypothesis and group allocation following established guidelines.|A randomization sequence will be computer-generated by a research assistant (RA) not involved in the study. To ensure concealment, the RA will distribute the results of the sequence to the therapist in consecutively numbered, opaque, and sealed envelopes. Participants will be unaware of the study hypothesis. Assessors (who will measure clinician-assessed tests and analyze imaging outcomes) and the statistician will be blinded to the hypothesis and group allocation, following established guidelines. Participants randomized to the treatment group will receive MCTF as described in the Intervention section. Participants randomized to the placebo group will receive placebo transcutaneous electrical nerve stimulation (TENS) as described in the Intervention section|t|f|t|t
33797201|NCT04616911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797202|NCT04928703|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Single Dose, Placebo-Controlled, 3-Arm Crossover|t|f|t|t
33797203|NCT05789485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and investigators will be blinded to results during study conduct.||t|f|t|f
33797204|NCT04594798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797205|NCT03185338|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797206|NCT01291615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797207|NCT03816228|||OTHER||PROSPECTIVE|||||||
33797208|NCT03843021|||OTHER||OTHER|||||||
33797209|NCT00970359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797210|NCT05415449|||OTHER||PROSPECTIVE|||||||
33797211|NCT02807493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797212|NCT04567355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study PI, statistician, co-investigators, and all personnel who are involved in endpoint assessments will be blinded. Only one team member (lead CRC) will have access to the assignment of each participant.||f|f|t|t
33797213|NCT04575493|RANDOMIZED|PARALLEL||OTHER||NONE||Clinical trials are designed to understand the nature of disease, its associated symptoms, and patient's response towards management. The study has aim to evaluate the effect of medical intervention with allopathic and herbal medicine to treat urinary tract infection. For this purpose, the patient suffering from urinary tract infection were examined and managed in different medical centers such as Shifa-ul-Mulk Memorial Hospital Hamdard University Karachi, Naseem ul Sehat Eastern Medicine Clinic Bahawalpur, Matab Hakeem Atta ur Rehman Siddique Lahore and khurshid Siddique Clinic Lahore.||||
33797214|NCT04583046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797215|NCT04843306|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This will be a prospective, randomized, and non-blinded trial to assess the benefit of xR technology for patient education, coaching, and comfort during radiation treatment of pancreatic cancer. Prior to any use of the xR platform for patients, the investigators will perform several dry runs with the Radiation Oncology Physics department to confirm the device and platform can be used safely.||||
33797216|NCT01202526|||CASE_CONTROL||PROSPECTIVE|||||||
33797217|NCT05685316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797218|NCT00477035|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797219|NCT03926884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941640|NCT04555993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941641|NCT03985358|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled||||
33941642|NCT00996385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941643|NCT04422951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33941644|NCT02172326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941645|NCT06227689|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33941646|NCT02449694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797220|NCT03851549|NA|SINGLE_GROUP||OTHER||NONE||||||
33797221|NCT06299293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797222|NCT04373590|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomization is accomplished using a HIPAA-compliant, Internet-based randomization service (studyrandomizer.com) using permuted blocks of 5. Patients and the participating psychiatrist are not blinded to the condition assigned to them; however, they are not given any explicit information on the DA. The psychiatrist was provided with the DA and received information about it as the DA is delivered by the psychiatrist for patients who are randomized to receive it. The RA who recruit and administer assessments to participants is not blinded to condition, except at baseline.||f|f|t|f
33797223|NCT03697538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients, nurses on the floor and physical therapists will be blinded to the nature of the patient assignment||t|f|f|f
33797224|NCT00210691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797225|NCT01139398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941647|NCT02223533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33941648|NCT03289676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person who assesses follow-up assessments will be blind to treatment condition.|": The proposed study has two phases.~1. Phase 1. Development of Narrative Video: We will first develop narrative videos in collaboration with community organizations of WLHIV in Boston. The video will be filmed in person at the University of Massachusetts Boston.~2. Phase 2. A Randomized Controlled Trial (RCT) of a Story Telling Narrative Communication Intervention: We will conduct a two-arm RCT assigning participants at a ratio of 1:1 to either one of the two arms (Experimental: HIV-tailored plus SNC interventions vs. Control: HIV-tailored plus attention-control interventions). Both arms will have eight weekly sessions of a 30-minute HIV-tailored cessation intervention (cognitive behavioral therapy plus nicotine patches). All research-related procedures will be conducted remotely."|f|f|f|t
33797226|NCT04291729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797227|NCT01178801|||||RETROSPECTIVE|||||||
33797228|NCT05470517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon and team administering the treatment will not be blinded; however, patients, patients' families, and hospital caregivers outside of the operating room will be blinded to the treatment.|Single-blinded randomized controlled pilot phase 2 study|t|f|f|f
34020431|NCT06337253|NA|SINGLE_GROUP||PREVENTION||NONE||"The intervention in this study is the administration of one cycle of SPAQ medicines. SPAQ medicines procured by Malaria Consortium are from one of the 3 manufacturers with WHO prequalification, with whom Malaria Consortium has framework agreements: Tridem Pharma, S Kant Healthcare Ltd, or MacLeods Pharmaceuticals Ltd.~Each monthly SMC cycle consists of one dispersible tablet of SP and three daily dispersible tablets of AQ. There are two doses of SPAQ: a lower dose for children aged three to \<12 months, and a higher dose for children aged 12 to 59 months. For children aged 12 to 59 months, the dosage comprises a single dose of a full tablet of SP 500/25mg and three daily doses of a full tablet of AQ 153mg. Those aged three to \<12 months are administered half the dose given to those aged 12 to 59 months, given as full dispersible tablets."||||
34020432|NCT03259438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not find out what interventional group they are placed in (qigong vs. healthy living) until after they have completed their first testing session.~Pre intervention data collection and post intervention data analysis will be completely masked."|This parallel, randomized non-inferiority trial will test whether qigong is not inferior to an exercise/nutrition active comparator group in terms of reducing fatigue in female cancer survivors. If non-inferiority is demonstrated during analysis, a secondary analysis will test whether qigong can be considered superior to the exercise-nutrition comparator|f|f|t|t
34020433|NCT05693207|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020434|NCT06278740|||COHORT||CROSS_SECTIONAL|||||||
34020435|NCT02280668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020436|NCT04030065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020437|NCT02563106|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34020438|NCT02770677|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Detail of intervention is Yoga training program. 3 times /week ,12 weeks .||||
34020439|NCT04320121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797229|NCT02731755|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33797230|NCT03882697|||COHORT||PROSPECTIVE|||||||
33797231|NCT00502424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33797232|NCT02482519|NA|SINGLE_GROUP||OTHER||NONE||||||
33797233|NCT01591304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797234|NCT06051786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797235|NCT04988568|||COHORT||CROSS_SECTIONAL|||||||
33797236|NCT02032069|||CASE_ONLY||PROSPECTIVE|||||||
33797237|NCT01681251|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33797238|NCT01317719|||COHORT||PROSPECTIVE|||||||
33797239|NCT02618486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33797240|NCT00393484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797241|NCT02496975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797242|NCT03957213|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
34020440|NCT03963024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020441|NCT04185051|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34020442|NCT00000130|RANDOMIZED|||TREATMENT||||||||
34020443|NCT00807248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020444|NCT01948466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020445|NCT06090773|||COHORT||PROSPECTIVE|||||||
34020446|NCT05077891|||COHORT||CROSS_SECTIONAL|||||||
34020447|NCT00540683|||CASE_ONLY||PROSPECTIVE|||||||
33797243|NCT00339742|||CASE_CONTROL||RETROSPECTIVE|||||||
33797244|NCT04992156|||COHORT||RETROSPECTIVE|||||||
33797245|NCT00575523|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33797246|NCT02607670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797247|NCT04759937|||CASE_ONLY||CROSS_SECTIONAL|||||||
33797248|NCT04682483|||COHORT||OTHER|||||||
33797249|NCT01924026|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797250|NCT05638945|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This study is a pilot stepped wedge cluster randomized trial (SW-CRT) of three diverse emergency department (EDs) randomized to receive the intervention at 3-month intervals over a 15-month period. Time of crossover from the control to intervention period will be unidirectional, and each crossover sequence will allow for a 3-month implementation period where data will not be collected.||||
33797251|NCT03133117|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797252|NCT01387334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33797253|NCT01395758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797254|NCT04878198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797255|NCT05414786|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797256|NCT00259961|||DEFINED_POPULATION||PROSPECTIVE|||||||
33797257|NCT00622219|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33797258|NCT00952263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797259|NCT04298788|RANDOMIZED|CROSSOVER||PREVENTION||NONE||participant meals were randomized to blue or white dishware conditions, matched for food choices||||
33797260|NCT04564196|||COHORT||PROSPECTIVE|||||||
33797261|NCT02420613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797262|NCT00786006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797263|NCT03316482|NA|SINGLE_GROUP||TREATMENT||NONE||Leuprorelin treatment||||
33797264|NCT06400719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797265|NCT05143255|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33797266|NCT04234776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will receive IM ketamine or IM saline applications as randomized. Applications will occur three times a week. It will be 4 weeks of IM application (12 initial applications). Injections will occur into the subjects' glutes (0.75 mg / kg). The ketamine group will use 2 placebo tablets and the parallel group escitalopram 15 mg and aripiprazole 5 mg. Thereafter, participants will receive weekly ketamine doses over 6 months as maintenance treatment. Research members will be submitted to Structured Clinical Interview for the DSM for diagnostic categorization and will be evaluated from other scales. Vital signs will be checked continuously for a period of 2 hours with each infusion. Patients will be observed in a quiet, comfortable room and subjected to medical monitoring for 2 hours. They will leave the environment in the company of a competent adult.|t|t|t|t
33797267|NCT04874558|||COHORT||PROSPECTIVE|||||||
33797268|NCT03769051|||COHORT||PROSPECTIVE|||||||
33797269|NCT06399029|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective single-center pilot study||||
33797270|NCT02531152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797271|NCT03400254|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||24 participants in Phase Ib and 80 participants in Phase II|t|f|f|f
33797272|NCT00719459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797273|NCT05068362|NA|SINGLE_GROUP||TREATMENT||NONE||Children with microtia||||
33797274|NCT04956679|||FAMILY_BASED||PROSPECTIVE|||||||
33797275|NCT04144322|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33797276|NCT03352778|||CASE_CONTROL||PROSPECTIVE|||||||
33797277|NCT05505071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797278|NCT04152421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797279|NCT01428297|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33797280|NCT00596310|NA|SINGLE_GROUP||SCREENING||NONE||||||
33797281|NCT00444600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797282|NCT00548574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797283|NCT06225388|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797284|NCT04468698|||COHORT||RETROSPECTIVE|||||||
33797285|NCT03365895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020448|NCT00995280|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34020449|NCT00351975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020450|NCT03768726|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects who participate in A1281198 will be transitioned under double blind conditions (during the first two weeks of the study) to 26 weeks of treatment with flexibly dosed opened label ziprasidone.|Subjects would completed A1281198 will be transitioned under double blind conditions to 26 weeks of treatment with flexibly dosed opened label ziprasidone.||||
34020451|NCT04981496|||OTHER||PROSPECTIVE|||||||
33721021|NCT04576130|RANDOMIZED|PARALLEL||PREVENTION||NONE|Treatment cannot be blinded, we will use several endpoints that do not require an endpoint committee evaluation.|Randomized, parallel-group, open-label, superiority trial with two arms with 1:1 randomization through an internet-based randomization module.||||
33721022|NCT04408482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721023|NCT03541265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a a randomized prospective study. Patients were assigned into two cohorts on the day of surgery using a randomization software by an independent observer. Randomization was based on age, gender, BMI and type of surgery. The investigators hypothesized that there would be no difference in the pain scores or morphine consumption. Sample size analysis for a randomized prospective trial was performed to achieve an 80% power to detect 20% difference in pain scores (2-point score difference on VAS 0-10 was deemed clinically relevant). A sealed envelope was given to the anesthesiologist and the surgeon on the day of surgery, stating the group that the patient was assigned to participate. All descriptive statistics (Mean, SD) and analysis were performed with SPSS version 21 (IBM) at a 0.05 level of significance.|t|f|t|t
33721024|NCT05023187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33721025|NCT05835609|NA|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment||||
33721026|NCT02047747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721027|NCT01304966|||CASE_ONLY||PROSPECTIVE|||||||
33721028|NCT02699554|||COHORT||PROSPECTIVE|||||||
33721029|NCT04430881|||COHORT||PROSPECTIVE|||||||
33721030|NCT01601782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721031|NCT00624052||||TREATMENT||||||||
33721032|NCT04119635|||COHORT||CROSS_SECTIONAL|||||||
33721033|NCT02631954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721034|NCT02493608|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721035|NCT05175417|||CASE_CONTROL||PROSPECTIVE|||||||
33721036|NCT05422677|||OTHER||PROSPECTIVE|||||||
33721037|NCT04128384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721038|NCT00074087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721039|NCT05951010|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721040|NCT04453033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Research suggests that certain wavelengths of light are more effective in treating Parkinson's, which means this therapeutic light device does not need to be nearly as bright as traditional light therapy. This study will test a light therapy device (Celeste® specialized light therapy device). We are testing two devices in this study: an active device which has these special wavelengths, and a control device which does not have the special wavelengths. Both lights look the same, and it is not possible to tell which light has the effective wavelength by looking at it. No one involved in the study (patients, families, doctors, investigative staff) knows which type of light therapy each person receives. A Device Technician, separate from the trial, will assist the participants in the device setup. Participants will be instructed not to disclose any aspects of their device. All study staff will be masked.|This is a six-month, randomized, double-blind, controlled, parallel group study with visits at screening, baseline, weeks 13 and 26, and blinded coordinator calls throughout the study for safety and efficacy assessments. This study will use a remote trial design, which will allow participants to be recruited nationally and evaluated centrally using video conferencing. All study participants will have their eligibility assessed and confirmed by a study coordinator and a PD specialist (primary investigator). Participants will complete the secondary outcome measures, which are Patient Response Outcomes (PRO's), and will be assisted by a blinded coordinator to ensure completeness of answers. A blinded rater will conduct the Primary Outcome Measure as well as the MDS-UPDRS. All assessments will be conducted by video at Baseline, Week 13, and Week 26 visits.|t|t|t|t
33721041|NCT06249425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721042|NCT01826487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721043|NCT03366402|||COHORT||PROSPECTIVE|||||||
33721044|NCT03711487|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33721045|NCT06137404|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33721046|NCT01894581|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33721047|NCT04225351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721048|NCT01394523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33721049|NCT01002950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721050|NCT06507449|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721051|NCT00114465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721052|NCT05959330|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33721053|NCT02024347|||CASE_CONTROL||PROSPECTIVE|||||||
33721054|NCT02062320|||COHORT||RETROSPECTIVE|||||||
33721055|NCT04442204|||OTHER||PROSPECTIVE|||||||
33797286|NCT01580293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797287|NCT05173714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797288|NCT01827787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is not a randomized trial rather participants are enrolled based on disease histology. Participants in each arm receive the same treatment regimen.||||
33797289|NCT03104387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33797290|NCT04177459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797291|NCT01982136|||COHORT||PROSPECTIVE|||||||
33797292|NCT03476746|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||A single application of LEO 90100 foam and Dovobet® ointment will be applied to multiple test sites on the innerside of both arms of trial subjects. The trial consists of 2 parts. The first part, (pilot part) will evaluate the pharmacokinetic profile of LEO 90100 foam and Dovobet® ointment by measuring the amount of each of the active ingredients in the stratum corneum and determine conditions for the second part of the trial. The second part (pivotal part) will compare the amount of each of the active ingredients at steady state or close-to-steady state between LEO 90100 foam and Dovobet® ointment. The sample size and the number of application sites in the pivotal part will be determined based on the results of the pilot part.||||
33797293|NCT03383146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797294|NCT03621696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797295|NCT00885157|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797296|NCT05200572|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33797297|NCT04856982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941649|NCT04250142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will not know the type of treatment they will receive. The data analysis will be carried out assigning a letter to the treatment arms, and the identity of the arms will not be revealed up until the end of the analysis.|A double blinded randomized controlled clinical trial|t|f|f|t
33797298|NCT00989937|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33797299|NCT06441786|NA|SINGLE_GROUP||TREATMENT||NONE||A clinical open trial evaluating feasibility, acceptability, as well as treatment effects measured before, after and at 6-month follow-up, for a 10-week group treatment based on metacognitive therapy, for adolescents aged 15-18 years of age with anxiety and/or depression and an autism diagnosis. The study is conducted at two psychiatric clinics for children and youth.||||
33941650|NCT00391443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941651|NCT01419574|||||PROSPECTIVE|||||||
33797300|NCT00428519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797301|NCT02401763|||||RETROSPECTIVE|||||||
33797302|NCT03189329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33797303|NCT02957981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797304|NCT00432523|RANDOMIZED|PARALLEL||||NONE||||||
33797305|NCT03672773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797306|NCT00981968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797307|NCT05060614|||COHORT||PROSPECTIVE|||||||
33797308|NCT05561881|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33797309|NCT04300257|||COHORT||PROSPECTIVE|||||||
33797310|NCT00140088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797311|NCT05206617|||COHORT||PROSPECTIVE|||||||
33797312|NCT03590080|||COHORT||PROSPECTIVE|||||||
33941652|NCT00579527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941653|NCT02862990|||CASE_ONLY||CROSS_SECTIONAL|||||||
33941654|NCT02961049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941655|NCT03040063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33941656|NCT00166803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941657|NCT04126629|||CASE_CONTROL||PROSPECTIVE|||||||
33941658|NCT03984916|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The appearance of the interventions is identical, appearing in capsules of identical appearance and with a numerical code.||t|t|t|t
33941659|NCT03243981|NA|SINGLE_GROUP||OTHER||NONE||Application of Skintyte and/or broadband light to skin||||
33941660|NCT03347461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941661|NCT05931575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941662|NCT04657328|||OTHER||PROSPECTIVE|||||||
33941663|NCT04421105|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33797313|NCT02986906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941664|NCT01421693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941665|NCT01808027|||COHORT||PROSPECTIVE|||||||
33941666|NCT00999882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941667|NCT05299112|NON_RANDOMIZED|PARALLEL||OTHER||NONE|This is not blinded or randomized.|There will be parallel assignment of supplemented parenteral nutrition (PN) and standard parenteral nutrition dependent upon stock availability of intervention PN.||||
33941668|NCT03726099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941669|NCT04918524|||COHORT||PROSPECTIVE|||||||
33941670|NCT02412826|||CASE_ONLY||PROSPECTIVE|||||||
33941671|NCT01797042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33941672|NCT02665039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941673|NCT00625963|||COHORT||RETROSPECTIVE|||||||
33941674|NCT00693524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941675|NCT03506464|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941676|NCT01085149|NON_RANDOMIZED|PARALLEL||||NONE||||||
33941677|NCT02050256|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33941678|NCT03899558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020452|NCT05362734|||COHORT||RETROSPECTIVE|||||||
33797314|NCT05756140|||CASE_ONLY||PROSPECTIVE|||||||
33797315|NCT05486364|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797316|NCT02457845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797317|NCT03751943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797318|NCT02113072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797319|NCT04661410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797320|NCT05544643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797321|NCT04360681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To minimize bias, all participants will be screened for assurance that they meet study eligibility criteria. A placebo drug will be employed as the comparison group to active study drug and the study will be conducted in a double-blinded fashion in that both the participants and the site investigators and staff interacting with participants and assessing study outcomes will be blinded to treatment assignment. The only individuals at the site with assess to treatment assignment information will be the research pharmacists.|This is a Phase 2 randomized, double-blind, placebo-controlled, single-site, parallel groups, 12-week treatment study|t|t|t|t
33797322|NCT00783133|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33941679|NCT01552408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797323|NCT00835770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797324|NCT02889237|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33797325|NCT00561886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797326|NCT02092077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797327|NCT03146065|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33941680|NCT04801615|||CASE_ONLY||PROSPECTIVE|||||||
33941681|NCT04467138|||COHORT||RETROSPECTIVE|||||||
33941682|NCT05343403|||COHORT||PROSPECTIVE|||||||
33941683|NCT04069026|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941684|NCT04683094|||COHORT||PROSPECTIVE|||||||
33941685|NCT06217926|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33941686|NCT03531099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941687|NCT06250192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020453|NCT04942158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, open label, non-inferiority randomized controlled trial||||
34020454|NCT00796679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020455|NCT02003521|||COHORT||PROSPECTIVE|||||||
34020456|NCT03453801|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33941688|NCT01787123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941689|NCT02994043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941690|NCT01230021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020457|NCT06360783|||CASE_ONLY||RETROSPECTIVE|||||||
34020458|NCT04465773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020459|NCT01020955|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34020460|NCT04575766|NA|SEQUENTIAL||TREATMENT||NONE||||||
34020461|NCT01324674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020462|NCT00271661|||||RETROSPECTIVE|||||||
34020463|NCT00950963|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020464|NCT04487938|||COHORT||PROSPECTIVE|||||||
33797328|NCT02308917|||COHORT||PROSPECTIVE|||||||
33797329|NCT04603417|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33797330|NCT05910918|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33797331|NCT05876013|||COHORT||PROSPECTIVE|||||||
33797332|NCT03427255|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial with a waiting list condition||||
33797333|NCT04075318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797334|NCT04801498|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797335|NCT01752166|||CASE_ONLY||PROSPECTIVE|||||||
33797336|NCT05936411|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797337|NCT05717751|||CASE_ONLY||RETROSPECTIVE|||||||
33797338|NCT06176924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797339|NCT01377766|||CASE_CONTROL||RETROSPECTIVE|||||||
33797340|NCT02950948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797341|NCT05801068|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797342|NCT05744193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33797343|NCT04351529|||OTHER||OTHER|||||||
33797344|NCT00362778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941691|NCT05004363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo|RCT|t|t|t|t
34020465|NCT05827835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020466|NCT00196625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020467|NCT01772758|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34020468|NCT04155307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716821|NCT03198949|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|During baseline phase and core phase, double-blind is maintained. Only one independent investigator who check trough drug level of everolimus and and one pharmacist who dispenses IND will be exposed. All the rest of the researchers will be masked.|This is a prospective, randomized, double-blind, placebo-controlled cross over study to evaluate the efficacy and safety of everolimus (trough 5-15 ng/mL) given as adjunctive therapy in patients with FCDII who already failed more than 2 antiepileptic drugs and surgery.|t|t|t|t
33716822|NCT03759054|||COHORT||PROSPECTIVE|||||||
33716823|NCT00273442|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716824|NCT00851383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33716825|NCT01911689|||CASE_CONTROL||PROSPECTIVE|||||||
33716826|NCT00089765||||TREATMENT||||||||
33716827|NCT01352689|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797345|NCT00459446|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33797346|NCT06677164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
33797347|NCT02400099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797348|NCT01438086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797349|NCT03195426|NA|SINGLE_GROUP||TREATMENT||NONE||This study aims at assessing the effectiveness of combined SSNB, ICB and supraclavicular nerve block (SCNB) as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery. The secondary objective was to test the hypothesis that SSNB-ICB-SCNB combination could spare phrenic nerve.||||
33797350|NCT06154239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All participants will have 3 samples taken: DAYE Diagnostic Tampon (DDT), self-swab and clinician administered swab. Participants will be randomised into 2 groups for sampling order between the DDT and self-swab.||||
33797351|NCT06611839|NA|SINGLE_GROUP||OTHER||NONE||||||
33797352|NCT02678572|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, single-arm, open-label study to evaluate the efficacy and safety of Melphalan/HDS in patients with hepatic dominant metastatic ocular melanoma. The study will be conducted at approximately 40 centers in the United States and Europe.||||
33797353|NCT02536430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797354|NCT00432588|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797355|NCT03876210|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797356|NCT01314352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797357|NCT04423146|||COHORT||PROSPECTIVE|||||||
33797358|NCT04679571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797359|NCT00676234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020469|NCT05528835|||COHORT||PROSPECTIVE|||||||
34020470|NCT02728570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34020471|NCT00815256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020472|NCT01523457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716828|NCT02601131|||COHORT||PROSPECTIVE|||||||
33716829|NCT04544254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716830|NCT01397474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33716831|NCT00619801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716832|NCT03386682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716833|NCT03336333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797360|NCT06677424|NA|SINGLE_GROUP||OTHER||NONE||Open-label, non-randomized, between-subject design||||
33797361|NCT01580241|||COHORT||PROSPECTIVE|||||||
33797362|NCT04088032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797363|NCT03236909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797364|NCT03003637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797365|NCT06195891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797366|NCT05426317|NA|SINGLE_GROUP||OTHER||NONE||metastatic solid tumor||||
33797367|NCT06502353|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797368|NCT05949242|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will have one eye randomized to each arm of the trial:~one eye will receive OMNI canaloplasty alone the other eye will receive OMNI canaloplasty and Hydrus microstent"||||
33797369|NCT06664762|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The main investigators will be in charge of randomizing all the patients ellegible for this protocol, and the care providers and endoscopists will be masked when it comes to knowing to which arm of the study each patient belongs to, untill the moment they need to perform the colonoscopy.|multicenter single-blind randomized clinical trial study|f|t|f|f
33797370|NCT06373549|||COHORT||PROSPECTIVE|||||||
33797371|NCT05878158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|t|f|f|f
33797372|NCT04906161|||COHORT||RETROSPECTIVE|||||||
34100875|NCT06159725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 is unmasked/open label Part 2 is masked with matching placebo|Part 1 is a single-group, unblinded study Part 2 is a randomized, parallel-group, placebo-controlled, double-blind study.|t|t|t|t
33941692|NCT00459680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100876|NCT05966194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100877|NCT06695585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Prospective, double-blinded, randomized superiority trial|t|t|t|t
33941693|NCT05326672|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941694|NCT01054794|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33941695|NCT03677440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be unaware if the treadmill walking exercise training or stretching-and-toning conditions represent the experimental or control conditions; outcome assessors will be treatment-blinded; MRI data analysts will be blinded to condition||t|f|t|t
33941696|NCT06212349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33941697|NCT03270527|NA|SEQUENTIAL||PREVENTION||NONE||||||
33941698|NCT04131881|||COHORT||PROSPECTIVE|||||||
33941699|NCT01293123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941700|NCT06137235|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33941701|NCT03893994|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33941702|NCT01116661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941703|NCT04921111|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33941704|NCT02348931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020473|NCT02513511|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020474|NCT03457467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020475|NCT05637346|NA|SINGLE_GROUP||OTHER||NONE||One group to evaluate the feasibility and accuracy of the proposed methods.||||
34020476|NCT01209130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020477|NCT00015769||||TREATMENT||||||||
34020478|NCT02316665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020479|NCT06152952|||COHORT||PROSPECTIVE|||||||
34020480|NCT05332028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study was planned as triple-blind; patients and investigators were blinded to the group allocation. An investigator opened the sealed opaque envelopes before the block application. An another anaesthetist who was blinded to the group assignment was responsible for collecting intra-and postoperative data.|Patients were randomly assigned to Group 1 (Patients undergoing PVB) or Group 2 (Patients undergoing MTP block) for a ratio of 1:1, including 32 patients each, using a computer-generated table of random numbers and concealed sealed opaque envelopes. An investigator opened the sealed opaque envelopes before the block application.|t|t|t|t
33716834|NCT05299515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the approximately 3-Month (or at completion/discontinuation of intervention) and approximately 6-Month Follow-Up assessments (or approximately 3 months after 3-month follow up assessment or at discontinuation of intervention), a trained and blinded member of the research team will complete assessments with the participant.|Participants will be randomized in parallel to receive either the Peer Activate intervention or treatment as usual (TAU: weekly group and individual counseling with an addiction counselor in addition to referral to other available services in the community through study contact). Assessments will take place for both groups at baseline, at an approximately 3-month follow-up (or at completion/discontinuation of the intervention), and at an approximately 6-month follow-up (or at 3 months after completion/discontinuation of the intervention).|f|f|f|t
33716835|NCT02250365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716836|NCT04154020|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who meet all inclusion and no exclusion criteria are randomly allocated to two arms in the study. The allocation is stratified by treatment center.||||
33797373|NCT01606124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020481|NCT04886258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020482|NCT03609723|||COHORT||PROSPECTIVE|||||||
34020483|NCT00128830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020484|NCT02452983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020485|NCT05961865|||COHORT||PROSPECTIVE|||||||
34020486|NCT03888950|NA|SINGLE_GROUP||OTHER||NONE||||||
34020487|NCT05055440|||COHORT||PROSPECTIVE|||||||
34020488|NCT04969510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020489|NCT05303337|||COHORT||PROSPECTIVE|||||||
34020490|NCT00839735|||COHORT||PROSPECTIVE|||||||
34020491|NCT01751932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020492|NCT02808156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020493|NCT01915706|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34020494|NCT04916158|||CASE_ONLY||PROSPECTIVE|||||||
33941705|NCT05430230|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All medication will be prepared in capsules identical in appearance and weight.|Participants will be entered into the trial and have an initial blinded 2-week treatment period of either naproxen or placebo and then entered into an open washout period of 2 weeks. At the end of this washout, participants will then receive either naproxen or placebo for a further 2 week period followed again by a 2 week washout. This sequence will then be repeated (total of 4 treatment periods) such that all participants receive naproxen for 2 treatment periods and placebo for 2 treatment periods. The order of treatment will be randomized and the treatment allocation and IP will be blinded.|t|f|t|t
33941706|NCT00517673|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33941707|NCT03794856|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941708|NCT03369925|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941709|NCT02967042|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941710|NCT03384316|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941711|NCT01048736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941712|NCT05917002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This study is double blinded. Both the investigators and the participants will be blinded as to which method of stimulation they receive first.|Participants will be randomly assigned to receive active or sham stimulation either first or second. All participants will receive active and sham during the study, only the order will be randomized.|t|f|t|f
33941713|NCT03031873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941714|NCT01265316|||CASE_ONLY||PROSPECTIVE|||||||
33941715|NCT03459794|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33941716|NCT03294798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941717|NCT01778764|||COHORT||OTHER|||||||
33941718|NCT05414422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941719|NCT05937503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not informed about the intervention|prospective randomized controlled study|t|f|f|f
33941720|NCT05136612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Individuals with CP will be assigned to group 1 or group 2 by simple randomization using the Research Randomizer program (https://www.randomizer.org/) prior to treatment."|f|f|f|t
33941721|NCT00697424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941722|NCT03996993|||COHORT||PROSPECTIVE|||||||
33941723|NCT02612558|NA|SEQUENTIAL||TREATMENT||NONE||||||
33941724|NCT04509206|NA|SINGLE_GROUP||OTHER||NONE||||||
33941725|NCT01924793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941726|NCT03432819|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941727|NCT00724789|||COHORT||PROSPECTIVE|||||||
33941728|NCT03389659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blined||t|f|t|f
33941729|NCT06189079|||COHORT||PROSPECTIVE|||||||
33941730|NCT03776331|||COHORT||PROSPECTIVE|||||||
33941731|NCT00372580|||DEFINED_POPULATION||OTHER|||||||
33941732|NCT02749643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941733|NCT04010201|||COHORT||PROSPECTIVE|||||||
34100878|NCT06643247|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34100879|NCT01169909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716837|NCT03544502|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33716838|NCT00828607|||COHORT||PROSPECTIVE|||||||
33716839|NCT03535103|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33716840|NCT06160154|||COHORT||RETROSPECTIVE|||||||
33716841|NCT06407960|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33716842|NCT04235049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716843|NCT01347450|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33716844|NCT05629624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will recruit a sample of malnourished children and randomly assign to different intervention arms. We will also have a control sample of well-nourished children for comparison analysis.||||
33716845|NCT03316664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||An 8-week, randomized, controlled, assessor-blind, three-parallel-arm trial is planned with patients diagnosed with a schizophrenic psychosis.|f|f|t|t
33797374|NCT02342210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797375|NCT06238869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33797376|NCT06677255|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33797377|NCT06204055|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|After the physical examination has been performed, each participant will be randomized to receive IMDN or SIMDN. Randomization will be completed by use of a computer-generated list of random numbers that will designate group assignment. The PI will inform the study PTs of the participants group assignment. The list will be maintained by a research assistant who is not involved with participant recruitment, examination or treatment. Participants will be blinded to group assignment.|"The first phase will be an RCT, 2 x 3 group (IMDN or Sham) by time (pretest, post-treatment week 1, post-treatment week 2, posttest, follow-up) with repeated measures on timeframe.~The second phase will utilize logistic regression analysis to identify associations between the groups' demographic, historical, clinical variables and short-term pain and disability outcomes. This type of analysis will be able to identify strong predictors of the treatment outcome. Various processes will be used to determine optimal model fit for analysis."|t|f|f|f
33797378|NCT06184152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Intervention is not masked for study team or investigator but all images are being interpreted by radiologist who is masked to clinical outcomes (development of HCC).|||||
33797379|NCT02220816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33797380|NCT02880241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797381|NCT02282085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941734|NCT05230992|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a clinical investigation of a CE (Communauté Européenne)-marked medical device that is monocentric, interventional, prospective, comparative, randomized, open-label, with cross-over design.||||
33941735|NCT05519033|||COHORT||RETROSPECTIVE|||||||
33941736|NCT02337855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33941737|NCT04963738|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941738|NCT04327505|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled, open label, multi-centre clinical trial||||
33941739|NCT00560872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941740|NCT01378156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941741|NCT01362062|||COHORT||PROSPECTIVE|||||||
33941742|NCT06028893|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941743|NCT01920087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941744|NCT02925780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941745|NCT04269629|||COHORT||PROSPECTIVE|||||||
33941746|NCT01716585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941747|NCT03596307|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blinded|Randomization 1:1. Acute phase study - Session 1 (2 days) ; Crossover; Session 2 ( 2 Days) Short Term Phase - Session 2 (Pretest), 16 day supplementation, Session 3 (Post test), Crossover; Session 4 (Pretest),16 day supplementation, Session 5 (Post test).|t|f|t|f
33941748|NCT04096781|RANDOMIZED|PARALLEL||PREVENTION||NONE||A Shared Decision-Making pathway focused on a digital shared decision-making tool (SDMT) that is augmented by a clinician tool and an optional lay coach||||
33941749|NCT03145428|||COHORT||PROSPECTIVE|||||||
33941750|NCT01363973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100880|NCT05686252|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Superiority Crossover Randomised Controlled Trial||||
34100881|NCT01825252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716846|NCT01304550|||CASE_CONTROL||RETROSPECTIVE|||||||
33716847|NCT03132376|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716848|NCT02705495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716849|NCT03858088|||COHORT||RETROSPECTIVE|||||||
33716850|NCT06506227|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33716851|NCT03012425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716852|NCT03042533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant Blinding||t|f|f|f
33716853|NCT00433030|||COHORT||PROSPECTIVE|||||||
33716854|NCT03798990|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33716855|NCT00608231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716856|NCT02279901|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
33716857|NCT03280420|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients were catheterized and received urinary antiseptic and then randomly divided into two groups : Group I :30 patients received Tamsulosin 0.4 mg once daily and catheter removed after 3 days. Group II :30 patients received Tamsulosin 0.4 mg once daily and catheter removed after 7 days.||||
33716858|NCT02095587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33716859|NCT01983982|||COHORT||PROSPECTIVE|||||||
33716860|NCT04496154|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33716861|NCT05782608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716862|NCT00926276|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716863|NCT01894451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716864|NCT06459908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33716865|NCT00902369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716866|NCT06101745|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33716867|NCT05329272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716868|NCT05744544|||COHORT||PROSPECTIVE|||||||
33716869|NCT05360511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716870|NCT01641770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716871|NCT03059654|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33716872|NCT02076880|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33716873|NCT03033511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716874|NCT03922425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33716875|NCT04949126|||COHORT||PROSPECTIVE|||||||
34100882|NCT06688227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100883|NCT06695598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34100884|NCT06566703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100885|NCT06688916|||CASE_CONTROL||PROSPECTIVE|||||||
34100886|NCT03769116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel up to the measurement of the primary outcome at Week 48. At the beginning of Part 2, participants who were originally assigned to placebo will have the opportunity to receive delandistrogene moxeparvovec. All participants will be followed for 5 years following treatment with delandistrogene moxeparvovec.|t|t|t|t
34100887|NCT06078514|||COHORT||PROSPECTIVE|||||||
34100888|NCT05368298|||OTHER||OTHER|||||||
34100889|NCT02169401|||COHORT||PROSPECTIVE|||||||
34100890|NCT03987880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are not aware which eye will receive the 4.0-mm ring-shaped zone treatment and which eye will receive the 3.5-mm ring-shaped zone treatment.|Prospective, single-masked intraindividually comparing randomized controlled trial. Participants will be randomized to receive ultraviolet (UV) light according to protocol A in one eye and protocol B in the other, which is masked to the participant. Both eyes will be treated during the same visit. Participants are randomized utilizing a computer list of unique random numbers between 1 and 27; an even number will be treated with the 4.0-mm zone in the right eye; an uneven number with the 4.0-mm zone in the left eye.|t|f|f|f
34100891|NCT06419101|||COHORT||PROSPECTIVE|||||||
34100892|NCT02605967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100893|NCT01109368|||COHORT||PROSPECTIVE|||||||
34100894|NCT01944761|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34100895|NCT04281576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100896|NCT04439903|NA|SINGLE_GROUP||OTHER||NONE||Single-arm, single center, non-randomized, uncontrolled pilot clinical trial||||
34100897|NCT05193305|||COHORT||PROSPECTIVE|||||||
34100898|NCT06164756|||COHORT||PROSPECTIVE|||||||
34100899|NCT04487730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This is a randomized controlled trial. Participants will be randomly assigned to 9-weeks of either Engage-S Psychotherapy or Symptom Review and Psychoeducation (SRP) Psychotherapy"|t|f|t|t
34100900|NCT06690073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34100901|NCT02912520|||COHORT||PROSPECTIVE|||||||
34100902|NCT06323473|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled single arm clinical trial||||
34100903|NCT05739643|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study from a low dose to a high dose following safety review||||
34100904|NCT03564730|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either simultaneous or staged bilateral KA procedures using randomly generated numbers permuted in blocks of 10.||||
34100905|NCT00063063|||COHORT||PROSPECTIVE|||||||
34100906|NCT06695936|||COHORT||PROSPECTIVE|||||||
34100907|NCT06564623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100908|NCT00545948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100909|NCT06695741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100910|NCT06274047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716876|NCT06367790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33716877|NCT00388271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716878|NCT00709046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716879|NCT05040841|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The investigators will randomize subjects to one of 16 conditions, using a fractional factorial design to determine the effects of five intervention components.||||
33716880|NCT00508807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716881|NCT01312688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716882|NCT05769881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33716883|NCT04827550|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33716884|NCT06138301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716885|NCT03283228|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33716886|NCT01957644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716887|NCT04608851|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The intervention drug or placebo will be given to participants in closed boxes without any labels. Appearance and dosing of the products will be similar. Investigators will not handle the boxes or study products.|Double Blinded, Placebo controlled and randomized clinical trial|t|t|t|t
33716888|NCT00150449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716889|NCT04734080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Throughout cannabinoid research, there has been concern about potential unblinding due to the side effect profile of this class of medication. Prior meta-analyses have advocated for the use of active placebo, with concern that unblinding may misrepresent the effects of clinical trials. However, due to evidence of histamine receptor involvement in pain transmission, as well as overlap in antihistamine antiemetic use and common cannabinoid side effect profiles, we have chosen to use non-active placebo. Our hope is to elicit maximum benefit of cannabinoid dosing perioperatively without confounding variables. With use of non-active placebo, we will perform a comprehensive blinding analysis following the study period to ensure adequate blinding.||t|t|t|f
33716890|NCT00001008||PARALLEL||TREATMENT||||||||
33716891|NCT01767779|||COHORT||PROSPECTIVE|||||||
33716892|NCT02908503|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33716893|NCT03881592|||COHORT||OTHER|||||||
34100911|NCT00666575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100912|NCT06688279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"There will be two groups included in this study. Group A: It will receive 8 weeks of upper and lower body plyometric exercises protocol.~Group B: It will receive 8 weeks of standard exercises protocol."|f|f|f|t
34100913|NCT05195632|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label, phase 2 study.||||
34100914|NCT06404684|NA|SINGLE_GROUP||TREATMENT||NONE||"we will use a multiple baseline single-case experimental design (SCED) with phase A (baseline) and phase B (treatment).~Participants are randomized to different lengths of phase A; 15-21 days, so-called open randomization.~Phase B is the CBT treatment. The B phase aims to last 84 days (12 weeks).~Seven participants will be included with the main diagnosis of voyeurism, exhibitionism and/or frotteurism, and seven participants with coercive-sexual sadism disorder. The participants in each group will be randomized to seven lengths of phase A. These two groups of seven participants will be treated and analyzed separately."||||
34100915|NCT06695455|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional research with minimal risks and constraints Prospective, Interventional, Monocentric, without a control group||||
34100916|NCT04720170|NA|SINGLE_GROUP||TREATMENT||NONE||26 week, single arm, single site||||
33716894|NCT01336920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716895|NCT05725109|||OTHER||OTHER|||||||
33716896|NCT01949350|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33716897|NCT05062681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RANDOMIZED CONT|t|f|f|f
33716898|NCT03593707|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33716899|NCT00462774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33716900|NCT04597827|||CASE_CONTROL||PROSPECTIVE|||||||
33716901|NCT02406482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33716902|NCT05244330|||COHORT||RETROSPECTIVE|||||||
34100917|NCT04545489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716903|NCT06230081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Nurses and physiotherapists evaluating the patients are blinded as well as the physician compiling the data|The patients are randomized to either block or no block therapy|f|f|f|t
34020495|NCT03203564|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|IMP (Modufolin® for Injection, 100 mg) and Placebo are not identical in appearance and all efforts will be made at the clinic in order to maintain the blind. Both the IMP and the placebo will be masked in such a way that study subjects and study staff will remain blinded during the study. An un-blinded study nurse will prepare the IMP/placebo for injection and will administer the IMP/placebo to the study subject. The un-blinded study nurse performing the dose administration will not be involved in any study-specific assessments or evaluations.|An adaptive, randomized, double-blind, single-center, placebo-controlled|t|f|t|t
34020496|NCT05084703|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020497|NCT03060616|||COHORT||PROSPECTIVE|||||||
33716904|NCT04883502|||COHORT||PROSPECTIVE|||||||
34020498|NCT04930419|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020499|NCT01850186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020500|NCT04252898|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The trial will include four sites (two pairs, with an intervention site and a control site) and two phases.~For each pair of sites:~* site n°1: one control phase with no intervention followed by an interventional phase with the Nutri-Score applied on products~* site n°2: control phases only, without the Nutri-Score applied during any of the two phases"||||
34020501|NCT05500196|||CASE_ONLY||PROSPECTIVE|||||||
34020502|NCT00003538||||SUPPORTIVE_CARE||||||||
34020503|NCT04682769|||COHORT||PROSPECTIVE|||||||
34020504|NCT05969613|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34020505|NCT00627315|||COHORT||PROSPECTIVE|||||||
34020506|NCT04796753|||OTHER||CROSS_SECTIONAL|||||||
34020507|NCT04457336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Subjects will be randomized in a 1:1:1:1 manner to one of three doses of Tildacerfont or Placebo.|t|t|t|f
34020508|NCT02916043|||COHORT||RETROSPECTIVE|||||||
34100918|NCT04987450|||OTHER||PROSPECTIVE|||||||
34100919|NCT05828901|||COHORT||PROSPECTIVE|||||||
34100920|NCT06556394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100921|NCT06671366|NA|SINGLE_GROUP||OTHER||NONE||||||
34100922|NCT05890573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716905|NCT01018186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716906|NCT00142584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716907|NCT06152978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716908|NCT00002079||||TREATMENT||||||||
33716909|NCT00005622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716910|NCT03600610|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33716911|NCT04775602|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716912|NCT06112782|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33716913|NCT01722071|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33716914|NCT06493721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716915|NCT02297074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33716916|NCT01763216|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33716917|NCT00525707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716918|NCT02239757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716919|NCT01639651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33716920|NCT03293810|||OTHER||PROSPECTIVE|||||||
34020509|NCT00278252||||TREATMENT||NONE||||||
34020510|NCT01303757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020511|NCT03108573|||CASE_ONLY||CROSS_SECTIONAL|||||||
34100923|NCT05996068|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||We use se before-after study type and only the after phase receive intervention. Before phase will retrospectively collect data from patient without arterial line intervention.||||
34100924|NCT04541693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100925|NCT06694532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be carried out in Patients in two Groups aged between 17 to 70 years , of both sexes, who had painful symptoms, with or without presence of joint noise, and had unilateral or bilateral internal derangement of the TMJ proven by clinical examination, with no improvement after conservative treatment, were included in the study.||f|t|f|f
33797382|NCT04358549|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized (1:1 ratio) to receive favipiravir plus standard of care or standard of care alone.||||
34100926|NCT05411198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100927|NCT02662582|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34100928|NCT06494371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100929|NCT01798823|||COHORT||PROSPECTIVE|||||||
33941751|NCT03769753|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center phase I study.||||
34100930|NCT06532890|||COHORT||PROSPECTIVE|||||||
34100931|NCT06359561|||COHORT||PROSPECTIVE|||||||
34100932|NCT04754074|NA|SINGLE_GROUP||OTHER||NONE||||||
34100933|NCT06212739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor was blinded to the intervention.|Randomized controlled trial|f|f|f|t
34100934|NCT05624632|||COHORT||PROSPECTIVE|||||||
34100935|NCT04568902|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941752|NCT00841854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941753|NCT03744572|||COHORT||PROSPECTIVE|||||||
33941754|NCT03960294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941755|NCT01515813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941756|NCT05007912|||COHORT||PROSPECTIVE|||||||
33941757|NCT04960332|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial||||
33941758|NCT00210067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33716921|NCT00763477|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33716922|NCT04434794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716923|NCT02759679|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
33941759|NCT01683058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941760|NCT03024944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020512|NCT00856219|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34020513|NCT04438226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020514|NCT06168786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020515|NCT01577563|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020516|NCT03552094|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34020517|NCT00926224|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020518|NCT02472171|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34020519|NCT05656001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the outcomes assessor will not know if the participants receive actual or sham feedback.|Participants will be randomized to either an active feedback intervention or a control condition, consisting of a sham feedback.|t|f|f|t
34020520|NCT01339481|||COHORT||PROSPECTIVE|||||||
34020521|NCT04600778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34100936|NCT03385642|||COHORT||PROSPECTIVE|||||||
34100937|NCT06496971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluators for radiological response assessment will be blinded to the patient's assigned treatment.||f|f|f|t
33716924|NCT00112593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716925|NCT03773679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33716926|NCT05566158|||COHORT||RETROSPECTIVE|||||||
33716927|NCT00549276|||COHORT||PROSPECTIVE|||||||
33716928|NCT06234657|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes Assessor will be randomly assigned to online interview the patient and caregiver (this person does not know and have previously treated the patient)|The telerehabilitation program for stroke patients is provided via a remote system with caregiver support during 3 months||||
33716929|NCT01414075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716930|NCT00638768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716931|NCT02936245|||COHORT||PROSPECTIVE|||||||
33941761|NCT05610865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941762|NCT02517502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33941763|NCT01385098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941764|NCT05488249|||COHORT||CROSS_SECTIONAL|||||||
33941765|NCT04509024|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33941766|NCT01083615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941767|NCT00561964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020522|NCT01622036|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34020523|NCT01220297|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020524|NCT01600690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020525|NCT03282630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020526|NCT04384744|||COHORT||PROSPECTIVE|||||||
34100938|NCT06161194|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be randomly assigned to IG or CG after baseline assessment. Due to the nature of the studied conditions, it will not be possible to blind researchers or participants.|cluster-randomized, two-arm parallel-group controlled trial||||
34100939|NCT06626347|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33797383|NCT03547791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Enrolled women will be randomly assigned in a 1:1 ratio to ACS (Group 1) or placebo (Group 2). The randomization will be done by web-based randomization system which is operated by medical research collaborating center of Seoul National University Hospital. The ACS or placebo will be prepared by unblended researchers \[clinical trial pharmacy\]. Unblinded researchers will be designated at the beginning of this trial, and they will not participate in the subsequent process of data management and data analysis. Neither the enrolled pregnant women nor the other investigators (except predeterminate unblinded researchers) will be aware of the result of random assignment.|In this multi-center, double-blind, randomized, placebo-controlled trial, women who are at risk for late preterm birth (34+0wks-36+5wks) will be enrolled and randomly assigned to two groups receiving betamethasone(ACS) or placebo.|t|t|f|f
33797384|NCT01220336|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33797385|NCT04147910|NA|SINGLE_GROUP||OTHER||NONE||||||
33797386|NCT03399916|RANDOMIZED|FACTORIAL||PREVENTION||NONE||PART B: A three-factor design with two-levels yielded eight experimental conditions, half of which encouraged standing more (stand; n prompt types = 80, n total prompts =800) and the other half encouraged moving more (move; n prompt types = 80, n total prompts =800).||||
33797387|NCT03912961|||CASE_ONLY||PROSPECTIVE|||||||
33797388|NCT02520908|||COHORT||PROSPECTIVE|||||||
33797389|NCT06676943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797390|NCT00293293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797391|NCT02887066|||CASE_ONLY||PROSPECTIVE|||||||
33797392|NCT06259474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The study was designed as randomized, single blind pretest and posttest controlled trial. Approval was granted by the Ethical Committee of the Faculty of Physiotherapy at Kafr El Sheikh University under the number (T/ WH /2/2023/38). Each participant signed a written informed consent agreeing to adhere to the treatment plan for two months after discussing the benefits, goals and strategy of this study. They were also free to leave the study whenever they wished, for any reason. The principal investigator placed copies of the subjects' numbers in a vase and randomly assigned them to groups (A, B).~2.2. Subjects"|t|f|t|t
33797393|NCT01130467|||CASE_CONTROL||PROSPECTIVE|||||||
33797394|NCT03973892|||COHORT||RETROSPECTIVE|||||||
33797395|NCT02206763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020527|NCT01551225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020528|NCT02317718|||COHORT||PROSPECTIVE|||||||
34020529|NCT05646420|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34020530|NCT02430779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34020531|NCT01988740|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020532|NCT04974866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020533|NCT00521027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020534|NCT04000763|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All experiments proposed in this grant application will be performed in female non-obstructive urinary retention patients. We chose not to study male patients in this study given the need to exclude bladder outlet obstruction from benign prostatic hyperplasia (BPH), an evaluation that is invasive and costly.||||
34020535|NCT03525158|NA|SINGLE_GROUP||OTHER||NONE||Single case experimental AB design with or without optional replication (ABAB) (ie no random assignment)||||
34020536|NCT03637725|||COHORT||PROSPECTIVE|||||||
34020537|NCT02286596|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34020538|NCT02163486|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34020539|NCT03814538|||COHORT||PROSPECTIVE|||||||
34020540|NCT02575911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020541|NCT04069871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34020542|NCT00968799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020543|NCT01749995|||COHORT||PROSPECTIVE|||||||
34020544|NCT05669638|||COHORT||PROSPECTIVE|||||||
34020545|NCT05385159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020546|NCT01546376|||||PROSPECTIVE|||||||
34020547|NCT01980966|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34020548|NCT03884452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020549|NCT02767895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34020550|NCT03134118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020551|NCT05515692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020552|NCT04502823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020553|NCT03155386|||COHORT||PROSPECTIVE|||||||
34020554|NCT00187382|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020555|NCT05204836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The cohort is randomized into a control and treatment group, where the treatment group receives a zoledronic acid injection within 6 weeks of ACL injury.|t|f|f|f
34020556|NCT05172466|NA|SINGLE_GROUP||OTHER||NONE||||||
34020557|NCT04456556|||CASE_ONLY||RETROSPECTIVE|||||||
34020558|NCT01478165|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020559|NCT05912439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Masking (blinding) procedures is not done after initial randomisation on group (school) level, since participants are aware of the intervention design, that is whether or not they use a mHealth application|The study is a randomised controlled study. Group randomisation is used to distinguish three participating schools into control, treatment-as-usual (TAU) and intervention groups. Measures are obtained at baseline and 42 days later. Participants in both the TAU group and the intervention group receive an approximately 10 minutes long introduction regarding the study specifications and the application. The control group receive no further contact, access to the application or information until study-end questionnaire measures. Participants in the intervention group are randomly assigned to teams consisting of 8 individuals that collectively and individually compete in point collection through completion of in-app health tasks. Participation in the TAU group and intervention group is defined as downloading the Sidekick app and completing at least 3 health exercises within it.||||
34020560|NCT02845765|||CASE_CONTROL||PROSPECTIVE|||||||
34020561|NCT01203020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020562|NCT05238818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020563|NCT02878941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34020564|NCT00002883|RANDOMIZED|||TREATMENT||||||||
34100940|NCT06359535|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34100941|NCT03142958|||COHORT||PROSPECTIVE|||||||
34100942|NCT06526169|||COHORT||RETROSPECTIVE|||||||
33797396|NCT05985824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with primary diagnosis of lung cancer who met the inclusion criteria of the study and volunteered to participate in the study will constitute the sample of the study. 35 per group for the sample of the study. A total of 70 people will be sampled.||||
33797397|NCT04200365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797398|NCT03286244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797399|NCT02308618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797400|NCT01723410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33797401|NCT02444130|||COHORT||PROSPECTIVE|||||||
33797402|NCT02444598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797403|NCT04141865|||COHORT||PROSPECTIVE|||||||
33797404|NCT05715957|||COHORT||PROSPECTIVE|||||||
33797405|NCT03477695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797406|NCT02540746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797407|NCT03967704|NA|SINGLE_GROUP||OTHER||NONE||||||
33797408|NCT05928637|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797409|NCT02403596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797410|NCT00177931|||COHORT||PROSPECTIVE|||||||
33797411|NCT05932082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797412|NCT05158153|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center (multi-clinic), non-randomized pilot study to investigate the feasibility, tolerability, and safety of a bundled intervention (cooled dialysate, high sodium dialysate, high dose diuretics, high ultrafiltration hold threshold, active dialysis weaning) designed to foster recovery from acute kidney injury requiring dialysis.||||
33797413|NCT02235272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797414|NCT01517347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797415|NCT02474394|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33797416|NCT01892553|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33797417|NCT03494881|NA|SINGLE_GROUP||TREATMENT||NONE||Mepolizumab for the treatment of chronic spontaneous urticaria||||
33797418|NCT02983617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797419|NCT00484913|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33797420|NCT01598259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797421|NCT05991999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797422|NCT00142558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797423|NCT04722003|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33797424|NCT06266780|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33797425|NCT03074331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797426|NCT03669354|||COHORT||PROSPECTIVE|||||||
34020565|NCT04227353|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study is prospective randomised controlled trial, open label, exploratory/feasibility trial. The study aims to test the Healthy Eating and Active Lifestyle After Bowel Cancer - HEAL ABC intervention and HEAL ABC resources for feasibility and will inform a future definitive randomised controlled trial.||||
34020566|NCT01770392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020567|NCT01096030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797427|NCT01767714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797428|NCT01214824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797429|NCT00126646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797430|NCT00681525|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797431|NCT02349503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797432|NCT06515431|||COHORT||PROSPECTIVE|||||||
33797433|NCT04380467|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33797434|NCT01005524|||COHORT||PROSPECTIVE|||||||
34020568|NCT00328068|||COHORT||PROSPECTIVE|||||||
34020569|NCT00993837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020570|NCT01857141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34020571|NCT00479778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020572|NCT04401865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34020573|NCT05298319|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33797435|NCT02021006|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797436|NCT00196014|||CASE_ONLY||PROSPECTIVE|||||||
33797437|NCT02092116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797438|NCT04528706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797439|NCT00131066|||CASE_CONTROL||PROSPECTIVE|||||||
33797440|NCT02059044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33797441|NCT03953222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797442|NCT00513526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797443|NCT03409913|||CASE_CONTROL||RETROSPECTIVE|||||||
33797444|NCT00390793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797445|NCT04745663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Both eyes of the participants are tested; one eye randomised to receive the intervention and the second eye to receive the standard disinfection.|t|f|f|f
33797446|NCT06677476|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Training will be given on the mobile application to be downloaded to the mobile phone.||||
33797447|NCT04738903|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797448|NCT04129658|||COHORT||PROSPECTIVE|||||||
33797449|NCT05756504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797450|NCT00131638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797451|NCT03127280|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control trial||||
33941768|NCT05094258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After collecting all data about patients and patients participating in the study, the independent person who will evaluate the data will be blinded.|Patients with medial knee arthrosis will be randomized to receive unicompartmental knee prosthesis using mobile inserts in 30 patients and fixed inserts in 30 patients. Patients will be evaluated after at least 1 year of follow-up|t|f|f|t
33941769|NCT06330727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33941770|NCT01513460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941771|NCT00283062|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34020574|NCT04647721|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Split-face|t|f|f|t
34020575|NCT05737342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This experiment adopts a block random assignment design, and the system assignment table (Block randomization, block size = 6) randomly generated by the program is given serial numbers and assigned to groups. The probability of assignment to each group is 1/2.||t|f|t|f
34020576|NCT01335386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34020577|NCT00643565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020578|NCT02894437|||CASE_CONTROL||PROSPECTIVE|||||||
34020579|NCT02402114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020580|NCT04809883|||COHORT||PROSPECTIVE|||||||
34020581|NCT04859621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To ensure that the randomized drug treatment period is double-blind, the study drug and placebo control have the same appearance, smell, and taste. Furthermore, the package and label are also adjusted correspondingly to ensure blindness.|A multicenter, randomized, double-blind, placebo-controlled trial|t|t|t|t
34020582|NCT01133886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020583|NCT03357965|||COHORT||PROSPECTIVE|||||||
34020584|NCT01517230|RANDOMIZED|PARALLEL||||NONE||||||
34020585|NCT02490267|||CASE_CONTROL||PROSPECTIVE|||||||
34020586|NCT01682616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020587|NCT04054960|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34020588|NCT00386763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34020589|NCT02177656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34020590|NCT01831453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020591|NCT05328336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020592|NCT00818688|||COHORT||CROSS_SECTIONAL|||||||
34020593|NCT03806374|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34020594|NCT01971970|||COHORT||PROSPECTIVE|||||||
34020595|NCT03358745|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34020596|NCT01428050|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33716932|NCT04767204|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33716933|NCT03785431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716934|NCT00172289|||CASE_CONTROL||PROSPECTIVE|||||||
33716935|NCT02762682|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33716936|NCT00533845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716937|NCT05049876|||CASE_ONLY||PROSPECTIVE|||||||
33716938|NCT03725696|||CASE_ONLY||PROSPECTIVE|||||||
33716939|NCT03326258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716940|NCT03393741|||COHORT||PROSPECTIVE|||||||
33716941|NCT04874727|||CASE_ONLY||CROSS_SECTIONAL|||||||
33716942|NCT00427466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33716943|NCT03428789|||COHORT||PROSPECTIVE|||||||
33716944|NCT01373801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716945|NCT01676389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33716946|NCT02103764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33716947|NCT05409573|NA|SINGLE_GROUP||OTHER||NONE|The clinician and caregivers in charge of the patient during the intubation procedure will be blinded: the facemask EtO2 and pharyngeal EtO2 will not be visible on the monitor for them|Non-comparative prospective interventional study||||
34020597|NCT02509299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34020598|NCT01340768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020599|NCT01316302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020600|NCT02217787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34020601|NCT01541813|||COHORT||PROSPECTIVE|||||||
34020602|NCT04097249|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34020603|NCT04099550|RANDOMIZED|PARALLEL||PREVENTION||NONE||participants were randomised to undertake a 12-week lifestyle intervention with either RT-CGM or SMBG||||
34020604|NCT06188013|||CASE_CONTROL||PROSPECTIVE|||||||
34020605|NCT05912283|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Each product will be labeled with a randomly generated code.|A sequential randomised 3-period cross-over trial comparing the functional performance of two synthetic male condoms against a control latex male condom.|t|f|t|t
34020606|NCT05521139|||CASE_CONTROL||RETROSPECTIVE|||||||
33716948|NCT03484481|||COHORT||CROSS_SECTIONAL|||||||
33716949|NCT00115687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33716950|NCT01286012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33716951|NCT05322304|RANDOMIZED|PARALLEL||PREVENTION||NONE||parallel arm randomized controlled||||
33716952|NCT00989794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716953|NCT01821521|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716954|NCT00403442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33716955|NCT05513079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33716956|NCT05230225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941772|NCT05713929|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||"1. 1st measurement (T0-SPONT): in spontaneous ventilation.~2. Induction, intubation and mechanical ventilation for 5 minutes.~3. 2nd measurement (T1-LYING): after induction.~4. Trendelenburg 30° and ventilatory constant parameters.~5. 3rd measurement (T2-TREND): after 5 minutes of Trendelenburg.~6. Division into 2 groups according to randomization:~   I. Supine position and recruitment manoeuvre. 4th measurement after 5 minutes. (T3-RM) II. Either put in the Anti Trendelenburg position. 4th measurement after 5 minutes. (TREND Q3- REV)~7. Horizontal supine position and surgical incision."|t|f|t|t
33941773|NCT05814406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941774|NCT04654819|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The control group did not have access to simulators during the period of the study.||t|f|f|f
34100943|NCT00536523|||COHORT||PROSPECTIVE|||||||
34100944|NCT00569127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100945|NCT05683275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33797452|NCT03565796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33797453|NCT04068207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100946|NCT06695390|||OTHER||CROSS_SECTIONAL|||||||
34100947|NCT04971837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The CBD and placebo formulations are prepared, bottled and coded by Caliper Foods. The participants will receive a coded bottle to consume of the different formulations of CBD and placebo.||f|f|f|t
33716957|NCT00309504|||CASE_ONLY|||||||||
33716958|NCT01928524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Two parallel phase 1/2a studies with 3+3 design with either DOS given every second week or every third week in Caucasian patients (Table 1). Patients were included into DOS2w and DOS3w in sequence.~In the DOS2w group: Patients received escalating doses of Docetaxel (30-50 mg/m2 on Day 1), fixed doses of O (70 mg/ m2 on Day 1) and S-1 (30-35 mg/m2/day twice daily orally on Days 1-7) every two weeks. In the DOS3w group: Patients received escalating doses of docetaxel (40-60 mg/m2 on Day 1), fixed doses of O (100 mg/ m2 on Day 1) and S-1 (25 mg/m2/day twice daily orally on Days 1-14) every three weeks."||||
33716959|NCT01359657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716960|NCT02425046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33716961|NCT02729844|||COHORT||PROSPECTIVE|||||||
33716962|NCT02792933|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33716963|NCT05981144|||OTHER||PROSPECTIVE|||||||
33716964|NCT00814528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716965|NCT03763123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838896|NCT03636529|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Placebo beverage was prepared in the ASU metabolic kitchen and matched for fructose and total carbohydrate concentrations as well as being artificially colored to match tart cherry juice.|In this study, the investigators recruited at-risk individuals who were overweight (25.0-29.9 kg/m2) and obese (\> 30.0 kg/m2) and likely to exhibit one or more conditions associated with MetS. In this 12-week placebo-controlled 2 x 2 crossover dietary intervention, the investigators randomized participants to consume 240 mL (8 ounces) daily of either placebo (artificial cherry-flavored, anthocyanin-free beverage) or TCJ for 4 weeks, followed by a 4-week washout period, then consumption of the alternate beverage for 4 weeks. Subsequently, the investigators determined the effect of TCJ in at-risk participants on markers of uricemia, lipidemia, glycemia, and inflammation.|t|f|f|f
33838897|NCT00694109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941775|NCT01663155|||COHORT||PROSPECTIVE|||||||
33941776|NCT03359382|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33941777|NCT04951882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941778|NCT02300922|NA|SINGLE_GROUP||OTHER||NONE||||||
33941779|NCT02772042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941780|NCT01071772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941781|NCT01626599|NA|SINGLE_GROUP||OTHER||NONE||||||
34100948|NCT04370847|||OTHER||PROSPECTIVE|||||||
34100949|NCT02569775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100950|NCT06013800|||COHORT||PROSPECTIVE|||||||
34100951|NCT06695715|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33716966|NCT03378362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716967|NCT02500303|||COHORT||PROSPECTIVE|||||||
33716968|NCT02293408|||CASE_ONLY||PROSPECTIVE|||||||
33716969|NCT06439992|||CASE_CONTROL||PROSPECTIVE|||||||
33716970|NCT03453307|||COHORT||CROSS_SECTIONAL|||||||
33716971|NCT04235270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33716972|NCT06108791|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33941782|NCT03307408|||COHORT||PROSPECTIVE|||||||
34100952|NCT05261490|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1/2 (dose escalation and dose expansion)||||
34100953|NCT01937468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100954|NCT05490446|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34100955|NCT06686212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100956|NCT05849116|||OTHER||PROSPECTIVE|||||||
33716973|NCT06371118|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33716974|NCT01569490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716975|NCT03059498|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33716976|NCT02630550|||CASE_ONLY||PROSPECTIVE|||||||
33716977|NCT02388945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716978|NCT04404751|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33716979|NCT01793675|||COHORT||PROSPECTIVE|||||||
33716980|NCT03107325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33716981|NCT06357598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716982|NCT01573572|NA|SINGLE_GROUP||OTHER||NONE||||||
33716983|NCT00075049|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33716984|NCT04387851|||OTHER||RETROSPECTIVE|||||||
33716985|NCT05677750|||CASE_ONLY||PROSPECTIVE|||||||
33941783|NCT06202313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797454|NCT03666403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Three modes with different ventilation (nose-close) rates were studied: mode A, spontaneous breathing, with only PhO2 support, no rate; mode B, rate of 15-20 per minute with Ti 1.0 seconds; and mode C, rate of 5-10 per minute with Ti 2-4 seconds. During FB, every patient underwent all these three modes sequentially, from A to C. When the oxygen desaturation (\<90%) or bradycardia (\<100 beat/min) persisted more than 10 seconds, the FB was terminated. After the child was stabilized, FB was resumed, starting from the nose-close, but shifted to the next mode of NIV support. When the mode C still failed to maintain an acceptable vital status, the FB procedure was aborted with the removal of the bronchoscope to allow more aggressive NIV or even traditional resuscitation technique including endotracheal intubation and manual ventilation with high FiO2.|Upon the pharyngeal oxygen setting, this classic NIV operation was performed as per our protocol illustrated in the following steps. Firmly closed the mouth, then intermittently applied: a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver, and simultaneous doing abdomen-compression. The above assisted ventilation cycle was performed at a rate of 0-20 cycles per minute. The bronchoscopist optionally executed both the FB and the nose- closure and release, whereas an assistant delivered the abdomen-compression.||||
33838898|NCT03251053|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33838899|NCT02833675|||CASE_CONTROL||PROSPECTIVE|||||||
33838900|NCT00000951||PARALLEL||TREATMENT||||||||
33941784|NCT03756805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with moderate to severe sleep apnea (apnea-hypopnea index (AHI) between 15 / h and 65 / h) are included in the period 2014-2018. The patients are assigned to two groups: group 1, who are receiving PAP therapy and group 2, who are receiving upper airway stimulation. All patients receive polysomnography (PSG) in the sleep laboratory prior to therapy and are followed up on average 12 months after initiation of therapy by PSG or a home sleep test. This protocol is close to the daily clinical routine.||||
33941785|NCT04045431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject and study staff will not know the treatment received. Only the unblinded injector will know the treatment.||t|f|t|f
33941786|NCT04226365|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941787|NCT04993144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33941788|NCT01143116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study subjects, study personnel and laboratory conducting the cultivations and analyses were blinded to the investigational products. The products had the same packaging and visual appearance. The treatment code was never broken during the study.||t|t|t|f
33941789|NCT03789864|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a single-arm, single-center, non-randomized feasibility study.||||
33941790|NCT03513835|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33941791|NCT00422955|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34020607|NCT04096508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33941792|NCT06172205|RANDOMIZED|PARALLEL||TREATMENT||NONE||arm1: infusional FOLFOX plus Camrelizumab and apatinib arm2: HAIC-FOLFOX plus Camrelizumab and apatinib||||
33941793|NCT06123962|||COHORT||PROSPECTIVE|||||||
33941794|NCT04998058|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Bone tissue samples and image data allocation identified only by sequential numbers, not by name, for the outcome assessor.|Double-blind, randomized controlled clinical trial, intra-individual (split-mouth design).|t|f|f|t
33941795|NCT02394457|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33941796|NCT05489276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941797|NCT01482598|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941798|NCT05862675|||CASE_CONTROL||PROSPECTIVE|||||||
33941799|NCT05207371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941800|NCT04097925|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Doravirine administered orally once daily in combination with Tenofovir alafenamide (TAF) and emtricitabine (FTC) co-formulated as single tablet (Descovy® TAF/FTC) and administered orally once daily.||||
33941801|NCT01488994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941802|NCT02183220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33941803|NCT03525613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941804|NCT03343990|||CASE_CONTROL||PROSPECTIVE|||||||
33941805|NCT03922919|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||stepped-wedge design||||
33941806|NCT02822274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941807|NCT01535638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941808|NCT05192252|||COHORT||CROSS_SECTIONAL|||||||
33941809|NCT00890851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941810|NCT00527722|RANDOMIZED|PARALLEL||||NONE||||||
33941811|NCT03244189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Principal Investigator and site investigators, along with the primary study statistician will remind blinded throughout the trial.||f|f|t|f
33941812|NCT04785781|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||individuals will perform cycle ergometer without mask, with surgical mask and FFP2/N95. there will be 48 hours wash-out between tests.|t|f|f|f
33941813|NCT04301349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941814|NCT04812457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020608|NCT04197427|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34020609|NCT01551108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020610|NCT00548509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020611|NCT05975138|||CASE_CONTROL||PROSPECTIVE|||||||
34020612|NCT01248689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34020613|NCT01195103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020614|NCT04481321|||COHORT||PROSPECTIVE|||||||
34020615|NCT02903719|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34020616|NCT00309725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34020617|NCT00988065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020618|NCT02255825|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020619|NCT04414462|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34020620|NCT03050710|NA|SINGLE_GROUP||OTHER||NONE||Princess® VOLUME Lidocaine for the correction of nasolabial folds||||
34020621|NCT02844400|||COHORT||PROSPECTIVE|||||||
34020622|NCT02733926|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34020623|NCT06162130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802064|NCT04403789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinding was used. The intervention group was renamed Group A and the delayed-intervention group as Group B to blind participants from the intervention. Participants were strongly encouraged not to disclose their allocation status during the health measurement assessments.|Intervention The intervention duration is 12 weeks and it will provide the employees exercise time of 2 hours per week. The 2 hours should be used in two days either at the middle or at the end of working hours. The 2-hours exercise session will be conducted under the supervision of a certified trainer in the gym workplace. The 12 weeks period was chosen based on recommendations from previous studies to examine the effect of exercise interventions. The delayed intervention group will be asked to perform their usual routine and continue their usual exercise/physical activity routines. However, after the intervention is completed the delayed intervention group will also receive 2 hours of exercise time per week from working hours for 4 weeks. The reason for this is to encourage participants to participate in the study regardless of which group they will be assigned in. Also, this will help us reduce contamination as participants will not be aware which group they were assigned in.|t|f|f|f
33802065|NCT05563740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802066|NCT05519670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802067|NCT00885924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802068|NCT05875987|||COHORT||PROSPECTIVE|||||||
34020624|NCT01727466|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34020625|NCT04781192|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, unblinded phase I/II study with safety dose-finding in Phase I followed by efficacy determination in Phase II if maximum tolerated dose (MTD) is found in Phase I.||||
34020626|NCT01691924|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34020627|NCT02041156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020628|NCT01103466|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020629|NCT00686075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020630|NCT02539862|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020631|NCT03775720|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020632|NCT04317183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020633|NCT03809988|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 2:1||||
34020634|NCT02936011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020635|NCT06486961|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34020636|NCT05433363|||COHORT||PROSPECTIVE|||||||
34020637|NCT05291065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and Researchers will be blinded to the interventions.||t|f|t|f
34020638|NCT05453773|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34020639|NCT04312529|NA|SINGLE_GROUP||SCREENING||NONE||||||
34020640|NCT02460367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020641|NCT05327192|||OTHER||OTHER|||||||
34020642|NCT00227786|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34020643|NCT02348723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020644|NCT00289536|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020645|NCT01381250|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34020646|NCT04310969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020647|NCT06155318|||COHORT||PROSPECTIVE|||||||
34020648|NCT06306586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020649|NCT00872885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020650|NCT05526326|||COHORT||PROSPECTIVE|||||||
34020651|NCT03370016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Double Blinded|Prospective, Randomized Trial|t|t|t|f
34020652|NCT04259463|||COHORT||PROSPECTIVE|||||||
34020653|NCT03862066|||COHORT||PROSPECTIVE|||||||
34020654|NCT00769093|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34020655|NCT04186923|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020656|NCT03341819|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020657|NCT03804502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020658|NCT00941148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020659|NCT00332449|||COHORT||PROSPECTIVE|||||||
34020660|NCT03508505|||COHORT||RETROSPECTIVE|||||||
34020661|NCT04873765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020662|NCT04162054|||COHORT||PROSPECTIVE|||||||
34020663|NCT00276861|NON_RANDOMIZED|||TREATMENT||NONE||||||
33797455|NCT04426500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"A randomization service called Sealedenvelope.com available at https://www.sealedenvelope.com/simple-randomiser/v1/ will be used for allocation concealment to ensure that retrieval of the treatment group assignment is only revealed to appropriate team members on a real time basis after each new patient has been screened and consented. This service allows for allocation concealment that would not be possible if the entire randomization list was made available to team members at the beginning of the study. The security and integrity of the codes used by Sealedenvelope.com follows the Food and Drug Administration (FDA) standards for electronic records and follows the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines.~Participants will be blinded to group allocation throughout the study. Due to the nature of the intervention, it is not possible to blind the investigator to group allocation."|"This is a single-center, single-blinded, (stratified) randomized placebo-controlled three-arm non-inferiority trial with 2:2:1 allocation ratio.~People who meet eligibility requirements and provide informed consent will be randomly allocated to 3 groups to receive either UTAP, LTAP or Placebo with a 2:2:1 allocation ratio. The allocation sequence will be stratified by type of surgery (prostatectomy or partial nephrectomy) using stratified block randomization with randomly varying block sizes. Random permuted blocks sizes within stratification groups will be used to minimize the chance of selection bias. Investigators will be blinded to the size of each block with only the study statistician responsible for generating the randomization list knowing this information."|t|f|f|f
33797456|NCT00189813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34100957|NCT06685796|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is designed with a total of 3 cohorts, enrolling patients with advanced triple-negative breast cancer. Subjets are randomly assigned to each cohort in a 1:1:1 ratio. Each cohort initially enrolls no fewer than 8 subjects for safety assessment, with the assessment period being the first cycle of medication (21 days). If the overall safety assessment is tolerable, the enrollment will be expanded to 30-40 subjects. During the trial, if the subjets in any of the above cohorts are unable to tolerate the treatment or there is no clinical benefit, the enrollment for that cohort will be terminated promptly.||||
33797457|NCT06677229|RANDOMIZED|PARALLEL||TREATMENT||NONE|Although this clinical trial is an open label study for both study subjects and site personnel, in order to minimise bias, the study will employ the use of blinded raters for performing the following efficacy-related endpoints/tests, hence the denomination of single-blinded study.|||||
33797458|NCT03600051|||COHORT||CROSS_SECTIONAL|||||||
33797459|NCT01343290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797460|NCT01914913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797461|NCT02038413|||COHORT||RETROSPECTIVE|||||||
33797462|NCT00433199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797463|NCT03022123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797464|NCT00585533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797465|NCT00951379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797466|NCT00251576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33797467|NCT03147391|||CASE_ONLY||RETROSPECTIVE|||||||
33797468|NCT01189331|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|With masking value of FFR derived from coronary CT angiography to the investigators, FFR is measured and patients have been followed-up.||f|f|t|f
33797469|NCT00947453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797470|NCT03385824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33797471|NCT00629850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33797472|NCT06339892|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33797473|NCT03535558|||COHORT||RETROSPECTIVE|||||||
33797474|NCT01394744|||COHORT||PROSPECTIVE|||||||
33797475|NCT02210806|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797476|NCT05243043|||CASE_CONTROL||RETROSPECTIVE|||||||
34100958|NCT05853939|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant is blind to the rTMS target hemisphere, the rTMS stimulation parameters, and the objective of the study|Cross-over: 1 Hz vs 10 Hz vs sham rTMS; stimulation to attended or unattended hemisphere|t|f|f|f
34100959|NCT04128748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100960|NCT04298658|||CASE_CONTROL||PROSPECTIVE|||||||
34100961|NCT05782244|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34100962|NCT01008046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716986|NCT02326025|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33716987|NCT00040664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716988|NCT00075179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33716989|NCT00450450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716990|NCT04413409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33716991|NCT01545986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33716992|NCT03792282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33716993|NCT06090279|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||a minimum of 3 rounds of game usage in the Trauma Intensive Care Unit (TICU). Each patient will receive at least 2 sessions per day.||||
33716994|NCT01881776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33716995|NCT02037321|||||PROSPECTIVE|||||||
33716996|NCT03629067|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33716997|NCT05294445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Additionally to ILR interrogation on each site, the ILR data will be reviewed by blinded core lab investigators. All observed primary endpoints and outcome parameters will be presented to ERC.|prospective, two-arm, randomized, open-label, blinded endpoint, multi-center study|f|f|f|t
33716998|NCT06295263|||CASE_CONTROL||RETROSPECTIVE|||||||
33716999|NCT06061965|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717000|NCT04593563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717001|NCT00563251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717002|NCT00311610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797477|NCT06523868|NA|SINGLE_GROUP||SCREENING||NONE||||||
33797478|NCT00664404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797479|NCT06611059|||OTHER||PROSPECTIVE|||||||
34100963|NCT01235416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100964|NCT02324829|||COHORT||CROSS_SECTIONAL|||||||
33797480|NCT06007352|RANDOMIZED|PARALLEL||PREVENTION||NONE||phase II, parallel randomized control trial with 1:1 allocation||||
33797481|NCT02556138|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33797482|NCT00215397|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33797483|NCT06414850|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Multicenter, non-randomized, controlled, open-label, two-arm clinical trial||||
33797484|NCT02761408|||COHORT||PROSPECTIVE|||||||
33797485|NCT01000597|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33797486|NCT05348096|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive oral ibrutinib (140mg QD) combined with a CYP3A4 inhibitor (oral itraconazole, 100mg BID) for six months.||||
33797487|NCT01234610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797488|NCT00857545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797489|NCT00944372|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33797490|NCT03551535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797491|NCT01580319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797492|NCT06307223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797493|NCT03309488|||COHORT||PROSPECTIVE|||||||
33797494|NCT02896517|||COHORT||RETROSPECTIVE|||||||
33797495|NCT01042639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33797496|NCT06547151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797497|NCT04808778|||COHORT||PROSPECTIVE|||||||
33797498|NCT00158769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797499|NCT00557024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797500|NCT04035668|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33797501|NCT01818830|||CASE_CONTROL||RETROSPECTIVE|||||||
33797502|NCT00744224|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33797503|NCT02904759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797504|NCT01904071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797505|NCT03621917|||CASE_ONLY||PROSPECTIVE|||||||
33941815|NCT00991913|||COHORT||PROSPECTIVE|||||||
33941816|NCT00902473|RANDOMIZED|CROSSOVER||||NONE||||||
33941817|NCT05204901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941818|NCT00640900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941819|NCT04030351|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33941820|NCT03474380|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Trial (where clusters are VAMC sites) - a form of crossover design with unidirectional crossover (from control to experimental) but with randomization of when each VAMC site undertakes the transition. In the stepped wedge design, there is a staggered roll-out of the intervention, where the time and sequence of VAMC sites that will start the intervention at each period are determined by random allocation.||||
33941821|NCT00470223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941822|NCT01594424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941823|NCT03643185|||COHORT||PROSPECTIVE|||||||
33941824|NCT00656981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941825|NCT01301534|||CASE_ONLY||PROSPECTIVE|||||||
33941826|NCT02686957|||COHORT||RETROSPECTIVE|||||||
33941827|NCT03224442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33941828|NCT02509195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941829|NCT03204136|||CASE_CONTROL||RETROSPECTIVE|||||||
33941830|NCT02256956|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33941831|NCT05341609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel|f|t|t|t
33941832|NCT02238392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941833|NCT03757026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941834|NCT00540228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33941835|NCT00087685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941836|NCT05275309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941837|NCT00577421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941838|NCT02451046|||COHORT||PROSPECTIVE|||||||
33941839|NCT04539444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941840|NCT01454531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941841|NCT04408716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a single center prospective single-blinded randomized controlled trial. Enrolled AF patients planning clinically-indicated catheter ablation is randomly assigned with 1:1 ratio to undergo catheter ablation with ablation index guided high-power short-duration strategy or the standard radiofrequency ablation technique. Besides the evaluation at baseline, all the participants will be followed up at 24-72 hours, 1 month and 3 months post ablation.|t|f|f|f
33797506|NCT04825028|||CASE_CONTROL||RETROSPECTIVE|||||||
33797507|NCT03648814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797508|NCT02699385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797509|NCT02824822|||FAMILY_BASED||PROSPECTIVE|||||||
33802069|NCT03021369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941842|NCT02546739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941843|NCT01701531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941844|NCT00582842|||COHORT||PROSPECTIVE|||||||
33941845|NCT02608099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941846|NCT01537458|||COHORT||RETROSPECTIVE|||||||
33941847|NCT00764530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941848|NCT01455064|||COHORT||PROSPECTIVE|||||||
33941849|NCT00141297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34100965|NCT05311982|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34100966|NCT06691750|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized, controlled, double-blind, two-parallel clinical trial.|t|f|t|t
33797510|NCT04237155|NON_RANDOMIZED|PARALLEL||OTHER||NONE||For step 1, two populations of participants: 30 healthy volunteers and 30 patients with schizophrenia will have to complete a verbal material scoring questionnaire. For step 2, two populations of participants: 30 healthy volunteers and 30 patients with schizophrenia will have to complete the source-monitoring task which will be created from step 1 as well as the task of reference (Brunelin et al., 2008).||||
33797511|NCT02089217|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials.|CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials.|f|f|t|f
33797512|NCT00194714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797513|NCT05218044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797514|NCT05767294|||COHORT||RETROSPECTIVE|||||||
33797515|NCT04287478|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Patient will be randomized to receive either active phage or placebo treatment.|Initially, patients with neurogenic bladder and urinary tract infections will be enrolled and followed for bacterial eradication. Results from this cohort will be used to confirm or modify the phage dosing regimen before proceeding to the patients with symptomatic infection at risk of recurrence. The trial will use pre-specified criteria to determine what phage regimens should be evaluated.||||
33797516|NCT05599152|||CASE_CONTROL||RETROSPECTIVE|||||||
33797517|NCT00155415|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33797518|NCT01909167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797519|NCT03993704|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34020664|NCT03889366|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34020665|NCT02013479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020666|NCT06431165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each patient will be assigned by a randomly computer generated number to one of the 3 groups and the group assignment will be put in a sealed envelope only accessible by the investigator responsible for preparing the drug syringes. The patient and data collectors will be blinded to the patient group allocation as well as the managing anesthiologists during the operation|A prospective randomized controlled double blinded study|t|t|t|f
34020667|NCT04964518|NA|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation||||
34020668|NCT02953470|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34020669|NCT05201196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020670|NCT01455311|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020671|NCT03368456|RANDOMIZED|PARALLEL||PREVENTION||NONE||To test the preliminary efficacy of S4E, we will conduct a Stage I RCT and use a mixed between/within-subjects design with two levels of intervention (S4E and Usual Care) as the between-subjects factor and three repeated measures assessments (Baseline, 3-, and 6-months post-Baseline) as the within-subjects factor.||||
34020672|NCT03890146|||COHORT||PROSPECTIVE|||||||
33717003|NCT00864045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020673|NCT03044717|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020674|NCT01282723|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020675|NCT02496936|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34020676|NCT03321630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020677|NCT01267747|||COHORT||PROSPECTIVE|||||||
34020678|NCT05496335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020679|NCT05541653|RANDOMIZED|PARALLEL||OTHER||NONE|The investigators are not masked. Our recruitment team will be masked until cluster recruitment is complete. The outcomes assessor will be masked.|||||
34020680|NCT01170013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34020681|NCT05473962|||COHORT||PROSPECTIVE|||||||
34020682|NCT03900065|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial comparing no preconditioning to preconditioning.||||
33717004|NCT05922150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33717005|NCT01195506|||CASE_ONLY||RETROSPECTIVE|||||||
33717006|NCT02045368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717007|NCT05874856|||COHORT||CROSS_SECTIONAL|||||||
33717008|NCT06125015|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717009|NCT05991076|||COHORT||PROSPECTIVE|||||||
33717010|NCT03306680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717011|NCT00467259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717012|NCT02677142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717013|NCT01586390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717014|NCT04792164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blinded ( Patient and researcher recruiter)|"2 Arms~Arm1) The experimental group will receive US guided nerve block by Lidocaine+Marcaine concentration (1%+.25%).~Arm2) The control group will receive usual infiltration by Lidocaine+Marcaine concentration (1%+.25%)."|t|f|f|t
33717015|NCT03041545|||COHORT||PROSPECTIVE|||||||
33797520|NCT05727241|||COHORT||PROSPECTIVE|||||||
33797521|NCT05834842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are not aware that there is an experimental group and a control group, the participants are not related and do not know each other. The conditions of the study are only known by the researcher, the therapists, and the Research Ethics Committee of the Universidad de Guadalajara.|The study has two arms, one is the experimental group that receives the treatment and the other is the comparison group that will receive treatment after the 9 sessions of the experimental group finished. The patients in both groups will be evaluated pre and post/treatment. The participants are assigned randomly to the intervention or comparison group.|t|f|f|f
33797522|NCT00002919||||TREATMENT||||||||
33797523|NCT01426269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797524|NCT03238391|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33797525|NCT03706690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor, excluding supply chain management personnel and unblinded monitors of site pharmacies, will remain blinded.||t|t|t|t
33797526|NCT01190007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797527|NCT00547469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797528|NCT06476860|||CASE_ONLY||PROSPECTIVE|||||||
33797529|NCT05052450|||COHORT||RETROSPECTIVE|||||||
33797530|NCT01271517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797531|NCT01923012|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33797532|NCT03378141|RANDOMIZED|PARALLEL||PREVENTION||NONE||"* The impact evaluation follows a cluster randomized controlled trial design with repeated cross-sectional surveys at baseline and endline~* The nested cohort study follows a prospective randomized controlled design (embedded in overall impact evaluation)"||||
33797533|NCT01747486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797534|NCT06501911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797535|NCT00238797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797536|NCT06131892|||OTHER||RETROSPECTIVE|||||||
33797537|NCT00291824|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33797538|NCT05142878|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797539|NCT04239586|NA|SINGLE_GROUP||TREATMENT||NONE||Switching insulin-treated diabetes patients with possibly disease causing mutations in HNF1A, HNF4A, or HNF1B to treatment with sulfonylurea.||||
33802070|NCT02164240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802071|NCT05407558|||COHORT||PROSPECTIVE|||||||
33802072|NCT04556981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802073|NCT00774904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717016|NCT01390311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717017|NCT02625272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717018|NCT04671550|||CASE_ONLY||CROSS_SECTIONAL|||||||
33717019|NCT00734903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717020|NCT00372112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717021|NCT04827927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717022|NCT00722033|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717023|NCT00512993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717024|NCT02345382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717025|NCT01549093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717026|NCT02600377|||||PROSPECTIVE|||||||
33717027|NCT04941001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|An electronic randomisation programme will be used to assign the patient to each arm of the study in primary care. However during the review, masking will not be possible.||f|t|f|f
33717028|NCT04387175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717029|NCT01365234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717030|NCT04756843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717031|NCT03119194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717032|NCT05728450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"* The points for applying laser acupuncture will be cleaned before application. All patients in the study group will be submitted to an infrared diode laser, wavelength 808 nm, Pulse duration: 200 ms, Power density: 0.4 W/cm2, energy density 4 J/cm2 (Chow, 2001).~* The plug of the laser unit will be inserted into the main current supply and the on/off switch will be switched on. The therapy form will be selected from the main menu and then the parameters will be set.~* Acupuncture detector (Pointer Excel II) will be used for the actual location of acupuncture points."|t|f|t|f
33717033|NCT04756791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717034|NCT06379477|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33717035|NCT04421729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor will not have previous knowledge of the respondent's interventional group assignment.||f|f|f|t
33717036|NCT00555321|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717037|NCT03965910|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinician evaluating the patient and the radiologist evaluating the MRI were blinded to the groups.||f|f|t|f
33717038|NCT02140229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33717039|NCT05047510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717040|NCT00939250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717041|NCT03804879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717042|NCT06455371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717043|NCT01988792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717044|NCT01972503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797540|NCT04444258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The sample will consist of 105 midwifery students, including 35 control, 35 experiment I and 35 experiment II, as a result of the G-power analysis calculated by 0.95 power, among the midwifery students who took theoretical 4 hours in their curriculum within the scope of the week of week, including fetal development.|f|f|t|f
33797541|NCT03704727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797542|NCT05166863|||COHORT||PROSPECTIVE|||||||
33797543|NCT00532922|||COHORT||PROSPECTIVE|||||||
33797544|NCT05765370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and study investigators were aware of the study-group assignments, but outcome adjudicators were not. All potential cardiovascular events and safety events were adjudicated according to prespecified criteria by an independent clinical events committee whose members were unaware of the trial-group assignments.||f|f|f|t
33797545|NCT01626612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941850|NCT03070054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, anesthesiologists and PACU nurses will be blinded to group assignment, however the surgeon administering the LIA will be unblinded.||t|t|f|f
33941851|NCT02677506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33941852|NCT02855996|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941853|NCT04168775|NA|SINGLE_GROUP||OTHER||NONE||||||
33941854|NCT00864656|||COHORT||PROSPECTIVE|||||||
33941855|NCT01191190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941856|NCT02517606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941857|NCT00374452|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33941858|NCT02952027|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33941859|NCT05445869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941860|NCT05007236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941861|NCT01064518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941862|NCT02712892|||FAMILY_BASED||PROSPECTIVE|||||||
33941863|NCT05422950|||COHORT||CROSS_SECTIONAL|||||||
33941864|NCT05875909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941865|NCT05162534|||COHORT||RETROSPECTIVE|||||||
33941866|NCT02359500|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941867|NCT04594473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33941868|NCT05091840|||COHORT||PROSPECTIVE|||||||
33941869|NCT03499496|||CASE_ONLY||RETROSPECTIVE|||||||
33941870|NCT04071028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941871|NCT00101790|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33941872|NCT05408676|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33717045|NCT03695107|||OTHER||OTHER|||||||
33717046|NCT04929704|||COHORT||RETROSPECTIVE|||||||
33717047|NCT05256160|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a comparative study looking at differences in electrophysiologic measures of cortical excitability between those with Cyclic Vomiting Syndrome and healthy controls.||||
33717048|NCT04723745|||COHORT||PROSPECTIVE|||||||
33717049|NCT05403177|||COHORT||PROSPECTIVE|||||||
33717050|NCT01534871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33717051|NCT04758754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blind to intervention|Three arms: 1) active exercise training (single leg knee extension); 2) passive exercise training (passive static training); 3) controls (no training)|f|f|f|t
33717052|NCT03453944|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33717053|NCT01109654|||CASE_ONLY||PROSPECTIVE|||||||
33717054|NCT04022772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717055|NCT05431452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717056|NCT00396591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717057|NCT01349803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717058|NCT00714389|||COHORT||PROSPECTIVE|||||||
33717059|NCT05248191|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Placebo capsules are indistinguishable from study FMT capsules.|Single blinded randomized controlled trial|t|f|f|f
33717060|NCT05534386|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"The investigator, care provider, investigator and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to intervention or control arms.~The participants are masked in terms of not knowing that one intervention is hypothesized to yield larger effects than the other."|"First stage intervention: We will use a block randomization with randomly permuted block sizes of 2,4, and 6 to ensure close balance of the numbers in each arm. Participants will be randomised to the intervention group (i.e. Cancer survivorship care intervention) or control group (i.e. a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations).~Second stage intervention: We will use a block randomization with randomly permuted block sizes of 2,4, and 6 to ensure close balance of the numbers in each arm. Participants will be randomised to continue in the trial as usual (i.e. those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlets) or to attend a step-up targeted personalized intervention."|t|t|t|t
33717061|NCT03131050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||GROUP 1: The patients received intramuscular injection treatment of scopolamine (0.3 mg/ml) at 9 am and 0.9% saline treatment at 3pm. GROUP 2: The patients received intramuscular injection treatment of scopolamine (0.3 mg/ml) at 9 am and 3 PM. GROUP 3: The patients received intramuscular injection treatment of 0.9% saline (1 ml) at 9 am and 3 PM.|t|t|t|t
33717062|NCT01917474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717063|NCT05156489|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot open not comparative||||
33717064|NCT04080817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717065|NCT00874965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797546|NCT01268878|||COHORT||PROSPECTIVE|||||||
33797547|NCT03101410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind||t|f|f|f
34020683|NCT04594707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020684|NCT05986461|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020685|NCT05059483|||OTHER||CROSS_SECTIONAL|||||||
34020686|NCT06048432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Two groups of patients with post-stroke hemiplegia will be treated only with conventional physiotherapy or with physiotherapy plus telecare.|Two groups of patients with post-stroke hemiplegia will be treated only with conventional physiotherapy (CONTROL) or with physiotherapy plus telecare (INTERVENTION).|t|t|f|f
34020687|NCT00369317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020688|NCT03790150|||COHORT||PROSPECTIVE|||||||
34020689|NCT01789827|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020690|NCT03633734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020691|NCT01333891|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34020692|NCT05392335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34020693|NCT03237949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020694|NCT04127214|||COHORT||PROSPECTIVE|||||||
34020695|NCT03047798|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"The experiment was carried out in double-blind manner for the subjects and the examiner by providing the mouthrinses in opaque white bottles, labeled A, B and C."|Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.|t|t|t|t
34020696|NCT01674153|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020697|NCT00030043|NON_RANDOMIZED|||TREATMENT||NONE||||||
34020698|NCT04791878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020699|NCT03460535|||CASE_ONLY||PROSPECTIVE|||||||
34020700|NCT06276049|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020701|NCT04617054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020702|NCT00813566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020703|NCT01709838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020704|NCT04781101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020705|NCT01169428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020706|NCT00063219|NON_RANDOMIZED|||TREATMENT||NONE||||||
34020707|NCT05710939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants' personal information is hidden||t|f|f|f
34020708|NCT01524679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020709|NCT00015340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020710|NCT01898650|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||individual participants will serve as their own controls by using affected and unaffected regions of the brain for paired analysis||||
34020711|NCT03173638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797548|NCT04804046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34020712|NCT04846036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo controlled, double-blind|t|t|t|t
34020713|NCT03322930|||CASE_ONLY||PROSPECTIVE|||||||
34020714|NCT01372774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020715|NCT03547700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020716|NCT01806506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020717|NCT05988632|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34020718|NCT00927693|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020719|NCT03683368|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797549|NCT05685030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Phase II randomized, placebo-controlled, triple-blind clinical trial.|t|t|t|t
33797550|NCT01204346|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33797551|NCT04222686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The double-blind model is applied to the study. Only the adjudicator, responsible for the distribution of medication knew the different regimes. Perindopril and Losartan were packaged in boxes of identical appearance and labeled for each participant by name and number of the randomization program. The randomization and packaging of the drugs was done by an investigator who had no clinical involvement.|CARE-PLP trial is a double blind, randomized, controlled parallel clinical trial conducted in the National Obesity Center, Yaounde, Cameroon|t|f|t|f
33797552|NCT05796739|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33797553|NCT04010006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797554|NCT05968859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797555|NCT01528306|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797556|NCT00087880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797557|NCT04174027|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797558|NCT04122937|||COHORT||PROSPECTIVE|||||||
33797559|NCT02755181|||COHORT||PROSPECTIVE|||||||
33797560|NCT03403413|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33797561|NCT03264443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33797562|NCT03641703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797563|NCT06219642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797564|NCT02071836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797565|NCT01090544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797566|NCT03402633|||CASE_ONLY||CROSS_SECTIONAL|||||||
33797567|NCT00319306|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797568|NCT01755065|||COHORT||CROSS_SECTIONAL|||||||
33797569|NCT04369495|||CASE_ONLY||PROSPECTIVE|||||||
33797570|NCT00431704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100967|NCT06549049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind study. Participants will not know to which group they are assigned.|The study involves a randomized, controlled, single-blind trial to evaluate the effectiveness of TranS-C modified for Veterans with PTSD (TSC-PTSD) in male and female Veterans who are enrolled in primary and/or mental health care in the VA system. Study treatment will be implemented remotely via live video visits using a VA-approved platform. Enrolled participants will be randomly assigned to the TSC-PTSD group or to the sleep psychoeducation control (SPC) group.|t|f|f|f
34100968|NCT03381651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797571|NCT01670968|||COHORT||PROSPECTIVE|||||||
33797572|NCT04971447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797573|NCT01278394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797574|NCT01489982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797575|NCT00441636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797576|NCT03833661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797577|NCT04487431|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797578|NCT02147678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797579|NCT01667796|NA|SINGLE_GROUP||OTHER||NONE||||||
33797580|NCT02403024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797581|NCT02367924|||OTHER||PROSPECTIVE|||||||
33797582|NCT01644513|||CASE_CONTROL||PROSPECTIVE|||||||
33797583|NCT04206098|||OTHER||OTHER|||||||
33797584|NCT02197975|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797585|NCT06674083|||COHORT||CROSS_SECTIONAL|||||||
33797586|NCT00296361|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797587|NCT04305704|||COHORT||PROSPECTIVE|||||||
33797588|NCT01939171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797589|NCT06111040|NA|SINGLE_GROUP||OTHER||NONE||Family-based, prospective observational study with interventions at the measurement level||||
33797590|NCT02700191|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33797591|NCT01367483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797592|NCT00925210|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100969|NCT04032262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34100970|NCT06690892|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34100971|NCT02613507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797593|NCT05074654|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33797594|NCT05323266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical outcome assessors in this study were blinded, and blinding was not possible for participants, investigators and care providers.|Patients with acute ischemic stroke were admitted to the Intensive Care Unit of the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Patients were diagnosed with sleep apnea after polysomnography monitoring. They were divided into 3 groups according to the randomization principle, the usual care group (nasal cannula or mask), the nasal continuous positive airway pressure (nCPAP) group, and the high-flow nasal cannula (HFNC) group. In this study, nCPAP and HFNC were used as 2 different interventions in comparison to the usual care group.|f|f|f|t
33797595|NCT01760109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797596|NCT05684094|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33797597|NCT03437850|||COHORT||PROSPECTIVE|||||||
33797598|NCT02229019|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33797599|NCT02667743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797600|NCT02747381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797601|NCT06552260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797602|NCT01115959|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33797603|NCT01815008|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797604|NCT04792086|||COHORT||PROSPECTIVE|||||||
33797605|NCT01475123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797606|NCT02617069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34100972|NCT02398474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797607|NCT06198114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797608|NCT05693311|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797609|NCT00149279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797610|NCT04302805|RANDOMIZED|PARALLEL||PREVENTION||NONE||The present study is a prospective randomized single-centre open-label two-arm Phase III.b non-inferiority clinical trial. This trial aims to prove similar efficacy of PE/rATG and PE/rATG/IVIG (centre standard of care) induction regimens to prevent biopsy proven antibody-mediated changes and TCMR as composite endpoint within 12 months after HLA incompatible kidney transplantation.||||
33797611|NCT00505791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797612|NCT05157724|||COHORT||PROSPECTIVE|||||||
33797613|NCT06417346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797614|NCT00439569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797615|NCT00531830|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33797616|NCT05081570|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking is needed|||||
33797617|NCT01043458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797618|NCT02568644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33797619|NCT03098368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The active drugs and placebo were labeled from the company and the study nurse would give the drug to participants who were randomized.|"Active group is the group of PD patients who received rotigotine transdermal patch titration from 2 mg/day to maximum effect dose which participants had no side effect or reach 16 mg/day every week.~Placebo group is the group of PD patients who received the placebo patch titration every week the same protocol as the active group."|t|t|t|t
33797620|NCT00632424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797621|NCT01574807|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33797622|NCT04966416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33941873|NCT04395924|||COHORT||PROSPECTIVE|||||||
33941874|NCT01032057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941875|NCT00308659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941876|NCT02280382|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33941877|NCT01333865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941878|NCT04945239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941879|NCT05434728|||OTHER||CROSS_SECTIONAL|||||||
33941880|NCT04951557|||COHORT||RETROSPECTIVE|||||||
33941881|NCT03838692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941882|NCT00295152|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33941883|NCT03238209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941884|NCT05280223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941885|NCT02117024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941886|NCT05956223|NA|SINGLE_GROUP||OTHER||NONE||Single group assignment. Up to 90 participants with Essential Tremor and up to 30 Control participants will be recruited to the study. Both groups will undergo the same intervention.||||
33941887|NCT06188039|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941888|NCT01991431|||CASE_ONLY||PROSPECTIVE|||||||
33941889|NCT01420523|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941890|NCT04830293|||COHORT||PROSPECTIVE|||||||
33941891|NCT02862028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941892|NCT03213106|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||5 sessions of active and sham rTMS separated by at least 4 weeks washout.|t|t|t|t
33941893|NCT05968196|||COHORT||RETROSPECTIVE|||||||
33941894|NCT04459858|||COHORT||RETROSPECTIVE|||||||
33941895|NCT04656769|||COHORT||RETROSPECTIVE|||||||
33941896|NCT00103207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941897|NCT05465824|||OTHER||RETROSPECTIVE|||||||
33941898|NCT02650518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941899|NCT05238246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Behavioral: Behavioral guidance Other: Physiological state Other: Dental anxiety assessment|f|f|f|t
33941900|NCT05724641|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33941901|NCT03366935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33941902|NCT05810324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941903|NCT04711954|||COHORT||CROSS_SECTIONAL|||||||
33941904|NCT02146352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797623|NCT01997944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797624|NCT02490254|||OTHER||PROSPECTIVE|||||||
33797625|NCT00819325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797626|NCT01582646|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797627|NCT00002270||||TREATMENT||||||||
33797628|NCT05883475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797629|NCT05386953|||COHORT||RETROSPECTIVE|||||||
33797630|NCT00304135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797631|NCT04052113|||COHORT||CROSS_SECTIONAL|||||||
33797632|NCT00049790||||TREATMENT||||||||
33802074|NCT05591755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941905|NCT01388114|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941906|NCT03336307|||CASE_CONTROL||PROSPECTIVE|||||||
33941907|NCT03615586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33941908|NCT05608122|||COHORT||PROSPECTIVE|||||||
33941909|NCT03770078|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33941910|NCT01497899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941911|NCT01917565|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33941912|NCT04302363|||CASE_CONTROL||RETROSPECTIVE|||||||
33941913|NCT05789823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941914|NCT03310879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941915|NCT04153591|||OTHER||RETROSPECTIVE|||||||
33941916|NCT02115620|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33941917|NCT04306575|||CASE_ONLY||OTHER|||||||
33941918|NCT05202249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941919|NCT04759391|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly divided into two groups (control and exercise) for treatment.||||
33941920|NCT00668876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941921|NCT02641665|||COHORT||PROSPECTIVE|||||||
33797633|NCT04854395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Three unblinded anesthesiologists, including the sponsor, are responsible for performing the peripheral nerve block and will not be involved in any clinical assessments, data collection or interpretation of adverse events.~During the nerve block procedure, an opaque cloth hung over the stomach level, prevents the patient for monitoring block procedure and the ultrasound monitor. All patients experience three needle insertions in the skin (one for PPB, one for FTB incl. IFCN and one for ACB). The same time is used for each needle insertion, regardless of injection of active drug (active nerve block) or simulation of injection (sham block). Most patient are sensible to the needle insertion but are not able to feel the injection of local anesthetics. All this will ensure that the patient is blinded.~None of the blinded outcome assessors, including primary investigator, are present during the opening of the randomization or during the nerve block procedure."|"Patients assigned for total knee arthroplasty are randomized into one of the three study groups in accordance to a computer-generated block randomization list in a 1:1:1 ratio (each block containing 15 numbers). Prior to surgery the patients receive the peripheral nerve blocks allocated to the group/arm they belong to:~Group A: FTB (active) + ACB (sham) + PPB (active) Group B: FTB (active) + ACB (sham) + PPB (sham) Group C: FTB (sham) + ACB (active) + PPB (sham)"|t|t|t|t
33797634|NCT02502344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941922|NCT02723474|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797635|NCT02439827|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33941923|NCT01375491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941924|NCT00006025|NA|SINGLE_GROUP||TREATMENT||||||||
34020720|NCT04333238|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020721|NCT02559765|||COHORT||CROSS_SECTIONAL|||||||
34020722|NCT00440960|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34020723|NCT04620135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study adopted a single-masked study design. Treatment assignments were masked to the Investigator, the clinical study team (Sponsor, designated personnel involved in day-to-day study management, Monitors, Data Managers, and Statisticians), and the subjects for the duration of the study. The netarsudil and ripasudil bottles were different in the study, however, investigators and subjects were masked to study drug assignment.||t|f|t|f
33797636|NCT05678023|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Sealed envelope randomisation||t|f|f|f
33797637|NCT05017571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797638|NCT03389191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797639|NCT01263002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797640|NCT00943358|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33797641|NCT00368186|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33797642|NCT01264679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797643|NCT05000216|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Adults and Pediatrics~Stage 1: Participants in Cohorts A and B will be randomized into two immunosuppressive (IS) medication treatment plans as follows:~* Participants continue to take their cohort-defining IS medications without alterations in schedule and dosing~* Participants withhold their cohort-defining IS medications before and after additional homologous vaccine dose, per protocol instruction~* Cohort C: No randomization-Participants continue to take their IS medications without alterations in schedule and dosing.~  * Stage 2: Participants in Cohorts D and E will withhold their cohort-defining IS medications before and after additional alternative vaccine dose, per protocol instruction. Cohort F: No randomization-Participants withhold their IS medications before and after additional alternative vaccine dose, per protocol instruction"||||
33797644|NCT05463432|NA|SINGLE_GROUP||TREATMENT||NONE||HR19024 for all enrolled subjects||||
33797645|NCT04583306|||CASE_CONTROL||PROSPECTIVE|||||||
33797646|NCT04412018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941925|NCT04171752|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open-label, non-randomized, single-center, single-dose, two arms Phase 1 study in healthy elderly, aged of at least 75 years old (inclusive) and in healthy young adults, aged between 18 and 45 years old (all inclusive)||||
33941926|NCT01640704|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33941927|NCT01619436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33941928|NCT01567254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33941929|NCT05814107|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33941930|NCT05234762|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33941931|NCT01134640|||COHORT||PROSPECTIVE|||||||
33941932|NCT00384969|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941933|NCT02538705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941934|NCT03579004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941935|NCT04643769|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Placebo-controlled, double blind||t|t|t|f
33941936|NCT02073149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33941937|NCT00431132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941938|NCT02159911|||CASE_CONTROL||PROSPECTIVE|||||||
33941939|NCT02134340|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33941940|NCT00444639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941941|NCT06492421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020724|NCT02352779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34020725|NCT00943267|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34020726|NCT04236570|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will attended two experimental sessions at the Research Center on Aging of the Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie, Sherbrooke, during which the efficacy of their excitatory and inhibitory mechanisms was assessed. In one session, this assessment was done using TENS protocol; in the other, using a standardized protocol (thermode and cold water bath). Session order was randomized between participants (randomization by block of 4 stratified by sex, using a random number table). The two sessions were separated by 24 to 72 hours and lasted approximately one hour each.||||
34020727|NCT01593514|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34020728|NCT06334965|NA|SINGLE_GROUP||OTHER||NONE||||||
34020729|NCT06126068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prevention of Eclampsia in severe pre-eclampsia and further fits in Eclampsia.|t|f|f|t
34020730|NCT00042458|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34020731|NCT05665114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020732|NCT06349252|||COHORT||RETROSPECTIVE|||||||
34020733|NCT00110526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721056|NCT05428488|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This study will include a 12 weeks non-randomized phase. This phase will include RA patients ACPA+ with insufficient response to cs DMARDs and eligible for TNF inhibitors. All included patients will receive TNF inhibitors subcutaneous for 12 weeks.~At 12 weeks visit (W12), patients who have at least a moderate EULAR response (delta DAS28-CRP between and W0 and W12\>0.6 and DAS28-CRP≤5.1 at W12) will be randomized with a 1:1 ratio in the sequential strategy arm or the control arm. Then, the randomized phase will be 36 weeks long."||||
33797647|NCT02810080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721057|NCT01859754|||COHORT||PROSPECTIVE|||||||
33797648|NCT02947958|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33797649|NCT02994173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797650|NCT05425199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797651|NCT05407571|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33797652|NCT06335862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All participants, parents/caregivers, investigators and treating healthcare personnel, except for the surgical team performing the OA correction, will be blinded to which study arm the participant is assigned. None of the data gathered is affected by the unblinded surgical team since the primary and key secondary outcome measures are evaluated based on pseudonymised video footage. Furthermore, this video footage is assessed by otolaryngologists who are blinded to the patient and study arm. Moreover, the follow-up and documentation of the secondary endpoints are typically performed by the paediatrician and speech- and language therapists (not the paediatric surgeon or otolaryngologist).|Patients will be randomized 1:1 into either the intervention group (PPT-group) or the wait-and-see group (no-PPT). Since the sutures of the PPT remain in place (in the PPT-group), the participants are allocated to one arm for the duration of the study. After the PPT was or was not performed, the participants will follow the same follow-up schedule.|t|t|t|f
33797653|NCT00332917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797654|NCT01103999|||COHORT||PROSPECTIVE|||||||
33797655|NCT05956613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797656|NCT01860820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797657|NCT04329364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Allocation is provided through calling the study administrator at time of Examination under Anaesthesia. Thus, the participant is blinded to the procedure. There will also be no cross-over from one study arm to another.~An independent research administrator, not part of the randomisation process, will also contact the patient 3 months and 1 year after the procedure as mentioned above."|The investigators would be conducting a single-centre RCT simultaneously comparing the conventional open Milligan-Morgan haemorrhoidectomy (COH) and the laser haemorrhoidoplasty procedure (LAH) for the treatment of symptomatic grade ll-lV haemorrhoids.|t|f|f|t
33797658|NCT02407834|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33797659|NCT02725762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020734|NCT01307839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020735|NCT06053775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study, a double-blind design will be used, since the device used for the tDCS/tACS intervention allows for total blinding. The patient and the researchers involved in treatment will be blinded to the group of treatment (except for the OCT group). Evaluation and data analysis will be blinded to group assignment until the participant has completed the study. Only the members of the research team in charge of generating the randomization list will have access to the patient's intervention status.|Randomized, four-arm, placebo-controlled, parallel-structured, double-blinded clinical trial.|t|f|t|f
33721058|NCT02742987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721059|NCT03946384|||COHORT||RETROSPECTIVE|||||||
34020736|NCT03880916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020737|NCT03180463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020738|NCT03550573|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34020739|NCT03682458|||COHORT||PROSPECTIVE|||||||
34020740|NCT02686645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020741|NCT02861079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020742|NCT01327144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34020743|NCT02833701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020744|NCT05480644|||CASE_ONLY||PROSPECTIVE|||||||
34020745|NCT03544489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||home walking exercise|f|t|f|t
34020746|NCT01167257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020747|NCT04104048|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34020748|NCT02948153|||COHORT||CROSS_SECTIONAL|||||||
34020749|NCT02972918|||CASE_CONTROL||PROSPECTIVE|||||||
34020750|NCT04810130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020751|NCT02871271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020752|NCT06151496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34020753|NCT04492865|||COHORT||PROSPECTIVE|||||||
34020754|NCT05133791|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||non-randomized, non-blinded, prospective, mono-center safety/ feasibility dose optimization study||||
34020755|NCT02838810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020756|NCT02554136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020757|NCT03465826|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34020758|NCT06456983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a multi-center, observer-blind, randomized, and actively controlled parallel-group clinical trial to examine the effectiveness of mECT in clozapine resistant patients with schizophrenia (CRS) who improved after a full course of routine ECT.|f|f|f|t
34020759|NCT05560126|||COHORT||PROSPECTIVE|||||||
34020760|NCT06058286|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Because of the nature of the intervention, district health officials and healthcare providers will be aware of allocation. Fieldworkers collecting outcome data and women interviewed for the process evaluation will be masked as to allocation. The team analysing the outcome data and interpreting the results will be masked to the study arm until all primary outcome analyses outlined in the statistical analysis plan are completed.|||||
34020761|NCT02395952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33941942|NCT03334994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded participants: patient will be ensured by masking the instruments during the surgery. The patient will be informed of the steps of the surgery (as mentioned in the consent form) without getting into details. Blinding to the clinical, radiographic assessors is done by not involving them in sequence generation or allocation concealment or surgery performing.|"The patients was randomly classified into two groups:~Group A: Patient will be treated with immediate implant alone. Group B: Patients will be treated with connective tissue graft combined with immediate implant."|t|f|t|t
33941943|NCT04980300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941944|NCT05653115|||COHORT||RETROSPECTIVE|||||||
33941945|NCT04312737|||OTHER||CROSS_SECTIONAL|||||||
33941946|NCT05243199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941947|NCT03950505|NA|SINGLE_GROUP||TREATMENT||NONE|No masking is applied, as this is an open label study|This is a prospective, open-label, single-arm, single-center clinical Study. All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks.||||
33941948|NCT00331058|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33941949|NCT00427687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33941950|NCT00377273|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941951|NCT04748159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941952|NCT03810599|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-post comparison.||||
33941953|NCT04470960|NA|SINGLE_GROUP||PREVENTION||NONE||A framework is being evaluated in order to assess if a Community center has the capacity of serving as a healthy setting.||||
33941954|NCT00760994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33941955|NCT00060333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941956|NCT02461342|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33941957|NCT03956459|NA|SINGLE_GROUP||OTHER||NONE||||||
33941958|NCT00754312|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33941959|NCT05673057|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33941960|NCT06247462|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33941961|NCT01913275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941962|NCT01817218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941963|NCT04287673|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33941964|NCT02748018|RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be three cohorts sequentially enrolled for the study. Cohort 1: Continuous Subcutaneous Insulin Infusion (CSII cohort): randomized to HCL (treatment arm) or CSII (Control arm) Cohort 2: Multiple Daily Injections (MDI cohort): randomized to HCL (treatment arm) or MDI (Control arm) Cohort 3: Sensor-Augmented Pump therapy (SAP cohort): randomized to HCL (treatment arm) or SAP (Control arm) Note: Subjects 2-6 years of age will automatically enter the HCL arm at the end of the run-in period||||
33721060|NCT04390945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721061|NCT00378209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721062|NCT04443582|||CASE_ONLY||PROSPECTIVE|||||||
33721063|NCT00320099|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33721064|NCT01388803|||CASE_ONLY||RETROSPECTIVE|||||||
33721065|NCT06063577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded after the assignment.||t|f|f|f
33721066|NCT02181439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33721067|NCT04105933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721068|NCT04482842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33721069|NCT04218227|||CASE_CONTROL||RETROSPECTIVE|||||||
33797660|NCT03522454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor who will perform the 3 and 6 month visits will be blinded to the participant's assigned intervention.||f|f|f|t
33797661|NCT06127199|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797662|NCT02399943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797663|NCT02701036|||COHORT||PROSPECTIVE|||||||
33797664|NCT00107796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797665|NCT03695536|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797666|NCT03418805|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33797667|NCT05573542|||COHORT||PROSPECTIVE|||||||
33797668|NCT04042129|||CASE_ONLY||RETROSPECTIVE|||||||
33797669|NCT05615116|||COHORT||PROSPECTIVE|||||||
33941965|NCT00650689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797670|NCT06093243|||CASE_ONLY||CROSS_SECTIONAL|||||||
33797671|NCT01846936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797672|NCT02136407|||COHORT||CROSS_SECTIONAL|||||||
33941966|NCT06186674|||COHORT||PROSPECTIVE|||||||
33941967|NCT02584660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941968|NCT05157178|RANDOMIZED|PARALLEL||PREVENTION||NONE|Only the laboratory technician is blind|||||
33941969|NCT00556283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941970|NCT03163290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33941971|NCT04047342|||CASE_CONTROL||PROSPECTIVE|||||||
33941972|NCT00153699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33941973|NCT00917553|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33941974|NCT01567280|||COHORT||PROSPECTIVE|||||||
33941975|NCT05502276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941976|NCT06366035|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single Blinded, Pilot Randomized Control Trial|f|f|t|f
33941977|NCT04606810|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"Participants in group 1 received the usual care plus the multidisciplinary educational intervention at baseline.~Participants in group 2 first received usual care, and after 3 months were offered the intervention."||||
33941978|NCT01914042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33941979|NCT01230489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941980|NCT00499733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941981|NCT05916794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941982|NCT00986817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33941983|NCT01005875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941984|NCT05273203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33941985|NCT03797391|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation followed by Protocol at 100mg, 200mg, 350mg, 500mg, 700mg, 900mg, 1200mg, 1600mg, 2100mg, 2700mg and 3000mg .||||
33797673|NCT06092697|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A superiority frame randomized, controlled, parallel clinical trial with 1:1 allocation ratio.|t|t|t|t
33797674|NCT00534183|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33797675|NCT05543057|||COHORT||PROSPECTIVE|||||||
33797676|NCT00137371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797677|NCT06553365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797678|NCT03212079|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a single center three arms randomized trial.|f|f|f|t
33797679|NCT02474238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797680|NCT04193410|||COHORT||PROSPECTIVE|||||||
33797681|NCT01013246|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33797682|NCT01514344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797683|NCT05493254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33797684|NCT04187664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi-experimental study, nonrandomized, pre-post intervention study||||
33797685|NCT05688644|||COHORT||RETROSPECTIVE|||||||
33797686|NCT06013072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33797687|NCT03926442|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33797688|NCT03009305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797689|NCT05619861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941986|NCT04787146|||COHORT||PROSPECTIVE|||||||
33941987|NCT05870891|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33941988|NCT01866839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941989|NCT03497975|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Matching Placebo|Randomized, double-blinded, placebo-controlled, 2-arm study with an open label extension period following double-blind treatment.|t|t|t|t
33941990|NCT01294761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941991|NCT05464849|||COHORT||CROSS_SECTIONAL|||||||
33941992|NCT00211692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941993|NCT00139373|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33941994|NCT04166136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The permanence of the new foot strike pattern will be investigated as mediator of the pain and disability outcomes in the presence of the forefoot / midfoot pattern. It will be assessed by a blind assessor through observation of the participants' running footage using their usual sneakers three months after randomization||f|f|f|t
33941995|NCT03377985|RANDOMIZED|PARALLEL||OTHER||||||||
33941996|NCT01299636|NA|SINGLE_GROUP||||NONE||||||
33941997|NCT00005089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33941998|NCT03178591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33941999|NCT01880320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942000|NCT04963660|||COHORT||CROSS_SECTIONAL|||||||
33942001|NCT02700932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942002|NCT01831570|NA|SINGLE_GROUP||OTHER||NONE||||||
33942003|NCT03962127|||COHORT||PROSPECTIVE|||||||
33942004|NCT01183299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33942005|NCT00001151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020762|NCT02767830|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34020763|NCT00006216||||TREATMENT||||||||
34020764|NCT01501864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020765|NCT02700126|||COHORT||PROSPECTIVE|||||||
34020766|NCT05948514|||COHORT||PROSPECTIVE|||||||
34020767|NCT04430257|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Individuals collecting the primary outcome data will be blinded to intervention condition.||f|f|f|t
34020768|NCT02212288|||CASE_CONTROL||PROSPECTIVE|||||||
34020769|NCT02950818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020770|NCT01026155|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34020771|NCT04758975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797690|NCT02278627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33797691|NCT06426823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Single blind, placebo controlled, randomized, crossover study|t|f|f|f
33797692|NCT00915239|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||||||
33797693|NCT03194958|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33797694|NCT01231568|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33797695|NCT03830658|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.||||
33797696|NCT02600520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797697|NCT02009813|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797698|NCT02487927|||COHORT||PROSPECTIVE|||||||
33797699|NCT05623553|NA|SINGLE_GROUP||SCREENING||NONE||||||
33797700|NCT00906529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797701|NCT00420901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797702|NCT02634541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797703|NCT04947072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797704|NCT04734132|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|One member of the research team was in charge of product preparation and delivery to the participants following the randomization list.|Double blind, randomized, parallel group, placebo-controlled dietary intervention in prediabetic subjects.|t|t|t|t
33797705|NCT02058017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797706|NCT02875938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797707|NCT01316263|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797708|NCT04707729|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The ROX-1 trial is an international, multicenter, parallel, open-label randomized controlled two-arm trial that will be performed in patients with AHRF, supported by nasal high flow, who are admitted to the intensive care unit (ICU).~Patients will be randomized after stratification according to PaO2/FiO2, through an online automatic centralized and computerized system to one of the study groups (1:1 ratio): traditional intubation criteria or traditional intubation criteria + ROX criteria."||||
33797709|NCT03419442|||COHORT||RETROSPECTIVE|||||||
33797710|NCT03812575|||COHORT||PROSPECTIVE|||||||
33797711|NCT02576613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797712|NCT01110759|||CASE_CONTROL||RETROSPECTIVE|||||||
33797713|NCT04128358|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a randomized clinical trial aimed to assess the effect of strong immunosuppression in patients with ITP on Triple therapy on acquiring viral hepatitis infection C or B.||||
33797714|NCT05231408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Triple-blind study; the patients will not be informed about their groups (training group or the control group) and they will be evaluated and trained at different places and times.~Evaluations and interventions will be performed different physiotherapist. In addition, before statistical analysis patients' groups will be coded."||t|f|t|t
33797715|NCT03385681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two parallell groups- intervention and control||||
33797716|NCT00404417|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33797717|NCT04129619|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33797718|NCT03996278|||OTHER||OTHER|||||||
33797719|NCT04470401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients will receive placebo or botulinum toxin in the same characteristics. Just a assessor of the study will know the groups|Two arms, a placebo group versus a abobotulinumtoxina (400 IU), to be applied in both muscles (200 IU each) subscapularis and pectoral major|t|f|t|f
33797720|NCT06382649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33797721|NCT01699152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797722|NCT00000265|||COHORT||PROSPECTIVE|||||||
34020772|NCT01673243|||COHORT||PROSPECTIVE|||||||
34020773|NCT02507544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020774|NCT05533827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34020775|NCT02067273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020776|NCT00188110|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020777|NCT00805753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721070|NCT00463346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721071|NCT05248841|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33721072|NCT02951156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721073|NCT04745598|||COHORT||PROSPECTIVE|||||||
33721074|NCT03016247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721075|NCT00378274|||||PROSPECTIVE|||||||
33721076|NCT02299986|||COHORT||PROSPECTIVE|||||||
33721077|NCT04385823|||COHORT||RETROSPECTIVE|||||||
33721078|NCT06422260|||COHORT||PROSPECTIVE|||||||
33721079|NCT00660530|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721080|NCT03319446|||COHORT||PROSPECTIVE|||||||
33721081|NCT00368654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721082|NCT02060604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721083|NCT05264077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33721084|NCT00480597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721085|NCT01693406|||COHORT||PROSPECTIVE|||||||
33721086|NCT04368819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo pills will be manufactured to be indistinguishable from the active treatment and dispensed by a registered pharmacist (who also will be blind to the intervention assigned to each individual participant) from our center.|Patients will randomly be assigned to receive either placebo or allopurinol 300mg once daily for four weeks, up titrate to 600mg for another 12 weeks for a total of 16 weeks of treatment.|t|t|t|t
33721087|NCT03597854|||COHORT||PROSPECTIVE|||||||
33721088|NCT04208399|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721089|NCT02053467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33721090|NCT04018833|||COHORT||PROSPECTIVE|||||||
33721091|NCT02888522|||COHORT||PROSPECTIVE|||||||
34100973|NCT05664646|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The visits during Study 1 (4\&5) and Study 2 (6\&7), the participants will be blinded to the order of completing the study with and without stimulation.|All participants will complete an orthostatic tilt without stimulation, then go through transcutaneous stimulation mapping sessions to determine the optimal parameters. During the study 1 visits, the participants will complete an arm ergometry exercise with the optimal stimulation parameters and without (sham). During study 2 visits, the participants' body core temperature will be measured about being exposed to a cool environment with stimulation and without (sham).|t|f|f|f
34100974|NCT06300307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34100975|NCT04883645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100976|NCT01496859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100977|NCT04128228|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Following baseline assessments including multimodal neuroimaging, AUD individuals with and without a history of early trauma received an equivalent 8-week outpatient treatment. Control participants with and without early trauma did not receive any treatment after baseline assessments.||||
34100978|NCT00705965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34100979|NCT01656447|||COHORT||PROSPECTIVE|||||||
34100980|NCT04149457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100981|NCT01000766|||COHORT||PROSPECTIVE|||||||
34100982|NCT06688838|||COHORT||RETROSPECTIVE|||||||
34100983|NCT06694090|||OTHER||CROSS_SECTIONAL|||||||
34100984|NCT01386385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100985|NCT06687057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34100986|NCT04111549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blinded to which condition (in-person or home-based telehealth) a participant completed.|After a 5-week delay repeat baseline, participants will be randomized to receive either in-person GOALS or GOALS delivered via home-based video telehealth.|f|f|f|t
34100987|NCT05527314|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Care provider and investigator (anesthesiologist) cannot be blinded for different appearance of sevoflurane and remimazolam.|This is a RCTs.|t|f|f|t
34100988|NCT03706833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34100989|NCT01595178|NA|SINGLE_GROUP||SCREENING||NONE||||||
34100990|NCT06463899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34100991|NCT04558138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After consent, patients will be randomized into one of two groups, either discharged day of surgery, or discharged day after surgery||||
34100992|NCT04128215|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34100993|NCT03210662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34100994|NCT03240055|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34100995|NCT06398418|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34100996|NCT05214027|||OTHER||OTHER|||||||
34100997|NCT05233917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34100998|NCT00825448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34100999|NCT06101329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101000|NCT04944017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797723|NCT00686504|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797724|NCT06020963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluate the treatment effect of Low-intensity shockwave therapy on acupoint (CV-4, ST-28, SP-6 once a week for 8 weeks) and the control group is oral tamsulosin 0.2mg daily for 8 weeks.||||
33797725|NCT04280497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797726|NCT03648346|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33797727|NCT06490991|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797728|NCT03093298|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797729|NCT03939195|||COHORT||PROSPECTIVE|||||||
33797730|NCT05328011|||CASE_CONTROL||PROSPECTIVE|||||||
33797731|NCT03315884|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33797732|NCT04134078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797733|NCT01124734|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, open label study||||
33797734|NCT06060652|||COHORT||OTHER|||||||
33797735|NCT00115713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797736|NCT03226899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|active vs placebo visually identical tablets|Randomized, Double-Blind, Multicenter, Placebo-Controlled|t|t|t|f
33797737|NCT05102409|NON_RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797738|NCT00506298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797739|NCT05088629|NA|SINGLE_GROUP||OTHER||NONE||||||
33797740|NCT02986412|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101001|NCT04900376|||COHORT||PROSPECTIVE|||||||
34101002|NCT03287349|||CASE_ONLY||PROSPECTIVE|||||||
34101003|NCT05988892|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34101004|NCT04869410|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigator||f|f|t|f
34101005|NCT04245865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101006|NCT01203579|||COHORT||PROSPECTIVE|||||||
33797741|NCT02284555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797742|NCT06196099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34101007|NCT01546779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101008|NCT02620865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101009|NCT04848571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101010|NCT04460157|||COHORT||PROSPECTIVE|||||||
34101011|NCT05890001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101012|NCT06250257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized placebo-controlled trial||||
33797743|NCT04605016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797744|NCT02902471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33797745|NCT06169735|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is already a pre-approved drug by FDA.||||
33797746|NCT03043768|||COHORT||PROSPECTIVE|||||||
33797747|NCT01906788|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33797748|NCT02622672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33797749|NCT06367816|||COHORT||PROSPECTIVE|||||||
33797750|NCT05179902|||COHORT||PROSPECTIVE|||||||
33797751|NCT02529995|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33797752|NCT00004423|RANDOMIZED|||TREATMENT||||||||
33797753|NCT02704936|||COHORT||PROSPECTIVE|||||||
33797754|NCT03289962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33797755|NCT03375151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797756|NCT00665444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797757|NCT02575352|||OTHER||PROSPECTIVE|||||||
33797758|NCT03734692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797759|NCT05663151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797760|NCT06325111|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33797761|NCT02925351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||pilot||||
33797762|NCT00559286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797763|NCT00874471|||CASE_CONTROL||PROSPECTIVE|||||||
33797764|NCT03230786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797765|NCT04434586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942006|NCT06292026|NA|SINGLE_GROUP||TREATMENT||NONE||The objective of this data collection is to look at outcomes and time points for ProgenaMatrix™ in the treatment of diabetic foot ulcers. Additionally, use the collected data to develop predictive wound closure models. There is a 1-week lead in period after initial debridement. If the wound is rapidly moving to closure after initial debridement and standard moist dressings, the withdrawal of these patients will prevent corruption of the true closure rate of ProgenaMatrix™. The objective of the treatment with ProgenaMatrix™ is to evaluate the closure rate in patients not responding to traditional moist therapy.||||
33942007|NCT00623350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942008|NCT02695615|||CASE_CONTROL||PROSPECTIVE|||||||
33942009|NCT02122965|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33942010|NCT02536209|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33942011|NCT04252872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942012|NCT00386152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942013|NCT00287976||||TREATMENT||NONE||||||
33942014|NCT02728804|||COHORT||PROSPECTIVE|||||||
33942015|NCT04854603|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Treatments will be blinded. The Investigator will be blinded.||t|f|t|f
33942016|NCT05798299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942017|NCT03988465|||COHORT||PROSPECTIVE|||||||
33942018|NCT01048827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942019|NCT00694239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33942020|NCT01097057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942021|NCT05133102|||COHORT||PROSPECTIVE|||||||
33942022|NCT03472339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A computer generated block randomization sequence will be generated and stored with sequential coding known to the clinical pharmacist only. Within the randomization another stratified randomized sequence will be generated, for the patients to be enrolled for the PK study. Among the 300 trial packets prepared for the study, 20 packets will contain one additional code that will indicate the subject to be enrolled in the PK study.|Double blind randomized trial|t|f|f|t
33942023|NCT04514705|NA|SINGLE_GROUP||TREATMENT||NONE||Exercise||||
33942024|NCT03693391|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33942025|NCT06444724|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33942026|NCT06323629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942027|NCT02180854|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33942028|NCT01130831|||CASE_ONLY||PROSPECTIVE|||||||
33942029|NCT00004569||||DIAGNOSTIC||||||||
33942030|NCT01825811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942031|NCT05878340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel intervention study design.||||
33942032|NCT00830479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942033|NCT02139709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942034|NCT00636233|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33942035|NCT04658992|||COHORT||PROSPECTIVE|||||||
33942036|NCT02229513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942037|NCT05582382|||OTHER||RETROSPECTIVE|||||||
33942038|NCT01212627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942039|NCT03036891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The investigators have included a unique aspect of this study to better balance the benefits for patients participating in this randomized double-blind study in which half the patients receive a placebo agent. All patients in the treatment group and the placebo group will be invited to participate in the 4-week open-label extension for this study|t|t|t|t
33942040|NCT02033824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942041|NCT00004024||||TREATMENT||NONE||||||
33942042|NCT01568957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942043|NCT04582695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020778|NCT04532801|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||physiologic studies|t|t|t|t
34020779|NCT05322551|||COHORT||PROSPECTIVE|||||||
34020780|NCT01888666|||COHORT||PROSPECTIVE|||||||
34020781|NCT03785366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects are blinded until the Day 57 Visit||t|f|f|f
34020782|NCT05509816|NA|CROSSOVER||BASIC_SCIENCE||NONE||||||
33797766|NCT02105025|||||PROSPECTIVE|||||||
33797767|NCT01462981|||COHORT||RETROSPECTIVE|||||||
33797768|NCT03924882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797769|NCT00465816|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797770|NCT06677359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Unicenter Randomized Clinical Trial|t|f|t|f
33797771|NCT03452189|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||randomized double-blinded placebo-controlled crossover study|t|t|f|f
33797772|NCT04036877|||COHORT||PROSPECTIVE|||||||
33797773|NCT00595790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33797774|NCT03209921|||COHORT||RETROSPECTIVE|||||||
33797775|NCT03486171|||COHORT||PROSPECTIVE|||||||
33797776|NCT00247208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797777|NCT00648349|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33797778|NCT01326039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797779|NCT02633267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797780|NCT06139315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797781|NCT01985542|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33797782|NCT05356689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797783|NCT05747495|NA|SINGLE_GROUP||OTHER||NONE||||||
33797784|NCT05957406|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE|HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff|HemoSphere Advanced Monitor with Acumen Hypotension Prediction Index (HPI) software feature, and Acumen IQ sensor||||
33797785|NCT01305252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797786|NCT00539292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797787|NCT00314860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797788|NCT02847702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797789|NCT01170962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797790|NCT01875250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797791|NCT04712851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797792|NCT05990777|||OTHER||PROSPECTIVE|||||||
33797793|NCT03381820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised control trial|f|f|f|t
33797794|NCT06285786|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will be masked of the proper technique/training during the pre-intervention session (with and without the use of technology). Specifically, on how to manually move the patient in both beds.|"One single group of participants will be performing the same patient handling tasks:~1. During session 1 (Pre-Intervention) participants will not receive any instruction on how to perform the patient handling techniques on both beds.~2. During session 2 (Post-Intervention) participants will be asked to perform the patient handling techniques as seen during the intervention on both beds."||||
33942044|NCT04282343|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Trained research assistants and oncologists|Patients are randomized to 1 of 2 arms: ARM I: Patients receive usual care consisting of general cancer treatment information on a sheet of paper before attending video-recorded meetings with their oncologist to discuss treatment plan; or ARM II: Patients use the DISCO education and communication app before attending video-recorded meetings with their oncologist to discuss treatment plans. After completion of study, patients are followed up at 3 months.|f|t|f|t
33942045|NCT02245295|||CASE_CONTROL||RETROSPECTIVE|||||||
33942046|NCT06322511|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Families include both parents and children. Parents fill the questionnaires, but all family members attend on the meetings during the intervention (six meetings).|"Families attending the study Group I: receives Dialogical Family Guidance intervention and they fill questionnaires before and after the intervention.~Group II: Families do not receive Dialogical Family Guidance (but belong to the same focus group)"|t|t|f|f
33942047|NCT02483715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942048|NCT02966912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942049|NCT01344213|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33942050|NCT01896596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33942051|NCT01999205|NA|SINGLE_GROUP||||NONE||||||
33942052|NCT04730739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942053|NCT03845842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33942054|NCT02134912|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942055|NCT02350660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942056|NCT00372905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942057|NCT00312390|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33942058|NCT05230693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942059|NCT05916534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942060|NCT00041119|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33942061|NCT03814642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942062|NCT05013476|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and staff will be aware of each of the study conditions.|Participants will be divided into 2 groups which will experience different experimental conditions.||||
33942063|NCT05079724|||COHORT||PROSPECTIVE|||||||
33942064|NCT01513824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33942065|NCT04930627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942066|NCT03520842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942067|NCT03949894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942068|NCT00815373|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33942069|NCT01393561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942070|NCT01012700|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33942071|NCT03240003|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33942072|NCT05284383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|"One of the groups is an open-label group, meaning there is no masking. For the other two groups, participants are not aware of group allocation, but as verbal suggestions are given regarding the device, they are not fully masked (despite being unaware of the procedures that are used).~Investigators are masked until the end of calibration, to prevent the influence of the investigator on the calibration process as much as possible. Afterwards, blinding of the investigator is not possible due to the nature of the study."|||||
33942073|NCT03363126|||CASE_ONLY||RETROSPECTIVE|||||||
33942074|NCT00952133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33942075|NCT01388205|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942076|NCT02816255|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Subjects will complete two week baseline with nasal mask then will complete two week treatment with full face either with new algorithm or old algorithm.|t|f|f|f
33942077|NCT00962780|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33942078|NCT03026764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33942079|NCT02795871|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942080|NCT02935010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942081|NCT04413825|||COHORT||PROSPECTIVE|||||||
33942082|NCT04384952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind||f|f|f|t
33942083|NCT00872586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942084|NCT02020811|NA|SINGLE_GROUP||||NONE||||||
33942085|NCT02251782|||CASE_CONTROL||PROSPECTIVE|||||||
33942086|NCT01567046|||COHORT||RETROSPECTIVE|||||||
34101013|NCT01724307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101014|NCT04294160|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101015|NCT03539198|||CASE_ONLY||PROSPECTIVE|||||||
34101016|NCT05509192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34101017|NCT01565694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101018|NCT06096038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101019|NCT02858661|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101020|NCT03388788|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34101021|NCT01286272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101022|NCT01681303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101023|NCT06012773|||OTHER||PROSPECTIVE|||||||
34101024|NCT01625078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101025|NCT03907631|||COHORT||PROSPECTIVE|||||||
34101026|NCT06695104|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized into one of two study arms: intervention or control. All participants, regardless of study arm, will be enrolled in a year-long Produce Rx Program through which they will receive weekly deliveries of grocery bags containing fresh produce. Additionally, participants assigned to the intervention arm will be enrolled in a Diabetes Prevention Program, coordinated by the Y, through which they will receive health education, coaching, and peer support for a year via 26 virtual group sessions.||||
34101027|NCT06691919|RANDOMIZED|PARALLEL||TREATMENT||NONE|Biostatistician will be blinded to the study groups while performing final study analysis.|"Endoscopy arm will receive direct endoscopic necrosectomy and Surgery arm will undergo transgastric surgical necrosectomy."||||
34101028|NCT06565546|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33717066|NCT05982392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Clinician and participants both will be blind to the medicine given to the participants. Participants will be allowed to pick envelopes and a paramedical staff will be trained in giving medication to the participants. Procedure will be performed by an intern (who is not part of the research)Investigator will also be masked to the treatment being provided Outcome Assessor will be an intern who is not on research.|The participants will be randomly divided into 3 groups by envelope method. Group A will receive premedication of Oral tramadol 100mg, Group B will receive premedication of oral naproxen sodium 550mg. Both medicines will be given 60 minutes prior to the local anesthesia administration. The third group, Group C, will be the control group and no active preoperative medication will be given to these participants. A placebo will be given to these participants. These medications will be given as a single intervention only.|t|t|t|t
33717067|NCT03740958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717068|NCT05625672|RANDOMIZED|PARALLEL||OTHER||NONE|None (Open Label)|Randomized, parallel-group, placebo-controlled study||||
33717069|NCT02385045|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33717070|NCT01000441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717071|NCT03251066|NA|SINGLE_GROUP||TREATMENT||NONE||"Every participant of the study will specify at the beginning of the investigation his subjective starting situation concerning the nasal discomfort.The participant records his/ her personal impression on the change of severity of the general symptoms or selected individual symptoms of unspecific nasal discomfort following the single administration of Proponent Nasal Spray. Every Patient serves as his own control."||||
33717072|NCT03010163|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33717073|NCT00788151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The observer-blind design was implemented. The person who performed vaccinations knew which product was administered while neither the participant nor the Investigator in charge of safety evaluation knew which product was injected. To maintain the blind and minimize any potential bias, the control group used the same route and schedule as the study vaccine.||t|t|t|t
33717074|NCT03649464|NA|SEQUENTIAL||TREATMENT||NONE||"Dose escalation cohort: 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort: MTD defined in the dose escalation study."||||
33717075|NCT01819402|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717076|NCT06166498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Fully placebo controlled|Children assigned to group 1-SP will receive a 7-day course of placebo artesunate, whereas children in the group 2-AS will be given a 7-day course of active artesunate. This will span Day -7, -6, -5, -4, -3, -2, and -1. Then, on Day 0, children who had been given placebo artesunate will receive SP, whereas children in the AS group will receive placebo SP.|t|t|t|t
33717077|NCT01791829|||COHORT||PROSPECTIVE|||||||
33717078|NCT05570565|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33717079|NCT04534023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717080|NCT04492839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will be masked to the name of the product, but will be informed it is an intestinal adsorbent, class IIa medical device, available to buy over the counter.|||||
33717081|NCT05773287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717082|NCT00758212|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717083|NCT04447261|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33717084|NCT05808491|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|control group and experimental group|control group and experimental group|t|f|f|f
33942087|NCT02590627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942088|NCT00455780|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33942089|NCT05638529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101029|NCT00926900|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34101030|NCT05284513|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Stepped-wedge design||||
34101031|NCT01749293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717085|NCT00403663|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717086|NCT06037434|||COHORT||PROSPECTIVE|||||||
33717087|NCT02604108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717088|NCT03221400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717089|NCT05543876|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33717090|NCT05590754|||CASE_CONTROL||PROSPECTIVE|||||||
33717091|NCT01384968|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33717092|NCT03927131|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33717093|NCT01905657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717094|NCT04726423|||OTHER||PROSPECTIVE|||||||
33717095|NCT01810354|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33717096|NCT00764153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942090|NCT03602911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Proof of Concept||||
33942091|NCT02812550|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33942092|NCT00214942|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33942093|NCT03452059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942094|NCT02683330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942095|NCT04306627|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Endpoints of study The primary endpoints in the study is the change in mean IMT of the CCA from baseline to 6 months in two groups and antihypertensive treatment efficacy in both groups .~The secondary endpoints are assessment of level of total and LDL cholesterol concentrations in blood plasma after 6 months of treatment in both groups and correlation between carotid IMT and values of total cholesterol and LDL levels in blood plasma."||||
33942096|NCT01380925|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33942097|NCT05761158|||CASE_ONLY||PROSPECTIVE|||||||
33942098|NCT03710343|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is designed as a 48 week limited institution two-site single case ABA study feasibility trial.||||
33942099|NCT00743626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942100|NCT01844310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942101|NCT04899752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be award of group assignments as all participants are provided a face-to-face interaction with the provider.|Participants are randomly assigned to one of three groups.|t|f|f|f
33942102|NCT04524130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942103|NCT00114894|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33942104|NCT01244971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942105|NCT03136029|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33942106|NCT01756209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33797795|NCT03865758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will use a quasi-experimental design, comparing patients from two similar rehabilitation units operated by the same organization who have similar patient populations.||||
33797796|NCT03968354|||COHORT||PROSPECTIVE|||||||
33797797|NCT00779636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797798|NCT00455494|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797799|NCT03446859|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects were randomly allocated to two groups, experimental and control||||
33797800|NCT03094013|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33797801|NCT03631550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797802|NCT06216470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797803|NCT05561452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797804|NCT02018003|||COHORT||PROSPECTIVE|||||||
33797805|NCT05684354|||COHORT||PROSPECTIVE|||||||
33797806|NCT00893425|NA|SINGLE_GROUP||TREATMENT||SINGLE||||||
33797807|NCT00000924||||TREATMENT||||||||
33797808|NCT00236340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797809|NCT01601041|||COHORT||PROSPECTIVE|||||||
33797810|NCT03507816|||COHORT||RETROSPECTIVE|||||||
33797811|NCT01865253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797812|NCT00738699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797813|NCT02728349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797814|NCT03720236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797815|NCT05936333|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33797816|NCT02550691|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33797817|NCT01219205|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797818|NCT02847780|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33797819|NCT00468702|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33797820|NCT04113707|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pre and post two group intervention||||
33797821|NCT04048993|||COHORT||PROSPECTIVE|||||||
33797822|NCT01524952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797823|NCT01736891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797824|NCT02363192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33797825|NCT05076799|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33797826|NCT01456715|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34020783|NCT01162746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020784|NCT00667030|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34020785|NCT06084650|||COHORT||PROSPECTIVE|||||||
34020786|NCT05736627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The randomisation result will be opened for course participants and investigator when sending out the welcome letter about 3 weeks prior to running the course.||f|f|f|t
34020787|NCT05837572|NA|SINGLE_GROUP||OTHER||NONE||Participants are involved in two identical trials where they complete the ES-LFPQ under fasted and fed states (immediately after a standardised meal), at least one week apart.||||
34020788|NCT03046407|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
34020789|NCT00918840|||COHORT||PROSPECTIVE|||||||
34020790|NCT04075162|||COHORT||OTHER|||||||
34020791|NCT04832516|RANDOMIZED|PARALLEL||OTHER||NONE||After first session evaluation, employees will be randomly assigned to one of the 2 followings groups: (1) group with traditional exercise (CLA) and group with adapted and personalized exercises (IND). The CLA group will perform exercises following World Health Organization (WHO) prescription while the IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.||||
34020792|NCT03378050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized, controlled trial (RCT) will be used to compare a 12-week intervention group with a waiting-list control group.|f|f|f|t
34020793|NCT04008654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34020794|NCT00906386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34020795|NCT01545661|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34020796|NCT01038440|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34020797|NCT04602910|NA|SINGLE_GROUP||OTHER||NONE||||||
34020798|NCT03858543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020799|NCT04581174|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking is being used in this study|The study subjects will be enrolled to a total of four study arms, depending on the degree of inferior turbinates hypertrophy (according to Camacho)||||
34020800|NCT01118897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020801|NCT02642575|||COHORT||PROSPECTIVE|||||||
34101032|NCT06690606|||COHORT||PROSPECTIVE|||||||
34101033|NCT03907566|||COHORT||PROSPECTIVE|||||||
33797827|NCT04974450|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking in terms of taste and appearance is applied to yield a similar product. Researchers prepare artificial honey formula with citrus flavor to mimic the natural taste of trigona honey. Neither the care provider nor the investigator aware of the allocation.|Two different groups will be given two different honey. In the intervention group, trigona honey will be administered for 8 weeks whereas the control group will be given artificial honey that has a similar taste and appearance to the intervention group|t|t|t|t
33797828|NCT03002805|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797829|NCT02273544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797830|NCT01457612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797831|NCT00731523|NA|SINGLE_GROUP||OTHER||NONE||||||
33797832|NCT00160914|||||PROSPECTIVE|||||||
33797833|NCT00838253|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34020802|NCT04993014|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Patients will be divided into 2 cohorts, based on HER2 positivity in CTCs at baseline of neoadjuvant therapy.~Cohort 1: HER2 positive CTCs: randomization to adjuvant trastuzumab versus trastuzumab + pertuzumab in patients with pathological complete response Cohort 2: HER2 negative/absent CTCs: randomization to adjuvant trastuzumab versus trastuzumab + pertuzumab in patients with pathological complete response"||||
34020803|NCT03401125|||COHORT||RETROSPECTIVE|||||||
33717097|NCT05482763|||COHORT||PROSPECTIVE|||||||
33717098|NCT01059825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717099|NCT02988531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942107|NCT00784836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942108|NCT06077682|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33942109|NCT03763942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This trial will include 657 participants with 2:1 allocation for the intervention (438) and control (219) conditions. Recruitment strategies will be formulated to increase enrollment of MSM who identify as members of racial/ethnic minority groups.||||
33942110|NCT05811143|||CASE_ONLY||PROSPECTIVE|||||||
33942111|NCT00918905|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942112|NCT06425185|||OTHER||CROSS_SECTIONAL|||||||
33942113|NCT05901142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942114|NCT05142124|||CASE_ONLY||PROSPECTIVE|||||||
33942115|NCT00003874||||TREATMENT||||||||
33942116|NCT03607435|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942117|NCT05784558|||COHORT||PROSPECTIVE|||||||
34020804|NCT01715792|||||RETROSPECTIVE|||||||
34020805|NCT06399848|NA|SEQUENTIAL||OTHER||NONE||||||
34020806|NCT06075459|||COHORT||OTHER|||||||
34020807|NCT00724048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020808|NCT03591523|||COHORT||PROSPECTIVE|||||||
34020809|NCT02838121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020810|NCT00653679|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34020811|NCT05786183|||OTHER||CROSS_SECTIONAL|||||||
34020812|NCT03317886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020813|NCT04271735|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34020814|NCT00889369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020815|NCT02740387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020816|NCT01476592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020817|NCT03915353|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33717100|NCT01716351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717101|NCT01991028|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33717102|NCT02826707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717103|NCT04867850|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Eligible clinicians and patients will be independently randomized to receive nudges using a 2x2 factorial design.|f|f|t|f
33717104|NCT02118389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717105|NCT06504758|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33717106|NCT01250262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717107|NCT03898050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will employ a prospective crossover design in which participants will function as their own controls. It will compare the pacing threshold of the two most common pacer pad placement positions. Pad placement order will be randomized to eliminate carry-over effect.||||
33717108|NCT00382278|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717109|NCT05432414|RANDOMIZED|PARALLEL||TREATMENT||NONE||2(PVD):1(VD) random inclusion||||
33717110|NCT05070598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717111|NCT03807869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717112|NCT03681392|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized open-label crossover design with 1:1 allocation of first regimen as once daily or twice daily||||
33717113|NCT05784064|||OTHER||PROSPECTIVE|||||||
33717114|NCT02278198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717115|NCT00479661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717116|NCT04271605|NA|SINGLE_GROUP||TREATMENT||NONE||Behavior Intervention and Pharmacological Therapy||||
33717117|NCT02104700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717118|NCT00345254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717119|NCT00001576||||TREATMENT||||||||
33717120|NCT05992610|NA|SINGLE_GROUP||OTHER||NONE||Interventional, open, allocation to concomitant chemotherapy and low-dose ionizing radiotherapy||||
33717121|NCT04811391|||COHORT||PROSPECTIVE|||||||
33717122|NCT01922206|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33717123|NCT01107041|NA|SINGLE_GROUP||OTHER||NONE||This study is collecting phone sensor data and ecological momentary assessment data to try to develop algorithms that can passively detect behavioral patterns in participants||||
33717124|NCT01096225|||COHORT||PROSPECTIVE|||||||
33717125|NCT01645696|NON_RANDOMIZED|FACTORIAL||DEVICE_FEASIBILITY||NONE||||||
33717126|NCT05087784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33717127|NCT05762094|||COHORT||RETROSPECTIVE|||||||
33717128|NCT00111592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717129|NCT00407823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717130|NCT06507592|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
33717131|NCT00776347|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717132|NCT04334291|||COHORT||CROSS_SECTIONAL|||||||
33717133|NCT06125353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33717134|NCT00844051|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721092|NCT01541969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33721093|NCT03610022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721094|NCT01280214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721095|NCT01290640|||CASE_CONTROL||RETROSPECTIVE|||||||
33721096|NCT03949205|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial and randomized crossover trial.||||
33942118|NCT04589221|||COHORT||CROSS_SECTIONAL|||||||
33942119|NCT01611558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020818|NCT04738474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020819|NCT01219374|||CASE_ONLY||PROSPECTIVE|||||||
34020820|NCT02712333|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34020821|NCT03184974|||COHORT||PROSPECTIVE|||||||
34020822|NCT00006083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34020823|NCT00987753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020824|NCT00326963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020825|NCT04902092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717135|NCT03562481|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||"Study subjects will serve as their own controls in this crossover AB/BA study design which is uniform within sequences (groups, i.e. AB/BA, of order of drug formulation administration), uniform within periods (equal time between administration of alternating drug formulations), and balanced (equal number of subjects within each study arm).~The randomization will be performed to the type of drug given first, using a balanced randomization (half subjects buffered, half unbuffered) implemented with SAS software routines. During the first session, each subject will receive an IAN block with the first randomly assigned anesthetic formulation using the Halstead technique. At least a week later, substantially longer than the elimination half-life of the drug lidocaine (1.5-2hr), local anesthetic injections will be done using the alternate local anesthetic formulation."|t|t|f|t
33797834|NCT02055794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797835|NCT00726544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797836|NCT00407082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797837|NCT00005027||||TREATMENT||||||||
33797838|NCT03301025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33797839|NCT01519752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33797840|NCT03842488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797841|NCT06554756|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Saliva, serum and gingival crevicular fluid of periodontitis patients collected for analyzing anxa1, anxa2 and IL-1beta||||
33797842|NCT05742126|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33797843|NCT01713946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797844|NCT02759588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797845|NCT03616535|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33797846|NCT00199966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797847|NCT03107117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blind to treatment condition to which subject is assigned|a computer-assisted adolescent motivational interview plus an online parenting program for substance abuse will be compared to usual care.|f|f|f|t
34020826|NCT05716386|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective open labelled randomized controlled trial study||||
34020827|NCT05809791|||OTHER||CROSS_SECTIONAL|||||||
34020828|NCT01267721|||COHORT||PROSPECTIVE|||||||
34020829|NCT04770467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34020830|NCT02768714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33797848|NCT02665988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797849|NCT01595061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797850|NCT02265276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33797851|NCT00194896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797852|NCT05813444|||COHORT||CROSS_SECTIONAL|||||||
33797853|NCT00010738|RANDOMIZED|||TREATMENT||||||||
33797854|NCT04425629|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1/Phase 2/Phase 3||||
33797855|NCT04213053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||detect if there are any change in motility after concomitant horizontal muscle surgery||||
33797856|NCT05583110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797857|NCT05412199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33797858|NCT05289349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||prospective, randomized (1:1), double blind clinical trial|t|f|f|t
33797859|NCT05861063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33797860|NCT04747743|||COHORT||PROSPECTIVE|||||||
33797861|NCT06555653|||CASE_CONTROL||PROSPECTIVE|||||||
33797862|NCT02095171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797863|NCT06242041|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Treatment group: routine treatment, and oral potassium reduction by SZC on non-dialysis day.~Control group: routine treatment."||||
33797864|NCT02202395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797865|NCT01591239|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33797866|NCT01346982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797867|NCT00648726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802075|NCT06215053|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Blind patients and postoperative follow-ups will not know which group the patient is in the study|Randomized double blinding|t|t|f|f
33802076|NCT05598554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single||t|f|t|f
33802077|NCT05101941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802078|NCT05271994|||COHORT||PROSPECTIVE|||||||
33802079|NCT02919449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802080|NCT03308513|||COHORT||RETROSPECTIVE|||||||
33802081|NCT02717117|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802082|NCT03096236|||COHORT||PROSPECTIVE|||||||
33802083|NCT00000994||||TREATMENT||DOUBLE||||||
34101034|NCT04380025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a double blind study. The participant and the medical care provider will not know the identity of the placebo or study product.|A prospective, parallel-group, double-blind, randomized placebo-controlled clinical trial will be conducted with an estimated 72 primary open-angle glaucoma patients. A double blind RCT was chosen to minimize bias and yield similar groups with the same prognostic at baseline to avoid compromising the validity of the study results. The primary efficacy endpoint of the study will be IOP and the secondary endpoint will be the safety analysis.|t|t|f|f
34101035|NCT01693237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34101036|NCT04477512|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101037|NCT05507164|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101038|NCT03463239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101039|NCT06343532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101040|NCT02393703|||COHORT||PROSPECTIVE|||||||
34101041|NCT06521853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34101042|NCT06248177|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The products (experimental and placebo), will be produced by an external producer, who will save the codes. None of the researchers involved in the study development or analyses will know the association until the end of the study.|Randomised, double blinded, crossover intervention|t|t|t|t
34101043|NCT02181413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101044|NCT06686498|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||"In coherence with the recovery model and from a transformative paradigm, to meet the objectives, a mixed research study will be conducted, with a concurrent design constituted by two collection threads QUAN (quantitative) and QUAL (qualitative). This design is characterized by collecting, analyzing, and merging quantitative and qualitative data and results simultaneously, opting for one paradigm at the base rather than mixing paradigms.~The longitudinal-type quantitative strand comprises a single-blind Randomized Clinical Trial (RCT) with two arms in parallel, in which two groups are compared: a waiting group that will function as a control group, which will receive its treatment as usual (TAU) called Group A. Furthermore, an experimental group called Group B, will receive both the usual treatment (TAU) and the IMR-ACS intervention. For ethical considerations, Group A will receive the"|f|f|t|t
34101045|NCT06690060|NA|SINGLE_GROUP||TREATMENT||NONE||This is a cohort study in which all participants will receive the mind-body intervention. This is an exploratory study to help hone elements of the protocol through participant feedback and to determine variance and optimal survey measurement tools. We will not modify participant medication regimens and no pain or other medication prescriptions will be issued by the research team.||||
34101046|NCT06690983|||COHORT||PROSPECTIVE|||||||
34101047|NCT04579380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101048|NCT03948789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101049|NCT00485342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101050|NCT04089085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One Group Pilot Study||||
34101051|NCT00320320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101052|NCT05529173|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients are assigned to treatment group or placebo|f|f|f|t
34101053|NCT04189588|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Double Blind|Randomized Double Blind Study|t|t|t|f
34101054|NCT02868710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34101055|NCT02181621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101056|NCT00600431|||CASE_CONTROL||PROSPECTIVE|||||||
34101057|NCT06457321|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Participants will be randomized into 2 groups which receive dentures fabricated by two different methods.~Group 1: Participants receive denture made from Conventional method, followed by denture made from partial digital method Group 2: Participants receive denture made from partial digital method, followed by denture made from conventional method"|t|f|f|f
34101058|NCT03575000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101059|NCT04650841|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34101060|NCT06260748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717136|NCT02147340|||COHORT||PROSPECTIVE|||||||
33717137|NCT05745779|||OTHER||RETROSPECTIVE|||||||
33717138|NCT02496533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33717139|NCT06337331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717140|NCT04533698|||OTHER||RETROSPECTIVE|||||||
33717141|NCT03009435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717142|NCT04014842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717143|NCT02700815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717144|NCT05299125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717145|NCT02145364|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33717146|NCT00951808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717147|NCT01752907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33717148|NCT01347008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717149|NCT02502643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717150|NCT02653391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717151|NCT01489592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33717152|NCT06078761|||COHORT||PROSPECTIVE|||||||
33717153|NCT01023750|||||PROSPECTIVE|||||||
33717154|NCT05394909|||CASE_ONLY||PROSPECTIVE|||||||
33717155|NCT05990972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717156|NCT01721330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717157|NCT03662685|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717158|NCT04832672|||COHORT||RETROSPECTIVE|||||||
33717159|NCT01692327|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33717160|NCT03902197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717161|NCT00937625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717162|NCT02678260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717163|NCT00989339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33717164|NCT00849810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717165|NCT03033381|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Statistician was masking|operated and nonoperated side testis of each patient accepted two different group.|f|f|f|t
34101061|NCT04830709|||COHORT||PROSPECTIVE|||||||
33802084|NCT01919775|||COHORT||CROSS_SECTIONAL|||||||
33942120|NCT01227161|||CASE_ONLY|||||||||
33721097|NCT05303207|NA|SINGLE_GROUP||OTHER||NONE||Open label||||
33942121|NCT01337440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942122|NCT02189239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942123|NCT04004026|||OTHER||PROSPECTIVE|||||||
33721098|NCT04311996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33942124|NCT03011164|||COHORT||PROSPECTIVE|||||||
33942125|NCT00189059|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33942126|NCT02143427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942127|NCT05640141|||COHORT||PROSPECTIVE|||||||
33942128|NCT05751915|||COHORT||PROSPECTIVE|||||||
34101062|NCT05531344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101063|NCT02835521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34101064|NCT04993768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101065|NCT06495554|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34101066|NCT06246721|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101067|NCT00678860|||||PROSPECTIVE|||||||
34101068|NCT05041582|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34101069|NCT05253326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34101070|NCT05073510|||COHORT||PROSPECTIVE|||||||
34101071|NCT05574764|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101072|NCT00322959|||CASE_CONTROL||PROSPECTIVE|||||||
34101073|NCT05514444|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101074|NCT00109070|RANDOMIZED|||TREATMENT||||||||
34101075|NCT03399773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101076|NCT05898594|NA|SINGLE_GROUP||SCREENING||NONE||||||
34101077|NCT05670197|||CASE_ONLY||CROSS_SECTIONAL|||||||
34101078|NCT01366014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101079|NCT06694428|||COHORT||OTHER|||||||
34101080|NCT00007774||||||DOUBLE||||||
34101081|NCT04544111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101082|NCT04779593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101083|NCT05035927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101084|NCT06237764|||COHORT||PROSPECTIVE|||||||
34101085|NCT06694805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101086|NCT03972098|||CASE_CONTROL||PROSPECTIVE|||||||
34101087|NCT03671148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101088|NCT06044623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101089|NCT02129881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101090|NCT04117087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101091|NCT00005684|||||RETROSPECTIVE|||||||
34101092|NCT03566667|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic randomized controlled trial||||
34101093|NCT01637571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101094|NCT04072432|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34101095|NCT03984461|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A - PRP plus Lipoaspirate Group B - PRP plus Bone Marrow Aspirate Group C - PRP plus Lipoaspirate plus Bone Marrow Aspirate||||
34101096|NCT05431088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part B only||t|t|t|t
34101097|NCT03822325|||COHORT||PROSPECTIVE|||||||
34101098|NCT03625648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo controlled|t|t|t|t
34101099|NCT02152982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101100|NCT04017468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34101101|NCT06548672|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101102|NCT06334120|||COHORT||PROSPECTIVE|||||||
34101103|NCT03749174|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Patients are subdivided into 3 groups where one group is further subdivided into 2 groups|f|f|f|t
34101104|NCT02362412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101105|NCT06017128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Individuals will be included in the groups using the randomization method. The randomization of the groups was conducted using the simple-random technique through the use of the website www.random.org.|This randomized controlled, pre-test-post-test measurement experimental study was designed to determine the impact of sexual counseling based on the PLISSIT model on sexual function, quality of life, and comfort levels in individuals who have undergone total hip replacement surgery.||||
34101106|NCT02060188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101107|NCT04308993|||COHORT||RETROSPECTIVE|||||||
33721099|NCT06417242|||COHORT||PROSPECTIVE|||||||
33721100|NCT05333393|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single Blinded|The child with type 1 diabetes will be divided into two as the experimental and control group. Children in the experimental group will be informed about the diabot application and how they will use the application to manage their disease processes. Children/adolescents in the study group and their parents will be evaluated 5 times, once every 3 months, through data collection tools. Data will be collected from the children/adolescents in the control group and their parents by means of pre-test and data collection tools 5 times, once every 3 months. If the training is found effective after the study is completed, similar training will be given to the control group via the mobile application.|t|f|f|f
33721101|NCT03538158|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34101108|NCT01504399|||COHORT||PROSPECTIVE|||||||
33721102|NCT01547000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721103|NCT06293885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721104|NCT03232281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721105|NCT01154218|RANDOMIZED|CROSSOVER||||NONE||||||
33721106|NCT02508454|||COHORT||PROSPECTIVE|||||||
33721107|NCT00380978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721108|NCT05826886|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34101109|NCT06695572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101110|NCT06685380|||CASE_CONTROL||PROSPECTIVE|||||||
34101111|NCT01725282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101112|NCT00461812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33797868|NCT03947086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants enrolled in the study using the eligibility criteria will be allocated randomly, with 1: 1 block exchange. A random number generator will be used through an online randomization program (www.random.org). Hidden allocation will be employed with numbered, opaque and sealed sequential envelopes, so that the person in charge of the allocation will not have contact with the patients, nor with the work of the others.~In addition, all examiners will be blind as to the type of treatment the patient will receive (active stimulation or sham-controlled), which will be done by a specific investigator. The protocol for simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing. In this way, the effects of the active stimulation by short stimulation period are simulated, without inducing clinical effects. These factors characterize this trial as a double-blind study."|this study is a sham-controlled, double-blind, randomized clinical trial aiming to evaluate the efficacy of anodic TDCS in aspects of social cognition of children between 8 and 12 years old with mild ASD. In total there will be 16 children, diagnosed with ASD according DSM-V, will be randomized to two groups, one with active stimulation (1.5 mA) and the other with a placebo current, in which the anode will be positioned over the left dorsolateral prefrontal cortex (F3), while the cathode (reference electrode) will be placed in the right supraorbital area. The intervention will be applied for 5 consecutive days for 20 minutes. Participants and investigators will be blinded. Furthermore, everyone will receive Social Cognition Training concomitantly with neurostimulation to enhance social skills in children with ASD. Patients will undergo three social cognitive assessments: at baseline, week 2 (after stimulation), and 1 month later (follow up).|t|f|t|f
33797869|NCT05303415|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797870|NCT02990546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797871|NCT02011698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33797872|NCT00164333|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33942129|NCT02860676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942130|NCT01408862|||||CROSS_SECTIONAL|||||||
33942131|NCT02303730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101113|NCT01391299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34101114|NCT05704036|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33942132|NCT05441124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942133|NCT04611204|||COHORT||PROSPECTIVE|||||||
33942134|NCT06376201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101115|NCT06660446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101116|NCT06636487|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Participants will be informed that the trial is assessing the impact of pulmonary rehabilitation models on predetermined outcomes, but not the specific nature of the models of interest, and the predetermined hypothesis about the purpose, acceptability, willingness and adherence to intervention group allocated.~All assessors are blinded to group allocation and previous test results. In case of failure keeping the outcome assessor blinded (that is, if a participant reveals his/her allocation) a second assessor will be available to step in and conduct the assessment on another day. To avoid investigators (subconscious) bias the biostatistician who perform the data analyses and validate the results is blinded to group allocation. The research group will interpret the results, before the allocation code is broken."|A randomized clinical, assessor- and statistician blinded multicentre trial with three parallel-groups|f|f|t|t
34101117|NCT03644446|||COHORT||PROSPECTIVE|||||||
34101118|NCT05557292|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33942135|NCT04120025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942136|NCT01485289|||CASE_ONLY||PROSPECTIVE|||||||
33942137|NCT01982942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942138|NCT05712174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020831|NCT02181426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34020832|NCT01989962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020833|NCT03783273|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know if they receive juice with complex-bound vitamin D3 or not.|A multiple crossover study using a balanced latin square design. Each participant will receive all five treatments with a wash-out period of 10-21 days between each treatment.|t|f|f|f
34020834|NCT01074489|||COHORT||PROSPECTIVE|||||||
34020835|NCT00327860|||COHORT||PROSPECTIVE|||||||
34020836|NCT01495156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020837|NCT01167959|||CASE_CONTROL||PROSPECTIVE|||||||
34101119|NCT06384781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101120|NCT04837846|||CASE_CONTROL||PROSPECTIVE|||||||
34103399|NCT05175378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"* All patients were randomly assigned to either the control or the intervention group, using single randomization. An independent researcher applied a computerized sequence to generate the randomization list. Next, the principal investigator who was responsible for the completion of each participant's form recorded the patient trial number in a sealed envelope. Maintenance of the blind-to-treatment allocation was performed in order to avoid bias. Treatment data were exposed to the analyst only after assessing outcomes. During the 3-month intervention, dietitians performed regular phone interviews on a 15-day basis to assist nutritional and lifestyle consultation in both groups.~* All patients were instructed to keep (a) weekly food diaries (2 weekdays and 1 weekend day) and (b) 24-hour dietary records, which all were assessed remotely via emails and unexpected phone calls."|Randomized, case control study|t|f|t|f
34020838|NCT02043587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020839|NCT04948060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Pair-matched cluster-randomized controlled implementation trial with delayed intervention in the control group|f|f|f|t
34020840|NCT03208361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Arm 1: Penicillin V (phenoxymethylpenicillin) Arm 2: Amoxicillin (control)|t|t|t|t
34020841|NCT02890654|||COHORT||PROSPECTIVE|||||||
34020842|NCT04097236|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34020843|NCT02203422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020844|NCT05500053|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34020845|NCT04711616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020846|NCT00891917|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34020847|NCT02098239|NON_RANDOMIZED|||TREATMENT||NONE||||||
34020848|NCT03512132|||COHORT||PROSPECTIVE|||||||
34020849|NCT06345365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942139|NCT00958230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942140|NCT03264976|||CASE_CONTROL||PROSPECTIVE|||||||
33942141|NCT05535452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Due to the nature of the intervention, physiotherapists who supervise the application of the photobiomodulation technique will not be blinded and only patients and evaluators of the results will be blinded to the allocation of the groups.|After recruitment, the women will be allocated to: Intervention Group and Control Group. The randomization of the study will be performed in an allocation ratio of 1:1 for the two groups and generated per block of envelopes, sealed and opaque, every 10 patients, which will contain the allocation code (five codes for the intervention group and five codes for the control group). This choice was chosen to avoid influences of the therapist's or patient's preference in relation to the intervention. The patients will be oriented in relation to the group that will be inserted and that the follow-up will be performed while the patient is on radiotherapy and up to three months after treatment. All evaluations, intervention and data collection will be performed by professionals trained and qualified for this purpose.|t|f|f|t
33942142|NCT05768360|NA|SEQUENTIAL||OTHER||NONE||||||
33942143|NCT00426842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942144|NCT00036660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942145|NCT01165515|||||PROSPECTIVE|||||||
33942146|NCT05815004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants, who are randomized to the ERT control arm, will have the opportunity to cross over and receive AVR-RD-02 gene therapy.|t|t|t|t
33942147|NCT00570089|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33942148|NCT01140646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942149|NCT03240666|||COHORT||OTHER|||||||
33942150|NCT01226758|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33717166|NCT04521075|NA|SINGLE_GROUP||TREATMENT||NONE||"Stage I:~Cohort A: Fifteen Melanoma patients will be treated with FMT capsules originating from 5 different donors.~Cohort B: Two NSCLC patients will be treated with FMT capsules originating from 2 different donors.~Cohort C: Three MSI-H or dMMR patients will be treated with FMT via colonoscopy and capsules combined with anti-PD-1 (Nivolumab).~An interim analysis will be conducted following completion of recruitment of 15 patients.~Based on the interim analysis, the abovementioned independent cohorts will be expanded to include additional patients as~Stage II:~Cohort A expansion will include 15 melanoma patients Cohort C expansion will include seven MSI-H or dMMR patients.~Patients will be treated with FMT originating from selected donors, combined with anti-PD-1 (Nivolumab)."||||
33942151|NCT06201585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942152|NCT01453439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942153|NCT01914536|||COHORT||PROSPECTIVE|||||||
33942154|NCT03223649|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942155|NCT03824756|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020850|NCT05939635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Researchers, surgeons and nurses, and those involved in study outcome analysis will not be aware of the randomization of the group. Block quality and standardization will be performed by an anesthetist experienced in regional anesthesia for EOIB and M-TAPA block.|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program.|t|t|t|t
34020851|NCT03084367|||COHORT||PROSPECTIVE|||||||
34020852|NCT00384644|||COHORT||PROSPECTIVE|||||||
33717167|NCT03031977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717168|NCT05421234|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33717169|NCT02300584|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717170|NCT02041286|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717171|NCT05459324|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Statistics will be performed comparing the HR-SCS to commercial SCS devices. Additionally, we will correlate patient reported outcomes and spinal measurements to IONM outcomes to determine overall device capabilities.||||
33717172|NCT04811625|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33717173|NCT02058576|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33717174|NCT02985554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717175|NCT03789045|||CASE_ONLY||CROSS_SECTIONAL|||||||
33717176|NCT05451160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717177|NCT03331419|||CASE_ONLY||PROSPECTIVE|||||||
33717178|NCT05975515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled clinical trial, parallel groups, three-arm, superiority trial with 1:1:1 allocation ratio.|f|f|f|t
33717179|NCT02632955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717180|NCT00989014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717181|NCT00387439|RANDOMIZED|PARALLEL||||NONE||||||
33717182|NCT05061810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Block randomisation sequence generation (allocation ratio of 1:1:1) to ensure equilibrium between the groups. Allocation concealment will be achieved through the use of an independent healthcare provider (HCP) who will retain the random allocation sequence|A single centre feasibility three-arm parallel randomised control trial (RCT) study. The trial consists of three groups which are, Group A, Arm 1 (standard respiratory outpatient care with a smartphone app self-management programme with follow up monthly phone calls), Group B, Arm 2 (standard respiratory outpatient care with a smartphone app and Group C, control group (standard respiratory outpatient care).|t|t|f|t
33717183|NCT02344160|||||PROSPECTIVE|||||||
33717184|NCT02967497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717185|NCT05605314|||COHORT||PROSPECTIVE|||||||
33717186|NCT02654483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Research personnel not involved in this study was responsible for blinding. This was the only personnel with access to the code linking study drug bottle numbers to treatment (i.e. active or placebo). The code was broken when all data was captured and locked on an electronic data capture system.|Phase 2 investigator-initiated, randomized, double-blind, placebo-controlled, parallel-arm trial evaluating the comparative effect of serlopitant 5 mg by mouth daily versus placebo in treatment of chronic pruritus in pediatric and adult EB patients|t|t|t|t
33717187|NCT04891783|||CASE_CONTROL||RETROSPECTIVE|||||||
33797873|NCT06006052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797874|NCT05525364|||COHORT||RETROSPECTIVE|||||||
33797875|NCT00006446|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797876|NCT01093430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797877|NCT01561989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797878|NCT01925469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797879|NCT00382850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33797880|NCT01557855|||COHORT||PROSPECTIVE|||||||
34020853|NCT00005143|||COHORT||PROSPECTIVE|||||||
33797881|NCT02773303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33797882|NCT01982890|||COHORT||PROSPECTIVE|||||||
33797883|NCT03989986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33797884|NCT02738372|||COHORT||PROSPECTIVE|||||||
33797885|NCT02390544|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797886|NCT03267966|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33797887|NCT04776265|||COHORT||PROSPECTIVE|||||||
33797888|NCT06019299|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomized allocation to Mindfulness-Based Cognitive Therapy intervention or positive control intervention.||||
33797889|NCT06106555|||CASE_ONLY||OTHER|||||||
34020854|NCT04068649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020855|NCT04663295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020856|NCT00555386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34020857|NCT03598868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020858|NCT05545358|||CASE_CONTROL||PROSPECTIVE|||||||
34020859|NCT02605993|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34020860|NCT01229163|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34020861|NCT05303103|||OTHER||OTHER|||||||
34020862|NCT01630967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020863|NCT04211727|||COHORT||PROSPECTIVE|||||||
34020864|NCT05940753|||COHORT||PROSPECTIVE|||||||
34020865|NCT06633536|||COHORT||RETROSPECTIVE|||||||
34020866|NCT05069194|||COHORT||PROSPECTIVE|||||||
34020867|NCT06394700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020868|NCT00164151|RANDOMIZED|FACTORIAL||||SINGLE||||||
34020869|NCT04695145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The baseline and outcome assessor is not working at the clinic and is not informed of treatment mode. The patient is informed at the beginning of the interview not to disclose any information about mode of treatment. All interviews are recorded.|Randomized Controlled Study - pilot version|f|f|f|t
34020870|NCT02013011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020871|NCT00060138|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34020872|NCT02450955|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34020873|NCT01206049|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020874|NCT04013321|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34020875|NCT00543946|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34020876|NCT03188666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020877|NCT04354116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020878|NCT00883909|||OTHER||PROSPECTIVE|||||||
34020879|NCT04565925|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Both the subjects and the investigators will be blinded to the treatment.|Each subject will be administered both sildenafil 20mg TID for 4 weeks and placebo (lactose) TID for 4 weeks in a crossover fashion with a 2 week washout period between treatments.|t|f|t|t
34103400|NCT06655714|||CASE_ONLY||CROSS_SECTIONAL|||||||
34103401|NCT05483400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Simon 2 stage design with 4 cohorts.||||
34103402|NCT06006468|||OTHER||RETROSPECTIVE|||||||
33797890|NCT01291446|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33797891|NCT03555214|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33797892|NCT05238480|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33797893|NCT01274299|||COHORT||CROSS_SECTIONAL|||||||
33797894|NCT00239434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797895|NCT03357289|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797896|NCT05740657|||COHORT||PROSPECTIVE|||||||
33797897|NCT05910749|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-experimental repeated measured design||||
33797898|NCT05111483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797899|NCT04836806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797900|NCT01394510|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33797901|NCT04260906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797902|NCT00181753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797903|NCT02976116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797904|NCT05833906|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33797905|NCT05955391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797906|NCT00703950|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33797907|NCT00295724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797908|NCT04484415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797909|NCT00813449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797910|NCT02854813|||COHORT||PROSPECTIVE|||||||
34103403|NCT06366919|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33797911|NCT01348035|||CASE_CONTROL||PROSPECTIVE|||||||
33797912|NCT05814328|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33797913|NCT01352611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797914|NCT02462499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797915|NCT06155071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33802085|NCT02044809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802086|NCT02133820|RANDOMIZED|CROSSOVER||||NONE||||||
34103404|NCT00872287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103405|NCT06538064|||COHORT||PROSPECTIVE|||||||
34103406|NCT00912873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103407|NCT05566782|||COHORT||PROSPECTIVE|||||||
34103408|NCT06137664|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34103409|NCT02372773|||FAMILY_BASED||PROSPECTIVE|||||||
34103410|NCT06543758|NA|SINGLE_GROUP||TREATMENT||NONE||Researchers will compare pre- and post-intervention walking speeds, body composition, spatiotemporal parameters, balance, and satisfaction survey in participants and does not establish a control group.||||
34103411|NCT03912987|||COHORT||PROSPECTIVE|||||||
34101121|NCT06688006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The generated numbers are written on small pieces of paper, folded and placed in a small box. The box will be given to the pregnant woman by a midwife not involved in the study and she will be asked to draw a number. This will determine whether the pregnant woman is in the intervention group or the control group. This reduces the possibility of bias in the study. During the data collection process of the study, the researcher will know which group the pregnant women are in, but the pregnant women will not know which group they are in. A single-blind method will be used. The statistics of the trial will be done by a statistician who is not involved in the trial. The intervention and control groups will be given a code or colour so that the statistician does not know which group the data belong to.|To ensure randomization in the study, the blocks will first be created by stratifying the pregnant women according to their age and level of education using the stratified sampling method, and then it will be decided whether the pregnant women in the groups will be in the intervention or control group using simple randomization. Then, a table of random numbers between 1-288 will be generated using the Random.org website with simple random sampling method (https://www.random.org/sequences/).|t|t|t|f
34101122|NCT06679452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101123|NCT05712889|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101124|NCT05380453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33797916|NCT04062760|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multicenter, randomized, open-label, parallel-arm trial. Eligible patients will be randomized in a 1:1 proportion to treatment with either high-dose oral furosemide or sequential nephron blockade with different classes of diuretics at low doses.~The primary endpoint will be the bivariate change in body weight and serum creatinine value at 96 hours since patient randomization."||||
33797917|NCT02296463|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33797918|NCT00813059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797919|NCT01372761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797920|NCT02738320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33797921|NCT00366171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797922|NCT05935527|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The participant, PI, sponsor will be masked until visit 5 at which time unmasking will occur to whether placebo or treatment so that placebo subjects can cross over to receive active treatment.||t|f|t|t
33797923|NCT00891436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797924|NCT00642980|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33797925|NCT05790746|||COHORT||RETROSPECTIVE|||||||
34020880|NCT03140852|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34020881|NCT05250466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020882|NCT05000879|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020883|NCT00430820|||||PROSPECTIVE|||||||
34020884|NCT00808886|||CASE_ONLY||PROSPECTIVE|||||||
34020885|NCT02080013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34020886|NCT00106067|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34020887|NCT01853631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020888|NCT00073619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020889|NCT03343652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020890|NCT02954263|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34020891|NCT03222583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020892|NCT05477511|||COHORT||CROSS_SECTIONAL|||||||
34020893|NCT04248218|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective randomized control trial of pediatric patients in the emergency department (ED) diagnosed with an acute concussion.~The randomization plan will include randomization based on sex.~Group A: active care Group B: routine/standard care"||||
34020894|NCT02515149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020895|NCT04851652|||COHORT||PROSPECTIVE|||||||
34020896|NCT00663520|||CASE_CONTROL||PROSPECTIVE|||||||
34020897|NCT03021109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020898|NCT05122936|||COHORT||PROSPECTIVE|||||||
34020899|NCT05275803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34020900|NCT05670574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Testing three new surgical techniques for small bowel tumors. Tumor feeding vessel and vascular anatomy of each patients is identified preoperatively on CT scan and based on this we produce a 3D reconstruction. Based on tumor location we choose one of the three techniques and perform extended D3 mesenterectomy. The results will be reported on as described in the project description section"||||
34020901|NCT03052218|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34020902|NCT04091659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020903|NCT02498106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020904|NCT06353711|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34020905|NCT00085930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020906|NCT04658017|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled subjects will receive treatment with the GARNET device||||
34020907|NCT01278719|||CASE_CONTROL||PROSPECTIVE|||||||
34020908|NCT02766374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34020909|NCT03524989|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized blinded controlled 2 groups with SHAM treatment|t|t|t|t
34020910|NCT00426361|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020911|NCT02870179|||CASE_ONLY||PROSPECTIVE|||||||
34020912|NCT01299259|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34020913|NCT04260438|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020914|NCT04328857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020915|NCT00914953|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34020916|NCT02362555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34020917|NCT00593736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020918|NCT05906108|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34020919|NCT00070096||||TREATMENT||NONE||||||
34020920|NCT04675723|||COHORT||PROSPECTIVE|||||||
34020921|NCT05888623|||COHORT||PROSPECTIVE|||||||
34020922|NCT02929186|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34020923|NCT00912925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942156|NCT04873609|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33942157|NCT01709240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942158|NCT00266604|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797926|NCT03429998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Non-controlled intervention study to evaluate the different therapies in the treatment of hypercholesterolemia, in which each patient will be self-controlled. The variables will be analyzed during different phases~1. Phase LDL apheresis:~2. evolocumab phase~3. Combined phase"||||
33797927|NCT04689061|||COHORT||PROSPECTIVE|||||||
33797928|NCT02804425|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33797929|NCT04212195|||COHORT||PROSPECTIVE|||||||
33797930|NCT00651105|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797931|NCT03359889|||COHORT||CROSS_SECTIONAL|||||||
33797932|NCT01733095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797933|NCT05263115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33797934|NCT00155038|||DEFINED_POPULATION||OTHER|||||||
33797935|NCT03163212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation design||||
33797936|NCT03593213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33797937|NCT02178111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797938|NCT04122612|||COHORT||PROSPECTIVE|||||||
33797939|NCT06436144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802087|NCT06142357|||COHORT||PROSPECTIVE|||||||
33802088|NCT06243094|||COHORT||PROSPECTIVE|||||||
33942159|NCT03724799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942160|NCT02179216|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33942161|NCT03702439|||COHORT||PROSPECTIVE|||||||
33942162|NCT01357928|||COHORT||PROSPECTIVE|||||||
33942163|NCT03316027|||CASE_ONLY||CROSS_SECTIONAL|||||||
33942164|NCT04796454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020924|NCT03653117|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, single centre, interventional pilot study.||||
34020925|NCT00258050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020926|NCT02789397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34020927|NCT05321511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020928|NCT05231538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor was blind to treatment regimen administered to both groups|Participants are assigned to one of two groups in parallel for the duration of the study|f|f|f|t
34020929|NCT02011386|||COHORT||PROSPECTIVE|||||||
34020930|NCT02029586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020931|NCT00104143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34020932|NCT05410132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020933|NCT02029573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020934|NCT05016193|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34020935|NCT01030653|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34020936|NCT01022944|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34020937|NCT04475783|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1-randomization, parallel design, stratified by Center.||||
34020938|NCT02912169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020939|NCT05342701|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020940|NCT03169712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020941|NCT04326465|NA|SINGLE_GROUP||TREATMENT||NONE||Efficacy and safety trial for Fractional CO2 Laser Therapy with pre- and post-treatment comparisons (3 laser therapy sessions over 12 weeks in men with Peyronie's Disease).||||
34020942|NCT04146116|NA|SINGLE_GROUP||PREVENTION||NONE||50 patients will receive PROFEND intranasal povidone-iodine prior to surgery and after surgery. The study aims to evaluate the real-world effectiveness of PROFEND® in reducing S. aureus colonization and surgical site infections (SSIs).||||
34020943|NCT04709835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020944|NCT05284487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020945|NCT02545348|||CASE_ONLY||PROSPECTIVE|||||||
34020946|NCT00550940|||CASE_CONTROL||PROSPECTIVE|||||||
34020947|NCT00021580|NON_RANDOMIZED|||TREATMENT||NONE||||||
34020948|NCT00866736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34020949|NCT04242914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded participants and investigator.|randomized control, double blind trial|t|f|t|t
34020950|NCT00418301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020951|NCT04477772|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34020952|NCT06253026|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34020953|NCT05533762|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34020954|NCT01300910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020955|NCT02141425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34020956|NCT06494345|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101125|NCT06671054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34101126|NCT00646022|||FAMILY_BASED||PROSPECTIVE|||||||
33942165|NCT00061828|||COHORT||PROSPECTIVE|||||||
33797940|NCT06554041|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This clinical trial employs an interventional study model with a parallel assignment. A total of 40 edentulous patients, will be randomized into four groups.~The study is open-label, meaning that both the researchers and the participants will know which material is being used for each patient. This design is intended to evaluate the impact of these different materials on the health of the peri-implant soft tissue by measuring inflammatory markers and clinical outcomes such as bleeding on probing and pocket depth over a six-month period."||||
34103412|NCT06688461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103413|NCT06596772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34103414|NCT05094102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797941|NCT06294275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797942|NCT01275105|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33797943|NCT02658370|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33797944|NCT04479969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33797945|NCT06131385|||COHORT||PROSPECTIVE|||||||
33797946|NCT01495663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797947|NCT01866969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33797948|NCT01850511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020957|NCT04779515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"none of the participants knew at which pressure they will be operated on, nor the physicians who followed participants at floor or those analyzing blood samples, not the assigned physician to collect data, nor the personnel doing the analysis.~only the operating surgeon and circulating nurse were aware of the meaning of the participant assigned label at time of operation. The masking was revealed post completion of analysis."|participants were divided into two masked groups, labelled red and green; those operated at low-pressure pneumoperitoneum (green-label) and those operated at standard-pressure pneumoperitoneum (red-label).|t|t|t|t
34020958|NCT05358470|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34020959|NCT02504190|||COHORT||PROSPECTIVE|||||||
34020960|NCT05484037|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Research coordinator (RC) and certified respiratory educators (CRE) are unblinded. The main investigator and an independent clinical coordinator will be blinded and collected data for primary and secondary outcomes. Statistician and economic evaluator will be blinded to the study randomized orientation.|Will be added later|t|t|t|t
34020961|NCT03801265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The person who perform the block will be unblinded. The participants and the outcomes assessor will be blinded to the treatment allocations.|Lumbar plexus block vs Quadratus lumborum type 3 block|t|f|f|t
34020962|NCT02448264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34020963|NCT04866732|NA|SINGLE_GROUP||PREVENTION||NONE||This project involves a mixed methods study with sequential design.||||
34020964|NCT01865240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020965|NCT05025514|||COHORT||RETROSPECTIVE|||||||
34020966|NCT02322463|||CASE_CONTROL||RETROSPECTIVE|||||||
34020967|NCT01879748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020968|NCT04842773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34020969|NCT01058460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34020970|NCT00986063|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020971|NCT02836938|||CASE_CONTROL||PROSPECTIVE|||||||
34020972|NCT05101837|NA|SINGLE_GROUP||OTHER||NONE||independent interventional non pharmacological pilot study with APP for mindfulness practice on android||||
34020973|NCT05132036|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34020974|NCT05892939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|f
34020975|NCT05578456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020976|NCT03884543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33797949|NCT01998711|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33797950|NCT00096967||||TREATMENT||NONE||||||
33797951|NCT04367272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33797952|NCT01296191|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33797953|NCT04855903|RANDOMIZED|PARALLEL||OTHER||SINGLE||Multiple Baseline case experimental design (N-of-1 trial)|f|f|f|t
33797954|NCT05126121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797955|NCT04194749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797956|NCT06332404|||COHORT||PROSPECTIVE|||||||
33797957|NCT06522724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||random selection to two groups (study group and control group)|t|f|t|t
33797958|NCT00766298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797959|NCT06514222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluators responsible for data collection and analyses are blinded to the analgesic medication regime used by the patients|A single-center, double-blind, parallel-group, randomized controlled clinical trial|f|f|t|t
33797960|NCT04428736|||COHORT||CROSS_SECTIONAL|||||||
33797961|NCT01493310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33802089|NCT01515436|RANDOMIZED|||TREATMENT||SINGLE|||f|f|t|f
33802090|NCT06140719|||COHORT||OTHER|||||||
33802091|NCT04140331|||COHORT||PROSPECTIVE|||||||
33802092|NCT05814146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020977|NCT01264926|||CASE_ONLY||CROSS_SECTIONAL|||||||
34020978|NCT00788749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34020979|NCT04227613|||COHORT||PROSPECTIVE|||||||
34020980|NCT00525447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103415|NCT03057301|||COHORT||PROSPECTIVE|||||||
34103416|NCT06650098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33797962|NCT05721924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The recruited patients and the attending anaesthetist will be blinded to the type of block provided for the patient.|"The recruited patients will be randomly divided into two groups via stratified randomization based on patient's hips fractures classification. Intra-articular fractures involving fractures within the hip joint. While extra-articular fractures are those fractures outside the capsule of the hip joint which are intertrochanteric and subtrochanteric. Two envelopes will be prepared which is intra-articular and extra-articular fractures envelope. In each envelope, there will be 10 A blocks and 10 B blocks."|t|t|f|f
33797963|NCT01296334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33797964|NCT01241916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797965|NCT02000167|||CASE_CONTROL||PROSPECTIVE|||||||
33797966|NCT00930098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797967|NCT02589340|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33797968|NCT01719666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797969|NCT05849311|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33797970|NCT06007118|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is designed as binary outcome parallel group non-inferiority trial.||||
33797971|NCT01351493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797972|NCT00769275|||COHORT||PROSPECTIVE|||||||
33797973|NCT02545036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797974|NCT01763086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797975|NCT03262623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33797976|NCT03086161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Care providers delivering usual prenatal care are unaware of condition assignment.||f|t|f|f
33797977|NCT06335654|||CASE_ONLY||PROSPECTIVE|||||||
33797978|NCT02879695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797979|NCT03803605|NA|SINGLE_GROUP||PREVENTION||NONE||Single Arm: All participants will receive combination therapy consisting of VRC07-523LS and Vorinostat.||||
33797980|NCT05919368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33797981|NCT02550067|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33797982|NCT00344994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797983|NCT01677936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020981|NCT04729309|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34020982|NCT06361979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020983|NCT00148642|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34020984|NCT00002608||||TREATMENT||NONE||||||
34020985|NCT03756467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The impact evaluation is a cluster-randomized controlled trial with three study arms: control (no program), GE, and GE+. GE refers to the Girl Empower program alone, while GE+ adds small cash transfers to the families of eligible girls as an incentive to increase take-up of GE attendance in weekly sessions. The study team will conduct a baseline survey of all girls age 13-14 and their caregiver in 100 communities in Nimba County, Liberia. Communities will then be randomized, blocking on number of girl in the community and % of girls enrolled in school, to one of the 3 study arms. Two years following the baseline survey (1 year following program completion), the study team will conduct an endline survey in all 100 communities with the same girls and caregivers and compare outcomes in the three study arms.|The impact evaluation study is a cluster-randomized controlled trial among 100 communities with three study arms: control (no intervention), GE, and GE+.|t|f|f|f
34020986|NCT04669691|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34020987|NCT05200546|||OTHER||PROSPECTIVE|||||||
34020988|NCT03360591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34020989|NCT03623386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|f|t
34020990|NCT05632211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded/unblinded site teams||t|f|t|f
34020991|NCT06324318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34020992|NCT00963781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020993|NCT01743248|||COHORT||PROSPECTIVE|||||||
34020994|NCT05644600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020995|NCT00895414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34020996|NCT03009630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34020997|NCT05234593|NA|SINGLE_GROUP||OTHER||NONE||Feasibility||||
34020998|NCT06167356|||COHORT||PROSPECTIVE|||||||
34020999|NCT04285593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34021000|NCT05371860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021001|NCT03730818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an assessor-blind study. Physiotherapist in charge of performing the baseline and post-intervention assessment will be blinded to participants allocation||f|f|f|t
34021002|NCT00727870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021003|NCT02310711|||CASE_ONLY||PROSPECTIVE|||||||
34021004|NCT01045213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021005|NCT06117878|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34021006|NCT00718913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021007|NCT02195089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021008|NCT04471337|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021009|NCT04625725|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34021010|NCT03324932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33797984|NCT03375554|||COHORT||PROSPECTIVE|||||||
33797985|NCT06014827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33797986|NCT02355197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021011|NCT04784754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-controlled randomized double-blind trial|t|t|t|t
34021012|NCT03924089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Open to the intake of ONS or diet, but double-blind to the intake of probiotics|Randomized, multicenter, parallel-group trial.|t|t|t|t
34021013|NCT02841657|||OTHER||PROSPECTIVE|||||||
33797987|NCT00191412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33797988|NCT03751891|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participant masking was only done for laboratory measurements. For home trial testing no masking was done.||t|f|f|f
33797989|NCT06106516|||COHORT||PROSPECTIVE|||||||
33797990|NCT03785834|||COHORT||PROSPECTIVE|||||||
33797991|NCT01569308|||COHORT||CROSS_SECTIONAL|||||||
33797992|NCT02647268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33797993|NCT00035828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33797994|NCT03054571|||OTHER||CROSS_SECTIONAL|||||||
33797995|NCT01754168|||COHORT||PROSPECTIVE|||||||
33797996|NCT04479865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33797997|NCT00417781|||CASE_CONTROL|||||||||
33797998|NCT02228356|||COHORT||PROSPECTIVE|||||||
33797999|NCT04674293|||CASE_ONLY||CROSS_SECTIONAL|||||||
33798000|NCT04781881|||COHORT||PROSPECTIVE|||||||
33798001|NCT00700336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798002|NCT04225403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798003|NCT01041417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798004|NCT05344326|NA|SINGLE_GROUP||TREATMENT||NONE|The PWP and service users will be aware of the intervention|Mixed methods, small N, case series||||
33798005|NCT00812877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798006|NCT02120911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798007|NCT06103630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021014|NCT04619095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021015|NCT05994001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Each cycle of the first phase was defined as cardonilizumab (6mg/kg,Q2W) combined with different concentrations of 1.6mg/kg or 1.8mg/kg LM-302 (Q2W), 14 days as a course of treatment, and the combined dose (RP2D) of LM-302 during combination therapy was determined according to the 3+3 design.~In the second phase, Claudin18.2 expression was positive, and the positive population was randomly assigned to trial group 1, trial group 2, and trial group 3.~Group 1:6 mg/kg cardonilizumab, 14 days for 1 course. Group 2:1.8mg /mg LM-302 was treated for 1 course for 14 days. Group 3: 6 mg/kg cardonilizumab for 14 days was a course of treatment; RP2D LM-302 is 1 course of treatment for 14 days."|"Each cycle of the first phase was defined as cardonilizumab (6mg/kg,Q2W) combined with different concentrations of 1.6mg/kg or 1.8mg/kg LM-302 (Q2W), 14 days as a course of treatment, and the combined dose (RP2D) of LM-302 during combination therapy was determined according to the 3+3 design.~In the second phase, Claudin18.2 expression was positive, and the positive population was randomly assigned to trial group 1, trial group 2, and trial group 3.~Group 1:6 mg/kg cardonilizumab, 14 days for 1 course. Group 2:1.8mg /mg LM-302 was treated for 1 course for 14 days. Group 3: 6 mg/kg cardonilizumab for 14 days was a course of treatment; RP2D LM-302 is 1 course of treatment for 14 days."|t|f|f|f
34021016|NCT06015243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021017|NCT00373698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021018|NCT03011138|||COHORT||PROSPECTIVE|||||||
34021019|NCT00331240|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34021020|NCT02001831|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34021021|NCT03074123|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021022|NCT06490614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants will be assigned to one of two groups in parallel for the duration of the study, either group A (Dexmedetomidine group) or group B (nalbuphine group).|t|f|t|f
34021023|NCT01214915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021024|NCT02521935|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021025|NCT00566566|||COHORT|||||||||
34021026|NCT04526886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021027|NCT00271154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021028|NCT00620100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021029|NCT05157906|RANDOMIZED|PARALLEL||OTHER||NONE||This is a randomized, controlled education-based interventional study without any investigational product. Study subjects are randomized to the intervention or control groups with a follow-up period of 12 weeks.||||
34021030|NCT02834676|||||RETROSPECTIVE|||||||
34021031|NCT06404658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34021032|NCT04674748|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34021033|NCT03817437|||COHORT||RETROSPECTIVE|||||||
34021034|NCT05623072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not know that which group they will be in|It is an experimental, randomised controlled trial. The data will be collected with the convenience sampling method from healthy and volunteer participants. The matched-group design method will be used.|t|f|f|f
34021035|NCT05292833|||CASE_ONLY||PROSPECTIVE|||||||
34021036|NCT00792363|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34021037|NCT00428636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021038|NCT05302830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34021039|NCT04040608|||COHORT||CROSS_SECTIONAL|||||||
34021040|NCT00628537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021041|NCT04778553|||OTHER||PROSPECTIVE|||||||
34021042|NCT04721444|||COHORT||RETROSPECTIVE|||||||
34021043|NCT00714896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021044|NCT02279134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021045|NCT03735316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Masking and blinding will be carried out by the research pharmacy with unmasking to be performed at study completion through the research pharmacy and statistician.||t|t|t|f
34021046|NCT03986138|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34021047|NCT06080100|RANDOMIZED|PARALLEL||TREATMENT||NONE||According to the latest data, the need for xenon analgosedation occurs in 10% of cases from all excimer laser operations. N= 1,96\*10\*90/25=70.||||
34021048|NCT06218875|||COHORT||PROSPECTIVE|||||||
34021049|NCT02808689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798008|NCT01600729|||COHORT||PROSPECTIVE|||||||
33798009|NCT02847507|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33798010|NCT00427323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798011|NCT00360698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798012|NCT03049969|NA|SINGLE_GROUP||TREATMENT||NONE||20 sessions of cognitive remediation while receiving 20 minutes of up to 2.0 mA tDCS using a DLPFC montage||||
33798013|NCT01211093|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33798014|NCT01548716|||CASE_ONLY||PROSPECTIVE|||||||
33798015|NCT00473902|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33798016|NCT05640154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33798017|NCT03050814|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33798018|NCT01304342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798019|NCT01373346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798020|NCT03109795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized, parallel, double-blind|t|f|t|t
33798021|NCT06439901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multicentre, Interregional , feasibility study||||
33798022|NCT03009994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021050|NCT01224730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021051|NCT04271579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021052|NCT04008628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome will be assessed on video recordings of the procedures which will be prepared so that assessors will not know to which group the children assigned. This correspond to a blind assessment of the primary outcome.||f|f|f|t
34021053|NCT01989988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021054|NCT02912585|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34021055|NCT04644822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021056|NCT00107510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021057|NCT04053686|NA|SINGLE_GROUP||OTHER||NONE||||||
34021058|NCT06483347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021059|NCT03948139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects and parents are blinded until after consent to the study in which they are randomized into the functional brace group or spica cast group.||t|f|f|f
34021060|NCT02148289|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34021061|NCT05882994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single|After obtaining the consent of 44 patients who met the inclusion criteria of the study, the selection of the patients to form the sample will be made at random according to the patient list in which the patient names in the institution are determined in alphabetical order and numbers. Two groups will be formed with at least one patient in each group, using a simple randomization method created on a computer (www.randomizer.org) by an independent researcher who was not involved in the study.|f|f|f|t
34021062|NCT00822796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021063|NCT01581866|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021064|NCT06190418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021065|NCT04631952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021066|NCT06453135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021067|NCT00202423|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34021068|NCT03716414|||COHORT||PROSPECTIVE|||||||
34021069|NCT02866006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021070|NCT01423656|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34021071|NCT01654614|||CASE_CONTROL||PROSPECTIVE|||||||
34021072|NCT02629354|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021073|NCT01113944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34021074|NCT03880786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021075|NCT00399880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021076|NCT03293407|||COHORT||PROSPECTIVE|||||||
34021077|NCT02338193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34021078|NCT02304627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021079|NCT06633211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the interventional nature of the study, the surgeon cannot be blinded. A randomization sequence will be generated, and each patient will be assigned a number. To ensure allocation concealment, the surgeon will be blinded to the group assignment of each patient until just before performing the alveolar preservation procedure. The investigator responsible for conducting the radiological measurements and the histomorphometric study will be blinded to the patient's group assignment.|Two parallel groups|t|f|t|t
34021080|NCT03269318|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be allocated to one of two groups as per block randomisation, with no stratification or minimisation to Group 1; Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA). While Group 2, Standard Care will be prescribed controller medication based on guidelines.||||
34021081|NCT03204708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021082|NCT01366950|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34021083|NCT01315132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021084|NCT01857843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021085|NCT04413331|||COHORT||PROSPECTIVE|||||||
34021086|NCT02286310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021087|NCT04645966|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Open label for Groups 1-5,7,8,10 and 11, no masking; Groups 13-14 is blinded.||f|t|t|f
34021088|NCT02517463|||COHORT||PROSPECTIVE|||||||
34021089|NCT02882243|||COHORT||PROSPECTIVE|||||||
34021090|NCT01342900|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34021091|NCT04661683|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34021092|NCT00151112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021093|NCT00525551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021094|NCT05869903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021095|NCT01714232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798023|NCT01903798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798024|NCT00945386|||COHORT||PROSPECTIVE|||||||
33798025|NCT05836285|||COHORT||PROSPECTIVE|||||||
33798026|NCT04831190|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility-Implementation Study||||
33798027|NCT01869543|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33798028|NCT03039361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798029|NCT00851396|||CASE_CONTROL||PROSPECTIVE|||||||
33798030|NCT01858519|||OTHER||PROSPECTIVE|||||||
33798031|NCT01841437|||COHORT||PROSPECTIVE|||||||
34101127|NCT06345703|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The trial consists of three parts: the first part is a single ascending dose (SAD) study, the second part is a multiple ascending dose (MAD) study, and the third part is food effect (FE) study. The first two parts (SAD and MAD) will be randomized, double-blind, single or multiple ascending dose and placebo-controlled study designs. The third part (FE) will be a randomized, open-label, two-period, crossover study design. To evaluate the safety, tolerability, pharmacokinetic profile, and the effect of food on the PK profile of NS-136 in healthy subjects and to determine the maximum tolerated dose (MTD)|t|t|t|f
34101128|NCT05238220|||COHORT||PROSPECTIVE|||||||
34101129|NCT06685237|||COHORT||PROSPECTIVE|||||||
34101130|NCT04949451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34101131|NCT03643588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101132|NCT01512251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101133|NCT02375256|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33717188|NCT04803357|NA|SINGLE_GROUP||TREATMENT||NONE|If you are in the control group, you will not be given a RT-CGM. Instead, you will be given a blinded CGM device. You will not be able to view your blood sugar results on the blinded CGM device. If you are in the control group, you will also be given a blood glucose meter to check your glucose using finger sticks according to the recommendations of your provider.|Real- time continuous glucose monitoring using the DexCom G6.||||
33717189|NCT02417974|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34101134|NCT05974111|||COHORT||PROSPECTIVE|||||||
34101135|NCT00770809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101136|NCT05449067|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Non-diabetic patients on maintenance peritoneal dialysis will be randomly assigned into groups A and B in a 1:1 ratio: group A receives APD from week 1 to 12 and changes to CAPD from week 13 to 24; group B receives CAPD from week 1 to 12 and changes to APD from week 13 to 24. Outcomes were evaluated at week 12 and week 24.||||
34101137|NCT03979794|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial (intervention vs. standard care)||||
33717190|NCT05489055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717191|NCT00968656|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717192|NCT01949168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717193|NCT04032314|||OTHER||CROSS_SECTIONAL|||||||
33717194|NCT05678894|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33717195|NCT05039151|||COHORT||PROSPECTIVE|||||||
33717196|NCT06157814|RANDOMIZED|PARALLEL||OTHER||SINGLE||All patients recruited, aside from their caregivers, will have already received OR are scheduled for ostomy surgery. Patient and caregivers will be randomized 1:1 to the control and intervention group. The intervention group of patents and caregivers will be given access to the STOMA Care app while the control group of patents and caregivers will NOT be given access to the STOMA Care app during the course of the study.|t|f|f|f
33717197|NCT04326231|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33717198|NCT03180151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717199|NCT01988805|||COHORT||CROSS_SECTIONAL|||||||
33717200|NCT00052208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717201|NCT01324336|||CASE_ONLY||PROSPECTIVE|||||||
33717202|NCT05931159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717203|NCT04478474|||COHORT||RETROSPECTIVE|||||||
33717204|NCT00707668|||COHORT||PROSPECTIVE|||||||
34101138|NCT04012710|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101139|NCT06695273|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34101140|NCT04009135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A research assistant not affiliated with the study will use Research Randomizer (http://www.randomizer.org/) to generate lists of randomly sequenced numbers to allocate patients to trial arm. To reduce biases and expectation effects, the research assistant will not be aware of what condition the patients are allocated when conducting baseline assessments and a research assistant not affiliated with the research will complete outcome assessments without being aware of allocation. Interventionists will be aware of which group patients are allocated to, as will patients.|Doubly-randomized, patient-preference trial with two active study interventions and one control.|f|f|t|t
34101141|NCT00782379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101142|NCT04105634|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101143|NCT05117125|||CASE_CONTROL||PROSPECTIVE|||||||
34101144|NCT04658368|||COHORT||PROSPECTIVE|||||||
34101145|NCT06645704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101146|NCT02719366|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34101147|NCT05400941|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34101148|NCT01642667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101149|NCT04860336|||COHORT||PROSPECTIVE|||||||
33717205|NCT00676351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717206|NCT06466109|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single-group, pretest-posttest clinical trial||||
33717207|NCT04435860|||COHORT||CROSS_SECTIONAL|||||||
33717208|NCT06477458|||OTHER||PROSPECTIVE|||||||
33717209|NCT00927784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33717210|NCT00198965|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33717211|NCT00902005|||COHORT||PROSPECTIVE|||||||
33717212|NCT03124433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717213|NCT05982626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717214|NCT01991067|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717215|NCT03912766|||CASE_ONLY||PROSPECTIVE|||||||
33717216|NCT03552653|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Randomized, cross-over, comparator-controlled|f|f|t|f
33717217|NCT03807063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717218|NCT00638378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717219|NCT01516320|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717220|NCT01910610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717221|NCT03489720|RANDOMIZED|CROSSOVER||PREVENTION||NONE||balanced order-randomized, 16-week within-subject crossover study||||
33717222|NCT04049123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33717223|NCT00166114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717224|NCT02749981|||OTHER||PROSPECTIVE|||||||
33717225|NCT01183897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717226|NCT03847454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798032|NCT04302246|||COHORT||PROSPECTIVE|||||||
33717227|NCT06219057|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To attain this project's aims a longitudinal research will take place. Adolescents living in residential youth care will be invited to participate. According to a criteria of convenience, 15 adolescents will receive the intervention (experimental group) and 15 other adolescents will receive the care as usual (control group).|f|f|f|t
33717228|NCT04671225|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The RCT: Outpatients from the two-referral hospitals in Rwanda will be invited to participate and be allocated to the intervention group or waiting list.~The district trial: This trial compares the impact of the intervention given at the district level with the intervention conducted at the referral hospital.~Randomization:~Study participants at the hospital level who meet the inclusion criteria and sign the informed consent form will be randomized individually into either intervention-arm or waiting list through block-randomization with a ratio of 1:1.~Patients at the district level will not be randomized since we are unsure of the number of patients with Bipolar Disorder at these levels fearing that the sample size will be too small. Instead, all will be offered participation."||||
33717229|NCT02655094|||COHORT||RETROSPECTIVE|||||||
33798033|NCT03428958|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a three-part study of NUC-3373 administered by IV across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (LV, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab).~Part 1 will determine if NUC-3373 should be administered with LV. Part 2 consists of a dose escalation phase, to assess the safety/tolerability of different doses of NUC-3373 in combination with either oxaliplatin (NUFOX) or irinotecan (NUFIRI), and an expansion phase, to assess weekly schedules of NUFOX and NUFIRI regimens selected in the escalation phase. Part 3 will assess the safety/efficacy of NUFOX and NUFIRI regimens administered in combination with bevacizumab, cetuximab or panitumumab.~Additional patients may be enrolled in all parts to replace patients who withdraw prior to completing the 28-day safety evaluation period to complete the min number patients per cohort. Enrolment may be expanded at the DSMCs discretion."||||
33798034|NCT00095667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798035|NCT02906735|||COHORT||PROSPECTIVE|||||||
33798036|NCT04189744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Partially placebo controlled||t|t|t|t
33798037|NCT02834598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798038|NCT02617368|||CASE_CONTROL||PROSPECTIVE|||||||
33798039|NCT04329793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021096|NCT03361475|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021097|NCT00989820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021098|NCT04536532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021099|NCT02958982|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33717230|NCT04684355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717231|NCT03626922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717232|NCT04083170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798040|NCT02751138|||COHORT||PROSPECTIVE|||||||
33798041|NCT03663504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798042|NCT01281163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021100|NCT02578030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798043|NCT04944407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798044|NCT04627493|RANDOMIZED|PARALLEL||OTHER||NONE||The study will be a randomized parallel-group trial||||
33798045|NCT01149395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798046|NCT00130117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33798047|NCT02797717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798048|NCT00021008||||TREATMENT||||||||
34021101|NCT00252239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021102|NCT00573404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021103|NCT00804167|||COHORT||CROSS_SECTIONAL|||||||
34021104|NCT05527574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021105|NCT05816057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021106|NCT01996332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021107|NCT02911896|||COHORT||PROSPECTIVE|||||||
34021108|NCT00619112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021109|NCT03253835|||COHORT||PROSPECTIVE|||||||
34021110|NCT04968665|||COHORT||PROSPECTIVE|||||||
34021111|NCT03918694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded pilot randomized control trial|2 groups: placebo and Vitamin C|t|t|f|t
34021112|NCT01627353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34021113|NCT00051987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021114|NCT06002737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021115|NCT01830205|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021116|NCT03039660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021117|NCT02748967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021118|NCT05567120|NA|SINGLE_GROUP||OTHER||NONE||||||
33802093|NCT04599088|NA|SINGLE_GROUP||OTHER||NONE||||||
34021119|NCT00099710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021120|NCT05385965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned with equal allocation to an intervention or a standard care control condition, using a stratified block randomization scheme to ensure group balance based on patient performance status (i.e., Eastern Cooperative Oncology Group \[ECOG\] score of 0 vs. 1 or 2) and pain interference (i.e., Patient-Reported Outcomes Measurement Information System \[PROMIS\] Pain Interference 8-item raw score of 25 or lower vs. 26 or higher) at screening.||||
34021121|NCT01268501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021122|NCT02135835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021123|NCT04467801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021124|NCT05934955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021125|NCT05398900|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34021126|NCT02724930|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34021127|NCT06552065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021128|NCT02384135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021129|NCT04399044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103417|NCT06685016|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
34101150|NCT02584244|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Six groups enrolling up to 11 patients each. Groups are patients with colorectal cancer, patients with esophageal cancer, patients with pancreatic cancer receiving neoadjuvant chemotherapy, patients with pancreatic cancer not receiving neoadjuvant chemotherapy, gastric cancer patients who have received neoadjuvant therapy, and patients with early stage gastric cancer or precancerous lesions||||
34101151|NCT03704922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101152|NCT06547359|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, two-cohort, fixed-sequence, drug-drug interaction study||||
34101153|NCT01725308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101154|NCT04080232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101155|NCT05107934|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34101156|NCT01698905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021130|NCT03301623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study team will randomize the study on the provider level and use a random number generator to assign providers to study arms.~Patients within the physicians randomized to the Informed Decision Making (IDM) arm will not receive the PEAT materials; their physicians will receive the CDS alerts via the EHR when certain order criteria are triggered appropriately.~Patients within the physicians randomized to the Shared Decision Making (SDM) arm will receive the PEAT materials via REDCap two days before their PCP office visit. They will receive these materials every time they have an office visit with their PCP."||||
34021131|NCT01612299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021132|NCT04326114|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34021133|NCT06123923|||COHORT||RETROSPECTIVE|||||||
34021134|NCT05310162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021135|NCT01080664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021136|NCT02361970|||CASE_CONTROL||PROSPECTIVE|||||||
34021137|NCT06425497|||COHORT||RETROSPECTIVE|||||||
34101157|NCT05803551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101158|NCT04867954|||COHORT||PROSPECTIVE|||||||
34101159|NCT02596984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101160|NCT05269940|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101161|NCT03878069|||COHORT||OTHER|||||||
34101162|NCT06345118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101163|NCT02375802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101164|NCT05988931|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101165|NCT05051735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101166|NCT00387309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717233|NCT03275051|NA|SINGLE_GROUP||OTHER||NONE|No study treatment will be administered.|No study treatment will be administered in this study. Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study.||||
33717234|NCT06151795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717235|NCT01549444|||COHORT||PROSPECTIVE|||||||
33717236|NCT05350150|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717237|NCT02012998|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33717238|NCT05945693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The masking process will ensure that both the participants and the investigators involved in the study remain unaware of the treatment assignments throughout the entire duration of the study. A unique identification code will be assigned to each participant upon enrollment, which conceals their treatment allocation. The allocation sequence will be generated by a person not directly involved in the study. The capsules in the experimental intervention and the control treatment, will be packaged identically to maintain visual similarity. The packaging materials and labeling will be designed to be indistinguishable between the two groups. In addition, all outcome assessments and data collection procedures will be performed by personnel who are blinded to the treatments.|This study consists of a 16-week intervention with omega-3 polyunsaturated fatty acids (n-3 PUFAs) and/or aerobic exercise (AEx) training. The subjects will be randomly assigned in a double-blinded manner to one of four groups: placebo control (PLA), PLA+AEx, n-3, or n-3+AEx. The training sessions will be conducted at the Laboratorio de Ciencias del Ejercicio en el Ciclo Vital (Lab-CERVITAL), Universidad de O'Higgins. The week before intervention the participants will perform RA-specific tests (e.g., Disease Activity Score-28) and functional measurements (e.g., handgrip strength), peak aerobic capacity test, a dietary and physical activity assessment, and blood samples will be collected. Subsequently, participants will start their 16-week intervention (PLA, PLA+AEx, n-3, or n-3+AEx). At the end of the intervention the same initial measurements, questionnaires, and assessments will be collected.|t|t|t|t
33717239|NCT00176826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717240|NCT04566224|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33717241|NCT02341053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717242|NCT04216017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717243|NCT04814433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717244|NCT01401270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717245|NCT00278655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717246|NCT01808053|||CASE_ONLY||PROSPECTIVE|||||||
33717247|NCT05079295|||COHORT||PROSPECTIVE|||||||
33717248|NCT01116869|||CASE_CONTROL||PROSPECTIVE|||||||
33717249|NCT01539356|||CASE_ONLY||PROSPECTIVE|||||||
33717250|NCT05916391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Central Involvement Diabetic Macular Edema||||
33717251|NCT03905746|||CASE_ONLY||PROSPECTIVE|||||||
33717252|NCT06347536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717253|NCT03021265|||COHORT||PROSPECTIVE|||||||
33717254|NCT01148940|||COHORT||PROSPECTIVE|||||||
33717255|NCT06370832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Ascertainment of post-transplant clinical outcomes (including histopathology assessments) will be blinded by assessors to study group up to 3 months post-transplant.|Pre-lung transplant candidates will be randomized to one of two groups: (1) IMT + exercise training; or (2) exercise training alone.|f|f|f|t
33717256|NCT00820157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717257|NCT03141242|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33717258|NCT04379882|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717259|NCT03327298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798049|NCT03809312|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomisation by the pharmacy, no one in the investigator and the participant will know the intervention|During the surgery, 4 groups will be formed as described in the figure below. Patients will be divided according to the presence or absence of polyps at the endoscopy and randomized in one of the 2 groups by the pharmacy of the CHU of Quebec. This will give either a prescription of Clavulin 875 mg per os to be taken twice a day for 10 days, or a placebo of similar visual appearance according to the same dosage|t|t|t|t
33798050|NCT02692417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798051|NCT01830738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942166|NCT06326658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942167|NCT00278213||||TREATMENT||NONE||||||
33942168|NCT01089075|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33942169|NCT00784680|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33942170|NCT05838586|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Participants will complete three interventions in a randomized order, separated by \>=6 and \<90 days. The interventions are:~1. 4 hours of prolonged SB (control, CON)~2. 4 hours of SB broken up by 5 minutes of self-paced walking every hour (BREAK)~3. 4 hours of SB with one 20-minute bout of self-paced walking (BOUT)"||||
33942171|NCT02217176|||COHORT||CROSS_SECTIONAL|||||||
33942172|NCT04613076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942173|NCT01986166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021138|NCT03024658|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33798052|NCT02365766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798053|NCT01136486|||CASE_ONLY||RETROSPECTIVE|||||||
33798054|NCT00583817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798055|NCT02317965|||COHORT||PROSPECTIVE|||||||
33798056|NCT01471145|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798057|NCT03106142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention group Control group (usual care)||||
33798058|NCT02540408|||CASE_CONTROL||PROSPECTIVE|||||||
33798059|NCT03635151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33798060|NCT02133404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798061|NCT05167877|||COHORT||PROSPECTIVE|||||||
33798062|NCT05652933|||COHORT||PROSPECTIVE|||||||
33942174|NCT03676712|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33942175|NCT04851522|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942176|NCT01425242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942177|NCT01353976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942178|NCT04939064|||CASE_CONTROL||PROSPECTIVE|||||||
33942179|NCT02768428|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33942180|NCT06404476|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20).||||
34021139|NCT05341908|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34021140|NCT02532725|||CASE_CONTROL||PROSPECTIVE|||||||
34021141|NCT06452875|||COHORT||PROSPECTIVE|||||||
33942181|NCT01070381|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021142|NCT03279497|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34021143|NCT02885181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021144|NCT01356264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021145|NCT01004094|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34021146|NCT02564211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021147|NCT04433338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021148|NCT05937984|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34021149|NCT02828306|||CASE_CONTROL||PROSPECTIVE|||||||
34021150|NCT04649567|||COHORT||PROSPECTIVE|||||||
34021151|NCT03654599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34021152|NCT00145275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021153|NCT00756483|||CASE_CONTROL||PROSPECTIVE|||||||
34021154|NCT02468895|||COHORT||PROSPECTIVE|||||||
34021155|NCT05681793|||OTHER||CROSS_SECTIONAL|||||||
34021156|NCT05552170|||COHORT||RETROSPECTIVE|||||||
34021157|NCT02166814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021158|NCT02323516|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021159|NCT04158700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021160|NCT02129452|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34021161|NCT02927613|||CASE_ONLY||PROSPECTIVE|||||||
34021162|NCT05027243|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective study||||
34021163|NCT02783248|||COHORT||PROSPECTIVE|||||||
34021164|NCT03469336|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|This study is a single arm multi-intervention study. The interventions are masked to participant, investigator, providers and assessors.|||||
34021165|NCT04569396|||CASE_ONLY||PROSPECTIVE|||||||
34021166|NCT04844762|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34021167|NCT03249337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101167|NCT05158166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101168|NCT02226653|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33717260|NCT03959566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laboratory staff, analysing and evaluating the sputum and blood samples of the participants, will be blinded to the treatment arm.|"75 participants will be randomized to one of five arms (15 participants per arm) to receive study medication containing bedaquiline, delamanid, and moxifloxacin with different doses of sutezolid, ranging from 0mg sutezolid up to 800mg sutezolid twice a day. Participants will be randomised and stratified by site and HIV status.~Participants will visit the study clinic on a weekly basis for sputum collection, safety monitoring and receipt of study medication.~After the completion of three months of experimental treatment participants in the experimental arms will be handed over to government TB programmes to complete their course of anti-TB treatment."|f|f|f|t
33717261|NCT02315781|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33942182|NCT00842829|RANDOMIZED|PARALLEL||||NONE||||||
33942183|NCT03589794|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33942184|NCT01935622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942185|NCT06419062|||COHORT||RETROSPECTIVE|||||||
33942186|NCT01427855|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33717262|NCT04075565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The study design is a crossover design.|f|f|t|f
33717263|NCT01804374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717264|NCT00717340|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717265|NCT06293807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the surgeon and patient will be blinded as to the intervention provided by covering identifying marks of the anesthetic carpules to be administered. Randomization will be assured by random selection of a slip of paper drawn from a sealed envelope assigning the patient to one of three groups.|A randomized, placebo-controlled, parallel design study.|t|f|t|f
33717266|NCT04085068|||OTHER||OTHER|||||||
33717267|NCT03252301|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717268|NCT00452010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717269|NCT02751996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33717270|NCT06366568|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717271|NCT02956265|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717272|NCT01409564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717273|NCT01979484|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33717274|NCT02055690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717275|NCT01523574|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798063|NCT04989387|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33798064|NCT04909346|||COHORT||PROSPECTIVE|||||||
33798065|NCT01116635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798066|NCT02525796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||3-parallel-armed double-blinded randomized controlled trial wherein monotherapy of eplerenone or amiloride or placebo administered for 4 weeks. After weeks, an open-label extension addition of cinacalcet to all 3 arms conducted for 2 weeks.|t|t|t|t
33942187|NCT04193228|||CASE_CONTROL||PROSPECTIVE|||||||
33942188|NCT01759095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942189|NCT01756391|||COHORT||PROSPECTIVE|||||||
33942190|NCT01728194|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942191|NCT05047601|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind Double Dummy|"Eligible participants who are asymptomatic household contacts of an individual with symptomatic COVID-19 will be randomized (1:1:1) to receive orally every 12 hours:~PF-07321332/ritonavir for 5 days followed by placebo for 5 days or PF-07321332/ritonavir for 10 days or Placebo for 10 days"|t|t|t|t
33942192|NCT03576456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||placebo controlled, double blind|t|t|t|t
33942193|NCT01207336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942194|NCT01294722|||CASE_ONLY||RETROSPECTIVE|||||||
33942195|NCT04824118|||COHORT||PROSPECTIVE|||||||
33942196|NCT01756482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942197|NCT04669106|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942198|NCT06334237|||COHORT||PROSPECTIVE|||||||
33942199|NCT03651011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942200|NCT06265974|||COHORT||RETROSPECTIVE|||||||
33942201|NCT03006952|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942202|NCT02499380|||COHORT||PROSPECTIVE|||||||
33942203|NCT03602521|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942204|NCT05992051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This experiment was performed as a single-blind experiment. The outcomes assessors are specialized personnel who do not participate in the trial intervention process and are not clear about the grouping of participants situation and the intervention situation. Outcome statistics were also performed by dedicated data analysts.|"Randomized clinical trial with 39 adults with self-reported chronic neck pain recruited. They were randomly assigned into two groups. The experimental group received online exercise therapy and the control group received conventional exercise therapy.~Participants in both groups completed the same exercise program three times a week for six weeks. Visual analogue scale (VAS), the Neck Disability Index (NDI), Work Limitations Questionnaire (WLQ) and The Hospital Anxiety and Depression Scale (HADS) and its subscales were evaluated. Participants were assessed at baseline and at 6 weeks while the changes in WLQ were assessed biweekly. To ensure the effectiveness of online exercise therapy, therapists delivered the online exercise 3 times a week for 6 weeks, with videoconferencing once a week and posting of exercise record on social media twice a week."|f|f|f|t
33942205|NCT02017769|||CASE_CONTROL||PROSPECTIVE|||||||
33942206|NCT04576962|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33942207|NCT05459428|||OTHER||PROSPECTIVE|||||||
33942208|NCT02274987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942209|NCT04737551|||COHORT||PROSPECTIVE|||||||
33942210|NCT06309368|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking. This is a non-blinded randomized controlled trial|Participants will be randomly assigned to one of the two treatment groups.||||
33942211|NCT00169273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942212|NCT03459976|||CASE_CONTROL||PROSPECTIVE|||||||
33942213|NCT03550508|NA|SINGLE_GROUP||TREATMENT||NONE|Open|"The accelerated titration and traditional 3+3 dose-escalation designs are applied in this study."||||
34101169|NCT06695624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34101170|NCT05568095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021168|NCT04428333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blind study.|This will be a randomized, parallel group treatment study with eligible participants receiving either GSK3359609 in combination with pembrolizumab and 5FU-platinum chemotherapy or placebo in combination with pembrolizumab and 5FU-platinum chemotherapy.|t|f|t|f
34021169|NCT02241421|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34021170|NCT02969681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021171|NCT03256331||SEQUENTIAL||TREATMENT||NONE||A sequential Dose Escalation Part of four doses following a 3 + 3 design.||||
34021172|NCT04385394|||CASE_ONLY||PROSPECTIVE|||||||
34021173|NCT00746018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021174|NCT03712215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021175|NCT01062867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021176|NCT04376762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34021177|NCT01552265|||COHORT||PROSPECTIVE|||||||
34021178|NCT03964649|||COHORT||RETROSPECTIVE|||||||
34021179|NCT02540759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34021180|NCT03467139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021181|NCT05149157|||COHORT||PROSPECTIVE|||||||
34021182|NCT01687478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021183|NCT03603548|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021184|NCT04540354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The PROFID-Reduced trial is an open-label, blinded outcome assessment study. Thus, unblinding proce-dures for investigators are not applicable.||f|f|f|t
34021185|NCT00441506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021186|NCT04495283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Up to 80 subjects will be randomized (32 in each active treatment group, 16 placebo).~Eligible subjects will be randomized on Day 1 in a 2:2:1 ratio to receive either a combination of PGB and APAP administered (Group A), APAP (Group B), or placebo (Group C)."|Parallel Assignment|t|t|t|f
34021187|NCT02939833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021188|NCT01957176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021189|NCT04428515|||CASE_ONLY||PROSPECTIVE|||||||
34021190|NCT04361903|||COHORT||RETROSPECTIVE|||||||
34021191|NCT04275882|||COHORT||RETROSPECTIVE|||||||
34021192|NCT02143635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021193|NCT05157958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021194|NCT05691686|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34021195|NCT00309049|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021196|NCT00590811|||COHORT|||||||||
34021197|NCT00616629|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34021198|NCT03934320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021199|NCT06427837|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34021200|NCT02480868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021201|NCT05918731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34021202|NCT01463735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021203|NCT00391235|||CASE_CONTROL||PROSPECTIVE|||||||
34021204|NCT00500136|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34021205|NCT02788682|||COHORT||PROSPECTIVE|||||||
34021206|NCT02517086|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34021207|NCT02931903|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34021208|NCT06455007|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Patients in both groups were prescribed antipyretics and antihistamines when deemed appropriate by the clinician. Propolis 3x10 drops (7 days) were used in the propolis group. Both the investigators and the patients were aware of the drug being given.~A computerized randomization program was used for group selection."|control and treatment group||||
34021209|NCT00150943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021210|NCT01510548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34021211|NCT02451332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021212|NCT04016220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|senior ED and patient do not know the randomization group||t|t|f|f
34021213|NCT04730882|||COHORT||PROSPECTIVE|||||||
34021214|NCT06086418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34021215|NCT00004180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021216|NCT03908762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021217|NCT00002785||||TREATMENT||||||||
34021218|NCT00406744|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021219|NCT01018589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021220|NCT04710316|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"Interventions~* Serological screening of caregivers at D0, M1, M2, M3.~* Screening of patients by molecular biology: a nasopharyngeal swab will be performed to symptomatic hospitalized patients or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures to search for SARS-CoV-2 genome. Positive clinical isolates will be sequenced.~* Screening of caregivers by molecular biology: a nasopharyngeal swab will be performed to symptomatic caregivers or who have seroconverted to SARS-CoV-2 or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures to search for SARS-CoV-2 genome. Positive clinical isolates will be sequenced."||||
34021221|NCT02325518|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34021222|NCT03173144|||COHORT||PROSPECTIVE|||||||
34021223|NCT04775186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021224|NCT01283594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34021225|NCT04938323|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and investigators will be blinded. Designated staff whose responsibility will be to administer the BCG vaccine or placebo will not be blinded. These designated staff members will not be involved in the collection of outcome data|Participants will be randomized in a 1:1 allocation to receive intradermal administration of BCG vaccination or placebo.|t|f|t|t
34021226|NCT03465124|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Groups will be randomized. Randomization information will be put in a sealed envelope on screening date and opened in operating theatre right before procedure start.|Bilateral cataract surgery will be performed in individuals with age-related cataract. Eyes will be randomized into two groups receiving either Femtosecond Laser assisted Cataract Surgery (LCS) or conventional Manual Cataract Surgery (MCS).|t|t|t|t
34101171|NCT05847686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942214|NCT05238324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33717276|NCT01829230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717277|NCT01325974|||COHORT||PROSPECTIVE|||||||
33717278|NCT06228547|||CASE_ONLY||PROSPECTIVE|||||||
33717279|NCT02086994|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33717280|NCT04396431|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33942215|NCT04306003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ERAS is a complex intervention in which care providers cannot be blinded. Patients were provided a brief overview of ERAS without specific details of its interventions but were not informed of the group allocation. Patients were unaware of group allocation as they were unaware of the specific differences in the perioperative care between ERAS and standard care.|Parallel Assignment|t|f|f|f
33942216|NCT00282607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33942217|NCT02534675|||OTHER||PROSPECTIVE|||||||
33942218|NCT02957500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33942219|NCT03350412|||COHORT||PROSPECTIVE|||||||
34101172|NCT03865355|||COHORT||PROSPECTIVE|||||||
34101173|NCT04474158|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This cluster-randomized community-partnered study will examine the effectiveness of a trauma-sensitive, gender transformative youth violence prevention program called Creating Peace that integrates racism and discrimination prevention among youth ages 14-19. The study will be located in Pittsburgh, Pennsylvania across 24 neighborhoods with concentrated disadvantage ('clusters'), randomized either to receive the Creating Peace program (i.e., intervention neighborhood, n=12) or to a job skills training program (n=12 schools)."||||
33717281|NCT02152839|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717282|NCT00047840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717283|NCT02014896|||COHORT||PROSPECTIVE|||||||
33717284|NCT05265000|NA|SINGLE_GROUP||TREATMENT||NONE|Individuals performing the analysis will be blinded to the condition (baseline vs. post therapy)|||||
33717285|NCT06441344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717286|NCT05548725|||COHORT||PROSPECTIVE|||||||
33717287|NCT05036434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717288|NCT05111158|||OTHER||PROSPECTIVE|||||||
33717289|NCT00490854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717290|NCT02511184||||TREATMENT||NONE||||||
33717291|NCT02857933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717292|NCT05778747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717293|NCT03232047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33717294|NCT00782223|||COHORT||PROSPECTIVE|||||||
33717295|NCT02845453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717296|NCT03855280|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 3/4, single arm, open-label study with three defined phases:~* PK Phase: Initial PK evaluation - single dose of APVO101~* Treatment Phase: APVO101 prophylaxis treatment for 50 ED~* Continuation Phase: After completion of the Treatment Phase, subjects may continue APVO101 prophylaxis treatment (for an additional ≥ 50 ED)"||||
33717297|NCT01709591|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717298|NCT03559257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717299|NCT05947812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717300|NCT04688710|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, 3-group parallel design, 333-subject clinical trial to test the efficacy of Self-Hypnosis (HYP) and Mindfulness Meditation (MM) compared to Treatment as Usual (TAU) for individuals with multiple sclerosis and clinically significant fatigue||||
33717301|NCT02118844|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33717302|NCT05248022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is an open-label study. The Participants and investigators are not blinded, but the outcomes assessor are blinded.||f|f|f|t
33717303|NCT03447990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a a two part study. The first part is a randomized, crossover, double-blind, placebo-controlled, two cohort, sequential ascending single dose study. All patients will receive placebo and active doses of MYK-491.~The second part is a randomized, parallel, double-blind, placebo-controlled, sequential ascending multiple dose study. All patients will receive placebo and/or active doses of MYK-491."|t|t|t|t
33717304|NCT00731289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33717305|NCT05339854|||COHORT||RETROSPECTIVE|||||||
33717306|NCT01103011|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33942220|NCT03812198|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|3-part, single (open-label) and multiple (double-blind, placebo-controlled)|Part 1 (single dose, cross-over) Part 2 (single dose, cross-over with food effect evaluation) Part 3 (multiple dose, parallel)|t|t|t|f
33942221|NCT03869502|||CASE_ONLY||PROSPECTIVE|||||||
33942222|NCT04044625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942223|NCT02452034|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942224|NCT03146195|||CASE_CONTROL||RETROSPECTIVE|||||||
33942225|NCT03934333|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942226|NCT03927703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942227|NCT04541394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942228|NCT03417726|||CASE_CONTROL||PROSPECTIVE|||||||
33942229|NCT00636116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942230|NCT03145584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942231|NCT02736487|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33942232|NCT00154986|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33798067|NCT04450199|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be blinded for the duration of the study. This will be accomplished by providing the patients with over encapsulated vitamin D and placebo in pill bottles. Twelve (12) over encapsulated 50,000 IU vitamin D2 or placebo tablets will be packaged in pill bottles for patient use. The Foot \& Ankle Institute CRC will document which drug the patients received.|The specific aim of this study is to assess if vitamin D status in the elective foot and ankle fusion population affects fusion healing rates. With this information the investigators hope to ascertain if vitamin D supplementation in the perioperative period leads to superior fusion rates than does no supplementation.|t|f|f|f
33798068|NCT01653834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798069|NCT03119558|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798070|NCT05537155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798071|NCT02951013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798072|NCT00542789|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798073|NCT00869258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798074|NCT02152813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942233|NCT05512273|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split mouth||||
33942234|NCT03673150|||CASE_CONTROL||RETROSPECTIVE|||||||
34021227|NCT06270212|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"For practical reasons, study participants, sedationists and study investigators on site cannot be masked to study interventions.~However, procedural interventionists on site and study investigators scrutinizing study outcome data will be masked to study interventions.~The number of enrolled study participants reported below (46) refers to evaluable ones."|"Prospective randomized unpaired, and paired crossover, evaluations of study outcome measures in healthy volunteer study participants (PART A), and prospective randomized unpaired evaluation of study outcome measures in study patients (PART B).~The number of arms reported below (3) refers to unpaired comparisons (PARTS A-B)."|f|f|f|t
33798075|NCT00009217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798076|NCT02860286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798077|NCT05942768|||COHORT||RETROSPECTIVE|||||||
33798078|NCT04920812|||COHORT||OTHER|||||||
33798079|NCT02449863|||COHORT||PROSPECTIVE|||||||
33798080|NCT02378337|||COHORT||OTHER|||||||
33798081|NCT05446363|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33798082|NCT05591040|RANDOMIZED|PARALLEL||TREATMENT||NONE||simple randomization in two groups||||
33798083|NCT01981837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798084|NCT05188118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798085|NCT02889016|||COHORT||PROSPECTIVE|||||||
33798086|NCT02378597|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798087|NCT02304952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33798088|NCT00910767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798089|NCT03349762|||COHORT||PROSPECTIVE|||||||
33942235|NCT03313440|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33942236|NCT04060706|||COHORT||PROSPECTIVE|||||||
33942237|NCT06205459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942238|NCT01434498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942239|NCT02113891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942240|NCT00750074|||COHORT||PROSPECTIVE|||||||
33942241|NCT06093321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Randomized, Subject-Independent Rater blinding, Paired Matching, Active-Controlled, Single Institution, Non-Inferiority Pivotal Trials|t|f|f|t
33942242|NCT05707403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942243|NCT04781946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942244|NCT05692427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021228|NCT06344663|||CASE_CONTROL||PROSPECTIVE|||||||
34021229|NCT00296634|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34021230|NCT04527445|RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects notified of the arm after the procedure is performed|||||
34021231|NCT03063840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021232|NCT06442306|RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental study with a Pain Neuroscience Education group and a General Health Education group.||||
33942245|NCT00842010|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942246|NCT01907750|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33942247|NCT02365961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942248|NCT02709239|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33942249|NCT04588298|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomised, open-label, parallel-group study. The study is divided into three stages as follows:~1. Stage 1: In this stage post-menopausal participants will be randomised in 2 cohorts in 1:1 ratio to receive AZD9833 with 12 evaluable participants in each cohort.~2. Stage 2: In this stage post-menopausal participants may be randomised in up to 3 cohorts, which may include up to 3 doses of AZD9833.~3. Stage 3 : In this stage post-menopausal participants may be randomised in up to 2 cohorts in 1:1 ratio, which may include up to 2 doses of AZD9833."||||
33942250|NCT04613687|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi centre, non-comparative study||||
33942251|NCT00336986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942252|NCT03515031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blind to the treatment allocation|open randomized controlled trial|f|f|f|t
33798090|NCT02615769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798091|NCT03737591|||COHORT||PROSPECTIVE|||||||
34101174|NCT06305624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, controlled, Type 1 hybrid implementation-effectiveness trial.||||
34101175|NCT04031963|||CASE_ONLY||PROSPECTIVE|||||||
34101176|NCT04834388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||PROBE design|f|f|f|t
34101177|NCT05168566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101178|NCT05101798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101179|NCT02225938|||COHORT||CROSS_SECTIONAL|||||||
34101180|NCT06321393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798092|NCT03349294|||CASE_ONLY||PROSPECTIVE|||||||
33942253|NCT05810415|||COHORT||PROSPECTIVE|||||||
33942254|NCT04984252|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33942255|NCT00572858|||COHORT||PROSPECTIVE|||||||
33942256|NCT05539742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||randomized crossover single-blinded intervention study|t|f|f|t
33942257|NCT04006431|||OTHER||RETROSPECTIVE|||||||
34101181|NCT01536769|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34101182|NCT04522375|NA|SINGLE_GROUP||TREATMENT||NONE||Phase of dose escalation to OBD followed by 3 months of treatment||||
34101183|NCT02941783|||COHORT||PROSPECTIVE|||||||
34101184|NCT06230393|||COHORT||RETROSPECTIVE|||||||
34101185|NCT04494971|||CASE_ONLY||PROSPECTIVE|||||||
34101186|NCT04589988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be masked.|Parallel-group, randomized control, participants in the waitlist control group will receive the intervention after 6-month follow up is completed|f|f|f|t
34101187|NCT06694597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101188|NCT00276003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101189|NCT06687694|||COHORT||PROSPECTIVE|||||||
34101190|NCT05127785|||COHORT||RETROSPECTIVE|||||||
34101191|NCT03924869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101192|NCT01694186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101193|NCT06107686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101194|NCT03862053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|medications will be covered by blank labels|randomized, double-blind placebo controlled|t|f|t|f
34101195|NCT03615599|||COHORT||PROSPECTIVE|||||||
34101196|NCT02100033|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34101197|NCT06685913|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Coded, known only to one independent individual||t|t|t|t
34101198|NCT05546385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sham device|Prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study|t|t|t|t
34101199|NCT04718896|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717307|NCT04017585|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Interventional study|t|f|t|f
33717308|NCT04160208|||COHORT||PROSPECTIVE|||||||
33717309|NCT01012128|||||PROSPECTIVE|||||||
33717310|NCT05620563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717311|NCT06136702|RANDOMIZED|PARALLEL||PREVENTION||NONE||Longitudinal||||
33717312|NCT01214356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942258|NCT03232151|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single center, open label, single-arm, pilot study||||
33942259|NCT01475227|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942260|NCT05798286|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Randomized, Parallel group|t|f|f|f
33942261|NCT02657109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101200|NCT06135012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717313|NCT03487757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717314|NCT04704167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717315|NCT00911495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717316|NCT01868685|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33717317|NCT00705081|||COHORT||PROSPECTIVE|||||||
33717318|NCT02120729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717319|NCT00618059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798093|NCT04643340|||COHORT||PROSPECTIVE|||||||
34101201|NCT05920616|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101202|NCT02142803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101203|NCT02730286|||||CROSS_SECTIONAL|||||||
34101204|NCT05882214|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34101205|NCT04641975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101206|NCT05977179|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101207|NCT06356350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101208|NCT04725903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101209|NCT06284798|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34101210|NCT04180423|||OTHER||PROSPECTIVE|||||||
34101211|NCT06694818|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101212|NCT04130022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101213|NCT01142388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101214|NCT06059248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34101215|NCT03037008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101216|NCT05389371|RANDOMIZED|PARALLEL||PREVENTION||NONE||parallel-arm randomized trial||||
34101217|NCT06670586|RANDOMIZED|PARALLEL||TREATMENT||NONE||Oocytes obtained from every participant are divided in two groups and each group is randomly allocated to one of the two techniques that we want to analyze. So, there are not two groups of participants but two groups of oocytes from every participan||||
34103418|NCT05867069|||COHORT||PROSPECTIVE|||||||
34103419|NCT05928208|||COHORT||PROSPECTIVE|||||||
34101218|NCT02924402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will enroll two parallel disease groups in escalation: patients with non-CLL B cell malignancies and patients with CLL/SLL/Richter's Transformation. In expansion it will enroll DLBCL and FL||||
34101219|NCT04407117|||COHORT||RETROSPECTIVE|||||||
33798094|NCT01731041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798095|NCT00668863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101220|NCT06514729|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|The researchers in this study enrolled suitable patients using a random number table method before surgery, and then performed different intraoperative single lung ventilation modes according to the grouping after unblinding the patients upon entering the room. The postoperative follow-up personnel or data analysts are unaware of the grouping status.|This study was divided into 3 groups, one groups was ventilation side volume control ventilation+continuous positive pressure ventilation on the non ventilation side, the other groups was ventilation side volume control ventilation+continuous positive pressure ventilation on the non ventilation side; the other groups was ventilation side pressure regulated volume control ventilation+continuous positive pressure ventilation on the non ventilation side.|t|f|t|t
34101221|NCT05555732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101222|NCT05743140|||OTHER||CROSS_SECTIONAL|||||||
34101223|NCT05561140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101224|NCT06687824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101225|NCT06389591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101226|NCT04181762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
34101227|NCT00005557|||COHORT||PROSPECTIVE|||||||
34101228|NCT06487065|||CASE_ONLY||RETROSPECTIVE|||||||
34101229|NCT06432452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101230|NCT02430610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34101231|NCT03254641|||CASE_ONLY||PROSPECTIVE|||||||
33717320|NCT05624203|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with acute ST-segment elevation myocardial infarction undergoing Percutaneous coronary intervention (PCI) were randomly divided into extracorporeal cardiac shock wave treatment group and blank control group.||||
33717321|NCT04669483|||OTHER||PROSPECTIVE|||||||
33717322|NCT01396720|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33717323|NCT00237874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717324|NCT02010554|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33717325|NCT00680043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717326|NCT04734444|NA|SINGLE_GROUP||OTHER||NONE|"The following measures have been taken to minimize or avoid bias:~* Core-lab evaluation of the CNR outcome in a blinded fashion~* SIR clinical rating of US images by an independent expert panel in a blinded fashion~Due to the nature of brain surgery and the diversity of the tumours, it is seen as a strength to the trial that the patient can act as its own control even though the images can never be 100% the same in the separate image acquisition. This is especially true for 2D US images, whereas with a 3D US image it is more likely to obtain the same position for sequential image acquisition."|A prospective, multi-centre single arm study||||
33717327|NCT04043091|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomization in 2 groups||||
33798096|NCT06677073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33942262|NCT00380601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942263|NCT02218346|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101232|NCT02629809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101233|NCT05001165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101234|NCT06688123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101235|NCT06688474|||COHORT||PROSPECTIVE|||||||
34101236|NCT04877691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double Blind (Participant, Care Provider and Investigator) and OLE||t|f|f|f
34101237|NCT04691492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101238|NCT04024657|||COHORT||RETROSPECTIVE|||||||
34101239|NCT02424786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101240|NCT04747626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101241|NCT02113813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101242|NCT05039632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798097|NCT04181255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798098|NCT06105333|||COHORT||RETROSPECTIVE|||||||
33798099|NCT02190578|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798100|NCT01047852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798101|NCT04056039|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A pilot study with 30 patients per group, according to Browne, will be recalculated based on the preliminary result and the power of effect. This is a randomized controlled trial blind to the rheumatologist and the cardiologist who will carry out the evaluation of the patient. The randomization was performed in blocks. Description: Random assignment of n subjects with an equal number in all N conditions can be done by randomizing blocks, where the size of the block is the number of experimental conditions. The number of independent variables and the number of levels in each IV are specified as input. The output is a random design block.|f|t|f|t
33798102|NCT01332058|NA|SINGLE_GROUP||||NONE||||||
33798103|NCT02848638|||CASE_ONLY||PROSPECTIVE|||||||
33798104|NCT05028959|NON_RANDOMIZED|PARALLEL||OTHER||NONE||2 groups : female athletes and leisure sports women||||
33798105|NCT02398617|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33798106|NCT04117789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducting post- and follow-up assessments will be blind to treatment allocation, for the full duration of the trial. The outcome measures are identical for both groups, ensuring that the assessors remain blind. At each follow-up assessment, participants will be reminded by their assessor to not reveal their arm allocation. To measure blinding integrity, all assessors will record whether the participating families inadvertently reveal their group allocation, and subsequently guess each participant's treatment allocation at each assessment point and motivate their choice. The blinding will be broken after the trial's final participant has finished his/her 3-month follow-up assessment (primary endpoint). The trial will end when the trial's final participant has finished his/her 3-month follow-up assessment.||f|f|f|t
33798107|NCT04476472|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, multi-center, prospective clinical study||||
33798108|NCT02379299|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33798109|NCT04692909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798110|NCT00262730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798111|NCT01257555|||COHORT||PROSPECTIVE|||||||
33798112|NCT03977935|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33798113|NCT00002964||||DIAGNOSTIC||||||||
33798114|NCT01069471|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33798115|NCT00638963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798116|NCT05215925|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942264|NCT03519815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942265|NCT05151952|||CASE_ONLY||PROSPECTIVE|||||||
33942266|NCT01098435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942267|NCT05003687|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part A: randomized, double-blind, sequential. Part B: randomized, open-label, cross-over.|t|f|t|f
33717328|NCT02408458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717329|NCT02990091|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33717330|NCT00277290|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717331|NCT02567942|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33717332|NCT01847157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717333|NCT03235076|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33717334|NCT04034381|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33717335|NCT03235154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942268|NCT00990522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942269|NCT04419558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the Open-label extension phase, all participants will receive pamrevlumab in an open-label manner. No unblinding of participant's treatment assignment in the treatment phase (main study) will occur for purposes of open-label extension participation.||t|t|t|t
33942270|NCT05964296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942271|NCT02519127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33942272|NCT06085404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942273|NCT03602209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942274|NCT03220594|||CASE_CONTROL||PROSPECTIVE|||||||
33942275|NCT01365104|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33717336|NCT03791476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Intervention versus placebo|t|t|t|f
33717337|NCT05342259|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33798117|NCT04951492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798118|NCT06554418|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized at the districts level in two regions of Somalia||||
33798119|NCT04231721|||COHORT||PROSPECTIVE|||||||
33798120|NCT05692024|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798121|NCT03045354|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33798122|NCT03688906|||OTHER||PROSPECTIVE|||||||
33798123|NCT00636207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798124|NCT05187780|||OTHER||CROSS_SECTIONAL|||||||
33798125|NCT03156595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798126|NCT01645423|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798127|NCT02034903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798128|NCT03611205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798129|NCT04981158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33798130|NCT00011531|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021233|NCT03052127|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34021234|NCT03177174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021235|NCT03768518|||CASE_ONLY||PROSPECTIVE|||||||
34021236|NCT02485171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021237|NCT00496353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021238|NCT02712060|||CASE_CONTROL||PROSPECTIVE|||||||
34021239|NCT03775759|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled, non-blinded, single center||||
33717338|NCT01057654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33717339|NCT00819221|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717340|NCT04667767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717341|NCT05841251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717342|NCT00000210||||TREATMENT||||||||
33717343|NCT04219332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although it was not feasible to blind the surgeons and participants, the pathologists were unaware of the intervention received by the patients. The researcher performing the statistical analyses was blinded to the patient group allocation.||f|f|f|t
33717344|NCT03590587|||COHORT||RETROSPECTIVE|||||||
33717345|NCT03845907|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Unblinded feasibility study in healthy subjects||||
33717346|NCT00262158|||||OTHER|||||||
33717347|NCT01751867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717348|NCT02738151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717349|NCT01941901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient and treating doctor only knew the size of the treated tumor, and the injection volume, but not the content of the syringe (either calcium or bleomycin).|Patients with cutanoues tumors of any cancer histology were included, and metastases were marked, numbered and photographed. Syringes with either calcium or bleomycin were prepared by a pharmacist, blinded for the treating clinician. After injection of study drug (calcium or bleomycin), electroporation was performed. Metastases were followed and at the 6 month follow-up response was recorded for treated metastases and the actual drug used for each metastasis was revealed.|t|t|t|t
33717350|NCT00529542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717351|NCT01974245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802094|NCT05706870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802095|NCT01534494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802096|NCT05674149|NA|SINGLE_GROUP||OTHER||NONE||||||
33942276|NCT05233319|||FAMILY_BASED||PROSPECTIVE|||||||
33942277|NCT02424708|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33942278|NCT00298766|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942279|NCT03334682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The products used in both arms will be over-encapsulated by the Pharmacy of Nantes University Hospital||t|f|t|f
33942280|NCT02899026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942281|NCT00600639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942282|NCT04136574|||OTHER||PROSPECTIVE|||||||
33942283|NCT03490123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data collection teams separate from the teams responsible for MDA and screening.|Community intervention study|f|f|f|t
33942284|NCT03655015|||OTHER||PROSPECTIVE|||||||
33942285|NCT01562327|||COHORT||PROSPECTIVE|||||||
33942286|NCT00784316|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942287|NCT03221127|||COHORT||PROSPECTIVE|||||||
33942288|NCT01227694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942289|NCT04948840|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"The are 5 groups of patients:~* Group A and B : cohort prospective~* Groups C and D : cohort retrospective~* Group E : control group, samples from French blood establishment~For groups A and B, the only intervention consists in a blood sample."||||
33942290|NCT06106399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthiologist who perform postoperative pain will not know the group.|2 Arms model|t|f|f|t
33942291|NCT01371721||||TREATMENT||NONE||||||
33942292|NCT03655951|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Outcomes Assessor and Care Provider - NA This is a web-based study.||t|t|f|t
33942293|NCT04335227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Lab technician who test the blood samples of the female with Polycystic Ovary Syndrome (PCOS) will be blinded to the trial|Recruited female with PCOS with 128 female with PCOS will be randomly divided into four parallel groups, yoga therapy (YT) group, aerobic exercise (AE) group, combined YT and AE (cYTAE) group and control group|f|f|f|t
33942294|NCT03596840|||COHORT||PROSPECTIVE|||||||
33942295|NCT04622878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942296|NCT05321264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33942297|NCT04846634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802097|NCT06224946|||COHORT||RETROSPECTIVE|||||||
33942298|NCT00000894||PARALLEL||TREATMENT||||||||
33942299|NCT04843527|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942300|NCT00980850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942301|NCT03140150|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33942302|NCT01547494|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33942303|NCT05852964|||CASE_CONTROL||PROSPECTIVE|||||||
33942304|NCT01372020|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942305|NCT03958149|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942306|NCT01734967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942307|NCT01466972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021240|NCT03205891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021241|NCT05960812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942308|NCT01688362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942309|NCT00350610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942310|NCT01493024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33942311|NCT01945229|||COHORT||PROSPECTIVE|||||||
33942312|NCT04920305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942313|NCT00495794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942314|NCT02241460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101243|NCT02013284|||COHORT||PROSPECTIVE|||||||
34101244|NCT06440746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942315|NCT04849429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomly selected based on computer generated number to receive one undistinguishable injection of PRP ex or placebo.|"1. Arm I will be assigned to receive placebo (trigger point injection under carm)~2. Arm II: to receive PRP with exosomes at the center of the nucleus pulposus (2ml)"|t|f|t|t
33942316|NCT02337075|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This study used a delayed control design||||
33942317|NCT03104686|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Personnel involved in randomization, in the analyses of the samples collected, and who were involved in the data processing were blinded.||f|f|f|t
33942318|NCT01284127|||COHORT||PROSPECTIVE|||||||
33717352|NCT06203860|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Randomization in the ProtecT-2-D is carried out using the Randomization Module in the electronic Case Report Form (e-CRF) system, REDCap. To ensure concealed allocation the allocation table is created by a REDCap team member, who is independent of the ProtecT-2-D project staff.~Participants will be randomized to either the Cardio-Metabolic Clinic or usual care in a ratio of 2:1~1. Cardio-Metabolic Clinic~2. Usual care"||||
33717353|NCT03297996|||CASE_CONTROL||PROSPECTIVE|||||||
33717354|NCT00284661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717355|NCT05877781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind, placebo controlled study|t|t|t|t
33717356|NCT04112836|||COHORT||PROSPECTIVE|||||||
33717357|NCT05872672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33717358|NCT01858090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717359|NCT03117712|||COHORT||PROSPECTIVE|||||||
33717360|NCT05450341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and the outcomes assessor (speech and language therapist conducting the assessment tests and the eyetracking experiment) will be blind as to which experiment group the participant belongs to. The investigator / clinician providing rTMS will not be blind to the experimental condition.|The two groups receive one of the two treatments: right frontal versus right temporal stimulation.|t|f|f|t
33717361|NCT02671422|||COHORT||PROSPECTIVE|||||||
33717362|NCT05142865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717363|NCT01490476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717364|NCT01365325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33717365|NCT05823584|||COHORT||PROSPECTIVE|||||||
33717366|NCT03679650|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717367|NCT03791840|||COHORT||PROSPECTIVE|||||||
33717368|NCT00837304|||CASE_CONTROL||PROSPECTIVE|||||||
33717369|NCT03643640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717370|NCT03140384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717371|NCT01806831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717372|NCT03362398|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717373|NCT00421538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717374|NCT02424747|||COHORT||PROSPECTIVE|||||||
33717375|NCT04963933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717376|NCT03382938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Investigator, Outcomes Assessor)|Parallel Assignment|f|f|t|t
33717377|NCT03861715|||COHORT||PROSPECTIVE|||||||
33717378|NCT05336799|||COHORT||PROSPECTIVE|||||||
33717379|NCT05534750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717380|NCT03867305|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33717381|NCT05548829|||CASE_ONLY||RETROSPECTIVE|||||||
33717382|NCT04579692|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33717383|NCT06123104|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33717384|NCT06411704|||COHORT||PROSPECTIVE|||||||
33717385|NCT02168179|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717386|NCT05615571|||COHORT||RETROSPECTIVE|||||||
33717387|NCT03578991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717388|NCT01506479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717389|NCT02060149|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33717390|NCT00909389|||COHORT||PROSPECTIVE|||||||
33717391|NCT04062331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blind. Investigator who applies transcranial stimulation knows the kind of treatment (placebo, TMS 1 Hertz, TMS 5 Hertz). The patients don't know the frequency (measured Hertz) which TMS is running (0 Hertz= placebo, 1 Hertz, 5 Hertz) and the device and duration of sessions are the same.|"Phase I clinical trial, unicentric, controlled, randomised, single blind. Three arms.~The patients included will be assigned under the 1:1:1 randomization formula, constituting three groups for the present study: 30 patients treated with natalizumab + white (placebo) + 30 patients treated with natalizumab + TMS (1 Hertz) + 30 patients treated with natalizumab + TMS (5 Hertz)."|t|t|f|t
33717392|NCT03886350|||CASE_CONTROL||PROSPECTIVE|||||||
33717393|NCT05891587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, between-subject, double-blind, and placebo-controlled.|t|f|t|t
33717394|NCT03615976|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is prospective case series study The aim is to evaluate the effect of arthroscopic denervation of patella In management of ant. Knee after High tibial osteotomy operation in pain reduction, improving knee joint function, quality of life, and deferring arthritic progression||||
33717395|NCT02496650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717396|NCT04676646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All participants entering the double-blind, randomised treatment period will be centrally assigned to randomised study intervention using an Interactive Response Technology/Randomisation and Trial Supply Management (IRT/RTSM). Randomisation will be stratified by the sK+ cohort determined by central laboratory at the start of the open-label phase (Day 1). Before the study is initiated, the telephone number and call-in directions for the IRT and/or the log in information and directions for the RTSM will be provided to each site.~The IRT/RTSM will provide to the investigator(s) or pharmacists the kit identification number to be allocated to the participant at the dispensing visit. Routines for this will be described in the IRT/RTSM user manual that will be provided to each centre.~The randomisation code should not be broken except in medical emergencies when the appropriate management of the participant requires knowledge of the treatment randomisation."|REALIZE-K is a Phase 4, multinational, multicenter, double-blind, placebo-controlled, randomized-withdrawal, parallel-group study.|t|f|t|f
33717397|NCT00679146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717398|NCT03403595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798131|NCT05253664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants didn't know which group they were allocated. The participants will be blind when they take Woman-Centered Care from investigators.|The study was conducted as a single blind, prospective, and simple randomized controlled trial. The sample was calculated through Power analysis. In the power analysis, the sample size was calculated as a minimum of 105 for each group, according to α:0.05 and 1-β= 0.95. Considering the possibility of loss or separation of the selected specimens during the conduct of the study, 240 women who met the inclusion criteria were assigned to the experimental (120) and control (120) groups. The size and number of blocks divided into two groups as E and C was calculated as 20 (6E and 6C) with twelve mothers in each block. Using Microsoft Office Excel 2016, numbers ranging from 1 to 20 were randomly generated. A total of 240 mothers were evenly assigned to both groups. At the time of the study, 22 women were excluded from the study. The research was completed with 218 mothers, 109 women in each of the experimental and control groups.|t|f|f|f
33798132|NCT01366898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798133|NCT00995306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798134|NCT04459169|||CASE_ONLY||PROSPECTIVE|||||||
33798135|NCT03802708|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|this is N/A|pilot. 5 children with FASD- 5 healthy children||||
33798136|NCT00587652|||COHORT||PROSPECTIVE|||||||
33798137|NCT02743078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798138|NCT04981015|||COHORT||RETROSPECTIVE|||||||
33798139|NCT01763970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798140|NCT00172224|||CASE_ONLY||PROSPECTIVE|||||||
33798141|NCT06399679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33798142|NCT00855400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798143|NCT01128075|||COHORT||PROSPECTIVE|||||||
34021242|NCT03043859|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants who have consented to participate in this study will be assigned a number, those who receive an even number will be assigned to the intervention arm and those who receive an odd number will be in the control arm.|This is a randomized, controlled trial of two arms \[intervention (PPLP) and wait-listed controls (CON)\]. Baseline data will be collected from all participants. PPLP participants will then receive 5 educational session on healthy eating, behaviour change and lifestyle in addition to usual care, whereas the controls will only receive usual care (no education intervention). Data for primary outcomes will be collected at 3 and 6 month period (from baseline). After the 6 month assessment all participants from the Control group will then recieve intervention and will complete the 3 and 6 month assessments.|t|f|t|f
34021243|NCT00899990|||COHORT||PROSPECTIVE|||||||
34021244|NCT02447744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021245|NCT02623348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021246|NCT03802253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021247|NCT03123458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021248|NCT04571151|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind study. Medication's label will be covered. Only the study coordinator would be able to identify the medication.|Subjects will be randomized to study treatment at a 1:1 ratio: of Lexette plus Sorilux for 2 weeks versus Lexette plus vehicle for 2 weeks. Those subjects who are clear or almost clear at the end of 2 weeks will be re-randomized into Sorilux for 6 weeks versus vehicle for 6 weeks at 1:1 ratio.|t|f|t|f
34021249|NCT04131777|||COHORT||PROSPECTIVE|||||||
34021250|NCT00357084||||SUPPORTIVE_CARE||||||||
34021251|NCT01226771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021252|NCT04439695|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021253|NCT02465294|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34021254|NCT06303479|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021255|NCT03713775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open-label randomised controlled study and patients will be aware of their treatment allocation. Potentially subjective measurements will be undertaken by observers blinded to treatment allocation; in particular, all imaging and ECG monitoring data will be anonymised prior to post-processing, and PPT score will be assessed by a research nurse blinded to treatment allocation. All study assessments will be coded and recorded blinded to treatment allocation.||f|f|f|t
34021256|NCT01458730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021257|NCT05396261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021258|NCT04405167|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label phase 1 study with pilot expansion cohorts at the maximum tolerated dose||||
34021259|NCT01375153|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34021260|NCT01857271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021261|NCT02936453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021262|NCT01470911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34021263|NCT05177718|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, prospective longitudinal study.||||
34021264|NCT06088134|||COHORT||RETROSPECTIVE|||||||
34021265|NCT00095316|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34021266|NCT02519738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021267|NCT00093873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021268|NCT03617757|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective and Cohort study (Compare different cohorts)||||
34021269|NCT04058249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021270|NCT02410980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021271|NCT03382730|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Multi-centered stepped wedge cluster randomized controlled trial|f|f|f|t
34021272|NCT04243083|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34021273|NCT04237337|||CASE_CONTROL||RETROSPECTIVE|||||||
34021274|NCT04047914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher responsible for performing the treatments (which will open the randomization envelopes) will know which treatment is assigned to each patient. The researcher responsible for collecting the microbiological samples (nasal discharge) and the microbiologist will be blind to the treatments assigned to the groups (they do not know the nature of treatments). The patient will not be blinded in view of the difference between the nature of the treatments.|34 individuals will be randomly divided into 2 groups: G1 - Experimental Group (n = 17) - Treatment will be performed with methylene blue and red light-emitting diode (LED) in the nostrils. G2 - Control group (n = 17) - Standard treatment will be performed conventionally with topical mupirocin.|f|f|f|t
34021275|NCT03715361|||COHORT||PROSPECTIVE|||||||
33798144|NCT04152317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33798145|NCT00705588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798146|NCT00955695|RANDOMIZED|||PREVENTION||||||||
33942319|NCT00121459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942320|NCT03374228|NA|SINGLE_GROUP||OTHER||NONE||||||
33942321|NCT02638285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942322|NCT02902276|||CASE_ONLY||PROSPECTIVE|||||||
33942323|NCT05297240|||CASE_ONLY||RETROSPECTIVE|||||||
33942324|NCT05153252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33942325|NCT00004333||||TREATMENT||||||||
33942326|NCT00626327|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33942327|NCT06454227|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33942328|NCT01398631|||COHORT||PROSPECTIVE|||||||
33942329|NCT00000799|RANDOMIZED|||TREATMENT||||||||
33942330|NCT01903096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A computer-generated allocation sequence was used to randomly assign patients (1:1) to receive either TD-GCBT plus TAU or TAU alone. All patients were assigned a code for blinding purposes and then the patient characteristics were sent to one of the investigators to check that they met the inclusion criteria. Patients who met the inclusion criteria were then randomized as described above.|Randomised, controlled, two arm single-blind trial|f|f|t|t
33942331|NCT05910489|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942332|NCT05290389|||CASE_ONLY||PROSPECTIVE|||||||
33942333|NCT03654638|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942334|NCT05161949|||CASE_CONTROL||PROSPECTIVE|||||||
33942335|NCT04627389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942336|NCT00702949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33942337|NCT04063059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33942338|NCT01967082|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33942339|NCT02384629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942340|NCT02063906|||OTHER||RETROSPECTIVE|||||||
33942341|NCT05791487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician||f|t|f|f
33942342|NCT04930133|||CASE_ONLY||RETROSPECTIVE|||||||
33942343|NCT05804344|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Device is pre-set so that individual applying stimulation does not know what condition is being applied. Participants are not informed either. All data are coded by individuals who are not informed as to the condition of the participants.|All five groups are compared in a linear mixed effects model.|t|t|t|t
33942344|NCT00158301|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33942345|NCT04694079|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, multicentric open-label study with control group. Superiority of VT ablation including myocardial scar characterization (group 1+2) in comparison with only EAM-guided ablation (group 3: control) in terms of 12-months freedom of recurrences, will be evaluated as primary hypothesis.||||
33942346|NCT05891457|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33942347|NCT00245726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942348|NCT01360892|||||PROSPECTIVE|||||||
33942349|NCT02051257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942350|NCT01049789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942351|NCT02406599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33942352|NCT05080686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The surgeon will not know the patients' group before or during the surgery. The outcome assessor will not know the group during the whole research.||f|t|f|t
33942353|NCT01226602|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33942354|NCT00526227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942355|NCT03861832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are assigned to one of two or more groups in parallel for the duration of the study|t|t|f|t
33942356|NCT02872090|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33942357|NCT03973827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942358|NCT00753233|||||RETROSPECTIVE|||||||
33942359|NCT06077409|RANDOMIZED|PARALLEL||PREVENTION||NONE||Premature babies who apply to the blood collection room to take blood, were included in the gentle human touch, skin to skin and control groups. Randomization occurred on: www.randomizer.org||||
33942360|NCT04244227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research staff will not provide any details that would cause participants to become unblinded to the treatment groups.|At enrollment, participants will be randomized (1:1) to receive either the active or sham treatment for the duration of the 3-week study.|t|f|f|f
33942361|NCT01496781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942362|NCT02949544|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
33942363|NCT04264260|NA|SINGLE_GROUP||TREATMENT||NONE||open labeled||||
33942364|NCT05689294|||COHORT||PROSPECTIVE|||||||
33942365|NCT03866824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942366|NCT03918356|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33942367|NCT01442142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942368|NCT00836199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942369|NCT01807442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942370|NCT02857049|NA|SINGLE_GROUP||||NONE||||||
33942371|NCT02917161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942372|NCT01446744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942373|NCT04416074|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942374|NCT02249377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942375|NCT00954356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942376|NCT02200549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942377|NCT05381272|||CASE_CONTROL||RETROSPECTIVE|||||||
33942378|NCT06358261|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||pilot group-randomized controlled trial|f|f|f|t
33942379|NCT05560412|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The products (experimental and Placebo), will be produced by an external producer, who will retain the codes. None of the researchers involved in the study development or analyses will know the association until the end of the study.|Randomised, double blind crossover intervention|t|t|t|t
33942380|NCT01234558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942381|NCT02155660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101245|NCT05216146|RANDOMIZED|PARALLEL||OTHER||TRIPLE|All subjects except the main investigator will be blinded for group allocation and physical training program, including coaches (care provider), soldiers (participants) and outcomes assessors.|Randomized controlled trial|t|t|f|t
34101246|NCT06454487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101247|NCT03266640|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients will be given CMV specific CTLs and dose is based on donor source: HLA matched and HLA mismatced||||
34101248|NCT06689501|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A single-centre, double-blind, placebo-controlled, 2-arm, 12-week trial with randomisation to either the study product (blend of ingredients composed of L-carnitine tartrate, dihydrocapsiate and protein yeast hydrolysate) or placebo.|t|t|f|f
34103420|NCT06688617|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33717399|NCT02353598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717400|NCT04844632|||COHORT||PROSPECTIVE|||||||
33717401|NCT00148187|||COHORT||PROSPECTIVE|||||||
33717402|NCT01091493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717403|NCT06164223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"There are two Groups with parallel properties. The first group is the experimental group using virtual reality glasses.~The second group is the control group without intervention."||||
33717404|NCT01725620|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33717405|NCT03835494|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Transthoracic echocardiography including TDI is performed at rest, during PLR, HG and CPX in Fallot patients and healthy controls. In Fallot patients, transthoracic ultrasound at rest and during CPX are part of the routinely follow-up. PLR and HG were performed additionally as part of the investigator's study to analyze TDI parameters during various endurance testings||||
33717406|NCT05217433|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This is a single-centre, double-blind, placebo controlled, randomised 2-arms parallel group study.|This is a single-centre, double-blind, placebo controlled, randomised 2-arms parallel group study.|t|f|t|t
33717407|NCT02518828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717408|NCT04682067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717409|NCT00754611|||CASE_ONLY||PROSPECTIVE|||||||
33717410|NCT05357274|||COHORT||PROSPECTIVE|||||||
33717411|NCT01084174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717412|NCT05390957|NA|SINGLE_GROUP||TREATMENT||NONE||The study is an open label, single site, single arm, pilot study. The primary goal of the study is to examine the efficacy of the ABBT-R program via comparison of pre-treatment and post-treatment scores on measures of pain and other related concerns, as well as examination of participant satisfaction with the program.||||
33717413|NCT02924220|||CASE_CONTROL||RETROSPECTIVE|||||||
33717414|NCT03842098|||COHORT||PROSPECTIVE|||||||
33717415|NCT02651298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717416|NCT05520931|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33717417|NCT02738450|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33717418|NCT04889469|||CASE_CONTROL||PROSPECTIVE|||||||
33717419|NCT00661622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717420|NCT03709160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717421|NCT02111772|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717422|NCT02953327|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33717423|NCT04876443|||CASE_ONLY||PROSPECTIVE|||||||
33717424|NCT03263494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717425|NCT03134989|NA|SINGLE_GROUP||OTHER||NONE||||||
33717426|NCT03019302|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717427|NCT06117150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717428|NCT06299033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798147|NCT05339893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient will not know whether they are receiving taVNS, all patients will feel a tingling in the ear as the current is ramped up and then down to determine a stimulation threshold, but only the active group will receive timed stimulation bursts during the robotic protocol that engages the affected limb. The measuring clinician will not know a patient's group assignment.|To determine whether treatment with taVNS during the robotic training of a patient with stroke and a paralyzed arm will alter the motor impairment.|t|f|t|f
33798148|NCT06383117|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Investigator, participants, team distributing pills blinded to treatment arm|Randomized placebo crossover trial|t|t|t|t
33798149|NCT01302236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798150|NCT01408849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798151|NCT03013452|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 modes of physiotherapy: 1- autogenic drainage; 2- oscillating positive expiratory pressure device||||
34103421|NCT02018679|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33717429|NCT05249361|||COHORT||PROSPECTIVE|||||||
33717430|NCT02814253|||COHORT||PROSPECTIVE|||||||
33717431|NCT00247884|||CASE_CONTROL||PROSPECTIVE|||||||
33717432|NCT00050596|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717433|NCT05696678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the anesthesiologist in charge in the operating room will be aware of treatment group.|Randomized double-blinded and controlled study|t|f|t|t
33717434|NCT01269060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717435|NCT02520401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717436|NCT02454881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33717437|NCT03433768|||CASE_CONTROL||PROSPECTIVE|||||||
33717438|NCT03966378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717439|NCT02634762|||COHORT||PROSPECTIVE|||||||
33717440|NCT04464343|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33717441|NCT04573816|||COHORT||PROSPECTIVE|||||||
34103422|NCT00534586|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34103423|NCT06535893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103424|NCT05607849|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Label|Parallel Assignment||||
34103425|NCT05875831|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33717442|NCT01991015|||||CROSS_SECTIONAL|||||||
33798152|NCT00933400|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33717443|NCT00785395|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33717444|NCT00442975|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33717445|NCT02430584|||FAMILY_BASED||PROSPECTIVE|||||||
33717446|NCT03590145|||CASE_ONLY||CROSS_SECTIONAL|||||||
33717447|NCT00447642|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33717448|NCT00191555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717449|NCT02842918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717450|NCT03499223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717451|NCT01554423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717452|NCT06066645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33717453|NCT02584114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717454|NCT00708006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717455|NCT01306357|||CASE_ONLY||PROSPECTIVE|||||||
33717456|NCT02311010|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717457|NCT01589744|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33717458|NCT04041804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717459|NCT00170053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717460|NCT03886376|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||For the control group, immediately after the resistance training the athletes were instructed to wait for 12 minutes until the beginning of the swimming training. The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures. The superficial massage group received superficial massage on the same sites than the intervention group. The three conditions were performed after a resistance training and before a swimming training.|t|f|f|t
33717461|NCT05199298|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33717462|NCT03487029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717463|NCT02278588|||CASE_CONTROL||PROSPECTIVE|||||||
33717464|NCT02237859|NA|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33717465|NCT05859789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717466|NCT00168727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717467|NCT03894579|NA|SINGLE_GROUP||TREATMENT||NONE|open-label|Non-randomized, open label, single center trial. Subjects will receive SNK01 using a 3 + 3 dose escalating design||||
33717468|NCT00047814|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33717469|NCT06261320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717470|NCT02176876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717471|NCT03921554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717472|NCT06228560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33717473|NCT05373329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717474|NCT03773705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717475|NCT02315170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33717476|NCT03106220|RANDOMIZED|CROSSOVER||PREVENTION||NONE||home exercise vs standard care with cross-over||||
33717477|NCT03249298|RANDOMIZED|PARALLEL||TREATMENT||NONE||one group will get crystalloids and one grou will get colloids for fluid optimisation||||
33717478|NCT02033122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33717479|NCT05653687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717480|NCT01938599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717481|NCT06261554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717482|NCT03357159|NA|SINGLE_GROUP||TREATMENT||NONE||The patients will get conventional GVHD prophylaxis consisting of ATLG 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation. Cyclophosphamide at 25mg/kg dose will be administrated at day +3 post infusion of the stem cell (SC) graft to the first 3 patients. If no \> grade II toxicity\* occurs, the next 3 patients will receive cyclophosphamide at 25mg/kg dose at day +3 and +4 post SC graft infusion. If no \> grade II toxicity\*occurs, the next 3 patients will receive cyclophosphamide at 37.5 mg/kg dose at day +3 and +4 post SC graft infusion. If no \> grade II toxicity\* occurs, the next 3 patients will receive the target dose of cyclophosphamide at 50 mg/kg dose on day +3 and +4 post SC graft infusion. The residual 18 patients will receive cyclophosphamide at the maximal tolerated dose (MTD) established in the first part of the study. Patients will also receive GVHD prophylaxis consisting of a cyclosporine and cellcept starting on day +5 after transplantation.||||
33717483|NCT03838640|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33717484|NCT04217473|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single arm, dose escalation||||
33717485|NCT05780567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717486|NCT00081380|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33717487|NCT04226378|||COHORT||RETROSPECTIVE|||||||
33717488|NCT01761110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717489|NCT01521455|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717490|NCT05838885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717491|NCT05467436|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33717492|NCT03460483|NA|SINGLE_GROUP||SCREENING||NONE||||||
33717493|NCT04123054|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, randomized, controlled, two-way parallel study to compare glucose control between sensor-augmented MDI therapy and our basal-bolus optimizing algorithm over 3 months. Adults with type 1 diabetes who are enrolled in the study will randomly undergo one of the two interventions for the entire study duration.||||
33717494|NCT02326376|||COHORT||PROSPECTIVE|||||||
33717495|NCT01435954|||COHORT||RETROSPECTIVE|||||||
33717496|NCT01533233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717497|NCT05885789|||OTHER||PROSPECTIVE|||||||
33717498|NCT06360666|||COHORT||RETROSPECTIVE|||||||
33717499|NCT05871827|||COHORT||RETROSPECTIVE|||||||
33717500|NCT01344161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798153|NCT06154746|||COHORT||PROSPECTIVE|||||||
33798154|NCT00214266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798155|NCT04346732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In both groups, immediately following venipuncture, pain assessment was made with the VAS by the researcher, who did not know which group each participant belonged to.|The participants were separated into two groups with the randomisation method.These groups were named the vapocoolant spray group and the control group|f|f|t|f
33798156|NCT03786991|||COHORT||PROSPECTIVE|||||||
34101249|NCT05441449|RANDOMIZED|FACTORIAL||DEVICE_FEASIBILITY||NONE||"After the cooling vest has been fully bench-tested, two phases (AB safety; SCI efficacy) will be performed.~Phase 1 (Safety): Descriptive design: because persons with SCI have impaired sensation, one group of able-bodied (AB) participants will wear the wet smart cooling vest during a heat challenge (sitting in a warm room) to determine its safety.~Phase 2 (Efficacy): 1 x 2 Repeated Measures design: one group of persons with Hi-SCI will undergo 2 heat challenges (sitting in a warm room) under 2 conditions (experimental: wet vest, control: no vest) in random order to determine efficacy of the cooling vest in maintaining Tcore and thermal comfort.."||||
34101250|NCT03000803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101251|NCT06348589|||COHORT||CROSS_SECTIONAL|||||||
34101252|NCT05325944|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34101253|NCT00792948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101254|NCT04825587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The overall aim of this multicenter RCT is to determine whether concomitant ALL reconstruction in children undergoing and ACL reconstruction will result in a lower rate of graft failure than ACL reconstruction alone.|t|f|f|f
34101255|NCT05930067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101256|NCT05995665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34101257|NCT05061095|||COHORT||PROSPECTIVE|||||||
34101258|NCT02684292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717501|NCT02560584|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a prospective, open, comparative, within-patient controlled Phase 3 multicenter study in patients with bladder cancer. There is a maximum of three study visits for an enrolled patient:~Visit 1: Screening visit Visit 2: Surveillance cystoscopy in white light (WL) followed by blue light (BL) Visit 3: Operating room (OR) cystoscopy in WL followed by BL for patients with suspicion of recurrence after surveillance cystoscopy.~Cystoscopy in WL followed by BL is performed in all patients after Cysview instillation. Only patients with suspicious lesions at Visit 2 continue to a second cystoscopy in WL followed by BL at Visit 3."||||
33717502|NCT01455337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33717503|NCT05817188|||COHORT||PROSPECTIVE|||||||
33717504|NCT01148758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101259|NCT00292370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101260|NCT01029964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101261|NCT00935909|||CASE_CONTROL||PROSPECTIVE|||||||
34101262|NCT06690021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent anesthesiologist randomly using computer-generated random numbers divided the patients into 2 groups :(Group 1 and Group 2). Each group will include 15 patients. We discreetly placed the randomization results in envelopes until the end of the study. The researchers who were responsible for postoperative follow-up and data processing were blinded to the group allocation during the whole study period. All patients were also blinded to the group allocation||t|t|t|t
34101263|NCT01830101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101264|NCT04857983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized to TCT and memantine or TCT and placebo. The research will be provided with a randomization scheme to follow and will dispense the pills identified only by a code.|Subjects will be randomized to targeted cognitive training (TCT) and memantine (MEM) or targeted cognitive training (TCT) and placebo (PBO)|t|f|t|f
34101265|NCT05491980|||OTHER||PROSPECTIVE|||||||
34101266|NCT03033576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101267|NCT06694623|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Split mouth||||
34101268|NCT04553536|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33717505|NCT02969512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33717506|NCT01821365|||||PROSPECTIVE|||||||
33717507|NCT00743314||||DIAGNOSTIC||NONE||||||
33717508|NCT03258489|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33717509|NCT00933309|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717510|NCT00536601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717511|NCT04837157|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33717512|NCT06456060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded about the use of honey or Alveogyl in the dressing.|"Patients will be divided into the following two groups:~1. Study group~2. Control group~In the study group, after flushing the socket with normal saline, 2 ml of Honey soaked in a sterile gauze will be applied to cover the socket, whereas in the control group, a gauze with Alveogyl will be used to cover the socket instead of Honey."|t|f|f|f
33717513|NCT04337749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single blind controlled trial between participants, drug preparing team, doctors, investigators, and outcome assessors.||f|f|t|t
33798157|NCT00382681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798158|NCT01082809|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798159|NCT01954797|||CASE_CONTROL||PROSPECTIVE|||||||
33798160|NCT05176106|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parishes will be randomized to intervention or control. VHTs in the intervention parishes will receive the incentives package as part of the intervention.||||
33798161|NCT00765778|||CASE_ONLY||PROSPECTIVE|||||||
33798162|NCT06235424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798163|NCT04053816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798164|NCT04985136|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized，Open，Controlled, International Multi-Center||||
34101269|NCT05436444|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34101270|NCT05614336|NA|SINGLE_GROUP||OTHER||NONE||||||
34101271|NCT06686810|||COHORT||RETROSPECTIVE|||||||
33798165|NCT03511651|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33798166|NCT05944003|||COHORT||RETROSPECTIVE|||||||
34101272|NCT06689657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Adolescent group therapy (CARES) and parent group therapy (RNV) vs Adolescent groupe therapy (CARES) only|t|f|f|f
33798167|NCT02537483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33798168|NCT03174171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798169|NCT04723394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798170|NCT03883529|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a pilot feasibility study, exploring a new type of intervention after birth, for women who had their antenatal care provided at a high-risk maternity clinic. The intervention involves women writing about and reviewing their birth experience, six to eight weeks after birth, with the midwife who provided antenatal care.||||
34101273|NCT01580722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101274|NCT01385995|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34101275|NCT06084052|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|The participants will be randomised (using 'sealed envelope') to either 'care as usual' or 'use of device'.|||||
33798171|NCT02287441|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34101276|NCT06686420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101277|NCT01433965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101278|NCT06688240|||COHORT||PROSPECTIVE|||||||
34101279|NCT06694909|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34101280|NCT03905174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34101281|NCT06035510|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101282|NCT05264675|||COHORT||PROSPECTIVE|||||||
34101283|NCT06448143|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101284|NCT02759263|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34101285|NCT05362799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101286|NCT05784597|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Patients are divided into two cohorts:~* Cohort A: 3 female + 3 male patients with a primary tumor only~* Cohort B: patients with a primary tumor and/or advanced/metastatic disease with a quantifiable number of lesions (6 - 14 patients)"||||
33798172|NCT04125810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798173|NCT06354140|NA|SINGLE_GROUP||TREATMENT||NONE|The study was a one-arm open study|||||
33798174|NCT04780035|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942382|NCT02558595|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33717514|NCT04212104|RANDOMIZED|PARALLEL||OTHER||SINGLE||The study randomly assigned participants to watch either a mukbang, or a non-food content video. Participants report their attitudes such as satiation and disgust, and report their desire to eat several kinds of foods after watching the assigned video.|t|f|f|f
33942383|NCT05519891|||COHORT||PROSPECTIVE|||||||
33942384|NCT03216564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942385|NCT03547882|||OTHER||OTHER|||||||
33942386|NCT00701181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942387|NCT03536689|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||Factorial 2-by-2 open labeled randomised controlled trial||||
33942388|NCT01966952|||COHORT||PROSPECTIVE|||||||
34101287|NCT05538130|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101288|NCT00382928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101289|NCT03765359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|placebo controlled||t|t|t|f
34101290|NCT05390827|||COHORT||PROSPECTIVE|||||||
34101291|NCT06359626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-way crossover||||
34101292|NCT06690203|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Open Label|||||
34101293|NCT05948943|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Stage 1 is open label. For adult and pediatric participants 6-17 years of age, Stage 2 comprises a 24-week double-blind period followed by an open-label period. For pediatric participants 2-5 years of age, Stage 2 is open label.||t|t|t|t
34101294|NCT04879732|NA|SINGLE_GROUP||OTHER||NONE||||||
34101295|NCT04963413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717515|NCT01199523|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33717516|NCT03352206|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33717517|NCT00044356||PARALLEL||TREATMENT||NONE||||||
33717518|NCT04904887|NA|SINGLE_GROUP||TREATMENT||NONE||patients undergoing cataract surgery are managed with phacoemulsification and insertion of Eyehance intraocular lens in order to improve their intermediate vision.||||
33717519|NCT04700618|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Study group is PPV23 revaccination and control group PPV23-vaccination.||||
33717520|NCT04519151|NA|SINGLE_GROUP||TREATMENT||NONE|Open Lable|single arm||||
33717521|NCT00656474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717522|NCT02324374|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33717523|NCT02396433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717524|NCT01454947|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33717525|NCT05058443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33717526|NCT01716598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717527|NCT00045500||||TREATMENT||||||||
33717528|NCT04462003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||t|f|f|f
33717529|NCT05585697|||OTHER||CROSS_SECTIONAL|||||||
33717530|NCT05460117|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33717531|NCT05589233|||COHORT||RETROSPECTIVE|||||||
33717532|NCT04730245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717533|NCT01072812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717534|NCT02805621|||COHORT||RETROSPECTIVE|||||||
33717535|NCT03958721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717536|NCT05278247|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||confirmatory, open, single-arm, mono-centric||||
33717537|NCT02826031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101296|NCT06114485|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34101297|NCT06132360|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34101298|NCT03328273|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942389|NCT00043992|||DEFINED_POPULATION||PROSPECTIVE|||||||
33942390|NCT03955289|||OTHER||RETROSPECTIVE|||||||
33942391|NCT03440606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||participants will be randomly assigned to either the intervention or waitlist control group. Those assigned to in the intervention group will attend 6 weekly Mindful-Compassion Art Therapy supervision led by a credentialed art therapist and an experienced mindfulness practitioner at the training facilities of HCA. Each session will last for 3 hours and each group will consists of 15 participants. Outcome assessments will be conducted at two-time-points: immediately after intervention \[T2\] and four weeks post intervention \[T3\]. Those assigned to the waitlist control group will receive no intervention until approximately three month later; equivalent intervention and assessment procedures will be administered.||||
33942392|NCT00129220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942393|NCT01028794|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942394|NCT00072215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942395|NCT05836428|||CASE_CONTROL||RETROSPECTIVE|||||||
33942396|NCT01156246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33942397|NCT02036567|||COHORT||PROSPECTIVE|||||||
33942398|NCT05342376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Two color coded envelops containing drug and placebo.|Parallel Assignment The study design is prospective double-blinded randomized controlled parallel trial with allocation ratio of 1:1.|t|t|f|f
33942399|NCT04414150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101299|NCT05230407|||COHORT||PROSPECTIVE|||||||
34101300|NCT06694883|||COHORT||PROSPECTIVE|||||||
34101301|NCT06059339|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34101302|NCT00005078||||TREATMENT||||||||
34101303|NCT01217411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101304|NCT03285893|||COHORT||PROSPECTIVE|||||||
34101305|NCT05059522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798175|NCT03310112|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Participants will be assigned into three groups: (i) a 4-week MT group (MT4, n = 40) that will receive MBAT in 4, 2-hour sessions over 4 weeks; (ii) a 2-week MT group (MT2, n = 40) that will receive MBAT in 4, 2-hour sessions over 2 weeks; (iii) a no-training control group that will be tested before and after a no-training interval (NTC4, n = 40). After the end of the course sessions, participants from the training groups will still be assigned homework exercises until third testing session (T3). Hence, the MBAT program consists of delivery of the MBAT course, including homework mindfulness practice, and followed by an interval of homework mindfulness practice without course meetings.~The design relies on group randomization at the level of individual military cohort units. This is due to the military requirement that organic unit structure can be maintained during testing and course session scheduling."||||
33798176|NCT03801967|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This study is single-blind (in which the study center staff have to remain blinded during the clinical conduct of a given cohort) with regard to treatment (AZD9977 or placebo) at each dose level. AZD9977 and placebo will be matched for formulation, appearance, and amount.|Multiple ascending dose, placebo-controlled, single blind sequential group design|t|f|f|f
33798177|NCT04975945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798178|NCT03264261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures of each subject will be evaluated before training, after 6 weeks of training, and at 8 weeks after the end of training by a physical therapist who is blinded by subject group assignment, and subjects will be requested not to disclose his/her group assignment to this physical therapist.|Subjects will be blocked by gait speed into slow (\< 0.4 m/s) or fast (≥ 0.4 m/s) subgroups and randomized to either the CIMT or treadmill training only groups at the initial test.|f|f|f|t
33798179|NCT01377428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798180|NCT06014775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798181|NCT05346978|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33798182|NCT00173446|||DEFINED_POPULATION||OTHER|||||||
33798183|NCT01256736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798184|NCT01541631|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33798185|NCT05384496|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single center trial enrolling up to 20 evaluable total patients.||||
33798186|NCT04338893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942400|NCT04998175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942401|NCT03467035|||COHORT||PROSPECTIVE|||||||
33942402|NCT01678469|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798187|NCT02095327|||COHORT||RETROSPECTIVE|||||||
33798188|NCT01496521|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798189|NCT05758597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798190|NCT02903615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798191|NCT00749749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798192|NCT02772263|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33942403|NCT01265511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942404|NCT00877929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33942405|NCT01741285|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942406|NCT05601271|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34021276|NCT00742066|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34021277|NCT00315237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021278|NCT04013984|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34021279|NCT02717897|||COHORT||CROSS_SECTIONAL|||||||
34021280|NCT02592135|||COHORT||PROSPECTIVE|||||||
34021281|NCT02337296|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101306|NCT06675981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101307|NCT05495230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cluster randomized controlled trial|f|f|f|t
34101308|NCT05478824|||COHORT||PROSPECTIVE|||||||
34101309|NCT04276701|NA|SINGLE_GROUP||OTHER||NONE||||||
34021282|NCT01851200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021283|NCT03630250|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Cohort||||
34021284|NCT00420459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021285|NCT02099682|||COHORT||PROSPECTIVE|||||||
34101310|NCT05979272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101311|NCT06466161|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized, non blinded trial||||
33798193|NCT00217841|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33798194|NCT04319874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798195|NCT02259543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798196|NCT02869022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798197|NCT00357097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798198|NCT03036813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is a double-blind study.||t|t|t|f
33798199|NCT02534311|||CASE_CONTROL||PROSPECTIVE|||||||
33798200|NCT03411369|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind study design. The dietary supplement of Creatine, D-Ribose, B1 Vitamin, and B6 vitamin will come in the form of water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin. The same administration will come for placebo group with the inert product sachets consisting of starch powder.|Two groups, one receiving treatment (Creatine, D-Ribose, B1 Vitamin, and B6 vitamin), and one receiving placebo.|t|f|t|f
33798201|NCT03957798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798202|NCT03062358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798203|NCT05531032|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Phone Interview||||
33798204|NCT05157022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798205|NCT04641741|||CASE_CONTROL||PROSPECTIVE|||||||
33798206|NCT04456725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed that their care is different than usual care.||t|f|f|f
33798207|NCT05858749|||COHORT||RETROSPECTIVE|||||||
33798208|NCT03974763|||CASE_CONTROL||PROSPECTIVE|||||||
33798209|NCT03270124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798210|NCT05452759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33942407|NCT04314258|RANDOMIZED|CROSSOVER||OTHER||SINGLE|A coding system will be used whereby each subject will be attributed a code upon signing the consent form. Only the Principal Investigator assisted by a second investigator will have access to the name-code list.|"This randomized clinical study will consist of two parallel groups with a crossover design.~There will be two arms as follows:~1. Intervention group \[Drinking Moringa tea\]~2. Control group \[Drinking plain water\].~Computer-generated random numbers will be used for simple randomization of subjects to either the experimental or control group.~With the cross over design, there will be two phases with an interchange of the groups during Phase 1 and 2 as follows:~Four-week Phase 1 - Group A drinking Moringa tea v/s Group B drinking plain water One-week washout Four-week Phase 2 - Group A drinking plain water v/s Group B drinking Moringa tea"|f|f|f|t
33942408|NCT05970159|||COHORT||RETROSPECTIVE|||||||
33942409|NCT00074789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942410|NCT03935945|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33942411|NCT04778111|||CASE_CONTROL||PROSPECTIVE|||||||
33942412|NCT02488265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942413|NCT04927585|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33942414|NCT03067701|NA|SINGLE_GROUP||OTHER||NONE||||||
33942415|NCT00052494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942416|NCT04554888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33942417|NCT02699489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942418|NCT00002362||||TREATMENT||||||||
34021286|NCT05044377|||COHORT||PROSPECTIVE|||||||
34021287|NCT02293889|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34021288|NCT03970928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34021289|NCT04885465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34021290|NCT02590250|||COHORT||PROSPECTIVE|||||||
34021291|NCT00046280|||COHORT||PROSPECTIVE|||||||
34021292|NCT00140218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021293|NCT03659097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021294|NCT03038594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021295|NCT01557361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021296|NCT02459548|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33798211|NCT02728765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798212|NCT02033148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798213|NCT03731624|||COHORT||PROSPECTIVE|||||||
33798214|NCT04650386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798215|NCT05463029|||COHORT||OTHER|||||||
33798216|NCT02735291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798217|NCT03244046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798218|NCT04625257|||COHORT||PROSPECTIVE|||||||
33798219|NCT03559348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021297|NCT04125849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101312|NCT03055065|||COHORT||CROSS_SECTIONAL|||||||
34101313|NCT05024786|||COHORT||PROSPECTIVE|||||||
34101314|NCT04107285|||COHORT||PROSPECTIVE|||||||
34101315|NCT03932201|||COHORT||PROSPECTIVE|||||||
34101316|NCT06604598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||BUPARDEX (iBUprofen, PARacetamol, DEXamethasone) is a parallel 3-group, blinded, randomized controlled trial. Participants were randomized using random generator application, and divided to 3 groups in a 1:1:1 ratio. Ibuprofen (Peinlos) 400 mg iv, Paracetamol (Bernofarm) 1 gr iv, dexamethasone (Phapros) 5 mg iv will give within IBU-PCT-DEX intervention. Ibuprofen (Peinlos) 400 mg iv; Paracetamol (Bernofarm) 1 gr iv; and placebo (normal saline alike dexamethasone) will give within the IBU-PCT-placebo intervention. Paracetamol (Bernofarm) 1 gr iv; placebo (normal saline alike paracetamol); placebo (normal saline alike dexamethasone) will give within PCT-placebo-placebo intervention. All drugs manufactured by Indonesia. The study was conducted after obtaining an ethical clearance from the Medical Research Ethics Commission, Faculty of Medicine, Universitas Jenderal Soedirman (No. 052/KEPK/PE/VII/2024). Participant, care provider, investigator, outcome assessor will be blind during trial.|t|t|t|t
34101317|NCT06691373|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34101318|NCT02021318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101319|NCT04598919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized clinical trial, in which the patients and investigators are masked to treatment assignment.|This will be a randomized (8:1 ratio), double blind, parallel design, placebo controlled trial.|t|f|t|t
34101320|NCT06652828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34101321|NCT06494150|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy in patients with recurrent LGSOC.||||
34101322|NCT06168578|||COHORT||PROSPECTIVE|||||||
34101323|NCT06228326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101324|NCT05455229|||COHORT||PROSPECTIVE|||||||
34101325|NCT04951453|||COHORT||PROSPECTIVE|||||||
34101326|NCT05030441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101327|NCT05418920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101328|NCT06460051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A 1:1 randomization table for patient allocation will be generated by a statistician who will not otherwise be involved in the study. Immediately upon the patient's arrival to the operating room, the research anesthesiologist will open a sealed, sequentially numbered opaque envelope containing the patient's assignment (block before surgery or block after surgery). Only anesthesiologists and operating room surgeons will not be blinded to patient assignment. This will be a double-blind study (patient and nurse). Patients will be unaware of the group they have been consecutively assigned to; and both the postoperative resuscitation nurses and the hospitalization ward nurses who will record visual analogue scale, analgesic consumption, onset of oral tolerance, postoperative nausea-vomiting and postoperative complications, will also be unaware of the analgesic treatment that the patient has received in the operating room.|The researchers propose a double-blind (patient and nurse) prospective comparative experimental study. The patients included in the study will be scheduled for bimaxillary osteotomy and will be assigned consecutively and prospectively to one of the two groups (maxillary nerve block before surgery or block after surgery) with a plan to register up to 50 patients.|t|t|f|t
34101329|NCT05366660|NA|SINGLE_GROUP||PREVENTION||NONE||Multicenter feasibility study||||
34101330|NCT00557739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101331|NCT03915756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101332|NCT02761057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101333|NCT00986102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101334|NCT04713007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34101335|NCT00899639|||COHORT||RETROSPECTIVE|||||||
34101336|NCT05861752|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34101337|NCT06022458|||COHORT||OTHER|||||||
34101338|NCT05177328|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study, as all participants will receive active and placebo treatment. Participants will receive active treatment on one of their ventral arms and placebo on their contralateral ventral arm. Investigators, all investigational site staff, including those responsible for preparing/administering the investigational product, and all participants in this study will be blinded as to which arm received which treatment.|||||
34101339|NCT05302609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101340|NCT06688344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101341|NCT06401772|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34101342|NCT04210089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101343|NCT06484400|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Model Description: This study employs a randomized, controlled, parallel-group design to compare the effectiveness of Cognitive Behavioral Therapy (CBT) and Ericksonian Hypnotherapy in treating symptoms of depression and anxiety. The study includes three arms:~CBT Group: Participants in this group will receive Cognitive Behavioral Therapy aimed at modifying negative thought patterns and behaviors to alleviate symptoms of depression and anxiety.~Ericksonian Hypnotherapy Group: This group will undergo Ericksonian Hypnotherapy, which uses hypnosis and indirect suggestion to influence subconscious processes and mitigate psychological distress.~Control Group: Participants in this group will not receive any intervention during the study period but will be monitored and offered therapy sessions after the study concludes, serving as a comparator to evaluate the efficacy of the interventions."||||
33798220|NCT00430872|||CASE_ONLY||PROSPECTIVE|||||||
34101344|NCT06177990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101345|NCT03596983|NA|SINGLE_GROUP||OTHER||NONE||||||
34101346|NCT04829656|||COHORT||PROSPECTIVE|||||||
33942419|NCT02643316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33942420|NCT01122992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101347|NCT06023368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101348|NCT04695119|||COHORT||PROSPECTIVE|||||||
34101349|NCT06689631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101350|NCT05570318|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking not possible, since the add-on treatment requires training of parents and children and is a physical device to be handed out|50 children randomized into 2 groups. Group a receives current standard treatment, group b receives current standard treatment plus low volume trans anal irrigation as add-on.||||
34101351|NCT02914678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101352|NCT06184763|||COHORT||RETROSPECTIVE|||||||
34101353|NCT03944876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101354|NCT06681194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101355|NCT02953457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101356|NCT04736121|NA|SINGLE_GROUP||TREATMENT||NONE||A pivotal, prospective, multicenter, open-label single arm study||||
34101357|NCT02268851|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101358|NCT00392509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101359|NCT04087655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group of obese adults studied before and after exercise training||||
34101360|NCT05377216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34101361|NCT06327490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101362|NCT04695782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101363|NCT03911271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101364|NCT05791929|||COHORT||PROSPECTIVE|||||||
34101365|NCT03241420|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34101366|NCT04615988|||COHORT||PROSPECTIVE|||||||
34103426|NCT02502383|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34103427|NCT06686745|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33942421|NCT00273715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942422|NCT00551629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942423|NCT06341738|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||10 units are divided into 2 arms (e.g. intervention and control) by cluster randomisation using the number of units into a sealed envelope. the participants are unaware of which group they were placed in||||
33942424|NCT05730049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible participants who consent to study participation will be randomized to one of two groups: active taVNS, or sham taVNS. Each group will undergo 1 hour of the respective treatment.|t|f|f|f
33942425|NCT04176016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942426|NCT01854918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942427|NCT03490734|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Experimental and flavor conditions will be blinded to those performing analyses.|Stratified randomization techniques will be used to distribute: 1) male \& females, 2) those with a BMI \> 26.1 \& those with a BMI \< 26.1, and 3) regular SSB consumers (\> 1/day; 12 fl oz) \& low or non-SSB consumers equally across the 2 experimental conditions (SSB vs. unsweetened beverage) and then to the two flavors within each experimental condition. BMI of 26.0 was selected as it is the midpoint of inclusion criteria 18 \< BMI \< 34.|t|f|f|f
33942428|NCT03677752|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33942429|NCT01974414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33942430|NCT04135599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33942431|NCT04390334|RANDOMIZED|CROSSOVER||OTHER||NONE||4 treatment arms in 2 sequences, ABCD or BACD.||||
33942432|NCT01201902|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33942433|NCT04786899|||COHORT||PROSPECTIVE|||||||
33942434|NCT06089226|||CASE_ONLY||RETROSPECTIVE|||||||
33942435|NCT02628262|||CASE_CONTROL||RETROSPECTIVE|||||||
33942436|NCT03764904|||COHORT||PROSPECTIVE|||||||
33942437|NCT01623492|||COHORT||PROSPECTIVE|||||||
33942438|NCT00792922|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"The study was a factorial study model to begin with in all 3 countries (Niger,Tanzania and Gambia) but because we never stopped treatment in Tanzania and Niger site.Hence the study design was collapsed to a simple design in Tanzania and Niger.The study model was kept as a factorial design for the Gambia site.~Protocol Enrollment refers to the number of communities, not the number of participants enrolled."|f|f|f|t
33942439|NCT04982276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942440|NCT01165268|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33942441|NCT01926366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33942442|NCT01647477|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942443|NCT00004937||||TREATMENT||||||||
33942444|NCT00420823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942445|NCT02883010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942446|NCT05752591|||COHORT||PROSPECTIVE|||||||
33798221|NCT05042024|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Patients were grouped by stratified randomization into three groups: the SRP Group (patients received conventional periodontal therapy including scaling and root planing as a full-mouth procedure, n=25); the Arg Group (patients received oral L-arginine aspartate (Yuria-Pharm, Ukraine) at a dose of 1 g t.i.d. for 10 days after conventional periodontal therapy, n=25); and the Orn Group (patients received oral L-ornithine aspartate (Farmak, Ukraine) at a dose of 3 g t.i.d. for 15 days after conventional periodontal therapy, n=25).||||
33798222|NCT03647969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798223|NCT06379711|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-Post Study||||
33798224|NCT02781766|NA|SINGLE_GROUP||OTHER||NONE||||||
33798225|NCT03332992|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33798226|NCT05228054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients with hemorrhoids 2-3st will be randomized in two groups|f|f|t|f
33798227|NCT05992701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798228|NCT00317577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798229|NCT00465192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798230|NCT05342818|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33798231|NCT02620813|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33798232|NCT03817060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798233|NCT06583460|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Category 2 clinical trial, monocentric, prospective, comparative, controlled but not randomized||||
33798234|NCT05832190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798235|NCT00106678|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942447|NCT00133640|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33942448|NCT02164890|NA|SINGLE_GROUP||OTHER||NONE||||||
33942449|NCT03132740|||COHORT||PROSPECTIVE|||||||
33942450|NCT04020224|RANDOMIZED|PARALLEL||OTHER||NONE||10 patients in the Test arm 10 patient in the Control arm||||
33942451|NCT05831956|||COHORT||RETROSPECTIVE|||||||
33942452|NCT03080389|||COHORT||PROSPECTIVE|||||||
33942453|NCT01761682|||COHORT||PROSPECTIVE|||||||
33942454|NCT03884868|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two consecutive study groups (no-concurrent).||||
33942455|NCT03873259|NA|SINGLE_GROUP||TREATMENT||NONE|Some outcomes assessors will be blinded to the treatment conditions. This will include review of video data for tissue injury.|||||
33942456|NCT03341728|RANDOMIZED|CROSSOVER||TREATMENT||NONE|No Masking|"In two 20 min sessions, on different days in a randomized cross-over design, older adults will walk with (treatment session) and without (control session) prolonged exposure to optical flow perturbations."||||
33942457|NCT03162302|||COHORT||PROSPECTIVE|||||||
33942458|NCT05142033|||OTHER||PROSPECTIVE|||||||
33942459|NCT05001672|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients who fulfilled in all inclusion and exclusion criteria will be randomized into TAF 25mg qd or observation arm in 1:1 ratio.~* 54 patients will be randomized into TAF arm\*.~* 54 patients will be randomized into observation arm initially."||||
33942460|NCT00719693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33942461|NCT01760356|||COHORT||PROSPECTIVE|||||||
33942462|NCT01638546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942463|NCT04197999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942464|NCT05465850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942465|NCT00242658|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33942466|NCT05280691|RANDOMIZED|PARALLEL||OTHER||NONE||"The trial is designed as a multi-center, parallel-cluster randomized, superiority trial with 16 clusters of ICUs in the German-speaking part of Switzerland.~The study aims to determine the effect of a nurse-led, interprofessional family support intervention on quality of family care, family management, and individual mental health compared to usual care provided to family members. The study also aims to identify implementation barriers/enablers in the real-world context in which the study intervention is implemented to discern determinants and strategies of implementation success."||||
33942467|NCT01979029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942468|NCT05771246|||CASE_CONTROL||RETROSPECTIVE|||||||
33942469|NCT04621825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942470|NCT00166504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942471|NCT04118127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021298|NCT06414720|||COHORT||PROSPECTIVE|||||||
34021299|NCT00002752||||TREATMENT||||||||
34021300|NCT04600102|||COHORT||PROSPECTIVE|||||||
34021301|NCT06199063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021302|NCT01323751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021303|NCT05379231|NA|SINGLE_GROUP||OTHER||NONE||||||
34021304|NCT03509805|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021305|NCT02518516|||COHORT||RETROSPECTIVE|||||||
34021306|NCT02743910|||COHORT||PROSPECTIVE|||||||
33717538|NCT04977908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label, single-centre, randomised, two-period, crossover study comparing closed-loop glucose control compared to standard insulin pump therapy combined with continuous glucose monitoring||||
33942472|NCT04853069|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open label, randomized controlled trial, with patients randomized 1:1 to usual care, or usual care + oestrogen therapy.~Prior to enrolment, an online CRF will be completed which will confirm that the patient meets the inclusion and exclusion criteria. Randomisation will be undertaken by the statistician in Qatar. Separate randomisation codes will be allocated for patients in Qatar and those in India, and separate randomisation will be performed for males and females. Randomisation will be enclosed in sequentially numbered sealed envelopes (with separate envelopes for males and females). Patients will be allocated to either the treatment or control group."||||
33942473|NCT01522391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942474|NCT01970384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942475|NCT01019733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942476|NCT03900182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"After signing an informed consent form, the patients were invited for baseline evaluation. Included patients were randomized into two groups. The neuropsychological functions were the primary endpoints of the study. Secondary end point included quality of life evaluation. Evaluations were made by medical and neuropsychological practitioners who were blinded to patients' inclusion in the control-crossed or the treated groups.~Patients in the treated group were evaluated three - at baseline, after 6 weeks of HBOT and after 6 weeks of neuropsychological treatment or no treatment. Patients in the crossover group were evaluated three times: baseline, after 6 weeks control period of no treatment, and after subsequent 6 weeks of HBOT. The post-HBOT neuropsycological evaluations were performed more than 1 week (1-2 weeks) after the end of the HBOT protocol. The following HBOT protocol was practiced: 30 daily sessions, 5 days/week, 60 minutes each, 100% oxygen at 1.5ATA."||||
33942477|NCT02404324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942478|NCT05706831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three groups of neurological patients will be considered for the study. For each group, participants will be randomly allocated to one of three intervention groups. These interventions will consist of a combination of musical stimulation, sham stimulation, tDCS and noise.|t|f|f|t
33942479|NCT03661658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021307|NCT03093389|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34021308|NCT06460207|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to either the positive or negative valence condition. They will encounter stimuli from their assigned valence only during the fMRI task, but from both valences during the behavioral tests, so that the investigators can evaluate whether any learning generalizes across emotional valence.||||
34021309|NCT03190759|||OTHER||PROSPECTIVE|||||||
34021310|NCT01119716|||COHORT||PROSPECTIVE|||||||
34021311|NCT01242995|||CASE_ONLY||PROSPECTIVE|||||||
34021312|NCT00045292|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34021313|NCT00388401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021314|NCT04158388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34021315|NCT01235195|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34021316|NCT02718508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021317|NCT02140411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103428|NCT04725071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717539|NCT05470426|||COHORT||PROSPECTIVE|||||||
33717540|NCT03249233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717541|NCT00848367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717542|NCT00751244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717543|NCT04337606|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717544|NCT01291992|||COHORT||PROSPECTIVE|||||||
33717545|NCT03649698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* Participant: Yes blinded for protein and omega-3~* Investigator: Yes blinded for protein and omega-3~* Outcomes Assessor: Yes blinded for protein and omega-3~* No blinding for exercise intervention.~* Statistician is blinded for protein, omega-3 and exercise intervention."||t|f|t|t
33717546|NCT03421821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The investigators random divided subjects into two groups, the subfascial injection groupand the extrafascial injection group. Two groups were injected 0.33% ropivacaine 30 ml to the target location."|t|t|f|t
33717547|NCT05242848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding is regarded as difficult and infeasible. Patients will be informed of the follow-up they will receive, but not on other follow-up alternatives that are used or the exact hypotheses for the study. Outcomes assessor will be blinded.|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.|f|f|f|t
33717548|NCT04162015|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single institution pilot study of nivolumab with pemetrexed and cisplatin or carboplatin prior to surgery for patients with potentially resectable malignant pleural mesothelioma (MPM).||||
33717549|NCT03595033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717550|NCT02031926|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33717551|NCT02702505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717552|NCT05802667|||COHORT||PROSPECTIVE|||||||
33717553|NCT03701347|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33717554|NCT02998840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717555|NCT05714215|||COHORT||PROSPECTIVE|||||||
33717556|NCT05000125|||OTHER||RETROSPECTIVE|||||||
33717557|NCT03796429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717558|NCT05649254|||COHORT||PROSPECTIVE|||||||
33717559|NCT01079091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798236|NCT03611972|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|All outcomes measures are analyzed using only the participant's study ID number.|Dietary intervention||||
33798237|NCT04107402|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33798238|NCT04279548|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33798239|NCT02952209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798240|NCT05673252|||COHORT||PROSPECTIVE|||||||
33798241|NCT06331611|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33798242|NCT00159783|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798243|NCT01502969|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33798244|NCT05657730|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798245|NCT03988023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798246|NCT00857649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798247|NCT03110965|NA|SEQUENTIAL||TREATMENT||NONE|Radiologists are unaware of study.|Patient's change in previous X-ray compared with baseline, and baseline compared with X-ray done 4-10 months later||||
33798248|NCT03811574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33798249|NCT01689844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798250|NCT01638611|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33798251|NCT04304924|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial that compares two weight loss programs (control health education program vs. personalized telephone-based health education program) for overweight patients with early breast cancer||||
33798252|NCT05692778|||CASE_CONTROL||PROSPECTIVE|||||||
33798253|NCT04929431|||COHORT||RETROSPECTIVE|||||||
33798254|NCT03410446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798255|NCT06677437|||COHORT||RETROSPECTIVE|||||||
33798256|NCT03670368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798257|NCT05904340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798258|NCT00534300|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33798259|NCT00044863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798260|NCT01445158|||COHORT||PROSPECTIVE|||||||
33798261|NCT05296148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798262|NCT03565055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798263|NCT03797924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|In order to blind anesthesia providers in the room and nurses in Post-op Anesthesia Care Unit (PACU), the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.|Patients will be randomized to receive ICBN with ropivacaine or no ICBN or ropivacaine.|t|t|f|f
33798264|NCT01171625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798265|NCT00137995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798266|NCT02539108|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021318|NCT05151666|NA|SINGLE_GROUP||OTHER||NONE||Single arm pre-post intervention study design||||
34021319|NCT01489631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021320|NCT03821870|||COHORT||PROSPECTIVE|||||||
34021321|NCT06186934|||COHORT||PROSPECTIVE|||||||
34021322|NCT00446537|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34021323|NCT06402617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to their treatment group, and outcomes will be studied prospectively on both an intention-to-treat and a per-protocol basis.|This will be a single-centre pilot study that will take place over 36 months. We will randomise 110 participants, half to a control arm that receives standard clinical care, and half to a treatment arm that receives the same care alongside adjunctive ablation of sites of focal activation identified by RETRO-Mapping. Both arms will also undergo additional intraprocedural measurements using RETRO-Mapping, and atrial fibrillation cycle length with standard tools. Randomisation will be by block randomisation for each site by closed envelope in sets of 10 containing five control arm and five test arm allocations.|t|f|f|t
34021324|NCT02841943|||COHORT||PROSPECTIVE|||||||
34021325|NCT01851239|||CASE_ONLY||RETROSPECTIVE|||||||
34021326|NCT04644835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33798267|NCT00006517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798268|NCT02974634|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33798269|NCT03733522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the evaluator of the restorations will be blind to the type of treatment (absolute or relative isolation). As the procedures are different, it will not be possible to blind operators and patients.||f|f|f|t
33798270|NCT01721434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798271|NCT02416518|||CASE_ONLY||PROSPECTIVE|||||||
34021327|NCT00955526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021328|NCT04301908|||COHORT||RETROSPECTIVE|||||||
34021329|NCT02861742|NA|SINGLE_GROUP||OTHER||NONE||||||
34021330|NCT03739567|||CASE_ONLY||CROSS_SECTIONAL|||||||
33798272|NCT00184041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798273|NCT05652244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798274|NCT00946842|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798275|NCT02396316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798276|NCT05320666|RANDOMIZED|PARALLEL||PREVENTION||NONE||The YYC...MSC! is an 11-lesson curriculum that will be delivered to 9th graders in Newark, New Jersey public schools during 40-minute health classes. The curriculum will be delivered in-person over approximately 2 weeks by NJPAG educators. The goal of the program is to prevent teen pregnancy and enhance character development in youth. Each time an NJPAG educator is in the classroom, they will deliver a single lesson of the curriculum. All NJPAG educators have received internal training for the program. YYC...MSC! is delivered like a traditional classroom curriculum, including lectures and activities, meaning all students in a given classroom will receive the lectures concurrently. The intervention addresses the following adult preparation subjects: parent-child communication, healthy relationships, healthy life skills, adolescent development, and financial literacy.||||
33798277|NCT01318382|NA|SINGLE_GROUP||OTHER||NONE||||||
34021331|NCT00699374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021332|NCT01323712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021333|NCT04013230|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021334|NCT00313339|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33798278|NCT01503749|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33798279|NCT00621569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798280|NCT01404182|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33942480|NCT06196372|RANDOMIZED|PARALLEL||OTHER||SINGLE||The design of this study is a randomized controlled experimental study with a single-blind pretest-posttest control grou|f|t|f|f
33942481|NCT05042531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|According to the random number table|The patients were randomly divided into two groups among intermediate and high-risk AML, namely azacitidine group, azacitidine combined with low-dose dasatinib group, with overall survival and disease-free survival as the main research endpoints , taking mortality and recurrence rates as secondary research endpoints, assessing the incidence of adverse events, and studying its related mechanisms.|f|f|t|f
33942482|NCT02275052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33942483|NCT02389868|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021335|NCT06483568|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will not be aware of whether their activities are considered the active or control activities as both will be described as self-improvement activities. The PI and all research staff interacting with participants will not be aware of their condition assignment.|Participants will be randomly assigned to complete positive psychology intervention activities or procedure-matched activities related to personal organization.|t|f|t|f
34021336|NCT02390609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021337|NCT02119923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021338|NCT04791514|NA|SEQUENTIAL||TREATMENT||NONE||||||
34021339|NCT03555331|||COHORT||PROSPECTIVE|||||||
34021340|NCT00704574|||CASE_ONLY||PROSPECTIVE|||||||
34021341|NCT01016886|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|t|f
34021342|NCT02472223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021343|NCT03986827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be stratified into two age groups (12-14 and 15-17) using permuted block design with a fixed block size of 8 at a 1:1 ratio to the CK or the CK-E condition. Randomization will be conducted with an online computer random number generator (www.random.org) by an independent secretary. The sequence list will be kept concealed from therapists until treatment starts. Participants are not informed about their specific treatment condition.|The study is a randomized controlled superiority trial comparing two active groups of treatment: 1) Cool Kids Anxiety Program - Social Enhanced (CK-E), 2) Cool Kids Anxiety Program (CK). The study design is a mixed between-within design, with data points pre- and post-treatment, and at 3- and 12-month follow-ups.|t|f|f|t
34021344|NCT00253695|||CASE_CONTROL||PROSPECTIVE|||||||
34021345|NCT04305587|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind (investigator- and participant-blind), sponsor-open||t|f|t|f
34021346|NCT02879734|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34021347|NCT02069483|RANDOMIZED|PARALLEL||||NONE||||||
34021348|NCT03812744|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Investigators, participants, and the sponsor were all blind.|Single-site, randomized, placebo-controlled, cross-over, within-subjects design. Study sessions are no more than 72 hours apart. Visits included pre-post assessments following ingestion of either placebo or WCCE.|t|f|t|t
34021349|NCT03565458|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021350|NCT05703269|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Participants will be randomized 1:1 to either SSRS or FSRS, using minimization randomization strategy considering 5 prognostic factors of interest: radiosurgery platform (GK vs. LINAC), timing of immunotherapy relative to radiation (ICI within 30 days of Day 1 prior to SRS or not), surgical status (any resection cavity vs. intact metastases only), predominant tumor type (Melanoma vs. all others), and prior courses of SRS for brain metastases (yes vs. no). All baseline patient-reported outcomes and neurocognitive assessments will be collected prior to randomization to minimize bias.||||
34021351|NCT01447420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021352|NCT02387515|NA|SINGLE_GROUP||OTHER||NONE||||||
34021353|NCT02760992|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021354|NCT02266134|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34021355|NCT01796613|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021356|NCT00224926|||COHORT||PROSPECTIVE|||||||
34021357|NCT05868252|||CASE_CONTROL||RETROSPECTIVE|||||||
34021358|NCT06351475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021359|NCT06432270|||COHORT||PROSPECTIVE|||||||
34021360|NCT01433549|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34021361|NCT05427201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
34021362|NCT04128020|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34021363|NCT04407208|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||single-arm, pre, and post-test dependent group||||
34021364|NCT03205280|||COHORT||PROSPECTIVE|||||||
34021365|NCT04635293|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Retrospective|t|f|f|t
34021366|NCT03468335|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, multicenter phase IIIb trial||||
34101367|NCT05999851|NA|SINGLE_GROUP||PREVENTION||NONE||The study is a single group study (Principal Arm) with a sub-group of participants undergoing additional experimental analyses. The additional analyses will be performed in participants who will develop hypertensive disorders of pregnancy and matched (age and body mass index before conception) controls with healthy pregnancies.||||
34101368|NCT01326637|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101369|NCT01667952|||FAMILY_BASED||PROSPECTIVE|||||||
34101370|NCT06546735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Test Group: N0728 - each participant should take 2 tablets a day, in the morning, after feeding. In a blinded manner, participants in the test group will be required to take 1 tablet of the test drug (N0728) and 1 tablet of placebo of alpha-adrenergic antagonists.~Comparator Group: alpha-adrenergic antagonists - Participants in the control group will be required to take 1 tablet of the comparator drug (alpha-adrenergic antagonists) and 1 tablet of the placebo of the test drug."|t|t|t|t
34101371|NCT03539705|||OTHER||OTHER|||||||
33798281|NCT01274871|||||RETROSPECTIVE|||||||
33798282|NCT02784132|RANDOMIZED|||DIAGNOSTIC||NONE||||||
33798283|NCT00974831|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33798284|NCT03366870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798285|NCT03964376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798286|NCT04956575|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798287|NCT00656721|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33798288|NCT05293548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798289|NCT05887063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798290|NCT05481463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798291|NCT04861532|||OTHER||OTHER|||||||
33798292|NCT01000480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798293|NCT00269789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34021367|NCT04023162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of interventions that will be applied in this study, blinding of therapists who will carry out the intervention regarding Therapy Exercise will not be possible to implement, but physiotherapists (apart from the study designer) will not know the study hypothesis. Fully blinding of the examinees is also impossible to implement, but partially blinding will occur, as the participants in the Graded Activity group will not explain the applied behavioral therapy. Blinding will be applied to researchers who will collect data (measure outcomes) and statisticians.|By randomization, the participants will be divided into three groups, two experimental groups, and a control group. In the first experimental group, the investigated interventions will consist of Therapy Exercise and Back School. In the second experimental group, in addition to the Therapy Exercise and the Back School, operative conditioning will be performed by the master of physiotherapy. The participants in the control group will be exposed to the usual treatment.|f|f|f|t
34021368|NCT03131492|||COHORT||PROSPECTIVE|||||||
34021369|NCT01741051|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34021370|NCT03916510|NA|SEQUENTIAL||TREATMENT||NONE||CEDAR is a dual escalation phase 1 trial using continual reassessment method .||||
34021371|NCT01470768|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34021372|NCT02767882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021373|NCT00732550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021374|NCT00553306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021375|NCT02200861|||||RETROSPECTIVE|||||||
34021376|NCT00527865|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34021377|NCT00948727|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34021378|NCT02906566|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34021379|NCT02256527|||CASE_ONLY||RETROSPECTIVE|||||||
34021380|NCT04007991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021381|NCT03420664|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Research subjects receive lower limb immobilisation with cast and with orthosis alternatively, randomised so as subsequent persons begin with different modality.||||
34101372|NCT06214520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33717560|NCT04360954|||CASE_ONLY||RETROSPECTIVE|||||||
34101373|NCT06678997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34101374|NCT06694181|||CASE_ONLY||RETROSPECTIVE|||||||
33717561|NCT01509833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717562|NCT00298220|RANDOMIZED|FACTORIAL||||NONE||||||
33717563|NCT02426892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717564|NCT02296268|||COHORT||PROSPECTIVE|||||||
33717565|NCT01806948|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33717566|NCT00323115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717567|NCT02564042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717568|NCT03584022|RANDOMIZED|PARALLEL||OTHER||NONE||Patients planned for diagnostic sural nerve biopsy will be screened. Nerve conduction study of the sural nerve is part of standard of care for patients who are screened for the study. If the amplitude of sensory nerve action potential (SNAP) is equal to or greater than 2 μV and the patient meets the other inclusive criteria, the patient will be recruited to enter the study. Ultrasonography of the sural nerve will be conducted. If the diameter of the sural nerve is greater than 2.75mm, the patient will be assigned to the control group. If sural nerve diameter is equal to or smaller than 2.75mm, the patient will be randomized to either the control or study group. A study team member (clinical coordinator) will draw a number from an envelope that holds equal amount of odd and even numbers. If the number drawn is an odd number, the patient will be assigned to the control group. If the number drawn is an even number, the patient will be assigned to the intervention group.||||
33717569|NCT04913025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717570|NCT03838133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33717571|NCT06140303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the test article, a placebo harvest procedure or placebo treatment is not possible. Patients will be treated by the investigator. Wounds will be assessed at each visit by the investigator. Wound closure determined by the investigator will be confirmed by 3 blinded adjudicators.|multi-center, randomized controlled trial|f|f|f|t
33717572|NCT04766125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33717573|NCT02685020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33717574|NCT00055081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717575|NCT02129725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33717576|NCT01122706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717577|NCT01863212|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717578|NCT04646707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a double blind, randomized control clinical trial.|t|t|t|f
33717579|NCT03395886|||COHORT||PROSPECTIVE|||||||
33717580|NCT03259854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717581|NCT01321515|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717582|NCT00543348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717583|NCT04405986|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33717584|NCT01334814|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33717585|NCT01866501|NA|SINGLE_GROUP||||NONE||||||
33717586|NCT01548482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717587|NCT00061880||||TREATMENT||NONE||||||
33717588|NCT01913912|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33717589|NCT04635215|||COHORT||PROSPECTIVE|||||||
33717590|NCT00001054||||TREATMENT||NONE||||||
33798294|NCT00508924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798295|NCT04294329|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33798296|NCT04243980|||COHORT||PROSPECTIVE|||||||
33717591|NCT01220947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717592|NCT00536406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717593|NCT01857388|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717594|NCT03210753|||COHORT||RETROSPECTIVE|||||||
33717595|NCT06248892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33717596|NCT06037967|||COHORT||PROSPECTIVE|||||||
33717597|NCT04774107|NA|SINGLE_GROUP||OTHER||NONE||||||
33717598|NCT03966001|||COHORT||PROSPECTIVE|||||||
33717599|NCT01906151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717600|NCT02867787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717601|NCT05967611|||OTHER||CROSS_SECTIONAL|||||||
33717602|NCT01909050|||OTHER||PROSPECTIVE|||||||
33717603|NCT00931814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717604|NCT02889484|||COHORT||PROSPECTIVE|||||||
33717605|NCT01113450|||||RETROSPECTIVE|||||||
33717606|NCT01918761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717607|NCT04620720|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33717608|NCT04236011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717609|NCT02600949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717610|NCT02821182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717611|NCT03251768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717612|NCT02642614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717613|NCT05040997|||COHORT||OTHER|||||||
33717614|NCT04341454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717615|NCT04974710|||COHORT||PROSPECTIVE|||||||
33942484|NCT01060410|||CASE_ONLY||PROSPECTIVE|||||||
33942485|NCT05527418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942486|NCT02132312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942487|NCT04160494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942488|NCT04264611|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942489|NCT04736251|||COHORT||PROSPECTIVE|||||||
33942490|NCT05393986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942491|NCT06462391|NA|SINGLE_GROUP||OTHER||NONE||open label pilot feasibility study||||
33942492|NCT01404689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33942493|NCT06173973|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind|Placebo controlled, Double blinded study|t|t|t|f
33942494|NCT04977778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33942495|NCT06137027|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The patient, researcher administering the agent and the attending anaesthetist will all be blinded to the agent administered. Only the pharmacist preparing the oil will know what it contains.~Patients will be allocated into one of two groups:~Group 1 - Intervention group Group 2 - Placebo group"|The intervention group will receive Cannabidiol oil 5.5mg sublingually (10 drops). The control group will receive a peppermint based oil sublingually (10 drops).|t|t|t|f
33942496|NCT01732380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942497|NCT01736176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942498|NCT03556644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942499|NCT03223129|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Patients with either normal glucose tolerance, impaired glucose tolerance or with diagnosed type 2 diabetes mellitus will undergo oral glucose tolerance tests with an increasing load of glucose and thereafter isoglycemic intravenous glucose infusion.||||
33942500|NCT03479424|||COHORT||PROSPECTIVE|||||||
33942501|NCT01493362|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942502|NCT03920046|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942503|NCT00983827|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942504|NCT02827747|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942505|NCT05034029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942506|NCT00132405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33942507|NCT02063958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942508|NCT02330731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942509|NCT01434927|||COHORT||PROSPECTIVE|||||||
33942510|NCT06143449|||COHORT||PROSPECTIVE|||||||
33942511|NCT03775733|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942512|NCT02303535|||COHORT||PROSPECTIVE|||||||
33942513|NCT02478736|||CASE_CONTROL||PROSPECTIVE|||||||
33942514|NCT04168359|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33942515|NCT01719627|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33942516|NCT04121637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the person who will make the analysis will not know the applications|Control group Working group|t|f|f|t
34021382|NCT00388076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021383|NCT02655666|||COHORT||PROSPECTIVE|||||||
34021384|NCT05495958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34021385|NCT05189782|||COHORT||PROSPECTIVE|||||||
34021386|NCT02183207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021387|NCT04276363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021388|NCT05182320|||CASE_CONTROL||PROSPECTIVE|||||||
34021389|NCT06288503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021390|NCT00299026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021391|NCT00636948|||||PROSPECTIVE|||||||
34021392|NCT06415877|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34021393|NCT05190809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021394|NCT03244501|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a double-blind study, meaning that neither the participant nor the experimenter knows what kind of stimulation the participant is receiving. An unblinded monitor (separate from the staff that interacts with the participant) is responsible for providing the study coordinator with the active and sham magnet sequence. Each magnet has a number; the study coordinator is not aware which number corresponds to active or sham magnets.|All participants will receive three stimulations: left frontal, right frontal, and sham tSMS.|t|f|t|f
34021395|NCT03218059|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34101375|NCT03048019|||COHORT||PROSPECTIVE|||||||
34101376|NCT06007794|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101377|NCT05229354|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|While clinical staff, all investigators, and study volunteers will remain blinded until each cohort's respective unblinding timepoint, the PI will assign an unblinded statistician to analyze the safety data. This designee will provide safety data to study staff as a summary report with blinding maintained.|Eligible volunteers will be enrolled to receive TetraVax-DV TV005 or placebo (2:1) on an outpatient basis in one of three cohorts based on intended treatment with the attenuated virus strain timepoint (6, 12 or 24 months). The sequence of treatment assignments to either TV005 or placebo will be generated using block randomization. Randomization will occur sequentially at the time of study enrollment (vaccination) using a pre-generated list. All enrolled volunteers will be followed for 3 years post-vaccination for safety.|t|t|t|t
34101378|NCT06297343|||COHORT||PROSPECTIVE|||||||
34101379|NCT06535139|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We will test our hypotheses with a three-arm cluster randomized study design of nested strategies. Randomization will occur at the clinic level. All clinics will receive implementation strategy A: clinician-targeted recommendation training. A random 20 of 30 of clinics will also receive facilitation of parent-targeted motivational aids (B) for an implementation strategy package of A+B. Finally, a random half of the clinics who receive A+B will also receive community-targeted healthcare access (C) for a total implementation strategy package of A+B+C. This equates to a three-arm cluster randomized trial in which 10 clinics receive clinician- targeted recommendation training alone (A), 10 clinics receive clinician-targeted recommendation training and parent-targeted motivational aids (A+B), and 10 clinics receive clinician-targeted recommendation training, parent-targeted motivational aids, and community-targeted healthcare access (A+B+C).|f|f|f|t
34101380|NCT00816673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101381|NCT06500845|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The participants and recruiters will not know the study group to which the next participant will be assigned.~The trial participants, outcome assessors, and data analysis will be blinded after assignment to interventions.~Emergency un-blinding: In cases of emergency to decrease or prevent any harms for the participants."||t|f|f|t
34101382|NCT05064670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101383|NCT05962138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Baseline assessment, randomisation and facilitation of the intervention will be performed by members of the research team who will be blinded to group allocation. The investigators analysing the data will be blinded to group allocations.|A randomised controlled trial with two parallel study arms: (1) digital cognitive behavioural therapy for insomnia (experimental condition), and (2) treatment as usual (control condition). Randomisation will be using a 1:1 ratio (experimental:control), within minimisation of between group differences in sex, and inclusion status in imaging sub-study|f|f|t|t
34101384|NCT06575595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101385|NCT00122863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34101386|NCT03902483|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34101387|NCT05821088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101388|NCT05014230|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34101389|NCT06284278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101390|NCT06689683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101391|NCT06072586|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101392|NCT04596631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101393|NCT02323581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101394|NCT06177912|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34101395|NCT02245724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942517|NCT06131294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth design: Meaning that each patient receives both treatments, but on different teeth.|t|f|f|t
33942518|NCT06261216|||COHORT||PROSPECTIVE|||||||
33942519|NCT01586013|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33942520|NCT02936206|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942521|NCT00038116|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33942522|NCT01976403|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33942523|NCT02723539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942524|NCT04202627|||COHORT||OTHER|||||||
34021396|NCT04377880|||OTHER||PROSPECTIVE|||||||
34021397|NCT03151408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021398|NCT00654966|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021399|NCT00369655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717616|NCT05575011|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Blinded for Part A and open-label for Part B of the study.|Sequential for Parts A and B, parallel for Cohorts 1-4 within Part A, parallel for Cohorts 5-6 within Part B|t|t|t|t
33717617|NCT00102882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717618|NCT06147310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participlant will be masked Care provider and investigator could not be masked due to the intrinsic nature of the intervention, however the allocation will be concealed until the extraction of teeth is completed.~Outcome assessor will be masked"|Prospective, parallel group, randomized-controlled, single-blinded, superiority clinical study.|t|f|f|t
33717619|NCT02260050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717620|NCT00632411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717621|NCT04334408|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33717622|NCT03280914|||CASE_CONTROL||PROSPECTIVE|||||||
33717623|NCT04013724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the group assessments (Weeks 4, 12, and 26), participants who reported continued tobacco use abstinence and consented to a saliva test were tested using a nicotine cotinine strip (Devon Medical: Nicotine/tobacco test kit). The saliva tests were evaluated by the nurses working at the hospital who were blinded to treatment allocation and were not otherwise part of the study.|The participants in the intervention group were introduced to a structured group tobacco cessation program. They met twice a month, for a period of 3 months, then were followed up once a month for a period of 3 months. Each meeting session lasted for a period of 45 minutes. They shared their feelings, and experiences with cessation attempt at the beginning of each session. The facilitator then documented their quit attempts, any changes in numbers of cigarettes smoked, and any challenges with cessation attempts noted. The facilitator then introduced the topic of the day and facilitated discussion on the same. Where skills practice was involved, the facilitator demonstrated to the participants how to apply the skill.|f|f|f|t
33717624|NCT00296894|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33717625|NCT02701504|||COHORT||PROSPECTIVE|||||||
33717626|NCT00534989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717627|NCT05156320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active treatment, randomized, double-blind, placebo-controlled.||t|t|t|t
33717628|NCT03582072|RANDOMIZED|PARALLEL||OTHER||NONE||"930 practices (this will be the number of datapoints), 478 in the intervention, 452 in the control; letter sent to individual GPS (4796 subjects, as below), 2340 in the intervention, 2456 in the control~practices"||||
33717629|NCT01073982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717630|NCT01259323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717631|NCT01325389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33717632|NCT01785732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717633|NCT01726153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717634|NCT04045340|||COHORT||PROSPECTIVE|||||||
33717635|NCT04719507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33717636|NCT03912116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717637|NCT00548925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717638|NCT00222196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717639|NCT00041327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717640|NCT04492618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717641|NCT03902067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717642|NCT00818662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717643|NCT06392503|||OTHER||OTHER|||||||
33717644|NCT04909320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33717645|NCT05538403|||COHORT||RETROSPECTIVE|||||||
33717646|NCT05402592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|In the study, the participant, caregiver and outcome evaluator other than the researcher will be blinded.|Randomized Controlled prospective trial, double blind|t|t|f|t
33717647|NCT05395806|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Randomized controlled trial- Multicenter Registered patients at three primary care clinics were randomly allocated to intervention or control groups at each clinic.~The intervention group received access and technical supprot for using a new App to help improve their control vs control group that received general information and usual care."||||
33717648|NCT02190357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717649|NCT02818322|RANDOMIZED|PARALLEL||||NONE||||||
33717650|NCT05251909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a parallel-group efficacy and safety study with 2 arms that are participant and investigator blinded, with an open-label extension.||t|t|t|f
33717651|NCT05369455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|neither investigator nor outcome assessors know which block patient had received||f|f|t|t
33717652|NCT04563793|||COHORT||PROSPECTIVE|||||||
33798297|NCT05515900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798298|NCT04088123|||OTHER||PROSPECTIVE|||||||
33798299|NCT02275377|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33798300|NCT05537298|||COHORT||PROSPECTIVE|||||||
33798301|NCT00075933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021400|NCT04864405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021401|NCT06160570|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021402|NCT00870597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021403|NCT01250197|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34101396|NCT06083142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798302|NCT01149369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101397|NCT06395714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101398|NCT01927861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798303|NCT02750072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798304|NCT04162444|||COHORT||PROSPECTIVE|||||||
33798305|NCT00238836|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33798306|NCT05142202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798307|NCT04887675|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33798308|NCT03288753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798309|NCT03339258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942525|NCT05342727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Allocation Concealment is used to perform a random sequence on study participants. Also, non-transparent envelopes sealed with random sequences will be used, in a way that each random sequence is recorded on a card, and the cards are placed in the envelope in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the envelopes are glued and placed inside a box. At the beginning of the registration, according to the order of entry of the eligible participants, one of the envelopes will be opened in order and the assigned group of the participant will be revealed.|Parallel group and each group with crossover design|t|t|f|t
33942526|NCT05107700|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34101399|NCT01173458|||CASE_ONLY||PROSPECTIVE|||||||
34101400|NCT03361007|||COHORT||PROSPECTIVE|||||||
34101401|NCT04016402|||CASE_ONLY||PROSPECTIVE|||||||
34101402|NCT05997615|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101403|NCT01509456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34101404|NCT06669494|||COHORT||PROSPECTIVE|||||||
34101405|NCT06129734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101406|NCT05250583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101407|NCT01742299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101408|NCT04798339|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101409|NCT05849662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be concurrently enrolled into both the lower-risk and high-risk arm starting at Dose Level 1. The rolling 6 design will be used during Phase 1 of the study to confirm the recommended Phase 2 dose, separately for the lower-risk and high-risk arm, with one possible de-escalation.||||
34101410|NCT06436183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101411|NCT05206604|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33798310|NCT01062126|||COHORT||PROSPECTIVE|||||||
33942527|NCT05807646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942528|NCT05961761|NA|SINGLE_GROUP||TREATMENT||NONE||A Simon´s optimum two-stage design||||
33942529|NCT03725904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942530|NCT04139161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942531|NCT03804138|||CASE_CONTROL||PROSPECTIVE|||||||
33942532|NCT02924311|||COHORT||PROSPECTIVE|||||||
33942533|NCT04169126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942534|NCT04741022|||COHORT||PROSPECTIVE|||||||
33942535|NCT04500626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942536|NCT04542525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942537|NCT00004911||||SUPPORTIVE_CARE||||||||
34021404|NCT04576299|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34021405|NCT05965453|||COHORT||OTHER|||||||
34021406|NCT01563276|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34021407|NCT00030979||||TREATMENT||||||||
34021408|NCT06405217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021409|NCT03035344|||CASE_CONTROL||PROSPECTIVE|||||||
34021410|NCT02205983|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33798311|NCT04337307|||COHORT||PROSPECTIVE|||||||
33798312|NCT03284905|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798313|NCT05898074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be double blinded (video endoscopy will be performed and scoring will be performed by non-operative surgeon, blinded to the intervention group).|Prospective, Randomized Cohort Study|f|f|f|t
34021411|NCT01064050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021412|NCT00081536|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021413|NCT02928367|||CASE_CONTROL||PROSPECTIVE|||||||
34021414|NCT04970537|||COHORT||RETROSPECTIVE|||||||
34103429|NCT06687096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All elective colonoscopies were performed by two experienced endoscopists who were unaware of the group assignments.||f|t|f|f
34103430|NCT05192031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34103431|NCT04450901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103432|NCT06530303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103433|NCT02477033|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33798314|NCT00200213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33798315|NCT04065802|NA|SINGLE_GROUP||TREATMENT||NONE||Adult patients with a cardiomyopathy and ventricular tachycardia who have failed conventional anti-arrhythmic management.||||
33798316|NCT01423097|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33798317|NCT06190522|||COHORT||PROSPECTIVE|||||||
33798318|NCT02803801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798319|NCT02108236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798320|NCT00177086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798321|NCT01403168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798322|NCT04834648|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|At LEI the staff will be blinded about the intervention/ control referring centers||f|t|f|f
33798323|NCT04112069|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798324|NCT01480505|||COHORT||RETROSPECTIVE|||||||
33798325|NCT01151839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103434|NCT05756556|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2a, open-label study of T3011 given via intratumoral (IT) injection in combination with Cobimetinib given via oral administration in patients with advanced melanoma. This study is planned to enroll approximately 62\~68 patients with BRAF V600E/V600K mutation-positive or RAS mutation-positive, which will be conducted in 2 parts (part 1 and part 2)||||
34101412|NCT05998616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and outcomes assessors will be blinded to participant group assignment (exercise intervention or flexibility control group). However, it is important to note that due to the nature of the intervention, participants and outcomes assessors will be aware of the type of intervention received (aerobic/resistance training exercise or flexibility exercises). This is because the exercise intervention and flexibility control involve different activities. Randomization will be conducted by the investigator, who will not be involved in consent, delivery intervention, data collection, and outcome assessment.|FERLA MS is a parallel-group, randomized controlled trial, where eligible participants with MS will be randomly assigned to either the remotely-delivered exercise intervention group or the remotely-delivered and supported flexibility control group. Both groups will receive intervention materials and support via teleconferencing or phone calls. The exercise group will follow a theory-based aerobic and resistance training program, while the control group will engage in flexibility exercises.|t|f|t|t
34101413|NCT06479863|NA|SINGLE_GROUP||TREATMENT||NONE||The primary objective of the study is to evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM, The primary outcome measures are: IBM-Functional Rating Scale (IBM-FRS) change from screening visit through week 104. (2)IBM Physical Functioning Assessment (sIFA) change from screening visit through week 104||||
34101414|NCT03162536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single group assignment (definition : A type of intervention model describing a clinical trial in which all participants receive the same intervention/treatment.)||||
34101415|NCT06662292|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34101416|NCT03680508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101417|NCT00885976|||COHORT||PROSPECTIVE|||||||
34101418|NCT06048705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101419|NCT06687707|||COHORT||CROSS_SECTIONAL|||||||
34101420|NCT05608291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101421|NCT04690348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will be blinded to their treatment until postoperatively.|Prospective randomized phase II multicenter trial.|t|f|f|f
34101422|NCT05087680|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34101423|NCT01775306|||COHORT||PROSPECTIVE|||||||
34101424|NCT00752271|||CASE_CONTROL||PROSPECTIVE|||||||
34101425|NCT06585462|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33798326|NCT00190008|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33798327|NCT00762879|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33798328|NCT00666068|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33942538|NCT05359575|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The outcomes assessor only enters the laboratory after the participant has attempted to apply the cervical collar (c-collar). Therefore, the outcomes assessor is unaware of the instructional intervention that was employed. The outcomes assessor will collect cervical range of motion (CROM) measurements using a CROM device to verify correct c-collar placement by evaluating whether the c-collar was appropriately sized and if neck movement is restricted in five cardinal directions: flexion, extension, and bidirectional rotation.|"Participants are initially randomized to 1 of 4 arms. Once the initial instructional intervention is completed, participants are subsequently randomized to either a 1-month or 2-month follow-up.~Participants initially randomized to the two arms with flashcards (v. 1) are not randomized to either follow up, because version 1 of the flash cards was confusing and thus was piloted with these initial participants."|f|f|f|t
33942539|NCT04832633|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33942540|NCT05858645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942541|NCT03362827|||OTHER||CROSS_SECTIONAL|||||||
33942542|NCT06157411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942543|NCT06300866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942544|NCT03070262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942545|NCT04271189|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open label pragmatic phase IIb/III RCT with a duration of 3 years||||
33942546|NCT03798366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942547|NCT02138552|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33942548|NCT03349957|||COHORT||RETROSPECTIVE|||||||
33942549|NCT02579889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942550|NCT03370133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942551|NCT03627442|RANDOMIZED|PARALLEL||OTHER||NONE|Initially, only breast surgeons knows which of the two devices was used for each breast, not plastic surgeon|Single blinded, randomized controlled pilot study (n=15) Only breast surgeon knows which device was used for each breast at initiation of surgery||||
33942552|NCT04102124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942553|NCT06113276|||COHORT||OTHER|||||||
33942554|NCT00417898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942555|NCT04984629|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the HYDRAFIL implant||||
33942556|NCT00107536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942557|NCT01409642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942558|NCT02636049|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33942559|NCT03498911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942560|NCT05771974|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101426|NCT05499169|||COHORT||PROSPECTIVE|||||||
34101427|NCT01585701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101428|NCT03019653|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33798329|NCT05171621|||OTHER||PROSPECTIVE|||||||
33942561|NCT03351582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798330|NCT04217512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798331|NCT05532345|||OTHER||RETROSPECTIVE|||||||
33798332|NCT02511613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798333|NCT03697655|RANDOMIZED|PARALLEL||PREVENTION||NONE||treatment arm and control (observation) arm||||
33798334|NCT04481672|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33798335|NCT00697489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798336|NCT01415349|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101429|NCT01561612|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101430|NCT02917538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34101431|NCT00592527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101432|NCT05849376|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Some participants will receive the intervention immediately and some participants will be assigned to a waitlist control for a brief period, after which they will receive the intervention.||||
34101433|NCT02635672|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101434|NCT06404086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|This platform protocol is designed to allocate participants into an intervention appendix based on their symptoms of sleep disturbance. Within the appendix, participants will be randomly assigned based on the appendix study design. Site investigators and personnel will be informed as to which study intervention appendix participants are assigned, but they will be blinded to whether participants are receiving the active study intervention or control, when possible. Similarly, participants will be blinded to active intervention or control, when possible. Randomization will be stratified by the study site; other stratification factors may be considered per appendix.|t|t|t|f
34101435|NCT04584320|||CASE_CONTROL||PROSPECTIVE|||||||
34101436|NCT04597112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101437|NCT05770622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101438|NCT06694220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34101439|NCT06689930|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is primarily a qualitative study designed to identify implementation strategies for the Adapted Staying Healthy After Childbirth (A-STAC). This pre-implementation phase includes 10 pilot participants and at least 2 CBO staff.||||
34101440|NCT04125719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101441|NCT06686043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101442|NCT01331330|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34101443|NCT06221254|RANDOMIZED|PARALLEL||TREATMENT||NONE||200 CD patients divided into two equal groups: Intervention and control.||||
34101444|NCT02103946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101445|NCT06523153|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||Randomized, double blind, placebo controlled|t|t|t|t
34101446|NCT06484595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101447|NCT04103645|NA|SINGLE_GROUP||TREATMENT||NONE||This is an intra-patient dose finding study which starts with low dose of vactosertib.||||
34101448|NCT05441345|||OTHER||PROSPECTIVE|||||||
33942562|NCT03021733|||COHORT||PROSPECTIVE|||||||
34101449|NCT00252889|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101450|NCT06522568|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101451|NCT06057454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind placebo controlled trial|Double Blinided, placebo controlled, Phase 1B study.|t|f|t|f
34101452|NCT01045265|||COHORT||PROSPECTIVE|||||||
34101453|NCT06468176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101454|NCT06649773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101455|NCT06541249|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Stage 1: 9 participants will be accrued to each of three cohorts of patients with MPNs: PV, ET, and MF. Low-dose, weekly MTX will be added to current therapy. If 0 responses occur within a given cohort, the study will be stopped within that cohort for futility; if ≥3 responses occur within a given cohort, the study will be stopped for early evidence of efficacy within that cohort.~If 1-2 responses occur within any given cohort, that cohort will proceed to Stage 2. An additional 1 participant will be accrued to account for potential dropout. Stage 2: 9 additional participants will be accrued to each of three cohorts. If a total of \>3 of 20 participants enrolled achieve responses in any cohort, the study will be considered successful and MTX worthy of further study within that cohort. An additional 1 participant will be accrued to account for potential dropout."||||
34101456|NCT05980299|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101457|NCT04480580|||COHORT||RETROSPECTIVE|||||||
34101458|NCT02620852|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34101459|NCT03367351|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, un-blinded intervention/control design||||
34101460|NCT06132503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101461|NCT04229381|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101462|NCT06380738|||COHORT||PROSPECTIVE|||||||
34101463|NCT04702139|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33717653|NCT04384666|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This is a randomized, open-label, 2-sequence, 2-treatment cross-over study to evaluate the rotigotine PK profiles after a single dose of 28 mg LY03003 IM injection and 7 days of 4 mg NEUPRO® patch q24h in healthy subjects.~Subjects will be screened according to the inclusion and exclusion criteria (Days -28 to -1) prior to randomization. Each subject will be randomized 1:1 to 1 of the 2 treatment sequences and will participate in 2 treatment periods."||||
33942563|NCT02137902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942564|NCT02802527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942565|NCT02519777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942566|NCT04515589|||COHORT||PROSPECTIVE|||||||
33942567|NCT03397095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||S-CURE study has a two-stage design. Stage 1 is an open-labled, lead-in study. 20 participants will be enrolled in this stage. It is conducted to assess the feasibility and safety of the study procedures as well as the bioactivity of the products. Stage 2 is an randomized, placebo controlled study, 100 participants will be enrolled in this stage.|t|t|t|t
33942568|NCT00723489|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34101464|NCT01978847|||OTHER||RETROSPECTIVE|||||||
34101465|NCT06658756|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a pragmatic clinical treatment, randomized-controlled, parallel, open, two-arm trial.||||
34101466|NCT06686589|||CASE_ONLY||PROSPECTIVE|||||||
34101467|NCT04305041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101468|NCT03646617|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103435|NCT01093573|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103436|NCT06691113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103437|NCT00406731|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34103438|NCT06256432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101469|NCT06344286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The feeding materials were prepared inside an opaque syringe and serially numbered by Total Parenteral Nutrition Department in our institution. The investigators who made all measurements, examinations and collected data, and the nurses of the babies were blinded. All of the infants in the study group were fed with breast milk during the trial.|"An enteral intake of breast milk with a volume of 10-20 mL/kg/day was defined as minimal enteral feeding. Minimal enteral feeding was initiated at postnatal 24 hours with breast milk via an orogastric tube. A total daily intake of 120 ml/kg/day was defined as full enteral feeding.~The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements."|t|t|t|f
34101470|NCT00540761|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34101471|NCT02596490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101472|NCT03325803|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34101473|NCT04816292|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34101474|NCT06219122|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline single case experimental design wherein all patients are first assigned to the control condition (or control period) and are then assigned to the intervention condition (or intervention period) and finally the follow-up period (control period). Patients are randomized for the time (t) at which they start with the intervention. CONSORT recognizes this design as an N=1 Trial, please refer to https://www.consort-statement.org/extensions/overview/n-of-1||||
34101475|NCT06214481|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34101476|NCT00345592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101477|NCT04090359|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial with two groups: revision THA with dual mobility components vs revision THA with large head, single bearing designs (36mm and 40mm).||||
34101478|NCT05226884|||CASE_CONTROL||PROSPECTIVE|||||||
34101479|NCT04179656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101480|NCT04796818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101481|NCT03515304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Persons performing the PET imaging, laboratory technicians are all masked.|Double-blind, placebo controlled trial|t|t|t|t
34101482|NCT01340118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101483|NCT05026619|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34101484|NCT06157827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101485|NCT04135352|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101486|NCT05156814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101487|NCT06689397|||COHORT||PROSPECTIVE|||||||
33717654|NCT02528656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101488|NCT04940052|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34101489|NCT04850274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101490|NCT05964166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717655|NCT05611203|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717656|NCT00079118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717657|NCT06336850|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717658|NCT03444519|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33717659|NCT03792867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717660|NCT01980914|NA|SINGLE_GROUP||PREVENTION||NONE||We propose a pilot study in 20 patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %. All patients will have well controlled hypertension and hyperlipidemia. Patients with a GFR less than 40ml/min, poorly controlled CHF and active coronary artery disease or cerebrovascular disease will be excluded, although a past history of CAD or stroke will not result in exclusion||||
33717661|NCT06194383|||COHORT||PROSPECTIVE|||||||
33717662|NCT02694874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717663|NCT02422628|||CASE_CROSSOVER||PROSPECTIVE|||||||
33717664|NCT02155179|||COHORT||RETROSPECTIVE|||||||
33717665|NCT03518073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717666|NCT03541824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717667|NCT00002144||||TREATMENT||||||||
33717668|NCT02144389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33717669|NCT00426192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33717670|NCT01272440|||COHORT||PROSPECTIVE|||||||
33717671|NCT03267498|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label clinical trial of concurrent and adjuvant nivolumab, including a run-in phase to establish basic feasibility of the nivolumab schedule followed by expansion.||||
33717672|NCT05810623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717673|NCT04447144|||COHORT||PROSPECTIVE|||||||
33717674|NCT01074957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717675|NCT04742933|||COHORT||PROSPECTIVE|||||||
33717676|NCT04831203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33717677|NCT02733367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717678|NCT01967251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717679|NCT01876342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717680|NCT06314568|||COHORT||PROSPECTIVE|||||||
33717681|NCT03231033|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33717682|NCT02058888|||OTHER||PROSPECTIVE|||||||
33717683|NCT00143403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101491|NCT05522829|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34101492|NCT03912415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101493|NCT06315894|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34101494|NCT05715346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double masked|Double-masked parallel|t|t|t|t
34101495|NCT06691074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101496|NCT06435520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized trial to compare the combined digital cognitive behavioral therapy (dCBTI) / structured medication taper (SMT) intervention, to the SMT intervention delivered alone for producing hypnotic discontinuation and insomnia symptom improvement.||||
34101497|NCT06690801|||COHORT||PROSPECTIVE|||||||
34101498|NCT04495998|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101499|NCT02536339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101500|NCT06003621|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicentre, single-arm, open-label, phase II signal-seeking trial||||
34101501|NCT04575961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101502|NCT06686082|||COHORT||PROSPECTIVE|||||||
34101503|NCT06395415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101504|NCT04701983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101505|NCT03769168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
33798337|NCT03718598|||CASE_CONTROL||PROSPECTIVE|||||||
34101506|NCT02080000|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34101507|NCT05051410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|it is doubled blinded study in which participants will be blinded. the assessor, who will assess the postoperative pain of participant will also be blinded regarding the intervention.|subject are randomly placed into one of the three groups:control,intracanal cryotherapy with needle irrigation, intracanal cryotherapy with EndoVac system. cold saline will be used in intracanal cryotherapy for five minutes. postoperative pain will be evaluated for 7 days using visual analogue scale.|t|f|f|t
34101508|NCT06378190|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I/II, pilot, open, national, prospective, multicentre, non-randomised||||
34101509|NCT05807893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798338|NCT02092519|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33798339|NCT02700958|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33798340|NCT04982445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798341|NCT04167163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798342|NCT03899324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798343|NCT00739141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798344|NCT05533515|||COHORT||PROSPECTIVE|||||||
33798345|NCT05920746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessor evaluating the patients' condition had no knowledge of the outcome of randomization of patients to the study groups.||t|f|f|t
33798346|NCT00738023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798347|NCT03823196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33798348|NCT01449422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798349|NCT00000493|RANDOMIZED|||PREVENTION||DOUBLE||||||
33798350|NCT00835952|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798351|NCT01215344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798352|NCT00951704|||COHORT||PROSPECTIVE|||||||
34101510|NCT06123468|NA|SINGLE_GROUP||TREATMENT||NONE||"All eligible enrolled patients will receive Sacituzumab-govitecan 10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W).~Patients will receive the treatment for a maximum of 12 months or until disease progression, unacceptable toxicity or withdrawal of consent, whichever occurs first."||||
34101511|NCT06321601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101512|NCT06647472|||CASE_ONLY||CROSS_SECTIONAL|||||||
34101513|NCT04365270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All participants and assessors will be masked,the wil just deal with the randomized numbers.~except the care provider because the materials consistency before mixing is obvious in 2 of the 3 groups"||t|f|t|t
34101514|NCT06688500|||COHORT||PROSPECTIVE|||||||
34101515|NCT01573728|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34101516|NCT02999360|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101517|NCT04460261|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study was designed as a prospective and experimental study. The participants were divided into two groups as geriatric individuals with and without chronic obstructive pulmonary disease (COPD). Both groups were trained 3 days a week under the supervision of a physiotherapist and other days of the week without a supervisor. The treatment program consisted of 4 weeks of foundation IMT followed by 4 weeks of functional IMT.|f|f|f|t
34101518|NCT06411691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798353|NCT01937507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798354|NCT00203372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798355|NCT02541565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798356|NCT03849495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798357|NCT03320434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798358|NCT06651294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators will be provided with coded products which are identical in appearance. Each individual involved in the study will be blinded to the treatment assignment until study completion. Considering the established safety profile of the formula of phytotherapeutic extracts, emergency unblinding of treatment assignment will not be necessary. So no copies of the treatment assignments will be stored at the enrollment sites. No information about the subjects will be shared with the company conducting the randomization.|Prospective, multicenter, double-blind, placebo-controlled, randomized, parallel-arm clinical study|t|f|t|t
33798359|NCT01954407|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33798360|NCT00124878|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33798361|NCT05653583|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33798362|NCT03573063|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Clinical study with biological sampling in healthy young women being nutrionally restricted (using encoded data)||||
33942569|NCT01029691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101519|NCT05377424|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34101520|NCT06053411|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34101521|NCT06683807|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34101522|NCT03845166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||single-agent and combination therapy dose-escalation followed by cohort-expansion||||
34101523|NCT06286098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34101524|NCT04253678|||COHORT||CROSS_SECTIONAL|||||||
34101525|NCT04344860|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, Controlled Trial||||
34101526|NCT06253728|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34101527|NCT06679855|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34101528|NCT03512080|||COHORT||CROSS_SECTIONAL|||||||
34101529|NCT04512183|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
34101530|NCT05558254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization is performed after baseline assesment. The outcomes assessor will be blinded to treatment/control group at follow-up assesment|The patient's legs will be randomised to either training with ROBERT® or usual training (control)|f|f|f|t
34101531|NCT05471856|NA|SEQUENTIAL||TREATMENT||NONE||||||
34101532|NCT06691412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101533|NCT02367040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101534|NCT04267861|||COHORT||RETROSPECTIVE|||||||
34101535|NCT05868954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101536|NCT00000778||||TREATMENT||||||||
34101537|NCT02513628|||COHORT||PROSPECTIVE|||||||
33942570|NCT06368375|||COHORT||CROSS_SECTIONAL|||||||
34101538|NCT04836910|||CASE_CONTROL||PROSPECTIVE|||||||
34101539|NCT00937937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101540|NCT04057794|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||All participants will undergo genetic counseling service post-genetic testing either locally or through central services.||||
34101541|NCT06685120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"They will be blinded patients, health care professionals who will assess clinical and functional outcomes (outcome assessors), and professionals who will analyze the data"|This is a double-blind randomized controlled clinical trial with 1:1:1 allocation|t|f|f|t
34101542|NCT05965466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Distal gastrectomy and Total gastrectomy||||
34101543|NCT04046952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101544|NCT04401475|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"This is a multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of EB05 in adult hospitalized patients with COVID-19. Following enrollment in the study, eligible subjects will be randomized at a ratio of 1:1 at baseline to receive an infusion of either EB05 or Placebo. In addition to study treatment, all patients will receive SOC treatment per routine care at each participating site. Randomization is stratified by site and baseline WHO COVID-19 severity strata defined as Levels 3-4 and Levels 5-6 for the phase 2 study and Levels 6-7 for the phase 3 study.~The total follow-up duration of each patient will be until 60-days from treatment with the investigational product. All assessments will take place in-hospital except for the 28-day and 60-day follow-up assessment which will be by telephone if the patient has been discharged before this assessment."|t|t|t|f
34101545|NCT06559969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patient and bedside observer will be blinded to which group the patient is in|Randomized controlled clinical trial|t|f|f|t
34101546|NCT03640988|NA|SINGLE_GROUP||TREATMENT||NONE||Pulsed acoustic wave on-label application on acute and chronic defects of the skin and subcutaneous soft tissues||||
34101547|NCT00917020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34101548|NCT04938466|||COHORT||PROSPECTIVE|||||||
34101549|NCT04195477|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101550|NCT04651374|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial of 20 participants in each arm.||||
34101551|NCT00558207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101552|NCT03228537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101553|NCT06502184|||COHORT||RETROSPECTIVE|||||||
33942571|NCT03349840|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomised prospective study||||
33942572|NCT04805606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942573|NCT04778995|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33942574|NCT00292513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101554|NCT04508413|NA|SINGLE_GROUP||OTHER||NONE||||||
34101555|NCT06695689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101556|NCT03378934|RANDOMIZED|PARALLEL||TREATMENT||NONE||"On the first day of the treatment period (Visit 1), eligible patients will be randomized into the Berberine Arm and the Control Arm.~In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.~In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks."||||
34101557|NCT01647256|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34101558|NCT04810078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101559|NCT06063031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, multicentric, double-blind randomized clinical trial|t|t|f|t
33717684|NCT01051050|RANDOMIZED|PARALLEL||||NONE||||||
33717685|NCT04431648|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single-Centre, Single-Arm, Non-Randomized, Phase-I MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Head and Neck Cancers||||
33942575|NCT00186121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942576|NCT04749303|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Large screen vs standard screen||||
33942577|NCT03158233|||COHORT||PROSPECTIVE|||||||
33942578|NCT04305158|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33717686|NCT06473766|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717687|NCT03970954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942579|NCT00465894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942580|NCT05232903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33942581|NCT03060109|||COHORT||PROSPECTIVE|||||||
33798363|NCT02751580|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33798364|NCT02155010|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33798365|NCT00761709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798366|NCT01071408|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||f|f|t|t
34101560|NCT04469530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Three cohorts of patients will be treated: 1) common solid tumors in complete remission, 2) common solid tumors in second complete remission, and 3) historical control cohort of patients derived from the electronic medical record matched with same diagnosis, metastatic site, and date of diagnosis utilizing a 2:1 ratio|||||
34101561|NCT06081530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101562|NCT06002074|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101563|NCT04818177|||OTHER||PROSPECTIVE|||||||
34101564|NCT05217966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101565|NCT06673199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Postmenopausal women (n=40), aged 45-65.|f|f|f|t
34101566|NCT05594251|||COHORT||PROSPECTIVE|||||||
34101567|NCT03039985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798367|NCT02434744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798368|NCT01820780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798369|NCT00002018||||TREATMENT||DOUBLE||||||
33798370|NCT00273078|||DEFINED_POPULATION||PROSPECTIVE|||||||
33798371|NCT01062087|||COHORT||RETROSPECTIVE|||||||
33798372|NCT02034968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798373|NCT05187975|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33798374|NCT04152694|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942582|NCT03104361|NA|SINGLE_GROUP||TREATMENT||NONE||Intravesicai injection of platelet-rich plasma||||
33798375|NCT05199142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798376|NCT02336438|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798377|NCT03221478|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33798378|NCT01854229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798379|NCT06407024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798380|NCT03482804|||OTHER||PROSPECTIVE|||||||
33798381|NCT01319617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798382|NCT05173324|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33942583|NCT03909035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942584|NCT06056245|||COHORT||PROSPECTIVE|||||||
34101568|NCT06602752|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Data will be collected through household surveys, vegetable vendor surveys, in-depth interviews, and focus group discussions. The study team has selected a subset of intervention FFZs for the evaluation and identified an equal number of geographic areas of similar size and level of urbanicity to serve as controls.||||
34101569|NCT06686979|||COHORT||PROSPECTIVE|||||||
34101570|NCT03599726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34101571|NCT05106764|||OTHER||RETROSPECTIVE|||||||
34101572|NCT05998642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101573|NCT06509074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors blinded to treatment allocation Blinded independent clinical event committee PROBE initiative|Randomized trial with 2 arms|f|f|f|t
34101574|NCT03137407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101575|NCT03390673|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34101576|NCT05130463|||COHORT||PROSPECTIVE|||||||
34101577|NCT06686355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Inclusion criteria:~1. Patients hospitalized in the ICU of Beijing Tongzhou Traditional Chinese Medicine Hospital and the ICU of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine from January 2024 to December 2026.~2. Meeting the diagnostic criteria for Qi deficiency and water overflow syndrome of septic cardiomyopathy.~3. Age ≥50 and ≤80 years old;~4. SOFA score: 2 to 12 points;~5. Diagnosis of septic cardiomyopathy within 24 hours;~6. Patient or family member has signed the informed consent form."|t|t|t|t
34101578|NCT03897010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101579|NCT05443334|||COHORT||PROSPECTIVE|||||||
34101580|NCT06695182|||COHORT||CROSS_SECTIONAL|||||||
34101581|NCT03294954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101582|NCT04295759|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I study and we will use a design similar to the Rolling-6 design and open 6 slots initially on Dose level 1. If we observe no-more than 1 DLT in these 6 subjects then we would expand this cohort to at least 12 patients for PK and additional safety information. If more than 1 DLT is observed on dose level 1 in 2-6 subjects, then further enrollment to dose level 1 will stop, the dose will be de-escalated to dose level 0 and the same approach will be repeated. Based on the above-outlined de-escalation rules, if dose level 0 is found to be too toxic, then the trial will be closed to accrual and the merits of amending or closing the trial permanently will be reconsidered.||||
34101583|NCT04463979|||COHORT||PROSPECTIVE|||||||
34101584|NCT00753077|||CASE_CONTROL||PROSPECTIVE|||||||
34101585|NCT06686459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101586|NCT06679660|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Single blinded randomized clinical study|f|f|t|t
34101587|NCT06087328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101588|NCT02595879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101589|NCT04573946|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34101590|NCT05293314|||CASE_CONTROL||PROSPECTIVE|||||||
34101591|NCT01433978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101592|NCT03266627|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients will receive one dose of CTLs at the same dose. Patients who meet the criteria may need additional CTL doses up to 5 total.||||
34101593|NCT04042311|NA|SINGLE_GROUP||TREATMENT||NONE||"Workstream 1: An initial single group cohort of 30 patients will be recruited and analysed to refine/alter the intervention and exclusion criteria based on its feasibility.~Workstream 2: This altered intervention and inclusion criteria will be considered in a further proof of concept study which will be multi-centre aiming to recruit a further x40 patients."||||
34101594|NCT04740918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101595|NCT05125627|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34101596|NCT00293982|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34101597|NCT05406570|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101598|NCT04887805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942585|NCT06048627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101599|NCT02572687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101600|NCT01266057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101601|NCT01602458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101602|NCT05249348|RANDOMIZED|CROSSOVER||OTHER||NONE||Single-dose crossover study one dose with food and one dose without food.||||
34101603|NCT02527265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101604|NCT05390320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101605|NCT06183463|||CASE_CONTROL||RETROSPECTIVE|||||||
34101606|NCT06109441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101607|NCT06694415|||COHORT||PROSPECTIVE|||||||
34101608|NCT06543589|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"The randomization unit in this study is the center, rather than individual patients. Centers will be randomized to either the ARM A or ARM B at each time period using a stepped-wedge cluster-randomized design. A randomization schedule will be generated using a computer-based random number generator to ensure unbiased allocation. At each of the specified time periods, a random subset of centers will be selected to switch from control to intervention.~While it is not feasible to blind the centers to their intervention status due to the nature of the study, the data analysts will be blinded to the group assignments to minimize bias. The randomization will be implemented by the study coordinator, who will notify each center of their assignment at the beginning of each time period. This approach ensures that each center will eventually receive the intervention, allowing for both within-center and between-center comparisons, thus enhancing the robustness of the study findings."||||
33942586|NCT03121625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942587|NCT02307331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942588|NCT00225394|||DEFINED_POPULATION||PROSPECTIVE|||||||
33942589|NCT04826315|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942590|NCT02948452|||CASE_CONTROL||PROSPECTIVE|||||||
33942591|NCT00665002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942592|NCT04590976|||COHORT||PROSPECTIVE|||||||
33942593|NCT01090167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942594|NCT01475214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942595|NCT02514889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942596|NCT06296602|NA|SINGLE_GROUP||PREVENTION||NONE||"A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.~A questionnaire will be completed by the doctor to record the data of interest."||||
33942597|NCT04552340|||COHORT||PROSPECTIVE|||||||
33942598|NCT04196244|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34021415|NCT06355999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Observers are naive as to the purpose of the experiment until after participation|Two groups, each receiving different feedback|t|f|f|f
34021416|NCT02761005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021417|NCT01706237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717688|NCT02953314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717689|NCT05595356|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33717690|NCT06398535|||CASE_ONLY||PROSPECTIVE|||||||
33717691|NCT00729989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717692|NCT01315067|||COHORT||CROSS_SECTIONAL|||||||
33717693|NCT00498602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717694|NCT04406961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||After the anatomical justification of the structure of the sphincter of Oddi. The technique of sphincterotomy with dissection of only the circular muscle layer of the sphincter of Oddi has been developed. A new knife design has been developed for this technique. The confidence interval and relative risk of complications was determined in patients who are treated with standard methods or with the new method of Dr. Dovbenko.|t|f|f|f
33717695|NCT00737074|||COHORT||RETROSPECTIVE|||||||
33717696|NCT05733624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717697|NCT03940664|||CASE_CONTROL||RETROSPECTIVE|||||||
33717698|NCT05319145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33942599|NCT03977363|||COHORT||PROSPECTIVE|||||||
33942600|NCT02242305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942601|NCT06313242|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33942602|NCT01219686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942603|NCT00053404|||COHORT||PROSPECTIVE|||||||
33942604|NCT02471625|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942605|NCT04855474|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Eight men and eight women will be provided three different amino acid intakes on three separate occasions (metabolic trials) over 8 hours following a 20km run. All protein intakes have an amino acid composition modelled off of the profile of egg protein.||||
33942606|NCT02286622|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942607|NCT00417248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942608|NCT01379404|||COHORT||PROSPECTIVE|||||||
33942609|NCT04137484|||COHORT||RETROSPECTIVE|||||||
33942610|NCT05547360|||COHORT||CROSS_SECTIONAL|||||||
33942611|NCT05139550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942612|NCT06081881|||COHORT||OTHER|||||||
33942613|NCT01834937|||COHORT||PROSPECTIVE|||||||
33942614|NCT04794530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942615|NCT05764694|||OTHER||CROSS_SECTIONAL|||||||
33942616|NCT05032196|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33942617|NCT02781662|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33942618|NCT01884935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942619|NCT03725709|||COHORT||PROSPECTIVE|||||||
33942620|NCT00548366|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33942621|NCT01480193|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Data management and analysis will be provided by blinded personnel.|This pilot trial will employ a randomized controlled design in a 3:1 allocation series to gain experience with the experimental intervention.|f|f|t|t
33942622|NCT03306849|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942623|NCT00106626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942624|NCT00014560||||TREATMENT||NONE||||||
33942625|NCT00892879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798383|NCT05317572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients were randomly divided into three groups of 50patients each. In the system where computer generated random numbers (SPSS v23.0, IBM,- Page 2 of 6 \[DRAFT\] -NewYork, USA) were used, groups were determined at a ratio of 1:1:1 . Sealed and sequentially numbered envelopes were created. One hour before the operation, an experienced anesthesiologist, who was not involved in the intraoperative and postoperative follow-up of the patient and would only perform the spinal anesthesia procedure, opened a sealed opaque sealed envelope to learn the group that the patient would be included in. There were two different physicians who performed intraoperative and postoperative follow-up. Both of the follow-up physicians were blind to the patient group|The patients were randomly divided into three groups of 50patients each. In the system where computer generated random numbers (SPSS v23.0, IBM,- Page 2 of 6 \[DRAFT\] -NewYork, USA) were used,|t|f|f|t
33798384|NCT02217904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798385|NCT00414544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798386|NCT04160429|||COHORT||PROSPECTIVE|||||||
33798387|NCT03963336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798388|NCT00566072|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33798389|NCT00834951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798390|NCT02549313|||COHORT||PROSPECTIVE|||||||
33798391|NCT06459063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798392|NCT04381975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798393|NCT02873312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The implanting investigator, the study subjects, and the individuals who assess the outcome measures for each subject will be blinded to the subjects' randomization groups. Each study site's programmers will be unblinded to the randomization assignment and will receive each subject's randomization assignment. The programmers will then set the stimulation parameters and train the subjects on device use.||t|t|t|f
33798394|NCT02012569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798395|NCT03260647|||CASE_ONLY||PROSPECTIVE|||||||
33798396|NCT00923871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798397|NCT00367159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798398|NCT04828148|||COHORT||CROSS_SECTIONAL|||||||
33798399|NCT05906940|NA|SINGLE_GROUP||SCREENING||NONE||||||
33798400|NCT04404686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Caregivers will receive a closed envelope with the drug to be used. since the routes of administration are different, from that point on the caregiver and patient will be aware of chosen drug||f|f|t|t
33798401|NCT04987021|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33798402|NCT01947790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798403|NCT04423016|||COHORT||PROSPECTIVE|||||||
33798404|NCT00253734|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798405|NCT05089526|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798406|NCT03664401|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Prospective, randomized controlled, split mouth (within subject) non-inferiority, single-center trial.||||
33798407|NCT06148831|RANDOMIZED|PARALLEL||OTHER||NONE|At the time of consent, the participant is randomly assigned to the intervention or control group.|||||
33798408|NCT05961462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798409|NCT02778828|NA|SINGLE_GROUP||OTHER||NONE||||||
33798410|NCT01922830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798411|NCT02205853|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
33798412|NCT03724578|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33798413|NCT03204565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021418|NCT02739945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021419|NCT04917289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021420|NCT02958423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021421|NCT03402555|||COHORT||PROSPECTIVE|||||||
34021422|NCT06330181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomly assigned to one of two intervention arms. Both groups receive the same number of sessions, duration of sessions, and measures procured.|t|t|t|f
34021423|NCT06633744|||COHORT||RETROSPECTIVE|||||||
34021424|NCT02336035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021425|NCT05813262|||COHORT||RETROSPECTIVE|||||||
34021426|NCT06179927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021427|NCT00605761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34021428|NCT04048044|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34021429|NCT02705404|||CASE_ONLY||PROSPECTIVE|||||||
34021430|NCT02932306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798414|NCT04306718|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798415|NCT01387009|||OTHER||CROSS_SECTIONAL|||||||
33798416|NCT01820182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798417|NCT01576107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021431|NCT03414411|||COHORT||PROSPECTIVE|||||||
34021432|NCT05531318|||OTHER||CROSS_SECTIONAL|||||||
34021433|NCT00309894|NON_RANDOMIZED|||TREATMENT||NONE||||||
34021434|NCT04164225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021435|NCT04320654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sealed envelopes|different groups each will receive specific intervention at the same time|t|f|f|f
34021436|NCT02823418|||COHORT||PROSPECTIVE|||||||
34021437|NCT03857750|||OTHER||PROSPECTIVE|||||||
34021438|NCT02730351|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34103439|NCT04062565|NA|SINGLE_GROUP||TREATMENT||NONE||"All participants will receive Treprostinil 2-3 times per day as tolerated.~* Subsequently, participants will receive Riociguat at 0.5 mg taken orally three times a day.~* Participants will receive the first dose inpatient prior to discharge.~* Participants will continue on a 2 ng/kg/min increase every other day for one week.~* Riociguat will subsequently be increased by 0.5 mg taken orally three times a day the following week as tolerated.~* Increases in Treprostinil and Riociguat will then alternate weeks such that only one medication is changed per week."||||
34103440|NCT02594852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021439|NCT01690741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021440|NCT04425135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103441|NCT02098473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798418|NCT05217849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization sequence will be generated in advance by Dr. Chao's research team using a random number generator and will be maintained in a secure location. Individuals who collect or analyze outcome data will be blinded to group assignment.|Participants will be randomly assigned to an on-line Tai Chi class, an on-line mindful movement class, or to an on-line Health and Wellness Education classes. All classes will meet twice a week for one hour for 12-weeks. The randomization sequence will be generated in advance by Dr. Chao's research team using a random number generator and will be maintained in a secure location. Individuals who collect and analyze outcome data will be blinded to group assignment.|f|f|f|t
33798419|NCT02918279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798420|NCT03638440|||OTHER||PROSPECTIVE|||||||
33798421|NCT04193969|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants are not informed about test results during or after the sessions. The test equipment is computer controlled and user independent.|The study has a cohort design and will include a patient group (male and female) attending a treatment program at the Spine Centre of Southern Denmark and an equally large control group matched on age and gender.|t|f|f|f
33798422|NCT04731948|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blind.|A double-blind randomized controlled trial.|t|f|t|t
33798423|NCT05628792|||CASE_ONLY||RETROSPECTIVE|||||||
33798424|NCT05520294|||OTHER||PROSPECTIVE|||||||
33798425|NCT05468398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798426|NCT01574339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798427|NCT01683149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798428|NCT04277715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798429|NCT01831700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798430|NCT03401034|||COHORT||PROSPECTIVE|||||||
33798431|NCT01551953|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33798432|NCT02479906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798433|NCT05372588|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798434|NCT02058875|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33798435|NCT05957653|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33942626|NCT04446273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Initial and outcome assessments will be administered by a well-trained and certified occupational therapist who is blinded to the group assignment, study hypotheses, and intervention of the patients.|Participants will be randomized into the proximal priority robotic priming and impairment-oriented training or the distal priority robotic priming and impairment-oriented training groups and receive 18 intervention sessions|f|f|f|t
34021441|NCT03544710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Mothers scheduled to deliver by emergency Caesarean section were randomly assigned to either bathing or routine care arms in a ratio of 1:1. We did simple randomization to either bathing or routine care arm without any blocks. We generated patient group assignments using the computer algorithm (computer-generated list of random numbers). The research assistant who enrolled mothers into the study assigned the study arm by checking from the list of random numbers. The research assistant and the PI, who were on the outcomes assessment arm was not allowed to ask the study participant concerning the allocation arm. Single blinding of PI and one of the research assistants assessing outcomes was done to minimize bias.|"The participants in the bathing arm were each given warm water and a tablet of soap containing chloroxylenol antiseptic and they were asked to bathe using it within at most two hours prior to the surgery. After bathing, the participants were given a clean theatre gown to put on, after which they were taken through the routine pre-operative preparation procedures according to the existing ward protocol.~The participants in the control arm were only taken through the routine preoperative preparation procedures according to the existing ward protocol"|f|f|f|t
34103442|NCT04996394|||COHORT||PROSPECTIVE|||||||
34103443|NCT02616952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103444|NCT00363363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103445|NCT06011824|||COHORT||PROSPECTIVE|||||||
33798436|NCT00139672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798437|NCT02380209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798438|NCT03496103|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH|||Investigator received de-identified biological material for further studies.|Healthy non allergic and ragweed allergic subjects were exposed to ragweed pollen in a pollen exposure chamber for 3 hrs and symptom score was recorded||||
33942627|NCT02026427|||CASE_CONTROL||PROSPECTIVE|||||||
33942628|NCT03144596|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized, parallel-group clinical trial||||
33942629|NCT01442545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103446|NCT06570707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798439|NCT03427034|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||all eligible patients will be recruited||||
33798440|NCT00580112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021442|NCT01841476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021443|NCT00256984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021444|NCT00620555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021445|NCT01208623|||CASE_ONLY||RETROSPECTIVE|||||||
34021446|NCT00475150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717699|NCT03855098|NA|SINGLE_GROUP||OTHER||NONE||Each participant is asked to eat a test food (mixed vegetables (spinach and lettuce), green beans and mixed berries (strawberries and blueberries). They are asked for urine samples for up to 6 hours after eating each food. They are also asked for a urine sample one day after eating the foods. The samples are then analysed for dietary biomarkers.||||
33717700|NCT01850550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717701|NCT01705652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717702|NCT01780103|||CASE_ONLY||RETROSPECTIVE|||||||
33717703|NCT00662610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717704|NCT05800795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|assessor of clinical parameters, histological samples and scanning electron microscopy samples|comparison between three groups|f|f|f|t
33717705|NCT03502408|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33717706|NCT05339594|||COHORT||PROSPECTIVE|||||||
33717707|NCT04841902|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33717708|NCT05241067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717709|NCT05966168|NA|SINGLE_GROUP||OTHER||NONE||||||
33717710|NCT00022620||||TREATMENT||NONE||||||
33717711|NCT02550366|||COHORT||PROSPECTIVE|||||||
33717712|NCT01948453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33717713|NCT02865187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717714|NCT02041611|NA|SINGLE_GROUP||OTHER||NONE||||||
33717715|NCT05356494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The results of the study are in accordance with current study but for improvement in oxygen saturation. However, other variables of ABGs did not show significant improvement after both techniques in community acquired pneumonia patients. In contrast to previous study, the techniques are only effective for improving saturation in patients with community acquired pneumonia.~single blinded study only participant blind."|The study concluded that both techniques are effective in improving oxygen saturation and reported statistically significant differences, but no other parameter was statistically improved.|t|f|f|f
33717716|NCT04734223|||CASE_CONTROL||RETROSPECTIVE|||||||
33717717|NCT05576740|||CASE_ONLY||PROSPECTIVE|||||||
33717718|NCT06040554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717719|NCT03965533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717720|NCT02289079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33717721|NCT00613249|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33717722|NCT02442869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Independent Evaluator was blind to condition assignment when conducting the assessments.|"This study used a Sequential Multiple Assignment Randomized Trial (SMART) design to pilot 4 adaptive treatment strategies (ATSs): ATS1 - Start with Stage 1 CAMS; if responding, end treatment; if not, continue on to Stage 2 CAMS. ATS2 - Start with Stage 1 CAMS; if responding, end treatment; if not, continue on to Stage 2 DBT. ATS3 - Start with Stage 1 TAU; if responding, end treatment; if not, continue on to Stage 2 CAMS. ATS4 - Start with Stage 1 TAU; if responding, end treatment; if not, continue on to Stage 2 DBT.~For Stage 1, we hypothesized that CAMS would show more improvement on suicide-related variables than TAU and would be more effective with suicidal college students presenting with less complexity at baseline. We did not identify hypotheses for clinical outcome variables in Stage 2 because it was exploratory in nature and focused on the feasibility and acceptability of implementing a SMART design to address suicidal risk in college students."|f|f|f|t
33717723|NCT01578356|||COHORT||PROSPECTIVE|||||||
33717724|NCT00643682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717725|NCT05825846|RANDOMIZED|PARALLEL||OTHER||NONE||"Subjects will be randomly assigned to one of two treatments:~1. slow breathing 1 (SB1)~2. slow breathing 2 (SB2)"||||
33717726|NCT02769325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717727|NCT00914524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717728|NCT03787953|||COHORT||CROSS_SECTIONAL|||||||
33717729|NCT01986660|NA|SINGLE_GROUP||||NONE||||||
33717730|NCT05076474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717731|NCT01831999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717732|NCT05407467|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33717733|NCT02622542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant and investigator/treating physician would be blinded until the day of treament initiation||f|f|f|t
33717734|NCT00337506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717735|NCT01166724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717736|NCT02689024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942630|NCT01380847|||COHORT||OTHER|||||||
33942631|NCT04149210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There will be masking of patients, surgeons and study staff at field site to the assigned treatment group of the subject.|This is a 1:1 randomized, double-masked, placebo controlled clinical trial|t|t|t|f
33942632|NCT05366881|||CASE_CONTROL||PROSPECTIVE|||||||
33942633|NCT00142714|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33942634|NCT04843228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to their assigned condition. They will have ID numbers created by random.org which will allow the care provider to be blinded to the assigned conditions of participants.|"Condition 1: Cognitive Bias Modification for active group~Condition 2: Cognitive Bias Modification for control group"|t|t|f|f
34021447|NCT02546401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021448|NCT01987973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021449|NCT04471974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021450|NCT06149715|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021451|NCT03472417|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34021452|NCT01913925|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34021453|NCT04296058|||COHORT||RETROSPECTIVE|||||||
34021454|NCT02129244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021455|NCT01877226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717737|NCT05571098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The design type was determined as a randomized controlled experimental study with a pretest-posttest control group, with repeated measurements.|t|f|f|f
33717738|NCT02268864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717739|NCT05308745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717740|NCT02983474|||COHORT||PROSPECTIVE|||||||
33717741|NCT02277301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33717742|NCT02592785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717743|NCT04367610|||CASE_ONLY||RETROSPECTIVE|||||||
33798441|NCT04380155|NA|SINGLE_GROUP||PREVENTION||NONE||Single group, cross-over, random order||||
33798442|NCT01659216|||COHORT||PROSPECTIVE|||||||
33798443|NCT01000077|||OTHER||OTHER|||||||
33798444|NCT03684044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798445|NCT00000900|||NATURAL_HISTORY||OTHER|||||||
33717744|NCT05122273|||CASE_ONLY||PROSPECTIVE|||||||
33798446|NCT01337635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33798447|NCT00978172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942635|NCT03181776|NA|SINGLE_GROUP||PREVENTION||NONE||The study will investigate the effect of different tilting angles on the hemodynamics of full term pregnants before and after spinal anesthesia||||
33942636|NCT02122302|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33942637|NCT02288663|NA|SINGLE_GROUP||OTHER||NONE||||||
33717745|NCT04298554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798448|NCT04144595|||COHORT||PROSPECTIVE|||||||
34021456|NCT01054235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021457|NCT00123474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798449|NCT02944188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798450|NCT03145155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33798451|NCT03000049|||COHORT||PROSPECTIVE|||||||
33798452|NCT04504786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33798453|NCT02726828|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33798454|NCT02051491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798455|NCT04111328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33798456|NCT03417869|||OTHER||PROSPECTIVE|||||||
33798457|NCT05622396|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798458|NCT00667056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798459|NCT06451185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A single centre, prospective, open label, randomised, controlled, adaptive investigation.||||
33798460|NCT01373697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798461|NCT06499714|||COHORT||PROSPECTIVE|||||||
33798462|NCT02059382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798463|NCT03311893|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33798464|NCT06444958|||CASE_ONLY||RETROSPECTIVE|||||||
33798465|NCT04894565|NA|SINGLE_GROUP||PREVENTION||NONE||Consecutive women with breast cancer who underwent breast cancer surgery||||
33798466|NCT01677130|||COHORT||PROSPECTIVE|||||||
33798467|NCT04788641|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798468|NCT04954638|||COHORT||PROSPECTIVE|||||||
33798469|NCT03524534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798470|NCT05263609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798471|NCT05763524|||COHORT||RETROSPECTIVE|||||||
33798472|NCT05081999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798473|NCT03175861|||CASE_ONLY||PROSPECTIVE|||||||
33798474|NCT06516315|NA|SINGLE_GROUP||OTHER||NONE||Prospective feasibility study||||
33798475|NCT06516861|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|masks the subjects and care provider from knowing which study treatment|The design of this study used a double-blind randomized controlled clinical trial with pre test post test with control group design, to assess the comparison of hemodynamics and post-intubation cortisol in the administration of intravenous Magnesium sulfate and intravenous Lidocaine. The study sample was all patients who underwent surgery who met the inclusion and exclusion criteria.|t|t|f|f
33798476|NCT00417950|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798477|NCT00006368||||TREATMENT||||||||
33798478|NCT00411034|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798479|NCT05319457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798480|NCT01485653|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33798481|NCT03674814|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be sequentially enrolled to increasing dose escalation cohorts based on safety and PK.||||
33798482|NCT04164056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798483|NCT06162897|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33798484|NCT01088659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798485|NCT06108778|||OTHER||PROSPECTIVE|||||||
33798486|NCT00539734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021458|NCT06483321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021459|NCT01948713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021460|NCT00851318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798487|NCT01566968|||COHORT||PROSPECTIVE|||||||
33798488|NCT02441881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798489|NCT01063972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798490|NCT03489915|||CASE_ONLY||PROSPECTIVE|||||||
33798491|NCT00589667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798492|NCT04730713|||COHORT||RETROSPECTIVE|||||||
33798493|NCT00265200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798494|NCT00459745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798495|NCT01384201|||||PROSPECTIVE|||||||
33798496|NCT01499992|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33798497|NCT05298020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798498|NCT00782158|||||OTHER|||||||
33798499|NCT03475524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021461|NCT05165316|||COHORT||CROSS_SECTIONAL|||||||
33798500|NCT06250413|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33798501|NCT00955825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798502|NCT00117936|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33798503|NCT04370418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798504|NCT02003469|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798505|NCT01760564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798506|NCT06061575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021462|NCT02730117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798507|NCT03195608|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Outcomes assessor will be masked regarding the pre or post-test status of the assessment.||f|f|f|t
33798508|NCT00211419|NON_RANDOMIZED|||TREATMENT||NONE||||||
33798509|NCT05458817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798510|NCT05517564|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33798511|NCT04901936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798512|NCT01238263|||CASE_CONTROL||PROSPECTIVE|||||||
33798513|NCT04530747|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798514|NCT05633719|||COHORT||PROSPECTIVE|||||||
33798515|NCT05221281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33798516|NCT02662894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798517|NCT01900834|||COHORT||PROSPECTIVE|||||||
33798518|NCT02318134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798519|NCT00766558|||COHORT||PROSPECTIVE|||||||
33798520|NCT00980473|RANDOMIZED|PARALLEL||TREATMENT||||||||
33798521|NCT05177601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798522|NCT04169698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798523|NCT04026594|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33798524|NCT06233500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This study will include 28 eyes with idiopathic full thickness macular hole; All eyes in this study will be subjected to pars plana vitrectomy procedure, they will be divided into two groups:~Group A: 16 eyes will be treated with only wide internal limiting membrane (ILM) peeling up to the arcades without ILM flap Group B : 16 eyes will be treated by ILM peeling with ILM flap."|t|f|f|f
33798525|NCT06154668|||COHORT||PROSPECTIVE|||||||
33798526|NCT03554460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798527|NCT03588715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will evaluate the impact of the combination of 3BNC117 and 10-1074 with or without antiretroviral therapy in virological rebound during an ATI and effects on the HIV reservoir.~This will be a pilot phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of a combination of Pegylated Interferon alpha 2b with the two broadly neutralizing antibodies (3BNC117 and 10-1074) in 14 (all recruited first) individuals or the combination the broadly neutralizing antibodies alone in 7 (only 1 was able to be recruited due to COVID delays and drug availability) HIV-1 infected individuals, undergoing a brief analytical treatment interruption (ATI)."||||
33798528|NCT05181592|NA|SINGLE_GROUP||TREATMENT||NONE|open label|International, multicenter, non-comparative, open-label, single arm study||||
33798529|NCT05183490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a single center, Phase 1, non-randomized open-label dose escalation study in two groups of immunocompromised patients. The recipients of allogeneic HCT who have will be enrolled in Group A, while SOT recipients will be enrolled in Group B. Each group will undergo independent dose escalation.~Dose levels selected for Group A are based on previous experience with VST cells in HCT recipients and are lower than in Group B (SOT recipients), as donor-derived R-MVST cells are more likely to persist in recipients of HCT from the same donors. Thus, there is theoretically a higher risk for development of GVHD in this subset of patients. Starting dose proposed for Group B is based on our previous experience with virus-specific cells used for therapy of JC-PML, where multiple infusions of PyVST cells were used at the doses of up to 2x106 TNC/kg. R-MVST cells will target a particular virus (or several viruses), based on the pattern of viral reactivation seen in each patient."||||
33798530|NCT02685189|||COHORT||PROSPECTIVE|||||||
33798531|NCT00108823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798532|NCT01362153|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798533|NCT04487600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Voiding trial protocols for each group (AVT and PVT) as well as data collection sheets were stored in sequentially numbered, opaque, sealed envelopes which were assigned after enrollment and were opened in the operating room at the completion of surgery by the surgical assistant. Attending surgeons and investigators were blinded to the individual patient study assignment. Due to the nature of the study, participants were not masked to their intervention.|Patients who were scheduled to undergo a same day discharge laparoscopic hysterectomy were assessed for eligibility to participate in this study. A computer generated blocked randomization schema was utilized with alternating block sizes to determine study groups. Participants were randomized 1:1 to each study group (active voiding trial vs. passive voiding trial). There was no cross-over between arms. If the participant did not receive the study intervention as allocated they were withdrawn from the study.|f|f|t|f
34103447|NCT03682146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were blinded with respect to the surgical method until the end of the 3-month evaluation and extraction of the primary study outcome.||t|f|f|f
34103448|NCT04837222|||COHORT||PROSPECTIVE|||||||
34103449|NCT01455090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103450|NCT04303169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103451|NCT05730478|||OTHER||OTHER|||||||
34103452|NCT05691569|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled open label trial with two parallel arms||||
33798534|NCT00418496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798535|NCT05781347|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be devided into 2 groups (obese and non-obese). Each group will be randomized (ratio 1:1) into 2 subgroups receiving the therapy (Stretta : Conservative/PPI)||||
33798536|NCT00183352|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33798537|NCT00237991|||||PROSPECTIVE|||||||
33798538|NCT04746131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103453|NCT02757768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798539|NCT03203538|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants will not be given information on the hypotheses/ expected effects from the different interventions (light conditions).|"Three related night shift studies have been planned. Each study investigates how different lighting conditions, administered through LED-based bright light integrated standard room lighting, affects adaptation to simulated night shifts and re adaptation to a day oriented schedule.~In each study, 28 participants (84 in total) will be exposed to the interventions (light conditions) in a randomized, blinded, controlled, crossover study.~The simulated night shifts will last from 11pm to 7am. The specific light conditions will last from 11pm to 5am (study 1: 1000 lux vs. 100 lux; study 2: 7000 K vs. 2500 K; study 3: 455 nm vs. 615 nm) where after (from 5am to 7am) all participants will be exposed to the same light conditions (200 lux, 4000 K). After completion of one bout of night work (three consecutive shifts for study 1 and 2; one night shift for study 3) there will be a washout period of four weeks before the participants cross over."|t|f|f|f
33798540|NCT06263673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798541|NCT00038506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798542|NCT06676683|||COHORT||PROSPECTIVE|||||||
33798543|NCT00505323|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33798544|NCT01517815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798545|NCT03995992|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two groups whih differ by the type of sport training: multisport versus diving||||
33798546|NCT00941655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798547|NCT00011154|||DEFINED_POPULATION||OTHER|||||||
33798548|NCT00521755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798549|NCT01542229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33798550|NCT05001529|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33798551|NCT05434624|RANDOMIZED|PARALLEL||TREATMENT||NONE||"For this study, it was planned to recruit 40 patients who would have FOB in the ICU of Abant İzzet Baysal University Anesthesia. All intubated patients over 18 years of age who do not meet the exclusion criteria will be included. Volume-controlled ventilation modes will be preferred during FOB. The pre-trade-inspired FiO2 will be increased to 100%. During the procedure, mean blood pressure, heart rate, oxygen saturation, respiratory rate, CVP, airway pressure, and BIS will be closely monitored. Enteral feeding will be discontinued at least 6 hours before the procedure. At the end of the procedure, the endotracheal tube position will be checked.~FOB will be performed using mobile bronchoscopy (Storz FB; 5.0 mm outer diameter). All patients will be monitored with BIS (Bispectral Index A-2000, Aspect Medical Systems, Netherlands) to measure the depth of sedation."||||
33798552|NCT05528146|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33798553|NCT00520546|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798554|NCT00535145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798555|NCT04307199|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Clinicians performing a membrane sweep cannot be blinded and it is not feasible to genuinely blind membrane sweeping for women. Therefore, neither clinicians administering the intervention nor women will be blinded to group assignment. Data will be reviewed by two assessors blinded to group allocation|"Women will initially be randomised in a 2:1 ratio to:~• Membrane sweep (2) versus no membrane sweep (1).~Those allocated to the intervention group will then be further randomised in a factorial fashion to A, B, C or D:~A. Membrane sweep @ 39 weeks' gestation only B. Membrane sweep @ 40 weeks' gestation only C. Membrane sweep @ 39, 40 and 41 weeks' gestation or until onset of labour D. Membrane sweep @ 40 and 41 weeks' gestation or until onset of labour"|f|f|f|t
33798556|NCT02828943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798557|NCT04049435|||CASE_ONLY||PROSPECTIVE|||||||
33798558|NCT03037086|||COHORT||RETROSPECTIVE|||||||
33798559|NCT03407846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798560|NCT03726424|||COHORT||PROSPECTIVE|||||||
33798561|NCT04877067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The cases were divided into 3 groups according to their similar demographic characteristics. Prospective open label||||
33798562|NCT05971680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798563|NCT03479034|||COHORT||PROSPECTIVE|||||||
33798564|NCT01024088|||||PROSPECTIVE|||||||
33798565|NCT00001277|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33798566|NCT04732260|NA|SINGLE_GROUP||OTHER||NONE||||||
33798567|NCT05623163|NA|SINGLE_GROUP||OTHER||NONE||||||
33798568|NCT05489536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798569|NCT04399148|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, cross-over study|t|f|f|t
33798570|NCT06345586|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants received Drospirenone will be assess for cervical mucus change by modified Insler score||||
34021463|NCT00111423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021464|NCT01445210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798571|NCT03038555|||COHORT||RETROSPECTIVE|||||||
33798572|NCT01489748|||COHORT||PROSPECTIVE|||||||
33798573|NCT03359967|||COHORT||PROSPECTIVE|||||||
33798574|NCT03440034|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open-label, non-randomized trial in 15 patients with sIBM||||
33798575|NCT00026234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798576|NCT00753480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798577|NCT04353934|||CASE_ONLY||CROSS_SECTIONAL|||||||
33798578|NCT00018668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798579|NCT06032117|||CASE_CONTROL||PROSPECTIVE|||||||
33798580|NCT01384240|NA|SINGLE_GROUP||SCREENING||NONE||||||
33798581|NCT05082935|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798582|NCT03608475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021465|NCT03629561|||COHORT||PROSPECTIVE|||||||
34021466|NCT00671918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021467|NCT02064114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021468|NCT02102516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021469|NCT02677714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021470|NCT00229320|RANDOMIZED|PARALLEL||||NONE||||||
34021471|NCT03512418|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot randomized controlled trial||||
34021472|NCT00229983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021473|NCT05004584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34021474|NCT01383135|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33798583|NCT06087549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomly allocated to receive ultrasound-guided PENG block, ESP block, or only spinal anesthesia by computer software 1:1:1. A researcher who will not involve in the study will prepare the randomization list and concealed group assignments in consecutively numbered, sealed, opaque envelopes. A consultant anesthesiologist will follow management to open the envelopes shortly before the nerve block performance to reveal the group allocation and perform the procedure according to the assignment. The patients and their anesthesia team, surgeon, operating room staff, and parents will be masked to the study group allocation. Group blinding unmasking will only occur once the statistical analysis is complete.|"Three groups:~Group I -control Group II - PENG block Group III - ESP block"|t|t|f|t
33798584|NCT02655458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798585|NCT02882035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33798586|NCT01491646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33798587|NCT04993898|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798588|NCT04562844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||single group for 1 study and multiples singles cases study for rehabilitation||||
33798589|NCT05773313|NA|SINGLE_GROUP||OTHER||NONE||||||
33798590|NCT04838496|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicentre, single-arm, prospective phase 2 study.||||
33798591|NCT03775785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The decision to start fortification will be made by the attending physician blinded to the intervention allocated. An employee outside the research team will feed data into the computer in separate datasheets so that the researchers can analyse data without having access to information about the allocation.|"This is a multi-centre superiority randomised parallel group, 1:1 allocation study.~After reaching 80 ml/kg/day of enteral feeding, patients will be randomised to receive standard fortification-SF (Bebilon HMF, Nutricia) or targeted fortification -TF (proteins, lipids,carbohydrates). Allocation will be performed electronically."|t|t|t|t
33798592|NCT03837600|||COHORT||OTHER|||||||
33798593|NCT03032224|||COHORT||PROSPECTIVE|||||||
33798594|NCT05161429|||COHORT||RETROSPECTIVE|||||||
33798595|NCT04759482|||CASE_ONLY||RETROSPECTIVE|||||||
33798596|NCT02024685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798597|NCT01806116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798598|NCT05369169|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects will complete an active treatment of slow resonance paced breathing and a control visual color block task on separate days, separated by approximately one week||||
33798599|NCT03432403|||CASE_CONTROL||PROSPECTIVE|||||||
33798600|NCT00991107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798601|NCT02180763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798602|NCT01044303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798603|NCT02035670|||COHORT||PROSPECTIVE|||||||
33798604|NCT00134069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798605|NCT02497716|NA|SINGLE_GROUP||OTHER||NONE||||||
33798606|NCT00995163|||COHORT||PROSPECTIVE|||||||
33798607|NCT05800041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798608|NCT01079065|RANDOMIZED|CROSSOVER||||NONE||||||
33798609|NCT05521061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33798610|NCT00521131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798611|NCT01495091|||OTHER||CROSS_SECTIONAL|||||||
33798612|NCT01671358|||COHORT||PROSPECTIVE|||||||
33798613|NCT06335576|||COHORT||PROSPECTIVE|||||||
33798614|NCT04537403|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798615|NCT03858868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798616|NCT05904925|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33942638|NCT03270631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant are not aware which treatment and exercises they will have, physical therapist who perform treatments and exercise prescription were blinded for measurements and each others work. Outcome assessor was blinded for baseline study results and treatment groups. Investigator was blinded for all the work done by others.|Five groups: 1) control, 2) fascial manipulation (FM) + movement control exercise (MCE), 3) FM + sham-MCE, 4) MCE + sham-FM and 5) sham-FM and sham-MCE|t|t|t|t
33942639|NCT05953896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||this study is designed as a parallel randomized controlled clinical trial|t|f|f|f
33942640|NCT05188560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798617|NCT02544152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider and outcomes assessor were also blinded||t|f|t|f
33798618|NCT04425668|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single blinded- dentists to be blinded; Analyses will be done by blinded analyst||t|f|f|t
33798619|NCT04816799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33798620|NCT00528944|||COHORT||PROSPECTIVE|||||||
33798621|NCT03032913|||COHORT||PROSPECTIVE|||||||
33798622|NCT00701896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021475|NCT01589965|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021476|NCT04875923|||COHORT||PROSPECTIVE|||||||
34021477|NCT04153383|||OTHER||PROSPECTIVE|||||||
34021478|NCT04622215|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34021479|NCT01906463|||COHORT||PROSPECTIVE|||||||
34103454|NCT05375266|||CASE_CONTROL||PROSPECTIVE|||||||
33798623|NCT01715636|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798624|NCT01957124|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33798625|NCT02486835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798626|NCT01137708|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798627|NCT04877652|||COHORT||PROSPECTIVE|||||||
33798628|NCT02274142|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33798629|NCT01945125|RANDOMIZED|PARALLEL||||NONE||||||
33798630|NCT03882554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798631|NCT02601170|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798632|NCT05728008|||COHORT||RETROSPECTIVE|||||||
33798633|NCT03206684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798634|NCT05793723|||CASE_CONTROL||PROSPECTIVE|||||||
33798635|NCT01897155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33798636|NCT06267131|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center prospective observational cohort study||||
33798637|NCT05395546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798638|NCT06175000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
33798639|NCT02093312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33717746|NCT02331836|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
33798640|NCT05378828|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798641|NCT03665779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A double-blind study is one in which neither the participants nor the experimenters know who is receiving a particular treatment. This procedure is utilized to prevent bias in research results. Double-blind studies are particularly useful for preventing bias due to demand characteristics or the placebo effect. In a double-blind study, the investigators who interact with the participants would not know who was receiving the actual drug and who was receiving a placebo.|"The patients will be divided into 2 groups:~Group 1:~70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)~Group 2:~70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix."|t|f|t|f
33717747|NCT04828447|RANDOMIZED|CROSSOVER||OTHER||NONE||Pilot prospective randomized crossover clinical trial||||
33798642|NCT00376363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798643|NCT02159846|||CASE_CONTROL||PROSPECTIVE|||||||
33798644|NCT04933890|||COHORT||CROSS_SECTIONAL|||||||
33798645|NCT01689090|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33798646|NCT05815797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798647|NCT05106634|||OTHER||CROSS_SECTIONAL|||||||
33798648|NCT02663778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798649|NCT05357469|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798650|NCT01267383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717748|NCT06125587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798651|NCT02108210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798652|NCT04469855|||COHORT||PROSPECTIVE|||||||
33798653|NCT00417703|||||PROSPECTIVE|||||||
33798654|NCT05429034|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33798655|NCT04600440|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label||||
33798656|NCT06437600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798657|NCT00329251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798658|NCT04960072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798659|NCT00003432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798660|NCT04760834|||COHORT||PROSPECTIVE|||||||
34021480|NCT06223243|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Tthe assessor was not involved in the mouthrinse assignment. Besides, the bottles were covered to prevent from showing the color of mouthrinse.|randomised clinical trial, blinded and performed in 3 parallel groups.|t|f|t|t
34021481|NCT00527306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021482|NCT04040023|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Prospective monocentric superiority study in two successive steps||||
34021483|NCT06424210|||COHORT||RETROSPECTIVE|||||||
34021484|NCT00077753|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34021485|NCT06178432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798661|NCT04356430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021486|NCT02015559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021487|NCT05900128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021488|NCT00303121|||DEFINED_POPULATION||OTHER|||||||
34021489|NCT05848414|||COHORT||PROSPECTIVE|||||||
34021490|NCT03102801|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34021491|NCT00987389|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34021492|NCT01459562|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34021493|NCT01330459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021494|NCT02427035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021495|NCT05571865|RANDOMIZED|PARALLEL||PREVENTION||NONE||Diabetic, and non-diabetic subjects.||||
34021496|NCT04281173|||COHORT||PROSPECTIVE|||||||
34021497|NCT05451992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798662|NCT00130156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798663|NCT02036307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798664|NCT01353001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798665|NCT02015546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33798666|NCT05631210|RANDOMIZED|PARALLEL||OTHER||NONE||Two groups were randomly created. Both groups were given an imaginary privacy agreement about a wearable that would collect health data from the participant. Group 1 was given that privacy agreement with only words and group 2 was given the privacy agreement with the addition of pictograms at the top. Those pictograms were meant to summarize the content of the privacy agreement and highlight the most important parts.||||
33798667|NCT06123871|||COHORT||RETROSPECTIVE|||||||
33798668|NCT00334594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798669|NCT06191666|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33798670|NCT00911521||PARALLEL||PREVENTION||NONE||||||
33798671|NCT05624112|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798672|NCT05709899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798673|NCT02933944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798674|NCT03310866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798675|NCT03924037|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study will utilize a between-subjects design with random assignment to the control (ZS) and the experimental groups (ZS+).||||
33798676|NCT05800639|||COHORT||PROSPECTIVE|||||||
33798677|NCT03436277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798678|NCT04327167|NA|SINGLE_GROUP||OTHER||NONE||||||
33798679|NCT00328731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717749|NCT01189812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717750|NCT00799604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717751|NCT04528849|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717752|NCT03474354|||COHORT||PROSPECTIVE|||||||
34021498|NCT05040438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103455|NCT06305234|||COHORT||PROSPECTIVE|||||||
33798680|NCT04275245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103456|NCT06523387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103457|NCT01293955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103458|NCT02370186|||OTHER||PROSPECTIVE|||||||
33717753|NCT04054388|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|All patients will be instructed not to tell colonoscopists, nurses and investigators before, during and after the procedure about their preparation method and when they receive instructions.|LINE is a popular application (App) which can share free words, photos, videos and voice messages (http://line.me/en/). LINE is available on all smart phone devices and personal computer. LINE re-education before colonoscopy to confirm optimal bowel cleansing.|f|f|t|f
33717754|NCT02508402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717755|NCT00460408|||||PROSPECTIVE|||||||
33717756|NCT01586169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717757|NCT04288648|||OTHER||OTHER|||||||
33717758|NCT03702946|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33717759|NCT01614067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717760|NCT02786251|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33717761|NCT01287689|||COHORT||PROSPECTIVE|||||||
33717762|NCT04053192|||COHORT||RETROSPECTIVE|||||||
33717763|NCT00763308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717764|NCT04399577|NA|SINGLE_GROUP||OTHER||NONE||||||
33717765|NCT03206853|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Traditional therapy group：the aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.~Hybrid operation group: Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion."|f|f|f|t
33717766|NCT03829150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717767|NCT05118074|||COHORT||PROSPECTIVE|||||||
33717768|NCT04791566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717769|NCT04602182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The person responsable for carrying out the statistical analysis will be blinded|Single-blind randomized clinical trial in parallel groups and controlled with standard clinical practice.|f|f|f|t
33717770|NCT02202408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717771|NCT03827304|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This study aimed to explore:~* patient and staff perceptions of the effect of active and passive VR on perceived pain and anxiety during painful dressings changes;~* patient perceptions of the usability, acceptability, engagement with and enjoyment of active and passive VR scenarios;~* staff perceptions about the usability and implications of the VR technology within a Burns Unit inpatient setting.~Methods: This was a small-scale qualitative usability study, employing qualitative methods to intervention development and feasibility work.~Patients: Participants were adult inpatients at the local Burns Unit who were undergoing regular dressing changes during the study period. Exclusion criteria included head and neck burns, wound infection, current diagnosis of PTSD, active psychotic symptoms or high levels of distress. Suitable patients were briefly introduced to the study and supplied with a full information sheet, with details about aims, procedures and rights."||||
33717772|NCT01569646|||CASE_ONLY||RETROSPECTIVE|||||||
33717773|NCT01883830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717774|NCT00492687||||TREATMENT||NONE||||||
33717775|NCT00271050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717776|NCT00416078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717777|NCT03037411|||COHORT||PROSPECTIVE|||||||
33717778|NCT00293254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717779|NCT06120231|NA|SINGLE_GROUP||OTHER||NONE||||||
33717780|NCT00541489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717781|NCT03051035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717782|NCT02379806|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33717783|NCT04694144|||CASE_ONLY||PROSPECTIVE|||||||
33717784|NCT05357950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717785|NCT03993340|||COHORT||PROSPECTIVE|||||||
33717786|NCT04199572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The physicians, participants, nurses and the outcome assessor will all be blinded to the intervention. The trial packets will be prepared containing the active drugs and placebos.|Combination 1- Diclofenac Placebo Paracetamol (Oral) Combination 2- Diclofenac Paracetamol (IV) Placebo Combination 3- Diclofenac Placebo Placebo|t|t|f|t
34103459|NCT02957903|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34103460|NCT02506439|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34103461|NCT01345942|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34103462|NCT02242903|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34103463|NCT00635466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103464|NCT01097681|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103465|NCT03996018|||COHORT||PROSPECTIVE|||||||
33942641|NCT04879576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942642|NCT02354599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942643|NCT02349841|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942644|NCT04293081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942645|NCT01941160|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33942646|NCT06006676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel group randomised prospective open label trial of two ventilation strategies during V-V ECMO for ARDS with standardised crossover weaning studies||||
34101609|NCT05945355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|For every 1 participant allocated to sham, 2 will be active IT. Among them, half will be allocated low-dose and half high dose. To provide balance among treatment groups regarding sex/obesity-status, randomization will occur within four strata (males obese,females obese,males non-obese,females non-obese).Treatment assignment will be obtained using Duke REDCap enrollment/randomization system. All study staff and participants will be blinded to the treatment assignment at screening/enrollment and prior to treatment group allocation. Participants in the active IT and sham arms will use the same device. Participants may try to discern their device resistance. Although true masking of active IT versus sham may not be possible in all cases, participants will only be told that they are receiving 1 of 3 possible resistances. However, staff members who are assessing endpoints and performing statistical analyses will be blinded to treatment assignment until after the database is locked|This is single-center cross-sectional mechanistic study in lean and obese children with moderate-severe asthma, followed by a randomized, SHAM-controlled trial of Inspiratory Training (IT).|t|t|t|t
34101610|NCT03865706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blind, randomized|placebo-controlled trial with 1:1:1 enrollment into three arms: inulin 32 g/day, inulin 16 g/day, and placebo|t|t|t|t
34101611|NCT06584409|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants were randomized by computer software (Excel 2016 for Windows) and the randomization process was overseen by the Institutional Review Board at Taichung Veterans General Hospital. All the participants and our collaborative case-manager were blinded to treatment types.|The patients was divided to sham group or laser acupuncture group. After 1 months treatment, and followed up for 6 months., the sham group received complementary laser acupuncture for 1 months and followed up for another 3 months.|t|t|f|t
34101612|NCT06687018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101613|NCT05896124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101614|NCT02276833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101615|NCT01568697|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34101616|NCT00634855|||CASE_CONTROL||PROSPECTIVE|||||||
34101617|NCT04922073|||COHORT||PROSPECTIVE|||||||
34101618|NCT03598465|||COHORT||PROSPECTIVE|||||||
34101619|NCT02100644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101620|NCT01366404|||COHORT||PROSPECTIVE|||||||
34101621|NCT06158360|||COHORT||PROSPECTIVE|||||||
34101622|NCT05810038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717787|NCT00740844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717788|NCT05729464|||CASE_CONTROL||RETROSPECTIVE|||||||
33717789|NCT00299455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942647|NCT00271362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942648|NCT02974673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942649|NCT04665492|||COHORT||PROSPECTIVE|||||||
33717790|NCT06498947|||COHORT||PROSPECTIVE|||||||
33942650|NCT00003410||||DIAGNOSTIC||||||||
33942651|NCT06205212|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33942652|NCT03689114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a multicenter randomized pragmatic parallel-group single-blind non-inferiority trial.|t|f|f|f
33942653|NCT01757028|||CASE_CONTROL||PROSPECTIVE|||||||
33942654|NCT02430298|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33942655|NCT01486979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942656|NCT04542863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942657|NCT02230644|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33717791|NCT05492617|||COHORT||RETROSPECTIVE|||||||
33942658|NCT02058966|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33942659|NCT01721213|||||PROSPECTIVE|||||||
33942660|NCT03514394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research Assistants and expert reviewers of therapy sessions will not be made aware of which condition the therapist is assigned to.|Phase 1 will consist of observation and qualitative interviews; Phase two will consist of iterative design methods; phase three is a pilot randomized clinical trial|f|f|f|t
33942661|NCT04384276|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||A single experimental group will be enrolled prospectively to use the Weigh Easy system. Due to the potential impacts of weight gain within this patient population and the lifelong implications of early malnutrition, we do not feel we can safely randomize a prospective control group. As a result, a retrospective control group will be enrolled to enable a comparison of outcomes between those families using the Weigh Easy system and those who did not. All patients, both retrospective and prospective, will be treated according to the standard cleft lip and/or palate treatment protocols and followed by the registered nutritionists who routinely participate in the Cleft and Craniofacial Clinic||||
33717792|NCT03463343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33717793|NCT02536352|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33717794|NCT03178981|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33717795|NCT00344747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717796|NCT05822531|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot study is being conducted to inform feasibility of the next phase of this research project.||||
33798681|NCT06198712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717797|NCT05412654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blinded randomised controlled trial|t|f|f|t
33717798|NCT05281991|||COHORT||PROSPECTIVE|||||||
33717799|NCT04480437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The proposed trial is designed as an explorative, open label, non-randomised, uncontrolled clinical trial.||||
33798682|NCT03090776|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Investigational Drug service will prepare ketamine vs placebo infusion for administration during surgery|arm 1:unenriched for risk of PPMP, ketamine vs placebo arm 2: enriched for risk of PPMP, ketamine vs placebo|t|t|t|t
33717800|NCT02668133|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33942662|NCT03327740|||COHORT||PROSPECTIVE|||||||
33942663|NCT04059328|||OTHER||PROSPECTIVE|||||||
33942664|NCT01369394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021499|NCT01120509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717801|NCT05184920|||COHORT||PROSPECTIVE|||||||
33717802|NCT01564797|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021500|NCT03654469|||COHORT||PROSPECTIVE|||||||
34021501|NCT02397408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021502|NCT00801580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021503|NCT05713968|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34021504|NCT01404715|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021505|NCT02299024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021506|NCT05789693|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Blinded|Parallel Assignment|t|f|f|f
34021507|NCT06017076|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021508|NCT04311788|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021509|NCT04059458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021510|NCT04824157|||OTHER||RETROSPECTIVE|||||||
34021511|NCT04769063|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34021512|NCT05201352|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021513|NCT03056157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021514|NCT03096743|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34021515|NCT04896749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021516|NCT04763564|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, double-blind, 2-period, placebo-controlled, crossover proof of concept study.|t|t|t|t
34021517|NCT00150891|||DEFINED_POPULATION||PROSPECTIVE|||||||
34021518|NCT03858192|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective cohort study||||
34101623|NCT05297019|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Participants, the principal investigator, and outcomes assessor will be blinded to patient's HBOT dosing. Technicians at the clinic will know which treatment dose each participant is receiving in order to deliver appropriate dosing.|"The control group will crossover to active treatment after 3 months of observation."|t|f|t|t
34101624|NCT06565936|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33717803|NCT02557646|||COHORT||PROSPECTIVE|||||||
33717804|NCT00481000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798683|NCT04691635|||CASE_CONTROL||PROSPECTIVE|||||||
33942665|NCT05620160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942666|NCT01799291|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33942667|NCT00012870|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34021519|NCT00348452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021520|NCT06634251|||COHORT||RETROSPECTIVE|||||||
34021521|NCT00471952|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34021522|NCT02443259|||COHORT||PROSPECTIVE|||||||
34021523|NCT06370130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34021524|NCT04029311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021525|NCT02066103|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34021526|NCT00040768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021527|NCT00422578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021528|NCT00157079|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34021529|NCT00050323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021530|NCT03866902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The statistician has created a randomization table in RedCap. After enrollment and baseline assessment, dyads will be randomized to either the intervention or control group using a computer-generated randomization table, stratifying by BMI group, overweight (25 - 29.9 kg/m²) and obese (\>30 kg/m²), and utilizing blocking to help ensure balance between the groups. Mothers will be informed of their group assignment by telephone.|Two group randomized controlled repeated measures study|t|t|t|t
34021531|NCT04590066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
34101625|NCT03975647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101626|NCT04666155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|f|f|t|t
34021532|NCT02355483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021533|NCT04140435|||COHORT||PROSPECTIVE|||||||
34021534|NCT03402750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021535|NCT05437367|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Randomized experimental, controlled study (pretest- posttest measurement). Inclusion Criteria|t|f|f|f
34021536|NCT01340326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021537|NCT05579275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021538|NCT03282474|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, single-arm multicenter, phase II pilot trial||||
34021539|NCT00942435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101627|NCT03012152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101628|NCT06064526|||COHORT||RETROSPECTIVE|||||||
34101629|NCT03620981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101630|NCT06351189|||CASE_ONLY||PROSPECTIVE|||||||
34101631|NCT06651554|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
33717805|NCT05152901|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33717806|NCT00260403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33717807|NCT03438175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717808|NCT05253170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717809|NCT03274401|RANDOMIZED|PARALLEL||SCREENING||NONE||Patients with newly diagnosed pulmonary embolism will be randomized to screening for atrial fibrillation or standard of care||||
33717810|NCT01453257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717811|NCT03483883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717812|NCT02313181|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33798684|NCT01130727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021540|NCT05840237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Individual patients will be randomized, and will receive a numbered bottle that corresponds to either Oxaloacetate or placebo. At the end of the trial, the blind will be broken to reveal which participant is in which group.|Single Center, Randomized, Placebo Controlled, Double Blind|t|t|t|f
34101632|NCT04824066|||COHORT||PROSPECTIVE|||||||
34101633|NCT06223698|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two separate cohorts will be randomized (two arms in each study cohort)||||
34101634|NCT06686550|||COHORT||PROSPECTIVE|||||||
34101635|NCT02240784|||COHORT||PROSPECTIVE|||||||
34101636|NCT05250726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101637|NCT02714543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34101638|NCT05496231|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blinded for study vs comparator vaccine; double-blinded for 3 formulations of study vaccine||t|t|t|t
34101639|NCT05249426|RANDOMIZED|PARALLEL||TREATMENT||NONE|Partly randomized trial. Patients will be randomized into cohort A, B, C and D. No randomization in cohort E.|||||
34101640|NCT04356703|||COHORT||PROSPECTIVE|||||||
34101641|NCT06691685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717813|NCT03578289|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33717814|NCT05230810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717815|NCT05503641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33717816|NCT01029574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33717817|NCT03012958|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33798685|NCT01361945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798686|NCT00293358|NON_RANDOMIZED|||TREATMENT||||||||
33798687|NCT06281808|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798688|NCT02178098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798689|NCT02539225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798690|NCT00785512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798691|NCT03872362|||COHORT||RETROSPECTIVE|||||||
33798692|NCT04251013|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||National prospective multicenter RCT||||
33798693|NCT02917343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798694|NCT01612169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798695|NCT05664477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798696|NCT05975749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798697|NCT01505452|||OTHER||CROSS_SECTIONAL|||||||
34021541|NCT00283023|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Cell culture||||
34021542|NCT01462773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021543|NCT00210990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021544|NCT03791723|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups,group one is for Sacubitril/valsartan 200mg bid or tolerable maximum dose, group two is for valsartan 80mg qd or tolerable maximum dose.||||
34021545|NCT00978263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021546|NCT00734981|||CASE_CROSSOVER||PROSPECTIVE|||||||
34021547|NCT00801099|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34101642|NCT06682975|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Parallel (active or placebo), sequential (dose escalation)|t|f|t|f
33717818|NCT01606345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717819|NCT04993456|||COHORT||PROSPECTIVE|||||||
33717820|NCT04801160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717821|NCT04484792|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33717822|NCT00132145|RANDOMIZED|PARALLEL||||NONE||||||
33717823|NCT01518166|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33798698|NCT03887650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||single-center, prospective, randomized controlled cross-sectional study|t|t|f|t
33798699|NCT02517450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33798700|NCT01958866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798701|NCT06513117|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot single arm trial of a structured responsive exercise program and psychological/behavioural support.||||
33798702|NCT01123408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798703|NCT05862610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798704|NCT05184036|||OTHER||CROSS_SECTIONAL|||||||
33798705|NCT05186714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798706|NCT00223535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33798707|NCT00085436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798708|NCT03454646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798709|NCT04597203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33798710|NCT03878199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798711|NCT00150176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798712|NCT01213303|||COHORT|||||||||
33798713|NCT04022616|||COHORT||PROSPECTIVE|||||||
33798714|NCT04446078|NA|SINGLE_GROUP||TREATMENT||NONE|patient coding|prospective cohort||||
33798715|NCT05084612|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double blinded||t|f|f|t
33798716|NCT03454529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021548|NCT02734654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34021549|NCT01061619|||CASE_ONLY||RETROSPECTIVE|||||||
34021550|NCT02857751|||COHORT||PROSPECTIVE|||||||
34021551|NCT02318186|||COHORT||PROSPECTIVE|||||||
34021552|NCT03418090|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Open label crossover study||||
34021553|NCT02548130|||COHORT||RETROSPECTIVE|||||||
34021554|NCT03292536|NA|SINGLE_GROUP||TREATMENT||NONE||a single arm, open label, pharmacodynamics, intrapatient dose escalation phase 1B study||||
34101643|NCT06683924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101644|NCT06160440|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Parallel assignment|t|t|t|t
34101645|NCT05457140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101646|NCT05816187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798717|NCT03687892|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33798718|NCT04613336|||CASE_CONTROL||PROSPECTIVE|||||||
33717824|NCT02659631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942668|NCT04273620|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Due to the implicit constraints of cognitive interventions (no placebo possible as opposed to drug studies), neither the patient himself nor the therapist of the study can be blinded to the patient's allocation arm. However, the assessment of the functional impairment will be performed by rehabilitation staff who are blind to the patient's allocation. Furthermore, the assessment of neglect severity by use of a computerized neuropsychological test battery is robust and objective and largely independent of the investigator who is administering the test.|This study will be a mono-centric, randomized, controlled, clinical trial. Using a crossover design with two arms, patients will either receive the intervention therapy first and then the control treatment or they will start in the control arm and then switch to the intervention.|f|t|f|t
33942669|NCT02873039|||COHORT||PROSPECTIVE|||||||
33942670|NCT00495274|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717825|NCT04771507|NA|SINGLE_GROUP||TREATMENT||NONE||Patients treated with ibrutinib for at least 6 months and have achieved at least partial response will after inclusion stop the ibrutinib treatment and be followed-up for the study. If progress, they will re-initiate ibrutinib treatment. When they achieve at least partial response they stop the treatment again, and so on.||||
33717826|NCT05728307|||COHORT||PROSPECTIVE|||||||
33717827|NCT02240199|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33717828|NCT04040478|||COHORT||PROSPECTIVE|||||||
33717829|NCT03120819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participant are randomized after receiving an exercise recommendation by their oncologist and thus oncologists are masked; however, study staff will administer survey questions including acceptability of the DVD and thus outcomes assessors are not masked|2 x 3 repeated measures design with 2 groups and 3 time points|f|t|t|f
33717830|NCT04532957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717831|NCT04081311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All clinical measurements were taken by a single blinded investigator (Periodontal Resident) while a single dental hygienist was responsible for prophylaxis and delivery of oral hygiene instructions to the study participants|Randomized, controlled clinical trial in a single center.|f|f|t|f
33717832|NCT05497674|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717833|NCT02348827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33717834|NCT04737343|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized, open-label, control, non-inferiority study||||
33717835|NCT02823288|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33717836|NCT01822340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717837|NCT05789147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study to evaluate the effects of 6-month tVNS (1 hour/day) in heart failure patients on autonomic biomarkers.||||
33717838|NCT00301574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717839|NCT00464087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717840|NCT05793476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant doesn't know if she receives the sham or laser therapy.||t|f|f|f
33717841|NCT01753427|||CASE_ONLY||CROSS_SECTIONAL|||||||
33717842|NCT04471012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33717843|NCT05503940|||COHORT||PROSPECTIVE|||||||
33717844|NCT05268939|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Performance Evaluation study||||
33717845|NCT02651727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942671|NCT03807336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial|t|f|f|f
33942672|NCT03385395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942673|NCT00000610|RANDOMIZED|||TREATMENT||||||||
33942674|NCT02160743|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942675|NCT03288558|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33942676|NCT00085189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942677|NCT01262040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942678|NCT05261321|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded masking.||t|f|t|f
33942679|NCT03023436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942680|NCT06496399|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942681|NCT03757702|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942682|NCT02612194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942683|NCT01289730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942684|NCT02444611|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33942685|NCT01404884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942686|NCT05568251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators and outcome assessors will be blinded.||t|f|t|t
33942687|NCT02811367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942688|NCT01230827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942689|NCT03570476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942690|NCT02081664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942691|NCT05150925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942692|NCT03495999|||COHORT||PROSPECTIVE|||||||
33942693|NCT05661500|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessments will be performed by a investigator who was blinded to group allocation.|This study is a randomized controlled trial with experimental and control groups including pretest, posttest and persistence test.|f|f|f|t
33942694|NCT01209299|||OTHER||RETROSPECTIVE|||||||
33942695|NCT06145269|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942696|NCT04073680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942697|NCT00638651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942698|NCT05151549|NA|SINGLE_GROUP||TREATMENT||NONE||Patients fulfilling Eligibility Criteria will be included in this study.Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 17 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.||||
33942699|NCT02793531|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717846|NCT00002067||||TREATMENT||DOUBLE||||||
34021555|NCT03311035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will be classified into two groups according to the surgical procedure performed as follows:~* Group A: Patients undergoing cutting Seton.~* Group B: Patients undergoing LIFT technique"|t|f|f|f
34021556|NCT00004089||||TREATMENT||||||||
34021557|NCT00934297|||COHORT||PROSPECTIVE|||||||
34021558|NCT02619435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021559|NCT00357123|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34021560|NCT03069950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021561|NCT04901598|||COHORT||PROSPECTIVE|||||||
34021562|NCT02176408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021563|NCT03788304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither the participant , care provider , the investigator nor the outcome assessor will select patients in both groups , see results of other patients till the end of the study or informed by literature opinion in this intervention|patients with will be randomly enrolled to either non invasive group or HFNC group and improvement and patient satisfaction will be assessed|t|t|t|t
34021564|NCT04009512|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021565|NCT06148142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only the outcome evaluators will be blinded from group allocation due to the nature of the intervention. CP will deliver the intervention and research assistants (field enumerators and supervisors) will engage in data collection from the participants. However, pharmacists and research assistants will not be blinded since they are involved in interventional processes.|Two-arm cluster randomized controlled trial (cRCT) will be conducted among hypertensive subjects in Bangladesh and Pakistan.|t|f|f|f
34021566|NCT02320760|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34021567|NCT00399256|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34103466|NCT04729426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The volunteer who is in the latent phase of labor will not know which group she will be in before joining the study. After accepting to participate in the study, the volunteer will be informed about which group she will be in.|There will be two group. One is interventional group; other is control group.|t|f|f|f
34103467|NCT06351761|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34103468|NCT03688139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34101647|NCT04208178|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1 was the open-label, safety run-in part of the study designed to confirm the recommended phase 3 dose (RP3D) dose of alpelisib in combination with trastuzumab and pertuzumab. Once the alpelisib dose was confirmed, Part 2 with masking for participant, care provider, investigator and outcome assessor started. Participants in Part 2 are to be unblinded with the implementation of protocol amendment 03.|Part 1 was the open-label, safety run-in part of the study designed to confirm the recommended phase 3 dose (RP3D) dose of alpelisib in combination with trastuzumab and pertuzumab. Following Part 1, Part 2 was initiated, which is the randomized, Phase III part of the study with two treatment arms.|t|t|t|t
34101648|NCT05898646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101649|NCT03742102|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1:~At least 20 patients in the durvalumab-paclitaxel arm and at least 30 patients in each of the other novel treatment combination arms will be enrolled, for a total of approximately 140 patients (durvalumab + paclitaxel arm and 4 novel treatment combination arms). Additional patients may be enrolled in order to have 20 or 30 evaluable (i.e. dosed) patients per durvalumab - paclitaxel arm or novel treatment combination arm, respectively.~Part 2:~Approximately 27 patients will be assigned to each treatment arm, for an anticipated total of 57 response-evaluable patients per arm (ie, 30 patients in Part 1 and 27 patients in Part 2 per treatment arm, with the exception of Arm 1, which will enroll 20 patients in Part 1 and will not be expanded to Part 2). Patient expansion from 30 patients in Part 1 to an additional 27 patients from Part 2 will be determined based on a futility analysis utilizing a Simon 2 Stage design."||||
34101650|NCT05653141|||COHORT||PROSPECTIVE|||||||
34101651|NCT00960856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34101652|NCT04121871|||OTHER||CROSS_SECTIONAL|||||||
34101653|NCT06690515|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101654|NCT05205720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101655|NCT00951873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101656|NCT05026632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34101657|NCT04918914|NA|SINGLE_GROUP||TREATMENT||NONE||Addition of dapsone to COVID19 patient treated with standard treatment||||
34101658|NCT05405166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101659|NCT03258957|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101660|NCT04209855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101661|NCT06689722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101662|NCT06695507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101663|NCT05909709|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101664|NCT06283589|NA|SINGLE_GROUP||TREATMENT||NONE||The SEAPORT 1 (INZ701-401) study is a Phase 1, open-label, multi-center study to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of INZ-701, given once per week over 4 weeks, in study participants with end-stage kidney disease undergoing hemodialysis.||||
34101665|NCT03186378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34101666|NCT04105725|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34101667|NCT05626777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101668|NCT06691776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, non-randomized basket trial of the technical feasibility and safety of new software/technologies for CBCT-guided online adaptive radiotherapy. Patients will be enrolled in multiple parallel cohorts, each defined by tumor type(s), and a technical design for the online adaptation.||||
34101669|NCT06295120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101670|NCT04770779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101671|NCT03989908|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants are blinded to the noodles served.|This study is a within-subject cross-over trial design to assess the glycemic response of microfluidic noodle consumption by human subjects as compared to mee sua (control noodle).|t|f|f|f
34021568|NCT00069511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021569|NCT04183075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34021570|NCT02802449|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34021571|NCT02472028|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021572|NCT04068415|||COHORT||PROSPECTIVE|||||||
34021573|NCT02852720|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021574|NCT06424015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34021575|NCT01406483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021576|NCT03764761|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Within subjects alternating treatment design||||
34021577|NCT01064752|||CASE_ONLY||PROSPECTIVE|||||||
34021578|NCT04601610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021579|NCT00019864||||TREATMENT||NONE||||||
34021580|NCT03250559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101672|NCT05002816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101673|NCT06466603|||CASE_CONTROL||PROSPECTIVE|||||||
34101674|NCT01812018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101675|NCT06687798|||OTHER||CROSS_SECTIONAL|||||||
34103469|NCT01489826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103470|NCT02224079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34103471|NCT06333158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798719|NCT02570568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021581|NCT05331196|||COHORT||RETROSPECTIVE|||||||
34021582|NCT03322618|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34021583|NCT01877746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021584|NCT03473626|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34021585|NCT00632112|||||PROSPECTIVE|||||||
34021586|NCT02968836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34021587|NCT04122066|||COHORT||PROSPECTIVE|||||||
34021588|NCT04966273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021589|NCT02549235|||COHORT||PROSPECTIVE|||||||
34021590|NCT04899388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|douple||t|t|f|f
34021591|NCT01676415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021592|NCT03667209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021593|NCT05597137|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021594|NCT03257514|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34021595|NCT06403124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798720|NCT03817476|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717847|NCT03485768|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, one-center, controlled clinical study with random assignment to PDCN or manual therapy group to explore their effectiveness and safety for the treatment of cervicogenic dizziness. Participants will be randomized and allocated to either PDCN group or manual therapy group with 1:1 ratio and with 35 patients in each group.||||
33717848|NCT04626297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717849|NCT02302781|||COHORT||PROSPECTIVE|||||||
33717850|NCT06315439|||COHORT||PROSPECTIVE|||||||
33717851|NCT03315208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717852|NCT03061838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33717853|NCT05829889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798721|NCT03718546|||COHORT||PROSPECTIVE|||||||
33798722|NCT02825368|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33798723|NCT06041373|||COHORT||PROSPECTIVE|||||||
33798724|NCT00404573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798725|NCT04937842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798726|NCT01460446|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798727|NCT00945607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33798728|NCT04426890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798729|NCT04014634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021596|NCT03782909|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34021597|NCT00986713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021598|NCT05535153|||COHORT||PROSPECTIVE|||||||
34021599|NCT02658838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021600|NCT04006483|||OTHER||RETROSPECTIVE|||||||
34021601|NCT05227911|||OTHER||CROSS_SECTIONAL|||||||
34021602|NCT01987037|||CASE_ONLY||PROSPECTIVE|||||||
34021603|NCT01123135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021604|NCT04673682|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34021605|NCT04020757||SEQUENTIAL||TREATMENT||NONE||||||
34021606|NCT05061186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021607|NCT05379816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Conservative management indicates medication treatment. Interventional treatment indicate injection treatment|t|f|f|f
34021608|NCT06406218|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34021609|NCT00634881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021610|NCT00186888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021611|NCT00345943|||CASE_CONTROL||PROSPECTIVE|||||||
34021612|NCT05144087|||COHORT||PROSPECTIVE|||||||
34021613|NCT04244123|||CASE_ONLY||PROSPECTIVE|||||||
34021614|NCT02281292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021615|NCT02599038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021616|NCT00152737|||COHORT||PROSPECTIVE|||||||
34021617|NCT06055530|||COHORT||PROSPECTIVE|||||||
34021618|NCT02884401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021619|NCT04171206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34021620|NCT03422939|||CASE_ONLY||OTHER|||||||
34021621|NCT05819216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021622|NCT06110481|||COHORT||PROSPECTIVE|||||||
34021623|NCT05637619|||CASE_CONTROL||PROSPECTIVE|||||||
34021624|NCT03893435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021625|NCT00201409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021626|NCT03856112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021627|NCT01264536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021628|NCT06021535|||CASE_CONTROL||PROSPECTIVE|||||||
34021629|NCT04299906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021630|NCT00579696|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34021631|NCT05476419|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34021632|NCT01392092|||CASE_ONLY||PROSPECTIVE|||||||
34021633|NCT05428410|||CASE_CONTROL||RETROSPECTIVE|||||||
34021634|NCT04814212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization to the study groups is done using the Random generator in blocks of 20 without stratification|Randomized controlled clinical trial|t|f|t|t
34021635|NCT02125253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34021636|NCT06049459|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes assessor will be masked to past performance and adherence.|This is a within-subject study, and all participants complete both study conditions. Each participant completes 16 weeks of optical correction alone (if needed) followed by 16 weeks of Therapeutic (Dichoptic) Virtual Reality Games plus continued optical correction. Each subject serves as their own control.|f|f|f|t
34021637|NCT05068453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021638|NCT05797818|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||A single open-label healthy group is being evaluated for any changes to the normal nasal microbiome. Each week nasal cultures will be done and the subject exposed to different interventions including red light alone, and several disinfectants. Nasal cultures will be done for 48 hours after the intervention to determine the effect, if any, on the nasal microbiome.||||
34021639|NCT02878486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021640|NCT04674865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021641|NCT02175316|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101676|NCT06682637|NA|SINGLE_GROUP||OTHER||NONE||"Treatment consists in 28-day cycles:~* Melflufen 40 mg total dose (30 mg in patients with body weight ≤60 kg and/or in patients with eGFR\<45 mL/min) intravenously on day 1.~* Dexamethasone 10 mg orally or intravenously on day 1-2, 8-9, 15-16, 22-23. Cycles are repeated until clinical relapse or progression, or unacceptable toxicity."||||
34101677|NCT06688097|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34101678|NCT01886872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101679|NCT02533128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34101680|NCT06684535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101681|NCT06095128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101682|NCT06685094|||COHORT||PROSPECTIVE|||||||
34101683|NCT06137482|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34103472|NCT02716246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717854|NCT04233554|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33717855|NCT03921086|NA|SINGLE_GROUP||TREATMENT||NONE||Initiate anti-hypertensive therapy in surgical patients who are identified as hypertensive at the time of their admission. Identify the co-morbidities of these patients (diabetes mellitus, dyslipidemia, renal impairment, obesity and ECG changes)||||
33717856|NCT03285620|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Dose Escalation|t|f|t|t
33717857|NCT03178578|||CASE_ONLY||PROSPECTIVE|||||||
33717858|NCT02329249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717859|NCT06420453|||COHORT||PROSPECTIVE|||||||
33717860|NCT04610944|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33717861|NCT01196923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717862|NCT03445338|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717863|NCT04106921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Difference in differences parallel randomized controlled trial.||||
33717864|NCT00229632|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33717865|NCT03236740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717866|NCT04178499|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33717867|NCT01565785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717868|NCT01870960|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33717869|NCT01845350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717870|NCT06474364|RANDOMIZED|PARALLEL||OTHER||NONE||"Youth with high likelihood of HIV acquisition shall be randomized to receive injectable PrEP (CABLA) services in either the facility model (at CRPS) or in the community model via drop-in centers or alternative community, drug distribution points. Participants shall receive PrEP (CAB-LA) at baseline or enrolment, 4 weeks after 1st dose and every 8 weeks until end of the study. Participants shall undergo blood tests for safety monitoring prior to and after initiation (6 monthly) of CAB-LA.~Youth living with HIV will be identified from existing CRPS cohorts or from newly diagnosed patients seeking care. These participants shall either be non-suppressed in spite of ART experience (existing cohorts) or have a high risk for non-suppression (e.g. those newly identified, those who use alcohol, those who interrupt care or those that have not disclosed their status). Participants will receive the standard MOH plus the SY HIV care package."||||
33717871|NCT01096264|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33717872|NCT05505903|||COHORT||RETROSPECTIVE|||||||
33717873|NCT06167044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717874|NCT02113761|||COHORT||PROSPECTIVE|||||||
33717875|NCT04508868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717876|NCT03187093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717877|NCT05131074|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717878|NCT05678309|||CASE_ONLY||PROSPECTIVE|||||||
33717879|NCT03888547|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33717880|NCT01203150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717881|NCT03645551|||COHORT||PROSPECTIVE|||||||
33717882|NCT06423820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717883|NCT03542968|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717884|NCT00607529|||COHORT||PROSPECTIVE|||||||
33717885|NCT03358290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717886|NCT04688762|||COHORT||PROSPECTIVE|||||||
33717887|NCT00719251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33717888|NCT01444326|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33717889|NCT01248377|||CASE_ONLY||PROSPECTIVE|||||||
33717890|NCT04034420|NA|SINGLE_GROUP||OTHER||NONE||An online platform to provide training learning and sharing to social and service-related professionals for enhancing the quality of family services||||
33717891|NCT04893603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717892|NCT00006488||||TREATMENT||||||||
33717893|NCT05548166|||OTHER||PROSPECTIVE|||||||
33717894|NCT00539331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717895|NCT05517928|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33717896|NCT00938379|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33717897|NCT03886012|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Neither the subject nor the investigators in the study will know the calendar's schedule for normal or placebo power levels. At both settings, the device will be felt to vibrate, making it unlikely that participants will be able to guess which setting is effective and which is ineffective.|"Subjects will be given the transcranial vibrating system (the Otoband) to use when they have migraine associated vertigo (MAV). The Otoband will function for up to 4 periods of 30 minutes per day, at one of two possible pre-set power levels.~The possible power levels are A) a level deemed to be effective, or B) a placebo (ineffective) power level. On a given calendar day, the power level remains constant. The sponsor will provide Otobands with a predetermined, randomly assigned power schedule based on calendar day.~Subjects will use the Otoband during each MAV episode. They will fill out questionnaires about associated symptoms (dizziness, nausea, headache, brain confusion) 2 \& 20 minutes after using turning the Otoband on, and 20 minutes after they stop using the Otoband.~Outcomes measured will be compared between days with device at effective versus placebo power to determine if the Otoband affects dizziness, nausea, headache and brain confusion symptoms during MAV attacks."|t|f|t|f
33717898|NCT01986985|NA|SINGLE_GROUP||||NONE||||||
33717899|NCT02441777|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33717900|NCT03072628|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33717901|NCT02189746|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717902|NCT01555294|||||PROSPECTIVE|||||||
33717903|NCT04906044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717904|NCT01717807|||COHORT||PROSPECTIVE|||||||
33798730|NCT00591500|||CASE_CONTROL||PROSPECTIVE|||||||
33798731|NCT02753192|NA|SINGLE_GROUP||||NONE||||||
33798732|NCT00142285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798733|NCT04750044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942700|NCT03289442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942701|NCT06017349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942702|NCT03772197|||COHORT||RETROSPECTIVE|||||||
33942703|NCT03955731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942704|NCT00270816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942705|NCT01017211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798734|NCT05330234|NA|SINGLE_GROUP||OTHER||NONE||This study aims to assess the usability of the OnTrack Tools GUI under simulation. The study follows up from a study of the OnTrack system that demonstrated the feasibility and acceptability of the patient-facing component of the system by stroke survivors and therapists. The design of this study was developed through a collaborative approach between the study researchers, patients, and front-line therapists. The OnTrack intervention is being developed by Imperial College, this usability study is part of the development process.||||
33798735|NCT00964730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798736|NCT03947684|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798737|NCT06460688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment|It will be Randomized control trial in which non probability convenient sampling will be used. two groups of age 6-12will be formed in which participants will be randomly divided. Group A will receive Mother Rehabilitative Aid Education program with routine neurophysical therapy and Group B will only receive routine neurophysical therapy|t|f|f|f
33798738|NCT01673555|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33798739|NCT05677061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patient and Assessor blinded randomized controlled trial|t|f|f|t
33798740|NCT02515838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798741|NCT03690596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798742|NCT00003612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798743|NCT02645149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798744|NCT02743195|NA|SINGLE_GROUP||||NONE||||||
33798745|NCT04807556|||CASE_ONLY||PROSPECTIVE|||||||
33798746|NCT06453798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798747|NCT03703336|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Eligible infants will be randomized to receive either ROTAVIN or ROTAVIN-M1 vaccines in the ratio of 2:1.|t|f|t|t
33798748|NCT00727922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798749|NCT04676334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798750|NCT03639558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798751|NCT00002842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798752|NCT02238210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798753|NCT04324333|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798754|NCT02301208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798755|NCT06300424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798756|NCT04414995|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The study medication will be masked by the pharmacy. Participants, those administrating the intervention, other caregivers, outcome assessors, data managers, statisticians, and investigators drawing conclusions will be blinded to the intervention.|"Patients in Group 1 received a combination of 1000 mg IV paracetamol and 800 mg IV ibuprofen at the end of operation followed by 1000 mg IV paracetamol and 800 mg IV ibuprofen every 6 hours up to 72 hours.~Patients in Group 2 received 1000 mg IV paracetamol and 100 ml IV normal salines at the end of operation followed by 1000 mg IV paracetamol and 100 ml IV normal salines every 6 hours up to 72 hours.~Patients in Group 3 received 800 mg IV ibuprofen and 100 ml IV normal salines at the end of operation followed by 800 mg IV ibuprofen and 100 ml IV normal salines every 6 hours up to 72 hours."|t|t|t|f
33798757|NCT01599117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798758|NCT03082326|||OTHER||PROSPECTIVE|||||||
33798759|NCT03084744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors of the primary outcome will be blinded to treatment assignments.|Participants will be randomly allocated into two groups using a web-based central allocation system. This system will confirm allocation concealment and random sequence generation.|f|f|f|t
33798760|NCT02858882|||COHORT||PROSPECTIVE|||||||
33798761|NCT01625013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798762|NCT02014129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798763|NCT02383472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798764|NCT03680417|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|laboratory analyst are masked for the evaluation of antibody against measles and rubella. The immunogenicity is measured before and after vaccination.|Safety Group: open labeled, prospective intervention study, only assess the safety outcome Sub Group: open labeled, prospective intervention study, evaluate safety and protectivity outcome|f|f|f|t
33798765|NCT00168519|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33798766|NCT06677177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798767|NCT05732649|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"In Experiment 1, participants will receive three different interventions (auditive neurofeedback, tactile neurofeedback, or both) in different sessions. The order of interventions will be counterbalanced across participants.~In Experiment 2, participants will be randomized to one out of three parallel treatment arms (i.e., Group A, B, or C). Randomization, stratified for age and gender, will be generated with a computer random number generator.~In both Experiments, participants will be blinded to the intervention order and group allocation."|"In Experiment 1, to disentangle which is the neurofeedback modality that most efficiently modulates brain connectivity, the investigators will compare auditory, tactile, or both modalities in a within subject design.~In Experiment 2, to investigate whether enhanced brain connectivity at visual areas through real-time neurofeedback can boost visuo-motor learning, the investigators will compare Group A (active) to Group B (first control) and C (second control) in a between subjects design."|t|f|f|f
33798768|NCT01833923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798769|NCT00567333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798770|NCT01061671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798771|NCT01068743|RANDOMIZED|CROSSOVER||||NONE||||||
33798772|NCT01437332|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33798773|NCT03265886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double-blind design||t|t|f|f
33798774|NCT04261465|NA|SINGLE_GROUP||OTHER||NONE||||||
33798775|NCT02190643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798776|NCT04435236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33798777|NCT01032486|||COHORT||PROSPECTIVE|||||||
33798778|NCT01565148|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33798779|NCT01339234|NA|SINGLE_GROUP||||NONE||||||
34101684|NCT06695039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A phase 2, open-label, non-randomized, single center study||||
34101685|NCT04465487|NA|SEQUENTIAL||TREATMENT||NONE||||||
34101686|NCT06565663|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101687|NCT05494697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101688|NCT05649540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798780|NCT02455297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798781|NCT05374681|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33798782|NCT05701397|NA|SINGLE_GROUP||SCREENING||NONE||||||
33798783|NCT02548221|||COHORT||PROSPECTIVE|||||||
33798784|NCT00309907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798785|NCT02107339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798786|NCT02093715|||COHORT||PROSPECTIVE|||||||
33798787|NCT01198275|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798788|NCT04490252|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33798789|NCT02242695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798790|NCT04521530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798791|NCT00332241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798792|NCT03596853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking: Triple (Participant, Outcomes Assessor)||t|f|f|t
33798793|NCT04826445|||COHORT||PROSPECTIVE|||||||
33798794|NCT05208242|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multi-centre, randomised, open-label, feasibility study.||||
33798795|NCT05572060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33798796|NCT03238313|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798797|NCT01134237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33798798|NCT03051165|NA|SINGLE_GROUP||TREATMENT||NONE|Interpretation of all tests (sleep tests, ambulatory blood pressure monitoring, vascular test and blood tests) will be done by an outcomes assessor who is blinded to whether treatment is active or withheld at the time of testing.|All participants will undergo the intervention of temporary treatment withdrawal to examine cardiac measurements before treatment, during treatment, and after cessation.||||
33798799|NCT03787966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33798800|NCT01393002|||COHORT||PROSPECTIVE|||||||
33798801|NCT01122901|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798802|NCT05860179|||CASE_CROSSOVER||PROSPECTIVE|||||||
33798803|NCT00816751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798804|NCT02297061|||COHORT||PROSPECTIVE|||||||
33798805|NCT02519517|NA|SINGLE_GROUP||SCREENING||NONE||||||
33798806|NCT05076058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo with the same appearance, taste, smell, and packing box to the experimental supplement was used. 118 serial numbers matched to each one participant, and corresponding to study arms (named as 1 or 2 on the tablet box), were used to replace the original label of supplement or placebo after randomization. The code of serial number corresponding to the group code (1 or 2) of tablets was kept by the PI, and will not be disclosed until the completion of all data collection. The group code corresponding to the two types of tablets was/will be kept by the producer till the completion of data analysis.||t|t|t|t
33798807|NCT04834219|||OTHER||PROSPECTIVE|||||||
33798808|NCT00743444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33798809|NCT03792204|||CASE_ONLY||CROSS_SECTIONAL|||||||
33798810|NCT02267967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798811|NCT05167656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers involved in recording outcome measures will not be aware of treatment allocation. Patients will be encouraged to not tell the evaluators about the received treatment.||f|f|f|t
33798812|NCT01084707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33798813|NCT03069313|NA|SINGLE_GROUP||TREATMENT||NONE||Vitamin B12 is to be taken sublingually on a daily basis for 90 days||||
33798814|NCT01641198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798815|NCT01016522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798816|NCT03195075|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will include 40 consecutive jaundiced patients with distal malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography. Twenty patients with failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography-guided biliary drainage will be performed by single endoscopist and another 20 patients with failed endoscopic retrograde cholangio-pancreaticography for percutaneous trans-hepatic biliary drainage.||||
33798817|NCT02270710|||COHORT||RETROSPECTIVE|||||||
33798818|NCT00306397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798819|NCT01499199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798820|NCT06196788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798821|NCT02761239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798822|NCT03059394|||OTHER||PROSPECTIVE|||||||
33798823|NCT03318484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021642|NCT04791423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The phase II part of the study is a parallel-group preventive study with 3 arms that is participant and investigator blinded (observer blinded). The blinding of the phase III will depend on the scenario that will be implemented.|"In the phase II part approximately 900 participants will be randomized in a 1:1:1 ratio to receive 1 single IM dose of GRAd-COV2 2x10\^11 vp plus 1 dose of placebo after 21 days (n= approximately 300 subject) or 2 repeated (21 days apart) IM dose of GRAd-COV2 1x10\^11 (n = approximately 300 subjects) or two doses of placebo (n = approximately 300 subjects) on day 1 and day 22.~Once the phase III expansion is granted, according to the epidemic evolution,the availability on the market of alternative vaccine(s) and the characteristics of vaccination campaign, the phase III study design will be adapted following these 3 potential scenarios: 1) a superiority trial vs placebo on overall population; 2) a superiority trial vs placebo on an subset of population (low risk subjects for infection outcome) or 3) a non-inferiority trial vs the available alternative vaccine on a surrogate endpoint (correlates of protection), if available."|t|t|t|t
34021643|NCT02015429|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34021644|NCT02881840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021645|NCT01539135|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34021646|NCT00119067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021647|NCT00684892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101689|NCT05883449|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103473|NCT06695013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798824|NCT01336946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798825|NCT06167213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021648|NCT03944174|||COHORT||PROSPECTIVE|||||||
34021649|NCT04364425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021650|NCT02149108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021651|NCT03557424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, randomized|Three armed, parallel, double blind, Placebo-controlled, interventional study|t|t|t|f
34021652|NCT05107141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798826|NCT01301716||PARALLEL||TREATMENT||NONE||||||
33798827|NCT06187246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized control trial|t|t|f|f
33798828|NCT00338624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798829|NCT01895023|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33798830|NCT01758328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798831|NCT01587053|||COHORT||PROSPECTIVE|||||||
33798832|NCT04968756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798833|NCT03701386|RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking|The eligible participant will be allocated to groups, group one will receive cesarean hysterectomy and group 2 will be received N\&H sandwich technique||||
33798834|NCT01210820|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798835|NCT02614625|||CASE_ONLY||PROSPECTIVE|||||||
33798836|NCT00162292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798837|NCT03175172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798838|NCT02153541|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33798839|NCT02206269|||COHORT||PROSPECTIVE|||||||
33798840|NCT03222323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The participants will attend two trial days and receive two treatments on each trial days|t|t|t|t
33798841|NCT03791892|RANDOMIZED|PARALLEL||OTHER||SINGLE||Experimental|t|f|f|f
33798842|NCT02967458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798843|NCT01665092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798844|NCT06217874|||COHORT||PROSPECTIVE|||||||
33798845|NCT01388881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798846|NCT05597280|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798847|NCT00014794||||TREATMENT||||||||
33798848|NCT02993744|||COHORT||PROSPECTIVE|||||||
33798849|NCT02698228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33798850|NCT04877496|||COHORT||PROSPECTIVE|||||||
33798851|NCT01150383|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33798852|NCT01373398|NA|SINGLE_GROUP||||NONE||||||
34021653|NCT04473911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021654|NCT04439916|||COHORT||PROSPECTIVE|||||||
34021655|NCT00716287|||CASE_ONLY||CROSS_SECTIONAL|||||||
34021656|NCT02361294|||OTHER||PROSPECTIVE|||||||
34021657|NCT00210249|||COHORT||PROSPECTIVE|||||||
33798853|NCT01387906|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33798854|NCT06045845|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33798855|NCT02892903|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33798856|NCT02657200|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33798857|NCT02320877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798858|NCT05486897|||COHORT||RETROSPECTIVE|||||||
33798859|NCT00118768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798860|NCT05253612|RANDOMIZED|CROSSOVER||SCREENING||NONE||The participants will be randomized to one of two conditions: 1) ISPOCD test battery followed by Mindmore digitalized cognitive test battery, or 2) Mindmore digitalized cognitive test battery followed by ISPOCD test battery, with 2 weeks passing between the cognitive testing for both groups||||
33798861|NCT02500264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798862|NCT02206750|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33798863|NCT05806255|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33798864|NCT00332813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798865|NCT00067691|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33798866|NCT06206824|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33798867|NCT03674034|||CASE_ONLY||RETROSPECTIVE|||||||
33798868|NCT01944306|||COHORT||PROSPECTIVE|||||||
33798869|NCT00000217||||TREATMENT||||||||
33798870|NCT03132922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798871|NCT04223297|||OTHER||PROSPECTIVE|||||||
33798872|NCT00001730||||TREATMENT||||||||
33798873|NCT00761605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798874|NCT06411834|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021658|NCT00902031|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021659|NCT03163524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34021660|NCT05449717|||COHORT||PROSPECTIVE|||||||
34021661|NCT05280730|||COHORT||PROSPECTIVE|||||||
34021662|NCT00491140|||COHORT||RETROSPECTIVE|||||||
34021663|NCT03983083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34021664|NCT00000259|NON_RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34021665|NCT04300010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021666|NCT00678197||||HEALTH_SERVICES_RESEARCH||||||||
33798875|NCT02176772|||CASE_CROSSOVER||PROSPECTIVE|||||||
33798876|NCT01112033|||CASE_CONTROL||PROSPECTIVE|||||||
33798877|NCT05340114|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33798878|NCT03036644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33798879|NCT02464293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798880|NCT00482729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33798881|NCT02272816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798882|NCT04652583|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33798883|NCT00253110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798884|NCT03819816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798885|NCT04738058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Closed sealed envelopes|Group A: preterm infants with feeding intolerance receive lactoferrin Group B: preterm infants with feeding intolerance receive placebo|t|f|t|f
33798886|NCT02444416|||COHORT||PROSPECTIVE|||||||
33798887|NCT00435578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798888|NCT05997966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798889|NCT00111085|RANDOMIZED|PARALLEL||PREVENTION||||||||
33798890|NCT06210334|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective, Single-armed, Stage II Clinical Trial||||
33798891|NCT02328963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798892|NCT01291381|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33798893|NCT06411743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798894|NCT00939432|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33798895|NCT04431297|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33798896|NCT04366908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798897|NCT04329130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798898|NCT03954301|||CASE_ONLY||PROSPECTIVE|||||||
33798899|NCT05261997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be divided into conservative treatment group or endoscopic treatment group.|f|f|f|t
33798900|NCT05881317|NA|SINGLE_GROUP||OTHER||NONE||||||
33798901|NCT02147054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798902|NCT00110864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33798903|NCT06177106|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33798904|NCT03019913|||COHORT||PROSPECTIVE|||||||
33798905|NCT00396513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798906|NCT06107894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798907|NCT02538107|||COHORT||PROSPECTIVE|||||||
33798908|NCT01652417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798909|NCT04848233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798910|NCT03068078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798911|NCT00492271|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33798912|NCT05554185|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798913|NCT06461871|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group A received moderate intensity aerobic exercises which include walking, cycling, with each session lasting 15 minutes for 3-5 days per week in combination with balance training which include heel raise, standing march with 10 repetitions each for 3-5 days per week. Group B receive moderate intensity resistance exercises which include biceps curls, triceps curls , with each session lasting 10 repetitions for 3-5 days per week in combination with balance training which include heel raise, standing march with 10 repetitions each for 3-5 days per week. The study will be completed with time duration of six months .Primary outcome of research will be glycemic control, cardio respiratory fitness, and quality of life.|t|f|f|f
33798914|NCT00919685|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798915|NCT06250569|||OTHER||CROSS_SECTIONAL|||||||
33798916|NCT00084292|||COHORT||PROSPECTIVE|||||||
33798917|NCT03762291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798918|NCT03066115|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33798919|NCT06222918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942706|NCT02528461|||COHORT||PROSPECTIVE|||||||
33942707|NCT04449185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942708|NCT00720291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942709|NCT01500538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942710|NCT05217004|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942711|NCT00207363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942712|NCT03410641|||OTHER||PROSPECTIVE|||||||
33942713|NCT01593800|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942714|NCT00000322|RANDOMIZED|||TREATMENT||DOUBLE||||||
33942715|NCT02265575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942716|NCT02587845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33942717|NCT03000920|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33942718|NCT04589260|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Randomized, Double-Blinded, Placebo-Controlled|t|t|t|t
33942719|NCT02662374|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33942720|NCT00464841|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33942721|NCT05223374|||OTHER||OTHER|||||||
33942722|NCT03860181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942723|NCT01464073|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942724|NCT05539040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a single centre pilot study with a control arm and outcomes will be measured prospectively on both an intention-to-treat and per-protocol basis.|t|t|f|f
33942725|NCT04245813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial|f|t|t|t
33942726|NCT01592773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942727|NCT00863434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942728|NCT03402308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942729|NCT01636674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942730|NCT05823155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942731|NCT03763292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33942732|NCT05370235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942733|NCT00182364|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33942734|NCT04193982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942735|NCT04450394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942736|NCT03637959|NA|SINGLE_GROUP||OTHER||NONE||||||
33798920|NCT06514027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study initially sets up two cohorts. In cohort 1, the treatment is BEBT-109 combined with investigator-selected chemotherapy (injectable pemetrexed disodium combined with carboplatin or cisplatin injection). In cohort 2, the treatment is monotherapy with BEBT-109 (BEBT-109 capsule at a dose of 180mg, taken orally once daily). Based on different dosing regimens of BEBT-109 capsules, cohort 1 is divided into three dose groups: A (BEBT-109 capsule at a dose of 180mg, taken orally once daily), B (BEBT-109 capsule at a dose of 120mg, taken orally twice daily), and C (BEBT-109 capsule at a dose of 120mg, taken orally once daily).~The decision to initiate cohort 2 will be based on the safety and efficacy results from cohort 1."||||
33798921|NCT00413257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798922|NCT06326632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind protocol was adopted. The researcher who collected the data was blind to the allocation of treatment|A prospective, three-arm, randomized controlled trial|f|f|f|t
33798923|NCT00781378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798924|NCT05861193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798925|NCT02468297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798926|NCT02968225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Given the design of the study, parents and adolescents will know the condition to which they have been assigned. However, researchers involved in data collection will be blinded from condition assignment during the pre-intervention data collection session as these data will be collected prior to randomization. Also, the research team is not involved in the randomization process. The research team members who are involved in ensuring the fidelity of the intervention are not involved in data collection procedures. Although we will attempt to limit unblinding, it is not possible for researchers involved in data collection to be completely blinded to the assignment of participant condition at the post-intervention visit as we cannot prohibit participants from talking to researchers about their experience in the study. Importantly, the primary outcome measures are believed to be robust to investigator bias.|Participants randomized into intervention or standard care control conditions|t|f|t|f
33798927|NCT03908671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942737|NCT01695499|||COHORT||PROSPECTIVE|||||||
33942738|NCT01876056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942739|NCT04717154|NA|SINGLE_GROUP||TREATMENT||NONE||"Open label, single treatment, phase II study:~* Cohort A1 will assess the efficacy of ipilimumab+nivolumab in mCRPC patients with RECIST1.1 measurable disease that are naïve for immune checkpoint inhibition~* Cohort A2 will assess the efficacy of ipilimumab+nivolumab in patients without RECIST1.1 measurable disease that are naïve for immune checkpoint inhibition~* Cohort B will assess the efficacy of ipilimumab+nivolumab in patients with RECIST1.1 measurable disease and prior progression to immune checkpoint inhibitor monotherapy (CTLA-4 or anti-PD1/PDL1)"||||
33942740|NCT03373006|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking|Cohort||||
33942741|NCT06111729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942742|NCT03679572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942743|NCT01673373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942744|NCT00551200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942745|NCT00735839|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942746|NCT05365256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942747|NCT03092141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients will submitted to physical training (12-weeks, twice/week)||||
33942748|NCT02055976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942749|NCT00019331||||TREATMENT||||||||
33942750|NCT01573364|||COHORT||PROSPECTIVE|||||||
33798928|NCT05907473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798929|NCT00687167|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33798930|NCT01926678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33798931|NCT01112670|RANDOMIZED|CROSSOVER||||NONE||||||
33798932|NCT05583539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798933|NCT00263952|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942751|NCT03480360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942752|NCT00969462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942753|NCT00208715|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33798934|NCT03247504|||COHORT||CROSS_SECTIONAL|||||||
33717905|NCT05030974|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Based on their immunosuppressive treatment, patients will participate in one of the following strata:~* stratum A: patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids,~* stratum B: patients treated with any combination of immunosuppressive drugs.~In stratum A, patients will be randomized to one of two third or fourth vaccination strategies:~* A1: one extra dose of mRNA-1273 (100 μg, i.m)~* A2: one extra dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the 3rd dose~In stratum B, patients will be randomized to one of three third vaccination strategies:~* B1: 3rd dose of mRNA-1273 (100 μg, i.m)~* B2: 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms~* B3: Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)"||||
34101690|NCT05358639|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is designed as an open-label multi-center Phase I interventional and translational study. It will identify the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and RP2D of olaparib combined with navitoclax for study in Phase II.||||
34101691|NCT01902173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101692|NCT02434809|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101693|NCT06600802|NA|SINGLE_GROUP||OTHER||NONE||||||
33717906|NCT04696445|||COHORT||PROSPECTIVE|||||||
33942754|NCT00003389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101694|NCT06696040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101695|NCT06434506|||CASE_CONTROL||RETROSPECTIVE|||||||
34101696|NCT03233971|||OTHER||PROSPECTIVE|||||||
34101697|NCT03345810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101698|NCT06496230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101699|NCT06324357|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101700|NCT06643962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101701|NCT04452162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101702|NCT01778621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717907|NCT05609045|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33717908|NCT02452398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717909|NCT02105428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33717910|NCT03038698|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33717911|NCT03037255|||COHORT||PROSPECTIVE|||||||
33717912|NCT06497192|||OTHER||OTHER|||||||
33717913|NCT02398851|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33717914|NCT00508625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717915|NCT01105195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717916|NCT01051024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717917|NCT03114813|||COHORT||PROSPECTIVE|||||||
33717918|NCT04078061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participating children will be randomized to EIBI or MABA with equal probability. All randomizations will occur within site and will be further stratified on 1) baseline Vineland Adaptive Behavior Scale-3 (VABS-3) Composite SS (\>65 vs ≤65) and 2) age (\<3yrs vs. \>3yrs). This procedure will ensure that treatment groups are balanced for these two baseline variables, which are known to correlate highly with outcome during- and post-treatment. The project statistician will use blocked randomization with randomly selected blocks of size 4, 6 and 8 to generate each allocation sequence. All block-randomized allocation sequences will be concealed from all other study personnel.|f|f|f|t
33717919|NCT01074866|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33942755|NCT00754273|||CASE_ONLY||PROSPECTIVE|||||||
33942756|NCT05987709|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33942757|NCT02260609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942758|NCT02896959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942759|NCT04547452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942760|NCT05980494|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942761|NCT03807258|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||COPD Patients vs. Controls||||
33942762|NCT00628680|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942763|NCT04383041|||COHORT||CROSS_SECTIONAL|||||||
33942764|NCT03244111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The MOCA is a one page test that assesses cognition. The MOCA will be administered and participants with total scores \<= 25 will be in the lower cognition group, whereas participants with total scores \> 25 will be in the higher cognition group. These are recommended cut off scores to detect mild cognitive impairment (MCI).||||
33942765|NCT01511211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942766|NCT04253652|||COHORT||PROSPECTIVE|||||||
33942767|NCT00003089||||TREATMENT||||||||
33942768|NCT02665273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942769|NCT01634087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942770|NCT00531466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942771|NCT01004159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942772|NCT03859115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942773|NCT01296321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942774|NCT05671029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942775|NCT04777422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942776|NCT01823991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33942777|NCT01897779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942778|NCT01279421|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33942779|NCT02911324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942780|NCT01180829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942781|NCT02144662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942782|NCT06334380|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded assessor will conduct adherence calls.|Participants randomized to one of two arms, VR self-paced modules with live PT guidance and VR without live PT guidance.|f|f|f|t
33942783|NCT02527291|||CASE_CONTROL||PROSPECTIVE|||||||
33942784|NCT03439007|||COHORT||PROSPECTIVE|||||||
33942785|NCT03421899|||OTHER||PROSPECTIVE|||||||
33942786|NCT03024151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942787|NCT05905692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33942788|NCT00620815|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33942789|NCT05032131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942790|NCT04119167|||CASE_CONTROL||RETROSPECTIVE|||||||
33942791|NCT05521828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942792|NCT02651038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942793|NCT00160147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942794|NCT05828524|||CASE_ONLY||PROSPECTIVE|||||||
33942795|NCT02883894|||CASE_ONLY||PROSPECTIVE|||||||
33942796|NCT06321796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part 1: Randomized, Double-Blinded, Placebo-Controlled Treatment (14 weeks) Part 2: Open-Label Observation and Cross-over or Treatment Part 3: Follow Up (Group B Only)|t|t|t|t
33942797|NCT03398187|||CASE_ONLY||CROSS_SECTIONAL|||||||
33942798|NCT00741624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942799|NCT02815982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942800|NCT01075022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942801|NCT00508118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942802|NCT03259607|RANDOMIZED|CROSSOVER||OTHER||NONE||single-center, randomized, single-dose, open-label, cross-over study||||
33942803|NCT02468076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942804|NCT06210828|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33942805|NCT03486067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942806|NCT00155428|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717920|NCT01563003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717921|NCT01569178|RANDOMIZED|PARALLEL||TREATMENT||NONE|The advanced therapy treatment product used in this trial is open label, hence no masking|||||
33717922|NCT00847054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717923|NCT05789446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717924|NCT02447549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717925|NCT02328755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717926|NCT04197089|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment stratified with 10.000 IU or 50.000 IU Vitamin D depending of baseline 25(OH)Vitamin D plasmatic levels||||
33717927|NCT01961323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717928|NCT01522989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717929|NCT01157949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717930|NCT03929575|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Blocked-randomized, crossover design|t|f|t|t
33717931|NCT03914781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717932|NCT06185504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33717933|NCT02184689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717934|NCT05266742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33717935|NCT01819077|||||PROSPECTIVE|||||||
33717936|NCT06522048|||COHORT||OTHER|||||||
33717937|NCT00277888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717938|NCT03202797|||COHORT||PROSPECTIVE|||||||
33717939|NCT03269942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717940|NCT06316141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33717941|NCT05835778|||COHORT||PROSPECTIVE|||||||
33717942|NCT00300586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717943|NCT02107482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33717944|NCT04665284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717945|NCT04075058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717946|NCT05226325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33717947|NCT00389363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33717948|NCT05125978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33717949|NCT04876625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators scoring sleep studies and doing data analysis will be blinded with regard to group identity.|Single center, randomized trial using a parallel group design|f|f|f|t
33717950|NCT05417061|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Saliva and serum of periodontitis patients collected for analyzing SIRT6, LPXA4, CASP8||||
33717951|NCT05053789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study will be carried out in an observer-masked fashion, therefore the investigator performing the measurements will not be informed about the treatment group that patients are assigned to.||f|f|t|f
33717952|NCT03036072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717953|NCT03256214|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33717954|NCT05560984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717955|NCT03645980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33717956|NCT02969304|||COHORT||RETROSPECTIVE|||||||
33717957|NCT01899794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717958|NCT04988711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||descriptive||||
33942807|NCT02408016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942808|NCT00709813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33942809|NCT02896972|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942810|NCT04130360|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Participants are not told that they are being randomised or that they are participating in an intervention trial until they complete the follow-up. Randomisation is computerized and participants have no contact with a care provider or an investigator.|Intervention and control group. Participants are randomised to one of them.|t|t|t|t
33942811|NCT01652651|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34021667|NCT01383213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021668|NCT06438809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021669|NCT01350583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34021670|NCT02188914|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33717959|NCT05641233|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33942812|NCT02139891|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33942813|NCT01226134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942814|NCT06249074|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||All participants followed normocaloric gluten-free diet for 8 weeks. After first 4 weeks participants were randomly assigned to one of two groups. One group over next 4 weeks additionally to gluten-free diet received gluten in gastrosoluble capsules and second group - rice starch (placebo).|t|f|t|f
33942815|NCT01005355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942816|NCT03151928|||CASE_ONLY||CROSS_SECTIONAL|||||||
33717960|NCT05861856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33717961|NCT01372280|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33717962|NCT00770289|||COHORT|||||||||
33717963|NCT04053023|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This will be a non-randomized study. Eligible subjects will receive OCA and OCA+linerixibat in a fixed sequence.||||
33717964|NCT01808287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717965|NCT00363922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717966|NCT04824885|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33717967|NCT00330564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33717968|NCT03276884|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33717969|NCT06332651|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||It is a parallel intervention study. The intervention does not involve a drug or biologic product, however does involve an adaptation diet and a diet with measured amino acids dissolved in water, during the test day. We investigate the amino acid metabolic availability using the IAAO method.||||
33717970|NCT01610947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717971|NCT03406104|RANDOMIZED|PARALLEL||TREATMENT||NONE||intra patient comparaison||||
33717972|NCT04867538|||COHORT||RETROSPECTIVE|||||||
33717973|NCT03886233|||COHORT||RETROSPECTIVE|||||||
33717974|NCT01830699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717975|NCT00703079|||COHORT||PROSPECTIVE|||||||
33717976|NCT05743179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717977|NCT04926350|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33717978|NCT06420843|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33717979|NCT00558025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717980|NCT01487226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717981|NCT02123745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717982|NCT01432886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717983|NCT06479798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This prospective, interventional cohort research was performed on 40 cases with suspected lung malignancies. All cases were examined via FDG-PET/CT followed by convex probe EBUS-TBNA for diagnosis of suspected lung cancer \& staging of concurrent mediastinal lymphadenopathy.||||
33717984|NCT01516424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33717985|NCT05725811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33717986|NCT00696176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33717987|NCT01572194|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717988|NCT05761977|||COHORT||PROSPECTIVE|||||||
33717989|NCT03096379|||COHORT||PROSPECTIVE|||||||
33717990|NCT01690247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717991|NCT03325361|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33717992|NCT00710710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33717993|NCT04106986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators and outcome assessor are blinded to subject assigned group|Randomized control trial study to investigate the effect of pulsed electromagnetic field and progressive resistance exercise on knee osteoarthritis regard pain level ,physical function, and quality of life|f|f|t|t
33717994|NCT01230268|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33717995|NCT00170716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33717996|NCT05205421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33717997|NCT02936791|||COHORT||PROSPECTIVE|||||||
33717998|NCT00970333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33717999|NCT04090840|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective observation study of lifestyle intervention with intermittent fasting (time-restricted eating) of 16 hours every day.||||
33718000|NCT03435744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind plcaebo controlled trial|1-Simvastatin plus TAU, 2- Placebo plus TAU|t|t|t|t
33718001|NCT05244577|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, double-blind, placebo-controlled||||
33718002|NCT00252954|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718003|NCT04010682|||CASE_ONLY||PROSPECTIVE|||||||
33718004|NCT05573945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Double (Investigator, Outcomes Assessor) Investigator and Outcomes assessors are blind to the group assignment of the infant. Care provider (Parents and Research staff supporting parents in intervention can not be masked to the group assignment).|Two intervention groups, Randomised Controlled Trial|f|f|f|t
33718005|NCT01414907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718006|NCT01859533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718007|NCT00211445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718008|NCT01509430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33718009|NCT04711408|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718010|NCT02584335|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33718011|NCT00432107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798935|NCT02077426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798936|NCT04536519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It was a double blinded study in which assessors and patientswere blinded. Close shoe type make it possible to blind patients because receiving identical conventional treatment in both groups.|a randomized controlled trial with 2 group|t|t|f|f
33798937|NCT02000349|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33942817|NCT00006162|RANDOMIZED|||PREVENTION||||||||
33942818|NCT02785588|NA|SINGLE_GROUP||OTHER||NONE||||||
33942819|NCT02195349|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33942820|NCT02075580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942821|NCT06000891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Unblinding for Part 1 will be performed after completion of Part 1 (cohort 1-3) of the trial. Everyone involved in the conduct of Part 2 of the trial will be blinded until completion of Part 2 (cohort 4) of the trial and the final data review.|The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts for Part 1 in a semi-parallel design and one cohort for Part 2.|t|f|t|f
33942822|NCT02745093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942823|NCT05805332|||CASE_CONTROL||PROSPECTIVE|||||||
33942824|NCT02600715|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33942825|NCT05191927|||COHORT||RETROSPECTIVE|||||||
34021671|NCT00867997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021672|NCT01631071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021673|NCT00894101|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021674|NCT01566903|||CASE_CONTROL||PROSPECTIVE|||||||
34021675|NCT04295135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021676|NCT02771886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021677|NCT05375526|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Pilot trial||||
34021678|NCT01874067|||CASE_ONLY||PROSPECTIVE|||||||
34021679|NCT02674321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101703|NCT05894564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
33798938|NCT03426878|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The participant will not know if they are receiving traditional or modified genetic counseling.|All participants will receive exome sequencing. The randomization will be into one of two types of genetic counseling - traditional and modified.|t|f|f|f
33798939|NCT00865436|RANDOMIZED|CROSSOVER||||NONE||||||
33798940|NCT00322920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798941|NCT00173524|||COHORT||PROSPECTIVE|||||||
33798942|NCT04246307|||COHORT||PROSPECTIVE|||||||
33798943|NCT02047981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798944|NCT00677391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33798945|NCT00540748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798946|NCT01655888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798947|NCT04066725|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33798948|NCT05798273|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||non-randomized, single center, prospective imaging study.||||
33798949|NCT01778283|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33798950|NCT05868772|||COHORT||PROSPECTIVE|||||||
33798951|NCT05289258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a three-arm randomized clinical trial, with a pre-post-follow-up repeated measures intergroup design.|t|t|f|t
33798952|NCT02240446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798953|NCT05075941|||OTHER||CROSS_SECTIONAL|||||||
33798954|NCT05536830|||COHORT||CROSS_SECTIONAL|||||||
33798955|NCT03946007|||OTHER||CROSS_SECTIONAL|||||||
33798956|NCT03133039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101704|NCT02838706|||COHORT||PROSPECTIVE|||||||
33718012|NCT06204718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33798957|NCT01533870|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33798958|NCT04701879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33798959|NCT01368198|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33798960|NCT00944333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798961|NCT00643929|||COHORT||PROSPECTIVE|||||||
33798962|NCT06314763|NA|SINGLE_GROUP||OTHER||NONE||An open label single-sequence pharmacokinetic drug-drug interaction study.||||
34101705|NCT03851185|||COHORT||PROSPECTIVE|||||||
34101706|NCT06644768|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label study.||||
33718013|NCT02905331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718014|NCT01434069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718015|NCT03557151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Persons completing data scoring and entry tasks will be kept blinded to a given participant's treatment assignment. Most scoring is automated via the REDCap platform.|The study design randomizes participants to standard care or transdisciplinary care delivered through various modalities (in person; telehealth). Data collection occurs at 5 Time Points (0, 3, 6, 9 and 12 months).|f|f|f|t
33718016|NCT02562794|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718017|NCT03520374|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33718018|NCT05489809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798963|NCT01839526|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33798964|NCT04753580|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34101707|NCT06686199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101708|NCT06399471|NA|SINGLE_GROUP||OTHER||NONE||||||
34101709|NCT06690853|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103474|NCT05843721|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718019|NCT02432404|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718020|NCT02309489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33718021|NCT01711177|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718022|NCT01744990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718023|NCT00539448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718024|NCT02299479|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33798965|NCT02840422|||OTHER||PROSPECTIVE|||||||
33798966|NCT05386498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Two consultants will be assessors who will be calibrated by demonstration of outcome assessment.~Series of assessments will be done on patients and inter assessor reliability will be determined.~An agreement of 0.7 by intraclass correlation coeffiecient will be considered as good reliability.~At the time of treatment a single assessor out of the two, will be blinded to the treatment allocation and will check the contact tightness of the filling. Masking will be ensured as the assessors will not be present at the time of treatment allocation or at the time of treatment administration and will be involved only once the procedure is complete. Assessment will be done using a waxed floss passed between the filling and the adjacent tooth. Due to interventional nature of the study the treating dentist cannot be blinded to the allocation of treatment."|"The study is a single centre based randomized control trial where the intervention arm 1 will get their class 2 restorations done with precured composte insert technique.~The intervention arm 2 will recieve treatment with contact making instrument technique.~The intervention arm 3 patients will be the control group and will recieve treatment of their class 2 restoration with the incremental composite layering techique. The study will be conducted on patients seeking class 2 restorations at the operative department of foundation university college of dentistry. Allocation of the patients in treatment groups will be done by simple randomization using the lottery method."|t|f|f|t
33718025|NCT03108027|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a double-blind masking.|This study is to assess the bronchodilator effects of QVM149 dosed once daily either in the morning or in the evening for 2 weeks compared to placebo. It will provide evidence of the comparability of lung function effects of QVM149 irrespective of the administration schedule|t|t|t|t
33718026|NCT00894452|||CASE_ONLY||CROSS_SECTIONAL|||||||
33718027|NCT02007018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33798967|NCT05110105|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33798968|NCT02015520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798969|NCT03472755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients provided written informed consent to participate in this study, as approved by the local ethics committee. Prior to surgery, patients were informed about the benefits and risk of the conventional posterolateral and direct anterior approaches. Then they performed postural test and a Performance-Oriented Mobility Assessment Walking test with and without step. After randomization, patients were operated according the conventional posterolateral or direct anterior techniques.||||
33798970|NCT01323231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33798971|NCT00616668|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33798972|NCT05075083|NA|SINGLE_GROUP||PREVENTION||NONE||subjects aged ≥60 with chronic bronchitis and COPD receive two doses inactivated COVID-19 vaccine||||
33798973|NCT05384210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33798974|NCT05403567|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome Assessor for primary outcome measure is blinded to the time of assessment (eg., baseline, pre-intervention, intervention or post-intervention).|||||
33798975|NCT05598580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33798976|NCT06451913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The 2 types of investigational products will be checked for blind maintenance before release (capsules will be identical in size, shape, color and appearance). The principal investigator does not have access to the randomization (treatment) code, except in exceptional circumstances for valid medical or safety reason, such as occurrence of a serious adverse event for which the knowledge of the study medication would be considered essential for treating the patient.|Randomized, double-blind, placebo-controlled, parallel-group, comparative study|t|t|t|t
33798977|NCT01993160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33798978|NCT06394271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Endpoint adjudication committee will be blinded to randomisation allocation.|Women will be randomised 1:! to either early endovascular aneurysm repair or to routine surveillance until the aneurysm diameter reaches 5.5 cm. Randomisation will be stratified by country, age ( below 76 years or older) and aneurysm diameter (4.0-4.9 cm and larger).|f|f|f|t
33798979|NCT03731377|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33798980|NCT03107546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The location of each (i.e., radial or ulnar side of the web) will be randomized and blinded. The participant and family will be blinded to which side of the web receives either the full-thickness graft or the skin substitute|"Sample:~The overall recruitment goal for the study is 40 participants within the first 5 years of the study.~For phase one, a sample size of 10 participants is the goal, and the investigators anticipate that this will take at most 18 months to attain based on their historical data.~For phase two, the investigators anticipate 30 months will be required to accumulate a sample size of 30 additional participants. Recruitment for phase two is expected to begin in year 2. Issues identified in the feasibility phase will be addressed as needed and the protocol amended."|t|f|f|t
33798981|NCT06552728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798982|NCT00003868||||TREATMENT||||||||
33798983|NCT05948592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33798984|NCT03062332|||COHORT||PROSPECTIVE|||||||
33798985|NCT01844492|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||Sample size listed is for patients (n=1420), for whom 809 surrogates completed long-term follow-up|f|f|f|t
33798986|NCT02639910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33798987|NCT05448846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33798988|NCT05951309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33798989|NCT01771731|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34021680|NCT05405972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Randomization to group was blinded and done by an independent statistician.|This study employed a randomized control trial design of a behavioral intervention with foster families caring for a CDFC as well as a permanent child in the home. The intervention tested is self-paced and delivered via technology to include foster families in rural and underserved locations. Behavioral changes of caregivers and children in the home were predicted to improve family functioning and facilitate healing from relationship-based trauma and its associated symptoms. Stratified randomization was used to assign participants into the experimental or control group. Blinding of the two groups to participants was not done (participants knew whether or not they received the video intervention). However, the team blinded the statistical analysis to group with the use of a statistician. Families assigned to the control did have the opportunity to participate in the intervention post-data collection and analysis and outside of the research protocol.||||
34021681|NCT03853148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34021682|NCT04326205|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34021683|NCT04935424|||CASE_ONLY||PROSPECTIVE|||||||
34021684|NCT02912650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103475|NCT06612151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103476|NCT06051617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103477|NCT06497686|||CASE_ONLY||PROSPECTIVE|||||||
34103478|NCT04248673|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718028|NCT01464385|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33718029|NCT03183375|RANDOMIZED|PARALLEL||TREATMENT||NONE||One is intervention arm which will be given investigational drug along with standard treatment and one will be control arm which will be given standard treatment only. Both groups will be assigned to only one treatment parallelly.||||
33718030|NCT05076526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a single-blinded randomised controlled trial.|t|f|f|f
33718031|NCT03666845|||CASE_ONLY||PROSPECTIVE|||||||
33798990|NCT03160599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942826|NCT01295073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34103479|NCT06675708|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34021685|NCT03400085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This is a single-center, prospective, randomized control trial with two arms. Participants in the intervention arm will use an mHealth application to complete their mandated living kidney donor follow-up at 6 months, 1 year, and 2 years, and participants in the control arm will receive the current standard of follow-up care and complete their required follow-up without the use of an mHealth application.~Living Kidney Donors at the Vanderbilt University Medical Center are also being given the option to use the mKidney system, however, these study participants are not a part of the Pilot RCT."||||
34021686|NCT00501501|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34021687|NCT00737750|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34021688|NCT04091711|NA|SINGLE_GROUP||TREATMENT||NONE||Open study for subjects receiving home-based oral oncolytic treatment. Subjects receive these medication by ReX-C device. Medication adherence, treatment instructions and side effects are recorded and monitored online in real time during the Study, by the ReX-C system.||||
34103480|NCT00285714|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021689|NCT02378350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021690|NCT06499857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment Prospective, Randomized and Blinded|t|t|t|f
34021691|NCT02045082|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33718032|NCT03935906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718033|NCT03910608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718034|NCT01512082|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33718035|NCT00774319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718036|NCT01001611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021692|NCT06088056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021693|NCT06457165|||OTHER||PROSPECTIVE|||||||
33718037|NCT00948623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718038|NCT04101981|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718039|NCT00611286|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33718040|NCT02938871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34021694|NCT06031987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Open label|randomized, parallel, open labeled study||||
34021695|NCT01123967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021696|NCT05808192|||CASE_CONTROL||RETROSPECTIVE|||||||
34021697|NCT05490485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021698|NCT02755077|RANDOMIZED|CROSSOVER||||NONE||||||
34021699|NCT00469911|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Compare magnetic resonance imaging measurements of triglyceride accumulation in myocardial tissue with ex vivo myocardial tissue collected from heart transplant patients who have had routine clinical heart biopsy.||||
33718041|NCT02288559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021700|NCT03917017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103481|NCT04348058|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||prospective||||
33718042|NCT03271112|NA|SINGLE_GROUP||PREVENTION||NONE||Pilote study||||
33718043|NCT02312895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33718044|NCT02566226|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34021701|NCT06408948|NA|SINGLE_GROUP||OTHER||NONE||Single oral dose of \[14C\]SHR7280||||
34021702|NCT01907568|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34021703|NCT04245956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||MitraFLOW is a prospective, investigator-initiated, monocentric, open-label, non-randomized pilot study.||||
34021704|NCT03545035|||COHORT||RETROSPECTIVE|||||||
33718045|NCT03231865|||COHORT||PROSPECTIVE|||||||
33718046|NCT03552146|||COHORT||PROSPECTIVE|||||||
33718047|NCT02597348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718048|NCT05138575|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All personnel will be masked except for the IDS pharmacist dispensing the drugs.|3 interventions will be randomized and administered in a double-blind fashion|t|t|t|t
33718049|NCT05534997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||pre and post test parallel groups randomized controlled trial|f|f|f|t
33718050|NCT03686163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718051|NCT01330589|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103482|NCT02715856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34103483|NCT01893814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103484|NCT06375863|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34103485|NCT06444542|||OTHER||PROSPECTIVE|||||||
33718052|NCT01404845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33718053|NCT01479153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718054|NCT01720992|RANDOMIZED|PARALLEL||||NONE||||||
34021705|NCT06316648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multidisciplinary cooperation was performed for the effective and efficient conduct of the study. In determining the patients to administer Whey according to the study's inclusion criteria, an orthopedic and traumatological specialist's support was received, as well as that of an anesthesiologist. On the other hand, the researcher cooperated with a nutritionist in preparing and assessing the Whey content to be administered to the patients.||||
34021706|NCT03996096|||COHORT||PROSPECTIVE|||||||
34021707|NCT03599492|||COHORT||PROSPECTIVE|||||||
34021708|NCT01147263|||||PROSPECTIVE|||||||
34021709|NCT04771403|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021710|NCT02714517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021711|NCT03559400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will receive gentamicin in saline solution or placebo saline injection while under anesthesia during the index surgery. Only the local research pharmacist, the UCSF clinical trial manager, and the DSMC will be unmasked.||t|t|t|t
34021712|NCT01666197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021713|NCT02416414|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34021714|NCT00567047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021715|NCT00586352|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021716|NCT00829803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34021717|NCT04934449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding the participants and investigator to the splint types employed in patients|Randomized clinical trial|t|f|t|f
34021718|NCT02318238|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34021719|NCT02351271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021720|NCT05567263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants will be informed about the nature and objectives of the study; however, they will not be informed what material they would receive.|The design of study will be a split-mouth randomized clinical trial with two study groups.|t|f|f|f
34021721|NCT05269602|||COHORT||CROSS_SECTIONAL|||||||
34021722|NCT02337959|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34021723|NCT00301093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021724|NCT01473524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021725|NCT04319185|NA|SINGLE_GROUP||OTHER||NONE||A mixed-methods feasibility design using quantitative and qualitative techniques will be used to meet the aims of this study.||||
34021726|NCT04865393|NA|SINGLE_GROUP||OTHER||NONE||||||
34021727|NCT01283529|||COHORT||PROSPECTIVE|||||||
34021728|NCT00311402||PARALLEL||PREVENTION||||||||
34021729|NCT01648660|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34021730|NCT03155321|||OTHER||CROSS_SECTIONAL|||||||
34021731|NCT04447339|||COHORT||RETROSPECTIVE|||||||
34021732|NCT01760525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021733|NCT00265395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021734|NCT03393806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized in a 1:1 ratio to receive either 10 mg/kg GSK3772847 or matching placebo intravenously.|t|f|t|f
34021735|NCT02829294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021736|NCT03584724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Up to 60 eligible patients will be randomly assigned to NORFLO® ORO or placebo treatment groups in a 1:1 ratio using a stratified randomization blocks scheme.||t|t|t|t
34021737|NCT00081692|||COHORT||CROSS_SECTIONAL|||||||
34021738|NCT00405444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021739|NCT05712421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021740|NCT06385561|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34021741|NCT04070235|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2 is parallel;Phase 3 is single group||||
34021742|NCT05888194|RANDOMIZED|PARALLEL||OTHER||NONE||A multicenter, prospective, randomized controlled study||||
34021743|NCT04832126|||FAMILY_BASED||PROSPECTIVE|||||||
34021744|NCT02040168|||CASE_ONLY||PROSPECTIVE|||||||
34021745|NCT04078126|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021746|NCT01196325|||COHORT||PROSPECTIVE|||||||
33942827|NCT05725837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"After 20 patients randomized the advisory board will unblind subjects to determine if the fluoxetine arm should be continued. Since it is not expected to have any beneficial effect of this treatment (it is only a comparative control to the effect of paroxetine on serotonin metabolism). Based on the decision of the committee the study could exclude the serotonin arm and the definitive sample size is going to be calculated.~The fluoxetine group was removed from the study after analysis of the first 20 patients (as foreseen in the initial protocol, after 20 patients included the blind would be broken to determine the final sample size) as it did not present an apparent benefit in the primary outcome. Considering that it had been included as a comparator for the effect of paroxetine on serotonin metabolism, and no beneficial effect from its use was anticipated, the study management committee decided to withdraw it."|t|t|t|t
33942828|NCT05384873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942829|NCT02386605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942830|NCT05620394|||CASE_ONLY||RETROSPECTIVE|||||||
33718055|NCT05778825|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33942831|NCT01329991|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33942832|NCT01721668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33942833|NCT02715115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942834|NCT03243201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021747|NCT06399809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double blinded study where both the participant and the investigators collecting data will be blinded.|To achieve the trial's specific aims, the investigators will randomize 34 participants age 50 and older with PAD to one of two groups: Fisetin vs placebo. Participants will be followed for four months|t|t|t|t
34101710|NCT06689774|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||In this pilot study, both participating Salvation Army sites will receive the experimental enhanced implementation support intervention, with the timing of launch staggered across sites to facilitate refinement of the implementation support intervention. Both sites will start implementing referral to the Wisconsin Tobacco Quit Line without consumer incentives for connecting with the Quit Line immediately, and will add these incentives a few months after launching Quit Line referral. The timing of incentive introduction will be staggered across the 2 pilot sites to permit refinement of the incentive strategy.||||
34101711|NCT04150757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Patients and treating providers will be aware of the medication administration.|Enrolled patients will receive one dose of Intranasal Ketamine dosed at 1mg/kg (Ketamine 500mg/10 mL solution) after triage while waiting for IV placement (max 50mg). This is an observational study.||||
33718056|NCT01024803|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33718057|NCT05490745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The interventional model is a simple two-arm RCT study (intervention vs. waiting-list), with 3 to 4 assessment waves (Time 0, Time 0+, Time 1, Time 2).~If the child is included in the study, they will be subject to a randomization process, being allocated, considering a sequence of random numbers generated by computer in a 1:1 ratio. In the randomization, half of the children are allocated to the IIG and the other half to the DIG."|f|f|f|t
33718058|NCT04924647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718059|NCT01267812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942835|NCT00405795|||COHORT||PROSPECTIVE|||||||
33942836|NCT04824092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942837|NCT02400268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021748|NCT01864850|RANDOMIZED|PARALLEL||OTHER||NONE||Radiotherapy||||
34021749|NCT05396378|||COHORT||PROSPECTIVE|||||||
34021750|NCT03433898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021751|NCT04053361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34021752|NCT01944176|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34021753|NCT01359969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021754|NCT05719688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021755|NCT05149677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021756|NCT04664790|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34021757|NCT06059443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be randomly assigned to one of two trial arms using the randomization module in REDCap. We will use block randomization with randomly permutated blocks to reduce opportunities for selection bias||t|f|f|f
33718060|NCT04277078|||COHORT||RETROSPECTIVE|||||||
33718061|NCT02107027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718062|NCT02986789|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33718063|NCT01327885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718064|NCT02200445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718065|NCT03905187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33718066|NCT05584176|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open-label, prospective study to evaluate the sensitivity and specificity of the Rapid SARS-CoV-2 Antigen Test when a lay person conducts the test on themselves or another study participant. Potential subjects will be those presenting for COVID-19 testing. The study will evaluate the performance of the Rapid SARS-CoV-2 Antigen Test by comparing it to a high sensitivity EUA SARS-CoV-2 RT-PCR assay to calculate both the positive percent agreement (PPA, or sensitivity) and the negative percent agreement (NPA, or specificity).||||
33718067|NCT03969394|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942838|NCT00851721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942839|NCT06482957|||COHORT||PROSPECTIVE|||||||
33942840|NCT04184674|NA|SINGLE_GROUP||OTHER||NONE||||||
33942841|NCT04838678|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33942842|NCT00027027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942843|NCT02102776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021758|NCT06633718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021759|NCT05375877|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, longitudinal study with event-based design||||
34021760|NCT02759601|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34101712|NCT06462573|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34103486|NCT03689088|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34101713|NCT06070350|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The University of Pittsburgh Medical Center Investigational Research Pharmacy will provide each site the placebo and TXA. The research pharmacy at each site will draw the dose syringes. They will be blinded with a label indicating either drug A or B, and the pharmacy will log which patients received TXA or placebo, with all drugs labeled as investigational products.|MATIC-2 is a Bayesian, randomized, multicenter, adaptive platform phase III trial to examine the effectiveness and safety of LTOWB versus CT and TXA vs placebo in 1000 children at minimum 20 US high volume academic pediatric trauma centers. Mechanisms of Trauma induced Coagulopathy (TIC) and resuscitation effects will also be investigated. The trial will stratify pediatric trauma centers based on their reported Massive Transfusion Protocol (MTP) volume and then randomize them into four treatment combinations. After an initial enrollment phase, treatment sites will cross over to ensure that all treatments are tested across every site, eliminating biases by the time of the first interim analysis.|t|t|t|t
34101714|NCT02423070|||COHORT||PROSPECTIVE|||||||
34101715|NCT00706537|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34101716|NCT06525454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||1:2 ratio||||
34101717|NCT06687603|NA|SINGLE_GROUP||PREVENTION||NONE|All endoscopic images will be reviewed by an examiner who will be blinded to the endoscopy report. BE will be defined as the presence of \> 1 cm of columnar appearing epithelium in the tubular esophagus as confirmed by the blinded reviewer plus the presence of intestinal metaplasia on biopsies. I|||||
34101718|NCT01044043|||||PROSPECTIVE|||||||
34101719|NCT05827081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101720|NCT03976141|||COHORT||RETROSPECTIVE|||||||
34101721|NCT06688149|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34101722|NCT05337631|||COHORT||RETROSPECTIVE|||||||
34101723|NCT06695962|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34101724|NCT02339675|NA|SINGLE_GROUP||OTHER||NONE||||||
34101725|NCT04193189|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101726|NCT06375655|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101727|NCT05514535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101728|NCT06688682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||90 subjects were randomly divided into three groups, with 30 cases in each group. (1) HA group: The patients were given intraarticular injection of sodium hyaluronate injection, 2ml each time, and normal saline injection of 1ml at Xuehai point, Yanglingquan point and Wezhong point, once a week for 4 weeks. (2) PRP joint cavity injection group: PRP knee cavity injection was given, 3.5ml each time, and normal saline injection was given at Xuechai point, Yanglingquan point and Weizhong point 1ml, once a week for 4 weeks; (3) PRP joint cavity combined with acupoint injection group: PRP was given intraventricular injection of knee joint, each injection was 3.5ml, while PRP was given 1ml injection of Xuehai point, Yanglingquan point and Weizhong point, once a week for 4 weeks.|t|f|f|f
34101729|NCT05652140|||COHORT||PROSPECTIVE|||||||
34101730|NCT02628145|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101731|NCT06689579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101732|NCT06691295|||COHORT||RETROSPECTIVE|||||||
33942844|NCT02587780|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33942845|NCT06345287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942846|NCT00100542|||CASE_CONTROL||PROSPECTIVE|||||||
33942847|NCT01957904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101733|NCT06690385|||COHORT||PROSPECTIVE|||||||
34101734|NCT02206438|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34101735|NCT05837247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101736|NCT06560307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101737|NCT06690866|||COHORT||CROSS_SECTIONAL|||||||
34101738|NCT05156112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessors will be blinded to treatment condition to minimize bias in outcome assessments|The investigators aim to examine the effects of PAP treatment on Veterans with PTSD and SUD on a 28-day residential unit. The investigators are proposing a randomized controlled study comparing two groups: an early intervention PAP treatment group receiving PAP treatment while on the residential unit, compared to a waitlist control group who will receive PAP treatment at 3-months post-discharge follow-up.|f|f|f|t
34101739|NCT06579391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This is a two-arm, randomized, placebo-controlled, double-blinded, single-center clinical trial.|t|t|t|t
34101740|NCT02920294|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34101741|NCT02258919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101742|NCT05783596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101743|NCT06691633|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Clinical staff other than the anesthesia providers|Prospective, randomized cohort analysis study|t|f|t|f
33942848|NCT04021342|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The treatment drink (tart cherry concentrate) and placebo are matched for colour and packed in identical plastic containers. The assigned beverages are packed and given to the participants by an independent researcher not involved in the study.||t|f|t|t
33942849|NCT00508001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942850|NCT04027504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942851|NCT02846337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33942852|NCT00461552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33942853|NCT03427203|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33942854|NCT01417949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942855|NCT01414686|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33942856|NCT02774499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942857|NCT03374059|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled||||
33942858|NCT04938882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33942859|NCT00769821|||COHORT||PROSPECTIVE|||||||
33942860|NCT01074060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942861|NCT05899946|NA|SINGLE_GROUP||OTHER||NONE||||||
33942862|NCT05568966|NA|SINGLE_GROUP||OTHER||NONE||||||
33942863|NCT06199791|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33942864|NCT06365840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942865|NCT06221085|||OTHER||CROSS_SECTIONAL|||||||
34021761|NCT04542616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will sign a consent form indicating they will be randomly receiving one of the 2 tube shunt models. It would be impossible to mask the patient or care provider to the type of tube shunt a patient received. The patients cannot bias the clinical data recorded on their follow up exams. All data will be recorded objectively. The outcome assessor will be masked to the type of shunt used.|Comparison between 2 groups of patients requiring tube shunt implantation to treat their severe uncontrolled glaucoma. One group will receive a unilateral Baerveldt 350 tube shunt and the other a unilateral Ahmed ClearPath 250 tube shunt. The patients will be sequentially randomized into one of these tube shunts.|f|f|f|t
34021762|NCT02028494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021763|NCT06040775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021764|NCT05950230|||CASE_CONTROL||RETROSPECTIVE|||||||
34021765|NCT05535985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34021766|NCT01181960|||COHORT||PROSPECTIVE|||||||
34021767|NCT00094003|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021768|NCT03560648|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34021769|NCT03612557|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021770|NCT04140305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021771|NCT04830059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and investigators are blinded, and part of the outcome assessors are blinded.|Double blind randomized controlled trial|t|f|t|t
34021772|NCT04702438|||COHORT||PROSPECTIVE|||||||
34021773|NCT00886223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021774|NCT04226326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021775|NCT01194518||||PREVENTION||||||||
34021776|NCT01344278|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34021777|NCT04536935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021778|NCT00233701|||||PROSPECTIVE|||||||
34021779|NCT05318430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021780|NCT05254600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34021781|NCT00979914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021782|NCT03157648|||CASE_CONTROL||PROSPECTIVE|||||||
34021783|NCT05248763|||COHORT||PROSPECTIVE|||||||
34021784|NCT02146963|||COHORT||PROSPECTIVE|||||||
34021785|NCT05126355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34021786|NCT03726853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021787|NCT04431583|||COHORT||RETROSPECTIVE|||||||
34101744|NCT04254250|||COHORT||PROSPECTIVE|||||||
34101745|NCT06588400|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101746|NCT02062684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101747|NCT06688487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101748|NCT06001775|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101749|NCT06688929|||CASE_ONLY||CROSS_SECTIONAL|||||||
34101750|NCT00708448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101751|NCT04157738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101752|NCT05282394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101753|NCT03989674|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33798991|NCT06155877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|For ethical reasons, pupils' parents were informed that their children would take part in an experiment aiming to test pedagogical materials about vaccination. Thus, the pupils were aware that they were participating in an experiment, and of the broad purpose of this experiment. However, the investigators asked teachers not to tell pupils about the different experimental conditions, and to arrange for another colleague to administer the questionnaires to their pupils. This limits the risk that pupils bias their behavior to fit the hypotheses associated with their experimental group - whether because of their own reaction or because of their teachers' reaction. Furthermore, since vaccination is part of the French national curriculum, the investigators argue that it is difficult for pupils to know whether the materials they were presented with is the standard one or one of our interventions.|"Participants were randomized at the school level, to minimize contamination between experimental conditions. Using administrative data, schools were stratified by their Priority Education status and by geographical categories (urban with high density, urban with medium density, rural). Then, within each stratum, schools were matched by triplets using the closest-neighbors approach, minimizing the quadratic distance between schools' success rate at the national end-of-middle school exam and Covid vaccination rate at the EPCI3 level. This resulted in 149 triplets. Within each triplet, schools were randomly assigned to one of the three experimental groups.~Randomization code is available at the experiment's OSF repository:~https://osf.io/rf5w9/?view_only=de759e4e36914c909adeac5fd541babf"|f|f|f|t
33798992|NCT04867902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798993|NCT01976312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33798994|NCT01398124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33798995|NCT03298724|NA|SINGLE_GROUP||TREATMENT||NONE||Single case experimental design (multiple baseline across setting)||||
33798996|NCT04666857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to the allocation of participants|prospective monocentric single-blinded, two-arm feasibility randomised controlled interventional pilot trial|f|f|f|t
33798997|NCT02364349|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33798998|NCT00924807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021788|NCT01875458|||CASE_CONTROL||PROSPECTIVE|||||||
34021789|NCT03850925|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split-face comparison study||||
33718068|NCT03864250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718069|NCT06518135|||CASE_ONLY||PROSPECTIVE|||||||
33718070|NCT05830201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||control group or therapy group||||
33718071|NCT00262808||||TREATMENT||NONE||||||
33718072|NCT02589951|||||RETROSPECTIVE|||||||
33718073|NCT03103633|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients were followed up by an investigator unaware of the patients' achievement or not of the oxygen dynamic goal|"Interventional group:MAP declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.~Control group：no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr."|t|t|t|t
33718074|NCT01667757|||CASE_ONLY||CROSS_SECTIONAL|||||||
33718075|NCT05436951|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking|Randomized crossover study design||||
33718076|NCT02157298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718077|NCT03502044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Both the participants and investigator are blinded with regarding the administration of KOS or placebo treatments during the first 8 treatments.~During the following 8 treatments only the patients, not the investigator, are blinded."|Double blinded placebo controlled trial design during the first 8 treatments. Single blinded (patient is blinded) controlled trial design during the last 8 treatments.|t|f|t|f
33718078|NCT02338531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718079|NCT03957707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718080|NCT00338702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718081|NCT03724539|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|"The OPTICA study is partially blinded, with blinding being implemented as follows:~* Due to the nature of the study intervention participating GPs (care providers) cannot be blinded.~* Patients remain blinded. They will not be informed to which treatment arm their GP is allocated to, in order to minimize performance and other reporting biases. Despite this, they receive a high-level description of the study question and the study procedures.~* Data collection for primary and secondary outcome analyses will be conducted by blinded study team members.~* Outcome adjudication (MAI and AOU assessment) will be performed by blinded study team members."|"Clusters will be randomized 1:1, to either the intervention arm receiving STRIPA or to the control arm undergoing a sham intervention. Each cluster is defined by one GP.~The patients assigned to a cluster (i.e. GP) which was allocated to the intervention arm will undergo a systematic pharmacotherapy optimization by their GP using the STRIP assistant and shared decision making. Patients assigned to a cluster that was assigned to the control arm will receive a sham intervention, which consists of a usual medication review by the GP in accordance with usual care and shared decision making.~This RCT randomizes GPs instead of patients to prevent contamination, which would occur if the same GPs treated patients in the intervention and the control arm simultaneously."|t|f|t|t
33718082|NCT01912651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718083|NCT01064401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718084|NCT04276623|||COHORT||PROSPECTIVE|||||||
33718085|NCT02589574|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33718086|NCT01101347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718087|NCT02730455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718088|NCT01503281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33718089|NCT00549523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33718090|NCT01735513|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33718091|NCT04811833|||CASE_ONLY||PROSPECTIVE|||||||
33718092|NCT01953133|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33718093|NCT00315198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718094|NCT05063669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718095|NCT02573727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718096|NCT01609985|||CASE_ONLY||PROSPECTIVE|||||||
33798999|NCT06075472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
33942866|NCT03458468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded randomized||t|t|t|t
33942867|NCT01191359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021790|NCT06421883|RANDOMIZED|PARALLEL||PREVENTION||NONE|(Open Label)|"Patients will be randomized into two groups each group includes 40 patients:~Control group: 40 patients will receive their standard therapy only. Intervention group (probiotic group): 40 patients will receive probiotic 5 billion unit per day with their standard therapy for 3 months."||||
34021791|NCT02520037|||CASE_ONLY||PROSPECTIVE|||||||
34021792|NCT00095797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021793|NCT02100943|||COHORT||PROSPECTIVE|||||||
34021794|NCT05400408|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel Assignment||||
34021795|NCT02391818|||COHORT||PROSPECTIVE|||||||
34021796|NCT00421395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021797|NCT03256279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Only one of the investigators are going to know the archwire assigment, the other ones who are going to do the measures are going to be blinded.||t|f|f|t
34021798|NCT05930548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021799|NCT00191113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021800|NCT03828916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021801|NCT00269243|RANDOMIZED|PARALLEL||||DOUBLE||||||
34021802|NCT00006019||||TREATMENT||NONE||||||
34021803|NCT00721630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021804|NCT00442039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021805|NCT05354635|||CASE_ONLY||PROSPECTIVE|||||||
34021806|NCT02065700|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021807|NCT05055830|||OTHER||PROSPECTIVE|||||||
34021808|NCT00198237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021809|NCT04395495|||COHORT||PROSPECTIVE|||||||
34021810|NCT04077918|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34021811|NCT01058772|RANDOMIZED|PARALLEL||||NONE||||||
34021812|NCT03859765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021813|NCT00045188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021814|NCT01754337|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021815|NCT01844466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942868|NCT01075568|RANDOMIZED|CROSSOVER||||SINGLE||||||
33942869|NCT06148805|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. Patients diagnosed with rotator cuff tendinopathy for duration greater than three months (Eda and Emin,2016).~2. 40 and 60 years of age from both genders (Yamamoto et al.,2019)~3. Patient's BMI within normal range between 18.5 and 24.9 (Gumina et al.,2014)~4. patients complain of shoulder pain at the tip of the shoulder and the upper, outer arm. The pain is aggravated by reaching, pushing, pulling, lifting, positioning the arm above the shoulder level, or lying on the side (Stiphen and Micheal,1021).~5. The arm pain during resisted testing (usually abduction and/or lateral rotation) (Eda and Emin,"||||
33942870|NCT02409017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942871|NCT04104399|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33942872|NCT06336109|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33942873|NCT04353752|||COHORT||PROSPECTIVE|||||||
33942874|NCT03389490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942875|NCT01142960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33942876|NCT01135368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942877|NCT02671786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942878|NCT05079100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33942879|NCT04438642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded||t|t|t|t
33942880|NCT04340167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942881|NCT02572492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942882|NCT05782660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33942883|NCT00733096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942884|NCT05977283|||COHORT||PROSPECTIVE|||||||
33942885|NCT02432027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942886|NCT04051320|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33942887|NCT04126499|||COHORT||RETROSPECTIVE|||||||
33942888|NCT02206958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942889|NCT05021159|||CASE_ONLY||PROSPECTIVE|||||||
33942890|NCT05899127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942891|NCT05076981|||COHORT||PROSPECTIVE|||||||
33942892|NCT02561572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942893|NCT03953794|||COHORT||PROSPECTIVE|||||||
33942894|NCT04862689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942895|NCT05848128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942896|NCT06154044|NA|SINGLE_GROUP||TREATMENT||NONE|Imaging core lab employees will be blinded to the patient's status (before or after cell therapy)|||||
33942897|NCT00402662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942898|NCT02409966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942899|NCT03699670|||COHORT||PROSPECTIVE|||||||
33942900|NCT05454696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33942901|NCT04322799|RANDOMIZED|PARALLEL||TREATMENT||NONE|Two different acetabular cups in total hip arthroplasty. No difference in surgical surgical technique and type of stem. The cup have the identical outlining.|Randomized controlled trial||||
33942902|NCT04331314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Twenty patients scheduled for lateral-window sinus floor Elevation SFE will be randomized to an HA and a β-TCP/HA Group.|t|f|t|f
33942903|NCT04279509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942904|NCT01365195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101754|NCT05785000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors of outcomes at the end of the project are different to the assessors of clinical test at entry to the project|"Patients are recruited through our professional networks, via clinics, hospital emergency departments, general practitioners, physiotherapeutic clinics, flyers at educational institutions and patient associations. Inclusion age is 18-70 years, both genders. PCS symptoms of at least 4 weeks persistence after initial trauma and patients must be able to document the traumatic brain event from either emergency room or other medical doctor. Exclusion criteria: other diseases interfering with presentation of PCS symptoms.~Up to fifty healthy controls are included only in the MRI part. Healthy controls are recruited by advertising in public media. This part of the project is also constituted as a separate case control study comparing PCS patients and healthy controls~Seventy patients with PCS are randomized to either intervention as an add on to usual care or to control. Randomization is performed as a block-randomization with permuted block of size 2-6 generated via computer."|f|f|f|t
34101755|NCT06162468|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm trial of the feasibility of endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary mucinous neoplasms (IPMN) in two New Zealand tertiary interventional endoscopy centres.||||
34101756|NCT06354777|||CASE_ONLY||PROSPECTIVE|||||||
34101757|NCT05179408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor will be blinded to participant allocation group.|This project will evaluate multi-targeted telerehabilitation with Veteran lung cancer survivors following curative intent therapy. Targets include: 1) inspiratory muscle training + walking promotion to reduce dyspnea and improve physical activity; 2) resistance training to reduce cancer-related fatigue and improve social/role functioning; and 3) mindfulness training to reduce fear of cancer recurrence and cancer-related anxiety.|f|f|f|t
34101758|NCT03291236|||COHORT||PROSPECTIVE|||||||
34101759|NCT04588077|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101760|NCT06426628|||COHORT||PROSPECTIVE|||||||
34101761|NCT01856192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101762|NCT05792722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101763|NCT05250557|||COHORT||PROSPECTIVE|||||||
34101764|NCT05677126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34101765|NCT06428474|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101766|NCT06436742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101767|NCT06457139|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34101768|NCT06171802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded trial|Randomized placebo-controlled|t|t|t|t
34101769|NCT06328114|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The TMS intensity delivered at each TMS visit will be masked|Single-arm crossover study design with subjects receiving TMS at two different intensities|t|t|f|t
34101770|NCT06567704|||CASE_ONLY||PROSPECTIVE|||||||
34101771|NCT05532657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34101772|NCT03785132|||COHORT||RETROSPECTIVE|||||||
34101773|NCT03508700|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label Study||||
34101774|NCT00456911|RANDOMIZED|PARALLEL||||SINGLE||||||
34101775|NCT06158438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101776|NCT06529692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101777|NCT06686368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All products will have their label removed and placed a white sticker showing the group (A or B or C). Products with be put in a white box with the letter indicated on it.|in vivo, human patient with confirmed Evaporative dry eye disease|t|t|t|f
34101778|NCT03533491|NA|SINGLE_GROUP||TREATMENT||NONE||All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app.||||
34101779|NCT04398706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The study will be performed in a modified double-blind fashion:~* Investigators and study staff who conduct the safety assessment and the participant will not know which vaccine is administered~* Only the study staff who prepare and administer the vaccine and are not involved with the safety evaluation will know which vaccine is administered This study will be observer-blinded between any SP0202 formulation and Prevnar 13 and double-blind across the 3 SP0202 formulations"||t|t|t|t
34101780|NCT06695663|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101781|NCT06686537|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34101782|NCT05286385|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34101783|NCT03477591|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33942905|NCT02114905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942906|NCT02594280|||COHORT||PROSPECTIVE|||||||
33942907|NCT04725734|||COHORT||PROSPECTIVE|||||||
33942908|NCT00188162|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942909|NCT03136809|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label treatment extension study||||
33799000|NCT05843708|RANDOMIZED|CROSSOVER||OTHER||NONE||"The substudy A (low-fat meal) is an open-label, randomized, balanced, single-dose, 2-treatment, 2-period, crossover study designed to assess the effect of a low-fat meal on the PK following a single oral dose of 40 mg vorasidenib in healthy adult subjects.~The substudy B (CYP1A2 inhibition) is an open-label, nonrandomized, 2-period, 1-sequence crossover study designed to evaluate the effect of multiple-dose ciprofloxacin (strong CYP1A2 inhibitor) on the single-dose PK of vorasidenib in 28 healthy adult subjects"||||
33799001|NCT05273788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799002|NCT00424086|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34021816|NCT05173675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research staff responsible for biomedical data collection at the sites are blinded to the status of the participant as part of control or intervention group. Self-reported outcomes are reported by participants on a tablet.|Randomized controlled trial, stratified by PHQ-9 baseline scores (cut-off ≥5), on a 1:1 ratio|f|f|t|t
34021817|NCT05569551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Masking on participants and investigator||t|f|t|f
34021818|NCT03012984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021819|NCT00317707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021820|NCT00837473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021821|NCT04051112|NA|SEQUENTIAL||TREATMENT||NONE||||||
34021822|NCT01156142|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34021823|NCT03141814|||CASE_CONTROL||PROSPECTIVE|||||||
34021824|NCT06288230|NA|SEQUENTIAL||TREATMENT||NONE||||||
34021825|NCT06370286|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomly assigned to either a concurrent exercise (CE), aerobic exercise (AE), or control (CON) group. Participants in the CE group engaged in 12-minutes of AE (40%-59% of heart rate reserve \[HRR\]) coupled with 13-minutes of resistance exercise (1 set, with 75% of 10-repetition maximum, and 12 repetitions of 8 movements). The AE group participated in 25 minutes of AE (40%-59% HRR). Prior to and following exercise onset, participants in both the CE and AE groups completed a 5-minute warm-up and cool-down. Participants in the CON group read books for 35 minutes. Lactate concentrations were measured at timepoint of 0-, 17-, and 30-minutes relative to the treatment onset. Response time (RT) and accuracy in the Stroop test, as well as P3 amplitudes, were assessed before and after the treatment.||||
34021826|NCT04923789|||COHORT||PROSPECTIVE|||||||
34021827|NCT05328934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover design with first intervention randomized.||||
34021828|NCT05316883|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||To compare biomarkers between clozapine responders and non-responder before and after 12 weeks of treatment||||
34021829|NCT02936414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021830|NCT05312320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34021831|NCT04851938|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34021832|NCT01750489|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021833|NCT00810576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021834|NCT05410782|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with male factor infertility, who have a document abnormal semen analysis (at least 1 of 3 abnormal parameters - concentration, progressive motility or morphology) will be recruited to take a 3 month course of supplements (Power Prenatal for Sperm), and a repeat semen analysis will be performed after the intervention to compare results||||
34021835|NCT00057421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34021836|NCT05498675|||COHORT||OTHER|||||||
34021837|NCT01568060|||COHORT||PROSPECTIVE|||||||
34021838|NCT03365752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021839|NCT00077857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021840|NCT06419595|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021841|NCT00006458||||TREATMENT||||||||
34021842|NCT01329900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021843|NCT00670163|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34021844|NCT00205244|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34021845|NCT02827838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021846|NCT06172244|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|In statistical analysis, blinding will be done before and after the application.|A total of 5 sets of vibration will be given at 30 Hz, 2 mm amplitude, 1 minute of application and 1 minute of rest.||||
34021847|NCT02943928|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34021848|NCT05540028|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Single center, randomized, active-controlled, observer-blind Phase 1study in which adults were randomized in a 1:1 ratio to evaluate safety and tolerability of IVT PCV 25 to comparator.|t|t|t|t
34021849|NCT06380868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization will be performed in the catheter laboratory by an invasive nurse. Staff in the catheter laboratory will be not blinded to the treatment allocation.|Patients will undergo 1:1 randomization to either intravascular imaging (including intravascular ultrasound or optical coherence tomography)-guided DES implantation which will be the treatment group or Angio-guided DES implantation which will be the control group, stratified by research sites.|t|t|f|t
34021850|NCT01556360|||COHORT||PROSPECTIVE|||||||
34021851|NCT02492880|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021852|NCT00149812|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34021853|NCT04332887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One research assistant is trained for being a outcomes assessor in this study who did not know the allocation of participants.|Patients in the intervention group will receive a 12-week exercise program including individual nursing consultation, exercise program, nutrition assessment and instructions, and support.|f|f|f|t
34021854|NCT05394311|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A parallel-group, two-arm, superiority, cluster-randomised controlled trial with 1:1 allocation to intervention and control arms will be used in the study. Two cross-sectional household surveys of adolescents, one at baseline and one at end line will be conducted.|t|t|f|t
34021855|NCT03874286|||CASE_ONLY||PROSPECTIVE|||||||
34021856|NCT02297698|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021857|NCT04405830|||COHORT||PROSPECTIVE|||||||
34021858|NCT04419792|||CASE_ONLY||CROSS_SECTIONAL|||||||
34021859|NCT02651259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021860|NCT06372327|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This will be a 2 (Exercise snack number) x 2 (Exercise snack length) factorial design.||||
34101784|NCT00106015|||COHORT||PROSPECTIVE|||||||
34101785|NCT06668909|||COHORT||OTHER|||||||
34101786|NCT06656572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101787|NCT05714384|||COHORT||PROSPECTIVE|||||||
34101788|NCT02344355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101789|NCT06686069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A and B vials given by physicians to the enrolled patients|Treatment with L-arginine vs placebo|t|f|t|f
34021861|NCT05160233|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|All outcomes are derived from secondary administrative data.|"Cluster-randomized trial with 2x2 factorial randomization of two experimental strategies resulting in four arms: 2x2 factorial design to four approaches: (1) standard implementation; (2) standard implementation plus practice facilitation; (3) standard implementation plus health coach; and (4) standard implementation plus both."|f|f|f|t
34021862|NCT01943110|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101790|NCT06161025|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101791|NCT03273023|||CASE_ONLY||PROSPECTIVE|||||||
34101792|NCT06687486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Individuals assigned as intervention and control will complete the research in these groups.|t|f|f|f
34101793|NCT06694077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021863|NCT02329938|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34101794|NCT01907789|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101795|NCT05656573|NA|SEQUENTIAL||TREATMENT||NONE||||||
34101796|NCT06343298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101797|NCT06680401|||COHORT||PROSPECTIVE|||||||
34101798|NCT06280664|||COHORT||PROSPECTIVE|||||||
34101799|NCT04190771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-blind, parallel-group, randomized controlled trial|f|f|t|t
34101800|NCT03734536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101801|NCT06227026|NA|SINGLE_GROUP||TREATMENT||NONE|This study will utilize a staggered enrollment design. Following the CAR-T infusion of the first subject, further enrollment will be paused for a 28 day safety observation period. If deemed safe by the Data Safety Monitoring Committee (DSMC) after this period (i.e. no stopping rules have been satisfied), enrollment of the second subject may proceed. Following the CAR-T infusion of the second subject, enrollment will again be paused for a 28 day safety observation period. Enrollment of the remaining subjects may only proceed after approval from the DSMC following the safety observation period for the second subject.|||||
34101802|NCT02527083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34101803|NCT06686225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101804|NCT04566731|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Crossover assignment|t|t|t|f
34101805|NCT01391494|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34101806|NCT04765384|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34101807|NCT05225012|NA|SINGLE_GROUP||TREATMENT||NONE||Case series design||||
34101808|NCT05554263|||COHORT||PROSPECTIVE|||||||
34101809|NCT06368531|||COHORT||PROSPECTIVE|||||||
34101810|NCT04189783|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101811|NCT04900493|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34101812|NCT03420963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021864|NCT00093119|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021865|NCT01089244|||COHORT||PROSPECTIVE|||||||
34101813|NCT05520762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cluster-randomized design with crossover||||
34101814|NCT05459935|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham intervention (nonactivated/unpowered phototherapy intervention)||t|f|f|f
34101815|NCT04146207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101816|NCT05826587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101817|NCT06687473|NA|SINGLE_GROUP||TREATMENT||NONE||"The multi-resistant H. pylori eradication rates between bismuth-susceptibility-based regimen and history physicians' discretion regimen are compared."||||
34101818|NCT05169970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase II nonrandomized noninferiority trial that aims to evaluate the efficacy of dose escalated radiation therapy in the absence of androgen deprivation therapy for Decipher genomic score stratified NCCN unfavorable intermediate risk prostate cancer.||||
34101819|NCT03776240|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34101820|NCT04195672|||COHORT||PROSPECTIVE|||||||
34101821|NCT05162794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101822|NCT02124980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101823|NCT04409119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the staff performing and evaluating echocardiography and hall-walk tests are blinded to the treatment arm||t|f|f|t
34101824|NCT06689007|NA|SINGLE_GROUP||OTHER||NONE||||||
34101825|NCT03227575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101826|NCT03468127|||OTHER||PROSPECTIVE|||||||
34101827|NCT02577302|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Controlled, Non-Inferiority||||
34101828|NCT05676450|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021866|NCT01273935|||CASE_ONLY||RETROSPECTIVE|||||||
34021867|NCT01085734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34021868|NCT02828241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34021869|NCT02065856|NA|SINGLE_GROUP||||NONE||||||
34021870|NCT02875964|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34021871|NCT06182761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021872|NCT02913092|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34021873|NCT00935610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34021874|NCT00730223|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34021875|NCT05146297|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799003|NCT00975039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799004|NCT06218303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799005|NCT06281054|||COHORT||RETROSPECTIVE|||||||
33799006|NCT00488410|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33799007|NCT01186198|||COHORT||PROSPECTIVE|||||||
33799008|NCT03281616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799009|NCT05350475|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized phase 3 study, randomizing 1:1 between photon vs. proton therapy for prostate cancer patients with high risk disease||||
33799010|NCT02285413|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799011|NCT04065113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799012|NCT01716936|||COHORT||RETROSPECTIVE|||||||
33799013|NCT02997917|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33799014|NCT00447733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799015|NCT05119764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Observer/Investigators are unaware of the treatment arm of each patient. Patients cannot be blinded, due to the obvious treatment intervention (manual lymphatic drainage 15 minutes for 5 days).|Randomized controlled trial with three treatment groups, two intervention groups and one control group|f|f|t|f
33799016|NCT04218110|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Samples are blinded to the Microbiology group, participant, sponsor (1 of 2) and statistician||t|f|t|t
33799017|NCT03653169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799018|NCT02772471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942910|NCT02843113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942911|NCT00757159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33942912|NCT06082011|||COHORT||CROSS_SECTIONAL|||||||
33942913|NCT01577446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942914|NCT00861627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942915|NCT05699304|||COHORT||RETROSPECTIVE|||||||
33942916|NCT03580707|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33942917|NCT01305616|NON_RANDOMIZED|PARALLEL||||NONE||||||
34021876|NCT01507363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021877|NCT03963986|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized to the STANDARD group for which management will be standard or to the STIMUL group with digital coaching program||||
33942918|NCT04927858|||COHORT||RETROSPECTIVE|||||||
33942919|NCT00252798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942920|NCT02663024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942921|NCT02576106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942922|NCT04035408|||COHORT||PROSPECTIVE|||||||
33942923|NCT03718624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942924|NCT00526084|||DEFINED_POPULATION||OTHER|||||||
33942925|NCT05707364|||COHORT||PROSPECTIVE|||||||
33942926|NCT02778594|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33942927|NCT00367146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942928|NCT00787280|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33942929|NCT01359319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942930|NCT03171688|||COHORT||PROSPECTIVE|||||||
33942931|NCT05741528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942932|NCT01965691|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33942933|NCT02897830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942934|NCT04656262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942935|NCT03757936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942936|NCT01549327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101829|NCT06525870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment is unknown to the patient but the physicians will know because the different degree of cervical tissue whitening.|Patients then will be randomized between the two groups. Group 1 will be intervention arm and receive 85%TCA topical application at cervical lesion and transformation zone. Group 2 will be control arm and receive topical application of 3% acetic acid at cervical lesion and transformation zone in the same manner.|t|f|f|f
34101830|NCT05262764|||COHORT||PROSPECTIVE|||||||
34101831|NCT00108563|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34101832|NCT05816161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101833|NCT05393908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101834|NCT04799119|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial experimental/treatment group and control.||||
34101835|NCT02618733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101836|NCT06333860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101837|NCT05792930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101838|NCT06567301|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|double blinded controlled randomized study (pretest-posttest measurement)||t|f|f|t
34101839|NCT05396170|||COHORT||PROSPECTIVE|||||||
34101840|NCT05893030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101841|NCT06694896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Newborns with two major or one major and two minor, or three or more minor congenital anomalies were included. Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.||||
34101842|NCT05566054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101843|NCT05470296|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-/post design||||
34101844|NCT06644456|||CASE_ONLY||PROSPECTIVE|||||||
34101845|NCT03278340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be aware of the condition in which their organization is assigned.||t|f|f|f
34101846|NCT06569277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All elective colonoscopies were performed by two experienced endoscopists who were unaware of the group assignments.||f|t|f|f
33718097|NCT04204954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and outcomes assessors were blinded to the treatment allocation of each participant. Outcome assessors were anterior segment surgeons who evaluated cases prior to cataract surgery. There was no indication of group allocation in the electronic medical records (EMR), only the participation of each candidate in the study. Similarly, investigators were blinded to group allocation and only recorded data directly from EMR. Blinding was kept after data analysis.|Patients diagnosed with Demodex spp. infestation undergoing cataract surgery were randomly allocated into four comparison groups a control group (standard treatment) and three new modalities of Demodex therapy (Blephaclean, baby shampoo, and tea tree oil) + conventional treatment.|f|f|t|t
33718098|NCT05270746|||OTHER||CROSS_SECTIONAL|||||||
33718099|NCT05893407|||COHORT||PROSPECTIVE|||||||
33718100|NCT06146426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This is an open label randomized controlled trial with two parallel groups. No blinding will be considered.Patients will be randomly assigned to either early or conventional oral feeding group using software STATA 17.0 or SPSS 24.0. Sequentially numbered opaque sealed envelopes (SNOSE) which contain the allocation will be used. These envelopes are prepared by an independent person who is not a research team member. It will be sealed and provided to the principal investigator or co-investigator or statistician.Subjects will be enrolled as per the inclusion criteria. The patients will be approached directly in the preoperative period and informed consent will be obtained.~They will be allocated to early and conventional diet groups by randomization."||||
34101847|NCT04997018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101848|NCT05970796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34101849|NCT06687928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Randomized, Double-blind, Two-arm, Parallel-group, Single-dose, Phase 1 Study|t|t|t|f
34101850|NCT05313256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101851|NCT05019521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking of treatment allocation will be observed until Week 104.||t|t|t|t
33799019|NCT03299322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a Double-blind Trial|All treatment group received a standard anti-asthma treatment plus Jia Wei Yang He Formula on study entry, and the control group received Jia Wei Yang He Formula placebo instead.|t|t|t|f
34021878|NCT00372411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021879|NCT03360084|||COHORT||RETROSPECTIVE|||||||
34021880|NCT03516110|||COHORT||PROSPECTIVE|||||||
34021881|NCT02549027|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34021882|NCT03482700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are two groups: An intervention group and a control group. The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations. The control group will receive the usual standard of care.||||
34021883|NCT04373486|||CASE_ONLY||OTHER|||||||
34021884|NCT00307437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021885|NCT06112392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021886|NCT06187558|||OTHER||RETROSPECTIVE|||||||
34021887|NCT01759732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021888|NCT04359511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021889|NCT05910476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021890|NCT03828513|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34021891|NCT02436967|||CASE_ONLY||PROSPECTIVE|||||||
34021892|NCT05512637|||COHORT||PROSPECTIVE|||||||
34021893|NCT02258854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021894|NCT04699500|||COHORT||PROSPECTIVE|||||||
34021895|NCT01925599|||CASE_ONLY||PROSPECTIVE|||||||
34021896|NCT00936897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021897|NCT03507023|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33799020|NCT04447209|||COHORT||PROSPECTIVE|||||||
33799021|NCT03100513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021898|NCT04290975|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blinded physicians will evaluate outcomes for both arms of the study.|"The basic framework of these studies is a cRCTin which 60 PHCs (clusters) will be randomly selected from about 399 eligible PHCs in three major cities in the Hausa-speaking areas of northern Nigeria -30 of about 167 PHCs in Kano, 15 of about 124 PHCs in Kaduna, and 15 of about 108 PHCs in Zaria. Half of the overall PHCs will be randomly assigned to the task-shifted care arm of the cRCT, in which epilepsy treatment and follow-up care is provided by a CHW. The other half will be assigned to enhanced usual care in which the care is provided by a physician and a CHW serves to record events and collect other standardized data."|f|f|f|t
34021899|NCT02826772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021900|NCT00683631|||OTHER||OTHER|||||||
34021901|NCT02934659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021902|NCT01840865|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34021903|NCT05104190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34021904|NCT03388489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34021905|NCT04216667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The nature of the ablation procedures precludes blinding of physicians to patient treatment. However, patients will be blinded to their ablation strategy (single-blind design) and endpoint assessment will be made by blinded adjudicators from an independent core laboratory.|A total of 932 patients will be randomized with equal allocation to one of four treatment groups. This sample size provides 90% power to detect pairwise differences in response rates between groups ranging from 0.12 to 0.15 based on two-tailed 0.05 level intention to treat chi-squared tests. Specifically, the response rates under the alternative upon which sample size is determined are 0.45, 0.60, 0.75, 0.87 for PVI alone, PVI + PWI, PVI + PWI + LAAEI and PVI + PWI + LAAEI + CSI respectively.|t|f|f|t
34021906|NCT03220061|RANDOMIZED|PARALLEL||PREVENTION||NONE||music therapy was soft and relaxing instrumental piano music which was given among haemodialysis patients for 30 minutes||||
34021907|NCT01679639|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34021908|NCT06632210|||OTHER||CROSS_SECTIONAL|||||||
34021909|NCT03634475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021910|NCT05200000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021911|NCT01194986|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34021912|NCT06159777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34021913|NCT00811356|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34021914|NCT02252991|RANDOMIZED|PARALLEL||||NONE||||||
34021915|NCT06429579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021916|NCT01982279|||COHORT||CROSS_SECTIONAL|||||||
34021917|NCT01140503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021918|NCT03665441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021919|NCT05912361|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34021920|NCT01682395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021921|NCT01600430|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34021922|NCT03574948|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34021923|NCT02303041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort assignment based on disease status.||||
34021924|NCT05941455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101852|NCT02040376|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34101853|NCT06691061|||COHORT||RETROSPECTIVE|||||||
33718101|NCT05682105|||COHORT||PROSPECTIVE|||||||
33718102|NCT00190996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33718103|NCT04035928|NA|SINGLE_GROUP||OTHER||NONE||||||
33718104|NCT02846922|||COHORT||RETROSPECTIVE|||||||
33718105|NCT01569711|||||PROSPECTIVE|||||||
33718106|NCT00258882|||COHORT||OTHER|||||||
34021925|NCT03424018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021926|NCT04975009|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021927|NCT00901992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799022|NCT05355623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||compare between the usage of Gamma irradiated sterilized amniotic membrane as a graft versus conventional classical repair in terms of: Effectiveness, symptoms relief, healing, and infection rate.|t|f|t|t
33799023|NCT00260910|||FAMILY_BASED||RETROSPECTIVE|||||||
34021928|NCT04961463|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a control group quasi-experimental study with a pre-test, post-test and follow-up design||||
34021929|NCT03322735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021930|NCT05119348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigators were not made aware of participants study condition.|The study design is a type 2 hybrid cluster (household) randomised controlled trial, with outcomes assessed on index patients and their household contacts. After completing consent, 120 households will be randomised in a 1:1 ratio (60 per arm).|f|f|t|f
34021931|NCT03878771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with chronic multiple oral lesions due to benign mucous membrane Pemphigoid, Pemphigus vulgaris, ans Steven Johnson's Syndrome||||
34021932|NCT04264702|||CASE_CONTROL||PROSPECTIVE|||||||
34021933|NCT06384391|||COHORT||PROSPECTIVE|||||||
34021934|NCT04335903|||CASE_ONLY||CROSS_SECTIONAL|||||||
34021935|NCT02195453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34021936|NCT06308614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021937|NCT01087489|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34021938|NCT05003934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021939|NCT06387602|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34021940|NCT03275064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 142 participants were randomized, but only 141 received treatment. One participant in Part B was discontinued due to poor veins that were not adequate for blood samples.|t|f|t|f
34021941|NCT02875015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021942|NCT04278950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34021943|NCT04311372|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"N=100 participants will be randomized to one of two groups.~Group 1 \| n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)~Group 2 \| n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)"||||
34021944|NCT05608980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A prospective, controlled, randomized study.|f|f|t|t
34021945|NCT05935111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34021946|NCT00027248|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34021947|NCT05134753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34021948|NCT02815358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34021949|NCT00813527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021950|NCT05379907|||COHORT||PROSPECTIVE|||||||
34021951|NCT02572063|||COHORT||PROSPECTIVE|||||||
34021952|NCT01001988|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34021953|NCT00853463|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021954|NCT02413216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021955|NCT04313998|||COHORT||PROSPECTIVE|||||||
34021956|NCT00555360|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34021957|NCT00093561||||PREVENTION||||||||
34021958|NCT02052050|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34021959|NCT05806619|||COHORT||PROSPECTIVE|||||||
34021960|NCT05483595|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34021961|NCT04620928|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Present a behavioral intervention to a single group of participants and measure subsequent electrical activity in the brain.||||
34021962|NCT04558268|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups. a treatment group and a placebo group||||
34021963|NCT01498731|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34021964|NCT00715936|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33799024|NCT05579054|||COHORT||PROSPECTIVE|||||||
34021965|NCT01377376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021966|NCT04842838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34021967|NCT06414317|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34021968|NCT05988853|||COHORT||PROSPECTIVE|||||||
34021969|NCT03056586|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34021970|NCT04776837|||COHORT||PROSPECTIVE|||||||
34021971|NCT00471289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021972|NCT04683744|||OTHER||OTHER|||||||
34021973|NCT02398630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34021974|NCT03870282|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34021975|NCT02208986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021976|NCT03283319|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomized to one of the six treatment groups at Day 1 and will receive the assigned dose of antigen and adjuvant on Day 1 and Day 29.|t|t|t|t
34021977|NCT00699062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34021978|NCT05607979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Study Participant, The Care Provider, and the Investigator are all blinded from the treatments.|Multicenter, randomized controlled, double-blinded clinical Non-inferiority trial|t|t|t|f
34021979|NCT06206200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34021980|NCT05363514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug and placebo will be masked by the pharmacy.||t|t|t|t
34021981|NCT05395455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021982|NCT01774552|||CASE_ONLY||PROSPECTIVE|||||||
34021983|NCT05951855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021984|NCT00227110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34021985|NCT05400083|||COHORT||PROSPECTIVE|||||||
34021986|NCT01284621|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34021987|NCT03074773|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34021988|NCT06634342|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34021989|NCT02955381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34021990|NCT02334592|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34021991|NCT00044967|||CASE_ONLY||PROSPECTIVE|||||||
34021992|NCT03335449|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
34021993|NCT01525264|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34021994|NCT05109806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants are only blinded|"The study has already approved from FIC a tertiary care unit for ethical committee review. Personal informed consent of patients and their parents will also be taken. Before starting the phases of study all the permissions regarding the measures will also be taken from original authors.~The registered participant in 1st study will get information letters explaining the purpose and the content of the study. All the participants will be given a research card and reference code for registration and information. Randomization: After informed consent have been obtained, Families will receive an anonymous study code and will be invited for medical and psychological baseline assessments. Thereafter, All participants will be randomly assigned to experimental and control groups."|t|f|f|f
34021995|NCT01478386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34021996|NCT03835676|NA|SINGLE_GROUP||OTHER||NONE||In a group of patients with PAH treated with treprostinil, the current study aims to investigate the effect of treatment on RV structure and function; and correlate changes in RV structure and function with: WHO class, Six-minute walk test, Quality of life (QoL), and Pre-specified biomarkers (NT-ProBNP, Tissue growth factor-B BNP, and Profibrotic markers)||||
34021997|NCT03275714|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34021998|NCT05241028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34021999|NCT02878122|||COHORT||RETROSPECTIVE|||||||
34022000|NCT03759119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor investigator will be masked to all medical diagnoses of the infant|This will be a randomized controlled trial using a pretest /posttest control group design to allow for comparison between an intervention group that receives tummy time and parent education and a standard of care group that receives parent education only|f|f|t|f
34022001|NCT06165250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022002|NCT05121792|NA|SINGLE_GROUP||OTHER||NONE||Study 1 is an open-label (non-randomized) study to generate pilot data on effectiveness, and to evaluate feasibility and acceptability of the therapist online training program.||||
34022003|NCT00971776|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34022004|NCT01037296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022005|NCT05990153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the assessor is unaware of the type of treatment the patients have received|The allocation sequence will occur by 1:1:1:1 randomization, using the Clinical Trial Randomization tool (web https://ctrandomization.cancer.gov/), stratifying by headache type. The allocation of patients will be hidden, through the use of sealed envelopes in which the randomization will be contained. The enrollment will be carried out by the medical doctors of the Headache and Neurosonology Center clinics of the Campus Bio-Medico University Hospital Foundation, who will communicate the patient's name to a third person external to the study who will assign the patient according to the randomization plan developed.|f|f|f|t
34022006|NCT00898235|||OTHER||PROSPECTIVE|||||||
34022007|NCT00330226|||COHORT||PROSPECTIVE|||||||
34022008|NCT03186781|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33799025|NCT02574195|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022009|NCT03330210|||OTHER||PROSPECTIVE|||||||
34022010|NCT04034537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients are planned to perform coronary angiography without contraindications.||||
34022011|NCT00019786||||TREATMENT||NONE||||||
34022012|NCT05263622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-mouth design|t|f|t|t
33718107|NCT04410224|NA|SEQUENTIAL||TREATMENT||NONE||Escalating doses of ASN004||||
33718108|NCT02853578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022013|NCT00537420|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34022014|NCT01286935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718109|NCT02415881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718110|NCT01942291|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718111|NCT02477254|||CASE_CONTROL||PROSPECTIVE|||||||
34022015|NCT00097396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022016|NCT06118606|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study of the feasibility of the intervention||||
34022017|NCT00827632|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022018|NCT04021849|RANDOMIZED|PARALLEL||OTHER||SINGLE||Students will be randomly assigned to one of two groups until a total of 134 participants are recruited: 67 in the intervention group and 67 in the control group.|f|f|f|t
34022019|NCT00866801|||||PROSPECTIVE|||||||
34022020|NCT05214703|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment a clinical trial with experimental and control groups with|t|f|f|f
34022021|NCT00888056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022022|NCT00707382|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34022023|NCT05545371|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34022024|NCT05491876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This evidence supports current study that the use of ACBT exercises with Breathing exercises is helpful to improve respiratory performance.~single blinded study only participant blind"|"The study came to the conclusion that both techniques, breathing exercises with and without ACBT were beneficial in raising PaO2, FEV1, FVC, and the FEV1/FVC ratio as well as oxygen saturation.~However, based on their mean differences, ACBT with breathing exercises was more beneficial in terms of the indicated end measures."|t|f|f|f
34022025|NCT00642681|||COHORT||PROSPECTIVE|||||||
33718112|NCT01304901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022026|NCT04098289|||CASE_CONTROL||RETROSPECTIVE|||||||
34022027|NCT01025271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022028|NCT05600790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022029|NCT01008982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022030|NCT00616798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022031|NCT00128050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022032|NCT02511821|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34022033|NCT03936426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718113|NCT01108705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718114|NCT05002855|||COHORT||RETROSPECTIVE|||||||
33799026|NCT04732338|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799027|NCT05933551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34022034|NCT05743205|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33799028|NCT04447482|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718115|NCT05944809|NA|SINGLE_GROUP||PREVENTION||NONE||All patients are planned to receive concurrent BMS thoracic radiotherapy (\>45Gy, 1.8Gy per fraction), chemotherapy (five cycles of weekly intravenous paclitaxel \[50 mg/m²\] and cisplatin/nedaplatin \[25 mg/m²\], or two cycles of intravenous paclitaxel \[135-175 mg/m²\] and cisplatin/nedaplatin \[80 mg/m²\]) , and rhTPO，15000U ih. qw(during the radiotherapy)||||
33718116|NCT01326689|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718117|NCT02235012|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33718118|NCT01941641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718119|NCT04290884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718120|NCT02781922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718121|NCT05721963|||COHORT||PROSPECTIVE|||||||
33718122|NCT03622307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718123|NCT06119360|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33718124|NCT05951868|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33718125|NCT04465539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33718126|NCT03468257|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718127|NCT05937191|RANDOMIZED|PARALLEL||TREATMENT||NONE||Leflunomide+Stroid treatment Group||||
33718128|NCT02711540|||COHORT||RETROSPECTIVE|||||||
33718129|NCT02068833|||COHORT||PROSPECTIVE|||||||
33718130|NCT05548231|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718131|NCT00824603|||COHORT||CROSS_SECTIONAL|||||||
33718132|NCT02093754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718133|NCT05353231|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718134|NCT04322253|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33718135|NCT02211521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718136|NCT02275650|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718137|NCT00002245||||TREATMENT||NONE||||||
33718138|NCT05020990|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33718139|NCT01020851|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718140|NCT03479606|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33718141|NCT02743481|||COHORT||PROSPECTIVE|||||||
33718142|NCT02392741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718143|NCT00225160|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33718144|NCT03447756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718145|NCT06493695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||a randomized controlled experimental design with three groups||||
33718146|NCT02348606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718147|NCT00002667||||SCREENING||||||||
34022035|NCT06050889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022036|NCT06049979|||COHORT||PROSPECTIVE|||||||
34022037|NCT03937336|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Control Trials|t|f|f|f
34022038|NCT01276301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718148|NCT02533830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33718149|NCT05855460|||CASE_CONTROL||PROSPECTIVE|||||||
33718150|NCT00946959|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33718151|NCT02025244|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33718152|NCT06087666|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||stepped wedge cluster controlled trial||||
33718153|NCT05755685|NA|SINGLE_GROUP||OTHER||NONE||||||
33718154|NCT06265740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718155|NCT05529121|||COHORT||PROSPECTIVE|||||||
33718156|NCT01057602|||COHORT||CROSS_SECTIONAL|||||||
33718157|NCT05999136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33718158|NCT02793102|NON_RANDOMIZED|PARALLEL||||NONE||||||
33799029|NCT02242487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799030|NCT04395378|||COHORT||OTHER|||||||
33799031|NCT01522742|||COHORT||PROSPECTIVE|||||||
33799032|NCT04943419|||COHORT||PROSPECTIVE|||||||
33799033|NCT02988037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799034|NCT06408493|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799035|NCT00925886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799036|NCT05711914|||OTHER||RETROSPECTIVE|||||||
33799037|NCT01837472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799038|NCT04377815|||COHORT||OTHER|||||||
33799039|NCT00174382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799040|NCT00143949|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34022039|NCT03183648|||CASE_ONLY||PROSPECTIVE|||||||
34022040|NCT03303183|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34022041|NCT01672216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022042|NCT02870218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34022043|NCT00935688|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34022044|NCT03913819|||COHORT||PROSPECTIVE|||||||
34022045|NCT04300283|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot testing of a pre-operative hypnosis intervention.||||
34022046|NCT04144478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34101854|NCT06036810|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101855|NCT05228015|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 dose escalation: BOIN design; Part 2 dose expansion: 4 parallel cohorts, Simon 2-stage||||
34101856|NCT01141868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022047|NCT03246646|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The intervention will be approximately 12, 30-45 min. telephone sessions, every 2-3 weeks, and will last 4-6 months. The Coach helps the participant individualize the content of a web-based course (VA-CRAFT) based on an intervention to encourage a loved one to seek treatment for substance abuse. The VA-CRAFT course has 8 modules that follow the original CRAFT intervention: 1) Introduction, 2) Overview, 3) Getting Started: Safety Planning, 4) Understanding substance abuse, 5) How to respond to substance abuse, 6) Rebuilding your life together, 7) Helping someone consider treatment, 8) Wrapping up. The goals include understanding triggers and long-term reinforcement of substance misuse, ignoring unhealthy behaviors and rewarding healthy behaviors, getting support, and how to help the CSO caller help the Veteran enter treatment. The participants in the active intervention will be compared to a treatment as usual, matched comparator group drawn from regular clinical operations.||||
34022048|NCT01135186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101857|NCT06695221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718159|NCT04056676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized group of patient is identified and sealed in envelope. There is not written group in anesthetic record. Postoperative outcomes are assessed by Acute Pain Service nurse or a resident (co-investigator who blinds to the technique).|group A Intraoperative modified PEC block only group B Preoperative thoracic paravertebral block plus intraoperative modified PEC block|t|t|f|t
33718160|NCT05273138|||CASE_CONTROL||PROSPECTIVE|||||||
33718161|NCT03963362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718162|NCT03249766|||COHORT||PROSPECTIVE|||||||
33718163|NCT06117410|||COHORT||PROSPECTIVE|||||||
33718164|NCT03648060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718165|NCT02187484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718166|NCT00006903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718167|NCT02736409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718168|NCT00853801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33718169|NCT04761289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33718170|NCT04566211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33718171|NCT04332354|||COHORT||PROSPECTIVE|||||||
33718172|NCT03038958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33718173|NCT01486914|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718174|NCT00531050|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718175|NCT03454581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718176|NCT05104164|NA|SINGLE_GROUP||TREATMENT||NONE|The physiotherapist in charge of the evaluations was blinded to the conditions and study objectives.|||||
33718177|NCT01131923|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718178|NCT00210041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101858|NCT02777190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101859|NCT02579551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718179|NCT00556036|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718180|NCT05721989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942937|NCT03773510|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized, open-label , two arm study All the patients who will complete 6 cycles of treatment without disease progression will be be randomized to continue Trabectedin versus treatment interruption followed by re-challenge at progression. Patients randomized to discontinue treatment will be candidate to other 6 cycles of treatment and if they do not progress, to another interruption. The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under Trabectedin."||||
33942938|NCT03917394|||COHORT||RETROSPECTIVE|||||||
33942939|NCT04966442|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33942940|NCT04818034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942941|NCT05910242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33942942|NCT00933816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942943|NCT05049915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942944|NCT02010489|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942945|NCT00003309||||TREATMENT||||||||
33942946|NCT00931515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942947|NCT01353521|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942948|NCT00408408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942949|NCT02396680|||COHORT||PROSPECTIVE|||||||
33942950|NCT03443921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942951|NCT04006028|||CASE_ONLY||RETROSPECTIVE|||||||
33942952|NCT00034606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942953|NCT05109949|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33942954|NCT02705001|||||RETROSPECTIVE|||||||
33942955|NCT05689229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942956|NCT00899626|||CASE_CONTROL||PROSPECTIVE|||||||
33942957|NCT00765726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942958|NCT06399458|||OTHER||CROSS_SECTIONAL|||||||
33942959|NCT00464854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942960|NCT02155166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942961|NCT04156984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942962|NCT06198946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33942963|NCT04456114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||parallel-group, split mouth, triple blinded, randomized control trial|t|t|t|t
33942964|NCT04981886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33942965|NCT03637504|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33942966|NCT00348686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33942967|NCT06518330|||CASE_CONTROL||RETROSPECTIVE|||||||
33942968|NCT02667262|||OTHER||RETROSPECTIVE|||||||
33942969|NCT04850066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942970|NCT01047631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942971|NCT05553886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, positive drug parallel control, multicenter|t|t|t|t
33942972|NCT01990001|RANDOMIZED|PARALLEL||||NONE||||||
33942973|NCT03494764|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33942974|NCT04484610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33942975|NCT03336164|NA|SINGLE_GROUP||OTHER||NONE||After a control period with no specific front-of-pack labeling, the intervention consists in the apposition of a front-of-pack labeling (Nutri-Score) to individual foods in a campus university restaurant. All foods are individually labeled.||||
33942976|NCT00069654|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33942977|NCT03114475|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The non-irradiated side of the mouth will receive a placebo light (i.e. not the laser beam).|Split mouth design, the mouth will be split into four quadrants. Two quadrants will receive the active treatment, whereas the opposing two quadrants will receive the placebo.|t|f|t|t
33942978|NCT05245240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33942979|NCT00876759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718181|NCT06405061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718182|NCT05928897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718183|NCT00330616||||TREATMENT||NONE||||||
33718184|NCT05828888|||COHORT||PROSPECTIVE|||||||
33718185|NCT05682521|||OTHER||OTHER|||||||
33718186|NCT04427774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718187|NCT02411474|||CASE_CONTROL||PROSPECTIVE|||||||
33718188|NCT01945177|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33718189|NCT05890040|||COHORT||PROSPECTIVE|||||||
33718190|NCT06372782|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33718191|NCT04535960|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be randomized to initial therapy with empagliflozin 25mg PO daily or liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks and patients in the liraglutide group will also receive empagliflozin 25mg PO daily for 6 weeks (combination therapy).||||
33718192|NCT00001929||||TREATMENT||||||||
33718193|NCT03005028|||COHORT||RETROSPECTIVE|||||||
33718194|NCT06244225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718195|NCT06458608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"hile the patients were randomized; In order to keep the possibility of being affected by each other at a minimum level, the study was continued with the same application group in the same session group. For example; It's like working only with the robot cat group in the 08:00-12:00 session group on Mondays. In order to reduce the possibility of selection bias due to sample selection, single-stage cluster type random sampling, which is a subtype of random sampling, was used. In addition, before the study, patients were informed about the study and their consent was obtained."|No study could be taken as a reference due to the number of samples, the amount of error in the G\*Power 3.1.9.6 program, α=0.05, and the lack of a previous study with 2 groups on the subject; With an effect size of 0.80 and the power of the targeted test being 0.80 (80%), a total of 42 patients (21 for each group) were calculated for two groups (experimental group, control group). Considering situations such as wanting to leave the study or death during the research, each group will be increased by 20% and a total of 50 patients will be included in the study, 25 patients for each group.||||
33718196|NCT05956860|||OTHER||PROSPECTIVE|||||||
34022049|NCT03958253|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||This is a stepped wedge cluster randomized trial in which the intervention condition (toolbox) is sequentially assigned to participating hospitals (screening centers) in 6 clusters at different time-delays and where pre-intervention data serves as the control. By the end of the study, all clusters have been exposed to the intervention and each cluster has provided data for the control and intervention conditions. Independent samples of primary care providers are enrolled at each period within a cluster, thus, it is a repeated cross-sectional study. The order of the entry into the intervention phase is randomized based on levels of readiness||||
34022050|NCT05920512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022051|NCT04220931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022052|NCT00004025||||TREATMENT||||||||
34022053|NCT05684783|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022054|NCT04100720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022055|NCT05900258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022056|NCT04173832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022057|NCT01730066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022058|NCT02185053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022059|NCT00476983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022060|NCT00147953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022061|NCT04632160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022062|NCT04478630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Subjects and all members of the research team will not know which group, either peppermint essential oil, ginger essential oil, or placebo (vanilla extract group), the potential subject would be randomly assigned to as the research team members involved in consenting will open a prefilled envelope to determine the group which will be labeled with the correlating diffuser (A, B, or C).|This study is a three group, randomized, double blind, placebo-controlled trial with two repeated measurements. The same measurements will be collected for each participant during two consecutive chemotherapy treatment cycles.|t|t|f|t
34022063|NCT01687244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant did not know if they received a high or low dose.||t|f|f|f
34022064|NCT04934410|||COHORT||PROSPECTIVE|||||||
34022065|NCT00315393|||COHORT||PROSPECTIVE|||||||
34022066|NCT03895671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022067|NCT06504420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022068|NCT00928161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022069|NCT02260297|||COHORT||PROSPECTIVE|||||||
34022070|NCT00002393||PARALLEL||TREATMENT||||||||
34022071|NCT05420870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101860|NCT05950438|||COHORT||PROSPECTIVE|||||||
34101861|NCT04893109|RANDOMIZED|PARALLEL||TREATMENT||NONE||participants are randomized in a 2-1 fashion to Arm A vs. Arm B||||
34101862|NCT06663241|||CASE_ONLY||PROSPECTIVE|||||||
34101863|NCT05942040|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33718197|NCT01890551|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718198|NCT03970161|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718199|NCT04617444|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
33718200|NCT05767892|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34022072|NCT03670290|||COHORT||PROSPECTIVE|||||||
34022073|NCT00521469|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34101864|NCT02694055|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34101865|NCT04700072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718201|NCT05714657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022074|NCT05131243|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34022075|NCT01348412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022076|NCT01166165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022077|NCT02444923|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The practitioner who measures the visual outcomes is naive to the type of lens the participant is wearing|Randomised control trial with a 2x2 crossover|f|f|t|f
34022078|NCT03771248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022079|NCT02078427|||COHORT||PROSPECTIVE|||||||
34022080|NCT02249130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022081|NCT05267743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022082|NCT02192320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33942980|NCT04470596|||COHORT||RETROSPECTIVE|||||||
34101866|NCT05023174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research personnel will be aware of whether the patient is in the treatment or control arm. The patient will be blinded from this knowledge.|Patients will be randomized into a treatment arm and a control arm|t|f|f|t
34101867|NCT06686849|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34101868|NCT05554224|||COHORT||PROSPECTIVE|||||||
34101869|NCT04188509|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Extension study available to eligible participants from GBT-sponsored voxelotor clinical studies.||||
34101870|NCT00980629|RANDOMIZED|||||DOUBLE||||||
34101871|NCT05494359|||CASE_CONTROL||PROSPECTIVE|||||||
34101872|NCT06288763|||CASE_ONLY||PROSPECTIVE|||||||
34101873|NCT05793151|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomization||||
33942981|NCT06028763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"40 participants will divide into 2 groups main and control. Main group (n=20): implantation of heparin-conjugated fibrin hydrogel with autologous MSCs and growth factors (TGF-β1 and BMP-4) into the cartilage defect during arthroscopy.~Control group (n=20): arthroscopic debridement of the joint with microfracturing (traditional method of treatment)."||||
33942982|NCT01381601|||COHORT||RETROSPECTIVE|||||||
33942983|NCT04420390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33942984|NCT03241485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All patients will receive intrathecal intervention and will not know which group they are assigned to. The provider performing the procedure and collecting the data will also be blinded to the intervention assignment.|The patients will be randomized into 2 groups. The placebo group will receive intrathecal saline. The morphine group will receive intrathecal morphine.|t|t|t|t
33942985|NCT04330586|RANDOMIZED|PARALLEL||TREATMENT||NONE||This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm (standard care)||||
33942986|NCT00578331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33942987|NCT03551041|||COHORT||CROSS_SECTIONAL|||||||
33942988|NCT03977376|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|RCT|||||
33942989|NCT04552821|||COHORT||PROSPECTIVE|||||||
33942990|NCT05578040|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||A randomized controlled and single blinded trial|t|f|f|f
33942991|NCT04001426|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Subjects will wear a device and will be monitored non-invasively during activation of the device.||||
33942992|NCT05686668|||CASE_ONLY||PROSPECTIVE|||||||
33942993|NCT04429269|||COHORT||PROSPECTIVE|||||||
33942994|NCT01038609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33942995|NCT05354115|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33942996|NCT01597076|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33942997|NCT06412965|||OTHER||RETROSPECTIVE|||||||
33942998|NCT00635804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33942999|NCT03955211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943000|NCT01558206|||CASE_ONLY||PROSPECTIVE|||||||
33943001|NCT03843567|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33943002|NCT04718038|||COHORT||PROSPECTIVE|||||||
33943003|NCT01767844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943004|NCT00513331|||||PROSPECTIVE|||||||
33943005|NCT03434860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
33943006|NCT00300794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943007|NCT01410331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943008|NCT05445999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943009|NCT01066819|||COHORT||PROSPECTIVE|||||||
33943010|NCT05875272|||CASE_ONLY||PROSPECTIVE|||||||
33943011|NCT02719028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943012|NCT02180035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33943013|NCT01302340|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33943014|NCT04071899|||COHORT||PROSPECTIVE|||||||
33943015|NCT03463720|||COHORT||RETROSPECTIVE|||||||
33943016|NCT04256642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33943017|NCT05551195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1:1 randomization|t|f|t|t
33943018|NCT00535236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33943019|NCT01677520|||CASE_ONLY||CROSS_SECTIONAL|||||||
33943020|NCT04312958|||COHORT||PROSPECTIVE|||||||
33943021|NCT04153799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943022|NCT00211198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943023|NCT00529594|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33943024|NCT05419596|||COHORT||PROSPECTIVE|||||||
33943025|NCT03293706|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33943026|NCT04645628|NA|SINGLE_GROUP||OTHER||NONE||||||
33943027|NCT03026556|||COHORT||RETROSPECTIVE|||||||
33943028|NCT01832753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33943029|NCT05872243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943030|NCT00634933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943031|NCT03863964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study to determine the pharmacokinetics/pharmacodynamics of tranexamic acid administered after delivery to patients at high risk for postpartum hemorrhage, and coinciding coagulation testing using ROTEM®.||||
33943032|NCT02533011|||COHORT||PROSPECTIVE|||||||
33943033|NCT03083613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943034|NCT02364362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799041|NCT06484855|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|f|t|f
33799042|NCT03496194|||OTHER||PROSPECTIVE|||||||
33799043|NCT04489498|||CASE_CONTROL||OTHER|||||||
33799044|NCT04562259|||COHORT||PROSPECTIVE|||||||
33799045|NCT03484065|||COHORT||CROSS_SECTIONAL|||||||
33799046|NCT02882204|||COHORT||PROSPECTIVE|||||||
33799047|NCT01684150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799048|NCT02125695|||COHORT||CROSS_SECTIONAL|||||||
33799049|NCT00436072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799050|NCT05150067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessor was blinded to the group assignment so that the scores remained unbiased.||f|f|f|t
33799051|NCT06223048|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Phase 2, randomized, parallel arm, open-label, masked endpoint study|f|f|f|t
33799052|NCT05993351|||COHORT||PROSPECTIVE|||||||
33799053|NCT00002542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799054|NCT05989035|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a prospective single-site study, consisting of two groups of participants. Group 1 will be younger participants between the ages of 18 and 30 years old. Group will be older participants that are 65 years and older. Each participant will have an abdominal subcutaneous adipose tissue (AT) biopsies. Two aliquots from each biopsy will be incubated for conditioned media with and without MetAP2 inhibition||||
33799055|NCT04882553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||a single-centre physiological cohort study to evaluate the feasibility of using the thickening fraction as a parameter for diaphragm activity during spontaneous breathing in sedated children.||||
33799056|NCT05628493|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799057|NCT00566514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33799058|NCT06238752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799059|NCT03678558|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33799060|NCT02191319|||COHORT||PROSPECTIVE|||||||
33799061|NCT03632811|||COHORT||PROSPECTIVE|||||||
33799062|NCT04410458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799063|NCT03504423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101874|NCT05572632|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The masked research coordinator will administer questionnaires and conduct clinical assessments at all study visits. Condition assignment will remain masked through data analysis and interpretation from study investigators and any team members involved in the data analysis. Furthermore, the COPD Wellness Coach leading weekly sessions, in addition to the research coordinator collecting endpoint measurements, will be masked to participant group status.|Wait-list randomized controlled trial.|f|f|t|t
34101875|NCT06138067|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33718202|NCT06427031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Multicenter, Randomized, Double-blind, Active control for Evaluating the Efficacy and Safety of the test drug(TJO-083) Compared with the control drug in Dry Eye Sydrome|t|f|t|f
33718203|NCT04544098|NA|SINGLE_GROUP||TREATMENT||NONE||This is an early-phase trial in which a total of 10 patients with progressive, inoperable, liver-dominant, metastatic GEP, bronchial or unknown primary NETs will be enrolled in this combined intraarterial/intravenous therapeutic approach with 177Lu-DOTATATE.||||
33718204|NCT04247360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718205|NCT05741567|||COHORT||RETROSPECTIVE|||||||
33718206|NCT00758082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718207|NCT05605223|||CASE_ONLY||RETROSPECTIVE|||||||
33799064|NCT02423291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799065|NCT01472146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799066|NCT06295913|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants will be randomly allocated to treatment A and B. Both pills will have the same aspect and will be packed similarly|Group 1, hydroxytyrosol-rich extract pill (Hytolive®); Group 2, placebo pill|t|t|t|f
33799067|NCT03595852|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|patients and investigator will be blinded for intervention|antibiotic prophylaxis versus placebo in clean non prosthetic surgery. impact on surgical site infection and patient cost.|t|f|t|f
33799068|NCT01828775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718208|NCT01432353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799069|NCT04014114|||COHORT||PROSPECTIVE|||||||
33799070|NCT04916145|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two study arms. One group (treatment) will receive an experimental digital device for 13 weeks while the other group (control) will maintain daily activity as usual.||||
33799071|NCT03169244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The design is a 1:1 random assignment to placebo or bupropion XL (300mg/d).||t|t|t|t
33799072|NCT04348617|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Participants will take part in a randomized exercise and control (rest) condition.|t|f|f|f
33799073|NCT01054924|||COHORT||PROSPECTIVE|||||||
33799074|NCT01751958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943035|NCT04220645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic clinical trial. Cluster randomised with stepped wedge design||||
33943036|NCT02557828|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33943037|NCT00864968|RANDOMIZED|CROSSOVER||||NONE||||||
33943038|NCT02792387|||OTHER||RETROSPECTIVE|||||||
33718209|NCT00224055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718210|NCT02329561|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33718211|NCT01854840|||CASE_ONLY||PROSPECTIVE|||||||
33718212|NCT01748643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33718213|NCT05232240|||COHORT||PROSPECTIVE|||||||
33718214|NCT05527392|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enhanced Usual Care HINT Synchronous Intervention Group HINT Asynchronous Intervention Group||||
33943039|NCT02902406|||CASE_CONTROL||PROSPECTIVE|||||||
33718215|NCT05390879|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Assessors are blind concerning the principal outcome (ruminations and post-OSCE meditation groups, via standardized informatic questionnaires) Performance is evaluated by assessors who are blind to the intervention|2 parallels groups|t|f|f|t
33943040|NCT03891199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943041|NCT05023239|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33943042|NCT02825589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943043|NCT03872739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943044|NCT01842282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718216|NCT01057550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33943045|NCT00149227|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33943046|NCT03489460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718217|NCT05543525|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718218|NCT02724475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718219|NCT01929850|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718220|NCT01169610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943047|NCT01503567|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33943048|NCT04600115|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33943049|NCT05309785|NA|SINGLE_GROUP||TREATMENT||NONE||"We will conduct a single center, prospective, single-arm, open-label interventional study in 2 cohorts.~Substudy 1: patients with advanced CKD, not yet on HD (N=36) Substudy 2: patients receiving HD (N=8)"||||
33943050|NCT01488175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943051|NCT00000291||||TREATMENT||DOUBLE||||||
33943052|NCT04048434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943053|NCT06303011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943054|NCT05767437|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind.|One group is the abdominal drawing-in maneuver exercise, afterward conventional physiotherapy in Participants With stroke survivors. On the contrary, Another group is conventional physiotherapy afterward the abdominal drawing-in maneuver exercise.|t|f|t|f
33943055|NCT01508182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943056|NCT05973825|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943057|NCT00430703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943058|NCT03273933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943059|NCT05196074|||OTHER||PROSPECTIVE|||||||
33943060|NCT04209140|||COHORT||PROSPECTIVE|||||||
33943061|NCT01049360|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33943062|NCT01494909|NA|SINGLE_GROUP||OTHER||NONE||||||
33943063|NCT05389761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33943064|NCT03802331|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943065|NCT04854122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|As this is an exercise intervention, both the study team and the participant will be aware of which group the participant is assigned to.|This intervention study will be set up as a randomized controlled trial comparing the effects of a 12-weeks exercise program to 12-weeks of non-exercise usual care in participants with Down syndrome.||||
33943066|NCT05652361|NA|SINGLE_GROUP||OTHER||NONE||||||
33943067|NCT05855382|||COHORT||CROSS_SECTIONAL|||||||
33943068|NCT03820388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Patients in 3 cohorts will be administered 30 second bolus by manual hand push|t|f|f|f
33943069|NCT02185040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943070|NCT03674645|NA|SINGLE_GROUP||OTHER||NONE||||||
33943071|NCT05199389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943072|NCT01731951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943073|NCT05430724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The patients included in the study will be divided into 2 groups according to the closed envelope system. Patients given esmolol infusion will be named Group E (n:40), patients given nicardipine infusion will be named Group N (n:40).|t|f|f|f
33943074|NCT04655820|||COHORT||CROSS_SECTIONAL|||||||
33943075|NCT00701064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943076|NCT05986409|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33943077|NCT04058860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients undergoing open heart surgery with minimal invasive extracorporeal circulation (MiECC) according to accepted indications||||
33943078|NCT03054311|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33943079|NCT01820169|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101876|NCT06597942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The first stage will involve 5-10 participants receiving open-label active treatment to refine the protocol. After refinement, the second stage will consist of a 1:1 randomized, double-blind, sham controlled clinical trial to study feasibility and tolerability while exploring target engagement and short-term efficacy for memory. Participants will undergo 16 total rTMS brain stimulation sessions over the course of 5 weeks. A full course of open-label active treatment will be offered as an extension to the sham group after unblinding.|t|t|t|t
33943080|NCT06204003|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive placebo at Day 0. CBD 5 mg/kg will begin Day 15. CBD 10 mg/kg will begin Day 30. CBD 15 mg/kg will begin Day 45. CBD 20 mg/kg will begin Day 60. CBD 25 mg/kg will begin Day75. CBD 30 mg/kg will begin Day 90.||||
34101877|NCT01744418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943081|NCT01726309|||COHORT||PROSPECTIVE|||||||
33943082|NCT02427412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943083|NCT01503528|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized clinical trial. For safety and logistical reasons, it cannot be blinded. In the perioperative period multiple factors contribute to discharge readiness. The major impediments to early discharge include poor pain control, opioid related adverse events, surgical/ medical complications, inability to achieve physiotherapy end points and patient's unwillingness to be discharged. We want to compare head to head, two previously evaluated fast-track paradigms. We are not comparing just the analgesic technique alone. We are comparing the pathways where the analgesic regimes are a component and differ, keeping the common factors similar between the groups. If a technique does not allow early ambulation, patients cannot be ready for discharge and thus resource utilization will be affected.||||
34022083|NCT00604123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022084|NCT05076695|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will enter the single-arm treatment group and they will receive a combination regimen (trastuzumab, pyrotinib, palbociclib plus Fulvestrant, TPPF) as neoadjuvant therapy.||||
34022085|NCT03638778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943084|NCT04553796|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022086|NCT02067468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34022087|NCT04405843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022088|NCT00020371||||TREATMENT||||||||
34022089|NCT03333590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a dose escalation trial that will begin with the minimal efficacious dose as determined by preclinical studies and approved by the FDA. During the course of the trial, if safety is shown the dose will be escalated according to the clinical protocol.||||
34022090|NCT02854592|||COHORT||PROSPECTIVE|||||||
34022091|NCT06396767|||COHORT||PROSPECTIVE|||||||
34101878|NCT06407154|||COHORT||PROSPECTIVE|||||||
34101879|NCT06048588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718221|NCT03084029|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718222|NCT01737788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718223|NCT02977689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718224|NCT01389544|NA|SINGLE_GROUP||||NONE||||||
33718225|NCT05962970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718226|NCT06021782|||COHORT||PROSPECTIVE|||||||
33718227|NCT00513474|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718228|NCT03251079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718229|NCT05276544|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33718230|NCT03350633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718231|NCT00503009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718232|NCT04350788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33718233|NCT00126841|||CASE_ONLY||PROSPECTIVE|||||||
33718234|NCT01721382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718235|NCT01321268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718236|NCT01134796|||COHORT||PROSPECTIVE|||||||
33718237|NCT05221814|||OTHER||RETROSPECTIVE|||||||
33718238|NCT04071730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33718239|NCT04159025|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718240|NCT05938543|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718241|NCT01359358|||||RETROSPECTIVE|||||||
33718242|NCT00165347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718243|NCT02610179|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33718244|NCT04803097|||COHORT||PROSPECTIVE|||||||
33718245|NCT02014844|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718246|NCT02484963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718247|NCT01484873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718248|NCT01133301|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33718249|NCT02670954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718250|NCT02850393|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33718251|NCT00789451|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33718252|NCT00905554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33718253|NCT03562104|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Description of swallowing||||
33718254|NCT04317456|||COHORT||PROSPECTIVE|||||||
33718255|NCT02136186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|patients deidentified||t|f|f|f
33718256|NCT03226392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718257|NCT03061331|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33799075|NCT04622722|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is an open-label, randomized cross-over study.~The study date will be 1 day for group A and 1 day for group B, separated by 7-day wash out period.~The tolerability of DSF, assessed by questionnaire, will be collected while the subjects consume DSFs daily 7 days before the study date (only group A). The questionnaire will ask about gastrointestinal symptom including abdominal distention, nausea, vomiting, and stool frequency.~Group A participants will be asked to drink 360 ml of Nutren Diabetes which provides 360 kcal.~Group B participants will be asked to consume isocaloric diet (360 kcal)comprising one carton of soy milk (250 ml) and bologna and mayonnaise sandwiches (two slices of bread).~Plasma glucose and insulin will be collected at baseline (minute 0) and 30, 60, 120 minute postprandially. The participants will be asked to complete the questionnaire (Visual analog scale) to assess hunger and satiety at minute 0, 30, 60 and 120 minute."||||
33799076|NCT01102231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799077|NCT02545920|||CASE_ONLY||PROSPECTIVE|||||||
33943085|NCT02127970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943086|NCT05882487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943087|NCT06479577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33943088|NCT04586920|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33943089|NCT01921842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799078|NCT03757572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will exist at the level of the investigator who will record the data postoperatively. There will be no blinding at the level of the surgeon or the patient.||f|f|t|t
33943090|NCT00495963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799079|NCT03830086|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33799080|NCT01566916||||TREATMENT||||||||
33799081|NCT05511766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33799082|NCT03837431|||COHORT||CROSS_SECTIONAL|||||||
33799083|NCT04157426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799084|NCT04446598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799085|NCT00035971||||TREATMENT||||||||
33799086|NCT00536341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799087|NCT03424499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (sterile single-use catheter) Group B (Reused catheter with benzalkonium chloride solution) and Group C (Reused catheter)|Subjects assigned into 3 parallel groups: Group1 assigned to use a single-use PVC catheter for Intermittent bladder catheterization for neurogenic bladder. Group2 and Group3 will use a reused PVC catheter. Both groups will have a follow-up of 8 weeks. Subjects will be randomized into block sizes of 6 using an electronic list. Both groups will be instructed to use sterile water-soluble lubricant in each catheterization. In the reused catheter group, PVC catheter is washed with water and soap, stored in a container with 0.5% benzalkonium chloride, Group3 catheter washed with water and soap alone. Each catheter is programmed to last a week. Patients/parents are going to be instructed to use clean technique by hand washing with water and soap, and penis/vulva cleansing with antiseptic wipes. Urine cultures will be taken day 0,7,14,28,42 and 56, collecting urine samples from fresh midstream catheter specimen, and evaluation of symptoms related to urinary tract infections.|f|f|f|t
33799088|NCT04433078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study will randomize 20 patients with confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients to Doxycycline (100 mg BID) or Placebo.|t|t|t|f
33799089|NCT00071253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943091|NCT00788801|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943092|NCT02699632|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33943093|NCT03559595|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33943094|NCT04424589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943095|NCT03896334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33943096|NCT03444389|||CASE_CONTROL||PROSPECTIVE|||||||
33943097|NCT01475812|||||CROSS_SECTIONAL|||||||
33943098|NCT04180891|||COHORT||PROSPECTIVE|||||||
33943099|NCT01977573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943100|NCT00363662|||COHORT||PROSPECTIVE|||||||
33943101|NCT04718376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943102|NCT05121129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943103|NCT01621516|||CASE_CONTROL||PROSPECTIVE|||||||
33943104|NCT02996162|||CASE_ONLY||PROSPECTIVE|||||||
33943105|NCT02493075|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33943106|NCT05864105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943107|NCT03474991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||KIDS-STEP is a phase III strategic investigator-initiated, randomised, placebo-controlled, fully blinded multicentre superiority trial with two parallel groups|t|t|t|t
33943108|NCT01510392|||OTHER||PROSPECTIVE|||||||
33943109|NCT05288439|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This prospective, cross-sectional, pilot clinical trial will incorporate rs-fcMRI and a full post- PBRT cognitive battery including quality of life assessment for pediatric patients using a multidisciplinary team.||||
33943110|NCT04939441|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be treated for 96 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy||||
34101880|NCT05936138|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34101881|NCT06691841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34101882|NCT06688643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34101883|NCT02775656|||COHORT||PROSPECTIVE|||||||
34101884|NCT00005819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101885|NCT06643689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Single-Blind Method with Investigator Blinding~Specific blinding measures:~1. Randomization and drug allocation: Randomization and drug allocation should be managed by a third party (e.g., data management team or pharmacist). The treatment options (Tranilast or steroids) should be distributed in identical appearance, packaging, and dosage forms to ensure that the investigators cannot determine the group assignment based on the drug's appearance.~2. Protection of subject information: Ensure that investigators have no access to any information regarding the drug name and group assignment. Anonymous numbers or subject codes can be used for labeling, with only the personnel or system responsible for drug allocation knowing the specific group assignments.~3. Data monitors or independent assessors: Independent monitors or assessors can be introduced, responsible only for follow-up and evaluation of post-procedure stricture, without knowledge of the patients' treatment groups."|Participants will be randomized into two parallel groups (Tranilast group and steroid group). Each group will receive their respective treatments concurrently, and outcomes will be assessed independently for each group. This model ensures that participants are not crossed over between treatment arms during the study.|f|f|t|t
34101886|NCT06676982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101887|NCT06686927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101888|NCT02767687|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34101889|NCT06110871|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|"PERSON USING IUD. IT WILL ALWAYS BE THE SAME AND THERE WILL BE ONE PERSON WHO HAS NOTHING TO DO WITH THE RESEARCH.~THE RESEARCHER WILL HAVE NO INTERVENTION DURING IUD APPLICATION."|In our research, there will be 3 interventions (Group 1 is a focus group, Group 2 is the Group where inhaled kavanta is used, Group 3 will be listened to music) and 1 control group (The group where IIA is applied and receives routine care). .|f|t|t|t
34101890|NCT04681313|||CASE_ONLY||PROSPECTIVE|||||||
34101891|NCT04058756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101892|NCT03867084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101893|NCT06558214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101894|NCT02416388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101895|NCT02934217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101896|NCT06687005|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34101897|NCT04191135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101898|NCT06497946|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34101899|NCT05792150|||COHORT||PROSPECTIVE|||||||
34101900|NCT05786196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943111|NCT04795752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943112|NCT06041594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101901|NCT06313957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101902|NCT02466997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34101903|NCT04874961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101904|NCT06682000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101905|NCT06696014|||COHORT||PROSPECTIVE|||||||
34101906|NCT06082960|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101907|NCT01064648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101908|NCT01633385|||CASE_CONTROL||PROSPECTIVE|||||||
34101909|NCT06287853|||COHORT||PROSPECTIVE|||||||
34101910|NCT05931965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101911|NCT01707446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101912|NCT01018537|||OTHER||PROSPECTIVE|||||||
34101913|NCT05787119|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34101914|NCT05919212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101915|NCT05478018|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34101916|NCT05385692|NA|SEQUENTIAL||TREATMENT||NONE||||||
34101917|NCT03874858|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101918|NCT06278311|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943113|NCT05794334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943114|NCT00003855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943115|NCT01467817|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33943116|NCT05543980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943117|NCT02090699|||CASE_CONTROL||PROSPECTIVE|||||||
33943118|NCT01349881|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33943119|NCT02681094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943120|NCT04974853|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33943121|NCT05308420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization and study drug preparation by person(s) not involved in patient care, data gathering or outcome evaluation. Group allocation kept in sealed opaque envelope until all data gathered. Outcome assessor/statistician will be blinded as to which group received which intervention|Non-inferiority randomized triple-blinded controlled trial|t|t|t|t
33943122|NCT05850637|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective phase 2 non-randomized single-arm study||||
33943123|NCT05221658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943124|NCT03049189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943125|NCT01612494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33943126|NCT06207864|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33943127|NCT05429528|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33943128|NCT06305793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|In each Appendix trial, each participant will be assigned with equal probability to one of the factorial combinations based on two factors: (1) a study intervention/control and (2) non-pharmacologic intervention/control if the participant is eligible for the study intervention.|t|t|t|f
33943129|NCT04325490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the two interventions were prepared in an identical neutral package. The same investigator evaluated the skin condition at each follow-up visit. Patients were followed up at 2 weeks.|A double-blined, randomized study|t|f|t|t
33943130|NCT01071902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943131|NCT02473029|||CASE_ONLY||CROSS_SECTIONAL|||||||
33943132|NCT03943524|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||"Allocation: Non-Randomized An electronic medical record, DrApp, will be used, which will include a drug interaction program, Interax-AI, which will automatically indicate the medication prescriptions that involve a risk for the patient.~All indications of each outpatient will be registered. The indications will be compared in the 4 months prior to the incorporation of the Interax-AI program with the 4 months after the incorporation of the program. Between both stages a period of 2 weeks will be established in which the data will not be recorded. The minimum number of patients that will be included in each stage is 100 and the maximum 200.~Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Prevention"|t|t|t|t
33943133|NCT01365416|||OTHER||PROSPECTIVE|||||||
33943134|NCT03682926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943135|NCT03946072|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33943136|NCT03417102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943137|NCT01667731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943138|NCT03550976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943139|NCT02609087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943140|NCT04629105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Double-blinded, randomized, placebo-controlled study with 2 cohorts.~Cohort 1: Subjects with ARDS and acutely infected with SARS-CoV-2. Arm 1: 25 subjects treated with up to 3 doses of 100 million LMSCs. Arm 2: 10 subjects treated with up to 3 doses of Placebo.~Cohort 2: Subjects with ARDS and acutely infected with influenza virus. Arm 3: 25 subjects treated with up to 3 doses of 100 million LMSCs. Arm 4: 10 subjects treated with up to 3 doses of Placebo.~Each subject will be intravenously infused with 100 million LMSCs or placebo on Day 0. If no treatment-related AEs are seen after the infusion, a second infusion will be given on Day 3. If no treatment-related AEs are seen after the second infusion, a third infusion will be given Day 6.~Follow-up visits will be conducted: daily until hospital discharge; at Week 4 after treatment (with LMSCs or placebo) for patients already discharged; and at Month 6 after treatment (with LMSCs or placebo)."|t|f|t|f
33943141|NCT00266331|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33943142|NCT00000758||PARALLEL||PREVENTION||||||||
33943143|NCT00072085|RANDOMIZED|||TREATMENT||||||||
34022092|NCT03479567|NON_RANDOMIZED|PARALLEL||OTHER||NONE||cross-sectional||||
34022093|NCT06130098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomized: Participants are assigned to intervention groups by chance and control groups will be established. In the randomization method, whether the participants will be in the study group or the control group will be determined by the simple random numbers method using a computer program.|There are two groups: control and study groups. Certain applications were planned to be applied to the control group and the study group.|t|f|t|f
33718258|NCT03927664|||COHORT||OTHER|||||||
33718259|NCT00874991|||COHORT||RETROSPECTIVE|||||||
33718260|NCT01190709|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022094|NCT01975727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022095|NCT06189547|||COHORT||RETROSPECTIVE|||||||
34022096|NCT06125132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022097|NCT00294463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022098|NCT06186180|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Single blinded randomized clinical trial|f|f|t|t
34022099|NCT02080169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022100|NCT02405884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022101|NCT04485039|RANDOMIZED|CROSSOVER||OTHER||NONE||5 period crossover||||
34022102|NCT06063265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33943144|NCT02801487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718261|NCT00353561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718262|NCT00232817|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718263|NCT01453712|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33718264|NCT02118012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718265|NCT05072561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718266|NCT02064647|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33943145|NCT02777294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943146|NCT01168297|||COHORT||CROSS_SECTIONAL|||||||
33943147|NCT03529552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943148|NCT05135494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33943149|NCT00862927|||CASE_ONLY||PROSPECTIVE|||||||
33943150|NCT02774824|||OTHER||OTHER|||||||
33943151|NCT03145207|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33943152|NCT05732740|NA|SINGLE_GROUP||TREATMENT||NONE||The purpose of this research project is to assess the preliminary effect of a novel internet-based cognitive behavioral therapy (iCBT) program called Empower@Home:Connected. The program is delivered in small groups remotely. It is intended to decrease depression, social isolation, and loneliness in participants by encouraging participants to take part in meaningful and enjoyable activities while challenging problematic thinking patterns.||||
33943153|NCT00612573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943154|NCT01078389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943155|NCT06382415|||COHORT||RETROSPECTIVE|||||||
33943156|NCT04856293|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33943157|NCT03878706|||COHORT||PROSPECTIVE|||||||
33943158|NCT02373176|NA|SINGLE_GROUP||||NONE||||||
33943159|NCT04531436|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot feasibility trial||||
33943160|NCT05621109|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33943161|NCT05376163|||OTHER||PROSPECTIVE|||||||
33943162|NCT02790320|||||RETROSPECTIVE|||||||
33943163|NCT01996956|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33943164|NCT04579458|||CASE_ONLY||PROSPECTIVE|||||||
33943165|NCT03556527|||COHORT||RETROSPECTIVE|||||||
33943166|NCT02809872|||COHORT||RETROSPECTIVE|||||||
33943167|NCT03033290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943168|NCT05115812|||OTHER||RETROSPECTIVE|||||||
33943169|NCT04858516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943170|NCT00483431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943171|NCT01248923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943172|NCT03942536|||COHORT||PROSPECTIVE|||||||
33943173|NCT05208749|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33943174|NCT01754142|||CASE_ONLY||PROSPECTIVE|||||||
33943175|NCT03278834|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Treatment and intervention group|t|f|f|t
33943176|NCT01591577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943177|NCT01810081|||COHORT||PROSPECTIVE|||||||
34022103|NCT01043653|||COHORT||PROSPECTIVE|||||||
34022104|NCT03755323|||COHORT||PROSPECTIVE|||||||
34022105|NCT01441713|||COHORT||CROSS_SECTIONAL|||||||
34022106|NCT02337023|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33718267|NCT01138631|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718268|NCT02532790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718269|NCT04170257|NA|SINGLE_GROUP||SCREENING||NONE||||||
33718270|NCT01151644|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718271|NCT00073554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718272|NCT02289690|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Phase 1 was open-label, phase 2 was conducted in a double-blind manner.||t|f|t|f
33718273|NCT03703765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718274|NCT04468204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718275|NCT01698047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718276|NCT03051607|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will begin dosing with tozadenant at a dose of 120 mg twice daily. At Week 2 or thereafter, the investigator may adjust the patient's IMP dose as clinically indicated; doses of 60 mg BID and 120 mg BID will be permitted.||||
33718277|NCT05483751|||COHORT||PROSPECTIVE|||||||
33718278|NCT03293550|||COHORT||PROSPECTIVE|||||||
33718279|NCT02614950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718280|NCT06017440|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718281|NCT04966754|||COHORT||PROSPECTIVE|||||||
33718282|NCT00634166|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718283|NCT05067829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective randomized contrrolled study|t|t|f|t
33718284|NCT04762797|||COHORT||RETROSPECTIVE|||||||
33718285|NCT00099346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718286|NCT02213016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022107|NCT06453629|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participant and their adult caregiver will be blinded. The Outcomes Assessor (Clinician) with the adult caregiver will also be blinded.|Experimental: Floreo VR- 12 week with follow up Active Comparator: VR Control- 12 week with ability to crossover or follow up Other: VR Control Crossover- 12 week of Floreo VR|t|f|f|t
34022108|NCT02831608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022109|NCT01119183|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022110|NCT03441932|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* Dysphagia screening in the Emergency department for any patient admitted to Hotêl-Dieu de France university hospital for Stroke based on the  Emergency department dysphagia-screening tool.~* Subjets will be then sorted in two groups:~\> 1-Screening passed \> 2-Screening failed~• Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention."||||
34022111|NCT01794026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022112|NCT06627491|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34022113|NCT05640336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022114|NCT04435535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022115|NCT04470687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022116|NCT02938559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022117|NCT05962203|NA|SINGLE_GROUP||PREVENTION||NONE||Multivariable logistic regression; Multivariable Cox regression, Chi-Square-Test, Propensity score matching||||
34022118|NCT01768013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022119|NCT02149329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022120|NCT02470273|||COHORT||CROSS_SECTIONAL|||||||
34022121|NCT04885153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|200 mg of micronized fenofibrate and placebo (lactic acid) were repackaged into identical capsules and then put inside identical plastic pot by the Pharmacy Unit of Cipto Mangunkusumo Hospital.|Patients were divided into two groups, which were intervention group (simvastatin+fenofibrate) and control group (simvastatin+placebo).|f|t|f|f
34022122|NCT03598335|||CASE_CONTROL||PROSPECTIVE|||||||
34022123|NCT05921357|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022124|NCT02331290|||COHORT||PROSPECTIVE|||||||
34022125|NCT03043976|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Partial crossover. A group of 10 underwent the intervention, a group of 10 was observed for 8 weeks without receiveng any feedback, then underwent the intervention. The main outcome was evaluated as the difference between the end of intervention and baseline (paired data). We did not recuit any patient in arm 3.||||
34022126|NCT02468570|||COHORT||PROSPECTIVE|||||||
34022127|NCT01982812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022128|NCT06317090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither the patient, nor the outcome assessor was aware at which side which grafting material was used|split-mouth 2 arm RCT|t|f|f|t
34022129|NCT01418963|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34022130|NCT01363024|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022131|NCT00638027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022132|NCT02009514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022133|NCT04626453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022134|NCT00110136|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34022135|NCT06293378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022136|NCT00191971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022137|NCT00067899|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34022138|NCT04493866|||CASE_ONLY||RETROSPECTIVE|||||||
34022139|NCT03474497|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive pembrolizumab and intralesional IL-2 in combination with hypofractionated radiotherapy.||||
34022140|NCT06309654|RANDOMIZED|PARALLEL||TREATMENT||NONE||Seventy overweight or obese patients with KOA and T2DM (62.2 ± 6.1 years; 56% female) were randomly assigned to the intervention group (n = 35, HBCT) or the no-exercise control group (n = 35, CON). HBCT performed a progressive protocol (seven exercises; 15-30 repetitions per exercise, 1 min passive rest between exercises; 2-4 rounds per session; 20-60 min total session duration). The knee injury and osteoarthritis symptoms, cardiovascular and metabolic risk factors, cardiorespiratory fitness, and renal function were assessed at baseline and following the 12-week intervention.||||
34022141|NCT04305951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022142|NCT04557020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022143|NCT02077673|||CASE_ONLY||PROSPECTIVE|||||||
34022144|NCT04111393|||COHORT||RETROSPECTIVE|||||||
34022145|NCT01421173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022146|NCT06049810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Care Provider, Investigator||t|t|t|f
34022147|NCT00951496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022148|NCT04709770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799090|NCT05264870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the patient and the observant/study physician are fully blinded. Randomization, preparation of study medication and administration of CSE anesthesia is performed by a protocol trained anesthesiologist. He or she is further excluded to any other study related intervention. A second protocol trained anesthetist comes in and will adapt the norepinephrine infusion according to the needs of the patient. He will do routine care observations and interventions until end of surgery.|Norepinephrine infusion is given for treatment of postspinal hypotension in treatment group A and B|t|f|f|t
33799091|NCT00824135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101919|NCT06015165|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label trial.|Patients undergoing complex anorectal surgery under general anesthesia will be included in this study. In Anes Group, the anesthesiologist routinely works in the operating room, and will communicate with anorectal physicians through bedside visits, video telephone calls, and a hospital-wide electronic medical record system in the operating room. Anesthesiologists will administer opioids or non-opioids at the optimal interval and standard dose until discharge. The anesthesiologist and the surgeon will jointly formulate the discharge medication plan and give the patient guidance on analgesic treatment. Patients in the Surg. Group will be given local anesthesia during the operation, and will receive routine ambulatory surgery anesthesia plan, and routine postoperative analgesia plan in the ward will be given to the patients, under the guidance of the department of pharmacy. The patients will receive rescue opioids and standardized NSAIDs until discharge.||||
34101920|NCT06685679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799092|NCT03379051|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799093|NCT01198028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799094|NCT03667911|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33799095|NCT02759913|||COHORT||PROSPECTIVE|||||||
34101921|NCT06679478|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The participants are not informed of which group they are in. The investigators will not inform the person performing the statistical analysis which group the collected data belongs to.|The participants in the control group are given the mobilization applied in routine clinics. The participants in the intervention group are given the mobilization protocol created in accordance with the enhanced recovery after surgery guidelines.|t|f|f|t
34101922|NCT02853773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34101923|NCT06311175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to one of three intervention groups in parallel for the duration of the study|f|f|f|t
34101924|NCT04503642|||CASE_CONTROL||PROSPECTIVE|||||||
34101925|NCT06025058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101926|NCT06422052|||COHORT||PROSPECTIVE|||||||
34101927|NCT06694779|||COHORT||RETROSPECTIVE|||||||
34101928|NCT03113552|||COHORT||RETROSPECTIVE|||||||
34101929|NCT05992493|||COHORT||PROSPECTIVE|||||||
34101930|NCT06083493|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34101931|NCT05909202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34101932|NCT05448027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34101933|NCT00968630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101934|NCT06268132|||COHORT||PROSPECTIVE|||||||
34101935|NCT00000472|RANDOMIZED|||TREATMENT||DOUBLE||||||
34101936|NCT06694831|||COHORT||PROSPECTIVE|||||||
34101937|NCT00588770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101938|NCT05719233|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799096|NCT05744258|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33799097|NCT01082289|NA|SINGLE_GROUP||||||||||
33799098|NCT02709304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33799099|NCT00592605|||COHORT||PROSPECTIVE|||||||
33799100|NCT00373373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799101|NCT04232371|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized within each participating center, not by center, into study groups:~1. New Ablation Technique - will undergo ablation using voltage mapping and triangle of Koch propagation wave collision mapping. Ablation will be performed at or slightly above the site of wave front collision.~2. Standard Ablation Technique - ablation performed using the traditional anatomical / electrogram guided ablation approach.~Randomization will occur through a module in Redcap."||||
34101939|NCT03139253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101940|NCT04331769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34101941|NCT06003829|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34101942|NCT05257018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101943|NCT04994483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomized treatments will be assigned by subject numbers in a randomly generated numeric sequence. Randomization (1:1) will be stratified by low or high Mini-Mental State Exam (MMSE; 16-20 and 21-27).~The randomization code will not be revealed to study subjects, Investigators, clinical staff, study monitors, or the Sponsor until all subjects have completed therapy and the database has been finalized and locked."|Approximately 750 patients will be enrolled into the study. All patients will be randomized (1:1) to receive either placebo or 100 mg tablets of simufilam, twice daily, for 52 weeks.|t|t|t|t
34101944|NCT05346640|NA|SINGLE_GROUP||TREATMENT||NONE||A one-group, pre-test post-test study.||||
33799102|NCT00875160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34101945|NCT06310824|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34101946|NCT03549507|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101947|NCT05867940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Four groups of participants will be included in this study; 1) children and adolescents with physical disabilities, 2) children and adolescents with intellectual disabilities, 3) children and adolescents with autism, and 4) adults with physical or intellectual disabilities, or with autism.||||
34101948|NCT00003192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101949|NCT06011889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34101950|NCT05817994|||COHORT||PROSPECTIVE|||||||
34101951|NCT06694987|NA|SINGLE_GROUP||OTHER||NONE||This is a quasi-experimental, one group, pre-post design study.||||
34101952|NCT01871727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101953|NCT06442228|NA|SINGLE_GROUP||SCREENING||NONE||||||
34101954|NCT05703256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomly assigned to receive amygdala neurofeedback or yoked sham neurofeedback (seeing the amygdala activity of another participant)|t|f|f|t
34101955|NCT06686446|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, interventional, randomised trial, evaluating the impact and effectiveness of a new AR education package used in conjunction with daily INCS/INAH treatment to reduce AR-related symptomatology and improve quality of life, in comparison to the standard of care education that is currently provided. A decentralized clinical trial model will be used to facilitate and augment the recruitment of participants across different geographical locations around Australia to align with the seasonal pollen changes in various states and territories.~Participants will be randomised 1:1 to receive either the Enhanced Education Package (EEP) or continue with the standard of care education that they receive from their treating clinician. The EEP includes an advanced patient education toolkit and reminders delivered by email/SMS."||||
34101956|NCT06032598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101957|NCT06689228|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Orem's Self-Care Deficit Theory and Tele-Monitoring||||
34101958|NCT06695338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101959|NCT06254495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101960|NCT02756091|||OTHER||PROSPECTIVE|||||||
34101961|NCT03760081|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101962|NCT06688513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34101963|NCT06694506|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"We aim to include both male and female adult patients with a diagnosis of childhood onset-GHD, registered in BELGROW, that stopped the GH therapy for growth after 2011 and have a persistent GHD in adolescence/transition period. After completing a questionnaire, each participant will be assigned an analysis group:~* Group 1: Patients with regular follow-up for their GHD (treated with rhGH or not) in a adult endocrinology department including a clinical examination and endocrine blood work-up at least once a year~* Group 2: Patients who are lost to follow-up or not regularly followed for their GHD (or only followed by their GP with no endocrine assessment)"||||
34101964|NCT03921541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34101965|NCT05852717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34101966|NCT06691802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799103|NCT05830942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799104|NCT00388661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799105|NCT03802890|||COHORT||PROSPECTIVE|||||||
33799106|NCT00296036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33799107|NCT02509637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33943178|NCT03077399|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This study is a monocentric observational clinical study. During the first week, the assessments used in routine in our center will be performed. During the second week, the assessments of lateropulsion by SCALA-V1, postural verticality perception in sitting and the representation of longitudinal body axis in lying position will be performed twice, 2 days apart, by 2 different raters in order to determine their inter-rater reliability. During the third week, mass distribution on lower limbs in frontal plan during standing position and body orientation in frontal plan during sitting position, standing position and sit-to-stand will be assessed.||||
33943179|NCT01968473|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33799108|NCT01801514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943180|NCT05135637|||OTHER||PROSPECTIVE|||||||
33943181|NCT01298661|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799109|NCT01618643|||COHORT||PROSPECTIVE|||||||
33799110|NCT02794194|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33799111|NCT00823225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799112|NCT06478992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799113|NCT02382328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799114|NCT04929587|||CASE_CONTROL||OTHER|||||||
33799115|NCT03364595|||COHORT||RETROSPECTIVE|||||||
33799116|NCT04585412|RANDOMIZED|CROSSOVER||OTHER||NONE||An open-label, randomized, balanced, two-treatment, two-period, twosequence, single dose, two-way crossover study||||
33799117|NCT05712993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799118|NCT00726596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799119|NCT00335049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33799120|NCT06554743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799121|NCT01765543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943182|NCT01018069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943183|NCT06428929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Newborns were randomly assigned groups as the musical and lighted baby crib mobile (intervention) group (40 newborns) and the control group (40 newborns) by the computer program (www.randomizer.org). Newborns of parents who did not meet the study criteria and did not agree to participate in the random selection were not included in the study. Parents and researchers could not be blinded. Newborns were included in the study by evaluating their compliance with the inclusion criteria according to the order of admission to the hospital. 10 children in the control group (5 parents did not volunteer and 5 newborns were crying) and 10 children in the intervention group (7 newborns received paracetamol and 3 newborns were crying) were excluded from the study. For this reason, the research was completed with 60 newborns.|f|f|f|t
33943184|NCT02230501|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|For the second part of the study, i.e. the open-label registry, 4000 subjects are anicipated.|For the second part of the study, i.e. the open-label registry, there ist no randomization.|f|t|t|t
33943185|NCT05908422|||OTHER||PROSPECTIVE|||||||
33943186|NCT02793115|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33943187|NCT01509651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022149|NCT03511326|NA|SINGLE_GROUP||OTHER||NONE||||||
34022150|NCT02345629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022151|NCT01151228|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
34022152|NCT00858143|||CASE_ONLY||PROSPECTIVE|||||||
34022153|NCT04137016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022154|NCT00863395|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022155|NCT02816099|NA|PARALLEL||OTHER||NONE||||||
34022156|NCT03260985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022157|NCT03995186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants will be randomly assigned to either the behavioural activation intervention (40 participants), activity monitoring (40 participants) or passive waiting-list control group (40 participants). This study is not intended to be administering treatment, it is investigating the possible mechanisms of this intervention.|f|f|f|t
34022158|NCT06020287|||COHORT||RETROSPECTIVE|||||||
34022159|NCT05486793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All follow-up clinician-administered interviews will be completed by independent evaluators blinded to randomized condition.|Participants will be randomized in a 1:1:1 ratio using a permuted block strategy (random block sizes of 2 and 4) and stratified by PTSD severity (met full PTSD criteria/not) and major depressive diagnosis (MDD).|f|f|f|t
34022160|NCT05193643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022161|NCT00719030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022162|NCT03251235|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The care provider is not aware of whether a patient is allocated to the treatment group or the waiting group.||f|t|f|f
34022163|NCT04959591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The designated research pharmacist will prepare the both study drug (IV acetaminophen) and placebo and will dispense the study drug according to treatment allocation. Treatment allocation will remain concealed from all other investigators involved in the conduct and analysis of the trial. All other medical staff involved in patient care during the hospital stay of study participant and the study participants itself along with guardians will be also blinded throughout.||t|t|t|t
34022164|NCT05824416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34022165|NCT02312908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022166|NCT00565617|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|We are currently monitoring participants that were implanted with Epidural Cortical Stimulators starting back in 2008. Primary investigation is completed, but they have implanted devices for investigational treatment of depression. We will keep the study open while they are monitored.||||
34022167|NCT03002571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022168|NCT01337258|||COHORT||RETROSPECTIVE|||||||
34022169|NCT02555748|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022170|NCT06084897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022171|NCT03261986|NA|SINGLE_GROUP||OTHER||NONE||||||
34022172|NCT00005634||||TREATMENT||||||||
34022173|NCT04358289|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022174|NCT02392351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022175|NCT04992650|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34101967|NCT05084378|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|The orthopaedic team (including the study coordinators) cannot be blinded to the treatment allocation as the solutions are visually distinguishable and these individuals need to lead the data collection at their clinical site. The participants, the Adjudication Committee Members, and the data analysts will be blinded to the study treatment. Participants may request to be unblinded following the completion of their 12-month visit.||t|f|f|t
34101968|NCT02704832|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34101969|NCT06688175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101970|NCT05720884|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The intervention researcher is not blinded since the researcher should perform different intervention according to the group. However, we separate the person and location to keep the blindness as robust as possible. Both the participant and the assessor are blinded and the location where intervention is performed is separate from the location where assessment is performed.|acupuncture group and placebo group|t|t|f|t
33799122|NCT06335472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|pain control and range of motion in adhesive capsulitis|Ultrasound-guided effect of three nerves pulsed radiofrequency versus supra-scapular nerve pulsed radiofrequency both combined with hydro-dissection in reducing the intensity of pain in adhesive capsulitis|t|f|t|f
34101971|NCT04002063|RANDOMIZED|PARALLEL||TREATMENT||NONE||a full-scale multi-site randomized clinical trial (RCT) to measure the efficacy of CBT-D enhanced with CBT MobileWork-V, a comprehensive CBT skill training smartphone app (the experimental arm) for improving CBT understanding and skill acquisition and depressive symptoms, in OEF/OIF Veterans with depression compared to standard CBT-D.||||
34101972|NCT03008473|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34101973|NCT04408209|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
34101974|NCT01522183|||OTHER||OTHER|||||||
34101975|NCT06327256|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The multiple rising dose part of the trial will be blinded to the participants and investigators . The effect of midazolam will be assessed open label.|The multiple rising dose part of the trial will be conducted in a parallel group assignment. The effect of midazolam interaction will be assessed sequentially.|t|t|t|f
34101976|NCT03576820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The medication and placebo doses will be prepared in the pharmacy at the study site and provided to the investigators in deidentified syringes.||t|t|t|t
34101977|NCT06687564|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Experimental, descriptive, prospective, non-randomized, controlled, comparative, monocentric in recruitment but multicentric study in procedures and analyses.||||
34101978|NCT03106402|||CASE_ONLY||RETROSPECTIVE|||||||
34101979|NCT04609566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101980|NCT05635409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a multicentre, single arm, dose escalation, first in human advanced therapy investigational medicinal product (ATIMP) trial.||||
34101981|NCT06674772|||CASE_CONTROL||PROSPECTIVE|||||||
34101982|NCT04380753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101983|NCT00771186|||COHORT||PROSPECTIVE|||||||
34101984|NCT02165787|||OTHER||OTHER|||||||
34101985|NCT01671774|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
34101986|NCT05900843|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34101987|NCT06145048|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label study in which all subjects will receive a dose of 0.32mg/kg VGT-309 (based on their weight) at 12-36 hours pre-surgery.||||
34101988|NCT06695078|||COHORT||PROSPECTIVE|||||||
34101989|NCT05075577|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34101990|NCT05078879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101991|NCT06083467|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34101992|NCT06686628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34101993|NCT00742742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34101994|NCT06668883|||CASE_ONLY||PROSPECTIVE|||||||
34101995|NCT05549882|||COHORT||PROSPECTIVE|||||||
34101996|NCT00641212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34101997|NCT04978506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34101998|NCT05656274|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34101999|NCT03272893|||COHORT||PROSPECTIVE|||||||
34102000|NCT00225602|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102001|NCT06468046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The pilot randomized controlled trial (RCT) of the adapted 'Mama Empoderada' intervention with Migrant Mothers will include N=100 \[N(treatment)=50; N(control)=50\] (Aims 2-3). The intervention group (IG) will participate in trauma- informed group and individual sessions addressing parenting, active linkage to resources, social support, and resilience. The control group will receive standard of care programming, including referrals to drop-in migrant and community-based supports, childcare, and referrals to reproductive, mental health, and other services. Control group participants will have the opportunity to participate in the full intervention following completion of the intervention and all questionnaires by the intervention group (post 6-month visit). Both groups will complete baseline, exit, and follow-up (2, 4, 6-months) surveys.|f|f|t|f
34102002|NCT06312124|NA|SEQUENTIAL||PREVENTION||NONE||||||
34102003|NCT05378100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102004|NCT06694194|||CASE_ONLY||CROSS_SECTIONAL|||||||
34102005|NCT04825262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Single interventional group with historical control group|t|f|f|f
34102006|NCT03268499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients, doctors and other caretakers are not blinded to group allocation. Data collectors and analysts who assessed the study outcome and radiologists who assessed tumor response are blinded to group allocation.|prospective, multi-center, parallel-group, open-label, phase III randomized control trial|f|f|t|t
34102007|NCT06576570|NA|SINGLE_GROUP||OTHER||NONE||Within-subject pre-post design||||
34102008|NCT02088411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102009|NCT02225795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799123|NCT06011109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799124|NCT03107767|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A prospective cohort, following the introduction of an evidence based algorithm, will be compared to a matched historical cohort from the previous years.||||
33799125|NCT02729506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799126|NCT05132478|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34022176|NCT03898089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Randomized|f|f|t|f
34022177|NCT04084600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022178|NCT05321173|||COHORT||PROSPECTIVE|||||||
34022179|NCT04141124|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Intervention will not be observed by outcomes assessor Performance will be evaluated on video recording after the simulation|3 paralel arms of interventions|f|f|t|t
34022180|NCT00988442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34022181|NCT01171118|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34022182|NCT02340130|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022183|NCT03373773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34022184|NCT05623306|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"Stage 1: Invasive SEEG Monitoring and Recovery~Stage 2: SEEG-guided DBS Implantation and Optimization of DBS Programming~Stage 3: Randomized Sham-controlled Crossover Trial"|t|t|t|f
34022185|NCT05251519|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
34022186|NCT05379049|||CASE_ONLY||PROSPECTIVE|||||||
34022187|NCT00715221|||CASE_CONTROL||PROSPECTIVE|||||||
34022188|NCT02373189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34022189|NCT05749250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022190|NCT05886010|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34022191|NCT05854810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022192|NCT02879357|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022193|NCT04445363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"In phase I of this study, Forty enrolled subjects were randomly assigned to four groups at 1:1:1:1. (1) concentration of 0.5%, twice daily (Bid) group; (2) concentration of 1.5%, bid group; (3) concentration of 2.5%, once daily(Qd) group; (4) concentration of 2.5%, bid group.Ten subjects in each group were randomly assigned to receive Jaktinib hydrochloride cream (8 cases) and placebo (2 cases) at 4:1, respectively,The duration of administration was 24 weeks.~In phase II of this trial, 120 Enrolled subjects are randomly assigned to 3 groups (placebo bid group,concentration of 1.5% bid group and concentration of 2.5% bid group)."|t|f|t|f
34022194|NCT03285100|||COHORT||PROSPECTIVE|||||||
33718287|NCT03314753|||OTHER||RETROSPECTIVE|||||||
33718288|NCT04466254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718289|NCT01898728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33718290|NCT02047760|||CASE_CONTROL||PROSPECTIVE|||||||
33718291|NCT05855239|||COHORT||PROSPECTIVE|||||||
33718292|NCT00799487|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718293|NCT04458233|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33718294|NCT04394104|||OTHER||RETROSPECTIVE|||||||
33718295|NCT01229059|||OTHER||PROSPECTIVE|||||||
33718296|NCT05783115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718297|NCT00860964|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718298|NCT03641651|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33718299|NCT01851564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718300|NCT01320462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718301|NCT03398291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718302|NCT05947370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33718303|NCT04691284|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718304|NCT06387745|NA|SINGLE_GROUP||SCREENING||NONE||||||
33718305|NCT03867929|||COHORT||CROSS_SECTIONAL|||||||
33718306|NCT05291247|||COHORT||PROSPECTIVE|||||||
33718307|NCT01632969|||FAMILY_BASED||RETROSPECTIVE|||||||
33718308|NCT01361386|||COHORT||PROSPECTIVE|||||||
33718309|NCT05328791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718310|NCT05980650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022195|NCT05353010|NA|SEQUENTIAL||TREATMENT||NONE||||||
34022196|NCT03838510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34022197|NCT04849962|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34022198|NCT05220189|||COHORT||PROSPECTIVE|||||||
33718311|NCT05513495|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A single-center, prospective, randomized trial||||
33718312|NCT04797793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33718313|NCT02568150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718314|NCT00217139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718315|NCT05792371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718316|NCT04326907|RANDOMIZED|PARALLEL||TREATMENT||NONE||This monocentric randomized controlled study was designed to test the efficacy and safety of injection of CAT for treatment of complex fistula-in ano, not associated with CD . Eligible patients were randomly assigned, according to a 1:1 scheme, to receive treatment with or without CAT. In the experimental arm, anal fistulas were treated by conventional surgery, and CAT injection. No experimental treatment (CAT) was administered to the control arm.||||
33718317|NCT04270123|||COHORT||PROSPECTIVE|||||||
33718318|NCT00004224||||TREATMENT||||||||
33718319|NCT03382522|||COHORT||RETROSPECTIVE|||||||
33718320|NCT01406431|RANDOMIZED|CROSSOVER||||NONE||||||
33718321|NCT03472469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718322|NCT04892888|||COHORT||PROSPECTIVE|||||||
33718323|NCT02233309|||CASE_ONLY||PROSPECTIVE|||||||
33718324|NCT04307693|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open labelled, randomized clinical trial||||
33718325|NCT04036552|||COHORT||CROSS_SECTIONAL|||||||
33718326|NCT05514691|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Enrolled subjects with anterior nasal swab are tested on both iStatis COVID-19 and RT-PCR.|t|f|f|f
33718327|NCT00000854||PARALLEL||TREATMENT||||||||
33718328|NCT00223951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33718329|NCT02352714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33718330|NCT06189651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, clinical trials|f|f|f|t
33718331|NCT01418833|||CASE_ONLY||PROSPECTIVE|||||||
33718332|NCT00330941|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33718333|NCT02090660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718334|NCT03134820|||COHORT||PROSPECTIVE|||||||
33718335|NCT00004443||||TREATMENT||||||||
33799127|NCT05103358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799128|NCT03332758|||COHORT||PROSPECTIVE|||||||
33799129|NCT01896310|||COHORT||PROSPECTIVE|||||||
33799130|NCT01123421|||CASE_CONTROL||RETROSPECTIVE|||||||
33799131|NCT03634280|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients were randomised using randomisation software and divided into two groups each comprising 120 patients. Tape and splint were kept on the patients for 5 days.||||
33799132|NCT01947088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799133|NCT03101930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Treatment with liraglutide or sitagliptin will be masked using matching placebo.||t|t|t|t
33799134|NCT06059560|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799135|NCT00811278|||COHORT||PROSPECTIVE|||||||
33799136|NCT03134625|||COHORT||PROSPECTIVE|||||||
33799137|NCT04730362|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope|Control group : a Guedel oral airway will be inserted for airway management versus supraglottic group patients in which supraglottic airway laryngeal mask airway (LMA) will be used|t|f|t|f
33943188|NCT02892357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799138|NCT05467319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Intravenous treatment will be prepared by an unblinded provider and placed in opaque bags/tubing to blind the patient, administrator of the medication, and subsequent outcome assessors and care providers.|Parallel groups, randomized placebo-controlled, double blind|t|t|t|t
33799139|NCT03658460|||COHORT||PROSPECTIVE|||||||
33799140|NCT05341869|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33799141|NCT01117519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799142|NCT04578392|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized according to post-operative recurrence risk to either a high ligation of ileocolic artery or mesenteric sparing ileocolic resection for terminal ileal Crohn's disease.||||
33799143|NCT03421678|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799144|NCT03020979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799145|NCT00529516|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33799146|NCT02087345|||COHORT||PROSPECTIVE|||||||
33799147|NCT00121329|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33799148|NCT05446077|||COHORT||CROSS_SECTIONAL|||||||
33799149|NCT04114786|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799150|NCT04760340|||COHORT||PROSPECTIVE|||||||
33799151|NCT00068601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799152|NCT01359592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799153|NCT04802148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799154|NCT06672718|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33799155|NCT04247074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943189|NCT02090140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943190|NCT01540006|||COHORT||PROSPECTIVE|||||||
33943191|NCT03230240|||COHORT||PROSPECTIVE|||||||
33943192|NCT04418752|NA|SINGLE_GROUP||TREATMENT||NONE||The second phase of the research consists of a Sequential Measurement Single Case Study Series (SMSCSS) to explore the effectiveness of NET in reducing symptoms of traumatic stress in adults with ID. This requires measures to be completed at various time points across the research by both participants and carers. Inferences can then be made about changes in behaviour as a result of the therapy, particularly when a stable baseline has been established. In a naturalistic clinical setting, such as the current research, it is difficult to gain a stable baseline as the investigators would expect the potential for some change to occur in anticipation of the therapy. The investigators aim to collect three baseline measures prior to NET commencing; however, the investigators do not want to withhold therapy and risk attrition to obtain a stable baseline.||||
33943193|NCT03138707|||CASE_CONTROL||RETROSPECTIVE|||||||
33943194|NCT00460642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943195|NCT04937127|||COHORT||PROSPECTIVE|||||||
33943196|NCT05745415|||COHORT||PROSPECTIVE|||||||
33943197|NCT03995199|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943198|NCT00426569|||CASE_ONLY||PROSPECTIVE|||||||
33943199|NCT04870294|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The study has double blind masking: as for patients and professional evaluator of the results|Comparison of two types of intervention: composite resin restoration and cavity lining before composite resin restoration.|t|f|f|t
33943200|NCT02785094|||COHORT||PROSPECTIVE|||||||
33943201|NCT04421430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were randomized into the experimental and control groups using a block randomization method. Literature shows that age, gender, and fear are three factors affecting procedural pain and anxiety in children (Ball, Bindler, \& Cowen, 2010; Twycross, 2009). Therefore, the variables of age (7-9 and 10-12 years), gender (girls and boys), and fear of procedure (yes and no) were used for block randomization. The blocks were repeated five times in each group (2X2X2X5), and 40 participants were assigned to each. The sealed envelope method was used to randomly assign participants to the groups.|f|f|t|f
33943202|NCT00178789|||||OTHER|||||||
33943203|NCT02030795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022199|NCT01740635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022200|NCT00752011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022201|NCT04575064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022202|NCT00132028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022203|NCT00977379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102010|NCT05591768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102011|NCT06665789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant)||f|f|f|t
34102012|NCT04624204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102013|NCT06683092|||COHORT||PROSPECTIVE|||||||
34102014|NCT06501144|||COHORT||PROSPECTIVE|||||||
34102015|NCT03289195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This prospective single institution pilot study.||||
33718336|NCT02943720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718337|NCT04890223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33718338|NCT01980875|RANDOMIZED|PARALLEL||TREATMENT||NONE||Safety Run-In Phase: Single Group; Randomized Phase: Parallel||||
33718339|NCT05639374|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33718340|NCT03316131|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The pharmacokineticist will remain blinded during the study conduct, unless otherwise required based on study findings. The pharmacokineticist will be unblinded to perform the final PK analyses after all patients have completed the study, final bioanalytical results are available and all required study data are considered clean. This may occur before database lock.||t|f|f|t
33718341|NCT05443932|NA|SINGLE_GROUP||PREVENTION||NONE||There won´t be comparator arms in our study. Instead, the investigators plan to do blood- and 24h-urine screenings including oxalate and citrate as well as metabolomics tests out of blood and urine samples at crucial points of time of the study to get baseline and therapeutic data of the participants.||||
33718342|NCT00782145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33718343|NCT00603551|||CASE_ONLY||CROSS_SECTIONAL|||||||
33718344|NCT00051402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33718345|NCT06095427|RANDOMIZED|PARALLEL||OTHER||DOUBLE||This is a multi-center, randomized, double-blind, single-dose, three-arm, parallel-group study designed to demonstrate the PK similarity between LY06006, US-Prolia and EU-Prolia and to evaluate the safety, tolerability, immunogenicity and PD of LY06006 compared with US-Prolia and EU-Prolia.|t|f|t|f
33718346|NCT04166266|||COHORT||PROSPECTIVE|||||||
33718347|NCT02356497|||COHORT||PROSPECTIVE|||||||
33718348|NCT01922089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943204|NCT04196231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943205|NCT00667381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943206|NCT03943602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943207|NCT01966367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943208|NCT04187612|||COHORT||PROSPECTIVE|||||||
33943209|NCT00485615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943210|NCT01636076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943211|NCT02074059|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential escalating dosing groups, each group contained an active and control arm of equal size.||||
33943212|NCT03266159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study. Hence, masking will not be performed.|A sequential combined therapy of GSK525762 plus trametinib will be given to the subjects. Subjects will receive escalating doses in part 1 and the dose combination selected at the end of part 1 will be provided in part 2.||||
33943213|NCT00453635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943214|NCT00612456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943215|NCT05651724|||COHORT||PROSPECTIVE|||||||
33943216|NCT01105429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943217|NCT05723172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33943218|NCT03648047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will be assessed by an independent outcomes assessor||f|f|f|t
33943219|NCT00417911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943220|NCT05698342|||CASE_ONLY||PROSPECTIVE|||||||
33943221|NCT00303290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943222|NCT06076863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research assistants who review charts will be masked to patient group status.||f|f|f|t
33943223|NCT01245296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33943224|NCT01809158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943225|NCT01399931|||COHORT||PROSPECTIVE|||||||
33943226|NCT01712763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943227|NCT01243047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943228|NCT03907072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943229|NCT04033328|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Modified interval 3+3 dose escalation design, followed by dose expansion||||
33943230|NCT00483067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943231|NCT05138731|||COHORT||PROSPECTIVE|||||||
33718349|NCT02549183|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33943232|NCT02741336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943233|NCT05499208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943234|NCT01059955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943235|NCT00361504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943236|NCT00459329|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33943237|NCT04602468|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|No blinding. The decision to implement Kaftrio treatment is made completely independently of the decision to enter the study. Those determined to begin treatment on Kaftrio clinically will undergo eligibility assessment.|The decision to implement Kaftrio treatment is made completely independently of the decision to enter the study. The investigators will follow the requirements of the local approved Kaftrio SmPC for the patient management as detailed in the 'special warnings and precautions for use' (e.g. management of hepatic impairment, rash, ophthalmological monitoring, between others), and for the management of interaction with other medicinal products and other forms of interactions. The 12+ cohort will be enrolled first on the basis the drug will be approved for children aged 12 and over first. The 6-11 year cohort will only be enrolled when the license is extended to this age group, and treatment with Kaftrio will only occur in the context of prescription by a physician in compliance with marketing authorization and the SPC.|t|f|f|f
33943238|NCT04415749|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blind|3 parallel groups defined by dosing position and number of doses|t|f|t|f
33943239|NCT00978705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943240|NCT05500742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33943241|NCT05033106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943242|NCT03181139|||COHORT||RETROSPECTIVE|||||||
33943243|NCT03578211|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33943244|NCT02174406|||CASE_ONLY||PROSPECTIVE|||||||
33943245|NCT05512039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943246|NCT05246735|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a clinical study to evaluate MR-guided near infrared absorption and fluorescence imaging||||
33943247|NCT03191604|||COHORT||PROSPECTIVE|||||||
33943248|NCT02365246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943249|NCT04274972|||COHORT||PROSPECTIVE|||||||
34022204|NCT04468516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"There are two groups (treatment and placebo). Participants will not know which group they are in until the end. Masking will be maintained by the following plan:~1. Researcher assigning participants to treatment and control groups: Dr. Abdullah Mosabbir.~2. Researcher(s)/clinician(s) performing pre-treatment/post-treatment assessments: Dr. Aslam Khan, or a Clinician hired by KKT who is NOT doing #3.~3. Researcher(s)/clinician(s) performing treatments or sham procedure: Dr. Peter Dyback, or a Clinician hired by KKT who is NOT doing #2.~4. Researcher who will assemble these data, code it, and do the data analysis: Dr. Abdullah Mosabbir.~5. Researchers who will supervise the design and ethical conduct of the study as well as data analysis: Dr. Heidi Ahonen and Dr. Quincy Almeida.~6. Researchers whose role is conceptual: Dr.Karim Bayanzay, Dr. Lidan You, and Dr. Lee Bartel."|Parallel double blind randomized controlled trial|t|t|t|t
34022205|NCT05973292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessors and participants were blinded throughout the whole procedure. The dentist practitioner was responsible for all clinical procedures.|All patients received their treatment at the same time. Follow-up periods were parallel for all participants.|t|f|f|t
34022206|NCT04111055|NA|SINGLE_GROUP||TREATMENT||NONE||Single prospective pilot study||||
34022207|NCT03670693|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022208|NCT03413293|||CASE_ONLY||PROSPECTIVE|||||||
34022209|NCT00549289|NA|SINGLE_GROUP||||NONE||||||
34022210|NCT04372472|||COHORT||PROSPECTIVE|||||||
34022211|NCT02049450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022212|NCT02455050|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34022213|NCT01788592|||COHORT||PROSPECTIVE|||||||
34022214|NCT01195792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022215|NCT03795766|||COHORT||PROSPECTIVE|||||||
34022216|NCT00777036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022217|NCT03534843|||COHORT||RETROSPECTIVE|||||||
34022218|NCT03112785|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with bilateral degenerative hip osteoarthritis are operated with a short stem total hip arthroplasty on one side and a conventional stem on the opposite side. Implant selection is randomised on the most symptomatic side, the second side receives the type of stem not used on the first one.||||
34022219|NCT03494335|||COHORT||RETROSPECTIVE|||||||
34022220|NCT04981730|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34022221|NCT03483246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022222|NCT03456583|||CASE_ONLY||PROSPECTIVE|||||||
34022223|NCT01437943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022224|NCT00521534|||CASE_CONTROL||PROSPECTIVE|||||||
34022225|NCT01205386|||CASE_ONLY||PROSPECTIVE|||||||
34022226|NCT03463408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||two cohort, open label, non-randomized study||||
34022227|NCT01234922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022228|NCT06169189|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34022229|NCT05729685|RANDOMIZED|PARALLEL||OTHER||NONE||A parallel group research design was used in the present study. Initially, 26 participants (10 males and 16 females), using stratified randomization (gender was the variable of stratification) were randomly assigned (1:1), according to a random-number table, either to an intense continuous training group (CON) or to a high-intensity interval training group (INT).||||
34022230|NCT01844856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022231|NCT03167723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator masked to outcomes data.||f|f|t|f
34102016|NCT05337137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102017|NCT06539897|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718350|NCT00775151|RANDOMIZED|CROSSOVER||||NONE||||||
33718351|NCT03952000|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33718352|NCT03913793|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718353|NCT05446506|||COHORT||PROSPECTIVE|||||||
34102018|NCT04712227|||CASE_CONTROL||PROSPECTIVE|||||||
34102019|NCT05639647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded observer assigned by each site|Randomized, open-label, parallel study comparing ATM-AVI with or without metronidazole (MTZ) compared to BAT for the treatment of serious gram-negative bacterial infections. For every 3 participants assigned to ATM-AVI therapy one will be assigned to BAT.|f|f|t|f
34102020|NCT04787042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion||||
34102021|NCT06333678|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II randomized trial||||
34102022|NCT01326936|RANDOMIZED|PARALLEL||||NONE||||||
34102023|NCT03976375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102024|NCT02009449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102025|NCT06081439|||COHORT||PROSPECTIVE|||||||
34102026|NCT01467856|||CASE_ONLY||PROSPECTIVE|||||||
34102027|NCT03717844|||COHORT||PROSPECTIVE|||||||
34102028|NCT06691087|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34102029|NCT05594589|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102030|NCT06643598|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34102031|NCT05353829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102032|NCT06695260|NA|SEQUENTIAL||DIAGNOSTIC||NONE||"Part 1:~To assess the normal dynamics of the scapholunate joint in patients without scapholunate instability with CT when the wrist is under loading compared to normal conditions~Part 2:~To assess the dynamic character of the scapholunate joint in patients with scapholunate instability with CT when the wrist is under loading compared to normal conditions"||||
34102033|NCT06690827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102034|NCT00059267|||COHORT||PROSPECTIVE|||||||
34102035|NCT03852615|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective case control study including all women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that are planned to go through laparoscopic surgery||||
34102036|NCT00861705|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34102037|NCT06674616|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34102038|NCT06350630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blind trial randomized|t|t|t|t
34102039|NCT05793125|||OTHER||PROSPECTIVE|||||||
34102040|NCT03326921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102041|NCT06548971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102042|NCT04310774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102043|NCT04480450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102044|NCT05653752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102045|NCT06678503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple ( Participant, Care provider, outcomes Assessor )||t|t|f|t
34102046|NCT05149768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102047|NCT05157893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102048|NCT03748212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102049|NCT00941421|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718354|NCT03612297|||CASE_ONLY||PROSPECTIVE|||||||
33718355|NCT00475891|||COHORT||RETROSPECTIVE|||||||
33718356|NCT04798014|||COHORT||PROSPECTIVE|||||||
33718357|NCT03696511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|data sheet will be blinded for the analyses||f|f|f|t
33718358|NCT00271609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718359|NCT00197730|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718360|NCT01455142|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718361|NCT05688189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The principal investigator and the research nurse will be blinded to block size and number. The person responsible for data analysis will be provided an anonymized dataset, thus rendering him/her blinded to the type of treatment the patients received.||f|f|t|f
33799156|NCT03544736|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, non-randomized, Parallell Groups, Study of Nivolumab and Radiotherapy in Patients With Esophageal Cancer||||
33799157|NCT05210257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799158|NCT01740531|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33799159|NCT03017183|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799160|NCT04306705|||COHORT||RETROSPECTIVE|||||||
34022232|NCT06634108|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1b/2a study to evaluate~1. the safety of escalating doses of genistein~2. the effects on cardiac function and exercise capacity"||||
34022233|NCT00003224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022234|NCT03783039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022235|NCT02189980|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34022236|NCT06633354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022237|NCT03803930|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34022238|NCT02728843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo tablets had the same appearance as the deferiprone tablets, and within each dosing cohort, all participants took the same number of tablets at each dose.||t|t|t|t
34022239|NCT05475886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022240|NCT04709211|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34022241|NCT04120038|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34022242|NCT04047186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022243|NCT03881020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022244|NCT05006768|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34022245|NCT03286010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022246|NCT05029830|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022247|NCT00190190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022248|NCT00840515|||CASE_CONTROL||PROSPECTIVE|||||||
34022249|NCT01650701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022250|NCT04364659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022251|NCT02494180|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34022252|NCT05621408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022253|NCT03017703|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34022254|NCT00152178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022255|NCT03141866|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33718362|NCT03021239|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102050|NCT06167083|||COHORT||RETROSPECTIVE|||||||
33718363|NCT04358666|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomization between surgery and focal radiosurgery of the surgical site and hypofractionned radiosurgery of the tumor|f|f|f|t
33718364|NCT03523754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Primigravida.~* From 20 to 30 years old.~* Singleton term (between 40 to 42 weeks of gestation).~* Good general condition with straightforward enthusiasm for the trial."||||
33718365|NCT00967798|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33718366|NCT05415085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33718367|NCT00877058|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33799161|NCT02793154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799162|NCT00721565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799163|NCT02309034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799164|NCT02102841|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33799165|NCT03489187|||CASE_ONLY||RETROSPECTIVE|||||||
33799166|NCT01620034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022256|NCT00730587|||COHORT||CROSS_SECTIONAL|||||||
34022257|NCT05735340|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022258|NCT00732576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34022259|NCT05802732|||OTHER||CROSS_SECTIONAL|||||||
33799167|NCT02897882|NA|SINGLE_GROUP||OTHER||NONE||||||
33799168|NCT02313363|NA|SINGLE_GROUP||||NONE||||||
33799169|NCT02972944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799170|NCT04891835|||COHORT||RETROSPECTIVE|||||||
33799171|NCT05722431|||COHORT||PROSPECTIVE|||||||
34022260|NCT00537303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022261|NCT06244849|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A case-control study from a prospective bicentric cohort of CD patients. Proof of concept and exploratory study with minimum risks (type 2)||||
34022262|NCT02628743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022263|NCT00429195|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34022264|NCT05782959|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799172|NCT02415140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799173|NCT05377567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33799174|NCT02301559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799175|NCT06555900|||OTHER||OTHER|||||||
33799176|NCT04575077|||CASE_ONLY||PROSPECTIVE|||||||
33799177|NCT00957411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799178|NCT02843217||CROSSOVER||SCREENING||||||||
33799179|NCT00682708||||PREVENTION||||||||
33799180|NCT05346523|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||Cluster-Randomized Cross-Over Trial|t|f|f|t
33799181|NCT06327386|||CASE_ONLY||PROSPECTIVE|||||||
33799182|NCT04011631|NA|SINGLE_GROUP||TREATMENT||NONE|The participants / patients treated in the study are blinded for the sponsor.|Prospective interventional study with medical device.||||
33799183|NCT01611831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799184|NCT02531113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799185|NCT03372473|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Children allocated on different arms will receive montelukast + loratadine vs. montelukast + placebo. Both product are identical in appearence and flavor|Randomized clinical crossover trial, in 80 children who were allocated to receive montelukast + loratadine vs montelukast in two different periods of 4 weeks each, with a 2 weeks of wash-out between periods of treatment|t|t|t|t
33799186|NCT00572286|||COHORT||PROSPECTIVE|||||||
33799187|NCT05421364|NA|SINGLE_GROUP||TREATMENT||NONE||"Both prior to and following PBMC treatment endometrial biopsies will be obtained on day 7 after LH peak.~The endometrial samples will be stained immunohistochemically with antibodies against specific endometrial cell types.The endometrial cell composition and the specific cell types quantities will be evaluated by microscopic observation and flowcytometric analysis.~The cell composition and their quantities will be compared before and after intrauterine administration of PBMC in the endometrial biopsies."||||
33799188|NCT00149045|||DEFINED_POPULATION||OTHER|||||||
33799189|NCT01647438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799190|NCT05762159|||COHORT||PROSPECTIVE|||||||
34102051|NCT06318416|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33799191|NCT02073578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799192|NCT06555679|||COHORT||RETROSPECTIVE|||||||
33799193|NCT02967536|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799194|NCT00176839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799195|NCT01257932|||CASE_ONLY||PROSPECTIVE|||||||
33799196|NCT05362110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799197|NCT02903199|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33799198|NCT05579899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Matching vehicle||t|f|t|t
33799199|NCT02324010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33799200|NCT02652689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799201|NCT01126918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799202|NCT01231802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022265|NCT01119794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022266|NCT03261960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022267|NCT00782574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022268|NCT03131544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022269|NCT04041349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022270|NCT05532371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34022271|NCT03994601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022272|NCT02553083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022273|NCT06389643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022274|NCT05653310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34022275|NCT02191631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022276|NCT01799525|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33799203|NCT04951362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799204|NCT00044057|RANDOMIZED|||TREATMENT||DOUBLE||||||
33799205|NCT02214550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33799206|NCT05104294|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799207|NCT04992364|||CASE_CROSSOVER||PROSPECTIVE|||||||
33799208|NCT04210180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799209|NCT04101968|||COHORT||CROSS_SECTIONAL|||||||
33799210|NCT04773327|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799211|NCT06522880|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33799212|NCT05976295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799213|NCT01456013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799214|NCT03023800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799215|NCT02810184|||COHORT||PROSPECTIVE|||||||
33799216|NCT02167984|||COHORT||RETROSPECTIVE|||||||
33799217|NCT03861364|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 03Prop). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.|Randomized, controlled, double blind.|t|t|t|t
33799218|NCT00994097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799219|NCT04153747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799220|NCT05191316|||OTHER||PROSPECTIVE|||||||
33799221|NCT03561064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799222|NCT06412445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799223|NCT00000675||||TREATMENT||||||||
33799224|NCT00189969|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33799225|NCT02622984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799226|NCT00203216|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799227|NCT04418999|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022277|NCT03173430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022278|NCT01190553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022279|NCT01069276|||CASE_ONLY||PROSPECTIVE|||||||
34102052|NCT04961515|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799228|NCT00773370|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799229|NCT00761189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799230|NCT01061151|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators and outcomes assessor did not receive by-arm tabulations while the study was ongoing.||f|f|t|t
33799231|NCT03983681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be blind as to which treatment group they are being placed. Study staff conducting baseline and follow-up assessments will also be blind as to which group participants are placed. Study staff conducting intervention sessions will be blind to participants' baseline and follow-up assessment performance.||t|t|t|f
33799232|NCT00765271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799233|NCT05640869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799234|NCT03806907|||COHORT||PROSPECTIVE|||||||
33799235|NCT06038799|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parents that receive Caregiver Skills Training will be unaware of whether their group leaders were trained/supervised remotely or face-to-face.|The investigators will be comparing two types of training/supervision models. One will be provided remotely and one will be provided face-to-face. In addition, investigators will compare two types of treatment: face-to-face sessions versus remote sessions.|f|t|f|f
33799236|NCT00609310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33799237|NCT01897870|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33799238|NCT06001190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33799239|NCT02781623|||CASE_CONTROL||PROSPECTIVE|||||||
33799240|NCT03200626|||COHORT||PROSPECTIVE|||||||
33799241|NCT01169454|||CASE_CONTROL||PROSPECTIVE|||||||
33799242|NCT04596215|||CASE_ONLY||PROSPECTIVE|||||||
33799243|NCT00879463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33799244|NCT05140434|||COHORT||OTHER|||||||
33799245|NCT04238429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799246|NCT05125029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799247|NCT06048835|||CASE_CONTROL||PROSPECTIVE|||||||
33799248|NCT00818454||CROSSOVER||TREATMENT||||||||
33799249|NCT00592410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799250|NCT01127373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799251|NCT00012454||||TREATMENT||||||||
33799252|NCT06188377|||CASE_ONLY||CROSS_SECTIONAL|||||||
33799253|NCT04900636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799254|NCT02990949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022280|NCT06633731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022281|NCT02335983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022282|NCT05984979|||OTHER||OTHER|||||||
34022283|NCT04592835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022284|NCT05477095|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022285|NCT06633224|||COHORT||PROSPECTIVE|||||||
34022286|NCT03885479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022287|NCT01206101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022288|NCT01260519|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34022289|NCT03659292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022290|NCT05584592|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022291|NCT00460538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022292|NCT06080256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|investigator-initiated, open-label, blinded endpoint assessment, controlled, randomized pilot trial|Patients meeting the enrollment criteria will be randomly assigned to one of the two treatment groups (1:1) and will be followed up for 6 months.|f|f|t|t
34022293|NCT03156335|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34022294|NCT05755776|||COHORT||PROSPECTIVE|||||||
34022295|NCT01996618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022296|NCT01934335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022297|NCT03680066|NA|SINGLE_GROUP||OTHER||NONE||||||
34022298|NCT04001127|NA|SINGLE_GROUP||TREATMENT||NONE|No masking.|This study is a single group clinical trial. A pragmatic design will be applied for this study as participants will be included consecutively as they are referred to the Center for Cancer and Health Copenhagen for cancer rehabilitation and agrees to participate in the study.||||
34022299|NCT02016703|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34022300|NCT00090363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799255|NCT05033314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33799256|NCT00637936|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33799257|NCT03294499|||OTHER||PROSPECTIVE|||||||
33799258|NCT02759016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799259|NCT06445686|||COHORT||RETROSPECTIVE|||||||
33799260|NCT04630535|||COHORT||PROSPECTIVE|||||||
33799261|NCT00068198|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33799262|NCT04618757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33799263|NCT05075213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799264|NCT01443845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799265|NCT03882502|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33799266|NCT02014142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799267|NCT00731497|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799268|NCT04381273|||COHORT||CROSS_SECTIONAL|||||||
33799269|NCT04153058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799270|NCT02504086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799271|NCT04743310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799272|NCT02186769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799273|NCT03997682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33799274|NCT01542593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799275|NCT02658240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799276|NCT02202772|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799277|NCT03677349|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Comparison of primary and secondary outcomes measures between group 1 (resensitization by neurorrhaphy) and group 2 patients (No resensitization by neurorrhaphy).~Patients randomly included in the groups according to a randomization software (RedCap)"||||
33799278|NCT00861029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799279|NCT04063852|||COHORT||PROSPECTIVE|||||||
33799280|NCT06451471|||OTHER||CROSS_SECTIONAL|||||||
33799281|NCT04421924|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799282|NCT06235294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients, physicians, and embryologists will be blinded to group assignments of the participants in the trial.|Participants will be randomly assigned to groups according to random numbers generated by a computer and implemented via a sealed envelope. The random allocation, enrollment of patients and assignment of intervention will be performed by the principal investigator.|t|t|f|f
33799283|NCT04791592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients randomly will be classified into two groups using opaque sealed envelopes. Randomization will be performed using a computer-generated random number list, and a statement indicating the patient's group is placed in a closed envelope numbered according to the result. Each patient will be asked to choose an envelope, and the patients will be assigned to the study according to the group written in the envelope. An anesthesiologist with expertise in regional anesthesia will perform PIF and TTP block to ensure the block's quality and consistency.|The patients will be randomly classified into two groups.|t|f|t|f
34022301|NCT03533023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022302|NCT05876988|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34022303|NCT01934725|||CASE_CONTROL||PROSPECTIVE|||||||
34022304|NCT00416884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022305|NCT03148561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022306|NCT04973930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be blinded to treatment and therapist. Patients will be alerted not to mention the type of treatment they are receiving or the name of their therapist to independent evaluators.|Pilot randomized 12-week clinical trial of tele-interpersonal psychotherapy vs. tele-serotonin reuptake inhibitor (escitalopram or venlafaxine) for patients with major depressive disorder and breast cancer to test the acceptability of randomization and treatment.|f|f|f|t
34022307|NCT00849758|||CASE_CONTROL||PROSPECTIVE|||||||
34022308|NCT01527812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022309|NCT04559737|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34022310|NCT03516253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind|"This study is a parallel, randomized, double blind, controlled, 3-months supplementation, investigating health effects of dietary intake of fish oil and EPO, in patients with breast cancer undergoing chemotherapy.~At the beginning of the study, all patients received nutritional counseling, where half of the study subjects are randomly assigned to a treatment arm with fish oil and EPO, or control arm with mineral oil as placebo. Treatment arm is provided with 2 gel capsules of fish oil and 3 gel capsules of EPO (400 mg eicosapentaenoic acid, 600 mg docosahexaenoic acid and 351 mg gamma-linolenic acid). Control arm will consume 5 gel capsules of 1g of mineral oil."|t|f|t|t
34022311|NCT05243953|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34022312|NCT01103726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33799284|NCT03710057|||COHORT||PROSPECTIVE|||||||
33799285|NCT02599545|||CASE_ONLY||PROSPECTIVE|||||||
34022313|NCT03283462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34022314|NCT05103566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022315|NCT04949711|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34022316|NCT05311748|||CASE_CROSSOVER||PROSPECTIVE|||||||
34022317|NCT02376543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022318|NCT01296282|||COHORT||PROSPECTIVE|||||||
34022319|NCT03792763|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Placebo controlled, randomized|t|t|t|t
33799286|NCT00405535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799287|NCT01431586|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33799288|NCT01875848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799289|NCT05133375|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33799290|NCT01852071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799291|NCT00098553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799292|NCT01430338|||COHORT||CROSS_SECTIONAL|||||||
33799293|NCT04902378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799294|NCT00060684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799295|NCT01109524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799296|NCT06075394|||COHORT||RETROSPECTIVE|||||||
33799297|NCT03117023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799298|NCT05226793|||CASE_ONLY||RETROSPECTIVE|||||||
33799299|NCT00180258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799300|NCT01024881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799301|NCT04434677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799302|NCT03931265|||CASE_ONLY||PROSPECTIVE|||||||
33799303|NCT04282824|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33799304|NCT06118827|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33799305|NCT03586817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799306|NCT04092231|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799307|NCT03961906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking only for baseline visit.||t|f|t|f
33799308|NCT02390986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799309|NCT00716859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799310|NCT01493778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799311|NCT03960398|||COHORT||RETROSPECTIVE|||||||
33799312|NCT04575740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799313|NCT04593914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799314|NCT01137617|||CASE_ONLY||CROSS_SECTIONAL|||||||
33799315|NCT06147167|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33799316|NCT03348917|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Single|Twelve healthy volunteers will be randomized into three arms with three different treatment sequences with four healthy volunteers in each arm. Up to fifteen healthy volunteers may be recruited with the consideration that up to three subjects may drop out.|f|f|f|t
33799317|NCT04600752|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study.|This is a single arm, multicenter, non-comparative study.||||
33799318|NCT01376089|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33799319|NCT00477568|||OTHER||CROSS_SECTIONAL|||||||
33799320|NCT04597658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799321|NCT05198531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799322|NCT05420090|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ınvestigator|1. Experimental: Banana arm Experimental: Milk arm Control arm|f|f|t|f
33799323|NCT02878772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102053|NCT00253955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799324|NCT00666445|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799325|NCT03231722|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|||||
33799326|NCT06075069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799327|NCT01871675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799328|NCT04688866|||CASE_CONTROL||RETROSPECTIVE|||||||
33799329|NCT00103324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799330|NCT04065334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799331|NCT05263336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33799332|NCT04574349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799333|NCT05195775|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pre/post single dose tadalafil||||
33799334|NCT04178226|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"1. Control group~2. Acupuncture group~3. Laser acupuncture group Patients in acupuncture/ laser acupuncture group will be crossover to another group after 3 courses of treatment."||||
33799335|NCT04581733|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 3b study. All participants will receive MT1621 up to a target dose of 400 mg/kg/day||||
33799336|NCT04295993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799337|NCT06497855|||COHORT||PROSPECTIVE|||||||
33799338|NCT05074069|||COHORT||RETROSPECTIVE|||||||
34022320|NCT01143428|||||OTHER|||||||
34022321|NCT03839030|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34022322|NCT04955028|||CASE_CONTROL||RETROSPECTIVE|||||||
34022323|NCT05039138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102054|NCT04355689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-masked|NPI-001 Tablets versus Placebo|t|t|t|t
34102055|NCT06694740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799339|NCT02725086|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799340|NCT05989542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799341|NCT05425992|||COHORT||PROSPECTIVE|||||||
33799342|NCT00432718|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33799343|NCT03014947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33799344|NCT05328271|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Supplements blinded to participant and investigator by third party|Randomized, double-blind, placebo-controlled, crossover design|t|f|t|f
33799345|NCT01865149|||CASE_ONLY||RETROSPECTIVE|||||||
33799346|NCT03573518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022324|NCT05894967|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34022325|NCT02627248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799347|NCT01028118|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799348|NCT00226018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799349|NCT01032798|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33799350|NCT01608347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799351|NCT06518668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799352|NCT05107024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799353|NCT00566124|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33799354|NCT04508348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physician Investigator will be blinded|A randomized, blinded, controlled trial|f|f|t|f
33799355|NCT03926936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799356|NCT05344924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in cohort I will receive TACE combined with penpulimab and anlotinib (TACE-A-A Cohort), and patients in cohort II will just receive penpulimab and anlotinib (A-A Cohort).||||
33799357|NCT00067353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33799358|NCT06502275|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799359|NCT06103149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799360|NCT03164408|||COHORT||RETROSPECTIVE|||||||
33799361|NCT05382104|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022326|NCT00396838|||||PROSPECTIVE|||||||
34022327|NCT04443348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102056|NCT06517329|||CASE_ONLY||CROSS_SECTIONAL|||||||
33799362|NCT01407198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799363|NCT06145867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799364|NCT03592069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799365|NCT00151567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799366|NCT03303651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are not informed about the group assignement (intervention takes place in general anesthesia). Outcome assessors are persons without knowledge on former treatment in intervention/control group.|Participants are assigned to intervention groups by chance|t|f|f|t
33799367|NCT04436614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Single (Participant)|t|f|f|f
33799368|NCT05632471|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blind randomized controlled experimental study||t|f|f|f
33799369|NCT05049434|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Evaluator-blinded||t|f|f|t
33799370|NCT03532906|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33799371|NCT00970658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799372|NCT01182571|||CASE_ONLY||CROSS_SECTIONAL|||||||
33799373|NCT05447507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799374|NCT00477308|NA|SINGLE_GROUP||TREATMENT||NONE||salvage therapy||||
33799375|NCT00262301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799376|NCT01479647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33799377|NCT05454228|||COHORT||PROSPECTIVE|||||||
33799378|NCT01551355|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33799379|NCT05266066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized 1:1 to Clinical observation without antibiotic therapy for VAT vs. 7 day antibiotic course.|f|f|f|t
33799380|NCT01544855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799381|NCT02271854|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33799382|NCT02725294|||COHORT||PROSPECTIVE|||||||
33799383|NCT00919594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799384|NCT02273986|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33799385|NCT03714815|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects who remained in main study (SERENADE/AC-055G202, NCT03153111) after randomization and who meet the eligibility criteria described will be eligible to enter this single-arm OL extension study. All enrolled subjects will receive macitentan 10 mg. For this OL extension study no primary efficacy endpoint has been defined and all efficacy endpoints are of exploratory nature. The ones listed below are considered safety endpoints.||||
33799386|NCT00609336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799387|NCT01912131|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799388|NCT04141150|NA|SINGLE_GROUP||OTHER||NONE||||||
33799389|NCT01234363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799390|NCT05728060|||CASE_CONTROL||OTHER|||||||
33799391|NCT02727296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799392|NCT01381471|||COHORT||RETROSPECTIVE|||||||
33799393|NCT06081049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799394|NCT02847689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33799395|NCT01434862|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799396|NCT04526834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799397|NCT00224510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33799398|NCT05051449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799399|NCT02120430|RANDOMIZED|PARALLEL||||NONE||||||
33799400|NCT06397144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33799401|NCT02904642|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33799402|NCT06311617|||COHORT||PROSPECTIVE|||||||
33799403|NCT01537419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799404|NCT03532243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799405|NCT04413812|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized single-centre open-label clinical trial with two parallel groups. The randomization will be stratified according to age, sex, current BMI, surgical procedure, and educational level using a dedicated software.||||
33799406|NCT03886402|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, non-randomized, non-blinded, interventional, consecutive series, single site study||||
33799407|NCT03791008|NA|SINGLE_GROUP||SCREENING||NONE||||||
33799408|NCT05967429|||CASE_ONLY||PROSPECTIVE|||||||
33799409|NCT02070666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799410|NCT00825630|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799411|NCT04775992|||OTHER||RETROSPECTIVE|||||||
33799412|NCT06152939|||COHORT||PROSPECTIVE|||||||
33799413|NCT00538122|||||PROSPECTIVE|||||||
33799414|NCT02436213|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33799415|NCT02650544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799416|NCT05048914|||COHORT||PROSPECTIVE|||||||
33799417|NCT03201861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799418|NCT00468806|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102057|NCT04740879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799419|NCT00175292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33799420|NCT01153880|||||RETROSPECTIVE|||||||
33799421|NCT02706717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33799422|NCT05731999|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomized to one out of four arms, i.e., single application of either phenethylamines, benzodiazepines, cannabinoids, or opioids. The investigation aims to enroll 11 subjects, i.e., healthy volunteers, per medicinal product group that have completed the clinical investigation until the telephone follow-up call. For four medicinal products, the total will be 44 subjects. In order to take account for a drop-out rate of 10%, 12 subjects will be included per medicinal product group and in total 48 subjects in the clinical investigation. As this is an early feasibility and explorative investigation, the sample size is not derived from a sample size calculation as no hypothesis is pre-defined.||||
33943250|NCT03942991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943251|NCT05302999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33943252|NCT03656315|NA|SINGLE_GROUP||SCREENING||NONE||All recruited participants will be included in the study||||
33943253|NCT05994105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022328|NCT05445674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind, placebo-controlled study. Masking of investigational products will ensure that both the investigator and the participant are blinded to the type of exchange procedure. Patients will be unable to distinguish true from sham procedures at the end of the study. Each procedure will take approximately 2 hours to complete. In the sham procedure, the patients will also underwear 6 procedures lasting approximately 2 hours each. Blinding will be maintained throughout the study until after 3-month follow-up assessment of the last patient exchanged|Prospective, randomized (1:1), double-blind, placebo-controlled study|t|f|t|f
34022329|NCT04570462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022330|NCT00879957|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34022331|NCT04731753|||CASE_ONLY||PROSPECTIVE|||||||
34022332|NCT00708773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022333|NCT03903809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022334|NCT02354209|||COHORT||OTHER|||||||
34022335|NCT03590912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022336|NCT02930967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022337|NCT05843019|||COHORT||CROSS_SECTIONAL|||||||
34022338|NCT01531829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022339|NCT05519319|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessor are unaware about the results|Three parallel groups|f|f|f|t
33799423|NCT02466516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799424|NCT06515301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799425|NCT05925140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799426|NCT03618524|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799427|NCT01075113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799428|NCT03950622|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33799429|NCT00173459|||CASE_CONTROL||RETROSPECTIVE|||||||
33799430|NCT00025324||||TREATMENT||NONE||||||
33799431|NCT01247831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799432|NCT03150303|||COHORT||PROSPECTIVE|||||||
33799433|NCT03562884|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33799434|NCT05209581|||COHORT||PROSPECTIVE|||||||
33799435|NCT05631405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799436|NCT01897272|||COHORT||PROSPECTIVE|||||||
33799437|NCT00171184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799438|NCT00646035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799439|NCT01723631|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799440|NCT03000842|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33799441|NCT01855334|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33799442|NCT06553053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799443|NCT06242782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799444|NCT03109223|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double blind|Double-blind randomized|t|t|t|t
33799445|NCT03125863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799446|NCT01691690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799447|NCT04921293|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33799448|NCT03348371|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33799449|NCT03230942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All patients will be assessed for functional outcomes by a rater blinded to the study arm||t|f|t|t
33799450|NCT05669170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799451|NCT04459897|||COHORT||RETROSPECTIVE|||||||
33799452|NCT01941758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799453|NCT02976532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799454|NCT02143739|||OTHER||PROSPECTIVE|||||||
33799455|NCT03366636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799456|NCT04167020|||COHORT||PROSPECTIVE|||||||
33799457|NCT00757133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799458|NCT03832894|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Randomization will be held by using the computer generated randomization codes, which will then be placed in the sealed envelopes by a third party (nurse).~Each patient will choose a sealed envelope containing randomization number either group A or B. Both participant and health provider will be blinded to patients grouping"||t|f|t|f
33799459|NCT01885793|||CASE_ONLY||PROSPECTIVE|||||||
33799460|NCT01070069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799461|NCT04442815|||CASE_ONLY||PROSPECTIVE|||||||
33799462|NCT01154985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799463|NCT02668250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799464|NCT05961020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943254|NCT02600195|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33943255|NCT01632345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943256|NCT00795717|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33943257|NCT03395613|RANDOMIZED|PARALLEL||PREVENTION||NONE||Preoperative randomization||||
33943258|NCT05939336|NA|SINGLE_GROUP||OTHER||NONE||||||
33943259|NCT02915133|||CASE_ONLY||PROSPECTIVE|||||||
33943260|NCT00027846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943261|NCT06482905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"a 3+3 design is used to determine Maximum Tolerated Dose (MTD) and the recommended phase 2 dose (RP2D)"||||
33943262|NCT00958399|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33943263|NCT05078268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943264|NCT04887012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943265|NCT04647929|RANDOMIZED|PARALLEL||TREATMENT||NONE||Te patients will be randomly assigned in a 1:1 ratio to either (1) Santen PRESERFLO implant (intervention arm) or (2) trabeculectomy (standard therapy) .||||
33799465|NCT05105126|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study investigators will utilize the generated randomization schedule to provide active tDCS and sham stimulation codes that will be entered into the tDCS device (by the caregiver) prior to each session. These numeric codes will be random numbers and not distinct to the study group assignment, protecting the blind. One of the study investigators who will program the tDCS device will remain unblinded and will not be involved in any treatment outcome assessments. All other study staff, including the PI and the co-PIs remain blind. Parents, participants, and ABA providers will also remain blind.|"The study will use a randomized double-blind controlled placebo (sham vs. active tDCS) crossover design. The study will involve 5 total months of participation. Participants will be randomized into one of the two groups:~Group A) 20 active tDCS stimulation followed by 20 sham stimulation; or~Group B) 20 sham stimulation followed by 20 active tDCS stimulation"|t|t|t|t
33799466|NCT01579916|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33799467|NCT00879060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799468|NCT00120367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799469|NCT06232577|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33799470|NCT05724420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Sequence generation: computer-generated randomization in REDCAP program to two groups for each resident year cohort; STRIVE program and control group.~Blinding: Post-interventional analysis will be performed by a dedicated team member blinded to the intervention assignment who will not participate in course delivery."|This is a randomized controlled trial with a 1:1 allocation ratio between intervention (STRIVE course) and control groups.|t|f|f|t
33799471|NCT04454151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799472|NCT00853918|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799473|NCT00364117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799474|NCT05035303|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double- blinded||t|t|f|t
33799475|NCT01698125|||COHORT||PROSPECTIVE|||||||
33799476|NCT01753284|||CASE_ONLY||RETROSPECTIVE|||||||
33799477|NCT03273777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799478|NCT03661957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799479|NCT01714960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799480|NCT00411216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799481|NCT03260140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators will randomly assign participants to one of two groups.|f|f|f|t
33799482|NCT05445440|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799483|NCT02722473|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34022340|NCT02623283|||COHORT||PROSPECTIVE|||||||
34022341|NCT03415061|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33799484|NCT01339130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799485|NCT00525486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799486|NCT04250935|||OTHER||PROSPECTIVE|||||||
33943266|NCT01522963|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33943267|NCT05722418|NA|SEQUENTIAL||TREATMENT||NONE||||||
33943268|NCT04776668|||COHORT||CROSS_SECTIONAL|||||||
33943269|NCT03268603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943270|NCT04873323|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33943271|NCT01813136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943272|NCT05381740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be told they will receive brain stimulation, but will be given no indication as to whether they will receive real or sham stimulation. Investigators analyzing functional outcome data, neurophysiology data and MRI data will receive coded data that conceals the identity of the subject. Therapists involved in training patients will not know which type of rTMS the participant receives.|In a prospective randomized controlled trial, an anticipated 18 stroke survivors with chronic (≥6 months) upper limb impairment will receive real or sham stimulation to the non-stroke hemisphere (cHMC). Stimulation will be delivered in conjunction with upper limb rehabilitation for 2 days a week for 6 weeks.|t|f|t|t
33943273|NCT02409576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943274|NCT02215486|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33943275|NCT03871803|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The examination tests will be performed by two blinded cardiologist to patients' allocation group|This is a prospective, crossover, randomized (1:1) and single center study. After randomization, clinical and cardiac rhythm will be continuously registered during 30 days. The primary endpoint (peakVO2) will be assessed by CPET at 15 and 30-day in both groups. Patients with HFpEF, functional class NYHA II-III, chronic treatment with betablockers, and chronotropic incompetence will be enrolled. A sample size estimation \[alfa: 0.05, power: 90%, a 15% loss rate, and delta change of mean peakVO2: +1.2 mL/kg/min (SD±2.5)\] of 52 patients would be necessary to test our hypothesis.|f|f|t|f
33943276|NCT00963742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943277|NCT02529358|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33943278|NCT00155077|||DEFINED_POPULATION||PROSPECTIVE|||||||
33943279|NCT01320774|||COHORT||PROSPECTIVE|||||||
33943280|NCT04307264|||COHORT||PROSPECTIVE|||||||
33943281|NCT04613804|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-center, single-arm Phase II study. Qualified subjects will be treated with toripalimab every three weeks as a treatment cycle. After every two cycles, they will be evaluated the efficacy of tumor treatment by imaging and the safety of treatment.||||
33943282|NCT01317368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943283|NCT06016166|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33943284|NCT00211536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943285|NCT01133808|||COHORT||PROSPECTIVE|||||||
33943286|NCT02184520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718368|NCT05789979|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The trial is a single group pre-post test study at HOH Nursing Home (NH), Sister Annie Skau Holistic Care Centre (SASHCC), and Care \& Attention Home for Severely Disabled (CASD). During the 4-week trial, one floor in SASHCC and one floor in NH will utilize the resident-handling device for residents with high dependency (i.e., lower-limb cannot bear weight). CASD and another floor in NH will use the resident-handling device for residents with low dependency (i.e. lower-limb can bear weight). Outcome indicators are examined during the 1-week pre-test the 4-week trial. Additionally, opinions and comments from care staff and residents regarding the new resident-handling devices will be collected at the end of the trial.||||
33718369|NCT00341835|||FAMILY_BASED||OTHER|||||||
33718370|NCT01503268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718371|NCT04239820|||COHORT||PROSPECTIVE|||||||
33718372|NCT03467841|||COHORT||PROSPECTIVE|||||||
33718373|NCT02360956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718374|NCT03896776|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799487|NCT01546753|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Subjects will be randomized in a 2:1 ratio to either active treatment (final dose 1500mg walnut protein (WP), n=20) or placebo (n=10). Subjects will do a 1-day desensitization to enable subjects to tolerate 6 mg of WP or placebo (initial day escalation). After the initial escalation day obtaining at least 1.5mg and up to 6mg of WP or placebo, dosing build-up will be every 2 wks thru dose 24 (34 wks). A maintenance dose will be given for 4 wks, then a 5g protein OFC to walnut \& a 5g protein OFC to a 2nd tree nut (\~38 wks), then the study will be unblinded. Placebo subjects that fail the OFC will cross-over to active treatment and escalate to 1500mg target dose. Subjects will be followed for 298 wks (\~6 yrs) total on active treatment including an OFC (both on \& off therapy) to walnut and 2nd tree nut at 142 wk \& end of study. Subjects with reduced serum specific IgE to \<5kU/L to walnut and 2nd tree nut at yearly visits before the end of study at 298 wks are eligible for a tolerance OFC.|t|t|t|t
33799488|NCT03656406|||COHORT||PROSPECTIVE|||||||
33799489|NCT03427346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799490|NCT00595413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799491|NCT04689685|||OTHER||PROSPECTIVE|||||||
33799492|NCT04207294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33799493|NCT04964908|||COHORT||RETROSPECTIVE|||||||
33799494|NCT01039948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799495|NCT04263519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799496|NCT02359188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33799497|NCT01708798|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33799498|NCT00099086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799499|NCT03429972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799500|NCT03240978|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33799501|NCT02971943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799502|NCT05434273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34022342|NCT00154271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022343|NCT05792696|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34022344|NCT00370812|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022345|NCT04049110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized, placebo-controlled, open-label, crossover||||
34022346|NCT04136457|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34022347|NCT06287749|||COHORT||PROSPECTIVE|||||||
34022348|NCT01712750|||COHORT||PROSPECTIVE|||||||
34022349|NCT00003324||||TREATMENT||||||||
34022350|NCT00723723|||COHORT||PROSPECTIVE|||||||
34022351|NCT01912027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022352|NCT01463215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022353|NCT04380766|||CASE_CONTROL||PROSPECTIVE|||||||
34022354|NCT00556400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022355|NCT02393248|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34022356|NCT03499886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022357|NCT04066595|NA|SINGLE_GROUP||TREATMENT||NONE||2 cohorts. Cohort 1 will consist of patients who have been pre-treated with checkpoint inhibitors only (2nd line setting for cabozantinib). Cohort 2 will consist of patients who have been pre-treated with cisplatin-based chemotherapy and checkpoint inhibitors (3rd line setting for cabozantinib).||||
34022358|NCT02087995|NA|SINGLE_GROUP||OTHER||NONE||||||
34022359|NCT04342468|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022360|NCT01081834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022361|NCT00437840|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34022362|NCT04597632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022363|NCT04105127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022364|NCT00256438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34022365|NCT01709253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022366|NCT01212588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022367|NCT02435095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022368|NCT02319694|||OTHER||OTHER|||||||
34022369|NCT03055650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022370|NCT06082895|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Two groups, intervention and control groups, will be created by randomization method for pregnant women who have fear of birth and are determined to have low birth self-efficacy. Pregnant women in the intervention group will be given a 4-session motivational interview program. The control group will continue routine monitoring. After the training, birth self-efficacy levels will be compared between the two groups.|t|f|f|f
33718375|NCT02529514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799503|NCT06070337|NA|SINGLE_GROUP||PREVENTION||NONE||This is a prospective, open label, pilot study of H-Guard® administered as a priming solution to both the blood tubing sets and dialyser of patients who are undergoing haemodialysis.||||
33799504|NCT03663036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799505|NCT01366677|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33799506|NCT00242359|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799507|NCT01638026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799508|NCT02336386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799509|NCT02722551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799510|NCT04586309|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to the TM training (group 1), or delayed TM training (group 2). Study outcomes will be assessed at baseline and at 1 and 3 months post-training. Participants who are assigned to group 2 , will receive the TM training following the three month assessment, and then complete assessments at 1 and 3 months post-training.||||
33799511|NCT06217692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33799512|NCT01674699|||COHORT||PROSPECTIVE|||||||
33799513|NCT00779870|||COHORT||CROSS_SECTIONAL|||||||
33799514|NCT03610308|||COHORT||PROSPECTIVE|||||||
33799515|NCT01411592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799516|NCT00016341|RANDOMIZED|||TREATMENT||||||||
33799517|NCT04574986|||CASE_ONLY||RETROSPECTIVE|||||||
33799518|NCT01877343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799519|NCT04821219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943287|NCT03341091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|An independent assessor who was blinded to group allocation assessed the participants' motor performance variables.|"A two-arm parallel (single-blinded) cluster randomised controlled trial involves two groups of participants (Tai-chi and the control group). Four community health centers that provide dementia care services were recruited through convenience sampling and each was viewed as one cluster and was randomised to either the Tai-chi or the control group, based on computer-generated random numbers. So during the trial, participants in one group receive Tai-chi group programme in parallel to participants in the other group, who took part in group recreational activities and continue their usual lifestyles and levels of physical activity."|f|f|f|t
33943288|NCT01735552|||CASE_ONLY||PROSPECTIVE|||||||
33943289|NCT00824759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943290|NCT01682694|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33943291|NCT03198585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943292|NCT06221722|||COHORT||PROSPECTIVE|||||||
33943293|NCT05331144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33943294|NCT01465984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943295|NCT00224952|||CASE_ONLY||PROSPECTIVE|||||||
33943296|NCT06152367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943297|NCT06167031|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33943298|NCT02013999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34022371|NCT02877459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022372|NCT00695812|||COHORT||PROSPECTIVE|||||||
33718376|NCT01800864|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718377|NCT03670550|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Investigators and participants cannot be blinded as to whether or not the brace is worn.|Evaluation of knee stability with brace wear. Control is same subject without the brace.||||
33718378|NCT02769247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718379|NCT03808051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718380|NCT02867033|NA|SINGLE_GROUP||OTHER||NONE||||||
33718381|NCT04658095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718382|NCT06377254|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Those undertaking analysis of biological samples and MRI data will be masked as to the group the participant is allocated to.|Non-randomised, parallel design lifestyle intervention|f|f|f|t
33718383|NCT05630612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigators will be blinded as will the participants.|Randomised, double blind, active control, parallel group study|t|t|t|t
33718384|NCT04931355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718385|NCT04225728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718386|NCT02985307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33718387|NCT03080779|||COHORT||PROSPECTIVE|||||||
33718388|NCT04759703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718389|NCT05666258|||OTHER||PROSPECTIVE|||||||
33718390|NCT04763915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718391|NCT02658357|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718392|NCT03884218|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33718393|NCT02063412|||OTHER||CROSS_SECTIONAL|||||||
33718394|NCT03876912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718395|NCT02747901|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33718396|NCT02902965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718397|NCT01994460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718398|NCT01214954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718399|NCT02248389|NA|SINGLE_GROUP||OTHER||NONE||||||
33718400|NCT04519125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Participant will not be informed that is either receiving or not the product of intervention, additionally, placebo will have a similar taste of the product of intervention and packaging will be the same for both.~Investigators will be masked because there is a central randomization and only the pharmacist of the study will now in which arm is assigned the participant Data analysis will be performed with an encrypted dataset which doesn't reveal which one is the intervention or which one is placebo"|Randomized triple masked multicentric controlled trial to evaluate the effectiveness and safety of Tenofovir/Emtricitabine in addition to personal protective equipment in comparison to the use of personal protective equipment alone for the prevention of infection with severe acute respiratory syndrome coronavirus 2 / COVID-19 in health care personnel in Colombia.|t|t|t|f
33718401|NCT06363968|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33718402|NCT04926909|||COHORT||CROSS_SECTIONAL|||||||
33718403|NCT00795756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718404|NCT00940394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33718405|NCT01157936|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33718406|NCT00807157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33718407|NCT02449460|||COHORT||CROSS_SECTIONAL|||||||
33718408|NCT01364207|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33718409|NCT05439512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718410|NCT05567289|||COHORT||PROSPECTIVE|||||||
33718411|NCT06061653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943299|NCT03161184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants assigned to one of two groups in parallel for the duration of the study||||
34022373|NCT04283201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||30 persons from this category were additionally advised to consume insoluble dietary fiber 15 g per day (Vitacel wheat fiber) for 3 months, after which a repeat anthropometric and biochemical study.|t|f|f|f
34022374|NCT03816852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022375|NCT03151811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022376|NCT03751618|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Prospective, monocentric, randomized, double blind study|t|f|t|f
34022377|NCT04500418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"A monocentric, randomized, double-blind, placebo-controlled trial.~Randomization will be stratified by:~* Presence of baseline score of 3 on 7-point ordinal scale versus presence of baseline score of 4 or 5 on seven-point ordinal scale~* Presence of one or more of the following comorbidities: Diabetes mellitus, Obesity (BMI \>30kg/m2), COPD or Asthma, Heart failure (NYHA Class I or II)"|t|t|t|f
34022378|NCT00072592||||TREATMENT||||||||
34022379|NCT03454178|||OTHER||PROSPECTIVE|||||||
34022380|NCT02407886|||COHORT||PROSPECTIVE|||||||
34022381|NCT06116084|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34022382|NCT00300508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022383|NCT02967796|||CASE_CONTROL||PROSPECTIVE|||||||
34022384|NCT04732026|||CASE_CONTROL||PROSPECTIVE|||||||
33718412|NCT04279951|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33718413|NCT05982275|NA|SEQUENTIAL||TREATMENT||NONE||||||
34022385|NCT00554606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022386|NCT01333371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022387|NCT06071169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022388|NCT05194137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The researcher responsible for assessment and inclusion of participants in the study will be blinded to which group participants will be allocated to. The research assistant who is responsible for generate the list of randomized numbers and seal the envelope as well as the research assistant responsible to perform patients' allocation will not be involved in the recruitment, assessment of participants or interventions.~Blinding of participants, and treatment providers: not possible Blinding of outcome measurement: Primary outcome - blinded assessment by a physiotherapist not involved in delivery of therapy or with knowledge of group allocation. All other outcomes - not blinded because they are patient-reported."|The randomization of the participants will be done using a computer-generated list of numbers (www.randomization.com). This list will be put in a sealed envelope and participants allocation will be concealed.|f|f|f|t
34022389|NCT06013839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022390|NCT04142957|||COHORT||OTHER|||||||
33718414|NCT01907204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718415|NCT00004663|||||OTHER|||||||
33943300|NCT05281146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Theoretically, fortified biscuits based on chickpea flour and crushed peanuts in addition to wheat germ, and Cinnamon help in enhancing immunity, fighting viruses, maintaining regular and healthy bowel movement, regulating blood sugar and cholesterol levels, and more importantly improving cognitive abilities of school aged children. It is important to practically evaluate the effectiveness of the fortified biscuits intake for 4 months in terms of its acceptability and impact on cognitive performance for a sample of children aged 8-12 years attending rural primary schools in an Egyptian village. Eighty Children were randomly allocated in either chickpea and peanuts biscuits dependent group (40 children) or the non-dependent group (40 children).||||
33943301|NCT00977366|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33943302|NCT03765554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33943303|NCT05152836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943304|NCT01979692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943305|NCT05403775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943306|NCT05943548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Masking is not possible due to the cluster randomized trial design|A parallel arm cluster randomized trial will be used to compare the effectiveness of the intervention to the control.||||
33943307|NCT03061617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33943308|NCT00561028|||CASE_CONTROL||PROSPECTIVE|||||||
33943309|NCT04067076|||COHORT||CROSS_SECTIONAL|||||||
33943310|NCT02508012|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33943311|NCT00103831||||TREATMENT||||||||
33943312|NCT01654224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33943313|NCT00768365|||||PROSPECTIVE|||||||
33943314|NCT05505487|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study is a quasi-experimental study; no equal control design||||
33943315|NCT03815201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34022391|NCT00859586|NA|SINGLE_GROUP||TREATMENT||NONE||The CliniMACS CD34 Reagent System is a medical device used in vitro to select and enrich specific cell populations (CD34+ cells from heterogeneous hematological cell populations). In stage 1, subjects will receive 1 x 108 CD3 cells/kg on day 0. We will progress to stage 2 where the dose of CD3+ cells will be increased to 2 x 108 cells/kg.||||
34022392|NCT03223792|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34022393|NCT01868893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022394|NCT05727072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34022395|NCT00151138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34022396|NCT03570671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022397|NCT03967535|||CASE_CONTROL||PROSPECTIVE|||||||
34022398|NCT04473755|||CASE_CONTROL||PROSPECTIVE|||||||
34022399|NCT00005727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022400|NCT03506906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022401|NCT05942807|||COHORT||PROSPECTIVE|||||||
34022402|NCT03778398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022403|NCT05436262|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34022404|NCT06195319|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34022405|NCT00593047|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34022406|NCT04697836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||the new indication for cervical plexus block.|t|f|f|f
34022407|NCT02895607|||COHORT||PROSPECTIVE|||||||
34022408|NCT01584557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022409|NCT00390559|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33943316|NCT01724021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943317|NCT01763099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943318|NCT03379324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible patients will be randomized to FlōGraft®-augmented repair versus repair alone. Surgeons cannot be blinded to treatment; however, follow-up MRIs will be assessed by blinded radiologists.|This will be a stratified, randomized, radiograph and patient blinded, prospective trial enrolling 260 subjects undergoing rotator cuff repair|t|f|f|t
33943319|NCT02769689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943320|NCT06010264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized||||
33943321|NCT04043676|NA|SINGLE_GROUP||TREATMENT||NONE|This is a single-arm, open label study designed to determine the rate of successful treatment free remission (TFR) in patients who achieved and maintained molecular response 4 (MR4) on ponatinib. This study has 2 main phases: ponatinib consolidation (48 weeks), and ponatinib TFR phases (96 weeks). All patients who have received a minimum of 4 years of imatinib therapy as unique TKI therapy, he/she has documented MR4 at least 12 months for study entry, and he/she shall continue with MR4 before the discontinuation of the ponatinib treatment.|40 patients of both genders with chronic myeloid leukemia in MR4. Each patient will enter in the ponatinib consolidation phase (48 weeks) and them in the ponatinib treatment-free remission (96 weeks).||||
33943322|NCT01397409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943323|NCT05879848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943324|NCT05240573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33943325|NCT01389310|||COHORT||PROSPECTIVE|||||||
33943326|NCT04568382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33943327|NCT02151045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943328|NCT01790451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943329|NCT00580827|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33943330|NCT02412241|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33943331|NCT03732040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33943332|NCT01192581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943333|NCT03730987|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943334|NCT04694820|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33943335|NCT05262842|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33718416|NCT01096121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943336|NCT01273207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718417|NCT04905446|NA|SINGLE_GROUP||OTHER||NONE||||||
33718418|NCT00649623|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33718419|NCT04993989|||OTHER||PROSPECTIVE|||||||
33718420|NCT06242249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718421|NCT05631886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718422|NCT05429190|||COHORT||PROSPECTIVE|||||||
33718423|NCT00745147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34022410|NCT00085475||||TREATMENT||NONE||||||
34022411|NCT02744118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34022412|NCT04732624|RANDOMIZED|PARALLEL||TREATMENT||NONE||Feasibility study of randomized trial of enteral-based resuscitation (intervention arm) vs. IV fluid resuscitation (standard-of-care arm) for moderate sized burn injuries.||||
34022413|NCT06396065|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022414|NCT05250648|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Recruitment will be carried out at the outpatient clinic, once the indication of CRS ± HIPEC (CC-PM of apparently limited volume without metastasis at other sites) has been established after presenting the case in the Multidisciplinary Tumour Board. Eligible patients need to meet the presurgical inclusion criteria (even though some criteria have to be confirmed during surgery for randomization), and sign the informed consent.~Randomization occurs intraoperatively, once the extension of peritoneal disease is found to be truly limited (PCI ≤ 20) after complete surgical exploration, and only after radical surgery (CCS 0) has been possible. At this time, patients are randomized to receive HIPEC with MMC for 90 minutes (Arm 1), or no HIPEC and therefore surgery is finished (Arm 2)."||||
34022415|NCT04810286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022416|NCT03777423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022417|NCT03045991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022418|NCT00946686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022419|NCT02906761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022420|NCT01902368|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33718424|NCT01338493|||CASE_ONLY||PROSPECTIVE|||||||
33718425|NCT06251778|||COHORT||PROSPECTIVE|||||||
33718426|NCT05473338|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718427|NCT05924750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718428|NCT02326753|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33718429|NCT05164224|||COHORT||CROSS_SECTIONAL|||||||
33718430|NCT01256554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718431|NCT05928377|||CASE_CROSSOVER||PROSPECTIVE|||||||
33718432|NCT02187601|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718433|NCT04379089|||COHORT||PROSPECTIVE|||||||
33718434|NCT05688046|||COHORT||RETROSPECTIVE|||||||
33718435|NCT06494683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718436|NCT03857243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33718437|NCT04971473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718438|NCT04517253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718439|NCT01179945|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33718440|NCT00895323||||DIAGNOSTIC||NONE||||||
33718441|NCT02633033|||CASE_ONLY||PROSPECTIVE|||||||
33718442|NCT03218553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718443|NCT02066233|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718444|NCT01026792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718445|NCT00708162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33718446|NCT03184415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718447|NCT02785354|||COHORT||RETROSPECTIVE|||||||
33718448|NCT00394628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799520|NCT03569982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Patients will be referred by the surgeon to MOHS surgery without knowing if integrative care will be provided at the surgery day. Allocation of integrative care to specific surgery days will be determined by a 1:1 randomization.|Prospective randomized controlled|t|t|f|t
33799521|NCT01409252|||CASE_ONLY||RETROSPECTIVE|||||||
33799522|NCT01860612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799523|NCT04159493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a prospective, multicenter, randomized, double-blind, placebo-controlled, dose de-escalation study whose purpose is to establish the lowest efficacious dose of Ovestin|t|t|t|f
33718449|NCT04242615|||COHORT||OTHER|||||||
33718450|NCT03349749|||CASE_ONLY||CROSS_SECTIONAL|||||||
33718451|NCT03589950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022421|NCT00973609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022422|NCT03957252|||COHORT||PROSPECTIVE|||||||
34022423|NCT05795556|||COHORT||CROSS_SECTIONAL|||||||
33718452|NCT02070692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799524|NCT05639777|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33799525|NCT06522711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After the participants meet all the inclusion criteria and meet no exclusion criteria, patients will then be randomized by an unbiased algorithm in a 1 for 1 ratio (one control patient for each patient in the virtual reality group). However, the chosen scenario in the virtual reality group will be a result of each patient's personal preference; the patients will also be able to switch between scenarios at will.||||
33799526|NCT05875714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799527|NCT05993507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799528|NCT06162858|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33799529|NCT02764944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799530|NCT00495885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799531|NCT06498544|||COHORT||PROSPECTIVE|||||||
33799532|NCT02467946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022424|NCT04441710|||COHORT||PROSPECTIVE|||||||
34022425|NCT06633250|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34022426|NCT03521180|||COHORT||PROSPECTIVE|||||||
34022427|NCT02564146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022428|NCT05915975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022429|NCT00328016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799533|NCT01739907|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33799534|NCT03427216|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33799535|NCT04917224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799536|NCT02886286|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33799537|NCT04805996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799538|NCT00739739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799539|NCT02414412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33799540|NCT01041612|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33799541|NCT02079844|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33799542|NCT04706052|||CASE_CONTROL||RETROSPECTIVE|||||||
33799543|NCT00971269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799544|NCT05032794|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
33799545|NCT05006586|||COHORT||PROSPECTIVE|||||||
33799546|NCT06284642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799547|NCT05012241|||COHORT||PROSPECTIVE|||||||
33799548|NCT00661869|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33799549|NCT03279861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799550|NCT06268990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799551|NCT00134446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33799552|NCT05638308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||FAZA PET/MRI Scan||||
33799553|NCT04933526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799554|NCT04071756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799555|NCT01224015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799556|NCT05672888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799557|NCT00687856|||CASE_ONLY||PROSPECTIVE|||||||
33799558|NCT01947634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799559|NCT01450228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943337|NCT03188991|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose rising trial. During the dose escalation phase, subjects will be enrolled in sequential cohorts of NanoPac®. Each cohort will have three subjects, with cohorts enrolled sequentially starting at the lowest concentration. Following DSMB review of the cohort data, the next cohort may begin enrolling, an additional three subjects at the current dose may be enrolled, or, if the first dose does not provide adequate safety and tolerability, the study may be halted. The dose determined to be the most suitable for further evaluation, defined as the highest dose with an acceptable safety and tolerability profile (as determined by the DSMB), will be the dose used in the second phase of the study which will enroll 9 additional subjects. Subjects enrolled in the second phase of the study will also receive a second injection of NanoPac at the same dose 12 weeks after the first NanoPac injection.||||
33943338|NCT00411229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943339|NCT02297620|||CASE_CONTROL||PROSPECTIVE|||||||
33943340|NCT05062642|||COHORT||RETROSPECTIVE|||||||
33943341|NCT00989417|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33943342|NCT01200251|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33943343|NCT00686894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943344|NCT00219531|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943345|NCT05647889|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|To control the research in terms of bias; During the data collection phase, help will be taken from the clinical nurse who takes care of the patient. The nurse, who does not know which intervention is applied, will be asked to evaluate the patient's pain and anxiety. In this respect, the research will be considered single-blind.|In the study, 80 individuals, including 2 experimental and 1 control group, were included in the study.|f|t|f|f
33943346|NCT05630742|||CASE_CONTROL||PROSPECTIVE|||||||
33943347|NCT05747170|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943348|NCT00817752|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33943349|NCT02406131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33943350|NCT04515849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943351|NCT01011959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943352|NCT04691518|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Outcomes assessor will be blinded to Treatment or Placebo treatment when applicable|Participants will participate in any of the interventions|f|f|f|t
33799560|NCT02224924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799561|NCT06434441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking in not applicable for the patients or the operators|"A) The Study group:~The patients within the study group will receive mono-cortical bone block calvarial grafts~B) The Control group:~The patients within the control group will receive mono-cortical bone block iliac crest grafts,"|f|f|f|t
33799562|NCT03796936|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot, controlled clinical trial in which all 20 participants with comorbid PTSD and mTBI receive 10 sessions (3 preparatory, 6 3MDR treatment, and 1 conclusion), but will be randomized to either include eye movement, EM (EM+), or not (EM-).||||
34102058|NCT03136094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will not be given details about how text messaging differs for the 2 study groups. Instead, patients will be told that the clinic is testing a program to support people who are having hard times, and that they will receive periodic text messages from the Site Coordinator for the next 12 months.|The Investigators will conduct a randomized controlled trial to test the effectiveness of an augmented Screening, Brief Intervention, and Referral to Treatment (SBIRT) model that includes sending caring text messages for 12 months after an at-risk patient is identified.|t|f|f|t
34102059|NCT03674450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102060|NCT06617806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic randomized controlled trial||||
34102061|NCT03575364|||COHORT||PROSPECTIVE|||||||
34102062|NCT03036488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102063|NCT04899466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102064|NCT06689137|||COHORT||PROSPECTIVE|||||||
34102065|NCT05263791|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102066|NCT02407717|||COHORT||PROSPECTIVE|||||||
34102067|NCT06634849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102068|NCT06451770|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single ascending dose escalation/adaptive design||||
34102069|NCT06539650|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34102070|NCT05445804|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be counterbalanced across participants.|t|f|t|t
33799563|NCT05772923|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective study with a mixed design. It concerns a phase II feasibility study for patients in whom a good, but not complete response has been achieved after (chemo)radiation (OPAXX study): two parallel single study-arms evaluate the efficacy of experimental organ preservation approaches. To allow for a better comparison of secondary parameters (toxicity and morbidity of both additional local treatments) eligible patients will be randomized between two experimental arms. Furthermore, an observational cohort study is established to register rectal cancer patients with a good but not complete clinical response after (chemo)radiation who are not eligible for randomisation in the OPAXX study (OPAXX registration study).||||
33799564|NCT06498336|||CASE_CONTROL||PROSPECTIVE|||||||
33799565|NCT03292120|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33799566|NCT04050969|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will undergo screening and eligibility to make sure they meet all criteria for the trial. If patients meet all defined criteria, they will undergo informed consent and will be randomized with equal allocation to the catheter ablation only and bariatric surgery plus AF catheter ablation arms. Randomization will be stratified by site and type of AF (paroxysmal or persistent) using permuted blocks to limit effects of clinician variation.||||
33799567|NCT03990285|NA|SINGLE_GROUP||OTHER||NONE||To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression vs pseudoprogression. To determine a multidimensional signature using 18F-fluciclovine PET, MRI, and plasma cfDNA that accurately differentiates tumor progression from pseudoprogression in post-chemoradiation GBM.||||
33799568|NCT03430258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799569|NCT05309733|||COHORT||PROSPECTIVE|||||||
33799570|NCT01681381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799571|NCT03356223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799572|NCT00826657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34022430|NCT04227847|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Parts B and C may enroll in parallel after enrollment of Part A is complete. Part D will enroll after Part A is complete. Parts E and F will enroll in parallel once Part D is complete.||||
34022431|NCT01962584|||COHORT||PROSPECTIVE|||||||
34022432|NCT04362748|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34022433|NCT06158256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34022434|NCT04859543|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022435|NCT04230005|||CASE_ONLY||OTHER|||||||
34022436|NCT06382480|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The trial will have a cross-over design and compare metabolic effects of two isocaloric 4-week interventions with opposite timely distribution of macronutrient intake divided by a 4-week wash-out phase.||||
34022437|NCT00001049||||TREATMENT||DOUBLE||||||
34022438|NCT03624608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022439|NCT05652738|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34022440|NCT00541216|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34022441|NCT00969540|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34022442|NCT06447311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022443|NCT04735861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022444|NCT05083130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open label randomised controlled trial comparing standard care to prone position||||
34022445|NCT05268835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022446|NCT03915028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022447|NCT02235090|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34022448|NCT03981419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022449|NCT01051219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022450|NCT05947110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blinded to the treatment allocation.|A prospective, randomized controlled clinical trial|f|f|f|t
34022451|NCT03362112|||COHORT||RETROSPECTIVE|||||||
34022452|NCT02164474|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022453|NCT04289597|||COHORT||PROSPECTIVE|||||||
34022454|NCT05832710|||OTHER||CROSS_SECTIONAL|||||||
34022455|NCT00668161|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34022456|NCT04636164|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022457|NCT03705130|||CASE_ONLY||PROSPECTIVE|||||||
34022458|NCT05141331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022459|NCT00665938|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34022460|NCT02767154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022461|NCT00003920||||TREATMENT||||||||
34022462|NCT03681236|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34102071|NCT06269601|NA|SINGLE_GROUP||OTHER||NONE||14-18 years basketball players||||
33799573|NCT03335748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind evaluation Participant and assessor are blind|Participants were randomized into an experimental group that received the Cogmed program and an active control group that received a low-intensity comparison version of the training|t|f|f|t
33799574|NCT06015399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799575|NCT02138604|||COHORT||PROSPECTIVE|||||||
33799576|NCT03964870|||COHORT||PROSPECTIVE|||||||
33799577|NCT02780440|||COHORT||PROSPECTIVE|||||||
33799578|NCT01837966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799579|NCT01748110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799580|NCT02628678|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799581|NCT01406223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33799582|NCT04313205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799583|NCT04204993|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Biological: Influenza A/Belgium/4217/2015 at a dose of 5x105 TCID50 in a volume of 0.5 milliliters via intranasal drops||||
33799584|NCT06552819|||COHORT||CROSS_SECTIONAL|||||||
33799585|NCT02020252|||OTHER||PROSPECTIVE|||||||
33799586|NCT06014216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799587|NCT02063425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799588|NCT05780528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|mulligan mobilization and instrumented-assisted soft tissue mobilization|f|f|t|t
33799589|NCT01088113|||COHORT||PROSPECTIVE|||||||
33799590|NCT00391846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799591|NCT05725135|||COHORT||PROSPECTIVE|||||||
33799592|NCT01896349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799593|NCT01853410|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799594|NCT00397475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33799595|NCT04837976|||CASE_ONLY||RETROSPECTIVE|||||||
33799596|NCT03516240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33799597|NCT01248936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799598|NCT04050644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* Prospective, randomized controlled trial, investigator masked.~* Patients requiring cataract surgery and who consent to participate will be enrolled in this study.~* The patient can opt to participate in an sub-investigation researching a correlation between the microbiome and ocular surface inflammation post cataract surgery."|f|f|t|f
33799599|NCT00042848|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33799600|NCT02282267|NA|SINGLE_GROUP||TREATMENT||NONE||Iressa treatment oral daily||||
33799601|NCT00373386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799602|NCT05032534|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The children will use either the old or the new cone for transanal irrigation for 6 weeks and then crossover to the contrary cone.||||
34022463|NCT01570803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022464|NCT01036139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022465|NCT06050161|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The patient will not be told which surgical approaches were used during surgery|"Those in the study scheduled for a laparoscopic hysterectomy will be randomly selected for the Artisential vs. Robotic vs. Laparoscopic vaginal cuff closure.~Those in the study scheduled for sacrocolpopexy will have half the mesh sutured on by the primary surgical approach (robotic or laparoscopic) and the other half sutured on by the Artisential laparoscopic instrument"|t|f|f|f
34022466|NCT03648853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022467|NCT00586235|||CASE_CONTROL||PROSPECTIVE|||||||
34022468|NCT01550627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022469|NCT02092896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022470|NCT04002908|||COHORT||PROSPECTIVE|||||||
34022471|NCT03994718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022472|NCT02701270|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33799603|NCT06124066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All medicines were placed in the same 3 boxes, which were held by the paramedics so that the patients and paramedics did not know the allocation of the types of drugs given.|Patients will be divided into 3 groups of drug administration: Group A, Group B, and Group C.|f|f|t|f
33799604|NCT00102258||||TREATMENT||||||||
34102072|NCT03941262|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799605|NCT05965388|||COHORT||PROSPECTIVE|||||||
33799606|NCT05554614|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33799607|NCT04643899|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Monocentric; prospective; opened ; randomized; controlled study~* Distribution of patients in groups according to a ratio (1: 1)"||||
33799608|NCT05184361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799609|NCT03669913|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomized trial where the intervention is structured comprehensive sexuality education lesson packages||||
33799610|NCT03416712|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Quantify unmet socioeconomic determinants of health (SDH) needs using a screening tool in the inpatient settings at Texas Children's Hospital (TCH). Screen will assess educational attainment, employment, literacy, language skills, substance dependence, childcare and child behavior, mental health, domestic violence, housing insecurity and conditions, medical insurance, access to primary care, transportation to medical appointments, ability to pay for prescriptions, legal issues and immigration services. 2. Increase vulnerable family enrollment in community resources to decrease unmet psychosocial and economic needs in the study population 3. Evaluate impact of this intervention on health outcome indicators and hospital resource utilization (body mass index (BMI), return visit to ED, hospital readmission, and parent's perception of child's health).||||
33799611|NCT01369498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799612|NCT01066026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799613|NCT06666829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799614|NCT00973115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102073|NCT05877846|NA|SINGLE_GROUP||OTHER||NONE||This pilot study is a 12-week, single arm, pre/post intervention of β-hydroxymethyl butyrate (HMB) in n=18 older adults at risk for sarcopenia. There will be no randomization.||||
34102074|NCT02522260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799615|NCT03366701|||COHORT||PROSPECTIVE|||||||
33799616|NCT04571606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799617|NCT06143371|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33799618|NCT05010655|||COHORT||CROSS_SECTIONAL|||||||
33799619|NCT00252369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799620|NCT05344014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799621|NCT05765019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799622|NCT02720965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799623|NCT01042197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33799624|NCT06524973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799625|NCT06307301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799626|NCT02111889|NA|SINGLE_GROUP||OTHER||NONE||||||
33799627|NCT06497959|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799628|NCT01499381|||COHORT||PROSPECTIVE|||||||
33799629|NCT02073370|||COHORT||PROSPECTIVE|||||||
33799630|NCT02711059|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33799631|NCT00233038|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33799632|NCT00933426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799633|NCT03173105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants won´t know if they will be using the activated tDCS or Sham. The care provider also won´t know whether the participant used the tDCS or Sham as well as the outcome evaluator won´t know which is the patient´s condition.|Participants will be randomly allocated to four groups: Group 1 (G1) - active tDCS + dynamic proprioceptive exercises; Group 2 (G2) - sham tDCS + dynamic proprioceptive exercises; Group 3 (G3)- active tDCS + static proprioceptive exercises; and Group 4 (G4) - sham tDCS + static proprioceptive exercises. Randomization will be performed with the use of sealed opaque envelopes containing a card stipulating to which group the volunteer will be allocated (G1, G2, G3 or G4).|t|t|f|t
33799634|NCT04110223|||OTHER||OTHER|||||||
33799635|NCT04339855|||OTHER||OTHER|||||||
33799636|NCT01429350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799637|NCT01724242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943353|NCT02254876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33943354|NCT01091116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943355|NCT05157009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943356|NCT02550821|||CASE_CONTROL||PROSPECTIVE|||||||
33943357|NCT03595072|||COHORT||PROSPECTIVE|||||||
33943358|NCT04277286|||CASE_CONTROL||PROSPECTIVE|||||||
33943359|NCT03303131|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33943360|NCT01948544|||COHORT||PROSPECTIVE|||||||
33799638|NCT03999034|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Every patients and healthy controls will fill in all the tests and questionnaires||||
33799639|NCT06168149|||CASE_ONLY||PROSPECTIVE|||||||
33799640|NCT04103723|||COHORT||PROSPECTIVE|||||||
33799641|NCT05511428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799642|NCT02382744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943361|NCT00134199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943362|NCT06337656|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943363|NCT03851302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33943364|NCT00982800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943365|NCT06021912|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943366|NCT03029494|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|It will be a single-blind interventional study (as placebo splint cannot be mistaken for a stabilization splint by a clinician).|"TMD patients will be randomized into two treatment groups. Each group will have two sets of interventions: one presumably active treatment and other a placebo:~Treatment group 1: stabilization splint and placebo tablet daily. Treatment group 2: placebo (ineffectively designed) splint and 1000 mg Vitamin C tablet (an antioxidant agent) daily."|t|f|f|f
33943367|NCT06026137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33943368|NCT02372539|||OTHER||PROSPECTIVE|||||||
33943369|NCT06187519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||15 patients with gout \[10 patients no recent urate-lowering therapy (ULT) and 5 patients on stable urate-lowering therapy (ULT)\] will be invited to participate in a standardized meal at the UCLA Human Nutrition Center||||
33943370|NCT05360472|||CASE_ONLY||CROSS_SECTIONAL|||||||
33943371|NCT02119780|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799643|NCT04153110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799644|NCT01547546|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943372|NCT04126759|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33943373|NCT05352451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Aims to evaluate the feasibility of the methods and procedures required to mount a cluster-randomized study to improve prognostic understanding in persons with advanced cancer and their family caregivers. Building on the successful Values and Options in Cancer Care (VOICE) intervention conducted in Western NY and Northern CA from 2012-2018, we have made substantive changes to VOICE and developed VOICE 2. In this pilot cluster randomized trial, we will recruit 8 to 10 oncologists and approximately 32 to 40 patient-caregiver dyads in an effort to examine the acceptability and feasibility of study and intervention methods and procedures. The long-term goal of our research program is to improve patient and caregiver prognostic understanding, optimize healthcare utilization at the end-of-life (EOL), patient and caregiver quality of life at patient EOL, and caregiver bereavement adjustment.||||
33943374|NCT01790633|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33943375|NCT03187314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943376|NCT05779410|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A double-blind, matched-pair study design|Healthy male participants were divided into vitamin D group and placebo group.|t|f|t|f
33943377|NCT04434703|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33943378|NCT00266799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943379|NCT01288742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943380|NCT03302923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102075|NCT06642558|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34102076|NCT05330546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102077|NCT06393426|||CASE_ONLY||RETROSPECTIVE|||||||
33799645|NCT02239913|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33799646|NCT04970446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation tables will be computer generated by an independent statistician. The indistinguishable aspect of the FMT syringes (colour, packaging) will ensure the blindness of both patients and physicians in charge.|Prospective, two clinical center, parallel-arm, randomised, double-blind, placebo-controlled trial|t|t|t|t
33799647|NCT04997616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33799648|NCT02060669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799649|NCT02598596|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33799650|NCT05506436|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33943381|NCT00453349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943382|NCT04726943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943383|NCT00270010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943384|NCT06241144|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
34022473|NCT03778827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34022474|NCT00880737|||COHORT||PROSPECTIVE|||||||
34022475|NCT04422782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022476|NCT01561508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022477|NCT00563576|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022478|NCT04632511|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Children with overweight and obesity and normal-weight children||||
34022479|NCT02637661|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022480|NCT02752906|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34022481|NCT03934411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34022482|NCT03852173|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants in the control group are not aware that they serve as control group.|Intervention versus no intervention|t|f|f|f
34102078|NCT06650592|||COHORT||PROSPECTIVE|||||||
34102079|NCT04869917|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||This study will utilize a 2x2 factorial design to test the effectiveness of the two proposed interventions on outcomes. Each of the participating clinical sites will be randomized to one of 4 treatment conditions. Employing a full factorial design, the participating clinics sites will be randomized to 1 of the following 4 treatment conditions: a) prediabetes decision aid intervention alone; b) text messaging intervention alone; c) both interventions; and d) usual care \[i.e. neither intervention\].|t|t|t|t
34102080|NCT00660959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022483|NCT01687426|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34022484|NCT02264470|||COHORT||PROSPECTIVE|||||||
34022485|NCT05070000|||CASE_ONLY||RETROSPECTIVE|||||||
34022486|NCT00478426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022487|NCT01034254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34022488|NCT03318731|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Three groups: placebo, 300mg dose (low) and 500mg dose (high)|t|f|t|f
33799651|NCT04456322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022489|NCT06632522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022490|NCT05837013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022491|NCT02854852|||CASE_ONLY||PROSPECTIVE|||||||
34022492|NCT04106167|||CASE_ONLY||PROSPECTIVE|||||||
34022493|NCT00865787|||CASE_CONTROL||PROSPECTIVE|||||||
34102081|NCT02090491|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34102082|NCT05029882|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102083|NCT06695442|||COHORT||PROSPECTIVE|||||||
34102084|NCT00792155|||COHORT||PROSPECTIVE|||||||
34102085|NCT06189872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943385|NCT03804476|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The participants, care providers, investigators, outcome assessors, and safety monitoring board will be blind to the administration of AER-271.|A double-blind, randomized, placebo-controlled, sequential-group, single and multiple intravenous dose escalation study conducted in 2 parts. Both Parts A and B will comprise an adaptive design. Part A sentinel dosing will randomize the first 2 subjects 1:1 AER-271:placebo. The remaining 6 subjects in a cohort will be randomized 5:1 AER-271:placebo and administered drug after the Safety Monitoring Board (SMB) has reviewed the first 24 hours of safety data for the first 2 subjects. Part B sentinel dosing will randomize the first 4 subjects 2:2 AER-271:placebo. The remaining 6 subjects in a cohort will be randomized 4:2 AER-271:placebo and administered study drug after the SMB has reviewed the first 24 hours of safety data for the first 4 subjects. Part A will have 6 cohorts and Part B will have 3. Additional cohorts may be enrolled to explore additional dose levels. The planned study design may be modified in accordance with the adaptive features of the clinical study protocol.|t|t|t|t
33943386|NCT06098001|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants receive same treatment in dose escalation design||||
33799652|NCT05383859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33799653|NCT06109220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799654|NCT04072653|NA|SINGLE_GROUP||TREATMENT||NONE||In the first stage, the negative predictive value is evaluated in patients with negative preoperative axillary assessment, including LymphPET and routine imaging examinations. In the second stage, sentinel lymph node biopsy will be spared in the patients with negative preoperative axillary assessment.||||
33799655|NCT02346526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799656|NCT03253731|||COHORT||PROSPECTIVE|||||||
33799657|NCT05088954|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||transforaminal epidural steroid injection|t|f|f|t
33799658|NCT02752503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799659|NCT00654316|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33799660|NCT03915340|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department.|There will be two sequences in the study: A-B-A-B and B-A-B-A, where A = the test product, B = the reference product (see detailed description of A and B items below).|f|f|f|t
33799661|NCT03015896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799662|NCT03586258|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799663|NCT03966846|RANDOMIZED|PARALLEL||TREATMENT||NONE||There were two experimental groups. The kefir group, that received orally kefir, and the control group received milk||||
33799664|NCT05327049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799665|NCT05540496|||COHORT||PROSPECTIVE|||||||
33799666|NCT05459259|||OTHER||OTHER|||||||
33799667|NCT05908669|||COHORT||PROSPECTIVE|||||||
33799668|NCT03216213|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33799669|NCT05384691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799670|NCT03407131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799671|NCT04455633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799672|NCT04372004|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Each subject will be tested using 3 different samples on two testing platforms (serology and viral-RNA detection)||||
33799673|NCT00957242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799674|NCT00617331|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33799675|NCT03423277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799676|NCT05911581|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799677|NCT04314323|||COHORT||PROSPECTIVE|||||||
33799678|NCT03344536|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single institution, phase Ib/phase II non-randomized trial.||||
33799679|NCT00846326|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33799680|NCT06412770|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33799681|NCT02779998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799682|NCT02424071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799683|NCT05241041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the first year, there is no masking to participant and researcher.||t|f|f|f
33799684|NCT00584246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799685|NCT01255670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799686|NCT04266912|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022494|NCT00094406|RANDOMIZED|||TREATMENT||||||||
34022495|NCT05980195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022496|NCT00566007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022497|NCT05009914|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33799687|NCT03372746|||COHORT||PROSPECTIVE|||||||
33799688|NCT01416558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799689|NCT05783739|||COHORT||OTHER|||||||
33799690|NCT04504708|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799691|NCT02214160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799692|NCT00010725|RANDOMIZED|||TREATMENT||||||||
33799693|NCT01628419|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33799694|NCT00713063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799695|NCT05822063|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33799696|NCT02945098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799697|NCT05486052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prior to the study, an assessment of the reliability, reproducibility and validity of the instrument will be conducted among healthy individuals followed by random selection into two groups (study group and control group)|t|f|t|t
33799698|NCT02270645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799699|NCT02719600|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799700|NCT01350024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33799701|NCT06518876|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799702|NCT00232180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799703|NCT06196177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799704|NCT00456196|||COHORT||RETROSPECTIVE|||||||
33799705|NCT02365779|NA|SINGLE_GROUP||SCREENING||NONE||||||
33799706|NCT05900765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799707|NCT02771899|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022498|NCT04819048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102086|NCT06688747|||COHORT||PROSPECTIVE|||||||
33799708|NCT05629182|||COHORT||PROSPECTIVE|||||||
33799709|NCT04310358|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, open label study.||||
33799710|NCT06033118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799711|NCT04056611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799712|NCT00371787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799713|NCT01000831|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33799714|NCT03425734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33799715|NCT06439732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022499|NCT03510780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022500|NCT00006395||||TREATMENT||||||||
34022501|NCT03193073|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"two groups of patients (group A: CKD and group B newly transplanted patients) are assigned for detailed echocardiography , serum FGF-23, flow mediated dilatation of the forearm before anaemia correction in group A and renal transplant in group B .~Also assesment of FGF-23 in different stages of group A, assessment of FGF-23 before and after renal transplant"||||
34022502|NCT04653272|||CASE_CONTROL||PROSPECTIVE|||||||
34022503|NCT06344936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022504|NCT04034563|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022505|NCT03544619|||CASE_ONLY||PROSPECTIVE|||||||
34022506|NCT02086903|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34022507|NCT05658458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022508|NCT01152151|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34022509|NCT01355315|||CASE_ONLY||PROSPECTIVE|||||||
34022510|NCT05325307|RANDOMIZED|PARALLEL||OTHER||TRIPLE|In the study, a researcher (T.Ç.Y.) will determine the acupressure and placebo points to be applied to patients. However, the researcher (Z.Y.) who will apply acupressure and placebo acupressure be blinded without knowing whether these points are acupressure or placebo points. Participants will not know that they are in the acupressure or placebo group. When the research is completed, the data of the control and study groups (A or B) will be transferred to the computer environment by a researcher independent of the research, and the data will be analyzed by a statistician and the findings will be reported.|Prospective, parallel, three-arm randomized controlled clinical trial|t|t|f|t
34022511|NCT02992418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840238|NCT03667976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The investigator will (a) screen, determine eligibility, and obtain consent from eligible peers, (b) schedule and deliver the peer training session, (c) provide support and answer questions of peers as required, (d) assist in the organization of peer meetings and discussions as required, and (e) will pair participants with the appropriate peer based on having children (peer-participant dyad) via telephone.~The outcome assessor (research assistant) will be blinded. Study participants will be assigned a unique study identification (ID) number and will use this study ID number when they electronically submit step counts to the research assistant at weeks 6 and 12. Intervention group participants will additionally submit step counts weekly until study completion. All other outcome data will be collected by the research assistant at the 12-weeks post-intervention follow-up."|A pragmatic two-arm parallel 12-week pilot randomized controlled trial.|f|f|f|t
34022512|NCT05217719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022513|NCT03577418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022514|NCT01203410|||COHORT||PROSPECTIVE|||||||
34022515|NCT03690661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blinded||t|f|f|t
33799716|NCT04386356|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|An investigator not involved in assessing the patient outcome will open the sealed envelope according to the serial number of the patient enrolled into the study.Tracheal intubation will then be performed by first year anaesthesia trainee using either Airtraq or Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer. The data will be analysed by an investigator not involved in administering anaesthesia.|"First year anaesthesia trainee are those residents in their first year of anaesthesia training and has not had any prior experience using either laryngoscope. They will be given adequate training and instructions before intubation on patients.~On the day of surgery, the baseline airway variables and the baseline hemodynamic values will be recorded. An investigator not involved in assessing the patient outcome will open the sealed envelope according to the serial number of the patient enrolled into the study.~Following standard induction technique of preoxygenation with 100% oxygen, injection fentanyl, injection propofol, injection veruronium and mixture of isoflurane and oxygen, tracheal intubation will then be performed by first year anaesthesia trainee using either Airtraq or Macintosh laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer."|t|f|t|t
33799717|NCT00342407|||CASE_ONLY||OTHER|||||||
34022516|NCT02105974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102087|NCT05626686|NA|SINGLE_GROUP||OTHER||NONE||The investigation is designed as an open-labelled, single-arm investigation including subjects currently using single use catheters.||||
34102088|NCT06306144|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34102089|NCT04404283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102090|NCT05612295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022517|NCT03220347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022518|NCT03544918|||COHORT||CROSS_SECTIONAL|||||||
34022519|NCT00529282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022520|NCT05479916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Randomized, double-blind|Double blind, randomized, cross-over intervention study|t|f|t|t
34022521|NCT05635383|||OTHER||PROSPECTIVE|||||||
34022522|NCT02048930|||COHORT||RETROSPECTIVE|||||||
34022523|NCT05999058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022524|NCT02026115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022525|NCT01867359|||CASE_CONTROL||OTHER|||||||
34022526|NCT04657926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022527|NCT03577548|||CASE_ONLY||PROSPECTIVE|||||||
34022528|NCT00094861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022529|NCT04205305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Three months after discharge, the independence assessment will be performed by the researcher who don't know the patients group.|"1. The study is a multicenter, prospective, randomized, open-label trial with blinded end-point assessment (PROBE) design study.~2. After successful revascularization, the active blood pressure control group and the standard blood pressure control group will be randomized by 1: 1.~3. Patients who have undergone intraarterial thrombectomy due to acute cerebral infarction and have successfully reopened arteries will be enrolled.~4. Medical history, laboratory findings and blood pressure parameters (systolic blood pressure, diastolic blood pressure, blood pressure variability, etc.), neurological scores, functional recovery, and quality of life indicators will be collected.~5. Neurological scores, functional recovery scores, and quality of life indicators are performed by independent researchers in the blind state.~6. All data is collected using e-CRF, and the image study will be anonymized and sent to the central adjudication."|f|f|f|t
34022530|NCT01685411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022531|NCT02226757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022532|NCT05362838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022533|NCT01835054|||COHORT||PROSPECTIVE|||||||
34022534|NCT04053920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022535|NCT06017479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study uses a single-blinded design because the outcome assessed in this study is urinalysis which is the objective outcome. The urinalysis evaluator is blinded to the drug regimen obtained by the research subjects.|This study is an experimental study with a single-blinded randomized clinical trial design to compare the proportion of UTIs in a group of patients receiving fosfomycin 3 grams and patients receiving levofloxacin 500 miligrams single dose one hour before urodynamic examination. To determine the sample treatment group, blocked randomization technique is used in this study.|f|f|f|t
34022536|NCT03848637|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022537|NCT04325204|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022538|NCT03562559|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022539|NCT03518801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study. Only pharmacist will have access to randomization table.|Participants randomly assigned to one of two treatment conditions.|t|t|t|t
34022540|NCT00824616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022541|NCT01752309|||COHORT||PROSPECTIVE|||||||
34022542|NCT00140426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022543|NCT00719771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022544|NCT06299917|RANDOMIZED|PARALLEL||OTHER||NONE|Statistical analyses will be blinded for group allocation|Single center parallel randomized study||||
34022545|NCT03552835|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||occlusal dentinal caries were managed by either partial caries removal upto soft dentin or partial caries removal upto firm dentin or no caries removal and were compared|t|f|f|f
34022546|NCT00491153|||COHORT||PROSPECTIVE|||||||
34022547|NCT01783548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022548|NCT02272634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102091|NCT03949114|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Responsible nurses will conduct daily life skills and sputum assessments for all patients, and the data collector will collect the data needed for the study.|During the period from June 1, 2019 to December 31, 2019, 150 patients with craniotomy who met the criteria and signed informed consent were included in the control group, from January 1, 2020 to June 30, 2020. During the period, 150 patients who met the standard neurosurgical craniotomy were included in the observation group.|f|f|f|t
33799718|NCT04565418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799719|NCT04960644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799720|NCT00352976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799721|NCT00105092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799722|NCT01275287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799723|NCT02201043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799724|NCT02284412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799725|NCT05293431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled trial|t|f|t|f
33799726|NCT00096915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799727|NCT02979808|NA|SINGLE_GROUP||OTHER||NONE||||||
33799728|NCT00457275|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799729|NCT04787653|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Each participant will be assigned to one of the study's two arms. Participant's in Arm One will receive the effective device first and the placebo device second. Participants in Arm Two will receive the placebo device first and then the effective OtoBand. At the midpoint of a participant's enrollment, the first device will be returned and the second device sent. The participants and researchers will be blinded to which arm of the study a participant is assigned so they will not know if the device in use is effective or placebo.||t|f|f|t
33799730|NCT00214240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799731|NCT06335719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a randomized, controlled, double-blinded (patient and evaluator) prospective study. Plan is to enroll up to 30 patients, with a minimum of 20 completing full follow-up. Randomization 2:1 treatment to control due to previous peripheral nerve research demonstrating intraoperative stimulation accelerates axonal regeneration|"Patients will undergo all the standard steps of the facial reanimation procedures. The difference in care is 2/3 participants may receive the brief electrical stimulation therapy.~Other 1/3 of study participants will undergo the surgery as they normally would if they had not chosen to participate."|t|f|f|f
33799732|NCT06320912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799733|NCT01634516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799734|NCT03245580|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective, randomized, multicenter study||||
33799735|NCT01304355|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799736|NCT01610297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799737|NCT03135184|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, unblinded, interventional study||||
33799738|NCT06244615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799739|NCT06153810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022549|NCT06483841|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their parti|f|f|f|t
34022550|NCT01673971|||COHORT||OTHER|||||||
34022551|NCT01293539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022552|NCT00789737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022553|NCT01920607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022554|NCT05632328|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022555|NCT02315196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022556|NCT02653430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022557|NCT02520063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022558|NCT06299020|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34022559|NCT02092467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022560|NCT05819723|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34022561|NCT02472535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022562|NCT05719324|||COHORT||RETROSPECTIVE|||||||
34022563|NCT00986518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022564|NCT02781870|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34022565|NCT03463473|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation : 3mg/kg Q3W, 10 mg/kg Q3W, 20 mg/kg Q3W, 10 mg/kg Q2W||||
34102092|NCT06694961|||COHORT||CROSS_SECTIONAL|||||||
33799740|NCT00908505||CROSSOVER||TREATMENT||NONE||||||
33799741|NCT06235619|||COHORT||CROSS_SECTIONAL|||||||
33799742|NCT05083702|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33799743|NCT05053568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33799744|NCT05792280|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33799745|NCT05559281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799746|NCT03675581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799747|NCT01836133|||COHORT||PROSPECTIVE|||||||
33799748|NCT02250118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799749|NCT00373529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799750|NCT01001936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799751|NCT01604161|||COHORT||PROSPECTIVE|||||||
34022566|NCT00581126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022567|NCT02740699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022568|NCT04914221|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022569|NCT05407324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022570|NCT01735955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102093|NCT06159127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102094|NCT04964466|||COHORT||PROSPECTIVE|||||||
33943387|NCT04974294|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Participants will remain blinded until the completion of the last participant, last study visit (Day 23: 7-month challenge). As the appearance of the vaccines are different, physical blindfolds may be worn by the participant to maintain blinding. This method of blinding has been used by our team previously and the time wearing the blindfold is kept to an absolute minimum for participant comfort. Un-blinded clinical team members will prepare and administer the vaccines/placebo to the participants in a blinded manner, shielding the vaccine formula, syringe and box from the participant when it is administered. The vaccine will be checked and prepared in a separate room to the participant and in a separate location to the blinded team. The participant will be seated in the vaccination room, the un-blinded clinical members will enter the vaccination room immediately prior to administration. Local SOPs will be followed to ensure appropriate participant team blinding.|double blind RCT|t|t|t|t
33943388|NCT02646501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943389|NCT01621659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Supportive care intervention|f|f|f|t
33943390|NCT02219750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33943391|NCT00389922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943392|NCT01724749|||COHORT||PROSPECTIVE|||||||
33799752|NCT01893970|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799753|NCT01285986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799754|NCT01277614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799755|NCT01188369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799756|NCT02450344|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33799757|NCT00188890|||COHORT||PROSPECTIVE|||||||
33799758|NCT02965846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799759|NCT00024063||||TREATMENT||||||||
33799760|NCT03806088|||OTHER||PROSPECTIVE|||||||
33799761|NCT02150967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943393|NCT05493579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943394|NCT01619631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022571|NCT03862755|NA|SINGLE_GROUP||PREVENTION||NONE||Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously one time a day no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).||||
34022572|NCT05341349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022573|NCT02553031|||CASE_ONLY||PROSPECTIVE|||||||
34022574|NCT00985712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022575|NCT02651779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022576|NCT01043835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022577|NCT00752648|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022578|NCT01627509|||COHORT||PROSPECTIVE|||||||
34022579|NCT03183336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102095|NCT05836636|||COHORT||PROSPECTIVE|||||||
34102096|NCT05726383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102097|NCT06004674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placental pathologist will be masked to the outcome when assessing for maternal vascular malperfusion.||f|f|f|t
34102098|NCT06082817|NA|SINGLE_GROUP||TREATMENT||NONE||Open label 50mg daily dosing with pharmacokinetics assessed by multiple blood draws||||
34102099|NCT03997591|||CASE_CONTROL||PROSPECTIVE|||||||
34102100|NCT04334681|||COHORT||RETROSPECTIVE|||||||
33799762|NCT05291104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33799763|NCT00440011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33799764|NCT04954196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Amlodipine 5 mg capsules (Arrow Generics®) will be deblistered and repackaged in pill boxes of 28 capsules.~Placebo capsules will be made of microcrystalline cellulose and will be identical in size and color to generic Amlodipine Arrow capsules. A mass uniformity check will be carried out. Placebo capsules will also be packaged in pill boxes of 28 capsules."||t|f|t|f
33799765|NCT01473186|||COHORT||PROSPECTIVE|||||||
33799766|NCT05226221|||COHORT||PROSPECTIVE|||||||
33799767|NCT04297371|||COHORT||PROSPECTIVE|||||||
33799768|NCT06029387|||COHORT||OTHER|||||||
33799769|NCT04854863|||COHORT||PROSPECTIVE|||||||
33799770|NCT05868161|||COHORT||RETROSPECTIVE|||||||
33943395|NCT04470362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943396|NCT02138864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943397|NCT04284579||SEQUENTIAL||TREATMENT||NONE||||||
33943398|NCT02838186|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33943399|NCT02828982|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33943400|NCT02239302|||COHORT||PROSPECTIVE|||||||
33943401|NCT00669240|||CASE_ONLY||PROSPECTIVE|||||||
33799771|NCT02823938|||COHORT||RETROSPECTIVE|||||||
33799772|NCT01285635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799773|NCT00683696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799774|NCT04548024|||COHORT||PROSPECTIVE|||||||
33799775|NCT00004440|RANDOMIZED|||TREATMENT||NONE||||||
33799776|NCT04544904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799777|NCT04860401|NA|SINGLE_GROUP||OTHER||NONE||||||
33799778|NCT02363452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799779|NCT04580771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799780|NCT02573675|||COHORT||RETROSPECTIVE|||||||
33799781|NCT06079931|NA|SINGLE_GROUP||PREVENTION||NONE||Simon's optimal two-stage design||||
33799782|NCT05661994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients with CAD were divided into the Omega-3 Group (n:16) and Control Group (n:18). Low-fat diet principles were explained to both groups at baseline. While 1.560 mg/day omega-3 FA supplementation was given to the patients in the omega-3 group for eight weeks, but not in the control group."|f|f|t|f
34102101|NCT03943511|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102102|NCT06694337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34102103|NCT04210115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102104|NCT03641560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102105|NCT03824054|||COHORT||RETROSPECTIVE|||||||
34102106|NCT06306157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A quadruple blinded study where the patient, research team, treating clinician, and outcomes assessor are unaware of the randomization results until after study conclusion. The research pharmacy will not be blinded and will be responsible for preparing the medication and securely handing it off to the research assistant according to the pre-approved dispensation plan.|This is a feasibility, randomized, placebo-controlled interventional drug study.|t|t|t|t
34102107|NCT05477641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will be randomized into one of the 2 groups, but will not know which group. Also, the insertion site for both techniques is similar, so they won't be able to tell which group form that evidence either.|Randomized, single-blinded, controlled study|t|f|f|f
34102108|NCT02393469|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34102109|NCT06689111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102110|NCT06613139|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover Assignment two-way crossover||||
34102111|NCT05333029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102112|NCT05385354|||OTHER||PROSPECTIVE|||||||
34102113|NCT06466434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102114|NCT06690229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34102115|NCT02555358|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34102116|NCT05818943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102117|NCT05134519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102118|NCT05757349|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102119|NCT04857034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799783|NCT04383730|||COHORT||RETROSPECTIVE|||||||
33799784|NCT04005482|||COHORT||PROSPECTIVE|||||||
33799785|NCT03930121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two daily sessions of intensive speech-language therapy combined with transcranial direct current stimulation of the left primary motor cortex (M1)|f|f|t|f
34102120|NCT06580743|||COHORT||PROSPECTIVE|||||||
34102121|NCT04879485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102122|NCT06038487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Every patient will be given a participant identification number. An independent investigator, not involved with patient treatment, will generate the allocation list. Computer software will be used to randomize the participant identification numbers into one of the two groups. This information will be concealed in sealed opaque envelopes, which will be open after implants are placed. Neither the surgeon, nor the patient will be aware of the group assignment until after implant insertion.||f|t|t|f
33718453|NCT06135701|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Experimental setup Femoral blood flow will be measured by Doppler ultrasound at rest and during one-knee leg extensor exercise.~Preliminary maximal knee extensor test The maximal workload (WLpeak) of the thigh muscles during one-legged knee-extensor exercise on a customized one-leg kicking chair will be determined.~One-legged knee-extensor exercise protocol In rest upright and supine 0 watt 20%watt max 10 watt. This study day will be repeated within 2-7 days.~Doppler ultrasound Doppler-based blood flow in the common femoral artery (QDop) is obtained using a linear probe (4.3-5.0 MHz) to obtain two-dimensional (2D) femoral arterial cross-sectional area (A) and mean blood velocity (v ̅)."||||
33718454|NCT04933942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718455|NCT06218355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718456|NCT02561650|NA|SINGLE_GROUP||||NONE||||||
33718457|NCT04537507|||COHORT||OTHER|||||||
33718458|NCT00633386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33718459|NCT01053611|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718460|NCT00158509|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33718461|NCT01882621|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33799786|NCT01675258|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799787|NCT05589441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799788|NCT05918614|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33799789|NCT00353171|||COHORT||PROSPECTIVE|||||||
33799790|NCT00493649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799791|NCT02423798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799792|NCT05848531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Unmarked bags of products, randomised before administration.|Double Blinded, randomised, prospective|t|t|t|f
33840239|NCT03823573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33840240|NCT02845232|||COHORT||RETROSPECTIVE|||||||
33840241|NCT02884284|||||PROSPECTIVE|||||||
33718462|NCT01378351|||COHORT||PROSPECTIVE|||||||
33943402|NCT01942564|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943403|NCT05892094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33943404|NCT04008160|||OTHER||PROSPECTIVE|||||||
33943405|NCT01047215|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943406|NCT01645215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102123|NCT06687252|||COHORT||RETROSPECTIVE|||||||
33718463|NCT06376110|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33718464|NCT03461744|||COHORT||PROSPECTIVE|||||||
33718465|NCT04991155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718466|NCT04487639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718467|NCT05200533|RANDOMIZED|PARALLEL||TREATMENT||NONE|Data analysis will be blinded.|Cluster randomized controlled trial||||
33718468|NCT03097874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33718469|NCT03530111|||COHORT||CROSS_SECTIONAL|||||||
33718470|NCT05695690|||COHORT||PROSPECTIVE|||||||
33718471|NCT03020680|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||two 14-day intervention phases with a 2-week washout between each phase. randomized to receive 200mg/day ubiquinol or 200mg/day ubiquinone|t|f|t|f
33718472|NCT05711849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Phase II randomised sham-controlled trial|t|f|f|t
33718473|NCT05042349|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718474|NCT03596528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718475|NCT01721642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718476|NCT02260479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33718477|NCT01252940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718478|NCT02859675|||CASE_ONLY||PROSPECTIVE|||||||
33718479|NCT03027726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718480|NCT03254927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718481|NCT01417520|||COHORT||PROSPECTIVE|||||||
33718482|NCT00834860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718483|NCT04566081|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33943407|NCT03658213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943408|NCT04324983|NA|SINGLE_GROUP||PREVENTION||NONE||"In this single-arm prospective clinical study, various blood- and serum-based biomarkers, from patients with early PSMA PET positive limited metastatic prostate cancer relapse after radical prostatectomy, will be examined according to their potential predictive significance for a successful salvage surgery. Results from the various biomarker values, after salvage surgery, with following clinical endpoints will be assessed:~1. postoperative complete biochemical response (cBR: PSA \<0,2ng/ml)~2. biochemical relapse-free without further prostate cancer specific treatment (time from salvage surgery to first PSA level \>0,2ng/ml)~3. prostate cancer specific treatment-free interval (time from salvage surgery to initiation of a prostate cancer specific treatment)"||||
33718484|NCT01156311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718485|NCT05481645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943409|NCT04704869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943410|NCT01868126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33943411|NCT02487576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33943412|NCT01922869|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943413|NCT01828346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943414|NCT01598831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943415|NCT03035175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33943416|NCT03321591|||CASE_ONLY||CROSS_SECTIONAL|||||||
33943417|NCT01909492|||CASE_CONTROL||PROSPECTIVE|||||||
33943418|NCT00468013|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33943419|NCT00740116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943420|NCT01343940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33943421|NCT02344758|RANDOMIZED|PARALLEL||||||||||
33943422|NCT01689831|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33943423|NCT02501486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943424|NCT01061762|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33943425|NCT04443855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessment team is separate from the implementation team, however due to the nature of the interventions there may be intervention contents visible during the assessment. Data analysis will be masked to randomization status of clusters.||f|f|t|f
33943426|NCT04681469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943427|NCT01177943|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943428|NCT05579938|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33943429|NCT04399499|||COHORT||RETROSPECTIVE|||||||
33943430|NCT02332616|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33943431|NCT01026558|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33943432|NCT02458989|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33943433|NCT03937739|||CASE_CONTROL||PROSPECTIVE|||||||
33943434|NCT05440227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943435|NCT05058066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943436|NCT05768776|||COHORT||PROSPECTIVE|||||||
33943437|NCT04594421|||COHORT||PROSPECTIVE|||||||
33943438|NCT01237665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943439|NCT00598585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943440|NCT04900961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943441|NCT04880148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33943442|NCT04929782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The follow-up evaluations by using the modified United States Public Health Service (USPHS) criteria were completed independently by two calibrated investigators who were blinded to the groups and a forced consensus was sought in any case of disagreement.|Two intervention groups and split-mouth design|f|f|f|t
33943443|NCT06320223|||COHORT||PROSPECTIVE|||||||
33943444|NCT04536181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943445|NCT04354870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|"Total number of participant: 350 (Group A and B)~* Group A: projected 300 (HCW choose to be provided HCQ)~* Group B: projected 50 (HCW choose not to be provided HCQ)"||||
33799793|NCT01996605|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"Randomization is prepared by a statistician not otherwise involved in the study or data analysis and is maintained by the Wake Forest University School of Medicine research pharmacy. Study drug is dispensed by the research pharmacy labelled as Study drug containing normal saline or oxytocin 15 mcg in normal saline or oxytocin 150 mcg in normal saline to indicate the possible contents of the solution, thereby maintaining blind."|Subjects are randomized into one of 3 groups to receive, in a double-blind manner, intrathecal saline or intrathecal oxytocin, 15 mcg or 150 mcg|t|f|t|t
33799794|NCT06480942|||COHORT||PROSPECTIVE|||||||
33718486|NCT04980859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718487|NCT03185572|||COHORT||PROSPECTIVE|||||||
33718488|NCT06347666|NA|SINGLE_GROUP||TREATMENT||NONE||One group will receive the caregiver coaching intervention.||||
33718489|NCT01313767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718490|NCT02921698|||COHORT||PROSPECTIVE|||||||
33718491|NCT01659463|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33718492|NCT04415255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718493|NCT05327686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799795|NCT01827917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33799796|NCT00006431||||TREATMENT||||||||
33799797|NCT02060955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799798|NCT01761552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718494|NCT04615663|||COHORT||PROSPECTIVE|||||||
33718495|NCT01907880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799799|NCT02650791|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33799800|NCT00301652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799801|NCT02909439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799802|NCT05674136|NA|SINGLE_GROUP||OTHER||NONE||||||
33799803|NCT03213327|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Patients are examined at two time points: baseline and 12 weeks after the Intervention.~The Intervention consists of health-promoting advices provided by the software algorithm. The effect of this intervention is evaluated 12 weeks after."||||
33799804|NCT05212181|||CASE_ONLY||PROSPECTIVE|||||||
33799805|NCT03576833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799806|NCT06459024|||COHORT||PROSPECTIVE|||||||
33799807|NCT00825084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799808|NCT03067116|||COHORT||PROSPECTIVE|||||||
33799809|NCT03482635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840242|NCT06148363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840243|NCT05853380|||COHORT||PROSPECTIVE|||||||
33840244|NCT02463045|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33840245|NCT00753064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840246|NCT00545415|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33840247|NCT00770744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840248|NCT02852356|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33840249|NCT06422000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943446|NCT02493101|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943447|NCT05330195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Block Randomized controlled study|f|f|f|t
33943448|NCT03942029|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|The capsule versus tablet formulation comparison will be open label.||t|f|t|f
33943449|NCT01116895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943450|NCT00740766|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943451|NCT04437524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840250|NCT00304759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718496|NCT00449046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718497|NCT03675607|||OTHER||CROSS_SECTIONAL|||||||
33718498|NCT05001074|RANDOMIZED|PARALLEL||TREATMENT||NONE||De novo cohort, 2 arms: de novo lung transplant recipients. Conversion cohort, 2 arms: stable lung transplant recipients||||
33718499|NCT02442960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718500|NCT03003312|||COHORT||PROSPECTIVE|||||||
33718501|NCT04685915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718502|NCT02715076|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33718503|NCT01075724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840251|NCT01707862|||COHORT||RETROSPECTIVE|||||||
33840252|NCT01442922|||CASE_ONLY||PROSPECTIVE|||||||
33840253|NCT00543231|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33840254|NCT03905343|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an international, multicenter, open-label, randomized phase III trial.||||
33840255|NCT01161238|||COHORT||PROSPECTIVE|||||||
33840256|NCT01022541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840257|NCT00631267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33840258|NCT00966121|RANDOMIZED|PARALLEL||PREVENTION||NONE||Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol||||
33840259|NCT03970538|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center pivotal study||||
33943452|NCT05895591|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102124|NCT04991454|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102125|NCT01242215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102126|NCT03690999|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34102127|NCT06657976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943453|NCT00357643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33943454|NCT00365872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943455|NCT04212221|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33943456|NCT02004457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022580|NCT01021059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022581|NCT05572671|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.||||
34022582|NCT01413490|||COHORT||PROSPECTIVE|||||||
34022583|NCT04795830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to which group they are assigned to. Both materials used have the same white color and any labels on syringes will be hidden with appropriate wrap. Teeth treated will be assigned codes so that outcome evaluators at follow up appointments are blinded. Furthermore, baseline clinical and radiographic findings of sound teeth as well as after pulp therapy and stainless steel crown placement will not reveal the material being used at the intervention, since the stainless steel crown obscures the view clinically and radiographically. On the other hand, the operator/primary investigator cannot be blinded as she is already familiar with the nature of the materials used and their different modes of application. For statistical analysis, codes will also assure blinding and confidentiality.|After informed consent, baseline clinical and radiographic assessment will be obtained and recorded in the patient's examination sheet. Enrolled participant's tooth will be then randomly allocated to the experiment or control intervention group. Participant will be recalled for follow up assessments at 1, 3, 6 and 12 months. A 14 day window, defined as 7 days before and 7 days after the due date, will be available to complete the 1 and 3 month follow-up evaluations and a 28 day window, defined as 7 days before and 21 days after the due date, will be available to complete the 6 and 12 month follow up evaluations.|t|f|f|t
34022584|NCT02674906|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34022585|NCT03379389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022586|NCT03202524|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
34022587|NCT01006226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022588|NCT04322110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022589|NCT02283983|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022590|NCT00528411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022591|NCT04651894|||COHORT||RETROSPECTIVE|||||||
34022592|NCT04330716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022593|NCT02261350|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34022594|NCT06423443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022595|NCT02976324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022596|NCT05522985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022597|NCT03033082|||CASE_CONTROL||PROSPECTIVE|||||||
34022598|NCT00769990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022599|NCT04755933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022600|NCT01625962|||COHORT||PROSPECTIVE|||||||
34022601|NCT04290273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34022602|NCT00467935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022603|NCT00250016|||COHORT||PROSPECTIVE|||||||
34022604|NCT00681850|||COHORT||PROSPECTIVE|||||||
34022605|NCT01877044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022606|NCT00416650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022607|NCT01172119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022608|NCT05200897|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022609|NCT05819203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigational device and the comparator were indistinguishable. The comparator (isotonic nasal spray) used the same technology and the same packaging than Healsea Babykids. A white label with regulatory mentions for clinical investigations was stuck on the vial A white label with regulatory mentions was sticked on a white cardboard box used as secondary packaging. The IFUs (Bulgarian version) was included in the secondary packaging (on one face, Healsea Babykids, on the other face Placebo|Randomized controlled trial double blind|t|f|t|t
34022610|NCT06240247|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022611|NCT01607307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34022612|NCT04044911|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Crossover randomized control|f|f|f|t
34022613|NCT05783830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022614|NCT06220747|||CASE_CONTROL||OTHER|||||||
34022615|NCT04423029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022616|NCT02242916|||COHORT||RETROSPECTIVE|||||||
34022617|NCT03525652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022618|NCT02564081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022619|NCT04731337|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34022620|NCT01778686|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34022621|NCT04730349|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34022622|NCT03868150|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized control trial of Amiodarone versus standard of care in patients with intraoperative inducible atrial fibrillation undergoing non emergent first-time cardiac surgery.||||
34102128|NCT05993234|||COHORT||PROSPECTIVE|||||||
33718504|NCT01437215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943457|NCT05021731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943458|NCT01480401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33943459|NCT05936827|||CASE_ONLY||PROSPECTIVE|||||||
33943460|NCT00976521|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33718505|NCT03892590|||COHORT||PROSPECTIVE|||||||
33943461|NCT02432924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943462|NCT04449016|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This study was a longitudinal, repeated measures between subjects design.||||
33943463|NCT03762785|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33943464|NCT01475513|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Same drug (orthocyclen) was administered to 2 groups (Caucasian women of reproductive age, and African American women of reproductive age)||||
33840260|NCT03411083|||COHORT||PROSPECTIVE|||||||
33718506|NCT04729569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840261|NCT02700360|RANDOMIZED|CROSSOVER||||NONE||||||
33943465|NCT03367091|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943466|NCT00838422|||COHORT||PROSPECTIVE|||||||
33943467|NCT01334138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943468|NCT01933542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943469|NCT01834040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943470|NCT05215106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840262|NCT02614378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840263|NCT00418223|||CASE_CONTROL||PROSPECTIVE|||||||
33718507|NCT03503240|||CASE_CROSSOVER||PROSPECTIVE|||||||
33718508|NCT06493396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840264|NCT02642692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840265|NCT05183568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840266|NCT00227942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840267|NCT00953186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840268|NCT01738659|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33840269|NCT01802177|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33840270|NCT03616496|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33840271|NCT00968071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840272|NCT03153553|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33840273|NCT04968717|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943471|NCT03016260|||COHORT||PROSPECTIVE|||||||
33943472|NCT03281512|||COHORT||PROSPECTIVE|||||||
33943473|NCT03235245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943474|NCT02582008|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943475|NCT04302311|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34102129|NCT06689852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary objective is to evaluate the effectiveness of Enriched and Loceryl® in the treatment of onychomycosis based on the blinded evaluation of the percentage of healthy nail surface compared to baseline||f|f|f|t
34102130|NCT03213704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102131|NCT05174312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102132|NCT02549820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840274|NCT03610672|RANDOMIZED|FACTORIAL||TREATMENT||NONE||The current study is a two-armed, open randomized clinical trial design.||||
33943476|NCT00805194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943477|NCT01028859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943478|NCT02539680|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33943479|NCT05836688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33943480|NCT04361695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943481|NCT03635645|NA|SINGLE_GROUP||OTHER||NONE||||||
33943482|NCT00816712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943483|NCT02280265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943484|NCT06393205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33943485|NCT00749489|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33799810|NCT03875963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Determination of union assessed by two independent assessors blinded to treatment arm|The proposed study is a multi-centered, prospective, randomized controlled trial, comparing current standard of care for defect management to placement of antibiotic loaded Stimulan as a bone void filler in patients undergoing treatment of infected tibial defects or infected tibial nonunions.|f|f|f|t
33799811|NCT03495713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799812|NCT01407393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799813|NCT00547352||CROSSOVER||||NONE||||||
34022623|NCT06422312|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022624|NCT06063616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The two interviewers responsible for data collection and the patients were blinded as to which group they were in.~According to the lists created after block randomization in the computer environment, the researcher and the sham Reiki practitioner evaluated the individuals in the groups in which they would apply and received written consent from those who agreed to participate in the research. It was stated that Reiki treatment would be applied to the patients in both groups and the patients were blinded. The group of patients who agreed to participate in the study was not written on the data collection forms until the end of the study. In addition, the interviewer who collected the data was blinded by ensuring that he did not enter the HD hall before the applications were completed."||t|f|f|t
34022625|NCT06407986|||COHORT||PROSPECTIVE|||||||
34022626|NCT05924854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the particularity of acupuncture research, acupuncturist only carries out electroacupuncture. Blinded evaluation visitor will be used in the trial, and the efficacy will be evaluated by a third party not envovled in assignments. Blind statistical analysis was used in the data summary stage, and the researchers, operators and statisticians were separated to ensure the authenticity and reliability of the study results.|Randomization according to center will be used. Subjects were randomly assigned to the sevoflurane general anesthesia group（S group） and the electroacupuncture group（E group） at a ratio of 1:1.|t|f|t|t
34022627|NCT05631223|NA|SINGLE_GROUP||TREATMENT||NONE|As a pilot study to understand implementation barriers, assess feasibility, and effectiveness, this study is not blinded or randomized.|This is a single-arm, multisite pilot study||||
33718509|NCT04392947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The usage of a special active/placebo (A/P) coil in combination with an electrical co-stimulation will guarantee masking.~A hard cover surrounds the A/P coil and for this reason it is not possible to see which side is the active side of the coil. By entering a randomized code into the stimulator, the operator receive information whether the coil is in the correct position or has to be flipped around. The code does not allow third parties to identify to which study arm a patient has been assigned. The concealment of the assignment remains until the statistical analysis is finished."||t|t|t|t
34022628|NCT02208635|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34022629|NCT04596514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded from the statisticians who carry out analyses||f|f|f|t
34022630|NCT04422353|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|f|f|t|t
34022631|NCT01367665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022632|NCT01325727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718510|NCT04333784|||CASE_CONTROL||PROSPECTIVE|||||||
33718511|NCT01093547|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33718512|NCT00157950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33718513|NCT01355731|||CASE_ONLY||PROSPECTIVE|||||||
33718514|NCT01119131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718515|NCT05162131|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33799814|NCT03005197|||COHORT||PROSPECTIVE|||||||
33799815|NCT00002072||||TREATMENT||DOUBLE||||||
33799816|NCT01254188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022633|NCT01910389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022634|NCT00941512|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022635|NCT00630929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022636|NCT00274820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022637|NCT01695863|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34022638|NCT02171494|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022639|NCT00090181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022640|NCT02212327|||CASE_CONTROL||PROSPECTIVE|||||||
34022641|NCT04715932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022642|NCT05443581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022643|NCT01626443|RANDOMIZED|PARALLEL||||NONE||||||
34022644|NCT02374489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718516|NCT02632539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718517|NCT00128778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718518|NCT04263207|||COHORT||PROSPECTIVE|||||||
33718519|NCT03009565|||COHORT||CROSS_SECTIONAL|||||||
33718520|NCT00192829|||||PROSPECTIVE|||||||
33799817|NCT04058626|||OTHER||PROSPECTIVE|||||||
34022645|NCT06632431|||OTHER||RETROSPECTIVE|||||||
34022646|NCT01341782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102133|NCT06312670|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2, single-arm study composed of 2 stages: in the first stage, 13 subjects diagnosed with mHSPC will be enrolled and treated with EPI-7386 in combination with enzalutamide. If there are 8 or less subjects with a biochemical response at 6 months, then the trial will be suspended. Otherwise, 22 additional subjects will be enrolled and treated.||||
34102134|NCT05883137|||COHORT||PROSPECTIVE|||||||
34102135|NCT02864914|||COHORT||RETROSPECTIVE|||||||
34102136|NCT03750513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102137|NCT00495781|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33799818|NCT06113770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799819|NCT03855007|NA|SINGLE_GROUP||TREATMENT||NONE||"Drug: Iguratimod（T-614），25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.~Drug: Methotrexate （MTX），7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.~Drug: Hydroxychloroquine （HCQ），200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Drug: Prednisone （Pred）： 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response"||||
33799820|NCT04257071|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022647|NCT05892692|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||"Participants in the EMA/EMI condition will complete EMA as specified in Study 1. In addition, they will receive a personalized intervention regarding their level of risk during EMA. The EMI content will include three types of targeted feedback intervention options that will be provided to participants in near real-time after random and event-contingent reports based on tailoring variables (i.e., predictors of risk taking, assault, and substance use) identified during Study 1.~Participants will be given feedback about their drinking, drug use, and safe-sex practices, as well as their performance on risk judgment and response-selection tasks at baseline. They will receive behavioral comparisons to the average UNM undergraduate woman, and will be provided strategies for reducing risk for sexual assault, negative consequences of substance use, and STIs."|t|f|f|f
34022648|NCT04645264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022649|NCT04056286|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Outcome Assessor will be blinded for all interventions and will recieve raw data sequentially numbered, and will therefore not know which data are from the same test object and which intervention was given.|"In a randomized crossover design, eight healthy lean young men will undergo either:~i) Healthy conditions (overnight fast) + whey protein ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + whey protein iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest) + 3-OHB/whey protein"|f|f|f|t
34022650|NCT03214796|||COHORT||PROSPECTIVE|||||||
34022651|NCT05485701|||COHORT||PROSPECTIVE|||||||
34022652|NCT04332965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022653|NCT01590004|||CASE_ONLY||PROSPECTIVE|||||||
34022654|NCT03636412|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be recruited pre-transplant but on re-evaluation post-transplant based on mobility post-transplant will be enrolled in the ambulatory intervention.||||
34022655|NCT01136967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022656|NCT05367583|||COHORT||PROSPECTIVE|||||||
34022657|NCT06389539|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Study staff involved in participants' outcome assessments will be masked to the intervention assignment.|Participants will be randomized to either SBD111 medical food or placebo capsules for a period of 18 months.|t|t|t|t
34022658|NCT04638530|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34022659|NCT02640053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022660|NCT02185716|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34022661|NCT05873829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The patients, whose written and verbal consents were obtained in accordance with the inclusion criteria, were randomly assigned to the intervention and control groups.~Hand-foot exercises were applied to the patients in the intervention group. The patients in the control group did not undergo any intervention other than standard care."||||
34022662|NCT05384080|||COHORT||PROSPECTIVE|||||||
34022663|NCT04190537|||OTHER||PROSPECTIVE|||||||
34022664|NCT03875859|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single-arm study||||
34022665|NCT02174380|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34022666|NCT03330821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102138|NCT03505424|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102139|NCT01570907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102140|NCT06686823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102141|NCT03484195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102142|NCT06679530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to one of two groups including mindful music listening or standard care.||||
34102143|NCT04081012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It will be through sealed, opaque and numbered envelopes sequentially. The assignment sequence will be done by the pharmacist, the principal investigator will recruit the patients. Researchers and site staff (with the exception of the investigating pharmacologist) will be blinded to the assigned treatment. There will be no circumstances to unmask and reveal the intervention.|Randomized, double-blind clinical trial of the treatment will be the treating physician and radiologist, of parallel groups in patients undergoing EAP and BPA.|t|t|t|f
34102144|NCT05264051|||CASE_ONLY||PROSPECTIVE|||||||
34102145|NCT01270555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799821|NCT03131869|||COHORT||PROSPECTIVE|||||||
33799822|NCT05746754|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33799823|NCT04080336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799824|NCT02308319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33799825|NCT01198145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33799826|NCT05103423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799827|NCT01148134|||CASE_CONTROL||PROSPECTIVE|||||||
33799828|NCT01105117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799829|NCT05757583|||OTHER||CROSS_SECTIONAL|||||||
33799830|NCT01739270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33799831|NCT06421259|||COHORT||RETROSPECTIVE|||||||
33799832|NCT02023710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799833|NCT02708108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799834|NCT01144468|||COHORT||PROSPECTIVE|||||||
33799835|NCT02376530|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33799836|NCT06105125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33799837|NCT05527912|NA|SEQUENTIAL||TREATMENT||NONE||||||
33799838|NCT01777750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799839|NCT01149512|||COHORT||RETROSPECTIVE|||||||
33799840|NCT05175339|||CASE_ONLY||PROSPECTIVE|||||||
33799841|NCT01058499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799842|NCT06170073|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33799843|NCT03427307|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33799844|NCT01253031|||COHORT||PROSPECTIVE|||||||
33799845|NCT03169296|||COHORT||PROSPECTIVE|||||||
33799846|NCT00978042|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33799847|NCT04646902|||CASE_CONTROL||RETROSPECTIVE|||||||
33799848|NCT03608202|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Controlled clinical trial. Prospective, randomized controlled clinical trial. The type of design is with posttest only and control group. Two groups will be compared, a study group (experimental) undergoing a focal ultrasound protocol, versus a control group with conventional conventional management."||||
33799849|NCT01924676|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33799850|NCT02995655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799851|NCT04134273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799852|NCT06521723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33799853|NCT04718688|NA|SINGLE_GROUP||OTHER||NONE||single case experimental study design (SCED) with multiple baselines across individuals and behaviors||||
34022667|NCT01456455|||COHORT|||||||||
34022668|NCT00802594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022669|NCT05191017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33799854|NCT03743506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799855|NCT00003542||||TREATMENT||||||||
33799856|NCT01644916|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33799857|NCT02529839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799858|NCT00490802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799859|NCT06031012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33799860|NCT06473090|RANDOMIZED|PARALLEL||OTHER||SINGLE|The evaluation will be based on video recordings of the 2 scenarios assessed by 2 independent, blinded experts.|Parallel assignment, blinded, randomized study|f|f|f|t
33799861|NCT03010813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799862|NCT05998252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799863|NCT02940951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33799864|NCT01643616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799865|NCT03999671|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Control group and intervention group, were selected randomly from consecutive cases and standard management|t|t|f|f
33799866|NCT05603013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799867|NCT05820269|||COHORT||PROSPECTIVE|||||||
33799868|NCT03712306|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be randomized intro one of the three study groups.~Stratification by gender and habitual protein intake (low protein (\>=0.9 g/kg aBW/day - \<1.0 g/kg aBW/day), very low protein (\<0.9 g/kg aBW/day)), since we expect a different intervention effect for participants with a very low baseline habitual protein intake (\< 0.9 g/kg aBW/d) compared to participants with a low baseline habitual protein intake (≥ 0.9 g/kg aBW/d), and because of potential differences in how women and men respond to the intervention.~In case couples participate, we will make sure they will be allocated to the same intervention group. This will ensure no interference between intervention groups. We will randomly select whether the randomization for the intervention group is based on the men or the women."||||
33799869|NCT00011986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799870|NCT00847834||PARALLEL||TREATMENT||NONE||||||
33799871|NCT02555449|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799872|NCT00424645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34022670|NCT03753763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022671|NCT02169700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022672|NCT05367050|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34022673|NCT03603379|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34022674|NCT02005263|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022675|NCT01466010|||COHORT||RETROSPECTIVE|||||||
34022676|NCT00182468|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34022677|NCT04675619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022678|NCT02789618|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34022679|NCT00397059|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34022680|NCT00222521|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102146|NCT01603251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102147|NCT05628948|||CASE_ONLY||PROSPECTIVE|||||||
34102148|NCT06691048|||COHORT||RETROSPECTIVE|||||||
34102149|NCT05157789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799873|NCT01130246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799874|NCT05705505|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1: 3+3 dose escalation Phase2: Expansion cohort||||
33799875|NCT01799668|||COHORT||PROSPECTIVE|||||||
33799876|NCT05752175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799877|NCT00105313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799878|NCT00394407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799879|NCT05123742|||COHORT||PROSPECTIVE|||||||
33799880|NCT03084549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799881|NCT02582086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799882|NCT02621632|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33943486|NCT02690506|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33943487|NCT01107483|||COHORT||PROSPECTIVE|||||||
33943488|NCT02141594|||CASE_CONTROL||PROSPECTIVE|||||||
33943489|NCT00166595||||TREATMENT||||||||
34022681|NCT03449680|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The anesthesiologist performing the nerve block will be aware of group allocation; but a separate anesthesiologist providing intra-operative care will remain blinded. The patient and the research staff collecting outcome data will remain blinded until all data are collected.|Patients will be randomized between one of two treatment groups. The intervention of femoral articular branch block or the control group (non-invasive placebo).|t|t|f|t
34022682|NCT03409393|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The participants will be randomly assigned (1:1) to either an Intervention Group that in the initial study phase (week 0-8) receives the COPUS intervention plus usual care (i.e. OPUS treatment) or to a Control Group that only receives usual care in the initial phase. In the second phase of the study (week 8-16), participants allocated to the control group are offered the COPUS intervention.||||
34022683|NCT01236586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022684|NCT03560986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded treatment in Treatment Period A, open-label infusion in Treatment Period B.||t|t|t|t
34022685|NCT04530708|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre randomized phase 3 trial||||
34022686|NCT03052296|||COHORT||PROSPECTIVE|||||||
34022687|NCT00296231|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102150|NCT05576207|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022688|NCT06632561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022689|NCT00654290|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022690|NCT04428216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is rhomboid intercostal block group. The second one is no intervention control group|f|f|f|t
34022691|NCT05016895|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34022692|NCT04892225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Patients will be randomly assigned to text message in Urdu language on dietary sodium and fluid restriction daily for 8 weeks. Control group will not receive any text message.|t|t|f|t
34022693|NCT03048188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022694|NCT04744883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022695|NCT05226546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022696|NCT03885752|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34022697|NCT04172116|||COHORT||PROSPECTIVE|||||||
34022698|NCT04863599|NA|SINGLE_GROUP||OTHER||NONE||||||
34022699|NCT01604135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022700|NCT01288014|||CASE_ONLY||PROSPECTIVE|||||||
34022701|NCT01134003|||COHORT||CROSS_SECTIONAL|||||||
34102151|NCT02446600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102152|NCT03941860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102153|NCT01435746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102154|NCT01824966|||COHORT||RETROSPECTIVE|||||||
34102155|NCT03468465|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102156|NCT03917836|||CASE_ONLY||PROSPECTIVE|||||||
34102157|NCT05490875|||COHORT||PROSPECTIVE|||||||
33799883|NCT03700294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840275|NCT04890405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of the scale does not know the grouping of patients when assessing the patient.|Diarrhea-type irritable bowel syndrome patients were randomly divided into 2 groups, and each group was given a different treatment method|f|f|f|t
33840276|NCT00174694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840277|NCT02518035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840278|NCT05268536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840279|NCT01419470|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33840280|NCT02997826|NA|SINGLE_GROUP||OTHER||NONE||||||
33840281|NCT03883100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840282|NCT00317018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840283|NCT00703066|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33840284|NCT03942692|||CASE_ONLY||PROSPECTIVE|||||||
33840285|NCT02838992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840286|NCT00435175|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33840287|NCT01913834|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33840288|NCT04709588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840289|NCT05756296|||COHORT||PROSPECTIVE|||||||
33840290|NCT03979534|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840291|NCT04246164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded|placebo controlled|t|f|t|t
33840292|NCT00584077|||COHORT||CROSS_SECTIONAL|||||||
33840293|NCT00267514|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33840294|NCT02822430|||COHORT||PROSPECTIVE|||||||
33840295|NCT02976077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840296|NCT00010153||||TREATMENT||||||||
33840297|NCT05779124|||COHORT||PROSPECTIVE|||||||
33840298|NCT00657969|||CASE_CONTROL|||||||||
33840299|NCT01574196|||COHORT||PROSPECTIVE|||||||
33840300|NCT01582230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799884|NCT04064866|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigator, care provider, and participant were all blinded to injection contents (e.g., hemocyte autograft intervention vs. placebo control) An independent blinded evaluator assessed subjects at 4 weeks and 8 weeks. An unblinded or blinded evaluator will assess subjects at 26 weeks.|"This is a multi-center, randomized, controlled, double-blind clinical trial comparing hemocyte autograft (platelet rich plasma) to control injection (placebo) in subjects with reported cervical, thoracic or lumbar pain for at least 3 months with Pfirrmann grade changes at 7 or less and who are being considered for discography in order to identify pain generator discs in evaluation of potential surgical candidates. Randomization ratio was 2:1. After 8 weeks subjects who received placebo are eligible for crossover to treatment arm with hemocyte autograft, and subject who received treatment arm are eligible for surgery if not improved.~For subjects who cross over, follow-up schedule will reset with visits at 8 weeks and 26 weeks post-crossover."|t|t|t|t
33799885|NCT04477330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33943490|NCT03555227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All patients will be receiving both interventions i.e. USG PECS blocks and wound infiltration anesthesia, with local anesthetic 0.25% levobupivacaine (active) and 0.9% Saline depending on the randomized group allocations. As such patients will be blinded.The anaesthetist and surgeon doing the interventions will both be blinded as to the pharmacological contents of the drug. This will be done as mentioned with pharmacy labelling the drugs as PRE used for USG pecs block and POST for wound infiltration. Also the observer, in this case the recovery nurse who will be titrating analgesia in the immediate postoperative period shall be blinded as to what group the patient belongs to."|"This is a single-centre, prospective; double blinded randomised case control interventional study.Patients will be randomly allocated to group X or Y. Following anesthesia induction, all patients will receive USG modified Pecs2 blocks as described by Blanco et al with 30 mls of pharmacy prepared Drug A (active drug 0.25% levobupivacaine) or Drug P (placebo 0.9% NaCl), labelled PRE respectively based on the group allocation. After surgery, the surgeon shall infiltrate the wound with 30 mls of Drug P or Drug A respectively, labelled POST. Drug P has no active role in terms of outcomes being assessed in this study. Intraoperative analgesia will be provided by TCI Remifentanil. Following surgery, patients will be recovered by dedicated recovery nurses who will titrate intravenous morphine in the immediate postoperative period aiming to keep the NRS pain scores below 1."|t|t|t|t
33943491|NCT04594616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943492|NCT02622217|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33943493|NCT01402882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943494|NCT02240901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943495|NCT03470506|||COHORT||PROSPECTIVE|||||||
33943496|NCT02760420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943497|NCT04058782|||COHORT||PROSPECTIVE|||||||
34102158|NCT06694753|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|The study team will be blinded to treatment assignment within a cohort but not across cohorts|Cohorts 1A and 2A in Part A will be enrolled concurrently. Randomization to study product or placebo will take place within each cohort. After Part A is fully enrolled, there will be a planned safety hold to review all safety data from participants for one month following the final participant's first vaccination (week 0) in Part A. Enrollment in Part B will not proceed without the formal approval of the Protocol Safety Review Team (PSRT). Similar to enrollment in Part A, Cohorts 1B and 2B in Part B will be enrolled concurrently. Randomization to study product or placebo will take place within each cohort.|t|t|t|t
34102159|NCT05712447|||COHORT||PROSPECTIVE|||||||
34102160|NCT06079398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943498|NCT04951726|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective randomized non-inferiority trial 2 Arms:~1. 1.0 mg subcutaneous repeated q8hr until resolution for up to 24 hours (3.0 mg total in 24 hours)~2. 2 mg slow intravenous injection over five minutes repeated q6hr until resolution for up to 24 hours. (8 mg total in 24 hours) (CONTROL GROUP)"||||
33943499|NCT03651960|NA|SINGLE_GROUP||SCREENING||NONE||||||
33943500|NCT00948389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943501|NCT00578006|RANDOMIZED|PARALLEL||||NONE||||||
33943502|NCT03654963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Only pharmacy assistants and clinical pharmacists, who will obtain the best possible medication history and perform medication reconciliation, will know the assignment to either the intervention or the control group. Participants and outcomes assessor will be masked.|Allocation: centralized randomization; a unique list of randomization will be generated by the clinical trial unit (CTU) of the EOC with an ad hoc software, and patients will be allocated 1:1 in either the intervention or the control group.|t|f|f|t
33943503|NCT00733122|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33943504|NCT06185309|||COHORT||PROSPECTIVE|||||||
33943505|NCT04802226|RANDOMIZED|PARALLEL||PREVENTION||NONE||Naturalistic randomized controlled trial||||
33943506|NCT03328325|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33943507|NCT00216827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943508|NCT00026819||||TREATMENT||||||||
33943509|NCT03547219|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943510|NCT04430491|||COHORT||RETROSPECTIVE|||||||
33943511|NCT00183495|||CASE_ONLY||PROSPECTIVE|||||||
33943512|NCT01359865|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33943513|NCT05411731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943514|NCT02416375|||COHORT||PROSPECTIVE|||||||
33943515|NCT05471453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943516|NCT01741610|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33943517|NCT03600311|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33943518|NCT04549766|||COHORT||PROSPECTIVE|||||||
33943519|NCT00836342|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943520|NCT00945945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943521|NCT05476965|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943522|NCT02127580|||CASE_ONLY||PROSPECTIVE|||||||
33943523|NCT00002176|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943524|NCT05763030|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943525|NCT03061864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943526|NCT04862273|||COHORT||PROSPECTIVE|||||||
33943527|NCT01490385|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33943528|NCT00913731|||||PROSPECTIVE|||||||
33943529|NCT02921594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943530|NCT05498207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants that have a Android will be assigned to the no intervention arm.||||
33943531|NCT06227429|||CASE_ONLY||PROSPECTIVE|||||||
33943532|NCT01031368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943533|NCT03439319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A two-arm, parallel group, multicentre, single-blind, randomized controlled trial|f|f|f|t
33943534|NCT05884606|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Single Arm Cohort Pilot Study||||
33943535|NCT01861587|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33943536|NCT04440176|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34102161|NCT06679062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To minimize bias, all participants will be screened for assurance that they meet study eligibility criteria. A placebo drug will be employed as the comparison group to active study drug and the study will be conducted in a double-blinded fashion in that both the participants and the site investigators and staff interacting with participants and assessing study outcomes will be blinded to treatment assignment. The only individuals at the site with access to treatment assignment information will be the research pharmacists.|Each participant will be given a placebo run-in (Day -7 to Day -1). On baseline (Day 0), the participant will be randomized to receive SUV or placebo (1:1 ratio) and administered 10mg SUV or placebo for an additional 7 days (Day 0 to Day 6). On Day 7, the participant previously randomized to SUV will be given 20 mg SUV, and participant previously randomized to placebo will continue with placebo.|t|t|t|f
33943537|NCT00336960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102162|NCT03375164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102163|NCT06113614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1 Researcher, who will prepare the randomization and envelopes to ensure allocation concealment.~1 Researcher (resident physician) who will include subjects, open the envelope with the allocation, deliver the appropriate PBM device, and provide instructions.~4 Surgeons all surgical procedures and eligibility assessments. 4 Orthopedic physician evaluators (blinded to the experimental group of each participant), responsible for all evaluations from the postoperative period through outpatient follow-up.~1. The Principal Investigator will be aware of the groups; he will centralize data collection and will not participate in any evaluations.~1 Physical Therapist (blinded to the experimental group of each participant) 3 resident Physicians (blinded to each participant's experimental group) will contact participants daily"|Forty-two participants will be randomly assigned (1:1) into two groups: the Control group (standard physical therapy combined with simulated PBM) and the PBM group (standard physical therapy combined with active PBM). Participants will apply PBM at home daily for 10 minutes using a device containing 318 light-emitting diodes (LEDs), with 159 LEDs at 660 nm (28.5 mW; 12 J/cm2; 17 J per LED) and 159 LEDs at 850 nm (23 mW; 10 J/cm2; 14 J per LED). PBM and physical therapy sessions (30 minutes, twice a week) will be conducted over 12 weeks.|t|f|f|t
33943538|NCT02666079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718521|NCT03116607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||parallels groups: control arm will recieve normal healthcare, intervention arm will recieve a pharmaceutilcal intervention program.|f|f|f|t
33718522|NCT03451344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To minimize the risk of biased results as much as possible, the persons who conduct the urine tests and complete the evaluation of the ASI will be different from those who provides the intervention. But subjects may talk about the CAREs intervention during the assessment so it is not possible to completely 'blind' the evaluators to the intervention group of the subjects.||f|f|f|t
33943539|NCT02718365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943540|NCT02491593|||CASE_CONTROL||PROSPECTIVE|||||||
33718523|NCT03758144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718524|NCT00561080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943541|NCT00545584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943542|NCT04882579|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||150 patients with suspected pulmonary embolism, requiring CTPA or VQ to finally confirm or dismiss the diagnosis will be enrolled and randomized 1:1 to receive a multiorgan ultrasound investigation or continue to CTPA or VQ as planned.||||
33943543|NCT02003287|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33943544|NCT03119428|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943545|NCT00391911|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33943546|NCT01072227|||CASE_ONLY||PROSPECTIVE|||||||
33943547|NCT00208702|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33943548|NCT04568265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943549|NCT00787527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943550|NCT01668017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102164|NCT06690749|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study design and setting sample were drawn from patients randomly assigned to one of three parallel groups, initially in a 1:1:1 ratio to invite the subject to receive either NPT dosage.||||
33718525|NCT06014489|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||the study consists of a run-in phase and an extension phase||||
33718526|NCT05642754|RANDOMIZED|FACTORIAL||OTHER||SINGLE||3 options for describing bias/uncertainty about results 2 options for margin of error around main result (we will run the trial twice on 2 different online platforms)|f|f|t|f
33718527|NCT03779789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pragmatic, multicenter, open-label, parallel-group, superiority, randomized trial.|f|f|f|t
33718528|NCT04388267|||CASE_ONLY||PROSPECTIVE|||||||
33718529|NCT01839773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718530|NCT02251002|||CASE_CONTROL||PROSPECTIVE|||||||
33718531|NCT01739478|RANDOMIZED|PARALLEL||||NONE||||||
33718532|NCT05898815|||OTHER||RETROSPECTIVE|||||||
33718533|NCT03930043|||OTHER||PROSPECTIVE|||||||
33718534|NCT05404919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718535|NCT03022344|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33718536|NCT00111618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718537|NCT01914744|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718538|NCT02255981|NA|SINGLE_GROUP||TREATMENT||NONE|Masking is neither accurate nor reliable in a procedure such as acupuncture or massage.|Interventional, no randomized, no masking||||
33718539|NCT02887495|||COHORT||PROSPECTIVE|||||||
33718540|NCT04107233|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33718541|NCT00176007|RANDOMIZED|CROSSOVER||ECT||SINGLE||||||
33718542|NCT04715763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Patients will be randomized 1:1 to Telmisartan (80 mg) vs placebo|t|t|t|t
33718543|NCT02006381|||COHORT||CROSS_SECTIONAL|||||||
33718544|NCT04961645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718545|NCT06471894|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718546|NCT05366803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718547|NCT01865539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33718548|NCT00064207|RANDOMIZED|||TREATMENT||||||||
33718549|NCT03142633|||COHORT||PROSPECTIVE|||||||
33718550|NCT06152757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718551|NCT02184182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718552|NCT04060550|||COHORT||PROSPECTIVE|||||||
33718553|NCT01846507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718554|NCT02522026|||COHORT||PROSPECTIVE|||||||
33718555|NCT02429947|||COHORT||CROSS_SECTIONAL|||||||
33718556|NCT04827329|||COHORT||RETROSPECTIVE|||||||
33718557|NCT04425707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718558|NCT05069454|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a prospective longitudinal cohort study, which will compare SARS-CoV-2 incidence among COVID-19 vaccinated and unvaccinated HWs who are eligible for COVID-19 vaccination in Azerbaijan.~Upon approval of the protocol, all HWs working at six hospitals of Baku capital and who are eligible for COVID-19 vaccination will be offered to participate in the study and followed up regularly over time. The participation is completely voluntary."||||
33718559|NCT03402789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not be informed of whether they are taking the treatment drug or the placebo. Technicians measuring participants' visual outcomes are also masked. The principal investigator and co-investigators will know how the patient's are randomized.|single blinded randomized controlled pilot study with 2/3 of participants randomized into the treatment arm and 1/3 of participants randomized into the placebo arm.|t|f|f|f
33718560|NCT02405845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718561|NCT00697203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718562|NCT00304499|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33718563|NCT03137472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single, blinding of participant||t|f|f|f
33718564|NCT01594125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718565|NCT06454110|NA|SINGLE_GROUP||TREATMENT||NONE||The study will enroll a planned total of 10 patients as subjects for the trial, with extra enrollment if needed, at the discretion of the Investigator. All subjects will be administered 17 mg/kg of NM8074 intravenously every week, for a total of 15 doses from Day 1 to Day 99 of the Treatment Period.||||
33718566|NCT05575167|||COHORT||PROSPECTIVE|||||||
33718567|NCT02066974|||COHORT||PROSPECTIVE|||||||
33943551|NCT01672827|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33943552|NCT01144897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943553|NCT03331393|||COHORT||RETROSPECTIVE|||||||
33943554|NCT02968277|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||No washout period between different arms||||
33943555|NCT00699582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943556|NCT03390049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Each subject will be assigned a study identification number, and demographic and clinical data will be recorded in REDCAP on de-identified data collection forms. The lead research coordinator will maintain the key linking the identification number to each subject in a locked, password-protected site. A random number generator in REDCAP will then randomly assign each subject to either fractional CO2 laser or sham laser.~The physician administering the laser sessions will be blinded to treatment arm assignment."||t|f|f|t
33943557|NCT04071249|||COHORT||PROSPECTIVE|||||||
33943558|NCT04041648|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33943559|NCT05294627|||COHORT||PROSPECTIVE|||||||
33943560|NCT00916903|||FAMILY_BASED||RETROSPECTIVE|||||||
33718568|NCT00502177|||CASE_CONTROL||PROSPECTIVE|||||||
33718569|NCT01430156|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34022702|NCT03779737|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The person responsible for the analyzes will be blind about the interventions. The analysis will be by intention to treat. There would be three arms of the study (strength group, aerobic exercise group and control group) of adolescents of 12 to 17 years old. A balanced randomization will be carried out using random numbers generated in software systematized form, guaranteeing the homogeneity of the number of subjects in each arm, with internal random assignment with a ratio of 1:1:1 to receive the study intervention.|The study is divided into two phases carried out in several visits: Phase I is constituted by a visit -1 and 1, which includes the selection of the sample and the randomization. Phase II includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week defined for SIMAC (three sessions). The control group will be monitored passively for the detection of adverse or secondary events. At the end of this phase, anthropometric, clinical and biochemical markers will be monitored in the two intervention groups and in the control group. In Phase III a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.|f|f|t|t
34022703|NCT02620644|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022704|NCT03476733|||COHORT||PROSPECTIVE|||||||
34022705|NCT00170638|||||PROSPECTIVE|||||||
34022706|NCT03077555|RANDOMIZED|PARALLEL||OTHER||TRIPLE||two intervention groups|f|t|t|t
33718570|NCT05883930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718571|NCT05461677|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718572|NCT00310583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33718573|NCT02237950|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718574|NCT06503419|||OTHER||CROSS_SECTIONAL|||||||
33718575|NCT01712854|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33718576|NCT02716064|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718577|NCT04683536|||COHORT||CROSS_SECTIONAL|||||||
33718578|NCT02715414|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33718579|NCT00810290|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33718580|NCT06122129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718581|NCT00528385|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718582|NCT00560079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718583|NCT04290689|||COHORT||PROSPECTIVE|||||||
33718584|NCT05741008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718585|NCT01920217|||CASE_CONTROL||PROSPECTIVE|||||||
33718586|NCT05464160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33718587|NCT03241355|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022707|NCT03694327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022708|NCT02935153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022709|NCT03673527|NA|SINGLE_GROUP||OTHER||NONE||||||
34022710|NCT04888598|||COHORT||PROSPECTIVE|||||||
34022711|NCT03967171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022712|NCT02085135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022713|NCT04728503|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022714|NCT00527553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34022715|NCT01467414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022716|NCT01910779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022717|NCT02001220|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34022718|NCT01740726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022719|NCT03247816|||COHORT||CROSS_SECTIONAL|||||||
34022720|NCT01366430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022721|NCT01345916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022722|NCT00007527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022723|NCT01235832|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34022724|NCT03466437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022725|NCT05984875|||COHORT||PROSPECTIVE|||||||
33718588|NCT04653805|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33718589|NCT03683446|||COHORT||OTHER|||||||
33718590|NCT04645641|NA|SINGLE_GROUP||OTHER||NONE|All systems worn will be blinded. Sensor wear locations will be pre-assigned. All sensor insertions will be performed at the clinic by study staff.|||||
33718591|NCT02680912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718592|NCT03104595|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 + 3 dose escalation||||
33718593|NCT01835067|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33718594|NCT03690115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718595|NCT06538337|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized, trial of adjuvant SBRT to the pelvis with adaptive planning using CT or MRI guidance for endometrial and cervical cancers||||
33718596|NCT01488539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718597|NCT06486090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The biostatistician performing the main analysis will be blinded to group assignment||f|f|t|f
33718598|NCT05361993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33718599|NCT01590238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718600|NCT04018950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718601|NCT00815581|RANDOMIZED|PARALLEL||||DOUBLE||||||
33718602|NCT02308852|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||tDCS real versus sham tDCS (this is what this is)|t|t|t|t
33718603|NCT01537744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022726|NCT05523154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022727|NCT03275116|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022728|NCT02369991|||||CROSS_SECTIONAL|||||||
34022729|NCT03384082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022730|NCT01822275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799886|NCT05757388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Normal saline is prepared in the same packages as parecoxib and paracetamol.|Group P receives the parecoxib 40 mg iv slowly push plus paracetamol 1 gm (100 mL) infusion drip in 30 min after induction or group C receives the normal saline in the same process.|t|t|f|t
33799887|NCT00821184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799888|NCT03277534|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33943561|NCT02201199|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33943562|NCT04227561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943563|NCT00002075||||TREATMENT||||||||
33943564|NCT02792569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33943565|NCT04952792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943566|NCT03266211|||OTHER||PROSPECTIVE|||||||
33943567|NCT05423847|||COHORT||PROSPECTIVE|||||||
33943568|NCT01495741|||COHORT||RETROSPECTIVE|||||||
33943569|NCT04329273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33943570|NCT05374070|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Participants will be randomly assigned to one of the 4 groups consuming powder containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotic:~1. Probiotic Streptococcus salivarius K12 Powder (Dose: 1 Billion cfu/g)~2. Probiotic Streptococcus salivarius K12 Powder with prebiotic (Dose: 1 Billion cfu/g)~3. Probiotic Streptococcus salivarius M18 Powder (Dose: 1 Billion cfu/g)~4. Probiotic Streptococcus salivarius M18 Powder with prebiotic (Dose: 1 Billion cfu/g)"||||
34022731|NCT04383223|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022732|NCT05493137|||COHORT||PROSPECTIVE|||||||
34022733|NCT03411096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022734|NCT04270318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022735|NCT00927797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022736|NCT03548701|||CASE_CONTROL||PROSPECTIVE|||||||
34022737|NCT03527381|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Trial participants, data analysts, and report writers are blinded.|Single-center prospective, randomized, placebo-controlled study|t|t|f|t
34022738|NCT04334694|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients will undergo detailed screening using echocardiography, impedance cardiography and right heart catheterization prior to AFR implantation.||||
34022739|NCT05710692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022740|NCT06189729|RANDOMIZED|CROSSOVER||SCREENING||NONE||This is a stepped wedge trial. In this study, the 1-year observation period is divided into four three-month intervals. All sequences would start with a control period. The three sequences would cross over to the intervention at Month 3, 6, and 9, respectively. All participants would therefore eventually receive intervention.||||
34022741|NCT02504671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022742|NCT05102214|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34022743|NCT06086392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34022744|NCT01782300|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34022745|NCT03579927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022746|NCT05408234|NA|SINGLE_GROUP||TREATMENT||NONE||The study was conducted in the control and treatment groups where the control group will get the treatment of doing modified leg exercises for one week. The control group did not get the modified leg exercise. Both groups received standard therapy for type 2 diabetes.||||
34022747|NCT04308226|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomized in a 2:1 ratio to usual care with (N=200) or without (N=100) lung cancer screening (LCS) navigation. Randomization will be stratified by smoking status, housing status, clinical site, and whether participants have already discussed LCS with their primary care provider (PCP) to ensure balance between study arms on these variables.||||
34022748|NCT01120704|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34022749|NCT01278901|||COHORT||PROSPECTIVE|||||||
34022750|NCT06437574|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34022751|NCT03849183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34022752|NCT04493086|||COHORT||PROSPECTIVE|||||||
34022753|NCT02476240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022754|NCT06009627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022755|NCT01274676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022756|NCT00150761|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34022757|NCT05599061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022758|NCT05384288|||CASE_ONLY||PROSPECTIVE|||||||
34022759|NCT04717765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34022760|NCT04719260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization sequence will be generated by computer in the data center using alphanumeric codes and implemented through the Research Electronic Data Capture (REDCap®) software. The professionals who will carry out the interventions during the protocol will be trained for one of the two interventions, without knowledge of the outcomes (except, bioimpedance results), evaluations performed during the study or comparison intervention. After the assignment to one of the groups, the participants, and those who will evaluate all the outcomes, will remain blind until the end of the study and results analysis.|This is a parallel randomized clinical trial, where individuals will be allocated to one of the arms - experimental intervention (Nutrition Thinking®) or control (standard intervention) - in a 1:1 ratio. The sample size calculation suggests that 82 subjects (41/each arm) are required. At the end of the clinical trial, individuals will be part of a cohort study where they will be followed up every three months for 12 months.|t|f|t|t
33799889|NCT06369701|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subjects repeated measures design||||
34022761|NCT02895152|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022762|NCT03760003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double blind, placebo controlled, parallel groups|t|t|t|t
34022763|NCT04953572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022764|NCT05655221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34022765|NCT05296538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers conducting assessments will be masked to treatment allocation|The MISST study is a two-armed feasibility randomised controlled trial.|f|f|f|t
34022766|NCT02829151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718604|NCT04208204|NA|SINGLE_GROUP||OTHER||NONE||Three measurements time points: baseline, after treatment, and 8 months after baseline. Additionally two interviews per participant; first - between baseline and treatment ending and second after 8 months follow up||||
33718605|NCT00849381|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33718606|NCT02316041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718607|NCT04369651|||COHORT||PROSPECTIVE|||||||
33718608|NCT04974112|||OTHER||RETROSPECTIVE|||||||
33718609|NCT03698747|||CASE_CONTROL||PROSPECTIVE|||||||
33718610|NCT00770796|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718611|NCT01028339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718612|NCT05701774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022767|NCT06568055|||COHORT||RETROSPECTIVE|||||||
34022768|NCT02984085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718613|NCT03356951|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718614|NCT02677987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718615|NCT04092101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind dosing of tobacco cigarette nicotine levels.|Randomized parallel groups research design.|t|f|t|t
33718616|NCT04284618|||COHORT||RETROSPECTIVE|||||||
33718617|NCT03935191|||COHORT||PROSPECTIVE|||||||
33718618|NCT01654094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022769|NCT01129843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022770|NCT01846910|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022771|NCT05567861|||COHORT||PROSPECTIVE|||||||
34022772|NCT01284946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022773|NCT06633471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022774|NCT04505748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022775|NCT06369233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022776|NCT06002789|NA|SINGLE_GROUP||TREATMENT||NONE||MSI-H/MSS (dMMR/pMMR) mixed sMPCC or all-MSI-H (dMMR) sMPCC||||
34022777|NCT02212613|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34022778|NCT01345487|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34022779|NCT02576912|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34022780|NCT05603377|NA|SINGLE_GROUP||SCREENING||NONE||||||
34022781|NCT06264401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"intervention: medication the experimental and control groups received (Alendronate) 70 mg 1 tab every week for 4 months.~treatment exercises the experimental group performed core stability and dynamic resistance exercises, a 45-min lumbar-pelvic/core strength and stability exercise program which include 5 min warming up and 5 min cooling down at the end of the session each exercise was executed for three sets of 15 seconds, which gradually upgraded to three sets of 45-second at the fourth month and 10 sec rest between each set and dynamic resistance exercise performed by each woman for 2 sets for 8-12 repetitions gradually along the study of 90 sec rest between each set for a duration of 60 min including 10 min warming up and 10 min cooling down in form of stretching."|t|f|f|t
34022782|NCT06447363|||OTHER||CROSS_SECTIONAL|||||||
34022783|NCT05479656|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34022784|NCT06016036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022785|NCT02036359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022786|NCT05782127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022787|NCT05445661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject and Outcome Assessor will be unaware of which side of the subject is treated with the study device and which is treated with saline.|This is a prospective, single-site, double-blinded, split-body, randomized controlled trial.|t|f|f|t
34022788|NCT00193466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022789|NCT03983824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022790|NCT01567475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022791|NCT02985190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022792|NCT06077383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34022793|NCT05237336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This three-group randomised controlled trial recruited 80 Malay Muslims with psychological distress. Participants will be randomly allocated to an MBCT-IPS experimental group, an MBCT group, or individual counselling-as-usual.|t|t|f|f
34022794|NCT05726903|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34022795|NCT03641521|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||controlled, non-randomized community nutrition intervention|t|f|f|f
34022796|NCT02378792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022797|NCT05803174|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022798|NCT04732910|||COHORT||PROSPECTIVE|||||||
34022799|NCT00872638|RANDOMIZED|PARALLEL||||NONE||||||
34022800|NCT04500093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022801|NCT06632353|||CASE_CONTROL||RETROSPECTIVE|||||||
34022802|NCT02679235|NA|SINGLE_GROUP||TREATMENT||NONE||The participant will receive THN treatment, compared to PRE supplementation condition.||||
34022803|NCT05908630|||COHORT||RETROSPECTIVE|||||||
34022804|NCT00517556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022805|NCT03925350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022806|NCT04607161|||CASE_ONLY||PROSPECTIVE|||||||
34022807|NCT05826795|||COHORT||RETROSPECTIVE|||||||
34022808|NCT04181073|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomised Controlled Trial||||
34022809|NCT04541316|||COHORT||RETROSPECTIVE|||||||
34022810|NCT00054665|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022811|NCT05346536|NA|SINGLE_GROUP||OTHER||NONE||Single-centre prospective cohort Cohort of newly diagnosed major patients with metastatic pancreatic cancer, naïve of any treatment||||
33718619|NCT04954781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718620|NCT05442320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Same packages of toothpastes with different concentration Key known only to principal investigator|Two parallel groups with different toothpaste fluoride concentrations (500 ppm, 1000 ppm)|t|t|t|t
33718621|NCT06137716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718622|NCT03387839|||COHORT||OTHER|||||||
33718623|NCT00955591|NA|SINGLE_GROUP||SCREENING||NONE||||||
33718624|NCT01366560|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33943571|NCT03279731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Novo Nordisk's Clinical Services (CS) will label, package, and ship the labelled study drugs to the Penn's Investigational Drug Service (IDS). Dr. Rockwell from Penn's IDS service will generate the randomization code using a 1:1 randomization scheme of liraglutide and placebo. The first subject to meet the treatment criteria will be assigned the first number in the sequence; each subsequent subject to meet treatment criteria will be assigned the next number in the sequence. Unblinding of the treatment codes will occur after all data have been verified and deemed clean by the data managers and statistician, and right before analysis of the data occurs.~The code for a particular subject may be broken in a medical emergency if knowing the identity of the treatment allocation would influence the treatment of the subject or if demanded by the subject. Whenever a code is broken, the staff-member breaking the code will record the time, date and reason."|Single-center, double-blind, randomized placebo-controlled trial with parallel groups.|t|t|t|t
33943572|NCT04041401|||COHORT||PROSPECTIVE|||||||
33943573|NCT04490902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943574|NCT03907085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33943575|NCT01142362|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943576|NCT02089165|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33943577|NCT05699382|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33943578|NCT03102164|||CASE_CONTROL||PROSPECTIVE|||||||
33943579|NCT03672474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943580|NCT01241643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943581|NCT05798559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Randomized Controlled Trial~Mothers of children with neurodevelopmental disorders will be included in the study.~Inclusion criteria for the study:~* Having a child with a neurodevelopmental disorder~* Be over 18 years old and literate~* Having a child(s) of pre-school age (3-6 years old)~* Communicating and collaborating~Intervention and study group will be formed by simple randomization."||||
33943582|NCT03507049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded|Randomized controlled trial comparing sacroiliac joint fusion and sham surgery. A prospective double blinded randomized controlled multicenter trial.|t|t|t|t
33943583|NCT04896606|RANDOMIZED|PARALLEL||TREATMENT||NONE||A run-in pilot will be done treating patients with COVID CTLs for safety. If there are no DLTs per definition in the study, study will proceed with a randomized trial of COVID CTLs + standard of care versus just standard of care alone.||||
33943584|NCT04915742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomize|t|f|t|t
33943585|NCT06262009|||OTHER||PROSPECTIVE|||||||
33943586|NCT04054050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718625|NCT02480543|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33718626|NCT05127447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly divided into two groups (such as ES and sham groups)|f|f|f|t
33718627|NCT04464915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The trial design is open label, given that blinding the scent of alcohol swabs is difficult. As such, no blinding of the study participants nor the research team to interventions will occur, as there will be no placebo intervention given.|||||
33799890|NCT03278769|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799891|NCT05588115|||COHORT||PROSPECTIVE|||||||
33799892|NCT05845177|||COHORT||CROSS_SECTIONAL|||||||
33799893|NCT00241241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799894|NCT02788604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33943587|NCT01812564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33943588|NCT01932671|||COHORT||PROSPECTIVE|||||||
33943589|NCT03778476|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant is masked to the hypotheses of the treatment.|The two groups will participate in two sessions receiving intervention or no intervention in a randomized manner.|t|f|f|f
33943590|NCT04454632|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33943591|NCT02695758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943592|NCT00564759|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33943593|NCT04703959|||CASE_CONTROL||PROSPECTIVE|||||||
33799895|NCT04761146|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33943594|NCT06431139|RANDOMIZED|PARALLEL||OTHER||SINGLE|The trial will use assessors blinded to the allocation and in charge of testing the following outcomes: 30 seconds chair stand test, 10-meter walk test, 6-minute walking test, and the Montreal Cognitive Assessment Scoring (MoCA) Two statisticians that will perform the statistical analysis are blinded to the allocation||f|f|f|t
33943595|NCT03083262|||COHORT||RETROSPECTIVE|||||||
33943596|NCT03964311|NA|SINGLE_GROUP||OTHER||NONE||||||
33943597|NCT05061329|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943598|NCT00031824|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE||||||
33943599|NCT00981266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943600|NCT05330728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943601|NCT00660816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943602|NCT01745159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943603|NCT01156636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943604|NCT04944966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022812|NCT05729516|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a wait-list control study design. Participants are assigned to one of two groups at random (intervention and wait list) for 6 months. After 6 months, participants in the wait list group are able to receive the intervention.||||
34022813|NCT05668078|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34022814|NCT01231399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022815|NCT03425695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized placebo-controlled parallel design|t|f|t|t
34022816|NCT05476952|||CASE_CONTROL||PROSPECTIVE|||||||
34022817|NCT03547037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022818|NCT00711438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34022819|NCT02903030|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34022820|NCT05326230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34022821|NCT00000535|RANDOMIZED|FACTORIAL||TREATMENT||||||||
34022822|NCT00637650|RANDOMIZED|PARALLEL||||NONE||||||
33799896|NCT00480077|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Intervention: in the access arm the patiens had programmmed the audible OptiVol Fliud status alert on. Control patienst had programmed the audible alert off"||||
33799897|NCT01781585|||CASE_CROSSOVER||PROSPECTIVE|||||||
33799898|NCT06492070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799899|NCT06034522|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33799900|NCT00938054|||||OTHER|||||||
33799901|NCT04866238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799902|NCT05073562|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33799903|NCT04196504|||CASE_ONLY||PROSPECTIVE|||||||
33799904|NCT02944760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799905|NCT04750850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799906|NCT00337545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799907|NCT03113617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33799908|NCT04911634|||COHORT||RETROSPECTIVE|||||||
33799909|NCT04792905|||CASE_ONLY||CROSS_SECTIONAL|||||||
33799910|NCT04292132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799911|NCT03631953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943605|NCT00307073|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33943606|NCT04084275|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial||||
33943607|NCT02961231|RANDOMIZED|PARALLEL||PREVENTION||NONE|"43068 children participated in the PCV vaccination activity during the study period.~A total of 18652 children were enrolled in the pneumococcal carriage surveys to evaluate the non-inferiority of VT reduction in 1p+1, 0p+1 vs 2p+1 and 3p+0 arms."|||||
33943608|NCT00006358|NA|SINGLE_GROUP||TREATMENT||||||||
33943609|NCT02943876|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33943610|NCT03846323|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33943611|NCT00386035|||COHORT||PROSPECTIVE|||||||
33943612|NCT00469391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943613|NCT03380806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943614|NCT05943340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be anonymized with a number and randomized with a web program (random.org)||t|f|f|f
33943615|NCT04135222|||OTHER||PROSPECTIVE|||||||
33943616|NCT04697199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943617|NCT05038306|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33943618|NCT01289964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943619|NCT01738906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33943620|NCT01657773|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943621|NCT00887601|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33943622|NCT00611351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943623|NCT03608189|||CASE_CONTROL||PROSPECTIVE|||||||
33943624|NCT05959876|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome evaluations will be conducted by a researcher blinded to group allocation.|This study is a randomized controlled study with experimental and control groups consisting of pre-test and post-test|f|f|f|t
33943625|NCT02898662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022823|NCT00236912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022824|NCT04345601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022825|NCT03466255|||COHORT||PROSPECTIVE|||||||
34022826|NCT02757573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022827|NCT01624701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799912|NCT02139696|||COHORT||PROSPECTIVE|||||||
33799913|NCT00225004|||||RETROSPECTIVE|||||||
33799914|NCT01437605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799915|NCT00774852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799916|NCT02648503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799917|NCT03324945|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33799918|NCT02830906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799919|NCT02045459|NA|SINGLE_GROUP||OTHER||NONE||||||
33799920|NCT01571596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799921|NCT02600052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33799922|NCT05598684|||COHORT||PROSPECTIVE|||||||
33799923|NCT05906875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799924|NCT01036217|||||PROSPECTIVE|||||||
33799925|NCT01058785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799926|NCT03475316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33799927|NCT02086097|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33799928|NCT01609075|||COHORT||PROSPECTIVE|||||||
33799929|NCT02253537|||CASE_ONLY||PROSPECTIVE|||||||
33799930|NCT05748015|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33799931|NCT00041548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33799932|NCT06514937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799933|NCT02616900|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33799934|NCT05401474|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33799935|NCT01919450|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799936|NCT04255940|||CASE_ONLY||PROSPECTIVE|||||||
33799937|NCT01504659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33799938|NCT02881203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799939|NCT04748575|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Smoothies were prepared by the Laboratory Technician and blinded from the participant and investigator. Acai and placebo smoothies were matched nutritionally including for carbohydrate, total sugars, protein, fat and fibre. Additionally, the smoothies were matched for colour, taste and temperature and were served in opaque containers.|Randomised double-blind crossover|t|f|t|f
33799940|NCT05204394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799941|NCT05551065|||CASE_ONLY||PROSPECTIVE|||||||
33799942|NCT04353102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799943|NCT00910078|||COHORT||RETROSPECTIVE|||||||
33799944|NCT04358939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799945|NCT01620684|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33799946|NCT05865145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799947|NCT03401138|||COHORT||PROSPECTIVE|||||||
33799948|NCT05702775|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, low-intervention, superiority clinical trial with parallel groups for the two treatment strategies.||||
33799949|NCT05202912|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799950|NCT01561144|||COHORT||OTHER|||||||
33799951|NCT00462358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799952|NCT01942018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799953|NCT04958343|||COHORT||RETROSPECTIVE|||||||
33799954|NCT01519037|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33943626|NCT00850356|||||PROSPECTIVE|||||||
33943627|NCT03760562|||COHORT||RETROSPECTIVE|||||||
33799955|NCT03844269|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention group will be compared to historical controls.||||
33799956|NCT03433586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind|participants will be randomized to aspirin or placebo|t|f|t|f
33799957|NCT04357951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, therapists, investigators, and outcome assessors will all be masked to treatment assignment. Only the study coordinator will be aware of random assignment to treatment condition.|This trial will evaluate the feasibility and initial efficacy of behavior therapy augmented with d-cycloserine (DCS) compared to behavior therapy augmented with placebo.|t|t|t|t
33799958|NCT03482011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799959|NCT04630600|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33799960|NCT02304055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33799961|NCT01078116|||COHORT||PROSPECTIVE|||||||
33799962|NCT01420549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799963|NCT03643939|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adaptive, non-inferiority randomized, open-label, controled clinical trial||||
33799964|NCT01295697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799965|NCT06252974|||CASE_ONLY||RETROSPECTIVE|||||||
33799966|NCT04773678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33799967|NCT03278379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799968|NCT03143842|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Within-subject design:~To investigate whether VNS can accelerate learning and improve associative memory when learning word pairs, we will investigate the performance of VNS implanted participants on a Verbal Paired-Associate memory task and compare their performance on the words that were learned while paired with VNS in contrast to their performance on the words that were learned while unpaired with VNS and in contrast to their performance on the words that were learned without VNS (i.e. 3 types/groups of words: paired with VNS, unpaired with VNS and without VNS) during the first visit and 1 day,1 week and 1 month after their first visit."||||
33943628|NCT04436042|NA|SINGLE_GROUP||OTHER||NONE||||||
33943629|NCT04642911|||CASE_ONLY||PROSPECTIVE|||||||
33799969|NCT02833506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799970|NCT00214591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33799971|NCT00268671|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33799972|NCT04115683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799973|NCT02935998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943630|NCT05356637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943631|NCT02297672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943632|NCT02463812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943633|NCT00507312|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33943634|NCT00950755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943635|NCT05078476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33718628|NCT03222596|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be randomly selected into 2 groups: ambulatory and non-ambulatory (wheelchair) MS individuals that will exercise - group (MSE), with related control group (ambulatory and non-ambulatory (wheelchair) individuals who will not exercise) (MSC). In addition, a group of healthy control subjects without MS (HC) will be evaluated.~Ambulatory and non-ambulatory group of individuals will exercise under the guidance of a physiotherapist."||||
33718629|NCT04918264|||COHORT||RETROSPECTIVE|||||||
33718630|NCT03752359|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33718631|NCT04505774|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|There will be independent masked adjudicators.|This is an adaptive design||||
34022828|NCT02616965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718632|NCT01085409|||||PROSPECTIVE|||||||
33943636|NCT00097916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943637|NCT00865176|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943638|NCT04000074|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Potential enrollees are identified from a predictive model operating on an administrative database. There are two types of service delivery systems: in-home visits and telephonic. Each month, a population of the highest risk clients are identified as eligible for the home-visit and a population of elevated risk clients are identified as eligible for telephonic services. From these populations, sufficient new enrollees are identified to reach program capacity, and twice this number of controls. Persons previously identified as controls are eligible for enrollment into the program in subsequent months||||
33943639|NCT03646955|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinically controlled randomized trial||||
33943640|NCT03080727|||OTHER||OTHER|||||||
33943641|NCT00804596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943642|NCT02872129|||COHORT||PROSPECTIVE|||||||
33943643|NCT04274361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943644|NCT01234142|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33943645|NCT05785559|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Uterine biopsy and cesarean scar dehiscence||||
33943646|NCT05735093|||COHORT||PROSPECTIVE|||||||
33943647|NCT02398643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943648|NCT00002276||||TREATMENT||||||||
33943649|NCT05997511|RANDOMIZED|PARALLEL||PREVENTION||NONE||Our study will use a cluster- randomized design with two active arms - one arm targeting COVID-19-related misinformation and a second arm targeting misinformation related to mental health.||||
33943650|NCT00222066|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943651|NCT00656331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943652|NCT03484780|NA|SINGLE_GROUP||TREATMENT||NONE|Independent data review and analysis by the University of Glasgow Department of Biostatistics|Patients implanted with the VisONE implantable system for delivering chronic Asymptomatic Diaphragmatic Stimulation (ADS).||||
33943653|NCT00352404|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022829|NCT01312571|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34022830|NCT03024008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022831|NCT01615237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022832|NCT05828576|||COHORT||PROSPECTIVE|||||||
34022833|NCT05498181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded (quadruple) and placebo-controlled|Parallel group randomized trial of sacubitril/valsartan versus placebo|t|t|t|t
34022834|NCT00001474||||TREATMENT||||||||
34102165|NCT06032715|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|GPs will be cluster randomized based on GP to two sequential teaching programs to learn the Brief Intervention procedure. The patients of those who have the course first will constitute the intervention arm while patients of GPs who are in the second course will constitute parallel business as usual controls in the masked part of the study. When the second group of GPs have their course, open cross-over will be possible.|Parallel masked and controlled first part intervention vs Business as usual with follow-up after 6 months by masked assessors. Subsequently open single cross-over of business as usual patients to also receive the same intervention.|t|t|t|t
34102166|NCT06694792|||COHORT||PROSPECTIVE|||||||
34102167|NCT06541964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33799974|NCT03462823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized patient-blinded two-group parallel comparison trial using an active comparator.|t|f|f|f
33799975|NCT00394940|||COHORT||PROSPECTIVE|||||||
33840301|NCT04577053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The independant analyst will assess the results provided in the survey, which are collected by a third party (the Google Forms app) and therefore cannot be tampered with by the Investigator. Participants complete surveys on their own mobile devices or computers at home, without any possible supervision or influence by the Investigator. The Participants are each assigned a code with which they complete the surveys on-line. The codes do not imply hierarchy (e.g. 'Alpha'), do not include numbers so as not to prime participants' answers, and have been carefully selected to remain neutral from gender, nationality, ethnicity or religious references.~Participants have been allocated randomly using a web-based random number generator. (Screenshots of results along with participants can be requested from the Investigator.)"|Control group and treatment group, no placebo|f|f|f|t
34102168|NCT06694688|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"44 patients will be included in this study. Randomization will be carried out to determine the order of the 5 conditions studied:~* No compression,~* Class 2 compression socks,~* Class 3 compression socks,~* Class 2 compression tights,~* Dynabelt abdominal belt + Class 2 compression socks."||||
34102169|NCT05530915|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34102170|NCT06452277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840302|NCT02783573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840303|NCT00734591|||COHORT|||||||||
34102171|NCT05261139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102172|NCT03735498|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102173|NCT04901078|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double blinded, randomised, placebo study.|Dosing will be based on the assigned treatment group. The single ascending dose cohorts will evaluate doses of KNX100 starting with 25 mg and increasing up to a maximum of 50 mg per day. The multiple ascending dose cohorts will evaluate a low-, mid-, and high-dose KNX100 administered for 7 consecutive days. Individual doses will be dispensed by unblinded site pharmacy staff. Dose escalation will progress upon Cohort Review Committee (CRC) approval.|t|f|t|f
34102174|NCT06058455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102175|NCT02567032|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34102176|NCT01708941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102177|NCT00791687|||CASE_CONTROL||PROSPECTIVE|||||||
34102178|NCT04274218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No masking.|Participants will receive a small treadmill belt disturbance while walking.||||
34102179|NCT04505280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102180|NCT04841798|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102181|NCT03031730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102182|NCT01368185|||COHORT||RETROSPECTIVE|||||||
34102183|NCT06263738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary outcome data will be collected by trained raters blinded to participant group assignment and study visit number. The randomization list will be prepared by an unblinded study statistician and administered by study personnel with no other involvement in study activities. The participant will be blinded to their treatment assignment until the end of the WBH treatment, at which point they will be directed to either complete a cool-down period in the sauna device or proceed to the cold plunge.|Participants who meet inclusion/exclusion criteria will be stratified by use of antidepressant medication and randomized with a 1-to-1 allocation to receive a single session of WBH or a single session of WBH followed immediately by cold plunge (WBH+cold).|t|f|f|t
34102184|NCT06686758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34102185|NCT05212935|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34102186|NCT06695143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102187|NCT06695156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||It is a pilot study investigating the impact of Transcendental Meditation on migraine as a basis for a larger randomized control study.||||
34102188|NCT06324370|NA|SEQUENTIAL||BASIC_SCIENCE||NONE|This will be an open-label pharmacokinetic study in healthy Filipino male human participants under fed conditions.|This will be a two-sequence (single- and multiple-dose) pharmacokinetic study in healthy Filipino male human participants under fed conditions.||||
34102189|NCT06684678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||1:1 ratio||||
34102190|NCT04229966|||COHORT||PROSPECTIVE|||||||
33718633|NCT02902640|||COHORT||PROSPECTIVE|||||||
33718634|NCT04946539|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718635|NCT04700982|||OTHER||RETROSPECTIVE|||||||
33718636|NCT00129454|RANDOMIZED|FACTORIAL||OTHER||||||||
33718637|NCT01516814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718638|NCT05706142|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33718639|NCT03179865|||CASE_ONLY||CROSS_SECTIONAL|||||||
33718640|NCT05160454|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||patients and controls||||
33718641|NCT01465087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718642|NCT01216527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718643|NCT04651088|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33718644|NCT00937157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718645|NCT01052051|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718646|NCT04275791|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718647|NCT01575665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718648|NCT03917108|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33840304|NCT05846958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840305|NCT06208904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718649|NCT03512743|||COHORT||PROSPECTIVE|||||||
33718650|NCT04404842|||COHORT||CROSS_SECTIONAL|||||||
33718651|NCT01427894|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33718652|NCT06385860|||COHORT||OTHER|||||||
33718653|NCT05474742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33718654|NCT03533179|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Interventions will be administered behind a curtain covering half the participant and thus the arm in which intervensions are administered. A list allocating participants to interventions are kept in an opaque envelope in a locked cabinet at the trial site. Outcome assessor will not have access to this list.|5-arm, participant and outcome-assessor blinded, randomized, placebo-controlled study.|t|f|f|t
33840306|NCT00433758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33840307|NCT05262517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102191|NCT03382873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The proposed translational study applied an innovative experimental approach, an adaptive design, to optimize treatment for weight loss and weight loss maintenance in individuals with prediabetes. All participants initiated a standard lifestyle intervention to promote weight loss. Those who did not achieve \>2.5% weight loss during the first month of the intervention were stratified to augmented care to enhance weight loss during the intensive intervention phase. Following the intensive phase, participants were randomly assigned to either the standard intervention or the enhanced intervention for the maintenance study phase. By randomly assigning participants to either the standard maintenance phase of the intervention or the innovative maintenance phase of the intervention following the initial core phase, the impact of extended training in self-regulation for weight loss maintenance was evaluated.|f|f|f|t
34102192|NCT04984590|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment with IOPCL AMD MAG at least 6-months after cataract surgery with Alcon Model SN60WF or SA60AT||||
34102193|NCT02912611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102194|NCT05669677|||COHORT||PROSPECTIVE|||||||
34102195|NCT06366165|NA|SINGLE_GROUP||SCREENING||NONE||Testing the procedure of using a different mode of teaching medical content||||
34102196|NCT06543121|||OTHER||PROSPECTIVE|||||||
34102197|NCT06184503|||OTHER||OTHER|||||||
34102198|NCT06695793|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34102199|NCT03721458|||CASE_ONLY||RETROSPECTIVE|||||||
34102200|NCT06688071|||COHORT||PROSPECTIVE|||||||
34102201|NCT06420076|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group.|Patients enrolled in this clinical trial will receive a carefully designed treatment regimen. Prior to the infusion of CD5 and CD7 CAR-T cells, participants will undergo preconditioning chemotherapy. This chemotherapy serves to create an optimal environment for CAR-T cell therapy to effectively target and eliminate malignant B cells. Following chemotherapy, participants will receive the infusion of CD5 and CD7 CAR-T cells.||||
34102202|NCT05008081|||COHORT||PROSPECTIVE|||||||
34102203|NCT04015141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102204|NCT05835895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102205|NCT06690788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102206|NCT01171937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102207|NCT03842111|||OTHER||CROSS_SECTIONAL|||||||
34102208|NCT04052555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102209|NCT05872945|||COHORT||PROSPECTIVE|||||||
34102210|NCT05497882|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||this is not a clinical trial.||||
34102211|NCT05097950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102212|NCT02741193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102213|NCT04043104|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102214|NCT06592521|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102215|NCT03436238|||COHORT||PROSPECTIVE|||||||
34102216|NCT06687837|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label, two dosage tiers||||
34102217|NCT06190275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102218|NCT01381887|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34102219|NCT06496243|NA|SEQUENTIAL||TREATMENT||NONE||8 weeks on 10 mg daily obicetrapid followed by 8 weeks on obicetrapib 10 mg daily/Repatha 140 mg SC every 2 weeks combination therapy||||
34102220|NCT06612281|NA|SINGLE_GROUP||SCREENING||NONE|Participant and physician performing colonoscopy will be masked to FIT and Gixam test outcome until colonoscopy procedure us completed.|All subjects enrolled will undergo the same study procedures and assessments in the following order: FIT, Gixam, and colonoscopy. Gixam is an investigational medical device determined by the FDA to be a nonsignificant risk device. Colonoscopy is the ground-truth (Gixam outcome is compared to colonoscopy findings). Gixam performance will be evaluated and reported per FIT outcome (the primary efficacy endpoint is sensitivity and specificity in a FIT negative population).||||
34102221|NCT06675773|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The training will be conducted by the investigator. The experimental and control groups will be assigned by a statistics expert other than the investigators.|Two groups were mindfulness-based psychoeducation controls.|f|f|t|f
34102222|NCT02616302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102223|NCT06694324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102224|NCT03203603|||CASE_CONTROL||PROSPECTIVE|||||||
34102225|NCT05685407|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33840308|NCT04623749|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34102226|NCT04849507|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|blinded to study treatment assignment to active or sham taVNS. Perceptual threshold (PT) will be determined in both treatment groups.|If progress in daily oral feeding volumes is \<4ml/kg/d (based on response rate in pilot trial) after 10 days with either treatment A or B, we will offer cross-over to the alternate treatment.|t|t|f|t
34102227|NCT01340170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102228|NCT03702738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102229|NCT01281280|||COHORT||PROSPECTIVE|||||||
33840309|NCT01355276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840310|NCT03766776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840311|NCT04646291|||COHORT||RETROSPECTIVE|||||||
33840312|NCT02986191|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33840313|NCT05908851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102230|NCT05128448|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All measurements will be conducted by research assistants unaware of the interventions applied. Statistical analyses will be performed by a blinded research assistant.||f|f|f|t
34102231|NCT05186077|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34102232|NCT06691503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Group:mediastinoscopic-assisted transhiatal laparoscopic esophagectomy (MATLE);Thirty-five eligible patients with ESCC were assigned to the MATLE group||||
34102233|NCT02631031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102234|NCT06603831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34102235|NCT03288025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102236|NCT06689163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102237|NCT06689293|||COHORT||PROSPECTIVE|||||||
34102238|NCT06691191|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed investigation will be a prospective, randomized, parallel-design, open-label study.||||
34102239|NCT06691607|||CASE_ONLY||PROSPECTIVE|||||||
34102240|NCT06686511|||CASE_CONTROL||PROSPECTIVE|||||||
34102241|NCT06591975|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34102242|NCT06411158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome will be assessed at 6 months postpartum by blinded outcomes assessors.|The primary analyses will use an intention-to-treat (ITT) population to compare change from baseline in ICIQ-SF score at 6 months between treatment groups using a general linear mixed model.|f|f|f|t
34102243|NCT04305652|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No Intervention: Control group Experimental: Experimental group|A Randomized Controlled Trial||||
34102244|NCT05116189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102245|NCT06684977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34102246|NCT03735979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102247|NCT06297213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102248|NCT01467284|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34102249|NCT06119542|||COHORT||PROSPECTIVE|||||||
33840314|NCT05366543|||CASE_ONLY||PROSPECTIVE|||||||
34102250|NCT06006585|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102251|NCT04040231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102252|NCT04211870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102253|NCT01778231|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34102254|NCT06647628|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||8 participants will be randomized to receive either placebo or MK-1708 dose level 1, then 8 participants will be randomized to receive either placebo or MK-1708 dose level 2.|t|t|t|f
34102255|NCT06181643|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34102256|NCT06307015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102257|NCT05783960|||COHORT||PROSPECTIVE|||||||
34102258|NCT00021359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799976|NCT05707624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Simple random sampling method was used in the study. Parents who met the research inclusion criteria were assigned to the groups by drawing lots. In the lottery method, first of all, the control and intervention groups were written by the researcher on 1st paste and 80 g/m2 A4 papers of 4x4 cm size and the papers were placed in a bag that is invisible. Then, when the first parent who met the criteria for inclusion in the emergency room came, any nurse working in the service other than the researcher was asked to choose a paper from the bag (by blinding). If a control group is written on the paper, it is assigned to the parent control group, and if it is written as an intervention group, it is assigned to the parent intervention group. When the second parent who met the criteria for inclusion in the emergency department came, lots were not drawn, and the parent was assigned to the other group. The same procedure was repeated for all subsequent participants.|t|t|t|f
33718655|NCT05517382|RANDOMIZED|PARALLEL||PREVENTION||NONE||Eligible individuals will be assigned to either the 1) supportED group (n=30) or 2) control group (n=30).||||
33718656|NCT02899910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718657|NCT01840709|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33718658|NCT00461682|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33718659|NCT00358228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718660|NCT03326791|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Eligible patients will be allocated in a 1:1 ratio using a computer randomization procedure stratified by centre. The randomization will be blocked within each stratum.|Multi-centre, double-blinded, randomized, placebo-controlled clinical intervention trial.|t|t|t|t
33718661|NCT00022633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718662|NCT04320381|||COHORT||PROSPECTIVE|||||||
33718663|NCT00982592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799977|NCT05004597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||all subjects longitudinally received 3D image||||
33799978|NCT02740400|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33943654|NCT02549040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943655|NCT04346251|||COHORT||CROSS_SECTIONAL|||||||
33943656|NCT02934919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102259|NCT06687265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34102260|NCT03948620|||COHORT||RETROSPECTIVE|||||||
34102261|NCT00677040|||CASE_ONLY||PROSPECTIVE|||||||
33718664|NCT04324554|||OTHER||CROSS_SECTIONAL|||||||
33718665|NCT02054416|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33718666|NCT00383279||||OTHER||||||||
33718667|NCT03022565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718668|NCT05193656|||COHORT||PROSPECTIVE|||||||
33718669|NCT01647282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33718670|NCT04419454|||COHORT||RETROSPECTIVE|||||||
33718671|NCT01638806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718672|NCT01502423|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33718673|NCT01373437|||CASE_ONLY||PROSPECTIVE|||||||
33718674|NCT00549302|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718675|NCT03654950|||COHORT||CROSS_SECTIONAL|||||||
33718676|NCT02581449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33799979|NCT06024824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).|||||
33799980|NCT04948801|||OTHER||PROSPECTIVE|||||||
33799981|NCT03766971|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Research staff will be blind to the age of tobacco onset condition.|The effects of 7- and 21-days of tobacco cessation on cannabis relapse in daily cigarette-smoking, cannabis smokers will be compared, with half the participants in each group initiating tobacco cigarette smoking early (\<16 years) and the other half later (\>=16 years).|t|f|t|t
33799982|NCT04580316|RANDOMIZED|PARALLEL||OTHER||NONE|Only biostatistician was blinded|||||
33799983|NCT03565315|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33943657|NCT01506310|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33943658|NCT00575003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943659|NCT02906644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33943660|NCT00034476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943661|NCT01880996|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943662|NCT02950428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943663|NCT00125736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33943664|NCT01569568|||COHORT||PROSPECTIVE|||||||
33943665|NCT03053466|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33943666|NCT02361372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943667|NCT02127931|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The participant does not know if they have ADHD symptoms or not and the investigator who is administering the game does not know what group the patient is in.|Video Game Diagnostic Tool Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD.|t|f|t|f
33943668|NCT02424227|||CASE_ONLY||PROSPECTIVE|||||||
33943669|NCT00056472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943670|NCT04473989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943671|NCT00143039|||CASE_CONTROL||PROSPECTIVE|||||||
33943672|NCT00302731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943673|NCT00417495|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943674|NCT03608345|||CASE_CONTROL||PROSPECTIVE|||||||
33943675|NCT02049385|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33943676|NCT00689299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33943677|NCT03960476|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All study participants receive access to the web-based study intervention, PlanYourLifespan.org.||||
33943678|NCT04401488|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33943679|NCT02540811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022835|NCT05575258|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be masked to the type of diet (Agroecological or Conventional) they are consuming.|"This work will utilize a randomized cross-over design to compare an agroecological vs conventional sourced diet, and determine their effects on inflammation and cardio metabolic health signatures in middle-aged adults (35-60 y old). Diets will be isocaloric and matched for macronutrient content, and consumed for 44 days each with a 14-day washout (habitual diet) period in between. Blood, urine, and stool samples will be obtained at baseline and after the dietary interventions, in addition to data about physical activity and questionnaires regarding quality of life.~Participants will be asked to complete four testing visits throughout their participation in the study (pre and post visits for each of the diets, which are 44 days each). Participants will be blinded to the diet they are consuming."|t|f|f|f
34022836|NCT02418663|NA|SINGLE_GROUP||SCREENING||TRIPLE|||t|t|f|t
34022837|NCT05423795|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Stepped wedge design||||
34022838|NCT02910557|||COHORT||PROSPECTIVE|||||||
34022839|NCT01216618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718677|NCT04690751|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||• This study is an open-label, randomized, single-dose, single-center, three-period, six-sequence, balanced crossover study in healthy male and female subjects to assess the relative bioavailability of 200 mg of cenobamate given as an oral tablet or oral suspension and to evaluate the effect of food on the bioavailability of a 200 mg dose of cenobamate given as an oral suspension in fasting and fed conditions||||
34022840|NCT02390687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022841|NCT00159627|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34022842|NCT03364868|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022843|NCT01008332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022844|NCT04555720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022845|NCT04271995|||COHORT||PROSPECTIVE|||||||
34022846|NCT02123082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34022847|NCT00534807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022848|NCT05224310|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34022849|NCT00197288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34022850|NCT00273039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34022851|NCT06633822|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34022852|NCT03122080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34022853|NCT02575105|||CASE_CONTROL||PROSPECTIVE|||||||
34022854|NCT04257045|||COHORT||PROSPECTIVE|||||||
34022855|NCT06000943|||COHORT||OTHER|||||||
34022856|NCT03122197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718678|NCT00065507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718679|NCT03964155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The investigators and personals in charge of measuring protein markers in this study will be unaware of the fluid type (either AnaConDa-S® fluid,or undiluted pulmonary edema fluid or plasma). In addition, the study statistician will also be blinded during statistical analyses.|Analysize correlation between sample from undiluted pulmonary edema andsample from AnaConDa-S® filter from patients presenting ARDS since 24 hours and sedated with inhaled sevoflurane.||||
33718680|NCT05309564|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718681|NCT04598555|||COHORT||PROSPECTIVE|||||||
33718682|NCT03258190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|LPR and Placebo were prepared in the same containers with code that was provided by investigators|Randomized control trial|t|f|f|f
33718683|NCT05327140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718684|NCT03772145|||COHORT||PROSPECTIVE|||||||
33718685|NCT05230537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigator and Participant|This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of LNP023 in participants with early to intermediate age-related macular degeneration (e/iAMD) in one eye and neovascular age-related macular degeneration (nAMD) in the other eye.|t|f|t|t
33718686|NCT04723550|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33718687|NCT05544331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718688|NCT06013540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718689|NCT04952142|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33718690|NCT04231539|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||The participant and researcher will be blinded to solution flavor and nicotine concentrates.|t|f|t|f
33718691|NCT05072574|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio||||
33718692|NCT05766644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718693|NCT01938378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718694|NCT03349112|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||During both the anesthetized and non-anesthetized conditions as per standard of care, the study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. During only the anesthetized condition, subjects will receive up to .8 ml of a 4% Lidocaine spray to both nares.||||
33718695|NCT03342690|||CASE_ONLY||PROSPECTIVE|||||||
33718696|NCT03319355|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33718697|NCT03045328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718698|NCT03181087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718699|NCT04262505|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of dietary interventions, blinding will not be possible|Mediterranean diet vs. Irish healthy eating guidelines||||
33718700|NCT01772706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718701|NCT00367848|||||PROSPECTIVE|||||||
33718702|NCT05491330|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33718703|NCT01657279|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33718704|NCT02031731|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718705|NCT02753101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718706|NCT00546845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718707|NCT01349790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718708|NCT03695562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|f|t
33718709|NCT05029674|||COHORT||PROSPECTIVE|||||||
33718710|NCT02946645|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Testing Bite device A"|f|t|t|t
33718711|NCT00671502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022857|NCT04641585|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34022858|NCT03136965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects and assessors will be blinded to the subject group allocation. Subjects will be identified to study personnel using a unique study number only and results of the imaging studies will be blinded, batched, and evaluated in a randomized manner.|Double-blinded randomized controlled trial|t|f|f|t
34022859|NCT01807286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718712|NCT06408623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718713|NCT01182545|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33718714|NCT01558830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718715|NCT00551733|RANDOMIZED|||TREATMENT||NONE||||||
33718716|NCT06141590|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022860|NCT06470815|||CASE_ONLY||PROSPECTIVE|||||||
34022861|NCT01885026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022862|NCT05495672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022863|NCT03151291|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34022864|NCT04886076|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022865|NCT03210714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022866|NCT02377427|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022867|NCT02123810|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33718717|NCT03707327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718718|NCT00820131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33718719|NCT01575496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718720|NCT05620004|RANDOMIZED|PARALLEL||TREATMENT||NONE||Select patients with advanced hepatocellular carcinoma who have been clinically consulted by MDT ,those patients will be treated with carrilizumab and apatinib mesylate,and divide them into two groups randomly .Collect the stool specimens and clinical data from those who will be treated with oral bifidobacterium or without bifidobacterium during immunotherapy.||||
33718721|NCT05443867|||COHORT||PROSPECTIVE|||||||
33718722|NCT03164200|RANDOMIZED|PARALLEL||OTHER||NONE|Patients were randomized to either a egg breakfast or a carbohydrate breakfast|||||
33718723|NCT05829486|||COHORT||PROSPECTIVE|||||||
33718724|NCT00681655|NA|SINGLE_GROUP||OTHER||NONE||Two session, within subjects, single blind||||
33718725|NCT04207385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718726|NCT02315378|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718727|NCT01577329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718728|NCT04774874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This trial will be conducted as a double-blind trial. Neither the Investigator nor the subject will know the identity of the IP assigned. Also, all other persons involved in the trial (e.g. Data Manager and Trial Statistician) remain blinded until all possible queries are resolved and 'closure of the data base' is done, i.e. after quality assurance of the data and hard lock of the data base clean files.||t|t|t|t
33718729|NCT04997785|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33718730|NCT04304391|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33718731|NCT04550247|||COHORT||PROSPECTIVE|||||||
33718732|NCT06401616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Blinding of patients and physicians is not possible due to different types of oral anticoagulant therapy within the same interventional arm and the need for continuous monitoring of treatment with warfarin.However, since the primary outcome is not a subjectively reported outcome, lack of blinding presents less risk of bias.~The investigators responsible for data collection and the Endpoint Adjudication Committee will be blinded to the randomization."|Patients will be randomized to either continue or discontinue oral anticoagulant therapy|f|f|f|t
33718733|NCT01518777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718734|NCT00613938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718735|NCT03542344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022868|NCT06632847|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022869|NCT02430285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022870|NCT01798355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022871|NCT04584385|||COHORT||PROSPECTIVE|||||||
34022872|NCT05811806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022873|NCT05050110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Evaluation of Increased fruits and vegetables consumption in chronic kidney disease patients maintaining normokalemia with patiromer||||
34022874|NCT03430388|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022875|NCT03002129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022876|NCT06322173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022877|NCT00086827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022878|NCT06593639|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two groups of head and neck cancer patients, one undergoing surgery plus (chemo)radiotherapy and the other undergoing definitive concomitant chemo-radiotherapy. Both groups will receive the prehabilitation intervention.||||
34022879|NCT00593151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022880|NCT02664714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34022881|NCT04487951|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022882|NCT03122925|||CASE_CONTROL||PROSPECTIVE|||||||
34022883|NCT04709367|||CASE_ONLY||PROSPECTIVE|||||||
34022884|NCT00403507|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34022885|NCT05245318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study patients will be blinded towards the group they will be randomised to, but the therapist cannot be blinded, as she knows whether a patient receives the treatment every week or every two weeks. To limit the risk of bias related to lack of blinding of the therapist, all evaluation measurements will be performed by a blinded assessor.|The study is designed as a single-blind two-arm 1:1 randomised controlled trial. The study is designed as a non-inferiority trial of a continuous response variable comparing independent control and experimental subjects. After baseline measurements, patients will be randomised into either the experimental group or the control group. A stratified randomisation according to the grade of tinnitus severity obtained by use of the Tinnitus Functional Index (TFI) and gender will be used. A minimisation procedure will be used to perform the stratified randomisation using the web-based online randomisation tool Qminim.|t|f|t|t
34022886|NCT05788614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022887|NCT04260555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34022888|NCT02330536|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|f|t
34022889|NCT06002841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatment and placebo solutions will be indistinguishable in terms of their appearance. Stringent protocols will be established to guarantee that the physicians responsible for assessing patient safety, evaluating efficacy outcomes, and conducting laboratory analyses will be blinded to the randomization codes.|Parallel Assignment|t|f|t|f
34022890|NCT06260709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022891|NCT00482807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022892|NCT00004230|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34022893|NCT04505956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34022894|NCT02845193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022895|NCT04366934|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34022896|NCT02150135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022897|NCT04810949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022898|NCT06296082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments will be conducted by blinded assessors for treatment allocation. Participants and staff cannot be blinded due to the nature of the intervention, but are instructed not to disclose their treatment allocation. Data will be anonymized and an independent researcher will enter coded data into secure databases. Data will be analyzed by a blinded statistician. Code breaks will only be allowed in crucial cases for patient management.|A prospective randomized, controlled, multiple-baseline, and assessor blinded multicenter equivalence trial with two parallel groups.|f|f|t|t
34102262|NCT02575183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34102263|NCT03680131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102264|NCT06689982|NA|SINGLE_GROUP||TREATMENT||NONE||tofacitinib (5mg per tablet)||||
34102265|NCT05669703|||FAMILY_BASED||PROSPECTIVE|||||||
33718736|NCT02121288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718737|NCT06494943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718738|NCT05693675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718739|NCT01940679|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33718740|NCT01862198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718741|NCT06136754|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33718742|NCT04097808|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|double-blind study|The clinical study will be performed in a double-blind, randomized, monocentric cross-over design.|t|f|t|t
33718743|NCT05248945|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33718744|NCT05195827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718745|NCT01397123|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
33718746|NCT03711045|||COHORT||CROSS_SECTIONAL|||||||
33718747|NCT05168267|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are assigned to CPT therapy-intervention group.||||
33718748|NCT04319120|||COHORT||PROSPECTIVE|||||||
33718749|NCT05258890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34022899|NCT01659086|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34022900|NCT00806286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022901|NCT00839254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33718750|NCT05745558|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective Cohort Study||||
33718751|NCT04599920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718752|NCT01348347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022902|NCT02702661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34022903|NCT05750862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022904|NCT06391255|||COHORT||PROSPECTIVE|||||||
34022905|NCT02530658|||COHORT||PROSPECTIVE|||||||
34022906|NCT05503810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized clinical trial design with 1:1 randomization||||
34022907|NCT00038532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022908|NCT03333044|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34022909|NCT06634394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022910|NCT03328195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102266|NCT06618664|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a randomized, controlled, open-label phase III study designed for efficacy evaluation.||||
34102267|NCT06276348|NA|SINGLE_GROUP||SCREENING||NONE||Single group, multiple interventions. All enrollees receive all interventions.||||
33718753|NCT05585528|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, longitudinal, open, non-comparative (single arm), monocentric study.||||
33718754|NCT06293170|RANDOMIZED|SEQUENTIAL||SCREENING||DOUBLE|||t|f|f|t
33718755|NCT00876629|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022911|NCT02455037|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34022912|NCT02752087|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34022913|NCT04187339|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34022914|NCT01404832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022915|NCT04605224|||CASE_CONTROL||PROSPECTIVE|||||||
34022916|NCT06551571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34022917|NCT02789553|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34022918|NCT01475097|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34022919|NCT06451055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Nursing staff conducting outcome assessments will be blinded to participants' treatment status.||f|f|f|t
34022920|NCT05854394|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients were randomly assigned to the prehabilitation group and control group by online randomization software||||
34022921|NCT04053049|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Meals will be provided in a randomized fashion with only the metabolic research unit kitchen (which prepares the meals) knowing what is being provided to the subject.|Each subject will receive 4 meals of different composition.|t|f|t|f
34102268|NCT05541276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022922|NCT02336724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022923|NCT05360940|||CASE_CONTROL||PROSPECTIVE|||||||
34022924|NCT04544410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind for first 24 weeks, then open label|Subjects will be randomized in a 1:1 manner to either Tildacerfont or Placebo for 24 weeks followed by 52 weeks open label Tildacerfont|t|t|t|f
34022925|NCT04129073|||COHORT||PROSPECTIVE|||||||
34022926|NCT00524732|||||CROSS_SECTIONAL|||||||
34022927|NCT06297954|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|As it is double-blind, both physician and patient will not know the treatment they are receiving and it will only be revealed later at the end of the protocol. Following the previous folios, both the treatment and the placebo will be distributed in boxes by default by the research staff, delivering them to the personnel who will apply the drug or placebo, indicating the doses and frequencies of these when administered.|Patients will be randomized to receive metoclopramide 20 mg IV or placebo, this randomization will be performed by means of a computer sequence to receive each of the treatment sequences. The sequence of treatment (metoclopramide) and placebo in which they will be distributed to patients will be determined using randomization software. A folio number will be assigned and depending on the sequence the treatment or placebo will be administered. Subsequently, the upper endoscopy will be performed in the following 120 minutes, and the endoscopic visualization will be evaluated by the physician performing the procedure by means of the modified Avgerinos scale|t|t|f|f
34022928|NCT04591951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34022929|NCT04719962|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022930|NCT03504397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022931|NCT03825341|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022932|NCT04510051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022933|NCT05095571|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a multicenter open label study as a follow up of the NO-ALS trial. Newly diagnosed ALS cases were included in the study arm 1. Earlier ALS cases were included in study arm 2 to allow patients with earlier ALS to participate in the study as the treatment options outside the study were limited. The NO-ALS study will be stopped when we reach 180 patients in the group with newly diagnosed ALS cases (arm 1). This is the follow up study for patients completing 1 year follow up in the NO-ALS study.||||
34022934|NCT04292652|||COHORT||PROSPECTIVE|||||||
34022935|NCT02113189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022936|NCT00372151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022937|NCT03696225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be masked to participant condition.|This is a parallel randomized controlled pilot trial.|f|f|f|t
34022938|NCT03713853|||COHORT||PROSPECTIVE|||||||
34022939|NCT05110482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34022940|NCT05890495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study medication provided per randomization table. Study participants allocated sequentially. Subject and provider blinded to allocation||t|t|f|f
34022941|NCT01675843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022942|NCT05988684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022943|NCT03713619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This was a Multicenter, randomized, double-blind, placebo-controlled, parallel group study, with two secukinumab dose regimens in 541 patients with moderate to severe HS.|t|t|t|f
34022944|NCT03718312|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34022945|NCT00799448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022946|NCT03924518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The participants in treatment group receive intravenous granisetron. The participants in control group receive normal saline.|t|f|f|t
34102269|NCT06571968|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Dental professionals who were not informed about the group assignments carried out the assignment and randomization of patients to the treatment groups.|randomized controlled clinical trial|f|f|t|f
34102270|NCT06690762|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718756|NCT02349581|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718757|NCT05219656|||OTHER||OTHER|||||||
33718758|NCT00391274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718759|NCT01718080|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33718760|NCT02742584|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718761|NCT06249412|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant (patient) will not see the treatment mode set on their INEX/MI-E. Only the care givers will know.||t|f|f|f
33718762|NCT00237757|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33718763|NCT02891460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718764|NCT05748977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718765|NCT00815009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718766|NCT05611879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33799984|NCT05518253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799985|NCT04509505|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33799986|NCT02290067|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33799987|NCT01084031|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33799988|NCT04133298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* Blinding of the participants is not applicable.~* Blinding of the operator is not applicable.~* The outcome assessor and biostatistician will be blinded."||f|f|f|t
33799989|NCT02064959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33799990|NCT01227278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799991|NCT04421261|||COHORT||PROSPECTIVE|||||||
33799992|NCT02701257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33799993|NCT05710575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization will be carried out in blocks of 10, and the list of random numbers will be generated by the subprogram Epitable from Epi-Info 6.04 (Centers for Disease Control and Prevention, Atlanta, GA). Two trained external personnel from the NICU will be responsible for obtaining this list and for randomly assigning the infants to the probiotics and control groups. A sealed envelope with the identification number in ascending order, containing information about which group they belonged to, will be provided for each infant and will be sent to the hospital's nutritional center. Three previously trained research assistants, who will not be a part of the neonatal team, will interview the mothers, recruit the infants, and they will also be responsible for sending the envelopes to the nutritional unit.|Randomization will be carried out in blocks of 10, and the list of random numbers will be generated by the subprogram Epitable from Epi-Info 6.04 (Centers for Disease Control and Prevention, Atlanta, GA). Two trained external personnel from the NICU will be responsible for obtaining this list and for randomly assigning the infants to the probiotics and control groups. A sealed envelope with the identification number in ascending order, containing information about which group they belonged to, will be provided for each infant and will be sent to the hospital's nutritional center. Three previously trained research assistants, who will not be a part of the neonatal team, will interview the mothers, recruit the infants, and they will also be responsible for sending the envelopes to the nutritional unit.|t|f|f|f
34102271|NCT06654271|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|It is not possible to blind the bronchoscopist or the patient to the platform used for each procedure, as they are both large distinctive-appearing pieces of equipment. However, allocation will be concealed until the morning of the procedure. Thoracic pathologists and bronchoscopy schedulers will remain blinded, thus allocations will not influence scheduling of procedures or histopathological interpretation.|This study will be performed as a pragmatic, cluster randomized controlled trial with parallel group assignment.|f|t|f|t
33799994|NCT03452085|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The two types of pump-spray had a different bottle design but the bottles were blank with no identification|"Patients were randomized to two groups, whereas one group starts treatment with AS and the other group starts treatment with TT (control).~After a wash out phase of 3 days, the patients have to take the other product for also 3 days.~(e. g. randomized patient takes AS for 3 days, after a wash out period of 3 days he takes TT also for three days.)"||||
33799995|NCT01405807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33799996|NCT04771351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33799997|NCT01706354|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33799998|NCT01068756|NA|SINGLE_GROUP||||NONE||||||
33799999|NCT01613716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840315|NCT02368457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840316|NCT05990790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33840317|NCT03557671|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34022947|NCT01376791|||CASE_CONTROL||PROSPECTIVE|||||||
34022948|NCT05705648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo control|Randomised placebo-controlled clinical trial|t|t|t|t
34022949|NCT02996214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022950|NCT03828786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022951|NCT06279559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022952|NCT03993782|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34022953|NCT03553953|||CASE_ONLY||PROSPECTIVE|||||||
34022954|NCT02968849|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34022955|NCT00963560|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34022956|NCT04180631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022957|NCT02748811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34022958|NCT06052930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34022959|NCT06247865|||COHORT||PROSPECTIVE|||||||
34022960|NCT00421980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34022961|NCT05352347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022962|NCT00237783|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34022963|NCT01646138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34022964|NCT05496660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34022965|NCT00509366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102272|NCT06685952|||COHORT||PROSPECTIVE|||||||
34102273|NCT06494436|||COHORT||PROSPECTIVE|||||||
34102274|NCT05395494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102275|NCT04792216|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34102276|NCT06690541|||COHORT||PROSPECTIVE|||||||
34103487|NCT06687447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Random distribution of women included in the study to intervention groups and control groups was carried out at www.random.org. Which groups were intervention or control groups were determined by drawing lots at the beginning of the study. The numbers in the intervention groups and the control group will be placed in opaque envelopes, and the group in which the women who meet the criteria will be will be decided by drawing lots of sealed envelopes after the pre-test data is completed.The statistical analysis phase is blind since an independent statistician other than the researcher will perform the statistical analysis of the study.|It was planned for three groups: oxytocin massage group, reflexology group and control group.|t|f|f|t
34103488|NCT06467708|NA|SINGLE_GROUP||TREATMENT||NONE||TBI patients in the ICU with Glasgow Coma Scale score of 12 or below and acute traumatic intradural blood on head CT||||
34103489|NCT02958072|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34103490|NCT06687902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022966|NCT03869086|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"The randomised allocation of treatment order for each participant will be performed by an independent researcher with experience in statistical randomisation. The Principle Investigator will receive notification of the treatment coding order for each subject (in a tamper-evident sealed envelope) which will be prepared by the independent researcher trained in statistics. The coding of the treatment randomisation will only be known to this researcher; and will only be broken at the analysis stage of the study unless a serious adverse event occurs. As the intervention material is a powdered food product, or placebo material, it is considered unlikely that this eventuality may occur.~During the analysis stage, a blind review of data quality and outlier data will be performed prior to unblinding. Researchers analysing the raw data will remain blind and the data will be locked prior to unblinding of the statistician (which will only occur after the completion of the statistical analysis)."|Our research design involves screening individuals and then prospectively recruiting on the basis of two distinct blueberry metabolism profiles based on our previous research findings (in a population with metabolic syndrome). Our study will assess whether individuals with SLOW and FAST anthocyanin metabolism profiles respond differently and will test if the difference in processing may influence cardio metabolic responses. Our study involves feeding a single energy-dense meal which we anticipate will have a transient deleterious effect on acute markers of health. We will test whether adding blueberries to the energy dense meal improves acute responses compared against when adding the equivalent isocaloric amount of placebo. Participants will experience the blueberry and placebo treatments in random order|t|f|t|t
34022967|NCT02784353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The result of allocation in control and intervention group would be blinded to primary and secondary outcomes assessor.|2 arm, parallel, randomized controlled study|f|f|f|t
34022968|NCT06484725|||COHORT||RETROSPECTIVE|||||||
34022969|NCT05269979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022970|NCT01804348|NA|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
34022971|NCT06399302|||COHORT||PROSPECTIVE|||||||
34022972|NCT05272748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103491|NCT05883748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718767|NCT01693575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718768|NCT00268996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718769|NCT03654651|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33718770|NCT01683955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33718771|NCT00840554|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33718772|NCT03764137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718773|NCT02003612|||COHORT||RETROSPECTIVE|||||||
33718774|NCT05312398|NA|SINGLE_GROUP||TREATMENT||NONE||3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.||||
33718775|NCT02415751|||COHORT||PROSPECTIVE|||||||
33718776|NCT01337947|||COHORT||PROSPECTIVE|||||||
33718777|NCT02773355|||COHORT||PROSPECTIVE|||||||
33718778|NCT03579589|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sugammadex vs Neostigmine||||
33718779|NCT01953120|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718780|NCT01681732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718781|NCT04055142|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase III, randomized, one-site, pilot, open-label, parallel groups trial for evaluating the efficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir within the treatment to high-grade anal intraepithelial neoplasia in HIV homosexual males.||||
34022973|NCT04466241|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IIb, comparative, multicenter, randomized, superiority, parallel-group, open-label clinical trial||||
34022974|NCT04005235|||COHORT||PROSPECTIVE|||||||
34022975|NCT03313063|||CASE_CONTROL||RETROSPECTIVE|||||||
34022976|NCT02711735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34022977|NCT05202730|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34022978|NCT01824628|||COHORT||PROSPECTIVE|||||||
34022979|NCT03872934|||COHORT||PROSPECTIVE|||||||
34022980|NCT02512653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022981|NCT04365777|||OTHER||PROSPECTIVE|||||||
34022982|NCT06035263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Subjects will also be blinded and will not know which group they have been allocated to and therefore which intervention they will receive. In order to minimise any contamination between groups, the assessment process will be carried out by external research staff who will perform the measurements and who have been previously trained and educated to avoid subjective bias in the process, as they will be unaware of the intervention group to which each elderly centre is assigned, so the clinical trial will have a masking of the blinded assessment by third parties.||t|f|f|f
34022983|NCT06633900|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to either receive the study medication or usual care.||||
34022984|NCT04331938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022985|NCT00576797|||||PROSPECTIVE|||||||
34022986|NCT04321330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022987|NCT03240237|NA|SINGLE_GROUP||OTHER||NONE||This pilot study is designed and powered for evaluating the efficacy and safety of CCM therapy in heart failure patients with baseline EF≥50% (HFpEF) who have NYHA Class II or III symptoms despite appropriate medication, for potential expansion of the CE Mark indication for use in the HFpEF population.||||
34022988|NCT02689050|||CASE_ONLY||CROSS_SECTIONAL|||||||
34022989|NCT01167101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34022990|NCT00720252|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34022991|NCT05338216|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The participants will not be told explicitly that there are two arms or which arm they are in.|Twenty PWA will participate in this pilot study, randomly assigned to the µEMA condition (n = 10) or traditional EMA condition (n = 10). In both the µEMA and traditional EMA protocols, the smartwatch will vibrate to alert the participant to a prompt to complete either a single picture naming trial (in the µEMA condition) or a set of picture naming trials (in the traditional EMA condition). The only difference between conditions will be the trial delivery schedule: PWA in the µEMA condition will complete a single naming trial at a time, 36 times per day whereas PWA in the traditional EMA condition will receive four prompts per day to complete a set of nine picture naming trials per prompt.|t|f|f|f
34022992|NCT02029014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34022993|NCT02845141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34022994|NCT01717716|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34022995|NCT00080314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34022996|NCT01462812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34022997|NCT05268068|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34022998|NCT03317834|||COHORT||PROSPECTIVE|||||||
34022999|NCT04933968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023000|NCT01154517|||||PROSPECTIVE|||||||
34023001|NCT02529891|||CASE_CONTROL||PROSPECTIVE|||||||
34023002|NCT00635232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023003|NCT05568901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34023004|NCT03040557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The intervention groups were: minimalist flexible footwear group-MFG (n=12 women with PF; n=15 women with CS), Orthopedic insole on minimalist footwear group-COIG (n=14 women with PF; n=14 women with CS) and control-GC group (n=24). Both groups were followed for six months and were assessed at baseline condition and after three and six months (end of intervention).|A randomized, parallel and controlled clinical trial with blind assessor was conducted in which 79 women were randomized and allocated to the intervention groups|f|f|t|t
34023005|NCT05328635|||COHORT||PROSPECTIVE|||||||
34023006|NCT00845624|||COHORT||PROSPECTIVE|||||||
34023007|NCT02777073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023008|NCT06224465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"intervention: aerobic exercises: walking :30 min on treadmill 30min at least three times per week for 12 weeks 2)Muscle strength Exercises: For upper extremity : hand grip exercise, arm flexion exercise ten repetition for each exercise three times per week.~Theraband exercises for upper limb exercise ten repetition for each exercise three times per week.~3) Flexibility Exercise : Curl up exercise and Seat and reach up exercises exercise ten repetition for each exercise three times per week.~Lateral flexibility exercises for ten repetition for each exercise three times per week,for 12 weeks"|f|f|f|t
34023009|NCT00010621|RANDOMIZED|PARALLEL||TREATMENT||||||||
34023010|NCT05918744|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will serve as their own controls. Due to the nature of the intervention (extending time in bed by 1 hour) all participants will be measured in their habitual sleep state followed by their extended sleep state.||||
34023011|NCT03664492|NA|SINGLE_GROUP||OTHER||NONE||The recruited group of health care professionals/parents will answer a pre-questionnaire, then watch an educational video, then answer a post-questionnaire. If they agree, these participants will be asked to complete a third questionnaire (retention questionnaire) 4 to 6 months later.||||
34023012|NCT05259995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023013|NCT00922272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023014|NCT03393663|||COHORT||PROSPECTIVE|||||||
34023015|NCT04395144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023016|NCT06197373|||COHORT||PROSPECTIVE|||||||
34023017|NCT02445976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34023018|NCT03139227|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34023019|NCT06332729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023020|NCT05213455|||COHORT||PROSPECTIVE|||||||
34023021|NCT03444376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718782|NCT03330808|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33718783|NCT01707186|||COHORT||PROSPECTIVE|||||||
34103492|NCT06689514|RANDOMIZED|PARALLEL||TREATMENT||NONE||"For patients who meet the inclusion criteria, the control group takes oral alpha receptor antagonists (according to the dosage specified in the instructions for treating BPH) (n=10); Low dose group: oral administration of 100mg TID of tranilast capsules (Qu Ke Shen, Yao Da Pharmaceutical)+oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH) (n=10); The high-dose group received oral administration of 200mg TID of tranilast capsules (Qu Ke Shen, Yao Da Pharmaceutical) and oral administration of alpha receptor antagonists (according to the instructions for treating BPH) (n=10). Take medication continuously for 6 months.~This trial allows the combination of various drugs taken by patients for the treatment of hypertension, diabetes, hyperlipidemia and other chronic diseases, and allows the combination of antibiotics."||||
34103493|NCT00252148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33718784|NCT05068557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both type of capsules were deposited in equally labeled flaks under sterile conditions. Every flask was identified and tagged with a specific number by an associate researcher who is not involved in the recruitment, attention, or follow-up of the enrolled subjects. Finally, block randomization was the selected technique for this purpose.|Double-blind randomized parallel clinical trial|t|f|t|f
33718785|NCT01172457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023022|NCT05387850|||COHORT||PROSPECTIVE|||||||
34023023|NCT01681407|||CASE_CONTROL||PROSPECTIVE|||||||
34023024|NCT04142892|NA|SINGLE_GROUP||TREATMENT||NONE||window of opportunity, prospective, multicenter, phase 0 trial||||
33718786|NCT03967964|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, open-label comparative, single-site study with 5 treatment groups. Each participant receives a single Treatment for 72 hours. Allocation to Treatment is in a 1:1:1:1:1 order.||||
33718787|NCT02105792|||COHORT||PROSPECTIVE|||||||
33718788|NCT04947605|||COHORT||OTHER|||||||
33718789|NCT01626560|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718790|NCT01209364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33718791|NCT03750812|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718792|NCT05105061|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34023025|NCT04485832|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34023026|NCT00021827|RANDOMIZED|||TREATMENT||DOUBLE||||||
34023027|NCT04444674|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded, placebo controlled. Pharmacist and vaccine administrators will be unblinded only. DSMB will be unblinded if required to assess safety signal|Four groups will be enrolled to receive either one or two doses of investigational vaccine or placebo. Follow up intensity and blood draws differ between groups|t|t|t|t
34023028|NCT04808180|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023029|NCT00899041|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34023030|NCT05982288|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|In this study, the single-blind method will be used to prevent nurses from interacting with each other. For this, the interventions will be performed on the same day and time using different areas.|The study is a single-center, randomized controlled experimental design.||||
34023031|NCT05345743|||COHORT||PROSPECTIVE|||||||
34023032|NCT03529825|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pilot, single arm prospective study with retrospective control arm||||
34023033|NCT02924636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023034|NCT01056042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023035|NCT05156905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023036|NCT00054808|NON_RANDOMIZED|||TREATMENT||NONE||||||
34023037|NCT01922804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34023038|NCT02743338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023039|NCT00460135|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023040|NCT03899441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023041|NCT03383237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023042|NCT00872794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023043|NCT05629897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator performing the analysis will be blinded to which group is the active intervention group.|Intervention or waiting list|f|f|f|t
34023044|NCT05920733|NA|SINGLE_GROUP||OTHER||NONE||||||
34023045|NCT00767169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023046|NCT02554565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023047|NCT03268551|||COHORT||PROSPECTIVE|||||||
34023048|NCT00609518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023049|NCT05042544|||COHORT||PROSPECTIVE|||||||
34023050|NCT01539018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023051|NCT03343444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023052|NCT05721118|||CASE_ONLY||RETROSPECTIVE|||||||
34023053|NCT03604315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023054|NCT02290301|||COHORT||PROSPECTIVE|||||||
34023055|NCT00196924|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023056|NCT05390801|||CASE_ONLY||PROSPECTIVE|||||||
33718793|NCT02335489|||COHORT||PROSPECTIVE|||||||
33718794|NCT03676933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718795|NCT01204164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718796|NCT06049745|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients undergoing hysteroscopic myomectomy will be divided into two groups, the study group will receive misoprostol before the procedure. the control group will not receive treatment with misoprostol.||||
33718797|NCT03445572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800000|NCT03260010|NA|SINGLE_GROUP||TREATMENT||NONE||In this open prospective interventional clinical study patients with hip, knee or shoulder PJI (as defined below) caused by fosfomycin-susceptible staphylococci, streptococci, enterococci or gram-negative bacilli will be included. After inclusion and PJI-surgery, intravenous fosfomycin will be given 5 g every 8 hours for 1, 2, 3-or -4 weeks according to the pathogen and surgery procedure and generally as a part of the antibiotic combination therapy of the treatment algorithm. This Treatment is followed by oral antibiotics for a total of 3 months.||||
34023057|NCT01930565|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34023058|NCT02792608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023059|NCT00213135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102277|NCT06691620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Using the block randomization technique, participants were divided into four groups. A web-based randomization list generation tool was used to assign participants to groups. Control and intervention groups were coded as A, B, C and D using the sealed envelope method. Randomization information was withheld from the researcher involved in data collection until data was collected. The researcher determines which group each baby is in. The researcher found out during the painful procedure. (investigator blinding). Within the scope of the research, parents knew which group the baby was in. However, due to the nature of the sample group, the babies were blind. To avoid statistical bias, study groups were coded as A, B, C and D; statistical blinding was performed (statistician blinding).|Participants were assigned to the groups using the block randomization method. Age (6-12 and 13-24 months) and sex (male and female) were used as variables for randomization. Blocks were repeated eight times in each group to achieve the calculated sample size, and 32 participants were included in each group. An online tool was used to generate the randomization list with 2 × 2 × 8 blocks (Sealed Envelope Ltd., 2022).|t|f|t|t
34023060|NCT05509738|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomly assigned into two groups that differ only in the order of receiving the text message-based healthcare assistance as an adjunct to their children's standard care.||||
34023061|NCT03996148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023062|NCT01375686|||COHORT||PROSPECTIVE|||||||
34023063|NCT02678650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102278|NCT06691490|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind|Effort Perception; fMRI; EEG; Networks; Propioception|t|f|t|f
34102279|NCT02656173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102280|NCT01818648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34102281|NCT06695416|||COHORT||RETROSPECTIVE|||||||
34102282|NCT05573906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102283|NCT02207101|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34102284|NCT02284854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102285|NCT05855109|||COHORT||PROSPECTIVE|||||||
34102286|NCT05230758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|We are implementing a double-blind procedure to ensure that neither participants nor members of the research team have knowledge of the randomized treatment group to prevent bias in reporting, outcome assessment and analysis.|We elect to employ a parallel arm superiority trial. As there is no standard of care equivalent for the intervention being investigated (i.e. metformin for improved cognition and white matter growth), a placebo is being used to prevent any potential response bias.|t|t|t|t
34102287|NCT06222957|||CASE_CONTROL||PROSPECTIVE|||||||
34102288|NCT05557812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102289|NCT04688138|||COHORT||PROSPECTIVE|||||||
34102290|NCT00227955|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102291|NCT04524429|||COHORT||RETROSPECTIVE|||||||
34102292|NCT05921162|||COHORT||PROSPECTIVE|||||||
34102293|NCT06655194|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34102294|NCT06689462|||COHORT||RETROSPECTIVE|||||||
34103494|NCT05095441|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33718798|NCT03264209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33718799|NCT05098925|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718800|NCT03913650|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33718801|NCT01831544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718802|NCT03103607|||COHORT||PROSPECTIVE|||||||
33718803|NCT05560997|||COHORT||RETROSPECTIVE|||||||
33718804|NCT00215163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33718805|NCT02402543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718806|NCT00988455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718807|NCT03704272|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group (Treatment as usual) vs. Treatment group (screening, brief intervention and referral to treatment)||||
33718808|NCT00939328||||TREATMENT||NONE||||||
33718809|NCT02190084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718810|NCT00240253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33718811|NCT02630355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718812|NCT05791851|||OTHER||PROSPECTIVE|||||||
33718813|NCT03164096|NA|SINGLE_GROUP||SCREENING||NONE||evaluating relationship of sensory level and other patient factors||||
33718814|NCT00005972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718815|NCT03833973|||COHORT||PROSPECTIVE|||||||
33718816|NCT03232801|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33718817|NCT01930747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33718818|NCT01110707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718819|NCT06475950|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"The process of setting rehabilitation goals with Kid'EM app requires collaboration between the professional, the child and the family, preventing rehabilitation professionals and children and their families from being blindsided."|"Kid'EM app experimental group~Rehabilitation professionals have access to the Kid'EM app tool, which guides them in setting goals.~The app offers functionalities, including the selection of avatars by children, the identification of children's tastes and needs, the definition of SMART objectives, and the setting up of exchange spaces with parents and other professionals.~The application enables the identification of environmental elements that may impact on the child's progress, and provides a note-taking space for the professional.~Kidem app control group~Rehabilitation professionals have access to a control application which has the same design, but does not offer guidance or a space for exchange with parents.~The functionalities of the control application include the creation of the professional's account, selecting the child's pathology, identifying the child's tastes, and entering objectives without guidance.~Professionals use their usual strategy to set goals."||||
33718820|NCT00862745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33718821|NCT03143569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33718822|NCT01316120|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718823|NCT05762003|||COHORT||RETROSPECTIVE|||||||
33718824|NCT02834208|RANDOMIZED|PARALLEL||||NONE||||||
33718825|NCT00728780|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718826|NCT04599894|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33718827|NCT04158557|||COHORT||RETROSPECTIVE|||||||
33718828|NCT05553002|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized, controlled study will be conducted at a research laboratory of our university. Participants will be randomly assigned to to either the treatment group or the control group||||
33718829|NCT06215599|||COHORT||CROSS_SECTIONAL|||||||
33718830|NCT05083104|||CASE_CONTROL||RETROSPECTIVE|||||||
33718831|NCT00884208|||COHORT||PROSPECTIVE|||||||
33718832|NCT03072615|||COHORT||PROSPECTIVE|||||||
33718833|NCT01952431|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33718834|NCT00846131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718835|NCT03144388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors at each measurement|Parallel-group with optional crossover|f|f|f|t
33718836|NCT00144976|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33718837|NCT04071496|||COHORT||PROSPECTIVE|||||||
33718838|NCT05985018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718839|NCT04483011|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double-blind|randomized, double-blind, comparator-controlled, cross-over|t|t|t|t
33718840|NCT03388060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718841|NCT06077292|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33718842|NCT02409992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718843|NCT05527145|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||investigator-initiated, prospective, phase III, randomized, controlled clinical trial At the 6-month follow-up, there is a possibility of cross- over from group B to group A. After crossover to surgery, the after-treatment of these patients will be as in group A.|f|t|f|t
33718844|NCT04975360|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||A randomized, double-blind, placebo controlled, cross-over design.|t|t|t|t
33718845|NCT00003644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718846|NCT03999450|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33718847|NCT02746016|NA|SINGLE_GROUP||OTHER||NONE||||||
33718848|NCT01335581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718849|NCT00198757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718850|NCT00255450|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33718851|NCT06413342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718852|NCT05849103|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Research personnel assessing outcomes will be masked to the intervention|A factorial study design will be used where participants will be randomized in a 1:1:1:1 ratio to two intervention types (blood pressure target, hypertension care model) or four total interventions.|f|f|f|t
33718853|NCT00036504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718854|NCT03930576|||COHORT||PROSPECTIVE|||||||
33718855|NCT05264155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718856|NCT01988857|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718857|NCT03716882|||COHORT||PROSPECTIVE|||||||
33718858|NCT04857515|||COHORT||PROSPECTIVE|||||||
33718859|NCT00735592|||COHORT||RETROSPECTIVE|||||||
33718860|NCT06327867|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, single center, prospective, randomized, comparative, intervention study.||||
33800001|NCT05953870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33800002|NCT02459782|NA|SINGLE_GROUP||||NONE||||||
33800003|NCT05574452|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Pilot Study||||
33800004|NCT02067949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33800005|NCT03388281|||COHORT||RETROSPECTIVE|||||||
33800006|NCT04336059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33718861|NCT03907293|||COHORT||PROSPECTIVE|||||||
33718862|NCT01778829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800007|NCT05035004|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33800008|NCT05855291|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800009|NCT02436317|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800010|NCT00516321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800011|NCT02461264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800012|NCT03654235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients Evaluator and Outcomes Assessor are masked||f|f|f|t
33800013|NCT00541333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800014|NCT05316246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800015|NCT03527160|||COHORT||PROSPECTIVE|||||||
33800016|NCT05617742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800017|NCT00609908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800018|NCT02299752|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800019|NCT03873337|NA|SINGLE_GROUP||TREATMENT||NONE||Due to the pandemic, this study was modified from a randomized clinical trial to test the feasibility, initial efficacy, and mechanisms of action of our PTSC-S intervention to a feasibility and acceptability test of our intervention when delivered via telehealth in a single group, within-subjects design.||||
33800020|NCT01340417|NA|SINGLE_GROUP||SCREENING||NONE||||||
33800021|NCT06149819|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a controlled, single centre, non-randomized, open-label interventional study evaluating the implementation of a nursing pathway management for chest pain. This study is an external comparison with a control group consisting of patients meeting the same eligibility criteria admitted to the Emergency Department over the same period and included prospectively with a 1:1 ratio. This design was chosen because of the difficulty of randomizing patients (few trained nurses) and the need to conduct a pivotal study.||||
33800022|NCT01011946|NA|SINGLE_GROUP||||NONE||||||
33800023|NCT04593251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800024|NCT00224601|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800025|NCT01347892|||COHORT||OTHER|||||||
33800026|NCT06435637|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Double-blind, parallel-group, placebo-controlled intervention study|t|f|t|t
33800027|NCT04143204|||COHORT||PROSPECTIVE|||||||
33800028|NCT00801658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800029|NCT05575622|||COHORT||PROSPECTIVE|||||||
33800030|NCT06521801|||COHORT||PROSPECTIVE|||||||
33800031|NCT03029598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023064|NCT02971735|RANDOMIZED|PARALLEL||OTHER||NONE||This study was a prospective randomized controlled trial.||||
34023065|NCT00463697|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34023066|NCT03309995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023067|NCT01723579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023068|NCT03767335|NA|SEQUENTIAL||TREATMENT||NONE||Step 1 Dose escalation / Step 2 Cohort expansion in two selected breast cancer sub-populations||||
34023069|NCT02469259|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34023070|NCT05700370|NA|SINGLE_GROUP||SCREENING||NONE||||||
34023071|NCT02266537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34023072|NCT01085123|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023073|NCT03049605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|By randomization of participants recruitment||t|f|t|f
34023074|NCT06470282|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34023075|NCT04256811|||OTHER||PROSPECTIVE|||||||
34023076|NCT02116608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023077|NCT03473769|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34023078|NCT00005983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023079|NCT06010537|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34023080|NCT02051400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34023081|NCT02153008|||OTHER||PROSPECTIVE|||||||
34023082|NCT01158092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023083|NCT03653910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023084|NCT04829110|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34023085|NCT01696851|||CASE_CONTROL||PROSPECTIVE|||||||
34023086|NCT02799368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023087|NCT00823108|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023088|NCT03269227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023089|NCT04186351|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34023090|NCT02078765|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800032|NCT04962477|||CASE_CONTROL||PROSPECTIVE|||||||
33800033|NCT05948644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800034|NCT01284075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800035|NCT01925339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800036|NCT05801367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patients and assessors involved in the study from randomization, allocation, bacteriological outcome, and data analysis will be blinded to which medicament group the patients belonged as all data will be coded.||t|f|f|t
33800037|NCT02009215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800038|NCT05794568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33800039|NCT04553523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800040|NCT02983669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800041|NCT03149991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800042|NCT01901081|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33800043|NCT02250235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34023091|NCT03168581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023092|NCT00091494|||COHORT||PROSPECTIVE|||||||
34023093|NCT05930457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023094|NCT05739253|||COHORT||PROSPECTIVE|||||||
34023095|NCT03450174|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
34023096|NCT02036775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023097|NCT03858634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023098|NCT06083012|||COHORT||PROSPECTIVE|||||||
34023099|NCT00756769|||COHORT||PROSPECTIVE|||||||
34023100|NCT03286335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023101|NCT04147923|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel study|t|t|t|t
34023102|NCT03953989|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study, one center, open, non-controlled, one group pre-post treatment||||
34023103|NCT00601562|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023104|NCT01906450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023105|NCT04630158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
34023106|NCT06495489|||COHORT||PROSPECTIVE|||||||
34023107|NCT02750748|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800044|NCT05456126|||COHORT||PROSPECTIVE|||||||
33800045|NCT02389907|||COHORT||PROSPECTIVE|||||||
33800046|NCT00141349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33800047|NCT03419572|||COHORT||PROSPECTIVE|||||||
33800048|NCT03485950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800049|NCT01766154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800050|NCT06020885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800051|NCT05106075|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|patients are anonymized|||||
33943680|NCT00055939|NON_RANDOMIZED|||TREATMENT||NONE||||||
33943681|NCT05357105|||CASE_ONLY||PROSPECTIVE|||||||
33943682|NCT01527058|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943683|NCT05771415|||COHORT||PROSPECTIVE|||||||
33943684|NCT04915365|RANDOMIZED|PARALLEL||PREVENTION||NONE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) An independent pharmacist will prepare identically looking active and placebo capsules labelled with secret codes. Codes will be concealed to investigators and patients until completion of data analysis.|randomized, placebo-controlled, double-blind||||
33943685|NCT05617274|||COHORT||RETROSPECTIVE|||||||
33800052|NCT00252278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33800053|NCT01845259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800054|NCT05546359|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33800055|NCT03903822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800056|NCT02617771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33943686|NCT05136326|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, multicentre, non-randomized, open-label trial||||
33943687|NCT04686396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Randomization shall be performed during surgery after intra-operative inclusion/exclusion eligibility has been met.|Patients will be randomized to have either the addition of demineralized bone matrix to their procedure (Interpositional Group), or standard Rotator Cuff repair without demineralized bone matrix administered (Control group).|t|f|f|f
33943688|NCT02885506|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part A of the study was conducted as a dose escalation, and that Part B utilized a cross-over design.|t|t|t|t
34023108|NCT06388967|||CASE_CONTROL||PROSPECTIVE|||||||
34023109|NCT03398070|||COHORT||PROSPECTIVE|||||||
34023110|NCT04657796|||OTHER||PROSPECTIVE|||||||
34023111|NCT00850434|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34023112|NCT06306508|||OTHER||CROSS_SECTIONAL|||||||
34023113|NCT05875792|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, before and after feasability study||||
34023114|NCT00000114|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34023115|NCT01517373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023116|NCT01451086|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34023117|NCT06262802|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
34023118|NCT06312657|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34023119|NCT00507130|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34023120|NCT02041065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023121|NCT03781284|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34023122|NCT05214105|||COHORT||PROSPECTIVE|||||||
34023123|NCT06633146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomised controlled study||||
34023124|NCT04514068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023125|NCT00700830|||CASE_ONLY||PROSPECTIVE|||||||
34023126|NCT04602715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Hospital pharmacies will be provided with the randomization code and will dispense the appropriate medication to subjects. A fire-wall exists between the pharmacies and the investigational staff.|two arm, randomized, placebo controlled|t|t|t|t
34023127|NCT04100863|||CASE_ONLY||PROSPECTIVE|||||||
34023128|NCT01031030|RANDOMIZED|||TREATMENT||NONE||||||
34023129|NCT05851625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34023130|NCT03232632|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34023131|NCT02656511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023132|NCT03265418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023133|NCT01963286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023134|NCT00128271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023135|NCT00773630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023136|NCT05631275|||COHORT||PROSPECTIVE|||||||
34023137|NCT03639454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023138|NCT02377050|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34023139|NCT00144781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023140|NCT05505175|||COHORT||RETROSPECTIVE|||||||
34023141|NCT04587063|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and providers are not aware that different mailer versions exist, and they do not know what elements in the letter are being tested.|1 x 5 design|t|t|f|f
34023142|NCT04549103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised controlled trial|f|f|t|t
34023143|NCT02074917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023144|NCT05413616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023145|NCT01094886|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33800057|NCT00326144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800058|NCT01348594|||COHORT||PROSPECTIVE|||||||
33800059|NCT06181695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800060|NCT05191810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800061|NCT01699633|||COHORT||PROSPECTIVE|||||||
33943689|NCT04225182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943690|NCT02833142|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33943691|NCT06413030|||OTHER||CROSS_SECTIONAL|||||||
33943692|NCT04371068|||OTHER||PROSPECTIVE|||||||
33943693|NCT04527458|||COHORT||PROSPECTIVE|||||||
33943694|NCT06448520|NA|SINGLE_GROUP||OTHER||NONE||||||
33943695|NCT02812602|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33943696|NCT05304078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33943697|NCT04892095|||OTHER||CROSS_SECTIONAL|||||||
33943698|NCT05907031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718863|NCT04882267|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Subjects will serve as own controls to establish a baseline of physical activity (first arm). After the baseline period, subjects will partake in the 4-week intervention in which they receive access to home exercise apps and receive motivational interviewing phone calls (second arm). After the intervention period, subjects will continue to have access to apps, but no longer receive phone calls. Activity and surveys will be measured at the end of 4 weeks (third arm).||||
33718864|NCT04823039|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33718865|NCT01477606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718866|NCT01904682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718867|NCT03273192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34023146|NCT03666650|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023147|NCT06102083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718868|NCT06257810|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a multicentric study which will be carried out in four hospitals, two in Burkina Faso and two in Ivory Coast. In each of these two countries, an intervention site and a control site will be included in the study. The study is interventional as the investigators collected additional blood samples than the routine practices."||||
33718869|NCT05332340|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33718870|NCT02853591|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33718871|NCT05756374|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718872|NCT05792631|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718873|NCT05983276|NA|SINGLE_GROUP||TREATMENT||NONE||"Once selected for therapy, the participant will receive the following treatment in the outpatient setting:~Days 1-5: Decitabine 10 mg; m2 IV daily Day 6: carboplatin AUC 5 and paclitaxel 80 mg; m2 Days 13, 20, and 27: paclitaxel 80 mg/m2 For a single 28 day cycle.~Assess Response toxicities and immune effector cell changes.~Days 1-5: Decitabine 10 mg/m2 IV daily; Day 6: carboplatin AUC 5 and paclitaxel 80 mg/ m2; Day 7 and weekly thereafter (day 14, 21, 28, 35...) Selinexor 60 mg PO Days 13, 20, and 27: paclitaxel 80 mg/m2 each given x five 28 day cycles~Assess responses by exam, CT scan and blood tests, assess toxicities, and immune effector cell changes as well as progression and overall survival"||||
34023148|NCT04800549|NA|SINGLE_GROUP||PREVENTION||NONE|The power of the test in the study was calculated by using G\*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.|The power of the test in the study was calculated by using G\*Power 3.1 program. While Type I error is 0.05 and the power of the test is 0.80 (α= 0.05, 1-β= 0.80), minimal sample size was calculated as 62 children (31 children in each group). By considering the losses that may occur from the sample during the study due to any reason, it was planned to include 40 children in both experimental and control groups. Follow-up lost occurred in 5 patients from experimental group and 6 patients in the control group during the study. The study was completed with 69 paediatric patients including 34 in the experimental group and 35 in the control group.||||
34023149|NCT06035809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to which treatment arm a participant was assigned.|This is a study investigating SMART as an intervention for symptoms of PTSD. Participants will be randomized to one of two conditions: SMART or Wait List (i.e., delayed treatment), and both groups will be assessed at 3 time points.|f|f|f|t
34023150|NCT01040598|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718874|NCT01121887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718875|NCT04464122|||CASE_CONTROL||PROSPECTIVE|||||||
33718876|NCT05988047|||COHORT||PROSPECTIVE|||||||
33718877|NCT04643548|||COHORT||PROSPECTIVE|||||||
33718878|NCT04954612|||OTHER||CROSS_SECTIONAL|||||||
33718879|NCT03128112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33718880|NCT00478569|||CASE_ONLY||PROSPECTIVE|||||||
33718881|NCT01761981|||COHORT||PROSPECTIVE|||||||
33718882|NCT04311424|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33718883|NCT03520231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718884|NCT02093286|||CASE_CONTROL||PROSPECTIVE|||||||
33718885|NCT03344432|||OTHER||PROSPECTIVE|||||||
33718886|NCT02178631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33718887|NCT03813979|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33718888|NCT04730830|NA|SINGLE_GROUP||OTHER||NONE||Observational study with questionnaires||||
33718889|NCT01743131|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33718890|NCT02539277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718891|NCT06526637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will use direct observational methods in a workshop setting. Participants will be randomised to receive one of three Palliate training and material versions. Randomisation will be completed ahead of study commencement using a random number generator to allow the researcher time to prepare and set up the selected training information and materials. Randomisation will be conducted in blocks of three to ensure an even number randomised to each of the study arms (intervention version 1,2 and 3).||||
33718892|NCT00998660|NA|SINGLE_GROUP||||NONE||||||
33718893|NCT02982850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718894|NCT03124914|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718895|NCT05417165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718896|NCT02177045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718897|NCT04120831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This randomized, phase 2, single centre exploratory proof of concept study uses a sequential Rituximab/Abatacept treatment in ACPA positive rheumatoid arthritis. The study is composed of a non-blinded two arm design with a randomization of 1:1. A total amount of 20 ACPA positive RA patients are planned for enrolment. Duration of this study is planned for 52 weeks.~Subjects willing to participate in the study have to sign a written informed consent prior to any study specific procedure, after being informed about the possible risks and possible benefits."|f|f|f|t
33800062|NCT04565834|||CASE_CONTROL||RETROSPECTIVE|||||||
33800063|NCT04033107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840318|NCT03876470|||COHORT||PROSPECTIVE|||||||
33840319|NCT05352841|||CASE_CONTROL||PROSPECTIVE|||||||
34102295|NCT06656507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study employs a Double-Blind masking approach to minimize bias. Both the patients and the healthcare providers (including postoperative care staff) will be unaware of which block (Quadro Iliac Plane Block or Erector Spinae Plane Block) was administered. The anesthesiologists performing the blocks will be informed of the assigned intervention but will not participate in postoperative care or outcome assessment. The outcome assessors, who will evaluate pain scores, opioid consumption, and other outcomes, will also be blinded to the group allocation to ensure unbiased data collection.|This study follows a Parallel Assignment model where eligible patients undergoing lumbar vertebra surgeries will be randomized into one of two groups. One group will receive the Quadro Iliac Plane Block (QIPB), while the other group will receive the Erector Spinae Plane (ESP) Block. Both interventions will be administered pre-awakening following surgery, with each group receiving only their assigned block. The groups will be assessed independently for postoperative pain control, opioid consumption, side effects, and overall patient satisfaction. This parallel approach ensures that each group's treatment and outcomes are evaluated without crossover, allowing for a direct comparison of the two regional anesthesia techniques.|t|t|f|t
33840320|NCT04654949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943699|NCT00004795|RANDOMIZED|||TREATMENT||DOUBLE||||||
33943700|NCT00808197|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943701|NCT02793024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943702|NCT00987558|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023151|NCT01624792|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34023152|NCT00800007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102296|NCT01812746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102297|NCT01779206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102298|NCT04550728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102299|NCT05735652|||COHORT||OTHER|||||||
33943703|NCT01851031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023153|NCT06505447|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Three phase single center pilot study||||
33943704|NCT04506606|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943705|NCT01030731||PARALLEL||BASIC_SCIENCE||NONE||||||
33943706|NCT04710628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023154|NCT04759053|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34023155|NCT01955837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023156|NCT06292585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023157|NCT05160272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023158|NCT00049530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023159|NCT06110624|||COHORT||PROSPECTIVE|||||||
34023160|NCT06367608|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34023161|NCT04958278|||COHORT||PROSPECTIVE|||||||
34023162|NCT05980663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized stratified controlled clinical study|t|t|f|f
33840321|NCT01512316|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33840322|NCT03697122|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention group has only one arm. All patients will use active warming via traditional methods (ie forced air warming blankets) and Heated Humidified breathing circuits (HHBC) via ANAPOD Heated Humidification System® (ANAPOD). Those patients will be matched with a retrospective historical cohort of patients that received active warming via traditional methods only (forced air warming blankets).||||
33840323|NCT01170793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943707|NCT00000912||||TREATMENT||||||||
33943708|NCT00387621|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33943709|NCT00797043|||COHORT||PROSPECTIVE|||||||
33943710|NCT03487562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33943711|NCT00736840|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33943712|NCT01026727|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023163|NCT06286696|||COHORT||PROSPECTIVE|||||||
34023164|NCT00401986|||COHORT||PROSPECTIVE|||||||
34023165|NCT02917070|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34023166|NCT00810316|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34023167|NCT02699060|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34023168|NCT00000474|RANDOMIZED|||PREVENTION||||||||
34102300|NCT05787483|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|||||
34102301|NCT02893436|||CASE_ONLY||PROSPECTIVE|||||||
34102302|NCT02124421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943713|NCT00670098|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33943714|NCT01832272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840324|NCT00458081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840325|NCT01523067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840326|NCT02318615|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33840327|NCT00777764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840328|NCT05176938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840329|NCT04407689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|randomized controlled of treatment vs placebo|t|t|t|t
33840330|NCT04458922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943715|NCT00630942|NA|SINGLE_GROUP||TREATMENT||||||||
33943716|NCT04211506|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants may not know to which study arm they are assigned.|Each participant will undergo one of four separate arms manipulating levels and timing of sleep in a controlled laboratory setting.|t|f|f|f
33943717|NCT02651311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33943718|NCT02155725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943719|NCT06263504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943720|NCT04917666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors have no knowledge of whether the participants are in the treatment of control groups. They distribute and collect questionnaires from participants, and gave observation rating on the participants in both group.||f|f|f|t
34023169|NCT05357118|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators||||
34023170|NCT05600465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023171|NCT06548308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34023172|NCT03268707|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34023173|NCT04780282|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||It will be divided into 2 groups as scapular stabilization exercise group and control group.||||
34023174|NCT06506214|||COHORT||PROSPECTIVE|||||||
34023175|NCT05858502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023176|NCT04708574|RANDOMIZED|PARALLEL||PREVENTION||NONE||RCT||||
34023177|NCT01830634|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023178|NCT00339092|RANDOMIZED|PARALLEL||||NONE||||||
34023179|NCT04707781|||COHORT||PROSPECTIVE|||||||
34023180|NCT00135863|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34023181|NCT02040779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023182|NCT02991326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023183|NCT01995760|||COHORT||RETROSPECTIVE|||||||
34023184|NCT03371459|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023185|NCT02556229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023186|NCT02172235|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023187|NCT06024889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023188|NCT03165838|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34023189|NCT02537808|||CASE_ONLY||PROSPECTIVE|||||||
34023190|NCT05252598|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Participants will be assigned a blister pack containing all the pills for the duration of the study. Each participant will consume 10 capsules each day of the study. The investigational agent will be an encapsulated mushroom powder formulation (derived from Psilocybe cubensis strain) containing varying amounts of psilocybin. The formulation will be altered to ensure each day contains the proposed amount of psilocybin (1, 2, 5, 8, 10mg) or placebo to be tested. Participants and researchers will be blinded to the dose which was consumed on each day of the study|t|t|t|t
34023191|NCT06632743|||COHORT||PROSPECTIVE|||||||
34023192|NCT03651882|RANDOMIZED|PARALLEL||PREVENTION||NONE||Before c-section the patients will be randomized to the oxytocin or the carbetocin group.||||
34023193|NCT01154816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023194|NCT00684489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023195|NCT03184155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized double blind, placebo controlled, study|t|t|t|f
34023196|NCT02951091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Biomarker-integrated multi-arm with shared standard of care (SOC) control arm||||
34023197|NCT05404945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840331|NCT04915274|NA|SINGLE_GROUP||OTHER||NONE||||||
33840332|NCT03686423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840333|NCT03807895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840334|NCT04419129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102303|NCT06036836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840335|NCT04068233|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|It is decided by coin tossing which pacing mode is programmed first (randomization). Sonographer and patient are both blinded to the pacing mode.|Each patient will represent their own control, as both pacing modes (asynchronous and synchronous) are applied in each patient.|t|f|t|f
33718898|NCT03996954|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Recordings with Alivecor and 12 lead ECGs with be acquired from patients with known arrhythmias/normal heart rhythm and blinded physicians will report on recordings and ECGs. Reports for each patient will be compared at the end of the study in order to assess diagnostic accuracy of the Alivecor to detect and differentiate between different kinds of abnormal heart rhythms.|f|f|f|t
33840336|NCT02906826|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34102304|NCT05756829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102305|NCT02585180|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33718899|NCT01059786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718900|NCT04670081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33718901|NCT01781182|||COHORT||PROSPECTIVE|||||||
33718902|NCT02855216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718903|NCT01778933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718904|NCT03070574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33840337|NCT04912427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840338|NCT04497740|||CASE_ONLY||RETROSPECTIVE|||||||
33840339|NCT04052295|||CASE_ONLY||RETROSPECTIVE|||||||
33840340|NCT00572364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718905|NCT02463539|||||PROSPECTIVE|||||||
33840341|NCT02016677|||COHORT||PROSPECTIVE|||||||
33718906|NCT03282188|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||This is a open-label, non-randomised, single centre study.||||
33718907|NCT05585151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718908|NCT00934154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718909|NCT03761147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718910|NCT01584687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718911|NCT05487638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718912|NCT01668550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718913|NCT01433601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33718914|NCT06336460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research associate/outcome assessor will not have access to group assignment and will therefore be blinded to the type of block. Although the patient, their caregiver(s), and the clinician caring for the patient will not be directly informed of the group assignment, a note will be logged in the clinical record by the physician placing the block indicating the details of the block after this procedure has been completed.||t|t|f|t
33718915|NCT01946425|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718916|NCT03267186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718917|NCT04563689|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33718918|NCT03966703|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|patients are computer sorted in each group. samples were anonymous tagged by numbers and not by patient name|10 patients from each group|t|f|f|f
33718919|NCT00529061|||COHORT|||||||||
33718920|NCT00494988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718921|NCT06020365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718922|NCT00893191|||CASE_CONTROL||PROSPECTIVE|||||||
33718923|NCT01770548|NON_RANDOMIZED|PARALLEL||||NONE||||||
33718924|NCT04122092|||CASE_CONTROL||PROSPECTIVE|||||||
33718925|NCT05608109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102306|NCT01455844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102307|NCT05284747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718926|NCT01491503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718927|NCT06469866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34102308|NCT01269320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102309|NCT04837547|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102310|NCT06688539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102311|NCT03430973|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Seven driving simulation experiments on aggressive driving and road rage (see descriptions above).||||
34102312|NCT04292496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33718928|NCT00825747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33718929|NCT06160960|||COHORT||PROSPECTIVE|||||||
33718930|NCT04992455|||OTHER||PROSPECTIVE|||||||
33718931|NCT01848002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718932|NCT05536258|||OTHER||PROSPECTIVE|||||||
33718933|NCT01727973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718934|NCT00189657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718935|NCT02433756|||CASE_ONLY||PROSPECTIVE|||||||
33943721|NCT00627991|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33943722|NCT06289543|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33718936|NCT03484884|||COHORT||PROSPECTIVE|||||||
33718937|NCT02867189|NON_RANDOMIZED|PARALLEL||||NONE||||||
33718938|NCT00449540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33718939|NCT05641051|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The drugs will be prepared by a dedicated anesthesiologist who is aware of the allocated group and will have no subsequent role in the study.||t|f|t|f
33943723|NCT04064463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943724|NCT06139978|||CASE_ONLY||PROSPECTIVE|||||||
33943725|NCT02990325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943726|NCT02014753|||COHORT||PROSPECTIVE|||||||
33943727|NCT05770882|NA|SEQUENTIAL||TREATMENT||NONE||||||
33943728|NCT02926833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study uses a single group design. The arms reported in the Arms and Intervention section are based on the atezolizumab dosing schedule in the 4 Cohorts.||||
34023198|NCT05502081|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023199|NCT02149290|||CASE_ONLY||PROSPECTIVE|||||||
34023200|NCT05487534|||CASE_CONTROL||PROSPECTIVE|||||||
34023201|NCT03153761|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34023202|NCT00985179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023203|NCT05744180|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33718940|NCT02743806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718941|NCT03695679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33943729|NCT05015959|||COHORT||RETROSPECTIVE|||||||
33943730|NCT01491776|||COHORT||PROSPECTIVE|||||||
33943731|NCT06510192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943732|NCT00768040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943733|NCT02573142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943734|NCT04929314|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The trial is single-blinded, as the participants are unaware of their group allocation. The community nurses will not be blinded, as they will know whether they perform the intervention or not.||t|f|f|f
33943735|NCT03288987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943736|NCT05460468|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|This is a within-subjects design, such that both active and sham stimulation (i.e., masking) trials will occur in all subjects.|"The study has three Aims and thus three models.~For Aim 1, the primary outcome measure is fMRI BOLD. Researchers will estimate the dose-response relationship between TMS intensity and BOLD response in two cortical sites for response to TMS.~For Aim 2 the primary outcome measure is impact of closed-loop TMS treatment on working memory task performance.~For Aim 3, the primary outcome measure is the strength of mediation of brain health (e.g., vascular density) predictors of cognition."|t|f|f|f
33943737|NCT03919032|||COHORT||PROSPECTIVE|||||||
33943738|NCT01088360|||COHORT||PROSPECTIVE|||||||
33943739|NCT04415931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized prior to their scheduled surgery date by our research team using a randomization protocol developed by our department biostatistics team. The surgeons and anesthesiologists will be blinded about the group assignment until the day before surgery. The group assignment will be sealed in an envelope and delivered to the surgeon.||f|f|f|t
33943740|NCT03110497|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I/ Phase II single arm study||||
33943741|NCT04406155|||COHORT||PROSPECTIVE|||||||
33943742|NCT05540808|||OTHER||CROSS_SECTIONAL|||||||
33943743|NCT04576585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|randomly assigned|Investigators will randomly assign recruited participants to one of two groups. One group will receive training in the lexicon of appetite (Hunger, Fullness, Desire to Eat, and Prospective Consumption), and the other group will be trained in the basic tastes (Sweetness, Sourness, Bitterness, and Saltiness) as an attention control. All participants will participate in two preload trials with mixed meals before training and six paired preload trials after training. Trials will be held once per week. On another day of the trial week, participants will record their appetite during the waking hours of one day through an online survey. The total duration of participation will be in 9 weeks.|t|f|f|f
33943744|NCT05539664|RANDOMIZED|PARALLEL||TREATMENT||NONE||The test group will use the investigational medical device Hydrogen-Oxygen Generator with Nebulizer (Shanghai Asclepius Meditec Co., Ltd.) + basic treatment (the investigator provides corresponding symptomatic support treatment based on the condition of the patients), and the control group will use the hospital routine oxygen supply equipment (wall oxygen or cylinder oxygen) + basic treatment||||
33943745|NCT05358158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943746|NCT03005691|||COHORT||CROSS_SECTIONAL|||||||
33943747|NCT01199874|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943748|NCT00247962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943749|NCT02711306|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33943750|NCT06030531|||CASE_CONTROL||PROSPECTIVE|||||||
33943751|NCT02390167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840342|NCT02037620|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33840343|NCT01979406|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33840344|NCT00253682|||COHORT||PROSPECTIVE|||||||
33943752|NCT04192552|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients taking apixaban, dabigatran, or rivaroxaban will be randomly assigned to follow 1) PAUSE or 2) ASRA perioperative DOAC management.||||
33943753|NCT02277418|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102313|NCT05312892|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34102314|NCT01323543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102315|NCT06496659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102316|NCT03769467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102317|NCT01150370|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102318|NCT06116032|||COHORT||PROSPECTIVE|||||||
34103495|NCT05520866|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will be randomized in a 2:1 ratio||||
34103496|NCT05691361|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double blinded|Phase 1, Single-Center, Randomized, Placebo-Controlled, Double Blind Single Ascending Dose Study in HV with expansion into HAE|t|t|t|t
34103497|NCT00049283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840345|NCT03963869|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Quasi-experimental cluster-assigned stepped-wedge study||||
33840346|NCT02132832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33840347|NCT05689242|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|t|f
33840348|NCT04494451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840349|NCT01397422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840350|NCT06028243|RANDOMIZED|PARALLEL||OTHER||NONE|Blinding in the study was not feasible. Blinding could not be performed because the researchers were aware of the interventions and carried out the implementation.|||||
33840351|NCT05320510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840352|NCT03423329|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33840353|NCT02878694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943754|NCT03537417|||CASE_ONLY||PROSPECTIVE|||||||
33943755|NCT04046029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943756|NCT02185638|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33718942|NCT00412022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943757|NCT04556942|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients receiving routinely performed bronchoscopic lung volume reduction (BLVR) using endobronchial valves due to severe emphysema with hyperinflation are eligible for this study. After obtaining written informed consent, the participating patients will be randomized into an immediate (within 1-2 weeks) BLVR group and a delayed BLVR group (6-8 weeks) using counted and sealed envelopes. Patients in both groups will undergo baseline study specific measurements of primary and secondary endpoints (T0). The immediate BLVR group will be re-assessed 4-6 weeks after successful endobronchial valve (EBV) treatment, whereas the delayed BLVR group will be re-assessed prior EBV treatment (T1). Results of group 1 and 2 will be compared for final analysis.||||
33943758|NCT05177666|||COHORT||PROSPECTIVE|||||||
33943759|NCT05277597|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study used a randomized, parallel group design. The participants were randomly assigned to exercise training (ET) without or with post-exercise sauna treatments (ET+S) by using a permuted blocks of block size 4. design with a computer.||||
33943760|NCT04772417|||OTHER||CROSS_SECTIONAL|||||||
33943761|NCT04176809|RANDOMIZED|PARALLEL||OTHER||NONE||Eligible patients who agree to participate will be randomized into two parallel arms (ratio 1:1) by the minimization technique with stratification by age, stage, presence or absence of comorbidities and type of endocrine therapy prescribed||||
33943762|NCT03550989|||OTHER||OTHER|||||||
33943763|NCT00511966|||COHORT||PROSPECTIVE|||||||
33943764|NCT05421559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023204|NCT04497948|NA|SINGLE_GROUP||TREATMENT||NONE||Single group multi dose study. Participants to receive Acalabrutinib + PPI and Best Supportive Care.||||
34023205|NCT05484219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023206|NCT02006693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023207|NCT00746876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023208|NCT02546466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023209|NCT03468075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718943|NCT02377466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718944|NCT04321148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718945|NCT02703389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718946|NCT01338545|||COHORT||PROSPECTIVE|||||||
33718947|NCT04918550|||OTHER||CROSS_SECTIONAL|||||||
33718948|NCT04200456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators are blinded to the treatment code, they will see the platelet values.||t|t|t|t
33718949|NCT04576832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33718950|NCT05691296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718951|NCT01529346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718952|NCT05601258|||CASE_CONTROL||RETROSPECTIVE|||||||
33718953|NCT02968745|||||CROSS_SECTIONAL|||||||
33718954|NCT00531817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33718955|NCT02069366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718956|NCT04588792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718957|NCT02404285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33718958|NCT00510133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718959|NCT00541073|NON_RANDOMIZED|||TREATMENT||||||||
33718960|NCT04987957|RANDOMIZED|PARALLEL||PREVENTION||NONE||The sample groups of the research will be divided into two groups as experiment and intervention.||||
33718961|NCT03388333|||COHORT||RETROSPECTIVE|||||||
33718962|NCT03398057|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33718963|NCT03434054|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Study medication and placebo are over-encapsulated to look identical, and both the participants and investigators in direct contact with partiicpants are blind to group allocation.|This is a double-blind, placebo-controlled experimental medicine study, where healthy volunteers are randomised to receiving either a single dose of losartan (50mg) or matching placebo.|t|f|t|f
33718964|NCT02895906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718965|NCT01747941|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33718966|NCT04609787|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-IVR MPPTh and MTSP with post IVR levels will be compared.||||
33718967|NCT04258345|NA|SINGLE_GROUP||OTHER||NONE||||||
33718968|NCT05356247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718969|NCT02463474|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33718970|NCT03762109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33718971|NCT02175498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718972|NCT00528398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718973|NCT04741061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized, double-blind (blinded for the study subject and investigators), placebo-controlled|t|f|t|f
33718974|NCT04358575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33718975|NCT01230801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718976|NCT01403714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718977|NCT01725438|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33718978|NCT04366076|||COHORT||PROSPECTIVE|||||||
33718979|NCT00422175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34023210|NCT02632461|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34023211|NCT05164887|||CASE_CONTROL||PROSPECTIVE|||||||
33718980|NCT05314855|||COHORT||PROSPECTIVE|||||||
33718981|NCT04422223|||COHORT||PROSPECTIVE|||||||
33718982|NCT02894931|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33718983|NCT01472081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718984|NCT02101645|NA|SINGLE_GROUP||||NONE||||||
33718985|NCT05066373|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33718986|NCT04151667|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33718987|NCT00524368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33718988|NCT04830020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33718989|NCT03989557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800064|NCT03906435|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This will be a non-blinded randomized control to assess the outcomes of infants and parents receiving either Cognitive Behavioral Therapy (CBT) sessions focusing on NICU trauma, emotional responses, and parent perceptions of child vulnerability (PPCV) versus standard of care without CBT sessions.~English and/or Spanish speaking parents of infants born at 30.6 weeks gestational age (GA) or less who survive to 33 weeks GA will be eligible to participate in the study. Once enrolled, the mother (and father, if willing) will be randomized into a control group (standard NICU and follow up care information) versus the intervention group (standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU). The CBT sessions will be standardized with a manual. Scales used for assessment will be distributed at enrollment to the study and upon completion of the CBT sessions."||||
33800065|NCT05146440|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib/II, multicohort, single arm, open-label, multicenter, international clinical trial||||
33718990|NCT02579850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800066|NCT05146271|||OTHER||OTHER|||||||
33718991|NCT03794414|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718992|NCT00987077|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33718993|NCT00541034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718994|NCT02505230|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33800067|NCT03197571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33718995|NCT01206231|||||PROSPECTIVE|||||||
33718996|NCT05502900|RANDOMIZED|PARALLEL||PREVENTION||NONE||100 patients will be randomized into either adjuvant treatment with Melatonin or to a control group that will undergo standard follow-up with radiological examinations but no adjuvant treatment.||||
33718997|NCT03772275|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33718998|NCT04940650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943765|NCT03471143|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1/2a, open-label, dose escalation, multi-center study of adrabetadex (VTS-270) in subjects with NPC dosed twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations, followed by a six month open-label extension phase in which the subjects are dosed monthly with IV adrabetadex (VTS-270) for six months for a total of six administrations||||
33943766|NCT00847951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943767|NCT02621138|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943768|NCT00603369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943769|NCT05453318|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study where women presenting with cervical lesions eligible to ablation were treated and followed-up for cure and adverse events.||||
33718999|NCT03963791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719000|NCT03084874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33719001|NCT02161627|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33719002|NCT03128333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719003|NCT04826770|||COHORT||PROSPECTIVE|||||||
33719004|NCT01585428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800068|NCT03199209|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800069|NCT01816022|||CASE_CONTROL||PROSPECTIVE|||||||
33800070|NCT00653276|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800071|NCT01673516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943770|NCT04472962|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33943771|NCT04953182|||COHORT||PROSPECTIVE|||||||
33943772|NCT04511533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943773|NCT05336877|||CASE_CONTROL||PROSPECTIVE|||||||
33943774|NCT04450420|RANDOMIZED|PARALLEL||OTHER||SINGLE|Expert raters assessing outcomes by watching videos of surgery were masked to the identity of the participating surgeon, their institutional affiliation, and the sequence in which they performed procedures in the trial.||f|f|f|t
33943775|NCT00915421|||CASE_CONTROL||PROSPECTIVE|||||||
33943776|NCT01512758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943777|NCT02354027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943778|NCT03396172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943779|NCT04355923|||COHORT||PROSPECTIVE|||||||
33943780|NCT02314299|NON_RANDOMIZED|||TREATMENT||NONE||||||
33943781|NCT02489994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943782|NCT00370994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33943783|NCT04808141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of investigators and patients regarding allocation arm will not be possible, given the nature of the intervention. Analysis of study results will be performed by a statistician blinded to allocation groups.|Randomized controlled study|f|f|f|t
33943784|NCT06256679|||COHORT||RETROSPECTIVE|||||||
33943785|NCT00771420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943786|NCT05217017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943787|NCT05294510|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Stepped wedge, cluster randomized trial with 5 clusters or treatment sequences of 3 villages each. Villages are first stratified by altitude, proximity to the local health center, and size (based on approximate number of children seen by the village health workers per year) into one of three strata: (1) low altitude, proximal, large, (2) low altitude, mid-distance, medium, (3) high altitude, distal, small. One village is then randomly selected from each strata for each of the 5 clusters. All clusters start in the control condition and one cluster crosses over from control to intervention each month.||||
33943788|NCT04866147|||COHORT||PROSPECTIVE|||||||
33943789|NCT06319365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943790|NCT02702076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943791|NCT06497816|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943792|NCT06080308|||COHORT||PROSPECTIVE|||||||
33719005|NCT02493374|||COHORT||PROSPECTIVE|||||||
33719006|NCT02062034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719007|NCT03582202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Results handled without knowledge of randomization group|Randomized controlled|f|f|f|t
33719008|NCT05519423|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33943793|NCT00943566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943794|NCT05440500|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33943795|NCT04461899|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719009|NCT03064191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33719010|NCT05974033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719011|NCT05060159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33719012|NCT03327415|||COHORT||CROSS_SECTIONAL|||||||
33719013|NCT00770276|||CASE_CONTROL||PROSPECTIVE|||||||
33719014|NCT04962633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719015|NCT04843423|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal, open-label, single arm, within-subject, adjective flexible-dose intervention study||||
33719016|NCT03406351|||CASE_CONTROL||PROSPECTIVE|||||||
33719017|NCT03121547|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33719018|NCT05107687|||CASE_CONTROL||PROSPECTIVE|||||||
33719019|NCT02366845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33719020|NCT05587205|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|2 arms are masked as indicated and 2 arms are open label||t|f|f|t
33719021|NCT01220882|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719022|NCT02511366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33719023|NCT04977583|RANDOMIZED|PARALLEL||OTHER||NONE||"The investigators are implementing a three-armed randomized controlled trial (RCT) at three VA sites to compare outcomes among Veterans with one or more unmet social needs randomized within each site to one of three intervention arms. The investigators have the following study arms/conditions: unmet needs screening only by Research Assistant (Screening arm; Screening plus provision of a tailored Resource Sheet listing available resources to address identified needs (Awareness arm); Screening plus provision of tailored Resource Sheet plus research team social worker-supported referral to assist with connection to resources to address unmet needs (Assistance arm)."||||
33719024|NCT05455788|||COHORT||PROSPECTIVE|||||||
33719025|NCT01170507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719026|NCT02883634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719027|NCT04675203|||COHORT||PROSPECTIVE|||||||
33719028|NCT00109889|NA|SINGLE_GROUP||OTHER||NONE||||||
33719029|NCT05070117|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719030|NCT04673331|||CASE_CONTROL||PROSPECTIVE|||||||
33719031|NCT05354752|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33719032|NCT01004133|||OTHER||OTHER|||||||
33719033|NCT05523661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719034|NCT06023420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719035|NCT00042770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719036|NCT03774511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"HII group, each patient in this group were conducted a program of high-intensity aerobic exercise for 8 weeks, three times per week with each exercise session lasting for nearly 40 minutes morning. Each patient was instructed to not eat for 2 hours before the exercise session to avoid exercise induced airway obstruction. MIC group, each patient was received (MIC 3 times/week) for eight weeks, according to following parameters; 5 minutes warm up, followed by 30 minutes of continuous aerobic exercise on a cycle Ergometer with constant intensity at 70 to 75% of peak HR and 5 minutes cool down. Also, these measures were obtained at the beginning and the end of the intervention.~Control group only received medical treatment with no exercise intervention"||t|f|f|t
33719037|NCT03835611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719038|NCT05404373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719039|NCT03706781|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33719040|NCT01327950|||CASE_ONLY||PROSPECTIVE|||||||
33719041|NCT02596581|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719042|NCT03255486|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719043|NCT05320523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719044|NCT05700045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33719045|NCT03620695|||COHORT||PROSPECTIVE|||||||
33800072|NCT03010631|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800073|NCT03762668|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33943796|NCT03546101|||COHORT||PROSPECTIVE|||||||
33943797|NCT04972773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Blinding will be established by having a separate collaborator randomize participants to one of the two arms and manage the notification of participants of their allocation, while the primary investigator and outcomes assessor is not informed of this randomization.~Only the researchers will be blinded to a subject's group. Because of the nature of asking the intervention group, but not the control group, to complete additional MM practice, the participants will not be blinded. Thus no provisions need to be made to break the code of the blinding protocol in an emergency. The researchers (investigator and outcomes assessors) will be unaware of participants group assignment, so as not to show preference to one group. The master code that connects participant data to a participant ID will be stored separately from the rest of the data on a USB, otherwise keeping researchers blind to the participant's group assignment."|Treatment: Computer-based randomization (https://www.randomizer.org/) will assign half of the participants taken in on a rolling basis to a MM intervention group (in addition to standard-therapy) and half of the participants to the standard-therapy control group which run in parallel.|f|f|t|t
33943798|NCT03584399|||OTHER||PROSPECTIVE|||||||
33943799|NCT01376115|||COHORT||PROSPECTIVE|||||||
33943800|NCT03382639|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33943801|NCT01852565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943802|NCT00002021||||TREATMENT||||||||
33943803|NCT02554409|||COHORT||PROSPECTIVE|||||||
33943804|NCT04956133|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33943805|NCT04378855|||COHORT||PROSPECTIVE|||||||
33943806|NCT01391026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943807|NCT05754242|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33943808|NCT04698200|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943809|NCT03149731|||CASE_ONLY||PROSPECTIVE|||||||
33943810|NCT05358301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|By keeping both the experimenters and the participants blind, bias is less likely to influence the results of the experiment.|Randomized double-blind parallel controlled trial|t|t|t|t
33943811|NCT05962073|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hypoxemic respiratory failure who required endotracheal intubation||||
34102319|NCT04953169|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Each participant will be randomly be assigned either the video or the written consent.|"Intervention: Study participants will be randomized to one of two forms of consent for participation in a biorepository as part of another study in the PICU. One version of consent will be the standard consent used in the study for which they are eligible. The second version of consent will present the standard consent + a biobanking video. The primary outcome will be to assess enrollment in the biorepository based upon consent version. Because the participants will be randomly assigned to groups and this may impact their behavior regarding enrollment in the biorepository, it is an interventional design.~Secondary outcomes and factors which may correlate with participation will be assessed using qualitative and quantitative measures through an electronic survey. A survey contains questions that will measure knowledge, comprehension, retention, and evaluation of two modes of information delivery, the video + written consent and written information only."|t|f|f|f
34102320|NCT06686784|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||"The crossover occurs after the first semester (end of Month 4). The study will occur with two middle schools.~Months 1-4 Participants at School A (Arm 1) receive the Afterschool as Usual condition in the first semester. Participants at School B (Arm 2) receive the Afterschool Plus condition in the first semester.~Months 5-8 Participants at School A (Arm 1) receive the Afterschool Plus condition in the second semester. and the participants at School B (Arm 2) receive afterschool as Usual condition in the second semester."||||
34102321|NCT04284969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102322|NCT05337696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102323|NCT03429907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800074|NCT05936177|NA|SINGLE_GROUP||PREVENTION||NONE|The study does not involve masking for participants, investigator and assessors as the primary objective is to assess the impact of pre and post-education interventions on awareness scores, which are objective measures not subject to potential bias from knowledge of the intervention status.|In this study, we plan to employ a statistical model as its primary framework for evaluation and analysis. The main focus of the study will center around the statistical modeling of data collected through pre and post-education questionnaires, as well as the demographic information of the participants and changes in their lifestyle habits. The study design will include cluster randomization, wherein two out of the four elderly homes in our municipality will be randomly selected using a simple random sampling technique (via coin toss) to be part of the study. Participants attending to these selected houses will be recruited as volunteers through short message service (SMS) invitations. This approach will enable us to examine and analyze the impact of the education intervention on participants' knowledge levels, as well as their potential shifts in lifestyle choices.||||
33800075|NCT01992692|||CASE_CONTROL||PROSPECTIVE|||||||
33800076|NCT02429570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102324|NCT04757142|||COHORT||PROSPECTIVE|||||||
33800077|NCT02820116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102325|NCT04743206|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||This is a pilot study where the investigators aim to compare initial use of the standard airway clearance device (SACD) with subsequent use of a PIAPD in patients with stable cystic fibrosis ages 6 -21 years. The primary hypothesis (Stated as Null) being that there is no effect of PIAPD on FEV1 2 hours after use, there is no effect on perception of effort and efficacy for the PIAPD.||||
33800078|NCT03386539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Coronary Angiography Core Laboratory readers will be blinded to treatment assignment and time point (study visit). The Adjudication Committee members will be blinded to treatment assignment.|Multicenter open-label randomized clinical trial with randomization within 4 strata, defined by donor-specific antibody status and center annual transplant volume. There are 2 parallel groups of equal sizes for randomization: everolimus/low-dose tacrolimus and tacrolimus/mycophenolate mofetil.|f|f|f|t
33800079|NCT04439747|||COHORT||RETROSPECTIVE|||||||
33800080|NCT04410367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Positron Emission Tomography (PET) Imaging study||||
33800081|NCT04790604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The ENCOMPASS study will evaluate the effectiveness of a community health navigator program using a two-armed, pragmatic, randomized waitlist-controlled trial. The intervention arm will receive the CHN program for six months. The waitlist control arm will have a six month waiting period followed by six months of CHN program. This study will employ patient-level block randomization. Research staff will be blinded to block size. In the case where participants live together in the same residence, they will be randomly assigned to the same study arm.||||
33800082|NCT02395978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Part I is a open label, dose escalation with two dosage levels study. Part II is a randomized (1:1:1), double-blind, placebo-controlled, parallel groups with three treatment arms.|t|t|t|f
33800083|NCT03778645|||COHORT||RETROSPECTIVE|||||||
33800084|NCT03038581|||COHORT||RETROSPECTIVE|||||||
33800085|NCT01759186|||COHORT||PROSPECTIVE|||||||
33800086|NCT04377698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943812|NCT05129644|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||This was a single center, double-blind, randomized, active control, single dose escalation study, with P1101 (24, 48, 90, 180, 225, 270 mcg) as the test drug and Pegasys (180 ug) as the control drug.|t|f|t|f
33943813|NCT04012866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023212|NCT05682859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators as well as the participating patients are blinded during the RCTs phase 1 of roflumilast/placebo. No one is blinded in phase 2 because it is an open-label extension.|Multicentre, double-blinded, randomized, placebo-controlled, clinical trial with open-label extension|t|f|t|f
34023213|NCT01985113|||COHORT||PROSPECTIVE|||||||
34023214|NCT05109338|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34023215|NCT01729455|||COHORT||PROSPECTIVE|||||||
34023216|NCT02868645|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34023217|NCT03717025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023218|NCT03214029|||COHORT||PROSPECTIVE|||||||
33800087|NCT00212134|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 3 is 10.5-year follow-up study since Phase 1. There is no intervention.||||
33719046|NCT05555212|NA|SEQUENTIAL||TREATMENT||NONE||This is a phase 1, open-label, dose escalation and cohort expansion study and conducted in China and the United States to investigate the safety, tolerability and preliminary efficacy of QLH11811 in advanced or metastatic NSCLC patients who have progressed after prior EGFR-TKI treatment. The study consists of the following 2 phases: phase 1: dose escalation (1a) and phase 2: cohort expansion (1b), as detailed in Overall Schematic of Study Design. Phase 1a: this dose escalation study will be conducted in China and the United States, respectively, and the dose escalation will start from starting dose in China and from dose level next to the MTD determined in Chinese subjects in the United States. Phase 1b: after the determination of RP2D, this cohort expansion study will be conducted in China and the United States concurrently to observe the safety, tolerability and efficacy of QLH11811 in advanced NSCLC patients who have EGFR mutation||||
33719047|NCT06409884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719048|NCT05109039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719049|NCT04533347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719050|NCT03971890|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800088|NCT03648762|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with heart failure will complete 1 of 3 exercise training interventions (aerobic vs. aerobic and strength vs. inspiratory) for 12 weeks and will be assessed pre and post to determine if any differences occur in their skeletal muscle and functional capacity as part of the exercise intervention.||||
33800089|NCT02002052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800090|NCT02672722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800091|NCT05563168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800092|NCT00203411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800093|NCT02120222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800094|NCT02703701|||CASE_CONTROL||PROSPECTIVE|||||||
33800095|NCT00925899|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33800096|NCT00125645|NA|SINGLE_GROUP||PREVENTION||NONE||Comparison with EF||||
33800097|NCT04771793|||CASE_CONTROL||OTHER|||||||
33800098|NCT05622123|NA|SINGLE_GROUP||OTHER||NONE||||||
33800099|NCT01634893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800100|NCT05893459|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Debrief - Following exposure to a laboratory stressor, adolescent participants will be randomly assigned to either debrief their experience with a friend or sit by themselves (standard procedure) while their psychophysiological reactivity is recorded using an electrocardiogram (ECG).|f|f|t|f
33800101|NCT03310645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Part 1: Ascending multiple doses in healthy volunteers Part 2: Ascending doses within two-way crossover design in patients|t|t|t|t
33800102|NCT02928224|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33800103|NCT04241354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800104|NCT02768545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800105|NCT05454410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800106|NCT05015010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800107|NCT02708927|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800108|NCT00585052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800109|NCT01714869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023219|NCT03470168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||30 alcohol dependent patients were divided into A: Treatment group and B: Placebo group using simple randomization technique.|t|f|f|t
34023220|NCT00685672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023221|NCT04128280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023222|NCT02695680|||COHORT||PROSPECTIVE|||||||
34023223|NCT04067986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023224|NCT05784532|||COHORT||PROSPECTIVE|||||||
34023225|NCT01165827|||COHORT||PROSPECTIVE|||||||
34023226|NCT04141826|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Production in separate facility, randomisation key kept by third party||t|t|t|t
34023227|NCT01502410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023228|NCT00468260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023229|NCT03886740|RANDOMIZED|PARALLEL||OTHER||NONE||One arm will be treated with tympanostomy with pressure equalization tube placement and the other with Eustachian tube (ET) dilation. Their Eustachian Tube Dysfunction Questionnaire-7 scores will be collected over time and compared.||||
34023230|NCT03980574|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||2 arms of studying with first arm involving a cross-over from active intervention to no intervention and a second arm involving active intervention with no cross-over.|t|t|t|f
34023231|NCT05508841|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34023232|NCT03712878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023233|NCT05453565|||OTHER||OTHER|||||||
34023234|NCT05228938|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33719051|NCT05814939|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33719052|NCT05516706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There were two groups one group perform dynamic stretching and the other group performed plyometric pushups.|There were two groups|t|f|f|f
33719053|NCT05766982|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be a 1:1 randomized controlled trial with parallel group assignment.||||
34023235|NCT00106964|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023236|NCT04689867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023237|NCT05907889|||COHORT||PROSPECTIVE|||||||
34023238|NCT01104467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023239|NCT03908879|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|There is only one arm because all participants will be undergoing the same protocol. To evaluate inter-operator variability for methods 2 and 3, co-investigators will be reviewing saved images recorded by the physicians who placed the intraosseous (IO) catheter. Saved images include the color flow Doppler image for method 2 and the pressure waveform for method 3. Two co-investigators will review saved images from method 2, blinded and independently. Two other co-investigators will review saved images from method 3, blinded and independently. If the results of the two co-investigators for method 2 or method 3 is discordant then a third blinded reviewer will review the saved image for the method with discordant results.|All study participants will undergo all confirmation tests||||
33800110|NCT06261606|RANDOMIZED|PARALLEL||OTHER||NONE||Participants undergo permuted block randomization with block sizes of four via a web-based system will be used for the study, in a 1:1 ratio between the hybrid strategy or control arms.||||
33800111|NCT05870410|||CASE_ONLY||CROSS_SECTIONAL|||||||
33800112|NCT01935544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800113|NCT00370019||||TREATMENT||||||||
33800114|NCT00041938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34102326|NCT05453201|NA|SINGLE_GROUP||TREATMENT||NONE||"PACS Patients will be recruited through recruitment from James J. Peters VAMC PACS clinical program and clinician referrals. The Bronx had significantly higher rates of COVID-19 infection than other boroughs in New York City. Thus, recruitment of up to 36 Veterans is feasible within the 18-month timeframe.~Veterans will participate in a LCCR group (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists."||||
34102327|NCT06589518|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102328|NCT05979818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102329|NCT06377930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800115|NCT03868397|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800116|NCT03638427|||COHORT||PROSPECTIVE|||||||
34102330|NCT06141460|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation||||
34102331|NCT04228237|||COHORT||PROSPECTIVE|||||||
33800117|NCT05283447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800118|NCT04326192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800119|NCT06266845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33800120|NCT04192916|||COHORT||RETROSPECTIVE|||||||
33800121|NCT04082611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be assigned with a participant identification number (ID), so that data will not be identified by any names or personally identifiable information. This ID will be used throughout this study.||t|f|f|f
33800122|NCT00257348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800123|NCT02769858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102332|NCT06686836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study compared two groups: one receiving DBBM alone (control) and the other receiving a combination of DBBM and an L-PRF block (test group).|f|f|t|t
34102333|NCT06680830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Sponsor is also masked.||t|t|t|t
33943814|NCT03301272|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blinded study whereby the subject, the movement disorder specialist injecting neurotoxin, and the movement disorder specialist rating the patient will be unaware of the solution injected and/or planned for injection same day. To ensure that the injecting specialist is blinded to the solution, syringes will be premixed by a separate member of the research team and de-identified of any possible labels that would indicate the properties of the solution being administered to the subject.|The study will comprise of a double blinded, crossover study where the subjects will serve as their own controls. There will be no medication changes made to Parkinson's disease medications throughout the subjects' participation in the study.|t|t|t|f
33943815|NCT03822390|||COHORT||PROSPECTIVE|||||||
34023240|NCT05783544|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34023241|NCT02863783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800124|NCT00969137|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34023242|NCT04028193|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34102334|NCT04088292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary endpoint will be assessed by assessor blinded to the intervention|Randomized clinical trial with 1:1:1 allocation to treatment strata|f|f|f|t
34102335|NCT06688942|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33800125|NCT03557411|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-1210 Simultaneously Combined with Hypofraction Radiotherapy||||
34102336|NCT05940246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102337|NCT06222424|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102338|NCT06689280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102339|NCT06547996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102340|NCT05253534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Evaluation of the efficacy and safety of GlaucoT in patients with primary open-angle glaucoma (POAG)|t|f|f|f
34102341|NCT06691425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102342|NCT04636437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102343|NCT02657551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102344|NCT06542484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023243|NCT06379724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to their randomization group. Study subject number will be linked to their randomization group. Blinding may be broken if the subject experiences an adverse reaction to the medication utilized for their group so that they are aware that they cannot receive the medication in the future. The research coordinator will have the code to the blind. The surgical team will not be blinded as the overall consistency of the topical agents will differ and may be apparent.|Prospective, randomized, blinded, non-inferiority study|t|f|f|f
34102345|NCT00005898||||TREATMENT||||||||
34023244|NCT03784053|||COHORT||PROSPECTIVE|||||||
34023245|NCT00224380|RANDOMIZED|PARALLEL||||SINGLE||||||
34102346|NCT05200780|||COHORT||PROSPECTIVE|||||||
34102347|NCT06551961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Servings provided in identical pots whose content is only known by one assistant who is not involved in collecting outcomes or analysis of results|2 treatment two period cross-over trial|t|f|t|t
34102348|NCT06689150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102349|NCT01840163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34102350|NCT06691321|||COHORT||RETROSPECTIVE|||||||
34102351|NCT05300737|||COHORT||PROSPECTIVE|||||||
34102352|NCT06633042|NA|SEQUENTIAL||TREATMENT||NONE||Total target count of CD3+CAR+ viable cells of 1E6/kg 、2E6/kg and 4E6/kg||||
34102353|NCT06694675|||COHORT||CROSS_SECTIONAL|||||||
33800126|NCT01424670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800127|NCT03086369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023246|NCT04008849|||COHORT||PROSPECTIVE|||||||
34023247|NCT02592083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023248|NCT05780632|||OTHER||PROSPECTIVE|||||||
34023249|NCT05938907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023250|NCT01838668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102354|NCT06160206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102355|NCT04952844|||OTHER||RETROSPECTIVE|||||||
34102356|NCT04782180|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102357|NCT05909397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102358|NCT02549300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102359|NCT01752829|||COHORT||PROSPECTIVE|||||||
34102360|NCT04876950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34102361|NCT03035097|||OTHER||OTHER|||||||
34102362|NCT06590337|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on their age and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.|t|f|t|f
33800128|NCT02838199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800129|NCT01969461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800130|NCT00243529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102363|NCT02662907|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102364|NCT06695091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Triple blinded: The trial participants, the outcome assessors and the data analysis statistician are blinded||t|f|f|t
34102365|NCT02410200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102366|NCT06615726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34102367|NCT06207227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102368|NCT06684899|||COHORT||PROSPECTIVE|||||||
33800131|NCT06215092|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800132|NCT01811706|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33800133|NCT05300542|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33943816|NCT04467216|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors at both pre- and post-observations will be blinded to the group label|"A total of 16 subjects with cognitive frailty will be assigned into 2 groups. Eight participants will be assigned to the intervention group in which they will undertake VR simultaneous motor-cognitive training and eight participants will be assigned to the control group in which existing forms of non-VR sequential motor-cognitive training will be provided.~Both intervention and control groups will employ the same intervention dosage including course, session duration and frequency. The following dosage is employed because they are also the same dosage used in the VR simultaneous motor-cognitive training that we proposed. I.e.,~* Course: eight weeks~* Session duration: 30 minutes~* Frequency: twice per week"|f|f|f|t
33943817|NCT00144417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943818|NCT01140958|||COHORT||RETROSPECTIVE|||||||
33943819|NCT06371560|||OTHER||CROSS_SECTIONAL|||||||
33943820|NCT00987909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943821|NCT01851434|||COHORT||PROSPECTIVE|||||||
33943822|NCT01791166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943823|NCT03815006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943824|NCT04846543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943825|NCT02569268|||COHORT||PROSPECTIVE|||||||
33943826|NCT05607927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943827|NCT04156464|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 arms||||
33943828|NCT04923009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Consecutive patients prospectively included in one of the two study groups||||
33943829|NCT06427616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33943830|NCT02911285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943831|NCT01762111|||COHORT||PROSPECTIVE|||||||
33943832|NCT02362295|||||PROSPECTIVE|||||||
33943833|NCT05020470|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants cannot be masked to the three treatment groups. The PI and Co-Is will be blinded regarding group assignment and will not contact or interact with the participants during the intervention and outcome assessments. Data collector for outcome assessments will be blinded since there will be no seeds placed on the ears when the data are collected.|This prospective, multisite study will randomly assign at least 30 participants into three groups: (1) Self-guided mAPA (S-mAPA), (2) In-Person Training + mAPA (IP-mAPA), and (3) Usual Care Control (UC). Data will be collected at pre- (T1), post-completion of intervention (T2), follow-ups at post 1M- (primary endpoint) (T3), 2M (T4), and 3M (secondary endpoint, long-term sustained effect) (T5) for a total of four assessments. Participants assigned to IP-mAPA but are unable to come in for the in person training can choose to be in the S-mAPA group; this data will be collected. EMA will be used to assess momentary pain outcomes and APA adherence. This pilot study will collect feasibility and pain-related outcomes at more than 1 study site. The consent process will occur virtually (via secure email). Due to the nature of this pilot study, the anticipated enrollment will be a total of at least N = 30.|f|f|t|t
33943834|NCT00052403||||TREATMENT||NONE||||||
33943835|NCT00004409|RANDOMIZED|||TREATMENT||DOUBLE||||||
33943836|NCT01960036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943837|NCT06278831|||COHORT||PROSPECTIVE|||||||
33943838|NCT03936868|||COHORT||PROSPECTIVE|||||||
33943839|NCT00386529|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33943840|NCT05331326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943841|NCT03164304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943842|NCT05749159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943843|NCT00195117|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33943844|NCT02924129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943845|NCT05398939|||COHORT||PROSPECTIVE|||||||
33943846|NCT00519597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943847|NCT05407168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33943848|NCT03355872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943849|NCT00962624|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33943850|NCT04220294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943851|NCT04609436|||CASE_ONLY||PROSPECTIVE|||||||
33943852|NCT02983968|||COHORT||RETROSPECTIVE|||||||
33943853|NCT02135848|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33943854|NCT04621474|||CASE_ONLY||PROSPECTIVE|||||||
33943855|NCT01403324|NA|SINGLE_GROUP||||NONE||||||
33943856|NCT02073292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33943857|NCT03515499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33943858|NCT03463980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33943859|NCT03817814|||CASE_ONLY||PROSPECTIVE|||||||
33943860|NCT00520273|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943861|NCT06035666|RANDOMIZED|PARALLEL||PREVENTION||NONE|Not possible|Prospective randomized controlled trial||||
33943862|NCT01042561|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
33943863|NCT06496347|||CASE_CONTROL||PROSPECTIVE|||||||
33943864|NCT00493909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33943865|NCT01390727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943866|NCT03448458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943867|NCT05608811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants in the control and intervention groups were not provided with any information about which group they were in.|Randomized controlled trial|t|f|f|f
33943868|NCT05936190|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
33943869|NCT04773691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943870|NCT06326138|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Group 1: 12 patients waiting for a sleeve gastrectomy surgery and 12 patients waiting for a Roux-en-Y gastric bypass surgery.~Group 2: 12 patients 12 months after Roux-en-Y gastric bypass surgery."||||
33943871|NCT03520361|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single Blind (Investigator)||f|f|t|f
33943872|NCT04659356|||COHORT||PROSPECTIVE|||||||
34023251|NCT02040506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800134|NCT00799396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800135|NCT05531708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800136|NCT01227876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33800137|NCT01697059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800138|NCT04296227|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The Vital Detect blood pressure monitor will be evaluated as a comparative, single center, non-randomized, study in a minimum of 30 subjects, conducted in 2 phases. The maximum number of subjects enrolled is 150 for both phases, to achieve 85 valid data sets. Each subject test is expected to take up to 1 hour||||
34023252|NCT03619681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023253|NCT02909283|||CASE_ONLY||PROSPECTIVE|||||||
34023254|NCT06634329|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34023255|NCT01830894|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34102369|NCT05673291|||OTHER||PROSPECTIVE|||||||
34102370|NCT00569998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800139|NCT04018859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800140|NCT05233007|||COHORT||PROSPECTIVE|||||||
33800141|NCT02467166|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800142|NCT03764475|NA|SINGLE_GROUP||TREATMENT||NONE||Note: Subjects that consent to enter this open-label safety study have previously completed a companion study (ARQ-151-201 Phase 2 randomized controlled trial)||||
33800143|NCT05498818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The study staff responsible for preparing and distributing SynaquellTM will not be blinded to the intervention, but all subjects and other study staff will be blinded.||t|f|t|f
34102371|NCT06158477|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102372|NCT03588429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102373|NCT06694636|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled patients will receive intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma||||
34102374|NCT01659710|||CASE_CONTROL||PROSPECTIVE|||||||
34102375|NCT02923778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102376|NCT02174445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102377|NCT05156203|NA|SEQUENTIAL||TREATMENT||NONE||||||
33800144|NCT00316953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800145|NCT00214773|||COHORT||PROSPECTIVE|||||||
33800146|NCT01898741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800147|NCT02768467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33800148|NCT01424397|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33800149|NCT02840006|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33840354|NCT03112824|RANDOMIZED|PARALLEL||OTHER||TRIPLE|A designated MD who is not involved in the study design, application, or interpretation will be available to unblind study participants when medically indicated|If the PSS score is than 20, those patients who are interested in participating are consented to the Ashwagandha study. The patients will then be randomized in a double-blind fashion to receive a 31 day supply of study capsules which will be either Ashwagandha 300mg twice a day or identical placebo capsules in a 1:1 ratio. They will be given careful directions into the use of the study capsules and will be asked to mark a daily log (See addendum #3: Treatment Log) of taking the capsules in the morning and at night.|t|t|t|f
33840355|NCT02917603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023256|NCT00729248|||||CROSS_SECTIONAL|||||||
34023257|NCT06633523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023258|NCT05082792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023259|NCT03143426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34023260|NCT03985644|||COHORT||RETROSPECTIVE|||||||
34023261|NCT04626648|RANDOMIZED|CROSSOVER||OTHER||NONE||A randomized controlled cross-over trial was conducted in a simulator environment||||
34023262|NCT03946553|||CASE_CONTROL||OTHER|||||||
34023263|NCT00403637|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33840356|NCT00004551|RANDOMIZED|||TREATMENT||NONE||||||
34023264|NCT03566797|||COHORT||PROSPECTIVE|||||||
34023265|NCT05486481|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34023266|NCT04236323|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34023267|NCT03681015|||CASE_ONLY||PROSPECTIVE|||||||
34023268|NCT04618640|NA|SINGLE_GROUP||PREVENTION||NONE||DTaP-IPV combined vaccine, 0.5mL, imtramuscular||||
34023269|NCT03729817|NA|SINGLE_GROUP||OTHER||NONE||Subjects will be recruited into a prospective single-arm multi-center pilot study to assess the safety of submaximal balloon angioplasty in conjunction with intensive medical therapy in patients with hemodynamically-compromised symptomatic 70-99% atherosclerotic intracranial stenosis (ICAS).||||
34023270|NCT01248013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023271|NCT03109561|||COHORT||PROSPECTIVE|||||||
34023272|NCT03654820|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34023273|NCT05158036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly divided into two groups|f|f|f|t
34023274|NCT04954027|||COHORT||PROSPECTIVE|||||||
34023275|NCT02755155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023276|NCT04643561|NA|SINGLE_GROUP||OTHER||NONE||||||
34023277|NCT04903951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102378|NCT06656221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102379|NCT06130033|||COHORT||PROSPECTIVE|||||||
34102380|NCT05176249|||COHORT||PROSPECTIVE|||||||
34102381|NCT05243290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||We will administer either NR or placebo to the study participants over a blinded period of 10 weeks, followed by an open label phase with all participants receiving NR for 5 weeks.|t|t|t|t
34102382|NCT06694558|||OTHER||CROSS_SECTIONAL|||||||
34102383|NCT05426681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102384|NCT06686030|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102385|NCT06290011|||CASE_CONTROL||OTHER|||||||
34102386|NCT06689878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102387|NCT06691139|||OTHER||OTHER|||||||
34102388|NCT05114291|||COHORT||PROSPECTIVE|||||||
34102389|NCT04130867|||COHORT||PROSPECTIVE|||||||
33943873|NCT01004861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719054|NCT05715073|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|This will be a double-blind study, participants and those involved in data collection and analysis will not know which arm they have been assigned each visit.|This is a crossover intervention, in which participants will partake in all 3 conditions with at least 96 hours of washout between conditions.|t|f|t|t
33719055|NCT03446183|||CASE_CONTROL||OTHER|||||||
33719056|NCT02050581|||CASE_ONLY||CROSS_SECTIONAL|||||||
33719057|NCT05319522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719058|NCT02919501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719059|NCT00240903|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33719060|NCT01953055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719061|NCT03420469|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||This is an open-label, four-phases, fixed sequence healthy volunteers study investigating: the steady state stereoselective disposition of bupropion and metabolites; and effect of multiple doses of bupropion on CYP2D6 activity, as measured by the metabolism and pharmacokinetics of a single dose of dextromethorphan||||
33943874|NCT01074086||FACTORIAL||TREATMENT||NONE||||||
33943875|NCT04862351|RANDOMIZED|PARALLEL||OTHER||SINGLE|A single blinding will be implemented for the outcome assessor as the participants will not be able to be blinded due to the nature of the interventions. The participants will not be informed directly whether they are in the intervention group or control group but the information regarding the intervention will be stated in the Participant Information Sheet. Thus, the participants may know their group allocation.|The eligible participants will be randomly assigned into either intervention group (IG) or control group (CG) in 1:1 ratio using the computerised permuted blocks, alternating block sizes of 4 or 6. Once the eligible participants have consented to participate and the baseline data is collected, they will be given an opaque sealed envelope prepared by an independent statistician (not involved in the research) with assignment information and group allocation specified in the envelope. According to Polit and Beck (2017), the risk of selection bias can be reduced through allocation concealment by shielding the researcher from knowing the next group allocation of an individual.|f|f|f|t
33943876|NCT03428490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible participants will be randomized to the Fully Integrated Treatment (FIT; N =30) or usual care in the Matrix Institute IOP (UC; N = 30).|f|f|f|t
33943877|NCT01478490|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33943878|NCT02569996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943879|NCT03164291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943880|NCT00349960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943881|NCT01177046|||COHORT||PROSPECTIVE|||||||
33943882|NCT04342858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A dental assistant will allocate the participants in the study to their respective groups. The examiner will not be informed about the study participant's group allocation information. The orthodontist performing the fixed orthodontic treatment will not know about the study participant's group allocation information as the topical fluoride varnish application in this study will be performed by another operator.|This is a randomized controlled trial with three parallel groups. In the proposed study, individual participants, and not parts of the mouth, will serve as the unit of randomization. This approach unlike a split-mouth design will eliminate the problems of cross-contamination.|t|f|f|t
33943883|NCT03646916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33943884|NCT01449604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943885|NCT02369575|||CASE_ONLY||PROSPECTIVE|||||||
33943886|NCT02062749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943887|NCT04717505|||CASE_CONTROL||PROSPECTIVE|||||||
33943888|NCT00808665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943889|NCT05233956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943890|NCT05896605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943891|NCT04896476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943892|NCT05267327|||OTHER||PROSPECTIVE|||||||
33943893|NCT04334876|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943894|NCT06453421|||COHORT||PROSPECTIVE|||||||
33943895|NCT00425165|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33943896|NCT03182673|NA|SINGLE_GROUP||TREATMENT||NONE||SHR7390,SHR-1210 and SHR3162||||
33800150|NCT04722588|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|"Masking members of the interdisciplinary team is not possible as a new member of staff is being introduced. However, the study will not be announced to patients presenting to the EDs.~Patients will know that there is a study ongoing, but will not have to consent to participation."|"The intervention comprises implementing the clinical pharmacists in the interdisciplinary team in three emergency departments (EDs) in Northern Norway. A non-randomized stepped-wedge design will be applied. This design allows the intervention to be rolled out sequential, allowing us to control for differences between study sites (vertical control) and secular trends (horizontal control) during the study period. This is the gold standard when a conventional randomized controlled trial is not possible.~The intervention will be implemented over a 12-month period, starting with a three-month control period in all EDs. This period allows for baseline data collection before the intervention. After this period, the investigators will consecutively roll out the intervention at three months interval to the EDs. The intervention will start in Tromsø, which is the largest ED, continue in Bodø and finish in Harstad, which is the smallest of the three EDs."||||
33800151|NCT00181740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800152|NCT03289468|||OTHER||CROSS_SECTIONAL|||||||
33800153|NCT01574794|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33800154|NCT01555099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800155|NCT02412683|||COHORT||PROSPECTIVE|||||||
33800156|NCT03467386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800157|NCT00295464|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34023278|NCT06000774|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will complete a 14-week therapeutic ketogenic diet (TKD)||||
34023279|NCT03745157|||COHORT||PROSPECTIVE|||||||
34023280|NCT05773833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023281|NCT01569932|||COHORT||PROSPECTIVE|||||||
34023282|NCT04890301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023283|NCT05699486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023284|NCT06077838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34023285|NCT01086397|||||PROSPECTIVE|||||||
34023286|NCT01682486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34023287|NCT01675466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023288|NCT02332954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023289|NCT02458287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023290|NCT00605540|||COHORT||PROSPECTIVE|||||||
34023291|NCT01004003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023292|NCT03107247|||OTHER||OTHER|||||||
34023293|NCT05256524|||COHORT||RETROSPECTIVE|||||||
34023294|NCT03786718|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34023295|NCT06201429|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm early feasibility study. The study will comprise of patients who will receive MTR™ therapy to remove fluid from the surgical site in patients that have undergone a craniotomy/craniectomy.||||
34023296|NCT05529667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023297|NCT06633445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023298|NCT05657392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023299|NCT00620087|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34023300|NCT01422629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023301|NCT00378612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023302|NCT02287818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023303|NCT04283500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023304|NCT04706286|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023305|NCT01450917|||CASE_CONTROL||RETROSPECTIVE|||||||
34023306|NCT02675569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023307|NCT04384653|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023308|NCT01563835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023309|NCT03483727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|with or without the cognitive aid|t|f|f|f
34023310|NCT02031458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102390|NCT05810311|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research design is a randomized prospective, open-label study with parallel groups of 15 patients/group with non-dialysis dependent DKD CKD stage 3-4 with Hb \<10g/dl.||||
34102391|NCT06689813|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group A was given oral vitamin D supplements Group B was given isphagula husk tablets|t|f|f|f
34102392|NCT06678581|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34102393|NCT06401733|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The study consists of two phases. Phase 1 is a cross-sectional study conducted to gather baseline data and identify eligible participants. Phase 2 involves recruiting participants from the pool established in Phase 1 for an intervention phase. This sequential design allows Phase 1 findings to inform participant selection and eligibility for Phase 2, facilitating a targeted approach to the intervention.||||
34102394|NCT06689254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102395|NCT06690580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102396|NCT02018809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34023311|NCT04335786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102397|NCT05902858|RANDOMIZED|PARALLEL||OTHER||NONE||open-label, randomized, 3-parallel arm, monocentric trial||||
34102398|NCT05786131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102399|NCT03967522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102400|NCT05829330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102401|NCT06620458|||COHORT||RETROSPECTIVE|||||||
34102402|NCT05286684|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023312|NCT01879930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102403|NCT00335426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102404|NCT04171869|||COHORT||CROSS_SECTIONAL|||||||
34102405|NCT03568058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102406|NCT04941729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102407|NCT05869773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102408|NCT02639273|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34102409|NCT05159960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatment protocol is masked for the patient and for the nurses and optometrists conducting measurement of intraocular pressure during follow-up.||t|f|f|t
34102410|NCT05306145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102411|NCT05860296|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102412|NCT05781750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102413|NCT06694662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102414|NCT06535646|NA|SINGLE_GROUP||OTHER||NONE||||||
34102415|NCT06148948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800158|NCT02370758|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34023313|NCT01238380|||OTHER||CROSS_SECTIONAL|||||||
34102416|NCT04263727|||COHORT||OTHER|||||||
34102417|NCT03648372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102418|NCT06572449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102419|NCT03649178|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and nutrition staff will know when participants are on a high salt or low salt diet. Outcomes Assessor will be kept blinded. Participants will be told not to inform outcomes assessor what diet they are on.|This will be a random-order, 2 period crossover study with washout|f|f|t|t
34023314|NCT00144261||||PREVENTION||||||||
34023315|NCT04015713|||OTHER||PROSPECTIVE|||||||
34023316|NCT06351436|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-group non-randomized uncontrolled trial||||
34023317|NCT05778487|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The control group will include retrospectively recruited patients who did not receive preoperative carbohydrate loading, and the carbohydrate (CHO) group will include prospectively recruited patients, who will consume a carbohydrate drink prior to surgery.||||
34023318|NCT05604456|||CASE_ONLY||RETROSPECTIVE|||||||
34023319|NCT03697863|||COHORT||RETROSPECTIVE|||||||
33800159|NCT02655588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800160|NCT04995718|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800161|NCT01827345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800162|NCT06012617|||COHORT||PROSPECTIVE|||||||
33800163|NCT00963625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023320|NCT00006301|||COHORT||PROSPECTIVE|||||||
34102420|NCT06694727|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Participants will be randomized in a 1:1 fashion to receive either the experimental intervention or placebo for each of the two nutritional supplements.|t|t|t|t
34102421|NCT06001320|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, Historical Controlled, Single Center Open Label Pilot Study||||
34102422|NCT06062108|||COHORT||PROSPECTIVE|||||||
34102423|NCT03662620|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, open-label, single-dose, 2-treatment, 2-sequence, 4-period replicate crossover design||||
34102424|NCT03357497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34102425|NCT04456517|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study|t|t|t|t
34102426|NCT00178828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102427|NCT06106984|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The investigators will conduct pilot testing of serial sessions of Graded Motor Imagery with Veterans using telehealth to their home environment.||||
34102428|NCT05886894|||COHORT||RETROSPECTIVE|||||||
34102429|NCT05983900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102430|NCT06500000|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34102431|NCT02639312|||CASE_CONTROL||PROSPECTIVE|||||||
34102432|NCT04224142|||COHORT||PROSPECTIVE|||||||
33800164|NCT00711581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800165|NCT01726842|||CASE_CONTROL||PROSPECTIVE|||||||
33800166|NCT02806934|||CASE_ONLY||PROSPECTIVE|||||||
33800167|NCT04470375|NA|SINGLE_GROUP||TREATMENT||NONE||single group of students receiving Virtual Reality education||||
34102433|NCT06305559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind set-up; post randomization LDL values are not provided to sites (alert triggers are programmed for urgent follow-up)||t|t|t|t
34102434|NCT04070027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34102435|NCT03457987|||COHORT||PROSPECTIVE|||||||
33800168|NCT06172673|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33800169|NCT03372070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800170|NCT00088413||SEQUENTIAL||TREATMENT||NONE||||||
33800171|NCT03789955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800172|NCT03632759|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||two independent open label, proof of concept studies||||
33800173|NCT00925977|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800174|NCT02703246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800175|NCT01381406|||COHORT||RETROSPECTIVE|||||||
33800176|NCT04804930|||CASE_CONTROL||PROSPECTIVE|||||||
33800177|NCT06258824|||COHORT||PROSPECTIVE|||||||
33800178|NCT02190981|||COHORT||PROSPECTIVE|||||||
33800179|NCT05079646|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33800180|NCT02831712|NA|SINGLE_GROUP||SCREENING||NONE||||||
33800181|NCT03740009|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800182|NCT02438904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800183|NCT02613546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800184|NCT02764242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800185|NCT01603758|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33800186|NCT05700630|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102436|NCT06117540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102437|NCT05607459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, parallel, controlled and single-blinded clinical trial|f|f|f|t
34102438|NCT04794478|NA|SINGLE_GROUP||OTHER||NONE|All systems worn will be blinded. Sensor wear locations will be pre-assigned. All sensor insertions will be performed at the clinic by subjects and/or caregivers.|||||
34102439|NCT06594913|||CASE_CONTROL||OTHER|||||||
34102440|NCT00808756|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|t|f
33800187|NCT03508518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33800188|NCT02989103|||COHORT||PROSPECTIVE|||||||
33800189|NCT00807937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800190|NCT04498663|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both patient and research assistant interviewer will be blinded to condition assignment during the baseline assessment.|Participants will be randomized at a 1:1 ratio to one of two groups--either the therapeutic interview condition or the waitlist control condition.||||
33800191|NCT03649113|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm investigating the safety and efficacy of percutaneous sclerotherapy of hepatic hemangiomas with the mixture of Bleomycin and Lipiodol||||
33800192|NCT02578589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800193|NCT00422006|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800194|NCT06275035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800195|NCT04055246|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33800196|NCT03319797|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Multicenter, Single-arm Phase III||||
33800197|NCT02118675|||OTHER||RETROSPECTIVE|||||||
33800198|NCT00640549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800199|NCT00770757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800200|NCT05007665|||COHORT||PROSPECTIVE|||||||
33800201|NCT01157663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800202|NCT02928354|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800203|NCT01444417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800204|NCT05875883|||COHORT||PROSPECTIVE|||||||
33800205|NCT01736215|||CASE_ONLY||PROSPECTIVE|||||||
33800206|NCT03872635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102441|NCT04869449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943897|NCT01294319|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33943898|NCT02809651|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34023321|NCT05986591|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, placebo-controlled, single dose, three-way crossover design.|t|f|t|f
34023322|NCT04479553|||COHORT||PROSPECTIVE|||||||
34102442|NCT06240208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33800207|NCT04865146|||COHORT||PROSPECTIVE|||||||
33800208|NCT04425616|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomised phase III interventional trial||||
33800209|NCT00098319|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33800210|NCT01330147|||COHORT||PROSPECTIVE|||||||
33800211|NCT05096806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800212|NCT00002049||||TREATMENT||DOUBLE||||||
33800213|NCT04517136|||COHORT||PROSPECTIVE|||||||
33800214|NCT05496777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800215|NCT02146716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800216|NCT00002380||||TREATMENT||NONE||||||
33800217|NCT06322316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients will be randomly assigned into two equal comparable groups using computer- generated random numbers in opaque closed envelopes, each of which will include 30 patients. Randomization will be done by statistician and each group of the patient will revealed only when the included patient is transferred to preanesthetic room.|To determine the analgesic effect of ultrasound guided Retrolaminar Block and Erector Spinae Plane Block in patients undergoing modified radical mastectomy regarding the following : 1-Post-operative opioid (morphine) consumption in the 1st 24 hours 2- Postoperative Numeric Pain Rating Scale. 3. Effect on hemodynamics: Mean arterial blood pressure and Heart rate. 4. Intraoperative fentanyl consumption. 5. Duration of analgesic effect|t|f|t|f
33800218|NCT02685969|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33943899|NCT00563901|||COHORT||RETROSPECTIVE|||||||
33800219|NCT00036244|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33800220|NCT03379740|RANDOMIZED|PARALLEL||OTHER||NONE|This is an open-label study; however the site (except the pharmacy staff preparing the IPs for administration) will be masked to the randomization sequences until they are assigned. Subjects will not be informed of the complete sequence to which they have been assigned to receive the P4M3 products.|||||
33800221|NCT03311737|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33800222|NCT03828240|NA|SINGLE_GROUP||OTHER||NONE||Activity-based intervention||||
33800223|NCT04426916|||CASE_CONTROL||PROSPECTIVE|||||||
33800224|NCT04048668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33800225|NCT05592925|||COHORT||RETROSPECTIVE|||||||
33943900|NCT01884142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943901|NCT02718131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943902|NCT00617942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943903|NCT03339622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33943904|NCT03342209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943905|NCT04348825|||CASE_CONTROL||PROSPECTIVE|||||||
33943906|NCT04246996|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The subject will be masked as to whether she has been assigned to the gentamicin arm or the control arm. The subject will be unmasked at the completion of the 6 week follow up period.||t|f|f|f
33943907|NCT02502591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023323|NCT04327739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor-blind randomized control trial. A masked assessor conducted the measurements.|An assessor-blind randomized control trial with a duration of ten weeks and a 6-month follow up will be performed in 80 women with chronic neck pain. The participants will be allocated into four groups of 20 persons each (three intervention groups and one control group). The first three groups will follow the same exercise program. Only exercise will be applied to the first group. The second group will apply a combination of soft tissue mobilization techniques and exercise. The third group will follow a combination of spinal manipulation and exercise, while the fourth group will not receive any treatment|f|f|f|t
34023324|NCT03327792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023325|NCT04320251|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023326|NCT00794755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023327|NCT03580083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open-Label|Sequential Assignment Dose escalation||||
34102443|NCT02549638|||CASE_ONLY||PROSPECTIVE|||||||
34102444|NCT04250259|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34102445|NCT05722353|NA|SINGLE_GROUP||OTHER||NONE||||||
34102446|NCT04547712|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Randomization to a crossover sequence of aDBS single threshold and aDBS dual threshold modes|t|f|f|f
34102447|NCT05165966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34102448|NCT05206227|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||This is a series of Basic Experimental Studies with Humans (BESH, as defined by PA-20-184). Subjects are enrolled (non-randomized) in different arms of the overall study.|t|f|t|t
34102449|NCT04586231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719062|NCT03036761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023328|NCT00996138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34023329|NCT03062423|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34023330|NCT03033966|||COHORT||PROSPECTIVE|||||||
34023331|NCT02162953|||OTHER||PROSPECTIVE|||||||
33719063|NCT04389424|||CASE_ONLY||CROSS_SECTIONAL|||||||
33719064|NCT02452346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023332|NCT04287335|||CASE_ONLY||PROSPECTIVE|||||||
34023333|NCT03207243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double blind study and subjects and investigator will be masked.|This will be a parallel intervention model in which GSK3772847 and placebo will be administered in parallel manner to randomized subjects.|t|f|t|f
34023334|NCT01035983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023335|NCT02923986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023336|NCT01894035|||COHORT||PROSPECTIVE|||||||
34023337|NCT02293369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023338|NCT02675439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023339|NCT03877991|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized Open Label, three way cross-over study||||
34023340|NCT06426615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective inclusion of patients implanted with intracranial electrodes.||||
34023341|NCT05563376|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023342|NCT04159935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023343|NCT02727881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023344|NCT00229463|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34023345|NCT00866190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023346|NCT00653718|||CASE_ONLY||PROSPECTIVE|||||||
34023347|NCT01140555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023348|NCT00749021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023349|NCT02240030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023350|NCT05637164|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023351|NCT00169481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34023352|NCT03850548|||COHORT||RETROSPECTIVE|||||||
34023353|NCT00887055|||COHORT||PROSPECTIVE|||||||
34023354|NCT05260112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023355|NCT05832567|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34023356|NCT06007924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase II clinical trial evaluating avutometinib in combination with defactinib in radioiodine-refractory (RAIR), recurrent and/or metastatic differentiated thyroid cancer (DTC) (Cohort A) and anaplastic thyroid cancer (ATC) (Cohort B) patients.||||
34023357|NCT01119508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023358|NCT01996683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023359|NCT06476951|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023360|NCT06368115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The study design will be a prospective, randomized, open-label educational intervention trial with three arms: (1) a combined patient/caregiver and provider educational intervention mailed one time; (2) a combined patient/caregiver and provider educational intervention mailed two times; and (3) usual care."||||
34023361|NCT02640092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023362|NCT01310270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023363|NCT03675230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023364|NCT01685450|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33719065|NCT03852641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719066|NCT05356455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blind structures were sent to the statistician by grouping them.||f|f|f|t
33719067|NCT01047267|||CASE_ONLY||PROSPECTIVE|||||||
34102450|NCT03761914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1/2, open-label, non-comparative, multicenter, multi-arm study (basket-type)||||
34102451|NCT06126575|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102452|NCT04951206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102453|NCT06694402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719068|NCT02350725|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33719069|NCT06135987|||OTHER||PROSPECTIVE|||||||
33719070|NCT01028365|||COHORT||PROSPECTIVE|||||||
33719071|NCT03828357|||CASE_ONLY||PROSPECTIVE|||||||
33719072|NCT05282017|||OTHER||PROSPECTIVE|||||||
33719073|NCT01806324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33719074|NCT02371109|||COHORT||PROSPECTIVE|||||||
33719075|NCT00399360|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33719076|NCT00743327|||COHORT||PROSPECTIVE|||||||
33719077|NCT01654367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719078|NCT02950454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023365|NCT05261295|||COHORT||PROSPECTIVE|||||||
34023366|NCT03521466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Coordinators calling the patient to assess quit status are blinded to group assignment.||f|f|f|t
34023367|NCT04269681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will have no access to randomisation list and won't be able to guess which group participant was allocated to.|Participants will be randomised for 2 groups: high flow nasal cannula or standard care with no crossover between them.|f|f|f|t
34023368|NCT04105140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34023369|NCT05145179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023370|NCT03206463|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||The study is a double-blind, randomized, placebo-controlled, crossover laboratory evaluation of the acute subjective, cognitive and psychophysiological effects of 2 mg and 4 mg inhaled THC in Healthy Control individuals and individuals with euthymic Bipolar Disorder.|t|t|t|t
34023371|NCT00185666|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023372|NCT01996449|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34023373|NCT02171078|||OTHER||OTHER|||||||
34023374|NCT04918498|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Non-contemporaneous control||||
34023375|NCT06010849|||OTHER||PROSPECTIVE|||||||
34023376|NCT01229709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023377|NCT03511586|||COHORT||PROSPECTIVE|||||||
34023378|NCT03748030|||COHORT||PROSPECTIVE|||||||
33800226|NCT04701866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary investigator and outcome assessors will be masked throughout the trial. Participants and clinicians administering the ketamine treatments will not be masked, given the nature of the music intervention.||f|f|t|t
33800227|NCT03451721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800228|NCT06166225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943908|NCT05355454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary endpoint is assessed through objective measures of facial volume, obtained using standardized, three-dimensional (3D), digital photographic images. Measurement will be made by an independent expert who will be blinded, as image files will not reveal subject treatment randomization, or the time point at which the image was taken.|"Multi-Center, Prospective, Randomized, No-Treatment Controlled Trial. Subjects will be randomized (5:1 ratio) to the STYLAGE® XXL (treatment) arm or the no-treatment control arm.~After 24 weeks, the no-treatment control arm (delayed treatment group) will receive their first treatment and will then follow the same schedule as the initial treatment group. After the no-treatment control group receives treatment, data from both groups will be pooled."|f|f|f|t
33800229|NCT03413761|||COHORT||PROSPECTIVE|||||||
33800230|NCT01484353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800231|NCT04818931|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33800232|NCT02298452|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33800233|NCT01432613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800234|NCT02094807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943909|NCT01659437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943910|NCT01317264|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33943911|NCT02515604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943912|NCT06439251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943913|NCT02038244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943914|NCT01327833|||||CROSS_SECTIONAL|||||||
33943915|NCT01822782|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943916|NCT05964933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding will be done to the outcomes assessors to reduce bias during radiographic healing assessment. Participants also will not be informed of which treatment they are undergoing.|Study subject (tooth) will be randomized in a 1:1 allocation ratio between the two treatment groups.|t|f|f|t
33943917|NCT05772039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pragmatic randomized controlled trial|t|t|t|t
33943918|NCT04076865|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The participant are blind about the location of EMLA and placebo application|||||
33943919|NCT00676468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943920|NCT02735876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023379|NCT06437483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, participants are blinded to their assigned treatment groups.|Randomized Controlled Trial|t|f|f|f
34023380|NCT03882528|NA|SINGLE_GROUP||SCREENING||NONE||||||
34023381|NCT02444117|||COHORT||PROSPECTIVE|||||||
34023382|NCT04549753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800235|NCT01717820|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33800236|NCT06555588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be randomly assigned with equal (1:1) allocation to either ENGAGE or Supportive Care. A stratified block randomization scheme will be used to ensure group balance based on: 1) the primary outcome of symptom interference (i.e., 3 to 6 vs. 7 to 10); and 2) cancer type (i.e., breast, prostate, lung, or colorectal).|f|f|f|t
33719079|NCT05991037|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|The groups will be constituted after the inclusions according to the results of the psychoactive drug blood concentration measures, so that Participants, Care Provider and Investigators will be blinded.|"The severity of the fall will be assessed in the 400 patients included. The groups will be defined a posteriori, according to the results obtained for the psychoactive drug dosages.~Approximately 80 patients expected in the overdosed group matched to the same number of subjects on gender, age and cognition from the 320 subjects in the non-overdosed group to meet the primary objective at risk α = 5% and a power = 80%."||||
33719080|NCT01132131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719081|NCT04190615|||COHORT||PROSPECTIVE|||||||
33719082|NCT06094673|||COHORT||CROSS_SECTIONAL|||||||
33719083|NCT04378842|||COHORT||PROSPECTIVE|||||||
33800237|NCT00563446|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800238|NCT03380234|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomised controlled trial||||
33800239|NCT03700853|||OTHER||PROSPECTIVE|||||||
34023383|NCT04889287|NA|SEQUENTIAL||OTHER||NONE||||||
34023384|NCT05297695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023385|NCT05876767|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34023386|NCT00849186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023387|NCT03839823|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a randomized, phase II, open label, multi-center trial comparing the combination of NSAI (letrozole or anastrozole) + goserelin + ribociclib versus combination chemotherapy (either of docetaxel/capecitabine or paclitaxel/gemcitabine or capecitabine/vinorelbine). Premenopausal or perimenopausal women with HR+, HER2- negative, advanced breast cancer with ECOG performance status of 0 to 2 and having symptomatic visceral metastases, or rapid progression of disease or impending visceral compromise, or markedly symptomatic non visceral disease were considered for this study.||||
34023388|NCT03323437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34023389|NCT00892996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023390|NCT01303770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34023391|NCT02581397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023392|NCT01078883|||COHORT||PROSPECTIVE|||||||
34023393|NCT01299688|||COHORT||PROSPECTIVE|||||||
34023394|NCT04063423|||COHORT||CROSS_SECTIONAL|||||||
33800240|NCT02756377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800241|NCT06009536|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800242|NCT01577836|||CASE_ONLY||PROSPECTIVE|||||||
33800243|NCT02721134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800244|NCT06362278|||CASE_CONTROL||RETROSPECTIVE|||||||
34023395|NCT01161407|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34023396|NCT02826837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023397|NCT04429438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023398|NCT06443411|||COHORT||PROSPECTIVE|||||||
34102454|NCT05961709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102455|NCT05958225|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly selected (using a stratified random sampling, stratified by gender) and assigned to either the intervention group (n=400) or wait-listed control group (n=400).||||
33719084|NCT01272414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719085|NCT05786144|||OTHER||PROSPECTIVE|||||||
33719086|NCT05364931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800245|NCT01675895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800246|NCT04502901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800247|NCT05282472|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE||A prospective, crossover designed study was conducted in 2 phases. Cardiopulmonary exercise test was performed with and without surgical mask in all participants in between 48 hours. The participant group was further divided into two groups as athlete and non-athlete. In first step, parameters were compared between the CPET tests performed with and without surgical masks. In second step, athletes' and non-athletes' parameters were compared during CPET tests performed with surgical mask.|f|f|f|t
33800248|NCT02178423|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33800249|NCT03434652|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Each subject randomized to active vs sham therapy, then cross over to the other during next illness cycle|t|t|t|t
33800250|NCT03297281|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33800251|NCT03848910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800252|NCT04263675|||COHORT||CROSS_SECTIONAL|||||||
33800253|NCT02234128|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800254|NCT06048172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment as usual group compared to intervention group.|Randomised controlled trail (RCT).|t|f|f|f
33800255|NCT00360386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023399|NCT06196814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be devided into three cohorts. Cohort A for EGFR mutation NSCLC, Patient with NGS idenfied EGFR sensitive mutation NSCLC who failed from first line Osimertinib will be included. The 3+3 stud will conducted for dose escalation for AK112 （from 20mg to 30mg), and than the fix dose will be set up for cohort A, B and C.~Cohort B for ALK fusion NSCLC, Patient with NGS idenfied ALK fusion NSCLC who failed from first line Alectinib will be included. All the patients will be devided two group,3'ALK and 3'ALK with reteintion of 5'ALK. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.~Cohort C for ROS1 fusion NSCLC, Patient with NGS idenfied ROS1 fusion NSCLC who failed from first line crizotinib or Entrectinib will be included. All the patients will be treated with PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.~We will colect the satety and efficacy data for all the patients."||||
34023400|NCT04277143|||OTHER||PROSPECTIVE|||||||
34023401|NCT04598750|||COHORT||PROSPECTIVE|||||||
34023402|NCT04856423|||OTHER||PROSPECTIVE|||||||
34023403|NCT00661011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023404|NCT02041910|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023405|NCT00759187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023406|NCT00581087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023407|NCT05641090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023408|NCT05830149|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Subjects will be randomized to either receiving cryoinsufflation or surgical deroofing||||
34023409|NCT00183560|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023410|NCT03219619|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34023411|NCT06362668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023412|NCT00933348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023413|NCT03632863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34023414|NCT03844217||SEQUENTIAL||DIAGNOSTIC||NONE||Prospective, proof-of concept diagnostic study||||
34023415|NCT04990427|NA|SEQUENTIAL||TREATMENT||NONE||||||
33719087|NCT02646280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33719088|NCT00597545|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33719089|NCT05813795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719090|NCT01397032|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33719091|NCT06200233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719092|NCT00269282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719093|NCT00138476|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33719094|NCT00042172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719095|NCT01040897|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33719096|NCT05931939|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, controlled, randomized intervention study, comparing the effect of revisional surgery by laparoscopic Ileal Interposition with traditional surgical technique||||
33719097|NCT03692364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized study|f|f|f|t
33719098|NCT00137423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719099|NCT02428660|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33719100|NCT04417881|||COHORT||PROSPECTIVE|||||||
33719101|NCT00103142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719102|NCT03219489|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33719103|NCT00608283|||COHORT||RETROSPECTIVE|||||||
34023416|NCT00003960||||TREATMENT||||||||
34023417|NCT05231330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023418|NCT04987385|NA|SINGLE_GROUP||TREATMENT||NONE||proof-of-concept study, no control group needed since patients serve as their own control in the second treatment phase||||
34023419|NCT04691726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102456|NCT06125327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800256|NCT05382936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be assigned to the QD or BID regimen based on cohort assignment.||||
33800257|NCT05972213|||COHORT||PROSPECTIVE|||||||
33800258|NCT03447249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800259|NCT05032638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800260|NCT02861846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102457|NCT06043765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102458|NCT05704244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102459|NCT04381559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Counsellors cannot be blinded as they are providing treatment, however assessors will be blinded to treatment condition. Participants will not be provided with details on the treatment condition to which they were not assigned to minimize the possibility that participant beliefs about which condition is better will impact outcomes.|"Our proposed research is a single blind, two arm randomized trial. Participants will be randomly assigned to the CBT or Applied Relaxation (AR) arm.~Participants will be randomly assigned to CBT, the experimental arm, or the AR arm, which serves as the control condition. Both arms are active treatment conditions; however, we hypothesize that the Sexual Confidence CBT arm will have a significantly larger effect on sexual risk behaviour than the AR arm as AR does not discuss or address substance use, sexual risk reduction, or sexual behaviour."|f|f|f|t
34102460|NCT04573075|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Ghost ileostomy (short: ghost stoma) as an alternative to protective loop ileostomy or no outlet after colorectal resection||||
34102461|NCT06690931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial with two groups|t|t|t|t
34102462|NCT05037500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102463|NCT06055699|||COHORT||PROSPECTIVE|||||||
33800261|NCT01943916|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33800262|NCT06403956|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33800263|NCT03152344|||OTHER||PROSPECTIVE|||||||
33800264|NCT00490100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800265|NCT02390570|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33800266|NCT00003375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800267|NCT02219724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800268|NCT04277221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800269|NCT01711905|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33800270|NCT02962817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33800271|NCT00244959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023420|NCT03207867|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Part 1, Part 3 and the Japanese safety run-in part were not randomized. In Part 2, patients were randomized to one of the 3 treatment arms in a ratio of 1:1:1.||||
34023421|NCT06292403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"2 groups~1. Strength training only group~2. strength training and mirror therapy group"|t|f|t|f
34023422|NCT06213935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023423|NCT02951975|||COHORT||PROSPECTIVE|||||||
34023424|NCT01318486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023425|NCT03555006|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34023426|NCT00315731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023427|NCT04451681|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34023428|NCT02167373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34023429|NCT04749238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023430|NCT02566356|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34023431|NCT04431726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102464|NCT05202171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102465|NCT02013908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102466|NCT02810132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102467|NCT02315326|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102468|NCT04356027|||COHORT||PROSPECTIVE|||||||
34102469|NCT06688565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102470|NCT06234475|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34102471|NCT05868148|||COHORT||PROSPECTIVE|||||||
34102472|NCT06238856|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34102473|NCT05956535|||COHORT||RETROSPECTIVE|||||||
34102474|NCT01299532|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33800272|NCT00718848|||COHORT||PROSPECTIVE|||||||
33800273|NCT01678872|NA|SINGLE_GROUP||OTHER||NONE||||||
33800274|NCT04356820|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||randomized|t|f|f|f
33800275|NCT05872724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||cohort study||||
33800276|NCT04382404|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm||||
33800277|NCT04421469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800278|NCT04525651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800279|NCT04046536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blinded study where only the statistician is aware of the randomization|There will be two groups: one will receive active rTMS and the other group will receive sham rTMS.|t|t|t|f
33800280|NCT02190097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800281|NCT02554786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800282|NCT04370314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800283|NCT00110929|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800284|NCT00240149|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800285|NCT06322797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800286|NCT03041584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800287|NCT00151424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800288|NCT01007396|NA|SINGLE_GROUP||SCREENING||NONE||||||
33800289|NCT05391464|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, single-center, superiority||||
33800290|NCT01336543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800291|NCT02375399|||CASE_ONLY||PROSPECTIVE|||||||
33800292|NCT03772652|||COHORT||CROSS_SECTIONAL|||||||
33800293|NCT02887898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800294|NCT05334199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800295|NCT01154439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102475|NCT06675019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943921|NCT05002049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||High schools located in deprived areas will be randomized to the intervention group (IG) which will receive the whole citizen science intervention of the SEEDS project, or the controls group (CG) which will not receive any kind of intervention. As the high-schools will be the unit of randomization, this study is a cluster-randomized.|f|f|f|t
33943922|NCT06036940|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33943923|NCT01809717|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33943924|NCT00852735|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33943925|NCT05363046|||COHORT||PROSPECTIVE|||||||
33943926|NCT01473108|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33943927|NCT02450656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33943928|NCT05657301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943929|NCT02120573|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33943930|NCT05751850|RANDOMIZED|PARALLEL||TREATMENT||NONE||HR070803 in combination with oxaliplatin, 5-FU/LV compared with AG||||
33943931|NCT02050945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33943932|NCT05615948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943933|NCT01617356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943934|NCT03606018|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This study was blinded for Sponsor, investigators and analytical laboratory|two-way crossover|f|f|f|t
33943935|NCT04065711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943936|NCT02702115|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34023432|NCT01114932|||||PROSPECTIVE|||||||
34023433|NCT06400134|||OTHER||OTHER|||||||
34023434|NCT06219278|||COHORT||RETROSPECTIVE|||||||
34023435|NCT03058094|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023436|NCT02777814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023437|NCT06167863|||COHORT||RETROSPECTIVE|||||||
34023438|NCT02155543|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34023439|NCT01941082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023440|NCT05101681|||OTHER||CROSS_SECTIONAL|||||||
34023441|NCT06324851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023442|NCT06032650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023443|NCT02105558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023444|NCT04699851|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant do not know if they received tailored or general recommendations.|The project has 2 arms. The intervention arm are participant who will receive tailored recommendations about health prevention in a pandemic based on their answers in the survey. The control group will receive general recommendations about health prevention in a pandemic.|t|f|f|f
34023445|NCT00490217|||DEFINED_POPULATION||OTHER|||||||
34023446|NCT05084716|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023447|NCT05288712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor|This will be a randomized controlled trial with 3 different groups|f|f|f|t
34023448|NCT00912912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023449|NCT01796938|NON_RANDOMIZED|PARALLEL||||NONE||||||
34023450|NCT03891030|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34023451|NCT02816411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34023452|NCT01899443|||COHORT||PROSPECTIVE|||||||
33943937|NCT03984851|||COHORT||RETROSPECTIVE|||||||
33943938|NCT04455958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943939|NCT05475119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943940|NCT05147194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943941|NCT00241371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943942|NCT05270564|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
33943943|NCT01926964|||CASE_ONLY||PROSPECTIVE|||||||
33943944|NCT05236829|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33943945|NCT02207413|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33943946|NCT00422942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943947|NCT04917536|RANDOMIZED|PARALLEL||TREATMENT||NONE||Approach through the rotator cuff or through the rotator cuff split||||
33943948|NCT02948998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943949|NCT02271763|NON_RANDOMIZED|SINGLE_GROUP||||DOUBLE|||f|t|t|f
33943950|NCT00215020|||CASE_ONLY||PROSPECTIVE|||||||
33943951|NCT04799509|||COHORT||PROSPECTIVE|||||||
33943952|NCT01332422|||||PROSPECTIVE|||||||
33943953|NCT02276274|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33943954|NCT04204967|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm, single-center, prospective randomized controlled trial.||||
33943955|NCT02438787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33943956|NCT05963581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to either the salsa dancing intervention (46 participants) or the passive waiting-list control group (46 participants). Randomization will be stratified by gender.||||
33943957|NCT00000721||||TREATMENT||NONE||||||
33943958|NCT03841500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023453|NCT01716715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023454|NCT02382055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023455|NCT05567146|RANDOMIZED|PARALLEL||PREVENTION||NONE||It is an experimental study with randomized pretest-posttest control group.||||
34023456|NCT00175188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023457|NCT04206982|RANDOMIZED|PARALLEL||PREVENTION||NONE||The Marshall Plan is a prospective randomized, parallel-group, monocentric clinical trial of superiority.||||
34023458|NCT03756506|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study will enroll 12 total research participants (6 control research participants and 6 research participants) with approximately 120 pin sites (approximately 60 in the Control group and 60 in the DuraDerm® group). Each research participant undergoing Deformity Correction and/or Traumatic Provisional Surgery will be asked to participate in the study to evaluate if the topical application of a Novel Microbicidal Liquid Polymer as an additional step in the management of post-operative pin track site care reduces the incidence of pin track infections. Investigational Review Board (IRB) approval will be obtained and informed research participant consent will be obtained from each research participant.|f|t|f|f
34023459|NCT00886288|||CASE_ONLY||PROSPECTIVE|||||||
33719104|NCT06084403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are threemodels for this study. 20 ml volume adductor canal block group, 30 ml volume adductor canal block group and 40 ml volume adductor canal block group|t|f|f|t
33719105|NCT04838756|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants have the possibility to opt-out. If they do not opt-out, neither the participant nor the nurse performing the screen exam will know to what study arm the participant was allocated. The radiologist reading the screen exam will however not be blinded to allocation information.||t|f|f|f
33719106|NCT00131833|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33719107|NCT02932033|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33719108|NCT02295150|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719109|NCT01502189|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33719110|NCT02812147|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33719111|NCT05392725|||CASE_CONTROL||RETROSPECTIVE|||||||
33719112|NCT02011347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33719113|NCT01792674|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33719114|NCT00180414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719115|NCT04758819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719116|NCT06294964|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719117|NCT01770379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719118|NCT00003150|RANDOMIZED|||TREATMENT||||||||
33719119|NCT05328882|||COHORT||PROSPECTIVE|||||||
34023460|NCT05775952|||CASE_CONTROL||PROSPECTIVE|||||||
34023461|NCT02087189|||CASE_ONLY||PROSPECTIVE|||||||
34023462|NCT01874353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023463|NCT02865421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023464|NCT04133285|||COHORT||OTHER|||||||
34023465|NCT03375203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102476|NCT06694376|||CASE_ONLY||CROSS_SECTIONAL|||||||
34102477|NCT03847818|NA|SINGLE_GROUP||TREATMENT||NONE||Pyrotinib (400mg orally daily)+Trastuzumab (8mg/kg iv load followed by 6mg/kg iv 3-weekly)+Docetaxel (75mg/m2)+ Carboplatin(AUC=5/6), for a total of 4 cycles.||||
33719120|NCT05422014|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719121|NCT02631226|||COHORT||PROSPECTIVE|||||||
34023466|NCT05346016|||COHORT||PROSPECTIVE|||||||
34023467|NCT04312386|NA|SINGLE_GROUP||PREVENTION||NONE||Four schools from one county Sweden meet inclusion criteria and are eligible to participate in the intervention. These schools will all serve the baseline menu followed by the new menu. Each period will last for four weeks.||||
34023468|NCT02470533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023469|NCT02442076|||CASE_ONLY||PROSPECTIVE|||||||
34023470|NCT01138982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023471|NCT00952211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34023472|NCT06284603|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two study groups (dependent on frequency of HBOT treatments) and control group||||
34023473|NCT02425904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023474|NCT00944619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102478|NCT05327946|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102479|NCT06689865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800296|NCT06449170|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This is a randomized, open, crossover, and controlled design study. A total of 12 healthy subjects (six males and six females) aged 18-40 years with a BMI of 18.5-24.9 kg/m\^2 were recruited. Participants underwent seven interventions (each featuring one of the selected foods or a control beverage), with a washout period of 7 days between interventions.~Each intervention is as follows:~150g of mango + 150ml of control beverage, 120g of avocado + 150ml of control beverage, 300g of cooked nopal + 150ml of control beverage, 3 corn tortillas + 150ml of control beverage, 3 guavas + 150ml of control beverage,~½ cup of amaranth + 150ml of control beverage, 290ml of control beverage"||||
33719122|NCT02506140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943959|NCT03737305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Assessor, or secondary investigator does nor have the knowlegde of the group of patients that is being evaluated.|This is a randomized controlled clinical trial, in a unique investigation center, non-blinded, parallel-group, comparative and interpretive study of the results of clinical use of a TMJ distraction device in patients with diagnosis of Articular Disorders, compared to the traditional method of treatment using manual physiotherapy.|f|f|f|t
33719123|NCT02227589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Duke site has masked outcomes assessor; University of Connecticut site does not have masked outcomes assessor||f|f|f|t
33719124|NCT02968927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719125|NCT04246294|||COHORT||PROSPECTIVE|||||||
33719126|NCT03165279|||CASE_ONLY||PROSPECTIVE|||||||
33719127|NCT05286307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719128|NCT04021004|||COHORT||CROSS_SECTIONAL|||||||
33719129|NCT02854735|||COHORT||PROSPECTIVE|||||||
33719130|NCT00869206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719131|NCT02985164|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719132|NCT03741179|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase III, multicentric, Randomized, open-label, parallel-group clinical trial||||
33719133|NCT04859881|||CASE_CONTROL||RETROSPECTIVE|||||||
33719134|NCT03486132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719135|NCT00280956|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33719136|NCT01979809|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33800297|NCT02692469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33943960|NCT04584619|||COHORT||PROSPECTIVE|||||||
33943961|NCT01793012|||COHORT||PROSPECTIVE|||||||
33943962|NCT05794347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33943963|NCT04196010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943964|NCT01452685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943965|NCT04686591|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33943966|NCT02114723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33943967|NCT01382758|||CASE_CONTROL||PROSPECTIVE|||||||
33943968|NCT00289510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33943969|NCT02837874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943970|NCT01199913|||CASE_CONTROL||PROSPECTIVE|||||||
33943971|NCT01922336|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33943972|NCT00498069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33943973|NCT06370494|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A randomized controlled trial (RCT) was conducted to assess the outcomes associated with different technological intervention approaches. This 3-arm RCT assessed independent and combined interventions:||||
33943974|NCT01331876|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33943975|NCT00298506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943976|NCT02033369|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33943977|NCT03578341|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Masking Description: The colostrum and placebo will be preparing by a Human Milk Bank person, who will be knowing the treatment of both 2nd and 1st group. Both colostrum and placebo, will be administrating by nursing staff in syringes in such a way that it is not detected that it contains each of them. Neither the parents of the participants nor the researchers will be involved in the care or analysis of the data, until the end of the study.|Intervention Model Description: The Participants will be randomly and assigned to Group 1, or Group 2 . using a table of random numbers, generated by a computer. The Human Milk Bank Staff, will prepares the colostrum and water (placebo) doses in syringes in such a way that it is not detected that it contains each of them, . Group 1: Will receive 0.3 mL orally colostrum every 4 h during three days, Group 2: will receive 0.3 mL orally Sterile water. Serum immunoglobulins A, G and M concentration will be determined before de start the orally doses, day 7 and 28 days of life.he nurse in charge of the patient's care, administer the dose, a doctor will take the laboratory exams and another researcher will collect and analyze the data. The syringes will be covered, to prevent the patiente´s nurse from observing the contents.|t|t|t|f
33943978|NCT05648305|||COHORT||RETROSPECTIVE|||||||
33943979|NCT01200758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33943980|NCT03585829|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|the treatment has been put in capsules with the same size and color|crossover clinical trial|t|t|f|f
33943981|NCT02443727|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33943982|NCT05471739|||CASE_ONLY||PROSPECTIVE|||||||
33943983|NCT02297867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943984|NCT06163144|||COHORT||PROSPECTIVE|||||||
33943985|NCT02359942|RANDOMIZED|PARALLEL||DIAGNOSTIC||||||||
33943986|NCT05148351|||COHORT||CROSS_SECTIONAL|||||||
33943987|NCT06212973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33943988|NCT00967811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023475|NCT02955758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023476|NCT02202070|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34023477|NCT01925300|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34023478|NCT04431609|||COHORT||PROSPECTIVE|||||||
33719137|NCT00509782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719138|NCT06157723|||OTHER||OTHER|||||||
33719139|NCT01313936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719140|NCT03279328|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719141|NCT02611778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023479|NCT00852774|||COHORT||PROSPECTIVE|||||||
34023480|NCT03722667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The investigators hypothesize that African Americans' hypertension self-management behaviors are influenced by the ability of the individual to task differentiate between the DMN and TPN neural processing. Furthermore, such behaviors will lead to improved BP control and HRQoL. Using a two-arm RCT pilot study, investigators will compare the effects of TechSuPPorT and the Technology-based component arm on BP, HRQoL, and psychological health (affective well-being, depressive symptoms, anxiety) and cognitive task differentiation of the DMN and TPN neural networks. Data will be collected at three points: baseline, 8 weeks and 12 weeks. Brain scans (fMRIs) will be captured at baseline and following the intervention at 8 weeks.||||
34023481|NCT06231056|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Control group|Probiotic supplement group||||
34023482|NCT03290703|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023483|NCT03463382|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34023484|NCT03283761|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
34023485|NCT05907629|||COHORT||PROSPECTIVE|||||||
34023486|NCT00977886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023487|NCT02472327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34023488|NCT01442428|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34023489|NCT02552212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023490|NCT06609226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023491|NCT01485744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023492|NCT04461158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34023493|NCT00572403|||COHORT||PROSPECTIVE|||||||
34023494|NCT00371397|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34023495|NCT02852343|||COHORT||PROSPECTIVE|||||||
34023496|NCT04740320|||COHORT||PROSPECTIVE|||||||
34023497|NCT06255158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34023498|NCT03673657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023499|NCT05436067|NA|SINGLE_GROUP||OTHER||NONE||||||
34023500|NCT04084093|NA|SINGLE_GROUP||TREATMENT||NONE||This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.||||
34023501|NCT04837183|||CASE_ONLY||PROSPECTIVE|||||||
34023502|NCT03821181|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023503|NCT02567643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719142|NCT04512209|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719143|NCT00056407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33719144|NCT05620550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will receive ramdomly one of the bottles with oil, identified as A or B. One contains sunfower ozonated oil and the other non ozonated sunflower oil. Both the patient and the operator will be blinded,|This is a prospective longitudinal clinical trial, being a patient-centered, double-blinded (patient and examiner), randomized by lottery, placebo-controlled study.|t|t|f|f
33719145|NCT04541576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719146|NCT01148121|NA|SINGLE_GROUP||||NONE||||||
33719147|NCT01372215|||CASE_CONTROL||PROSPECTIVE|||||||
33719148|NCT02848183|NA|SINGLE_GROUP||TREATMENT||||||||
33719149|NCT01002703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719150|NCT06275568|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33943989|NCT04160884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33943990|NCT03220620|||COHORT||PROSPECTIVE|||||||
33943991|NCT00723060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023504|NCT03112330|NA|SINGLE_GROUP||TREATMENT||NONE||Platelet Rich Plasma Injection group : 12 patients anticipated Saline spray group : 12 patients anticipated||||
34023505|NCT01160003|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34023506|NCT02784873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33719151|NCT03102021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719152|NCT02485301|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33719153|NCT03566927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719154|NCT01361464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719155|NCT00755157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719156|NCT01902264|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719157|NCT06456151|||CASE_ONLY||PROSPECTIVE|||||||
33719158|NCT04667663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33943992|NCT03721406|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33943993|NCT03169842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33943994|NCT05474482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinding||t|t|t|f
33943995|NCT04663386|||COHORT||RETROSPECTIVE|||||||
33800298|NCT01317836|||COHORT||PROSPECTIVE|||||||
33800299|NCT02106182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800300|NCT01996631|||COHORT||PROSPECTIVE|||||||
33800301|NCT02355275|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800302|NCT03976570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800303|NCT00851474|||CASE_ONLY||PROSPECTIVE|||||||
33800304|NCT01393067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800305|NCT03405714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33943996|NCT03280446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023507|NCT06505941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34023508|NCT03710993|||OTHER||PROSPECTIVE|||||||
34023509|NCT01467986|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34023510|NCT00056394|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34023511|NCT05255796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023512|NCT06060379|RANDOMIZED|PARALLEL||OTHER||NONE||"The trial consists of three meetings. In the first meeting all enrolled participants will take part in a seminar. Before the seminar starts and at the end, a questionnaire will be administered to them to investigate their prior and acquired knowledge on the subject.~At the end the participants will be divided into two groups, the control group will not participate in the second phase, the intervention group will be invited to a game meeting. The third meeting will take place days later, where the third and final game will be conducted with the intervention group. At the end of the game, the questionnaire will be administered."||||
34023513|NCT01816659|RANDOMIZED|PARALLEL||||NONE||||||
34023514|NCT01894594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023515|NCT00002865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023516|NCT01191827|||COHORT||CROSS_SECTIONAL|||||||
34023517|NCT03908515|||OTHER||PROSPECTIVE|||||||
34023518|NCT01637727|||CASE_CONTROL||RETROSPECTIVE|||||||
34023519|NCT02648100|||COHORT||RETROSPECTIVE|||||||
34023520|NCT05458180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023521|NCT05605015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023522|NCT05903014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023523|NCT01292226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023524|NCT04540406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023525|NCT06182514|||COHORT||RETROSPECTIVE|||||||
34023526|NCT00644683|||CASE_CONTROL||RETROSPECTIVE|||||||
33943997|NCT05419791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor has been masked.|Individuals have been assigned to groups by Research Randomizer program.|f|f|f|t
33943998|NCT06399172|||COHORT||PROSPECTIVE|||||||
33943999|NCT02477631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944000|NCT01986179|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33944001|NCT06338527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33944002|NCT01988844|||COHORT||PROSPECTIVE|||||||
33944003|NCT00829595|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33944004|NCT03100929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944005|NCT06098976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944006|NCT06115343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944007|NCT02637869|||CASE_CONTROL||PROSPECTIVE|||||||
33944008|NCT03852901|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944009|NCT05411705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944010|NCT01258738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944011|NCT01247376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944012|NCT00183027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944013|NCT04174430|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33944014|NCT01230073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944015|NCT04495166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33944016|NCT02062385|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33944017|NCT05863065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944018|NCT00310440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944019|NCT06435052|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33944020|NCT03085160|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944021|NCT03303755|||OTHER||PROSPECTIVE|||||||
33944022|NCT03286114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023527|NCT04492644|||CASE_ONLY||CROSS_SECTIONAL|||||||
34023528|NCT04182724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023529|NCT04960033|||COHORT||CROSS_SECTIONAL|||||||
34023530|NCT01910012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719159|NCT00969150|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33719160|NCT04244279|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All the he REBA assessment will be analyzed by a therapist who is blinded to the participants group belonging.|A comparative experimental study will be conducted with a sample of 50 postnatal women, divided into two groups: 1. An intervention group that will be sampled in a convenience sample. 2. A control group that will be matched to the intervention group according to maternal age and number of children.|f|f|t|t
33719161|NCT05336955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719162|NCT04540757|||OTHER||PROSPECTIVE|||||||
33719163|NCT03958799|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Modified double-blind: the study participant, the Investigator, and other study personnel remain unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator will administer the appropriate vaccine but will not be involved in safety assessment and data collection.|t|t|t|t
33719164|NCT01702454|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719165|NCT05163353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719166|NCT03012412|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102480|NCT05318560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944023|NCT00489216|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33944024|NCT06067373|||COHORT||PROSPECTIVE|||||||
33944025|NCT03724552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944026|NCT01874288|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944027|NCT01265706|||||PROSPECTIVE|||||||
33944028|NCT02357108|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33944029|NCT02366624|||CASE_CONTROL||PROSPECTIVE|||||||
33944030|NCT05057962|||COHORT||RETROSPECTIVE|||||||
33944031|NCT02715635|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944032|NCT02986321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944033|NCT00265109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944034|NCT01932528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944035|NCT00000829|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34023531|NCT06096922|||COHORT||PROSPECTIVE|||||||
34023532|NCT02475330|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
34023533|NCT04876365|||COHORT||RETROSPECTIVE|||||||
34023534|NCT00764686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023535|NCT00509795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023536|NCT01133314|||CASE_ONLY||PROSPECTIVE|||||||
34023537|NCT02397187|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023538|NCT06105827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023539|NCT03497169|||CASE_ONLY||PROSPECTIVE|||||||
34023540|NCT02430831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023541|NCT05278728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023542|NCT03242200|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This project is a longitudinal one-group pilot study evaluating the use of a Mobile Health (mHealth) app intervention. This study will examine: 1) the amount/type of usage, 2 ) compliance with study evaluations and 3) the association of this mHealth app use with perceived self-efficacy in managing survivorship related needs, perceived health illness and health related quality of life. The study period will be nine months, with four measurement points to assess the study's outcomes: baseline, three, six, and nine months post initiation of the mHealth app.||||
34023543|NCT00397774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023544|NCT03408535|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single-centre feasibility study of a clinical study with one arm (intervention-only). A before and after intervention design will be used. A sub-group of participants will take part in a qualitative follow-up session.||||
34023545|NCT04067453|||COHORT||PROSPECTIVE|||||||
34023546|NCT01713881|||COHORT||RETROSPECTIVE|||||||
34023547|NCT00625625||||DIAGNOSTIC||||||||
34023548|NCT00522561|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023549|NCT02662283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023550|NCT01405716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023551|NCT03437226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023552|NCT01796912|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34023553|NCT00928707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023554|NCT02474875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023555|NCT03238612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Prospective Randomised Controlled Trial|t|f|t|f
34023556|NCT00866658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023557|NCT04720131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023558|NCT00699283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023559|NCT04251520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023560|NCT06484699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102481|NCT06579885|||COHORT||PROSPECTIVE|||||||
34102482|NCT03745313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102483|NCT01153542|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102484|NCT04419389|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102485|NCT06368193|NA|SINGLE_GROUP||OTHER||NONE||||||
34102486|NCT00736736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719167|NCT00774150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944036|NCT06410833|NA|SEQUENTIAL||TREATMENT||NONE||||||
34023561|NCT00185445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023562|NCT03288701|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023563|NCT00006043||||TREATMENT||||||||
34023564|NCT04024839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023565|NCT00674349||PARALLEL||BASIC_SCIENCE||NONE||||||
34023566|NCT01839318|RANDOMIZED|CROSSOVER||||NONE||||||
34023567|NCT02201212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023568|NCT04229927|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023569|NCT01320150|||COHORT||PROSPECTIVE|||||||
34023570|NCT04810026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023571|NCT05287022|||OTHER||PROSPECTIVE|||||||
34023572|NCT04668911|||COHORT||CROSS_SECTIONAL|||||||
34023573|NCT02864810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023574|NCT00945100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023575|NCT01399567|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34023576|NCT02204306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102487|NCT00063362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102488|NCT05685160|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a diagnostic study with a patient and a control group.||||
34102489|NCT05095792|||COHORT||PROSPECTIVE|||||||
34102490|NCT06222333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102491|NCT05358249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102492|NCT04840771|||COHORT||PROSPECTIVE|||||||
34102493|NCT06694051|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102494|NCT06500442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102495|NCT06687122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34102496|NCT05761951|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800306|NCT02512341|||COHORT||CROSS_SECTIONAL|||||||
33800307|NCT03570437|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, three-arm open-label trial with multi-arm-multi-stage (MAMS) design.||||
33800308|NCT03191981|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I/II trial with an initial dose finding phase for cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab||||
33800309|NCT05973578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800310|NCT00640250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800311|NCT00812461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800312|NCT03292913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800313|NCT00226538|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33800314|NCT00598377|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800315|NCT02258815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800316|NCT03922061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944037|NCT06088511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers who perform the outcome assessment and analysis will be blinded to the group allocations of participants.|A two-arm, assessor-blinded, parallel design randomized control trial (RCT) consisting of an experimental and a control group will be adopted to evaluate the effectiveness of a e-Health System delivered in a dyadic approach to encourage older adults with sarcopenia to maintain healthy lifestyles.|f|f|f|t
33944038|NCT02891096|||COHORT||PROSPECTIVE|||||||
33944039|NCT05845554|||CASE_CONTROL||PROSPECTIVE|||||||
33944040|NCT04797572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944041|NCT00689728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944042|NCT03437980|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33719168|NCT05725850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719169|NCT02786316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719170|NCT03643094|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open-labeled 8-week study design with evaluation at baseline, 4, and 8 weeks.||||
33944043|NCT04035356|||CASE_ONLY||PROSPECTIVE|||||||
33944044|NCT06066463|||COHORT||PROSPECTIVE|||||||
33944045|NCT02082743|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944046|NCT03723746|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33944047|NCT05737927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Part 1: randomised, open label, five-treatment, five-period, five-sequence, crossover, at one study site~Part 2: open label, one-treatment, one-period, at one study site"||||
33944048|NCT01730768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944049|NCT03506529|||CASE_CONTROL||PROSPECTIVE|||||||
33944050|NCT02730234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944051|NCT02160509|||COHORT||PROSPECTIVE|||||||
33944052|NCT01099670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944053|NCT01142011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944054|NCT04466592|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will receive the supportive intervention based on the results of the HEADS-DQ during the post operative period.||||
33944055|NCT03931928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944056|NCT05450380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944057|NCT02789566|NA|SINGLE_GROUP||||NONE||||||
33944058|NCT02206230|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1, randomized, open label||||
33944059|NCT05183932|||COHORT||PROSPECTIVE|||||||
33944060|NCT00182793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944061|NCT01013805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944062|NCT04179266|NA|SINGLE_GROUP||TREATMENT||NONE||open label - proof of concept study||||
33719171|NCT01496547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719172|NCT03535870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719173|NCT05625009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigators who assessed pain scores postoperatively are blinded to the study groups Care providers on the yard are blinded to the study groups Outcome assessors are blinded to the study groups||f|t|t|t
33719174|NCT04804410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719175|NCT01341964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719176|NCT03704454|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33719177|NCT04533308|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33719178|NCT02416440|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33719179|NCT04826705|||COHORT||PROSPECTIVE|||||||
33719180|NCT06120816|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33944063|NCT03396406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33944064|NCT04370041|NA|SINGLE_GROUP||TREATMENT||NONE||This study intends to reinforce the current clinical information regarding safety and efficacy of the Dokimos Plus aortic valve prosthesis in patients over 65 or younger with contraindication for long-term anticoagulation, in which an aortic valve replacement with a bioprosthesis has been indicated.||||
33944065|NCT00876902|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944066|NCT06342440|||CASE_CONTROL||RETROSPECTIVE|||||||
33944067|NCT02249858|||CASE_ONLY||PROSPECTIVE|||||||
33944068|NCT01967134|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33944069|NCT02108158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719181|NCT05376969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719182|NCT02821481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33719183|NCT05416320|RANDOMIZED|PARALLEL||TREATMENT||NONE||10 patients for the study will be randomized to one of two groups who consent to participate in a novel treatment with calcipotriol, or the control (no additional treatment besides Subject's already prescribed drug)||||
33719184|NCT03168308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33719185|NCT03194555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719186|NCT05784454|||OTHER||CROSS_SECTIONAL|||||||
33719187|NCT01040533|||COHORT||RETROSPECTIVE|||||||
33719188|NCT00816231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33719189|NCT06120920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be unaware of the treatment group.||f|f|f|t
33719190|NCT00909116|||COHORT||PROSPECTIVE|||||||
33719191|NCT03018509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102497|NCT05952323|RANDOMIZED|PARALLEL||SCREENING||SINGLE||A two-tailed test at a 5% significance level with a power of 95% indicated that a sample size of 90 was required for an effect size of 0.37. Considering potential data loss during the research process, 5 students will included in each group (teach-back group = 35, video-assisted teaching group = 35, control group = 35). Since it is anticipated that student performance may affect competency, students will be stratified based on their overall academic average in this study. Subsequently, computer-assisted randomization will be used to assign an equal number of students from each stratum to each group.|f|f|f|t
33800317|NCT03300492|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single center, open-label, single arm study||||
34102498|NCT05108974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102499|NCT02118415|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants of the intervention group receive biological product (ex vivo activated, autologous NK cells), participants of the control group receive no biological product||||
34102500|NCT04879563|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33800318|NCT01429805|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33800319|NCT02410018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800320|NCT00886756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33800321|NCT03053024|||COHORT||RETROSPECTIVE|||||||
34102501|NCT04236804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800322|NCT01486524|||||RETROSPECTIVE|||||||
34102502|NCT04114084|||COHORT||PROSPECTIVE|||||||
34102503|NCT03297060|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not know which arm their institution has been assigned to.|This study utilizes a stepped wedge design.|t|f|f|f
33800323|NCT00498511|||DEFINED_POPULATION||PROSPECTIVE|||||||
34102504|NCT05640635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102505|NCT06687746|||COHORT||PROSPECTIVE|||||||
33800324|NCT05393804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two cohort feasibility trial with 15 patients in each cohort to assess the ability to produce and manufacture anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T cells (idecabtagene vicleucel, Ide-Cel) in patients with multiple myeloma (MM).||||
34102506|NCT06568796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800325|NCT02594631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800326|NCT04875624|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800327|NCT03481816|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944070|NCT03283813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is a triple blind study in which the treatment or intervention is unknown to the research participant, the individuals who administer the treatment or intervention, and the researchers who assess the outcomes.||t|t|t|t
34102507|NCT06302621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102508|NCT05394116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102509|NCT01252485|||CASE_ONLY||PROSPECTIVE|||||||
34102510|NCT03814629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102511|NCT05879302|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|All study personnel involved in screening and enrollment will be masked to upcoming randomization assignments||f|f|f|t
34102512|NCT05643924|||COHORT||CROSS_SECTIONAL|||||||
34102513|NCT01460537|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102514|NCT05763420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be blinded to the type of treatment they will receive to reduce bias in the reporting of pain.~Since it is not possible to blind the care providers, they will only be informed of the type of treatment once cleaning and shaping has been completed and the tooth is ready to be obturated. This will reduce care provider bias.~Assessors will be blinded to the treatment option to reduce bias during the assessment of healing."|Permuted block randomization using a block size of 4 will be used to randomly select 212 participants (106 participants in each group). The Study Randomizer website (http://www.studyrandomizer.com) will be utilized to generate the randomization list and participants will be assigned to the selected treatment group accordingly.|t|f|t|t
34102515|NCT01844986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800328|NCT04065958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800329|NCT04764006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800330|NCT03435666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944071|NCT01376765|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944072|NCT05489146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant, outcome assessor, investigator, and therapist providing the intervention were blinded.||t|t|t|t
33944073|NCT00888992|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33944074|NCT02698020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944075|NCT04794491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944076|NCT02027324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944077|NCT03939858|||COHORT||PROSPECTIVE|||||||
33944078|NCT03812614|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Outcomes Assessor will be unaware of the arm assignment of the participant when assessing main outcomes.|"This is a randomized comparative effectiveness trial comparing two interventions.~The participants and staff delivering the interventions will not be blinded, but the data analyst will be.~This trial aims to compare the effect of the FAM-ACT intervention on patients' diabetes-related health behaviors and outcomes compared to patient-focused DSME and support (I-DSMES)."|f|f|t|t
33944079|NCT04132817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944080|NCT05995548|||COHORT||PROSPECTIVE|||||||
33944081|NCT03579862|||COHORT||PROSPECTIVE|||||||
33944082|NCT01248429|||COHORT||PROSPECTIVE|||||||
33944083|NCT02377401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800331|NCT04290572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All the interventions will be similar in appearance and all the participants will take the same quantity of capsules.|Randomized clinical trial of three-arms|t|f|f|t
33800332|NCT06077110|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33800333|NCT02065024|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33800334|NCT04766034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800335|NCT04295915|||OTHER||PROSPECTIVE|||||||
33800336|NCT04727840|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study in 20 patients||||
33800337|NCT03559582|||COHORT||PROSPECTIVE|||||||
33800338|NCT05583253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800339|NCT03071081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||3 dose groups (2 arms per dose group)|t|t|t|t
33800340|NCT00714714|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33800341|NCT02755116|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33800342|NCT04771780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800343|NCT02990754|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800344|NCT04372316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800345|NCT04925336|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34023577|NCT03547076|NA|SEQUENTIAL||DIAGNOSTIC||NONE|All study personnel will be masked for findings by other study personnel. Patients will first be examined by nurses or GP in a random order, then subsequently, reference examination will be performed by cardiologist experienced in heart failure diagnostics and echocardiography.|The focused Pocket ultrasound examination and evaluation will be performed by a general practitioner. A similar focused ultrasound examination will be performed by a nurse without evaluation by the nurse. The complete echocardiographic examination by a cardiologist, using a state of the art ultrasound machine is considered the gold standard method.||||
34023578|NCT02437240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023579|NCT06171724|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34023580|NCT01654133|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34023581|NCT01879163|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34023582|NCT01470495|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
34023583|NCT05937997|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 therapy groups receiving different intensity of training||||
34023584|NCT00552851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023585|NCT02646852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023586|NCT03226028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023587|NCT01468818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023588|NCT00772421|||||CROSS_SECTIONAL|||||||
34023589|NCT06216223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023590|NCT05669963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Assuming the cure rate was 70.8% vs 33.3% in intervention vs placebo group. At 80% power and 95 % CI, the estimated sample will be 66 cases, 33 cases in each group.||||
34023591|NCT02784444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023592|NCT05046964|||COHORT||PROSPECTIVE|||||||
34023593|NCT04318223|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II, multicentre, single-arm study following a Simon's two-stage optimal design||||
34023594|NCT03036254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023595|NCT02032095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023596|NCT00422552|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34023597|NCT02216370|||CASE_CONTROL||PROSPECTIVE|||||||
34023598|NCT00535665|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023599|NCT04901988|RANDOMIZED|PARALLEL||TREATMENT||NONE|No participants were randomised prior to early termination.|||||
34023600|NCT03671889|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Subjects who meet study eligibility will undergo treatment procedures||||
34023601|NCT04712981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102516|NCT01104870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102517|NCT06545500|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Each participant is expected to complete all 4 treatment periods, each consisting of a different dose level of blinded medication depending on the treatment sequence they were assigned to|t|t|t|f
34102518|NCT05911295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102519|NCT03249558|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34102520|NCT06357078|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102521|NCT03947385|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102522|NCT06133712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102523|NCT04560296|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster Controlled Study||||
33800346|NCT01932203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800347|NCT03083067|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800348|NCT06516328|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800349|NCT04534400|||COHORT||RETROSPECTIVE|||||||
33800350|NCT01525277|||COHORT||PROSPECTIVE|||||||
33800351|NCT01239758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800352|NCT03380611|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33800353|NCT00741546|||CASE_CONTROL||PROSPECTIVE|||||||
33800354|NCT04225949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33800355|NCT03113266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800356|NCT06159569|NA|SINGLE_GROUP||TREATMENT||NONE||Open, non comparative study with a medical device||||
33800357|NCT01858831|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33800358|NCT05492409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800359|NCT02742519|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33800360|NCT06450496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33800361|NCT00204113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800362|NCT06275113|||COHORT||PROSPECTIVE|||||||
33800363|NCT00211731|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800364|NCT03336515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800365|NCT00254657|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33800366|NCT04634695|||CASE_ONLY||PROSPECTIVE|||||||
33800367|NCT00111813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800368|NCT00390273|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33800369|NCT03427632|||COHORT||PROSPECTIVE|||||||
33800370|NCT03754959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800371|NCT00529100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102524|NCT06334211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind (placebo appears the same as active FP-020)|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FP-020 in Healthy Volunteers|t|t|t|f
34102525|NCT01081262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102526|NCT03678727|||COHORT||PROSPECTIVE|||||||
33719192|NCT06443970|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||In each group of study infants (open and closed ETT suctioning), the enrolled subjects will experience ETT suctioning with both methods, i.e. with ED and SCW suctioning systems. Each study infant will undergo two sequential suctioning procedures each day during the two-day study period. On day-1, the infant will be randomly assigned the ED or SCW suctioning device during the first maneuver and the devices will be alternated during the second maneuver. The suctioning device order will be reversed on study day-2 as shown in the study protocol below. In all each infant will have four suctioning maneuvers over two days, two each with ED and SCW suctioning devices.||||
34102527|NCT06651190|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|t|f
34102528|NCT06688721|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Within subject design Each participant will be allocated to both the intervention (i.e. driving shifts with EDA-equipped buses) and the control (i.e. driving shifts with non-EDA-equipped buses) conditions||||
34102529|NCT06418984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||one control group and 3 experimental groups|t|f|f|t
34102530|NCT03440190|||CASE_ONLY||PROSPECTIVE|||||||
34102531|NCT01400152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102532|NCT06689787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102533|NCT04271488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102534|NCT02217982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102535|NCT06676085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102536|NCT01832194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102537|NCT06689085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719193|NCT02743650|NA|SINGLE_GROUP||OTHER||NONE||||||
33719194|NCT02201186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719195|NCT01396707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719196|NCT00362115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719197|NCT01905384|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33719198|NCT03415750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719199|NCT02904512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719200|NCT00514033|||COHORT||PROSPECTIVE|||||||
33719201|NCT00806325|||COHORT||PROSPECTIVE|||||||
33800372|NCT00544752|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33944084|NCT06354075|||COHORT||PROSPECTIVE|||||||
33944085|NCT03458351|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944086|NCT01768624|||CASE_ONLY||RETROSPECTIVE|||||||
33944087|NCT01129219|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33944088|NCT00159068|||OTHER||PROSPECTIVE|||||||
33944089|NCT03494140|||OTHER||PROSPECTIVE|||||||
33944090|NCT01645449|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944091|NCT03876509|||COHORT||PROSPECTIVE|||||||
33944092|NCT05604781|||COHORT||PROSPECTIVE|||||||
33944093|NCT05043896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944094|NCT00308568|RANDOMIZED|PARALLEL||OTHER||SINGLE||||||
33944095|NCT06151743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944096|NCT01127529|||COHORT||PROSPECTIVE|||||||
33944097|NCT00113321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944098|NCT03480334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944099|NCT00829920|||COHORT||PROSPECTIVE|||||||
33944100|NCT03802500|||CASE_ONLY||PROSPECTIVE|||||||
33944101|NCT03672006|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Centralized pharmacy will prepare and blind the study drug (t-PA) and the control (heparin)||t|t|t|t
33944102|NCT06150404|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participation in intervention or control groups will occur using simple randomization techniques. Randomization will be achieved by creating a randomization list using specialized software. The randomization algorithm will be protected. The allocation sequence will be done using sealed opaque envelopes (making it impossible to read the contents), each numbered sequentially, containing the indication of assignment to the intervention group or the control group.||||
33944103|NCT04169620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944104|NCT01642823|||CASE_ONLY||RETROSPECTIVE|||||||
33944105|NCT05487807|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial with 4 arms||||
33944106|NCT00544154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944107|NCT02534181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944108|NCT05814965|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||280 patients 140 in DM (70 each with AP and 70 without AP) and 140 Systemically healthy (70 each with AP and 70 without AP)will be enrolled and compared for systemic markers .Subjects with AP will be provided Endodontics treatment and levels of markers will be assessed one year after Endodontics treatment. markers.|f|t|t|t
33944109|NCT06103773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944110|NCT06234995|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|A motor exam will be performed and video recorded for blinded analysis by a movement disorders neurologist.|Healthy controls and persons with PD will be compared in Aim 1. In Aim 3, participants with PD, who have had DBS leads implanted will complete study assessments under four different DBS stimulation settings.|f|f|f|t
33944111|NCT00291109|||||PROSPECTIVE|||||||
33944112|NCT02233192|||COHORT||PROSPECTIVE|||||||
33944113|NCT02146274|||COHORT||PROSPECTIVE|||||||
33944114|NCT00532233|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944115|NCT03629834|||COHORT||PROSPECTIVE|||||||
33944116|NCT03331939|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
33800373|NCT03795194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800374|NCT01622868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800375|NCT06347575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800376|NCT04350541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33800377|NCT04556539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944117|NCT02482727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944118|NCT01224171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944119|NCT06519903|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944120|NCT02441387|||CASE_ONLY||PROSPECTIVE|||||||
34025522|NCT03426137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Oxycodone and Placebo will be identical in terms of appearance, taste, and smell so as to keep the investigators, care providers, and participants blind to their treatment allocation. Oxycodone and placebo oral suspensions will be manufactured and dispensed by the pharmacy at University of Maryland Medical Center. All research personnel, aside from the pharmacists and team members responsible for final review and write-up of the study, will be blinded to participants' treatment groups. For participants in the Partial Reduction group (Arm 2), the pharmacy will dispense the study drug such that participants in Arm 2 will receive four doses of Oxycodone (5mg) followed by one of four repeating schedules of administration alternating between Oxycodone (5mg) and placebo.|Patients will be randomized to three arms. Arm 1 will be a Full Dose (FD) group, which will receive all NSAIDs will be dosed in accordance with the STC Guidelines for NSAID use and Oxycodone (5mg). Arm 2 will be a Partial Reinforcement (PR) group, which will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids. Finally, Arm 3 will be a Control (C) group receiving NSAIDs and placebos.|t|t|t|f
33800378|NCT00802464|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33800379|NCT05938166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800380|NCT06371170|||COHORT||PROSPECTIVE|||||||
33800381|NCT02574455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800382|NCT04368312|||COHORT||PROSPECTIVE|||||||
33800383|NCT02317874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800384|NCT00000223||CROSSOVER||TREATMENT||DOUBLE||||||
33800385|NCT01338675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800386|NCT00083902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800387|NCT02561702|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33800388|NCT05882617|RANDOMIZED|PARALLEL||OTHER||SINGLE|only statistician was masked|three parallel arms one comparator and two interventions|f|f|f|t
33800389|NCT00920738|||COHORT||PROSPECTIVE|||||||
33800390|NCT03169894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800391|NCT01236001|||COHORT||PROSPECTIVE|||||||
33800392|NCT05816902|||COHORT||RETROSPECTIVE|||||||
33800393|NCT01183936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800394|NCT05779215|||COHORT||PROSPECTIVE|||||||
33800395|NCT02290613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800396|NCT04452539|||COHORT||RETROSPECTIVE|||||||
33800397|NCT01448512|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33800398|NCT06355492|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33800399|NCT00084552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944121|NCT00616005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944122|NCT04191928|NA|SINGLE_GROUP||TREATMENT||NONE||Single-dose pharmacokinetic study||||
33944123|NCT04676581|||CASE_CONTROL||RETROSPECTIVE|||||||
33944124|NCT05614362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33944125|NCT02108561|||COHORT||PROSPECTIVE|||||||
33944126|NCT05323370|||CASE_CONTROL||PROSPECTIVE|||||||
33944127|NCT02903121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800400|NCT04079400|||OTHER||PROSPECTIVE|||||||
33800401|NCT02030158|||OTHER||PROSPECTIVE|||||||
33800402|NCT00940043|||COHORT||PROSPECTIVE|||||||
33800403|NCT04275908|||COHORT||PROSPECTIVE|||||||
33800404|NCT06521944|||COHORT||PROSPECTIVE|||||||
33800405|NCT01202136|||COHORT||PROSPECTIVE|||||||
33800406|NCT02186743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800407|NCT00003540||||TREATMENT||||||||
33800408|NCT01298934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800409|NCT06116708|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33800410|NCT05799742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking couldn't be possible because of the surgical technique|Randomized clinical trial with two groups, in according to hernioplasty correction approach|f|f|f|t
33800411|NCT01915459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800412|NCT01203995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800413|NCT04048382|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33800414|NCT06285149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944128|NCT04035369|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Study personnel involved in visual acuity assessments and imaging will be masked to group assignment.|||||
33944129|NCT03473821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded, but due to the nature of the study, neither the primary investigator, participant, nor the care providers can be blinded|1:1 single assessor-blinded adaptive randomized controlled trial, which will conform to the CONSORT statement|f|f|f|t
33800415|NCT05100589|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33800416|NCT05106946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800417|NCT06186492|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33800418|NCT06251570|||CASE_CONTROL||OTHER|||||||
33800419|NCT00613782|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33800420|NCT03340857|NA|SINGLE_GROUP||OTHER||NONE||||||
33800421|NCT01522924|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800422|NCT00575614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944130|NCT04390711|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33944131|NCT01475981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944132|NCT04480905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944133|NCT04557189|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944134|NCT00902122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944135|NCT04967729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944136|NCT06343259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944137|NCT03577028|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944138|NCT03961984|||COHORT||PROSPECTIVE|||||||
33944139|NCT05728528|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025523|NCT06619626|||COHORT||PROSPECTIVE|||||||
33944140|NCT05262946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|measurements and statistical analysis were made without knowing who participated in control or experimental group|2 arms and single blinded randomized controlled trial|f|f|t|t
33944141|NCT05611281|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33944142|NCT03216499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944143|NCT01531049|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34025524|NCT03357718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Retrospective clinical trial|f|f|t|f
34025525|NCT04854044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025526|NCT02730299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102538|NCT05309577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719202|NCT02499250|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719203|NCT01822405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719204|NCT05692765|RANDOMIZED|PARALLEL||OTHER||NONE||This was a randomized intervention study conducted on 104 adolescents: 49 in the control group and 55 in the intervention group. The researcher provided a brief presentation about the health benefits and appropriate serving sizes of F\&Vs and explained how to use the smartphone application. An instructional brochure was provided in Arabic to all adolescents in the intervention group. The participants in the intervention group were required to choose three of seven goals for each F\&V.After choosing six goals (three for fruit and three for vegetables), the participants were required to mark the goal that they chose daily and were requested to adhere to their chosen goals until the end of the study. They were encouraged to turn on notifications for the application to receive reminder messages. Adolescents in the control group were not exposed to the smartphone application and did not receive any advice to promote their F\&V consumption, which may have affected their F\&V consumption.||||
33719205|NCT05670366|NA|SINGLE_GROUP||OTHER||NONE||||||
33719206|NCT05133947|||OTHER||PROSPECTIVE|||||||
34025527|NCT01767324|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34025528|NCT05093764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102539|NCT06599073|NA|SINGLE_GROUP||OTHER||NONE||||||
34102540|NCT06109181|NA|SEQUENTIAL||TREATMENT||NONE||||||
34102541|NCT06686017|||COHORT||PROSPECTIVE|||||||
34102542|NCT03621254|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Design||||
34102543|NCT04038008|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department.||f|f|f|t
33719207|NCT03892109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|unkown the group during recording the results of outcome|Randomized|f|f|f|t
33719208|NCT00965588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719209|NCT04861155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719210|NCT00825045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719211|NCT01951742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719212|NCT01114321|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719213|NCT05081011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800423|NCT01184326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I study with multiple arms related to planned dose escalation.||||
33800424|NCT02617927|||CASE_CONTROL||PROSPECTIVE|||||||
33800425|NCT01873313|||CASE_ONLY||PROSPECTIVE|||||||
33800426|NCT00522951|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33800427|NCT01420458|RANDOMIZED|CROSSOVER||||NONE||||||
33800428|NCT05708144|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800429|NCT05265481|RANDOMIZED|PARALLEL||OTHER||NONE||"The investigators will make the measurements four times for each vein and participant:~1. Baseline: In this phase, the investigators will not apply any venodilation method~2. Tourniquet applied: The investigators will apply a blood pressure cuff tourniquet inflated to 60 mmHg pressure.~3. Tourniquet plus tapping directly over the vein manually~4. Tourniquet plus tapping directly over the vein with a massage device The investigators will change the 3rd and 4th items between two arms of the same participant. In other words, the investigators will do 1-2-3-4 for a left arm but 1-2-4-3 for the right arm."||||
33800430|NCT05036408|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33800431|NCT04339348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800432|NCT03576742|||COHORT||PROSPECTIVE|||||||
33800433|NCT05045534|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33800434|NCT00585156|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
33800435|NCT01064336|||COHORT||PROSPECTIVE|||||||
33800436|NCT00859794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800437|NCT04961021|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800438|NCT02657733|NA|SINGLE_GROUP||||NONE||||||
33800439|NCT04853706|NA|SINGLE_GROUP||OTHER||NONE||||||
33800440|NCT02395744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944144|NCT04646668|RANDOMIZED|CROSSOVER||OTHER||NONE||"1. 20 eligible African American and white smokers will be randomized. A 1:1 randomization to product order (combustible cigarette, e-cigarette, heat-not-burn vs. combustible cigarette, heat-not-burn, e-cigarette). Randomization will be determined by computer-generated random numbers. Randomization assignments will be placed in sealed envelopes with sequential study identification numbers. After baseline data collection has been completed, the research assistant will select the sequential study identification number to determine the randomization assignment~2. No blinding is involved.~3. Due to the pilot nature of the current study, formal power calculations were not conducted. ANOVAs will be conducted to detect within-subject differences between products. A Bonferroni correction will be applied to adjust for multiple comparisons."||||
33944145|NCT04369599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944146|NCT00806000|||COHORT||PROSPECTIVE|||||||
33944147|NCT04426227|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33944148|NCT04977622|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33944149|NCT03769792|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944150|NCT00650975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944151|NCT03284931|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33944152|NCT03438773|RANDOMIZED|PARALLEL||OTHER||NONE||"Patients randomized into the study group will be prescribed Envarsus, mycophenolate and prednisone as a regimen vs. standard therapy with twice a day tacrolimus, mycophenolate and prednisone.~Patients randomized to the control group will be prescribed standard immunosuppression with tacrolimus twice a day, anti-proliferative twice a day, and prednisone once a day at doses that are standard at our institution."||||
33944153|NCT03650387|NA|SINGLE_GROUP||TREATMENT||NONE|Rater-blinded live evaluation of scale scores (the blinded rater does not know which indications were treated)|||||
33944154|NCT02176031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944155|NCT04763460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients blinded to which group they are randomized and how their CRT device is programmed during the study. Individuals (readers) who perform cardiac magnetic resonance and echocardiographic imaging measurements blinded to patient randomization and CRT programming.|Parallel (with 6 month crossover) 1:1 randomization - active comparator and experimental arm (note: at 6 month, the active comparator arm will crossover to the experimental arm)|t|f|f|t
33944156|NCT02574429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944157|NCT04034225|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33944158|NCT01733394|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33944159|NCT00995202|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This study is a surveillance study not an interventional study with products||||
33944160|NCT05494047|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Subjects will be randomized by a computer system. Investigators and care providers will not be able to know the vaccine administered. Statistical analysis will not have access to the information of immunization. Nonetheless, personnel study who will administer the vaccine will know the group because they will have access to the envelope of the vaccine then this personnel will not have any other responsibility during the study moreover, they will not have mantain regular contact with investigational team.|Individuals will be randomized to receive Vaxigrip Tetrs TM or equivalent vaccine developed by Sinovac Biotech Co. It is a a comparative, double blind, propsective clinical trial with 2 active compunds.|t|t|t|t
33944161|NCT05376410|||CASE_CONTROL||PROSPECTIVE|||||||
33944162|NCT04409262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944163|NCT04060589|||COHORT||PROSPECTIVE|||||||
33944164|NCT00396864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944165|NCT01663246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944166|NCT05946564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind (investigators and patients)|Comparative, multicentre, prospective, randomized, placebo-controlled double-blind phase III trial, evaluating the efficacy of add-on pioglitazone therapy on top of a standard of care (SOC) immunosuppressive therapy, in patients with ANCA-associated vasculitis and biopsy-proven renal involvement. Patients eligible for the study will be assigned in a 1:1 randomized fashion to additional treatment by pioglitazone (30 mg/day orally) or to placebo for 26 weeks on top of a SOC immunosuppressive treatment.|t|f|t|t
33944167|NCT01345162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944168|NCT01310426|||COHORT||RETROSPECTIVE|||||||
33944169|NCT02118493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944170|NCT03285581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944171|NCT05630326|||CASE_CONTROL||RETROSPECTIVE|||||||
33944172|NCT02486263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944173|NCT04717700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023602|NCT03323047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will blinded to the group that they have been allocated to. Blinding will be possible as all patients will be given either acetaminophen or medication without active ingredients (placebo pilll) and dexamethasone will be administered while the participant is asleep. Participants will be debriefed on which group they were assigned to after all study material is returned (i.e., at their post-operative follow-up appointment).|A prospective, randomized, longitudinal, double-blinded trial at a single centre with 3 groups of 20 children each. Group 1 receives acetaminophen (15 mg/kg) 30 min-1 hr pre-operatively and high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia. Group 2 receives acetaminophen (15 mg/kg) 30 min- 1 hr pre-operatively and low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. Group 3 receives placebo 1 hr pre-operatively and low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia. We will recruit a convenience sample of 60 patients aged 3-13 scheduled for tonsillectomy with the principal investigator or co-investigators. The patients will be placed in one of the groups by a computerized randomization table.|t|f|f|f
33800441|NCT06020313|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The researchers who will do the experiment will be blind. They will not know who is the experimental group and the control group. The distribution of groups will be carried out by a partner researcher who is part of our research group, but is not directly involved in the current research.|This research is a randomized, double-blind, crossover, placebo-controlled clinical trial. Volunteers of both sexes aged between 20 and 59 years, with overweight or obesity grade I. Therefore, on the first day of collection, volunteers will be allocated to one of the following treatment protocols: Protocol I) Placebo or Protocol II) Experimental (Resveratrol, 500 mg). After ingestion, the heart rate receiver Polar RS800CX (Polar Electro, Finland) will be positioned on the chest of the volunteers. The blood pressure of the participants will be measured before (Rest) and after the submaximal strength exercise, during the first recovery time (REC1- 00-05 minutes) in 5 intervals, using an aneroid sphygmomanometer and stethoscope. Participants will be previously informed about blood collection for the evaluation of the biochemical profile of the following serum analytes: glucose, triglycerides, total cholesterol and fractions, albumin, total proteins and uric acid.|t|f|f|t
34102544|NCT06694272|||COHORT||PROSPECTIVE|||||||
34102545|NCT05544929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023603|NCT06209541|RANDOMIZED|PARALLEL||TREATMENT||NONE||After recruitment finished, participants will be randomized to one of four groups that differ in type of treatment content (Unified Protocol or individually tailored) and type of support (by a specific therapist or by a team): (1) Unified Protocol with weekly support by a specific therapist, (2) Unified Protocol with weekly support by the team, (3) Individually tailored treatment with weekly support by a specific therapist, (4) Individually tailored treatment with weekly support by the team.||||
34102546|NCT05272579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In a block randomized trial with 14 days of follow up between each step, a total of 10 infants will be treated with fecal filtrate transfer and 10 infants will be treated with placebo. The structure will be: 2+2, 2+2, 2+2, 6+6|t|t|t|t
33800442|NCT05339113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800443|NCT03609008|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind placebo-controlled study with healthy volunteers.|t|t|t|t
34102547|NCT01395602|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34102548|NCT03052257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34102549|NCT06690918|||OTHER||CROSS_SECTIONAL|||||||
33800444|NCT01991301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800445|NCT00154011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33800446|NCT05457049|||COHORT||PROSPECTIVE|||||||
33800447|NCT04218266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023604|NCT04916444|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|A sham coil was used for sham rTMS. Both conditions underwent the exact same study procedures except the sham coil did not deliver pulses; it did still deliver a sound and tapping sensation meant to mimic the real rTMS coil, but no real stimulation was provided in this condition. Patients and outcomes assessors were not made aware of the condition that the participant was partaking in.|Patients were randomized to one of two conditions during session 1: active or sham rTMS. During session 2, patients underwent whichever condition they did not undergo in session 1.|t|t|f|t
34023605|NCT04235361|||COHORT||PROSPECTIVE|||||||
34023606|NCT06634121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023607|NCT04460508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023608|NCT05809167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023609|NCT06377033|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34023610|NCT02365194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023611|NCT00174954|||||PROSPECTIVE|||||||
34023612|NCT04091828|||CASE_CONTROL||PROSPECTIVE|||||||
34023613|NCT01724489|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34023614|NCT01581294|||COHORT||PROSPECTIVE|||||||
34023615|NCT04642651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023616|NCT03832101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34102550|NCT05726227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102551|NCT03000166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102552|NCT03535987|||COHORT||PROSPECTIVE|||||||
34102553|NCT04250415|||COHORT||PROSPECTIVE|||||||
34102554|NCT05816083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102555|NCT03537729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102556|NCT05836259|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a first-in-human, non-randomized, open label Phase 1b/2 study. The study will consist of 2 escalating dose cohorts. The study will enroll at least 6 and as many as 30 patients. All patients will receive active drug.||||
34102557|NCT05445323|NA|SEQUENTIAL||TREATMENT||NONE||||||
33800448|NCT04820686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800449|NCT03101371|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients with normal urinary analysis (UA) pre-surgery will be randomized 1:1 to one of two arms prior to surgery:~1. Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter or~2. Standard of care (SOC) catheter insertion in which catheter is inserted right out of package/non-treated catheter."||||
33800450|NCT03761472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102558|NCT01386645|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34023617|NCT05386940|||COHORT||PROSPECTIVE|||||||
34102559|NCT04209153|||COHORT||PROSPECTIVE|||||||
34102560|NCT06586957|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Randomized for the Expansion Phase|Dose Escalation and Dose Expansion||||
33719214|NCT00362908|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33719215|NCT02041403|||COHORT||PROSPECTIVE|||||||
34023618|NCT05546463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34023619|NCT05646043|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking is used in this study.|The study subjects will be enrolled in two parallel groups.||||
34023620|NCT05971303|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34023621|NCT02683512|||COHORT||OTHER|||||||
34023622|NCT03249792|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34023623|NCT01739348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102561|NCT03495635|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research team will collect the 18-month follow-up surveys from participating youth and parents; masking of study condition will not be feasible for data collection staff, but primary study analyses will be conducted by the investigators with study condition masked. Juvenile justice authorities providing arrest record information will be masked to study arm of participants as will all those on the research team who are involved in coding this information.|Enrolled participants will be assigned randomly to participate in the Big Brothers Big Sisters Community-Based Mentoring Program (treatment group) or to a wait-list control group that is not eligible to participate in the program for a period of 4 years.|f|f|t|f
34102562|NCT04780048|||COHORT||PROSPECTIVE|||||||
33719216|NCT01053364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719217|NCT03992157|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34023624|NCT03451539|||OTHER||OTHER|||||||
33719218|NCT05611047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719219|NCT04051047|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719220|NCT04896320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023625|NCT02804022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023626|NCT03684967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102563|NCT06686264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102564|NCT06144853|||COHORT||PROSPECTIVE|||||||
34102565|NCT06311513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"This is a single-blinded randomized controlled trial. Participants will be allocated to either:~1. Investigational arm (Revision ACLR + cBMA)~2. Control arm (Revision ACLR + Sham Incision)"|t|f|f|f
34102566|NCT01045239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102567|NCT03600441|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
33719221|NCT02968251|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33719222|NCT05016973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719223|NCT03641144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719224|NCT04138329|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33719225|NCT04382573|||COHORT||OTHER|||||||
33800451|NCT05855655|RANDOMIZED|PARALLEL||PREVENTION||NONE||The methodological approach includes a 2-arm trial of MBQR vs. a health education control group, with up to n=30 per arm (total Aim 3 sample size = up to 60 participants enrolled and randomized). The study is intended to evaluate the impacts of MBQR on the specified outcomes.||||
33800452|NCT01970319|||COHORT||PROSPECTIVE|||||||
33800453|NCT03017625|||COHORT||PROSPECTIVE|||||||
34023627|NCT00070200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023628|NCT04868994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719226|NCT04461171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two-group, prospective, consecutively enrolled, comparative non-randomized trial (N = 120) is to determine the feasibility and efficacy of implementing an enhanced recovery after surgery (ERAS) pain management pathway to patients undergoing surgical treatment for an extremity sarcoma.||||
33719227|NCT03007381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719228|NCT01843764|||COHORT||PROSPECTIVE|||||||
33719229|NCT04813094|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33719230|NCT04695379|||COHORT||PROSPECTIVE|||||||
33719231|NCT04210310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719232|NCT06476457|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We will recruit 10 participants to assess the feasibility of using STAIR Coach mobile based app for PTSD in Kenya||||
33719233|NCT01737515|||COHORT||PROSPECTIVE|||||||
34023629|NCT05551819|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023630|NCT01624896|||CASE_ONLY||RETROSPECTIVE|||||||
34102568|NCT06695819|||CASE_ONLY||CROSS_SECTIONAL|||||||
33944174|NCT05561192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Given the nature of this project, it will not be possible to blind the samples (classes) participating in the study due to the clarity of the intervention process (diaphragmatic breathing exercises, cardiorespiratory and strength exercises and cooperative sports activities) not even from teachers or external applicators. However, it is important to note that there will be blinding of the process within the following points:~* Applicators of the instruments (questionnaires) and evaluators teachers, who will carry out the anthropometric evaluations of the subjects;~* Tabulation and data analysis;"||f|f|t|t
33944175|NCT00921973|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33944176|NCT00005627||||TREATMENT||||||||
33944177|NCT04865380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Surgeons are blinded to group allocation and all treatment is administered by the anesthesia care provider. Patients will not be informed of their allocation.||t|t|t|t
33944178|NCT04401982|||COHORT||PROSPECTIVE|||||||
33944179|NCT05070182|||COHORT||RETROSPECTIVE|||||||
33944180|NCT00205010|||||PROSPECTIVE|||||||
33944181|NCT00026559|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944182|NCT04382209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944183|NCT04722731|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33944184|NCT04099940|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The investigators plan to conduct a single-blind, randomised, controlled trial in a cross-over design to assess the feasibility and efficacy of VRAT in patients with acoustic hallucinations, independent of the main diagnosis.|f|f|f|t
34023631|NCT04987697|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot Study||||
34023632|NCT02419144|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34023633|NCT01952210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34023634|NCT04317859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023635|NCT05434429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023636|NCT05183386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023637|NCT04488835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023638|NCT00837772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023639|NCT04286711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023640|NCT00833001|||COHORT||PROSPECTIVE|||||||
34023641|NCT05419609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023642|NCT04447950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Rotating nurse assigning the arm, scrubbed nurse preparing syringe for injection with a clear liquid - saline vs saline and Marcaine, surgeon blinded to type of liquid in syringe.|2 arms of a RCT.|t|t|t|f
34023643|NCT01458873|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|f|t
33719234|NCT01374412|||COHORT||PROSPECTIVE|||||||
33719235|NCT01457066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719236|NCT02567955|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33719237|NCT03264495|||OTHER||PROSPECTIVE|||||||
33719238|NCT01712607|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33719239|NCT01069107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719240|NCT03954951|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, parallel-group, cluster randomized clinical trial||||
33719241|NCT01973647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719242|NCT02845245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33719243|NCT02057198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719244|NCT02988921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719245|NCT05989789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800454|NCT05439395|||COHORT||RETROSPECTIVE|||||||
33800455|NCT05134324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800456|NCT05510895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800457|NCT03381781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800458|NCT02231983|||COHORT||PROSPECTIVE|||||||
33944185|NCT00175734|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944186|NCT00783822|RANDOMIZED|PARALLEL||||NONE||||||
33944187|NCT04115020|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33944188|NCT01476982|||CASE_ONLY||CROSS_SECTIONAL|||||||
33944189|NCT05671302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944190|NCT05125458|||COHORT||CROSS_SECTIONAL|||||||
33944191|NCT00669253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944192|NCT04201444|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944193|NCT03919682|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33944194|NCT03117192|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Secretary to the department held an envelope that shows sample allocation after randomization. The envelope is only revealed after data gathering is finished.|This interventional study is a randomized controlled trial comparing the parallel provision of zinc and placebo in 2 groups of splenectomized thalassemia major patients.|t|t|t|f
33944195|NCT04087551|NA|SINGLE_GROUP||OTHER||NONE||"Phase 1 Participants will be requested to report the incidence of no fall, near-fall or a fall daily over the next 21-day period. There will be 3 options given to the participants: (1) a daily telephone call at a prearranged timing or (2) a daily text message given at a prearranged timing or both. A study administrator will contact the participant daily using the preferred mode of reporting. All information will be recorded in a logbook.~Phase 2 The development of the Balance Recovery Falls-Efficacy scale will be guided using the COSMIN methodology. This development is based on inputs from the community-dwelling older adults to ensure relevance, comprehensiveness and comprehensibility. The scale would then be validated with a group of healthcare professionals and another new group of community-dwelling older adults using the Delphi method."||||
33944196|NCT02028052|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944197|NCT00209079|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944198|NCT00724243|||COHORT||PROSPECTIVE|||||||
33944199|NCT05707104|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33944200|NCT02503111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023644|NCT00258700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023645|NCT03387306|||CASE_CONTROL||RETROSPECTIVE|||||||
34023646|NCT02342639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34023647|NCT03914911|NA|SINGLE_GROUP||OTHER||NONE||||||
34023648|NCT00446901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023649|NCT04139343|||CASE_CONTROL||PROSPECTIVE|||||||
34102569|NCT02609763|||COHORT||CROSS_SECTIONAL|||||||
34023650|NCT02909946|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34023651|NCT00124761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023652|NCT01037400|||COHORT||PROSPECTIVE|||||||
34023653|NCT03354767|||COHORT||PROSPECTIVE|||||||
34023654|NCT06017310|||COHORT||RETROSPECTIVE|||||||
34023655|NCT06400277|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34023656|NCT00483483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34023657|NCT05735041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023658|NCT01250886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023659|NCT04733703|||COHORT||PROSPECTIVE|||||||
34023660|NCT04260971|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This study adopts a blind design. Only the programmer is aware of the randomisation details and the parameters will be kept separately in order to keep others blind about the intervention. Unblinding of the study will occur at the 3rd month of the study.|Patients will be randomized into 2 groups with either cyclical or continuous stimulation. Patients will cross-over to the 2nd mode of stimulation after 1 month and then continued on the preferred mode of stimulation for the 3rd month. Open label follow-up starts at this point and continues for another 9 months.|t|t|t|t
34023661|NCT02107365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023662|NCT00898638|||COHORT||CROSS_SECTIONAL|||||||
34102570|NCT06686680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel study model of randomization to placebo or true shockwave. Elective cross-over design after each participant completes the study who was assigned placebo can receive shockwave.|t|f|f|f
34023663|NCT02288156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023664|NCT03582748|||COHORT||PROSPECTIVE|||||||
34023665|NCT00280163|||||PROSPECTIVE|||||||
34023666|NCT05658978|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group will continue neuromuscular training exercises and the control group will continue previous regular exercises with coaches' guidelines. Each group has equally male players.|t|f|t|t
34023667|NCT02952898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023668|NCT02941757|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34023669|NCT01104779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023670|NCT06633081|||OTHER||CROSS_SECTIONAL|||||||
34023671|NCT05394649|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two parallel arms:~* Intravascular lithotripsy arm~* Rotational Atherectomy arm"||||
34023672|NCT05022589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023673|NCT00658515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023674|NCT03833401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized|This study will involve two Arms; one serving as sham comparator, and the other arm serving as experimental (test) group.|t|f|f|f
34023675|NCT00146497|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34023676|NCT05669183|||COHORT||PROSPECTIVE|||||||
34023677|NCT04869566|||CASE_ONLY||RETROSPECTIVE|||||||
34023678|NCT06624878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023679|NCT00209105|||CASE_ONLY||PROSPECTIVE|||||||
34102571|NCT04846868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102572|NCT01232582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102573|NCT06687408|||COHORT||RETROSPECTIVE|||||||
34102574|NCT05658640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102575|NCT03785847|||COHORT||CROSS_SECTIONAL|||||||
34102576|NCT06686329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102577|NCT05389150|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023680|NCT00780910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023681|NCT01683292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023682|NCT01784939|||COHORT||PROSPECTIVE|||||||
34023683|NCT05275920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34023684|NCT02871219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023685|NCT05460481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102578|NCT02277366|||CASE_CONTROL||PROSPECTIVE|||||||
34102579|NCT06272058|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102580|NCT06681558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102581|NCT05359016|NA|SINGLE_GROUP||SCREENING||NONE||||||
33800459|NCT01388777|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the rate of complete tumor ablation in patients treated with cryoablation, with complete tumor ablation defined as no remaining invasive or in situ carcinoma present upon pathological examination of the targeted lesion.||||
33800460|NCT03081611|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not possible|Non Inferiority Randomized Control Trial||||
33800461|NCT02283242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800462|NCT05308056|||OTHER||PROSPECTIVE|||||||
33800463|NCT05429307|||OTHER||CROSS_SECTIONAL|||||||
33800464|NCT00797017|||COHORT||PROSPECTIVE|||||||
33800465|NCT00185549|RANDOMIZED|PARALLEL||ECT||NONE||||||
33800466|NCT05235906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800467|NCT06107101|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"* Treatment group:20 subjects with CRSwNP and asthma that will start Mepolizumab treatment~* Disease control group: 10 subjects with CRSsNP without asthma that will not start Mepolizumab and will continue their standard of care treatment.~* Control group: 10 healthy subjects without any sinus disease"||||
33800468|NCT02996669|||CASE_CONTROL||PROSPECTIVE|||||||
33800469|NCT02084849|||COHORT||PROSPECTIVE|||||||
33800470|NCT05616754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33800471|NCT06247046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, Randomized, Double-blind, Placebo Controlled|t|t|t|t
33800472|NCT01558986|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33800473|NCT05127681|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800474|NCT05464316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800475|NCT00972075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944201|NCT03947073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944202|NCT00875043|||CASE_CROSSOVER||PROSPECTIVE|||||||
33944203|NCT01354964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944204|NCT00660829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944205|NCT00690209|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34023686|NCT01683838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023687|NCT06551441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023688|NCT05079932|||COHORT||PROSPECTIVE|||||||
34023689|NCT03563651|||CASE_ONLY||PROSPECTIVE|||||||
34023690|NCT02033057|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023691|NCT02084602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023692|NCT01568970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023693|NCT02581722|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023694|NCT03988283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023695|NCT03897803|||COHORT||PROSPECTIVE|||||||
34023696|NCT01716689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023697|NCT03307265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023698|NCT05119153|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects provided placebo and coffee beverages in a color coded bottles|Randomized, single-blinded, partial block, crossover design|t|f|f|f
34102582|NCT03359395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|study med prepared by a provider not involved in the anesthesia care of the subject||t|t|f|f
34102583|NCT03772990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102584|NCT06695208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102585|NCT06694285|||COHORT||PROSPECTIVE|||||||
34102586|NCT00045331||||DIAGNOSTIC||||||||
34102587|NCT06152575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102588|NCT04795453|||COHORT||PROSPECTIVE|||||||
34102589|NCT04572841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102590|NCT06695611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|As this is an open-label cluster randomization, the unit staff and patients will be aware of their unit's target blood pressure. The statistician performing the data analysis will be blinded to treatment assignment.|This pilot study is a 4-centre pragmatic, two-arm, parallel-group, open-label cluster-randomized trial evaluating the feasibility of implementing a higher versus lower blood pressure target protocol|f|f|f|t
34102591|NCT05799625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33800476|NCT02619786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800477|NCT02192242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023699|NCT02906358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33800478|NCT03015311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800479|NCT03811587|RANDOMIZED|PARALLEL||TREATMENT||NONE|Only measurements by assessors will be blinded.|Patients will be randomised to the intervention or control group.||||
33800480|NCT01290185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800481|NCT05085067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800482|NCT03338868|||CASE_CONTROL||PROSPECTIVE|||||||
33800483|NCT01615393|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33800484|NCT04245644|||COHORT||PROSPECTIVE|||||||
33800485|NCT04385680|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33944206|NCT03771859|||COHORT||OTHER|||||||
33944207|NCT05951881|||COHORT||PROSPECTIVE|||||||
33944208|NCT00683852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944209|NCT02205580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944210|NCT03710395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023700|NCT02977897|||COHORT||PROSPECTIVE|||||||
34023701|NCT00552578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023702|NCT06634134|||COHORT||PROSPECTIVE|||||||
34023703|NCT06589505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023704|NCT02391480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023705|NCT06194942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023706|NCT03307616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102592|NCT05886881|||COHORT||RETROSPECTIVE|||||||
34102593|NCT06295159|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102594|NCT05745883|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
34102595|NCT01871194|||COHORT||PROSPECTIVE|||||||
33800486|NCT00637585|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33800487|NCT02343029|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800488|NCT02374307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33800489|NCT04133337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800490|NCT03681054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33800491|NCT02991534|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33800492|NCT06004505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944211|NCT01673204|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34023707|NCT02621749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023708|NCT03122288|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pre-post two-group experimental design will be used.||||
33944212|NCT05423600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023709|NCT03086759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023710|NCT03021889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34023711|NCT00798148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023712|NCT00929890|RANDOMIZED|PARALLEL||||NONE||||||
34023713|NCT05614427|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34023714|NCT00759850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023715|NCT04504305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023716|NCT01439009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023717|NCT01147107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025529|NCT04697082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The patients were divided into three groups randomly. A simple randomization diagram was used for randomization.~The open surgical method and a moist dressing were applied to patients in group A.~Open surgery and then PRP application were performed on patients in group B. PRP was applied to the patients in group C after curettage of the sinus cavity.~49 patients were included in the analysis. In this study, we compared the impact of autologous platelet-rich plasma (PRP) with that of minimally invasive techniques on pain reduction, return to daily activities, quality of life, and duration of wound healing after open excision and secondary closure."|t|f|f|t
33944213|NCT04868760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944214|NCT04297111|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||The study will be a randomised, double-blind, placebo-controlled crossover study. Each participant will undergo 8 weeks of Bacillus coagulans (probiotic) supplementation and 8 weeks of placebo supplementation in a counterbalanced order. There will be a 5-day trial period at the end of each supplementation phase. There will be a wash-out period of 8 weeks between probiotic and placebo supplementation.|t|f|t|t
33944215|NCT00282373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944216|NCT05124145|||CASE_ONLY||OTHER|||||||
33944217|NCT02917369|||CASE_CONTROL||RETROSPECTIVE|||||||
33944218|NCT03971773|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33944219|NCT02759939|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33944220|NCT01383317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944221|NCT02087085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33944222|NCT03908658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944223|NCT02645812|||COHORT||PROSPECTIVE|||||||
33944224|NCT03747731|||OTHER||PROSPECTIVE|||||||
33944225|NCT00800085|NA|SINGLE_GROUP||||NONE||||||
33944226|NCT05102773|||COHORT||PROSPECTIVE|||||||
33944227|NCT04593979|||COHORT||CROSS_SECTIONAL|||||||
33944228|NCT06428331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944229|NCT04806191|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessor will be blinded for treatment allocation. Randomization will be done after recruitment of GPs. GPs and study coordinators and outcome evaluators will be blinded to the allocation sequence with only the allocation of the next GP surgery being revealed by randomization list holder approximately 6 weeks before each intervention implementation point.|Stepped wedge randomized study|f|f|f|t
33944230|NCT01722552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33944231|NCT04550234|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944232|NCT05984914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944233|NCT05629377|||COHORT||OTHER|||||||
33944234|NCT00034801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944235|NCT00003230||||TREATMENT||||||||
33944236|NCT02960802|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944237|NCT01829529|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33944238|NCT04678557|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||There are two Cohorts in this study design. Cohort 1 (Phase 1) enrolls up to 30 subjects total. After Cohort 1 enrollment is completed, Cohort 2 enrollment then occurs with up to an additional 40 subjects. A total of up to 70 subjects will be enrolled under this Phase 1/2 protocol.||||
33944239|NCT00000740||||TREATMENT||DOUBLE||||||
33944240|NCT02780869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944241|NCT01156857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944242|NCT02661789|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33944243|NCT02054624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944244|NCT00401726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944245|NCT00303004|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33944246|NCT00002102||||TREATMENT||NONE||||||
33944247|NCT05617417|NA|SINGLE_GROUP||TREATMENT||NONE||Thirty patients with pure stress urinary incontinence were included in the study. Autologously prepared injectable platelet-rich fibrin from the patients was applied locally. The procedure was repeated for the same patient three times with an interval of one month. The severity of urinary incontinence was evaluated and recorded by filling out questionnaires before and after the procedure.||||
33944248|NCT05363787|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33944249|NCT03080675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33944250|NCT04561960|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33944251|NCT02005458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944252|NCT02619942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944253|NCT02828098|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34023718|NCT06006065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessments of sensorimotor upper limb function at all three time points will be performed by a blinded assessor who is not involved in the conception of the study or the provision of therapy to the participants. Assessments that were video-recorded (Assisting Hand Assessment and Goal Attainment Scaling) will be scored afterwards by another evaluator who will be blinded to group allocation and time point of assessment. Since the robotic measurements and three-dimensional motion analysis are fully automated, these assessments will be performed by a physiotherapist not blinded to group allocation. Participants and parents will be blinded to the study hypotheses. The treating therapists will not be blinded to group allocation.|Randomization will be performed by an independent person who is not involved in the selection procedure and will not have access to any additional clinical information about the participants.|f|f|f|t
34023719|NCT03814525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The pre and postoperative evaluations will be done by two examiners who will not be aware of the group in which each patient is allocated. The information that will be obtained in the evaluations will be noted in the clinical evaluation card. Participants will not be aware of whether or not they have received the FBM, since the person responsible for the application will position the equipment in the irradiation locations in all participants and will only trigger the light when and where predicted in the specific experimental group. The characteristic sound of the device will be triggered by recording in the control group.||t|f|f|t
34023720|NCT03097510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|data collectors and investigators were blind to treatment status of the subject|randomized controlled trial|f|f|t|t
34023721|NCT04409951|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34023722|NCT01402349|||COHORT||PROSPECTIVE|||||||
34023723|NCT06299930|||CASE_ONLY||RETROSPECTIVE|||||||
34023724|NCT01160172|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34023725|NCT01963143|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023726|NCT04380363|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects randomized into device or control group.||||
34023727|NCT01909063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023728|NCT01550029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023729|NCT04152187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023730|NCT04639492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023731|NCT02798432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023732|NCT04641078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023733|NCT04037774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized control design|f|f|t|f
34023734|NCT01798316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023735|NCT04074629|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023736|NCT05630690|NA|SINGLE_GROUP||OTHER||NONE||||||
34023737|NCT00459901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023738|NCT03471923|||COHORT||CROSS_SECTIONAL|||||||
34023739|NCT05396521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023740|NCT05183152|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||BCI Task x Stimulation Modality||||
34023741|NCT06168279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||comparison between conventional occlusal articulation and virtual occlusal articulation for accurate of occlusal registration|t|f|f|t
34023742|NCT03725332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023743|NCT02414776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023744|NCT06044012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023745|NCT00462124|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023746|NCT02076373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023747|NCT03888781|||COHORT||RETROSPECTIVE|||||||
34023748|NCT00368979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023749|NCT04522323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023750|NCT06104995|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will fill out online questionnaires. No outcome assessor will be present or in contact with the participants. The investigator that will analyse the data will not be aware of which participants are in which group.||t|f|t|t
34023751|NCT01144507|||COHORT||PROSPECTIVE|||||||
34023752|NCT03262038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study drug (ondansetron/placebo) will be masked for all but the pharmacist|Randomized, double blinded, placebo-controlled trial of ondansetron to prevent pruritus in children who receive intrathecal morphine|t|t|t|t
34023753|NCT06270186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023754|NCT05944614|||COHORT||PROSPECTIVE|||||||
34023755|NCT01616342|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34023756|NCT02400853|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34023757|NCT05665829|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|non|This is a prospective randomised controlled trial||||
34023758|NCT00160069|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023759|NCT03741699|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, interventional, randomised, unblinded and controlled study with 2 parallel groups||||
34023760|NCT02735993|||CASE_ONLY||PROSPECTIVE|||||||
34023761|NCT05129007|||CASE_CROSSOVER||PROSPECTIVE|||||||
34023762|NCT05910112|||COHORT||PROSPECTIVE|||||||
34023763|NCT03466268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023764|NCT01318707|||||PROSPECTIVE|||||||
34023765|NCT05308082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||It is proposed that a total of 140 participants will be recruited, with 70 assigned to the intervention group, and 70 to the active control group. For the active control group, health talk will be delivered to participants which will match the length of contact and interval of contact of that in the intervention group. For the intervention group, dance movement therapy will be delivered on a regular basis.|t|f|f|f
33944254|NCT02015858|||COHORT||PROSPECTIVE|||||||
33944255|NCT04629235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944256|NCT03405324|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33944257|NCT04981080|||CASE_CONTROL||RETROSPECTIVE|||||||
33944258|NCT02067065|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34023766|NCT01327508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023767|NCT04182282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Wait-list RCT||||
34023768|NCT04051034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo or Omega 3 supplementation||t|f|t|f
34023769|NCT02654860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Phase II only|4 arms for Phase II only|t|f|t|f
34023770|NCT04339283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023771|NCT03960203||||DIAGNOSTIC||NONE||||||
34023772|NCT04933448|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34023773|NCT03421730|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open label trial.|"This is an open label, randomized, balanced, incomplete block design trial. Eligible subjects will be randomized to 1 of 12 treatment sequences (A,B), (A,C), (A,D), (B,A), (B,C), (B,D), (C,A), (C,B), (C,D), (D,A), (D,B) or (D,C), corresponding to the following treatment regimens:~* (A) 5 breaths of VR647 Inhalation Suspension delivered by the VR647 Inhalation System~* (B) 10 breaths of VR647 Inhalation Suspension delivered by the VR647 Inhalation System~* (C) 20 breaths of VR647 Inhalation Suspension delivered by the VR647 Inhalation System~* (D) 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer nebulized to empty~The treatment period comprises 2 dosing visits. Each subject will receive their first treatment regimen during Visit 2 and their second treatment regimen during Visit 3."||||
34023774|NCT05955196|||CASE_ONLY||PROSPECTIVE|||||||
34023775|NCT00486941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023776|NCT01188278|||COHORT||PROSPECTIVE|||||||
34023777|NCT03216044|||COHORT||PROSPECTIVE|||||||
34023778|NCT03339167|NA|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 3 levels of lysine provided as free amino acids, millet, or millet combined with lentils for a total of 8 studies x 3 days per study.||||
34023779|NCT02077218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023780|NCT02424110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023781|NCT05822258|NA|SEQUENTIAL||DIAGNOSTIC||NONE||"Patients will be evaluated in the ON state phase and in the OFF state phase.~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions: motor task, verbal, normal."||||
34023782|NCT03407066|||COHORT||PROSPECTIVE|||||||
34023783|NCT01210612|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023784|NCT01328665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34023785|NCT04074616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The Study is designed to look at the difference in high dose group, which will be submotor amperage, compared to low dose which will be set to 1 mA. Both groups will need to stimulate the tibial nerve and visualize toe movement, and then decrease to the amperage of either high dose or low dose. Both groups will use the device for 30 minutes, 5 days per week. A urodynamic study will be performed to measure bladder capacity, sensations while filling, and detrusor pressures before starting using the device and one last time at the end of the study.~We are also conducting surveys to describe differences in preferences with using bladder medications versus devices."|randomized sham-control trial|t|f|t|t
34023786|NCT03565679|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Subjects will recline for the study. Reference sensors will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk. Simultaneous data collection will be set up for devices under test. The data from the test devices will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.||||
34023787|NCT03703869|||COHORT||PROSPECTIVE|||||||
34023788|NCT04220424|||COHORT||PROSPECTIVE|||||||
33944259|NCT02908815|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33944260|NCT01491828|NA|SINGLE_GROUP||||NONE||||||
33944261|NCT00396110|||DEFINED_POPULATION||PROSPECTIVE|||||||
33719246|NCT04541056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719247|NCT00778089|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944262|NCT02715089|||COHORT||PROSPECTIVE|||||||
33944263|NCT01696175|||COHORT||PROSPECTIVE|||||||
33944264|NCT02856295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944265|NCT01068015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719248|NCT03578029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33719249|NCT01326416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719250|NCT03322254|||OTHER||OTHER|||||||
33719251|NCT04888156|||OTHER||RETROSPECTIVE|||||||
33719252|NCT03834701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719253|NCT01248442|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33719254|NCT00954746|||COHORT||PROSPECTIVE|||||||
33719255|NCT01166178|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33719256|NCT04830852|||COHORT||PROSPECTIVE|||||||
33719257|NCT03304574|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will be blinded to their group assignment.|Participants will be randomly assigned to one of two groups, a control or intervention group. Those assigned to the control group will complete the electronic health assessment only and will not receive integrated personalized feedback. Those assigned to the intervention group will complete the electronic health assessment and will receive integrated personalized feedback.|t|f|f|f
33719258|NCT01453114|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33719259|NCT00829231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719260|NCT00951990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719261|NCT00212030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719262|NCT05052385|||COHORT||RETROSPECTIVE|||||||
33800493|NCT05582044|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind; participants and outcome assessors are blinded to the intervention until data entry and analysis are completed|Double-blind, placebo-controlled with randomized repeated measures|t|f|f|t
33800494|NCT01868958|||CASE_CONTROL||PROSPECTIVE|||||||
33944266|NCT00702637|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33800495|NCT02789215|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33800496|NCT00147485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944267|NCT01674868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944268|NCT01143662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944269|NCT04737226|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Professional male athletes (basketballers, voleyballers, runners) will participate and divided to groups. AT, PF and ITB mechanical properties will evaluate with MyotonPro device (Myoton Ltd, Estonia). Ankle mobility will measure with inclinometer during a knee to wall lunge test.|f|f|f|t
33944270|NCT03811782|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944271|NCT00290329|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33944272|NCT06098157|||COHORT||CROSS_SECTIONAL|||||||
33944273|NCT00250042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944274|NCT03984643|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|participants will be blinded to the timing of the experimental settings|||||
33944275|NCT00914472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944276|NCT02264132|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944277|NCT05299905|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944278|NCT04662957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944279|NCT01554475|||COHORT||PROSPECTIVE|||||||
33944280|NCT01070511|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33944281|NCT04796649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|sham control|Single center, Prospective, Double Blind, Randomized, Sham-Controlled, Parallel Group, Superiority comparison|t|f|t|f
33944282|NCT03204331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944283|NCT04946331|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944284|NCT06421727|NA|SINGLE_GROUP||TREATMENT||NONE||combined vestibular rehabilitation incorporating optokinetic stimulation and virtual reality exercises on persistent postural perceptual dizziness patients.||||
33944285|NCT04970927|||OTHER||OTHER|||||||
33944286|NCT02844751|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944287|NCT03844620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944288|NCT01176422|||CASE_ONLY||CROSS_SECTIONAL|||||||
33944289|NCT00232531|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33944290|NCT01206894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944291|NCT03125421|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33944292|NCT01215045|||CASE_ONLY||PROSPECTIVE|||||||
33944293|NCT06272773|||COHORT||PROSPECTIVE|||||||
33944294|NCT03350009|||CASE_CONTROL||OTHER|||||||
33944295|NCT03017066|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944296|NCT05186220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33944297|NCT01488227|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33944298|NCT00033514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944299|NCT02332460|||COHORT||PROSPECTIVE|||||||
33944300|NCT04220502|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinded study where investigator does not know what method of facial hair removal subjects have used|Comparing an experimental to control group|f|f|t|f
33944301|NCT01151475|||CASE_ONLY||PROSPECTIVE|||||||
33944302|NCT02714621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944303|NCT02993133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944304|NCT01519648|||COHORT||PROSPECTIVE|||||||
33944305|NCT04150523|||COHORT||CROSS_SECTIONAL|||||||
33944306|NCT00134563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33944307|NCT03607747|||CASE_ONLY||PROSPECTIVE|||||||
33944308|NCT00367380|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944309|NCT06403605|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers||||
33944310|NCT02984228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33944311|NCT03217565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944312|NCT05314621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944313|NCT01207427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800497|NCT06051175|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33944314|NCT00021346||||TREATMENT||||||||
33944315|NCT06320821|||COHORT||RETROSPECTIVE|||||||
33944316|NCT00625027|||CASE_ONLY||PROSPECTIVE|||||||
34023789|NCT06633679|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated to either intervention or control group. Participants in the control group will receive the same treatment once the intervention group has finished the treatment.||||
34023790|NCT04868968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023791|NCT01959854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023792|NCT03510962|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|only primary investigator will know the intervention done by the subject. The outcome investigator(assessor) will be unaware (blinded) to which intervention the subject is undertaken.||f|f|f|t
34023793|NCT06030986|||COHORT||RETROSPECTIVE|||||||
34023794|NCT04116762|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. The first part is to perform a pilot study at the lead site only, which will recruit 5 patients to have their surgery using TissuePatchDS-P alone to ensure that the product is safe to use and that no immediate complications are observed.~2. If the pilot data suggests that TissuePatch is not associated with immediate, short or medium term complications (as confirmed by the investigators, sponsor and independent Trial Steering Committee) the trial will progress to the randomised controlled phase. A total of 50 patients will be recruited from the outpatient setting at participating National Health Service (NHS) trusts - 25 will be randomised to the control group (surgical drain) and 25 will be randomised to the intervention arm (TissuePatch)."||||
34023795|NCT06634277|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single group pilot study with sequential implementation in 4 hospitals||||
34023796|NCT04776538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sponsor, investigators, study staff (except for staff involved in stem cells preparation and staff involved in bioanalytical analyses) and patients will be blinded to treatment assignment and care will be taken to ensure the study team is kept blinded.|The study is a prospective, double-blinded, randomized, placebo-controlled trial|t|f|t|f
34023797|NCT02346266|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34023798|NCT06436066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34023799|NCT05927948|RANDOMIZED|CROSSOVER||OTHER||NONE||The patient has one side exposed to treatment and the other side receives no treatment as the comparison. Hence, patient serves as their own control.||||
34023800|NCT03859453|||COHORT||PROSPECTIVE|||||||
34023801|NCT02434237|||COHORT||PROSPECTIVE|||||||
34023802|NCT01595763|||COHORT||PROSPECTIVE|||||||
34023803|NCT03610516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023804|NCT02302053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023805|NCT04307576|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Master protocol with risk-stratification. The risk-stratified groups will proceed to non-randomised or randomised interventions in single arm (TKI) and (Blinatumomab) and parallel (R1/R2/R3) models respectively.||||
34023806|NCT06633107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023807|NCT02505308|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34023808|NCT05304247|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34023809|NCT00010426||||TREATMENT||||||||
34023810|NCT00554190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023811|NCT02607085|||CASE_ONLY||PROSPECTIVE|||||||
34023812|NCT00990860|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33800498|NCT03116620|NA|SINGLE_GROUP||OTHER||NONE||||||
33800499|NCT00039000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800500|NCT00616031|RANDOMIZED|||TREATMENT||||||||
33800501|NCT00686855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800502|NCT04961749|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33800503|NCT06201858|||CASE_CROSSOVER||PROSPECTIVE|||||||
33800504|NCT00808106|||COHORT||PROSPECTIVE|||||||
33800505|NCT02208869|||COHORT||PROSPECTIVE|||||||
33800506|NCT04474418|||COHORT||PROSPECTIVE|||||||
33800507|NCT05965141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800508|NCT06515951|||COHORT||RETROSPECTIVE|||||||
33800509|NCT01824420|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was designed in this study|Prospective, open-label study. The overactive bladder patients maintained their previous antimuscarinic medication and we flexibly added on the second antimuscarinic drug (oxybutynin ER 5 mg QD) or not.||||
33800510|NCT03435770|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, open label||||
33800511|NCT02698813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33800512|NCT05408767|||COHORT||OTHER|||||||
33800513|NCT04478851|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Hybrid implementation effectiveness study||||
33800514|NCT05640180|||COHORT||RETROSPECTIVE|||||||
33800515|NCT01831245|||COHORT||PROSPECTIVE|||||||
33800516|NCT02677129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800517|NCT00338650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800518|NCT05537675|||OTHER||RETROSPECTIVE|||||||
33800519|NCT06357234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Treatment arm of participants will be masked until data collection is complete.|This is a randomized double-blind placebo controlled study|t|t|t|t
33800520|NCT01923480|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33800521|NCT02200523|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33800522|NCT01045252|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800523|NCT01625104|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33800524|NCT05876143|||COHORT||PROSPECTIVE|||||||
33800525|NCT02906891|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800526|NCT04187599|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open label, 12 month follow up study||||
33800527|NCT04982536|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Each subject will have biopsy performed with both the study needle and a standard of care needle||||
34023813|NCT05289973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||patients having mandibular molars with necrotic pulp|t|f|t|t
34023814|NCT01886196|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023815|NCT06450795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023816|NCT00000693||||TREATMENT||NONE||||||
34023817|NCT01197144|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34023818|NCT02465268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800528|NCT02034773|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33800529|NCT01736514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800530|NCT00166283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800531|NCT04680520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800532|NCT04427800|||COHORT||CROSS_SECTIONAL|||||||
33800533|NCT01647724|||COHORT||PROSPECTIVE|||||||
33800534|NCT03764787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800535|NCT02563080|||CASE_ONLY||PROSPECTIVE|||||||
33800536|NCT05178225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800537|NCT03320746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800538|NCT00634621|||CASE_ONLY||PROSPECTIVE|||||||
33800539|NCT01259167|||CASE_CONTROL|||||||||
33800540|NCT04728919|||CASE_CONTROL||PROSPECTIVE|||||||
33800541|NCT03671252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800542|NCT00204646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800543|NCT02318407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800544|NCT04110054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800545|NCT05952895|||CASE_ONLY||PROSPECTIVE|||||||
33800546|NCT00334776|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800547|NCT05419570|||COHORT||PROSPECTIVE|||||||
33800548|NCT03046810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800549|NCT01332045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800550|NCT02745340|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33800551|NCT02601820|||COHORT||PROSPECTIVE|||||||
33800552|NCT01886729|RANDOMIZED|||||NONE||||||
33800553|NCT04113798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800554|NCT05871112|||COHORT||PROSPECTIVE|||||||
33800555|NCT00421070|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800556|NCT00079846|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33800557|NCT03898024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800558|NCT01869946|||CASE_ONLY||PROSPECTIVE|||||||
33800559|NCT05950542|||CASE_ONLY||PROSPECTIVE|||||||
34023819|NCT06550258|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Before - after trial|f|t|f|f
34023820|NCT06633068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|• Patients will be randomized using a computer-generated randomization list. Random group assigned will be enclosed in a sealed envelope to ensure concealment of allocation sequence. The sealed envelope will be opened by an anaesthesiologist who will not be involved in the study to prepare the drug solution according to randomization. The anaesthesiologist performing the block and observing the patient will be blinded to the treatment group.|A double blinded randomized controlled study|t|t|t|f
33800560|NCT05865834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A two-stage cluster sampling will be employed. Randomization will occur at school level for 2 arms i.e. interventional and control groups. Students will be selected randomly from each group||||
33800561|NCT03531840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800562|NCT05552924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33800563|NCT01131780|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800564|NCT03807661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800565|NCT02531737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800566|NCT05447975|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33800567|NCT02252042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800568|NCT01186549|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33800569|NCT05073159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled study||||
33800570|NCT06518538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800571|NCT06006949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800572|NCT01671267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800573|NCT04134793|||CASE_CONTROL||PROSPECTIVE|||||||
33800574|NCT04626180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800575|NCT02330458|||COHORT||PROSPECTIVE|||||||
33800576|NCT02010944|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33800577|NCT02140645|||COHORT||RETROSPECTIVE|||||||
33800578|NCT01782170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800579|NCT00710775|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33800580|NCT01052259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800581|NCT03165175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33800582|NCT01888848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800583|NCT02309996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800584|NCT03859869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800585|NCT01792934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800586|NCT02226822|||COHORT||PROSPECTIVE|||||||
33800587|NCT01093820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800588|NCT03241017|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, prospective, single-center, open-label, single-arm, non-comparative and non-randomized phase II study||||
33800589|NCT01150916|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33800590|NCT02974465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800591|NCT04249713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open Label Single Arm Study||||
33800592|NCT00737035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800593|NCT01116596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800594|NCT01286623|||COHORT||PROSPECTIVE|||||||
33800595|NCT01470508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800596|NCT05237453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800597|NCT04073199|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33800598|NCT03167034|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33800599|NCT00089544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800600|NCT06177444|||COHORT||RETROSPECTIVE|||||||
33800601|NCT03737903|||COHORT||PROSPECTIVE|||||||
33800602|NCT02036424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800603|NCT05066958|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800604|NCT00809939|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800605|NCT02444858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800606|NCT01973075|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34023821|NCT02598947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023822|NCT03545230|NA|SINGLE_GROUP||TREATMENT||NONE||"all childre with delayed union and nonunion lateral humeral condyle will be included.~After informed consent and full explanation.The Four Not Techniqueswill be done"||||
34023823|NCT03792295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800607|NCT05608213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800608|NCT04850768|||OTHER||CROSS_SECTIONAL|||||||
33800609|NCT01074567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800610|NCT04997213|RANDOMIZED|PARALLEL||TREATMENT||NONE||We have two groups. First group received biofeedback exercise and conventional exercise group, second group received only conventional exercise treatment||||
33800611|NCT06176391|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective pilot study||||
34023824|NCT04317118|||COHORT||CROSS_SECTIONAL|||||||
34023825|NCT00006183|RANDOMIZED|PARALLEL||TREATMENT||||||||
34023826|NCT01884337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023827|NCT00245830|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34023828|NCT05580965|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33800612|NCT00084110|||DEFINED_POPULATION||PROSPECTIVE|||||||
33800613|NCT00224445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800614|NCT03827369|||CASE_ONLY||PROSPECTIVE|||||||
33800615|NCT02612844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800616|NCT05573334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800617|NCT03892564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||One treatment with MC2-01 Cream, MC2-01 vehicle and control on defined applications site (N=5), followed by irradiation/non-irradiation and evaluation 24 or 48 hours post irradiation, within subject comparison model|t|f|f|t
33800618|NCT04805216|||OTHER||PROSPECTIVE|||||||
33840357|NCT04468594|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the process of allocation will be concealed using non transparent envelops that contain a code number. these codes indicated one of the three groups. the interpretation of these codes will be with an author who will not be involved in assessment or treatment procedures. At the day of the first intervention session, the code interpretation will be available|double-blind randomized controlled trial|t|t|t|t
33840358|NCT00630734|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840359|NCT00573742|||CASE_ONLY||PROSPECTIVE|||||||
34023829|NCT05545384|RANDOMIZED|PARALLEL||TREATMENT||NONE|The adjudication committee is responsible the evaluation of all relapses reported during the the follow-up period. Relapses assessments will use blinded data and will be performed in real time.|This is a multicentre, randomized controlled, open-labelled, parallel group study.||||
33800619|NCT03762434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Randomisation and masking: A statistician will use computer-generated randomisation to determine random allocation. Eligible participants will be randomly allocated to either the control ( booklet group ) or the intervention group ( MetS app group) according to an allocation sequence prepared by the statistician before the start of the study. The patients will be randomised at a ratio of 1:1, with stratification by study site. Small cards indicating the group assignments will be placed in opaque sealed envelopes, which will be opened by the research assistant after each patient has completed the baseline questionnaires. In this study, the statisticians, outcome assessors and research assistant assigned to perform data input will be blinded to the allocation sequence. Given the type of intervention, however, the intervention group will be unmasked to the participants and the research nurse performing the intervention.|A multisite randomized controlled trial with two arms: MetS app group and , booklet group|f|t|t|t
33800620|NCT03094182|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34023830|NCT04835623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800621|NCT06081075|||COHORT||PROSPECTIVE|||||||
33800622|NCT06009458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800623|NCT05834270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33800624|NCT01946724|||OTHER||OTHER|||||||
33800625|NCT00687713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800626|NCT00532142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800627|NCT04385056|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800628|NCT04004819|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental: Rituximab group Drug: Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused~Placebo Comparator: Control group Patients will receive usual care and drug use."||||
33800629|NCT05899270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Two investigators performing intubation of DLT will be blinded to the intervention. All participates and researchers responsible for surgery, bronchoscopy assessment, follow-up, data management and analysis will also be blinded to the grouping.|Participates recruited from Sichuan Cancer Hospital will randomized to 3D group and control group in 1:1 ratio via a random number list generated by a computer.|t|t|t|t
33800630|NCT05992298|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800631|NCT01599104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800632|NCT05580380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33800633|NCT04114422|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800634|NCT04085094|||CASE_CONTROL||PROSPECTIVE|||||||
33800635|NCT06117332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800636|NCT00903851|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800637|NCT03262935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840360|NCT01002677|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33840361|NCT04497389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840362|NCT01955187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840363|NCT01779570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840364|NCT05153876|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34023831|NCT03813953|RANDOMIZED|PARALLEL||OTHER||NONE||Long term follow up of previously randomised populations.||||
34023832|NCT04096755|||CASE_CONTROL||PROSPECTIVE|||||||
34023833|NCT01560650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023834|NCT00960635||||PREVENTION||||||||
34023835|NCT01189487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023836|NCT05351671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the entire study, subjects, Investigators, the Sponsor, and all other persons involved in the conduct of the study will be blinded to treatment.|Subjects will be randomly allocated to either of the treatment arms with RLS-0071 or the placebo arm in a 1:1:1 ratio. Subjects will be permitted to participate in only 1 arm of the study.|t|t|t|t
34023837|NCT03805711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023838|NCT02106897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023839|NCT04434300|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subcutaneous administration of daptomycin and placebo will be done blind to the participant. Given the yellow coloration of daptomycin, a masking of the pockets of daptomycin and NaCl will be carried out with a pocket cover and an opaque tube will be used for the administration||t|f|f|f
34023840|NCT04831463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
34023841|NCT01004653|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023842|NCT01939574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023843|NCT03316235|||COHORT||RETROSPECTIVE|||||||
34023844|NCT05377892|NA|SEQUENTIAL||BASIC_SCIENCE||NONE|single blinded (participant)|Longitudinal||||
34023845|NCT00002444||||TREATMENT||||||||
34023846|NCT04123561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023847|NCT01555671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Both drug provider and patient do not know which drug or placebo was given|Randomized parallel double blind plasebo controlled study|t|t|t|f
34023848|NCT02887456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34023849|NCT01997216|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33840365|NCT05765643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a single-blinded, randomized controlled trial with two-armed repeated measures||||
33840366|NCT01531777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840367|NCT02136953|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33840368|NCT00004139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840369|NCT03990792|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33840370|NCT05781126|||COHORT||PROSPECTIVE|||||||
33840371|NCT00623259||||DIAGNOSTIC||||||||
33840372|NCT06502392|||OTHER||CROSS_SECTIONAL|||||||
33840373|NCT01720576|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33840374|NCT04315753|||CASE_CONTROL||PROSPECTIVE|||||||
33840375|NCT05357976|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840376|NCT01780259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33840377|NCT04221464|NA|SINGLE_GROUP||OTHER||NONE||||||
33840378|NCT00546208|||||PROSPECTIVE|||||||
33840379|NCT01749267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840380|NCT05787327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840381|NCT00569114|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33840382|NCT03285607|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840383|NCT00006501|||COHORT||PROSPECTIVE|||||||
33840384|NCT05217667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023850|NCT03426163|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34025530|NCT04283968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The care providers, investigators, outcome assessor, and the participants do not know which of the transplantations is placebo and which is fecal microbial one during the first phase of the study. After the 4 transplantations the patients of the placebo group will have the possibility to enter an open label study in which they will receive 4 fecal transplantations.||t|t|t|t
34025531|NCT04113863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025532|NCT00843479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34102596|NCT06232252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant: This trial is blinded to treatment but not to dose level. The dose level will be known to the participant.~Outcome assessor: ECG laboratory"|The groups will be dosed sequentially. Within each dose group, some subjects will receive BI 765423 and some will receive placebo.|t|f|f|t
34102597|NCT05950659|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34102598|NCT06691711|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Waitlist controlled||||
34102599|NCT00233961||||TREATMENT||NONE||||||
33840385|NCT06373198|||COHORT||PROSPECTIVE|||||||
33840386|NCT03262649|||COHORT||PROSPECTIVE|||||||
33840387|NCT03156881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Since this study does not involve a sham treatment, the researcher and Dr. Peltekian have decided to have two consent forms. Patients will be assigned a code number and will be divided randomly into treatment or non-treatment groups via Dr. Peltekian opening up sealed envelops made by researcher Jenna Wilcox. Part one of the study will involve Dr. Peltekian asking potential participants consent to be a part of a study measuring  Quality of life and readiness for management of NAFLD. Upon consent, he/she will fill out the two questionnaires and give consent that their routine blood work can be analysed anonymously. During the same time, Dr. Peltekian will open up a sealed envelope revealing a code number and either an invitation to Part 2 of the study or not to invite and to remain as a control participant. By using this method the control group is not informed of the osteopathic research of the study (Part 2), thus reducing bias."|"24 participants in control group receiving no global osteopathic treatment. Just standard care, baseline blood work every three months, improving their diet and exercise. They will also complete two questionnaires to measure their quality of life and readiness to change.~Experimental group will also do the above with additional four osteopathic treatments to compare the differences in quality of life and liver function in both groups."|t|f|f|f
33840388|NCT06448949|||COHORT||PROSPECTIVE|||||||
33840389|NCT03339232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are randomized into one of three arms||||
33840390|NCT05584683|NA|SINGLE_GROUP||TREATMENT||NONE||single site, single dose, open label, pharmacokinetic study||||
33840391|NCT01739023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840392|NCT01208103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840393|NCT02297490|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33840394|NCT02057211|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33840395|NCT00317733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840396|NCT04530383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33840397|NCT02979249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840398|NCT02741453|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102600|NCT06499948|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Timeline:~* First visit - screening and eligibility: assessing eligibility and adjusting the renin-angiotensin-system inhibitor dose (2 weeks);~* Second visit - stable dose of renin-angiotensin-system inhibitor (4 weeks);~* Third visit - randomization: patients are randomized to receive either Spironolactone 25 mg od or Dapagliflozin 10 mg od (first treatment period: 4 weeks);~* Fourth visit - first wash-out: the intervention is stopped (4 weeks);~* Fifth visit - second treatment period: switching the treatment between the two groups (second treatment period: 4 weeks);~* Sixth visit - second wash-out: the intervention is stopped (4 weeks);~* Seventh visit - third treatment period: the whole cohort will receive the combined therapy consisting in Dapagliflozin 10 mg od and Spironolactone 25 mg od (4 weeks);~* Eighth visit - third wash-out: the intervention is stopped (4 weeks);~* Ninth visit - end of study: after the third wash-out period is finished."||||
34102601|NCT03163264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34102602|NCT06675903|||CASE_CONTROL||PROSPECTIVE|||||||
34102603|NCT01314248|||CASE_CROSSOVER||PROSPECTIVE|||||||
34102604|NCT03917498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102605|NCT06688591|NA|SINGLE_GROUP||PREVENTION||NONE||The pilot OptiMed randomised pragmatic trial will focus on the feasibility components using an open-label design where participants know what they are signing up for. It will support the development of a standardised, evidence-based, multi-component, interprofessional intervention programme to reduce MRPs.||||
34102606|NCT03615326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800638|NCT04257409|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomization of diabetic patients with healed diabetic foot according the randomization scheme|60 patients with Type 2 diabetes mellitus. These patients will be randomized into 3 study groups - patients with type 2 DM with mild form of peripheral sensory neuropathy (20 subjects), patient with severe peripheral neuropathy (20 subjects) and those with diabetic foot syndrome, without active lesion (20 subjects). All patients will undergo 12 week lasting active intervention program consisting of recommendations by a physiotherapist focusing on the improvement of physical fitness, muscle strength and foot joint improvement. Control group will be consisted of 20 patients with healed diabetic foot.|t|f|f|f
33800639|NCT03733119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800640|NCT01599793|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800641|NCT05451095|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33800642|NCT03760354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinded trial|Prospective Phase II, Bayesian, single-blinded, monocentric, randomized, prospective clinical trial|t|f|f|f
33800643|NCT05673434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023851|NCT04440670|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A hospital ethics committee reviewed the study data during the trials. None of them were involved in the study or aware of the treatment-group assignments of the infants. Only nurses and physicians staff conducted the infusion were aware of the treatment assignment, and these individuals had no contact with the staff who collected and analyzed the patients data. The parents are not aware of the assignment. This study is double-blinded.|In this prospective, randomized controlled double-blind multi-center clinical trial, 140 preterm neonates less than 28 weeks are randomly assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) or placebo ( normal saline) within 24 hours after birth in a 1:1 ratio using a central randomization system.|t|t|f|t
34023852|NCT06076083|||COHORT||PROSPECTIVE|||||||
34023853|NCT06075953|RANDOMIZED|PARALLEL||TREATMENT||NONE||RECAST-DCIS is an open-label, multi-site platform study designed to offer women with Ductal cell Carcinoma In Situ (DCIS) 6 months of neo-adjuvant exposure to endocrine therapy with the intent of determining their suitability for long-term active surveillance without surgery.||||
33800644|NCT04441008|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Investigator and outcomes assessor will be blinded to patient's designation.|Single-blind with crossover of experimental (aiTBS) group into standard of care (ECT) group.|f|f|t|t
33800645|NCT01845428|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800646|NCT02931175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800647|NCT01414738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800648|NCT06366399|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33800649|NCT04861233|||COHORT||PROSPECTIVE|||||||
33800650|NCT01037985|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33800651|NCT06074549|||COHORT||PROSPECTIVE|||||||
33800652|NCT01579370|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34023854|NCT01073137|||COHORT||PROSPECTIVE|||||||
34023855|NCT04516759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomised double-blind study. Eligible patients will be randomly assigned to one of two groups (AZD1656 plus usual care or placebo plus usual care) on a 1:1 basis|t|f|t|f
34023856|NCT02068235|RANDOMIZED|CROSSOVER||||NONE||||||
34023857|NCT01685840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023858|NCT06111352|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open level, Randomized controlled trial||||
34023859|NCT03414086|||COHORT||PROSPECTIVE|||||||
34023860|NCT01400802|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34023861|NCT00846534|||COHORT||PROSPECTIVE|||||||
34023862|NCT06629987|||COHORT||OTHER|||||||
34023863|NCT00080873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34023864|NCT00359593|RANDOMIZED|PARALLEL||||SINGLE||||||
34023865|NCT02422589|NA|SINGLE_GROUP||OTHER||NONE||||||
33800653|NCT04498234|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33800654|NCT02575560|||CASE_ONLY||PROSPECTIVE|||||||
33800655|NCT00446459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800656|NCT02249559|||CASE_ONLY||PROSPECTIVE|||||||
33800657|NCT01680250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023866|NCT01711892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023867|NCT03021863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34023868|NCT06273267|||COHORT||RETROSPECTIVE|||||||
34023869|NCT04801381|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized and non-randomized trial||||
34023870|NCT04429347|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Each participant will have an identification number and randomization of drug sequence allocation will be performed a priori using a random number generator by the study pharmacist. The 3 treatments will be identically encapsulated by the study pharmacist. The study pharmacist will place the drug capsules in identical sealed plastic bags labeled Treatment 1 through Treatment 3."|Randomized, Double-bind, Placebo-controlled, Crossover Trial|t|t|t|t
34023871|NCT04880863|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive obinutuzumab, 1,000 mg, administered by IV infusion on Days -13 and -12 of the first treatment cycle in order to reduce the titer of anti-drug antibodies to NAP. NAP will be administered by IV bolus on Days 1 - 4 of treatment cycles 1-6, followed by docetaxel on Day 5. Treatment cycles with the combination NAP/docetaxel will be 21 days in duration. Starting cycle 7, NAP at a higher dose will be administered on Day 1 and docetaxel on Day 2, in 21 days treatment cycles. Once NAP is given as monotherapy and not earlier than C7, cycles will be of 28 days of duration.||||
34023872|NCT02361242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023873|NCT00143923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102607|NCT05766254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant) Participants will be blinded as to TMS condition (active or sham)||t|f|f|f
34102608|NCT06687135|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A two-arm randomised controlled trial.|f|f|t|f
33800658|NCT06135623|||COHORT||PROSPECTIVE|||||||
33800659|NCT05208372|||CASE_CONTROL||PROSPECTIVE|||||||
33719263|NCT03598192|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The TAP group will be performed the four points TAP block under the ultrasound guidance with the ultrasound machine of Logiq E, and linear 12S probe. The participants will be performed TAP block at subcostal and lateral abdominal wall at right and left side with stimuplex needle (sized 18G, length 100 mm). The investigators will approach position between aponeurosis internal oblique and transversus abdominal muscle with in-plane real-time ultrasound technique. The investigators will inject 10 ml of ropivacaine 0.375% at each one. Then, the investigators will access one catheter at TAP at right side to continuously infuse ropivacaine 0.375% during 48 hours after surgery.~PVB group: the investigators will access one catheter into the right thoracic paravertebral space at T7 before beginning general anesthesia. At the end of surgery, the investigators will inject 20 ml of ropivacaine 0.5% through catheter, and continuously infuse ropivacaine 0.25% during 48 hours after surgery."||||
33719264|NCT00415103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719265|NCT00468572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719266|NCT03715166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||6-month, randomized, double-blind, placebo-controlled, parallel groups followed by an open label active 6-month treatment period with bumetanide.|t|t|t|t
33719267|NCT00471744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719268|NCT03113019|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with breast cancer receive a cellular preparation consisting of dendritic cells loaded with tumor lysate antigens and activated mononuclear cells. Patients receive this treatment in the adjuvant mode at IIa-IIIc stages and in neoadjuvant regimen with progression or 4 stages of the disease||||
33719269|NCT01067456|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized diagnostic trial, two arms||||
33719270|NCT05192551|||CASE_ONLY||PROSPECTIVE|||||||
33719271|NCT06320795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719272|NCT04495842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33719273|NCT00861432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944317|NCT03464162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will choose if they want to receive Social Network Meetings or be in a group that does not receive Social Network Meetings. Entrance of clients into the study will be staggered with no more than approximately 5 individuals in the Social Network group and no more than 5 individuals not in the Social Network group enrolled each month. There will be a maximum of 15 participants (clients) in each group.~For participants who choose Social Network Meetings, at least one member of their social network will participate in the study as well."||||
33944318|NCT05069623|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two vaccine candidates are investigated in parallell.||||
34025533|NCT06633185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1st arm includes those patients who underwent application of topical phenytoin cream after anal fissure surgery, while the other arm includes those without application of any creams( control).|t|f|f|t
34025534|NCT06328062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719274|NCT05821842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|t|f
33719275|NCT00791167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33719276|NCT05331287|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|f|t
33719277|NCT02442362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719278|NCT05399381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33719279|NCT05252000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719280|NCT04678154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719281|NCT01226446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719282|NCT00204607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719283|NCT03444714|NA|SINGLE_GROUP||TREATMENT||NONE||3 + 3 dose escalation study design||||
33719284|NCT05567133|||OTHER||OTHER|||||||
33719285|NCT03781128|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double-blind|Double-blind, randomized, placebo-controlled two-phase cross-over study design.|t|t|t|t
33800660|NCT02082548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944319|NCT05756062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944320|NCT06337773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33944321|NCT03502265|NA|SINGLE_GROUP||TREATMENT||NONE||single subject research design case series||||
33944322|NCT02668510|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33944323|NCT00987857|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33944324|NCT05463315|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A Mixed Methods Sequential Explanatory Study||||
33944325|NCT00203294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944326|NCT01111331|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944327|NCT01073384|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33944328|NCT05205681|||COHORT||RETROSPECTIVE|||||||
33944329|NCT04291430|||COHORT||PROSPECTIVE|||||||
33944330|NCT00757380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944331|NCT05994690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944332|NCT04454281|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33944333|NCT04115969|||COHORT||RETROSPECTIVE|||||||
33944334|NCT06309524|||COHORT||PROSPECTIVE|||||||
33944335|NCT03641599|||COHORT||CROSS_SECTIONAL|||||||
33944336|NCT02178982|||COHORT||PROSPECTIVE|||||||
33944337|NCT01114191|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944338|NCT00224757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944339|NCT01785342|||COHORT||PROSPECTIVE|||||||
33944340|NCT01700452|||COHORT||PROSPECTIVE|||||||
33944341|NCT00937703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944342|NCT03773146|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomized to one of three airtime incentive structures: 1) no incentive; 2) a fixed 1X incentive for all participants who completed the noncommunicable disease risk factor survey; or 3) a lottery incentive (10-20 times larger than the fixed incentive) given to 1 out of every 20 participants who completed the same survey.|f|f|f|t
34025535|NCT05852561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025536|NCT02640690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025537|NCT00182247|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34025538|NCT04005365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025539|NCT00926783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800661|NCT06079515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|close envelope method|A total of 60 patients who met the criteria and agreed to participate in the trial were included in the study. The patients were randomized into two groups suprascapular nerve block (SSNB) and intra-articular injection (IAI) using the closed envelope method.|f|f|t|f
33800662|NCT00737958|||CASE_CROSSOVER||PROSPECTIVE|||||||
33800663|NCT06220149|||COHORT||PROSPECTIVE|||||||
33800664|NCT00549848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800665|NCT01851317|||COHORT||PROSPECTIVE|||||||
33800666|NCT05264168|||COHORT||RETROSPECTIVE|||||||
33800667|NCT00903162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800668|NCT00973986|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34023874|NCT03302026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment-seeking smokers complete an intake session and then be randomized to an active NFT group or a control group.|The proposed study will evaluate the effects of rt-fMRI neurofeedback training on the ability to resist craving for cigarettes. The study will be conducted in two phases: a technical development phase and a proof-of-concept phase focused on efficacy. The technical development phase will be completed before beginning the proof-of-concept phase. Eligible consenting treatment-seeking smokers complete an intake session and then be randomized to an active NFT group or a control group. Both groups will complete three scanning sessions, followed by a smoking resist evaluation.|t|f|f|f
34023875|NCT01056315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023876|NCT05811897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023877|NCT03897985|||CASE_ONLY||PROSPECTIVE|||||||
34023878|NCT03781037|NA|SINGLE_GROUP||TREATMENT||NONE||open label pilot study||||
34023879|NCT00787059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023880|NCT06174597|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34023881|NCT04297033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023882|NCT00003445||||TREATMENT||||||||
34023883|NCT01635218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023884|NCT04395066|||COHORT||PROSPECTIVE|||||||
34023885|NCT06453252|||COHORT||RETROSPECTIVE|||||||
34023886|NCT05055583|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, sigle-center, prospective phase II study.||||
33800669|NCT00002755|RANDOMIZED|||TREATMENT||||||||
33800670|NCT01950780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800671|NCT05296213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023887|NCT00006630||||TREATMENT||||||||
34023888|NCT02553759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34023889|NCT01028924|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34023890|NCT04061525|||COHORT||PROSPECTIVE|||||||
34023891|NCT05026996|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This was a Phase I, open-label, single dose, parallel-group study in participants with mild HI (n=8) and matched healthy participants with normal hepatic function (n=8) designed to evaluate the PK of pelacarsen. Participants were matched by gender, age (± 10 years), and body weight (± 15%).||||
34023892|NCT01655576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023893|NCT05592314|||OTHER||CROSS_SECTIONAL|||||||
34023894|NCT05794360|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||2 arm clustered RCT. Two levels of clustering: The students (level 1) will be clustered within the classroom (level 2).|f|f|f|t
34023895|NCT03881423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Double blinded||t|t|t|f
34023896|NCT00788138|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34023897|NCT04988087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34023898|NCT00304837|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34023899|NCT03357653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The investigators will test the effect of ARB to prevent the development of significant proteinuria, defined as random urine protein-to-creatinine ratio of \>1g/g creatinine. In this study, the investigators choose losartan as a testing ARB. The investigators will compare the rate of significant proteinuria development between 2 arms, namely losartan group and placebo group after 144 weeks' treatment.|t|t|t|t
34023900|NCT05323279|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Double (Participant, Investigator)||f|f|t|f
34023901|NCT03457935|||COHORT||PROSPECTIVE|||||||
34023902|NCT05739279|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34023903|NCT02572245|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34023904|NCT03581409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023905|NCT06462560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023906|NCT03485651|||COHORT||PROSPECTIVE|||||||
34023907|NCT00465465|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102609|NCT06355778|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33800672|NCT05223517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800673|NCT06013891|||COHORT||PROSPECTIVE|||||||
33800674|NCT02912208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800675|NCT01494922|NON_RANDOMIZED|||TREATMENT||NONE||||||
33800676|NCT02158819|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800677|NCT02653508|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33800678|NCT02810236|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33800679|NCT00961623|||CASE_ONLY||PROSPECTIVE|||||||
33800680|NCT04625231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both patients and investigators were blinded to group assignment until an envelope was opened after the patient consented.||t|t|t|f
34023908|NCT06632977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023909|NCT01630577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025540|NCT00117910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800681|NCT00977158|||COHORT||PROSPECTIVE|||||||
34102610|NCT01122368|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33800682|NCT04244058|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be unaware of the medication used during the pharmacological challenge for the PET approach.||t|f|f|f
33800683|NCT02290470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800684|NCT01199536|||CASE_ONLY||PROSPECTIVE|||||||
33800685|NCT05368831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800686|NCT05435313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800687|NCT02122640|||||PROSPECTIVE|||||||
33800688|NCT03090763|||CASE_CONTROL||PROSPECTIVE|||||||
33800689|NCT00355095|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34102611|NCT06686693|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and Investigator will be blinded to who receives iron or placebo. A investigator not participating in data collection is responsible for randomly assigning participants to the intervention. The medical care providers will be unblinded to intervention assignment.|This is a double-blind, parallel research study design where one group will receive iron or placebo intravenously.|t|f|t|f
34102612|NCT05626608|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Two of the 4 investigators will not be aware of the stimulation modality programmed in the patient.||t|t|t|f
34102613|NCT05696782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102614|NCT02505672|||COHORT||PROSPECTIVE|||||||
34102615|NCT02350998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102616|NCT05947422|||CASE_ONLY||PROSPECTIVE|||||||
34102617|NCT06343792|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102618|NCT06585696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel +Single Group|t|t|t|t
34102619|NCT06694610|NA|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102620|NCT06691568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34102621|NCT04267926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject and investigator will be blinded.|Double-blind, randomized trial|t|f|t|f
34102622|NCT06690879|||CASE_CONTROL||RETROSPECTIVE|||||||
34102623|NCT06686472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sponsor, investigators, and study staff will be masked throughout the study. The study site will have the capacity to unmask in case of emergency. Following completion of the study, the randomization code will be unmasked once all data has been entered into the study database for every subject, and the database has been locked.||t|t|t|t
34102624|NCT03782883|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34102625|NCT05416281|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Exposure will be evaluated before vacuuming and again after 8 weeks of vacuuming.||||
34102626|NCT05797649|||CASE_CONTROL||PROSPECTIVE|||||||
34102627|NCT03128710|||COHORT||PROSPECTIVE|||||||
34102628|NCT06690528|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase-2 multicenter randomized controlled trial with a 1:1 allocation ratio. Eligible patients with pancreatic cancer oligometastatic to the liver with response/stability after first-line chemotherapy will receive surgical resection or observation/continued chemotherapy. The study will be conducted at different international referral centers with high expertise in pancreatic cancer treatment to ensure the highest standards of quality and an adequate sample size. After the enrollment of the first 20 cases, an independent data monitoring committee (IDMC) will review safety and futility (using 90 days major morbidity + mortality as the endpoint), to allow for early study termination or modification if necessary.||||
34102629|NCT00930800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800690|NCT04222946|NA|SINGLE_GROUP||TREATMENT||NONE||Pretest posttest of bilateral Flexor digitorum Brevis dry neddling intervention||||
33800691|NCT00947635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800692|NCT02121002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800693|NCT00035308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33800694|NCT05239013|NA|SINGLE_GROUP||OTHER||NONE||||||
33800695|NCT03376152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800696|NCT01020045|||COHORT||CROSS_SECTIONAL|||||||
33800697|NCT05959590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800698|NCT01034059|||COHORT||PROSPECTIVE|||||||
33944343|NCT01102439|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33944344|NCT03355001|||COHORT||PROSPECTIVE|||||||
33944345|NCT01356615|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33944346|NCT04926129|||COHORT||PROSPECTIVE|||||||
33944347|NCT02972658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944348|NCT04309175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944349|NCT02324426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944350|NCT00394173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944351|NCT03342807|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102630|NCT06522503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized controlled experimental study|t|t|t|t
34102631|NCT06313346|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The products (experimental and placebo), will be produced by an external producer, who will save the codes. None of the researchers involved in the study development or analyses will know the association until the end of the study.|Randomised, double blinded, parallel intervention|t|t|t|t
34102632|NCT04238182|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34102633|NCT04493203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102634|NCT05978232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102635|NCT05273437|NA|SINGLE_GROUP||TREATMENT||NONE||See study description for details. All participants will receive all intervention elements, with provision varying across time experimentally using procedures appropriate for system identification.||||
34102636|NCT06691347|RANDOMIZED|PARALLEL||TREATMENT||NONE|The Investigator will be blinded to the random allocation of patients, but will have knowledge of the interventions when treatment begins.|||||
34102637|NCT00359398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800699|NCT01552577|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800700|NCT03425552|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33800701|NCT04702256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800702|NCT02990234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800703|NCT00752752|||COHORT||PROSPECTIVE|||||||
33800704|NCT04353310|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33800705|NCT04077164|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33800706|NCT00903539|||COHORT||PROSPECTIVE|||||||
33800707|NCT00967434|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33800708|NCT06044467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800709|NCT03767452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800710|NCT00069901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800711|NCT03352596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33800712|NCT01086982|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800713|NCT01324453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800714|NCT03346616|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants were randomly assigned to a Texting Group or a Non-Texting Group using a random number generator. The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2pm and 3pm. To minimize perceived impropriety, the non-texting group received access to the journal articles from which the content was derived, but did not receive any text messages or any of the synthesized material. The primary outcome was performance on the NBME Pediatric Subject Examination."||||
33800715|NCT00879749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800716|NCT03272399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800717|NCT01086826|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33800718|NCT05025995|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33800719|NCT06407258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944352|NCT06349109|||CASE_CONTROL||PROSPECTIVE|||||||
33944353|NCT05585099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944354|NCT01028599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944355|NCT05375058|||COHORT||RETROSPECTIVE|||||||
34023910|NCT04416165|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects with various types of cancer undergo contemporaneous 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT either for an initial assessment or for recurrence detection.||||
33800720|NCT02579031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800721|NCT04962750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800722|NCT06189534|RANDOMIZED|PARALLEL||TREATMENT||NONE||It was an experimental pre-test post-test research design which investigated the social media addiction, insomnia poor family bonding and effectiveness of cognitive behavior interventions in managing social media addiction.||||
34023911|NCT01543295|||COHORT||PROSPECTIVE|||||||
33800723|NCT06375603|||COHORT||PROSPECTIVE|||||||
33800724|NCT06521411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800725|NCT03339115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800726|NCT01226849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944356|NCT01247727|||CASE_ONLY||PROSPECTIVE|||||||
33944357|NCT02361606|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34023912|NCT04126590|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34023913|NCT05444530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34023914|NCT05603312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are enrolled in one of three groups in parallel for the duration of the study.|t|f|t|t
34023915|NCT05297578|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Triple (Participant, Investigator, Outcomes Assessor)||t|t|t|t
34023916|NCT02754856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023917|NCT02665845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34023918|NCT03621501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical event adjudication committee, consisting of cardiologists who are not participating in the study, will be blinded for the treatment arm of the patients to avoid a potential bias in the adjudication process of events|This study is a prospective, multicenter, randomized, two-arm, international, open-label, non-inferiority study. Due to the design characteristics of the study, the study investigators and operators cannot be blinded.|f|f|f|t
34023919|NCT05346926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023920|NCT02180178|||COHORT||OTHER|||||||
34023921|NCT04297319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient and the outcomes assessor and principal investigator has not access to the randomization system|Double blind, randomized, control clinical trial|t|f|t|t
34023922|NCT04312516|||COHORT||PROSPECTIVE|||||||
34023923|NCT00103610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023924|NCT02521376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023925|NCT01917981|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34023926|NCT03379298|||COHORT||RETROSPECTIVE|||||||
34023927|NCT06041152|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34023928|NCT04156958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023929|NCT02586246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023930|NCT00004378||||TREATMENT||||||||
34023931|NCT06500624|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944358|NCT03016520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33944359|NCT02247726|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33944360|NCT03699774||SEQUENTIAL||BASIC_SCIENCE||NONE||Fixed sequence||||
33944361|NCT01343121|NA|SINGLE_GROUP||OTHER||NONE||||||
33944362|NCT00918242|||COHORT||PROSPECTIVE|||||||
34023932|NCT04292665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34023933|NCT05043441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34023934|NCT00737152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023935|NCT05769257|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025541|NCT06247371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Only participants are masked to the randomization allocation.|This study incorporates a prospective single centre, two arms parallel randomised controlled trial with 1:1 patient allocation.|t|f|f|f
34025542|NCT01707771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025543|NCT03460080|||CASE_CROSSOVER||OTHER|||||||
34025544|NCT03630107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025545|NCT04191499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102638|NCT03973489|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Subjects will be grouped into either the CV or WT group. Neither they nor the researchers will know which group they are in. In addition, subjects will be randomly assigned to receive drug then placebo or placebo than drug. Neither researchers or subjects will know in which order they will receive drug.||t|f|t|f
34102639|NCT04195685|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study is a randomized controlled clinical trial using Neurofeedback (NFB) as the study intervention. The control group members will continue with their usual care and will receive a 15-minute phone call from an Investigator on a weekly basis to briefly discuss one of eight possible health topics (sleep hygiene, basic nutritional concepts, beverage choices, positive thinking, thought reframing, fitness, daily calming activity, and enhancement of focus strategies) that the treatment group would receive as a normal part of their NFB session. At the end of the Control group activities, the participant will enter the delayed intervention group. Twenty, one-hour, NFB training sessions will be provided to each participant in the intervention group by a trained NFB specialist over an 8-10-week period (up to 5-sessions but usually 3 sessions a week).||||
34102640|NCT03004677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34102641|NCT05013905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102642|NCT06659341|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102643|NCT05788328|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open label|||||
34102644|NCT06690437|||COHORT||RETROSPECTIVE|||||||
34102645|NCT06606119|||CASE_CONTROL||PROSPECTIVE|||||||
34102646|NCT06220266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Unmasked due to patient preference trial|Patient preference trial||||
34102647|NCT05725655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34102648|NCT05970939|||CASE_ONLY||PROSPECTIVE|||||||
34102649|NCT03258593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102650|NCT06141031|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34102651|NCT04082273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102652|NCT04331951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The pathologists will be blinded for the result of endoscopic finding|||||
34102653|NCT06694129|||COHORT||PROSPECTIVE|||||||
33719286|NCT04047433|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"two arms -~1. with external anal sphincter injury~2. without injury both will go through genetic screening test the arm with the external anal sphincter injury will also be tested for advanced genetic testing"||||
34102654|NCT03098927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Eight subjects with spinal cord injury (SCI) will be recruited during the sub-acute phase (3-6 months following injury). Four participants will immediately undergo motor imagery training in an immersive virtual reality environment at NASA. EEG assessments and motor function testing will be performed at intervals during the 3-4 week motor imagery training period to assess improvement in cortical signature generation and motor recovery. The other four participants will undergo the same protocol after a 6 week delay, in order to assess the effect of training timing after injury in both cortical signature generation and motor function recovery.||||
34102655|NCT04895956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be informed which arm of the trial they have been placed in until after the conclusion of their involvement with the study. To ensure blinding of the physicians, follow up assessments will not be performed by the doctors who administered the injection and will instead be performed by residents who will not be informed which group the patient has been placed in.|The trial will be a double blinded randomized controlled trial with half of the subjects randomized to receive intra-sheath injection and the other half receiving extra-sheath injection.|t|t|f|f
34102656|NCT02380157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34102657|NCT05032911|||CASE_CONTROL||PROSPECTIVE|||||||
34102658|NCT04082572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102659|NCT03223805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102660|NCT00619398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102661|NCT04376008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33719287|NCT06105151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719288|NCT04998747|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33719289|NCT03736356|||COHORT||PROSPECTIVE|||||||
33719290|NCT03153228|||CASE_CONTROL||PROSPECTIVE|||||||
33719291|NCT05346341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719292|NCT04006249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719293|NCT03103919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719294|NCT01042327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719295|NCT04506489|||COHORT||PROSPECTIVE|||||||
34102662|NCT06184087|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||A prospective quasi-experimental study||||
33800727|NCT03086863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800728|NCT04008550|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944363|NCT01809028|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33944364|NCT02705859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944365|NCT03137212|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients with STEMI will be divided into two group randomly. Patients of A group will be treated by thrombolysis and then 3-6 hours will be treated by PCI. Patients of B group will be treated by thrombolysis and then 6-24 hours will be treated by PCI.||||
33944366|NCT00247052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34102663|NCT04392362|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomizes Control trial||||
34102664|NCT05019807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34102665|NCT06499792|||CASE_CONTROL||RETROSPECTIVE|||||||
33719296|NCT00350714|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719297|NCT02100059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719298|NCT00276159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719299|NCT04864379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800729|NCT05310916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800730|NCT04290819|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Double blind study|4 groups. Comparing each group against one another. Creatine vs. Caffeine vs. Caffeine and Creatine vs. Placebo|t|f|t|f
33800731|NCT01244672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800732|NCT01388725|||CASE_CONTROL||PROSPECTIVE|||||||
33800733|NCT02802995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102666|NCT03503799|||CASE_ONLY||PROSPECTIVE|||||||
34102667|NCT06691009|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|There will be an outcome assessor who do not know which group recieved which treatment. Also, the participants will not know to which group they will be included.|Random assignment of intervention will be done after subjects have been assessed for eligibility and recruited and after final diagnosis. This will be done by crossover method 1:1. Patients with ODD number will be included in group 1, and patients with even number will be included in group 2.|t|f|f|t
34102668|NCT06514898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102669|NCT03007693|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34102670|NCT00760305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34102671|NCT06571318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind|Randomized, Double blind, Parallel Group, Placebo Controlled Trial|t|f|t|f
34102672|NCT01933516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102673|NCT02822690|||FAMILY_BASED||PROSPECTIVE|||||||
34102674|NCT00592280|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102675|NCT05721729|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34102676|NCT03606213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102677|NCT05783349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102678|NCT04481438|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34102679|NCT06324110|NA|SINGLE_GROUP||SCREENING||NONE||||||
34102680|NCT06164730|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single ascending dose escalation/adaptive design.||||
34102681|NCT02850406|NA|SEQUENTIAL||TREATMENT||NONE||||||
34102682|NCT06564818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102683|NCT02506153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102684|NCT02016599|||COHORT||PROSPECTIVE|||||||
34102685|NCT02965456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102686|NCT02899754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34102687|NCT05018091|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34102688|NCT06686901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102689|NCT00330811|||COHORT||PROSPECTIVE|||||||
34102690|NCT06442397|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102691|NCT05378529|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34102692|NCT04448912|||OTHER||RETROSPECTIVE|||||||
34102693|NCT06427642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719300|NCT06235788|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Double (Participant and Expert Rater)~Participants are unaware of the intervention being used in the study - the pause. They are informed that they will be acquiring and honing technical skills relevant to neurosurgery, with the added feature of receiving feedback from an intelligent system during subpial tumour resection simulations.~Experts, when providing OSATS ratings, do not know to which group the video performance they are rating belongs."|Randomized Controlled Trial|t|f|f|t
33719301|NCT05870709|||COHORT||PROSPECTIVE|||||||
33719302|NCT00866684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719303|NCT03992820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"After obtaining informed consent patients will be randomised to two groups using codes generated by web-based randomisation system- Research Randomizer. This is a free resource for researchers.~The website is http://www.randomizer.org The numbers generated will be placed in separate sealed envelopes by the department secretary and made available to the investigators."||f|f|f|t
33719304|NCT01425957|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719305|NCT03109301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719306|NCT06022380|||COHORT||PROSPECTIVE|||||||
33719307|NCT02497950|||OTHER||PROSPECTIVE|||||||
33719308|NCT01142700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719309|NCT01529840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719310|NCT01036035|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33719311|NCT05277701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719312|NCT05434182|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719313|NCT04079829|||COHORT||RETROSPECTIVE|||||||
33719314|NCT04108520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719315|NCT02063009|||COHORT||PROSPECTIVE|||||||
33719316|NCT01829516|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33719317|NCT03394092|||CASE_CONTROL||PROSPECTIVE|||||||
33719318|NCT02772081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719319|NCT05933512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Group A was designed as double-blinded and Group B was open label.||t|t|t|t
33719320|NCT04900194|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719321|NCT02835807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33719322|NCT05130619|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33719323|NCT04375137|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33719324|NCT03867604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800734|NCT05212675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102694|NCT02905591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102695|NCT03172559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data manager uploading the data into a database and the statistician analyzing the data will be blinded to the allocation.|Explanatory, multicenter, open label, 2-arm parallel group superiority randomized trial with stratification by center and blood group, random permuted blocks (lengths of 4 or 6) and balanced allocation (1:1).|f|f|f|t
33719325|NCT06188936|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"The study consists of three work packages. Work package 1 is a questionnaire to be completed by clinicians and scientists. This concludes their involvement.~Work package 2 is a survey for patients from which work package 3 participants are recruited - they are able to opt to take part in the subsequent work package at the end of the survey."||||
33800735|NCT01629316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102696|NCT05766280|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Assessors will not be providing the intervention|Randomized Controlled Trial|f|f|f|t
34102697|NCT06494761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102698|NCT04775524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102699|NCT03672981|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102700|NCT05965167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102701|NCT04572243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800736|NCT00541268|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800737|NCT03062813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800738|NCT00338572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944367|NCT03172026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||We plan a parallel group, randomized controlled pilot trial at 3 sites, UCLA, Yale and Burke Neurological Institute in White Plains, NY, to gather enough entries in a shorter time and to better generalize the results of this phase II/III pilot trial.|t|t|t|t
33944368|NCT02490111|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944369|NCT01306682|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944370|NCT01159665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944371|NCT05541380|||COHORT||PROSPECTIVE|||||||
33944372|NCT06432582|||COHORT||PROSPECTIVE|||||||
33944373|NCT03471494|||COHORT||PROSPECTIVE|||||||
33944374|NCT04762420|||COHORT||PROSPECTIVE|||||||
33944375|NCT06099860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944376|NCT02207127|||COHORT||PROSPECTIVE|||||||
34023936|NCT06628947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double masked study. As there is a colour difference between KIO-301 and placebo, IMP administration will be performed by an unmasked dose administrator. The dose administrator will not discuss treatment administered with any other study staff, participants, or sponsor representatives, and will not conduct any other study activities or participant assessments.|"Cohort design:~Cohort 1A:~• RP who have NLP will be randomised (2:1) to receive 50 μg KIO-301 or placebo~Cohort 1B:~• RP who have LP or ULV will be randomised (2:1) to receive 50 μg KIO-301 or placebo~Cohort 2A:~• RP who have NLP will be randomised (2:1) to receive 100 μg KIO-301 or placebo~Cohort 2B:~• RP who have LP or ULV will be randomised (2:1) to receive 100 μg KIO-301 or placebo~Cohort 3A:~• RP who have NLP will be randomised (2:1) to receive 25 μg KIO-301 or placebo~Cohort 3B:~• RP who have LP or ULV will be randomised (2:1) to receive 25 μg KIO-301 or placebo"|t|t|t|t
34023937|NCT01814553||PARALLEL||TREATMENT||NONE||||||
34023938|NCT03628625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized|t|t|t|t
34023939|NCT02449096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023940|NCT03558386|||CASE_CONTROL||PROSPECTIVE|||||||
34023941|NCT05645159|NA|SINGLE_GROUP||OTHER||NONE||Students of physiotherapy of the University of Valencia||||
34023942|NCT01103830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023943|NCT00186095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023944|NCT04576923|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|This is an open label study in that all participants will receive the same study procedures.|All participants will undergo quantitative ultrasound with Liver Incytes by a certified technician.||||
34023945|NCT02356432|||COHORT||PROSPECTIVE|||||||
34023946|NCT04956432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||To evaluate the efficacy and safety of SHR4640 monotherapy tablets in patients with gout|t|f|t|f
34023947|NCT04380090|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34023948|NCT05923463|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34023949|NCT01602718|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34023950|NCT00753857|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34023951|NCT00678886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023952|NCT06552052|||COHORT||PROSPECTIVE|||||||
34023953|NCT00492024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023954|NCT06358235|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34023955|NCT00469144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023956|NCT06226012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||assignment|t|f|f|f
34023957|NCT04610372|RANDOMIZED|PARALLEL||TREATMENT||NONE||There is one standard arm (5500/20) and 3 alternative arms. The alternative arms are center (or investigator) specific. Thus, each randomization is 2-way, but with a 3:1 weighting so that the 4 treatment arms have equal numbers of patients.||||
34023958|NCT02762461|||COHORT||PROSPECTIVE|||||||
34025546|NCT00176423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025547|NCT04163510|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One group of 10 sets of parents and their children will participate. The study design will use pre-intervention and post-intervention measures.||||
34025548|NCT01982448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025549|NCT05333731|||COHORT||PROSPECTIVE|||||||
34102702|NCT03976726|||CASE_CONTROL||PROSPECTIVE|||||||
34102703|NCT03408808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the treatment received.|Randomised controlled trial with two arms. Control - Aspiration alone. Intervention - aspiration plus injection of platelet righ plasma.|f|f|f|t
33800739|NCT01072006|||CASE_CONTROL||PROSPECTIVE|||||||
33800740|NCT04728724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800741|NCT06550245|||CASE_ONLY||CROSS_SECTIONAL|||||||
33800742|NCT04649021|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33800743|NCT03688360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800744|NCT03390075|||CASE_ONLY||CROSS_SECTIONAL|||||||
34025550|NCT05547620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025551|NCT04315571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944377|NCT04148976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The DP and placebo were packed in identical form and appearance. The treatment was provided in sealed boxes to the participants by an individual external to the study, but who performed the randomization. Furthermore, the researcher and the volunteer were unaware of the allocation of treatment.|"This study had two stages. In the first stage, subjects underwent dietary standardization with low saturated fat dietary treatments (LSFD) designed according to NCEP, ATP III criteria, and that provided the same amount of energy as that of the habitual diet of the volunteers, as assessed by 24-hour dietary recalls.~In the second stage, subjects were randomly allocated to two different treatments, 1) LSFD plus placebo or, 2) LSFD plus dietary portfolio. Subjects were instructed to consume two packets of the corresponding treatment a day dissolved in 250-300 ml of water before breakfast and dinner for two consecutive months."|t|f|t|f
33944378|NCT04089423|||COHORT||PROSPECTIVE|||||||
33944379|NCT06313567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944380|NCT04186754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33800745|NCT02372253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800746|NCT06322212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be assigned a number to be used instead of their names with double-blind randomization until visits are complete and data is analyzed.|Compare BBB function, cognition, and mood in T2DM adults with and without Thiamine treatment.|t|f|f|f
33944381|NCT00816543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944382|NCT05346731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944383|NCT05396196|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33944384|NCT06306417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944385|NCT02809963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944386|NCT01941472|NA|SINGLE_GROUP||SCREENING||NONE||||||
33944387|NCT05948800|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants will be divided into two groups using the binary coin-toss method (random.org) with similar physical and demographic characteristics. The first group will use an isotonic seawater solution as a nasal spray for 10 days, while the control group will not use such a solution. The group with the isotonic seawater solution applied as a nasal spray will use it at least three times a day, and necessarily before exercise (about 20 minutes before).||||
33944388|NCT02033486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944389|NCT02766699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944390|NCT01815996|||CASE_CONTROL||PROSPECTIVE|||||||
33944391|NCT00516945|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944392|NCT02361307|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33944393|NCT00250601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944394|NCT03658031|RANDOMIZED|PARALLEL||TREATMENT||NONE||After completing baseline measurements, subjects will be randomized to receive in a double blind fashion dapaglfilozin (10 mg/day) or placebo. The drug will be administered each morning before breakfast.||||
33944395|NCT02978339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025552|NCT04733261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025553|NCT01438996|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025554|NCT01420471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800747|NCT04135885|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33800748|NCT05891366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34025555|NCT06249815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025556|NCT02366429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025557|NCT03587116|NA|SINGLE_GROUP||OTHER||NONE||The data obtained from this lead-in study will serve as the control group for the subsequent Phase 3 gene therapy study.||||
34025558|NCT00788944|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34025559|NCT03007992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025560|NCT00976417|||||PROSPECTIVE|||||||
34025561|NCT06484478|||COHORT||CROSS_SECTIONAL|||||||
34025562|NCT06574360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025563|NCT00422500|||COHORT||PROSPECTIVE|||||||
34025564|NCT02031718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025565|NCT01125371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34102704|NCT03402581|||CASE_CONTROL||PROSPECTIVE|||||||
34102705|NCT06541301|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, randomized, multicenter, open-label, non-inferiority clinical trial||||
33800749|NCT00566735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800750|NCT05555719|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 treatment groups, both have class II malocclusion||||
33944396|NCT03703609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Analyst blinded|The study is a single-blind parallel two-arm randomized controlled study with 1:1 distribution to intervention and control group. In total 300 persons with long-term conditions will be recruited from three hospitals and randomized to an intervention of medical yoga at home (tele-yoga) using a live videoconference link and a yoga-app on the participants tablet for 12 weeks or a control group receiving individual advice of physical activity. Data will be collected at baseline measurement, after 3 and 6 months.|f|t|t|t
33944397|NCT05460728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944398|NCT00204568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944399|NCT04614142|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34023959|NCT06353568|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* 1 physician-researcher who will conduct all initial evaluations and follow-up examinations (excluding Doppler ultrasound, Ankle-Brachial Index - ABI, and Toe-Brachial Index - TBI), without knowledge of the subjects' allocation, and will administer the Informed Consent Form (ICF).~* 1 Vascular surgeon researcher who will perform Doppler ultrasound, Ankle-Brachial Index (ABI), and Toe-Brachial Index (TBI) measurements during the initial assessment and follow-up examinations, without knowledge of the subjects' allocation.~* 1 Nurse researcher who will retrieve the allocation envelope and provide the appropriate PBM equipment (active or placebo), as well as provide recommendations for its use at home.~* 1 Researcher, who will not participate in any assessments, will prepare randomization and envelopes to ensure allocation confidentiality.~* 2 physician residents who will provide daily contact for device usage control, guidance, addressing inquiries, etc."|"The PBM Group will use a boot with 1344 LEDs once daily for 6 minutes, over 60 days, and will receive therapeutic education.~The Control Group will use a non-therapeutic LED boot (placebo) for 6 minutes once daily for 60 days and will also receive therapeutic education.~Participants will be assessed at the beginning of the study (baseline) and after 30 days (clinical examination) and 60 days (clinical examination, assessment of Peripheral neuropathy, assessment of peripheral artery disease, blood and urine tests, and quality of life evaluation)."|t|f|t|t
34023960|NCT03278392|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34023961|NCT04808336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719326|NCT04137003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects are randomised to one of the two groups: Rouge et or program or Chu protocol. The assessor that perform the multiple assessments is blinded to the randomisation.|Experimental research with pre-post repeated measures with a control group. It is a randomised control trial with a blinded assessor|f|f|f|t
33719327|NCT05283057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719328|NCT00541476|||||PROSPECTIVE|||||||
33719329|NCT01132157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719330|NCT04565431|||CASE_CONTROL||PROSPECTIVE|||||||
34023962|NCT03557879|||FAMILY_BASED||RETROSPECTIVE|||||||
33719331|NCT02781051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023963|NCT04603235|NA|SINGLE_GROUP||TREATMENT||NONE|The participants identities are masked for researchers|||||
34023964|NCT02897583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023965|NCT06163924|||COHORT||PROSPECTIVE|||||||
34023966|NCT04135326|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34023967|NCT05949710|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data analyzer (PI) will be blinded but the participants and intervener will not be.|Particiapnts will be divided into two groups: normal weight group and overweight/obese group.|f|f|f|t
34023968|NCT06227572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023969|NCT04232280|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Observer-Blind||t|f|t|f
34023970|NCT05403255|||COHORT||PROSPECTIVE|||||||
34023971|NCT03573778|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled trial comparing active treatment to usual care||||
34023972|NCT01796418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34023973|NCT04319016|||COHORT||OTHER|||||||
34023974|NCT05733221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once the subjects are identified the research coordinator will conduct a screening of the patient to ensure they meet the inclusion/ exclusion criteria for the study and then randomize the patient into either normal standard of care for surgical repair of the fractured mandible or normal standard of care for surgical repair of the fractured mandible aided by a 3D printed model of the patient's jaw.|The investigators propose a parallel design randomized control trial to study the value of 3D printing for preoperative planning in patients with a fracture of the mandible who require open reduction, internal fixation. The study will be split into two arms: 1) Patients that will have a 3D model generated for the surgical procedure 2) The control group who will follow normal standards of care as outlined above and won't have the additional 3D model created pre-operatively.|t|f|f|f
34023975|NCT02212379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34023976|NCT06200324|||COHORT||RETROSPECTIVE|||||||
34102706|NCT05673902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102707|NCT05299957|||COHORT||PROSPECTIVE|||||||
34102708|NCT04365569|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102709|NCT04330339|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34102710|NCT06480890|||COHORT||OTHER|||||||
34102711|NCT03626662|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The subjects and the investigative site staff, except for the unblinded pharmacist, will be blinded to treatment assignment.||t|t|t|f
34102712|NCT06687200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102713|NCT04097860|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Individuals monitoring breast milk production and sodium levels will be blinded||f|f|f|t
34102714|NCT06224153|||COHORT||PROSPECTIVE|||||||
34102715|NCT06695533|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The workbook will be designed with the help of 5 focus group discussions. Five focus groups will include participants from one of the following categories: patients, caregivers, providers, and diabetes educators. Each focus group will have 6-10 participants.||||
34102716|NCT01260831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102717|NCT00666978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102718|NCT04551053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind||t|f|t|t
34102719|NCT05522400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34102720|NCT05360888|RANDOMIZED|PARALLEL||PREVENTION||NONE||Half of the participants will be randomly assigned to Tools for Life, and the other half will receive Tools for Life plus a Motivational Interviewing Social Network intervention (MISN) and two booster sessions approximately 2 and 6 weeks post-intervention.||||
34102721|NCT02633527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102722|NCT04613089|||OTHER||OTHER|||||||
34102723|NCT00189878|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34102724|NCT00092742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102725|NCT06465290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial with the study group and control group|f|f|f|t
34102726|NCT00667043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102727|NCT06680648|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||one arm is oxygen insufflation first followed by no-insufflation the second arm is: no insufflation followed by oxygen insufflation|f|f|f|t
34102728|NCT01272258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102729|NCT02571543|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34102730|NCT04604366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|lottery method will be used .one hundred and twenty slips will be made .60 will be marked as group A and 60 will be as Group B. these will be put in basket .and will be picked by the team member||t|f|f|f
34102731|NCT04515810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34102732|NCT00339365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34102733|NCT05672615|||COHORT||PROSPECTIVE|||||||
34102734|NCT06521593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients were in the operation room and werent aware of||t|f|f|f
34102735|NCT02636335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102736|NCT04990310|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719332|NCT00617045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719333|NCT01164956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||The N-of-1 design randomized participants to 3 potential treatment pairs; Each pair incorporated the 2 drugs under investigation but with different sequence: Methylphenidate then Placebo or Placebo then Methylphenidate. With this design, there are 8 potential permutations/arms.|t|t|t|t
33719334|NCT00622960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34023977|NCT05899491|RANDOMIZED|CROSSOVER||TREATMENT||NONE|A Randomized Sham Control Trial|A Randomized Sham Control Trial||||
34023978|NCT05144490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34102737|NCT05411120|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34102738|NCT04514276|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34102739|NCT01026428|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34102740|NCT02893605|||CASE_CONTROL||RETROSPECTIVE|||||||
34102741|NCT05513105|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34102742|NCT03196089|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34102743|NCT06500871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34102744|NCT04136288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800751|NCT02627469|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800752|NCT00854191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33800753|NCT03427021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800754|NCT00459602|||||PROSPECTIVE|||||||
33800755|NCT03969524|||OTHER||PROSPECTIVE|||||||
33800756|NCT01061034|NA|SINGLE_GROUP||||NONE||||||
33800757|NCT00620997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33800758|NCT03850613|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The recruited subjects (n=30) will be assigned to the intervention group and use the newly developed app for 8 weeks.||||
33800759|NCT01812096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800760|NCT00374192|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33800761|NCT01969981|||COHORT||PROSPECTIVE|||||||
33800762|NCT01636687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800763|NCT02713906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800764|NCT05032261|||COHORT||RETROSPECTIVE|||||||
33800765|NCT03457948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800766|NCT04223388|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel study|t|t|t|t
33800767|NCT01840826|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33800768|NCT04775654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and the individuals providing informed consent are masked.||t|f|f|t
33800769|NCT05541341|||COHORT||OTHER|||||||
33800770|NCT00392054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800771|NCT03778242|RANDOMIZED|PARALLEL||PREVENTION||NONE|open label Randomized Clinical Tria|open label Randomized Clinical Tria||||
33800772|NCT03675256|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The study is blinded. The pharmacists, unblinded data manager, and unblinded statistician are the only ones who will know treatment assignment.|At the start of our study, young women will be randomly sorted into three arms. In arm 1, the women will receive the bivalent HPV vaccine. In arm 2, the women will receive the nonavalent HPV vaccine. And in arm 3, the women will receive a meningococcal vaccine. At the crossover vaccine timepoint, those in arms 1 and 2 will receive the meningococcal vaccine, while those in arm 3 will receive either the bivalent or nonavalent HPV vaccine. The three arm study structure makes it possible to compare the women who received an HPV vaccine to those who did not receive an HPV vaccine during the study.|t|t|t|t
33800773|NCT06176482|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33800774|NCT06394284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800775|NCT01142375|||COHORT||PROSPECTIVE|||||||
33800776|NCT04108923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800777|NCT04775056|||COHORT||PROSPECTIVE|||||||
33800778|NCT03205436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800779|NCT00158782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800780|NCT05155917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800781|NCT02929147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800782|NCT05390749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800783|NCT05035446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840399|NCT00756457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840400|NCT02073240|||OTHER||PROSPECTIVE|||||||
33840401|NCT01353118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840402|NCT00136877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840403|NCT03478449|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33840404|NCT02308397|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33840405|NCT04441944|||COHORT||RETROSPECTIVE|||||||
33840406|NCT03556800|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33840407|NCT01613482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840408|NCT01342198|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33944400|NCT04469309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944401|NCT01766024|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33944402|NCT04411316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944403|NCT00106860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944404|NCT06177145|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||double-blind randomised controlled pretest-posttest experimental research||||
33944405|NCT01277458|||COHORT||RETROSPECTIVE|||||||
33944406|NCT00433979|||||PROSPECTIVE|||||||
33840409|NCT00376077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840410|NCT03147703|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33840411|NCT02950610|||COHORT||PROSPECTIVE|||||||
33840412|NCT01626508|||COHORT||PROSPECTIVE|||||||
33840413|NCT03221166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840414|NCT05113108|||COHORT||PROSPECTIVE|||||||
33840415|NCT03787342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider and investigator cannot be blinded as they are involved in the surgical procedure so blinding is not feasible.|Three Groups of intervention compared to one group of comparator. Each group contains 10 patients.|t|f|f|t
33840416|NCT04524377|NA|SINGLE_GROUP||TREATMENT||NONE|The Radiologist who evaluated X-rays ist masked regarding timepoint of investigation|Deep Brain Stimulation (DBS) of the Nucelus subthalamicus (STN) in patients with Parkinson's Disease (PD).||||
33840417|NCT03293524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840418|NCT00974194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840419|NCT05917652|||OTHER||PROSPECTIVE|||||||
33719335|NCT04220450|||COHORT||CROSS_SECTIONAL|||||||
33719336|NCT04144556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719337|NCT00006337||||TREATMENT||||||||
33719338|NCT00094627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719339|NCT00805311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719340|NCT03280290|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33719341|NCT05266755|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter clinical trial. Adult patients who consult the Hospital Emergency Department (ED) of the Hospital de la Santa Creu i Sant Pau (HSCSP) for an FxF PSM as a primary or secondary diagnosis will be selected and will be randomized with a 1:1 distribution to be included in the FLS -CTSPau (intervention group) or to receive usual care (control group). The result of the intervention will be evaluated in terms of health outcomes (re-consultations, hospital readmissions and quality of life).||||
33719342|NCT04648345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomized, single-blinded, controlled clinical trial|t|f|t|t
33719343|NCT04961554|||OTHER||PROSPECTIVE|||||||
33719344|NCT03472404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719345|NCT02608749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719346|NCT05298332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719347|NCT03103386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719348|NCT02305108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719349|NCT05381467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719350|NCT06203847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant: adult patients with OHCA Outcomes Assessor: in-hospital care providers (physicians, nurses...etc)|a pragmatic randomized clinical trial|t|f|f|t
33719351|NCT05882799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded.|Randomized Trial|f|f|f|t
33719352|NCT05003154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719353|NCT01219920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719354|NCT00473642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719355|NCT02913547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719356|NCT00757744|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33719357|NCT02155140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719358|NCT00237601|||COHORT||PROSPECTIVE|||||||
33719359|NCT06313931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719360|NCT01983852|||COHORT||RETROSPECTIVE|||||||
33719361|NCT01488357|||COHORT||PROSPECTIVE|||||||
33719362|NCT06176573|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33719363|NCT03874520|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The operators at the medical helpline 1813 will triage children meeting the inclusion criteria using video every other day they are at work, and over telephone the other days. Consequently, the operators are always the same, and the only difference between the two groups of patients will be if video triage or telephone triage is performed.||||
33719364|NCT06092489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719365|NCT05289414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple blind study (participant ,investigator and outcome assessor) will be masked and will not konw what is the type of treatment patients receive|two groups of patients diagnosed with cervicogenic headache Will be randomly subjected to either RF or greater occipital nerve block|t|f|t|t
33719366|NCT00562939|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33719367|NCT06386133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Boost group: Use of MSCopilot Boost and wear of an actimeter during the whole study participation duration.~Control group: Standard practice and wear of an actimeter during the whole study participation duration."||||
34023979|NCT03900897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label, non-randomized, repeated-measures design with two study arms as follows. Prospective: interventional study arm with prospective enrollment and treatment through one year of implant use. Retrospective: observational study arm with retrospective protocol for systematic chart review of patients with at least one year of implant use.||||
34023980|NCT04177784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were told they would be participating in a study that aims to determine the effectiveness of online education in dietitians. They were unaware that determining the effect of the videos on weight bias was the objective of the study.||t|f|f|f
34023981|NCT05801952|RANDOMIZED|PARALLEL||TREATMENT||NONE||The 4-day physiotherapy program consists of performing bronchial drainage using one of the three devices (Aerobika\* OPEP, PARI O-PEP, PARI PEP® S System). Frequency: twice a day. Physiotherapy session consist of breathing through the device for 15 breaths in one cycle, and taking a few (3-5) relaxed exhalations in accordance with the forced exhalation technique (FET). This cycle is repeated at least three times. The maximum number of cycles is five considering the need. Duration: 10 - 20 min.||||
34023982|NCT05942625|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34023983|NCT01006135|||||PROSPECTIVE|||||||
34023984|NCT02293863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34023985|NCT04365218|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|This study is blinded for subjects, Investigator and site staff, and Contract Research Organization staff with regard to treatment (MEDI8367 or placebo) at each dose level. The Sponsor will be unblinded to treatment allocation.||t|f|t|t
34023986|NCT00855179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34023987|NCT06027385|NA|SINGLE_GROUP||SCREENING||NONE||All newborns whose parents have agreed to participate in the pilot project will be tested for three mutations in the CTNS gene and a homozygous deletion of exon 7 in the SMN1-gene.||||
34023988|NCT03335215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34023989|NCT02481362|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34023990|NCT03578666|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34023991|NCT02707445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34023992|NCT00482586|||CASE_CONTROL||RETROSPECTIVE|||||||
34023993|NCT02161315|||CASE_CONTROL||PROSPECTIVE|||||||
34023994|NCT01275430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34023995|NCT06341829|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34023996|NCT00513279|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34023997|NCT05384171|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomized to an assessment only condition or to the full MBTA intervention (assessment, feedback and resource recommendations)||||
33719368|NCT02320149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800784|NCT04918758|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomised to Purastat or treatment as usual (sucralfate enemas) using block sizes of 4 or 6, with block size itself determined at random. Randomisation will be stratified by Hospital~Post-Market Phase"||||
33719369|NCT01526616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719370|NCT05245747|||COHORT||PROSPECTIVE|||||||
33719371|NCT06267950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33719372|NCT04291391|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||4-parallel arm study||||
33719373|NCT06093009|||COHORT||CROSS_SECTIONAL|||||||
33719374|NCT00589914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719375|NCT02746874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719376|NCT00656344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719377|NCT04138420|||COHORT||PROSPECTIVE|||||||
33719378|NCT03705507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group P will enrol all patients under 18 years of age and Group A will enrol all patients who are 18 years or older.||||
33719379|NCT00265954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944407|NCT05654740|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||We will compare outcomes for a 12-month period where all patients are offered Virtual Reality experiences regularly to outcomes for a 12-month period with no availability of Virtual Reality experiences in one specified closed psychiatric ward.||||
33944408|NCT02624713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This research is an open clinical study with two branches: a retrospective follow up and a prospective follow up||||
33944409|NCT01791543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944410|NCT05604482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719380|NCT01251549|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33719381|NCT01879501|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33719382|NCT00202644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719383|NCT05059067|||COHORT||PROSPECTIVE|||||||
33719384|NCT03945396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|A randomized, placebo-controlled, double-blind, parallel, superiority trial with 3 month study duration.|t|t|t|f
33800785|NCT00308698|||DEFINED_POPULATION||PROSPECTIVE|||||||
33800786|NCT00832325|||COHORT||PROSPECTIVE|||||||
33800787|NCT01981304|||||PROSPECTIVE|||||||
33800788|NCT04728568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944411|NCT03193281|NA|SINGLE_GROUP||TREATMENT||NONE||"A Phase II, multicentre, open-label, prospective non-randomised study of treatment modification in response to maintenance of MR3.0 at 12 months.~Molecular response will be measured 3 monthly. Patients who achieve MR3.0 by 12 months, with a confirmed response at 13 months on treatment, will switch treatment to imatinib. Those patients who do not achieve this confirmed response will remain on dasatinib.~For patients who achieve confirmed MR3.0 by 13 months we define two study stages. Stage 1 is the first 12 months after recruitment (i.e. before the possible switch to imatinib) and Stage 2 includes the months 13 - 37."||||
33944412|NCT05666466|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33944413|NCT00715780|||COHORT||PROSPECTIVE|||||||
33944414|NCT03950271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944415|NCT02048501|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944416|NCT01639846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944417|NCT03752502|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33944418|NCT01618929|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33944419|NCT00208858|RANDOMIZED|PARALLEL||||DOUBLE||||||
33944420|NCT01287403|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33944421|NCT05089773|||CASE_ONLY||RETROSPECTIVE|||||||
34023998|NCT06089434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719385|NCT04782089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719386|NCT00004323||||TREATMENT||||||||
33719387|NCT06380842|||COHORT||PROSPECTIVE|||||||
33719388|NCT03010254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719389|NCT03178773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719390|NCT00231595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719391|NCT04923087|||CASE_ONLY||PROSPECTIVE|||||||
33719392|NCT04493281|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33719393|NCT03480750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719394|NCT03635957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719395|NCT04476433|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944422|NCT03378882|||COHORT||PROSPECTIVE|||||||
33944423|NCT04241705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944424|NCT05162495|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The participant's breath sample is taken by blowing preferably three times into a disposable TeraTube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis of its bio-chemical spectral signature. This will take place once during the study.||||
33944425|NCT02039687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944426|NCT05130736|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944427|NCT00918489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944428|NCT06419023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33944429|NCT05981560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944430|NCT04692285|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33944431|NCT03077646|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944432|NCT03518307|||OTHER||RETROSPECTIVE|||||||
33944433|NCT01384513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944434|NCT04406324|||COHORT||PROSPECTIVE|||||||
33944435|NCT03778281|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patient privacy needs to be protected||t|f|f|f
33944436|NCT04198376|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be assigned into two treatment groups Group A (Test Group) comprises of patient undergoing The Laterally Closed Tunnel Technique with SCTG and Group B(Control Group) comprises of patients undergoing Modified Coronally Advanced Tunnel Technique with SCTG||||
33944437|NCT00988910|||COHORT||PROSPECTIVE|||||||
33944438|NCT00759551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944439|NCT02592980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34023999|NCT01806766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102745|NCT05109195|||COHORT||PROSPECTIVE|||||||
34102746|NCT06311331|||CASE_ONLY||PROSPECTIVE|||||||
34102747|NCT03374332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102748|NCT02504775|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34102749|NCT00752362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102750|NCT06258304|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102751|NCT03266653|NA|SINGLE_GROUP||TREATMENT||NONE||All patients given identical treatment with CTLs for refractory EBV.||||
34102752|NCT04840875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102753|NCT04260607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple masked study (patient, healthcare provider, outcomes assessor) performed by pharmacy investigators not involved in study recruitment or assessment.|Experimental versus Placebo|t|t|t|t
34102754|NCT02677051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102755|NCT03258554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102756|NCT06695637|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34102757|NCT06688994|||COHORT||PROSPECTIVE|||||||
34102758|NCT06688968|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Multicenter observational pilot study||||
34102759|NCT05298046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34102760|NCT06419660|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102761|NCT06695702|||OTHER||CROSS_SECTIONAL|||||||
34102762|NCT01883973|||COHORT||PROSPECTIVE|||||||
34102763|NCT05513508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102764|NCT06162312|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34102765|NCT05964868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, surgeons, and research team will be blinded to the group that the subject was randomized to. The pharmacy will prepare equivalent drugs for each study group to visually appear similar so that blinding can be maintained. In the event if the patient experiences a concerning or an adverse reaction, the patient, the surgeons and the research team will be immediately unblinded from the study. If unblinding is required, the pharmacy will be notified and then will provide, from the randomization list, information as to which study group the patient was assigned.|This will be a randomized controlled, single-blinded study.|t|t|t|f
33719396|NCT03218007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719397|NCT00913042|||CASE_ONLY||PROSPECTIVE|||||||
33719398|NCT01486628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33719399|NCT03493009|RANDOMIZED|PARALLEL||SCREENING||NONE|No blinding is applicable in this study .|"Randomization in blocks will be applied for each site to allocate patients to one of two different bowel preparation regimens (Prep A- split doae of 10mg of Magnesium citrate versus Prep B- split doae of 15mg of Magnesium citrate). The study will utilize randomization in blocks using the standard envelope procedure, which will be applied in order to allocate patients into two arms:~* Group 1 - Will go through the Prep A procedure~* Group 2 - Will go through the Prep B procedure The site randomization plan will be provided to the study coordinator prior the study start."||||
33719400|NCT02150096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33719401|NCT01811173|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719402|NCT01067014|||CASE_ONLY||PROSPECTIVE|||||||
33719403|NCT04834427|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental group : Control group=2:1||||
33719404|NCT06067386|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33719405|NCT04934345|||COHORT||PROSPECTIVE|||||||
33719406|NCT04062838|NA|SINGLE_GROUP||TREATMENT||NONE|evaluating radiologist will all be blinded to the dates of the scans.|The aim of this trial is to study the effects of injected glucose on injured or degenerative rotator cuff tears of the shoulder. Glucose is not recognised by the FDA for this purpose but is used in 2 main concentrations: 50% solution to treat hypoglycemia and 5% solution for fluid replacement.||||
33800789|NCT04802369|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The 185 women over 40 years of age hospitalized for arterial hypertension in the Department of Cardiology will be included in the study, including: the study group who demonstrated maximal oxygen consumption measured during incremental exercise indexed per kilogram - VO2max\<17 ml/kg/min and a second group who presented VO2max\>17 ml/min/kg.||||
33800790|NCT05319626|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33800791|NCT02869334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800792|NCT03768752|||COHORT||PROSPECTIVE|||||||
33800793|NCT00065832|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800794|NCT01890811|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33944440|NCT02174952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944441|NCT02887508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944442|NCT03324282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944443|NCT00275834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102766|NCT06439771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102767|NCT00658814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102768|NCT05497960|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102769|NCT04491955|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102770|NCT03004144|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34102771|NCT05800002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34102772|NCT06695975|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The intervention group will participate in te 'Occupational self-analysis' program while the control group will have free time.|t|f|f|f
33800795|NCT05287217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Adult patients will be screened and consented. Group assignment will be determined on an alternating basis. After FESS surgery patients will be given post-operative pain management instructions according to group assignment. Group 1 will take 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 consecutive days after surgery regardless of whether they experience pain or not. Group 2 will take the 650mg of acetaminophen every 6 hours and 600mg of ibuprofen every 8 hours for 10 days after surgery only when needed to control pain. Patients in both groups will record post-operative pain medications for 10 consecutive days after surgery and their level of pain once per day. The patients' post-op follow-up visit will occur 10-14 days after surgery. Medications prescribed for this study are standard of care following FESS surgery. The instructed use of the medications following surgery are being done strictly for comparative and research purposes.||||
33800796|NCT03111160|RANDOMIZED|PARALLEL||TREATMENT||NONE||Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.||||
33800797|NCT01849978|RANDOMIZED|PARALLEL||TREATMENT||||||||
33800798|NCT00493350|||CASE_ONLY||PROSPECTIVE|||||||
33800799|NCT02088424|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800800|NCT04218890|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800801|NCT01675999|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800802|NCT05874830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient and the endoscopists are blinded when the FMT/plasebo is given|Double blinded plasebo controlled study with two treatment cohorts and one plasebo cohort|t|t|t|f
33800803|NCT00925587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800804|NCT05456698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800805|NCT01136876|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33800806|NCT06342154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized study with experimental and control group||||
33800807|NCT05239650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800808|NCT04896034|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The experimental group (real device) and the control 1 group ( fake device) will be in double-blind, neither the investigator nor the patient will know the allocated group.|"Single-center, adaptive, prospective, three-arm randomized, controlled, double-blind study for 2 arms.~3 groups will be constituted, according to a 1:3:3 ratio:~* 1 group  control 1  with 2 sessions of PBM ( fake device).~* 1 experimental group with 2 sessions of PBM (real device)~* 1 group  control 2  with standard pain management (i.e. medication)."|t|f|t|f
33800809|NCT00840177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800810|NCT01049503|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33800811|NCT00543816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800812|NCT00708188|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33800813|NCT01118858|||CASE_CONTROL||PROSPECTIVE|||||||
33800814|NCT00529789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800815|NCT05182385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024000|NCT03583047|||COHORT||PROSPECTIVE|||||||
34024001|NCT04913948|||COHORT||PROSPECTIVE|||||||
34024002|NCT05023837|||COHORT||RETROSPECTIVE|||||||
34024003|NCT03906578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024004|NCT03781401|||COHORT||CROSS_SECTIONAL|||||||
34024005|NCT05162014|||COHORT||RETROSPECTIVE|||||||
34024006|NCT04594317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will be blinded to the study hypothesis as to which intervention is expected to be better.|randomized parallel clinical trial|t|f|f|f
34024007|NCT00642278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024008|NCT00835965|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34024009|NCT03337243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024010|NCT00790335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024011|NCT05462171|||COHORT||CROSS_SECTIONAL|||||||
34024012|NCT00991419|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024013|NCT03357835|||CASE_CONTROL||PROSPECTIVE|||||||
34024014|NCT05478512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800816|NCT03059212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Real rTMS, sham rTMS|t|f|f|t
33800817|NCT05210569|||COHORT||PROSPECTIVE|||||||
33800818|NCT06160557|||COHORT||PROSPECTIVE|||||||
33800819|NCT00004387|RANDOMIZED|||TREATMENT||DOUBLE||||||
33800820|NCT00048217|RANDOMIZED|||TREATMENT||NONE||||||
33800821|NCT03608787|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||We will: (a) identify ten pairs of matched college/university communities for a total of 20 communities; (b) recruit a minimum of 12 on-premises serving establishments in each community for participation in the project; (c) conduct 3 Pseudo-Intoxicated Mystery Shop (P-I/MS) baseline inspections in all participating outlets in all 20 communities to observe pre-intervention over-service conduct; (d) randomly assign one community from each pair to receive S-STOP immediately (Cohort 1) and the other (Cohort 2) to serve as a control group and then to receive S-STOP later; (e) implement S-STOP in Cohort 1 communities for 3 months and conduct P-I MS in Cohort 2 control communities with no feedback to the licensees or community; (f) at the end of the 3 months, end S-STOP in Cohort 1 communities, but continue unreported P-I/MS and begin S-STOP in Cohort 2 communities for 3 months.|t|f|f|f
33800822|NCT05694442|NA|SINGLE_GROUP||OTHER||NONE||||||
33800823|NCT02477605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33800824|NCT00580918|||COHORT||PROSPECTIVE|||||||
33800825|NCT03080324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800826|NCT04083664|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800827|NCT01356069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33800828|NCT00621634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800829|NCT02191098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800830|NCT02134951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800831|NCT04134611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800832|NCT01402531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800833|NCT04085874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800834|NCT02437006|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33800835|NCT05520658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800836|NCT00431834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800837|NCT04592575|||CASE_CONTROL||PROSPECTIVE|||||||
33800838|NCT02639975|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33800839|NCT01881386|||COHORT||PROSPECTIVE|||||||
33800840|NCT01348217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800841|NCT05877469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800842|NCT03606915|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33800843|NCT00788034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800844|NCT03930225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|the outcome will be assessed by a different personnel than the investigator conducting the sessions of the intervention. The outcomes assessor will be blinded to which arm each participant belongs.|Randomized Controlled Study|f|f|f|t
33800845|NCT02361229|||COHORT||PROSPECTIVE|||||||
33800846|NCT01902147|||CASE_ONLY||PROSPECTIVE|||||||
33800847|NCT03815136|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The patients were instructed not to tell the endoscopist or the investigators about whether or not they used chewing gum before, during, or after the SBCE procedure.|Patients aged 16-80 years who were scheduled to undergo the small bowel capsule endoscopy(SBCE).|f|f|t|t
33800848|NCT03591159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33800849|NCT01571804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800850|NCT02151370|||COHORT||PROSPECTIVE|||||||
33800851|NCT04611932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800852|NCT00140790|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800853|NCT01164098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944444|NCT00218439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33800854|NCT06518369|||COHORT||PROSPECTIVE|||||||
33800855|NCT02578836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800856|NCT02582736|||COHORT||RETROSPECTIVE|||||||
33800857|NCT05097417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944445|NCT03511222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944446|NCT02384096|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33944447|NCT03031613|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33944448|NCT02554721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944449|NCT00974727|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944450|NCT04060758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944451|NCT04064047|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33944452|NCT05455060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944453|NCT03647098|||COHORT||PROSPECTIVE|||||||
33944454|NCT02308839|||COHORT||PROSPECTIVE|||||||
33944455|NCT00481533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33944456|NCT05874895|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in this study.|The study subjects will be randomized in two study arms.||||
33944457|NCT01270139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944458|NCT01787019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944459|NCT05627999|||CASE_ONLY||PROSPECTIVE|||||||
33944460|NCT04675437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944461|NCT03103724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944462|NCT01419223|||CASE_CONTROL||PROSPECTIVE|||||||
33944463|NCT02312934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944464|NCT06049511|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The dentist who evaluated oral mucositis did not know which group the patients belonged to.|randomized controlled group|f|t|f|t
33944465|NCT03051906|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
33944466|NCT05150392|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944467|NCT04772118|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33944468|NCT02956408|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944469|NCT02693405|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944470|NCT05663775|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33944471|NCT01283724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944472|NCT00519766|||COHORT||RETROSPECTIVE|||||||
33800858|NCT04149808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was never initiated and study was terminated.|Patients under age 18 presenting to Children's Hospital of Michigan burn center or burn clinic with partial thickness, second degree scald burns.The burn must be at least 1% total body surface area (TBSA) or greater. The burn is divided approximately in half, with 50% of the wound receiving xeroform dressing and the remaining 50% receiving Mepilex Ag. Patients must present within 48 hours of injury. Patients must have a signed consent form (and oral assent for patients ages 7-12 or written assent for patients 13 years of age or greater).|t|f|f|f
33800859|NCT04713735|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33800860|NCT05260359|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|Subjects will be blinded to the name of the investigational products|A 21-Day controlled study to evaluate the skin Irritation and sensitization potential of 6% Bemotrizinol (BEMT) in topical products with vehicle controls after repeated patch applications to healthy human participants by following conventional Repeated Insult (HRIPT) and Cumulative Irritation (CIT) methodologies.|t|f|f|f
33800861|NCT00639795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33800862|NCT02931214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800863|NCT00780949|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800864|NCT06051955|NA|SINGLE_GROUP||OTHER||NONE||This study will enroll participants who have experienced difficult or incomplete bowel cleansing in the past. All participants will use oral sodium sulfate as their cleansing agent.||||
33800865|NCT01037634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800866|NCT00522782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800867|NCT03352024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33800868|NCT06057116|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|f|f|t|f
33800869|NCT04644341|||CASE_ONLY||RETROSPECTIVE|||||||
33800870|NCT00106080|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33800871|NCT03072914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800872|NCT04652791|||COHORT||PROSPECTIVE|||||||
33800873|NCT05546307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800874|NCT04164459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800875|NCT00814905|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33800876|NCT02646358|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33800877|NCT01104675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800878|NCT02753738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33800879|NCT00133458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33800880|NCT00763152|||COHORT||PROSPECTIVE|||||||
33800881|NCT00873405|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024015|NCT05450601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024016|NCT04032236|NON_RANDOMIZED|PARALLEL||OTHER||NONE||case-control||||
34024017|NCT02151877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024018|NCT06608537|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024019|NCT05124392|||COHORT||PROSPECTIVE|||||||
34024020|NCT04996550|||COHORT||PROSPECTIVE|||||||
34024021|NCT04809051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34024022|NCT06633172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33800882|NCT01761201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800883|NCT00132964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800884|NCT05262543|||COHORT||PROSPECTIVE|||||||
33800885|NCT04739280|||COHORT||PROSPECTIVE|||||||
33800886|NCT00803387|||COHORT||PROSPECTIVE|||||||
33800887|NCT03339180|||COHORT||PROSPECTIVE|||||||
33800888|NCT06133049|||COHORT||RETROSPECTIVE|||||||
33800889|NCT01985334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800890|NCT02594735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800891|NCT03646136|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|PACU nurses and patients will not be aware of which arm patient was randomized to.||f|t|f|f
33800892|NCT05077618|||CASE_CONTROL||PROSPECTIVE|||||||
33800893|NCT04165967|NA|SINGLE_GROUP||TREATMENT||NONE||Tumor-infiltrating infiltrate will be expanded from resected melanoma samples from the patient and expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment.||||
33800894|NCT02799134|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33800895|NCT00317486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33800896|NCT05598866|||COHORT||PROSPECTIVE|||||||
34024023|NCT05258097|||OTHER||CROSS_SECTIONAL|||||||
34024024|NCT04308707|||OTHER||CROSS_SECTIONAL|||||||
34024025|NCT01005277|||CASE_ONLY||RETROSPECTIVE|||||||
34024026|NCT06213493|||CASE_CONTROL||RETROSPECTIVE|||||||
34024027|NCT04737096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024028|NCT00898612|||COHORT||PROSPECTIVE|||||||
33719407|NCT06031454|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33800897|NCT00972439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33800898|NCT01087255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024029|NCT06141967|NA|SINGLE_GROUP||SCREENING||NONE||||||
34024030|NCT02352818|||COHORT||PROSPECTIVE|||||||
34024031|NCT06422910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024032|NCT01181362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024033|NCT00401609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800899|NCT05618002|||CASE_CROSSOVER||PROSPECTIVE|||||||
34024034|NCT06598878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024035|NCT00127218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024036|NCT04820530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024037|NCT04241315|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800900|NCT05493449|NON_RANDOMIZED|FACTORIAL||OTHER||NONE|No masking is involved as participants, investigator and assessor know intervention types|There were three groups in study. Group A is the one which received UHT Milk, Group B received Flavored Milk and Group C was a control group.||||
33800901|NCT02459015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800902|NCT04531592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In addition to the individuals listed above, Sponsor's representatives such as clinical research associates who will perform site monitoring, the pharmacovigilance medical monitor, and all staff at the research sites other than the pharmacist of record will be masked.|A phase 2, single-dose, multicenter, double-blind, randomized, placebo-controlled study|t|t|t|f
33800903|NCT04076631|||COHORT||PROSPECTIVE|||||||
33800904|NCT00081601|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800905|NCT01694446|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33800906|NCT00999167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800907|NCT03991754|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Phase III Clinical trial, multiple sites, controlled, randomized, double blind, parallel groups.|t|t|t|f
33800908|NCT04658693|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The project will take the form of a series of controlled single-subject feasibility and proof-of-concept studies with repeated measures. Subjects will act as their own concurrent controls with and without sensory stimulation, as well as their own longitudinal (historical) controls pre- and post-implementation of the Sensory Neuroprosthesis.||||
33800909|NCT00378222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800910|NCT01704300|||COHORT||RETROSPECTIVE|||||||
33800911|NCT00914589|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33800912|NCT01204359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33800913|NCT00858117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800914|NCT01824485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800915|NCT04626011|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34024038|NCT00054574||||TREATMENT||NONE||||||
34024039|NCT02662660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024040|NCT06262932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719408|NCT04415788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719409|NCT02143440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024041|NCT02115438|||COHORT||PROSPECTIVE|||||||
33719410|NCT04372667|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Community score card approach||||
34024042|NCT00120679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024043|NCT04181723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800916|NCT00220519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800917|NCT03447236|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800918|NCT02505321|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33800919|NCT00780351|||CASE_ONLY||PROSPECTIVE|||||||
33800920|NCT00476346|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33719411|NCT05486468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject and the examining doctor will be masked to the treatment the subject receives on day 1.|1 year, prospective, randomized, collaborative study.|t|t|f|f
33800921|NCT04313816|||OTHER||PROSPECTIVE|||||||
33800922|NCT01522794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800923|NCT01595334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800924|NCT04704258|NA|SINGLE_GROUP||OTHER||NONE||||||
33800925|NCT05508243|NA|SINGLE_GROUP||OTHER||NONE||||||
34024044|NCT05695131|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The outcomes assessor will be masked to group allocation (VR-delivered therapy + standard care, or traditional standard care alone). Participants will be asked by a research assistant not to reveal details of the group allocation prior to assessments.|Study 1: Single-Subject Experimental Design Studies will be Implemented (A-B Design) Study 2: Feasibility randomized controlled trial (control and intervention groups)|f|f|f|t
34024045|NCT05266339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024046|NCT05812443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024047|NCT03083080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025566|NCT04305353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34025567|NCT01811316|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34025568|NCT01243112|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34025569|NCT01044264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719412|NCT00110825|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33719413|NCT05057442|||CASE_ONLY||CROSS_SECTIONAL|||||||
33719414|NCT02248194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719415|NCT04492995|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33719416|NCT05894421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800926|NCT00895531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33800927|NCT01593319|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33800928|NCT02515305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800929|NCT03022812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800930|NCT00180505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800931|NCT05264844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only the statistician will be masked|Randomized controlled trial|f|f|f|t
33800932|NCT02176538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800933|NCT06495944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800934|NCT04955431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized cross-over design||||
33800935|NCT03500393|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be blind to study hypotheses, data collector will be blind to treatment assignment|Participants will be randomized to the remotely supervised exercise (REM) or the unsupervised exercise (UNSUP) arm upon completion of the baseline assessment battery.|t|f|f|t
34025570|NCT00516373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025571|NCT03239743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800936|NCT00040313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025572|NCT03777163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33944473|NCT03338608|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups. One group will have the vertical platysma incision and the other group will have the transverse incision.||||
33944474|NCT00052013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944475|NCT03290196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944476|NCT00575458|||COHORT||PROSPECTIVE|||||||
33944477|NCT01955642|||CASE_ONLY||PROSPECTIVE|||||||
33944478|NCT02874222|||COHORT||PROSPECTIVE|||||||
33944479|NCT02974452|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33944480|NCT05057000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944481|NCT00237146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944482|NCT05973565|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will be randomly (randomizer.org) assigned by a researcher blinded to the study either to start with the synchronous intervention or with the asynchronous remote video-based intervention. Two evaluators also blinded to the scope of the study will take all measurements before and after interventions. It will be not possible to blind participants as the delivery of the class will reveal their allocation|Volunteers will be asked to attend three conditions in a randomized order, separated by at least a week of washing out period. Levels of anxiety, kinematic, and DLPFC hemodynamic activity data will be collected before and after the two different interventions, while, on a third occasion, control data will be collected at the same time-points but without any intervention|f|t|f|t
33800937|NCT00006330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944483|NCT00125138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944484|NCT02978404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944485|NCT03193918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944486|NCT01883596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944487|NCT02789761|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944488|NCT05814744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|randomized|t|f|t|f
33944489|NCT02441517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944490|NCT02391649|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessors are blind to the group assignment and intervention undertaken and concealed to the participant list.|Repeated-measures, three-arm design (and in phase 1, two pilot 2-arm controlled trials with repeated-measures design; sample size 112 for the two pilot studies)|f|f|f|t
33944491|NCT05463146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944492|NCT02980211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944493|NCT03241134|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33944494|NCT02477215|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944495|NCT01189396|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33944496|NCT04449874|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944497|NCT05386368|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The patient would be randomized and blinded to either left perioral or right perioral RECELL application. The surgeon would also be blinded to which side received RECELL treatment or Placebo (saline spray).|The perioral area of the face will be treated with CO2 laser. Laser setting will be determined by the treating surgeon for each individual patient - . The patient would be randomized and blinded to either left perioral or right perioral RECELL application - The surgeon would also be blinded to which side received RECELL treatment or Placebo (saline spray)|t|t|f|t
33944498|NCT05519189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33944499|NCT04592822|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33944500|NCT03868085|||CASE_CONTROL||PROSPECTIVE|||||||
33944501|NCT06022627|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||66 individuals with COPD included by randomization were divided into two groups as 33 (16 Stage I and 17 Stage II) study group and 33 (16 Stage I and 17 Stage II) control group.||||
33944502|NCT04279041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944503|NCT00656136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944504|NCT05529524|||OTHER||PROSPECTIVE|||||||
33944505|NCT01824732|||||PROSPECTIVE|||||||
33944506|NCT01640353|||COHORT||PROSPECTIVE|||||||
33944507|NCT00013780|||NATURAL_HISTORY||OTHER|||||||
33944508|NCT00211133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944509|NCT03811899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm study to determine whether HG EOC are 18F-DCFPyL-avid.||||
33944510|NCT03527875|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800938|NCT06394375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomized into two groups for control (opioid balanced anesthesia) or intervention (opioid free anesthesia)|t|f|f|f
33800939|NCT01823133|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800940|NCT00843687|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33800941|NCT01967836|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33800942|NCT01796067|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33800943|NCT06522958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33944511|NCT01003691|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33944512|NCT02164591|||CASE_ONLY||PROSPECTIVE|||||||
33944513|NCT05645939|||COHORT||OTHER|||||||
33944514|NCT02451137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944515|NCT02319798|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944516|NCT04235959|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33944517|NCT04993183|NA|SINGLE_GROUP||OTHER||NONE||All recruited participants will receive the intervention.||||
33944518|NCT04040725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025573|NCT04986384|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102773|NCT03615430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34102774|NCT06248086|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102775|NCT04333862|||COHORT||PROSPECTIVE|||||||
34102776|NCT05706376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102777|NCT06690099|||COHORT||PROSPECTIVE|||||||
34102778|NCT05726630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102779|NCT06690619|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Statistical analysis was masked|N/A. Full detail provided in Study Description|t|t|t|t
34102780|NCT06266403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"PALS and age-matched adults will participate in one solo speech production task (clear speech) and three interactive tasks (structured communicative interaction, unstructured communicative interaction, and clear speech structured communicative interaction) in which they work with an unfamiliar, naive interlocutor. This study is designed to examine the differences in speech produced in the four tasks. Comparisons of speech produced by PALS and age-matched adults will clarify whether differences in speech observed across the four tasks are a function of the speech difficulties experiences by PALS.~Plans for Assignment - This is a single group study in which all participants will engage in the same tasks."||||
34102781|NCT02554838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102782|NCT01504542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800944|NCT01047241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800945|NCT02534064|RANDOMIZED|PARALLEL||||NONE||||||
33800946|NCT00774124|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33800947|NCT01850836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33800948|NCT06409117|RANDOMIZED|PARALLEL||TREATMENT||NONE||"3rd generation resorbable magnesium scaffolds Freesolve will be compared to the biodegradable polymer drug eluting stents Orsiro in patients with NSTE/ACS"||||
33800949|NCT04334746|||COHORT||CROSS_SECTIONAL|||||||
33800950|NCT00581854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800951|NCT05169372|||COHORT||RETROSPECTIVE|||||||
33800952|NCT03608995|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33800953|NCT06169254|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33800954|NCT00479635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800955|NCT03419013|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800956|NCT04620902|||CASE_CONTROL||PROSPECTIVE|||||||
33800957|NCT02234778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800958|NCT01203813|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33800959|NCT04927520|||COHORT||PROSPECTIVE|||||||
33800960|NCT01369004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800961|NCT05481242|||COHORT||RETROSPECTIVE|||||||
33800962|NCT00094822|||COHORT||PROSPECTIVE|||||||
34102783|NCT02292160|||COHORT||PROSPECTIVE|||||||
34102784|NCT05144997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800963|NCT03772015|||CASE_CONTROL||PROSPECTIVE|||||||
34102785|NCT06687629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102786|NCT06694714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Two volumes of local anesthetic will be injected into the nasal skin of each participant by a dermatologic surgeon (PI of the study, Dr. Kira Minkis, KM). Dr. Minkis will be unblinded to the laterality of the anesthetic volumes and will not be involved in further assessments.||t|f|t|t
34102787|NCT06196138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800964|NCT00681603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33800965|NCT02990117|||OTHER||CROSS_SECTIONAL|||||||
33800966|NCT01017146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800967|NCT02909413|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33800968|NCT05234853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800969|NCT03278587|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33800970|NCT00981643|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33800971|NCT05993078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800972|NCT01668940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A computerized randomization table will be prepared by a third party who is not otherwise involved in the study. After a participant has given consent to enrol in the study, the next participant number in sequence will be assigned and the appropriate corresponding sealed envelope will be opened by the study coordinator, determining which product (if any) the participant will receive. The boxes will be given unique codes depending on whether they contain Lillipops (4 flavours), Ginger Lillipops or Mr. Freeze freezies, and the different flavours will also be coded. Participants will be shown a list of the ingredients that are found in Lillipops and Mr. Freeze freezies to ensure that they do not have allergies or take medications that interact with any ingredient(s) that they may be asked to consume.|Four parallel groups: 1) Lillipops Group (4 flavours): 2) Ginger Lillipops Group; 3) Mr. Freeze Control Group; 4) Natural Course Group. The main comparison is Group 1 vs Group 3.|t|t|t|t
33800973|NCT00168649|RANDOMIZED|PARALLEL||||DOUBLE||||||
33800974|NCT04438343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33800975|NCT04404166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800976|NCT02238483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33800977|NCT02218060|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33800978|NCT03097770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944519|NCT02078674|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33944520|NCT03223025|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102788|NCT06163807|||COHORT||PROSPECTIVE|||||||
34102789|NCT01505426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102790|NCT04873856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34102791|NCT05226078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34102792|NCT02317042|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34102793|NCT05736913|RANDOMIZED|PARALLEL||PREVENTION||NONE||prospective, open-labelled, randomized trial||||
33944521|NCT04246073|||CASE_ONLY||PROSPECTIVE|||||||
33944522|NCT03552172|||COHORT||RETROSPECTIVE|||||||
33944523|NCT05960006|||CASE_ONLY||PROSPECTIVE|||||||
34102794|NCT06002594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two groups were randomly selected and received two different treatments||||
33800979|NCT06416267|||COHORT||PROSPECTIVE|||||||
33800980|NCT06134258|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||randomized, open label, cross-over, monocentric trial in healthy volunteers||||
33944524|NCT02043704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33944525|NCT00044811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33944526|NCT05405738|||COHORT||CROSS_SECTIONAL|||||||
33944527|NCT01365182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A biobehavioral interveniton was tested|f|f|f|t
33944528|NCT01377194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33944529|NCT04189198|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34024048|NCT03480386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization will be stratified by whether the participant has poor lung function (forced expiratory volume \[FEV1\] \<50% predicted) and whether the participant has severe dyspnea (recorded modified Medical Research Council Dyspnea Scale \[mMRC\] score, 3-4; scale, 0-4); critical factors that can make the study arms unbalanced regarding risk factors.||||
34024049|NCT03990597|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024050|NCT01987479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102795|NCT05589714|||COHORT||CROSS_SECTIONAL|||||||
34102796|NCT03581292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944530|NCT04250246|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, non-comparative, phase II study designed according to a two stages optimal design by Simon||||
33944531|NCT00876291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944532|NCT04809142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944533|NCT01866891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944534|NCT04833634|||CASE_ONLY||RETROSPECTIVE|||||||
33944535|NCT00641017|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33944536|NCT06107348|||CASE_ONLY||RETROSPECTIVE|||||||
33944537|NCT05162599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a cross-sectional diagnostic study with collection of information from the gold standard (or reference tests) and the new device||||
33944538|NCT03270540|||CASE_ONLY||PROSPECTIVE|||||||
33944539|NCT03604016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944540|NCT02094131|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33944541|NCT01234662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944542|NCT02632097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944543|NCT02254616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024051|NCT02358135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024052|NCT00662623|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024053|NCT04395014|||COHORT||PROSPECTIVE|||||||
34024054|NCT00018408|||||RETROSPECTIVE|||||||
34024055|NCT04928092|||COHORT||PROSPECTIVE|||||||
34024056|NCT02128061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024057|NCT05773248|||CASE_CONTROL||PROSPECTIVE|||||||
34024058|NCT02051361|||||PROSPECTIVE|||||||
33944544|NCT05025306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were not aware of the intervention used|randomized controlled trial with simple random sampling technique|t|f|f|f
33944545|NCT01354834|||COHORT||PROSPECTIVE|||||||
33944546|NCT02847364|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34025574|NCT02937389|||COHORT||PROSPECTIVE|||||||
34025575|NCT00626392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33800981|NCT05670834|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33800982|NCT04665440|RANDOMIZED|CROSSOVER||OTHER||NONE||prospective randomised crossover study||||
33800983|NCT04223258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33800984|NCT01316731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800985|NCT02710851|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33800986|NCT01309932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025576|NCT06551363|||COHORT||PROSPECTIVE|||||||
34025577|NCT00206323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944547|NCT01693991|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34102797|NCT04007549|RANDOMIZED|PARALLEL||OTHER||NONE||Screening, Brief Intervention and Referral to Treatment (SBIRT)||||
33944548|NCT03429569|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|||||
33944549|NCT04640792|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33944550|NCT04901702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944551|NCT04501991|||COHORT||RETROSPECTIVE|||||||
34102798|NCT01923974|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34102799|NCT01872754|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34102800|NCT04156100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102801|NCT03497117|NA|SINGLE_GROUP||OTHER||NONE||Participants undergoing treatment for a pulmonary exacerbation will perform multiple breath washout and undergo an MRI with inhalation of a gas contrast agent (79% perfluoropropane (PFP) mixed with 21% oxygen) at the beginning and end of treatment.||||
34102802|NCT00141193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102803|NCT02661815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102804|NCT05672537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102805|NCT02624232|||COHORT||PROSPECTIVE|||||||
34102806|NCT02729012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102807|NCT02262221|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34102808|NCT01539525|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants received a behavioral intervention that could not be masked. Outcome data were self report and urine tests rom the participants.|||||
34102809|NCT06563752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944552|NCT00081900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719417|NCT02645214|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33719418|NCT00888251|||COHORT||RETROSPECTIVE|||||||
33719419|NCT03522857|||COHORT||CROSS_SECTIONAL|||||||
33944553|NCT03190304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind, randomized clinical trial|t|t|t|t
33944554|NCT01821001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944555|NCT04800406|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Ten completely edentulous patients aged from 50-60 years||||
33944556|NCT02769988|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33944557|NCT03017131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102810|NCT04957927|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||Randomized control trial|t|f|f|f
34102811|NCT06608277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and outcomes assessor will be blinded to the study group received.|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial|t|f|f|t
34102812|NCT00178659|||COHORT||PROSPECTIVE|||||||
34102813|NCT03706612|||COHORT||PROSPECTIVE|||||||
34102814|NCT00725231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719420|NCT01686633|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33719421|NCT04528654|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are unblinded. Participants will know if they were assigned to the intervention or control group|Participants will be randomized using a web-based blocked randomization list and a 1:1 allocation ratio to one of two possible groups, an intervention group or an educational control group.|t|f|f|f
33719422|NCT01864447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719423|NCT05017506|||OTHER||PROSPECTIVE|||||||
33719424|NCT04660448|||OTHER||PROSPECTIVE|||||||
33719425|NCT05687422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33944558|NCT06380049|||OTHER||CROSS_SECTIONAL|||||||
34102815|NCT02399527|||COHORT||PROSPECTIVE|||||||
34102816|NCT05609786|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102817|NCT02084186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719426|NCT03703128|||CASE_CONTROL||RETROSPECTIVE|||||||
33719427|NCT00653146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719428|NCT02839915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719429|NCT00643032|RANDOMIZED|||TREATMENT||||||||
33719430|NCT05770947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719431|NCT00422591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719432|NCT03474120|||COHORT||PROSPECTIVE|||||||
33944559|NCT03941652|||OTHER||PROSPECTIVE|||||||
33944560|NCT04570124|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33944561|NCT04791462|||CASE_ONLY||PROSPECTIVE|||||||
33944562|NCT03143465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double Blind||t|t|t|t
33944563|NCT01096758|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33944564|NCT04508517|||COHORT||OTHER|||||||
33944565|NCT04545645|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33944566|NCT00002624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944567|NCT05000034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944568|NCT02395445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944569|NCT02119559|NA|SINGLE_GROUP||||NONE||||||
33944570|NCT05370300|||CASE_CONTROL||PROSPECTIVE|||||||
34102818|NCT03319654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center, university setting, no commercial affiliation||||
34102819|NCT06143072|||CASE_ONLY||OTHER|||||||
33944571|NCT03808194|RANDOMIZED|PARALLEL||OTHER||TRIPLE||HIV-positive men who meet the study eligibility criteria will be randomized to one of two study arms: 1) Optimized ART linkage package, or 2) Optimized ART linkage package + conditional lottery incentive.|t|t|t|f
33719433|NCT04659967|NA|SINGLE_GROUP||OTHER||NONE||Staff will be invited to participate in an experiential virtual sensitivity training. A pre/post quasi-experimental design will be undertaken. Staff will be asked to complete a pre-training questionnaire as well as follow-up questionnaires immediately after the training and one month, three months, and six months post training to measure knowledge gained and to probe for behavior change related to the communication strategies taught during the training. Some participants who complete questionnaires will be contacted and invited to participate in a research interview about their communication experiences at PACE. The training session will last for up to 1 hour. All questionnaires are expected to take approximately 15 minutes each. Interviews will take 1-hour.||||
33719434|NCT01408914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33719435|NCT05036031|||COHORT||RETROSPECTIVE|||||||
33719436|NCT06120556|||COHORT||RETROSPECTIVE|||||||
33719437|NCT05913180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded||t|t|f|f
33719438|NCT00108667||||TREATMENT||||||||
33719439|NCT06380088|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33719440|NCT00492115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33719441|NCT05603689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33944572|NCT04946916|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Four groups of participants will be recruited: participant with psychiatric condition without cognitive impairment, participants with psychiatric condition with cognitive impairment, participants with biological Alzheimer's disease, and participant with fronto-temporal dementia||||
33944573|NCT04247802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33944574|NCT01134458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024059|NCT05986253|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||A two arm, acute, randomised, double blind, placebo controlled, crossover design feeding study will be used to establish the impact of co-ingestion of BioDulse (a protein hydrolysate from Irish seaweed) with maltodextrin on postprandial blood glucose and insulin concentrations.|t|f|f|f
34024060|NCT01110135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024061|NCT04340596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719442|NCT02192866|||CASE_CONTROL||OTHER|||||||
33719443|NCT01082965|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33719444|NCT04573907|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33719445|NCT03240796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719446|NCT05483179|||COHORT||RETROSPECTIVE|||||||
33719447|NCT00366145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719448|NCT05819554|||CASE_CONTROL||PROSPECTIVE|||||||
33719449|NCT00159640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719450|NCT04489576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, investigator and the outcome assessor will be blinded as regards the outcome measures evaluation|Keratin hair application|t|f|t|t
33719451|NCT00119002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719452|NCT01822873|||OTHER||PROSPECTIVE|||||||
34024062|NCT05102812|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34024063|NCT00362544|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34024064|NCT06028321|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Part 2 was single - blind study (subject blinded). Masking was not triple for all parts of the study or all arms.|"Part 1: part - blinded, part randomized, partial cross- over study. Group 1: double - blinded and randomized to two treatment sequences in a two period cross- over.~Group 2: open label, non-randomized and in parallel with Group 1. Part 2: single-blind (subject blinded), randomized, parallel-group."|t|f|t|t
33719453|NCT00064376||||TREATMENT||NONE||||||
33719454|NCT05725954|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719455|NCT03902535|||COHORT||PROSPECTIVE|||||||
33719456|NCT01203046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719457|NCT00773292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719458|NCT02766062|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33719459|NCT00023543|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719460|NCT01657045|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33719461|NCT02755324|NA|SINGLE_GROUP||OTHER||NONE||||||
33719462|NCT03437720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719463|NCT00083681|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34102820|NCT01890538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33800987|NCT02831361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719464|NCT01942187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719465|NCT03206645|NA|SINGLE_GROUP||TREATMENT||NONE||This trial will utilize a traditional 3+ 3 design with dose escalation.||||
33719466|NCT04945785|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33719467|NCT00115856|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719468|NCT01460420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719469|NCT06242314|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719470|NCT02892760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719471|NCT05580315|||COHORT||PROSPECTIVE|||||||
33719472|NCT05891509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Other design features: The investigators will conduct a multicenter randomized controlled trial, as well as a concurrent prospective observational study including all ICH patients who decline participation in the trial and will therefore receive minimally invasive hematoma evacuation or best medical therapy and consent to be followed up. All participants will be followed up at the same time using the same outcomes measures. The primary outcome will be collected by a blinded assessor.|f|f|f|t
33719473|NCT01738763|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719474|NCT00439426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719475|NCT02345811|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33719476|NCT05735392|NA|SINGLE_GROUP||OTHER||NONE||||||
33719477|NCT05479955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33719478|NCT00588848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33719479|NCT04983069|||COHORT||RETROSPECTIVE|||||||
33719480|NCT02335723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719481|NCT03296657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||subject will brush twice a day for 2 weeks with stannous fluoride paste for at least 1 minute||||
33719482|NCT01917201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719483|NCT06005844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719484|NCT01806753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719485|NCT04474067|||CASE_CONTROL||PROSPECTIVE|||||||
33800988|NCT03218306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024065|NCT00294775|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34024066|NCT06344013|||COHORT||CROSS_SECTIONAL|||||||
34024067|NCT00244478|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024068|NCT03548831|||CASE_ONLY||PROSPECTIVE|||||||
34024069|NCT03103139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024070|NCT06633510|||CASE_CONTROL||PROSPECTIVE|||||||
34024071|NCT01177475|NON_RANDOMIZED|PARALLEL||||NONE||||||
34024072|NCT03243058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization will be performed by the Coordinating Center at the University of Miami. The participants will not be informed regarding the intervention assignment until the end of the study. The investigators and clinic personnel will also be masked as to study assignment. Laboratories performing assays for this protocol will be masked as to the identity and group assignment of biological materials to be studied.|ILT-101 (aldesleukin; Interleukin-2, IL-2), 0.5 million IU (body surface area \<2 m2) or 1 million IU (body surface area \>2 m2), or placebo, will be given for 5 consecutive days (days 1-5), and then on day 15 and every 15 days thereafter, for one year; at the one-year endpoint, approximately half the subjects on ILT-101 will continue therapy and the other half will switch to placebo for 1 more year.|t|t|t|f
34024073|NCT03902730|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Investigators will randomize treatments for all participants.|Participants will complete all four trials in a crossover design. A one week washout period is required between treatments.|t|f|f|f
34024074|NCT02837614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024075|NCT06260124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33944575|NCT03803956|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The mode of intervention (active or placebo photobiomodulation) will be coded by an independent researcher. The randomization schedule will contain only codes (not the actual intervention). The output from the laser device is exactly the same from either the active or the placebo interventions. These features will guarantee that participants, therapists and outcomes assessor will be blinded to the treatment arms.|The volunteers who will receive active PBMT in the first stage of the study, will receive placebo PBMT in the second stage, while the volunteers that will receive placebo PBMT in the first stage, will receive active PBMT in the second stage of the study.|t|f|t|t
33944576|NCT01769846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102821|NCT02844075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102822|NCT06389682|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102823|NCT02390999|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34102824|NCT05681936|||COHORT||PROSPECTIVE|||||||
33800989|NCT05369507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At time of randomization, participant is informed of study group assignment and provided instructions on use of app. Care provider is aware of group assignment as the provider is also using the platform to communicate with participants during course of treatment.||f|f|t|f
33800990|NCT05231317|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single-blind|Cross-over single-blinded|t|f|f|f
33800991|NCT01510717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33800992|NCT05715398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800993|NCT04968366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33800994|NCT02818335|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33800995|NCT01595802|||CASE_CONTROL||PROSPECTIVE|||||||
33944577|NCT02285699|NA|SINGLE_GROUP||OTHER||NONE||||||
33944578|NCT05821998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944579|NCT01616173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33944580|NCT03549546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944581|NCT05322694|||CASE_ONLY||PROSPECTIVE|||||||
33944582|NCT03809702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blinded randomized controlled trial|t|f|f|t
34102825|NCT04629157|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Paired testing||||
34102826|NCT04710563|||COHORT||PROSPECTIVE|||||||
34102827|NCT06681974|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34102828|NCT05218980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102829|NCT03191734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102830|NCT06691815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The order in which the tests will be performed will be randomized at the time the patients are included in the study.~1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Lu"||||
34102831|NCT03102528|||COHORT||RETROSPECTIVE|||||||
34102832|NCT04308590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102833|NCT05591287|||COHORT||PROSPECTIVE|||||||
34102834|NCT06374459|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The Phase I portion of the study is sequential and patients will not be randomized and the Phase II portion is parallel and patients will be randomized.||||
34102835|NCT05101161|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33800996|NCT01871324|NA|SINGLE_GROUP||OTHER||NONE||||||
33944583|NCT00963040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944584|NCT03698032|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33944585|NCT04944121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944586|NCT06446297|||OTHER||PROSPECTIVE|||||||
33944587|NCT05011240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study will be single-blinded with the researchers conducting and coding the outcome measures unaware of the intervention/control status of the study participants.||f|f|f|t
33944588|NCT05677841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719486|NCT01044940|||COHORT||PROSPECTIVE|||||||
33719487|NCT05247645|||COHORT||OTHER|||||||
33719488|NCT04853979|RANDOMIZED|PARALLEL||TREATMENT||NONE|Prone position cannot be masked to any member in the trial|||||
33944589|NCT04090294|NA|SINGLE_GROUP||TREATMENT||NONE||35 patients will receive roflumilast for three months and improvement regarding performance , frequency of exacerbation and pulmonary function test will be assessed.||||
33944590|NCT05093660|||COHORT||PROSPECTIVE|||||||
33944591|NCT00280059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33944592|NCT04790214|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients with stable CHF in stage II or III of the New York Heart Association.||||
33944593|NCT05368766|||COHORT||PROSPECTIVE|||||||
34024076|NCT03760185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single arm study in which all enrolled subjects will receive eye drops to only one eye. The alternative eye will serve as the control for efficacy.||||
34024077|NCT06156826|||COHORT||CROSS_SECTIONAL|||||||
34024078|NCT04475835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024079|NCT02529215|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34024080|NCT05209152|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024081|NCT03276078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024082|NCT04637932|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Group 1 was determined as endotracheal tube and group 2 as pro-seal laryngeal mask group.|t|t|t|t
34024083|NCT03679182|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024084|NCT00335114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34024085|NCT01594710|||COHORT||PROSPECTIVE|||||||
33719489|NCT03053414|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of four treatment arms for the duration of the study. Labs will be checked every 3 months as part of standard of care to help delineate the best strategy for repletion and maintenance of Vitamin D levels throughout the study.||||
33719490|NCT00879281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719491|NCT02673489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719492|NCT04850690|||CASE_ONLY||CROSS_SECTIONAL|||||||
33944594|NCT03547674|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order: To determine the order, the 4 conditions will be noted on a piece of paper and randomly picked from an envelope.|Prospective, cross-sectional within-subjects comparison||||
33944595|NCT04647708|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33944596|NCT03451058|||COHORT||CROSS_SECTIONAL|||||||
33944597|NCT03341338|||COHORT||PROSPECTIVE|||||||
34024086|NCT02227446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024087|NCT01812681|||COHORT||PROSPECTIVE|||||||
34024088|NCT05079581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intervention group will perform pelvi floor exercises at home, control group will take education session|t|f|f|t
34024089|NCT05314816|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024090|NCT01865942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024091|NCT06421077|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34024092|NCT05279300|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024093|NCT04095312|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"In a study involving relatively small groups of 10 to 50 people, the study showed a high success rate of more than 90% similar to the study of more than 100 large groups, and the stability was well proven.~total 33 patients (10 pancreaticobiliary tracts, 13 urinary tract areas, 10 colonic areas), the minimum number of clinical studies that can be statistically analyzed within the limits to meet the study objective of evaluating the accuracy of procedure"||||
34024094|NCT03192423|||COHORT||PROSPECTIVE|||||||
34024095|NCT04058067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024096|NCT04864314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024097|NCT01114100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024098|NCT06484842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024099|NCT00696501|||COHORT||PROSPECTIVE|||||||
34024100|NCT00400816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024101|NCT03149445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study.|t|t|t|t
34024102|NCT04990700|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Patients do not know which study group they are in. The researchers know which group the patients are in.|Clinical data of intervention group and control groups will be compared|t|f|f|f
34024103|NCT03340207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024104|NCT05091021|||COHORT||PROSPECTIVE|||||||
34024105|NCT01704794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024106|NCT05642845|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34024107|NCT03097848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024108|NCT02817945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024109|NCT05076240|||COHORT||RETROSPECTIVE|||||||
34024110|NCT04368689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024111|NCT06228599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102836|NCT01340534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33800997|NCT04432389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33800998|NCT00752713|||CASE_CONTROL||PROSPECTIVE|||||||
33800999|NCT03399669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801000|NCT00473252|||COHORT||PROSPECTIVE|||||||
33801001|NCT04307511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801002|NCT04290013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801003|NCT03658408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801004|NCT04593056|||COHORT||RETROSPECTIVE|||||||
33801005|NCT02773693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801006|NCT02954211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801007|NCT02101281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944598|NCT05737108|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Only investigators and outcomes assessors have knowledge on whether the samples given are tests or placebo.|Intervention with oral intakes of either test samples or placebo for 30 days, followed by a 20-day period of washout, and then crossover for another 30 days of either test samples or placebo.|t|t|f|f
33944599|NCT02861521|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33944600|NCT01867996|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944601|NCT04095611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon performing the operation will be aware which treatment the participant is receiving.||t|f|f|t
33944602|NCT01559142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944603|NCT03839446|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm||||
33944604|NCT03741257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34024112|NCT04197050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024113|NCT06124495|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33719493|NCT06521359|||CASE_CONTROL||RETROSPECTIVE|||||||
33719494|NCT00187811|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33719495|NCT05218473|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an interventional study without concurrent controls. We will compare the detection rate of paroxysmal atrial fibrillation in acute ischemic stroke patients without known atrial fibrillation, using 14-day continuous ECG patch monitoring, with a historical control group of patients who received serial 12-lead ECGs or 24-hour Holter monitoring.||||
33721109|NCT03287440|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|The principal investigator and outcome assessor will be masked to when the participant completes the intervention and to whether or not they received the Health Advocates adherence strategy.|"A step-wedge design will allow all participants to receive the intervention. Participants not immediately enrolled into the intervention will serve as controls. At the time of the intervention, these participants will move over to the treatment arm.~The first two groups will be used to refine the COPD Wellness intervention and identify social barriers specific to individuals living with COPD. Starting with group 3, we will alternate the addition of the Health Advocates (HA) program as an adherence strategy in order to determine the HA's effect on participation in COPD Wellness."|f|f|t|t
33721110|NCT04183920|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33801008|NCT02054923|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33801009|NCT02853565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801010|NCT02498717|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801011|NCT01725464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801012|NCT02502708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024114|NCT00089024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024115|NCT05517811|||CASE_CONTROL||PROSPECTIVE|||||||
34024116|NCT06584422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding interventionalists and participants is not possible, given the nature of the intervention. However, assessment staff will be blinded when possible.||f|f|f|t
34024117|NCT04680858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two-armed study||||
34024118|NCT03147755|||COHORT||PROSPECTIVE|||||||
34024119|NCT06128070|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33801013|NCT00593697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801014|NCT02553161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801015|NCT05600335|||COHORT||RETROSPECTIVE|||||||
33801016|NCT06430788|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33801017|NCT01981174|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34024120|NCT05546112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024121|NCT02257385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024122|NCT04104802|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024123|NCT02456935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024124|NCT00213447|||COHORT||PROSPECTIVE|||||||
34024125|NCT04199871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024126|NCT05169450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024127|NCT04784533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024128|NCT03587324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024129|NCT00896480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024130|NCT02132858|||CASE_ONLY||PROSPECTIVE|||||||
34024131|NCT03615859|||COHORT||CROSS_SECTIONAL|||||||
34024132|NCT03696238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34024133|NCT05405348|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||In this study, one group patients were observed two different times. First meeting(T0, patients took routine care which include fed state during the hemodialisis.Second meeting (T1) patients took intervention which include fasting state during the hemodialisis.||||
34024134|NCT03477903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024135|NCT04055038|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized phase II/III trial to assess the efficacy of platinum-based chemotherapy vs standard non-platinum therapy in patients with platinum-resistant recurrent ovarian cancer (ROC)||||
34024136|NCT00376038|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34024137|NCT01449448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024138|NCT04676659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|open to patient, medical cares, and investigators, but blind to outcome evaluators|Multicentre, prospective, randomization, open label, active and parallel control|f|f|f|t
33944605|NCT05469451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients participating in the clinical trial, the statistician, the students and the study operators who are going to measure Little's irregularity index will be blinded to the interventions, except the principal investigator.|50 randomized subjects, 25 per group, seen during the alignment phase with ages between 20 and 40 years, male or female, with all lower permanent teeth or at least 36 to 46, with Little's irregularity index 3mm to 6mm, without prior orthodontic treatment, periodontally stable, non-smokers and who voluntarily agreed to participate in the study by signing the informed consent.|t|t|f|t
33944606|NCT05551182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944607|NCT04769258|||CASE_CONTROL||PROSPECTIVE|||||||
33944608|NCT00039936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944609|NCT03824574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944610|NCT01540721|RANDOMIZED|CROSSOVER||||NONE||||||
33944611|NCT02418000|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33944612|NCT04046289|||COHORT||CROSS_SECTIONAL|||||||
33944613|NCT02347345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944614|NCT02190396|||CASE_CONTROL||PROSPECTIVE|||||||
33719496|NCT04092790|NA|SINGLE_GROUP||PREVENTION||NONE||Eligible subjects will be scored either as low-risk for sarcopenia-related adverse outcomes (\<4) or high risk (≥4) via the SARC-F scoring system, and will be evaluated for sarcopenia of the lower limbs using a B-mode portable ultrasound machine used for standard clinical practice at the Rambam Health Care Campus. A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations as outlined in the investigator brochure. On day 4, ultrasound of the lower limbs will be repeated for all subjects, with repeat imaging every subsequent second day for admissions extending beyond 4 days and a maximum of 10 days after the application of the VGD. The study will include all eligible patients in the internal department (internal medicine ward Het) who agree to participate in the study and provide written informed consent.||||
33719497|NCT02396901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719498|NCT05998200|NA|SINGLE_GROUP||OTHER||NONE||||||
33719499|NCT01529879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33719500|NCT01779739|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33719501|NCT00851812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33719502|NCT00772733|||||PROSPECTIVE|||||||
33801018|NCT00093015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719503|NCT03186833|||CASE_ONLY||PROSPECTIVE|||||||
33719504|NCT01757054|RANDOMIZED|PARALLEL||||NONE||||||
33719505|NCT04629053|||CASE_ONLY||PROSPECTIVE|||||||
33801019|NCT01022892|||CASE_CONTROL||PROSPECTIVE|||||||
33801020|NCT02730871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801021|NCT00004104|RANDOMIZED|||TREATMENT||||||||
33801022|NCT01891084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33801023|NCT00546754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801024|NCT05436119|||COHORT||PROSPECTIVE|||||||
33801025|NCT02522468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944615|NCT05896800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024139|NCT06172621|RANDOMIZED|PARALLEL||OTHER||SINGLE||After a run-in phase of 2-4 months to determine individualized stimulation parameters, participants will be randomized into Group A and Group B. Group A will undergo 2 weeks (6 sessions) of SCAP alone. Group B will undergo 2 weeks (6 sessions) of SCAP plus upper extremity task-oriented exercise.|f|f|f|t
34024140|NCT01246063|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024141|NCT04229173|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801026|NCT01232712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024142|NCT04293796|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801027|NCT03072316|||CASE_CONTROL||RETROSPECTIVE|||||||
34024143|NCT05645705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34024144|NCT05094856|||COHORT||CROSS_SECTIONAL|||||||
34024145|NCT02893501|||CASE_CROSSOVER||PROSPECTIVE|||||||
34024146|NCT02089035|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34024147|NCT04304040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024148|NCT04331574|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024149|NCT02704403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024150|NCT03597659|||COHORT||RETROSPECTIVE|||||||
34024151|NCT05470283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024152|NCT02176785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33801028|NCT05193695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801029|NCT00591708|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34024153|NCT02188173|||COHORT||PROSPECTIVE|||||||
34024154|NCT03448497|||COHORT||RETROSPECTIVE|||||||
34024155|NCT03303196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This will be an open-label, pilot clinical trial to assess efficacy and safety of the bihormonal bionic pancreas in children and young adults with HI who have developed post-pancreatectomy diabetes. Subjects will be studied during two research inpatient admissions at the CHOP HI Center. The order of the interventions will be randomized.||||
34024156|NCT05864963|||COHORT||RETROSPECTIVE|||||||
34024157|NCT00815360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024158|NCT05823324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801030|NCT01625234|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33801031|NCT03681522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33801032|NCT05517616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801033|NCT02378896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801034|NCT04192305|||COHORT||PROSPECTIVE|||||||
33801035|NCT00359658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801036|NCT06520332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944616|NCT01211795|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34024159|NCT04702308|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Cluster randomized controlled trial||||
34024160|NCT02782832|||COHORT||RETROSPECTIVE|||||||
34024161|NCT00277173|RANDOMIZED|PARALLEL||ECT||NONE||||||
34102837|NCT06687980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719506|NCT05039242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719507|NCT05554757|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33719508|NCT03899142|NA|SINGLE_GROUP||OTHER||NONE||||||
33719509|NCT00412854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719510|NCT05893433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient are masked through out the study and health care providers who provide routine care of the patient whether are nurses, physicians or existed physiotherapist are also masked||t|t|f|f
33719511|NCT00365573|||COHORT||PROSPECTIVE|||||||
33719512|NCT06207773|NA|SINGLE_GROUP||OTHER||NONE||||||
33719513|NCT00405587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719514|NCT01394679|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Patients receive Standard PET imaging with FDG then receive SPECT-CT imaging with investigational EC-DG imaging agent||||
33719515|NCT01900327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719516|NCT02062879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719517|NCT05411679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719518|NCT03485690|||COHORT||PROSPECTIVE|||||||
33801037|NCT04149002|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention Arm vs. Active Control Arm||||
33719519|NCT00827983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801038|NCT03157401|||OTHER||PROSPECTIVE|||||||
33944617|NCT05364203|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|The processing of the heart rate data will be carried out blind from the device used. Indeed, the investigator must not be aware of the device used during the session so as not to have an influence and draw hasty conclusions.|"Patients will be selected during the physical medicine and rehabilitation consultation of the MPR department. They will be given the protocol newsletter. After their agreement to participate in the study, the following data will then be collected: age, sex, pathology, date of the first botulinum toxin injection. Randomization can then take place. The injections will be performed in day hospitalization. During the 1st injection, no particular device will be used. The following injections will be performed with the mask off or with virtual reality will be the randomization scheme.~The stress before, during and after the 1st and the last injection will be measured at each session by collecting the frequency variability by a heart rate monitor or equivalent, in four stages, at rest, before the procedure, during the procedure and after the procedure), during the 1st and last injection at each session. Pain during injection will be assessed using a vertical visual analogue scale."|f|f|t|f
33944618|NCT06252831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Objectives of the study: Determine the safety and tolerability of the study medicine AS-Probionorm (powder 1 g in a sachet) in healthy study subjects.~The study included the following stages:~Stage 1 of the study (introductory stage) included recruitment and screening of healthy volunteers - study participants, signing of informed consent, medical examination and laboratory tests.~Stage 2 of the study (baseline control stage) included clinical measurements before the start of the study (baseline measurements) on each subject to obtain baseline data, which were then compared with the results after the end of the study.~Stage 3 of the study (the stage of dynamic observation of the treatment effect and safety monitoring after the study) included clinical observations in each subject daily during the use of the study medicine and a week after the last use (21 days in total)."||||
33944619|NCT02107781|||COHORT||PROSPECTIVE|||||||
33944620|NCT01251666|NA|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|f|t
33719520|NCT02175888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944621|NCT01579994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944622|NCT00630760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944623|NCT02938858|||CASE_CONTROL||PROSPECTIVE|||||||
33944624|NCT05129618|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Approximately 200 subjects with CIC who meet all eligibility criteria will be randomized in a 1:1 ratio, with equal numbers of each in each successive group of 50 subjects, to receive either MHS 1031 \[1 g (1.4 ml) per day\] or 1.4 ml of placebo (1:1) for 8 weeks (Product/Placebo Phase). Upon completion of the 8 week Product/Placebo Phase, Subjects will enter a 4 week open label Product Phase, during which all subjects will receive MHS 1031.|t|f|t|t
33719521|NCT01065233|||CASE_CONTROL||PROSPECTIVE|||||||
33719522|NCT01709851|||CASE_ONLY||PROSPECTIVE|||||||
33719523|NCT00532584|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33719524|NCT02297269|||COHORT||PROSPECTIVE|||||||
33719525|NCT04347239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719526|NCT01762631|||OTHER||PROSPECTIVE|||||||
33719527|NCT00151099|RANDOMIZED|PARALLEL||||NONE||||||
33719528|NCT03310554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding of endoscopists and patients is impossible.But the endoscopists are not involved in the assessment of outcomes. The outcomes assessments are performed by reviewing physicians blinded to the randomization process. The data manager and statistician are not blinded.||f|f|f|t
33944625|NCT01219959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944626|NCT05503043|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33944627|NCT02939508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944628|NCT01905241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944629|NCT05485194|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33944630|NCT05932420|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33719529|NCT05453344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719530|NCT03189758||SEQUENTIAL||TREATMENT||NONE||Observational control followed by dietary intervention||||
33719531|NCT03479099|||COHORT||PROSPECTIVE|||||||
33719532|NCT04946292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33719533|NCT04489329|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33801039|NCT02630823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801040|NCT03206515|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801041|NCT02628171|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
33801042|NCT02961569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801043|NCT01390818|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721111|NCT01978587|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801044|NCT05738707|||COHORT||PROSPECTIVE|||||||
33801045|NCT01808339|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33801046|NCT06445699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801047|NCT03538717|||COHORT||RETROSPECTIVE|||||||
33944631|NCT00938743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719534|NCT05077709|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants receive IO102-IO103 for three different indications.||||
33719535|NCT05063747|||CASE_CONTROL||RETROSPECTIVE|||||||
33719536|NCT06220422|||COHORT||RETROSPECTIVE|||||||
33719537|NCT00974909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719538|NCT03331679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719539|NCT06149507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719540|NCT02245074|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33719541|NCT02615587|||COHORT||RETROSPECTIVE|||||||
33719542|NCT04117425|NA|SINGLE_GROUP||OTHER||NONE||Protocol to determine the optimal dose of levetiracetam during pregnancy||||
33719543|NCT02046109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33719544|NCT03863990|||COHORT||RETROSPECTIVE|||||||
33719545|NCT00480272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719546|NCT05944341|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33719547|NCT00100126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33719548|NCT00003492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719549|NCT01665066|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33719550|NCT04597307|||COHORT||PROSPECTIVE|||||||
33719551|NCT03730493|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719552|NCT04669392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719553|NCT03465241|||COHORT||PROSPECTIVE|||||||
33719554|NCT05762601|||COHORT||PROSPECTIVE|||||||
33719555|NCT00791466|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33719556|NCT03933150|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"Type of randomization:~Patients were randomly divided into 2 treatment groups. For allotting, bunches bits of paper were set up in a similar number of patients. The name of treatment strategies was composed on the bits of paper. At that point, patients were made a request to take one paper and this is the treatment sort for every individual was determined."||||
33719557|NCT06107712|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33719558|NCT05025189|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be a two phase intervention study.||||
33719559|NCT02661542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719560|NCT02335099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719561|NCT02922608|||COHORT||PROSPECTIVE|||||||
33719562|NCT03021421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719563|NCT02404376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719564|NCT02165020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719565|NCT04202991|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33719566|NCT04506476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33719567|NCT04751344|RANDOMIZED|PARALLEL||OTHER||SINGLE|Data will be encrypted using BRMS||t|f|f|f
33719568|NCT01076946|||COHORT||PROSPECTIVE|||||||
33719569|NCT02958150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719570|NCT03781609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719571|NCT05864508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719572|NCT05780112|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33719573|NCT03228589|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Aspirin challenge model|t|t|t|t
33719574|NCT05851781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either lacosamide or propranolol from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrolment numbers starting from 1, which were mentioned on their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included lacosamide, and Drug B included propranolol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will assess The number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.|f|f|t|t
33721112|NCT01986855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721113|NCT01278485|||COHORT||RETROSPECTIVE|||||||
33721114|NCT02934906|||COHORT||PROSPECTIVE|||||||
33801048|NCT01404598|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944632|NCT04462731|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Non-surgical root canal treatment:~All teeth were isolated with a rubber dam during root canal treatment. The procedures were performed under a microscope (OPMI Pico; Carl Zeiss, Gottingen, Germany). After access, location of canals, and determination of working length (WL) with Root ZX II apex locator (J Morita, Kyoto, Japan), the canals were instrumented using various .04 taper rotary NiTi instruments to a minimum apical size of 35. 4% NaOCl was used as the main irrigant. 17% EDTA was used as the final irrigant. Passive ultrasonic irrigation with size 20 Acteon tip inserted 2mm short of WL was performed with both 4% NaOCl and 17% EDTA for 10 seconds in each canal. After final irrigation, the canals were dried with paper points. The master gutta-percha cone fit was verified with periapical radiographs before filling the tooth."|t|f|t|t
33944633|NCT03607968|||CASE_ONLY||RETROSPECTIVE|||||||
33944634|NCT00074399|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33944635|NCT04679064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944636|NCT03629405|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33944637|NCT04721626|||COHORT||PROSPECTIVE|||||||
33944638|NCT05768113|||COHORT||PROSPECTIVE|||||||
33944639|NCT06261658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944640|NCT05657379|NA|SINGLE_GROUP||OTHER||NONE||||||
33944641|NCT00148980|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33944642|NCT02569398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944643|NCT03162380|||COHORT||RETROSPECTIVE|||||||
34024162|NCT04953936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024163|NCT05159167|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34024164|NCT01371383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024165|NCT03994783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024166|NCT05258448|||COHORT||PROSPECTIVE|||||||
34024167|NCT00000116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this trial neither the participants, nor the clinicians, nor the investigators were aware of treatment group assignment.||t|t|t|t
34024168|NCT01225861|||COHORT||PROSPECTIVE|||||||
34024169|NCT01903135|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34024170|NCT04326621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024171|NCT01900951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024172|NCT03906552|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||randomized controlled trial|f|f|t|f
34024173|NCT00625053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024174|NCT03837002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized-controlled trail|t|f|f|f
34024175|NCT06259188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024176|NCT05228535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||2 groups. 1 group will be controlled, following standard NICU feeding protocol. 1 group will be intervention, receiving early introduction of human milk fortifier to enteral feeds.|t|t|t|t
34024177|NCT04338204|||COHORT||PROSPECTIVE|||||||
33719575|NCT03649711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"CKD participants will be randomly assigned into one of the 2 study groups: ticagrelor (90 mg) one pill in the morning and one pill in the evening, or, clopidogrel (75 mg) one pill in the morning + placebo one pill in the evening. Placebo looks like the study drug but has no medicine in it. Neither participant nor the study personnel will know about allocation. The study drugs will look the same, except aspirin pill which will be dispensed to everyone in an open label manner.~There is no masking for control with normal kidney function. Participants will be asked to take open label ticagrelor, 90 mg twice daily (one pill in the morning and one pill in the evening) and aspirin 81 mg/day."|"CKD participants will be double-blind randomized in these two arms:~Arm 1 - Ticagrelor, 90 mg twice daily (one pill in the morning and one pill in the evening) + Aspirin 81 mg/day. Ticagrelor is the test treatment.~Arm 2 - Clopidogrel, 75 mg/day in the morning and a matching placebo in the evening + Aspirin 81 mg/day. Clopidogrel is the reference treatment.~Arm 3: Control with normal kidney function will be recruited after matching for age and diabetes status to the Arm 1 participants. Participants will be asked to take Ticagrelor, 90 mg twice daily (one pill in the morning and one pill in the evening) and aspirin 81 mg/day. Open label treatment.~All participants are required to take the oral treatment for a total of two weeks."|t|f|t|t
33719576|NCT05820308|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomly assigned and masked to their group assignment||t|f|f|f
33719577|NCT01375907|NA|SINGLE_GROUP||||NONE||||||
33719578|NCT01111149|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33719579|NCT03430596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719580|NCT00455364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719581|NCT04110093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719582|NCT05461794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719583|NCT00831142|||CASE_ONLY||PROSPECTIVE|||||||
33719584|NCT05147493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719585|NCT03212612|||CASE_CONTROL||OTHER|||||||
33719586|NCT00221754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719587|NCT05969873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment.|The study will be randomized controlled trial used to evaluate the effectiveness of pilates on posture and balance in children with down's syndrome. Subjects with down's syndrome meeting the pre-detremined inclusion and exclusion criteria will be divided into two groups using non-probability sampling technique.|t|f|f|f
33719588|NCT03234192|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33719589|NCT01603459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719590|NCT02228551|NA|SINGLE_GROUP||SCREENING||NONE||||||
33719591|NCT02310945|||COHORT||PROSPECTIVE|||||||
33719592|NCT04840290|NA|SINGLE_GROUP||TREATMENT||NONE|this is a single-arm study, masking is not require.|Sintilimab Plus Paclitaxel (Albumin Bound) and Platinum Doublet Chemotherapy in Stage of IIIA NSCLC, as the Neoadjuvant treatment.||||
33719593|NCT01996709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33719594|NCT02913079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33719595|NCT01729754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719596|NCT05704608|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33719597|NCT00539409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719598|NCT04609501|||COHORT||PROSPECTIVE|||||||
33719599|NCT05710549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719600|NCT02461355|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33719601|NCT00227162|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33801049|NCT04748939|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blind for the identity of the drugs|double-blind randomized controlled trial|t|f|t|t
33801050|NCT03786042|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34024178|NCT05347212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024179|NCT03326713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be single blinded. Research team members who are assessing the outcomes will be blinded to study arm assignment. Research staff who are conducting follow-up interviews will be blinded to group assignment as much as possible. At the beginning of the follow-up interviews, the interviewer will request that the participant does not reveal the study arm they were assigned to.|3-arm Randomized Controlled Trial|f|f|t|t
34024180|NCT06397027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024181|NCT05938608|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label pharmacokinetic study in 20 healthy adult subjects. Subjects will be admitted in the hospital and will receive 3 regimens of primaquine and its metabolite. Every subject will have 1 screening and 3 admissions in the hospital.||||
34024182|NCT02445274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024183|NCT01173081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102838|NCT01470820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719602|NCT04436185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|In the study, a multi-stage randomization method was used as follows: 1) random selection of the family health centres in the city in which the research was conducted; 2) selection of the mothers and infants to be included in the study at each centre; and 3) selection of the groups to which the participants were assigned using a computer-based block randomization method (https://www.randomizer.org). The infants, randomized via a computer system, were assigned to the ShotBlocker® group (n= 35), ShotBlocker®-placebo group (n = 35), sucrose group (n = 35), sucrose-placebo group (n = 35), or the control group (n=35).|This study was designed as a randomized experimental study with placebo and control groups in order to compare the effects of ShotBlocker® and sucrose on pain reduction during vaccine injections.|t|t|t|t
33719603|NCT06399120|||CASE_ONLY||PROSPECTIVE|||||||
33719604|NCT00321282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944644|NCT02020681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025578|NCT04492592|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Participants were not told what arm of the intervention they were in (i.e., they were not told if they were receiving the intervention or not).||t|f|f|f
33719605|NCT00256373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33719606|NCT06540209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719607|NCT00695175|||COHORT||PROSPECTIVE|||||||
33719608|NCT00195676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719609|NCT04516590|||COHORT||PROSPECTIVE|||||||
33719610|NCT00535223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719611|NCT02602860|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33719612|NCT01981291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33719613|NCT04554329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719614|NCT03735433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719615|NCT04750720|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology)||||
33719616|NCT01518010|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719617|NCT02138760|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33719618|NCT00134251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719619|NCT05587920|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33719620|NCT04969120|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33719621|NCT03627754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33719622|NCT03287505|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33719623|NCT02723032|NA|SINGLE_GROUP||||NONE||||||
33719624|NCT05383768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719625|NCT03486795|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33719626|NCT02133027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719627|NCT01863225|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719628|NCT02808520|||COHORT||PROSPECTIVE|||||||
33719629|NCT02029950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719630|NCT01243879|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33719631|NCT02133287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719632|NCT00845169|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33719633|NCT06268093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719634|NCT06010940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719635|NCT00553150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719636|NCT04690088|||COHORT||PROSPECTIVE|||||||
33719637|NCT04890639|NA|SINGLE_GROUP||OTHER||NONE||||||
33719638|NCT04446377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
33719639|NCT02188589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944645|NCT05517031|||CASE_ONLY||CROSS_SECTIONAL|||||||
33944646|NCT03475173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944647|NCT05950399|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33944648|NCT03982069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33944649|NCT05744466|||COHORT||PROSPECTIVE|||||||
33944650|NCT02564627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944651|NCT05413655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944652|NCT03984682|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33944653|NCT01319539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944654|NCT00121485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944655|NCT02931357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944656|NCT01757821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33944657|NCT05099458|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33944658|NCT00867594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944659|NCT00156962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944660|NCT03400228|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33944661|NCT04418908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants were randomized to either receiving a gonadotropin-releasing antagonist (GnRHant) with estradiol add-back (+E2) or placebo (+PL). Investigators and participants were blinded to randomization status until the study was completed.|t|t|t|t
33944662|NCT05659342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33944663|NCT05818475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801051|NCT01708811|||CASE_ONLY||PROSPECTIVE|||||||
33801052|NCT01522898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944664|NCT01211860|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33944665|NCT06236594|||CASE_ONLY||PROSPECTIVE|||||||
33944666|NCT04477564|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33944667|NCT00265876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944668|NCT04710459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944669|NCT00486720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944670|NCT04167904|||COHORT||PROSPECTIVE|||||||
33944671|NCT01052558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944672|NCT03431246|NA|SINGLE_GROUP||PREVENTION||NONE||Single group exploratory study||||
33944673|NCT01411059|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33944674|NCT01526343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944675|NCT00307658|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801053|NCT04751838|||COHORT||RETROSPECTIVE|||||||
33801054|NCT00016250|RANDOMIZED|||TREATMENT||NONE||||||
33801055|NCT02652806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944676|NCT02173158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944677|NCT04212026|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot, multicenter, single-arm phase II trial.||||
34102839|NCT05394051|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single group randomized trial. After baseline measures of burnout, well-being, and health behaviors are obtained, participants will be recruited for participation in the Positive Affect Regulation sKills (PARK) intervention from the NM HCW SARS-CoV-2 Cohort via direct email. Interested individuals will be provided with the URL (Uniform Resource Locator) to complete eligibility screening via REDCap. All HCWs will be eligible to participate unless they have already been identified as a participant in a previous PARK trial. Once they agree to enroll, they will be randomized to participate in the intervention (PARK) or the 'wait list control' arm (No PARK, but offered at the end of follow-up).||||
34102840|NCT04255563|||COHORT||PROSPECTIVE|||||||
34102841|NCT03307824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102842|NCT06689943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34102843|NCT05472181|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This study uses a double-blinded between- and within-subjects crossover sham-controlled design across two different treatment phases to enhance the effects of behavioural training on stuttering.|t|t|f|t
34102844|NCT06690710|NA|SINGLE_GROUP||TREATMENT||NONE||First in Human, single (expected therapeutic) dose study||||
34102845|NCT05974540|||COHORT||PROSPECTIVE|||||||
34102846|NCT00769379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102847|NCT06111287|||COHORT||RETROSPECTIVE|||||||
34102848|NCT04309500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Stage II will involve a clinical trial, with the risk disclosure feedback serving as the behavioral intervention. The study will use a single-group design with no control group. All 10 participant-co-participant dyads (5 Non-Hispanic African-American, 5 Non-Hispanic White) will receive feedback about the participant's DAT risk. Outcomes will be measured immediately following feedback and at 1- and 6-weeks following risk disclosure.||||
34102849|NCT00771147|||COHORT||PROSPECTIVE|||||||
34102850|NCT06469281|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102851|NCT02413359|||CASE_ONLY||CROSS_SECTIONAL|||||||
34102852|NCT04790968|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102853|NCT05907018|||CASE_ONLY||PROSPECTIVE|||||||
34102854|NCT03203707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and parents complete clinical monitoring assessments with an evaluator blind to treatment condition.|Randomized trail comparing Data-Informed Referral (DIR) for any clinical condition detected at intake assessment versus DIR + Brief Interpersonal Social Rhythm Therapy (IPSRT)|f|f|f|t
34102855|NCT03844412|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Two-center, randomized, double-blind, placebo-controlled 2x2 factorial study enrolling 400 women to participate for 24-week duration.|t|t|t|t
34102856|NCT06693973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102857|NCT00891891|||COHORT||PROSPECTIVE|||||||
34102858|NCT06380686|||CASE_ONLY||PROSPECTIVE|||||||
34102859|NCT04423211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102860|NCT05065671|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34102861|NCT03722628|||CASE_CONTROL||PROSPECTIVE|||||||
34102862|NCT05712538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and investigator masking only applies to Phase 1 healthy volunteers only. For Phase 1b, there is no masking, None (Open Label) should be applied.|Double-blind, placebo controlled (Phase 1 only)|t|f|t|f
34102863|NCT02540902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102864|NCT02464098|||COHORT||PROSPECTIVE|||||||
34102865|NCT00772525|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33719640|NCT06366867|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|Random allocation, 1:1 ratio by a computer-based randomizer|The experimental group will receive VibrantMinds, which consists of sessions with serious computer games in addition to the standard care, whilst the control group will receive the standard of care used at the healthcare facilities.|f|f|t|t
33719641|NCT03945487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719642|NCT03684954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single investigator|Patallel Assignment|f|f|t|f
33719643|NCT00732615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719644|NCT03736317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719645|NCT02653807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719646|NCT03274414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719647|NCT03864211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719648|NCT02074787|||COHORT||PROSPECTIVE|||||||
33719649|NCT01374620|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719650|NCT01194479|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33719651|NCT02626637|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33719652|NCT03831347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719653|NCT05168410|||COHORT||OTHER|||||||
33719654|NCT05294172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|multicenter, double-blind, randomized, controlled phase III trial|t|t|t|t
33719655|NCT06296108|||COHORT||RETROSPECTIVE|||||||
33719656|NCT03439020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801056|NCT00117702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801057|NCT05955989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the patient is not know the type of prosthesis he will receive|Three groups of completely edentulous patients. Each group will receive complete denture processed with different technique. After one year the patients will recalled and relining of the denture were made to gain the retention. After one year assessment of retention by digital force gauge, occlusion equilibrium by T-Scan and patient satisfaction (PS)|t|f|f|f
33801058|NCT05174234|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801059|NCT05086354|NA|SINGLE_GROUP||TREATMENT||NONE|the physical therapist performing the baseline and post-training does not have involvement with the intervention|Feasibility study||||
33801060|NCT00741455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801061|NCT04672018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Clinical Trial|t|f|t|f
33944678|NCT00479973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33944679|NCT02218424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944680|NCT05147766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944681|NCT00006082||||TREATMENT||||||||
33944682|NCT05071742|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33944683|NCT02549261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33944684|NCT00952146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33944685|NCT04350034|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||"The Xbox group participated in a 12-week of routine physiotherapy program supplemented with Xbox training program. The control group participated in the routine physiotherapy program.~In the study group received Xbox training, the dose of Xbox training was 50 min, three times a week for 12 weeks, using the Xbox gaming system. The games were anticipated onto a 45-inch Samsung television. The playing area was 16 \* 12 m. The content of Xbox training consisted of practicing five Xbox games (Rally Ball, Reﬂex Ridge, River Rush, 2000 Leaks and parkour). Children practiced each game for 10 min, bringing about every session enduring 50 min."|t|f|f|t
33944686|NCT02658331|||CASE_ONLY||CROSS_SECTIONAL|||||||
34102866|NCT06690190|||CASE_CONTROL||RETROSPECTIVE|||||||
34102867|NCT03584386|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34102868|NCT04226105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102869|NCT06689319|||CASE_ONLY||CROSS_SECTIONAL|||||||
34102870|NCT00423462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34102871|NCT03154567|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34102872|NCT00631241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102873|NCT06467656|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This will be a parallel group, non-randomized study.||||
34102874|NCT06478615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102875|NCT05021562|||COHORT||PROSPECTIVE|||||||
34102876|NCT01641666|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102877|NCT03882372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be unaware of the patient's allocation.|Single blind randomized study.|f|f|f|t
34102878|NCT00674063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34102879|NCT06548620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102880|NCT02524899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34102881|NCT03073070|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34102882|NCT02553473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102883|NCT06690125|||CASE_CONTROL||PROSPECTIVE|||||||
34102884|NCT03784326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34102885|NCT02192086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102886|NCT04973293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102887|NCT05018598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The extension phase will be unblinded.||t|t|t|t
34102888|NCT06688201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102889|NCT01530516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102890|NCT04925089|||COHORT||PROSPECTIVE|||||||
34102891|NCT01674062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102892|NCT00057798|NA|SINGLE_GROUP||TREATMENT||||||||
34102893|NCT04917510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Erector spinae block will be performed after general anesthesia has been induced. Patients will be unaware which arm of the study they are in.|Patients will be randomized to either the study group or control group prior to undergoing surgery|t|f|f|f
34102894|NCT04954183|||COHORT||PROSPECTIVE|||||||
34102895|NCT06269666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719657|NCT05487781|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Double (Participant, Investigator) The random assignment codes to the administration sequence will be under the protection of the Statistics Department. The Analytical Unit, the group of researchers from the Clinical Unit (medical staff) and the IS will remain blinded during the conduct of the study, the processing and analysis of the biological samples and in this way avoid biasing the results generated. Once the Clinical Phase is over, the opening code for the issuance of the Clinical Report and the Safety Report will be shared with the group of researchers of the Clinical Unit (medical staff).|Assess the biological safety and pharmacokinetics of tyrphostin AG-17 present in the solid oral formulations of the fixed-dose combination, in three different concentrations of the compound tyrphostin AG-17 contained 10 mg, 3.3 mg and 1 mg, respectively, with 700 mg of L-Carnitine tartrate each presentation, in a single dose in healthy research subjects of Mexican nationality.|t|f|t|f
33719658|NCT04890366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719659|NCT05237908|||CASE_CONTROL||PROSPECTIVE|||||||
33719660|NCT01197053|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33719661|NCT01404390|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33719662|NCT00267046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33944687|NCT03586063|||COHORT||PROSPECTIVE|||||||
33944688|NCT05631873|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33944689|NCT06430008|||CASE_CONTROL||RETROSPECTIVE|||||||
33944690|NCT03377218|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34102896|NCT06472791|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Participants will be randomized to take either a placebo or a Centella Asiatica-containing dietary supplement for four weeks|t|t|t|t
34102897|NCT04589624|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34102898|NCT01829763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102899|NCT04779736|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34102900|NCT06169527|||COHORT||PROSPECTIVE|||||||
34102901|NCT06686134|||COHORT||PROSPECTIVE|||||||
34102902|NCT00645138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102903|NCT06327971|||COHORT||RETROSPECTIVE|||||||
33801062|NCT04996589|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33801063|NCT04032353|NA|SINGLE_GROUP||SCREENING||NONE||||||
33719663|NCT02709031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801064|NCT04238793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33801065|NCT06419569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|high power laser and low level laser|f|f|t|t
33801066|NCT00929760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801067|NCT04425551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Each participant's clinically worse eye was selected for treatment, while the other eye was observed as control. If both eyes were clinically same, one of them was randomly selected.~\*Please note that there was one group of participants, but two groups of eyes (treated/untreated). Thus, PARALLEL was selected, referring to eyes, not participants"||||
33801068|NCT05380336|||OTHER||RETROSPECTIVE|||||||
33944691|NCT04079699|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33944692|NCT01298011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944693|NCT03188458|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33944694|NCT04884009|RANDOMIZED|PARALLEL||TREATMENT||NONE||SHR-1701 in combination with or without famitinib||||
33944695|NCT01681004|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group randomized controlled trial||||
33944696|NCT03092076|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33944697|NCT00019565||||DIAGNOSTIC||||||||
33944698|NCT00174460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944699|NCT02255942|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33944700|NCT06050707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944701|NCT02604134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the radiographic progression of caries is assessed by a masked investigator||f|f|f|t
33944702|NCT03328741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33944703|NCT01967992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719664|NCT06520852|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33719665|NCT02771158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33719666|NCT03792308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized in a 3:1 ratio of SPR206 to placebo.|Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose (SAD and MAD) trial|t|t|t|t
33719667|NCT00646529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719668|NCT00775645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33719669|NCT02314650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33719670|NCT02334995|||CASE_CROSSOVER||PROSPECTIVE|||||||
33719671|NCT05212649|||COHORT||RETROSPECTIVE|||||||
33719672|NCT00298545|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33719673|NCT00755287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719674|NCT05281185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open label, all participants received individual low-dose PK-guided extended FVIII concentrates prophylaxis.|Patients aged 5-25 years with clinically severe haemophilia A (FVIII:C ≤3%), no inhibitor, on low-dose weight-based prophylaxis at King Chulalongkorn Memorial Hospital (KCMH) Thailand||||
33719675|NCT00128570|RANDOMIZED|||PREVENTION||||||||
33719676|NCT04108936|||CASE_CONTROL||PROSPECTIVE|||||||
33719677|NCT01279551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719678|NCT00419627|||NATURAL_HISTORY||PROSPECTIVE|||||||
33719679|NCT04053959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research assistants who collect study outcome data will be masked to participants' intervention assignment. In addition, the adjudicators for end-points will not be aware of study-group assignments.|A paralle group, randomized, controlled study to assess the effect and safety of artificial intelligence assisted insulin dosage titration system on glucose control in type 2 diabetic patients|t|f|f|t
33719680|NCT03282942|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33719681|NCT00616681|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33719682|NCT02484729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719683|NCT04688307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944704|NCT05184868|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33944705|NCT00516217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944706|NCT02716207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944707|NCT00809549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719684|NCT05744453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Block Randomization|Randomized double-blinded placebo controlled|t|f|t|t
33719685|NCT06180590|||CASE_CONTROL||PROSPECTIVE|||||||
33719686|NCT02786342|||COHORT||PROSPECTIVE|||||||
33719687|NCT01549392|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33944708|NCT03826849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944709|NCT01527760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33944710|NCT01110603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33944711|NCT01712529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33944712|NCT05773885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blind to the study protocol|This study is a multicentre, single-blind (evaluator), Randomized Controlled Trial (RCT)|f|f|f|t
33944713|NCT00585676|||COHORT||PROSPECTIVE|||||||
33944714|NCT01822886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024184|NCT06628557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study aims to evaluate the effects of mandala art therapy on anxiety and pain in patients undergoing total hip replacement. The data obtained from the research is expected to provide evidence regarding the impact of mandala art therapy, a non-pharmacological approach, on anxiety and pain levels in post-operative patients who have undergone total hip replacement.|t|f|t|f
34024185|NCT05713383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34024186|NCT02242032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024187|NCT03661697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024188|NCT00517127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719688|NCT01494480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719689|NCT06045026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719690|NCT01647633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719691|NCT06477614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719692|NCT02537340|||COHORT||PROSPECTIVE|||||||
34024189|NCT05440123|||COHORT||PROSPECTIVE|||||||
34103498|NCT04948268|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study uses a sequential multiple assignment randomized trial (SMART) design. The first level of randomization is to one of the three treatment conditions: self-guided non-personalized intervention, self-guided adaptive intervention, or active control. The second level of randomization occurs during the first two weeks of intervention. Participants who meet criteria for disengagement from either the non-personalized or adaptive intervention are then randomized to receive coaching or continue as self-guided. This will provide the investigators with preliminary information on the need for and value of coaching. Participants will receive the assigned intervention from baseline to week 8, followed by an 8 week follow-up period||||
34103499|NCT06422923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103500|NCT04879940|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33719693|NCT05643768|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|This is a randomized trial and participants will be blinded to their allocation group.|Participants will be randomly allocated using a 1:1 ratio to A) High-Intensity Training Group (75 % maximal inspiratory pressure) or B)Low-Intensity Training Group (15% maximal inspiratory pressure)|t|f|f|f
33719694|NCT04855097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and treating physicians will have no access to the BVA data in the Standard Care arm.|Prospective, two-center, parallel design, interventional, single-blinded pilot study|t|t|t|t
33719695|NCT05520944|||COHORT||RETROSPECTIVE|||||||
33719696|NCT01776775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33719697|NCT04138134|||COHORT||CROSS_SECTIONAL|||||||
33719698|NCT05549206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33719699|NCT04417920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719700|NCT05003076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33719701|NCT02716103|||COHORT||PROSPECTIVE|||||||
33719702|NCT01060930|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33719703|NCT01416922|||COHORT||PROSPECTIVE|||||||
33719704|NCT01499667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33719705|NCT03630120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers consenting the patients will become unblinded upon treatment assignment.||f|f|t|f
33719706|NCT06437899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719707|NCT04411589|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33719708|NCT01031940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719709|NCT06226233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups. This trial aims to investigate the impact of the Juniver program on self-reported eating disorder symptoms, as well as on symptoms of depression, anxiety, psychosocial impairment associated with eating disorders, and perceived stress. This will occur via a randomised controlled trial comparing Juniver to a wait-list control condition over a 12-week period, with further evaluation of the effects of Juniver up to 24-weeks.|f|f|f|t
33719710|NCT01928329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719711|NCT03938584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719712|NCT05605392|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33719713|NCT00768807|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33719714|NCT03087760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719715|NCT02153112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33719716|NCT03006744|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33719717|NCT02150954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719718|NCT05673044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33719719|NCT03443440|||COHORT||PROSPECTIVE|||||||
33719720|NCT03266289|||OTHER||PROSPECTIVE|||||||
33719721|NCT00826020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719722|NCT06181097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible patients will be recruited and randomized to either NPWT and standard dressing.|f|f|f|t
33719723|NCT05332509|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33719724|NCT05775315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719725|NCT05457673|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33719726|NCT04273217|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33719727|NCT04624009|||COHORT||PROSPECTIVE|||||||
33719728|NCT06291844|||COHORT||PROSPECTIVE|||||||
33719729|NCT02500290|||COHORT||PROSPECTIVE|||||||
33719730|NCT00001339||||TREATMENT||||||||
33719731|NCT02776423|||COHORT||PROSPECTIVE|||||||
33719732|NCT05244408|||COHORT||PROSPECTIVE|||||||
33719733|NCT04086290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719734|NCT01270711|||COHORT||RETROSPECTIVE|||||||
33719735|NCT05747092|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||group test free gingival graft group control connective tissue graft|f|f|t|f
33719736|NCT02535845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33719737|NCT01342146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719738|NCT03520608|||CASE_ONLY||CROSS_SECTIONAL|||||||
33719739|NCT05100524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment||||
33719740|NCT01892501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719741|NCT01185457|||CASE_CROSSOVER||PROSPECTIVE|||||||
33719742|NCT01622972|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33719743|NCT01114165|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33719744|NCT04860791|||OTHER||PROSPECTIVE|||||||
33719745|NCT04834947|||COHORT||PROSPECTIVE|||||||
33719746|NCT03218033|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33719747|NCT01998633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719748|NCT01572909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719749|NCT00243789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719750|NCT05281445|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Tic suppression task||||
33719751|NCT01502579|||||PROSPECTIVE|||||||
33719752|NCT02657382|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33719753|NCT05087095|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33719754|NCT04741074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a placebo-controlled double-blind clinical trial. Study investigators and participants will be blinded to treatment allocation.||t|t|t|t
34102904|NCT04946253|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants are not directly informed of the implementation condition to which the practice site has been randomized. All formal standardized assessments will be conducted via secure electronic web-based data collection systems, limiting the potential for assessment bias. In the event that a caregiver requests that a staff member administer an assessment via phone, the assessor would be unaware of the implementation condition assigned to the child's practice where the caregiver receives care.|The investigators propose a randomized trial using a factorial design to test effects of implementation support strategies on uptake of an evidence-based intervention (DOCC) in up to 24 primary care practices. Practices will receive DOCC training in accord with the Replicating Effective Programs model. Practices will be randomized to 1 of 4 implementation support conditions: 1) No TEAM/LEAD (training and technical support only); 2) provider care team consultation (TEAM); 3) practice leadership facilitation (LEAD); and 4) combination of provider care team and leadership implementation (TEAM+LEAD). Care teams in each practice will identify families and deliver DOCC to 20 caregivers and their children with externalizing behavior. Investigators will collect measures from 90 practice staff over 5 assessments (24 months) and 360 caregivers over 4 assessments (12 months) to support analyses.|f|f|f|t
34102905|NCT06349304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34102906|NCT04806945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34102907|NCT03247673|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34102908|NCT05958875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label, except for the assessors of the primary outcome|Parallel randomization to the 2 arms, treatment as usual (TAU) or early-intensified pharmacological treatment (EIPT).|f|f|f|t
34102909|NCT04950764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Seladelpar 10 mg||||
33801069|NCT04960098|||COHORT||PROSPECTIVE|||||||
34102910|NCT05671887|||COHORT||PROSPECTIVE|||||||
34102911|NCT01143675|||CASE_ONLY||PROSPECTIVE|||||||
33944715|NCT03931629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|NO MASKING|Study design. This study was composed of two phases and was carried out by three consultant surgeons. No resident or trainee was involved in the performance of the surgeries. In Phase I, one of the three surgeons operated the LensX®, another performed the FLACS surgery (FLACS I) in one operating room (OR1), while the third surgeon performed the conventional phacoemulsification procedure (MANUAL) in another operating room (OR2). On subsequent days, the surgeons rotated between LensX®, FLACS and MANUAL surgery (Figure 1). All the settings for the Infiniti® and the LensX® were the same for all surgeons (see below). The cataracts included in the FLACS I group were presumably straightforward, as they were part of the learning curve for the surgeons and were evaluated by consultant ophthalmologists (it must be considered that the maximum best-corrected visual acuity \[BCVA\] for being eligible for cataract surgery in the Andalusian public System is 0.4 logMAR).||||
34102912|NCT06688305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34102913|NCT06458192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103501|NCT06571825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103502|NCT03445442|||COHORT||RETROSPECTIVE|||||||
33801070|NCT03981926|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pragmatic, randomized, controlled, equivalency trial.||||
33944716|NCT01994070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34024190|NCT05438914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The patients will be randomly allocated in a 1:1 ratio, with block sizes of four and six using a randomization sequence.||||
34024191|NCT06633484|||COHORT||PROSPECTIVE|||||||
34024192|NCT06053684|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-blinded, randomized clinical trial||||
34024193|NCT03247192|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34024194|NCT05705765|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34024195|NCT05895955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Unblinded study staff, including the site pharmacist, will be responsible for preparing study products (in accordance with the randomly determined assignment), and handling all drug accountability procedures. These personnel will not participate in the other aspects of the clinical trial, to help ensure the integrity of the blind at the site. Unblinded staff will retrieve a participant's randomization assignment after being informed by the PI or designee that a participant is eligible for randomization. They will provide the prefilled 0.5 ml dose of study product based on the participant's randomization|Double (Participant, Investigator)|t|f|t|f
34024196|NCT04229667|||OTHER||PROSPECTIVE|||||||
34024197|NCT00024284||||TREATMENT||||||||
34024198|NCT05307510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801071|NCT03668197|||COHORT||PROSPECTIVE|||||||
33801072|NCT02326987|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33801073|NCT03582722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801074|NCT06516250|RANDOMIZED|PARALLEL||OTHER||SINGLE|Once the data is obtained, it will be sent to the results analysts who will also not know the authorship of the data obtained.|"Students enrolled in 5th and 6th year medicine or 3rd and 4th year nursing degree programs. They can be from various faculties.~Residents in training in medicine or nursing, from various years of residency and specialties."|f|f|f|t
33801075|NCT01303445|RANDOMIZED|CROSSOVER||||NONE||||||
33801076|NCT01448317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801077|NCT04847414|||COHORT||CROSS_SECTIONAL|||||||
33801078|NCT05284136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801079|NCT01002521|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34024199|NCT06582849|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024200|NCT02873741|||COHORT||PROSPECTIVE|||||||
34024201|NCT05372653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024202|NCT06550973|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024203|NCT03966183|||COHORT||PROSPECTIVE|||||||
34024204|NCT02332837|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34024205|NCT01404078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024206|NCT03101644|NA|SINGLE_GROUP||OTHER||NONE||||||
34024207|NCT01897038||PARALLEL||TREATMENT||NONE||||||
34024208|NCT00005399|||COHORT||PROSPECTIVE|||||||
34024209|NCT03429010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024210|NCT05886387|||COHORT||PROSPECTIVE|||||||
34024211|NCT05147324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024212|NCT01653301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801080|NCT02570022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801081|NCT01864889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801082|NCT04597684|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801083|NCT03437369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34024213|NCT04201691|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants are grouped randomly. First group and second group are applied different rehabilitation programs. Both of group is rest four weeks. Than second group is applied first group's rehabilitation program and first group is applied second group's rehabilitation program.|t|f|t|f
34024214|NCT03996135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024215|NCT04591223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34024216|NCT03761563|||COHORT||PROSPECTIVE|||||||
34102914|NCT06688019|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patients will be randomly allocated to 2 groups using computer-generated randomization method. Neither participants nor physicians will be blinded to the groups because of organizational reasons.|Arm 1: conventional nasal cannula group Arm 2: high-flow humidified oxygen-delivery system (OptiFlow THRIVE) group||||
34102915|NCT04737603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102916|NCT02985775|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34102917|NCT05941000|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE|No Masking|This study uses a 2-arm crossover design.||||
34102918|NCT04677153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102919|NCT04699305|||OTHER||PROSPECTIVE|||||||
34102920|NCT04379271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Trial participants, the investigator and all other personnel directly involved in the conduct of the trial will be blinded to treatment assignments.~To maintain the blind, IMU-838 and placebo tablets will have identical appearance, shape and color, and will have identical labeling and packaging. To minimize the potential for bias, treatment randomization information will be kept confidential by the responsible personnel and will not be released to investigators, other trial center personnel, or the Sponsor's designee(s)."|double-blind, placebo-controlled, randomized, parallel-group trial|t|f|t|f
34102921|NCT06633666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be assigned to the treatment group or the control group according to the ratio of 1:1. This process is carried out by an independent researcher (Research Assistant), and the evaluators and outcome assessor will not know the grouping of the participants until the end of the study.||f|t|f|t
34102922|NCT04502186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34102923|NCT06616766|NA|SEQUENTIAL||TREATMENT||NONE||||||
34102924|NCT06147869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will be carried out on forty lactating women suffering from De Quervain's tenosynovitis after 6 weeks from the delivery. They will be selected randomly from the out patient clinic of orthopedic in Kasr El Aini Hospital. Their ages will be ranged from 25-35 years old, their body mass index (BMI) will not exceed 30 Kg/m2 and their parity will be ranged from (2-4 children).|t|f|f|f
34102925|NCT03304639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102926|NCT02170155|||CASE_CONTROL||PROSPECTIVE|||||||
34102927|NCT06688955|NA|SINGLE_GROUP||OTHER||NONE||||||
34102928|NCT06678984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102929|NCT06075745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102930|NCT03238196|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024217|NCT00822406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024218|NCT03766412|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024219|NCT01708148|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34024220|NCT02820649|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34024221|NCT02021357|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34024222|NCT05310695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients are randomized to either of three intervention arms:|f|f|f|t
34024223|NCT06232473|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Randomization for both the open-label parent trial and the nested blinded study drug trial will be carried out using REDCap. The randomization code will be generated by an independent employee through REDCap. Coded (numbered) packs of study drug and active placebo will be produced according to the randomization schedule. Patients, clinicians, investigators, and all other staff involved in the conduct or data analysis of the nested trial will be masked to study drug treatment allocation for the duration of the study and throughout all data analysis. Patients and clinicians will be asked to guess allocated treatment (duloxetine or active placebo) and indicate reason at endpoints to evaluate blinding efficacy.|"This is a nested design. The parent trial (EDULOX 1) is an open-labelled randomized controlled trial comparing patient education (PE) with enhanced usual care (EUC). The parent trial nests a concomitantly running, two-by-two factorial, double-blinded, randomised controlled trial (EDULOX 2) comparing duloxetine with active placebo in combination with the PE program or EUC.~Participants in the parent trial will be randomized (open-label) to receive either EUC or the PE program. Participants in the nested trial will be randomized (open-label + blinded) to receive either EUC or PE along with either duloxetine or active placebo. This will result in a total of six randomization groups for the full EDULOX trial.~A total of 424 participants will be recruited for the EDULOX parent trial, of these 212 participants will participate in the nested study drug trial.~Biological material for the biobank will be collected from all participants and an additional 75 healthy controls."|t|t|t|t
34024224|NCT02902367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024225|NCT02495259|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34024226|NCT05943808|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34024227|NCT06360055|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34024228|NCT00284024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34024229|NCT04655430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024230|NCT05865730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||1 cohort of patients with NSCLC recruited in parallel to 1 cohort recruiting RCC patients.||||
34024231|NCT01001624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024232|NCT00394524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024233|NCT03968978|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized 1:1 to either an accessorized pre-filled syringe or an autoinjector. Both will be administered 210 mg tezepelumab subcutaneously.||||
34024234|NCT05471492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to one of two groups in parallel for the duration of the study|t|t|t|t
33801084|NCT05284435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801085|NCT01791816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801086|NCT03780686|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33801087|NCT06067035|||COHORT||RETROSPECTIVE|||||||
33801088|NCT06006611|||COHORT||RETROSPECTIVE|||||||
33801089|NCT01501604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801090|NCT03657030|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||Single ascending dose and multiple ascending dose study|t|t|t|t
33801091|NCT01216722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801092|NCT04030624|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801093|NCT02025257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33801094|NCT01240434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33801095|NCT03201822|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomized, double-masked and cross-over dietary intervention study in healthy young adult males|t|t|t|t
33801096|NCT04272645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801097|NCT01526291|||COHORT||PROSPECTIVE|||||||
33801098|NCT04324450|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801099|NCT04929067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024235|NCT05623618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024236|NCT06403280|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34024237|NCT01823835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024238|NCT05958888|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will see the same 4 labels (3 sodium labels \[text only, text + icon, and text + pictorial\] and a control bar code label) in a random order.||||
34024239|NCT03259659|||CASE_CONTROL||PROSPECTIVE|||||||
34024240|NCT02368951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024241|NCT02398383|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34024242|NCT01802450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024243|NCT01497808|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024244|NCT04131738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* If all 3 patients in the safety lead-in for the 2 mg dose level achieve engraftment, 9 additional patients will be enrolled at that dose level.~* If all 3 patients in the safety lead-in for the 4 mg dose level achieve engraftment, 9 additional patients will be enrolled at that dose level."||||
34024245|NCT05643053|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34024246|NCT03850314|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024247|NCT06237439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not be informed of the arm of participants prior to conducting assessments.||f|f|f|t
34024248|NCT03019159|||CASE_CONTROL||PROSPECTIVE|||||||
34024249|NCT03910387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024250|NCT01382654|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34024251|NCT02173314|RANDOMIZED|PARALLEL||TREATMENT||||||||
34024252|NCT04819841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024253|NCT05326776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34024254|NCT04808310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and outcome assessors will be blinded to the randomization group.|Patients will be randomized 1:1 to one of the two study arms. Randomization will be done by using a computer-generated random sequence (Medcalc, Mariakerke, BE).|t|f|f|t
34024255|NCT04282083|||COHORT||OTHER|||||||
34024256|NCT06102681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single|all participants will assigned to two grup. one grup will be intervention the other will be control.|t|f|f|f
34024257|NCT04245241|||OTHER||PROSPECTIVE|||||||
34024258|NCT05179538|NA|SINGLE_GROUP||TREATMENT||NONE|Speech-language pathologists who will be providing assessments and therapy will be blinded to participant genotypes.|There will be four subgroups based on the expression of BDNF and ApoE.||||
34024259|NCT00444379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024260|NCT02600689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34024261|NCT01363882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34024262|NCT04775849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cataract surgery will be performed in individuals with age-related cataract.||||
34024263|NCT06552143|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor did not know whether the patient being measured belonged to the control or intervention group.|The patients were divided into control and intervention groups according to the time of their visit to the clinic. The patients who met the inclusion and exclusion criteria of the study from February to May 2023 were the control group and the patients who met the inclusion and exclusion criteria of the study from June to September 2023 were the intervention group. The number of patients in each group was 60.|f|f|f|t
34024264|NCT06359106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024265|NCT05408585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All blocks will be performed by the same experienced anesthetist to ensure block quality and homogeneity. The anesthetist applying the block will not take part in the patient follow-up, the independent assistant following the patient will be blinded to the study.|As suggested by Durham et al and described by Dixon, study randomization will be performed using the biased-coin design up-down sequential method.|f|t|f|t
34024266|NCT06045923|||COHORT||PROSPECTIVE|||||||
33801100|NCT05760235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801101|NCT04190316|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33801102|NCT06145568|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33801103|NCT02894658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801104|NCT01737489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801105|NCT05551455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Masking not possible as food quantity/type will vary between interventions.|Participants will complete two five-day trial-arms in randomised order, with an \~10-day washout period between interventions.||||
33801106|NCT00507338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801107|NCT02387242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801108|NCT04481074|NA|SINGLE_GROUP||OTHER||NONE||Quasi-experimental||||
33801109|NCT02724592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801110|NCT03501264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33801111|NCT05296330|||COHORT||PROSPECTIVE|||||||
33801112|NCT00813657|RANDOMIZED|||PREVENTION||||||||
33719755|NCT00050843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719756|NCT04237090|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33801113|NCT00212693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801114|NCT03917303|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter randomised controlled trial||||
33801115|NCT06517875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801116|NCT00168753|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801117|NCT03014375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024267|NCT02531750|||COHORT||PROSPECTIVE|||||||
34024268|NCT01322867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34024269|NCT05918406|NA|SINGLE_GROUP||TREATMENT||NONE||Nasal guide will be used to aid in the administration of Tyrvaya® (varenicline solution 0.03 mg) Nasal Spray||||
34024270|NCT00785460|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34024271|NCT03004287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024272|NCT04590638|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34024273|NCT03887494|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024274|NCT03987321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are blinded to the filter type.|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava.|t|f|f|f
34024275|NCT04202003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024276|NCT00198250|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34024277|NCT05707754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024278|NCT02299115|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024279|NCT05594264|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The two phase study, included a feasibility phase. During the feasibility phase 30 participants would be recruited to provide feedback on the design of the website, the impact of the study, and preferences for future study designs. The second phase of the study was the pilot study. The objective of the 6-week study was to explore the impact of a web-based storytelling program on medication adherence and blood pressure.||||
34024280|NCT02556463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024281|NCT00927394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024282|NCT06079346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024283|NCT06633029|||COHORT||RETROSPECTIVE|||||||
34024284|NCT00000494|RANDOMIZED|||TREATMENT||DOUBLE||||||
34024285|NCT01247883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34024286|NCT02684630|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34024287|NCT06112496|||OTHER||PROSPECTIVE|||||||
34024288|NCT04458792|NA|SINGLE_GROUP||OTHER||NONE||||||
34024289|NCT01401556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33719757|NCT03946904|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33719758|NCT01147029||||TREATMENT||||||||
33719759|NCT04260542|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33719760|NCT00630279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719761|NCT00597766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719762|NCT02015650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719763|NCT06073353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is a double-blind single-site randomized efficacy trial of the THRIVE-M App in 120 patients with multiple myeloma. Patients will be recruited from the Massachusetts General Hospital Cancer Center and randomized in a 1:1 fashion, stratified by diagnosis type (newly diagnosed versus maintenance versus relapsed), to assign each participant to either THRIVE-M versus usual care.||f|f|f|t
33719764|NCT04803669|RANDOMIZED|PARALLEL||TREATMENT||NONE||Conventional Treatment Conventional Treatment + Instrument-assisted soft tissue mobilization technique||||
33719765|NCT04232072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anesthesiologist who performs postoperative pain evaluation will not know the group.|There are three models for this study. The first group is erector spinae plane block group, the second one is intravenous ibuprofen group, the third group is the no intervention control group|f|f|f|t
33719766|NCT03513302|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blind, placebo-controlled, crossover|t|f|t|t
33719767|NCT04489212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719768|NCT04867681|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33719769|NCT01619683|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33719770|NCT01108601|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33719771|NCT04787029|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719772|NCT04368988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024290|NCT02013674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024291|NCT06046794|NA|SINGLE_GROUP||OTHER||NONE||||||
34024292|NCT00001110||||TREATMENT||||||||
34024293|NCT00447993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024294|NCT04581369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|One member of the study team will randomize the participants and all other study personnel will remain blinded.|"Block randomization will be utilized to ensure balancing of treatment groups throughout enrollment. 20 participants will be assigned to the direct home interventions group and 20 will be assigned to standard of care.~Caregivers (40) belong to a single arm of the study with no randomization. All receive the same study procedures."|t|t|t|f
34024295|NCT05668130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024296|NCT04495036|||COHORT||PROSPECTIVE|||||||
33719773|NCT00119418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33719774|NCT03906045|NA|SINGLE_GROUP||TREATMENT||NONE||"This will be a single-dose study to assess the pulmonary deposition of Radiolabelled BGF MDI following administration in male and female patients with moderate to severe/very severe COPD. SAEs will be recorded from the time of signing of informed consent form to Post-study Follow-up phone call. Non-serious AEs will be collected from the first dose on Day 1 to Post-study Follow-up phone call. Study drug will be administered by inhalation.~The study will comprise of a Screening Visit, followed by a single Treatment Period and a Post-study Follow-up phone call."||||
34024297|NCT02910063|NA|SEQUENTIAL||TREATMENT||NONE||||||
34024298|NCT04839692|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Standard photographs will be blindly reviewed by a physician.|Investigators will enroll 40 subjects; 20 subjects who are 21-30 years old and 20 subjects who are post-menopausal women. Both groups will receive identical treatments.|f|f|t|f
34024299|NCT00745784|||COHORT||PROSPECTIVE|||||||
33719775|NCT05633121|||COHORT||RETROSPECTIVE|||||||
33719776|NCT06002347|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33719777|NCT03026608|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34024300|NCT05691088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Clinical efficacy of acetaminophen in mechanical ventilation in children with new coronary pneumonia|t|f|t|t
33719778|NCT04358653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33719779|NCT00207207|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719780|NCT00631566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024301|NCT05530187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33719781|NCT04938557|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an unblinded trial. Both participants and their clinical care team will be aware of the allocation.|An open-label, multi-centre, randomized, two-arm parallel group trial||||
33719782|NCT03909295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719783|NCT05545566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024302|NCT04898855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34024303|NCT00956800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024304|NCT00681590|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024305|NCT00312169|||||PROSPECTIVE|||||||
34024306|NCT01734200|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34024307|NCT02643355|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024308|NCT05631197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024309|NCT06498869|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization will be conducted by an independent researcher (AY) using computer software and will be securely stored in sealed envelopes. An independent researcher (AŞ) will open the envelope 30 minutes prior to the procedure. The researcher administering anesthesia and the researcher conducting patient follow-ups and assessments (BG) will be blinded to each other. The participants will also be unaware of their assigned study group. Consequently, both the participants and the researcher assessing sleep quality (BG) will be blinded to the treatment administered. The study will be designed as a double-blind study.|Our participants will be randomized into two separate groups. One group will receive midazolam and propofol, which will be our control group. The other group will receive ketamine in addition to midazolam and propofol during the procedure.|t|f|t|f
34024310|NCT04296084|||CASE_ONLY||PROSPECTIVE|||||||
34024311|NCT00991705|RANDOMIZED|CROSSOVER||||NONE||||||
34024312|NCT03449004|||OTHER||CROSS_SECTIONAL|||||||
33719784|NCT03793582|||COHORT||PROSPECTIVE|||||||
33719785|NCT05589207|||COHORT||PROSPECTIVE|||||||
34024313|NCT04918589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized on the REDCap system. Their assignment will be made available to research team member, which will be preparing syringes with either TXA or placebo.|"Randomized Controlled Trial (RCT) with 2 arms: the interventional arm (receiving topical TXA) and the control arm (receiving placebo).~Intervention: Topical application of 3 grams of tranexamic acid (30 mL of 100 mg/mL) diluted in 10 mL of normal saline in the breast.~Placebo: Topical application of 40 mL of 0.9% normal saline to the breast."|t|t|f|f
33719786|NCT04102592|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to control (25) or intervention group (25)||||
33719787|NCT02692599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33719788|NCT04733092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719789|NCT01950845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33719790|NCT00751647|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024314|NCT05097235|||COHORT||CROSS_SECTIONAL|||||||
34024315|NCT03608865|NA|SINGLE_GROUP||TREATMENT||NONE||Drug:Durvalumab + tremelimumab Dose/Potency: Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental||||
34024316|NCT06483503|||CASE_ONLY||PROSPECTIVE|||||||
34102931|NCT05657639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102932|NCT06501170|||COHORT||RETROSPECTIVE|||||||
34102933|NCT06559241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719791|NCT01641692|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33719792|NCT06258655|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A quasi-experimental before and after intervention design||||
33719793|NCT01189214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024317|NCT04878848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations will be made by a single investigator and participants will be blinded to what treatment is being administered.|Within the scope of the research, it is planned to apply a traditional rehabilitation program consisting of stretching and strengthening exercises prepared in accordance with the guidelines for one group, and PNF approaches for the upper extremity and scapula in the other group.|t|f|f|f
34024318|NCT05001217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719794|NCT02055014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024319|NCT02186834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024320|NCT01794897|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34024321|NCT04437459|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34024322|NCT00820443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024323|NCT00203593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34024324|NCT06632665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024325|NCT05549323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to one of the two groups in parallel for the duration of the study.|t|t|t|t
34024326|NCT00813800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024327|NCT06228300|||COHORT||PROSPECTIVE|||||||
34024328|NCT01649401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024329|NCT00625885|||COHORT||PROSPECTIVE|||||||
34024330|NCT03201432|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|||||
34024331|NCT04826692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34024332|NCT02058550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024333|NCT04496115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34024334|NCT05952518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102934|NCT01257893|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
34102935|NCT05424315|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34102936|NCT03608007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34102937|NCT06695325|||CASE_CONTROL||PROSPECTIVE|||||||
34102938|NCT01409200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34102939|NCT04256837|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|A randomization schema will be generated by the BU-FIMR by study strata (recipients of a kidney from a living donor and recipients of a kidney from a deceased donor) using the method of permuted blocks. For those receiving their kidneys from living donors, subjects will be randomly assigned in a 1:1 ratio to either 'aVNS' or 'sVNS. For those receiving their kidneys from deceased donors, subjects will also be randomly assigned in a 1:1 ratio to either 'aVNS' or 'sVNS'. Details of the randomization procedure, including required record keeping will be further developed upon approval of the protocol.|"The objective of this pilot, feasibility study is to examine the effects of transcutaneous electrical auricular vagus nerve stimulation (VNS) in adult patients undergoing a single kidney transplant using donors who are either living or deceased.~Kidney transplantation patients will be stratified into two groups, namely, those receiving their kidney from a living donor and those receiving their kidney from a deceased donor. Within each strata, patients will be randomized to receive either active VNS or sham VNS. VNS will be applied for 5 minutes prior to start of surgery. The device to be used for VNS will include a handheld electrical pulse generator and a pair of electrodes to be placed at the left ear for stimulation, targeting the auricular branch of the vagus nerve which innervates the skin overlying the cymba conchae of the ear canal."|t|f|f|f
34102940|NCT05403151|||CASE_ONLY||PROSPECTIVE|||||||
34102941|NCT06649110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34102942|NCT06170606|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single arm study||||
34102943|NCT06689306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The sample of the study consists of 70 second-year nursing students studying at the Nursing Department of the Faculty of Health Sciences at Erzincan Binali Yıldırım University, who have chosen the Development of Caring Behaviors course as an elective course and will be divided into sections A and B (without any intervention) through the system. In the study, one section will be selected by flipping a coin by someone other than the researcher using the simple randomization method and the other section will be the experimental group and the other section will be the control group. The study will be designed so that the students will not know whether they are in the intervention or control group, and one-way blinding will be applied in the study.|t|f|f|t
34102944|NCT06528093|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34102945|NCT02145520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34102946|NCT06673589|||COHORT||CROSS_SECTIONAL|||||||
34102947|NCT00203242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103503|NCT03701334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024335|NCT04730037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024336|NCT03724214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pre and post study design. All patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study site. All patients with simple gastroschisis presenting to a study site following implementation will receive the interventional care bundle (if consent is provided).||||
34024337|NCT04521582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024338|NCT02697240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024339|NCT03462979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34024340|NCT05105412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024341|NCT06634186|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024342|NCT05742763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34024343|NCT03330054|||CASE_CONTROL||RETROSPECTIVE|||||||
33719795|NCT02244489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719796|NCT00672789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33719797|NCT02548494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33719798|NCT01643811|||CASE_CONTROL||PROSPECTIVE|||||||
33719799|NCT01103284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719800|NCT03721276|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will either be immediately enrolled or wait listed for the intervention.|||||
33719801|NCT01977508|||COHORT||PROSPECTIVE|||||||
33719802|NCT04906551|||OTHER||PROSPECTIVE|||||||
33719803|NCT00737620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801118|NCT05901896|||COHORT||PROSPECTIVE|||||||
33801119|NCT06299228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801120|NCT04277936|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34024344|NCT06600126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801121|NCT01830036|||||PROSPECTIVE|||||||
33801122|NCT02755415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801123|NCT02256254|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33801124|NCT00225797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801125|NCT05067621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Yale Investigational Drug Services Pharmacy will handle the masking of drug and placebo pens.|Participants will undergo baseline tests at the beginning of the study and will be randomized to receive experimental drug or placebo. Dose escalation will be achieved within 16 weeks to reach up to 2.4mg of Semaglutide, weekly, which they will be on for 6 months. All tests will be repeated after 6 months of treatment followed by a wash-out period of 3 months, after which the same tests will be repeated.|t|t|t|t
33801126|NCT03742050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801127|NCT04958798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024345|NCT02360176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024346|NCT00886405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024347|NCT05670535|||COHORT||PROSPECTIVE|||||||
34024348|NCT01773837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024349|NCT06492278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024350|NCT02131961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024351|NCT00603837|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34024352|NCT00142194|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34024353|NCT05055050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024354|NCT06007911|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024355|NCT02969265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024356|NCT02138058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34024357|NCT00005827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024358|NCT00667901||||TREATMENT||NONE||||||
34024359|NCT05044312|NA|SINGLE_GROUP||SCREENING||NONE||||||
34024360|NCT00126282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024361|NCT05596565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"An exploratory-descriptive qualitative study will be conducted. There will be three groups in the study with each of them will consist of ten participants. Within the scope of the study, each group will perform a similar exercise program, 2 sessions a week, for 6 weeks, in one of the 3 groups below; Group~1. Exercising under the supervision of a face-to-face physiotherapist, Group~2. Exercise under the observation of the physiotherapist via video-conference (telerehabilitation), Group 3: Exercising in the absence of the observer (home based exercise program)."|f|f|f|t
34024362|NCT06430359|||COHORT||PROSPECTIVE|||||||
34024363|NCT01290562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024364|NCT06409208|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024365|NCT03489109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024366|NCT02648932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024367|NCT03597529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024368|NCT05798026|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34024369|NCT06000527|||COHORT||PROSPECTIVE|||||||
34024370|NCT01413607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024371|NCT03893565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double-blind study. Induction doses will be matched with placebo. For Maintenance dosing, participant and investigator will be masked. Participants will be allocated to the next treatment phase according to their Responder status. Non-responders to the double-blind Induction Phase will receive treatment in Open-Label Induction phase where there will be no masking.|This is a parallel group, placebo controlled study where participants will be randomized to receive either GSK2831781 or placebo.|t|f|t|f
34024372|NCT04799938|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Exercise intervention will be applied to intervention group All participiants will be applied to standard recommendations|f|f|f|t
34024373|NCT04150263|RANDOMIZED|PARALLEL||TREATMENT||NONE||1 arm included 56 patients, the other arm included 61 patients. Sixty controls with ordinary pseudophakia.||||
34024374|NCT05010616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024375|NCT02542553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34024376|NCT03477474|||COHORT||PROSPECTIVE|||||||
34024377|NCT00529139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024378|NCT05160857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024379|NCT01890135|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34024380|NCT04267029|||CASE_CONTROL||PROSPECTIVE|||||||
34024381|NCT05756283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34024382|NCT04385303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024383|NCT00224419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024384|NCT06148584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024385|NCT04032249|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34024386|NCT05856643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024387|NCT03515590|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34024388|NCT03936712|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|To avoid identification, two opaque and unmarked cans \[24-26\] of Red Bull or Placebo were ingested by each participant (i.e., 500 mL) in the presence of a researcher.|A double blind, placebo-controlled, and counterbalanced crossover design was used for this work|t|f|f|f
34024389|NCT04888559|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34024390|NCT01531543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024391|NCT05804916|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Control group: Patients with left breast cancer treated with traditional laser alignment with a free breathing treatment Study group: Patients with left breast cancer treated with SGRT combined with the DIBH technique||||
34024392|NCT02841163|||CASE_ONLY||RETROSPECTIVE|||||||
34024393|NCT05368311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024394|NCT03146962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024395|NCT01221363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024396|NCT01169285|||CASE_ONLY||CROSS_SECTIONAL|||||||
34103504|NCT05466799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801128|NCT01211405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801129|NCT03958136|NON_RANDOMIZED|PARALLEL||OTHER||NONE||monocentric, open, prospective database with specific biopsy and blod collections done (biocollection)||||
33801130|NCT02432950|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801131|NCT02422784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801132|NCT03888768|RANDOMIZED|PARALLEL||TREATMENT||NONE|patient will be randomised into ProPBM and standard care arm|ProPBM arm and standard Care arm||||
33801133|NCT02960204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33801134|NCT00033098||CROSSOVER||TREATMENT||DOUBLE||||||
33801135|NCT00809497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33801136|NCT02740231|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33801137|NCT05662449|||COHORT||PROSPECTIVE|||||||
33801138|NCT00343486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33801139|NCT04457752|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Dual Layer Amniotic Membrane (DLAM). Artacent® Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.~Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers."||||
33801140|NCT02995460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801141|NCT01557985|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801142|NCT01041794|||COHORT||OTHER|||||||
33801143|NCT00867867|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33801144|NCT01837927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801145|NCT03248271|||COHORT||PROSPECTIVE|||||||
33801146|NCT03333018|||COHORT||PROSPECTIVE|||||||
33801147|NCT06065332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blind evaluator were not aware which side of the face received the mask||f|f|f|t
33801148|NCT01164670|||COHORT||PROSPECTIVE|||||||
33801149|NCT00752453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33801150|NCT04003675|||CASE_CONTROL||PROSPECTIVE|||||||
33801151|NCT05096559|||COHORT||PROSPECTIVE|||||||
33801152|NCT03260413|||CASE_ONLY||RETROSPECTIVE|||||||
33801153|NCT01577225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024397|NCT04465695|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomised controlled trial||||
33801154|NCT00557206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801155|NCT01808768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801156|NCT01294215|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33801157|NCT03980873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801158|NCT06111924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33801159|NCT01238744|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33801160|NCT02880137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33801161|NCT04593810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801162|NCT01495624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33801163|NCT04764994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluators who will perform all assessments throughout the study will not take part in the intervention program. They also will not been informed about which group; each evaluated patient will belong (blind assessors).||f|f|f|t
33801164|NCT04030533|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33801165|NCT02265432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801166|NCT05325931|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33801167|NCT03674047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801168|NCT03788590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801169|NCT01402479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024398|NCT03031886|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blinded, subjects was blinded from knowing if foods were low or high GI, researchers analyzing the data were blinded from food preparation.|A randomized,crossover design with either a low or high GI diet with a 5 day washout period in between the 2 interventions..|t|f|t|f
34024399|NCT04917042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024400|NCT04494880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34024401|NCT02908048|||CASE_CONTROL||PROSPECTIVE|||||||
34024402|NCT00170664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024403|NCT04371094|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|double-blinded||t|t|t|f
34024404|NCT03173326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024405|NCT03295981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
34024406|NCT01089634|||OTHER||PROSPECTIVE|||||||
34024407|NCT03219190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34024408|NCT04516993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024409|NCT02217254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024410|NCT04734405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel-arm, Randomized, Active-controlled, Double-blind, Double-dummy|t|t|t|t
34024411|NCT01971957|||CASE_ONLY||PROSPECTIVE|||||||
34024412|NCT02552732|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34024413|NCT06195488|||COHORT||PROSPECTIVE|||||||
34024414|NCT02115932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34024415|NCT05267730|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled trial|f|f|f|t
34024416|NCT05180357|||COHORT||RETROSPECTIVE|||||||
33801170|NCT00702559|||CASE_ONLY||PROSPECTIVE|||||||
33801171|NCT00581035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801172|NCT00320762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34024417|NCT02186626|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34024418|NCT00788320|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34024419|NCT05127512|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33801173|NCT00450359|RANDOMIZED|||SCREENING||||||||
33801174|NCT03381053|||COHORT||PROSPECTIVE|||||||
33801175|NCT01417910|||COHORT||PROSPECTIVE|||||||
34024420|NCT01265810|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34024421|NCT01399879|||CASE_ONLY||CROSS_SECTIONAL|||||||
34024422|NCT03292159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024423|NCT04856410|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study will investigate 10 astronauts on 12-month ISS missions, 10 astronauts on 12-month ISS missions, 10 astronauts on 12-month ISS missions and 10 control subjects that are matched to 12-month mission astronauts and investigated at similar time points.||||
34024424|NCT00418002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34024425|NCT03155945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024426|NCT06022900|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (Participant); single blind study, participants do not know their group|Parallel Assignment randomised control trial|t|f|f|f
34024427|NCT02990780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34024428|NCT01205984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024429|NCT04122144|RANDOMIZED|PARALLEL||OTHER||NONE||Comparative effectiveness cluster-randomized trial||||
34024430|NCT00405808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024431|NCT04386486|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34024432|NCT03563911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024433|NCT00005182|||COHORT||PROSPECTIVE|||||||
34024434|NCT01852500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024435|NCT05597735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Placebo-controlled, Double-blinded Trial|t|t|t|f
34024436|NCT02977312|||COHORT|||||||||
34024437|NCT02819700|||COHORT||PROSPECTIVE|||||||
34024438|NCT03460639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the sham group, the laser will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.|Tiredness will be induced by isometric contraction occlusion time. Patients will be evaluated in two stages. The first moment will be maximum occlusion in all patients in order to be able to measure the individual time for fatigue of the masseter muscle (evaluation by electromyography). The second will have the application of the laser in a group (at the wavelength of 780nm, 134 J / cm2, power of 50 mW irradiance of 1.675 W / cm2, for 80 seconds per point in 3 points in the masseter muscle and one in the temporal muscle on each side); simulation of the application (placebo-psychic factor), control (without application); after this first moment, we will have maximum occlusion in all the patients in order to be able to measure the individual time for fatigue (evaluation by electromyography).|t|f|f|f
34024439|NCT03503526|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized wait list control study with a mixed methods design||||
34024440|NCT00967655||||TREATMENT||NONE||||||
34024441|NCT00525798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34024442|NCT04029753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34024443|NCT00927732|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34024444|NCT06632314|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34024445|NCT06168630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34024446|NCT01781481|||COHORT||CROSS_SECTIONAL|||||||
34024447|NCT00770081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34024448|NCT04780568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024449|NCT01333774|||COHORT||PROSPECTIVE|||||||
34024450|NCT04943276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024451|NCT04410237|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34024452|NCT04239027|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label study||||
34024453|NCT03894514|||COHORT||PROSPECTIVE|||||||
34024454|NCT02955823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024455|NCT03701854|||CASE_CONTROL||PROSPECTIVE|||||||
34024456|NCT03696953|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Double Blind Randomized Placebo Controlled Trial.|Healthy pregnant participants will be randomly assigned to one of two groups (Probiotic vs Placebo) that are blind to participants and researchers. Both groups will take one capsule daily and have the same study measures at the same times.|t|t|t|f
34025579|NCT06549283|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients were divided into two groups: the NIPPV group and the standard care group.~In the NIPPV group, NIPPV was implemented during the entire intubation process (pre-intubation to intubation to the end of successful intubation).~In the standard care group, the intubation attempt proceeded without NIPPV or supplemental oxygen."||||
34025580|NCT00567905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025581|NCT03692884|||COHORT||PROSPECTIVE|||||||
34103505|NCT06688318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33801176|NCT05749523|NA|SINGLE_GROUP||OTHER||DOUBLE|||t|t|f|f
33801177|NCT04484935|NA|SINGLE_GROUP||PREVENTION||NONE|Open: no masking is used. All involved know the identity of the intervention assignment.|||||
33801178|NCT05146375|||FAMILY_BASED||PROSPECTIVE|||||||
33801179|NCT04900766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801180|NCT04456751|||COHORT||RETROSPECTIVE|||||||
33801181|NCT03450200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33801182|NCT00423098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801183|NCT04578496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801184|NCT02207972|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33801185|NCT05372146|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This was a single-center, prospective, non-randomized, non-inferiority comparative study conducted on patients with primary varicose veins|t|f|f|f
34024457|NCT03594058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor representatives Site monitors Data managers Statistician|This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Eligible female subjects (N=1200) with symptoms of overactive bladder for at least 6 months will enter a 14-day single-blind Run-in Period. Subjects (N=375) who meet prespecified criteria based on data entered into an electronic diary over 3 days will be randomized 1:1:1 (125 subjects per arm) to receive solabegron modified release tablets, low dose or high dose, or matching placebo.|t|f|t|f
34024458|NCT00087282||||TREATMENT||NONE||||||
34024459|NCT03263975|RANDOMIZED|PARALLEL||TREATMENT||NONE||Between groups design||||
34024460|NCT04339881|||OTHER||PROSPECTIVE|||||||
34024461|NCT02278055|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34024462|NCT03495349|||COHORT||PROSPECTIVE|||||||
34024463|NCT06374420|||OTHER||PROSPECTIVE|||||||
33719804|NCT01388218|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34024464|NCT02441764|||OTHER||PROSPECTIVE|||||||
34024465|NCT03017612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024466|NCT06349590|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34024467|NCT03303209|||COHORT||PROSPECTIVE|||||||
34024468|NCT03367208|||COHORT||RETROSPECTIVE|||||||
34024469|NCT04730648|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34024470|NCT01664130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024471|NCT04782674|||CASE_ONLY||PROSPECTIVE|||||||
34024472|NCT06016491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|81 people who attended the menopause school and met the inclusion criteria were selected by simple random sampling. Each of the women was allowed to draw from the numbers in the bell, and those who drew odd numbers were assigned to the placebo group, and those who drew even numbers were assigned to the acupressure group. Acupressure pressure point was applied to all women included in the study. Participants were blinded because they did not know whether the women were given acupressure or placebo acupressure. Researchers could not be blinded because they were also practitioners (Melek Yeşil Bayülgen and Fatma Hikmet Yeşil). When the research was completed, the data were analyzed by a statistician who did not know the groups and the findings were reported||t|f|f|f
34024473|NCT01339338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34024474|NCT05293912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024475|NCT04720118|||OTHER||CROSS_SECTIONAL|||||||
34024476|NCT06097455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024477|NCT06160700|||CASE_CONTROL||PROSPECTIVE|||||||
34024478|NCT00919854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024479|NCT05776251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34024480|NCT02079779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34024481|NCT04645836|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|None (Open Label)|Parallel Assignment||||
34024482|NCT03578575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||120 subjects are divided into experimental group and control group (placebo).|t|t|t|f
34024483|NCT01308905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||PET scans will be performed to show the distribution throughout the body of substances containing a small amount of radioactive material.||||
33719805|NCT01058889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719806|NCT00702013|||||CROSS_SECTIONAL|||||||
33719807|NCT05013567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719808|NCT06216145|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33719809|NCT04656145|RANDOMIZED|PARALLEL||TREATMENT||NONE||A paired study design will be used and subjects will serve as their own control.||||
33719810|NCT02756884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719811|NCT04577118|NA|SINGLE_GROUP||OTHER||NONE||||||
33719812|NCT05545254|||OTHER||CROSS_SECTIONAL|||||||
33719813|NCT02278263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719814|NCT00000296||CROSSOVER||TREATMENT||DOUBLE||||||
33719815|NCT00676455|||COHORT||PROSPECTIVE|||||||
33719816|NCT01926314|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33719817|NCT00488345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719818|NCT00055263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719819|NCT00740142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33719820|NCT01303887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719821|NCT03985514|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Selected patients with assumed uncomplicated acute appendicitis are allocated to groups Active observation or Antibiotic treatment in a 1:1 ratio."||||
33719822|NCT01012518|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33719823|NCT06246318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33719824|NCT01005420|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33719825|NCT03194698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33719826|NCT05670990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigators are not involved in recruitment of the participants, and have connections to them in a roll such as employees at the recruiting locations.|The randomization will take place after informed consent has been given. To achieve balance between the two groups (horse-assisted therapy or no horse-assisted therapy) we will use a minimization, so important prognostic factors are evenly distributed between the two study groups, as minimization variables we will use biological sex, age and whether the participants have contact with the child and youth psychiatry or not.|f|f|t|f
33719827|NCT01254526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719828|NCT03263442|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33719829|NCT02890706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33719830|NCT02775734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801186|NCT04156789|||OTHER||PROSPECTIVE|||||||
33801187|NCT01043601|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33801188|NCT03114410|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33801189|NCT00698919|||||PROSPECTIVE|||||||
33801190|NCT02354469|||COHORT||PROSPECTIVE|||||||
33801191|NCT00963404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801192|NCT05402813|||COHORT||PROSPECTIVE|||||||
33801193|NCT03980496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33801194|NCT04638322|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assignment to the groups will be of simple random type and hidden. Those responsible for admitting patients to the intervention phase will not know what group has been assigned each. This assignment will be made in advance by a researcher who will not intervene in the later stages of evaluation, intervention, data recording and elaboration of database. The assignment will be communicated through sealed and totally opaque envelopes.|Randomized Controlled Trial|f|t|t|t
33801195|NCT00593866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33801196|NCT02616068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801197|NCT03840122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33801198|NCT01845844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33801199|NCT04185571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized and included in one of the following 2 groups group 1: PEPA membrane / group 2: non-adsorbent synthetic membrane . The randomization will be stratified on the center|Randomized, single-blind, prospective, multicenter trial, in two parallel arms|t|f|f|f
33801200|NCT00693121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33801201|NCT02840747|||OTHER||PROSPECTIVE|||||||
34024484|NCT05882422|||COHORT||PROSPECTIVE|||||||
34024485|NCT01700101|||COHORT||PROSPECTIVE|||||||
34024486|NCT06632730|||COHORT||RETROSPECTIVE|||||||
34024487|NCT03589040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, non-randomized, open-label, parallel, two-group, sparse-sampling pharmacokinetic study to describe etonogestrel (ENG) pharmacokinetic parameters in two treatment groups (rilpivirine or darunavir- based antiretroviral therapy) in 60 HIV-1 infected women. The primary endpoint is the comparison of the mean ENG concentrations at month 6 between the rilpivirine or darunavir treatment groups versus historical controls.||||
34024488|NCT00387556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34024489|NCT06619769|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Participants will be randomized to receive either the cognitive-behavioural- or mindfulness-based arm of a digital therapeutic known as eSense-Cancer. Participants will also be randomly assigned to a condition that does or does not include support from a treatment navigator - a non-expert study team member to provide support throughout the treatment. Therefore there will be four groups to be compared:~* Cognitive-behavioural therapy + navigator support~* Cognitive-behavioural therapy + no navigator support~* Mindfulness-based therapy + navigator support~* Mindfulness-based therapy + no navigator support"||||
34024490|NCT01265433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34024491|NCT03051932|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34024492|NCT05868512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34024493|NCT06187090|NA|SINGLE_GROUP||TREATMENT||NONE||12-week, open-label, investigator-initiated proof-of-concept study||||
34024494|NCT06633848|||COHORT||PROSPECTIVE|||||||
34024495|NCT05452122|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33719831|NCT00523250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33719832|NCT05737212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In the Phase I clinical study, the 3+3 dose escalation design is applied to evaluate the dose limiting toxicity (DLT) and 3 study subjects are enrolled to each group (Group 1, Group 2, Group 3). Depending on whether or not DLT occurs, 3 subjects at minimum to 18 subjects at maximum are enrolled.~However, in the event a subject assigned a subject number withdraws from the study before starting BNCT or within 90 days from starting BNCT for reasons other than safety, up to 3 additional subjects can be enrolled for each dose group, resulting in 27 subjects at maximum allowed for enrollment for the Phase I clinical study.~In the Phase IIa clinical study, up to 12 subjects are enrolled. However, subjects who are included in a group that has received the radiation dose confirmed as the maximum tolerated dose (MTD) in the Phase 1 clinical study AND satisfy all inclusion/exclusion criteria of the Phase IIa are included in the number of subjects of Phase IIa."||||
33719833|NCT04082325|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33719834|NCT03109587|RANDOMIZED|PARALLEL||OTHER||SINGLE|The study product will be prepackaged and will be supplied and labeled only with the Protocol Number.||f|f|f|t
33719835|NCT04937660|||COHORT||PROSPECTIVE|||||||
33719836|NCT05874661|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not be aware of their group allocation compared to the other.|This study will be a randomized cross over study. Individuals will be randomized into either an internal or external focus condition for the first week of the study and be crossed over to the other condition in the second week.|t|f|f|f
33719837|NCT06130644|||COHORT||CROSS_SECTIONAL|||||||
33719838|NCT06495346|||COHORT||PROSPECTIVE|||||||
33719839|NCT03688581|||COHORT||OTHER|||||||
33719840|NCT04679792|||COHORT||PROSPECTIVE|||||||
33719841|NCT06263751|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Due to the open study design, the NutriConnect team will not be able to have either patient or research coordinator/Schnucks intervention delivers blinded on group assignment. However, the assignment will be hidden from research faculty, the study biostatistician, and study analyst.|"240 patients will be randomized to three arms: usual care, NutriConnect Credit, and NutriConnect Delivery with equivalent monetary value to credit. The interventions will last 6 months."|f|f|f|t
33719842|NCT01441310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33719843|NCT04855825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33719844|NCT02585609|||COHORT||CROSS_SECTIONAL|||||||
33719845|NCT05685082|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33719846|NCT00384722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33719847|NCT03675802|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33719848|NCT01095016|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33719849|NCT01909154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721456|NCT04342845|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Upon receiving a participant's consent form, the independent administrative research assistant would generate a random number by computer to determine allocation to the intervention or control group. For concealment purposes, there was no medical information relating to the participant on the consent form. The assistant only informed participants of their attendance time and not of their grouping. We used the blocked randomization by number 8 which guaranteed that there were four people in both groups in each of the eight people. This method can avoid overbalance between two groups as there might be some people missing halfway."|Two hundred and twenty-five patients, recruited from community health centers (CHCs) and the family medicine clinic in the University of Hong Kong-Shenzhen Hospital in Shenzhen, were randomly assigned to the intervention or control groups. Patients in the intervention group (n = 117) received a four-session PEP in small groups over 1 month by trained nurses and doctors. The control group (n = 108) received the traditional lecture-style health education on DM. All the patients were followed up for 3 months. Outcomes included problem areas in diabetes (PAID) that measures diabetes-related emotional distress, patient enablement index (PEI), mental health, patient satisfaction respectively as well as lifestyle behaviors were assessed at baseline, post-activity and 3 months.|t|f|f|f
33721457|NCT00841087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721458|NCT05359666|RANDOMIZED|PARALLEL||OTHER||NONE||The randomization methodology was controlled by the site for the IRR-CT-901-2013-01 trial. There was no additional randomization for CLP-01.||||
33721459|NCT00192907|||DEFINED_POPULATION||PROSPECTIVE|||||||
33721460|NCT01561820|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721461|NCT02659527|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721462|NCT03394482|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721463|NCT05576493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721464|NCT00726076|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33721465|NCT01797640|||COHORT||RETROSPECTIVE|||||||
33721466|NCT03130166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
33721467|NCT03556579|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33721468|NCT04484233|||CASE_CONTROL||PROSPECTIVE|||||||
33721469|NCT05124951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721470|NCT01912846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33721471|NCT05390229|||COHORT||PROSPECTIVE|||||||
33721472|NCT03664947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721473|NCT02340598|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721474|NCT03577704|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study used the Bayes optimal interval design (BOIN) to assign the subject's dose level and determine the maximum tolerated dose (MTD) of HLX07 in combination with chemotherapy.Each cohort contains 3 subjects and the patient in the first cohort receives treatment at the lowest dose level (single dose of 400 mg). The decision to increase or decrease the dose after each train is based on the probability of a predefined safety and toxicity threshold. When the observed rate of dose limiting toxicity (DLT) is less than 0.237 (low target safety margin), the dose for the next cohort escalates; when the observed rate of DLT is higher than 0.359 (target high toxicity cutoff), the dose deescalates. Otherwise, the dose remains the same. After each cohort is finished, a safety review committee will be held to determine the escalates or deescalates in the next cohort. The enrollment continues until the maximum 30 patients are reached.||||
33721475|NCT05854589|RANDOMIZED|PARALLEL||TREATMENT||NONE||A pilot randomized controlled study, whereas a number of patients with clinically-diagnosed skin Melanoma (any location and any stage), and who were poorly responsive to at least one cycle of conventional and standard therapy, are equally divided into 2 groups, Active and Control groups. Each patient of the Active group will have their Melanoma covered by 2 drops of water, followed by applying Sodium Chloride granules to saturate the melanoma surface then add 2 more drops of water, then cover the NaCl-granules-covered Melanoma with a bandage. The bandage will stay in place for 12 hours daily and the procedure will be repeated daily for a total of 7 consecutive days, in addition to their standard treatments they receive from their health care providers, if any. Each patient of the Control group will undergo the same treatment as the Active group patients minus the Sodium Chloride granules.||||
33721476|NCT05569850|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33721477|NCT06199102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721478|NCT05718258|NA|PARALLEL||TREATMENT||NONE||||||
33721479|NCT03343808|||CASE_ONLY||RETROSPECTIVE|||||||
33721480|NCT00132184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721481|NCT05985850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 1: 1:1 randomization Phase 2: Open-label|t|t|t|t
33721482|NCT00084981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721483|NCT01297140|NA|SINGLE_GROUP||||NONE||||||
33721484|NCT03136679|||CASE_CONTROL||PROSPECTIVE|||||||
33721485|NCT02542878|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721486|NCT06419387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|EMDR Mobile App (Intervention) Group vs. Psycho-educational (Video) Control Group|t|f|f|f
33721487|NCT05849181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Care provider and Investigator blinded|Subject are randomized to either treatment or placebo arm.|t|t|t|f
33721488|NCT05104034|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721489|NCT03336775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes, inclduing VDS, rosenbek Penetration-Aspiration Scale scores, opening of upper esophageal sphincter(UES) and excursion of hyoid bone would be evaluated by two radiologists with blind method.||f|f|f|t
33721490|NCT00795522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721491|NCT05326477|NA|SINGLE_GROUP||OTHER||NONE||||||
33721492|NCT02532647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33721493|NCT04377477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721494|NCT04552392|||CASE_ONLY||CROSS_SECTIONAL|||||||
33721495|NCT05153512|||COHORT||PROSPECTIVE|||||||
33721496|NCT02941445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721497|NCT00946426|||CASE_ONLY||PROSPECTIVE|||||||
33721498|NCT01528254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721499|NCT01127711|||COHORT||PROSPECTIVE|||||||
33721500|NCT00654407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802224|NCT06298305|||COHORT||PROSPECTIVE|||||||
33802225|NCT04048681|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34025667|NCT04392427|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|This search will focus on patients with COVID 19 infection this study is a prospective cohort study based on the analysis of response in comparative panel between two arm Nitazoxanide, Ribavirin and Ivermectin plus Zinc arm and other arm without any intervention as regards the safety and efficacy and cost effective result. Two years duration of the project would be enough to cover the stages of the work as shown below in the time plan. Initial stage of collecting materials and patients' clinical data, each patient will undergoes strict follow up period to reveal the clinical, laboratory and radiological response. The procedures are to be approved by the institutional ethical committee.|"a sequential clinical trial in this design sample size is not fixed in advance. Instead data will be evaluated as they are collected, and further sampling is will be stopped in accordance with a pre-defined stopping rule as soon as significant results are observed. After n (10 subjects in each group) subjects in each group are available an interim analysis will be conducted. A statistical test will be performed to compare the two groups and if the null hypothesis is rejected the trial is terminated; otherwise, the trial continues, another n subjects per group will be recruited, and the statistical test is performed again, including all subjects. If the null is rejected, the trial is terminated, and otherwise it continues with periodic evaluations until a maximum number of interim analyses have been performed, at which point the last statistical test is conducted and the trial is discontinued"|f|f|f|t
34025668|NCT04893018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025669|NCT04735926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025670|NCT05263310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|care provider will not be informed of patient status; outcomes assessor will be blinded to allocation status|pragmatic, clinical efficacy, patient-level randomized clinical trial|f|t|f|t
34025671|NCT02583958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025672|NCT03981692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In the study; sit-up, stand on one leg (eye open-closed), standing 30 sec stop (eye open closed stop), 10 m walk backward, sitting on top of the ball (eye open-closed), transfer of weight on the top-left, walking in a straight line, 30 sec. stop on soft ground (eye open-close), balance training which does not force their efforts will be given in two groups.~Group 1: Integrated Dual Task Training Group performed balance and cognitive tasks simultaneously.~Group 2: Consecutive Dual Task Training Group performed balance and cognitive tasks sequentially.~The cognitive tasks; They were expected to find the letters Z in the mixed letters, search for the five words you read on the previous page, find the similarities between the concepts, find the letter in the given tables, derive the fruit names starting with the letter, count the days of the week, etc. Attention, memory and arithmetic training will be given the ability to run."|t|f|f|f
34025673|NCT05080153|||COHORT||PROSPECTIVE|||||||
34025674|NCT00435812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025675|NCT06338462|NA|SINGLE_GROUP||PREVENTION||NONE||target sample size is an anticipated 120 index persons with TB enrolled over three design cycles||||
34025676|NCT03245112|||CASE_ONLY||OTHER|||||||
34025677|NCT03287843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025678|NCT02563392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025679|NCT02985671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025680|NCT06361875|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Modified double-blind (Participants; Sites except for those preparing/administering study intervention; Sponsor's except Sponsor unblinded internal safety review committee)|Parallel with dose escalation for sentinel cohort|t|f|t|t
34025681|NCT00381914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025682|NCT05248165|||COHORT||PROSPECTIVE|||||||
34025683|NCT03486366|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"With EPIMARKER we aim to develop clinically useful tools enabling accurate and early detection of risk of drug resistant or recurrent seizures and stablish the new therapeutic and preventative possibilities for epilepsy.~The Epimarker algorithms will include selected data obtained in 3 unique models of epilepsy in developing brain.~* EEG recordings and clinical data from a prospective study of drug-resistant epilepsy development in young children with TSC,~* EEG recording and clinical data from a prospective study of epilepsy after antiepileptic drug withdrawal in children with TSC~* Molecular biomarkers in both above clinical setting, established by means of a broad range of molecular analyses, including a diverse set of cutting edge analyses of blood samples, that will be obtained at study entry, at the onset of drug- resistance or recurrent epilepsy, and after 12-month follow-up and the verified in a Epimarker cellular model."||||
34025684|NCT00792350|||COHORT||PROSPECTIVE|||||||
34025685|NCT01023048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025686|NCT03132779|NA|SINGLE_GROUP||TREATMENT||NONE||Women with unexplained recurrent spontaneous abortions having increased NKcells activity||||
34025687|NCT01919788|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34025688|NCT00029029||||SUPPORTIVE_CARE||||||||
34025689|NCT04899544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome raters and video coding rating are blinded to group.||f|f|f|t
34025690|NCT06423807|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025691|NCT01568554|||COHORT||PROSPECTIVE|||||||
34025692|NCT06452667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization numbers will be generated via SAS software version 9.4 by independent blinded personnel outside our research team. We will use the randomization numbers to determine the treatment method for both sides of each case before the study.|Each case will receive 3 sessions of injection therapies with one month interval (T0, T1, and T2). Each case will receive PRP therapy on one side of the face. The other side of the face was treated with platelet-rich fibin (PRF).|t|f|t|t
34025693|NCT01774708|||COHORT||PROSPECTIVE|||||||
34025694|NCT01657812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34025695|NCT00000620|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34025696|NCT01154361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025697|NCT04063150|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148833|NCT01729494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148834|NCT04046172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single-blinded study in which cardio-vascular technician will be blinded.|Total 200 Participants for part 1 (baseline). Randomization (Part 2) Control Test group (n=15) control group (n=15)|f|f|f|t
33802226|NCT02849054|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802227|NCT03840421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802228|NCT00197613|RANDOMIZED|PARALLEL||||NONE||||||
33802201|NCT04127669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization done externally. IMP codes are contained in sealed envelopes (one envelope for each randomized patient) locked in a drawer at the Gottfries Clinic AB. No envelope is opened prior to the end of the study unless it is critical for the treatment/outcome of an adverse event. In the event of a medical emergency, essential for the clinical management or welfare of the patient, the Investigator may decide to break a patient's treatment code. If the blind is broken, the Investigator must notify the monitor as soon as possible without revealing the patient's study treatment assignment, unless the information is important for the safety of the patients remaining in the study. The Investigator will record the date and reason for breaking the blind for that patient in the hospital records. The coded medicine packages are distributed to the site where the study nurse/investigator are responsible for dispensing the packages to the patients according to the randomization list.|This study is a randomised, placebo-controlled, parallel-group (two-armed) study of 16 weeks' treatment duration, comparing OSU6162 with placebo treatment in patients with residual symptoms after stroke.|t|t|t|t
34103603|NCT02301793|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Within strata, a coin toss (ERH) was used to randomize floors into either the Dynamic education arm or the Static education arm. Based on the outcome of the coin toss, nurses were then remotely assigned the online education module by an institutional nurse educator (DLS). The assigned educational module then appeared in the nurse's list of education assignments for completion within the institutional Learning Management System. Nurses are required to complete clinically relevant education regularly as part of ongoing professional practice and a waiver of consent was provided by the IRB; therefore nurses were not aware of their participation in a trial nor were they aware that two education modules existed. Additionally, the VTE prophylaxis medication non-administration dataset provided to the biostatistical team (i.e. outcomes assessors) for analysis was blinded by treatment arm and department.|One arm was provided linear static education (Static) using PowerPoint slides with voiceover to cover the concepts. The other arm was provided interactive learner-centric dynamic scenario-based education (Dynamic), where each scenario resulted in either positive reinforcement or corrective feedback with an opportunity to apply knowledge to a new scenario.|t|f|f|t
34103604|NCT05159739|||COHORT||PROSPECTIVE|||||||
34103605|NCT01704573|||COHORT||PROSPECTIVE|||||||
34103606|NCT06569966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103607|NCT06196320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802202|NCT02560649|RANDOMIZED|||TREATMENT||NONE||||||
33802203|NCT04064086|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The study compares a comprehensive education with the standard of care. Thus it is not possible to mask investigator, participant or care provider. However, our statistician will assess the outcomes aggregates in a blinded manner.||f|f|f|t
33802204|NCT04024124|||COHORT||PROSPECTIVE|||||||
33802205|NCT02232295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802206|NCT02523716|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33802207|NCT02621086|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Ascending dose tolerability study||||
33802208|NCT03810859|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802209|NCT00276796||||TREATMENT||NONE||||||
33802210|NCT04011813|||COHORT||PROSPECTIVE|||||||
33802211|NCT05075486|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pre- and post- interventional study in one group.||||
33802212|NCT03841175|||COHORT||RETROSPECTIVE|||||||
33802213|NCT00550394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802214|NCT02055742|||COHORT||PROSPECTIVE|||||||
33802215|NCT04772300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||1:1-randomization, parallel design, stratified by center.|t|f|f|t
33802216|NCT02472275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802217|NCT06255262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802218|NCT05363436|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Control group, measurement, intervention group||||
33802219|NCT02795754|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33802220|NCT01821989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33802221|NCT04718610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||For each cancer type, 30 patients will be included. These patients will be randomized into two groups.||||
33802222|NCT06150833|NA|SINGLE_GROUP||TREATMENT||NONE|The trial will be open-label and single-arm. Therefore, there will be no randomization or blinding.|Patients with primary immunodeficiency will switch to Boya IVIG and optimize the posology in a run-in period of 2 to 6 administrations. In the one-year test period, the patients will receive the test IVIG at 21- or 28-day intervals and be followed. IgG trough levels will be collected from all participants, at all visits. The remaining pharmacokinetic parameters will be measured between visits 4 and 5 in 20 adult participants, collecting additional blood samples.||||
33802223|NCT06482632|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"This study intends to report the incidence of dysphagia in patients who underwent multilevel Anterior Cervical Discectomy and Fusion with or without omohyoid transection during the surgical approach. Patients selected for this study will be those who are treated at the University District Hospital (UDH) of the UPR - SOM.~The study is composed of patients who underwent ACDF at our institutions. Randomization of dissected Omohyoid was performed utilizing an online computer-generated sequence (www.graphpad.com/quickcalcs/randomN1.cfm). A request for the waiver of authorization to release health information will be completed. After the research committee approves, medical records will be reviewed to gather information such as age, gender, smoking status, diabetic status, body mass index (BMI), inpatient medications, and discharge medications. After discharge, patients undergoing this procedure are followed up at outpatient clinics."|f|t|t|f
34103608|NCT06671392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103609|NCT03884920|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34103610|NCT01018771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103611|NCT01473784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103612|NCT00395447|||COHORT||PROSPECTIVE|||||||
34103613|NCT04767646|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103614|NCT05114551|||COHORT||PROSPECTIVE|||||||
34103615|NCT04560998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34103616|NCT06520553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103617|NCT00181545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103618|NCT02448173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103619|NCT06660030|||COHORT||PROSPECTIVE|||||||
34103620|NCT04710303|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103621|NCT04223687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103622|NCT04886063|NA|SINGLE_GROUP||TREATMENT||NONE||Open label extension||||
34103623|NCT05476848|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Care provider, investigator and outcome assessors are chosen from separate specialists (Intensive Care Unit, Dentistry, Infectious Disease Departments).||f|t|t|t
34103624|NCT05818007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103625|NCT01259531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103626|NCT05851365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103627|NCT00698412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721501|NCT03804944|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Patients will be randomly assigned to one of the following arms. 1. Anti-PD1 antibody pembrolizumab (Keytruda, Merck) will be infused day 12, at the standard dose of 200 mg IV over 30 minutes, repeated every 3 weeks until disease progression or unacceptable toxicity. 2. FLT3L (CDX-301, the recombinant human protein by Celldex) will be self-administered subcutaneously, in 5 consecutive daily injections, week 1, day 1-5.~3. For all arms radiation therapy to the breast tumor will begin on week 2 (Day 8,10,12), at dose of 8 Gy x 3 fractions, every other day. 4. Letrozole (Femara ®, Novartis) 2.5 mg tabs, once a day, daily for 4 months, until surgery, and thereafter is decided by the treating physician"|"Patients will be on the study for a total of 5 months, this includes 4 months on active study intervention, with breast surgery at week 16 and one month follow up period, after surgery. Patients will be randomly assigned to one of the following arms. 1. Anti-PD1 antibody pembrolizumab (Keytruda, Merck) will be infused day 12, at the standard dose of 200 mg IV over 30 minutes, repeated every 3 weeks until disease progression or unacceptable toxicity. 2. FLT3L (CDX-301, the recombinant human protein by Celldex) will be self-administered subcutaneously, in 5 consecutive daily injections, week 1, day 1-5.~3. For all arms radiation therapy to the breast tumor will begin on week 2 (Day 8,10,12), at dose of 8 Gy x 3 fractions, every other day. 4. Letrozole (Femara ®, Novartis) 2.5 mg tabs, once a day, daily for 4 months, until surgery, and thereafter is decided by the treating physician"||||
33836959|NCT02185105|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34103628|NCT03428828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103629|NCT05660291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103630|NCT01154998|||CASE_CONTROL||RETROSPECTIVE|||||||
34103631|NCT06687369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34103632|NCT01757496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103633|NCT04518943|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Data will be masked to the principal investigator.|The MOST trial design involves optimizing an intervention before it is tested against a usual control. It is optimized in that the various components of the intervention are tested against one another in a screening phase to assess which components add value to the intervention, and then only the valuable components are included in the final intervention. It is especially useful when an intervention has many potential combinations of components, as is the case with incentives. In a traditional trial, researchers would use theory or evidence from prior studies to choose an incentive design and test this package against usual care. Even if this package outperforms usual care in a randomized trial, the investigators cannot tell whether it was optimal. Some components could have provided no benefit or delivered in too small a dose to be effective. Other components could have been detrimental to subjects. There is no way to know if the components are all tested as a single package.|f|f|t|f
34103634|NCT04245579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103635|NCT01661465|||OTHER||RETROSPECTIVE|||||||
34103636|NCT02580006|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34103637|NCT06550310|||COHORT||PROSPECTIVE|||||||
34103638|NCT06498791|||COHORT||PROSPECTIVE|||||||
34103639|NCT05750004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103640|NCT02172651|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34103641|NCT03138382|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double-blind|"* Crossover design~* Double-blind~* Randomized"|t|f|t|t
34103642|NCT03594656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103643|NCT01003964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103644|NCT01443611|||CASE_ONLY||RETROSPECTIVE|||||||
34103645|NCT02120248|RANDOMIZED|SINGLE_GROUP||PREVENTION||||||||
34103646|NCT01272219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103647|NCT02576704|||COHORT||PROSPECTIVE|||||||
34103648|NCT05430919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103649|NCT06682832|||COHORT||CROSS_SECTIONAL|||||||
34103650|NCT01275677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103651|NCT00002011||||TREATMENT||NONE||||||
34103652|NCT04835597|||COHORT||PROSPECTIVE|||||||
34103653|NCT01924663|||CASE_ONLY||OTHER|||||||
34103654|NCT01866735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34103655|NCT06651060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized to view a menu based on a real-world restaurant with one of six labeling schemes applied: 1) a QR code on all items (control); 2) High Climate Impact label; 3) High Climate Impact Warning label; 4) Climate Grade label; 5) Climate Grade label also displaying full range of possible grades; 6) Estimated Environmental Cost label. Menus will include main items only. Labels will only appear alongside main menu items and will be assigned using thresholds for greenhouse gas emissions set a priori in kilograms of CO2 equivalent per kilogram of food. Each participant will view a menu based on a real-world restaurant with one of the 6 labels shown on applicable menu items, select the menu item(s) they would like, then respond to survey questions about each label.|f|f|t|f
34103656|NCT06549907|||COHORT||PROSPECTIVE|||||||
34148835|NCT01956370|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34148836|NCT05338203|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148837|NCT00226135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148838|NCT00930969|||COHORT||PROSPECTIVE|||||||
34148839|NCT01051401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148840|NCT06088160|||COHORT||PROSPECTIVE|||||||
34148841|NCT00768872|||CASE_ONLY||PROSPECTIVE|||||||
34148842|NCT00109356|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721502|NCT05946850|||COHORT||PROSPECTIVE|||||||
34103657|NCT05898334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each qualified patient to receive a coded subject number and the same code-matched product. Other than the Informed Consent form, all study information will be recorded by using the coded subject number. Before the blinded statistical report is issued, no one knows the type of the study products - either a positive or a placebo product.|The biostatistician will prepare a randomization schedule including a serial of subject numbers/product codes. Each placebo or treatment product will be individually labeled with a code. The study coordinator will randomly assign each qualified patient to receive a coded subject number and the same code-matched product. Other than the Informed Consent form, all study information will be recorded by using the coded subject number. The Principal Investigator, study physicians, study coordinator, study specialist, data-entry specialist, biostatistician, as well as the participant and caregiver, will be blinded about who received the placebo or treatment product. At the end of the 4-week study, the participants in the Control Group can be treated with the active device for 4 weeks to observe the efficacy. Their data will be used for a self-comparison analysis.|t|t|t|t
34103658|NCT04437823|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1 (15 subjects) Fifteen (15) subjects will be treated with three intravenous infusion (IV) of 5 x 10\^5 (per Kg body weight) UCMSCs delivered via peripheral intravenous infusion on days 1, 3 and 5 besides the standard care (SOC).~Group 2 (5 subjects) Five (5) subjects will be treated under SOC. From two subjects in group 1 will not be treated 24hrs apart. Patients will be randomized in a 1:3 ratio (SOC: UCMSC)."||||
34103659|NCT02322931|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103660|NCT05481164|||COHORT||PROSPECTIVE|||||||
34103661|NCT02355509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34103662|NCT00000501|RANDOMIZED|||PREVENTION||||||||
34103663|NCT01908699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34103664|NCT06113198|NA|SINGLE_GROUP||PREVENTION||NONE|Data will be collected in an open label manner.|||||
33721503|NCT04810676|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34103665|NCT06432725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34103666|NCT04939103|||CASE_ONLY||PROSPECTIVE|||||||
34103667|NCT04590963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded study|Parallel study. Participants will be randomized in a 2:1 ratio to monalizumab and cetuximab or placebo and cetuximab.|t|t|t|t
34103668|NCT06508502|||COHORT||PROSPECTIVE|||||||
34103669|NCT02344498|||COHORT||PROSPECTIVE|||||||
34103670|NCT05865886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148843|NCT00346645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148844|NCT02064972|||CASE_ONLY||PROSPECTIVE|||||||
34148845|NCT05693454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double blind|randomized, double blind, controlled|t|f|t|f
34148846|NCT03233438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150978|NCT02475616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721504|NCT03731884|||COHORT||PROSPECTIVE|||||||
33721505|NCT01622699|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33721506|NCT01948128|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721507|NCT02378363|||||PROSPECTIVE|||||||
33721508|NCT01983358|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33721509|NCT01813539|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33721510|NCT00000999||||TREATMENT||NONE||||||
33721511|NCT05376696|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Students will not be told whether they are receiving the intervention or the active control treatment.|In this study, the students will be randomized to either the treatment group to receive the proposed intervention (Set for Variability) or the active control arm. This group will receive current best practices reading. After randomization, each participant will stay in their assigned treatment arm for ten weeks.|t|f|f|f
33721512|NCT02933710|||OTHER||PROSPECTIVE|||||||
33721513|NCT04617990|||COHORT||CROSS_SECTIONAL|||||||
33721514|NCT04969549|NA|SINGLE_GROUP||TREATMENT||NONE||Active TBS.||||
33721515|NCT00579956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721516|NCT04562285|||COHORT||RETROSPECTIVE|||||||
33721517|NCT02604524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721518|NCT05894733|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33721519|NCT04264598|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33721520|NCT00823927|||CASE_CONTROL||PROSPECTIVE|||||||
33721521|NCT01974375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721522|NCT05058248|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective non-randomized study comparing the group of patients who received general anesthesia and pudendal block in a historical cohort of patients treated by the standard establishment protocol, that is to say under general anesthesia without locoregional anesthesia.||||
33802229|NCT04156204|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal Pilot Study||||
33802230|NCT00677469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33836960|NCT00809367|NA|SINGLE_GROUP||||NONE||||||
33721523|NCT03619187|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is an open-label, single-arm, multicenter study||||
33721524|NCT02263755|||COHORT||OTHER|||||||
33721525|NCT00926874|||COHORT||PROSPECTIVE|||||||
33721526|NCT03935373|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721527|NCT03370354|||COHORT||PROSPECTIVE|||||||
33721528|NCT06053073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721529|NCT01109251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836961|NCT03428906|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The study utilized a randomized, double-blind, PBO controlled, within-subject design, in which each participant was tested under two acute treatment conditions separated by at least 1 wk wash-out period.|t|f|t|f
33837700|NCT01611597|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33837701|NCT00335751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837702|NCT05089747|||COHORT||PROSPECTIVE|||||||
33837703|NCT04641169|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33837704|NCT03483610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837705|NCT02224547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721530|NCT06370559|||COHORT||RETROSPECTIVE|||||||
33721531|NCT02165436|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103671|NCT04991597|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blind to the solution ratio of each injection, injector will not be blind to solution to ensure safety.|Palmar aspect of participants forearms will be randomized to have either a cold compress pack or a room temperature compress pack placed on it. The cold compress pack serves as the trial intervention and the room temperature compress pack serves as the placebo. Each forearm will then be injected with both a 3:1 (experimental ratio) and a 9:1 (standard ratio) mixture of lidocaine with epinephrine:sodium bicarbonate in a randomized order.|t|f|f|f
34025698|NCT05379673|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be blinded to the received treatment. The investigators, who will monitor the patients and collect the data in the PACU, will be blinded to the primary outcome, but not to the received treatment.|In the post-anesthesia care unit (PACU), participants will be randomized to receive conservative (titrated to an SpO2 between 90 and 94%) versus liberal (titrated to SpO2 \> 96%) oxygen supplementation, via a non-rebreather mask.|t|f|f|t
34025699|NCT02018380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025700|NCT05339334|NA|SINGLE_GROUP||OTHER||NONE||||||
34025701|NCT03437031|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel randomized controlled trials||||
34025702|NCT05856006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025703|NCT00384930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025704|NCT06467799|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025705|NCT04368390|||CASE_ONLY||OTHER|||||||
34025706|NCT00506584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34025707|NCT03496610|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025708|NCT04638075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a randomized controlled trial comparing the SNS to bottle feeding. Once eligibility is determined and consent is obtained, the Primary Investigator (PI)/ Co-Investigator (CI) will randomize the mother-neonate dyad to either bottle supplemental feedings (group A) or SNS supplemental feedings (group B). Randomization will be done by using a computer-generated table of random numbers. Breast milk feeding and exclusive breastfeeding rates will be compared between both groups during the last 24 hours of hospitalization, at day of life 14 and at day of life 28.||||
34025709|NCT00086281|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34025710|NCT04215276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025711|NCT03523078|||COHORT||PROSPECTIVE|||||||
34025712|NCT05778903|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34025713|NCT01161134|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025714|NCT02473679|||COHORT|||||||||
34025715|NCT03940625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025716|NCT01233739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025717|NCT05421026|||OTHER||CROSS_SECTIONAL|||||||
34025718|NCT02987452|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34025719|NCT06355102|||CASE_CONTROL||PROSPECTIVE|||||||
34025720|NCT06125808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025721|NCT00627861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025722|NCT04717492|||COHORT||PROSPECTIVE|||||||
34025723|NCT06007833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants didn't know taking which exercise treatment methods.|Experimental, Randomized Controlled Study|t|f|f|f
34025724|NCT06602960|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34025725|NCT02766933|||COHORT||PROSPECTIVE|||||||
34025726|NCT05520515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be implemented for the outcome assessors. All tests and questionnaires will be supervised by an evaluator blinded to the participant's group. Due to the type of intervention, the investigator conducting exercise sessions and participants will not be blinded.|The WaterMama trial is a randomized, single-blinded, three-arm, parallel, superiority trial. Forty-eight women, ≥18 years of age, who have completed primary treatment and been diagnosed with stage I-III breast cancer are recruited. Participants are randomly allocated on a 1:1:1 ratio to 12-week interventions of aerobic exercise training programs either on the aquatic or land environment two times per week plus health education, or an active-control group receiving health education intervention, once a week.|f|f|f|t
34025727|NCT02207712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025728|NCT02194348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025729|NCT04880603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34025730|NCT02572414|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34025731|NCT02888587|||COHORT||PROSPECTIVE|||||||
34025732|NCT05204082|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025733|NCT06352918|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34025734|NCT04932161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025735|NCT05213039|||CASE_ONLY||PROSPECTIVE|||||||
34103672|NCT03997500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025736|NCT01728129|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34025737|NCT04645537|||COHORT||RETROSPECTIVE|||||||
34103673|NCT00683072|||CASE_ONLY||PROSPECTIVE|||||||
34103674|NCT02940223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34103675|NCT03207087|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Single group assignment||||
34103676|NCT06693947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721532|NCT00310128||||TREATMENT||||||||
33721533|NCT00149084|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33721534|NCT05643365|||CASE_ONLY||OTHER|||||||
33721535|NCT02605707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721536|NCT02545101|||COHORT||RETROSPECTIVE|||||||
33721537|NCT01456104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721538|NCT01879241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025738|NCT05629975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34025739|NCT01427530|||CASE_ONLY||PROSPECTIVE|||||||
34025740|NCT04925193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721539|NCT03986320|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Sites will enroll participants in order of recruitment. No other randomization procedure will be applied.|Device: Keeogo™ Dermoskeleton This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.||||
34025741|NCT01371812|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34025742|NCT01520870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025743|NCT01900561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025744|NCT00099879|RANDOMIZED|||TREATMENT||||||||
34025745|NCT04646005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025746|NCT00323466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025747|NCT05615831|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025748|NCT02904824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025749|NCT06233903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025750|NCT01860352|NA|SINGLE_GROUP||OTHER||NONE||||||
34025751|NCT01577589|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34025752|NCT05884294|RANDOMIZED|PARALLEL||OTHER||SINGLE|This study will be blind to statistical analysis.|randomized, parallel, open, controlled, and single-center clinical trial.|f|f|f|t
34025753|NCT03521843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|only the doctors know the group the patient goes into||t|f|f|f
34025754|NCT04026386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025755|NCT06632288|||OTHER||PROSPECTIVE|||||||
34025756|NCT02538965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025757|NCT01722201|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025758|NCT03938623|||CASE_CONTROL||PROSPECTIVE|||||||
34025759|NCT04924257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025760|NCT01582152|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025761|NCT06015763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Endoscopic||||
34025762|NCT04141930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025763|NCT06548178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025764|NCT00659958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025765|NCT02110498|||COHORT||PROSPECTIVE|||||||
34025766|NCT01012310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025767|NCT01256944|||COHORT||PROSPECTIVE|||||||
34025768|NCT03257865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants received a dose of brexpiprazole or placebo for a maximum of 21 days and were evaluated throughout the duration of the study.|t|t|t|t
34025769|NCT01199016|||COHORT||PROSPECTIVE|||||||
34025770|NCT03844386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study in which both the participant and the investigator are blinded to what the participant receives.|Participants will be randomized 7(M3):7(M4):7(M3+M4):3(Placebo) to one of four study arms, and receive study treatment or placebo at Day 0.|t|f|t|f
34025771|NCT01014377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025772|NCT02985216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025773|NCT01352416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025774|NCT03510026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025775|NCT05786209|NA|SINGLE_GROUP||OTHER||NONE||||||
34103677|NCT04725188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Arm 1 and Arm 3: Double-blind with in-house blinding Arm 2: Unblinded Open-label||t|f|t|f
34103678|NCT06685978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103679|NCT01713322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33721540|NCT05436847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721541|NCT05409144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721542|NCT04378140|||COHORT||PROSPECTIVE|||||||
33721543|NCT00296933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025776|NCT01680003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025777|NCT04616430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025778|NCT00071279|RANDOMIZED|||||DOUBLE||||||
34025779|NCT00916760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025780|NCT03568097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025781|NCT03223844|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34025782|NCT01577940|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34025783|NCT04222803|||CASE_CONTROL||PROSPECTIVE|||||||
34025784|NCT00003602|RANDOMIZED|||TREATMENT||||||||
34025785|NCT00240565|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025786|NCT04748965|||COHORT||PROSPECTIVE|||||||
34025787|NCT00753662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025788|NCT02522715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025789|NCT01226407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025790|NCT06121934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The recruiter, caregiver, randomizer, and investigator all are blinded, except for the manufacturer|Two arms are being used in this study, One arm contains active drug and other contains placebo|t|t|t|t
34025791|NCT03451552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There is no masking in the study.The participant, their primary care provider, and the study team will know which arm the patient is in.|"This is a prospective, mixed method (patient) randomized controlled trial of navigation services provided by Ontario 211 vs. navigation services provided by a lay Patient Navigator. Randomization is 1:1 control:intervention.~The mixed method design is a sequential, explanatory design. Patients having consented to participate in the study will complete a survey, after which their random assignment to one of two arms (intervention or control) will be revealed.~The randomization schedule will be blocked at the practice level to ensure a balance of control and intervention patients for each practice, including all providers.~Patients randomized to the intervention arm will have access to services provided by the ARC Patient Navigator, whereas patients randomized to the control arm will be directed to the Ontario 211 navigation service."||||
34025792|NCT06633809|||COHORT||PROSPECTIVE|||||||
34025793|NCT01908907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025794|NCT04590352|||COHORT||PROSPECTIVE|||||||
34025795|NCT00721227|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025796|NCT01326650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721544|NCT00843583|||CASE_ONLY||CROSS_SECTIONAL|||||||
34025797|NCT03171974|NA|SINGLE_GROUP||TREATMENT||NONE||one treatment group||||
34025798|NCT03638544|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double blind placebo controlled Gluten Sensitivity|t|t|t|f
34025799|NCT06197165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025800|NCT05567276|||COHORT||PROSPECTIVE|||||||
34025801|NCT06002581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34025802|NCT04787679|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721545|NCT03630575|NA|SINGLE_GROUP||OTHER||NONE||||||
34025803|NCT06223386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33721546|NCT06186531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo-controlled, parallel group design with open-label extension.|t|t|t|t
33802231|NCT05359653|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"This is a 6-month randomized double-blinded, placebo-controlled, delayed treatment study examining clemastine fumarate as a remyelinating agent in participants with multiple sclerosis. This trial will include n = 74 patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis.~Patients who fulfill the enrollment criteria will be randomly assigned (1:1) via block randomization using a random number generator to receive either clemastine for 90 days followed by placebo for 90 days (Clemastine 8 mg, then Placebo) or placebo for 90 days followed by clemastine for 90 days (Placebo, then Clemastine 8 mg).~If they are on one, patients will be permitted to remain on their standard disease-modifying treatment during the course of the study. These therapies have no identified effect on remyelination."|t|t|t|t
34025804|NCT01013558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33838983|NCT02767752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025805|NCT05673811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838984|NCT02387268|NA|SINGLE_GROUP||SCREENING||NONE||||||
33838985|NCT03081273|||COHORT||RETROSPECTIVE|||||||
34025806|NCT03507647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be assessed by independent research assistants blind to condition. Participants will be instructed to avoid unblinding as much as possible.|Randomized, multicenter, prospective, evaluator-blinded clinical trial of MBCT added to treatment as usual (TAU) versus TAU alone|f|f|f|t
34025807|NCT00843635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34025808|NCT03741712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025809|NCT04106661|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data was de-identified prior to analysis.|Pretest-posttest control group design: The groups were determined by convenience sample due to the time-sensitive need to form the exercise groups. There were two arms of the study that aligned with two concurrent academic years. The first six participants to express interest were placed in the first Tai Chi intervention group. The next three participants were in the first control group. The second arm of the study had five participants who made contact before the second exercise group began. The second control group had three participants.|f|f|f|t
34025810|NCT06398275|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025811|NCT01867203|||COHORT||PROSPECTIVE|||||||
34025812|NCT05410886|||OTHER||PROSPECTIVE|||||||
34025813|NCT06499740|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"It is anticipated that primary care physicians will deliver initial suicide risk screening, and will refer participating patients and their caregivers to an embedded social worker or integrated mental health clinician within the clinic who will deliver either treatment as usual (TAU; months 1 and 2 of the trial) or the pilot intervention (months 3 and 4 of the trial) to patients endorsing low to moderate suicide risk.~Patients will only participate in treatment as usual or the pilot intervention. Outcomes will be compared across the TAU and intervention conditions."||||
34025814|NCT03486691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025815|NCT03423186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study was designed to include three arms, up to 20 mg/kg. After a company decision to end the development of the compound it was decided to not start a third cohort, but if stated safe the dose could increase up to 20 mg/kg in cohort 1 and 2.||||
34025816|NCT01830790|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34025817|NCT00391963|||||PROSPECTIVE|||||||
34025818|NCT03039270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the color evaluator nor the statistician were aware of the allocation of the hemiarcs, according to the sonic activation or not of them. In the execution of the intervention, the sonic activation was applied in sites such as marginal gingiva, premolars, palatal face of the teeth, in order to mask the treatment.|Randomized, controlled clinical trial, triple-blind, split-mouth type.|t|f|t|t
34025819|NCT05436314|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34025820|NCT03407248|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34025821|NCT01130597|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025822|NCT04779554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025823|NCT01693796|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025824|NCT06197269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025825|NCT06626295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103680|NCT03848052|||COHORT||RETROSPECTIVE|||||||
34103681|NCT06681012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103682|NCT05999721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33721547|NCT01365507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721548|NCT02553850|||COHORT||PROSPECTIVE|||||||
33721549|NCT04760366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721550|NCT01531374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721551|NCT03077802|RANDOMIZED|PARALLEL||OTHER||DOUBLE||randomized controlled trial|t|f|f|t
33838986|NCT00867464|||CASE_CONTROL||PROSPECTIVE|||||||
33838987|NCT06179225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838988|NCT04664075|||CASE_ONLY||CROSS_SECTIONAL|||||||
33838989|NCT04976647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838990|NCT02931253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838991|NCT04953962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838992|NCT03831542|||CASE_CONTROL||PROSPECTIVE|||||||
33838993|NCT03388476|||COHORT||PROSPECTIVE|||||||
33838994|NCT00867984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33838995|NCT01227291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838996|NCT03454841|||COHORT||PROSPECTIVE|||||||
33838997|NCT05137314|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-Label, Dose-Escalating||||
33838998|NCT04708951|RANDOMIZED|PARALLEL||SCREENING||NONE||Subjects will be randomized to one of two groups - ECV colonoscopy or G-EYE® colonoscopy||||
33838999|NCT03714568|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33839000|NCT00122213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839001|NCT03078569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103683|NCT02269774|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34103684|NCT05227014|||COHORT||PROSPECTIVE|||||||
34103685|NCT04300790|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This is a multicenter, open-label, three-cohort, Simon's two stage design, phase II clinical trial.~Cohort A: Normal fasting glycemia \< 100 mg/dL and HbA1c \< 5,7: 48 patients (20 stage 1 + 28 stage 2). Patients in cohort A will receive.~Cohort B: fasting glycemia 100 mg/dL (5.6 mmol/L) to 140mg/dL (7.8 mmol/L). 20 patients (7 stage 1 + 13 stage 2).~Cohort C: T2DM diagnosed clinically ≥ 90 days prior to screening, HbA1c \< 7,5 %, insulin naïve (5 during stage I + 15 during stage II)."||||
34103686|NCT06688045|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34103687|NCT06115603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and researchers interacting with participants will be blind to condition. An unblinded researcher team will randomize and label all pipettes containing CBG or placebo prior to each participants' session. Participants will receive individual, 1 mL pipettes containing CBG and placebo (pipettes are indistinguishable).||t|f|t|t
34103688|NCT04473833|NA|SINGLE_GROUP||SCREENING||NONE||||||
34103689|NCT06569329|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802232|NCT04750070|RANDOMIZED|PARALLEL||TREATMENT||NONE||Systematic evaluation of the effects of inotrope(s) and vasopressor or blood transfusion in children with dehydrating diarrhea (for example, in cholera) and SAM or severe underweight having shock and unresponsive to WHO standard fluid therapy||||
34103690|NCT04850625|||COHORT||RETROSPECTIVE|||||||
33802233|NCT00704314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34103691|NCT01837953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103692|NCT02327780|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103693|NCT03047044|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34103694|NCT05535855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103695|NCT00005995||||TREATMENT||||||||
34103696|NCT02496156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2 group (Usual Clinical Practice or Shared Medical Decision Making X 5 time points (0, 3, 6, 9 and 12 months) repeated measures randomized treatments design.||||
34103697|NCT02026154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34103698|NCT03662529|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were effectively block-randomized either into individual treatment as usual (TAU)(practitioners who administered TAU) OR individual therapy with the study intervention (Mind Freedom Plan), where data from both arms was collected in parallel.||||
34103699|NCT01674361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103700|NCT00470808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103701|NCT05156177|||COHORT||PROSPECTIVE|||||||
34103702|NCT06468930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103703|NCT06690502|||COHORT||RETROSPECTIVE|||||||
34103704|NCT05600257|||COHORT||RETROSPECTIVE|||||||
34103705|NCT06690320|RANDOMIZED|PARALLEL||SCREENING||SINGLE|statistical evaluation of the research results will be made by an expert other than the researcher|"Research population: The population of this research consists of women who received 301 or more points from the breast cancer risk assessment form who applied to the family medicine polyclinic and general surgery breast polyclinic of Ordu University Training and Research Hospital in Ordu province between 2023-2024.~In the study, the sample size was calculated at a 95% confidence level using the G. Power-3.1.9.2 program. As a result of the analysis, the standardized effect size was found to be 1.1270 at the α=0.05 level, based on the previous study, and the minimum sample size was calculated as 60 with a theoretical power of 0.99, 30 for the experimental group and 30 for the control group. Considering the losses, it was decided to collect 20% more and it was aimed to reach 72 people, 36 for the experimental group and 36 for the control group."|f|f|f|t
34103706|NCT02423954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103707|NCT04519138|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|The order of the instruments to be used is blinded to the endoscopist until after the tumor has been visualized to avoid and minimize the influence of the choice of instrument of where the sample is taken. Closed envelopes prepared according to a randomization list stratified by site are available at each site. The envelope is opened by an assistant and not shown to the examiner until the tumor has been visualized.|Both the Endodrill Model X device and the standard instrument are used on the same lesion and patient to evaluate both instruments and their functions under as similar circumstances as possible.||||
34103708|NCT06543537|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34103709|NCT02594943|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34103710|NCT06691152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721552|NCT03851042|RANDOMIZED|PARALLEL||OTHER||SINGLE|Upon enrollment, the patient will be randomized using the REDcap randomization tool.|patients will be randomized to either receive virtual reality headsets in the post anesthesia recovery unit (PACU) as an adjunct therapy or undergo routine postoperative management.|t|f|f|f
33721553|NCT01802723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721554|NCT00499018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721555|NCT03342287|||COHORT||PROSPECTIVE|||||||
33721556|NCT02870660|||COHORT||PROSPECTIVE|||||||
33721557|NCT05175690|||CASE_ONLY||PROSPECTIVE|||||||
33721558|NCT05741515|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinicians doing the functional outcome measures (FGA, DVA, SOT) will not know the result of the vestibular function tests.|prospective single arm feasibility clinical trial. We will also enroll 3 children in a control intervention group, but these will be children without the condition, to determine the feasibility of the control intervention.|f|f|f|t
33721559|NCT03453684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721560|NCT02201654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721561|NCT01481142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802234|NCT01730352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802235|NCT00230672|||COHORT||PROSPECTIVE|||||||
33802236|NCT00099931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802237|NCT01392638|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33802238|NCT02178241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802239|NCT04047719|||COHORT||PROSPECTIVE|||||||
33802240|NCT02879760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802241|NCT02672930|||COHORT||PROSPECTIVE|||||||
33802242|NCT01586936|||COHORT||RETROSPECTIVE|||||||
34025826|NCT04593576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721562|NCT05635227|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|"The dexamethasone intervention will be carried out by the nurse anesthetist and the perfusionist, and accordingly will be un-blinded. The perfusionists and the nurse anaesthetist will not be involved in any postoperative clinical care, outcome evaluation, or data analyses. The participant, trial staff, and all clinical personnel with the exception of the nurse anaesthetist and perfusionist will be blinded.~The olanzapine intervention will be blinded for all; including the participant, trial staff, and all clinical personnel.~The hemodynamic and ventilatory strategy interventions will be unblinded for the staff in the operating theatre (OR). The interventions will be blinded for the participants, trial staff and clinical personnel outside the OR."|The trial assumes a priori that any effect of each of the four interventions are independent from any effect of another intervention.|t|f|t|t
33721563|NCT01735643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721564|NCT06162442|||COHORT||PROSPECTIVE|||||||
33721565|NCT00045279||||TREATMENT||NONE||||||
33721566|NCT01754233|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33721567|NCT03914040|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721568|NCT01522755|||COHORT||PROSPECTIVE|||||||
33721569|NCT01786954|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33721570|NCT01331954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721571|NCT01764009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721572|NCT03413813|||OTHER||PROSPECTIVE|||||||
33721573|NCT02910076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721574|NCT05214482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721575|NCT01080690|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33721576|NCT05568147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721577|NCT05492331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721578|NCT04085133|||CASE_ONLY||CROSS_SECTIONAL|||||||
33721579|NCT01684631|||COHORT||PROSPECTIVE|||||||
33721580|NCT04588987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721581|NCT03251820|||COHORT||PROSPECTIVE|||||||
33721582|NCT00368056|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34025827|NCT03164538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025828|NCT04166565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025829|NCT02159079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025830|NCT04234659|||COHORT||RETROSPECTIVE|||||||
34025831|NCT02695537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025832|NCT04001946|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34025833|NCT01365312|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025834|NCT01910246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025835|NCT02242045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025836|NCT03069326|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, two stage phase II trial designed to assess the effect of ruxolitinib and thalidomide combination in subjects with Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF, post-PV MF, or post-ET MF).||||
34025837|NCT00819637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150979|NCT00697281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150980|NCT01443663|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150981|NCT01297205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150982|NCT04576689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150983|NCT00213096|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34150984|NCT02344901|||COHORT||CROSS_SECTIONAL|||||||
34150985|NCT01873690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34150986|NCT02186717|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150987|NCT04157283|||CASE_CONTROL||RETROSPECTIVE|||||||
34150988|NCT01980719|||CASE_CONTROL||PROSPECTIVE|||||||
34150989|NCT05548985|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150990|NCT01831817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150991|NCT06506890|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34150992|NCT05004948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150993|NCT03514901|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|A randomized, open-label study||||
34150994|NCT00450034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150995|NCT05205655|NON_RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||f|t|t|t
34150996|NCT00006026||||TREATMENT||||||||
34150997|NCT00629473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150998|NCT00665236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150999|NCT02275312|||OTHER||PROSPECTIVE|||||||
34151000|NCT01077687|||FAMILY_BASED||PROSPECTIVE|||||||
34151001|NCT00577213|||COHORT||CROSS_SECTIONAL|||||||
34151002|NCT05074420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151003|NCT05498116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151004|NCT04394936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is an observational and interventional study in up to 40 patients with chronic plaque psoriasis and 10 healthy volunteers (observational only).|t|f|t|t
34151005|NCT00734071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151006|NCT05303688|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34151007|NCT06499883|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025838|NCT03316547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Parents were asked to participate in a study investigating 2 different approaches to sensory exposures in the NICU. The approach (SENSE or standard of care) were described after enrollment, based on which group they were randomized to. The evaluator was blinded to treatment assignment.|SENSE program-treatment; standard-of-care-control|f|t|f|t
34025839|NCT03810092|||OTHER||PROSPECTIVE|||||||
34025840|NCT05950178|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Non-randomized controlled single-center trial.||||
34025841|NCT02032056|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025842|NCT04573114|||COHORT||PROSPECTIVE|||||||
34025843|NCT03541980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025844|NCT06452979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34103711|NCT04898309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|At the first stage - the study will be blinded, at the second stage - open-label|Two-stage study. In the first stage - 4 groups are presented. At the second stage - 2 study groups 200 HAE attacks to be randomized in 50 patients|t|f|t|f
34103712|NCT04969770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025845|NCT05543343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103713|NCT05193045|||COHORT||RETROSPECTIVE|||||||
34103714|NCT06688877|||OTHER||PROSPECTIVE|||||||
34103715|NCT06687733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025846|NCT04900519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103716|NCT01127204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721583|NCT04416087|NA|SINGLE_GROUP||TREATMENT||NONE||Each subject will serve as their own control (tumor blood flow at rest vs. blood flow during exercise).||||
34103717|NCT00274950||||TREATMENT||NONE||||||
34103718|NCT04352556|||COHORT||OTHER|||||||
33721584|NCT02489344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103719|NCT06672939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103720|NCT03280615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Identical sachets containind the study supplement or corn oil will be number coded and provided to participants|Participants will be randomly selected to receive 3.7 g of a supplement containing docosahexanoic and eicosapentanoic acids or a supplement containing corn oil. The supplements will be provided for 12 weeks|t|t|t|f
34103721|NCT06689124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103722|NCT03399747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103723|NCT06365853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103724|NCT06455280|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Study||||
34103725|NCT03378635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103726|NCT02197364|||COHORT||RETROSPECTIVE|||||||
34103727|NCT00866775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103728|NCT03405753|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34103729|NCT03916419|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103730|NCT03898973|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34103731|NCT03659721|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|As the participants are offered extra support as the intervention neither participants nor care providers can be blinded. Outcome assessor and data analyst will be blinded.|The study is a prospective randomized controlled trial with two study arms: intervention (FACAM) and care as usual (CAU). Pregnant women are randomized to receive either FACAM or CAU.|f|f|t|t
34103732|NCT00205634|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33721585|NCT01092533|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33721586|NCT04416503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|t|f|f|f
33721587|NCT06536803|RANDOMIZED|PARALLEL||OTHER||SINGLE|single outcome assessor who will take the reading is blind|Randomized controlled Trial|f|f|f|t
33721588|NCT03878745|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE|Participants will not see any labeling for the pen needles used for injections|BD Nano™PRO (Test Device) will be compared to the Terumo Nanopass® through a series of randomized abdominal saline injections||||
33721589|NCT01919060|||COHORT||PROSPECTIVE|||||||
33721590|NCT04628676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33721591|NCT03200496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721592|NCT04022720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721593|NCT00584142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721594|NCT02721927|||CASE_ONLY||RETROSPECTIVE|||||||
33721595|NCT06388863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721596|NCT04007042|||COHORT||PROSPECTIVE|||||||
33721597|NCT04358848|||COHORT||PROSPECTIVE|||||||
33802243|NCT04705311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802244|NCT02805816|||COHORT||PROSPECTIVE|||||||
33802245|NCT03305146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||First 20 patients for pilot study to test the feasibility of the molecular analysis then 120 patients to continue the trial.||||
33802246|NCT04805853|||COHORT||PROSPECTIVE|||||||
33802247|NCT00017472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802248|NCT03809416|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33802249|NCT05621499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721598|NCT06339073|||COHORT||RETROSPECTIVE|||||||
33721599|NCT06208059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721600|NCT02085785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721601|NCT02444260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721602|NCT02561637|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721603|NCT01813084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802250|NCT04484675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A computer-generated randomization table divided patients into 2 equal groups randomly allocated patients.||t|t|t|t
33802251|NCT06461468|||CASE_CONTROL||RETROSPECTIVE|||||||
34025847|NCT06552221|||CASE_ONLY||RETROSPECTIVE|||||||
34025848|NCT05603533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025849|NCT05970666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025850|NCT01724450|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025851|NCT06620133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025852|NCT00396643|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802252|NCT02678936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025853|NCT03783429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, placebo controlled|A national, multicenter, randomized, double-blind placebo controlled, clinical trial.|t|t|t|t
34025854|NCT01590277|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34025855|NCT01105715|||CASE_CONTROL||PROSPECTIVE|||||||
34025856|NCT00203710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025857|NCT01132924|||COHORT||RETROSPECTIVE|||||||
33721604|NCT02133248|||OTHER||PROSPECTIVE|||||||
33721605|NCT05098860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Evaluations are made by another person who does not know about the research topic and research groups.||t|f|t|f
34025858|NCT00340678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103733|NCT03377998|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33721606|NCT02911181|||COHORT||PROSPECTIVE|||||||
34103734|NCT03236805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103735|NCT05623514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103736|NCT04077437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Use of separate databases for outcome measures and safety data. Assessment made by pool of independent raters. Randomization will be managed via an Interactive Web Randomization System (IWRS) based on a centralized randomization schedule developed by an independent thirdparty vendor to maintain blinding.|Randomized, double-blind between group comparison of change in PTSD symptoms|t|f|t|t
33721607|NCT04426331|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized study: screening events (clusters) randomized to one of three interventions, outcomes from individuals within clusters tracked.||||
33721608|NCT02367677|||OTHER||PROSPECTIVE|||||||
33721609|NCT00469560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721610|NCT05372848|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
33721611|NCT05847231|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Single (Participant) Perceived Stress, Anxiety Level and Quality of Life|Mandala|t|f|f|f
33721612|NCT02848014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33721613|NCT06543069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721614|NCT01558752|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33721615|NCT05663307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721616|NCT01068119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721617|NCT00505843|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33721618|NCT02087527|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721619|NCT02045576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721620|NCT02496832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721621|NCT00628992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721622|NCT00374725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721623|NCT06201117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research assistants who are blinded for the participant groups evaluate the outcomes including anxiety, 30 minutes after the intervention or usual care and 48 hours after the surgery and treatment adherence 1 time, 48 hours after the surgery.|2-arm parallel randomized controlled trial study|f|f|f|t
33721624|NCT02444286|||COHORT||PROSPECTIVE|||||||
33721625|NCT03459378|||CASE_ONLY||RETROSPECTIVE|||||||
33721626|NCT04681170|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721627|NCT00535990|||CASE_ONLY||PROSPECTIVE|||||||
33721628|NCT02410954|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33721629|NCT00227903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721630|NCT04380259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721631|NCT04061811|||OTHER||CROSS_SECTIONAL|||||||
33721632|NCT05608044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721633|NCT02307955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721634|NCT06054347|||COHORT||CROSS_SECTIONAL|||||||
33721635|NCT03657758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721636|NCT03099044|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blind (subjects unaware of treatment identity)|Healthy adults; three groups: Placebo, vs Single-Dose and Double Dose of Fermented Dairy Beverage consumed for 10 days. Subjected to stressful exercise at beginning and end of study. Primary outcomes: immune/inflammatory markers. Assess changes in treatment vs placebo.|f|f|t|f
33721637|NCT05970757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721638|NCT01462721|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721639|NCT01882374|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33802253|NCT03189589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study and subjects and investigator will be blinded.|Healthy subjects will be randomized to receive GSK2269557 750 µg or GSK2269557 500 µg.|t|f|t|f
33802254|NCT05736185|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33802255|NCT02559362|||COHORT||PROSPECTIVE|||||||
33802256|NCT01091740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802257|NCT05007587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|60 HCC participants were divided into test group and control group by random drawing|Prospective, multi-center, randomized controlled study|t|f|f|f
33802258|NCT02330926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802259|NCT00002446||||TREATMENT||DOUBLE||||||
33802260|NCT04029909|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33802261|NCT01322477|||COHORT||PROSPECTIVE|||||||
33802262|NCT04884295|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1 is open-label, single ascending dose (completed per protocol); Phase 2 is double-blind, randomised, placebo-controlled (cancelled due to due to change in company strategy for phase II design)||||
33802263|NCT01571570|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802264|NCT04953273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802265|NCT01663181|||COHORT||PROSPECTIVE|||||||
33802266|NCT03548857|||COHORT||PROSPECTIVE|||||||
33802267|NCT04524494|||COHORT||PROSPECTIVE|||||||
33802268|NCT01741441|||COHORT||PROSPECTIVE|||||||
33802269|NCT02819414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802270|NCT05700487|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The person applying the data sheets is an unbiased surveyor who does not know about the groups.||f|f|t|f
33802271|NCT05938426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025859|NCT03458260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025860|NCT03629080|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participants, investigators and care providers (study site personnel) will be blinded.|This phase 2 study will be conducted in three groups stratified by treatment intent. In Group 1, patients will be randomized to receive HB-101 (1a) or placebo (1b) and followed preemptively post-transplant. Approximately 50 patients will be randomized in Group 1. In Group 2, patients will be randomized to receive HB-101 (2a) or placebo (2b) before transplant. Post-transplant patients will receive 3-6 months of anti-viral prophylaxis following institutional standards. Approximately 100 patients will be randomized in Group 2. In Group 3, all patients will receive HB-101 (open label) vaccination(s) prior to their transplant surgery. Post-transplant CMV management will follow either preemptive or prophylactic care as defined at study enrollment by the investigator and institutional standards. Approximately 25 patients will be randomized in Group 3.|t|t|t|f
34025861|NCT02842138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025862|NCT03359954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025863|NCT06277232|NA|SINGLE_GROUP||TREATMENT||NONE||Repeated measures, single-subject withdrawal design. All subjects who enroll in the study will receive the intervention and there is no randomization.||||
34025864|NCT04716868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Powder is flavored in order to mask at minimum the differences between type of fibers|a prospective, randomized, controlled and single blind study to determine the efficacy of the blue agave Tequilana Weber fructans intake in subjects with functional constipation.|t|f|t|f
34025865|NCT01008189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34025866|NCT03149757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34025867|NCT06021626|NA|SEQUENTIAL||TREATMENT||NONE||This is a single center, phase I study with escalation and expansion cohort.||||
34025868|NCT00143247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025869|NCT04962386|||COHORT||PROSPECTIVE|||||||
34025870|NCT03309527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A two-arm parallel design involves two groups of participants with insomnia. One group receives internet delivered sleep hygiene education, and the other group receives internet delivered cognitive behavior therapy.|t|f|f|t
34025871|NCT06067269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025872|NCT01068262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025873|NCT01402635|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34025874|NCT04386616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025875|NCT00308880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34025876|NCT04691154|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort A: Tyvaso stabilized PAH or PH-ILD patients Cohort B: Prostacyclin naive - PAH patients||||
34025877|NCT04225910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025878|NCT06251245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103737|NCT01046669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103738|NCT04652999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible participants will be randomised into the three groups into blocks of variable size, multiples of three; and will be stratified according to: i) data collection site; ii) Chronic Renal Disease; and iii) Peripheral Arterial Disease; because they are factors of poor prognosis in the DFU healing (Ferreira et al., 2014). This procedure will be performed using an online random number generator, by a researcher external to the team involved in the implementation of this study, in order to ensure the concealment of the allocation of participants by the various groups (Pandis, 2012). After this procedure, it will not be possible to conceal the group to which the patient belongs from the researcher who will perform the psychological intervention. However, health professionals (doctors and nurses) will be blinded during the entire procedure, because they fill in the RESVECH 2.0, which assesses the DFU healing.|"This is a Pilot Randomised Controlled Study of a Psychological Intervention (Eldridge et al., 2016; Grant et al., 2018). This study will use a mixed-methods approach nested in a pilot 3-arm randomized control design. Qualitative and quantitative data will be collected in order to provide better understanding about the feasibility and acceptability of the relaxation intervention in patients with DFU.~Participants will be randomised at a ratio of 1:1 for the three conditions - EG, ACG and PCG; and will be evaluated on the day of the first chronic DFU appointment or nursing treatment (T0), two months later (at the end of the intervention in EG and ACG; T1), as well as six months later (T2) in a follow-up evaluation. Participants from all three groups will undergo standard treatment for the DFU, according to the guidelines of the Portuguese General Health Direction (DGS, 2010) and the International Working Group on the Diabetic Foot (IWGDF, 2015)."|t|f|f|t
34103739|NCT05900830|RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi experimental||||
34103740|NCT02375711|NA|SINGLE_GROUP||OTHER||NONE||||||
34103741|NCT05431556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103742|NCT00117442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103743|NCT02268305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103744|NCT01594814|||COHORT||PROSPECTIVE|||||||
34103745|NCT06136819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103746|NCT02674828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103747|NCT01407887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103748|NCT02184442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103749|NCT00188435|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802272|NCT03176654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Experimental Group (HVLAT manipulation) Control Group (sham HVLAT manipulation)|t|f|f|f
33802273|NCT06185166|||CASE_ONLY||RETROSPECTIVE|||||||
33802274|NCT05945017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential study with consecutive recruitment with a washout period of 12 months between groups||||
33802275|NCT00253890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802276|NCT03932162|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802277|NCT01952769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802278|NCT02034916||PARALLEL||TREATMENT||NONE||||||
33802279|NCT05783570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802280|NCT04219215|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33802281|NCT06038045|||OTHER||PROSPECTIVE|||||||
33802282|NCT06408818|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33802283|NCT02005406|||CASE_CONTROL||PROSPECTIVE|||||||
33802284|NCT02546999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802285|NCT00391196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802286|NCT06239012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||exploratory, monocentric, reliability-validity clinical investigation||||
33802287|NCT03567252|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be compared between walking and non-walking groups to assess dietary behavior.||||
33802288|NCT05363449|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802289|NCT01318655|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802290|NCT02538653|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802291|NCT05663346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33802292|NCT01408394|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33802293|NCT05893719|||CASE_ONLY||PROSPECTIVE|||||||
33802294|NCT00331136|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33802295|NCT04364451|||CASE_CONTROL||PROSPECTIVE|||||||
33802296|NCT05224557|||COHORT||RETROSPECTIVE|||||||
33802297|NCT03614273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802298|NCT02456467|||COHORT||PROSPECTIVE|||||||
33802299|NCT06224517|||COHORT||PROSPECTIVE|||||||
33802300|NCT03926039|RANDOMIZED|PARALLEL||OTHER||SINGLE|Blocked Randomization is a common disease in patients with liver cancer. In order to avoid excessive concentration of the patient control group and the experimental group, the mining blocks are randomly assigned.|Blocked Randomization is a common disease in patients with liver cancer. In order to avoid excessive concentration of the patient control group and the experimental group, the mining blocks are randomly assigned.|t|f|f|f
33802301|NCT04954911|||COHORT||PROSPECTIVE|||||||
33802302|NCT05826860|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802303|NCT03590275|||COHORT||RETROSPECTIVE|||||||
33802304|NCT05880355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, single blind study.|t|t|f|t
33802305|NCT04044859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802306|NCT02304835|||COHORT||PROSPECTIVE|||||||
33802307|NCT02782507|||CASE_ONLY||PROSPECTIVE|||||||
33802308|NCT03420196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-Blind||f|f|f|t
33802309|NCT04760938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Within OBH programs, the field guides are unaware of which participants are study participants.|This is a multi-center, stratified (\<$47,000 family income, $47,001-$140,000 family income, \>$140,001 family income, with balanced randomization \[1:1\]), partially-blind, parallel-group study conducted in the United States (7 OBH sites and up to 42 CBT therapists).|f|t|f|f
33802310|NCT02480205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802311|NCT03693937|||COHORT||RETROSPECTIVE|||||||
33802312|NCT02918591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802313|NCT03848572|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
34103750|NCT06434805|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A single group with outcome assessments will be taken at baseline, post-intervention, and at 3-month follow-up.||||
34103751|NCT06676878|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34103752|NCT00626665|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103753|NCT03931811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33802314|NCT00819546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802315|NCT01639131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802316|NCT04101656|||CASE_ONLY||PROSPECTIVE|||||||
33802317|NCT02035904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802318|NCT01885975|||CASE_ONLY||PROSPECTIVE|||||||
33802319|NCT03004391|||CASE_ONLY||PROSPECTIVE|||||||
33802320|NCT03497949|||COHORT||RETROSPECTIVE|||||||
33802321|NCT05931510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802322|NCT04532450|||COHORT||PROSPECTIVE|||||||
34103754|NCT03167658|RANDOMIZED|PARALLEL||OTHER||NONE||Each worksite (and all employees at that site) randomly assigned to Treatment or Control arm.||||
34103755|NCT03191032|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802323|NCT04291092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802324|NCT03898310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33802325|NCT05837455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802326|NCT04286113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802327|NCT02009228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802328|NCT02026128|||CASE_ONLY||PROSPECTIVE|||||||
33802329|NCT00047528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802330|NCT00138255|||||PROSPECTIVE|||||||
33802331|NCT01172418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802332|NCT04553458|||COHORT||RETROSPECTIVE|||||||
33802333|NCT02173717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802334|NCT00327561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802335|NCT01534741|RANDOMIZED|CROSSOVER||||NONE||||||
33802336|NCT02587169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802337|NCT05685433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103756|NCT05814549|||COHORT||PROSPECTIVE|||||||
34103757|NCT03351959|||COHORT||OTHER|||||||
34103758|NCT02702999|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34025879|NCT05913505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Baseline measurements will be collected by undergraduate research assistants blinded to group conditions to reduce possible experimenter bias effects. Additionally, research assistants will be blinded to conditions for all testing sessions.|Twenty-five participants will complete the treatment condition in a pseudo-randomized order (determined by random number generator with constraints) such that half of the participants will be given the heart rate variability biofeedback active condition and half will be given the sham control condition. However, the participants in the sham control condition will be offered treatment with heart rate variability biofeedback after study completion. The heart rate variability biofeedback active condition is designed to increase heart rate oscillations (Osc+ condition) consistent with current best practices, while the sham control heart rate variability biofeedback condition is designed to decrease heart rate oscillations (Osc- condition).|t|f|f|t
34025880|NCT05186675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025881|NCT02068092|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025882|NCT00186940|||OTHER||PROSPECTIVE|||||||
34025883|NCT00894829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34025884|NCT00215280|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34025885|NCT04614753|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34025886|NCT03513055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025887|NCT05458882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34025888|NCT03712514|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34025889|NCT04820660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34025890|NCT02538380|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34025891|NCT03081793|||COHORT||PROSPECTIVE|||||||
34025892|NCT04874805|NA|SINGLE_GROUP||OTHER||NONE||||||
34025893|NCT00043810|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025894|NCT00229723|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34025895|NCT01192048|||FAMILY_BASED||PROSPECTIVE|||||||
34025896|NCT00738114|||COHORT||RETROSPECTIVE|||||||
34025897|NCT00200408|||CASE_CONTROL||PROSPECTIVE|||||||
34025898|NCT00877162|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34025899|NCT01753297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025900|NCT03813810|||COHORT||PROSPECTIVE|||||||
34025901|NCT00593905|||COHORT||OTHER|||||||
34025902|NCT00143390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802338|NCT02351310|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802339|NCT06114602|||COHORT||RETROSPECTIVE|||||||
33802340|NCT06181916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025903|NCT06632548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34025904|NCT03276130|||COHORT||RETROSPECTIVE|||||||
34025905|NCT02354794|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34025906|NCT02109653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025907|NCT06633939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025908|NCT00645632||||TREATMENT||||||||
34025909|NCT04836897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025910|NCT06626464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34025911|NCT02784912|||COHORT||PROSPECTIVE|||||||
34025912|NCT03048552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study is a randomized control trial. Caregiver-youth dyads are randomized to either the control (standard of care) or experimental (Family CONNECT) group based on the youth's probation officer (randomization occurs at the level of the youth's probation officer). If randomized to the control (standard of care) group, caregiver-youth dyads will work with their probation officer as usual to link to substance use services. If randomized to the experimental (Family CONNECT) group, caregiver-youth dyads will work with a linkage specialist to link to substance use services. Youth in both groups will be compared to a baseline stand of care collected during the pre-implementation period.||||
34025913|NCT01562561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025914|NCT05605769|||COHORT||PROSPECTIVE|||||||
34025915|NCT01708551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025916|NCT06612177|||COHORT||RETROSPECTIVE|||||||
34025917|NCT06170879|||OTHER||OTHER|||||||
34025918|NCT03270878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34025919|NCT05583305|||COHORT||CROSS_SECTIONAL|||||||
34025920|NCT06331767|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34025921|NCT03904264|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||For this pilot study 20 eligible adults with bothersome tinnitus and normal hearing thresholds from audiometric frequencies .25 kHz through 4 kHz will be provided with hearing aids. Eligible adults with tinnitus and normal hearing are the only participants for whom an intervention will be provided as part of the study. Fifteen VA clinical audiologists will be interviewed to document opinions, procedures, and rationale used clinically to make decisions regarding fitting mild amplification for tinnitus on Veterans with bothersome tinnitus and normal hearing thresholds. No intervention will be provided to the participating audiologists.||||
34025922|NCT05173857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34025923|NCT06629844|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025924|NCT05232266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103759|NCT06669156|||COHORT||PROSPECTIVE|||||||
34103760|NCT06136884|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103761|NCT06045754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103762|NCT06229873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|f|f|t|t
34103763|NCT03357172|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34103764|NCT06570031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103765|NCT06687317|||OTHER||OTHER|||||||
34151008|NCT03256435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151009|NCT05941260|||COHORT||PROSPECTIVE|||||||
34151010|NCT02337985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802341|NCT02075554|NA|SINGLE_GROUP||TREATMENT||NONE||Lumbar interbody cages||||
33802342|NCT04545918|||COHORT||PROSPECTIVE|||||||
33802343|NCT03369509|||COHORT||PROSPECTIVE|||||||
33802344|NCT05000424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33802345|NCT05865561|||COHORT||PROSPECTIVE|||||||
34151011|NCT05747417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33802346|NCT00377182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802347|NCT04452201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802348|NCT00002945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802349|NCT05103618|RANDOMIZED|CROSSOVER||OTHER||NONE||This is an Open Label study. Subjects will be assigned a study number that will be used on the research files. Two group of couple pairs will be enrolled into this study: one group will be healthy couple pairs in which neither member has PD. The other couple pairs will include a female member with PD. For subjects who are enrolled in the meditation training programs couple pairs in which the female member has PD may be assigned to an active group or a waitlist control group.||||
33802350|NCT05749224|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33802351|NCT00868504|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802352|NCT05456659|||CASE_CONTROL||RETROSPECTIVE|||||||
33802353|NCT01634789|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33802354|NCT00162344|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802355|NCT00704769|||COHORT||PROSPECTIVE|||||||
33802356|NCT05845515|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33802357|NCT04669028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802358|NCT00767754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802359|NCT06497881|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802360|NCT03450434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Single-blinding was conducted during the run-in period of the study (each patient received simultaneously 3 tablets of Placebo matching 2, 10, and 100 mg XC8), the form of the package (a blister with three lines of tablets of each dosage), corresponding package labeling of the study drug (IP kit numbers).~Double-blinding in the treatment period was provided by Placebo masking (each patient received simultaneously 3 tablets corresponding to 2 mg or Placebo, 10 mg or Placebo, 100 mg or Placebo), the form of the package (a blister with three lines of tablets of each dosage), corresponding package labeling of the study drug (IP kit numbers) and distribution of the drug by IWRS."|At Visit 2, Week -1 the patients who meet all inclusion/exclusion criteria were included in the single-blind placebo run-in period. At Visit 3, Week 0 all patients were randomized to 4 treatment groups in 1:1:1:1 ratio (30 patients per each group of XC8 2 mg, 10 mg or 100 mg; and 30 patients to Placebo group).|t|f|t|f
33802361|NCT00692783|||||PROSPECTIVE|||||||
33802362|NCT02647905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802363|NCT03137836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802364|NCT02994316|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802365|NCT03037892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802366|NCT04657172|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33802367|NCT04511767|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802368|NCT02007590|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33802369|NCT03547102|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33802370|NCT02345174|NA|SINGLE_GROUP||OTHER||NONE||||||
33802371|NCT02877797|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33802372|NCT05751161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33802373|NCT00111631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802374|NCT02545634|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33802375|NCT03003572|||COHORT||PROSPECTIVE|||||||
33802376|NCT01535690|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33802377|NCT00414024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148847|NCT04578925|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study staff will randomize patients to the intervention or control arm and not inform subjects of their randomization assignment. Intervention group participants will receive text messages that provide resources and encouragement related to breast-feeding. Control group participants will receive text messages with non-breast-feeding related content.|Mother partner pairs will be randomly assigned to the HHL program or care as usual.|t|f|f|f
33802378|NCT02422615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Following protocol amendment 4 (29-Jan-2020), study participants were unblinded, with an opportunity for those patients still in the study in the arm of placebo + fulvestrant to transition to the treatment of ribociclib + fulvestrant.|t|t|t|t
33802379|NCT04287985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient, Investigator, Care Provider, Outcomes Assessor||t|t|t|t
33802380|NCT03750539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II Comparative Randomized Open-label||||
33802381|NCT05178459|||COHORT||PROSPECTIVE|||||||
33802382|NCT02567656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802383|NCT00603954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802384|NCT00329264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802385|NCT01691846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802386|NCT04910698|||COHORT||RETROSPECTIVE|||||||
33802387|NCT03945123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802388|NCT00599469|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802389|NCT01837394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802390|NCT04562675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802391|NCT01268228|||CASE_CONTROL||PROSPECTIVE|||||||
33802392|NCT06413095|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This is a cohort substudy of a Master Protocol (PBI-MST-01, NCT04541108) framework, under which comparisons will not be made between substudy cohorts.||||
33802393|NCT00665340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802394|NCT03800212|||COHORT||PROSPECTIVE|||||||
33802395|NCT00873613|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|f|t
33802396|NCT06324903|||OTHER||PROSPECTIVE|||||||
33802397|NCT02987192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802398|NCT05953675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802399|NCT06256640|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot clinical trial||||
33802400|NCT04235738|||COHORT||PROSPECTIVE|||||||
33802401|NCT04183452|||COHORT||PROSPECTIVE|||||||
33802402|NCT03144518|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33802403|NCT05427305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148848|NCT02940782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148849|NCT00060580||||TREATMENT||||||||
34148850|NCT05374187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, sham-controlled||t|t|t|t
34151012|NCT04451473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151013|NCT04466527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151014|NCT06260969|||COHORT||PROSPECTIVE|||||||
33721640|NCT05040854|||COHORT||PROSPECTIVE|||||||
33721641|NCT02442167|||COHORT||PROSPECTIVE|||||||
33721642|NCT06423144|||COHORT||RETROSPECTIVE|||||||
33721643|NCT01408979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721644|NCT06302179|||COHORT||RETROSPECTIVE|||||||
33721645|NCT02474992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721646|NCT00875225|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33721647|NCT01314833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721648|NCT02014038|||COHORT||PROSPECTIVE|||||||
33721649|NCT03036787|||FAMILY_BASED||PROSPECTIVE|||||||
33721650|NCT04119479|||CASE_ONLY||PROSPECTIVE|||||||
33721651|NCT03989999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The evaluation at 3 months after TBI will be centralized by the coordinating centre and blinded.|Prospective, multicenter, open, non-inferiority, randomized, controlled, study with blinded evaluation.|f|f|f|t
33721652|NCT05395520|||OTHER||RETROSPECTIVE|||||||
33721653|NCT01243970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721654|NCT03021850|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33721655|NCT04052984|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||An intervention group compared to a similar historical group attended by the same group of doctors at an immediate previous time||||
33721656|NCT06366321|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33802404|NCT00731614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33802405|NCT00005299|||COHORT||PROSPECTIVE|||||||
33802406|NCT02808351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802407|NCT02876016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802408|NCT00614094|||COHORT||RETROSPECTIVE|||||||
33802409|NCT04327843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802410|NCT00094016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802411|NCT01086163|||CASE_CONTROL||PROSPECTIVE|||||||
33802412|NCT01457313|||||PROSPECTIVE|||||||
33802413|NCT01421407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802414|NCT05165459|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33802415|NCT01408524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721657|NCT04662047|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33802416|NCT00611559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802417|NCT03498196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802418|NCT02885636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802419|NCT06220994|||CASE_CONTROL||PROSPECTIVE|||||||
33802420|NCT04177147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinicians were randomized to see, or not see, a clinical decision-support alert tool when evaluating outpatients with diabetes mellitus||||
33802421|NCT01189149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802422|NCT06510595|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Case-Control study Child A: The child will receive active elbow flexion exercise with electrotherapy.~Child B: The child will be managed by conservative treatment with brace only."||||
33802423|NCT05208125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Upon preparation, masking of the study products will take place in the same preparation room.|Participants will be randomized to receive either the combined regimen with T- and B-cell immunogens (CSSMS) or placebo (PPPPP) in a double-blinded fashion at a ratio of 2:1.|t|f|t|f
33721658|NCT04188522|||CASE_CONTROL||PROSPECTIVE|||||||
33721659|NCT04723381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33721660|NCT02680743|NA|SINGLE_GROUP||SCREENING||NONE||||||
33721661|NCT00986635|||COHORT||RETROSPECTIVE|||||||
33721662|NCT05205226|||COHORT||RETROSPECTIVE|||||||
33721663|NCT01968590|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33721664|NCT03103997|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants undergo each biopsy in the protocol. The care provider will be directing and performing each needle pass. The outcome assessor will be unaware of each group.|Subjects enrolled will undergo EUS-guided biopsies in the following manner. First pass needle out of package without preparation and full suction. Second pass: needle flushed with heparin, then flushed with air and suction, dry heparin. Third pass: needle flushed with heparin and then 2 cc of liquid added to suction syringe and attached, wet heparin.|f|f|f|t
33721665|NCT03294733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||ultrasound carpal tunnel size on subjects||||
33721666|NCT04323280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, non-blinded trial||||
33721667|NCT00862446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721668|NCT04759209|||COHORT||RETROSPECTIVE|||||||
33721669|NCT03019107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33721670|NCT00251446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721671|NCT01570374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721672|NCT02406651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721673|NCT00160940|||DEFINED_POPULATION||OTHER|||||||
33721674|NCT06300242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33721675|NCT00293644|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721676|NCT02706743|||COHORT||PROSPECTIVE|||||||
33721677|NCT05487482|NON_RANDOMIZED|PARALLEL||OTHER||NONE||We will consist of two gorup. Control group and intervention group||||
33721678|NCT00910312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721679|NCT05945654|||CASE_CONTROL||OTHER|||||||
33721680|NCT03410355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to the intervention|randomized control trial|f|f|f|t
33721681|NCT05704504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721682|NCT01518920|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33721683|NCT00999791||PARALLEL||TREATMENT||||||||
33721684|NCT00230464|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33721685|NCT03038412|||OTHER||CROSS_SECTIONAL|||||||
33802424|NCT00894543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802425|NCT06420570|||COHORT||CROSS_SECTIONAL|||||||
34148851|NCT04887389|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Selected children will be divided randomly into three groups:~* Group 1: Children receiving Nano Silver Fluoride varnish (NSF) (n =39).~* Group 2 Children receiving Nano-hydroxyapatite varnish (n = 37).~* Group 3: Children receiving Sodium Fluoride Varnish (n = 39) Procedure for material application The application of single drop (0.1 mL) of either (5%) NSF, (10%) n-HAP, (5%) NaF varnishes with a disposable micro-applicator tip for 10 seconds. NSF will be used in a single application and no repetition. While n-HAP, NaF varnishes will be applied each 6 months ."||||
33721686|NCT00375739|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33721687|NCT04566354|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721688|NCT03902912|NA|SINGLE_GROUP||TREATMENT||NONE||The participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.||||
33721689|NCT01195428|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33721690|NCT05483855|||OTHER||PROSPECTIVE|||||||
33721691|NCT02074631|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721692|NCT05774158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721693|NCT03586856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Main study design: Two armed randomized cross-over comparison of leakage for two interfaces. The trial also investigates simple measures to reduce leakage (observational)||||
33721694|NCT04666233|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The statistician performing data analysis will be masked to treatment allocation.|||||
33721695|NCT04152603|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).||||
33721696|NCT05941364|||OTHER||OTHER|||||||
33721697|NCT01375387|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33721698|NCT04275440|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33721699|NCT05020496|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34025925|NCT06550466|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"In this three-arm randomised crossover study, sixteen young adult men (age: 28 ± 4) will be recruited in good physical condition. Participants will be exercised following a 12-hour overnight fast (FAST) and exercised 90 minutes after a meal (FED) to test the temporal sensitivity of the loaded bone to absorbed nutrients. Participants will also attend a breakfast-only arm (without the exercise protocol).~Participants will undergo a baseline assessment for health history (PAR-Q). The blood samples will be collected (10ml) and osteogenic response to exercise will be determined by measuring markers of bone formation; P1NP and resorption; CTX-1 and cortisol; marker of physiological and psychological stress. Insulin and glucose measurements will allow to assess the change of concentrations in fasted and fed states."||||
34025926|NCT04684043|||COHORT||RETROSPECTIVE|||||||
34025927|NCT04570787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33721700|NCT04907539|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33721701|NCT02994901|||COHORT||CROSS_SECTIONAL|||||||
33721702|NCT01842256|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721703|NCT02461108|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
33721704|NCT03605303|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33721705|NCT04777708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721706|NCT06287333|||COHORT||RETROSPECTIVE|||||||
33721707|NCT04237441|||COHORT||RETROSPECTIVE|||||||
33721708|NCT03495323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721709|NCT00735787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721710|NCT05855005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721711|NCT01870583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721712|NCT06219850|||COHORT||PROSPECTIVE|||||||
33721713|NCT01482754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721714|NCT00226954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721715|NCT02884596|||OTHER||PROSPECTIVE|||||||
33721716|NCT01797003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721717|NCT05343975|||COHORT||PROSPECTIVE|||||||
33721718|NCT03459742|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled trial. The randomization unit will be the schools. The primary outcome will be measured individually, but the effect size will also be calculated at the school level.||||
33721719|NCT01011660|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33721720|NCT00298181|||COHORT||CROSS_SECTIONAL|||||||
33721721|NCT05158959|||COHORT||PROSPECTIVE|||||||
33721722|NCT03163225|||COHORT||PROSPECTIVE|||||||
33721723|NCT05939375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This non-randomized experimental study, which employs a pre/post-test design, was conducted with the participation of 130 nurses and 100 parents. An educational training, grounded in six weeks of nurse centered interactions, was implemented. Nurse centered interactions and group discussions were conducted by supervising nurses with at least a master of science degree in pediatric nursing, together with the researchers. One week before the educational training, the nurses were administered the Nurse Information Form and FCCAS pre tests, which were conducted using an online form.Six weeks after the completion of the six week educational training, the nurses were administered the FCCAS post-test via an online form.The PedsQL HCPSS was utilized to assess the level of healthcare satisfaction among parents whose children received care in pediatric clinics.||||
33721724|NCT00227305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721725|NCT04308837|NA|SINGLE_GROUP||TREATMENT||NONE||The study design involves a single arm of patients that will all receive the same treatment.||||
33721726|NCT00679263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33721727|NCT02255721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721728|NCT04127331|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721729|NCT04612556|||COHORT||PROSPECTIVE|||||||
33721730|NCT01066247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33721731|NCT00015301||||DIAGNOSTIC||DOUBLE||||||
33721732|NCT00642239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802426|NCT00255359|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34025928|NCT03787134|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34025929|NCT02687217|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025930|NCT01867983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025931|NCT03417687|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Open label crossover study||||
34025932|NCT06359639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802427|NCT04062396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34025933|NCT04602546|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, Randomized study to collect data to evaluate the relationship between BIS and inhaled anesthetics||||
34025934|NCT04241926||CROSSOVER||OTHER||SINGLE|||f|f|f|t
34025935|NCT04704570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025936|NCT04867174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34025937|NCT00339144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025938|NCT01350570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103766|NCT04980963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"A minimum total of 90 students will be recruited for the study. Study personnel will recruit 30 students in each of years 2, 3, and 4. Of the 30 students per year, 15 will be randomly assigned to the full treatment intervention and 15 students will be randomly assigned to the control group. Participants will range in age from approximately 18 years to 25 years, but all ages are welcome to participate.~The selection of the target population for this research study is based on the bleak employment outcomes of students with ASD compared to students without disabilities. In addition, it is based on the lack of practices that integrate the cognitive and vocational needs of students with ASD who are pursuing postsecondary education to help them successfully complete academic requirements, address career development, enhance career readiness skills, and obtain and maintain employment."|t|f|f|f
34103767|NCT04722679|||OTHER||PROSPECTIVE|||||||
34025939|NCT06188624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103768|NCT05444088|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a multicenter, open-label, dose-finding and efficacy-expansion phase Ib/II study. The phase Ib design is for dose finding and dose confirmation, using modified 3+3 design; the phase II design is for efficacy expansion through randomization.||||
34025940|NCT02374775|||CASE_CONTROL||RETROSPECTIVE|||||||
34025941|NCT03361774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical examiner will be blinded to treatment received. The study statistician, data management staff, other employees of the Sponsor and vendors acting on behalf of the sponsor, who may influence study outcomes will also be blinded to the treatment allocation.||f|f|f|t
34025942|NCT04015908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025943|NCT02180737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025944|NCT05151783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34103769|NCT05161273|||COHORT||PROSPECTIVE|||||||
34103770|NCT06691464|||CASE_ONLY||PROSPECTIVE|||||||
34103771|NCT01560559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025945|NCT02104115|RANDOMIZED|CROSSOVER||||NONE||||||
34103772|NCT03071302|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34103773|NCT01789502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025946|NCT03332979|||COHORT||PROSPECTIVE|||||||
34025947|NCT00002960||||TREATMENT||||||||
34103774|NCT02554474|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34025948|NCT05308628|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34025949|NCT05056662|||COHORT||PROSPECTIVE|||||||
34025950|NCT02593110|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34025951|NCT03787862|||CASE_ONLY||PROSPECTIVE|||||||
34025952|NCT04881019|||CASE_CONTROL||PROSPECTIVE|||||||
34025953|NCT05158088|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34025954|NCT01329783|||COHORT||RETROSPECTIVE|||||||
34025955|NCT00775125|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025956|NCT00950131|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34025957|NCT02147964|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34025958|NCT01633931|||COHORT||PROSPECTIVE|||||||
34025959|NCT06310304|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025960|NCT03391726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103775|NCT06672081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103776|NCT06691581|||COHORT||PROSPECTIVE|||||||
34103777|NCT04021368|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalating Cohorts with a safety expansion Cohort||||
34103778|NCT03090542|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34103779|NCT06570408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802428|NCT03754036|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Sleep restriction (-1.5 hours of sleep per day for 1 week) and Sleep extension (+1.5 hours of sleep per day for 1 week)||||
33802429|NCT02358616|||COHORT||RETROSPECTIVE|||||||
33802430|NCT03036176|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33802431|NCT05398861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802432|NCT04664270|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomly allocated to either treatment or control||||
33802433|NCT01483066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34025961|NCT05730569|||CASE_CONTROL||PROSPECTIVE|||||||
34025962|NCT05319210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025963|NCT04228835|RANDOMIZED|PARALLEL||OTHER||NONE||Patients are divided into two arms: ICG enhanced fluorescence cholangiography assisted laparoscopic cholecystectomy (ICGFC- LC) and conventional laparoscopic cholecystectomy.||||
34025964|NCT00022334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802434|NCT00995904|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802435|NCT03102853|RANDOMIZED|PARALLEL||PREVENTION||||||||
33802436|NCT04138316|||COHORT||PROSPECTIVE|||||||
33802437|NCT05102500|||COHORT||PROSPECTIVE|||||||
33802438|NCT04559126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839002|NCT00005977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025965|NCT04399486|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025966|NCT01269541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025967|NCT03750292|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34151015|NCT05633329|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33721733|NCT06368960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721734|NCT03129243|||COHORT||PROSPECTIVE|||||||
33721735|NCT05494242|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33802439|NCT04132141|NA|SINGLE_GROUP||OTHER||NONE|all data is collected by the Research assistant and de-identified. The investigator will not know which data belongs to which participant|Each recruited subject completes 6 shifts with observation. Half the shifts have normal or wild type breaks, the other half are virtual reality breaks. The order is random.||||
33802440|NCT04602975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Every team will be masked except the pharmacist and the pharmacy team on site and one dedicated personal within Sponsor team.|Randomized, age descending (3 cohorts), with dose escalation in the target cohort|t|t|t|t
33802441|NCT05951140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802442|NCT05736094|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721736|NCT05787691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802443|NCT04325685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33802444|NCT00826475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802445|NCT02522312|||COHORT||RETROSPECTIVE|||||||
33802446|NCT01895582|||CASE_ONLY||PROSPECTIVE|||||||
33721737|NCT01435109|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33721738|NCT05839522|||CASE_ONLY||PROSPECTIVE|||||||
33721739|NCT01866514|NA|SINGLE_GROUP||||NONE||||||
33721740|NCT04345575|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group design where enrolled participants are randomly assigned to one of two treatment groups: Virtual reality behavioral medicine for chronic pain or Audio behavioral medicine for chronic pain||||
33721741|NCT02250755|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721742|NCT04146025|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721743|NCT03163082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Within-subject design over 2 visits.||||
33721744|NCT04877379|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Part 1: Unblinded Parts 2\&3: Blinded|Part 1: Crossover Parts 2\&3: Parallel|t|f|t|f
33721745|NCT04422054|||COHORT||RETROSPECTIVE|||||||
33721746|NCT00993291|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33721747|NCT01472250|||COHORT||PROSPECTIVE|||||||
33721748|NCT00005010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721749|NCT01926873|||COHORT||PROSPECTIVE|||||||
33721750|NCT01199289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721751|NCT06064890|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33721752|NCT03442621|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33721753|NCT04349618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721754|NCT03330522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33721755|NCT02426073|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721756|NCT01319812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721757|NCT00966602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721758|NCT02493673|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33721759|NCT03931421|NA|SINGLE_GROUP||TREATMENT||NONE|It's an open-label trial.|In this trial, T cells were seperated from refractory/relapsed multiple myeloma patients and engineered into BMCA-targeted CAR-T cells, and then transfused back into the patients for the treatment of their multiple myeloma.||||
33721760|NCT05275764|||COHORT||PROSPECTIVE|||||||
33721761|NCT06210490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721762|NCT03508817|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Intervention group: Optimal myopia correction with single vision glasses and topical atropine 0.01%, one drop at night time.~Control group: Optimal myopia correction with single vision glasses"||||
33721763|NCT01687322|||||PROSPECTIVE|||||||
33721764|NCT06309212|||COHORT||RETROSPECTIVE|||||||
33721765|NCT05952063|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33721766|NCT04028076|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33721767|NCT04443504|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups will be created using random assignment: an intervention group and a waitlist control group who will receive the intervention 3 months after the intervention group||||
33721768|NCT04450147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721769|NCT03209427|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33721770|NCT00888576|||COHORT||PROSPECTIVE|||||||
33721771|NCT03071978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721772|NCT00448474|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33721773|NCT00121550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721774|NCT00483808|NA|SINGLE_GROUP||||NONE||||||
33721775|NCT00874354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721776|NCT00837655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802447|NCT03307278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802448|NCT01156155|||CASE_CONTROL||PROSPECTIVE|||||||
33802449|NCT06103916|||COHORT||PROSPECTIVE|||||||
33802450|NCT00996749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802451|NCT05018013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802452|NCT02413866|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802453|NCT01408251|||||PROSPECTIVE|||||||
33802454|NCT00961831|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802455|NCT02355236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802456|NCT05115058|NA|SINGLE_GROUP||OTHER||NONE||A New Successful Approach for Emmetropic Presbyopic Patients Using Intrastromal Pocket With Smile Module||||
33802457|NCT04785950|||COHORT||PROSPECTIVE|||||||
33802458|NCT03358446|||CASE_ONLY||PROSPECTIVE|||||||
33839003|NCT05858684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839004|NCT05524662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839005|NCT05661318|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33839006|NCT03289351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839007|NCT04433299|||COHORT||PROSPECTIVE|||||||
34025968|NCT01872286|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34025969|NCT01885195|NA|SINGLE_GROUP||TREATMENT||||||||
34025970|NCT05150847|NA|SINGLE_GROUP||SCREENING||NONE||||||
34025971|NCT04040192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025972|NCT02230774|||COHORT||PROSPECTIVE|||||||
34025973|NCT02268968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025974|NCT02692144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34025975|NCT03095638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025976|NCT06359028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34025977|NCT00682357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34025978|NCT06548945|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34025979|NCT05651607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025980|NCT03063918|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34025981|NCT02792699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025982|NCT00343356|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34025983|NCT05847803|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34025984|NCT06382610|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Repeated measures crossover trial||||
34025985|NCT00749892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34025986|NCT05435937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non randomized control||||
34025987|NCT04543890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34025988|NCT02794870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34025989|NCT06104943|||COHORT||PROSPECTIVE|||||||
34025990|NCT00318877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025991|NCT04384835|||CASE_ONLY||PROSPECTIVE|||||||
34025992|NCT01866098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34025993|NCT04614948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34025994|NCT00887991|||CASE_CONTROL||PROSPECTIVE|||||||
34025995|NCT04107792|RANDOMIZED|PARALLEL||PREVENTION||NONE||pilot randomized waitlist control design||||
34025996|NCT05317338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34025997|NCT04639804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34025998|NCT00002926|RANDOMIZED|||TREATMENT||||||||
34025999|NCT00191165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026000|NCT04951986|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||"First intervention (open label):~a) Experimental arm: Standard first-line anti-tuberculosis therapy plus additional rifampicin to reach 35mg/kg/day for 14 days plus levofloxacin 750mg/day for weight \<50kg and 1g/day for weight \>50kg for 14 days b) Control arm: Standard TB therapy containing rifampicin 10mg/kg for 14 days (standard of care) After 14 days both study arms will continue standard TB therapy with rifampicin at 10mg/kg to complete 2 months of intensive phase in total. This will be followed by standard continuation phase TB therapy.~2. Second intervention (double-blind):~1. Experimental arm: Prednisone 1.5mg/kg per day for 14 days~2. Control arm: Identical placebo for 14 days"|t|t|t|t
34026001|NCT02849483|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34103780|NCT06685900|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participant and Sub-investigator||t|f|t|f
34026002|NCT00381160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026003|NCT06449144|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who are decided to undergo surgery and meet the inclusion criteria will be informed about the study and invited to participate. Patients who agree to participate in the study will be randomly divided into groups. Block randomization will be applied because the participants will receive preoperative and postoperative care in the same clinic and are likely to interact with each other. Awareness training will be given face-to-face by the investigators 24 hours before surgery.||||
34026004|NCT05454670|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This study will be a double-blind randomized controlled study. After random allocation, the participants (parents/ patients) will be unaware of the study group they belong to. Also, the surgeon assessing postoperative outcomes will not perform the surgery and will be unaware of the study group of the participant being examined. Since the collagen graft will be placed between the nasal/ muscular layers and the oral layer, it is expected that after apposition of the oral layer, no collagen matrix will be visible intraorally to reveal the study group of participants.|The study will be a parallel randomized controlled study involving two groups of participants. The test group will include participants with who will undergo cleft palate repair with collagen graft used as superpositional graft between the nasal mucosa/muscle layer and the oral mucosa layer when two-flap palatoplasty is performed while the control group will include participants who undergo two-flap palatoplasty without the use of collagen graft|t|t|f|t
34026005|NCT02430038|||COHORT||PROSPECTIVE|||||||
34026006|NCT03020537|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34103781|NCT05248009|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Arm Pilot Trial||||
34103782|NCT00707369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103783|NCT03415048|||CASE_ONLY||PROSPECTIVE|||||||
34103784|NCT04739215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103785|NCT03747757|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103786|NCT05835570|||COHORT||PROSPECTIVE|||||||
33721777|NCT03518333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham treatment|Prospective, multi-center, two-arm, blinded, randomized treatment. Covariate adaptive randomization will be used. Covariates included in the adaptive randomization process will be investigational center, history of diabetes, and radical prostatectomy.|t|f|f|f
34026007|NCT00636389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026008|NCT06282783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026009|NCT06211543|||COHORT||OTHER|||||||
34026010|NCT04693897|||COHORT||PROSPECTIVE|||||||
34026011|NCT01531439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33802459|NCT04131907|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subjects in the Randomization arm of the study are randomized in a 2:1 allocation of Test to Control. The treating physician is unblinded to the treatment assignment. A blinded person at the study site conducts all study follow-up visits through the 12-Month follow-up visit (or until the subject is unblinded). The subject may be unblinded prior to the 12-Month visit if it is medically necessary, which includes the subject seeking alternative BPH therapy due to continued or recurrent BPH symptoms.|"Randomized study with a non-randomized, Pharmacokinetics arm. Subjects randomized to the Control arm are allowed to crossover to the Test arm if they meet the eligibility criteria after completing the 3-Month Follow-up Visit and prior to the close of the 12-Month visit window.~Up to 625 subjects will be enrolled (i.e. consented) in the study in order to identify 162 eligible subjects (147 randomized subjects and 15 Pharmacokinetic subjects)"|t|f|f|t
34026012|NCT05367011|||COHORT||PROSPECTIVE|||||||
34026013|NCT00576446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026014|NCT04378738|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||a survey study of a cohort about social media awareness regarding coronavirus pandemic||||
34026015|NCT06633159|||COHORT||PROSPECTIVE|||||||
34026016|NCT02274831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34026017|NCT06041789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026018|NCT06495112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34026019|NCT00025259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026020|NCT03548337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026021|NCT06523660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026022|NCT01061476|NA|SINGLE_GROUP||||NONE||||||
34026023|NCT06551766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026024|NCT02094911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34026025|NCT00015873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026026|NCT02722915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026027|NCT00598598|||COHORT||PROSPECTIVE|||||||
34026028|NCT05329259|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34026029|NCT02197910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026030|NCT06348615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026031|NCT02988635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026032|NCT03645239|||CASE_CONTROL||PROSPECTIVE|||||||
34026033|NCT04722146|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34026034|NCT03159338|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigator will be blunt about side of treatmen and control.None of surgical team will be as an investigator.Patients will unware about which side is treatment or control.|one side of osteotomies randomally will be considered as a treatment group and another side as a control group.|t|f|f|f
34026035|NCT06447129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026036|NCT02628886|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34026037|NCT06448260|||CASE_CONTROL||PROSPECTIVE|||||||
34026038|NCT01326923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026039|NCT00637767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026040|NCT06050304|||CASE_ONLY||PROSPECTIVE|||||||
34026041|NCT04251572|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34026042|NCT03349983|NA|SEQUENTIAL||TREATMENT||NONE||||||
34026043|NCT06633367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The investigators will determine nature opportunities at each school using park and sports field mapping, remote sensing, and tree canopy assessment within 30 miles of campuses to identify disparities. As Fall semester starts, the investigators will recruit 160 students/school for an RCT. Students will complete baseline surveys on nature connectedness, nature belongingness, mental health, and demographics. Students will download the NatureDose™ app, which uses 30+ datasets and machine learning models to quantify nature. The app calculates how much nature is near users whenever they are outdoors, and weekly minutes in nature. App data will be collected over a 2-week baseline period, after which students will be randomized to receive 1) standard information about the health benefits of nature or 2) standard health information, a request to increase time in nature, eligibility to receive a prize, and information on peer performance. After 2 weeks, students will repeat baseline surveys.|t|f|f|f
34026044|NCT01291771|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026045|NCT04478812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802460|NCT03778541|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients were randomized to 2 parallel groups, namely the concurrent chemoradiotherapy group and radiotherapy alone group||||
34026046|NCT01763190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802461|NCT01367405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802462|NCT01506934|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33802463|NCT02182336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026047|NCT05576077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled into a Cohort based on malignancy.||||
34103787|NCT06613477|NA|SINGLE_GROUP||TREATMENT||NONE||Each subject will receive population specific PK model-derived digoxin dosing.||||
34103788|NCT05647252|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single-Center, Unblinded, Superiority, Randomized-Controlled Trial (Randomization 1:1)||||
34103789|NCT01515254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103790|NCT01333826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151016|NCT03468582|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Monocentric, open-label and uncontrolled study||||
34151017|NCT04253457|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33802464|NCT04093895|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, uncontrolled, open-label||||
33802465|NCT03394885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802466|NCT03014453|||COHORT||PROSPECTIVE|||||||
33802467|NCT01334489|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33802468|NCT01006577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802469|NCT02338024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103791|NCT06605027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Subjects will be able to choose which arm they participate in.|Subjects will be given the option to participate in the study intervention or continue to receive standard of care treatment in a structured high level of care eating disorders program.||||
34103792|NCT06060041|||COHORT||PROSPECTIVE|||||||
34103793|NCT03008980|||COHORT||CROSS_SECTIONAL|||||||
34103794|NCT04562090|RANDOMIZED|PARALLEL||TREATMENT||NONE|This was an open label study.|Participants fulfilling the screening inclusion/exclusion criteria were randomized in a 2:1 ratio, 50 mg mirabegron and 25 mg mirabegron, using a computer-generated randomization to reduce selection bias.||||
34103795|NCT03767387|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34151018|NCT01008124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151019|NCT01833234|||COHORT||PROSPECTIVE|||||||
34151020|NCT03203733|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151021|NCT04971252|||CASE_ONLY||PROSPECTIVE|||||||
33721778|NCT01761214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721779|NCT00140569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721780|NCT03531307|||CASE_ONLY||RETROSPECTIVE|||||||
33721781|NCT01466023|||CASE_CONTROL||PROSPECTIVE|||||||
33721782|NCT03034421|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721783|NCT01829555|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33721784|NCT00862810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721785|NCT04490720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721786|NCT01264146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721787|NCT03781570|||COHORT||PROSPECTIVE|||||||
33721788|NCT05890612|||CASE_ONLY||OTHER|||||||
33721789|NCT02802592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721790|NCT03185728|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Childcare sites will be randomized to one of 3 study arms, and we will use a stepped wedge design to recruit patients to complete one of two interventions. During the first year of implementation, 1/3 of participants will not be contacted (Control arm). In the other 2 arms, participants will be recruited to complete either the iLookOut intervention or the Standard online mandated reporter training. The next year, participants in the Standard arm will then be asked to complete the iLookOut intervention, and participants in the Control arm will, again, not be incentivized to complete any training. In the final year, participants in the Control arm will be recruited to complete the iLookOut intervention.||||
33721791|NCT00728130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721792|NCT03893136|||COHORT||OTHER|||||||
33721793|NCT06114355|||CASE_ONLY||RETROSPECTIVE|||||||
33721794|NCT02956486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721795|NCT03247075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721796|NCT04011501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721797|NCT02368795|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33802470|NCT04303325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33802471|NCT01522573|||CASE_ONLY||PROSPECTIVE|||||||
33802472|NCT03237416|NA|SINGLE_GROUP||OTHER||NONE||||||
33802473|NCT02006758|||CASE_ONLY||PROSPECTIVE|||||||
33802474|NCT02139436|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three intervention groups (Control, AO-Row, and FES-RT) run in parallel||||
33802475|NCT05815030|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33839008|NCT03471546|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients newly diagnosed with World Health Organization (WHO) Grade IV malignant glioma will be referred to a Palliative Care provider in the clinic, in order to assess the impact of early palliative care intervention.||||
33839009|NCT05661435|||COHORT||PROSPECTIVE|||||||
33839010|NCT04559178|||COHORT||PROSPECTIVE|||||||
33839011|NCT05636553|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A convergent parallel mixed-methods, single arm repeated measures pilot trial design||||
33839012|NCT02015507|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839013|NCT00166959|||DEFINED_POPULATION||PROSPECTIVE|||||||
33839014|NCT03264937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839015|NCT04313257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33839016|NCT00380302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839017|NCT04311710|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33839018|NCT05109000|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE||Subjects will receive both treatments: one in each thigh. Random allocation of subcutaneous injections of 10 mL of normal saline into one anterior thigh and 10 mL of bacteriostatic saline into the contralateral anterior thigh. Paired t-tests to compare the clinical effects of the two solutions.|t|f|t|t
33839019|NCT03285555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839020|NCT03680651|||COHORT||RETROSPECTIVE|||||||
33839021|NCT05448573|||COHORT||PROSPECTIVE|||||||
33839022|NCT00178555|RANDOMIZED|PARALLEL||||SINGLE||||||
33839023|NCT01271504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839024|NCT02143661|||COHORT||PROSPECTIVE|||||||
33839025|NCT04828941|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Each patient will use the electronic headache diary and the paper diary for a period of 13 weeks, the order of their use will be determined by randomisation.|f|f|f|t
33839026|NCT03730506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33839027|NCT02330094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839028|NCT01173068|||CASE_CONTROL||PROSPECTIVE|||||||
33839029|NCT02963090|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839030|NCT03149575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839031|NCT02156323|RANDOMIZED|CROSSOVER||||NONE||||||
33839032|NCT00086151|||||RETROSPECTIVE|||||||
33839033|NCT03902366|||COHORT||PROSPECTIVE|||||||
33839034|NCT02472340|||COHORT||CROSS_SECTIONAL|||||||
33839035|NCT01707797|||COHORT||PROSPECTIVE|||||||
33839036|NCT04194840|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33839037|NCT00001905||||TREATMENT||||||||
33839038|NCT03807960|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33839039|NCT00678301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839040|NCT04674189|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34151022|NCT03446417|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34151023|NCT00116363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151024|NCT03959202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33721798|NCT02556268|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33721799|NCT00664742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721800|NCT01446692|||||RETROSPECTIVE|||||||
33721801|NCT04698720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) Eligible participants will be randomized into the four groups into blocks of variable size, multiples of three; and will be stratified according to: i) data collection site; ii) Chronic Renal Disease (CRD); and iii) Peripheral Arterial Disease (PAD); since CRD and PAD are factors of poor prognosis in the DFU healing (Ferreira et al., 2014). This procedure will be performed using an online random number generator by an independent researcher unaware of the numeric coding for each group. After this procedure, it will not be possible to conceal the group to which the patient belongs from the researcher that will perform the psychological and placebo interventions. However, health professionals will be blinded during the entire procedure as they will only fill in the clinical questionnaire (doctors) and the RESVECH 2.0 (nurses), which assesses the DFU healing.|"Parallel Assignment This is a Randomized Controlled Study of a Psychological Intervention (Grant et al., 2018). This study will use a mixed-methods approach nested in a 4-arm randomized control design. Qualitative and quantitative data will be collected in order to provide better understanding about the effectiveness of the hypnosis intervention in patients with DFU.~Participants will be randomised at a ratio of 1:1 for the four conditions - EG1, EG2, ACG and PCG; and will be evaluated on the day of the first chronic DFU appointment or nursing treatment (T0), two months later (at the end of the intervention in EG, EG2, and ACG; T1), as well as six months later (T2) in a follow-up evaluation. Participants from all four groups will undergo standard treatment for the DFU, according to the guidelines of the Portuguese General Health Direction (DGS, 2010) and the International Working Group on the Diabetic Foot (IWGDF, 2015)."|t|f|f|t
33721802|NCT00070187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721803|NCT00705107|||CASE_ONLY||PROSPECTIVE|||||||
33721804|NCT04007523|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33721805|NCT06219447|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||It will be a waitlist study||||
33721806|NCT00034333|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721807|NCT03505944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721808|NCT06200077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721809|NCT04554277|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective|t|f|f|f
33721810|NCT05481073|||CASE_ONLY||PROSPECTIVE|||||||
33721811|NCT02248610|||COHORT||PROSPECTIVE|||||||
33721812|NCT06325358|||CASE_ONLY||CROSS_SECTIONAL|||||||
33721813|NCT01564121|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721814|NCT05846061|||COHORT||PROSPECTIVE|||||||
33721815|NCT02710045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33721816|NCT00309842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721817|NCT00360373|||COHORT||PROSPECTIVE|||||||
33721818|NCT03821298|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort Study||||
33721819|NCT03970733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802476|NCT06435650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study phase is not applicable as whilst cannabis suppositories are part of this research study, participants are not randomised into cannabis groups. Participants would already be using cannabis suppositories for at least one month and are used as part of sexual intimacy.~Randomisation was based on whether participants were using cannabis suppositories and consisted of one of four groups, including a cannabis suppository-only group, mindful- compassion only group, a combined mindful-compassion and cannabis suppository group and a care-as-usual group"||||
33802477|NCT02446340|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33802478|NCT06045208|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33802479|NCT03032458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802480|NCT01446497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802481|NCT00993460|||COHORT||PROSPECTIVE|||||||
33802482|NCT02987816|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33802483|NCT03631238|||CASE_CONTROL||PROSPECTIVE|||||||
33802484|NCT01471756|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33802485|NCT04919057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802486|NCT05397275|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33802487|NCT01790672|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33802488|NCT04221828|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single group, safety, efficacy, and pharmacokinetic study.||||
33802489|NCT02479217|||CASE_CONTROL||PROSPECTIVE|||||||
33802490|NCT03039244|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|A random number table will be generated by a computer program, each of the selected pairs dental receive the following treatments: SRP or SRP + several aPDT episodes. The clinical, immunological and microbiological parameters will be evaluated at baseline (pre-intervention) and after the completion of non-surgical periodontal therapy. The periodontal clinical examinations (pre and post-intervention) will be performed by a single trained and calibrated examiner, who unknown the experimental groups of this study. Examiners are also blind to study the immunological and microbiological analyzes. SRP procedures and use of the aPDT protocol should be performed by other trained operator for these purposes.|The study type will be split mouth with two pairs of contralateral uni-root teeth with proximal periodontal sites presenting probing depth ≥ 5 mm for the clinical, microbiological and immunological assessment. A random number table will be generated by a computer program, each of the selected pairs dental receive the following treatments: SRP or SRP + several aPDT episodes|t|t|t|t
33802491|NCT05092113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33802492|NCT05364216|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33802493|NCT01102673|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33802494|NCT02564744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The interventional study model is sequential for Part 1 and Part 2/3 of the study, and parallel for Cohorts 1 and 2 of Part 1, and for Cohorts A and B of Part 2/3.||||
33802495|NCT00212251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802496|NCT01086813|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802497|NCT03002428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802498|NCT02867254|||CASE_CONTROL||PROSPECTIVE|||||||
34026048|NCT05331807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|All eligible participants will be randomly selected and included in either one of these four (4) experimental groups (arms).The participants for each experimental will matched and stratified based on age group (± 5 years), menopausal status and BMI status (± 2 kg/m2). Each participant will be randomly allocated into four groups, based on their age, menopausal status and BMI status to ensure the standardization of general characteristics of study participants included in the study as a baseline data.|An open-label randomized clinical trial of breast cancer women that are undergoing chemotherapy treatment for total duration of 2 months (approximately 9 weeks in total), in which participants will be randomly selected and included in either one of these four (4) experimental groups (arms).||||
34026049|NCT06498167|||COHORT||PROSPECTIVE|||||||
33721820|NCT02904473|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34026050|NCT05456230|||COHORT||RETROSPECTIVE|||||||
33721821|NCT01371474|||OTHER||PROSPECTIVE|||||||
34026051|NCT01447277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026052|NCT06632535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026053|NCT06218576|||COHORT||RETROSPECTIVE|||||||
34026054|NCT06427707|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||compare the effect of; propofol- lidocaine-magnesium and ketamine- lidocaine- magnesium infusions to dexmedetomidine- lidocaine- magnesium infusion on surgical field quality in patients undergoing nasal surgeries.|t|t|t|t
34026055|NCT04333030|||COHORT||PROSPECTIVE|||||||
34026056|NCT00003911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026057|NCT06522217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|starting 2 conventional then 2 CAD NAM patients|2 groups : Group A receiving conventional nasoalveolar molding appliance and Group B receiving CAD NAM|t|t|f|f
34026058|NCT00166582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026059|NCT04258319|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The unaffected arm will be used to serve as control for the affected extremity.||||
33721822|NCT02039674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721823|NCT05747729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721824|NCT00121420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721825|NCT02189473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721826|NCT01358357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34026060|NCT02901548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721827|NCT02882854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026061|NCT03111771|||OTHER||RETROSPECTIVE|||||||
33721828|NCT01871246|||CASE_ONLY||PROSPECTIVE|||||||
34103796|NCT06687161|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will test the combination of neuromodulation by repetitive transcranial magnetic stimulation (rTMS) with cognitive behavioral therapy for insomnia (CBT-I). All participants will receive the active intervention. Participants will be randomized to receive one or two treatments of rTMS per day.||||
33721829|NCT06473259|||COHORT||PROSPECTIVE|||||||
33721830|NCT05623267|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721831|NCT04889339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will be separated into two stages. Each patient will initially try a control brace and a test brace in a crossover study model to evaluate the immediate correction. Each patient will then use one brace from either the control arm or test arm to evaluate the long-term correction of the brace.|t|f|f|t
34148852|NCT06198335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Modified Perichondral Approach Thoracoabdominal Nerve block (M-TAPA block) group, and Transversus Abdominal Plane Block (TAP block) group|t|f|f|t
33721832|NCT06069973|||COHORT||PROSPECTIVE|||||||
33721833|NCT00213083|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33721834|NCT02505620|||COHORT||PROSPECTIVE|||||||
33721835|NCT00341185|||COHORT||RETROSPECTIVE|||||||
33721836|NCT00620828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33721837|NCT04996459|||COHORT||PROSPECTIVE|||||||
33721838|NCT04352114|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34026062|NCT04139759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34026063|NCT04743492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026064|NCT04011163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026065|NCT05008601|||CASE_ONLY||PROSPECTIVE|||||||
34026066|NCT01542151|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34026067|NCT01349777|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026068|NCT01992718|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34026069|NCT05393206|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34026070|NCT00036192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026071|NCT02352935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34026072|NCT02764151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026073|NCT01181557|||COHORT||PROSPECTIVE|||||||
34026074|NCT00589927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026075|NCT06551376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721839|NCT03929718|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, pilot study||||
33721840|NCT03689803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721841|NCT00123864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721842|NCT00638313|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33721843|NCT06209892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721844|NCT01901718|||COHORT||PROSPECTIVE|||||||
33721845|NCT05848167|||COHORT||PROSPECTIVE|||||||
33721846|NCT00866411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721847|NCT00501293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721848|NCT05725720|||COHORT||PROSPECTIVE|||||||
33721849|NCT03454750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721850|NCT02197806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721851|NCT06547866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721852|NCT05590065|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33721853|NCT01059474|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721854|NCT06536777|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessor who will take the readings is blind|Randomized Clinical Trial|f|f|f|t
33802499|NCT02542683|||COHORT||PROSPECTIVE|||||||
33802500|NCT04434742|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34026076|NCT03574350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The nurses who did anthropometrics measures didn't know the interventions assigned to each participant of the study, because the night shift was in charge of taking the data at 7:00 am in the mornings and the interventions were delivered in the morning shifts from 8:00 am until 5:00 pm. No interventions were delivered in the night.|Two interventions groups of 33 each, participated in the study. The first group received Kinesthetic Stimulation in Kangaroo Position (KSKP) and the second group received Kinesthetic Stimulation In incubator (KSI ), both of the interventions were delivered by parents during the period of hospitalization and at home when the infant was discharged from Hospital until 40 weeks of gestational age.|f|f|t|t
33802501|NCT03578536|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group: Clinical trials with a single arm||||
33802502|NCT05588817|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34026077|NCT02895828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33802503|NCT04523922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802504|NCT00027729||||TREATMENT||||||||
33802505|NCT03205072|||COHORT||PROSPECTIVE|||||||
33802506|NCT06257680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802507|NCT01407458|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802508|NCT03157466|||COHORT||PROSPECTIVE|||||||
33802509|NCT03639896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802510|NCT04870749|||COHORT||PROSPECTIVE|||||||
33802511|NCT01932970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802512|NCT02291913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802513|NCT01109498|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802514|NCT02076568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802515|NCT03872310|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33802516|NCT04037813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802517|NCT03628885|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Intervention videos delivered via anonymous online surveys through Survey Sampling International. Randomization to condition is built into the online survey. Participants will not know to which condition they will be randomized. Investigators are blinded by virtue of the built in randomization and anonymity of the survey.|Factorial Assignment|t|f|t|f
33802518|NCT05512182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802519|NCT05527613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is not possible to blind the interventions to the patients, nor to the clinicians performing the orthodontic treatment, however the operators, should not know the assignment of the study participants, the processing of the microbiological samples and the statistical advisor will also be blinded, this will be done by means of codes for each group.|consort scheme|f|f|f|t
33802520|NCT06037993|NA|SINGLE_GROUP||TREATMENT||NONE||We will evaluate the study viability through an internal pilot that will assess the ability of the study to identify, consent, and follow up CHR patients experiencing APS in the study. We propose a 12-week, open-label, investigator-initiated proof of concept study (Phase-2 Pilot Study) of PEA (600 mg/day) for the treatment of APS in CHR patients. We plan to enrol 20 CHR young adults. Those completing the 12-week initial phase, will be proposed to enter a 24-week extension phase to evaluate the clinical stability of treatment, with the possibility of PEA titration to 1200 mg/day based on clinical improvement obtained so far.||||
33802521|NCT01837238|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33802522|NCT02329639|||COHORT||PROSPECTIVE|||||||
33802523|NCT03002675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802524|NCT03739918|||OTHER||RETROSPECTIVE|||||||
33802525|NCT04816175|NA|SINGLE_GROUP||TREATMENT||NONE|Because all children will receive the intervention all parties involved will be aware that the participant has received the intervention.|As an early phase study, all enrolled children will receive the intervention.||||
33802526|NCT00015067||CROSSOVER||TREATMENT||||||||
33802527|NCT03244813|RANDOMIZED|PARALLEL||OTHER||SINGLE|The medical team assessing patient functional capacities and caregiver burden at 3 and 6 months will not know which treatment the patient received||f|f|f|t
34026078|NCT02399319|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026079|NCT02862561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026080|NCT00818987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026081|NCT01208987|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34148853|NCT01142024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34148854|NCT04718168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148855|NCT01321203|||CASE_CONTROL||PROSPECTIVE|||||||
33802528|NCT00174252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802529|NCT01327664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802530|NCT00684242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026082|NCT01091324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026083|NCT00073710|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33802531|NCT06519617|RANDOMIZED|PARALLEL||TREATMENT||NONE||The treatment group received an optimized program combining Chinese and Western medicine for pSS glandular injury, while the control group received a conventional program for pSS glandular injury.||||
33802532|NCT00790413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802533|NCT02316301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026084|NCT03838497|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34026085|NCT00549991|||CASE_ONLY||RETROSPECTIVE|||||||
34026086|NCT05468931|NA|SINGLE_GROUP||OTHER||NONE||||||
34026087|NCT02865460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026088|NCT02564887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026089|NCT03940131|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm Phase II study||||
34026090|NCT01027195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026091|NCT02520297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026092|NCT03668392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148856|NCT01384032|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148857|NCT04246957|||CASE_ONLY||PROSPECTIVE|||||||
34148858|NCT03883113|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148859|NCT02176603|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34148860|NCT05779904|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802534|NCT00426829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802535|NCT03415360|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33802536|NCT05461313|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized, Open-Label, Two-Arm, Non-Inferiority Study||||
33802537|NCT00497575|||DEFINED_POPULATION||PROSPECTIVE|||||||
33802538|NCT03484910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33802539|NCT00468156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721855|NCT06279689|NA|SINGLE_GROUP||OTHER||NONE||||||
33721856|NCT04256785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721857|NCT05633524|||CASE_CONTROL||RETROSPECTIVE|||||||
33721858|NCT03190161|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33721859|NCT03076957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721860|NCT05114850|||CASE_ONLY||OTHER|||||||
33721861|NCT02308410|||COHORT||PROSPECTIVE|||||||
33721862|NCT03893812|||COHORT||PROSPECTIVE|||||||
33721863|NCT00100815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721864|NCT03993431|RANDOMIZED|PARALLEL||TREATMENT||NONE||split mouth||||
33721865|NCT00991055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721866|NCT01950377|||OTHER||PROSPECTIVE|||||||
33721867|NCT06541015|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721868|NCT04487054|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre and post phase study evaluating the utility of pro-active palliative care in high risk ICU patients identified using integrated prediction model||||
33721869|NCT04521465|||CASE_ONLY||PROSPECTIVE|||||||
33721870|NCT01650233|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721871|NCT03933787|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The participants, investigator and care provider were not aware when the placebo or Saxagliptin was provided. The biochemical assays were performed in a random order with anonymised sample numbers. The data were analysed before revealing to which session each participant received the placebo or Sitagliptin|double-blind placebo-controlled crossover study|t|t|t|t
33721872|NCT03832582|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33721873|NCT02307357|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721874|NCT02469454|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33721875|NCT02357901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721876|NCT01387347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721877|NCT00616655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721878|NCT00278083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33721879|NCT03416257|||COHORT||PROSPECTIVE|||||||
33721880|NCT02940847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33721881|NCT00002091||||TREATMENT||DOUBLE||||||
33721882|NCT00591942|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subject unaware of the dental cement used on which crown or retainer|2 crowns per subject or one dental bridge with two retainer crowns for a total of 72 Teeth.|t|f|f|f
33721883|NCT05982509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33721884|NCT01724060|||CASE_CONTROL||PROSPECTIVE|||||||
33721885|NCT05876741|||CASE_ONLY||PROSPECTIVE|||||||
33721886|NCT00357487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721887|NCT04463095|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721888|NCT03233958|||CASE_ONLY||PROSPECTIVE|||||||
33721889|NCT04951245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721890|NCT03454919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721891|NCT03775980|||COHORT||PROSPECTIVE|||||||
33721892|NCT05346159|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33721893|NCT04320485|||COHORT||PROSPECTIVE|||||||
33721894|NCT06392542|NA|SINGLE_GROUP||OTHER||NONE||A single-arm feasibility trial||||
33721895|NCT01679379|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33721896|NCT05102383|NA|SINGLE_GROUP||OTHER||NONE||||||
33721897|NCT02492347|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33721898|NCT04526275|||COHORT||PROSPECTIVE|||||||
33721899|NCT03352986|||COHORT||PROSPECTIVE|||||||
33721900|NCT04102215|NA|SINGLE_GROUP||TREATMENT||NONE||SIngle arm study||||
33721901|NCT04123847|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721902|NCT00946712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721903|NCT05569187|||COHORT||RETROSPECTIVE|||||||
33721904|NCT00749372|NA|SINGLE_GROUP||SCREENING||NONE||||||
33721905|NCT05195112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721906|NCT05337592|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|For the Single Rising Dose (SRD) part the participant is blinded. For the bioavailability (BA) part no masking is applicable.|This study has 2 parts: a single rising dose (SRD) part and a bioavailability (BA) part. For the SRD part the intervention study model is sequential, while for the BA part the intervention study model is crossover.|t|f|f|f
33721907|NCT05039008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721908|NCT01864733|RANDOMIZED|PARALLEL||||NONE||||||
33721909|NCT00827970|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33721910|NCT02102074|||COHORT||PROSPECTIVE|||||||
33721911|NCT01452607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33721912|NCT06197815|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33721913|NCT05864560|||COHORT||PROSPECTIVE|||||||
33721914|NCT00632255|||COHORT||PROSPECTIVE|||||||
33721915|NCT04297137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33721916|NCT02746211|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33721917|NCT03667560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721918|NCT03332576|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33721919|NCT00303498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721920|NCT04019314|NA|SINGLE_GROUP||SCREENING||NONE||||||
33721921|NCT06470230|||COHORT||PROSPECTIVE|||||||
33721922|NCT02986568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721923|NCT03345667|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33802540|NCT01754636|||COHORT||PROSPECTIVE|||||||
33802541|NCT05114967|||COHORT||PROSPECTIVE|||||||
33802542|NCT03465813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802543|NCT04338399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802544|NCT04019444|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34103797|NCT05447858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor)|"Randomization will be handled by a person not involved in intervention or evaluation. Investigators/ assessors will be blinded for randomization.~This is a prospective, longitudinal, randomised, controlled multi-centre trial with two parallel treatment arms and blinded investigators conducted according to a detailed protocol. A total of 240 employees with WRNP will be recruited. The main outcome is neck pain intensity. Secondary outcomes are work ability, function, health-related quality of life, work absenteeism, work-related factors, work adjustments made. Cost-effectiveness will be studied if significant differences appear between randomization groups regarding health-related quality of life and will in that case be reported in a separate paper."|f|f|t|t
33802545|NCT05602207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802546|NCT00939510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802547|NCT00403598|||||OTHER|||||||
33802548|NCT00984048|||CASE_ONLY||PROSPECTIVE|||||||
34103798|NCT05648747|||COHORT||RETROSPECTIVE|||||||
34103799|NCT00787800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103800|NCT06688773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33802549|NCT00486070|||||RETROSPECTIVE|||||||
34103801|NCT04575688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103802|NCT06680375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|This is an observer-blind study.||t|f|t|t
34103803|NCT05761496|||COHORT||PROSPECTIVE|||||||
34103804|NCT05062707|||COHORT||PROSPECTIVE|||||||
34103805|NCT04843839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Paired eye study- So one eye will be subjected to test drug, while the other eye will be subjected to a placebo|t|t|t|t
33802550|NCT03492866|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Assessing in 8 patients the efficacy of topical gentamycin treatment on 1 side of the scalp by determining the amount of hair loss on the treated versus the untreated side of the scalp||||
33802551|NCT02966275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Glucagon and placebo were blinded by the research pharmacy. Subjects were given bags of blinded medication labeled with which day they were to be used, and then were asked to label the bags with which day the medication was actually used. The contents of the bags were verified with the research pharmacy's blinding key upon completion of the study.||t|t|t|t
33802552|NCT03602950|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention group will receive PRP at surgery, whereas the control group will receive the usual care. All patients will be evaluated at baseline, one week, four weeks and eight week after the cesarean section.||||
33802553|NCT05960994|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|For technical reasons, it is impossible to perform blinding for patients, health care staff, professionals involved in patient care, and data collectors in the ICUs participating in the study.|The TELESCOPE II study is an open-label, national, multicenter, stepped-wedge cluster randomized controlled trial. The randomization unit will be the ICU, since the intervention will be applied to the entire multiprofessional team. Therefore, 25 ICUs participating in the study will be allocated and randomized to one of the five sequences. In each sequence, the initial period will serve as the control period without any intervention. Subsequently, as the intervention is stepwise implemented, new control periods will be introduced based on the assigned sequence. Due to the multifaceted nature of the intervention, a delay in onset of effect is expected; thus, the study design contemplates a transition period, which will occur in all sequences, when the intervention will be occurring, but these data will not be used in the main analysis. All groups will receive all interventions, but at different times||||
33802554|NCT04246944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802555|NCT02320370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802556|NCT02496325|NA|SINGLE_GROUP||||NONE||||||
33802557|NCT03230643|||CASE_CONTROL||PROSPECTIVE|||||||
33802558|NCT06282107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802559|NCT00186849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026093|NCT04272749|NA|SINGLE_GROUP||OTHER||NONE||||||
34026094|NCT00548470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026095|NCT05976126|||COHORT||RETROSPECTIVE|||||||
34026096|NCT02931929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026097|NCT02376816|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34026098|NCT02455518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026099|NCT05405582|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Restricted randomisation was used to randomly allocate administrative areas in equal measure (to early and delayed roll-out of the intervention steps (20:20). Restricted randomisation was used to ensure that the intervention steps are reasonably balanced with respect to key characteristics (obtained from the HDSS) specifically, adolescent and young adult population size and density, new versus old areas, and geographic location along the N2 road. Interventions were assigned during a public ceremony to ensure transparency and fairness in the randomisation and engagement of the community. Randomisation and allocation were kept separate throughout. The statistician and investigators did not participate in the public randomisation and will remain blinded until the analyses of primary and randomised secondary outcomes have been finalised. Investigators remain blinded to allocation throughout. The participants and intervention delivery teams are not blinded.|step wedge cluster randomised controlled trial|f|f|t|t
34026100|NCT06234943|NA|SINGLE_GROUP||SCREENING||NONE||||||
34026101|NCT06448806|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026102|NCT05916274|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34026103|NCT02127385|||CASE_ONLY||RETROSPECTIVE|||||||
34026104|NCT00002737|RANDOMIZED|||TREATMENT||||||||
34026105|NCT04917471|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34103806|NCT06566768|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103807|NCT05569252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103808|NCT06675084|||COHORT||PROSPECTIVE|||||||
34103809|NCT06689371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103810|NCT05062200|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34103811|NCT06316063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33802560|NCT01311622|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33802561|NCT02612233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103812|NCT03945253|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103813|NCT06686173|||COHORT||PROSPECTIVE|||||||
34103814|NCT00265005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802562|NCT05490524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The patients, research assistants, nurses, social workers, physiotherapists and psychologists responsible for data collection will not have access to the information of which group (control or intervention) the participant is.|"The Control group will receive standard health care with no technical support, where the intervention groups will receive platform and device services provided to each user. In that respect, Intervention Group 1 will receive no real-time feedback, where Intervention Group 2 will unhand with real data and notifications.~group)"|t|t|t|t
33802563|NCT03172234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802564|NCT03636334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802565|NCT06495359|RANDOMIZED|PARALLEL||OTHER||SINGLE||A parallel group (experiment-control) randomized controlled design, which is one of the experimental methods|t|f|f|f
33802566|NCT04024176|NA|SINGLE_GROUP||PREVENTION||NONE||Each participant will perform the quantified gait analysis examination and a clinical examination. The experiments will be carried out in a single measurement session, including several steps.||||
34103815|NCT05912725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103816|NCT06117813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33721924|NCT03256539|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34103817|NCT06453486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802567|NCT00809068|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34026106|NCT06525103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Thirty patients (male and female) who suffering from second degree burn with burned body surface area 10% _25% BSA will participate in this study, they will be recruited from Al-Ahrar Teaching Hospital at Alsharqiya Governorate, Egypt. Their ages will be ranged from 25 to 40 years|Thirty patients (male and female) who suffering from second degree burn with burned body surface area 10% _25% BSA will participate in this study, they will be recruited from Al-Ahrar Teaching Hospital at Alsharqiya Governorate, Egypt. Their ages will be ranged from 25 to 40 years|t|f|f|f
33802568|NCT04091178|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A phase 2 clinical trial not randomized||||
34103818|NCT05308641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34103819|NCT06003790|NA|SINGLE_GROUP||OTHER||NONE||Single arm, multi-site, prospective hybrid implementation and feasibility trial.||||
34103820|NCT04098783|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study had a single-blind, randomized controlled experimental design. To avoid bias, the participants were not told whether they were in the experimental or the control group.|Randomized controlled experimental design|t|f|f|f
33802569|NCT05631860|||COHORT||PROSPECTIVE|||||||
33802570|NCT00139984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33802571|NCT01939691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked outcome assessment (evaluation of OCT and visual acuity)|Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial|f|f|f|t
34103821|NCT06412055|NA|SINGLE_GROUP||TREATMENT||NONE||pilot self-controlled intervention study with measurements of three spring-like AFOs (WalkOn Reaction® (Ottobock, Duderstadt), the Matrix Max2® (TruLife, Dublin, Ireland), and the Matrix® (TruLife, Dublin, Ireland)) having the same stiffness in both directions, and a newly custom-made spring-hinged AFO with the NEURO SWING® system ankle joint with individualized spring settings (Fior\& Gentz, Lüneburg In Duderstadt, Germany) directly after delivery and 6 weeks post-delivery.||||
34103822|NCT03324412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026107|NCT01823601|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34103823|NCT00292903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103824|NCT00504556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34103825|NCT04250766|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103826|NCT03810365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103827|NCT06456684|||CASE_CONTROL||PROSPECTIVE|||||||
34103828|NCT03612414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Randomization code|randomized, double-blind, placebo-controlled clinical study|t|t|t|f
34103829|NCT03232892|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Phase 2, single-arm, open label, multicenter clinical trial.||||
34103830|NCT03733782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103831|NCT03743142|||COHORT||PROSPECTIVE|||||||
34103832|NCT03816137|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Volunteers will be blinded to their treatment regimes, and laboratory teams undertaking immunological analysis will be blinded to group and dosing regimen to prevent in-house analysis bias. The clinical team will remain un-blinded throughout.|This is a single-blind study with volunteers being randomised into five groups of n=10 (Groups A-E) and eight groups of n=8 (Groups F-M), stratified by gender|t|f|f|t
34103833|NCT06344923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103834|NCT02365064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103835|NCT03104751|||COHORT||PROSPECTIVE|||||||
34103836|NCT06571630|||CASE_ONLY||CROSS_SECTIONAL|||||||
34103837|NCT05984992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose|t|t|t|t
34103838|NCT02262663|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33721925|NCT03118154|||CASE_CONTROL||OTHER|||||||
33721926|NCT00604292|||COHORT||PROSPECTIVE|||||||
33721927|NCT00452829|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33802572|NCT05294393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double||t|f|f|t
33802573|NCT01762059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802574|NCT03177824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802575|NCT06111586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802576|NCT05783843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded as to the comparators for their arm.|Participants randomized to the text-only condition will see six packages with different text warnings. Participants randomized to the pictorial condition will see six packages with different pictorial warnings. Participants in the control condition will see a single package without a warning.|t|f|f|f
33802577|NCT01422603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802578|NCT06152640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33802579|NCT05422846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups to be applied two different exercises progressing together with the control group|t|f|f|f
33721928|NCT03434847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"At enrollment, each patient will be assigned a study number, which will match a previously prepared computer-generated list of randomization numbers to determine whether they will be in the intervention or control arm. Pre-operatively, all patients will complete an initial questionnaire. The patients in the intervention group (n=50) will, in addition to the standard pre-operative assessment, also receive pre-operative educational instruction of what to expect from a post-operative pain perspective including education material to take home.~For this study, we will be using deception, with the reasoning that the patients' knowledge of the different education materials will affect their rating of the impact of the intervention on satisfaction scores."|Prospective, randomized, single-blind study|t|f|f|f
33802580|NCT03716336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were assigned randomly used sealed envelope into two groups (A\&B) equally in number.|were randomly assigned to group A participated in aerobic and resistive exercise program, and group B participated in aerobic exercise and followed prescribed diet restriction program. Both of the groups (A\&B) followed the treatment program 3 times per weeks for 8 weeks. Assessment of the fasting glucose, fasting insulin, and HOMA test of insulin resistance were measured for all subjects in both groups (A and B) was carried out before and after the end of the treatment program.|f|f|f|t
33802581|NCT04185636|||COHORT||PROSPECTIVE|||||||
33802582|NCT01102725|||CASE_ONLY||PROSPECTIVE|||||||
33802583|NCT05043272|||COHORT||PROSPECTIVE|||||||
33802584|NCT03312322|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Sham placebo will be used to blind patient. The outcome assessor will be invited to join the room after the experimental condition is installed.|"Three constant workload testing will be performed on three different days.~Every test will be carried out with a different condition :~* Sham transcutaneous electrical nerve stimulation;~* High-frequency transcutaneous electrical nerve stimulation;~* Low-frequency transcutaneous electrical nerve stimulation."|t|f|f|t
33802585|NCT06214442|||OTHER||CROSS_SECTIONAL|||||||
33802586|NCT04413838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802587|NCT00818246|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33802588|NCT02492516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802589|NCT02632071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802590|NCT04778670|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|Positive disease status is ascertained by pathology-verified breast cancer. Disease status is not known to any of the actors (except for the outcomes assessor by necessity). AI decision is not known by the care provider radiologists until they have made their decisions. In the subsequent consensus discussion where a decision is made to recall or not to recall a woman, the AI decision is known. After AI decision has been recorded and outcomes have been assessed, the investigators will have full information on outcomes and AI decisions.|This is a prospective clinical trial following a paired screen-positive design (Pepe, Alonzo; 2001), with the aims to assess the performance of an AI algorithm combined with radiologists(s) compared to standard-of-care being two radiologists assessing screening mammograms in a true screening population. Since all decisions by individual readers will be recorded, it is possible to determine what the outcome would have been had one or two of the readers not been allowed to assess images, and to determine what the outcome would have been had the recall decision been performed by consensus decision (actual) compared to single reader arbitration of discordant cases.|t|t|t|f
33802591|NCT06357559|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802592|NCT00257998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802593|NCT02198469|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33802594|NCT04005287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded||t|t|t|t
33802595|NCT01514149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802596|NCT04762758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PXT3003 and its matching placebo will have the same presentation, the same aspect and taste in order to be indistinguishable, and they will be supplied and used in the same conditions.||t|f|t|f
33802597|NCT01324713|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802598|NCT02008916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802599|NCT02922088|||OTHER||PROSPECTIVE|||||||
33802600|NCT03877159|||COHORT||RETROSPECTIVE|||||||
33802601|NCT03060317|||COHORT||CROSS_SECTIONAL|||||||
33802602|NCT06302920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802603|NCT04620421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The randomization will be conducted by staff members not involved in the data collection. Moreover, the randomization code will only be available for non-blinded research staff to maintain allocation concealment.|"After baseline assessments, participants will be randomly allocated to either the training or control group. To produce groups of similar size a permuted block randomization will be used. Allocation concealment will be maintained using random block sizes (4, 6, or 8) and by the randomization code only being available for non-blinded research staff.~The intervention group will undergo 6 months of RYMA training, meanwhile, the control group will continue their regular activity schedule."|f|f|f|t
33802604|NCT01643499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802605|NCT01951807|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33802606|NCT06345170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802607|NCT04857294|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Study||||
33802608|NCT02389855|||COHORT||RETROSPECTIVE|||||||
33802609|NCT02419703|||COHORT||PROSPECTIVE|||||||
33802610|NCT03128359|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802611|NCT03809936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Using a sham-controlled randomized double-blind design, 20 patients were randomly assigned to either a real or sham stimulation group. Each intervention week included 10 daily sessions of 20-minute therapy with either anodal transcranial direct current stimulation (2 mA, 20 minutes; experimental group) or sham transcranial direct current stimulation (control group) over the left dorsolateral prefrontal cortex (DLPFC).|t|f|f|t
33802612|NCT01655563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33802613|NCT02752659|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802614|NCT03793413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802615|NCT00642850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802616|NCT01765231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802617|NCT06180889|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802618|NCT01541059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33721929|NCT03402685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician is not informed about the group names, the APGAR scores are awarded by independent neonatologists/pediatricians and gynaecologists.|Randomisation of patients using a randomisation list drawn up by an independent statistician in either NIBP or ClearSight group. In both groups, the above-mentioned standard procedure according to SOP and also the non-invasive continuous blood pressure measurement to improve blood pressure monitoring with the ClearSight system, so that all patients are monitored by both monitoring systems. In the NIBP Group, anaesthetists are blinded against the ClearSight measurement. In the ClearSight group, anaesthetists are blinded against the NIBP measurement. Blinding is achieved by completely covering the measured values of the other method.|t|f|f|t
33721930|NCT00829543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33721931|NCT03008083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721932|NCT05831761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomised by random number generator after meeting the inclusion criteria.|4 parallel groups with different method of analgesia after laparoscopic colorectal resection.|t|f|f|t
33721933|NCT05241522|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721934|NCT03322722|||COHORT||PROSPECTIVE|||||||
33721935|NCT03162692|||COHORT||PROSPECTIVE|||||||
33721936|NCT00243581|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33721937|NCT00000806|RANDOMIZED|||TREATMENT||||||||
33721938|NCT02195063|||CASE_ONLY||PROSPECTIVE|||||||
33721939|NCT01821534|||COHORT||PROSPECTIVE|||||||
33721940|NCT05284669|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33721941|NCT05348161|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33721942|NCT01661192|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721943|NCT00364884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721944|NCT05106855|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33721945|NCT02005250|||COHORT||PROSPECTIVE|||||||
33721946|NCT00010075||||TREATMENT||||||||
33721947|NCT05195723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33721948|NCT03297385|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II prospective single-arm analysis. With a power of 80% to detect an expected reduction in positive surgical margin rate from 34% to 17% we will have to included 55 men. For the AR/DNA interaction patients will serve as there own control since biopsies will be taken before and after enzalutamide treatment.||||
33721949|NCT06024421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active and placebo will not be visually distinguishable. Packaging and labeling of active and placebo tablets will be done in such a way as to not allow unblinding without access to the randomization list or the investigational drug unit list.|Dose-escalation trial|t|t|t|t
33721950|NCT01045642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33721951|NCT03854617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721952|NCT05892042|RANDOMIZED|PARALLEL||TREATMENT||NONE||Acute ST segment elevation myocardial infarction complicated with left ventricular thrombus weather or not treated with primary PCI.||||
33721953|NCT02220582|||COHORT||PROSPECTIVE|||||||
33721954|NCT06012201|||COHORT||PROSPECTIVE|||||||
33721955|NCT05019365|||CASE_CONTROL||RETROSPECTIVE|||||||
33721956|NCT04728061|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33721957|NCT01730105|||COHORT||PROSPECTIVE|||||||
33721958|NCT02977988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33721959|NCT05864066|||CASE_ONLY||CROSS_SECTIONAL|||||||
33721960|NCT05546047|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 12-month treatment with combination Acthar gel and Tacrolimus therapy will be superior to Acthar gel therapy alone in lowering urinary protein to creatinine ratios in patients with Fibrillary glomerulonephritis||||
33721961|NCT01528956|||CASE_ONLY||RETROSPECTIVE|||||||
33721962|NCT05711225|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||The research was conducted as a pretest-posttest control group experimental model.|t|f|f|f
33721963|NCT01185938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33721964|NCT04515342|||COHORT||CROSS_SECTIONAL|||||||
33721965|NCT01907672|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721966|NCT05803811|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel trial|t|t|t|t
33721967|NCT04964154|RANDOMIZED|PARALLEL||SCREENING||NONE|No masking employed in this study.|Participants will be randomized to receive information about testing and vaccination based on zip code.||||
33721968|NCT04038515|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|This is a double-blind study. Although participants will receive all conditions in this within-subject cross-over study, the participant and researcher will be blinded to the order of e-liquid conditions (nicotine level, flavor) across and within test sessions.|This is a within-subject, cross-over design. Participants will be invited to complete 4 test sessions. Across those 4 test sessions, participants will self-administer e-cigarettes containing all 20 e-liquid conditions (4 nicotine \* 5 flavor conditions) in both 'directed' and ad libitum self-administration study components. The order of nicotine and flavor will be randomized across participants.|t|f|t|f
33721969|NCT04444414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject does not know the group that belonged The evaluator and therapist were different people|A randomized controlled trial with 2 groups (experimental and control)|t|f|f|t
33802619|NCT00077675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103839|NCT05815784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103840|NCT01793571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103841|NCT01103518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103842|NCT03958097|NA|SINGLE_GROUP||TREATMENT||NONE||sintilimab plus NK cell||||
34103843|NCT04632342|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103844|NCT04467489|||CASE_CONTROL||PROSPECTIVE|||||||
34103845|NCT00776412|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34103846|NCT05704634|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103847|NCT06674460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103848|NCT06296706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103849|NCT04989218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103850|NCT06691737|NON_RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34103851|NCT06694519|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34103852|NCT02544763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026108|NCT06625892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessors dose not know the allocation of groups.|The first-year research adopts a descriptive, correlational, and repeated-measures design, while the second-year research employs an experimental design. Participants are randomly assigned to either the experimental or control group. The experimental group undergoes a 12-week comprehensive intervention, while the control group receives no intervention.|f|f|f|t
34026109|NCT02264860|NA|SINGLE_GROUP||OTHER||NONE||||||
34026110|NCT04785755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026111|NCT02781038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34026112|NCT00748384|||COHORT||PROSPECTIVE|||||||
34026113|NCT04283604|RANDOMIZED|CROSSOVER||OTHER||NONE||The study will be divided into two sub studies (100 participants each), in which 50 ADHD and 50 non-ADHD participants will be included. In the first session, all participants will undergo motor tests, in the same conditions. In the second session, half of ADHD participants (25) will be asked to take their regular MPH treatment, before the session. All other participants (25 ADHD and 50 non-ADHD) will perform the motor tests without treatment, and serve as control groups.||||
34026114|NCT03502434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Principal Investigator, subjects, and the site personnel who will be performing Reaction Grade assessments will be blinded to the Test Material identity, with the exception of the Positive Control.||t|f|t|f
34026115|NCT05954286|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||An adaptive, randomized, double-blind, platform trial|t|t|t|f
34026116|NCT06456853|||CASE_ONLY||PROSPECTIVE|||||||
34026117|NCT00086593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026118|NCT00237393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026119|NCT02836314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026120|NCT05171608|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The attending anesthesiologist, participant and outcomes assessors will be blinded to randomization and result of preoperative ultrasound scans. The attending anesthesiologist (not aware of randomization and ultrasonographic findings) gives a dose recommendation for fluid therapy for all patients. The investigator will be aware of the randomization and ultrasound results. This investigator will choose the fluid therapy (conforming to the ultrasound based protocol OR to the dose-recommendation of the attending anesthesiologist) following the results of randomization and ultrasound scans in the USP group.|Randomized, controlled study|t|t|f|t
34026121|NCT00002231||||PREVENTION||NONE||||||
34026122|NCT01858272|NA|SINGLE_GROUP||||NONE||||||
34026123|NCT03183167|||COHORT||RETROSPECTIVE|||||||
34026124|NCT06093438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026125|NCT02421224|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34026126|NCT05263830|||COHORT||PROSPECTIVE|||||||
34103853|NCT02928822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103854|NCT06677554|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721970|NCT03192592|NA|SINGLE_GROUP||PREVENTION||NONE||This study aim to verify the improvement of texture, elasticity and general appearance of the skin through the application of the cosmetic product Apotech®.||||
33721971|NCT02729974|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33721972|NCT02249533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34103855|NCT03755154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103856|NCT06542380|||COHORT||RETROSPECTIVE|||||||
33721973|NCT03899584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721974|NCT03559322|||CASE_ONLY||PROSPECTIVE|||||||
33721975|NCT02751515|NA|SINGLE_GROUP||||NONE||||||
34103857|NCT03191331|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||intervention group and control group.||||
33721976|NCT00881933||PARALLEL||TREATMENT||NONE||||||
33721977|NCT03585439|||COHORT||RETROSPECTIVE|||||||
33721978|NCT05476861|||CASE_CONTROL||RETROSPECTIVE|||||||
33721979|NCT04067557|||OTHER||PROSPECTIVE|||||||
34103858|NCT06691178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103859|NCT05428007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103860|NCT01266200|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34103861|NCT00538278|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34103862|NCT06688448|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, open-label, single-center clinical study with randomization of 200 patients with indication of first-time or re-replacement aortic valve surgery to receive Dafodil® and Inspires Resilia® prostheses in the aortic position, conducted at a tertiary cardiology hospital of Brazilian Unified Health System (SUS)||||
34103863|NCT06443593|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34103864|NCT05196503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34103865|NCT05810649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103866|NCT04868071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103867|NCT02691494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103868|NCT04983238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34103869|NCT04881097|||COHORT||PROSPECTIVE|||||||
34103870|NCT06372366|||OTHER||CROSS_SECTIONAL|||||||
33721980|NCT03535350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A standard phase 1 design will be used with 3 patients treated at each dose level and monitored for treatment-related toxicities. Escalation to the next dose will proceed in the absence of dose-limiting toxicities (DLTs).||||
33721981|NCT06069687|NA|SINGLE_GROUP||OTHER||NONE||||||
33721982|NCT03178747|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33721983|NCT00187954|||COHORT||PROSPECTIVE|||||||
33802620|NCT02084420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802621|NCT00976105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721984|NCT01874847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|Placebo controlled|t|t|t|t
33721985|NCT04962061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"This clinical trial is a double-blinded study. Research personnel performing the outcome assessments will be blinded to group allocation. Participants will be aware of the type of training they receive, but they will be blinded to the active intervention and study hypotheses."||t|f|f|t
33721986|NCT05196542|RANDOMIZED|PARALLEL||OTHER||SINGLE|participants will be aware of procedure but unaware of the material used for repair||t|f|f|f
33721987|NCT04903249|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33721988|NCT05414279|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33721989|NCT04882228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33721990|NCT00963287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33721991|NCT01239433|||CASE_ONLY||PROSPECTIVE|||||||
33721992|NCT02941965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721993|NCT03896243|||CASE_CONTROL||RETROSPECTIVE|||||||
33802622|NCT02297919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103871|NCT01313325|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34103872|NCT02011542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103873|NCT04902482|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34148861|NCT01548742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34148862|NCT02099305|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33721994|NCT04463550|||COHORT||RETROSPECTIVE|||||||
33721995|NCT01288794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721996|NCT05954624|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33721997|NCT05899907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33721998|NCT03467113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33721999|NCT06046456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722000|NCT02788968|NON_RANDOMIZED|PARALLEL||||NONE||||||
33722001|NCT04674384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722002|NCT02473354|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33722003|NCT02547467|||COHORT||PROSPECTIVE|||||||
33722004|NCT02176850|||COHORT||PROSPECTIVE|||||||
33722005|NCT05837416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor and biostatistician will be blinded.||f|f|f|t
33722006|NCT05323942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722007|NCT01985581|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33722008|NCT04949165|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722009|NCT00947973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722010|NCT03625791|||COHORT||PROSPECTIVE|||||||
33722011|NCT06319755|||CASE_CONTROL||PROSPECTIVE|||||||
33722012|NCT06221514|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|In this study, double-blinding will be optimized to ensure that the participants are unaware of the study's aim and exact details; in addition, the pre- and post-radar gun assessments will be performed by someone other than the researchers, preferably a tennis coach. Furthermore, shoulder and core training will be performed in the BAU gym under the direction and supervision of coaches and physical therapists; the training program will be given and performed with the coaches before implementing them with the participants.||t|t|t|t
33722013|NCT06029634|||COHORT||PROSPECTIVE|||||||
33722014|NCT05446402|NA|SINGLE_GROUP||TREATMENT||NONE|All sets of products will be provided to Northwestern in identical, unlabeled bottles for the purpose of blinding.|Participants will be using Product 1 regimen on left side of face for 12 weeks and Product 2 regimen on right side of face for 12 weeks.||||
33722015|NCT01502111|||COHORT||PROSPECTIVE|||||||
33722016|NCT02604212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722017|NCT00140647|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33722018|NCT03684512|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722019|NCT05618964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722020|NCT02988791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722021|NCT05780333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)|This is a double blind, randomized control clinical trial.|t|t|t|f
33722022|NCT02464345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722023|NCT03787628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722024|NCT05757921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Principal investigator and investigator (the periodontologists) were calibrated prior to the study.~Outcome assessments were performed separately by the periodontologists and blinded. The statisticians were also blinded."|Test group: non-surgical mechanical treatment and adjunctive treatment Perisolv Control group: non-surgical mechanical treatment|f|f|t|t
33722025|NCT01730157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722026|NCT06067542|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33722027|NCT01736150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722028|NCT06365801|||COHORT||PROSPECTIVE|||||||
33722029|NCT04702867|||OTHER||RETROSPECTIVE|||||||
33722030|NCT01947920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722031|NCT03023969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722032|NCT06308120|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Pathologist reviewing biopsy results will be blinded|Stratified, randomized controlled trial with parallel group assignment|f|f|f|t
33722033|NCT00263146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33722034|NCT04157608|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Crossover clinical trial||||
33722035|NCT00087711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722036|NCT06427811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722037|NCT00994292|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33722038|NCT00430560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722039|NCT00832585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722040|NCT04166435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802623|NCT04185961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A Double-blind Pilot Study|EVERA-RAPHA with 60 mmHg: EVERA-RAPHA apply 15 minutes with 60mmHG every day for 4 weeks EVERA-RAPHA with 100 mmHg: EVERA-RAPHA apply 15 minutes with 100mmHG every day for 4 weeks|t|f|f|t
34026127|NCT02448368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34026128|NCT02121873|||COHORT||PROSPECTIVE|||||||
33722041|NCT00774228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722042|NCT01092182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026129|NCT01596738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722043|NCT02071888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722044|NCT00450333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026130|NCT06304168|||COHORT||PROSPECTIVE|||||||
33722045|NCT01760512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722046|NCT04057014|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective partially randomized parallel study groups clinical trial investigation.||||
33722047|NCT04262843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722048|NCT03780868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||compare external dacryocystorhinostomy versus canalicular silicone intubation with the use of Mitomycin C (MMC) in primary acquired nasolacrimal duct obstruction (NLDO).|t|f|f|f
33722049|NCT00888095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722050|NCT04213365|NA|SINGLE_GROUP||OTHER||NONE||||||
33722051|NCT05029986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722052|NCT06431854|NA|SINGLE_GROUP||TREATMENT||NONE||This study will compare prospective data with retrospective data of patients that followed Treatment As Usual (TAU). Treatment As Usual (TAU) involves arranging visits for external consultations, partial hospitalization, and inpatient admissions as necessary, by following clinical guidelines. The retrospective control group consists of 60 patients, matched in age, sex, Body Mass Index (BMI), and diagnosis of eating disorder (ED) with the prospective group. Subjects are identified by reviewing medical records of patients treated at the ED unit of Hospital Sant Joan de Déu before the initiation of the MINERVA program. The temporal reference is the first day of admission to acute total hospitalization. Subjects present the same criteria of poor treatment response as the prospective group, ensuring severity comparability with the prospective group. Exclusion occurs if there is ≥20% missing data.||||
33722053|NCT02872493|||COHORT||PROSPECTIVE|||||||
33722054|NCT03688477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722055|NCT00985842|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722056|NCT02456142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722057|NCT02110342|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33722058|NCT05678829|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33722059|NCT02942446|NA|SINGLE_GROUP||OTHER||NONE||||||
33722060|NCT03959293|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A safety analysis will be performed on 11 patients to ensure that treatment is well tolerated. This is not a phase 1/phase 2 study but a phase 2 with stop and go."||||
33722061|NCT02278107|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33722062|NCT03741660|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722063|NCT04905212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722064|NCT04156776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were not aware about the groups|Group A (MET) and Group B (AIS)|t|f|f|f
33802624|NCT00311714|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33802625|NCT02942862|||COHORT||RETROSPECTIVE|||||||
33802626|NCT04080141|||COHORT||PROSPECTIVE|||||||
33802627|NCT01095796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802628|NCT05277441|||COHORT||PROSPECTIVE|||||||
33802629|NCT00976495|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33802630|NCT01782846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33802631|NCT01404585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026131|NCT00436865|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026132|NCT05555823|RANDOMIZED|PARALLEL||OTHER||DOUBLE|matching placebo tablets|Randomized, double-blind, placebo-controlled, mono-centre; SAD, MAD, FDI, DDI part|t|f|t|f
34026133|NCT03694470|||COHORT||RETROSPECTIVE|||||||
34026134|NCT05795322|||OTHER||RETROSPECTIVE|||||||
34026135|NCT05842044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After study recruitment, the patient will be randomized to the NSAID group (group 1) vs. the no-NSAID group (group 2). Randomization will be masked until after the renorrhaphy is completed and the surgical team will administer versus not administer ketorolac based on group assignment.||f|t|t|f
34026136|NCT01956305|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34026137|NCT03482258|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Blinding of supplements will be conducted by Frieslandcampina who are providing both prebiotic and maltodextrin||t|f|t|f
34026138|NCT00724828|||COHORT||PROSPECTIVE|||||||
34026139|NCT00275574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026140|NCT03626688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103874|NCT05547854|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Independent evaluators will be masked to treatment condition|Effectiveness-implementation hybrid non-inferiority trial|f|f|f|t
34103875|NCT06377592|||CASE_ONLY||RETROSPECTIVE|||||||
34103876|NCT03485885|||COHORT||PROSPECTIVE|||||||
34103877|NCT03147885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802632|NCT01763853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802633|NCT05654467|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||A 12-arm, randomized, observer-blind, controlled, age de-escalation, dosage escalation study.|t|t|t|t
33802634|NCT02262767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33802635|NCT00593489|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802636|NCT02212496|||COHORT||PROSPECTIVE|||||||
33802637|NCT03017469|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802638|NCT05966350|||CASE_CONTROL||RETROSPECTIVE|||||||
33802639|NCT01203306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802640|NCT05897632|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized with equal probability (1:1) to the outpatient arm or the hospitalization arms using permuted block randomization.||||
34026141|NCT04553016|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"To maintain blinding, all volunteers will receive two injections with half dose into the deltoid region of each arm of ChAdOx1.tHIVconsv1 or placebo at enrolment, and two injections (MVA.tHIVconsv3 or placebo into one deltoid region and MVA.tHIVconsv4 or placebo into the other) at 4 weeks after enrolment.~Unblinded study pharmacist(s) staff at each site will be responsible for investigational medicinal product preparation and accountability. All other site staff and all trial volunteers will be blinded to treatment assignment (i.e., active versus placebo)."|double-blind placebo-controlled|t|t|t|t
34026142|NCT05134857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A phase II randomized, double-blind, placebo-controlled clinical trial|t|f|t|t
34026143|NCT01015937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026144|NCT04130750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026145|NCT05198518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant and all study staff will be blinded to which device they are receiving, either the study device or the identical sham device. Devices will be labeled A or B, with only the device manufacturer knowing which device is the active study device and which is the sham.|Subjects will be randomly assigned in a 1:1 ratio to receive the intervention or placebo. Randomization will be completed via a computer-generated randomization table.|t|t|t|t
34026146|NCT06423092|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33802641|NCT05879419|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Subproject A: Randomized prospective study of adult patients with ARDs who will receive two intramuscular doses of RZV 6 weeks apart or placebo.~Subproject B: Specific studies will to evaluate the effect of drug withdrawal (MTX and MMF) after vaccination in increasing the immune response in patients with ARDs with controlled baseline disease. Randomization of patients with ARDs with well-controlled disease selected for the MTX discontinuation protocol will divide them into two groups: MTX-suspension, in which MTX will be suspended for 2 weeks after each vaccine dose, and another group that will maintain stable therapy (MTX-maintenance).~The same applies to patients undergoing the MMF discontinuation protocol (but the MMF suspension time will be one week after each vaccine dose)."|"Subproject A: Randomized prospective study of adult patients with ARDs who will receive two intramuscular doses of RZV 6 weeks apart or placebo.~Subproject B: Specific studies will evaluate the effect of drug withdrawal (MTX and MMF) after vaccination in increasing the immune response in patients with ARDs with controlled baseline disease. Randomization of patients with ARDs with well-controlled disease selected for the MTX discontinuation protocol will divide them into two groups: MTX-suspension, in which MTX will be suspended for 2 weeks after each vaccine dose, and another group that will maintain stable therapy (MTX-maintenance), with assessments of immunogenicity and disease activity. The same applies to patients undergoing the MMF discontinuation protocol (but the MMF suspension time will be one week after each vaccine dose)."|t|f|t|f
33802642|NCT04121546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802643|NCT00710567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802644|NCT00202436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802645|NCT04638816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802646|NCT00402896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802647|NCT05296889|||COHORT||PROSPECTIVE|||||||
33802648|NCT04129203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802649|NCT03642106|RANDOMIZED|PARALLEL||PREVENTION||NONE||"To accomplish the mentioned aims, we propose an attention placebo randomized control trial. For this trial, we will recruit a sample of youth and their parents (N=120 dyads) from a random sample of Latino 6th and 7th grade students in Tulsa Public Schools. Those meeting the inclusion/exclusion criteria and agreeing to participate will provide baseline data before being randomly assigned to either the treatment or control condition (n=60 dyads each).~Participants will be followed for 12 months post-baseline, during which time we will collect psychosocial measures annually near the end of each school year (May to June). The study will collect psychosocial measures from parents and youth."||||
33802650|NCT05973279|||OTHER||OTHER|||||||
33802651|NCT01521169|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33802652|NCT02538900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals collecting the outcome assessment will not be aware of group assignment.||f|f|f|t
33802653|NCT00589875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802654|NCT01074294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026147|NCT01513746|||COHORT||CROSS_SECTIONAL|||||||
34026148|NCT06200545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026149|NCT00711321|||||PROSPECTIVE|||||||
34026150|NCT06463002|||COHORT||CROSS_SECTIONAL|||||||
34026151|NCT04207463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026152|NCT01883388|||COHORT||PROSPECTIVE|||||||
34026153|NCT05385549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026154|NCT06469632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026155|NCT02667067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026156|NCT06473012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A multi-site RCT with one intervention group and one control group is planned to be implemented. The intervention group will receive a novel group intervention based on cognitive behavioral therapy, lifestyle intervention, and effective communication skills. It is tailor-made for caregivers of older adults in Hong Kong identified with psychological symptoms or risks through empirically validated screening assessment. It is devised and administered with the consideration of the Hong Kong local culture.|f|f|f|t
34026157|NCT06329427|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34103878|NCT02685852|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103879|NCT04567771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722065|NCT04184245|||COHORT||PROSPECTIVE|||||||
33722066|NCT01089959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722067|NCT00228917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722068|NCT04150276|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722069|NCT01227772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722070|NCT03762148|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33722071|NCT05190731|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants randomized to sham group or osteopathic cranial manipulative medicine treatment group|t|f|f|f
33722072|NCT04469114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722073|NCT06478537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722074|NCT04286360|||COHORT||PROSPECTIVE|||||||
33722075|NCT06280573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722076|NCT03327311|||CASE_ONLY||PROSPECTIVE|||||||
33722077|NCT03540147|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participants will not know which condition they will receive on the day of testing.|Each participant will undergo five visits to the laboratory for repeated testing under five different conditions. The sessions will be randomized and will take 2.5 hours to complete.|t|f|f|f
33722078|NCT05212714|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This study seeks to conduct a randomized, double-blind placebo-controlled parallel-design pilot study, to determine whether the taVNS intervention and study methodology are feasible and acceptable for use with WTC responders with PTSD. It is important that the design is double-blind and placebo-controlled in order to have the most appropriate control and to limit bias on the part of the participant and investigators. In addition, as this is a feasibility study, it is important to replicate the methodology that will eventually be used with a larger trial in order to truly assess whether the intervention and methodology are acceptable, feasible and efficacious.|t|f|t|t
33722079|NCT05322642|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33722080|NCT00629499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722081|NCT04395209|NON_RANDOMIZED|PARALLEL||OTHER||NONE||individuals with stroke and healthy subject||||
33722082|NCT03384979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Patients will be assigned to the TBW or LBW group based on a randomization generated by a computer, the progressive sequences containing the randomization code will be perform by an outside operator to the experiment group. Only CT technician and nurse that will record patient's data and results from scale analysis will know and will register in which group the patients will be assigned.|The study design is monocentric, comparative, randomized, double blinded. Patients will undergo a CT scan of abdomen (multi-phasic) with contrast agent and will be measured: TBW, height, LBW and body mass index (BMI) through formulas known in literature and with a balance for bioelectrical impedance analysis. There is no administration of drugs other than indicated in the request of the treating physician.|t|t|t|f
33722083|NCT05085275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, placebo controlled, double-blind, parallel assignment|t|t|t|t
33722084|NCT02556333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722085|NCT02389998|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open placebo. No masking|||||
33722086|NCT04023448|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722087|NCT02155647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722088|NCT00458627|||DEFINED_POPULATION||OTHER|||||||
33722089|NCT03011307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722090|NCT04862845|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33722091|NCT05670392|RANDOMIZED|PARALLEL||TREATMENT||NONE||a two-arm parallel assignment, randomized control trial||||
33722092|NCT01739582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722093|NCT01108133|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33722094|NCT02225756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722095|NCT03900000|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33722096|NCT06243887|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33802655|NCT04894851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802656|NCT03746938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802657|NCT02061501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802658|NCT03335397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802659|NCT02014831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802660|NCT01245400|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33802661|NCT04352400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be done with an algorithm tailored to the study design. Investigators and patients will be blinded to the treatment administered.|Randomized, double blind, placebo-controlled parallel-group trial, on top of best standard of care|t|f|t|f
33802662|NCT03875040|||OTHER||CROSS_SECTIONAL|||||||
33802663|NCT03933371|||COHORT||PROSPECTIVE|||||||
33802664|NCT02132559|||COHORT||RETROSPECTIVE|||||||
33802665|NCT01236846|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33802666|NCT05447936|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The participants were divided into men and women. Within each of these two arms, a three-step dose escalation was performed according to a Respons Surface Pathway procedure.||||
33802667|NCT00589277|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33802668|NCT01130194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802669|NCT06321224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802670|NCT00476385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802671|NCT03563690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026158|NCT04795596|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients with platinum resistant cancer ovary will be randomized to one of two arms; either chemotherapy alone or surgical resection followed by chemotherapy||||
34026159|NCT05805215|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study participant and researcher applying brain stimulation will be blinded to the stimulation condition. high-frequency stimulation (\>1Khz) will be used as a control condition.|"Participants will undergo 3 types of TIS in randomized order:~1. targeting the hippocampus~2. targeting the precuneus~3. control condition with high-frequency stimulation"|t|t|f|f
34026160|NCT00873457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026161|NCT04358952|||OTHER||PROSPECTIVE|||||||
34026162|NCT04556071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026163|NCT06158555|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026164|NCT02974712|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34026165|NCT05260060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Chief investigator, research assistants and statisticians will be blind to treatment allocation of participants.||f|f|t|f
34026166|NCT00311324|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33802672|NCT06516705|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants in the experimental group receiving multimedia hypoglycemia education and participants in the contrast group receiving conventional hypoglycemia education.|f|f|t|f
34026167|NCT03364543|||COHORT||PROSPECTIVE|||||||
34026168|NCT02942030|||COHORT||CROSS_SECTIONAL|||||||
34026169|NCT03819894|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||Stepped-wedge cluster-randomized trial. Unidirectional crossover design where clusters cross over sequentially, in random order, from the control to intervention phase.|t|f|f|t
34026170|NCT00492986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026171|NCT03369197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34026172|NCT00005000||CROSSOVER||TREATMENT||||||||
34026173|NCT06107803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34026174|NCT00900835|NA|SINGLE_GROUP||||NONE||||||
34026175|NCT05326048|||COHORT||RETROSPECTIVE|||||||
34026176|NCT04856501|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026177|NCT00337181|||COHORT||PROSPECTIVE|||||||
34026178|NCT00930163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026179|NCT06432374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026180|NCT05962762|NA|SEQUENTIAL||TREATMENT||NONE||||||
34026181|NCT04435184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled, randomized interventional trial.|t|t|t|t
34026182|NCT01722422|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34026183|NCT04284540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026184|NCT02553447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026185|NCT02341898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33802673|NCT02337036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802674|NCT01881412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802675|NCT00766649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802676|NCT00622856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103880|NCT03208569|||COHORT||PROSPECTIVE|||||||
34103881|NCT02251470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103882|NCT00191698|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103883|NCT03419624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802677|NCT00933257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802678|NCT05384470|NA|SINGLE_GROUP||OTHER||NONE||||||
33802679|NCT04432142|||COHORT||PROSPECTIVE|||||||
33802680|NCT04431375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802681|NCT00774397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802682|NCT00006241||||TREATMENT||||||||
33802683|NCT01798667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103884|NCT00890656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103885|NCT05802849|RANDOMIZED|PARALLEL||TREATMENT||NONE||Acetazolamide is a diuretic with a mild diuretic effect which will be used for treatment||||
34103886|NCT04511741|||CASE_ONLY||PROSPECTIVE|||||||
34103887|NCT02167685|||CASE_ONLY||PROSPECTIVE|||||||
34103888|NCT00272805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802684|NCT02356341|||COHORT||PROSPECTIVE|||||||
33802685|NCT04554108|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial of non inferiority, with active control, in open multicenter.||||
33802686|NCT05634382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33802687|NCT03577223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33802688|NCT03556449|||CASE_CONTROL||PROSPECTIVE|||||||
33802689|NCT04422236|||CASE_ONLY||PROSPECTIVE|||||||
33802690|NCT05607823|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants did not know which treatment group they were in.|There are three study groups: 1.CST group: Participants in this group will be received core stabilization training, orofacial manuel therapy and conventional physiotherapy (Home exercise program and patient education). 2. OMT group: Participants in this group will be received orofacial manuel therapy and conventional physiotherapy (Home exercise program and patient education) as treatment. 3. Control Group: Participants in this group received only conventional physiotherapy (Home exercise program and patient education) as treatment.|t|f|f|f
33802691|NCT03285542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802692|NCT02695264|NA|SINGLE_GROUP||SCREENING||NONE||||||
34026186|NCT04710979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34026187|NCT03762044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In order to masking, investigator who assess the subject before and after the treatment will not know which group the subjects belong, and so the biostatistician.|After proposing to the subjects the enrollment to the study and once they accept, they will be randomly allocated to experimental TAPA treatment group or standard CDT treatment. They will be assessed 1 to 3 days before and after completing the treatment. It will be consists in a total of 10 sessions of 30 minutes of treatment, twice per week in a total 5 weeks period.|f|f|t|t
34026188|NCT05235711|||OTHER||PROSPECTIVE|||||||
34026189|NCT01625832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34026190|NCT05389631|||COHORT||RETROSPECTIVE|||||||
34026191|NCT00253448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103889|NCT00707304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103890|NCT02327143|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34103891|NCT06693141|||CASE_CONTROL||PROSPECTIVE|||||||
33722097|NCT03253887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Following inclusion, the patients were randomized into two groups, the ethanol-lock group and the control group, using allocation concealment with a list of random numbers generated using the Random Allocation Software|It's a randomized controlled clinical trial.|f|f|f|t
33722098|NCT03038815|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722099|NCT00961844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722100|NCT02123355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722101|NCT00004489||||TREATMENT||||||||
34026192|NCT05826535|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Analysis of response will be performed by Blinded Independent Central Review (BICR) Discordance between the Investigator assessment and BICR assessment will be evaluated for each efficacy endpoints based on tumor assessments if BICR assessments are performed.|Dose finding Phase I followed by a Phase II part. Two Phase I dose levels and one Phase II dose level. Three cohorts in each phase.|f|f|f|t
34026193|NCT02047734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026194|NCT05693974|||CASE_CONTROL||RETROSPECTIVE|||||||
34026195|NCT04669301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34026196|NCT03471000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026197|NCT04380961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026198|NCT02733380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026199|NCT01343316|||COHORT||PROSPECTIVE|||||||
34026200|NCT02234219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103892|NCT03878602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722102|NCT00824044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33722103|NCT03854656|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33722104|NCT06209229|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|"Independent sequential randomization of patients admitted over short periods of time into treatment groups will be conducted.~Study participants will be recruited as patients present to the clinic, up to a maximum of 12 patients per week.~Each patient included in the study will be assigned an ordinal number sequentially according to a table of a random sequence.~For the purpose of blinding, the number will be assigned by the registrar of the admission department and will not be further involved in the study.~The intake nurse and the researcher will not know the patient's chart except for the assigned number.~The physician performing the examination and prescribing therapy will not know the results of the functional assessment of blood and GFR.~The results will be entered into the subject's chart at the end of the course of treatment and supplemented by a follow-up examination after 12 months.~Blinded follow-up"|Simon's two-stage plan will be used (Simon R (1989). Controlled Clinical Trials 10: 1-10.). The first stage will test the Null Hypothesis that the true response rate is \[p0=0.4\] will be tested against the one-sided alternative hypothesis. In the first stage, \[n0=16\] patients will be recruited. If these \[n1=34\] patients have \[r1=17\] or fewer responses, the study will be stopped. Otherwise, \[n - n1=39-34=5\] additional patients will be accrued, totaling \[n=39\]. In the second step, the Null Hypothesis will be rejected if \[r2 + 1= 20+1\] or more responses are observed in \[n=39\] patients. This plan yields a Type I error rate \[Type I error rate=0.05\] and power \[w=0.8\] when the true response rate is \[p1=0.6\]. Patients will be followed up for 1 year||||
33722105|NCT02220933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722106|NCT04836728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722107|NCT06430138|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Single Blind(with masked participant)|Acute intervention in populations with and without colon|t|f|f|f
33722108|NCT05872711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study design is a randomized, parallel assignment clinical trial without blinding (open label) due to the impracticality of blinding diets||||
33802693|NCT02639637|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Crossover Arms 1 and 2, Crossover Arms 3 and 4|t|t|t|t
33802694|NCT06363149|||COHORT||PROSPECTIVE|||||||
33802695|NCT00299143|||CASE_CONTROL||PROSPECTIVE|||||||
33802696|NCT03908775|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33802697|NCT06349655|||COHORT||RETROSPECTIVE|||||||
33802698|NCT05564611|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This will be double blind study. The order of receiving the Test (T) or Reference product (R) for each subject during the study will be based on randomization schedule generated by SAS® version 9.4 or higher, The randomization will be balanced. The randomization code will be kept under controlled access. The study drug will be blinded by the CRO.|This will be parallel group design having single study period|t|f|t|t
33802699|NCT06178588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026201|NCT05742035|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|Assessors of quality parameters don't know the diagnosis of the included participants|Prospective inclusion of individual and group allocation according to the collected clinical data and diagnoses.|f|f|t|t
34026202|NCT00985491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026203|NCT04275986|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled Patients will receive concurrent chemoradiotherapy per protocol. The radiotherapy clinical target volume will include 2 cm above and below the tumor bed and high-risk lymph nodal area. Intensity modulated radiotherapy techniques will be used with a total dose of 45Gy in 25 fractions. Chemotherapy will be conducted weekly up to 5 weeks. The specific chemotherapy regimen are Paclitaxel Liposome 45mg/m2, d1 and Nedaplatin 25mg/m2, d1.||||
34026204|NCT04887155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026205|NCT04144361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34026206|NCT02897310|||COHORT||RETROSPECTIVE|||||||
34026207|NCT03847298|||CASE_CONTROL||PROSPECTIVE|||||||
34026208|NCT01855828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026209|NCT01346787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026210|NCT04219826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026211|NCT03007238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026212|NCT05842174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026213|NCT05251610|RANDOMIZED|PARALLEL||PREVENTION||NONE||clinical superiority open-labeled randomized controlled trial||||
34026214|NCT05018312|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking will be applied in the data analysis process|Naturalistic, superiority trial||||
34026215|NCT06487208|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34026216|NCT00289120|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34026217|NCT05298761|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34026218|NCT00863772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026219|NCT05597150|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026220|NCT03179215|||CASE_CROSSOVER||PROSPECTIVE|||||||
34026221|NCT06130423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026222|NCT05351658|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study will be carried out in an Arrhythmia Unit or Intensive Care Unit. Patients who need urgent temporary cardiac pacing due to bradycardia, or elective pacing to prevent heart rhythm disturbances during high-risk arrhythmia interventions, such as transcatheter aortic valve implantation (TAVR), alcoholic septal ablations, etc., will be included. After the temporary pacemaker implantation with active fixation electrode in a correct way, the KronoSafe® external pacemaker fixation system will be placed. The correct functioning of the system (R wave detection, lead impedance and right ventricle threshold) will be checked at 24 hours and every other day until the end of cardiac stimulation. During temporary pacing, associated complications are going to be recorded: lead displacement, capture or sensing failure, generator or lead detachment, and cardiac perforation.||||
34026223|NCT03578549|||CASE_ONLY||OTHER|||||||
34026224|NCT05860361|||COHORT||PROSPECTIVE|||||||
34026225|NCT06137625|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34026226|NCT00769938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026227|NCT03311750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026228|NCT04660240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Diabetic patients undergoing percutaneous coronary intervention in de novo lesions are going to be randomized to two groups. One will have percutaneous coronary intervention with Abluminus sirolimus eluting stent implantation, and the other will have percutaneous coronary intervention with Orsiro Sirolimus Eluting stent implantation. The implantation of both stents will be guided by angiography only. In a subgroup of both arms (100 patients per group) the implantation will be also guided by intravascular ultrasound.|t|f|f|f
34026229|NCT04906421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects with liver fibrosis stage F2-F3, will be enrolled and randomized in a 2:1 ratio to receive TVB-2640, or placebo PO QD|t|f|t|f
34026230|NCT02226471|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34026231|NCT05924607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026232|NCT04807647|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34026233|NCT02032797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026234|NCT03946280|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized study, patients are allocated to 1 of the 2 groups|t|f|f|t
34026235|NCT01727726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026236|NCT00740012|RANDOMIZED|PARALLEL||||NONE||||||
34026237|NCT00620399||||TREATMENT||||||||
34026238|NCT06584292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The nurse was blinded to the face, legs, activity, cry, and consolability (FLACC) scores. An anesthesiologist was blinded to data collection regarding analgesic requirement and postoperative complications. Transparent sterile drapes were applied to the injection sites, and both blocks were administered to all patients to evaluate postoperative complications. Thus, the anesthetist was blinded to the postoperative complications.||t|t|f|f
34026239|NCT01410643|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34026240|NCT01434810|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority trial comparing the two methods of phototherapy||||
34026241|NCT00134667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026242|NCT03108053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026243|NCT01164696|||COHORT||PROSPECTIVE|||||||
34026244|NCT03997617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026245|NCT05321641|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The participants can tell if they are receiving adherence messages or general public health messages. The clinicians will interact with participants and may therefore get to know what kind of messages they receive. However, the investigators, who will conduct the analysis and the assessors will be blinded.|We plan to randomize 1200 people with epilepsy at each site, from a defined area in Kilifi and Nairobi County, Kenya. They will be divided into four groups of 300 each, to receive either text SMS, graphic SMS, both text and graphic or SMS on public health promotion not related to epilepsy e.g. use of bednets (for comparison).|f|f|t|t
34026246|NCT02843360|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34026247|NCT05575206|||COHORT||CROSS_SECTIONAL|||||||
34026248|NCT02691143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026249|NCT03152734|||COHORT||PROSPECTIVE|||||||
34026250|NCT05426980|||COHORT||RETROSPECTIVE|||||||
34026251|NCT03513133|NA|SINGLE_GROUP||TREATMENT||NONE||a group of 10 patients with severe TBI will receive 3-month rehabilitation of working memory and will be compared to a group of 10 healthy controls||||
34026252|NCT00875797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026253|NCT01141855|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34026254|NCT05734248|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE||Split-face model|t|t|t|t
34026255|NCT04093375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026256|NCT00776087|RANDOMIZED|PARALLEL||TREATMENT||NONE|HM ON vs. HM OFF|Randomized prospective multicenter international clinical trial||||
34026257|NCT01617252|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026258|NCT03086551|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34026259|NCT04210050|RANDOMIZED|PARALLEL||TREATMENT||NONE||The model is a prospective, randomized, comparative effectiveness clinical trial to evaluate the role of non-invasive nocturnal ventilation in addition to usual care, compared to usual care alone in the management of adult COPD patients with chronic hypercapnic respiratory failure.||||
34026260|NCT01795911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026261|NCT01335334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026262|NCT03834285|||COHORT||PROSPECTIVE|||||||
34026263|NCT05968092|||CASE_CROSSOVER||PROSPECTIVE|||||||
34026264|NCT03531138|NA|SINGLE_GROUP||OTHER||NONE||||||
34026265|NCT05689957|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34026266|NCT05616637|||OTHER||CROSS_SECTIONAL|||||||
34026267|NCT03484143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026268|NCT02750826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026269|NCT00704847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026270|NCT06551714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802700|NCT00000911|||CASE_ONLY||PROSPECTIVE|||||||
33802701|NCT04336436|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive mindfulness based training and nutritional consultation.||||
33802702|NCT03118323|||CASE_ONLY||PROSPECTIVE|||||||
33802703|NCT04386772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802704|NCT02776475|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33802705|NCT05680649|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802706|NCT04992585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Retrospective comparison of two similar interventions with small modification||||
33802707|NCT02462759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026271|NCT05329324|||OTHER||CROSS_SECTIONAL|||||||
34026272|NCT00041626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026273|NCT03893097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026274|NCT02203331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026275|NCT01243775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026276|NCT06413043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103893|NCT04115241|||CASE_ONLY||PROSPECTIVE|||||||
33802708|NCT02586090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors blind to hypotheses and allocation Interventionsts blinded to hypotheses||f|t|f|t
33802709|NCT04351828|||CASE_ONLY||CROSS_SECTIONAL|||||||
34103894|NCT05206045|||COHORT||RETROSPECTIVE|||||||
34026277|NCT05992766|RANDOMIZED|PARALLEL||OTHER||NONE||The participants were divided into 3 groups with closed envelope randomization method.||||
34026278|NCT01559389|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Women presenting with UUI symptoms will receive up to 16 weeks of solifenacin.||||
34026279|NCT04529837|||COHORT||PROSPECTIVE|||||||
34026280|NCT02776137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026281|NCT06206629|||CASE_CONTROL||PROSPECTIVE|||||||
34026282|NCT02357238|||CASE_CONTROL||PROSPECTIVE|||||||
34026283|NCT06216678|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34026284|NCT01666392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34026285|NCT01129687|||COHORT||PROSPECTIVE|||||||
34026286|NCT03623347|||CASE_ONLY||RETROSPECTIVE|||||||
34103895|NCT01897896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026287|NCT04167540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 12 study participants will be administered the investigational product in this Phase 1b trial. Participants will be enrolled into cohorts, based upon the duration and stage of their PD. Six (6) participants will be dosed in each cohort.||||
34026288|NCT03203850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103896|NCT02156505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103897|NCT06690047|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34103898|NCT05319015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103899|NCT02239042|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34103900|NCT05307094|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Outcome assessor is masked to all primary outcome data collection and data coding/ratings.|Sequential Multiple Assignment Randomized Trial|f|f|f|t
34103901|NCT03124602|NA|SINGLE_GROUP||OTHER||NONE||||||
34103902|NCT06683170|||COHORT||PROSPECTIVE|||||||
34103903|NCT06083311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple Blind Study||t|f|t|t
34103904|NCT05231252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||pilot||||
34103905|NCT05814614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are assigned to three parallel arms for the duration of the study.|t|f|f|t
34103906|NCT05747937|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|There are not masking participants|||||
34103907|NCT03016702|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34103908|NCT06289062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103909|NCT06658067|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34103910|NCT05985174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34103911|NCT06690723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103912|NCT01916226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103913|NCT03359200|||OTHER||RETROSPECTIVE|||||||
34103914|NCT01885338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103915|NCT00345280|||COHORT||PROSPECTIVE|||||||
34103916|NCT04420182|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective non-randomized cohort study||||
34103917|NCT03151603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103918|NCT00306098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103919|NCT01046994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026289|NCT03353883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|sealed envelopes||t|t|t|t
33802710|NCT00679770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026290|NCT02943135|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33802711|NCT00366249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802712|NCT00249769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802713|NCT05283408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026291|NCT06455540|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802714|NCT02035631|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026292|NCT00794508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026293|NCT05418114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026294|NCT01746030|||||PROSPECTIVE|||||||
34026295|NCT00627510|||CASE_ONLY||PROSPECTIVE|||||||
34026296|NCT03161925|||OTHER||RETROSPECTIVE|||||||
33802715|NCT02129595|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34026297|NCT06440993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026298|NCT02458859|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026299|NCT00950365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802716|NCT05792488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026300|NCT04128683|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34026301|NCT05322109|||COHORT||RETROSPECTIVE|||||||
34026302|NCT01004744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026303|NCT04608110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026304|NCT03777618|||COHORT||RETROSPECTIVE|||||||
34026305|NCT01809782|||COHORT||PROSPECTIVE|||||||
34026306|NCT04427579|||COHORT||PROSPECTIVE|||||||
34026307|NCT01241747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026308|NCT00841828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026309|NCT03450044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802717|NCT05295342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802718|NCT03311516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026310|NCT03289273|||COHORT||PROSPECTIVE|||||||
34026311|NCT05709197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded considering their treatment allocation. The house officer, ward nurses and data managers who extract data concerning the primary and secondary endpoint will be blinded for the allocation as well. For this reason, this will be a patient- and observer blinded RCT.||t|f|f|t
33802719|NCT01082575|||CASE_ONLY||PROSPECTIVE|||||||
33802720|NCT05656053|||COHORT||PROSPECTIVE|||||||
33802721|NCT05177939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802722|NCT02402569|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33802723|NCT02740491|||CASE_ONLY||PROSPECTIVE|||||||
33802724|NCT04337840|||OTHER||RETROSPECTIVE|||||||
33802725|NCT03230903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33802726|NCT05848609|NA|SINGLE_GROUP||SCREENING||NONE||||||
34026312|NCT03769207|NA|SINGLE_GROUP||OTHER||NONE||||||
34026313|NCT03115268|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34026314|NCT06457893|RANDOMIZED|PARALLEL||OTHER||NONE||Structured education and physical activity.||||
34026315|NCT03735004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026316|NCT00670202|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, placebo controlled, parallel arm design|t|t|t|t
34026317|NCT02652611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026318|NCT04204473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026319|NCT03526783|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026320|NCT05231005|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective intervention study, to test the effect of a 4th dose, by comparing the immune response before and after the 4th dose, given to 150-200 volunteers, as well as comparing their responses with a control group of individuals vaccinated with 3 doses but without the 4th||||
34026321|NCT01316315|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34026322|NCT01781195|||COHORT||PROSPECTIVE|||||||
34026323|NCT01152619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026324|NCT06355011|||COHORT||PROSPECTIVE|||||||
34026325|NCT01693510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026326|NCT00750581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026327|NCT03523299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026328|NCT03927014|||CASE_CONTROL||PROSPECTIVE|||||||
34026329|NCT03815526|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34026330|NCT03464630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessment coders and participants are naive to treatment condition|Two arm, randomized controlled intent to treat trial|t|f|f|t
34026331|NCT02790515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026332|NCT03485352|||COHORT||PROSPECTIVE|||||||
34026333|NCT01953978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026334|NCT04718948|||CASE_CONTROL||PROSPECTIVE|||||||
34026335|NCT02374346|||COHORT||PROSPECTIVE|||||||
34026336|NCT04693416|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34026337|NCT00898573|||CASE_ONLY||CROSS_SECTIONAL|||||||
34026338|NCT03486665|||CASE_ONLY||PROSPECTIVE|||||||
34026339|NCT03218124|NA|SINGLE_GROUP||OTHER||NONE|Patient under general anesthesia unaware of the effect site concentration of remifentanil before extubation|Prospective observational study. Decreasing/increasing remifentanil effect site concentrations (Dixon's up and down model) to obtain cough-free extubation after thyroidectomy||||
34026340|NCT02695810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722109|NCT05227794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant Masking: Yes (partial)~Participants will not be informed of the training they are randomly assigned. However, participants assigned to the waitlist will know they are in the control group (as they will not receive any training). Thus, comparisons between CCT and MBSR will be masked, but comparisons between CCT and MBSR with the control will not.~Outcomes Assessor Masking: Yes (partial)~For all self-reported outcomes (Primary Outcomes), partial participant blinding to condition will necessarily imply partial outcomes assessor blinding. Specifically, for CCT vs. MBSR comparisons, outcomes assessor blinding for self-reports will be masked, but comparisons between CCT and MBSR with the control will not be masked. For all peer rating outcomes (Other Outcomes), full outcomes assessor blinding will be possible (peers will not know what training group participants are in).~Masking Conclusion:~Double-blinding of the trial is possible (but see the above notes)."|A three-arm randomized controlled trial will be conducted with eligible participants allocated to one of three parallel groups based on blinded randomization procedures (ratio of 1:1:1): 1) Compassion Cultivation Training (CCT), 2) Mindfulness-Based Stress Reduction (MBSR), and 3) Waitlist Control (WL). Randomization will take place after baseline assessment, so condition assignment does not influence pre-test data.|t|f|f|t
34026341|NCT06633627|||CASE_CONTROL||PROSPECTIVE|||||||
34026342|NCT03744429|NA|SINGLE_GROUP||OTHER||NONE||||||
34026343|NCT01178710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33722110|NCT01761838|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33722111|NCT03896555|||CASE_ONLY||PROSPECTIVE|||||||
34026344|NCT05088811|||CASE_CONTROL||PROSPECTIVE|||||||
34026345|NCT03581591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026346|NCT06251050|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Phase 1 containes 5 arms including 0.03, 0.06, 0.10, 0.15 and 0.21 mol/L lithium mouthwash.~Phase 2 containes 2 arms including lithium mouthwash group and palcebo group."|t|t|t|t
33722112|NCT05612633|NA|SINGLE_GROUP||TREATMENT||NONE||In Stage 1, up to 2317 subjects will be enrolled and will complete 6 cycles of treatment. If fewer than 2 subjects achieve \<CR?/PR?/CBR?/PBR?\> in Stage 1, the trial will be stopped for futility. If 2 or more subjects achieve \<CR?/PR?/CBR?/PBR?\>a response , an additional 33 subjects will be enrolled, enrollment will begin in Stage 2 for a total of 56 subjects.||||
34026347|NCT03931525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34026348|NCT03596814|||COHORT||RETROSPECTIVE|||||||
34026349|NCT00282451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026350|NCT04340024|||COHORT||PROSPECTIVE|||||||
34026351|NCT01038362|RANDOMIZED|CROSSOVER||||NONE||||||
34026352|NCT05786846|||CASE_ONLY||PROSPECTIVE|||||||
34026353|NCT06315361|||COHORT||OTHER|||||||
34026354|NCT01117493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026355|NCT04556851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026356|NCT03700385|NA|SINGLE_GROUP||TREATMENT||NONE||Patients undergoing catheter ablation of paroxysmal atrial fibrillation and meeting all protocol inclusion/exclusion criteria will be treated with the IOWA Approach Endocardial Ablation System.||||
34026357|NCT00292786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34026358|NCT03301571|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All patients will receive the same interventions||||
34026359|NCT06091540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to the conditions of the participants.||f|f|f|t
34026360|NCT03494101|||COHORT||PROSPECTIVE|||||||
34026361|NCT02432157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34026362|NCT05018546|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34026363|NCT05063032|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 parallell, randomized, controlled, open-label, single center clinical trial.||||
34026364|NCT01799369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34026365|NCT00282919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103920|NCT00004856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103921|NCT00124657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722113|NCT01447810|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722114|NCT03043989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722115|NCT04503759|||COHORT||PROSPECTIVE|||||||
33722116|NCT00531024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722117|NCT06472908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722118|NCT04309643||SEQUENTIAL||OTHER||NONE||||||
33722119|NCT02158104|||COHORT||PROSPECTIVE|||||||
33802727|NCT01355549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103922|NCT06089746|NA|SINGLE_GROUP||OTHER||NONE||||||
33802728|NCT03727958|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Current or former heavy smoker subjects with suspected or known coronary artery disease will be randomized to undergo CT assessment of both coronary arteries and thoracic area for simultaneous coronary artery and lung cancer screening||||
34026366|NCT00115830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34103923|NCT05025605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind, Placebo-controlled|Study will randomize subjects in Group one 1:1:1 to receive BXCL501 80 μg, BXCL501 120 μg, or matching placebo film; Group two 2:1 to receive BXCL501 60 μg or matching placebo film|t|f|t|f
34103924|NCT05917964|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34103925|NCT04988490|||COHORT||PROSPECTIVE|||||||
34103926|NCT05992740|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||analytical cross sectional|t|f|f|f
34103927|NCT00801255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802729|NCT03248505|RANDOMIZED|PARALLEL||TREATMENT||NONE||3x6||||
33802730|NCT03649243|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802731|NCT02517892|NA|SINGLE_GROUP||OTHER||NONE||||||
33802732|NCT00767702|||||PROSPECTIVE|||||||
34026367|NCT03672045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biased coin up-and-down design.|t|t|t|t
34103928|NCT00324857|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34103929|NCT04431284|||OTHER||RETROSPECTIVE|||||||
33802733|NCT01696916|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802734|NCT02291094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34026368|NCT02875691|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34026369|NCT06155695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802735|NCT03949101|RANDOMIZED|PARALLEL||TREATMENT||NONE||Children are randomly allocated into two groups: combined use of 1% atropine and 0.01% atropine (experimental group) and 0.01% atropine (control group), each group includes 111 children,||||
34026370|NCT01888510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026371|NCT04771975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34026372|NCT02506283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34026373|NCT04670276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026374|NCT03079635|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33802736|NCT01254916|||COHORT||PROSPECTIVE|||||||
34026375|NCT03886415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026376|NCT05222698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026377|NCT00825877|||||OTHER|||||||
34026378|NCT02309138|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33802737|NCT04924218|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34103930|NCT02783963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026379|NCT06634303|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Fist-in-human investigational device study||||
34103931|NCT00272246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802738|NCT02378779|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The study is based on the participation of general practitioners in a training, the test is necessarily open for doctors. However patients will not know if their doctor has received training and will be blinded .|This study is a multicenter trial. Patients will be followed either by GPs from the interventional group who trained in communication skills or by the control group who never participated. The distribution of general practitioners in the groups is done thanks random draw .||||
34026380|NCT06410313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026381|NCT06625567|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||A prospective, non-blinded, randomized comparative study including patients undergoing hysteroscopy without anesthesia in the outpatient hysteroscopy clinic at Shamir (Assaf Harofe) medical center. In the control group, patients will receive the standard education regarding the procedure. In the study group, patients will also watch a short educational video.||||
34026382|NCT05439083|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Two groups of patients:~Immunosuppressed Group: N=90 Immunosuppressed patients, consisting of HIV-infected children and adolescents, hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients and post-chemotherapy patients (PCT) under follow-up at Hospital La Paz in Madrid Spain.~Control Group: N=30 Healthy controls aged 9-14. Both groups receive the 9-valent HPV vaccine."||||
34026383|NCT01966588|||COHORT||PROSPECTIVE|||||||
34026384|NCT01994291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026385|NCT06069115|||COHORT||PROSPECTIVE|||||||
34026386|NCT05013437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026387|NCT03337958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A randomized clinical trial.|t|f|f|f
34103932|NCT06402474|||CASE_CONTROL||PROSPECTIVE|||||||
34103933|NCT06687499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103934|NCT06674343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103935|NCT02011529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103936|NCT01830465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802739|NCT05360901|NA|SINGLE_GROUP||OTHER||NONE||Single group, micro-randomized pilot trial design||||
33802740|NCT03953859|||OTHER||PROSPECTIVE|||||||
33802741|NCT03890848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802742|NCT02778659|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33802743|NCT03117582|||COHORT||PROSPECTIVE|||||||
34026388|NCT03140371|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34026389|NCT00034008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34026390|NCT05501990|NA|SINGLE_GROUP||OTHER||NONE||||||
34026391|NCT02897245|||COHORT||RETROSPECTIVE|||||||
34026392|NCT03103841|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34026393|NCT00933647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026394|NCT05795647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026395|NCT01345578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103937|NCT06689410|NA|SINGLE_GROUP||OTHER||NONE||||||
34103938|NCT01755754|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33802744|NCT05985590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802745|NCT00630487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802746|NCT03208491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802747|NCT06061744|||CASE_CONTROL||RETROSPECTIVE|||||||
33802748|NCT04408872|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an open-label two-arm, single center, superiority trial with 1:1 allocation ratio between EUS and standard intervention EGD.||||
33802749|NCT00988858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802750|NCT01302158|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33802751|NCT05082636|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802752|NCT01619410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802753|NCT02426996|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33802754|NCT03460301|||COHORT||PROSPECTIVE|||||||
33802755|NCT02292329|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33802756|NCT04164316|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is using Kinesio Tape which is difficult to blind the patients and clinicians.|Exploratory Randomized Control Study||||
33802757|NCT02652091|||COHORT||PROSPECTIVE|||||||
34103939|NCT06143423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103940|NCT05460169|RANDOMIZED|PARALLEL||TREATMENT||NONE||RDN-ADPKD is a prospective, randomized (1:1, central randomization), single-centre, hypothesis-generating, feasibility study. Patients are randomized into I-RDN-group and D-RDN-group, respectively. After 3 months, patients in the D-RDN-group will undergo RDN-procedure and will be followed for additional 36 months. Hence, study design allows several comparisons both of whole study group (at same time-point of follow-up) as well as between I-RDN-group and D-RDN-group.||||
34103941|NCT05091450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722120|NCT04244513|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This study adopts a blind design. One day before the first programming, the grouper and the programmer will release the cover independently. Only the grouper and the programmer will know the group information of each patient, in which the programmer does not communicate with the patient about the programming parameters. After each programming, the results are uniformly placed in the programmer to keep the others (patients, neurologists) blind about grouping and parameters. The evaluation will be finished by neurologists and video records of the patient's motor assessment. Neurologists do not participate in the surgical treatment and programmer. The statistical team is independent of other researchers. When performing statistical analysis, only the group information is known, the programming parameters corresponding to the group are blinded. The Medtronic company only provides equipment support and does not participate in any clinical research process.|Patients will be randomized into two groups, of which the first group will be routinely activated after surgery and then stimulated for 6 months. The second group of patients will be re-launched 3 months after surgery, continued stimulation for 3 months, and then entered the open study. Patient data will be collected before surgery, 3 months after surgery, and 6 months after surgery.|t|t|t|t
34026396|NCT05360485|RANDOMIZED|PARALLEL||OTHER||NONE||This is preliminary efficacy, acceptability, and feasibility pilot with a randomized controlled design. The preliminary efficacy pilot will test the effects of MOV'D, a socially-supported, evidence-based behavior change technique educational and behavioral intervention to increase the number of active hours (an indirect measure of prolonged sitting bouts) (Hypothesis 1) and number of MVPA minutes (Hypothesis 2). The pilot will gather important estimates of the effect sizes, the variance, and covariance of the primary outcomes to calculate the sample size needed to power a larger trial.||||
34026397|NCT03734315|||OTHER||PROSPECTIVE|||||||
34026398|NCT01697553|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34026399|NCT05349552|||COHORT||PROSPECTIVE|||||||
33722121|NCT05506852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be aware of the difference across the two conditions.||t|f|f|f
33722122|NCT04768465|||COHORT||PROSPECTIVE|||||||
34026400|NCT05209165|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722123|NCT03573479|||COHORT||PROSPECTIVE|||||||
34026401|NCT01862484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722124|NCT02087475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026402|NCT01453179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026403|NCT02794597|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026404|NCT05057806|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and investigators will be blinded to the randomization.|A randomized (2:1) placebo controlled double blind study|t|f|t|f
34026405|NCT05164783|NA|SINGLE_GROUP||OTHER||NONE||Implementation study with stepwise approach||||
33722125|NCT02587065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026406|NCT02714426|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34026407|NCT00010530|RANDOMIZED|||TREATMENT||SINGLE||||||
34026408|NCT05422638|RANDOMIZED|PARALLEL||OTHER||NONE||"RBSTE is a group-based approach that combines cultural adaptations of established psychotherapeutic techniques with novel strategies to foster resilience and empowerment for VOC.~PCT is a group-based approach that provides a safe space for VOC to discuss stressors and find adaptive of responding to them."||||
34026409|NCT02174289|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34026410|NCT03619200|||COHORT||PROSPECTIVE|||||||
34026411|NCT03714828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839041|NCT05369949|RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient's parents will be informed of the study allocation in case they wish to know this, otherwise they are not supposed to be aware of group allocation. Persons who will assess the neurodevelopment outcome will not be aware of group allocation.|The Intervention Drug is DEXMEDETOMIDINE||||
34026412|NCT03922776|NA|SINGLE_GROUP||OTHER||NONE||||||
34026413|NCT04762277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026414|NCT03651830|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34026415|NCT00022282||||TREATMENT||NONE||||||
34026416|NCT01056354|||COHORT||PROSPECTIVE|||||||
34026417|NCT04875936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to the nature of real-time fMRI neurofeedback they will receive: contingent or non-contingent.|Participants are randomly assigned to one of 2 groups|t|f|f|f
34026418|NCT05340829|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34026419|NCT00905970|||COHORT||PROSPECTIVE|||||||
34026420|NCT06355544|||COHORT||CROSS_SECTIONAL|||||||
34026421|NCT02769273|||CASE_ONLY||PROSPECTIVE|||||||
34026422|NCT01054404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026423|NCT06291415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1: Dose escalation stage - subjects will receive one of 3 dose levels of HMPL-523 to determine the recommended dose of HMPL-523 for the randomized dose optimization- stage (Part 2)~Part 2: subjects will be randomized in a 1:1 ratio between the 2 dose levels recommended by the SRC to better understand the exposure/efficacy/toxicity relationship. At the end of Part 2, the SRC will evaluate the safety, tolerability, preliminary efficacy, and PK data to determine the Recommended Phase 3 dose (RP3D) of HMPL-523."||||
34026424|NCT02077361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026425|NCT01404130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026426|NCT00508131|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34026427|NCT03704415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026428|NCT03585920|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|All samples provided to the participant are labelled with 3 digit random codes.|This is a 3 way crossover design using a pre-load study protocol that is standard for behavioural appetite studies. The study will be conducted single-blind, as it is not feasible to blind the researcher to the pre-load food products. Each participant will attend 3 visits, the pre-load study foods will be presented to them with random blinding codes.|t|f|f|f
34103942|NCT01608308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34103943|NCT05077111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||the study will include 40 participants, randomized into 2 equal groups, Group A: Awake participants will receive sole Thoracic Epidural Anesthesia. Group B: Participants receiving General Anesthesia with One Lung Ventilation.||||
33839042|NCT00400998|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34026429|NCT02558348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722126|NCT05045976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study participants will be randomly assigned 1:1 to the intervention or the control group by the stratified permuted block randomization and block 4, 6, 8 will be used. The randomization will be stratified by cancer stage (stage I-IIA; stage IIB-III). The Sealed Envelope software (Sealed Envelope Ltd., 2016) will be used to generate the random sequences and sealed envelopes will be used to conceal the assignment of each participant.||||
33722127|NCT01909596|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33722128|NCT03253107|||CASE_CONTROL||PROSPECTIVE|||||||
33722129|NCT02929823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722130|NCT02617511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722131|NCT00000278||||TREATMENT||||||||
33722132|NCT00867451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722133|NCT04339296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants were assigned to two groups. Intervention participants were assigned to use spencer medication dispenser system. Whereas, control participants continued to use their current method of medication management. Block randomization was used to assign the participants into the intervention or control group as soon as they enrolled in the study. Blocks varied in sizes (10, 12, 14) to reduce the predictability of the allocation assignment within participants and research staff.||||
33722134|NCT05543941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722135|NCT02127242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722136|NCT00159250|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33722137|NCT06519188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pretest, posttest randomized controlled trial||||
33722138|NCT03822247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722139|NCT02258321|RANDOMIZED|CROSSOVER||||NONE||||||
33722140|NCT02981823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026430|NCT05378594|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||20 participants with silver birch pollen allergic rhinitis, 20 with house dust mite allergic rhinitis, dual allergic participants will be able to take part in both arms of the study.||||
33722141|NCT00654173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722142|NCT01357408|||COHORT||PROSPECTIVE|||||||
33722143|NCT04011527|||COHORT||PROSPECTIVE|||||||
33722144|NCT04315337|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Outcome assessor is blind to participants' study condition.|"The intervention is task specific. Participants are given an intervention for a specific task, and outcomes include the specific task for which they received the intervention (i.e., trained task), as well as a control task for which they do not receive the intervention."|f|f|f|t
34026431|NCT06380881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722145|NCT00431210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026432|NCT03555292|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34026433|NCT03975231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722146|NCT03887000|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722147|NCT03984591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722148|NCT04692428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34026434|NCT04060290|||OTHER||PROSPECTIVE|||||||
34026435|NCT00805961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026436|NCT02201277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|analysis of the imaging data will be masked and filter type and PHI will be redacted so the radiologist assessor will not know which patients receive either the option or denali..||f|f|f|t
34026437|NCT05358509|RANDOMIZED|PARALLEL||TREATMENT||NONE|Oral iron use will not be masked (as tablets will be provided). However, blinding will occur for the two IV iron intervention arms, as participants, primary health center (PHC) staff, and community health center (CHC) infusion teams will only know that participants have been randomly assigned to receive an IV iron infusion without knowing the specific arm and formulation to be used. A pharmacist associated with each CHC performing infusions for the trial will be designated to prepare the randomly assigned IV iron formulation (according to participant weight and manufacturer instructions) on the day of treatment.|3-arm, randomized-controlled trial involving two intervention arms (two formulations of intravenous iron) and one active, comparator arm (oral iron, standard of care). Pregnant participants will be randomized with a one-to-one-to-one ration to the three study arms.||||
34026438|NCT02390024|||COHORT||PROSPECTIVE|||||||
34026439|NCT02813265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026440|NCT02186288|||||CROSS_SECTIONAL|||||||
34026441|NCT04194294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34026442|NCT00004137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026443|NCT04806048|||COHORT||PROSPECTIVE|||||||
34026444|NCT00839553|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34026445|NCT00655343|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026446|NCT01025453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026447|NCT00567684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026448|NCT02650843|||COHORT||PROSPECTIVE|||||||
34026449|NCT00264550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026450|NCT02283008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026451|NCT02980289|||COHORT||PROSPECTIVE|||||||
34026452|NCT03128021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Although this is a double-blinded study, one staff member will be unblinded regarding study randomization. Should the need ever arise, the blind can be instantly broken for the participant's safety and well-being.|"Participants will be randomly assigned to take either escitalopram or levomilnacipran throughout the 12-week trial.~The following information applies to the original study design. Enrollment according to this design was complete as of April 2018: During Phase I, participants will be randomly assigned to take escitalopram or placebo daily for 6 weeks. After 6 weeks, participants who are randomly assigned to placebo will be given the option to have an open-label of escitalopram for Phase II. Those who did not respond to escitalopram in Phase I will be referred for alternate treatment. All participants, regardless of outcome will be asked to return for follow-up procedures."|t|t|t|t
34026453|NCT05373628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026454|NCT04129229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026455|NCT04603157|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34026456|NCT05978024|||COHORT||PROSPECTIVE|||||||
34026457|NCT02681211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026458|NCT02317289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34026459|NCT04022408|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34026460|NCT05042258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103944|NCT00337454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026461|NCT05853042|||COHORT||PROSPECTIVE|||||||
34103945|NCT04499001|||OTHER||PROSPECTIVE|||||||
34026462|NCT02929524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103946|NCT00128492|NON_RANDOMIZED|||TREATMENT||NONE||||||
34026463|NCT02482961|||COHORT||PROSPECTIVE|||||||
34026464|NCT04895982|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34026465|NCT03887793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34026466|NCT02226601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026467|NCT06076460|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34026468|NCT00150787|RANDOMIZED|PARALLEL||||DOUBLE||||||
34026469|NCT04981327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Strategies to protect against bias include randomization with allocation concealment, enrolling consecutive patients. Patients will be advised to not disclose to study personnel during follow-up to which arm they were randomized to. Adjudicators will be blinded from treatment allocation group, and we will use standardized, validated measures to diagnose DVT, PE, PTS, and bleeding. We plan to allow phone follow-up to limit the risk of lost to follow-up and the impact on patients' in person consultation of a COVID wave during the course of the study.||f|f|f|t
34026470|NCT05238454|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This is a randomized, double-blind, positive-controlled Phase II clinical trial to evaluate the immunogenicity and safety of SCTV01C in population aged ≥18 years previously fully vaccinated with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with COVID-19 and compared with either Sinopharm inactivated COVID-19 vaccine or Comirnaty.|t|t|t|f
34026471|NCT00487968|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34026472|NCT02495623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026473|NCT05984186|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34026474|NCT01920022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026475|NCT00310882|||CASE_CONTROL||PROSPECTIVE|||||||
34026476|NCT01716975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34103947|NCT04130971|||COHORT||PROSPECTIVE|||||||
34103948|NCT06643663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34103949|NCT05875610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103950|NCT02446288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103951|NCT02292355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722149|NCT00525733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103952|NCT03903341|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34103953|NCT03418363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind||t|f|t|t
34103954|NCT03301415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103955|NCT06134999|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103956|NCT05652218|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||single arm crossover study|t|t|f|f
34103957|NCT05839821|||COHORT||CROSS_SECTIONAL|||||||
34103958|NCT06372041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34103959|NCT06374979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722150|NCT05434260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722151|NCT06127992|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33722152|NCT02192918|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722153|NCT02686879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722154|NCT03642210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722155|NCT03975855|||CASE_ONLY||PROSPECTIVE|||||||
33722156|NCT01628601|||COHORT||PROSPECTIVE|||||||
33722157|NCT02283047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722158|NCT05925023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722159|NCT02548247|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33722160|NCT02576288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722161|NCT05950789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722162|NCT01229423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722163|NCT03325738|||COHORT||RETROSPECTIVE|||||||
33722164|NCT00410644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33722165|NCT03016962|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33722166|NCT01147705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722167|NCT00322842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722168|NCT02537054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722169|NCT00326950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722170|NCT02850809|||COHORT||RETROSPECTIVE|||||||
33722171|NCT00183092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722172|NCT06112951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722173|NCT04908553|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33722174|NCT02016482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722175|NCT05283798|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722176|NCT02144441|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722177|NCT00568750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722178|NCT01237535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722179|NCT02202642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722180|NCT03773887|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33722181|NCT04814420|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Twenty participants would be an adequate sample size for this pilot study to represent all stages of OSA and controls (5 mild, 5 moderate, 5 severe OSA, and 5 controls with no OSA).||||
33722182|NCT04675294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722183|NCT04592029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722184|NCT02475551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722185|NCT03739112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Surveillance personnel is blinded from investigational product injection|This is a randomized, observer-blind, active comparator-controlled, multicenter, Phase 3 efficacy study.|t|t|t|t
33722186|NCT04892043|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33722187|NCT03346499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722188|NCT05762900|NA|SINGLE_GROUP||TREATMENT||NONE||The treatment is not a drug.||||
33802758|NCT03941119|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is an open trial, unblinded to both participants and research staff, due to the nature of the intervention. The randomization into VR-therapy or standard of care (no VR-therapy) will be performed using a randomization tool within a secure web application. The sequence allocation will be concealed from those assigning participants to the intervention groups, until the moment of assignment. Participants will be assigned to groups only after informed consent has been obtained.||||
33722189|NCT00891644|||CASE_CONTROL||PROSPECTIVE|||||||
33802759|NCT04877340|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33802760|NCT03305445|NA|SINGLE_GROUP||TREATMENT||NONE||This multi-center study open-label trial will enroll a single cohort of relapsed/refractory diffuse large B cell lymphoma (DLBCL) patients whom are ineligible for autologous stem cell transplant (ASCT).||||
34026477|NCT04409314|||COHORT||PROSPECTIVE|||||||
33722190|NCT05908188|||OTHER||PROSPECTIVE|||||||
33722191|NCT00590447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722192|NCT06054087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33722193|NCT02657460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722194|NCT00918658|||CASE_CONTROL||PROSPECTIVE|||||||
33722195|NCT06450626|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722196|NCT02137733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722197|NCT01291758|||COHORT||CROSS_SECTIONAL|||||||
33722198|NCT04564456|RANDOMIZED|CROSSOVER||OTHER||SINGLE|laboratory-blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33722199|NCT04517214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722200|NCT02583776|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33722201|NCT03479788|||COHORT||PROSPECTIVE|||||||
33722202|NCT03154554|||COHORT||PROSPECTIVE|||||||
33722203|NCT06541288|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33722204|NCT00696852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722205|NCT03662347|||COHORT||PROSPECTIVE|||||||
33722206|NCT03585205|||COHORT||CROSS_SECTIONAL|||||||
33722207|NCT06473870|||COHORT||PROSPECTIVE|||||||
33722208|NCT03893604|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|The device is preprogrammed by a third party non participating in any element in the study. They then chose (using opaque envelopes) the treatment code for each participant|Randomized, triple-blind, sham-controlled, crossover|t|f|t|t
33722209|NCT00343200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722210|NCT03787251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722211|NCT03980457|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label pragmatic study||||
33722212|NCT04175769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722213|NCT06520930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|statistical analysis|Parallel Assignment two groups|t|f|f|f
33722214|NCT03205410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients were randomly assigned in 1:1 ratio to either the RIPC group or the control group by means of a computerized randomization table.||f|f|t|f
33722215|NCT00459836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722216|NCT05265260|||COHORT||RETROSPECTIVE|||||||
33722217|NCT05023811|NA|SINGLE_GROUP||OTHER||NONE||||||
33722218|NCT01271920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722219|NCT02913391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722220|NCT03691896|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33802761|NCT02809794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802762|NCT00083551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802763|NCT04595474|||OTHER||CROSS_SECTIONAL|||||||
33802764|NCT00001958||||TREATMENT||||||||
33802765|NCT06096831|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802766|NCT01616888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802767|NCT04589520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33802768|NCT00867256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802769|NCT06389435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802770|NCT02059616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802771|NCT05051982|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802772|NCT05747716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722221|NCT02902185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722222|NCT03264287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33722223|NCT04746703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The investigators propose an exploratory study aiming at assessing the impact of surgical bariatric treatment on the improvement of pancreatic lesions detected by MRI.||||
33722224|NCT02559089|||CASE_CONTROL||PROSPECTIVE|||||||
33722225|NCT00949325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722226|NCT02347267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722227|NCT02972554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33722228|NCT00306761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722229|NCT00451386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722230|NCT01563718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722231|NCT01050257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722232|NCT04289246|RANDOMIZED|PARALLEL||OTHER||NONE||The study included baseline, intervention, and postintervention phases. Half of the participants were randomly allocated to the treatment group (n=8), and the other half was assigned to the control group (n=8). During the study phases, research assistants measured medication adherence weekly through the pill counting technique.||||
33722233|NCT03784404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722234|NCT02542631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722235|NCT00058604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722236|NCT05031533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722237|NCT01988831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802773|NCT02755259|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34026478|NCT06381557|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34026479|NCT03244644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34103960|NCT04304196|RANDOMIZED|PARALLEL||OTHER||DOUBLE||This pilot study is a multicenter, stratified, parallel, two-group randomized controlled trial.|f|f|t|t
34103961|NCT00382863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34103962|NCT01919476|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33802774|NCT01869179|RANDOMIZED|PARALLEL||OTHER||NONE|Randomization assignment was not revealed to study personnel or study participants until after baseline assessments were completed for each pair of centers.|Cluster-randomized controlled design||||
34103963|NCT05601063|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34103964|NCT03933631|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The Treatment Group will use 2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin). The Control Group will use only Prednisolone acetate and Ofloxacin, without pilocarpine."||||
33802775|NCT04613375|||CASE_CONTROL||PROSPECTIVE|||||||
33802776|NCT00805844|||COHORT||PROSPECTIVE|||||||
33802777|NCT04790357|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802778|NCT04605731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802779|NCT04328155|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel assingment||||
33802780|NCT02634450|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802781|NCT00775294|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802782|NCT04749784|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33802783|NCT00833313|||COHORT||PROSPECTIVE|||||||
33802784|NCT05821569|||OTHER||CROSS_SECTIONAL|||||||
33802785|NCT02891915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802786|NCT00515814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802787|NCT06058767|RANDOMIZED|PARALLEL||SCREENING||NONE||Each subject will undergo both PTA and OAE screening and be assigned post hoc to both TS-PO and SS-O groups with within-subject comparison of hearing screening outcomes.||||
33802788|NCT06339541|||CASE_ONLY||OTHER|||||||
33802789|NCT01550549|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33802790|NCT04884165|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomised, parallel group controlled, unblinded clinical trial||||
33802791|NCT04174768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802792|NCT00764335|||CASE_CONTROL||PROSPECTIVE|||||||
33802793|NCT05307536|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 54 patients with autism spectrum disorder (3-7 years old) will be recruited and divided into two groups: the controlled group (only intervention education) (n = 27) and the treatment group (Bone marrow mononuclear cell infusions combined educational intervention (n =27)||||
33802794|NCT03094169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Uncontrolled, open label, non-randomized, Enrollment in the order of confirmation of eligibility, Escalating doses of study drug in sequential patient cohorts (Phase 1a). Uncontrolled, open label, non-randomised. Enrollment into three individual Phase 2a study cohorts||||
33802795|NCT03610789|||COHORT||OTHER|||||||
33802796|NCT03055689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33802797|NCT01464710|||COHORT||PROSPECTIVE|||||||
33802798|NCT00117026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802799|NCT06440642|||CASE_CONTROL||PROSPECTIVE|||||||
33802800|NCT00909649|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33802801|NCT03104036|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be split into two branches of the study by randomization criteria (gender, imunosupresive therapy). Each branch of the study will have 25-30 patients. The first group will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week. A second group of patients will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.||||
33802802|NCT03513367|||OTHER||PROSPECTIVE|||||||
33802803|NCT05395403|NA|SINGLE_GROUP||SCREENING||NONE||||||
33802804|NCT03196882|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The study will be triple blind: the participant, the health-care professional, and the investigator-statistician. The treatment drug will be administered blind i.e. the doses are not identifiable since the packaging has the same format, presentation, and visual characteristics. For Stratum 1, the treatments will be designated as A or B, and for Stratum 2 they will be designated as C or D. The laboratory of MEIJI TEDEC FARMA, SA will be responsible for manufacturing, packaging and labeling the study medications. Only MEIJI TEDEC FARMA, SA and the Clinical Pharmacology Service of the Vall d'Hebron Hospital in Barcelona will know the distribution codes and the composition of each of the treatments."|"Multi-centered, parallel groups, controlled, triple blind, randomized clinical trial (RCT) subdivided in 2 strata as a function of the hemoglobin (Hb) levels at the start of the pregnancy:~Stratum 1: If Hb from 110 to 130 g/L, randomly assigned at week 12 to receive iron supplement of 40 or 80 mg/d.~Stratum 2: If Hb \>130 g/L, randomly assigned at week 12 to receive iron supplement of 40 or 20 mg/d.~The study is structured as a RCT with 2 stratum, depending on the Hb levels before week 12 of gestation. In each stratum there are two arms of intervention. Total 4 arms."|t|t|t|t
33802805|NCT03894436|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33802806|NCT00792636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802807|NCT04699786|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33802808|NCT03039634|||COHORT||PROSPECTIVE|||||||
33802809|NCT05065203|||COHORT||PROSPECTIVE|||||||
33802810|NCT05090631|||OTHER||PROSPECTIVE|||||||
33802811|NCT05176054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33802812|NCT02797444|||COHORT||PROSPECTIVE|||||||
33802813|NCT03951805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802814|NCT02484599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802815|NCT03261908|||COHORT||OTHER|||||||
33802816|NCT04761016|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33802817|NCT01006434|||COHORT||PROSPECTIVE|||||||
33802818|NCT05850975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants are not told whether they are in an intervention or control condition. The app is both the care provider and the outcomes assessor. The investigator will be blinded while analysing the data.|Participants will be randomly assigned to an intervention or control condition.|t|t|t|t
33802819|NCT00772044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802820|NCT02343913|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33802821|NCT02332382|||CASE_ONLY||PROSPECTIVE|||||||
33802822|NCT01866215|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34103965|NCT01746069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802823|NCT06222983|||COHORT||PROSPECTIVE|||||||
34103966|NCT02989025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34103967|NCT06685887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802824|NCT06270628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT with two study arms: exercise group and wait list control group||||
34103968|NCT04409769|||COHORT||RETROSPECTIVE|||||||
34103969|NCT06168357|||COHORT||PROSPECTIVE|||||||
33802825|NCT04564365|||COHORT||PROSPECTIVE|||||||
34103970|NCT04928131|||COHORT||RETROSPECTIVE|||||||
33802826|NCT05296772|NA|SEQUENTIAL||TREATMENT||NONE||Single group assignment||||
34103971|NCT03039010|||COHORT||PROSPECTIVE|||||||
33802827|NCT00533494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34103972|NCT06554899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34103973|NCT02511743|||||PROSPECTIVE|||||||
33802828|NCT04523701|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients, care providers and outcome assessors are blinded, the surgical team is not blinded.|Prospective randomized, controlled, observer and patient blinded multicentric (4 centres) superiority trial with 2 parallel study groups|t|t|f|t
34103974|NCT05562856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34103975|NCT03890107|||COHORT||PROSPECTIVE|||||||
34103976|NCT05169944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103977|NCT03715829|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Dose ranging period is blinded. The partially blinded extension period includes open arms and blinded arms.|Dose ranging period is a parallel design. Extension period is a sequential design.|t|f|t|t
34103978|NCT06673771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33802829|NCT02966938|||CASE_ONLY||RETROSPECTIVE|||||||
33802830|NCT02477813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802831|NCT00073749|NON_RANDOMIZED|||TREATMENT||NONE||||||
33802832|NCT04264013|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study will be a randomized parallel-group trial||||
33802833|NCT06426238|||CASE_ONLY||PROSPECTIVE|||||||
33802834|NCT03298074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802835|NCT00942487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802836|NCT01762475|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33802837|NCT02820233|||COHORT||PROSPECTIVE|||||||
34103979|NCT01903733|NA|SINGLE_GROUP||||NONE||||||
33802838|NCT03283371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|This is a 6-month randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of natalizumab as adjunctive therapy in the treatment of adult subjects with drug-resistant focal epilepsy. The placebo-controlled phase is followed by a 6-month open-label phase during which all subjects receive natalizumab.|t|f|t|t
34103980|NCT06577948|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigators, participants, and parents/legal guardians will be masked to the identity of the study product worn by each participant. All spectacle lenses will be fitted into the chosen spectacle frame. P.A.U.S.E.® optical elements may be visible under certain lighting conditions, and therefore, it may not be possible to completely mask test spectacle lenses from control spectacle lenses. However, complete masking is possible between test spectacle lenses. Regardless, investigators who perform crucial measurements (axial length and autorefraction) should not view a participant's study product to further minimise the chance of de masking||t|t|t|f
34103981|NCT06689384|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34103982|NCT06192160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802839|NCT06433102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The technical staff and research assistants involved in subject enrollment, outcome measurement, and data collection are blinded to the intervention allocation.|randomized controlled trial|f|f|f|t
33802840|NCT01644994|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label, single dose local intracavitary application of Cisplatin bound to Fibrin after surgery (removal of Tumor)||||
33802841|NCT03238261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802842|NCT02035046|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802843|NCT02333513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802844|NCT03067142|||CASE_CONTROL||OTHER|||||||
33802845|NCT03014518|||CASE_CONTROL||PROSPECTIVE|||||||
33802846|NCT00439413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33802847|NCT05121467|||CASE_ONLY||PROSPECTIVE|||||||
33802848|NCT04848168|||CASE_ONLY||PROSPECTIVE|||||||
33802849|NCT03805529|||CASE_ONLY||PROSPECTIVE|||||||
33802850|NCT02362867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802851|NCT01340716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33802852|NCT03753984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33802853|NCT00956852|||CASE_ONLY||PROSPECTIVE|||||||
34103983|NCT06137092|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34103984|NCT05954312|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34103985|NCT01292993|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33802854|NCT02713126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802855|NCT03426800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33802856|NCT00937131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802857|NCT01262339|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33802858|NCT06102616|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802859|NCT03939312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802860|NCT02614235|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33802861|NCT02748317|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34103986|NCT04882605|||CASE_CONTROL||OTHER|||||||
34103987|NCT05802836|||OTHER||OTHER|||||||
34103988|NCT06419907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103989|NCT00772200|||CASE_ONLY||PROSPECTIVE|||||||
34103990|NCT04198337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103991|NCT06687213|||CASE_CONTROL||PROSPECTIVE|||||||
34103992|NCT00666614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34103993|NCT05428670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34103994|NCT06675617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34103995|NCT04833907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802862|NCT03813433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33802863|NCT04850586|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802864|NCT00103363||||SCREENING||||||||
33802865|NCT02664558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802866|NCT00278304||||TREATMENT||||||||
33802867|NCT04758416|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802868|NCT01797354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802869|NCT00629954|||COHORT||PROSPECTIVE|||||||
33802870|NCT03936023|||COHORT||RETROSPECTIVE|||||||
33802871|NCT01278420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802872|NCT02269475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33802873|NCT00443001|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33802874|NCT06605924|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will view ads in each of four conditions manipulating presence of different marketing features.||||
33802875|NCT00558454|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33802876|NCT06358534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pretest-posttest, control and intervention groups||||
33802877|NCT04743440|||OTHER||PROSPECTIVE|||||||
33802878|NCT01079949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802879|NCT06109493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know that two different treatments were delivered.|"Randomization assigned participants to 2 arms:~* ACT group~* Waiting list"|t|f|f|f
33802880|NCT05715437|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|t|f
33802881|NCT02421185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802882|NCT03366506|||COHORT||PROSPECTIVE|||||||
33802883|NCT03079817|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802884|NCT03443661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802885|NCT04380558|||COHORT||PROSPECTIVE|||||||
33802886|NCT05623033|||OTHER||CROSS_SECTIONAL|||||||
33802887|NCT05909072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802888|NCT05656560|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33802889|NCT03434587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802890|NCT03304041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802891|NCT02837796|RANDOMIZED|PARALLEL||||NONE||||||
33802892|NCT00203554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802893|NCT03065569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802894|NCT06094231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802895|NCT00186784|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33802896|NCT02928172|NA|SINGLE_GROUP||SCREENING||NONE||||||
33802897|NCT05398289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802898|NCT00975585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802899|NCT03832140|||CASE_CONTROL||PROSPECTIVE|||||||
33802900|NCT04965415|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Businesses are randomly assigned to one of two arms, and the intervention is evaluated using a stepped wedge design. In the active comparator arm, businesses participate in an existing organizational-level intervention called Health Links in the first year of the study. Businesses randomly assigned to the experimental arm in the first year receive the TWH leadership program, in addition to Health Links. Businesses in the active comparator arm eventually receive the experimental intervention in the second year of the study.||||
33802901|NCT02463448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802902|NCT02147717|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33802903|NCT06108024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802904|NCT03746470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802905|NCT02400931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33802906|NCT04376567|RANDOMIZED|PARALLEL||TREATMENT||NONE||Assigned to either a one-stage or two-stage approach for brachial-basilic arteriovenous fistula (BBAVF) creation in a 1:1 ratio.||||
33802907|NCT00761553|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802908|NCT05437653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a double-blinded study, and the study participant and assessor will be unaware of the nature of the drink. Subjects will be invited into 2 MRI scan visits to investigate the brain and gut responses (brain-gut axis) to a high fat drink and a carbohydrate drink. Drinks will be randomised across participants using research randomizer software (https://www.randomizer.org/).|Randomised parallel trial in human volunteers. Control (normal weight) group VS Obese group and High fat drink VS iso-caloric, iso-viscous Carbohydrate drink|t|f|f|t
33802909|NCT05641506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802910|NCT05048251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802911|NCT06083766|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802912|NCT02827474|||OTHER||OTHER|||||||
33802913|NCT04289324|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center randomized controlled study||||
33802914|NCT05249842|||COHORT||RETROSPECTIVE|||||||
33802915|NCT02219568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802916|NCT04044807|||COHORT||PROSPECTIVE|||||||
33802917|NCT05643456|RANDOMIZED|PARALLEL||TREATMENT||NONE||69 Patients with exotropia of (40-55) PD who are ≥ 5 years old. The 1st group will do two muscles surgery; bilateral lateral rectus recession. The 2nd group will do three muscles surgery; bilateral lateral rectus recession and unilateral medial rectus tucking.||||
33802918|NCT01690572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802919|NCT03272087|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802920|NCT00423020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33802921|NCT00421889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802922|NCT02119650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33802923|NCT01318967|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802924|NCT02041728|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802925|NCT02894879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802926|NCT01595789|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33802927|NCT00038454|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33802928|NCT00989469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802929|NCT03486574|||FAMILY_BASED||PROSPECTIVE|||||||
33802930|NCT03980613|||CASE_CONTROL||RETROSPECTIVE|||||||
34103996|NCT00383565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148863|NCT06213779|||COHORT||PROSPECTIVE|||||||
34148864|NCT01400399|||COHORT||PROSPECTIVE|||||||
33802931|NCT02405013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802932|NCT03822988|||CASE_ONLY||CROSS_SECTIONAL|||||||
33802933|NCT01657604|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33802934|NCT00926354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802935|NCT01635712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802936|NCT00001258|||COHORT||PROSPECTIVE|||||||
33802937|NCT04803409|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention Model Description: The participants will be randomized to two groups: ultrasound group and control group. All participants will still receive standard clinical care. The ultrasound group will receive daily ultrasound application to the spleen for up to 7 days, in addition to the standard clinical care. The control group will receive standard clinical care without ultrasound stimulation.||||
33802938|NCT05783791|||COHORT||PROSPECTIVE|||||||
33802939|NCT01294956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802940|NCT04595305|NA|SINGLE_GROUP||OTHER||NONE||||||
33802941|NCT01778907|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33802942|NCT03438903|||CASE_CONTROL||PROSPECTIVE|||||||
33802943|NCT03721913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be masked for assessments of family empowerment||f|f|f|t
33802944|NCT00225407|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33802945|NCT04601974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802946|NCT06092255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802947|NCT06004765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802948|NCT03728764|NA|SINGLE_GROUP||OTHER||NONE||||||
33802949|NCT00160498|RANDOMIZED|PARALLEL||||DOUBLE||||||
33802950|NCT03750968|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33802951|NCT05101954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802952|NCT01238146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802953|NCT00586313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802954|NCT03276403|||COHORT||PROSPECTIVE|||||||
33802955|NCT01074359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802956|NCT01011582|||COHORT||PROSPECTIVE|||||||
33802957|NCT01241370|||CASE_CONTROL||PROSPECTIVE|||||||
33802958|NCT00258609|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33802959|NCT05129930|||CASE_ONLY||RETROSPECTIVE|||||||
33802960|NCT01964300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802961|NCT04082624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33802962|NCT00348751|RANDOMIZED|PARALLEL||||NONE||||||
33802963|NCT05050383|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802964|NCT06127602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blinded to group existence and assignment and outcome assessors will be blinded to group assignment|Double-blinded Randomized Controlled Trial|t|f|f|t
33802965|NCT03111537|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33802966|NCT05917275|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33802967|NCT04736485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802968|NCT01074788|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33802969|NCT00706875|||COHORT||RETROSPECTIVE|||||||
33802970|NCT05119491|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33802971|NCT00274469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802972|NCT04310514|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33802973|NCT00620698|||COHORT||PROSPECTIVE|||||||
33802974|NCT04195113|||COHORT||PROSPECTIVE|||||||
33802975|NCT00585624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33802976|NCT02999763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802977|NCT03821636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33802978|NCT00550823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33802979|NCT04649996|||COHORT||RETROSPECTIVE|||||||
33802980|NCT01158417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802981|NCT02115828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802982|NCT05713526|RANDOMIZED|PARALLEL||OTHER||NONE||Pretest-posttest with the control group.||||
33802983|NCT00623194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33802984|NCT04863677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33802985|NCT02454283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802986|NCT06278870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802987|NCT05629845|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33802988|NCT05152992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802989|NCT03743649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33802990|NCT03488394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33802991|NCT00799552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33802992|NCT06518772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33802993|NCT05698758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33802994|NCT01739244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148865|NCT00043927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148866|NCT04830124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148867|NCT00890344|||||PROSPECTIVE|||||||
34148868|NCT03662659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148869|NCT02763436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34148870|NCT01299402|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34148871|NCT02455076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148872|NCT01589913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148873|NCT02482402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722238|NCT05517889|||COHORT||PROSPECTIVE|||||||
33722239|NCT00606476|NON_RANDOMIZED|PARALLEL||||NONE||||||
33722240|NCT06161220|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blinded (for test and negative control) and open label (for active control)||t|f|t|t
33722241|NCT04983576|||COHORT||RETROSPECTIVE|||||||
33802995|NCT00578916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026480|NCT03307629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026481|NCT00484640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026482|NCT04623086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026483|NCT00564330|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34026484|NCT06634433|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study employs a two-phase Training of Trainers Program (TTP) designed for health professionals. The first phase is a three-day online theoretical training, while the second phase consists of two days of face-to-face practical training. Participants were assigned to different small groups to engage in interprofessional education (IPE) activities and scenarios, facilitated by experts from various healthcare professions.||||
33722242|NCT03680365|||CASE_ONLY||CROSS_SECTIONAL|||||||
33722243|NCT01581307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722244|NCT04923724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know which group they are in.|Patients are put into 2 study groups. One group gets a tourniquet during surgery and one group does not.|t|f|f|f
33722245|NCT05916729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722246|NCT00786487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33722247|NCT00212732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722248|NCT06238232|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33722249|NCT05363384|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722250|NCT04577937|NA|SINGLE_GROUP||SCREENING||NONE||cohort study, pilot||||
33722251|NCT01718847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722252|NCT01330485|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Assessors were blinded to study conditions.|Group (3 groups) x time|f|f|f|t
33722253|NCT04738344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33802996|NCT01952366|||COHORT||PROSPECTIVE|||||||
33802997|NCT05335642|||COHORT||RETROSPECTIVE|||||||
33802998|NCT04147494|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33802999|NCT05570838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33803000|NCT04505358|RANDOMIZED|PARALLEL||TREATMENT||NONE|Packages will be labeled to mask the distinction between PU AD and placebo.|3:2 randomization||||
33803001|NCT02310113|||COHORT||PROSPECTIVE|||||||
34026485|NCT05289297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026486|NCT03834454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Simple randomization will be conducted using a software by one of the researchers (HA) into two groups with equal size. To ensure the concealment, the randomization list will be kept in a sealed enveloped and opened by the physician who administered the spinal anesthesia just before the surgery. Data recording will be conducted by independent observers. This is a double-blinded study for the subjects and for the observers. The enrollment of the participants will be conducted by HA. Patients will not be notified about the dose scheme. Physician who performed the spinal anesthesia are different from the observers. Observers are junior residents trained to test the spinal adequacy and to perform monitoring in spinal anesthesia. It us not possible to blind the physicians who perform the spinal anesthesia because they will notice the volume difference.||t|f|t|f
34026487|NCT03376061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The pharmacy will prepare 1 syringe of 50 ml of topical TA (5 g) or placebo. They will also prepare for the same patient 2 syringes of 50 ml (5 g) for intravenous (i.v.) injection or placebo. TA is similar in all aspects to normal saline. Blinding of both teams will be easy. The syringes will be prepared and randomized in pharmacy before the surgery.|Tranexamic Acid intravenous + Placebo topical versus Placebo intravenous + Tranexamic Acid topical|t|t|t|t
34026488|NCT01741883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34026489|NCT00557089|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34026490|NCT00109408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026491|NCT02343783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148874|NCT01119677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148875|NCT05948618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The team statistician will be blinded to experimental condition to reduce the possibility of bias. Only after analyses have been completed will the blinds be revealed.||f|f|f|t
34148876|NCT02272179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148877|NCT02925169|||COHORT||RETROSPECTIVE|||||||
34148878|NCT00199667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148879|NCT02342080|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33722254|NCT05990101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|By the nature of the awake prone intervention, it will not be possible to blind clinicians; however, interventions will be blinded to data analysts and outcome assessors.|Participants will be allocated to the awake prone or standard care groups on a 1:1 ratio.|f|f|t|t
33803002|NCT00032435||||||DOUBLE||||||
33803003|NCT02230137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803004|NCT03882450|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148880|NCT02496923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148881|NCT05690750|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34151025|NCT01207089|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33722255|NCT03816085|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33722256|NCT01123109|NA|SINGLE_GROUP||OTHER||NONE||||||
33722257|NCT02360592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722258|NCT00739037|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
33722259|NCT05351242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722260|NCT00301444|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33722261|NCT05700981|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A randomized controlled trials||||
33722262|NCT04318990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomized, single-center clinical trial||||
33722263|NCT01578889|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34026492|NCT04685408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026493|NCT01006018|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34026494|NCT06054165|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Stepped-wedge cluster randomized trial||||
34026495|NCT02140385|RANDOMIZED|PARALLEL||||NONE||||||
34026496|NCT04614415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026497|NCT01374269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34026498|NCT06202131|||COHORT||PROSPECTIVE|||||||
34026499|NCT01343446|||||CROSS_SECTIONAL|||||||
34026500|NCT04423185|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026501|NCT04117919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803005|NCT05766540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803006|NCT00588471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803007|NCT01742169|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33803008|NCT00291954|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803009|NCT00329862|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803010|NCT00570466|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803011|NCT03631433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|identical appearing tablets and random allocation||t|t|t|f
33803012|NCT06321952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Controlled Trial|t|t|t|t
33803013|NCT00199407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803014|NCT02253459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803015|NCT03190603||SEQUENTIAL||TREATMENT||NONE||||||
33803016|NCT03771313|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Open-label, single center, prospective study||||
33803017|NCT03804580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803018|NCT03947346|||COHORT||PROSPECTIVE|||||||
33803019|NCT03594500|RANDOMIZED|PARALLEL||TREATMENT||NONE||Consenting participants will be randomly assigned to the control or intervention arm of the study. Participants in the intervention arm will receive PockeTalkers (hearing assistance devices) for the duration of their time in the emergency department. Participants in the control group will not receive hearing assistance devices during their time in the emergency department.||||
33803020|NCT00310973|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33803021|NCT00882934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803022|NCT04059042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Personnel who interact directly with the study subjects (either human or non-human subjects) will not be aware of the assigned treatments. (Commonly known as double blind) Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group."|Two-arm (Music, Nature Sounds) parallel randomized controlled pilot study in patients with fibromyalgia with between-subject counterbalanced repeated measure control (Silence). The primary outcome measure will be pain threshold and tolerance as measured by the quantitative sensory testing (QST) battery.|f|f|t|t
33803023|NCT03664635|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803024|NCT02932579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803025|NCT02068066|||COHORT||CROSS_SECTIONAL|||||||
33803026|NCT03042039|||CASE_CONTROL||PROSPECTIVE|||||||
33803027|NCT00002697||||TREATMENT||NONE||||||
33803028|NCT03329482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One of the Physiotherapist who carried out the assessment especially when the intervention started did not aware of the study|A total number of 50 subjects were enrolled for the study: 25 subjects for the PUS group and 25 subjects for the KM group in order to give room for attrition. For the purpose of the study the following instruments were used: verbal-rating scale, Roland-Morris disability questionnaire, and an ultrasound machine|f|f|f|t
33803029|NCT03960606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be performed in a double-blind manner. All study drug will be supplied in identical packaging and will be similar in color, smell, taste, and appearance to enable double-blind conditions. All study personnel will remain blinded until after database lock, unless the nature of their activities in the study specifically requires them to be unblinded. Any study documents, supplies, and tools will be reviewed to identify components that have the potential to unblind the study, and blinding restrictions will be applied where appropriate.|Following screening and confirmation of eligibility, subjects will be randomly assigned (1:1:1:1) into 4 arms of 16 subjects each and will receive 10 mg, 20 mg, or 35 mg of PUR1900 or placebo, administered via dry powder inhalation daily for 28 days.|t|f|t|t
33803030|NCT05949359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803031|NCT00574834|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33803032|NCT03788200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803033|NCT05297175|NA|SINGLE_GROUP||TREATMENT||NONE||Early feasibility study||||
33803034|NCT01477255|||CASE_CONTROL||PROSPECTIVE|||||||
33803035|NCT02035605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803036|NCT04351932|RANDOMIZED|PARALLEL||TREATMENT||NONE|A randomized non blind clinical trial with active control. For this purpose, the random number generator, found on the RANDOM.ORG ® website (available at https://www.random.org/integers/)|A total of 54 patients with the diagnosis of knee OA grade II and III will be recruited to receive a single intra-articular injection of MSC: Group 1 (n 18 patients) will receive BM-MSC, Group 2 (n 18 patients) will receive AD-MSC. Group 3 (18 patients) will receive a combination of BM-MSC and AD-MSC.||||
33803037|NCT03428698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34026502|NCT05885984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcomes assessor who is independent of the research will be trained before formally conducting data collecting.|Participants are assigned to two groups in parallel for the duration of the study. Participants in Group A receive Acceptance and Commitment Therapy in addition to health education. Participants in Group B receive health education.|f|f|f|t
34026503|NCT06634355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026504|NCT03909880|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34026505|NCT05007821|RANDOMIZED|PARALLEL||TREATMENT||NONE||A5356 is a phase II, prospective, randomized, two-arm, open-label, multicenter clinical trial to evaluate the anti-tuberculosis (TB) activity, safety, and tolerability of an injectable-free short course regimen for treatment of multidrug-/rifampicin-resistant (MDR-/RR-), pre-extensively drug-resistant (pre-XDR-), and extensively drug-resistant (XDR-) TB comparing two dosing strategies of linezolid (LZD) combined with bedaquiline (BDQ), delamanid (DLM), and clofazimine (CFZ).||||
33803038|NCT03717467|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patient will be randomly assigned to one of the two groups. An independent anesthesiologist who will not be participating in the study prepares the study medications.||t|t|t|f
33803039|NCT01078285|||COHORT||PROSPECTIVE|||||||
33803040|NCT02476435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34026506|NCT00710866|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34026507|NCT03769961|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34026508|NCT05382585|||COHORT||PROSPECTIVE|||||||
34026509|NCT06549855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026510|NCT06172426|||COHORT||RETROSPECTIVE|||||||
34026511|NCT05767931|||COHORT||PROSPECTIVE|||||||
34026512|NCT00451646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026513|NCT03951025|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33722264|NCT01413555|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722265|NCT05221333|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||a single group of health participants||||
34026514|NCT03207386|NA|SEQUENTIAL||PREVENTION||NONE||Multiple baseline survey design across three years including two baseline surveys prior to prevention programming and rollout of doses of programming across two years.||||
34026515|NCT03288181|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026516|NCT04159870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026517|NCT03133650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026518|NCT01955083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026519|NCT01793948|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34026520|NCT06634238|||CASE_CONTROL||PROSPECTIVE|||||||
34026521|NCT06632574|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive the same treatment, and there is no comparison group.||||
34026522|NCT00408746|||CASE_CONTROL||PROSPECTIVE|||||||
34026523|NCT05503511|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34026524|NCT00685776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026525|NCT04382287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The three provided pastes had a similar physical appearance|A randomised double-blind clinical trial, with three parallel study groups (two experimental and one control), whose participants were randomly assigned to one of te three groups.|t|t|t|f
34026526|NCT02018575|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34026527|NCT02053337|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34026528|NCT04778085|||OTHER||OTHER|||||||
34026529|NCT03131804|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34026530|NCT05277662|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026531|NCT04513288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prospective, multicenter, placebo-controlled, randomized, double-blind study on two parallel groups.|Prospective, multicenter, placebo-controlled, randomized, double-blind study on two parallel groups.|t|f|f|f
34026532|NCT03560180|||COHORT||PROSPECTIVE|||||||
34026533|NCT01377012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026534|NCT02175992|||COHORT||PROSPECTIVE|||||||
34026535|NCT03197181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participants are blind to whether the participants receive anodal or sham stimulation in a session.|In two separate sessions, participants receive either anodal or sham transcranial direct current stimulation while the participants are performing a decision-making task on the computer.|t|f|f|f
34026536|NCT00235404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026537|NCT04538625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind, placebo controlled|A randomized, placebo controlled, double blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors receiving targeted cancer therapy containing regimens. Diarrhea grading will be done according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE Ver. 5.0).|t|t|t|t
34026538|NCT02759692|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34026539|NCT01089894|||CASE_ONLY||PROSPECTIVE|||||||
34026540|NCT04666389|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026541|NCT01021280|||CASE_CONTROL||PROSPECTIVE|||||||
34026542|NCT03145389|||CASE_CONTROL||PROSPECTIVE|||||||
34026543|NCT01191944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026544|NCT03848390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026545|NCT05769010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026546|NCT02686736|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026547|NCT05352412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026548|NCT02945423|||CASE_ONLY||CROSS_SECTIONAL|||||||
33722266|NCT01517672|NA|SINGLE_GROUP||||NONE||||||
33722267|NCT01822184|||COHORT||PROSPECTIVE|||||||
33722268|NCT01010906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722269|NCT04404075|||OTHER||PROSPECTIVE|||||||
33722270|NCT03593265|NA|SINGLE_GROUP||OTHER||NONE||||||
33722271|NCT03961607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator assesses photographs without prior knowledge of intervention||f|f|f|t
33722272|NCT01467947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722273|NCT06320145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722274|NCT02083731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722275|NCT01721421|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33722276|NCT01722240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722277|NCT03911414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722278|NCT03533192|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors were blind to condition.||f|f|f|t
33722279|NCT04120974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722280|NCT01172847|RANDOMIZED|CROSSOVER||||NONE||||||
33722281|NCT00574054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722282|NCT00031889|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33722283|NCT00039754|NON_RANDOMIZED|||TREATMENT||NONE||||||
33722284|NCT00071760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722285|NCT04368286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722286|NCT01897012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722287|NCT02109120|||COHORT||PROSPECTIVE|||||||
33722288|NCT00951665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803041|NCT02263573|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803042|NCT06161415|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study will consist of two stages:~Stage One - Open label dose escalation:~Up to three subsequent dose-escalation groups will receive Laquinimod eye drops for 2 weeks and samples will be assayed for Laquinimod concentration in aqueous humor, vitreous and plasma.~Stage Two- Randomized, Controlled Comparison of 2 Laquinimod doses:~After the dose escalation cohorts are analysed, 2 Laquinimod doses will be selected for a randomized comparison. The doses in stage 2 will not exceed those studied in stage 1."||||
33803043|NCT05050799|||COHORT||PROSPECTIVE|||||||
33803044|NCT02582424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803045|NCT03592602|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34026549|NCT02938377|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34026550|NCT03170531|||COHORT||PROSPECTIVE|||||||
33803046|NCT06461390|RANDOMIZED|PARALLEL||TREATMENT||NONE|fluid loading with norepinephrie|Interventional subject will be received fluid loading with early norepinephrine administration with dose 0.1 mcg/kgBW/minute control subject will be received fluid loading only||||
33803047|NCT05361733|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"In Part A, 24 healthy volunteers will be enrolled in a total of 3 cohorts (Cohorts 1 to 3) with ascending doses of XFB-19: 5mg (Cohort 1), 10mg (Cohort 2), and 20mg (Cohort 3). Each cohort will enroll 8 participants with 6 participants randomised to receive XFB-19 and 2 participants randomised to receive placebo.~In Part B, 16 healthy volunteers will be enrolled in a total of 2 cohorts (Cohorts 4 and 5). Each cohort will enroll 8 participants with 6 participants randomised to receive XFB-19 and 2 participants randomised to receive placebo. Cohorts 4 and 5 will accept the second highest and highest XFB-19 doses for evaluation from Part A."|t|f|t|f
33803048|NCT06590441|||COHORT||PROSPECTIVE|||||||
34026551|NCT01613313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803049|NCT04829604|NA|SINGLE_GROUP||TREATMENT||NONE||One single arm, open label with intravenous infusion of ARX788||||
33803050|NCT00545519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803051|NCT01286064|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33803052|NCT04707001|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||open label||||
33803053|NCT04762238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803054|NCT01150656|||CASE_ONLY||RETROSPECTIVE|||||||
33803055|NCT01330537|||COHORT||CROSS_SECTIONAL|||||||
33803056|NCT06350812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803057|NCT04319913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The analgesia nociception index sensors are a pair of patches. They would be placed on the participant's right shoulder and the left side of the chest before the induction of general anesthesia, recording the ANI value throughout the operation. In the control group, the ANI monitor would be covered up, so that the care provider could only titrate remifentanil based on clinical experience. The participants would be masked from which group they were allocated into. The surgeon would be masked from the participant's allocation, and surgeon's satisfaction to the operation field would be surveyed by a questionnaire right after the operation, also the estimated blood loss amount would be recorded by the same surgeon.||t|f|f|t
33803058|NCT02398487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803059|NCT03257644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803060|NCT01488734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33803061|NCT03928652|||COHORT||PROSPECTIVE|||||||
33803062|NCT00769353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33803063|NCT00448552||||TREATMENT||NONE||||||
33803064|NCT00331942|||DEFINED_POPULATION||OTHER|||||||
33803065|NCT01113931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803066|NCT04547764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803067|NCT00754000|||COHORT||PROSPECTIVE|||||||
33803068|NCT03619642|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803069|NCT05646004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803070|NCT00004149||PARALLEL||TREATMENT||||||||
33803071|NCT00861770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803072|NCT02611609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803073|NCT01813773|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803074|NCT02652442|NA|SEQUENTIAL||OTHER||NONE||"To determine optimal stimulus parameters for off-axis rotation (OAR), participants progressed through the study starting with off-axis distance (3.5 vs 7.0 cm), off-axis duration (1 vs 3 minutes) and finally training schedule (daily vs biweekly). SVV was measured immediately before and after training.~To determine optimal distance, OAR was first performed at 3.5 cm and then 7.0 cm off-axis for 1 minute and the change in SVV compared. Participants trained daily for 5 consecutive days at 3.5 cm followed by a washout period of two weeks, then trained at 7.0 cm.~To determine optimal duration, participants were rotated at 3.5 cm off-axis (determined to be optimal) for 3 minutes and the change in SVV was compared to 3.5 cm off-axis for 1 minute.~To determine optimal training schedule, participants were rotated at 3.5 cm off-axis for 3 minutes (determined to be optimal) on a biweekly schedule for a total of 5 sessions and change in SVV was compared to the daily training schedule."||||
34026552|NCT04228497|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34026553|NCT05301595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients will be randomized by using forty-six sealed, opaque envelopes to receive a TAP block or QL block.~This is a double-blind study. Patient, surgeon and study staff will know which group patient has been assigned to. The anesthetist will know which group you are in for logistical purposes. The patient and surgeon will not know which nerve block the patient received."|Patients will be randomized to receive intraoperative TAP block (Group A) or preoperative ultrasound- guided QL block (Group B).|t|t|t|f
34026554|NCT03373370|||COHORT||PROSPECTIVE|||||||
34026555|NCT04423887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026556|NCT01180426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026557|NCT04222972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026558|NCT03685877|||OTHER||CROSS_SECTIONAL|||||||
34026559|NCT05243446|||CASE_CONTROL||PROSPECTIVE|||||||
34103997|NCT05592379|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Participants may receive placebo (saline) or psilocybin during their treatment on overnight 2 but will not be told which they will receive.|placebo first followed by placebo+clonidine or psilocybin+clonidine in asleep healthy volunteers|t|f|f|f
34103998|NCT06673641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026560|NCT05659693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Women who meet the inclusion criteria will be included in the sample using a simple random method. Before the research numbers were produced from random.org, envelopes of the same size and characteristics were created for each participant by a person other than the researcher (IU-C, Research Assistant B.Y) and numbers between 1 and 120 were written on them. Then, considering the data losses, numbers from 1 to 120 were generated from random.org. The researcher will use online spinning games (https://www.kodvizit.com/cekilis/cark) while dividing the participants into groups. Numbers from 1-120 will be written on the online wheel on the site. The researcher will first apply a digital literacy scale to the woman who accepts the research. The woman with a scale score of 3.40 and below will be asked to spin the wheel from the online spinning games site and the experimental - control group will be determined.~Experimental Group: 50 people Control Group: 50 people"|Type of Study: This study is a randomized controlled trial. The pre-test-post-test will be carried out with a pattern.|t|f|t|f
34103999|NCT00587080|||COHORT||PROSPECTIVE|||||||
34026561|NCT01886079|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34104000|NCT02891954|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026562|NCT06111261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104001|NCT02290574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104002|NCT06596356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104003|NCT04365881|||OTHER||CROSS_SECTIONAL|||||||
34104004|NCT02915601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104005|NCT06687239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104006|NCT06304012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104007|NCT06569784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104008|NCT06003647|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34104009|NCT00002256||||TREATMENT||NONE||||||
34104010|NCT06475495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-stage interventional, prospective, randomized, controlled, open label, parallel-group phase I/II trial in patients with active, ACPA-positive and treatment refractory rheumatoid arthritis||||
34104011|NCT06553898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104012|NCT03731455|NA|SINGLE_GROUP||OTHER||NONE||The neurosurgical intervention will be performed with both devices: investigational (Wise Cortical Strip, WCS) and comparator device.||||
34104013|NCT02621853|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104014|NCT05365880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104015|NCT02653755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104016|NCT02811419|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34104017|NCT03731000|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
34104018|NCT02320071|||CASE_ONLY||PROSPECTIVE|||||||
34104019|NCT02003898|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects are assigned to treatment with the Medtronic 530G Insulin Pump||||
34104020|NCT06257875|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34104021|NCT02362763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104022|NCT00033826|||CASE_ONLY||CROSS_SECTIONAL|||||||
34104023|NCT01962753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104024|NCT01309100|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34104025|NCT06085638|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104026|NCT01392885|||COHORT||PROSPECTIVE|||||||
34104027|NCT04071535|||CASE_CONTROL||RETROSPECTIVE|||||||
34104028|NCT01507103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104029|NCT05815199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104030|NCT01992081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104031|NCT02812537|||COHORT||PROSPECTIVE|||||||
34104032|NCT06641817|||COHORT||PROSPECTIVE|||||||
34104033|NCT05950360|||COHORT||CROSS_SECTIONAL|||||||
34104034|NCT00392288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104035|NCT04941573|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open label longitudinal study.||||
34104036|NCT01748214|||CASE_CROSSOVER||PROSPECTIVE|||||||
34104037|NCT04821245|||COHORT||PROSPECTIVE|||||||
34026563|NCT05289947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026564|NCT02540850|||COHORT||PROSPECTIVE|||||||
34026565|NCT00576108|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34026566|NCT06398119|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34026567|NCT00683345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026568|NCT01051947|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34026569|NCT03155516|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34026570|NCT05154461|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026571|NCT04655001|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants are randomly assigned to a 24-week intervention or a no-contact control|f|f|t|t
34026572|NCT01296997|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34104038|NCT06677996|NA|SINGLE_GROUP||OTHER||NONE||||||
34026573|NCT02021513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026574|NCT04585230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34026575|NCT00970827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34026576|NCT04589663|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|Single-sequence crossover study||||
34026577|NCT02581644|||CASE_ONLY||CROSS_SECTIONAL|||||||
34026578|NCT01969786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34104039|NCT03977298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
34104040|NCT05333510|||COHORT||PROSPECTIVE|||||||
34104041|NCT04338620|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, randomized, open-label, parallel controlled trial.||||
34104042|NCT02203279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104043|NCT03778697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104044|NCT04264845|||COHORT||PROSPECTIVE|||||||
34104045|NCT00919360|||CASE_CONTROL||PROSPECTIVE|||||||
34104046|NCT01878474|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34104047|NCT05373680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104048|NCT04158258|||COHORT||PROSPECTIVE|||||||
34104049|NCT05048264|||COHORT||PROSPECTIVE|||||||
33722289|NCT00950547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722290|NCT01950533|||COHORT||PROSPECTIVE|||||||
33722291|NCT03890549|||CASE_ONLY||PROSPECTIVE|||||||
33722292|NCT01951339|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33722293|NCT05027412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722294|NCT04537000|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33722295|NCT01351844|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33722296|NCT03239587|||CASE_CONTROL||PROSPECTIVE|||||||
33722297|NCT03488654|||OTHER||PROSPECTIVE|||||||
33722298|NCT01511523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33722299|NCT03997149|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Immediately following each condition, participants were provided with snacks to eat at their leisure. Participants were not told that their post-condition food consumption would be measured and was part of the research study.|Participants completed a stress condition and rest condition in random order.|t|f|f|f
33722300|NCT01498718|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33722301|NCT04595513|NA|SINGLE_GROUP||PREVENTION||NONE||"This trial is a single stage, phase I/II clinical trial design. Treatment is open-label to verify safety and dosing for TAVT-18 in TSC infants.~Note that this clinical trial originally planned for a follow-up second stage employing a randomized, double-blind, placebo-controlled multisite design. In October 2021, the second stage of this study was replaced by the TSC-STEPS clinical trial (clinicaltrials.gov NCT05104983)."||||
33722302|NCT00196560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722303|NCT05947682|NA|SINGLE_GROUP||OTHER||NONE||||||
33722304|NCT05224674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722305|NCT00002233||||TREATMENT||NONE||||||
33803075|NCT04801199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator, patient, study staff, data monitors and database personnel will be blinded to the study treatment.|Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled study|t|t|t|t
33803076|NCT04178889|||COHORT||PROSPECTIVE|||||||
33803077|NCT03270670|||CASE_ONLY||PROSPECTIVE|||||||
33803078|NCT01013584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803079|NCT02357472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803080|NCT01567813|||COHORT||RETROSPECTIVE|||||||
33803081|NCT03351699|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803082|NCT01243814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33803083|NCT03610594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803084|NCT04881175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803085|NCT00739908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803086|NCT02107261|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33803087|NCT00415402|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33803088|NCT00133250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803089|NCT04503772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026579|NCT06010186|NA|SINGLE_GROUP||OTHER||NONE||||||
34104050|NCT02046876|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||f|t|f|t
34104051|NCT05653011|||CASE_CONTROL||PROSPECTIVE|||||||
34104052|NCT03248661|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34104053|NCT06407401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104054|NCT00183612|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104055|NCT06255626|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an open label study. Immunological assessors, only, will remain blinded.|||||
34104056|NCT04559139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104057|NCT01082458||||PREVENTION||||||||
34104058|NCT02773823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104059|NCT06686251|NA|SINGLE_GROUP||OTHER||NONE||"This is a type of stepped wedge cluster randomized clinical trial. In the model standard of this design, interventions are implemented in the clusters randomly and graduate."||||
34104060|NCT02040012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104061|NCT02969226|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33803090|NCT01718600|||COHORT||PROSPECTIVE|||||||
33803091|NCT02932761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104062|NCT04528342|||COHORT||PROSPECTIVE|||||||
34104063|NCT04450212|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a two-phase study. Healthy adults are screened by genetic analysis in phase I and two sub-groups with specific CYP4F2 genotypes (\*1/\*1 and \*1/\*3 or \*3/\*3) are selected to receive vitamin K supplementation in phase II.||||
33803092|NCT03920592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants are unaware of which condition is being tested|"Each participant, depending on their sex, watch two minutes of each video content:~1. Bullying content in virtual reality~2. Bullying content in a regular 2D screen~3. Pupils playing without bullying content in virtual reality~4. Pupils playing without bullying content in a regular 2D screen"||||
34104064|NCT03146793|||COHORT||RETROSPECTIVE|||||||
34026580|NCT03883802|RANDOMIZED|PARALLEL||TREATMENT||NONE||two-arm study, 1 to 1 randomization: treatment group and standard therapy||||
33722306|NCT04532099|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Part A is double masked. Part B is single masked (trial subject).|Part A is a crossover study. Part B is a single group study.|t|f|t|f
33722307|NCT03309358|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This is a multiple-site, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to assess the safety and tolerability of inhaled SNSP113 in healthy subjects (Part A) and subjects with stable CF (Part B).|t|f|t|f
33803093|NCT05770427|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722308|NCT04244188|||COHORT||RETROSPECTIVE|||||||
33803094|NCT03432338|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34026581|NCT03201445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803095|NCT03399604|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will evaluate the long term safety and tolerability of LIQ861 in PAH patients transitioning from stable doses of inhaled treprostinil therapy, or who are taking no more than 2 approved, non-prostacylcin, oral PAH therapies.~Patients transitioning from inhaled treprostinil will be initiated at a comparable dose of LIQ861, and then titrate in 25ug incremental doses to tolerance and symptom relief. Patients adding LIQ861 to current oral therapies will start at a 25ug dose, and increase in 25ug increments on a weekly basis to tolerance and symptom relief.~A subset of the patients transitioning from inhaled treprostinil will be enrolled in a one-directional crossover to compare the bioavailability and pharmacokinetics of treprostinil as they transition to LIQ861. Serial PK sample collections will be taken on back to back days for transitioning and LIQ861 treprostinil formulations. These patients will then continue to be followed as all other patients enrolled in the study."||||
34026582|NCT05931978|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Pre-post study with longitudinal follow up of participants with an additional control group.||||
33803096|NCT01139944|||CASE_ONLY||RETROSPECTIVE|||||||
33803097|NCT00078624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803098|NCT00931710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026583|NCT02766283|||COHORT||RETROSPECTIVE|||||||
34026584|NCT01043224|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34026585|NCT04628897|||COHORT||CROSS_SECTIONAL|||||||
34026586|NCT03047629|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Phase 1 is a single group; Phase 2 will begin subsequent to the safe completion of Phase 1. Phase 2 patients will undergo randomization for parallel study during one period of observation of the course of the study phase.|t|t|t|t
34026587|NCT04036110|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34026588|NCT03350607|||COHORT||PROSPECTIVE|||||||
34026589|NCT03677583|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026590|NCT04898530|||OTHER||CROSS_SECTIONAL|||||||
34026591|NCT04820205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026592|NCT05327985|||COHORT||PROSPECTIVE|||||||
34026593|NCT03476538|||CASE_ONLY||PROSPECTIVE|||||||
34026594|NCT02347150|||COHORT||PROSPECTIVE|||||||
34026595|NCT05173441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026596|NCT02198963|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34026597|NCT01796652|||COHORT||PROSPECTIVE|||||||
34026598|NCT01017796|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34026599|NCT01667237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34026600|NCT06125730|NA|SINGLE_GROUP||OTHER||NONE||||||
34026601|NCT05917600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026602|NCT06088030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026603|NCT02054689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026604|NCT01959295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026605|NCT02646761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026606|NCT03195179|||COHORT||RETROSPECTIVE|||||||
34026607|NCT05727826|NA|SEQUENTIAL||OTHER||NONE|The sample number of the study was calculated with the program named G\*Power 3.1.9.2. The sample size of the study was calculated as 10 in total, with an error of +/-0.5, an effect size of 0.44 calculated for an estimated standard deviation of 1.26, a power of 80% and a margin of error of 5%.|"The research subjects were divided into two groups of five, experimental and control. A random number generator was used to generate the groups. The experimental group received a 60 Hz vibration stimulation treatment using the SMV method three times per week for two weeks (EG). The patients were seated on a chair, with the affected arm fixed so that there was no movement during vibration application. Several tests are used to determine the progression of the EG before and after the vibration protocol. These tests include:~The box and block test (BBT) is used to assess unilateral gross manual dexterity and upper extremity functional abilities, specifically hand and wrist functionality. The Visual Analogue Scale (VAS) is used to assess the severity of pain in patients. It can also be used to track patients' pain progression or to compare pain severity between people who have similar conditions. In the evaluation of light touch and pressure protective senses, a monofilament test is used."||||
33722309|NCT01591876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722310|NCT05095987|NA|SINGLE_GROUP||TREATMENT||NONE||prospective nonrandomized cohort study||||
33722311|NCT05447351|||COHORT||PROSPECTIVE|||||||
33722312|NCT05880810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722313|NCT03879655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722314|NCT02007564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722315|NCT05511883|||CASE_ONLY||RETROSPECTIVE|||||||
33722316|NCT03388294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors at all time points after randomization will be blind to the child's treatment arm allocation. Since parents are being coached as part of the intervention, it is not possible to keep them blind to their treatment arm.|The intervention phases of the study will use a randomized comparative trial design, with two phases. For Study Phase 1, dyads will participate in pretesting; then families will be randomized, stratifying by child age, to one of two treatment arms. Arm 1 families will participate in initial coaching on the PIE sensory reactivity (SR) domain, and Arm 2 families will participate in initial coaching on the PIE prelinguistic communication (PC) domain. Families will participate in 6 weekly coaching sessions in their respective treatment arms, and return for Posttest-1. For Study Phase 2, dyads in Arm 1 will receive 6 weekly coaching sessions on the PC domain, and dyads in Arm 2 will receive 6 weekly coaching sessions on the SR domain. Then families will return for Posttest-2.|f|f|f|t
33722317|NCT02914652|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722318|NCT06018714|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-arm, phase II study aimed at exploring the clinical efficacy and safety of fruquintinib as maintenance therapy for advanced CRC patients who achieve NED after adjuvant chemotherapy. Patients will receive full supportive care while on this study.||||
33722319|NCT02424383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722320|NCT01216579|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33803099|NCT05074316|||OTHER||PROSPECTIVE|||||||
33803100|NCT01308567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803101|NCT05239936|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33803102|NCT00920972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803103|NCT04949503|||COHORT||RETROSPECTIVE|||||||
33803104|NCT01631851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803105|NCT01956552|NA|SINGLE_GROUP||OTHER||NONE||||||
33803106|NCT04810767|||COHORT||RETROSPECTIVE|||||||
33803107|NCT05778526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The investigator and outcomes assessor will be blinded to the study intervention period.||f|f|t|t
33803108|NCT06027489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33803109|NCT01499316|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803110|NCT05057936|||COHORT||PROSPECTIVE|||||||
33803111|NCT01227213|||||PROSPECTIVE|||||||
33803112|NCT04169256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803113|NCT04938752|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803114|NCT00494949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803115|NCT04687293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803116|NCT02892214|||CASE_ONLY||PROSPECTIVE|||||||
33803117|NCT03840902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803118|NCT00039234|RANDOMIZED|||TREATMENT||||||||
33803119|NCT02872480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803120|NCT05111951|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher responsible for data management and analysis of the secondary outcomes will be blinded to group allocation.||f|f|t|f
33803121|NCT04476810|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-comparative, uncontrolled, non-randomized interventional case series. Consecutive patients with medically-treated glaucoma and visually-significant cataract underwent combined surgery. Subgroup analysis of glaucoma subtypes was performed.||||
33803122|NCT03447496|||CASE_CONTROL||PROSPECTIVE|||||||
34026608|NCT03138655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026609|NCT00208845|||COHORT||PROSPECTIVE|||||||
33722321|NCT03054870|NA|CROSSOVER||OTHER||NONE|Independent blinded readers will assess all ventilation scintigraphy images, masked as to subject identity and re-identified with a unique random code number (different code numbers for Xe-133 and Technegas images). The Xe-133 and Technegas images will be read in separate reading sessions in random order.|Subjects will undergo standard of care Xe-133 ventilation scintigraphy per medical needs followed by investigational Technegas ventilation scintigraphy per protocol.||||
33722322|NCT04002596|NA|SINGLE_GROUP||TREATMENT||NONE||ExAblate Neuro Treatment Group||||
33722323|NCT00101907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722324|NCT02981342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722325|NCT04418986|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, parallel two-arm interventional study, the patients were divided into a 1:1 ratio, the study included eyes with visually significant cataract and preoperative corneal regular astigmatism between 0.75 and 2 Diopters undergoing phacoemulsification surgery. They were divided into two groups: controls underwent phacoemulsification with on-axis incision (CCI Group), and patients underwent phacoemulsification with opposite clear corneal incisions (OCCI Group).||||
33722326|NCT01982851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722327|NCT03816059|||COHORT||PROSPECTIVE|||||||
33722328|NCT05584644|||CASE_ONLY||RETROSPECTIVE|||||||
33803123|NCT01746706|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803124|NCT06175520|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Under this model, eligible participants (newlywed married women) from each of the intervention clusters (union catchment area considered as a cluster) will be provided preconception care by community-based healthcare providers. To provide preconception care and counseling the investigators will involve different strategies which include counseling by the Marriage registrar, use of digital platforms to deliver messages, distribution of FP methods, PCC card, and MCH handbook intervention clusters. Overall the intervention components will be evaluated in parallel against a comparison group.||||
33803125|NCT05043805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803126|NCT04842513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803127|NCT00308997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33803128|NCT00990808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803129|NCT05937685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803130|NCT00162422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803131|NCT01851668|||CASE_CONTROL||PROSPECTIVE|||||||
33803132|NCT04049058|||OTHER||PROSPECTIVE|||||||
33803133|NCT00703820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803134|NCT03244449|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34026610|NCT02784041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34026611|NCT00751556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026612|NCT03951324|||OTHER||RETROSPECTIVE|||||||
34026613|NCT05516979|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multi-center, randomized, double-blind, placebo-controlled study with 12 weeks of treatment with AP1189 or placebo|t|f|t|t
34026614|NCT03616145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding. The PI, statistician, recruitment personnel, research assistants conducting the assessment sessions, and data entry/verification clerks will be blind to participant's group assignment until data is unlocked at the end of the study. Only the Project Manager who will develop and oversee the randomization procedure, prepare progress reports, and inform participants of their treatment condition will be unblinded.|The overall design proposed in this study is a randomized, placebo controlled, single-blind controlled trial. Data will be collected in this developmental study to assess potential differences in gait, balance, and quality of life of patients in the intervention arm (6-week OMT intervention coupled with standard of care (SOC) versus the light touch comparator arm (6-week light touch coupled with SOC) versus the non-intervention control arm (SOC alone).|t|f|t|t
34026615|NCT06081179|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blinded|single-center, double-blind, parallel-group, randomized study design|t|f|t|f
34026616|NCT03576079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026617|NCT06550284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026618|NCT06456034|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026619|NCT06052280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This pilot study is designed to assess the feasibility of the integrated multidimensional approach in treating and rehabilitating PD patients in a local clinical setting, both for the Telerehabilitation Exercise (TrE) arm and for the Home Self-Exercise (HSE) arm, by:~1. assessing participants' inclusion/exclusion criteria, testing instruments/procedures, testing data collection method;~2. obtaining preliminary data to estimate sample size for the primary outcome, in both arms;~3. evaluating appropriateness of the consent form, recruitment potentials, and the required number of researchers needed for study management;~4. assessing patients' acceptability of the intervention and their compliance. Secondary objectives are the monitoring of patients' perceived quality of life, and of motor performance and non-motor symptoms through specific rating scales."||||
34026620|NCT06550570|||COHORT||PROSPECTIVE|||||||
34026621|NCT02072603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026622|NCT01987310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026623|NCT05755347|||COHORT||PROSPECTIVE|||||||
34026624|NCT02218554|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34026625|NCT00760734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026626|NCT04293900|||COHORT||PROSPECTIVE|||||||
34026627|NCT04446923|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The samples will be sent to the laboratory with numbers.|Crossover design is used|f|f|f|t
34026628|NCT03551288|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be enrolled in 1 of 3 cohorts; Cohort 1 (Food Effect Cohort), Cohort 2 (Gender Effect Cohort), and Cohort 3 (Age Effect Cohort). Subjects in Cohort 1 will receive a single oral dose of SUVN-911 on Day 1 under fasted or fed conditions and again on Day 8 under fasted or fed conditions (crossover design). Subjects in Cohort 2 and Cohort 3 will receive a single oral dose of SUVN-911 on Day 1.||||
34026629|NCT00561639|||COHORT||PROSPECTIVE|||||||
34026630|NCT03491657|RANDOMIZED|CROSSOVER||TREATMENT||NONE|"Blinding can be challenging in behavioral studies. To help control for demand characteristics, the current study uses an active comparator music distraction vs. the experimental treatment condition immersive virtual reality."|Within-subject design with repeated measures, with random assignment to initial treatment.||||
34026631|NCT03706937|||CASE_ONLY||PROSPECTIVE|||||||
34026632|NCT01960049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026633|NCT01168752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026634|NCT01338870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026635|NCT05968417|||COHORT||PROSPECTIVE|||||||
34026636|NCT06408506|NA|SINGLE_GROUP||TREATMENT||NONE|The positioning and loading protocols of the implants under investigation are blinded to the investigator during the analysis of peri-implant bone heights, which are measured using periodontal probes, as well as during the analysis of intraoperative scans and impressions.|||||
34026637|NCT04332393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026638|NCT05324410|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34026639|NCT04408235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomisation will be centrally performed by using a secure, web-based system, which will be developed by the Methodological and Statistical Unit at the Azienda Ospedaliero-Universitaria of Modena. Randomisation stratified by 4 factors: 1) Gender (M/F); 2) Age (\<75/≥75 years); 3) BMI (\<30/≥30); 4) Co-morbidities (0-1/\>2) with random variable block sizes will be generated by STATA software. The web-based system will guarantee the allocation concealment.|This is a multicentre, randomised controlled, open label, investigator sponsored, two arms study.|f|f|t|f
33803135|NCT04480918|||COHORT||PROSPECTIVE|||||||
33803136|NCT06209684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803137|NCT05831969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803138|NCT03392038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026640|NCT01442688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026641|NCT01736969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34026642|NCT01425411|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026643|NCT04604795|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Parts A and B will be double blind and Part C will be open label.|This is a 3-part study. Parts A and C will have a 5 period crossover design Part B will be conducted as a parallel group dose escalation study.|t|f|t|f
34026644|NCT01455298|NA|SINGLE_GROUP||SCREENING||NONE||||||
34026645|NCT00097032|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34026646|NCT01111825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026647|NCT02976987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026648|NCT01236911|||COHORT||PROSPECTIVE|||||||
34026649|NCT04134338|||OTHER||OTHER|||||||
34026650|NCT05609630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026651|NCT02037386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026652|NCT04528407|||OTHER||PROSPECTIVE|||||||
33803139|NCT00233090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803140|NCT00530569|||||PROSPECTIVE|||||||
34026653|NCT04726176|||COHORT||PROSPECTIVE|||||||
34026654|NCT06113302|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026655|NCT04204538|||OTHER||CROSS_SECTIONAL|||||||
34026656|NCT05678543|||COHORT||PROSPECTIVE|||||||
34026657|NCT03904108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026658|NCT01045135|||COHORT||PROSPECTIVE|||||||
34026659|NCT04575376|||OTHER||RETROSPECTIVE|||||||
34026660|NCT01958073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34026661|NCT00961402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026662|NCT03296878|RANDOMIZED|FACTORIAL||OTHER||NONE||This study will utilize a three factor design, with one between-subject factor and two within-subject factors. The between-subject factor is participation in a federal food assistance program. The within-subject factors are price change condition and price change scenario.||||
33803141|NCT03644849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026663|NCT04594564|||COHORT||PROSPECTIVE|||||||
34026664|NCT00580515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026665|NCT01404286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026666|NCT02379572|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104065|NCT01713829|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34104066|NCT06675305|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34104067|NCT02039206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104068|NCT00185614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104069|NCT02169258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104070|NCT03919019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||monocentric, prospective, double blind randomized six months study|t|f|t|t
34104071|NCT04885530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
34104072|NCT02770365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104073|NCT05474859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 design||||
34104074|NCT05500846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803142|NCT03822234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33803143|NCT00485329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803144|NCT03259516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803145|NCT05222399|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33803146|NCT04694014|||COHORT||PROSPECTIVE|||||||
33803147|NCT01391832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803148|NCT01217905|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33803149|NCT05168085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803150|NCT04154384|RANDOMIZED|PARALLEL||PREVENTION||NONE||There were 121 participants in the single-arm pilot trial of this study where the intervention was refined. The clinical trial portion of this study randomizes participants to receive the intervention or the standard of care.||||
33803151|NCT02387645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803152|NCT02926794|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33803153|NCT06038695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803154|NCT03074617|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33803155|NCT06513975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803156|NCT02280148|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33803157|NCT00496743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803158|NCT05101772|||CASE_ONLY||PROSPECTIVE|||||||
33803159|NCT03617315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients did not know the artificial tear that should be applied. The researcher in charge of processing the results and drawing the conclusions did not know the name of the artificial tears|Contralateral Eye Study|t|f|f|t
33803160|NCT02824458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803161|NCT05786352|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33803162|NCT02446145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803163|NCT05031234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient does not know which treatment is used for the anesthesia|"Single-centre prospective randomised study carried out in two parallel groups of patients undergoing laparoscopic colectomy.~* Group 1: conventional general anaesthesia with morphine~* Group 2: general anaesthesia without opiates"|t|f|f|f
33803164|NCT05099549|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subjects will be enrolled sequentially in cohorts of 3 to 6 subjects into Phase 1/dose escalation. The dose escalation will follow the standard oncology Phase 1 3 + 3 dose escalation design. A minimum of 3 cohorts will be utilized and dose increases will be determined by the Safety Review Committee.~Once RP2D is determined in Phase 1/dose escalation, the Phase 2a/expansion phase will begin enrolling up to 121 subjects."||||
33803165|NCT00004257||||TREATMENT||||||||
33803166|NCT05871658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||the electroacupuncture group (experimental group) and the sham electroacupuncture group (control group)|t|f|f|f
33803167|NCT01661569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803168|NCT04978233|||OTHER||PROSPECTIVE|||||||
33803169|NCT05857020|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Any patient who has been scheduled for a provider visit in the Urology clinic for a diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) who fulfills eligibility criteria will be considered for participation in this study.||||
33839043|NCT04681053|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"All current study participants will be classified into 4 equal groups~: Group (A) received both oral and inhaled ivermectin in addition to the standard of care.~Group (B)received inhaled ivermectin only Group (C) received oral ivermectin in addition to the standard of care, Group (D) received the current standard of care only"||||
33839044|NCT03157297|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34104075|NCT02719574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104076|NCT02529488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104077|NCT05197374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722329|NCT03348345|RANDOMIZED|CROSSOVER||PREVENTION||NONE|A computer system will randomly select participants to be enrolled in the program or waitlisted at both time points.|A computer system will randomly select 100 participants (from 200) to be enrolled in the Eat Breathe Thrive (EBT) intervention group (once a week for two hours) and the other 100 will be wait-listed (WL) for seven weeks. Assessments will be done at week 1 and week 7. At week 7, WL will be enrolled in the 7-week Eat Breathe Thrive program. A second post-test will be given at the end of the second round of Eat Breathe Thrive, administered to those 100 participants only. There will also be three month follow up for all 200 participants.||||
33722330|NCT03255382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722331|NCT04135833|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722332|NCT03169582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||non- inferiority, randomized, crossover, open clinical trial||||
33722333|NCT05540548|||COHORT||PROSPECTIVE|||||||
33722334|NCT01062282|||||PROSPECTIVE|||||||
33722335|NCT02451228|||CASE_ONLY||PROSPECTIVE|||||||
33722336|NCT01301976|||||CROSS_SECTIONAL|||||||
33722337|NCT02245841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722338|NCT00484939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722339|NCT02738047|||OTHER||OTHER|||||||
33722340|NCT03670303|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is limitation of study that at base line data collection and data analysis masking is not possible as investigator has to do herself. Only outcome assessor can be masked to see how many students are using spectacles in intervention group and in control group. he will not be aware about type of groups.|Study will involve two groups intervention group and no intervention (control) group. each group will include two boys and two girls schools. Educational intervention will be given to two boys and two girls schools. Remaining two boys and two girls schools will not receive educational intervention. Simultaneous follow-ups will be carried out in two groups to assess compliance towards spectacles use.|f|f|f|t
33722341|NCT03678532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722342|NCT05783687|||OTHER||PROSPECTIVE|||||||
33722343|NCT00196079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722344|NCT05755009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722345|NCT01265849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722346|NCT03081507|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Study participants will be randomized to an LHW-led small media intervention arm (SM-LHW) or a LHW-led patient navigation plus small media intervention arm (PN-LHW) upon determination of study eligibility and informed consent procedures.||||
33722347|NCT01978665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||RCT study with steroid.|t|f|t|f
33722348|NCT00004733|RANDOMIZED|||TREATMENT||DOUBLE||||||
33722349|NCT05302154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Behavioral: Behavioral guidance Other: Pain assessment Other: Dental anxiety assessment||||
33722350|NCT02921776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722351|NCT00555750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33722352|NCT02838056|NA|SINGLE_GROUP||OTHER||NONE||||||
33722353|NCT06258876|||COHORT||PROSPECTIVE|||||||
33722354|NCT02335164|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33722355|NCT04780854|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33722356|NCT05336474|||COHORT||PROSPECTIVE|||||||
33722357|NCT03191760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722358|NCT06482021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||the study will be designed to compare the effect of extracorporeal shock wave therapy and acetylcholine iontophoresis on microcirculation changes as a possible new therapy for type 2 diabetic peripheral neuropathy.|t|f|f|f
33722359|NCT04508192|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The person performing the strength tests will be blinded to group allocation, and participants will be instructed not to reveal any information about their group allocation. In addition, the physiotherapist supervising the intervention procedures will not be allowed to know the results of the strength measurements of each player.|Randomisation will be performed after baseline strength testing. Participants will be individually randomized to perform either the CA or the SQ exercise protocol. The randomisation sequence will be obtained using an online software (e.g. randomizer.org), and sealed, opaque envelopes containing group allocation will be prepared by an independent person not otherwise involved in the study, and who will be unaware of the baseline strength test results. All participants will be instructed not to perform any additional adductor exercise other than their allocated exercise and to keep their regular training as usual.|f|f|t|t
33722360|NCT01838031|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33722361|NCT02385084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722362|NCT00150839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722363|NCT02411292|NA|SINGLE_GROUP||OTHER||NONE||||||
33722364|NCT00507442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722365|NCT04576611|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722366|NCT06397703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722367|NCT05023746|||CASE_ONLY||RETROSPECTIVE|||||||
33722368|NCT02569216|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722369|NCT03164343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722370|NCT01291056|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33722371|NCT03668938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|masking of outcome assessor to T0||f|f|f|t
33722372|NCT02432846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026667|NCT05012826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To ensure the expectation of treatment is equally balanced between the groups the participants will not be aware of the study hypothesis regarding the between-group comparisons. It is not possible to blind the clinicians regarding the groups and the participants regarding their treatment. The outcome assessor and statistician will be blind to the allocations of groups.|Two-arm, controlled, assessor-blinded, pragmatic randomized controlled superiority trial|f|f|f|t
34026668|NCT03168230|||COHORT||PROSPECTIVE|||||||
34026669|NCT04094727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026670|NCT06324435|NA|SINGLE_GROUP||OTHER||NONE||||||
34026671|NCT02110784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026672|NCT00275119||||TREATMENT||NONE||||||
34026673|NCT05914688|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33722373|NCT06454409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722374|NCT01602809|||||PROSPECTIVE|||||||
33803170|NCT05465382|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Randomization will occur by the opening of pre-prepared envelopes which will be stored in the orthopaedic resident office. Envelopes will be labeled #1-#60. Thirty envelopes will contain a note card labeled Group 1 and Thirty envelopes will contain a note card labeled Group 2. Envelopes will be pre-prepared by key study personnel not involved in the consent or randomization process."|Patients will be randomized into one of two groups: 1) intra-articular saline lavage, vs 2) no intra-articular saline lavage. Intra-articular aspiration of synovial fluid from the injured ankle will occur both at the time of presentation to the emergency department and at the time of surgery.|t|f|f|f
33722375|NCT01741181|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33722376|NCT00991666|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026674|NCT06551831|||OTHER||PROSPECTIVE|||||||
34026675|NCT02939053|||COHORT||PROSPECTIVE|||||||
34026676|NCT02939625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722377|NCT01930851|||COHORT||RETROSPECTIVE|||||||
33722378|NCT04923503|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|subject with random allocation Investigator do not know the group the analysator do not know the group|"three arm parallel group with 45 subjects:~1. fasting in lean group~2. fasting in obese group~3. fasting in diabetics group"|t|f|t|t
33722379|NCT03164928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33722380|NCT01460264|||COHORT||PROSPECTIVE|||||||
33722381|NCT01400516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803171|NCT04987801|||COHORT||PROSPECTIVE|||||||
33803172|NCT02220439|||CASE_CONTROL||PROSPECTIVE|||||||
33803173|NCT05460793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, open, blinded endpoint (PROBE) clinical trial|f|f|f|t
33803174|NCT03700034|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803175|NCT05021341|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind|Randomized, double-blind, crossover study design|t|f|t|f
33803176|NCT00879333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803177|NCT00110552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803178|NCT02376842|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33803179|NCT00402259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803180|NCT01087359|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33803181|NCT04770324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803182|NCT04353232|||COHORT||PROSPECTIVE|||||||
33803183|NCT03891316|||COHORT||PROSPECTIVE|||||||
33803184|NCT05533658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803185|NCT00044564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803186|NCT02747394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803187|NCT01671449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026677|NCT04479644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026678|NCT05238714|NA|SINGLE_GROUP||SCREENING||NONE||||||
34026679|NCT02753920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026680|NCT02137486|||CASE_CONTROL||PROSPECTIVE|||||||
33803188|NCT04027439|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34026681|NCT01689727|NA|SINGLE_GROUP||OTHER||NONE||||||
34026682|NCT01851330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026683|NCT04803305|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-blind, sponsor open for 6-week double-blind treatment period followed by an optional 18-week open-label treatment period.||t|t|t|f
34026684|NCT06223087|||COHORT||PROSPECTIVE|||||||
34026685|NCT01141205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026686|NCT06500208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026687|NCT00609180|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34026688|NCT04244383|RANDOMIZED|FACTORIAL||OTHER||NONE||chronic hepatitis C virus patients||||
34026689|NCT02165878|||COHORT||PROSPECTIVE|||||||
34104078|NCT03111108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104079|NCT02976844|||CASE_CROSSOVER||PROSPECTIVE|||||||
33803189|NCT00537212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803190|NCT01646450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803191|NCT02275611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839045|NCT03265353|RANDOMIZED|CROSSOVER||PREVENTION||NONE||All participants will complete each arm. It is a crossover, randomized design.||||
33839046|NCT00148408|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33839047|NCT05418127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only one representative of sponsor and two Atlantia Clinical Trials representatives are unmasked.|Randomized, double-blinded, placebo-controlled, parallel study.|t|t|t|t
33839048|NCT04210440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839049|NCT00208559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839050|NCT04297332|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33839051|NCT03759782|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label||||
33839052|NCT03112109|||COHORT||PROSPECTIVE|||||||
33839053|NCT02622555|||CASE_ONLY||PROSPECTIVE|||||||
33839054|NCT03617276|||COHORT||PROSPECTIVE|||||||
33839055|NCT00795275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839056|NCT02126852|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839057|NCT04012177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839058|NCT04701723|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study||||
33839059|NCT01913457|||COHORT||PROSPECTIVE|||||||
33839060|NCT05096520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839061|NCT03076905|NA|SINGLE_GROUP||TREATMENT||NONE||Assessment of IV pharmacokinetics||||
33839062|NCT05308394|||OTHER||CROSS_SECTIONAL|||||||
33839063|NCT01863147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839064|NCT02717104|||COHORT||PROSPECTIVE|||||||
33839065|NCT03168542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||While this study utilizes two contact lenses, the purpose was to evaluate the JJVC fitting guide. This was a non-randomized study in which eye care practitioners used the JJVC fitting guide to fit subjects with a study contact lens. Subjects may fit either in a bilateral or a contralateral fashion.||||
34026690|NCT04283019|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|dosing will be double-blind|Participants (N=60), will be randomized to 1 of 3 oral dosing conditions that include: 100mg CBD/3.7mg THC (0.39% THC), 100mg CBD/2.8mg THC (0.3% THC), or 100mg CBD/0mg THC (0.0% THC).|t|f|f|t
33803192|NCT05255835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Investigated knee sleeves appear identical, a printed code reveals to investigator if knee sleeves contains semiconductors (intervention group) or are cotton only (placebo group).~Participants, care provider and outcome assessors are blinded to intervention/placebo grouping."|Randomized controlled trial (RCT)|t|t|f|t
34026691|NCT02842073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026692|NCT02252406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026693|NCT02630979|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34026694|NCT03591497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Cohort study involving cases with use of intervention. Matched control cohort subjects were selected using pre-specified matching criteria (for matching with interventional cohort) as comparison group.||||
34026695|NCT02627651|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34026696|NCT03685422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026697|NCT00553176|||CASE_ONLY||PROSPECTIVE|||||||
34026698|NCT01871571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026699|NCT02008812|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34026700|NCT02851745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026701|NCT05096260|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individually randomized control design: control participants will receive the intervention after completion of the follow-up survey (at six months).||||
34026702|NCT02513030|||COHORT||PROSPECTIVE|||||||
34026703|NCT06611280|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34026704|NCT05461196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026705|NCT04521101|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34026706|NCT05578183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026707|NCT05176444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026708|NCT03417635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026709|NCT04992208|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34026710|NCT03458182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722382|NCT04731987|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|drinks kits will be labelled and packaged according to the pre-established randomization plane by the pharmacy department of University Hospital of Clermont-Ferrand, France. Kits will be distributed in a blind fashion for each cross over period on the basis of the randomization schedule.||t|t|t|t
33722383|NCT02308254|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722384|NCT02671279|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33722385|NCT03375411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722386|NCT00691535|||||OTHER|||||||
33722387|NCT06415422|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722388|NCT01062321|||CASE_CONTROL||PROSPECTIVE|||||||
33722389|NCT01950923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722390|NCT01295515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722391|NCT03057665|||CASE_ONLY||PROSPECTIVE|||||||
33722392|NCT03609515|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A prospective study of service use during a period by a cohort of patients compared to service use by the same cohort during av similar period before inclusion.||||
33722393|NCT01696994|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33722394|NCT02447081|||OTHER||PROSPECTIVE|||||||
33722395|NCT05812976|||COHORT||PROSPECTIVE|||||||
33722396|NCT03797209|||COHORT||PROSPECTIVE|||||||
33722397|NCT01571414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722398|NCT00803868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722399|NCT04407312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722400|NCT03082599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722401|NCT01620073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33722402|NCT02507583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722403|NCT02193373|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33722404|NCT06146933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722405|NCT03698474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722406|NCT06187610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722407|NCT04542135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33722408|NCT04404647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722409|NCT00004984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The oral insulin study was masked, but the parenteral insulin study was not masked||t|t|t|t
33722410|NCT02478554|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33722411|NCT01179477|||CASE_ONLY||PROSPECTIVE|||||||
33722412|NCT03674242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722413|NCT01488903|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33722414|NCT00156455|||||PROSPECTIVE|||||||
33722415|NCT03345589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722416|NCT01173718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722417|NCT03888872|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33722418|NCT02555332|||COHORT||PROSPECTIVE|||||||
33722419|NCT03914560|||COHORT||PROSPECTIVE|||||||
33722420|NCT01379742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722421|NCT04784221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722422|NCT06391736|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33722423|NCT05653544|||COHORT||PROSPECTIVE|||||||
33722424|NCT02738333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722425|NCT05193058|||COHORT||RETROSPECTIVE|||||||
33722426|NCT01288287|||COHORT||PROSPECTIVE|||||||
33722427|NCT02975219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722428|NCT04571710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722429|NCT04025658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biased coin up-and-down design.|t|t|t|t
33722430|NCT02007265|||COHORT||PROSPECTIVE|||||||
33722431|NCT05190380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722432|NCT00403247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722433|NCT00454987|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026711|NCT02793505|||COHORT||PROSPECTIVE|||||||
34026712|NCT04577664|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026713|NCT00194701|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026714|NCT01635816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34026715|NCT02390128|||COHORT||PROSPECTIVE|||||||
33803193|NCT00418613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026716|NCT00212680|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026717|NCT01239108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026718|NCT04379791|||CASE_CONTROL||RETROSPECTIVE|||||||
34026719|NCT06321679|||COHORT||PROSPECTIVE|||||||
34104080|NCT04769778|RANDOMIZED|PARALLEL||PREVENTION||NONE||Treatment with valsartan versus no treatment||||
34104081|NCT06501105|||COHORT||PROSPECTIVE|||||||
34104082|NCT03777215|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34104083|NCT03042975|||COHORT||CROSS_SECTIONAL|||||||
34104084|NCT00484328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104085|NCT05630365|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104086|NCT01584297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104087|NCT04854499|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104088|NCT02278744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803194|NCT03000101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33803195|NCT03079700|||CASE_ONLY||PROSPECTIVE|||||||
33803196|NCT03694691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803197|NCT02481466|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||This is a 2 x 2 factorial design|f|f|t|t
33803198|NCT03681366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double masked design:~The investigator(s) who were responsible for refracting and performing relevant ocular data measurement were masked from the grouping of the subjects.~The unmasked investigator(s) were responsible for group allocation, spectacle-dispensing work, measuring lens visual performance, record keeping, data entry and compliance checking. Data input was carefully checked by the unmasked investigator and the other researchers independently.~The children and their parents were also masked to group allocation until the data analysis was completed."||t|f|t|f
33803199|NCT00290069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803200|NCT03124017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33803201|NCT00624442|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33803202|NCT03427866|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803203|NCT03643055|||CASE_ONLY||PROSPECTIVE|||||||
33803204|NCT02229721|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33803205|NCT00275392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803206|NCT01091649|RANDOMIZED|CROSSOVER||||NONE||||||
33803207|NCT01704053|||CASE_CONTROL||PROSPECTIVE|||||||
33803208|NCT00609297|||COHORT||PROSPECTIVE|||||||
33803209|NCT02378649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803210|NCT04788459|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33839066|NCT00211380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839067|NCT01753726|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33839068|NCT04741594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839069|NCT01464775|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839070|NCT03487965|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Interventions coded, blinded code kept in sealed envelope until study closed|individuals are assigned prospectively to two different interventions according to a protocol, to evaluate the effect of the interventions|t|t|t|f
33839071|NCT02412735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839072|NCT00551330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839073|NCT05370729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33839074|NCT03850977|||COHORT||PROSPECTIVE|||||||
33839075|NCT01522170|||CASE_ONLY||OTHER|||||||
33839076|NCT02571088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839077|NCT00996606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839078|NCT00427570||||TREATMENT||||||||
33839079|NCT05761470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839080|NCT05292872|||COHORT||RETROSPECTIVE|||||||
33839081|NCT00521157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839082|NCT03349502|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, single arm, open-labeled phase 2 trial||||
33839083|NCT00823537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839084|NCT05759351|||COHORT||OTHER|||||||
33839085|NCT02655289|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33839086|NCT06542640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and investigators will be blinded to whether participants at CHR for psychosis are randomized to either the real treatment or to the sham conditions for either of the mb-rt-fMRI-NFB or the rTMS conditions. Similarly, outcomes assessors and clinical care providers will be blinded as well.|The study will consist of two interventions and 2 full assessments, (pre- and post-intervention) (year 1) followed by two clinical/NP/NLP/ERP assessments in years 2 and 3 relative to a CHR's entry to the study. To minimize the time lag between HC's assessment and the last follow-up assessment of the CHR, 50 HC participants will be recruited at the study onset and 50 additional HC will be recruited at years 3 and 4 of the grant. Baseline assessments will be followed by random assignment of CHR subjects to either an intervention group (100 CHR) or sham group (100 CHR). The intervention group will receive either the TMS (50 CHR) or rt-fMRI NFB (50 CHR), with the random CHR assignment to the arm of the study. The sham groups will also be counterbalanced across subjects, with 50 CHR in the TMS-sham and 50 CHR in the rt-fMRI NFB-first group. The two interventions will be delivered over two-week period, followed by post-intervention assessments.|t|t|t|t
33839087|NCT02511444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839088|NCT01264432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839089|NCT01537692|RANDOMIZED|CROSSOVER||||NONE||||||
33839090|NCT03557645|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover Assignment|f|f|t|t
33839091|NCT04192110|NA|SINGLE_GROUP||TREATMENT||NONE||Single group open label initiation or dose increase of loop or thiazide-type diuretics||||
33839092|NCT00360217|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33839093|NCT02857075|||CASE_CONTROL|||||||||
34026720|NCT05443178|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"3 subjects are planned to enter each cohort. No more than 3 subjects will receive the same dose during the dose escalation phase.~3 participants are initially enrolled into the first dose cohort (100mg daily). If there is no DLT observed at Day 30, the investigators enroll 3 additional subjects into the second dose cohort (200mg daily). The targeted maximum dose of Nivaquine® is 300mg (cohort 3).~Development of DLTs in ≥ 1 subject(s) in a specific dose cohort suggests that the RP2D has been exceeded, and further dose escalation is not pursued. In this case, the preceding dose level will be assumed to be the dose level for another 7 participants in the extension part of the study. If in cohort 3, no DLT is observed, an additional 7 participants will receive 300 mg chloroquine daily in the dose extension phase."||||
34026721|NCT06021418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"1. Blind: Participant, Outcomes Assessor~2. Un-blind: Investigator(Care Provider)"||t|f|f|t
34026722|NCT05946499|||CASE_CONTROL||PROSPECTIVE|||||||
34104089|NCT03764033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical evaluators will be kept blind to treatment condition throughout the study period.|The investigators propose to conduct a multi-site, randomized, controlled trial to test the efficacy of an individual treatment for PTSD stemming from moral injury called IOK, compared to a present-centered therapy (PCT) control condition.|f|f|f|t
34026723|NCT01654172|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34104090|NCT04743063|||COHORT||RETROSPECTIVE|||||||
34104091|NCT04118426|||CASE_CONTROL||RETROSPECTIVE|||||||
34104092|NCT06402721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151026|NCT00991783|NA|SINGLE_GROUP||||NONE||||||
34151903|NCT03972956|||CASE_ONLY||PROSPECTIVE|||||||
33722434|NCT00720057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722435|NCT00149123|RANDOMIZED|PARALLEL||||DOUBLE||||||
33722436|NCT05891483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722437|NCT00320983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722438|NCT04300595|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|In the Group G, Local infiltration of 10 ml normal saline at site of skin incision after marking and analgesia was provided by 40 µg/kg nalbuphine loaded in 10 ml syringe IV before skin incision and subsequent injections of 10-20 µg/kg nalbuphine as necessary. The last supplemental bolus of nalbuphine was given at least 30 min before the end of the operation In the Group L, Local infiltration of 10 ml mixture of 20 mg/ml lidocaine and 10 µg/ml epinephrine (instead of saline used in Group G) and normal saline in 10 ml syringe was given IV (instead of nalbuphine used in Group G).|The day before surgery and after obtaining written informed consent and full history taking, all patients were assigned randomly to receive either general anesthesia with intravenous opioids and local infiltration of saline (Group G) or general anesthesia with intravenous saline and local infiltration of a mixture of lidocaine/epinephrine (Group L).|t|t|t|t
33722439|NCT05855668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026724|NCT05810688|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33722440|NCT01524848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722441|NCT00355862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722442|NCT02877823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722443|NCT05064033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized control trial(double-blind)|t|f|t|t
33722444|NCT00495833|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
33722445|NCT06214650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722446|NCT00762242|||CASE_CONTROL||PROSPECTIVE|||||||
33722447|NCT03784885|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33722448|NCT04432051|RANDOMIZED|PARALLEL||OTHER||TRIPLE||patients will be divided into two groups, those with and without ultrasound.|t|t|f|t
33722449|NCT02522286|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33722450|NCT06172764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722451|NCT06429462|||CASE_CONTROL||PROSPECTIVE|||||||
33722452|NCT03806959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||every patient will have both pan-capsule and colonoscopy. comparison intra-group between lesions found by the two examinations.||||
33722453|NCT04176900|NA|SINGLE_GROUP||OTHER||NONE||All patients will have both the rigid and flexible 3D printed boluses made. Each will be used on alternate days during radiation therapy treatments.||||
33722454|NCT04087252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722455|NCT01112852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722456|NCT00687765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722457|NCT01301638|||CASE_ONLY||RETROSPECTIVE|||||||
33722458|NCT00870896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722459|NCT02294344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722460|NCT01947439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722461|NCT00374881|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33722462|NCT00893750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722463|NCT06291142|||CASE_ONLY||PROSPECTIVE|||||||
33722464|NCT03504696|||COHORT||RETROSPECTIVE|||||||
33722465|NCT04571580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722466|NCT00822068|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33722467|NCT05371574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Be in brown envelop|Will receive 100mg of tablet Vitamin C (placebo) and 1gram of intravenous tranexamic acid|t|f|t|f
33722468|NCT03887364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722469|NCT03432741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722470|NCT04249310|||COHORT||RETROSPECTIVE|||||||
33722471|NCT01482247|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33722472|NCT03492216|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|t|f|f
33722473|NCT04010123|||COHORT||PROSPECTIVE|||||||
33722474|NCT04400786|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly divided into the continuous treatment group and the on-demand treatment group.||||
33722475|NCT04178187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803211|NCT06438094|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There are two treatments but they are based on the tooth-level|f|f|t|t
33803212|NCT05308069|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33803213|NCT01300975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151904|NCT00787501|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026725|NCT04752059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026726|NCT05070026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026727|NCT00233402|RANDOMIZED|PARALLEL||||NONE||||||
34026728|NCT02366273|||COHORT||RETROSPECTIVE|||||||
34026729|NCT03086382|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026730|NCT06230406|||OTHER||CROSS_SECTIONAL|||||||
34026731|NCT06632912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026732|NCT01322230|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33722476|NCT03534154|||COHORT||PROSPECTIVE|||||||
34026733|NCT01008735|||COHORT||RETROSPECTIVE|||||||
34026734|NCT04131348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective||||
34026735|NCT04343378|||COHORT||PROSPECTIVE|||||||
34026736|NCT04421235|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34026737|NCT03378752|||COHORT||PROSPECTIVE|||||||
34026738|NCT06413511|NA|SEQUENTIAL||TREATMENT||NONE||||||
34026739|NCT02570594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026740|NCT05999487|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|. Cardiac assessment will be done by a blinded pediatric cardiologist.||f|f|t|f
34026741|NCT00437918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722477|NCT02276729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34026742|NCT06632938|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33722478|NCT02760446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026743|NCT00138554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026744|NCT02101580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026745|NCT01608061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026746|NCT02293980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104093|NCT06168669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigators, clinical teams and subjects will be blinded to the outcomes provided by xBar system. Post operative monitoring will be as per SOC.|All eligible subjects will be assigned with the investigational device.||||
34104094|NCT01621035|||COHORT||PROSPECTIVE|||||||
34104095|NCT05855278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722479|NCT02211573|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722480|NCT02616042|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33722481|NCT03849833|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single-centre, open and non-blinded clinical trial.||||
33722482|NCT02825927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722483|NCT05654155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The auricular acupressure group (AAG) participants received auricular acupressure three times a day for five days every week for three weeks. Using Dr. Huang's ear reflex theory, our AAG intervention included six acupoints (i.e., shenmen, subcortex, heart, kidney, anxious, and neurasthenia points) that have been demonstrated to be effective in improving sleep and emotional stability. Participants in SAG (sham auricular acupressure group) received the same protocol of auricular acupressure as the AAG, but six acupoints were used near the treated acupoints (e.g., sacroiliac, neck, stomach, wrist, tonsil, and tongue), which would have had no effects on participants' sleep and mood status.|t|f|f|f
33722484|NCT01574612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722485|NCT06129721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722486|NCT03519347|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722487|NCT05643040|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group I: Femoral nerve block Group II: Adductor canal block Group III: 4in1 block|t|f|f|f
33803214|NCT01574716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803215|NCT03278873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Follow-up of patients from two separate trials but there is no difference in follow-up assessments for the patients therefore they can be considered a single group"||||
33803216|NCT03598946|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33803217|NCT05558423|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803218|NCT03612375|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
33803219|NCT05838677|RANDOMIZED|PARALLEL||OTHER||NONE||This study is an open-label, two-arm, multicentre, pragmatic cluster randomised controlled feasibility trial.||||
33803220|NCT03063866|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33803221|NCT00832169|NA|SINGLE_GROUP||||NONE||||||
34026747|NCT05369312|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34026748|NCT04207489|||COHORT||PROSPECTIVE|||||||
34026749|NCT02613182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026750|NCT01917916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026751|NCT02607267|||CASE_ONLY||PROSPECTIVE|||||||
34026752|NCT03122977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34026753|NCT01954745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026754|NCT06206135|||COHORT||PROSPECTIVE|||||||
34026755|NCT01102556|||COHORT||PROSPECTIVE|||||||
34026756|NCT06455943|||COHORT||PROSPECTIVE|||||||
34104096|NCT01546987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104097|NCT03918408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized at outset|Treatment of patients with disease|t|f|f|t
34104098|NCT02138188|||COHORT||PROSPECTIVE|||||||
34104099|NCT03692026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||It's a Randomized Clinical Trial|t|f|f|t
34104100|NCT00003067||||TREATMENT||||||||
34104101|NCT02113280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104102|NCT06687187|||CASE_CONTROL||RETROSPECTIVE|||||||
34104103|NCT03992482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722488|NCT04471389|||COHORT||PROSPECTIVE|||||||
33722489|NCT02192255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722490|NCT01629368|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33722491|NCT04098224|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026757|NCT03588546|||COHORT||PROSPECTIVE|||||||
34104104|NCT01485367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104105|NCT04228003|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a single site, prospective, open label, observational, single arm trial in 30 patients with type 2 diabetes with gastrointestinal complaints.||||
34104106|NCT03382171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104107|NCT04424251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104108|NCT02880605|||COHORT||PROSPECTIVE|||||||
34104109|NCT03841474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be assigned to intervention group if they have symptoms of depression, i.e. to control group if they do not show depressive symptoms.~A psychiatrist will then, according to clinical impression, prescribe either sertraline or escitalopram to intervention group (i.e. groups). Both groups (sertraline and escitalopram) will be described as one intervention group."||||
34104110|NCT03115515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104111|NCT06674512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34104112|NCT03410771|||COHORT||PROSPECTIVE|||||||
34104113|NCT05552339|||COHORT||OTHER|||||||
34104114|NCT03376529|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104115|NCT03844815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803222|NCT00467272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803223|NCT05900505|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803224|NCT05246943|||COHORT||PROSPECTIVE|||||||
33803225|NCT05055700|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33803226|NCT05979922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803227|NCT00004559|RANDOMIZED|||PREVENTION||DOUBLE||||||
33803228|NCT03142672|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33803229|NCT05054920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803230|NCT01075152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803231|NCT04794218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33803232|NCT00982917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33839094|NCT00223847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839095|NCT00023998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839096|NCT00284232|RANDOMIZED|PARALLEL||||NONE||||||
33839097|NCT04398121|||OTHER||PROSPECTIVE|||||||
34104116|NCT00526851|||||PROSPECTIVE|||||||
34104117|NCT03059888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151088|NCT06340490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151905|NCT00381030|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151906|NCT05830877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33722492|NCT03822208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722493|NCT06419972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722494|NCT02129387|||CASE_ONLY||PROSPECTIVE|||||||
33722495|NCT05778786|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33722496|NCT04352855|||CASE_CONTROL||RETROSPECTIVE|||||||
33722497|NCT01801644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722498|NCT03439670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722499|NCT05130931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722500|NCT00302042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722501|NCT00798538|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722502|NCT05749575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722503|NCT01687959|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33722504|NCT02526888|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33722505|NCT02355691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722506|NCT02140099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722507|NCT00496093|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722508|NCT03553407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722509|NCT01815125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722510|NCT01352988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722511|NCT01032876|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722512|NCT01848587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722513|NCT05128877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The women included in the study will be divided into 2 groups as experimental and control groups by applying randomization using the random drawing method.|This study is a randomized controlled experimental study.|t|f|f|f
33722514|NCT03498625|NA|SINGLE_GROUP||OTHER||NONE||||||
33722515|NCT05669560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722516|NCT05202743|||CASE_ONLY||PROSPECTIVE|||||||
33722517|NCT01616446|||CASE_ONLY||PROSPECTIVE|||||||
33722518|NCT00945139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722519|NCT00598663|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722520|NCT03712319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind. The type of intervention (presence-based, app or waiting list) can not be masked neither for the participant nor for the intervention provider. Thus, the masking only applies to the assessor of the results.|Randomized, prospective, controlled and single-blind trial of 16 weeks. Students of Medicine, Nutrition, Psychology and Nursing are randomly assigned to the app group, the presential-based MBSR program or a waiting list. Three evaluations take place: pre-intervention, at 8 weeks (post-intervention) and at 16 weeks.|f|f|f|t
33722521|NCT03731520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722522|NCT04919577|||COHORT||RETROSPECTIVE|||||||
33722523|NCT06376747|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients will be randomized into two groups: a group with standard blood sampling technique and a group with closed technique blood sampling by using randomizing software.||f|f|t|f
33722524|NCT01014520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722525|NCT04819087|NA|SINGLE_GROUP||TREATMENT||NONE||It is planned to include patients diagnosed with pelvic floor dysfunction between the ages of 18-65 in the study.||||
33722526|NCT04375189|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722527|NCT02051777|RANDOMIZED|PARALLEL||||NONE||||||
33722528|NCT00295347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722529|NCT00231335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722530|NCT06398054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Upon confirmation of eligibility, subjects will be randomly assigned (with a 1:1 allocation as per a computer generated randomization list with the same number of patients in each group) into one of two treatment arms||t|f|t|f
33722531|NCT00665353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722532|NCT04415632|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34026758|NCT03886883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were blinded to the results of all measurements and naïve to research hypotheses.|This was a randomized, repeated-measures cross-over study. Passive knee extension range of motion was measured three consecutive times with five-minute intervals between measurements. Both groups underwent a static stretch protocol consisting of two bouts of thirty-second constant-angle static stretching of the knee flexors with a one-minute rest between bouts. Subjects were instructed to keep the limb relaxed as the lower leg was passively moved towards extension. Following stretching, the post-stretch measurement was performed. Finally, subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. A Biodex system 4 pro dynamometer was used to quantify range of motion and passive resistive torque. Pressure pain thresholds was assessed using a handheld pressure algometer (Somedic AB, Hörby, Sweden).|t|f|f|f
34026759|NCT03905720|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||2x2 randomized factorial design|t|f|f|f
34026760|NCT06006390|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026761|NCT05264129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026762|NCT01381315|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026763|NCT05758233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|prospective randomize study|Prospective randomize study||||
34026764|NCT05840679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026765|NCT05321368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026766|NCT00124124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026767|NCT00832156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026768|NCT00807716|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34026769|NCT06205329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026770|NCT03495921|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized 1:1 to either Group A (Vigil + irinotecan and temozolomide) or Group B (irinotecan and temozolomide alone). Participants randomized to Group B were able to receive Vigil (Cross-Over) after confirmation of progression by central radiologist and sponsor approval.||||
34026771|NCT00477633|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34026772|NCT04637555|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|This is a multicenter, open-label extension study following-up to PARADISE-MI, which evaluated the efficacy and safety of LCZ696 compared to ramipril, in reducing the occurrence of CV death, heart failure (HF) hospitalization and outpatient HF (time-to-first event analysis) in post-acute myocardial infarction (AMI) patients with evidence of left ventricular (LV) systolic dysfunction and/or pulmonary congestion, without a known prior history of chronic HF. The study duration is up to approximately 24 months with visits at Days -14 to 1, 1, 15, 29 and Months 3, 6, 12, 18, and 24. Participants will receive LCZ696 at maximally tolerated doses with a target dose of 200 mg twice daily at all visits between day 1 and the last visit.||||
34026773|NCT02268578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026774|NCT04760496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"An out-of-protocol healthcare professional (midwife / nurse) will prepare oxytocin. The out-of-protocol healthcare professional (midwife / nurse) will not be a study's investigator, and will not be involved in the patient's care. The randomization group will not be communicated to the investigator or any medical personnel involved in the study or patient by the out-of-protocol nurse/midwife, in order to preserve the double-blind design."|"There is two group of patient for which the prescription of oxytocin is required for the care :~the control group will receive will receive oxytocin at 2 mIU/mL (standard dose) the experimental group will receive oxytocin at 4 mIU/mL"|t|t|t|t
34026775|NCT05184543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026776|NCT04220970|||COHORT||OTHER|||||||
34026777|NCT04600258|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Chocolate group Control Group|t|t|t|t
34026778|NCT06033092|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34026779|NCT06501716|||COHORT||PROSPECTIVE|||||||
34026780|NCT01550679|||COHORT||PROSPECTIVE|||||||
34026781|NCT04999891|||COHORT||PROSPECTIVE|||||||
34026782|NCT00878176||CROSSOVER||SCREENING||NONE||||||
34104118|NCT05609058|NA|SINGLE_GROUP||TREATMENT||NONE||Breast cancer patients with T1-T2N0M0 stage who underwent radiation therapy after conserving surgery were enrolled. Supine and Prone scan sets were acquired during free breathing for all patients. Target volumes and organs at risk (OARs) including heart, ipsilateral lung and bilateral breast were contoured by the same radiation oncologist.||||
34104119|NCT03709030|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomised Controlled Trial||||
34026783|NCT06474208|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34026784|NCT00111553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026785|NCT06509503|RANDOMIZED|PARALLEL||TREATMENT||NONE||We have two groups; the first group will include 200 patients who received COCs, while the second group will receive mechanical contraception We will assess the number of migraine days after three months of treatment and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months and the phenotypic features of migraine in each group||||
34026786|NCT00351455|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026787|NCT00000978||||TREATMENT||||||||
34026788|NCT00396812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026789|NCT01973595|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34104120|NCT04799717|||COHORT||PROSPECTIVE|||||||
34104121|NCT02427204|||CASE_ONLY||PROSPECTIVE|||||||
34104122|NCT04139902|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104123|NCT01943084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104124|NCT01347086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34104125|NCT05546372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104126|NCT04111601|||COHORT||PROSPECTIVE|||||||
34104127|NCT06132308|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34104128|NCT02363426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104129|NCT01055119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34104130|NCT04760236|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34026790|NCT01061268|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026791|NCT06181708|||OTHER||PROSPECTIVE|||||||
34026792|NCT02149147|||COHORT||PROSPECTIVE|||||||
34026793|NCT01261923|NON_RANDOMIZED|PARALLEL||||NONE||||||
34026794|NCT01146756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026795|NCT01902225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803233|NCT05591872|RANDOMIZED|FACTORIAL||PREVENTION||NONE||"2x2 Heparin: Low dose (LD) vs. standard dose (SD) Device type: InnoSEAL + TRBand (I+TRB) vs. TRBand alone (TRB)~Intervention arms:~1. LD+I+TRB~2. LD+TRB~3. SD+I+TRB~4. SD+TRB"||||
34026796|NCT04389957|||COHORT||RETROSPECTIVE|||||||
34026797|NCT03362606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026798|NCT03619265|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||A double-blinded, randomized, placebo-controlled, parallel-arm clinical study design will be used.|t|t|f|t
34026799|NCT00993421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026800|NCT02600533|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026801|NCT04393324|||COHORT||OTHER|||||||
34104131|NCT05274451|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, dose-escalation and -expansion study||||
34148882|NCT04569994|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|"Part 1 will be a placebo-controlled trial in healthy subjects; Part 2 will be an active-controlled trial in subjects with T1D.~Part 3 of this trial, will be an open-label, two-period cross-over, randomised, single dose trial in subjects with T1D."|t|t|t|t
34148883|NCT03813381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803234|NCT02798367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803235|NCT04452318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803236|NCT02190149|||OTHER||PROSPECTIVE|||||||
33803237|NCT02461628|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803238|NCT01307085|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33803239|NCT02515071|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33803240|NCT04987294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects, Investigators and laboratories involved in the conduct of the study will be blinded to subject treatment assignment|Subjects will be randomized 2:1 to receive ALLN-346 or placebo.|t|f|t|f
33803241|NCT00933712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803242|NCT03449173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803243|NCT06520306|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33803244|NCT02596919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803245|NCT03971851|||COHORT||RETROSPECTIVE|||||||
33803246|NCT04929106|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33803247|NCT02448576|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803248|NCT06499766|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Lotions looks the same. Participants, investigators or outcome assessors don't know which lotion (placebo or active ingredient) is used in which arm.||t|f|t|t
33803249|NCT00995696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33803250|NCT00266448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803251|NCT02088372|||CASE_ONLY||PROSPECTIVE|||||||
33803252|NCT02746549|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33803253|NCT01823536|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33803254|NCT04302142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33803255|NCT01121991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803256|NCT06413693|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33803257|NCT04463875|||CASE_ONLY||PROSPECTIVE|||||||
33803258|NCT00405054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803259|NCT06648837|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803260|NCT01260896|RANDOMIZED|CROSSOVER||||NONE||||||
33803261|NCT01235806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803262|NCT01855516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803263|NCT03380013|NA|SINGLE_GROUP||TREATMENT||NONE||Infants recruited for this study are treated with OMT upon completion of hypothermia. They are compared 1:3 with matched historical controls.||||
33803264|NCT03039803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803265|NCT04063514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803266|NCT00281892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803267|NCT02217514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803268|NCT01784744|||CASE_CONTROL||PROSPECTIVE|||||||
33803269|NCT00000777||PARALLEL||TREATMENT||||||||
33803270|NCT06330064|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803271|NCT00568867|||COHORT||PROSPECTIVE|||||||
33803272|NCT06371755|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33803273|NCT04172038|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|8-week and 18-week follow-up assessments will be performed by a research assistant who will be blind to participants' treatment group assignment. Participants will be reminded by the research assistant not to discuss aspects of their treatment during assessments. If a research assistant becomes unblinded during the course of a participants study participation, he or she will not be allowed to conduct additional follow-up assessments. Instances of unblinding during an assessment will be recorded as an unexpected event.|Sequential Multiple Randomization Trial (SMART) comparing the effectiveness and cost-effectiveness of Stepped Care pain management options, examining sequencing, and heterogeneity of effects in pre-specified subgroups.|f|f|f|t
34026802|NCT03988686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026803|NCT01546454|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026804|NCT05517083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026805|NCT06414226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomised Controlled Double-Blinded|t|f|t|f
34026806|NCT05777616|||OTHER||CROSS_SECTIONAL|||||||
34026807|NCT03780660|||COHORT||PROSPECTIVE|||||||
34026808|NCT00425373|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34148884|NCT01936493|||CASE_ONLY||PROSPECTIVE|||||||
34148885|NCT02786680|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34148886|NCT05703594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective methodological study||||
34026809|NCT03999749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148887|NCT04391166|||COHORT||PROSPECTIVE|||||||
34026810|NCT05924269|||CASE_ONLY||PROSPECTIVE|||||||
33722533|NCT03889158|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The vascular response to acute inflammation and oxidative stress is non-invasively assessed in individuals who are young with low fitness, older with low fitness, or older with high fitness.||||
33722534|NCT04500210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Half of the volunteers are given placebo and half of the volunteers are given Turmeric extract|t|t|t|t
33722535|NCT04324060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803274|NCT05129722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomisation allocation will be blinded to all participants, physicians, and study team members, except an unblinded study statistician and study drug manufacturer. All individual, standard, and regulatory approved medications will be over-encapsulated and concealed by identical packaging, labelling, and administration scheduling.|This pilot research project will be a multi-centre, double-blinded randomised control trial (1:1) of the use of a low dose combination polypill (bumetanide 0.5mg + eplerenone 25mg + empagliflozin 10mg) versus empagliflozin 10mg alone on top of their background therapy. There will be 15 patients per arm (n=30 across two sites).|t|t|t|f
33803275|NCT02629679|||COHORT||PROSPECTIVE|||||||
33722536|NCT06502626|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single|Assignment|t|f|f|f
33722537|NCT05268614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803276|NCT03486600|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Trauma patients of both sexes and diagnosed to be in hemorrhagic shock and there is an expected delay in blood and blood products transfusion for more than 40 minutes||||
33803277|NCT04044651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722538|NCT04001881|||COHORT||PROSPECTIVE|||||||
33803278|NCT00707772|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722539|NCT02177279|NON_RANDOMIZED|PARALLEL||||NONE||||||
33803279|NCT04710849|||COHORT||PROSPECTIVE|||||||
33803280|NCT02078232|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33722540|NCT05968807|RANDOMIZED|PARALLEL||OTHER||SINGLE||Waitlist randomized controlled trial|f|f|t|f
33803281|NCT06082635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803282|NCT02379936|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33803283|NCT01296646|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33803284|NCT00691366|||CASE_ONLY||CROSS_SECTIONAL|||||||
33803285|NCT04164784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803286|NCT00401869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803287|NCT01345422|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33803288|NCT05239156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"Sixteen patients will be administered Janesse® 15 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).~Sixteen patients will be administered Janesse® 20 (Cross-linked Hyaluronic Acid) for the treatment of medium-sized facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).~Sixteen patients will be administered Janesse® 25 (Cross-linked Hyaluronic Acid) for the treatment of major facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects)."|This is a multi-center, open-label, non-randomized clinical investigation||||
33803289|NCT03983759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803290|NCT04230200|||COHORT||OTHER|||||||
33803291|NCT04241952|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33803292|NCT02420431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803293|NCT00800579|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33803294|NCT06058585|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The default position within CAPTIVATE is that treatment allocations determined by randomisation will be provided on a blinded basis. Blinding, however, may not always be feasible particularly for behavioural or device-related interventions.|Adaptive platform trial evaluating multiple interventions in multiple domains of therapeutic care. Additional interventions and participants will be added as the trial grows.|t|t|t|t
33803295|NCT05220943|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33803296|NCT01233115|||COHORT||RETROSPECTIVE|||||||
33803297|NCT00971724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803298|NCT06366490|NA|SINGLE_GROUP||TREATMENT||NONE|Open label Phase I trial with no masking|The study is a 2-part design. For each participant, Part 1 will involve tissue procurement and confirmation of the ability to manufacture the Innocell vaccine, followed by Part 2 which is the treatment phase, involving Innocell administration to patients.||||
33803299|NCT06417892|||COHORT||PROSPECTIVE|||||||
33803300|NCT01094626|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803301|NCT00007163||||TREATMENT||||||||
33803302|NCT04255979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled single dosing, dose escalation|t|f|t|f
33803303|NCT06145802|NA|SEQUENTIAL||TREATMENT||NONE||||||
34026811|NCT01761760|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34026812|NCT00315783|||NATURAL_HISTORY||OTHER|||||||
34026813|NCT00536692|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026814|NCT00782704|||||PROSPECTIVE|||||||
34026815|NCT05938504|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34026816|NCT03810326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026817|NCT00085384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026818|NCT01875640|||OTHER||PROSPECTIVE|||||||
34026819|NCT05738044|||CASE_CONTROL||PROSPECTIVE|||||||
34026820|NCT03016819|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Indication D (Leiomyosarcoma, AL3818 vs placebo) of study AL3818-US-004 is double-blinded. Indications A (alveolar soft part sarcoma, single arm with AL3818), B (Leiomyosarcoma, AL3818 vs dacarbazine), C (Synovial sarcoma, AL3818 vs dacarbazine) are open-label.||t|t|t|t
34026821|NCT01883349|||CASE_CONTROL||PROSPECTIVE|||||||
34026822|NCT05577195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148888|NCT04375176|||CASE_ONLY||PROSPECTIVE|||||||
34148889|NCT04369508|||CASE_ONLY||PROSPECTIVE|||||||
34148890|NCT02995551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34148891|NCT04056780|||COHORT||PROSPECTIVE|||||||
33722541|NCT01627821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722542|NCT04699409|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722543|NCT05516433|||COHORT||PROSPECTIVE|||||||
34026823|NCT06174467|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||"Elementary school students from public schools (N = 600) will be invited to participate in the Learning for Hearts and Minds Training.~Inclusion criteria: being students of the 4th and 5th years of elementary school I.~Exclusion criteria: not having both terms signed (free and informed consent by those responsible and assent by the students). The student is undergoing neurological or psychiatric treatment (in this case, students will be invited to participate in the training, but will not be included in the study sample). The teacher responsible for the classroom is undergoing neurological or psychiatric treatment, or has a condition that prevents him from applying the TACM. The teacher in charge did not sign the free and informed consent form for their participation."|t|f|f|f
34026824|NCT05786664|||CASE_ONLY||PROSPECTIVE|||||||
34026825|NCT00669084|||||PROSPECTIVE|||||||
34026826|NCT00535405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026827|NCT02767986|||CASE_ONLY||CROSS_SECTIONAL|||||||
34026828|NCT05645952|||COHORT||OTHER|||||||
34026829|NCT06065215|||COHORT||PROSPECTIVE|||||||
33803304|NCT02097381|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026830|NCT04831424|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants will undergo TSST and have samples With DNA collected (blood plasma and serum, purified leukocytes, saliva, urine, buccal epithelial cells, hair are stored).||||
34026831|NCT01644630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026832|NCT00588458|NA|SINGLE_GROUP||||NONE||||||
34026833|NCT01967914|||COHORT||PROSPECTIVE|||||||
34026834|NCT00176618|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34026835|NCT05817682|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026836|NCT04439617|||CASE_CONTROL||PROSPECTIVE|||||||
34026837|NCT06634095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Outcomes Assessor)|Experimental, randomised controlled, single-blind study|t|f|f|t
34026838|NCT00451048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026839|NCT01509703|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026840|NCT04759768|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34026841|NCT02735785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34026842|NCT02022748|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026843|NCT06173271|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34026844|NCT00936247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34026845|NCT02015065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803305|NCT02189434|||CASE_ONLY||PROSPECTIVE|||||||
33803306|NCT02436174|||COHORT||PROSPECTIVE|||||||
33803307|NCT01154387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803308|NCT05859945|||CASE_CROSSOVER||PROSPECTIVE|||||||
34026846|NCT06456905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026847|NCT06142318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026848|NCT00242632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026849|NCT03138590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||participants will be randomly assigned to one of 2 groups: (1) active tDCS (2) sham tDCS|t|f|f|t
34026850|NCT02458209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34026851|NCT01890447|||COHORT||CROSS_SECTIONAL|||||||
34026852|NCT05110820|||COHORT||PROSPECTIVE|||||||
34026853|NCT05296863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026854|NCT04445597|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026855|NCT02633748|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34026856|NCT01097512|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026857|NCT05848947|NA|SINGLE_GROUP||OTHER||NONE||||||
34026858|NCT05746598|||CASE_CONTROL||PROSPECTIVE|||||||
34026859|NCT01534130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026860|NCT01319500|||||RETROSPECTIVE|||||||
34026861|NCT04648800|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Due to trial blindness, the team (a doctor and nurse) participating in visits 2 (V2) and 3 (V3) (as unblinded staff) is excluded from further contacts with trial subjects and from participating in the trial.~After the visit, the investigator enters its results into the medical documentation and the e-CRF system.~In the medical records of visit 3 (written and electronic), the result of randomization is not disclosed.~After visit 3, the division of subjects into Groups II and III (randomisation) is recorded only in separate written records; the physician participating in visit 2 and 3 sends the documentation to the leading centre after the end of visit 3, where it is stored and fully protected against access of blinded personnel.~The subject must not be informed about the group he/she belongs to."|"* Running the RT 23 test (visit No.2 - V2)~* RT23 test reading and BCG -10 vaccination (visit No. 3-V3):~Positive subjects:~1. assigned to Group I, not randomised and not vaccinated against tuberculosis~2. when the RT23 test indicates a strongly positive result /induration diameter \> 15 mm/, the subject is informed to contact his/her family doctor to obtain a referral to a pulmonary outpatient clinic~Negative subjects:~1. undergo a physical examination before vaccination performed by the doctor (investigator)~2. are remotely randomised by the e-CRF IT system to Group II receiving BCG-10 or to placebo Group III (control). The subject must not be informed about the group he/she belongs to receive BCG-10 or a placebo"|t|f|t|t
34026862|NCT04314895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026863|NCT04775615|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Multi-dose, dose escalation study in healthy subjects.|t|t|t|t
33803309|NCT03818100|||COHORT||PROSPECTIVE|||||||
33803310|NCT02731599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803311|NCT02023346|||COHORT||PROSPECTIVE|||||||
33803312|NCT04527094|||COHORT||PROSPECTIVE|||||||
34026864|NCT02394093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026865|NCT06239857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026866|NCT05258903|RANDOMIZED|PARALLEL||OTHER||DOUBLE|randomization after general anesthesia induction, or deep sedation in PICU|Non-inferiority randomized trial|t|f|f|t
34026867|NCT00253721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026868|NCT00768547|||COHORT||PROSPECTIVE|||||||
34026869|NCT04617912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026870|NCT04877457|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization and blinding will be employed to minimize bias in treatment assignment and to provide the basis for valid statistical inference.||t|t|t|t
34026871|NCT05976165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026872|NCT06034782|||OTHER||OTHER|||||||
33722544|NCT00712829|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34026873|NCT04928768|||OTHER||CROSS_SECTIONAL|||||||
33722545|NCT01975909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33722546|NCT03852550|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Embedded experimental model design, embedding a qualitative component within the randomized controlled trial (RCT). Randomization will be stratified by region with a 1:1 allocation ratio for patients: intervention group (receiving MyREADY Transition\[TM\] BBD App intervention) or control group (continuing with usual care). The unit of randomization is the patient, using variable block randomization with block sizes of 2, 4, 6 and 8.||||
33722547|NCT02558712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026874|NCT00368017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722548|NCT05955118|||CASE_CONTROL||PROSPECTIVE|||||||
33722549|NCT03809507|||OTHER||PROSPECTIVE|||||||
34026875|NCT01971437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026876|NCT06141603|||CASE_CROSSOVER||PROSPECTIVE|||||||
34026877|NCT03939663|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34026878|NCT00030225|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026879|NCT05191537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026880|NCT00360087||||TREATMENT||||||||
34026881|NCT06040151|||COHORT||PROSPECTIVE|||||||
34026882|NCT00157924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026883|NCT06468436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34026884|NCT04290143|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Both medical water and tap water will be colored. The temperature and the pH of the tap water will be adjusted to the temperature pH of the healing water.|double blind study for testing a placebo development method|t|t|f|t
34026885|NCT06633783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026886|NCT00900822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026887|NCT01529710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026888|NCT01775189|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34026889|NCT02814890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026890|NCT05052476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026891|NCT06091670|||OTHER||CROSS_SECTIONAL|||||||
33722550|NCT02289976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34026892|NCT01480362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Wound photographs are analysed by blinded outcome assessors||f|f|f|t
34104132|NCT05240924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Immediately following the baseline assessment, Veterans who meet inclusion criteria will be randomized to either ERP or stress management training. Randomization will be conducted by the study biostatistician. Given that one of the primary reasons ERP must be tested in the Veteran population specifically is the potentially confounding role of comorbid PTSD, allocation to ERP or stress management training will be stratified by the presence or absence of PTSD in order to ensure 50% comorbid PTSD in each group. Block randomization with randomly selected block sizes will be carried out to ensure that the outcome assessor is masked to condition.|A hybrid type 1 effectiveness-implementation trial evaluating the effectiveness of ERP in Veterans while also assessing the implementation context. This two-arm, participant-level randomized trial will compare ERP to a stress management training control. All participants will receive treatment via video telehealth (VTH). Because one of the primary unanswered questions is whether ERP is effective in individuals with comorbid PTSD, the investigators considered only testing ERP in patients with comorbid PTSD. However, given that the investigators could find no published treatment trials of OCD in Veterans, or trials of OCD delivered via VTH, the investigators believe the effectiveness of ERP in this population must also be tested. Effect sizes in the OCD-only group will serve as comparators for those in the OCD+PTSD group. Implementation context will be evaluated using a mixed-methods formative evaluation guided by the RE-AIM Quest framework.|f|f|f|t
34104133|NCT03255200|||COHORT||PROSPECTIVE|||||||
34104134|NCT01793454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34104135|NCT02667561|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34104136|NCT06679517|||COHORT||PROSPECTIVE|||||||
34104137|NCT03063164|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eye to eye comparison||||
34148892|NCT02450968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148893|NCT02679365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34148894|NCT05219019|||OTHER||PROSPECTIVE|||||||
34151907|NCT03437707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, Randomized, Placebo-Controlled Clinical Trial|t|f|f|f
34151908|NCT00254891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722551|NCT02672423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722552|NCT06523036|NA|SINGLE_GROUP||OTHER||NONE||||||
33722553|NCT06001554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33722554|NCT00003010|RANDOMIZED|||TREATMENT||||||||
33722555|NCT05757947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722556|NCT03388619|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33722557|NCT05353127|||COHORT||RETROSPECTIVE|||||||
33722558|NCT00229255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722559|NCT01287273|||COHORT||PROSPECTIVE|||||||
33722560|NCT04734509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722561|NCT02563795|||CASE_CONTROL||PROSPECTIVE|||||||
33722562|NCT01061242|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722563|NCT01423344|||||PROSPECTIVE|||||||
33722564|NCT06242587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722565|NCT04327232|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33722566|NCT02280564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722567|NCT00383149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722568|NCT00913367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026893|NCT05026827|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34026894|NCT02480348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026895|NCT05410587|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter prospective interventional clinical investigation||||
34026896|NCT00002200||||TREATMENT||||||||
34104138|NCT05463887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"With the exception of the study biostatistician(s) and a safety assessor(s), all Co-Investigators participating in the randomized trial will be blinded to outcomes and safety events by study arm.~The nature of the randomized trial requires interaction with participants throughout the study (e.g., ongoing feedback from intervention arm providers, qualitative interviews with patients and providers), the assignment of participants to the intervention vs. control arm will be unblinded for the entire study team. Only the stratification of outcomes and safety events by study arm will be blinded."|parallel, partially-blinded, 1:1 allocation ratio.|f|f|t|f
33722569|NCT04225299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722570|NCT06253611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722571|NCT03176992|RANDOMIZED|PARALLEL||TREATMENT||||||||
33722572|NCT02045797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722573|NCT02681120|||CASE_CONTROL||PROSPECTIVE|||||||
33722574|NCT03525210|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722575|NCT05114616|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33722576|NCT02596594|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Intraumbilical amino acid and glucose suplementation of human fetuses with a severe IUGR via a subcutaneously implanted port system|t|f|f|f
33722577|NCT02205333|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722578|NCT00281684|RANDOMIZED|PARALLEL||TREATMENT||||||||
33722579|NCT04979741|||COHORT||PROSPECTIVE|||||||
33722580|NCT00372931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722581|NCT05537077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722582|NCT05693714|||CASE_CONTROL||PROSPECTIVE|||||||
33722583|NCT03165110|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722584|NCT01617915|||COHORT||PROSPECTIVE|||||||
33722585|NCT00459173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722586|NCT05488691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722587|NCT04481633|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722588|NCT01165255|||COHORT||RETROSPECTIVE|||||||
33722589|NCT01819454|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33722590|NCT02164747|||CASE_CONTROL||PROSPECTIVE|||||||
33722591|NCT03432546|||COHORT||PROSPECTIVE|||||||
33722592|NCT00636909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722593|NCT00003573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722594|NCT03946033|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Immunoscore Colon Test Result will be disclosed in Multidisciplinary Meeting only after the first therapeutic decision|||||
33722595|NCT05132959|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33722596|NCT01565109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722597|NCT04823637|||OTHER||OTHER|||||||
33722598|NCT02207790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722599|NCT01254227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722600|NCT04972084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104139|NCT04122690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||PDAE compared with WAE||||
33722601|NCT05559255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Thirty individuals with pain and spasticity after SCI will undergo the counterstrain manual manipulative treatment three times per week for four weeks. Pre and post program measures for pain, spasticity, and quality of life will be performed.||||
33722602|NCT06110429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective open randomized single center study comparing Sodium lactate (SL) to Hypertonic Saline Solution (HSS) in brain injured adult ICU|t|f|f|f
33722603|NCT06371404|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33722604|NCT03852303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized clinical trial|f|t|t|t
33722605|NCT04608786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722606|NCT02062333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722607|NCT01962129|||CASE_ONLY|||||||||
33722608|NCT00072618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722609|NCT00101114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722610|NCT00631527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722611|NCT05215301|||OTHER||CROSS_SECTIONAL|||||||
33722612|NCT00003752|RANDOMIZED|||TREATMENT||||||||
33722613|NCT00954902|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33722614|NCT03722550|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Unique coding of the study products||t|t|t|t
33722615|NCT02786147|||COHORT||PROSPECTIVE|||||||
33722616|NCT04853745|||OTHER||OTHER|||||||
33722617|NCT00805623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722618|NCT01958775|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33722619|NCT00103181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722620|NCT05077592|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|A statistician not directly involved in the study or analysis will prepare a computer-generated randomization sequence. No blocking will be used. The sequence will be provided to the trialists in the form of serially numbered opaque envelopes containing details of either the intervention or the control and a random identifier.||t|f|t|t
33722621|NCT01980355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722622|NCT02144233|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722623|NCT00994240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722624|NCT02781532|||COHORT||PROSPECTIVE|||||||
33722625|NCT06362187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, controlled|t|t|t|t
33722626|NCT00134160|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722627|NCT00491010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33722628|NCT05384067|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention and control group||||
33803313|NCT03190850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator will not know the final result of the tests performed until the end of the study||f|f|t|f
33803314|NCT01218490|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803315|NCT01995903|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722629|NCT04243187|NA|SINGLE_GROUP||OTHER||NONE||"10 subjects, 8 visits, once a week, for bean intake (80 grams of dried beans, soaked for 12 hours, cooked in new water for 1.5 - 2 hours. This is approximately 160 grams of cooked beans).~Four varieties of beans (3 native and 1 commercial) will be analyzed, which will be consumed by duplicate for participants (8 visits).~A ninth visit will be made to perform a exhaled hydrogen test with raffinose (5 grams), as a positive control."||||
34026897|NCT01449370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026898|NCT02286258|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34026899|NCT00327795|||CASE_CONTROL||RETROSPECTIVE|||||||
34026900|NCT01823432|||COHORT||OTHER|||||||
34026901|NCT03389815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026902|NCT00641225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026903|NCT02594670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026904|NCT05790603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|One of the primary outcome of radial artery occlusion will be assessed by masking the assessor. The data analyzers will also be blinded.||f|f|f|t
34026905|NCT00424229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026906|NCT00755443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34026907|NCT04217616|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34026908|NCT01178528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026909|NCT02643667|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34026910|NCT04831359|||COHORT||PROSPECTIVE|||||||
34026911|NCT03782324|||CASE_ONLY||PROSPECTIVE|||||||
34026912|NCT05465655|NA|SINGLE_GROUP||OTHER||NONE||||||
34026913|NCT01947998|||COHORT||PROSPECTIVE|||||||
34026914|NCT01859910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34026915|NCT04554940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026916|NCT06067503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34026917|NCT06633380|RANDOMIZED|CROSSOVER||PREVENTION||NONE||5-arm randomized crossover trial||||
34026918|NCT02698033|||COHORT||PROSPECTIVE|||||||
34026919|NCT03443830|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Time Lagged, Parallel-Group, Single Ascending Dose Study||||
34026920|NCT06633120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026921|NCT02679638|||CASE_ONLY||CROSS_SECTIONAL|||||||
34026922|NCT02237703|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34026923|NCT06418516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment A prospective cohort study||||
34026924|NCT01740050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026925|NCT01791270|||CASE_CONTROL||PROSPECTIVE|||||||
34026926|NCT06467110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026927|NCT00998868|||CASE_ONLY||CROSS_SECTIONAL|||||||
34026928|NCT04322565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026929|NCT00555152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104140|NCT06294431|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on their gender assigned at birth and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.|t|f|t|f
34104141|NCT02471677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722630|NCT00727974|||OTHER||PROSPECTIVE|||||||
34026930|NCT00754546|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34026931|NCT06571513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34026932|NCT03596138|||OTHER||PROSPECTIVE|||||||
34026933|NCT06173856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026934|NCT01708967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026935|NCT02803658|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34026936|NCT04817020|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Randomize,controlled double-blind clinical trials|t|f|t|f
34104142|NCT03725319|||COHORT||RETROSPECTIVE|||||||
34104143|NCT03275831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104144|NCT05422157|||CASE_CONTROL||PROSPECTIVE|||||||
34104145|NCT02094885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104146|NCT00532415|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34104147|NCT03288259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104148|NCT00306280|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026937|NCT02483546|RANDOMIZED|PARALLEL||||NONE||||||
34026938|NCT04533997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Based on an automated online system, blinded to the physicians who evaluated the patient.~Randomization was performed by a trained nurse in a separate room"|Randomization 1:1 to treatment with a 1-hour infusion of IV furosemide plus HSS (2.6-3.4% NaCl depending on plasmatic sodium levels) versus a 1-hour infusion of IV furosemide at the same dose (125-250 mg, depending on basal loop diuretic dose).|t|t|t|t
34026939|NCT06006377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||conventional physiotherapy and backup device therapy|f|f|f|t
34026940|NCT02478203|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34026941|NCT04032717|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Arm 1 will enroll 3 participants to receive the open-label Q-GRFT enema. The remaining 18 participants will be randomized 2:1 (Q-GRFT enema: placebo enema) resulting in twelve participants enrolled into Arm 2 and six participants enrolled into Arm 3. The randomization scheme will be generated by the statistical group.|randomized, double-blind|t|t|t|t
34026942|NCT00093275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026943|NCT00003302||||DIAGNOSTIC||||||||
34026944|NCT05961501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026945|NCT04024930|||CASE_CONTROL||RETROSPECTIVE|||||||
34026946|NCT01692366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026947|NCT03977714|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34026948|NCT05204498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34026949|NCT04362553|||COHORT||PROSPECTIVE|||||||
34026950|NCT04879680|||CASE_ONLY||RETROSPECTIVE|||||||
34026951|NCT02813980|||COHORT||PROSPECTIVE|||||||
34026952|NCT02296931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104149|NCT05223829|NA|SINGLE_GROUP||TREATMENT||NONE||This project is a Phase 1 (open-label, single arm, proof of concept) laboratory design. It will investigate the feasibility and safety of administering brexanolone to men and women and collect preliminary data to understand brexanolone's efficacy to reduce stress-induced drinking in individuals with PTSD/AUD.||||
34104150|NCT04535362|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|The cigarette condition is unblinded but the nicotine infusion is blinded to participant|subjects will be unblinded to smoking menthol or non menthol for two weeks before each test session. Each session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes. Once the participants complete the test session, participants will be crossed-over to the alternative treatment.|t|f|f|f
33722631|NCT03928847|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Open Label|||||
33803316|NCT04689178|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33803317|NCT01868399|||COHORT||PROSPECTIVE|||||||
33803318|NCT02317783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803319|NCT01412736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803320|NCT02766946|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803321|NCT06127147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803322|NCT00167765|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33722632|NCT02440477|||COHORT||OTHER|||||||
33803323|NCT00000587|RANDOMIZED|||TREATMENT||DOUBLE||||||
33803324|NCT05383599|||OTHER||PROSPECTIVE|||||||
33803325|NCT00476463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803326|NCT02380105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803327|NCT01859559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803328|NCT01065506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803329|NCT00378300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803330|NCT03640403|RANDOMIZED|PARALLEL||PREVENTION||NONE||"A randomized, controlled, open label study assessing the effectiveness and safety of 2 antimalarial drugs for IPTsc, namely DP and ASAQ by a 3-arm trial using a balanced block design with the standard of care arm as reference."||||
33803331|NCT03273894|||COHORT||PROSPECTIVE|||||||
33803332|NCT01057433|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33803333|NCT04095884|||COHORT||PROSPECTIVE|||||||
33803334|NCT04303377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803335|NCT04826978|||COHORT||PROSPECTIVE|||||||
33803336|NCT04777383|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Iontophoresis of vasoactive substances in 5 different concentrations. Each concentration is administrated 3 times to the same localisation.||||
33803337|NCT00192946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803338|NCT00858650|||COHORT||PROSPECTIVE|||||||
33803339|NCT01020643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803340|NCT02374463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803341|NCT05485532|||COHORT||PROSPECTIVE|||||||
33803342|NCT04072419|||COHORT||PROSPECTIVE|||||||
33803343|NCT01939899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803344|NCT02901522|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33803345|NCT05948449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026953|NCT04114487|RANDOMIZED|CROSSOVER||OTHER||NONE||The 45-person study group will be randomized to 3 groups of 15 persons each. The first group will not be subjected to any application except education. The second group will be the control group and will be taken to the balance training in addition to normal education. In the third group, dual task balance training will be applied within the scope of cognitive rehabilitation.||||
34026954|NCT01589497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026955|NCT00385008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026956|NCT05593419|||COHORT||PROSPECTIVE|||||||
34026957|NCT06434623|||OTHER||OTHER|||||||
33722633|NCT01402674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722634|NCT03169673|||COHORT||CROSS_SECTIONAL|||||||
33722635|NCT05024058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722636|NCT04645407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722637|NCT01908257|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722638|NCT05306301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722639|NCT04500834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will be tested with 11 experimental metal allergens and corresponding metal allergens prepared in petrolatum||||
33722640|NCT05328128|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803346|NCT01596296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803347|NCT02576275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803348|NCT04025164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803349|NCT01691079|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33803350|NCT06234956|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33803351|NCT06394206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33803352|NCT00982644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803353|NCT05792293|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blind||t|f|f|f
33803354|NCT01323686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803355|NCT03894566|||COHORT||PROSPECTIVE|||||||
33803356|NCT04971070|||COHORT||RETROSPECTIVE|||||||
33803357|NCT05063045|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A quasi-experimental design using experimental and control group but without random assignment||||
33803358|NCT05150106|||CASE_CONTROL||PROSPECTIVE|||||||
33803359|NCT06593938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803360|NCT03200808|NA|SINGLE_GROUP||TREATMENT||NONE||Pations with nonneoplastic epithelial disorders（NNEDS） of vulva.||||
33803361|NCT05681234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803362|NCT01746641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803363|NCT01715194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803364|NCT04827524|||COHORT||PROSPECTIVE|||||||
33803365|NCT00687219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803366|NCT06318507|||CASE_ONLY||PROSPECTIVE|||||||
34026958|NCT03126500|||OTHER||CROSS_SECTIONAL|||||||
33803367|NCT03471585|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"A lab member that knew the design of the study but was not running participants sorted placebo and THC capsules into bags labeled first capsule and second capsule for each participant."|Half of the participants will receive placebo during the second session in the first experimental arm and THC during the second session in the second experimental arm. The other half of participants will receive THC during the second session in the first experimental arm and placebo during the second session in the second experimental arm.|t|f|t|f
33803368|NCT04667858|||COHORT||PROSPECTIVE|||||||
33803369|NCT02097394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803370|NCT05124613|||COHORT||CROSS_SECTIONAL|||||||
34026959|NCT05884684|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A spine physician will not discuss images with the first group of participants immediately following their procedure. A spine physician will discuss images with the second group of participants immediately following their procedure.||||
34026960|NCT01249573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026961|NCT05640960|||CASE_ONLY||RETROSPECTIVE|||||||
34026962|NCT04844944|||COHORT||PROSPECTIVE|||||||
34026963|NCT00221377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34104151|NCT06673797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will get separate treatment protocol and possible efforts will be put to mask the both groups about the treatment.|It will be randomized controlled trial in which non probability convenient sampling will be used two groups of ages 5-8 age will be formed in which participants will be randomly divided group A will be receive effects of swiss ball exercises and group B will receive Frenkel exercises on both dynamic and static balance.|t|f|f|f
33722641|NCT03683758|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Participants from both teams will be aware of whether or not they received the intervention warm-up since the intervention warm-up would be a deviation from what each team typically performs for a warm-up.~Investigator, Dr. Matt Wentzell is not blinded to which group is receiving the intervention warm-up since he will be leading the warm-up over the 8-week period.~The three trained assistants will be performing the performance pre- and posttesting. They will be blinded to the group each player has been allocated to.~Any study member that is not blinded will not be performing the pre- and posttesting."|"A parallel, two-group, pre-post comparative trial is proposed for this study. Two soccer teams comprise the convenience sample. One team (Impact) will be allocated to the control group while the other team (Hearts) are allocated to the intervention group. Participant allocation is premeditated due to Dr. Matt Wentzell's regular paramedical involvement with the Hearts and therefore his ability to oversee and administer the intervention warm-up. The control warm-up will be run by the coaching staff of the control group.~Performance pre-testing will be performed by three trained assistants one week after the 2018/2019 soccer season begins. Tests will be performed three times with the best test score being recorded.~Both groups will then complete their assigned warm-up three times per week for eight weeks. Both groups will complete posttesting within three days of the trial period concluding in a fashion identical to that of the pre-testing session."|f|f|f|t
33722642|NCT03756688|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The provider and outcome assessor will be blinded to the patient's study arm for all length assessments. Additionally, the assessor will be blinded to prior length measurements.|"Patients will be randomized into one of four groups:~1. Penile Traction Therapy (PTT) for 30 min 2x/day x 3 months, followed by no treatment x 3 months~2. PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months~3. PTT for 30 min 2x/day x 6 months~4. Control (no treatment)"|f|t|t|t
33722643|NCT04804943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722644|NCT00561756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722645|NCT06071442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722646|NCT05772936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722647|NCT01109199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722648|NCT05196009|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722649|NCT02397421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722650|NCT05501184|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33722651|NCT02115711|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33722652|NCT05180214|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33722653|NCT01558388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722654|NCT01701843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722655|NCT05135520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Transvaginal specimen extraction vs Transabdominal specimen extraction|f|t|t|f
33722656|NCT05301296|RANDOMIZED|PARALLEL||SCREENING||NONE|Cancer registry staff members blinded to study group assignments collected data on the date of diagnosis, stage, treatment and follow-up details of breast cancer patients by visiting hospitals and laboratories where breast cancer cases are diagnosed and treated. The cause of death was assessed by two independent experts blinded to group allocation after evaluation of data from hospital records, death certificates, house visits and interviews of relatives and friends.|The control group received standard of care while the intervention group received 3 rounds of screening with clinical breast examination, each 3 years apart. After the 3 rounds of screening, the participants were followed up for an additional 4 years to accrue information on breast cancer incidence and mortality, and the vital status.||||
33722657|NCT05016557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33722658|NCT03921697|||COHORT||PROSPECTIVE|||||||
33722659|NCT06287528|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803371|NCT04295382|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33803372|NCT02672891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803373|NCT02031185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803374|NCT00005974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803375|NCT05808595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803376|NCT02229812|||COHORT||RETROSPECTIVE|||||||
33803377|NCT01623908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803378|NCT06376552|||COHORT||RETROSPECTIVE|||||||
33803379|NCT02426138|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34026964|NCT03249831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026965|NCT02374138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34026966|NCT00315887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026967|NCT02304666|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33803380|NCT06248229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the unblinded pharmacist will be aware of the subject's assigned group for the duration of the study.|"8-week single center, randomized, double-blind, placebo-controlled, flexible titration trial evaluating the efficacy of Dyanavel (Dyanavel XR) XR in the treatment of fatigue symptoms in adult subjects with a diagnosis of ADHD. Subjects will be randomly assigned (1:1) to a Dyanavel (Dyanavel XR) XR (flexible titration dosing) group (n = 22 to 25) or placebo group (n = 22 to 25). The study will utilize an intent to treat model and impute data, if statistically feasible, from dropouts utilizing a MNAR (missing not at random) approach.~50 subjects qualifying for a ADHD diagnosis with co-occurring clinically significant fatigue symptoms will be randomized into the trial in two groups to ensure a minimum of 44 subjects completing the trial ( 25 per group, 10% hypothesized attrition rate)."|t|t|t|t
33803381|NCT01284920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803382|NCT02011854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803383|NCT05326971|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathologist and mitochondrial researchers performing biopsy studies are blinded for the study groups.|A cross sectional study recruiting participants with their own regular home medication.|f|f|f|t
34026968|NCT06570187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomly distributed into two groups:~1. Group one: 64 adult participants receiving standard treatment of sepsis and septic shock with dexmedetomidine.~2. Group two: 64 adult participants receiving standard treatment of sepsis and septic shock and the standard sedatives without dexmedetomidine.~Both groups can receive other sedatives as add-ons if needed. Guided by Richmond Agitation and Sedation Scale (RASS) and clinical response."||||
34026969|NCT06057402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026970|NCT03951220|||CASE_CONTROL||PROSPECTIVE|||||||
34026971|NCT06368518|||COHORT||PROSPECTIVE|||||||
34026972|NCT03624309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026973|NCT06251089|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34026974|NCT01933646|||CASE_ONLY||PROSPECTIVE|||||||
34026975|NCT04619589|||COHORT||CROSS_SECTIONAL|||||||
34026976|NCT06632119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34026977|NCT03624907|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either daily or non-daily stereotactic body radiotherapy (SBRT).||||
34026978|NCT05210010|NA|SINGLE_GROUP||SCREENING||NONE||||||
34026979|NCT05019950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026980|NCT02369302|RANDOMIZED|CROSSOVER||||NONE||||||
34026981|NCT00098358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34026982|NCT02052011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104152|NCT01013870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722660|NCT03294395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants receive either intramuscular treatment and if applicable intramuscular placebo. Both particpant and care provider are blind to the regimen.|"A double-blind randomized clinical trial with non-inferiority design~\*since October 2018 one study arm (fosfomycin) has been dropped. In a subset of these participants the plasma concentration of ceftriaxone, ertapenem and gentamicin is measured.~An open-label randomized substudy evaluating the pharmacokinetics of ceftriaxone ertapenem and fosfomycin in 60 healthy volunteers (this number is in addition to the 346 NABOGO participants with gonorrhea)"|t|t|t|t
33722661|NCT01457885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722662|NCT04390477|RANDOMIZED|PARALLEL||TREATMENT||NONE|Random numbers table. One branch placebo and other one no intervention|||||
33722663|NCT02290509|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33722664|NCT01199744|||OTHER||PROSPECTIVE|||||||
33722665|NCT00935844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722666|NCT02002923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722667|NCT00877877|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722668|NCT02963337|||COHORT||PROSPECTIVE|||||||
33722669|NCT02126956|NA|SINGLE_GROUP||||NONE||||||
34026983|NCT00789997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34026984|NCT06222320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34026985|NCT04890912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026986|NCT01616355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34026987|NCT05475327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34026988|NCT01062711|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34026989|NCT05391815|||COHORT||PROSPECTIVE|||||||
34026990|NCT02904603|||CASE_ONLY||PROSPECTIVE|||||||
34026991|NCT04005612|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34026992|NCT02295540|NA|SINGLE_GROUP||TREATMENT||NONE||Preoperative hypofractionated radiation followed by surgical resection||||
34026993|NCT03148665|||CASE_CONTROL||PROSPECTIVE|||||||
34026994|NCT03915509|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34026995|NCT03976544|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to either natural cycle frozen-thawed embryo transfer (group A), or hormonal replacement therapy cycle frozen-thawed embryo transfer (group B).||||
34026996|NCT00596076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34026997|NCT05607420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34026998|NCT04613492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34026999|NCT05770895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027000|NCT02108093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104153|NCT06674759|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34104154|NCT03706066|||CASE_ONLY||PROSPECTIVE|||||||
34104155|NCT05645887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104156|NCT05951179|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.||||
34104157|NCT05596591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician will be blinded to group allocation.|Prospective, randomized, single-blind, controlled, parallel group study.|f|f|f|t
34104158|NCT04477837|||COHORT||PROSPECTIVE|||||||
34027001|NCT04735978|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1 - Dose Escalation - Participants will be enrolled into two sequential dose level cohorts.~* Cohort 1: 1 × 105 plaque-forming units (PFU)/mL on Day 1 followed by 1 × 106 PFU/mL every 2 weeks (Q2W) for up to 5 doses.~* Cohort 2: 1 × 106 PFU/mL on Day 1 followed by 1 × 107 PFU/mL Q2W for up to 5 doses.~Part 2 - Dose Combination - Patients will be enrolled into 1 of 5 dose-expansion cohorts. Expansion Cohorts 1, 2, and 4 will enroll patients with head and neck cancer, lung cancer, breast cancer, or GI cancer. Expansion Cohort 3 will enroll patients with any solid organ malignancy who have at least 2 tumors that can be injected and biopsied. Expansion Cohort 5 will enroll patients with melanoma.~* Expansion Cohort 1 (RP3 + Nivolumab)~* Expansion Cohort 2 (RP3 Followed by Nivolumab)~* Expansion Cohort 3 (RP3 Monotherapy Translational Cohort)~* Expansion Cohort 4 (RP3 Monotherapy)~* Expansion Cohort 5 (RP3 + Nivolumab in Melanoma)"||||
34027002|NCT02191644|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34027003|NCT02466685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027004|NCT00309803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027005|NCT02594865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027006|NCT03986411|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Mixed methods feasibility study. Three phases: Phase 1: Interviews Health car professionals, Phase 2: Intervention, Phase 3: Interviews of Participants||||
34027007|NCT01591343|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027008|NCT03857282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34027009|NCT02614274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027010|NCT00224289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027011|NCT02965586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34027012|NCT03962283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104159|NCT01952158|||||PROSPECTIVE|||||||
34104160|NCT01730573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104161|NCT06391489|NA|SINGLE_GROUP||OTHER||NONE||||||
34104162|NCT00088881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104163|NCT01501500|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34104164|NCT04555239|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34104165|NCT00364195|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104166|NCT00833729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104167|NCT04402814|||COHORT||PROSPECTIVE|||||||
34104168|NCT06679088|||OTHER||PROSPECTIVE|||||||
34104169|NCT02303483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104170|NCT05978128|NA|SINGLE_GROUP||SCREENING||NONE||||||
34104171|NCT02634697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104172|NCT01670149|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104173|NCT00742157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104174|NCT05950997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104175|NCT06548295|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34104176|NCT00385489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34104177|NCT00215657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104178|NCT05639803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722670|NCT02461225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33722671|NCT00930150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722672|NCT04056442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Patients will be randomized at a 2:1 Cannabidiol:placebo ratio. After 3 month of treatment a blinded assessor will assess the patient response.~Cannabidiol Non-responders will be removed from the trial, and Placebo Non-responders will be switched over to Cannabidiol"|t|f|t|f
34104179|NCT05405257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Participant will be blinded to the sequence of treatment assignment. Infusion bags containing either the placebo and drug will not be labeled or known to the participant.|This will be a single-blind study. This study will include two treatment periods. One for placebo and one for oxytocin. The participants will be blinded to the sequence of treatment assignment.|t|f|f|f
34104180|NCT00309946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104181|NCT01880775|RANDOMIZED|PARALLEL||||NONE||||||
34104182|NCT03060707|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34104183|NCT00370955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104184|NCT00072995||||PREVENTION||||||||
34104185|NCT04028232|||COHORT||OTHER|||||||
34104186|NCT03794544|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be enrolled and randomized into a durvalumab monotherapy arm or into a durvalumab plus other novel therapy arms. Up to approximately 25 sites globally will participate in this study. New treatment arms may be added in the future. Participants will be treated with a single durvalumab dose alone or in combination with other agents. After the single cycle treatment period participants will have the standard surgical resection planned. All participants will have a post-resection monitoring visit. Study treatment will be discontinued upon disease progression, unacceptable toxicity, or other investigators' reasons.||||
33722673|NCT02287064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104187|NCT00989443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722674|NCT04568980|||COHORT||RETROSPECTIVE|||||||
33722675|NCT04888871|||COHORT||PROSPECTIVE|||||||
33722676|NCT00374296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722677|NCT01380509|RANDOMIZED|CROSSOVER||||NONE||||||
33722678|NCT02128633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722679|NCT05577585|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"This study will apply a randomized, double blind, comparator-controlled cross-over design.~The order of treatment modality will be randomized and double-blind. Participants will undergo one infusion of ketamine and midazolam as comparator. They will be assigned to one of two sequenced treatment groups, with one group first receiving verum and after 14 days the comparator infusion, the other group vice versa. The randomization into these two sequence groups will be stratified for symptom severity, defined as moderate (YBOCS baseline \>16) or severe (YBOCS baseline \>25)."|t|t|t|f
33722680|NCT02607436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722681|NCT00536107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722682|NCT03120546|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33722683|NCT05229120|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33722684|NCT03644199|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33722685|NCT03594279|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention is based on the Behavior Change Theory.||||
33803384|NCT03466242|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a feasibility pilot study, and as such, will be non-blinded, and utilize a convenience sample of children aged 2-18 years old requiring closed reduction under conscious sedation for distal forearm fractures. 20 children recruited in IN Dex arm and 20 children in Ketamine arm||||
33803385|NCT03185052|NA|SINGLE_GROUP||OTHER||NONE||||||
33803386|NCT01330160|||COHORT||PROSPECTIVE|||||||
33803387|NCT02254720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33803388|NCT03682250|||OTHER||PROSPECTIVE|||||||
33803389|NCT01010685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803390|NCT05793541|NA|SINGLE_GROUP||TREATMENT||NONE||"During the four weeks following discharge from psychiatric hospitalization for suicidal thoughts or behaviors, participants will be prompted to complete up to 4 brief smartphone surveys per day that assess current suicidal urges and intent on a 0 to 10 scale. After each completed survey, participants will be micro-randomized to one of several brief just-in-time interventions. Both the intervention method (phone call from a clinician, text messaging from a clinician, automated interactive smartphone-based tool, or automated non-interactive pop-up messages) and intervention content (reminder to either use their safety plan \[any and all included components\] or a specific component of their safety plan) will be randomized according to the current level of suicidal urges and intent."||||
33803391|NCT01974102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803392|NCT04180579|NA|SINGLE_GROUP||OTHER||NONE||||||
33803393|NCT04755920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803394|NCT04741113|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803395|NCT00710294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803396|NCT01693211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803397|NCT03355534|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33803398|NCT06522178|||COHORT||RETROSPECTIVE|||||||
33803399|NCT04851743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the assessor will not know if patients have received the dry needling technique or not.|A randomized within-participant clinical trial|f|f|f|t
33803400|NCT03247842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33803401|NCT00790894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803402|NCT04464759|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803403|NCT00824642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33803404|NCT04124185|||COHORT||PROSPECTIVE|||||||
33803405|NCT05262738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be double blinded with the research participants and providers/nursing masked to the interventions.|Participants are assigned to one of two groups (intervention versus control) in parallel for the duration of the study. Randomization will occur according to a predetermined computer-generated stratified randomization scheme prepared by a study statistician.|t|t|f|f
33803406|NCT02883660|||CASE_CONTROL||RETROSPECTIVE|||||||
33803407|NCT05621278|||COHORT||PROSPECTIVE|||||||
33803408|NCT01536834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803409|NCT01615770|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33803410|NCT05343715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803411|NCT03103048|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33803412|NCT05055752|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|All investigators, Sponsor personnel, clinical monitors, independent PK analyst, and subjects in the study will be unblinded to the treatment allocation as all of the primary and secondary endpoints are based on objective criteria of laboratory findings. Laboratory personnel involved in the analysis will be blinded to the treatment allocation|Randomized, open-label, single dose 2-way crossover study in healthy volunteers|f|f|f|t
33803413|NCT02134106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803414|NCT03093428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803415|NCT03516942|||COHORT||PROSPECTIVE|||||||
33803416|NCT01343459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803417|NCT02627391|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803418|NCT00582972|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33803419|NCT05867927|||COHORT||PROSPECTIVE|||||||
33803420|NCT01701401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803421|NCT04852315|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33803422|NCT03963141|||COHORT||RETROSPECTIVE|||||||
33803423|NCT02788695|||COHORT||PROSPECTIVE|||||||
33803424|NCT01672060|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33722686|NCT05243368|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33722687|NCT00464568|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33722688|NCT05721833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients were randomized to receive one hour each of the two non-invasive ventilation modes before and after, and one hour of washout after receiving the first mode of ventilation before receiving the second intervention.||||
33722689|NCT02255500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722690|NCT03503786|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2 randomized with a safety run-in cohort for the experimental arm||||
33722691|NCT03204305|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Cannabis THC content (dose) is masked for participant|Two groups will be recruited. Female cannabis users and nonusers.|t|f|f|f
33722692|NCT03888196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722693|NCT05858346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722694|NCT06271252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722695|NCT03642223|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722696|NCT03647865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722697|NCT05544786|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722698|NCT06449807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722699|NCT01765153|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33722700|NCT00366158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722701|NCT02533947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722702|NCT04626232|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722703|NCT02328560|||CASE_CONTROL||PROSPECTIVE|||||||
33722704|NCT03777007|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722705|NCT03916757|NA|SINGLE_GROUP||TREATMENT||NONE|This is open label study, no masking is required|All patients who passed eligibility requirement will receive daily dose of V-Boost||||
33722706|NCT02498457|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722707|NCT00150072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803425|NCT01994798|||CASE_ONLY||PROSPECTIVE|||||||
33722708|NCT03816098|||COHORT||CROSS_SECTIONAL|||||||
33803426|NCT03657693|||COHORT||PROSPECTIVE|||||||
33803427|NCT05889299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803428|NCT03539952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803429|NCT03417479|||COHORT||PROSPECTIVE|||||||
33803430|NCT01354444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803431|NCT03952871|||OTHER||PROSPECTIVE|||||||
33803432|NCT01297894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803433|NCT05879705|RANDOMIZED|PARALLEL||TREATMENT||NONE||A mixed method, two group, randomized controlled trial (RCT).||||
33803434|NCT00245791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803435|NCT03830567|||COHORT||PROSPECTIVE|||||||
33803436|NCT00862706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803437|NCT00979121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803438|NCT03208881|||COHORT||PROSPECTIVE|||||||
33803439|NCT04678375|||COHORT||RETROSPECTIVE|||||||
33803440|NCT04977700|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803441|NCT01962090|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803442|NCT03707236|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722709|NCT00605475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803443|NCT02530190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027013|NCT06452901|RANDOMIZED|PARALLEL||OTHER||SINGLE|Evaluators, who are external to the researchers, will be single-blinded to assess the effectiveness of different interventions. They will remain unaware of the participants' group assignments. Privacy will be maintained through coding and presenting de-identified data. Data will also be presented without voices, glove usage, and image distortion to prevent identification of personal details such as gender, race, or other characteristics.|A triple-arm, randomized, simple-blinded clinical trial will be conducted. A control sequence and an intervention sequence of three subgroups with different exposure levels to the simulation program are proposed. Group 1: open abdominal aortic repair (AAOR), Group 2: vascular anastomosis (VA) and AAOR, and Group 3: specific micro-surgical skills, VA and AAOR|f|f|f|t
34027014|NCT02760745|||CASE_CONTROL||PROSPECTIVE|||||||
34027015|NCT02473926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027016|NCT00400699|NA|SINGLE_GROUP||||NONE||||||
34027017|NCT00579566|||CASE_CONTROL||PROSPECTIVE|||||||
34027018|NCT01352780|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34027019|NCT00362466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027020|NCT04971187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027021|NCT03838900|||COHORT||PROSPECTIVE|||||||
33722710|NCT03492099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722711|NCT01519440|||CASE_CROSSOVER||PROSPECTIVE|||||||
33722712|NCT01523886|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33722713|NCT05383547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722714|NCT04941456|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants and care providers are unable to be masked to the intervention arm due to the nature of the study. As data was collected, investigators were unable to blind the data prior to exporting.|6 period Quasi-Randomized Crossover Controlled Study. Enrollment will occur based off tracheostomy census report, site investigators will perform weekly pull of tracheostomy report to recruit appropriate patients.||||
33722715|NCT02296385|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33722716|NCT04318236|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants only know that the delivery or the context of online interventions are to be improved and investigated. However, they don't know the exact interventions.|Multifactorial design (factorial trial), following the Multiphase optimisation Strategy (MOST)|t|f|f|f
33722717|NCT00001482||||TREATMENT||||||||
33722718|NCT02708147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803444|NCT04873388|||COHORT||PROSPECTIVE|||||||
33803445|NCT05538494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double blinding between investigator and study participants|"The first group, which we will call the BFR group, will be trained using low-load exercises with blood flow restriction. To the second group, which we will call high load group, an exercise program with high loads will be applied."|f|f|t|f
33803446|NCT06463977|||OTHER||CROSS_SECTIONAL|||||||
33803447|NCT01485406|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33803448|NCT00409838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803449|NCT02874534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803450|NCT04056702|||COHORT||PROSPECTIVE|||||||
33803451|NCT00220740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803452|NCT01989455|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33803453|NCT00505934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803454|NCT04579198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803455|NCT01847716|||COHORT||OTHER|||||||
33803456|NCT01721291|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33803457|NCT03562338|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33803458|NCT05896774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803459|NCT00448669|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33803460|NCT03239301|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803461|NCT04267458|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33803462|NCT00940524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803463|NCT02374606|||COHORT||PROSPECTIVE|||||||
33803464|NCT05209555|||COHORT||PROSPECTIVE|||||||
33803465|NCT02512250|||COHORT||PROSPECTIVE|||||||
33803466|NCT01913691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803467|NCT03976557|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot, randomized, open label, controlled trial||||
33803468|NCT03349970|||OTHER||PROSPECTIVE|||||||
33803469|NCT02478177|||COHORT||PROSPECTIVE|||||||
33803470|NCT01838343|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803471|NCT01485887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803472|NCT01998958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803473|NCT02911441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803474|NCT04111471|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants will be randomized by an independent statistician based on patient enrollment number (LCH 001- LCH 040). Randomization will be 1:1. The statistician will randomly assort LCH 001-020 into Inulin/Placebo and LCH 021- LCH 040 into Inulin/placebo. This will ensure that an equal number of enrolled participants will be in each arm at 20 patients, and then again at anticipated full 40 patients|Qualified patients that are admitted to Lurie Children's Hospital and agree to participate will either be randomized to receive the placebo or prebiotic, inulin. Randomization will occur 1:1|t|t|t|f
33803475|NCT01780675|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34027022|NCT05734612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Colchicine and placebo (lactose) will be packed in capsules with the same appearance by the pharmacist. The pharmacist will code the capsules containing colchicine or the capsules containing placebo into group A or group B without informing the participant, care provider, investigator, and outcome assessor regarding the content of each group of capsules. Participant, care provider, investigator, and outcome assessor do not know the content of the capsules given to the participants.|Participants will be grouped into two groups which are intervention group and control group. Patients in the intervention group receive loading dose of colchicine 1 x 2 mg followed by colchicine 2 x 0,5 mg daily for two consecutive days. Patients in the control group receive loading dose of placebo (lactose) 1 x 2 mg followed by lactose 2 x 0,5 mg daily for two consecutive days.|t|t|t|t
34027023|NCT01853800|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34027024|NCT04385121|||COHORT||PROSPECTIVE|||||||
34027025|NCT01171755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027026|NCT01960023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027027|NCT05139810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027028|NCT03123276|NA|SINGLE_GROUP||OTHER||NONE||||||
34027029|NCT00006435|||COHORT||PROSPECTIVE|||||||
34027030|NCT02171780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34027031|NCT02870010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027032|NCT04794036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027033|NCT04611529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027034|NCT04214626|NA|SINGLE_GROUP||TREATMENT||NONE||"R-CHOP combined with Lenalidomide in the first-line treatment for patients with medium to high risk/high risk DLBCL.~The individuals with the same propensity score according to high-risk factors (IPI score, double-expressor and P53 protein positive) were set as external control group (1:1) treated with R-CHOP."||||
34027035|NCT03101865|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34027036|NCT02713919|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027037|NCT03900520|||COHORT||PROSPECTIVE|||||||
34027038|NCT01242722|||CASE_ONLY||PROSPECTIVE|||||||
34027039|NCT00686361|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34027040|NCT02976285|||COHORT||PROSPECTIVE|||||||
34027041|NCT01034956|||COHORT||CROSS_SECTIONAL|||||||
34027042|NCT00520819|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027043|NCT05412355|||COHORT||RETROSPECTIVE|||||||
34027044|NCT01909921|||CASE_ONLY||RETROSPECTIVE|||||||
34027045|NCT00489827|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027046|NCT06632366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This research was designed as a randomized controlled experimental type.||||
34027047|NCT02143076|||COHORT||PROSPECTIVE|||||||
34027048|NCT06106165|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027049|NCT06536959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027050|NCT05248802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104188|NCT01767311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104189|NCT02126631|||CASE_ONLY||PROSPECTIVE|||||||
34148895|NCT06380127|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"The trial will follow a 28-week crossover design: 12 weeks for the first intervention period, a 4-week washout, and another 12 weeks for the second intervention period. Nursing homes (clusters) were randomized into sequences (AB or BA), where intervention A involve concurrent exercise training, and B is usual care.~Data collection will occurre at four points: baseline, post-first intervention period, post-washout/pre-second intervention period and post-crossover."|f|f|f|t
34148896|NCT01031771|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34148897|NCT04375397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027051|NCT05668585|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027052|NCT06547411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34027053|NCT05393479|RANDOMIZED|PARALLEL||TREATMENT||NONE||The health facility is the unit of randomization. Altogether 4 health facilities will be selected for the study, where two health facilities will be allocated to each arm. The female community health volunteers (FCHVs) from the health facilities in the intervention arm will receive 10 days training on detection of perinatal depression and THP whilst the FCHVs from control arm will receive 3 days training on detection, psychoeducation, and referral.||||
34027054|NCT06634212|||OTHER||PROSPECTIVE|||||||
34027055|NCT02046486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148898|NCT04664582|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment with sentinel lymph node biopsy cannot be masked for the participant, care provider, nor investigator.|||||
34148899|NCT00050284|||||PROSPECTIVE|||||||
34027056|NCT00717483|||COHORT||RETROSPECTIVE|||||||
34027057|NCT04352868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027058|NCT04226950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027059|NCT05745597|||COHORT||PROSPECTIVE|||||||
34027060|NCT03638414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027061|NCT02713555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027062|NCT01137994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027063|NCT06340386|||OTHER||PROSPECTIVE|||||||
34027064|NCT05233111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803476|NCT04783025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research team members who are responsible for data collection and involved in data analysis will be blinded to the group allocation.|20 clusters (Residentials care homes, RCHs) involved in the study will be randomly allocated to two study groups (the intervention group, IG; and the control group, CG). All of the healthcare personnel in one cluster will receive the assigned treatment in the study group accordingly. All units in one RCH will be grouped as IG or CG. Group designations will be decided by a computer-generated randomization list using a free online generator by a statistician in the research team (DYPL) and will have no potential contact with the participants of the study. An opaque, numbered envelope containing a code generated by computerized randomizations will be prepared by a project assistant unconnected to this study. The random coding will also be concealed from the participants and outcome assessors to be involved in the assessments. A standardized checklist will be used for outcome measurements to minimize bias.|f|f|f|t
33803477|NCT02292004|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33803478|NCT00402246|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803479|NCT00105963|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33803480|NCT04425863|||COHORT||PROSPECTIVE|||||||
33803481|NCT03680638|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject has one control site and three experimental sites concurrently tested within the same study using intradermal microdialysis on the dorsal forearm.||||
33803482|NCT06459193|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803483|NCT00164216|||||PROSPECTIVE|||||||
33803484|NCT05629793|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators performing the tests will be blinded to the diagnostic group.|Persistent COVID group vs. Recovered COVID group|f|f|t|f
33803485|NCT00275288|||||PROSPECTIVE|||||||
33803486|NCT00327119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803487|NCT06035536|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33803488|NCT03755752|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Randomization was done using an envelope technique wherein, after each patient was placed on the operating bed, the surgeon opened the patient's corresponding envelope, which contained information about whether Trypan Blue should be used for anterior capsular staining or not.||f|f|t|f
33803489|NCT05379075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group will exercise Chen Taichi based on Relaxation guidelines, and the control group will exercise Chen Taichi with Coordination guidelines. Each parallel group has male and female separately.|t|f|t|t
33803490|NCT06449859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803491|NCT01448681|||CASE_ONLY||PROSPECTIVE|||||||
34027065|NCT05416788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027066|NCT00030706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027067|NCT02300155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027068|NCT01927198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027069|NCT01869855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027070|NCT04965077|NA|SEQUENTIAL||TREATMENT||NONE||||||
34027071|NCT03687411|NA|SINGLE_GROUP||OTHER||NONE||||||
34027072|NCT01378247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34027073|NCT06453850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027074|NCT06543173|RANDOMIZED|PARALLEL||OTHER||NONE||Subjects will be randomized in a 1:1 fashion to undergo either prophylactic catheter-based ventricular tachycardia (VT) ablation within 3 months of primary ICD implantation or continued medical management after ICD implantation.||||
34027075|NCT02012348|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027076|NCT01767038|NA|SINGLE_GROUP||||NONE||||||
34027077|NCT02132806|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027078|NCT01620294|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34027079|NCT00366405|||CASE_CONTROL||RETROSPECTIVE|||||||
34027080|NCT00000108|RANDOMIZED|PARALLEL||PREVENTION||||||||
34027081|NCT05056038|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34027082|NCT03390426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34027083|NCT03166137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027084|NCT06385548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027085|NCT05639075|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34027086|NCT01756079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027087|NCT04290195|NA|SINGLE_GROUP||TREATMENT||NONE||Resistant diabetic macular edema,non ischaemic central retinal vein occlusion and myopic choroidal neovascularisation||||
34027088|NCT05274555|||CASE_ONLY||CROSS_SECTIONAL|||||||
34027089|NCT03636997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34027090|NCT02329626|||COHORT||PROSPECTIVE|||||||
34027091|NCT03172494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027092|NCT04357080|||CASE_CONTROL||RETROSPECTIVE|||||||
34027093|NCT03566615|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34027094|NCT02125877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027095|NCT04204057|NA|SINGLE_GROUP||TREATMENT||NONE|None (open label)|The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.||||
34027096|NCT01767948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027097|NCT03196219|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|In the single-blind Study Arm 2, active and placebo will be identical in appearance and labeled in a blinded fashion|Study Arms 1 and 2 will be enrolled in parallel followed by Study Arm 3.|t|f|f|f
34027098|NCT02148471|||COHORT||CROSS_SECTIONAL|||||||
34027099|NCT05006547|||COHORT||PROSPECTIVE|||||||
34027100|NCT03328975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027101|NCT00242684|||COHORT||PROSPECTIVE|||||||
34027102|NCT05232812|NA|SINGLE_GROUP||OTHER||NONE||||||
34027103|NCT01305044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027104|NCT00709488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027105|NCT01831258|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34027106|NCT02143921|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34027107|NCT01162707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027108|NCT04366687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803492|NCT05530317|NA|SINGLE_GROUP||TREATMENT||NONE||pre- post-||||
33803493|NCT05142046|||COHORT||RETROSPECTIVE|||||||
33803494|NCT00829634|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803495|NCT00485459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803496|NCT01965665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803497|NCT04540588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803498|NCT05371275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803499|NCT04190108|||CASE_CONTROL||PROSPECTIVE|||||||
33803500|NCT01083316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803501|NCT04308083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803502|NCT00409799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803503|NCT05741489|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803504|NCT06330298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neuropsychologist who leads T1 and T2 measurements will be masked for the fact of which patient will be draw in which clinical condition (experimental group or control group), however this cannot be guaranteed since patients may talk about their experience.|"Experimental condition T0, baseline measurement at point of inclusion (at least \> 6 months post-acute injuries) T1, post measurement within 2 weeks after treatment T2, follow-up measurement within 3 - 5 months after treatment~Waiting list condition T0, baseline measurement at point of inclusion (at least \> 6 months post-acute injuries) T1, post measurement within 3 months after T0 T2, follow-up measurement within 3 - 5 months after T1~TBI group T1, post measurement within 2 weeks after treatment T2, follow-up measurement within 3 - 5 months after treatment~The participating patients are randomly allocated into two groups: an experimental condition and a waiting list condition.~In addition, a group of patients with Traumatic Brain Injury will receive T-ScEmo following regular care."|f|f|t|f
33803505|NCT00185276|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803506|NCT02424201|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33803507|NCT01510236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803508|NCT02209246|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||||||||
33803509|NCT03450460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027109|NCT02836210|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|f|t
34027110|NCT03829787|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027111|NCT03583086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027112|NCT05801224|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In a prospective, single-center, physiological, crossover study, the investigators will recruit 70 adults meeting the ARDS criteria based on the Berlin definition who have not previously received inhaled vasodilators.||||
34027113|NCT05948176|||OTHER||CROSS_SECTIONAL|||||||
34027114|NCT00845078|||COHORT||PROSPECTIVE|||||||
34027115|NCT00256399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027116|NCT01499433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027117|NCT01368315|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34027118|NCT05871034|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027119|NCT06265194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not have the knowledge of group interventions.|Eligible participants were randomized into two groups: one receiving TAU treatment (control group) and the other receiving both TAU and EMDR (experimental group).|t|f|f|f
34027120|NCT01509014|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34027121|NCT02113618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027122|NCT01559883|||COHORT||PROSPECTIVE|||||||
34027123|NCT02794246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027124|NCT01794559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The subject is masked as to assignment to Control or Treatment Group.~The blinded subject acts as the blinded rater in providing the primary outcome measure of the QIDS-SR16"|This study is prospective in nature. Control group subjects will be treated according to treatment as usual. Experimental group physicians will follow the guidance of the subject's PEER Interactive Report. Subjects will be washed out of medications prior to EEG. The wash out period for outpatients is no longer than 14 days. Subjects will be followed for 6 months after baseline, or until the patient has achieved maximum medical improvement (MMI). Subjects will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health. Subjects will be closely evaluated for any psychiatric specific adverse events. The investigator is allowed to treat the patient according to best medical judgment, which may include adding or changing medications, seeing the patient more frequently, or other interventions such as the use of sleep aids.|t|f|f|t
34027125|NCT05980572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor blind to the arm of the subjects||f|f|f|t
33722719|NCT00206414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722720|NCT01148745|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33722721|NCT00163475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722722|NCT01752452|||CASE_CONTROL||PROSPECTIVE|||||||
33722723|NCT01288950|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33722724|NCT04147455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722725|NCT02983383|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33722726|NCT02049463|||COHORT||RETROSPECTIVE|||||||
33722727|NCT02015780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722728|NCT03404479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722729|NCT05394987|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subject, pre-post interventional study, measuring the effect of optical correction on visual function.||||
33722730|NCT02519530|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33803510|NCT05769413|||CASE_ONLY||PROSPECTIVE|||||||
33803511|NCT03188341|||COHORT||PROSPECTIVE|||||||
33803512|NCT00643188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803513|NCT01125254|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33803514|NCT06699264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722731|NCT01994629|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33722732|NCT00002384||||TREATMENT||||||||
33722733|NCT04382833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33722734|NCT00625859|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722735|NCT05145933|||CASE_ONLY||CROSS_SECTIONAL|||||||
33722736|NCT00789893|||COHORT||PROSPECTIVE|||||||
33803515|NCT04579250|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Dose escalation study||||
33803516|NCT05463913|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|Blinded for FDG PET/CT conducted for research results.||f|t|t|f
33803517|NCT05180591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803518|NCT03199404|||COHORT||PROSPECTIVE|||||||
33803519|NCT03214185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803520|NCT01777009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803521|NCT02854241|NA|SINGLE_GROUP||SCREENING||NONE||||||
33803522|NCT00002036||||TREATMENT||||||||
33803523|NCT01898585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722737|NCT05034107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A pre-post quasi-experimental study will be conducted over a two-month period in nursing homes with persons with dementia. During the pre-intervention phase, essential oil diffusers containing water will be diffused in the common area of the nursing homes. During the intervention phase, Ylang-Ylang essential oil will be diffused using an identical diffuser. Behavioural parameters and blood samples will be taken after pre and post intervention phase.||||
33722738|NCT03407573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33722739|NCT02930551|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33722740|NCT04665050|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33722741|NCT05426226|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|participants allocation by third party|The subjects were randomly assigned to group A and group B, the group A will take light acupuncture in the first month, and sham in the next month; Group B is opposite.|t|f|t|t
33722742|NCT04100304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722743|NCT03420651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|When patients are randomized to the non-peak flow guided therapy, physicians are blinded to the peak flow values||f|t|f|f
33803524|NCT00580593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803525|NCT01888744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803526|NCT01921075|||COHORT||PROSPECTIVE|||||||
33803527|NCT04148482|NON_RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||This is a recall-by-genotype study|t|t|f|t
33803528|NCT00450528|||||PROSPECTIVE|||||||
33803529|NCT06150924|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33803530|NCT06700317|NA|SINGLE_GROUP||OTHER||NONE||||||
34027126|NCT01392625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027127|NCT04389892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients diagnosed with unclear cystic lesions who underwent CH-EUS at our Institute||||
34027128|NCT04185623|||CASE_CONTROL||PROSPECTIVE|||||||
34027129|NCT03990610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027130|NCT03147625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research nurse not involved in the delivery of SHAPE intervention will be blinded to the participants' group assignment to conduct data collection.|In this two-armed randomized controlled trial, participants will be allocated to either the intervention group or the control group through stratified permuted block randomization. Participants in the intervention will undergo SHAPE while participants assigned to the control group will receive usual care, which refers to existing community services provided by the local community centre, senior activity centre and voluntary welfare organisations.|f|f|f|t
34027131|NCT03281395|||CASE_CONTROL||RETROSPECTIVE|||||||
34027132|NCT06582043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization for product allocation will consider: number of papules/pustules (\<3, ≥3), age (18-35, 35-50, \>51), phototype (I-III and IV), sun protector (always, sometimes, never)|Multicentric and double-blind randomised comparative clinical study in Argentina and Brazil. Under dermatological and ophthalmological control|t|t|t|f
34027133|NCT03492086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027134|NCT05306509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027135|NCT01845727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027136|NCT00431483|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34027137|NCT03655548|||COHORT||PROSPECTIVE|||||||
34027138|NCT02971020|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34027139|NCT03804814|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027140|NCT04023227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Endpoint Adjudication Committee will be blinded to treatment allocation.|This is a Phase 4, multinational, multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, active-controlled study to demonstrate superiority of sacubitril/valsartan over enalapril in improving a composite of CV events (CV death or first HF hospitalization), or in causing greater reduction or lesser increase in NT-proBNP levels at Week 12 in participants with HFrEF caused by CCC.|f|f|f|t
34027141|NCT02181790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027142|NCT01589718|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34027143|NCT00702988|||OTHER||PROSPECTIVE|||||||
34027144|NCT00002825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027145|NCT04621019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027146|NCT05959252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027147|NCT00550030|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027148|NCT04774744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027149|NCT02922738|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34027150|NCT06202612|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be two independent cohorts of subjects who will each receive two treatments (quick release tablets and sustained-release tablets), and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability.||||
34027151|NCT03020589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027152|NCT03412799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803531|NCT02669771|||COHORT||PROSPECTIVE|||||||
33803532|NCT05038618|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33803533|NCT03908060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation and study medication will be handled by the hospital pharmacy. All research team members, caregiving clinicians and enrolled patients will be blinded to the study allocation arms and the randomisation list will be concealed until all statistical analyses are made.|Randomized controlled trial|t|t|t|t
33803534|NCT05486598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803535|NCT00879125|||CASE_ONLY||RETROSPECTIVE|||||||
34104190|NCT05681585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking Patients and next-of-kin will not be informed about the hospital unit's allocation status. However, they may deduce this from the kind of intervention they receive. It's impossible to blind the care providers and for practical reasons we won't be able to blind the investigators or the outcomes assessors.|"The study is a cluster RCT, with a complex intervention containing implementation interventions and strategies, and a clinical intervention (ACP). Twelve clusters were recruited and stratified into two strata according to number of beds and randomized to intervention or control arms (allocation ratio of 1:1). The six hospital units in the intervention arm will receive a comprehensive implementation support program, whereas the control units receive no support in the intervention period.~A similar number of patients, relatives and attending clinician will be recruited from both arms in triads for the quantitative sub-study. Data for each patient will be supplemented by health record and register data. Patients, relatives, staff and implementation teams will be recruited from the intervention units to qualitative interviews. All health personnel in the participating units will be recruited to answer a questionnaire twice. We will also interview key stakeholders in a wider context."||||
34027153|NCT00668694|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34027154|NCT04102189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|f|t|f
34027155|NCT01243463|||COHORT||PROSPECTIVE|||||||
34104191|NCT01514279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027156|NCT00125112|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027157|NCT03694899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027158|NCT03905616|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104192|NCT05516407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104193|NCT00204581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027159|NCT05348447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will be blinded to treatment group and will be sedated (part of standard of care surgery) at the time the treatment occurs||t|f|f|f
34027160|NCT00375895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027161|NCT05998629|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Comparison of sweat chloride measure using standard of care versus experimental device in both control and cystic fibrosis subjects||||
34027162|NCT00497913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34027163|NCT04590040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027164|NCT01564264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027165|NCT01415102|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027166|NCT03666286|||COHORT||PROSPECTIVE|||||||
34027167|NCT00224471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34027168|NCT02422134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34027169|NCT06581055|||COHORT||RETROSPECTIVE|||||||
34027170|NCT05780476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two-arm randomized controlled design|f|f|f|t
34027171|NCT05076214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient is at the follow-up interview instructed not to disclose any information about mode of treatment. All interviews are recorded.|Randomised controlled study|f|f|f|t
34027172|NCT03889080|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027173|NCT05388513|||COHORT||PROSPECTIVE|||||||
34027174|NCT06008275|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34027175|NCT06229548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027176|NCT05866419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027177|NCT01738451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027178|NCT01662596|||||CROSS_SECTIONAL|||||||
34027179|NCT03763357|NA|SINGLE_GROUP||TREATMENT||NONE||All of the subjects in this study will receive leg heat therapy.||||
34104194|NCT01333787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104195|NCT06329622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104196|NCT05889741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The clinical staff, research staff, and the participant will be blind to study condition until after the 1-month follow-up assessment. After which time, the blind will be broken, and participants in the control condition will be offered the SGB.||t|f|t|t
34104197|NCT00023972|RANDOMIZED|||TREATMENT||NONE||||||
34104198|NCT06430411|||COHORT||PROSPECTIVE|||||||
34104199|NCT06541080|||COHORT||PROSPECTIVE|||||||
34104200|NCT04562519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104201|NCT05746273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blinded, using matching placebo patches.||t|f|t|t
34104202|NCT03412552|||COHORT||PROSPECTIVE|||||||
34104203|NCT02452593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104204|NCT02920047|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34104205|NCT02189629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104206|NCT06045247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104207|NCT05773586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104208|NCT06674954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104209|NCT04562805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patients will be blinded to the assigned device from the point of randomization onward. Study site personnel will be trained not to disclose the treatment assignment to the patient. Site personnel assigned to conduct phone follow-up visits will be provided with a standard interview script in order to reduce bias.~The Clinical Event Committee will be blinded to the fullest extent possible with only redacted source documents included in the event packages."||t|f|f|f
34104210|NCT01908387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104211|NCT05938816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104212|NCT04413708|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33722744|NCT06189222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||study group: children evaluated with virtual reality glasses control group: children receiving standard care||||
33722745|NCT04287712|||COHORT||PROSPECTIVE|||||||
33722746|NCT05058300|||CASE_ONLY||PROSPECTIVE|||||||
33722747|NCT00696514|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33722748|NCT05601986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33722749|NCT03343873|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33803536|NCT02065193|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33803537|NCT02126982|||OTHER||PROSPECTIVE|||||||
34104213|NCT04203771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Probiotic and placebo tablets with identical appearance were provided in anonymous packages to the investigators, solely labelled with the volunteer's randomization number||t|t|t|t
33803538|NCT00319293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34104214|NCT06481813|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This cohort will include 5 distinct patient populations.||||
34104215|NCT00005775|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33722750|NCT00798044|RANDOMIZED|PARALLEL||||NONE||||||
34104216|NCT00295412|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34104217|NCT05900349|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33803539|NCT00000119|RANDOMIZED|||TREATMENT||||||||
33803540|NCT06455488|||COHORT||PROSPECTIVE|||||||
33803541|NCT01658241|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803542|NCT01618500|||COHORT||PROSPECTIVE|||||||
33803543|NCT00645359|||COHORT||PROSPECTIVE|||||||
33803544|NCT06514183|||COHORT||RETROSPECTIVE|||||||
33803545|NCT04531059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803546|NCT06499441|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803547|NCT05521672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803548|NCT02285114|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803549|NCT01800487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33803550|NCT00111683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803551|NCT05953363|||CASE_ONLY||PROSPECTIVE|||||||
33803552|NCT04970511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803553|NCT01238042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803554|NCT02409667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803555|NCT01581372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803556|NCT02829931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803557|NCT00347204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803558|NCT00144287|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803559|NCT04351386|||COHORT||PROSPECTIVE|||||||
33803560|NCT03150446|NA|SINGLE_GROUP||PREVENTION||NONE||From April 2009 to June 2015, 97 male patients with stones \>1.8 cm in the upper ureter underwent intracorporeal double-J stenting of the ureter after laparoscopic ureterolithotomy performed by four different surgeons. The 50 participants was performed with flexible cystoscopy through the urethral route to confirm the position of the double-J stent.||||
33722751|NCT06488963|RANDOMIZED|PARALLEL||TREATMENT||NONE||The sample will consist of pediatric oncology patients aged 7 to 18 with select diagnoses (see inclusion criteria) who receive VCR. The G\*Power software was used to analyze the sample's size (Faul et al., 2007). Since no similar previous study was identified, we aimed to reach a medium effect size for sample size calculation. Based on a medium effect size (f:0.40), 80% (1 - β error) power, and 95% (α error) confidence level within two groups and six repeated measurements, the sample size was calculated as 16 for each group, and a total of 32 children. Considering the expected dropout rate, the number was increased %10 and so 36 children will be recruited.||||
33722752|NCT05634551|||COHORT||PROSPECTIVE|||||||
33722753|NCT02436551|||COHORT||PROSPECTIVE|||||||
33803561|NCT02757898|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803562|NCT03333109|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33803563|NCT02796586|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803564|NCT05804994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803565|NCT01735500|||COHORT||PROSPECTIVE|||||||
33803566|NCT03494959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803567|NCT01989117|||CASE_CONTROL||PROSPECTIVE|||||||
33803568|NCT06151301|||CASE_CONTROL||PROSPECTIVE|||||||
33803569|NCT01521052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803570|NCT00587275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34148900|NCT04856254|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The pregnant females will be classified according to clinical and ultrasound score as patient suitable to undergo trial of labor after CS \[TOLAC\] or not suitable for \[TOLAC\] so undergo from the beginning to elective repeated cesarean section.||t|f|f|f
34148901|NCT00875940|||CASE_ONLY||RETROSPECTIVE|||||||
34148902|NCT02097342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148903|NCT03255759|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34148904|NCT05740319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722754|NCT05044754|||COHORT||PROSPECTIVE|||||||
33803571|NCT00124735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803572|NCT02387866|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803573|NCT04405921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33803574|NCT02675244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803575|NCT05622110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physician doing follow up will be masked to the type of closure in each side||f|t|f|f
33803576|NCT01768689|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The adherence assessed per study protocol was masked to participants and care providers during the preintervention and post intervention phases. At the time of intervention participants were notified once of their adherence as part of the feedback-based intervention||t|t|f|f
33803577|NCT04994795|||COHORT||OTHER|||||||
34148905|NCT00130923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148906|NCT01369680|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803578|NCT06461286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803579|NCT03927820|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803580|NCT00459524|||CASE_ONLY||PROSPECTIVE|||||||
33803581|NCT03176888|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33803582|NCT02426229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803583|NCT01865474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803584|NCT01111513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803585|NCT01145729|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33803586|NCT05898191|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33803587|NCT03000595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803588|NCT01811394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803589|NCT00404742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803590|NCT04105712|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Multi-method, within subjects, prospective, experimental design||||
33803591|NCT00854490|||COHORT||PROSPECTIVE|||||||
33803592|NCT01737021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803593|NCT01997346|||||CROSS_SECTIONAL|||||||
33803594|NCT04674995|||COHORT||RETROSPECTIVE|||||||
33803595|NCT06464692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803596|NCT04175899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803597|NCT03322124|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33803598|NCT01032668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803599|NCT01154192|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803600|NCT01291810|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33803601|NCT01470300|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33803602|NCT03762772|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will use a single combination TAF/EVG vaginal insert.||||
33803603|NCT02754596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803604|NCT05398055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized through the program ¨Randomizer for Clinical Trial¨ to be assigned in group of treatment A or B. One of the treatments will be azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days and the other schedule it will be doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses.|Controlled randomized trial with placebo, triple blinded, multicenter study|t|t|t|f
33803605|NCT03148600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803606|NCT02766517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803607|NCT04514718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803608|NCT00001752||||TREATMENT||||||||
33803609|NCT01920191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803610|NCT02828618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803611|NCT01310348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33803612|NCT03838978|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Study Design||||
33803613|NCT00692809|||||PROSPECTIVE|||||||
33803614|NCT02930200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803615|NCT06463249|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||All participants will receive Core Helpline intervention in the first two months. If participants achieve 2% or more weight loss in two months (i.e. early responders), they will continue to the Extended Helpline. If participants do not achieve at least 2% of weight loss in two months (i.e. early non-responders), they will be randomized to one of two stepped-up interventions: Enhanced Helpline or Intensive Helpline.||||
33803616|NCT06274879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803617|NCT06294223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803618|NCT05835934|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, single-dose, non-randomized, open-label design.||||
33803619|NCT01943994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803620|NCT02339519|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33803621|NCT03257410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803622|NCT00538759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803623|NCT02492412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803624|NCT05470231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blinded (Participant, Investigator and Outcomes Assessor) The participant was blinded not knowing the treatment to which he was submitted, investigator and outcome assessor responsible for collecting the results, without commenting on the group from which the subject came.|Parallel allocation was carried out in the two groups|t|f|t|t
33803625|NCT05565508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33803626|NCT02691169|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33803627|NCT06120049|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective head-to-head comparison with 5 subject panels (healthy controls, Parkinson's disease, Multiple System Atrophy, Dementia with Lewy Bodies and Alzheimer's disease). The main study is a prospective diagnostic study in three cohorts (1/ CON, 2/ PD vs. MSA-P, 3/ DLB vs AD). The study in healthy controls is designated part 2. The study in patients is designated part 3. There is a seperate dosimetry study, designated as part 1.||||
33803628|NCT03631290|||COHORT||PROSPECTIVE|||||||
33803629|NCT04807790|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33803630|NCT01547871|||||OTHER|||||||
33803631|NCT05869617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome questionnaires are completed prior to participants being allocated to treatment groups. Unable to blind participants as it is obvious that they will be exercise on land or in water.||f|f|f|t
33803632|NCT01839682|||CASE_ONLY||PROSPECTIVE|||||||
33803633|NCT03387189|||COHORT||OTHER|||||||
33803634|NCT06389890|||COHORT||RETROSPECTIVE|||||||
33803635|NCT02020694|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33803636|NCT06373835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803637|NCT05125874|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33803638|NCT04437641|||CASE_ONLY||PROSPECTIVE|||||||
33803639|NCT04826094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33803640|NCT02352220|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33803641|NCT01814839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803642|NCT00073255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803643|NCT01206972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33803644|NCT05307835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803645|NCT06614270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803646|NCT01585454|||COHORT||PROSPECTIVE|||||||
33803647|NCT05551286|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33803648|NCT06165146|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33803649|NCT06521619|||COHORT||RETROSPECTIVE|||||||
33803650|NCT04859296|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.|t|f|t|f
33803651|NCT04508010|RANDOMIZED|PARALLEL||OTHER||SINGLE|Data cleaning and analysis will be conducted by a statistician blinded to the study arm||f|f|f|t
33803652|NCT03229213|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027180|NCT05798910|RANDOMIZED|PARALLEL||OTHER||NONE||The members of the conventional group had to complete pretest at the beginning of the study. Afterwards they had to take part at an interactive classroom based lecture about ALS. The next step was the skills training with task trainers in order to teach them compression skills. Afterwards, the conventional group was divided into three blue code teams consisting of each 5 participants for the simulation session. Two independent instructors evaluated the video recordings in terms of technical and nontechnical skills. The final stage of the study were completing the post-test. The members of VR group had a similar study flow but they had to play with the VR based ALS serious game module instead of the theoretical lecture. A survey about preference of VR based trainings was conducted for the members of the VR group. Mann Whitney U Test and Wilcoxon Signed Ranks Test were used for statistical analysis of the two groups' performances in this study.||||
34027181|NCT01840306|||COHORT||PROSPECTIVE|||||||
34027182|NCT04860609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||control group will recevie conventional physiotherapy sessions while the experimental group receive conventional along with decompression|f|f|f|t
34027183|NCT03685201|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34027184|NCT02000765|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027185|NCT06632327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104218|NCT06413875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were informed about the research, and then participants who agreed to participate in the research were given a number respectively. After the targeted sample number was reached, all participants were divided into intervention and control groups using a simple random numbers table.|The population of the study, which has a classical experimental design with a pretest-posttest control group, was comprised of women between the ages of 45-65 across Turkey. According to the power analysis performed in the G\*Power3.1 Program, the sample size was calculated as 64 participants for each group, with an effect size (0.418), 95% power and 0.05 type 1 error, and was completed with 158 women. Data were collected with the Introductory Information Form, the Menopause-Specific Quality of Life Scale (MSQLS) and the Female Genital Self-Image Scale (FGSIS). The research was conducted online via WhastApp in a pretest-educational intervention-posttest design. The data were analyzed in the SPSS 26.0 package program.|t|f|f|f
34027186|NCT04588025|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The healthy group is going to be the group to establish a baseline for the pancreatic group.||||
33803653|NCT02438137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104219|NCT00423865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104220|NCT05069740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|These treatments/placebo are blinded to the investigators. The subjects, physician, and the nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.|This is a single blind placebo controled cross over study. Two groups of women complete this study: 1) healthy women between the ages of 18 and 45 years (Controls); 2) women between the ages of 18 and 45 years with endometriosis. Once consented and screening, each subject is randomized to either 5 days of salsalate or placebo. On day 5, each subject participates in a cutaneous microdialysis (MD) and flow mediated dilation (FMD) experiment. After a 2-week washout, the participant returns to repeat the study with the other oral drug (salsalate/placebo). These treatments are blinded to only the investigators. The participants and nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.|f|f|t|f
34104221|NCT06655727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33803654|NCT01119313|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34104222|NCT02986438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind randomized control trial|t|f|t|f
33803655|NCT05406765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization, allocation, and blinding: Randomization will be conducted by using sealed, opaque envelopes. An independent colleague at the Clinical Research Department will randomize these envelopes in blocks of 5. These envelopes will be stacked and stored outside the operating room. The upper envelope will be opened by the attending anesthesiologist when an included patient arrives in the operating theater. The patient, surgical team, nurses on the ward, and researcher team will be blinded. Only the attending anesthetic team will be aware of the randomization. They will be instructed not to tell the patient or any other health care worker which group the patient was allocated to.||t|t|t|t
34027187|NCT04191850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104223|NCT03982693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind||t|t|t|f
34027188|NCT05461326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34027189|NCT03263897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104224|NCT02462629|NA|SINGLE_GROUP||OTHER||NONE||||||
34027190|NCT04558918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027191|NCT02513212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027192|NCT06057272|||CASE_CONTROL||PROSPECTIVE|||||||
34027193|NCT04302636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34027194|NCT02901977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027195|NCT05776823|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34027196|NCT03578094|||COHORT||PROSPECTIVE|||||||
34027197|NCT02056912|NA|SINGLE_GROUP||||NONE||||||
33722755|NCT03669692|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Randomized Clinical Trials||||
33722756|NCT04474860|||COHORT||PROSPECTIVE|||||||
33722757|NCT05665790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722758|NCT00703612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722759|NCT04778189|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||patients will be scheduled for lower abdominal surgery under spinal anesthesia will randomly be allocated into two groups, group SD and group SN, After placement of standard monitors and peripheral IV access, with aseptic technique we will insert, a 25-G pencil-point Pencan(B. Braun, Mississauga, Ontario, Canada) needle intrathecally at the L4-5 or L3-4 interspace, with the patient in a seated position. We will confirm Intrathecal positioning by observation of cerebrospinal fluid return through the needle. Then we will inject the hyperbaric bupivacaine. All patients will receive spinal anesthesia with 12-mg hyperbaric bupivacaine 0.5%. Patients will be randomly assigned to one of the 2 Groups. Beginning during the intrathecal injection, patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline (total, 502 mL), while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes,|t|t|t|t
34027198|NCT04968184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All individuals directly involved in the conduct of the study, including participants, Investigators, site staff, clinical research organization (CRO) personnel, and Sponsor study personnel, will remain blinded to treatment assignments until all participants have completed the Week 56 end of study (EOS) Visit (Visit 17) and the database locked in preparation.||t|t|t|t
34027199|NCT02925104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027200|NCT05912270|RANDOMIZED|PARALLEL||OTHER||SINGLE|Orchestra in Class is the first Experimental Condition, compared to Visual Arts (second Experimental Condition) and an active Control Group that will receive 6 cultural outings per year. We will present the study to the participants as a comparison between the two art interventions and a cultural intervention.|The study is a 1) block-randomized, 2) 3-arm, 3) open, 4) monocentric (primary schools in Geneva) 5) national (Switzerland) 6) intervention study.|t|f|f|f
34027201|NCT06493006|||COHORT||PROSPECTIVE|||||||
33803656|NCT04307550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"An intervention/care provider will remove the packaging so that participants will be unable to identify the inhaled substance. We acknowledge that the smell of isopropyl alcohol may be familiar and thus identifiable for some treatment arm participants. However, participants will not be informed of the identity of the treatment and placebo during the consent process, instead only being told that we are comparing two inhaled substances to assess their relative effectiveness. Thus, recognizing they are inhaling isopropyl alcohol should not bias participants' responses, given they will not know whether isopropyl alcohol is a treatment or control.~The outcomes assessor will be blinded, because the randomization and intervention delivery are both completed by the intervention/care provider, who will not be involved in screening/baseline assessment nor outcome assessments."|Participants in Arm 1 will nasally inhale an isopropyl alcohol pad with 10 inhalations (intervention). Participants in Arm 2 will nasally inhale a sterile saline pad of similar appearance with 10 inhalations (placebo).|t|f|f|t
33722760|NCT03826862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This group with intervention will be compared previous group without intervention.||||
33722761|NCT02749812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722762|NCT00379626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803657|NCT02500758|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33803658|NCT05297136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803659|NCT01520259|||CASE_CONTROL||RETROSPECTIVE|||||||
33803660|NCT05562089|NA|SINGLE_GROUP||OTHER||NONE||||||
33803661|NCT00070694||||TREATMENT||||||||
33803662|NCT01773746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33803663|NCT06091995|||CASE_ONLY||RETROSPECTIVE|||||||
33803664|NCT05216770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Only one of three arms includes Intervention. The other two arms are Observational. The Interventional arm has a parallel study model where patients with laryngeal dystonia and voice tremor will be assigned to laryngeal sensory block in parallel. Allocation will be non-randomized.|t|t|t|t
33803665|NCT02641912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803666|NCT04541303|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Physician/surgeon, nurses, patient, and patient family will be blinded.|One arm will receive topical application of tranexamic acid (intervention). Other arm with receive topical application of normal saline (placebo).|t|t|t|f
34027202|NCT01410656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027203|NCT03391414|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722763|NCT05749302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027204|NCT05544279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|There are 2 groups: experimental and control groups.||||
34027205|NCT05727618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027206|NCT01148615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722764|NCT05938751|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking was not possible due to the resources of this study.|Participants were assigned to the experimental group (which received the intervention) or to the control group (in a waiting list to receive the intervention after the conclusion of the study)||||
33722765|NCT04165512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722766|NCT06341972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||pilot randomized controlled trial|f|f|f|t
33722767|NCT05864300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722768|NCT02047357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33722769|NCT02467569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722770|NCT03104114|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pharmacist-led intervention group vs historical-control group||||
33722771|NCT00613015|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33722772|NCT05011864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In a pragmatic RCT design with randomization prior to consent rather than the traditional consent-to-randomization design, we will follow six steps in recruitment, enrollment, and intervention delivery: 1) identification of potential participants by case managers / social workers during in-home or telephone assessments and referral to the research team; 2) randomization into TBF (combined Tele-behavioral activation and fall prevention), Tele-BA, FP, and Attention Control (AC: telephone support calls) arms by the research team; 3) calling each person for consent for telephone eligibility screening; 4) conducting in-depth, in-home screening and baseline assessment for eligible, consenting seniors; 5) delivering TBF, Tele-BA alone, FP alone, or AC; and 6) conducting follow-up assessments.|f|f|f|t
33722773|NCT05155007|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722774|NCT01655979|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722775|NCT04923204|||COHORT||RETROSPECTIVE|||||||
33722776|NCT05163028|NA|SEQUENTIAL||TREATMENT||NONE||3+3 Dose Escalation Design with Expansion||||
33722777|NCT03409172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors involved in data analysis will not be aware of the arm to which the participants were allocated (single-blinded masking)|Three-arm parallel, Randomized-controlled study|f|f|f|t
33722778|NCT04812054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Following provision of informed consent, recipients will be randomly assigned in a 1:3 ratio to either hypothermic perfusion group or simple static cold storage group. Randomization will be performed in the blocks of 8 by drawing a sealed envelope by the investigator immediately after organ procurement.|t|f|f|t
33722779|NCT03303378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention|f|f|f|t
34104225|NCT04050436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104226|NCT06569615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104227|NCT01378273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104228|NCT06470919|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Mothers will be randomized to receive the digital vaccine card access with short message service (SMS) reminders versus mothers who did not receive digital vaccine card access with SMS reminders (treatment/control).||||
34104229|NCT05532163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104230|NCT02867423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104231|NCT02290951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104232|NCT06674226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34104233|NCT03188380|||COHORT||PROSPECTIVE|||||||
34104234|NCT05137626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104235|NCT06674941|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33803667|NCT04900467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803668|NCT06454682|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible subjects will receive a single intrathecal administration of investigational product. 9 subjects will be involved in 3 doses cohort from low to high: 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person, 3 subjects for each cohort.||||
33803669|NCT06699654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomly assigned to one of three arms: Spirulina Gel, Spirulina Nanoparticles Gel, or control. The interventions are administered over a defined period with radiological and biochemical assessments conducted at baseline and post-treatment.|t|t|f|f
34104236|NCT06380504|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Evaluator teams will be blinded from intervention allocation|Cluster randomized controlled trial. Unit/cluster of assignment is health post catchment area. Parallel Assignment: baseline-endline design||||
34104237|NCT02998125|||COHORT||PROSPECTIVE|||||||
34104238|NCT06684379|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Subjects will be randomized in blocks; the study will be conducted in 2 parts in sequential groups of two increasing doses of PRS CK STORM (A and B) and consecutively evaluated in 2 sentinel groups of 4 patients. Patients will be randomized to receive treatment in groups of 2, for 5 consecutive days, until 48 hours after the last drug administration (short-term safety follow-up period).|t|f|t|f
34104239|NCT04162158|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148907|NCT06171074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148908|NCT01913704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722780|NCT03169647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33722781|NCT00495456|||COHORT||PROSPECTIVE|||||||
33722782|NCT00853723|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33722783|NCT05023265|NA|SINGLE_GROUP||TREATMENT||NONE||Patients diagnosed with Inoperable Renal Cell Carcinoma||||
33722784|NCT04528745|||COHORT||PROSPECTIVE|||||||
33722785|NCT01004588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722786|NCT05162547|||OTHER||PROSPECTIVE|||||||
33722787|NCT02287558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722788|NCT00457782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722789|NCT04777695|||COHORT||PROSPECTIVE|||||||
33722790|NCT01223287|||COHORT||PROSPECTIVE|||||||
33722791|NCT03411681|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33722792|NCT05196841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33722793|NCT02687984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722794|NCT02662127|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33722795|NCT03710226|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33722796|NCT01253759|||CASE_ONLY||RETROSPECTIVE|||||||
33722797|NCT01675687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722798|NCT00457600|||DEFINED_POPULATION||PROSPECTIVE|||||||
33722799|NCT04483908|||COHORT||PROSPECTIVE|||||||
33722800|NCT02360189|||OTHER||PROSPECTIVE|||||||
33722801|NCT04868279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In a randomized controlled study, blinding will be done in terms of statistician and reporting. Research data will be encoded and transferred to the computer without specifying the intervention and control group (for example; A group and B group). The analysis of these data coded in terms of groups will be done by a statistician. After the statistical analysis is done and the research report is written, the researcher will explain the coding for the intervention and control group. In this way, detection bias, statistical bias and reporting bias will be controlled.||f|f|f|t
33722802|NCT02141282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722803|NCT02266459|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722804|NCT04571775|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33722805|NCT01638156|||CASE_ONLY||PROSPECTIVE|||||||
33722806|NCT02443012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33722807|NCT02258126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722808|NCT01948973|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33722809|NCT05147909|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Investigational drug service at UT Southwestern will dispense Sodium Phosphate vs. NaCl tablets and the study subjects will be blinded to the type of supplement they receive.||t|f|t|f
33722810|NCT02402985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33722811|NCT02653456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722812|NCT05375695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722813|NCT00529854|||||PROSPECTIVE|||||||
33722814|NCT03613051|||COHORT||PROSPECTIVE|||||||
33722815|NCT00982488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722816|NCT04432311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803670|NCT01432106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803671|NCT01844349|||||CROSS_SECTIONAL|||||||
33803672|NCT00733811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803673|NCT01205048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803674|NCT04119063|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Feasibility assessment of powered orthosis assistance and resistance during walking. All participants received high frequency gait training followed by a washout period then low frequency gait training.||||
33803675|NCT00455650|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34148909|NCT01496105|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33803676|NCT06355063|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, multicenter, single arm, non-randomized, feasibility study.||||
33803677|NCT04225507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803678|NCT00213395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803679|NCT04564443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803680|NCT00804648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33803681|NCT01036724|||CASE_ONLY||PROSPECTIVE|||||||
33803682|NCT03954275|||COHORT||RETROSPECTIVE|||||||
33803683|NCT00071799|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803684|NCT01946386|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33803685|NCT05912088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803686|NCT02917512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803687|NCT02247375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803688|NCT06000800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The trial was unblinded; where the participants and researchers were aware of the group a participant belonged to|A randomized controlled trial was used to fulfill the aim of the study. The randomized control trial (RCT) is a trial in which subjects are randomly assigned to one of two groups: one (the experimental group) receiving the intervention that is being tested, and the other (the comparison group or control group) receiving an alternative treatment||||
33803689|NCT05594511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participants will be blinded because in both groups they were following the treatment and medical recommendations and they will also be attended by a physiotherapist, in one case the mandibular muscular energy technique will be performed and in the other the placebo technique.~The evaluators did not know to which group the participants belonged."|randomized, controlled, prospective, double-blind, clinical trial|t|f|f|t
33803690|NCT05049421|||COHORT||PROSPECTIVE|||||||
33803691|NCT04664998|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The two groups are male participants enrolled in the Align study, and their sexual partners enrolled in the parent study, Kampala Women's Bone study.||||
33803692|NCT00288288|||COHORT||PROSPECTIVE|||||||
33803693|NCT04986475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|In order to ensure randomization in the study, a random numbers table was created by dividing them into two groups based on the number determined on the site https://www.randomizer.org/. In order to prevent bias, in order to divide the women into groups according to the randomization list, the groups were written and sealed in two separate opaque envelopes as intervention (the ney sound is played during the NST procedure) and control (the routine NST procedure was applied). Double blinding was done on request.||t|f|t|t
33803694|NCT00215787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803695|NCT00407628|||CASE_CONTROL||RETROSPECTIVE|||||||
33803696|NCT06014697|||COHORT||PROSPECTIVE|||||||
33803697|NCT01344642|||COHORT||PROSPECTIVE|||||||
33803698|NCT04664426|||OTHER||CROSS_SECTIONAL|||||||
33803699|NCT00735852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027207|NCT01605812|||CASE_CONTROL||PROSPECTIVE|||||||
34027208|NCT01233895|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027209|NCT02127346|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027210|NCT05489666|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind masking; neither the investigator nor the participants will know, the assigned intervention placement.|A two-arm parallel assignment; one group receives the treatment (vitamin D3 supplement 5,000IU/day) and one group receives the placebo (control).|t|f|t|f
34027211|NCT04813783|||CASE_CONTROL||PROSPECTIVE|||||||
34027212|NCT06465082|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34027213|NCT02315274|NA|SINGLE_GROUP||TREATMENT||NONE||Patients were provided help with insulin pump and CGM between visits throughout the pregnancy.||||
34027214|NCT03482115|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34027215|NCT04977531|||COHORT||CROSS_SECTIONAL|||||||
34027216|NCT03352466|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Double-blind||t|f|t|f
34027217|NCT06633094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027218|NCT03876626|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34027219|NCT00638053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027220|NCT05622240|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027221|NCT02989324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027222|NCT03259412|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027223|NCT06501469|||COHORT||PROSPECTIVE|||||||
34027224|NCT05151289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Regarding the placenta study : for each patient included, the placenta is sent to anatomo-pathology and a referent anatomo-pathologist designated for the study in each center makes an analysis (blind of dosages of sFlt-1/PlGF but not of the clinic)|Patients consulting in one of the participating centers for intra uterine growth restriction.||||
34027225|NCT02811432|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking of parents, caregivers, or healthcare workers was not possible due to the nature of the KMC intervention. The independent statistician who conducted the analyses was masked to treatment allocation.|||||
34027226|NCT02758639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027227|NCT01998841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027228|NCT04061148|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Repeated NIRS measure comparison of patients being treated for Major Depressive Disorder with control, non-depressed subjects.||||
34027229|NCT01850251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027230|NCT04168008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be assigned in equal proportions to either the WISH Adherence arm or to the WISH Parenting arm|f|f|f|t
34027231|NCT05133934|||COHORT||CROSS_SECTIONAL|||||||
34027232|NCT01179711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027233|NCT00789243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34027234|NCT04748627|||COHORT||PROSPECTIVE|||||||
34027235|NCT06156332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027236|NCT03997851|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The antipruritic effect of 3 topical treatments of varying doses and 1 vehicle treatment will be explored in each subject. One study visit will consist of testing all topical formulations on histaminergic induced itch, and second study visit will test all topical formulations on non-histaminergic induced itch.|t|f|t|f
33722817|NCT06037720|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33722818|NCT05028439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722819|NCT02030379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722820|NCT02022098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722821|NCT04052048|||COHORT||PROSPECTIVE|||||||
33803700|NCT03230006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to one of two conditions: 1) treatment with the UP or 2) treatment with therapist-guided Take Control (TC; a computerized alcohol reduction program). In addition, in a subset of twenty-five participants, functional magnetic resonance scanning (fMRI) will be used to examine the effects of the UP on changes in brain activity in areas important to regulation of emotional and reward processes implicated in excessive alcohol consumption.|f|f|f|t
33722822|NCT01020279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722823|NCT05851950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722824|NCT03822676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722825|NCT05158868|||CASE_CONTROL||RETROSPECTIVE|||||||
33722826|NCT05562973|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33722827|NCT04919954|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722828|NCT05548842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722829|NCT06340646|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722830|NCT06215404|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33722831|NCT01887574|NA|SINGLE_GROUP||OTHER||NONE||||||
33803701|NCT05681286|||CASE_ONLY||CROSS_SECTIONAL|||||||
33722832|NCT01166477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722833|NCT05169723|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33722834|NCT05734079|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722835|NCT00002504||||TREATMENT||||||||
33722836|NCT00768144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722837|NCT04059679|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33722838|NCT00304564|NA|SINGLE_GROUP||SCREENING||NONE||||||
33803702|NCT02169869|RANDOMIZED|PARALLEL||OTHER||NONE||randomized-controlled trial||||
33803703|NCT05902845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803704|NCT04164940|||COHORT||OTHER|||||||
33803705|NCT05948813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803706|NCT05113810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803707|NCT03693066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803708|NCT00068458|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803709|NCT05145205|||COHORT||RETROSPECTIVE|||||||
33803710|NCT03769870|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33803711|NCT04544982|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33803712|NCT00084396||||TREATMENT||NONE||||||
33803713|NCT05598359|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33803714|NCT04804566|||COHORT||PROSPECTIVE|||||||
33803715|NCT03833440|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm A: combination of Durvalumab + NKG2A inhibitor Monalizumab (IPH2201), to target a PD-L1 co-inhibitory pathway~* Arm B: combination of Durvalumab + CD73 antibody MEDI9447, to target limitations of antitumor T-cell immunity caused by adenosine receptor signaling~* Arm C: combination of Durvalumab + ATR inhibitor AZD6738, to potentially enhance anti- tumour T-cell responses~* Arm D: a standard third or forth-line chemotherapy maintenance (Docetaxel).~* Arm E : combination of Durvalumab + MET kinase inhibitor Savolitinib (AZD6094)"||||
33803716|NCT05618951|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33803717|NCT01248260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33722839|NCT01531712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803718|NCT00006017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722840|NCT01955161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722841|NCT00416559|NON_RANDOMIZED|||SUPPORTIVE_CARE||||||||
33722842|NCT02364544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722843|NCT04652479|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803719|NCT01298076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803720|NCT00504322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803721|NCT03685071|||CASE_ONLY||PROSPECTIVE|||||||
33803722|NCT01532388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803723|NCT02210442|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803724|NCT05356676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803725|NCT00130546|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33803726|NCT02966613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803727|NCT01602640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34027237|NCT01328379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027238|NCT04597697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027239|NCT06395805|||FAMILY_BASED||PROSPECTIVE|||||||
34027240|NCT04977479|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34027241|NCT02443987|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34027242|NCT00970593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027243|NCT05881525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722844|NCT02408393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722845|NCT01600352|||CASE_ONLY||PROSPECTIVE|||||||
33722846|NCT02925091|||COHORT||PROSPECTIVE|||||||
33722847|NCT00279890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722848|NCT03252873|||COHORT||RETROSPECTIVE|||||||
33722849|NCT00775931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722850|NCT05958355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722851|NCT02032966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722852|NCT04164615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33722853|NCT00456547|||CASE_CONTROL||PROSPECTIVE|||||||
33722854|NCT01998698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722855|NCT02081482|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33722856|NCT04984993|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets after a 4 -6 week screening period||||
33722857|NCT06063395|||COHORT||PROSPECTIVE|||||||
34104240|NCT00498966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two groups with regard to pre-treatment: patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor, while patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor.~One treatment group: all patients will receive perifosine 100 mg qhs daily orally. Patients are to be instructed that perifosine is to be taken with food."||||
34104241|NCT03105765|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104242|NCT03796221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803728|NCT03822520|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33803729|NCT01594957|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803730|NCT00910338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104243|NCT01963832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104244|NCT06357000|||COHORT||RETROSPECTIVE|||||||
34104245|NCT00167531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34104246|NCT04592562|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Patients who meet study eligibility will undergo the novel Genicular artery embolization procedure by a licensed Interventional Radiologist at the University of Chicago Medical Center.||||
33803731|NCT06450301|||COHORT||PROSPECTIVE|||||||
33803732|NCT00604955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803733|NCT04957849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803734|NCT01905462|||COHORT||RETROSPECTIVE|||||||
33803735|NCT02837211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803736|NCT00324350|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33803737|NCT04116372|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33803738|NCT05878470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803739|NCT01910896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803740|NCT02974322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803741|NCT04491201|||COHORT||CROSS_SECTIONAL|||||||
33803742|NCT03819166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33803743|NCT03942445|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All muscle biopsies are immediately labeled and routed to the lab where technicians and assessors are blinded.||f|f|f|t
33803744|NCT03865056|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33803745|NCT03480776|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33803746|NCT06433713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803747|NCT03167736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803748|NCT02957799|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803749|NCT04565028|NA|SINGLE_GROUP||OTHER||NONE||||||
33803750|NCT04820049|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33803751|NCT03895515|||COHORT||RETROSPECTIVE|||||||
33803752|NCT04672967|||CASE_CONTROL||PROSPECTIVE|||||||
33803753|NCT03640195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Intervention is divided into two parts: part of The Experimental group received Transcutaneous acupoint electrical stimulation 20 minutes/weeks, the acupoints are unilateral Hegu (LI4) and LU7; This study used Transcutaneous nerve electrical stimulation , 20 minutes each time, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3).A seeds embedding method with seeds attached to the four sides of the unilateral ear, using the thumb and forefinger to apply pressure, the participants will feel sour, each point is 1min, 5days/week, 3 times/day.~Control group: without intervention"||||
33803754|NCT02548806|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34104247|NCT06296030|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||This project's research design is a two-by-two factorial design. Factor one, the type of ACT intervention delivered, has two levels - POOF delivery (level 1) and a classic ACT delivery (level 2). Factor two, the facilitator's first group treatment delivery, also has two levels. There are four (4) group facilitators. The first two facilitators deliver traditional ACT first (level 1), and the second two facilitators deliver POOF first (level 2). Each facilitator providing group treatment will facilitate two groups (classic and POOF), one after the next. However, facilitators will be randomized to the order in which they deliver their first group to reduce experimenter/ clinician history bias. All of the facilitators are licensed, mental health clinicians.|t|t|f|f
33803755|NCT06207565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803756|NCT00681213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803757|NCT03865199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Women aged 18 or older undergoing medical or surgical abortion at Planned Parenthood of Illinois will be eligible for inclusion in the study. Recruitment will occur two days a week, altering days of the week, and all patients seen on recruitment days not meeting exclusion criteria will be offered the opportunity to enroll after their confirmatory ultrasound. This will be a non-blinded 1:1 randomized controlled trial. Randomization will be done using a computer-generated randomization sequence. A research assistant will place study group assignment in a sealed, opaque, sequentially numbered envelope. This envelope will be opened by the researcher obtaining consent, who will not be involved in clinical care.||||
33803758|NCT06190717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803759|NCT06449677|RANDOMIZED|PARALLEL||TREATMENT||NONE||13-week RCT followed by a 13-week Extension Phase in which all participants use the iLet BP System||||
33803760|NCT02638337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803761|NCT02978716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803762|NCT04010435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33803763|NCT03884296|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803764|NCT04000516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803765|NCT01042275|||CASE_CONTROL||RETROSPECTIVE|||||||
33803766|NCT00201149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33803767|NCT03877198|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The outcome assessor/investigator will be blinded for treatment allocation||f|f|f|t
33803768|NCT00167999|||CASE_CONTROL||PROSPECTIVE|||||||
33803769|NCT04286269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be maintained by using identical headphones and MP3 players for all subjects. The PI, any personnel involved in collecting the clinical outcomes (e.g., PIPP) or collecting or quantifying EEG outcomes, and the statistician will be blinded.||t|t|t|t
33803770|NCT00228475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803771|NCT00051298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33803772|NCT05046613|||COHORT||PROSPECTIVE|||||||
33803773|NCT04995627|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Single subject multiple randomized double-blinded multi-crossover placebo-controlled trials (N-of-1 trials)|t|t|t|t
33803774|NCT02059538|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33803775|NCT03304834|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric study||||
33803776|NCT04623567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803777|NCT03169413|||CASE_CONTROL||RETROSPECTIVE|||||||
33803778|NCT04400136|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
33803779|NCT03749785|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33803780|NCT06119711|||COHORT||PROSPECTIVE|||||||
33803781|NCT00604669|||||RETROSPECTIVE|||||||
33803782|NCT06698848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803783|NCT04194710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803784|NCT01171976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803785|NCT04959669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803786|NCT02847715|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803787|NCT06697301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803788|NCT04670887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803789|NCT03582592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33803790|NCT03592732|||OTHER||CROSS_SECTIONAL|||||||
33803791|NCT01137175|||CASE_ONLY||PROSPECTIVE|||||||
33803792|NCT02056236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803793|NCT05171985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33803794|NCT05004207|||COHORT||PROSPECTIVE|||||||
33803795|NCT03074656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803796|NCT05482945|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention (Ar/O2 or standard ventilation) is assigned to the patient using a centrally generated randomization plan, balanced by centre.||||
33803797|NCT06540443|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33803798|NCT05652075|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33803799|NCT00715884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803800|NCT03532165|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||In all enrolled patients with concern for pulmonary embolism, a lower extremity ultrasound will be performed at the patient's bedside by the emergency room provider. If it is positive for a deep vein thrombosis, then a confimatory ultrasound will be performed by the vascular lab, and the patient started on anticoagulation to treat both the DVT and presumed PE. No CTA will be obtained in this group. Everyone else who had a negative bedside ultrasound performed by the ER provider will not receive a second ultrasound, but will rather go on to get the CT angiogram of the chest they would have likely received if not in the study.||||
33803801|NCT00746655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803802|NCT02137616|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803803|NCT03933800|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803804|NCT01954836|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33803805|NCT06405841|||COHORT||PROSPECTIVE|||||||
33803806|NCT06451016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803807|NCT02572700|||COHORT||PROSPECTIVE|||||||
33803808|NCT06465485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803809|NCT04587505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33803810|NCT00644514|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803811|NCT05971875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803812|NCT01289314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722858|NCT00747955|||COHORT||PROSPECTIVE|||||||
33722859|NCT01517009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722860|NCT02994823|||CASE_CROSSOVER||PROSPECTIVE|||||||
33722861|NCT00994955|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33722862|NCT05270954|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The Phase 1 is Open Label; The Phase 2 is double-blind.||t|t|t|f
33722863|NCT04478357|RANDOMIZED|CROSSOVER||OTHER||NONE||This is an open-label, randomized, single-dose, 4-period, 4-treatment, 2-sequence, two 2-way crossover study in healthy participants. This study will assess the BE of Fesoterodine (Toviaz™) 4 mg and 8 mg ER tablets manufactured at Zwickau (Reference) versus Freiburg (Test). Study participants will include healthy male and/or female individuals between the ages of 18 and 55 years, inclusive. Approximately 18 participants who fulfill entry criteria will be randomized to 1 of the 2 treatment sequences as shown in the table below.||||
33722864|NCT03626220|||CASE_CONTROL||PROSPECTIVE|||||||
33722865|NCT00981955|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33722866|NCT03679910|||CASE_CONTROL||RETROSPECTIVE|||||||
33722867|NCT03084588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722868|NCT04225169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722869|NCT00783601|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722870|NCT05184114|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33722871|NCT00893087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722872|NCT05572112|||COHORT||PROSPECTIVE|||||||
33803813|NCT00150163|||||PROSPECTIVE|||||||
33803814|NCT03028389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33803815|NCT02623894|||CASE_ONLY||CROSS_SECTIONAL|||||||
33803816|NCT04418973|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803817|NCT00504023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803818|NCT01149759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803819|NCT00731341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803820|NCT06287944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803821|NCT01926249|||COHORT||PROSPECTIVE|||||||
34027244|NCT06500169|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34027245|NCT02959424|||COHORT||CROSS_SECTIONAL|||||||
34027246|NCT04615650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be plotted into a database by an independent blinded data manager.|Randomised controlled multicentre trial|f|f|f|t
34027247|NCT03857269|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34027248|NCT05976230|||COHORT||PROSPECTIVE|||||||
34027249|NCT00851435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027250|NCT03944824|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking, patients and physicians will be aware of their study arm assignment|The investigators will recruit 25 patients who will receive the exercise plans and once weekly visits from the exercise physiologists. 25 patients will be control. All 50 patients will receive pre and post physical function testing.||||
34027251|NCT02205190|RANDOMIZED|CROSSOVER||||NONE||||||
34027252|NCT04832009|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Randomized, double-blinded, parallel-design approach study.|Comparisons of outcome variables will be made using a mixed model ANOVA.|t|t|t|f
34027253|NCT00476775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34027254|NCT06361121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients will be randomized into two groups: MTP block group and TPV block group in a 1:1 ratio using a computer-generated random table. The patient's assigned group information will be elicited from a sealed opaque envelope by the anesthesiologist who will perform the US-guided MTP and TPV block and will not be involved in further data collection or patient care. The patients and both the surgical and anesthesia teams, who are responsible for patient care and data collection are blinded from the group assignments||t|t|t|t
34027255|NCT00890604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027256|NCT01807247|||COHORT||PROSPECTIVE|||||||
34027257|NCT06038162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027258|NCT02953977|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Block randomized|f|f|f|t
34027259|NCT06048263|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027260|NCT01118065||||TREATMENT||NONE||||||
34027261|NCT01342757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027262|NCT04792424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking of post-filter ionized calcium result in no-monitoring arm||f|t|f|f
34027263|NCT04974749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027264|NCT05142280|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Web-based randomized controlled trial|t|f|f|f
34027265|NCT03713632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027266|NCT06377514|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34027267|NCT04123626|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Single dose cohorts are open label. Repeat dose cohorts are randomized, double masked.||t|t|f|t
34027268|NCT02555956|||CASE_ONLY||PROSPECTIVE|||||||
34027269|NCT03660306|||COHORT||PROSPECTIVE|||||||
34027270|NCT06089200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027271|NCT04069338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027272|NCT05782881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027273|NCT01291394|||COHORT||OTHER|||||||
34027274|NCT00365313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34027275|NCT00997204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027276|NCT05256394|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped-wedge, cluster randomized trial using mixed methods to assess the multilevel determinants of CDS implementation success. The investigators will use both quantitative and qualitative data to provide a comprehensive understanding of the clinical context of the participating sites before and after the trial, and identify system, clinic and provider-level factors that may influence the implementation process. In summary, this is a complete, open-cohort stepped-wedge cluster-randomized design with 5 time periods (including the baseline), with each period spanning 1 month and 2 clinics switching from control to intervention at each of the 4 steps (for a total study duration of 5 months).||||
34104248|NCT06103799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The information-motivation-behavioral skills (IMB) model, first proposed by Fisher, is composed of three elements-information, motivation, and behavioral skills-and is aimed at transferring patients' behavior into a positive direction, including self-behavior management ability, medication compliance and so on. For diabetic patients with poor adherence, the IMB model of care can be considered.|t|f|f|f
34104249|NCT04794686|||COHORT||PROSPECTIVE|||||||
34027277|NCT00741507|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34027278|NCT00610610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027279|NCT05071976|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027280|NCT05167799|||CASE_ONLY||PROSPECTIVE|||||||
34027281|NCT02349867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027282|NCT03604276|||COHORT||PROSPECTIVE|||||||
34027283|NCT05666245|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34027284|NCT03961659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027285|NCT00261781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027286|NCT04140162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027287|NCT02040441|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34027288|NCT06622642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027289|NCT05468424|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
34027290|NCT00220831|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34027291|NCT04017650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027292|NCT03509857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027293|NCT06157190|||COHORT||RETROSPECTIVE|||||||
34027294|NCT00766779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027295|NCT05017597|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34104250|NCT02124005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104251|NCT03912753|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will recruit, screen, assess, and randomize gay and bisexual men at risk for HIV infection and alcohol abuse to either the Comunică intervention (n=163) or EAC (n=163).||||
34104252|NCT06207201|||COHORT||PROSPECTIVE|||||||
34104253|NCT01027754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104254|NCT05625165|||CASE_CONTROL||RETROSPECTIVE|||||||
34104255|NCT03996395|||COHORT||PROSPECTIVE|||||||
34104256|NCT05456399|||COHORT||CROSS_SECTIONAL|||||||
34104257|NCT00018720|||||PROSPECTIVE|||||||
34104258|NCT02264821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027296|NCT03225872|||FAMILY_BASED||RETROSPECTIVE|||||||
34027297|NCT04647565|||OTHER||PROSPECTIVE|||||||
34027298|NCT05404334|||CASE_CONTROL||PROSPECTIVE|||||||
34104259|NCT06549868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104260|NCT05438095|||COHORT||PROSPECTIVE|||||||
34148910|NCT04645745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148911|NCT02140541|||COHORT||RETROSPECTIVE|||||||
34104261|NCT04869514|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The data collection and analysis will be conducted by a research assistant blind to treatment allocation. The study subjects will be blinded with respect to the hypothesis.|The study design consists of a four-arm (1:1:1:1 ratio) randomized controlled trial.|t|t|f|t
34104262|NCT06074406|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34104263|NCT02664298|||COHORT||PROSPECTIVE|||||||
34104264|NCT06175065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104265|NCT05627492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104266|NCT06690177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104267|NCT00002656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104268|NCT05350267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Treatment versus enhanced standard of care|f|f|t|t
34104269|NCT06674369|||CASE_CROSSOVER||PROSPECTIVE|||||||
34104270|NCT04768478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722873|NCT01983527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722874|NCT04682184|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33722875|NCT01366339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722876|NCT05846529|||CASE_CONTROL||RETROSPECTIVE|||||||
33722877|NCT00123539|RANDOMIZED|||PREVENTION||DOUBLE||||||
33722878|NCT04979169|RANDOMIZED|PARALLEL||PREVENTION||NONE||The proposed study will utilize a randomized, prospectively collected, convenience sample and a longitudinal design.||||
33722879|NCT01798472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722880|NCT06229496|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33722881|NCT06349681|||COHORT||PROSPECTIVE|||||||
33722882|NCT03724812|NA|SINGLE_GROUP||TREATMENT||NONE||Devices under investigation in this clinical investigation include the FlexNav™ Delivery System(s) (18 F and 19 F) and FlexNav™ Loading System(s) (Small and Large), which are both approved for investigational use only. Other devices to be used in the clinical investigation include all four (4) market released Abbott Portico™ valve sizes (23mm, 25mm, 27mm and 29mm).||||
33722883|NCT00001053||||PREVENTION||DOUBLE||||||
33722884|NCT01912417|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33722885|NCT00758030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722886|NCT03370003|||COHORT||OTHER|||||||
33722887|NCT00183300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33722888|NCT03134482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803822|NCT05412316|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The SWD will be applied using a CEC M-8 shortwave thermotherapy unit (CEC Electrónica S.R.L., Argentina) that emits RF at a frequency of 27.12 MHz. The device has two rectangular capacitive applicators (18 × 12 cm), which will be placed below and above the dominant shoulder. The coplanar application will be done using the continuous wave mode. The intensity of SWD will be gradually increased until the volunteer perceives a sensation of heat, and once familiar with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the SWD application. Once the first application is completed, the volunteer will be allowed to rest for a period of 2-3 minutes and three repetitions will be performed. Healthy volunteers will be in a lateral supine position, and a cotton towel will be used to absorb perspiration and avoid unwanted heat effects.||||
33803823|NCT05166070|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a single center, open label, non-controlled, exploratory study. The 3+3dose escalation design will be implemented to evaluate the safety and tolerability of RD133 in the treatment of subjects with relapsed/refractory MSLN-positive solid tumors."||||
33803824|NCT05672095|NA|SEQUENTIAL||TREATMENT||NONE||||||
33803825|NCT01435252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803826|NCT03992274|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803827|NCT01956032|||||PROSPECTIVE|||||||
33803828|NCT06514417|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803829|NCT02639936|||COHORT||PROSPECTIVE|||||||
33803830|NCT05089266|NA|SEQUENTIAL||TREATMENT||NONE||||||
33803831|NCT06109454|||CASE_CONTROL||PROSPECTIVE|||||||
33803832|NCT00662519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803833|NCT04436289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants and members of the research team recruiting and implementing the strategy will be unmasked to randomization assignment due to the behavioral nature of the strategy and need for team members to explain the study arm procedures to participants. Study assignments will be masked to the investigators until all outcome data have been collected.|Participants will be randomized 1:1 to care as usual or Home Link arm. We will perform individual randomization blocked by HIV-status to enroll 30 HIV-uninfected per arm and 90 PWH per arm.|f|f|t|f
33803834|NCT01219790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803835|NCT05381532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants may not know to which study arm they are assigned.||t|f|f|f
33803836|NCT00520221|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33803837|NCT04430634|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33803838|NCT02315456|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33803839|NCT05811936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Study personnel (Coordinator, Nurse, Data Collectors) will not be blinded to group as intervention activities differ by group.|Patient and Caregiver dyads will be randomized to either the SNAP intervention group or the Usual Care (UC) group after baseline assessment. Dyads will be randomized to study arm (SNAP or UC) using permuted block randomization with block sizes of 2 or 4. Randomization will be stratified by patient gender (male or female) and treatment (radiation only, radiation + surgery OR chemotherapy, radiation + surgery + chemotherapy).||||
34104271|NCT06159582|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-arm RCT with 2:1 randomization to eSTEP treatment group or usual care control group||||
34104272|NCT05497245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104273|NCT06689709|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|not able|Prospective study.||||
34104274|NCT06685874|||COHORT||RETROSPECTIVE|||||||
34104275|NCT05103111|||OTHER||PROSPECTIVE|||||||
34104276|NCT06455800|||COHORT||PROSPECTIVE|||||||
34104277|NCT04052126|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33722889|NCT02174068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104278|NCT02372357|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148912|NCT01659255|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027299|NCT03150407|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|VR101 devices and Sham control rings differ only in that VR101 device rings contain glycerol-based lubricant, whereas the Sham controls do not. The product, either VR101 device or Sham ring, is randomly assigned to participants when they are enrolled in the study. Once inserted in the vagina, the devices are indistinguishable. Thus, Investigators cannot tell whether a VR101 device or Sham is in place while performing any vaginal examination. All products (VR101 devices or Sham rings) are intravaginally placed by participants in a room that is not occupied by Care Providers or Investigators, so it is impossible for them to know which product has been assigned. The packaging of all products is identical.|"Participants randomly assigned to GROUP V1S2 will insert a VR101 device and leave it in place for 7 days, then remove the first device and replace it with a fresh device on day 7. Subsequently, 2 additional devices will be inserted and removed serially on a 7-day schedule until a total of 4 devices are used by each study participant, with the last device removed at day 28.~Participants assigned to S1V2 will insert a sham control ring and leave it in place for 7 days, then remove the first ring and replace it with a new ring on day 7. Subsequently, 2 additional sham rings will be inserted and removed serially on a 7-day schedule until a total of 4 sham rings are used by each study participant, with the last sham ring removed at day 28.~Following completion of the first 28-day treatment course with either VR101 or sham control, participants will undergo a 21-day washout period during which no devices will be used, before crossing over to treatment with the other device."|t|t|t|f
34027300|NCT01393886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027301|NCT05094089|||COHORT||PROSPECTIVE|||||||
34027302|NCT04975191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803840|NCT00909324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803841|NCT02136641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33803842|NCT03589625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge cluster-randomized trial||||
33803843|NCT01183598|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803844|NCT05395234|NA|SINGLE_GROUP||PREVENTION||NONE|Masking was not possible due to the nature of the interventions|Cook Like A Boss Online is a single-group pre post intervention design||||
33803845|NCT02259049|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33803846|NCT01959321|||OTHER||PROSPECTIVE|||||||
34027303|NCT05062213|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34027304|NCT06080854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027305|NCT03167983|||CASE_CONTROL||PROSPECTIVE|||||||
34027306|NCT02318303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027307|NCT05456503|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34027308|NCT03333265|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34027309|NCT03593018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027310|NCT01680107|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34027311|NCT03555383|||COHORT||PROSPECTIVE|||||||
34104279|NCT03630510|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. The maneuver was performed for 5 min, followed by tracheal aspiration. To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.||||
34104280|NCT06640192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803847|NCT04207424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803848|NCT04257487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The subjects enrolled in the study, the experimenters, and the members of the Steering Committee, Adjudication Committee, Data Monitoring and Safety Board will not be aware of the assignment of the 3 treatments following their distribution.||t|t|t|t
33803849|NCT02438059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33803850|NCT05018910|NA|SINGLE_GROUP||OTHER||NONE|All infants enrolled had their heart rate variability measured.|All infants enrolled in the study had their heart rate variability measured before, during, and after skin-to-skin sessions. There was no randomization or testing of efficacy.||||
33803851|NCT05078255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803852|NCT04467671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803853|NCT03095872|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33803854|NCT03238755|||COHORT||PROSPECTIVE|||||||
33803855|NCT04531800|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33803856|NCT01695954|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803857|NCT06210659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups; intervention and control group||||
33803858|NCT01421667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803859|NCT01894074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803860|NCT04549831|||CASE_CONTROL||PROSPECTIVE|||||||
33803861|NCT00946413|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33803862|NCT00491959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803863|NCT02282709|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803864|NCT01884805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027312|NCT04539652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027313|NCT05414344|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either 1) a standard brief intervention 2) a modified brief intervention with peer coaching and trauma-related information or 3) assessment only||||
34027314|NCT06003296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027315|NCT02940808|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027316|NCT05424458|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The subjects completed the Modified Dental Anxiety Scale (MDAS), the Orofacial Esthetic Scale (OSE) and the Oral Health Impact Profile-14 (OHIP-14), before implant surgery and after definitive prosthesis placement.||||
33803865|NCT01650896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803866|NCT01250769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803867|NCT04008316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||prospective, controlled, double blind, randomized clinical trial: colchicine 1mg/day versus placebo for 6 months, with a 12 months total follow-up.|t|t|t|f
34148913|NCT00024011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803868|NCT01070940|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34027317|NCT00735397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027318|NCT00055042||||TREATMENT||||||||
34027319|NCT00216138|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722890|NCT06022120|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"Using a stepped-wedge design, participants at the enrolled schools function as their own control. Thus, the effect of the intervention is evaluated as in an RCT design. All participants are asked to indicate whether they want to participate in the scientific evaluation of the intervention. Those who wish to participate are invited to the data collection containing: Signing of consent and answering questionnaires. No preparation is required of the participants before data collection begins. Smaller groups of students and teachers participate in focus groups as part of the process evaluation. All intervention activities take place at the participants' school. Calculation, analysis and interpretation of data will take place at the Department of Occupational and Social Medicine, Holbæk Hospital.~The intervention activities are developed by a student commitee, accoording to a participatory approach and following the Work Health Improvements Network concept."||||
33722891|NCT03747874|NA|SINGLE_GROUP||SCREENING||NONE||||||
34027320|NCT06124937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither the participants nor the researchers know which treatment or intervention patients are receiving|Two arms, parallel-group, phase 3, randomized, double-blind, placebo-controlled trial with allocation sequence concealment and blinded endpoint adjudication on 492 patients|t|t|t|t
34027321|NCT04274231|||OTHER||PROSPECTIVE|||||||
34027322|NCT00865371|RANDOMIZED|CROSSOVER||||NONE||||||
34027323|NCT02845700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027324|NCT00742118|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34027325|NCT01670591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027326|NCT06508320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34027327|NCT02006329|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104281|NCT05633056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||An adaptive, randomized controlled trial comparing the effectiveness of 4 adherence support intervention arms. Interventions arms include: enhanced standard of care; psychosocial support; mHealth using cellular-enabled electronic dose monitoring; combined mHealth psychosocial support. Level of support will be adjusted using a differentiated service delivery (DSD)- informed assessment of treatment support needs.||||
34148914|NCT00996346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148915|NCT01804166|NA|SINGLE_GROUP||OTHER||NONE||||||
33722892|NCT00385996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722893|NCT02659709|||COHORT||PROSPECTIVE|||||||
33722894|NCT04179695|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722895|NCT04248608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148916|NCT04219514|||COHORT||OTHER|||||||
33722896|NCT05069766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722897|NCT02248350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33722898|NCT05880927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722899|NCT04846803|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"Inclusion with 6 months observation (standard treatment). Randomisation in ratio 3:1 for treatment initiation at baseline.~1. Patients with prophylactic bladder flushing with an ABU strain.~2. The control group with saline bladder flushing ."|t|t|t|t
33722900|NCT02612935|||COHORT||RETROSPECTIVE|||||||
33722901|NCT02009046|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722902|NCT01466387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722903|NCT01405963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722904|NCT05447754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722905|NCT02232425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722906|NCT04748133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722907|NCT03721315|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722908|NCT00708539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33722909|NCT03585179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will receive both topical and oral interventions. Group 1: pills of tranexamic acid 250 mg bid plus placebo gel bid, Group 2: pills of placebo bid plus 5% tranexamic acid gel bid and Group 3: pills of placebo bid plus 4% hydroquinone cream at night and a placebo cream at morning. Containers will be of identical appearance.|Three-arm clinical trial|t|f|t|t
33722910|NCT02430675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33722911|NCT04212260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The parties involved consist of patients, sleep medicine team (includes sleep clinician and research personnel who collect/assess sleep data), and speech-language pathology team (research personnel who provide instructions on exercises and collect/assess speech data).~All patients and members of the sleep medicine team will be masked to the condition assigned to each patient. The speech-language pathology team is not blinded to the patient assignments."||t|t|t|t
33722912|NCT03144674|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33722913|NCT00914355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722914|NCT02423538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803869|NCT06597058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803870|NCT06151314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803871|NCT02739152|||CASE_ONLY||PROSPECTIVE|||||||
33803872|NCT05138133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Participant, Care Provider and Investigator)||t|t|t|t
33803873|NCT04400734|||COHORT||PROSPECTIVE|||||||
33803874|NCT04518813|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803875|NCT02555475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803876|NCT02920710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027328|NCT01859897|||COHORT||PROSPECTIVE|||||||
34148917|NCT04363450|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be randomized to the investigational drug (hydroxychloroquine) or placebo. Both will have identical appearance and will be taken at the same dosing interval. The administration of the drug and assessment will be blinded. After final analysis, study arms will be unmasked.|Randomized, placebo-controlled, double-blind study with 1:1 randomization of hydroxychloroquine to placebo|t|t|t|t
34027329|NCT05608473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34148918|NCT03648216|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study advertisements and information provided to participants will focus on non-specific behaviour change, in order to mask participants to the purpose of the study.|Upon obtaining consent, eligible participants will complete a week-long baseline period and then will be randomly assigned to either a 1-week intervention or control group, followed by a 1-week follow-up period.|t|f|f|f
33803877|NCT01700296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148919|NCT06526156|||COHORT||PROSPECTIVE|||||||
33803878|NCT05512962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be masked to the dose level of triamcinolone acetonide administered with the suprachoroidal Oxulumis® microcatheter|Parallel Two-Dose Group Assignment|t|f|f|f
34027330|NCT05681715|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803879|NCT03102034|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027331|NCT03430765|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
34027332|NCT03973307|||COHORT||PROSPECTIVE|||||||
34027333|NCT02213510|RANDOMIZED|PARALLEL||||NONE||||||
33803880|NCT03817762|||OTHER||RETROSPECTIVE|||||||
33803881|NCT00056966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803882|NCT05374525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027334|NCT03338725|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster Randomized Trials and The Stepped Wedge (Cluster Analysis Mesh Terms)|f|f|f|t
34027335|NCT06550700|||COHORT||RETROSPECTIVE|||||||
33803883|NCT04251442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803884|NCT00468052|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33803885|NCT04840433|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will be invited to have MACE before their endoscopy and colonoscopy.||||
34027336|NCT04490616|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"In the project will be applied a two-site repetitive transcranial magnetic stimulation (rTMS) stimulation.~MCI patients that obtained a score ≤ 10 percentiles, at least one performance/domain of social cognition assessment will be considered impaired at social cognition abilities. In the same day of cognitive-behavioral assessment, patients will be randomly assigned to one of the two groups:~1) RR-Gr received 4 weeks of rTMS stimulation of the RTPJ and MPFC; (2) SR-Gr received of the RTPJ and MPFC sham stimulation during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment consisted of five sessions. This paradigm has proven to be effective for improve cognitive performances in AD patients. In the sham condition, a sham coil will be used."|t|t|f|f
33803886|NCT05750966|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients and investigators will know in which group they are assigned.|This study is designed as an open-label multicenter non-inferiority RCT. Patients will be randomly assigned to the intervention group (one day of ABT after ERCP) or the comparator group (4 to 7 days of ABT after ERCP).||||
33803887|NCT03484416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33803888|NCT01662154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803889|NCT05986734|||COHORT||PROSPECTIVE|||||||
33803890|NCT02941484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803891|NCT01721343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803892|NCT02752230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803893|NCT03640299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803894|NCT03177044|NA|SINGLE_GROUP||TREATMENT||NONE|All assessments are conducted by an assessor not providing the intervention|Prospective cohort||||
33803895|NCT03912831|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803896|NCT01905826|||COHORT||PROSPECTIVE|||||||
34027337|NCT03374007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027338|NCT05019599|RANDOMIZED|PARALLEL||PREVENTION||NONE||nutritional intervention with low protein diet (\< 0.8 G protein/kg body weight/day)||||
34027339|NCT01307748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34027340|NCT04800679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027341|NCT04429308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027342|NCT02445430|||FAMILY_BASED||PROSPECTIVE|||||||
34027343|NCT00735618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027344|NCT06370481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027345|NCT05189834|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34027346|NCT05350605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Experimental Design||||
34027347|NCT00438217|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027348|NCT00562523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027349|NCT00631657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027350|NCT03039426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33803897|NCT01136694|||COHORT||PROSPECTIVE|||||||
33803898|NCT00246805|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33803899|NCT06365489|||COHORT||PROSPECTIVE|||||||
33803900|NCT02797184|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the participant and the investigator will be masked to which KNO3 dose is administered at each visit. However, it is known at the outset that each patient will receive 10 mmol KNO3 during one visit and 20 mmol KNO3 at another visit, with the order randomly assigned.|Subjects will receive one drug dose on the first dose visit and the second drug dose on the second dose visit. The order of the two drug doses (10 and 20 mmol KNO3) will be randomized, so that some subjects will receive the lower dose first and others will receive the higher dose first|t|f|t|f
33803901|NCT04449835|||COHORT||PROSPECTIVE|||||||
33803902|NCT02776085|||OTHER||PROSPECTIVE|||||||
33803903|NCT04899024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33803904|NCT05146505|||CASE_ONLY||PROSPECTIVE|||||||
33803905|NCT00934817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33803906|NCT02135679|||COHORT||PROSPECTIVE|||||||
33803907|NCT02129283|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33803908|NCT05128968|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33803909|NCT01066767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33803910|NCT03887806|||COHORT||RETROSPECTIVE|||||||
34027351|NCT00822978|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34027352|NCT05122559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027353|NCT03153007|||CASE_ONLY||CROSS_SECTIONAL|||||||
34027354|NCT04935229|NA|SINGLE_GROUP||TREATMENT||NONE||"Sentinel Cohort: Two doses of SD-101 (0.5mg and 2mg) administered 2 weeks apart via PEDD/HAI using the TriNav device.~Cohorts A, B, C, and Phase 1b: Three weekly doses of SD-101 (given over two 52-day cycles) in dose-escalation fashion (2mg, 4mg, 8mg-optional) via PEDD/HAI using the TriNav device.~Cohort D (optional): Two weekly doses of SD-101 (given over two 52-day cycles) via PEDD/HAI using the TriNav device."||||
34027355|NCT04150770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803911|NCT02293733|||||RETROSPECTIVE|||||||
34104282|NCT04512625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The application of the stimuli and the desensitizers and collection of subjects' responses during the visits was carried out by two well-trained examiners. After providing informed consent, the first examiner allocated a number to each patient. The patients were blinded to whether they were in the control group or one of the desensitizer groups. The application of the agents was also carried out by the same examiner. The tests were carried out by the second examiner who also recorded the sensitivity during the visits. Group allotment and the application of the agents were thus carried out by the first examiner, which were concealed from the second examiner who assessed and recorded the sensitivity scores, making the study double-blinded.|The present study was designed as a single-center, parallel, double-blind, randomized, controlled clinical trial|t|f|t|t
34104283|NCT00131742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34104284|NCT02815254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148920|NCT02638155|||CASE_CONTROL||PROSPECTIVE|||||||
33803912|NCT01493375|||COHORT||PROSPECTIVE|||||||
33803913|NCT02986984|||COHORT||PROSPECTIVE|||||||
33803914|NCT05848024|||COHORT||PROSPECTIVE|||||||
33803915|NCT01426412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33803916|NCT02959229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34027356|NCT03510598|NA|SEQUENTIAL||TREATMENT||NONE||Kybella and Zeltiq CoolSculpting CoolMini||||
33803917|NCT00144066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803918|NCT05318066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding Preparation for tracheal intubation will be done as per the ICU protocol \* The airway operator will be blinded to the intervention and thus sent out of the patient's cubicle. The study team will administer a fluid bolus over 10 minutes. in the FL arm. No fluid will be administered in the VP arm. The fluid bag will be brought into the cubicle in a concealed bag. After fluid administration or not the fluid bag will be taken out in the same bag. A vasopressin infusion or saline infusion will be started at as per the assigned arm at the same time as the fluid bolus. The airway operator will enter the room and proceed with tracheal intubation.|"Randomization and treatment allocation All patients in ICU will be screened at the time the clinical team decides that tracheal intubation is required. Consent will be obtained from the patient's surrogate once they meet the inclusion and have no exclusion criteria. Once consent is obtained, the patient will be randomized.~Study assignments will be placed in opaque randomization envelopes, and will be available to operators in the ICU. Study group assignment will remain concealed to study personnel and operators until after the decision has been made to enroll the patient in the study. The operator will open the next consecutively numbered envelope and follow the assignment of either fluid loading (FL arm) or low dose vasopressor (VP arm)."|t|t|t|t
33803919|NCT01323166|||CASE_CONTROL||RETROSPECTIVE|||||||
33803920|NCT04291638|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Independent evaluators assigned to assess outcomes at Post-IGBT and School Year Follow-Up time points will be unfamiliar with families' progress during the IGBT, as well as masked to treatment participation (i.e., whether or not families participated in the remote IGBT)."|All participating families attend videoconferencing-based group parent training sessions. Families are given the opportunity to opt in to participate in the videoconferencing-based intensive group behavioral treatment program (remote IGBT).|f|f|f|t
33803921|NCT02095717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33803922|NCT02378922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803923|NCT04355221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33803924|NCT02162225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803925|NCT06244771|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1A: sequential; Phase 1B and Phase 2: parallel||||
33803926|NCT01929759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Treatment switch study||||
33803927|NCT04453332|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective randomized controlled study||||
33803928|NCT00569387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33803929|NCT02273999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33803930|NCT04102059|||OTHER||CROSS_SECTIONAL|||||||
33803931|NCT02482701|||CASE_ONLY||PROSPECTIVE|||||||
33803932|NCT05933213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803933|NCT02860741|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33803934|NCT06225310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803935|NCT04294862|NA|SINGLE_GROUP||OTHER||NONE||||||
33803936|NCT04761939|||OTHER||PROSPECTIVE|||||||
33803937|NCT01259557|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027357|NCT05326282|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Men with suspected or low grade prostate cancer||||
34027358|NCT00144157|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027359|NCT06402760|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027360|NCT02603991|||COHORT||PROSPECTIVE|||||||
34027361|NCT03864887|||CASE_CONTROL||PROSPECTIVE|||||||
34027362|NCT03306446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027363|NCT05327231|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027364|NCT05952674|RANDOMIZED|PARALLEL||TREATMENT||NONE|None of the parties involved in this research will be masked.|Patients (166) suffering from resistant depression will be enrolled over a 24-month period and will be randomized in a (1:1) ratio to receive either Vagus Nerve Stimulation (VNS) along with the Best Medical Treatment (VNS+BMT arm) or the Best Medical Treatment only (BMT arm).||||
34027365|NCT02254434|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34027366|NCT05698225|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027367|NCT01873378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34027368|NCT00002505||||TREATMENT||||||||
34148921|NCT03228485|||COHORT||PROSPECTIVE|||||||
34027369|NCT06633055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027370|NCT01792154|||CASE_CONTROL||PROSPECTIVE|||||||
34104285|NCT05472987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to the intervention. The primary outcome will be determined by a surgeon other than the operating surgeon who is blinded to the intervention. Patients will also receive the same dressings over their wounds and an abdominal binder will be placed over the abdomen in attempts to limit the unblinding of the patient.||t|f|f|t
34027371|NCT03403075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027372|NCT01510626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027373|NCT00141778|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027374|NCT03035929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027375|NCT02803424|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33803938|NCT06699004|||OTHER||CROSS_SECTIONAL|||||||
34027376|NCT03183596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"There has been no large, randomized study to define optimal location of injection based on analgesia and duration. Patients will be randomized to receive a deep Serratus Anterior Block (DSAB) where local anesthetic is deposited deep to the serratus or a superficial Serratus Anterior Block (SSAB) where the local anesthetic is placed between serratus and latissimus dorsi."||||
34027377|NCT01906515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34027378|NCT01474200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027379|NCT04268199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027380|NCT01538082|||COHORT||PROSPECTIVE|||||||
34104286|NCT05388825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34104287|NCT06688110|NA|SEQUENTIAL||SCREENING||NONE|Participants and physician performing colonoscopy will be blinded to the Gixam outcome|All enrolled subjects will undergo the Gixam test followed by a standard of care colonoscopy||||
34104288|NCT03859856|||CASE_CONTROL||PROSPECTIVE|||||||
34027381|NCT03947944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027382|NCT01589289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027383|NCT03173287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Open|||||
34027384|NCT05523791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027385|NCT03240263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34027386|NCT05852223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027387|NCT00796055|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104289|NCT06418698|||COHORT||PROSPECTIVE|||||||
34104290|NCT05150561|||COHORT||PROSPECTIVE|||||||
34104291|NCT00590200|||OTHER||PROSPECTIVE|||||||
34104292|NCT01832298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148922|NCT05455801|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomly apply a negative pressure therapy dressing in the operating room to heal a surgical wound or a conventional dressing without negative pressure in those patients at high risk of presenting complications and surgical site infections||||
33803939|NCT05316766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33803940|NCT03866967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803941|NCT03972046|NA|SINGLE_GROUP||TREATMENT||NONE||Patients, aged 18+, seen at the TriHealth Cancer Institute and/or TriHealth Surgical Institute with a palpable regional melanoma metastasis at the time of initial presentation or with regional recurrence and tumors with a BRAF mutation will be considered for participation in this study.||||
33803942|NCT05595057|||COHORT||PROSPECTIVE|||||||
33803943|NCT00701701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803944|NCT00010777|RANDOMIZED|||TREATMENT||||||||
34148923|NCT02163213|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34148924|NCT01123473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148925|NCT00915148|||CASE_ONLY||PROSPECTIVE|||||||
34148926|NCT00975143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148927|NCT02653716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34148928|NCT03085472|||COHORT||PROSPECTIVE|||||||
34148929|NCT01977690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803945|NCT05780619|||COHORT||PROSPECTIVE|||||||
33803946|NCT03609359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027388|NCT01144247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027389|NCT02503059|||CASE_ONLY||RETROSPECTIVE|||||||
34027390|NCT01213277|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34027391|NCT05068154|||COHORT||PROSPECTIVE|||||||
34027392|NCT02064517|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34027393|NCT04521972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34148930|NCT01953900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148931|NCT04981028|||COHORT||PROSPECTIVE|||||||
34148932|NCT05883618|||COHORT||PROSPECTIVE|||||||
34148933|NCT04731532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|pulmonary department, physical therapy and rehabilitation, anesthesiology and reanimation|randomized, controlled study|t|t|f|f
34148934|NCT05242094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148935|NCT00073424|||||PROSPECTIVE|||||||
34148936|NCT04385225|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34148937|NCT02721108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34148938|NCT02544373|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148939|NCT06273046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148940|NCT00576576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148941|NCT00201123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34148942|NCT03125811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148943|NCT00523497|RANDOMIZED|PARALLEL||||NONE||||||
33803947|NCT02433613|||COHORT||PROSPECTIVE|||||||
34027394|NCT06283732|NA|SINGLE_GROUP||OTHER||NONE||||||
34027395|NCT04566289|||COHORT||PROSPECTIVE|||||||
34027396|NCT04874155|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind|Study consists of two phases. Phase 1: Randomized 1:1 between Active treatment and Sham control Phase 2: Non-randomized, Active treatment|t|f|t|t
34027397|NCT03516513|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Research Assistants and expert raters will not be informed of condition therapists are assigned to.|Phase 1 will consist of qualitative interviews; Phase 2 will consist of rapid iterative design that includes qualitative interviews; Phase 3 will be an interventional pilot randomized trial. Data reported on ClinicalTrials.gov are for Phase 3.|f|f|f|t
34027398|NCT06400524|||COHORT||CROSS_SECTIONAL|||||||
34027399|NCT00812448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027400|NCT02429284|||COHORT||PROSPECTIVE|||||||
33803948|NCT02261649|||CASE_CONTROL||PROSPECTIVE|||||||
33803949|NCT05674669|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||In Part 1, each subject was allocated to open label treatment with a single dose of 50 µg, 75 µg, or 100 µg LSD. Part 1 was conducted in hallucinogen non-naive participants. In Part 2, each subject was randomized to double blind treatment and received 50 µg LSD followed by 75 µg LSD (experimental non-crossover group), or placebo followed by 75 µg LSD (placebo-controlled crossover group), with dosing separated by at least 7 days. Part 2 was conducted in hallucinogen naive participants.|t|t|t|t
33803950|NCT05443464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722915|NCT04898257|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase IV, open-label, single-center, proof-of-concept, pilot study to evaluate the effect of Lactibiane Tolerance® in treating leaky gut in IBS-D patients.||||
33803951|NCT05838469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722916|NCT04267133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027401|NCT05437315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027402|NCT01505582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027403|NCT01159080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027404|NCT05690490|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, single-center, randomized, non inferiority||||
34027405|NCT02497638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027406|NCT03229135|||CASE_CONTROL||RETROSPECTIVE|||||||
34027407|NCT00423371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027408|NCT06060431|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34027409|NCT06240195|||OTHER||PROSPECTIVE|||||||
34027410|NCT00235677|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34027411|NCT06442787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Orthognathic surgery is a surgical procedure performed to correct dentofacial deformities. In recent years, with the use of virtual surgical planning, cutting guides, and patient-specific osteosynthesis plates, highly predictable results can be achieved. While there are many positive reports regarding the use of patient-specific plates in maxillary positioning in orthognathic surgery, there is a lack of sufficient studies comparing the results obtained in mandibular positioning. Additionally, numerous designs of proximal segment positioning devices have been published, but comparative studies on their effectiveness have not been conducted. Therefore, a study comparing these approaches has been planned|t|f|f|f
34027412|NCT02035358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104293|NCT05539352|NA|SINGLE_GROUP||PREVENTION||NONE|This is a single-arm pilot study with no random assignment to groups. No masking is applicable.|The study design is a single arm, receiving PST+EUC. Both parts of the treatment are evidence-based interventions, and the treatment protocol is delivered in six sessions. The study will occur at VA Palo Alto.||||
34104294|NCT03521609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104295|NCT06164600|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104296|NCT06688526|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34104297|NCT05800626|||COHORT||PROSPECTIVE|||||||
34104298|NCT01444924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34104299|NCT05633355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148944|NCT01057524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722917|NCT06200727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722918|NCT00605813|||CASE_ONLY||PROSPECTIVE|||||||
33722919|NCT01682902|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33722920|NCT03388229|||OTHER||RETROSPECTIVE|||||||
33803952|NCT01520272|||COHORT||CROSS_SECTIONAL|||||||
33803953|NCT03621735|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33803954|NCT04680845|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33803955|NCT02972788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33803956|NCT04224792|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33803957|NCT01784328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803958|NCT06154876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assignment|t|f|f|f
33803959|NCT05142189|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33803960|NCT03075254|||CASE_CONTROL||PROSPECTIVE|||||||
33803961|NCT04209712|NA|SINGLE_GROUP||TREATMENT||NONE||haploid allogeneic NK cell therapy with chemotherapy||||
33803962|NCT05297214|||COHORT||CROSS_SECTIONAL|||||||
33803963|NCT02109601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33803964|NCT02240420|RANDOMIZED|PARALLEL||PREVENTION||NONE||Hybrid type 1 effectiveness implementation design, focusing on weight loss and behavior change outcomes, as well as engagement and acceptability of the intervention||||
33803965|NCT01260870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803966|NCT03476798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803967|NCT05477316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803968|NCT04229368|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|900 patients to be enrolled total including controls, and two additional study arms|Prospective randomized|t|t|t|t
33803969|NCT03243006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33803970|NCT03409055|||COHORT||RETROSPECTIVE|||||||
33803971|NCT00269451|||DEFINED_POPULATION||PROSPECTIVE|||||||
33803972|NCT06187298|||COHORT||RETROSPECTIVE|||||||
33803973|NCT01571466|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33803974|NCT02799875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027413|NCT03887312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not be blind to treatment allocation. The team providing treatment and conducting in-session assessments will not be blind to treatment allocation.~One individual will be responsible for processing raw data and hence will not be blind as to treatment allocation.~The team carrying out independent assessments will be blind to treatment allocation.~The investigator team carrying out data analysis will be blind to treatment allocation."|"There are two arms in the RCT, t-CETA and treatment as usual (TaU), to which children will be randomly assigned. A stratified randomization model will be used, with randomization occurring within four separate groups:~1. Males aged 8-12 years~2. Males aged 13-17 years~3. Females aged 8-12 years~4. Females aged 13-17 years~A third group will consist of participants who do not wish to be randomised, but who will receive t-CETA. Their data will not form part of the RCT but will be used to provide additional data on efficacy, implementation, and acceptability of t-CETA."|f|f|t|t
34027414|NCT00660907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027415|NCT04663230|||COHORT||PROSPECTIVE|||||||
34027416|NCT00987779|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027417|NCT02908087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027418|NCT05169632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027419|NCT01586793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027420|NCT06403254|||COHORT||PROSPECTIVE|||||||
34027421|NCT00773474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027422|NCT03929991|||CASE_CONTROL||PROSPECTIVE|||||||
34027423|NCT04646876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The researcher did not know the type of medication given to the patients, placebo or treatment actually Only investigator knew the key|2 groups, comparative|t|t|f|t
34027424|NCT02199886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027425|NCT01551875|||||PROSPECTIVE|||||||
34027426|NCT04819763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unblinded with respect to the examiner and to the patient, blinded to the statisticians in the evaluation.|Prospective, randomized study with control group, stratified by gender.|f|f|f|t
34027427|NCT00049179|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027428|NCT00590512|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|t|f|t
34027429|NCT03816943|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34027430|NCT00000691||||TREATMENT||||||||
34027431|NCT05969249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803975|NCT03217669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||For the Dose Escalation cohort: Traditional 3+3 dose escalation design. For the Dose Expansion cohort: Once recommended phase two dose (RP2D) is defined by the PI, a total of 10 NSCLC patients who meet eligibility will be enrolled in the dose expansion cohort. If RP2D is not defined for any reason, the study will be terminated.||||
34027432|NCT03364842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33803976|NCT03801148|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33803977|NCT05510310|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, two-arm, active-comparator, randomized, controlled||||
33803978|NCT04124120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The endpoint assessors will be blinded to treatment allocation (PROBE).|Patients undergoing coronary artery bypass surgery will be in one of two groups. One group will receive a single arterial graft and the second group will receive two or more arterial grafts.|f|f|f|t
33803979|NCT03493724|||OTHER||PROSPECTIVE|||||||
34027433|NCT03348735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Stratified randomization by site and Neuropathic Pain Symptom Inventory (NPSI) will be applied, and coordinated centrally which randomizes eligible patients to one of three treatment arms, and assigns patient numbers. Medication will be dispensed by the hospital pharmacies of the individual participating multidisciplinary pain centres, after proper labelling.|A multicentre, randomized, open-label comparative trial evaluating topical treatment options (lidocaine 5% or capsaicine 8% patch) versus oral systemic treatment (pregabaline as standard of care) in adult patients suffering from localized neuropathic pain (LNP) syndromes.|f|f|t|t
34027434|NCT00052637|NON_RANDOMIZED|||DIAGNOSTIC||NONE||||||
34027435|NCT05372965|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Our study will include 42 people with periodontitis and 42 healthy periodontal patients (84 individuals in total), and these two groups will be divided into two as smokers and non-smokers. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis.|f|f|t|f
34027436|NCT05620537|||COHORT||RETROSPECTIVE|||||||
34027437|NCT01270191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027438|NCT00200044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027439|NCT06435884|||CASE_ONLY||PROSPECTIVE|||||||
34027440|NCT06550232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The group allocation will be double blind. The randomization table will be available only to one member of the study, who will prepare the medications according to the allocated intervention. Participants will receive intravenous 0.9% normal saline with or without papaverine. The same bottles of normal saline will be use for the papaverine and placebo groups. Accordingly, the participants will be masked for the intervention. The participants, the researchers including the obstetricians who inserted the PGE2 (propess), the caregiver nurse who administrated the medication, the data collector, and the statistician will be blinded to the group allocations throughout the study||t|t|t|t
34027441|NCT03901976|NA|SEQUENTIAL||PREVENTION||NONE||"The study has several distinct phases:~* Silent Phase: The devices run in the background, activity is blinded for clinicians, settings are optimized by the research team.~* Run-In Phase: Bed exit notifications are turned on, notifications will be configurable for acceptability by clinical teams. Data extraction and data evaluation will be tested.~* Phase I: Data collection of bed exit data of sensors as well as data related to falls~* Phase II: Data collection of bed exit data with optimization of predictive algorithms~* Phase III: Data collection for validation using predictive data for early notification"||||
33803980|NCT00753493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148945|NCT01410708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803981|NCT02670109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803982|NCT01807481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803983|NCT04017793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33803984|NCT06699459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803985|NCT03741049|||CASE_ONLY||PROSPECTIVE|||||||
33803986|NCT05662124|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33803987|NCT03883152|||CASE_ONLY||PROSPECTIVE|||||||
33803988|NCT05435794|||COHORT||PROSPECTIVE|||||||
33803989|NCT05344573|||COHORT||PROSPECTIVE|||||||
33803990|NCT04703283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33803991|NCT02089763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33803992|NCT02362139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33803993|NCT02405559|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803994|NCT05766462|||CASE_CONTROL||PROSPECTIVE|||||||
33803995|NCT06498414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes (Adverse event and tuberculosis (TB) disease) judge by independent blinded panel|We plan an initial randomization ratio of 1:2:2 for 4 months of rifampin 10mg/kg (4R10), 2 months of rifampin 20mg/kg (2R20), and one month levofloxacin and rifapentine (1LP).|f|f|f|t
33803996|NCT01767350|||COHORT||RETROSPECTIVE|||||||
33803997|NCT02345720|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33803998|NCT02475343|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33803999|NCT04036955|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804000|NCT03149302|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||a 2 x 2 factorial blinded design|f|f|t|t
33804001|NCT03955575|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33804002|NCT04421365|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Patients will be assigned to active neurofeedback BCI and sham neurofeedback BCI groups to assess the feasibility of the BCI system and the efficacy of neurofeedback.|t|f|t|f
33804003|NCT03514836|NA|SINGLE_GROUP||TREATMENT||NONE||Open label combination treatment||||
33804004|NCT02612142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804005|NCT05326789|NA|SINGLE_GROUP||TREATMENT||NONE||single-center, single-arm, open (unblinded), feasibility, experimental study||||
33804006|NCT01936051|||OTHER||OTHER|||||||
33804007|NCT04769596|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Subjects, site investigator, site personnel, and sponsor will be blinded to which study arm they are randomized to.|Randomized, Double-blind, Sham Controlled Study|t|f|f|f
33804008|NCT05398224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804009|NCT04073953|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804010|NCT03638674|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804011|NCT05368350|NA|PARALLEL||TREATMENT||NONE|Study participants will be assigned to either Pre-SMA or LIFG arm.|||||
33804012|NCT04646733|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled clinical study. Subjects are assigned to one of two groups: the intervention group (group A or high protein diet or HPD) and the group without high protein diet or NHPD. The assignment is done with the use of MedCalc software and the option to create random groups. Both groups are treated equally except for the procedure or diet. The blind or double-blind procedure is not used in this study. Both groups are treated during the same study period. The maximum number of patients to be evaluated per day will be three. Patients are not mixed from one group or another in each evaluation.||||
33804013|NCT01290341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804014|NCT06655480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804015|NCT00698113|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33804016|NCT02132455|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33804017|NCT04160936|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33804018|NCT03467529|||COHORT||PROSPECTIVE|||||||
33804019|NCT05705856|||COHORT||RETROSPECTIVE|||||||
33804020|NCT06464224|||COHORT||PROSPECTIVE|||||||
33804021|NCT01863485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804022|NCT00873782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804023|NCT02190708|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34027442|NCT06582940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027443|NCT02488954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027444|NCT02655705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027445|NCT06633978|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804024|NCT04238858|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective open-label, before-after-control group comparisions||||
33804025|NCT04886505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804026|NCT03323203|||COHORT||PROSPECTIVE|||||||
33804027|NCT02789020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804028|NCT00451607|||CASE_ONLY||PROSPECTIVE|||||||
33804029|NCT00874536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804030|NCT01138254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804031|NCT05733507|||COHORT||RETROSPECTIVE|||||||
33804032|NCT01277250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804033|NCT04406701|||CASE_ONLY||RETROSPECTIVE|||||||
33804034|NCT02765100|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804035|NCT03377205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804036|NCT05585346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804037|NCT02984332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33804038|NCT01738438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804039|NCT03210896|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33804040|NCT00525954|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33804041|NCT06409897|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All the participants will be exposed to the same situations (head-of-bed elevations), in the same order. An alveolar recruitment maneuver followed by a PEEP titration with 10-degree head-of-bed elevation will be performed.||||
33804042|NCT02704416|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027446|NCT03532373|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking will occur|Participants are randomly assigned to either the intervention or control group||||
34027447|NCT00259233|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34027448|NCT03337269|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34027449|NCT05285904|||COHORT||PROSPECTIVE|||||||
33804043|NCT00391898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804044|NCT04144335|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33804045|NCT03658616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804046|NCT05297851|||CASE_CONTROL||PROSPECTIVE|||||||
33804047|NCT03290859|||CASE_CONTROL||PROSPECTIVE|||||||
33804048|NCT04738201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804049|NCT06404723|||CASE_CONTROL||PROSPECTIVE|||||||
33804050|NCT01951170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804051|NCT03167944|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33804052|NCT03966898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||SHR6390 in combination with Letrozole or Anastrozole versus placebo in combination with Letrozole or Anastrozole|t|f|t|f
33804053|NCT01627561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33804054|NCT01429324|||COHORT||PROSPECTIVE|||||||
33804055|NCT05729997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804056|NCT00176800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804057|NCT06275477|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single-center, descriptive and analytical pilot study, which will be implemented in 13 distinct and independent populations of patients with chronic inflammatory and/or fibrosing disease.||||
33804058|NCT03784170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will wear a device and will be treated at 1 of 2 device settings for approximately 3 days.|t|t|t|t
33804059|NCT04944563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804060|NCT05888805|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be prescribed with a pair of DIMS spectacle lenses for 24 months.||||
33804061|NCT05225376|NA|SINGLE_GROUP||PREVENTION||NONE||all participants will receive the same intervention||||
33804062|NCT03480451|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804063|NCT05661708|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33804064|NCT05979038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804065|NCT05370287|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||One cohort of subjects with clinically diagnosed glaucoma and one cohort of age-matched healthy controls with no evidence of ocular disease||||
33804066|NCT06510790|||CASE_ONLY||PROSPECTIVE|||||||
33804067|NCT05577767|||COHORT||PROSPECTIVE|||||||
33804068|NCT00145236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804069|NCT03434496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33804070|NCT00960024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34027450|NCT04422041|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessors consisted of hospital staff not involved in the investigation.|They were selected based on a random computer program in a 1: 1 model, assigning each subject randomly to one of the two study groups|f|f|f|t
34027451|NCT05009511|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34027452|NCT00549679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804071|NCT03122236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To control for intensity, participants will maintain a rating of perceived exertion of 4 (moderate to strong) on the Borg Category/Ratio Scale during walking. Exertion will be adjusted by modifying walking speed and/or by modifying the rest time between walking bouts.|Participants will take part in a 6-week, 18-session neurorehabilitation led by qualified and trained study personnel. Participants will be randomized to one of three groups: 1) standard walking neurorehabilitation with sham tDCS ('standard/sham' group), 2) complex walking neurorehabilitation with sham tDCS ('complex/sham' group), or 3) complex walking neurorehabilitation with active anodal tDCS ('complex/active' group). Training logs will be maintained to gauge the content and intensity of training.|t|f|t|f
33804072|NCT04324099|||OTHER||CROSS_SECTIONAL|||||||
33804073|NCT02019459|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33804074|NCT03428620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104300|NCT06306976|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"Specific Aim 1:~Determine the elasticity of abdominal wall muscles (rectus abdominis, external oblique, internal oblique, and transversus abdominis) through shear wave elastography in patients with midline incisional hernias of varying complexity and morphology.~Specific Aim 2:~Correlate shear wave elastography measurements of the abdominal wall with the extent of MFR required to achieve fascial closure.~Specific Aim 3:~Correlate SWE-determined elasticity of abdominal wall to intraoperative assessment of tension required to achieve fascial closure."||||
34104301|NCT06430684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104302|NCT01392066|||COHORT||PROSPECTIVE|||||||
34104303|NCT06683898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33804075|NCT06314932|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34104304|NCT05860868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804076|NCT02224105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34104305|NCT06641258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804077|NCT05350904|RANDOMIZED|PARALLEL||TREATMENT||NONE||The control group will receive usual physical therapy care. The experimental group will receive a hybrid of in-person and telehealth services to address in-home functional skills.||||
33804078|NCT03058445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104306|NCT01687595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104307|NCT06673238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104308|NCT04098913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104309|NCT05356429|||COHORT||PROSPECTIVE|||||||
34104310|NCT00300170|||||OTHER|||||||
34104311|NCT06570135|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34104312|NCT06689527|NA|SINGLE_GROUP||OTHER||NONE||A single-center, open-label, single-arm, fixed-sequence, design. Healthy male and female subjects (18 to 55 years, inclusive) are eligible.||||
34104313|NCT02976688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104314|NCT01627093|||COHORT||OTHER|||||||
33804079|NCT05820594|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single centre, prospective longitudinal controlled human infection study after intradermal injection with BCG SSI||||
33804080|NCT03279224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both the patient and the study team (clinical team, study coordinator, data analyst) will be blinded to group assignments.|Adults with BD depression being treated with an approved medication will be assigned to either allogenic FMT (from a healthy, screened individual with no personal or family history of an Axis 1 disorder) or autologous FMT (re-infusion of own feces)|t|t|t|t
33804081|NCT01948661|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804082|NCT05829525|NA|SINGLE_GROUP||OTHER||NONE||||||
33804083|NCT00692185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804084|NCT01198366|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804085|NCT04160741|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33804086|NCT00411151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804087|NCT05391061|||CASE_ONLY||PROSPECTIVE|||||||
33804088|NCT00476905|||CASE_CONTROL||PROSPECTIVE|||||||
33804089|NCT05099341|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804090|NCT06326125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33804091|NCT02763449|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804092|NCT00052364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804093|NCT04682288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804094|NCT01804387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027453|NCT03254498|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||It is a randomised back to back study to compare the performance of cap assisted colonoscopy (CAC) and Endocuff assisted colonoscopy (EAC)|f|f|t|f
34027454|NCT01887769|||COHORT||RETROSPECTIVE|||||||
34027455|NCT00706862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104315|NCT04943068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104316|NCT01265147|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104317|NCT05378425|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34148946|NCT00016965||||TREATMENT||||||||
34027456|NCT06160219|RANDOMIZED|PARALLEL||PREVENTION||NONE||"At the end of CPB, the patients will be assigned randomly into 2 groups by using computer generated random numbers sequences and sealed envelopes.~Group (OH CO): 30 patients will receive hydroxycobolamin (Cyanokit) 5 gm intravenously(iv) through the central venous catheter as bolus over 15 min reconstituted in 200 ml of NS.~Group (C) control: 30 patients will receive 200ml of NS over 15 min iv.~Primary outcome will be change in MAP between baseline and all time points (30 \& 60 min after CPB initiation) and (30 \& 60 min after CPB separation) between the two groups and within the same group.~Secondary outcomes were:"||||
34027457|NCT04260087|||COHORT||PROSPECTIVE|||||||
34027458|NCT05125965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027459|NCT05011318|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027460|NCT01890434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027461|NCT06023459|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 24-month randomized controlled open-label pilot study will be conducted in approximately 6 clinics in rural settings. Participants will be randomized within each clinic to XR-BUP or SL-BUP in a ratio of 2:1 (overall approximately 96 in the XR-BUP condition, 48 in the SL-BUP condition). They will receive study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.||||
34148947|NCT01908088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104318|NCT06416982|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will be randomized to intervention vs no intervention at the first visit without stratification, then will undergo the opposite intervention at the second visit. While participants cannot be blinded to the intervention, providers performing the pessary checks and providing provider-perceived pain scores will be blinded to the intervention as someone on the research team other than the provider will perform the intervention prior to the pessary check. If there is unexpected breaking of the blind (e.g. participant tells provider which intervention was performed), the provider will report this to the research team and this will be noted in the study results.||f|t|t|f
34104319|NCT06395220|||COHORT||PROSPECTIVE|||||||
33804095|NCT03786211|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33804096|NCT02282657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104320|NCT06127810|||COHORT||PROSPECTIVE|||||||
34104321|NCT00588198|||COHORT||PROSPECTIVE|||||||
33804097|NCT03862963|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel-arm study, although the control group was allowed to crossover after completing the control condition.||||
34104322|NCT02956863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804098|NCT05692817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104323|NCT03370835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104324|NCT06641947|||COHORT||RETROSPECTIVE|||||||
33804099|NCT05509855|||OTHER||PROSPECTIVE|||||||
33804100|NCT04347824|||CASE_ONLY||RETROSPECTIVE|||||||
34104325|NCT02066259|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804101|NCT04567979|||COHORT||PROSPECTIVE|||||||
33804102|NCT00167921|RANDOMIZED|CROSSOVER||||NONE||||||
34104326|NCT05739162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804103|NCT06154694|||COHORT||PROSPECTIVE|||||||
33804104|NCT05494294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients were randomly assigned into intraorally de-epithelialization group (n=25) and extraorally de-epithelialization group (n=25) groups by one of the authors with an allocation ratio of 1:1 using a computer-generated program after successful completion of the phase I periodontal treatment. One calibrated author masked the applied surgical technique and recorded all clinical variables. The surgeon opened the labeled envelope containing the intervention name.||t|f|t|t
33804105|NCT06387381|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804106|NCT06322446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804107|NCT03756571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcomes are Gait Profile Score (GPS), Gait Deviation Index (GDI), gait speed from three dimensional gait analysis and community walking activity are all collected via technology (three dimensional gait lab, accelerometry, thus masked.|Study Design and Randomization. A randomized waitlist trial will be used to compare the AFO-FC to TSAFO in ambulatory children with CP.|f|f|f|t
33804108|NCT05104866|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel||||
33804109|NCT04363866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded Study.||t|t|t|t
33804110|NCT05606484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and the evaluator will be blind.|Experimental, controlled and randomized study, whose methodology complies with the CONSORT standards for clinical trials|t|f|f|t
33804111|NCT04216394|||CASE_ONLY||PROSPECTIVE|||||||
33804112|NCT05983185|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Outcome assessors will not be aware of the location of the Veteran's stroke.|The investigators are examining predictors of treatment response, hypothesized to relate to brain imaging biomarkers.|f|f|f|t
33804113|NCT05374642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804114|NCT00204672|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33804115|NCT01472510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804116|NCT06700031|||COHORT||PROSPECTIVE|||||||
33804117|NCT06527703|||OTHER||CROSS_SECTIONAL|||||||
33804118|NCT06296992|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33804119|NCT06324786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||mindfulness or/and active/sham neurofeedback|t|t|t|t
33804120|NCT02910713|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34104327|NCT02510274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104328|NCT01084135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104329|NCT05983250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blind is maintained by the use of a matching placebo.|Double blind, randomized, placebo controlled|t|t|t|t
34104330|NCT05692323|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34104331|NCT06674668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34104332|NCT05194072|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104333|NCT06688162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104334|NCT06037083|||COHORT||PROSPECTIVE|||||||
34104335|NCT02914483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104336|NCT05009043|||OTHER||CROSS_SECTIONAL|||||||
34027462|NCT04388553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"After the patient is put under GA and turned lateral, the sealed opaque envelope is opened. Unilateral lumbar ESP block is performed in participants under treatment arm, while no regional block is performed for control arm.~The patient is assessed by an independent assessor from the acute pain service team 24 hours after the operation, who is blinded from the allocation result."|For the treatment arm, lumbar ESP block is performed while for control arm no regional anaesthesia is performed nor saline is injected into the ESP. Before proceeding to ESP block, the back is cleaned with aseptic technique and draped. 40 mL of 0.25% levobupivacaine (or maximum of 2mg/kg body weight made up to same volume) is injected into the ESP.|t|f|f|t
34027463|NCT05205694|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027464|NCT00506701|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34027465|NCT01406587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027466|NCT00769873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027467|NCT00448383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027468|NCT06623474|||COHORT||PROSPECTIVE|||||||
34027469|NCT01131468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027470|NCT01528007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027471|NCT05753878|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027472|NCT00802932|||COHORT||PROSPECTIVE|||||||
34027473|NCT00939016|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34027474|NCT05332873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104337|NCT05478213|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104338|NCT04867629|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Oils were in identical amber glass bottles labelled A or B. Oils blinded to participants and investigators. However, the control group was unblinded due to them not receiving any intervention|A randomized, double-blind, placebo-controlled trial|t|f|t|f
34104339|NCT00606099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722921|NCT04726345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Subjects and the study urologist will be blinded to treatment allocation. Treatment allocation will be known by the investigator performing data analysis, who will not be directly participating in patient care.|Subjects will be randomized in a 1:1 ratio to receive fexofenadine or placebo in addition to the standard of care. A total of 39 subjects will be randomized to each group.|t|t|f|f
33722922|NCT01057017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722923|NCT03238638||PARALLEL||TREATMENT||NONE||||||
33722924|NCT02182531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33722925|NCT02064166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722926|NCT03329495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722927|NCT01393808|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33722928|NCT00478985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33722929|NCT03613935|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a monocentric, controlled, randomized, open, complete crossover study design||||
33722930|NCT03515772|||CASE_CONTROL||PROSPECTIVE|||||||
33722931|NCT01304914|||COHORT||PROSPECTIVE|||||||
33722932|NCT05799807|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Acute Lisfranc injuries are investigated with weight-bearing diagnostics to determine the degree of TMT stability. Patients are examined using both CT and conventional radiography during full weight and non-weight-bearing sequences. 3 foot- and ankle surgeons will examine the scans independently, starting with the conventional radiographs. Distance between the medial cuneiform and second metatarsal bone (C1-M2) is measured. For the CT images, measuring method previously described by Y. Sripanich et al. (DOI: 10.1007/s00402-020-03477-5) will be used.~CT findings will determine the treatment outcome. If the C1-M2 diastasis is \>2mm, as opposed to the uninjured side, the injury will be determined unstable and surgical fixation will be recommended (Cohort 2). All other patients (≤ 2mm) are considered stable and treated conservatively (Cohort 1)."||||
33722933|NCT01277952|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33722934|NCT02465177|||COHORT||PROSPECTIVE|||||||
33722935|NCT05338892|||COHORT||RETROSPECTIVE|||||||
33722936|NCT00302874|NON_RANDOMIZED|PARALLEL||||NONE||||||
33722937|NCT06490029|||CASE_CONTROL||PROSPECTIVE|||||||
33722938|NCT00941044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722939|NCT03069495|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33722940|NCT01640483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722941|NCT01801150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722942|NCT05264545|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, non-randomized, controlled||||
34027475|NCT06625918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027476|NCT06399575|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34027477|NCT04208750|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34027478|NCT03960125|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027479|NCT03179423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The first part of the trial is double-blind and the second part is open-label with all participants receiving the active treatment.|t|t|t|t
34027480|NCT03267901|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34104340|NCT04265118|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34104341|NCT02921282|||OTHER||PROSPECTIVE|||||||
34104342|NCT03940157|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be exposed to the intervention||||
34148948|NCT05827601|||COHORT||PROSPECTIVE|||||||
34148949|NCT04969315|NA|SEQUENTIAL||TREATMENT||NONE||||||
33722943|NCT02154191|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33722944|NCT02949492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148950|NCT01092793|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34148951|NCT04934436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In terms of the reliability of the study results, the patients in this study will be allocated to the groups with a stratified randomization method. Patients will be randomly matched to the intervention (I) and control (C) group according to their gender, age, and circadian rhythms.||||
34148952|NCT00758589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148953|NCT03699137|||OTHER||RETROSPECTIVE|||||||
34148954|NCT01629719|||||PROSPECTIVE|||||||
34148955|NCT05086510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148956|NCT06113575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148957|NCT01233388|||||PROSPECTIVE|||||||
34027481|NCT06630169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804121|NCT06398600|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be achieved using computer-generated random numbering of each study patient. opaque sealed envelopes will be used and opened in the operating room by a anesthesia resident who will be blinded to the study. The patient and researcher who collects the data after the block will be blinded to the study group. All study outcomes will be evaluated by a dedicated anesthesiologist who will be blinded to the group allocation. Patients will be randomized into three groups.||t|t|t|t
33804122|NCT00138541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34027482|NCT04228016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027483|NCT00716794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804123|NCT01101711|||COHORT||PROSPECTIVE|||||||
33804124|NCT05100784|||COHORT||PROSPECTIVE|||||||
33804125|NCT06266936|||COHORT||PROSPECTIVE|||||||
34027484|NCT01016470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027485|NCT04627428|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027486|NCT02682927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027487|NCT00493415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027488|NCT02645903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34027489|NCT03387566|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027490|NCT06259305|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Observational,||||
34027491|NCT06282146|NA|SINGLE_GROUP||OTHER||NONE||||||
34027492|NCT03741426|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Bayesian Adaptive||||
34027493|NCT02028741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34027494|NCT00060983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34027495|NCT06525207|||CASE_CONTROL||PROSPECTIVE|||||||
34027496|NCT00551668|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027497|NCT04087434|||COHORT||CROSS_SECTIONAL|||||||
34027498|NCT00976911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027499|NCT01653717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027500|NCT05232188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027501|NCT05857852|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|Single-blind study|At each of two intervention visits, participants will receive either LIFU or sham. At the completion of both visits, all participants will have received both, LIFU and sham.|t|t|f|t
34027502|NCT04751071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027503|NCT00001946||||TREATMENT||||||||
34027504|NCT04363827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027505|NCT06028880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104343|NCT06484543|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a single-blind study in which the participants will not know which group will be assigned to and only the investigators will know.|Single blinded study|t|f|f|f
34104344|NCT06673979|||COHORT||PROSPECTIVE|||||||
33804126|NCT03468634|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804127|NCT03921866|||COHORT||RETROSPECTIVE|||||||
33804128|NCT05222646|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Will receive 20 mg of Hyoscine bromide,|Will receive single dose of 10mg of Metoclopramide intramuscularly|t|f|t|f
33804129|NCT03562325|NA|SINGLE_GROUP||TREATMENT||NONE||Open case trial||||
33804130|NCT00477893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804131|NCT06241560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027506|NCT06634264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sleep technician grading the sleep studies would be blind from the group, The ENT surgeons/treating physicians would be blinded from the group.|Children with a sleep study positive for Obstructive Sleep Apnea would be randomized in the intervention arm (flexible oral appliance) or control group (nasal hygiene). They will be followed in parallel groups for 3 months before another sleep study/clinical examination (pre surgical) and once again after surgery ( post surgical sleep study/clinical examination).|f|t|f|t
34027507|NCT00482781|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34027508|NCT00953251|||COHORT||PROSPECTIVE|||||||
34027509|NCT05327673|||COHORT||PROSPECTIVE|||||||
34027510|NCT05705037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34027511|NCT03535389|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Case-control study, cross-sectional, monocentric, with prospective recruitment.|f|f|t|f
34027512|NCT00243412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027513|NCT00551018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027514|NCT01707979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027515|NCT01188291|||CASE_ONLY||CROSS_SECTIONAL|||||||
34104345|NCT06673849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study design will be a Randomized Clinical Trial in which non probability convenient sampling will be used. Two groups of 6-12 age will be formed in which participants will be randomly divided. Group A will receive Rhythmic Stabilization exercises and Group B will receive Ball Balancing.|t|f|f|f
34104346|NCT01740518|||CASE_CONTROL||PROSPECTIVE|||||||
34104347|NCT04422834|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A group of students who studying at Faculty of Health Sciences will be asked to fill Turkish version of JSE-HPS and ETS. JSE-HPS will be asked to re-fill after seven days for retest analysis.||||
34104348|NCT06688864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34104349|NCT06039800|||OTHER||PROSPECTIVE|||||||
34027516|NCT03938285|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||12 patients will be included, they will be divided in 4 groups: high flux HD, extended HD (HDx), OL-HDF, and OL-HDF with medium cut-off membrane. All sessions will be performed in a 5008S CorDiax that enables HD and OL-HDF, we will use an FX CorDiax 80 dializer (effective area 1.8 m2) for OL-HDF and conventional HD, and the Theranova 400 dializer (effective area 1.7 m2)for OL-HDF with medium cut-off membrane, and HDx. Every patient will be in each of the 4 groups, and they will receive 3 sessions in each group. Every session will have a duration of 240 minutes with a Qb of 300 mL/min. Blood samples will be drawn in every session, every blood sample will consist of 4-6 mL of EDTA plasma; this volumen would include 0.5 mL for biobanking, blood will be drawn from the arterial, and venous outlet, and a dialysate sample will be drawn in every time point.||||
34027517|NCT04842292|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027518|NCT00355953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34104350|NCT04645030|||COHORT||CROSS_SECTIONAL|||||||
34027519|NCT02156167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104351|NCT00674843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027520|NCT02568605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104352|NCT00001311||||TREATMENT||||||||
34104353|NCT06362889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104354|NCT05904379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104355|NCT02044146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34104356|NCT01178541|||COHORT||PROSPECTIVE|||||||
34027521|NCT04495881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104357|NCT06605534|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34104358|NCT04589468|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34104359|NCT06690554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33722945|NCT00035464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33722946|NCT00195182|||COHORT||PROSPECTIVE|||||||
34027522|NCT04031755|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34027523|NCT06634017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This trial will be a double-blind trial where the examiner and the patient both will be blind. Since the placebo and i-PRF will be in similar looking glass tubes the patient and the investigator/ examiner who is the orthodontist will not know which side of the maxilla has been intervened with i-PRF and which one with the placebo injection.|All routine history and medical records will be taken before commencing the treatment. The rate of orthodontic tooth movement and the root length of the canine will be measured using the calipers on cast model and the digital periapical X-Ray respectively using millimeter unit. All measurements will be recorded at the baseline (T0) followed by at the end of 8weeks (T1), before giving second dose of PRF, to assess single dose PRF outcomes and at end of 20 weeks (T2) to assess multiple dose PRF outcomes. Periapical x-rays to assess effect of single dose of PRF on root length will be taken at baseline (T0) just before injecting PRF and starting canine retraction and will be compared with the second periapical x-ray taken at the end of 8week (T1), just before injecting second dose of PRF.|t|f|t|f
33722947|NCT01700855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34027524|NCT04264676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027525|NCT00879411|||CASE_ONLY||PROSPECTIVE|||||||
33722948|NCT05297825|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722949|NCT00628433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722950|NCT02047188|||CASE_ONLY||PROSPECTIVE|||||||
33722951|NCT02450032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722952|NCT00148889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33804132|NCT02847013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33804133|NCT03158805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||We will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP.|t|t|t|t
33804134|NCT06263881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804135|NCT03794024|||COHORT||PROSPECTIVE|||||||
33804136|NCT03789734|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34027526|NCT04419012|||COHORT||PROSPECTIVE|||||||
34027527|NCT04538183|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|The test areas were 5 x 5 cm squares on both inner (volar) forearms. The areas were randomized and double-blinded (regarding the two test products). For randomization, the permutated orthogonal Latin square method was used on condition that both test areas are always contralateral.|Exploratory, Randomized, Double-blind (regarding the two test products), Intra-individual comparison|t|t|t|t
34027528|NCT04976413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessment and assignment to experimental and control conditions will be carried out by an independent evaluator who will be blind to the research hypotheses; treatment providers will be blind to the scores of participants.|Randomized Control Clinical Trial|f|f|t|t
34027529|NCT00270907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027530|NCT01492920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
34027531|NCT00438061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027532|NCT02654119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027533|NCT04411797|||COHORT||CROSS_SECTIONAL|||||||
34027534|NCT05128760|||COHORT||PROSPECTIVE|||||||
34027535|NCT04223375|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||Non-randomized controlled experimental study|t|f|f|f
34027536|NCT05300828|||COHORT||PROSPECTIVE|||||||
34027537|NCT00717379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027538|NCT00004757|RANDOMIZED|||TREATMENT||DOUBLE||||||
34104360|NCT05506631|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34104361|NCT06686407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104362|NCT05967455|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34104363|NCT05692557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants were not aware of which treatment they were receiving (blind participants); however, they were informed that they would receive one of the two interventions. Due to the nature of the interventions, it was not possible to blind the therapist who treated the patients.|This trial was a randomized, parallel-group, clinical controlled trial conducted at the department of health and rehabilitation sciences, college of applied medical sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.|t|f|f|t
34148958|NCT02602665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33722953|NCT01946997|||CASE_CONTROL||PROSPECTIVE|||||||
33804137|NCT06264531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804138|NCT00750620|NON_RANDOMIZED|PARALLEL||||NONE||||||
33804139|NCT06229730|||COHORT||PROSPECTIVE|||||||
33804140|NCT05106270|||COHORT||PROSPECTIVE|||||||
33804141|NCT03695757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Intramuscularly administrations of autologous total IgG in healthy subjects and patients with advanced solid tumor||||
33804142|NCT01340859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804143|NCT02376790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804144|NCT05613088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804145|NCT05801549|||COHORT||RETROSPECTIVE|||||||
33804146|NCT01717651|||CASE_ONLY||PROSPECTIVE|||||||
33804147|NCT02867072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104364|NCT05758142|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The proposed trial will employ placebo control and blinding of participants and study staff recording participant information. A Bioinformatics and Biostatistics Core will control the randomization and intervention allocation, preserving the blinding of the investigators and study staff in charge of day-to-day operations. Study participants will receive potassium tablets or placebo and will be unaware of their placebo or dosing assignment.|Eligible participants will be randomly assigned to placebo or 1 of 3 active intervention groups in a 1:1:1:1 ratio.|t|f|t|t
34027539|NCT04391504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers will participate in the operation to record operative parameters. Other researchers including follow-up personnel and the ultrasonic data analyst are uninformed about the random situation of the patients (patient information is recorded according to the random number.Random numbers corresponding to the random allocation list are stored in the research center. After follow-up of the last patient is completed, the random allocation list is published by the random number designer; and the designer does not participate in the data collection and statistics.|A total of 60 patients with atrial fibrillation were scheduled to receive left atrial appendage occlusion combined with radiofrequency ablation, which were divided into two groups. The operation was performed under the guidance of intracardiac echocardiography and transesophageal echocardiography respectively (allocation ratio 1:1).|t|f|f|t
34027540|NCT03308812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027541|NCT05835908|||COHORT||RETROSPECTIVE|||||||
34027542|NCT01331629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027543|NCT04400422|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34027544|NCT01123915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027545|NCT05705076|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027546|NCT04554446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104365|NCT06686485|||COHORT||PROSPECTIVE|||||||
34104366|NCT02868879|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34104367|NCT06304896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34027547|NCT05602883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Since there is no placebo group, masking will not be done.|While the experimental group will listen to music at night, Routine midwifery care will be applied to the control group.||||
34027548|NCT01509768|||COHORT||PROSPECTIVE|||||||
34027549|NCT00641615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027550|NCT01686230|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34027551|NCT01168518|||COHORT||PROSPECTIVE|||||||
34027552|NCT02871544|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34104368|NCT06689189|||COHORT||PROSPECTIVE|||||||
34104369|NCT03818971|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||mono centric study, in parallel groups, controlled, non-randomized and open||||
34104370|NCT01663363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804148|NCT05459701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This is a prospective, randomized (1:1), double-blind clinical trial, will be carried out on 50 patients who are candidate to detect the hepato-protective effect of Dapagliflozin on diabetic type 2 patients with non- alcoholic fatty disease (dapagliflozin 10 mg once daily for 24 - 48 weeks~-Patients will be randomly allocated into two equal groups (25 patients each); group (A) for controlled (placebo), and the other group (D) for Dapagliflozin."|t|f|t|f
33804149|NCT03631407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804150|NCT04072328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34104371|NCT05122143|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34104372|NCT04906187|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34104373|NCT03169374|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34104374|NCT04849078|||OTHER||CROSS_SECTIONAL|||||||
34104375|NCT02993666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104376|NCT06209450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104377|NCT02973152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104378|NCT06686186|||COHORT||PROSPECTIVE|||||||
34104379|NCT06687850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104380|NCT06034262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104381|NCT06696053|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34104382|NCT05360602|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104383|NCT06559176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104384|NCT05447663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104385|NCT06689436|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34104386|NCT03907579|NA|SINGLE_GROUP||SCREENING||NONE||||||
34104387|NCT06500936|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Women were randomly allocated either to the intervention or to the control group (1:1 ratio) using a computer-generated random number list generated by the study statistician. Blinding allocation was guaranteed, because neither the recruiters nor the field coordination knew the group to which women would be assigned. The local field coordinator sent the list of recruited women to the study coordinator on a weekly basis.|We carried out with a mixed-method study including a pragmatic randomized controlled trial to evaluate effectiveness of the intervention and quantitative and qualitative evaluation of the implementation from women and stakeholders' perspective|t|t|f|f
34104388|NCT06370663|NA|SINGLE_GROUP||TREATMENT||NONE||Combining radiotherapy with Hepatic Arterial Infusion Chemotherapy||||
34027553|NCT05972148|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027554|NCT03161340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34027555|NCT04206969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34027556|NCT03775044|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|No masking is possible for this study.|This study is a stepped wedge design where all individuals receive the intervention but at different time points after enrollment in the study. Each person will have two observations before the intervention and three observations after the intervention. Health service use data will be collected for two years prior to enrollment and two years after enrollment.||||
34027557|NCT02890784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804151|NCT05246124|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34104389|NCT06685991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study employs a triple-blinded design. Participants, care providers, investigators, and outcomes assessors are all blinded to the group assignments to prevent bias. Additionally, the study coordinators and data analysts responsible for interpreting results are also masked to maintain objectivity in data collection and analysis. Randomization is handled by an independent party, and group assignments are concealed until the completion of data analysis.|"Participants in this study will be randomly assigned to one of three parallel groups to evaluate the effects of timing of dexamethasone administration during anesthesia induction on postoperative outcomes.~Group 1 will receive dexamethasone before fentanyl administration. Group 2 will receive dexamethasone after the muscle relaxant administration. Group 3 (control) will receive no dexamethasone. This parallel assignment model allows for a direct comparison of outcomes across the three groups, examining factors such as postoperative nausea and vomiting, pain, glycemic control, and hemodynamic stability. Randomization and triple-blinding are implemented to minimize bias and improve the reliability of results."|t|t|t|t
34027558|NCT00855907|||OTHER||CROSS_SECTIONAL|||||||
34027559|NCT03041428|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34027560|NCT02685683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027561|NCT03840187|||COHORT||PROSPECTIVE|||||||
34027562|NCT03022097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027563|NCT04170010|||COHORT||PROSPECTIVE|||||||
34027564|NCT03044626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027565|NCT03931109|||COHORT||PROSPECTIVE|||||||
34027566|NCT01853332|||COHORT||CROSS_SECTIONAL|||||||
34027567|NCT06226181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104390|NCT02240914|||COHORT||PROSPECTIVE|||||||
34104391|NCT04619745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A graduate student, blind to study group allocation, will conduct all assessments at each visit.|In this model there is an intervention group and a wait-list control group. The intervention group will be receiving a 6-month, home-based, parent-led physical activity program, where as the control group will not receive this intervention until after the 12-month assessment.|f|f|f|t
33804152|NCT04725136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804153|NCT06118749|||CASE_CONTROL||PROSPECTIVE|||||||
33804154|NCT02761616|||COHORT||RETROSPECTIVE|||||||
33804155|NCT00000834|RANDOMIZED|||TREATMENT||||||||
33804156|NCT04280289|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"This study is a single center, prospective, Phase I PK trial. A total of 10 healthy subjects will be enrolled into the study. This study will evaluate the pharmacokinetics of CBDE.~The PK of CBD, 9-tetrahydrocannabinol (THC) and their principal metabolites will be determined after a single CBDE dose delivering 2.5 mg/kg CBD. ). CBDE will be provided in liquid concentration of 50mg/ml in sesame seed oil (SSO)."||||
33804157|NCT00067496||||TREATMENT||||||||
33804158|NCT00439270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804159|NCT00645034|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33804160|NCT03814369|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33804161|NCT03628313|||CASE_ONLY||RETROSPECTIVE|||||||
33804162|NCT06349577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804163|NCT05673746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804164|NCT01824056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804165|NCT02332512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804166|NCT05299346|||CASE_ONLY||PROSPECTIVE|||||||
33804167|NCT04921488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with indication for colonoscopy as part of a screening colonoscopy.||||
33804168|NCT02993094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804169|NCT06026800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804170|NCT05456334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||half-side comparative randomized controlled study|f|f|t|f
33804171|NCT02183506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804172|NCT04633941|||COHORT||CROSS_SECTIONAL|||||||
33804173|NCT03689920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804174|NCT03792932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804175|NCT02958800|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804176|NCT06518070|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33804177|NCT00670046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804178|NCT02167958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804179|NCT06515457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804180|NCT05744596|||COHORT||PROSPECTIVE|||||||
33804181|NCT03829436|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33804182|NCT01816672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804183|NCT05076110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804184|NCT00730509|NA|SINGLE_GROUP||||NONE||||||
33804185|NCT02767765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804186|NCT03814837|||COHORT||PROSPECTIVE|||||||
34027568|NCT03277924|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial||||
34027569|NCT02964572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027570|NCT02473198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027571|NCT04598386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027572|NCT03151304|NA|SINGLE_GROUP||TREATMENT||NONE||Two-Stage, Open-Label||||
34027573|NCT06456801|||CASE_CONTROL||PROSPECTIVE|||||||
34027574|NCT03437837|||CASE_ONLY||RETROSPECTIVE|||||||
33804187|NCT05126342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study population will be divided into 2 cohorts:~Cohort A: Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse after more than 6 months of PARPi maintenance therapy.~Cohort B: Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse within 6 months of PARPi mainte-nance therapy.~Both cohorts will receive the selective PARP 1/2 inhibitor niraparib in combination with the anti-PD-1 checkpoint inhibitor dostarlimab (TSR-042)."||||
33804188|NCT00786513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804189|NCT06324981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33804190|NCT02930954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804191|NCT06699810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33804192|NCT04278755|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33804193|NCT03656211|||COHORT||PROSPECTIVE|||||||
33804194|NCT02962284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804195|NCT00231504|||COHORT||PROSPECTIVE|||||||
33804196|NCT02187536|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33804197|NCT00115089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804198|NCT01461759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804199|NCT03106922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During the study a single-blind design with respect to the investigational products will be achieved by providing the randomisation list only to the unblinded study staff personnel who will handle study drug management, preparation, dispensation and collection but who will not be involved in colonoscopy performing. The colonoscopy will be performed by experienced endoscopists who are unaware of the treatment actually being dispensed in each case. The endoscopist will be blinded by instructing all the other involved clinical staff, patients and patients' families to not discuss with him the specifics of the preparation.||f|f|f|t
33804200|NCT01072838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804201|NCT02311452|||COHORT||RETROSPECTIVE|||||||
33804202|NCT00257881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804203|NCT05690152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804204|NCT02227134|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804205|NCT01144559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804206|NCT05565534|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a quasi-experimental study with non-randomized intervention and control groups. A nurse practitioner (NP) who is trained in diabetes on the oncology team will help manage diabetes for breast cancer patients undergoing cancer treatments. The control group will be enrolled first, followed by the experimental group.||||
33804207|NCT03791996|RANDOMIZED|PARALLEL||TREATMENT||NONE|1:1 block central randomisation with assignments written on a card sealed in an opaque envelop.|"2-arm randomised study with subjects centrally randomised by assigning them into either the control late cranioplasty group or the intervention early cranioplasty group.~All subjects will eventually receive the cranioplasty procedure."||||
33804208|NCT02566902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33804209|NCT05425953|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804210|NCT06700265|||OTHER||CROSS_SECTIONAL|||||||
33804211|NCT01771484|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33804212|NCT02955719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804213|NCT02714075|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34027575|NCT02257697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027576|NCT00898287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027577|NCT00271830|||||PROSPECTIVE|||||||
34027578|NCT02740114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027579|NCT01619566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027580|NCT02797197|NA|SINGLE_GROUP||OTHER||NONE||||||
34027581|NCT05446259|||CASE_CONTROL||PROSPECTIVE|||||||
34027582|NCT05188677|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027583|NCT05706883|||COHORT||PROSPECTIVE|||||||
34027584|NCT04624477|||COHORT||PROSPECTIVE|||||||
34027585|NCT05326555|||COHORT||PROSPECTIVE|||||||
34027586|NCT01898273|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027587|NCT00796107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027588|NCT01842997|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027589|NCT04109729|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, prospective, trial that begins with a phase Ib safety run-in followed by a phase II expansion cohort.||||
34027590|NCT00000139|RANDOMIZED|||TREATMENT||||||||
34027591|NCT03649347|RANDOMIZED|PARALLEL||TREATMENT||NONE||15 AR Therapy Intervention for Spider Phobia vs 15 No Treatment Control Group for Spider Phobia; 30 intervention vs 30 non intervention control group for fear of snakes||||
34027592|NCT00959218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027593|NCT01669603|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027594|NCT02885766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027595|NCT00791895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027596|NCT04277962|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027597|NCT06235827|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34027598|NCT01121562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027599|NCT02303821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027600|NCT05985135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34027601|NCT06055829|||CASE_ONLY||OTHER|||||||
34027602|NCT05185765|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34027603|NCT00582660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027604|NCT01853345|||COHORT||PROSPECTIVE|||||||
34027605|NCT01593046|RANDOMIZED|PARALLEL||||NONE||||||
34027606|NCT04274257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027607|NCT04727801|||COHORT||PROSPECTIVE|||||||
34027608|NCT02029157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027609|NCT01772797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027610|NCT00644930|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027611|NCT02122692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027612|NCT06247410|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34027613|NCT02798588|NA|SINGLE_GROUP||OTHER||NONE||||||
34027614|NCT05106608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants who meet the inclusion and exclusion criteria will be randomized to one of the three study groups using a random number generation program (www.randomizer.org). The randomization sequence will be prepared by a member external to the investigation to respect the masking in terms of randomization of the participants, thus reducing the risk of bias during the evaluations. Therefore both patients and evaluator will be masked.|Randomized controlled trial|t|f|f|t
34027615|NCT04682522|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomized 1:1 study groups||||
34027616|NCT05005897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027617|NCT03785327|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"Autistic participants were going to be recruited for an active or sham tDCS session. However, no participants were enrolled in these conditions due to COVID.~TD participants were assigned to receive or not receive a training session."|t|f|f|f
34027618|NCT01298414|||CASE_ONLY||RETROSPECTIVE|||||||
34104392|NCT06417788|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Due to the nature of the treatment, it is impossible to mask the treatment from the participant and the care provider. However, the data for analysis will be masked to the investigator responsible for assessing the accuracy of each implant placement system.|Patients who need dental implants and fulfill the inclusion criteria will be randomly allocated to test group (dynamic guided system) or control group (static stereolithographic pilot drill guided system)|f|f|t|f
34027619|NCT05096429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Modeling teams will be blinded to intervention control group assignment. All of the investigators on the modeling teams are blinded.|We will conduct a randomized policy experiment to evaluate whether targeting overdose prevention interventions to neighborhoods at highest risk reduces overdose morbidity and mortality. The state's department of health will receive PROVIDENT model predictions for half of the 39 cities/towns in Rhode Island.|f|f|f|t
34027620|NCT03918460|NA|SINGLE_GROUP||TREATMENT||NONE||The current study is a follow up study on the previous feasibility study where ACP-T5 was used; after increasing the % tantalum in ANEUFIX to make the product more detectable under X-ray, the current study evaluates the end-points in a total of 40 patients.||||
34027621|NCT04988919|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|All investigators and participants will be blinded to the treatment groups.|Participants will consume the 4D dietary supplement and the placebo in a randomized order on different testing days. Both the supplement and the placebo will be mixed with 24 fluid ounces of water. All drinks will have a similar appearance and taste. Researchers and participants will be blinded to the contents.|t|f|t|f
34027622|NCT04187547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027623|NCT02995525|||CASE_ONLY||PROSPECTIVE|||||||
34027624|NCT03101176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027625|NCT03425305|||COHORT||PROSPECTIVE|||||||
34027626|NCT03685812|||OTHER||CROSS_SECTIONAL|||||||
34027627|NCT01911897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027628|NCT02847871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027629|NCT04859205|NA|SINGLE_GROUP||OTHER||NONE||This study is a non-randomized pre-post trial.||||
34027630|NCT03004339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027631|NCT01174043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027632|NCT02986477|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027633|NCT04669561|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, prospective, open label, self-controlled, single group study||||
34027634|NCT05477108|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34027635|NCT02229474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34027636|NCT05904782|||OTHER||PROSPECTIVE|||||||
34027637|NCT04545320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded from the group allocation and the participants will be instructed not to reveal his/her intervention assignment.||f|f|f|t
34027638|NCT01098487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027639|NCT03132233|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Double-blind||t|f|t|t
34027640|NCT00653900|||COHORT||PROSPECTIVE|||||||
34027641|NCT04298268|||COHORT||PROSPECTIVE|||||||
34027642|NCT01966874|||COHORT||PROSPECTIVE|||||||
34027643|NCT06344585|||CASE_CONTROL||RETROSPECTIVE|||||||
34027644|NCT03289819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027645|NCT03786458|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34104393|NCT06690645|||COHORT||PROSPECTIVE|||||||
34104394|NCT03133377|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34104395|NCT06661915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104396|NCT00637156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104397|NCT00047580|RANDOMIZED|||TREATMENT||NONE||||||
34104398|NCT04178863|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104399|NCT06690450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104400|NCT03509480|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of ultraporous beta-tricalcium phosphate (Vitoss) with autologous bone marrow aspirate vs ultraporous beta-tricalcium phosphate with calcium sulfate (Prodense)||||
34104401|NCT03416387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104402|NCT01548885|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104403|NCT06688630|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The participants, the ophthalmologist conducting the eye examinations, and the outcome assessors will be blinded to group allocation.|"This study will compare the combination of laser acupuncture therapy and artificial tears with the combination of sham laser acupuncture therapy and artificial tears.~The laser acupuncture and artificial tears therapy will be designated as the intervention group, while the sham laser acupuncture and artificial tears therapy will be designated as the control group."|t|f|t|t
34104404|NCT02194582|||FAMILY_BASED||PROSPECTIVE|||||||
34104405|NCT01659151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027646|NCT03356288|||COHORT||PROSPECTIVE|||||||
34104406|NCT04565353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms at the end of the study.|Participants will be randomly assigned to the different arms. Randomization will be stratified by age (65+ vs. 18-64), vaccine receipt in 2019-2020 flu season (yes vs. no/unknown), and study site (Penn Medicine vs. Geisinger).|f|t|f|t
34027647|NCT06250946|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34104407|NCT01522274|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104408|NCT01714063|||CASE_ONLY||PROSPECTIVE|||||||
34104409|NCT00000437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind tablet and patch active study medications, and matched tablet and patch placebos||t|t|t|t
34104410|NCT04196920|||OTHER||RETROSPECTIVE|||||||
34104411|NCT03621215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomly allocated to consume either tart cherry juice or a fruit-flavoured placebo drink (matched as closely as possible for energy and sensory characteristics) daily for 12 months.|t|t|t|t
34104412|NCT06358508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104413|NCT00561821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104414|NCT03871504|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are blinded to the hypothesis of this study.|All subjects will participate in two randomized sessions (an exercise session and control session). The exercise session consists of submaximal isometric exercise while the quiet rest session consists of a rest for a period that mimics the time spent in exercise.|t|f|f|f
34104415|NCT06596135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104416|NCT06135324|||OTHER||PROSPECTIVE|||||||
34104417|NCT01635530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027648|NCT04495335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Implants were randomly divided into two groups and implants placed in the test group were treated with Gallium-aluminum-arsenate (GaA1As) diode laser with photobiomodulation therapy immediately after surgery and for 15 days. In the control group, implants were not irradiated.|t|f|t|f
33804214|NCT03689946|NA|SINGLE_GROUP||TREATMENT||NONE||Early development, single-arm, prospective, open-label study of evolocumab injection in patients with calcified plaque in the coronary artery detected by CCTA. Fifty-five (55) evaluable subjects will be enrolled in the study.||||
33804215|NCT02907905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804216|NCT01764516|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027649|NCT01212289|||CASE_CONTROL||PROSPECTIVE|||||||
34027650|NCT00799825|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027651|NCT01469078|RANDOMIZED|PARALLEL||||NONE||||||
34027652|NCT04877821|NA|SINGLE_GROUP||TREATMENT||NONE||Patient enrollment followed a Simon two-stage design.The Simon design required 11 patients for the first stage and called for termination at stage 1 if there were less than 5 responders (Pathological complete response, pCR) among 11 patients. Otherwise, if seven or more responders were identified in up to 11 patients, additional 20 patients would be enrolled. Treatment was considered of clinical interest if, at the end of the second stage, there were more than 16 responders among 31 patient.||||
34027653|NCT02089659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027654|NCT01857479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027655|NCT00583388|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34027656|NCT00004315||||TREATMENT||||||||
34027657|NCT04011670|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|A statistician prepares a randomization list. Only the pharmacist knows the medication type (caffeine or placebo) and the type of electrical stimulation. The researcher knows only the vigilance conditions (\*\*passive or \*active) . An investigator is blinded to the type of electrical stimulation and medication. In addition, all participants are naive to electrical stimulation and do not know if they receive placebo or verum drug.|15 participants are assigned to caffeine group and another 15 are assigned to placebo group. Then, the participants who were initially in the caffeine group now be in placebo group and those who were in the placebo group were assigned to caffeine group. Finally, all participants received both placebo and caffeine|t|f|t|f
34027658|NCT03883503|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34027659|NCT01563497|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027660|NCT05235516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027661|NCT02677350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027662|NCT04637802|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Randomized and double-blinded controlled trial of cognitive-behavioral intervention vs education at two phases (pre-operative and post-operative)|t|t|t|t
34027663|NCT06063057|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027664|NCT05798455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104418|NCT04628052|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34104419|NCT05836220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104420|NCT02257021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104421|NCT01066299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33722954|NCT05903885|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The on-site distribution group will receive FIT kits at a designated DMV location (4606 N 56th St, Omaha, NE) distributed by research staff, while the on-site with social media advertising group will receive FIT kits at the same location but with additional exposure to targeted ads on Facebook, Instagram, and YouTube. The social media campaign will run from August 19 to October 29, 2024, targeting African American residents of Omaha, aged 45-75. Both groups will receive a free FIT kit, prepaid return envelope, educational brochure, reminder messages, and post-FIT navigation support if needed. Participants' information and perceptions will be collected via surveys. FIT return rate, positive screening rate, and follow-up colonoscopy completion rate will be compared between groups, controlling for covariates. The study aims to recruit 1,200 participants (600 per group) over 3-6 months to evaluate these strategies in improving colorectal cancer screening rates among African Americans.|t|f|f|f
33804217|NCT05682950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027665|NCT02460146|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34027666|NCT02552901|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027667|NCT00000246||||TREATMENT||||||||
34027668|NCT04736225|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027669|NCT00008307||||TREATMENT||||||||
34027670|NCT00004263|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027671|NCT02317029|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34027672|NCT04414774|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking in this research, since the research team needs to know what stage the subjects are in in order to conduct the study. Due to ethical considerations, the subjects are aware that the purpose of the app is to reduce mental distress and suicidal ideation.|Participants will be randomly assigned to either the control or experimental group. The experimental group will immediately start using the GGSI app, for a period of 15 days (T1), while the control group waits. After 15 days (T2) the experimental group ceases its use of the app. At the same time, the control group will start its 15-days usage of the app. The end of these 15 days is marked T3.||||
34027673|NCT01109147|NON_RANDOMIZED|PARALLEL||||NONE||||||
34027674|NCT02029196|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027675|NCT03526159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027676|NCT03331835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027677|NCT02376400|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34027678|NCT05986695|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Statistician will be blinded to treatment assignment.|This is a type 3 hybrid (implementation focused), four group, pragmatic trial of cardiology and primary care clinicians at a single VA medical center. The trial will include a 3-month preintervention period and 3-month intervention period. Clinicians will be randomized to one of four arms: usual care, informational alert, peer comparison feedback, and combination of alert and peer comparison.|f|f|t|f
34027679|NCT00461201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34027680|NCT01048372|||COHORT||PROSPECTIVE|||||||
34027681|NCT00747032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027682|NCT05107596|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34027683|NCT05465109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34027684|NCT05847829|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34027685|NCT05518188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027686|NCT03793127|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single site cross sectional study.||||
33722955|NCT01209884|||COHORT||PROSPECTIVE|||||||
33722956|NCT00876954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722957|NCT04851886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study participants will be randomized to either 1) one-on-one robot-assisted upper-limb rehabilitation, and 2) group (up to three subjects per session) robot-assisted upper-limb rehabilitation|f|f|f|t
33722958|NCT01631058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722959|NCT00741039|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722960|NCT00146146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722961|NCT04626947|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804218|NCT02840929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804219|NCT04958317|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|This is a single masking study.||f|f|t|f
33804220|NCT06699303|NA|SEQUENTIAL||TREATMENT||NONE||It was planned as a randomized controlled and single blinded study.||||
33804221|NCT03084172|||COHORT||PROSPECTIVE|||||||
33804222|NCT03961841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027687|NCT04936711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027688|NCT00791544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027689|NCT06362863|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective randomized controlled study divided into intervention and control groups.||||
34027690|NCT03097146|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34027691|NCT06582966|NA|SINGLE_GROUP||PREVENTION||NONE||Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.||||
34027692|NCT06013826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027693|NCT03577782|NA|SINGLE_GROUP||TREATMENT||NONE||HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increases above 10e5 HIV-RNA copies/mL (two consecutive measurements).||||
34027694|NCT00457483|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34027695|NCT05676515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34027696|NCT03092973|||COHORT||PROSPECTIVE|||||||
34104422|NCT00235625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104423|NCT06439329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104424|NCT00663195|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34104425|NCT06026332|||COHORT||PROSPECTIVE|||||||
34104426|NCT05012618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104427|NCT06114641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104428|NCT01872208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104429|NCT06144658|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34027697|NCT05944926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Masked (blinded) field-based assessors will conduct all outcome assessments|Fluoxetine versus a contextually adapted version of behavioral activation called the Healthy Activity Program (HAP) delivered by non-specialists for treatment of depression|f|f|f|t
34027698|NCT00125515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027699|NCT05115487|||CASE_CONTROL||PROSPECTIVE|||||||
33722962|NCT01012687|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027700|NCT04556786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722963|NCT01096810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027701|NCT01783912|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34027702|NCT06171828|RANDOMIZED|PARALLEL||OTHER||SINGLE|We plan to mask the identity of participant groups from the evaluators during the assessment process of the effectiveness of ultrasound education using tele-education. This blinding is intended to ensure the objectivity and integrity of the evaluation results.|Interventional Clinical Trial, Parallel Assignment|f|f|t|f
34027703|NCT03612349|RANDOMIZED|CROSSOVER||OTHER||NONE|There is no masking since participants experience both marketplace conditions.|Participants will complete the Experimental Tobacco Marketplace Task under two marketplace conditions. One condition has all tobacco products available in menthol and non-menthol flavors. The other condition does not include alternative flavored combusted products.||||
33722964|NCT05696912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Ex-vivo approach concerning 25 patients with blood sample in PAXgene tubes or skin biopsy and RNA-Seq analysis.~In-vitro approach concerning 25 patients without specific samples needed for analysis in minigene or luciferase assay."||||
33722965|NCT00945009|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722966|NCT06053294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33722967|NCT03047642|||CASE_ONLY||PROSPECTIVE|||||||
33722968|NCT01718652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722969|NCT03013439|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722970|NCT02295033||||TREATMENT||||||||
33722971|NCT00790881||PARALLEL||TREATMENT||NONE||||||
33722972|NCT04723940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722973|NCT00199927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722974|NCT02816892|||COHORT||PROSPECTIVE|||||||
33722975|NCT01203228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33722976|NCT02722447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722977|NCT00518323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33722978|NCT01916356|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33722979|NCT01185119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33722980|NCT00885716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33722981|NCT00818428|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33722982|NCT00002631|RANDOMIZED|||TREATMENT||||||||
33722983|NCT05951387|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33722984|NCT04835025|||COHORT||OTHER|||||||
33804223|NCT04572906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All study personnel involved in the surgical procedure will be unblinded. Patient and outcomes evaluators will be blinded.|Treatment vs. Standard of Care|t|t|f|t
33804224|NCT06445244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804225|NCT02990481|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027704|NCT04097873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027705|NCT06136000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027706|NCT03198676|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE||Randomised partially blinded, partially placebo controlled, repeat dose|t|f|f|f
34027707|NCT01515917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027708|NCT05797844|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027709|NCT00367978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34027710|NCT01320384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027711|NCT05607654|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33722985|NCT02258230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33722986|NCT02099097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33722987|NCT05358067|||COHORT||PROSPECTIVE|||||||
33722988|NCT05080933|||COHORT||RETROSPECTIVE|||||||
33722989|NCT01613625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027712|NCT02983747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027713|NCT00546195|||||PROSPECTIVE|||||||
34027714|NCT06008873|||COHORT||PROSPECTIVE|||||||
34027715|NCT00810511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027716|NCT06303843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34027717|NCT00272051|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33722990|NCT02974296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33722991|NCT00838058|RANDOMIZED|CROSSOVER||||NONE||||||
33722992|NCT01046682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027718|NCT01181570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027719|NCT05537974|RANDOMIZED|CROSSOVER||SCREENING||NONE||"This is a crossover study and suction procedure was made in a random order with 60 minutes wash out period between two suction maneuvers. Patients were randomized after intubation; randomization was made with sealed envelopes.~All patients mechanically ventilated with lung protective ventilation strategy. Before the suctioning the patients ventilated with 100% of oxygen for 60 seconds. In open suction, the patient was disconnected from mechanical ventilator, the aspiration catheter advanced until resistance met after that the catheter withdraw 1 cm before aspiration. During endotracheal suctioning a negative pressure applied two times for 5 seconds. The negative pressure was set 150 mmHg. All suctioning maneuvers performed by intensivists."||||
33722993|NCT01141881||||TREATMENT||SINGLE|||f|f|t|f
33722994|NCT00854945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33722995|NCT04089059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722996|NCT01814566|||COHORT||PROSPECTIVE|||||||
33722997|NCT00437554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33722998|NCT05321615|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33722999|NCT04355325|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||This single-blind split mouth study will enroll 60 participants, having to receive 120 dental Implants. They will be recruited from 3 dental centers in Jordan .|t|f|t|t
33723000|NCT05023525|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34027720|NCT03907657|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027721|NCT00940316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027722|NCT03900052|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||"1: Naïve - Conventional cane with no instruction given. 2A: Scale training - Conventional cane, scale training, and instruction on proper cane use.~2B: Scale recall - Conventional cane with no further instruction or practice given 3A: Haptics training - Haptic biofeedback cane with explanation and training. 3B: Haptics recall - Haptic biofeedback cane with no further instruction or practice given."||||
34027723|NCT05772026|||CASE_CONTROL||PROSPECTIVE|||||||
34027724|NCT02690987|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34027725|NCT04936035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027726|NCT02445963|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027727|NCT00582010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027728|NCT00408083|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34027729|NCT01769456|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027730|NCT02965040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027731|NCT00002704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027732|NCT04718454|||OTHER||OTHER|||||||
34027733|NCT04891003|||COHORT||PROSPECTIVE|||||||
34027734|NCT05349045|||COHORT||PROSPECTIVE|||||||
34027735|NCT02467478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027736|NCT02982837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027737|NCT01267487|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34027738|NCT05812274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||People who meet eligibility requirements and provide informed consent will be randomly allocated to the two arms with a 1:1 allocation ratio.The randomization will match patients according to: 1) age, 2) performance status (ECOG \<2 vs \>=2) and 3) receiving ICI monotherapy vs. ICI plus chemotherapy.||||
33723001|NCT04096625|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The investigators plan a double-blind, randomised, sham-controlled trial in a cross-over design to assess the efficacy and safety of tDCS as an add-on intervention to a psychotherapeutic treatment for patients with a severe psychiatric condition requiring hospitalization.|t|f|t|t
33723002|NCT02530450|||CASE_CROSSOVER||PROSPECTIVE|||||||
34027739|NCT04077190|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027740|NCT00143871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027741|NCT05931653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027742|NCT03277755|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027743|NCT03620045|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized crossover design||||
34027744|NCT05751343|NA|SINGLE_GROUP||TREATMENT||NONE||The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks||||
34027745|NCT04352790|||COHORT||PROSPECTIVE|||||||
34027746|NCT03624959|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34027747|NCT02521272|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104430|NCT05007860|||COHORT||PROSPECTIVE|||||||
34104431|NCT00310843|||CASE_CONTROL||RETROSPECTIVE|||||||
34104432|NCT05690204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104433|NCT02105012|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double Blind||t|f|t|f
34104434|NCT02489617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723003|NCT00418132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33723004|NCT02867709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723005|NCT04294511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723006|NCT06523504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804226|NCT05423119|||COHORT||PROSPECTIVE|||||||
33804227|NCT03481751|||COHORT||PROSPECTIVE|||||||
34027748|NCT05957744|||COHORT||PROSPECTIVE|||||||
34027749|NCT00750685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027750|NCT02813941|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34027751|NCT01371539|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34027752|NCT02279108|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104435|NCT06691555|||OTHER||CROSS_SECTIONAL|||||||
33804228|NCT06694155|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE||The study will enroll 20 prediabetic (A1C 5.7%-6.4%) and 20 diabetic (A1C 6.5%-7.5%) subjects, 50-70 yrs of age, in randomized, crossover fashion. Each subject will participate in two 7d studies, with and without Whey Protein ingestion. Study order will be randomized. Subjects will consume their habitual diets (recorded by dietary log), with the dietary intervention being the additional consumption of two 30g doses of whey on the treatment assignment. Thirty grams of whey or placebo will be ingested within 1hr of waking and prior to breakfast, and a second 30g dose of WPI will be consumed 30min prior to the dinner meal. Main outcomes will be Matsuda index, 24hr glucose AUC, dietary intake (total kcal and macronutrients), and whole-body protein balance. The Matsuda index utilizes an oral glucose tolerance test to derive insulin sensitivity as assessed by euglycemic insulin clamp. Secondary outcomes will be satiety, satiation, and appetite score.|t|f|t|t
33804229|NCT02923206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104436|NCT02199275|||CASE_ONLY||PROSPECTIVE|||||||
33804230|NCT03006367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804231|NCT01155206|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33804232|NCT03746236|||CASE_ONLY||PROSPECTIVE|||||||
33804233|NCT01532648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104437|NCT01019174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804234|NCT04699058|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34027753|NCT00994578|RANDOMIZED|FACTORIAL||||NONE||||||
34027754|NCT02468856|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34104438|NCT06220253|RANDOMIZED|PARALLEL||OTHER||NONE||"Patients will be randomized 1:1 in two groups:~1. Study group: bipolar coagulation technique~2. Comparison group: reabsorbable stitches"||||
34027755|NCT04153903|||COHORT||PROSPECTIVE|||||||
34104439|NCT06687525|||OTHER||OTHER|||||||
34027756|NCT00005052|RANDOMIZED|||TREATMENT||NONE||||||
34104440|NCT01821846|||COHORT||PROSPECTIVE|||||||
34027757|NCT03104478|||COHORT||PROSPECTIVE|||||||
34027758|NCT02806024|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34104441|NCT03889015|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"1. Allocation concealment: Operator H.M. will choose between numbers in an opaque sealed envelope, which will be arranged by D.K. who will not be involved in any of the phases of the clinical trial. Data will be recorded on a computer by H.M. and O.S. and all records of all patients will be kept with the main supervisor M.I.~2. Implementation: D.K. will generate the allocation sequence, enroll participants, and assign participants to interventions.~3. Blinding: The assessors M.A. and R.E. will be blinded to the material assignment."|The subjects will be assigned randomly into two equal groups to receive either probiotic yogurt or xylitol-containing chewing gum for three months|f|f|t|t
34027759|NCT02348255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104442|NCT06307366|||CASE_ONLY||PROSPECTIVE|||||||
34104443|NCT04341012|||COHORT||PROSPECTIVE|||||||
34027760|NCT05430217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104444|NCT02091128|||COHORT||CROSS_SECTIONAL|||||||
34027761|NCT03504683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomization will be stratified by fasting insulin. Within the lowest insulin strata, randomization will be further stratified by biological sex.|f|f|t|t
34027762|NCT00435760|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34104445|NCT05396612|||CASE_CONTROL||PROSPECTIVE|||||||
34104446|NCT02532907|||COHORT||PROSPECTIVE|||||||
34104447|NCT05541666|||CASE_CONTROL||PROSPECTIVE|||||||
34104448|NCT01627912|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34104449|NCT03220256|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34104450|NCT03829683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug will be double-blind with matching placebo. Vitamin C 200mg/kg/24hours or placebo (Dextrose 5% in water) will be given intravenously every 6 hours for up to 96 hours of treatment.||t|t|t|t
34104451|NCT05579288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104452|NCT00718731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104453|NCT00966446|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104454|NCT05235828|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The member of the research team who is assessing outcome measures will be blinded to the randomization outcome.|Waitlist control design with an active intervention (ACT) and waitlist control (WLC) group. The ACT group will receive the v-SKY intervention after the baseline assessment while the WLC group will have a 6-week waitlist period. Afterwards, the WLC group will receive the v-SKY intervention while the other group will receive no intervention for 6 weeks.|f|f|f|t
34104455|NCT06674200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104456|NCT05041699|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34104457|NCT05187988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104458|NCT00005931||||TREATMENT||||||||
34104459|NCT01609400|||OTHER||PROSPECTIVE|||||||
33804235|NCT04439500|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33804236|NCT04560946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to treatment group assignment.|Two group randomized controlled trial.|f|f|f|t
33804237|NCT05679479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804238|NCT03572803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804239|NCT01733862|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33804240|NCT01119755|||CASE_ONLY||PROSPECTIVE|||||||
33804241|NCT03574103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804242|NCT02036112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027763|NCT06115083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The interpreter of the urodynamic evaluations will be blinded regarding intervention/control group|A randomized controlled single blinded clinical study with a study period of 12 months from inclusion until completion. The study subjects are then randomly assigned in a 1:1 ratio either to treatment or control group. After 6 months the study subjects in the control group are offered to be included in the intervention group.|f|f|t|f
34027764|NCT05258383|||COHORT||RETROSPECTIVE|||||||
34027765|NCT05513391|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Modified double-blind (participant, Sponsor, and Investigator blinded)||t|f|t|t
34104460|NCT04138277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104461|NCT02946411|||CASE_ONLY||PROSPECTIVE|||||||
34104462|NCT00449787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104463|NCT06678568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804243|NCT03177590|NA|SINGLE_GROUP||OTHER||NONE||||||
33804244|NCT03002259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104464|NCT04037397|RANDOMIZED|PARALLEL||TREATMENT||NONE||120 patients will be randomized in a 2:1 fashion (80 in the RFCA arm; 40 in the AADs arm)||||
34104465|NCT04691115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Part A (SAD) Within each group, subjects will be randomised in a 3:1 ratio to receive either AM1476 (n=6) or placebo (n=2). The first 2 subjects in each group will be dosed in a sentinel fashion; 1 subject will receive AM1476 and the other will receive placebo as randomised.~Part B (MAD) Within each group, subjects will be randomised in a 3:1 ratio to receive either AM1476 (n=6) or placebo (n=2)."|t|t|t|t
34104466|NCT00153790|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34104467|NCT06063720|||COHORT||PROSPECTIVE|||||||
34104468|NCT00952562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104469|NCT04298333||SEQUENTIAL||SUPPORTIVE_CARE||NONE||The study will be open-label, multi-center with a sequential safety design based on 3-level between-patient Response Surface Pathway (RSP) algorithm. Three patients will be recruited consecutively to each sequence of three dose levels (dose level 1 - cumulative dose 0.64 mg/kg body weight, dose level 2 - cumulative dose 0.96 mg/kg body weight, dose level 3 - cumulative dose 1.12 mg/kg body weight).||||
34104470|NCT04747431|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, multi-center, dose escalation||||
33804245|NCT06135922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027766|NCT01044108|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34027767|NCT06036992|||COHORT||PROSPECTIVE|||||||
34104471|NCT06691594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027768|NCT03637387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104472|NCT03616093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104473|NCT06094738|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34027769|NCT06552182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||healthy volunteers||||
34104474|NCT01080547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027770|NCT03874728|||CASE_ONLY||CROSS_SECTIONAL|||||||
34104475|NCT06566716|||CASE_CONTROL||PROSPECTIVE|||||||
34027771|NCT06076447|||OTHER||CROSS_SECTIONAL|||||||
34104476|NCT03570385|NA|SINGLE_GROUP||OTHER||NONE||Interventional pilot study with minimal risks and constraints, descriptive, prospective, monocentric||||
34104477|NCT00023023|||COHORT||PROSPECTIVE|||||||
34104478|NCT04883554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34104479|NCT04875533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34104480|NCT02749461|||COHORT||PROSPECTIVE|||||||
34104481|NCT00730600|NA|SINGLE_GROUP||||NONE||||||
34104482|NCT04858347|||COHORT||PROSPECTIVE|||||||
34104483|NCT06291727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and participants will not know which anesthetic agent they receive. Anesthesia providers will be aware in order to provide correct randomization.|Patients will be randomized 1:1 to one of two groups; one receiving Mepivacaine spinal anesthesia and the other receiving Bupivacaine spinal anesthesia for total knee arthroplasty (TKA).|t|f|t|f
34148959|NCT05216055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study is a randomized single blinded trial to minimize bias and provide highest level of evidence in use as part of effort to reduce opioid use consumption. This study cannot be performed as a double blinded RCT due to Exparel being milky white color in appearance and cannot be altered or shielded from being visible by the operating surgeon performing the TAP block.||t|f|f|f
34148960|NCT02337725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148961|NCT00002299||||TREATMENT||||||||
34027772|NCT00122759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027773|NCT02214537|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34027774|NCT03002701|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34027775|NCT06469203|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|randomization will be done by hospitals pharmacy. A total of 160 patients will be included in the sample size resulting in a net total of 80 patients per group as described below. Patients who choose to withdraw from the study will still be analyzed as intention-to-treat patients.|"Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline."|t|t|t|t
34027776|NCT01118975|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027777|NCT04687683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027778|NCT00612664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027779|NCT05575609|||OTHER||PROSPECTIVE|||||||
34027780|NCT06236841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148962|NCT00368121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148963|NCT02108665|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34148964|NCT01731093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027781|NCT05785884|RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants assigned to a single diet intervention. Between-groups differences and within-group changes will be assessed.||||
34027782|NCT02889523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027783|NCT04117802|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34027784|NCT00327886|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34027785|NCT02931981|||CASE_CONTROL||RETROSPECTIVE|||||||
33723007|NCT05847075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the interventions, the researcher conducting the exercise sessions as well as participants will not be blinded. To ensure assessor masking, the subjects are asked to omit their assigned group and not to talk about their interventions during the outcome evaluation sessions. In the case of unintentional unblinding for any reason, the involved researcher will notify the principal researcher.|Volunteers who meet the inclusion criteria will be guided in the study and asked to sign a written informed consent before enrollment in the trial. Participants will be randomized into intervention groups Control (C), Resitance/Strength training (RT) or Heat Therapy (HT).|f|f|f|t
33723008|NCT02090647|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34027786|NCT02836691|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804246|NCT01596972|RANDOMIZED|PARALLEL||||NONE||||||
34027787|NCT00380744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027788|NCT01007045|||COHORT||PROSPECTIVE|||||||
34027789|NCT05046743|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34104484|NCT06570642|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||The study will use a partial factorial, crossover, within x between subjects design. Participants randomly receive affect- or intensity-based goals for 8-weeks (Part 1), followed by a 2-week washout period, then cross-over to the other condition for 8-weeks (Part 2). During the affect-based goal condition, participants randomly receive one of four combinations of intervention enhancements: TYPE/CONTEXT (with vs. without) x SAVOR (with vs. without). In summary, participants are randomly assigned to one of eight groups based on order and intervention components: (1) intensity \> affect without enhancements; (2) intensity \> affect with TYPE/CONTEXT; (3) intensity \> affect with SAVOR; (4) intensity \> affect with both TYPE/CONTEXT and SAVOR; (5) affect without enhancements \> intensity; (6) affect with TYPE/CONTEXT \> intensity; (7) affect with SAVOR \> intensity; and (8) affect with both TYPE/CONTEXT and SAVOR \> intensity.|t|f|t|t
33804247|NCT01331044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34104485|NCT03902210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34104486|NCT00720083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104487|NCT00100750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104488|NCT05384223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be monitored by the Principal Investigator.||f|f|f|t
34104489|NCT06221046|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Patients will be randomized after obtaining consent. The research coordinator will have a list for arm 1 and arm 2 where the code for the patient enrolled will be entered daily. The first patient to be enrolled on any given day will be assigned to arm 1, and the second patient to arm 2. The research coordinator will have 30 envelopes with the protocols coded with arm 1 or arm 2, and cream containers also coded with arm 1 and arm 2. The nurses providing the experimental treatment will be blind to the content of the cream containers. The research coordinator will provide the clinical nurse with an envelope with an established treatment protocol according to the study arm the patient has been assigned.|A total of 30 patients will be enrolled in a randomized double-blind controlled cross-over study, where fifteen (15) patients will be assigned to the experimental group receiving cream D, and fifteen (15) patients will be assigned to the control group receiving usual care. Patients who after seven days have not improved by 2 points on Severity of Erythema scale will be asked by the investigators to continue the study in the other study arm. After obtaining written consent, the research coordinator will enroll the patient in the opposite study arm and provide documents and tools to the primary care nurse to proceed with the treatment per protocol.|t|t|f|t
34104490|NCT02844712|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34104491|NCT06671548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104492|NCT00558480|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34104493|NCT04938531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104494|NCT06691542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34104495|NCT03434886|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104496|NCT00467467|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
34104497|NCT00910130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804248|NCT06110468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33804249|NCT00491894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804250|NCT00724399|||CASE_ONLY||PROSPECTIVE|||||||
33804251|NCT06500559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804252|NCT02770326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027790|NCT02002559|||COHORT||PROSPECTIVE|||||||
34027791|NCT00952354|||COHORT||CROSS_SECTIONAL|||||||
34027792|NCT02216097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027793|NCT01911286|||COHORT||PROSPECTIVE|||||||
34027794|NCT03629197|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Physicians will be randomized after physician recruitment is complete. This ensures that arm assignment does not impact physicians' decision to participate. Arm assignment will be done using a random number generator. Due to the nature of the intervention, blinding participants (physicians) is not feasible. However, patients will not be aware of their physician's arm assignment.|Physicians will be randomized to receive the intervention versus control; patients will be recruited to see study physicians; patients will not be randomized.||||
34027795|NCT03484650|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The patient, physician, and data abstractors will be blinded to the arm.|Prospective randomized controlled trial|t|t|f|t
34027796|NCT06551870|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study includes an experimental design (randomized controlled trial), double-blind, with repeated measures, parallel groups and a quantitative approach.|t|f|f|t
34027797|NCT00437359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027798|NCT06390709|||COHORT||PROSPECTIVE|||||||
34027799|NCT01221389|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34027800|NCT00786409|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027801|NCT04625244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027802|NCT00281957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027803|NCT02265926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104498|NCT06573242|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34027804|NCT06292117|||COHORT||PROSPECTIVE|||||||
34027805|NCT05998148|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34027806|NCT01650584|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027807|NCT05184881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34027808|NCT03640416|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No masking needed.|||||
34104499|NCT06570109|||COHORT||PROSPECTIVE|||||||
34027809|NCT06241469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104500|NCT06056544|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34027810|NCT06202729|||COHORT||PROSPECTIVE|||||||
34027811|NCT03500380|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027812|NCT06598241|||COHORT||PROSPECTIVE|||||||
34027813|NCT04493567|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027814|NCT03299946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027815|NCT03106389|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, parallel-arm, randomized controlled trial between two groups; each consisting of 54 women, undergoing termination of pregnancy during the second trimester for various medical reasons. The first group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours. The second group will receive the same regimen, but in addition will have a transcervical balloon (Foleys') catheter that will be inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix. The target sample size is 108 cases randomized in a ratio of 1:1 using a computer-generated random sequence, allocation will be concealed in sealed, opaque consecutively-numbered envelopes. Women are counseled about the procedure, consenting women will be randomly assigned to one of the two groups.||||
34027816|NCT04113785|||CASE_CONTROL||RETROSPECTIVE|||||||
34027817|NCT02391987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34027818|NCT06632652|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A quasi-experimental pre- and post-intervention design will be implemented. Investigators will enroll the participants and collect baseline data and then investigators will educate participants, and after 6 months investigators will evaluate participants and compare the baseline (pretest) and endline (posttest) data of individual participants.||||
34027819|NCT00309686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34027820|NCT02198183|||COHORT||PROSPECTIVE|||||||
34027821|NCT05529446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34027822|NCT02234492|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34027823|NCT05368064|||COHORT||CROSS_SECTIONAL|||||||
34027824|NCT01820234|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34027825|NCT02645331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027826|NCT06125977|||COHORT||PROSPECTIVE|||||||
34027827|NCT04498117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027828|NCT01741168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027829|NCT04557033|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34027830|NCT00001797||||TREATMENT||||||||
34027831|NCT06488339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34027832|NCT00467324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027833|NCT05015283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027834|NCT03656588|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027835|NCT05823012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027836|NCT03928067|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking of participants not possible|||||
34027837|NCT01739660|NA|SINGLE_GROUP||||NONE||||||
34027838|NCT03129555|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The Outcome Assessor will only have a code of each drug and a code for each cluster. Therefore he will not know what drug the clusters have been using. The randomization key will be safely stored at servers at Statens Serums Institute (An institute under the Danish Ministry of Health). After the primary and secondary outcome have been evaluated data will be unblinded."|Cluster randomized cross-over study|f|f|f|t
34027839|NCT01085357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027840|NCT03874273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027841|NCT02388893|||CASE_ONLY||PROSPECTIVE|||||||
33723009|NCT00003055||||TREATMENT||||||||
33723010|NCT01157884|||COHORT||PROSPECTIVE|||||||
33723011|NCT02708342|||OTHER||RETROSPECTIVE|||||||
33723012|NCT00388635|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723013|NCT06010225|||COHORT||PROSPECTIVE|||||||
33723014|NCT03013556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723015|NCT02395718|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33723016|NCT03229668|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, double-blind,randomized, placebo controlled trial|t|t|t|t
33723017|NCT06387914|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Blinding maintained using the hand held controller (shows ON at all times) and programs which ensure equivalent battery drain at all stimulation settings.~Pseudo-ON =high frequency, low amplitude stimulation. Frequency up to 250 Hertz(Hz), Amplitude less than 0.5 milliamps(mA), Pulse Width 500 microseconds(uS)."|Double-blind trial, within subject randomisation and cross-over.|t|f|t|t
33723018|NCT05318183|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be randomized to receive 4 servings per day of whole wheat bread (WWB) or white bread (WB) for 2 weeks. During each study arm, participants will be provided eucaloric standardized diets that are devoid of whole wheat products, probiotic-containing foods, and fermented foods. Before and after each study arm, a fasting blood sample and fecal sample will be obtained for metabolomic and clinical measures. Anthropometric measurements and blood pressure will be assessed at days 0, 7, and 14 of each study arm. On day 14, participants will complete an oral glucose tolerance test (OGTT) with collection of blood samples every 30 minutes for 3 hours and a simultaneous gut permeability test that entails ingesting non-digestible sugar probes and subsequent 24-h collection of urine. Upon completion of these procedures, participants will undergo a \~1 month washout before repeating the study identically, with the crossover to the alternate bread diet.||||
33804253|NCT03851367|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects were recruited from an inpatient rehabilitation department, specializing in the treatment of children and adolescents with degenerative disorders. The research population consisted of 40 adolescents-girls, who were diagnosed with juvenile osteochondrosis (according to the International classification of Diseases - ICD M 42.0). All subjects were randomly divided into two groups: Sling Suspension Therapy, and Gymball therapy.||||
33804254|NCT03513692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804255|NCT06699446|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33804256|NCT01048476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104501|NCT06690697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804257|NCT06698471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors are masked to study arm|Cluster randomized controlled trial|t|f|f|t
34104502|NCT04572269|||CASE_ONLY||PROSPECTIVE|||||||
33804258|NCT05949567|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33804259|NCT01268436|||COHORT||PROSPECTIVE|||||||
33804260|NCT00826995|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33804261|NCT06192433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants: Participants are masked or blinded to their group assignment. This blinding is implemented to reduce potential bias in the study, as participants are unaware of the treatment they receive.~Assessors: The individuals who perform the cognitive function assessments are also blinded to the group assignment of the participants. They do not know whether a participant belongs to the high-frequency group (40Hz) or the moderately high-frequency group (10Hz). This dual blinding, of both participants and assessors, is important to ensure the integrity and validity of the study's results."|This study is a Randomized Controlled Trial designed to investigate the effects of different frequencies of transcranial magnetic stimulation (TMS) as non-pharmacological treatment for patients with mild cognitive impairment or dementia. The trial employs a Parallel Study Design, where two groups of participants are treated concurrently with either high-frequency transcranial magnetic stimulation (40 Hz rTMS) or moderately high-frequency transcranial magnetic stimulation (10 Hz rTMS).|t|f|f|t
33804262|NCT00171431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804263|NCT04243941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804264|NCT06444984|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33804265|NCT02379260|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804266|NCT06492135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804267|NCT02251652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804268|NCT00732966|NA|SINGLE_GROUP||||NONE||||||
33804269|NCT05861570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)||t|f|f|t
33804270|NCT00913289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804271|NCT01637402|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Simon's 2 stage minimax design for accrual.||||
33804272|NCT03203525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804273|NCT06497010|NA|SEQUENTIAL||TREATMENT||NONE||||||
33804274|NCT06299670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804275|NCT03624335|RANDOMIZED|PARALLEL||OTHER||NONE||Randomised controlled trials comparing early and late cord clamping||||
33804276|NCT06698822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804277|NCT01553942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804278|NCT04090151|||COHORT||PROSPECTIVE|||||||
33804279|NCT05514275|NA|SINGLE_GROUP||TREATMENT||NONE||Radiotherapy Combined With Endostatin and Capecitabine||||
33804280|NCT05824559|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.~Subjects in Cohort 1 will receive ME-344 (IV) on Days 1, 8 and 15 combined with bevacizumab (IV) on Days 1 and 15 of each 28-day cycle.~Subjects in Cohort 2 will receive ME 344 (IV) on Days 1 and 15 combined with bevacizumab (IV) on Days 1 and 15 of each 28-day cycle."||||
33804281|NCT04974567|||COHORT||PROSPECTIVE|||||||
33804282|NCT06489353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"1. Randomization and Allocation: Participants are randomly assigned to one of three groups using a computer-generated table. Group assignments are sealed in opaque envelopes and revealed by a research coordinator not involved in assessments.~2. Blinding Care Providers: The nurse is unaware of the group assignment. The coordinator informs the parent and child of the intervention just before the procedure.~3. Blinding outcomes assessor: Outcome assessors and data analysts are kept blind to group assignments and only receive anonymized data."|"Participants will:~* Be randomly assigned to one of three groups in parallel for the duration of the study:~* Watch their preferred cartoons on an iPad during the venipuncture process.~* Blow paper pinwheels to distract themselves during the venipuncture process.~* Receive standard care without any additional distractions."|t|t|f|t
34027842|NCT05186792|||COHORT||RETROSPECTIVE|||||||
34027843|NCT03936595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each participant will perform in a random order all four different experimental conditions||||
34027844|NCT06223776|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|t|f|f
34027845|NCT01313585|||COHORT||RETROSPECTIVE|||||||
34027846|NCT04338269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027847|NCT05972330|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|None, Open Label|Participants will be assigned an oral lozenge formulation based on the baseline analysis of their oral microbiome.||||
34027848|NCT03316274|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027849|NCT05102552|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34027850|NCT01653912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027851|NCT05547841|||COHORT||PROSPECTIVE|||||||
34027852|NCT00616070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104503|NCT02098486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104504|NCT00963885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104505|NCT05118529|RANDOMIZED|PARALLEL||TREATMENT||NONE||Routine care vs additional mobilization||||
34104506|NCT02042144|||COHORT||PROSPECTIVE|||||||
34104507|NCT01817946|||CASE_ONLY||CROSS_SECTIONAL|||||||
34104508|NCT01855503|||CASE_ONLY||PROSPECTIVE|||||||
34104509|NCT01407614|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34104510|NCT05474716|NA|SINGLE_GROUP||TREATMENT||NONE||A longitudinal, prospective, interventional, uncontrolled study||||
34027853|NCT06484686|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027854|NCT00230178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027855|NCT00920790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027856|NCT05489250|||COHORT||PROSPECTIVE|||||||
33723019|NCT04915755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study||t|f|t|f
34027857|NCT05538078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027858|NCT02439970|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34027859|NCT05446584|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|The subjects will be informed that sham and active HD-tDCS will be used in the study, but they will be masked to condition. Aside from the PI, other study team members who perform assessments will be masked to HD-tDCS condition.|All subjects will complete 3 conditions of HD-tDCS. Each HD-tDCS condition is comprised of 3 days of active or sham stimulation targeting the left frontal and temporal lobes (i.e., within-subjects design), randomized by order, and separated by 14 days to avoid carry-over effects.|t|f|f|t
34027860|NCT02896790|||CASE_ONLY||PROSPECTIVE|||||||
34027861|NCT03852537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027862|NCT00073697|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027863|NCT03907878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027864|NCT03209557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027865|NCT04537832|||COHORT||PROSPECTIVE|||||||
34027866|NCT05668546|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|After the surgical decision was made, the patients were referred to the physiatrist by the orthopedist without informing which knee would be operated on. The physiatrist and the patient did not know which knee would be operated, so the tests were performed blindly.||t|f|t|f
34027867|NCT02886624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027868|NCT00468364|||DEFINED_POPULATION||OTHER|||||||
34027869|NCT05566184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34027870|NCT06235684|||COHORT||PROSPECTIVE|||||||
34027871|NCT04308057|||OTHER||OTHER|||||||
34027872|NCT05812066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34027873|NCT01976884|||CASE_CONTROL||PROSPECTIVE|||||||
34027874|NCT05771844|NA|SINGLE_GROUP||TREATMENT||NONE|All participants receive same amount of TES stimulations over the course of the study, but they are blind to which night or blocks of 2 weeks they receive the stimulation in Phases I and II of the study (stimulation either on the second night or the last night of Phase I and stimulation on either the first or last block of 2 weeks in Phase II).|During Phase I of the study, all participants receive the same amount of TES stimulations, but in randomized order (stimulation either on the second night or the last night of Phase I). All participants receive stimulation and placebo in Phase II on a daily basis for up to two weeks at a time. The order participants receive placebo or treatment in the two week blocks are randomized.||||
34027875|NCT04080544|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027876|NCT03762694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34027877|NCT01396915|||COHORT||RETROSPECTIVE|||||||
34104511|NCT03413449|||COHORT||PROSPECTIVE|||||||
34104512|NCT03069924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027878|NCT03261011|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
33723020|NCT00990496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723021|NCT05211713|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention and control group||||
34027879|NCT06501326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104513|NCT04831619|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104514|NCT02842242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104515|NCT06689020|||CASE_CROSSOVER||PROSPECTIVE|||||||
34104516|NCT01000428|||COHORT||PROSPECTIVE|||||||
34104517|NCT00000603||||TREATMENT||||||||
34104518|NCT02564731|||COHORT||PROSPECTIVE|||||||
34104519|NCT04212442|RANDOMIZED|PARALLEL||OTHER||NONE||This is a pilot study testing the adapted Function Focused Care intervention. The study employs a wait-list control design and site randomization.||||
34104520|NCT03127163|NA|SINGLE_GROUP||TREATMENT||NONE||Intraestromal corneal ring||||
34104521|NCT05327543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104522|NCT02853214|NA|SINGLE_GROUP||SCREENING||NONE||||||
34104523|NCT02591407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723022|NCT04568057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"NIR light is invisible to the human eye, therefore the placebo units will operate in an identical manner to that of the active units.~The active and placebo helmets will look identical and their external operation will appear identical, each device will be marked with a code by the manufacturer, there will be no way to identify a device from active or placebo."|Double-blind placebo-controlled, one group received a placebo device and once group an active device.|t|f|t|t
33723023|NCT03331146|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33723024|NCT05133219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723025|NCT05052099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723026|NCT03451149|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A single group of up to 10 participants will be enrolled to evaluate a radiofrequency wire for cutting through liver parenchyma instead of the standard trocar needle during transjugular intrahepatic portosystemic shunt creation. This will be to test this device for feasibility and not health outcomes.||||
33723027|NCT00652236|||CASE_CONTROL||RETROSPECTIVE|||||||
33723028|NCT03068273|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33723029|NCT06250231|||CASE_ONLY||PROSPECTIVE|||||||
33723030|NCT02400879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33723031|NCT05373420|||COHORT||RETROSPECTIVE|||||||
34104524|NCT04343833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant, investigator)|A total of 20 patients, distributed in two groups with ten patient each (experimental and control) were included in this study. All patients signed a double informed consent, one for implant placement and one for their participation in the study. The study follows the Declaration of Helsinki recommendations. The Ethics Committee of the University of Murcia approved the study protocol with ID: 2076/2018.|t|f|t|f
34104525|NCT06504966|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double Blind||t|f|t|f
34148965|NCT00798317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148966|NCT04936347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148967|NCT05647668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33804283|NCT06309134|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned by algorithm to either complete the program or to waitlist. Allocation to conditions will be 50/50. Randomization will occur at the dyad level.||||
33804284|NCT06164704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027880|NCT03928210|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with at least one CTC cluster (if homotypic ≥ 2 CTCs, if heterotypic ≥ 1 CTC and ≥ 1 white blood cell (WBC)) at screening entered the treatment phase. During treatment phase, patients received a daily maintenance dose of digoxin for a total of seven days, with a digoxin target level of ≥ 0.7 ng/ml in serum during treatment. Blood draws for capture and enumeration of CTCs and CTC clusters were obtained on day 0 (pre- and 2 hours post digoxin), day 3 and day 7. Regular study visits included clinical and laboratory assessments such as vital signs, electrocardiogram (ECG), serious adverse events (SAE), and digoxin serum levels on day 0 and 7.||||
34027881|NCT06505798|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a randomised, adaptive open label multicentre clinical trial which compares optimal medical therapy (as per standard of care) with catheter ablation plus optimal medical therapy alone in participants with HfrEF (LVEF\<50%) and paroxysmal or persistent atrial fibrillation.~This design is adaptive in that the required sample size is reviewed in an interim analysis at 80% recruitment. This interim analysis aims to ensure that sufficient patients are recruited to maintain the conditional power of the study at 80% or higher. Options which can be deployed at the interim analysis include increasing patient numbers and increasing duration of follow up."||||
34027882|NCT06361719|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34027883|NCT04497012|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The participants, care givers, medical teams, investigator, and outcome assessors are blinded from the iron treatment dose for the duration of the study. Only research pharmacists and members of the Data and Safety Monitor Board are unblinded during the study period.~In an event when the medical team urgently needs to know the iron dose the participant is receiving for proper clinical management of the subject, the principal investigator or a designee will be notified by cell phone. Their contact information are located in the medical workrooms and the unit pharmacy. The principal investigator or the designee will immediately call the research pharmacy phone to request an emergency unblinding of that particular participant. The principal investigator will inform IRB and the sponsor of the unblinding event within 24 hours."|Randomize subjects to low and high dose iron supplementations|t|t|t|t
33804285|NCT06698965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804286|NCT00995631|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804287|NCT01629589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804288|NCT06288854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||olanzapine vs placebo|t|f|f|f
33804289|NCT05577936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804290|NCT04754022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804291|NCT05364697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804292|NCT04816955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator, all researchers and analysts will be blinded to treatment. Participants can not masked.||f|f|t|t
33804293|NCT05773092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104526|NCT04077086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study personnel assessing trial outcomes will be masked as to children's study group assignment, which will be simplified by the fact that there will be participants with and without glasses at both Intervention and Control schools. It is not ethical in this setting to provide Control participants with placebo treatment (glasses with zero power lenses), but students, parents and teachers will not be informed of either the overall design of the study or the explicit treatment intervention assignment. Only one school will be selected in each township, minimizing the possibility of cross arm communication and contamination.|Children in Year 1 at 111 randomly-selected middle-schools in Liaoning, northern China, will be randomized by school to receive free glasses and a teacher-based incentive to promote wear, or prescriptions only.|t|f|t|t
33804294|NCT03997994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804295|NCT02852824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804296|NCT00462475|||CASE_CONTROL||PROSPECTIVE|||||||
33804297|NCT00054210|RANDOMIZED|||TREATMENT||NONE||||||
33804298|NCT05940298|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
33804299|NCT06062875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Patients will then be randomized in a double-blind fashion to receive adalimumab 40 mg every 2 weeks or placebo injection (saline) every 2 weeks.|The purpose of this study is to investigate whether an anti-inflammatory drug commonly used for a range of autoimmune diseases may be useful to provide symptomatic relief, prostate shrinkage, and/or decrease prostatic inflammation in patients with benign prostatic hyperplasia (BPH), sometimes described as prostatic enlargement.||||
33804300|NCT05854446|||OTHER||PROSPECTIVE|||||||
33804301|NCT01802827|||COHORT||PROSPECTIVE|||||||
34104527|NCT05347797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104528|NCT03635879|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34104529|NCT05899959|||COHORT||PROSPECTIVE|||||||
33804302|NCT00802126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804303|NCT06334107|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804304|NCT05009862|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33804305|NCT01936818|||CASE_ONLY||PROSPECTIVE|||||||
33804306|NCT05268302|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33804307|NCT06527755|NA|SINGLE_GROUP||OTHER||NONE||This study is a single-arm study.||||
33804308|NCT06549296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804309|NCT04926597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This trial is single blinded (regarding outcome assessment)|Pragmatic, single blinded, open label randomised-controlled trial|f|f|f|t
33804310|NCT06605391|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804311|NCT01705886|||COHORT||PROSPECTIVE|||||||
33804312|NCT01463176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804313|NCT00405158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804314|NCT04756440|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||Randomized controlled experimental design|t|f|f|f
34027884|NCT02963233|||COHORT||PROSPECTIVE|||||||
34104530|NCT06393140|||COHORT||PROSPECTIVE|||||||
34148968|NCT01477008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148969|NCT04199819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148970|NCT03224065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723032|NCT00939276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723033|NCT02004028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104531|NCT03066518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Selection for a treatment group was determined by a computer-generated randomization list, in a 1:1 ratio using the randomized permuted blocks method.|A randomized, double-blinded, placebo-controlled study|t|t|t|t
34104532|NCT05518981|||COHORT||RETROSPECTIVE|||||||
34104533|NCT05528445|||CASE_ONLY||PROSPECTIVE|||||||
34104534|NCT06481072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804315|NCT04217330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be informed that the trial is assessing the impact of pulmonary rehabilitation models on patient and health system outcomes, but not the specific nature of the models of interest, or the intervention group to which their site has been allocated.~Assessors will be blinded to the site allocation."|Cluster randomized trial|t|f|f|t
33804316|NCT06080282|||CASE_CONTROL||PROSPECTIVE|||||||
33804317|NCT03791736|NA|SINGLE_GROUP||PREVENTION||NONE||A phase II prospective, single-center, non-randomized study.||||
33804318|NCT00466869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804319|NCT06221137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel groups, two arm, superiority Randomized Controlled Clinical Trial, with 1:1 allocation.|f|f|f|t
33804320|NCT00879840|||CASE_ONLY||RETROSPECTIVE|||||||
34027885|NCT01707264||SEQUENTIAL||TREATMENT||NONE||||||
33723034|NCT02341807|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723035|NCT00921180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723036|NCT04926532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723037|NCT04852458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be an observation cohort, from which individuals who can be approached within the critical time thresholds and who meet inclusion criteria will be invited to join an open label treatment arm.||||
33723038|NCT04366037|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cuasiexperimental||||
33804321|NCT05438992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33804322|NCT06397118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A trained anthropometrist will be masked to the study allocation.|Eligible participants will be randomly allocated to intervention or control groups in a 1:1 ratio via a permuted block allocation scheme stratified by sex.|f|f|f|t
34027886|NCT05065255|||COHORT||PROSPECTIVE|||||||
34027887|NCT00549744|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34027888|NCT03796052|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the same study regimen consisting of 3 products: a body wash, a body cream, and an anti-itch balm.||||
34027889|NCT03062046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723039|NCT03284996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33723040|NCT05782751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34027890|NCT05890534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Data analyst is also masked.||t|t|t|t
33723041|NCT05982054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723042|NCT01976234|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33723043|NCT03498742|||CASE_CONTROL||PROSPECTIVE|||||||
33723044|NCT01048021|||COHORT||PROSPECTIVE|||||||
33723045|NCT05109988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome measures will be collected by a research assistant who is blind to the group allocation.|Randomized controlled trial|f|f|f|t
33723046|NCT05161169|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Randomized controlled trial (control group vs. genome sequencing intervention)|t|t|f|f
33723047|NCT00520975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723048|NCT02002364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723049|NCT01818076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723050|NCT02935608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723051|NCT03842384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723052|NCT00257647|||||PROSPECTIVE|||||||
33723053|NCT01334723|||COHORT||RETROSPECTIVE|||||||
33723054|NCT02723084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723055|NCT01107587|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33723056|NCT01030523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723057|NCT06325007|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33723058|NCT01045356|||COHORT||PROSPECTIVE|||||||
33723059|NCT05690555|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33723060|NCT01338831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723061|NCT03839212|NA|SINGLE_GROUP||OTHER||NONE||||||
33723062|NCT01285245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804323|NCT00156845|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804324|NCT00124254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804325|NCT01358669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804326|NCT03570970|RANDOMIZED|PARALLEL||TREATMENT||NONE||250 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed. After completion of observation and confirming that the drug can be safely tolerated, study on 1000 mg group is then performed||||
33804327|NCT01507935|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33804328|NCT05369130|||COHORT||PROSPECTIVE|||||||
33804329|NCT04813133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804330|NCT03325218|||OTHER||CROSS_SECTIONAL|||||||
33804331|NCT02629224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027891|NCT00354692|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34027892|NCT01566227|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34027893|NCT04948892|||COHORT||PROSPECTIVE|||||||
34104535|NCT04078516|||CASE_CONTROL||PROSPECTIVE|||||||
34104536|NCT01918020|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723063|NCT00152750|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33723064|NCT01788670|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723065|NCT02797847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723066|NCT02635828|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723067|NCT01750008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study compares two laparoscopic interventions for the treatment of symptomatic uterine fibroids.|f|f|f|t
33723068|NCT01103609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104537|NCT04210076|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34104538|NCT03919305|||COHORT||PROSPECTIVE|||||||
34104539|NCT06690372|NA|SINGLE_GROUP||TREATMENT||NONE||A repeated measures, single group, crossover design will be used, with 16 participants. Once enrolled, participants will serve as their own control with a 4-week control phase (baseline) followed by participation in the 12-week home-based VR-Move exercise protocol (intervention phase).||||
34104540|NCT05855096|||OTHER||PROSPECTIVE|||||||
34104541|NCT02901561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104542|NCT06571071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind|Randomized, Double blind, Parallel Group, Placebo Controlled Trial|t|f|t|f
34104543|NCT06691360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104544|NCT06446323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigators responsible for assessing the primary outcome measure, pain intensity using the Premature Infant Pain Profile (PIPP), are blinded to the treatment allocation. While neonates and healthcare providers administering the interventions are aware of the treatment groups, the investigators conducting the outcome assessments remain unaware of which dose of sucrose solution each neonate received. This masking of the investigators helps mitigate potential bias in the assessment of pain relief efficacy. However, it is acknowledged that complete masking of all parties involved is not feasible due to the nature of the interventions|"In this parallel interventional study, neonates who have undergone minor procedures and are admitted to the neonatal intensive care unit are randomly assigned to one of two groups: Group I or Group II. Group I receives a 0.2 ml dose of sucrose solution, while Group II receives a 0.5 ml dose.~The study follows a parallel design, where each group receives a different intervention (different doses of sucrose solution) simultaneously. This design allows for a direct comparison between the two interventions while minimizing potential biases.~After administration of the respective doses, the neonates are monitored for pain intensity using the Premature Infant Pain Profile (PIPP). Data on pain scores are collected and analyzed using statistical methods, such as those performed with SPSS version 25.0.~The primary objective of this parallel interventional study is to determine which dose of sucrose solution (0.2 ml or 0.5 ml) is more effective in reducing post-procedural pain in neonates."|f|f|t|f
34104545|NCT03720808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104546|NCT05783271|||COHORT||PROSPECTIVE|||||||
34104547|NCT03574389|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104548|NCT06685822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104549|NCT02363894|||COHORT|||||||||
34104550|NCT01955265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34104551|NCT01934231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104552|NCT01122680|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34104553|NCT04822558|NA|SINGLE_GROUP||OTHER||NONE||||||
34104554|NCT00397046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This was an open-label, phase 1, ascending single and multiple oral dose study of neratinib administered to subjects with advanced solid tumors. Each subject participated in only 1 dose group and received a single dose of neratinib. This was followed by a 1-week observation period, and the subject then received neratinib administered as a continual oral daily dose for up to 6 months (6 cycles). Daily dose administration could continue beyond 6 cycles at the same dose level after consultation with the sponsor if neratinib was well tolerated and there was no evidence of progressive disease.||||
34104555|NCT04026958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104556|NCT04523519|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104557|NCT02542280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104558|NCT00601185|||COHORT||PROSPECTIVE|||||||
34104559|NCT06231472|RANDOMIZED|PARALLEL||SCREENING||NONE||In the preoperative period, two groups were created: patients who received fluid infusion and patients who did not receive fluid infusion.||||
34104560|NCT06460766|||COHORT||PROSPECTIVE|||||||
34104561|NCT00521352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33723069|NCT03817385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723070|NCT00104455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723071|NCT00304408|||COHORT||PROSPECTIVE|||||||
33723072|NCT00967993|||||RETROSPECTIVE|||||||
33723073|NCT05239273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723074|NCT00524550|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33723075|NCT03273881|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723076|NCT04263701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Self-controlled study||||
33723077|NCT00056563|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723078|NCT03927612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assignment will be sealed for the experimenter until immediately prior to Visit 3 (for visit preparation, experimenter must be unblinded).|This project will examine how levels of a virtual reality treatment that provides users with the alternate perspective of an interpersonal interaction impacts psychological and neurobiological markers of perspective taking. Following the initial screening visit, participants will be randomly assigned to different VR perspective conditions, stratified by sex, presence/absence of ADHD diagnosis, and ODD/CD diagnosis, via an a priori randomization chart. An equal number of youth will be randomly assigned to either the alternate perspective condition or control condition. Visits 1 and 2 will be identical for both groups. At Visit 3, the initial VR scenarios and assessments will be identical. The participant will then re-experience the VR scenarios depending on their assigned condition. Additional VR assessments and the MRI scan will be identical for both groups.|t|f|t|t
33723079|NCT01247610|||COHORT||OTHER|||||||
33723080|NCT05309109|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723081|NCT00253474||||TREATMENT||||||||
33723082|NCT01353287|||CASE_CONTROL||RETROSPECTIVE|||||||
33723083|NCT01618409|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33723084|NCT02773927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723085|NCT05334290|||OTHER||PROSPECTIVE|||||||
33723086|NCT01153243|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723087|NCT05434520|||COHORT||RETROSPECTIVE|||||||
33723088|NCT00861146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723089|NCT02196779|||CASE_ONLY||PROSPECTIVE|||||||
33723090|NCT05603559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723091|NCT02362009|||COHORT||PROSPECTIVE|||||||
33804332|NCT03676413|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33804333|NCT03611166|||COHORT||PROSPECTIVE|||||||
33804334|NCT04876495|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||single-blind, randomised, triple crossover|t|f|f|f
33804335|NCT05831865|||COHORT||PROSPECTIVE|||||||
33804336|NCT03803475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104562|NCT06055569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148971|NCT01092962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804337|NCT00903474|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804338|NCT00328692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804339|NCT02499159|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804340|NCT03509909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome evaluator is blind to experimental condition|Experimental condition: Manualized hatha yoga, a 12-session group-based yoga class led by a trained teacher Control condition: Manualized supportive physical activity, a 12-session group-based stretching and strengthening class led by a trained instructor|f|f|f|t
33804341|NCT03001440|||COHORT||CROSS_SECTIONAL|||||||
33804342|NCT06101927|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33804343|NCT06086054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33804344|NCT00810849|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33804345|NCT01492049|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804346|NCT05737121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|"IC/BPS patients will be randomly assigned to receive a single dose of one of the following treatments in a ratio of 3:1:3:1:~* VNX001 (n=45): alkalinized buffered lidocaine HCl (200 mg) and heparin sodium (50,000 USPU), administered as an intravesical instillation~* Placebo (n=15): alkalinized buffer, administered as an intravesical instillation~* Lidocaine (n=45): alkalinized buffered lidocaine HCl (200 mg), administered as an intravesical instillation~* Heparin (n=15): alkalinized buffered heparin sodium (50,000 USPU), administered as an intravesical instillation~* At 24-48-hours post-dose, all subjects will be given the option of requesting a single open-label dose of VNX001."|t|f|t|f
33804347|NCT05768282|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804348|NCT04110743|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804349|NCT02494336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33804350|NCT06359548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804351|NCT02299349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804352|NCT00332319|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33804353|NCT01099566|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33804354|NCT04541797|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|"A stratified block randomisation process will be used. Two blocks will be created for randomisation which are 1) Positive stress CMR patients who did not have significant coronary artery disease; 2) Negative stress CMR patients. This will ensure equal spread of these two groups of patients into the control and intervention arm.~Patients will be randomised into control and intervention arms. Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).~Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group."|double blinded randomised control trial study|t|f|t|f
33804355|NCT02586272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804356|NCT00592345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804357|NCT00781469|||COHORT||CROSS_SECTIONAL|||||||
33804358|NCT01805219|||COHORT||PROSPECTIVE|||||||
33804359|NCT03956628|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are randomly assigned to control and experimental group.|There are two groups, experimental and control group. Experimental group will be provided with psycho education about safety skills related to child abuse. Control group will not be given any intervention.|t|f|f|f
33804360|NCT04612868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804361|NCT00879710|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804362|NCT04218383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33804363|NCT03484741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804364|NCT06151275|||COHORT||PROSPECTIVE|||||||
33804365|NCT04876417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804366|NCT03168750|||COHORT||PROSPECTIVE|||||||
34027894|NCT01263938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027895|NCT01550328|||COHORT||PROSPECTIVE|||||||
34027896|NCT01632397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027897|NCT01590303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027898|NCT01128309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027899|NCT00306995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027900|NCT04357548|||COHORT||PROSPECTIVE|||||||
34027901|NCT00154518|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34027902|NCT02613442|||COHORT||CROSS_SECTIONAL|||||||
34027903|NCT06233773|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE||This research is a randomized controlled experimental study.|t|f|t|f
34027904|NCT02879903|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34027905|NCT01887171|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34027906|NCT01912378|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34027907|NCT03245866|||COHORT||PROSPECTIVE|||||||
34027908|NCT01703624|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34027909|NCT02447601|NA|SINGLE_GROUP||OTHER||NONE||||||
34027910|NCT02593292|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34027911|NCT03761940|||OTHER||CROSS_SECTIONAL|||||||
34027912|NCT00531414|||||PROSPECTIVE|||||||
34027913|NCT02998177|||CASE_ONLY||PROSPECTIVE|||||||
34027914|NCT06550765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental Group: The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.||||
34027915|NCT01098630|||COHORT||PROSPECTIVE|||||||
34027916|NCT06164366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34104563|NCT04774562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients and their relatives were given physiotherapy and video-assisted discharge education by the same physiotherapist without being told which group they were in.|This study included 31 participants who were randomly divided in the physiotherapy (PT) group (n=18), and the video-assisted discharge education (VADE) group (n=13). Both groups received a physiotherapy program. VADE group was additionally received VADE program. The physiotherapy program included breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation. The VADE program included information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities, home settings by modifying the treatment and discharge protocols of Lucas (2008). The whole program was taught verbally and practically and a physiotherapy booklet prepared with the same content was given to the participants and their relatives.|t|f|f|f
33723092|NCT03202147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723093|NCT00413192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723094|NCT03382119|||COHORT||PROSPECTIVE|||||||
33723095|NCT06435533|NA|SINGLE_GROUP||TREATMENT||NONE||peri-ampullary FAP polyps of size smaller than 10 mm will be treated with low energy argonplasma coagulation||||
33723096|NCT02211001|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34027917|NCT02441660|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Study participants are assigned to both strengths of the intervention, so all study participants receive both strengths, thus acting as their own control. Data will be compared according to intervention, rather than following each subject from beginning of study through both interventions.|t|f|f|f
33723097|NCT04325958|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"Participants will complete a session with active cannabis and a session with placebo cannabis.~Order of sessions is randomized.~Participants and Investigator are blinded.~Allocation to arms is not randomized. Arms are based on their age."|t|f|t|f
34027918|NCT01859663|||CASE_CONTROL||RETROSPECTIVE|||||||
34027919|NCT01944111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723098|NCT02608268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723099|NCT00378040|||CASE_ONLY||PROSPECTIVE|||||||
33723100|NCT01447524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723101|NCT05632549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723102|NCT05508763|||COHORT||PROSPECTIVE|||||||
33723103|NCT02434731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723104|NCT01661127|||CASE_ONLY||PROSPECTIVE|||||||
33723105|NCT00156221|||NATURAL_HISTORY||OTHER|||||||
33723106|NCT05338411|||COHORT||PROSPECTIVE|||||||
33723107|NCT04130230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723108|NCT02059850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723109|NCT02418923|||COHORT||PROSPECTIVE|||||||
33723110|NCT02034786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027920|NCT06342115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027921|NCT03714919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027922|NCT06467396|||COHORT||PROSPECTIVE|||||||
34027923|NCT05291611|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be treated with cognitive behavioural therapy during our feasibility study.||||
34027924|NCT02333656|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34027925|NCT01711463|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34027926|NCT05391386|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34027927|NCT04952818|||CASE_CONTROL||RETROSPECTIVE|||||||
34027928|NCT06257381|||CASE_CONTROL||PROSPECTIVE|||||||
34027929|NCT04065360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34027930|NCT06329609|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34027931|NCT01139112|||||RETROSPECTIVE|||||||
34027932|NCT03661801|||OTHER||PROSPECTIVE|||||||
34027933|NCT03490656|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027934|NCT03544944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027935|NCT05860114|NA|SINGLE_GROUP||TREATMENT||NONE|The study was conducted as open label. Blinding procedures were not applicable.|||||
34027936|NCT06486857|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34027937|NCT06550960|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two-arm study of study biopsy needle and standard of care biopsy needle||||
34027938|NCT01679509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027939|NCT05088785|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34027940|NCT02737904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34027941|NCT00998309|||CASE_ONLY||PROSPECTIVE|||||||
34027942|NCT01026311|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34027943|NCT02551484|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34027944|NCT03360955|||COHORT||CROSS_SECTIONAL|||||||
34027945|NCT02108184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027946|NCT00474266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34027947|NCT03527953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
34027948|NCT00901576|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34027949|NCT04928976|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34027950|NCT05762692|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34027951|NCT05281705|||COHORT||CROSS_SECTIONAL|||||||
34027952|NCT03616717|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|University of California, San Diego Experimental Pharmacy randomizes dose order and provides masked pills|Experimental medicine model; not an intervention. Within-subject double-blind placebo-controlled dose-response study.|t|f|t|t
34027953|NCT05083897|||OTHER||CROSS_SECTIONAL|||||||
34027954|NCT02638025|||CASE_ONLY||PROSPECTIVE|||||||
34027955|NCT06013748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027956|NCT00703872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027957|NCT00103714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027958|NCT05478252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027959|NCT03352258|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, monocentric, prospective pilot study, pre- and post-intervention intraindividual comparison in the treated arm comparison of changes in neuropsychological performance in the treated and observational arms||||
34104564|NCT01861275|||CASE_CONTROL||PROSPECTIVE|||||||
34148972|NCT00424411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804367|NCT05906550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The software of the HD03 Hemodialysis Monitor will be adjusted to allow blinded measurements that will be sent to the trial coordinator; patients and health care providers remain unaware of treatment allocation and surveillance findings. Flow measurements will only be used to refer patients for correction of vascular access stenosis in the control group. To maintain blinding, whenever a measurement must be repeated to confirm low flow volumes, another trial participant will randomly be selected for confirmation of vascular access flow volumes after the next measurement. Patients will be censored and randomized anew following an intervention for flow dysfunction, as soon as the indicator for vascular access intervention has been resolved and vascular access function has been restored.|Double blind randomized controlled trial with hybrid parallel-crossover design|t|t|t|t
33804368|NCT03440346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104565|NCT05073731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|f|f|f|t
33804369|NCT04393389|||COHORT||PROSPECTIVE|||||||
34104566|NCT04157582|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33804370|NCT05481905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804371|NCT00918203|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804372|NCT02124668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804373|NCT04946682|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33804374|NCT03611075|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804375|NCT04679662|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-arm registry||||
33804376|NCT02348632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804377|NCT06367023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804378|NCT00972049|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33804379|NCT01857635|||CASE_ONLY||PROSPECTIVE|||||||
33804380|NCT06285253|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label, safety study||||
33804381|NCT05708365|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33804382|NCT03311360|||COHORT||PROSPECTIVE|||||||
33804383|NCT03466931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804384|NCT05261607|||COHORT||RETROSPECTIVE|||||||
33804385|NCT01170624|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804386|NCT00785200|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33804387|NCT00756405|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804388|NCT05571384|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804389|NCT06009393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804390|NCT01153113|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804391|NCT00000234||CROSSOVER||TREATMENT||||||||
33804392|NCT06433050|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
33804393|NCT03516032|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The specific purpose of the clinical staff study not directly involved in the study is not specified in terms of not affecting the participants.||f|t|f|f
33804394|NCT05335928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804395|NCT04217694|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804396|NCT05361070|||COHORT||PROSPECTIVE|||||||
33804397|NCT06571136|||CASE_CONTROL||PROSPECTIVE|||||||
33804398|NCT06101875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804399|NCT00163046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33804400|NCT05911451|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, multicenter randomized controlled trial.||||
33804401|NCT03347851|||CASE_CONTROL||PROSPECTIVE|||||||
33804402|NCT02854033|||COHORT||PROSPECTIVE|||||||
33804403|NCT04383184|||COHORT||RETROSPECTIVE|||||||
33804404|NCT01515501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804405|NCT03166085|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, phase Ib study of PU-H71 plus nab-paclitaxel (Abraxane) in patients with HER2-negative metastatic breast cancer (MBC).||||
33804406|NCT02808858|||CASE_ONLY||PROSPECTIVE|||||||
33804407|NCT00093496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804408|NCT00127387|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33804409|NCT05839067|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||100 participants will be trained to use a 5-step theoretically driven problem-solving process to manage heart failure problems experienced in the home.||||
33804410|NCT01862016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804411|NCT04930406|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804412|NCT05286788|NA|SINGLE_GROUP||TREATMENT||NONE||MEKTOVI® (binimetinib)||||
33804413|NCT00507494|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33804414|NCT04688060|||CASE_CONTROL||PROSPECTIVE|||||||
33804415|NCT02967861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33804416|NCT06116721|||COHORT||RETROSPECTIVE|||||||
33804417|NCT04428710|||COHORT||CROSS_SECTIONAL|||||||
33804418|NCT00811941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804419|NCT02130557|RANDOMIZED|PARALLEL||TREATMENT||NONE|NOTE: Value was Open Label in old format; This study has an open-label design. Although most efficacy studies have a double blind design, this is not feasible in this trial, due to the complexity of the dose reduction and dose escalation schemes with tablets of various sizes, dosage strengths, as well as the number of tablets that would be required daily. However, the opportunity for bias is mitigated by the use of objective outcome measures (MMR, CCyR, CHR). The Investigators will be instructed to ensure that laboratory/pathology personnel are blinded to treatment information. For these reasons, an open-label, randomized study is appropriate.|||||
34104567|NCT04954989|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104568|NCT05978310|||CASE_CONTROL||PROSPECTIVE|||||||
34104569|NCT01768871|||COHORT||PROSPECTIVE|||||||
34104570|NCT01342042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104571|NCT00855166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104572|NCT04717479|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34104573|NCT01901757|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104574|NCT05817344|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104575|NCT02115243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104576|NCT06289283|||CASE_CONTROL||PROSPECTIVE|||||||
34104577|NCT06674590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027960|NCT05907239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One of the researchers will keep the randomization codes out of the patients' sight. Other medical researchers, separately, will apply the shockwaves and the placebo in a non-blinded manner. One researcher will assess the outcome measures, and will be blinded to the allocation of patients into groups throughout the study.|"A double-blind randomized controlled clinical trial will be carried out with 50 patients in the control group and 50 patients in the intervention group. Patients will be prospectively selected at the Orofacial Pain Outpatient Clinic of the Division of Dentistry of HCFMUSP and will be referred to the Acupuncture Center of the Institute of Orthopedics and Traumatology of HCFMUSP. The control group will initially undergo treatment with guidelines for muscular temporomandibular disorders and treatment by shockwave therapy with a placebo applicator for 5 weeks, while the intervention group will undergo the same guidelines and treatment by shockwave therapy. focal point on the masticatory muscles during 5 sessions, once a week (totaling 5 weeks). Groups will be evaluated and compared in terms of improvement in pain and quality of life, in addition to follow-up after 1 month, 3 months and 6 months after the procedure."|t|f|f|t
34027961|NCT02290223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027962|NCT06621446|||COHORT||PROSPECTIVE|||||||
34027963|NCT00258128|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34027964|NCT01652547|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027965|NCT00727597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027966|NCT05682651|||COHORT||RETROSPECTIVE|||||||
34027967|NCT01049646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34027968|NCT05100160|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34027969|NCT02876757|||COHORT||RETROSPECTIVE|||||||
34027970|NCT01499446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34027971|NCT02015026|||CASE_ONLY||PROSPECTIVE|||||||
34027972|NCT06490679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34027973|NCT00187993|||DEFINED_POPULATION||PROSPECTIVE|||||||
34027974|NCT05886868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027975|NCT05565079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study involves an investigator (surgeon) and an examiner. The examiner measures the clinical parameters before and after surgery and is blinded to the surgical procedure and if the patient receives biologic materials.|24 patients will be recruited and randomly grouped as control or test treatment for root coverage using a coronally positioned flap and alloderm with (test) or without (control) enamel matrix derivative.|t|f|t|t
34027976|NCT00481403|||COHORT||PROSPECTIVE|||||||
34027977|NCT05441501|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34027978|NCT02928445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34027979|NCT05357066|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patient and assessor blinded to study group assigned|Participants are randomly assigned to a treatment group schedule, group-1 (nitrous, placebo), or group-2 (placebo, nitrous). Dosing consists of 50% Nitrous oxide in oxygen mixture (FiO2 0.5) vs placebo (oxygen-air mixture FiO2 ≈0.3).|t|f|f|t
34027980|NCT04261101|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34027981|NCT03174379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34027982|NCT01287026|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34027983|NCT03590054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34027984|NCT03413579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34027985|NCT00364000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027986|NCT06435910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027987|NCT00681031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027988|NCT00478244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34027989|NCT03221244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will not be told in detail about the specific differences between the VR Treatment and the VR Active Control. Therefore participants will not know which VR condition they received."|"Participants are randomly assigned to one of two groups. Group 1: the treatment arm is the VR Treatment which presents distractors with increasing intensity as performance on attention measures improves. Group 2: in this active control arm (VR Active Control) participants interact with the VR classroom with no distractors presented."|t|f|f|f
33723111|NCT03994692|RANDOMIZED|PARALLEL||TREATMENT||NONE|because the two intervention in this trial are clearly different and easily recognized by participant and investigator , neither investigators nor participant can be blinded|"* randomized control trial~* trials will be carried out in hospital of oral \& maxillofacial department at faculty of oral and dental medicine of Cairo university~* equal randomization participants with equal probabilities for intervention~* positive controlled , both groups receiving treatment~* parallel group study , each group of patient receive single treatment simultaneously"||||
33723112|NCT04009421|||COHORT||PROSPECTIVE|||||||
33723113|NCT00396045|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723114|NCT01536379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104578|NCT06348147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723115|NCT04265274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723116|NCT04902716|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34027990|NCT01150812|NA|SINGLE_GROUP||||NONE||||||
34027991|NCT01590797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34027992|NCT00101283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027993|NCT05637203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34027994|NCT05021432|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34027995|NCT04143243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be told which group they are being allocated to. Follow-up assessments will be administered by anl interviewer blinded to patient assignment.|ACT plus Education, Resources and Support ('ACT on Life') workshop compared to Education, Resources, \& Support only workshop (ERS)|t|f|f|t
33723117|NCT05300906|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will not be informed about their randomized condition (personalized or non-personalized), but it is likely that they will infer it from the intervention that they receive.|participants are randomized to either the personalized or the non-personalized intervention.||||
33723118|NCT04698733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723119|NCT06039423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33723120|NCT06291051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723121|NCT01423487|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34027996|NCT02128672|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34027997|NCT05546008|||CASE_CONTROL||RETROSPECTIVE|||||||
34027998|NCT03336528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34027999|NCT01862276|||CASE_ONLY||RETROSPECTIVE|||||||
34028000|NCT00606164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028001|NCT03555110|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34028002|NCT01461447|NA|SINGLE_GROUP||||NONE||||||
34028003|NCT05721976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028004|NCT01115478|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34028005|NCT04110379|RANDOMIZED|PARALLEL||OTHER||NONE||The eligible participants will be randomly and equally divided into group I (study) and group II (control). Each group will be further subdivided according to age into subgroup A (preschool aged children) and subgroup B (school aged children).||||
34028006|NCT04585880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34028007|NCT02135471|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34028008|NCT02609438|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028009|NCT03300583|||COHORT||PROSPECTIVE|||||||
34028010|NCT00695058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028011|NCT04169152|||COHORT||PROSPECTIVE|||||||
34028012|NCT03864016|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34028013|NCT00555841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028014|NCT05858112|||COHORT||CROSS_SECTIONAL|||||||
34028015|NCT06526624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104579|NCT06687382|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104580|NCT06690944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34104581|NCT03474601|||COHORT||PROSPECTIVE|||||||
34104582|NCT06608732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723122|NCT00661076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723123|NCT01075204|||COHORT||PROSPECTIVE|||||||
33723124|NCT06180447|||COHORT||RETROSPECTIVE|||||||
33723125|NCT03608514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients will be randomly assigned in 1:1 manner|Fifty patients will be enrolled in each arm of the study \& randomly assigned in a 1:1 manner to receive either terlipressin alone versus the standard therapy (norepinephrine +/- epinephrine).|t|f|f|f
33804420|NCT05683990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804421|NCT02103361|||CASE_ONLY||OTHER|||||||
33804422|NCT04576975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of patients and assigning them randomly to their groups will be done by giving patients serial numbers, using a computer program (Microsoft Excel 365). Investigators will be blinded to group assignments and drug coding.||t|f|t|f
33804423|NCT06648395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804424|NCT04373512|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Design: Prospective, randomized pilot intervention clinical trial. Target Enrollment: 182 subjects total at least 1-year post-SCI. Setting: National sample (N=114 intervention only, no urine collection) and local Washington, DC metropolitan area (N=68 intervention + urine collection).~Controls: This is a 2-arm dose-finding pilot clinical trial, as such there is no control group."||||
33804425|NCT05421832|||COHORT||PROSPECTIVE|||||||
33804426|NCT03049319|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33804427|NCT05035134|||COHORT||PROSPECTIVE|||||||
33804428|NCT04270045|||COHORT||PROSPECTIVE|||||||
33804429|NCT06699381|||OTHER||CROSS_SECTIONAL|||||||
33804430|NCT01791140|||COHORT||PROSPECTIVE|||||||
33804431|NCT06447389|NA|SINGLE_GROUP||OTHER||NONE|The investigator, who performed the statistical analysis, will not know which group the obtained primary and secondary data belong to until all evaluations are completed.|||||
33804432|NCT05729503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804433|NCT02381470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804434|NCT06654323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33804435|NCT00930306|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33804436|NCT05394636|||COHORT||RETROSPECTIVE|||||||
33804437|NCT06396975|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33804438|NCT02278666|||COHORT||PROSPECTIVE|||||||
33804439|NCT04570072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33804440|NCT01815242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804441|NCT00982436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804442|NCT01503970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804443|NCT06639074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, provider and principal investigator are blinded||t|t|t|f
34104583|NCT00773461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104584|NCT00190528|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104585|NCT05658276|||CASE_ONLY||PROSPECTIVE|||||||
34104586|NCT01744626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104587|NCT06464367|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34104588|NCT06465641|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Placebo|N-of-1 series (aggregated N-of-1 trial)|t|t|t|t
34104589|NCT03622905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723126|NCT04372680|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multicenter, Randomized, Controlled, open-label, in parallel group||||
33723127|NCT00713336|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33723128|NCT02955979|||COHORT||PROSPECTIVE|||||||
33723129|NCT05303584|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723130|NCT01951157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723131|NCT04497077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723132|NCT00712231|||COHORT||PROSPECTIVE|||||||
33723133|NCT06005922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||temporomandibular joint mobilization and temporomandibular joint exercises|f|f|f|t
33723134|NCT03573947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723135|NCT01369979|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33723136|NCT00521768|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723137|NCT05270681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723138|NCT06348992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34028016|NCT03647670|RANDOMIZED|CROSSOVER||OTHER||NONE||Natural log transformed area under the curve from zero to infinity, area under the plasma concentration-time curve from 0 to the time of last measurement and max plasma concentration of midazolam will be analyzed using a mixed effect model with sequence, period and treatment as fixed effects and subject within sequence as a random effect. Estimates of the adj mean differences (Test-Reference) and corresponding 90% CIs will be obtained from the model. The adjusted mean differences and 90% CIs for the differences will be exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% confidence intervals for the ratios. Midazolam alone will be the Reference treatment, while the midazolam co-administered with PF-04965842 will be the Test treatment. The lack of an effect of PF-04965842 on midazolam PK will be concluded if the 90% CI for the ratio of adjusted geometric mean for AUCinf falls wholly within acceptance region (80%, 125%).||||
34028017|NCT05885321|||OTHER||PROSPECTIVE|||||||
34028018|NCT02986867|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028019|NCT04168879|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34028020|NCT05284266|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients are randomized to two different conservative treatment protocols;either standard conservative treatment (SCT) or standard treatment plus additional lymphedema treatment (intermittent pneumatic compression -IPC). After 6 months the effects of the conservative treatment are evaluated. Patients who still want surgery and fulfill the criteria are randomized (1:1) to early (cases(liposuction initiated 6-9 months after inclusion)) or late surgery (controls (liposuction initiated 18-21 months after inclusion)). Randomization to the surgical group is stratified by conservative treatment arm.||||
34028021|NCT02401997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028022|NCT06359912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028023|NCT03295682|||OTHER||PROSPECTIVE|||||||
34028024|NCT03456388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028025|NCT01711515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028026|NCT05092984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028027|NCT03447743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028028|NCT01785277|||COHORT||PROSPECTIVE|||||||
34028029|NCT06550427|||COHORT||PROSPECTIVE|||||||
34028030|NCT02944773|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34028031|NCT00449215|||DEFINED_POPULATION||OTHER|||||||
34028032|NCT06416956|||COHORT||PROSPECTIVE|||||||
34028033|NCT01654003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028034|NCT00559806|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34028035|NCT00288730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028036|NCT06200051|||COHORT||CROSS_SECTIONAL|||||||
34028037|NCT01000948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028038|NCT03718650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028039|NCT00314951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028040|NCT00153972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33723139|NCT02206425|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723140|NCT05319795|NA|SINGLE_GROUP||TREATMENT||NONE|This is a single arm study. However, individuals responsible for rating the videofluoroscopy x-ray data to determine outcomes will be blinded to timepoint of evaluation.|This is a prospective single arm case series treatment study involving a behavioral intervention (the Effortful Swallow Maneuver).||||
33723141|NCT03240679|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot study 10 in each group||||
34028041|NCT01356212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028042|NCT06006429|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028043|NCT05024357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028044|NCT04302714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028045|NCT04201626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34028046|NCT03293316|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Randomized Double-Blind||t|f|t|f
34028047|NCT02090166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028048|NCT04848727|||COHORT||PROSPECTIVE|||||||
34028049|NCT02623985|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028050|NCT05403086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel with optional Crossover for the control arm|t|f|t|t
34028051|NCT01700231|||CASE_ONLY||PROSPECTIVE|||||||
34028052|NCT01739127|||CASE_CONTROL||PROSPECTIVE|||||||
34028053|NCT04797221|||CASE_ONLY||CROSS_SECTIONAL|||||||
34028054|NCT06501430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects of both groups (Group A and B) will be kept unaware of the treatment type given to other group. All the information will be kept in lock and key, and will be accessible to author only.|After recruitment and signing the informed consent, baseline readings of all study variables will be taken and all subjects will be assigned into 2 groups, GROUP A (received autogenic inhibition with conventional treatment) and GROUP B (received reciprocal inhibition with conventional physiotherapy treatment) randomly divided by computer-generated software.|t|f|t|f
34028055|NCT01390532|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028056|NCT06469502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028057|NCT02583490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028058|NCT03912545|||COHORT||PROSPECTIVE|||||||
34028059|NCT02637531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028060|NCT02487303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34028061|NCT06222073|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028062|NCT05440890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors are not aware of the allocation group of the participants|Randomized controlled trial, with two parallel groups (control and intervention)|f|f|f|t
34028063|NCT05014841|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028064|NCT06499467|||COHORT||PROSPECTIVE|||||||
34028065|NCT03782051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028066|NCT05195801|||COHORT||PROSPECTIVE|||||||
34028067|NCT06172634|NA|SINGLE_GROUP||TREATMENT||NONE||dentritic cell + immunechekpoint inhibitor||||
34028068|NCT05429866|NA|SINGLE_GROUP||OTHER||NONE||This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.||||
33723142|NCT03394287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804444|NCT05580003|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|PART-1, 2 and 6 are double-blind, sponsor-open while PART-3, 4 and 5 are open label|PART-1 and -2 are a randomized, double-blind, sponsor-open, placebo-controlled trial to evaluate safety, tolerability and PK of single and multiple escalating oral doses of PF 07817883 in healthy adult participants, respectively. PART-1 is crossover while PART-2 is parallel cohort study design. PART-2 of the study may also evaluate the safety, tolerability and PK in Japanese and Chinese participants. PART-3 is a randomized, open-label, cross-over, study to evaluate relative bioavailability and food effect of up to 2 new PF 07817883 oral formulations. PART-4 is an open label, non-randomized, single period cohort to evaluate the metabolism and excretion of PF 07817883. PART-5 is an open-label, randomized, cross-over cohort to evaluate the effect of steady state PF-07817883 on PK of midazolam in healthy participants. PART-6 is a sponsor-open, randomized, 3-treatment, 3-period, cross over study to evaluate safety, tolerability, and PK of PF 07817883 at supratherapeutic exposure.|t|f|t|f
33804445|NCT01584752|||CASE_ONLY||PROSPECTIVE|||||||
33804446|NCT00042731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804447|NCT04747561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804448|NCT00482742|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804449|NCT02597751|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33804450|NCT01595282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804451|NCT03582085|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind|Half of the subjects will be placed in the multi-dose BCG group and half will be placed in the placebo group.|t|t|t|f
33804452|NCT04353089|||OTHER||OTHER|||||||
33804453|NCT01577524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33804454|NCT03911531|||COHORT||PROSPECTIVE|||||||
33804455|NCT01115400|||CASE_ONLY||PROSPECTIVE|||||||
33804456|NCT06609187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804457|NCT00321152|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33804458|NCT00402428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804459|NCT01612312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804460|NCT01690416|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33804461|NCT06255860|||CASE_CONTROL||RETROSPECTIVE|||||||
33804462|NCT01988935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804463|NCT00280228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804464|NCT02417376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804465|NCT03360513|||OTHER||RETROSPECTIVE|||||||
33804466|NCT02633215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028069|NCT04868500|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028070|NCT03203681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028071|NCT03545893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028072|NCT02914353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028073|NCT03885583|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34028074|NCT01658540|||CASE_ONLY||PROSPECTIVE|||||||
33804467|NCT02866942|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028075|NCT06323148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028076|NCT05273047|||COHORT||RETROSPECTIVE|||||||
34028077|NCT00582049|||CASE_CONTROL||PROSPECTIVE|||||||
34028078|NCT03364946|||OTHER||CROSS_SECTIONAL|||||||
34028079|NCT02274506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028080|NCT04913012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028081|NCT02715570|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34028082|NCT04807400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open-Label|||||
34028083|NCT03741400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor that will be performing the interval assessments will be blinded to treatment arm.||f|f|f|t
34028084|NCT00633243|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028085|NCT06176651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028086|NCT02137876|||CASE_ONLY||PROSPECTIVE|||||||
34028087|NCT06353269|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028088|NCT00486031|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34028089|NCT01632280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028090|NCT04311671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028091|NCT03089710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104590|NCT05145816|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, dose-escalation trial consisting of two parts: a Part 1 dose escalation phase and a Part 2 cohort expansion phase for safety and clinical activity testing.||||
33804468|NCT00998413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028092|NCT05830344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (placebo or active) and will be instructed not to inform the patients or other researchers as to the type of treatment (placebo or active). Therefore, the researcher responsible for the treatment, the investigator and the outcome assessor will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or active).||t|t|t|t
34028093|NCT02132793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34028094|NCT03448887|RANDOMIZED|PARALLEL||TREATMENT||NONE||Exploratory, Multicenter, Randomized||||
34028095|NCT02012426|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34028096|NCT01935518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028097|NCT06412679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Type II Hybrid Effectiveness-Implementation Design||||
34028098|NCT02862730|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028099|NCT00247780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028100|NCT04005352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double arm, multi-center|t|f|t|t
34028101|NCT05659212|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34028102|NCT06453369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028103|NCT01246310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104591|NCT01002729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104592|NCT05560880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104593|NCT02787174|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34104594|NCT06295471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028104|NCT03016975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028105|NCT01577550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028106|NCT01944163|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028107|NCT06551818|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34028108|NCT02404116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028109|NCT04401215|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Intervention group and control group|t|f|f|f
34028110|NCT06387524|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi experimental study||||
34028111|NCT02930759|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028112|NCT01783886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028113|NCT03169231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028114|NCT01254383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34028115|NCT05612568|||COHORT||RETROSPECTIVE|||||||
34028116|NCT05044559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028117|NCT01675648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028118|NCT00925639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028119|NCT00459043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028120|NCT05990985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028121|NCT05792111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The staff who will evaluate the patient before and after the procedure will not know which group the patients belong to, and the study will be blinded.|Trigger point injection was added to the gluteus medius and gluteus Maximus muscles in addition to caudal epidural steroids.|f|f|t|f
34028122|NCT03008174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028123|NCT01577771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028124|NCT01065402|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34028125|NCT01635348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028126|NCT01649986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028127|NCT03130530|||OTHER||RETROSPECTIVE|||||||
34028128|NCT01611857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028129|NCT02676765|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104595|NCT06695234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"A 2 (Group: Intervention vs. Treatment-as-usual Control) x 4 (Time Points: baseline, week 4, week 9 post-intervention and six-month follow-up) design will be adopted.~Those in TAU group will be offered the intervention once the study is complete.~Qualitative interviews will be conducted with randomly selected participants from MAT intervention group, at one month follow-up and 6 month follow-up.~Those in MAT group invited to submit weekly online diary entries throughout the intervention."||||
33723143|NCT03904238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to receive CBT-H in one of two formats: 1) individually or 2) small groups. However, the contents of the intervention are the same.||||
33723144|NCT06091280|NA|SINGLE_GROUP||TREATMENT||NONE||Single-group, longitudinal, intervention study||||
33723145|NCT01227941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723146|NCT05852743|||COHORT||PROSPECTIVE|||||||
33723147|NCT04696939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723148|NCT03689998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized clinical trial|f|f|f|t
34028130|NCT01688557|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33723149|NCT01489293|||CASE_CONTROL||OTHER|||||||
33723150|NCT03616899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723151|NCT05492175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723152|NCT04278547|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase IV clinical trial (with authorized treatment), randomized (2:1), controlled, open label and multicentric, with two parallel groups (Experimental group: preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis; Control group: Standard of care, universal prophylaxis with valgancyclovir for 3 months).||||
33723153|NCT02420691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804469|NCT06228573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804470|NCT06352632|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Adaptive Platform Trial evaluating multiple interventions in multiple states and domains|f|f|f|t
34028131|NCT01966250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34028132|NCT00315796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028133|NCT04170465|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34028134|NCT02653833|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34028135|NCT01279369|||COHORT||PROSPECTIVE|||||||
34028136|NCT03103516|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||200 acute spinal cord injury patients (complete and incomplete) will undergo pre-hospital treatment in the Beijing Emergency Medical Center and Beijing Red Cross Emergency Rescue Center, and will receive in-hospital treatment in the Peking University People's Hospital, Peking University Third Hospital, Beijing Friendship Hospital Affiliated to Capital Medical University, Chaoyang Hospital Affiliated to Capital Medical University, and Chinese PLA General Hospital, China. There were 100 patients undergoing epidural decompression surgery within 24 hours and 100 patients receiving surgery after 24 hours.|f|f|f|t
34028137|NCT03493256|||COHORT||PROSPECTIVE|||||||
34028138|NCT05370469|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028139|NCT06257095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34028140|NCT02125864|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028141|NCT01632657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028142|NCT04202055|||COHORT||RETROSPECTIVE|||||||
34104596|NCT06560879|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Interventions packaged in identical, odorless, tasteless, opaque capsules; stored in identical white plastic bottles.|An experimental, longitudinal, prospective, prolective, analytical, concurrent, randomized, triple-blind: randomized controlled clinical trial|t|t|f|t
34104597|NCT06044714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104598|NCT01623427|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34104599|NCT03538808|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|double-blind|Balanced placebo design|t|f|t|f
33804471|NCT03986840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028143|NCT05163392|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomly assigned to one of 2 arms conducted in parallel.~The trial arm kits include:~1. For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly.~2. For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly.~The control arm kits include:~1. For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours.~2. For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr."||||
33723154|NCT04145999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A single researcher will perform the treatment and he/she will not perform any evaluation. Pre- and post-treatment evaluations will be made by four examiners (three plastic surgeons and one pathologist) who will not be aware of the group to which each patient will be allocated. Participants will not be aware of whether or not they have received the PRP, the application syringes will be camouflaged with opaque adhesive on the outside and they will not be aware whether or not they have received the PBM application as they will be using eye protection and the person who applies it will position the equipment at the irradiation sites on all participants and will only turn on the light in the specific experimental group. The characteristic sound of the device will be triggered by recording in the placebo groups for the PBM.||t|f|f|t
33723155|NCT02067299|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34028144|NCT05297773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be followed in a randomized controlled trial conducted during the full duration of neoadjuvant treatment (i.e. 4- to 6-months, depending on patient treatment plan) and two cohorts will be defined: A - breast cancer patients undergoing chemotherapy; B - breast cancer patients undergoing endocrine therapy. Within each cohort, the participants will be divided into three groups: 1) aerobic training; 2): resistance training; 3): control group.~The intervention is designed to have equal energy expenditure throughout the exercise sessions in both exercise groups (10 kcal/kg/week). All training groups will complete 3 sessions/week. To ensure that both exercise groups are isoenergetic, a portable gas analyzer will be used and blood lactate will be collected.~Mandatory thematic sessions about several topics such as physical activity guidelines, active lifestyle will be implemented."||||
33723156|NCT03779464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028145|NCT00520117|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028146|NCT03555643|||COHORT||PROSPECTIVE|||||||
33723157|NCT05771142|||COHORT||PROSPECTIVE|||||||
33723158|NCT03636347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|placebo-controlled, dose ascending, sequential group|t|t|t|t
33723159|NCT06372015|||CASE_CONTROL||OTHER|||||||
33723160|NCT05481515|||COHORT||PROSPECTIVE|||||||
34028147|NCT00976196|||COHORT||PROSPECTIVE|||||||
34028148|NCT05453097|||COHORT||PROSPECTIVE|||||||
33723161|NCT03885141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo|Assessment of the efficacy of Zolpidem treatment. The following will be evaluated: improvement of maintenance insomnia through the Sleep Diary and the Severity Index of the Insomnia (IGI), as well as sleep latency through polysomnography and treatment safety through the reporting of adverse events and laboratory tests.|t|f|t|f
33723162|NCT00622479|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028149|NCT04539327|||CASE_ONLY||RETROSPECTIVE|||||||
33723163|NCT02736045|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33723164|NCT06496776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723165|NCT06333769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723166|NCT02133950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723167|NCT04192877|||COHORT||CROSS_SECTIONAL|||||||
33723168|NCT04811170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723169|NCT01382017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723170|NCT03836547|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with lung disease and a BMI of 35 or greater with significant shortness of breath will be randomized to a multicomponent intervention vs a wait-list control group.||||
33723171|NCT02280772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723172|NCT02331147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723173|NCT02344030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723174|NCT01245270|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33723175|NCT00003679|RANDOMIZED|||TREATMENT||||||||
33723176|NCT02225743|||CASE_ONLY||PROSPECTIVE|||||||
33723177|NCT05229432|||CASE_ONLY||CROSS_SECTIONAL|||||||
33723178|NCT00937872||CROSSOVER||BASIC_SCIENCE||NONE||||||
34028150|NCT06578143|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34028151|NCT01661062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028152|NCT03190031|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized in 2 different groups, one being involved in an endurance respiratory muscle training program, the other being involved in resistance inspiratory muscle training.||||
34028153|NCT03765788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028154|NCT01510782|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34028155|NCT02694328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028156|NCT01897805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028157|NCT04252092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028158|NCT02713412|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34028159|NCT02695784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34028160|NCT05114278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Upper endoscopy with duodenal biopsy will be performed at most one month before randomization, and one month after the last infusion (experimental group) and between the 12th and the 13h month after randomization (control group). Histological analysis (villous recovery, primary endpoint) will be centrally performed by an expert pathologist blind to the group of treatment.|Phase IV, open, randomized, 2-arms parallel controlled trial with blinded assessment of end-point.|f|f|f|t
34028161|NCT05755971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Intervention providers and participants are not aware of the purpose of the study or group selection|Blinded randomized controlled trial|t|f|t|f
33804472|NCT06300879|NA|SINGLE_GROUP||TREATMENT||NONE||Patients included in this group will receive totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique，which is an innovative surgery that investigators first began to apply in patients with proximal gastric cancer.||||
34028162|NCT02003950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33804473|NCT04297579|||CASE_ONLY||RETROSPECTIVE|||||||
33804474|NCT00795184|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34104600|NCT00945880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104601|NCT06686108|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804475|NCT04626037|NA|SINGLE_GROUP||PREVENTION||NONE||"Using a pre-test, post-test design, this study will be comprised of a single group in which all participants are offered two Drop-In Zoom group sessions during the school semester.~Exposure will vary at participant discretion."||||
33804476|NCT02823028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804477|NCT06069700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cas-crossover clinical trial||||
33804478|NCT05566249|||CASE_CONTROL||PROSPECTIVE|||||||
33804479|NCT05560659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804480|NCT02969759|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804481|NCT01367236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104602|NCT03463460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804482|NCT05770440|||COHORT||PROSPECTIVE|||||||
33804483|NCT01255514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804484|NCT02588313|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33804485|NCT05171777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804486|NCT00166322|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804487|NCT02307396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028163|NCT01359891|||COHORT||PROSPECTIVE|||||||
34104603|NCT04850443|||COHORT||PROSPECTIVE|||||||
34104604|NCT02105480|||COHORT||CROSS_SECTIONAL|||||||
34104605|NCT05102461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A statistician will provide the randomization scheme to the unblinded pharmacy research staff who will carry out the process. The chance that subjects will receive Florajen Digestion or the placebo will be 1:1.|This is a randomized, double-blinded, placebo-controlled study in SUNY Upstate University Hospital's Department of Surgery/Transplant Division. The total number of subjects enrolled will be 70 for both arms - placebo, 35 and treatment, 35. In order to eliminate bias, subjects will be randomized into two groups (treatment and placebo) using block randomization.|t|t|t|t
33804488|NCT06601218|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Randomization into 4 arms - each arm administers a dose of oral cannabis or placebo|t|t|t|t
34104606|NCT02548819|||CASE_ONLY||PROSPECTIVE|||||||
34104607|NCT01436890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104608|NCT06689202|||OTHER||CROSS_SECTIONAL|||||||
34104609|NCT01903720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104610|NCT02101853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804489|NCT04876846|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Generation 3||||
34104611|NCT02842385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804490|NCT02540824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804491|NCT03868579|NA|SINGLE_GROUP||OTHER||NONE||||||
33839098|NCT04643483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The study will be conducted in 3 parts:~* Part A will investigate 2 certolizumab pegol (CZP) dosing regimens with the objective of selecting a regimen that provides the highest rate of clinical remission. A cohort of participants will receive adalimumab (ADA) as a reference arm in Part A to assess clinical remission rates at Week 26 in this population. Endoscopic remission at Week 26 will also be evaluated~* Part B will assess maintenance of clinical remission from Week 26 through Week 52~* Part C is an optional open-label extension (OLE) of CZP after Part B, and will evaluate the long-term safety of CZP through Week 156"|t|t|t|t
34028164|NCT04302038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Potato protein will be provided pre-mixed into prepared pudding. The control group will receive pudding without protein.|Parallel group, single blind, randomized controlled trial|t|f|f|f
34028165|NCT04108624|NA|SINGLE_GROUP||OTHER||NONE||||||
34028166|NCT01573962|||COHORT||PROSPECTIVE|||||||
34028167|NCT04420494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028168|NCT04972357|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028169|NCT00696787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028170|NCT02914860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028171|NCT04010474|||COHORT||PROSPECTIVE|||||||
34028172|NCT03414476|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Monocentric, Exploratory study, open, comparative, in parallel groups|"1 group of women with effluvium télogène~1 group of women without effluvium télogène"||||
34028173|NCT05434689|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028174|NCT06581783|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34028175|NCT01687972|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34028176|NCT06418347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104612|NCT06689488|||COHORT||PROSPECTIVE|||||||
34104613|NCT02456883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104614|NCT00338000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104615|NCT06674265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104616|NCT06479707|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34104617|NCT03396575|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients in this study will either receive concurrent TMZ during RT and dose-intensive TMZ as maintenance treatment (Group A) or radiotherapy only prior to DC vaccination and without maintenance DI TMZ (Group B). Immune responses during cycles of DC vaccination with or without DI TMZ will be evaluated in both treatment groups.~Once Group A accrual is completed and evaluated for toxicity, 6 Group B patients will be enrolled and treated at the Maximally Achievable Dose (MAD) or (Maximum Tolerated Dose) MTD determined in Group A cohort."||||
34104618|NCT03163329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104619|NCT05835596|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Women are ranomized to MumCare app access or not for the 14-18 month intervention time||||
34104620|NCT03851666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104621|NCT00997698|||COHORT||PROSPECTIVE|||||||
34104622|NCT01357746|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804492|NCT05213312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Enrolled patients will receive the following medications:~1. Neoadjuvant immunotherapy : Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;~2. Neoadjuvant chemotherapy (investigator's choice) : Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cistaplin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.~3. MIE : Esophagectomy plus two/three field lymphadenectomy, 4-6 weeks after neoadjuvant therapy.~4. Adjuvant immunotherapy : 4-6 weeks after operation, (for subjects with non-pCR) Nivolumab injection, 240mg intravenous infusion, Q2W for 16 weeks, followed by 480mg intravenous infusion, Q4W. The maximum duration of adjuvant Nivolumab therapy is one year."|t|f|t|f
33804493|NCT03878979|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study will accrue to 2 cohorts, each of which consists of about 12 patients. If enrollment on 1 cohort is significantly faster, the lesser enrolling cohort number of patients may be decreased in favor of the better enrolling cohort to keep the total number of evaluable patients at 24 patients.Total of 24 patients will be accrued to the study.|t|f|f|f
33804494|NCT04540003|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|It is not feasible to blind students or their families or SST members as there are obvious differences in care procedures between the two groups.|This project will be a prospective cohort quasi-experimental study design to compare the benefits of using SBHCs as opposed to the traditional health care by evaluating educational achievements. The study period includes September 2017-June 2018 and September 2018-June 2019. Of 16 inner city schools not previously exposed to the SBHC in the TDSB, some schools (n=8) will be in the control arm following the standard of care while others (n=8) will have access to SBHC. Students presented to SST meetings whose outcomes include the need for a developmental/pediatric assessment at the 16 schools will be identified by TDSB internal research staff. To conduct our primary analysis, standardized test scores and numeric data from report cards will be analyzed using a linear mixed effect model where the schools are the random effects and the baseline test scores and report cards are adjusted for by including it as a covariate.||||
33804495|NCT05793996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804496|NCT04776096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||MULTICENTRIC, DOUBLE BLIND, RANDOMIZED, CONTROLLED, 60 DAYS, GROUP PARALLEL GROUPS, TO SHOW SUPERIORITY.|t|f|t|f
33804497|NCT06120218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804498|NCT06097091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We will employ a triple masking protocol in which the PNE educator, participants, and data collectors will all be blinded to group assignments. In addition, we will mask the group assignment to the data analyzer.||t|f|f|f
33804499|NCT02663219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804500|NCT02806674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804501|NCT05613985|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomised, two arms study to evaluate the efficacy and safety of topical application of the system VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care, versus the Usual Care alone.||||
33804502|NCT04163042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804503|NCT05273944|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804504|NCT04359784|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804505|NCT06700018|||COHORT||RETROSPECTIVE|||||||
33804506|NCT01698151|||CASE_ONLY||PROSPECTIVE|||||||
34028177|NCT01808573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028178|NCT06206798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34028179|NCT00990925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028180|NCT00295061|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34028181|NCT01696279|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104623|NCT02683954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028182|NCT05944198|||COHORT||PROSPECTIVE|||||||
34028183|NCT03237507|||COHORT||PROSPECTIVE|||||||
34028184|NCT04577209|NA|SINGLE_GROUP||OTHER||NONE||||||
34028185|NCT00717041|||COHORT||PROSPECTIVE|||||||
34028186|NCT05847348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study aims to recruit 110 prostate cancer patients with elevated PSA (BCR) after radical prostatectomy or radical radiotherapy||||
34028187|NCT05794503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded|Single site, randomized, controlled|t|t|t|t
34028188|NCT03094637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028189|NCT05410964|||COHORT||PROSPECTIVE|||||||
34028190|NCT03248973|||CASE_ONLY||RETROSPECTIVE|||||||
34028191|NCT06011707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The students who will be conducting the interviews for the primary objective of the study (using the Vineland Adaptive Behavior Scales, Version 3) will be blind to the treatment arm the family is assigned to.||f|f|t|f
34028192|NCT02089607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028193|NCT02673814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028194|NCT05473143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028195|NCT05464524|||COHORT||PROSPECTIVE|||||||
34028196|NCT05537636|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort longitudinal||||
34028197|NCT03009773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028198|NCT06148467|||COHORT||PROSPECTIVE|||||||
34028199|NCT03685344|NA|SEQUENTIAL||TREATMENT||NONE||||||
34028200|NCT05741177|||COHORT||PROSPECTIVE|||||||
34028201|NCT04036838|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028202|NCT01924559|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34028203|NCT04475172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple||t|t|t|t
34028204|NCT00641069|||COHORT||PROSPECTIVE|||||||
34028205|NCT03935438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028206|NCT00109226|RANDOMIZED|||TREATMENT||DOUBLE||||||
34028207|NCT03446807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The first phase is double-blind and the second phase is open label.||t|f|t|f
34028208|NCT01820273|||CASE_CONTROL||PROSPECTIVE|||||||
34104624|NCT05054907|||COHORT||PROSPECTIVE|||||||
34104625|NCT05181696|||CASE_CONTROL||RETROSPECTIVE|||||||
34104626|NCT03371225|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
34104627|NCT05982379|RANDOMIZED|PARALLEL||OTHER||SINGLE|Among the identified strata, intervention and control groups were randomized by an independent statistician using the website www.randomizer.org. The data of the study were entered by a person other than the researcher. Statistical analysis was performed by a person other than the researcher.|A randomized controlled trial|f|f|f|t
34104628|NCT04919473|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104629|NCT05224219|||COHORT||PROSPECTIVE|||||||
34104630|NCT05407766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104631|NCT06431633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104632|NCT05844319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104633|NCT04917939|||CASE_CONTROL||RETROSPECTIVE|||||||
34104634|NCT01379937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104635|NCT05454007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104636|NCT05704699|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104637|NCT02900404|||COHORT||OTHER|||||||
34104638|NCT02565459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104639|NCT05630118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104640|NCT02196727|||COHORT||PROSPECTIVE|||||||
33723179|NCT03479476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723180|NCT00725556|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33723181|NCT00600938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723182|NCT00391989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723183|NCT01317745|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33723184|NCT00540345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104641|NCT06438250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Drug: 68Ga-JH04||||
34104642|NCT04295928|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Cluster Stepped-wedge; Inclusions per cluster: Control period-\>Leeadin period-\>Interventionnal period||||
34104643|NCT01873508|RANDOMIZED|CROSSOVER||||NONE||||||
33723185|NCT04776707|||CASE_ONLY||CROSS_SECTIONAL|||||||
34104644|NCT01269437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723186|NCT00842686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723187|NCT05061979|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34028209|NCT03844256|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Patients will be treated with radiation therapy over 4 weeks and receive MMC IV on day1 of radiation therapy and capecitabine on each day of radiation therapy as radiosensitizers.~Phase-1b: enrollment of maximum of 30 patients with a maximum of 10 patients per treatment regimen, in order to determine optimal regimen based on the occurrence of dose limiting toxicities (DLT).~* Regimen-A: immunotherapy (w1-12) consists of nivolumab 480mg (fixed dose), on day(d)1, d29 and d57.~* Regimen-B: immunotherapy (w1-12) consists of ipilimumab 1 mg/kg together with Nivolumab 3mg/kg on d1, d22, d43 and d65.~* Regimen-C: immunotherapy (w1-12) consists of ipilimumab 3 mg/kg and nivolumab 1 mg/kg on d1, d22, d43 and d65.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52.~Phase-2: enrollment of an additional 20 subjects at the regimen determined to be optimal in the phase-1b part."||||
34104645|NCT03583710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104646|NCT01952262|||OTHER||PROSPECTIVE|||||||
33723188|NCT02081690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723189|NCT01214018|||COHORT||PROSPECTIVE|||||||
33723190|NCT05243225|||COHORT||PROSPECTIVE|||||||
33723191|NCT03326492|||COHORT||PROSPECTIVE|||||||
33723192|NCT00005888|RANDOMIZED|||TREATMENT||DOUBLE||||||
33723193|NCT03529240|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33723194|NCT00308503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723195|NCT02315755|||OTHER||PROSPECTIVE|||||||
33723196|NCT05089682|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723197|NCT01042223|||CASE_CONTROL||PROSPECTIVE|||||||
33723198|NCT01626807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33723199|NCT02232542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33723200|NCT00149487|RANDOMIZED|PARALLEL||OTHER||SINGLE||Examination of the efficacy of a tailored problem-solving intervention compared with family-based education in improving adherence to treatment regimens for children diagnosed as having asthma and their caregivers|f|f|t|f
34028210|NCT03653884|||COHORT||PROSPECTIVE|||||||
34028211|NCT06447194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded by investigational drug service|Randomized controlled trial|t|t|t|t
34028212|NCT04573894|||COHORT||RETROSPECTIVE|||||||
34028213|NCT05523583|||COHORT||PROSPECTIVE|||||||
34028214|NCT06444178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028215|NCT04642404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients who satisfy eligibility criteria and provide written informed consent will be randomly assigned to either 1) CBD 10mg/kg single dose (drug: Epidiolex 100mg/ml solution) or 2) CBD 20mg/kg single dose, or 3) Placebo group (drug: placebo)||t|t|t|t
34028216|NCT04194645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028217|NCT00307021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34028218|NCT06187805|||OTHER||RETROSPECTIVE|||||||
34028219|NCT03912597|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34028220|NCT02068703|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34028221|NCT04825782|||COHORT||PROSPECTIVE|||||||
34028222|NCT01630070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028223|NCT04521127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be aware of group distribution due to the nature of the taping and DN procedures. Therefore, the only outcome assessor will be blinded|Three groups with a conventional therapy control group.|f|f|f|t
34028224|NCT05092152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028225|NCT05108402|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Single-center, randomized study, organized in 2 stages.||||
34028226|NCT03669185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34028227|NCT05065710|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, the Dose Escalation Phase of the study will enroll patients with locally advanced or metastatic solid tumors of any histology with positive CLDN18.2. Phase II, the Cohort Expansion Phase of the study, will be conducted after determination of the dose level (RP2D) for cohort expansion based on the results of Phase I to explore the preliminary efficacy.||||
34028228|NCT03050138|||OTHER||CROSS_SECTIONAL|||||||
34028229|NCT02970448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104647|NCT04411199|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"This is a double-blind clinical trial. The sponsor, the subjects, outcomes assessor and all staff involved in the collection and recording of the clinical and laboratory data, based on which the independent adjudication committee will perform their assessment, will be blind to treatment assignment. In addition, all aspects of data management and clean-up will be done in blinded datasets.~The study site personnel, who perform the index surgery (Operation room staff), will be trained not to disclose the treatment arm to the blinded Investigator, to the subject, his/her family, to other health care providers not present during the surgery or to the study Sponsor representatives. Wound assessment throughout the study follow-up visits will be done by a blinded Investigator, that will not be involved in the surgery. An emergency card containing the Study Name, NIH number, Center Name/number, PI's name and contact details will be provided to the subjects."|Males and females, \>18 years old, undergoing scheduled abdominal colon surgery involving resection and anastomosis or a stoma, who meet the inclusion criteria and none of the exclusion criteria and provide signed informed consent will be enrolled in the study.|t|t|t|f
34104648|NCT03897270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104649|NCT01366274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104650|NCT05516472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blinded|Prospective, randomized, placebo-controlled|t|f|f|f
34104651|NCT00742690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104652|NCT06674044|||COHORT||PROSPECTIVE|||||||
34104653|NCT01244412|||CASE_ONLY|||||||||
34104654|NCT04665895|RANDOMIZED|PARALLEL||OTHER||SINGLE|Observer-blind||f|f|f|t
34104655|NCT00900042|||||PROSPECTIVE|||||||
34104656|NCT06674213|||OTHER||PROSPECTIVE|||||||
34104657|NCT01566565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104658|NCT06332755|NA|SEQUENTIAL||TREATMENT||NONE||||||
34104659|NCT01048359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34104660|NCT05143515|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34104661|NCT02594579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104662|NCT06687083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104663|NCT04020913|||CASE_CONTROL||PROSPECTIVE|||||||
34104664|NCT02311283|||COHORT||CROSS_SECTIONAL|||||||
34104665|NCT02735642|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|We utilized an approach called permuted blocks randomization for participant assignment to the SMART trial linkage to care intervention.|Adaptive linkage to care interventions for newly diagnosed HIV-positive participants. Total N recruited will depend on HIV prevalence found in the study.|t|f|f|f
34104666|NCT02368873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104667|NCT04606849|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34104668|NCT01729429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34104669|NCT03844035|RANDOMIZED|PARALLEL||PREVENTION||NONE||Forty-five patients with periimplant mucositis having at least one implant (age range:45-60) were included in study. Study was planned as randomized, single-blind, parallel-design. Patients were divided into 3 equal groups; i)toothbrush+oral irrigator ii)toothbrush+interdental brush, iii)only toothbrush. After baseline examinations \[Silness-Löe plaque index(PI), Löe-Silness gingival index(GI), probing pocket depth(PPD), clinical attachment level(CAL), bleeding on probing(BOP)\], initial periodontal therapy was completed using full-mouth disinfection method. Periimplant crevicular fluid(PCF) were taken from patents to assess levels of interleukin-1beta(IL-1β), Transforming growth factor-beta(TGF- β), tissue-type plasminogen activator(t-PA), plasminogen activator inhibitor-1(PAI-1). Clinical records were repeated at 2, 4 and 12 weeks.||||
34104670|NCT06686914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34104671|NCT03893916|NA|SINGLE_GROUP||OTHER||NONE||||||
34104672|NCT06199830|||CASE_CONTROL||RETROSPECTIVE|||||||
34104673|NCT05288751|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104674|NCT03355092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104675|NCT04526457|RANDOMIZED|PARALLEL||OTHER||NONE||Probands were randomized 2:1 to genetic testing for FH plus lipid testing or lipid testing alone||||
34148973|NCT03984487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Coordinator who is assessing goals of participants id masked from knowing which group each participant was randomized to.|Randomized Clinical Trial - A study in which the participants are divided by chance into separate groups that compare different treatments or other interventions.|f|f|f|t
33723201|NCT04851678|||COHORT||PROSPECTIVE|||||||
33723202|NCT00704535|||COHORT||PROSPECTIVE|||||||
33723203|NCT03281954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33804507|NCT04039906|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804508|NCT01900249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33723204|NCT05106244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723205|NCT00940212|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723206|NCT02885961|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723207|NCT02654535|||OTHER||PROSPECTIVE|||||||
33723208|NCT02981719|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723209|NCT01572233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723210|NCT05096845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33723211|NCT03492255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723212|NCT03713203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723213|NCT06095323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723214|NCT04708938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Prospective, randomized-controlled|t|t|t|t
33804509|NCT06700083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804510|NCT02700269|||CASE_ONLY||PROSPECTIVE|||||||
33804511|NCT05470088|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804512|NCT06145932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804513|NCT06052436|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33839099|NCT01306539|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE||||||
33839100|NCT03116568|||CASE_CONTROL||PROSPECTIVE|||||||
33839101|NCT05442281|||CASE_CONTROL||PROSPECTIVE|||||||
33839102|NCT04400110|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33839103|NCT06023251|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33839104|NCT00788970|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34104676|NCT04840186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicentre RCT with two parallell arms. One with second line chemotherapy (standard care) and the other with second line chemotherapy + resection. We estimate an overall survival of 12 months in the standard care group. We aim to decide whether resections added to chemotherapy can increase this to 24 months. A two-sided parallel-group test of proportions to answer this with a power of 0.80 and an alpha of 0.15, will require 28 completed patients per group to show superiority for resections. Adding 11 % for a modified intention-to-treat analysis, we aim to randomise a total of 62 patients, i.e. 31 patients per group.|t|f|f|f
34104677|NCT06391086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104678|NCT04392570|||CASE_CONTROL||PROSPECTIVE|||||||
33804514|NCT04872478|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Patients will be accrued using a 3+3 approach. Cohorts will be escalated based on review of safety data for each patient and cohort.~The highest dose level administered prior to the dose in which ≥ 33% of patients experience a dose-limiting toxicity \[DLT\]) will be defined as the MTD. Based on PK, pharmacodynamic data, efficacy, safety and patient tolerability, a recommended dose for further development (RP2D) may be identified that is less than the formal MTD. A dose expansion arm of approximately 12 patients (with 6 patients being FLT3 ITD+ and 6 patients being Mer+/FLT3 WT) will be accrued to further evaluate patients at the RP2D."||||
34104679|NCT01485198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804515|NCT01902914|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34104680|NCT03686982|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104681|NCT01827306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804516|NCT05800236|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804517|NCT00140725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104682|NCT04682691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804518|NCT06180070|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33804519|NCT02189174|NA|SINGLE_GROUP||TREATMENT||NONE||Phase ll part of the study was not conducted as Novartis decided to terminate the study considering safety and tolerability concerns and limited clinical activity.||||
33804520|NCT00563134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804521|NCT02437422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804522|NCT04200287|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34028230|NCT03254264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."|f|f|f|t
34028231|NCT06112847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028232|NCT03960034|||COHORT||PROSPECTIVE|||||||
34028233|NCT05510284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028234|NCT04774497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028235|NCT02323828|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34028236|NCT01010113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028237|NCT06231095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028238|NCT05052112|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, Placebo-controlled, Double-blind, Cross-Over Study|t|t|t|t
34028239|NCT03226535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028240|NCT00534404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028241|NCT02590965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028242|NCT04455321|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Rapid vicryl will used in study group and vicryl will used in control group for uterine closure in cesarean section.||||
34028243|NCT02295917|||COHORT||PROSPECTIVE|||||||
34028244|NCT03743155|NA|SINGLE_GROUP||TREATMENT||NONE||single arm due to not alternative treatment exist||||
34028245|NCT04365192|||COHORT||PROSPECTIVE|||||||
34028246|NCT03827720|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The Sensor Evaluation of Neurologic Status in Emergencies (SENSE) device (Sense Diagnostics LLC; Cincinnati, OH) is a non-invasive radiofrequency (RF) sensor that detects and monitors intracranial hemorrhage (ICH).||||
34028247|NCT05102747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028248|NCT05277584|||CASE_CONTROL||RETROSPECTIVE|||||||
33804523|NCT00034489|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804524|NCT03836222|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33804525|NCT06381739|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804526|NCT00732849|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804527|NCT06116929|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804528|NCT04826822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804529|NCT03209700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028249|NCT06036628|||CASE_ONLY||PROSPECTIVE|||||||
34028250|NCT06363903|||CASE_ONLY||PROSPECTIVE|||||||
34028251|NCT02724228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028252|NCT02786225|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028253|NCT00852722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028254|NCT05456958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both investigators and participants will be blinded with regards to arm assignment.|PTSD participants (N=60) will be randomly assigned to receive neurofeedback targeting one of two regions-of-interest - amygdala (N=20) or PCC (N=20) - or to the sham-control arm (N=20), where individuals will receive a fake neurofeedback signal (i.e., from a successful participant in one of the experimental arms, thereby controlling for motivational effects).|t|f|t|f
34028255|NCT05056623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34028256|NCT03766386|||COHORT||OTHER|||||||
34028257|NCT02352012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028258|NCT05597319|||COHORT||RETROSPECTIVE|||||||
34028259|NCT02052193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028260|NCT00996892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028261|NCT01611779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028262|NCT04190017|||COHORT||PROSPECTIVE|||||||
34028263|NCT03394157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028264|NCT05063851|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104683|NCT04349371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104684|NCT00791869|||CASE_ONLY||CROSS_SECTIONAL|||||||
33723215|NCT04474951|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028265|NCT06292221|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|There is no masking|Two groups of participants (64 per group) will be enrolled and will participate in the study over a 3 month period . Both will receive standard of care depression treatment with their respective providers in the clinic. Both groups will undergo standard depression assessment using depression questionnaires as well as behavioral assessments using a mobile health (mHealth) tool 'DepWatch' developed by the study team in the phase I of the study. Study clinicians will receive weekly behavioral assessment reports for participants enrolled in the first 'experimental' group and will not receive such reports for the second 'control' group||||
34028266|NCT01282411|||CASE_ONLY||PROSPECTIVE|||||||
34028267|NCT04414345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723216|NCT05188209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723217|NCT02636868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33723218|NCT02034461|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34028268|NCT04003896|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study to confirm tolerability of abemaciclib and provide an estimate of the overall response rate. A sample size of 10 subjects is determined to be minimally sufficient for these pilot study objectives. There will be no protocol scheduled hiatus and daily dosing will be continuous unless there is unacceptable toxicity, disease progression, or death.||||
33723219|NCT01591291|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33723220|NCT02227342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028269|NCT05740618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723221|NCT01485640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028270|NCT04477070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723222|NCT01759108|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34028271|NCT01194063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723223|NCT06031207|||CASE_ONLY||CROSS_SECTIONAL|||||||
33723224|NCT03811431|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Investigator|A prospective parallel group clinical trial|t|f|t|f
33723225|NCT03559140|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Certified endodontists trained in the procedures, devices, and systems investigated took part in the research. All experts tracked a pre-established procedure for Reciproc instrument systems and cryotherapy.|Random Selection of instrumentation groups. Of the sample of 216 teeth, 72 were randomly assigned to the one of the 3 irrigating methods. Treatment was performed by 3 experienced endodontists; each prepared 72 teeth, 24 per technique.|t|f|t|f
33723226|NCT00566150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723227|NCT06245291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028272|NCT03260725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Internet-delivered treatment v. clinic-delivered treatment|f|f|f|t
34028273|NCT00053183||||TREATMENT||||||||
33804530|NCT04911166|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic NSCLC whose disease has progressed on first-line immunotherapy with or without chemotherapy. Approximately 16 patients will be enrolled on the study. ADV/IL-12 will be intratumorally injected on Day 0 of the study. The starting dose of ADV/IL-12 will be 5 × 1011 vp. Starting on Day 2 of the study, atezolizumab will be administered at 1200 mg IV Q3W for 2 cycles. Patients with SD or better after completion of 2 cycles of atezolizumab will continue to receive atezolizumab Q3W until disease progression, unacceptable toxicity, or up to 12 months.||||
33804531|NCT05172271|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
34028274|NCT05833087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Outcome assessors are blinded to treatment condition and to the hypotheses of the study. Different assessors will be assigned at each measurement time point.~Participants and therapists are instructed to withhold information about the treatment from the research team. The research team has no clinical contact with the participants from assessment to end of intervention, and the assessors have no knowledge about the participant's randomization status at the end of intervention.~Statistical analyses will be made with the two intervention groups coded as 'A' and 'B'. The results will remain coded when writing the outcome section of the relevant scientific articles, and the code will only be broken at the conclusion of this write-up."|The study is a multi-center, two-arm, parallel group, assessor-blinded, randomized controlled superiority study.|f|f|f|t
34028275|NCT01207895|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028276|NCT04004416|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Study coordinator and participant are blinded to medication administration.|The two MRI sessions will will be scheduled about 1 week apart. If you are a woman, we may need to schedule the scanning session to coincide with a certain phase of your menstrual cycle.|t|t|f|f
34028277|NCT01890863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028278|NCT04472676|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34028279|NCT01777230|||COHORT||PROSPECTIVE|||||||
34028280|NCT01638598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028281|NCT02997748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028282|NCT03518645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028283|NCT05652595|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||double-blind, randomized, cross-over study of comparative pharmacodynamics and pharmacokinetics|t|t|t|f
34028284|NCT00758966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028285|NCT03010683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34028286|NCT03366441|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34028287|NCT00074828|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34028288|NCT01708018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028289|NCT04909229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028290|NCT03108885|||CASE_ONLY||PROSPECTIVE|||||||
34028291|NCT06438900|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028292|NCT05937737|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34028293|NCT02961088|||||PROSPECTIVE|||||||
34028294|NCT04271917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Since TAU participants will receive tablets instead of oil like the other 3 arms, the design is not completely double-blinded; however, the study will be double-blinded between the other three arms which all receive oil in a dropper vial.||t|f|f|t
34028295|NCT02457923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34028296|NCT05102227|||COHORT||PROSPECTIVE|||||||
34028297|NCT02389231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804532|NCT02755805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804533|NCT01990508|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104685|NCT06225037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804534|NCT03344094|||COHORT||PROSPECTIVE|||||||
34104686|NCT06286072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomised Controlled Trial|t|f|f|f
33804535|NCT06030700|||CASE_CONTROL||PROSPECTIVE|||||||
33804536|NCT01891370|||COHORT||CROSS_SECTIONAL|||||||
33804537|NCT03932513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804538|NCT03624972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804539|NCT06016400|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33804540|NCT01981031|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33804541|NCT03141749|||COHORT||RETROSPECTIVE|||||||
33804542|NCT04733833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804543|NCT06699420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804544|NCT04798261|||COHORT||PROSPECTIVE|||||||
34104687|NCT01722643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804545|NCT04354389|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33804546|NCT05611346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104688|NCT06679127|||COHORT||PROSPECTIVE|||||||
33804547|NCT04203394|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33804548|NCT00002156||||TREATMENT||NONE||||||
33804549|NCT02574806|||COHORT||PROSPECTIVE|||||||
33804550|NCT02368626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804551|NCT05819242|||OTHER||CROSS_SECTIONAL|||||||
33804552|NCT01589939|||COHORT||PROSPECTIVE|||||||
33804553|NCT06292689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804554|NCT00570700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804555|NCT06132529|||COHORT||PROSPECTIVE|||||||
33804556|NCT01751516|||CASE_ONLY||PROSPECTIVE|||||||
33804557|NCT02161146|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33804558|NCT01747707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804559|NCT06071702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804560|NCT01089335|||COHORT||PROSPECTIVE|||||||
33804561|NCT06246253|||CASE_ONLY||CROSS_SECTIONAL|||||||
33804562|NCT04775667|||CASE_ONLY||CROSS_SECTIONAL|||||||
33804563|NCT00754065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804564|NCT04255706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804565|NCT06521424|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, Double-Blind, Placebo Controlled Design|t|f|t|t
33804566|NCT00989196|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804567|NCT06338540|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Group 1: Yellow caries color Group 2: dark brown caries color Group 3: light brown caries color Group 4: black caries color||||
34028298|NCT04280640|||COHORT||PROSPECTIVE|||||||
34028299|NCT05358080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028300|NCT01391897|||COHORT||PROSPECTIVE|||||||
34028301|NCT06490185|||COHORT||RETROSPECTIVE|||||||
34028302|NCT05013307|NA|SINGLE_GROUP||SCREENING||NONE||||||
34028303|NCT06416046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, examiner and outcomes assessor will not know which group has been allocated (triple-blind). Another person (the applicator) will carry out the randomization and know which group the patient belongs to.|Participants will be allocated and randomized into 2 groups: Group I: PBM (n=17) photobiomodulation intra oral high potency laser (4.5J) and Group II: control (n=17).|t|f|t|t
34028304|NCT04325932|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34028305|NCT01934426|||COHORT||PROSPECTIVE|||||||
34028306|NCT04128501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028307|NCT06328179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028308|NCT03490578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial|f|f|f|t
34028309|NCT03403647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028310|NCT06632821|||OTHER||CROSS_SECTIONAL|||||||
34104689|NCT01564329|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104690|NCT06663969|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104691|NCT04063462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804568|NCT05915715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804569|NCT06698705|||COHORT||PROSPECTIVE|||||||
33804570|NCT05674929|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33804571|NCT02071043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804572|NCT02808403|||COHORT||PROSPECTIVE|||||||
33804573|NCT06698692|||COHORT||RETROSPECTIVE|||||||
33804574|NCT01756924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804575|NCT03343184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804576|NCT06652750|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||During each session, the CIED patient undergoes both the experimental and control methods.||||
33804577|NCT06364852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804578|NCT06435169|||CASE_ONLY||PROSPECTIVE|||||||
33804579|NCT02871206|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34028311|NCT01828801|||COHORT||CROSS_SECTIONAL|||||||
34028312|NCT05440201|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34028313|NCT05870618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028314|NCT05149326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028315|NCT05017961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028316|NCT05328219|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34104692|NCT05518162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34104693|NCT01689688|||COHORT||PROSPECTIVE|||||||
34104694|NCT06637670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised, placebo-controlled, double-blinded study|t|f|f|t
34104695|NCT02067598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104696|NCT06691230|||COHORT||PROSPECTIVE|||||||
34104697|NCT02695771|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34104698|NCT05198661|NA|SINGLE_GROUP||OTHER||NONE||Blood sample||||
34104699|NCT03318393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104700|NCT02478749|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34028317|NCT04196140|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, multi-center, prospective clinical study.||||
34028318|NCT03458299|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|Allocation: Randomized Intervention Model: Parallel Assignment||||
34028319|NCT06505070|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34028320|NCT01912261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028321|NCT01638585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104701|NCT04095026|||COHORT||PROSPECTIVE|||||||
33804580|NCT04838860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Enrolling in Stage 1a and Stage 1b of this study in parallel will be up to 6 patients each with siltuximab-relapsed or refractory IL-6-driven iMCD and TAFRO-iMCD patients, respectively, who will undergo intrapatient dose escalation of siltuximab beginning with 22 mg/kg q3w, then possibly dose escalating to 33 mg/kg q3w then 44 mg/kg q3w if clinically indicated in the absence of DLT. The justifications for escalating siltuximab doses up to 44 mg/kg q3w will be based on intrapatient dose escalation and DLT assessments as described below.||||
33804581|NCT00051792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804582|NCT03559413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804583|NCT05911243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33804584|NCT00359606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804585|NCT00557596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804586|NCT05121636|||COHORT||PROSPECTIVE|||||||
33804587|NCT04910776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804588|NCT00156208|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33804589|NCT00003222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804590|NCT04394897|||CASE_CONTROL||RETROSPECTIVE|||||||
33804591|NCT01421836|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804592|NCT01678079|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804593|NCT01321164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33804594|NCT04866641|NA|SEQUENTIAL||TREATMENT||NONE||||||
33804595|NCT02746926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804596|NCT00112034|RANDOMIZED|FACTORIAL||||DOUBLE||||||
33804597|NCT04248322|||COHORT||PROSPECTIVE|||||||
33804598|NCT02433782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804599|NCT01728974|NA|SINGLE_GROUP||OTHER||NONE||||||
33804600|NCT04810975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33804601|NCT02900859|||CASE_ONLY||RETROSPECTIVE|||||||
33804602|NCT02128113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33804603|NCT02488148|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804604|NCT01876966|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33804605|NCT05421117|||CASE_CONTROL||RETROSPECTIVE|||||||
33804606|NCT05792956|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33804607|NCT03488719|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Tesofensine dosing will be performed open-label. Metoprolol dosing will be performed single-blind."|Each subject will participate in a Screening Period (Day 28 to Day 3), a Baseline Period (Day -2 to Day -1) and a Treatment Period (Day 1 to Day 24) and will have two Follow-up phone calls (Day 30 and Day 50).|t|t|t|f
33804608|NCT02712879|||COHORT||PROSPECTIVE|||||||
33804609|NCT06545643|NA|SINGLE_GROUP||SCREENING||NONE||All participants will initially undergo a screening night at a sleep lab before being equipped with a Dreem EEG headband and a Fitbit for continuous monitoring of sleep patterns and epileptic activity at home. Over 21 days, participants will wear the Fitbit daily and the Dreem headband exclusively at night as part of the data collection protocol. Additionally, participants will maintain daily sleep and seizure diaries.||||
33804610|NCT02745249|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33804611|NCT05092841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804612|NCT00432016|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34104702|NCT00389480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104703|NCT04190446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104704|NCT01103115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104705|NCT02644057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104706|NCT06687031|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34104707|NCT03457415|||COHORT||OTHER|||||||
34104708|NCT06029166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104709|NCT03340935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104710|NCT05823441|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34104711|NCT05751226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104712|NCT02376855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34104713|NCT03364257|||OTHER||PROSPECTIVE|||||||
34104714|NCT02608515|||OTHER||RETROSPECTIVE|||||||
34104715|NCT06391333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33804613|NCT03593642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|Randomized controlled|t|t|t|t
34028322|NCT05142956|||COHORT||RETROSPECTIVE|||||||
34028323|NCT01715571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028324|NCT04181606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The participants, investigators, and data analysts (outcomes assessors) will be blinded to the treatment (drug) order. The care providers (research nurse and physician) will be aware of the treatment order for safety reasons i.e., they will be assessing heart rate, blood pressure and symptoms before, during, and after the infusion.||t|f|t|t
34104716|NCT01380132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104717|NCT01664715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104718|NCT04755231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104719|NCT06689748|||OTHER||OTHER|||||||
34104720|NCT06499961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34104721|NCT00262613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148974|NCT02698371|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|f|t
34148975|NCT02411370|||CASE_ONLY||PROSPECTIVE|||||||
34148976|NCT00507273|||CASE_ONLY||PROSPECTIVE|||||||
34148977|NCT02985463|||COHORT||PROSPECTIVE|||||||
34148978|NCT02965690|RANDOMIZED|PARALLEL||TREATMENT||NONE|Non-blind|Prospective, parallel-group, non-blind, randomized clinical study||||
34148979|NCT01182311|||COHORT||CROSS_SECTIONAL|||||||
34028325|NCT05314101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028326|NCT03909282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028327|NCT01184079|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028328|NCT03106987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028329|NCT00559065|||COHORT||RETROSPECTIVE|||||||
34028330|NCT06463522|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous Tumor-infiltrating Lymphocytes Therapy||||
34028331|NCT03794479|||COHORT||PROSPECTIVE|||||||
34028332|NCT04539912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34028333|NCT01114607|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028334|NCT05635032|||COHORT||PROSPECTIVE|||||||
34028335|NCT02075307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028336|NCT01721304|RANDOMIZED|PARALLEL||||NONE||||||
34028337|NCT05624398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, single-surgeon, single-arm, descriptive study||||
34028338|NCT04011605|||COHORT||PROSPECTIVE|||||||
34028339|NCT02422524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028340|NCT00693043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028341|NCT00171665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028342|NCT04802044|||COHORT||PROSPECTIVE|||||||
34028343|NCT04482387|NA|SEQUENTIAL||SCREENING||NONE||Patients will test their own vision twice using the DigiVis app twice, subsequently they will have visual acuity assessment in eye clinic by a trained examiner. The results of visual acuity will be compared using Bland Altman statistical analysis.||||
34028344|NCT03997279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028345|NCT02006225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028346|NCT05968118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028347|NCT02018965|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028348|NCT04521387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028349|NCT04151043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34028350|NCT01333397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33723228|NCT00763347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723229|NCT05953454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33723230|NCT03630809|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723231|NCT02809690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723232|NCT03635710|||COHORT||PROSPECTIVE|||||||
33723233|NCT03311659|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|The treatment allocation would be non-randomised and stratified by age into four strata \[4-9 years (children), 10-17 years (adolescents), 18-64 (adults) years and ≥65 years (elderly population)\].|||||
33723234|NCT00668941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723235|NCT04295512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33723236|NCT01683981|NA|SINGLE_GROUP||||NONE||||||
33723237|NCT00660582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723238|NCT01434238|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723239|NCT05031182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723240|NCT05133687|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|The concealed envelopes will be opened by an anesthesia resident (who will not be involved in patient management) and he will be responsible for preparing and giving the caudal block for the caudal groups as instructed in the envelope. the data will be collected by another anesthetist who is blinded to the group assignment.|Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.|t|t|t|t
33723241|NCT05420207|||COHORT||CROSS_SECTIONAL|||||||
33723242|NCT06502236|||COHORT||CROSS_SECTIONAL|||||||
33723243|NCT01888796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723244|NCT02360384|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33723245|NCT03812887|||OTHER||PROSPECTIVE|||||||
33723246|NCT03072069|||CASE_ONLY||PROSPECTIVE|||||||
33723247|NCT04828512|||COHORT||PROSPECTIVE|||||||
33723248|NCT00003799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723249|NCT04816695|NA|SINGLE_GROUP||OTHER||NONE||||||
33723250|NCT03987061|NA|SINGLE_GROUP||TREATMENT||NONE||Application of the MOTIV Bioresorbable Scaffold in Patients with Lesions Below-The-Knee (BTK)||||
33723251|NCT04657614|RANDOMIZED|CROSSOVER||OTHER||SINGLE|A sock will be placed over the prosthesis in order for the participant to not know which alignment is used.||t|f|f|f
33723252|NCT01129908|||COHORT||PROSPECTIVE|||||||
33723253|NCT06113133|||COHORT||OTHER|||||||
33723254|NCT05872581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33723255|NCT05726396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723256|NCT01187927|||||PROSPECTIVE|||||||
33723257|NCT02694406|||CASE_ONLY||PROSPECTIVE|||||||
33723258|NCT00238121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723259|NCT01369576|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33723260|NCT02726256|||COHORT||PROSPECTIVE|||||||
33723261|NCT06299566|||OTHER||PROSPECTIVE|||||||
33723262|NCT00736008|||COHORT||RETROSPECTIVE|||||||
33723263|NCT03745144|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33723264|NCT00798109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723265|NCT01480076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723266|NCT04989400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723267|NCT00593671|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33723268|NCT04162028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723269|NCT04886986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723270|NCT01633892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723271|NCT04286607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104722|NCT05308719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||An adaptive, multicentre, parallel group randomised controlled clinical trial with embedded cost-effectiveness analysis.|f|f|f|t
34104723|NCT02665650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104724|NCT05632601|NON_RANDOMIZED|PARALLEL||OTHER||NONE||A single-site, two-group, matched-cohort Vanguard study will be completed to test feasibility outcomes to inform a large, multi-site, two-group, longitudinal matched-cohort study.||||
34104725|NCT06066099|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104726|NCT06642688|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Ninety-six participants who met the inclusion criteria were enrolled in the study and were divided into three groups: the sacroiliac joint manipulation group (n=32), the cervical manipulation group (n=32), and the control group (n=32). Sacroiliac joint manipulation was performed in the lateral decubitus position, while cervical manipulation was applied in the supine position, and no treatment was administered to the control group. All measurements were repeated before and immediately after the manipulations. The Mann-Whitney U test was used to determine whether the scores differed according to a dichotomous variable, while the Kruskal-Wallis test was used for variables with more than two categories. In cases where significant differences were found between categories, the Mann-Whitney U test with multiple comparisons was used to identify the source of the difference between the pairwise groups.|t|f|f|t
34104727|NCT02369939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104728|NCT00140920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804614|NCT06699992|||COHORT||CROSS_SECTIONAL|||||||
33804615|NCT00629096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104729|NCT06196203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104730|NCT06267014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients will follow the Virtual Reality program developed for the study, during the cognitive rehabilitation sessions||||
33804616|NCT01208116|||COHORT||PROSPECTIVE|||||||
33804617|NCT03459989|||COHORT||PROSPECTIVE|||||||
33804618|NCT04337931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Enrolled participants will be alternately assigned to one of the following 2 cohorts (groups) as long as the cohorts are open:~Cohort 1: APX005M administered IV at 0.3 mg/kg every 3 weeks (21-day cycle) Cohort 2: APX005M administered IV at 0.3 mg/kg every 2 weeks (14-day cycle) Enrolled participants assigned to Cohorts 1 or 2 that do not receive sotigalimab or are not evaluable for tumor response will be replaced in that cohort before assigning new participants to the other cohort.~Cohort 3: Participants who have failed any number of prior lines of therapy, sotigalimab administered IV at 0.3 mg/kg in combination with radiation therapy every 2 weeks (14 day cycle) up to 16 weeks followed by sotigalimab administered IV at 0.3 mg/kg every 2 weeks (14-day cycle)."||||
33804619|NCT03919721|NA|SINGLE_GROUP||OTHER||NONE||All children enrolled in the study will already receiving ABA therapy Each tutor-child pair will have worked together regularly for at least 3 months prior to the study. Each child will have 15-20 active therapy programs, each of which will be randomly assigned to one of two sets: the experimental (Motivity-enabled) or control (therapy-as-usual). For the control set, BTs will use their existing methods, either paper-based or a competitor's data collection system. Tutors will use Motivity for 8 weeks in therapy under supervision in a single case-study pilot.||||
34104731|NCT04309266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804620|NCT06364553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804621|NCT03350698|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective Single-Subject Experimental Design||||
33804622|NCT03718013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104732|NCT06675474|||CASE_ONLY||CROSS_SECTIONAL|||||||
34104733|NCT03638180|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34104734|NCT06675409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34104735|NCT03854435|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34104736|NCT05075473|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|single|44 patients with chronic low back pain, distributed randomly in to two groups.|f|f|t|f
34104737|NCT03186183|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804623|NCT02697201|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804624|NCT03452982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Controlled, prospective, descriptive and not randomized||||
34104738|NCT02569008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34104739|NCT01326572|||COHORT||PROSPECTIVE|||||||
33804625|NCT02326181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804626|NCT06419777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804627|NCT00176085|||||PROSPECTIVE|||||||
33804628|NCT06079242|||COHORT||OTHER|||||||
33804629|NCT05475717|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804630|NCT06471322|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Control Arm: Historical group of patients admitted for DKA In the prior 1 year Intervention: Patients with type 1 diabetes mellitus admitted to the hospital with confirmed diabetic ketoacidosis treated with intra-venous insulin infusion.||||
33804631|NCT03576521|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|A double blind. The masking will be maintained until the analysis of the data. However, access to the code will be allowed if serious adverse events arise related to the research product.|Phase II randomized, controlled, double blind clinical trial.|t|t|t|f
33839105|NCT01754753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104740|NCT02808611|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104741|NCT03649087|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Vitrification of ovarian tissue||||
34104742|NCT02196974|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104743|NCT02766478|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34104744|NCT00628615|||||PROSPECTIVE|||||||
34104745|NCT01284738|NON_RANDOMIZED|PARALLEL||||NONE||||||
34104746|NCT06215157|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104747|NCT05109559|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34104748|NCT06642961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104749|NCT06673706|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34104750|NCT02364271|||COHORT||PROSPECTIVE|||||||
34148980|NCT00865085|RANDOMIZED|CROSSOVER||||NONE||||||
34148981|NCT05628207|||CASE_CONTROL||PROSPECTIVE|||||||
34148982|NCT00308074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148983|NCT02481713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804632|NCT04155905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients don't know the procedure|comparison between two groups of patients with simple anal fistula subjected to different types of treatment|t|f|f|f
33804633|NCT04504721|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33804634|NCT00035100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804635|NCT04935177|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, controlled and randomized||||
34028351|NCT04583189|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028352|NCT06546774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028353|NCT00043628||||TREATMENT||||||||
34028354|NCT06633601|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental Arm||||
34028355|NCT04391296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723272|NCT03558399|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Results of the ERA analysis will not be disclosed to the patient or the physician or the outcome assessor, nor will the study arm to which the patient was assigned, though the patient/physician may be able to intuit assignment to the ERA arm based on the frozen embryo transfer time that she is assigned. The date and time of embryo transfer will be provided by the investigator/research team.||t|t|f|t
33723273|NCT04725292|||OTHER||OTHER|||||||
33723274|NCT01140321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723275|NCT01899534|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33723276|NCT03836196|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33723277|NCT05933928|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled single-blind quasi-experimental study|t|f|f|f
33723278|NCT03479307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723279|NCT01809873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||||||||
33804636|NCT02790281|||COHORT||PROSPECTIVE|||||||
34148984|NCT01622907|||COHORT||PROSPECTIVE|||||||
34148985|NCT00428961|||COHORT||CROSS_SECTIONAL|||||||
33804637|NCT06033105|||CASE_CONTROL||PROSPECTIVE|||||||
33804638|NCT01053325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804639|NCT06082323|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33804640|NCT03471559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804641|NCT00263159|RANDOMIZED|PARALLEL||||NONE||||||
33804642|NCT05877872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804643|NCT00530153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804644|NCT02132949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839106|NCT05351320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028356|NCT05801588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028357|NCT04167592|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34028358|NCT05708989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34028359|NCT05554081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028360|NCT00840489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028361|NCT04020783|||COHORT||PROSPECTIVE|||||||
34028362|NCT00745550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028363|NCT01121367|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028364|NCT04351633|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34028365|NCT06129305|||CASE_ONLY||PROSPECTIVE|||||||
34148986|NCT02752464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148987|NCT05701891|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a two-arm cluster-randomized controlled trial. Twenty physiotherapists with expertise in chronic LBP treatment will be recruited and equally randomised (10 in each arm) on the level of physiotherapy practice using allocation concealment. This clustered design means that eligible patients consulting a participating physiotherapist will be automatically allocated to the study arm (experimental or control arm) to which the physiotherapy practice was allocated.||||
34148988|NCT05451355|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial (RCT)||||
34148989|NCT05044624|NA|SINGLE_GROUP||OTHER||NONE||||||
34148990|NCT02782026|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34148991|NCT00957333|||CASE_ONLY||CROSS_SECTIONAL|||||||
34148992|NCT02395198|||COHORT||CROSS_SECTIONAL|||||||
33804645|NCT06597279|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a non-randomized controlled trial using historical control as a comparator. It involves comparing outcomes from a group of participants receiving the current intervention with outcomes from a previously treated group (historical control) that did not receive the intervention.||||
33804646|NCT00257075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804647|NCT01467128|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33804648|NCT03388840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804649|NCT00238901|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804650|NCT03807752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The provider of the dietary supplement deliver the supplement prepared and packed in equal bags (active/placebo) that we hand out to the participants in an randomized order.|A parallel group randomized, controlled clinical trial for eight weeks|t|t|t|f
33804651|NCT02968329|||CASE_CONTROL||RETROSPECTIVE|||||||
33804652|NCT05609929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804653|NCT05119543|||COHORT||RETROSPECTIVE|||||||
33804654|NCT05742815|||OTHER||OTHER|||||||
33804655|NCT00274261|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33804656|NCT04111510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804657|NCT05661487|||CASE_ONLY||RETROSPECTIVE|||||||
33804658|NCT00532116||CROSSOVER||DIAGNOSTIC||NONE||||||
33804659|NCT02179268|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804660|NCT03907306|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804661|NCT04124432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|placebo controlled, double-blind|All participants will complete all dose conditions (study arms) in a randomized order|t|f|f|t
33804662|NCT01808534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804663|NCT01605448|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804664|NCT01896843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804665|NCT05048758|||OTHER||PROSPECTIVE|||||||
33804666|NCT05920642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not know which arm of the study he/she has been enrolled into.|The study subjects will be randomized into two parallel groups.|t|f|f|f
33804667|NCT04396782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33804668|NCT05311527|NA|SINGLE_GROUP||TREATMENT||NONE|Non-blinded|||||
33804669|NCT04192773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804670|NCT02463214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804671|NCT00083967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028366|NCT03727880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028367|NCT04740697|NA|SINGLE_GROUP||OTHER||NONE||||||
34028368|NCT03784027|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Device: CamAPS FX~The automated closed loop system (CamAPS FX) will consist of:~* Dana RS insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data."||||
34028369|NCT05845502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028370|NCT05873933|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be assigned to either one of two groups and their outcomes will be compared separately.||||
34028371|NCT03484546|||COHORT||PROSPECTIVE|||||||
34028372|NCT03082144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028373|NCT00613652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028374|NCT00493896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34028375|NCT00163488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028376|NCT02800642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028377|NCT06418412|||COHORT||RETROSPECTIVE|||||||
34028378|NCT02774642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028379|NCT01820975|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34028380|NCT02286687|NA|SINGLE_GROUP||TREATMENT||||||||
34028381|NCT04258462|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028382|NCT05656261|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34028383|NCT02461160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028384|NCT06633861|NA|SINGLE_GROUP||OTHER||NONE||||||
34028385|NCT04496518|||COHORT||PROSPECTIVE|||||||
34028386|NCT01526473|NA|SINGLE_GROUP||OTHER||NONE||||||
34028387|NCT01038297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028388|NCT03377101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804672|NCT02143375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804673|NCT05927220|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33804674|NCT00575419|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33804675|NCT01044888|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34028389|NCT05283564|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028390|NCT01998724|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34028391|NCT05015452|||COHORT||PROSPECTIVE|||||||
34028392|NCT01231204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028393|NCT01059578|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34028394|NCT02875223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028395|NCT05702229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804676|NCT03081013|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33804677|NCT00047190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804678|NCT04228913|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single (Participant)|t|f|f|f
34028396|NCT01459042|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34028397|NCT06633705|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"There are 2 intervention groups and 2 control groups. Control group1 consists of menopause patients without symptoms of GUS and examination findings. Control group 2 consists of menopause patients without symptoms of GUS but have examination findings.~Intervention groups are those with GUS symptoms. They were randomly divided in 2 groups: one group had vaginal oestrogen treatment first other group had the treatment after the samples were taken."||||
34028398|NCT02859142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028399|NCT03729726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028400|NCT06451211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804679|NCT05176392|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The participant, study coordinators and the investigators will be blinded to the rTMS treatment. The participant will be blinded to the therapy group (headache management or headache education).|Each participant will be randomized into one of 4 groups. Blocked randomization will be used with random block size of 4 or 8. Participants will be randomized to study groups in a 1:1:1:1 ratio.|t|t|t|f
34104751|NCT05420337|RANDOMIZED|PARALLEL||OTHER||TRIPLE|In the postoperative period, the effectiveness and safety of the block will be evaluated by another researcher (blind) who does not know which group the patient is in.|"Group I: TAP block with bupivacain and morphine intramuscular will be applied at the end of the operation. Patients will receive paracetamol 1gr 30 minutes before the end of the operation. All patients will undergo IV morphine patient-controlled analgesia (PCA). Pain, opioid consumption, hemodynamic parameters and complications will be monitored in the first 24 hours in the postoperative period.~Group T: TAP block with bupivacain and morphine will be applied at the end of the operation. Patients will receive paracetamol 1gr 30 minutes before the end of the operation. All patients will undergo IV morphine patient-controlled analgesia (PCA). Pain, opioid consumption, hemodynamic parameters and complications will be monitored in the first 24 hours in the postoperative period."|t|f|t|t
34028401|NCT03283267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804680|NCT05412017|NA|SINGLE_GROUP||SCREENING||NONE||||||
34104752|NCT03791424|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|Placebo of the same volume and colour as active substance|Multimeter DM 3900 was used for measurements of SR. The device was approved for use in humans by the Department of Medical Biophysics and Informatics of the 3rd Medical Faculty of Charles University. Observer's Assessment of Alertness and Sedation scale was used as a standard tool for measurements of sedation level at the same intervals as measurements of SR. 10 min. rest break was given to participants in order that they adapt to the test situation. The rest value of SR was noticed and next all patients were administered placebo first and after 5 min period midazolam 2 mg i.v. After next 5 minutes patients were administered standard general anaesthesia with propofol, oxygen, nitrous oxide 60 % and isoflurane 1 MAC via laryngeal mask and sufentanil as needed. Changes in skin resistance were measured again immediately after stop of volatile anaesthetics till eye opening and verbal contact.|t|f|t|t
34104753|NCT06571903|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34104754|NCT04478734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804681|NCT03973034|||COHORT||PROSPECTIVE|||||||
33804682|NCT04132167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804683|NCT06275464|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33804684|NCT06125197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804685|NCT03375892|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33804686|NCT00405990|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33804687|NCT04874103|||CASE_ONLY||PROSPECTIVE|||||||
33804688|NCT03447457|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||FLORAL-ER is a before/after study||||
33804689|NCT02477514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804690|NCT01818180|RANDOMIZED|||||DOUBLE|||t|f|t|f
33804691|NCT00454675|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33804692|NCT06282354|||OTHER||PROSPECTIVE|||||||
33804693|NCT01643538|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33804694|NCT03277404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804695|NCT06134089|||COHORT||PROSPECTIVE|||||||
33804696|NCT01515267|||||PROSPECTIVE|||||||
33804697|NCT05346094|||COHORT||PROSPECTIVE|||||||
33804698|NCT02133547|||COHORT||PROSPECTIVE|||||||
33804699|NCT05254067|||COHORT||PROSPECTIVE|||||||
33804700|NCT04251169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804701|NCT06452212|||OTHER||CROSS_SECTIONAL|||||||
33804702|NCT00651859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028402|NCT06093230|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Parallel||||
34028403|NCT06035978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028404|NCT00967460|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34028405|NCT03846583|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34028406|NCT02960490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028407|NCT05022212|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||We will conduct a randomized, placebo-controlled trial of the vaginal live biotherapeutic product LACTIN-V in 60 young South African women, randomizing women 2:1 to LACTIN-V vs. placebo.|t|t|t|f
34028408|NCT04625491|||COHORT||OTHER|||||||
34028409|NCT04335539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028410|NCT00683579|||COHORT||PROSPECTIVE|||||||
34028411|NCT00159237|||OTHER||PROSPECTIVE|||||||
34028412|NCT04731363|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804703|NCT04420767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804704|NCT05168306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804705|NCT02213146|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33804706|NCT01359150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804707|NCT06091449|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33804708|NCT05587699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804709|NCT03877016|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34028413|NCT02224157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028414|NCT05767320|RANDOMIZED|PARALLEL||TREATMENT||NONE||patients presenting with perforated peptic ulcer are divided into two groups ,one group undergoes open exploration and the other group undergoes laparoscopy||||
34028415|NCT01555697|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34028416|NCT04529954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804710|NCT04737291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804711|NCT02099123|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804712|NCT04887337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804713|NCT01053793|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33804714|NCT00002748||||TREATMENT||||||||
33804715|NCT06698874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104755|NCT06136299|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All staff members measuring performance at the pre- and post-intervention testing sessions were unaware of which group the subject was randomized to.|There are two groups for this study. The control group performs their standard warm-up during soccer practice sessions and the experimental group performs neuromuscular training (NMT) in the form of the FIFA 11+ Kids program as their warm up.|f|f|f|t
34028417|NCT05390593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804716|NCT02430961|||COHORT||PROSPECTIVE|||||||
34104756|NCT03768050|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33804717|NCT02261506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104757|NCT00124033|RANDOMIZED|PARALLEL||ECT||NONE||||||
33804718|NCT05793307|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104758|NCT06572150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804719|NCT01856400|||CASE_CONTROL||PROSPECTIVE|||||||
34104759|NCT03325855|||OTHER||PROSPECTIVE|||||||
34104760|NCT06689267|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104761|NCT05289908|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104762|NCT02231580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104763|NCT06642233|||COHORT||PROSPECTIVE|||||||
33804720|NCT06699498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028418|NCT02125721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028419|NCT05605847|||COHORT||RETROSPECTIVE|||||||
34028420|NCT05640258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028421|NCT03656744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028422|NCT04595422|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028423|NCT06583473|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028424|NCT06577207|||OTHER||CROSS_SECTIONAL|||||||
34028425|NCT04218578|||CASE_CONTROL||RETROSPECTIVE|||||||
34028426|NCT04236882|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34028427|NCT04233073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028428|NCT06628804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34028429|NCT01321827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028430|NCT01272492||PARALLEL||PREVENTION||||||||
34028431|NCT05739149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34028432|NCT04082156|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34028433|NCT05329662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028434|NCT03431545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34028435|NCT02032680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028436|NCT02011477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34028437|NCT00348504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028438|NCT06633835|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Active comparator|This is a prospective interventional study of health care workers (HCW) and first responders (FR) receiving an updated 2024-25 COVID-19 vaccination at the University of Utah (UT). Participants can choose which COVID-19 vaccine type they would like to receive from the study team.||||
34028439|NCT02351141|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104764|NCT05187910|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34104765|NCT00295503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104766|NCT01558505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104767|NCT01848457|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33804721|NCT00263549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804722|NCT06000956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804723|NCT06389357|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The research is a technical/scientific/collaborative action research design.||||
33804724|NCT00112359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804725|NCT06541522|NA|SINGLE_GROUP||OTHER||NONE||Once the patient is included in the research, two PEEP titrations monitored by EIT will be performed, each with the electrode belt positioned at a different chest height. The order will be drawn at random.||||
33804726|NCT05310968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804727|NCT06095440|||COHORT||RETROSPECTIVE|||||||
33804728|NCT05791162|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33804729|NCT03782870|||COHORT||PROSPECTIVE|||||||
33804730|NCT06143709|||COHORT||PROSPECTIVE|||||||
33804731|NCT02412033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33804732|NCT04244942|||CASE_ONLY||PROSPECTIVE|||||||
34028440|NCT02975778|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028441|NCT05921552|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34028442|NCT01105871|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34028443|NCT04368351|||CASE_CONTROL||RETROSPECTIVE|||||||
34028444|NCT00229177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028445|NCT05097365|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34028446|NCT02655783|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34028447|NCT01772485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34028448|NCT03883308|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34028449|NCT03461731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participant cannot tell if the laser is turned on because the fan runs for the placebo as well|Each participant receives placebo and two different light treatments in random order|t|f|f|f
34028450|NCT02208739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028451|NCT00040131|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34028452|NCT01360463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028453|NCT02208804|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34104768|NCT03302429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Eighteen patients will be divided into two equal groups. Each group comprises nine patients.~Group A: Platelet-rich Fibrin combined with Biphasic Calcium Phosphate.(interventional group) Group B: autogenous bone graft (controlled group)"|f|f|f|t
34104769|NCT06645145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028454|NCT02256436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804733|NCT05874414|NA|SEQUENTIAL||TREATMENT||NONE||||||
34028455|NCT04851392|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|"Double-blind, placebo-controlled, crossover experiment with drug condition block randomised and stratified by age-group and gender, such that drug order is counterbalanced.~There are two groups: adolescents (16-17 years old) and adults (26-29 years old). These groups are matched on current cannabis use frequency.~There are three drug conditions: (1) cannabis with delta-9-tetrahydrocannabinol (THC) and without cannabidiol (CBD), (2) cannabis with THC but without CBD, and (3) placebo cannabis without THC and without CBD."|t|f|t|f
34104770|NCT03907891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The data collectors are also masked in the clinical trial.|A three group RCT will be used to test the effectiveness of a mHealth intervention (Heart Up!) versus attention control to promote increased physical activity and reduce state hopelessness. Patients will be randomized to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). Data will be collected at baseline, and 2, 6, 9 and 12 months.|f|t|t|t
34028456|NCT06273501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028457|NCT06151769|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Pomegranate seed oil: Pomegranate seed oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. This process will continue for six days.~Sesame oil: Sesame oil will be applied to the sacrum and heels twice a day between 09.00-21.00 without pressing. This process will continue for six days."||||
33723280|NCT05225142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation concealment of surgeon until completion of common part of surgical intervention. Examiner (clinical and radiographic ) and other carers blind to allocation|Long term follow up of RCT|f|f|t|t
33723281|NCT02662881|||COHORT||PROSPECTIVE|||||||
33723282|NCT01421758|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723283|NCT06011681|||COHORT||PROSPECTIVE|||||||
33723284|NCT00787085|||CASE_CONTROL||PROSPECTIVE|||||||
33723285|NCT06024044|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33723286|NCT01039233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723287|NCT04927390|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible participants will be randomised 1:1 to receive Mycophenolate Mofetil plus Standard of Care (MMF Group) or Standard of Care alone (Control Group).||||
33723288|NCT05442164|||COHORT||PROSPECTIVE|||||||
33723289|NCT04935112|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||2 period crossover||||
33723290|NCT05048810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723291|NCT01474876|||||PROSPECTIVE|||||||
33723292|NCT02171260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723293|NCT01424254|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33723294|NCT03754894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723295|NCT00208962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723296|NCT02297828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723297|NCT00909779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723298|NCT04197414|||COHORT||PROSPECTIVE|||||||
33723299|NCT01130610|||COHORT||PROSPECTIVE|||||||
33723300|NCT06094647|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723301|NCT01734330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723302|NCT00278954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723303|NCT06198556|NA|SINGLE_GROUP||TREATMENT||NONE||Compare the pharmacokinetic effects of Rifampicin on HRS-1167 in healthy subjects.||||
33723304|NCT01086540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723305|NCT05825937|||COHORT||PROSPECTIVE|||||||
33723306|NCT00001442||||TREATMENT||||||||
33723307|NCT03226340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723308|NCT01057420|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33723309|NCT02591355|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33723310|NCT04466540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization (1:1) is generated by a validated software and performed in permuted blocks of size 8. Concealment of the randomization list is maintained through a 24-hour, centralized, automated, internet-based randomization system. Furthermore, as placebo-controlled study, the placebo will have the same structural characteristics as the active drug and will be dispensed in cartridges that do not allow the identification of what is being given|Pragmatic, double-blind, placebo-controlled randomized parallel-group, two-arm clinical trial (with allocation ratio 1:1)|t|t|t|t
33723311|NCT04119856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723312|NCT04371679|||COHORT||RETROSPECTIVE|||||||
33723313|NCT00778011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33723314|NCT03966755|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723315|NCT00822458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723316|NCT01758185|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33723317|NCT01902342|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33723318|NCT02479256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33723319|NCT05397054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723320|NCT00715325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723321|NCT05368740|||CASE_ONLY||PROSPECTIVE|||||||
33723322|NCT02990208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723323|NCT04733365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723324|NCT00293696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723325|NCT01894165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723326|NCT00939913|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33723327|NCT03041246|RANDOMIZED|PARALLEL||TREATMENT||NONE||On enrollment, dividing the healthy ( n=40) from the pathological function of the pelvic floor ( n=40). From the second group, randomizing the groups to study group: recieving pelvic floor fascial mobilization (PFFM) treatment (n=20)compared to control group (n=20).||||
33723328|NCT01097018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723329|NCT03207932|||CASE_CONTROL||PROSPECTIVE|||||||
34104771|NCT04008069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study doctor and personnel will not know whether you are assigned to the sarilumab group or the placebo group after Week 16.|All subjects will all receive sarilumab 200 mg subcutaneously every two weeks for the first 16 weeks of the study. At Week 16, those patients who were able to successfully taper off of prednisone will then be assigned randomly to receive either sarilumab 200 mg subcutaneously every two weeks (study drug) or placebo subcutaneously for an additional 12 weeks.|t|t|t|f
33804734|NCT03510104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104772|NCT01251211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804735|NCT02394106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804736|NCT06664151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804737|NCT03412617|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33804738|NCT00914966|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723330|NCT01927809|||OTHER||PROSPECTIVE|||||||
34028458|NCT04575311|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34028459|NCT05233852|||COHORT||RETROSPECTIVE|||||||
34028460|NCT06254456|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34028461|NCT04292288|||COHORT||PROSPECTIVE|||||||
34104773|NCT04065841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104774|NCT00892866|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34028462|NCT03436056|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation phase with 2 dose levels followed by an Expansion phase||||
34028463|NCT02405130|RANDOMIZED|PARALLEL||||NONE||||||
34028464|NCT05967884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104775|NCT06230679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028465|NCT00286026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34028466|NCT02733224|||CASE_ONLY||PROSPECTIVE|||||||
34028467|NCT04657211|||COHORT||PROSPECTIVE|||||||
34028468|NCT02827695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028469|NCT00922740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028470|NCT06550752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028471|NCT06344767|||COHORT||RETROSPECTIVE|||||||
34028472|NCT03511092|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34028473|NCT05593497|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients with high-risk prostate cancer exhibiting \<= 10% PTEN staining by IHC will be exposed to a 4-week run-in of iADT, followed by dedicated research biopsy of the tumor to be used for correlative research, then treated with 16 weeks of combined iADT with AKT inhibition (capivasertib). Patients will then undergo radical prostatectomy as standard of care, with assessment of pathological response (pT0 or minimal residual disease) via central pathology review.||||
33723331|NCT03030573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723332|NCT01763437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723333|NCT05660564|||CASE_CROSSOVER||PROSPECTIVE|||||||
33723334|NCT04634864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33723335|NCT04777162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723336|NCT03760120|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Technicians performing multiple-breath washout tests are blinded to treatment allocation; physiotherapists performing the treatment are blinded to multiple breath washout results; patients are blinded to the purpose of the study; the statistician will be blind to treatment allocation together with outcome assessors.|Cross-over randomized controlled trial. Procedure: two nitrogen multiple-breath washout tests, one before and one after the intervention with PEP-Mask, either standard or sham allocation, during two subsequent mornings.|t|f|t|t
33723337|NCT00463749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723338|NCT03695510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723339|NCT01075698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723340|NCT04404855|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel||||
33723341|NCT03697668|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"The research method will be a Phase 2 trial, 2 arms, randomized, open label (only the microscopist will be blinded), adaptive, dose de-escalation, trial conducted in adult male subjects with uncomplicated P.falciparum malaria.~In all phases, patients will be treated by a triple combination IMA-DHA-PPQ (ARM 1) or by the standard DHA-PPQ treatment (ARM 2)."|interventional||||
33723342|NCT02441933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723343|NCT01855633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723344|NCT00780325|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33723345|NCT00415909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723346|NCT01912144|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723347|NCT00930566|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33804739|NCT06638463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104776|NCT02281864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804740|NCT01433315|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33804741|NCT02731846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804742|NCT00352131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804743|NCT04644679|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33804744|NCT02550951|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804745|NCT04448561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804746|NCT01378416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804747|NCT00588406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33804748|NCT00147719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804749|NCT04530630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804750|NCT03117426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33804751|NCT02957396|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33804752|NCT02682485|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804753|NCT01964534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804754|NCT00909025|NA|SINGLE_GROUP||OTHER||NONE||||||
33804755|NCT03947216|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804756|NCT00171769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804757|NCT01379482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804758|NCT05122468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A connective tissue graft will be harvested from the palate as a free gingival graft, which will be de-epithelialized with a 15-c blade(Zucchelli et al. 2010) before opening of the opaque envelopes, which contains the allocation concealment. Afterwards, test or control procedure will be carried out.|"The two intervention groups will be the CAF group (standard of care control) and Tunnel group (TUN, Test group). Two experienced clinicians (ML, or JG) will deliver treatment consisting of root coverage surgery using a coronally advanced flap in combination with a connective tissue graft (Control group), or a tunnel technique (Test group) in combination with a connective tissue graft.~Follow-up of individual patients will be 6 months (to be extended to 3 years to observe differences in a long-term basis)"|t|f|t|t
33804759|NCT00004840|RANDOMIZED|||TREATMENT||DOUBLE||||||
33804760|NCT05660356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to their assigned group. Following completion of the study, participants will be informed of their group allocation and be given the option to complete the treatment group if they were originally assigned to the placebo group.|Treatment group and placebo group. Participants assigned placebo group will be given the option to complete...|t|f|f|f
33804761|NCT00909961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804762|NCT02966665|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804763|NCT06700226|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single-center, open, single-arm, exploratory clinical investigation. This clinical investigation will include up to 10 subjects in 1 site. All subjects treated will be followed up for 3 months or up to re-treatment||||
33804764|NCT04824274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804765|NCT05856084|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34028474|NCT03803982|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The patients, surgeons, ward and PACU nurses, research assistants, and surgical house-staff will be blinded to the randomization. The anesthesiologist will be aware of the randomization as this will directly impact the anesthetic delivered to the patients.|The investigators propose to conduct a double-blind RCT comparing deep neuromuscular blockade to standard blockade during bariatric surgery. Participants will be randomized to one of the two groups in a 1:1 ratio.|t|t|t|t
34028475|NCT04107909|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34028476|NCT02042456|||COHORT||PROSPECTIVE|||||||
34028477|NCT03579381|||COHORT||PROSPECTIVE|||||||
34028478|NCT00041132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028479|NCT04045483|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Raters of efficacy measures are blind to the group of a participant.|This study is a single-blind, randomized, controlled, two-period crossover trial.|f|f|f|t
34028480|NCT01522612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028481|NCT05124886|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34028482|NCT04169945|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34028483|NCT03995823|||COHORT||PROSPECTIVE|||||||
34028484|NCT04514484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028485|NCT06192056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intervention group vs waitlist group|f|f|f|t
34028486|NCT06633289|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34028487|NCT04409483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028488|NCT01128179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028489|NCT02413567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028490|NCT01249560|||COHORT||PROSPECTIVE|||||||
34028491|NCT04380597|||OTHER||PROSPECTIVE|||||||
34028492|NCT04714073|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||In the first treatment period all subjects are planned to undergo the reference treatment (R), and in the second treatment period all subjects are planned to undergo the test treatment (T).||||
34028493|NCT01266031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028494|NCT01443897|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34028495|NCT01727037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028496|NCT03926520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028497|NCT00137761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028498|NCT01792687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028499|NCT05042895|RANDOMIZED|PARALLEL||TREATMENT||NONE||A cross-sectional study.||||
34028500|NCT00100880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028501|NCT02671929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028502|NCT05896735|||OTHER||RETROSPECTIVE|||||||
34028503|NCT00167284|RANDOMIZED|PARALLEL||ECT||NONE||||||
34028504|NCT04799496|||COHORT||PROSPECTIVE|||||||
34028505|NCT04683679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028506|NCT04521738|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34104777|NCT06571006|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33804766|NCT00787969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804767|NCT01630226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723348|NCT05220579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The TOR device was provided by the sponsor to the investigators with screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."|Randomized placebo controlled double-blind trial|t|t|t|t
33804768|NCT01428934|||COHORT||PROSPECTIVE|||||||
33804769|NCT03005119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028507|NCT03552848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Part 1: totally 30 patient will be enrolled, and 15 patients will be given MSC immediately after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD.~Part 2: totally 30 patient will be enrolled, and 15 patients will be given MSC after onset of multiple organ dysfuntion syndrome after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD."|f|f|f|t
34028508|NCT03906422|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"The investigator will assemble the opaque, sealed envelopes containing the archwires. The envelopes will be labeled A, B or C corresponding to 0.016 Nitinol (3M Unitek, Monrovia, CA), 0.016 27o CuNiTi (Ormco, Glendora, CA) or 0.016 35o CuNiTi (Ormco, Glendora, CA) respectively. Randomization sequences will be created by using Research Randomizer online software. The investigator will enroll patients into the study. This trial will be completed with two blocks of 63 subjects each, one block per year, with subject randomization within each block.~An independent third party will maintain possession of all envelopes and distribute as needed once a subject is enrolled and ready to receive fixed orthodontic appliances. The same independent third party will maintain a log with subject identification and consent forms."|prospective, triple-blind, randomized controlled clinical trial|t|t|t|t
34028509|NCT00399633|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34028510|NCT00003627|RANDOMIZED|||TREATMENT||||||||
33723349|NCT05919303|||OTHER||CROSS_SECTIONAL|||||||
33723350|NCT01571258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028511|NCT02129608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028512|NCT05114876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028513|NCT00991874|||COHORT||PROSPECTIVE|||||||
34028514|NCT02771470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34028515|NCT03437070|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation||||
34028516|NCT02681835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028517|NCT04952350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, caregivers, data collectors, and data analysts will be blinded for the study group. The Delta Pharma company (Egypt) will provide the atorvastatin and a similar placebo. The company will not participate in any step of the study including participant recruitment, data collection, data analysis, or results reporting. The company will prepare a similar package of drug and placebo (labeled as A and B). Even the pharmacist involved in treatment allocation will not know what is the treatment group, just A or B. For emergency unmasking, one of the directors of the COVID19 research council, who will not participate in the study, will know the true labels and the randomization table.||t|t|t|t
34028518|NCT05446012|||COHORT||PROSPECTIVE|||||||
34028519|NCT04411914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel group inpatient study|t|t|t|t
34028520|NCT06032000|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||LEM-mR203 vs placebo|t|t|t|t
34028521|NCT01392235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028522|NCT04078997|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34028523|NCT01931878|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34028524|NCT04975295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723351|NCT01416727|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33723352|NCT05759442|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label, prospective, clinical trial||||
33723353|NCT02195076|||CASE_CONTROL||PROSPECTIVE|||||||
33723354|NCT01665456|||CASE_CONTROL||RETROSPECTIVE|||||||
33723355|NCT05473273|||COHORT||PROSPECTIVE|||||||
33723356|NCT02862197|||CASE_ONLY||PROSPECTIVE|||||||
33723357|NCT02615730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723358|NCT02861703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723359|NCT02419742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723360|NCT00727753|||COHORT||PROSPECTIVE|||||||
33723361|NCT02136576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33723362|NCT01393340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723363|NCT00001960||||TREATMENT||||||||
33723364|NCT04026477|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723365|NCT00849160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723366|NCT00178035|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33723367|NCT04448405|||COHORT||PROSPECTIVE|||||||
33723368|NCT01163708|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33723369|NCT01914185|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723370|NCT06135155|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33723371|NCT00746993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723372|NCT02563678|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33723373|NCT04727229|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33723374|NCT05049070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The Best Corrected Visual Acuity (BCVA) assessor will be masked to GoEyes and Standard of Care refraction results.|||||
33723375|NCT00369512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723376|NCT05525156|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33723377|NCT01429272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723378|NCT03795311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723379|NCT00335972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33804770|NCT04763759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is double-blind and placebo-controlled.|Phase 1, Double-Blinded, Single Ascending Dose Study|t|t|t|t
33804771|NCT05452525|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804772|NCT03445364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804773|NCT04637256|||COHORT||PROSPECTIVE|||||||
34104778|NCT05459779|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|To minimize bias, this study will be randomized and conducted in single blind. The patient will not be aware of the activation or not of the assistance module placed on the electric wheelchair. Indeed, the investigative team will be in charge of the activation of the robotic module.|Each patient included will test a wheelchair equipped with a collision avoidance assistance module in 2 conditions, assistance activated or not.|t|f|f|f
34104779|NCT02102802|||CASE_CROSSOVER||PROSPECTIVE|||||||
34104780|NCT00233168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804774|NCT01108003|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804775|NCT01874964|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804776|NCT01267370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33804777|NCT04004494|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33804778|NCT03580200|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Quasi-experimental study utilizing a pretest-posttest randomized control design||||
33804779|NCT02387658|||COHORT||PROSPECTIVE|||||||
34104781|NCT04426357|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34104782|NCT06408441|||COHORT||PROSPECTIVE|||||||
33804780|NCT05033275|||COHORT||PROSPECTIVE|||||||
33804781|NCT03960099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33804782|NCT04505371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33804783|NCT06247241|NA|SEQUENTIAL||TREATMENT||NONE||Single and multiple ascending dose||||
34104783|NCT06679504|||COHORT||PROSPECTIVE|||||||
33804784|NCT03160521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study drug will be administered under double-blind conditions so that investigators, site staff, and patients will not be aware about the identity of the study drug (ie, blinded Risperidone ISM 75 mg, Risperidone ISM 100 mg, or placebo) administered to any given patient.||t|t|t|f
33804785|NCT06360133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104784|NCT01258699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804786|NCT04162457|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|This study is double blind. All participants are completing 4 testing sessions in randomised and counterbalanced order. Participants and researchers (who are also outcome assessors) are blinded to the beverages content. Un-blinding will be performed following analysis of results|Counter-balanced, double-blind, crossover, within-subject design.|t|f|t|t
34104785|NCT00394225|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34104786|NCT02510742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33804787|NCT03554083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804788|NCT01271309|||COHORT||PROSPECTIVE|||||||
33804789|NCT06251674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804790|NCT03660618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804791|NCT03351075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34104787|NCT00234793|RANDOMIZED|PARALLEL||||NONE||||||
34104788|NCT05388968|||COHORT||PROSPECTIVE|||||||
34104789|NCT02784496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104790|NCT05995561|||OTHER||RETROSPECTIVE|||||||
33804792|NCT00596336|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33804793|NCT00100698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804794|NCT04337944|NA|SINGLE_GROUP||PREVENTION||NONE||Interventional prospective study on patients receiving a Boston keratoprosthesis type 1, using a retrospective group as the control group.||||
33804795|NCT00910832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804796|NCT01220869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804797|NCT02993211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33804798|NCT02392234|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33804799|NCT05484648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804800|NCT00829036|NA|SINGLE_GROUP||||NONE||||||
33804801|NCT06000813|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34104791|NCT06690671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104792|NCT04504812|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Individuals randomized to a nerve procedure will be blinded to whether they have a long acting block or nerve ablation.|Using a stepped care model, Phase 1 participants will be randomly assigned to minimally invasive treatments, including best practices, best practices plus duloxetine, and best practices plus duloxetine combined with a web-based pain coping skills training program. Those who note interest in additional treatment following completion of Phase 1, as well as those that are not eligible for Phase 1 treatment, will be randomly assigned to more aggressive procedures: intra-articular hyaluronic acid, steroid and local anesthetic injection, or a nerve procedure that would either include a long acting block or nerve ablation. Interim analyses will be completed for both phases, and pre-specified stopping rules will determine if all study arms will continue. Modified Intention to Treat (mITT) and per protocol analyses will be conducted.|t|f|f|f
33804802|NCT03760913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|This will be a double-blind, randomized, placebo-controlled, single and multiple subcutaneous dose study.|t|t|t|f
33804803|NCT06252805|||COHORT||PROSPECTIVE|||||||
33804804|NCT03148652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804805|NCT04683315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804806|NCT06190132|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33804807|NCT00181311|||DEFINED_POPULATION||OTHER|||||||
33804808|NCT05784259|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33804809|NCT01645566|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33804810|NCT06699758|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Standard 3+3 dose escalation design to determine the optimal dosage of the investigational product, consisting of CD45RA- memory T lymphocytes, for intranasal administration in healthy female volunteers. The dose escalation will be based on the observed occurrence of dose-limiting toxicities (DLTs).||||
33804811|NCT02155868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804812|NCT03595969|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804813|NCT06698926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33804814|NCT04566250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given that patients in the intervention group will receive a pamphlet explaining how to use their prescription allocation, patient blinding is not feasible. Surgeons cannot be blinded as they will need to sign the prescriptions and provide any necessary advice about the medications being prescribed. Outcome assessors and data analysts will be blinded.|Eligible patients will be randomized using the centralized 24-hour computerized randomization system to allocate patients to the control (standard of care) or intervention (non-opioid prescription and infographic) group.|f|f|f|t
33804815|NCT04075396|NA|SEQUENTIAL||TREATMENT||NONE||||||
33804816|NCT02540525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804817|NCT04305821|||COHORT||PROSPECTIVE|||||||
33804818|NCT02743533|||COHORT||PROSPECTIVE|||||||
33804819|NCT01019213|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33804820|NCT00229658|||||PROSPECTIVE|||||||
33804821|NCT05814653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804822|NCT06268015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028525|NCT00928044|||CASE_CONTROL||PROSPECTIVE|||||||
34028526|NCT01357083|||CASE_CONTROL||RETROSPECTIVE|||||||
34028527|NCT04152863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028528|NCT02393352|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34028529|NCT05537350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34028530|NCT04303780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028531|NCT00843895|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34028532|NCT01105624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028533|NCT00761657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028534|NCT04526847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The proposed study is a parallel arm, randomized controlled trial compare two different dietary patterns: 1) intermittent energy-restriction (IER) diet also known as intermittent fasting (5:2 eating pattern: 5 days of habitual intake and 2 very low energy diet on two non-consecutive days (Mondays and Thursdays) per week, and 2) Continuous (daily) energy-restricted diet (CER) on the reduction of body weight, and cardiometabolic risk factors among overweight/obese Nepalese population (Figure 2). This study will adopt a parallel randomized trial design with an equal allocation of participants between the IER and CER arm. The participants will be recruited from the general population through social media advertisements. The study will be carried out for six months, from baseline data collection, follow-up midline data collection, and end-line data collection for outcome measure.||||
34028535|NCT00811928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028536|NCT03817541|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One Group of morbidly obese patients for bariatric surgery One Group of normal weight cholecystectomy||||
34028537|NCT01783795|NA|SINGLE_GROUP||SCREENING||NONE||||||
34028538|NCT02499484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028539|NCT02240615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028540|NCT05803239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028541|NCT00161863|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34028542|NCT05575232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028543|NCT03632018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Because we are intentionally changing the clinic environment, study participants and care providers will not be masked to the study condition. However, the investigator and the outcome assessors will be unaware which study arm a given participant is in to reduce bias.|Cluster randomized controlled trial|f|f|t|t
34028544|NCT02597127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028545|NCT05994885|NA|SINGLE_GROUP||OTHER||NONE|The care provider is not aware about clinical parameters and biochemical analysis of GCF (E-cadherin and total antioxidant capacity).|Patients with periodontitis, of any stage, having periodontal pockets of a moderate depth (4 to 6 mm) treated with nonsurgical periodontal therapy.||||
34028546|NCT00451243|||CASE_CONTROL||OTHER|||||||
34028547|NCT02524457|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028548|NCT04871672|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects will be randomly assigned to two groups:~1. pilates and home exercises (PAH) group~2. home exercises group (COH)"||||
34028549|NCT02535793|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028550|NCT02699073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028551|NCT04218734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028552|NCT05311579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028553|NCT04465981|||COHORT||OTHER|||||||
34028554|NCT03825718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028555|NCT04348695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028556|NCT01009502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028557|NCT04738695|||COHORT||PROSPECTIVE|||||||
34028558|NCT00003183||||TREATMENT||||||||
34028559|NCT02418832|NA|SINGLE_GROUP||OTHER||NONE||||||
34028560|NCT02929056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028561|NCT06170697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723380|NCT01782807|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028562|NCT03074786|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Phase 2a, open-label, multi-site, two-sequence, crossover, randomized trial||||
34028563|NCT00618332|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33723381|NCT02784990|||COHORT||PROSPECTIVE|||||||
33723382|NCT05629832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33723383|NCT03025542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is an Investigator- and Subject-blind study.||t|f|t|f
33723384|NCT04804397|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33723385|NCT05298748|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The order of the sound exposure will be randomized within each subject. The outcomes assessor (quantifying cardiorespiratory events) will be blinded as to the order of the 6 hour randomization blocks within the 24 hour study.|This is a single site, single visit study. The order of exposure, two 6 hour periods of ambient noise and two 6 hour periods of sound, will be randomized within each subject for a total of 24hrs of sound exposure.|f|f|f|t
33723386|NCT01113632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723387|NCT00555659|||CASE_ONLY||PROSPECTIVE|||||||
33723388|NCT03400319|||COHORT||PROSPECTIVE|||||||
33723389|NCT03068247|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33723390|NCT00908726|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33723391|NCT02826460|||COHORT||RETROSPECTIVE|||||||
33723392|NCT02701647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723393|NCT02982967|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723394|NCT02158390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723395|NCT06449313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723396|NCT01330511|||COHORT||PROSPECTIVE|||||||
33723397|NCT00366600|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723398|NCT05445765|NA|SEQUENTIAL||TREATMENT||NONE||||||
33723399|NCT04706195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723400|NCT04781673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Medication infusion and medication IV bag will be covered with brown protect from light bag|Prospective Randomized Trial, Single-blinded|t|f|f|f
33723401|NCT05546931|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel-arm, randomized clinical trial||||
33723402|NCT00376909|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33723403|NCT03571581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723404|NCT03358992|||COHORT||PROSPECTIVE|||||||
33723405|NCT00895258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723406|NCT02629341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723407|NCT03198741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723408|NCT02081144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33723409|NCT01779180|||COHORT||PROSPECTIVE|||||||
33723410|NCT00108056||||TREATMENT||||||||
33723411|NCT06181890|||COHORT||OTHER|||||||
33723412|NCT02293655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723413|NCT02109614|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33723414|NCT00809003|||COHORT||PROSPECTIVE|||||||
33723415|NCT05023226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33723416|NCT04498728|||OTHER||PROSPECTIVE|||||||
33723417|NCT03040466|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to each 3 type of ureteroscope and receive the flexible ureteroscopy. In each ureteroscopy, only one type of ureteroscope will be used; therefore this study will be parallel model.||||
33723418|NCT00527930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723419|NCT03727412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723420|NCT03099876|||CASE_CONTROL||PROSPECTIVE|||||||
33723421|NCT02716558|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33723422|NCT03163888|||COHORT||PROSPECTIVE|||||||
33723423|NCT04139707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pilot Randomized Controlled Trial|t|f|f|t
33723424|NCT02555033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723425|NCT01010308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723426|NCT01510379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723427|NCT02598427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723428|NCT02558257|||COHORT||PROSPECTIVE|||||||
33723429|NCT06301815|||COHORT||CROSS_SECTIONAL|||||||
33723430|NCT01970839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723431|NCT01940809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723432|NCT05792943|||CASE_ONLY||PROSPECTIVE|||||||
33723433|NCT04487873|||CASE_CONTROL||PROSPECTIVE|||||||
33723434|NCT00002173||||TREATMENT||||||||
33723435|NCT03837561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723436|NCT02515955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723437|NCT04318509|NA|SINGLE_GROUP||OTHER||NONE||||||
33723438|NCT04720729|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase 2 study, Chemotherapy monitoring based on ctDNA early changes||||
33723439|NCT02449226|||COHORT||PROSPECTIVE|||||||
33723440|NCT05797493|||COHORT||PROSPECTIVE|||||||
33723441|NCT00777647|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723442|NCT00559520|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|||t|f|t|f
33723443|NCT03696810|NA|SINGLE_GROUP||OTHER||NONE||||||
33723444|NCT01367158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33723445|NCT06093412|||COHORT||PROSPECTIVE|||||||
33723446|NCT03350854|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33723447|NCT02117999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Consecutive patients were randomized, using block randomization model, in one of the arm||||
33723448|NCT06275282|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723449|NCT03864640|||CASE_ONLY||RETROSPECTIVE|||||||
33723450|NCT03694860|||OTHER||PROSPECTIVE|||||||
33723451|NCT05870033|||COHORT||CROSS_SECTIONAL|||||||
33723452|NCT00415233|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33723453|NCT00019396||||TREATMENT||||||||
33723454|NCT03189615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104793|NCT03373669|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an open label, randomized, phase 2 clinical trial of the immunogenicity of OCV when the vaccine is administered to participants of three age cohorts (1-4 years, 5-14 years, and \>14 years) and in two dose interval groups (DIGs). The subjects in each age cohort will be randomized to a DIG of 2 weeks (DIG-1) or 6 months (DIG-2). A total of 120 subjects will be enrolled and these are equally divided between the different groups (20 per age/dose interval group).||||
33723455|NCT03640585|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients were randomized and divided into 2 groups of 20 people. A randomized list is prepared in a computer environment by a statistician for randomization. In this list, the odd numbers for the control group and the MT group were given double numbers. The group identification is printed on sequentially numbered cards placed in sealed envelopes. After enrollment, the numbered envelope was opened by the patient and the blind investigator.||||
33723456|NCT04983056|||COHORT||RETROSPECTIVE|||||||
33804823|NCT03763682|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, open-label, 2 groups||||
33804824|NCT04544319|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33804825|NCT01462149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804826|NCT06415591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, sham placebo controlled. Randomization will be performed by a research coordinator, who will assign each participant a study number and keep a record of whether they are receiving true or sham PENFS, thus maintaining blinding of the participant, the study physicians, the research assistant, and the data analysis team including the P.I. (A.W.) until completion of the follow-up period and data analyses can be performed.|Participants will be randomized 1:1 to either true or sham PENFS using the auricular device (series of 4, weekly placement with ongoing 5 day (M-F) stimulation - manufacturer recommended) treatments, then assessed for changes in pain and function at 12 and 24 weeks post-treatment. The 12-week time point is chosen to evaluate longer-term neural changes as an indicator of neural plasticity, given the continued improvements seen in the investigators' PENFS group based on preliminary data. The 24- week timepoint is chosen to evaluate longer term (6 months) pain outcomes related to PENFS.|t|t|t|t
33804827|NCT04663698|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33804828|NCT06548607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804829|NCT02644369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804830|NCT00005820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804831|NCT02966626|||CASE_ONLY||RETROSPECTIVE|||||||
33804832|NCT05910203|RANDOMIZED|CROSSOVER||OTHER||SINGLE||"The research was designed experimentally with pretest-posttest control group."|t|f|f|f
33804833|NCT00244413|||COHORT||PROSPECTIVE|||||||
33804834|NCT06698978|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||"The research consists of two 3-month treatment periods, spaced out by a 1-month wash-out period:~Arm with complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months)~Arm with complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS) in period 2 (3 months)"|t|f|t|f
33804835|NCT04139434|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"A classic 3+3 design will be used to establish dose-limiting toxicity (DLT), MTD, and RP2D."||||
33804836|NCT01638975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804837|NCT02593149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804838|NCT05517655|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33804839|NCT03035851|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33804840|NCT06408077|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804841|NCT05472207|||COHORT||PROSPECTIVE|||||||
33804842|NCT03022994|||CASE_CONTROL||PROSPECTIVE|||||||
33804843|NCT01431430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804844|NCT05820217|||COHORT||PROSPECTIVE|||||||
33804845|NCT02138071|||COHORT||PROSPECTIVE|||||||
33804846|NCT06598553|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hybrid effectiveness-implementation trial||||
33804847|NCT05408624|||OTHER||PROSPECTIVE|||||||
33804848|NCT01700205|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Between- and within-subject longitudinal trial|t|t|f|t
33804849|NCT04811924|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study will be double blinded from the patients and the researchers. An external pharmacy will be responsible for preparing the investigational product (IP) in an open manner, which will be transferred to the research pharmacy of the CIUSSS de l'Est-de-l'Île-de-Montréal. The research pharmacy will label and dispense the IP in a blinded manner for study team on the day of treatment and according to the randomization list provided by the study team.|Randomized double blinded prospective clinical trial|t|t|t|f
33804850|NCT03019835|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33804851|NCT02241538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33804852|NCT00050063|||||PROSPECTIVE|||||||
33804853|NCT05798117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804854|NCT00940069|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804855|NCT06243900|||CASE_ONLY||PROSPECTIVE|||||||
33804856|NCT01175187|||CASE_CONTROL||RETROSPECTIVE|||||||
33804857|NCT03175159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will not be aware of the intervention assignment.|"Two-arm RTC, equally randomized between two arms: (1) the Project IMPACT intervention, BA-RR (behavioral activation and HIV risk reduction) counseling, which lasts ten sessions; and (2) the standard of care comparison condition, including two equivalent sexual risk reduction counseling sessions."|f|f|f|t
33804858|NCT04810546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33804859|NCT01357018|||CASE_ONLY||PROSPECTIVE|||||||
34028564|NCT04638101|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"For young adolescents enrolled in the randomised controlled trial design, families were randomised either to the intervention group or the waiting group.~Participants enrolled in the RCT completed three assessments at three different time points: Time 1, Time 2, Time 3. Participants from the intervention group participated in Mindfulness-based intervention between Time 1 and Time 2. Participants from the waiting group took part in the Mindfulness-based intervention between Time 2 and Time 3."||||
34028565|NCT02565940|||CASE_ONLY||PROSPECTIVE|||||||
34028566|NCT03046641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028567|NCT05299528|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34104794|NCT01941342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104795|NCT00879619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104796|NCT01310751|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104797|NCT06075537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104798|NCT06599320|||COHORT||CROSS_SECTIONAL|||||||
34104799|NCT04402073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Phase II, comparative, randomized (experimental : standard arm 1:1, no blinding, no active or placebo control, parallel group, therapeutic||||
34104800|NCT02241031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104801|NCT05544344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research interviewers are blinded to study condition.|The intervention includes 4 components: establishing a working alliance with a health coach, completing an online inventory to assess personal wellness in eight life areas, developing a Restart plan that includes personalized life goals, and follow-along with a health coach to address barriers to goal attainment and to reinforce achievement.|f|f|f|t
34104802|NCT03320083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104803|NCT01456403|||COHORT||CROSS_SECTIONAL|||||||
34104804|NCT06528184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104805|NCT02346812|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34104806|NCT01767857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104807|NCT01514422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104808|NCT02242656|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34104809|NCT04351672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723457|NCT05966324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study included 4 cohorts and each cohort consisted of 10 subjects, randomized 4:1 (active:placebo).|This was a single and multiple oral dose study of the safety/tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy Japanese subjects compared with a cohort of healthy Caucasian subjects. total of 41 subjects were enrolled in this study: 31 Japanese subjects and 10 Caucasian subjects. The study included 4 cohorts and each cohort consisted of 10 subjects, randomized 4:1 (active:placebo). The Japanese cohorts (Cohorts 1, 2, and 4) were performed in parallel. The Caucasian cohort (Cohort 3) was performed after Cohort 2 was complete so that the Caucasian subjects could be matched by certain demographic factors.|t|t|t|t
33723458|NCT02250443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723459|NCT04518254|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The pharmacist, carrying out the packaging and labelling of the treatment units, will ensure the blinding. Neither the participant nor the investigator will know what treatment is being administered.|"The study is composed of 4 arms:~1. Tyrosine treatment without stress exposure~2. Tyrosine treatment with stress exposure~3. Placebo treatment without stress exposure~4. Placebo treatment with stress exposure~Every participants will participate in the 4 arms in a random order."|t|f|t|t
33723460|NCT01327300|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33723461|NCT05245708|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723462|NCT03895281|||CASE_ONLY||PROSPECTIVE|||||||
33723463|NCT00930579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723464|NCT00668044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723465|NCT05045560|||CASE_CONTROL||RETROSPECTIVE|||||||
33723466|NCT00363779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723467|NCT04476979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723468|NCT03518385|||CASE_CONTROL||PROSPECTIVE|||||||
33723469|NCT01433510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723470|NCT00087451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723471|NCT04504799|||CASE_CONTROL||PROSPECTIVE|||||||
33723472|NCT01981447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723473|NCT00657007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723474|NCT03305328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were unaware of the presence of a Sham condition. Therefore, all participants believed they received the Active stimulation.|Participants were randomly assigned to either an Active or Sham Control group. The Active group received the 30 minutes of alpha-tACS for four consecutive days, whereas the Sham Control group received Sham (no) stimulation.|t|f|f|f
33723475|NCT04700358|||OTHER||OTHER|||||||
33723476|NCT01012622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723477|NCT04283162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723478|NCT00641407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723479|NCT02488655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723480|NCT02098577|||COHORT||PROSPECTIVE|||||||
33723481|NCT01867827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723482|NCT04867265|RANDOMIZED|CROSSOVER||OTHER||NONE||Medical students trained as BLS providers (first group) and Medical student trained as teachers will perform mouth-to-mouth ventilation in 3 case scenarios on 3 different mannequins.||||
33723483|NCT06294418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723484|NCT00245674|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723485|NCT06195059|||COHORT||CROSS_SECTIONAL|||||||
33723486|NCT00755131|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33723487|NCT01992861|||COHORT||PROSPECTIVE|||||||
33723488|NCT05125328|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34104810|NCT01517178|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104811|NCT05586685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patients and investigator do not know the groups receive treatment||t|f|f|t
34104812|NCT02034266|NA|SINGLE_GROUP||PREVENTION||NONE||open label study with no placebo.||||
33804860|NCT03516370|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|patients were masked they didnt know which mixture they recived during treatment ensuring single blind study||t|f|f|f
34104813|NCT05451329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple masking|Double-masked, randomized, parallel|t|t|t|t
34104814|NCT02395627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104815|NCT03906955|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be blinded to the true purpose of the study. The investigators will be blinded to group assignment. The research assistants will be blinded to the true purpose of the study.|Participants will be randomized to one of two groups.|t|f|t|t
34104816|NCT00003158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104817|NCT01100580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104818|NCT02918630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104819|NCT05081271|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label study. No masking.|The proposed pilot study is a prospective, randomized open label study with two treatment assignments: one group will receive a homologous booster vaccine and the other a heterologous booster vaccine.||||
34104820|NCT05952375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104821|NCT03995472|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104822|NCT06675448|||CASE_CONTROL||PROSPECTIVE|||||||
33804861|NCT06308562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33804862|NCT02172560|||CASE_ONLY||RETROSPECTIVE|||||||
34104823|NCT00304148|||COHORT||PROSPECTIVE|||||||
34104824|NCT01346917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34104825|NCT05106062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104826|NCT05686720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104827|NCT06674876|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||Palliative care nurses who participated in Presurvey were then divided under one control and two intervention groups|t|f|f|f
34104828|NCT06054061|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter cluster randomized clinical trial will be conducted. The trial will consist of two arms, the experimental group will receive a 15-week intervention based on the promotion of hedonic and eudaimonic well-being. The control group will remain on a waitlist with their Treatment as Usual. Participants will be recruited from centers that focus on the psychosocial rehabilitation of people diagnosed with schizophrenia spectrum, bipolar disorder, personality disorders and severe affective disorders. Random allocation to the groups will be stratified according to the typology of the center. In the event that there is only a single representative of one of the center typologies, the entire center will be assigned to one of the study conditions. Assessments will be made before the intervention (E1), immediately after the 15-week intervention period (E2) and three (E3) and six (E4) months after the end of the intervention.||||
34104829|NCT06290037|NA|SINGLE_GROUP||SCREENING||NONE||||||
34104830|NCT02189967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104831|NCT03194529|NA|SINGLE_GROUP||OTHER||NONE||Primary outcome is safety in children with Crohn's disease in remission.||||
34104832|NCT06241430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Evaluating the effect of hemodynamic-guided GDMT titration with CardioMems on HFH in individuals with functional MR and HF undergoing mTEER, compared to usual care involving GDMT.|t|f|f|f
34104833|NCT06688981|||CASE_ONLY||RETROSPECTIVE|||||||
33804863|NCT00790699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804864|NCT01120977|||||CROSS_SECTIONAL|||||||
33804865|NCT06196749|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33804866|NCT05917015|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33804867|NCT03526406|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Acute on chronic|t|f|t|t
33804868|NCT06259032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33804869|NCT03575624|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm model.||||
33804870|NCT04570358|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804871|NCT02369484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804872|NCT03677037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33804873|NCT03981588|||COHORT||PROSPECTIVE|||||||
33804874|NCT06294756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the participants nor any of the medical researchers or laboratory staff involved in the screening, enrolment, clinical evaluation, monitoring, and laboratory as well as statistics of the participant's analyses were aware of the study intervention received (STW vs SDW). A randomization list (1:1 active vs placebo) was created prior to recruiting. The inhalation assistant randomized the participant according to the list and administered the intervention. Therefore, the inhalation assistant was unblinded to the treatment assigned but blinded to the medical condition of the participants.|The study is a double-blind, interventional, randomized case-control, pilot trial assessing the efficacy of sulfureous thermal water (STW) inhalations in patients diagnosed with long-COVID. The eligible subjects were randomized in a 1:1 ratio to either: active (STW) or placebo (SDW) group for the inhalation therapy and tested at 3 timepoints: Visit 1 (prior treatment), Visit 2 (just after treatment) , Visit 3 (3 months after treatment).|t|f|t|t
33839107|NCT05017428|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will take a supplement containing 4 metabolites at escalating doses compared with placebo after a standardized meal and their blood will be drawn at mutliple points throughout a postprandial time course to evaluate markers of inflammation, circulating levels of each metabolite, and plasma functionalities.||||
33839108|NCT00975468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104834|NCT01079390|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34104835|NCT00661154|||COHORT||PROSPECTIVE|||||||
34104836|NCT04507269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104837|NCT06482853|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34104838|NCT06548113|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34104839|NCT05363215|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104840|NCT04164186|||COHORT||RETROSPECTIVE|||||||
34104841|NCT02999997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104842|NCT03614832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34104843|NCT04391608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804875|NCT06581133|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a single blind study and patients will not know which group they are in.|During their epilepsy monitoring unit (EMU) admission, patients will be divided into either the alarm group or the control group. Patients in the alarm group will have an alarm system placed in their room, scheduled to sound at several timepoints during the night. This intervention will be conducted throughout the whole EMU admission. Patients in the control group will have an alarm system placed in their room, but the alarm system will not sound during any of the nights during their EMU admission.|t|f|f|f
33804876|NCT03253367|||COHORT||OTHER|||||||
34104844|NCT06687759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104845|NCT02338557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104846|NCT04858997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104847|NCT05391958|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34104848|NCT04180462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34104849|NCT06689072|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104850|NCT06033859|||COHORT||PROSPECTIVE|||||||
34104851|NCT03611361|||CASE_ONLY||PROSPECTIVE|||||||
34104852|NCT02683798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104853|NCT04677361|NA|SINGLE_GROUP||TREATMENT||NONE||Prior to treatment of MILs™ patients will receive non-myeloablative lymphodepletion with cyclophosphamide and fludarabine to increase the efficacy of adoptive T cell therapy. Bone marrow aspirate (BMA) will be collected from the patient to manufacture the MILs™. Upon progression and after the bone marrow is collected, a subject may receive bridging treatment of pembrolizumab until the MILs™ are received, after which treatment of the MILs™ and pembrolizumab will begin.||||
34104854|NCT00562198|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34104855|NCT01978015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104856|NCT02708368|||CASE_CONTROL||PROSPECTIVE|||||||
33804877|NCT05871749|||COHORT||PROSPECTIVE|||||||
33804878|NCT05317390|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33804879|NCT06008236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A comparison of the two groups to be assigned as experimental and control groups will be made.|f|f|f|t
33804880|NCT03459950|||COHORT||PROSPECTIVE|||||||
33804881|NCT00687414|||OTHER||PROSPECTIVE|||||||
33804882|NCT04069416|||COHORT||RETROSPECTIVE|||||||
33804883|NCT06699615|||COHORT||PROSPECTIVE|||||||
33804884|NCT05568017|NA|SINGLE_GROUP||TREATMENT||NONE||Patients affected by unresectable or borderline resectable P-NETs and limited liver disease will be enrolled||||
33804885|NCT04637763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The CB10A clinical study consists of (Part A) 3 + 3 design with three dose levels.~(Part B) Expansion portion patients will receive CB-010 at the dose determined in Part A."||||
33804886|NCT00999336|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804887|NCT01211184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33804888|NCT02672033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804889|NCT06231368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804890|NCT05320289|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33804891|NCT03322995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804892|NCT05521386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33804893|NCT06581965|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinded endpoint adjudication|This trial consists of 3 study arms. DISTINCT 1 (low VTE risk \<1.0%): randomized (2 arms) DISTINCT 2 (intermediate VTE risk 1.0%-1.5%): observational DISTINCT 3 (high VTE risk \>1.5%): randomized (2 arms) Participants will be allocated to a study arm based on their predicted VTE risk which is determined by the TRiP(plasty) score.||||
33804894|NCT06211972|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|As there is single group on this study, there is no randomization and masking.|A mixed-methods approach nested in a pre-to-post follow-up design||||
33804895|NCT06020352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804896|NCT05728840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804897|NCT03554889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804898|NCT04362046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804899|NCT00667316|||OTHER||PROSPECTIVE|||||||
33804900|NCT04448652|||COHORT||PROSPECTIVE|||||||
33804901|NCT03789071|||OTHER||PROSPECTIVE|||||||
33804902|NCT06074679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33804903|NCT04905797|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33804904|NCT05011045|||COHORT||PROSPECTIVE|||||||
33804905|NCT04726449|||COHORT||PROSPECTIVE|||||||
33804906|NCT00145470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804907|NCT01335828|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33804908|NCT03234374|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a single-blind study in which the study subject is blinded to treatment group. All precautions will be taken to ensure that the blinding of the treatment group is maintained throughout the study period. Unblinding to the subject will not be permitted unless it is deemed necessary for appropriate treatment of a medical emergency.||t|f|f|f
34104857|NCT06695429|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34104858|NCT03179709|||OTHER||CROSS_SECTIONAL|||||||
33804909|NCT04074096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804910|NCT00121849|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33804911|NCT04216342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804912|NCT00968149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804913|NCT05928390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804914|NCT06534957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Given the nature of the intervention, the study will be open and participants will know which group they were randomized to. However, the study will be blinded to the statistician in order to reduce the risk of introducing bias when interpreting the data.||f|f|f|t
33804915|NCT05986305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804916|NCT04319549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804917|NCT06186375|||CASE_ONLY||PROSPECTIVE|||||||
34104859|NCT00653705|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34104860|NCT06675838|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Intervention Content~Training Program Name: Time Management and Procrastination Behavior Management Training Duration: 3 sessions of 1 hour each, 5-day program Target Audience: Intern Nurses~Training Content:~Fundamentals of Time Management:~Definition and importance of time management. Fundamental principles for effective time use (prioritization, time blocking, planning).~Understanding Procrastination Behavior:~Definition and reasons for procrastination behavior. Effects of procrastination on student success.~Time Management Strategies:~Task Prioritization: Differentiating between urgent and important tasks. Time Blocking: Completing specific tasks in designated time slots. Daily Planning: Organizing daily tasks and activities.~Managing Procrastination Behavior:~Identification and analysis of procrastination habits. Coping strategies for procrastination (e.g., goal setting, increasing motivation, self-rewarding).~Effective Teaching Techniques:~Presentations and Information Sh"||||
34104861|NCT03829514|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34104862|NCT06400121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104863|NCT05234060|||COHORT||OTHER|||||||
34104864|NCT00752219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104865|NCT00160368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34104866|NCT06498180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104867|NCT06688604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after cesarean and vaginal birth.|f|f|t|f
33804918|NCT04340479|||COHORT||PROSPECTIVE|||||||
34104868|NCT05859672|||CASE_CROSSOVER||PROSPECTIVE|||||||
34104869|NCT02261610|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33804919|NCT06635538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804920|NCT05928845|||CASE_ONLY||PROSPECTIVE|||||||
33804921|NCT01638000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104870|NCT00001476||||TREATMENT||||||||
34104871|NCT05160441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind intervention||t|f|f|f
34104872|NCT00085020||||TREATMENT||NONE||||||
34104873|NCT01016041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804922|NCT01440166|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34104874|NCT00236197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104875|NCT05100992|||CASE_ONLY||OTHER|||||||
34104876|NCT00831155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104877|NCT01071785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104878|NCT06617364|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33804923|NCT00000958||||TREATMENT||||||||
33804924|NCT03266081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804925|NCT04256512|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804926|NCT01697891|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804927|NCT04175405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34104879|NCT06690164|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm, parallel group assignment: Arm 1: Atorvastatin 40mg + Omeprazole 20mg Arm 2: Atorvastatin 40mg onl||||
34104880|NCT02498795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104881|NCT05853952|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104882|NCT04545892|NA|SINGLE_GROUP||OTHER||NONE||||||
34104883|NCT01579877|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34104884|NCT04416490|||COHORT||PROSPECTIVE|||||||
34104885|NCT02513251|||OTHER||PROSPECTIVE|||||||
34104886|NCT06687330|||COHORT||PROSPECTIVE|||||||
34104887|NCT05584137|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34104888|NCT06033209|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The overall design of this trial involves 2 parts. In Part A, the goal is to establish the tolerability of both N332-GT5 and the SMNP adjuvant. This is a partially randomized design - Part A is nonrandomized, and Part B is randomized.||||
34104889|NCT01229202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34104890|NCT01084759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104891|NCT06549920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804928|NCT01400958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33839109|NCT02438553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34104892|NCT06314152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104893|NCT01520103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104894|NCT04491708|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33804929|NCT03402854|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and care providers will not be told of their group allocation. Participants in the sham group will receive a brief stimulation of the scalp, which will give them a feeling of being stimulated. This sham stimulation has been shown to effectively blind participants to group. Assessors will not be told the type of study being conducted.|Children will be randomly allocated to one of two parallel arms of the study.|t|t|f|t
33804930|NCT00575016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804931|NCT06242366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"These Sixty participants are stratified block randomization using NIHSS (5-9) and (10-14) score 30 participant each and then sample random into 2 groups; control group (n=30) and intervention groups (n=30) by Investigator . they do not know that their group.~The Outcomes Assessor will be collecting the data for primary and secondary outcome for 4 and 12 weeks and do not who are control or intervention group."|"This study based on Transitional Care Model by Naylor. Sixty participants with stroke patients with hemiplegia and can use Line Application will be recruited. These participants are stratified block randomization using NIHSS (5-9) and (10-14) score 30 participant each and then sample random into 2 groups; control group (n=30) and intervention groups (n=30).~The program consisted of 2 phases: 1) Phases I during hospital admission and 2) Phases II following hospital discharge for 12 weeks will collecting the data are 1) The Personal Data Form, 2) The Self-care Behavior Questionare and 3) The Stroke Impact Scale (SIS) 3.0. Data will be analyzed using descriptive statistics and two-way repeated measures ANOVA."|t|f|f|t
33804932|NCT04897633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33804933|NCT00196521|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33804934|NCT06698575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33804935|NCT06645665|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33804936|NCT06518551|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33804937|NCT03613740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
33804938|NCT01288443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804939|NCT03092726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33804940|NCT04566263|NA|SINGLE_GROUP||TREATMENT||NONE||"the Neuroform EZ Stent System was initially developed by SMART Therapeutics (San Leandro, CA, USA), with FDA HDE approval in 2002. This Stent system was later acquired by Boston Scientific, and then later acquired by Stryker Inc., Neurovascular Division. The Stent system was initially named the Neuroform Microdelivery Stent System, and now has been re-branded as the Neuroform EZ Stent System,"||||
33804941|NCT03529305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33804942|NCT02809989|||COHORT||PROSPECTIVE|||||||
33804943|NCT01605409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804944|NCT00986375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33804945|NCT01503372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804946|NCT00580866|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804947|NCT05916612|||COHORT||PROSPECTIVE|||||||
33804948|NCT02839395|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33804949|NCT00664690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33804950|NCT01025128|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33804951|NCT00552955|||||OTHER|||||||
33804952|NCT06443073|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33804953|NCT02910973|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33804954|NCT03903614|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|In this study, since the Principal Investigator was the intervener to both study groups, and also the data collector, an effort was made to ensure that both the pre- and posttest were administered in the presence of one other Occupational Therapist, Registered (OTR) and/or a Physical Therapist, who shared the use of the room with Mrs. Teng, test booklets were encrypted, and, that the participants, parents, test graders (one different OTR to each test instrument), and statisticians were kept blind to the group assignment of each participant.||t|f|f|t
33804955|NCT06124573|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33804956|NCT02313675|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33804957|NCT01880736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804958|NCT03781375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33804959|NCT05639400|||COHORT||PROSPECTIVE|||||||
33804960|NCT00755144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804961|NCT05088798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839110|NCT00477503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839111|NCT01060397|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33839112|NCT01627535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104895|NCT06673784|||COHORT||PROSPECTIVE|||||||
34104896|NCT04389463|||COHORT||PROSPECTIVE|||||||
34104897|NCT00103701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104898|NCT01647880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34104899|NCT05179005|||OTHER||OTHER|||||||
34104900|NCT04231565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104901|NCT06566300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||To evaluate the efficiency autologous nanofat injection versus autologous nanofat delivered by microneedling in management of post burn atrophic and traumatic scars.||||
34104902|NCT03818074|NA|SINGLE_GROUP||TREATMENT||NONE|Patients will be required to adhere to the study and attend all follow up visits. Informed consent and questionnaires will be administered at visit 0. They will be followed up 4, 12, 24 weeks and 12 months, 24 months after their SCS permanent implant. Questionnaires will be administered at each visit.|To investigate the clinical response to high frequency (1,000Hz) in patients who are due to have percutaneous spinal cord stimulation for intractable back and lower limb neuropathic pain||||
34104903|NCT02219100|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34104904|NCT03910894|||COHORT||PROSPECTIVE|||||||
34104905|NCT04591691|||COHORT||PROSPECTIVE|||||||
34104906|NCT00002431||||TREATMENT||||||||
34104907|NCT04985110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization process will be conducted before the study started. Computers will generate random numbers, which will put the participants into two groups. These numbers can only be accessed by the clinical research supporting unit team, while the investigators, surgeons, residents, nurses, and pharmacologists involved will be blinded to this information. To ensure patient blinding, the placebo will be manufactured as identical capsules.|This randomized controlled trial aims to compare the rate of perioperative infection complications in transperineal prostate biopsy between the group that receives prophylactic antibiotic and the group that receives placebo.|t|t|t|f
34104908|NCT02364895|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|t|f
34104909|NCT04903093|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Part A: open label / Part B: single-blind|||||
34104910|NCT05560763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104911|NCT01810172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104912|NCT04286776|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All enrolled patients are considered eligible to receive direct electrical stimulation. Subjects have the option to receive non stimulation testing only.||||
34104913|NCT05438771|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Which patients would be assigned to the study or control group was determined with the support of a person who was independent of the study and had no knowledge of the research. This person, who had no knowledge about the research, was asked to specify a number, and in the next process, patients were assigned to the study or control group depending on whether the random number was even or odd. Study and control group patients were first evaluated in terms of inclusion criteria. The Consolidated Reporting Trials (CONSORT) diagram was used to randomize patients. The use of the consort diagram has been used to greatly improve the conduct and reporting of randomized controlled trials and to allow the study to be included in future meta-analyses.|The study was designed as a randomized controlled experimental study on patients newly diagnosed with colorectal cancer who would receive the first course of FOLFOX combination chemotherapy.|t|t|f|f
34104914|NCT03989479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34104915|NCT02688166|||CASE_CONTROL||PROSPECTIVE|||||||
34104916|NCT05954494|||COHORT||PROSPECTIVE|||||||
34104917|NCT01294930|||COHORT||PROSPECTIVE|||||||
34104918|NCT06501339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104919|NCT02451007|NA|SINGLE_GROUP||OTHER||NONE||||||
34104920|NCT03401879|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34104921|NCT02176759|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34104922|NCT06687538|RANDOMIZED|PARALLEL||OTHER||TRIPLE|During the data collection process, when the patients were admitted to the urology clinic, their inclusion in the study will be evaluated by the consultant M.B. and the executive G.B. Patients who meet the inclusion criteria will be assigned to the control and mobile application arm by block randomization (1:1) according to permutations (BABBAB, AABBAB) created in the computer environment by a statistical expert not involved in the study. After the randomization list is created, which letter (A, B) will represent which group will be determined by lottery method. The other consultant (SY), who will not be involved in the data collection process of the research, will write numbers from 1 to 68 on the envelopes as many as the number of the sample and letters representing the groups according to the randomization list will be added to each envelope. When a patient meets the inclusion criteria, agrees to participate in the study and signs the informed consent form, the GB will inform the co|The study was planned as a prospective, two-arm (1:1), randomized controlled trial.|t|f|t|t
34104923|NCT05398692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two groups:~1. Post exertional Malaise (PEM) present who will receive virtual low intensity rehabilitation.~2. No Post Exertional Malaise group (no PEM) who will receive 10 weeks of traditional pulmonary rehabiltiation."||||
34104924|NCT05336357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104925|NCT03595124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104926|NCT03117621|||OTHER||PROSPECTIVE|||||||
34104927|NCT00764426|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34104928|NCT03094377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a quasi-randomized-controlled pilot. Participants were randomly allocated by admission sequence to a multisensory therapy group or a conventional training group||||
34104929|NCT01825863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104930|NCT06686433|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34104931|NCT06690567|||COHORT||OTHER|||||||
34104932|NCT02489045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104933|NCT03637816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33839113|NCT01954225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839114|NCT04321421|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal assessment of COVID-19 patients treated with hyperimmune plasma||||
34104934|NCT05846919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participant under general anesthesia|Triple group randomized controlled pilot trial|t|f|f|f
34104935|NCT06690736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34104936|NCT03241160|||COHORT||PROSPECTIVE|||||||
34104937|NCT03189927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104938|NCT03015948|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34104939|NCT02397369|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33804962|NCT06215391|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Conceptual Hypothesis:~The use of personalized 3D-printed masks may reduce leaks, adverse effects in the form of skin lesions, and the percentage of upper airway obstructive events in two distinct populations: patients with ALS and patients with COPD requiring inspiratory pressures greater than 22 cmH2O.~Operational Hypothesis:~The automatic AHI and the median leaks over 1 month are lower when the patient uses the custom-fit 3D-printed mask (M3D) compared to when they use the commercial mask (MC) that was prescribed.~Statistical Hypothesis:~H0: There are no differences in the median leaks over 1 month (and AHI) between commercial masks (MC) and personalized 3D-printed masks (M3D).~H1: The median leaks are significantly lower during the month of using the personalized mask (M3D) than during the use of the commercial mask."||||
33804963|NCT04433637|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomized controlled clinical trial|t|f|f|f
33804964|NCT06699017|NA|SINGLE_GROUP||OTHER||NONE||Patient with moderate to severe ARDS under sedation and curarization keep on going||||
33804965|NCT00849238|RANDOMIZED|PARALLEL||||NONE||||||
33804966|NCT06406400|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Participant (Part 1b, Part 2) Care Provider (Part 1b, Part 2) Investigator (Part 1b, Part 2)||t|t|t|f
33804967|NCT02564705|||COHORT||PROSPECTIVE|||||||
33804968|NCT04097145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804969|NCT04768712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33804970|NCT04210037|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||APG-1252 at the selected dose-level on days 1, 8 and 15 plus a fixed-dose of paclitaxel 80 mg/m˄2 on days 1 and 8 of a 21-day cycle. There will be three dose-levels of APG-1252 (-1, 80 mg; 1, 160 mg; 2, 240 mg).||||
33804971|NCT03027128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804972|NCT00371670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33804973|NCT01894308|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804974|NCT03656042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33804975|NCT03380494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind, randomised controlled trial|t|f|t|t
33804976|NCT04734600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|AEROBIC TRAINING VERSUS MYOFACIAL RELEASE ON CLAUDICATION AMONG PREPHERAIL ARTERAIL INSUFFIECENCY PATIENTS|40 patient having single leg intermittent claudication pain|t|f|f|f
33804977|NCT02863315|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|tsDCS|tsDCS|t|f|f|f
33804978|NCT04612244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33804979|NCT05609734|||COHORT||RETROSPECTIVE|||||||
33804980|NCT03055559|||CASE_ONLY||PROSPECTIVE|||||||
33804981|NCT06673511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33804982|NCT04325217|||COHORT||PROSPECTIVE|||||||
33804983|NCT03746613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804984|NCT03394534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33804985|NCT05230264|||COHORT||PROSPECTIVE|||||||
33804986|NCT06699238|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups, one group was provided home exercise program and one group run on the treadmill in addition to their home exercise program||||
33804987|NCT01819571|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33804988|NCT00727909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33804989|NCT05348603|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||To examine the effectiveness of enhanced online patient portal features in increasing interest and participation in clinical trials, a randomized trial that will employ a full 2X2X2X2 factorial design.|t|f|f|t
33804990|NCT05543044|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33804991|NCT01571557|||COHORT||PROSPECTIVE|||||||
33804992|NCT05403359|||COHORT||RETROSPECTIVE|||||||
33804993|NCT05525455|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multiple ascending dose and dose-expansion of TT-816 administered as a single agent or in combination with a PD-1 inhibitor.||||
33804994|NCT00358943|||COHORT||PROSPECTIVE|||||||
33804995|NCT05508607|||COHORT||RETROSPECTIVE|||||||
33804996|NCT00026689|||CASE_ONLY||CROSS_SECTIONAL|||||||
33804997|NCT01953224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33804998|NCT03367338|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33804999|NCT05170620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805000|NCT02431273|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33805001|NCT04919499|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Description to masking:~In Part A no masking will be performed. In Part B participant and investigator will be masked.~Description to randomisation:~In Part A no randomisation will be performed. In Part B randomisation will be performed."||t|f|t|f
33805002|NCT00507884|||CASE_ONLY||PROSPECTIVE|||||||
33805003|NCT00936182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805004|NCT04409470|||COHORT||PROSPECTIVE|||||||
33805005|NCT03013894|||COHORT||PROSPECTIVE|||||||
33805006|NCT05977335|||COHORT||PROSPECTIVE|||||||
33805007|NCT05387044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805008|NCT06571695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The design will be a single blinded format where the surgeon will be aware of what treatment the patient will receive (Control vs. Intervention). The patient will not be informed of what arm of treatment they were selected for.|Anatomic Long Head of Biceps Tensioning Treatment Group vs. Traditional Long Head of Biceps Tensioning Control Group|t|f|f|f
33805009|NCT02251860|||COHORT||PROSPECTIVE|||||||
33805010|NCT05342246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805011|NCT03329612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34104940|NCT06671496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104941|NCT03784729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34104942|NCT01235117|NON_RANDOMIZED|||TREATMENT||||||||
34104943|NCT06688253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028568|NCT06291714|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All patients are connected to the Clearsight device but the interface is masked in the control group.|Management of interventional group patients Prior to the surgery the rest cardiac index and contractility (dp/dt) must be quantified. For this purpose, the cardiac index will be measured in the preoperative night by applicating the HPI ClearSight system through a study team member. If the rest cardiac index is not available throughout the night because the patient´s sleep is altered by the measurements, the awake cardiac index will be quantified until the monitoring is stopped for the night sleep of the patient. This mean baseline measurements (CI and dp/dt) will then be the target cardiac index throughout the study algorithm (figure 1). In case no sleep measurement was achievable, the awake measurement will be accounted as baseline value. The perioperative study intervention period starts with the beginning of anesthesia and ends at the end of surgery. Intraoperative mean arterial pressure will be maintained at least at 65 mmHg and cardiac index and dp/dt will be individually|t|t|f|f
33805012|NCT06458179|||COHORT||RETROSPECTIVE|||||||
34028569|NCT01093092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028570|NCT03389347|NA|SINGLE_GROUP||OTHER||NONE||||||
34028571|NCT03112642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028572|NCT01428154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028573|NCT06501677|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028574|NCT00266539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104944|NCT06310694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In our study, a comparison was made of PIVCs applied to patients in the control (fixation of PIVC with a sterile transparent dressing) and intervention (fixation of PIVC with a sterile transparent dressing and application of an elastane circular dressing on it) groups.||||
34028575|NCT02506829|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34028576|NCT01107197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34028577|NCT01045330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34028578|NCT00048737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028579|NCT02220062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028580|NCT03694756|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No need for masking, all patients will undergo TMEM-MRI|Patients were originally intended to be enrolled in 2 cohorts (A and B), based on breast biopsy status; however, the study design was changed following Protocol Amendment.||||
34028581|NCT03697031|||COHORT||PROSPECTIVE|||||||
34104945|NCT00694928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104946|NCT06689995|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double Blind||t|f|t|f
34104947|NCT03708809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152395|NCT03254550|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Healthcare facilities will not be informed as to when they are expected to start implementing the intervention (the PrEP Promotion Package) until two weeks prior to the start of the intervention phase.|This is a stepped-wedge randomized design (there was no option for stepped-wedge design in the drop-down menu) with two sequences (each consisting of three healthcare facilities) and three periods.||||
34152396|NCT05505409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805013|NCT03575936|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33805014|NCT05914896|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Priming of the heart-lung machine performed by a staff member not affiliated to the study protocol.|Randomisation into two groups based on the osmolality level in the priming solution used for cardiopulmonary bypass.|t|t|t|t
33805015|NCT06099548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805016|NCT05990452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805017|NCT04347733|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33805018|NCT05599048|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33805019|NCT04989296|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33805020|NCT01576029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805021|NCT05728645|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34152397|NCT02412332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805022|NCT02098837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805023|NCT05148988|||COHORT||PROSPECTIVE|||||||
33805024|NCT06352619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805025|NCT01268306|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33805026|NCT01917942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805027|NCT05900895|NA|SEQUENTIAL||TREATMENT||NONE||Single-arm, 3+3 design with a dose-expansion cohort.||||
33805028|NCT02505191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805029|NCT02988193|RANDOMIZED|PARALLEL||TREATMENT||NONE||The medication treatment intervention between arms differs in that the optima4BP arm uses an analytic intelligence algorithm to optimize drug treatment.||||
33805030|NCT03249142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839115|NCT01800890|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33839116|NCT01102764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33839117|NCT03160612|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34104948|NCT05197270|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Dose Escalation will be open-label. During Dose Expansion, outcome assessors will be masked to treatment assignment. Other site personnel (including investigator) and subjects will be unmasked to treatment assignment but will be masked to 4D-150 dose level. The Sponsor and its representatives and the site dose preparer/pharmacist will be unmasked to treatment assignment. Steroid Optimization and Population Extension will be open-label.|In Dose Escalation, the safety and tolerability of multiple dose levels of 4D-150 will be examined following an open-label, 3+3 dose escalation design (n=3-5 per dose level). In Dose Expansion, subjects (n=50) will be randomized to receive one of 2 dose levels of 4D-150 (n=20 for each dose level) based on results from Dose Escalation, or aflibercept (n=10). In Steroid Optimization (n=up to 96) and Population Extension (n=up to 45) Cohorts, subjects will be assigned sequentially to receive 4D-150 at doses cleared by the DSMC.|f|f|f|t
34104949|NCT06606275|||COHORT||RETROSPECTIVE|||||||
34104950|NCT06686576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104951|NCT04020263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be double-blinded. Investigator masking to group assignment after randomization will be guaranteed by use of a placebo.|The LevoHeartShock trial is a prospective, double-blind, multicenter, randomized controlled trial comparing the early initiation of levosimendan versus placebo in patients with cardiogenic shock treated with vasopressor therapy according to a conventional strategy of inotrope use (dobutamine as first line agent).|t|t|t|f
34104952|NCT00288561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104953|NCT06537466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805031|NCT02357966|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"This is a Phase I/II, double blind placebo controlled trial of the True Human monoclonal antibody 514G3 in subjects hospitalized with Staphylococcus Aureus bacteremia.~A phase I of the trial is a dose escalation study intended to assess the possible toxicity and to determine the recommended phase 2 dose of the study drug (514G3). Eligible subjects will be randomized (3:1) to receive single dose of 514G3 (Either 2, 10, 40 mg/kg) plus standard IV antibiotic therapy or single dose of placebo plus standard IV antibiotic therapy.~A phase 2 of the trial is designed to assess the preliminary efficacy through randomization of subjects in two arm groups i.e. a single dose of 514G3 administered at the RP2D with standard IV treatment or placebo plus standard IV treatment.~Eligible subjects will be randomized (2:1) to receive either a single dose of 514G3 plus standard IV antibiotic therapy versus a single dose of placebo plus standard IV antibiotic treatment."|t|f|t|f
33805032|NCT02040363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34104954|NCT06284564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104955|NCT05023902|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The volunteers were screened for eligibility and signed an informed consent form. Then, they were randomized to Pilates and NIA groups using the sealed envelope method. An identification number (i.e., 1-54) was allocated to each volunteer. Each number was written on a separate piece of folded white paper and placed into an opaque envelope. The randomization process was performed by picking a random number from the sealed envelope to allocate each volunteer to either the intervention or control group.|f|f|t|f
34104956|NCT00188032|RANDOMIZED|PARALLEL||||NONE||||||
34104957|NCT06689670|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single-Arm, Open-label, Single-Center Clinical Study||||
34104958|NCT00594308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104959|NCT05905198|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34104960|NCT05385523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104961|NCT04194697|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34104962|NCT03833583|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
34104963|NCT01627197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104964|NCT00993473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104965|NCT02191995|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34104966|NCT01337505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104967|NCT00323986|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34104968|NCT03538821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34104969|NCT01331512|||||OTHER|||||||
34104970|NCT04870554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be under sedation. The outcome assessor for delirium (primary outcome) is not blinded. Assessors rating the sleep quality (secondary outcome) will be blinded.|Patients will be randomly assigned to one of two treatment groups: standard continuous feeding or timed feeding.|t|f|f|f
33805033|NCT04941703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Blinded, single-center, placebo-controlled randomized clinical trial|t|t|t|f
33805034|NCT02979184|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805035|NCT05396638|NA|SINGLE_GROUP||OTHER||NONE||The contingency management (CM) procedure will consist of a four-week abstinence-based incentive program. At the initial visit, participants will be instructed to refrain from using cannabis for the next month and abstinence will be monitored by urine and saliva drug tests. Participants will be paid at each study visit for attendance and abstinence. CM payment rates for abstinence will revert to the initial payment level following a missed study visit or if THC levels rise or are detected by saliva drug screen, respectively.||||
33805036|NCT03411174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805037|NCT04797767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805038|NCT02101138|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805039|NCT02310152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805040|NCT01614405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805041|NCT00004831|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33805042|NCT00012805|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33805043|NCT00951691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805044|NCT02260024|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839118|NCT05286125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33839119|NCT05570604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A blinded and trained tester will perform data collection and neuropsychological testing at two time points|The purpose of this translational research is to conduct a home based single-blind, randomized controlled trial to test the feasibility, satisfaction, and preliminary efficacy of cognitive training compared to attention control in breast cancer survivors (BCS) as well as to explore potential biomarkers of intervention effects.|f|t|f|f
34104971|NCT04202094|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||"This study is a prospective comparative interventional cohort study.~The fertility status of young adults (≥18 years) cured of childhood cancer or hematological disorders for which they received high-risk gonadotoxic treatment (with an ≥80% risk of later fertility problems) during childhood will be compared between patients who did and those who did not undergo a testicular tissue biopsy procedure at a young age as a fertility preservation strategy in order to identify a possible association between the biopsy procedure (which is performed to harvest testicular tissue) and the later fertility outcome.~Their fertility status will also be compared to the reproductive health of spontaneously conceived young adults that has already been published (Belva F et al., 2016/2017/2019)."||||
34028582|NCT04234971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"To prevent surgeon bias in operative time and therefore cost, randomization assignments will be concealed at the beginning of surgery. The surgeon will start with closure of the oronasal fistula first. Once that is completed, the envelope will be opened and reveal the type of bone graft selected. The surgeon will then either harvest the additional ICBG or open the packets for the DBM/BMP and pack the selected type of bone into the alveolus.~Outcomes assessor including orthodontist and clinical research evaluator will be blinded to treatment arms."||f|f|f|t
34104972|NCT04873193|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34028583|NCT05282563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34104973|NCT06152055|||COHORT||RETROSPECTIVE|||||||
34104974|NCT00258570|||COHORT||OTHER|||||||
34104975|NCT04003389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104976|NCT05559606|||COHORT||PROSPECTIVE|||||||
34104977|NCT05918146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34104978|NCT05579522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34104979|NCT05544396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104980|NCT03487458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104981|NCT06689332|NA|SINGLE_GROUP||OTHER||NONE||||||
34104982|NCT02529956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34104983|NCT06687863|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Data analysis will be carried out by evaluators who do not know the allele of the participant's genetic polymorphism|||||
34104984|NCT06673953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104985|NCT06691789|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34104986|NCT06524648|||COHORT||PROSPECTIVE|||||||
34104987|NCT02333474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34104988|NCT06421454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34104989|NCT01905085|||COHORT||PROSPECTIVE|||||||
34104990|NCT01641055|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34104991|NCT03946930|||COHORT||PROSPECTIVE|||||||
34104992|NCT06642779|||CASE_CONTROL||PROSPECTIVE|||||||
34104993|NCT05014126|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled, prospective, single arm, pre-post intervention study||||
34104994|NCT02430714|||OTHER||PROSPECTIVE|||||||
34104995|NCT04412239|NA|SINGLE_GROUP||OTHER||NONE||||||
34104996|NCT04245605|||COHORT||RETROSPECTIVE|||||||
34104997|NCT04482621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized double blind placebo controlled Phase 2 trial with a 12 patient lead-in to evaluate safety, prior to full enrollment to an additional 28 patients (for a total of 40 patients) to assess efficacy of decitabine in the treatment of critically ill patients with COVID-ARDS. The patients will be randomized in a 1:1 ratio to receive standard of care plus Decitabine or standard of care plus saline based placebo.|t|f|t|f
34104998|NCT05973656|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34104999|NCT02800746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105000|NCT00311831|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34105001|NCT00636337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105002|NCT05211960|NA|SINGLE_GROUP||TREATMENT||NONE|All participants will be recruited knowing that a mindfulness app will be provided.|||||
34105003|NCT03376412|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking.|The study will be a prospective, single-center, open label clinical trial where a maximum of 60 consecutive non-dominant eyes are implanted with the Raindrop Near Vision Inlay.||||
34105004|NCT05281653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person who evaluates the athletes before and after the training is blind to the study groups and training.|Randomized controlled single-blind study|f|f|f|t
34105005|NCT02115672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105006|NCT06005636|||COHORT||PROSPECTIVE|||||||
34105007|NCT03454152|||COHORT||CROSS_SECTIONAL|||||||
34105008|NCT06569433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The following criteria for inclusion and exclusion of participants have been established:~Inclusion criteria:~* Patients aged between 18 and 40 years.~* Patients with chronic or acute knee tendinosis.~* Patients with pain or functional limitation~Exclusion criteria:~* Patients with any contraindication to treatment.~* Patients with a history of recent knee surgery or serious injury~* Who present neurological pathologies~* Who are using other physiotherapy techniques~Prior to registration each participant must undergo a physical assessment, including a medical history check and provide information on neurological and trauma pathologies. Those who meet the criteria will be assigned to one of the two study groups."|t|f|f|f
34028584|NCT04352725|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34028585|NCT02884804|||COHORT||PROSPECTIVE|||||||
34105009|NCT02862262|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|All eligible specimens (de-identified remnants) enrolled are tested using both the investigational device as well as the reference method.|"The study is comprised of three arms:~Arm 1: Blinded, Prospective Arm Primary arm comprised of prospectively collected, de-identified, left-over nasopharyngeal swab specimens.~Arm 2: Blinded, Pre-selected Arm Because both B. pertussis and B. parapertussis exhibited low prevalence rates in the prospective study cohort, the prospective sample set was supplemented with banked (pre-selected) positive specimens collected at selected sites.~Arm 3: Contrived Specimens Because the number of B. parapertussis positive clinical specimens tested in Arm 1 and Arm 2 of the study was insufficient for accurate estimate of positive percent agreement (PPA) for this target, fifty (50) contrived specimens spiked with relevant B. parapertussis strains at different levels were also prepared. The analyte concentrations covered clinically relevant titers."||||
34105010|NCT01906138|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028586|NCT03862924|RANDOMIZED|PARALLEL||OTHER||NONE||Once the baseline interview is complete, the study coordinator, who is not involved in conducting assessments, will randomize eligible participants to either of two study conditions. A computerized urn randomization will be used to ensure the groups are balanced on gender and Fagerström Test of Cigarette Dependence (FTCD) score, (0-5 low; 6-10 high). Participants will be randomized to an active condition (in which they will be provided with the ECs) or the standard condition (in which they will continue to smoke their usual brand). All participants will receive a daily diary and will be asked to record daily how many CCs they smoke, how many EC cartridges they use, or any use of other tobacco products (i.e. cigars, cigarillos).||||
34028587|NCT02876718|||COHORT||PROSPECTIVE|||||||
34028588|NCT04538586|||COHORT||CROSS_SECTIONAL|||||||
34028589|NCT00098423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028590|NCT05906524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34028591|NCT00610246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028592|NCT03744299|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34028593|NCT05793970|||COHORT||PROSPECTIVE|||||||
34028594|NCT03404739|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Sequentially numbered, opaque sealed envelopes(SNOSE) will be the method to conceal allocation from the study team.|single- versus multiple-dose antimicrobial prophylaxis|t|t|t|f
34028595|NCT03461601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Vaginal flushing with 10 ml saline was performed in the control group|intrauterine injection of human chorionic gonadotropin before intrauterine insemination (IUI) compared to IUI alone|t|f|f|f
34028596|NCT02130115|NA|SINGLE_GROUP||||NONE||||||
34028597|NCT04342195|||CASE_ONLY||CROSS_SECTIONAL|||||||
34028598|NCT04042844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All subjects will be randomized (2:1) to receive either intradiscal BRTX-100 or saline.|t|f|t|f
34028599|NCT05952531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028600|NCT03666273|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34028601|NCT01970774|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34028602|NCT01644383|RANDOMIZED|PARALLEL||||NONE||||||
34028603|NCT03997773|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm parallel design RCT with women with prior GDM as the unit of randomisation comparing a health promotion intervention with a usual care group||||
34028604|NCT04647903|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34028605|NCT05511311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028606|NCT06468241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34028607|NCT01403220|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723489|NCT04782531|NA|SINGLE_GROUP||OTHER||NONE||||||
34028608|NCT01899612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028609|NCT03893019|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34028610|NCT03266939|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34028611|NCT04862910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded||t|f|f|t
34028612|NCT01756430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028613|NCT04815928|||COHORT||PROSPECTIVE|||||||
34028614|NCT02438592|||COHORT||OTHER|||||||
34028615|NCT04677101|||CASE_CONTROL||PROSPECTIVE|||||||
34028616|NCT01019668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028617|NCT00001021||||PREVENTION||DOUBLE||||||
34028618|NCT00625872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028619|NCT03322345|||COHORT||PROSPECTIVE|||||||
34028620|NCT01831102|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105011|NCT00151073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028621|NCT05333705|NA|SINGLE_GROUP||TREATMENT||NONE||Study Arms: Experimental arm: Cytokine Arm Infusions of Natural Killer (NK) cells||||
34028622|NCT02945969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028623|NCT03168334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028624|NCT02322203|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This novel pilot study will be carried out at the NIH Clinical Center outpatient clinic 7 in healthy volunteers. We will screen up to 200 subjects, males and females, to obtain at least 32 completed studies. Participants will be recruited via flyer, and/or recruitment advertisement placed in the NIH Record, the NHLBI Recruitment website, the Clinical Center News and by email/listserv.||||
34028625|NCT06140446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT||||
34028626|NCT05131828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028627|NCT00359801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028628|NCT01308502|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028629|NCT02297256|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34028630|NCT01915745|RANDOMIZED|PARALLEL||||NONE||||||
34028631|NCT06632964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028632|NCT02153164|||COHORT||PROSPECTIVE|||||||
34028633|NCT04108026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028634|NCT03915405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028635|NCT06185881|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participants and both assessors will be blind to the type of material used|split mouth|t|f|f|t
34028636|NCT00790348|||||CROSS_SECTIONAL|||||||
34028637|NCT02918812|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34028638|NCT03912935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only participant is masked from knowing the assigned group|"* All patients undergoing elective surgery under general anaesthesia from age 18 years old to 75 years old selected.~* Written informed consent will be obtained prior to enrolment.~* Randomisation into 2 groups (BUHE and sniffing position) will be done via computer generated sequences. Subsequently, will be placed into sealed envelopes.~* The next available envelope will be selected and open for that particular patient at the time of enrolment."|t|f|f|f
33723490|NCT06104358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028639|NCT05746832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028640|NCT02497911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028641|NCT06105723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34028642|NCT03410394|||COHORT||PROSPECTIVE|||||||
34028643|NCT00210431|||OTHER||PROSPECTIVE|||||||
34028644|NCT02565511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105012|NCT05957094|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant will not know whether they are receiving placebo or SSRI. The primary investigator will also no know if the participant is receiving placebo or SSRI|Participants will complete all interventions (control and experimental) following drug washout|t|f|t|f
34028645|NCT00420732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105013|NCT04602598|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study in symptomatic subjects with histopathologically confirmed IgG4-related disease affecting the submandibular and/or lacrimal glands. Ten subjects will be included in the study. All eligible subjects will receive zanubrutinib 80mg BID over a period of 24 weeks and will be followed up for an additional 8 weeks after the last dose.||||
34028646|NCT04427072|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants randomized to docetaxel treatment will be eligible to crossover to receive capmatinib treatment after blinded independent review committee (BIRC)-confirmed, RECIST 1.1- defined disease progression.||||
34105014|NCT03510533|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Eating disorders compared to healthy volonteers||||
34028647|NCT03998397|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34028648|NCT02022878|||COHORT||RETROSPECTIVE|||||||
34028649|NCT02031419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105015|NCT06465966|NA|SINGLE_GROUP||OTHER||NONE||||||
34105016|NCT05996653|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028650|NCT01153295|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34105017|NCT06480266|||COHORT||PROSPECTIVE|||||||
34028651|NCT01199380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105018|NCT05209295|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105019|NCT02460939|||CASE_ONLY||RETROSPECTIVE|||||||
34105020|NCT06689423|||CASE_ONLY||PROSPECTIVE|||||||
34105021|NCT02252510|||||PROSPECTIVE|||||||
34028652|NCT05013047|||OTHER||RETROSPECTIVE|||||||
34105022|NCT00000726||||TREATMENT||NONE||||||
34105023|NCT04968600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
34105024|NCT06527872|||COHORT||PROSPECTIVE|||||||
34028653|NCT04004585|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028654|NCT06253806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34028655|NCT04769531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After enrolling the patient, informed consent will be taken from each taken. All patients will be blinded to the type of information to avoid biasness.|"It is a randomized control trial. Total 66 patients will be carry out, 22 in each of the three groups that include 2 patients as a drop out per group.~There will be two interventional groups and one control group. Treatment will be allocated normally using random number sheet generated by statistician."|t|f|f|f
34028656|NCT02352688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028657|NCT00486525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34028658|NCT01362543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028659|NCT01078870|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34028660|NCT00822692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028661|NCT00717288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028662|NCT03000478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028663|NCT06343220|||COHORT||CROSS_SECTIONAL|||||||
34028664|NCT00594373|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34028665|NCT01983241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028666|NCT06583057|||COHORT||RETROSPECTIVE|||||||
34028667|NCT03277066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028668|NCT02904863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028669|NCT00018538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028670|NCT01887496|||CASE_ONLY||PROSPECTIVE|||||||
34028671|NCT05861297|RANDOMIZED|FACTORIAL||TREATMENT||NONE||comparsion between five groups||||
34028672|NCT03180645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028673|NCT04752865|||OTHER||RETROSPECTIVE|||||||
34028674|NCT03564392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723491|NCT01907477|NA|SINGLE_GROUP||OTHER||NONE||||||
34028675|NCT02765763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028676|NCT04859452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028677|NCT04628091|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028678|NCT04079465|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled parallel study||||
34028679|NCT00369486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028680|NCT00366366|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028681|NCT03822104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34028682|NCT03798925|||CASE_ONLY||OTHER|||||||
34028683|NCT01108783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028684|NCT04975204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028685|NCT02871323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028686|NCT04641052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028687|NCT03456141|||CASE_ONLY||PROSPECTIVE|||||||
34028688|NCT00905671|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028689|NCT04588493|||CASE_ONLY||RETROSPECTIVE|||||||
34028690|NCT00031148|RANDOMIZED|||PREVENTION||DOUBLE||||||
34028691|NCT05835674|||COHORT||PROSPECTIVE|||||||
34105025|NCT06216262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105026|NCT04859231|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34105027|NCT04348630|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant identifier and experimental arm will be blinded from investigator responsible for analyzing outcomes in the cardiovascular battery (see detailed description).||f|f|f|t
34105028|NCT00417287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028692|NCT06471855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm, parallel, randomized prospective quasi-experimental study design||||
34028693|NCT01776255|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34028694|NCT00396565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805045|NCT04259047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This RCT will be double-masked in that all participants will receive an active intervention, and investigators and outcome assessors will be masked to treatment assignment. To maintain masking: 1) the Outcome Assessor will be masked to treatment assignment; 2) interventionists who deliver study treatments gather no outcome data; and 3) only primary care physicians (PCPs) who treat participants in the active group\[, and the Study Coordinator, Project Director, and Statistician will be unmasked. Because the 2 interventions (DREAM and EUC) share identifying characteristics (i.e., in-home delivery by CHWs, same educational materials, same visit frequency), the risk of unmasking is reduced. At each outcome assessment, the Outcome Assessor will instruct participants on the purpose and importance of maintaining masking, and will request that they reveal no information about their study participation.||f|f|t|t
33805046|NCT06581406|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will consist of 3 periods: Screening, Treatment, and Follow-up.~* 28-day Screening Period~* Treatment Period: Tumor measurements will be assessed every 12 weeks (Q12W)~* Safety Follow-Up - up to 100 days after the last dose of study drug.~* Efficacy Follow-Up,Tumor measurements by serial radiographic imaging Q12W~* Survival Follow-Up, survival information will be collected every 3 months for a minimum of 3 years"||||
33805047|NCT01511159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805048|NCT00140400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837706|NCT05676970|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We propose to use a individually randomized group treatment trial design with a baseline survey to assess social determinants of health, COVID-19 experience and knowledge, baseline demographic information and vaccine hesitancy as relates to potential COVID-19 vaccine uptake in our target population. We will then randomize participants in a 1:1 fashion to a vaccine intervention arm and a control arm matched baseline vaccine hesitancy score. Given this is an IRGT (Individualized Randomized Group Treatment) trial design, a priori matching should assist in preventing a Type I error. Individuals will then complete 8 individual or group based behavioral health interventions via a Telehealth model conducted by a Clinical Pharmacist.||||
34028695|NCT01157988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028696|NCT04712279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028697|NCT02058329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34028698|NCT00313079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028699|NCT05015686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33837707|NCT02364596|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028700|NCT04204434|||COHORT||PROSPECTIVE|||||||
34028701|NCT00948324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028702|NCT04513366|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028703|NCT00649779|RANDOMIZED|CROSSOVER||||NONE||||||
34028704|NCT01960335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028705|NCT00626457|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34028706|NCT05545124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028707|NCT04563182|||OTHER||CROSS_SECTIONAL|||||||
34028708|NCT04000282|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34028709|NCT02886780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028710|NCT02407639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34028711|NCT06632275|||OTHER||PROSPECTIVE|||||||
34028712|NCT02291640|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028713|NCT06425965|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34028714|NCT06228014|||COHORT||PROSPECTIVE|||||||
34028715|NCT04221230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028716|NCT05439967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805049|NCT03246724|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The subject and their entire medical team (including the anesthesiologist and surgeon) will all be masked to the subject's randomized intervention group. The randomization groups will be assigned by the statistician who will be unmasked. All medications will be provided to the medical team on the day of the procedure completely masked. The clinical research coordinator, the clinical research assistant, and the pharmacy will be unmasked to the intervention group. Any member of the medical team can be unmasked at any time after the intervention is administered in the case of an emergency resulting in a serious adverse event or an unanticipated problem.|"Interventions: triazolam oral sedation with sodium chloride 0.9% IV placebo or microcrystalline cellulose oral placebo with midazolam IV sedation~Subjects will be randomized (1:1) to one of the two study arms listed above. On the day of surgery, the subject, anesthesiologist/CRNA, and surgeon will be blinded to the treatment assignment. The anesthesiologist/CRNA or pre-operative nurses will administer the blinded oral medication approximately 30 minutes before the procedure beings. The anesthesiologist/CRNA will administer the blinded IV medication approximately 5 minutes before the procedure begins. At the completion of the procedure, the anesthesiologist/CRNA and the surgeon will complete a satisfaction survey. The subject will then return within 2 days for their first post-operative clinical visit and complete a satisfaction survey."|t|t|t|f
33805050|NCT05996627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be conducted in a double-blinded fashion||t|f|t|f
34028717|NCT05911061|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34028718|NCT00125671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028719|NCT00719615|||CASE_CONTROL||PROSPECTIVE|||||||
34028720|NCT01325844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34028721|NCT02319278|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028722|NCT03044821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028723|NCT05865548|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arm study comparing standard of care with or without aspirin||||
33723492|NCT02950077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723493|NCT03365817|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment||||
33805051|NCT00116649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805052|NCT01834846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805053|NCT03842085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805054|NCT02696161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805055|NCT05631808|||COHORT||PROSPECTIVE|||||||
33805056|NCT06509412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805057|NCT02134262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805058|NCT06193343|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, longitudinal pre-test post-test study design||||
33805059|NCT06425250|||COHORT||RETROSPECTIVE|||||||
33805060|NCT00042965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805061|NCT06517771|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||randomized controlled study|t|t|f|t
33805062|NCT03293914|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an implementation trial being conducted in a real-world clinical setting in which masking is not appropriate.|||||
33805063|NCT00142636|||DEFINED_POPULATION||PROSPECTIVE|||||||
33805064|NCT01854151|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33805065|NCT05738369|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The investigated supplements were provided to the participants by a research assistant. The participants in the negative control group, however, were not blinded because they did not receive any supplements|Three arm parallel design|t|t|t|t
33805066|NCT02036177|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33805067|NCT03790215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805068|NCT02583113|||COHORT||RETROSPECTIVE|||||||
33805069|NCT04010136|RANDOMIZED|PARALLEL||SCREENING||NONE||"The GPs (fellows and specialists) from Center Healthcare Administrative Region will be invited to take part in this trial. The invitations will be conducted with the help of the Center Healthcare Administrative Region and by spreading the invitation in some general practice professionals' mailing lists and online platforms.~First, GPs will be contacted and those who accept to participate will be randomized into one of the four-harm study groups - 1. Control Group, 2. Identification tool group, 3. Standard PC training, 4 - Clinical cases based PC training.~The accuracy on the identification before and after intervention will be compared within each group and between the four groups using a clinical record based identification tool (CCB-PCId).~A PC expert panel will build a tool, clinical record based, to evaluate the accuracy of palliative care needs identification."||||
34028724|NCT06551662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028725|NCT01504997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028726|NCT05800158|||CASE_ONLY||PROSPECTIVE|||||||
34028727|NCT03324295|||OTHER||CROSS_SECTIONAL|||||||
34028728|NCT02535286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723494|NCT02742012|||COHORT||PROSPECTIVE|||||||
33723495|NCT05886296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33723496|NCT01888146|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33723497|NCT03575312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The subjects are exposed to 250 µg of enrofloxacin on three different dosing days that are separated by at least 7 days. On the first dosing day, enrofloxacin is administered via the dermal route. On the second dosing day, enrofloxacin is administered via inhalation of 5 mL solution in a concentration of 50 µg/mL by an ultrasonic nebulizer. On the third dosing day, enrofloxacin is administered orally as a 20 mL solution in a concentration of 12.5 µg/mL.||||
33723498|NCT00629837|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33723499|NCT03543592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723500|NCT05658679|||CASE_CONTROL||RETROSPECTIVE|||||||
33723501|NCT06462651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723502|NCT05601856|||COHORT||PROSPECTIVE|||||||
33805070|NCT04653506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary investigator will be the only one to have the information about envelopes contain|"* Women participating in the study will receive postpartum analgesia immediately while reporting pain requiring analgesia (NRS \<3)~* Pain Reliefs will be given in a double-blind mechanism, in closed envelopes~* The envelopes will contain Paracetamol 1000 mg or Ibuprofen 400 mg~* Women participating in the study will answer a questionnaire to characterize the pain while taking the pain relief (time 0), an hour later (time 1), 4 and 6 hours later (time 4 and time 6)"|t|t|f|f
33805071|NCT03904069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805072|NCT02295189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805073|NCT05220501|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All three arms will be active at the same time and subjects will be randomized to one arm.||||
33805074|NCT02118870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805075|NCT00503906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805076|NCT03555175|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33805077|NCT05170074|||COHORT||PROSPECTIVE|||||||
33805078|NCT04327752|||CASE_ONLY||PROSPECTIVE|||||||
33805079|NCT03637296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective cohort with comparison group||||
33805080|NCT04489355|||OTHER||PROSPECTIVE|||||||
33805081|NCT03642366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33805082|NCT05927623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physical measures including balance, muscle strength, and gait speed will be recorded by an outcome assessor blind to group assignment.|Assessor-blind parallel group multicenter pilot RCT of 12 months duration.|f|f|f|t
33805083|NCT01911767|||COHORT||PROSPECTIVE|||||||
33805084|NCT02809599|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33805085|NCT01251705|||COHORT||PROSPECTIVE|||||||
33805086|NCT04553549|||COHORT||PROSPECTIVE|||||||
33805087|NCT05420480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805088|NCT03279406|||CASE_ONLY||PROSPECTIVE|||||||
34028729|NCT05094661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028730|NCT04876105|||OTHER||CROSS_SECTIONAL|||||||
33805089|NCT06285422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805090|NCT02127749|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33805091|NCT05260398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Enrolled family random study cohort assignment will be masked from school teachers, who will complete outcome measure questionnaires about enrolled child participants at baseline and follow-up.||f|f|f|t
33805092|NCT05957198|||COHORT||RETROSPECTIVE|||||||
34028731|NCT03146429|||COHORT||RETROSPECTIVE|||||||
34028732|NCT02184767|NA|SINGLE_GROUP||OTHER||NONE||||||
34028733|NCT00768534|||COHORT||PROSPECTIVE|||||||
34028734|NCT03356197|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34028735|NCT04619212|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 different groups, where 1 group does SoC (comparator device), the second uses the new device.||||
34028736|NCT05871554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028737|NCT00663026|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028738|NCT01632631|||CASE_CONTROL||PROSPECTIVE|||||||
34028739|NCT04370834|NA|SINGLE_GROUP||OTHER||NONE||||||
34028740|NCT03566758|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34028741|NCT02234076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028742|NCT00595309|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34028743|NCT00559533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028744|NCT03594760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028745|NCT02268877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open Label|||||
33723503|NCT03948256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention with two arms with different time course it is not possible to mask patients nor investigators or care providers|1:1 randomisation|f|f|f|t
33723504|NCT00136305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723505|NCT04977076|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, multicenter, 1:1 randomized, investigator initiated study.||||
33805093|NCT01670474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805094|NCT05403476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805095|NCT04751799|RANDOMIZED|PARALLEL||OTHER||NONE|No masking possible due to the nature of the intervention (using a virtual reality headset vs. not using a VR headset)|Prospective randomized open interventional study||||
33805096|NCT06698354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805097|NCT03948438|||COHORT||PROSPECTIVE|||||||
33805098|NCT01466049|||COHORT||PROSPECTIVE|||||||
33805099|NCT05080413|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is a single group pre-post intervention comparison study.||||
33805100|NCT04436250|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|The research pharmacist prepares the syringe with a placebo or active drug (group 1 with 0.2mg/kg or group 2 with 0.4 mg/kg of S-Ketamine) and anonymizes it before giving it to care provider.|"Patients will be randomized in a 2:1 ratio (S-ketamine : placebo) per block of 15 patients sequentially into the first 2 groups, one with placebo and one with first dose of S-Ketamine Low Dose (0.2mg/kg).~A second group will receive S-Ketamine High Dose (0.4 mg/kg) with the same randomized ratio (2:1)."|t|t|t|f
33805101|NCT05237466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805102|NCT02523222|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805103|NCT02564536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805104|NCT03134300|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||2 groups for the same intervention (AT), one from low SES, one from high SES. Cytokine draw periprocedurally, and 3 weeks post procedure||||
33805105|NCT02460549|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33805106|NCT03479411|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study has 3 parts: 1) Single Ascending Dose Escalation and 2) Multiple Ascending Dose Escalation to be conducted in Normal Healthy Volunteers and 3) A two-period crossover study of single doses of PUR1900 and Sporanox in Adults with Asthma||||
33805107|NCT03948542|||COHORT||RETROSPECTIVE|||||||
33805108|NCT06477588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805109|NCT05353894|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837708|NCT02991924|||CASE_ONLY||PROSPECTIVE|||||||
33837709|NCT00126659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837710|NCT03687008|NA|SINGLE_GROUP||TREATMENT||NONE||one group, pre- post-intervention design||||
33837711|NCT00211302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837712|NCT00304382|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33837713|NCT01452568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837714|NCT00106301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837715|NCT02830282|||COHORT||PROSPECTIVE|||||||
33837716|NCT00582725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837717|NCT06221501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837718|NCT05584358|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33837719|NCT04259359|||COHORT||PROSPECTIVE|||||||
33837720|NCT03028597|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33837721|NCT01398904|||CASE_CONTROL||PROSPECTIVE|||||||
33837722|NCT01081886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837723|NCT03046264|||COHORT||CROSS_SECTIONAL|||||||
33837724|NCT03346005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837725|NCT05580835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with an imaging diagnosis of hepatocellular carcinoma and candidates to a liver transplant or surgical resection will be submitted to a novel imaging scan, PET / MRI with PSMA. The role of this imaging scan on diagnosis and staging of HCC will be evaluated.||||
33837726|NCT04259697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A controlled study||||
33837727|NCT00545649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33837728|NCT00068172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837729|NCT00746304|||COHORT||RETROSPECTIVE|||||||
33837730|NCT03655457|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33837731|NCT06058715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837732|NCT01234883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837733|NCT05811598|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups for the 2 lighting lever (0.37mW and 0.6mW）for 2 groups of ages (3\~4 years old and 5\~6 years old)||||
33837734|NCT04558892|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837735|NCT01913145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837736|NCT01986088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837737|NCT05633069|||COHORT||RETROSPECTIVE|||||||
33837738|NCT04161651|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33723506|NCT05836064|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|A clinical coordinator will be responsible for patients' randomization. The endoscopist will perform the endoscopy by assessing primary and secondary endpoints, blinded to the patient's study group.|The following is a cross-section simple-blind and single-center controlled randomized trial. Two groups will be established: the GastroBot-assisted bowel preparation (GB-group) and the conventional-assisted bowel preparation (C-group) group. Patients from both study groups will receive the same type of preparation with polyethylene glycol in split dose, establishing the intake time according to three-time segments (8-11 am, 11-2 pm, 2-4 pm).|f|f|t|t
33723507|NCT01577147|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105029|NCT06476392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participating patients, investigators, outcome assessors and statistical analysts are all blinded to treatment allocation. All patient reported data will be filled in by the patient via an online questionnaire using REDCap. An assessor blinded to study treatment will perform all protocol specific objective outcome assessments at baseline and 6 weeks follow-up. Unblinding will first take place after the primary analysis of the data has taken place. A data manager, otherwise, not involved in the study, will prepare the randomization list, using a computerized algorithm in REDCap.||t|t|t|t
34105030|NCT04693377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805110|NCT05837533|NON_RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Participants will not be informed whether they will be allocated to the control or intervention group.|During the first half of the study, patients will be assigned to the control group where they will receive information through their usual care from their oncologist during their medical consultation. In the second half of the study, patients will be assigned to the intervention group where they will receive information through the communication model used by their oncologist during their medical consultation. In this way, the contamination of the control group with attention corresponding to the systematized communication model under study will be avoided.|t|f|f|t
33805111|NCT00960141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105031|NCT00435097|||DEFINED_POPULATION||PROSPECTIVE|||||||
34105032|NCT05253651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105033|NCT05519774|||CASE_ONLY||PROSPECTIVE|||||||
34105034|NCT00488293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805112|NCT00435318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805113|NCT05224765|||COHORT||PROSPECTIVE|||||||
34105035|NCT00842803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105036|NCT05870657|||COHORT||RETROSPECTIVE|||||||
33805114|NCT02000089|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking of the diagnostic test results|Evaluation of the effect of diagnostic tests for pancreatic cancer||||
34105037|NCT06652490|||COHORT||PROSPECTIVE|||||||
33805115|NCT05695469|RANDOMIZED|CROSSOVER||OTHER||NONE||The randomly selected participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). In the first round, group 1 will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes. On the other hand, group 2 will perform the same way as group 1, but without ResuGlove. After 30 minutes of recovery, in the second round, they will crossover. Ultimately, we will ask participants to fill out the SUS questionnaire.||||
33805116|NCT04915261|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The trial is a single centre non-inferiority cluster crossover trial. Arm restriction protocol will cross over every 8 months with a one month run-in then 7 months of data collection.||||
33805117|NCT06474143|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Polysomnography results not available to device|Each patient will wear the device and polysomnograph at the same time||||
34105038|NCT03263390|||CASE_ONLY||RETROSPECTIVE|||||||
34105039|NCT06689046|||COHORT||RETROSPECTIVE|||||||
33805118|NCT01183832|||COHORT||PROSPECTIVE|||||||
34105040|NCT06125301|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105041|NCT05489458|||COHORT||RETROSPECTIVE|||||||
34105042|NCT03850301|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The people who undertake the analysis of the blood test will be blind about whether the blood sample came from an MS patient or a healthy volunteer.||f|f|f|t
34105043|NCT05825001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723508|NCT01207531|||CASE_CONTROL||PROSPECTIVE|||||||
33723509|NCT01329094|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33723510|NCT02984033|||COHORT||PROSPECTIVE|||||||
33723511|NCT02392962|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33723512|NCT00457509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33723513|NCT00878709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723514|NCT03830554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||96 CHD participants were approached to participate in this RCT. out of those, 22 participants reported good sleep quality (PSQI SCORE \<5), their participation finished at phase one. The rest 74 participants reported poor sleep quality (PSQI score =\>5) were randomly assigned either to intervention or control group.||||
33723515|NCT05918679|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33723516|NCT01733407|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33723517|NCT04087187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The following treatments will be given in crossover design:~* Treatment A: AZD5718 Dose A tablet~* Treatment B: AZD5718 Dose B tablet~* Treatment C: AZD5718 Dose C tablet~There will be 6 arms consisting of all possible treatment sequences. The treatment sequence per arm will be:~Arm1: ABC Arm2: ACB Arm3: BAC Arm4: BCA Arm5: CAB Arm6: CBA"||||
33805119|NCT06475248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105044|NCT03813121|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|single-blind||t|f|f|f
34105045|NCT06641440|RANDOMIZED|PARALLEL||TREATMENT||NONE||25 mg prednisone plus 75 microgram levothyroxine daily 75 micrograms levothyroxine daily||||
34105046|NCT02392728|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34105047|NCT03752372|||COHORT||PROSPECTIVE|||||||
33805120|NCT01968967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028746|NCT03065946|||COHORT||PROSPECTIVE|||||||
33723518|NCT04800211|RANDOMIZED|PARALLEL||OTHER||NONE||This research study utilized a parallel-group, open-label, controlled design and was conducted at multiple study sites.||||
34028747|NCT03506256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723519|NCT04267991|||COHORT||PROSPECTIVE|||||||
33723520|NCT03873389|||COHORT||PROSPECTIVE|||||||
33805121|NCT06662968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33805122|NCT05913349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028748|NCT03298217|NA|SINGLE_GROUP||SCREENING||NONE||||||
34028749|NCT00997867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028750|NCT01408602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028751|NCT00004212||||TREATMENT||||||||
34028752|NCT06372184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105048|NCT00489476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105049|NCT03564067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723521|NCT03625245|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double Blind (Participant and Investigator)||t|f|t|f
33723522|NCT05862532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Triple blinded|Two intervention arms and one placebo|t|t|t|t
33837739|NCT02035696|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34028753|NCT01121081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028754|NCT05863169|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33723523|NCT00073359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723524|NCT02092662|||COHORT||PROSPECTIVE|||||||
33837740|NCT04663477|||OTHER||PROSPECTIVE|||||||
33837741|NCT02534571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837742|NCT02204657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837743|NCT06395883|||CASE_ONLY||PROSPECTIVE|||||||
34028755|NCT04172597|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Each treatment cycle is 28 calendar days in duration. This is a basket study with five distinct cohorts. Eligible patients will be enrolled into the five cohorts concurrently based on tumor type and mutational status.||||
34028756|NCT00381433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028757|NCT00633347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028758|NCT04515381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028759|NCT06161779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028760|NCT05695066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Computerized randomization. Randomization outcome distributed via sealed envelopes. Randomization key stored on secure server.|Randomized controlled trial.|f|f|t|t
34028761|NCT06040801|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028762|NCT03032679|||COHORT||PROSPECTIVE|||||||
34028763|NCT01320891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028764|NCT03778684|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028765|NCT01244503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028766|NCT05876637|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34028767|NCT03533309|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34105050|NCT04332770|||COHORT||PROSPECTIVE|||||||
34105051|NCT03403127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105052|NCT01688791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105053|NCT06468943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105054|NCT06570265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105055|NCT04774549|||CASE_ONLY||PROSPECTIVE|||||||
34105056|NCT02187263|||COHORT||PROSPECTIVE|||||||
34028768|NCT02914210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34028769|NCT03223701|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center clinical study. Ten patients will be enrolled and undergo an Transforaminal Lumbar Interbody Fusion (TLIF) with a spinal fixation system and receive Solum IV (Celling Biosciences) and patient's bone marrow concentrate with general fluid concentrate (GFC).||||
34105057|NCT03019263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105058|NCT06675682|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34105059|NCT06687590|||COHORT||PROSPECTIVE|||||||
34105060|NCT05069415|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34105061|NCT04802005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105062|NCT02970058|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34105063|NCT00549211|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34105064|NCT00100893|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34105065|NCT00434941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837744|NCT00656747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105066|NCT02608086|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34105067|NCT00814736|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34105068|NCT01251757|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34105069|NCT04105257|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105070|NCT02457598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105071|NCT03918291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The tests were performed by an experienced examiner who was blind to the group allocation.|Randomized, controlled trial in which the variables were assessed 24 h before and 24 h after a 12-week training program. For the allocation of participants, a 1:1 ratio randomization was performed.|f|f|f|t
34105072|NCT05667558|||CASE_ONLY||PROSPECTIVE|||||||
34105073|NCT06355141|||CASE_ONLY||PROSPECTIVE|||||||
34105074|NCT04951544|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34105075|NCT06433245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The operator, patient and the outcome assessor will be masked to the group allocation||t|t|t|t
34105076|NCT03414437|||CASE_ONLY||OTHER|||||||
34105077|NCT01440751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105078|NCT06501573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105079|NCT03098706|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33723525|NCT02968979|||COHORT||CROSS_SECTIONAL|||||||
33723526|NCT05295927|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34105080|NCT01917032|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105081|NCT04494737|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34105082|NCT01968278|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105083|NCT04812015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34105084|NCT04614662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster Randomized Trial||||
34105085|NCT05314075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105086|NCT02704377|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34105087|NCT06564688|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105088|NCT06673732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single( Participant) Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.||t|f|f|f
34105089|NCT06568393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment was completed by a another therapist.|The study was conducted in 2 groups, one intervention and one control group.|f|f|f|t
34105090|NCT01122745|||||PROSPECTIVE|||||||
33723527|NCT04167007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723528|NCT02540460|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33723529|NCT01837992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723530|NCT02034955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723531|NCT00536250|||COHORT||PROSPECTIVE|||||||
34105091|NCT03199651|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34105092|NCT05051059|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723532|NCT03375021|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|200 mg of drug product or placebo in matching size 0 capsules|A Randomized, Double-Blind, Two-Period Crossover Study|t|t|t|t
33723533|NCT03724409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a sequential early phase 1 study using Storer's phase 1 design B.||||
33723534|NCT00002627||||TREATMENT||||||||
33723535|NCT06418503|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be masked to which intervention they receive (balance training or EMG-biofeedback balance training).||t|f|f|f
33723536|NCT00983151|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33723537|NCT02190812|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33723538|NCT05256667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837745|NCT01647542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837746|NCT01967069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105093|NCT06686615|||COHORT||PROSPECTIVE|||||||
34105094|NCT05931497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomized to one of two WBH groups.|t|f|f|t
34105095|NCT00009542||||TREATMENT||||||||
34105096|NCT02273427|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837747|NCT02418936|||CASE_ONLY|||||||||
33837748|NCT05099432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837749|NCT00218270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837750|NCT05847907|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|patients, centralized radiographic assessor, outcome assessors, and the statistical advisors will be blind to the used implants|Multicenter, randomized controlled trial.|t|f|f|t
33837751|NCT04916951|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33837752|NCT04883177|||COHORT||PROSPECTIVE|||||||
33837753|NCT01144377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837754|NCT02471989|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33837755|NCT05725772|||COHORT||PROSPECTIVE|||||||
33837756|NCT01139788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837757|NCT00529477|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837758|NCT02598219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837759|NCT01502046|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33837760|NCT05941247|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33837761|NCT02034097|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837762|NCT03408405||SEQUENTIAL||DIAGNOSTIC||NONE||"Inclusion Criteria:~1. Patients between the ages of 2-21 years who fail a minimum of 12 weeks of cumulative therapy with prednisone OR one other alternate immunosuppressive agent for treatment of nephrotic syndrome, will be eligible for inclusion. Nephrotic syndrome is defined as: Presence of edema, Edema, UP/C ≥2, ≥300mg/dl or 3+ protein on Albustix, and hypoalbuminemia ≤2.5 g/dL~2. Calculated GFR (eGFR) using modified Schwartz formula of \> 50 mls/min/m2. (Modified Schwartz formula = 0.413 x height (cms) ÷ serum creatinine mg/dL)~3. A clinical or biopsy diagnosis of nephrotic syndrome within the last 3 years prior to enrollment in the study.~4. Renal biopsy (if available) consistent with a diagnosis of Minimal Change Disease, IgM nephropathy, Mesangioproliferative Glomerulonephritis, Primary Focal Segmental Glomerulosclerosis or C1q Nephropathy"||||
33837763|NCT01564277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837764|NCT02614547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837765|NCT05790070|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33837766|NCT05321199|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33837767|NCT06269978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837768|NCT04985695|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33837769|NCT05764135|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||There will be a total of 50 participants enrolled in the study, 25 will be randomized into the intervention group (SCI-Lynx App) and 25 into the control group (usual care).|f|f|t|t
33837770|NCT02671188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837771|NCT05863767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837772|NCT02172001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837773|NCT03882151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator has no access to Epilog Preop result during first case description.|All patients included will have Epilog Preop analysis||||
33837774|NCT00663975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837775|NCT00345098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837776|NCT01618370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837777|NCT06324123|||COHORT||PROSPECTIVE|||||||
33837778|NCT03998449|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33837779|NCT06498284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|matching placebo control|single oral dose escalation study|t|f|t|f
33837780|NCT05170347|||COHORT||PROSPECTIVE|||||||
33837781|NCT04398329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837782|NCT02579590|||OTHER||CROSS_SECTIONAL|||||||
33837783|NCT03850132|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837784|NCT06366412|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33837785|NCT01750970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837786|NCT02912637|||OTHER||CROSS_SECTIONAL|||||||
33837787|NCT01541852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33837788|NCT01475461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837789|NCT05627453|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinding is not possible due to the nature of the intervention|The AAGaTT study, is a monocentric, two-arm, open-label, randomized controlled trial. The superiority of arm-in-arm synchronized gait training will be assessed versus standard walking (i.e., walking side-by-side without gait synchronization).||||
33837790|NCT05494970|||OTHER||PROSPECTIVE|||||||
33837791|NCT02643225|||CASE_CONTROL||PROSPECTIVE|||||||
33837792|NCT02975102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33837793|NCT01043003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837794|NCT05932953|||OTHER||OTHER|||||||
33837795|NCT05311254|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, randomized, prospective, open-label||||
33837796|NCT03063944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837797|NCT03735589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837798|NCT00909831||||TREATMENT||||||||
33837799|NCT05831137|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||In each patient one side of the chest will be treated by standard metod and the second side will be treated with the novel method.|t|f|f|f
33837800|NCT01415934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33837801|NCT03504722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33837802|NCT04584918|||COHORT||OTHER|||||||
33837803|NCT03780777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33837804|NCT02544165|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837805|NCT01727505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837806|NCT06202976|||COHORT||PROSPECTIVE|||||||
33837807|NCT04507568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33837808|NCT05261373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The project is a randomized controlled clinical trial with T2DM and obesity|f|f|f|t
33837809|NCT00508209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837810|NCT00450229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837811|NCT00309647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34028770|NCT01668810|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34028771|NCT03981913|||CASE_CONTROL||PROSPECTIVE|||||||
34028772|NCT01723475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105097|NCT03975179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105098|NCT00107614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105099|NCT05434598|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34105100|NCT06571578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomised control trial (RCT)|f|t|f|f
34105101|NCT05613179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805123|NCT05568381|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label study as participants will be informed immediately of their allocated group by an automatic email and/or text message (dependent on participant preference). Therefore, participants will not be blind to treatment allocation. Self-report questionnaires and cognitive tests will be completed online|"Eligible participants will be randomly allocated (1:1) to the intervention or wait-listed control arm. Participants allocated to the digital CBT-I arm (intervention) will receive the commercially available program. The program provides an online media-rich course of CBT-I delivered by an animated virtual therapist. This will be available for participants for 12 weeks. A wait-listed control of sleep health education will consist of 3 modules delivered biweekly of generalised sleep health information that could be found on the internet."||||
34105102|NCT00266032|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105103|NCT00449852|RANDOMIZED|FACTORIAL||||NONE||||||
33805124|NCT00090519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105104|NCT00048308|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34105105|NCT04472403|||COHORT||RETROSPECTIVE|||||||
34105106|NCT05024214|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105107|NCT06674681|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34105108|NCT02262325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105109|NCT04283279|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105110|NCT00000354||||TREATMENT||||||||
34105111|NCT01834378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105112|NCT06570083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105113|NCT03725527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105114|NCT05438576|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34105115|NCT05406531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34105116|NCT04859686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105117|NCT06023498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Performance-based outcomes measures will be collected by a research coordinator who is masked to participant group assignment.|Randomized controlled clinical trial - feasibility study|f|f|f|t
34105118|NCT06638593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105119|NCT03854149|||COHORT||PROSPECTIVE|||||||
34105120|NCT02719730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105121|NCT00383032|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105122|NCT03442972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single-blinded study with participant blinded to treatment|Participants will be randomly assigned to receive either teduglutide or placebo as a single subcutaneous injection, 1 hour prior to duodenal biopsy|t|f|f|f
34105123|NCT01260311|||COHORT||PROSPECTIVE|||||||
34105124|NCT00506311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105125|NCT04231019|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105126|NCT06197802|||COHORT||PROSPECTIVE|||||||
34105127|NCT06684925|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33805125|NCT00495677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805126|NCT00991549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805127|NCT02848794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805128|NCT03155100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105128|NCT03386058|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open study||||
34105129|NCT02356653|NA|SINGLE_GROUP||TREATMENT||NONE||"Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)~Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched."||||
34105130|NCT01177358|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105131|NCT05555693|||COHORT||PROSPECTIVE|||||||
34105132|NCT00090675|RANDOMIZED|||TREATMENT||DOUBLE||||||
34105133|NCT01019057|||COHORT||PROSPECTIVE|||||||
34105134|NCT06241014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105135|NCT00371163|||CASE_CONTROL||PROSPECTIVE|||||||
34105136|NCT00002046||||TREATMENT||||||||
33805129|NCT00220675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805130|NCT03923452|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researcher who engage in pre-post testing assessment will be blinded to participant allocation.|Randomized block design: 25 randomized to experimental group; 25 randomized to control group in blocks of 8|f|f|f|t
33805131|NCT02848560|||CASE_CONTROL||PROSPECTIVE|||||||
33805132|NCT05074810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33837812|NCT04292587|||COHORT||PROSPECTIVE|||||||
34105137|NCT06611813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105138|NCT03882801|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34105139|NCT03288935|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34105140|NCT05169957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105141|NCT00002101||||TREATMENT||DOUBLE||||||
34105142|NCT04488887|||CASE_CONTROL||PROSPECTIVE|||||||
34105143|NCT02349477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105144|NCT00165607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105145|NCT02618811|||COHORT||PROSPECTIVE|||||||
34105146|NCT00680914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34105147|NCT06682273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105148|NCT03707340|||COHORT||PROSPECTIVE|||||||
34105149|NCT06292325|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105150|NCT06467058|NA|SINGLE_GROUP||OTHER||NONE||convergent validity of a daily activity behavior questionnaire with the actigraph as reference among healthy adults||||
34105151|NCT03662373|||COHORT||PROSPECTIVE|||||||
34105152|NCT00004228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105153|NCT01442571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34105154|NCT06439927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105155|NCT02831335|||COHORT||CROSS_SECTIONAL|||||||
33805133|NCT06121479|NA|SINGLE_GROUP||TREATMENT||NONE||Oral branched-chain amino acid (BCAA) is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.||||
33805134|NCT00663494|||CASE_CONTROL||PROSPECTIVE|||||||
33805135|NCT05166577|RANDOMIZED|PARALLEL||TREATMENT||NONE||A traditional 3+3 dose escalation design followed first by a dose optimization cohort and then by dose expansion with 1:1 randomization to receive nanatinostat and valganciclovir with or without pembrolizumab in Phase 2.||||
33805136|NCT03702777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805137|NCT03927196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805138|NCT00936416|NA|SINGLE_GROUP||SCREENING||NONE||||||
33805139|NCT04255693|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The personnel involved to the assessment of outcomes (changes in diet, changes on endoscopy, changes on symptoms) will be blinded to the results of each other.|"According to the initial assessment, the patients will be allocated to the following subgroups: NERD, Erosive oesophagitis, hypersensitive oesophagus. Each patient will be provided with the standard recommendations on the diet and physical activity according to the initial assessment (calculated energy expenditures, physical activity, physical status and body composition) in addition to the standard drug treatment.~Repeated examinations will be performed to assess the disease status and change (if any) of diet."|f|f|f|t
33805140|NCT05212298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33805141|NCT03959384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient's parents and the doctors/nurses responsible for the patient's care will be blinded. At each center only a physician and a nurse will know and prepare the drug or placebo, being subsequently not clinically involved in the care of that particular patient. The assignment of the type of treatment will be communicated by the Coordinator centre in an individual way and reserved to the researcher attending the patient's bed. The same medical researcher will then take care of administering the treatment assigned to the patient, masking the procedure with appropriate precautions. The preparation and administration of treatment can be done with the help of a nurse who does not have to disclose the type of treatment assigned. Thereafter, such a nurse will not be involved in the patient's care until the conclusion of the study. The patient evaluation will be carried out by other physicians and/or nurses who will not be aware of the type of treatment carried out.|multicenter, double-blind, placebo-controlled, randomized trial|t|f|f|t
34105156|NCT00168285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34105157|NCT05554731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805142|NCT02686398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805143|NCT05166590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blind to their condition up until right before they begin their night of normal sleep or total restriction. Participants will also be blind to the nature of the social-rejection task until the debriefing.|All participants will be randomized to a night of normal sleep (8 hours) or total sleep restriction.|t|f|f|f
33805144|NCT05769816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805145|NCT05834452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805146|NCT01291472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805147|NCT01970553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805148|NCT04216381|||CASE_ONLY||PROSPECTIVE|||||||
33805149|NCT02455765|RANDOMIZED|CROSSOVER||||NONE||||||
33805150|NCT00418795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805151|NCT03886246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805152|NCT02457936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805153|NCT00514306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805154|NCT04885257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study personnel and participants will be blinded to the treatment (placebo vs methylphenidate).|double-blind placebo-controlled trial of methylphenidate. One arm receives placebo and the other receives methylphenidate.|t|t|t|t
33805155|NCT06631183|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants engage with a self-help online tool that provides information on depression and skills to deal with symptoms of depression. Outcomes are self-reported symptoms and behavioral task data collected from participants online. No humans are involved in providing care or outcome assessment of the study; instead, these parts are executed by computer software. Thus, the care provider and the outcome assessor are considered to be masked.||f|t|f|t
34028773|NCT05682612|||CASE_ONLY||PROSPECTIVE|||||||
34028774|NCT05481619|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028775|NCT01667328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028776|NCT01560741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34028777|NCT04584411|||COHORT||PROSPECTIVE|||||||
34028778|NCT05149560|NA|SINGLE_GROUP||TREATMENT||NONE||Single-centre, single-arm, prospective phase II study||||
34028779|NCT06077474|||COHORT||CROSS_SECTIONAL|||||||
34028780|NCT04563715|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized controlled trial||||
34028781|NCT02175901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028782|NCT04631536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34028783|NCT03539263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The trial design is parallel, with two groups (experimental group and control group) and four evaluation sessions at intervals of three weeks (T0wk = baseline, T3wk = intermediate, T6wk=final and T9wk = follow-up).|t|f|t|f
34028784|NCT01437488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028785|NCT03377257|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028786|NCT00256113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028787|NCT05980689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028788|NCT05644197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||the two groups will be followed in parallel, intervention group composed of 50 patients and control group composed of 50 patients, the duration of participation for each patient is 15 months||||
34028789|NCT01098474|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105158|NCT03615274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105159|NCT01110512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34028790|NCT03278691|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028791|NCT03438994|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||"This study will follow the Standard for Reporting Diagnostic accuracy studies (STARD) guidelines"|t|t|t|t
34028792|NCT01670617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028793|NCT01784055|||COHORT||PROSPECTIVE|||||||
34028794|NCT06551181|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data from study participants in China is collected in an observer-blind manner. The study is open labelled for overseas participants.||t|t|t|t
34028795|NCT05884502|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter prospective randomized-controlled||||
34028796|NCT03252730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028797|NCT05696379|||COHORT||RETROSPECTIVE|||||||
34028798|NCT05654311|||COHORT||PROSPECTIVE|||||||
34028799|NCT01838473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34028800|NCT03630380|||OTHER||PROSPECTIVE|||||||
34028801|NCT05035277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Separate endpoint adjudication committee blinded to randomized allocation of patients to treatment groups|Parallel group prospective randomized open blinded endpoint (PROBE) trial|f|f|f|t
34028802|NCT03674398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34028803|NCT00262665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028804|NCT03348618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105160|NCT05848843|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028805|NCT04302012|||CASE_ONLY||CROSS_SECTIONAL|||||||
34028806|NCT01144715|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34028807|NCT06582173|||CASE_ONLY||PROSPECTIVE|||||||
34028808|NCT01442324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028809|NCT05379842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34028810|NCT02432053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028811|NCT01837134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105161|NCT01585207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105162|NCT04903769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive the SMART-PD intervention and will take baseline and follow-up assessments to determine the impact of the program||||
34105163|NCT01724814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105164|NCT06687304|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34105165|NCT00903344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105166|NCT06673836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant will get separate treatment protocols and possible effort will be put to mask the both group about the treatment.|parallal assignment. it will be randomized controlled study,in which probability convenient sampling will be usd.two groups of hearing impaired children will be randomly divided.|t|f|f|f
34105167|NCT05284071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723539|NCT02628795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33723540|NCT05533931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723541|NCT02065960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723542|NCT00860912|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||collagen graft reinforcement|t|f|f|f
33723543|NCT04748315|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33723544|NCT04103762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723545|NCT04215380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723546|NCT00545155|||COHORT||PROSPECTIVE|||||||
33723547|NCT02157142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723548|NCT04930354|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential study model; first dose is 10mg, then 20mg, 40mg, 80mg and 160mg.||||
33723549|NCT03274531|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, cluster randomized, controlled trial||||
33723550|NCT01523548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723551|NCT02028351|||CASE_ONLY||PROSPECTIVE|||||||
33723552|NCT02541747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723553|NCT04919356|||OTHER||PROSPECTIVE|||||||
33723554|NCT05492565|||COHORT||PROSPECTIVE|||||||
33723555|NCT01557296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723556|NCT00180895|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723557|NCT05566210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33723558|NCT04159233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723559|NCT02574130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723560|NCT03071458|||COHORT||RETROSPECTIVE|||||||
33723561|NCT01893554|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33723562|NCT04429893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33723563|NCT01594996|||CASE_ONLY||RETROSPECTIVE|||||||
33723564|NCT02159755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723565|NCT04622839|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants will be masked to the aspect of post-operative pain management being manipulated in this study; investigator and outcomes assessor will be masked to randomization (group assignment) of participants|Participants undergoing shoulder surgery will be randomized into one of the three study arms.|t|f|t|t
33723566|NCT02487238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be aware of which type of enema they have been randomized to receive (fecal microbial enema, or normal saline enema). Patients who were randomized to the normal saline enema will still be eligible to receive the fecal microbial enema when they finish the trial; these patients will know what they are receiving and no longer need masking.|Patients will be randomized to receive either the fecal microbial enema containing healthy donor stool OR the normal saline enema placebo. Patients who receive the normal saline enema placebo may be eligible to still receive the fecal microbial enema when they finish the trial.|t|f|f|f
33723567|NCT00118976|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33723568|NCT01885546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723569|NCT06268561|||COHORT||RETROSPECTIVE|||||||
33723570|NCT06328153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33723571|NCT06389747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and assessors will be blind to different intensity BFR groups.||t|f|f|t
33723572|NCT05793528|||CASE_CONTROL||PROSPECTIVE|||||||
33723573|NCT04879004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105168|NCT06675240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105169|NCT04670315|||OTHER||CROSS_SECTIONAL|||||||
34105170|NCT01922895|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34105171|NCT04938843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105172|NCT00997659|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34105173|NCT03791060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105174|NCT05702489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105175|NCT04702607|||COHORT||PROSPECTIVE|||||||
34105176|NCT02925143|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34105177|NCT06570928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and caregivers will not know what they are using. The investigators evaluating it won't know either. Only a team member who is not part of the investigative team will know.|72 patients will be randomized into 2 groups. One group will receive a product containing CBD/THC and the other group will receive a placebo, a compound with the same characteristics, without an active ingredient.|t|t|t|f
34105178|NCT00010907|RANDOMIZED|||TREATMENT||||||||
34105179|NCT02029612|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34105180|NCT00178139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105181|NCT04214444|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105182|NCT03800901|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The Control arm, who are not offered CME or ABIM MOC credits for their participation, will be unaware of the interventional CME arm. The CME arm will also be unaware of the Control arm. Per recommendations from the IRB, all participants at the end of the study will receive a study debrief letter informing them of the other study arms.|"The study will enroll practicing PCPs in the US. Once eligibility is determined and providers are enrolled in the study, they will be randomized into one of two arms:~* Control: will not be offered CME or ABIM MOC credits for their participation.~* CME Arm: will be offered CME or ABIM MOC credits for their participation. Between the two arms, all other aspects of the study will remain constant.~All providers will then care for 1 Quality IQ patient simulation each week over the course of 6-8 weeks."|t|f|f|f
34105183|NCT02411045|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34105184|NCT05476731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105185|NCT05035628|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This clinical trial is a single-blinded study. Research personnel performing the outcome assessments and investigators will be blinded to group allocation.|parallel assignement with 2 groups (1:1)|f|f|t|t
34105186|NCT01557569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105187|NCT00005839||||TREATMENT||||||||
34105188|NCT00332566|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105189|NCT06673680|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34105190|NCT03597763|||COHORT||PROSPECTIVE|||||||
34105191|NCT06464913|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label design, where the assessors are not blinded to the group allocation.|||||
34105192|NCT06662513|||CASE_ONLY||RETROSPECTIVE|||||||
34105193|NCT00635050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105194|NCT02570425|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105195|NCT05281458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105196|NCT00257933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105197|NCT04704700|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105198|NCT06570837|||COHORT||CROSS_SECTIONAL|||||||
34105199|NCT06683677|NA|SINGLE_GROUP||OTHER||NONE||||||
34105200|NCT06675201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805156|NCT03287713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805157|NCT02796729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105201|NCT01893099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105202|NCT06658236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols, and possible efforts will be put to mask both groups about the treatment.|It will be a randomized control trial in which non-probability convenient sampling will be used. Two groups will be formed in which participants will be randomly divided. Group A will receive upper Extremity proprioceptive neuromuscular facilitation. Group B will receive chest expansion exercises.|t|f|f|f
34105203|NCT03177798|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34105204|NCT02890160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105205|NCT05855993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105206|NCT00055887|RANDOMIZED|||TREATMENT||NONE||||||
34105207|NCT04642079|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34105208|NCT06570876|||COHORT||PROSPECTIVE|||||||
34105209|NCT00934388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34105210|NCT02056951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105211|NCT01883375|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34105212|NCT03373513|RANDOMIZED|PARALLEL||TREATMENT||NONE||Women are randomized to either robotic single site or multi port lapsoscopic hystrectomy||||
34105213|NCT03104920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105214|NCT00987935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105215|NCT01620047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105216|NCT06640699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants will be blind to groups, outcomes assessor will be blind to groups.|randomized controlled study|t|f|f|t
34105217|NCT04787016|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33805158|NCT03411941|||COHORT||RETROSPECTIVE|||||||
33805159|NCT03048994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805160|NCT04772963|||COHORT||PROSPECTIVE|||||||
33805161|NCT00056654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805162|NCT01174797|||COHORT||RETROSPECTIVE|||||||
33805163|NCT05929833|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805164|NCT02629172|||COHORT||PROSPECTIVE|||||||
33837813|NCT06327776|||COHORT||PROSPECTIVE|||||||
34105218|NCT00458705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105219|NCT00385112|||COHORT||PROSPECTIVE|||||||
34105220|NCT06643208|||COHORT||PROSPECTIVE|||||||
34105221|NCT06688656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105222|NCT00638391|||CASE_ONLY||PROSPECTIVE|||||||
33805165|NCT06692296|RANDOMIZED|PARALLEL||TREATMENT||NONE||A monocentric, open-label randomized controlled trial.||||
33837814|NCT02222298|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837815|NCT00558792|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33837816|NCT02872558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33837817|NCT02172911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028812|NCT02620436|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028813|NCT00511641|||CASE_ONLY||PROSPECTIVE|||||||
34028814|NCT04246827|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomly assigned to one of two arms.|t|f|f|f
34028815|NCT02292940|||COHORT||RETROSPECTIVE|||||||
34028816|NCT01534169|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34028817|NCT01860625|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34028818|NCT05412238|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028819|NCT05093829|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34028820|NCT02884570|||COHORT||RETROSPECTIVE|||||||
34028821|NCT04853095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34028822|NCT02158715|||COHORT||PROSPECTIVE|||||||
34028823|NCT06312566|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34028824|NCT04683016|||COHORT||PROSPECTIVE|||||||
34028825|NCT00929279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028826|NCT06013098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028827|NCT00231543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028828|NCT06435442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PART 1: None (Open Label)/ PART 2: Double (Participant, Investigator)|PART 1: A open-label, multiple-dose, single group/ PART 2: A placebo-controlled, randomized, double-blind, multiple-dose, parallel group|t|f|t|f
34028829|NCT04274712|||COHORT||RETROSPECTIVE|||||||
34028830|NCT01495702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028831|NCT01476566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028832|NCT01968564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028833|NCT04550923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Total 180 patients were enrolled, and 180 patients were randomized into either investigational device (non-rigid) group or the control (rigid) group in a 2:1 ratio.||||
34028834|NCT02369198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028835|NCT01695642|||COHORT||PROSPECTIVE|||||||
34028836|NCT03062163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34028837|NCT01609023|||COHORT||PROSPECTIVE|||||||
34105223|NCT06142422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Remote coil change while keeping the patient and investigator blind|interventional, prospective, randomized, double-blind, multicenter study|t|f|t|f
34105224|NCT05597605|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34105225|NCT06048497|||CASE_CONTROL||PROSPECTIVE|||||||
34105226|NCT00662038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105227|NCT02673060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105228|NCT05281575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The co-PIs are masked, as are data analysts. The participants have not been told what arm of the trial they are in, and outcome assessors assigned to integrated nutrition centers have not been told if that center was re-trained or not, though it is conceivable that they could deduce this information.||t|f|t|f
34028838|NCT04085055|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|The patients, pathologists assessing the biopsy specimens and the research staff responsible for follow-up will be blinded to the FNB needle type utilized. Data will also be blinded for statistical analysis.|This is a randomized trial comparing four types of FNB needles and three sampling techniques. Patients will be randomized to one of the four different FNB needles. All patients will then undergo FNB using the specified needle and all three sampling techniques (one pass per technique using the assigned needle).|t|t|f|t
33805166|NCT05912218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a double-blind trial that keeps all patients, study investigators blinded to the treatment. Patients who have met all inclusion criteria and none of the exclusion criteria will be assigned to one of the two study arms (MEDI6570 or normal saline control) in a 1:1 ratio. Randomization will be accomplished using a permuted block scheme with variable block size and will be stratified by study site. The trial will use randomly generated treatment allocations within sealed opaque envelopes. Reconstitution of study drug and normal saline control will be by an unblinded study team member.|t|t|t|f
33805167|NCT05868291|||COHORT||RETROSPECTIVE|||||||
34105229|NCT01176500|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028839|NCT04096040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105230|NCT03733535|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm||||
34105231|NCT06564051|||COHORT||PROSPECTIVE|||||||
33805168|NCT02094560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805169|NCT06131372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805170|NCT00488566|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33805171|NCT01228669|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34028840|NCT01033331|||COHORT||PROSPECTIVE|||||||
34028841|NCT01706614|||COHORT||PROSPECTIVE|||||||
34028842|NCT04317079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Administration of hydroxytyrosol (15mg versus 5 mg daily) versus placebo for 6 months in combination with diet in order to assess effects in body weight, body fat mass and visceral fat mass loss|t|t|t|t
34028843|NCT06356857|||CASE_ONLY||PROSPECTIVE|||||||
34105232|NCT04080531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105233|NCT04050566|||COHORT||PROSPECTIVE|||||||
34105234|NCT05207943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The intervention to which the subjects have been assigned, the specialist and the researcher who collects the information and performs the follow-ups will be blinded, using the simulated NESA XSIGNAL® device. Data analysis will also be performed in a blinded fashion.~Patients will be assigned to NESA XSIGNAL® device 1 or 2. These devices will be labeled 1 and 2 and only the manufacturer will know which is the real or the simulated one. In the same way, to avoid subjective comparisons of the participants, in the same room, device 1 and 2 at the same time will not be used."||t|t|t|t
34105235|NCT06637449|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34105236|NCT02757963|NA|SINGLE_GROUP||SCREENING||NONE||||||
34105237|NCT06339684|||COHORT||PROSPECTIVE|||||||
34105238|NCT03194932|NA|SINGLE_GROUP||TREATMENT||NONE||Participants receive venetoclax plus cytarabine alone or combination chemotherapy of cytarabine plus idarubicin.||||
34105239|NCT04823052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects will be randomly assigned to 1 of 4 treatment arms. All treatment arms will be conducted in parallel. Fifteen subjects will be included in each arm. The study treatment will be blinded to patients, carers and physicians.|t|t|t|t
34105240|NCT06673667|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|The Sponsor is also masked to treatment allocation.||t|f|t|f
34105241|NCT05862584|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105242|NCT06686862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The analysis of the cardiac magnetic resonance imaging will be performed by evaluators blinded to the treatment and the timing of the imaging.||f|f|f|t
34105243|NCT02096926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105244|NCT04600414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes are assessed by patient survey, and survey administrators will be masked to randomizations status.|Cluster Randomized Trial. Clinics within healthcare systems are paired and randomized to intervention or control.|f|f|f|t
33805172|NCT01046136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805173|NCT00649805|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33837818|NCT01612819|||COHORT||PROSPECTIVE|||||||
33837819|NCT02623751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837820|NCT00470197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837821|NCT06375486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837822|NCT01795599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837823|NCT06286306|||COHORT||PROSPECTIVE|||||||
33837824|NCT01088542|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837825|NCT04371120|||OTHER||PROSPECTIVE|||||||
33837826|NCT00614562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837827|NCT00803192|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837828|NCT04974762|RANDOMIZED|PARALLEL||TREATMENT||NONE|The researcher assessing the subjects postoperatively will be different from the anesthesiologist that performs the interventions.|||||
33837829|NCT04635098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837830|NCT03656224|||CASE_ONLY||PROSPECTIVE|||||||
33837831|NCT05052918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837832|NCT01833377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837833|NCT05807906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33837834|NCT02478437|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33837835|NCT00169247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837836|NCT00758342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837837|NCT05026021|||COHORT||PROSPECTIVE|||||||
33837838|NCT01429220|||COHORT||PROSPECTIVE|||||||
34105245|NCT02459600|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34105246|NCT06641115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105247|NCT06168448|||COHORT||PROSPECTIVE|||||||
33805174|NCT05784194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|PhD student prepare evaluation form for each patient including patient characteristics and important disease states, medication lists during the study period, hospital and primary care contacts including reason for contact and medical notes. Errors, risks, and clinical consequences based on an error is evaluated first individually then in consensus by two blinded senior clinicians.||f|f|f|t
33805175|NCT06303674|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The design of the study is a within-participants crossover pretest-posttest comparison design under laboratory settings will be used. In this design, all participants will engage in all experimental conditions (on separate days), with the order of the experimental conditions being counterbalanced across participants and outcomes assessed following each experimental condition.|t|f|f|t
33805176|NCT02203500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805177|NCT05397262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805178|NCT02438007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105248|NCT06682598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805179|NCT01768793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34105249|NCT00832026|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105250|NCT02980900|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34105251|NCT04205916|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Patients undergoing bilateral cataract Surgery||||
34105252|NCT05768672|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105253|NCT05350774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105254|NCT01251861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805180|NCT04423796|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, parallel-group, open label pilot trial||||
34105255|NCT05919030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105256|NCT03493880|||COHORT||PROSPECTIVE|||||||
33805181|NCT01981603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33805182|NCT00299572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805183|NCT00372775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105257|NCT05890755|||COHORT||PROSPECTIVE|||||||
33805184|NCT03109080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105258|NCT02510248|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33805185|NCT05092009|||COHORT||PROSPECTIVE|||||||
34105259|NCT01005979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105260|NCT06047587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105261|NCT06036264|||COHORT||RETROSPECTIVE|||||||
33805186|NCT01000805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805187|NCT01432769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805188|NCT01992575|||CASE_CONTROL||PROSPECTIVE|||||||
33805189|NCT05917236|||CASE_ONLY||PROSPECTIVE|||||||
33805190|NCT01311921|||CASE_CONTROL||PROSPECTIVE|||||||
34105262|NCT05490472|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34105263|NCT05566769|NA|SINGLE_GROUP||OTHER||NONE||One group||||
34105264|NCT06464510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105265|NCT06308926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105266|NCT00493285|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105267|NCT05425355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study intervention will start after the surgery for the hip fracture with administration of the study drugs, starting in the post-anesthesia care unit (PACU). All patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In the intravenous (IV) group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet; vice versa, in the per oral (PO) group, the IV study drug will be normal saline and the pill will be acetaminophen. After 48 hours, all the patients will receive oral acetaminophen every 6 hours as per usual practice|t|t|t|t
34105268|NCT01783808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105269|NCT02007980|||CASE_ONLY||PROSPECTIVE|||||||
34105270|NCT04859075|||COHORT||PROSPECTIVE|||||||
34105271|NCT02319915|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34105272|NCT03390686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105273|NCT01907646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105274|NCT00552279|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105275|NCT05512819|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105276|NCT04945330|||COHORT||PROSPECTIVE|||||||
34105277|NCT06569225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105278|NCT06563674|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|The baseline data will be collected by research assistant (RA)1 before randomization, while the follow-ups data will be collected by RA2. The participant's group allocation is masked to the outcome assessors. But the participants know their group allocation after randomization because of the nature of the intervention. Different dates will be planned for different groups for all follow-ups respectively to avoid contamination of the subjects and blinding to the outcome assessors as far as possible|A 2-arm waitlist pilot randomized controlled trial will be adopted. After baseline data collection, participants in the intervention group will receive the health program for 6 weeks. On the other hand, participants in the waitlist-control group will receive the same health program week 8 and week 14.|f|f|f|t
34105279|NCT06674291|||COHORT||PROSPECTIVE|||||||
34105280|NCT00195611|||||PROSPECTIVE|||||||
34105281|NCT01977976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805191|NCT06699368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33805192|NCT05691842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837839|NCT01340001|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33837840|NCT04518046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Following the identification of the recommended dose of sitravatinib in combination with NIVO/IPI Phase 1 dose escalation, two Phase 1b dose expansion cohorts will enroll patients with ccRCC based on IMDC risk. All patients receive the same treatment.||||
33837841|NCT00862836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837842|NCT04785118|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33839186|NCT03798275|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34028844|NCT05019287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments regarding clinical recovery will be conducted by the outcomes assessors blind to treatment allocation. Due to the nature of the intervention, staff cannot be blinded to allocation, but the participants are blind to the group to which they belong. An employee outside the research team will feed data into the computer in separate datasheets so that the outcomes assessors can analyses data without having access to information about the allocation.|"1. Biological: allogeneic human menstrual blood stem cells secretome Intravenous injection of 5 ml menstrual blood stem cells secretome on day 1, day 2, day 3, day 4, and day 5, based on the routine treatment of COVID-19~2. Other: Intravenous saline injection (Placebo) Intravenous injection of 5ml of 0.9% saline on day 1, day 2, day 3, day 4, and day 5, based on the routine treatment of COVID-19"|t|f|f|t
34028845|NCT03753191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded, with randomized case-control|double-blinded, randomized case-control interventional study|t|t|t|t
34028846|NCT01423123|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723574|NCT05636930|||OTHER||CROSS_SECTIONAL|||||||
33723575|NCT01920919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028847|NCT05909280|||COHORT||PROSPECTIVE|||||||
34028848|NCT00537511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028849|NCT03209310|||OTHER||OTHER|||||||
34028850|NCT00808314|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33723576|NCT03045887|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34028851|NCT01870440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723577|NCT02994160|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028852|NCT03190811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028853|NCT02455895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34028854|NCT03183401|||COHORT||PROSPECTIVE|||||||
34028855|NCT06021691|||COHORT||PROSPECTIVE|||||||
34028856|NCT03414684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028857|NCT05178498|||COHORT||PROSPECTIVE|||||||
34028858|NCT05406921|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34028859|NCT04663191|||CASE_CONTROL||RETROSPECTIVE|||||||
34028860|NCT03991676|NA|SINGLE_GROUP||TREATMENT||NONE||All participants are enrolled into a single condition, consisting of a series of three, once-weekly values-infused weight loss workshops.||||
34028861|NCT04505254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028862|NCT02377973|||COHORT||PROSPECTIVE|||||||
34105282|NCT06067893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105283|NCT01798654|||COHORT||PROSPECTIVE|||||||
34105284|NCT05625867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105285|NCT04896931|||COHORT||PROSPECTIVE|||||||
34105286|NCT02683473|||COHORT||CROSS_SECTIONAL|||||||
34105287|NCT06160778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double dummy design|Two parallel interventional groups.|t|t|t|t
33723578|NCT04242004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants, and investigators assessing outcome measures were blind to the intervention condition. Blinding was maintained until data analysis was completed.|Randomization (1:1) was performed according to a computer-generated random sequence, which was used to allocate the participants either to the dietary supplement or the placebo group.|t|f|t|f
33723579|NCT05804175|||CASE_CONTROL||PROSPECTIVE|||||||
33723580|NCT00301210|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33723581|NCT01555268|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723582|NCT00446407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723583|NCT04996927|||COHORT||RETROSPECTIVE|||||||
33723584|NCT01952756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723585|NCT01344603|||CASE_CONTROL||RETROSPECTIVE|||||||
33723586|NCT06390969|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33723587|NCT05582668|||COHORT||RETROSPECTIVE|||||||
33723588|NCT04843748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723589|NCT00511615|||CASE_ONLY||PROSPECTIVE|||||||
33723590|NCT01420445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723591|NCT01879774|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33723592|NCT01356797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723593|NCT04859751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723594|NCT03892460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723595|NCT01196546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723596|NCT02393833|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34028863|NCT02786888|||COHORT||PROSPECTIVE|||||||
34105288|NCT06312254|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Participant and investigator/project involved personal is blinded to which cream is applied.||t|f|t|f
34105289|NCT06675162|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34105290|NCT06314048|||COHORT||PROSPECTIVE|||||||
33805193|NCT04679675|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The investigators will test interventions separately by prior cervical cancer screening behavior: Screening Adherent, Overdue, and Unknown history. Interventions will differ by screening behavior.~Previously Adherent: Previously screened for cervical cancer with a known due date within three months~Overdue: Never screened for cervical cancer; or HPV and Pap co-test \>5.25 years ago \[or Pap alone \>3.25 years ago\]; or no past Pap and continuously enrolled at Kaiser Permanente Washington for ≥3.25 years.~Unknown Prior Screening Behavior: Enrolled at Kaiser Permanente Washington for ≥6 months and \<3.25 years, with no recorded cervical cancer screening history.~Cohort randomization allocation will be assigned as follows to intervention arms: Previously Adherent (Usual Care, Education, Opt-in, and Direct Mail); Overdue (Usual Care, Education, and Direct Mail); and Unknown (Usual Care, Education, and Opt-in)."|f|f|t|f
34105291|NCT04467853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805194|NCT00247351|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33805195|NCT02336958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805196|NCT02230046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805197|NCT02724501|||COHORT||PROSPECTIVE|||||||
33805198|NCT04448366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805199|NCT02717468|NA|SINGLE_GROUP||||NONE||||||
33805200|NCT04187573|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, multi-center study.||||
33805201|NCT01292863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805202|NCT00276276|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805203|NCT05562427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805204|NCT03753932|NA|SINGLE_GROUP||TREATMENT||NONE||Single group for the control vs. intervention group. Crossover model within the intervention group.||||
33805205|NCT03024034|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34028864|NCT06432855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805206|NCT06642571|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105292|NCT04275869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805207|NCT05320874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805208|NCT00783497|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105293|NCT03379584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105294|NCT04101331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028865|NCT02228850|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34028866|NCT05368116|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34028867|NCT04068792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028868|NCT05167097|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Masking only applies to mindset manipulation.||t|f|t|f
34105295|NCT03570515|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34028869|NCT05644925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subjects as well as the investigator performing the procedure will not be blind to the study treatment. An independent experienced cardiologist, who will be blinded to all clinical data; will analyze anonymized Cardiac Magnetic Resonance (CMR) images for unbiased endpoints assessment.|Patients will be randomized (1:1) to PiCSO group or standard PCI control group. Once randomized, PiCSO group patients will receive PiCSO therapy inside the catheterization laboratory.|f|f|f|t
34028870|NCT04770675|||OTHER||PROSPECTIVE|||||||
34028871|NCT02716545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105296|NCT01189721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105297|NCT00803855|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34105298|NCT04297774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105299|NCT04801901|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized non-blinded study evaluating whether distal radial artery access (dTRA) from the anatomic snuffbox is associated with less trauma and adverse remodeling to the forearm radial artery compared to standardard forearm radial access (fTRA).||||
34028872|NCT01678950|||COHORT||PROSPECTIVE|||||||
34028873|NCT03335514|||CASE_CONTROL||PROSPECTIVE|||||||
34028874|NCT02291575|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34028875|NCT00588588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028876|NCT02460679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028877|NCT02304497|||CASE_CONTROL||PROSPECTIVE|||||||
34028878|NCT03327948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028879|NCT01516918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028880|NCT04684472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028881|NCT05712798|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028882|NCT00643812|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105300|NCT03001739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105301|NCT06572033|||OTHER||PROSPECTIVE|||||||
34105302|NCT06644482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805209|NCT06698341|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805210|NCT06587919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34105303|NCT06543862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805211|NCT01121965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105304|NCT06256939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805212|NCT05455697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805213|NCT03204032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105305|NCT04655976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805214|NCT02831816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34105306|NCT06690476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105307|NCT02496754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105308|NCT05700422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805215|NCT03413085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Paired-eye comparison|t|t|t|t
34105309|NCT02712216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105310|NCT05293262|||COHORT||RETROSPECTIVE|||||||
34105311|NCT01946646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105312|NCT03765983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805216|NCT03980418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105313|NCT06563713|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33805217|NCT02397096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105314|NCT04241432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105315|NCT02704000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34105316|NCT06026644|||COHORT||PROSPECTIVE|||||||
34105317|NCT05831410|||OTHER||CROSS_SECTIONAL|||||||
34105318|NCT01335685||PARALLEL||TREATMENT||NONE||||||
34105319|NCT03903042|||COHORT||PROSPECTIVE|||||||
33723597|NCT00405873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723598|NCT05793775|||CASE_ONLY||PROSPECTIVE|||||||
33723599|NCT02595086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723600|NCT02722850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805218|NCT06635759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805219|NCT00008242||||TREATMENT||||||||
33805220|NCT01836445|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33805221|NCT06580275|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33805222|NCT01183767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805223|NCT04898569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were offered the allocated treatment for ferric carboxymaltose or not, using the block randomization system. The selected agent was infused to patients after randomization.|In cardiac surgery, patients were randomized to receive Ferinject or placebo (n=50), respectively. The selected agent was intravenous infusion in general ward, preoperatively.|t|f|f|f
34105320|NCT01027351|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105321|NCT02137278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105322|NCT03670433|||COHORT||PROSPECTIVE|||||||
34105323|NCT02672605|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34105324|NCT06111742|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In the first phase (baseline measurement) neither participant nor investigator will be aware of the subjects group assignment. After this phase, due to the nature of the intervention, the experimental group will be aware they are in the intervention group when they see the gaming system.||t|f|t|f
34105325|NCT03494842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After the written informed consent is obtained, subjects will be randomly allocated into one of the two groups: (a) the active TENS group and (b) the placebo TENS group.||t|t|t|t
34105326|NCT00594997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105327|NCT02340546|||COHORT||PROSPECTIVE|||||||
34105328|NCT01050218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105329|NCT06686121|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) For the beetroot juice vs. placebo comparison, this will be a double blinded study where both the participant and the people collecting data will be blinded.~For the home-based exercise, the participant and investigator will not be blinded, but the outcomes assessor will be blinded."|Two x two factorial design|t|t|t|t
34105330|NCT04628494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105331|NCT06673537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105332|NCT06674434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105333|NCT06675006|||COHORT||PROSPECTIVE|||||||
34105334|NCT06637865|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind|There will be 7 cohorts in total: 5 single dose cohorts and 2 multiple dose cohorts|t|f|t|f
34105335|NCT04304287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34105336|NCT05215236|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105337|NCT01390519|||COHORT||PROSPECTIVE|||||||
33723601|NCT04199299|||CASE_ONLY||PROSPECTIVE|||||||
33723602|NCT01848756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723603|NCT04988347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Capsules containing Spirulina and placebo were identical|Forty-five regular users of PPIs entered in a 28-day run-in phase of pantoprazole 40 mg/day, followed by clinical and endoscopic evaluation. In the absence of large hiatal hernia, peptic ulcer, or moderate to severe reflux esophagitis, patients stopped PPIs and were randomly assigned to receive Spirulina (1.6 g/day) or placebo for 2 months, when evaluation was repeated. Primary outcomes were dyspepsia and typical reflux symptoms (either appearance or maintenance of symptoms \> 50% from baseline). Intention-to-treat analysis was applied.|t|f|t|f
33723604|NCT01226381|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33723605|NCT01946373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723606|NCT03797833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723607|NCT05791045|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33723608|NCT02494427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105338|NCT06631053|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are unable to be masked to their intervention (exercise v. non-exercise). Although other researchers from this team will be responsible for directly implementing exercise interventions, exercise sessions will be conducted in the same building as the PI's office. Therefore, it is likely that the PI will be aware of which subjects are completing exercise sessions. The PI and his team will be directly responsible for assessing primary and secondary research outcomes.|ULLS is the gold standard for assessing muscle disuse in ambulatory subjects. Velocity based resistance training and High Intensity Interval Training are gold-standard exercise strategies in terrestrial settings which tend to out-perform other exercise interventions. However, these exercise paradigms have not be applied to those undergoing unloading such as astronauts in space flight. Here, we aim to adopt principles from these established exercise interventions to determine their effectiveness in preserving muscle and aerobic fitness during 30d ULLS.||||
34105339|NCT01267136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105340|NCT06045286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105341|NCT03981055|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34105342|NCT04148755|||COHORT||PROSPECTIVE|||||||
34105343|NCT04990908|||COHORT||PROSPECTIVE|||||||
34105344|NCT05142319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only study participants will be blinded to the vaccine allocation. This is to reduce the risk of bias in participant-reported AEs. The study participant will be unblinded at Day-28 visit (Visit 3).||t|f|f|f
34105345|NCT06100978|||COHORT||PROSPECTIVE|||||||
34105346|NCT00563316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105347|NCT06509984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105348|NCT04901715|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105349|NCT04279093|||COHORT||PROSPECTIVE|||||||
34105350|NCT00121966|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34105351|NCT04100603|||CASE_ONLY||PROSPECTIVE|||||||
34105352|NCT02214212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105353|NCT04130425|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105354|NCT04824287|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723609|NCT00651755|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105355|NCT02798003|||COHORT||PROSPECTIVE|||||||
34105356|NCT00050011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105357|NCT04525469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105358|NCT05678127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The pathologists who will measure the nerve fibre density are blinded; they will not know if the biopsy is from the affected or non-affected side.|"Skin biopsies will be performed on patients with an unilateral ACNES. Biopsies will be taken at the triggerpoint (affected side) and contralateral, non-affected side of the abdominal wall.~Affected vs non-affected will be compared. The non-affected side serves as control."||||
34105359|NCT02075697|||COHORT||PROSPECTIVE|||||||
34105360|NCT02118246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105361|NCT00894010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34105362|NCT02062255|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105363|NCT03822715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105364|NCT06672822|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single-arm, single center US study||||
34105365|NCT00135876|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34105366|NCT01156467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105367|NCT01730079|||COHORT||PROSPECTIVE|||||||
34105368|NCT02344927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105369|NCT03004183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105370|NCT05792462|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105371|NCT03885206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The referring physician in a casualty in the casualty will judge the patients´ eligibility for inclusion, Study nurses in the casualty will invite participants, and receive patients´ written informed consent to participate, and then randomize the patients to either the MAW or the hospital, using a simple randomization procedure with numbered sheets in sealed, opaque envelopes. The patients will then be transported to the MAW or hospital according to the random allocation procedure.||||
33723610|NCT03754712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723611|NCT00312091|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723612|NCT00849407|||CASE_CONTROL||PROSPECTIVE|||||||
33723613|NCT04693507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Adaptive design - enrollment will open in Group 1 (6-weekly dosing regimen). Only if Group 1 dosing regimen is unsuccessful will enrollment open in Group 2 (4-weekly dosing regimen)||||
33723614|NCT02680483|||CASE_ONLY||PROSPECTIVE|||||||
33723615|NCT05103215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723616|NCT01643993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723617|NCT03410589|||OTHER||CROSS_SECTIONAL|||||||
33723618|NCT02159924|||CASE_ONLY||CROSS_SECTIONAL|||||||
33723619|NCT03790839|NA|SEQUENTIAL||TREATMENT||NONE||||||
33723620|NCT00212823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723621|NCT06490328|NA|SINGLE_GROUP||TREATMENT||NONE||Advanced Prostate Cancer||||
33723622|NCT02796040|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723623|NCT05584865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723624|NCT00690014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723625|NCT02146547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723626|NCT01680718|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723627|NCT02334007|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33723628|NCT03249311|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33723629|NCT05881603|||COHORT||PROSPECTIVE|||||||
33723630|NCT03628755|RANDOMIZED|PARALLEL||PREVENTION||NONE||The three group were digital manipulation of thyroid cartilage(DMT) group,fluency shaping therapy (FST) group,combination of DMT,FST. the intervention period for each subject was three month and data was collected on day one and at the end of every 2 weeks. 4th week , 8th week, and 12th week which were aimed to reduce severity of stuttering and improve fluency||||
33723631|NCT00973739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105372|NCT06570057|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm parallel study design would be used. Six clusters will be randomly selected from purely urban blocks of Karachi. The study sites will be selected in a manner that the risk of possible contamination between control and intervention groups is avoided. The intervention clusters will receive the 18-months long PLA intervention along with study assessments, while the control clusters will only go through assessments i.e., at baseline and end of study. A referral mechanism will be followed for both intervention and control arm, which will ensure that the individuals with newly diagnosed diabetes will be referred to the nearest diabetes care facility.||||
33805224|NCT02144597|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33805225|NCT04875767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors and those performing data entry and analysis will be blinded to the treatment allocation. Although patients will not be told which treatment they received, blinding may not be feasible given the intervention group will have an additional bone marrow harvest site incision at the iliac crest.||f|f|f|t
34105373|NCT01254539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805226|NCT06143501|||COHORT||PROSPECTIVE|||||||
34105374|NCT06639815|||CASE_CONTROL||PROSPECTIVE|||||||
33805227|NCT01723267|RANDOMIZED|PARALLEL||||NONE||||||
33805228|NCT03220724|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805229|NCT04345068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The participants will be blinded as to which group is receiving the intervention being assessed.||t|f|f|f
33805230|NCT03532100|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study will use a within-subject factorial design (3x5) to identify the optimal coupling ratio between transverse- and sagittal-plane motions using a torsionally adaptive prosthesis. Participants will all walk in a straight line, in a circle with their prosthesis on the inside, and in a circle with their prosthesis on the outside (i.e., 3 activity levels). The torsionally adaptive prosthesis can be set to 5 different coupling ratios (transverse:sagittal) including 0:0, 1:6, 1:4, 1:3, and 1:2. Each participant will walk with the torsionally adaptive prosthesis set to the 5 different coupling ratios (random order). Participants will not be blinded to the activity but will be blinded to the coupling ratio.||||
34105375|NCT06413069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|masking not possible; subjects are aware of their allocation after initiation of the intervention|parallel, single-blinded, prospective, randomised controlled trial in waiting list design|f|f|t|t
34105376|NCT06671899|||COHORT||RETROSPECTIVE|||||||
33805231|NCT06254183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Group I: 30 patients who will represent the control group and will receive oral placebo tab 2 days prior to surgery and 1 hr before surgery.~Group II: 30 patients who will represent the treatment group and will receive a single oral dose of Gabapentin 1200 mg, 1 hr before surgery.~Blood and urine samples will be collected before the surgery, then 24 hrs postoperatively.~Blood and urine samples will be collected in follow-up, 6 months postoperatively"|t|t|f|f
34105377|NCT06671210|||CASE_CONTROL||PROSPECTIVE|||||||
34105378|NCT00698165|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105379|NCT02006615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105380|NCT02682251|NA|SINGLE_GROUP||OTHER||NONE||||||
34105381|NCT04961580|||CASE_ONLY||PROSPECTIVE|||||||
33723632|NCT03057405|||CASE_CONTROL||RETROSPECTIVE|||||||
33723633|NCT05781295|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33723634|NCT00547742|||COHORT||PROSPECTIVE|||||||
33723635|NCT06344754|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|the person doing the statistical analysis will be blinded|pre-test and post-test interventional study||||
33723636|NCT01838993|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33723637|NCT03774433|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723638|NCT00441844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33723639|NCT01813669|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723640|NCT05459103|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33723641|NCT05045144|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Observer-blind (lot-to-lot consistency) \& single-blind (immunogenicity, safety and reactogenicity)||t|t|t|t
33723642|NCT01871116|RANDOMIZED|PARALLEL||TREATMENT||NONE||Weight loss intervention versus self-directed weight loss.||||
33723643|NCT04328324|||COHORT||CROSS_SECTIONAL|||||||
33723644|NCT03485820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, parallel-group, randomized controlled trial|f|f|f|t
33723645|NCT00005831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723646|NCT03501758|||COHORT||PROSPECTIVE|||||||
33723647|NCT06059911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723648|NCT02408939|||OTHER||RETROSPECTIVE|||||||
33723649|NCT01914406|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33723650|NCT02235142|NA|SINGLE_GROUP||OTHER||NONE||||||
33723651|NCT00482235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33723652|NCT02229136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723653|NCT00386737|||DEFINED_POPULATION||OTHER|||||||
33723654|NCT04361981|||COHORT||PROSPECTIVE|||||||
33723655|NCT03796481|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33723656|NCT05972499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723657|NCT00300950|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33723658|NCT01741922|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33723659|NCT03337100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33723660|NCT01154621|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33723661|NCT06203925|||COHORT||PROSPECTIVE|||||||
33723662|NCT02475577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33723663|NCT01412021|||COHORT||PROSPECTIVE|||||||
33723664|NCT02128399|||||PROSPECTIVE|||||||
33723665|NCT02937519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723666|NCT00453921|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33723667|NCT03195114|||COHORT||PROSPECTIVE|||||||
33723668|NCT03527199|||CASE_ONLY||PROSPECTIVE|||||||
33723669|NCT01236937|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723670|NCT04287777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723671|NCT03344042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant not aware of opioid administered||t|f|f|t
34105382|NCT02886364|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34105383|NCT02416479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34028883|NCT03302676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2:1 randomization in favor of chewing gum (intervention)||||
34105384|NCT03291119|||COHORT||PROSPECTIVE|||||||
34028884|NCT01869985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34028885|NCT06421298|NA|SINGLE_GROUP||TREATMENT||NONE||Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.||||
34028886|NCT06287138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028887|NCT02292095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34028888|NCT06194461|||COHORT||PROSPECTIVE|||||||
34028889|NCT04420273|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized Control Clinical Trial Arm 1: SSE educational intervention with optional physician supervised non-invasive adhesive patch-based home sample collection of a concerning mole for genomic analysis Arm 2: Active control|f|t|t|t
34028890|NCT01366625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028891|NCT03974555|||COHORT||RETROSPECTIVE|||||||
33805232|NCT06274086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028892|NCT02290405|||COHORT||CROSS_SECTIONAL|||||||
34028893|NCT05016609|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A cluster cross-over randomised controlled trial with cluster randomisation performed at the site level. Each site will be randomised to one of the three interventions and one standard of care period. All participants will receive the intervention or comparator that has been allocated to the service they present at.||||
34028894|NCT00518700|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34028895|NCT05594901|||COHORT||OTHER|||||||
34028896|NCT01473407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028897|NCT00356655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028898|NCT02665104|||COHORT||PROSPECTIVE|||||||
34028899|NCT04149093|||COHORT||RETROSPECTIVE|||||||
34105385|NCT05791630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multicenter stepped wedge cluster randomized trial||||
34028900|NCT02354625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105386|NCT01716637|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33805233|NCT05390905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805234|NCT05155644|||CASE_ONLY||RETROSPECTIVE|||||||
33805235|NCT06176443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805236|NCT06590064|||COHORT||PROSPECTIVE|||||||
34105387|NCT04921306|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34105388|NCT03629002|||CASE_CONTROL||PROSPECTIVE|||||||
34105389|NCT05882565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105390|NCT02542371|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105391|NCT06673927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Dose escalation|t|f|f|f
34105392|NCT01237886|||COHORT||PROSPECTIVE|||||||
34105393|NCT01723839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105394|NCT01065805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105395|NCT06673472|||COHORT||RETROSPECTIVE|||||||
34105396|NCT06691828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105397|NCT02458027|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33805237|NCT02904720|||COHORT||CROSS_SECTIONAL|||||||
34105398|NCT02615275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105399|NCT04204902|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33805238|NCT05723666|RANDOMIZED|PARALLEL||OTHER||SINGLE||"There are two Groups with parallel properties. The first group is the experimental group using virtual reality glasses.~The second group is the control group without intervention."|t|f|f|f
33805239|NCT03414645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805240|NCT03933137|||COHORT||RETROSPECTIVE|||||||
33805241|NCT05842382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805242|NCT00744913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028901|NCT05574361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028902|NCT00205387|||COHORT||PROSPECTIVE|||||||
34028903|NCT05375253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028904|NCT03833778|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33805243|NCT05459350|||COHORT||RETROSPECTIVE|||||||
33805244|NCT04815993|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||single ascending dose||||
33805245|NCT06699576|NA|SEQUENTIAL||TREATMENT||NONE||||||
33805246|NCT03932500|||COHORT||PROSPECTIVE|||||||
34028905|NCT00108706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34028906|NCT00397514|||COHORT||CROSS_SECTIONAL|||||||
34028907|NCT03062384|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34028908|NCT06210022|||COHORT||PROSPECTIVE|||||||
34028909|NCT01450683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028910|NCT00357253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028911|NCT06212544|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pilot waitlist randomized controlled trial||||
34028912|NCT02447146|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028913|NCT02909244|||OTHER||PROSPECTIVE|||||||
34028914|NCT03252561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34028915|NCT01952314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34028916|NCT06482073|||COHORT||PROSPECTIVE|||||||
34105400|NCT01509404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105401|NCT04317742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34105402|NCT06672133|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects who had SD/PR/CR assessed after induction immunotherapy were randomized 1:1 with PFS and OS set as co-primary endpoints for this study.~The HR of mOS in the maintenance phase was conservatively estimated to be meaningful in the adalimumab combined with thoracic radiotherapy group compared with the adalimumab group, with a significance level α of 0.05 (2-sided), and no less than 80% OS events would be observed (1-β difference between the 375 groups).~A total of 471 subjects are required to be enrolled. Considering a dropout rate of 10%, 524 subjects were required. In summary, a total of at least 524 subjects were required to be enrolled in this study."||||
34105403|NCT03152708|||OTHER||RETROSPECTIVE|||||||
33805247|NCT04053270|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33805248|NCT06052332|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805249|NCT04214756|||CASE_CONTROL||RETROSPECTIVE|||||||
33805250|NCT04004325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805251|NCT04033315|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All subjects will be assigned to use the L-PLUS meter||||
33805252|NCT05153070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|all participant receive the treatment with Ciclosporin and double Blind for the treatment with IL-2|Single group during ciclosporin treatment and parallel group during ILT-101 treatment|t|f|t|f
33805253|NCT05206240|||CASE_ONLY||PROSPECTIVE|||||||
34028917|NCT05623683|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"To blind the participants, they will be told that both walking interventions are equally likely to cause a decrease, no change, or an increase in knee pain, and we will compare potential differences between the two walking interventions.~To blind the outcome assessor, the assessor will assess outcomes in a different place from the place where the intervention takes place."|This is a randomized, controlled, single-blinded trial, with a 2-arm crossover design.|t|f|f|f
33805254|NCT05152849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805255|NCT06053424|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33805256|NCT01664741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805257|NCT05127967|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33805258|NCT02160119|||CASE_CONTROL||PROSPECTIVE|||||||
33805259|NCT05599282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Concealment of the allocation of study arms will be employed using opaque sealed envelopes, each labeled with a randomization number. Each envelope will contain information regarding the study arm associated with each randomization number. These envelopes will be readily available for the Qualified Investigator to open in the event that it becomes necessary to know which product a participant is taking for the sake of participant health care.~Unblinding should not occur except in the case of emergency situations. If a serious adverse event occurs, for which the identity of the investigational product (IP) administered is necessary to manage the participant's condition, the study arm assigned to the participant will be unblinded and the IP identified."||t|f|t|t
33805260|NCT03342820|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805261|NCT00018096|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805262|NCT04611373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805263|NCT03910855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive either a Mindfulness-based Intervention (MBI) or a Health Education Program (HEP). The intervention is for 4 weeks. Measures will be administered prior to and on completion of the intervention, and at 3-month follow-up.||||
33805264|NCT01212744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805265|NCT04613713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician analyzing the data will be blinded for group belonging|Parallel group randomized clinical trial|f|f|f|t
33805266|NCT04620200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805267|NCT06357533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label, sponsor-blinded|Parallel Assignment|f|f|f|t
33805268|NCT06292936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805269|NCT04551651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805270|NCT04989842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805271|NCT03180541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805272|NCT06678269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805273|NCT04926519|||COHORT||RETROSPECTIVE|||||||
33805274|NCT01672333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805275|NCT00143130|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805276|NCT02616276|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33805277|NCT05460741|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||there will be 2 groups. one will be given the education related to menstrual cycle and other will be given intervention along with education. then the outcomes will be assessed at multiple times of study.|t|f|f|t
33805278|NCT01741363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805279|NCT06088758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805280|NCT06121492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All of participants, care providers, investigators and outcome assessors will be blinded. Only a research nurse will know which arm the participants are assigned to. The packages of BCAA and placebo are identical.|The participants will be randomly and blindly divided into two groups: (branched-chain amino acids) BCAA group and the placebo group, using a 1:1 ratio, with each group consisting of 43 individuals. The blinded participants will take either BCAA or placebo for 24 weeks.|t|t|t|t
33805281|NCT01240707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805282|NCT02029092|||OTHER||PROSPECTIVE|||||||
33805283|NCT04687033|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33805284|NCT03707899|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805285|NCT05408091|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34028918|NCT05721911|||CASE_CONTROL||PROSPECTIVE|||||||
34028919|NCT01285297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028920|NCT06456866|||CASE_ONLY||PROSPECTIVE|||||||
34028921|NCT03105492|||COHORT||CROSS_SECTIONAL|||||||
34028922|NCT00328848|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34028923|NCT04775303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028924|NCT03593538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028925|NCT02371473|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34028926|NCT06143852|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both participants and investigators will know which intervention group each participant has been randomized into.|Three groups of 1) no intervention, 2) mindfulness, or 3) social media reduction + exercise replacement intervention arms||||
34028927|NCT04294628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028928|NCT00331292|||||PROSPECTIVE|||||||
33805286|NCT06244875|||COHORT||PROSPECTIVE|||||||
33837843|NCT06425523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Three-arm, parallel-group, 1:1:1 allocation, superiority, cluster-randomized controlled trial (cRCT)|f|f|f|t
33837844|NCT06302660|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33837845|NCT02844452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839187|NCT03415243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837846|NCT03863145|NA|SEQUENTIAL||TREATMENT||NONE||Part 1 (Dose Escalation): Subjects with advanced refractory solid tumors Part 2 (Dose Expansion): Defined subject subgroups considered likely to respond to CB-03-10 (eg, relapsed/refractory pancreatic adenocarcinoma, androgen independent prostate adenocarcinoma, triple-negative breast adenocarcinoma) or indications that demonstrated activity in Part 1||||
33837847|NCT01685749|||CASE_ONLY||PROSPECTIVE|||||||
33837848|NCT06515938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837849|NCT05863468|NA|SINGLE_GROUP||TREATMENT||NONE||4 chronic sinusitis patients will undergo unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation. Baseline and 12-week airflow rate and particle deposition will be analyzed with Computational Modeling Analysis. symptomatic improvement will be analyzed using SNOT-22 and NOSE questioners.||||
33837850|NCT03664427|||CASE_CONTROL||RETROSPECTIVE|||||||
34028929|NCT02009592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028930|NCT02743429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028931|NCT01770717|||CASE_ONLY||RETROSPECTIVE|||||||
34028932|NCT04208100|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34028933|NCT05939765|||CASE_ONLY||PROSPECTIVE|||||||
34028934|NCT03008317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028935|NCT03639818|NA|SINGLE_GROUP||OTHER||NONE||||||
34028936|NCT04660279|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34028937|NCT00311597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028938|NCT04220255|||COHORT||PROSPECTIVE|||||||
34028939|NCT05752825|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34028940|NCT02443597|||CASE_CONTROL||PROSPECTIVE|||||||
34028941|NCT02248883|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34028942|NCT05671536|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to reduce the selection bias in the determination of intervention and control groups, a list was created by a third party (dialysis center nurse) who did not have a direct role in the study, and intervention and control group assignments were made using the randomization method from the random numbers table. The intervention and control group patients were scheduled to have hemodialysis sessions on different days.|Patients, undergoing hemodialysis treatment will be assigned to either intervention or control group via simple randomization. Patients on control group will receive standard care. Patients on intervention group will receive 4 sessions of motivational interview at least 20 minutes and once a month. Resilience of all groups will be evaluated at the beginnig of the study and five months after the beginning of the study.|t|f|f|f
34028943|NCT00450801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028944|NCT03778073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028945|NCT02910011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028946|NCT03958292|NA|SINGLE_GROUP||PREVENTION||NONE||Each patient has self-control of the IODIM treatment in the eye undergoing to cataract surgery with the contralateral eye. Microbiological studies will be performed by means of conjunctival swabs evaluation.||||
34028947|NCT05344131|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34028948|NCT01134432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105404|NCT06536855|NA|SINGLE_GROUP||PREVENTION||NONE||At the first visit we will administer Gardasil 9 to women aged 23 to 29 years and screening them for HPV to get baseline information, after 24 months at the second visit, provide the second dose and screen again for HPV to be able to compare HPV prevalence at baseline and 24 months after administering the second dose of vaccine.||||
34105405|NCT04505787|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34105406|NCT00803374|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105407|NCT01788774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105408|NCT04078568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and physicians will not be masked to the assignment. Pediatric cardiologists who assess coronary artery lesions (CAL) by echocardiography will be masked to the allocation.||f|f|f|t
34105409|NCT03004495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105410|NCT02012777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105411|NCT05513456|||COHORT||PROSPECTIVE|||||||
34105412|NCT06688396|NA|SINGLE_GROUP||SCREENING||NONE||||||
34105413|NCT06214325|NA|SINGLE_GROUP||OTHER||NONE||||||
34105414|NCT03988439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028949|NCT02757326|NA|SEQUENTIAL||TREATMENT||NONE||||||
34028950|NCT01916174|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34028951|NCT01198132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34028952|NCT02446756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105415|NCT05333588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105416|NCT01118637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105417|NCT03038919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105418|NCT05499819|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34105419|NCT04665843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105420|NCT01421459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105421|NCT06675604|||COHORT||PROSPECTIVE|||||||
34105422|NCT06679543|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34028953|NCT00511823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028954|NCT04936165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105423|NCT04269785|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 patients with paroxysmal AF or short-lived persistent AF (less than 6 months' duration), randomised to receive ablation by radiofrequency (RF) or cryoballoon (CB) in a 1:1 allocation.||||
34105424|NCT05250180|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34105425|NCT00109668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34105426|NCT03199534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105427|NCT04074837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcome Assessor)|Placebo versus NNI-362 at 10 mg, 20 mg, 60 and 120 mg liquid suspension|t|t|t|t
34028955|NCT00378495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34028956|NCT02288026|||COHORT||PROSPECTIVE|||||||
34028957|NCT00005678|||NATURAL_HISTORY|||||||||
34028958|NCT03546127|||COHORT||PROSPECTIVE|||||||
34028959|NCT01905436|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34028960|NCT02381184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105428|NCT00537797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105429|NCT02981160|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33805287|NCT05413889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||intervention group (IG) or control group (CG). The IG will consist of placing the Epic 30-day unplanned readmission risk score in the story board of providers. If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board. Providers will determine which TSC is best for the patient and may order whichever TSC or any is appropriate for the patient. The CG will have the same TSC orders available to them; however, they will not have the risk of readmission score present in their workflow, as such the embedded link to TSC will also not be present. Providers, in both IG and CG, will have the option to order one or multiple TSC at their discretion.|t|f|f|f
34105430|NCT06641401|||COHORT||RETROSPECTIVE|||||||
33805288|NCT06598423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators plan to conduct a randomized controlled trial of specialized soft contact lenses for the treatment of myopia. Children will be randomized 1:1 to wearing a single type of soft contact lens or two types of soft contact lenses at alternate times daily for one year.|f|f|f|t
33805289|NCT00461019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805290|NCT03357861|||COHORT||PROSPECTIVE|||||||
33805291|NCT03919110|||CASE_CONTROL||PROSPECTIVE|||||||
33805292|NCT06290791|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33805293|NCT05597943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028961|NCT05113407|||COHORT||PROSPECTIVE|||||||
34028962|NCT04037709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the researcher responsible for conducting the treatments (who will open the randomized envelopes) will know which treatment is assigned to each patient. The identification of each group will only be revealed by this researcher after statistical analysis of the data for all those involved in the study. Therefore, the researcher responsible for data collection, the microbiologist and the statistician will be blind regarding the treatments assigned to the groups. The patient will also be blind to the type of treatment performed since the periodontal treatment will be identical in both groups and treatment with PDT will be simulated in the control group.|Patients will have their mouth divided into two groups: Control group (n = 17) - Scaling and Root Planing (SRP) + PDT placebo and Experimental group (n = 17) - SRP + PDT.|t|f|t|f
34028963|NCT03854630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028964|NCT05676814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be blinded to their treatment arm assignment, as will all research personnel who be responsible for collection of outcome data, as well as the surgeons performing the procedure, and critical care staff caring for the patients in the postoperative period. The anesthesiologist who will be performing the Pecto-intercostal Fascial Block (PIFB) will open the envelope informing them of the arm assignment; they will be the only care providers unblinded.||t|t|t|t
34028965|NCT03603873|||COHORT||PROSPECTIVE|||||||
34028966|NCT00946517|||FAMILY_BASED||PROSPECTIVE|||||||
34028967|NCT01475045|||||PROSPECTIVE|||||||
34028968|NCT03449446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028969|NCT04980989|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference. At baseline, 6 months and 12 months the patients answered the other questionnaires on patient satisfaction, quality of life, symptoms and use of other healthcare services.||||
34028970|NCT00515918|||DEFINED_POPULATION||PROSPECTIVE|||||||
34028971|NCT00860392|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028972|NCT03200717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028973|NCT05775133|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34028974|NCT05017038|||CASE_ONLY||PROSPECTIVE|||||||
34028975|NCT00904657|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34028976|NCT05170282|||COHORT||OTHER|||||||
34028977|NCT06557499|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The clinical investigation is designed to be a data analyst-masked investigation where the data analyst who will perform the data analysis (both CRO and Sponsor staff involved in analysing the data) will not know which condom type couples have been randomised to use in each assessment period.|The condom types will be tested in a 3-way cross-over design where couples will be randomised to use each of the 3 condom types in a defined order, according to the randomisation schedule.|f|f|f|t
34028978|NCT00118534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028979|NCT02027532|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34028980|NCT03349346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028981|NCT01613430|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34028982|NCT00645892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028983|NCT00738257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028984|NCT05252182|||COHORT||PROSPECTIVE|||||||
34028985|NCT02026687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028986|NCT00479960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34028987|NCT00131495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028988|NCT03031418|||COHORT||PROSPECTIVE|||||||
34028989|NCT05228431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028990|NCT03680989|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34028991|NCT06171100|||COHORT||RETROSPECTIVE|||||||
34028992|NCT02729584|||COHORT||PROSPECTIVE|||||||
34105431|NCT03801109|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34105432|NCT00529815|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105433|NCT03060265|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34105434|NCT01950598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105435|NCT01917370|||CASE_CONTROL||PROSPECTIVE|||||||
34105436|NCT04884074|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomization is done by telephone call to the randomization centre where a dedicated research assistant without detailed knowledge of the recruited patient's background will open a sealed envelope containing a computer-generated random number which indicates the mode of intervention. Both the patients and clinical assessors (independent of the operating surgeons) are blind to the mode of intervention in the first one year of enrollment.|Randomized double-blind controlled trial|t|f|t|t
34105437|NCT00460915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34028993|NCT03191591|NA|SINGLE_GROUP||PREVENTION||NONE||The First 1,000 Days program is a systems-level program that will reach all expectant mothers and families with 0-2 year olds receiving care at Boston-area community health centers. Mothers and infants at two similar non-intervention Boston-area health centers will be used as a comparison sample. Maternal and infant obesity-related clinical information is routinely recorded during patient visits in the EHR used at both the intervention and comparison sites. Sample size enrollment reflects maternal-infant dyads.||||
34028994|NCT01639157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34105438|NCT03424980|||COHORT||RETROSPECTIVE|||||||
33723672|NCT05947201|NA|SINGLE_GROUP||TREATMENT||NONE||Patients fulfilling Eligibility Criteria will be included in our study. ESCC participants in this study will be given intravenous administration of AK104 (10 mg/kg d1) combined with cisplatin (20 mg/m2 on d1-3) and albumin paclitaxel (100mg/m2 on d1, d8), fluorouracil (600 mg/m2 on d1-5) every three weeks for a cycle of treatment, which will be conducted two or three cycles, and radical surgery within 4-6 weeks after the last administration. Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment.||||
33723673|NCT05423028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723674|NCT06431568|||COHORT||PROSPECTIVE|||||||
33723675|NCT04878523|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33723676|NCT03128814|||COHORT||PROSPECTIVE|||||||
33723677|NCT03857984|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723678|NCT06455397|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants will complete 12 weeks of the BEAM program. This involves weekly mental health and parenting education videos, app-based social support forum, and check ins with a peer parent coach. Participants will additionally have access to systems navigation to help participants find community supports. Assessments of parent and child symptoms will occur at pre-test before BEAM begins (T1), immediately after the last week of the BEAM intervention (post-test, T2), 6-month follow-up (T3), and 12-month follow-up (T4).||||
33723679|NCT01997515|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33723680|NCT00493584|RANDOMIZED|PARALLEL||||NONE||||||
33723681|NCT00046696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723682|NCT00982475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723683|NCT05067582|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Two Period Crossover|t|t|t|t
33723684|NCT03967392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||DOUBLE BLINDED RANDOMELY CONTROLLED|t|t|t|t
33723685|NCT00177528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723686|NCT05995158|||CASE_CONTROL||PROSPECTIVE|||||||
33723687|NCT00329407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723688|NCT01454570|NA|SINGLE_GROUP||OTHER||NONE||||||
33723689|NCT03968302|RANDOMIZED|PARALLEL||TREATMENT||NONE||PARALLEL ASSIGNMENT||||
33723690|NCT03002012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723691|NCT04349488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||One group receives anodal tDCS, one placebo|t|t|t|t
33723692|NCT05774587|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Parallel assignment randomized control trial||||
33723693|NCT00734279|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33723694|NCT04475133|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Order of treatments was randomized by a third person not involved in any of the other phases. Also, after the care provider has inserted the needle in the three groups, another third person without involvement in any other phase of the study choose the assigned treatment between three pre-programmed closed set of parameters in the stimulation machine, thus leaving treatment unknown for the care provider, the participant, the investigator and the outcome assessor, which received only encoded names for the groups.|Randomized intervention of repeated measures, quadruple-blinded|t|t|t|t
33723695|NCT05422599|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind|Between and within groups model|t|f|t|t
33723696|NCT04103632|NA|SINGLE_GROUP||SCREENING||NONE||Recreational young athletes from different sport disciplines will be tested for lung function, atopy, FeNO, exercise-induced bronchoconstriction (EIB) measured by EVH and biomarkers for EIB will be studied in blood.||||
33723697|NCT02954510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Experts evaluating ferumoxytol-enhanced magnetic resonance imaging will be masked to the results of other invasive and non-invasive cardiac testing|case control||||
33723698|NCT00245206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723699|NCT05325528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723700|NCT04854811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Pharmacy will distribute pills with a code|Between subjects, double blind, placebo-controlled, randomized|t|f|t|f
33723701|NCT02938689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723702|NCT01828047|||COHORT||PROSPECTIVE|||||||
33723703|NCT01627054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723704|NCT02834104|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723705|NCT01067222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723706|NCT06044376|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33723707|NCT02637778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723708|NCT03727503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Agreement and precision between two methods to measure pulse pressure variation (PPV)||||
33723709|NCT02382679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723710|NCT05885074|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33723711|NCT02855437|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33723712|NCT03905122|||COHORT||PROSPECTIVE|||||||
33723713|NCT06460649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723714|NCT03725007|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33723715|NCT01984775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33723716|NCT00345137|RANDOMIZED|CROSSOVER||||SINGLE||||||
33723717|NCT03149107|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34028995|NCT03709212|||COHORT||CROSS_SECTIONAL|||||||
33723718|NCT02467465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723719|NCT06327958|||OTHER||CROSS_SECTIONAL|||||||
33723720|NCT02051946|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33805294|NCT05985200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105439|NCT02483910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105440|NCT04083079|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105441|NCT06686160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34028996|NCT00442455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105442|NCT01954511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34028997|NCT01704274|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||One arm placebo, two arms different GTN dose.|t|t|t|t
34028998|NCT05523466|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34028999|NCT03936803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029000|NCT06139302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029001|NCT03385850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105443|NCT04872946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029002|NCT02237391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34105444|NCT01793233|||CASE_ONLY||PROSPECTIVE|||||||
34029003|NCT05320887|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are told their shopping trips are randomly selected, when they are actually being randomly selected between the two marketplace groups where only one flavor of e-liquid is available.|Participants are randomly assigned to either low nicotine or normal nicotine content vaping devices with tobacco flavors only available|t|f|f|f
34029004|NCT01709539|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34105445|NCT04787341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105446|NCT05524792|||COHORT||PROSPECTIVE|||||||
34105447|NCT05885750|RANDOMIZED|CROSSOVER||OTHER||NONE||Crossover trial with two one-week wash-out periods in-between three interventions||||
33723721|NCT05084573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, investigators, and all parties involved in patient management or data collection will be blinded throughout the study period.|Patients will be allocated to receive either continuous interscalene nerve block (CISB) using standard bupivacaine OR a single interscalene injection of liposomal bupivacaine (LB).|t|t|t|f
33723722|NCT01583335|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33723723|NCT02730572|||COHORT||RETROSPECTIVE|||||||
33723724|NCT01990495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723725|NCT02803151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723726|NCT03350360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Random assignment and coded entry to a computer website||t|t|f|f
33723727|NCT01756495|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33805295|NCT02645942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805296|NCT03853538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805297|NCT06361524|||COHORT||PROSPECTIVE|||||||
33805298|NCT05746741|RANDOMIZED|PARALLEL||OTHER||NONE||Study participants will be clients at local WIC agency sites where either the telehealth solution is offered or where only usual care is available (control).||||
33805299|NCT00279981|||||PROSPECTIVE|||||||
34029005|NCT02289729|||COHORT||PROSPECTIVE|||||||
34029006|NCT01918202|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029007|NCT01106014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029008|NCT04682925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective Randomized Controlled Clinical Trial|t|f|f|t
34029009|NCT01881984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029010|NCT00715624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029011|NCT05771948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029012|NCT00716222|||COHORT||CROSS_SECTIONAL|||||||
34029013|NCT01491191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34029014|NCT06581562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label Single-Center Study||||
34029015|NCT00121537|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029016|NCT05698433|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34029017|NCT01137071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029018|NCT03451214|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029019|NCT04113018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029020|NCT02423421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029021|NCT05146648|RANDOMIZED|PARALLEL||OTHER||TRIPLE|A blinded evaluator will collect all the demographic (age, gender, time since injury, injury type), clinical and functional data of the participants. The investigator performing transcranial magnetic stimulation assessments will also be blinded.|Twenty adult individuals in the chronic phase of stroke, 20 people with cerebral palsy, 20 with Parkinson's Disease (intermediate stage) and 20 healthy volunteers will be randomized to receive sham or real AMPS intervention.|t|f|t|t
34029022|NCT03132155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029023|NCT04431765|RANDOMIZED|PARALLEL||OTHER||NONE||In one hand, Patients with Post-traumatic Stress Disorder who will receive Eye Movement desensitization reprocessing therapy and in other hand patient with post-traumatic Stress Disorder who will receive Trauma-Centred Cognitive and Behavioural Therapy||||
34029024|NCT02498028|||CASE_ONLY||PROSPECTIVE|||||||
34029025|NCT02646605|||CASE_ONLY||CROSS_SECTIONAL|||||||
33723728|NCT01568931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723729|NCT01271088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723730|NCT04022096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723731|NCT01042730|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029026|NCT05432661|||CASE_ONLY||OTHER|||||||
34029027|NCT04462432|||CASE_CONTROL||PROSPECTIVE|||||||
34029028|NCT02131350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029029|NCT03892499|NA|SINGLE_GROUP||OTHER||NONE||||||
34029030|NCT01013662|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34029031|NCT01964976|||COHORT||PROSPECTIVE|||||||
34029032|NCT03428711|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029033|NCT04873973|RANDOMIZED|PARALLEL||OTHER||NONE||Stepped-Wedge-Design||||
34029034|NCT01029145|||COHORT||PROSPECTIVE|||||||
34029035|NCT05759013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029036|NCT01412086|||COHORT||PROSPECTIVE|||||||
34029037|NCT04535687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029038|NCT00451945|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34029039|NCT04892537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029040|NCT06300710|||CASE_ONLY||RETROSPECTIVE|||||||
34029041|NCT02658799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029042|NCT02847988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029043|NCT01890525|||COHORT||PROSPECTIVE|||||||
34029044|NCT02796638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029045|NCT05532709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029046|NCT01806571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029047|NCT04510532|||COHORT||PROSPECTIVE|||||||
34029048|NCT03216863|NA|SINGLE_GROUP||OTHER||NONE||Patients with advanced or metastatic non-small cell lung cancer treated with oral targeted therapy (tyrosine kinase (TKI) inhibitors of EGF-R and ALK inhibitors), regardless of the treatment line.||||
34029049|NCT04015310|||COHORT||PROSPECTIVE|||||||
34029050|NCT06070558|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34029051|NCT03305367|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects complete three oral glucose tolerance tests (OGTT) on different days, with a minimum of one week in between. First visit is a combined screening and baseline OGTT, with no supplementation. At the second and third visit subjects are randomly assigned to either 3 g of hydrolyzed pine nut oil or 6 g of hydrolyzed pine nut oil.||||
34029052|NCT02548390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029053|NCT01730924|RANDOMIZED|||TREATMENT||||||||
34029054|NCT02010515|||CASE_ONLY||PROSPECTIVE|||||||
34029055|NCT02378987|||COHORT||PROSPECTIVE|||||||
34029056|NCT04084457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34029057|NCT00776178|||CASE_ONLY||RETROSPECTIVE|||||||
34029058|NCT05496244|||COHORT||PROSPECTIVE|||||||
34029059|NCT01384903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029060|NCT04639011|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029061|NCT02289456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029062|NCT05378555|NA|SINGLE_GROUP||TREATMENT||NONE||All patients in this study will receive oral ketamine for the treatment of pain from vaso-occlusive crisis.||||
34029063|NCT00708227|||CASE_CROSSOVER||PROSPECTIVE|||||||
34029064|NCT03683771|||COHORT||PROSPECTIVE|||||||
34029065|NCT00400842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029066|NCT04060446|||COHORT||PROSPECTIVE|||||||
34029067|NCT02233439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34029068|NCT04560608|||COHORT||OTHER|||||||
33723732|NCT01337219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723733|NCT00829374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723734|NCT03911895|||COHORT||PROSPECTIVE|||||||
33723735|NCT02447133|||COHORT||PROSPECTIVE|||||||
33723736|NCT00428896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723737|NCT06074913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33723738|NCT03145168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723739|NCT05259007|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind randomized controlled trial study will be utilized.|96 patients divided into three groups: Group 1 propolis with lactic acid extract on top of the treatment given by doctor Group 2 Lactic acid extract on top of the treatment by the doctor Group 3 the treatment given by the doctor and placebo treatment|t|f|t|f
34029069|NCT06538415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Investigator are masked.|This trial will use a randomized, controlled, parallel design. Control type I error α = 0.05 (two-tailed) and type II error β =0.2. Assume an equal number of participants in the two groups. The calculated sample size is 20 per group. Factoring in a 20% dropout rate, 50 women will be enrolled in this study using a parallel design.|t|f|t|f
34029070|NCT02117739|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34029071|NCT02902263|||CASE_ONLY||RETROSPECTIVE|||||||
34029072|NCT00650130|||CASE_CONTROL|||||||||
34029073|NCT01441895|||COHORT||PROSPECTIVE|||||||
34029074|NCT02552121|NA|SEQUENTIAL||TREATMENT||NONE||||||
34029075|NCT03448341|||COHORT||PROSPECTIVE|||||||
34029076|NCT01350245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029077|NCT03867097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029078|NCT03537131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029079|NCT01399658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029080|NCT03810040|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34029081|NCT05919615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple Blinded||t|t|t|f
34029082|NCT01045668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029083|NCT03398603|||CASE_CONTROL||PROSPECTIVE|||||||
34029084|NCT00141089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029085|NCT03655314|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029086|NCT03536611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029087|NCT04353895|RANDOMIZED|PARALLEL||OTHER||SINGLE|single-blind, only for the patient, after randomization|Medical device compared with gold standard|t|f|f|f
34029088|NCT04679493|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Blinding was carried out by using placebo equivalent to XC7 capsules without active pharmaceutical ingredients (API) and the corresponding labeling of the ID.|The dose cohorts cohorts will be included into the study subsequently based on preliminary safety results evaluation performed by the DSMC. 2 doses of XC7/placebo (100 mg, 200 mg) were used in the study.The duration of exposure to the ID is planned 1 day in single dosing cohorts and 14 days in multiple dosing cohort.|t|f|t|f
34029089|NCT03742947|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Double blind|Three blood samples of 20 ml each at T0 after the anesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of TRAAP2 study IMP (tranexamic acid or placebo).|t|f|t|f
34029090|NCT06198361|||COHORT||RETROSPECTIVE|||||||
34029091|NCT01933477|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34029092|NCT04990713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, treating anesthesiologist and surgical team, and outcomes assessor will be blinded to prevent bias. One of the study team co-investigators who is not the treating anesthesiologist during the participants's surgery will prepare the study drugs. The treating anesthesiologist will not be aware of the contents of the study drugs.|There will be two study groups. All study participants will receive serratus plane block (SAB) with catheter for continuous infusion and an intercostal block. Depending on the group allocation, the study participants may receive local anesthetics or placebo for the serratus plane block.|t|t|f|t
34029093|NCT03357744|||CASE_ONLY||CROSS_SECTIONAL|||||||
34029094|NCT05158543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029095|NCT06334224|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Due to the nature of the intervention, it is not possible to blind participants or outcome assessors to the treatment allocation. There is also no effective sham condition available. This is a common limitation within all blood flow restriction training research.|Two arm randomised control trial||||
34029096|NCT04460287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34029097|NCT03245827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029098|NCT05680181|||COHORT||PROSPECTIVE|||||||
34029099|NCT05096650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"1. The participants will blinded to receive platelet rich plasma and platelet poor plasma injections for treatment of photoaging of right side or left side of face.~2. The practitioner will inject these blood products into photoaging areas in bilateral face in each case without the knowledge of the content of injection materials.~3. The outcomes assessors will evaluate the response of the therapies without the knowledge of which blood products injected into bilateral face."|Double-blind, randomized, split-face|t|f|t|t
34029100|NCT05548387|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029101|NCT01523002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029102|NCT03239847|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Anesthesia team will not be made aware of the purpose of the trial.||f|t|f|f
34029103|NCT06257251|||COHORT||RETROSPECTIVE|||||||
34029104|NCT05341830|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Study participants will be added to one of two arms, treatment (recovery housing) or control (no recovery housing), through a structured waitlist. If a placement in recovery housing becomes available for an individual within two weeks of when they are placed on the waitlist for housing, they will be in the treatment group. If a placement does not become available for an individual within two weeks of when they are added to the waitlist, they will be in the control group.||||
34105448|NCT02595437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105449|NCT06513312|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105450|NCT01130428|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105451|NCT01773889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723740|NCT01559896|NA|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33723741|NCT01662908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723742|NCT00716911||||SUPPORTIVE_CARE||||||||
33723743|NCT00496756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723744|NCT06316531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723745|NCT05578534|||COHORT||PROSPECTIVE|||||||
33723746|NCT04337983|||COHORT||PROSPECTIVE|||||||
33723747|NCT01844609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34029105|NCT05294432|||COHORT||PROSPECTIVE|||||||
34029106|NCT04753762|||OTHER||RETROSPECTIVE|||||||
34105452|NCT02584738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105453|NCT06674057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029107|NCT03043404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029108|NCT00862732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029109|NCT05435690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, randomised, prospective comparative study in two parallel groups (conventional or computer-assisted arthroplasty).|t|f|f|f
34029110|NCT04582084|||OTHER||PROSPECTIVE|||||||
34029111|NCT04679428|||CASE_ONLY||PROSPECTIVE|||||||
34029112|NCT01662401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34029113|NCT03561324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029114|NCT04226521|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients are randomized after heart transplant into two groups. Those randomized for extracorporeal photopheresis undergo 10 procedures during first year, in addition to standard follow-up. Patients in the control group are treated and followed-up according to standard protocol of our transplant center.||||
34105454|NCT06642844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double blinding (patients and investigators) will be applied to this trial with respect to the dose of bevacizumab administered throughout the study, except in specific circumstances such as in emergency cases, and only if knowledge of the dose is likely to influence management.~The dose of bevacizumab will be administered in 2 preparations and in the following order:~* 1. Preparation at 5 mg/kg, open label;~* 2. Preparation at 5 mg/kg or placebo, blinded."|This project is a multicenter, double-blind, randomized trial in two parallel groups.|t|f|t|f
34105455|NCT04975165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029115|NCT01478373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029116|NCT02558439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029117|NCT04860232|||COHORT||PROSPECTIVE|||||||
34029118|NCT04912089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029119|NCT00003405||||TREATMENT||||||||
34029120|NCT05607745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|FMT is given blinded for the participant. The dieticians giving the nutritional advice are also blinded.|National multicenter placebo-controlled randomized pilot study|t|t|t|t
34029121|NCT02586155|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34029122|NCT03512873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029123|NCT00337337|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105456|NCT01800110|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34029124|NCT03120325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"15 participants planned enrollment in each arm:~* Diabetic Gastroparesis~* Functional Dyspepsia~* Idiopathic Gastoparesis"||||
34105457|NCT04361331|RANDOMIZED|PARALLEL||TREATMENT||NONE|Random number table grouping|Arm1: toripalimab combined with lenvatinib， Arm 2: lenvatinib combined with Gemox||||
34105458|NCT02235688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105459|NCT00421967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105460|NCT06355284|||CASE_ONLY||OTHER|||||||
34105461|NCT05584631|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34105462|NCT00299715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34105463|NCT00004061|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34105464|NCT06674408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723748|NCT00155337|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723749|NCT01001507|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33723750|NCT05931679|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant will receive a unique study ID which will be used throughout the life of the study|Participants will be randomized to one of three groups - interactive VR, 360o video, or theatre-based education.|t|f|f|f
33723751|NCT04637542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The research was designed in a randomized controlled experimental type. In the randomization of the study, using the Random.org website (Haahr, 2020) students were assigned to the experiment (mobile application group, n = 31) and control (traditional method group, n = 32) groups according to their numbers in the class list||||
34029125|NCT02445534|||COHORT||PROSPECTIVE|||||||
34029126|NCT00685386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34029127|NCT00534456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029128|NCT06220968|||COHORT||PROSPECTIVE|||||||
34105465|NCT04321031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind, double dummy, placebo controlled|dose ranging, dose finding|t|t|t|t
34105466|NCT00983801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723752|NCT04684381|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723753|NCT03796780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723754|NCT05812521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33723755|NCT02316067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723756|NCT02395900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723757|NCT02601742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723758|NCT03891420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723759|NCT02101047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723760|NCT03810508|||COHORT||PROSPECTIVE|||||||
33723761|NCT02968303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723762|NCT04057404|||CASE_ONLY||PROSPECTIVE|||||||
33723763|NCT02183831|||CASE_CONTROL||RETROSPECTIVE|||||||
33723764|NCT03563417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723765|NCT01069146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723766|NCT00632450|||OTHER||PROSPECTIVE|||||||
33723767|NCT03051321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723768|NCT00984243|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723769|NCT03424174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723770|NCT00819338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723771|NCT04833621|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||SINGLE CENTER, PROSPECTIVE, DOUBLE BLINDED|f|f|t|f
33723772|NCT01771432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805300|NCT04046159|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority trial||||
33805301|NCT05267769|NA|SINGLE_GROUP||OTHER||NONE||||||
33805302|NCT06442748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723773|NCT04467879|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Double Blinded|Prospective, double-blinded, randomized, sham-controlled study|t|f|t|f
33723774|NCT03687203|||COHORT||PROSPECTIVE|||||||
33723775|NCT01635959|||||CROSS_SECTIONAL|||||||
33723776|NCT01037387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723777|NCT00256698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723778|NCT00471848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723779|NCT04174287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723780|NCT01977170|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723781|NCT03257553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723782|NCT02258100|||COHORT||RETROSPECTIVE|||||||
33723783|NCT03717480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723784|NCT02512432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723785|NCT03747965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723786|NCT03853447|||COHORT||PROSPECTIVE|||||||
33723787|NCT04142021|||COHORT||PROSPECTIVE|||||||
33805303|NCT02008669|||CASE_ONLY||PROSPECTIVE|||||||
33805304|NCT04207736|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33805305|NCT06252402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805306|NCT02848105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805307|NCT04865172|||OTHER||CROSS_SECTIONAL|||||||
33805308|NCT00635869|||||PROSPECTIVE|||||||
33805309|NCT05923190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805310|NCT03802994|RANDOMIZED|PARALLEL||PREVENTION||NONE||Immune response to immunization with Prevnar in elderly aging renal transplant compared to comparison groups: healthy young, healthy elderly, healthy elderly hypertension (HTN) and young renal transplants.||||
34029129|NCT05322122|NA|SINGLE_GROUP||TREATMENT||NONE||"An operationally seamless, 2-stage, open-label, multicenter study enrolling up to 50 subjects at up to 5 study centers across Canada and Europe:~* Stage 1 first-in-human (FIH) and proof-of-concept with 5 subjects; and~* Stage 2 feasibility with 45 subjects.~There will be a pause after completing enrollment in Stage 1 to allow completion of Day 30 and evaluation of safety by the independent Data Safety Monitoring Committee (DSMB). The DSMB will confirm whether the study can advance to Stage 2. All subjects in Stage 1 and 2 will be followed for 12 months."||||
34029130|NCT03011593|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34029131|NCT01573299|RANDOMIZED|PARALLEL||||NONE||||||
34029132|NCT01876446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029133|NCT04359797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients and providers will necessarily be unblinded, but outcomes will be analyzed by a blind assessor.|This study will be performed as a pragmatic controlled clinical trial with parallel group assignment.|f|f|f|t
34029134|NCT03210792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029135|NCT05986227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029136|NCT00001526||||TREATMENT||||||||
34029137|NCT00016081|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34029138|NCT00824343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029139|NCT04934046|NA|SINGLE_GROUP||OTHER||NONE||All patients will undergo SPECT acquisitions with both new multipurpose CZT camera and conventional SPECT camera.||||
34029140|NCT03423719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33723788|NCT06112938|||COHORT||RETROSPECTIVE|||||||
33723789|NCT00497172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723790|NCT00075426||||TREATMENT||NONE||||||
33723791|NCT05551494|||CASE_CONTROL||PROSPECTIVE|||||||
33723792|NCT00678119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723793|NCT02129985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723794|NCT05174039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723795|NCT01038024|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33723796|NCT00325754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723797|NCT06171776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723798|NCT02380664|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723799|NCT05272904|RANDOMIZED|PARALLEL||PREVENTION||NONE|Surgical technique is not blinded for surgeon and/or patients. An independent panel of four surgeons will blindly assess cosmetics.|The QUILT study is a stepped wedge cluster randomized study.||||
33805311|NCT02054351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805312|NCT00545311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805313|NCT01057459|||COHORT||RETROSPECTIVE|||||||
33805314|NCT05747014|||COHORT||PROSPECTIVE|||||||
33805315|NCT01854385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805316|NCT02320266|||CASE_CONTROL||PROSPECTIVE|||||||
33805317|NCT06700278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805318|NCT05805826|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel assignment|t|f|t|t
33805319|NCT06518486|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors who assess the outcomes are blinded|Three arms parallel group design with 2 group interventions (foot-ankle exercise and walking exercise) and 1 control group|f|f|f|t
33805320|NCT02138123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805321|NCT05433415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33805322|NCT06318728|||COHORT||PROSPECTIVE|||||||
33805323|NCT02919787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029141|NCT02593643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805324|NCT00370942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805325|NCT05027581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029142|NCT03209817|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34029143|NCT02069548|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805326|NCT05321082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805327|NCT05206825|||CASE_CONTROL||PROSPECTIVE|||||||
33805328|NCT02409680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029144|NCT03305627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029145|NCT01308424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805329|NCT01712542|||CASE_ONLY||PROSPECTIVE|||||||
34029146|NCT04174612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805330|NCT06652360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805331|NCT05719519|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34029147|NCT04940637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029148|NCT02210845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029149|NCT04683224|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029150|NCT06321614|||CASE_CONTROL||RETROSPECTIVE|||||||
34029151|NCT06550713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029152|NCT02708771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029153|NCT00699998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029154|NCT05501535|||CASE_ONLY||PROSPECTIVE|||||||
34029155|NCT05493501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029156|NCT00963066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34029157|NCT04052620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029158|NCT05209607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34029159|NCT00785148|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34029160|NCT04200027|||COHORT||PROSPECTIVE|||||||
34029161|NCT03993379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029162|NCT03280888|||OTHER||PROSPECTIVE|||||||
34029163|NCT01090518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105467|NCT05757167|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Random assignment to either a) usual antenatal care or b) testing for malaria with a high-sensitivity rapid diagnostic test followed by treatment with artemether-lumefantrine if tested positive|f|f|f|t
34105468|NCT01681849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105469|NCT02748174|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105470|NCT00154245|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34105471|NCT04854317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105472|NCT00982579|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34105473|NCT06639555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105474|NCT02486770|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105475|NCT04147169|||COHORT||PROSPECTIVE|||||||
34105476|NCT06399692|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researchers and most study personnel (including those from the QOL follow-up center and events assessors, clinical events committee and angiographic core laboratory) will be blinded to allocated treatment.||f|f|f|t
34105477|NCT03607500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105478|NCT02980185|||COHORT||PROSPECTIVE|||||||
33805332|NCT03446521|||COHORT||PROSPECTIVE|||||||
33805333|NCT04717570|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive the study device||||
33805334|NCT00697060|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805335|NCT01341132|||COHORT||PROSPECTIVE|||||||
34029164|NCT01654016|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34029165|NCT05497791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized and placebo-controlled.|f|f|t|f
34029166|NCT02285088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029167|NCT05500950|||COHORT||RETROSPECTIVE|||||||
34029168|NCT06434974|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34029169|NCT05019443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029170|NCT04671693|NA|SINGLE_GROUP||PREVENTION||NONE||All patients in the study will benefit from the PASCA post-treatment program with 4 visits : at 1 month (T1), 6 month (T2), 24 month (T3) and 60 month (T4) after the end of treatment.||||
34029171|NCT06633874|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34029172|NCT03099057|||COHORT||PROSPECTIVE|||||||
34029173|NCT03261492|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The investigators will identify, recruit, and randomize ECEC to the SAGE intervention or a child safety attention comparison. After 16 weeks, intervention and comparison will cross over, allowing us to continue to investigate longitudinal and carry over effects. One ECEC of each pair will be randomized to the SAGE intervention and the other to the child safety attention comparison. ECEC will cross over and receive the treatment that they did not receive to ensure that all ECEC receive both curriculums.||||
34029174|NCT03001453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029175|NCT03104855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029176|NCT04594824|||COHORT||PROSPECTIVE|||||||
34029177|NCT06548997|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34029178|NCT03258203|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34029179|NCT04413201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805336|NCT00674752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805337|NCT05848713|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adaptive stratified randomized clinical trial with Bayesian stopping rules||||
34029180|NCT03149276|||CASE_CONTROL||PROSPECTIVE|||||||
34029181|NCT04939220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization to control group- deep sedation with propofol and natural airway or Experimental group-SGA Placement and maintenance with inhalational anesthetic or propofol.|Prospective, randomized control trial|t|f|f|f
34105479|NCT04804033|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34105480|NCT05274698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105481|NCT06683248|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34105482|NCT02688335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105483|NCT06570915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029182|NCT05099250|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"The groups allocated are concealed in sealed opaque envelopes which were not opened until patient consent was obtained.~The two groups were:~1. Control group: Bupivacaine Group (B group) N=25 :~   Included patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side.~2. Magnesium Group (M group) N=25 :~Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.~All patients were performed by the same anesthetic team with standard procedure."|"The groups allocated are concealed in sealed opaque envelopes which were not opened until patient consent was obtained.~The two groups were:~1. Control group: Bupivacaine Group (B group) N=25 :~   Included patients who received 17 mL of 0.25% bupivacaine + 3 mL saline 0.9% in a total volume of 20 ml on each side.~2. Magnesium Group (M group) N=25 :~Included patients who received 17 mL of 0.25% bupivacaine + 3 mL of 75 mg magnesium sulfate diluted in 0.9% saline in a total volume of 20 ml on each side.~All patients were performed by the same anesthetic team with standard procedure."|t|t|t|t
34029183|NCT00888160|||OTHER||PROSPECTIVE|||||||
34029184|NCT05643872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029185|NCT03649984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||cluster-randomized waitlist design||||
34029186|NCT02202707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029187|NCT06019884|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
34029188|NCT01941498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029189|NCT03149796|||CASE_CONTROL||RETROSPECTIVE|||||||
34029190|NCT05992857|RANDOMIZED|PARALLEL||TREATMENT||NONE||"National, Phase IIIb multicenter, centrally randomized open-label trial with two parallel arms. Participants will be distributed between the two arms at a ratio (1:1).~Randomization will be built by block of unequal size stratified by center and the prophylactic use of somatostatin/octreotide-Yes/No"||||
34029191|NCT01810510|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34029192|NCT06458647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029193|NCT02460406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029194|NCT01119781|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105484|NCT00324246|||CASE_ONLY||RETROSPECTIVE|||||||
34105485|NCT04010838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|People who involved with data analysis and outcomes assessment would be blind to the randomization procedure.|Random controlled trial|f|f|f|t
34105486|NCT05802537|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805338|NCT04503681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805339|NCT00175812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805340|NCT03213145|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||2-Part Single Group study.||||
33805341|NCT03739866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805342|NCT06597591|RANDOMIZED|PARALLEL||OTHER||NONE||Pseudo-randomisation (controlling for demographic and clinical features, and previous VR experience)||||
33805343|NCT05796037|||COHORT||OTHER|||||||
33805344|NCT04874519|||COHORT||PROSPECTIVE|||||||
33805345|NCT01611493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805346|NCT05094011|NA|SEQUENTIAL||TREATMENT||NONE||This study plans to enroll approximately 4 subjects to obtain 3 evaluable subjects successfully receiving 3×10\^7 cells/hemisphere (total 6×10\^7 cells, Cohort 1) and approximately 8 subjects to obtain 6 evaluable subjects for 1×10\^8 cells/hemisphere (total 2×10\^8 cells, Cohort 2)||||
34029195|NCT02470845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029196|NCT00005957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029197|NCT01810757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029198|NCT05133674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029199|NCT02508935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029200|NCT02501018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029201|NCT03104712|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The outcomes assessor will be unaware of the intervention associated with the samples being analyzed.||f|f|f|t
34105487|NCT06688383|||COHORT||PROSPECTIVE|||||||
34105488|NCT00004665||||TREATMENT||||||||
34105489|NCT06669208|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
34105490|NCT02096380|||CASE_ONLY||PROSPECTIVE|||||||
34105491|NCT02197065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105492|NCT06686992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34105493|NCT03468673|||OTHER||PROSPECTIVE|||||||
34105494|NCT00885898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105495|NCT06590428|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1:1 randomization.~Participants will receive 600mg daily dose of oral LZD for Rifampicin-resistant tuberculosis (RR-TB) as part of standard of care for both arms. This dosage may be reduced to 300mg daily based on the plasma trough concentration obtained from the first pharmacokinetic (PK) specimen."||||
34105496|NCT00548691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805347|NCT04543903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805348|NCT03358433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805349|NCT04023175|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33805350|NCT01991275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805351|NCT02189772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805352|NCT06369818|||COHORT||PROSPECTIVE|||||||
33805353|NCT03648190|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805354|NCT03165734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805355|NCT06079164|NA|SEQUENTIAL||TREATMENT||NONE||||||
33805356|NCT03666468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3 groups|f|f|t|t
33805357|NCT04496388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805358|NCT06053606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805359|NCT00258830|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805360|NCT01222442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33805361|NCT03355573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805362|NCT02146469|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805363|NCT04122885|||COHORT||PROSPECTIVE|||||||
33805364|NCT00502294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805365|NCT06490939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805366|NCT01447706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805367|NCT03779984|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Outcome accessor and participants are blinded.||t|f|f|t
34105497|NCT02769481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105498|NCT04187404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105499|NCT02624479|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34105500|NCT04390009|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Participants will be de-identified; results will be anonymized.|Different PET-CT scanners (make and model) determine the different study arms for the intervention defined as a PET-CT medical imaging scan with the Amyvid imaging agent.||||
34105501|NCT00476723|||CASE_ONLY||PROSPECTIVE|||||||
34105502|NCT03115463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical care team in the neonatal intensive care unit, investigators running the oxidative stress measurements and investigator assessing neurodevelopmental outcomes will be blinded to which arm the infant was randomized to in the delivery room.||f|f|f|t
34105503|NCT00912509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105504|NCT06232590|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34105505|NCT02229682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723800|NCT03134560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723801|NCT05448651|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33723802|NCT06334731|||COHORT||RETROSPECTIVE|||||||
33723803|NCT03134027|||COHORT||PROSPECTIVE|||||||
33723804|NCT02068222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723805|NCT00367081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33723806|NCT02323230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723807|NCT01103687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33723808|NCT05118451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single blind design was used in this study. Patients were not informed about whether to use 3D visualization technology, and the subjects were blinded. Random numbers used for grouping are generated by third-party statisticians using SPSS. After the patients were enrolled, the nurses provided the surgeons with random numbers and groups of the patients in identical, opaque, sealed envelopes. The 3 researchers who will not participate in the operation will be independently responsible for recording the preoperative 3D visualization or CT analysis results, surgical photos and information records, postoperative complications and prognosis follow-up of the patients. The statisticians on the team who analyzed the data did not know how the patients were grouped.|"Intervention of the experimental group: based on high-quality thin-slice CT image reconstruction 3d visualization model to guide preoperative planning and surgery. The surgical process and perioperative management are as follows: All patients in this study were operated by the medical team whose main member was the medical team leader, and all patients were treated with anatomic hepatectomy.~Intervention in the control group: preoperative planning and operation were guided based on high-quality thin-slice CT images."|t|f|f|f
33723809|NCT03147365|RANDOMIZED|PARALLEL||OTHER||NONE||Experimental controlled randomization using Block Stratified Randomized Software program, after obtaining informed consent from illegible patient or his caregiver.||||
33723810|NCT03139149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723811|NCT02301273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723812|NCT04356690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723813|NCT00885755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723814|NCT01547234|||||PROSPECTIVE|||||||
33723815|NCT05311696|||COHORT||PROSPECTIVE|||||||
33723816|NCT00230425|||DEFINED_POPULATION||OTHER|||||||
33723817|NCT01861548|||COHORT||PROSPECTIVE|||||||
33723818|NCT03090854|||OTHER||PROSPECTIVE|||||||
33723819|NCT03989245|||COHORT||PROSPECTIVE|||||||
33723820|NCT01328860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723821|NCT06008509|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Descriptive study where patients are going to recieve and abdominal image exam (gastric Ultrasound)||||
33723822|NCT03756298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723823|NCT03371992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723824|NCT02526940|||COHORT||PROSPECTIVE|||||||
33723825|NCT00245141||||TREATMENT||NONE||||||
33723826|NCT01370226|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33723827|NCT00927433|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33723828|NCT00429507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723829|NCT01412203|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723830|NCT00906152|||||PROSPECTIVE|||||||
33723831|NCT04586946|||COHORT||PROSPECTIVE|||||||
33723832|NCT02608554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723833|NCT02046460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PROBE-Design: Prospective, randomized, open-label, blinded assessment of end-points.||f|f|f|t
33723834|NCT06151587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723835|NCT06456333|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33723836|NCT00411164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33723837|NCT04035161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Study products cannot be blinded to staff member(s) performing product applications, sample collections.~Staff member(s) performing bacterial enumeration will be blinded from the identification of all study product assignments."|Healthy adult volunteers that meet inclusion/exclusion criteria will be randomized to receive 2 of the 4 products on bilateral site on the abdomen and/or groin.|f|f|f|t
33723838|NCT04028752|||CASE_ONLY||PROSPECTIVE|||||||
33723839|NCT00485407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33723840|NCT03897179|NA|SINGLE_GROUP||OTHER||NONE||||||
33723841|NCT03631901|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33723842|NCT02164305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723843|NCT05466747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723844|NCT05042947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723845|NCT05851859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723846|NCT06528522|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33723847|NCT00680433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34029202|NCT05717465|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Investigators were blind as to which arm participants were allocated to as the randomization and intervention/control exposure occurs after participants open the link to the study questionnaire. The same link would allocate participants to either the control/intervention group.~Outcomes were assessed within the questionnaire without any human input No care providers were present in this study"|Upon clicking the link to the study questionnaire, participants were randomized to either receive the control or intervention questionnaire. This was done through Qualtrics (Qualtrics, Provo, UT) built-in randomization.|f|f|t|t
34105506|NCT06570811|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This is an open label study where Patients will be classified as follow:~Control arm :20 Patients will receive 80 mg/m2 of paclitaxel chemotherapy weekly for 12 weeks after receiving 4 cycles of AC protocol (Adriamycin and cyclophosphamide)~Treatment arm : 20 Patients will receive the same regimen as group1 in addition to 200 mg Coenzyme Q10 twice daily for 3 months"|This study is a parallel study||||
34105507|NCT00318136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105508|NCT05646173|RANDOMIZED|PARALLEL||TREATMENT||NONE|Double (Participant, Outcomes Assessor)|60 patients, aged between 18 and 60, with persistent low back pain who voluntarily agreed to participate in the study will be included in the study. Patient Identification Form, Lumbal Region Joint Range of Motion and Mobility (Inclinometer, Modified Schober Test), muscle strength (CSMI-Cybex Humac-Norm isokinetic dynamometer and manual muscle strength measuring device) in the evaluation of patients with CKD and endurance tests, postural control and balance assessment (BBS, Biodex Medical Systems), Visual Analogue Scale (VAS), Beck Depression Inventory (BDI), Pittsburgh Sleep Quality Scale (PUKÖ), Oswestry Disability Index. Statistical analysis will be calculated using SPSS for Windows 22 program.||||
34105509|NCT01689649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805368|NCT04800042|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805369|NCT06648135|||COHORT||CROSS_SECTIONAL|||||||
34105510|NCT06640803|NA|SINGLE_GROUP||TREATMENT||NONE||This is a dissemination and implementation trial in which the study team is training staff at nine local community mental health centers to implement a screening protocol and stepped-care intervention. These clinics will be providing treatment and the study group will be evaluating it. There is no control group.||||
34105511|NCT06510621|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33805370|NCT01361321|||COHORT||CROSS_SECTIONAL|||||||
33805371|NCT03367754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805372|NCT06081738|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34105512|NCT06474962|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34029203|NCT06581367|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with acute RTIs will be randomized to either usual care (full-course antibiotic therapy based on current guidelines), or a tailored approach (patients will be advised to visit the center as soon as they feel better and are afebrile for a clinical assessment and C-reactive protein rapid testing after completing two full days of antibiotic).||||
34029204|NCT02759393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105513|NCT06457997|NA|SEQUENTIAL||TREATMENT||NONE||||||
34105514|NCT05226195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized controlled clinical trial|t|f|f|f
34029205|NCT01618344|||OTHER||PROSPECTIVE|||||||
34029206|NCT00002780||||TREATMENT||||||||
34029207|NCT04808973|NA|SINGLE_GROUP||TREATMENT||NONE||A group of 20 pregnant women will be enrolled, in two phases: the first one will include 10 women, and if no safety sign is detected after completion of this initial group, additional 10 women will be enrolled||||
34029208|NCT01437930|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34105515|NCT03734055|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34105516|NCT01091883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105517|NCT06022211|||OTHER||CROSS_SECTIONAL|||||||
34105518|NCT03039751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105519|NCT06636812|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|double-blind|Parallel randomised experimental medicine trial|t|f|t|t
34105520|NCT01550887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105521|NCT03773562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723848|NCT03371628|RANDOMIZED|PARALLEL||TREATMENT||NONE||A parallel group study is a simple and commonly used clinical design which compares two treatments. Usually a test therapy is compared with a standard therapy. The allocation of subjects to groups is usually achieved by randomisation. The groups are typically named the treatment group and the control group. Parallel group designs do not require the same number of subjects in each group, although often similar numbers are observed. The design is commonly used in randomised controlled trials. Statistical analysis often boils down to a simple t-test of the between group difference in the outcome, which is usually a mean or a proportion.||||
34105522|NCT05226338|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105523|NCT00124358|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105524|NCT04964752|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105525|NCT05313958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105526|NCT05026736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105527|NCT05216380|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34105528|NCT04053426|||OTHER||PROSPECTIVE|||||||
34105529|NCT06571084|||COHORT||PROSPECTIVE|||||||
34105530|NCT06640348|||CASE_CONTROL||PROSPECTIVE|||||||
34105531|NCT01059279|||CASE_ONLY||PROSPECTIVE|||||||
34105532|NCT06689241|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105533|NCT01993680|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34105534|NCT00846482|NA|SINGLE_GROUP||BASIC_SCIENCE||||||||
34105535|NCT05377814|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34105536|NCT04484428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105537|NCT02837952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105538|NCT04791020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105539|NCT04560530|||COHORT||RETROSPECTIVE|||||||
33723849|NCT06101199|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33805373|NCT05141539|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33805374|NCT03449771|NA|SINGLE_GROUP||OTHER||NONE||||||
33805375|NCT04844879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105540|NCT06673940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|stactician|Blinded randomized controlled trial|t|f|f|t
33805376|NCT05178420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is open-label, with blinded outcome adjudication. Identification of potential outcome events is performed by blinded study team members.|Study subjects are randomly assigned in a 1:1 ratio to either discontinue (intervention arm) or continue (control arm) statin therapy|f|f|f|t
34105541|NCT06542341|NA|SINGLE_GROUP||TREATMENT||NONE|Blinded photography- images masked|Open-label, single-centre trial.||||
34105542|NCT02869009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105543|NCT02439463|||OTHER||CROSS_SECTIONAL|||||||
34105544|NCT02005926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105545|NCT06674239|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34105546|NCT06675149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105547|NCT05504746|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34105548|NCT06640049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105549|NCT03673930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34105550|NCT06303752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105551|NCT00341874|||COHORT||PROSPECTIVE|||||||
34105552|NCT04986137|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105553|NCT02534623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105554|NCT00608790|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105555|NCT04594993|||OTHER||PROSPECTIVE|||||||
34105556|NCT06398574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105557|NCT05772156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34105558|NCT06639490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105559|NCT00376558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105560|NCT03938727|||COHORT||PROSPECTIVE|||||||
34105561|NCT00049946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34105562|NCT06579144|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Open-label, 2-period, fixed-sequence study for intra-participant comparison of PK-profiles.||||
34105563|NCT04802109|RANDOMIZED|CROSSOVER||OTHER||SINGLE|It is impossible to masking the participant, care provider during the CPR study.|This study is designed as a prospective randomized crossover trial . Each participant is required to perform a five-minute CPR in kneeling position using three different types of personal protective equipment. After each round of CPR for 5 minutes, the participants can rest for two hours before the next round of CPR with different type of personal protective equipment|f|f|f|t
34105564|NCT05894655|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The investigators chose a roll-out implementation optimization (ROIO) design to implement the study. This is a novel implementation science study design that affords a balance of rigor and flexibility to rapidly and iteratively refine in response to dynamic contexts like the pandemic.||||
34105565|NCT00854737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105566|NCT02098603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105567|NCT06510075|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Study is a randomized trial (n=400) randomizing eligible participants to usual care (n=100), or usual care plus a digital health intervention (n=100), or usual care plus a community health worker intervention (n=100), or usual care plus both a digital health intervention and a community health worker intervention (n=100).|f|t|f|f
34105568|NCT01607008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805377|NCT01567605|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33805378|NCT02180815|||COHORT||PROSPECTIVE|||||||
33805379|NCT01218841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805380|NCT01576796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837851|NCT01689415|||CASE_ONLY||PROSPECTIVE|||||||
33837852|NCT05840068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837853|NCT00999999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837854|NCT01851551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837855|NCT01126034|RANDOMIZED|PARALLEL||||NONE||||||
33837856|NCT02932930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837857|NCT01078961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837858|NCT05606289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigators will blind the rater, who would code the video-recorded outcome behaviors.|Single-blind, parallel-group RCT|f|f|f|t
33837859|NCT05676905|||COHORT||PROSPECTIVE|||||||
33837860|NCT00145964|||DEFINED_POPULATION||OTHER|||||||
33837861|NCT04047173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837862|NCT00297947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837863|NCT03924102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837864|NCT02588872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837865|NCT01228175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33837866|NCT04344951|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective, open label, Phase II study||||
33837867|NCT01518907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837868|NCT00167804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837869|NCT05673265|||COHORT||OTHER|||||||
33837870|NCT01746589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837871|NCT02713399|||COHORT||PROSPECTIVE|||||||
33837872|NCT06241937|NA|SINGLE_GROUP||OTHER||NONE|The simulated patient encounter used for this study is a regular component of the DGSOM curriculum used to assess student skills in history taking and physical examination. Students will not be told specifically before the activity that one of the assessments will be whether or not they counseled the simulated patient about firearm safety. Following the activity, the students will be invited to provide informed consent for investigators to view video recordings of the activity for educational research. The firearm screening and counseling performance will not be a factor in a student's grade for the simulated patient encounter.|Survey responses and student performances during the simulated patient encounter for members of the DGSOM Class of 2027 who consent to study participation will be compared with those of the students in the DGSOM Classes of 2023 and 2024 in the investigators' previous study of firearm safety counseling training, who consented to the future use of their study data (ClinicalTrials.Gov ID: NCT05242627). Surveys and simulated patient encounter scenario will be identical in both studies, to allow for optimal comparison to the historical controls.||||
34029209|NCT04284059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants and care providers don't know which group they are enrolled in. And the investigators just play a roll in recruiting the patients, inform the patients about the study, and then randomly assign the patients in a 1:1:1 ratio to the A group, B group or C group. The drugs are dispensed by staff who was not involved in the process of evaluation, diagnosis and treatment. The staff will take notes about the patients' basic information and medication records. After the study, the staff will give the unblinded results to to investigators and outcomes assessor. The investigators will provide the compensatory therapy for the patients. The outcomes assessor will do the statistic analysis.|The patients showed deficiency or insufficiency in vitamin A (≤1.05 umol/ L) and vitamin D (≤50 nmol/L) are randomly assigned in double-blind fashion in a 1:1:1 ratio to the vitamin AD supplementation group, vitamin D supplementation group or the placebo group. Vitamin AD supplementation group will be administrated vitamin AD capsules (3 capsules/time, once a day for 8 weeks), which contain vitamin A (2000 IU/capsule) and vitamin D (700 IU/capsule). Vitamin D supplementation group will be administrated vitamin D capsules (400 IU/capsule, 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks). The placebo capsules given to the placebo group (3 capsules/time, once a day for 8 weeks), consists of oily liquids which do not contain vitamin A and vitamin D, and were produced in strict accordance with China's drug management and packaging requirements for placebo by Shandong DYNE Marine Biopharmaceutical Co., Ltd in China.|t|t|t|f
33723850|NCT01273792|||COHORT||PROSPECTIVE|||||||
33723851|NCT04546347|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34029210|NCT03452137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723852|NCT04665921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723853|NCT02310685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34029211|NCT00003643|RANDOMIZED|||TREATMENT||||||||
34029212|NCT06281197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|double blind|t|f|f|t
34029213|NCT05445492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Non-randomized control trial||||
33723854|NCT03110250|||CASE_ONLY||CROSS_SECTIONAL|||||||
33723855|NCT03034265|||COHORT||PROSPECTIVE|||||||
33723856|NCT01787227|||CASE_ONLY||PROSPECTIVE|||||||
34029214|NCT01533012|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34029215|NCT02192398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029216|NCT02680951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723857|NCT05063942|||COHORT||PROSPECTIVE|||||||
33723858|NCT04640090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029217|NCT06133426|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study of feasibility and acceptability, non-comparative, non-controlled, non-randomized||||
33723859|NCT03974971|||OTHER||RETROSPECTIVE|||||||
33723860|NCT06222281|||OTHER||CROSS_SECTIONAL|||||||
33723861|NCT05567055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029218|NCT01221610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723862|NCT03755986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723863|NCT00284245|||COHORT||PROSPECTIVE|||||||
33723864|NCT03441841|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029219|NCT05273450|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029220|NCT02454855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34029221|NCT03643861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723865|NCT04566315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723866|NCT01991158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723867|NCT02308462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029222|NCT03479801|||CASE_CONTROL||PROSPECTIVE|||||||
34029223|NCT04162678|||CASE_CONTROL||PROSPECTIVE|||||||
34029224|NCT02837120|||CASE_ONLY||RETROSPECTIVE|||||||
34029225|NCT06318312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34029226|NCT05198180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029227|NCT05314088|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A two group RCT, one group receives the behavioral intervention and one receives an attention matched placebo control intervention.|f|f|t|t
34029228|NCT01742858|||COHORT||PROSPECTIVE|||||||
33723868|NCT05237479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"On the day of surgery, a sealed envelope with group allocation (Group A- Control vs. Group B - Intervention) will be opened by a team member not involved with data collection.~A separate anesthesia team consisting of an anesthesiologist and certified nurse anesthetist will be responsible for the spinal anesthetic and monitored anesthesia care for both groups in the operating room A separate acute pain service team will follow the patients in both groups on postoperative day 1 and evaluate sensory and motor distribution of LFCN, FN, and ON for both groups A research assistant blinded to the allocation of both groups will collect data from the EMR for analysis. In addition, a research assistant blinded to the allocation of both groups will call patients via telephone 24 hours post-discharge for a patient satisfaction survey."||f|t|f|t
33723869|NCT05824533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723870|NCT05402150|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33723871|NCT05683899|||COHORT||PROSPECTIVE|||||||
33723872|NCT06436573|||COHORT||RETROSPECTIVE|||||||
33723873|NCT04992403|||COHORT||CROSS_SECTIONAL|||||||
33723874|NCT05798390|||COHORT||PROSPECTIVE|||||||
33723875|NCT00708942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723876|NCT03337282|||COHORT||PROSPECTIVE|||||||
33723877|NCT05020314|NA|SINGLE_GROUP||TREATMENT||NONE||"Children receiving care at the implementation sites, and who are referred to and attend the Healthy Weight Clinic will receive the intervention as described.~A sample of demographically matched children who did not receive the intervention will serve as a comparison group."||||
33723878|NCT02064010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723879|NCT05863377|||COHORT||RETROSPECTIVE|||||||
33723880|NCT06475482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||This randomized, double-blind, controlled trial will be conducted at the Faculty of Dentistry, Chulalongkorn University. The 66 participants will be randomly assigned to receive either lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel. Both lip products will be given to allocated participants in the product container of identical appearance. Both subjects and investigators will be blinded to the study randomization.|t|f|t|f
34029229|NCT00238355|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34029230|NCT01965054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34029231|NCT00352417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029232|NCT04753697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029233|NCT02165735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029234|NCT03212248|||CASE_ONLY||PROSPECTIVE|||||||
34029235|NCT02996292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029236|NCT00736437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029237|NCT00462150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029238|NCT06119594|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Comparative, controlled, randomized by cluster 1:1 open, in two parallel arms||||
34029239|NCT02040077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34029240|NCT01861912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029241|NCT02100488|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34029242|NCT00028977||||TREATMENT||NONE||||||
34029243|NCT01308801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029244|NCT04525937|||COHORT||PROSPECTIVE|||||||
34029245|NCT05577221|NA|SINGLE_GROUP||OTHER||NONE||||||
34029246|NCT04144530|||COHORT||RETROSPECTIVE|||||||
34029247|NCT00782860|||||PROSPECTIVE|||||||
34029248|NCT00217555||||TREATMENT||NONE||||||
34029249|NCT03473015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029250|NCT02768831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029251|NCT03742791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Participant, Investigator)||t|f|t|f
34029252|NCT01422980|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34029253|NCT04019626|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34029254|NCT01537939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34029255|NCT05489614|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34029256|NCT01015469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029257|NCT01331850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029258|NCT02598921|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029259|NCT03597919|RANDOMIZED|PARALLEL||PREVENTION||NONE||a multi-center, randomized, open-label, seroconversion/immunogenicity study.||||
34029260|NCT01375179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029261|NCT02907879|||COHORT||PROSPECTIVE|||||||
34029262|NCT01607359|||CASE_CONTROL||RETROSPECTIVE|||||||
34029263|NCT01474811|||COHORT||PROSPECTIVE|||||||
34029264|NCT00327756|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34029265|NCT03831204|||CASE_CONTROL||PROSPECTIVE|||||||
34029266|NCT05727098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34105569|NCT05505786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Stratified to include similar number of forward and backs in each arm.|f|f|t|f
34105570|NCT06311734|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34105571|NCT06685770|||COHORT||PROSPECTIVE|||||||
34105572|NCT01764932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105573|NCT05259605|||COHORT||OTHER|||||||
34105574|NCT04290897|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34105575|NCT06640322|||OTHER||PROSPECTIVE|||||||
34105576|NCT06083571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105577|NCT01964209|||COHORT||PROSPECTIVE|||||||
34105578|NCT06380907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723881|NCT06539559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723882|NCT04363021|||CASE_CONTROL||PROSPECTIVE|||||||
33723883|NCT00289809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723884|NCT05326594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723885|NCT00837707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029267|NCT02466841|||COHORT||PROSPECTIVE|||||||
34029268|NCT02624180|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34029269|NCT01328522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029270|NCT03419689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029271|NCT01984827|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029272|NCT00195455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029273|NCT06259435|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Subjects will be randomly assigned to one of two groups. Except for the Director of the Metabolic Kitchen and the dietitians assigned to the study, all other researchers conducting the study will be blinded to the treatment group assignment of subjects.|Subjects will be randomly assigned to receive a diet low in energy density or the usual diet.|t|f|t|t
34029274|NCT05507736|NA|SINGLE_GROUP||OTHER||NONE||Pre-post feasibility||||
34105579|NCT00091897|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34105580|NCT01744366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105581|NCT06642766|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34105582|NCT05339425|||COHORT||PROSPECTIVE|||||||
34105583|NCT06640634|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
34105584|NCT01660373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105585|NCT00896844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34105586|NCT05872516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723886|NCT04384510|||COHORT||RETROSPECTIVE|||||||
34029275|NCT02802033|||CASE_ONLY||PROSPECTIVE|||||||
34029276|NCT02644473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029277|NCT04793594|||CASE_ONLY||PROSPECTIVE|||||||
34029278|NCT01584817|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34029279|NCT03062761|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029280|NCT01917292|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029281|NCT04402840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029282|NCT01998945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029283|NCT01335035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029284|NCT00202930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029285|NCT03469661|||COHORT||PROSPECTIVE|||||||
34105587|NCT04133038|||COHORT||PROSPECTIVE|||||||
34105588|NCT00022854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105589|NCT05193383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105590|NCT06645262|||COHORT||PROSPECTIVE|||||||
34029286|NCT04291625|NA|SINGLE_GROUP||TREATMENT||NONE||20 eyelids with congenital ptosis with levator function of 4 mm or better, who underwent levator muscle resection guided by the recent intraoperative lagophthalmos formula.||||
34029287|NCT03474458|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be an open-label parallel-group randomized (1:1) trial. Control patients receive standard supportive therapy.||||
34029288|NCT04987476|||COHORT||PROSPECTIVE|||||||
34105591|NCT02858778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34029289|NCT03776916|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34105592|NCT00078195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029290|NCT00129545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029291|NCT04571554|||COHORT||PROSPECTIVE|||||||
34029292|NCT06443723|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34029293|NCT05950308|||COHORT||RETROSPECTIVE|||||||
34029294|NCT01464632|||COHORT||PROSPECTIVE|||||||
34029295|NCT04322058|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34029296|NCT04941326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participans and outcome assessors will be blinded to group allocation. Control group will receive same amount of sham mobilisations.|Two groups with sham control group|t|f|f|t
34029297|NCT05882747|||COHORT||RETROSPECTIVE|||||||
34029298|NCT03953326|NA|SINGLE_GROUP||PREVENTION||NONE||Single-group pre-post change||||
34029299|NCT01155973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029300|NCT01891383|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34029301|NCT04387942|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||group A:patients were treated with IL-2.group B:patients were not treated with IL-2.||||
34029302|NCT00720382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029303|NCT01165528|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029304|NCT04805515|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention consists of 8 brief nicotine corrective public education messages delivered online. The messages will communicate misperceptions about nicotine's role in health harms as well as misperceptions that reduced nicotine content cigarettes are less harmful than tobacco cigarettes and that e-cigarettes contain less nicotine than tobacco cigarettes.||||
34029305|NCT00817518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723887|NCT02130661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029306|NCT00273988|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029307|NCT00219817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029308|NCT05242718|RANDOMIZED|PARALLEL||TREATMENT||NONE||8 participants assigned to Palmitoylethanolamide 8 participants assigned to Echinacea purpurea 8 participants assigned to Curcumin 8 participants assigned to N-Acetyl-L-cysteine||||
34029309|NCT00302445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029310|NCT06421025|||COHORT||PROSPECTIVE|||||||
34029311|NCT03098082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Cares providers, patients and study primary investigators will be blinded to 2 hour Urine Trypsinogen dip stick test results. Results will not be released or posted on subject chart.|All enrolled subjects who meet study inclusion /exclusion will have the Urine Trypsinogen dip stick test||||
34029312|NCT02083627|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029313|NCT02049970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029314|NCT03933215|||COHORT||PROSPECTIVE|||||||
34105593|NCT05286112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105594|NCT04869384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105595|NCT06597344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105596|NCT04816903|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Group-A Blinded Group-B Unblinded||||
34105597|NCT06639360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105598|NCT05867888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105599|NCT00663260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105600|NCT05746637|||OTHER||CROSS_SECTIONAL|||||||
34029315|NCT05373199|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Three-period crossover|t|f|t|f
34029316|NCT02203409|||COHORT||PROSPECTIVE|||||||
34029317|NCT01346293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029318|NCT05076461|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34029319|NCT00626119|||COHORT||CROSS_SECTIONAL|||||||
34029320|NCT04844060|||COHORT||OTHER|||||||
34029321|NCT05706857|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|Double|Randomized 1:1. Stratified by type of surgery (CABG, Valvular, Aorta)|f|f|t|t
34029322|NCT02318212|||CASE_ONLY||PROSPECTIVE|||||||
34029323|NCT06353347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029324|NCT03108378|||COHORT||OTHER|||||||
34029325|NCT01117571|||COHORT||PROSPECTIVE|||||||
34029326|NCT04428450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029327|NCT04063085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029328|NCT04905940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34029329|NCT04979936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029330|NCT02074280|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029331|NCT03229200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029332|NCT02871492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105601|NCT06168006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded for the group of the subjects||f|f|f|t
34105602|NCT04315922|||COHORT||PROSPECTIVE|||||||
34105603|NCT05792345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105604|NCT06083805|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105605|NCT01258426|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105606|NCT05422573|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34105607|NCT02732665|||COHORT||PROSPECTIVE|||||||
34105608|NCT06636331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34105609|NCT04583553|||COHORT||PROSPECTIVE|||||||
34105610|NCT04847037|RANDOMIZED|PARALLEL||PREVENTION||NONE|The experimental group which will use the connected tools will be compared with the control group according to the usual procedure.|This is a pilot, prospective, single-center, comparative, randomized, open-label study.||||
34105611|NCT00527631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105612|NCT06690840|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, phase II, single arm, multicenter study||||
34029333|NCT01290159|||COHORT||PROSPECTIVE|||||||
34105613|NCT05682677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029334|NCT05076448|||COHORT||PROSPECTIVE|||||||
34105614|NCT04679987|||COHORT||PROSPECTIVE|||||||
34105615|NCT02274233|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029335|NCT02487225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029336|NCT00569855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029337|NCT01161485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029338|NCT02307773|||CASE_CONTROL||RETROSPECTIVE|||||||
34105616|NCT04289402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study personnel administering tDCS and the participants will not be aware of tDCS intervention arm assignment. The investigators will ensure double-blinding by programming the tDCS software with intervention-specific stimulation codes, as supplied by personnel uninvolved in data collection prior to study initiation.|The investigators will conduct a single site, sham-controlled, double-blinded, randomized trial of tDCS. Participants will complete baseline cognitive and physical functioning assessments, as well as a structural MRI of the brain. They will then be assigned to a two-week, 10-session intervention of either personalized tDCS sham (i.e., control) stimulation, via permuted block randomization stratified by sex to ensure that equal number of men and women are randomized to each intervention arm.|t|f|t|t
34029339|NCT00394563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029340|NCT06630000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029341|NCT05666297|||COHORT||PROSPECTIVE|||||||
34029342|NCT05190692|||OTHER||PROSPECTIVE|||||||
34029343|NCT02452437|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105617|NCT00605657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029344|NCT02657928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029345|NCT02541968|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34105618|NCT06675422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105619|NCT03109769|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34029346|NCT03600987|NA|SINGLE_GROUP||TREATMENT||NONE||Single-subject adapted alternating treatment design.||||
34029347|NCT02060565|||COHORT||OTHER|||||||
34029348|NCT03545204|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants,and outcome assessor will be masked about the intervention provided in the other arm.|"A Community based Cluster Randomized Control Trial Group 1: Community Kangaroo Mother Care cKMC will be provided to low birth weight babies of randomly selected union councils.~Group 2: Essential newborn care will be provided as per standard country protocol Group 2: Only facility KMC and routine standard care is provided to low birth weight babies of randomly selected union councils."|t|f|f|t
34029349|NCT03870165|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029350|NCT03405922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34029351|NCT02075515|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34029352|NCT03353012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029353|NCT06072573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029354|NCT02765425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029355|NCT03758716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105620|NCT00948597|||CASE_ONLY||PROSPECTIVE|||||||
34105621|NCT00298701|RANDOMIZED|PARALLEL||||DOUBLE||||||
34105622|NCT04373551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34105623|NCT06232993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105624|NCT06356545|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105625|NCT05333965|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34029356|NCT06632704|||CASE_ONLY||PROSPECTIVE|||||||
34029357|NCT00002638||||TREATMENT||||||||
34029358|NCT04412278|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34029359|NCT03846193|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A dose escalation study of the safety and efficacy of a single subretinal injection of GT005 in subjects with Macular Atrophy due to AMD||||
34029360|NCT05494476|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||split mouth protocol|t|f|f|f
34029361|NCT01119365|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|The investigator is unaware of specific sequence of light that is given to the participant until all data are analyzed.||f|f|t|t
34029362|NCT05397678|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Following informed consent, the child's mother/guardian selects, from a stack of envelopes, a closed envelope that contains a sealed randomization lot indicating allocation to either BCG-Denmark or BCG-Bulgaria. The mother, inclusion assistant and vaccinator will thus not be blinded to the intervention allocation. All assistants assessing outcomes during follow-up procedures and providers of care will be blinded to the randomization allocation.|Outcome assessor-blinded RCT|f|t|f|t
34029363|NCT03994822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The blinded assessor performs all study assessments during and after hospital discharge (i.e., 24 hours, Day 7/Discharge (whichever is earlier), and 30 and day 90 visits|Prospective, multi-center randomized|f|f|f|t
34029364|NCT00853099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029365|NCT00682474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029366|NCT03921593|||COHORT||PROSPECTIVE|||||||
34029367|NCT05576246|||COHORT||PROSPECTIVE|||||||
34029368|NCT04309617|||COHORT||RETROSPECTIVE|||||||
34029369|NCT00658047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029370|NCT01209091|||||CROSS_SECTIONAL|||||||
34029371|NCT05534061|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34029372|NCT02006602|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029373|NCT05147012|||COHORT||RETROSPECTIVE|||||||
34029374|NCT02468050|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34029375|NCT04959773|||CASE_CONTROL||RETROSPECTIVE|||||||
33723888|NCT02804984|||CASE_ONLY||PROSPECTIVE|||||||
33723889|NCT01273402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723890|NCT03098173|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel, randomized, superiority trial||||
33723891|NCT04415281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33723892|NCT06065579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723893|NCT06088550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029376|NCT04935684|RANDOMIZED|PARALLEL||TREATMENT||NONE||A group patients will receive Fecal Microbiota Transplantation (FMT) within 4 weeks following neutrophils recovery after the allogeneic hematopoietic stem cell transplantation procedure and a control group of patients will not receive FMT.||||
34029377|NCT05153525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029378|NCT00995176|||COHORT||PROSPECTIVE|||||||
34029379|NCT04061187|||CASE_ONLY||OTHER|||||||
34029380|NCT02698111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029381|NCT01959373|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34029382|NCT02051712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723894|NCT01742507|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723895|NCT05228145|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation cohort study of NGN-101 administered by intracerebroventricular (ICV) infusion and intravitreal (IVT) injection; cohorts will be assigned sequentially.||||
33723896|NCT02003131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723897|NCT00788892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029383|NCT01447043|||||RETROSPECTIVE|||||||
34029384|NCT04546724|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33723898|NCT03322033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723899|NCT00451321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723900|NCT01200654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723901|NCT03449160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723902|NCT03559179|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33723903|NCT04540289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The PROFID-Preserved trial is an open-label, blinded outcome assessment study. Thus, unblinding proce-dures for investigators are not applicable.||f|f|f|t
33723904|NCT00913809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723905|NCT04139954|||COHORT||PROSPECTIVE|||||||
33723906|NCT01392248|||COHORT||PROSPECTIVE|||||||
33723907|NCT03720496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029385|NCT04439201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029386|NCT05860855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723908|NCT02446236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723909|NCT05362747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723910|NCT04428996|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33723911|NCT01312818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723912|NCT04716127|NA|SINGLE_GROUP||SCREENING||NONE||||||
34029387|NCT06551415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; in a one-to-one ratio, participants were randomly assigned to receive doses of Dabigatran or rivaroxaban by a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 580 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 580. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included dabigatran, and Drug B included apixaban. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We compared the efficacy and safety of a Dabigatran 150 mg Bid administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications|f|f|t|t
34029388|NCT03456505|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34029389|NCT00796757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029390|NCT04825340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34029391|NCT01351571|||COHORT||PROSPECTIVE|||||||
34029392|NCT04936399|||COHORT||PROSPECTIVE|||||||
34029393|NCT03513094|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, repeated measures.||||
34029394|NCT04843696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723913|NCT04341909|||COHORT||PROSPECTIVE|||||||
33723914|NCT01178593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723915|NCT00451867|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723916|NCT01751386|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33837873|NCT02870972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34029395|NCT03097991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837874|NCT04866381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837875|NCT04653428|||COHORT||PROSPECTIVE|||||||
33837876|NCT05358652|||COHORT||RETROSPECTIVE|||||||
34105626|NCT06010563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805381|NCT05068102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The trial is divided in 2 parts:~In Part 1 of each arm, the patients will be entered sequentially. After review of Part 1 data for each arm, the Data Review Committee (DRC) will make the decision whether or not to initiate Part 2 for each arm.~Patients entered in Part 2 will be treated in various dose cohorts of BI 765063 (Arm A) or BI 770371 (Arm B) at Cycle 2 and these dose cohorts will be managed sequentially based on the DRC decision."||||
33805382|NCT06463041|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33805383|NCT06476119|||COHORT||PROSPECTIVE|||||||
33805384|NCT04910438|||COHORT||PROSPECTIVE|||||||
33805385|NCT04802018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Single-blind, controlled, randomised clinical trial|f|f|t|t
33805386|NCT05465018|NA|SINGLE_GROUP||OTHER||NONE||||||
34029396|NCT03763474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes assessors were blinded as for the allocation of the patients in the 2 groups.||f|f|f|t
34029397|NCT00997230|||CASE_ONLY||PROSPECTIVE|||||||
33805387|NCT05923606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33805388|NCT03139331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805389|NCT01917994|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805390|NCT05888792|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both participants and their guardians will be masked from the grouping. The outcomes assessors will be also masked from the grouping.|Participants will be randomly allocated to either control (wearing single vision lenses) group or treatment (DG2 lens) group for first 12 months. After 12 months, the SV lens prescribed to the control group will be replaced with the DG2 lens and be monitored for another 12 months. In parallel, the DG2 treatment groups will continue their corresponding intervention for 12 months.|t|f|f|t
33805391|NCT06700148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805392|NCT03282045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33805393|NCT06026943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805394|NCT06284213|||CASE_CONTROL||PROSPECTIVE|||||||
33805395|NCT01113216|||FAMILY_BASED||PROSPECTIVE|||||||
33805396|NCT04524247|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients may be included in the study if the patient has at least one of the following indications and are anatomically appropriate for treatment with fenestrated/branched stent grafts.~1. Pararenal, paravisceral, and type I to IV thoracoabdominal aortic aneurysms or chronic post-dissection aneurysms with a diameter 5cm or 2 times the normal aortic diameter.~2. Aneurysm with a history of growth ≥ 0.5cm per year.~3. Saccular aneurysms deemed at significant risk for rupture based on physician interpretation.~4. Symptomatic aneurysm without hemodynamic instability~5. Aneurysms meeting any of the above criteria 1\~4, above or below the previous endovascular and/or open aortic repairs. Previously placed aortic stent graft or open aortic grafts may serve as seal zones."||||
33837877|NCT01460225|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33837878|NCT00562458|||||PROSPECTIVE|||||||
33837879|NCT00130065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837880|NCT00002439||||TREATMENT||||||||
33837881|NCT00208247|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33837882|NCT06311305|NA|SINGLE_GROUP||TREATMENT||NONE|NONE (open label single group)|we aim to assess if the early laparoscopic cholecystectomy after ERCP can reduce the risks or complications||||
33837883|NCT03318029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two controlled, randomized, double-blind clinical trials developed and undertaken (one in Brazil and the other in the UK) with an intervention period of 12 weeks. The women selected were randomly divided into two groups: Placebo Group and Supplemented Group, the latter will receive 600UI of vitamin D, in each country. Groups (arms): Placebo UK trial; Vitamin D UK trial; Placebo Brazuk trial; Vitamin D Brazil trial.|t|f|t|f
34029398|NCT05603403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The study will be double-blind. The participants and the investigator will be blinded in the study, in which they will not know the treatment that each participant will be receiving."|Investigational product (Probiatop) and Placebo|t|f|t|f
34029399|NCT01691235|||COHORT||PROSPECTIVE|||||||
34029400|NCT02503787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029401|NCT04947917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029402|NCT03423940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837884|NCT00376415|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33837885|NCT05996367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837886|NCT00664534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837887|NCT02095041|||OTHER||PROSPECTIVE|||||||
33837888|NCT03205670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837889|NCT05471531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837890|NCT05287997|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants will enrol into the Baseline Arm of the study. Participants will attend all Baseline Visits unless they experience a concussion at which point, they will transition to the Concussion Arm for further follow-up.||||
33837891|NCT04788745|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm study without placebo||||
33837892|NCT00253331|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33839188|NCT01330849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029403|NCT06327906|||COHORT||PROSPECTIVE|||||||
34029404|NCT03234504|||OTHER||PROSPECTIVE|||||||
34029405|NCT00146276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029406|NCT05432635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029407|NCT06256523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029408|NCT05935202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029409|NCT03983915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029410|NCT00426439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029411|NCT02353910|||COHORT||PROSPECTIVE|||||||
34029412|NCT05462197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029413|NCT00687024|||COHORT||PROSPECTIVE|||||||
34029414|NCT00562783|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34029415|NCT02004015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029416|NCT02186444|||COHORT||PROSPECTIVE|||||||
34029417|NCT02084160|||COHORT||RETROSPECTIVE|||||||
34029418|NCT01948531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029419|NCT02420912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029420|NCT05101343|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34029421|NCT02368314|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34029422|NCT04060186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029423|NCT02693860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029424|NCT03068039|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single blind (Investigator blind)||f|f|t|f
34029425|NCT02833337|||COHORT||RETROSPECTIVE|||||||
34029426|NCT03622424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, investigators, and sponsor will be blinded|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effects of Gelesis200 on Appetite Parameters, Food Intake, and Glycemic Control in Overweight or Obese Prediabetic Subjects: A Sub-Study of LIGHT-UP|t|t|t|f
34029427|NCT05185479|||CASE_ONLY||RETROSPECTIVE|||||||
34029428|NCT02490280|NA|SINGLE_GROUP||||NONE||||||
34105627|NCT05044039|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34105628|NCT01209494|||COHORT||PROSPECTIVE|||||||
34029429|NCT03077139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029430|NCT00616421|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34029431|NCT05618249|||CASE_ONLY||RETROSPECTIVE|||||||
34029432|NCT04410614|NA|SINGLE_GROUP||TREATMENT||NONE||Teeth and implants receiving free epithelial grafts harvested from the palate||||
34029433|NCT03791047|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34029434|NCT00805675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029435|NCT06341205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029436|NCT05949697|NA|SINGLE_GROUP||OTHER||NONE||||||
34029437|NCT03323242|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Blinding the surgical staff is impossible due to the use of different methods in the three groups under investigation. Since the primary endpoint total blood loss will be precisely recorded during surgery by independent staff and secondary endpoints are objective physiological findings, blinding the subjects is not needed. Therefore, the open design is not expected to cause any avoidable bias."|||||
34105629|NCT05696522|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional, pilots study with open label, non-randomised design.||||
34105630|NCT01686321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105631|NCT03400787|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be masked to treatment assignment through the 3-month assessment period.|Sham procedure participants will be allowed to crossover to receive Latera implants after the 3-month assessment if they continue to meet eligibility criteria. Crossover participants will be followed through 24 months post implant. Sham participants who do not crossover will be exited after the 3-month assessment.|t|f|f|f
33723917|NCT05787314|NA|SEQUENTIAL||TREATMENT||NONE|prospective, two-arm randomized-controlled trial, Researchers who have no knowledge about group allocation and study's objectives, will collected the post-intervention data.|Different nutrition programs were applied to obese individuals divided into control and experimental groups. While the experimental group was given a healthy/balanced nutrition program containing carbohydrates and aimed to lose weight, a nutritional program that was balanced and aimed to lose weight but did not make any classification was applied to the control group. At the end of 8 weeks, biochemical parameters and scales were compared.||||
33723918|NCT00458523||||TREATMENT||NONE||||||
33723919|NCT01984008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33723920|NCT04712890|||COHORT||PROSPECTIVE|||||||
33723921|NCT02740166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723922|NCT03369054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33723923|NCT04241328|||OTHER||PROSPECTIVE|||||||
33723924|NCT00977132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723925|NCT00000954||||TREATMENT||||||||
33723926|NCT04400903|||CASE_CONTROL||PROSPECTIVE|||||||
33723927|NCT04588402|||COHORT||PROSPECTIVE|||||||
33723928|NCT04796376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723929|NCT01769833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723930|NCT02917031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33723931|NCT03930706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723932|NCT06057792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723933|NCT01774786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723934|NCT03560050|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized trial where family child care home providers (the participant) are randomized to either nutrition or environmental health technical assistance intervention. Interventions are matched for time and contact||||
33723935|NCT00302458|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33723936|NCT03427736|||OTHER||PROSPECTIVE|||||||
33723937|NCT03731156|||COHORT||RETROSPECTIVE|||||||
33723938|NCT04894396|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723939|NCT01697865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33723940|NCT06086028|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34029438|NCT02829476|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33723941|NCT05777915|||OTHER||CROSS_SECTIONAL|||||||
33723942|NCT03044405|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who had reduced arterial blood pressure up to 30% from the baseline after major abdominal surgery (gastric resection, gastrectomy, liver resection, pancreatic-duodenal resection, colorectal surgery) were included in the study.||||
33723943|NCT06162156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Which group will be the intervention group and which group will be the control group will be determined by lottery. After the participant agrees to participate in the research, the person will draw envelopes from sealed envelopes by lottery and thus it will be determined which group he/she is in. Since the researcher and the mothers, who are massage practitioners, knew which group they were included in, the data collection phase of the study could not be blinded. Since the statistical analysis of the study will be performed by an independent statistician other than the researcher, the statistical analysis phase is blind. Therefore, the study is single blinded.|two groups with back massage experimental group and control group|f|f|f|t
34029439|NCT05805410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to two groups|f|f|f|t
34029440|NCT03924687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029441|NCT00001605||||TREATMENT||||||||
34029442|NCT02897518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029443|NCT04098510|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029444|NCT05581381|RANDOMIZED|PARALLEL||PREVENTION||NONE||The quantitative method is the experimental research method using randomization. The nurses receiving the intervention of empathy training program are in the experimental group, while those who do not receive it are in the control group. The effectiveness assessment will use the Empathy Construct Rating Scale (ECRS) and learning satisfaction scale, Empathy Construct Rating Scale (ECRS) required to be completed by both the experimental group and control group. ECRS perform the pre-test and post-test assessments. The pre-test perform before the implementation of empathy training program, and perform the post-test at week 8 the end of empathy training program.||||
34029445|NCT04860674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837893|NCT03455257|RANDOMIZED|PARALLEL||OTHER||NONE|Clarify randomization and masking|Participating families are randomized into one of two groups, an assessment-only controls group or a cash transfer group.||||
33837894|NCT00129935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837895|NCT03166995|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33837896|NCT02638883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837897|NCT01907906|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33837898|NCT02920970|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34029446|NCT04871256|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective study with 1 months period follow up. Patients with septal deviation and allergic rhinitis diagnosis will be included. Obstruction airflow will be evaluated before and after surgery with rhinomanometry (RNM). Life quality will be assessed with VAS and ESPRINTquestionnaires.||||
33839189|NCT04692701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029447|NCT01786889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34029448|NCT05921474|||COHORT||PROSPECTIVE|||||||
34029449|NCT02404766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34029450|NCT00269984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029451|NCT02587091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34029452|NCT05389644|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will receive active stimulation to two sites as well as sham stimulation to a third site.|This study will involve a within-subject crossover design. Every subject will undergo three interventions.|t|f|f|f
33839190|NCT00506246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33839191|NCT03039062|||OTHER||PROSPECTIVE|||||||
34029453|NCT05520125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029454|NCT05293821|||CASE_ONLY||PROSPECTIVE|||||||
34029455|NCT04406844|||COHORT||CROSS_SECTIONAL|||||||
34029456|NCT04957030|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
34029457|NCT04660331|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34029458|NCT01721317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029459|NCT05456490|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Each of the cohorts will be masked as to proceed to subsequent next dose escalation cohort.|The decision to proceed to the next cohort will be made following a full review of the safety, PK, sensory, motor, neurological history and assessment questionnaires, comprehensive neurological exam and Adverse Event data from the current completed cohort(s).|t|t|t|t
34029460|NCT04931979|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is designed as a phase II, open-label, monocentric, single-arm trial evaluating a combination therapy of pembrolizumab and salvage radiation therapy (SRT) in patients with biochemical recurrence (BCR) or persisting prostate-specific antigen (PSA) after radical prostatectomy (RP).||||
34029461|NCT02096744|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34029462|NCT05784025|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029463|NCT06581991|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open label, observational study of 5 subjects with MSUD for 56 days||||
34029464|NCT00979641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029465|NCT06412783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029466|NCT01386255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029467|NCT02204085|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029468|NCT01554319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029469|NCT02658942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029470|NCT03917927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029471|NCT05928312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029472|NCT02713009|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34029473|NCT04548765|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|Participants and providers are not aware of the different letter versions.|1 x 4 design|t|t|f|f
34029474|NCT02210624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029475|NCT02258763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029476|NCT03802071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029477|NCT03580473|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34029478|NCT03557502|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized parallel study design|f|f|f|t
34029479|NCT00611624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805397|NCT04858035|NA|SINGLE_GROUP||TREATMENT||NONE||This study follows a multiple-baseline across-subjects design with random assignment of participants to different baseline durations. Following the initial evaluation to determine eligibility, participants will be enrolled in a baseline phase in which perception and production abilities will be probed but not treated. Perception will be measured using the online identification and category goodness tasks and production will be measured from standard probes (20 syllables, 30 words, and 10 sentences containing /r/ in various phonetic contexts). Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks followed by 4 sessions of production training over 2 weeks.||||
33805398|NCT03391024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029480|NCT06377618|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34029481|NCT01512160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029482|NCT03834142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||10 subjects will be recruited in each surgical population (hip/knee, kidney, bariatric) to equal 30 total active participants. This will be compared to 10 controls in each surgical population, for a total of 60 participants in the entire pilot.||||
34029483|NCT01425658|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029484|NCT00706485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029485|NCT05011604|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 19 patients (22 implants) were included in the present study with mean follow-up time of 2 years. A full-digital workflow was performed on each patient through the design and printing of a surgical guide, the taking of the impression with an intraoral scanner and the CAD-CAM design of the crowns.||||
34029486|NCT06399744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029487|NCT05309811|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34029488|NCT02302989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34029489|NCT06265259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029490|NCT01171261|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029491|NCT00226291|RANDOMIZED|PARALLEL||||NONE||||||
34029492|NCT02735538|||CASE_CONTROL||PROSPECTIVE|||||||
34029493|NCT01652989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029494|NCT04457037|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with trophic ulcers received standard treatment and mesenchymal stem cells||||
34029495|NCT00313989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029496|NCT02411916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029497|NCT01645787|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34029498|NCT04588389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For the blinding purposes, the patients will be told that there are two possible sites at which they will receive the block. The sites will be either in the operating room before you wake up from anesthesia or in the post-anesthesia care unit (PACU). The patients on the medical management group will be told that they have received their block before recovering from anesthesia, the PACU nurse will be told the same as well to make him or her blinded as a pain assessor.|We will randomize 10 patients into one of three groups for a total of 30 patients. Each patient will be longitudinally followed until discharge.|t|f|f|t
34029499|NCT03910673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029500|NCT02188810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34029501|NCT03794050|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34029502|NCT04118023|||CASE_CONTROL||PROSPECTIVE|||||||
34029503|NCT05622019|||CASE_CONTROL||OTHER|||||||
34029504|NCT04230902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029505|NCT01471730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029506|NCT00061932|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029507|NCT02171195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029508|NCT05558566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029509|NCT00098774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029510|NCT06256614|||COHORT||PROSPECTIVE|||||||
34029511|NCT04524195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029512|NCT02044926|||COHORT||PROSPECTIVE|||||||
34029513|NCT01822626|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029514|NCT04581330|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34029515|NCT05082740|||OTHER||OTHER|||||||
34029516|NCT01022697|RANDOMIZED|PARALLEL||||NONE||||||
34029517|NCT01524978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029518|NCT06497582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34029519|NCT00524966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029520|NCT05741827|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34029521|NCT03503695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029522|NCT00803439|||COHORT||PROSPECTIVE|||||||
34029523|NCT00006509||||TREATMENT||NONE||||||
34029524|NCT00492778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029525|NCT02933437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029526|NCT00315289|||COHORT||PROSPECTIVE|||||||
34029527|NCT05018377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029528|NCT03763305|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34029529|NCT06414356|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||(1) Moderate-dose ketamine (0.50 mg/kg/hr) (Orhurhu et al., 2019), and (2) moderate-dose ketamine in combination with magnesium (750 mg/hr) (Urits et al., 2021) and (3) magnesium control (750mg/hr) will be assessed. Of note, we are adapting a delayed control treatment group design. The control group (Mg only control) will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full infusion treatment regime of the randomly selected treatment group.|t|f|f|t
34029530|NCT00697151|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029531|NCT00900419|||OTHER||PROSPECTIVE|||||||
34029532|NCT06456957|||COHORT||PROSPECTIVE|||||||
34029533|NCT01940991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805399|NCT06514677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For Outcomes Assessor Masking, Groups were not defined and anonymized and assessor will be blind.|Group I: Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment Group II: Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment|f|f|f|t
33805400|NCT06698523|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34029534|NCT00098618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029535|NCT00067743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029536|NCT03168022|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34029537|NCT03957850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant-blind clinical trial: the participants are blinded regarding the allocation to the respective training group (CR training or control training). Upon completion of the training (including questionnaire assessment), participants are unblinded regarding the allocation.|This study is designed as a short-term randomized controlled, participant-blind clinical trial including two groups of adolescents with MD. MD participants will be randomly assigned to a group that receives task-based training in CR or to a control training. Randomisation will be performed by a statistician, stratifying for age (14 years and younger and 15 years and older) and sex.|t|f|f|f
34105632|NCT06675045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105633|NCT06569628|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||Long-term Care Centres for old adults users will be divided into three groups: 1)Intervention group: participates directly in the incorporation of the proposed methodology; 2)Contact group: participates indirectly (implementation of the methodology in the centres in which they reside but not in them directly); 3)Non-contact control group: resides in a centre in which the methodology is not being implemented. This process will also involve the reference professionals involved in the implementation of the methodology and those family members who voluntarily become involved in the care of the participants based on this methodology.|t|f|f|f
34029538|NCT05036512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029539|NCT01226394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105634|NCT03975946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The efficacy will be assessed by a vascular surgeon blinded to the study group during consultation||f|f|t|f
34029540|NCT03541928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029541|NCT05146843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Clinical, randomized, double-blind, placebo-controlled trial.|t|f|t|f
34029542|NCT00411411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105635|NCT01390103|||CASE_ONLY||PROSPECTIVE|||||||
34029543|NCT00277693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029544|NCT04648787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34105636|NCT05795881|RANDOMIZED|PARALLEL||TREATMENT||NONE||Investigator-Initiated Randomized Controlled Trial||||
34105637|NCT01205412|||COHORT||PROSPECTIVE|||||||
34105638|NCT06675253|||COHORT||OTHER|||||||
34105639|NCT01177306|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105640|NCT00002171||||TREATMENT||||||||
34105641|NCT04773457|||COHORT||PROSPECTIVE|||||||
34105642|NCT06637592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105643|NCT01111552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105644|NCT06556173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105645|NCT00055185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105646|NCT00883311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105647|NCT03987685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105648|NCT03624556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The treatment consists in FontUp (EGCG on a dietary supplement with chocolate like shake flavor) taken dissolved in 100mL of water two times a day (breakfast and afternoon snack). The placebo treatment is the same product but without the EGCG in it, taken with the same posology.|"Cohort I (Down Syndrome children): Phase II Randomized, double-blind, placebo-controlled, parallel groups to evaluate safety and tolerability of EGCG in children. The experimental group will take 10mg/kg/day of FontUp (EGCG on a dietary supplement with chocolate like shake flavor, two times a day) while the placebo group will take the same product but without the EGCG in it, taken with the same posology.~Cohort II (Fragile X syndrome children): exploratory open label study (pilot study) to assess safety and tolerability of EGCG. These patients will receive 10mg/kg/day of FontUp.~This cohort will only be recruited in Spanish sites."|t|t|t|t
34105649|NCT03960346|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34105650|NCT02941029|||COHORT||PROSPECTIVE|||||||
34105651|NCT02002715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105652|NCT05688111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Two similar size syringes will be prepared and labeled as A (experimental group) containing 1 g/10mL Tranexamic acid diluted with 20mL of 5% glucose water, and syringe B (placebo group) containing 30 mL of 5% glucose water.~The 2 groups of syringes will be labeled with different numbers not known by the investigator or the patient"|"Randomization for both groups to the 2 groups will be done using Randomization Allocation Software program and whom will add the numbers on each syringe will be a pharmacist not involve in the study and will have the cods belong to the type of the intervention with him until the end of the research .~Random Allocation Software(https://random-allocation-software.software.informer.com/2.0/)"|t|t|t|f
34105653|NCT05510167|RANDOMIZED|PARALLEL||OTHER||NONE||"Paroxysmal and Persistent AF patients undergoing their first catheter ablation will be screened for eligibility and those that meet the criteria and consent to participate will be randomly assigned to group 1 or 2.~Study period will start from the day after the procedure and continue for 8 months (2-month blanking period+ 6 months follow-up).~Group 1: Complete abstinence or ≤2 drinks/week in group 1 during the study period Group 2: Allowed to continue their pre-ablation drinking habit"||||
34105654|NCT06638970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105655|NCT06673576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105656|NCT02254460|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34105657|NCT04726956|||COHORT||PROSPECTIVE|||||||
34105658|NCT06674278|||OTHER||PROSPECTIVE|||||||
34105659|NCT06642623|RANDOMIZED|PARALLEL||TREATMENT||NONE||his study was designed as a pragmatic clinical trial(pracmatic RCT), which demonstrates the real-world effectiveness of the intervention in broad patient groups.||||
34105660|NCT06285357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105661|NCT04034498|||CASE_ONLY||OTHER|||||||
34105662|NCT02894034|||CASE_ONLY||PROSPECTIVE|||||||
33805401|NCT02189252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805402|NCT00860236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805403|NCT06699550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33805404|NCT00176202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33805405|NCT02787005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805406|NCT03352726|NA|SINGLE_GROUP||OTHER||NONE||||||
33805407|NCT01664806|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33805408|NCT02844439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805409|NCT06019000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There will be a placebo match and blinded randomization.|"The study treatment of CYR-064 is administered for a 24-week Treatment Period. Patients who meet all study criteria and have consented to participation will be randomized (1:1:1) to three parallel study arms, with two different dose strengths and a placebo group over 24 weeks.~CYR-064 dose 1 CYR-064 dose 2 Placebo"|t|t|t|t
33805410|NCT06067763|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be masked to participant condition.||f|f|f|t
33805411|NCT06699836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029545|NCT01776931|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029546|NCT02975947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34029547|NCT02336646|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34029548|NCT04975854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029549|NCT04641598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not made aware of which arm they are randomized to until after the cycle outcome has been determined.|"Participants are randomized to endometrial scratch or sham procedure (speculum insertion but no endometrial scratch)"|t|f|f|f
34029550|NCT03840564|||COHORT||PROSPECTIVE|||||||
34029551|NCT01500473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029552|NCT00199524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029553|NCT01708668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029554|NCT06228534|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34029555|NCT04812808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029556|NCT02620579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029557|NCT02211196|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34029558|NCT03140787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029559|NCT03928301|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34029560|NCT05382234|||CASE_ONLY||CROSS_SECTIONAL|||||||
34029561|NCT02459938|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029562|NCT05720468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029563|NCT02028676|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34029564|NCT05873790|||COHORT||PROSPECTIVE|||||||
34029565|NCT03458611|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patients are not explicitly explained that a placebo and active version of the intervention will be compared, which makes it more likely for patients not to be aware of the treatment conditions. However they may notice a difference between the two interventions when they switch over from the first to the second intervention condition. In addition, the clinician who will administer the intervention to the patient on a daily basis cannot be blinded to the specific intervention that is administered to the patient, because the clinician will remain present during the intervention to guide the patient through the intervention. However, the clinicians that will perform the evaluation of symptoms using the tasks that are most sensitive to observer bias will be blinded to the treatment condition that is currently applied to the patient to avoid that the measurement of outcome is affected by observer bias.|The study design is a mix of a within-subject manipulation of the placebo and active intervention conditions and a between-subject manipulation of the order of these two within-subject conditions. To clarify, a placebo and active version of the VR game based attention training will be administered to each patient. The order of these two within-subject conditions is counterbalanced between-subjects to account for differences in order between the two treatment conditions.|t|f|f|t
34029566|NCT03957525|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Prospective randomized, controlled trial|f|f|t|t
34029567|NCT00008814|||NATURAL_HISTORY||OTHER|||||||
34029568|NCT05084482|||COHORT||PROSPECTIVE|||||||
34029569|NCT06061068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029570|NCT01228019|||CASE_ONLY||PROSPECTIVE|||||||
34029571|NCT01612065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029572|NCT01573104|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34029573|NCT02099565|||COHORT||PROSPECTIVE|||||||
34029574|NCT06551233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029575|NCT04542057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029576|NCT05756036|||COHORT||PROSPECTIVE|||||||
34029577|NCT01228578|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34029578|NCT00520897|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34029579|NCT05794698|||COHORT||PROSPECTIVE|||||||
34029580|NCT03475108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Controlled Crossover Trial||||
34029581|NCT04211116|||COHORT||PROSPECTIVE|||||||
34029582|NCT02422797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029583|NCT04774016|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34029584|NCT00378144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029585|NCT01755091|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029586|NCT02423629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029587|NCT05585021|RANDOMIZED|PARALLEL||OTHER||SINGLE||"The community hospital will recruit 140 preschool children, aged 5 to 6 years old, according to the inclusion and exclusion criteria, and randomly assigned them to 2 groups. 70 subjects in the placebo group and 70 in the experimental product group.~First entered a one-week washout period, and then entered a 25-week clinical intervention, and finally ensured that 100 volunteers completed the whole study, and the withdrawal rate was about 28%."|f|f|t|f
34029588|NCT01314937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029589|NCT06317831|||COHORT||PROSPECTIVE|||||||
34029590|NCT06489119|||COHORT||PROSPECTIVE|||||||
34029591|NCT02754843|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34029592|NCT01889147|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34029593|NCT00980525|||COHORT||PROSPECTIVE|||||||
34029594|NCT01957761|||COHORT||RETROSPECTIVE|||||||
34029595|NCT02934191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029596|NCT00050245||||TREATMENT||||||||
34029597|NCT05812534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029598|NCT01271218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34029599|NCT01994850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029600|NCT05175703|NA|SINGLE_GROUP||TREATMENT||NONE||The Passeo-18 Lux DCB||||
34029601|NCT05588414|NA|SINGLE_GROUP||OTHER||NONE||||||
34029602|NCT02023294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029603|NCT00362336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029604|NCT06068556|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34029605|NCT00442871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029606|NCT04518839|||COHORT||PROSPECTIVE|||||||
34029607|NCT03872518|||COHORT||PROSPECTIVE|||||||
34029608|NCT04201197|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo controlled, double blind||t|f|f|t
34029609|NCT01072617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029610|NCT05160740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029611|NCT01260701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029612|NCT00330317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029613|NCT03482973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029614|NCT00996489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029615|NCT01659125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029616|NCT00456300|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34029617|NCT00706589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029618|NCT06582342|||CASE_CROSSOVER||PROSPECTIVE|||||||
34029619|NCT04263025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be Blinded||t|f|f|f
34029620|NCT02176265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029621|NCT06462755|||COHORT||RETROSPECTIVE|||||||
34029622|NCT02451761|||OTHER||PROSPECTIVE|||||||
34029623|NCT02740192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029624|NCT06581913|||COHORT||PROSPECTIVE|||||||
34029625|NCT03390855|NA|SINGLE_GROUP||PREVENTION||NONE||The intervention consisted on a 10-week period which included daily consumption of a portion (30 g) of raw, fresh broccoli sprouts. After the intervention period, a follow-up recovery period for all subjects continued for other 90 days with no ingestion of broccoli sprouts.||||
34105663|NCT06289049|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and investigators will not be blinded to group assignment given the nature of the intervention.|||||
34105664|NCT02795962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33723944|NCT02373020|||COHORT||PROSPECTIVE|||||||
33723945|NCT03720470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029626|NCT00238758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029627|NCT06632886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33723946|NCT00392431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805412|NCT00973505|||CASE_ONLY||PROSPECTIVE|||||||
34029628|NCT04306536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029629|NCT05748951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029630|NCT03027024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029631|NCT03172195|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029632|NCT05324124|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029633|NCT02972190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029634|NCT00897910|||CASE_ONLY||PROSPECTIVE|||||||
34029635|NCT03689465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029636|NCT02290444|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029637|NCT00422604|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34029638|NCT03875924|||COHORT||RETROSPECTIVE|||||||
34029639|NCT05820334|||CASE_ONLY||PROSPECTIVE|||||||
34029640|NCT06416514|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34029641|NCT05141617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029642|NCT02795338|||COHORT||PROSPECTIVE|||||||
34029643|NCT00002897|RANDOMIZED|||TREATMENT||||||||
34029644|NCT06387355|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a parallel interventional model to assign participants to a treatment strategy in a clinical study||||
34029645|NCT05880511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029646|NCT03731442|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029647|NCT02509130|||COHORT||RETROSPECTIVE|||||||
34029648|NCT00299130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029649|NCT03647085|||COHORT||PROSPECTIVE|||||||
34029650|NCT03406754|||COHORT||PROSPECTIVE|||||||
34029651|NCT01380600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029652|NCT03752814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029653|NCT02072343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029654|NCT03450473|NA|SINGLE_GROUP||OTHER||NONE||||||
34029655|NCT02570737|||COHORT||PROSPECTIVE|||||||
34029656|NCT05281510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029657|NCT00616512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029658|NCT00324220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029659|NCT05475197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029660|NCT05761899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029661|NCT02964312|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm intervention with pre/post comparison for treatment response.||||
34029662|NCT06551792|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34029663|NCT03296501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029664|NCT01111318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029665|NCT03204682|NA|SINGLE_GROUP||TREATMENT||NONE|Open|All participants receive the same intervention throughout the protocol||||
34029666|NCT05446779|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34029667|NCT04860180|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34029668|NCT00430066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029669|NCT00683657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105665|NCT00779610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34105666|NCT05894083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105667|NCT01808170|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34105668|NCT03972670|||COHORT||PROSPECTIVE|||||||
34105669|NCT03201094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105670|NCT00693511|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105671|NCT04922879|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||experience summary||||
33805413|NCT02802384|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805414|NCT01578798|||COHORT||PROSPECTIVE|||||||
33805415|NCT05115864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837899|NCT04950595|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single (participants are blinded). The provision of the two test meals will be randomised and participants will be blinded to which meal they will receive (although we acknowledge they may be able to distinguish them by taste).|Single-centre, single-blinded, randomised, cross-over trial.|t|f|f|f
34029670|NCT03736031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34029671|NCT03440125|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34029672|NCT02214992|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029673|NCT05766137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Blinding of the operator is not applicable.~* Participants, outcome assessors and biostatistician will be blinded."|Parallel-group with allocation ratio of 1:1:1|t|f|f|t
34029674|NCT03281876|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Data will be collected in an observer-blind manner. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity and efficacy) will all be unaware of whether vaccine or placebo was administered. Each study site is responsible for having a blinding plan. To work in an observer-blind manner, vaccine preparation and administration will be done by authorised medical personnel who will not participate in any of the study clinical evaluation assays. Two teams of study personnel will hence be set up:~* A team of unblinded personnel (responsible for the preparation and the administration of the vaccines)~* A team of blinded personnel (responsible for the clinical evaluation of the subjects)."|Phase IIB, randomised, observer-blind, placebo-controlled, multi-centric study with two parallel groups.|t|t|t|t
34029675|NCT00005884|RANDOMIZED|||PREVENTION||||||||
34029676|NCT03842644|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029677|NCT06158919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029678|NCT05012189|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pragmatic Cluster Randomized Clinical Trial||||
34029679|NCT06372210|NA|SINGLE_GROUP||OTHER||NONE||||||
34029680|NCT03119779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029681|NCT03532828|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029682|NCT02819284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029683|NCT03323398|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029684|NCT00481117|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34029685|NCT06582186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029686|NCT01531660|NA|SINGLE_GROUP||||NONE||||||
34029687|NCT00129571|NON_RANDOMIZED|||TREATMENT||NONE||||||
34029688|NCT05105997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029689|NCT03096158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029690|NCT00345631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029691|NCT00118326||||TREATMENT||||||||
34029692|NCT00215423|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33837900|NCT02473965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837901|NCT06020950|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837902|NCT01739257|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33837903|NCT00590434|||CASE_CONTROL||RETROSPECTIVE|||||||
33837904|NCT01835353|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837905|NCT00520624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34029693|NCT03839966|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know if they are receiving the active or control treatment.|Participants will be randomized to receive one of two treatments|t|f|f|f
34029694|NCT02802904|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34029695|NCT04574687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029696|NCT01609205|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34029697|NCT01914692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34029698|NCT03381170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029699|NCT01185197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029700|NCT05858918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||comparing two antiplatelet drugs , head to head, randomized|t|t|t|t
34029701|NCT02605915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029702|NCT00325871|||CASE_CONTROL||PROSPECTIVE|||||||
34029703|NCT02972892|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34029704|NCT02773602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105672|NCT05273736|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|None (Open Label)|The study utilizes a modified Time-To-Event Continual Reassessment Method Dose-Finding Design||||
34105673|NCT03593278|NA|SINGLE_GROUP||OTHER||NONE||||||
34105674|NCT01726608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105675|NCT01149460|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34105676|NCT01882829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105677|NCT06637618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label cluster randomised crossover clinical trial, assessing the effect of upfront use of mineralocorticoid antagonists versus usual sequencing of heart failure medication||||
34105678|NCT06447480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105679|NCT02985138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105680|NCT01629563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105681|NCT04403685|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, superiority, open-label, controlled trial. Randomization 1:1 to best supportive care (BSC) versus Tocilizumab + BSC||||
34105682|NCT03139721|||COHORT||PROSPECTIVE|||||||
34105683|NCT03449147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants with refractory or unexplained chronic cough will be randomized to 1 of 3 treatment groups: gefapixant 45 mg twice daily (BID), gefapixant 15 mg BID, or placebo.|t|f|t|f
33837906|NCT02656589|||COHORT||PROSPECTIVE|||||||
34029705|NCT01988129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723947|NCT05278078|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants in the study will not know which group.|"1. st group of cancer patients given psychological support~2. nd group of cancer patients given nutrition education~3. rd group of cancer patients who received psychological support and nutrition education~4. th group of cancer patients who will not receive any support"|t|f|f|f
34029706|NCT05731193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The subject will be assigned a unique screening/enrolment number.|LSMU second-year and third-year medical students will be invited to participate in a single-arm, diagnostic study. Students will be trained for 4 days to recognise nonpathological lung sounds. The training will be via two lectures and a simulation-based study's website. Following the 4-day learning interval, students will be assessed via 3 tests, each test having different levels of white noise.The number of true positives, false positives, true negatives and false negatives will be recorded with the goal to assess students' diagnostic accuracy in identifying adventitious lung sounds.||||
34029707|NCT06007716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were informed about the study after obtaining an informed consent form. It was noted that the participants had not received reflexology or classical massage before.|consists of experimental and placebo groups.|t|f|f|f
34029708|NCT01992185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029709|NCT06400030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029710|NCT06123455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029711|NCT06287398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029712|NCT05860673|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized trial with 1:1 allocation.||||
33837907|NCT06485245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029713|NCT06550739|||COHORT||RETROSPECTIVE|||||||
34029714|NCT04991207|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34029715|NCT01188512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029716|NCT02522923|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34029717|NCT01910428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723948|NCT01198054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029718|NCT05144230|||OTHER||RETROSPECTIVE|||||||
34029719|NCT03390803|||CASE_CONTROL||PROSPECTIVE|||||||
34029720|NCT05809479|||COHORT||PROSPECTIVE|||||||
34029721|NCT01297985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34029722|NCT06553352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029723|NCT05624645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029724|NCT01960309|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34029725|NCT03064724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029726|NCT05086263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||A schedule of randomization matching and stratified in age and gender will be computer generated and used to determine which group the child will be placed in. Neither the investigator nor child will know which group they are in until after the parent and child complete the first set of questionnaires|t|t|t|f
33723949|NCT05792228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33723950|NCT02311738|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33723951|NCT05321212|||COHORT||RETROSPECTIVE|||||||
33837908|NCT05858255|NA|SINGLE_GROUP||TREATMENT||NONE|No masking is planned. A secondary aim of the study is to indicate the feasibility of the intervention in a daily clinical setting, with a minimum of additional assessments and involved personnel as compared to treatment as usual. Hence, the intervention will be conducted by designated personnel in line with all other treatment activities in the clinic, and (regular and additional) assessments will, for study purposes, be conducted by the PI instead of the participant's designated clinical team. Assessments and intervention sessions will however be conducted in close collaboration with the participants' designated clinical teams.|Clinical intervention study||||
33837909|NCT03805542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837910|NCT04199845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837911|NCT04517708|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33723952|NCT00464477|||CASE_ONLY||RETROSPECTIVE|||||||
33723953|NCT04508842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837912|NCT04913467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, partly blinded, multicenter clinical food trial|t|t|t|t
33837913|NCT01825577|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33837914|NCT04984005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723954|NCT04538144|||COHORT||PROSPECTIVE|||||||
33723955|NCT01077947|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33837915|NCT01266551||||TREATMENT||||||||
33837916|NCT02936882|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837917|NCT03869177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients and relatives will not be informed about their outpatient clinic's allocation status. However, they may deduce this from the kind of treatment they receive. It's impossible to blind the care providers and for practical reasons we won't be able to blind the investigators or the outcomes assessors.|"The study is a cluster randomised controlled trial. Fourteen clusters will be stratified into three strata according to their estimated number of patients with psychotic disorders currently in treatment. The clusters within each stratum will then be randomised to either intervention or control arms with an allocation ratio of 1:1.The seven outpatient units in the intervention arm receives a comprehensive implementation support program, whereas the outpatient clinics in the control arm receives no implementation support.~A similar number of patients and relatives will be recruited from both arms, preferably in dyadic pairs, for the quantitative patient- and relative sub study. Employees from the clusters in the intervention arm will be recruited to answer a questionnaire, as part of the implementation study. Patients, relatives and employees will be recruited from the clusters in the intervention arm to take part in qualitative interviews."||||
33837918|NCT05803681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33837919|NCT06383286|||OTHER||PROSPECTIVE|||||||
33837920|NCT06049602|||COHORT||RETROSPECTIVE|||||||
33837921|NCT04527484|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33837922|NCT03605888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839192|NCT05866042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837923|NCT04060693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Open, non-randomized comparison study between device and blood references with diabetic patients.||||
33837924|NCT03804177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blinded|it is randomized clinical trial|t|f|f|t
33837925|NCT02646956|||COHORT||CROSS_SECTIONAL|||||||
33837926|NCT05266703|NA|SINGLE_GROUP||OTHER||NONE||||||
33837927|NCT03243240|||CASE_ONLY||CROSS_SECTIONAL|||||||
33837928|NCT06383650|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33837929|NCT06237088|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33837930|NCT01594970|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34029727|NCT04634279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-arm randomized control trial (RCT) where participants are randomly assigned to intervention or control.|f|f|f|t
34029728|NCT02652949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029729|NCT06197178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029730|NCT00736632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029731|NCT00576095|||||PROSPECTIVE|||||||
34029732|NCT02899195|NA|SINGLE_GROUP||TREATMENT||NONE||Concurrent therapy with Durvalumab, Pemetrexed and Cisplatin (or Carboplatin) for up to 6 cycles followed by Maintenance Therapy with Durvalumab||||
34029733|NCT01028482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029734|NCT00072787|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029735|NCT01016327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029736|NCT02067962|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029737|NCT05906745|||COHORT||PROSPECTIVE|||||||
34029738|NCT06029504|||COHORT||PROSPECTIVE|||||||
34029739|NCT03608527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029740|NCT00948155|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34029741|NCT02934243|||CASE_ONLY||PROSPECTIVE|||||||
33837931|NCT05465590|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33837932|NCT02595099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029742|NCT06096805|||COHORT||PROSPECTIVE|||||||
34029743|NCT02833987|||COHORT||RETROSPECTIVE|||||||
34029744|NCT00258960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029745|NCT02567877|||COHORT||PROSPECTIVE|||||||
34029746|NCT05145426|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Sham trials will be utilized within subject. All subjects will receive sham and ultrasound conditions.|Multiple subject repeated measures||||
34029747|NCT05179330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029748|NCT00071292|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34029749|NCT01191034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029750|NCT00995527|||||PROSPECTIVE|||||||
34029751|NCT02215967||SEQUENTIAL||TREATMENT||NONE||||||
34029752|NCT05706584|RANDOMIZED|PARALLEL||OTHER||SINGLE|With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group.|The study was planned with a mixed method consisting of single-blind randomized controlled experiment and focus group interview methods. The research was planned to be carried out during the pediatric nursing course period between 2023-2024 Fall Semester October-December. Participants will be students taking a pediatric nursing course. Scales and Forms to be used in the Study; Informed Consent and Demographic Data Collection Form, Expert Opinion Form, Proficiency Scale for Nursing Students, Augmented Reality Applications Attitude Scale, Pre and Post Test, Student Case Form, Orogastric Catheter Application Procedure Steps Checklist and Distance Education Satisfaction Scale of university life.|t|f|f|f
34029753|NCT02595801|||COHORT||RETROSPECTIVE|||||||
34029754|NCT00334373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029755|NCT00691717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029756|NCT04884373|||COHORT||PROSPECTIVE|||||||
34029757|NCT02711878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029758|NCT05368493|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029759|NCT00422825|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029760|NCT02420067|||COHORT||PROSPECTIVE|||||||
34029761|NCT01241110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029762|NCT03638388|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental There will be two groups in this study, DN alone and DN/IES. Each group will have approximately 22 subjects, resulting in approximately 44 subjects total. Subjects will be randomized into one of the two groups via block randomization method based on order of entry into the study.||||
34029763|NCT02750956|||COHORT||PROSPECTIVE|||||||
34029764|NCT05298865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34029765|NCT03857555|||OTHER||CROSS_SECTIONAL|||||||
34029766|NCT00742963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029767|NCT01921686|||CASE_CONTROL||PROSPECTIVE|||||||
34029768|NCT01461538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029769|NCT00979199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029770|NCT01006798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34029771|NCT02729909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029772|NCT01427608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029773|NCT00852202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029774|NCT04272424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34029775|NCT04881487|RANDOMIZED|PARALLEL||TREATMENT||NONE||Trials within Cohorts (TwiCs)||||
34029776|NCT02201784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029777|NCT05868525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029778|NCT02498041|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34029779|NCT00953966|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34029780|NCT05041920|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a single-arm, open-label and fixed-sequence drug interaction study.||||
34029781|NCT05029219|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34029782|NCT02387411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029783|NCT06004791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029784|NCT06243276|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Split-mouth study|f|f|f|t
34029785|NCT05379244|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Pragmatic, within-group pilot study||||
34029786|NCT04514432|||OTHER||OTHER|||||||
34105684|NCT05225584|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34029787|NCT03742505|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The randomization lists will only be accessible to the Methods Centre at the Ottawa Hospital Research Institute and the research pharmacist(s). The active drug and placebo are identical (e.g. colour, consistency, volume, taste, smell, containers).|Pragmatic, Phase III, multi-centre, double-blinded randomized controlled trial|t|t|t|t
34029788|NCT04435249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029789|NCT02237092|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34029790|NCT02925039|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pilot Randomised controlled trial||||
34029791|NCT04022876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029792|NCT03900455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029793|NCT00273689|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34029794|NCT05453890|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33723956|NCT03170128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029795|NCT02687347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34029796|NCT05279911|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Patients were included in the study after fulfilling all the eligibility criteria and signing the informed consent form for participation and permission to use obtained data or research purposes. Patients were randomly allocated according to the type of treatment (control group: conventional implant placement and intervention group: LLLT) that were performed considering the implant as a unit. To ensure concealment of randomization, consecutively numbered envelopes were used. The team of surgeons only became aware of the type of intervention at the time of surgery, when the envelope was opened by a blinded investigator.|Study design: A randomized case control study. A total of 40 adult participants of both genders of at least 21 years old were included in the study. All participants were controlled T2DM patients for more than 2 years (diagnosed according to the American Diabetes Association criteria) \[21\]. Patients were able and willing to participate in the study. Patients were recruited from out-patient clinic of Oral Diagnosis at Faculty of Dental Medicine for Girls, Al-Azhar University, Cairo, Egypt.|f|f|t|f
34029797|NCT01377818|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34029798|NCT01124578|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34029799|NCT03789929|||COHORT||PROSPECTIVE|||||||
34029800|NCT06235489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029801|NCT04201184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be enrolled in one of two groups; active control or intervention groups. Participants in the control group will be provided with food boxes weekly for 12 weeks. Participants in the intervention group will be taught the 12 lessons on parenting, culture, and stress over a 12-week period in individual sessions with their community health worker.|f|f|f|t
34029802|NCT00732485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029803|NCT03633097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded, outcome assessor blinded||f|f|f|t
34029804|NCT02179944|||COHORT||PROSPECTIVE|||||||
34029805|NCT04479189|||OTHER||OTHER|||||||
34029806|NCT06296485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant randomization status will be masked during data collection (baseline and follow-up surveys) by research assistants|2-arm pragmatic randomized clinical trial|f|f|f|t
34029807|NCT01557517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029808|NCT02106234|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34105685|NCT04740346|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34105686|NCT02272985|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105687|NCT02214628|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723957|NCT04357015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33723958|NCT04173117|NA|SINGLE_GROUP||TREATMENT||NONE||Low energy meal replacement plan for 12 weeks||||
33723959|NCT01588691|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33723960|NCT02608931|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33723961|NCT05218018|NA|SINGLE_GROUP||OTHER||NONE||All participants undergo the same intervention||||
33723962|NCT05464459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029809|NCT03375177|||COHORT||PROSPECTIVE|||||||
34029810|NCT03768362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34105688|NCT01772693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single factor. ExAblate test verses ExAblate placebo randomized 2:1.|t|f|f|t
34105689|NCT06108609|||COHORT||PROSPECTIVE|||||||
34105690|NCT03523663|||COHORT||CROSS_SECTIONAL|||||||
33723963|NCT05595681|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center randomized open phase I clinical intervention||||
33723964|NCT00271089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723965|NCT03832621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723966|NCT04896710|NA|SINGLE_GROUP||SCREENING||NONE||||||
33723967|NCT05921019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Before study commencement, the statistician created a randomization sequence using IBM® SPSS® Statistics and contained it in sealed envelopes. The balanced sample size was ensured by dividing the participants into blocks of two. All eligible participants and assessors were unaware of the assignment order. Both the physician and participants will be unaware of the group allocation. Participants were allowed to withdraw from the study at any time.|Participants were randomized to either the laser acupuncture, the sham laser acupuncture group using a block randomization method with allocation ratio of 1:1. According to the previous randomization assignment, each patient will be assigned to 2 groups: (1) the laser acupuncture group and (2) the sham laser acupuncture group. Only the statistician is aware of the randomized order for each participant. Each participant will receive 24 interventions within 8 weeks, including three interventions per week for 8 weeks.|t|f|f|t
33723968|NCT03229824|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33723969|NCT03807011|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33723970|NCT03904758|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking will be used in the study.|The patients will be randomized into two study arms.||||
33723971|NCT03586388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723972|NCT03817242|RANDOMIZED|PARALLEL||TREATMENT||NONE||Tympanoplasty I is performed in these patients in Group 1 tragal cartilage graft is used while in group 2 temporalis fascia graft is used||||
33723973|NCT00238654|||COHORT||PROSPECTIVE|||||||
34105691|NCT03647137|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105692|NCT03851952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105693|NCT05870111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105694|NCT06382207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This proof-of-concept study will enroll infants, defined as individuals \<1 year of age. It will assess the feasibility and effectiveness of a physician and parent/caregiver in using the Eko DUO and CORE 500 to capture ECGs in patients \<10 kg in a clinic and home setting.||||
34105695|NCT02588859|||OTHER||PROSPECTIVE|||||||
34105696|NCT05593770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Which study drug arm the participant enters will be known to the research sites and the participants, but assignment to active versus placebo will be blinded. The randomized assignment, concealed from the research team, will be transmitted to the site pharmacy, who will provide study medication. The participant, treating clinicians, study personnel (other than the unblinded statistician who will prepare closed DSMB interim reports), and outcome assessors will all remain blinded to group assignment until after the database is locked and blinded analysis is completed.|Participants will be randomly allocated in a two-step process: 1) The participant will first be randomized in an m:1 ratio to receive an active study drug or placebo, where m represents the number of study drug arms for which the participant is eligible. 2) The participant will then be randomly assigned with equal probability to one of the study drug arms. Participants will receive the corresponding study drug or matching placebo.|t|t|t|t
34105697|NCT02755883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34105698|NCT05007158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105699|NCT04775979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105700|NCT06496100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double (Participant, Investigator) All participants will be submitted to the selection of a sealed envelope which will have a numerical code previously defined by a third party for each intervention group.~The total number of envelopes required to complete the minimum number of participants will have numerical codes that identify the bottle of intervention treatment that should receive the participant during the intervention period.~They will be divided into half blinded codes for triticum aestivum group and half for placebo to complete the size of each subsample. Chance guarantees blinding, neither the participant nor the researcher will know the type of treatment. The database for the blinded statistical analysis will be completed. The blind man will be removed once the statistical analysis has been completed."|"Controlled clinical trial, of two parallel groups, double blind, with random assignment and control group.~38 patients:~1. 19 patients with 500 mg of triticum aestivum orally every 12 hours for 120 days.~2. 19 patients with 500 mg of placebo orally every 12 hours for 120 days.~   * Visit 1/ Day -7: Screening period, information about the study, signing of informed consent, medical history, anthropometric measurements, baseline laboratory tests.~  * Visit 2/Day 0: Randomization, 60 tablets of Triticum aestivum or placebo will be given, general diet and exercise recommendations.~  * Visit 3,4,5/Day 30,60,90: Treatment adherence evaluation, laboratory tests, adverse events evaluation, general diet and exercise recommendations and 60 tablets of Triticum aestivum or placebo will be given.~  * Visit 6/Final/Day 120 ÷ 7: Anthropometric measurements will be taken, laboratory tests will be performed, adherence to treatment and adverse events will be"|t|f|t|f
34105701|NCT06421285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"* Patients aged 20 or older and younger than 80 years old who were first diagnosed with breast cancer~* BMI of 23 or higher~* Patients scheduled to undergo neoadjuvant chemotherapy before surgery"|"* Intervention group~* Control group"|t|f|f|f
34105702|NCT03508440|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no masking available as subject will know if they are receiving an intratympanic injection.|One arm will receive standard of care (SOC) in the form of high dose oral steroids for 10 days. The second arm will receive SOC plus 3 intratympanic steroid injections (space 7 days apart). Arm 3 is for patients who can not, for medical reasons, receive SOC; these patients will receive 3 intratympanic steroid injections (space 7 days apart).||||
34105703|NCT06638736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physician evaluating scars post closure will be blinded|Patients will be randomize into either the suture group or staple group for closure|f|f|f|t
34105704|NCT01676545|||CASE_CONTROL||RETROSPECTIVE|||||||
34105705|NCT05734807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105706|NCT02931227|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34105707|NCT02444832|||CASE_ONLY||RETROSPECTIVE|||||||
34105708|NCT03116100|||COHORT||PROSPECTIVE|||||||
34105709|NCT06250426|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, crossover, interventional and, open-label clinical study. The study includes 2 groups: 1) n=25: 1st visit: stimulation with Control, 2nd visit: stimulation with CS; and 2) n=25: 1st visit: stimulation with CS, 2nd visit: stimulation with Control.||||
34105710|NCT00908141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105711|NCT00070083||||TREATMENT||||||||
34105712|NCT04796805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34105713|NCT06133270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34105714|NCT06639581|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|All the data is going to be registered by Rec Trial Software, anonimize and blind to everybody|A baseline evaluation will be carried out and with the 9 doses of dorsal stimulation resulting from the combination of displacements of 3-5 -8 mm and 20-30-40 cycles per minute, randomized and performed by 2 operators each.|t|t|t|t
34105715|NCT00123942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105716|NCT06641869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837933|NCT05503199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837934|NCT02441998|||COHORT||PROSPECTIVE|||||||
33837935|NCT04211259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837936|NCT03004716|||COHORT||PROSPECTIVE|||||||
33837937|NCT05038605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33837938|NCT03427424|||COHORT||CROSS_SECTIONAL|||||||
33837939|NCT02114762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837940|NCT05525507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839193|NCT05521243|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33839194|NCT06196775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839195|NCT03328377|||CASE_CONTROL||PROSPECTIVE|||||||
33839196|NCT04937322|||OTHER||OTHER|||||||
33805416|NCT06174948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The masking only applies to investigation for a subgroup of people with Parkinson's disease (e.g., 30-40 participants) There is no masking for the single group intervention of people with Parkinson's related disorders and the first 10 participants with Parkinson's disease|"Initially, 10 people with idiopathic Parkinson's disease and 10-20 people with related movement disorders are firstly assigned into a single group study to investigate the feasibility, safety and tolerability of the CUE1 device.~Then a subgroup of participants (e.g., 30-40 new participants) with idiopathic Parkinson's disease only will be randomly allocated to one of the two intervention Groups; one group will receive the CUE1+ intervention at loud settings while the other at silent settings. The outcome assessor and statistician the group of the participants. Participants will know in which group they are but they do not know which is the active and which the passive intervention. This intervention is the main of this study and is double blind."|t|f|f|t
33805417|NCT02859844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805418|NCT00047125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805419|NCT05607199|NA|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation 3+3 Design"||||
33805420|NCT04593238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805421|NCT06293261|||CASE_CONTROL||PROSPECTIVE|||||||
34029811|NCT00208273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105717|NCT03110510|NA|SINGLE_GROUP||TREATMENT||NONE||D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Every 2 weeks||||
34105718|NCT00020007||||TREATMENT||||||||
34105719|NCT02904265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805422|NCT06587789|||COHORT||PROSPECTIVE|||||||
34029812|NCT02843984|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029813|NCT00059592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029814|NCT02333084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34029815|NCT04574440|||COHORT||PROSPECTIVE|||||||
34029816|NCT04736745|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||For dose escalation part Sequential study model will be used. For the rest of the study parallel assignment will be used.|t|t|t|t
34029817|NCT06208540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029818|NCT02656407|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34029819|NCT02861014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029820|NCT04681716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029821|NCT05295576|||CASE_CONTROL||PROSPECTIVE|||||||
34029822|NCT05422586|||COHORT||PROSPECTIVE|||||||
34029823|NCT06438835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029824|NCT04659603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029825|NCT01080183|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34029826|NCT00533312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029827|NCT04969731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029828|NCT03153033|||CASE_ONLY||CROSS_SECTIONAL|||||||
34029829|NCT01284361|RANDOMIZED|CROSSOVER||||NONE||||||
34029830|NCT04982302|||CASE_ONLY||PROSPECTIVE|||||||
34029831|NCT04215146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029832|NCT05019300|||COHORT||PROSPECTIVE|||||||
34029833|NCT03645863|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34029834|NCT02005835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029835|NCT02352870|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34029836|NCT00128401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029837|NCT01547702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029838|NCT01911273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029839|NCT06303700|||COHORT||CROSS_SECTIONAL|||||||
34029840|NCT05257226|||COHORT||PROSPECTIVE|||||||
34029841|NCT00004186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029842|NCT04376931|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, dose-escalating mono-center open label dose-finding study without control group (3+3 design), including a follow-up on-treatment observation.||||
34029843|NCT01918462|||COHORT||PROSPECTIVE|||||||
34029844|NCT05294666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029845|NCT04801511|NA|SINGLE_GROUP||TREATMENT||NONE||"Preoperative CRT: The eligible subjects will be treated with concurrent chemoradiotherapy and high-dose intravenous vitamin C. IMRT will be delivered to PTV-CTV (plan target volume-clinical target volume) with a dose of 45Gy/25f. If necessary, additional boost of 5-10Gy will be delivered to PTV-GTV (plan target volume- gross tumor volume). During the IMRT, 2-3 cycles of concurrent chemotherapy (mFOLFOX6) will be delivered. High-dose intravenous vitamin C (24g/d，QD) will be delivered on the day of radiotherapy from the beginning to the end. Three additional cycles of chemotherapy (mFOLFOX6) will be given after radiotherapy. Radical surgery will be performed approximately 10-12 weeks after the end of radiotherapy. Whether or not to select watch and wait or sphincter preserving surgery needs to refer to the tumor location, tumor regression, surgeon's opinion and patient's will."||||
34029846|NCT06319040|||COHORT||PROSPECTIVE|||||||
34029847|NCT05152056|||CASE_ONLY||RETROSPECTIVE|||||||
34029848|NCT04217954|NA|SEQUENTIAL||TREATMENT||NONE||||||
34029849|NCT03955003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Utilizing a randomized group pilot research design, the feasibility and exploratory impact of a group drumming intervention on fatigue, anxiety, and cognitive impairment in cancer patients will be compared to an attention control. Participants will be randomized to a six-week group drumming intervention or a six-week attention control group. The attention group is intended to control for time effects and the nonspecific effects of participating in a group learning activity.|t|f|f|f
34029850|NCT01919021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029851|NCT03142191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029852|NCT02371070|||COHORT||PROSPECTIVE|||||||
34105720|NCT06086873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105721|NCT05384483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105722|NCT05080478|||CASE_CONTROL||PROSPECTIVE|||||||
34105723|NCT00338611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105724|NCT06240728|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation and dose expansion||||
34105725|NCT03749018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105726|NCT06640400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105727|NCT04581577|||COHORT||CROSS_SECTIONAL|||||||
34105728|NCT03913286|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34105729|NCT03729141|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33805423|NCT04773626|||CASE_CONTROL||RETROSPECTIVE|||||||
34105730|NCT04377776|||COHORT||CROSS_SECTIONAL|||||||
34105731|NCT02518698|||COHORT||RETROSPECTIVE|||||||
34105732|NCT06373718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Enrolled participants will be randomized into either the Immediate Treatment group, or the Enhanced Sleep Hygiene group. Both study groups will receive CBT-I.|t|f|f|f
33805424|NCT01025167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34105733|NCT05292287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The researcher carrying out the follow up assessments will be blinded to the arm participants have been randomised to.||f|f|f|t
33805425|NCT05047458|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34105734|NCT01503177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805426|NCT00993174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34105735|NCT06644027|RANDOMIZED|PARALLEL||PREVENTION||NONE|Wound Ostomy and Continence Specialist Nurses and Dermatologists; laboratory technician|Experimental: Jefcare Sterile Medical Sheets Other: Molicare Premium Bed Mat||||
34105736|NCT06435858|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Investigator-initiated randomised, single-blind, placebo-controlled, cross-over study|t|f|f|f
34105737|NCT00879372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105738|NCT02437526|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105739|NCT03629717|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33805427|NCT01333605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805428|NCT05766319|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||10 patients who have been admitted to the ICU, at the Leiden University Medical Centre, and have been discharged to home will be using home monitoring for 3 consecutive months after hospital discharge||||
33805429|NCT06485141|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33805430|NCT05216796|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The investigators will employ a block randomization (n=10) between groups feeding trial where 100 participants will be assigned to receive either low-carbohydrate (LoCHO) or low-calorie (LoCAL) control diet for up to 3 weeks.||||
33805431|NCT06505954|||OTHER||CROSS_SECTIONAL|||||||
34029853|NCT05449860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029854|NCT06191835|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34029855|NCT00916643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029856|NCT02065076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029857|NCT04821193|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blind|Single blind Randomized controlled Experimental|t|f|f|f
34029858|NCT01623895|||CASE_ONLY||PROSPECTIVE|||||||
34029859|NCT00002397||||TREATMENT||NONE||||||
34029860|NCT03863548|||COHORT||PROSPECTIVE|||||||
34029861|NCT02213653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029862|NCT00445146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029863|NCT02755285|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029864|NCT03815214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is blinded to study group assignment||f|f|f|t
34029865|NCT01998763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029866|NCT01276145|||CASE_ONLY||PROSPECTIVE|||||||
34029867|NCT04005066|||COHORT||PROSPECTIVE|||||||
34029868|NCT05810428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physiotherapist, neurologists, neuropsychologists, radiologist and biomedical engineering assessing the patients are blinded to group allocation.|Single centre, randomized controlled trial, assessor blinded. The investigators plan to enroll 50 TN patients with indications to undergo surgical treatment. Fifty TN participants will be randomly allocated into two groups: individuals in the experimental group (GKRS-VR) will undergo GKRS followed by immersive VR-based sensorimotor neuromodulation training, whilst control group (CT) will undergo only GKRS. A group of 50 age- and sex-matched controls will also be recruited.|f|f|f|t
34029869|NCT03717012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029870|NCT02123446|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029871|NCT03321383|||CASE_ONLY||CROSS_SECTIONAL|||||||
34029872|NCT04620408|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34029873|NCT00004492|RANDOMIZED|||TREATMENT||||||||
34029874|NCT03791463|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029875|NCT05889312|||COHORT||PROSPECTIVE|||||||
34029876|NCT00679133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029877|NCT01804972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34029878|NCT02508129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34029879|NCT00292890|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029880|NCT05356507|||CASE_ONLY||CROSS_SECTIONAL|||||||
34029881|NCT01625988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029882|NCT00513136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029883|NCT04587999|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34029884|NCT01184443|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029885|NCT05650840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029886|NCT04206566|||COHORT||PROSPECTIVE|||||||
34029887|NCT00553735|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34029888|NCT06471374|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34029889|NCT05354921|RANDOMIZED|PARALLEL||OTHER||NONE|A clinical research coordinator that is blinded to the arm patients are randomized to will be responsible for recording all outcome measures of interest prospectively in the study's database from the patient's electronic medical records.|||||
34029890|NCT01208805|||COHORT||PROSPECTIVE|||||||
34029891|NCT05062538|||COHORT||PROSPECTIVE|||||||
34029892|NCT02503384|||COHORT||RETROSPECTIVE|||||||
34029893|NCT05925998|||COHORT||PROSPECTIVE|||||||
34029894|NCT04615351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029895|NCT03744624|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029896|NCT05806840|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029897|NCT05991869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029898|NCT01315327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34029899|NCT02397876|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34029900|NCT00401661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029901|NCT00455156|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34029902|NCT03061084|||COHORT||PROSPECTIVE|||||||
34029903|NCT06582667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|outcomes assessor|group I: PENG block with antithrombotic therapy group II: PENG block without antithrombotic therapy|t|f|f|t
34029904|NCT02285374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029905|NCT00402116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723974|NCT02500784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33723975|NCT06051188|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover physiological pilot study||||
33723976|NCT01948817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723977|NCT00175721|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33723978|NCT00000766||||TREATMENT||||||||
33723979|NCT03169465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723980|NCT02747420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723981|NCT05771207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33723982|NCT03137693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723983|NCT01257958|NA|SINGLE_GROUP||TREATMENT||||||||
33723984|NCT03316885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723985|NCT02299557|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33723986|NCT02304263|||COHORT||PROSPECTIVE|||||||
33723987|NCT00006028||||TREATMENT||||||||
33723988|NCT04273646|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33723989|NCT05275647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigator are blinded to the treatment arm.|This is a double-blind, randomized, placebo-controlled physician initiated study enrolled patients with refractory IC/BPS.|t|f|t|f
33723990|NCT00144209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33723991|NCT04741828|NA|SINGLE_GROUP||PREVENTION||NONE||One dose Vi-DT vaccine in clinical trial subjects which is received primary dose at 6-23 months old.||||
33723992|NCT00373867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33723993|NCT01642017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723994|NCT04536155|||COHORT||PROSPECTIVE|||||||
33723995|NCT05132504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33723996|NCT04094922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33723997|NCT02273895|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33723998|NCT04222582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33723999|NCT00819468|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33724000|NCT06250023|||COHORT||PROSPECTIVE|||||||
33724001|NCT03465332|||COHORT||CROSS_SECTIONAL|||||||
33724002|NCT06146582|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned upon consent randomly to an intervention or control group. The intervention group received support from Laguna Coaches and Laguna's mobile app for 90 days, the control group did not receive any support from Laguna coaches or Laguna's app.||||
33724003|NCT03922451|||COHORT||PROSPECTIVE|||||||
33724004|NCT00846755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724005|NCT02770586|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724006|NCT02952339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724007|NCT04965545|||COHORT||RETROSPECTIVE|||||||
33724008|NCT01378221|||COHORT||PROSPECTIVE|||||||
33724009|NCT05643261|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|The allocation to intervention or control groups is not random, but separated according to sports schools. This is the only way to ensure that there is no overlapping of training.|All players in the intervention group will complete the targeted muscle and technique training integrated into their handball training, while players in the control group only continue their regular handball training. There will be a training of the coaches on site, who assess the training of the intervention group during the entire period and document the participation of the players accordingly.The strength training consists of three exercises (clam shell, side plank, calf raises) with an progressive overload after two to three weeks to ensure a continuous muscle stimulation. The technique training consists of different cutting variations with a focus on forefoot landings and conscious control of the knee to avoid high knee valgus movement and KAM respectively.||||
33724010|NCT00149747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029906|NCT03687840|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Parallel Assignment||||
34029907|NCT04386395|||COHORT||PROSPECTIVE|||||||
34029908|NCT02229461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724011|NCT00078026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724012|NCT01746979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724013|NCT05110456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724014|NCT02877784|||COHORT||PROSPECTIVE|||||||
33724015|NCT00844363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724016|NCT00525668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724017|NCT04615611|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33724018|NCT01225575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724019|NCT06427018|||CASE_CONTROL||RETROSPECTIVE|||||||
33724020|NCT02256761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029909|NCT06339697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029910|NCT02888951|||COHORT||PROSPECTIVE|||||||
34029911|NCT01958138|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34029912|NCT04010552|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a multicenter, single-arm, interventional, open-label, non-randomized, phase II clinical trial, to evaluate the association of KRAS mutational load and histological tumour response after chemotherapy treatment in patients with PDAC. Due to its single-arm design patients will be assigned to a single group (non-randomized) and there will be no masking (open-label).||||
34029913|NCT01277159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029914|NCT02091024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34029915|NCT00330837|||||PROSPECTIVE|||||||
34105740|NCT05984862|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|This is a randomized, triple-blind, split-scalp study. The subjects will know what side of the scalp the bandage products are applied. However, during evaluation, the subjects and analyst will be shown close-up pictures of the two sides without exposing the patient's identity and actual sides.|This is a single center, triple-blind, within subject split scalp study investigating the comparison of bandage versus no bandage donor site post FUE. Twenty-five subjects desiring to undergo FUE for hair restoration will have bandage on one half of the donor area on the back of the scalp and no-bandage on the other side for 24 hours post procedure. The sides of the scalp will be randomized, and the evaluating physician will be blinded. Subjects will be evaluated, photographed, and will fill out subject reported questionnaires live at days 1 (+1) and 7 (±1) post procedure.|f|t|t|t
34105741|NCT01006486|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34105742|NCT04588558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Squat based exercise will be applied to the first group with isoinertial system. Electrotherapy (TENS, ultrasound and hot pack or cold pack) and squat-based home exercise program will be applied to the second group, and only squat-based home exercise program will be applied to the third group.|t|f|t|t
34105743|NCT01550965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105744|NCT04850963|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34105745|NCT02114944|||COHORT||PROSPECTIVE|||||||
34105746|NCT00803049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105747|NCT01258985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105748|NCT01706315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34105749|NCT04544605|||CASE_ONLY||OTHER|||||||
34105750|NCT05077605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105751|NCT04362254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105752|NCT02048631|||COHORT||RETROSPECTIVE|||||||
34105753|NCT04668599|||COHORT||PROSPECTIVE|||||||
34105754|NCT06640764|||COHORT||PROSPECTIVE|||||||
34105755|NCT04669197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105756|NCT03578263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|the participants blinded the arms of the study|The current study was a single-blinded randomized controlled trial conducted at a tertiary University Hospital Women included in the study were divided into 2 groups: Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after birth of the baby. Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and intramuscular ergometrine 0.2 mg.|t|f|f|f
34105757|NCT01928537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105758|NCT03087149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105759|NCT01655446|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34105760|NCT03173378|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34105761|NCT01013259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105762|NCT03226665|||COHORT||PROSPECTIVE|||||||
34105763|NCT02402907|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34105764|NCT01666366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105765|NCT06154850|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34105766|NCT03956108|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34105767|NCT02118831|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34148993|NCT03756831|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||3x3 factorial design, according to body mass index (Independent variable)subjects will be divided into three groups (Group I - normal subjects-BMI\<25 kg/m2, Group II -overweight subjects-BMI, 25-30 kg/m2), Group III -obese subjects- BMI\>30 kg/m2). Core stability (dependent variable) will be measured by three tests : bilateral static balance with open and close eye, uni-pedal static balance test, and dynamic balance test using Prokin System for balance||||
33805432|NCT01229384|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33805433|NCT03469596|||COHORT||RETROSPECTIVE|||||||
33805434|NCT01185600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805435|NCT05915000|||COHORT||PROSPECTIVE|||||||
33805436|NCT05869123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805437|NCT05823922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized clinical trial designed to compare the efficacy of clinician-delivered cognitive behavior therapy supplemented with a mobile cognitive behavioral therapy program in improving anxiety and depression in graduate students. Participants will be randomized to one of two conditions: 1) Clinician-delivered Cognitive Behavior Therapy 2) Clinician-delivered Cognitive Behavior Therapy and CBT mobile app|f|t|t|f
34029916|NCT01105793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029917|NCT05536999|||COHORT||PROSPECTIVE|||||||
34029918|NCT02720497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34029919|NCT03916705|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Data analysis will be performed by blinded personnel. As a single group trial involving a manual therapy, participant and provider blinding is not feasible.|Proof of concept study evaluating potential mechanisms of high-velocity low-amplitude spinal manipulation||||
34029920|NCT01662219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029921|NCT05166616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029922|NCT02523300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029923|NCT05665725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029924|NCT05101668|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single-arm objective performance criteria||||
34029925|NCT02085447|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34029926|NCT04413110|||CASE_CONTROL||RETROSPECTIVE|||||||
34029927|NCT01128543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34029928|NCT02588495|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34029929|NCT00255554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34029930|NCT04799197|NA|SINGLE_GROUP||PREVENTION||NONE||One-arm pilot||||
34029931|NCT03076775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029932|NCT00866944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029933|NCT02770898|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34029934|NCT00298727|NON_RANDOMIZED|PARALLEL||||NONE||||||
34029935|NCT02489097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029936|NCT06037005|RANDOMIZED|PARALLEL||OTHER||SINGLE|"In the study, data collection, statistics and reporting were blinded. The collection of research data and data entry (pre-tests and post-tests and transferring the data to the computer) were carried out by an instructor other than the researcher, who was unaware of the intervention and control groups. Data entries were entered with A and B codes without specifying the intervention or control group. The analysis of the data and the writing of the research report were coded as A and B groups. After the statistical analysis was made and the research report was written, the coding for the intervention and control groups was explained to the researcher by the coder."|Single-blinded study with parallel groups.|f|f|f|t
33724021|NCT02373787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33724022|NCT02259361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34029937|NCT05725863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34029938|NCT03059797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724023|NCT01652521|||COHORT||PROSPECTIVE|||||||
34029939|NCT03382223|||COHORT||PROSPECTIVE|||||||
34029940|NCT05264181|||COHORT||RETROSPECTIVE|||||||
33724024|NCT00026546|||COHORT||OTHER|||||||
33724025|NCT00110058||||TREATMENT||NONE||||||
34029941|NCT04610333|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33724026|NCT03210610|||COHORT||CROSS_SECTIONAL|||||||
34029942|NCT03451357|||CASE_ONLY||PROSPECTIVE|||||||
33805438|NCT03941665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind study|Double blind study|t|f|t|f
34029943|NCT00972595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029944|NCT03288818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029945|NCT04902937|||COHORT||PROSPECTIVE|||||||
34029946|NCT00980447|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34029947|NCT03420521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029948|NCT03204448|||COHORT||RETROSPECTIVE|||||||
34029949|NCT02441725|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029950|NCT00441220|||CASE_ONLY|||||||||
34029951|NCT00351403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029952|NCT04468451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34029953|NCT01517958|||CASE_CONTROL||PROSPECTIVE|||||||
34029954|NCT03214744|||CASE_ONLY||PROSPECTIVE|||||||
34029955|NCT03165292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029956|NCT06442215|||COHORT||RETROSPECTIVE|||||||
34029957|NCT04078321|NA|SINGLE_GROUP||TREATMENT||NONE||Single case studies||||
34029958|NCT04902014|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029959|NCT03766607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029960|NCT06328465|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029961|NCT02322827|||||RETROSPECTIVE|||||||
34029962|NCT03788070|||COHORT||PROSPECTIVE|||||||
34029963|NCT03280381|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Investigators will conduct a randomized crossover trial in mothers/caregivers with a preterm infant in the mother-baby unit at Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. Each caregiver/infant pair will use the Nifty Feeding Cup for two feeds and the standardized generic cup for two feeds. Cross-over means each caregiver/infant pair will use both cups, with the order of the cup used first and second randomized.|f|f|t|f
34029964|NCT04350450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029965|NCT05880602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34029966|NCT04743687|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open label study.|This will be a single center, single arm, phase 2 study.||||
34029967|NCT01884038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34029968|NCT03573830|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"PARTICIPANT MASKING: Participants will be told the purpose of the study is to evaluate parents' reactions to two different information materials about booster seats and seatbelts.~INVESTIGATOR MASKING: The study will be conducted entirely online using a online research platform, so allocation will be masked to all investigators.~OUTCOMES ASSESSOR MASKING: Outcome evaluation will be conducted online using an online survey tool, so allocation will be masked to outcome assessors.~STATISTICAL ANALYSIS: Allocation in the online survey will be coded using random numbers unknown to the person conducting statistical analysis."||t|f|t|t
34029969|NCT03310749|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open, randomized, multiple dose, three way, three period, cross over, drug-drug interaction, safety and tolerability study||||
34029970|NCT03259386|||COHORT||PROSPECTIVE|||||||
34105768|NCT05880784|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study is being conducted in public (primary level) health facilities with at least one PEN-trained staff in the Bhaktapur district in Nepal. The seventeen health facilities were randomized into control and intervention groups. Randomization was conducted in excel using the RAND function. Out of 17, nine facilities were categorized into intervention groups and the remaining eight into control groups. The intervention consists of peer coaching and clinical auditing processes reinforcement to promote a team-based care approach for NCD management in the health facilities.|t|f|f|f
34105769|NCT06257420|||CASE_ONLY||PROSPECTIVE|||||||
34105770|NCT05035173|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34105771|NCT04192838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105772|NCT06639568|||OTHER||CROSS_SECTIONAL|||||||
34105773|NCT06223880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105774|NCT04932473|||CASE_CONTROL||PROSPECTIVE|||||||
34105775|NCT03747237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105776|NCT05438160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029971|NCT05738278|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Due to the objectives of the study, the identity of test and control treatments will not be known when analysing data. Access to the randomization code will be strictly controlled.|Thirty-eight non-verbal patients are recruited. HR is taken as a marker of acute pain. HR-Variability (HRV) and pain-related inflammatory cytokines (MCP-1, IL-1RA, IL-8, TGFβ1, and IL-17) are collected as measures of long-term pain. Caregivers will be asked to what degree they observe pain in their patients and how well they believe they understand their patient's expression. Collection is set to primary care institutions. HR is measured 8 hours/day over 2 weeks to identify increase of HR associated with potentially painful situations. Changes in procedures are in the form of change in 1) rigorousness of stretching, 2) preparations for casts, 3) lifting technique, or 4) personal hygiene procedure. To differentiate effects due to procedure-change from effects of covariates such as increased attentiveness when using HR; half the study group will start intervention in week 3 while the delayed group will continue data collection for another 2 weeks before introducing procedure changes.|f|f|f|t
34029972|NCT04358055|NA|SINGLE_GROUP||OTHER||NONE||||||
34029973|NCT00880789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029974|NCT02618525|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34029975|NCT04243031|||COHORT||PROSPECTIVE|||||||
34029976|NCT00489255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029977|NCT03946618|NA|SINGLE_GROUP||TREATMENT||NONE||Epilepsy||||
34029978|NCT04796298|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study is designed as Randomized Uncontrolled Trial.||||
34029979|NCT01493921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34029980|NCT02322905|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34029981|NCT01598194|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029982|NCT05808478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34105777|NCT05488964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34105778|NCT02090894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105779|NCT04463927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34029983|NCT05013125|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34105780|NCT03635996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105781|NCT06690034|||COHORT||CROSS_SECTIONAL|||||||
34105782|NCT00913835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105783|NCT06174272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105784|NCT02031913|||COHORT||PROSPECTIVE|||||||
33724027|NCT05715372|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Computer-assigned.|Randomized, single-blinded prospective study.|t|f|f|f
33724028|NCT01799499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724029|NCT02601287|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724030|NCT05004376|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized controlled trial with a prospectively collected convenience sample||||
33724031|NCT01820455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724032|NCT01028508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724033|NCT03342547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724034|NCT04964128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724035|NCT00714519|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||f|t|t|t
33724036|NCT03510286|||COHORT||CROSS_SECTIONAL|||||||
33724037|NCT04076995|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33724038|NCT01797289|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724039|NCT03872089|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724040|NCT05139446|||CASE_ONLY||RETROSPECTIVE|||||||
33724041|NCT05533918|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients will not know what intervention arm they are in.|Patient-level, two-arm randomized design for Population Health Management interventions: (1) TM + No PN and (2) TM + Request PN|t|f|f|f
33724042|NCT01091389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724043|NCT01853046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724044|NCT00361179|||DEFINED_POPULATION||PROSPECTIVE|||||||
33724045|NCT00326443|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33724046|NCT03830944|||COHORT||PROSPECTIVE|||||||
33724047|NCT06446765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33724048|NCT04283006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724049|NCT02044133|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724050|NCT04863755|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33724051|NCT05459922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724052|NCT06496009|||COHORT||PROSPECTIVE|||||||
33724053|NCT01135758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724054|NCT02809625|||CASE_CONTROL||PROSPECTIVE|||||||
33724055|NCT00659256|||||OTHER|||||||
33724056|NCT01969812|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33724057|NCT01094496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724058|NCT02596269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724059|NCT01163279|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33724060|NCT01487590|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34105785|NCT05533372|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34105786|NCT05457205|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34105787|NCT00323245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724061|NCT02344680|||COHORT||PROSPECTIVE|||||||
33724062|NCT01556581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724063|NCT05337215|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33724064|NCT04176276|||COHORT||RETROSPECTIVE|||||||
33724065|NCT02112669|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724066|NCT02517996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724067|NCT01180673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724068|NCT04809220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724069|NCT03929861|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33805439|NCT00902213|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33805440|NCT05173987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805441|NCT03000257|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33805442|NCT06698744|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1 single arm, open label study||||
34029984|NCT01739049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029985|NCT02533180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029986|NCT02386124|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34029987|NCT03814655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"54 partially edentulous patients filling the inclusion criteria and with signed consent form are expected to be enrolled in this RCT.~Each patient will be randomly assigned to one of the following protocol for dental implant insertion:~* Full digital workflow (n=27 patients/sites),~* Partially digital workflow (n=27 patients/sites)."|f|f|t|t
34029988|NCT00377832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029989|NCT00178282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34029990|NCT03739047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34029991|NCT02730663|NA|SINGLE_GROUP||TREATMENT||NONE||The investigational device (ID) 'Niti-S SPAXUS Stent' is used for drainage of cystic fluid by being connected to the pancreatic pseudocyst through human organs such as stomach or duodenum. It is composed with a stent made of nitinol and introducer system.||||
34029992|NCT02574065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34029993|NCT04590105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Subjects were randomly assigned via block randomization to receive either written or software-based prep instructions. To eliminate bias, the four grading gastroenterologists who judged the quality of the subject's cleanout did not know whether subjects had used written or app instructions.|Subjects were randomly assigned via block randomization to receive either written or software-based prep instructions.|t|t|f|t
34029994|NCT03365557|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34029995|NCT01236443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34029996|NCT04680026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Allocation: Stage A: non-randomized; Stage B: randomized, double-blind and placebo-controlled Intervention Model: Two-stage study Masking: None; Stage A (open label); Stage B: randomized, double-blind and placebo-controlled|t|t|t|t
34029997|NCT03960463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34029998|NCT04520009|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34029999|NCT01256502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030000|NCT06064578|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Assessments will be completed independently by participants online. Investigators will be blinded to condition throughout the study.|Participants will be randomized to receive the intervention condition (Project SOLVE) immediately or after three months. Participants in the delayed SOLVE condition will complete a typical school activity instead (i.e., treatment as usual). All participants will complete follow-up measures online at baseline, immediately after receiving the intervention, and 1-, 3, 4-, and 6-months after baseline.|f|f|t|t
34030001|NCT03071276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030002|NCT05435846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030003|NCT00842205||PARALLEL||BASIC_SCIENCE||NONE||||||
34030004|NCT03672227|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There are two arms in this study. In the intervention arm, teachers will receive the Mealtime Matters training about child nutrition. In the control arm, the teachers do not receive the Mealtime Matters until the completion of the study.|f|f|t|f
34030005|NCT01682811|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34030006|NCT04607057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030007|NCT03080870|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030008|NCT04417413|||COHORT||RETROSPECTIVE|||||||
34030009|NCT05549531|NA|SINGLE_GROUP||OTHER||NONE||Open-label, fixed-sequence, drug-drug interaction (DDI) study||||
34030010|NCT05436483|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34030011|NCT03020771|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030012|NCT01666769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030013|NCT04138043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a parallel group study. Participants will be randomized to receive either GSK2330811 (450 mg) or placebo in an approximate ratio of 7:3.|t|f|t|f
34030014|NCT04931121|||COHORT||PROSPECTIVE|||||||
34030015|NCT05295719|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34030016|NCT00079430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030017|NCT00619060|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030018|NCT01823497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030019|NCT04148573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030020|NCT00413881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030021|NCT04306211|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Random assignment to oxygen delivery system: facial mask or SuperNO2VA Et. Crossover to other oxygen delivery system if patient experiences difficulty with assigned system.|Random assignment to oxygen delivery system: facial mask or SuperNO2VA Et. Crossover to other oxygen delivery system if patient experiences difficulty with assigned system.|t|f|f|f
34030022|NCT04941079|||OTHER||PROSPECTIVE|||||||
34105788|NCT01678365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105789|NCT03726879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34105790|NCT06674070|||COHORT||PROSPECTIVE|||||||
34105791|NCT05310357|||COHORT||PROSPECTIVE|||||||
34105792|NCT06686641|||COHORT||OTHER|||||||
34105793|NCT05318443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blind, parallel-controlled, multicenter Phase III clinical study.|t|t|t|t
34105794|NCT00909688|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
34105795|NCT05030389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030023|NCT04718831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34030024|NCT05859828|||COHORT||PROSPECTIVE|||||||
34030025|NCT04082338|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34030026|NCT05524337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34030027|NCT02310256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030028|NCT02852577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030029|NCT06408805|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34030030|NCT02587078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030031|NCT03759730|||OTHER||PROSPECTIVE|||||||
34030032|NCT00658879|||CASE_ONLY||PROSPECTIVE|||||||
34030033|NCT05637736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34030034|NCT00753311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030035|NCT00426101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030036|NCT05662839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will be assigned to one of two groups. Each group will receive standard of care and the additional procedures being investigated.||||
34030037|NCT02128321|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030038|NCT05154838|||CASE_ONLY||PROSPECTIVE|||||||
34030039|NCT02344082|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030040|NCT01323361|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030041|NCT05113784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030042|NCT02976948|||OTHER||PROSPECTIVE|||||||
34030043|NCT02166658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030044|NCT01420965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030045|NCT03613233|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030046|NCT06303531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030047|NCT04913142|||COHORT||PROSPECTIVE|||||||
34030048|NCT01843738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030049|NCT00294580|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34030050|NCT02904941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030051|NCT02796053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030052|NCT00321178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030053|NCT04795947|||OTHER||CROSS_SECTIONAL|||||||
34030054|NCT01061801|RANDOMIZED|||BASIC_SCIENCE||NONE||||||
34030055|NCT00386347|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34030056|NCT01769287|||COHORT||PROSPECTIVE|||||||
34030057|NCT05771389|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030058|NCT00098605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030059|NCT02463357|NON_RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34030060|NCT02189486|||COHORT||PROSPECTIVE|||||||
34030061|NCT02794727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030062|NCT03144310|||CASE_ONLY||PROSPECTIVE|||||||
34030063|NCT01172665|||CASE_ONLY||OTHER|||||||
34030064|NCT01467440|||CASE_CONTROL||RETROSPECTIVE|||||||
34105796|NCT04199689|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34105797|NCT01345903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105798|NCT06027398|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||To compare the efficacy of SARS-CoV-2 RNA detection from used surgical masks with standard detection methods||||
34105799|NCT00514397|NON_RANDOMIZED|||TREATMENT||||||||
34105800|NCT02793050|||COHORT||RETROSPECTIVE|||||||
34105801|NCT04876391|NA|SINGLE_GROUP||TREATMENT||NONE|All medication kit assignments will occur in an open label fashion except for medications provided for visit 1. Only administration of study medication at visit 1 is blinded.|||||
34105802|NCT04262271|||COHORT||PROSPECTIVE|||||||
34105803|NCT05679934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105804|NCT04497155|||COHORT||RETROSPECTIVE|||||||
34105805|NCT03830398|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Each drug for one week|t|t|t|f
34105806|NCT01348581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105807|NCT04236947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|During the assessments, research assistants will be blind to the allocation of schools.|This study is a randomized control trial with two arms.|f|f|f|t
34105808|NCT01498380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105809|NCT03635866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105810|NCT01668199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105811|NCT06124300|NA|SINGLE_GROUP||OTHER||NONE||||||
34105812|NCT05158049|||COHORT||PROSPECTIVE|||||||
34105813|NCT03270228|||COHORT||RETROSPECTIVE|||||||
34105814|NCT00127478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105815|NCT05848089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105816|NCT04003142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105817|NCT03808077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105818|NCT00337597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105819|NCT00958425|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105820|NCT03477331|||COHORT||PROSPECTIVE|||||||
34105821|NCT05230654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34105822|NCT01983670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030065|NCT04363957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||In this open-label study design, eligible participants will be randomized using a simple 1:1 schedule to either brachytherapy verbal standard consent (Arm A), or the brachytherapy specific video (Arm B), based on chronological arrival in clinic||||
34030066|NCT05560386|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030067|NCT01932866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030068|NCT00194779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030069|NCT06297915|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34030070|NCT03751007|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|For the randomized participants in the combination cohorts, blinding will be accomplished by arranging for AG019 and placebo components as well as teplizumab and placebo components to have identical packaging.|"The phase 1b part of the study will enroll 4 sequential AG019 cohorts of up to 6 participants, in ascending dose cohorts and descending age cohorts. All participants in these cohorts will be treated with AG019 in an open label fashion.~The phase 2a part of the study will evaluate 2 cohorts of participants administered AG019 and teplizumab. The first 2 participants will be treated with active treatment in an open label fashion. Participants 3-12 will be randomized (4:1) to receive active treatment or placebo in a double-blind fashion."|t|t|t|t
34030071|NCT02514369|||COHORT||CROSS_SECTIONAL|||||||
34030072|NCT03272724|||COHORT||OTHER|||||||
34030073|NCT05531110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will not be informed of which arm of the study they will be allocated to.||t|f|f|f
34030074|NCT05326035|NA|SEQUENTIAL||TREATMENT||NONE|None (Open Label)|||||
34030075|NCT03362372|RANDOMIZED|PARALLEL||PREVENTION||NONE||Controlled, parallel, multicenter, cluster-randomized clinical trial.||||
34030076|NCT01017627|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34030077|NCT04364776|||COHORT||PROSPECTIVE|||||||
34030078|NCT05338931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030079|NCT03414216|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030080|NCT02481869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030081|NCT03708302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030082|NCT03893630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030083|NCT03979755|||COHORT||CROSS_SECTIONAL|||||||
34030084|NCT04739098|||COHORT||PROSPECTIVE|||||||
34030085|NCT03759938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The Event Adjudication Committee is a study group (of at least three members) responsible for the review of clinical events to ensure consistent, standardized, objective and unbiased results throughout all participating sites and minimise the likelihood of discrepant interpretations.~This group consists of a panel of experts who have the relevant therapeutic area expertise, are experienced in clinical trials, and have been trained on the specific study protocol.~The Event Adjudication Committee will centrally review events reported using all available clinical and imaging data and evaluate efficacy and/ or safety endpoints in a blinded and unbiased manner on a regular basis to ensure accurate, consistent and standardized assessments of important study events such as recurrent symptomatic ischaemic stroke, systemic embolism and death."|Patients will be randomised in a 1:1 ratio to intervention or control arms of the study. Participants and their physicians will not be blinded to study arm allocation.The exact timing of anticoagulation within the period specified for the allocated study arm is at the discretion of the treating physician, as is the choice of DOAC. Apart from the timing of DOAC initiation, the DOAC should be prescribed in accordance with usual clinical practice|f|f|f|t
34030086|NCT05407311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030087|NCT03650530|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||An intervention study with a single group design.||||
34030088|NCT01252277|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030089|NCT04464070|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Participants may be participating in all 4 arms of the study or in less than 4 arms.||||
34030090|NCT00378573|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030091|NCT00447876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030092|NCT03389516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030093|NCT05412953|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34030094|NCT02850185|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34030095|NCT04207307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary endpoint is assessed by a rater who is otherwise not involved in the trial.|Cluster randomized controlled trial (1:1)|f|f|f|t
34030096|NCT00022113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030097|NCT05600673|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this design, subjects are randomized to 2 study arms and each study arm will be allocated a different intervention. After randomization each participant will stay in their assigned treatment arm for the duration of the study.||||
34030098|NCT01082497|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030099|NCT01225003|||||PROSPECTIVE|||||||
34030100|NCT05098847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030101|NCT05870059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As this is going to be a double-blind study, a third person will dispense the Propolis mouthwash (prepared in Ziauddin College of pharmacy) and Chlorhexidine mouthwash (commercially available) into dark-colored bottles of the same size and shape. The third person will code the bottles as A or B and seal the codes with the product name in envelopes accordingly.||t|t|f|f
34030102|NCT01047527|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030103|NCT05963724|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34030104|NCT00052455|RANDOMIZED|||TREATMENT||NONE||||||
34030105|NCT02658760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030106|NCT01581125|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34030107|NCT04778904|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants are randomised to the four treatment groups, as the groups are initiated. Allocation to the groups is 1:1:1:1. Version 6.0 of the study protocol has closed Groups 1 and 4 to further randomisation; recruitment will now be in a 1:1 ratio between Groups 2 and 3 only.||||
34030108|NCT02905032|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030109|NCT03577301|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34105823|NCT00138242||||TREATMENT||NONE||||||
33805443|NCT01450657|||COHORT||PROSPECTIVE|||||||
33805444|NCT00666419|||OTHER||CROSS_SECTIONAL|||||||
34105824|NCT01991886|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33805445|NCT05075421|||COHORT||RETROSPECTIVE|||||||
33805446|NCT03568175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805447|NCT01970007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805448|NCT05603182|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33805449|NCT05842603|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33805450|NCT04989816|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
33805451|NCT01091168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805452|NCT04219475|||COHORT||PROSPECTIVE|||||||
33805453|NCT03056183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805454|NCT00001208|||COHORT||PROSPECTIVE|||||||
33805455|NCT05721105|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805456|NCT00627172|||COHORT||PROSPECTIVE|||||||
33805457|NCT04595461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33805458|NCT06081985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805459|NCT05298358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805460|NCT02423642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805461|NCT05728684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805462|NCT02502461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant is fully anesthetized. 1)Depth of ETT not known or knowable until after objective measurement. 2) Pain assessor unaware of participant group.|Double-blind RCT|t|f|f|t
33805463|NCT04149119|RANDOMIZED|FACTORIAL||PREVENTION||NONE||"An open-label two-arm cluster randomized controlled trial (CRCT) design will be used comparing ATSB + LLINS vs LLINS alone (standard of care). A cluster trial design is indicated given the intended community-level effect of ATSBs on malaria transmission. Universal LLIN coverage will be ensured in both arms prior to start of the study and will serve as the standard of care. Arm 1 will receive ATSBs for two years. Arm 2 will receive the standard of care of universal LLIN coverage.~The incidence cohorts will be powered to detect a 30% reduction in incidence assuming follow-up over a two year period (see sample size section). Prevalence of infection will be powered to detect a 30% lower prevalence in the treatment arm of of the trial during each of the two post randomisation cross sectional surveys."||||
33805464|NCT03500822|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33805465|NCT02188836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sham electromagnetic device|Electromagnetic device|t|t|t|t
33805466|NCT05563766|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, patients will receive itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after standard of care neoadjuvant chemoradiation.||||
33805467|NCT00661336||||TREATMENT||NONE||||||
33805468|NCT06459284|||COHORT||RETROSPECTIVE|||||||
33805469|NCT00410254|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805470|NCT05340231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805471|NCT02823574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805472|NCT06309576|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805473|NCT01198431|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33805474|NCT03422549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805475|NCT01070082|||COHORT||PROSPECTIVE|||||||
33805476|NCT05089461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805477|NCT02034292|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33805478|NCT01302600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805479|NCT06697132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805480|NCT06562907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805481|NCT01852006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805482|NCT04789226|||OTHER||PROSPECTIVE|||||||
33805483|NCT06444607|||OTHER||OTHER|||||||
33805484|NCT02105259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805485|NCT02013115|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33805486|NCT06025344|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105825|NCT04706325|||CASE_CONTROL||PROSPECTIVE|||||||
34105826|NCT03908294|||COHORT||PROSPECTIVE|||||||
34105827|NCT00165308|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33805487|NCT05611060|NA|SINGLE_GROUP||TREATMENT||NONE||The study utilizes a pretest-posttest design, with surveys completed at baseline immediately prior to the start of the intervention onset, immediately after completion of the intervention, and at follow-up 3 months after the completion of the intervention.||||
33805488|NCT04402736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805489|NCT04325711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805490|NCT03703440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Data analysts|"Active arm: Patients randomized to the active arm will be asked to attend ≥ 3 group education sessions, in addition to their usual diabetes clinic visits every 3 months, over the 12-month intervention period. Group education sessions will coincide with regularly scheduled clinic visits.~Control arm: Patients randomized to usual care will attend their usual 3-month interval diabetes clinic visits, over the 12-month intervention period, which consists of visits with their diabetes care physician."|f|f|f|t
33805491|NCT01744808|RANDOMIZED|CROSSOVER||||NONE||||||
33805492|NCT01650103|||CASE_ONLY||CROSS_SECTIONAL|||||||
33805493|NCT01102699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805494|NCT02922517|||FAMILY_BASED||PROSPECTIVE|||||||
33805495|NCT01626950|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805496|NCT01905800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805497|NCT03003286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805498|NCT06015308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837941|NCT06433297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Considering the nature of intervention, masking of the operator will not be possible once he begins the caries removal. Patients will be unaware of the groups in which their allocation will take place. At the time of assessing data masking will be done by masking the entire crown of the tooth before evaluation by endodontist using Adobe Photoshop CS6.||t|f|f|f
34105828|NCT04127110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105829|NCT06426381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105830|NCT06601335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105831|NCT06675175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805499|NCT04693949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Prior to the beginning of the study 50 identification numbers were divided into 2 groups on the basis of a computer generated tables (www.randomization.com). The two groups were then randomly allocated to the zirconia pretreatment method using a random generator. The randomization process was conducted by a staff member not involved in the research protocol. For each identification number, the selected pretreatment is written on a card contained in an opaque sealed envelope. The envelopes are stored by a study supervisor. Each envelope is opened by a dental technician after the RBFDP's zirconia framework is milled and then once again stored by the study supervisor until the conclusion of a study.|This is a single-centre, prospective, randomized, controlled, double-blind clinical trial.|t|t|f|f
33805500|NCT05955040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805501|NCT00204685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33805502|NCT06240741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805503|NCT01202513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33805504|NCT04814108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805505|NCT01025323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33805506|NCT03194659|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All investigators interacting with participants will be masked to the study arm assignment. Only the Primary Investigator and Laboratory Manager (prepares supplements) will have access to participant's study assignment.||t|t|f|t
33805507|NCT03206086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805508|NCT00003459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805509|NCT03241706|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The subjects will not be informed which treatment they will receive for a given trial.||t|f|f|f
33805510|NCT03820050|||COHORT||PROSPECTIVE|||||||
33805511|NCT05093062|NA|SINGLE_GROUP||PREVENTION||||||||
33805512|NCT02687776|||COHORT||PROSPECTIVE|||||||
33805513|NCT05851495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33805514|NCT06337838|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Study drugs will be sourced locally and will be prepared by appropriately qualified center personnel who are independent of the study team to ensure blinding is maintained.|2x2 partial factorial design where patients are first randomized to receive prophylactic intravenous TXA versus placebo, and (when the study drug is available) to be randomized to receive prophylactic intravenous desmopressin versus placebo before noncardiac surgery.|t|t|t|t
33805515|NCT04132154|||COHORT||RETROSPECTIVE|||||||
33805516|NCT06213233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805517|NCT05981352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33805518|NCT03877575|||COHORT||PROSPECTIVE|||||||
33805519|NCT03542279|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33805520|NCT04041219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805521|NCT05858879|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In the usual care arm, patients or clinicians will not be notified.|Eligible patients will be randomized to: 1) notification of presence of CAC with a CT scan image; 2) notification of presence of CAC without a CT scan image; 3) or usual care.|t|t|f|f
33805522|NCT05573724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148994|NCT05363540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33805523|NCT03459846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805524|NCT05931406|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33805525|NCT01760382|||COHORT||PROSPECTIVE|||||||
33805526|NCT03699410|||CASE_ONLY||PROSPECTIVE|||||||
33805527|NCT00470314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805528|NCT06683157|||COHORT||PROSPECTIVE|||||||
33805529|NCT00031720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33805530|NCT05213624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805531|NCT05084638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805532|NCT06700200|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participant and investigator will not know the randomization order of tVNS|Subjects will receive two types of stimulation (i.e. taVNS vs sham) during a measurement with an antroduodenal manometry. The order of stimulation applied during each block is randomized.|t|f|t|t
33805533|NCT00976651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34148995|NCT01397604|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34148996|NCT00559130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148997|NCT05069753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking: The patients will be informed of the type of procedure they will undergo.|Participants will be randomly allocated to one of two groups using a digital coin toss. Thus they will either undergo same day-surgery of both eyes or have the two surgical procedures separated by one week.||||
33805534|NCT03616366|||COHORT||PROSPECTIVE|||||||
33805535|NCT03809949|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Doctors, patients and outcomes assessors will be blinded regarding the technique used in anesthesia.|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery|t|t|f|t
33805536|NCT02246946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805537|NCT04976348|||COHORT||PROSPECTIVE|||||||
33805538|NCT02526576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839197|NCT01848613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839198|NCT00140374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839199|NCT01836939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839200|NCT00478192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839201|NCT00602849|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839202|NCT05185505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839203|NCT05070364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839204|NCT04763226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839205|NCT04484727|||COHORT||PROSPECTIVE|||||||
33839206|NCT00016588||||TREATMENT||NONE||||||
33839207|NCT00195377|||COHORT||PROSPECTIVE|||||||
33839208|NCT06179004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As participants are enrolled in this study, a study identification will be created as their basic demographic information is entered into the secure RedCap database. At this time, the RedCap randomization tool will randomize the subject to either group 1 or 2.||t|f|t|f
33839209|NCT04654767|||COHORT||PROSPECTIVE|||||||
33839210|NCT03399253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105832|NCT03208179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be a partially placebo-controlled involving a single placebo for AZ. To further minimise bias, an objective primary outcome measure will be used and all staff will be masked to the treatment assignment of individual women. The trial statistician will also be masked in regard to the treatment code when he develops the statistical analysis plan and writes the statistical programmes, which will be validated and completed using dummy randomisation codes. The actual allocation will only be provided to the study team after locking of the database and approval of the statistical analysis plan by the independent Data Monitoring and Ethics Committee (DMEC) before they review any trial results. The study statistician conducting the interim analysis will remain masked throughout the analysis.||t|t|t|t
34105833|NCT05634070|NA|SINGLE_GROUP||OTHER||NONE||||||
33805539|NCT06406114|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|Skin test reagents will be labeled blinded and prepared by a trained clinical trials pharmacy to maintain blinding. Drug challenges will be performed double-blind in a similar manner. The administrator, reader, and participant will all be blinded for each of these procedure types.|The proposed study is a multi-site clinical trial of cephalosporin allergy diagnostic testing to determine the optimal diagnostic approach through unbiased assessments, including double-blind skin testing and double-blind placebo-controlled drug challenges using a crossover design.|t|t|t|t
33805540|NCT06436326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805541|NCT03817970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33805542|NCT03069859|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805543|NCT00944593|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33805544|NCT04779216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33805545|NCT06647511|||COHORT||PROSPECTIVE|||||||
33805546|NCT03394105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805547|NCT06514794|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is divided into 2 disease Cohorts:~Relapsed/Refractory (R/R) Cohort will evaluate patients with relapsed or refractory disease, defined as ≥5% blast in the BM and/or extramedullary disease (EMD) only.~Minimal Residual Disease (MRD) Positive Cohort will evaluate patients in complete remission with MRD positive disease (\>0.1% but \<5% BM blasts)."||||
33805548|NCT05357911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805549|NCT05839678|||OTHER||OTHER|||||||
33805550|NCT05225753|||OTHER||PROSPECTIVE|||||||
33805551|NCT06457971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805552|NCT05777304|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805553|NCT05444075|||CASE_ONLY||CROSS_SECTIONAL|||||||
33805554|NCT05529420|||COHORT||PROSPECTIVE|||||||
33805555|NCT01401231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805556|NCT04197622|NA|SINGLE_GROUP||OTHER||NONE||||||
33805557|NCT00943917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805558|NCT04862637|||CASE_CONTROL||PROSPECTIVE|||||||
33805559|NCT03692065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805560|NCT02605850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805561|NCT04243915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo controlled clinical trial.|t|f|f|t
33805562|NCT04043169|||CASE_ONLY||PROSPECTIVE|||||||
33805563|NCT03745170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805564|NCT01215747|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33805565|NCT06517641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel cohort study comprised of two cohorts - patients receiving haploidentical donor transplant and patients receiving unrelated donor transplant. The goal is 60 participants in total who initiate the protocol-specified conditioning regimen, 30 in each of the haploidentical and unrelated donor transplant cohorts. Additional participants may be screened, consented, and registered in order to reach accrual goals.||||
33805566|NCT05502094|||CASE_CONTROL||OTHER|||||||
33805567|NCT05454475|||COHORT||PROSPECTIVE|||||||
33805568|NCT02697305|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33805569|NCT06307743|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33805570|NCT05856552|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33805571|NCT06426966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative, quasi-experimental||||
33805572|NCT02069613|||COHORT||PROSPECTIVE|||||||
33805573|NCT02220452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33805574|NCT00003867||||TREATMENT||||||||
34030110|NCT00234962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030111|NCT06319300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030112|NCT03296111|||CASE_ONLY||CROSS_SECTIONAL|||||||
34030113|NCT05139888|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to two different groups||||
34030114|NCT00794339|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030115|NCT03340974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030116|NCT01048073|||||CROSS_SECTIONAL|||||||
34030117|NCT06550544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030118|NCT04569734|||COHORT||PROSPECTIVE|||||||
34030119|NCT01665326|||COHORT||PROSPECTIVE|||||||
34030120|NCT02965937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34030121|NCT05231434|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34030122|NCT06582498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A random allocation system will be applied to participants, which will be allocated to the Low Intensity Intervention Group (LIIG) or the Active Intervention Group (AIG). Both groups will attend a first, baseline visit offered to all participants with a trained dietitian, who will administer the Life S-Can questionnaire and a series of validated questionnaires. The LIIG will receive the standard care and recommendations already provided by the Oncology Department of the hospital and a set of recommendations for cancer prevention offered by the WCRF, the AICR and the ACS. The AIG will receive the same recommendations as the LIIG and will be offered to see an oncological dietitian (diet domain), a physical activity health professional (physical activity) and/or a psychologist (psychosocial distress) for two visits (one individual, one group session). All participants will attend a final visit after 3 months to collect data on feasibility, acceptability and efficacy of the intervention.|f|f|f|t
34030123|NCT00003056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
34030124|NCT03377374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization list will by assembled by independient organization not related with participant, care provider, investigators or sponsors. eCRF will include randomization selection|Randomized controlled trial, double blind allocation concealment, parallel assignment|t|t|t|t
34030125|NCT05096910|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030126|NCT00893269|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34030127|NCT02130622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030128|NCT04710615|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34030129|NCT03442361|||OTHER||RETROSPECTIVE|||||||
34030130|NCT03556124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Active and Sham controlled|t|f|f|t
34030131|NCT02702570|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030132|NCT03315078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030133|NCT03408379|||CASE_ONLY||PROSPECTIVE|||||||
34030134|NCT02358239|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34030135|NCT01549132|||COHORT||PROSPECTIVE|||||||
34030136|NCT03595007|||COHORT||PROSPECTIVE|||||||
34030137|NCT03278626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030138|NCT02438267|||COHORT||PROSPECTIVE|||||||
33805575|NCT06497374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805576|NCT02894099|RANDOMIZED|PARALLEL||||NONE||||||
33805577|NCT02877641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33805578|NCT06315985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participant will be masking.|This was a parallel group, randomized controlled trial conducted in a tertiary hospital in Mersin city center, Turkey. In parallel with the purpose of the study, participants were selected from the pregnant women diagnosed with preeclampsia who were hospitalized at Mersin City Training and Research Hospital.The population of the research is the G\* Power 3.1.9.4 was determined by analysis using. In the analysis, the sample size was taken as a sample size of at least 80%, a medium effect size (0.5) and a two-way type 1 error value of 0.05, since no study similar to the study could be found, and a total of 128 pregnant women were included in the two groups (in each group) to determine the difference between the averages of two independent groups. It was calculated as 64 pregnant women). Considering the drop out rate of 10% during the research, the total number of samples was found to be 142 (experimental group: n=71, control group: n=71) pregnant women.|t|f|f|f
34030139|NCT04653025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients with a failing maxillary anterior tooth were included in this study. After atraumatic extraction, test group patients received an immediate implant with provisional restoration, while patients in the control group received an implant after 6 weeks of healing. After 4 months (test group) and 6 months (control group) definitive restorations were delivered. All patients were followed for 1 year post restoration and pink esthetic score (PES), mid-buccal mucosal level (MBML), crestal bone changes (CBC) and peri-implant soft tissue parameters were recorded at several time points. In addition, patient chair time was recorded|t|f|f|f
34030140|NCT02428439|||COHORT||PROSPECTIVE|||||||
34030141|NCT01160328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34030142|NCT01860274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030143|NCT04927845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030144|NCT05178342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030145|NCT04659759|||COHORT||PROSPECTIVE|||||||
34030146|NCT00494962|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34030147|NCT01193179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030148|NCT01587287|||COHORT||PROSPECTIVE|||||||
34030149|NCT03333135|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Study team and participants will not know if they have received the PEMF therapy or the sham||t|f|t|t
34105834|NCT05318378|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|We built two series of images. Series one was composed of separated conventional and inverted images. Series two consisted of inverted and conventional X-rays of the same subject (BIXAM) shown together (Figure). An independent assessor randomly duplicated four and two images for series one and two, respectively, to evaluate the intra-observer agreement. The same assessor randomized the images' order of appearance for the two series with a free online available list randomizer (www.randomizer.org). The principal investigator was blinded to the randomization during the sessions.||t|t|t|t
34105835|NCT06332261|||COHORT||RETROSPECTIVE|||||||
34105836|NCT02727699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105837|NCT06687915|||CASE_CROSSOVER||PROSPECTIVE|||||||
34105838|NCT01903590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105839|NCT02473302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34105840|NCT05961631|||COHORT||PROSPECTIVE|||||||
34105841|NCT04054882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34105842|NCT02180867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105843|NCT04426513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105844|NCT04474301|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105845|NCT01639690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105846|NCT03719300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105847|NCT05845892|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||With this randomized controlled trial, it is aimed to determine the anxiety levels and comfort levels of the patients by using a total of 30 minutes of stress ball at the beginning and during 9 sessions of hemodialysis treatment in patients receiving hemodialysis treatment.||||
34105848|NCT01139970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805579|NCT02523170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805580|NCT01872494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805581|NCT01362075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805582|NCT02458924|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33805583|NCT03500549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805584|NCT01177670|||CASE_ONLY||PROSPECTIVE|||||||
33805585|NCT01736475|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805586|NCT05485818|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33805587|NCT02788019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805588|NCT04666246|||COHORT||PROSPECTIVE|||||||
33805589|NCT04365556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial comparing the TASC Intervention to a treatment as usual control arm.||||
33805590|NCT05140876|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33805591|NCT03234478|||COHORT||PROSPECTIVE|||||||
33805592|NCT06700291|||COHORT||PROSPECTIVE|||||||
33805593|NCT00789542|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805594|NCT03275961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805595|NCT01296815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805596|NCT04326140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33805597|NCT06328868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805598|NCT00612209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805599|NCT01970410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805600|NCT05162716|||COHORT||PROSPECTIVE|||||||
33805601|NCT00255307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805602|NCT05646290|||COHORT||PROSPECTIVE|||||||
33805603|NCT05265689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||180 adolescent-parent dyads will be recruited from email listservs (University of Iowa, local school districts, other partner organization), community events (bike rodeos, outdoor markets, etc.), and local after school and summer programs affiliated with community neighborhood centers. Each site (cluster) will be randomly assigned to one of three study arms: 1) Bicycle safety education (Bike Club), 2) Bicycle safety education plus parent training session (Bike Club Plus), and 3) Control (no bicycle safety education or parent training session). Additional dyads may be recruited through other means, such as the University of Iowa listserv. Individuals recruited by these means would be randomly assigned to a study arm, based on the school they attend. A group bicycle safety education intervention will be delivered to adolescent participants at sites assigned the two intervention study arms (Bike Club and Bike Club Plus).||||
33805604|NCT06432790|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33805605|NCT05473416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants were blind|The study was based on the research design of a randomized clinical trial. The single-blind study, in which participants were blind. The sample size of this study was 46. Patient was divided into 2 groups, 23 in each group.|t|f|f|f
33805606|NCT03807908|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|"Once consent has been obtained the senior chiropractors will review the intake questionnaire with the patients, ask any pertinent questions they may have regarding the patient's personal medical history and current pain pattern and perform a physical exam to differentiate pain patterns for each participant.~Following completion of baseline assessment and consent, participants will be stratified by their type of pain presentation and then be randomly allocated to 1 of the 2 intervention arms. Central randomization will be performed using stratified block randomization by the study biostatistician (SHJ) using SAS software\*. To ensure that the allocation sequence is concealed from the researchers varying block sizes of 2, 4 and 6 will be used and the biostatistician will provide the trial coordinator with 3 series (1 for each stratum) of sequentially numbered sealed opaque envelopes containing the intervention allocations."|The study will be a randomized clinical trial. As none of the current research delineates the 3 pains during pregnancy, it would be beneficial to further investigate the use of tape for LBP, PGP or combined pain during pregnancy. As such, the participants will be stratified upon pain presentation (via history and physical exam) and then randomized into either a treatment or sham protocol.|t|f|f|f
33805607|NCT03169933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805608|NCT04996706|||COHORT||PROSPECTIVE|||||||
34105849|NCT06098352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be measured at baseline and then during an attention task.||||
34105850|NCT06110910|||COHORT||OTHER|||||||
34105851|NCT00007943||||TREATMENT||||||||
34105852|NCT05360225|||CASE_ONLY||OTHER|||||||
34105853|NCT05019963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105854|NCT04076657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider will not be aware of group assignment; participant will be aware of receiving treatment||f|t|f|t
34105855|NCT06571981|||COHORT||PROSPECTIVE|||||||
34105856|NCT04680208|||CASE_ONLY||RETROSPECTIVE|||||||
34105857|NCT06199752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34105858|NCT00170365|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105859|NCT04642209|||CASE_ONLY||PROSPECTIVE|||||||
34105860|NCT03999073|||CASE_CONTROL||OTHER|||||||
34105861|NCT06183593|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34105862|NCT02202265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105863|NCT01030809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105864|NCT06506513|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients presenting both MASLD and an excessive muscle lipid content (myosteatosis) assessed by magnetic resonance imaging will be recruited. All patients will then be randomized in three groups corresponding to three physical activity programs of increasing intensity.||||
33805609|NCT03307694|||OTHER||PROSPECTIVE|||||||
33805610|NCT03616015|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805611|NCT00284752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805612|NCT06699680|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33805613|NCT00945321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805614|NCT04931524|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, non-randomized study. Blinding is not required.||||
33805615|NCT01384890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805616|NCT05214222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805617|NCT04357158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a multicenter prospective cohort study in participants eligible for colonoscopy with suspicion for (pre)malignant lesions of the colon||||
33805618|NCT05416827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33805619|NCT01624493|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805620|NCT05759260|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805621|NCT00442637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805622|NCT05728034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805623|NCT05779631|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||TURBT versus mpMRI plus a same-day cystoscopic bladder biopsy||||
33805624|NCT05305508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The central pharmacy of the HUG is responsible for preparation of the randomization list and of the blinding of the study treatments. Randomization will be done in variable-sized blocks (size 4) in random sequence.~Pharmacists will be un-blinded. Care providers and/or outcome assessors, nurses, clinical research associates, investigators and patients will be blinded. Participants will be allocated to either the treatment group (CaD) or placebo group at Day 1 visit through randomization process, and will be dispensed the full treatment regimen on-site, including instructions on intake and explanations of side-effects.~The investigators will receive from the central pharmacy of the HUG all the study treatments and the participant's allocated treatment randomization number. Thus, the subjects who meet the eligibility criteria will dynamically be randomized at 1:1 ratio and be assigned either to the CaD or to the placebo arms during Day 1 visit."||t|f|t|f
33805625|NCT06353334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805626|NCT04587648|||COHORT||PROSPECTIVE|||||||
33805627|NCT01979276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805628|NCT05073224|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33805629|NCT00371345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805630|NCT02884245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805631|NCT05461053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805632|NCT03053505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805633|NCT02620306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805634|NCT00232375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805635|NCT04105816|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33805636|NCT06589024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805637|NCT03172871|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33805638|NCT00260182|||COHORT||RETROSPECTIVE|||||||
33805639|NCT01010945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805640|NCT03056313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805641|NCT00978016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805642|NCT02575924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805643|NCT05359536|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805644|NCT01340066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805645|NCT04555577|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33805646|NCT05022615|||COHORT||PROSPECTIVE|||||||
33805647|NCT02761200|||COHORT||PROSPECTIVE|||||||
33805648|NCT00222924|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33805649|NCT01647932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805650|NCT01132560|||OTHER||RETROSPECTIVE|||||||
34105865|NCT03160573|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34105866|NCT06480591|||CASE_CONTROL||PROSPECTIVE|||||||
34105867|NCT03633058|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|double-blind|Patients will receive placebo and ketamine for 5 days BID each, in a double-blind treatment order, and will be assessed for 2 weeks after each treatment.|t|t|t|f
33805651|NCT03035084|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33805652|NCT04914403|NA|SEQUENTIAL||TREATMENT||NONE||Cohort 1: Low dose of UMC119-06-05 Cohort 1: High dose of UMC119-06-05||||
33805653|NCT06669611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805654|NCT03067974|NA|SINGLE_GROUP||TREATMENT||NONE||Children who meet inclusion and exclusion criteria will be approached for participation in the study.||||
33805655|NCT04618250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33805656|NCT01870830|RANDOMIZED|CROSSOVER||||NONE||||||
33805657|NCT03647241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805658|NCT03387826|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Single (outcome assessor)|Crossover Assignment|f|f|f|t
33805659|NCT06699901|||CASE_CONTROL||PROSPECTIVE|||||||
33805660|NCT02610608|||COHORT||PROSPECTIVE|||||||
33805661|NCT01084694|||OTHER||PROSPECTIVE|||||||
33805662|NCT06327815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805663|NCT01181154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805664|NCT05242562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized during the pre-colonoscopy hospital visit between a specialized low-volume 1-liter bowel preparation fluid (Pleinvue) or an intermediate-volume 2-liter bowel preparation fluid (Moviprep)||||
33805665|NCT06612840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805666|NCT03234959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805667|NCT06509022|||COHORT||CROSS_SECTIONAL|||||||
34105868|NCT06638541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105869|NCT06501248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All participants will be submitted to the selection of a sealed envelope which will have a numerical code previously defined by a third party for each intervention group.~The total number of envelopes required to complete the minimum number of participants will have numerical codes that identify the bottle of intervention treatment that should receive the participant during the intervention period.~They will be divided into half blinded codes for triticum aestivum group and half for placebo to complete the size of each subsample. Chance guarantees blinding, neither the participant nor the researcher will know the type of treatment. The database for the blinded statistical analysis will be completed. The blind man will be removed once the statistical analysis has been completed."|"Controlled clinical trial, of two parallel groups, double blind, with random assignment and control group.~36 patients:~1. 18 patients with 500 mg of triticum aestivum orally every 12 hours for 120 days.~2. 18 patients with 500 mg of placebo orally every 12 hours for 120 days.~   * Visit 1/ Day -7: Screening period, information about the study, signing of informed consent, medical history, anthropometric measurements, baseline laboratory tests.~  * Visit 2/Day 0: Randomization, 60 tablets of Triticum aestivum or placebo will be given, general diet and exercise recommendations.~  * Visit 3,4,5/Day 30,60,90: Treatment adherence evaluation, laboratory tests, adverse events evaluation, general diet and exercise recommendations and 60 tablets of Triticum aestivum or placebo will be given.~  * Visit 6 /Final/Day 120 ± 7: Anthropometric measurements will be taken, laboratory tests will be performed, adherence to treatment and adverse events will be evaluated."|t|f|t|f
34105870|NCT00104403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34105871|NCT02324907|||CASE_ONLY||PROSPECTIVE|||||||
34105872|NCT05403294|||COHORT||PROSPECTIVE|||||||
27920327|NCT06674993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105873|NCT06005623|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data will be analyzed by the PhD student blinded towards group allocation.|Multicenter randomized (1:1) parallel-group intervention study with blinded statistical analysis towards group allocation. Patients will be randomized to activity tracking and motivational feed-back by gamification for patient self-mobilization (INT) or 'care-as-usual' including activity tracking without motivational feed-back (CON).|f|f|t|f
34105874|NCT01791205|||COHORT|||||||||
34105875|NCT00101738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805668|NCT01894217|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33805669|NCT06057974|||COHORT||PROSPECTIVE|||||||
33805670|NCT02018900|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805671|NCT02324296|||COHORT||RETROSPECTIVE|||||||
33805672|NCT04905004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030150|NCT06582420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will be applied to participants during all the stay and to care providers until randomly opaque envelopes are opened.|"Patients will be randomly assigned to receive either standard trauma care or standard trauma care plus administration of fibrinogen concentrate (FC). The standard of care is determined by national guidelines on trauma, elaborated by the National Institute of Medical Emergency and taught to prehospital physicians and nurses at the time of enrollment in prehospital teams to ensure consistency in the treatment of trauma patients nationwide. The patients assigned to the intervention arm will receive the administration of a fixed dose of 4g fibrinogen, as per previous studies.~FC will be administered on-scene by prehospital teams as soon as possible, ideally within 60 minutes of injury. Randomization will be performed using sequentially numbered, sealed opaque envelopes. Blood samples will be taken at baseline, upon hospital admission, and at 24h after admission to measure fibrinogen levels and other coagulation parameters. At admission, the PTr and TIC score should be calculated."|t|t|f|f
34030151|NCT01255137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030152|NCT05638061|||OTHER||OTHER|||||||
34030153|NCT01489085|||CASE_ONLY||PROSPECTIVE|||||||
34030154|NCT04768426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030155|NCT04811937|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||prospective, multi-endoscopist, single center, clinical study at tertiary referral center (CHUM)||||
34030156|NCT04486365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030157|NCT00464789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030158|NCT01153373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34030159|NCT02892929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34030160|NCT06198244|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34030161|NCT02203890|||COHORT||CROSS_SECTIONAL|||||||
34030162|NCT03408171|RANDOMIZED|PARALLEL||OTHER||NONE||Participants are assigned to one of two groups for the duration of the study.||||
34030163|NCT04841005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Exercises will be applied with the telerehabilitation method to the individuals included in the study. Video and audio communication will be provided by free and widely used programs such as Whatsapp or Telegram. Pulse oximetry, tripod and exercise material will be given to each individual included in the study by the researcher. Individuals included in the study will be randomly divided into two groups. Exercises in both groups will be done 3 days a week for 8 weeks. Before and after each exercise session, the heart rate and oxygen saturation values of the patients will be measured by pulse oximetry, and their perception of dyspnea and leg fatigue according to the Borg scale will be recorded. The first and last evaluation of individuals will be done face to face.|t|t|f|f
34030164|NCT03893643|||COHORT||PROSPECTIVE|||||||
34030165|NCT00199147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030166|NCT03767660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030167|NCT05482711|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030168|NCT05800067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030169|NCT04779879|RANDOMIZED|PARALLEL||TREATMENT||NONE|Part A is double-blinded. Parts B and C are open label.|||||
34030170|NCT01843296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34105876|NCT00255645|||||PROSPECTIVE|||||||
34105877|NCT04520230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|randomized double blind prospective study.|t|f|t|f
34105878|NCT06498531|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805673|NCT03236272|||CASE_CONTROL||PROSPECTIVE|||||||
33805674|NCT06610994|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805675|NCT01318694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805676|NCT05730829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805677|NCT02013700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837942|NCT04209569|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study design is a three-arm cluster randomized controlled superiority design (cRCT) with a 1:1:1 allocation ratio. The study arms will be: Group 1: NIPP arm; Group 2: NIPP+ arm; and Group 3: Non-intervention control arm.~for the venous aflatoxin sub-study, 36 women will be purposively selected from the eligible communities."||||
33837943|NCT03411785|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030171|NCT04187170|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030172|NCT05550506|||OTHER||CROSS_SECTIONAL|||||||
34030173|NCT02211443|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030174|NCT00006286|RANDOMIZED|||TREATMENT||DOUBLE||||||
34030175|NCT02246114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030176|NCT04141982|||COHORT||PROSPECTIVE|||||||
34030177|NCT01426074||||TREATMENT||||||||
34030178|NCT00316758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030179|NCT02732262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030180|NCT00368758|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34030181|NCT01477723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030182|NCT01720888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030183|NCT02831426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030184|NCT01927575|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34030185|NCT03933566|||COHORT||RETROSPECTIVE|||||||
34030186|NCT05316610|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34030187|NCT03214783|||CASE_CONTROL||RETROSPECTIVE|||||||
34030188|NCT02096432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34030189|NCT04979351|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34030190|NCT03946852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030191|NCT04283422|||OTHER||CROSS_SECTIONAL|||||||
34030192|NCT00247494|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030193|NCT02943590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030194|NCT02290457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030195|NCT05632926|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34030196|NCT05998876|||COHORT||PROSPECTIVE|||||||
34030197|NCT02859753|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030198|NCT01476514||PARALLEL||BASIC_SCIENCE||NONE||||||
34030199|NCT06304246|||OTHER||PROSPECTIVE|||||||
34030200|NCT05972369|||OTHER||CROSS_SECTIONAL|||||||
34030201|NCT06323447|||OTHER||PROSPECTIVE|||||||
34030202|NCT00270855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030203|NCT01480245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030204|NCT00600587|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34030205|NCT05441397|||OTHER||CROSS_SECTIONAL|||||||
34030206|NCT00324987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030207|NCT03995654|||CASE_ONLY||PROSPECTIVE|||||||
34030208|NCT04003493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030209|NCT05982002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030210|NCT06196489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030211|NCT06459492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34030212|NCT01229137|||CASE_ONLY||PROSPECTIVE|||||||
34030213|NCT04601571|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A non-inferior cohort study design||||
34030214|NCT00002422||||TREATMENT||||||||
34030215|NCT05002088|||COHORT||OTHER|||||||
34030216|NCT00973063|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34030217|NCT03245411|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled Trial (RCT) Single Center||||
34030218|NCT05022914|||COHORT||PROSPECTIVE|||||||
34030219|NCT03714243|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective, single arm, single center||||
34030220|NCT02559180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030221|NCT06365411|||COHORT||PROSPECTIVE|||||||
34030222|NCT06141343|||CASE_CONTROL||PROSPECTIVE|||||||
34030223|NCT03980535|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34030224|NCT01402687|||COHORT||RETROSPECTIVE|||||||
34030225|NCT05579002|||COHORT||RETROSPECTIVE|||||||
34030226|NCT04198857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A user-centered design approach, here we propose to develop a culturally-appropriate smartphone application (app) to support self-management of GDM (GDM-DH), and test its usability and preliminary efficacy, among patients in a tertiary level hospital.||||
34030227|NCT02996773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030228|NCT02054286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030229|NCT01842867|||COHORT||CROSS_SECTIONAL|||||||
34030230|NCT06018038|||OTHER||PROSPECTIVE|||||||
34030231|NCT06353698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030232|NCT05679271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030233|NCT00333151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030234|NCT03437473|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
34030235|NCT06579235|||COHORT||PROSPECTIVE|||||||
34030236|NCT05709210|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030237|NCT05176873|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||f|t|t|t
34030238|NCT02272257|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34030239|NCT03334461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Unlabeled bottles containing testing agent|Randomized controlled trail|t|t|t|t
34030240|NCT00704132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030241|NCT04993066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030242|NCT06259097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030243|NCT00847964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030244|NCT03003650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105879|NCT05116644|||OTHER||CROSS_SECTIONAL|||||||
34105880|NCT06569641|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Infant feeding patterns during standard care. The Neoneur Feeding System captures data such the changes in these feeding patterns can be measured. This study is capturing longitudinal changes over a short period of time, to see if they reflect infant recovery from surgery.||||
34105881|NCT04384497|NA|SINGLE_GROUP||TREATMENT||NONE||An open, non-randomised controlled, safety and dose identifying clinical trial||||
34105882|NCT04377919|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34105883|NCT01821014|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34105884|NCT01604798|||CASE_CONTROL||PROSPECTIVE|||||||
34105885|NCT06100276|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34105886|NCT01443312|||CASE_ONLY||PROSPECTIVE|||||||
34105887|NCT02395328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105888|NCT04564014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34105889|NCT03003065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105890|NCT00474357||PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105891|NCT01603368|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105892|NCT06675786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Patients will be informed about the study and their consent will be obtained without revealing which group they are in.~A blind technique will also be applied in terms of statistical analysis in the study. Data will be recorded on the computer as Group A and Group B by the researcher without using the terms experimental and control group. Data analyses will be performed by a statistician other than the person who performed the randomization."||t|f|f|t
34105893|NCT05991687|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34105894|NCT05196529|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Three groups (controls, ME/CFS, COVID long-haulers) will all conduct an inspiratory training protocol and cardiovascular and autonomic measures will be measured before and after.||||
34105895|NCT06379607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105896|NCT06546592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105897|NCT02174770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105898|NCT03864705|||COHORT||PROSPECTIVE|||||||
34105899|NCT00569075|||COHORT||PROSPECTIVE|||||||
33837944|NCT01540942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837945|NCT04014244|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Each of three investigators performing one part of diagnostic evaluation (history and focal neurologic examination, EDx and (3) ultrasonographic (US) studies) will be blinded for findings of other parts of evaluation. Furthermore, patients will be blinded for laterality of the injected substance.|Patients with bilateral CTS symptoms and EDx mild to moderate CTS will be included. In the first part of the study examiner will randomize substance for left hand infiltration using a dice (odd number - corticosteroids; even number - 5% glucose). Right hand will be infiltrated with the remaining substance. In the second part of the study examiner will randomize treatment procedure for left hand using a dice (odd number - corticosteroids or 5% glucose; even number - surgery). Substance for injection will be determined according to the results of the first part of the study - more effective one, or in case of non-inferiority 5% glucose will be used. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.|t|f|t|f
34148998|NCT04901091|||COHORT||PROSPECTIVE|||||||
34148999|NCT04147936|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33837946|NCT03503305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It is a double-blinded trial in which the subjects, investigator and radiologists are blinded to treatment assignment.||t|f|t|f
33837947|NCT03689634|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33837948|NCT04966975|||COHORT||PROSPECTIVE|||||||
33837949|NCT00554996|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33837950|NCT01714167|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837951|NCT03681535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837952|NCT00450697|||COHORT||PROSPECTIVE|||||||
33837953|NCT04704726|||COHORT||CROSS_SECTIONAL|||||||
33837954|NCT02825342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837955|NCT05145543|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837956|NCT03804216|||CASE_ONLY||PROSPECTIVE|||||||
33837957|NCT02336451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837958|NCT00763490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837959|NCT05594290|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2, multicentre, single-arm, open-label clinical trial||||
33837960|NCT02119897|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33837961|NCT04921618|||OTHER||CROSS_SECTIONAL|||||||
33837962|NCT05435989|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33837963|NCT01701336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837964|NCT02980042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837965|NCT06512636|||OTHER||RETROSPECTIVE|||||||
33837966|NCT01322191|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837967|NCT05101512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837968|NCT05650970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The 40 people included in the study will be equally placed in the control and study groups in the order they applied to the clinic. Individuals in the two study groups will be included in an exercise program two days a week, accompanied by a physiotherapist for 4 weeks. The only difference between the groups is the content of the treatment programs.|t|f|f|f
33837969|NCT01490892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837970|NCT01226732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837971|NCT01643070|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33837972|NCT01241604|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33837973|NCT02931422|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33837974|NCT00245960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837975|NCT04878549|||COHORT||PROSPECTIVE|||||||
33837976|NCT05770960|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized double-blind cross-over design (three-way)|t|f|t|t
34030245|NCT04698226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030246|NCT01587157|NA|SINGLE_GROUP||PREVENTION||||||||
34030247|NCT00551512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030248|NCT05054504|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The primary intervention under study is the Butterfly iQ ultrasound, embedded in a larger program of training, iterative service delivery design, and a final program evaluation.||||
34030249|NCT05761665|||CASE_CONTROL||PROSPECTIVE|||||||
34030250|NCT06228586|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030251|NCT05383755|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The newly developed digital intervention will include SMS for reminder purposes and Web-based components such as virtual simulations, gamified elements, and didactic content to educate and build relevant skills (e.g., disclosure self-efficacy) to facilitate social support from caregiving family members. The intervention will (1) raise awareness about the intersecting stigmas of HIV and pregnancy; (2) highlight the effects of these stigmas on disclosure and social support; and (3) increase self-efficacy and communication skills for disclosure and enlistment of family members as social support allies. The goal of the intervention is to improve PMTCT engagement among pregnant unmarried ALHIV. Our theory-informed Web-based intervention will use 3C Institute's Dynamic e-Learning Platform (DeLP), a customizable software platform that implements the evidence-based cognitive theory of multimedia learning (CTML) to effectively engage users.||||
34030252|NCT02523261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030253|NCT02370524|NA|SINGLE_GROUP||OTHER||NONE||||||
34030254|NCT05635487|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030255|NCT05503576|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34030256|NCT01198808|||COHORT||PROSPECTIVE|||||||
34030257|NCT03420586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized into two groups by computer-generated random numbers. Each allocation number will be concealed in an opaque envelope before the start of the surgery and will be revealed 30 min before the end of the operation. Early recovery (eye opening, following verbal commands, time to extubation, orientation to time and place) will be recorded by an anesthesiologist blinded to the anesthesia technique. The same anesthesiologist blinded to the anesthesia technique will collect all postoperative data.|Intervention Model: Parallel Assignment|t|f|f|t
34030258|NCT00134901|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030259|NCT03579342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030260|NCT01332292|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34030261|NCT02442180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030262|NCT01465425|||CASE_CONTROL||RETROSPECTIVE|||||||
34030263|NCT02490644|||CASE_ONLY||PROSPECTIVE|||||||
34030264|NCT02521805|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34030265|NCT00171951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030266|NCT06551883|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34030267|NCT03514290|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Only principal investigator performed the clinical research steps. A single evaluator performed the assessment of the dental sensitivity without knowing which treatment was applied. The volunteers evaluated in this study also did not know which hemi-arch received the LLL.|Twenty-one volunteers were evaluated through the split-mouth model, so that the right and left maxillary/mandibular quadrants were randomized and allocated to one of two groups: GPLACEBO - the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP); GLASER - treated with LLL + tooth bleaching with 35% HP.|t|f|t|f
34030268|NCT04267432|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34030269|NCT02321033|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34030270|NCT02569918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030271|NCT03548727|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study includes two arms:~Arm1: FLT PET/CT on Day1 and Day2 Arm2: Combined FMISO/FLT PET/CT on Day1 and FLT PET/CT on Day2"||||
34030272|NCT03281759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030273|NCT05336188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Primary outcome will be evaluated by co-I Dr. Thompson and staff biostatistician, who will remain blind to participant group membership. Since intervention involves daily use of a smartphone, participants will not be blind to group membership. Care providers all will be blind to participants' group membership. PI Dr. James and/or study staff will enroll, provide training in smartphone use, and troubleshoot technical issues, thus will not be blind to group membership.|Participants will be randomized to one of two arms: a Monitor Only arm (aka treatment-as-usual, MAT only) and a Smartphone arm (aka OptiMAT plus MAT).|f|t|t|t
34030274|NCT02461251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030275|NCT04236934|||COHORT||PROSPECTIVE|||||||
34030276|NCT03636685|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34030277|NCT06432816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The treatments were received, previously labeled and randomly drawn by the sponsor.|This is a multicenter, prospective, analytical and longitudinal study. A sample calculation was made with a therapeutic efficiency of 30% in vasomotor syndrome, with a result of 210 participants, divided into 3 institutions.|t|t|t|t
34030278|NCT02015845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030279|NCT03608397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded|Approximately 300 subjects, recruited from study centers in the United States (US), Canada, and Europe will be randomized to DAXI high dose, DAXI low dose or placebo group.|t|t|t|t
34030280|NCT01650064|||COHORT||PROSPECTIVE|||||||
34030281|NCT00452556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030282|NCT00741338|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030283|NCT05733273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34030284|NCT03576664|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, cross-over, placebo-controlled study|t|f|t|f
34030285|NCT00104572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030286|NCT00823810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030287|NCT00039338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149000|NCT03166644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Simple Blind : participants are unaware of the intervention assignment; investigators are aware.|Participants receive an intervention throughout the protocol|t|f|f|f
34149001|NCT00259688|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149002|NCT01291888|||COHORT||PROSPECTIVE|||||||
34030288|NCT00006760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030289|NCT03705429|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34030290|NCT01235481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030291|NCT00100308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030292|NCT00245687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030293|NCT00911300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030294|NCT04278456|||COHORT||PROSPECTIVE|||||||
34030295|NCT01561846|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34030296|NCT02934867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030297|NCT04045353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030298|NCT01545518|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34030299|NCT05528601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||two arm study||||
34030300|NCT03386266|||COHORT||PROSPECTIVE|||||||
34030301|NCT01307345|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030302|NCT00656552|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34030303|NCT02661217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34030304|NCT01932918|||COHORT||PROSPECTIVE|||||||
34030305|NCT04331886|||COHORT||OTHER|||||||
34030306|NCT05107271|||COHORT||PROSPECTIVE|||||||
34030307|NCT05872022|||COHORT||PROSPECTIVE|||||||
34105900|NCT06239753|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The complete randomization technique will be used for participant allocation to groups. This will be conducted through the https://www.randomizer.org/ website. Three computer-generated randomization sequences will be applied on a one-to-one basis. It has been observed that some numbers are assigned to all three groups in this system. To manage this situation, for individuals matching the same number, the person corresponding to that number in the group where the number first appeared will be assigned, and the next person will be assigned to the next group with the first unassigned number.~Opaque envelope method will be used for group allocation. The researcher conducting the intervention and collecting the data forms will not be blinded to the groups, but the researchers responsible for measuring pelvic floor muscles, conducting analyses, and writing the findings will be blinded to the groups"||f|f|t|t
34105901|NCT04013854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105902|NCT03636230|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, 1:1 randomized trial, stratified by site and pacemaker dependence||||
34105903|NCT06650215|||CASE_ONLY||CROSS_SECTIONAL|||||||
34105904|NCT06439784|NA|SINGLE_GROUP||OTHER||NONE||||||
34105905|NCT01545310|NA|SINGLE_GROUP||||NONE||||||
34105906|NCT02343250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105907|NCT05462496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105908|NCT06468865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105909|NCT00245154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34105910|NCT01350479|||COHORT||PROSPECTIVE|||||||
34030308|NCT02940431|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34030309|NCT06465836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomization will be done by online research randomizer as follows (https://www.randomizer.org/about/ ):~2 Sets of 86 Unique Numbers Per Set Range: From 1 to 172"|"Patients will be randomized into two groups. One of two intraoperative surgical interventions that will be evolved during the study period:~Group A: In which 86 patients will have bilateral uterine artery ligations as described by the O- lreay technique in addition to standard conservative methods. The stitches were tied securely anteriorly.~Group B: which will include 86 patients we will do our simplified approach which include;~* After placental separation; try to grasp lower segment, or cervical flap.~* Close uterine cavity by continuous vicryl no 1 suture.~* Do 3 to 4 mattress sutures as the second layer of the uterus.~* Do uterine ligation with compression of the lower uterine segment (Modification of O, lreay suture)."|t|t|t|t
34030310|NCT01232933|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030311|NCT02763826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030312|NCT05015257|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open label randomized controlled trial to test the effectiveness of four diets in Kwashiorkor children in their transition phase.~When it is decided to move to the transition phase, the child will be assigned to one of the treatments depending on the treatment received during the stabilization phase and the results of the appetite test. That is a child who accepts the Plumpy Nut will receive it in combination with their regimen they had during the stabilization phase. If a child does not accept Plumpy Nut, then they will received F100 regardless of their initial therapeutic food regimen.~* For those who received F75 in the stabilization phase, they will receive standard F75 + Plumpy Nut~* For those who received alternative F75 with CMV in the stabilization phase, they will receive alternative F75 with CMV + Plumpy Nut®~* For those who received alternative F75 without CMV in the stabilization phase, they will receive alternative F75 without CMV + Plumpy Nut®."||||
34030313|NCT03070587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34030314|NCT00661895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030315|NCT02732171|NA|SINGLE_GROUP||SCREENING||NONE||||||
34030316|NCT03510390|NA|SINGLE_GROUP||OTHER||NONE||Window-of-opportunity||||
34030317|NCT04316793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030318|NCT00387777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030319|NCT02088697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030320|NCT06409819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Both the phage preparation and placebo will be packaged as 1 ml clear solution in a plastic syringe. For safety, the pharmacy and research team will be aware of the assigned intervention. Only the participants will be blinded to study arm assignment. The effectiveness of the blinding process will be assessed by querying participants which intervention they think they received after the final participant has completed the 180-day study period by assessing the level of agreement between self-report and actual assignment.~Study intervention will only be initiated while the participant is asymptomatic and does not have an active symptomatic UTI. Eligible participants will be randomized to phage therapy or placebo in a 1:1 fashion."|Eligible participants will be randomized to phage therapy or placebo in a 1:1 fashion. Participants will be blinded to study assignment.|t|f|f|f
34105911|NCT03333200|||COHORT||PROSPECTIVE|||||||
34105912|NCT05598515|NA|SINGLE_GROUP||OTHER||NONE||||||
34105913|NCT05081635|||OTHER||PROSPECTIVE|||||||
34105914|NCT04479852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
34030321|NCT02892552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030322|NCT02927470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030323|NCT02465138|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34030324|NCT01799044|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective ablate and resect trial where 10 patients with resecatble colorectal liver metastases were treated with irrevrsible electroporation approximately 2 hours before the tumors were resected.||||
34030325|NCT01936506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030326|NCT00012922|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34030327|NCT05655130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030328|NCT03624920|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Complete 3 way-Crossover|t|t|t|f
34030329|NCT01734161|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030330|NCT04414618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030331|NCT00251121|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030332|NCT02891668|||CASE_CONTROL||PROSPECTIVE|||||||
34030333|NCT06198166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will get separate treatment protocol as and possible efforts will be put to mask the both groups about their treatment.|Randomized Controlled Trial|t|f|f|f
34030334|NCT02108912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030335|NCT06353763|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were blinded in their group assignment.||t|f|f|f
34030336|NCT03536741|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030337|NCT05927597|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34030338|NCT00739063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030339|NCT01689779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030340|NCT01562938|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34030341|NCT01108627|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34030342|NCT05000242|||COHORT||OTHER|||||||
34030343|NCT05737355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This experiment adopts a block random assignment design, and the system assignment table (Block randomization, block size = 6) randomly generated by the program is given serial numbers and assigned to groups. The probability of assignment to each group is 1/2.||t|f|t|f
34030344|NCT02536846|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030345|NCT01404676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030346|NCT01372748|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34105915|NCT01201044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105916|NCT06440538|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34105917|NCT05736887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105918|NCT03131245|||CASE_ONLY||PROSPECTIVE|||||||
34105919|NCT02017834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34105920|NCT03959033|||COHORT||PROSPECTIVE|||||||
34105921|NCT00722826|||COHORT||CROSS_SECTIONAL|||||||
34105922|NCT04619628|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34105923|NCT01213251|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34105924|NCT02866331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105925|NCT06053320|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Both experiments include a sham condition: Sham electrical stimulation consisting of electrode placement with the stimulator turned off.|After treatment, three weeks will be allowed for washout, then participants will receive the opposite (second) PAT condition with sham stim or electrical stimulation.|t|t|f|f
34105926|NCT00071994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105927|NCT05942326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||16-week pilot study will use a single-blind, parallel-arm randomized controlled trial design. Participants will be randomized at a 1:1 ratio to Sleep GOALS intervention (n=20) or an education control group (n=20)|f|f|t|t
34105928|NCT00916526|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34105929|NCT04469946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pediatric hearing aid users (6 to 12 years old) participated in an intervention trial of a hearing aid with an integrated directionality and noise reduction program. Pre- to post-comparison measures were obtained after two months of intervention use.||||
34105930|NCT04591587|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Both models participated in this study. Model ages were from 20 up to 45|t|f|f|f
34105931|NCT00220792|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34105932|NCT02496312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030347|NCT03691727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All subjects will be randomized 2:1, Aggrastat vs. placebo.|t|f|t|f
34105933|NCT05557591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030348|NCT02051621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030349|NCT02315131|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34030350|NCT04833530|||COHORT||PROSPECTIVE|||||||
34030351|NCT05519176|||CASE_CONTROL||RETROSPECTIVE|||||||
34030352|NCT00131599|||CASE_ONLY||PROSPECTIVE|||||||
34030353|NCT00346918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030354|NCT02494167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030355|NCT05468801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Remedy vials will be filled according randomized allocation in 2 number sets; one for the experimental group and two for the control group. Randomization information will be kept by the Study pharmaceutical responsible who will be the only person in possession of the sequence from the beginning of the study. Only the pharmaceutical responsible will have access to the randomization codes during the study and only in case of clinical emergency can break the code of an individual patient. The pharmaceutical responsible will never have any direct nor indirect contact with the study subjects. The The study statistician/s will be masked.|Randomized, Triple-blind, Placebo Controlled|t|t|t|t
34030356|NCT05440318|||COHORT||PROSPECTIVE|||||||
34030357|NCT01527409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030358|NCT03170063|||COHORT||CROSS_SECTIONAL|||||||
34030359|NCT01382537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34105934|NCT00480025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34105935|NCT06639412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|outcome assessors will not informed about the intervention and the group to which the intervention is assigned to avoid social desirability bias|A cluster randomized controlled community trial design will also be used to evaluate the effect of Parent-Teachers-Development Agents network.|f|f|f|t
34105936|NCT06381960|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34105937|NCT01505985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34105938|NCT02714842|RANDOMIZED|CROSSOVER||||NONE||||||
34105939|NCT01613586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149003|NCT04893499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149004|NCT05563467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149005|NCT01221194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34149006|NCT01537055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030360|NCT01794455|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030361|NCT00693095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030362|NCT02181855|NA|SINGLE_GROUP||||NONE||||||
34030363|NCT03438292|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34030364|NCT06427850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030365|NCT00577603|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030366|NCT00102947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030367|NCT03791684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030368|NCT03659929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030369|NCT05722561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030370|NCT00899522|||CASE_CONTROL||RETROSPECTIVE|||||||
34030371|NCT05853419|||COHORT||PROSPECTIVE|||||||
34030372|NCT03005665|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34030373|NCT03247179|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to either the experimental condition (PTSD Coach app usage), or the treatment as usual condition.||||
34030374|NCT05376644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic Test: ADAPT6-SPECT and DARPinG3-SPECT Diagnostic SPECT for HER2-positive Breast Cancer primary tumour||||
34030375|NCT03196245|||COHORT||PROSPECTIVE|||||||
34030376|NCT01408043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030377|NCT01971047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030378|NCT05567510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030379|NCT01406574|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34030380|NCT01117649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030381|NCT01109810|||COHORT||PROSPECTIVE|||||||
34030382|NCT01907256|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34030383|NCT02532309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030384|NCT05567770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030385|NCT01562860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030386|NCT04814771|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030387|NCT06491316|||COHORT||RETROSPECTIVE|||||||
34030388|NCT04786587|||COHORT||PROSPECTIVE|||||||
34030389|NCT01258309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030390|NCT05257057|||COHORT||RETROSPECTIVE|||||||
34030391|NCT02641158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030392|NCT05298345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030393|NCT05509075|||COHORT||PROSPECTIVE|||||||
34030394|NCT02795247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030395|NCT01043887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030396|NCT06222931|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34030397|NCT00858182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030398|NCT03224195|||OTHER||PROSPECTIVE|||||||
34030399|NCT05949021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030400|NCT04009707|||COHORT||RETROSPECTIVE|||||||
34030401|NCT00857350|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34030402|NCT00226980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030403|NCT05843747|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030404|NCT04708015|||CASE_ONLY||RETROSPECTIVE|||||||
34030405|NCT01140165|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34030406|NCT02494661|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030407|NCT05229536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030408|NCT05904002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030409|NCT02792920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030410|NCT00640315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030411|NCT04934059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030412|NCT03088761|||COHORT||PROSPECTIVE|||||||
34030413|NCT00978614||PARALLEL||||DOUBLE|||t|t|f|f
34030414|NCT00611260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030415|NCT00002225||||TREATMENT||||||||
34030416|NCT05159024|||COHORT||PROSPECTIVE|||||||
34030417|NCT04342455|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|This study belongs to a diagnostic test of CT angiography . All participants use the same contrast agent. The interventions on the two groups are different in scanning protocol of CTA. The examinees and image readers are blind, and the scanning technician is unblinded.|All subjects undergo coronary CTA and invasive coronary angiography (ICA), but coronary CTA examinees are divided into two groups performing different scanning and contrast protocols.|t|f|f|t
34030418|NCT00051935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030419|NCT04578535|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34030420|NCT04366947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030421|NCT01273896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030422|NCT00621270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030423|NCT01867463|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34030424|NCT01288404|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34030425|NCT03475992|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study is performed on 3 groups of patients:~* Group 1: 15 patients with pre-diagnosed breast cancer (core needle biopsy performed ≥14 days before the microwave breast investigation).~* Group 2: 10 patients with breast cyst. No prior biopsy~* Group 3: 5 patients with pre-diagnosed benign lesion (core needle biopsy performed ≥14 days before the microwave breast investigation)."||||
34030426|NCT04634006|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, sham-controlled, parallel assignment|t|t|t|f
34030427|NCT06499324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The injection physician and surgeon will be blinded to the randomization group due to the transparency of BTA and the placebo.~The surgeon will not know the patient's treatment during surgery as BTA does not affect muscle appearance.~A blinded CT-scan, four to six weeks post-injection, will be performed; results will be kept from the surgeon to avoid unblinding, and patients will remain blinded to their randomization group."||t|t|t|t
34030428|NCT03511599|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34030429|NCT03280264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030430|NCT06242080|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The research statistician will randomize the participants into one of the intervention groups as soon as at least 24-30 (8-10 individuals per group) are consented. Randomization by group will be implemented using a modified miniRand procedure implemented in R software. Randomization will be stratified by ethnicity (Hispanic/Latino vs Black/African-American) to approximate equal representation in each arm.|3 parallel arms (MTIA intervention, MAPP intervention, wait-list control group)|f|f|t|f
34030431|NCT04766112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030432|NCT05688150|||COHORT||CROSS_SECTIONAL|||||||
34030433|NCT01495078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030434|NCT03127514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030435|NCT00995774|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34030436|NCT05662956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030437|NCT04729816|NA|SEQUENTIAL||OTHER||NONE||Fiber supplementation increasing by 10.2g per 2-week dosing period, from 0 to 30.6g supplemental fiber at the end of the dose escalation.||||
34030438|NCT02069509|||COHORT||PROSPECTIVE|||||||
34030439|NCT00002031||||TREATMENT||||||||
34030440|NCT03885115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030441|NCT03740373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030442|NCT04816071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030443|NCT00843661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030444|NCT06064305|||COHORT||PROSPECTIVE|||||||
34030445|NCT02171871|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34030446|NCT02017015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030447|NCT05123430|NA|SINGLE_GROUP||OTHER||NONE||||||
34030448|NCT06278480|||CASE_CONTROL||RETROSPECTIVE|||||||
34030449|NCT05260489|||COHORT||OTHER|||||||
34030450|NCT05806892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It is aimed to blind the puerperant women participating in the research.|"The first interview with women who gave birth will be held in the postpartum service of the relevant hospital. In this interview, Personal Information Form, Breastfeeding Observation Form (for the first 24 hours after birth), Bristol Breastfeeding Evaluation Scale, Breastfeeding Self-Efficacy Scale and Insufficient Milk Perception Scale will be filled. At the same time, the phone and address information of the participants will be obtained in this meeting, and the postpartum 2-7. and 10-15. You will be informed that there will be a home visit on days.~Thera Pearl application will be explained to the woman in detail and the first application will be carried out together in the hospital.~Then the participant is postpartum 2-7. on days and 10-15. They will be visited at home once a day and their status of applying Thera Pearl will be questioned. The final test will be applied."|t|f|f|f
34030451|NCT03237338|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34030452|NCT04269525|NA|SINGLE_GROUP||PREVENTION||NONE||reaching the criteria of pneumonia according to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV Infection(Trial Version 4)||||
34030453|NCT04603326|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34030454|NCT04406077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030455|NCT01733810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030456|NCT03051477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030457|NCT03395457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||pragmatic randomised control trial|f|f|f|t
34030458|NCT03016273|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34030459|NCT02452476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030460|NCT03514966|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34030461|NCT05061589|||OTHER||RETROSPECTIVE|||||||
34030462|NCT02827734|||COHORT||PROSPECTIVE|||||||
34030463|NCT01707017|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34030464|NCT05932043|||COHORT||CROSS_SECTIONAL|||||||
34030465|NCT04914169|||CASE_ONLY||RETROSPECTIVE|||||||
34030466|NCT05717660|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized between control arm (Androgen Deprivation therapy and Apalutamide) or treatment arm (Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease)||||
34030467|NCT06513689|||COHORT||PROSPECTIVE|||||||
34030468|NCT05492643|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030469|NCT04539392|||COHORT||PROSPECTIVE|||||||
34030470|NCT05347329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The arms randomization was performed using Interactive web response system (IWRS).|This was a randomized, double blind, placebo-controlled, Three-arm, multicenter, parallel groups, interventional phase II clinical trial evaluating the efficacy, and safety of a herbal medicinal product of dried roots of Eurycoma longifolia Jack (Tongkat Ali) and dried tuberous roots of Lepidium meyenii (Maca) for the improvement of sexual well-being and quality of life in men.|t|t|t|t
34030471|NCT00032383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34030472|NCT00775619|RANDOMIZED|CROSSOVER||||NONE||||||
34030473|NCT06581380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030474|NCT05063474|||COHORT||PROSPECTIVE|||||||
34030475|NCT04327011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030476|NCT03066258|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose escalation||||
34030477|NCT05775029|||COHORT||PROSPECTIVE|||||||
34030478|NCT05037825|||COHORT||PROSPECTIVE|||||||
34030479|NCT04731571|||CASE_ONLY||RETROSPECTIVE|||||||
34105940|NCT06570239|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a regional multicentre randomised controlled open-label study. Control arm : dry support and rehabilitation protocol for 3 weeks Intervention arm: support and rehabilitation protocol in natural mineral water for for 3 weeks.||||
34105941|NCT05795712|||COHORT||PROSPECTIVE|||||||
34105942|NCT01245257|||CASE_CROSSOVER||PROSPECTIVE|||||||
34105943|NCT06640504|||CASE_CONTROL||PROSPECTIVE|||||||
34105944|NCT02505074|||COHORT||RETROSPECTIVE|||||||
34105945|NCT01918046|||COHORT||PROSPECTIVE|||||||
34105946|NCT06368674|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Clinical control study|f|f|f|t
33805678|NCT04025255|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participants and study personnel will be blinded to group assignment. Study personnel will receive 24 bottles each of either active or placebo product from the supplier. The bottles would be numbered sequentially from 101 to 148 for the younger cohort and 201 to 248 for the older cohort. Within that sequence, randomized blocks of 4 bottles each would be filled with either active or placebo product, for a total of 12 blocks. The bottler will not reveal to anyone which bottles got filled with which type of product until after the conclusion of the trial. Except for having a different sequential number on the label, the bottles will be indistinguishable."|Randomized, double-blind, placebo-controlled study|t|f|t|t
33805679|NCT04172207|||OTHER||OTHER|||||||
33805680|NCT00104741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805681|NCT04934995|||OTHER||PROSPECTIVE|||||||
33805682|NCT04847375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor would be blind regarding the study groups||f|f|f|t
33805683|NCT06215547|NA|SINGLE_GROUP||TREATMENT||NONE||Medtronic - Enterra II Neurostimulator||||
33805684|NCT05071300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805685|NCT00773669|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33805686|NCT03484949|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33805687|NCT03202992|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will be conducted in 2 Phases: Part A, up to 5 cohorts of 3 subjects each will receive a single dose of ABI-1968 Topical Cream. In Part B, three cohorts (3 subjects per cohort) will receive multiple doses in 3 ascending dose strengths of ABI-1968 Topical Cream. After completing the ascending dose multiple-dosing cohorts, a multiple-dosing Cohort Expansion group of 30 subjects will be initiated.||||
33805688|NCT01645124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805689|NCT03387540|||CASE_ONLY||CROSS_SECTIONAL|||||||
33805690|NCT05614791|||CASE_CONTROL||RETROSPECTIVE|||||||
33805691|NCT06457516|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805692|NCT06658847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33805693|NCT03295994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805694|NCT03604146|||COHORT||PROSPECTIVE|||||||
33805695|NCT03550157|||COHORT||PROSPECTIVE|||||||
33805696|NCT06699745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33805697|NCT02549807|||COHORT||PROSPECTIVE|||||||
33805698|NCT01964781|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33805699|NCT06424340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805700|NCT01616472|||CASE_CONTROL||RETROSPECTIVE|||||||
33805701|NCT01141803|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33805702|NCT06303180|||COHORT||PROSPECTIVE|||||||
33805703|NCT05243784|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33805704|NCT03504904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805705|NCT02915315|||CASE_ONLY||PROSPECTIVE|||||||
33805706|NCT05169580|NA|SEQUENTIAL||TREATMENT||NONE||Open-label, multiple-dose study.||||
33805707|NCT04098575|||COHORT||RETROSPECTIVE|||||||
33805708|NCT06348225|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|It is not possible to mask the participant to treatments (exercise/no exercise, water temperature, etc) or the PI who is monitoring them during treatment. However, all data (hourly blood pressure, heart rate variability, and flow-mediated dilation) will be analyzed by an individual blinded to the trial/intervention.|A repeated-measures design will be used with all participants completing the three acute interventions (exercise, heat, or exercise + heat) as well as a control day.|f|f|f|t
33805709|NCT05916144|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and Outcome Assessors will be selected from medical students who did not have information about the allocation|The study was designed as a mixed methodology with semi-structured qualitative components for the pilot study and for post-intervention effectiveness while creating the intervention program, quantitative including pre-intervention and post-intervention analyses through scales.|f|f|t|t
33805710|NCT04422405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805711|NCT02448524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805712|NCT04198922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805713|NCT01687751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33805714|NCT06673368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A multi-center, randomized, double-blind, parallel, adaptive-design clinical trial|f|f|t|f
34105947|NCT02762890|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34105948|NCT05218161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33805715|NCT05922904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805716|NCT02406092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805717|NCT05697705|||CASE_CONTROL||RETROSPECTIVE|||||||
33805718|NCT06532097|||COHORT||PROSPECTIVE|||||||
34105949|NCT01543230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105950|NCT05246839|||COHORT||PROSPECTIVE|||||||
34105951|NCT06673446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105952|NCT06675071|||COHORT||PROSPECTIVE|||||||
34105953|NCT04059822|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will take part in the slow and deep breathing daily exercises.||||
34105954|NCT04779658|||COHORT||PROSPECTIVE|||||||
34105955|NCT00595075|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33805719|NCT01231971|||COHORT||PROSPECTIVE|||||||
33805720|NCT03331575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34030480|NCT06578273|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a prospective, homebased, interventional clinical study in which 8 subjects will be enrolled. Eight (8) subjects who suffer from Parkinson's disease will receive treatment using the NeuroGlove.||||
34030481|NCT04552860|NA|SINGLE_GROUP||TREATMENT||NONE||Video teleconference delivered Emotional Awareness and Expression Therapy||||
34030482|NCT01696760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030483|NCT02759705|||COHORT||PROSPECTIVE|||||||
34105956|NCT01813227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030484|NCT00711035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030485|NCT04665687|||COHORT||PROSPECTIVE|||||||
34105957|NCT05663554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34030486|NCT00611546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34105958|NCT03673072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105959|NCT04985682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105960|NCT05856942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34105961|NCT06691438|RANDOMIZED|PARALLEL||OTHER||SINGLE|The maximum value of the pain will be collected by the research associate or the coordinating nurse who will be blinded to the randomization arm||f|f|f|t
34105962|NCT05855759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105963|NCT06351020|RANDOMIZED|PARALLEL||TREATMENT||NONE||experimental arm:LM-302 control arm:Apatinib or Irinotecan||||
34105964|NCT01558258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34105965|NCT04111536|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participant, Investigators and Care Providers are blinded to LT3 vs. Placebo and T3 results. There will be 1 unblinded physician in the study.||t|t|t|f
34105966|NCT00874016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34105967|NCT05013736|||COHORT||PROSPECTIVE|||||||
34105968|NCT00694590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105969|NCT05989477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|After randomization patients will be told what experimental arm they are in.|The intervention group (n=100) will receive access to the app in addition to standard care for 13 months following their diagnosis. The control group (n=100) will have standard care.||||
34105970|NCT05320952|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single group study with three months active phase followed by three months washout.||||
34105971|NCT00489359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34105972|NCT06673823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment|A randomized controlled trial will be conducted to investigate the effects of mirror therapy in children with hemiplegic cerebral palsy. Children in the control group will receive conventional therapy for 60 minutes, while Children in the experimental group will receive 30 minutes of mirror therapy and 30 minutes of conventional therapy, for 12 weeks, 3 days every week|t|f|f|f
34105973|NCT01985282|||||CROSS_SECTIONAL|||||||
34105974|NCT05833139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105975|NCT04007679|NA|SINGLE_GROUP||OTHER||NONE||||||
34105976|NCT06186401|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34105977|NCT06636422|||COHORT||PROSPECTIVE|||||||
34105978|NCT06570590|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients find out their assignment group after their surgery.|58 patients total. 29 will be randomly assigned to arthroscopy group, 29 will be randomly assigned to mini open group.||||
33805721|NCT05911867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both participants and outcome assessors are blind for groups allocation and treatment modalities|controlled, single-blinded, and randomized clinical trial|t|f|f|t
33805722|NCT06406426|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805723|NCT00797212|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805724|NCT05941715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030487|NCT04263181|||COHORT||PROSPECTIVE|||||||
34030488|NCT03093701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030489|NCT01845688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030490|NCT05470608|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34030491|NCT01574690|||COHORT||PROSPECTIVE|||||||
34030492|NCT05930379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030493|NCT00316927|RANDOMIZED|||TREATMENT||||||||
34030494|NCT02301390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030495|NCT00481494|||||OTHER|||||||
34030496|NCT04315506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030497|NCT06583213|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34030498|NCT06398379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Fecal Virome Transplantation and Fecal Microbiota Transplantation capsules will look exactly the same.|Randomised controlled trial comparing study treatment (Fecal Virome Transplantation) to standard treatment (Fecal Microbiota Transplantation)|t|f|t|t
34030499|NCT03409354|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030500|NCT01130493|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34030501|NCT00136253|RANDOMIZED|PARALLEL||||NONE||||||
34030502|NCT01385774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030503|NCT04932421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind - the investigator is unaware of the intervention assignment|"1. experimental group (i.e., children and parents who benefit from the UP-C program).~2. control group (i.e., children who benefit from a psychoeducational intervention program, named ABC of Emotions)."|f|f|t|f
34030504|NCT00037583||||TREATMENT||||||||
34030505|NCT00251511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030506|NCT03392350|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The staff doing the end point assessment were blinded as to treatment assignment.|One Control group one Intervention arm. The intervention group are the only subjects receiving a body scan consultation and behavioral intervention.|f|f|t|f
34105979|NCT04920513|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34105980|NCT03358173|||COHORT||RETROSPECTIVE|||||||
34105981|NCT03700125|NA|SINGLE_GROUP||TREATMENT||NONE||Single centre feasibility study of a complex intervention||||
34030507|NCT00138008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030508|NCT01044121||CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34030509|NCT06575582|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The use of digital navigators in multi-professional treatment teams is a complex intervention.||||
34030510|NCT01993004|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34030511|NCT04780178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors are blinded to participant group assignment.|Participants will be randomly assigned to receive either the TACTICs telephone therapy or the minimally enhanced usual care packet of information.|f|f|f|t
34030512|NCT02463773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030513|NCT00325247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34105982|NCT06515106|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34105983|NCT01382784|||CASE_CONTROL||PROSPECTIVE|||||||
34105984|NCT02067156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105985|NCT06563830|NA|SINGLE_GROUP||PREVENTION||NONE|The three months incidence of medical device-related pressure injuries of patients admitted to intensive care before and after the training will be examined. At this stage, it will be conducted by two independent observers. Simultaneous monitoring will be carried out during the first week, and the harmony between the observers will be evaluated by a third party, and it will be ensured that the observations are measured Decently with the same standard. However, the bias will be reduced by having different people enter the data of the research and analyze the data.|It is planned to conduct the study as a semi-experimental, single-group pre-test-post-test.||||
34105986|NCT06399107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105987|NCT02637674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34105988|NCT04072939|||COHORT||PROSPECTIVE|||||||
33805725|NCT02513667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105989|NCT05739994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34030514|NCT00966472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030515|NCT06582485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030516|NCT02326636|||COHORT||PROSPECTIVE|||||||
34030517|NCT01821807|||||PROSPECTIVE|||||||
34030518|NCT02855476|||COHORT||PROSPECTIVE|||||||
34030519|NCT04817618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030520|NCT02806115|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030521|NCT03155243|||COHORT||PROSPECTIVE|||||||
34030522|NCT01159561|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030523|NCT00073346|RANDOMIZED|PARALLEL||TREATMENT||NONE||active treatment versus wait list control||||
34030524|NCT01205087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030525|NCT04371497|||COHORT||RETROSPECTIVE|||||||
34030526|NCT06582459|||COHORT||RETROSPECTIVE|||||||
34030527|NCT05137587|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34030528|NCT00641628|||CASE_CONTROL||PROSPECTIVE|||||||
34030529|NCT05669235|||CASE_CONTROL||PROSPECTIVE|||||||
34030530|NCT04289363|||COHORT||OTHER|||||||
34030531|NCT02756130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030532|NCT00002346||||TREATMENT||DOUBLE||||||
34030533|NCT00424359|||COHORT||PROSPECTIVE|||||||
34030534|NCT00109460||CROSSOVER||||SINGLE||||||
34030535|NCT01843387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030536|NCT03624192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Each subject serves as their own control.|t|f|f|t
34030537|NCT01056289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030538|NCT00078117||||TREATMENT||||||||
34105990|NCT01961180|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34105991|NCT05772130|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34105992|NCT03696693|||CASE_CONTROL||RETROSPECTIVE|||||||
34105993|NCT06675578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030539|NCT06397495|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34030540|NCT03299582|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"The first part of this study is in healthy subjects, followed by breast cancer patients receiving paclitaxel to study the effect of limb hypothermia in the prevention of chemotherapy-induced neuropathy.~The second part of this study is to study the effect of cryocompression in the prevention of chemotherapy-induced neuropathy."||||
34030541|NCT00327366|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34030542|NCT04652778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030543|NCT04328701|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants will undergo quantitative sensory testing, physical functioning testing, and pain-related outcomes assessment. Participants in the intervention arm will undergo brief mindfulness-based cognitive behavioral sessions.||||
34030544|NCT01679652|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34030545|NCT05549505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030546|NCT00425763|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030547|NCT06548425|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030548|NCT05208489|||COHORT||RETROSPECTIVE|||||||
34030549|NCT04536376|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34030550|NCT04180865|||COHORT||PROSPECTIVE|||||||
34030551|NCT05760248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|1:1 ratio|Active drug 6% vs Placebo|t|t|t|t
34030552|NCT05549180|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"The clinical trial is double blind.~The only people who will know the arm that patient has been randomized, the participant will be responsible for the pharmacy in charge of dispensing treatment and a non-blind person designated by the promoter. The masking of study will only be open upon completion of the study or in the event that a participant developes a serious adverse event that requires knowing the treatment the patient is receiving participant for clinical management.~If it is necessary a open blind premature manually, the investigator should contact the non-blind person designated by the the promoter by calling a phone number and indicating that they wish to break prematurely blinded a patient in the MIND study. After confirming that it is required to opening of the blind (because the condition described above occurs), the person not blind designated by the sponsor will indicate to the investigator the treatment arm that was receiving the patient"|"The drugs used will be drugs for commercial use that contain the active ingredients uses in this study:~* Experimental regimen:~  * Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (combined in a single tablet marketed under the name of Biktarvy®). This regimen is given as 1 tablet once a day.~ * Placebo dolutegravir 50mg/ lamivudine 300mg (combined in a single tablet marketed under the name Dovato®). This regimen istake as 1 tablet once a day.~* Control regimen:~  * Dolutegravir 50mg/ lamivudine 300mg (combined in a single tablet marketed under the name Dovato®). This regimen is administered as 1 tablet once a day.~ * Placebo bictegravir 50mg/ emtricitabine 200mg/ tenofovir alafenamide 25mg (combined in a single tablet marketed under the name of Biktarvy®). This regimen is given as 1 tablet once a day."|t|f|t|f
34030553|NCT02770378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030554|NCT04197778|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34030555|NCT02808416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030556|NCT02945189|||CASE_ONLY||PROSPECTIVE|||||||
34030557|NCT01926574|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030558|NCT05081986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34030559|NCT05721287|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34030560|NCT00700362|||CASE_CONTROL||PROSPECTIVE|||||||
34030561|NCT02205788|||CASE_CONTROL||PROSPECTIVE|||||||
34030562|NCT00550459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030563|NCT00403585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030564|NCT03555123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030565|NCT06099392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030566|NCT04944524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030567|NCT03399708|||COHORT||PROSPECTIVE|||||||
34030568|NCT02671747|NA|SINGLE_GROUP||OTHER||NONE||||||
34030569|NCT02412917|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34030570|NCT02304029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030571|NCT03493412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blinded study|1:1 Randomized, cross-over, double-blinded design|t|f|t|f
34030572|NCT05298917|NA|SINGLE_GROUP||OTHER||NONE||||||
34030573|NCT05854524|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participants and the outcomes assessors will be blinded to the main purpose and aims of the study. Additionally, both conditions are aerobic exercise conditions of different intensities so they will clearly know that they are exercising but will not know the main purpose behind the two different intensities.|This is a cross-over design with two arms (Parkinson Disease and healthy control) and two conditions (low and high intensity aerobic exercise). The interventions for this Phase II trial are two different intensities of aerobic exercise.|t|f|f|t
34030574|NCT01979991|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
34030575|NCT03182777|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34030576|NCT00531167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030577|NCT00168935|RANDOMIZED|PARALLEL||||NONE||||||
34030578|NCT03054584|||OTHER||PROSPECTIVE|||||||
34030579|NCT04174625|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34030580|NCT01371747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34105994|NCT06433921|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||2-part, 7-way cross-over (Part 1) and up to 7-way cross-over (Part 2).|t|f|t|t
34105995|NCT00536705|||CASE_CONTROL||PROSPECTIVE|||||||
34105996|NCT05960435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030581|NCT03972761|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030582|NCT06106347|||CASE_CONTROL||PROSPECTIVE|||||||
34030583|NCT02017470|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030584|NCT01169792|||COHORT||RETROSPECTIVE|||||||
34030585|NCT01485822|||COHORT||PROSPECTIVE|||||||
34030586|NCT01553669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030587|NCT00036361|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030588|NCT04746144|||CASE_ONLY||RETROSPECTIVE|||||||
34030589|NCT00261950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030590|NCT00308672|||||OTHER|||||||
34105997|NCT05827237|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A clustered randomized controlled trial in which general practices are randomized to the intervention- or control group in 2:1 ratio.||||
34105998|NCT01534221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34105999|NCT05336760|||COHORT||PROSPECTIVE|||||||
34030591|NCT02819492|||COHORT||PROSPECTIVE|||||||
34106000|NCT06184880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||a randomized, open label, controlled, monocentric, study||||
34030592|NCT04237272|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106001|NCT06150742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106002|NCT04115293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106003|NCT04753359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study is a four-arm RCT designed to test the effect of a weight-stable MedDiet alone (Med-A) lifestyle intervention, calorie restriction for WL with no diet composition change (WL-A) intervention, a MedDiet WL lifestyle intervention (WL-Med) compared to Control on BA metabolism, the gut microbiome, and gene expression in exfoliated intestinal epithelial cells. The study includes 1) screening potential subjects; 2) baseline assessment of diet, lifestyle behaviors (e.g., physical activity), anthropometrics, and blood and fecal sampling; 3) a four-arm RCT; and 4) mid-(month 3) and post-intervention (month 6) assessments.|f|f|f|t
34106004|NCT05967065|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34106005|NCT06674252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106006|NCT01407341|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106007|NCT05463471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106008|NCT05776004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo-controlled|Adaptive, randomized, double-blind, placebo-controlled study|t|f|t|f
34106009|NCT03607110|||COHORT||PROSPECTIVE|||||||
34106010|NCT02106546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106011|NCT02993120|||COHORT||OTHER|||||||
34106012|NCT06520098|RANDOMIZED|PARALLEL||TREATMENT||NONE||The addition of Venetoclax to BTKi for 12 months in anticipated to improve both the clinical response rates and the quality of life of patients as compared to indefinite use of BTKi monotherapy in CLL/SLL patients||||
34106013|NCT04578418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106014|NCT04482062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106015|NCT06063551|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The same protocol applies to all subjects.||||
34106016|NCT06619236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805726|NCT05558072|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33805727|NCT06286800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030593|NCT06581185|||COHORT||PROSPECTIVE|||||||
34030594|NCT01799837|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030595|NCT00314210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34030596|NCT06338722|RANDOMIZED|PARALLEL||TREATMENT||NONE|People will know what group they are in when they are invited to attend the intervention sessions|Intervention receives the Making it work program Wait list Control receives usual care but will be offered the program after the intervention groups finish||||
34030597|NCT01006681|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34030598|NCT02220517|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030599|NCT04455165|||COHORT||RETROSPECTIVE|||||||
34030600|NCT02892149|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor was blinded during the study|||||
34030601|NCT00524420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030602|NCT02479126|||COHORT||RETROSPECTIVE|||||||
34030603|NCT04800640|RANDOMIZED|PARALLEL||TREATMENT||NONE|He sample will consist of 132 individuals, of both men and women, where they will be randomly included in two groups: 1) Intervention group composed of 66 patients who will effectively receive the treatment through electroanalgesia via TENS; and 2) Control Group, which will also consist of 66 individuals; however, they will not be subjected to electroanalgesia. For division of groups, a sortition will be carried out through envelopes where it will be decided to which study group the patient will be allocated.|This is an uncontrolled cross-sectional clinical trial with a sample of 132 individuals between 18 and 50 years of age in a hospital in the West of Paraná. Pain assessment will be performed through analogue pain scale, pulmonary function through spirometry and respiratory muscle strength through manovacuometry. Four TENS applications will be performed for a period of 30 minutes.||||
34030604|NCT01561261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030605|NCT03872531|||COHORT||RETROSPECTIVE|||||||
34030606|NCT06469437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030607|NCT05870722|||CASE_CROSSOVER||PROSPECTIVE|||||||
34030608|NCT01690702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030609|NCT06581653|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030610|NCT02756208|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106017|NCT02799043|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34106018|NCT06673992|||CASE_CONTROL||RETROSPECTIVE|||||||
34106019|NCT04883047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The study was planned as a single center stratified block parallel group randomized controlled experimental study.|t|f|t|t
34106020|NCT02130037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106021|NCT06643741|||CASE_CONTROL||PROSPECTIVE|||||||
34106022|NCT06553157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106023|NCT05770180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34106024|NCT05424705|||COHORT||PROSPECTIVE|||||||
34106025|NCT04414930|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34106026|NCT02946983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34106027|NCT06488833|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Quasi-experimental pre-post design with control group||||
34106028|NCT02475863|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34106029|NCT05270031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cross Over after 3 months possible||||
34106030|NCT03941093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Participants will be randomized in a 1:1 ratio to one of the two study treatment arms; pamrevlumab with G/NP or FOLFIRINOX or placebo with G/NP or FOLFIRINOX.|t|t|t|t
34106031|NCT06042608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34106032|NCT04770545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106033|NCT04781972|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a double-blind cross over of a single dose of methylphenidate (10mg or 15mg) and matching placebo.|t|f|t|f
34106034|NCT05434754|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106035|NCT04391751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106036|NCT06673693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106037|NCT04104477|||COHORT||CROSS_SECTIONAL|||||||
34106038|NCT04910165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34106039|NCT01754740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106040|NCT02909257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34106041|NCT05484557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106042|NCT04526158|RANDOMIZED|PARALLEL||TREATMENT||NONE|The randomization list will be concealed from the research team within the tracking portal, so team members will not know the next study assignment. Permuted blocks will be used to aid in the concealment of treatment assignment while ensuring balance in treatment arms across time.|Three arm parallel assignment design||||
34106043|NCT03209765|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34030611|NCT05965752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants assigned to active comparator will be considered part of pooled analyses if the intervention was active at the time of the participant's enrollment and the participants were eligible to receive that intervention. This will result in approximately a 1:1 allocation ratio for any intervention to pooled control.~Sites will be informed to which intervention appendix participants are randomized, but, when applicable, not whether the participants are allocated to the active intervention arm or active comparator arm within that appendix. The participants and investigators will be blinded throughout the study, when possible.~If open intervention appendices do not have the ability to pool controls but have independent controls, at the second stage participants will be randomized in a 1:1 ratio to intervention vs active comparator inside the specific intervention appendix the participants were randomized to at the first stage of the randomization procedure."|"To achieve blinding and an equitable randomization probability, a two-step randomization process will be used. The study will employ a simple (unstratified) randomization scheme.~At the first stage, each participant will be assigned with equal probability to one of the intervention appendices for which the participant is eligible, after applying any intervention-specific safety exclusions. At the second stage, each participant will be assigned according to the specific appendix's randomization procedure. Participants will have an equal chance of being randomized into any of the intervention groups."|t|t|t|f
34030612|NCT05477043|||COHORT||PROSPECTIVE|||||||
34030613|NCT04798092|||COHORT||RETROSPECTIVE|||||||
34030614|NCT06278896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030615|NCT00001725||||TREATMENT||||||||
34030616|NCT05220644|||COHORT||PROSPECTIVE|||||||
34030617|NCT03675061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030618|NCT00512577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030619|NCT01232452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030620|NCT04511260|NA|SINGLE_GROUP||TREATMENT||NONE||The NuEra device family is FDA cleared (K151296) for a wide range of indications including, but not limited to, selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation. The NuEra Tight - model VRF with the small area handpiece is CE marked in Europe and currently under review by the FDA. In this study, the Radio Frequency treatment will be administered in a continuous motion to the vaginal mucosa and the introitus using the small area handpiece.||||
34030621|NCT01955941|||COHORT||PROSPECTIVE|||||||
34030622|NCT00196326|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030623|NCT04400162|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34030624|NCT05044702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030625|NCT04269473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030626|NCT04173325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030627|NCT03435471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030628|NCT04459741|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Participants are instructed on salt deprivation for a week followed by a low salt (4 grams) diet for one week and switched to high salt (9 grams) for the following one week||||
34030629|NCT05583825|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||The status of the participants in the experimental or control group was determined by simple random sampling method. Accordingly, the sample calculation was created by logging into the site https://www.randomizer.org/.||||
34030630|NCT01085760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030631|NCT01445704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030632|NCT03547297|||COHORT||PROSPECTIVE|||||||
34030633|NCT00070551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030634|NCT02885402|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030635|NCT00079950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030636|NCT03971786|NA|SINGLE_GROUP||OTHER||NONE||||||
34030637|NCT06170216|||CASE_ONLY||PROSPECTIVE|||||||
34030638|NCT03593395|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster Randomized Parallel group study||||
34030639|NCT02436226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030640|NCT02251899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030641|NCT04927234|RANDOMIZED|PARALLEL||TREATMENT||NONE||Standard block randomisation||||
34030642|NCT04392895|||COHORT||RETROSPECTIVE|||||||
34030643|NCT05963815|||COHORT||PROSPECTIVE|||||||
34030644|NCT05001646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030645|NCT05355376|||COHORT||RETROSPECTIVE|||||||
34030646|NCT01491451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030647|NCT00919126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030648|NCT00365092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34030649|NCT00032786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34106044|NCT03514693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106045|NCT04066829|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Intervention is assigned based on location. Participants and providers are 'nudged' but not masked.|||||
34106046|NCT06005831|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The 482 patients who had CS were divided into two groups, control group (n = 246), weighted group (n = 236) was randomized.|It is a prospective, randomized, controlled single-center study.||||
33724070|NCT04127786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"For cohort 1 primary series and booster dose and cohort 2 primary series. The study is conducted in an observer-blind manner. Unblinded staff members, independent of the safety evaluation and other study evaluations, prepare and administer the vaccine. The Investigator or delegate in charge of safety assessment as well as the participants are blinded and do not know which vaccine is administered.~In addition to the participants, health care providers, data collectors, outcome assessors (e.g., Investigator who assess the safety), the Sponsor personnel (e.g., Clinician, Data Management, Biostatistician) will remain blinded until the first statistical analysis.~For cohort 2 immunogenicity persistence and booster phase: this phase is open label, however, the laboratory analysts who will be involved in the blood sample testing will remain blinded during the whole study."|"Primary series will be observer-blinded for both Cohort 1 (3-dose pre-exposure prophylaxis \[PrEP\] regimen) and Cohort 2 (one week 2-dose PrEP regimen).~Booster phase will be conducted in a blinded manner (vaccine received in the primary series) with an adult subset from Cohort 1 and hereafter referred as Booster Phase Cohort 1 (with booster dose 1 year after the 1st primary series vaccine injection).~Evaluation of immunogenicity persistence after primary series and a booster phase will be conducted in an open label manner with an adult subset from Cohort 2 and hereafter referred as Immunogenicity Persistence and Booster Phase Cohort 2 (including blood samples collection at Month 6, Month 12, Month 18, pre-booster between Month 24 up to Month 36, and post-booster between Month 24 up to Month 36+Day 14; and a booster dose between Month 24 up to Month 36)."|t|t|t|t
33805728|NCT00219791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724071|NCT05350319|||COHORT||PROSPECTIVE|||||||
33724072|NCT05257811|||COHORT||PROSPECTIVE|||||||
33724073|NCT01770483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724074|NCT02191228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805729|NCT03890289|NA|SINGLE_GROUP||TREATMENT||NONE||"Single arm: Regimen: GAUDEALIS q28 days~* Obinutuzumab Dose: 1000 mg IV Day 1, 8, 15 (1st cycle)~* Obinutuzumab Dose: 1000 mg IV Day 1 (2nd cycle onward)~* Idelalisib Dose: 150 mg BID oral Daily (24 weeks) Obinutuzumab will be administered intravenously at a flat dose of 1000 mg on day 1, 8, 15, of the first cycle, then repeated on day 1 of each subsequent cycle, for 6 cycles in total (each cycle is completed in 28 days). Idelalisib will be given concomitantly with obinutuzumab on a daily 150 mg bid schedule orally and continuously (24 weeks)."||||
33805730|NCT03363984|NA|SINGLE_GROUP||OTHER||NONE||||||
33805731|NCT05206058|||COHORT||PROSPECTIVE|||||||
34106047|NCT01887197|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106048|NCT06645067|||COHORT||PROSPECTIVE|||||||
33724075|NCT05700435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster randomized, pragmatic-explorative two-arm multi-site study. Arm 1: Randomization Arm 2: Self-selection||||
33724076|NCT03403959|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor and the participant is unaware of ipRGC function prior to and during treatment|The study combines two models: a case/control study with observational outcomes where all cases are consequently included in a non-randomized interventional study|f|f|f|t
33724077|NCT01834287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724078|NCT00014209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724079|NCT00006240||||TREATMENT||||||||
33724080|NCT05352009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724081|NCT00657241|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Drugs names omitted on patient bottles|Run-in period with lisinopril is followed by random entry into valsartan followed by carvedilol CR or carvedilol CR followed by valsartan|t|f|f|f
33724082|NCT00077103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724083|NCT01854905|||CASE_ONLY||PROSPECTIVE|||||||
33724084|NCT00685581|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33724085|NCT01415063|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33724086|NCT05552677|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized Clinical Trial|t|f|f|f
33724087|NCT05365633|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm pilot design||||
33724088|NCT01990274|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724089|NCT02046408|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33724090|NCT01548612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724091|NCT00232258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724092|NCT03403465|NA|SINGLE_GROUP||OTHER||NONE||||||
33724093|NCT00918021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724094|NCT03839511|||COHORT||PROSPECTIVE|||||||
33724095|NCT06023732|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The research question will be investigated using a multiple baseline single-case A-B design. A will be the baseline phase, varying between 7 and 14 days, assessing the pattern of depression, behavioral activation and difficulties in emotion regulation before the intervention. Phase B comprise behavioral activation and emotion focused interventions as the independent variable and makes it possible to evaluate the effect of treatment on the dependent variable depressive symptoms.||||
33724096|NCT00188513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724097|NCT01109225|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724098|NCT02275481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724099|NCT02590939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724100|NCT00020696||||TREATMENT||||||||
33724101|NCT01486654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805732|NCT04761042|RANDOMIZED|PARALLEL||OTHER||SINGLE|"After being screened for recruitment by the primary investigator, participant are randomized into the two group. Randomization is made by a second team member that up till then had no contact with participants or knows their names (based on screening numbers).~After being notified of groups assignment the primary investigator again contacts participants to enter the into the study and give information on group assignment.~Outcome data will be entered confidential, and the outcomes assessor will be blinded regarding group assignment and identification of participants."|A Randomized control design where participants are randomized to one of the two groups, stratification is made for gender and age (older/younger).|f|f|f|t
34149007|NCT04714021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"* single step PEG technique group divided to co2 or air insufflation group during endoscopy~* pull technique PEG group divided to co2 or air insufflation group during endoscopy"|t|f|t|f
34149008|NCT05046691|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34030650|NCT05429892|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The community health workers who will deliver the intervention will not have access to the randomization information. The participants will also not have access to the information the randomization information.|The 3-arm trial (180 smokers per arm) will enroll 540 smokers in Chicot, Desha, Lee, and Phillips and deliver the intervention over 6 months. The study is powered to examine our primary outcome, cotinine-verified 7-day point prevalence abstinence, after 6 months and we will conduct a 12-month follow-up survey. The secondary outcome will be food security. 180 smokers aged 21-75 will be randomized to each condition.|t|t|f|f
34030651|NCT01597778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030652|NCT01047514|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34030653|NCT02373449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805733|NCT01593020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805734|NCT03869970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805735|NCT02345603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805736|NCT06383390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805737|NCT01557036|||CASE_ONLY||PROSPECTIVE|||||||
33805738|NCT02148185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805739|NCT00144040|RANDOMIZED|FACTORIAL||||NONE||||||
33805740|NCT03551379|||COHORT||PROSPECTIVE|||||||
33805741|NCT00137800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805742|NCT05014035|NA|SINGLE_GROUP||OTHER||NONE||Single-arm feasibility trial||||
33805743|NCT00781118|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33805744|NCT00137098|||COHORT||PROSPECTIVE|||||||
33805745|NCT02339259|||OTHER||PROSPECTIVE|||||||
33805746|NCT00818506|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805747|NCT01759862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805748|NCT02785029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805749|NCT02933359|||OTHER||PROSPECTIVE|||||||
33805750|NCT03155113|NA|SINGLE_GROUP||OTHER||NONE||||||
33805751|NCT00821301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837977|NCT03092817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33837978|NCT02487043|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837979|NCT00312598|||COHORT||PROSPECTIVE|||||||
33837980|NCT01947569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837981|NCT02775006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837982|NCT02234947|||COHORT||PROSPECTIVE|||||||
33837983|NCT03497403|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were assigned to one of two groups in parallel for the duration of the study.||||
33837984|NCT02766127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837985|NCT02360722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837986|NCT00371384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837987|NCT05174962|||OTHER||CROSS_SECTIONAL|||||||
33837988|NCT01885247|||COHORT||PROSPECTIVE|||||||
33837989|NCT01351168|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33837990|NCT01507649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837991|NCT00024505|||COHORT||PROSPECTIVE|||||||
33837992|NCT03849703|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||An intent-to-treat randomized design coupled with a time-series design will be used to assess differential adjustment between the treatment and control groups, and to assess differential changes in adjustment between adolescent parents across four time-points. A block randomization design will be used to randomly assign eight participating schools into one of four treatment conditions based on curriculum assignment. Schools can receive a co-parenting (COPAR), healthy romantic relationship (HRR), and/or a control (CONT) curriculum each semester. Treatment conditions reflect schools which receive a full treatment model (i.e., COPAR-HRR, HRR-COPAR) or a partial treatment model (i.e., COPAR-CONT, and HRR-CONT).|t|f|f|f
33837993|NCT03092128|||CASE_ONLY||RETROSPECTIVE|||||||
33837994|NCT00243594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837995|NCT01792531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837996|NCT01839942|||COHORT||RETROSPECTIVE|||||||
33837997|NCT04112511|||COHORT||PROSPECTIVE|||||||
33837998|NCT00476242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837999|NCT06178770|||COHORT||RETROSPECTIVE|||||||
33838000|NCT05876390|||COHORT||PROSPECTIVE|||||||
33838001|NCT03949400|||COHORT||PROSPECTIVE|||||||
33838002|NCT02193490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838003|NCT02116569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838004|NCT05827094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33838005|NCT04451447|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Compare one group with a historical cohort. masked outcome for the tested and control arms.|Non randomized controlled Interventional trial Compare the study group with a historical cohort.|f|f|f|t
33838006|NCT02649777|||CASE_ONLY||PROSPECTIVE|||||||
33838007|NCT00624247|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33838008|NCT00188201|||DEFINED_POPULATION||PROSPECTIVE|||||||
33838009|NCT02063542|||CASE_ONLY||PROSPECTIVE|||||||
33838010|NCT06169072|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838011|NCT02630680|||COHORT||PROSPECTIVE|||||||
33838012|NCT00636740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838013|NCT05338385|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838014|NCT01317329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838015|NCT03486483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838016|NCT02939339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838017|NCT03274115|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Patients with at least one polyp \<1 cm in size will be randomized in two groups. In the Group 1 (White Light Group), all polyps \<10mm will be evaluated with white light and prediction of histology (hyperplastic versus adenomatous) will be made. In the Group 2 (BLI Group) , all polyps \<10mm in size will be evaluated with BLI and scored as hyperplastic (type 1) or adenomatous (type 2) by applying the NICE ( Narrow-band Imaging International Colorectal Endoscopic) classification. The level of endoscopist's confidence in predicting real-time histology (high or low confidence) for any polyp will be also recorded.|t|f|f|f
33805752|NCT05284240|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single arm study Patients with symptomatic peripheral vascular disease who underwent infrapopliteal percutaneous intervention using the Auryon laser system 4 sites in United States||||
34149009|NCT01595594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805753|NCT00571298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805754|NCT00925470|||COHORT||CROSS_SECTIONAL|||||||
33805755|NCT00188045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33805756|NCT05070559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805757|NCT03131128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The researchers will explain the purpose and steps of the study to all the participants and get their informed consent.|The workers with overweight or obesity provided by the company will be randomly assigned to Group A (by MBI) or Group B (by the intervention of health education).||||
33805758|NCT06264583|||COHORT||RETROSPECTIVE|||||||
33805759|NCT04290533|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||t|f|t|f
33805760|NCT04885166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33805761|NCT02928250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149010|NCT06275308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a descriptive case series.||||
33805762|NCT05948059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805763|NCT03664011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805764|NCT06060769|||COHORT||PROSPECTIVE|||||||
33805765|NCT04920188|||COHORT||PROSPECTIVE|||||||
33805766|NCT01232959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805767|NCT04381949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805768|NCT00179933|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805769|NCT00837954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805770|NCT03328364|||COHORT||RETROSPECTIVE|||||||
33805771|NCT06664021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805772|NCT05513365|NA|SEQUENTIAL||TREATMENT||NONE||"Patients will be included into two cohorts based on their previous treatments, either ADT-naïve (cohort A) or ADT-resistant patients (cohort B). In cohort A, the randomization will result in the allocation of the control arm (goserelin and bicalutamide) and experimental arm (goserelin, bicalutamide, and dutasteride) in a 1:1 ratio. In cohort B, patients ADT-resistant will be enrolled receiving similar therapy to the experimental arm, i.e. goserelin, bicalutamide, and dutasteride.~Cohort A is closed for inclusion as of April 18, 2024."||||
33805773|NCT05623436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple blind||t|f|t|t
33805774|NCT06064669|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33805775|NCT04109352|||COHORT||PROSPECTIVE|||||||
33805776|NCT02490956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805777|NCT05048186|||COHORT||RETROSPECTIVE|||||||
33805778|NCT02717611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805779|NCT00767741|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33805780|NCT04840316|||COHORT||RETROSPECTIVE|||||||
33805781|NCT04195919|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805782|NCT00180791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805783|NCT03181711|||CASE_ONLY||PROSPECTIVE|||||||
34030654|NCT02471040|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||The added 3rd arm does not apply to the crossover design.|t|f|f|f
34030655|NCT00111241|||COHORT||CROSS_SECTIONAL|||||||
34030656|NCT03332810|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030657|NCT06354426|||COHORT||PROSPECTIVE|||||||
33805784|NCT03959813|||COHORT||PROSPECTIVE|||||||
33805785|NCT05878288|NA|SINGLE_GROUP||OTHER||NONE||||||
34030658|NCT02706444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030659|NCT01778634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030660|NCT03281018|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030661|NCT00390208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030662|NCT01959061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030663|NCT01668914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030664|NCT02819089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030665|NCT02836548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030666|NCT01281605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030667|NCT03897634|NA|SINGLE_GROUP||TREATMENT||NONE||Within-subject design: Baseline assessments compared to post-trial results.||||
34030668|NCT05610423|||COHORT||OTHER|||||||
34030669|NCT05578599|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm study - treatment with the Swiftsure CSS device in addition to standard oral care procedures. Using a measuring scale of 1 to 5, for each patient, whereas 1 is low outcome of standard oral care and using the Swiftcare device, and 5 is best results for using standard oral care and the Swiftcare device.||||
34030670|NCT02376673|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030671|NCT04013893|||COHORT||PROSPECTIVE|||||||
34030672|NCT01458691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030673|NCT03815461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030674|NCT04592146|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre, non-inferiority, randomized, simple blind and prospective pilot study.||||
34030675|NCT00114660|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34030676|NCT04110730|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34030677|NCT06582121|NA|SINGLE_GROUP||OTHER||NONE||All participant will do polysomnographies during a 2-days stay in hospital with electroencephalogram, electromyogram and questionnaries. The urine will be also collected during 2 days.||||
34030678|NCT02010645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030679|NCT00714116||SEQUENTIAL||TREATMENT||NONE||||||
34030680|NCT05850364|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030681|NCT04341324|||COHORT||PROSPECTIVE|||||||
34030682|NCT00842192|||CASE_ONLY||PROSPECTIVE|||||||
34030683|NCT03835273|||COHORT||PROSPECTIVE|||||||
34149011|NCT05908968|NA|SINGLE_GROUP||TREATMENT||NONE||Adults with type 2 diabetes and diabetic foot ulcer which has not healed with conventional therapy for at least 30 days prior to recruitment||||
33805786|NCT05240300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805787|NCT01737749|||COHORT||PROSPECTIVE|||||||
33839211|NCT02145468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34106049|NCT06637475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Individuals who meet the inclusion criteria and who have signed the consent form will be randomly divided into 2 groups (treatment and control groups). Randomization will be done by a researcher who is not involved in the study using computer-assisted randomization blocks. The treatment group patients will receive 3 sessions of external stimulation per week for 8 weeks, while the control group will not receive any intervention (consisting of patients waiting on the treatment list).|t|f|f|f
33724102|NCT06038279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study. Blinding of active/placebo assignment is critical to the integrity of this clinical study. Those blinded to study drug assignment include the Sponsor, the PI (or delegate), clinical study personnel participating in participants' care or clinical evaluations, the CRO project team (with exceptions noted below) and the study participants. INI-2004 and placebo will be administered to the participant in a manner to ensure treatment assignment remains blinded. Blinded data will be provided to the SRC so as not to reveal treatment assignment.|This is a Phase I/Ib, randomised, double-blind, placebo-controlled study of INI-2004, administered as single or multiple doses.This study will be conducted in two parts: Phase I (SAD) and Phase Ib (MAD).|t|t|t|t
33724103|NCT05648370|||COHORT||PROSPECTIVE|||||||
33724104|NCT05505032|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Group F30 : FiO2 value is %30 Group F50 : FiO2 value is %50 Group F80 : FiO2 value is %80|t|f|t|f
33724105|NCT00923559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724106|NCT04317911|||CASE_CONTROL||PROSPECTIVE|||||||
33724107|NCT03059420|||COHORT||OTHER|||||||
33724108|NCT01170494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724109|NCT00192504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724110|NCT05150353|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33724111|NCT01318096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724112|NCT02921048|||COHORT||PROSPECTIVE|||||||
33724113|NCT01142310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33724114|NCT00578747|||||PROSPECTIVE|||||||
34030684|NCT04449211|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective participants with health insurance admitted to the Orthopaedic and Traumatology Department of Cho Ray hospital who get the diagnosis of bone defect greater than 5cm due to trauma or tumour resection.||||
34030685|NCT04235244|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|All SC injections, ecchymosis measurements, VAS evaluation and post-injection follow-up will be performed by the researcher. Immediately after injection, pain intensity at 24, 48 and 72 hours and ecchymosis at 24, 48 and 72 hours will be evaluated|"It will be determined by simple randomization method which SC injection will be applied to these four regions. According to the results of randomization;~* Buzzy, a thermomechanical-analgesia device, was placed 30 seconds before the injection in the right upper abdominal region, and the SC injection was applied by sliding the device to the side of the selected region during the injection~* SC-LMWH injection was applied to the right lower abdominal region without any cold application~* Local coolant spray was applied to the left upper abdominal region from a distance of 15 cm for 5 seconds and~* Before and after the application to the left lower abdominal region, the cold application was performed with a cool-pack for 5 minutes.~The application of 2x0.6cc standard ready-to-use injectable Enoxiparin, which was requested by the physician according to the SC injection application steps, was applied together with the cold application method determined by randomization."||||
34030686|NCT01023035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030687|NCT04149652|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Experimental study of feasibility of an ultrasound technique for diagnostic purposes||||
34030688|NCT03068728|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||After sinus surgery, the surgeon will randomize the patient to one of six hemostatic agents and place that product in one sinus cavity, while leaving the other sinus cavity without packing. The treatment group will be compared to control.||||
34030689|NCT00226096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030690|NCT06500325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030691|NCT05209789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|group attribution blinded to evaluators for the evaluation of the primary endpoint via video tapes|Multicenter, interregional, comparative, prospective therapeutic study in 2 parallel groups (1: 1), superiority, randomized, blinded for the evaluation of the primary endpoint.|t|f|f|f
34030692|NCT02557763|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030693|NCT04469504|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34030694|NCT03567980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030695|NCT03716362|||CASE_CROSSOVER||PROSPECTIVE|||||||
34030696|NCT01757275|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030697|NCT04511585|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||a 24-month (6 weeks each year) multilevel and TPB-based program aiming to promote PA practice||||
34030698|NCT01739699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030699|NCT00807274|||COHORT||PROSPECTIVE|||||||
34030700|NCT00770328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030701|NCT01822106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030702|NCT02573961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030703|NCT00300690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34030704|NCT00356525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030705|NCT02375165|||CASE_ONLY||PROSPECTIVE|||||||
34030706|NCT04944186|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective quasi-experimental study||||
34030707|NCT06550583|||COHORT||CROSS_SECTIONAL|||||||
33724115|NCT03571542|NA|SINGLE_GROUP||OTHER||NONE||||||
34030708|NCT03515512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030709|NCT04805112|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be recruited through the DREAMS (Determined, Resilient, Empowered, AIDS-Free, Mentored, Safe) program being implemented in Siaya County, western Kenya, as well as other community groups and venues, by the host institution (Impact Research and Development Organization, IRDO). Participants will be randomized in a 1:1 ratio to either an intervention group (receive multiple oral HIV self-test kits) or control (receive referral vouchers for clinic based testing). About 300 women will be recruited to patriciate in this study.||||
34030710|NCT06177860|||COHORT||OTHER|||||||
34030711|NCT02688738||PARALLEL||PREVENTION||||||||
33724116|NCT05969288|||COHORT||PROSPECTIVE|||||||
34030712|NCT03776149|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The supplement and placebo will be distributed to the individual by a member of the research team who is not involved with data collection or analysis.|This study utilizes a 7-day randomized, double-blind, placebo-controlled crossover study design, in which individuals are initially supplemented with a nitrate-rich supplement in the form of a specifically formulated beetroot juice, or nitrate-poor placebo. Individuals will then entered a 7-day washout period before entering the opposing arm of the study.|t|f|t|f
33724117|NCT03341832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724118|NCT06451042|||COHORT||PROSPECTIVE|||||||
34030713|NCT04640415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33724119|NCT04033601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724120|NCT01614990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724121|NCT05481177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030714|NCT02172807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34030715|NCT06238453|||CASE_CONTROL||PROSPECTIVE|||||||
34030716|NCT01223391|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030717|NCT06485934|||COHORT||PROSPECTIVE|||||||
34030718|NCT04321681|||COHORT||PROSPECTIVE|||||||
34030719|NCT02941835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030720|NCT05560165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030721|NCT06301191|||CASE_CONTROL||PROSPECTIVE|||||||
34030722|NCT01165489|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34030723|NCT02766335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030724|NCT06333704|||COHORT||PROSPECTIVE|||||||
34030725|NCT01636115|||CASE_CROSSOVER||PROSPECTIVE|||||||
34030726|NCT04062292|||CASE_CONTROL||PROSPECTIVE|||||||
34030727|NCT02033031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030728|NCT02403258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030729|NCT05336032|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34030730|NCT05149391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030731|NCT02443740|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34030732|NCT00655772|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34030733|NCT05296174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34030734|NCT02969421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030735|NCT04488315|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34030736|NCT01485133|||CASE_CONTROL||PROSPECTIVE|||||||
34030737|NCT00052598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030738|NCT03220854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Steriotactic Radiotherapy followed by a commercially available PD-1 or PD-L1 inhibitor drug||||
34030739|NCT03240783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, care-provider (general-practitioner and/or specialist), investigator, and outcomes assessor are masked to the treatment arms. All personnel except the radiologist delivering the procedure and the investigator responsible for randomisation will be masked to the randomisation arm. The participant, study personnel, other investigators, participant's treating physician and study analyst will be blind to the results.|Randomised 1:1:1:1|t|t|t|t
34030740|NCT03678571|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34030741|NCT06566690|||CASE_CONTROL||PROSPECTIVE|||||||
34106050|NCT06644716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106051|NCT02096887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724122|NCT03496948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Study arms: TeGeCoach (Intervention); Treatment-as-Usual (TAU)|f|f|t|t
33724123|NCT02784821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030742|NCT04983186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030743|NCT04874831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030744|NCT06550609|NA|SINGLE_GROUP||TREATMENT||NONE||This proof-of-concept phase 2 trial will enroll 20 moderate-to-severe ML patients. The primary endpoint is the cure rate for moderate-severe patients in comparison to literature values for miltefosine alone. If mild ML patients present, up to 10 will also be enrolled. The secondary endpoint is demonstrating that the cure rate for mild disease is 90%-100%.||||
34030745|NCT04199052|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34030746|NCT00637494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030747|NCT03830372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030748|NCT01301729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030749|NCT01729949|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34030750|NCT03918330|||COHORT||PROSPECTIVE|||||||
34106052|NCT05558085|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724124|NCT05750927|||CASE_ONLY||RETROSPECTIVE|||||||
33724125|NCT03978260|||COHORT||PROSPECTIVE|||||||
33724126|NCT05819333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be masked as to whether study participants received Respiratory Muscle Training or Relaxation Training||f|f|f|t
34106053|NCT03460704|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030751|NCT02789137|||COHORT||PROSPECTIVE|||||||
34030752|NCT03498495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030753|NCT06329921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will be performed as a pragmatic, randomized controlled clinical trial with parallel group assignment.||||
34030754|NCT00934687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030755|NCT05596656|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34030756|NCT04847154|||COHORT||OTHER|||||||
34030757|NCT05088135|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34030758|NCT00866359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030759|NCT00711880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34030760|NCT04509934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analyses will be performed by the statistics specialist that does not know anything about the methodology of the study.||f|f|f|t
34030761|NCT05936515|||OTHER||RETROSPECTIVE|||||||
34030762|NCT04214197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030763|NCT00887289|||||PROSPECTIVE|||||||
34030764|NCT05568667|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030765|NCT00972296|||CASE_ONLY||CROSS_SECTIONAL|||||||
34030766|NCT00586534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030767|NCT00797589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34030768|NCT04292041|||COHORT||PROSPECTIVE|||||||
34030769|NCT00980031|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34030770|NCT05223140|||CASE_CONTROL||RETROSPECTIVE|||||||
34030771|NCT03394469|NA|SINGLE_GROUP||SCREENING||NONE|No masking|||||
34030772|NCT01122186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030773|NCT04160624|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||ECLS-assisted TAVR for patients with very low EF(\<20%). Only TAVR for patients with fair EF(\>20%)|t|f|f|f
34030774|NCT06490367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030775|NCT05707793|||OTHER||CROSS_SECTIONAL|||||||
34030776|NCT02208830|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34030777|NCT05961917|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34030778|NCT02547688|NA|SINGLE_GROUP||OTHER||NONE||||||
34030779|NCT01709929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030780|NCT03672253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030781|NCT00641446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030782|NCT03242525|||CASE_CONTROL||PROSPECTIVE|||||||
34030783|NCT06194617|||COHORT||PROSPECTIVE|||||||
34030784|NCT01669187|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030785|NCT03637426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For this double-blind study, the evaluator and the patient were blinded. Only one evaluator assessed pain sensitivity, who did not participate in the randomization process, and also did not know in which group the patient was. The volunteers evaluated in the experiment also were not aware of the treatment to which they were submitted. Both the Nano-P desensitizer and the placebo toothpaste have the same coloration and similar visual appearance. The desensitizers were placed in equal containers so that patients were not identified as to the application of the product.|Volunteers 18 to 50 years old with hypersensitive teeth were randomly assigned to 4 groups: GPLACEBO - positioning of the laser tip without light emission + placeo substance; GnHAP - positioning of the laser tip without light emission + nano-hydroxyapatite; GLASER - positioning of the laser tip with light emission + plcebo substance; GLASERnHAP - positioning by laser beam with light emission + nano-hydroxyapatite.|t|f|t|f
34030786|NCT02764346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030787|NCT06191588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized|f|f|f|t
34030788|NCT02751671|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34030789|NCT01525914|||COHORT||RETROSPECTIVE|||||||
34030790|NCT03959969|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030791|NCT00507533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030792|NCT03683290|||COHORT||PROSPECTIVE|||||||
34030793|NCT02984371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34030794|NCT02567630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34030795|NCT02678208|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34030796|NCT00826007|||||RETROSPECTIVE|||||||
34030797|NCT01431365|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34030798|NCT01238107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030799|NCT00805467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030800|NCT04233996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030801|NCT00192803|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34030802|NCT05603325|||OTHER||CROSS_SECTIONAL|||||||
34030803|NCT05013008|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030804|NCT00403195|||CASE_CONTROL||PROSPECTIVE|||||||
34030805|NCT00269425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030806|NCT00490984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030807|NCT05867043|||COHORT||PROSPECTIVE|||||||
34030808|NCT01795417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106054|NCT05063136|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34106055|NCT03790956|NA|SINGLE_GROUP||TREATMENT||NONE||Single vocal fold injection of study material with possible booster injection, and follow-up of 12 months post injection.||||
34106056|NCT03896568|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106057|NCT05665881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study could not be blinded to the treating anesthesiologists. However, blinding was maintained for the patients and the assessors of outcome indicators. Postoperative follow-up was performed by a specially trained physician who did not have access to any information about the patients' cases and subgroups.||t|f|f|t
34106058|NCT02495142|||COHORT||PROSPECTIVE|||||||
34030809|NCT02361996|||CASE_ONLY||PROSPECTIVE|||||||
34030810|NCT00191126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030811|NCT01548105|||CASE_CONTROL||PROSPECTIVE|||||||
34030812|NCT01570114|||COHORT||RETROSPECTIVE|||||||
34030813|NCT02444910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030814|NCT04449003|||COHORT||CROSS_SECTIONAL|||||||
34030815|NCT04767438|||COHORT||PROSPECTIVE|||||||
34030816|NCT01080560|RANDOMIZED|CROSSOVER||||NONE||||||
34030817|NCT03636178|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind clinical trial||t|f|f|t
34030818|NCT02631889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030819|NCT06582394|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030820|NCT00019240||||TREATMENT||||||||
34030821|NCT02514902|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34030822|NCT03832205|||COHORT||PROSPECTIVE|||||||
34030823|NCT04371107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030824|NCT01570686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030825|NCT04077580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomisation list will be generated by computer with individual randomisation. Kragerø Tablettproduksjon AS will pack and label IMP with active substance and placebo according to the randomisation list. Participants will be dispensed Investigational Medical Product (IMP) in consecutive order at each study site, through a designated pharmacy, one site in each country. Kragerø Tablettproduksjon AS will have the list available at all times with the possibility to break the code. In addition there will be one envelope for each medication identification (ID) available in each country, at the coordinating centres, containing information of active substance or placebo regarding IMP delivered to that specific country. These envelopes will be stored together with the IMP in a locker. In acute situations, the PI in each country will be able to break the code and disrupt the unblinding process without the consent of the sponsor in order not to hamper necessary medical treatment.|We will perform a randomised trial in the targeted population, women \>70 years in general practice in the 4 countries. Nursing home patients may be included, all shall give informed consent. Approximately 100 patients in each country.|t|t|t|t
34030826|NCT02574494|||COHORT||PROSPECTIVE|||||||
34030827|NCT02608047|||CASE_CONTROL||RETROSPECTIVE|||||||
34030828|NCT00808951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030829|NCT00320840|||DEFINED_POPULATION||PROSPECTIVE|||||||
34030830|NCT01662687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030831|NCT01319526|||COHORT||PROSPECTIVE|||||||
34030832|NCT04580264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030833|NCT04340076|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicentre, pragmatic, randomized, controlled, non-inferiority trial. Patients will be randomized 2:1 to dose reduction and usual care.||||
34030834|NCT03524521|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030835|NCT03228797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||comparative study between 3 groups using ropivacaine||||
34030836|NCT02649569|||COHORT||PROSPECTIVE|||||||
34030837|NCT01103492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030838|NCT03358836|||COHORT||PROSPECTIVE|||||||
34030839|NCT00030472||||TREATMENT||||||||
34030840|NCT04695769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030841|NCT04102917|||COHORT||RETROSPECTIVE|||||||
34030842|NCT04405297|||COHORT||PROSPECTIVE|||||||
34030843|NCT00003274|RANDOMIZED|||TREATMENT||||||||
34030844|NCT05190705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030845|NCT03908437|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030846|NCT00453050||||TREATMENT||NONE||||||
34030847|NCT06529471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Double blinding was used in the study. For this purpose, the participants were not specified in which group they belonged to the research. Therefore, a separate informed consent form was prepared for each group. In order to avoid bias in the analysis of the research data, statistician blinding was also applied.~While coding the research data, the research groups were coded as A and B, and the statistician was prevented from knowing which letter represented which group."|The study was conducted experimentally with a pre-test and post-test control group.|t|f|f|t
34030848|NCT01331993|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34030849|NCT04393714|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Split-mouth prospective randomized clinical trial with 1:1 assignment|t|t|f|t
34030850|NCT04721808|||COHORT||RETROSPECTIVE|||||||
34030851|NCT03657186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030852|NCT00538369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030853|NCT05387187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030854|NCT06301906|||COHORT||PROSPECTIVE|||||||
34030855|NCT02756611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030856|NCT04467294|||COHORT||PROSPECTIVE|||||||
34030857|NCT03505086|||CASE_CONTROL||PROSPECTIVE|||||||
34030858|NCT03232840|||OTHER||PROSPECTIVE|||||||
34030859|NCT02478879|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030860|NCT00457132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34030861|NCT01605747|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030862|NCT06487247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030863|NCT00191191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030864|NCT04957238|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34030865|NCT00347386|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030866|NCT04399668|||CASE_ONLY||PROSPECTIVE|||||||
34030867|NCT01306110|||COHORT||PROSPECTIVE|||||||
34030868|NCT01407237|||COHORT||CROSS_SECTIONAL|||||||
34030869|NCT04725851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34030870|NCT04196647|||COHORT||PROSPECTIVE|||||||
34030871|NCT04766645|||COHORT||PROSPECTIVE|||||||
34030872|NCT05645549|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030873|NCT06360185|||COHORT||RETROSPECTIVE|||||||
34030874|NCT05845983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030875|NCT01946932|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33805788|NCT03363529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Hamilton depression interview is done by external assessor blinded to condition|Standard versus dynamic lighting|f|f|f|t
33805789|NCT02238769|||CASE_ONLY||PROSPECTIVE|||||||
33805790|NCT02933294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805791|NCT05779761|RANDOMIZED|PARALLEL||OTHER||SINGLE||All participants will be randomly assigned to one of three skills trainings for coping with distress.|t|f|f|f
33805792|NCT05873686|NA|SEQUENTIAL||TREATMENT||NONE||Sequential assignment, dose escalation||||
33805793|NCT04255212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are blinded to their allocation that will not be communicated till the conclusion of the research. The outcome assessors are blinded to the allocation of the participants|Randomized trial|t|f|f|t
33805794|NCT02002845|||COHORT||RETROSPECTIVE|||||||
33805795|NCT03328806|||CASE_ONLY||CROSS_SECTIONAL|||||||
33805796|NCT03259269|||COHORT||PROSPECTIVE|||||||
33805797|NCT02131584|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33805798|NCT01301118|||CASE_ONLY||PROSPECTIVE|||||||
34030876|NCT05975528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030877|NCT03855267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34030878|NCT03105518|NA|SINGLE_GROUP||TREATMENT||NONE||Assessment of immediate and delayed postoperative pain||||
34030879|NCT01248676|NA|SINGLE_GROUP||||NONE||||||
34030880|NCT05107648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030881|NCT02301195|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34030882|NCT02176954|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34030883|NCT04639284|||COHORT||PROSPECTIVE|||||||
34030884|NCT03400592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030885|NCT06035835|||COHORT||RETROSPECTIVE|||||||
34030886|NCT00999817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34030887|NCT03252743|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial without control group to test feasibility and evaluate preliminary effects.||||
34106059|NCT01121029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106060|NCT01877278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805799|NCT02896335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805800|NCT04839185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805801|NCT04549155|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"The study has two Aims, and thus two models. For Aim 1, the primary outcome measure is the difference in memory accuracy between TMS conditions, based on a mixed-effects design consisting of 4 repeated measurements per subject (2 memory conditions \[successful, unsuccessful\] x 2 TMS targeting \[network-based, standard\]).~For Aim 2, the primary outcome measure comprises longitudinal changes in both memory performance, as well as brain imaging measures of functional and structural connectivity, and neurovascular change. For the behavioral estimates, we analyze the TMS Condition x Session interaction, which comprised 4 sessions of TMS with longitudinal estimates of behavior in 30 older adults."||||
34030888|NCT00182325|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34030889|NCT03008759|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34030890|NCT01720225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030891|NCT01436630|||COHORT||CROSS_SECTIONAL|||||||
34030892|NCT01385514|||COHORT||PROSPECTIVE|||||||
34030893|NCT06582836|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34030894|NCT00754650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030895|NCT03872973|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34030896|NCT02771288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030897|NCT04038138|NA|SINGLE_GROUP||OTHER||NONE||||||
34030898|NCT03953612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible participants will be randomly assigned to 2 doses of PREG (300/500 mg/day) vs placebo (PLA) treatment (N=20/group) over 8 weeks.|t|f|f|f
34030899|NCT04205565|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34030900|NCT03127111|||COHORT||PROSPECTIVE|||||||
34030901|NCT05088850|||COHORT||RETROSPECTIVE|||||||
34030902|NCT01401452|||COHORT||PROSPECTIVE|||||||
34030903|NCT06581276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030904|NCT05311904|||COHORT||PROSPECTIVE|||||||
33805802|NCT06662630|NA|SINGLE_GROUP||TREATMENT||NONE|Analysis of data will be conducted by a statistician not involved in interventions at bedside|Interventional study evaluating the beneficial impact of continuous high-frequency oscillatory ventilation in patients with mechanical ventilation||||
33805803|NCT02964741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805804|NCT01237496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805805|NCT01437319|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33805806|NCT06649708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805807|NCT01904669|||COHORT||PROSPECTIVE|||||||
33839212|NCT04248478|||CASE_CONTROL||PROSPECTIVE|||||||
33839213|NCT06246695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839214|NCT05973344|||COHORT||PROSPECTIVE|||||||
33839215|NCT04621253|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Ciprofloxacin, Fluconazole and Placebo Capsules were produced under good manufacturing practice conditions and randomized by the responsible pharmacist. The investigator received emergency envelops in case of severe adverse reactions connected to the pretreatment to unblind the study, however the pharmacist retained the detailed randomization plan.|Randomized cross-over treatment with 3 different sequences|f|f|t|f
33839216|NCT06118905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839217|NCT03913390|||OTHER||PROSPECTIVE|||||||
33839218|NCT01810939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106061|NCT04883775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a phase I, open label, nonrandomized, dose-escalation trial of a fixed dose of MVT-2163 (89Zr-DFO-HuMab-5B1) and varying antibody masses of MVT-5873 (HuMab-5B1), designed to identify an optimal dose (total antibody mass) and optimal timing, for tumor imaging. This trial will include dose escalation, which includes up to 5 cohorts, an expansion phase, a re-entry phase, and a pre-surgery phase.||||
34106062|NCT05668923|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106063|NCT04250207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106064|NCT06641297|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34106065|NCT05396287|||CASE_CONTROL||PROSPECTIVE|||||||
34106066|NCT02411851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33805808|NCT06668571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|MRI-tech, Radiologist, and Clinical Research Trial Unit Nurses. Any staff involved in the ratings will be blinded to the treatment of the subject for infusion. Only the study investigator present during infusion in the MRI will be unblinded for safety precautions during the infusion.||t|f|t|t
33805809|NCT05962606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo-controlled|Multi-center, interventional, randomized, double-blind, placebo-controlled study.|t|t|t|t
33805810|NCT01303510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805811|NCT01056432|||CASE_ONLY||RETROSPECTIVE|||||||
33805812|NCT00115011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805813|NCT03001206|||COHORT||RETROSPECTIVE|||||||
33805814|NCT02961868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030905|NCT06552039|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Proof-of-Science, Prospective, Interventional, Three-arm, Double-Blind, Randomized, Safety and Efficacy|t|f|t|f
34030906|NCT02079740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030907|NCT01924754|||COHORT||PROSPECTIVE|||||||
34030908|NCT01943383|||COHORT||CROSS_SECTIONAL|||||||
34030909|NCT05783232|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.|Participants will be stratified based on gender at birth then randomized to one of the study arm|t|f|t|f
34030910|NCT03248427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030911|NCT05924412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
34030912|NCT04134195|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34030913|NCT01322074|||COHORT||PROSPECTIVE|||||||
34030914|NCT06387134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34030915|NCT04201730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030916|NCT04252339|NA|SEQUENTIAL||TREATMENT||NONE||||||
34030917|NCT01884779|||OTHER||CROSS_SECTIONAL|||||||
34030918|NCT00956072|RANDOMIZED|||TREATMENT||||||||
34030919|NCT00369941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030920|NCT03545542|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Neuroblastoma group: Children with neuroblastoma enrolled after verification of diagnosis. Sampling before initiation of chemotherapy and under chemotherapy.~Control group: healthy children without gastro-intestinal or pulmonary disease recruited from paediatric surgery."||||
34030921|NCT01050465|RANDOMIZED|PARALLEL||||NONE||||||
34030922|NCT02754765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030923|NCT05349708|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34030924|NCT01609452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030925|NCT02322255|||CASE_ONLY||PROSPECTIVE|||||||
34030926|NCT03086486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, trial investigators and staff, including laboratory staff, will be blinded to dose and scheduled duration of linezolid. Bedaquiline and pretomanid dosing will not be blinded. There will be three unblinded analyses which will contain results by linezolid treatment group in aggregate. The first analysis will be after all participants have completed 26 weeks of treatment and here sites, participants, and Sponsor staff will not be unblinded to individual linezolid treatment information. A limited number of statisticians will have access to individual linezolid treatment assignments. The blind for all individual participants will be broken for the primary endpoint analysis (the second unblinded analysis) once all clinical data and outcome parameters have been captured, no more data queries are pending, and the statistical analysis plan has been finalized. The third analysis will occur when all participants have completed 78 weeks of follow-up after end of treatment.||t|t|t|f
34030927|NCT00444587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030928|NCT02791451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030929|NCT00665782|||OTHER||PROSPECTIVE|||||||
34030930|NCT05966415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|randomized, double-blind, placebo-controlled study|t|t|t|f
34030931|NCT06455813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030932|NCT05491486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The condition will be revealed to the participants after all T0 assessments have been completed||t|f|f|f
34030933|NCT06552000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030934|NCT00584454|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34030935|NCT03081780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030936|NCT00601575|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34030937|NCT04832022|||CASE_CONTROL||PROSPECTIVE|||||||
34030938|NCT06178003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030939|NCT04233424|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"This is a double-blind clinical trial. The sponsor, the subjects, outcomes assessor and all staff involved in the collection and recording of the clinical and laboratory data, based on which the independent adjudication committee will perform their assessment, will be blind to treatment assignment. In addition, all aspects of data management and clean-up will be done in blinded datasets.~The study site personnel, who perform the index surgery (Operation room staff), will be trained not to disclose the treatment arm to the blinded Investigator, to the subject, his/her family, to other health care providers not present during the surgery or to the study Sponsor representatives. Wound assessment throughout the study follow-up visits will be done by a blinded Investigator, that will not be involved in the surgery. An emergency card containing the Study Name, NIH number, Center Name/number, PI's name and contact details will be provided to the subjects."|"Males and females, \>18 years old, undergoing scheduled abdominal colon surgery involving resection and anastomosis or a stoma, who meet the inclusion criteria and none of the exclusion criteria and provide signed informed consent will be enrolled in the study.~The final number of subjects will be determined following a comparative interim analysis for an early efficacy or futility stop or unblinded sample size re-estimation: when about 750 subjects will complete their 30 days (1 month) follow-up and evaluated for primary endpoint."|t|t|t|f
34106067|NCT00002985|RANDOMIZED|||TREATMENT||||||||
33805815|NCT05783531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Stepped-wedge cluster randomized|f|f|f|t
33805816|NCT00807313|||COHORT||PROSPECTIVE|||||||
33805817|NCT03614663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805818|NCT01773993|||CASE_ONLY||PROSPECTIVE|||||||
33805819|NCT02109575|||COHORT||PROSPECTIVE|||||||
33805820|NCT00244673|RANDOMIZED|PARALLEL||||NONE||||||
34106068|NCT04210102|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective and randomised study in 2 parallel groups to compare diagnosis performance of LUS and CR as a primary imaging for diagnosis of CAP||||
34106069|NCT06673459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724127|NCT04151290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All participants and healthcare providers will be blinded to the diagnosis results.|All subjects will undergo both investigational and comparator diagnosis for ASD.||||
33724128|NCT02503332|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33724129|NCT04518514|NA|SINGLE_GROUP||OTHER||NONE||||||
33724130|NCT02157155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33724131|NCT00706979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030940|NCT04167111|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Subjects will be started on Vitamin D3 4000 per day or 2400 IU per day at baseline and based on 3 month 25(OH)D levels, will be adjusted to a different vitamin D dose if needed||||
34030941|NCT02340481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030942|NCT03270969|NA|SINGLE_GROUP||OTHER||NONE||||||
34030943|NCT03354715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34030944|NCT00762112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030945|NCT00109434|||||PROSPECTIVE|||||||
34030946|NCT02216500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030947|NCT00004126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030948|NCT04851847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34030949|NCT03955458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030950|NCT06277765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34030951|NCT06083519|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34030952|NCT06357585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participant blinding was done because the parents who participated in the study voluntarily did not know which group they were in until the end of the study.|Web-based training will be provided to parents in the experimental group, and parents in the control group will continue their routine treatment and care process.|t|f|f|f
34030953|NCT00504751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030954|NCT05532033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34030955|NCT03488082|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030956|NCT04520126|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||"30 patients will be randomized to Olivomed (5 mg hydroxytyrosol po twice daily) or placebo for one month and then they will be crossed over to the alternate treatment for another one month.~30 patients will be randomized to OlivomedSmart ((OL:HT:OC 2:1:3) - 5 mg hydroxytyrosol po twice daily) or placebo for one month and then they will be crossed over to the alternate treatment for another one month."|t|t|t|t
34030957|NCT00869076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34030958|NCT01259271|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34030959|NCT02678078|||COHORT||PROSPECTIVE|||||||
34030960|NCT03719651|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge design with three cohorts||||
34030961|NCT04087915|||COHORT||PROSPECTIVE|||||||
34030962|NCT04159246|||COHORT||PROSPECTIVE|||||||
34030963|NCT02206360|||OTHER||PROSPECTIVE|||||||
34030964|NCT02898272|||COHORT||CROSS_SECTIONAL|||||||
34030965|NCT03161977|||CASE_ONLY||PROSPECTIVE|||||||
34030966|NCT01382888|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34030967|NCT02419781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030968|NCT03166098|||CASE_CONTROL||PROSPECTIVE|||||||
34030969|NCT02509169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030970|NCT03681249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34030971|NCT04323943|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, cross-over, open labelled, monocentric, controlled trial||||
34030972|NCT03647527|||CASE_ONLY||PROSPECTIVE|||||||
34030973|NCT00852007|NA|SINGLE_GROUP||||NONE||||||
34030974|NCT06550557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants into both the intervention and control groups didnot know of the other participants or the ongoing intervention nature|pre intervention assessment of nomophobia score, mental health and self-esteem scores, then random allocation into intervention or control groups, intervention group received counselling sessions based on health belief model merged with smart phone action cues, post intervention scores were remeasured and compared to control group|t|f|f|f
34030975|NCT04071834|||CASE_CONTROL||PROSPECTIVE|||||||
34030976|NCT06101160|||COHORT||PROSPECTIVE|||||||
33724132|NCT03098537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724133|NCT02229318|NA|SINGLE_GROUP||OTHER||NONE||||||
33724134|NCT03768596|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|In the first pat of the study, participants are unaware of the fact we are trying to nudge them. In the second part, they are explained and asked what they feel about nudging|one group receives a form with the nudge, one group receives the same form without nudge and another group doesn't receive any form||||
33724135|NCT00279734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724136|NCT05393141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724137|NCT02976974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33724138|NCT03340025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724139|NCT01655017|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34030977|NCT01179386|||CASE_CONTROL||PROSPECTIVE|||||||
34030978|NCT02797171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34030979|NCT03632915|||COHORT||PROSPECTIVE|||||||
34030980|NCT02829645|NA|SINGLE_GROUP||||NONE||||||
34030981|NCT05880329|||COHORT||PROSPECTIVE|||||||
34030982|NCT01954862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106070|NCT06475820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106071|NCT04043247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34106072|NCT06211218|||CASE_CONTROL||PROSPECTIVE|||||||
34106073|NCT05701345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multiple-Group Assignment|t|t|t|t
34106074|NCT04245410|||OTHER||RETROSPECTIVE|||||||
34106075|NCT01433861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106076|NCT01992939|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34106077|NCT01487161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106078|NCT02565394|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34106079|NCT06170242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106080|NCT04798820|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|double blind|"Simplified dietary education(SE) versus Intensive dietary education(IE)~1. Subtotal gastrectomy group (n=258)~2. Total gastrectomy group (n=100)"|t|f|t|t
34106081|NCT01793129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106082|NCT02155972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are randomized to receive either ALIGN (probiotic) or Placebo|t|t|t|t
34106083|NCT06639308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|anesthesia ,|"•This is a Prospective, randomized control trial. The study will be conducted on 30 patients complaining of chronic Achilles tendon rupture, Achilles insertional tendinopathy, Haglund syndrome planned for FHL transfer in Assiut university hospital.~Patients will be randomized to two groups one group endoscopic FHL will be conducted in other hand second group open FHL will be conducted."|f|f|t|t
34106084|NCT04045145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106085|NCT04872647|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pilot Randomized Control Trial comparing usual diabetic care to usual diabetic care plus virtual health coaching utilizing lifestyle action plans in under resourced adults with type II diabetics||||
34106086|NCT03295786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Randomised, Double-Blind, Placebo Controlled|t|t|t|t
34106087|NCT05033561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106088|NCT06644846|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention type: Spatially Fractionated Radiation Therapy (SFRT)||||
34106089|NCT04637620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106090|NCT02442531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106091|NCT05052892|||COHORT||PROSPECTIVE|||||||
34106092|NCT01866150|||COHORT||RETROSPECTIVE|||||||
34106093|NCT02003157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106094|NCT06675123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106095|NCT04325607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106096|NCT00713193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106097|NCT00974532|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34106098|NCT05679622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106099|NCT06640543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106100|NCT05007639|||COHORT||PROSPECTIVE|||||||
34106101|NCT02420314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106102|NCT06563570|NA|SINGLE_GROUP||OTHER||NONE||||||
34106103|NCT05222789|||COHORT||PROSPECTIVE|||||||
34106104|NCT06571175|||COHORT||PROSPECTIVE|||||||
33724140|NCT01318447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106105|NCT01931826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106106|NCT00159185|||DEFINED_POPULATION||PROSPECTIVE|||||||
33724141|NCT02175420|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34106107|NCT04791748|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106108|NCT05852418|||COHORT||OTHER|||||||
34106109|NCT06641167|||OTHER||PROSPECTIVE|||||||
33724142|NCT05133518|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Factorial-designed, randomized, double-blind, placebo-controlled, parallel-cohort safety and efficacy study.|t|t|t|t
33724143|NCT03618485|||CASE_ONLY||PROSPECTIVE|||||||
33724144|NCT03646682|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724145|NCT02778412|||COHORT||PROSPECTIVE|||||||
33724146|NCT04160364|||OTHER||PROSPECTIVE|||||||
33724147|NCT02353585|||COHORT||PROSPECTIVE|||||||
33724148|NCT06050499|||COHORT||PROSPECTIVE|||||||
33724149|NCT00616460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724150|NCT02381444|||CASE_ONLY||PROSPECTIVE|||||||
33724151|NCT03997656|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blinded approach|Control group|f|f|t|f
33724152|NCT00462761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724153|NCT03149692|NA|SINGLE_GROUP||OTHER||NONE||Proof of concept||||
34106110|NCT03034811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106111|NCT06379620|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open label, pilot treatment study. Screening data will be reviewed to determine subject eligibility. Upon successful completion of all screening procedures, subject will be considered eligible for enrollment.~The subject will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask, twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days. Subjects will be asked to return to the clinic for additional evaluations on Days 15 and 45."||||
34106112|NCT06370208|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34106113|NCT06586827|RANDOMIZED|PARALLEL||TREATMENT||NONE||The proposed study will be a randomized control trial, participants will be recruited for the study and once consented they will be randomly assigned to the Control group which entails accessing the current VCU-RRTC online course or the intervention group which will receive the VCU-RRTC course plus TA. TA activities and outlines are attached. Participants who are assigned to the control group will have the opportunity to opt in to the TA sessions after the completion of the third data collection time period. The decision to use an RCT is a natural evolution of the initial two phases of the study and will help provide a comparison of the impact and benefit of additional TA. The addition of the additional two measures that will ask participants to self-report on their employment skills and employment outcomes will also provide important information for future studies.||||
34106114|NCT04316650|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106115|NCT01592747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724154|NCT01066754|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724155|NCT01206647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724156|NCT01927406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33724157|NCT00445965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724158|NCT02625090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724159|NCT00047021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724160|NCT05152888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study protocol is an open label pilot study with a parallel control group.||||
33724161|NCT03574740|||OTHER||RETROSPECTIVE|||||||
33724162|NCT00826800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805821|NCT05907603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106116|NCT06524180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106117|NCT02933151|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106118|NCT05931718|||COHORT||PROSPECTIVE|||||||
34106119|NCT04967001|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34106120|NCT06672627|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106121|NCT06397625|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34106122|NCT05185453|RANDOMIZED|PARALLEL||OTHER||NONE||This pilot community-partnered cluster-randomized trial will examine the feasibility and acceptability of a social network-based youth violence prevention program called Strengthening Connections for Change for youth ages 13-17 and their key adult supports. The study will be located in four lower resource Pittsburgh, Pennsylvania neighborhoods ('clusters') randomized to receive either the Strengthening Connections for Change program (i.e. intervention neighborhoods, n=2) or to a job skills training program (i.e. control neighborhoods, n=2).||||
34106123|NCT06674005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34106124|NCT05686980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106125|NCT06265441|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805822|NCT06451952|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, single blinded randomized controlled trial, parallel arm, allocation ratio 1:1, to evaluate the superiority of virtual darkness as add on to treatment as usual.||||
33805823|NCT05443542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33805824|NCT04881409|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomization to NHF or NIV||||
33805825|NCT05080036|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805826|NCT04474496|||OTHER||CROSS_SECTIONAL|||||||
33805827|NCT05324878|||COHORT||PROSPECTIVE|||||||
33805828|NCT03836105|||COHORT||PROSPECTIVE|||||||
33805829|NCT05254912|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Subjects will be blinded to the name of the investigational products. The Investigatory staff will not be blinded.|This study will evaluate the potential of an investigational product (6% Bemotrizinol (BEMT) in a suitable vehicle (i.e., sunscreen oil SU E 101413 85) or petrolatum (SU-E-101413-82)) to produce a photoallergic response after application to the skin of human subjects followed by exposure to UV radiation.|t|f|f|f
33805830|NCT05056493|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33805831|NCT03657316|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805832|NCT06517914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This is a double-blind study, meaning that YH35995 tablets and placebo tablets will be identical in appearance and will be packaged in the same way.~Information about the treatment arm to which participants are assigned must remain blinded for the duration of the study unless information about the causal relationship between the adverse event and the Investigational Product that meets the drug withdrawal criteria becomes essential or, in an emergency, if the information about the Investigational Product becomes critical for treating the participant."||t|f|t|f
33805833|NCT02893969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805834|NCT01540318|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33805835|NCT05677269|||COHORT||PROSPECTIVE|||||||
33805836|NCT03054415|NA|SINGLE_GROUP||OTHER||NONE||||||
33805837|NCT02940249|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33805838|NCT02925988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805839|NCT04241640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805840|NCT02641938|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34106126|NCT04125758|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Researchers involved in participant testing will not know the participant's group. Researchers conducting data analysis will not know data codes assigned to groups.|Participants are randomly assigned after a baseline testing to either a mindfulness intervention or control group.|f|f|t|t
34106127|NCT02698787|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34106128|NCT03917901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||If participant meets eligibility criteria, the participant will be randomly assigned to complete a one-session computer-delivered intervention: either (1) anxiety sensitivity reduction treatment or (2) health information control.|t|f|f|f
34106129|NCT06644638|||COHORT||RETROSPECTIVE|||||||
33805841|NCT02284113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805842|NCT06698588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Whilst we are conducting an RCT we are planning on taking a modern approach to data-analysis - time-varying network analysis. This approach moves beyond the traditional medical model and its diagnostic categories where the assumption is that symptoms stem from a common underlying cause, and treating that cause (via medication or therapy) should alleviate the symptoms. This approach has been largely unsuccessful.~In contrast, network analysis views mental health disorders as complex, interrelated systems of symptoms and does not lend itself to calculating composite of global scores (see project description for further information."|t|t|t|t
33805843|NCT05521906|RANDOMIZED|PARALLEL||PREVENTION||NONE||SGMY (N=300) are randomly assigned to a treatment (n=200) or wait-list (n=100) control condition.||||
33805844|NCT03805243|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||All subject would likely test each the 5 devices||||
33805845|NCT02138994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805846|NCT04899011|||COHORT||RETROSPECTIVE|||||||
33805847|NCT00351299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805848|NCT06052657|||CASE_ONLY||OTHER|||||||
33805849|NCT01940107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838018|NCT04046458|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators' intervention, which is a notification to the physician that is seen in the EHR, is randomized at the patient level. The patients randomized to the control group do not have a notification shown to their physician while the intervention patients do.||||
33838019|NCT01935752|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33838020|NCT06207305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838021|NCT04761653|||COHORT||RETROSPECTIVE|||||||
33838022|NCT05988723|||COHORT||PROSPECTIVE|||||||
33838023|NCT03119545|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838024|NCT03126071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838025|NCT03019081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838026|NCT01975298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838027|NCT03638076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106130|NCT05051345|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106131|NCT00216931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34030983|NCT03171012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be by randomization.com software, where a third person, who will not participate in the other stages of the survey, execute the process and deliver the opaque and numbered envelopes to the researcher responsible for the training, thus ensuring the confidentiality of the allocation. The patient may be allocated to the LL's CRT + PNF group, LL's CRT + Breathing, UL's CRT + PNF or UL's CRT + Breathing.|"Forty individuals into four groups: Experimental Lower Limbs (LL's CRT with PNF); Group control Lower Limbs (LL's CRT with respiration). Experimental Upper Limbs (UP's CRT with PNF) and Group control Upper Limbs (UP's CRT with respiration). Individuals will be assessed before and immediately after 20 program sessions and one month after the end of treatment.~The treatment program will have the full duration of One hour including: ten minutes of stretching (five minutes before and five Minutes after the therapeutic intervention), ten minutes of rest and 40 minutes of Aerobic treatment associated with PNF or to respiration, being performed in 20 Sessions three times a week. For therapy with the CRT used the cycle ergometer for lower or upper limbs, Based on the criteria of the ACSM and monitoring Constant blood pressure, oxygen saturation and perceived exertion. The PNF patterns will be performed in seated, dorsal, ventral and Side."|t|f|t|f
34030984|NCT02281422|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34030985|NCT03167268|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double blind study||t|t|t|t
34106132|NCT01554358|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34106133|NCT05283629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106134|NCT03057340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106135|NCT06638645|||COHORT||PROSPECTIVE|||||||
34106136|NCT02063438|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34106137|NCT06609304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030986|NCT06583122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030987|NCT04513392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the statistician and the research coordinator, who are not involved in the care of the patients, will know the randomization codes for allocation concealment. To further minimize bias from the open-labeled design, outcome measures will be collected and assessed by a blinded outcome assessor.|Once consented, study participants will be randomized in a 1:1 ratio to one of two arms using a concealed permutated block randomization scheme to one of 2 arms - an experimental arm of BL laser treatment or a control arm of KTP laser treatment. Randomization sequence will be generated using a random number generator with randomly varying block sizes by the study statistician prior to the initiation of the study. Only the statistician and the research coordinator, who are not involved in the care of the patients, will know the randomization codes for allocation concealment. The intervention, i.e. type of laser used for treating the vocal fold lesions, is impossible to blind. Therefore this study is open-labeled. To further minimize bias from the open-labeled design, outcome measures will be collected and assessed by a blinded outcome assessor.|f|f|f|t
34030988|NCT02647697|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34030989|NCT04259372|||COHORT||PROSPECTIVE|||||||
34030990|NCT03774407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-group prospective repeated-measures pilot trial. Duration is 12 months,||||
34030991|NCT05668702|NA|SINGLE_GROUP||SCREENING||NONE||crossover design||||
34030992|NCT06125431|||COHORT||PROSPECTIVE|||||||
34030993|NCT06582862|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be divided into 2 groups. One group will do aerobic exercise and other group will do anaerobic exercise||||
34030994|NCT02856802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34030995|NCT02920671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34030996|NCT00698711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34030997|NCT05209529|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients after central screening are randomized to olaparib vs olaparib and durvalumab||||
34030998|NCT00626808|||COHORT||RETROSPECTIVE|||||||
34030999|NCT06445621|||COHORT||PROSPECTIVE|||||||
34031000|NCT05509517|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031001|NCT01245283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031002|NCT05743010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031003|NCT06582329|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Therapeutic exploratory trial:~the trial is designed as a prospective, single center, open label, randomized controlled pilot study"||||
34031004|NCT03852732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031005|NCT04786847|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately 50 eligible patients will be enrolled and evaluated for safety and tolerability as well as undergo imaging to allow determination of the biodistribution and dosimetry 177Lu-DOTA-TLX591. Twenty-five patients will also be enrolled in a biodistribution and dosimetry sub-study, involving the collection of quantitative single-photon emission computerized tomography (SPECT) or single-photon emission computerized tomography/computerized tomography (SPECT/CT) data in a subset of patients.||||
34031006|NCT04622748|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031007|NCT02396719|||||PROSPECTIVE|||||||
34031008|NCT00612092|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34031009|NCT01657435|||COHORT||PROSPECTIVE|||||||
34031010|NCT00395161|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34031011|NCT03757312|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031012|NCT04196881|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031013|NCT04238650|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34031014|NCT00792961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031015|NCT06228001|||CASE_ONLY||PROSPECTIVE|||||||
34106138|NCT02121639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106139|NCT03576651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106140|NCT06642831|||CASE_CONTROL||PROSPECTIVE|||||||
34106141|NCT01505803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149012|NCT03262116|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded to the type of insulin used in the iLet bionic pancreas each arm of the study.||t|f|f|f
34149013|NCT03286179|||COHORT||PROSPECTIVE|||||||
34149014|NCT02784600|||COHORT||PROSPECTIVE|||||||
34149015|NCT01345383|||CASE_ONLY||PROSPECTIVE|||||||
34149016|NCT00663845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724163|NCT05447364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomized and assigned to 75 mg of Pregabalin and 150 of Pregabalin groups in parallel for the duration of the study|t|f|t|f
33724164|NCT04662801|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33724165|NCT02369341|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838028|NCT03052660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838029|NCT02230241|||COHORT||PROSPECTIVE|||||||
34031016|NCT03685214|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||One model using normal saline for resuscitation fluid,the other using acetated Ringer's solution|t|f|f|f
34031017|NCT01439256|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34031018|NCT03322644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34031019|NCT04043455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031020|NCT03742193|NA|SINGLE_GROUP||TREATMENT||NONE|An Independent radiologic reviewing committee assess the radiological tumor response in a blinded manner. Data Safety and Monitoring Board (DSMB) access the outcome in the interim analysis and final analysis|||||
34031021|NCT05628649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031022|NCT00781807|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34031023|NCT01832571|NA|SINGLE_GROUP||||NONE||||||
34031024|NCT03584087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031025|NCT04555317|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to either an observational arm or an interventional arm consisting of a musculoskeletal health package||||
34031026|NCT03404674|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34031027|NCT02825771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031028|NCT00172276|||CASE_CONTROL||OTHER|||||||
34031029|NCT06423378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031030|NCT01872923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031031|NCT04650217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-Blind|t|t|t|t
34031032|NCT04122040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|block of 4|randomised control study|f|f|t|f
34031033|NCT00346983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031034|NCT01531517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031035|NCT01163864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031036|NCT05561725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031037|NCT04994405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34031038|NCT04500717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031039|NCT00931645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031040|NCT05864989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031041|NCT04063215|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, non-randomized study to determine safety and treatment effect of three infusions of HB-adMSC (2 x 10\^8 total cells per dose) in adult patients with sub-acute or chronic neurological injury||||
34031042|NCT06090201|||COHORT||CROSS_SECTIONAL|||||||
34031043|NCT05944146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031044|NCT05954221|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34031045|NCT05444894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031046|NCT02358512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031047|NCT03075020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34031048|NCT02413229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031049|NCT04970628|||CASE_CONTROL||RETROSPECTIVE|||||||
34031050|NCT05314803|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34031051|NCT00165763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031052|NCT02137057|||COHORT||PROSPECTIVE|||||||
34031053|NCT02368418|||COHORT||PROSPECTIVE|||||||
34031054|NCT03188744|||COHORT||PROSPECTIVE|||||||
34031055|NCT00000543|RANDOMIZED|||PREVENTION||DOUBLE||||||
34031056|NCT01601340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031057|NCT03789305|||COHORT||PROSPECTIVE|||||||
33838030|NCT02617953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34031058|NCT04708223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth Design|t|f|f|t
34031059|NCT01108718|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34031060|NCT03196843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031061|NCT02074007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031062|NCT04905628|||COHORT||PROSPECTIVE|||||||
34031063|NCT02211417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031064|NCT01215474|||CASE_ONLY||RETROSPECTIVE|||||||
34031065|NCT00237978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031066|NCT01774162|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031067|NCT06346925|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031068|NCT01456806|RANDOMIZED|FACTORIAL||||NONE||||||
34031069|NCT01224197|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031070|NCT05134363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||comparative study between two doses and a 3rd control group|f|f|t|f
34031071|NCT01461915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031072|NCT00360984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031073|NCT02660905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031074|NCT00391560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single treatment arm. Two disease related analyses groups, i.e.: Group 1: AML, MDS, CML-BP non-lymphoid, CMML, Agnogenic Myeloid Metaplasia (AMM); Group 2: CLL, ALL, CML-BP lymphoid||||
34031075|NCT01342601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106142|NCT06229093|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The assignment of older adults to OA and OAg will be randomized. The within-subjects factor of stimulation modality includes 2 levels, to be administered in counterbalanced order: Visual (V, i.e., lights-only) and Audiovisual (AV, i.e., music-plus-lights). Each subject will be aware that they are receiving V and AV stimulation, and thus infer that we are comparing these two forms of stimulation and therefore assessing the effects of music. However, and important to the design of this study, all subjects will be blinded with respect to their group assignment; i.e., they will not know, until post-study debriefing, about the other arms of the study, and that the gamma-band stimulation is an active ingredient of the intervention.||t|f|f|f
34106143|NCT06088043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106144|NCT06641284|||COHORT||PROSPECTIVE|||||||
34106145|NCT04650165|||COHORT||PROSPECTIVE|||||||
34149017|NCT06103994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149018|NCT05085912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149019|NCT02102152|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149020|NCT00313976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34149021|NCT06088836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149022|NCT00906958|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34031076|NCT03869944|NA|SINGLE_GROUP||PREVENTION||NONE||Phase II trial, non-randomized, open-label, mono-country and multi-center trial||||
34149023|NCT01212614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149024|NCT03697044|||COHORT||PROSPECTIVE|||||||
34149025|NCT06198088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149026|NCT02187315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34149027|NCT06490211|||COHORT||PROSPECTIVE|||||||
34149028|NCT00112177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149029|NCT03344263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149030|NCT02395211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149031|NCT01930890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149032|NCT00905086|||COHORT||PROSPECTIVE|||||||
34149033|NCT04689711|||COHORT||PROSPECTIVE|||||||
34149034|NCT02584920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149035|NCT01293981|||COHORT||PROSPECTIVE|||||||
34031077|NCT04348201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Fifty volunteer, single females with premenstrual syndrome (PMS) were selected randomly from outpatient clinic of obstetrics and gynecology at Kasr El Ainy University Hospital, Faculty of Medicine, Cairo University to share in this study, their age ranged from 18 to 25 years old and their body mass index (BMI) did not exceed 30kg/m2, the participants were assigned into two groups of equal numbers. The group (A) received therapeutic foot reflexology with dietary modification 3 times/week for8 weeks, while the group (B) received dietary modifications only for 8 weeks|f|f|t|f
33724166|NCT05863637|NA|SINGLE_GROUP||TREATMENT||NONE||Controlled study; participants (e.g. primary care patients with an anxiety disorder) will be recruited consecutively to the study, they will be put on a waiting-list for 3 months (= standard procedure) and thus be their own control person.||||
33724167|NCT05693285|||CASE_CONTROL||PROSPECTIVE|||||||
33724168|NCT03668626|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33724169|NCT00456534|||DEFINED_POPULATION||OTHER|||||||
33724170|NCT05441527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724171|NCT02744573|||CASE_CONTROL||PROSPECTIVE|||||||
33724172|NCT02057471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031078|NCT01068548|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34031079|NCT06583018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34031080|NCT02685735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031081|NCT02977819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34031082|NCT01195441|||COHORT||PROSPECTIVE|||||||
34031083|NCT02103855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031084|NCT03426189|||COHORT||PROSPECTIVE|||||||
34031085|NCT03771287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded randomized control trial of OpenSound Navigator (OSN) enabled/disabled hearing aids. Only the fitting audiologist will know if the OSN algorithm is enabled or disabled in the research hearing aids. Will be un-blinded after data collection is complete in order to carry out group comparison analysis.||t|f|t|f
34031086|NCT04343131|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031087|NCT05270408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34031088|NCT05300750|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trail (Parallel group design) is an experimental study design in which each subject is randomized to one of two or more distinct treatment/intervention groups. Those who are assigned to the same treatment are referred to as a treatment group||||
34031089|NCT00461253|||CASE_CONTROL|||||||||
34031090|NCT03629184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031091|NCT04671121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients were randomly classified into 2 groups using opaque sealed envelopes. Randomization was performed using a computer-generated random number list, and a statement indicating the patient's group was placed in a closed envelope numbered according to the result. Each patient was asked to choose an envelope, and the patients were assigned to the study according to the group written in the envelope.|The patients were randomly classified into 2 groups. The patients given the low-pressure pneumoperitoneum (8 mmHg) treatment were called Group LP (n = 30), and the patients given the standard pressure treatment (14 mmHg) were called Group SP (n = 30). Each patient and the anesthesiologist responsible for that patient's anesthesia management were blinded to the group assignments.|t|t|f|f
34031092|NCT01651793|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34031093|NCT04505566|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"At the baseline visit, only patients from the moderate NPDR group will be randomized into one of 2 groups, using a red cap database for randomization in a block manner to ensure near equal randomization in both groups.~A report is generated every 4 months for assessment of the number of patients in each randomized category.~Patients in this group will have both eyes randomized to either Acuvail or placebo-control (preservative-free artificial tear) in double-masked fashion."|"This is a 2 aim, randomized and double-masked Phase I study on topical Ketorolac for the prevention of diabetic retinopathy.~164 adult type II diabetic patients, aged 18 years or greater will be enrolled in addition to 100 age-matched patients without diabetes who are undergoing unilateral vitrectomy surgery for non-inflammatory conditions such as epiretinal membrane or macular hole will also be enrolled."|t|f|t|f
34031094|NCT03723356|||CASE_CROSSOVER||PROSPECTIVE|||||||
34031095|NCT00722904|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031096|NCT05095844|||CASE_ONLY||RETROSPECTIVE|||||||
34031097|NCT03669224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031098|NCT04418102|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Randomised controlled trial with 2x6 week interventions separated by a 3 week washout.|t|t|t|t
34031099|NCT04978987|||OTHER||CROSS_SECTIONAL|||||||
34031100|NCT06263452|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|This is a double blind, randomized, placebo-controlled mechanistic clinical trial. The Investigational Drug Service will randomly assign patients to the experimental group (propranolol) or the placebo group. Research staff who have direct contact with the participant will be blind to their condition.|Subjects (n = 60 per condition, N = 120) will either take a one-time, 40mg dose of propranolol or an encapsulated placebo.|t|t|t|f
34031101|NCT00003131||||TREATMENT||||||||
34031102|NCT04984915|||COHORT||PROSPECTIVE|||||||
34031103|NCT03888963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031104|NCT06249061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031105|NCT03893084|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"The women who came to the institution were evaluated in terms of sample criteria and randomized sampling was divided into two groups. In order to be able to perform randomized sampling, random number table was obtained automatically by means of programs on internet sites by specifying the number of samples. The selection of the groups to the intervention and control group was determined by throwing a coin.~In the data collection phase of the study, 218 women were evaluated in terms of sampling criteria. 10 women (who did not meet the criteria or refused to participate) were excluded from the study. 208 randomized women were divided into two groups as intervention and control group. During the follow-up, 15 women in the intervention group and 13 women in the control group were excluded from the study or were excluded because of pregnancy."|t|f|f|f
34031106|NCT05321004|||OTHER||CROSS_SECTIONAL|||||||
34031107|NCT00373633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34031108|NCT01801904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031109|NCT05998798|||CASE_CROSSOVER||PROSPECTIVE|||||||
34031110|NCT00373763|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34031111|NCT00530205|||COHORT||PROSPECTIVE|||||||
34106146|NCT04966585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both subject and clinical staff will be masked to treatment group assigned.|Subjects will be randomly assigned to receive posaconazole or placebo in 1:1 fashion.|t|t|f|t
34106147|NCT03906708|||COHORT||PROSPECTIVE|||||||
34031112|NCT04841577|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031113|NCT03213444|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with stage II disease undergoing adjuvant 5-FU treatment will be allocat in chemotherapy-1 group, while stage III patients undergoing combined adjuvant chemotherapy (5FU + Oxaliplatin) will be allocat to the Chemotherapy group -2.||||
34031114|NCT04525573|||COHORT||CROSS_SECTIONAL|||||||
34031115|NCT05815017|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031116|NCT04705272|||COHORT||PROSPECTIVE|||||||
34031117|NCT01790074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031118|NCT06432803|||COHORT||RETROSPECTIVE|||||||
34106148|NCT02093520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106149|NCT01906320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106150|NCT02607163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106151|NCT06640062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106152|NCT06559540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106153|NCT04380740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724173|NCT00352521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724174|NCT06434662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724175|NCT01048723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724176|NCT06098378|||CASE_ONLY||RETROSPECTIVE|||||||
33724177|NCT00211029|||COHORT||PROSPECTIVE|||||||
33724178|NCT01002833|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33724179|NCT03205865|||COHORT||PROSPECTIVE|||||||
33724180|NCT00901758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724181|NCT03161028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724182|NCT02023450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724183|NCT05333900|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||5-week crossover pilot study||||
33724184|NCT02940288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33724185|NCT02864849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724186|NCT00218296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724187|NCT05449054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724188|NCT00081354|||CASE_CONTROL||OTHER|||||||
33724189|NCT00623064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724190|NCT04221685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant) single ( participant ) because the two interventions used in this trial are easily recognized by the investigator but the participant and the statistician will be blinded.||t|f|f|f
33724191|NCT02261714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724192|NCT03078621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724193|NCT04713826|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33724194|NCT01707953|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724195|NCT02310464|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33724196|NCT01772303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724197|NCT04692207|||COHORT||RETROSPECTIVE|||||||
33724198|NCT04055831|||CASE_CONTROL||PROSPECTIVE|||||||
33724199|NCT05078853|||OTHER||CROSS_SECTIONAL|||||||
33724200|NCT04107467|||COHORT||PROSPECTIVE|||||||
33724201|NCT06541184|||CASE_ONLY||OTHER|||||||
33724202|NCT04730479|||COHORT||PROSPECTIVE|||||||
33724203|NCT05793346|||OTHER||RETROSPECTIVE|||||||
33724204|NCT01603446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724205|NCT01892631|RANDOMIZED|PARALLEL||||NONE||||||
33724206|NCT01808430|||COHORT||PROSPECTIVE|||||||
33724207|NCT03999190|||OTHER||PROSPECTIVE|||||||
33724208|NCT04391790|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, multicenter, randomized clinical trial||||
33724209|NCT03936361|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be randomized at 1:1 ratio to either continue the same statin drug and dosage that they are taking at the time of ICH onset or to discontinue it for up to 24 months after ICH. No placebo will be prescribed for those randomized to discontinue statins.|f|f|f|t
33724210|NCT02436278|||COHORT||PROSPECTIVE|||||||
33724211|NCT00470574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724212|NCT05289323|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724213|NCT04087460|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724214|NCT02196272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724215|NCT01742741|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838031|NCT03240822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All subjects receive transplant and immunosuppression therapy||||
33838032|NCT02369471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838033|NCT03655743|||COHORT||PROSPECTIVE|||||||
34031119|NCT02625597|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34031120|NCT02325076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031121|NCT03347825|||COHORT||RETROSPECTIVE|||||||
34031122|NCT02390882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031123|NCT04320043|||CASE_ONLY||RETROSPECTIVE|||||||
34031124|NCT02647801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34031125|NCT01807312|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34031126|NCT02068313|||COHORT||PROSPECTIVE|||||||
34031127|NCT00115453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031128|NCT05186649|||COHORT||RETROSPECTIVE|||||||
34106154|NCT04965064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106155|NCT01355666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106156|NCT04719312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106157|NCT05856526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724216|NCT02943733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724217|NCT01522365|RANDOMIZED|PARALLEL||TREATMENT||NONE||Split-mouth design, i.e. each subject have both treatment arms.||||
33724218|NCT05188651|||COHORT||PROSPECTIVE|||||||
33724219|NCT01678417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724220|NCT00409617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724221|NCT01807897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Continuous positive airway pressure (CPAP) and supplemental oxygen|f|f|f|t
33724222|NCT02469428|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33724223|NCT05094219|||COHORT||PROSPECTIVE|||||||
33724224|NCT01828892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838034|NCT03409861|||OTHER||OTHER|||||||
33838035|NCT01857375|||||PROSPECTIVE|||||||
34031129|NCT02396511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031130|NCT00003198||||TREATMENT||||||||
34031131|NCT05475860|||COHORT||PROSPECTIVE|||||||
34031132|NCT04456088|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two phase study. The first 10 subjects will be treated with 80ppm NO; The remaining 40 subjects will be randomized in 1:1 ratio with subjects receiving 150 NO+SST or the SST alone.||||
34031133|NCT02829203|||CASE_CONTROL||PROSPECTIVE|||||||
34031134|NCT04561271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"2 arms, one called foot reflexology who receive one session, the second called toucher massage."||||
34031135|NCT02277379|||COHORT||PROSPECTIVE|||||||
34031136|NCT01930201|||COHORT||RETROSPECTIVE|||||||
34106158|NCT01465165|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106159|NCT06455631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34106160|NCT02489487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149036|NCT05040906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149037|NCT00114920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34031137|NCT03835702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34031138|NCT01391715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031139|NCT04631783|||CASE_CONTROL||RETROSPECTIVE|||||||
34031140|NCT05330260|||COHORT||PROSPECTIVE|||||||
34031141|NCT03740581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031142|NCT02666729|||CASE_ONLY||PROSPECTIVE|||||||
34031143|NCT05811416|||COHORT||RETROSPECTIVE|||||||
34031144|NCT02989909|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031145|NCT02784561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149038|NCT05332418|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group which received the selected exercise program and the study group received the same exercise training program in addition to electromagnetic field therapy, three times per week for four weeks.||||
34149039|NCT04252495|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Healthy subjects will be matched to subjects with moderate hepatic impairment||||
34149040|NCT00514228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149041|NCT00987701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149042|NCT00421642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149043|NCT01081639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149044|NCT00081211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149045|NCT05992194|||COHORT||PROSPECTIVE|||||||
34149046|NCT05957614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149047|NCT02049138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149048|NCT01669213|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33724225|NCT04177602|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil based chemoradiotherapy (CRT) and a standard - calibration arm (internal control) with capecitabine CRT flanked by translational research|t|f|f|f
33724226|NCT01168635|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724227|NCT01820754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724228|NCT01386736|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34031146|NCT02348112|||COHORT||PROSPECTIVE|||||||
34031147|NCT05250297|||COHORT||PROSPECTIVE|||||||
34031148|NCT00470964|RANDOMIZED|PARALLEL||||DOUBLE||||||
33724229|NCT05487742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|no participant ,investigator or outcome assessor in ICU know in which group patient is allocated||t|f|t|t
34031149|NCT06297421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724230|NCT06310330|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking|Randomization 1:1 to two different modes of follow-up||||
33838036|NCT05963945|||COHORT||RETROSPECTIVE|||||||
33838037|NCT00691249|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33838038|NCT02868840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33838039|NCT06098053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Just participants were unaware of which intervention they are being given|Single blind RCT in which Two groups were formed|t|f|f|f
34031150|NCT05045690|||OTHER||CROSS_SECTIONAL|||||||
34031151|NCT02567279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031152|NCT04253665|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 group pre/post-intervention comparative design: 90 control patients will be recruited before the implementation of the intervention in study units. This recruitment will last approximately two months, according to the estimated turnout of patients in these units. After this control period, 30 other patients will be recruited to receive the intervention. In this sense, participants are assigned to one group or the other, depending on the phase of the study.||||
34031153|NCT05323708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Patient, Investigator)||t|f|t|f
34031154|NCT02208089|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Interventional case series with matched historical controls||||
34031155|NCT04192461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724231|NCT06220708|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724232|NCT06322329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031156|NCT06578871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The SUPERIOR trial employs a 1:2 randomization ratio using a permuted block design with block sizes known only to the statistician. Stratification factors include smoking status (\>10 pack-years vs. ≤10 pack-years) and pathologic nodal burden (1 node positive vs. \>1 node positive). Although participants and treating clinicians are aware of the treatment allocations, outcome assessors and data analysts are blinded to the treatment arms to ensure unbiased assessment and analysis of trial results.|This is a randomized phase II study. Patients will be randomized between current standard of care treatment (Arm 1) vs. omission of radiation mucosal surfaces (Arm 2) in a 1:2 ratio.|f|f|f|t
34031157|NCT03189992|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34031158|NCT02057887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031159|NCT02354404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031160|NCT05697614|RANDOMIZED|PARALLEL||TREATMENT||NONE||The subjects will be randomized into 2 groups : intervention and control. The subjects will be recruited by consecutive sampling technique||||
34031161|NCT06328049|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33838040|NCT00720031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838041|NCT02847429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838042|NCT00129753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838043|NCT02826382|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838044|NCT03503929|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Open label, prospective, single site, multi-investigator||||
33838045|NCT01575873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838046|NCT04243057|||OTHER||OTHER|||||||
33838047|NCT04261764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838048|NCT00531336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839219|NCT05187429|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"In Part 1 (Cohort A) - there is no masking and the Nivolumab administered is open-labeled. There is no randomization in this group.~In Part 2 (Cohort B) - the participant, care provider and investigator are all masked to the treatment allocation. Participants in this group will be assigned to intervention treatment by chance."||t|t|t|f
33839220|NCT04991376|||CASE_ONLY||PROSPECTIVE|||||||
34106161|NCT03253627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will complete the baseline assessment and be randomly assigned to study group in a permuted block design stratified by receipt of chemotherapy (i.e., two strata). It will not be possible to blind study participants or interventionists to group assignment. To reduce bias, research staff who conduct assessments, including the PI, will be blinded to group assignment (i.e., single blind). Participants will be reminded not to reveal their group assignment to study staff conducting assessments. The study biostatistician will have no direct contact with study participants and will not be blinded to group assignment. The biostatistician will produce and maintain the randomization codes for the permuted blocks. Randomization may only be unmasked by the biostatistician at the completion of data collection, or for reporting of serious adverse events or unanticipated problems for which it will be essential to provide information to the PI on group assignment.|A pilot, single-center randomized controlled trial of the preliminary efficacy of an eight-week, group-based Mindfulness-Based Stress Reduction intervention versus Health Enhancement Program active control (i.e., two groups, parallel design) to improve neural markers of changes in cognitive function in postmenopausal women receiving aromatase inhibitor therapy for breast cancer. Participants will be stratified in a permuted block design by receipt of chemotherapy (i.e., two strata). Data will be collected at up to three time points using a repeated measures design (i.e., pre-intervention, post-intervention, approximately three months after the intervention). The study groups will meet at NYU for MBSR or HEP. Neuropsychological, self-report, and biospecimen data collection will be conducted at the Bluestone Center. Neuroimaging data will be collected at the NYU Center for Brain Imaging.|f|f|t|t
34106162|NCT05713838|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients eligible for this trial will be enrolled into one of two cohorts:~Cohort 1 will consist of participants with PD-L1 combined positive score (CPS) \< 10.~Cohort 2 will consist of participants with PD-L1 CPS ≥ 10.~Patients in both cohorts will receive immunotherapy with durvalumab in parallel to 2 cycles FLOT chemotherapy induction followed by immunotherapy with durvalumab in parallel with 3 cycles of modified FOLFOX chemotherapy plus concomitant radiation (50 Gy).~After initial core treatment and endoscopic re-evaluation patients with complete remission will receive durvalumab monotherapy (1500 mg, IV, Q4W) for a maximum of 12 cycles.~Patients in whom a locoregional persistence is confirmed will be offered surgical resection instead of entering the the maintenance period."||||
34106163|NCT06296355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106164|NCT05752838|||OTHER||CROSS_SECTIONAL|||||||
34106165|NCT00281437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106166|NCT05384548|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome measures will be collected electronically without involvement of the researchers.|||||
34106167|NCT06570226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34106168|NCT04174482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106169|NCT05943574|||COHORT||OTHER|||||||
34106170|NCT06418269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34106171|NCT02412436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106172|NCT00621114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106173|NCT01877057|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34106174|NCT04106635|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The group assignments were sealed in opaque envelopes by a research assistant not involved in the study.|Randomized double blinded clinical trial|t|f|t|t
34106175|NCT05805150|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34106176|NCT02743312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34106177|NCT04109482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106178|NCT01527955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805850|NCT03901989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The clinical study is a randomized, double-blinded, controlled study aimed to assess the effect of zeolite-intervention in osteoporotic patients on the bone mineral density and bone turnover in comparison to osteoporotic patients control group that received the placebo over a period of for 12 months. The study population will consist of 100 patients with osteoporosis defined according BMD criteria: T score -2, 5 on the femoral neck, and, or T -2, 5 on L1-L5, who have not been treated before, or in whom privies treatment did not been successful, despite a gender or age. The Panaceo and Placebo groups will be divided into 50 and 50 patients.|t|f|t|f
34106179|NCT06458374|||CASE_ONLY||PROSPECTIVE|||||||
34106180|NCT06478524|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|Masking cannot be performed as participants will know whether they are receiving live or recorded music.|Non-Parallel, Sequentially Allocated study design: This study involves two arms, with one arm receiving a live music intervention, and the other arm receiving a pre-recorded music intervention. The interventions are administered sequentially, with the live music intervention being conducted first across four patient groups, followed by the pre-recorded music intervention for a separate set of four patient groups.||||
34106181|NCT05571839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106182|NCT01514578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106183|NCT05219487|||OTHER||PROSPECTIVE|||||||
34106184|NCT03629678|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34106185|NCT00656643|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34106186|NCT01348906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34106187|NCT06641674|||CASE_ONLY||PROSPECTIVE|||||||
34106188|NCT06675877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||the child lay on the bed and wore virtual reality eyeglasses, the eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.|t|f|f|t
34106189|NCT06641570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34106190|NCT01767987|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34106191|NCT05010005|NA|SEQUENTIAL||TREATMENT||NONE||This phase I study includes a dose escalation phase and a dose expansion phase.||||
34106192|NCT00385515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106193|NCT04989166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106194|NCT06638840|||CASE_ONLY||PROSPECTIVE|||||||
33805851|NCT02524769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805852|NCT03018561|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33805853|NCT03766191|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33805854|NCT03344718|||COHORT||CROSS_SECTIONAL|||||||
34106195|NCT03717454|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106196|NCT03193515|||COHORT||PROSPECTIVE|||||||
34106197|NCT00002809||||TREATMENT||NONE||||||
34106198|NCT05550428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|It is doubled blinded, a subject 's specific ID card will be provided for each of the enrolled subject and the investigators don't know whether it is PEMF or Sham treatment for that subject's specific ID card. And the investigator will ask the manufactory about the number of grouping at the end of the study.|Participants will be assigned into either treatment group or sham group.|t|t|t|t
34106199|NCT02136355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106200|NCT06511193|||COHORT||PROSPECTIVE|||||||
34106201|NCT01173003|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34106202|NCT03696186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106203|NCT05878366|RANDOMIZED|PARALLEL||OTHER||NONE|"Laboratory analysis and impact analysis teams will be blinded to intervention arm.~Entomology staff involved in the mosquito feeding assays will be blinded for the parasitology results."|This study involves and Operational evaluation of a modified existing intervention delivered in independent clusters. The project and its implementation are prepared in direct interaction with the Ministry of Health (MoH) to tailor data collection to local needs.||||
34106204|NCT06639932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34106205|NCT04279067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be blinded to the whether participants are in Group 1 or 2.|The study is design as an early Phase II two-arm randomized trial. The experimental group will receive BCI-FES dorsiflexion therapy paired with conventional physiotherapy (Group 1), while the control arm will receive dose- and intensity-matched conventional physiotherapy (Group 2). A total of 80 chronic stroke survivors with gait impairment due to foot-drop will be recruited and randomized evenly into the 2 groups (33/group).|f|f|f|t
34106206|NCT04914273|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33805855|NCT06682728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805856|NCT00680199|||COHORT||PROSPECTIVE|||||||
33805857|NCT01988649|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33805858|NCT06509243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized, placebo-controlled, double-blind 12-month trial|f|f|t|f
34031162|NCT03352687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031163|NCT00527410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031164|NCT00193050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031165|NCT04189601|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031166|NCT04728009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34031167|NCT01868347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031168|NCT03345680|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34031169|NCT00074555|||COHORT||PROSPECTIVE|||||||
34031170|NCT02567240|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34031171|NCT04077944|||CASE_CONTROL||PROSPECTIVE|||||||
34031172|NCT00628875|||CASE_ONLY||PROSPECTIVE|||||||
34031173|NCT04177446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031174|NCT01596439|||COHORT||PROSPECTIVE|||||||
34031175|NCT03156504|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34031176|NCT06498843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031177|NCT03048227|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34031178|NCT05588310|||COHORT||RETROSPECTIVE|||||||
34031179|NCT04441151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34031180|NCT04370002|||OTHER||PROSPECTIVE|||||||
34031181|NCT05584111|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031182|NCT02903706|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34031183|NCT06239727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031184|NCT02771769|||CASE_ONLY||PROSPECTIVE|||||||
34031185|NCT04665986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031186|NCT03138408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031187|NCT01173952|||CASE_ONLY||PROSPECTIVE|||||||
34031188|NCT03438019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031189|NCT02864355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031190|NCT02068612|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031191|NCT05708430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031192|NCT06142474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031193|NCT06372574|NA|SEQUENTIAL||TREATMENT||NONE||||||
34031194|NCT01725971|||||CROSS_SECTIONAL|||||||
33724233|NCT03554226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724234|NCT02617823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031195|NCT00412386|||CASE_CONTROL||PROSPECTIVE|||||||
33724235|NCT02269865|||CASE_CONTROL||PROSPECTIVE|||||||
34031196|NCT00003392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031197|NCT04363567|||COHORT||OTHER|||||||
34031198|NCT00836784|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34031199|NCT01920529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34031200|NCT04304092|RANDOMIZED|PARALLEL||TREATMENT||NONE|exercise trial, no blinding|||||
34031201|NCT02683421|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031202|NCT05884944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34031203|NCT00626561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031204|NCT00492440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031205|NCT05741229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031206|NCT01514461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031207|NCT02543944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031208|NCT05856851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031209|NCT05691816|||OTHER||PROSPECTIVE|||||||
34031210|NCT01749423|||CASE_ONLY||RETROSPECTIVE|||||||
34031211|NCT04333485|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34031212|NCT00273897||||TREATMENT||||||||
34031213|NCT03635476|||OTHER||OTHER|||||||
34031214|NCT01277211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031215|NCT05298826|||OTHER||RETROSPECTIVE|||||||
34031216|NCT02995863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031217|NCT05729490|NA|SINGLE_GROUP||OTHER||NONE||||||
34031218|NCT03516656|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031219|NCT05466045|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34031220|NCT01470092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031221|NCT00000542|RANDOMIZED|||PREVENTION||||||||
34031222|NCT02633787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031223|NCT02688660|||OTHER||OTHER|||||||
34031224|NCT01513278|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34031225|NCT06340607|||COHORT||RETROSPECTIVE|||||||
34031226|NCT05082974|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34031227|NCT01815476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031228|NCT06576648|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34031229|NCT02715011|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031230|NCT01949220|||COHORT||PROSPECTIVE|||||||
34031231|NCT01380548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34031232|NCT00971373|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34031233|NCT03409237|||CASE_CONTROL||PROSPECTIVE|||||||
34031234|NCT00564512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031235|NCT00789035||PARALLEL||TREATMENT||||||||
34031236|NCT04622241|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not possible due to the nature of the intervention.|Phase II will be carried out as a cluster-randomized trial with 3 arms (2 interventions selected from the pilot study, and 1 control). There will be 20 clusters per arm (60 clusters total) and a cluster will be defined as an enumeration area within a village. All participating households in the selected clusters will have PBO LLINs, and households in intervention clusters will also receive the specified housing modifications. The impact of the interventions on malaria burden will be assessed through a cohort study, cross-sectional community surveys, entomology surveillance, a qualitative study, and an economic evaluation. The primary outcome of the trial will be clinical malaria incidence in children aged \< 60 months.||||
34031237|NCT02881697|||OTHER||PROSPECTIVE|||||||
34031238|NCT03872687|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34031239|NCT02430480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031240|NCT00365703|RANDOMIZED|PARALLEL||||NONE||||||
34031241|NCT03478722|||COHORT||CROSS_SECTIONAL|||||||
34031242|NCT03026998|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031243|NCT02719275|||COHORT||RETROSPECTIVE|||||||
34031244|NCT03892018|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This will be an open-label, 2-part, crossover study to assess the effect of food on Oraxol exposure. The study will consist of the following periods: Screening, Baseline, Periods 1 and 2 (Part A), Treatment (Part B), and Follow-up. Part A will assess the effect of food on Oraxol pharmacokinetics. In Part A, subjects will be randomized to the sequence (fed/fasted or fasted/fed conditions) under which they will be administered single-dose treatment after an overnight fast. There will be a minimum of 7 days after Period 1 treatment before subjects cross over to Period 2 treatment. Subjects who have participated in the PK assessments in Part A of the study may continue into Part B, during which Oraxol will be dosed for 3 consecutive days per week under fasting conditions.||||
34031245|NCT02166710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031246|NCT00293111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031247|NCT03892603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031248|NCT06277089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031249|NCT03923647|||CASE_CONTROL||PROSPECTIVE|||||||
34031250|NCT04050215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031251|NCT05694689|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34031252|NCT05257681|NA|SINGLE_GROUP||TREATMENT||NONE||This study is expected to enroll a total of 20 subjects with a follow-up period of 3 months. All interventions and follow-up will be performed at the BIDMC. In current medical practice, emphysema patients that fail to achieve target lung volume reduction after endobronchial valves placement, are continued on current medical management for their COPD, with consideration for lung transplantation should they be eligible depending on clinical circumstances and degree of lung function impairment. The investigators plan to offer this patient population the possibility to undergo a VATS fissure completion and adhesiolysis.||||
34031253|NCT03123068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo and active treatments will be formulated in identical capsules, and bottled and labeled with coded study numbers that will allow for all parties to remain blinded throughout the data collection phase.||t|t|t|t
34106207|NCT03518060|||COHORT||PROSPECTIVE|||||||
34106208|NCT02320552|||COHORT||PROSPECTIVE|||||||
34106209|NCT05942222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106210|NCT03605550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106211|NCT02167347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34106212|NCT03320993|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Data analysis will be carried out by a person not involved in the study (she/he will be blind to the study condition)|3-period, 3-treatment crossover design|f|f|f|t
34106213|NCT05392283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106214|NCT04046991|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34106215|NCT00775671|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34106216|NCT01162785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106217|NCT04585581|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106218|NCT00576745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106219|NCT03766906|NA|SINGLE_GROUP||OTHER||NONE||One-arm, single-group, feasibility study with parent/student dyads.||||
34106220|NCT06198777|||OTHER||CROSS_SECTIONAL|||||||
34106221|NCT05351229|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Intervention is intrathecal morphine in the intervention group. The drug is PF morphine|t|t|t|t
34106222|NCT03092011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The family of the patient (baby), medical provider team and nursing will be masked to the specific arm. Investigator, unless is an active medical provider at the time, and pharmacist will not be masked.|Randomized double blind prospective trial|t|t|f|f
34106223|NCT04501705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106224|NCT03735901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Study participants will be randomized 1:1|t|t|t|t
34106225|NCT06632860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106226|NCT04776824|||CASE_ONLY||PROSPECTIVE|||||||
34106227|NCT02973022|||CASE_CONTROL||PROSPECTIVE|||||||
34106228|NCT03027765|||OTHER||CROSS_SECTIONAL|||||||
34106229|NCT06522386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106230|NCT06284915|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The study will be performed in a modified double-blind fashion:~* Investigators and study staff who conduct the safety assessment, and the participants parent/ legally acceptable representative will not know which study intervention is administered~* Only the study staff who prepare and administer the study intervention and are not involved with the safety evaluation will know which study intervention is administered"||t|f|t|t
34106231|NCT06537375|||COHORT||RETROSPECTIVE|||||||
34106232|NCT03934684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106233|NCT06381791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is designed as a randomized, double-blinded controlled trial. Patients will be recruited in clinic preoperatively prior to their scheduled procedure. Patients and the treating physician/research study team will be blinded to the treatment arm. Patients will be randomized to either the test group, which will be prescribed Epidiolex (cannabidiol) postoperatively in addition to the standard pain regimen, or the control group, which will have a placebo provided in addition to the standard pain regimen.|t|t|t|f
34106234|NCT05516147|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive the intervention||||
34106235|NCT06644625|||COHORT||PROSPECTIVE|||||||
34106236|NCT06674980|RANDOMIZED|PARALLEL||TREATMENT||NONE|"In addition to the principal investigator's determination of complete closure an independent assessment of the primary endpoint will be performed. Two wound care specialists not associated with the trial (The Reviewers) will review the digital images of ulcers that have healed. They will review the closed visit and the closure confirmation visit. Deidentified digital images taken with the imaging device will be provided to the reviewers. Two reviewers will assess each photograph and be blinded to the arm in the study."|||||
34106237|NCT05175001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|None of the participants know which group they were in,neither of the investigators and outcomes assessor.|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.|t|f|t|t
34106238|NCT01197300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106239|NCT05753228|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Case-control study||||
34106240|NCT06168968|||COHORT||PROSPECTIVE|||||||
34106241|NCT06564402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106242|NCT06230146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|"Group I (n=15): Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution) Dose: injection of 0.1 ml\\cm3 of the lesion (10) avoiding subcutaneous injection as much as possible especially in fatty areas.~Group II (n=15): Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible.~Group III (control group) (n=15): Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml ."|t|f|f|t
34106243|NCT02576197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34106244|NCT06643897|NA|SINGLE_GROUP||OTHER||NONE||"The substudy is a transversal, one arm, multicentric study including the staff participating in the HOLA study, to identify the barriers and facilitators of implementation of the out-of-hospital administration of CAB+RPV LA following a qualitative descriptive design.~All study staff who participate in the substudy will be interviewed through a 40-50 minute-qualitative interview"||||
34106245|NCT03627468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106246|NCT05912634|||COHORT||RETROSPECTIVE|||||||
34106247|NCT06637553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106248|NCT02275533|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106249|NCT06642467|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34106250|NCT03032809|||OTHER||PROSPECTIVE|||||||
34106251|NCT06422247|||COHORT||RETROSPECTIVE|||||||
34106252|NCT05214508|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149049|NCT05108805|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34149050|NCT02454153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149051|NCT01008462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805859|NCT04856085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805860|NCT05063864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34106253|NCT06300437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"In this study, children undergoing elective surgery under general anesthesia will be randomized into 2 groups.~* Group (J): will include the children who will receive jaw thrusting during fiberoptic intubation.~* Group (C): will include the children who will not receive jaw thrusting (just sub laxed open mouth)"|t|f|f|t
34106254|NCT06643533|||COHORT||PROSPECTIVE|||||||
34106255|NCT04507581|||OTHER||PROSPECTIVE|||||||
34106256|NCT01428713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106257|NCT03895476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106258|NCT02445365|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34106259|NCT06643715|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The PANDA (Pancreatic Cancer Detection with Artificial Intelligence) early screening model was developed by Alibaba DAMO Academy.It employs a fully automated pancreatic segmentation model using the VoxelMorph algorithm, which enhances registration speed and accuracy. By building a self-learning framework, the model efficiently obtains precise annotations of non-contrast CT images. The core network is based on Transformer technology, combined with the MaskFormer model to improve diagnostic accuracy.~The upgraded PANDA PLUS model has improved upon the original PANDA model by enhancing its ability to differentiate between pancreatitis, pancreatic cystic lesions, and eliminating interference from adjacent organs such as the common bile duct and duodenum. These advancements have effectively increased the model's clinical utility, making it more reliable for real-world applications in diagnosing pancreatic conditions."||||
34106260|NCT06577441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106261|NCT06638125|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase I is a single centre, prospective, clinical trial evaluating the safety, feasibility, and learning curve of adding 3D VR anatomical reconstructions and real-time intraoperative mapping using the Elucis platform to NIF-guided targeted segmental resection. Phase II is a single centre, prospective, randomized controlled trial evaluating if this novel operation (Intervention) can increase the rate of successful completion of a segmental resection when compared to Synapse 3D with intraoperative NIF-mapping using intravascular ICG (Control). Patients who are scheduled to undergo robotic pulmonary segmental resection at St. Joseph's Healthcare Hamilton will qualify for inclusion in the study. Exclusion criteria will be patients with tumors \> 3 cm or those with clinical evidence of N1 or N2 disease on preoperative imaging.||||
34106262|NCT01486329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106263|NCT06501352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34106264|NCT03787147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The sealed envelope is randomized and blinded so no one will know which group the participant falls and its revealed only after the participant opens the sealed envelope.||t|f|t|f
34106265|NCT03671395|||COHORT||PROSPECTIVE|||||||
34106266|NCT03030534|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are assigned to two groups. that is two locations (study centres) will be selected for the study||||
34106267|NCT05144737|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34106268|NCT06638086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The primary investigator collects and analyzes the data using self-designed questionnaires. Typically, in such studies, the intervention (route of acetaminophen) would be known to the healthcare providers administering. Therefore, masking of the participants and providers might not be feasible.|"The interventional study model for this article is a Parallel Assignment model.~In this study, neonates are randomly assigned to one of two groups: one group receives intravenous (IV) acetaminophen, and the other group receives rectal acetaminophen. The outcomes, such as the need for rescue analgesia, time to rescue analgesia, and reduction in pain scores, are then compared between these two parallel groups to assess the effectiveness of the different administration routes for managing postoperative pain in neonates."||||
34106269|NCT05571514|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Stratified randomization :~The study will be double-blinded to avoid follow-up bias and assessment bias. The maintenance of the blind will be guaranteed by the fact that the capsules of mother-of-pearl will be indistinguishable from those of CaCO3 (same shape, same color, same weight). Only the internal use pharmacies (IUP) of each center will be open, for the attribution of the treatment."|multicentre, double-blind randomized versus positive comparator study|t|t|t|t
34106270|NCT06643546|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106271|NCT01755403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106272|NCT06539442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106273|NCT05680636|||OTHER||PROSPECTIVE|||||||
34106274|NCT01531036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106275|NCT06318546|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34106276|NCT04499534|||COHORT||PROSPECTIVE|||||||
34106277|NCT03088111|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34106278|NCT04206943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106279|NCT06643793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106280|NCT04022213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106281|NCT01475825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106282|NCT05679557|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, multicenter, randomized clinical trial||||
34106283|NCT01157494|||COHORT||CROSS_SECTIONAL|||||||
34106284|NCT01946880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106285|NCT06365346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34106286|NCT00586937|||CASE_ONLY||PROSPECTIVE|||||||
33805861|NCT06601504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805862|NCT03572257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33805863|NCT05510700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805864|NCT02681900|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33805865|NCT05980559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805866|NCT06046859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers collecting survey data will be blinded to patients' intervention status.||f|f|t|f
33805867|NCT00457119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805868|NCT00429338|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33805869|NCT04700410|NA|SINGLE_GROUP||SCREENING||NONE|Independent assessment of BBPS (photos).|single arm international multicenter colonoscopy trial||||
33805870|NCT06221969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805871|NCT02757469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805872|NCT03709706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|Participants will receive GSK3377794, either as monotherapy or in combination with pembrolizumab.||||
33805873|NCT04139005|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34031254|NCT05710029|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031255|NCT01922505|||CASE_ONLY||PROSPECTIVE|||||||
34031256|NCT04604340|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031257|NCT02737774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031258|NCT05190939|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients undergoing hysterectomy are randomized to one of 4 study arms for cystoscopy: 1) dye/saline 2) dye/water 3) no-dye/saline and 4) no-dye/water||||
33805874|NCT04615520|||COHORT||PROSPECTIVE|||||||
33805875|NCT02139813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805876|NCT02157116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805877|NCT04634682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805878|NCT00421759|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33805879|NCT05359796|||COHORT||PROSPECTIVE|||||||
33805880|NCT04584866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective randomized single-blinded controlled superiority trial|f|f|f|t
33805881|NCT00872872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805882|NCT02673216|||COHORT||PROSPECTIVE|||||||
33805883|NCT05711693|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|MRI doctors will be blinded concerning LDV PWV values. Doctors performing LDV will not have access to MRI reports. Data will be consolidated and database frozen before reconciling MRI and LDV data|Comparison of methods||||
33805884|NCT04210258|||OTHER||PROSPECTIVE|||||||
33805885|NCT04615416|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive a 9-session version of Emotion Regulation Training delivered semi-weekly via synchronous telehealth using videoconferencing software and an asynchronous Internet-based Online platform to supplement the content covered in each session.||||
33805886|NCT00571649|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33805887|NCT04516057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805888|NCT01785446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33805889|NCT00000749||PARALLEL||PREVENTION||||||||
33805890|NCT05292521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805891|NCT01606813|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33805892|NCT04790331|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33805893|NCT03771066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be a double-blinded study. Research staff collecting data and participants will not know treatment allocation.|This experimental study is a 2-group randomized, clinical trial comparing a 4-day energy balance diet plus oral BPA consumption at 50 ug/kg body weight (Diet+BPA) vs. 4-day energy balance diet plus oral placebo consumption (Diet+No BPA). Forty participants will be randomized to Diet+BPA and Diet+No BPA and will reside in a supervised environment at Cal Poly's sleep research facilities for 6 days (2-day baseline run-in, followed by 4-day treatment). Main outcome measures (muscle insulin sensitivity and hepatic glucose suppression) will be assessed at baseline and treatment periods.|t|f|f|t
33805894|NCT06698510|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33805895|NCT01291628|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33805896|NCT06522893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805897|NCT04922242|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Cross-sectional model||||
33805898|NCT06638099|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805899|NCT05211232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33805900|NCT05737602|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33805901|NCT03758391|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective cohort study||||
33805902|NCT01258036|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805903|NCT02707666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805904|NCT06221215|||CASE_CONTROL||PROSPECTIVE|||||||
33805905|NCT00475241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Assessors|Prolonged Exposure and Present Centered Therapy|f|f|f|t
33805906|NCT04623489||||||NONE||||||
33805907|NCT01471691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805908|NCT02313350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805909|NCT03452254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be assigned to the active tDCS plus mCIMT group or to the sham tDCS plus mCIMT group using randomized blocking to ensure the balance between the treatments. Once the person in charge of recruiting receives the patient's informed consent, he will notify this to the person in charge of randomization who will not have any relationship with the patient, will not know the patient's clinical record, and will not be influenced by the head researchers, the evaluators, or the therapist. This person will send a text message to the person responsible for programming and installing the tDCS, who will proceed to set the tDCS either active or simulated. Patients, treating occupational therapists, and the results evaluator will be kept masked to the assignment process.|Sham randomized multicenter double clinical trial.|t|t|t|t
33805910|NCT04029090|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|This study is a single-blind study. Subjects and Electrocardiogram (ECG) reviewer will be blinded. Investigator and Sponsor will be unblinded.||t|f|f|t
33805911|NCT03903965|||COHORT||PROSPECTIVE|||||||
33805912|NCT01858285|||COHORT||CROSS_SECTIONAL|||||||
33805913|NCT05185245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839221|NCT05050747|||COHORT||PROSPECTIVE|||||||
33839222|NCT02491151|||COHORT||PROSPECTIVE|||||||
34031259|NCT00871208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031260|NCT05667025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031261|NCT05085262|||COHORT||PROSPECTIVE|||||||
34031262|NCT05225779|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34031263|NCT01133457|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031264|NCT01957397|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34031265|NCT02153983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In the randomized portion of the trial, all participants, Study Site staff, and pathology and laboratory personnel are blinded to the individual assignment of the order in which colchicine and placebo are administered.|Note that only 2 of the arms are randomized. Three arms are observational and one is open-label treatment.|t|t|t|t
34031266|NCT00556868|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34031267|NCT05915260|||COHORT||PROSPECTIVE|||||||
34031268|NCT01074944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031269|NCT04138381|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib/II, single-arm, two-cohort, non-randomized, open-label, multicenter, national clinical trial, single agent, combinations products||||
34031270|NCT04428814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031271|NCT04970303|||CASE_CONTROL||PROSPECTIVE|||||||
34031272|NCT02542956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031273|NCT00954343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031274|NCT01764399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031275|NCT02245412|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031276|NCT03352739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031277|NCT01509274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031278|NCT02139137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031279|NCT02841982|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34031280|NCT06241625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031281|NCT02392949|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34031282|NCT03956940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031283|NCT00958893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031284|NCT03837574|||COHORT||PROSPECTIVE|||||||
34031285|NCT02888730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031286|NCT04138498|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34031287|NCT00445029|||DEFINED_POPULATION||PROSPECTIVE|||||||
34031288|NCT02051556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34031289|NCT01748201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031290|NCT00978874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031291|NCT01644617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031292|NCT04407273|||CASE_ONLY||PROSPECTIVE|||||||
34031293|NCT00948532|||COHORT||PROSPECTIVE|||||||
34031294|NCT05892744|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single-arm treatment||||
34031295|NCT00451178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031296|NCT05543798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031297|NCT00670969|||COHORT||PROSPECTIVE|||||||
34031298|NCT06490978|||COHORT||PROSPECTIVE|||||||
34031299|NCT06581029|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031300|NCT03561649|NA|SINGLE_GROUP||SCREENING||NONE||||||
34031301|NCT06025240|||COHORT||OTHER|||||||
34031302|NCT03543215|||COHORT||PROSPECTIVE|||||||
34031303|NCT05708716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031304|NCT05124119|||OTHER||CROSS_SECTIONAL|||||||
34031305|NCT06124729|||COHORT||RETROSPECTIVE|||||||
34031306|NCT02928055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031307|NCT05366140|||COHORT||PROSPECTIVE|||||||
34031308|NCT00368797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031309|NCT06116630|||CASE_CONTROL||PROSPECTIVE|||||||
34031310|NCT05269095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031311|NCT01790087|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34031312|NCT05719935|||COHORT||PROSPECTIVE|||||||
34031313|NCT01275729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031314|NCT02191293|||COHORT||PROSPECTIVE|||||||
34106287|NCT04383639|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Since no placebo was found, the subjects will know the treatment they are receiving in each case. Nevertheless, the outcome assessor will not know to which treatment corresponds each sample.|A: control period; B: mixture of cocoa and carob consumed together with breakfast; C: mixture of cocoa and carob consumed 10 h before breakfast. All the subjects will pass the three treatments, in randomized order. The three periods will be separated by a two weeks washing period.|f|f|f|t
34106288|NCT03136432|||CASE_ONLY||PROSPECTIVE|||||||
34106289|NCT05127265|||CASE_ONLY||PROSPECTIVE|||||||
34106290|NCT06674317|RANDOMIZED|PARALLEL||OTHER||NONE||"Group 1: I-CBTi group: This group you will have access to the internet delivered cognitive behavioral therapy for insomnia intervention following the completion of the first study entry questionnaire.~Group 2: WLC group: This group will be offered access to the internet delivered cognitive behavioral therapy for insomnia intervention AFTER completion of the third online questionnaires 5 months after group assignment."||||
34106291|NCT06317779|||CASE_CONTROL||RETROSPECTIVE|||||||
34106292|NCT00370578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106293|NCT00998959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106294|NCT05130281|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a randomized clinical trial designed to assess the feasibility of Maya, an app-based CBT intervention, and provide preliminary efficacy data for three different incentive strategies. Participants will be randomized to one of three incentive conditions: 1) a social support condition, 2) a gain-framed condition in which participants can earn points for completing assigned therapy sessions, and 3) a loss-framed condition in which participants begin with a specified number of points that they can lose for failing to complete assigned therapy sessions on time."||||
34106295|NCT01830387|||CASE_CONTROL|||||||||
34106296|NCT06675214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106297|NCT05504083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106298|NCT02076009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031315|NCT03335137|||CASE_CONTROL||PROSPECTIVE|||||||
34031316|NCT03203200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031317|NCT00091611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031318|NCT01776632|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34031319|NCT00984724|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34031320|NCT03851029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031321|NCT06165887|||COHORT||PROSPECTIVE|||||||
34031322|NCT04960592|||COHORT||PROSPECTIVE|||||||
34031323|NCT04388449|||COHORT||PROSPECTIVE|||||||
34031324|NCT05333055|||COHORT||CROSS_SECTIONAL|||||||
34031325|NCT03905577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106299|NCT01283945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724236|NCT04754737|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled, un-blinded||||
34031326|NCT04663971|||COHORT||CROSS_SECTIONAL|||||||
33724237|NCT05948202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled trial|f|f|t|t
33724238|NCT01775943|||CASE_ONLY||RETROSPECTIVE|||||||
33724239|NCT06185959|||COHORT||PROSPECTIVE|||||||
33724240|NCT01102530|||COHORT||RETROSPECTIVE|||||||
33724241|NCT02989350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724242|NCT04253288|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33724243|NCT04020068|||OTHER||CROSS_SECTIONAL|||||||
33724244|NCT05071183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724245|NCT05217251|||COHORT||PROSPECTIVE|||||||
33724246|NCT02879409|RANDOMIZED|PARALLEL||OTHER||NONE|This is an randomized open label clinical trial.|||||
33724247|NCT02283710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33724248|NCT03905460|||COHORT||PROSPECTIVE|||||||
33724249|NCT00974012|RANDOMIZED|CROSSOVER||||NONE||||||
34031327|NCT02554162|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34031328|NCT01555216|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031329|NCT01364376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031330|NCT01457937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031331|NCT05723939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34031332|NCT03340090|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two randomized groups of 100 patients will undergo standard CABG procedure in Cardio-Pulmonary Bypass (CPB). In first group (100 patients) two pieces of Hemopatch will be applied in one patient. Second group is the control group without above described intervention.||||
34031333|NCT03133000|||COHORT||PROSPECTIVE|||||||
34031334|NCT04205058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are masked about the type of coffee administrated (standard coffee versus caffeine-free coffee). Masking about administration of hot water is not feasible.|randomised placebo-controlled single blinded trial|t|f|f|f
34031335|NCT02044913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031336|NCT06056141|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicentre randomised controlled trial||||
34031337|NCT05561218|||CASE_ONLY||PROSPECTIVE|||||||
34031338|NCT02539966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724250|NCT03024723|||COHORT||PROSPECTIVE|||||||
33724251|NCT00002304||||TREATMENT||||||||
33724252|NCT02109146|RANDOMIZED|PARALLEL||TREATMENT||NONE||After confirming eligibility by the investigators, patients without residual tumors on the CT/MRI were consented and randomly assigned in a 1:1 ratio into the adjuvant TACE group or the observation group. Allocation of treatment group was done with a computer-generated random number list.||||
33724253|NCT01802658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724254|NCT02086864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724255|NCT00003901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724256|NCT02664909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724257|NCT03870828|||COHORT||PROSPECTIVE|||||||
33724258|NCT01733446|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724259|NCT05071885|RANDOMIZED|PARALLEL||TREATMENT||NONE||Game-based Exercise program||||
34031339|NCT00442962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031340|NCT04678050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The pedo-dentist, the independent observer/data collector, and participants will be blind to the type of intervention. The study drugs will be prepared by an anesthesiologist who will not participate in the observation of the data. All the lines and syringes will be wrapped to mask colors of the sedative drugs, and the syringes will be label coded.|The study participants will be allocated into two equal groups. Subjects in group I will receive ketofol solution (ketamine/propofol mixture, each mL contains 5 mg of ketamine plus 10 mg of propofol). A loading dose of 0.125 mL/kg will be administered intravenously (IV) over 10 min, followed by maintenance infusion at a rate of 0.05-0.125 mL/kg/h. Subjects in group II will receive the Dex solution (4 µg/mL). A loading dose of 2 µg/kg will be administered IV over 10 min, followed by a maintenance infusion of 0.1-1 µg/kg/h. Non-invasive blood pressure (mean ABP) peripheral oxygen saturation, heart rate, and respiratory rate will be assessed at baseline, at 2 minutes, then at 5 minutes intervals till 60 minutes. Ramsay sedation and Aldrete's recovery rating scores were assessed before, during, and after the procedure.|t|t|t|t
34031341|NCT03907371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031342|NCT06550622|||COHORT||RETROSPECTIVE|||||||
34106300|NCT04654052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106301|NCT03981289|||COHORT||OTHER|||||||
34106302|NCT02462057|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106303|NCT00087672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106304|NCT06585865|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||After pre-testing, participants will be randomized to supplement with resveratrol (500 mg) or placebo for 14 weeks. All participants will complete two 6-week blocks of supervised strength training (full body, 3 days/week); each block will be followed by one week of testing.|t|f|t|t
34106305|NCT05454566|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Group 1: ICM-203 6x10e12 vg~* Group 2: ICM-203 2x10e13 vg~* Group 3: ICM-203 6x10e13 vg"||||
34106306|NCT03492385|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34106307|NCT06641596|RANDOMIZED|PARALLEL||OTHER||TRIPLE||24 participants per group equally comprised of men and women matched as closely as possible by age, gender, BMI, and body mass|t|f|t|t
34106308|NCT01446471|||COHORT||PROSPECTIVE|||||||
34106309|NCT00704587|||CASE_CONTROL||PROSPECTIVE|||||||
34106310|NCT04475380|||COHORT||PROSPECTIVE|||||||
34106311|NCT01202357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106312|NCT03338790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106313|NCT04287829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106314|NCT06121856|||CASE_ONLY||CROSS_SECTIONAL|||||||
34106315|NCT06638164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106316|NCT02440165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34106317|NCT04279587|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106318|NCT06471673|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106319|NCT03345225|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
34106320|NCT06642857|||COHORT||RETROSPECTIVE|||||||
34106321|NCT05272774|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated either to the intervention or control groups. The control group will use the intervention without feedback from therapist but with support on-demand. The control group will participate in the program at the same time as the intervention group with therapist support.||||
34031343|NCT05115695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations will be made twice, before and after the treatment. All assessments will be made by a different physician physiotherapist who is unfamiliar with the treatment groups.|The study will include 30 children with cerebral palsy (CP) diagnosed at the GMFCS I-II level with 15 controls and 15 treatment groups. Included individuals (n=30) will be randomized by simple random method and divided into 2 groups. 2 groups; different upper extremity strengthening training and 1 grup (n=15,control): Neurodevelopmental Treatment (NDT-Bobath) approaches will be applied to the second group for 6 weeks, 3 days a week, 45 minutes a day. Group 2: An exercise approach with Proprioceptive Neuromuscular Facilitation (PNF) (n=15, exercise group) UE patterns will be applied to the first group for 30 minutes, 3 days a week for 6 weeks.|f|f|f|t
34106322|NCT04248452|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33805914|NCT06699082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Control Group: Kaltenborn mobilization AP and PA glides 10 reps' x 3 sets along with conventional therapy (hot pack for 10 mins, tens for 5 mins, AROMS exercises 10 reps 2 sets). Control was treated with Kaltenborn mobilization AP and PA glides 10 reps' x 3 sets along with conventional therapy that include; hot pack for 10 mins, tens for 5 mins, AROMS exercises 10 reps 2 sets. Home plane exercises included pendulum exercise, towel stretch exercise, and finger ladder exercise, cross body adduction exercise.|"Experimental Group: kinesiotaping along with Kaltenborn mobilization AP and PA glides Experimental group was treated with kinesiotaping along with Kaltenborn mobilization AP and PA glides. The treatment protocol was administered in 10 reps' and 3 sets.~AP Glide and PA Glide were applied. Kinesiotaping: First the deltoid area was dried and cleansed, excessive hair were trimmed, the KT was cut into Y-shape and I- shape was applied. The conventional therapy included; hot pacK, TENS for 5 mins and AROMS exercises 10 reps 2 sets. Home plan exercises included pendulum exercise, towel stretch exercise, finger ladder exercises and cross body adduction exercise."|t|f|f|f
33805915|NCT06696105|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||the lesions will receive restorative minimally invasive treatment|f|t|f|t
33805916|NCT00328666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805917|NCT04752072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It was initially intended for the research assistant collecting post-intervention and follow-up outcome measures to be masked to arm allocation. However, it is noted that such masking is not feasible. This is not deemed a risk to the study as outcome measures are self-report measures.|Participants will be randomly allocated to the intervention arm (ESTAIR) or the control arm (TAU)|f|f|f|t
33805918|NCT05794659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|Single blind, randomized, placebo-controlled, multicenter, phase 2 clinical study|t|f|f|f
33805919|NCT06511284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Amounts of protein was not revealed for participants|Randomized Clinical Trial|t|f|f|t
33805920|NCT06243575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805921|NCT02355041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33805922|NCT04411888|||CASE_ONLY||RETROSPECTIVE|||||||
33805923|NCT06697106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805924|NCT02432274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805925|NCT05824871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, care providers, investigators, and outcome assessors will be blinded to the intervention assignments to ensure unbiased assessment.|Participants are randomized into two groups (Sudapyridine and Bedaquiline) for parallel treatment evaluation.|t|t|t|t
33805926|NCT04973163|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The following parts will be included in this trial:~* First: Monotherapy Arm~* After confirmation of safety: Combination Therapy Arm~Each arm consists of three parts (dose escalation (A), dose confirmation (B), and dose expansion (C))."||||
33805927|NCT03821506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of depression severity assessment||f|f|f|t
33805928|NCT02142751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031344|NCT06221826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031345|NCT05758857|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It is not possible to blind participants to their assigned intervention. Care providers are not involved. The outcome assessors for any assessments involving potential for subjectivity in data collection or analysis will be blinded to group assignment.|3-arm parallel-group randomized controlled trial|f|f|f|t
34031346|NCT05237492|NA|SINGLE_GROUP||OTHER||NONE||||||
34031347|NCT02755649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031348|NCT05286866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106323|NCT04377256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34106324|NCT00000373|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34106325|NCT01138306|||CASE_CONTROL||RETROSPECTIVE|||||||
34106326|NCT00991978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106327|NCT05155085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106328|NCT06501209|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||The study will be conducted in three community clinics (CC) and their catchment communities in 3 Unions (Sator, Mohonpur and Sotogram) in Dinajpur, a border-based district in Bangladesh. This small-scale intervention study will be conducted among men and women aged 18 and above. We will purposefully select 3 unions of Birganj upazila from Dinajpur district; one union will be selected for providing conventional 5A-5R based counselling service according to the national protocol for prevention of diabetes and hypertension to quit tobacco among current tobacco users, one union will be selected for delivering mobile phone assisted enhanced 5A-5R Based counselling service and the other one union will be selected as control that will continue with usual care without introducing any structured 5A-5R based counselling service for tobacco cessation.|t|f|f|f
34106329|NCT06675591|||COHORT||RETROSPECTIVE|||||||
34106330|NCT00090064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106331|NCT00968045|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106332|NCT02016885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106333|NCT00503672|||COHORT||PROSPECTIVE|||||||
34106334|NCT00940121|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34106335|NCT06449547|||CASE_ONLY||PROSPECTIVE|||||||
33724260|NCT04900688|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm multicenter study looking at real world results of ureteroscopy with the new digital flexible ureteroscope.||||
33724261|NCT04991545|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33724262|NCT05240404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805929|NCT06515691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcomes assessor and participants will be blinded to the study.|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification II-III, scheduled for laparoscopic sleeve gastrectomy operation will be included in the study. Patients will be randomly divided into two groups (Group M=M-TAPA block group, Group K = control group) including 30 patients each, before entering the operating room.|t|f|f|t
33805930|NCT00900341|||CASE_ONLY||PROSPECTIVE|||||||
34031349|NCT01225185|||CASE_CONTROL||PROSPECTIVE|||||||
34031350|NCT02655497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031351|NCT00108004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031352|NCT03730844|||COHORT||PROSPECTIVE|||||||
34031353|NCT01004809|||OTHER||PROSPECTIVE|||||||
34031354|NCT00150956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031355|NCT05135455|||COHORT||PROSPECTIVE|||||||
34031356|NCT05736861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
34031357|NCT04298632|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34031358|NCT00348829|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34031359|NCT03536884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031360|NCT05625074|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34031361|NCT04642365|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031362|NCT00321191|RANDOMIZED|CROSSOVER||||NONE||||||
34031363|NCT04778475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031364|NCT00047112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031365|NCT05611554|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants were aware of the existence of the two conditions|"Randomization assigned participants to 2 arms:~1. Treatment~2. Waiting list"||||
34031366|NCT05666076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34031367|NCT03910985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031368|NCT05985629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An unblinded pharmacist will prepare the study drugs consisting of IPACK block, or the sham block consisting of saline (control group). All patients will be premedicated with midazolam, which is standard of care prior to general anesthesia. The use of a sham block, administered by the anesthesia team, is to ensure that the Investigator is blinded to patient's treatment group.||t|f|t|f
34031369|NCT03381378|||COHORT||OTHER|||||||
34031370|NCT02449980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031371|NCT03541161|||CASE_CONTROL||RETROSPECTIVE|||||||
34031372|NCT04509687|||COHORT||PROSPECTIVE|||||||
34031373|NCT03560128|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34031374|NCT06581887|||COHORT||CROSS_SECTIONAL|||||||
34031375|NCT06456242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031376|NCT06551337|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||104 subjects will be separated into two groups according to their Baseline blood 25-hydroxyvitamin-D level: vitamin D deficient (below 50 nmol/L) and vitamin D non-deficient (at or above 50 nmol/L). There were initially 42 and 62 patients in the vitamin D deficient and vitamin D non-deficient groups respectively.||||
34031377|NCT03786887||SEQUENTIAL||TREATMENT||NONE||||||
34031378|NCT05273346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This trial is an open study. Subjects and physicians are not blinded, but outcome evaluators and statisticians are blinded. Doctors not involved in patient grouping and treatment will be appointed to evaluate the efficacy of patients. After locking the database, the third party statisticians who do not know the grouping should analyze it.||f|f|f|t
34031379|NCT00620685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031380|NCT04587726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34031381|NCT02925403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34031382|NCT04960293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031383|NCT03382587|||COHORT||OTHER|||||||
34031384|NCT03481010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031385|NCT01207310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031386|NCT02294045|||CASE_ONLY||PROSPECTIVE|||||||
34031387|NCT03785119|||COHORT||PROSPECTIVE|||||||
34031388|NCT01101113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031389|NCT00372814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031390|NCT02893085|||CASE_CONTROL||RETROSPECTIVE|||||||
34031391|NCT04742374|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Randomisation to one of two treatments before alternation.|Proof-of-concept, monocentric, prospective, Single-Case Experimental Design|t|f|f|f
34031392|NCT03295630|NA|SINGLE_GROUP||OTHER||NONE||Ankle mounted Actigraph GT3X accelerometer||||
34106336|NCT04482803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106337|NCT04215458|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The staff that analyses the samples will not know whether they come from patients or volounteers|case-control study||||
34106338|NCT06636838|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106339|NCT05124236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106340|NCT05301192|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34106341|NCT02394574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106342|NCT06569511|||COHORT||PROSPECTIVE|||||||
33724263|NCT04425395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724264|NCT01089439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724265|NCT00929682|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33724266|NCT01877629|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33724267|NCT02910193|||COHORT||CROSS_SECTIONAL|||||||
33724268|NCT05614375|||COHORT||PROSPECTIVE|||||||
33724269|NCT00012142||||TREATMENT||||||||
33724270|NCT00729729|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33724271|NCT02497027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33724272|NCT00896337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724273|NCT02463656|||CASE_ONLY||CROSS_SECTIONAL|||||||
34031393|NCT01823367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031394|NCT05622487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031395|NCT04442464|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031396|NCT04743726|||COHORT||PROSPECTIVE|||||||
34031397|NCT06498882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34031398|NCT06208137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031399|NCT01325402|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34031400|NCT01942421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031401|NCT00581165|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031402|NCT04623892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031403|NCT03409588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031404|NCT00478517|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34031405|NCT02742883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031406|NCT03672591|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031407|NCT01818115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031408|NCT02083068|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34031409|NCT06306261|||COHORT||PROSPECTIVE|||||||
34031410|NCT05886712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031411|NCT01938495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031412|NCT05327153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34031413|NCT03567928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Induction of anesthesia and subsequent use (or not) of the device (laryngeal mask)|Two groups: one receive sedation in spontaneous breathe, the other receive sedation with laryngeal mask|t|f|f|f
34031414|NCT00751192|RANDOMIZED|SINGLE_GROUP||SCREENING||||||||
34031415|NCT06113835|||COHORT||PROSPECTIVE|||||||
34031416|NCT06488144|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34031417|NCT06325605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34031418|NCT04290455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators who assess outcomes of anterior blepharitis will not know the arms that patients are in|A prospective, randomized, paired-eye trial.|f|f|t|t
34031419|NCT03399513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031420|NCT00142389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34031421|NCT04912232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031422|NCT03397225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031423|NCT05017246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031424|NCT01194167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031425|NCT03959111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031426|NCT03100123|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible and consenting subjects will be assigned to one of two study arms. Randomization is stratified by 'high-risk' or 'non-high risk' laboratory criteria and the timing of pregnancy loss (late loss or no late loss).||||
34031427|NCT00790725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106343|NCT03211546|||COHORT||PROSPECTIVE|||||||
34106344|NCT00353119|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33724274|NCT00056030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724275|NCT00939809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724276|NCT02385266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724277|NCT05853302|||CASE_CONTROL||RETROSPECTIVE|||||||
33724278|NCT01312090|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724279|NCT04375488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724280|NCT02382458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724281|NCT01410045|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724282|NCT03359642|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031428|NCT00743717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031429|NCT03637010|NA|SINGLE_GROUP||OTHER||NONE||||||
34031430|NCT03914573|||COHORT||RETROSPECTIVE|||||||
34031431|NCT01651078|||COHORT||PROSPECTIVE|||||||
34031432|NCT06550817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34031433|NCT06191029|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34031434|NCT00307086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724283|NCT04572607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33724284|NCT01498458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724285|NCT05531435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth design|f|f|t|t
33724286|NCT02762266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724287|NCT04710446|||CASE_CONTROL||PROSPECTIVE|||||||
34031435|NCT01221207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34031436|NCT06322784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers set blinding to reduce implementation bias|Experimental group=1,Control Group=2,|f|f|t|f
34031437|NCT05516355|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|MBSR and CCT instructors will be blind to the study hypotheses. Investigators collecting, analyzing data and assessing outcomes will be blind to the group assignment.||t|t|f|t
34031438|NCT06581718|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34031439|NCT02501928|NON_RANDOMIZED|||TREATMENT||NONE||||||
34031440|NCT00390637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031441|NCT00659243|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34031442|NCT06575543|||CASE_CONTROL||RETROSPECTIVE|||||||
34031443|NCT00934024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031444|NCT03790371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031445|NCT02134990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031446|NCT03296527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34106345|NCT00944840|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34106346|NCT01000116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106347|NCT05538858|||COHORT||PROSPECTIVE|||||||
34106348|NCT05740826|||COHORT||CROSS_SECTIONAL|||||||
34106349|NCT01894646|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34149052|NCT01378611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149053|NCT00645905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149054|NCT00841932|||CASE_ONLY||RETROSPECTIVE|||||||
34031447|NCT06581679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106350|NCT06036524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a two-phase, NIH-supported study. The first R61 phase (currently awarded) is an observational study with one control group and one patient group. The second R33 phase is a randomized clinical trial, which will be awarded by the end of the R61 phase. The study design provided here is for R61 only.||||
34106351|NCT05731544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject and the investigator involved in the treatment or clinical evaluation of the subjects will be unaware of the group assignments.||t|f|t|f
34106352|NCT04565080|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34106353|NCT06674720|||COHORT||PROSPECTIVE|||||||
33724288|NCT05346809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724289|NCT03809442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized control trial|t|f|t|t
33724290|NCT00814086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031448|NCT00329082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031449|NCT03971474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031450|NCT03595046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"1. The subjects were randomly assigned to erector spinae plane block group (group E) and thoracic paravertebral block group (group P), and the assigned results are unknown.~2. The Outcomes Assessor is not related to the study, and does not know its contents."|erector spinae plane block group (group E) thoracic paravertebral block group (group P)|t|f|t|f
34031451|NCT00290004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031452|NCT00549432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031453|NCT05469295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031454|NCT04722250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031455|NCT04320823|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Two-arm, randomized, controlled trial|t|f|t|t
34031456|NCT05451628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031457|NCT00038025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031458|NCT02836925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031459|NCT05869864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The primary goal of this study is to assess acceptability of the behavioral intervention in a small group of participants and to determine feasibility of the study design for a future fully-powered clinical trial. The secondary goal of this study is to evaluate under-powered directions of behavior change relating to prevention or reduction of HIV risk behavior and intimate partner violence.|f|f|t|f
34031460|NCT00248872|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031461|NCT01917214|||CASE_ONLY||RETROSPECTIVE|||||||
34031462|NCT02734407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031463|NCT01937871|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031464|NCT06438718|||OTHER||PROSPECTIVE|||||||
34031465|NCT04578405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031466|NCT06581107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031467|NCT00839397|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031468|NCT05382403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031469|NCT05565430|||OTHER||PROSPECTIVE|||||||
34106354|NCT06490666|||OTHER||PROSPECTIVE|||||||
34106355|NCT03913637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34106356|NCT03150888|||COHORT||PROSPECTIVE|||||||
34106357|NCT05566236|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34149055|NCT00733057|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33724291|NCT02436759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724292|NCT02563626|||COHORT||PROSPECTIVE|||||||
33724293|NCT01477060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724294|NCT00206947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724295|NCT05571605|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of two conditions:1) aerobic exercise training on a stationary bicycle, or 2) stretching and balance training.||||
33724296|NCT05160688|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724297|NCT01359254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724298|NCT04703439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724299|NCT03637803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724300|NCT05891678|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724301|NCT03744533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724302|NCT00703885|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33724303|NCT00813085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33724304|NCT01678963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724305|NCT04722796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and ourcome assessor are blind to treatment groups.||t|f|f|t
33724306|NCT01650662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724307|NCT04339699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A 640 participants indicated for percutaneous transcatheter closure of a PFO to reduce risk of recurrent Ischemic Stroke; between ages 18 - 60 years, who have had a Cryptogenic Stroke due to Paradoxical Embolism. To be conducted both in the USA and the European Union.||||
33724308|NCT02657707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724309|NCT00969865|||CASE_CONTROL||PROSPECTIVE|||||||
34031470|NCT02757755|RANDOMIZED|||||DOUBLE|||t|f|t|f
34031471|NCT01845480|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34031472|NCT03703076|||COHORT||OTHER|||||||
34149056|NCT06098664|||CASE_ONLY||PROSPECTIVE|||||||
33724310|NCT05815316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149057|NCT03612310|||COHORT||OTHER|||||||
34149058|NCT01347255|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33724311|NCT06514963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HRS-9813 compared with placebo|t|t|t|t
33724312|NCT04032561|||COHORT||RETROSPECTIVE|||||||
33724313|NCT04246606|||COHORT||RETROSPECTIVE|||||||
33724314|NCT00485238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724315|NCT01132482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724316|NCT06007599|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149059|NCT05597072|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34149060|NCT03331822|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is randomized crossover trial, in which each nursing subject will serve as his or her own control: i.e., matched. The subjects will be nurses from the 6FG Trauma Intensive Care Unit at UPMC Presbyterian hospital.||||
34149061|NCT01330966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149062|NCT02235103|||COHORT||PROSPECTIVE|||||||
34149063|NCT01146964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031473|NCT03481582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* After enrollment, participants would be given the next available number in a computer generated randomization plan .~* Allocation concealment (among unexplained infertile groups):~Opaque, serially-numbered, sealed envelopes will enclose the letter corresponding to the group the patient will follow. Envelopes will be opened when the patient is enrolled and she will receive the intervention accordingly.~-Blinding The study design precludes neither participant nor the doctor will be blinded."|"90 female patients will be divided into 3 equal groups:~* Group I: 30 female patients with unexplained infertility.~* Group II: 30 female patients with unexplained infertility will receive nitroglycerin trans-dermal patch."|t|t|f|f
34031474|NCT05848791|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34031475|NCT03490071|||COHORT||PROSPECTIVE|||||||
34031476|NCT02574832|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34031477|NCT01436318|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34031478|NCT03901092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|PET scans were obtained in an open-label fashion.|Physician PET scan readers are participants, blinded to demographic and clinical data from the source PET scans.||||
34031479|NCT00247676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031480|NCT03532152|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34031481|NCT03209895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031482|NCT03860324|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34031483|NCT00168779||PARALLEL||TREATMENT||||||||
34031484|NCT02720848|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34031485|NCT05416242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031486|NCT05182021|||COHORT||PROSPECTIVE|||||||
34031487|NCT00006207||||PREVENTION||||||||
34031488|NCT03366207|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study of ciprofloxacin for uncomplicated urinary tract infection||||
34031489|NCT01050959|||CASE_ONLY||PROSPECTIVE|||||||
34031490|NCT01888939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031491|NCT00405093|||CASE_ONLY||RETROSPECTIVE|||||||
34031492|NCT02513862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34031493|NCT04053127|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34031494|NCT04080466|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Non-randomized, single centre trial with 2 parallel groups||||
34031495|NCT05816109|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Assignment||||
33724317|NCT00002161||||TREATMENT||DOUBLE||||||
34031496|NCT05481671|||CASE_ONLY||OTHER|||||||
34031497|NCT04691427|NA|SINGLE_GROUP||TREATMENT||NONE|Examiner (Outcomes Assessor) will be masked by pooling participants from another study.|||||
34031498|NCT00271232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031499|NCT04552795|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, one arm study.||||
34031500|NCT01313377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031501|NCT06316011|||COHORT||PROSPECTIVE|||||||
34031502|NCT05224609|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031503|NCT05392218|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34031504|NCT04727567|||CASE_CONTROL||PROSPECTIVE|||||||
34031505|NCT01910818|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34031506|NCT03032848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34031507|NCT06166524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031508|NCT06369441|||CASE_ONLY||PROSPECTIVE|||||||
34031509|NCT01824381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031510|NCT05593744|||COHORT||PROSPECTIVE|||||||
34031511|NCT04293133|||COHORT||RETROSPECTIVE|||||||
34031512|NCT04966689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031513|NCT04563507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031514|NCT03888846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031515|NCT04768660|NA|SINGLE_GROUP||OTHER||NONE||||||
34031516|NCT01833663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031517|NCT02614105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031518|NCT03064178|||COHORT||PROSPECTIVE|||||||
34031519|NCT00491868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031520|NCT03883035|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34031521|NCT05175040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both the study participant and her primary obstetrician will be blinded to the assigned randomization arm prior to delivery, as involvement in this research study should not change their care. Clinical management will be left to the discretion of each participant's primary obstetrician managing her labor, according to standard obstetrical care, who again will not be involved in the research-related study procedures.||t|t|f|f
34031522|NCT01145469|||OTHER||RETROSPECTIVE|||||||
34031523|NCT00367302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031524|NCT01140789|||CASE_CONTROL||PROSPECTIVE|||||||
34031525|NCT00154752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724318|NCT03758196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031526|NCT02521649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031527|NCT05467631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Identical bottles given to participants with serial number, aroma and feel of each treatment group is the same|2 groups, plain tea tree oil control and formulated essential oil blend with permeation enhancer as treatment in a randomized trial|t|f|t|t
34031528|NCT05478616|||COHORT||PROSPECTIVE|||||||
34031529|NCT06408129|||COHORT||RETROSPECTIVE|||||||
34031530|NCT02368483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031531|NCT00902694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34031532|NCT04795895|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34031533|NCT02496182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031534|NCT04760717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724319|NCT03975907|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase I is an open-label, dose escalation study and 2 cohorts to evaluate the safety and tolerability of treatment with CT053 and to determine maximum tolerable dose (MTD) and the Recommended Phase 2 Dose (RP2D) for CT053.~Phase 2 is a single-arm, open, multi-center study, to evaluate the efficacy and safety of CAR-BCMA T cells (CT053) in subjects with RR/MM."||||
34031535|NCT00580502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031536|NCT00005603||||TREATMENT||NONE||||||
34031537|NCT04533035|||COHORT||PROSPECTIVE|||||||
34031538|NCT03232671|||CASE_CONTROL||PROSPECTIVE|||||||
34031539|NCT02550301|||CASE_ONLY||PROSPECTIVE|||||||
34031540|NCT04077554|||COHORT||OTHER|||||||
34031541|NCT02666443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724320|NCT06117384|||COHORT||PROSPECTIVE|||||||
33724321|NCT02009631|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33724322|NCT01668706|||COHORT||PROSPECTIVE|||||||
33724323|NCT06052007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724324|NCT06316752|||COHORT||PROSPECTIVE|||||||
33724325|NCT04669587|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724326|NCT06387992|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724327|NCT05070065|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|people with psychosocial disabilities|Randomized controlled open-label cross-over clinical feasibility study with waiting list|t|f|f|f
33724328|NCT01003509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724329|NCT02514837|||COHORT||PROSPECTIVE|||||||
33724330|NCT01785979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805931|NCT03600844|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Districts in high malaria transmission zones were assigned to intervention and comparison areas.||||
34031542|NCT06582823|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34031543|NCT05886205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031544|NCT01916044|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031545|NCT00297076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031546|NCT03464721|||COHORT||PROSPECTIVE|||||||
34031547|NCT02749500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031548|NCT05148091|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34031549|NCT05978752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients with GOV1 esophagogastric varices were treated with gastric variceal tissue gel injection, at the same time, the esophageal varices were treated with ligation, sclerotherapy, or no treatment. A new method for the treatment of esophageal varices was proposed to improve the effective rate and reduce the recurrence rates and mortality, shorter hospital stays, and lower treatment costs, while further expanding the value of HVPG testing.|t|f|f|t
34031550|NCT00261443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031551|NCT05184452|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34031552|NCT01396512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34031553|NCT03029728|||COHORT||PROSPECTIVE|||||||
34031554|NCT06371625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients will be randomly assigned into two equal comparable groups using computer- generated random numbers in opaque closed envelopes, each of which will include 11 per group. Randomization will be done by statistician and each group of the patient will revealed only when the included patient is transferred to preanesthetic room.|to determine the analgesic effect of ultrasound guided Transversus Thoracic and Pectoral Nerve Block compared to ultrasound guided Pectoral Nerve Block in patients undergoing modified radical mastectomy regarding the following : 1-Post-operative opioid (morphine) consumption in the 1st 24 hours 2- Postoperative Numeric Pain Rating Scale. 3. Effect on hemodynamics: Mean arterial blood pressure and Heart rate. 4. Intraoperative fentanyl consumption. 5. Duration of analgesic effect|t|f|t|f
34031555|NCT05467787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031556|NCT00561119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031557|NCT03181412|||COHORT||RETROSPECTIVE|||||||
34031558|NCT01187056|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34031559|NCT02644915|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34031560|NCT00004883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031561|NCT01804179|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34031562|NCT05924321|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The trial will consist of two parts; Part A and Part B. Part A is an open-label single group trial while Part B is a double-blind trial with 3 groups.||t|t|t|t
34031563|NCT01819870|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031564|NCT01699958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031565|NCT04469777|NA|SINGLE_GROUP||TREATMENT||NONE||"The study included 20 patients diagnosed as late onset optic neuropathy that are attending Alexandria main university hospital.~All patients underwent initially assessment of visual acuity, color vision, pupil reaction ,funduscopy and electrophysiological tests ( pattern visual evoked potential and pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control). Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies."||||
34031566|NCT06128486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031567|NCT00437697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031568|NCT03021330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031569|NCT02556957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34031570|NCT00580892|||CASE_ONLY||PROSPECTIVE|||||||
34031571|NCT06361199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031572|NCT03420911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sequenced study medications were prepared by a nurse, and another nurse administered the medications.|Participants were randomly assigned into two groups with a 1:1 allocation following simple randomization procedures by a program generating an online random number|t|f|t|t
34031573|NCT00958555|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34031574|NCT01648530|||COHORT||PROSPECTIVE|||||||
34031575|NCT04177082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031576|NCT03062709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34031577|NCT02354729|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031578|NCT01649063|||||PROSPECTIVE|||||||
34031579|NCT01749202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34031580|NCT06583161|||COHORT||PROSPECTIVE|||||||
34031581|NCT05584189|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open-label, prospective study to evaluate the usability of the Rapid SARS-CoV-2 Antigen Test when a lay person conducts the test on themselves or another study participant. Potential subjects will be those presenting for COVID-19 testing. The study will evaluate the layperson usability of the Rapid SARS-CoV-2 Antigen Test by assessing the performance of the Rapid SARS-CoV-2 Antigen Test under the supervision of qualified site personnel, as well as having the testing participant complete assessments measuring .||||
34031582|NCT00635310|NON_RANDOMIZED|PARALLEL||||NONE||||||
34031583|NCT01395446|||COHORT||PROSPECTIVE|||||||
34031584|NCT00676260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031585|NCT04319354|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031586|NCT06009276|||CASE_CONTROL||PROSPECTIVE|||||||
33724331|NCT04674046|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective cohort study where participants will be assigned to nonoperative or operative treatment based on minimally invasive arthroscopic evaluation.||||
33724332|NCT01017237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724333|NCT00559546|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33724334|NCT00360828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724335|NCT05889598|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724336|NCT03760796|NA|SINGLE_GROUP||PREVENTION||NONE||Single group assignment to the Corrie Health Digital Platform prospective intervention group (n=200), as compared with a historical standard of care comparison group (n=864)||||
34031587|NCT00814476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031588|NCT02324582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031589|NCT02257775|||CASE_ONLY||PROSPECTIVE|||||||
34031590|NCT02562573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031591|NCT03792022|||COHORT||RETROSPECTIVE|||||||
34031592|NCT05494073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031593|NCT00285064|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34031594|NCT03938909|||CASE_CONTROL||PROSPECTIVE|||||||
34031595|NCT04641104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This is a monocentric randomized, controlled, double blind study in patients undergoing elective cardiac surgery with extra corporal circulation. Anesthesia management of these patients is standardised in terms of volume-controlled ventilation, fluid and inotropes management.~Randomization of 100 patients for the administration, of a solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% versus a solution of 100 ml of NaCl 0.9% alone in adult patients (≥ 18 years-old) with a lactate ≥ 2 mmol / L in the first 6 hours of ICU admission."|t|f|t|t
34031596|NCT06581484|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34031597|NCT04450758|||COHORT||PROSPECTIVE|||||||
34031598|NCT04522726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"One group was given Weiyang Yupingfang Granules orally for 1 month on the Sanfudays and on the Sanjiu days each year for a total of 2 months one year; the other group was given Weiyang Yupingfang Granules orally for 1 month in the first month of each quarter in the four quarters of the year, for a total of 4 months one year."|t|t|t|f
34031599|NCT01618565|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34031600|NCT03657225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031601|NCT00633997|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34031602|NCT03369769|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Coders for the videotaped behavioral data collected via the OHAIRE-M tool were blind to specific study objective.|To investigate the effect of canine animal assisted activities (AAA) on physiological arousal levels in children and adolescents with autism spectrum disorder (ASD) (ages 4 to 17 years) in a specialized psychiatric hospital program. It is hypothesized that children with ASD will demonstrate lower physiological arousal in the presence of canines, compared to a non-animal control.|f|f|f|t
34031603|NCT01948115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031604|NCT02617797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031605|NCT03817827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031606|NCT05960058|||CASE_CONTROL||RETROSPECTIVE|||||||
34149064|NCT04473365|||COHORT||PROSPECTIVE|||||||
34149065|NCT01107938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149066|NCT05883358|||CASE_CROSSOVER||PROSPECTIVE|||||||
34149067|NCT05054543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34149068|NCT03474198|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study uses a multi-arm, multi-stage (MAMS) parallel study design||||
34149069|NCT05481099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149070|NCT02017522|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects will have be injected 11C-PBR28, a compound used as a radiotracer. They will then have a PET CT scan.||||
34149071|NCT04902664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||20 primary care physicians will be recruited and randomized to an intervention and a control arm. For each physician, we will recruit at least 10 of their patients with upcoming scheduled physicals. All included patients of intervention physicians will receive the intervention, and all included patients of control physicians will receive general patient visit prep materials.||||
34149072|NCT00844259|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34149073|NCT01627444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34149074|NCT00427882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149075|NCT04254029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149076|NCT00940485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149077|NCT00069992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149078|NCT06182696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149079|NCT06436586|||COHORT||PROSPECTIVE|||||||
34149080|NCT05019989|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Trial of Diet, Physical Activity and Breast Cancer Recurrences. The investigators recruited 1542 patients' high risk and randomized them in two groups: 773 (control group) have received general standard written recommendation for healthy lifestyle without, however, any active support; 769 (intervention group) have received a combination of individual and group contacts over the course of one year, including kitchen courses, gym and dance classes, common meals and reinforcing meetings, with emphasis on a comprehensive dietary and life-style change.||||
34149081|NCT06257836|||COHORT||PROSPECTIVE|||||||
34031607|NCT04555434|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Evaluates the effect of probiotic improvement on non-alcoholic fatty liver disease in patients diagnosed with non-alcoholic fatty liver disease.|t|f|f|f
34031608|NCT01835041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031609|NCT01320501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031610|NCT02823717|||COHORT||PROSPECTIVE|||||||
34031611|NCT02016183|||COHORT||PROSPECTIVE|||||||
34106358|NCT04504669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open Label|"This is a Phase I, FIH, multicentre, open-label, multiple arm study. Dose-escalation will occur with AZD8701 in monotherapy and in combination with durvalumab in selected participants with HNSCC, TNBC, NSCLC, ccRCC, gastroesophgeal cancer, melanoma, cervical cancer, small-cell lung cancer and/or participants with solid tumours who have demonstrated a response to prior PD-(L)1 treatment.~Disease specific expansions will occur with a selected dose of AZD8701 in participants with NSCLC and with a selected dose of AZD8701 and durvalumab in participants with TNBC and clear cell RCC."||||
34031612|NCT06454097|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031613|NCT04649944|||OTHER||PROSPECTIVE|||||||
34031614|NCT02633592|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106359|NCT05181085|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34106360|NCT02884479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106361|NCT06466655|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106362|NCT06213298|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34106363|NCT03348462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The aim of the present study was to develop an ethosomal delivery system anthralin and evaluate its effectiveness and safety in treatment of psoriasis and comparing it with liposomal delivery system anthralin.|t|f|f|f
34106364|NCT01346592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34106365|NCT04559464|NA|SINGLE_GROUP||TREATMENT||NONE||Stage 1 will address the closure of the lobar fissure gaps (or collateral air channels) to block collateral ventilation (CV) with the AeriSeal System (conversion of the CV+ target lobe to CV-). Stage 2 will include successfully converted subjects in Stage 1. Converted CV- target lobes will follow standard of care and receive the Zephyr Endobronchial valves per the Zephyr Instructions for Use (IFU) to perform bronchoscopic lung volume reduction (BLVR).||||
33724337|NCT00441311|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33724338|NCT02831166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724339|NCT04546165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33724340|NCT03009929|||COHORT||PROSPECTIVE|||||||
33724341|NCT04535895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724342|NCT04291339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33724343|NCT01054781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031615|NCT05309018|||COHORT||PROSPECTIVE|||||||
34031616|NCT02130908|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34031617|NCT00440349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031618|NCT03035578|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34031619|NCT06042244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031620|NCT03487289|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34031621|NCT01085071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031622|NCT00795327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031623|NCT05463640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031624|NCT02309307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031625|NCT01153425|RANDOMIZED|PARALLEL||TREATMENT||NONE||Postmenopausal women, ages ≥ 60 years, indicated for treatment with antiresorptive or anabolic drugs due to severe osteoporosis and high risk of fracture.||||
34031626|NCT05919719|||CASE_ONLY||PROSPECTIVE|||||||
34031627|NCT02289872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031628|NCT04805294|||COHORT||PROSPECTIVE|||||||
34031629|NCT02966977|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34031630|NCT05547217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031631|NCT04508738|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded about the true nature of the placebo intervention|Each participant will be tested on 4 different days with a control, a placebo and an interventional condition in random order.|t|f|f|f
34031632|NCT04812522|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster randomized stepped wedge design||||
33724344|NCT02696642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031633|NCT03748446|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The identity of the inhalant will be blinded to all except the anesthesiologist, who will not participate in any assessment of the depressive symptoms.|A randomized, double-blind crossover model that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.|t|f|t|t
34031634|NCT01205360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031635|NCT00186524|RANDOMIZED|PARALLEL||||NONE||||||
34031636|NCT01049178|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34031637|NCT02723344|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Biologic|t|t|t|t
34031638|NCT01848600|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34031639|NCT03355612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031640|NCT04493671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031641|NCT00946920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031642|NCT02540083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031643|NCT06138691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031644|NCT03126435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031645|NCT02006732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031646|NCT03223584|||CASE_ONLY||CROSS_SECTIONAL|||||||
34031647|NCT03434522|||CASE_ONLY||PROSPECTIVE|||||||
34031648|NCT00960219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031649|NCT04105010|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031650|NCT06340997|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34031651|NCT05434169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34031652|NCT00986050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031653|NCT02499796|NA|SINGLE_GROUP||OTHER||NONE||||||
34031654|NCT05506670|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34031655|NCT04599478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031656|NCT05714462|RANDOMIZED|PARALLEL||OTHER||SINGLE||A randomized cross-sectional controlled trial will be conducted to quantify whole-body and muscle protein turnover and skeletal muscle inflammation following 5-days of consumption of either beef or isonitrogenous plant-based sources of protein in normal/overweight and obese post-menopausal females.|f|f|f|t
34031657|NCT02899962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031658|NCT06345807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||interventional study, randomized in 3 parallel groups, single center,||||
34031659|NCT01096797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031660|NCT01654315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34031661|NCT01079728|||CASE_ONLY||PROSPECTIVE|||||||
34031662|NCT04480684|||COHORT||PROSPECTIVE|||||||
33724345|NCT03493984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724346|NCT01908361|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33724347|NCT01139450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724348|NCT03737747|||COHORT||RETROSPECTIVE|||||||
33724349|NCT04353011|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33724350|NCT00424138|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031663|NCT05955183|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33724351|NCT01648855|||CASE_ONLY||PROSPECTIVE|||||||
33724352|NCT04477811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805932|NCT01333800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031664|NCT06451341|||COHORT||PROSPECTIVE|||||||
34031665|NCT06582810|||COHORT||PROSPECTIVE|||||||
34031666|NCT00317694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031667|NCT02669355|||CASE_CONTROL||PROSPECTIVE|||||||
34031668|NCT00005805|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34031669|NCT02952586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031670|NCT05258201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Our study will be single-blinded, outcome assessor-blinded. The assessor will be blinded to avoid being biased during the outcome assessment.||f|f|f|t
34031671|NCT03357185|||COHORT||PROSPECTIVE|||||||
34031672|NCT06285292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031673|NCT03688633|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031674|NCT06384833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34031675|NCT00734058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031676|NCT03867747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031677|NCT00159224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031678|NCT00814268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031679|NCT06376058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031680|NCT04297709|||COHORT||PROSPECTIVE|||||||
34031681|NCT03541317|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34106366|NCT05308459|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A non-randomized clustered stepped-wedge design with two steps will be applied. Four VET schools (one from each of the four main educations tracks) are selected to early start (January 2022) and four to late start - also one from each of the four main educational tracks (6 months later). This design allows the intervention to be rolled out sequential, allowing us to control for differences between study sites (vertical control) and secular trends (horizontal control) during the study period.||||
34106367|NCT03571633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106368|NCT00498407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805933|NCT03936660|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34031682|NCT05309395|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031683|NCT03337399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031684|NCT05146830|||COHORT||PROSPECTIVE|||||||
34031685|NCT01707056|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031686|NCT06551194|||CASE_ONLY||RETROSPECTIVE|||||||
34031687|NCT03655730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"This study is a comparative, randomised controlled trial that aims at demonstrating the superiority of weekly psychotherapeutic intervention during one year in lowering depression symptoms compared to usual care.~The ratio between intervention and usual care arms will be 1:1."|t|f|t|f
34031688|NCT03038386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031689|NCT04446247|||OTHER||PROSPECTIVE|||||||
34031690|NCT06007235|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|Blinding codes on treatments||t|t|t|t
34031691|NCT02372279|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34031692|NCT06124898|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34031693|NCT03591510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031694|NCT03790657|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will not be told which dosage group they are assigned to. Outcomes Assessors will not be told which dosage group the participant was randomized to.|Participants will randomized to one of two dosages of transcranial direct current stimulation (tDCS): Dosage A or Dosage B|t|f|f|t
34031695|NCT00000846||||PREVENTION||DOUBLE||||||
34031696|NCT00370487|||DEFINED_POPULATION||OTHER|||||||
34031697|NCT06383455|||CASE_CONTROL||PROSPECTIVE|||||||
34031698|NCT04133987|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34031699|NCT02475928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031700|NCT03092219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031701|NCT05796076|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Investigator will not be involved the recruitment and data collection. Outcome assessor will be masked|Intervention and control group||||
34031702|NCT04944706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031703|NCT04262921|||OTHER||PROSPECTIVE|||||||
34031704|NCT04170556|NA|SINGLE_GROUP||TREATMENT||NONE||Regorafenib followed by Nivolumab||||
34031705|NCT02680236|||CASE_CONTROL||PROSPECTIVE|||||||
34106369|NCT06123676|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106370|NCT01697501|NA|SINGLE_GROUP||OTHER||NONE||||||
34106371|NCT04003402|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34106372|NCT06127771|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34106373|NCT04498273|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
34106374|NCT01412216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106375|NCT05280145|NA|SINGLE_GROUP||SCREENING||NONE||A single group, comparative, non-randomized, controlled study. Each patient represents her/his own control: the patient is examined consecutively with the echOpen probe, then with the probe routinely used in the department||||
34106376|NCT03338920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106377|NCT02914886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106378|NCT03523585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106379|NCT06611696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106380|NCT01996046|||CASE_ONLY||PROSPECTIVE|||||||
34106381|NCT06020937|||CASE_CONTROL||PROSPECTIVE|||||||
34031706|NCT05545189|||COHORT||PROSPECTIVE|||||||
34031707|NCT05725551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33805934|NCT00736463|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33805935|NCT00352599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805936|NCT03737409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805937|NCT00389194|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33805938|NCT04086849|||COHORT||RETROSPECTIVE|||||||
33805939|NCT03874819|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33805940|NCT04379557|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805941|NCT06033040|||CASE_ONLY||PROSPECTIVE|||||||
33805942|NCT05950867|NA|SINGLE_GROUP||SCREENING||NONE||||||
34106382|NCT05398666|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Patients will first receive White LED exposure, then they will be crossed over to Green LED exposure.|f|f|t|f
33805943|NCT01224613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805944|NCT02955407|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33805945|NCT06246110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805946|NCT01602913|||COHORT||RETROSPECTIVE|||||||
33805947|NCT06698419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The surgeon/principal investigator performing the canal wall down mastoidectomy will be aware of participant allocation. Participants and research co-investigators will not be aware of patient allocation.|Participants will be randomly allocated to the experimental group or the control group. All participants will undergo a canal wall down mastoidectomy in standard fashion. Participants in the experimental group will receive RADA16 gel in the mastoid cavity at the conclusion of the surgery whereas participants in the control group will not.|t|f|f|t
33805948|NCT05386108|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33805949|NCT00293397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805950|NCT06699329|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805951|NCT06264869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805952|NCT01467934|||||PROSPECTIVE|||||||
34106383|NCT02674763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106384|NCT06325852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106385|NCT06673563|||COHORT||PROSPECTIVE|||||||
34106386|NCT00247039|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34106387|NCT04222504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106388|NCT02082782|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm prospective trial with predefined endpoint: accept indication if at least 50% of patients are alive without local tumor progression at 12 months following irreversible electroporation (IRE) treatment for centrally located colorectal cancer liver metastases (CRLM)||||
34106389|NCT03923998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106390|NCT01384045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106391|NCT05607303|||CASE_CONTROL||PROSPECTIVE|||||||
34106392|NCT01548326|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106393|NCT04137757|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34106394|NCT05665751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106395|NCT05134883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106396|NCT00027300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106397|NCT06549062|||COHORT||PROSPECTIVE|||||||
34106398|NCT06638801|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34106399|NCT06457217|||COHORT||PROSPECTIVE|||||||
34106400|NCT06642012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106401|NCT05045417|||CASE_CONTROL||PROSPECTIVE|||||||
34106402|NCT01572441|||COHORT||PROSPECTIVE|||||||
34106403|NCT02134808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106404|NCT02944045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106405|NCT04968834|||COHORT||PROSPECTIVE|||||||
34106406|NCT06569563|||OTHER||PROSPECTIVE|||||||
34106407|NCT00077285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106408|NCT01417988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106409|NCT04804436|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34106410|NCT05437055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106411|NCT03823482|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106412|NCT06001697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In total a goal of 240 patients will be recruited and randomised in a 1:1 ration to either the intervention or control group. This means 120 of them will be assigned to the study group and 120 to the assigned to the control group. The intervention group will receive health advice and a park prescription by their health care provider while the control group will receive regular health advice regarding lifestyle.|t|f|f|f
34106413|NCT04776681|||COHORT||PROSPECTIVE|||||||
34106414|NCT03453515|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106415|NCT06639607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 30 patients (n=10 in each stratum) will be enrolled for the Phase I portion of this study. An additional 28 patients will be enrolled for the Phase II portion of this study.||||
34106416|NCT04629521|NA|SINGLE_GROUP||OTHER||NONE||||||
34106417|NCT03554330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34106418|NCT01432431|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106419|NCT06640413|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In Part I patients are assigned to 5 sequential dose escalation cohorts. In this part, two arms are foreseen:~Arm 1 foresees cohort 1-3 with monotherapy of \[177Lu\]Lu-OncoFAP-23 (3.7, 7.4, 11.1 GBq respectively); Arm 2, only opened when the MTD and RD is established, has cohorts 4-5 that are run with \[177Lu\]Lu-OncoFAP-23 in combination with L19IL2 at 22.5 Mio International Units (IU).~In Part II, 10 patients are randomly assigned to Arm 1 (monotherapy of \[177Lu\]Lu-OncoFAP-23 at the recommended dose) and 10 patients are randomly assigned to Arm 2 (combination of \[177Lu\]Lu-OncoFAP-23 and L19IL2 at the recommended doses)."||||
34106420|NCT06541587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes Assessor will perform physiological data extraction and questionnaire result analysis without knowledge of the group assignments of the data being analyzed.||f|f|f|t
33805953|NCT05086432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805954|NCT00309036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33805955|NCT05568082|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106421|NCT06539104|||COHORT||PROSPECTIVE|||||||
34106422|NCT05547542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106423|NCT05454891|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomly assigned (1:1) in blocks of two to the order in which they receive the two premeal insulin boluses: extended followed by standard bolus or a standard followed by extended bolus.||||
34106424|NCT02661347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106425|NCT05968742|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Longitudinal prospective clinical study using the experimental gingivitis model. Split Mouth design.||||
33805956|NCT01750684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33805957|NCT05786235|||CASE_CONTROL||PROSPECTIVE|||||||
34031708|NCT03222856|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II, multicenter, open-label study of pembrolizumab and eribulin in patients with HR- positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.||||
34031709|NCT04012567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031710|NCT00302289|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34031711|NCT05697523|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34031712|NCT06107244|||OTHER||PROSPECTIVE|||||||
34031713|NCT00257621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031714|NCT01088230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031715|NCT03063411|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34031716|NCT00055367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031717|NCT00296972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031718|NCT02046603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031719|NCT06124417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031720|NCT04031625|||COHORT||PROSPECTIVE|||||||
34031721|NCT03858010|||CASE_ONLY||CROSS_SECTIONAL|||||||
34031722|NCT04097340|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34031723|NCT02905188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031724|NCT04258176|||COHORT||PROSPECTIVE|||||||
34031725|NCT06281444|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients who meet the study conditions and agree to participate in this study will not know whether they are in the first group or the second group.|Patients who accepted to participate in the study by meeting the criteria will be randomly divided into two groups as the first group treatment ESWT + exercise, the second group sham ESWT + exercise.||||
34031726|NCT00712790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031727|NCT02256423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34031728|NCT05051514|||COHORT||CROSS_SECTIONAL|||||||
34031729|NCT02872428|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031730|NCT06176729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031731|NCT01867892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031732|NCT04324021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031733|NCT00743418|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34031734|NCT05808322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031735|NCT02712723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031736|NCT00669305|||COHORT||PROSPECTIVE|||||||
34031737|NCT03399045|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031738|NCT05615727|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|placebo-controlled crossover trial|"Each participant will take part in three sleep investigations. Each sleep investigation will take place after the participant has completed one night of sleep familiarization in the laboratory. The 3 sleep investigations will be conducted after administration of the following in a randomised manner:~1. Placebo~2. Intranasal dexmedetomidine~3. Zolpidem"|t|f|f|t
34106426|NCT02977871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106427|NCT03260322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106428|NCT01396876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106429|NCT05003700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106430|NCT06105398|||COHORT||RETROSPECTIVE|||||||
34106431|NCT04493138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106432|NCT06145711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031739|NCT01439581|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients were assigned randomly to either a medical intensive care unit with pressure mapping beds or a unit that did not have them||||
34106433|NCT06675851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blind, prospective, longitudinal (optional cross-over-design in selected patients)|t|t|t|f
34106434|NCT02500966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805958|NCT04100538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33805959|NCT02972359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805960|NCT04650191|||CASE_CONTROL||PROSPECTIVE|||||||
33805961|NCT04724759|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33805962|NCT06175299|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33805963|NCT04639869|RANDOMIZED|CROSSOVER||OTHER||NONE||Full replicate cross-over bioequivalence study||||
33805964|NCT04558723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805965|NCT05167318|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33805966|NCT00556478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33805967|NCT01189929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805968|NCT05081804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The providers taking care of the neonates will not know if the mother was randomized to receive the intervention (carbohydrate drink).||f|t|f|f
33805969|NCT04630899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805970|NCT06319430|RANDOMIZED|CROSSOVER||OTHER||NONE||The primary purpose is validation of..........||||
33805971|NCT03034525|||COHORT||RETROSPECTIVE|||||||
33805972|NCT05317273|||COHORT||RETROSPECTIVE|||||||
33805973|NCT01693822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805974|NCT06121375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33805975|NCT01583868|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34031740|NCT00668317|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34031741|NCT05424679|RANDOMIZED|PARALLEL||PREVENTION||NONE||This pilot intervention trial will utilize a randomized controlled design with 1:1 allocation to either the intervention or control group. Both intervention and control groups will receive individualized coping plans, facilitated connections to care, and COVID-19 safety messages. The intervention group will receive caring messages sent on a standardized schedule in addition to what the control group receives.||||
34031742|NCT03529201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A regional block will be performed under general anesthesia. Patients will not be aware of this procedure.|Patients will be randomly allocated to one of the study arms: QLB or control group.|t|f|f|f
34031743|NCT05332821|||COHORT||OTHER|||||||
34031744|NCT01190631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34031745|NCT01765335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031746|NCT00687830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34031747|NCT04284072|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34106435|NCT01299961|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34106436|NCT06409013|||COHORT||CROSS_SECTIONAL|||||||
34106437|NCT04551586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This will be a 3-sequence, 3-period crossover study in healthy adult participants.||||
34106438|NCT01204385|||CASE_ONLY||PROSPECTIVE|||||||
34106439|NCT01408108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106440|NCT02842346|||||PROSPECTIVE|||||||
34106441|NCT06602258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106442|NCT02019173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106443|NCT02315976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106444|NCT06088277|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106445|NCT03816579|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34106446|NCT06674967|||COHORT||PROSPECTIVE|||||||
34106447|NCT05143619|||COHORT||PROSPECTIVE|||||||
34106448|NCT02579057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106449|NCT06569849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind|Randomized, Double blind, Parallel Group, Placebo Controlled Trial|t|f|t|f
34106450|NCT03451136|||COHORT||PROSPECTIVE|||||||
34106451|NCT06395766|||FAMILY_BASED||PROSPECTIVE|||||||
34106452|NCT06068192|||CASE_CONTROL||PROSPECTIVE|||||||
34106453|NCT05157997|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34106454|NCT06570460|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The patients with TS will be randomized to receive either oral (tablet) or transdermal (gel) estrogen replacement therapy. The study is not blinded, as both investigator and study participants know which medication, they are receiving.|A randomized controlled trial||||
34106455|NCT04873154|||OTHER||PROSPECTIVE|||||||
34106456|NCT05812300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106457|NCT06639477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106458|NCT05874804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106459|NCT06642324|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106460|NCT00248235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106461|NCT05292703|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106462|NCT06674928|||COHORT||PROSPECTIVE|||||||
34106463|NCT01588925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106464|NCT03044899|||COHORT||PROSPECTIVE|||||||
34106465|NCT06207851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805976|NCT01231438|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33805977|NCT06698549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is non-randomized, open-label, parallel group study. In Part 1, Cohort 1 will enroll severely renally impaired subjects and Cohort 2 will enroll subjects without renal impairment. In Part 2, if triggered, Cohort 3 will enroll mildly renally impaired subjects and Cohort 4 moderately renally impaired subjects. Cohort 5 will enroll subjects without renal impairment.||||
33805978|NCT01526954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34106466|NCT06674161|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34106467|NCT06142305|NA|SINGLE_GROUP||TREATMENT||NONE||incidence of ipsilateral Supracondylar femoral fractures after cast removal for Developmental dysplasia of the hip (DDH) surgery||||
34106468|NCT02685436|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106469|NCT01783288|NA|SINGLE_GROUP||SCREENING||NONE||||||
34106470|NCT05804084|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, cross-over trial.|t|t|t|t
34106471|NCT06675552|||COHORT||PROSPECTIVE|||||||
34106472|NCT06192797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805979|NCT05166057|RANDOMIZED|PARALLEL||TREATMENT||NONE||The cases meeting the inclusion criteria will be randomized and divided into three groups, the groups will be named as Telerehabilitation Exercise Group (TGr), Video Group (VGr) and Standard pulmonary rehabilitation group (SGr).||||
33805980|NCT01663454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805981|NCT00808405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33805982|NCT02534285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33805983|NCT04110301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805984|NCT04650672|||COHORT||PROSPECTIVE|||||||
33805985|NCT00309166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33805986|NCT04509908|||COHORT||RETROSPECTIVE|||||||
33805987|NCT04623554|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, it is not possible to blind the participants, care providers or investigators. However, the outcome assessors of the primary endpoint (MRI assessment) will not be informed of the patients' allocation. Further, the statistician and data manager are blinded as the group allocation will be coded.|Randomized controlled trial with an intervention arm and a control arm|f|f|f|t
33805988|NCT05159453|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, crossover study of insulin supplementation beginning with 2 weeks monitoring of response to injected dosing, crossover to transdermal dosing, then back to injected dosing.||||
33805989|NCT06510764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33805990|NCT05274321|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33805991|NCT02574611|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33805992|NCT03235856|||OTHER||RETROSPECTIVE|||||||
33805993|NCT00005943||||TREATMENT||||||||
33805994|NCT01515241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33805995|NCT01285999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33805996|NCT06482112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33805997|NCT03987243|NA|SINGLE_GROUP||PREVENTION||NONE||This is a longitudinal, within-subject, repeated (A-B-A-B) measures design. Two interventions will be provided: structured education regarding pressure ulcer prevention through weight shifts at start of study and use of a mobile seat interface pressure map (IPM).||||
33805998|NCT04446481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Exp1. Protocol establishment: 15 cognitively intact and 15 Vets with mild cognitive impairment~Exp2. Efficacy Testing: 20 Vets over the age of 60"||||
33805999|NCT03813524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806000|NCT05925699|||COHORT||OTHER|||||||
33806001|NCT04823754|||COHORT||PROSPECTIVE|||||||
33806002|NCT02631369|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806003|NCT01365988|||||OTHER|||||||
33806004|NCT00817154|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33806005|NCT06698952|RANDOMIZED|PARALLEL||OTHER||NONE|Participants themselves cannot be blinded to their condition due to the nature of the intervention. However, the statistician conducting data analysis will receive de-identified and de-grouped datasets to ensure blinding during analysis.|Eligible participants will be randomised to either the intervention or control groups with the former receiving the chatbot-delivered structured psychological intervention and the latter receiving a different generative chatbot to have casual conversations at a similar frequency.||||
34031748|NCT03376334|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor (using balance test) was not aware of neither the group to which the subject belonged nor to the baseline values of the subjects' balance score|One group received Mental Motor Imagery training, and the other group acted as a control with no specific intervention.|f|f|f|t
34031749|NCT03032627|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34031750|NCT00603707|||CASE_CONTROL||PROSPECTIVE|||||||
34031751|NCT05999214|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34031752|NCT01395927|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34031753|NCT02071030|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34031754|NCT03042091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031755|NCT01213225|||||PROSPECTIVE|||||||
34031756|NCT03849157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant and investigator are not blinded. outcome assessor who are in charge of follow-up assement is masked.||f|f|f|t
34031757|NCT06046898|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Recordings will be analysed by investigators blind to ventilation conditions|Esophageal pressure, electrical activity of the diaphram (Eadi) and sMMG will be recorded in 10 healthy subjects in spontaneous ventilation (SV) and non-invasive ventilation with or without resistance.|f|f|f|t
34031758|NCT01934855|||COHORT||PROSPECTIVE|||||||
34031759|NCT06250218|NA|SINGLE_GROUP||OTHER||NONE||||||
34031760|NCT03825224|||CASE_ONLY||PROSPECTIVE|||||||
34031761|NCT06582030|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34031762|NCT01497769|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34031763|NCT06299787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031764|NCT01312558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031765|NCT06405594|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive the same intervention (language condition) and a single arm (language condition)||||
34031766|NCT01128907|||CASE_CONTROL||PROSPECTIVE|||||||
34031767|NCT01883466|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34031768|NCT04152967|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients involved in this research should meet the requirement that they need valved conduits to reconstruct right ventricular outflow tract, first time operation and reoperation to change the decayed conduit included.||||
34031769|NCT03724435|||COHORT||PROSPECTIVE|||||||
34031770|NCT05211635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo- controlled randomized 1:1 comparison|t|t|t|t
34031771|NCT01526057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031772|NCT03632213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Experimental group: 15 patients, both sexes, will receive Losartan 25 mg orally for 12 months.~Control group: 15 patients, both sexes, will receive oral placebo for 12 months.~Eligible research participants for treatment will be randomly assigned to a treatment group or a control group in a ratio of 1: 1. The groups will be stratified by age and type of MPS in the following strata:~A) Diagnosis of MPS IVA: 20 patients expected B) Diagnosis of MPS VI: 10 patients expected"|t|t|t|f
34106473|NCT02954562|||CASE_CROSSOVER||PROSPECTIVE|||||||
34106474|NCT01554709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106475|NCT03940521|||CASE_ONLY||PROSPECTIVE|||||||
34106476|NCT05043831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor is not aware if subject is treated with SLT or DSLT|1:1 randomization|f|f|f|t
34106477|NCT00974597|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106478|NCT03753074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106479|NCT02743221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106480|NCT04097665|||COHORT||PROSPECTIVE|||||||
34106481|NCT06383013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106482|NCT02150863|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34106483|NCT06429657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106484|NCT04503421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106485|NCT06448715|||CASE_ONLY||PROSPECTIVE|||||||
34106486|NCT02854267|||COHORT||PROSPECTIVE|||||||
34106487|NCT00888771|||COHORT||PROSPECTIVE|||||||
34106488|NCT03968406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106489|NCT06025708|||COHORT||PROSPECTIVE|||||||
34106490|NCT01892189|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34106491|NCT02592655|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34106492|NCT05928572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106493|NCT06253273|||OTHER||CROSS_SECTIONAL|||||||
34106494|NCT06675383|||COHORT||PROSPECTIVE|||||||
34106495|NCT06662695|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34106496|NCT02808884|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Blood test screening for all who wish to participant. Additional screening test for those who test positive twice.||||
34106497|NCT01629888|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34106498|NCT06295588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106499|NCT01254110|||||PROSPECTIVE|||||||
34106500|NCT00283985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106501|NCT06672341|||COHORT||PROSPECTIVE|||||||
34106502|NCT03217721|||COHORT||RETROSPECTIVE|||||||
34106503|NCT04105361|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106504|NCT05057546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||BESH clinical trial||||
34106505|NCT06012162|||COHORT||PROSPECTIVE|||||||
33806006|NCT05491135|NA|SINGLE_GROUP||TREATMENT||NONE||ATIMP||||
34106506|NCT02393625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806007|NCT06665022|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|A blinding code will be entered into the stimulation device to initiate the randomized stimulation condition.|Participants will enroll in a randomized double-blinded crossover within subject study. Each participant will undergo two MRI sessions. Each MRI session will include either one active tDCS or one sham tDCS. The order of delivering active or sham tDCS first will be randomized. A washout period between active and sham tDCS will be set for at least two-weeks to ensure no after-effect from the first stimulation session will be carried over to the second session.|t|f|f|t
33806008|NCT03136172|||COHORT||PROSPECTIVE|||||||
33806009|NCT05660174|||COHORT||OTHER|||||||
33806010|NCT05489913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806011|NCT06191016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806012|NCT06396546|||CASE_ONLY||PROSPECTIVE|||||||
33806013|NCT00091689|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806014|NCT02285270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806015|NCT04643574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106507|NCT05521178|||COHORT||PROSPECTIVE|||||||
33806016|NCT05829512|||CASE_ONLY||PROSPECTIVE|||||||
33806017|NCT00831688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806018|NCT00995592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806019|NCT04896099|||COHORT||PROSPECTIVE|||||||
33806020|NCT00002893|RANDOMIZED|||TREATMENT||||||||
33806021|NCT01860079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806022|NCT03983668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806023|NCT00912964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806024|NCT06142409|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33806025|NCT06539312|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106508|NCT04193176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106509|NCT03618069|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34106510|NCT06569745|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34106511|NCT06675396|||COHORT||PROSPECTIVE|||||||
34106512|NCT04365790|||COHORT||RETROSPECTIVE|||||||
34106513|NCT02157727|||CASE_CONTROL||PROSPECTIVE|||||||
34106514|NCT05277935|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106515|NCT06473103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106516|NCT04753567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106517|NCT01930708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106518|NCT05227365|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-site, single-arm repeated measures prospective investigation.||||
34106519|NCT05708690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subjects were not aware of the arms/treatment given as they were under general anesthesia during the application of interventions being studied. Besides, during the informed consent for the elective cardiac surgery, subjects were extensively given explanation of the purpose, methods, benefits and risks of the procedure including the randomized nature of the allocation to either arms of the study.~Principal investigators as well as outcomes assessor were kept unaware of the randomization of interventions as they both were restricted for assessing the patients' medical record and the patient identity were coded in the primary database."|A double-blind, single center, parallel phase 4 randomized clinical trial was conducted with two intervention arms: an intervention arm with the use of tranexamic acid topical and a control arm with the use of normal saline in which the subjects' recruitment and treatment were conducted simultaneously by means of a block randomization.|t|f|t|t
34106520|NCT06540014|||OTHER||RETROSPECTIVE|||||||
33806026|NCT04777357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106521|NCT04650256|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106522|NCT02399995|||COHORT||PROSPECTIVE|||||||
34031773|NCT02459743|||COHORT||PROSPECTIVE|||||||
34031774|NCT00271401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031775|NCT06008184|||OTHER||PROSPECTIVE|||||||
34031776|NCT03839537|NA|SINGLE_GROUP||SCREENING||NONE||||||
34031777|NCT01370031|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031778|NCT00425204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031779|NCT02741414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031780|NCT03561129|||COHORT||RETROSPECTIVE|||||||
34031781|NCT01570478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031782|NCT05713565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded for group assignment at the 6-, and 12-month follow-up visit.|Single center prospective randomized open blinded end-point (PROBE)|f|f|f|t
34031783|NCT02289703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031784|NCT01772875|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031785|NCT03427515|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Healthy medical students were assigned|t|f|t|t
34031786|NCT06551285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031787|NCT02585778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031788|NCT03022916|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031789|NCT00866021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031790|NCT00055731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031791|NCT04784611|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Given the nature of the intervention it is not possible to mask participants and interventionists to group assignment. Outcome assessors and investigators will be unaware of group assignment.|Participants will be randomly assigned to either the intervention or usual care groups using block randomization with randomly selected blocks of 4, 8 or 12. Randomization sequence will be generated using SAS algorithm.|f|f|t|t
34031792|NCT05636267|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031793|NCT01152372|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34031794|NCT04904133|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants were not informed about the study group and also which sweetener they consumed.|Volunteers were randomly divided into 4 groups (saccharin, sucralose, aspartame+acesulfame-K \[Asp+Ace-K\], control) and asked to drink the LNCS sweetened water once a day for 4-wks. All study groups and concentration of LNCS they consumed written as follows; Saccharin group: 330 mL water + 140 mg saccharine Sucralose group: 330 mL water + 66 mg sucralose Asp+Ace-K group: 330 mL water + 88 mg aspartame and 88 mg acesulfame-K Control group IV: 330 mL water only|t|f|t|f
34031795|NCT02377297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031796|NCT00271193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031797|NCT02255968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031798|NCT00688532|||COHORT||RETROSPECTIVE|||||||
34031799|NCT06551480|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34031800|NCT00599248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031801|NCT01918566|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34031802|NCT03065192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031803|NCT01847404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031804|NCT04422600|||COHORT||PROSPECTIVE|||||||
34031805|NCT03926351|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double blinded|A randomized, 24-week parallel-group placebo-controlled (Phase 2) pilot-study of high dose Omega 3 (DHA) in people at risk for dementia|t|t|t|f
34031806|NCT00139893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031807|NCT00006038||||TREATMENT||||||||
34031808|NCT01286753|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031809|NCT03552380|NA|SEQUENTIAL||TREATMENT||NONE||||||
33724353|NCT04455269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical examination, collection of periodontal parameters and clinical photographs were performed by the same trained dentist blinded to the treatment.|Mono-centric, double-blinded, randomized clinical trial (RCT) with a split-mouth design.|f|f|t|f
33724354|NCT02606188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724355|NCT05361317|NA|SINGLE_GROUP||OTHER||NONE||||||
33724356|NCT03602469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind study||t|f|f|t
33724357|NCT03287167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
33724358|NCT03461900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||stepped wedge cluster randomized trial|t|f|t|f
33724359|NCT05185960|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33724360|NCT02574247|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724361|NCT01420289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031810|NCT05153993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34031811|NCT01469728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031812|NCT01782014|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34031813|NCT05662527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031814|NCT01982955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031815|NCT06452134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34031816|NCT02748148|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34031817|NCT03147430|||COHORT||PROSPECTIVE|||||||
34031818|NCT03905694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031819|NCT05808608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031820|NCT01289145|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34031821|NCT00652561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724362|NCT03134755|||CASE_ONLY||PROSPECTIVE|||||||
33724363|NCT00428493|||||PROSPECTIVE|||||||
33724364|NCT03812055|||CASE_ONLY||PROSPECTIVE|||||||
33724365|NCT02085954|||COHORT||RETROSPECTIVE|||||||
33724366|NCT02121483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724367|NCT00973024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106523|NCT06074497|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106524|NCT05328765|||COHORT||RETROSPECTIVE|||||||
34106525|NCT00812539|RANDOMIZED|PARALLEL||||NONE||||||
34106526|NCT01838226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34106527|NCT06637982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106528|NCT01772771|||CASE_ONLY||PROSPECTIVE|||||||
34106529|NCT04031950|||COHORT||PROSPECTIVE|||||||
34106530|NCT04999202|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106531|NCT05247866|NA|SINGLE_GROUP||TREATMENT||NONE||All patients receive active therapy||||
34106532|NCT00726479||PARALLEL||TREATMENT||||||||
34106533|NCT05830097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106534|NCT05136027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Exercise group Atenttion Control|f|t|f|f
34106535|NCT05534490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Study, single-blind.|f|t|f|f
34106536|NCT00349986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106537|NCT05012813|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106538|NCT05720091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106539|NCT03984188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106540|NCT04085731|||COHORT||PROSPECTIVE|||||||
34106541|NCT04954066|||COHORT||PROSPECTIVE|||||||
34106542|NCT00001784||||TREATMENT||||||||
34106543|NCT05173363|||OTHER||CROSS_SECTIONAL|||||||
34106544|NCT04070846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106545|NCT00567229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106546|NCT06386432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Any outcome evaluator who has contact with participants will remain blinded to treatment group assignment until the final set of questions regarding acceptability of specific program components is asked.||f|f|f|t
34106547|NCT05822245|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Placebo sham|Dose escalation.|t|f|f|f
34106548|NCT02056145|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34106549|NCT01872000|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106550|NCT00517114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34106551|NCT02669641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106552|NCT06661421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols, and possible efforts will be put to mask both groups about the treatment.|A sample size of 38 was calculated using Epitool online software, and the mean values of dynamic balance from the previous study were taken. By adding a 10% attrition rate (34+4), the sample size will be 38.|t|f|f|f
34106553|NCT01737723|||CASE_CONTROL||PROSPECTIVE|||||||
34106554|NCT06085872|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34106555|NCT05681078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106556|NCT06417229|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33724368|NCT05481567|||COHORT||CROSS_SECTIONAL|||||||
34106557|NCT06060444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34106558|NCT02295579|||CASE_ONLY||PROSPECTIVE|||||||
34106559|NCT04204616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106560|NCT05540184|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106561|NCT06127901|||COHORT||PROSPECTIVE|||||||
34106562|NCT00471393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34106563|NCT06496607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106564|NCT06451458|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic, Cluster Randomized Clinical Trial||||
34106565|NCT01582555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106566|NCT06569927|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The intervention study used a single-blind design, blinded the subjects, and the patients did not know the specific intervention measures, and did not know whether they were included in the control group or the intervention group.|Subjects were grouped based on admission time to avoid contamination between groups, with data collection for the intervention group conducted after the control group.|t|f|f|f
34106567|NCT02904096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106568|NCT06177431|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Extension||||
33724369|NCT00119392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724370|NCT03171987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and care provider will be blind to group. Participant will know their treatment.|"1. Lidocaine patch group: 1 piece lidocaine patch per day at back pain area. The treatment lasts for 28 days.~2. Flurbiprofen patch group: 1 piece flurbiprofen patch per day at back pain area. The treatment lasts for 28 days."|f|t|t|f
33724371|NCT04855461|||OTHER||CROSS_SECTIONAL|||||||
33724372|NCT06127459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724373|NCT03989440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 - None; Part 2 - Quadruple|Part 1 is open-label single-ascending dose. Part 2 is double-blind, placebo-controlled, repeat dose.|t|t|t|t
33724374|NCT00911677|||COHORT||PROSPECTIVE|||||||
33724375|NCT01085799|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724376|NCT04307446|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106569|NCT04620668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be assigned to one of two groups. The treatment group will use a mental health chatbot (Wysa) over a period of four weeks. The control group will receive no intervention.|f|f|f|t
34106570|NCT06265818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34106571|NCT05830539|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106572|NCT06487559|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106573|NCT06570356|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106574|NCT04624399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106575|NCT06577675|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106576|NCT03497702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106577|NCT05597397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106578|NCT05462821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106579|NCT06352567|||CASE_ONLY||CROSS_SECTIONAL|||||||
34106580|NCT06642272|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment assignment will be blinded to the statistician analysing the trial data.|||||
34106581|NCT05757726|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34106582|NCT00260338|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806027|NCT05528549|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806028|NCT00640588|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33806029|NCT03107169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomized by a closed envelope method in a 1: 1 ratio to either oral vancomycin (every 6 h for 10-14 days) or a FMT-FURM||t|f|f|f
33806030|NCT01146522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806031|NCT06696599|||OTHER||CROSS_SECTIONAL|||||||
33806032|NCT02531841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106583|NCT01117662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106584|NCT06357715|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|the second physiotherapist who evaluate the pressure pain||f|f|f|t
34106585|NCT01321905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724377|NCT02690610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106586|NCT04336566|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|Participant, care provider, data manager/monitor, principle investigator all blinded||t|t|t|t
34106587|NCT00196612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106588|NCT02162173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106589|NCT05806528|||CASE_ONLY||PROSPECTIVE|||||||
34106590|NCT06637059|||COHORT||RETROSPECTIVE|||||||
34106591|NCT02117271|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106592|NCT02811614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106593|NCT01582581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106594|NCT06251973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106595|NCT02025218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106596|NCT03474484|||CASE_ONLY||RETROSPECTIVE|||||||
34106597|NCT05369000|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106598|NCT02244957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106599|NCT06375499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34106600|NCT06570499|NA|SINGLE_GROUP||SCREENING||NONE||a group of patients: 6 different impressions taken from the same patient. Analysis of the impressions in a second step||||
34106601|NCT06418763|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34106602|NCT05886244|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
34106603|NCT00647439|||CASE_CONTROL||OTHER|||||||
34106604|NCT00908908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106605|NCT04228731|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106606|NCT01414790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34106607|NCT02562703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34106608|NCT04667962|||COHORT||PROSPECTIVE|||||||
34106609|NCT06004583|||CASE_CONTROL||RETROSPECTIVE|||||||
34106610|NCT02370342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106611|NCT00181246|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106612|NCT03070834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106613|NCT00456365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106614|NCT06569888|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106615|NCT06691646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All researchers involved in data collection are masked until after data collection and preprocessing is complete.|Participants randomly assigned to undertake 2, 3 or 4 training sessions at home, per week, for 20 to 30 minutes per session over a period of two weeks. Total achieved training time is recorded and will be correlated with outcomes.|f|f|f|t
34106616|NCT03983239|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106617|NCT04674319|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106618|NCT00326014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106619|NCT03702595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106620|NCT06596759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106621|NCT03161496|||COHORT||PROSPECTIVE|||||||
34106622|NCT04361487|||COHORT||PROSPECTIVE|||||||
34106623|NCT04103931|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients are randomly assigned to receive the decision aid or usual care.||||
34106624|NCT03582397|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is an interventional pilot study with a pre-test/post-test design. All eligible subjects will receive the intervention. We plan to enroll up to 20 subjects, with the goal of having 10-12 evaluable subjects.||||
33724378|NCT04460820|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724379|NCT03892356|||CASE_CONTROL||PROSPECTIVE|||||||
33724380|NCT03323346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724381|NCT02206828|||COHORT||PROSPECTIVE|||||||
33724382|NCT02168010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724383|NCT06362434|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33724384|NCT01073852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724385|NCT03560531|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation cohorts are planned in monotherapy and combination as well as monotherapy dose expansion, and monotherapy and combination Phase 2.||||
33724386|NCT03043625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, double-blinded, sham-controlled, study|t|f|f|t
33724387|NCT01669447|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33724388|NCT00564655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724389|NCT03962153|||COHORT||PROSPECTIVE|||||||
33724390|NCT01215370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33724391|NCT02336022|||COHORT||PROSPECTIVE|||||||
33724392|NCT00260858|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724393|NCT01184547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724394|NCT03448965|||OTHER||CROSS_SECTIONAL|||||||
33724395|NCT00988754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724396|NCT00584558|||COHORT||PROSPECTIVE|||||||
33724397|NCT02226003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724398|NCT03895983|||CASE_CONTROL||PROSPECTIVE|||||||
33724399|NCT02959047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724400|NCT00366197|||||PROSPECTIVE|||||||
33724401|NCT00791518|||||PROSPECTIVE|||||||
33724402|NCT00109395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724403|NCT03395912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106625|NCT03116178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34106626|NCT06644937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106627|NCT05790031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106628|NCT05594875|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-1921 single arm study in pt. with Advance solid tumors||||
34106629|NCT04195256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-dummy|Adaptive, multi-centre, two-arm, randomized, blinded, double-dummy, controlled, parallel group, non-inferiority, phase II/III trial|t|t|t|t
34106630|NCT04963296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106631|NCT05486065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031822|NCT03886298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031823|NCT04443816|||COHORT||PROSPECTIVE|||||||
34031824|NCT05991791|NA|SINGLE_GROUP||OTHER||NONE||||||
34031825|NCT06581458|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34031826|NCT06583005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031827|NCT02431364|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34031828|NCT03014843|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34031829|NCT04983134|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031830|NCT00372840|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031831|NCT05646459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34031832|NCT04257539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator was masked to treatment group and all analyses were performed on masked data.|The 40 participants with chronic low back pain were randomized to either Intervention or Wait-list Control groups, while all 20 healthy control participants did not receive the intervention.|f|f|t|f
34031833|NCT01358747|RANDOMIZED|PARALLEL||||||||||
34031834|NCT02939794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031835|NCT04756115|||COHORT||RETROSPECTIVE|||||||
34031836|NCT06332014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031837|NCT03878212|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34031838|NCT03610152|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34031839|NCT03885687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031840|NCT02970487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031841|NCT01073085|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34031842|NCT02538822|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031843|NCT06054035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomization will be performed stratified by prediabetes cluster and by intake of antihypertensive medication (yes/no).|t|f|t|f
34031844|NCT02681510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031845|NCT06020144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031846|NCT06581302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031847|NCT01925963|||COHORT||PROSPECTIVE|||||||
34031848|NCT00416611|||COHORT||PROSPECTIVE|||||||
34031849|NCT01551030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031850|NCT00380835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031851|NCT04154631|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The assessment team will be blind to group allocation at post-treatment and six-month follow-up|CMHC sites will be cluster randomized to either Standard TranS-C or Adapted TranS-C. Then within each CMHC site, patients will be randomized to either TranS-C or to Usual Care followed by Delayed Treatment (UC-DT).|f|f|f|t
34031852|NCT00937716|||CASE_CONTROL||PROSPECTIVE|||||||
34031853|NCT04296591|||CASE_CONTROL||PROSPECTIVE|||||||
34031854|NCT00015886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031855|NCT03877679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor (CS) and statistician||f|f|f|t
34031856|NCT05180448|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Outcomes assessors will be blind to condition.|This is a 2x2x2 design. There are three factors, each with two levels: ON vs OFF|f|f|f|t
34031857|NCT04481555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"4-arm facultative designed, randomized controlled, multicenter, parallel group, double-blinded (azithromycin), non-inferiority intervention study in patients with severe and very severe COPD study.~Participants will be randomly allocated to one of four treatment groups."|t|t|t|t
34031858|NCT04504994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34031859|NCT06388005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34031860|NCT00599053|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031861|NCT03535012|||COHORT||PROSPECTIVE|||||||
34031862|NCT02988414|||COHORT||OTHER|||||||
34031863|NCT01960439|||COHORT||RETROSPECTIVE|||||||
34031864|NCT02656069|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34031865|NCT06530797|||COHORT||PROSPECTIVE|||||||
34031866|NCT03519789|||CASE_CONTROL||PROSPECTIVE|||||||
34031867|NCT02237586|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34031868|NCT02864992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031869|NCT05697016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031870|NCT03746392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34031871|NCT05645133|||COHORT||PROSPECTIVE|||||||
34031872|NCT04279210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031873|NCT01313052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031874|NCT00929851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031875|NCT02717455|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031876|NCT05821335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessment and treatment will be done by different investigators.||f|f|f|t
34031877|NCT01594255|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34031878|NCT03688048|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34031879|NCT00034138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031880|NCT00274339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031881|NCT00490841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031882|NCT05716126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106632|NCT00006377||||TREATMENT||||||||
34106633|NCT05293002|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive the Restorer stent of iVascular according to the IFU. Prospective, single-arm, multicentre, physician-initiated clinical study to assess the safety and efficacy of the study device during a two year FU period.||||
34106634|NCT05074303|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34106635|NCT03587090|||COHORT||PROSPECTIVE|||||||
34106636|NCT06642987|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34106637|NCT05516134|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the intervention||||
34106638|NCT05284617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo.|t|t|t|t
34106639|NCT03109067|NA|SINGLE_GROUP||SCREENING||NONE||Same intervention for everyone, two different groups||||
34031883|NCT05642715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treatment allocation will be concealed from the individual completing study assessments||f|f|f|t
34106640|NCT06466837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research assistant, who will be responsible for data collection, will be masked for the group allocation during the whole process.|Single-blinded, two-armed, randomized controlled trial.|f|f|f|t
33806033|NCT05619705|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||The design of the study is a randomized, two parallel-arm clinical trial. The investigators will be applying principles of a hybrid type 1 effectiveness-implementation randomized control trial|f|f|t|t
34031884|NCT03977142|||COHORT||PROSPECTIVE|||||||
34031885|NCT04757597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34031886|NCT06178627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031887|NCT01579747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34031888|NCT00198055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031889|NCT04190758|||COHORT||PROSPECTIVE|||||||
34031890|NCT03197441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031891|NCT04730583|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34031892|NCT04005001|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34031893|NCT02190370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106641|NCT05896202|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151089|NCT03133312|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant will not know which group they have been assigned to. The surgeon and OR staff performing the vaginal preparation will know, but the nursing staff in the recovery area will not. The lab will be blinded toward which type of surgical prep was used.|"Drug: Chlorhexidine Gluconate Applied to vagina pre-operatively for antiseptic; regulated as a drug by FDA~Other Name: CHG~Drug: Povidone-Iodine Scrub and Paint Applied to vagina pre-operatively for antiseptic; regulated as a drug by FDA~Other Name: Betadine"|t|t|f|t
34031894|NCT00004073||||TREATMENT||||||||
34031895|NCT00033007|RANDOMIZED|||TREATMENT||||||||
34031896|NCT06336265|||CASE_ONLY||PROSPECTIVE|||||||
34031897|NCT02219412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031898|NCT02480517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031899|NCT02940496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031900|NCT04635917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151090|NCT03307031|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A CONTROLLED CLINICAL TRIAL|f|f|t|t
34031901|NCT01913886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031902|NCT00172029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031903|NCT03709511|RANDOMIZED|PARALLEL||PREVENTION||NONE|Both the researchers and participants know which treatment is being administered(An open-label trial).|||||
34031904|NCT06550414|RANDOMIZED|PARALLEL||OTHER||SINGLE|double blind.|randomized control trial|f|f|t|f
34031905|NCT00264901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031906|NCT06200506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Study of a prospective longitudinal clinical trial: two intervention groups and a control group|f|f|t|t
33724404|NCT05398432|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Randomization was performed to ensure that any observed changes in outcomes between the experimental and control groups were free from bias. Four sessions in the hemodialysis unit were listed and four lots were drawn by a person who was unaware of the study. The first draw was the experimental group, the second draw was the control group, the third draw was the experimental group, and the fourth draw was the control group. Thus, the patients in the morning and afternoon sessions on Monday-Wednesday-Friday constituted the control group, and the patients in the Tuesday-Thursday-Saturday morning and afternoon sessions constituted the experimental group.|randomized controlled trial design||||
33724405|NCT06252220|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Masking is to be done at the pharmacy level. The pharmacists that do not have other responsibilities in the study will prepare and administer the drug.||t|f|t|t
33724406|NCT01193569|||COHORT||PROSPECTIVE|||||||
33724407|NCT00491387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724408|NCT01470742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724409|NCT03011255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724410|NCT01425554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724411|NCT00735774|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33724412|NCT05083793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|care provider||f|t|f|f
33724413|NCT06036420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724414|NCT04954963|||COHORT||PROSPECTIVE|||||||
33724415|NCT00460031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724416|NCT06388174|||COHORT||PROSPECTIVE|||||||
33724417|NCT01907503|RANDOMIZED|PARALLEL||||NONE||||||
33724418|NCT01678092|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33724419|NCT00725218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724420|NCT05315518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724421|NCT03160742|||COHORT||PROSPECTIVE|||||||
33724422|NCT05109507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724423|NCT03526419|||COHORT||PROSPECTIVE|||||||
33724424|NCT01917266|||COHORT||PROSPECTIVE|||||||
33724425|NCT03030690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724426|NCT00278109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031907|NCT01134302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34031908|NCT03169088|NA|SINGLE_GROUP||OTHER||NONE||monocentric study||||
34031909|NCT03354260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031910|NCT01624025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031911|NCT01027598|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33724427|NCT05041296|||CASE_CONTROL||PROSPECTIVE|||||||
33724428|NCT06244069|||COHORT||PROSPECTIVE|||||||
33724429|NCT00919776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806034|NCT00895609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806035|NCT01160354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806036|NCT01262963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806037|NCT02457806|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33806038|NCT01611337|NA|SINGLE_GROUP||OTHER||NONE||||||
34031912|NCT04858932|||COHORT||PROSPECTIVE|||||||
34031913|NCT00347984|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34031914|NCT03617783|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34031915|NCT05443815|||COHORT||PROSPECTIVE|||||||
34031916|NCT04498026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031917|NCT06147427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031918|NCT03815825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031919|NCT05782673|||COHORT||PROSPECTIVE|||||||
34031920|NCT02122029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031921|NCT06370741|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE||Pilot study|f|f|f|t
34031922|NCT01934985|||COHORT||PROSPECTIVE|||||||
34031923|NCT04997863|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34031924|NCT02289443|||COHORT||PROSPECTIVE|||||||
34031925|NCT05593094|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031926|NCT00242424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34031927|NCT05629819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients enrolled in the study were unaware of the study||t|f|f|f
34031928|NCT01905995|||CASE_ONLY||PROSPECTIVE|||||||
34031929|NCT00587860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031930|NCT02477410|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34031931|NCT00269139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031932|NCT05522127|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34031933|NCT03519087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34031934|NCT04566055|||COHORT||PROSPECTIVE|||||||
34031935|NCT05579457|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34031936|NCT03906110|||COHORT||PROSPECTIVE|||||||
34031937|NCT04273191|NA|SINGLE_GROUP||OTHER||NONE||||||
34031938|NCT05726786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multicenter, prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers||||
34031939|NCT00261560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031940|NCT00013442|||||PROSPECTIVE|||||||
34031941|NCT00003610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34031942|NCT06489210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34031943|NCT03817645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031944|NCT00181701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34031945|NCT05970224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031946|NCT05825443|NA|SINGLE_GROUP||TREATMENT||NONE||Four cycles of chemotherapy combine with camrelizumab, followed by maintenance with camrelizumab until one year or the disease progressed or unacceptable toxicity||||
34031947|NCT04175288|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34031948|NCT02998086|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724430|NCT04105998|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participant, Investigator, and outcomes assessor will be blinded. The Research Pharmacist will prepare the study medication and hold the randomization.|Double blinded crossover treatment with oxytocin and placebo (saline)|t|f|t|t
33724431|NCT02726074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724432|NCT02419404|||COHORT||PROSPECTIVE|||||||
33724433|NCT05217407|||OTHER||PROSPECTIVE|||||||
33724434|NCT00851799|||COHORT||PROSPECTIVE|||||||
33724435|NCT01352312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031949|NCT02995408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031950|NCT00830973|||COHORT||PROSPECTIVE|||||||
34031951|NCT05820126|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The investigator and participant will both be blinded to the study treatment (whether they receive cold stored vs. room temperature stored platelets)|Single center, Blinded, Randomized Controlled Trial|t|f|t|f
34031952|NCT00199394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031953|NCT00740233|||COHORT||PROSPECTIVE|||||||
34151091|NCT05883722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151092|NCT01241071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151093|NCT01291836|||COHORT||PROSPECTIVE|||||||
34151094|NCT02567045|RANDOMIZED|PARALLEL||SCREENING||NONE|Participants were randomized to either colonoscopy or faecal occult blood test|||||
34151095|NCT02083887|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34151096|NCT04465968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151097|NCT01280578|||COHORT||PROSPECTIVE|||||||
34151098|NCT04942236|||COHORT||PROSPECTIVE|||||||
34151099|NCT02152527|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806039|NCT03357926|||COHORT||PROSPECTIVE|||||||
33806040|NCT04621435|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806041|NCT01083134|||COHORT||PROSPECTIVE|||||||
33806042|NCT04070820|||CASE_ONLY||PROSPECTIVE|||||||
33806043|NCT00224432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151100|NCT05094830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151101|NCT04881747|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34151102|NCT05940818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151103|NCT02526108|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34152398|NCT06256653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinding of both study team and Participants will be ensured by only providing access to the randomisation list to the science and quality team which is stored in the quality drive. The relationship between the randomisation number and the group assignment will be unknown to the Participants, clinical study team, and the Sponsor, i.e., the study will be double-blinded.|Randomised, double-blinded, placebo-controlled, parallel study in overweight and obese adults.|t|f|t|t
34152399|NCT03330184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106642|NCT04327817|NA|SINGLE_GROUP||TREATMENT||NONE|"The ReActiv8 IPG, and the ReActiv8 leads (available in either 45 cm or 65 cm lengths), plus suture sleeves.~The Lead is designed to be placed using a commercially available 7 Fr Introducer Kit (not included with ReActiv8) and the Mainstay Model TUN1 Tunneler (included with ReActiv8) or commercially available equivalent. The electrodes are located at the distal end of a Stimulation Lead that is connected to an implantable pulse generator (IPG) placed in a surgical pocket typically above the buttocks (in a place similar to that used in Spinal Cord Stimulation implants). Two leads are placed (one each left and right side) and connected to the IPG. The IPG is externally programmable with a Programmer. Stimulation is manually initiated by an external device (Activator) and can be stopped with the Activator or Magnet."|The Mainstay ReActiv8 is an implantable electrical stimulation system that consists of an implantable pulse generator, implantable leads, programmer, activator and magnet.||||
34106643|NCT01418105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34106644|NCT00661687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106645|NCT01730729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106646|NCT06671119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106647|NCT05938283|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomised control trial, randomised 1:1 for Transvenous: Subcutaneous||||
34106648|NCT00173173|||DEFINED_POPULATION||OTHER|||||||
34106649|NCT03928015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open label, randomized controlled trial||||
34106650|NCT05315778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106651|NCT05770154|||COHORT||CROSS_SECTIONAL|||||||
34106652|NCT06641479|||COHORT||PROSPECTIVE|||||||
34106653|NCT00007098|||COHORT||PROSPECTIVE|||||||
34106654|NCT01480765|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106655|NCT06282198|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106656|NCT04096235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106657|NCT00648713|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34106658|NCT04629950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106659|NCT02542215|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106660|NCT01586897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106661|NCT02019836|||CASE_CONTROL||PROSPECTIVE|||||||
34106662|NCT00873886|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34106663|NCT03014505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106664|NCT01942460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106665|NCT00044733||||||NONE||||||
34106666|NCT06673758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get seperate treatment protocols and possible efforts will be put to mask the both group about treatment|parallel assignment It will be randomized control trail in which non probality convienent sampling will b used.two groups of 10 to 14 years will be formed in which participants randomly diveded.group one receive art and crafts activity and other receive tai chi exercises of two weeks sessions|t|f|f|f
34106667|NCT06670417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106668|NCT02236013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106669|NCT06640608|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Study participants and Outcome assessors are blinded|the study compare between intervention group (internet -based cognitive behavioral therapy therapy in addition to stander of care and the usual stander of care|t|f|f|t
34106670|NCT05949385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106671|NCT06640868|NA|SEQUENTIAL||TREATMENT||TRIPLE|||f|t|t|t
34031954|NCT00876330|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34106672|NCT05599321|||CASE_CONTROL||PROSPECTIVE|||||||
34106673|NCT06121921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152400|NCT03312205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031955|NCT03348163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031956|NCT06331169|NA|SEQUENTIAL||TREATMENT||NONE||||||
34031957|NCT06550856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031958|NCT01229501|||COHORT||PROSPECTIVE|||||||
34031959|NCT01892124|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34031960|NCT01699815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34031961|NCT05248347|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34031962|NCT02770482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031963|NCT04815577|||COHORT||RETROSPECTIVE|||||||
34031964|NCT04881786|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||from 90 premolars that were randomly divided into 3 groups of 30 premolars each, as follows: I) Untreated teeth control group (without orthodontic forces); II) Moderate force group; III) Severe force group. Teeth in moderate and severe orthodontic force groups were submitted to tipping and extrusion orthodontic movements.||||
34031965|NCT01810302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031966|NCT06575465|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Study Design: The study is designed as a controlled community intervention trial. Participants will be divided into two groups: an intervention group and a control group. The intervention group will receive a comprehensive community-based intervention program, while the control group will receive routine care.~Intervention Group:~* Will receive a tailored healthy lifestyle intervention program focusing on nutrition, physical activity, and behavioral changes.~* 10 sessions will be conducted separately for men and women.~* Each session will last for approximately 2 hours.~* The program will include educational workshops, cooking demonstrations, physical activity sessions, and group discussions.~Control Group:~• They will continue to receive standard care from their healthcare providers without additional intervention.~Duration of the Study:~• The study will last for one year, with follow-up assessments conducted at baseline, 6 months, and 12 months."||||
34031967|NCT04132687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031968|NCT00801502|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34031969|NCT00676832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34031970|NCT04019171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34031971|NCT04433754|||CASE_CONTROL||RETROSPECTIVE|||||||
34031972|NCT04309019|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34031973|NCT05296005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031974|NCT00322634|||COHORT||PROSPECTIVE|||||||
34031975|NCT04128189|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34031976|NCT00641888|||COHORT||PROSPECTIVE|||||||
33724436|NCT04424238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724437|NCT02285907|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33724438|NCT00751348|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724439|NCT01655394|||COHORT||PROSPECTIVE|||||||
34031977|NCT05320965|||COHORT||PROSPECTIVE|||||||
34031978|NCT00771498|NA|SINGLE_GROUP||||NONE||||||
34031979|NCT04519073|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|The Investigator, the laboratory and the subjects will be kept blind to the treatment arm (placebo/vaccine) to which the subject has been allocated up to the end of the study (Month 12).|Randomized, placebo-controlled, double-blind, sequential, parallel cohorts, dose-escalation (three dosages) study in one centre.|t|f|t|f
34031980|NCT03188224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||After completing the baseline assessment, participants will be randomized into one of two groups: intervention or control. Those in the control group will be thanked for their time and informed that the research coordinator will be in touch to set up the follow-up visits (3- and 6-months following baseline). Those in the intervention group will be provided access to the MyTransition app (intervention). The research coordinator will help them navigate through the app and will instruct them on how to use it. These participants will also receive monthly reminder messages from the research coordinator to promote the use of the app.|f|f|f|t
34031981|NCT02045901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34031982|NCT06582472|||COHORT||PROSPECTIVE|||||||
34031983|NCT00469664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34031984|NCT04662814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group A: shockwave therapy and dietary modification group B: dietary modification|t|f|f|f
34031985|NCT01833650|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34031986|NCT05294250|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34031987|NCT00719875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031988|NCT03342885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106674|NCT06312358|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will be assigned to the study intervention consisting of (1) a professional development workshop and (2) weekly job-embedded coaching sessions.||||
34031989|NCT04350411|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients and investigator collecting data were both blinded for which machine was used|Patients randomised between having their procedure performed with one of two different electrosurgery devices|t|f|t|f
34031990|NCT03261505|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34031991|NCT05085444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031992|NCT03162874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34031993|NCT01696747|||COHORT||PROSPECTIVE|||||||
34031994|NCT03267212|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigators and technicians helping for performing the test and encouraging the patient will be blind. Only one investigator will monitor the ventilation during the test and won't be blind but won't be participating to any encouragement or data acquisition.||t|t|t|t
34031995|NCT03649997|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34031996|NCT02704169|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34031997|NCT02033538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34031998|NCT05009017|||COHORT||PROSPECTIVE|||||||
34031999|NCT06042582|||COHORT||CROSS_SECTIONAL|||||||
34032000|NCT05593809|||COHORT||PROSPECTIVE|||||||
34032001|NCT04366323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032002|NCT00993356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032003|NCT00386984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032004|NCT01102101|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34032005|NCT00006073|||||OTHER|||||||
34106675|NCT02193347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106676|NCT05049824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106677|NCT03366831|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34106678|NCT06662799|||COHORT||PROSPECTIVE|||||||
34106679|NCT03907202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"To preserve the blinding of the study for KBP-089 and placebo, all study site personnel, except pharmacy staff who prepare and dispense study medication, and the Sponsor's medical monitor who interacts with site personnel will be blinded to treatment allocation. Blinding of KBP-089 and placebo will be maintained throughout the conduct of the trial until after the completion of the trial and final data review.~Treatment assignment will be kept strictly confidential and accessible only to authorised persons until after the time of unblinding. Codes with treatment assignment will, however, be readily available to the blinded personnel in case of an emergency."|Randomised, patient-blind, investigator-blind, placebo-controlled, multiple ascending dose study. There will be 3 cohorts in which patients are randomised to receive either treatment with KBP-089 or placebo.|t|t|t|f
34106680|NCT02796482|NA|SINGLE_GROUP||||NONE||||||
34106681|NCT04511468|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Independent party will mask the product.|"There will be two arms of intervention:~Arm 1: A combination of Zinc, Chromium, Vitamin C, and Copper (ZCC supplement) with standard healthy lifestyle intervention.~Arm 2: A combination of placebo with standard healthy lifestyle intervention."|t|t|t|t
34106682|NCT03683251|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The sub-study 1 and sub-study 2 are open-label studies.||f|f|f|t
34106683|NCT00833274||PARALLEL||DIAGNOSTIC||NONE||||||
34106684|NCT02963818|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34106685|NCT06642701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106686|NCT03062436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106687|NCT01681641|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106688|NCT03453541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|CRNAs, PACU nurses, and participants are all blinded||t|t|f|f
34106689|NCT02232932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106690|NCT01548300|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34106691|NCT05254418|NA|SEQUENTIAL||OTHER||NONE||||||
34106692|NCT03464461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinded drug|4 groups with 3 different treatments|t|t|f|f
34106693|NCT06675721|||OTHER||PROSPECTIVE|||||||
34106694|NCT05846893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106695|NCT00767208||PARALLEL||||SINGLE|||t|f|f|f
34106696|NCT06131840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106697|NCT03489083|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The aim of this study was to compare the heat shock response (HSR) between healthy middle-aged adults (45-59 years old), healthy elderly adults (\> 60 y.o.) and type 2 diabetic elderly people (\> 60 y.o.). In addition, considering the effects of strength exercise in promoting health, we aimed to test the effects of strength training over the HSR in diabetic elderly people.||||
34106698|NCT06675032|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34032006|NCT03904290|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects brought in for testing prior to PFO closure, then testing repeated 3 months post PFO closure||||
34032007|NCT05442801|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34032008|NCT01360112|||COHORT||PROSPECTIVE|||||||
34032009|NCT03616457|||COHORT||PROSPECTIVE|||||||
34032010|NCT01254773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032011|NCT02371434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032012|NCT01627678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032013|NCT02308124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032014|NCT01284452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032015|NCT01005147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032016|NCT06115525|||COHORT||PROSPECTIVE|||||||
34032017|NCT05411341|||COHORT||PROSPECTIVE|||||||
34032018|NCT05083065|||COHORT||RETROSPECTIVE|||||||
34032019|NCT01659957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032020|NCT02145715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032021|NCT03982147|||CASE_ONLY||PROSPECTIVE|||||||
34032022|NCT05506293|||COHORT||PROSPECTIVE|||||||
34032023|NCT02129322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032024|NCT01932333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032025|NCT06577922|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34106699|NCT05064618|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies.||||
34106700|NCT04310657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106701|NCT00390286|||COHORT||PROSPECTIVE|||||||
34106702|NCT06675318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical and demographic data collection and statistical analyses will be conducted by a blinded researcher with respect to the treatment group and clinical findings.|A prospective cohort study involving two parallel groups with randomization control|f|f|t|t
34106703|NCT04986189|NA|SINGLE_GROUP||SCREENING||NONE||||||
34106704|NCT04306120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106705|NCT04665765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106706|NCT04153162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106707|NCT04206787|||OTHER||PROSPECTIVE|||||||
34106708|NCT04632173|||COHORT||RETROSPECTIVE|||||||
34106709|NCT04909801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106710|NCT05819866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106711|NCT04788615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent EDSS (Expanded disability status scale) rater will be blind to the identity of the treatment throughout the study period. Patient MRI scans read by an independent central MRI reading center.||f|f|f|t
34106712|NCT02826681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106713|NCT04547387|||COHORT||PROSPECTIVE|||||||
34106714|NCT03263533|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34106715|NCT05490056|||OTHER||CROSS_SECTIONAL|||||||
34106716|NCT01929525|||COHORT||PROSPECTIVE|||||||
34106717|NCT01959919|||CASE_ONLY||PROSPECTIVE|||||||
34106718|NCT06675058|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a Selective Case Study ( Prospective Clinical Trial)|t|f|f|t
34106719|NCT04367389|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34106720|NCT02898610|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34106721|NCT02363283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106722|NCT01143636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||For the experiment in patients with pelvic pain, the design is parallel. For the experiment in healthy subjects, the design is crossover.|f|f|t|t
34032026|NCT05236192|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomized control trial effectiveness-implementation hybrid type 2 design will be used. Navy and Marine Corps installations participating in this study will be randomly assigned to one of two conditions: TRHV and SAU. Families receiving NPSP home visiting services will be administered TRHV or SAU depending upon the assignment of their installation.||||
34032027|NCT05044117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032028|NCT01228799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032029|NCT05748587|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106723|NCT06529237|||CASE_ONLY||CROSS_SECTIONAL|||||||
34106724|NCT01460277|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34106725|NCT04781842|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be deidentified prior to be provided for data analysis.|Pretest-posttest control group design. The intervention group is based on retrospective data provided to the investigators. The control group will be recruited from a population where a boxing program is not available.|f|f|f|t
34106726|NCT06637644|||COHORT||PROSPECTIVE|||||||
34106727|NCT04439357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106728|NCT01242384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032030|NCT02012270|||CASE_CONTROL||PROSPECTIVE|||||||
34032031|NCT02185079|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34032032|NCT01822717|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34032033|NCT02537691|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34032034|NCT05851027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032035|NCT05362630|||COHORT||OTHER|||||||
34032036|NCT01223378|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34032037|NCT01673230|NA|SINGLE_GROUP||OTHER||NONE||||||
34032038|NCT06582992|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106729|NCT02455726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106730|NCT05806190|||COHORT||PROSPECTIVE|||||||
34106731|NCT01871922|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34106732|NCT02344472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106733|NCT05513573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106734|NCT02071732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106735|NCT04179084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106736|NCT06643000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106737|NCT02579759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106738|NCT06640361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106739|NCT04699877|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34106740|NCT06174779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106741|NCT03552445|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34106742|NCT02520362|||OTHER||PROSPECTIVE|||||||
34106743|NCT00313521||||TREATMENT||NONE||||||
34106744|NCT02202577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106745|NCT05586282|||COHORT||PROSPECTIVE|||||||
34106746|NCT00003670||||TREATMENT||||||||
34106747|NCT06637228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study employs a parallel assignment model, consisting of two groups: an integrated exercise intervention group and a control group. Participants aged 65 years and older with a diagnosis of dementia were recruited from outpatient neurological/dementia clinics and community centers in Taiwan. The intervention group engaged in a 12-week structured exercise program that included strength training, aerobic exercise, stretching, and balance activities, meeting at least three times per week. In contrast, the control group continued their usual daily activities without any structured exercise regimen. Both groups were assessed at baseline and post-intervention to evaluate the effects of the integrated exercise on sarcopenia, depression symptoms, and quality of life.||||
34106748|NCT04359329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106749|NCT06569797|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This clinical study is a double-blind trial, and before unblinding, neither the researchers nor the subjects know whether they belong to the experimental group or the control group|multicenter, double-blind, randomized, controlled trial|t|f|t|f
34106750|NCT03492294|||COHORT||PROSPECTIVE|||||||
34106751|NCT06570317|||COHORT||PROSPECTIVE|||||||
34106752|NCT00967486|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34106753|NCT05732870|||CASE_ONLY||CROSS_SECTIONAL|||||||
34106754|NCT05039489|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106755|NCT00438282|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34106756|NCT04990947|||COHORT||PROSPECTIVE|||||||
34106757|NCT06567262|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34106758|NCT03261375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and site investigators who evaluate the patients were blinded to treatment assignment.||t|f|f|t
34106759|NCT02120261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106760|NCT02180672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106761|NCT03377322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded|Placebo Controlled|t|t|t|t
34106762|NCT02431026|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34106763|NCT06087536|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34106764|NCT04160598|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34106765|NCT06674824|||CASE_ONLY||PROSPECTIVE|||||||
34106766|NCT03989284|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106767|NCT04586751|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34106768|NCT01881932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34106769|NCT02990702|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34106770|NCT01929603|NA|SINGLE_GROUP||||NONE||||||
34106771|NCT01532219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106772|NCT02953431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106773|NCT03053232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106774|NCT00544947|||COHORT||PROSPECTIVE|||||||
34106775|NCT00918398|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34106776|NCT02048046|||CASE_CONTROL||PROSPECTIVE|||||||
34106777|NCT05938569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106778|NCT05459753|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106779|NCT04622267|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomly assigned to either the treatment arm or control arm of the study prior to commencement of the cesarean section and following informed consent. Allocation will be concealed to all researchers/providers until this point. The patients will be randomly allocated by block randomization. Generation of random sequence will be done by independent personnel, usually a statistician, who is not going to be involved in the conduct of the RCT. The access to this sequence should be restricted to only a few individuals who absolutely need to have access.||||
34106780|NCT06568432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"In parallel arm design, subjects are randomized to one or more study arms and each study arm will be allocated a different intervention. After randomization each subject stays in their assigned treatment arm for the duration of the study.~Subjects receive the same treatment throughout the trial. The results are then compared."|f|f|f|t
34106781|NCT04701944|||CASE_ONLY||RETROSPECTIVE|||||||
34106782|NCT02645370|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106783|NCT01903863|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34106784|NCT02839928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106785|NCT05952310|NA|SINGLE_GROUP||TREATMENT||NONE|There is no masking in this study|This is an exploratory, open-label, non-randomized, multicenter therapeutic study. It is considered phase I/II since it will seek safety and efficacy of the infusion of allogeneic haploidentical Natural Killer (NK) cells in combination with chemotherapy and/or radiotherapy in the treatment of pediatric, adolescent and young adult patients with refractory sarcoma.||||
34106786|NCT03721367|||OTHER||CROSS_SECTIONAL|||||||
34106787|NCT02943499|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34032039|NCT04146012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be randomized in a 2:1 ratio to either early or late vascular access. The randomization will be stratified by investigative site, and will use a random permuted block design within strata, with blocks of size 3 and 6 ordered randomly within site.~Once a patient signs informed consent, is determined to meet the inclusion/exclusion criteria, and is successfully implanted with the Artegraft, the site designated staff will open an envelope to determine the randomization number and whether the patient is randomly allocated to early or late vascular access."|Artegraft will follow all study patients enrolled in the proposed clinical trial and that have successful cannulation within 72 hours as defined above, for 6 months. If follow-up is necessary at 1 year after graft implantation, it will be done via phone survey. The late-access group \[\>/= 10 days\] will be followed to 30 days post-first cannulation. If follow-up is necessary at 6 months after graft implantation, it will be done via phone survey. Day 0 is defined as the day of first cannulation, for early-access and late-access groups, to allow full follow-up to at least 30 days for both groups.|f|f|t|f
34032040|NCT05228678|||CASE_CONTROL||PROSPECTIVE|||||||
34032041|NCT00309855|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032042|NCT03700502|||COHORT||CROSS_SECTIONAL|||||||
34032043|NCT01299012|||OTHER||RETROSPECTIVE|||||||
34032044|NCT05709379|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"This study will be conducted as randomized controlled crossover trials involving 3 different trial conditions in each of the studies. Randomization will be stratified based on sex. The order of trials will be assigned randomly by a third party using a computer software.~After pre-testing and familiarization (visit 1), the participants will undergo 3 different trial conditions of 7 hours. The trials are all iso-caloric, but with different intervals of sitting and executing moderate physical activity by treadmill walking/running corresponding to 25-30% or 80-85%, repectively of their individual VO2max values, estimated from the individual's pre-test. Blood samples will be taken and blood pressure measured every 30 minutes. The visits for main testing will be separated by a washout period of minimum 5 days, and women will be tested in the follicular phase."||||
34032045|NCT04458285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032046|NCT02850731|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032047|NCT04574570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032048|NCT02255799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032049|NCT05664269|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Randomization of interventional drinks will be performed by an independent researcher who will also prepare the drinks on the morning of the test day. Drinks will be prepared in a non-transparent shaker and matched for taste.|randomized, controlled, parallel-group, double-blind intervention trial.|t|f|t|t
34032050|NCT00004338||||TREATMENT||||||||
34032051|NCT05703087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A single-center feasibility study. We compared the use of positive cueing in the information video before a primary total knee arthorplasty (TKA) with the standard information video.|t|t|t|t
34032052|NCT04828174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032053|NCT04602338|||CASE_CONTROL||PROSPECTIVE|||||||
34032054|NCT04847518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A Randomization Sequence of A and B from 1 to 140 will be generated by a qualified pharmacist (QP) at the manufacturing site before the study using a Random number generator. Treatment Randomization Sequence contains information about the distribution of unique random numbers between groups A and B. The QP will keep in secrecy for the clinic, and the investigators the Randomization Sequence and treatment code at the manufacturing site until the study is finalized. Study medications (boxes of placebo and Kan Jang capsules with identical appearance) will be labeled per Treatment Randomization Sequence. It will be provided to an independent statistician for statistical analysis of datasets when all patients complete the treatment. QP will disclose the treatment code providing the information about the actual assignment of treatments A and B to Kan Jang and placebo after statistical analysis of the results of a study where the data obtained from groups A and B will be compared.|"Patients will be randomized in a manner of 1:1 for study drug Kan Jang and Standard of Care to Placebo and Standard of Care (Paracetamol)~The patient study period will last three weeks: active treatment for two weeks and a follow-up period for one week until Hospital discharge to check the side effects and study drug efficacy. During that time, patients will be monitored for adverse events."|t|t|t|t
34032055|NCT03507088|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will undergo FES-PET/CT at baseline and FES-PET after 28 days of fulvestrant treatment. Whenever possible, tumor biopsies will be performed to correlate to FES-PET results.||||
34032056|NCT03064555|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032057|NCT01200225|||COHORT||PROSPECTIVE|||||||
34032058|NCT01386801|||CASE_CONTROL||PROSPECTIVE|||||||
34106788|NCT03063645|RANDOMIZED|CROSSOVER||OTHER||NONE||16 healthy subjects enrolled, each subject will receive 1 dose of each treatment, with a 2 day washout in between.||||
34106789|NCT04403776|RANDOMIZED|CROSSOVER||OTHER||NONE||"Subjects will be randomized to one of the two treatment sequences. Each treatment sequence will consist of two periods, separated by a washout phase of no less than 72 hours from the AM dose on Day 7.~Treatment A (Test): Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.~Treatment B (Reference): Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7."||||
34106790|NCT06569654|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
34106791|NCT03652428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032059|NCT04661644|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1 is conducted to evaluate the tolerability of the IP Subjects receive the IP once and are checked for adverse events. Subjects are evaluated for adverse events after the administration of the IP by registering 3 subjects each at the dosing phase.~If the maximum tolerated dose (MTD) is determined with the test group 2 (high dose) in the Phase 1, the Phase 2a clinical trial will be conducted. However, if 1 adverse events occur, the test group 2 will be considered as the maximum tolerated dose (MTD), or but only the test group 1 will proceed to Phase 2a.~If 2 adverse events occur, a dose smaller than test group 1 (low dose) is determined to be the maximum tolerated dose. The Phase 2a clinical trial will not proceed and the clinical trial will end.~If tolerability and safety are secured, subjects meeting the final inclusion criteria are assigned to Phase 2a, admitted by the same procedure, and administered the IP once. Safety and efficacy assessments are performed."||||
34032060|NCT02597829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032061|NCT03091179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032062|NCT03439956|||CASE_CONTROL||PROSPECTIVE|||||||
34032063|NCT01525017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032064|NCT03745079|||OTHER||PROSPECTIVE|||||||
34032065|NCT02439021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032066|NCT05516862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34032067|NCT03101605|RANDOMIZED|PARALLEL||OTHER||SINGLE|The physicians evaluating the student performances will be blinded to the randomization||f|f|f|t
34032068|NCT04530955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will employ a single-blinded approach in which study participants will not be notified of pump dosing changes. After valve-gated pump implant and dose reduction, the appropriate spasticity therapy will be provided to adequately address spasticity management in the opinion of the study investigator using standard of care processes.|Randomized, open label, single-blind, multi-center, post-market study|t|f|f|f
34032069|NCT02748980|||COHORT||PROSPECTIVE|||||||
34032070|NCT05308433|NA|SINGLE_GROUP||OTHER||NONE||||||
34032071|NCT00694200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032072|NCT02295501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032073|NCT05089669|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34106792|NCT03344705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106793|NCT03161262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomly assigned to either the intervention group or control group. The test group constitutes receiving consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site for the duration of the full 3 months. The control group will not receive medication reminders or questions regarding their pain or surgical site. Both control and test groups will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.||||
34106794|NCT00836901|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34106795|NCT00310141|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106796|NCT01988558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106797|NCT06571643|||COHORT||PROSPECTIVE|||||||
34106798|NCT06077513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106799|NCT00468546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34106800|NCT05674565|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34106801|NCT01063569|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032074|NCT00704626|||COHORT||PROSPECTIVE|||||||
34032075|NCT02965417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032076|NCT01964079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032077|NCT03000062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|ID of participating patients are only available through the participating Family phyisican|Cluster randomized controlled trial|t|f|f|f
34032078|NCT01194401|||COHORT||PROSPECTIVE|||||||
33806044|NCT01223924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806045|NCT04611334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806046|NCT01591694|||COHORT||PROSPECTIVE|||||||
33806047|NCT06334666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806048|NCT05484661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34106802|NCT03349996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106803|NCT06429085|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open label, single arm, non-randomized, non-comparative feasibility study of Rex robot assisted training to improve balance and mobility for people living with MS.||||
34106804|NCT06441188|NA|SINGLE_GROUP||SCREENING||NONE||||||
34106805|NCT01791179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106806|NCT00875407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106807|NCT05723380|||COHORT||CROSS_SECTIONAL|||||||
34106808|NCT06637995|||COHORT||OTHER|||||||
34106809|NCT04013971|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The study outcomes will comprise objective biomechanical measures derived using motion capture, which will be processed by a lab personnel|This study aims to enroll 12 post-stroke and 12 able-bodied individuals who will complete gait trials with 2 different biofeedback interfaces in each experimental session. An optional session testing a VR version of the biofeedback game may be completed by some participants.|f|f|f|t
34106810|NCT06314295|||OTHER||PROSPECTIVE|||||||
34106811|NCT05620719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Independent evaluators will complete posttreatment and follow-up assessments with each participant. They will instruct participants not to share which treatment group they were assigned. The Principle Investigator will remain blind to treatment randomization outcomes.||f|f|t|t
34106812|NCT06539260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106813|NCT06058351|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A group of patients will be followed during standard outpatient rehabilitation before and after implementation of the ABI-motion program with 1 year follow-up.||||
34106814|NCT03380273|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|It is that preventino measures are enforced in the hospital. This will apply to all patients and no masking is required.|During two years, patients with fractures are recorded and the occurence of surgical site infections (SSI) in these patients is monitored in different sites over the world. After two years, a bundle of known prevention measures are teached and enforced in these sites. Then the occurence of SSI in fracture patients is monitored for another two years to see whether the bundle decreased the SSI occurence.||||
34106815|NCT06636968|||COHORT||PROSPECTIVE|||||||
34106816|NCT06452511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106817|NCT02913326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806049|NCT01420497|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806050|NCT04197557|||COHORT||CROSS_SECTIONAL|||||||
33806051|NCT05365191|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The patient will know they are going to accept near infrared zone II imaging during the sentinel lymph node biopsy procedure. They will not see the images and will not know the quality results.|The participants will be assigned to one single arm that accepted both near infrared zone I and near infrared zone II imaging during the near infrared fluorescence navigated sentinel lymph node biopsy procedure.||||
33806052|NCT04468412|||COHORT||PROSPECTIVE|||||||
33806053|NCT04003259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806054|NCT03812874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|For Phase II only.|Phase I: Singe-arm, open-labeled Phase II: Randomized, placebo-controlled|t|t|t|t
33806055|NCT00262782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806056|NCT02652585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33806057|NCT01368744|||CASE_ONLY||PROSPECTIVE|||||||
33806058|NCT05467813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806059|NCT03978728|||COHORT||PROSPECTIVE|||||||
33806060|NCT03951142|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||An open-label, single institutional phase II trial with an individual stepped-wedge, randomized, assessor-blinded, dose-finding design on three indications||||
33806061|NCT02463994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806062|NCT02022800|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806063|NCT00862043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806064|NCT00274417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33806065|NCT00354237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806066|NCT05912738|||COHORT||PROSPECTIVE|||||||
33806067|NCT05302076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806068|NCT02347332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106818|NCT03269266|||OTHER||PROSPECTIVE|||||||
34106819|NCT06548516|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients in the C group underwent primary wound healing with sutures, whereas patients in the L group did not get any sutures. Therefore, neither the clinicians (Z.T.E and K.Y) nor the patients were kept unaware of the study's details over the entire duration|||||
34106820|NCT04783428|||COHORT||PROSPECTIVE|||||||
34106821|NCT06637384|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34106822|NCT03428347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106823|NCT03116022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||we compared three groups: women using estriol in the proximal vagina wall, women using estriol in the distal vagina wall, and women using gel lubricant|f|f|t|f
34106824|NCT05059626|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|These treatments are blinded to the investigators. The subjects, physician, and the nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.|This is a single arm randomized study. Only women with endometriosis will complete this study. Once consented and screened, each subject is block randomized to either 30 days of a treatment (Simvastatin or 30 days of SERM (bazedoxifene + conjugated estrogen; BZE+CE)). This will be done in a counterbalanced fashion. Subjects will have the option of completing the other arm of the study but will undergo a 60 day washout to mimimize carry over effect. We will use Research Randomizer software. These treatments are blinded to the investigators collecting the data and performing the data analysis.|f|f|t|f
34106825|NCT06675136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106826|NCT06167746|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
34106827|NCT06284681|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
34106828|NCT05362305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34106829|NCT05918185|||COHORT||PROSPECTIVE|||||||
34106830|NCT02513641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806069|NCT02500147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106831|NCT06007157|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106832|NCT06638281|||OTHER||CROSS_SECTIONAL|||||||
34106833|NCT06640777|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, international, multicenter, open label, randomized, controlled, two-arm study.||||
34106834|NCT00214669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34106835|NCT06159517|||OTHER||PROSPECTIVE|||||||
34106836|NCT00968279|||COHORT||PROSPECTIVE|||||||
34106837|NCT05650827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34106838|NCT01373411|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34106839|NCT05968937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be carried out by a computer-based algorithm that will generate study/subject number. This number will correspond with treatment and communicate to The Louisville compounding pharmacy the appropriate drug to distribute without the unblinding of patient or provider. with a stratified block randomization scheme (with a random block size of 4, 6, and 8 participants). Randomization will be stratified based on pelvic muscle tenderness on exam - stratifying by 0-5/10 and 6-10/10 tenderness of pelvic floor musculature on physical exam|This is a single-center, double-blinded, placebo-controlled, randomized trial.|t|t|t|t
34106840|NCT05597124|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34106841|NCT01069718|||COHORT||PROSPECTIVE|||||||
34106842|NCT03211845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34106843|NCT01044459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106844|NCT05874037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34106845|NCT06472024|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106846|NCT05879159|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106847|NCT06083454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a descriptive, proof of concept, open-label, randomized, 3-arm, window of opportunity trial to evaluate the immunomodulatory role of pharmacological ascorbate with Durvalumab. Translational and clinical findings of this study can then be applied more broadly to design and address clinically oriented questions in various NSCLC treatment settings.|t|f|f|f
34106848|NCT03070067|||COHORT||PROSPECTIVE|||||||
34106849|NCT06641453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106850|NCT01215305|||CASE_ONLY||PROSPECTIVE|||||||
34106851|NCT03268278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106852|NCT02038647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34106853|NCT06230991|NA|SINGLE_GROUP||OTHER||NONE||All study subjects will receive the same study products.||||
34106854|NCT05287737|||COHORT||PROSPECTIVE|||||||
34106855|NCT06569420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106856|NCT06248710|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34106857|NCT05050955|||CASE_CONTROL||PROSPECTIVE|||||||
34106858|NCT06570681|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33724440|NCT03362086|||FAMILY_BASED||PROSPECTIVE|||||||
33724441|NCT04797949|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study personnel who will perform pill counts will be masked to the study arm.|Patients are randomized to receiving aspirin knowing their risk status vs those who are randomized to universal receipt.|f|f|f|t
33724442|NCT04765150|||COHORT||OTHER|||||||
33724443|NCT00142571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724444|NCT06167993|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33724445|NCT05419076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724446|NCT03061110|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomly assigned to usual care (palliation of symptoms) or injection of stromal vascular fraction.||||
33724447|NCT06240156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33724448|NCT02823275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33724449|NCT06224933|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33724450|NCT04828889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel groups: treatment group( with dilators) versus conservative treatment ( follow up)||||
33724451|NCT02210936|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724452|NCT02036502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724453|NCT04738916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33724454|NCT02909452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724455|NCT04548921|||COHORT||PROSPECTIVE|||||||
33724456|NCT00386087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724457|NCT03418909|||COHORT||PROSPECTIVE|||||||
33724458|NCT03458533|||COHORT||PROSPECTIVE|||||||
33724459|NCT03525015|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724460|NCT04881357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||pilot, parallel, double-blind, randomized, placebo-controlled, 12-week, clinical trial|t|t|t|t
33724461|NCT05751239|||OTHER||CROSS_SECTIONAL|||||||
33724462|NCT00790439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724463|NCT01511575|||CASE_CONTROL||RETROSPECTIVE|||||||
33724464|NCT05931328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724465|NCT01157507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724466|NCT05817019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The neuromuscular reversal agent is received and prepared in advance by a separate medical staff (a separate anesthesiologist who does not participate in the patient's anesthesia), and the corresponding prescription order is made separately when the patient leaves the recovery room. Since it is diluted with physiological saline and prepared in a total amount of 5cc, the patient and the patient's anesthetist do not know about the drug until they leave the recovery room (double-blinded).|A double-blind, randomized, parallel design study|t|t|t|t
33724467|NCT00006209||||TREATMENT||||||||
33724468|NCT05659628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724469|NCT03024307|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724470|NCT00382954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724471|NCT01218555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724472|NCT02482103|||COHORT||PROSPECTIVE|||||||
33724473|NCT06386796|||COHORT||PROSPECTIVE|||||||
33724474|NCT00697515|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33724475|NCT05142423|NA|SEQUENTIAL||TREATMENT||NONE||||||
33724476|NCT02493699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724477|NCT02221375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724478|NCT03133156|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||The current research will consist of 2 different exercise training protocols. Subjects will be randomized into each Arm based on screening criteria and compared to the control (Arm 1)||||
33724479|NCT03079609|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724480|NCT04219982|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|This study is double-blinded for the DPI-386 Nasal Gel and placebo nasal gel arms. All DPI-386 Nasal Gel and placebo nasal gel vials are opaque and indistinguishable. The DPI-386 Nasal Gel and placebo nasal gel are identical in color and viscosity, and without identifiable smell.|The sample size of 54 allows for an equal distribution of subjects within gender and treatment arm: 18 subjects per treatment arm with 9 per gender.|t|t|t|f
34032079|NCT03514108|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||"Patients can be allocated to either~1. both Hydralazine Isosorbide Dinitrate / Placebo and Metformin hydrochloride / Placebo~2. to only Hydralazine Isosorbide Dinitrate / Placebo.~3. to only Metformin hydrochloride / Placebo.~Patient characteristics are entered in an electronic CRF. According to in- and exclusion criteria they are randomized in three blocks:~1. Patients receiving both Hydralazine Isosorbide Dinitrate / Placebo and Metformin hydrochloride / Placebo~2. Patients receiving only Hydralazine Isosorbide Dinitrate / Placebo and~3. Patients receiving only Metformin hydrochloride / Placebo~Analysis will be performed in:~1. all patients who have received Hydralazine Isosorbide Dinitrate / Placebo (H-HeFT) and~2. all patients who have received Metformin hydrochloride / Placebo (Met-HeFT)~The study is event driven. Anticipated: both H-HeFT and Met-HeFT 900, only H-HeFT 400, only Met-HeFT 200 patients."|t|t|t|t
34032080|NCT03514095|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The randomization process it will be done in https://www.random.org/ by an independent person.|Participants will be assigned in two groups, a control group who will usual care by their caregivers and an experimental group who will receive the MD3 program.|t|t|t|t
34032081|NCT04379427|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The first 2 study parts include 12 patients each. In the third study part 36 patients will be enrolled. Study part 1 and 2 will be used for optimization and control of the measurement algorithms of the Sanmina biosensors. During the third study part with enrolment of 36 patients, the precision and accuracy of the final Sanmina biosensor algorithm will be demonstrated.||||
34032082|NCT03935698|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-treatment assessment - Intervention (12 weeks) - Post-treatment assessment||||
34032083|NCT04884139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032084|NCT04459234|||COHORT||PROSPECTIVE|||||||
34032085|NCT00725257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032086|NCT03950154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032087|NCT04571541|||COHORT||PROSPECTIVE|||||||
34032088|NCT03231774|||COHORT||PROSPECTIVE|||||||
34032089|NCT05114733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|part 1 is open label design. Next part is RCT waiting list control design. assessors will be unaware of whether the participant was in the waiting list condition or the active condition.|waitlist control design|f|f|f|t
34032090|NCT01694225|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032091|NCT06424197|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
34032092|NCT03764618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032093|NCT03719027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Retrospective and prospective cohort study||||
34032094|NCT05161338|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort unicentric pilot study||||
34032095|NCT00005811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032096|NCT02907060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032097|NCT06264063|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34032098|NCT00492505||||TREATMENT||||||||
34032099|NCT00200902|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34032100|NCT05547997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor who will conduct the measurements will be blinded. Assessor blinding will be obtained through an independent research assistant not knowing the study design and not specifically involved in any aspect of the trial|Parallel Assignment A prospective, double blinded, parallel-group, randomized clinical trial will be conducted at one of our university's research departments,|f|f|f|t
34032101|NCT05999383|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032102|NCT00727012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032103|NCT00794729|||||PROSPECTIVE|||||||
34032104|NCT05044195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34032105|NCT06069167|||COHORT||PROSPECTIVE|||||||
34032106|NCT03558438|||COHORT||PROSPECTIVE|||||||
34032107|NCT02779166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032108|NCT00233233|RANDOMIZED|||||||||||
33724481|NCT03935009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33724482|NCT01422863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724483|NCT02428881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724484|NCT00587483|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724485|NCT04130451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806070|NCT05676346|||COHORT||PROSPECTIVE|||||||
33806071|NCT04389385|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806072|NCT03861052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806073|NCT03018067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806074|NCT00361205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34032109|NCT05734651|||COHORT||PROSPECTIVE|||||||
34032110|NCT05193955|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34032111|NCT02207634|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34106859|NCT06580938|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34106860|NCT04582812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106861|NCT06060509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The packaging of intervention oil and control oil was consistent, and the subjects could not distinguish what was blend oil and what was control oil. Blinding was also used for outcome assessors, who did not distinguish between the intervention and control groups.|This is a randomised controlled intervention trial.|t|f|f|t
34106862|NCT00003907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806075|NCT04797468|NA|SEQUENTIAL||TREATMENT||NONE||||||
33806076|NCT05282966|||COHORT||PROSPECTIVE|||||||
33806077|NCT06575725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806078|NCT05766384|||COHORT||CROSS_SECTIONAL|||||||
34032112|NCT00779831|RANDOMIZED|CROSSOVER||||NONE||||||
34032113|NCT02168192|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34032114|NCT00545714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806079|NCT03204357|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a prospective randomized interventional trial of transfusion of fresh autologous whole blood versus standard of care expectant management of bleeding during elective cardiac surgery.||||
33806080|NCT05835375|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, parallel group, double-blind, placebo-controlled trial|t|t|t|f
33806081|NCT06699316|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33806082|NCT00051584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806083|NCT05966012|||COHORT||RETROSPECTIVE|||||||
34032115|NCT04364178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032116|NCT02982291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032117|NCT05096091|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34032118|NCT04812301|||CASE_CROSSOVER||PROSPECTIVE|||||||
34032119|NCT03631316|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Each participant will take both formulations. Groups will be formed regarding the order in which the different formulations of valganciclovir will be analyzed. Both formulations will be given in two identical container numbered in the specific order assigned. The order of administration of the drug will be randomized, neither the researcher nor the patient will know the order of the randomization.|Pharmacovigilance study, prospective, observational, analytical, single center, cross over design, with random assignment to the sequence of both formulations in the same patient. Our aim will be compare the pharmacokinetic parameters of the innovative versus generic formulation of valGCV in renal transplant recipients under valGCV prophylaxis in the early posttransplant stage.|t|t|t|t
34032120|NCT00719186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032121|NCT03578393|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032122|NCT03231488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032123|NCT01433367|||COHORT||PROSPECTIVE|||||||
34032124|NCT01606774|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032125|NCT02910804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032126|NCT00573261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032127|NCT02934464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032128|NCT06583070|||COHORT||OTHER|||||||
34032129|NCT01443728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032130|NCT01439412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032131|NCT02054338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032132|NCT06489236|RANDOMIZED|PARALLEL||PREVENTION||NONE||Public primary care center pediatric teams in Barcelona city and Central Catalonia that enroll in the study will be randomly allocated into two parallel groups: intervention and control groups. This allocation will be conducted through a web-based procedure by block design. Pediatric teams will be paired based on the assigned population under 14 years old, the socioeconomic status of the basic health area, immunization coverage, and location, using data from the Primary Care Services Information System (SISAP). Team names will be blinded throughout the randomization process. Once randomization is complete, allocation will be unblinded to the research team. The control group will follow the standard procedures for vaccination promotion and vaccine hesitancy management. Pediatric teams in the control group will be offered the intervention once it has been evaluated.||||
34032133|NCT00100828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032134|NCT02938143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032135|NCT00181558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032136|NCT06581770|||OTHER||PROSPECTIVE|||||||
34032137|NCT00631592|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34032138|NCT02848209|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34106863|NCT02826785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106864|NCT03557905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Ventilator adjustments, lung recruitment, PEEP titration and ultrasonographic assessments will be done by well-trained investigators not involved in data collection. The surgeon, the parents or legal guardians and the data collection personell will be blinded to the patients' group assignment.|To explore the clinical value of ultrasonic monitoring in the diagnosis of anesthesia-induced atelectasis, the assessment of the effects of lung recruitment, the best positive end-expiratory pressure (PEEP) after RM and in the detection of the point of lung re-collapse after RM in pediatric patients undergoing lengthy microsurgery operations using two levels of intraoperative FIO2 (0.5 VERSUS 0.3).|t|f|f|t
34106865|NCT03165500|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigadors selected 120 third molars , with the need for exodontia, in patients aged 18 to 30 years, ASA I, and with moderate to high anxiety level according to the Corah Dental Anxiety Scale (DAS). Patients were randomly assigned to three groups of 40 patients and submitted to the following anxiety control protocol:~* Group I - Sedation with 5 mg oral Diazepam 30 minutes before surgery;~* Group II - Sedation with 7.5 mg oral Midazolam 30 minutes before surgery;~* Group III - Inhaled sedation with a mixture of 40% of nitrous oxide and 60% of oxygen (Using the Porter MXR 3000 Flowmeter (Parker Hannifin - Hatfield, PA, Philadelphia)) started 5 minutes before surgery."||||
34106866|NCT03344887|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106867|NCT04393935|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34106868|NCT04628208|||CASE_ONLY||CROSS_SECTIONAL|||||||
33806084|NCT01758549|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34032139|NCT04071314|||CASE_CONTROL||PROSPECTIVE|||||||
34032140|NCT01656057|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032141|NCT03180281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032142|NCT02962518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032143|NCT04394039|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|participants do not know the hypothesis of the study, other people cannot influence the brainwave reaction|within-subjects before/ after study||||
34032144|NCT02875990|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032145|NCT00187512|||COHORT||PROSPECTIVE|||||||
34032146|NCT05222997|||CASE_ONLY||PROSPECTIVE|||||||
34032147|NCT05187390|||COHORT||PROSPECTIVE|||||||
34032148|NCT04327323|||COHORT||PROSPECTIVE|||||||
34032149|NCT02561325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34032150|NCT04640870|||COHORT||RETROSPECTIVE|||||||
34032151|NCT06581822|||COHORT||PROSPECTIVE|||||||
34032152|NCT03187535|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participant will be blinded to the treatment arm; all investigators and care providers will be blinded to the treatment arm. Only the anesthesiologist trained in acupuncture and administering the treatment will know the randomization group.||t|t|t|t
34032153|NCT05667376|NA|SINGLE_GROUP||TREATMENT||NONE|The patients with periodontitis groups were randomly selected into either group II or III using the coin toss method. Hence the study groups were classified into three groups as follows, group I (negative control group): eighteen subjects with clinically healthy gingiva were selected to participate in the study as a reference group, and group II (positive control group): eighteen patients with periodontitis (stage II grade A) were selected and treated with non-surgical periodontal therapy (SRP) only, and group III (study group): eighteen patients with periodontitis (stage II grade A) were selected and treated with SRP followed by curcumin gel application|patients (n=70) were selected from the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Mansoura University, sixteen patients (n=16) were excluded as eight patients (n=6) weren't met the inclusion criteria and the other eight patients (n= 6) declined to participate with (n=4) were excluded due to pregnancy and lactation. The participants fifty -four patients were classified into three groups: group I (healthy individuals), group II (SRP group), and group III (curcumin gel group). Patients in group II and group III included patients with stage II grade A periodontitis. Patients in group II were treated with SRP only while in group III curcumin gel was applied weekly for four weeks after SRP had been completed.||||
34032154|NCT06582381|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Laboratory staff and data scientists will not know the meals received when analyzing samples and initial statistical modeling||f|f|f|t
34032155|NCT00461942|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34032156|NCT00645970|||COHORT||PROSPECTIVE|||||||
34032157|NCT02435732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106869|NCT01235637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106870|NCT02997007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34106871|NCT03568123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are unaware of which prosthesis they receive and the research coordinator handling the collected questionnaires postoperatively is also unaware of which prosthesis the participant has received. The research assistant handling both standard RSA as well as dynamic RSA analysis is also unaware of which prosthesis the participant has received|This project is carried out as a 2-arm randomized controlled single-blinded trial, in which the clinical and radiological outcomes after treatment of hip osteoarthritis with insertion of either 1) Persona Total Knee System with MC polyethylene bearing or 2) Persona Total Knee System with CR polyethylene bearing. Allocation of the participants to one of the two treatment groups is done intraoperatively. A computer-generated random allocation sequence will be used. Non-transparent envelopes are used for the randomization process.|t|f|f|t
34106872|NCT05252702|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, international, single-arm, pivotal investigational study||||
34032158|NCT06017050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Youth assigned to the control group will receive message written to seem as if it is intervention content (i.e., address bullying behaviors).|Youth will be randomized to either the intervention or control group.|t|f|f|f
33724486|NCT06326294|RANDOMIZED|PARALLEL||TREATMENT||NONE||To compare TA, an ablative cervical treatment modality, and LEEP, an excisional cervical treatment modality, in screen-positive WLWH patients, for eradication of hrHPV and effectiveness of treating biopsy-confirmed CIN 2/3.||||
34032159|NCT04659642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032160|NCT01138787|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34032161|NCT04307888|||CASE_ONLY||PROSPECTIVE|||||||
34032162|NCT04007198|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The study site, participant and most vendors will be blinded. The site's pharmacist or designee will be unblinded to prepare the study drug. Relevant vendors including PK will be unblinded.|up to 5 cohorts of 8 patients randomized 3:1 with ascending doses|t|t|t|t
34032163|NCT04091477|||OTHER||RETROSPECTIVE|||||||
34032164|NCT00442208|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032165|NCT02263287|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34032166|NCT01427699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032167|NCT02308995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032168|NCT01106079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032169|NCT04575610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032170|NCT03727451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032171|NCT00102752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032172|NCT06261645|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Investigator: 6 physiotherapists are care providers, responsible for the Intervention . Two independent investigators does not know who is the actual care provider. However, all patients recieve the same intervention.~Outcome assessor: each participant is given a research code. The results from the assessments are entered in the data base by a research assistant, not involved in the study on any level.~Individuals are not identifiable. The outcome assessor are planning for all statistics used and is not in other ways involved in the study."|"A 16 week exercise program with specific exercises to restore total rotator cuff function individually selected during clinical physiotherapy visits and performed 2 - 4 times daily.~In addition, the patient will receive education and guidance in the daily use of the arm to adjust to appropriate load on the shoulder."|f|f|t|t
34032173|NCT03640494|||CASE_ONLY||PROSPECTIVE|||||||
34032174|NCT04844593|||COHORT||RETROSPECTIVE|||||||
34032175|NCT04949412|||COHORT||PROSPECTIVE|||||||
34032176|NCT01340131|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032177|NCT00613171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032178|NCT04782076|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34032179|NCT00132860|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34032180|NCT00246324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032181|NCT01926431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33724487|NCT00912314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724488|NCT00108160|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33724489|NCT04508374|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Evaluation of clinical photos and percentage closure by Ultrasound will be blinded.|The study is designed as a randomised, contralaterally-controlled, within-person design, where HS patients are randomised to undergo intralesional laser fibre treatment of HS tunnels in either right or left side of the body, whereas the other tunnel is left as an untreated control.|f|f|f|t
33724490|NCT05980533|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724491|NCT00204854|RANDOMIZED|PARALLEL||||SINGLE||||||
33724492|NCT00484887|||CASE_ONLY||PROSPECTIVE|||||||
33724493|NCT00110409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724494|NCT05718830|||CASE_CONTROL||PROSPECTIVE|||||||
33724495|NCT05171283|||OTHER||PROSPECTIVE|||||||
33724496|NCT04354207|||CASE_CONTROL||PROSPECTIVE|||||||
33724497|NCT06143670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724498|NCT01830439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724499|NCT05584553|||COHORT||RETROSPECTIVE|||||||
33724500|NCT01867905|||COHORT||PROSPECTIVE|||||||
33724501|NCT05874752|||OTHER||RETROSPECTIVE|||||||
33724502|NCT02676505|||CASE_CONTROL||PROSPECTIVE|||||||
33724503|NCT02496455|||COHORT||PROSPECTIVE|||||||
33724504|NCT03456596|||OTHER||PROSPECTIVE|||||||
33724505|NCT05112380|||COHORT||CROSS_SECTIONAL|||||||
33724506|NCT05041712|||COHORT||PROSPECTIVE|||||||
33724507|NCT01344187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724508|NCT04434365|RANDOMIZED|PARALLEL||TREATMENT||NONE||"On the first day of the treatment period (Visit 1), eligible patients will be randomized into the Berberine Arm and the Control Arm.~In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.~In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks."||||
33724509|NCT04446702|||COHORT||RETROSPECTIVE|||||||
33724510|NCT01471379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724511|NCT03447509|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know if they receive real or sham Stimulation and/or real or sham Startle|Magnetic Stimulation and Acoustic Startle|t|f|f|f
33724512|NCT02113865|||||CROSS_SECTIONAL|||||||
33724513|NCT01979315|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806085|NCT05288959|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subject serves as their own control. First, inter-regional conduction delays are measured in a uni-focal TMS session with EEG. Thereafter, bi-focal TMS (PAS) will be applied in three separate sessions, each using a different asynchrony. PAS may selectively increase or decrease effective connectivity depending on the asynchrony. Specifically, negative asynchronies (a few milliseconds shorter than the inter-regional conduction delay) are expected to decrease effective connectivity, zero asynchrony (equal to conduction delay) is predicted to have no effect, whereas positive asynchronies (a few milliseconds longer than the inter-regional conduction delay) are expected to increase it.||||
33806086|NCT02148705|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33806087|NCT04263610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806088|NCT04150042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806089|NCT03064594|||CASE_CONTROL||RETROSPECTIVE|||||||
33806090|NCT00131209|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33806091|NCT04720794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806092|NCT03132688|||CASE_ONLY||RETROSPECTIVE|||||||
33806093|NCT03961451|||CASE_CONTROL||PROSPECTIVE|||||||
33806094|NCT00918333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806095|NCT05605925|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806096|NCT04870398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33806097|NCT00640159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806098|NCT00131274|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33806099|NCT03592524|||CASE_ONLY||PROSPECTIVE|||||||
33806100|NCT03898505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806101|NCT06171711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806102|NCT06381531|||CASE_ONLY||RETROSPECTIVE|||||||
33806103|NCT01562834|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33806104|NCT03800914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessor||f|f|f|t
33838049|NCT03428308|NA|SINGLE_GROUP||SCREENING||NONE||Patients who meet the inclusion criteria will be identified and invited to participate by their general practitioner. Patients who agree to partcipate will be invited to a screening consultation focusing on selected somatic diseases. Patients who are diagnosed with one or more of the selected somatic diseases will be included in the intervention, which consists of individualized courses of treatment focusing on initiation and maintenance of medical treatment and complying with current clinical guidelines and course programmes. The intervention is planned to run for one year.||||
33838050|NCT00001072||||PREVENTION||DOUBLE||||||
33838051|NCT03115398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838052|NCT03701048|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33806105|NCT06699511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"In this clinical trial, masking will apply primarily to the Outcomes Assessor to ensure unbiased evaluation of results. The assessor, who will measure outcomes such as pain intensity, mobility, and quality of life, will be unaware of which intervention group (Pilates or home exercise) each participant belongs to. This masking minimizes the risk of bias in interpreting results based on prior knowledge of the intervention received by participants.~If there are additional parties involved in data analysis or reporting who might influence the results, they will also be masked to the intervention assignments to maintain the integrity of the study outcomes."|"This study utilizes a parallel-group interventional study model to compare the effects of Pilates exercises versus a standard home exercise program on subacute low back pain. Participants are randomly assigned to one of two groups:~Pilates Group: Participants in this group will receive a structured Pilates program targeting core stability, flexibility, and posture correction, which is specifically designed for low back pain management. Pilates exercises will be supervised by a qualified instructor to ensure proper technique and safety.~Home Exercise Group: Participants in this group will follow a standard home exercise regimen tailored to relieve low back pain. These exercises focus on general strength and flexibility but are not specific to Pilates techniques.~Both groups will participate in their respective programs for eight weeks. Outcomes, including pain levels, functional mobility, and quality of life, will be measured at three time points: baseline, post-treatment, and follow"|t|f|f|f
33806106|NCT06699472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806107|NCT01096472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806108|NCT05419466|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806109|NCT02208414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806110|NCT04724642|||CASE_ONLY||PROSPECTIVE|||||||
33806111|NCT03477305|NA|SINGLE_GROUP||OTHER||NONE||||||
33838053|NCT01790919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33838054|NCT04982770|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33838055|NCT03566745|||CASE_CONTROL||PROSPECTIVE|||||||
34032182|NCT01494116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032183|NCT05361863|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The appliance and archwires will be coded for each patient, so the investigator will be blinded about the size of brackets slot and archwires gauges. Moreover, data measurements and analysis will be carried out blindly too.|The study aimed to evaluate the effectiveness of canine retraction in terms of: rate of movement and rotation using 0.020-inch slot and dual-slot systems in comparison with the 0.022-inch slot system.|t|t|t|t
34032184|NCT04254341|||COHORT||OTHER|||||||
34032185|NCT01775826|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106873|NCT05757050|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The proposed design is a randomised, double-blind, controlled, crossover intervention assessing the effects of an active intervention, containing Scutellaria baicalensis and Crataegus, versus placebo, on stress, cognition, sleep and wellbeing in healthy human volunteers. Outcome measures will be assessed acutely on day 1 and following 14 days of supplement consumption. Some interim outcome measures will also be assessed throughout the supplementation period to monitor sub-chronic changes.|t|t|t|t
34106874|NCT00276315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34106875|NCT03728686|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34106876|NCT01518179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106877|NCT01909245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106878|NCT05885594|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34106879|NCT05997537|||COHORT||PROSPECTIVE|||||||
34106880|NCT06636669|RANDOMIZED|PARALLEL||TREATMENT||NONE||A multi-centered, randomized controlled trial (RCT) with two arms will be conducted at two academic, tertiary care centers.||||
34106881|NCT00192478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106882|NCT00931541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34106883|NCT00431379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106884|NCT06097897|NA|SINGLE_GROUP||OTHER||NONE||||||
34106885|NCT04996745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34106886|NCT01338597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106887|NCT02659371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106888|NCT05196061|||OTHER||PROSPECTIVE|||||||
34106889|NCT06080204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106890|NCT06119321|||CASE_CONTROL||PROSPECTIVE|||||||
34106891|NCT01772251|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34106892|NCT01769131|||CASE_ONLY||PROSPECTIVE|||||||
34106893|NCT03426397|||COHORT||PROSPECTIVE|||||||
34106894|NCT06428188|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group.|Patients enrolled in this clinical trial will receive a carefully designed treatment regimen. Before the infusion of BCMA and CD19 CAR-T cells, participants will undergo preconditioning chemotherapy. This chemotherapy serves to create an optimal environment for CAR-T cell therapy to effectively target and eliminate B cells. Following chemotherapy, participants will receive the infusion of CD19 and BCMA CAR-T cells.||||
34106895|NCT06536972|||OTHER||PROSPECTIVE|||||||
34106896|NCT05087446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106897|NCT03769948|||COHORT||RETROSPECTIVE|||||||
34106898|NCT06634862|RANDOMIZED|PARALLEL||TREATMENT||NONE||Four groups, together with a control group with no intervention. One group will receive pneumatic pressure treatment, one group will receive soft tissue mobilisation (graston) treatment and another group will receive percussive therapy treatment.||||
34106899|NCT06673875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106900|NCT05821894|||COHORT||PROSPECTIVE|||||||
34106901|NCT06644404|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34106902|NCT01194544|||COHORT||PROSPECTIVE|||||||
34106903|NCT03092193|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34106904|NCT00221221|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34106905|NCT01462331|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34106906|NCT06209372|||OTHER||RETROSPECTIVE|||||||
34032186|NCT04447560|NA|SINGLE_GROUP||OTHER||NONE||The study is planned as prospective. Aged between 18-75, ASA III risk group and are undergoing off pump coronary artery bypass grafting surgery are selected for the study. Who are allergic to planned-medications, chronic opioid or opioid receptor agonist users, those with preoperative neuropathies, psychiatric diseases will be excluded. Electrocardiography and pulse oximetry monitorization is performed in the recovery room where a peripheric intravenous line is opened afterwards. High frequency (12-24 MHz) linear probe is used for measurements. Images will be recorded by USG from the 3., 4. and 5. intercostal spaces for the LIMA and RIMA and 3cm proximal to the wrist for the right and left radial arteries. After images are saved, the researcher will perform ESP block with USG. ESP block will be performed to right and left sides equally with 40ml %0.25 bupivacaine in total. Artery images will be recorded again by the same researcher after 45 minutes.||||
33806112|NCT04329221|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"All participants, care giver and investigators measuring or analyzing the experimental data will be blinded to the interventions. Tissue samples collected will be labeled with 3-digit unique IDs and de-identified before studying in PI's lab. The study investigator will collect AK/skin samples and label them based on the study ID (e.g. 201) without compromising their blinded status. All the study records/photographs will be kept in a locked office or password-protected computer that is only accessible by the members of the research team."|Parallel assignment|t|t|t|f
33806113|NCT03443700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because of the use of an evident Medical Device (exoskeleton), enrolled subjects cannot be blind about their assignment group, however objective and standardized clinical measure scales will be employed; moreover, assessments (also neurophysiological and neuroimaging ones) will be conducted by blind experts.|Randomized controlled trial|f|f|f|t
34032187|NCT04740450|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34032188|NCT04922723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032189|NCT02245087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032190|NCT03889886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All investigational product (SDP-4 concentrations and vehicle) will be provided in single-use doses (SUDs) contained in foil pouches.|Subjects will be randomized to 1 of 3 concentrations (0.1%, 1.0% and 3.0%) of SDP-4 Ophthalmic Solution or vehicle in a 1:1:1:1 ratio in parallel groups.|t|t|t|t
34032191|NCT03288714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Sham Controlled|t|t|t|t
34032192|NCT02875327|||COHORT||RETROSPECTIVE|||||||
34032193|NCT02371655|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34032194|NCT05405504|||COHORT||PROSPECTIVE|||||||
34032195|NCT00142025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032196|NCT03437408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Ventricular Substrate maps in patients undergoing ablation for VT - maps collected with automated tagging in different pacing modalities. Validation of collected substrate. Collection of impedance and ablation index data during ablation||||
34032197|NCT03249532|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|treatment period will not be available to the assessors of secondary outcomes.|prospective, cross over, randomized order|f|f|f|t
34032198|NCT01595347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032199|NCT05361915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032200|NCT01927900|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34032201|NCT02358902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34032202|NCT00434369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032203|NCT06581952|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34032204|NCT02688946|||COHORT||PROSPECTIVE|||||||
34032205|NCT04505527|RANDOMIZED|PARALLEL||PREVENTION||NONE||Older adults will be screened and will be randomly assigned to three groups - (i) non-fallers, (ii) recurrent fallers - control group, and (iii) recurrent fallers - intervention group. A fourth group consisted of healthy young adults. This group will receive lateral stepping intervention and outcomes will be measured as a reference.||||
34032206|NCT04139824||SEQUENTIAL||TREATMENT||NONE||||||
34032207|NCT00614640|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806114|NCT06699173|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||randomize two grup intervention and control grup||||
33806115|NCT01440933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838056|NCT02896075|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The main study was conducted using a randomized controlled cross-over approach.||||
34032208|NCT04107272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34032209|NCT03859544|||OTHER||RETROSPECTIVE|||||||
34032210|NCT00862615|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34032211|NCT02112851|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032212|NCT02591524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032213|NCT01379846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34106907|NCT05027789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes examiner will be blinded to participants' study arm assignment.|This project will utilize a randomized controlled trial (RCT) design with single blinding (outcomes examiner) comparing the structured intervention (combined structured training in compensation and lifestyle modification, assisted by the EMMA) to the self-guided intervention group, which focuses on providing education and allowing participants to choose how to implement the information was chosen to account for the impact of two general factors: 1) the provision of information, and 2) the social support and stimulation provided by attending a group-based intervention.|f|f|f|t
34106908|NCT04216550|||COHORT||OTHER|||||||
34106909|NCT06019494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106910|NCT01418846|||COHORT||PROSPECTIVE|||||||
34106911|NCT04570943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106912|NCT02389738|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34106913|NCT06641622|||COHORT||RETROSPECTIVE|||||||
33806116|NCT06698666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"- Study Interventions The study is a 12-week, parallel group, randomised controlled trial (RCT) in participants with mild to moderate MDD. A baseline line assessment will be done by obtaining the socio-demographic data for the whole participants and The participants will be allocated into either groups First Group:Participants will receive Selective Serotonin Reutake Inhibitors (SSRI)(Sertraline).~Second Group:Participants will receive Selective Serotonin Reutake Inhibitors (SSRI) (Sertraline) and rosuvastatin 10 mg/day.~Assessments will be scheduled at baseline and weeks 4, 8, and 12. Randomisation and Blinding: Participants will be allocated into either 2 groups: control group (SSRI only) or interventional group (SSRI plus statins) randomly by giving them sealed envelopes containing code for control or interventional group Interventions: The participant will be randomly assigned to the interventional, or control group on a 1:1 basis."||||
33806117|NCT03340909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-controlled randomized 1:1 comparison.|t|t|t|t
33806118|NCT06025318|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806119|NCT06090513|||COHORT||PROSPECTIVE|||||||
33806120|NCT05968170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806121|NCT02736851|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806122|NCT00843934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806123|NCT03985774|||CASE_ONLY||PROSPECTIVE|||||||
33806124|NCT06699693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806125|NCT00277277|RANDOMIZED|PARALLEL||||NONE||||||
33806126|NCT04038424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34032214|NCT05866965|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||split-mouth study, 1 side would be the study side and other side would be control side|f|f|t|t
34032215|NCT00461916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032216|NCT00910676|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032217|NCT04044872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032218|NCT03763006|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Investigator will be masked|Ocudox lid wipes|f|f|t|f
34032219|NCT06094881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032220|NCT00398866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032221|NCT04110210|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Prospective randomized double blinded clinical study on humans|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.|t|t|f|f
34032222|NCT02267018|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032223|NCT06274294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The full sample size comprises 130 patients, with 65 patients allocated to each arm. The arms are defined as follows:~* Experimental Arm: Patients receive CT-P13 SC at weeks 0, 1, 2, 3, 4, and 6, followed by subcutaneous administration every two weeks until week 24.~* Control Arm: Patients receive CT-P13 IV at weeks 0 and 2, followed by subcutaneous administration every two weeks until week 24."|t|f|f|f
34032224|NCT04998656|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be told whether the Werewolf Flow 50 device was used during their surgery or not.||t|f|f|f
34032225|NCT04584684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, placebo-controlled, double-blind prospective trial to test the efficacy and acceptability of 5 therapeutic, antiseptic mouth rinses to inactivate SARS-CoV-2 virus in saliva of COVID-19 positive patients.|t|t|f|t
34032226|NCT01263587|||COHORT||PROSPECTIVE|||||||
34032227|NCT06058104|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The parent will know whether their child is receiving the treatment or not as they administer the treatment.|We will use block randomization stratified by sex to assign participants to the group where they will use the treatment immediately for 8 weeks or the cross over waitlist control, where they will be able to use the treatment after 8 weeks.|f|f|t|f
34032228|NCT04251247|||CASE_CONTROL||PROSPECTIVE|||||||
34032229|NCT00896974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032230|NCT03833687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032231|NCT02163265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032232|NCT00880178|||COHORT||PROSPECTIVE|||||||
34106914|NCT05515575|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a single-center, open label, phase II study of niraparib and will utilize Simon's two-stage design.||||
34106915|NCT04755387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106916|NCT03008213|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106917|NCT03211858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106918|NCT02848027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106919|NCT01933152|||COHORT||RETROSPECTIVE|||||||
34106920|NCT03366259|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34106921|NCT01681875|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34106922|NCT03228732|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants will be randomized into 2 groups. Group 1 will consist of a random order of Protocol 1 and Protocol 5. Group 2 will consist of a randomized order of Protocols 2, 3, 4|t|f|t|f
34106923|NCT06425341|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, random, open, parallel design||||
34106924|NCT06189365|||COHORT||PROSPECTIVE|||||||
34106925|NCT04804345|||OTHER||RETROSPECTIVE|||||||
33806127|NCT00562614|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33806128|NCT05774704|RANDOMIZED|PARALLEL||OTHER||TRIPLE||This is a 2-week double blinded, placebo-controlled, and randomized intervention trial with allocation 1:1 for two treatment arms (low curcumin group and high curcumin group).|t|f|t|t
33806129|NCT03159572|||COHORT||RETROSPECTIVE|||||||
33806130|NCT01611545|||COHORT||PROSPECTIVE|||||||
33806131|NCT00523419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806132|NCT06075017|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33806133|NCT06698484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806134|NCT05500690|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806135|NCT00702884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806136|NCT05224024|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806137|NCT06669351|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 12 subjects were planned to be enrolled. (Pharmacokinetic and safety data from at least 8 children are required.)||||
34032233|NCT03816475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032234|NCT00784004|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34032235|NCT01956201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032236|NCT00710671|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032237|NCT02498002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032238|NCT01149408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032239|NCT03781687|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|f|t
34032240|NCT01591083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032241|NCT02346292|||CASE_ONLY||RETROSPECTIVE|||||||
34032242|NCT03857815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032243|NCT03399071|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive chemo-immunotherapy consisting of FLOT chemotherapy and the PD-L1 inhibiting monoclonal antibody Avelumab. Four cycles of two-weekly chemo-immunotherapy will be administered before surgery and four further cycles post-operatively in patients who are fit enough to receive further chemo-immunotherapy after surgery. Resectional surgery will take place 4-8 weeks following the last dose of chemo-immunotherapy in patients who remain fit.||||
34032244|NCT01949402|||COHORT||PROSPECTIVE|||||||
34032245|NCT01262872|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34032246|NCT02908971|||CASE_CONTROL||PROSPECTIVE|||||||
34032247|NCT03146104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34032248|NCT06581900|||COHORT||PROSPECTIVE|||||||
34032249|NCT02547532|||COHORT||CROSS_SECTIONAL|||||||
34032250|NCT03684577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032251|NCT04888832|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34032252|NCT01171729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032253|NCT03803618|||CASE_CONTROL||PROSPECTIVE|||||||
34032254|NCT03495375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032255|NCT03018184|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032256|NCT03309501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||positive control|t|t|t|t
34032257|NCT03299673|||OTHER||PROSPECTIVE|||||||
34032258|NCT05638191|||COHORT||PROSPECTIVE|||||||
34032259|NCT01550094|||COHORT||PROSPECTIVE|||||||
34032260|NCT05671588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All participants of the study will undergo a clinical examination including a questionnaire survey and spiroergometry - examiners will not have access to intervention documents before and after the intervention (period of 6 months), as well as examiners will not perform the therapy.|The study subjects will be enrolled into two parallel groups.|f|f|f|t
34032261|NCT02107924|||CASE_CONTROL||PROSPECTIVE|||||||
34032262|NCT01753180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032263|NCT04703595|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032264|NCT01597973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032265|NCT03209843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032266|NCT03530839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032267|NCT05076357|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is an 8 week weight loss intervention with 3 randomly assigned groups: DIET, cold exposure (CE), and DIET+CE. Participants in the CE and DIET+CE groups will report to the laboratory every 2nd day for the 8 week intervention to undergo cold exposure. The DIET and DIET+CE groups will have a weekly nutritional consultation at the lab as well as a weekly check-in with the nutritionist via text, phone, or email.||||
34032268|NCT02180048|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34032269|NCT03345420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032270|NCT03251001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All clinical parameters were evaluated by a calibrated examiner (intraclass correlation coefficient = 0.98) blind to test and control groups.|Split-mouth design. One side of mouth was test group, other side was control group.|f|f|f|t
34032271|NCT06551025|||OTHER||PROSPECTIVE|||||||
34032272|NCT00494702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34032273|NCT06280521|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032274|NCT05602324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032275|NCT02498392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032276|NCT01117974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032277|NCT05387343|||COHORT||PROSPECTIVE|||||||
34032278|NCT00451204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032279|NCT05528978|||COHORT||CROSS_SECTIONAL|||||||
34032280|NCT02581605|||COHORT||PROSPECTIVE|||||||
34032281|NCT01268527|RANDOMIZED|PARALLEL||TREATMENT||||||||
34032282|NCT00987532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032283|NCT03710980|||OTHER||PROSPECTIVE|||||||
34032284|NCT01737073|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34032285|NCT00554684|||COHORT||PROSPECTIVE|||||||
34032286|NCT04355260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032287|NCT05900778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34106926|NCT05811013|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|All patients, caregivers, and investigators assessing outcomes will be blind to the intervention assignment.|We will conduct a randomized, sham-controlled, double-blind, within-subjects, cross-over study (allocation ratio 1:1) to test the ability of repeated sessions of tSMS to safely reduce disability progression in patients with PMS.|t|t|f|t
34032288|NCT04771559|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study consists of two groups : 1) Cancer patients, 2) Healthy controls Blood samples will be taken from the participants of the two groups 4 weeks after the second dose of the COVID-19 vaccine and antibody testing will be performed. Additionally participants will be questioned for side effects of the vaccine and the data will be registered.||||
34032289|NCT02961998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032290|NCT05823857|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomized controlled trial||||
34032291|NCT03591042|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34032292|NCT02663843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032293|NCT03416829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032294|NCT02630576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34032295|NCT04036357|||COHORT||PROSPECTIVE|||||||
34032296|NCT02121652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032297|NCT05806996|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34032298|NCT04030208|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34032299|NCT00080145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032300|NCT03752697|||COHORT||PROSPECTIVE|||||||
34032301|NCT02251600|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34032302|NCT00417170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34032303|NCT03911830|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032304|NCT01654692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032305|NCT01951924|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34032306|NCT02553772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032307|NCT05237778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032308|NCT06291194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032309|NCT06030375|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"The physical appearance of the KAND567 solution is a clear transparent solution with a distinct smell. An unblinded pharmacist or registered nurse at the study centre therefore prepared the dosing solutions.~There were two unblinded persons working together, one person handled the IMP and perform the dispensing according to the randomisation list and the other person monitored the process."||t|f|t|f
34032310|NCT04863443|||CASE_ONLY||PROSPECTIVE|||||||
34032311|NCT03513991|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant did not know which formula was assigned. Infant formulas were packed in the same presentation and identified by a number.|"The exclusively formula-fed infants were randomized to one of three study formulas with different protein profile.~A control group was selected with women that voluntarily chose to exclusively breast feed for at least 4 months."|t|f|f|f
34032312|NCT04335513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032313|NCT00556244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34032314|NCT02186002|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34032315|NCT01974531|||OTHER||PROSPECTIVE|||||||
34032316|NCT01546428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032317|NCT03112473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and outcome assessor were blinded to the group allocation|Parallel Assignment|t|f|f|t
34032318|NCT02964247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032319|NCT00727103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032320|NCT04118491|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|sham control- sham HBO2 treatments (air at near normal pressure (1.2 ATA)). Treatments will be done once daily for 2 hours, Monday through Friday.|treating with hyperbaric oxygen therapy vs sham in a randomized crossover fashion|t|f|f|f
34032321|NCT01174693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032322|NCT00178893|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34032323|NCT05305066|RANDOMIZED|PARALLEL||OTHER||NONE||"Two separate sub-studies will be conducted:~Sub-study 1: Subjects who have failed conventional DMARDS will be randomised to receive therapy with TNFi or anti-IL6 using covariate adaptive randomization.~Sub-study 2: Subjects who have failed TNFi will be randomised to receive therapy with anti-IL6 or JAKi using covariate adaptive randomization."||||
34032324|NCT02267044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032325|NCT04825912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032326|NCT05027152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1: Traditional resistance exercises. Group 2:The repetitive task training group|f|f|t|t
34032327|NCT05107947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Interventions constitutes of a different lighting environment therefore not possible to mask.|One intervention group and one control group||||
34032328|NCT04051346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34032329|NCT00709995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032330|NCT02962986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032331|NCT05626205|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33724514|NCT00006202||||TREATMENT||||||||
34032332|NCT04964102|NA|SINGLE_GROUP||OTHER||NONE||||||
34032333|NCT02411825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032334|NCT00137501|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34032335|NCT05310071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032336|NCT03744247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032337|NCT05546437|||CASE_ONLY||RETROSPECTIVE|||||||
34032338|NCT05462041|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34032339|NCT00323050|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724515|NCT00817115|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724516|NCT01476696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032340|NCT05203783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032341|NCT05396898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032342|NCT03486522|||COHORT||PROSPECTIVE|||||||
34032343|NCT04814173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806138|NCT04566861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The principal investigators and outcomes assessors will be blind to the randomization status of the 200 anxious women assigned to the intervention and enhanced usual care groups.|Within women in a larger randomized trial (randomized to the intervention or enhanced care group), we propose to study biological correlates of antenatal anxiety (i.e., immune and endocrine functioning) in 300 women: in addition to 200 drawn from our randomized trial (100 intervention, 100 usual care), we will also include 100 healthy women without anxiety or depression. These enrollment goals were modified after interruptions by the Covid-19 pandemic.|f|f|t|t
33806139|NCT05564468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33806140|NCT03213899|||COHORT||PROSPECTIVE|||||||
34032344|NCT01094015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806141|NCT05860504|||COHORT||PROSPECTIVE|||||||
33806142|NCT06700005|||CASE_CONTROL||PROSPECTIVE|||||||
33806143|NCT03872063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33806144|NCT06693648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806145|NCT01957332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806146|NCT04776239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806147|NCT05739370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806148|NCT02613403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806149|NCT06029842|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33806150|NCT06603623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806151|NCT05304624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806152|NCT01501617|RANDOMIZED|||TREATMENT||TRIPLE|||t|f|t|t
33806153|NCT02170337|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33806154|NCT06699043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A total of twenty patients will be diagnosed with stage III grade B periodontitis according to the Caton classification. They will be selected from the clinic of Department of Periodontology and Oral Medicine, Faculty of Dentistry, Mansoura University~Patients will be classified into two groups:~* Group I: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of nanocrystalline hydroxyapatite in putty form as grafting material.~* Group II: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of Demineralized Bone Matrix allograft putty as grafting material."|t|f|f|f
33806155|NCT00613405|RANDOMIZED|PARALLEL||||NONE||||||
33806156|NCT01756599|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33806157|NCT05971979|||COHORT||PROSPECTIVE|||||||
33806158|NCT05596331|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806159|NCT01157299|||CASE_CONTROL||PROSPECTIVE|||||||
33806160|NCT05769244|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33806161|NCT01458600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33806162|NCT00474799|RANDOMIZED|CROSSOVER||||NONE||||||
33806163|NCT00156507|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806164|NCT05750043|||OTHER||PROSPECTIVE|||||||
33806165|NCT01749319|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806166|NCT04291027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806167|NCT00290537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806168|NCT01608568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806169|NCT04745156|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33806170|NCT05593107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806171|NCT00023400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806172|NCT01094106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806173|NCT05437770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to intervention allocation.||f|f|f|t
33806174|NCT01006772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806175|NCT00125905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806176|NCT02221505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806177|NCT04145284|||COHORT||PROSPECTIVE|||||||
33806178|NCT06522438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806179|NCT05620472|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33806180|NCT00003087||||TREATMENT||||||||
34032345|NCT02732873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032346|NCT01081080|||COHORT||PROSPECTIVE|||||||
34032347|NCT03996811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34032348|NCT04177407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a single-center prospective cohort study and fulfill the IDEAL 2A stage principle. Rectal cancer patients undergoing laparoscopic ELAPE, suffering rigid pelvis or huge perineal peritoneum defect, and having difficulty in primary perineal wound closure will be considered eligible. Main exclusion criteria are being complicated with urgent complications, ASA grade \> 3 and accompanied with mental illness. Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.||||
34032349|NCT00000929||||PREVENTION||||||||
34032350|NCT02276807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032351|NCT03145415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|No other parties will be masked.|All Children will be randomly assigned to one of 2 groups of 30 patients each using a computer generated number table.|t|t|f|t
34032352|NCT06429293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals who interpret images and data will be blinded to assigned intervention|Participants are randomized to 12 weeks of cognitive processing therapy or waitlist control.|f|f|f|t
34032353|NCT00467974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032354|NCT00144729|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032355|NCT01689883|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The investigators will use a system to inject small currents in the arm while subjects perform upper-limb movements. Subjects will perform multiple trials. During half of the trials, subjects will receive actual stimulation. During the other half, subjects will receive sham stimulation.||||
34032356|NCT02051348|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34106927|NCT01321684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33806181|NCT02674841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806182|NCT03398876|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33806183|NCT02502526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106928|NCT05892393|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806184|NCT04305197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806185|NCT05340452|RANDOMIZED|CROSSOVER||OTHER||NONE||An Open Label, Randomized, Two Way Cross Over, Two Period, Two Treatment, Two Sequence Bioequivalence Study||||
33806186|NCT03195803|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Comparison, non-randomized single blind study|f|f|t|t
33806187|NCT00061906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806188|NCT02433587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806189|NCT01903109|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806190|NCT03022968|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806191|NCT06260670|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806192|NCT02403375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806193|NCT00442104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806194|NCT00325767|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34032357|NCT03929068|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Identified participants will be randomized to receive either placebo or carbidopa-levodopa for a period of three weeks before crossing over to the other arm of the study. The two periods will be separated by a one day washout period.|t|f|f|t
34032358|NCT04071405|||CASE_ONLY||OTHER|||||||
34032359|NCT06223802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032360|NCT03550911|||COHORT||PROSPECTIVE|||||||
34032361|NCT02252354|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34032362|NCT04581993|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34032363|NCT05606783|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032364|NCT02269098|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34032365|NCT02827955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032366|NCT05736055|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032367|NCT00882284|||COHORT||PROSPECTIVE|||||||
34032368|NCT05469334|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032369|NCT02571699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34032370|NCT00591773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032371|NCT04505969|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032372|NCT05472246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Our study is a prospective, randomized, controlled, single-center study involving 200 patients aged 18-70 years who are scheduled for port catheter implantation procedure in Dr Siyami Ersek Thoracic Heart and Vascular Surgery Training and Research Hospital Thoracic Surgery Clinic. The patients will be randomly divided into 2 groups and one group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure, while the control group will undergo the routine anesthesia procedure.||||
34032373|NCT04809922|||COHORT||PROSPECTIVE|||||||
34032374|NCT03347201|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032375|NCT03304301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032376|NCT01358461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032377|NCT01172041|||COHORT||PROSPECTIVE|||||||
34032378|NCT04655547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomized to control or intervention group, stratified on their FEDSS-score.~The study will include 34 participants - 17 in each group."||||
34032379|NCT05114213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032380|NCT04943133|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032381|NCT02417987|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34032382|NCT03749889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032383|NCT01228617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34032384|NCT02380326|||COHORT||PROSPECTIVE|||||||
34032385|NCT04389372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032386|NCT01625091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032387|NCT00173511|||DEFINED_POPULATION||OTHER|||||||
34032388|NCT03018678|||COHORT||PROSPECTIVE|||||||
34032389|NCT06248125|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34032390|NCT01433055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032391|NCT01360099|||||PROSPECTIVE|||||||
34032392|NCT05543083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032393|NCT00897182|||COHORT||RETROSPECTIVE|||||||
34032394|NCT06076733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34032395|NCT00919295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032396|NCT01059461|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032397|NCT02398864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032398|NCT00501995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032399|NCT06171399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032400|NCT02382003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032401|NCT03541629|||COHORT||RETROSPECTIVE|||||||
34032402|NCT04685512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Biologists in Endpoint Adjudication committee|Phase 2B: 30 treated, 30 untreated - 1 interim analysis planned after inclusion of 30 patients / Phase 3: 90 treated, 90 untreated - 2 interim analyses planned after inclusion of 60 and 120 patients|f|f|f|t
34032403|NCT01348256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032404|NCT00295425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032405|NCT01023503|||||RETROSPECTIVE|||||||
34032406|NCT01602822|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032407|NCT01026194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032408|NCT00003126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032409|NCT02118545|||COHORT||PROSPECTIVE|||||||
34032410|NCT00316290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032411|NCT00074308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032412|NCT00908544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032413|NCT01459783|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34032414|NCT02143544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032415|NCT02126826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032416|NCT00754078|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032417|NCT03225001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032418|NCT00932672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34106929|NCT06673719|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Monocentric, non-randomized sequence, pilot and feasibility study||||
34032419|NCT06199284|NA|SINGLE_GROUP||OTHER||NONE||The study will be conducted in 3 phases, each lasting 6 weeks, following the ABA procedure. Phase B represents the intervention phase, during which patients will practice their gait training at a rhythm of 3 sessions/week, as an add-on to usual care. In the two phases A, patients receive usual care with no additional treatment||||
34032420|NCT00133965|||COHORT||PROSPECTIVE|||||||
34032421|NCT05008874|||COHORT||OTHER|||||||
34106930|NCT06017986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34106931|NCT01831336|||OTHER||PROSPECTIVE|||||||
34106932|NCT02228330|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34106933|NCT02775643|||COHORT||PROSPECTIVE|||||||
34106934|NCT06657612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34106935|NCT04582487|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34106936|NCT06444061|||OTHER||CROSS_SECTIONAL|||||||
34106937|NCT05018728|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34106938|NCT06117631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34106939|NCT06190990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Assignment|t|f|t|f
34106940|NCT04369105|||COHORT||PROSPECTIVE|||||||
33806195|NCT00680771|||COHORT||PROSPECTIVE|||||||
33806196|NCT04373694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806197|NCT03975400|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33806198|NCT00076648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806199|NCT04437043|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Investigator-initiated, academic, prospective, interventional, multicenter study||||
33806200|NCT01943669|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806201|NCT05717127|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806202|NCT04886674|||COHORT||PROSPECTIVE|||||||
33806203|NCT06699199|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Children will receive one of two interventions~1. Silver diamine fluoride 38% (SDF only) or,~2. Silver diamine fluoride 38% + potassium iodide (SDF +KI) Both treatment are recommend and approved as an arresting treatment of Dental caries in children as an intermediate management"||||
33806204|NCT06668623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33806205|NCT05891132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a randomized controlled trial, randomization will be achieved by the following: the allocation treatment will be written on cards that will be sealed in sequentially numbered envelopes. The envelopes will be opened at the time of allocation after the enrolled participants will complete all baseline assessments. Group I comprised 30 women who will receive 10 ml of lidocaine 2% for perineal infiltration at the time of crowning while 30 women of Group II will have lidocaine prilocaine cream 15gm application on the perineum at 8 cm of cervical dilatation and then an additional dose every 1 hour until delivery is achieved, then another dose of the cream will be applied before repairing the episiotomy and finally daily 3 doses every 8 hours at the site of episiotomy for the first week post-partum.|"Group I comprised 30 women who will receive 10 ml of lidocaine 2% for perineal infiltration at the time of crowning while 30 women.~Group II will have lidocaine prilocaine cream 15gm application on the perineum at 8 cm of cervical dilatation and then additional dose every 1 hour until delivery is achieved, then another dose of the cream will be applied before repairing the episiotomy and finally daily 3 doses every 8 hours at the site of episiotomy for the first week post-partum."|t|f|f|f
33806206|NCT02616926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806207|NCT03927651|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806208|NCT03477968|||COHORT||PROSPECTIVE|||||||
33806209|NCT02414633|||COHORT||PROSPECTIVE|||||||
33806210|NCT05121259|NA|SINGLE_GROUP||TREATMENT||NONE||Single group feasibility study. Upon obtaining informed consent, participants will be allocated to the intervention group.||||
33806211|NCT03582566|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Assessors are blind to treatment condition. Intervention providers are blind to assessment outcomes.|The efficacy of phonological awareness (Earobics) and working memory (Cogmed) training alone and in combination are compared to an active control (Splashmath).|f|f|f|t
33806212|NCT05321992|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806213|NCT01337141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032422|NCT02078700|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032423|NCT03095664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106941|NCT00615160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106942|NCT00837135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106943|NCT04154163|||COHORT||PROSPECTIVE|||||||
34106944|NCT01840072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106945|NCT05764083|||COHORT||PROSPECTIVE|||||||
34106946|NCT06466096|||COHORT||PROSPECTIVE|||||||
34106947|NCT06644144|||COHORT||PROSPECTIVE|||||||
34106948|NCT06100224|||COHORT||PROSPECTIVE|||||||
34106949|NCT02150993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106950|NCT06240455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106951|NCT04229017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly assigned to either the treatment or control arms at 1:1 ratio.|prospective, randomized, controlled multi-center trial|t|f|f|f
34106952|NCT04873999|||CASE_ONLY||PROSPECTIVE|||||||
34106953|NCT00697385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106954|NCT03683082|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34106955|NCT01397591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106956|NCT04913116|||OTHER||PROSPECTIVE|||||||
34106957|NCT00814983|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106958|NCT06405347|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pre-post study. Over a two month period recently discharged patients from each participating unit will be asked to complete a study survey. Over the next two months, patients on that unit will be recruited to participate in the intervention. These intervention patients will be asked to complete the same study survey as during the pre-intervention phase once discharged.||||
34106959|NCT05544695|||OTHER||PROSPECTIVE|||||||
34106960|NCT01137565|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34106961|NCT06372080|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The study design is a single-blind (participants were unaware of their group allocation), randomized controlled trial.|t|f|f|f
34106962|NCT03411044|||COHORT||PROSPECTIVE|||||||
34106963|NCT05888233|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label unblinded drug pilot study to determine whether Allopurinol improves left ventricular diastolic function, exercise capacity, and quality of life in African American Veterans with resistant hypertension after 8-weeks of treatment.||||
34106964|NCT02261792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34106965|NCT00237627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34106966|NCT00747201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33806214|NCT01540591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106967|NCT06641726|||COHORT||CROSS_SECTIONAL|||||||
34106968|NCT06564740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is designed as a multicentric randomized controlled trial (RCT). Patients will be randomly divided into two groups. Treatment Group: 30 Kasai-operated BA patients who will receive UC-MSC transplantation, and Control Group: 30 BA patients who will only undergo Kasai operation. UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.|f|f|f|t
34106969|NCT05777863|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Participants come for baseline outcome measurement visits in Nijmegen and Wageningen prior to randomization. The follow-up measurements are carried out by researchers, investigators and research-assistants who are not guiding the intervention groups, have no contact with included participants after randomization, and are not involved in the randomization process.~Participants are aware of their group allocation, as it is clear to participants multiple groups are formed which differ in the way the intervention material is provided."|Multidomain lifestyle intervention. Participants are randomized in a 1:1 ratio to a multidomain lifestyle intervention characterized by group-sessions and supervision (high-intensity intervention group) versus access to general lifestyle-related health information in the form of biweekly leaflets which are provided through e-mail (low-intensity intervention group).|f|f|f|t
34106970|NCT04913090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106971|NCT04028167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106972|NCT06674148|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Qifangfeixian granules in the treatment of patients with fibrotic interstitial lung disease. The study drugs included Qi fangfeixian Granule and placebo, which was identical in appearance, taste and weight with Qifangfeixian Granule, and were given 1 bag twice a day. This study planned to enroll 124 subjects, who were randomly assigned at a ratio of 1:1, with 62 subjects in each group. Subjects who met all the inclusion criteria at baseline and did not meet the exclusion criteria were randomized to either of the following two groups: (1) Qifangfeixian Granule treatment group: oral administration of Qifangfeixian granule, 1 bag, 2 times a day; (2) Placebo (PRO) control group: oral administration of placebo, 1 bag, 2 times a day. Patients were evaluated after 12 weeks of treatment.||||
34106973|NCT00228956|||COHORT||PROSPECTIVE|||||||
34106974|NCT05701631|||OTHER||OTHER|||||||
34106975|NCT06188247|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34106976|NCT00378287|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34106977|NCT03141970|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentric, Parallel group, Open label randomized controlled trial||||
34106978|NCT05402345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34106979|NCT06675734|||CASE_CONTROL||PROSPECTIVE|||||||
34106980|NCT05346718|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are blinded to the pollen concentration of each allergen challenge, including placebo exposure.|The study design is mixed. Participants are randomized to the sequence of the placebo and first pollen concentration (cross over). Then they are exposed as a single group in all following allergen challenges.|t|f|f|f
34106981|NCT03712761|||CASE_CROSSOVER||PROSPECTIVE|||||||
34106982|NCT04466033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34106983|NCT01933763|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34106984|NCT03196479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34106985|NCT01415687|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34106986|NCT06564922|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The intervention will be single-blinded. The outcome assessors will be masked.|The study will have two arms, i.e., intervention and control groups. The intervention group will receive immediate postnatal breastfeeding counselling and control group will receive routine care.|f|f|f|t
33806215|NCT06393491|||COHORT||RETROSPECTIVE|||||||
33806216|NCT03259984|||COHORT||PROSPECTIVE|||||||
33806217|NCT05030415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806218|NCT02386098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806219|NCT01022125|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806220|NCT03524755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806221|NCT05516745|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||"4 arms -~1. arm - AioCare device spirometry~2. arm - AioCare device spirometry+ telerehabilitation of the respiratory system~3. arm - telerehabilitation of the respiratory system~4. arm - control arm - standard of care (no monitoring, no telerehabilitation)"||||
33806222|NCT04995588|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806223|NCT03507972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806224|NCT06455683|||COHORT||PROSPECTIVE|||||||
33806225|NCT01333007|||COHORT||PROSPECTIVE|||||||
33806226|NCT02493166|NON_RANDOMIZED|PARALLEL||||NONE||||||
33806227|NCT01267643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806228|NCT05868304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806229|NCT03590899|||COHORT||CROSS_SECTIONAL|||||||
34106987|NCT02965313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106988|NCT00298155|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34106989|NCT06189612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assessing clinician will be blinded to group allocation. Participants will be unaware of the hypothesis of this study to decrease performance biases.|Three groups (msk + cervical motor control training, msk + orofacial motor control training, msk + standard exercises) will receive the protocol at the same time period.|t|f|t|t
34106990|NCT01946269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34106991|NCT06642818|RANDOMIZED|PARALLEL||PREVENTION||NONE||Unblinded randomized clinical superiority trial in two parallel groups (intervention vs. no intervention) national multicentre.||||
34106992|NCT05321745|NA|SINGLE_GROUP||TREATMENT||NONE||Partial enteral nutrition,FMT||||
34106993|NCT04349098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34106994|NCT04642430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A pragmatic prospective randomized open blinded endpoint (PROBE) trial|f|f|f|t
34106995|NCT05267600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34106996|NCT06674395|||OTHER||CROSS_SECTIONAL|||||||
34106997|NCT02399566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34106998|NCT04248153|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Group A: BR55 CEUS will be performed in the early follicular phase first and in the late follicular phase thereafter; Group B: BR55 CEUS will be performed in the late follicular phase first and in the early phase thereafter.||||
34106999|NCT03608631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107000|NCT04576559|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34107001|NCT06675916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107002|NCT05338320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34107003|NCT03579719|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34107004|NCT02051387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107005|NCT05941585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107006|NCT02125422|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107007|NCT04725110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107008|NCT06536881|NA|SEQUENTIAL||OTHER||NONE||"Participants undergo a trial of 24-hour water only fasting before starting chemotherapy. At least one successful 24-hour fast is required. A total of 3 trials can be attempted. Participants can also progressively increase by 12 hours each week as tolerated or to a max of 48 hours. If a participant is unable to maintain at least a 24-hour fast during the study, participation in this study will end. Once the tolerated fasting time is established, this will be the starting fasting regimen used for Cycle 1 of 4 of the scheduled chemotherapy.~Investigators also aim to understand the impact of fasting on quality of life, inflammatory markers, and the bacteria in the gut. Participants will complete surveys weekly, blood samples for research and fasting labs with each cycle of chemotherapy (at 4 different time points). Investigators will also collect research bloods at baseline, stool samples 3 times in the study: baseline, and after fasting interventions for Cycle 1 and 3."||||
34107009|NCT05936437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107010|NCT06252532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34107011|NCT06421311|||COHORT||OTHER|||||||
34107012|NCT00607477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107013|NCT06023069|||COHORT||PROSPECTIVE|||||||
34107014|NCT03804255|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34107015|NCT04575298|||OTHER||PROSPECTIVE|||||||
34107016|NCT04606316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The neoadjuvant treatment administered prior to surgery will be blinded. The participants, Sponsor, site investigators, and site staff will not know the treatment administered. An assigned Site Investigational Pharmacist will not be blinded. Designated staff of the DF/HCC Office of Data Quality will be unblinded to facilitate randomization and safety monitoring. Treatment after surgery is not blinded.||t|f|t|f
34107017|NCT05815264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34107018|NCT04527744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and the outcomes assessor will be prevented from having knowledge of the interventions assigned to individual participants.|In this double-blind single-site randomized clinical trial, A total number of 36 patients with gummy smile will be enrolled in the study at Peking University School and Hospital of Stomatology over a period of 12 months. Patients will be included and randomized 1:1 to two groups for BTX-A treatment at different injection point.|t|f|f|t
34107019|NCT06638021|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||pre-post hybrid type 1 effectiveness implementation design||||
34107020|NCT06564350|||CASE_ONLY||PROSPECTIVE|||||||
34107021|NCT06669039|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34107022|NCT06207162|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107023|NCT05129969|||OTHER||PROSPECTIVE|||||||
34107024|NCT02312128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107025|NCT04696575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107026|NCT06640595|||CASE_CROSSOVER||PROSPECTIVE|||||||
34107027|NCT04099290|||COHORT||PROSPECTIVE|||||||
34107028|NCT05818930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107029|NCT03396861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107030|NCT06571604|||CASE_CONTROL||RETROSPECTIVE|||||||
34107031|NCT06643780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107032|NCT01291160|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107033|NCT05061836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107034|NCT03968042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107035|NCT02006290|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34107036|NCT06673862|||OTHER||PROSPECTIVE|||||||
34107037|NCT06108544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107038|NCT05902754|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"Labels of the product will be replaced with Tablets A and Tablets B labels."||t|t|t|f
34107039|NCT05849246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107040|NCT05837897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107041|NCT03930511|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34107042|NCT04809805|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34107043|NCT06675864|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107044|NCT02088554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806230|NCT02304614|||COHORT||CROSS_SECTIONAL|||||||
33806231|NCT00333372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33806232|NCT06642584|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806233|NCT02191891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806234|NCT01280513|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33806235|NCT05706246|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838057|NCT05789225|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be stratified for ambulation level (ambulatory/non-ambulatory) and a 1:1 allocation ratio of blocks of 8 will be used for randomization.|f|f|f|t
34032424|NCT03338530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Child testing and behavioral observations were completed by evaluators blinded to treatment condition; evaluators consisted of advanced graduate students with training in the specific outcome measures|The efficacy of the comprehensive school-based intervention (CSBI) was evaluated in a cluster randomized trial (pretest-posttest control group design). School buildings were randomly assigned to receive the CSBI or their typical educational programming. The CSBI was examined for its effect on the social performance/competence, ASD symptoms, and academic skills of children with HFASD compared to children with HFASD that did not receive the intervention. School staff delivered the multi-component intervention during the school year and research staff monitored intervention implementation (fidelity).|f|f|f|t
33838058|NCT05157945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032425|NCT04092140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032426|NCT04607135|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032427|NCT03806010|||COHORT||PROSPECTIVE|||||||
34032428|NCT04534452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032429|NCT02922127|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032430|NCT02934399|||CASE_CONTROL||PROSPECTIVE|||||||
34032431|NCT02486237|||COHORT||RETROSPECTIVE|||||||
34032432|NCT01221415|||OTHER||PROSPECTIVE|||||||
34032433|NCT02654028|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34032434|NCT00375986|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34032435|NCT00002528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032436|NCT04141774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032437|NCT04349202|||COHORT||PROSPECTIVE|||||||
34107045|NCT06638580|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34107046|NCT06640439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study was a double-blind study in which the patient, the surgeon, and the statistician were all unaware of whether the patient received treatment or a placebo control light . Only the operator using the LED light was aware of this information. The assigned group was recorded on sealed and opaque envelopes. These cards were prepared by an independent person who was not involved in the study protocol. Once the patient underwent extraction and agreed to participate in this trial, this independent person opened the envelope to reveal the allocation.|Patients who underwent mandibular third molar extraction|t|f|t|t
34107047|NCT03531541|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|"The blinding will be assessed by examiner 2 (responsible for administering TENS) asking the participants which TENS intervention they think they received, with 3 options for the answer: active, placebo or don't know. The same questions will be asked by examiner 2 for CJM. Next, examiner 3 (responsible for administering CJM) will receive the blinding outcome and have 3 options for the answer: active, placebo or don't know. Examiner 1 will receive the blinding outcome will be asked: Which group does the patient belong to: active TENS and CJM, active TENS and placebo CJM, placebo TENS and active CJM or placebo TENS and CJM Their responses to these questions will be recorded and used to measure the adequacy of participants and examiners"|The participants will be randomly allocated into 4 groups: (G1) active TENS and CJM, (G2) placebo TENS and CJM, (G3) placebo TENS and active CJM, (G4) active TENS and placebo CJM.|t|f|t|t
34107048|NCT00000930|||CASE_ONLY||PROSPECTIVE|||||||
34107049|NCT06211868|||COHORT||PROSPECTIVE|||||||
34107050|NCT03284385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107051|NCT00625105|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34107052|NCT06187714|||COHORT||PROSPECTIVE|||||||
34107053|NCT04601493|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||43 Primary Care Clinics will be randomized to be in one of 4 arms: 1) Care as usual, 2) Choice architecture nudge, 3) Prescription Drug Monitoring Program (PMP) Integration \& nudge, 4) Choice architecture nudge + PMP Integration \& nudge|f|f|t|t
34107054|NCT04270019|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||This study will be a randomized, double-blind, placebo-controlled human clinical trial.|t|t|t|t
34107055|NCT02776176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107056|NCT02408029|||CASE_ONLY||CROSS_SECTIONAL|||||||
34107057|NCT05743673|||CASE_ONLY||PROSPECTIVE|||||||
34107058|NCT03186157|||COHORT||PROSPECTIVE|||||||
34107059|NCT01643174|||CASE_ONLY||RETROSPECTIVE|||||||
34107060|NCT06674811|||CASE_ONLY||PROSPECTIVE|||||||
34107061|NCT00131885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107062|NCT04250051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107063|NCT06642870|||OTHER||CROSS_SECTIONAL|||||||
34107064|NCT02772120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107065|NCT06417879|||OTHER||CROSS_SECTIONAL|||||||
34107066|NCT00273780|RANDOMIZED|FACTORIAL||||NONE||||||
34107067|NCT01033669|||COHORT||PROSPECTIVE|||||||
33838059|NCT03485664|||CASE_CONTROL||PROSPECTIVE|||||||
34032438|NCT03564158|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Only Moxifloxacin will be administered open-label.||t|f|t|t
34032439|NCT03133858|||COHORT||PROSPECTIVE|||||||
34032440|NCT05688917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|double-blind randomised controlled study|160 obese patients supplemented with GCBE capsules (800 mg) daily for six months|t|f|t|f
34032441|NCT05292807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032442|NCT04061239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032443|NCT06011447|||COHORT||PROSPECTIVE|||||||
34032444|NCT04762472|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34032445|NCT02856555|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34032446|NCT03270839|NON_RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34107068|NCT05686486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Investigators, participants and professionals are aware of the experimental condition. Only the external evaluators do not know which experimental condition the participants are in.|"The experimental design is a cluster randomised controlled study with three arms corresponding to three experimental conditions. Sixty dyads will be recruited for a total of 120 participants (60 family caregivers and 60 residents) divided into 12 groups.~9 nursing homes are participating."|f|f|f|t
34107069|NCT04007731|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34107070|NCT00728533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107071|NCT06645158|||COHORT||PROSPECTIVE|||||||
34107072|NCT04456894|||COHORT||PROSPECTIVE|||||||
34107073|NCT06641362|||OTHER||PROSPECTIVE|||||||
34107074|NCT00859885|||COHORT||PROSPECTIVE|||||||
34107075|NCT00213525|||CASE_CONTROL||PROSPECTIVE|||||||
34107076|NCT02380235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107077|NCT01297296|||CASE_ONLY||PROSPECTIVE|||||||
34107078|NCT03644758|||OTHER||PROSPECTIVE|||||||
34107079|NCT02441400|||COHORT||PROSPECTIVE|||||||
34107080|NCT04191356|||CASE_ONLY||PROSPECTIVE|||||||
34107081|NCT00970177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34107082|NCT04019327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107083|NCT02055235|||||PROSPECTIVE|||||||
34107084|NCT06675500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"This study is a prospective, randomized controlled trial that will study the postoperative anti-arrhythmic effect of Magnesium Sulfate and clinical outcomes of administration of intravenous Mg Sulfate in patients undergoing open heart surgery.~Randomization will be performed using a computer-generated randomization sequence and allocation concealment to be maintained all through the time of procedure, by using opaque, numbered, and sealed envelopes.~Informed consent will be obtained from each patient before patients' allocation.~Patients will be randomly allocated by computer generated randomization into two groups A and B.~After completion of surgical procedure and successful weaning off Cardiopulmonary bypass the patients will be divided into two groups group A will receive 2 gm of Mg Sulfate diluted in 30 cc normal 0.9 % saline via intravenous infusion over 1 hour (1 Mg sulfate ampoule = 10 cc) and group B will receive 50 cc normal 0.9 % saline via intravenous infusion."|t|t|f|f
34107085|NCT05625802|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single site two-stage open label phase 2 clinical trial with one treatment arm and one external control arm||||
34107086|NCT06138158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107087|NCT04245098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107088|NCT02062008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107089|NCT06551727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107090|NCT06675279|||OTHER||CROSS_SECTIONAL|||||||
34107091|NCT06641648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107092|NCT06565000|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34107093|NCT06674551|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34107094|NCT05761964|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34107095|NCT06632613|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34107096|NCT01248819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107097|NCT06643559|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Before monotherapy, newly diagnosed epileptic patients evaluted by MoCA and P300. The patients began their treatments, and from the next day, computer-based cognitive rehabilitation was randomly assigned to some patients in each drug group, four times a week. For each drug, patients were randomly divided into those who did not receive (A) and those who received (B) cognitive rehabilitation.||||
34107098|NCT04878757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107099|NCT03206450|||COHORT||RETROSPECTIVE|||||||
34107100|NCT01787747|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34107101|NCT03686189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107102|NCT05327569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be divided into two groups using block randomization method. Participants will be randomly allocated into 2 blocks of 30 participants in each group using a random number generation technique by computer. All assessments will be done by researcher who were not in the study.|There will be two groups in this study. Each group will consist of 30 patients aged 25-50 years with patellofemoral pain syndrome. A total of 60 participants will take part in the study. Conventional physiotherapy will be applied to the control group, while myofascial release techniques will be applied to the experimental group in addition to conventional physiotherapy|f|f|f|t
34149915|NCT05191953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"Sealed opaque envelopes containing study participation numbers will be used for the purpose of assigning each patient. A researcher not involved in patient followup will use the web based Research Randomizer'' (Urbaniak and Plous 2013) tool in order to assign each participation number into a random group with a 1:1 ratio.~A nurse that is not an active investigator in the study will have each participant choose an envelope that contains the study participation number. An assistant not active in the study will inform the anesthetist who will administer the block/blocks about which group the patient is in, immediately prior to administration. Researchers, patients, surgeons, and nurses will not be aware of the randomization of groups."|A block randomization list will be created by a doctor who does not participate in patient follow-up using a web-based program, 'Research Randomizer (Urbaniak and Plous 2013)'.|t|t|t|t
34149916|NCT00740623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724517|NCT05266092|||CASE_CONTROL||PROSPECTIVE|||||||
33724518|NCT03491995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724519|NCT02413541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032447|NCT01851083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34032448|NCT01289678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032449|NCT01980030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032450|NCT00436410||||TREATMENT||||||||
34032451|NCT05854914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032452|NCT01491360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032453|NCT05463536|||COHORT||PROSPECTIVE|||||||
34032454|NCT00247312|RANDOMIZED|PARALLEL||||NONE||||||
34032455|NCT03314909|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is designed as a non-blinded trial because of the apparently different equipment of the interventions|Parallel Assignment||||
34032456|NCT06487793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are asked to complete one of two mobile phone-based programs. They may not know which condition is the experimental condition and which is the control.||t|f|f|f
34032457|NCT01553955|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34032458|NCT02333942|||COHORT||CROSS_SECTIONAL|||||||
34032459|NCT06134726|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032460|NCT00580788|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34032461|NCT05718414|||CASE_ONLY||PROSPECTIVE|||||||
34032462|NCT00149474|RANDOMIZED|||||||||||
34032463|NCT06132373|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We will conduct a mixed-methods evaluation with peer providers, participants, and key delivery stakeholders such as FHOK staff. We will collect quantitative data from: (1) peer mentors prior to their training and during the delivery of screening and treatment, (2) participants prior to entering treatment and after treatment. We will track rates of retention, engagement, and attrition during screening and treatment delivery. Lastly, we will collect qualitative data including interviews with 10 purposively sampled participants and Focus Groups with peer mentors and key delivery stakeholders post-treatment.||||
34032464|NCT03449914|||COHORT||PROSPECTIVE|||||||
34032465|NCT05606406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032466|NCT00124917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032467|NCT04190121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34032468|NCT01622829|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34032469|NCT06486870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032470|NCT03028116|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34032471|NCT01935830|NA|SINGLE_GROUP||OTHER||NONE||||||
34032472|NCT02890602|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032473|NCT02924623|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032474|NCT01586507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032475|NCT00165555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032476|NCT05516186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032477|NCT01111955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032478|NCT00361647|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032479|NCT02898376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34032480|NCT00017095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032481|NCT04940572|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
34032482|NCT00699426|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34032483|NCT04579900|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34032484|NCT00795262|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34032485|NCT03732430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032486|NCT01207583|||COHORT||PROSPECTIVE|||||||
34032487|NCT05212077|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34032488|NCT02304393|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34032489|NCT05513833|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Statisticians will also be masked to group allocation until analysis is complete.|"14 total counties (clusters) are participating in the stepped wedge randomized trial. There are two nested trials within the overall stepped-wedge trial: a complete design to evaluate the enhanced mHealth screening component and an incomplete design to evaluate the specialty telemedicine referral component combined with enhanced screening. Clusters will be randomized to cross over to enhanced mHealth hearing screening and specialty telemedicine referral in a stepwise manner until all clusters receive both the interventions.~The enhanced mHealth screening component will be rolled out in Years 2 or 3 (control period in Years 1 and 2) depending on sequence randomization. Specialty telemedicine referral will be rolled out in Years 3 and 4 (control period in Years 2 and 3) depending on sequence randomization."|f|f|f|t
34032490|NCT06449976|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||This study is designed with a total of four groups, where participants will sequentially and randomly undergo all the intervention procedures.|t|f|f|f
34032491|NCT00005598||||TREATMENT||||||||
34032492|NCT04447040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Post-operative dental pain following third molar extraction.|t|t|t|t
34032493|NCT04108286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032494|NCT00725491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107103|NCT05538208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During this double-blinded study, the Sponsor, subject, and investigator site staff will all be blinded to the subject's treatment assignment.|Eligible patients enrolled in the study will be randomized (1:1) at baseline to the 53-week double-blind, active comparator 2-part study to receive either MMFPK or MMFBSA. Subjects who are partial renal responders (PRR) to MMFBSA at week 26, will cross over to the MMFPK arm. Complete renal responders (CRR) at week 26 in MMFBSA arm will continue to be treated with MMFBSA. Subjects with at least a PRR (or even CRR) in the MMFPK arm at week 26 will remain in the MMFPK arm and continue to receive MMF dosage targeting MPA-AUC0-12 \> 60-70 mg\*h/l. Subjects whose LN fails to respond to therapy by week 26 will be discontinued from the study interventions to receive LN treatment as per their local physician's decision. Subjects who experience a single episode of a LN flare during Part 1 of the study or fulfill other criteria for discontinuation from the study intervention, will also receive LN treatment as per their local physician's decision.|t|t|t|t
33806236|NCT06698562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The study included 40 Frankl positive and definitely positive pediatric patients between the ages of 6 and 10, applied to Altinbaş University Faculty of Dentistry Pediatric Dentistry Clinic for routine dental treatments between January 2023 and April 2023, and had no previous local anesthesia experience.~This study designed as a randomized, single-center, split-mouth, double blind clinical trial."|t|f|f|t
33806237|NCT05598957|||CASE_CONTROL||PROSPECTIVE|||||||
33806238|NCT06108635|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A single blinded study will be used in which data analyzer will be blind.|Parallel Group Randomized Control Trial|f|f|f|t
33806239|NCT06163300|||COHORT||PROSPECTIVE|||||||
33806240|NCT00491296|||||PROSPECTIVE|||||||
33806241|NCT03588832|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33806242|NCT03501303|RANDOMIZED|PARALLEL||TREATMENT||NONE||In an online randomization module the randomization will be performed with permuted block randomization to 1:1 ratio.||||
33806243|NCT05776888|||COHORT||PROSPECTIVE|||||||
33806244|NCT04376775|||COHORT||PROSPECTIVE|||||||
33806245|NCT03695549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806246|NCT06699524|||COHORT||RETROSPECTIVE|||||||
33806247|NCT03461666|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||parallel group||||
33806248|NCT01078909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33806249|NCT03665792|||OTHER||CROSS_SECTIONAL|||||||
33806250|NCT01493882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806251|NCT02150616|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33806252|NCT04031365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806253|NCT00892541|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806254|NCT00644566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33806255|NCT02715518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical event adjudication and statistical analysis will be blindly performed by independent investigators.||f|f|t|t
33806256|NCT04466137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806257|NCT01419210|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806258|NCT01023698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032495|NCT03234543|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The study will be conducted in a double-masked fashion. Investigative team member/s that will carry out randomization and administer the intervention will not be involved in evaluation of clinical and laboratory outcomes. The primary surgical team, nurses, and any consulting services caring for the patient will be unaware of the group assignment. Other care providers will not be informed of the group assignment. Outcome assessors will not be involved in randomization and administration of the RIC intervention. Adequate steps are in place to mask the outcome assessors (clinical and laboratory) from knowing group assignment.~Subjects will be masked from recognizing which group they are in in the following manner: a) Subjects will not be informed of the group assignment throughout their participation in the study; b) subjects randomized to No RIPC will have a tourniquet placed on the thigh and inflated."|A prospective, randomized, double - masked clinical trial of RIC will be conducted in adult patients undergoing major abdominal surgery at University Hospital in Newark, NJ. Participants will be randomized into two groups: RIC and No RIC.|t|t|f|t
34032496|NCT02952469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032497|NCT01195610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032498|NCT02223988|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032499|NCT01104623|||COHORT||PROSPECTIVE|||||||
34032500|NCT06499532|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34032501|NCT00054405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032502|NCT00001271||||TREATMENT||||||||
34032503|NCT04384094|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032504|NCT00819663|||COHORT||RETROSPECTIVE|||||||
34032505|NCT01090414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032506|NCT05857683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032507|NCT05416840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032508|NCT04894370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032509|NCT00064987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032510|NCT00695474|||COHORT||CROSS_SECTIONAL|||||||
34032511|NCT05233462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Neither the patient nor the care provider nor the outcome assessor will know the allocation group.~Bupivacaine syringe will be prepare, according to the protocol, by a separate anesthetist not involved in the care of the patient. The solution in both groups will have the same volume."|randomized controlled double blind trial|t|t|t|t
34032512|NCT01893515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032513|NCT05495243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107104|NCT02285686|||COHORT||PROSPECTIVE|||||||
34107105|NCT05682443|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open label, active controlled, multi-center study||||
33806259|NCT00503061|||CASE_ONLY||PROSPECTIVE|||||||
33806260|NCT01303796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806261|NCT04199338|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Only participant masking was performed.|This study is a randomized controlled study||||
33806262|NCT02707198|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33806263|NCT00934505|||||PROSPECTIVE|||||||
33806264|NCT03608293|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33806265|NCT02102451|||OTHER||CROSS_SECTIONAL|||||||
33806266|NCT00968695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806267|NCT01035372|NA|SINGLE_GROUP||OTHER||NONE||||||
33806268|NCT03066609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806269|NCT00758550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806270|NCT06440226|||OTHER||RETROSPECTIVE|||||||
33806271|NCT06622226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806272|NCT03396107|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33806273|NCT02942784|||COHORT||RETROSPECTIVE|||||||
33806274|NCT01578941|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33806275|NCT01932632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806276|NCT01357512|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806277|NCT06476769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806278|NCT04586348|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Intervention and Control supplements will be packaged by Factors Group of Companies and labelled by contracted pharmaceutical personnel who are not involved in the trial. Study supplement bottles will be identified only by the blinded Product ID to match the randomisation schedule prepared by an independent statistician.~Research Personnel will access the Randomisation Module in REDCap and women will be allocated a random, unique, re-identifiable randomisation ID. Women will be issued with supplements labelled to match their unique assigned code."|"A multi-centre, randomised, controlled, clinician, researcher and participant blinded trial with two parallel groups. An independent statistician not otherwise involved in the study or data analysis will generate and keep the randomisation schedule. The computer-generated schedule will allocate women to intervention or control groups in the ratio of 1:1 using randomly permuted blocks of size 6 and 8, with stratification for state of enrolment.~Randomisations will be performed by approved study staff via a secure web-based randomisation service."|t|t|t|t
33806279|NCT00412646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33806280|NCT02698475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806281|NCT01324310|NA|SINGLE_GROUP||OTHER||NONE||||||
33806282|NCT05558683|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Our population will be subjects diagnosed with MS. Prior to the study, the informed consent will be presented to the subjects. Said confidentiality will be contemplated in Organic Law 15/99 of December 13 on the Protection of personal data.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.|t|f|t|t
33806283|NCT03317652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806284|NCT03502369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Adult 90 orthopaedic patient ASA physical status \|-\|\|\| will be randomly allocated in two groups each one 45 patients, one group will receive the anterior quadratus lumborum block and the other group will not receive the block."|f|f|f|t
34032514|NCT05780060|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study team will conduct a pragmatic comparative effectiveness study comparing standard stroke clinic follow up combined with RPM to aid with blood pressure management (n=30) versus standard stroke clinic follow, RPM and an added patient-facing smartphone application with educational modules and adherence incentives (n=30). Outcomes will include recruitment, retention and follow up metrics, self-reported adherence to medication regimens and life-style recommendations, patient engagement with RPM data and patient-facing application, cost-effectiveness of the interventions and changes in blood pressure as well as biomarkers such as HbA1c or LDL cholesterol levels. We hypothesize that RPM combined with a patient-facing application will improve patient reported and clinical outcomes of interest in the post-stroke transition of care setting.|t|f|f|f
33806285|NCT01331499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34032515|NCT02524847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806286|NCT03188731|||COHORT||PROSPECTIVE|||||||
34032516|NCT04245800|||COHORT||PROSPECTIVE|||||||
34032517|NCT00560820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032518|NCT01434914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032519|NCT01565889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032520|NCT03809689|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032521|NCT01895777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032522|NCT00634699|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34032523|NCT02525900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032524|NCT02905604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032525|NCT03197623|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study|t|t|t|f
34032526|NCT02107131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032527|NCT05383612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032528|NCT06281015|||OTHER||RETROSPECTIVE|||||||
34032529|NCT00886509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032530|NCT05156671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032531|NCT05976100|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032532|NCT01231776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34032533|NCT05983354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment will be randomly assigned using a random number generator by an independent research assistant who is not involved in data collection. Contents of treatment will be known only to the research pharmacist and this information will be stored remotely from the ED; patients, administering nurses and treating physicians will be blind to the treatment group, as well the research assistants collecting outcome data.||t|t|t|t
34032534|NCT02021162|||CASE_CONTROL||PROSPECTIVE|||||||
34032535|NCT01875328|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032536|NCT01626690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032537|NCT00710268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032538|NCT02345876|||CASE_CONTROL||PROSPECTIVE|||||||
34032539|NCT04659369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032540|NCT02711631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34032541|NCT03417778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032542|NCT05584384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants will be distributed between 2 arms using an aperiodic, nondeterministic, atmospheric random noise randomization algorithm. The stimulation type will be unblinded upon completing all the follow-ups or dropping out. The blinding will be ensured by a dedicated team member with no direct access to the participants or their data.|Prospective, randomized, double-blinded, placebo-controlled, two-arm trial.|t|t|t|t
33806287|NCT00068900|||||PROSPECTIVE|||||||
33806288|NCT01105234|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
33806289|NCT03783416|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||This is a double-blind, randomised, placebo-controlled trial. Randomisation will be stratified by disease stage, i.e. RRMS (and established on DMT) versus progressive MS (and not on DMT). The expected study duration is 36 months (a 12-month recruitment period and a 24-month treatment period). There will be 72 participants: 48 on ixazomib; 24 on placebo.|t|t|t|t
33806290|NCT05223959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806291|NCT03900585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806292|NCT03875066|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33806293|NCT04231279|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806294|NCT04165759|||COHORT||PROSPECTIVE|||||||
33806295|NCT06058858|||COHORT||CROSS_SECTIONAL|||||||
33806296|NCT01780649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806297|NCT05440058|||CASE_CONTROL||PROSPECTIVE|||||||
33806298|NCT01473485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806299|NCT01450163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33806300|NCT05869331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806301|NCT04030585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Treatment group: robot-assisted exercise program Control: Home exercise program|f|f|f|t
33806302|NCT06510881|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33806303|NCT05247437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33806304|NCT05609149|||COHORT||RETROSPECTIVE|||||||
33806305|NCT03828968|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806306|NCT00683800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806307|NCT04929795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806308|NCT02257333|||CASE_ONLY||PROSPECTIVE|||||||
33806309|NCT01249209|NA|SINGLE_GROUP||TREATMENT||||||||
33806310|NCT05610787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Label, Single Arm, Prospective, Non-Randomized||||
33806311|NCT01688765|||CASE_CONTROL||PROSPECTIVE|||||||
33806312|NCT05503368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator doing the procedure is the only one who will know which side is assigned to which procedure, but the rest of the investigators including the ones assessing the outcome will be blinded|self controlled study where 3 comparable lesions will be selected in each patient|f|f|f|t
33806313|NCT04407884|NA|SINGLE_GROUP||TREATMENT||NONE||Single group with longitudinal follow-up||||
33806314|NCT05660434|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|The Enroller is masked to the assignment. No need to mask for aroma inhaler as participants receive materials through the mail and do not interact with other participants. No sham inhaler is used.||f|f|t|t
33806315|NCT03345095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806316|NCT05967858|||COHORT||PROSPECTIVE|||||||
33806317|NCT04379375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806318|NCT04090632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study is a monocentric interventional prospective study||||
33806319|NCT03856619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806320|NCT02555345|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806321|NCT01401790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806322|NCT05035329|||OTHER||CROSS_SECTIONAL|||||||
34032543|NCT05594706|||CASE_CONTROL||PROSPECTIVE|||||||
34032544|NCT02726659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032545|NCT03362814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032546|NCT05327933|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34032547|NCT00717717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34032548|NCT04272788|||COHORT||PROSPECTIVE|||||||
34032549|NCT06351111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized, open-label, adaptive, optional extension study model||||
34032550|NCT05588479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Capsules will be masked by the manufacturer and will only be revealed at the end of the study.|Two-arm double blind parallel trial where participants will be randomly assigned to receive either placebo capsules (control) or pomegranate extract capsules (500mg) for 12 weeks.|t|f|t|f
34032551|NCT00916383|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34032552|NCT02000726|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34107106|NCT04722315|NA|SINGLE_GROUP||TREATMENT||NONE||15 participants with Kabuki syndrome will receive a 12 week dietary intervention.||||
34107107|NCT00935207|||||PROSPECTIVE|||||||
34107108|NCT06031779|||CASE_CONTROL||OTHER|||||||
34107109|NCT02640131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107110|NCT01123187|NA|SINGLE_GROUP||TREATMENT||NONE||Islet transplantation||||
33806323|NCT06098105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806324|NCT04379869|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stage 1: None Stage 2: Double-blind|Stage 1: Open-label, single dose with 2 dose cohorts. Stage 2: Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose (MAD) with 2 dose cohorts|t|t|t|t
33806325|NCT01016457|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838060|NCT05191602|||COHORT||PROSPECTIVE|||||||
33838061|NCT02770729|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34107111|NCT05499403|||COHORT||RETROSPECTIVE|||||||
34107112|NCT05545527|||COHORT||PROSPECTIVE|||||||
34032553|NCT06443229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be evaluated pre- and post-intervention by a blind evaluator, previously trained to obtain information and confirm eligibility criteria, in addition to primary and secondary outcomes. The evaluator will be asked to guess which group the participants were in (intervention or control) at the end of the study to measure the blindness of the evaluator. Regarding the data analyst, he will be blind to carry out this stage of the study.|A randomized controlled double-blind clinical trial, with a 1:1 allocation of 102 participants divided into two groups (intervention or control).|t|t|t|t
34032554|NCT03474874|NA|SINGLE_GROUP||OTHER||NONE||||||
34032555|NCT03757858|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032556|NCT01962818|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107113|NCT04464733|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34107114|NCT02419066|||COHORT||OTHER|||||||
34107115|NCT06674642|NA|SINGLE_GROUP||OTHER||NONE||The study will employ a single-subject experiment (personalized trial) approach with an ABAB design. The participants will act as their own controls. During Phase A participants will consume their usual (control) diet. During Phase B they will consume a Traditional Indigenous Foods diet provided by the GFHNRC. Randomization in single-subject designs takes the form of random assignment of treatment start times and phase lengths for each participant. Statistical analysis will consist of a mixed model that will be fit with a fixed effect of phase (A1, B1, A2, B2) and random intercept for subject for the for each item being examined.||||
33806326|NCT06192043|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control trial would be used in this study. It would be two two-arm study and two groups: The experimental and the control group. The experimental group will receive an intervention waitlist. In this research, a parallel group design will be used. We will give treatment to all participants in a parallel way. The allocation ratio and framework would be equivalence i.e., the treatment group and control group would be an equal number of participants.||||
33806327|NCT06698770|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33806328|NCT03708250|||CASE_ONLY||PROSPECTIVE|||||||
33806329|NCT02765711|||COHORT||PROSPECTIVE|||||||
33806330|NCT03607175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes assessor will be blinded to the side that the steroid eluting implant and the triamcinolone-impregnated foam in on.|Study is an intrapatient control design, each subject will receive both interventions, one in each nostril|t|f|f|t
33806331|NCT06486012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be collected using individual study codes for participants. Study codes do not reveal which group the participant has belonged to.|Randomized clinical study on a medical device.|f|f|f|t
33806332|NCT04015505|NA|SINGLE_GROUP||TREATMENT||NONE||"Single case experimental design, with non-concurrent across-participants multiple baselines. All participants will receive the intervention, with a period of measured baseline stability acting as the control for each participant. Participants will not need to take part in the study simultaneously.~Participants will be randomly allocated to one of three baseline conditions:~Group A = 2 weeks baseline Group B = 3 weeks baseline Group C = 4 weeks baseline~Following their baseline, each participant will complete a 5 week intervention period where they receive 5 sessions of the therapy. Throughout their baseline and intervention period, each participant will complete weekly measures of mood and a daily visual analogue scale. Each participant will also complete measures of self-compassion and wisdom at the start of baseline, end of baseline and end of intervention. Each participant will complete all measures again at one time point 1 month following the end of their intervention."||||
33806333|NCT02262299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806334|NCT05338567|||COHORT||RETROSPECTIVE|||||||
33806335|NCT06029244|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be unblinded, or unmasked, to treatment allocation given the nature of the intervention.|Study participants will be randomized to either a) EyeControl-Pro assisted active intervention arm or b) sham control||||
33806336|NCT04755179|||COHORT||PROSPECTIVE|||||||
33806337|NCT03933540|||COHORT||PROSPECTIVE|||||||
33806338|NCT06039059|||COHORT||RETROSPECTIVE|||||||
33806339|NCT00756574|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806340|NCT05838781|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||Siteless, randomized, 2x2 factorial design, superiority trial||||
33806341|NCT01568359|||CASE_CONTROL||PROSPECTIVE|||||||
33806342|NCT03884413|||COHORT||RETROSPECTIVE|||||||
33806343|NCT04447287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806344|NCT01588951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806345|NCT05935046|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33806346|NCT03205566|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33806347|NCT04714346|||OTHER||PROSPECTIVE|||||||
33806348|NCT02268708|||COHORT||PROSPECTIVE|||||||
33806349|NCT05085704|||COHORT||PROSPECTIVE|||||||
33806350|NCT04051333|||CASE_ONLY||PROSPECTIVE|||||||
33806351|NCT06699251|RANDOMIZED|PARALLEL||PREVENTION||NONE||Enhanced Usual Care vs Chat Intervention||||
33806352|NCT04690738|||COHORT||PROSPECTIVE|||||||
33806353|NCT00312806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806354|NCT02597920|||COHORT||PROSPECTIVE|||||||
33806355|NCT04629313|||CASE_CONTROL||PROSPECTIVE|||||||
33806356|NCT05515146|||COHORT||PROSPECTIVE|||||||
33806357|NCT00223600|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806358|NCT04142255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032557|NCT03073824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032558|NCT05747651|||COHORT||PROSPECTIVE|||||||
34107116|NCT01940744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107117|NCT06638567|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, matched, cluster-randomised||||
34107118|NCT00837122|||CASE_CONTROL||PROSPECTIVE|||||||
34107119|NCT05335434|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34107120|NCT04029662|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34107121|NCT04537156|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107122|NCT05102448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107123|NCT04494698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be instructed that non-drug interventions are being evaluated for their impact on opioid use and pain with low back pain, and that they will be self-assessing pain and reporting use of prescribed and over-the-counter medications. Study staff will train them on the device or TENS units via a pre-made video, but investigators and outcomes assessors will not be informed of the study arm. An assessment for blinding will be administered at the end of the data collection for participants.||t|f|t|t
34107124|NCT04660682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All of the participants must have subacromial impingement syndrome with glenohumeral internal rotation deficit (Bilateral IRROM difference ≥ 15º )|There are 3 groups. The first group will receive the modified static cross-body posterior shoulder stretching and the standard physiotherapy program. The second group will receive traditional static cross-body posterior shoulder stretching and the standard physiotherapy program. The Control group will receive sham stretching and the standard physiotherapy program. In standard physiotherapy program, there are TENS, hot-pack, posture, proprioceptive, and strengthening training. The treatment program will last for eight weeks. Patients will receive the treatment program 5 days a week under the physiotherapist's supervision and 2 days a week as a home program.|t|f|f|f
34107125|NCT03546257|||OTHER||PROSPECTIVE|||||||
34107126|NCT03615768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107127|NCT06690255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107128|NCT01690325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107129|NCT01652404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107130|NCT03308331|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34107131|NCT02163356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107132|NCT05305703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|t|f|f|f
34107133|NCT06434636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients will be divided into two groups: Intervention (M) and Control (C). Just before the operation begins, 10 mg/kg tranexamic acid (TXA) will be administered to the intervention group in 100 mL of 0.9% physiological saline (SF) solution in 15 minutes. 100 mL of 0.9% SF solution will be sent to the control group in 15 minutes.|f|f|t|f
34107134|NCT06495099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107135|NCT01717274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34107136|NCT02317445|||CASE_CONTROL||RETROSPECTIVE|||||||
34107137|NCT06675344|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a randomized, double-blind, sham device-controlled trial.|t|t|t|t
34107138|NCT04535115|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34107139|NCT06640452|NA|SINGLE_GROUP||OTHER||NONE||||||
34107140|NCT05657145|||CASE_ONLY||PROSPECTIVE|||||||
34107141|NCT02816112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107142|NCT03403738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (outcomes assessor)|Parallel Assignment|f|f|f|t
34107143|NCT06355050|||COHORT||PROSPECTIVE|||||||
34107144|NCT04486131|||OTHER||PROSPECTIVE|||||||
34107145|NCT05406453|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||cRCT||||
34107146|NCT04163081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34107147|NCT02356185|||CASE_ONLY||CROSS_SECTIONAL|||||||
33806359|NCT05786872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806360|NCT03110536|||COHORT||PROSPECTIVE|||||||
34107148|NCT02873052|||CASE_ONLY||PROSPECTIVE|||||||
34107149|NCT01234376|||OTHER||PROSPECTIVE|||||||
34107150|NCT05152485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107151|NCT05884528|||CASE_CONTROL||RETROSPECTIVE|||||||
34107152|NCT04115254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants will be assigned to one treatment arm only depending on their cancer type, and will be taken off study once treatment and follow up are complete.||||
34107153|NCT06332339|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107154|NCT06673745|RANDOMIZED|PARALLEL||OTHER||SINGLE|This will be a randomized upping c clinical trial on 28 participant on 6 to 15 years group A will get instrument assisted soft tissue mobilisation and group B will get dynamic|This will be a randomized clinical trail conducted on 28 participants of age 6 to 15 years .group A will get instrument assisted soft issue mobilisation and group B will get dynamic cupping therapy|t|f|f|f
34107155|NCT00273663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34107156|NCT06333652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107157|NCT04269863|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||150 patients randomized into two groups of 75 patients each, one control group receiving 81mg ASA and treatment group receiving a personalized dose of unto 325mg (within the recommended dosage limits)||||
34107158|NCT05278715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107159|NCT04627974|||COHORT||PROSPECTIVE|||||||
34107160|NCT01435642|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34107161|NCT06326541|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single group pretest-posttest||||
34107162|NCT02172261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107163|NCT06644196|||CASE_ONLY||PROSPECTIVE|||||||
34107164|NCT01443026|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34107165|NCT05887466|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 rule-based method||||
34107166|NCT04744792|||COHORT||PROSPECTIVE|||||||
34107167|NCT06638177|||COHORT||PROSPECTIVE|||||||
34107168|NCT06639022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107169|NCT01045733|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34107170|NCT01720836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107171|NCT06639113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107172|NCT05336565|||COHORT||OTHER|||||||
33806361|NCT02861456|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33806362|NCT05335044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107173|NCT04421664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107174|NCT03952351|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34107175|NCT06149442|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34107176|NCT05349812|||COHORT||PROSPECTIVE|||||||
34107177|NCT06639737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|statistician||t|t|f|t
34032559|NCT05585203|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A quasi-experimental design will be used. Half of the recovery houses residents will be randomly assigned to receive training in and to conduct contingency management. The other half will receive no additional training or interventions (usual care).||||
34032560|NCT04818983|||COHORT||PROSPECTIVE|||||||
34032561|NCT02286843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032562|NCT02275169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032563|NCT02921113|||COHORT||PROSPECTIVE|||||||
34032564|NCT00989482|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34032565|NCT01226927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032566|NCT01892956|||CASE_ONLY||PROSPECTIVE|||||||
34032567|NCT04436601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|It would be a double blinded study. Investigator assessing the participants and following the patient will be masked to the allocation of treatment group. Participants would be masked to their treatment group as well.||t|t|t|t
34032568|NCT00290550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032569|NCT01112059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032570|NCT00894712|||COHORT||PROSPECTIVE|||||||
34032571|NCT02271932|||CASE_CONTROL||PROSPECTIVE|||||||
34032572|NCT00006464||||TREATMENT||||||||
34032573|NCT01176513|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032574|NCT04829669|||COHORT||PROSPECTIVE|||||||
34032575|NCT01277783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032576|NCT04292444|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The study is designed as a double-blind, within-subject, placebo-controlled, non-clinical trial and will involve healthy male participants (n = 60), who will be scanned twice in a randomized order after a single dose of intranasal OXT (24 IU) or placebo. Furthermore participants will be pre-stratified based on a RAGE polymorphism (-374 T/A: rs1800624; n = 30 with TT alleles and n = 30 with TA/AA alleles).|t|f|t|f
34032577|NCT05846035|||COHORT||CROSS_SECTIONAL|||||||
34032578|NCT04108299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|t|f
34107178|NCT03286569|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33806363|NCT05746234|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The investigators will use a pre-post design with a multi-case study approach to evaluate the feasibility and implementation of the ER intervention in four university settings.~A mixed-methods design will be used to determine the feasibility and acceptability of the ER4ALL course."||||
33806364|NCT02022670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806365|NCT04617574|||CASE_ONLY||PROSPECTIVE|||||||
34032579|NCT04124445|RANDOMIZED|PARALLEL||TREATMENT||NONE||After performing patient's eligibility for neck RF and receiving information about procedure, patients will be book for two MBB 4-6 weeks apart. If the patient was eligible after the second MBB, Patient will be asked to sign Informed consent before screening. Screening and recruitment, and randomization, patients will be scheduled for one of the RF techniques.||||
34107179|NCT06016725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107180|NCT01472185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107181|NCT02512939|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107182|NCT01837550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34107183|NCT06645028|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Open clinical trail where participants are allocated via shared desicion making|f|f|t|t
34107184|NCT04415151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107185|NCT03788044|RANDOMIZED|PARALLEL||TREATMENT||NONE||AF patients will be divided in four groups (AF-EduCare study and AF-EduApp substudy): one group will have application-based education (AF-EduApp substudy), the second group will have in-person education (AF-EduCare study), the third group will have online education (AF-EduCare study) and the fourth group will receive standard AF care (AF-EduCare study and not eligible for AF-EduApp substudy). NOAC adherence will be compared between these groups.||||
34107186|NCT00941395|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107187|NCT03314896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107188|NCT06031402|RANDOMIZED|PARALLEL||TREATMENT||NONE||Before enrollment, all patients and/or their relatives will be informed about the study protocol, and sign the written informed consent forms. Eligible patients are randomly assigned at a ratio of 1:1 to early endoscopy group (within 12 hours after admission) and delayed endoscopy group (within 12-24 hours after admission)||||
34107189|NCT06571396|||COHORT||RETROSPECTIVE|||||||
34107190|NCT06640465|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34107191|NCT02776735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107192|NCT03757117|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Twelve-month, non-randomized, single-arm, pilot cohort study to assess the feasibility, acceptability, and potential effectiveness of integrating routine HIV prevention and treatment services with gender-affirming care supported by transgender woman community peer health navigators.||||
34107193|NCT03443401|||COHORT||RETROSPECTIVE|||||||
34107194|NCT04369612|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two Groups, randomized 1:1, to a) Standard of care and b) home-based monitoring. Followed between 1-2 to 7-8 weeks after transplantation||||
34107195|NCT05681949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The ADBoard study is a monocentric, prospective, parallel randomized controlled trial with a non-inferiority framework. Participants will be randomized 1:1 into one of two groups: either a) tumor conference with ADBoard, or b) tumor conference without ADBoard.|t|f|f|f
34107196|NCT06674707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107197|NCT02607722|||COHORT||PROSPECTIVE|||||||
34107198|NCT06053580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107199|NCT06597513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107200|NCT06443242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107201|NCT06637033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107202|NCT01831882|||CASE_CONTROL||PROSPECTIVE|||||||
34107203|NCT04433572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The active and placebo material provided to the operator in a blinded syringe or vial will be identical in size, color and appearance. Investigators and participants will be blinded to assignment. Any stents will be placed only after randomization, assignment, and adventitial drug therapy, although any stenting decisions (other than for treatment of AEs) must be made prior to randomization and adventitial drug delivery in order to avoid bias toward or against stenting.~Participants will not be told of their treatment assignment until after they complete the trial."|Block randomization will be stratified for Rutherford 3 and for Rutherford 4/5 participants such that each strata will be randomized 2:1. Block randomization will also be stratified by site such that each site will be assigned a 2:1 randomization.|t|t|t|t
33806366|NCT04282382|||COHORT||RETROSPECTIVE|||||||
33806367|NCT02072499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806368|NCT02695134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33806369|NCT03293875|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Quasi experimental design repeated time series analysis||||
33806370|NCT03510169|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34032580|NCT04109144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||single arm, single center, investigator initiated, prospective pilot clinical trial study.||||
34032581|NCT05124470|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107204|NCT04250844|||COHORT||PROSPECTIVE|||||||
33806371|NCT02095366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032582|NCT04179318|||COHORT||RETROSPECTIVE|||||||
34032583|NCT01424007|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032584|NCT04016454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"In order to investigate the impact of handover of anesthesia care on adverse postoperative outcomes, patients will be assigned to the two randomization groups:~1. Intervention group: handover of anesthesia~2. Control group: no handover of anesthesia"|t|f|t|t
34032585|NCT02449850|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|At all investigations, skin scoring is performed prior to any information from the study participants parents of intervention group. Also, no baths are allowed within 24 hours of investigation, to fascilitate blinding of the investigator to interventional allocation.|International, multi-center, prospective 2x2 factorially designed randomized controlled trial of primary prevention in children of enrolled mother-child pairs, with an additional exploratory aim|f|f|t|f
34032586|NCT05881434|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107205|NCT01481103|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107206|NCT06424119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||ICR-eligible patients are randomized into one of three groups of 150 patients: (1) ICR 72 session program with C2life® supplied food, (2) ICR 72 session without C2life® supplied food, or (3) TCR 36 session program without C2life supplied food (ICR-food, ICR-no food, and TCR-no food).|f|f|f|t
34107207|NCT06564168|||COHORT||PROSPECTIVE|||||||
34032587|NCT03321149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806372|NCT02189759|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806373|NCT05430087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All patients and physicians were blinded to group assignment and treatment allocation|Patients who fulfilled the inclusion and exclusion criteria were randomized into three parallel groups: Vitamin D + placebo (group I), Curcumin-Piperine + placebo (group II), and vitamin D + Curcumin-Piperine (group III). All patients and physicians were blinded to group assignment and treatment allocation|t|f|t|f
33806374|NCT06697431|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients who fulfill the eligibility criteria and whose parent/carer (legal representative) have provided informed consent will be randomized 1:1 to receive standard of care IVIG and aspirin or anakinra and ASA.~As epidemiological data suggest worse outcomes in terms of CAA for very young patients (age \<1 years), in this setting, proper randomisation 1:1 procedure will be matched for age \< or\> than 1 year"||||
33806375|NCT05532072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33806376|NCT02730624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806377|NCT06100159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|questionnaires and sleep outcome measures will be assessed by masked person|RCT with an intervention and a control group|f|f|f|t
34107208|NCT03656614|||COHORT||PROSPECTIVE|||||||
34107209|NCT06673901|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032588|NCT04264325|||CASE_ONLY||PROSPECTIVE|||||||
33806378|NCT01662505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107210|NCT04976855|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33806379|NCT01331642|||COHORT||PROSPECTIVE|||||||
33806380|NCT04434651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study will be performed in the Neurosurgical operating room and included 52 patients allocated into two groups: the treatment group (block group) and the control group (non-block group). 26 patients enrolled in block group and 26 patients in non-block group.~Intraoperative ICP monitoring by subdural ICP monitors will be done every 20 minutes in both block and non- block group.~Jugular venous bulb oxygen saturation changes will be recorded every 20 minutes in block and non- block."|f|t|f|t
34032589|NCT02627690|||CASE_CONTROL||RETROSPECTIVE|||||||
34032590|NCT05820464|||COHORT||PROSPECTIVE|||||||
34032591|NCT06364059|||CASE_ONLY||RETROSPECTIVE|||||||
34032592|NCT03719625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||controlled, prospective, randomised trial comparing 2 interventions|t|f|f|f
34032593|NCT01662778|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34032594|NCT00082277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032595|NCT06054321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|partial masking(participants, care providers, outcome assessor are not aware of treatment response scores in spite of opened status for prescribed information (mono vs step)||t|t|f|t
34107211|NCT05644132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107212|NCT06633549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107213|NCT04923997|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34107214|NCT04918771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107215|NCT05178654|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107216|NCT04874597|||COHORT||PROSPECTIVE|||||||
34107217|NCT02220400|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34032596|NCT06581445|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Participants were told that this experiment was to examine the different effects between video stimuli and audio stimuli.||t|f|f|f
34032597|NCT02862015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032598|NCT03054701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The outcome assessor will be blinded to the order of the exercises and the participants will be blinded to the study-hypothesis.|After providing informed consent the participants will determine which is their most painful knee. This limb will be marked and it will serve as the test limb throughout the study protocol. At the first step of the protocol the participants will be baseline tested with handheld and cuff pressure algometer. Secondly, participants will be randomized to either a hip or a knee exercise. Thirdly, participants will undergo the testing-procedure for the second time. Fourthly, participants will perform exercise focusing on the other joint (hip or knee). Finally, participants will undergo the testing-procedure for the last time. In order to avoid any carryover effect from the testing procedure, there will be at least 15-minutes between each of the three test sessions.|t|f|f|t
34032599|NCT01751256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032600|NCT03551821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032601|NCT02229435|||COHORT|||||||||
34032602|NCT03073876|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Study drug was prepared by research pharmacist who was the only person privy to group assignment. Drug and Placebo pills looked identical.|Double Blind Placebo Control|t|t|t|f
34032603|NCT00207519|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032604|NCT04413019|||COHORT||PROSPECTIVE|||||||
34032605|NCT04317092|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multicenter, single-arm, open-label, phase 2 study. All the patients enrolled are treated with tocilizumab||||
34032606|NCT02189837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032607|NCT04898452|||OTHER||CROSS_SECTIONAL|||||||
34032608|NCT05235373|||COHORT||RETROSPECTIVE|||||||
34032609|NCT04145765|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34032610|NCT06516211|||OTHER||PROSPECTIVE|||||||
34032611|NCT02244281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032612|NCT04612907|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to one of two treatment fractionations of radiotherapy||||
34032613|NCT01625650|||COHORT||PROSPECTIVE|||||||
34032614|NCT04089449|NA|SEQUENTIAL||TREATMENT||NONE||||||
34032615|NCT03899909|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34032616|NCT03100383|||CASE_ONLY||CROSS_SECTIONAL|||||||
34032617|NCT06217913|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34032618|NCT02665221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032619|NCT00128440|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34032620|NCT03158922|||CASE_CONTROL||PROSPECTIVE|||||||
34032621|NCT05370105|||CASE_CONTROL||PROSPECTIVE|||||||
34032622|NCT01974973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032623|NCT00398424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032624|NCT05311189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032625|NCT02562066|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34032626|NCT01604616|||CASE_CONTROL||RETROSPECTIVE|||||||
34032627|NCT01101412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34032628|NCT02203357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032629|NCT03442439|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34032630|NCT05731518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032631|NCT00087815|RANDOMIZED|||SUPPORTIVE_CARE||SINGLE||||||
34032632|NCT03435887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032633|NCT02478229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032634|NCT01609790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032635|NCT00237523|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34032636|NCT06097130|||OTHER||OTHER|||||||
34032637|NCT00379314|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032638|NCT04247373|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032639|NCT02248311|||CASE_CONTROL||PROSPECTIVE|||||||
34032640|NCT01739712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34032641|NCT00815464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032642|NCT05262387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032643|NCT06366763|NA|SINGLE_GROUP||TREATMENT||NONE||Among the 210 patients included in the study (82 males, 128 females; average age of 59 years), 7 patients were lost to follow-up, and the remaining patients completed the treatment and follow-up.To assess the clinical efficacy of different compression methods within 48 hours after endovenous radiofrequency ablation (RFA) in terms of great saphenous vein closure rate, postoperative complications, quality of life, time to return to normal work, and patient satisfaction.||||
34032644|NCT04808674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032645|NCT06477094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single Blinded Randomized Control Trial|t|f|f|f
34032646|NCT05004883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032647|NCT06499337|||COHORT||PROSPECTIVE|||||||
34032648|NCT00371436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032649|NCT01761383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032650|NCT01482312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032651|NCT02485093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032652|NCT00462904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032653|NCT01108614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032654|NCT00268073|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34032655|NCT04524208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032656|NCT02766114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032657|NCT02577991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107218|NCT06644690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes assessor is blinded to the group assignments to ensure objective evaluation of the study outcomes. Participants, care providers, and investigators are not blinded.|In this parallel-group randomized controlled trial, participants will be assigned to one of two groups. The first group will receive the CO-OP approach combined with creative dance, while the second group will receive only the CO-OP intervention. Both groups will participate in 8-week intervention programs, with sessions held three times a week. The outcomes of interest, such as improvements in executive functions, attention, memory, and dual-task performance, will be compared between the two groups at baseline, post-intervention, and follow-up assessments at 3 and 6 months.|f|f|f|t
34107219|NCT06644976|||CASE_CONTROL||PROSPECTIVE|||||||
34107220|NCT04119037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34107221|NCT05274919|||COHORT||PROSPECTIVE|||||||
34107222|NCT03002857|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34107223|NCT05654181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34107224|NCT02115971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107225|NCT06637852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107226|NCT06641999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107227|NCT05787782|NA|SEQUENTIAL||OTHER||NONE||||||
34107228|NCT04637347|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34107229|NCT04586660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107230|NCT06549647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107231|NCT01974947|||COHORT||PROSPECTIVE|||||||
34107232|NCT03705026|||COHORT||PROSPECTIVE|||||||
34107233|NCT03283956|||CASE_CONTROL||RETROSPECTIVE|||||||
34107234|NCT05894746|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Four week crossover trial with three arms, gluten-free, gluten and gluten with probiotic||||
34107235|NCT06195956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107236|NCT01813357|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107237|NCT01648322|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107238|NCT06638333|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34107239|NCT00157261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34107240|NCT01085955|||CASE_CONTROL||PROSPECTIVE|||||||
34107241|NCT04878471|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34107242|NCT05055427|RANDOMIZED|PARALLEL||TREATMENT||NONE|An open-label study was conducted because of the urgency of major public health events|"This is a prospective, open-label, randomized controlled trial, we recruited patients with Covid-19 from five temporary for COVID-19 treatment in Ho Chi Minh City, Viet Nam.~The protocol was designed based on the Good Clinical Practice guidelines and The Declaration of Helsinki. Number of Participants have 150 mild COVID-19 patient and 150 moderate COVID-19 patient. In each group of mild or moderate patients, we plan to randomize in a 1:1 ratio. Subjects in the investigational group will receive Shen Cao Gan Jiang Tang in addition to the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline. Subjects in the controlled group will receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline."||||
34107243|NCT04318301|||CASE_CONTROL||RETROSPECTIVE|||||||
34107244|NCT00658073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107245|NCT05711797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||80mg ZX-7101A||||
34032658|NCT04540653|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The intervention group (Reinforced Intervention Scheme - EIR) indicates 3 doses of 40 μg (2 mL) of hepatitis B vaccine, in months 0, 1 and 6, while the comparison group (Conventional Comparison Scheme - ECC) completes 3 doses of 20 μg (1 mL) of the vaccine, in months 0, 1 and 6. To evaluate the kinetics of the hepatitis B vaccine, after each dose administered, about 30 to 60 days, 5 mL of blood was again collected from the participants for quantitative detection of anti-HBs, using the Microparticle Chemiluminescent Immunoassay (CMIA) method, according to the manufacturer's instructions.|t|f|f|f
34032659|NCT02421055|||COHORT||PROSPECTIVE|||||||
34032660|NCT04470063|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34032661|NCT00707616|||COHORT||CROSS_SECTIONAL|||||||
34032662|NCT00248261|||CASE_ONLY||PROSPECTIVE|||||||
34032663|NCT02766270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032664|NCT06052046|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective, one-month, three-visit study will refit all participants into TOTAL30 for Astigmatism Contact Lenses.||||
34032665|NCT02906670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107246|NCT04977986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo formulated as a clear gel (transdermal delivery)|Randomized, Double-Blind, Placebo-controlled, multiple center study|t|t|t|t
34107247|NCT06644547|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Pragmatic stepped-wedge design||||
34107248|NCT06190379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34107249|NCT04169243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome is percentage of time in target of blood glucose values, measured with continuous glucose monitoring. The device will be masked for participants. Still, because the trial is a diet intervention, participants will know their group status. However, initial data reaching the Investigators will not have the code broken.|Parallel Assignment|f|f|t|t
34107250|NCT06510231|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34107251|NCT05626335|||CASE_ONLY||PROSPECTIVE|||||||
34107252|NCT00619918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107253|NCT06643078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind（Outcomes Assessor）||f|f|f|t
34107254|NCT06637696|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE||The study included a total of 320 (160 neonates in pre-bundle period, 160 neonates in post-bundle period) neonates.|t|f|f|f
34107255|NCT04573504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107256|NCT06319053|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Consecutive patients from who informed consent can be acquired. The number of twelve participants was determined in conjunction with the Ethical Board of Erasmus MC||||
34107257|NCT05722769|RANDOMIZED|PARALLEL||SCREENING||NONE|County-level|Randomization at Kentucky County level. Schools in counties randomized to the intervention receive the online intervention training. Schools in counties randomized to the attention control receive the attention control training.||||
34107258|NCT06313866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34107259|NCT01256047|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107260|NCT03277872|RANDOMIZED|PARALLEL||OTHER||NONE||"In this study, each patient will be exposed to three laryngoscopies; one with the single use blade for the GlideScope and without ETT; one with the Macintosh laryngoscopy and without ETT; and one with the ETT insertion (laryngoscopy done with either GlideScope or Macintosh according to second randomization). The order in which will be used either the GlideScope or the MAC blade for the first two laryngoscopies will be decided according to the first randomization.~This will lead to 2 different groups for the first randomization process regarding our primary objective:~* GVL / MAC-DL / GVL or MAC-DL+ETT,~* MAC-DL / GVL / GVL or MAC-DL+ETT.~The tool used for the third laryngoscopy will be decided according to a second randomization, necessary to one of our secondary objectives.~Each patient will be its own control when comparing nociceptive response to different laryngoscopy/intubation tool (no need for control group)."||||
34107261|NCT06639516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107262|NCT01933555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107263|NCT05918770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34107264|NCT02361697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107265|NCT02523027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34107266|NCT01308788|||COHORT||PROSPECTIVE|||||||
34107267|NCT05796193|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34107268|NCT05812170|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|The design of this study does not allow to mask participants, care providers, investigators or outcomes assessors.|A quasiexperimental controlled trial is designed, with two arms: an experimental group and a control group.||||
34107269|NCT01337479|||CASE_ONLY||PROSPECTIVE|||||||
34107270|NCT02487329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107271|NCT06454916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107272|NCT03362632|||CASE_ONLY||PROSPECTIVE|||||||
34107273|NCT02093273|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33806381|NCT04310449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||• To compare the volumetric changes in the buccal soft tissue contour between immediate implants with CTG and customized healing abutments, and immediate implants with bone grafting in the dual zone and customized healing abutmnets|f|f|f|t
34032666|NCT06301074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||For each cohort, participants will be assigned to receive HS-10509 or placebo in parallel|t|t|t|t
34032667|NCT02037425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032668|NCT02321059|||CASE_CONTROL||PROSPECTIVE|||||||
34032669|NCT02054052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032670|NCT00332670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032671|NCT04125485|||OTHER||CROSS_SECTIONAL|||||||
34032672|NCT05843669|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 4 real-world study||||
34032673|NCT00537849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032674|NCT01446172|||COHORT||PROSPECTIVE|||||||
34032675|NCT04204239|||CASE_ONLY||PROSPECTIVE|||||||
34032676|NCT01221701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032677|NCT05115175|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adolescents (N=25) aged 14 to 18 diagnosed with type 1 diabetes completed a baseline assessment. Participants were randomized to receive a 10-week self-guided mindfulness-based stress reduction program immediately (n=10) or after a 10-week wait (n=15). During the intervention period, participants completed weekly assignments and qualitative and quantitative feedback surveys. At 10-weeks and 20-weeks follow-up assessments were completed.||||
34032678|NCT01139229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032679|NCT04680572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032680|NCT06568224|||CASE_ONLY||RETROSPECTIVE|||||||
34032681|NCT04074850|||COHORT||PROSPECTIVE|||||||
34107274|NCT06637839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34107275|NCT06076135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107276|NCT03602495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032682|NCT02636478|||||PROSPECTIVE|||||||
34032683|NCT02649712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032684|NCT01027325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34032685|NCT02294214|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34032686|NCT02141607|||COHORT||PROSPECTIVE|||||||
34032687|NCT02812563|||FAMILY_BASED||PROSPECTIVE|||||||
34032688|NCT05373108|NA|SINGLE_GROUP||OTHER||NONE||||||
34032689|NCT06392854|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||obese vs lean||||
34107277|NCT01469156|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34107278|NCT01515215|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34107279|NCT04905641|||CASE_ONLY||RETROSPECTIVE|||||||
34107280|NCT06399484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34107281|NCT03469609|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open-label, randomized, parallel group, controlled trial||||
34107282|NCT04832152|NA|SINGLE_GROUP||OTHER||NONE|none. This is a feasiblity trial|"The purpose of this project is to adapt an existing, evidence-based occupational therapy intervention for children with ASD to a telehealth delivery model. The main objectives of the project are to 1) adapt the manual so that it operationalizes best-practices of occupational therapy telehealth50,51, 2) test its feasibility, and 3) evaluate preliminary outcomes.~Design: In the formative research aspect of this project will use survey methodology and a modified Delphi process to adapt our current intervention to a telehealth delivery model (Aim 1).~In Aim 2 we will conduct a feasibility trial (Figure 2) to assess therapists' fidelity, participant recruitment and retention, acceptability of the protocol by parents and therapists, and clinically meaningful differences."||||
34107283|NCT02868931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107284|NCT03684785|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107285|NCT05188885|||COHORT||PROSPECTIVE|||||||
34107286|NCT02594072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107287|NCT02323620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107288|NCT04808011|NA|SINGLE_GROUP||TREATMENT||NONE||"The subjects will undergo a single peritoneal dialysis exchange procedure at the PD clinic, under the supervision of the medical staff and instructed about its operation. Further exchanges will be performed by the subjects themselves at home.~The study includes two cohorts and two phases: in the first phase (phase I), 20 subjects will be recruited as Cohort 1 to undergo a single exchange in the medical center using the IDA. Following the completion of recruitment of all 20 subjects and the performance of the single on site exchange, the Sponsor will perform an interim analysis of the results for safety and initial feasibility, followed by submission of the results to the MoH and approval of the second phase (phase II).~Subjects will be treated with their routine dialysis device for 14 days, followed by a treatment with the IDA for a period of 30 days, and then an additional period of 14 days of treatment with their routine dialysis device."||||
34107289|NCT02884934|||COHORT||PROSPECTIVE|||||||
34107290|NCT00099814|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34107291|NCT03615131|||COHORT||PROSPECTIVE|||||||
34107292|NCT03035214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107293|NCT06636903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A biostatistician who is not involved in the study will be randomly assigned to groups A and B created by a biostatistician in a computer environment. As a result of the drawing of lots, whether groups A and B will be the study or control group will be determined by tossing a coin at the beginning of the study. Information indicating that the patients included in the study sample were assigned to groups A and B according to the randomization table will be placed in an opaque envelope. This envelope will be kept by the coordinator researcher (GAU) and when the researcher (EB) goes to the patient for the application, he will open the envelope after filling out the \&amp;amp;#34;Informed Consent Form\&amp;amp;#34; and learn which group the patient is in.|Randomized parallel controlled experimental study design|t|f|f|f
34107294|NCT05356130|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34107295|NCT05735119|||CASE_ONLY||PROSPECTIVE|||||||
34107296|NCT02951819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806382|NCT02182479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33806383|NCT06375278|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||For the safety study (aim 1), a single group (n=6) will receive the cooling treatment. For the efficacy study (aim 2) patients will be randomized to either a treatment or control arm in a 1:1 ratio (n=24 per group) in a parallel model.|t|f|f|t
33806384|NCT06400537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806385|NCT06161259|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33806386|NCT05904899|||COHORT||PROSPECTIVE|||||||
33806387|NCT05490732|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33806388|NCT03433794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention is an online program, not an individual, so masking is not necessary. Similarly, the same online survey is deployed in all follow-up assessments regardless of condition, and data are not collected by individuals, so making is not necessary.||t|f|f|f
34032690|NCT03330873|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34032691|NCT00632346|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34032692|NCT00003744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032693|NCT02198937|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032694|NCT04564092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032695|NCT05823688|||COHORT||PROSPECTIVE|||||||
34032696|NCT03435926|||COHORT||PROSPECTIVE|||||||
34032697|NCT06302569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032698|NCT03099109|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34032699|NCT06343753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34032700|NCT00917774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032701|NCT03282955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032702|NCT01289483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34032703|NCT03618017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants will be randomized to the intervention (website) or control (informational template) after completing an online questionnaire; they will not be informed of which arm of the study they are participating. The allocation of participants will be masked for the investigator and outcomes assessor.|A randomized control pilot trial of a web-based, personalized navigation tool to support the continuing and team-based care of early-stage breast cancer patients who have completed their primary cancer treatment. Patients will be randomized to either the intervention (n=30), a personalized website that guides team-based, survivorship care or to the control (n=30), an static online survivorship care plan.|t|f|t|t
34032704|NCT05883124|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34032705|NCT06387420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032706|NCT03722589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107297|NCT03617939|||CASE_CONTROL||PROSPECTIVE|||||||
34107298|NCT04471727|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107299|NCT06199882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107300|NCT01581671|||COHORT||PROSPECTIVE|||||||
34032707|NCT04048291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34032708|NCT02719184|||COHORT||PROSPECTIVE|||||||
34032709|NCT01811472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032710|NCT03308214|||CASE_ONLY||PROSPECTIVE|||||||
34107301|NCT01491919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032711|NCT01897428|RANDOMIZED|CROSSOVER||||NONE||||||
34032712|NCT00173498|||DEFINED_POPULATION||OTHER|||||||
34032713|NCT05707988|||COHORT||PROSPECTIVE|||||||
34032714|NCT06263192|||COHORT||PROSPECTIVE|||||||
34032715|NCT02404480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, first-in-human, safety and pharmacokinetic (PK)||||
34032716|NCT03078686|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34032717|NCT04028557|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34032718|NCT05488093|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032719|NCT01595685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724520|NCT06020560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724521|NCT01263756|||CASE_ONLY||CROSS_SECTIONAL|||||||
33724522|NCT01296256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032720|NCT05256186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was blinded to the investigators who performed both recruitment and assessments. In this way, detection bias could be controlled. It was not possible to perform a double-blind study, since it was a physical intervention and the player knew that he/she was undergoing an intervention program.|Randomized controlled trial|f|f|t|f
34032721|NCT03930537|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34032722|NCT03240029|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34032723|NCT02018991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34032724|NCT00101634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032725|NCT01168427|||CASE_ONLY||PROSPECTIVE|||||||
34032726|NCT04123405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032727|NCT05531864|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34032728|NCT01876225|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34032729|NCT05898971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind|Randomized Control trial|f|f|f|t
34032730|NCT04841837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032731|NCT05317819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a randomized, double-blind trial.|To evaluate efficacy and safety of ADI-PEG 20 or Placebo in patients with high-arginine-phenotypic and HCC|t|t|t|f
34032732|NCT06582316|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34032733|NCT05187104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032734|NCT04172935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032735|NCT02245607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032736|NCT05207891|RANDOMIZED|CROSSOVER||PREVENTION||NONE|No masking. This will be an open label study, because it will be impossible to mask the mattresses due to different lay-out and function.|Inclusion, collection of baseline data at day zero, then seven days use of the first mattress and data collection on day seven, new pressure measurement at day seven, seven days use of the second mattress and final data collection after seven days of use of the second mattress. Summarized, the data collection will be at baseline, at day seven and at day 14.||||
34032737|NCT02500043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032738|NCT02846571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032739|NCT05238610|||CASE_CONTROL||PROSPECTIVE|||||||
34032740|NCT05450419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34032741|NCT04479787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032742|NCT04403828|||COHORT||CROSS_SECTIONAL|||||||
33724523|NCT01637974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33724524|NCT05450471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032743|NCT05177185|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will undergo hippocampal-sparing stereotactic radiosurgery||||
34032744|NCT04495569|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort A: Intramuscular 0.3 mg/kg SYN023 Cohort B: Intramuscular 0.3 mg/kg SYN023 + China licensed Vero Cell Rabies Vaccine (PEP)||||
34032745|NCT05810103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032746|NCT02287714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032747|NCT02131987|||COHORT||RETROSPECTIVE|||||||
34032748|NCT01231646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032749|NCT02879344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032750|NCT02998697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032751|NCT02037412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032752|NCT05161910|||CASE_ONLY||PROSPECTIVE|||||||
33724525|NCT01498250|||CASE_CONTROL||PROSPECTIVE|||||||
33724526|NCT03591016|||COHORT||PROSPECTIVE|||||||
33724527|NCT02881242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032753|NCT00207883|||COHORT||PROSPECTIVE|||||||
34032754|NCT04987151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032755|NCT04248530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032756|NCT05649527|||COHORT||CROSS_SECTIONAL|||||||
34032757|NCT05005052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||two arms - the sulodexide arm compared to placebo arm|t|f|t|t
34032758|NCT05927870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032759|NCT02765256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032760|NCT00782314|||CASE_CONTROL||PROSPECTIVE|||||||
34032761|NCT01437839|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032762|NCT00601887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032763|NCT03899246|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, safety and feasibility trial assessing the suitability of an FDA approved medication for use in children with an off-label condition.||||
34032764|NCT01034020||||TREATMENT||||||||
34032765|NCT03135015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Capsule treatments will be fully blinded. Tablet treatments will be open label.|Each participant in 2 participant groups will undergo each of 6 treatments|t|t|t|t
33806389|NCT03569774|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Mechanical ventilation with individualized PEEP will be compared to mechanical ventilating with low PEEP during lung isolation in each subject. Each subject will receive one PEEP level then will receive the second PEEP level. The order in which each subject receives the PEEP level will be randomized.|t|f|f|f
33806390|NCT05892562|||OTHER||CROSS_SECTIONAL|||||||
33806391|NCT05680857|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34032766|NCT06237296|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* Participants, Investigators and site staff remain blinded during study conduct, except dedicated study staff preparing/administering the study intervention.~* Sponsor study staff will remain unblinded, except laboratory staff who handle primary/secondary endpoints"||t|t|t|f
34032767|NCT03806673|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||double blinded randomized|t|f|t|f
34032768|NCT06487169|||COHORT||PROSPECTIVE|||||||
34032769|NCT04213495|||COHORT||PROSPECTIVE|||||||
34032770|NCT03679689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Nobody involved with data acquisition had access to de assignment of the subjects|A randomized, blind, controlled clinical trial|f|f|t|f
34032771|NCT01295398|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032772|NCT01495000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032773|NCT04435834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participant and care provider will be aware randomization status. Investigator and outcomes assessor will be masked.|Subjects will be randomized in a stratified, blocked study design. Stratification is based on two factors: gestational age (2 groups: ≥37 weeks and ≤37 weeks) and postmenstrual age at MRI (2 groups: ≥37 weeks and ≤37 weeks). Blocking of each stratum is performed in groups of 4.|f|f|t|t
34032774|NCT02901353|||OTHER||PROSPECTIVE|||||||
34032775|NCT02861924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032776|NCT03652337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032777|NCT02574598|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned (1:1) using a random numbers table to receive either monotherapy Docetaxel for 6 cycles or Pembrolizuymab plus Docetaxel for 6 cycles, following with maintenance therapy with Pembrolizumab until disease progression or unacceptable toxicity.||||
34032778|NCT02255331|||COHORT||PROSPECTIVE|||||||
34032779|NCT03995277|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE||Participants take 10 mg/d of biotin at the same time each morning for 10 days. Blood draw for biobanking will be collected at baseline prior to starting biotin (day 1), after 10 days of biotin supplementation (day 10), and 10 days after participants stopped taking biotin (day 20).|f|f|f|t
34032780|NCT01306266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34032781|NCT00932191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032782|NCT03044028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032783|NCT01436955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032784|NCT04589637|||COHORT||CROSS_SECTIONAL|||||||
34032785|NCT04365803|||CASE_ONLY||PROSPECTIVE|||||||
34032786|NCT03691766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34032787|NCT04873596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34032788|NCT03956394|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Evaluation of 10 patients with active Takayasu disease, and 10 with non-active Takayasu disease.||||
34032789|NCT01608997|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34032790|NCT05351931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo similar to active study products|Randomized parallel two groups|t|t|t|t
34032791|NCT04886661|||COHORT||CROSS_SECTIONAL|||||||
34032792|NCT03383523|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a single-centre, open-label, randomized, parallel-group relative bioavailability study in healthy men. The study will be done in 2 parts, as follows:~Part 1 - single oral doses of 5 mg emodepside will be tested:~* Part 1a - the LSF (reference formulation) and 2 new IR-tablet formulations (test formulations) will be administered in the fasted state.~* Part 1b - the 2 new IR-tablet formulations will be administered in the fed state (high-fat, high-calorie meal).~Part 2 - single oral doses of 10 mg emodepside will be tested: depending on the results from Part 1, one or both IR-tablet formulations will be administered in the fasted state."||||
34032793|NCT03590210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two group, non-randomized||||
34032794|NCT02604407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032795|NCT02735109|NA|SINGLE_GROUP||SCREENING||NONE||||||
34032796|NCT04867343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is divided into two stages: the first stage is a dose verification trial, with a multicenter, open, single arm trial design, which is planned to enroll 10 children with general anesthesia surgery (all using HR020602 injection); If the result shows that the dose is low, 10 children under general anesthesia will be included again for higher dose verification. The second stage is designed as a multicenter, randomized, double-blind, parallel control trial with positive drugs, which is planned to include 25 children with general anesthesia surgery in the test group and 25 children in the control group. There should be at least 20 patients in each of \[2,12\] and \[12,18）age groups.|t|t|t|t
34032797|NCT00575237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34032798|NCT06239077|NA|SINGLE_GROUP||SCREENING||NONE|Patient information is confidential and shared exclusively with the treating physician|||||
34032799|NCT01656980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032800|NCT02816606|||COHORT||PROSPECTIVE|||||||
34032801|NCT02934672|||OTHER||CROSS_SECTIONAL|||||||
34032802|NCT03173157|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34032803|NCT06582979|NA|SINGLE_GROUP||TREATMENT||NONE||One group pre and post-test design||||
34032804|NCT04076163|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806392|NCT06112600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This prospective, randomised controlled study||||
33806393|NCT02847520|||CASE_ONLY||PROSPECTIVE|||||||
33806394|NCT05030493|||COHORT||RETROSPECTIVE|||||||
34032805|NCT03697824|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single arm treatment study.||||
34032806|NCT03301545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each study participant will be assigned a unique study identification number (study ID). All information/data regarding the participant will be collected using the Study ID. In this way, data analyses by the outcomes assessor will be blinded.|Patients consenting to participate will be randomized to one of two groups: (1) fast-track to bariatric surgery, or (2) Best diabetic care under the guidance of an endocrinologist for one year. Note: participants in the best diabetic care group will have the option to undergo bariatric surgery after one year if desired.|f|f|f|t
34032807|NCT06272721|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032808|NCT03057821|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34032809|NCT00395590|||DEFINED_POPULATION||OTHER|||||||
34032810|NCT01613768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032811|NCT05908227|RANDOMIZED|PARALLEL||OTHER||NONE|Due to the nature of the study design masking is not possible.|||||
34032812|NCT03676218|||COHORT||RETROSPECTIVE|||||||
33806395|NCT03665532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34032813|NCT05870189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032814|NCT03848494|||COHORT||PROSPECTIVE|||||||
34032815|NCT06568510|||CASE_ONLY||RETROSPECTIVE|||||||
34032816|NCT01200173|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032817|NCT04553393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032818|NCT03314207|||COHORT||PROSPECTIVE|||||||
34032819|NCT04849871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032820|NCT03523455|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Two groups: placebo, 30mg dose|t|f|t|f
34032821|NCT00590616|||COHORT||PROSPECTIVE|||||||
34032822|NCT06028295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032823|NCT01030302|||CASE_ONLY||PROSPECTIVE|||||||
34032824|NCT02753361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34107302|NCT03756961|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, non-blinded, non-commercial multi centre study. The intervention is divided into 2 phases, and the two phases will primarily be analysed separately (i.e., between the control group and intervention Phase 1 and between the control group and intervention Phase 2)||||
34107303|NCT01246518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107304|NCT06675643|||COHORT||PROSPECTIVE|||||||
34107305|NCT03361631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107306|NCT03090165|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34107307|NCT04577703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107308|NCT01799135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107309|NCT05338268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcomes assessors will not know what condition that the participant was allocated to, nor will the statistician who is one of the co-investigators.|Participants are randomized to one of two interventions.|f|f|t|t
34107310|NCT06632873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107311|NCT05218434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107312|NCT06549777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly assigned to either an intervention group (receiving brief psychoeducation - reading a text which takes approximately 30 min to read - about PTSD/CPTSD, including information about how to seek help/treatment within the Swedish health care system + 15-session body-oriented SE treatment conducted over 20 weeks) or a control group (receiving the same psychoeducation and information about treatment possibilities + regular phone calls during the same period to provide updates on their well-being and if they started a treatment).|f|f|f|t
34107313|NCT02419911|RANDOMIZED|PARALLEL||||NONE||||||
34107314|NCT05198245|||COHORT||RETROSPECTIVE|||||||
34107315|NCT00807482|||COHORT||PROSPECTIVE|||||||
34107316|NCT04231851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107317|NCT02458118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107318|NCT06076226|||COHORT||RETROSPECTIVE|||||||
34107319|NCT06643949|||COHORT||PROSPECTIVE|||||||
34107320|NCT06569381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34107321|NCT06637319|||COHORT||PROSPECTIVE|||||||
34107322|NCT01918358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107323|NCT03340116|||CASE_CONTROL||PROSPECTIVE|||||||
34107324|NCT06630689|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Since the study participants were newborns, the participants were naturally blinded to the study. Due to the nature of the study, the researcher who applied the nursing intervention to the experimental groups could not be blinded to which group the babies were assigned to. However, blinding was done for the other researchers and the statistical process in the study.|The study consisted of 3 groups: control group, dry whole body massage group and oily whole body massage group.|t|f|f|t
33806396|NCT01088841|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33806397|NCT04245995|||OTHER||PROSPECTIVE|||||||
33806398|NCT03674515|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806399|NCT01974843|||CASE_ONLY||PROSPECTIVE|||||||
33806400|NCT05782894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806401|NCT03938337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806402|NCT01778842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806403|NCT02660476|||COHORT||CROSS_SECTIONAL|||||||
33806404|NCT05063006|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||prospective crossover AB/BA study||||
33806405|NCT06700187|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33806406|NCT03385031|||COHORT||PROSPECTIVE|||||||
33806407|NCT04044781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806408|NCT01105988|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806409|NCT05317208|||OTHER||CROSS_SECTIONAL|||||||
33806410|NCT03220074|NA|SINGLE_GROUP||TREATMENT||NONE||Open labelled study||||
33806411|NCT03315065|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032825|NCT01439802|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34032826|NCT05608876|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
34032827|NCT05197543|||COHORT||PROSPECTIVE|||||||
34032828|NCT05708469|||CASE_CONTROL||RETROSPECTIVE|||||||
34032829|NCT03003351|||COHORT|||||||||
34032830|NCT01507311|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34032831|NCT04081909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34032832|NCT04745221|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34032833|NCT03027960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34032834|NCT01088958|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032835|NCT03298542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032836|NCT01243957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032837|NCT02271347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032838|NCT05010265|||OTHER||PROSPECTIVE|||||||
34032839|NCT02569190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032840|NCT00187824|||DEFINED_POPULATION||OTHER|||||||
34032841|NCT02969161|||COHORT||RETROSPECTIVE|||||||
34032842|NCT04353635|||COHORT||RETROSPECTIVE|||||||
34032843|NCT01092858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032844|NCT02713685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34032845|NCT03106324|||COHORT||PROSPECTIVE|||||||
34032846|NCT02122991|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032847|NCT03188796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34032848|NCT04763954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Game and control|t|f|f|f
34032849|NCT03473184|NA|SINGLE_GROUP||OTHER||NONE||Phototoxicity Potential Assessment (Photopatch test). All subjects received applications of 0.2 mL of diacerein 1% ointment and vehicle ointment under occlusive patch conditions to 2 skin sites at the infrascapular area of the back for approximately 24 (±2) hours. Following the removal of the patches, one site was irradiated and one remained non-irradiated.||||
34032850|NCT00923897|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032851|NCT04453540|||CASE_ONLY||RETROSPECTIVE|||||||
34032852|NCT04810715|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032853|NCT01017835|||CASE_CONTROL||PROSPECTIVE|||||||
34032854|NCT05698914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are masked to the names and specific details of each intervention arm at time of enrollment, and remain masked to the name and details of the intervention arm to which they are not randomized.||t|f|f|t
34032855|NCT06382532|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34032856|NCT04973566|RANDOMIZED|PARALLEL||OTHER||NONE||Part 1 is a single-sequence, 2-period study and Part 2 is a randomized, 2-cohort (Cohort 1 and Cohort 2), parallel study.||||
34032857|NCT01488773|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34032858|NCT00778388|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34032859|NCT03660176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032860|NCT02234102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032861|NCT05012020|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34032862|NCT06036186|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34032863|NCT01070953|||OTHER||PROSPECTIVE|||||||
34032864|NCT04470648|||OTHER||PROSPECTIVE|||||||
34032865|NCT02371382|||COHORT||PROSPECTIVE|||||||
34032866|NCT02351661|||COHORT||PROSPECTIVE|||||||
34032867|NCT04621344|||COHORT||PROSPECTIVE|||||||
34032868|NCT02152605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032869|NCT00283478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032870|NCT03353701|NA|SINGLE_GROUP||OTHER||NONE||Participants will serve as their own controls with pre- and post-measures.||||
34032871|NCT03282500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants and outcomes assessor are blind to the assigned condition.|Participants are randomly assigned to either the experimental condition or the active control condition.|t|t|f|t
34032872|NCT00185588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032873|NCT05630417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In order to keep the possibility of randomization of the elderly into groups and to minimize the possibility of their interaction with each other, the elderly who applied to Bayburt State Hospital Internal Medicine Outpatient Clinic randomly on Mondays and Wednesdays with the diagnosis of Type 2 diabetes will be included in the geriatric massage group, and the elderly who apply on Tuesday and Thursday will be included in the control group. In addition, individuals will be stratified according to age (65-74 years / 75-84 years old) while being assigned to the experimental and control groups.|The research was planned as a pre test-post test randomized controlled single-center study.|t|f|t|f
34032874|NCT03783325|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Patients will have the opportunity to participate in a questionnaire and then they are given the option to participate in substudy A (wear a UV dosimeter, complete questionnaires, and receive feedback based on the UV dosimeter results), subtstudy B (wear a skin patch, participate in a UV photo analysis, answer questionnaires), and/or substudy C (give biological samples via nevi).||||
34032875|NCT03396003|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032876|NCT00890617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032877|NCT03803969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, single arm, unblinded, non-randomized, open-label, multi-center, post-market clinical investigation.||||
34032878|NCT01214577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107325|NCT06402136|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-Blind, Placebo-Controlled||t|f|t|f
34107326|NCT00748527|RANDOMIZED|||TREATMENT||NONE||||||
34107327|NCT06252987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107328|NCT05372068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34107329|NCT03113188|NA|SINGLE_GROUP||TREATMENT||NONE||Dose finding cohort plus confirmatory expansion cohort||||
34107330|NCT06645392|||CASE_ONLY||PROSPECTIVE|||||||
34107331|NCT04543617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107332|NCT04355832|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34107333|NCT03201380|||COHORT||RETROSPECTIVE|||||||
34107334|NCT06113367|||COHORT||RETROSPECTIVE|||||||
34107335|NCT05868655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment and assessment in the study was performed by different physiotherapists.|Prior to and following the eight-week application, evaluation was conducted.|f|f|t|f
34107336|NCT05201495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107337|NCT02944331|||COHORT||PROSPECTIVE|||||||
34107338|NCT01399645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107339|NCT01127958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032879|NCT05934227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A random sequence will be generated (Excel, Microsoft Office 365) and participants will be allocated in the groups according to sequential numbered opaque envelopes. Each envelope containing one of the two treatments will be open only at the time of the periodontal procedure by the operator. Participants, as well as the researcher that evaluated treatment clinical outcomes won't know which group they were assigned.~It will be ensure that the patient, the main researcher, the operator, the examiner and the statistician will be unaware of study groups."|After clinical examination, participants will be randomly allocated into two treatment groups: 1) control group (SRP) - systemic administration of placebo after SRP (n = 25); 2) test group (SRP+AMX+MTZ) - systemic administration of AMX+MTZ after SRP (n=25).|t|t|t|f
34107340|NCT03735121|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Intervention study model can be sequential or in parallel.||||
34107341|NCT06162507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107342|NCT01013337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107343|NCT06369662|||CASE_ONLY||CROSS_SECTIONAL|||||||
34107344|NCT06302985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107345|NCT02731482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107346|NCT06369155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107347|NCT02500836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107348|NCT03536858|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|Hemodialysis staff will be unaware as to whether the patient was targeted based on their network centrality or clustering. Survey administrators will be unaware of which patient received the living donor intervention.|The investigators will assign every HD clinic shift to one of the two targeting strategies. They will measure the spread of information, attitudes, and behaviors by comparing the patients targeted to participate in the living donor intervention to the other patients on their shift.|f|t|f|t
34107349|NCT06674564|RANDOMIZED|PARALLEL||PREVENTION||NONE|open labelled|Model Description||||
34107350|NCT06076213|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization 1:1 in two treatment arms: artesunate-amodiaquine and artemether-lumefantrine||||
34107351|NCT04062552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107352|NCT00267488|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107353|NCT00657683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34107354|NCT03692169|||COHORT||PROSPECTIVE|||||||
34032880|NCT05807204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032881|NCT02386293|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34032882|NCT06048276|||COHORT||RETROSPECTIVE|||||||
34107355|NCT03136302|||CASE_ONLY||PROSPECTIVE|||||||
34107356|NCT03202173|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|f|t
34107357|NCT05866523|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This is a prospective, observational cohort study design with patients enrolled at Loma Linda University Medical Center (LLUMC), evaluating a multidisciplinary inpatient linkage to care program compared to historical control.||||
34032883|NCT01994785|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34032884|NCT01051362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107358|NCT05643430|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, open-label single-arm study||||
34032885|NCT00620386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34032886|NCT01207180|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34032887|NCT01305161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34032888|NCT05181046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34032889|NCT00312338|NON_RANDOMIZED|PARALLEL||||SINGLE||||||
34032890|NCT02802813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34032891|NCT00580450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032892|NCT05346042|||COHORT||RETROSPECTIVE|||||||
34032893|NCT02281825|||COHORT||CROSS_SECTIONAL|||||||
34032894|NCT02570620|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34107359|NCT01188993|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107360|NCT03345082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107361|NCT05305573|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Double (Participant, Investigator) Subjects and the clinical study team will remain blinded to treatment allocation.~Clinical/pharmacy staff involved in study drug preparation will be aware of which vaccine the subject is receiving."|This is a Phase IIb, double-blind, randomized, active controlled, multi-center, non-inferiority trial that aims to assess the immunogenicity and safety of a booster vaccination with a candidate vaccine.|t|f|t|f
34107362|NCT03508479|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107363|NCT00944645|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107364|NCT04201067|||CASE_ONLY||RETROSPECTIVE|||||||
34107365|NCT01969578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107366|NCT06384352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107367|NCT01950039|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34107368|NCT02475356|||COHORT||PROSPECTIVE|||||||
34107369|NCT02975115|||COHORT|||||||||
34107370|NCT05512455|||COHORT||CROSS_SECTIONAL|||||||
33806412|NCT05388045|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The intervention is not blinded to patients, clinicians, or investigators.|No randomization is involved, with all eligible patients invited to participate.||||
33806413|NCT01170208|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806414|NCT05144984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806415|NCT02417792|||CASE_CONTROL||PROSPECTIVE|||||||
33806416|NCT02469441|||CASE_CONTROL||PROSPECTIVE|||||||
33806417|NCT03934567|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33806418|NCT01553487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33806419|NCT04975217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806420|NCT04657887|||COHORT||PROSPECTIVE|||||||
33806421|NCT04975087|||OTHER||PROSPECTIVE|||||||
33806422|NCT02506270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806423|NCT05105984|||CASE_ONLY||PROSPECTIVE|||||||
33806424|NCT00686595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806425|NCT01563094|||COHORT||PROSPECTIVE|||||||
33806426|NCT02845466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806427|NCT06698679|||COHORT||PROSPECTIVE|||||||
33806428|NCT01558544|NA|SINGLE_GROUP||OTHER||NONE||||||
33806429|NCT03607591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33806430|NCT04068506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigators will divide the calculated sample size into two groups A and B in which all the participants have the same probability of being included in the study. Two unrecognizable envelopes separating both drugs gabapentin and paracetamol with equivalent dose will be administered with the specific code number labeled by the principal investigator and will be prescribed by the on-duty doctor to the patients in tablet form once orally allowed after surgery. Analgesic effects will be inquired after 6 hours of drug administration. Further questions will be asked according to the questionnaire by the co-investigators having no knowledge of the given drug to participant.|A total of 50 patients who fulfill the inclusion criteria will be approached and written consent will be signed by the participants prior to the interview. Participants will be divided into two groups divided equally i.e. gabapentin group and paracetamol group. Gabapentin group received 600 mg dose while the control/other group received 1 gram (1000 mg) of paracetamol as a postoperative analgesic agent.|f|f|t|t
33806431|NCT03235518|||OTHER||CROSS_SECTIONAL|||||||
33806432|NCT02238041|||||PROSPECTIVE|||||||
33806433|NCT02961075|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33806434|NCT03552276|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"Subjects will be not be randomized and will enter the long-term extension study with one fixed dose regimen of tildrakizumab, low dose regimen at Week 52 of the parent study.~Study was double blind until Databaselock of parent study happened to maintain blinding Subjects continue to assigned treatment from parent study up to week 52 in the Long term extension and there after all subjects began migrating to receive low dose injection Q12 weeks in an open-label fashion for up to an additional 4 years.."|||||
33806435|NCT04580459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806436|NCT01540305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806437|NCT03462485|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The project will be a randomised controlled trial with a partial crossover. Each condition will be followed for eight weeks, with the crossover occurring after eight weeks for the control group. The intervention group will continue for the full sixteen weeks.||||
33806438|NCT04452383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A computer-generated randomization table divided patients into 2 equal groups randomly allocated patients.||t|t|t|t
33806439|NCT00186446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806440|NCT04919811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806441|NCT02972034|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33806442|NCT05494866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806443|NCT04094519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806444|NCT04984889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806445|NCT05577624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806446|NCT06698835|RANDOMIZED|PARALLEL||PREVENTION||NONE||the study design indicates two arms (e.g., experimental and control) which will divide the group into small groups (5 in each) for experimental. and 10 students as a control group||||
34032895|NCT03405025|NA|SINGLE_GROUP||OTHER||NONE||All participants will undergo the intervention: endoscopic ultra-sound guided radiofrequency ablation of their left adrenal aldosterone producing adenoma. The primary outcome is safety and feasibility||||
34032896|NCT02814344|||COHORT||PROSPECTIVE|||||||
34032897|NCT03345693|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34032898|NCT01542801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032899|NCT06579625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||two group with a of Health Belief Model-Based cancer education control group|t|f|f|f
34032900|NCT02486874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107371|NCT05067985|||COHORT||RETROSPECTIVE|||||||
34107372|NCT06640517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107373|NCT05316740|||COHORT||PROSPECTIVE|||||||
34107374|NCT02609503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107375|NCT04427345|||COHORT||RETROSPECTIVE|||||||
34107376|NCT04522739|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34107377|NCT06639139|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34107378|NCT05294523|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34107379|NCT06636825|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomized, double-blind, placebo-controlled crossover trial|t|f|t|f
34107380|NCT03759197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107381|NCT06612866|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107382|NCT06136403|NA|SINGLE_GROUP||TREATMENT||NONE||challenge dechalenge rechalenge design||||
34107383|NCT06638229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107384|NCT06674746|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34152401|NCT03289117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Open label|"Arm 1: Experimental: Novel device: Assigned Interventions: Catheter change with novel device. Each subject will undergo catheter change with novel gel instillation device.~Arm 2: Comparator: Standard procedure: Assigned Interventions: Catheter change with standard procedure. Each subject will undergo catheter change with standard procedure."|f|f|f|t
34032901|NCT04247100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be sent home at baseline with a TENS unit and a sealed envelope with instructions for device settings. The envelope will contain instructions for either sham stimulation or active stimulation (unknown to the performing coordinator and participant). Both groups will receive a new device and another set of instructions from the study team at 4 weeks. It is possible and permitted that the performing study coordinator will become aware of which group the subject is in when checking in on the subject.|30 participants will be enrolled in this double-blind sham control study. Fifteen participants will undergo sham stimulation for 4 weeks followed by active microstimulation for 4 weeks. The other 15 participants will have active microstimulation for all 8 weeks.|t|t|f|f
34032902|NCT03670615|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research personnel that will be administering the cognitive assessments will be blinded to treatment allocation. The patients will be blinded to stimulation type.|This is a randomized, blinded, repeated-session, parallel-design study.|t|f|t|t
33806447|NCT06700174|||COHORT||PROSPECTIVE|||||||
33806448|NCT04923035|||CASE_CONTROL||PROSPECTIVE|||||||
33806449|NCT02052440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806450|NCT01505166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806451|NCT05500170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study participants and investigators will be blinded to group assignment. A statistician will assign participants into groups and a pharmacist will distribute treatment.|A clinical trial, randomized controlled trial, double-blinded. Participants will be assigned to intervention (NR supplementation) or placebo groups.|t|f|f|f
33806452|NCT03150875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806453|NCT01630824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806454|NCT02890524|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33806455|NCT02625818|||CASE_ONLY||PROSPECTIVE|||||||
34032903|NCT01508884|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34032904|NCT05484492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study involves an investigator (surgeon) and an examiner. The examiner measures the clinical parameters before and after surgery and is blinded to the surgical procedure and type of graft the patient receives.|Thirty patients will be treated using the principles of guided bone regeneration utilizing a full thickness flap for ridge preservation. Fifteen test patients will receive an intrasocket demineralized and mineralized combination putty allograft with a regenerative tissue matrix membrane. The positive control group of fifteen patients will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft covered with a regenerative tissue matrix membrane. Approximately four months post-surgery, a trephine core will be taken from the grafted site immediately prior to implant placement and submitted for histologic processing.|t|f|t|t
34032905|NCT02589730|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34032906|NCT03788343|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34032907|NCT04958655|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032908|NCT03252067|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032909|NCT00277329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34032910|NCT03068117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152402|NCT00861328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152403|NCT03992092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded, as will Anesthesiologist providing care, but the investigator who performs the intubation will be aware of the intubation technique he used. Similarly, the Radiologist measuring the C-spine movement will be able to see the device on the fluoroscopic images.|Parallel randomised controlled trial|t|t|f|f
34152404|NCT04492761|||COHORT||PROSPECTIVE|||||||
34152405|NCT02461745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152406|NCT01841255|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152407|NCT03488446|||COHORT||PROSPECTIVE|||||||
34152408|NCT02700594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152409|NCT04566692|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single sequence crossover design||||
34152410|NCT04752332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152411|NCT04383275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152412|NCT01865383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152413|NCT05476029|||COHORT||PROSPECTIVE|||||||
33806456|NCT04561089|||CASE_ONLY||PROSPECTIVE|||||||
33806457|NCT03284359|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33806458|NCT01235936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806459|NCT00828126|||CASE_ONLY||PROSPECTIVE|||||||
33806460|NCT03903692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806461|NCT03699163|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806462|NCT03421249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33806463|NCT02920034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806464|NCT02312830|||COHORT||CROSS_SECTIONAL|||||||
33806465|NCT01060306|||CASE_CONTROL||PROSPECTIVE|||||||
33806466|NCT03877354|||COHORT||RETROSPECTIVE|||||||
33806467|NCT04271774|||COHORT||PROSPECTIVE|||||||
33806468|NCT06117085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806469|NCT00856700|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33806470|NCT00428805|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33806471|NCT02408887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806472|NCT03158415|NA|SINGLE_GROUP||OTHER||NONE||Mixed Methods Exploratory Study||||
34152414|NCT02271945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152415|NCT04518033|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34152416|NCT01879046|NA|SINGLE_GROUP||OTHER||NONE||||||
34152417|NCT05749692|||COHORT||PROSPECTIVE|||||||
34152418|NCT00196768|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152419|NCT02690441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152420|NCT02342262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152421|NCT03922087|||COHORT||PROSPECTIVE|||||||
34152422|NCT00825721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152423|NCT05261009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152424|NCT05157581|||COHORT||PROSPECTIVE|||||||
34152425|NCT02650024|||COHORT||PROSPECTIVE|||||||
33806473|NCT04535856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, To maintain the double-blind of the study, a statistician who do not participate in this study will independently generate randomization code only using the PLAN procedure (Proc Plan procedure) of SAS (ver. 9.4 or higher, SAS Institute, Cary, NC, USA).|Randomized, Double-blind, and Placebo-controlled Clinical Trial|t|t|t|t
33806474|NCT02080585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33806475|NCT06699667|||CASE_CONTROL||RETROSPECTIVE|||||||
34032911|NCT06058624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research staff collecting trial outcome data will not be informed of the participant's group.|Two arm, randomized clinical trial comparing two online pain self-management interventions: Veteran ACT for Chronic Pain and Online Pain School. Both interventions are matched for attention and time, with 7 modules (each about 15 - 20 minutes) received over 7 weeks.|f|f|f|t
34032912|NCT00943748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032913|NCT00604682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032914|NCT01808547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032915|NCT04343157|NA|SINGLE_GROUP||TREATMENT||NONE||Study patients will undergo MR imaging with DTI and 3D volumetric imaging at baseline (pre-SRS), and 1 month, 3 months, and 6 months afterwards. This regimen of post-SRS MR imaging is clinical standard of care. Segmentation of critical white matter and hippocampal volumes will be performed pre-SRS for use in brain SRS planning. Formal neurocognitive assessments will be performed at baseline and 3 months post-SRS.||||
34032916|NCT06275438|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Our study was conducted on the placentas of 40 women admitted to the obstetrics clinics of Kars Harakani State Hospital and Kafkas University Training and Research Hospital, after obtaining necessary permissions. Out of 40 placentas, 5 were excluded due to blood incompatibility, 2 were excluded due to subsequent diagnosis of chronic conditions (thyroid disorder, Behçet's disease), and 1 was excluded due to the presence of an accessory placenta, resulting in a total of 32 placentas included in the study. Among these, 16 were from women who had undergone normal vaginal delivery (control group), and 16 were from women who had undergone cesarean section (case group). Tissue samples obtained from the placentas were subjected to histological and immunohistochemical methods to obtain various findings"||||
34032917|NCT01806194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032918|NCT01451463|||CASE_CONTROL||PROSPECTIVE|||||||
34032919|NCT05247229|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34032920|NCT05034016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032921|NCT04087200|||COHORT||PROSPECTIVE|||||||
34032922|NCT02705261|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34032923|NCT05187728|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34032924|NCT00036153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34032925|NCT04515134|||COHORT||PROSPECTIVE|||||||
34032926|NCT03157479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032927|NCT01973803|||CASE_ONLY||PROSPECTIVE|||||||
34032928|NCT00173225|||DEFINED_POPULATION||OTHER|||||||
34032929|NCT06338579|||COHORT||PROSPECTIVE|||||||
34032930|NCT00428233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032931|NCT01747954|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34032932|NCT02370238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34032933|NCT05215951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032934|NCT06029543|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34032935|NCT01410903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032936|NCT04370678|||OTHER||CROSS_SECTIONAL|||||||
34107385|NCT03112928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants will be informed that both treatments have been shown effective in previous studies, and in the present study we are comparing their efficacy.~The person conducting the pain evaluation (outcomes assessor) will not treat the participants and will be unaware of which treatment is given to each participant. The person treating the subject is different than the person evaluating.~The principal and coordinating investigator will receive blinded data from all participating centers to analyze the clinical trial outcomes."|International, multi-centre, double-blind, randomized, controlled clinical trial|t|f|t|t
34032937|NCT05642598|NA|SINGLE_GROUP||OTHER||NONE||||||
33806476|NCT03958019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study outcomes will be assessed by a blinded assessor.|Convergent parallel mixed methods design|f|f|f|t
33806477|NCT01818869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032938|NCT05066880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032939|NCT05583695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34032940|NCT02088801|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34032941|NCT05712239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To confirm blindness, all patients will be unaware of the group allocation and the exercises performed by the other group. Also, the pictures of craniovertebral angle will be coded before being measured||t|f|f|t
34032942|NCT04759807|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|A computerised randomisation scheme will be created and shall be considered blinded. The randomisation is available only to the clinical research unit pharmacy staff that are preparing the drug who will not be involved in any other aspect of the study including administration of the drug. It will not be made available to the subjects, site(s) PI(s), or members of the staff responsible for the monitoring and evaluation of safety assessments. PUR1800 and placebo capsules will be of the same shape, size, and color to ensure that the blind is maintained. A subject's treatment assignment will only be unblinded when knowledge of the treatment is essential for the further clinical management of the subject on this study or may potentially impact the safety of subjects currently enrolled or subjects in subsequent enrollment.|"PUR1800, or placebo is dosed daily for 14 consecutive days in adult subjects with stable COPD over three discrete TPs. Subjects will be randomised to one of the following 3 treatment sequences: Sequence Period 1 Period 2 Period 3~1. Placebo PUR1800 250 μg PUR1800 500 μg~2. PUR1800 250 μg Placebo PUR1800 500 μg~3. PUR1800 250 μg PUR1800 500 μg Placebo"|t|t|t|f
34032943|NCT00191607|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032944|NCT01960660|RANDOMIZED|CROSSOVER||||NONE||||||
34032945|NCT02896712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032946|NCT02854527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032947|NCT03987997|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only one leg receives the electrical muscle stimulation, the leg which receives the electrical stimulation is randomized. An outcome assessor assess the outcome blindly.|Leg with electrical muscle stimulation and cycling versus leg with cycling only|f|f|f|t
34032948|NCT04789551|||CASE_CONTROL||PROSPECTIVE|||||||
34032949|NCT03965195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34032950|NCT02225431|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34032951|NCT01838850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032952|NCT01446341|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34032953|NCT00708110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032954|NCT01842529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34032955|NCT04859829|||COHORT||PROSPECTIVE|||||||
34032956|NCT04168892|||COHORT||PROSPECTIVE|||||||
34032957|NCT05669534|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Multiphase Optimization Strategy|t|f|f|f
34107386|NCT05520736|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Cohort study||||
34107387|NCT00911157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107388|NCT03510715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806478|NCT06258044|||COHORT||RETROSPECTIVE|||||||
33806479|NCT00177619|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33806480|NCT04759833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032958|NCT05711420|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34107389|NCT02695888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34152426|NCT01133119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34152427|NCT02248402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806481|NCT05636293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33806482|NCT05179187|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants undergo the same behavioral interventions in which upper extremity movements are made in response to different sensory stimuli.||||
33806483|NCT03388736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33806484|NCT00002866||||TREATMENT||||||||
33806485|NCT03792061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33806486|NCT00977249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806487|NCT04334005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33806488|NCT00609050|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34032959|NCT05714878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34032960|NCT02666261|||COHORT||PROSPECTIVE|||||||
34032961|NCT02561117|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34032962|NCT06370611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation cannot be concealed from the participants, care providers or investigator. Outcome assessors will be blinded regarding allocation.|Bi-center, prospective, randomized, controlled, parallel (1:1), two-arm, open-label, blinded evaluation (PROBE) trial|f|f|f|t
34032963|NCT01081327|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34152428|NCT00332553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34152429|NCT04516772|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled subjects will undergo phakic eye surgery to have the STAAR Visian Toric Implantable Collamer Lens (TICL) implanted in one or both eligible eyes.||||
34152430|NCT04928118|||COHORT||PROSPECTIVE|||||||
34152431|NCT04042727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible patients will be randomized to receive either Dexmedetomidine or Placebo in addition to Standard of Care. Investigational pharmacy will be primarily responsible for randomization.|t|t|t|t
33806489|NCT02977832|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||alpha-antagonist (alfuzosin 10 mg)+ Odyliresin (Iresine celosia) 2 ml, 20 drops once daily.||||
33806490|NCT01465152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806491|NCT06162702|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806492|NCT01253213|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806493|NCT06148740|NA|SINGLE_GROUP||OTHER||NONE||||||
33806494|NCT03768466|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806495|NCT04068272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo and Study Drug have the same physical characteristics, labeling and packaging|1 Eye receives placebo, the other eye receives study drug. Eye elections is randomized|t|t|t|t
33806496|NCT04174339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806497|NCT00149591|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33806498|NCT02551237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806499|NCT05001126|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Primary investigator will be blinded from each participant's dose allocation.|Three dose groups|f|f|t|f
33806500|NCT04304937|||COHORT||PROSPECTIVE|||||||
33806501|NCT06306118|||CASE_ONLY||PROSPECTIVE|||||||
33806502|NCT04642287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All participants, care giver and investigators measuring or analyzing the experimental data will be blinded to the interventions. Tissue samples collected will be labeled with 3-digit unique IDs and de-identified before studying in PI's lab. The study investigator will collect AK/skin samples and label them based on the study ID (e.g. 201) without compromising their blinded status. All the study records/photographs will be kept in a locked office or password-protected computer that is only accessible by the members of the research team."|Parallel Assignment|t|t|t|f
33806503|NCT01350687|||COHORT||PROSPECTIVE|||||||
33806504|NCT02419300|||CASE_ONLY||PROSPECTIVE|||||||
33806505|NCT00259142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806506|NCT06695806|||OTHER||PROSPECTIVE|||||||
33806507|NCT02745990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33806508|NCT06104423|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33806509|NCT03987646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806510|NCT04402112|||COHORT||PROSPECTIVE|||||||
33806511|NCT05364385|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33806512|NCT04941794|||COHORT||PROSPECTIVE|||||||
33806513|NCT04060212|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806514|NCT01329952|||COHORT|||||||||
33806515|NCT01370928|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33806516|NCT06118307|||COHORT||OTHER|||||||
33806517|NCT04592185|||COHORT||PROSPECTIVE|||||||
33806518|NCT03524131|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806519|NCT02927249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806520|NCT06078696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806521|NCT00505336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806522|NCT01065649|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33806523|NCT02334917|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33806524|NCT02082652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806525|NCT04383067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806526|NCT01730456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806527|NCT04455204|||COHORT||PROSPECTIVE|||||||
33806528|NCT04942184|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34032964|NCT04020523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806529|NCT01788605|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806530|NCT03700996|||COHORT||PROSPECTIVE|||||||
33806531|NCT05480540|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806532|NCT02955563|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33806533|NCT06358755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators, including ophthalmologists and optometrists, who are responsible for collection of data related to myopia progression and analysis of data will be blinded to study intervention.|Eligible participants will be randomly allocated into 2 groups. One group will receive low dose atropine (0.01%) plus DIMS spectacles (ATD Group); another one will receive low dose atropine (0.01%) plus single vision spectacles (AT Group).|f|f|t|t
33806534|NCT04495426|||COHORT||CROSS_SECTIONAL|||||||
33806535|NCT06490718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple blind|Prospective, multicenter, randomized, triple-blind trial|t|t|t|t
33806536|NCT04029493|||OTHER||PROSPECTIVE|||||||
33806537|NCT06698393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Clinical Trial|t|f|f|t
33806538|NCT03798574|||CASE_CONTROL||OTHER|||||||
33806539|NCT05645068|NA|SINGLE_GROUP||OTHER||NONE||||||
33806540|NCT04738656|||COHORT||RETROSPECTIVE|||||||
33806541|NCT04000750|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will know their group. Training and Nutrition research team members will know the participants group. Data analysis team will be blinded to condition.||f|f|t|t
33806542|NCT05011292|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806543|NCT04415307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032965|NCT00784108|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34032966|NCT03586089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To conceal allocation, central randomization will be conducted by the Pharmacy Department of Unity Health Toronto - St. Michael's Hospital using a list of random treatment assignments created on www.randomize.net.|As soon as possible after randomization, patients will receive either a single IV dose of phenobarbital (7.5 mg per kg of ideal body weight, prepared in 250 ml D5W; n=26) or placebo (250 ml D5W; n=13)|t|t|t|f
33806544|NCT02103556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806545|NCT03500523|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806546|NCT04185181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806547|NCT02246075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806548|NCT00268723|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33806549|NCT03615352|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34032967|NCT03003195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032968|NCT05616793|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34032969|NCT04834609|NA|SINGLE_GROUP||TREATMENT||NONE|Characterisation of adipose tissue (AT-MSCs) was performed blinded to the result of the treatment responder/non-responder|||||
34032970|NCT03229226|||CASE_ONLY||OTHER|||||||
34032971|NCT05411146|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34032972|NCT05626842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032973|NCT03511027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study will utilize a multi-site randomized controlled trial design. One week prior to discharge from inpatient rehab, consenting patients will be randomly assigned to receive medication self-management education only (SME) or medication self-management education + Karie (SME+K).||||
34032974|NCT01547390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032975|NCT03774355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032976|NCT04211831|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34032977|NCT04101409|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34032978|NCT00249431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34032979|NCT04359147|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34032980|NCT01261897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032981|NCT04362670|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Sequential: Groups of participants are assigned to receive interventions based on prior milestones being reached in the study, such as in some dose escalation and adaptive design studies|t|f|t|f
34032982|NCT03648229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study personnel assessing IOP will be masked to treatment assignment during the first 12-month period and to all prior IOP measurements at every visit. IOP will be obtained using the iCare tonometer which provides an objective, digital reading.|Prospective, randomized, active-controlled parallel-group design|f|f|f|t
34032983|NCT02841501|||CASE_CONTROL||PROSPECTIVE|||||||
34032984|NCT06582537|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34107390|NCT06198010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patient Reported Outcome Measures will be administered at baseline by a study coordinator and at 3 and 6 months by a blinded, bilingual, assessor.||f|f|f|t
34107391|NCT06644794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107392|NCT06635694|||COHORT||PROSPECTIVE|||||||
34107393|NCT05917288|NA|SINGLE_GROUP||TREATMENT||NONE|Click here to enter text.|||||
34107394|NCT06640920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107395|NCT02834741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107396|NCT03855540|||CASE_CONTROL||PROSPECTIVE|||||||
34107397|NCT04937166|NA|SEQUENTIAL||TREATMENT||NONE||This study will involve sequential enrollment of approximately 36 patients accrued into six dose cohorts, each testing a different DSP107 dose level in combination with azacitidine (Part A) or DSP107 in combination with azacitidine and venetoclax (Part B).||||
34107398|NCT06290778|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107399|NCT02457793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806550|NCT02205515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806551|NCT02383043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33806552|NCT03861234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806553|NCT05374694|||CASE_CONTROL||PROSPECTIVE|||||||
33806554|NCT01034306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806555|NCT06699277|||OTHER||PROSPECTIVE|||||||
33806556|NCT01357694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806557|NCT06081608|||COHORT||PROSPECTIVE|||||||
33806558|NCT06137898|||COHORT||PROSPECTIVE|||||||
33806559|NCT06698458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||15 patients in each cohort for a total of 30 subjects.||||
34032985|NCT05578209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34032986|NCT05123378|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|All participants, care providers, investigators, and outcome assessors are aware of where and when the intervention is being delivered in each community in Grand Bassa.|The NCHAP is being implemented in Grand Bassa county on a staggered schedule across eight study districts between 2018 and 2022. In order to serve most indigent districts first, the order is not randomized. Districts with more need for health interventions have been prioritized in the implementation roll out. All program implementations are preceded by community engagement activities, especially in getting the involvement of political and traditional leaders in the community and a training period for CHWs of a few months. Within this time CHWs are recruited and trained in a modular approach with in class training followed by practice in the community for mastery before the next module. The implementation process is still ongoing and the NCHA program will continue after the end of the study in 2022.||||
34032987|NCT01644240|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34032988|NCT03264807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032989|NCT00850811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107400|NCT06322901|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34107401|NCT06566677|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34107402|NCT06572774|RANDOMIZED|PARALLEL||SCREENING||NONE||We are randomly assigning women to the three study arms. We are also requesting that the women select one caregiver for inclusion in the caregiver education sessions||||
34107403|NCT05073432|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34107404|NCT06421441|RANDOMIZED|PARALLEL||OTHER||SINGLE||Group 1: Experimental group (Education group) Goup 2: Control group|t|f|f|f
34107405|NCT01927848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107406|NCT04067622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Within-patient, randomized crossover design.||||
34032990|NCT04789837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724528|NCT03963115|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Subjects were randomly assigned to receive either epinephrine or normal saline (placebo) coated syringe for SCIT by a block of 4 randomization. These syringes were used to draw allergen extracts. The syringes for the second visit were coated with different agents from the first visit in the same patients. One investigator (K.B.) generated the allocation sequence and prepared the coated syringes. The physicians who drew and injected the allergen shots and the patients were blinded to the assignment from the beginning to the end of the interventions. Interventions were decoded at the end of the study by K.B.|A randomized, double-blind, crossover trial with epinephrine coated syringe before injected and placebo was done in each visit in patients who developed large local reactions after subcutaneous immunotherapy.|t|t|t|t
33724529|NCT01653496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724530|NCT02890979|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33724531|NCT02894177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Care providers will be blinded of tcPCO2 measurements to avoid influencing extubation decisions.|tcPCO2 will be monitored in all patients performing SBTs. The difference between maximal and initial tcPCO2 (ΔtcPCO2) in patients succeeding extubation will be compared with ΔtcPCO2 in patients failing extubation.||||
33724532|NCT00384800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724533|NCT00694759|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724534|NCT00589316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724535|NCT01599507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724536|NCT03890770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724537|NCT03815097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, randomized study. The study will not be blinded. Subjects will be recruited from those who are referred to the interventional pulmonary department for EBUS bronchoscopy and who will be undergoing monitored anesthesia care (MAC) for their procedure. Subjects will then be randomized (via an computer randomizing algorithm) to receive conventional MAC vs. MAC with a mapleson circuit and nasal trumpet.||||
33724538|NCT01592929|NA|SINGLE_GROUP||OTHER||NONE||||||
33724539|NCT00323492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724540|NCT02052232|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33724541|NCT03886220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724542|NCT06115811|NA|SINGLE_GROUP||OTHER||NONE||||||
34032991|NCT01807065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34032992|NCT01956474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032993|NCT01728844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34032994|NCT06581094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34032995|NCT06134037|||COHORT||PROSPECTIVE|||||||
34032996|NCT01320293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34032997|NCT02877225|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34032998|NCT05639582|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34032999|NCT04940988|||COHORT||PROSPECTIVE|||||||
34033000|NCT02020278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033001|NCT01727752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033002|NCT04529135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients are divided into the Dexmedetomidine group / control group by random assignment. Using a table of computer-generated random numbers(s), assign 68 people to each county by 34 people. Random tables, in turn, seal the results in an opaque envelope. An anesthesiologist who is unaware of the content of this study and does not participate in the study receives information only about drug administration and is in charge of anesthesia, and does not disclose information about the assigned group to postoperative observers. Also, they don't disclose information about the assigned group to the surgeon.|Randomized Double-blind Controlled Study|t|t|t|f
34033003|NCT03985540|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34033004|NCT01225250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033005|NCT02091856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033006|NCT05620446|RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking|"This prospective randomized controlled clinical trial included all patients who developed the manifestations of acute a cute sigmoid volvulus and referred to the Zagazig University Hospital Emergency Department between December 2020 and August 2022. The study was prospectively approved by Zagazig University Faculty of Medicine Institutional Review Board (Approval Number: 9989/23-10-2022), Included eligible patients were simply randomized at a 1:1 ratio to Endoscopic (SG) or Surgical Colostomy Group (EG) via the drawing of sealed envelopes containing computer-generated random numbers prepared by a third party before the start of the intervention"||||
34033007|NCT00370552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033008|NCT00445432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033009|NCT06033391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants that meet the inclusion criteria will complete the web-based baseline assessment (pre), with questionnaires relating to maladaptive beliefs, mood (anxiety and depressions), self-esteem and OCD symptoms. After, experimental group will use the GGOC-AD, and control group will use the GGN-AD for 14 days. Then, both groups will complete again the above-mentioned assessment instruments (post use of the app). Finally, all participants will complete the follow-up measures at one month.|t|f|f|f
34033010|NCT00399126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033011|NCT01068145|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34033012|NCT01379157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033013|NCT03219827|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34033014|NCT02585414|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34107407|NCT04785352|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|"Raters assessing responsive parenting and child development outcomes will be blind to the condition of mother-child dyads.~For investigators, they will be blinded to participants' assigned study arms before and during handling and analysis of the data."||f|f|t|t
34107408|NCT06636890|||COHORT||PROSPECTIVE|||||||
34107409|NCT00005626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107410|NCT04510740|||OTHER||PROSPECTIVE|||||||
34107411|NCT03660449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107412|NCT03030755|||COHORT||PROSPECTIVE|||||||
33806560|NCT06523699|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 2:1 to receive CYT107 + standard of care melphalan and AHCT or standard of care melphalan and AHCT alone.||||
33806561|NCT00998725|||COHORT||PROSPECTIVE|||||||
33806562|NCT05162560|||COHORT||RETROSPECTIVE|||||||
33806563|NCT06251336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||1:1|t|f|t|t
33806564|NCT05051592|||OTHER||CROSS_SECTIONAL|||||||
33806565|NCT00392899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806566|NCT00708045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806567|NCT05562102|||COHORT||PROSPECTIVE|||||||
33806568|NCT05380089|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Given the nature of the study, it is not possible to blind neither participants nor research team members regarding the allocated groups.|A randomized controlled trial (RCT)||||
34033015|NCT06128408|||COHORT||RETROSPECTIVE|||||||
34033016|NCT00795652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033017|NCT02912182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033018|NCT00495573|||CASE_ONLY||PROSPECTIVE|||||||
34033019|NCT00429429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033020|NCT03583476|||COHORT||RETROSPECTIVE|||||||
34033021|NCT01972399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033022|NCT02094417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033023|NCT03942601|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is an open-label study without randomization. Cohorts will be enrolled sequentially, with Group 1 followed by Group 2.~Study Drug: Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1 or Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2 Route of Administration: Bullfrog Micro-Infusion Device adventitial delivery Dosage Volume:0.5 mL per cm of target vessel length Up to 30 subjects in Group 1 and up to 30 subjects in Group 2. The study shall enroll subjects from up to 20 sites in the United States."||||
34033024|NCT01159730|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34033025|NCT01602393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033026|NCT01042769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033027|NCT02636517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033028|NCT02574182|||CASE_CONTROL||PROSPECTIVE|||||||
34033029|NCT03927456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033030|NCT03135002|||COHORT||RETROSPECTIVE|||||||
34033031|NCT00956111|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033032|NCT03288064|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34033033|NCT01610492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033034|NCT02312414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033035|NCT01264510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033036|NCT00302653|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033037|NCT00010764|RANDOMIZED|||TREATMENT||||||||
34033038|NCT04018651|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033039|NCT06103578|||CASE_CONTROL||PROSPECTIVE|||||||
34033040|NCT01068483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107413|NCT02668757|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34107414|NCT03218475|NA|SINGLE_GROUP||OTHER||NONE||||||
34107415|NCT03842280|||COHORT||PROSPECTIVE|||||||
34107416|NCT06002477|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34107417|NCT04603287|NA|SEQUENTIAL||TREATMENT||NONE||||||
34107418|NCT03066739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107419|NCT06383806|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Waitlist control||||
34107420|NCT02144337|RANDOMIZED|PARALLEL||||NONE||||||
34107421|NCT05669027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Examine effects of mobile neurofeedback on changes in pain intensity, pain interference, physical function, and EEG alpha (8-13 Hz) power.~Examine mediating effect of self-efficacy on changes in pain outcomes."|t|f|t|f
34107422|NCT02463435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107423|NCT02414841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107424|NCT02598973|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34107425|NCT04297735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107426|NCT05933603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107427|NCT01448304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107428|NCT01893450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34107429|NCT06429735|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34107430|NCT00945542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107431|NCT05930535|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will be allocated to the same intervention arm for this pilot feasibility study.||||
34107432|NCT05323734|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107433|NCT06641102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study team will remain unblinded for study procedures. Statistical analysis will be performed by a statistician who is blinded.||f|f|f|t
33724543|NCT05992597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724544|NCT05698147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806569|NCT04463654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33806570|NCT02588443|RANDOMIZED|PARALLEL||TREATMENT||||||||
33806571|NCT02298842|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33806572|NCT05254392|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants were blinded to the profession of the investigators and study arms, while outcome assessors were blinded to the interventions and study arms.||t|f|f|t
33806573|NCT06510166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33806574|NCT01290003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806575|NCT01406106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806576|NCT04715269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking will be done for all participants|This randomized, close label, placebo-controlled study with superiority framework as add-on therapy in ACS patients|t|t|t|t
34033041|NCT03732963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Randomization will be done via computer generated numbers and concealed by serially numbered, opaque and sealed envelopes. The details of series will be unknown to the investigators and the group assignment will be kept in a set of concealed envelopes each bearing only the case number on the outside. Prior to the start of the study, the appropriately numbered envelopes will be opened by the nurse, the card will determine the assigned intervention for each patient, which will be prepared by a clinical pharmacist with no other role in the study|(N-acetyl-5-methoxytryptamine) is a neurohormone secreted by the pineal gland. It is primarily responsible for the sleep awake cycle as its level decreases in the morning and increases by night; owing to reduced light intensity, leading to circadian rhythm. It provides circadian and seasonal timing through activation of G protein-coupled receptors (GPCRs) in target tissues. Melatonin exerts its hypnotic effects through the activation of the MT1 and MT2 melatonin receptors|t|t|t|f
34033042|NCT03443531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033043|NCT01850134|RANDOMIZED|CROSSOVER||||NONE||||||
34107434|NCT06639880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806577|NCT02401711|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33724545|NCT04335279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724546|NCT04136392|||COHORT||PROSPECTIVE|||||||
33724547|NCT03812692|||OTHER||PROSPECTIVE|||||||
33724548|NCT05162209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized, double blind, placebo controlled clinical study|t|t|t|f
33724549|NCT01824407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724550|NCT01329640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724551|NCT02968563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724552|NCT01971450|||COHORT||PROSPECTIVE|||||||
33724553|NCT02190227|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724554|NCT04851795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724555|NCT02635516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724556|NCT05621343|||COHORT||PROSPECTIVE|||||||
33806578|NCT00355888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806579|NCT05036837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033044|NCT01542814|||CASE_ONLY||PROSPECTIVE|||||||
34033045|NCT05933044|||COHORT||RETROSPECTIVE|||||||
34033046|NCT01029743|||COHORT||PROSPECTIVE|||||||
34033047|NCT04837144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033048|NCT05831371|||COHORT||RETROSPECTIVE|||||||
34033049|NCT04852523|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724557|NCT05689307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724558|NCT04928677|NA|SEQUENTIAL||TREATMENT||NONE||This is a phase I, open-label, dose-escalation, multi-center study in pediatric patients 12 months through 21 years of age with GPC3 expressing extra-cranial solid tumors.||||
33724559|NCT05524181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to intervention or control group||||
34033050|NCT03772717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033051|NCT04827498|||COHORT||PROSPECTIVE|||||||
34033052|NCT04040556|||COHORT||PROSPECTIVE|||||||
34033053|NCT06188221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To make this a double-blind study, the medical assistant will put a piece of tape around the syringe to cover up the volume.|Patients will be randomized in two groups for the corticosteroid injection, one group with lidocaine and one group without lidocaine.|t|t|f|f
34033054|NCT03646994|||COHORT||RETROSPECTIVE|||||||
34033055|NCT02531529|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34033056|NCT04115215|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators performing the follow-up assessments will be blind to randomization. In light of the difficulty to guarantee a complete blinding, these investigators will record if blinding is disclosed by participants during the interview.||t|f|f|t
34033057|NCT03390335|NA|SEQUENTIAL||PREVENTION||NONE||This design is a two factor, incomplete block design - three altitudes (8,000, 10,000, and 12,000 feet) and 2 breathing gases (air, 35% O2-N2). The investigators expect to see 0 events in the combinations tested, calculated by the Bayesian Method. If the rate of events is larger than expected, the investigators will use logistic regression to assess if the main effect Air (Air vs. 35% O2-N2) or altitude (8,000, 10,000 or 12,000 feet) or the interaction of these 2 factors imparts relative increased risk. The investigators will set a Type-I error rate of 0.05 (two-tailed).In the presence of 'zero cells', the investigators will either (1) collapse cells into reasonable groups, or (2) add a very small set of constants to the frequency and assess the impact on the effect sizes and tests of significance.1 In the absence of an interaction effect, main effects will be reported.||||
34033058|NCT02277535|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34033059|NCT01458353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34033060|NCT04060056|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34033061|NCT06281951|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033062|NCT00344448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033063|NCT02439216|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34033064|NCT02102854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033065|NCT06404918|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patients and Care Provider in this trial were blinded|Group I (35 patients): patients received US ESPB and group II (35 patients): patients received USAPB.|t|t|f|f
34033066|NCT05894837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152432|NCT04314076|RANDOMIZED|PARALLEL||OTHER||SINGLE|A blinded examiner will be used to perform the gait analysis, 6 minute walk , and timed 25 foot walk|a single blind parallel-group pilot randomized controlled trial comparing rhythmic auditory stimulation (RAS) with gait training to gait training without RAS.|f|f|f|t
33724560|NCT03988491|||COHORT||PROSPECTIVE|||||||
33724561|NCT01764568|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33724562|NCT01262781|||COHORT||PROSPECTIVE|||||||
33724563|NCT05754151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|All participants will receive the same intervention. Therefore, no masking is required.|||||
34152433|NCT02408523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152434|NCT05515939|||COHORT||PROSPECTIVE|||||||
34152435|NCT05890196|||CASE_ONLY||PROSPECTIVE|||||||
34152436|NCT02214043|||COHORT||PROSPECTIVE|||||||
34152437|NCT00820222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152438|NCT06191107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152439|NCT02175914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152440|NCT04088110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152441|NCT04464096|||CASE_ONLY||PROSPECTIVE|||||||
34152442|NCT05141604|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152443|NCT03969017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152444|NCT00556413|NA|SINGLE_GROUP||TREATMENT||||||||
33724564|NCT02013713|||COHORT||PROSPECTIVE|||||||
33724565|NCT01353417|||COHORT||PROSPECTIVE|||||||
33724566|NCT04495127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724567|NCT01883687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724568|NCT05945277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724569|NCT04528979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724570|NCT04007861|||CASE_CONTROL||RETROSPECTIVE|||||||
33724571|NCT04000048|||CASE_ONLY||OTHER|||||||
33724572|NCT00002007||||TREATMENT||||||||
33724573|NCT03204981|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724574|NCT01747109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724575|NCT03632187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multicenter double blinded randomized placebo controlled trial|t|f|t|f
33724576|NCT05078164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724577|NCT01116258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724578|NCT04445428|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are cluster randomised to OPV or no vaccine. Information on group assignment is not available to health center staff and staff at the health and demographic surveillance system||f|t|f|t
33724579|NCT04483713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724580|NCT00673179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724581|NCT01995084|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724582|NCT01474044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033067|NCT04256915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||For both treatment groups, the intervention will consist of 6 weekly sessions of cognitive behavioural therapy for insomnia (CBT-I) (90-min, 3-6 adolescents in each group). Participants in both groups will be also instructed to undergo morning light therapy (by wearing Re-timers) at home for 30 minutes daily. Re-timers can be worn like a pair of glasses, with 2 light-emitting diodes (LEDs) per eye. The following two conditions will be delivered by Re-timers: participants in the CBT-I group will receive a placebo light intervention where they will be exposed to dim red light (50lux), whereas participants in the CBT-I plus light therapy group will receive the active light treatment, with 2 LEDs emitting constant diffused blue-green light (500 nm, 506 lux).|t|f|f|t
33806580|NCT05485116|||COHORT||OTHER|||||||
34033068|NCT05977023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033069|NCT03024788|||COHORT||PROSPECTIVE|||||||
34033070|NCT05134415|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded to the specific tobacco or menthol flavor variant used during each study period.||t|f|f|f
34107435|NCT04491175|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will be instructed that non-drug interventions are being evaluated for their impact on opioid use and pain with low back pain, and that they will be self-assessing pain and reporting use of prescribed and over-the-counter medications. Study staff will train them on the device or TENS units via a pre-made video, but investigators and outcomes assessors will not be informed of the study arm. An assessment for blinding will be administered at the end of the data collection for participants.||t|f|t|t
33806581|NCT05823818|||COHORT||PROSPECTIVE|||||||
33806582|NCT03703414|||COHORT||PROSPECTIVE|||||||
33806583|NCT04051060|||CASE_CONTROL||PROSPECTIVE|||||||
33806584|NCT06639997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33806585|NCT02063659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806586|NCT06120855|RANDOMIZED|PARALLEL||OTHER||NONE||This is a multicenter, pragmatic, open-labelled randomized controlled trial from baseline to 6-months follow-up. After 6 months, the control group is allowed to purchase cannabis in pharmacies, too, and the study design changes to a cohort-study.||||
33806587|NCT03937804|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806588|NCT04314375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806589|NCT06514391|NA|SINGLE_GROUP||TREATMENT||NONE||all patients recieved 4 inter-foraminal compressive single piece dental implants in the mandible, then milled bar was digitally constructed and cemented to 4 implants to support mandibular implant overdenture||||
33806590|NCT03440996|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Three groups of 30 subjects (one group with Clinpro™ 5000, one group with MI-Paste Plus, and one group with Clinpro™ Tooth Crème) each will be evaluated as a protocol for the reduction of white spot lesions at the start of orthodontic treatment. Subjects will be recruited through the Orthodontic Postgraduate Clinic at the University of Alabama at Birmingham School of Dentistry.|t|f|f|t
33806591|NCT01412606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806592|NCT04603508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806593|NCT01332175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033071|NCT04842760|||CASE_CONTROL||PROSPECTIVE|||||||
33806594|NCT02111096|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33806595|NCT06383572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806596|NCT05840887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical evaluations will be carried out by medical personnel not involved in treatment to ensure double-blinding|Parallel Assignment|t|f|f|t
33806597|NCT02091752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806598|NCT06699095|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial||||
33806599|NCT06555575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33806600|NCT02235298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806601|NCT00401479|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33806602|NCT06699121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806603|NCT04694937|||CASE_CONTROL||PROSPECTIVE|||||||
34033072|NCT04999657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033073|NCT05352750|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34033074|NCT04762004|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|The pain score was assessed by two blinded independent and trained coders on muted video tracks. Oxytocin analysis were performed by an external Lab, blinded to the conditions.|Crossover clinical trial with a repeated measures design. Each patient is assigned to a sequence of three treatments (maternal speech, maternal singing, and standard treatment).|f|f|f|t
34033075|NCT04402411|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033076|NCT00829725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033077|NCT06365528|RANDOMIZED|PARALLEL||OTHER||SINGLE|Prospective Randomized Open, Blinded End-point (PROBE Study)||f|f|f|t
34033078|NCT06582797|NA|SINGLE_GROUP||OTHER||NONE||||||
33806604|NCT04626206|||COHORT||PROSPECTIVE|||||||
33806605|NCT02739100|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806606|NCT00743574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806607|NCT03518866|||OTHER||PROSPECTIVE|||||||
34033079|NCT05627843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033080|NCT00842166|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033081|NCT03198338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Drugs that are not directly involved in the study are delivered to the practitioner without specific labeling of the drug to be used in the block. The practitioner, the patient, and the observer all undergo TAP block without knowing which group the patient belongs to.|Randomized Double Blind study|t|t|t|t
34033082|NCT02528773|||COHORT||PROSPECTIVE|||||||
34033083|NCT02593617|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34033084|NCT06405035|||CASE_ONLY||PROSPECTIVE|||||||
34033085|NCT02521415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033086|NCT05048329|NA|SINGLE_GROUP||OTHER||NONE||||||
33724583|NCT05190198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724584|NCT04824170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724585|NCT05719805|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724586|NCT04482504|||COHORT||PROSPECTIVE|||||||
33724587|NCT01154309|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724588|NCT03424265|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33724589|NCT03365700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724590|NCT02149927|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033087|NCT05015829|||COHORT||PROSPECTIVE|||||||
34033088|NCT00038077|RANDOMIZED|||TREATMENT||DOUBLE||||||
34033089|NCT01957514|||CASE_ONLY||PROSPECTIVE|||||||
34033090|NCT00577863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033091|NCT05024825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107436|NCT01337661|||CASE_ONLY||PROSPECTIVE|||||||
34107437|NCT00622206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724591|NCT05287633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||the objective is to evaluate the interest of proton pump inhibitors in subjects with or without GI symptoms who intend to observe fasting in Ramadan. We will compare the effectiveness of proton pump inhibitors to prevent or reduce the signs of dyspepsia during at least Ramadan as compared to placebo.|t|t|f|f
34033092|NCT02493660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033093|NCT03623191|||CASE_ONLY||PROSPECTIVE|||||||
34033094|NCT05913544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033095|NCT02462863|NA|SINGLE_GROUP||TREATMENT||NONE||subjects will take arginine 4.5 grams BID plus Fish Oil 7 grams daily||||
34033096|NCT04442399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
34033097|NCT05902338|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033098|NCT04151680|||CASE_CONTROL||PROSPECTIVE|||||||
34033099|NCT03561038|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34033100|NCT02750137|||CASE_ONLY|||||||||
34033101|NCT00690066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033102|NCT02665156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033103|NCT03263676|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34033104|NCT06582199|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033105|NCT02253004|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34033106|NCT01772043|||COHORT||PROSPECTIVE|||||||
34033107|NCT02299323|||CASE_ONLY||PROSPECTIVE|||||||
34033108|NCT04477291|NA|SEQUENTIAL||TREATMENT||NONE||||||
34033109|NCT04875351|||CASE_ONLY||PROSPECTIVE|||||||
34033110|NCT03135717|||COHORT||CROSS_SECTIONAL|||||||
34033111|NCT02072980|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33724592|NCT00177970|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33724593|NCT06432179|||CASE_ONLY||PROSPECTIVE|||||||
33724594|NCT01147861|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33724595|NCT00005828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033112|NCT05087225|||CASE_ONLY||RETROSPECTIVE|||||||
34033113|NCT00404287|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033114|NCT00786214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033115|NCT02038257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033116|NCT01001754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033117|NCT03251170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033118|NCT01268410|||COHORT||PROSPECTIVE|||||||
34033119|NCT01392963|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34033120|NCT05451524|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Assessors and statisticians, participants will be masked to group allocation.||t|f|f|t
34033121|NCT03517501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033122|NCT04864028|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033123|NCT00682812|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033124|NCT04606160|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033125|NCT03633825|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34107438|NCT01416831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107439|NCT02771327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107440|NCT02007161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34107441|NCT06305390|||COHORT||PROSPECTIVE|||||||
34107442|NCT06549985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107443|NCT05700617|RANDOMIZED|CROSSOVER||TREATMENT||NONE||prospective, observational, crossover||||
34107444|NCT04635280|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34107445|NCT02559856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107446|NCT05435157|||CASE_CONTROL||PROSPECTIVE|||||||
34107447|NCT00322218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033126|NCT02135614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033127|NCT00799058|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Potential participants who provide inform consent will be invited to screen for the trial. All participants who consent to participate in the trial and meet specified inclusion/exclusion criteria will be invited to enrol. At enrolment women will be randomly assigned in a 1:1:1 ratio to one of three groups.|All enrolled participants will apply gel on a daily basis for 12 weeks, with clinical follow-up visits at weeks 2,4,8 and 12 to monitor safety and acceptability, and a final visit 4 weeks post gel discontinuation (Visit 6, week 16) Dapivirine concentration will be measured in blood and vaginal fluid and cervical tissue.|t|f|t|f
34033128|NCT01867528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107448|NCT06564727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||study the effect of a treatment and evaluate outcome postoperatively|f|f|t|f
34107449|NCT00450840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34107450|NCT01586910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107451|NCT06062355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107452|NCT06675747|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33806608|NCT04870775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806609|NCT03478969|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806610|NCT03925506|||CASE_ONLY||CROSS_SECTIONAL|||||||
33806611|NCT05033522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator and subjects will be informed of the treatment group to which the subject has been randomized.|Subjects are randomized 2:1 to experimental vs physician's choice. A two-sided logrank test with an overall sample size of 130 subjects (43 in the control group and 87 in the treatment group) achieves 80% power to detect at a 0.05 significance level a hazard ratio of 0.56 when the control group median survival is 6.5 months. A total of 150 subjects are planned to be accrued.|f|f|f|t
34033129|NCT02691325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34033130|NCT01392846|||COHORT||PROSPECTIVE|||||||
34033131|NCT04443972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033132|NCT03888742|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033133|NCT04183621|||COHORT||PROSPECTIVE|||||||
34033134|NCT05781256|||OTHER||CROSS_SECTIONAL|||||||
34033135|NCT06361927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033136|NCT03708094|||COHORT||PROSPECTIVE|||||||
34033137|NCT00908635|||COHORT||PROSPECTIVE|||||||
34033138|NCT03594071|||CASE_ONLY||RETROSPECTIVE|||||||
34033139|NCT03171376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34033140|NCT01860235|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34033141|NCT05365802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
34033142|NCT04359589|||COHORT||PROSPECTIVE|||||||
34033143|NCT00974922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107453|NCT05713110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107454|NCT04762927|||COHORT||PROSPECTIVE|||||||
34107455|NCT01277198|||CASE_CONTROL||RETROSPECTIVE|||||||
34107456|NCT05589597|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multi-cohort||||
34107457|NCT06641544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107458|NCT06186284|NA|SINGLE_GROUP||SCREENING||NONE||cohort study||||
34107459|NCT06642792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107460|NCT04275518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107461|NCT06673810|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34107462|NCT05841771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107463|NCT06499350|NA|SINGLE_GROUP||TREATMENT||NONE||FC084CSA in combination with Tislelizumab||||
34107464|NCT06639945|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34107465|NCT06563596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107466|NCT05080790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107467|NCT01225224|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34107468|NCT03410745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34107469|NCT01203137|||COHORT||PROSPECTIVE|||||||
34107470|NCT04925375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects ≥50 kg (cohort 1), with an additional cohort (#2) of pediatric subjects \<50 kg tested as a single arm, receiving open-label abatacept|t|t|t|t
34107471|NCT06644963|||COHORT||RETROSPECTIVE|||||||
34107472|NCT05703126|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34107473|NCT03235986|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part I is an ascending dose scheme of IMP versus nCPAP alone. Part II is a parallel group with 2 doses of IMP versus nCPAP alone. In part II, one additional dose may be administered between 3 and 12 hours after the start of the first dose.||||
34107474|NCT05442047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107475|NCT05032222|||OTHER||OTHER|||||||
34107476|NCT01687062|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34107477|NCT05202587|||COHORT||PROSPECTIVE|||||||
33806612|NCT03759249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033144|NCT01901926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033145|NCT03595956|||COHORT||PROSPECTIVE|||||||
34033146|NCT05237323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033147|NCT02636218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033148|NCT01184430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033149|NCT02807337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34033150|NCT01026246|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34033151|NCT02235454|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34033152|NCT01147068|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34033153|NCT02115490|||CASE_CONTROL||PROSPECTIVE|||||||
34033154|NCT04563936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033155|NCT00484068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033156|NCT01377220|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033157|NCT04166201|NA|SINGLE_GROUP||TREATMENT||NONE||22 patients with Incisional Hernia of Midline of the abdomen underwent hernioplasty by double mesh modification of Chevrel's technique follow up carried out for around 2 years for hernia recurrence pain early and late postoperative complications||||
34033158|NCT03168282|||OTHER||CROSS_SECTIONAL|||||||
34033159|NCT01588288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033160|NCT05183880|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34033161|NCT00425321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033162|NCT06328933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033163|NCT03505073|||COHORT||PROSPECTIVE|||||||
34033164|NCT00023413|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033165|NCT03917251|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34033166|NCT04222868|||COHORT||PROSPECTIVE|||||||
34033167|NCT04835857|||COHORT||PROSPECTIVE|||||||
34033168|NCT01414673|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34033169|NCT01907230|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033170|NCT05836714|||COHORT||PROSPECTIVE|||||||
34033171|NCT06499675|||CASE_ONLY||PROSPECTIVE|||||||
34033172|NCT02738138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033173|NCT05191485|||CASE_CROSSOVER||PROSPECTIVE|||||||
34033174|NCT02224989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033175|NCT01674218|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34033176|NCT04789993|||COHORT||RETROSPECTIVE|||||||
34033177|NCT00714194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033178|NCT00003080||||TREATMENT||||||||
34033179|NCT01555346|||CASE_ONLY||PROSPECTIVE|||||||
34033180|NCT01891630|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34033181|NCT06470191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033182|NCT00295997||||TREATMENT||NONE||||||
34033183|NCT05122169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34033184|NCT04206917|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Cardialen External Stimulation System (CESS) V1.0||||
34033185|NCT02063750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033186|NCT03170934|||CASE_ONLY||PROSPECTIVE|||||||
34033187|NCT00805324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033188|NCT01095302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033189|NCT05460702|||CASE_CONTROL||PROSPECTIVE|||||||
34033190|NCT03520556|||OTHER||PROSPECTIVE|||||||
34033191|NCT05681598|NA|SINGLE_GROUP||TREATMENT||NONE||all eligible patients received during the study period were included and received treatment.||||
34033192|NCT03346096|NA|SINGLE_GROUP||TREATMENT||NONE||TEAM conditioning consisted of THIOTEPA 5mg/kg on days -7-6, etoposide 200 mg/m2 , Cytosar (ARA-C) 200 mg/m2 on days -5,-4, -3, -2 and melphalan 140 mg/m2 on day -1 followed by autologous hematopoietic stem-cell transplantation as per standard institutional protocols.||||
34033193|NCT05675098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033194|NCT02134652|||||PROSPECTIVE|||||||
34033195|NCT02431377|NA|SINGLE_GROUP||||NONE||||||
34033196|NCT05623501|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-center dose-escalation study. A total of 12 participants are planned and will be divided into 4 cohorts with 3 participants per cohort. Cohort 1 will consist of three healthy volunteers who will receive DHM in two doses of 300 mg as liquid suspension. Cohort 2 will consist of three healthy volunteers who will receive DHM in two doses of 900 mg as liquid suspension. Cohort 3 will consist of three healthy volunteers who will receive DHM in two 50mL PO solution doses of 300 mg plus 140mg L-lysine. Cohort 4 will consist of three healthy volunteers who will receive DHM in two 50mL PO solution doses of 900 mg plus 420mg L-lysine. Each participant will be administered the study drug during a 24-hour period, requiring two consecutive days of visits to research clinic. Evaluations will be taken at uniform intervals.||||
34033197|NCT06193616|||COHORT||RETROSPECTIVE|||||||
34033198|NCT03333941|||COHORT||PROSPECTIVE|||||||
33806613|NCT06687226|NA|SINGLE_GROUP||OTHER||NONE||||||
33806614|NCT05716113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806615|NCT02533232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806616|NCT03568409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033199|NCT03194269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033200|NCT00307398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033201|NCT04099004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033202|NCT05091970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033203|NCT06032078|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||15 patients with keratosis pilaris (including subtypes) are recruited||||
34033204|NCT02710721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34033205|NCT06227767|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups of exercise and a control group||||
34033206|NCT04763629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033207|NCT05778812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033208|NCT03856801|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34033209|NCT01742897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033210|NCT01521650|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033211|NCT05291338|||COHORT||PROSPECTIVE|||||||
34033212|NCT00254709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033213|NCT05855603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033214|NCT03980652|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Randomisation is at the hospital level and hospitals will be randomised to the intervention (of separating sterile surgical instruments and gloves at the time of wound closure). Patients will not be made aware of the hospital/theatre randomisation, as patients would also not be aware of the specifics of any operation|Cluster randomised controlled trial|t|f|f|f
34033215|NCT01256879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34033216|NCT04996979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient, nurses and CRC will be blinded. Rest of study team is not blinded.||t|f|f|t
34033217|NCT03284723|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34033218|NCT05355870|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34033219|NCT01596790|NA|SINGLE_GROUP||OTHER||NONE||||||
34033220|NCT01398046|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34033221|NCT02297997|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033222|NCT04618731|||COHORT||CROSS_SECTIONAL|||||||
34033223|NCT02535689|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34033224|NCT03271684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded, participant and assessor blinded, randomised trial.||t|f|f|t
34033225|NCT00629018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033226|NCT02079597|||CASE_CONTROL||PROSPECTIVE|||||||
34033227|NCT04507295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033228|NCT02297399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34033229|NCT04942678|||COHORT||CROSS_SECTIONAL|||||||
34107478|NCT04148911|NA|SINGLE_GROUP||TREATMENT||NONE|Open label, non-blinded|This is an open-label (non-blinded), single arm safety study in which all participants will receive atezolizumab in combination with nab-paclitaxel.||||
34152445|NCT06203418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724596|NCT01505608|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724597|NCT00745992|||COHORT||PROSPECTIVE|||||||
33724598|NCT01483079|||COHORT||PROSPECTIVE|||||||
33724599|NCT01623323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724600|NCT02356692|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34152446|NCT02421679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152447|NCT03891368|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34152448|NCT02045693|NON_RANDOMIZED|PARALLEL||||NONE||||||
34152449|NCT02882100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34152450|NCT00005859|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34152451|NCT04680949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind trial|The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 over 28 days as measured by the ordinal scale of the 11-point WHO clinical progression scale (CPS).|t|t|t|t
34152452|NCT04325230|NA|SINGLE_GROUP||OTHER||NONE||||||
34152453|NCT03807284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor was masked to the intervention until the outcomes were complete.|A parallel group two arm feasiblity randomised controlled trial with 1:1 allocation in a single centre, comparing eleven week RCAS Course in addition to usual care, to usual care alone.|f|f|f|t
34152454|NCT04691856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, Randomized, Placebo-Controlled Clinical Trial|t|f|t|f
34152455|NCT03529279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152456|NCT00367276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152457|NCT04514211|||CASE_CONTROL||PROSPECTIVE|||||||
34152458|NCT00156169|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34152459|NCT02924740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152460|NCT02968628|||CASE_CONTROL||PROSPECTIVE|||||||
34152461|NCT02934711|||OTHER||PROSPECTIVE|||||||
34152462|NCT04306653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152463|NCT04463667|NA|SINGLE_GROUP||OTHER||NONE||The investigators will collect all basic information including intrahepatic fat and fibrosis severity, and assign them to the exercise intervention group (n = 80) and the observation group (n = 20) after conditional screening.||||
34152464|NCT06171646|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34152465|NCT04878913|||COHORT||RETROSPECTIVE|||||||
34152466|NCT05061498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152467|NCT04094675|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label pilot trial||||
34152468|NCT00837759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152469|NCT03728179|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34152470|NCT00245648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152471|NCT02762331|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34152472|NCT03905902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|parallel-group, placebo-controlled|t|t|t|t
34152473|NCT06264258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The investigators propose to conduct a longitudinal randomized controlled trial (RCT) over a 3-month period with a study population of 80 participants (40 in each arm) of 6-12 years old youth with type 1 diabetes (T1D).The investigators will quantify the impact of the mobile game app vs. standard care on T1D control (assessed by glycosylated hemoglobin or HbA1c measured during clinic visits and continuous glucose monitoring (CGM) parameters), physical activity levels and food choices of children (measured using food logs and surveys).~The study will also assess changes in children's knowledge about the measured outcomes and investigate the feasibility and acceptability of game adoption and the barriers and challenges faced by patients, families and clinicians."||||
34152474|NCT02687698|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152475|NCT02915913|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34152476|NCT05683002|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Block Randomization||t|f|t|t
34152477|NCT01254825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152478|NCT01074983|||COHORT||PROSPECTIVE|||||||
34152479|NCT03903887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107479|NCT05294146|NA|SEQUENTIAL||OTHER||NONE||All participants will receive a loading dose regimen of 300 mg clofazimine (CFZ) once daily for 4 weeks and will then continue with a standard dose of 100 mg CFZ once daily until a total 4 months of treatment with CFZ.||||
34107480|NCT06644001|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A prospective, interventional, randomized, double-blind, parallel, placebo-controlled clinical study. Eligible subjects were randomized at a ratio of 1:1 to receive Bacillus coagulans or placebo once daily for 28 days.|t|t|t|t
34107481|NCT06644495|||COHORT||OTHER|||||||
34107482|NCT06073119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107483|NCT00380146|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34107484|NCT05878093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107485|NCT04437745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107486|NCT03527979|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34107487|NCT01254929|||COHORT||PROSPECTIVE|||||||
34107488|NCT06192966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Probiotic and placebo products will be provided in identical packaging|Double-blind, randomized, placebo controlled trial|t|t|t|t
34107489|NCT06458998|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107490|NCT02832531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107491|NCT04379921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107492|NCT05440565|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34107493|NCT06638944|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107494|NCT06437457|||CASE_ONLY||RETROSPECTIVE|||||||
34107495|NCT04342546|NA|SINGLE_GROUP||OTHER||NONE||For all the patients, the NovaGray RILA Breast® test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy.||||
34107496|NCT02928835|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34107497|NCT06674889|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107498|NCT02256033|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107499|NCT06636994|||CASE_ONLY||CROSS_SECTIONAL|||||||
34107500|NCT00692328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34107501|NCT04650893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patients will be masked from which cohort they were randomized into.|25 patients into 3 separate arms.|t|f|f|f
34107502|NCT04516213|NA|SINGLE_GROUP||OTHER||NONE||||||
34107503|NCT06571474|||COHORT||CROSS_SECTIONAL|||||||
34107504|NCT03761641|||OTHER||PROSPECTIVE|||||||
34107505|NCT03288857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107506|NCT06639204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107507|NCT03093415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two parallel investigational groups in different community health clinic treatment settings assigned to treatment with elbasvir-grazoprevir as compared to an academic hepatology clinic retrospective cohort treated with elbasvir-grazoprevir.||||
34107508|NCT05725434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107509|NCT05215626|||COHORT||RETROSPECTIVE|||||||
34107510|NCT06292507|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34107511|NCT05272605|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34107512|NCT04833738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107513|NCT06570382|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34107514|NCT02302222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107515|NCT03079778|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized to radiation (RT) or TACE plus RT (TACERT)||||
34107516|NCT06638723|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were randomized to experience one of the two conditions (amputee peers vs. non-amputees) demonstrating how to perform motor tasks. Participants were masked to the study hypothesis and the existence of the other group.|The same group of participants will experience the two conditions, separated by a 4-week washout period. The initial condition is randomly decided.|t|f|f|f
34107517|NCT05932914|||COHORT||PROSPECTIVE|||||||
34107518|NCT00408174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34107519|NCT05543174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107520|NCT04875754|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"* Group 1: ICM-203 6x10e12 vg or Placebo~* Group 2: ICM-203 2x10e13 vg or Placebo~* Group 3: ICM-203 6x10e13 vg or Placebo (Optional)"|t|t|t|t
34107521|NCT03757949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34107522|NCT04658680|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants live in the catchment areas of one of 23 HFs. The HFs will be randomized to either BCG vaccination per usual practice or to extended BCG availability. The randomization of HFs will be crossed over after 12 months.||||
34107523|NCT02192476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107524|NCT03412591|NA|SINGLE_GROUP||TREATMENT||NONE||We intend to evaluate the efficacy of suvorexant in a group of opioid dependent (n=14) and a group of alcohol dependent subjects (n=14) in a residential treatment facility. It is an open label trial on subjects with opioid or alcohol dependence who are 5to 10 days post withdrawal.||||
34107525|NCT05501522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107526|NCT01601561|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34107527|NCT05692011|||COHORT||PROSPECTIVE|||||||
34107528|NCT05887336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pivotal, double-blind, randomized, multicentre study.|t|t|t|t
34107529|NCT06564987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107530|NCT06183567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study was double-blinded, patients were selected by closed envelope method, and different clinicians administered anesthesia and postoperative follow-up.|Patients were divided into two groups as sedoanalgesia group (SA=31 patients) and general anesthesia group (GA=31 patients).|t|f|t|f
34107531|NCT01821872|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34107532|NCT06637280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||randomised, prospective|t|f|f|t
34107533|NCT05832047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34107534|NCT06640842|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34152480|NCT05113992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||1. Intervention group 2. Placebo group 3. Control group. a randomized controlled study|t|f|f|f
34152481|NCT01081743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152482|NCT01531751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107535|NCT06561126|RANDOMIZED|PARALLEL||PREVENTION||NONE|Non-applicable|"The most commonly 2 armed parallel study design would be used to conduct the current study. The 72 cluster will be randomly allocated to one of the two arms. In the rural settings of Pakistan, two districts of the Khyber Pakhtunkhwa province which includes Peshawar and Swabi have been selected. From each cluster, groups will be formed based on the average population size of 1500 per cluster. This ensures the inclusion of diverse settings for a comprehensive study~The study sites will be selected in a manner that the risk of possible contamination between control and intervention groups is avoided. The intervention group will receive the PLA intervention, while the control arm will only go through assessments i.e., at baseline and end of study."||||
34107536|NCT01094327|||OTHER||RETROSPECTIVE|||||||
34107537|NCT00751985|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107538|NCT04305756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107539|NCT01644591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107540|NCT05479227|||COHORT||RETROSPECTIVE|||||||
34107541|NCT01182246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107542|NCT05548361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107543|NCT06088914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107544|NCT04347538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled will be randomized to one of three treatment groups (1. control- no intervention, 2. intervention 1 - nasal saline irrigations BID, 3. intervention 2- nasal saline irrigations with ½ teaspoon surfactant (Johnson's baby shampoo) BID).||||
34107545|NCT02593214|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34107546|NCT06638957|||COHORT||RETROSPECTIVE|||||||
34107547|NCT06637267|||COHORT||PROSPECTIVE|||||||
34107548|NCT06636851|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34107549|NCT06570070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107550|NCT04498767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107551|NCT06643013|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34107552|NCT00962338|||OTHER||PROSPECTIVE|||||||
34107553|NCT06641934|||COHORT||RETROSPECTIVE|||||||
34107554|NCT06328569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34107555|NCT06405581|||COHORT||PROSPECTIVE|||||||
34107556|NCT01344655|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33806617|NCT03901781|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This clinical trial is a dose escalating design in three (3) cohorts of three (3) subjects per Cohort. In the first cohort, subjects will be administered ST266, delivered intranasally, at a dose of two hundred microliters (200 µL) daily for 14 days, in alternating single nostrils. After 14 daily treatments there is a seven (7)-day follow-up period. If there are no SAEs and no pattern of concern in the AE's, the Investigator may proceed to the second cohort of three (3) subjects. In Cohort Two, three (3) subjects will be administered 200 µL to each nostril daily (400 µL total per day) for 14 days. There will be a seven (7)-day follow-up. Like Cohort One, if there are no safety concerns, the investigator may move on to the third cohort of three (3) subjects. In Cohort Three, three (3) subjects will be administered 200 µL to each nostril daily (400 µL total per day) for 28 days.||||
33806618|NCT03632876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects in parallel groups will be randomized to one of two doses of vitamin A supplementation.|t|t|t|t
33806619|NCT03387254|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33806620|NCT03865875|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33806621|NCT06114069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The patients were classified into 2 groups:~1. Group I; 4 patients received 4-implant supported fixed prosthesis.~2. Group II; 4 patients received 6-implant supported fixed prosthesis."|t|f|f|f
33806622|NCT02073500|||COHORT||PROSPECTIVE|||||||
34107557|NCT06501976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107558|NCT06644521|||CASE_CONTROL||PROSPECTIVE|||||||
34107559|NCT01327729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107560|NCT06569446|||OTHER||PROSPECTIVE|||||||
34107561|NCT05559385|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Randomized Controlled (One group received Robotic Rehabilitation, other group received conventional rehabilitation)||||
34107562|NCT03590548|||CASE_ONLY||OTHER|||||||
34107563|NCT05811832|||COHORT||OTHER|||||||
34107564|NCT03676270|||OTHER||RETROSPECTIVE|||||||
34107565|NCT04114825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107566|NCT06669702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Random allocation into either a control group or an exercise group (12-weeks of home based exercise).||||
34107567|NCT03436849|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34107568|NCT06046378|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34107569|NCT00087035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107570|NCT02034565|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34107571|NCT05379946|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107572|NCT06346119|RANDOMIZED|PARALLEL||OTHER||SINGLE|It's a person external to the care service and to the randomization process will collect the possible prescription of a chemical restraint or the evolution of this chemical restraint by the resuscitator, in order to maintain the blind.|"This study will be conducted in two parallel groups. At the inclusion, each patient will be assigned to one of two groups by randomization; one group will receive the touch and the second group will not receive it will be the control arm."|f|f|f|t
34107573|NCT06671626|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107574|NCT04464538|RANDOMIZED|PARALLEL||OTHER||NONE||Unblinded, single-centre randomized feasibility study||||
34107575|NCT05902975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107576|NCT05040932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107577|NCT05912400|||CASE_CONTROL||PROSPECTIVE|||||||
34107578|NCT01854762|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot randomized single-center open label clinical trial||||
34107579|NCT03875443|||COHORT||PROSPECTIVE|||||||
34107580|NCT06628960|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double blind|randomized controlled trial|t|t|t|t
34107581|NCT02333292|||COHORT||PROSPECTIVE|||||||
34107582|NCT03775109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107583|NCT01610401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107584|NCT01257243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107585|NCT05064423|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33724601|NCT01544751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724602|NCT06449963|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There are no additional masked parties in this clinical trial.|This study uses a parallel assignment model where participants are randomly assigned to either the intervention group or the control group. The intervention group will receive the Health Belief Model (HBM)-based education program, while the control group will receive no education. The purpose is to compare the effectiveness of the HBM-based education program on increasing daily water consumption among elderly individuals.||||
33724603|NCT01464346|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33724604|NCT04422028|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33724605|NCT05749042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724606|NCT01632202|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33724607|NCT02162290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724608|NCT00316979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33806623|NCT06100198|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033230|NCT06488534|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Both the investigator and the participants will be blinded, which means that they will not know which of the 3 FODMAPs is administered|Mannitol, fructans and fructose will be intracolonically administered on 3 different intervestigation days with at least 2 weeks between each investigation day to avoid overlap of the different FODMAPs and to allow the colon to return to its original state|t|f|t|f
34033231|NCT03706482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033232|NCT00062530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033233|NCT00505830|||DEFINED_POPULATION||PROSPECTIVE|||||||
34033234|NCT05081050|||COHORT||PROSPECTIVE|||||||
34033235|NCT02850692|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033236|NCT05084924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This study is designed to be double-blind. Participants and the researchers are unaware of each participant's assignment until the completion of all data collection. This is accomplished using randomization codes. Furthermore, this study utilizes an active sham stimulation. This means that the active sham condition includes some stimulation, mimicking the skin sensations associated with tACS. In a previously concluded trial, participants in the delta-beta tACS, theta-gamma tACS, and active sham groups responded similarly to the blinding questionnaire, indicating that the active sham stimulation successfully blinded the participants.|Participants are randomized into one of three arms of the study: delta-beta tACS, control tACS in theta-gamma, or active sham. Randomization is stratified by SHAPS level such that there are an equal number of participants that are high anhedonia (SHAPS \> 33) and low anhedonia (SHAPS \<=33).|t|f|t|f
33806624|NCT03542305|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33806625|NCT01898754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806626|NCT00325000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806627|NCT00933270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033237|NCT04650594|NA|SINGLE_GROUP||OTHER||NONE||||||
34033238|NCT04654793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033239|NCT00154154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033240|NCT02185339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34033241|NCT04385537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033242|NCT01549405|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34033243|NCT02635984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34033244|NCT02271295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033245|NCT00282529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033246|NCT02929888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033247|NCT04921917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is partially blinded. The wound surveyor and statistician(s) will be blinded to the treatment groups.||f|f|f|t
34033248|NCT00145951|||||PROSPECTIVE|||||||
34033249|NCT00549575|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033250|NCT01936350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033251|NCT01373138|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033252|NCT00763633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34033253|NCT03667638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033254|NCT05489302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033255|NCT00825786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107586|NCT00434811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107587|NCT06305403|||COHORT||PROSPECTIVE|||||||
34107588|NCT04427670|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT with intervention having experimental group. random Allocation of participants.|t|f|f|f
34107589|NCT05494619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724609|NCT02865993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33724610|NCT03446287|||CASE_CONTROL||PROSPECTIVE|||||||
33724611|NCT03524807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724612|NCT06315699|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34107590|NCT06629961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724613|NCT02515045|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724614|NCT02206555|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724615|NCT03774589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724616|NCT01536314|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724617|NCT03580850|||COHORT||RETROSPECTIVE|||||||
33724618|NCT00433823|RANDOMIZED|CROSSOVER||||NONE||||||
33724619|NCT02496247|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724620|NCT00634088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724621|NCT02945176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724622|NCT02060695|||CASE_ONLY||PROSPECTIVE|||||||
33724623|NCT01062555|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724624|NCT01042704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724625|NCT00945581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033256|NCT03778138|NA|SINGLE_GROUP||TREATMENT||NONE||Anlotinib and Pemetrexed||||
34033257|NCT03209089|||COHORT||OTHER|||||||
34033258|NCT01288963|||CASE_ONLY||PROSPECTIVE|||||||
34033259|NCT04012788|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033260|NCT04855968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107591|NCT05620134|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107592|NCT05798585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34107593|NCT03020316|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107594|NCT04839783|||COHORT||PROSPECTIVE|||||||
34107595|NCT06641804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107596|NCT06641583|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107597|NCT06127303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107598|NCT05358223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the design of the study, it is not possible for patients and specialists to be blinded.|Patients who applied to the urology outpatient clinic and whose prostate biopsy decision was made according to the criteria specified in the guidelines of the European Urology Society, firstly detailed information about the study will be given after excluding those who were not suitable for the study, and then they will be randomly divided into 5 groups with the help of a computer program.||||
34107599|NCT03078231|||CASE_ONLY||CROSS_SECTIONAL|||||||
34107600|NCT04684862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107601|NCT04758988|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"Participating doctors are either given access to an AI augmented digital educational online system or not. During the study period, doctors of both groups are registering skin lesions they encounter in their daily practice using the same hardware and software.~The expert dermatologists that evaluate the registered skin lesions are unaware of the registering doctors allocation."|A randomized superiority clinical trial. Participating doctors are randomized to either group A or B in a 1:1 ratio.|f|f|f|t
34107602|NCT03403790|||COHORT||PROSPECTIVE|||||||
34107603|NCT01040026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107604|NCT06644248|||CASE_CONTROL||RETROSPECTIVE|||||||
34107605|NCT00831883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34107606|NCT06459583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107607|NCT04098146|||CASE_CONTROL||PROSPECTIVE|||||||
34107608|NCT06477029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34107609|NCT02167126|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107610|NCT02624687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107611|NCT05475002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||two-group cluster randomised controlled trial|f|f|t|t
34107612|NCT01986023|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34107613|NCT05639725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107614|NCT03511287|NA|SINGLE_GROUP||TREATMENT||NONE||All patients from the advanced lung disease and pre lung transplantation ambulatory||||
34107615|NCT06281769|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34107616|NCT04759404|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals are randomly allocated into deep oscillation, myofascial relaxation and control groups||||
33724626|NCT03805932|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33724627|NCT06226779|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724628|NCT00402961|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806628|NCT05555628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients eligible to participate in the study will be assessed by a researcher who is blind to group assignment. The assessor will only see the patients during the evaluation. In this way, the masking of group assignment will be ensured.|"Patients in Groups I and II will be included in an exercise program that will last for 45 minutes, two days a week, for 6 weeks. All treatments will be carried out by a physiotherapist with more than 10 years of experience in the field. The patients will be treated independently from each other. The treatment protocols of the patients in exercise therapy group will be revised with 2-week controls, and their progress will be followed up with new exercises. Patients who do not come to two consequtive treatments to the treatment protocol will be excluded from the study.~Occlusal Splint Group; It will consist of two separate sessions, one week apart. It is aimed to eliminate possible incompatibilities by calling the patients for the control one week after the splints are delivered.~Assessments will be performed three times: prior to group assignment (baseline), immediately after the end of the treatment (week 6), and at the control of the 12th week."|f|f|f|t
33806629|NCT03874169|||COHORT||PROSPECTIVE|||||||
34033261|NCT03275142|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Only the Investigator will be interpreting outcomes. The technician/care provider will perform all testing and will mask the investigator to which eye tonometry was performed.||f|f|t|t
34033262|NCT01047254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033263|NCT03301649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033264|NCT06461000|||COHORT||PROSPECTIVE|||||||
34033265|NCT01867918|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033266|NCT02953119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033267|NCT02087657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107617|NCT06637761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple(Patients, radio-graphic outcome assessor(s), and statisticians) will be blinded in this study.~Blinding to participant: will not know either the intervention or the comparative will be applied to their teeth Blinding to outcome assessor: to overcome detection bias Blinding to statisticians: to overcome bias"||t|f|t|t
34107618|NCT05949892|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Students in the control group will be masked from any form of the proposed intervention arms.||t|f|f|f
34107619|NCT00057512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107620|NCT06674174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107621|NCT06349837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107622|NCT03075228|||COHORT||CROSS_SECTIONAL|||||||
34107623|NCT02694263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724629|NCT03389009|||OTHER||CROSS_SECTIONAL|||||||
33724630|NCT05004155|||COHORT||PROSPECTIVE|||||||
33724631|NCT00133874|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33724632|NCT03142412|||COHORT||PROSPECTIVE|||||||
33724633|NCT04599296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treating surgeon, who is also the PI, will be blind to randomization.|Patients randomized to wearing a hip brace after surgery 36 Patients randomized to not wearing a hip brace after surgery 36|f|t|t|t
33724634|NCT06421389|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724635|NCT04220372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724636|NCT04612647|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34107624|NCT00463411|||NATURAL_HISTORY||PROSPECTIVE|||||||
34107625|NCT04030650|||OTHER||PROSPECTIVE|||||||
34107626|NCT06642181|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34107627|NCT06511648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107628|NCT03135067|RANDOMIZED|PARALLEL||PREVENTION||NONE||Female sex worker hotspots and beach communities in the Nyanza region of Kenya will be grouped into clusters that will be randomly assigned to receive the intervention (provision of multiple HIV self-test kits over time) or control (provision of clinic-based HIV testing referral vouchers over time). About 66 clusters, with an average of 30 participants per cluster, will be selected for the study.||||
34107629|NCT02367885|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34107630|NCT06629740|RANDOMIZED|PARALLEL||OTHER||NONE||"Subjects will be randomized into one of two arms for deciding upon which of the two medicines (phenethylamine or cannabinoid) to be administered through a single application at visit 2. The randomization will also take into account which one of three different smartphone brands with the Previct Drugs mobile phone application preinstalled to be used by the subject during the study.~The study aims to enroll 30 subjects, 12 subjects in the phenethylamine group and 18 subjects in the cannabinoid group. The dropout rate is estimated to 10%."||||
34107631|NCT01430715|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34107632|NCT02895984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34107633|NCT03653546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107634|NCT06294899|||OTHER||PROSPECTIVE|||||||
34107635|NCT06220318|NA|SINGLE_GROUP||TREATMENT||NONE||"DRUG: C019199~The C019199 will be taken orally, once a day~DRUG: Sintilimab~Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks."||||
34107636|NCT05001113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107637|NCT06570720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107638|NCT03828526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34107639|NCT06596525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to study groups|"The study will be conducted as a single-blind randomized controlled trial with 3 parallel arms, including 2 experimental groups and 1 control group. Participants will be randomized into 3 groups at the beginning of the study.~One arm (Group 1) will be sham comparator and will receive sham WBVT in addition to conventional physical therapy. The other two arms are the experimental groups. Group 2 will receive WBVT with footwear in addition to conventional physical therapy, and Group 3 will receive WBVT with barefoot in addition to conventional physical therapy.~Group 1:Conventional physical therapy (PT) + WBVTsh (sham)~Group 2: PT + WBVTs (shod)~Group 3: PT+ WBVTb (barefoot)"|f|f|f|t
34107640|NCT06638346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|All the participants are within the same soccer organization and therefore complete masking of participants to group allocation is not possible. Coaches will be aware of allocations given that they will need to supervise the groups and give appropriate feedback if required. The primary investigator will be implicated in all aspects of the study (recruitment, data collection, supervision of training sessions, analysis) and thus will be aware of group allocations. Other research members that will help with data collection procedures will not be aware of group allocations.|"\[Part1: Warm-up intervention\]: It will consist of a longitudinal and prospective study conducted as a 2-group parallel quasi-randomized controlled trial with a 1:1 allocation and two time points (baseline, after 12-weeks). Both groups will complete a 12-week warm-up program. Group allocation will be done in a quasi-randomized fashion (see study detailed description).~\[Part2: Footwear study\]: It will consist of a prospective, crossover design at one time point. All female participants will test both types of footwear (female-specific and unisex)."||||
34107641|NCT00609349|NA|SINGLE_GROUP||SCREENING||NONE||||||
34107642|NCT02759510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107643|NCT01450631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107644|NCT03792737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107645|NCT04724252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is a double-blind, placebo controlled, randomized study. Physician and families will be blinded to the randomization.|Children meeting criteria will be randomized in a 1:1 ratio using 4 blocked randomization to either gabapentin or placebo (in addition to standard of care pain control treatment):|t|f|t|f
34107646|NCT03657485|RANDOMIZED|PARALLEL||PREVENTION||NONE||The patients we recruited were randomized into 2 groups- interventional or control group. For comparison we examined the stool samples of 32 healthy newborns delivered vaginally||||
34107647|NCT06582732|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107648|NCT04211948|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107649|NCT05715762|||COHORT||PROSPECTIVE|||||||
34107650|NCT06463730|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107651|NCT04246749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107652|NCT05471128|||CASE_ONLY||PROSPECTIVE|||||||
34107653|NCT03213951|||CASE_ONLY||PROSPECTIVE|||||||
34107654|NCT04783571|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34107655|NCT00002515||||TREATMENT||||||||
34107656|NCT03713411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107657|NCT06643624|RANDOMIZED|PARALLEL||OTHER||SINGLE|the athletes participating in the study did not know which group they were in, whether the other group received the same training, or if they did, what kind of procedure was applied.|There are two groups: one group is the control group and the other is the vision training group, in which vision training is applied.|t|f|f|f
34107658|NCT05187650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to treatment allocation and study participants will be instructed not to talk to assessors about their treatment within the study.|assessor-blinded, exploratory, randomized controlled trial|f|f|f|t
34107659|NCT02839629|||COHORT||RETROSPECTIVE|||||||
34107660|NCT05535972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107661|NCT05129735|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label single-arm observational trial||||
34107662|NCT05544409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107663|NCT02584647|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107664|NCT06405529|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34107665|NCT00708981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107666|NCT04584008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107667|NCT03777020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033268|NCT04791137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not blind as to whether they are receiving an intervention or monitoring only, but otherwise are blind to the status of which intervention they are receiving, i.e. 'original' version of the imagery CBM or an attempted improvement. Researchers are not blind to participant allocations, but the study is planned to be mostly automated, reducing opportunities to influence participants. Researchers will monitor performance of the arms as data accumulates, via the sequential analyses, and will therefore not be blind to outcomes as the trial progresses.|The leapfrog trial design is a parallel-arm design in which participants and randomly allocated to one of several treatment arms on a 1:1:1... ratio. One trial arm is designated the comparison arm, and all other arms are compared to this comparison arm via sequential Bayesian analyses. Depending on the outcomes of the sequential analyses (based on reaching Bayes Factor thresholds for 'success' or 'failure', trial arms may be removed, or take the place of the comparison arm while the trial is ongoing, and new arms may also be introduced into an ongoing trial.|t|f|f|f
34033269|NCT04900181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34033270|NCT01169168|||COHORT||PROSPECTIVE|||||||
34033271|NCT03640338|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34033272|NCT00858273|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34033273|NCT00912938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033274|NCT04142086|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"An observer-blind procedure is followed for the injection of vYF or YF-VAX. Neither the observer Investigator, nor the Sponsor, nor the participants know product is administered. The vaccinator is in charge of preparing and administering the products and is not authorized to collect any safety data."||t|t|t|t
34033275|NCT00625820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033276|NCT02347059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033277|NCT02480101|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033278|NCT03182426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033279|NCT03888066|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective Phase 3b multinational, multicenter, double-blind, placebo-controlled, randomized withdrawal, parallel group study that includes screening and 12 weeks Run-in Phase and a randomized withdrawal Blinded Treatment Phase.|t|t|t|t
34033280|NCT06022068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033281|NCT06209840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34033282|NCT00333294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033283|NCT06582017|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open-label|Modified 3+3 design||||
34033284|NCT01444261|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033285|NCT06512792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||IBD patients meeting the inclusion criteria will be stratified and randomly assigned to either the intervention group or the control group. Participants in the intervention group will undergo remote healthcare management by the researchers through the WeChat platform, including the establishment of electronic health records, health management monitoring, risk warning and intervention, and health education. On the other hand, participants in the control group will receive no specific guidance and will only receive standard traditional treatment services (i.e., medication according to prescription and routine outpatient follow-ups).Colonoscopy will be required for endoscopic assessment at baseline and at the 12-month follow-up. Additionally, participants will be surveyed monthly for one year to assess the utilization of healthcare resources. At the baseline, 6-month, and 12-month visits, researchers will evaluate disease activity, quality of life , and healthcare resource utilization.|f|f|f|t
34033286|NCT05895201|NA|SEQUENTIAL||TREATMENT||NONE||||||
34033287|NCT01564537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033288|NCT04877847|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant and clinical staff will be blinded to which arm the participant is randomized.|A total of up to 234 participants will be randomized 2:1|t|t|f|f
34033289|NCT01917682|||COHORT||OTHER|||||||
34033290|NCT05345106|||CASE_CONTROL||PROSPECTIVE|||||||
34033291|NCT02350816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033292|NCT06435689|||COHORT||PROSPECTIVE|||||||
34033293|NCT01519310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34033294|NCT02513225|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033295|NCT05514223|||COHORT||CROSS_SECTIONAL|||||||
34033296|NCT01295320|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033297|NCT04627792|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033298|NCT01870089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033299|NCT03159247|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a single group prospective behavioral intervention with a pre-post design. Adherence will be measured for three months at baseline, for an additional one month after an automated reminder system is initiated, for an additional six months during a personalized behavior change intervention and then for one year after the intervention.||||
34033300|NCT03894644|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033301|NCT04667624|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033302|NCT04238325|||COHORT||CROSS_SECTIONAL|||||||
34033303|NCT04092309|RANDOMIZED|PARALLEL||PREVENTION||NONE||one group after bone marrow transpalntation treated with ACE one group after bone marrow transpalntation treated with sacubitril-valsartan one group after bone marrow transpalntation treated with none of these (control group)||||
34033304|NCT00742209|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033305|NCT03716856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033306|NCT00470392|NON_RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33724637|NCT03197233|||COHORT||PROSPECTIVE|||||||
34033307|NCT03335826|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34033308|NCT03151174|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Any individuals involved in study measures will also be masked.|Subjects will either receive placebo, 5000IU, or 10000IU per day of Vitamin D for 8-12 weeks.|t|f|t|t
34033309|NCT01057680|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34033310|NCT00934167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033311|NCT02495662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107668|NCT03755401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assessments will be performed by blinded clinical assessors; randomization accomplished by computer algorhythm|Randomized controlled trial of psychosocial interventions|f|f|f|t
34107669|NCT02255656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033312|NCT04599075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those assessing the outcomes from the medical chart will be blinded to the randomization process and the assigned study arm. Patients, the primary investigator, and their care providers will be aware of their treatment status.|This is a prospective, single-center, randomized study evaluating intrapartum insulin delivery management strategies among pregnant women with type 1 diabetes mellitus.|f|f|f|t
33724638|NCT03788096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A prospective, 2-arm, single-blind, randomized controlled clinical feasibility trial design.|f|f|f|t
33724639|NCT02725047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33724640|NCT02482987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724641|NCT04528043|||COHORT||RETROSPECTIVE|||||||
34033313|NCT03309098|||COHORT||PROSPECTIVE|||||||
34033314|NCT06513481|||COHORT||PROSPECTIVE|||||||
34033315|NCT05334641|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34033316|NCT04700137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033317|NCT02854384|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033318|NCT00181714|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033319|NCT04222426|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033320|NCT03525886|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34033321|NCT05387889|RANDOMIZED|PARALLEL||TREATMENT||NONE|All participants will receive intervention according to the wait-listed control comparative groups. Therefore, masking is not applicable in this study.|wait-listed control comparative groups||||
34033322|NCT03682107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34033323|NCT04451148|||CASE_CONTROL||PROSPECTIVE|||||||
34033324|NCT00534950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033325|NCT00115414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033326|NCT06254040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033327|NCT00528047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033328|NCT01553357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033329|NCT05623423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34033330|NCT05083026|||CASE_ONLY||PROSPECTIVE|||||||
34033331|NCT01290549|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033332|NCT06194708|||COHORT||PROSPECTIVE|||||||
34033333|NCT03145675|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible patients are randomly assigned into the Planned Staged-dose Group and the Planned Single-dose Group.~All patients in the Planned Staged-dose Group will receive enoxaparin 0.5 mg/kg at the beginning of coronary angiography. Those with definite indication for subsequent PCI will be given additional enoxaparin 0.25 mg/kg at the beginning of PCI (Staged-dose PCI Group \[0.5+0.25 mg/kg\]); while, those have no indication for subsequent PCI will not receive additional anticoagulation (Standard-dose Group \[0.5 mg/kg\]).~All patients in the Planned Single-dose Group will receive enoxaparin 0.75 mg/kg at the beginning of coronary angiography no matter they will undergo subsequent PCI (Single-dose PCI Group \[0.75 mg/kg\]) or not (High-dose Group \[0.75 mg/kg\])."||||
34033334|NCT01795950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033335|NCT00247715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033336|NCT04981717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033337|NCT03125798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033338|NCT03845686|||COHORT||PROSPECTIVE|||||||
34033339|NCT05075850|||COHORT||CROSS_SECTIONAL|||||||
34033340|NCT01949246|||COHORT||PROSPECTIVE|||||||
34033341|NCT03975933|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34033342|NCT06105528|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind|There will be 5 sequential escalating dose cohort groups. Dose groups are 175 mg, 350 mg, 700 mg, 1400 mg and 2800 mg (optional) administered as a single 60-minute infusion.|t|f|t|f
34033343|NCT04488588|||COHORT||RETROSPECTIVE|||||||
34033344|NCT02531048|NA|SINGLE_GROUP||OTHER||NONE||||||
34033345|NCT03855982|||CASE_ONLY||CROSS_SECTIONAL|||||||
34033346|NCT00000525|RANDOMIZED|||||DOUBLE||||||
34033347|NCT00233948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033348|NCT05978401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Part1 section is a dose-escalation/expansion study in a single-arm setup； Part2 section sets up a control； All processes do not involve blind settings.|Part1 section is a dose-escalation/expansion study in a single-arm setup； Part2 section sets up a control.||||
34033349|NCT04187755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is a randomized controlled trial with single blinding, participants were assigned into ceftazidime and cefepime group. Investigator did not know the randomization done by the other party|Patients were randomly divided into two intervention groups, ceftazidime and cefepime, each group consist of 36 patients. Patients were treated, the results were noted after 72 hours.|f|f|t|f
34033350|NCT05457777|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be determined blindly by being assigned by a site.|Our study has two groups of 36 participants each. Our study is an experimental study with pretest-posttest control group.|t|f|f|f
34033351|NCT02776943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033352|NCT04904250|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34033353|NCT03811691|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study is an interventional, prospective, multicenter, open label, two arms parallel non-comparative non-randomized study.||||
34033354|NCT03532529|||COHORT||PROSPECTIVE|||||||
34033355|NCT01050439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033356|NCT04167553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033357|NCT01776710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107670|NCT00281385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149917|NCT04326855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a cross sectional interventional trial. The same group of COPD patients will perform four shuttle walking protocols. The intermittent shuttle walking protocol will be compared to the endurance shuttle walking protocol (control) which is commonly implemented in the PR settings. The intermittent shuttle walking protocol will be performed twice by all patients to obtain test re-test reliability in terms of distance walked, of cardiorespiratory and symptoms responses. The order of testing will be determined by balanced sequence.||||
33724642|NCT01533454|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34033358|NCT05570864|||COHORT||OTHER|||||||
34107671|NCT05544760|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This randomized clinical trial, first examines whether participants are good or bad multisensory integrators. If eligible and interested in participating, we will screen 300 participants level of multisensory integration. If participants are good integrators, no randomization will be necessary as these participants will not meet inclusion trial for the intervention trial. If participants are poor integrators, then they will be randomized into either the control (regular care) or intervention (CDC recommendations and falls counseling) arms. Note that be expect \~134 participants to be poor integrators. Those that are good integrators will not be included in the intervention trial but will be included in the larger observational study to test other study aims including 1) demonstrating acceptable concurrent validity of CatchU for identifying older adults' multisensory integration performance in older adults and 2) Examining predictive validity of CatchU in older adults.|t|f|t|f
34107672|NCT00394680|||COHORT||RETROSPECTIVE|||||||
34107673|NCT00373360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107674|NCT05703165|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34107675|NCT05949320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34107676|NCT05931822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107677|NCT03202303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Phase 2, 12-week double-blind, randomized, placebo-controlled trial|t|t|t|t
34107678|NCT03129997|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|volunteers received placebo or gluten corn muffins that are similar in taste and appearance. Investigator does not know who is receiving placebo or gluten muffins. During analyses, each sample is coded to avoid volunteer or phase identification.|crossover double masked model|t|f|t|f
34107679|NCT06569459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107680|NCT06642051|NA|SINGLE_GROUP||TREATMENT||NONE||The use of High Intensity Focused Ultrasound for the ablation of incompetent veins of the periphery.||||
34107681|NCT02412982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107682|NCT05580679|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||Randomized Controlled Trials|t|t|t|t
34107683|NCT05788991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107684|NCT03333889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind :outcome asessor,participant||t|f|f|t
34107685|NCT01713244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107686|NCT05151731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107687|NCT02909114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107688|NCT04784143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107689|NCT03241615|||COHORT||PROSPECTIVE|||||||
34107690|NCT04667572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107691|NCT02298946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724643|NCT03554356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107692|NCT06641336|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34107693|NCT00194311|||COHORT||PROSPECTIVE|||||||
34107694|NCT06639100|||COHORT||PROSPECTIVE|||||||
33724644|NCT04530006|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients eligible for the study who have provided consent will be asked to ingest a regular 200mg dose of FDA approved drug Amantadine, according to timelines proposed in the protocol.||||
34107695|NCT04573478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34107696|NCT01854775|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107697|NCT02821650|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34107698|NCT05115825|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34107699|NCT06641895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107700|NCT01715870|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34107701|NCT06146062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|use of placebo||t|t|t|t
34107702|NCT06446648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107703|NCT02887794|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107704|NCT02732496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107705|NCT00802503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107706|NCT06549816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107707|NCT06674902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A triple-blinded, pilot randomized controlled trial|t|f|t|f
34107708|NCT06512259|||CASE_ONLY||RETROSPECTIVE|||||||
34107709|NCT05407636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|ABBV-RGX-314 administration is performed as an outpatient surgical procedure in an operating room, while the active control, aflibercept, is administered via intravitreal injection in an office setting. This study will be partially masked which will include masking of key study assessors and study drug dose.|2 ABBV-RGX-314 treatment arms, 1 control arm (aflibercept)|t|t|t|t
34107710|NCT06639165|||COHORT||PROSPECTIVE|||||||
34107711|NCT04854473|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34107712|NCT06561243|||COHORT||RETROSPECTIVE|||||||
34107713|NCT03977155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107714|NCT04005833|||COHORT||PROSPECTIVE|||||||
34107715|NCT00860496||PARALLEL||PREVENTION||NONE||||||
34107716|NCT04974398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724645|NCT00785109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724646|NCT05584150|||COHORT||PROSPECTIVE|||||||
33724647|NCT05828199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724648|NCT02104544|||COHORT|||||||||
33724649|NCT03836963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized control trial. three arms to the study|t|t|t|t
33724650|NCT01722253|||CASE_CONTROL||RETROSPECTIVE|||||||
33724651|NCT05153109|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33724652|NCT03830060|||COHORT||PROSPECTIVE|||||||
33724653|NCT06278246|||CASE_CONTROL||PROSPECTIVE|||||||
33724654|NCT00854074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724655|NCT05609955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724656|NCT00857220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107717|NCT05149469|||CASE_ONLY||RETROSPECTIVE|||||||
34107718|NCT02392169|||CASE_ONLY||PROSPECTIVE|||||||
34107719|NCT04952519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107720|NCT05646693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|Clinical Trial Phase II A, controlled with placebo|t|f|t|f
34107721|NCT00398879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724657|NCT03617081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724658|NCT00799578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724659|NCT02045680|||CASE_ONLY||PROSPECTIVE|||||||
33724660|NCT01094548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724661|NCT05537571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724662|NCT04574804|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomisation of participants will be conducted by a researcher with no direct involvement in the study. The biostatistician will analyse blinded, de-identified data.||f|f|f|t
33724663|NCT02641769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724664|NCT00455507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724665|NCT01791842|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33724666|NCT05440279|RANDOMIZED|PARALLEL||TREATMENT||NONE||"National, monocentric, prospective, randomized and controlled clinical trial with 2 arms.~Arm 1: Control group - Standard Care (SC) Arm 2: Intervention group - Standard Care (SC) + digital patient support (DPS) tool"||||
33724667|NCT01237873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033359|NCT04756661|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033360|NCT00356226|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34033361|NCT02015143|||||RETROSPECTIVE|||||||
34033362|NCT03354598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033363|NCT00947921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033364|NCT05592457|||OTHER||PROSPECTIVE|||||||
34033365|NCT01679990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34033366|NCT05573958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033367|NCT03658044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized parallel group study||||
34033368|NCT02392585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033369|NCT01710787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033370|NCT03561077|NA|SINGLE_GROUP||OTHER||NONE||||||
34033371|NCT03610230|RANDOMIZED|CROSSOVER||TREATMENT||NONE||prospective randomized cross-over open-label trial||||
34033372|NCT03884985|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033373|NCT01598961|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34033374|NCT04104178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It's a double blinded placebo study. Only the pharmacy knows the randomization.||t|t|t|f
34033375|NCT04728802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Care Provider)|This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.|t|t|f|f
34033376|NCT04262648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033377|NCT00525980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033378|NCT03804957|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized two arms single center||||
34033379|NCT00961857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033380|NCT05089591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Bilateral comparison|t|f|t|f
34033381|NCT02259478|||CASE_CONTROL||PROSPECTIVE|||||||
34033382|NCT00005985||||TREATMENT||NONE||||||
34033383|NCT00214383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033384|NCT03454503|||COHORT||PROSPECTIVE|||||||
34033385|NCT03423797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107722|NCT06335706|||OTHER||CROSS_SECTIONAL|||||||
34107723|NCT04321187|||CASE_ONLY||PROSPECTIVE|||||||
34107724|NCT06289582|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34107725|NCT06497088|NA|SINGLE_GROUP||OTHER||NONE||||||
34149918|NCT02903394|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724668|NCT06110442|||OTHER||CROSS_SECTIONAL|||||||
33724669|NCT01592344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33724670|NCT02448238|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33724671|NCT04829877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33724672|NCT03406858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724673|NCT02916615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724674|NCT04324801|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724675|NCT00982709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724676|NCT03048656|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33724677|NCT00195247|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33724678|NCT05282082|||COHORT||CROSS_SECTIONAL|||||||
33724679|NCT01137942|||CASE_CONTROL||PROSPECTIVE|||||||
33724680|NCT03265197|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34033386|NCT03099031|||COHORT||PROSPECTIVE|||||||
34033387|NCT02492867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033388|NCT04742829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Observational study, open, controlled between homogeneous groups||||
34033389|NCT01130662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033390|NCT01564043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033391|NCT00002376||PARALLEL||TREATMENT||||||||
34033392|NCT05839314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033393|NCT00681421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033394|NCT04749225|||CASE_CONTROL||PROSPECTIVE|||||||
34033395|NCT02801123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34033396|NCT01105364||||DIAGNOSTIC||||||||
34033397|NCT02174627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033398|NCT00981487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033399|NCT04688645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033400|NCT04708704|NA|SEQUENTIAL||PREVENTION||NONE||"The effects of three interventions will be investigated:~1. Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)~2. SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)~3. Iodine, prepared in drinking water 0.075 mg/kg bw/day)~The erythrosine and iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. This protocol will be repeated for the three subsequent exposure weeks which will be spaced 2 weeks a part. Instead of receiving daily doses of erythrosine, participants will be given 500 mL of water containing photobleached erythrosine or iodine. The spacing between treatment weeks will serve as a washout period."||||
34033401|NCT03896698|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
33724681|NCT00464425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724682|NCT03210870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724683|NCT02202733|NA|SINGLE_GROUP||||NONE||||||
33724684|NCT04822207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724685|NCT02472938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724686|NCT01822080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033402|NCT00428272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033403|NCT05131672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033404|NCT01494259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033405|NCT05965375|||COHORT||OTHER|||||||
34033406|NCT02325492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033407|NCT06182371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As this research uses a behavioral intervention, it will conceal the grouping from the subjects. Random numbers will be placed in opaque envelopes by independent persons not involved in this experiment to achieve allocation concealment.|Intervention: After the insertion of a DLT under general anesthesia, the anesthesiologist disengaged the breathing circuit when the patient transitioned from the supine to the lateral position.|t|f|f|f
34033408|NCT01756183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033409|NCT02267681|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34033410|NCT00548639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033411|NCT01257620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724687|NCT05766930|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, single arm and before and after treatment||||
34033412|NCT06203613|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033413|NCT02489188|||COHORT||PROSPECTIVE|||||||
34033414|NCT01041144||||SUPPORTIVE_CARE||||||||
34033415|NCT01037452|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34033416|NCT00894621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724688|NCT05851430|||CASE_ONLY||PROSPECTIVE|||||||
33724689|NCT02564614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724690|NCT03226431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033417|NCT01410214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033418|NCT00667680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033419|NCT00108134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033420|NCT03241641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033421|NCT03482245|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||randomized pilot clinical trial||||
34033422|NCT03203122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assesor and primary invstigator are blinded and not present at treatments.|Patients are randomized to treatment in either left or right side, using the other side as control.|f|f|t|t
34033423|NCT05093075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All investigators and research staff will be blinded to the allocation schedules. The PLEXSIS pilot trial is designed as a prospective randomized open, blinded endpoint (PROBE) trial. This pragmatic design is necessary given impractical nature of blinding the TPE intervention.|A web-based randomization system maintained at the Center for Healthcare Innovation (CHI) (Winnipeg, Manitoba) will be used to allocate treatment assignments. The randomization process will consist of a computer-generated random listing of the treatment allocations in variable permuted blocks of 2 and 4. Participants will be randomized to Treatment (5 Therapeutic Plasma Exchanges) or Standard of Care.|f|f|t|t
34033424|NCT04677335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033425|NCT00033397|||COHORT||PROSPECTIVE|||||||
34033426|NCT02876341|||COHORT||RETROSPECTIVE|||||||
34033427|NCT03793764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients undergoing varicocele surgery under spinal anesthesia|f|f|t|t
34033428|NCT01927120|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033429|NCT03692507|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033430|NCT00836407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033431|NCT04209283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033432|NCT00150280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34107726|NCT04725513|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The first part of the study is a randomized control trial, the second part is an elective cross over||||
34033433|NCT04838730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033434|NCT01950221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724691|NCT05283187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33724692|NCT04311879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded||t|f|f|f
33724693|NCT02877277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033435|NCT04555187|||COHORT||RETROSPECTIVE|||||||
34033436|NCT04796493|||COHORT||PROSPECTIVE|||||||
34033437|NCT06581354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be based on different technical procedures for the fabrication of the frameworks. Since these differences are visible, the operator and the technician involved in the study as well as the outcome assessor cannot be blinded. But the statistician and patients will be blinded.|"Group I: Intervention will be treated using a glass fiber composite as a temporary framework followed by PEKKTON definitive framework.~Group II: Controls will be treated using PEKKTON definitive framework (no provisionalization)."|f|f|f|t
34033438|NCT00180999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033439|NCT05215444|||COHORT||PROSPECTIVE|||||||
34033440|NCT06582550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Note that the surgical intervention is the same in both study arms. The comparison is in regards to the post-operative instructions with the aim of quality improvement.||||
34033441|NCT03573154|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34033442|NCT02484937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033443|NCT04128930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033444|NCT01215773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033445|NCT04774484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033446|NCT05813886|||OTHER||CROSS_SECTIONAL|||||||
34033447|NCT04016519|||COHORT||PROSPECTIVE|||||||
34033448|NCT05264883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033449|NCT00868920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033450|NCT03593889|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.~The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units."||||
34033451|NCT02465398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033452|NCT02183779|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34033453|NCT01060072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033454|NCT06486714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind. The participant will be blinded to the assignment until one year after surgery. The study team and surgeon will not be blinded to the assignment.|Our study will randomize patients to receive either cemented MA-TKA or KA-TKA with the goal of assessing pain scores and PROMs at various time points following surgery.|t|f|f|f
34033455|NCT01744639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033456|NCT05725681|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34033457|NCT04967326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033458|NCT03745209|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033459|NCT03232593|||COHORT||PROSPECTIVE|||||||
34033460|NCT01404546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34033461|NCT01442597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033462|NCT00525681|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033463|NCT01937078|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34033464|NCT00002100||||TREATMENT||||||||
34033465|NCT01522456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34033466|NCT02179060|||CASE_CONTROL||PROSPECTIVE|||||||
34033467|NCT00558597|||CASE_CONTROL||PROSPECTIVE|||||||
34033468|NCT01354210|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34033469|NCT03106428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033470|NCT02497586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033471|NCT06295523|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34033472|NCT00965887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033473|NCT00684281|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34033474|NCT00291317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033475|NCT02846610|||COHORT||OTHER|||||||
34033476|NCT04108897|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34033477|NCT03632369|||OTHER||OTHER|||||||
34033478|NCT04156581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033479|NCT00994812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033480|NCT05560607|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34033481|NCT01777178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033482|NCT00240279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033483|NCT03564457|||COHORT||RETROSPECTIVE|||||||
34033484|NCT02817659|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033485|NCT00546663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033486|NCT04944173|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study subjects will be analyzed as a single cohort with respect to the primary outcome, with comparison to historical controls. Treatment assignment based on biomarker status after initial treatment.||||
34033487|NCT05259527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34033488|NCT05616338|NA|SINGLE_GROUP||OTHER||NONE||||||
34033489|NCT04109092|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34033490|NCT04203134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033491|NCT04957823|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033492|NCT05943717|||CASE_ONLY||CROSS_SECTIONAL|||||||
34033493|NCT01990248|||COHORT||PROSPECTIVE|||||||
34033494|NCT02042118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033495|NCT06354517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34033496|NCT06515119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors who are uninvolved in other study phases will be unaware of group allocation. Participants will be advised not to disclose their group assignment to outcome assessors during the data collection.|66 prediabetes participants will be randomized into the intervention group and control group. Randomization will be conducted using the Research Randomizer Software and performed by a research team member who will not contact participants. Allocation will be concealed in sealed envelopes and revealed until trials commence, that is, after participants' submission of consent forms and completion of baseline assessments.|f|f|f|t
34033497|NCT01796600|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34033498|NCT05423132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033499|NCT01702064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033500|NCT03808480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033501|NCT02254265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033502|NCT01350271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033503|NCT05291273|NA|SINGLE_GROUP||PREVENTION||NONE||This study is a monocentric interventional prospective study||||
34033504|NCT03126448|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34033505|NCT03212027|||CASE_ONLY||PROSPECTIVE|||||||
34033506|NCT06081478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033507|NCT05131555|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized double-blinded placebo-controlled cross-over interventional study|t|f|t|t
34033508|NCT03583307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033509|NCT01707290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033510|NCT02517008|RANDOMIZED|PARALLEL||||NONE||||||
34033511|NCT01326845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033512|NCT01668290|||COHORT||PROSPECTIVE|||||||
34033513|NCT01660425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033514|NCT01510951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34033515|NCT02177461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033516|NCT00619723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34033517|NCT01834534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033518|NCT01802021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34033519|NCT00000947||PARALLEL||TREATMENT||||||||
34033520|NCT02868957|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34033521|NCT05255731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One side the laser off will be applied, on the other side, the laser on will be applied,||t|f|f|f
34033522|NCT02848001|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033523|NCT03412695|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033524|NCT02936908|||COHORT||RETROSPECTIVE|||||||
34033525|NCT04447131|||CASE_CONTROL||PROSPECTIVE|||||||
34033526|NCT05756582|||CASE_ONLY||PROSPECTIVE|||||||
34033527|NCT02729571|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033528|NCT00920491|||COHORT||CROSS_SECTIONAL|||||||
34033529|NCT00043303|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34033530|NCT02608411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033531|NCT03661645|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized Controlled study||||
34033532|NCT06331182|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34033533|NCT02456740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033534|NCT05314231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033535|NCT03153358|NA|SINGLE_GROUP||TREATMENT||NONE||icotinib and SBRT treat the lung cancer with egfr mutation||||
34033536|NCT05219448|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All raw data provided to the statistician will include a participant-level variable indicating the community in which the participant lives.|There are 2 arms in the study. In Communities A and B, a total of 136 children (and at least one primary caregiver for each child) will be recruited for the intervention and outcomes measured over 12 months. In Community C, 56 children (and at least one primary caregiver for each child) will be recruited to a control group where outcomes are measured over 12 months but the intervention is not delivered until the study data collection period is over.|f|f|f|t
34033537|NCT02280200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033538|NCT01974622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033539|NCT04653649|NA|SINGLE_GROUP||TREATMENT||NONE||"Experimental: HSP-CAR30 (anti-CD30 CAR T cells)~Dose escalation phase:~Phase I:~Ten patients will be treated with HSP-CAR30 (anti-CD30 CAR T-cells) with an escalation approach to define maximum tolerated dose (MTD) from 3 x 106/kg to 10 x 106/kg.~Phase IIa:~Twenty patients will be treated with HSP-CAR30 at MTD to evaluate efficacy."||||
34033540|NCT03311204|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The clinical signs are photographed and an outcomes accessor grades the clinical signs. This process ensures that there is no bias in recording the results. This method was specially chosen, due to the lack or inability to mask the treatment procedures, due to their nature of treatment.|Single-center, randomized, cross-over, open-label interventional study|f|f|f|t
34033541|NCT04530643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033542|NCT00676702||CROSSOVER||||||||||
34033543|NCT06469723|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"Two General Medicine (GM) wards and two General Surgery (GS) wards will be used for the study.~One GM and one GS ward will be designated as INFA intervention wards while the remaining two wards will be designated as control.~Participants will be randomly sorted into either of the wards and outcome data will be collected from the participants at three timepoints: Baseline (Admission), discharge, and 6-months post discharge."|t|f|f|f
34033544|NCT05348083|||CASE_CONTROL||PROSPECTIVE|||||||
34033545|NCT04941092|||CASE_CONTROL||RETROSPECTIVE|||||||
34033546|NCT03575377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033547|NCT02641652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033548|NCT05049850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033549|NCT00555165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033550|NCT02063568|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34107727|NCT03829488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149919|NCT00861718|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34149920|NCT02995044|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724694|NCT00679185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724695|NCT04327219|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Twenty patients, at 0-3 months post ileostomy closure will be enrolled for the study. Patients will be randomized to receive the CDED or standard diet at a ratio of 1:1~2. Fourty two adults with a diagnosis of acute exacerbation of pouchitis will be included in the study. Participants will be randomised to receive the CDED or standard diet at a ratio of 1:1.~Upon initiation of the patient recruitment, 15 pouchitis patients will be treated with the study diet (modified CDED) for 24 weeks per treatment protocol as a pilot study."||||
33724696|NCT02081833|||COHORT||PROSPECTIVE|||||||
33724697|NCT02642432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724698|NCT02874742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724699|NCT02741908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724700|NCT03391596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724701|NCT06186037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724702|NCT05875233|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||Population will be split into 2 arms of 35 participants each: 1 group who are on hormonal birth control, and 1 group who are not on hormonal birth control. All participants will take the test product.||||
34033551|NCT05988580|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The products (experimental and placebo), will be produced by an external producer, who will retain the codes. None of the researchers involved in the study development or analyses will know the association until the end of the study.|Randomised, double blind crossover intervention|t|t|t|t
34033552|NCT06150339|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||This is a feasibility study which will use a quasi-experimental one group time series design.||||
34033553|NCT03074344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Visits were carried out in a blind fashion by investigators who were not aware to which group the patients belonged. The patients were allowed to know the brand name of the eye drops they were using.|Randomised, single-masked, parallel-group comparative study.|f|f|t|f
34033554|NCT05047666|||COHORT||PROSPECTIVE|||||||
34033555|NCT03015987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34033556|NCT04258592|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033557|NCT01772329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||n=80 Subjects for Aim 1 and another n=80 Subjects for Aim 2|f|f|t|f
34033558|NCT03499444|NA|SEQUENTIAL||TREATMENT||NONE||||||
34033559|NCT04330664|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34033560|NCT04015167|||COHORT||PROSPECTIVE|||||||
34033561|NCT03581019|NA|SINGLE_GROUP||TREATMENT||NONE||Observational study||||
34033562|NCT05721001|||COHORT||PROSPECTIVE|||||||
34033563|NCT00042601|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34033564|NCT00678210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033565|NCT00266630|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033566|NCT06408181|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033567|NCT05850117|RANDOMIZED|PARALLEL||TREATMENT||NONE||1.Tetracycline combined with levofloxacin quadruple therapy 2. standard tincture quadruple therapy 2. amoxicillin combined with levofloxacin quadruple therapy||||
34033568|NCT06582108|||COHORT||OTHER|||||||
34033569|NCT03528616|||CASE_CROSSOVER||PROSPECTIVE|||||||
34033570|NCT00726193|||CASE_ONLY||PROSPECTIVE|||||||
34033571|NCT03979391|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033572|NCT03196336|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Pharmacotherapeutic follow-up care known as Pharmacotherapy Workup.|t|f|f|f
34033573|NCT02196402|||COHORT||PROSPECTIVE|||||||
34033574|NCT03692832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033575|NCT05289869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, research staff, and clinical care providers will be blinded to the dosing regimen.||t|t|t|f
34033576|NCT04506034|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomized controlled trial|randomized controlled trial|t|f|f|f
34033577|NCT00241670|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34033578|NCT02023931|NA|SINGLE_GROUP||OTHER||NONE||||||
34033579|NCT05726201|||COHORT||PROSPECTIVE|||||||
34033580|NCT03067025|||CASE_CONTROL||PROSPECTIVE|||||||
34033581|NCT00867659|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34033582|NCT03693417|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34033583|NCT04445831|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34033584|NCT04133012|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033585|NCT04368338|||CASE_ONLY||PROSPECTIVE|||||||
34033586|NCT05941312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34033587|NCT01089465|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033588|NCT00473590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34033589|NCT01008358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033590|NCT03360383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033591|NCT05244122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Observers were naive about the hypothesis but could have figured out if a specific condition did or did not have feedback, for example. Once the data were collected, investigators could determine what conditions were tested on which observers|We tested \~800 observers on line in a study where they could participate in multiple conditions. We were looking for the effect of condition 1 on condition N+1||||
34033592|NCT03696290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trail management team will also be masked. A bespoke online randomisation system will be used to generate the treatment codes for each participant|Multi-centre randomised double-blind placebo controlled parallel group trial with four treatment arms|t|t|t|t
34033593|NCT04456140|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033594|NCT03143790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient and therapist are blind. Primary investigator is not blind. Unblinding occurs 3 months after the end of treatment|Randomization to active or placebo treatment.|t|t|f|t
34033595|NCT04198194|||OTHER||CROSS_SECTIONAL|||||||
34033596|NCT06031558|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34033597|NCT03266796|||OTHER||CROSS_SECTIONAL|||||||
34033598|NCT02534389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033599|NCT03827538|||COHORT||PROSPECTIVE|||||||
34033600|NCT04807010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Patients and those recording response will be blinded to cohort allocation.||t|f|f|t
34033601|NCT00651274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149921|NCT00512291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149922|NCT02517632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The intervention group performed exercise sessions, pharmaceutical and nutritional counceling. The control group had only pharmaceutical and nutritional counceling.|f|f|f|t
34149923|NCT01472744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149924|NCT03400813|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator / Outcomes Assessor||f|f|t|t
34152483|NCT03826199|NA|SINGLE_GROUP||PREVENTION||NONE||Open label cohort study||||
34152484|NCT00967096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152485|NCT06507683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152486|NCT01736618|||COHORT||OTHER|||||||
34152487|NCT02861599|NON_RANDOMIZED|PARALLEL||||NONE||||||
34152488|NCT01202058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152489|NCT06357052|||COHORT||CROSS_SECTIONAL|||||||
34033602|NCT01851044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033603|NCT05193838|||COHORT||PROSPECTIVE|||||||
34033604|NCT04347993|||CASE_ONLY||PROSPECTIVE|||||||
34033605|NCT03415646|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34033606|NCT02436161|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34033607|NCT06269458|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34033608|NCT03879785|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34033609|NCT05467501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not know the actual ultrasound application|RCT|t|f|f|f
34033610|NCT03707574|||COHORT||PROSPECTIVE|||||||
34033611|NCT00748761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033612|NCT02159313|RANDOMIZED|CROSSOVER||||NONE||||||
34033613|NCT03888469|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34033614|NCT05273411|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34033615|NCT04623047|||OTHER||PROSPECTIVE|||||||
34033616|NCT03523936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Double blind placebo controlled trial|f|f|t|f
34033617|NCT03266601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033618|NCT06109155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In the research process, any raw data will be kept and encrypted by the principal investigator, and it will not be accessible or interpretable by others.|During cardiac surgery with cardiopulmonary bypass support, participants will be divided into 4 groups. During procedure, they will recieve different doses of tranexamic acid and different level of activated clotting time. Then, we will monitor the amount of blood loss and blood transfusion.|t|t|t|t
34033619|NCT00721071|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033620|NCT05049395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34033621|NCT05975411|||COHORT||PROSPECTIVE|||||||
34033622|NCT00327418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34033623|NCT04364893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033624|NCT01791309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033625|NCT01756027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033626|NCT01042093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033627|NCT01514747|||COHORT||PROSPECTIVE|||||||
34033628|NCT03617666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033629|NCT05047224|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"Clinicians conducting in-person diagnostic evaluations will be blind to the outcomes of initial telehealth diagnostic appointments until after in-person assessments are administered and scored. Clinicians will be unblinded to telehealth diagnostic outcomes prior to sharing the results of in-person assessment with families.~Clinicians conducting the second telehealth appointments for test-retest and interrater reliability purposes will be blind to recruitment pathway and diagnostic outcome from the initial telehealth appointment."||f|t|f|f
34033630|NCT03944941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033631|NCT00593892|||CASE_ONLY||PROSPECTIVE|||||||
34033632|NCT00578266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033633|NCT04910594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033634|NCT03305848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033635|NCT03654833|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033636|NCT05690932|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-dose, open-label, randomized, three-way crossover design||||
34033637|NCT06157008|||COHORT||PROSPECTIVE|||||||
34033638|NCT05509530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033639|NCT00419497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033640|NCT00554034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033641|NCT01863914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033642|NCT01226030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033643|NCT05170295|||COHORT||PROSPECTIVE|||||||
34033644|NCT04215237|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107728|NCT06639152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were divided into those who received an oil-based contrast medium (ethiodized poppyseed oil) and a water-based contrast medium (Ioversol) based on a shared medical decision-making process between patients and healthcare providers.||||
34107729|NCT06525727|||COHORT||PROSPECTIVE|||||||
34107730|NCT03238053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Laser probe perform similar noise and movement without providing rays|Four Groups of women randomized for thre months to either laser og sham treatment|t|f|f|f
34107731|NCT05074381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107732|NCT06638203|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Expert A will assess the students' eligibility based on predetermined inclusion and exclusion criteria. From those who qualify, Expert B will use specialized software to randomly select 50 participants through systematic random sampling. An independent Expert C will then randomly assign these 50 students to either the control or intervention groups using block randomization. Expert D will administer the pre- and post-tests, which will then be sent to statisticians for analysis. After the statistical results are received and reported, the researchers will know which students were in the control or intervention group. The intervention group will participate in the game first, while the control group will be placed on a waitlist and will play the game after the statistical analysis is completed. Although the control group will also have the opportunity to develop their leadership skills through the game, their performance will not be evaluated post-play.||t|f|t|t
34107733|NCT06642298|||OTHER||CROSS_SECTIONAL|||||||
34107734|NCT02108808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107735|NCT01014780|||||CROSS_SECTIONAL|||||||
33806630|NCT01283568|||CASE_CONTROL||PROSPECTIVE|||||||
34107736|NCT04090606|||COHORT||PROSPECTIVE|||||||
34107737|NCT03906071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107738|NCT06041880|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Due to the nature of the intervention, participants will not be blinded to stretching vs no-stretching interventions. The study team will be blinded to intervention order when performing data analysis.|Participants will be randomized to 4-weeks of stretching or no stretching. Following the first 4-week intervention, participants will crossover and perform whichever intervention they did not receive previously.||||
34107739|NCT06638918|||CASE_ONLY||PROSPECTIVE|||||||
34107740|NCT00237159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107741|NCT06673264|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Participants undergoing brain resection due to tumor or epilepsy||||
34107742|NCT06428357|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-Blind|Randomized cross-over design|t|f|t|f
34107743|NCT05054439|NA|SEQUENTIAL||TREATMENT||NONE||||||
34107744|NCT03695978|||COHORT||OTHER|||||||
34107745|NCT00979758|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34107746|NCT06675630|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34107747|NCT04474847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107748|NCT06057623|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34107749|NCT06570733|||COHORT||PROSPECTIVE|||||||
34107750|NCT03992872|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Open Label Safety and Immunogenicity||||
34107751|NCT01564030|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34107752|NCT05516173|||CASE_ONLY||PROSPECTIVE|||||||
34107753|NCT03942653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107754|NCT02578537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107755|NCT06243250|||COHORT||PROSPECTIVE|||||||
34107756|NCT06674863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107757|NCT04221477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107758|NCT04077320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participants will be unaware of the content of alternate groups. Both arms will be described as Learning and Aging groups to the participants"||t|f|f|t
34107759|NCT00745667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107760|NCT04370886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34107761|NCT05460286|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals are randomly allocated into the CSMT or the SD groups||||
34107762|NCT06634615|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||There are three groups in the study: a patient education group with virtual reality glasses, a patient education group with virtual reality glasses and video family interview, and a control group without education and/or interview.|f|f|f|t
34107763|NCT02695186|||CASE_CONTROL||PROSPECTIVE|||||||
34107764|NCT06585618|||COHORT||PROSPECTIVE|||||||
34107765|NCT04408638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107766|NCT05515224|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34107767|NCT05051436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107768|NCT06441305|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Evaluator teams will be blinded from intervention allocation|Cluster randomized controlled trial. Unit/cluster of assignment is community unit catchment area. Parallel Assignment: baseline-endline design||||
34107769|NCT06640166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107770|NCT02412072|||COHORT||PROSPECTIVE|||||||
34107771|NCT04330859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34033645|NCT06509113|RANDOMIZED|PARALLEL||OTHER||NONE|"To avoid potential bias based on the timing of enrollment, The investigators will use block randomization with randomly permuted block sizes to avoid identification of the allocation of the last participant in a block. Once a nursing student completes their baseline stigma and empathy survey, participants will be assigned the next masked envelope from the randomization list by a research staff, which in turn assign the person to one of the two study arms. The research staff and participants are masked to study arm assignment prior to opening the envelopes. The person analyzing the data will be masked to study arm assignment."|The investigators will develop a 4-module online HIV stigma reduction training with simulated patients for nursing students in the intervention arm. This training includes three case scenarios: a male who injects drugs, a male who has sex with men, and a female sex worker, all with HIV. Interviews with people living with HIV (PLWH) and focus groups with nursing students and faculty will refine the content. The control group will receive a course on HIV epidemiology without stigma-specific content. To assess efficacy, 70 nursing students will initially have a clinical encounter with a simulated patient on a non-HIV topic. A week later, they will have an HIV visit and complete stigma and empathy scales. Participants will then be randomized into two groups: one receiving stigma training and the other, HIV epidemiology training. Afterward, they will have another HIV-related clinical encounter and complete the scales again.||||
34107772|NCT06538012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107773|NCT04620980|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033646|NCT00593593|||||PROSPECTIVE|||||||
34033647|NCT05117346|NA|SEQUENTIAL||TREATMENT||NONE||The study investigates three dosage levels of CARDIX-101 (CARDIX-101A, CARDIX-101B, and CARDIX-101C).||||
34033648|NCT05452018|NA|SINGLE_GROUP||OTHER||NONE||Single group assignment||||
34033649|NCT05920837|||OTHER||CROSS_SECTIONAL|||||||
34033650|NCT01569867|||COHORT||PROSPECTIVE|||||||
34033651|NCT02029118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033652|NCT05775887|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033653|NCT02830191|||COHORT||PROSPECTIVE|||||||
34033654|NCT03797807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033655|NCT06307314|||COHORT||PROSPECTIVE|||||||
34033656|NCT01493869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033657|NCT02698163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033658|NCT03215927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the site pharmacist is unblinded.|A 1:1 randomization scheme for abatacept 125 mg vs. placebo as a weekly subcutaneous (SQ) injection for 24 weeks.|t|t|t|t
34107774|NCT03345550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107775|NCT05179915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In addition to ensuring the blinding of the participants in the study, blinding was also performed during the data collection, hormone values analysis, statistics and reporting stages. Women who agreed to participate in the study were not informed about the group they were assigned to. Since the participants did not know to which group they were assigned, the study was conducted in a single-blind design.|A randomized sham controlled trial design was used in the study, which was conducted with 50 primiparous pregnant women. While Therapeutic Touch (25) focused on sacral region was applied in the intervention group, Sham Therapeutic Touch (25) was applied in the control group.|t|f|f|t
34107776|NCT06300684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the specific type of intervention they will receive, whether it is Cognitive Behavioral Therapy for Insomnia (CBTi) or basic sleep hygiene education.|This parallel-design interventional study randomly assigns participants to receive either Cognitive Behavioral Therapy for Insomnia (CBTi) or basic sleep hygiene education over four weeks. CBTi aims to enhance sleep quality, while the control group receives sleep hygiene education. Pre- and post-intervention assessments will measure sleep parameters and dietary habits, comparing outcomes between groups. Randomization ensures unbiased assignment. Statistical analysis evaluates CBTi's effectiveness in improving sleep patterns and diet, exploring the potential indirect impact of improved sleep on diet.|t|f|f|f
34107777|NCT06047028|||COHORT||PROSPECTIVE|||||||
34107778|NCT03688763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107779|NCT06549608|||COHORT||RETROSPECTIVE|||||||
34107780|NCT05052736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107781|NCT01429389|||CASE_ONLY||PROSPECTIVE|||||||
34107782|NCT02113878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107783|NCT06141993|||COHORT||PROSPECTIVE|||||||
34107784|NCT03097978|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||||||||
34107785|NCT04846699|||COHORT||PROSPECTIVE|||||||
34107786|NCT06639542|||COHORT||PROSPECTIVE|||||||
34033659|NCT04464850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Maintenance hemodialysis patients who are eligible to enrol into the study according to inclusion and exclusion criteria will be start with 2-week run-in period before randomization. During this run-in period, all iron supplements that patients receive including oral and intravenous iron will be discontinued.|f|f|f|t
34033660|NCT05045092|||COHORT||PROSPECTIVE|||||||
34033661|NCT03673917|RANDOMIZED|PARALLEL||OTHER||NONE||The study design protocol is as follows: Schools of cosmetology in Arkansas are randomized using simple randomization to receive either 1) our educational video on skin cancer for cosmetologists or 2) a publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer. Students view the video that was randomly assigned to the school they attended. Pre-video tests are administered at the school during classes or online at the students' convenience; the video intervention follows immediately, also during classes or online. Post-video test (in class or online) are administered 3 to 6 months after watching the video. All schools continued to also use their previous educational materials on skin cancer concurrent with our program.||||
34033662|NCT05888857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 independent single-arm, multicenter, phase II trials, based on a two-stage three-outcome design as described in Sargent et al.~Cohort A : patients with TLS+ IO-naïve solid tumor (miscellaneous) Cohort B: patients with TLS+ PD1/PDL1-experienced solid tumor (miscellaneous)"||||
34033663|NCT05765500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033664|NCT05661370|RANDOMIZED|PARALLEL||OTHER||NONE||Intervention and Controlgroup parallel design using sequential continues block randomization.||||
34033665|NCT04214977|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033666|NCT03247569|||COHORT||PROSPECTIVE|||||||
34033667|NCT02248987|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033668|NCT03422614|||CASE_CONTROL||PROSPECTIVE|||||||
34033669|NCT03588143|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34033670|NCT06342687|||COHORT||RETROSPECTIVE|||||||
34033671|NCT05637216|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, research staff and clinicians will be blinded from study group assignment.|"Participants will be blocked by surgical type (breast conservation surgery/mastectomy) and then randomized 1:1 in a parallel design into treatment and control arms. All participants will take an oral 25 milligram tablet once daily of either losartan or placebo.~Assessments of fibrosis will include provider assessments and participant reported outcomes of fibrosis and cosmesis, the participant's decision for reoperation, laboratory assessments of inflammatory biomarkers, a CT scan and bilateral mammograms."|t|t|t|t
34033672|NCT02490631|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34033673|NCT03087500|||CASE_CONTROL||PROSPECTIVE|||||||
34033674|NCT04797026|NA|SINGLE_GROUP||OTHER||NONE||5 care facility residents paired with a similar amount of students as a pilot. If this program is successful, we will plan to amend IRB to include larger numbers||||
34033675|NCT05629715|RANDOMIZED|PARALLEL||TREATMENT||NONE||A maximum of 300 subjects in each arm (900 total) are to be enrolled in this study. In order to minimize selection bias, the surgeon will randomize the instrumentation technique used. Randomization will be accomplished via a random number generator in Microsoft Excel in a 1:1:1 ratio. The patient will know which treatment arm they are in at the time of study consent. They will be ineligible for the study if they ask to change treatment arms.||||
34033676|NCT03845192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033677|NCT06252883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Group A (intervention group) will receive a bedside video call 2-3 days a week in addition to the daily NICU phone updates and/or bedside updates using the NICU iPad w/ Doximity app. This permits a link to be sent to the parent to call at a given time if the parent desires or the provider can call directly to the parent at the planned time. Parents will be shown their infant, allowed for direct talk to their baby and then updated on the baby's status and plans by the NICU team and answer any question or concern the parent may have. The device will be outside the incubator and the parents will be shown their infant through the open incubator window, so they can interact with their baby.~Group B (control group) will receive the daily phone and/or bedside updates done routinely in our NICU already without the intervention."||||
34033678|NCT05718934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Two groups of patients randomized into Group N for neostigmine and group S for sugammadex. Group N will receive the standard reversal (neostigmine 50 µg.kg-1 and glycopyrrolate 7 µg.kg-1) and group S will receive sugammadex 0.5 mg.kg-1. Randomization will be done prior to the entrance in the OR, the day of the surgery."|"Two groups of patients randomized into Group N for neostigmine and group S for sugammadex for a total of 144 participants."|t|t|t|t
34033679|NCT02779244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34033680|NCT05276362|||COHORT||PROSPECTIVE|||||||
34033681|NCT00462917|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34033682|NCT04722497|||COHORT||PROSPECTIVE|||||||
34033683|NCT02333903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033684|NCT06441123|||COHORT||PROSPECTIVE|||||||
34033685|NCT02761668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033686|NCT00723502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033687|NCT06079892|||COHORT||RETROSPECTIVE|||||||
34033688|NCT02477956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34033689|NCT02163057|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033690|NCT02166567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033691|NCT00488189|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34033692|NCT02540005|||COHORT||PROSPECTIVE|||||||
34033693|NCT02570464|RANDOMIZED|PARALLEL||||NONE||||||
34033694|NCT04105400|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033695|NCT03524651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Double-dummy, blind, randomized, phase IV clinical trial|t|f|t|f
34033696|NCT02810925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033697|NCT03290963|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Triple blinded study. The staff accessible to the blind includes pharmacy staff and one assigned investigator.||t|f|t|t
34033698|NCT02329509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34033699|NCT06147648|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033700|NCT00820781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34033701|NCT02631486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033702|NCT02881502|||CASE_CONTROL||PROSPECTIVE|||||||
34033703|NCT01007669|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34033704|NCT02689583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033705|NCT02335697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033706|NCT04981418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All outcomes measures are collected via self report means. This will enable the investigators to be blinded to the outcomes measures reported. Treating clinicians are also blinded to the outcome assessments.||f|f|t|t
34033707|NCT00618488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033708|NCT04858386|||COHORT||PROSPECTIVE|||||||
34033709|NCT03799432|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34033710|NCT03272178|||COHORT||PROSPECTIVE|||||||
34033711|NCT05523115|NA|SINGLE_GROUP||OTHER||NONE||||||
34033712|NCT01841593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033713|NCT03081832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033714|NCT05919277|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34033715|NCT05810233|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Tablets will be despensed by a research assistant|Participant assigned to only one intervention per arm either vitamin C or placebo tablets|t|t|t|t
34033716|NCT05436730|||COHORT||PROSPECTIVE|||||||
34033717|NCT03730207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033718|NCT02000791|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34033719|NCT02920801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033720|NCT02074150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34033721|NCT06488287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033722|NCT05446558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study was a parallel group trial with a 1:1 allocation ratio.|t|f|f|f
34033723|NCT00261287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033724|NCT05889429|||CASE_CONTROL||PROSPECTIVE|||||||
34033725|NCT01719614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033726|NCT06528379|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033727|NCT00490607|||DEFINED_POPULATION||PROSPECTIVE|||||||
34033728|NCT00547586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033729|NCT05323669|||COHORT||RETROSPECTIVE|||||||
34033730|NCT01044550|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34033731|NCT00101426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033732|NCT04080739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033733|NCT03334435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033734|NCT05204992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033735|NCT02937311|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34033736|NCT06550505|||COHORT||PROSPECTIVE|||||||
34033737|NCT04658914|RANDOMIZED|PARALLEL||PREVENTION||NONE||single centre open label study, randomized, controlled trial||||
34033738|NCT06460805|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033739|NCT04356989|||COHORT||PROSPECTIVE|||||||
34033740|NCT01010243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033741|NCT01210105|||||PROSPECTIVE|||||||
34033742|NCT01375946|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033743|NCT00052143|||COHORT||PROSPECTIVE|||||||
34107787|NCT05314387|||COHORT||PROSPECTIVE|||||||
34107788|NCT06068361|||CASE_CONTROL||PROSPECTIVE|||||||
34107789|NCT01334567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107790|NCT03048825|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|double-dummy masking of colchicine and spironolactone in 2x2 factorial||t|t|t|t
34107791|NCT04150497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033744|NCT01531088|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34107792|NCT05103605|||OTHER||OTHER|||||||
34107793|NCT05934396|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34033745|NCT00408525|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34107794|NCT01173146|||COHORT||PROSPECTIVE|||||||
34107795|NCT06564532|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|participants are not told the specific nature of the marital enhancement intervention and both experimental and control participants complete the same procedure with only one exception--whether their partner is paired with positive or neutral words and images.|The investigators will recruit a sample of 500 active-duty servicemembers and their partners from Naval Medical Center at Portsmouth, VA. Half of all servicemembers will be randomly assigned to complete our EC procedure that pairs their partner with positive stimuli whereas the other half will be randomly assigned to complete a control procedure in which their partner is paired with neutral stimuli. Crossed with this manipulation, and also by random assignment, the partners of half the servicemembers will complete our EC procedure whereas the partners of the other half will complete the control procedure.|t|f|f|f
34107796|NCT06549452|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, un-blinded, parallel group, Phase II study of 50 subjects with PAH. Eligible subjects will be randomly assigned to receive the mHealth intervention or usual care for twelve weeks.||||
34107797|NCT00626951|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34107798|NCT00459550|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33724703|NCT03849404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double blind study.||t|t|t|t
34033746|NCT03856723|||COHORT||PROSPECTIVE|||||||
34033747|NCT00811967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033748|NCT03738072|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033749|NCT02518061|||COHORT||RETROSPECTIVE|||||||
34033750|NCT04696536|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34033751|NCT03766815|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be able to distinguish branched-chain amino acid and fiber supplement by taste, color or scent as the supplements are provided in jelly.|Participants will be supplemented for 18 days with either 200mg BCAA/kg/day, 400mg BCAA/kg/day or placebo (fiber supplement) in jelly in a single-blind fashion. Followed by a muscle damaging exercise and subsequent MVC and blood sample for force and metabolite measurements.|t|f|f|f
34033752|NCT05671458|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033753|NCT00102622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033754|NCT01121250|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34107799|NCT03802851|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a small scale study with initial enrollment of 20 patients in the treatment arm of the study and an additional 10 patients enrolled in the control arm of the study.||||
34107800|NCT05510934|||COHORT||PROSPECTIVE|||||||
34107801|NCT04054362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107802|NCT00847730|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34107803|NCT04816721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107804|NCT00800345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107805|NCT06639373|||COHORT||PROSPECTIVE|||||||
34107806|NCT05853406|||COHORT||PROSPECTIVE|||||||
34107807|NCT00242892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107808|NCT06675656|||COHORT||PROSPECTIVE|||||||
34107809|NCT01842347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107810|NCT06193681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107811|NCT04569032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107812|NCT03742726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107813|NCT05046730|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34107814|NCT05315752|||CASE_ONLY||PROSPECTIVE|||||||
33724704|NCT02816840|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724705|NCT04025996|||CASE_ONLY||PROSPECTIVE|||||||
33724706|NCT05752110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33724707|NCT03604042|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33724708|NCT00527943|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33724709|NCT01040377|||COHORT||RETROSPECTIVE|||||||
33724710|NCT05840354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724711|NCT04577287|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33724712|NCT04319042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724713|NCT06190431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724714|NCT02211131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033755|NCT04245254|NA|SINGLE_GROUP||TREATMENT||NONE|All participants receive one brand of collegen protien powder|Single arm interventional study.||||
34033756|NCT01306305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033757|NCT04269993|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34033758|NCT04051203|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|All members of the study will be blinded (participants and healthcare practioners) except for the study coordinator.|Randomized controlled trial, participants are randomly assigned to one of three groups; an autologous PRP injection, a steroid injection, or normal saline.|t|t|t|f
34033759|NCT03007849|||CASE_CONTROL||PROSPECTIVE|||||||
34033760|NCT06583200|RANDOMIZED|SEQUENTIAL||SCREENING||TRIPLE|||t|t|f|t
34033761|NCT01805843|||COHORT||PROSPECTIVE|||||||
34033762|NCT01678508|||COHORT||RETROSPECTIVE|||||||
34033763|NCT02076087|||OTHER||CROSS_SECTIONAL|||||||
34033764|NCT00835302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033765|NCT00924300|||CASE_CONTROL||OTHER|||||||
34033766|NCT02035111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033767|NCT01144429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033768|NCT00262197|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34033769|NCT00685217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033770|NCT05260294|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The patients were divided into two groups of 20 each and underwent CESI with either an 18G or a 25G Tuohy needle.||||
34033771|NCT00646334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033772|NCT01027702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033773|NCT03730220|||COHORT||PROSPECTIVE|||||||
34033774|NCT06581978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033775|NCT03853031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly allotted to either TEE or CVP Group according to computer generated randomization thus will be masked .|During surgery Control group of patients will receive CVP guided fluids Study group of patients will receive TEE measured LVEDA guided fluids|t|f|f|f
34033776|NCT02291991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033777|NCT01358214|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033778|NCT03925675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Subject who agree to participate in this study prior to surgery and sign the consent document, will have the following procedures done:~1. Axumin (fluciclovine-F18) PET/CT scan will be done to evaluate possible recurrence to help differentiate scar (fake recurrence) from true tumor recurrence, which could be at any time point after initial surgery.~2. Standard of care imaging surveillance will be done after initial tumor surgery~3. Standard of care surgery will include the removal of the tumor.~Tumor sample will then be analyzed and compared to the imaging (comparison of MRI, MRSI, and Axumin (fluciclovine-F18) imaging) results to determine an accurate diagnosis and location of tumor in the body."||||
34033779|NCT03707210|RANDOMIZED|PARALLEL||OTHER||NONE||intervention: VR training; control group: ISO document||||
34033780|NCT00477880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033781|NCT03989492|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033782|NCT04164290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A is double-blind with regard to treatment (Jiashen Tablets or placebo) at each dose level. Jiashen Tablets and placebo will be matched for formulation, appearance, and amount. Part B and Part C are open-label with regard to treatment (Jiashen Tablets) at each dose level.||t|t|t|t
34033783|NCT02467140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033784|NCT05473494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34033785|NCT04109586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34033786|NCT00486850|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033787|NCT04629378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033788|NCT03338634|||CASE_ONLY||PROSPECTIVE|||||||
34033789|NCT02653248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033790|NCT00801567|NA|SINGLE_GROUP||||NONE||||||
34033791|NCT05439681|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Randomized controlled four-treatment, four-period crossover trial||||
34152490|NCT06002568|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A prospective randomized, placebo-controlled trial|t|f|t|t
34152491|NCT02039856|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled trial (cRCT) among 12 VAMCs with unbalanced allocation (2:1) blocked on VA network (Veterans Integrated Service Network or VISN)||||
34152492|NCT01940081|||COHORT||PROSPECTIVE|||||||
34152493|NCT05551052|||COHORT||PROSPECTIVE|||||||
34152494|NCT05847413|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||open label proof of concept study||||
34152495|NCT02204488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152496|NCT02757612|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152497|NCT03652675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After participants complete the screening assessment, the research coordinator will be able to determine alcohol use disorder status from the responses. The research coordinator will provide the counselor or PI with subject identification number (ID; assigned consecutively) and alcohol use disorder status. The counselor or PI will then randomize participants using pre-determined blocked lists created by a biostatistician, in order to balance treatment groups across alcohol use disorder status (the research coordinator will not randomize in order to remain blind to condition).||f|f|f|t
34152498|NCT02434965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152499|NCT05132777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152500|NCT04442685|||COHORT||PROSPECTIVE|||||||
34152501|NCT02356679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806631|NCT02148575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34152502|NCT00001088||||PREVENTION||DOUBLE||||||
33806632|NCT05456932|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806633|NCT05180838|||COHORT||PROSPECTIVE|||||||
33806634|NCT03085433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806635|NCT03489369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806636|NCT03852069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806637|NCT00210106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152503|NCT04708002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||stepped-wedge design||||
34152504|NCT02463864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152505|NCT05487183|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152506|NCT03649009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study is a single-blinded trial, with the participants from both intervention and placebo group will be masked|This study is a prospective, randomized controlled trial|t|f|f|f
34152507|NCT02541851|||COHORT||RETROSPECTIVE|||||||
34152508|NCT06502938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152509|NCT00479479|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34152510|NCT05770024|||COHORT||PROSPECTIVE|||||||
34152511|NCT00187070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152512|NCT01807377|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34152513|NCT04702659|||OTHER||OTHER|||||||
34152514|NCT05626127|||COHORT||PROSPECTIVE|||||||
34152515|NCT04546594|||COHORT||PROSPECTIVE|||||||
34152516|NCT01151163|||CASE_CONTROL||PROSPECTIVE|||||||
34107815|NCT06363981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo intervention will be delivered with a programmable coil for magnetic stimulation, which can be switched by a third person between modes of active (therapeutic) and sham stimulation. In the sham-mode coil elicits similar sounds as in the active stimulation, but induces only negligible magnetic field.|Parallel Assignment Prospective, randomized, sham-controlled clinical trial in parallel design|t|t|t|t
34107816|NCT06494644|NA|SINGLE_GROUP||OTHER||NONE||This is an open-label, single-group, 3 period fixed sequence study.||||
34107817|NCT03511846|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|In the oxygen portion of the study, subjects and the outcomes assessors will be told that they will be receiving either medical air or oxygen.||t|f|f|t
34107818|NCT06049160|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107819|NCT06352970|||COHORT||PROSPECTIVE|||||||
34107820|NCT03347669|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking|||||
34107821|NCT05454982|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34107822|NCT06637735|RANDOMIZED|PARALLEL||PREVENTION||NONE||experimental and control group||||
34033792|NCT03807726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Eligible participants will be randomly assigned to either intervention group or control group. A permuted block randomization method will be used to ensure equal number of subjects in each group. A block size of 4 including 6 different combinations, i.e., AABB, ABAB, ABBA, BBAA, BABA, and BAAB will be adopted. The sequence of block number will be generated randomly by the computer and then apply to the first four subjects and so on. The allocation concealment will be maintained by using opaque sealed envelopes containing the sequence number and will be prepared by the researcher who is not involved in participants' recruitment.|A single-blind randomized controlled trial with a two-arm design will be conducted among new mothers and their partners. The objectives are to determine whether an integrated breastfeeding education program based on breastfeeding self-efficacy theory \[28, 31\] will increase exclusive breastfeeding duration among women and psychological correlates of exclusive breastfeeding. This is a novel educational intervention incorporated simulation-based courses, mindfulness training, and professional support for targeting mother and her partner's self-efficacy enhancement.|t|f|f|f
34033793|NCT05066360|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||two groups (epileptic and healthy participants)||||
34033794|NCT06344273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"You are completely free to participate in the research or not. Not participating in this research will certainly not affect the service you receive. You have the right to withdraw from the study at any time by giving notice; you may also be excluded from the study by the investigator, if deemed necessary, provided that no harm is done to your medical condition.~If you participate in the research, you will not be charged or paid any fees for the expenses to be made in the study. In addition, at the end of the research, your information will only serve scientific purposes without revealing your identity."|"The patients will be divided into the intervention group (n=32) in which 20 minutes of ROM exercise was applied and the control group (n=32) in which routine nursing care was given. For the sample calculation of the study, G power analysis was performed, type 1 error was 0.05; type 2 error 0.20; With a power of 0.80, a minimum sample size of 64 people for the experimental and control groups. The case group will be given lower extremity ROM exercises for a total of two weeks. Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session. Piper's Fatigue Scale and Hemodialysis Comfort Scale in the data collection form will be applied again at the end of the 1st and 2nd weeks after the sessions have started. The vital signs of the individual will be followed and recorded at each session."|t|f|f|f
34033795|NCT05102929|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34033796|NCT06133361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033797|NCT03937505|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stage A is a dose-cohort escalation to determine optimal efficacious dose, Stage B is an expanded safety and efficacy evaluation of the optimal dose with a no-drug safety control group||||
34033798|NCT04371744|||COHORT||PROSPECTIVE|||||||
34033799|NCT04545840|||COHORT||PROSPECTIVE|||||||
34033800|NCT00379392|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34033801|NCT03223350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical appearing placebo cream used for control||t|t|t|t
34033802|NCT00422110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34033803|NCT06581315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033804|NCT00548613|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033805|NCT01750190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033806|NCT04435912|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization envelopes kept closed until the completion of patient registration.|Parallel group, randomized, controlled trial with 1:1 allocation ratio. Participants were Patients undergoing cardiac surgery using cardiopulmonary bypass.|f|t|t|f
34033807|NCT04552353|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single Group Assignment||||
34033808|NCT00661193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033809|NCT05869201|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34033810|NCT00477048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033811|NCT02342301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033812|NCT04716647|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Community Based Participatory Research||||
34033813|NCT04163965|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033814|NCT01961050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34033815|NCT05319379|||COHORT||PROSPECTIVE|||||||
34033816|NCT06581497|||COHORT||RETROSPECTIVE|||||||
34033817|NCT04113577|||COHORT||PROSPECTIVE|||||||
34033818|NCT05579028|||CASE_CONTROL||PROSPECTIVE|||||||
34033819|NCT04681560|||OTHER||PROSPECTIVE|||||||
34033820|NCT02263963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033821|NCT00767403|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34033822|NCT00269230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033823|NCT05080296|||COHORT||RETROSPECTIVE|||||||
34107823|NCT00370084|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34107824|NCT01965951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107825|NCT05032352|||COHORT||PROSPECTIVE|||||||
34152517|NCT06037408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34152518|NCT01420731|||||PROSPECTIVE|||||||
34033824|NCT03411161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be conducted in two successive parts:~* a dose escalation phase I part, which is a single arm, non-randomised and non-comparative study in patient with mBC~* a randomised phase II part, which is a two-arm, randomised study at RP2D (recommended phase II dose), to evaluate the efficacy and the safety of S 81694 in combination with paclitaxel (experimental arm) versus paclitaxel alone (comparator arm) in untreated mTNBC"||||
34033825|NCT00826969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033826|NCT02194361|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34033827|NCT05973968|||COHORT||PROSPECTIVE|||||||
34033828|NCT02435524|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033829|NCT04501406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized, placebo-controlled.|Parallel assignment.|t|t|t|t
34033830|NCT01569295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033831|NCT02288312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033832|NCT02738710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033833|NCT01315431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033834|NCT02203929|||COHORT||PROSPECTIVE|||||||
34033835|NCT06194968|||COHORT||PROSPECTIVE|||||||
34033836|NCT05898724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The present study will include 18 Egyptian males orthodontic patients divided into three groups; blank group, silver hydroxyapatite group, zinc oxide group. Each group will include six patients that will have a surgical procedure to install two orthodontic miniscrews (blank or nano-coated) (1.6 mm diameter and 6 mm length).|t|t|t|t
34033837|NCT00495807|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34033838|NCT04425525|||CASE_ONLY||OTHER|||||||
34033839|NCT05857150|||COHORT||PROSPECTIVE|||||||
34033840|NCT01522209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033841|NCT01366118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033842|NCT04664465|||COHORT||PROSPECTIVE|||||||
34033843|NCT00593515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34033844|NCT02947360|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033845|NCT04181619|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double-blind||t|t|t|t
34033846|NCT01977495|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34033847|NCT00153179|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34033848|NCT01101815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033849|NCT02692443|||COHORT||PROSPECTIVE|||||||
34033850|NCT06437015|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34033851|NCT02618759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033852|NCT01565356|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34033853|NCT04068493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blind to the condition that participants are assigned to.||f|f|f|t
34033854|NCT06581757|||COHORT||RETROSPECTIVE|||||||
34033855|NCT02872376|||COHORT||PROSPECTIVE|||||||
34033856|NCT03982992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033857|NCT05954390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blinded, randomized study. Only the administering pharmacist will have access to the randomization tables||t|t|t|t
34152519|NCT02901132|||COHORT||PROSPECTIVE|||||||
34152520|NCT03281083|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study.||||
34152521|NCT03251950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152522|NCT05278832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152523|NCT02986815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152524|NCT05606055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152525|NCT01900288|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152526|NCT04672850|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blinded||t|f|t|t
34152527|NCT05897697|||OTHER||CROSS_SECTIONAL|||||||
34152528|NCT06547073|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34152529|NCT05894811|||COHORT||PROSPECTIVE|||||||
34152530|NCT01756222|||CASE_ONLY||PROSPECTIVE|||||||
34152531|NCT00005014|RANDOMIZED|||TREATMENT||DOUBLE||||||
34152532|NCT03537313|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Factorial 2-by-2 open labeled randomised controlled trial|f|f|f|t
34152533|NCT00938522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152534|NCT04699461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152535|NCT01681524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152536|NCT04538313|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
34152537|NCT02461082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152538|NCT00303888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152539|NCT01306656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, investigator and study team will be blinded to study arm ramdomization.|"Active arm:~Month 1: 20,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.~Months 2-6: 10,000 IU vitamin D3 once a week, plus daily multivitamin with 400 IU vitamin D.~Placebo arm:~Month 1: Placebo once a week plus daily multivitamin with 400 IU vitamin D.~Months 2-6: Placebo every week plus daily multivitamin with 400 IU vitamin D."|t|f|t|t
34152540|NCT03189901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107826|NCT04883203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"the intervention group will have vitamin D supplementation (200,000 IU / 1 mL of Cholecalciferol (1 ml) Oral form).~Control group will have a placebo treatment (physiological saline)."|A randomized clinical trial with 2 parallel arms and participant masking|t|f|f|f
34107827|NCT05547867|||COHORT||RETROSPECTIVE|||||||
34107828|NCT02163863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107829|NCT06245655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34107830|NCT00251654|||||PROSPECTIVE|||||||
34107831|NCT06644950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized clinical trial|t|t|t|t
34107832|NCT02069847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107833|NCT03689179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study uses a full-powered pilot sample (n=150) and a randomized waitlist control design to examine feasibility and initial efficacy of the TLC intervention. After an initial orientation/control period (4 weeks), group A will receive access to the TLC intervention for 8 weeks, followed by an optional 8-week control period where they can continue to use the TLC intervention if they choose. After the initial 4-week orientation period, Group B will receive 8 weeks of waitlist (no treatment) control, followed by access to the TLC intervention for 8 weeks. Primary outcomes (defined as anxiety, caregiver burden) will be assessed by electronically delivered surveys every 4 weeks; respite time-use and time-use satisfaction will be assessed using ecological momentary analysis for each respite period taken during the 20-week study period; feasibility will be assessed using fixed-choice and open-ended survey questions collected post-intervention.||||
34107834|NCT03014414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107835|NCT05604586|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double (Participant/investigator)|Eligible volunteers will be randomly assigned to one of the research groups. One of the groups will be taking the supplement for a period of 7 days, while the other group will be taking a placebo. Then a 3 week washout period will be performed. After that the groups will be exchanged and each participant will be assigned to a different group than it was in the first period of the study.|t|f|t|f
34107836|NCT04502108|||COHORT||PROSPECTIVE|||||||
34107837|NCT06371352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo intervention will be delivered with a sham-coil for magnetic stimulation, which looks identical and elicits similar sounds as the coil used for active stimulation, but induces only negligible magnetic field.|Prospective, randomized, sham-controlled clinical trial in parallel design|t|f|t|t
34107838|NCT06643195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107839|NCT06644885|||COHORT||RETROSPECTIVE|||||||
34107840|NCT06640712|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||his study uses a parallel design to compare the oral health status among individuals with different substance use disorders (Methamphetamine, Cannabis, Polysubstance) and a healthy control group.||||
34107841|NCT03287063|||COHORT||PROSPECTIVE|||||||
34107842|NCT01657331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107843|NCT05509660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107844|NCT05406726|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Masking will occur as to the order of receiving either PEA or placebo for the first six weeks, then the reverse for the following six weeks.|This is a crossover clinical trial where 10 participants will receive palmitoylethanolamide (PEA) dietary supplement for 6 weeks and 10 participants will receive placebo for six weeks. Then the following six weeks they will reverse.|t|t|t|t
34107845|NCT03809533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107846|NCT06673615|||COHORT||PROSPECTIVE|||||||
33806638|NCT06157554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806639|NCT02628015|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806640|NCT01319838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806641|NCT02666066|||COHORT||RETROSPECTIVE|||||||
33806642|NCT03916341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single (outcomes assessor) code|Crossover with 4 week washout|f|f|f|t
33806643|NCT01928459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806644|NCT04719026|||CASE_CONTROL||PROSPECTIVE|||||||
34033858|NCT06487741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants are blinded to the results of the pressure pain threshold measurements. Participants and the outcome assessor are blinded to the range of motion measurement results. The outcome assessor (MPS) is blinded to the outcome of the FIQ-R, SF-36 and IPAQ questionnaires.~Blinding participants and the care provider (MPS) from delivering the intervention from treatment allocation is contrary to the nature of the investigated intervention and, therefore, is not considered feasible."||t|f|f|t
34107847|NCT06527937|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34152541|NCT02055300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806645|NCT05142215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806646|NCT03738709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806647|NCT04890938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study personnel (aside from the research coordinator) will be blinded to randomization, sputum biomarker results, and treatment arm. Sputum biomarker results (de-identified) will be available to site leads to optimize treatment.||f|t|f|f
33806648|NCT03683576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806649|NCT05309200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806650|NCT05940740|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806651|NCT03977194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806652|NCT04070963|||COHORT||PROSPECTIVE|||||||
33806653|NCT03515369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806654|NCT00255372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806655|NCT05112549|NA|SEQUENTIAL||TREATMENT||NONE||"This is a single arm phase 1 trial with two parts.~For part I (3+3 Design) there will be four cohorts:~Cohort 1 with a fix dose of 20 mg, Cohort 2 with a fix dose of 30 mg, Cohort 3 with a fix dose of 40 mg and Cohort 4 with a fix dose of 50 mg.~The dosage in the expansion part II will be fixe dosage for all patients depending on the results from Part I"||||
33806656|NCT04918875|||COHORT||PROSPECTIVE|||||||
33806657|NCT03428633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806658|NCT03733275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033859|NCT00257400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107848|NCT06397612|NA|SINGLE_GROUP||TREATMENT||NONE||The study corresponds to a non-randomized, single treatment arm, prospective, multicenter study. The subject, the assignor, the physiotherapist, the statistician and a person in charge of activating the protocol will know the stimulation parameters, to adjust, monitor and apply the treatment.||||
34107849|NCT03755336|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34107850|NCT04378790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107851|NCT06334146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107852|NCT00052897|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34107853|NCT02522221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107854|NCT03151668|RANDOMIZED|PARALLEL||TREATMENT||||||||
34033860|NCT05973799|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each subject will undergo two metabolic studies, one after having remained fasted and one after having eaten breakfast and lunch.||||
33806659|NCT06371456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033861|NCT02064296|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34033862|NCT03098160||SEQUENTIAL||TREATMENT||NONE||During the initial phase of the study a maximum tolerated dose will be determined based on the dose escalation scheme in the protocol. Once this dose is established, enrollment will be expanded for each of the 4 disease cohorts at that dose level.||||
34033863|NCT05404685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The randomization list is drawn up by the statistician of the Center for Methodology and Data Management (USMR of the Bordeaux University Hospital) before starting the research.~The numbers of the 2 strategy groups are balanced with a 1:1 ratio. The randomization will be stratified on the study centers and a detailed description of the analgesia practices of each center will be made at the beginning of the study.~The randomization will be done when the patient is under general anesthesia. Patients will not be told which group they have been randomized to."||t|f|f|t
34033864|NCT06571773|||COHORT||RETROSPECTIVE|||||||
34033865|NCT04459039|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34033866|NCT06582914|||COHORT||PROSPECTIVE|||||||
34033867|NCT04816643|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34033868|NCT03861624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033869|NCT05612581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033870|NCT05271656|NA|SINGLE_GROUP||SCREENING||NONE|The Sponsor and the C-Scan data analysis team shall be blind to subject's optical colonoscopy data until the C-Scan report is created.|||||
34033871|NCT05366452|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34033872|NCT02207205|NA|SINGLE_GROUP||OTHER||NONE||||||
34033873|NCT03817190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033874|NCT06333418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Investigator)|Parallel Assignment experimental model using randomized pretest and posttest with control group|t|f|t|f
34033875|NCT00399048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033876|NCT03305250|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34033877|NCT05085379|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033878|NCT05782777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033879|NCT01200069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34033880|NCT01259479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033881|NCT03305133|||COHORT||RETROSPECTIVE|||||||
34033882|NCT03225417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033883|NCT05053633|||OTHER||PROSPECTIVE|||||||
34033884|NCT01133067|||COHORT||PROSPECTIVE|||||||
34033885|NCT04893473|||COHORT||PROSPECTIVE|||||||
34033886|NCT04748484|NA|SINGLE_GROUP||TREATMENT||NONE|The medical device will be active or inactive, but the patient nor the investigator won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.|Single case experimental design : the principle is to evaluate intensively and prospectively a small group of subjects, each case being its own comparator||||
34033887|NCT05635591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033888|NCT02007525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34033889|NCT02009722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033890|NCT00573378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107855|NCT05116345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107856|NCT00019838||||TREATMENT||||||||
34107857|NCT05548296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with an OncoSignature positive test will enter a Phase 2 study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 tumor types, ovarian, endometrial, and urothelial carcinomas. Participants with an OncoSignature negative test will be entered in an exploratory Phase 2 study to assess the efficacy and safety of the combination of ACR-368 and ultralow dose gemcitabine (ULDG) in each of the 3 tumor types.||||
34107858|NCT03478488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107859|NCT05973045|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Controlled Clinical Study||||
34107860|NCT05629572|||COHORT||PROSPECTIVE|||||||
34107861|NCT05995600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Prospective, Randomized, Open-label, Blinded Endpoint (PROBE) trial||f|f|f|t
34107862|NCT05860751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107863|NCT02193191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107864|NCT01822327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107865|NCT01400412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107866|NCT05726370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107867|NCT06290323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher evaluating the survey does not know which group the patients are.|Patients with double J catheter inserted into ureteroscopic lithotripsy surgeries due to urethral stones|f|f|f|t
34107868|NCT05811858|||CASE_CROSSOVER||PROSPECTIVE|||||||
34107869|NCT02132260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107870|NCT06624345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033891|NCT06483867|||COHORT||PROSPECTIVE|||||||
34107871|NCT06260774|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation Study Design||||
34107872|NCT06445439|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.|f|f|t|t
34107873|NCT03342222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806660|NCT06698783|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806661|NCT01754051|||COHORT||PROSPECTIVE|||||||
34107874|NCT05421494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806662|NCT03074032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33806663|NCT04178213|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, non-randomised, single arm, single-centre First In Human clinical investigation||||
34033892|NCT00511732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033893|NCT03552510|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Laboratory assessment of GIT hormonal level will be masked|Oropharyngeal Administration of mother's milk (OPAMM)|f|f|f|t
34033894|NCT05464979|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34033895|NCT04428034|NA|SINGLE_GROUP||OTHER||NONE||A pre- and post-test design to test the Learning Skills Together program will be employed.||||
34033896|NCT03153163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033897|NCT00673439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033898|NCT04903431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033899|NCT05217576|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033900|NCT00946738|RANDOMIZED|PARALLEL||TREATMENT||||||||
34033901|NCT04966871|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033902|NCT00221455|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033903|NCT03660995|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34033904|NCT00136227|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033905|NCT01552161|||COHORT||PROSPECTIVE|||||||
34033906|NCT04656600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033907|NCT02603588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34033908|NCT04150172|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34033909|NCT00026065|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34033910|NCT05476705|||OTHER||CROSS_SECTIONAL|||||||
34033911|NCT06263933|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A control group and a intervention group||||
34033912|NCT00925704|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34033913|NCT05577533|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033914|NCT06399835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033915|NCT00019773||||TREATMENT||||||||
34033916|NCT02754050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033917|NCT01605851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033918|NCT02504528|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34033919|NCT00985244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34033920|NCT04857489|||COHORT||PROSPECTIVE|||||||
34033921|NCT02724514|||COHORT||PROSPECTIVE|||||||
34033922|NCT01722630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033923|NCT01384110|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34033924|NCT02389179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033925|NCT01841684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033926|NCT05210660|||COHORT||CROSS_SECTIONAL|||||||
34033927|NCT02990429|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34033928|NCT00437567|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34033929|NCT05679050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033930|NCT06044142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033931|NCT01849237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033932|NCT05895396|||COHORT||PROSPECTIVE|||||||
34033933|NCT00980694|NA|SINGLE_GROUP||||NONE||||||
34033934|NCT03337061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152542|NCT04353700|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants were randomly assigned either a yoga intervention group or a control group.||||
34152543|NCT05390658|||COHORT||OTHER|||||||
33806664|NCT01371994|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806665|NCT03876457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806666|NCT03155815|||COHORT||RETROSPECTIVE|||||||
34033935|NCT01231893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033936|NCT03376919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033937|NCT01055756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34033938|NCT03119870|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033939|NCT00681343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033940|NCT05876806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033941|NCT06261424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All participants will be assessed at their respective neuromuscular clinic (Saguenay, Quebec, Montreal or Calgary) by physiotherapists trained according to standard operating procedures (SOP). These physiotherapists will not be involved in the supervision of the program and will be blinded.|A multicentre and controlled trial design.|f|t|f|f
34033942|NCT01602068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033943|NCT02367976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033944|NCT04006002|||COHORT||PROSPECTIVE|||||||
34033945|NCT00544635|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033946|NCT00838526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033947|NCT03293537|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34033948|NCT06345911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34033949|NCT06048952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention and Non Intervention Group||||
34033950|NCT01268462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033951|NCT02983786|||OTHER||PROSPECTIVE|||||||
34033952|NCT05537207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806667|NCT03220334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806668|NCT00023920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806669|NCT04661306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033953|NCT02824055|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34033954|NCT05186389|||COHORT||OTHER|||||||
34033955|NCT02104570|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34033956|NCT02350465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033957|NCT02383017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind, placebo and supplement intervention|A 12-week training model with testing weeks at baseline, mid point (week 7) and post-training.|t|f|t|f
34107875|NCT05941429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded study. Participants were blinded towards agents used in the study by using two identical squeezable plastic droppers with tag codes A and B. Also the bio-statistician will be blinded from the meaning of codes.||t|f|f|t
34107876|NCT01585532|||CASE_ONLY||PROSPECTIVE|||||||
34107877|NCT06636916|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34107878|NCT06124924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107879|NCT06644352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107880|NCT06674629|||COHORT||PROSPECTIVE|||||||
34107881|NCT06275074|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors will be blinded to group assignment of participants.||f|f|f|t
34107882|NCT00736151|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||||||
34107883|NCT01743144|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34107884|NCT06640582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107885|NCT02786329|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107886|NCT05609253|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The primary purpose is to determine the ideal formulation (capsule versus solution) of itraconazole in this short-term pilot study.||||
34107887|NCT02687620|||COHORT||PROSPECTIVE|||||||
34107888|NCT05712395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized controlled clinical trial|f|f|f|t
34107889|NCT06570538|RANDOMIZED|PARALLEL||TREATMENT||NONE|In view of ethical considerations, the study was not blinded to anesthesiologists and patients, and the investigator responsible for postoperative follow-up was not involved in intraoperative anesthesia management.|||||
34107890|NCT02998866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107891|NCT03231735|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a randomized controlled trial with a 1:1 parallel allocation of infants to mid or standard frequency ventilation using stratified permuted block design.||||
34107892|NCT06563804|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107893|NCT04448847|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|a randomised, double-blinded, placebo-controlled, cross-over trial||t|t|t|t
34107894|NCT04421001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107895|NCT03795519|NA|SINGLE_GROUP||OTHER||NONE||||||
34033958|NCT01689051|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34107896|NCT00660231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033959|NCT04565574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033960|NCT03303235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient and obstetrician will all be blinded to group assignments. The anesthesiologist will make and administer the medication, as it is important for timely administration of the methylergonovine when it is asked to be used. The anesthesiologist directly taking care of the patient will not be blinded.||t|t|f|t
34033961|NCT05870384|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This study is a single group Remeasurement Quasi-experimental Study. The intervention in the study is the application of IPT-G to the caregivers of the patients with schizophrenia. The intervention consists of 10 sessions to be held once a week. The first 2 sessions will be individual, followed by 8 group sessions. Sessions will last an average of 90 minutes. The group is a closed group, no new participants will be accepted after the sessions have started. The study will measure the impact of the therapy on both the caregivers and patients, with follow-up evaluations at 3 and 6 months after the sessions. At the end of the experiment, the t-test for dependent groups will be used, in which the averages of the pre-test and post-test scores are compared whether the results are significant or not."||||
34033962|NCT05683704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033963|NCT04294407|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34033964|NCT02193919|||COHORT||PROSPECTIVE|||||||
34033965|NCT01729273|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34033966|NCT03205319|RANDOMIZED|PARALLEL||OTHER||NONE|Masking will be impossible in this study|Multicenter, randomised controlled, open label||||
34033967|NCT05172115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation sequence concealment and blinded outcome adjudication|1:1 open-label parallel group randomized controlled trial with concealed allocation sequence and blinded outcome adjudication|f|f|f|t
34033968|NCT04304989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34033969|NCT00366795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033970|NCT01043692|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033971|NCT06358768|||CASE_CROSSOVER||PROSPECTIVE|||||||
34033972|NCT02245516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34033973|NCT03982290|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigators, researchers, outcome assessors, subjects and caregivers will be blinded to the randomization. A research assistant who is not involved in this trial will do the randomization by using randomly permuted blocks within the strata of two assignments, the placebo group and PS128 group with the ratio of 1:1.|Double-blinded, randomized, placebo-controlled|t|t|t|t
34107897|NCT06641492|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34107898|NCT05757401|||COHORT||PROSPECTIVE|||||||
34107899|NCT05665452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107900|NCT05972785|||COHORT||RETROSPECTIVE|||||||
34107901|NCT00002759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107902|NCT05272488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107903|NCT06231264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107904|NCT04428905|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34107905|NCT04142723|||CASE_CROSSOVER||PROSPECTIVE|||||||
34107906|NCT04722809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107907|NCT05698498|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Single-blinded study||f|f|t|t
34107908|NCT03926247|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a pilot study of an intervention with a within-group longitudinal design. All participants will participate in the intervention.||||
34107909|NCT06643650|||COHORT||PROSPECTIVE|||||||
34107910|NCT05644301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107911|NCT05526157|||COHORT||RETROSPECTIVE|||||||
34107912|NCT03462121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|1:2||t|t|t|t
34107913|NCT06637072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152544|NCT05037058|||COHORT||OTHER|||||||
34152545|NCT01075503|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
34152546|NCT03172156|||COHORT||PROSPECTIVE|||||||
33806670|NCT01310140|||COHORT||PROSPECTIVE|||||||
33806671|NCT01410409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806672|NCT01982994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33806673|NCT06593457|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33806674|NCT06038942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107914|NCT04416815|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|The nature of the intervention means that neither participants nor the health care professionals (HCP) in the IHOPe intervention can be blinded to allocation in the RCT.|RCT: All older people who give consent for participation and who fulfill the inclusion criteria will be randomised. Randomisation will be conducted by research nurses. Participants will be randomly assigned to either control or intervention group with a 1:1 allocation as per a computer generated randomisation. The control group will receive usual care. The intervention group will receive person-centred care intervention during 6 month on top of usual care.||||
34107915|NCT05802134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107916|NCT05269797|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Behavioural||||
34152547|NCT02508324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152548|NCT01364311|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34152549|NCT05019768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152550|NCT03657095|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment during the first 4 weeks of this study will be double-blind. The Investigator and study staff, the participants, the monitors, and the Sponsor will remain blinded to the treatment group allocation from BPS-314d-MR-PAH-302 double-blind study (NCT01908699) and to study drug during the first 4 weeks of the OLE study while the participants transition to the OLE treatment. After the 4 weeks, the study will continue as unblinded and open label.|||||
34152551|NCT04628234|||COHORT||PROSPECTIVE|||||||
33806675|NCT04794972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806676|NCT02628106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806677|NCT03711084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33806678|NCT00931502|||CASE_ONLY||OTHER|||||||
33806679|NCT00822120|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806680|NCT04088630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Consented participants will be allocated to study groups using fixed allocation randomization and a computer-based random number-generating allocation.The study pharmacist will be the only unblinded member of the study and will provide the appropriate study agent based on the statistician's randomization schema.|Randomized, double-blinded, placebo-controlled pilot trial.|t|f|t|t
33806681|NCT03185936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806682|NCT00690131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033974|NCT04513301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033975|NCT04817046|||COHORT||PROSPECTIVE|||||||
34033976|NCT04840303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033977|NCT03958929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34033978|NCT03923140|NA|SINGLE_GROUP||TREATMENT||NONE||a single-arm prospective cohort study||||
34033979|NCT03709043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033980|NCT01486225|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34033981|NCT04993001|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Pilot, single-center, randomized, triple-blind controlled study|t|f|t|t
34033982|NCT02601014|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34033983|NCT03051672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033984|NCT05111327|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The research assistant will assign students randomly in either interventional or control group. Students also did not know which group their facilitator is responsible.|Students will be randomly assigned in either interventional group or control group. There are two facilitators. Each facilitator will be consistently responsible for either interventional group or control group.|t|f|f|t
34033985|NCT00543881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34033986|NCT04083547|||COHORT||PROSPECTIVE|||||||
34033987|NCT06033131|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34033988|NCT05204706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34033989|NCT01025089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033990|NCT01722578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34033991|NCT00290017|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33806683|NCT05352308|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33806684|NCT05889910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"To avoid selection bias, professionals were blinded to group assignment at the time of patient recruitment.~Once everyone had signed the informed consent, a cluster group was assigned to each of the 10 participating Health Centers."|Two-arm, parallel, multicenter, cluster-randomized clinical trial, 1:1 participant distribution ratio.|f|f|f|t
33806685|NCT06223633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806686|NCT02330588|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33806687|NCT01141075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806688|NCT04773431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806689|NCT00954668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806690|NCT05407272|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33806691|NCT05095974|||CASE_CONTROL||PROSPECTIVE|||||||
33806692|NCT00694889|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34033992|NCT05778461|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033993|NCT04708678|||COHORT||RETROSPECTIVE|||||||
34033994|NCT00143442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33806693|NCT05758506|||COHORT||PROSPECTIVE|||||||
33806694|NCT05561231|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective single blinded randomised controlled trial|t|f|f|f
33806695|NCT00223444|||CASE_CONTROL||PROSPECTIVE|||||||
34033995|NCT01001650|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34033996|NCT03165812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will involve two groups with equal allocation of patients in the intensive medical therapy (IMT) group and Single Anastomosis Duodeno Jejunal Bypass with Sleeve Gastrectomy (SADJB-SG) group with stratification by use of insulin at screening. All patients who agree to participate in this study will be assigned to one of the treatment groups by the doctor without randomization.||||
34033997|NCT01452516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34033998|NCT02399137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107917|NCT06637410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Group 1 (HILT group) received HILT 3 sessions per week for 3 weeks in addition to the therapeutic exercise program applied 5 sessions per week for 3 weeks. Group 2 (US group) received an ultrasound program 3 days a week in addition to a therapeutic exercise program of 5 sessions per week for 3 weeks. ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set under the supervision of an experienced physiotherapist while taking their treatments.|t|f|t|t
34107918|NCT03766399|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34107919|NCT03208790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107920|NCT00035984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34033999|NCT05392868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034000|NCT00618371|NA|SINGLE_GROUP||||NONE||||||
34034001|NCT02885545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034002|NCT06392529|||CASE_CONTROL||PROSPECTIVE|||||||
34034003|NCT05265338|RANDOMIZED|PARALLEL||OTHER||NONE||Double cycle, self crossover||||
34034004|NCT01345201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034005|NCT03431714|NA|SINGLE_GROUP||TREATMENT||NONE||The first group of 88 children were recruited first and given dihydroartemisinin- piperaquine, once the sample size was attained, the second group for artesunate amodiaquine followed and the follow-up for the two groups were running concurrently||||
34034006|NCT05593484|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Statisticians will also be masked to group allocation until analysis is complete.|Approximately 23 schools from 3 regions are participating in the effectiveness trial. Clusters (\~23 schools) will be randomized to one of two sequences. In academic year 2023-2024, all schools will receive enhanced screening (with standard referral). The Specialty Telemedicine Access for Referrals (STAR) intervention will be rolled out in a stepwise manner in academic years 2024-2025 and 2025-2026 depending on sequence randomization.|f|f|f|t
34034007|NCT01380561|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034008|NCT03052751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is an Investigator- and Subject-Blind study.||t|t|t|t
34034009|NCT05729737|||COHORT||PROSPECTIVE|||||||
34034010|NCT03989882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know their treatment assignment and energy balls will be in an opaque container.||t|f|f|f
34034011|NCT00218387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034012|NCT00317629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034013|NCT00127114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034014|NCT03196063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034015|NCT01597310|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34034016|NCT06582511|||COHORT||PROSPECTIVE|||||||
34034017|NCT00179881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034018|NCT03212235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034019|NCT04864067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034020|NCT00002425||||TREATMENT||||||||
34034021|NCT00877591|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034022|NCT03238651|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034023|NCT01204567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034024|NCT00197171|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034025|NCT02226211|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34034026|NCT02102113|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
34034027|NCT03897283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034028|NCT03642197|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A four-arm randomized controlled trial (RCT) using simple randomization will randomize female patients in romantic relationships into partner attended (PA) groups and treatment as usual (PA-TU) groups; patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups.~Patients in all arms will receive routine care. Support figures/partners of patients in the SFA and PA arms will be requested to attend the four pre-surgery classes with the patient and the three clinical visits; patients in the SFA-TU and PA-TU arms will attend individually.~Assessments will be completed by patients and support figures/partners (all four arms) at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4). The study will follow all groups for roughly six months."||||
34034029|NCT02561429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034030|NCT01257178|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34034031|NCT00000967||||TREATMENT||||||||
34034032|NCT04468685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034033|NCT05881824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034034|NCT03998267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects with T2DM will be randomised into an intervention arm and standard care arm. Subjects in the intervention arm receive usual diabetes care in addition to the mobile app while subjects in the standard care will receive usual diabetes care only.||||
34034035|NCT01738347|NA|SINGLE_GROUP||OTHER||NONE||||||
34034036|NCT02897024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034037|NCT03765450|||COHORT||PROSPECTIVE|||||||
34034038|NCT04132973|NA|SINGLE_GROUP||OTHER||NONE||This is an acceptability and feasibility study of a novel healthcare intervention, therefore there is only one study group.||||
34034039|NCT02125500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034040|NCT00366743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034041|NCT01385189|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107921|NCT03312543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107922|NCT06637111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107923|NCT04681885|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33806696|NCT02199626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806697|NCT05909670|NA|SINGLE_GROUP||TREATMENT||NONE||Caregivers of children will complete pre- and post-program assessments to determine the feasibility and acceptability of the intervention and exploratory effects on self-reported parenting stress and parenting sense of competence.||||
33806698|NCT00345046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806699|NCT05795088|NA|SINGLE_GROUP||OTHER||NONE||||||
33806700|NCT06415994|||COHORT||PROSPECTIVE|||||||
33806701|NCT00158483|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33806702|NCT04040296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33806703|NCT05990933|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will receive intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour. We will draw blood at baseline, 30 minutes, 60 minutes, 180 minutes, 24 hours 72 and a week after start of infusion. These samples will be used for phenotyping of the innate immune system and measuring inflammatory and atherogenic parameters. Throughout the infusion vital parameters will be monitored.||||
33806704|NCT02776982|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806705|NCT06698640|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33806706|NCT02250937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806707|NCT06270862|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33806708|NCT05995262|||COHORT||RETROSPECTIVE|||||||
33806709|NCT06699862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034042|NCT04937881|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This phase III study is a randomised control trial (RCT) of up to 60 pregnant women who will be recruited at first antenatal visit (ANC) from the Gugulethu Midwife and Obstetrics Unit.~Participants will be randomized into the TDF vs TAF arm:~TDF Arm: Women will receive a fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF) administered once daily under direct observation for 8 weeks during pregnancy and again for 8 weeks in postpartum period~TAF Arm: Fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF) administered once daily under direct observation for 8 weeks during pregnancy and again for 8 weeks in postpartum period Women will provide their own controls, providing pregnant and postpartum samples."||||
34034043|NCT04146103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034044|NCT04070261|||COHORT||PROSPECTIVE|||||||
34034045|NCT06582277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized assignment to 2 dose-level of experimental vaccine (180µg and 480µg) in a 1:1 ratio.|t|f|t|f
34034046|NCT00343525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034047|NCT06020118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034048|NCT03826342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34034049|NCT02251483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34034050|NCT02115607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034051|NCT00725920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034052|NCT05647577|||COHORT||PROSPECTIVE|||||||
34034053|NCT02499848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034054|NCT02654054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034055|NCT06549946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, single agent therapy||||
34034056|NCT03530683|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34034057|NCT02556801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study||t|t|t|t
34034058|NCT01651117|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
34034059|NCT05477836|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Traditional feasibility study, following a single-center prospective, non-comparative, with few patients design.||||
34034060|NCT04820426|||COHORT||PROSPECTIVE|||||||
34034061|NCT06531278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034062|NCT01288716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034063|NCT00147459|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034064|NCT01276860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034065|NCT04975711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34034066|NCT05751707|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric Parallel Group Controlled Randomized Clinical Trial||||
34034067|NCT03505970|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Double-blind crossover|t|f|t|t
34034068|NCT04951869|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|control group receives no protescal application while study group does|concurrent 2 arms with study arm and control arm of women undergoing caesarean section without any previous abdominal surgeries|t|f|f|f
34034069|NCT06280339|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be enrolled in dietary weight loss program. Before the first meeting they will be randomized to one of the two study groups that focus on teaching participants different strategies to cope with food cravings (Inclusion vs. Avoidance).. To ensure balanced representation and meaningful study results, the randomization process will consider specific characteristics, including BMI category, sex, and age. This stratified randomization method helps us compare the effects of the intervention between different groups of participants.||||
34034070|NCT00392691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034071|NCT06582069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034072|NCT00956423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034073|NCT04748107|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization to treatment of non treatment group||||
34034074|NCT04507464|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot randomized, controlled trial of a 6-week intervention for feasibility. Outcome measures will be obtained at baseline and at 6-weeks. Behavior choices and preference data will be continuously captured during the intervention. We will randomize 80 older Latinos from the Chicago Latino community to either an ecological momentary intervention using fitbits (n=40) or to physical activity guidelines (n=40).||||
34034075|NCT04420845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34034076|NCT06042543|NA|SINGLE_GROUP||SCREENING||NONE||||||
34034077|NCT01726829|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34034078|NCT02792517|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034079|NCT04186312|RANDOMIZED|PARALLEL||TREATMENT||||Randomized Controlled Trial comparing Immediate versus Delayed Treatment||||
34034080|NCT02604095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034081|NCT02570802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034082|NCT03727789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107924|NCT05269082|||COHORT||CROSS_SECTIONAL|||||||
34107925|NCT00410657|NON_RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34034083|NCT02566889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107926|NCT04265651|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34107927|NCT06569498|||CASE_ONLY||PROSPECTIVE|||||||
34107928|NCT00265122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107929|NCT05970237|||COHORT||PROSPECTIVE|||||||
34107930|NCT06674798|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||Qualitative exploratory phase -quantitative intervention phase -qualitative explanatory phase|t|f|f|f
33806710|NCT02186106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806711|NCT02001805|||COHORT||CROSS_SECTIONAL|||||||
34034084|NCT00825760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107931|NCT06638359|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|control trial|The effects of a single bout of moderate- aerobic continuous exercise (MACE) and high-intensity intermittent exercise (HIIE) on sleep during continuous night shifts in medical shift workers with mild sleep impairment.|f|f|t|f
34107932|NCT00085839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806712|NCT04587219|NA|SINGLE_GROUP||PREVENTION||NONE||Open prospective non-randomized study||||
34034085|NCT02790437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034086|NCT05706103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study model is parallel. Participants experiencing recurrent LBP patients will be randomly allocated (1:1) to receive either specific skilled motor training or general extension training (i.e. parallel study model). Both groups will first receive low-load training (i.e. at 25-30% of the individual's repetition maximum, sessions 1-9) followed by high-load training (i.e. at 40-60% of the individual's one repetition maximum, sessions 10-18) (i.e. cross-over study model).|t|t|f|f
34034087|NCT03241992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034088|NCT01695616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034089|NCT04366492|NA|SINGLE_GROUP||SCREENING||NONE||||||
34034090|NCT05289037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034091|NCT03499639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034092|NCT02519374|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34034093|NCT00729937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034094|NCT00749905|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34107933|NCT06614933|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will be blinded to which protocol they are receiving during data collection. The investigator responsible for processing HRV data will be blinded to group assignment, and investigators will be blinded to group assignment when conducting qualitative data analysis.||t|f|t|f
34107934|NCT04366531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Veterans will be randomly assigned to either begin an eight week (actual number of weeks is to be determined based on phase 2) active treatment program or to a no treatment phase. At eight weeks veterans will switch the condition they were assigned.||||
34152552|NCT03424122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152553|NCT03337464|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to subject group and intervention.|1 PD group and 1 one age matched non-PD subjects|f|f|f|t
34152554|NCT01533662|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34152555|NCT03050320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34152556|NCT00485082|||||RETROSPECTIVE|||||||
34152557|NCT00711789|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34152558|NCT00733941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152559|NCT05345028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152560|NCT05784519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152561|NCT00079677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152562|NCT06028360|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants were blind to allocation. They were allocated by simple randomization through lottery method.|A Randomized Control Trial with a Control and an Experimental group that will be given intervention 3 consecutive days.||||
34152563|NCT04557046|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Subject are asked to provide nasal swab or nasopharyngeal swab and saliva samples||||
34152564|NCT01767623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152565|NCT00922805|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34152566|NCT00679874|||COHORT||PROSPECTIVE|||||||
33806713|NCT06182475|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||To provide preliminary data on the efficacy and acceptability of the training program, we will employ a pre-post study design, with providers serving as their own controls (Aim 2). We will then test the indirect effects of the training on providers' communication with patients, patient and provider factors and live donor kidney transplant process outcomes.||||
34034095|NCT01669291|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34107935|NCT06174649|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Patient and care provider will not know which arm subject is randomized into until after the stewardship team has review the Reveal results and provided feedback on initial therapies prescribed.||t|t|f|f
34107936|NCT01760863|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34107937|NCT06673654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107938|NCT06644898|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34107939|NCT00515229|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33806714|NCT03021512|||COHORT||RETROSPECTIVE|||||||
33806715|NCT03989310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806716|NCT03568994|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Choice of Induction I regimen is at the treating physician's discretion (will be influenced based on drug availability)||||
33806717|NCT00070317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034096|NCT00440661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034097|NCT05031585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34034098|NCT04499469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034099|NCT02378129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034100|NCT04057729|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33806718|NCT03065049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806719|NCT04178421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806720|NCT00606333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806721|NCT05381311|||CASE_ONLY||CROSS_SECTIONAL|||||||
33806722|NCT03066284|||CASE_ONLY||OTHER|||||||
33806723|NCT04801823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806724|NCT04682418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806725|NCT04030832|||CASE_ONLY||PROSPECTIVE|||||||
34034101|NCT05590364|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|55 subjects undergoing Profhilo Body treatment in the back of the hands, 3 visits: Day 0 (treatment) Day 30 (1 month after Day 0 treatment) Day 120 (4 months after Day 0 - follow-up).||||
34034102|NCT02274883|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34034103|NCT04540419|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107940|NCT06256016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34107941|NCT06369545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controled Trial|t|f|f|f
34034104|NCT05469464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Tablets will be packaged in the same type of blister and the active and placebo tablets will have the same appearance (in terms of size, form, weight, and color).|Participants will be assigned randomly in a 1:1:1:1 ratio to receive 1 of the 3 orismilast modified release doses (20 mg, 30 mg, or 40 mg) or placebo twice daily (BID)|t|t|t|t
34034105|NCT03452943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107942|NCT06644443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152567|NCT03628274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152568|NCT05082727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind (Participant, Investigator)|Two arms: basic dose and placebo|t|f|t|f
34152569|NCT06583915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152570|NCT04476914|||COHORT||PROSPECTIVE|||||||
34152571|NCT05408026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152572|NCT04512924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152573|NCT00331188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152574|NCT04839120|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34152575|NCT04767152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34152576|NCT06075966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152577|NCT04004013|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34152578|NCT00370838|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34152579|NCT03610776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Masking is not possible due to the nature of the intervention (portion control vs. conventional plate).|Randomised, cross-over (within-subjects) design.||||
34152580|NCT03090555|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors are blinded to the study arm to which participants are assigned||f|f|f|t
34152581|NCT03262467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152582|NCT02768753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152583|NCT03869307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34152584|NCT02350504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152585|NCT03966885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcomes are evaluated via Audio Computer Assisted Self-Interviewing (ACASI)||f|f|f|t
34152586|NCT04675996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152587|NCT01431391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152588|NCT03389178|||CASE_CONTROL||PROSPECTIVE|||||||
34152589|NCT05196685|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34152590|NCT06007053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers who conduct baseline and follow-up visits will be blinded to the condition to which the patient has been assigned. The statistician and data manger will be blinded to treatment condition when analyzing data. The PI and therapists will be blinded to participant's baseline target scores.|Children with PNES and matched controls will be prospectively enrolled. PNES participants will be randomized to either supportive therapy or Retraining and Control Therapy (ReACT).|f|f|t|t
34152591|NCT02526225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34152592|NCT01685021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152593|NCT01415492|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34152594|NCT05673525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152595|NCT04833595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152596|NCT03344172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152597|NCT02169856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152598|NCT04476199|NA|SINGLE_GROUP||TREATMENT||NONE||These patients may undergo allo-SCT after 2 - 4 cycles of VEN-DEC||||
34152599|NCT03590249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The practitioner providing the OMT or No Treatment will not be involved in collecting data for each subject. The practitioner(s) and technicians collecting the data will not be involved in any aspect of the procedure performed (OMT or No Treatment) on the subjects.|The design of this preliminary pilot trial is a double-masked (blind), randomized, No Treatment-controlled, parallel group design.|t|f|t|t
34152600|NCT00373945|||||RETROSPECTIVE|||||||
34152601|NCT05419037|||CASE_ONLY||CROSS_SECTIONAL|||||||
34152602|NCT04943432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152603|NCT05899101|||COHORT||PROSPECTIVE|||||||
34152604|NCT05954767|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34152605|NCT01424527|||CASE_ONLY||CROSS_SECTIONAL|||||||
34152606|NCT02935413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152607|NCT05230849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Simple blind||f|f|t|f
34152608|NCT03045341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34152609|NCT01089790|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034106|NCT03987789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will not be possible to mask the assigned ventilation strategy from the treating clinicians because they have an ethical responsibility to ensure patient safety during the emergency procedures. However, procedures will be put in place to minimize the possibility of bias arising because research staff becomes aware of trial group allocation. At each participating center, patients will be followed up for primary and secondary endpoints by members of the research staff who will be unaware of the trial group allocation. Information on whether the primary and secondary outcomes occur will be collected and entered into the electronic web-based case report form (eCRF) by trial or clinical trained personal (clinical research associate), blinded to the allocation group, under the supervision of the local principal investigator (PI) or designee who will also be unaware of the trial group allocation.|Multicenter, prospective, randomized, stratified, parallel-group clinical trial with blinded outcome assessment and concealed allocation of patients undergoing emergency abdominal surgery using low VT lung-protective ventilation to a strategy of minimal alveolar distension using low PEEP level or to a strategy aimed at increasing alveolar recruitment (higher PEEP level individually titrated to minimize the driving pressure in addition to recruitment maneuvers)|f|f|f|t
34034107|NCT03397030|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was used in this study.|This study is designed randomized controlled, 2 arm parallel group pilot study.||||
34034108|NCT05938114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34034109|NCT04959526|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034110|NCT00524641|||||PROSPECTIVE|||||||
34034111|NCT01173120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034112|NCT05465837|||COHORT||RETROSPECTIVE|||||||
33806726|NCT06225336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806727|NCT06596564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This experiment will invite university students under the pretext of conducting other surveys. The content of this nudge intervention experiment will appear at the end of the Questionnaire Star platform, framed as a token of appreciation for participants' time and effort, offering a gift choice between cola and mineral water. This approach aims to prevent participants from guessing the true purpose of the experiment, which could potentially bias the experimental results.||t|f|f|f
33806728|NCT04407975|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33806729|NCT02974218|||COHORT||PROSPECTIVE|||||||
33806730|NCT04860505|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33806731|NCT02894554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806732|NCT05671510|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, active controlled, multi-center Phase 3 study.||||
33806733|NCT05657210|||COHORT||RETROSPECTIVE|||||||
33806734|NCT03739658|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33806735|NCT01227421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806736|NCT03409159|||COHORT||RETROSPECTIVE|||||||
33806737|NCT03454113|||COHORT||PROSPECTIVE|||||||
33806738|NCT00312208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806739|NCT01861015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806740|NCT02254759|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33806741|NCT06106100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33806742|NCT02600546|||CASE_CONTROL||PROSPECTIVE|||||||
33806743|NCT02005159|||COHORT||PROSPECTIVE|||||||
33806744|NCT03725800|||COHORT||PROSPECTIVE|||||||
33806745|NCT05629052|||COHORT||PROSPECTIVE|||||||
33806746|NCT00343408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806747|NCT00118586|||COHORT||PROSPECTIVE|||||||
33806748|NCT01185041|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33806749|NCT04350619|||COHORT||CROSS_SECTIONAL|||||||
33806750|NCT04574466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All instruments and questions will be administered using tablets by trained research staff blind to the allocation status of the participants.|"The definitive RCT will inform us about the effectiveness and implementation of the intervention.~After the baseline assessment, three hundred eighty participants (N = 380) will be involved in the exploratory RCT (assigned to either the PM+ intervention (n=190) or the ETAU control condition (n=190))."|f|f|f|t
33806751|NCT06419296|||OTHER||RETROSPECTIVE|||||||
33806752|NCT05228184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806753|NCT00435656|||COHORT||CROSS_SECTIONAL|||||||
33806754|NCT01988402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806755|NCT00898352|RANDOMIZED|||TREATMENT||||||||
33806756|NCT05473663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806757|NCT01898299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806758|NCT00692120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806759|NCT04233905|||CASE_CONTROL||RETROSPECTIVE|||||||
33806760|NCT06362291|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33806761|NCT04546191|||COHORT||CROSS_SECTIONAL|||||||
33806762|NCT01356524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806763|NCT03670121|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm Pilot Study||||
33806764|NCT03106259|||CASE_ONLY||PROSPECTIVE|||||||
33806765|NCT02147093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806766|NCT00452452|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806767|NCT04802681|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study is a prospective single center randomized controlled trial of FFR measurements comparing two commercially available pressure guidewires in consecutive patients undergoing routine FFR measurements in the catheterization laboratory.||||
33806768|NCT03849482|||COHORT||OTHER|||||||
33806769|NCT05279066|||COHORT||CROSS_SECTIONAL|||||||
34034113|NCT03295955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034114|NCT00141050|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34034115|NCT05191004|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential assignment or parallel assignment will be applied (in both Phase 1 and Phase 2), depending on the stage of the study at the time of a patient's enrollment.||||
34034116|NCT00828165|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34152610|NCT04067661|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study involved a randomized controlled trial comparing the couples-based HIV prevention to an enhanced standard of care control condition||||
34152611|NCT02085330|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34152612|NCT03337711|||COHORT||PROSPECTIVE|||||||
34034117|NCT05791396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To mask treatments to physicisans and recipients, both FMT bottles and syringes will be covered with dark-coloured paper before the infusion, and the patients will be unable to see the endoscopic display during the procedure. Moreover, the physicians who will evaluate patients at follow-up will not aware of the treatment being administered.|Randomized controlled trial|t|t|t|t
34034118|NCT04767399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034119|NCT03668678|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034120|NCT03410056|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34034121|NCT00738387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034122|NCT01666665|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34034123|NCT02317003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34034124|NCT04825392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034125|NCT04312074|||COHORT||PROSPECTIVE|||||||
34034126|NCT04184427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034127|NCT05024747|RANDOMIZED|CROSSOVER||OTHER||NONE|Open Label|||||
34034128|NCT05680584|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Three study groups|t|f|t|f
34034129|NCT00229775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034130|NCT01509716|||||CROSS_SECTIONAL|||||||
34034131|NCT01868906|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34034132|NCT06453499|||OTHER||PROSPECTIVE|||||||
34034133|NCT01122225|||COHORT||PROSPECTIVE|||||||
34034134|NCT01479231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034135|NCT00392483|||COHORT||PROSPECTIVE|||||||
34034136|NCT06198816|||COHORT||PROSPECTIVE|||||||
34034137|NCT01968772|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034138|NCT00270244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34034139|NCT03106675|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Potential participants are recruited by oncologist from oncology outpatient clinic. Pretreatment imaging with computer tomography and magnetic resonance imaging is performed to evaluate whether the patient is eligible for HIFU-treatment. Those eligible will continue to the treatment and unsuitable participants will continue in the study as a control group receiving radiation therapy.~Participants in these groups will have follow-up MRI:s, ct:s, laboratory exams and fill in VAS (visual analog scale) and health questionnaire SF-36 regularly. Also intake of pain medication will be followed."||||
34034140|NCT06341816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034141|NCT02913794|||OTHER||CROSS_SECTIONAL|||||||
34034142|NCT00662649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34034143|NCT04545125|||COHORT||PROSPECTIVE|||||||
34034144|NCT04038580|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34034145|NCT00002817||||TREATMENT||||||||
34034146|NCT02474277|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034147|NCT03520257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34034148|NCT06460480|||COHORT||PROSPECTIVE|||||||
34034149|NCT05177679|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, placebo-controlled, double-blind trial.|t|f|t|t
34034150|NCT03659214|||COHORT||RETROSPECTIVE|||||||
34034151|NCT06550947|||CASE_CONTROL||RETROSPECTIVE|||||||
34034152|NCT04386382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034153|NCT01371188|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34034154|NCT03334513|||CASE_CONTROL||RETROSPECTIVE|||||||
34034155|NCT00028171|NON_RANDOMIZED|||TREATMENT||NONE||||||
34034156|NCT03231111|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034157|NCT02834325|||COHORT||PROSPECTIVE|||||||
34034158|NCT00768248|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34034159|NCT02352701|||CASE_CONTROL||PROSPECTIVE|||||||
33806770|NCT03197649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant is blinded|The study patient will have one portion of their scar, measuring 5x5 cms (or 50% of the scar, for scars smaller than 5x10 cms) left untreated at the time of the study.|t|f|f|f
34107943|NCT06039761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded to the result of the randomization, unlike the investigator.|"Study patients will be divided into 2 arms (1:1) and will benefit from one of the following procedures:~* Arm A (experimental): Overall procedure = standard procedure + local intraperitoneal anesthetics + alveolar recruitment maneuver + abdominal compression maneuver.~* Arm B (control): Standard procedure."|t|f|f|f
34107944|NCT06534723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107945|NCT04843241|||OTHER||CROSS_SECTIONAL|||||||
34107946|NCT01017900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34107947|NCT06502418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34034160|NCT02816983|||CASE_ONLY||PROSPECTIVE|||||||
34034161|NCT05574439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The above-mentioned are masked in terms of semaglutide/placebo. Statistical analysis of primary outcome will be blinded to the assessor.|Four groups will be identified based on their previous response to structured lifestyle interventions. Non-responders (group A) and insufficient responders (group B) are randomized 2:1 to either Semaglutide 2.4 mg/ week sc or placebo for 68 weeks. Group C (excellent responders) and Group D (population-based reference group with normal weight development) will attend baseline examinations only and not undergo intervention.|t|t|t|t
34034162|NCT05544474|||COHORT||PROSPECTIVE|||||||
34034163|NCT01045824|||FAMILY_BASED|||||||||
34034164|NCT03412331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034165|NCT00524940|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34034166|NCT04801992|||COHORT||RETROSPECTIVE|||||||
34034167|NCT04001036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034168|NCT06409273|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"Mixed-methods study~1. Single-blind, randomized, controlled trial with two 1:1 parallel arms~2. Qualitative analysis of open-ended questions in a questionnaire"|t|f|f|t
34034169|NCT05582070|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||prospective, monocentric study, non-controlled study||||
34034170|NCT04967573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034171|NCT00657189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034172|NCT03524170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034173|NCT00560391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034174|NCT00423878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034175|NCT00491712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034176|NCT02575833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034177|NCT05128110|||CASE_ONLY||RETROSPECTIVE|||||||
34034178|NCT04107324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034179|NCT05649761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034180|NCT00318890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034181|NCT01471743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34034182|NCT03864419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034183|NCT06132061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034184|NCT06227039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33806771|NCT01645046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806772|NCT06395571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Randomized controlled trial|t|t|t|t
33806773|NCT00893555|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806774|NCT06699888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806775|NCT04546451|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will receive the information that 2 interventions to improve cognitive function in Mild Cognitive Impairment will be compared and that assignment to the interventions is random for scientific reasons.|2 experimental conditions (Music practice vs. Psychomotor training) and 1 passive control condition||||
33806776|NCT00221559|||||PROSPECTIVE|||||||
33806777|NCT00273052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806778|NCT05600114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034185|NCT00606632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034186|NCT03544723|NA|SINGLE_GROUP||TREATMENT||NONE||Intratumoral Ad-p53 combined with approved immune checkpoint inhibitor||||
34034187|NCT01288079|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034188|NCT04733976|||COHORT||CROSS_SECTIONAL|||||||
34034189|NCT04610905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034190|NCT02245009|||COHORT||PROSPECTIVE|||||||
34034191|NCT01366131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034192|NCT03878927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034193|NCT03385317|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806779|NCT05969899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806780|NCT02376309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806781|NCT05980507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107948|NCT04817436|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806782|NCT05995756|||COHORT||PROSPECTIVE|||||||
33806783|NCT01681654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33806784|NCT06207604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806785|NCT06179667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33806786|NCT06691035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806787|NCT00227175|||||PROSPECTIVE|||||||
33806788|NCT04950920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806789|NCT05738434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806790|NCT06132594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806791|NCT04713124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised controlled trial|t|f|f|t
33806792|NCT06027970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806793|NCT00192218|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33806794|NCT01203293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806795|NCT05220111|||CASE_ONLY||PROSPECTIVE|||||||
33806796|NCT03891563|||COHORT||PROSPECTIVE|||||||
33806797|NCT00404976|||||OTHER|||||||
33806798|NCT05208567|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33806799|NCT00734578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034194|NCT03026491|||COHORT||PROSPECTIVE|||||||
34034195|NCT05430646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034196|NCT04507399|RANDOMIZED|CROSSOVER||OTHER||SINGLE||This study involves both a crossover design where each participant tastes both the control product and the protein fortified product with an appropriate break between the two sessions. The study will be conducted single blind as it not feasible to blind the researcher. Each participant will attend 2 study visits and all foods will be presented with random blinding codes.|t|f|f|f
34034197|NCT04831814|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34034198|NCT01184495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034199|NCT00001630|NON_RANDOMIZED|||TREATMENT||NONE||||||
34034200|NCT00691730|||OTHER||PROSPECTIVE|||||||
34034201|NCT03295227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034202|NCT00810147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034203|NCT05175235|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-centre, one-arm, prospective pilot study of participants diagnosed with solid tumours. The participants will be enrolled for the duration of their treatment with Nivolumab. At 12-month mark, the decision on the patient engagement with the study will be made by the principal investigator in consultation with the study sponsors and treating physician.||||
34034204|NCT02554071|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034205|NCT04459793|||COHORT||PROSPECTIVE|||||||
34034206|NCT03588091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034207|NCT04835974|NA|SINGLE_GROUP||OTHER||NONE||||||
34034208|NCT04952181|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034209|NCT03333993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034210|NCT02120196|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034211|NCT03696134|||COHORT||PROSPECTIVE|||||||
34034212|NCT02262455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034213|NCT03751501|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Eligible participants will be randomized into one of the 2 study arms groups: standard of care group with sham laser or experimental group with laser.~Both group with laser or sham laser will be performed in combination with anti VEGF treatment"|t|f|f|t
34034214|NCT05211648|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective open-label single arm study.||||
34034215|NCT02040805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-arm parallel clinical trial with assessments pre- and post-treatment.|f|f|f|t
34034216|NCT00054795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034217|NCT00969111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034218|NCT05483790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blinding was pursued as much as possible: group allocation was not actively disclosed to participants, they were advised not to discuss the intervention during testing sessions, opportunities for between-group interactions were restricted, and outcome assessors were blinded to allocation and were not involved in the intervention activities.|the intervention group and the control group|f|f|f|t
34034219|NCT01116063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034220|NCT02257281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034221|NCT01265212|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34034222|NCT00986739|||COHORT||PROSPECTIVE|||||||
34034223|NCT04586673|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The first three participants will receive a low dose of ChAdOx1.tHIVconsv1 only. A further ten participants will receive a higher dose of ChAdOx1.tHIVconsv1 and a subsequent vaccination of MVA.tHIVconsv3 and MVA.tHIVconsv4||||
34034224|NCT03639779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a parallel two-arm study comparing sodium thiosulfate and saline control.|t|f|t|f
34034225|NCT02147041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034226|NCT05475314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The appearance including colour and thickness of the two products are similar|Patients were randomly allocated to ReFerm® (18 patients, two men) or placebo (12 patients, three men) arms. There were no significant differences between the groups in terms of age, BMI, or disease severity.|t|t|f|f
34034227|NCT00067041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034228|NCT05334030|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34034229|NCT05325827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034230|NCT03307226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34034231|NCT01687894|||COHORT||PROSPECTIVE|||||||
34034232|NCT01526655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034233|NCT00480337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034234|NCT05980845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34034235|NCT05560490|NA|SINGLE_GROUP||TREATMENT||NONE||multicentre, prospective, non-randomised, open-label, first-in-human||||
34034236|NCT02588963|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34107949|NCT05245058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107950|NCT04741633|||CASE_ONLY||PROSPECTIVE|||||||
34107951|NCT05547464|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Observer-blind||t|t|t|f
34107952|NCT01832038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107953|NCT05983705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The investigators providing the psychoeducation and collecting the data at the information meeting (baseline) will be blinded since the randomization is carried out after that meeting and by an independent researcher.~The individuals conducting the statistical analyses on the data from the RCT study will be blinded."|A randomized controlled trial (RCT) and a qualitative study.|f|f|t|t
34107954|NCT05395312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers do not know the group allocation until the end of study. An individual party is responsible to randomly allocate participants into blended stepped-care group and waitlist control group.||f|f|t|f
34107955|NCT06094855|||OTHER||PROSPECTIVE|||||||
33806800|NCT05845814|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Part 1, participants will be randomized in a 1:1:1 ratio to receive either Arm A (coformulated favezelimab/pembrolizumab plus EV), Arm B (coformulated vibostolimab/pembrolizumab plus EV), or Arm C (pembrolizumab plus EV). If Part 2 is conducted, participants will be randomized in a 1:1:1 ratio to Arms A, B, and C or in a 1:1 ratio to Arms A and C or B and C, depending on the treatment arm(s) that are expanded in Part 2.||||
34034237|NCT04941820|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients were followed up prospectively for their length of hospital stay, and recommendations concerning each identified TRP were provided to the surgeons responsible for patients in the intervention group. Likewise, patient counseling and encouraging adherence to therapy were provided solely to patients in the intervention group. Patients in the control group received usual care by the surgical team without a coordinated contribution from the clinical pharmacist.||||
33806801|NCT04565977|||COHORT||RETROSPECTIVE|||||||
33806802|NCT03676569|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental clinical treatment||||
33806803|NCT01484925|||COHORT||PROSPECTIVE|||||||
33806804|NCT02131922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806805|NCT04690075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806806|NCT02042703|||CASE_CONTROL||PROSPECTIVE|||||||
33806807|NCT03535272|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This study will be conducted as a double-blinded, placebo-controlled randomized clinical trial.|t|t|t|t
33806808|NCT02266654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806809|NCT01141972|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34034238|NCT01276041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034239|NCT04021888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An assessor who was blinded to treatment groups assessed clinical outcomes before the treatment process. The same assessor was also repeated assessments at 13th week (at the end of treatment process)||f|f|f|t
34034240|NCT01963741|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34034241|NCT03766516|||COHORT||OTHER|||||||
34034242|NCT01305668|||COHORT||PROSPECTIVE|||||||
34034243|NCT01995513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034244|NCT02404805|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34034245|NCT05536063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34034246|NCT00277940|||||RETROSPECTIVE|||||||
34034247|NCT01609868|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034248|NCT01725035|||CASE_CONTROL||PROSPECTIVE|||||||
34034249|NCT04583735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034250|NCT03612921|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)||t|t|t|t
34034251|NCT04352101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034252|NCT06291896|NA|SINGLE_GROUP||SCREENING||NONE||Clinical Investigation with class IIa medical device||||
34034253|NCT02635412|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034254|NCT06430593|||CASE_ONLY||PROSPECTIVE|||||||
34034255|NCT02386137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034256|NCT04419753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034257|NCT02258711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34034258|NCT05084157|||COHORT||PROSPECTIVE|||||||
34034259|NCT01640249|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34034260|NCT02806882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034261|NCT05588700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34034262|NCT01109446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034263|NCT00218933|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34034264|NCT03161379|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34034265|NCT06511765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034266|NCT02454933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034267|NCT04936737|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The order of treatments will be random||||
34034268|NCT00713037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034269|NCT04632225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034270|NCT00929461||||TREATMENT||||||||
34034271|NCT01197911|NON_RANDOMIZED|PARALLEL||||NONE||||||
34034272|NCT01313065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152613|NCT05018858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152614|NCT02758327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152615|NCT03135977|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34152616|NCT04862026|||OTHER||PROSPECTIVE|||||||
34152617|NCT04467125|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34034273|NCT01348048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34034274|NCT06407739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152618|NCT02197949|||COHORT||PROSPECTIVE|||||||
34152619|NCT02759848|||COHORT||PROSPECTIVE|||||||
34152620|NCT00493961|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34152621|NCT04194125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152622|NCT05382897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator and lab personnel involved in assessment of outcomes will be blinded to the group allocation.|This is an exploratory randomized double-blind parallel trial using a fasting-mimicking diet (FMD) in patients with inflammatory bowel disease (IBD) who are in clinical remission but experiencing depression|t|t|t|t
34107956|NCT04126785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In study 1 and 2 the participants will be aleatory randomized and the main investigator will perform the exercise session. The data will collected and assessed by a blinded investigator without knowledge of participants intervention.|The study 1 will be cross-over, randomized, controlled and single-blinded trial The study 2 will be randomized, parallel, controlled and single-blinded trial|f|f|t|t
34107957|NCT00773591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034275|NCT03854760|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34034276|NCT05016739|NA|SINGLE_GROUP||OTHER||NONE||||||
33724715|NCT04059731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The masking procedure of the reference treatment and the study treatment will be carried out in the pharmacy service, since the packaging of the two treatments is different, brick and bottle. Pharmacy will keep the list of randomization, so at all times the pharmacy service will know which group each patient belongs to.~Both treatments will be re-packaged in 250 ml topaz plastic bottles (Code 225433) with the same label. The re-packaging will be carried out daily in aseptic conditions and by pharmacy personnel, it will be done per patient and in no time neither the patient nor the researcher will know the group to which the patient belongs.~In the program that the pharmacy service uses for the realization of the master formulas, the formula NUTRICOLON will be created with its corresponding procedure and label, always keeping the confidentiality of the product used."|Randomized, multicentric, double-blind, controlled with active comparator, parallel groups trial, to demonstrate non-inferiority in efficacy and therapeutic safety|t|f|t|t
34034277|NCT03013816|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724716|NCT00304876|||COHORT||RETROSPECTIVE|||||||
33724717|NCT04426682|||CASE_CONTROL||RETROSPECTIVE|||||||
33724718|NCT00204347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806810|NCT05703698|NA|SINGLE_GROUP||TREATMENT||NONE||Formulation-based CBTp will be delivered with a maximum of 30 sessions over 6 months based on an established manual.||||
33806811|NCT00587886|||CASE_CONTROL||PROSPECTIVE|||||||
34034278|NCT01284010|||CASE_ONLY||CROSS_SECTIONAL|||||||
34034279|NCT00470535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034280|NCT04754841|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Cryopreserved samples will be labeled with a code unknown to the researcher and those who process the sample in the laboratory.|"A blind experimental study will be carried out (those who evaluate viability and functionality of platelets will not know the cryopreservation times or the concentration of the cryopreservative)~Aliquots of platelets with group and factor A +, A-, B +, B-, AB +, AB-, O + and O- obtained from those people who come to the hemotherapy center as voluntary donors and who in turn express their decision to participate in this protocol by signing an informed consent designed for this purpose."||||
34034281|NCT02060812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034282|NCT04470583|||COHORT||RETROSPECTIVE|||||||
34034283|NCT04521894|||COHORT||PROSPECTIVE|||||||
34034284|NCT03597295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034285|NCT04404660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034286|NCT01759602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034287|NCT04331613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034288|NCT01034878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034289|NCT06359301|||CASE_ONLY||PROSPECTIVE|||||||
34034290|NCT05842993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034291|NCT00652340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034292|NCT01123057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034293|NCT04527887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034294|NCT00512122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome adjudicators were unaware of study-group assignments||f|f|t|f
34034295|NCT01317628|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34034296|NCT03952182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034297|NCT00124748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034298|NCT00533286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034299|NCT06281366|||CASE_CONTROL||PROSPECTIVE|||||||
34034300|NCT04342819|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Open-Label|The study will be of a prospective, single-arm, crossover trial design over a 2-year period. Patients at the Eric Williams Medical Sciences Complex (EWMSC), Mt. Hope, Trinidad and Tobago.||||
34034301|NCT02789540|||CASE_ONLY||CROSS_SECTIONAL|||||||
34034302|NCT02926066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034303|NCT04040036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Children Aged 5-12 Years Old|prospective, parallel trial design|t|f|f|f
34034304|NCT04230928|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective randomized 2-group study||||
34034305|NCT04852029|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34034306|NCT05582798|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34034307|NCT02465905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034308|NCT00408512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034309|NCT02071225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034310|NCT00858494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034311|NCT05624918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034312|NCT04553159|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot single centre randomized controlled trail with a ratio of 1:1 conducted in the Surgical out patient of Mulago Hospital Kampala||||
34034313|NCT02094300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034314|NCT06103292|||COHORT||PROSPECTIVE|||||||
34107958|NCT05300607|||OTHER||OTHER|||||||
34107959|NCT06639893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152623|NCT04868149|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patient are randomly assigned into either open or laparoscopic approach. The ratio of open and laparoscopic is 1:1.||||
34152624|NCT05486585|NA|SINGLE_GROUP||TREATMENT||NONE||An open end pilot study including 30 children and 30 adolescents and their parents (n=60)||||
34152625|NCT05416307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152626|NCT04677127|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34152627|NCT04832763|NA|SINGLE_GROUP||OTHER||NONE||||||
34152628|NCT02772900|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34152629|NCT05001139|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open label, uncontrolled, single arm, post-market clinical folow-up study||||
34107960|NCT06643260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This trial will be conducted in 2 sequential Segments. When the planned number of subjects have completed Segment 1, enrollment will be paused to perform an interim analysis for futility. If futility is not declared, enrollment in Segment 2 will commence. There will be one decision made in this futility analysis that will be conducted by an outside committee. Blinding will remain in full except for a select group of this committee. The committee will decide either to stop the study because of futility, continue the study as is, or continue the study with an increase in sample size. The increase in sample size cannot be greater than 25% of the planned sample size.|t|t|t|t
34107961|NCT04369326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Cluster-randomized trial|f|f|t|t
34107962|NCT02402647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cognitive rehabilitation and exposure/sorting therapy (CREST) versus Exposure therapy only|f|f|f|t
34107963|NCT00670514|RANDOMIZED|PARALLEL||||SINGLE||||||
34107964|NCT03794947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34107965|NCT03843073|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34107966|NCT06181058|NA|SINGLE_GROUP||OTHER||NONE||The participant list will be uploaded to a program and teams of 6-8 people will be formed with random names. The participant list will be uploaded to a program and teams of 6-8 people will be formed with random names. Each team will play the escape game.||||
34107967|NCT06637189|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective, randomized non-inferiority study. There will be two groups of patients:~Patients in Group A (PPOS protocol - study group) will start controlled ovarian stimulation with the administration of FSHr gonadotropin at doses between 225 IU-300 IU/day (depending on patient characteristics) + 10 mg medroxyprogesterone/day (IMP).~Patients in Group B (Short protocol with GnRH antagonists - control group) will start controlled ovarian stimulation with the administration of FSHr gonadotropin at doses between 225 IU-300 IU/day (depending on patient characteristics) and will add treatment with a GnRH antagonist at a dose of 0.25 mg/day from the 6th day of stimulation or when a follicle with a size equal to or greater than 14 mm is present.~Once the two stimulations typical of the DuoStim strategy are completed, the results obtained in both groups will be compared."||||
34107968|NCT05708508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34107969|NCT00517231|||||PROSPECTIVE|||||||
34107970|NCT00403052|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107971|NCT01955356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107972|NCT03113929|||CASE_ONLY||CROSS_SECTIONAL|||||||
34107973|NCT04956016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107974|NCT06570889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34107975|NCT05803772|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34107976|NCT05607589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107977|NCT04285567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107978|NCT06501313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||prospective, double-blind, randomized|t|t|t|t
34107979|NCT06116526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are unblinded to the trial arm. Clinical outcomes will be assessed by a blinded investigator.||f|f|t|t
33806812|NCT06122818|||CASE_ONLY||PROSPECTIVE|||||||
34107980|NCT06555601|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34107981|NCT00834782|||COHORT||PROSPECTIVE|||||||
34107982|NCT06450314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107983|NCT03658304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107984|NCT06571799|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study evaluating the efficacy and safety|Open label study evaluating the efficacy and safety||||
34107985|NCT06675188|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34107986|NCT06346132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107987|NCT04124419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107988|NCT04060238|||CASE_CONTROL||PROSPECTIVE|||||||
34107989|NCT05021835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34107990|NCT02315950|NA|SINGLE_GROUP||OTHER||NONE||||||
34107991|NCT05935150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34107992|NCT06570291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34107993|NCT02971137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107994|NCT04416724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34107995|NCT01424137|RANDOMIZED|CROSSOVER||||NONE||||||
34107996|NCT05259501|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34107997|NCT01628952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34107998|NCT02797548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806813|NCT00278135|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34107999|NCT06431581|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108000|NCT06010719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108001|NCT01816399|||COHORT||RETROSPECTIVE|||||||
34108002|NCT02598167|||CASE_ONLY||CROSS_SECTIONAL|||||||
34108003|NCT06300632|||OTHER||PROSPECTIVE|||||||
34108004|NCT01271231|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34108005|NCT04825600|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34108006|NCT05752032|||OTHER||PROSPECTIVE|||||||
34108007|NCT05468177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108008|NCT06639295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108009|NCT03533569|||CASE_CONTROL||PROSPECTIVE|||||||
34108010|NCT05412979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108011|NCT05403268|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Usual care group undergoes DeltaScan measurements with blinded device to prevent the measurement result from influencing clinical decisions.|Randomized controlled trial with 2 parallel arms: control group (usual care) and intervention group.||||
34108012|NCT04805528|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108013|NCT05896826|||COHORT||PROSPECTIVE|||||||
34108014|NCT03924284|||OTHER||RETROSPECTIVE|||||||
34108015|NCT01555580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108016|NCT02591446|||OTHER||CROSS_SECTIONAL|||||||
34108017|NCT03043573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34108018|NCT05507437|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34108019|NCT06129903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034315|NCT06306300|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Study I is a population-based cross-sectional screening study (n=30,000 individuals) to determine the prevalence of HCV infection in people attending a Basic Health Care Unit. The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (n=1,500 participants included in Study I). Study II is a phase IV open-label randomized clinical trial (1:1) to evaluate the non-inferiority of simplified and decentralized hepatitis C treatment (Simplified-and-Decentralized (SD) HCV treatment; experimental arm) compared to specialist reference treatment (Standard-of-Care (SC) HCV treatment; control arm) within the SUS."||||
34034316|NCT05881395|||COHORT||PROSPECTIVE|||||||
34034317|NCT05974852|||CASE_ONLY||RETROSPECTIVE|||||||
34034318|NCT02283723|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34034319|NCT01354405|||COHORT||PROSPECTIVE|||||||
34034320|NCT05586555|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A control group with normal hearing subjects versus a CI group with cochlear implanted subjects.||||
34034321|NCT01864707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034322|NCT05292027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034323|NCT00638508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034324|NCT06583252|||COHORT||PROSPECTIVE|||||||
34034325|NCT05674825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034326|NCT04720053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034327|NCT06272565|||OTHER||PROSPECTIVE|||||||
34034328|NCT02505737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034329|NCT06404957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental study||||
34034330|NCT02321111|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participant, Care Provider, Investigator, Outcomes Assessor||t|t|t|t
34034331|NCT02449278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034332|NCT00690911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034333|NCT02548832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Someone of the team make a key number for each patient (36 enrolled, 12 for each intervention), and then put the numbers in to 36 paper envelopes and let the patient chose one. There was double-blind. And the placebo was calcined magnesia.||t|f|t|f
34034334|NCT01117896|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034335|NCT02166255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034336|NCT01126242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034337|NCT02346656|||COHORT||PROSPECTIVE|||||||
34034338|NCT04970615|||CASE_CONTROL||PROSPECTIVE|||||||
34034339|NCT00305474|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34034340|NCT05580250|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Part A and B are double blind and Part C is an open-label study.||t|f|t|f
34034341|NCT02502032|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34034342|NCT03623503|||CASE_ONLY||RETROSPECTIVE|||||||
34034343|NCT03500198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034344|NCT03963193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034345|NCT05092789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034346|NCT03579108|||OTHER||RETROSPECTIVE|||||||
34034347|NCT05243160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34034348|NCT03997630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034349|NCT02728700|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34034350|NCT03474666|RANDOMIZED|PARALLEL||TREATMENT||NONE||Insulin initially as continuous infusion/subcutaneous for first 24-48 hours followed by subcutaneous administration once subjects eating until hospital discharge.||||
34034351|NCT03233893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcome assessor will be blinded in this study||t|f|f|t
34034352|NCT00599365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034353|NCT01634841|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34034354|NCT02941471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034355|NCT02001987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034356|NCT04750889|||CASE_CONTROL||PROSPECTIVE|||||||
34034357|NCT05969535|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||According to the WIJMA version A scale, two groups will be formed by randomization method as intervention and control group for pregnant women who are determined to have fear of middle and higher birth. 8 sessions of psychoeducation program will be given to the pregnant women in the intervention group. The control group will continue routine monitoring. After the training, the level of fear of birth, prenatal attachment and anxiety levels will be compared between the two groups.|t|f|f|f
34034358|NCT01400542|||COHORT||PROSPECTIVE|||||||
34034359|NCT05134311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary analysis will compare the proportion of patients readmitted within 30 days of their ultrasound among those who received the 3D ultrasound vs. those who received the 2D ultrasound using a chi-square test. We will also compare the proportion of patients who showed up for their follow-up appointment among those who received the 3D ultrasound vs. those who received the 2D ultrasound using a chi-square test. We will assess for differences in baseline characteristics and factors known to be associated with readmission and compliance with follow-up among the two groups. If warranted, we will adjust for these differences using multivariable regression models.||||
34034360|NCT03711097|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Split mouth study|t|f|f|t
34034361|NCT05397080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034362|NCT02986529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34034363|NCT05436795|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The outcome evaluator (statistician) will be unaware of the intervention allocation (single-blind).||f|f|f|t
34034364|NCT01050530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034365|NCT05117216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|t|f|f|f
34034366|NCT05469672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034367|NCT03565900|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34034368|NCT01762800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034369|NCT03685916|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34034370|NCT01363193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034371|NCT02969044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034372|NCT02737241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034373|NCT00664079|||COHORT||PROSPECTIVE|||||||
34034374|NCT01817296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034375|NCT03854903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34034376|NCT02301169|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34034377|NCT04682392|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups with Randomized group assignments||||
34108020|NCT05541861|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Dose 1 is given observer-blind for Cohorts 1 to 4 and open-label for Cohort 5. Dose 2 is given open-label for Cohorts 1 to 5.||t|t|t|f
34108021|NCT06591728|NA|SINGLE_GROUP||OTHER||NONE||||||
34108022|NCT04005326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108023|NCT04838652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108024|NCT06640647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108025|NCT05602532|||COHORT||PROSPECTIVE|||||||
34108026|NCT04519567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108027|NCT06615219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34108028|NCT00959049|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108029|NCT05657171|||CASE_ONLY||PROSPECTIVE|||||||
34108030|NCT04189861|||COHORT||PROSPECTIVE|||||||
34108031|NCT05634343|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Simple random numbers table was used to determine the nurses to be sampled. 673 nurses working in KTU Farabi Hospital were listed and numbered, and the starting point was chosen from the random numbers table, followed by the columns downwards, and the sample number was reached. If the sample could not be reached due to reasons such as the criteria were not met or the research invitation was not accepted, the sample selection was continued from the random numbers table until the sample number was reached. Then, in order to create homogeneous groups in the assignment of nurses to the experimental and control groups, equal numbers of triple groups were formed by matching according to the unit/service (internal, surgical, specialized unit) and professional experience (10 years and below, 11 years and above).|The research examines the effects of laughter and mindfulness on some parameters (fatigue, performance and attention) in nurses.|t|f|t|f
34108032|NCT00003455||||TREATMENT||||||||
34108033|NCT03181984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108034|NCT05377723|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34108035|NCT06499376|||COHORT||OTHER|||||||
34108036|NCT02407938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108037|NCT06353841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analyst will be blinded to the procedure and results of randomization, group allocation, and intervention.||f|f|f|t
34108038|NCT05036330|||COHORT||PROSPECTIVE|||||||
34108039|NCT06001008|||COHORT||PROSPECTIVE|||||||
34108040|NCT04034927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108041|NCT02014103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34108042|NCT05375929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108043|NCT06258564|||COHORT||RETROSPECTIVE|||||||
34108044|NCT06499181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The control arm will be injected with 10cc of 0.5% bupivacaine with 1:50,000 epinephrine. The study arm will be injected with 133mg (10cc) of liposomal bupivacaine. Once the patient leaves the OR, the rest of the providers will be blinded to which arm the patient has been randomized. The identity will be linked to a key that will be kept in a locked box inside a keypad entry office. All future pain assessors will be blinded to the arm of the study in which the patient is attached. The patients will be taught about the surveys during the original evaluation, the consent process, and again post-operatively. An email will be sent to the patients on the following morning for the first 7 days post-operatively.|The control arm will be injected with 10cc of 0.5% bupivacaine with 1:50,000 epinephrine. The study arm will be injected with 133mg (10cc) of liposomal bupivacaine.|t|t|f|f
34034378|NCT00648778|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34034379|NCT02780258|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034380|NCT01870778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034381|NCT00064896||||TREATMENT||||||||
34034382|NCT01417637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034383|NCT04343846|||COHORT||RETROSPECTIVE|||||||
34108045|NCT02722330|NA|SINGLE_GROUP||OTHER||NONE||||||
34108046|NCT00414557|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
34108047|NCT06126172|NA|SINGLE_GROUP||OTHER||NONE||||||
34108048|NCT04678544|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|There will be no blindness of physician and patients. However, statisticians who will analyze the data will be blinded.|Randomized Controlled Trial, Single center|f|f|f|t
34108049|NCT02199912|NA|SINGLE_GROUP||OTHER||NONE||||||
34149581|NCT04980365|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Participants will have knowledge of the intervention they will receive but will have no knowledge of the other interventions used in the study.|Potential participants will be provided access to an informed consent form and baseline survey via Qualtrics. After baseline is completed and eligibility confirmed, the study coordinator will randomly assign the participant to one of three app-based intervention conditions: Gratitude, Mindfulness, or control group. Next, the study coordinator will email them to schedule a Zoom meeting. The meeting will last 15 minutes and participants will be informed of what app they will use. After a 14-day period, the study coordinator will send participants a follow-up survey, and a final follow-up Qualtrics survey one month after the intervention ends. Participants will receive $5 for completing the baseline questionnaire, $5 for the immediate post-survey, and $10 for the one-month follow-up survey (participants can receive up to $20). Participants recruited via PeRP will receive one credit for completing the baseline questionnaire, two for the post-survey, and one for the follow-up.|t|f|f|f
34152630|NCT00967759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34034384|NCT02566681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034385|NCT05787626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34034386|NCT06458465|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open labelled, three-arms, randomized, non-placebo, controlled, parallel clinical trial.||||
34034387|NCT01311687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034388|NCT02163512|||COHORT||PROSPECTIVE|||||||
34034389|NCT05735483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|All participants receive Lebrikizumab during the 16-week blinded treatment period. At Week 18, participants receive open-label lebrikizumab.|||||
34034390|NCT01852760|||COHORT||CROSS_SECTIONAL|||||||
33806814|NCT05325541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All participants will be blinded regarding treatment. A total of 36 patients will be recruited and assigned into two groups. Group A will receive visual biofeedback balance exercises and Group B will receive Conventional balance exercises.|"Experimental: Game-Based Rehabilitation: Device: Visual Biofeedback Therapy Session Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.~Placebo Comparator: Conventional Rehabilitation: Conventional Balance exercise Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks."|t|f|f|f
33806815|NCT05157113|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33806816|NCT02094534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806817|NCT03274076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study staff (with the exception of the study pharmacist) and the patient are blinded to the treatment assignment.|Eligible subjects will be randomized to tofacitinib or placebo in a 2:1 manner.|t|f|t|f
33806818|NCT05443945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Randomized, double-blind, placebo-controlled study~With a 4-7 days run-in period before a 14 days treatment/placebo period"|t|f|t|f
33806819|NCT00649272|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34034391|NCT06578390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patient will wear the device and polysomnograph at the same time||||
34034392|NCT05751213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034393|NCT00262028|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34034394|NCT04275154|||COHORT||PROSPECTIVE|||||||
34034395|NCT01019434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034396|NCT04708613|||CASE_CONTROL||PROSPECTIVE|||||||
34034397|NCT00150605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034398|NCT06492395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034399|NCT06513338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034400|NCT05217212|||COHORT||PROSPECTIVE|||||||
34034401|NCT00097448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034402|NCT05611983|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The outcome assessor/investigator are blinded from which intervention given.||f|f|t|t
34034403|NCT05802628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034404|NCT03901313|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34034405|NCT01339403|||COHORT||PROSPECTIVE|||||||
34034406|NCT04783402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single||f|f|f|t
34034407|NCT03207984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034408|NCT00999986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34034409|NCT03389503|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||1\~3 months: Right radial approach 4\~6 months: Left radial approach||||
34034410|NCT02839772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034411|NCT02394470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034412|NCT02924831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034413|NCT05081401|||COHORT||PROSPECTIVE|||||||
34034414|NCT06582303|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subacute stroke patients were randomly assigned to the experimental group and the control group. The experimental group received a VR hand game intervention along with conventional physical therapy, while the control group only received conventional physical therapy. Each patient's therapy consists of 24 sessions, with each session lasting 4 days per week for a total duration of 6 weeks. The VR intervention consists of four games that utilize a virtual reality device and are controlled by affected hand movements such as flexion/extension, close/open, supination/pronation, and pinch. The control group and experimental groups received conventional physical therapy, which consists of range of motion, stretching, resistance, and strengthening exercises.||||
34034415|NCT06342453|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33806820|NCT06699069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806821|NCT03280511|NA|SINGLE_GROUP||PREVENTION||NONE||Non-randomized, non-blinded phase 2 cohort study||||
33806822|NCT05871385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806823|NCT06067347|||COHORT||PROSPECTIVE|||||||
34034416|NCT02670616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034417|NCT02218138|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034418|NCT03024502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034419|NCT01452880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034420|NCT00711243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806824|NCT03918252|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33806825|NCT05604755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806826|NCT04169542|||COHORT||PROSPECTIVE|||||||
33806827|NCT05724966|||OTHER||PROSPECTIVE|||||||
33806828|NCT03565484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806829|NCT06492148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806830|NCT00869934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034421|NCT01525329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034422|NCT02257710|||OTHER||PROSPECTIVE|||||||
34034423|NCT01644656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034424|NCT03009942|||CASE_ONLY||PROSPECTIVE|||||||
34034425|NCT05056116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034426|NCT02303912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034427|NCT01318317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034428|NCT05677035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034429|NCT00054457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034430|NCT06583187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34034431|NCT04844112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034432|NCT03438838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized using computer generated table of random numbers contained in a sealed opaque envelope to be opened in operation theatre after induction anesthesia.||t|f|f|f
34034433|NCT05937360|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34034434|NCT04053621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034435|NCT02731716|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34108050|NCT05807945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking was performed once the patient agreed to participate; the physician in charge of randomization informs the anesthesiologist of the maneuver that corresponds to the patient programmed for surgery, who prepares the dose for the patient and hands it to the physician who applies the maneuver (who is blinded to the maneuver). All patients receive 10 ml of solution with different doses of ropivacaine, the application vehicles being equal in physical appearance. The physician who evaluate the outcome does not participate in the randomization, surgery or application of the maneuver, and remains blinded to the dose the patient receives, as does the patient.|After confirming that the patients meet the selection criteria, they are invited to participate in the study. Upon accepting through signed informed consent, the physician in charge of randomization (physician 1) is informed and the surgery scheduled. The day of the surgery, the physician in charge of randomization reports the maneuver to be received from the anesthesiologist (physician 2) in charge, who prepares the dose of ropivacaine and gives it to a physician blinded to the maneuver (physician 3); this physician applies the ropivacaine intraarticular to the patient. The level of pain is evaluated two hours after the end of surgery by a physician blinded to the maneuver the patient has received (physician 4), while the patient is in his room, and the presence of acute-moderate-severe pain (4-10 points) is evaluated by a visual analog scale (vas) while the patient is requested to flex and extend the knee.|t|t|t|t
34152631|NCT04499859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724719|NCT05695924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Partially Blinded: Patients will be informed which group they are randomized into and given the option to opt out of the study. Investigators (other than surgeons conducting surgery) and study personnel involved in patient measurements will be unaware of the patient treatment option.|Prospective, randomized, control arm|f|f|f|t
33724720|NCT03632655|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Men will be randomized to receiving either TPM or TRUS targeted biopsy.||||
33724721|NCT03686410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the participants and the study researchers will not know the group assigned to each subject. In fact, the evaluations will be carried out through the website.||t|t|f|t
33724722|NCT00284479|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33724723|NCT05442944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33724724|NCT04668950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724725|NCT00665977|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33724726|NCT04222569|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Each patient, serving as their own control, realize three SBT for 15 minutes: T-piece, PSV 7 cmH2O without PEEP and PSV 0 cmH2O without PEEP. The order is randomized. The randomization is stratified on pathology. For avoid a carry-over effect, a wash-out period of baseline ventilation for 10 minutes will be respected between trials. The humidification device is a heated humidifier, linked to the ventilator. Data are recorded before (guarantee of real return to baseline) and after each SBT.~Then, extubation is decided by clinician in charge, in accordance with guidelines. A 30 min of resting period is respected before. Data are recorded before and 20 minutes after extubation."||||
33724727|NCT02430337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034436|NCT01618448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034437|NCT04127773|||COHORT||PROSPECTIVE|||||||
34034438|NCT01854476|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34034439|NCT00982657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034440|NCT03280810|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34034441|NCT01428596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034442|NCT01197352|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34034443|NCT02817737|||COHORT||PROSPECTIVE|||||||
34034444|NCT05422001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034445|NCT04969146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research Coordinators will be masked|Participants are assigned to one of two groups receiving different interventions in parallel for the duration of the study|f|f|t|f
34034446|NCT01475799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034447|NCT01154231|||COHORT||PROSPECTIVE|||||||
34034448|NCT00980252|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34034449|NCT02164045|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34034450|NCT02070250|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034451|NCT05234801|||COHORT||RETROSPECTIVE|||||||
34034452|NCT02690038|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34034453|NCT04996628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants are assessed at baseline for nociceptive pattern via P-QST and followed longitudinally for the duration of the study||||
34034454|NCT00209040|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34034455|NCT05778201|NA|SINGLE_GROUP||PREVENTION||NONE||Baby Drink Intervention group||||
34034456|NCT05377463|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|The outcome assessors will be blind to the experimental condition that the participant was assigned to.|"The factorial experiment is guided by the Multiphase Optimization Strategy (MOST).~The 2 intervention components are:~Component 1. Peer recovery coaching to promote uptake and persistence of medication assisted treatment in the form of methadone.~Component 2. Behavioral activation therapy to reduce depression.~Participants will be randomly assigned to receive a total of 0 or up to 2 components. There are 4 conditions because there are 4 possible combinations of the 2 components (e.g., Condition 1 = Delivery of 1 whereas Condition 3 = Delivery of 1 and 2). All participants will receive a standard of care package which will consist of referral and patient navigation to HIV treatment services, linkage to a peer support group, and harm reduction education and materials."|f|f|f|t
34034457|NCT05630911|||COHORT||CROSS_SECTIONAL|||||||
34034458|NCT01511861|||COHORT||CROSS_SECTIONAL|||||||
34034459|NCT01607450|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034460|NCT02582229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034461|NCT00613808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034462|NCT01012336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034463|NCT05871762|||COHORT||PROSPECTIVE|||||||
34034464|NCT02058069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034465|NCT00149461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034466|NCT03831711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034467|NCT06511921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34034468|NCT01146171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034469|NCT03348878|NA|SINGLE_GROUP||OTHER||NONE||||||
34108051|NCT05913167|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Participants will not know which block was administered outcome assessors will not know which block was administered|erector spina and transversus abdominis plane blocks|t|f|f|t
34108052|NCT03577470|||COHORT||PROSPECTIVE|||||||
34108053|NCT04885504|||COHORT||CROSS_SECTIONAL|||||||
34108054|NCT04506892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|no masking is used in this protocol|||||
34108055|NCT03453242|||COHORT||PROSPECTIVE|||||||
34108056|NCT06639009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects will be blinded to the group assignment as they will receive PBMT ( Active or Sham as per group assignment ) both intraorally and extraorally The outcome assessor will be blinded to the group assignment of the subjects as they will be identified by unique randomization code only|A patient and outcome assessor blinded, multiple- arm, randomized, placebo controlled clinical trial|t|f|f|t
34108057|NCT02475993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108058|NCT06162728|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This trial will be performed as a three-part dose escalating clinical trial where Part 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.|"Part 1: Cohorts 1 and 2, 3+3 dose escalation design~Cohorts 1 through 7 will be enrolled sequentially in a dose escalating fashion starting from the lowest dose proposed.~The Treatment Period in Part 2 (Cohorts 3, 4, 5) and Part 3 (Cohort 6 and 7) will be performed in a double-blind, placebo-controlled manner."|t|t|t|t
34108059|NCT04981145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108060|NCT03470051|||OTHER||PROSPECTIVE|||||||
34108061|NCT04973319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two or more groups in parallel for the duration of the study.||||
34108062|NCT06642896|||COHORT||PROSPECTIVE|||||||
34108063|NCT05848570|||COHORT||PROSPECTIVE|||||||
34108064|NCT02073201|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34108065|NCT02805348|||COHORT||PROSPECTIVE|||||||
34108066|NCT06500130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a Open-label, single site, prospective, proof of concept evaluation of the effect of liraglutide, a NZ-approved daily injectableGLP-1 agonist, on Gastric Alimetry (GA) outputs in up to 20 healthy volunteers. GA will be performed at baseline, after a 12-14 day ascending dose of liraglutide, and after a minimum 5 day washout period.~This approach directly compares GA within subjects with a gastric-focused pharmacological intervention compared to baseline and after a washout phase. The primary endpoint is a change in GA-RI which isa metric used to define gastric dysrhythmia which is seen in disease states such as neuromuscular disorders and gastroparesis. Since there is no reference standard for GA to compare to, this study will instead allow fulfilment of key plausibility criteria for measuring GA in disease (i.e. inducing symptoms and GA changes in healthy subjects with no previous symptoms.) It will also show that the effects are reversible after stopping the medication."||||
34108067|NCT05042479|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108068|NCT06673498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108069|NCT05910424|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No Treatment|Pilot study concerning adults with autism spectrum disorder||||
34108070|NCT03899428|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108071|NCT06644313|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients received Vebreltinib neoadjuvant therapy.||||
34108072|NCT06340867|||OTHER||CROSS_SECTIONAL|||||||
34108073|NCT05064722|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108074|NCT06346327|||COHORT||RETROSPECTIVE|||||||
34108075|NCT04721106|||CASE_ONLY||PROSPECTIVE|||||||
34108076|NCT06639672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108077|NCT02709707|||CASE_ONLY||PROSPECTIVE|||||||
34108078|NCT04066504|||COHORT||PROSPECTIVE|||||||
34108079|NCT02531451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34108080|NCT03184025|NA|SINGLE_GROUP||TREATMENT||||||||
34108081|NCT00000397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34108082|NCT06151717|||COHORT||PROSPECTIVE|||||||
34108083|NCT06539728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34108084|NCT02065986|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34108085|NCT04209543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There are 3 blinded arms in the Efficacy part and 1 open-labeled arm in the Safety part|t|t|t|t
34108086|NCT06371378|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|single blind|We gave three different peep values on the mechanic ventilator; 3 groups: Group I: PEEP O, Group II: PEEP 4, Group III: PEEP 8|t|f|f|f
34108087|NCT04100993|||CASE_ONLY||CROSS_SECTIONAL|||||||
34108088|NCT05531942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108089|NCT05253196|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108090|NCT04108156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The substudy is a non-randomized, open-label study.||f|f|f|t
34108091|NCT06570174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34108092|NCT03574363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34108093|NCT05468918|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants were blinded as to which device they were wearing during the lab testing.||t|f|f|f
33724728|NCT01299623|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33724729|NCT04087707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Step1; No masking||t|t|t|f
33724730|NCT01113762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724731|NCT03429179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724732|NCT05839457|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806831|NCT04316936|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to 1 of 3 groups (1:1:1), each with a sample size of 25 (total n=75). Group 1 will receive DEXYCU + Omidria (Omidria = ketorolac + phenylephrine), group 2 will receive DEXTENZA + Omidria, and group 3 will receive prednisolone acetate + Omidria.||||
33806832|NCT06696521|NA|SINGLE_GROUP||OTHER||NONE||Patients randomized to telephonic or televideo participation once enrolled in the study.||||
34108094|NCT05581121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806833|NCT01171638|||COHORT||PROSPECTIVE|||||||
33806834|NCT02520219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806835|NCT02909205|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806836|NCT02929420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806837|NCT00916409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806838|NCT01428206|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108095|NCT06570200|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|the masking will be applied in the two test groups where iPRF will be used and neither the principle investigator nor the participants will know if vitamin D will be applied to the iPrf or a placebo.||t|t|f|t
34108096|NCT05775042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108097|NCT02684162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108098|NCT06502119|||OTHER||CROSS_SECTIONAL|||||||
34108099|NCT06307769|||OTHER||CROSS_SECTIONAL|||||||
33806839|NCT03863587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806840|NCT06699212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806841|NCT05989841|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33806842|NCT02290158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33806843|NCT05685511|RANDOMIZED|PARALLEL||TREATMENT||NONE|Study staff responsible for administering ratings throughout the study are blinded. This blinding is kept throughout the study until data collection is complete. At the end of the follow-up, the study coordinator will complete a blinding question to try to guess the arm to which each participant was allocated. This will allow to determine whether the blinding procedures in the study were effective.|||||
33806844|NCT00853255|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34108100|NCT04411069|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patient didn't know if he received the third anti emetic||t|f|f|f
34108101|NCT00413712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108102|NCT00020176||||TREATMENT||NONE||||||
34108103|NCT06570668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both CDD-2101 and placebo are packed in single-use plain laminated aluminum foil pouches (5 g/sachet). All subjects will take 20 g of granules, i.e. 4 sachets of CDD-2101 and/or placebo, at one time. This will be a double-blind study; group assignment will be blinded to subjects, investigators and all staff involved in the conduct of the study except the unblinded pharmacist.|A total of 20 subjects aged 18-65 years with a Body Mass Index (BMI) of 18.5-29.9 kg/m2 will be hospitalized and randomized in a 1:1:1:1:1 ratio (N=4/group) to receive one dose of CDD-2101 at 5, 10, 15 or 20 g and/or placebo by taking a suspension in water orally.|t|t|t|f
34152632|NCT02385435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152633|NCT04439318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152634|NCT03189966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152635|NCT05492916|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34152636|NCT05629507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34152637|NCT05229250|||CASE_CONTROL||PROSPECTIVE|||||||
34152638|NCT05501795|||COHORT||PROSPECTIVE|||||||
34152639|NCT05380167|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|A third party not involved with the conduct of the study provided research staff with the beetroot juice in participant specific coded bottles. The research staff then distributed these coded bottles to the participant. At the end of the trial, the code was revealed for intervention assignment.|Participants will be randomized into one of two groups. The first group will consume daily beetroot juice containing 380 mg of nitrate and the second group will consume daily beetroot juice with nitrate removed.|t|f|t|t
34152640|NCT01012323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152641|NCT05372549|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34152642|NCT04474314|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind||t|t|t|f
34152643|NCT03951558|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The capsules are the same color in the placebo group and the intervention group. The content of the capsules is similar in both groups.||t|f|f|f
34152644|NCT05848362|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|single group sample, there is no blinding as everyone will be treated equally|This is a quasi-experimental study with a single group and simultaneous (matched) sample will conduct with the purpose of to determine whether glucose values are different for a bedside glucose meter compared to the main clinical laboratory and whether the blood sampling site has a significant effect on glucose values.||||
34152645|NCT00692289|||COHORT||PROSPECTIVE|||||||
34152646|NCT06439303|||OTHER||RETROSPECTIVE|||||||
34152647|NCT05348486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152648|NCT02453555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152649|NCT06207734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152650|NCT04114110|||OTHER||RETROSPECTIVE|||||||
34152651|NCT04015674|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34152652|NCT01765725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34152653|NCT03404856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152654|NCT04316468|||CASE_ONLY||PROSPECTIVE|||||||
34152655|NCT03626545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152656|NCT06004570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34152657|NCT04199143|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open-label, Longitudinal, Monocentric, Physiological study comparing depressive patients (responders versus non-respondeurs to Nitrous Oxyde) and healthy volunteers||||
34152658|NCT03719339|||CASE_ONLY||PROSPECTIVE|||||||
34152659|NCT04687371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental, Randomized Controlled Study|t|f|f|f
34152660|NCT03754829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A three-armed randomized controlled trial with 2 experimental groups and 1 control group.|f|f|t|f
34152661|NCT00613093|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034470|NCT04009759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Acute bag for cardiopulmonary resuscitation (CPR) will have a trial pack containing 3 blinded ampules that will be labelled with only randomisation number. Anaesthesiologists and nurses performing CPR and research treatment will not know the content of the ampules as well as a meaning of the randomisation number. Neurologist, who will not be aware of treatment assignments, will assess neurological outcomes in all survived patients. Statistician, who will not be aware of treatment assignments, will assess statistical data in all included patients. An independent Data Monitoring Committee will assess the progress, safety data (death, long-term hospitalization, and disability) and, critical efficacy endpoints of the clinical study (survival at 1, 2, 3 and 28 days in patients after in-hospital CA) in all included patients.|240 adult patients with an in-hospital cardiac arrest will be evaluated by anesthesiologist on duty for inclusions criteria to the study and randomized to get the blinded study medicine as addition to the standard treatment of cardiac arrest.|f|f|f|t
34034471|NCT00413101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034472|NCT02477644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34034473|NCT01834625|||CASE_CONTROL||PROSPECTIVE|||||||
34034474|NCT04435873|||OTHER||PROSPECTIVE|||||||
34034475|NCT00548678|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34034476|NCT00857155|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34034477|NCT01157793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034478|NCT01008605|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34034479|NCT04826367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study consists randomly allocated exercise and control groups.|f|f|f|t
34034480|NCT02306993|||CASE_CONTROL||PROSPECTIVE|||||||
34034481|NCT03981172|||CASE_CONTROL||PROSPECTIVE|||||||
34034482|NCT02039193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034483|NCT00460603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034484|NCT02851784|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034485|NCT04632576|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34034486|NCT04004481|||COHORT||PROSPECTIVE|||||||
34034487|NCT02762929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034488|NCT01506869|||COHORT||PROSPECTIVE|||||||
34034489|NCT06295276|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Allocation concealment:~The results of the allocation sequence are placed in sequentially numbered, opaque, and sealed envelopes by an independent researcher to ensure confidentiality."|Parallel comparative randomized controlled trial||||
33806845|NCT03615612|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34034490|NCT04095039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034491|NCT04544774|||CASE_ONLY||PROSPECTIVE|||||||
34034492|NCT01237119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034493|NCT03164018|||COHORT||PROSPECTIVE|||||||
34034494|NCT01388972|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34034495|NCT00235755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034496|NCT03290378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34034497|NCT01159405|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034498|NCT04968613|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34034499|NCT05678660|||COHORT||PROSPECTIVE|||||||
34034500|NCT01189162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034501|NCT06583044|||COHORT||CROSS_SECTIONAL|||||||
34034502|NCT05911334|NA|SINGLE_GROUP||OTHER||NONE||||||
34034503|NCT00396682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034504|NCT03440840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Individuals will receive either active or sham tDCS. The outcomes assessor will be blind to treatment group assignment.|Randomized parallel group|t|f|f|t
34034505|NCT00323375|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Subjects randomized to either the AQ-13 or CQ arms of the study received 2 capsules of AQ-13 or CQ in the morning of day 1, 2 capsules of AQ-13 or CQ again on the morning of day 2 and 1 capsule of AQ-13 or CQ on the morning of day 3.|Individual subjects were randomized to receive either the investigational candidate 4-aminoquinoline (AQ-13) or the control 4-aminoquinoline which has been used to treat malaria for decades and is known to be safe (chloroquine=CQ).|t|t|t|f
34034506|NCT01820598|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34034507|NCT01738295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34034508|NCT03119402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are prevented from having knowledge of which experimental condition (active or sham tDCS) they are assigned to.||t|f|f|f
34034509|NCT02319317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34034510|NCT01657838|RANDOMIZED|PARALLEL||||NONE||||||
34034511|NCT00258726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034512|NCT05431894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were assigned upon consent randomly to an intervention or control group. The intervention group received support from Laguna Coaches for 30 days, the control group did not receive any support from Laguna coaches.||||
34034513|NCT06190392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034514|NCT00857571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34034515|NCT05937412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34034516|NCT01874028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034517|NCT04418557|||CASE_CONTROL||PROSPECTIVE|||||||
34034518|NCT06148116|||OTHER||CROSS_SECTIONAL|||||||
34034519|NCT05268991|||COHORT||PROSPECTIVE|||||||
34034520|NCT05952102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34034521|NCT06472297|NA|SINGLE_GROUP||PREVENTION||NONE|The CGM system feedback is unmasked. The CGM is automatically recorded and does not require an outcomes assessor.|A case series of participants wear an unmasked CGM sensor for a condition lasting 20 days while recording daily narratives of their experience.||||
34034522|NCT05302986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be conducted in a double-blind setting. The patient and the investigating surgeon will be blinded. The injection of the product will be performed by the anesthetist that will be aware of the injected product (tranexamic acid or sodium chloride).|"Interventional, prospective, national monocentric study, randomized in parallel groups, comparative versus placebo, double-blind (patient and investigating surgeon).~* Group 1: Surgery with intravenous injection of tranexamic acid~* Group 2: Surgery with intravenous injection of Placebo (0.9% sodium chloride)"|t|f|t|f
34034523|NCT04453319|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Block randomization|Randomized Comparative study|t|t|t|t
34034524|NCT01606826|||COHORT||PROSPECTIVE|||||||
34034525|NCT02397512|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34034526|NCT03484702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108104|NCT06638749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding tables to be held by investigational pharmacy. Surgeon and patient will be blinded from administration of TXA versus saline placebo.|Randomized Controlled Trial|t|t|t|t
34108105|NCT00099905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034527|NCT02797327|||COHORT||PROSPECTIVE|||||||
34034528|NCT03348540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34034529|NCT06582238|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34034530|NCT04208152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This study is double-blind. Treatment assignment will not be known to the subjects, the sponsor or the staff who are involved in the clinical evaluation of the subjects and the analysis of data. The randomisation schedule and disclosure envelopes will be generated by an unblinded statistician at Quotient Sciences.~The FES is an open label study which includes a randomized sequence of fasted and fed state."||t|t|t|t
34034531|NCT00071110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34034532|NCT00488202|||COHORT||RETROSPECTIVE|||||||
34034533|NCT00276484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034534|NCT01614873|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34034535|NCT05344495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034536|NCT01848925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034537|NCT03499067|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This will be a double-masked study in which both participant and investigator will be masked.|Each subject will be randomized to wear the test or control contact lens for 1 month and then crossed-over to wear the other contact lens for 1 month.|t|f|t|f
34034538|NCT04925843|||COHORT||RETROSPECTIVE|||||||
34034539|NCT00652054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108106|NCT06673888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108107|NCT06569485|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108108|NCT00112385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152662|NCT05435118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152663|NCT05836467|||COHORT||CROSS_SECTIONAL|||||||
34152664|NCT02872272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152665|NCT02386501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034540|NCT06283537|RANDOMIZED|PARALLEL||OTHER||SINGLE|After all students in the face-to-face education and online education groups complete their applications, the students will practice on the material one by one in the school environment and will be evaluated through the Episiotomy Skill Evaluation Form. In the evaluation, a blinding technique will be used to prevent the person conducting the study interventions from making an evaluation in favor of the intervention group. For this purpose, the faculty member conducting the research initiatives will not take part in the evaluation, instead the evaluation will be made by two different field experts. The experts to be consulted for the evaluation will consist of people working as academicians in the field of obstetrics, nursing and midwifery. After the evaluation, students will have to fill out the survey (Student Information Form) and scale (Student Satisfaction and Self-Confidence in Learning Scale).|A comparative randomized controlled trial|f|f|f|t
34034541|NCT04913558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034542|NCT05129774|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
34034543|NCT05079048|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34034544|NCT01793493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034545|NCT04385017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient with COVID-19 disease||||
34034546|NCT02537561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034547|NCT01167478|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34034548|NCT03158103|NA|SINGLE_GROUP||TREATMENT||NONE||The phase I study consists of a dose-escalation cohort and a dose-expansion cohort.||||
34034549|NCT04515017|||CASE_ONLY||PROSPECTIVE|||||||
34034550|NCT04766177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034551|NCT02042352|||COHORT||PROSPECTIVE|||||||
34034552|NCT04977804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The person assessing the outcome measures will be blinded to the group designation of the subjects.|Two group, randomized parallel group design.|f|f|f|t
34034553|NCT04322448|||COHORT||PROSPECTIVE|||||||
34034554|NCT03299699|||COHORT||PROSPECTIVE|||||||
34034555|NCT02771873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034556|NCT01230164|||||PROSPECTIVE|||||||
34034557|NCT04131140|||COHORT||PROSPECTIVE|||||||
34034558|NCT03021681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034559|NCT01582035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034560|NCT05335824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034561|NCT04982289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034562|NCT00310921|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34034563|NCT04707573|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034564|NCT01718197|||COHORT||PROSPECTIVE|||||||
34034565|NCT01869868|||CASE_ONLY||PROSPECTIVE|||||||
34034566|NCT05418101|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Part A will be double masked; Part B is open label.|This phase 1 study has two parts. Part A is a randomized, double-blind, placebo controlled SAD assessment of SC VIS171 in healthy participants. Part B is an open-label, MAD basket assessment of SC VIS171 in participants with an autoimmune inflammatory disease||||
34034567|NCT00399061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034568|NCT06158893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034569|NCT03108131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034570|NCT00758524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034571|NCT03221647|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34034572|NCT05356871|||COHORT||PROSPECTIVE|||||||
34034573|NCT03810716|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Quasi - experimental study design.||||
34034574|NCT02336945|||CASE_ONLY||PROSPECTIVE|||||||
34034575|NCT04215887|||OTHER||PROSPECTIVE|||||||
34034576|NCT05372354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034577|NCT01875146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034578|NCT06074393|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The clinical trial is a prospective study analysing the effect of a tailored support group on care partner burden, coping strategies, and quality of life in care partners of patients with advanced Parkinsonian syndromes.||||
34034579|NCT04261062|||OTHER||OTHER|||||||
34034580|NCT02892331|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034581|NCT02213159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034582|NCT02487914|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34034583|NCT04631354|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34034584|NCT02232984|||COHORT||PROSPECTIVE|||||||
34034585|NCT04252027|||CASE_ONLY||PROSPECTIVE|||||||
34034586|NCT06216275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34034587|NCT00684840|||CASE_ONLY||PROSPECTIVE|||||||
34034588|NCT02287922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034589|NCT00200564|RANDOMIZED|PARALLEL||||SINGLE||||||
34034590|NCT01132833|||||PROSPECTIVE|||||||
34034591|NCT04272892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be told that they will be assigned to one of two groups but will not be told whether one is hypothesised to be superior over another|Participants will be randomised (1:1 ratio) to the intervention or control group, using a computer generated minimisation method, with minimisation of between groups differences in age and baseline self-reported sleep quality (sleep condition indicator score)|t|f|f|f
34034592|NCT02118805|||OTHER||CROSS_SECTIONAL|||||||
34034593|NCT01709825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34034594|NCT06368011|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34034595|NCT04558229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All study team members will be blinded to the randomization, with the exception of the research member who will be delivering the counseling.|1:1 fashion with block sizes of 8 using a computer-generated random allocation|t|t|t|f
34034596|NCT00443690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034597|NCT01151124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034598|NCT01030419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034599|NCT03524443|||COHORT||PROSPECTIVE|||||||
34152666|NCT04311931|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34152667|NCT06188299|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Liberal Fluid Therapy Group and Targeted Fluid Therapy Groups.|t|f|f|t
34152668|NCT01672918|||||PROSPECTIVE|||||||
34108109|NCT06637774|NA|SINGLE_GROUP||SCREENING||NONE|Judges, examiners were blinded to participant diagnosis. Measurement/analysis judges were blinded to participant diagnosis.|Prospective study of patients referred for videofluoroscopic swallow study, consenting to parallel data collection of signals. No control group.||||
34108110|NCT06497140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Only the personal of the Interventional Radiology department of HEGP (only unblinded center) will have the knowledge of the trial arm.~Patient will be blinded from randomization arm using headphones and/or virtual headset.~The research personnel will be trained accordingly and will keep a separate file with patient's images to ensure that they are not transferred on the Pacs system (Carestream).~The research assistant will discard the products after completion of the procedure in specific containers, that will not be accessible to the patient or to nurses and technicians directly involved in the current patient's care.~Patient's blindness will be assessed using a blinding index after GAE and at the 3-month follow-up visit. The proposed blinding index is scaled to an interval of -1 to 1, 1 being complete lack of blinding, 0 being consistent with perfect blinding and -1 indicating opposite guessing which may be related to unblinding."|"Randomized, single-blind, multicenter trial comparing GAE using an ethiodized oil-based emulsion with a sham procedure in patients with symptomatic knee osteoarthritis.~Randomization in a 2:1 ratio of GAE using an ethiodized oil-based emulsion to the sham procedure will be performed with stratification on Kellgren and Lawrence score (2-3 versus 4)."|t|f|t|t
34108111|NCT00583531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108112|NCT06272578|||COHORT||CROSS_SECTIONAL|||||||
34108113|NCT05515237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108114|NCT02465112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108115|NCT00000845||||PREVENTION||DOUBLE||||||
34108116|NCT01839409|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108117|NCT06473714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34108118|NCT06675760|RANDOMIZED|PARALLEL||OTHER||NONE||: The research is a randomized controlled, quasi-experimental study. The population of the study consisted of 130 first-year students enrolled at Gülhane Faculty of Nursing, University of Health Sciences. Students were randomized into intervention and control groups using a computer program. A mobile augmented reality application was utilized to train students in the intervention group on pressure injury prevention, while students in the control group received traditional educational methods. Data collection occurred in two phases: preparation and implementation. In the preparation phase, presentation materials for the training, the mobile augmented reality application, and data collection forms were developed, and a pilot study was conducted. In the implementation phase, all students received the theoretical training together, while the laboratory sessions were conducted separately for each group. Then, the same evaluation steps were applied to all students.||||
34108119|NCT03119129|RANDOMIZED|PARALLEL||PREVENTION||NONE||Dynamic wait-listed control group design||||
34108120|NCT06561776|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34108121|NCT04539405|||CASE_CONTROL||PROSPECTIVE|||||||
34108122|NCT06054542|||OTHER||PROSPECTIVE|||||||
34108123|NCT05222945|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34108124|NCT06569589|||COHORT||PROSPECTIVE|||||||
34108125|NCT06501963|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34108126|NCT06636578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108127|NCT06569992|||COHORT||RETROSPECTIVE|||||||
34108128|NCT05444439|NA|SINGLE_GROUP||TREATMENT||NONE||Histopathological examination Of gastric endoscopic biopsies Detection of cag A and vac A Genotypes by PCR in endoscopic biopsies Culture and sensitivity of endoscopic biopsies. Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)) then follow up by H. pylori Ag in stool.||||
33724733|NCT01695694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33724734|NCT00815438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108129|NCT06240754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108130|NCT01484756|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108131|NCT06264596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Concealed irrigation bags||t|t|t|f
34108132|NCT00553969|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34108133|NCT05450237|||COHORT||PROSPECTIVE|||||||
34108134|NCT00802906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108135|NCT04809064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108136|NCT06570629|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34108137|NCT04427111|||CASE_ONLY||PROSPECTIVE|||||||
34108138|NCT06230640|||COHORT||PROSPECTIVE|||||||
34108139|NCT06175533|NA|SINGLE_GROUP||TREATMENT||NONE||chronic plantar fasciitis not responding to classical injection by steroid or regenerative therapy||||
34108140|NCT06571929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single-blind, meaning that the evaluator will not know the group to which the participant is assigned. Additionally, in the statistical analysis, the examiner will also remain blind regarding the type of intervention, referring to them as intervention 1 and intervention 2. However, the participants will not be blind to the treatments, due to the impossibility of blinding the type of intervention they will receive.|Group control and experimental group|f|f|f|t
34152669|NCT00240383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152670|NCT03504748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724735|NCT04709328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724736|NCT00102674|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724737|NCT00026793|||COHORT||PROSPECTIVE|||||||
33724738|NCT01304732|||CASE_ONLY||RETROSPECTIVE|||||||
33724739|NCT02994732|NA|SINGLE_GROUP||OTHER||NONE||||||
33724740|NCT05957783|||COHORT||RETROSPECTIVE|||||||
33724741|NCT03278990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are randomly assigned to treatment or control exercises involving writing for 5 minutes. Participants do not know there is another writing condition. Care providers do not see the written content provided by the participant. Neither the participants nor the care provider will know which condition the participant is in.|This is a parallel group randomized trial with 2 arms-a control arm with allocation ratio of 50%, and an intervention arm (future self-value affirmation) with an allocation ratio of 50%.|t|t|f|f
33724742|NCT00017147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108141|NCT05781685|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The investigational drug pharmacy providing the sublingual testosterone masked the drugs. Neither the participants nor the investigators knew who was receiving testosterone.||t|f|t|f
34108142|NCT06671301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108143|NCT00979407|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34108144|NCT06507956|||COHORT||PROSPECTIVE|||||||
34034600|NCT04333316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is prospective study was carried out on 180 patients with a unilateral arthritic hip between January 2011 and August 2018. Patients were divided into two groups, each group included 90 patients. Group A included patients received total hip with a large head (32-36mm.) made of cobalt-chrome. The femoral component was a cementless porous coated stem. The cup was a cementless porous coated Trilogy cup and was inserted press fit with primary additional one to three screws. Group B included those received total hip with a dual mobility cup|t|t|t|t
34034601|NCT04854161|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34034602|NCT01795963|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34034603|NCT04251104|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Psychologists responsible for participant recruitment will be blinded to the information about the group allocation. Due to the nature of the intervention neither participants nor psychologists responsible for the experimental phase can be blinded for the allocation, but the psychologist will be trained to decrease as much as possible her influence on the participants. For this, the psychologist will be provided with clear steps and norms to follow during the experimental intervention.|This is an exploratory randomized controlled study to compare the effectiveness of three types of autobiographical stimuli, classified according to their level of personal relevance, in the induction of positive emotions resulting from the retrieval of specific positive autobiographical memories. The study sample will comprise a group of adults aged 65 years or over and a group of young adults aged between 18 and 35. Each participant will be assigned randomly to one of three parallel groups (high, medium and low personal relevance images). The allocation ratio will be 1:1:1.|f|f|t|f
34034604|NCT06411964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double blind||t|f|t|f
34034605|NCT05293119|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants will undergo randomization into 1:1 ratio into two equal groups. Group A will receive oral Tofacitinib and Group B will receive topical 0.1%Mometasone furoate. All the participants will receive allotted intervention for 12weeks. The patient will be followed up at 6 weeks and end of 12 weeks. Primary outcome of the study will be improvement of Vitiligo Area Scoring Index (VASI) score at 6 and12 weeks in all groups. Secondary outcomes will include improvement in Vitiligo European Task Force (VETF) scoring.||||
34034606|NCT01573585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034607|NCT03022084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034608|NCT02392481|||COHORT||CROSS_SECTIONAL|||||||
34034609|NCT04759196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participant will not know the medication they are taking. When accepting to participate, they are going to have the full list of possible side effects, without knowing which one are link to which medication.~The doctors in charge of administering the questionnaires will be blind. The person in charge of analyzing the results will also be blind."|Patients with chronic subdural hematomas, transient neurological symptoms with negative EEG will be divided in two groups based on their NESIS scores (up to 3 (increased risk of epileptic seizures) and 4 or more (increased risk of cortical depression)). Those two groups are going to receive both Levetiracetam or Lamotrigine.|f|t|f|t
34034610|NCT03252405|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blind||f|f|t|t
34034611|NCT03408639|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034612|NCT02047474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034613|NCT03182933|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34034614|NCT02276456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034615|NCT02084225|||||PROSPECTIVE|||||||
34034616|NCT02002221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034617|NCT01506388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034618|NCT03573622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||open label, single-dose, randomized, two-period, two-treatment, two-sequence, crossover, comparative bioavailability study||||
34034619|NCT06582576|||COHORT||CROSS_SECTIONAL|||||||
34034620|NCT03304145|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034621|NCT03129724|||COHORT||RETROSPECTIVE|||||||
34034622|NCT04389229|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study has two cohorts which will open sequentially. This is not a randomized controlled trial.||||
34034623|NCT06329739|||COHORT||PROSPECTIVE|||||||
34034624|NCT04367779|||COHORT||OTHER|||||||
34034625|NCT00495391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034626|NCT05800886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34034627|NCT00050128||||TREATMENT||||||||
34034628|NCT02476019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034629|NCT06577805|||COHORT||PROSPECTIVE|||||||
34034630|NCT00301197|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034631|NCT03379337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034632|NCT04582032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34034633|NCT00762918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108145|NCT06161181|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108146|NCT06608303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152671|NCT05840536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152672|NCT05077007|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34152673|NCT02803996|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34152674|NCT00490620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152675|NCT03927404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a 16 weeks longitudinal study where subjects will serve their own control. A baseline measurement will be done prior to start of intervention that will continue for 16 weeks and a final measurement will be taken at the end of 16 weeks.||||
34152676|NCT02516228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152677|NCT01821482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152678|NCT06128746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152679|NCT01009866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152680|NCT00888485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34108147|NCT06643286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Care as usual is not altered in both study groups, as to where the care providers continue to deliver the same care. As they are unaware of availability of the intervention, the degree of information provision is not compromised.~During quantitative analyses we pursue masking the outcomes assessor(s)."|Multicentre randomized controlled trial, in which participants are randomised to either the intervention group (use of the intervention in addtion to care usual) or the control group (solely care as usual).|f|t|f|t
34108148|NCT04908046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108149|NCT00205985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108150|NCT06643182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34108151|NCT05405608|||CASE_CONTROL||PROSPECTIVE|||||||
34108152|NCT06400641|||COHORT||PROSPECTIVE|||||||
34108153|NCT03436732|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108154|NCT03221335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108155|NCT06099405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108156|NCT05770245|NA|SINGLE_GROUP||TREATMENT||NONE|An open label, single arm and before and after treatment comparison study|||||
34108157|NCT03708315|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The subjects will be randomized and will get either a sublingual formulation of dexmedetomidine or placebo.|t|t|t|t
34108158|NCT04732468|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108159|NCT00684684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108160|NCT04269265|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34108161|NCT05559047|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Data collected will be deidentified upon collection - surveys and assessment forms will be labelled with a numerical identifier.|||||
34108162|NCT06638216|NA|SINGLE_GROUP||SCREENING||NONE||||||
34108163|NCT04841148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108164|NCT03958643|||COHORT||PROSPECTIVE|||||||
34108165|NCT02603497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108166|NCT04470037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108167|NCT03789370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient and the outcomes assessor will not know what kind of anaesthetic drug was used for maintainance of anaesthesia.||t|f|f|t
34108168|NCT05849844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108169|NCT05430321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33724743|NCT02347189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724744|NCT00426582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724745|NCT04754776|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33724746|NCT06264206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724747|NCT04295421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724748|NCT05369845|NA|SINGLE_GROUP||OTHER||NONE||||||
33724749|NCT03603444|||CASE_CONTROL||RETROSPECTIVE|||||||
33724750|NCT05126147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108170|NCT06540495|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, Single Arm (Three Cohorts), Open Label, Feasibility study||||
34108171|NCT05303857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|randomized (1:1), double-blind, placebo controlled, parallel-group, prospective|t|t|t|f
34108172|NCT00338819|||DEFINED_POPULATION||OTHER|||||||
34108173|NCT02936323|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108174|NCT01817777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034634|NCT04191811|||COHORT||PROSPECTIVE|||||||
34034635|NCT01061593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034636|NCT02423200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034637|NCT05563454|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34034638|NCT02791737|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034639|NCT01509339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034640|NCT04467502|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034641|NCT04271228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034642|NCT01549717|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034643|NCT01722708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034644|NCT06211101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||parallel group (experimental-control)||||
34034645|NCT03738046|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34034646|NCT05576090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034647|NCT04091516|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective interventional study without a control group||||
34034648|NCT00348725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034649|NCT04173507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034650|NCT00517504|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34034651|NCT02930044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034652|NCT00443729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034653|NCT01985217|||||PROSPECTIVE|||||||
34034654|NCT00161603|||||PROSPECTIVE|||||||
34034655|NCT04133857|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34034656|NCT01236469|||COHORT||PROSPECTIVE|||||||
34034657|NCT01926405|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034658|NCT02883816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034659|NCT03281174|||OTHER||PROSPECTIVE|||||||
34034660|NCT01036854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034661|NCT03652402|||COHORT||PROSPECTIVE|||||||
34034662|NCT04650204|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034663|NCT01216735|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34034664|NCT03895814|NA|SINGLE_GROUP||TREATMENT||NONE|The single-group assessment prohibits participant/outcomes masking.|Multi-baseline assessment||||
34034665|NCT05784883|||COHORT||PROSPECTIVE|||||||
34034666|NCT02749617|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34034667|NCT01202045|||COHORT||PROSPECTIVE|||||||
34034668|NCT05378035|||COHORT||PROSPECTIVE|||||||
34034669|NCT05881837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A multicenter, randomized, double-blind, placebo- parallel controlled Phase II clinical study|t|t|t|f
34034670|NCT02036619|||COHORT||PROSPECTIVE|||||||
34034671|NCT01199146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034672|NCT01002924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034673|NCT01127256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034674|NCT05482217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034675|NCT04880486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034676|NCT03124277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034677|NCT03996902|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34034678|NCT02046811|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34034679|NCT04273308|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34034680|NCT01156545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034681|NCT01579773|||COHORT||PROSPECTIVE|||||||
34034682|NCT05027308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034683|NCT01342081||PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034684|NCT00615199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034685|NCT06067165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducting post- and follow-up assessments will be blind to treatment allocation, for the full duration of the trial. The outcome measures are identical for both groups, ensuring that the assessors remain blind. To ensure blinding integrity, participants receive explicit instructions not to disclose which treatment participants have received. After completing the assessment, the blind raters guess the participant's group allocation and disclose the reason for their guess and record whether the participants has inadvertently revealed their group allocation. Blind assessments will be recorded to allow for calculation of inter-rater reliability.||f|f|f|t
34034686|NCT03907137|||OTHER||PROSPECTIVE|||||||
34034687|NCT05409586|||COHORT||RETROSPECTIVE|||||||
34034688|NCT04238819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034689|NCT06284369|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants don't know which video each subject is randomized to||t|f|f|f
34034690|NCT01224405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034691|NCT02610751|||CASE_CONTROL||PROSPECTIVE|||||||
34034692|NCT02212314|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34034693|NCT04820738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034694|NCT04196283|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34034695|NCT00505063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034696|NCT02565745|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcome assessors unaware of the treatment allocation will be sent photographs of the target skin areas with suspected PUs.||f|f|t|t
34034697|NCT03885843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34034698|NCT03526016|||COHORT||PROSPECTIVE|||||||
34034699|NCT03401463|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will include patients staying in the intensive care unit, requiring ventilation of the artificial airways in the form of endotracheal or tracheostomy tube. Patients will be over 18 years of age.||||
34034700|NCT04143373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34034701|NCT00137150|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034702|NCT00264173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034703|NCT02860546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034704|NCT02951754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034705|NCT06452017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||there will be comparison between the two groups, experimental and control|f|f|f|t
33806846|NCT01732120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108175|NCT05584566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108176|NCT03925246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108177|NCT02810405|||COHORT||CROSS_SECTIONAL|||||||
34108178|NCT02002858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108179|NCT06643299|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34108180|NCT04951843|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108181|NCT06641206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108182|NCT04802590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108183|NCT06636799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34108184|NCT04526925|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34108185|NCT02087852|||CASE_CONTROL||PROSPECTIVE|||||||
34108186|NCT06641219|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, exploratory, single centre study. The subjects will receive a single injection of the labeled tracer.||||
34108187|NCT05580406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108188|NCT04605146|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108189|NCT04870346|||COHORT||PROSPECTIVE|||||||
33806847|NCT02377700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806848|NCT02520674|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33806849|NCT06052722|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34108190|NCT03709472|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization will be stratified by gender, type of self-harm, trauma exposure and LGBT status. The investigators will attempt to match overall contact hours (in the experimental condition some of these hours will be with technology). During the continuing care phase the CIFFTA families will interact with the therapist via the website for a period of 8 additional weeks. To match dosage time during aftercare, Treatment As Usual (TAU) will receive check-in telephone calls with the therapist."||||
34108191|NCT04775108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108192|NCT06439706|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34108193|NCT06267768|||COHORT||CROSS_SECTIONAL|||||||
34108194|NCT02788292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108195|NCT06502028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34108196|NCT02026557|||COHORT||RETROSPECTIVE|||||||
33806850|NCT05600387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806851|NCT04826406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806852|NCT02029469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806853|NCT06263946|NA|SINGLE_GROUP||TREATMENT||NONE||multicentre, European, prospective||||
33806854|NCT02300467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806855|NCT02359448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806856|NCT05537012|||OTHER||CROSS_SECTIONAL|||||||
33806857|NCT00177177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806858|NCT06579157|||COHORT||PROSPECTIVE|||||||
33806859|NCT00002281||||TREATMENT||NONE||||||
33806860|NCT01972776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34149582|NCT05920772|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A two-arm non-randomized controlled trail with a mixed-methods approach will be conducted. Youth social work organisations will be assigned to one of the two groups: 1. one group will receive the intervention (intervention group), 2. another group will not receive the intervention (control group). Measurements will take place in both groups at the same time.||||
34149583|NCT03119389|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149584|NCT01120795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149585|NCT06237556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34149586|NCT00787215|||CASE_ONLY||PROSPECTIVE|||||||
33806861|NCT03194516|||CASE_ONLY||PROSPECTIVE|||||||
33806862|NCT00958321|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108197|NCT06377748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Using the block randomization technique, participants will be divided into 4 groups. A web-based randomization list creation tool will be used to create the blocked randomization list. Control and intervention groups will be coded as A, B, C and D using the sealed envelope method. Randomization information will be kept from the researcher involved in data collection until data collection begins. The researcher will learn which group each baby is in just before the application (researcher blinding).~Parents will know which group the baby is in within the scope of the research. By the nature of the sample group, babies are blind.~Research data will be entered into the computer database by coding the group name as A, B, C and D, and statistical analysis will be performed using this coding (statistician blinding)."|Participants will be assigned to experimental and control groups using block randomization method. Birth weight (2500-3000 g, 3001-3500 g, 3501 g and above), gender (male and female) and mode of delivery (vaginal and cesarean section) variables will be used for block randomization.|t|f|f|t
34108198|NCT03633201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34108199|NCT06571617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomized using computer-generated random tables in a 1:1 ratio to be allocated to one of two groups, the first group will undergo mini-PNL, and the second group will undergo RIRS.|t|t|f|f
34108200|NCT05724771|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IV prospective open label interventional clinical study evaluating beneficial outcomes of the addition of CGRPmAb Fremanezumab in chronic migraine patients currently on monotherapy OnabotulinumtoxinA.||||
34108201|NCT01589640|||COHORT||PROSPECTIVE|||||||
34108202|NCT00593619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34108203|NCT05783466|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108204|NCT06522997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this double-blind study, participants will be randomly assigned to receive study intervention. Investigators, participants and study personnel will remain blinded to each participant's assigned study intervention throughout the course of the study|5+1 parallel-arm|t|t|t|t
34108205|NCT02392442|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108206|NCT04642976|||COHORT||PROSPECTIVE|||||||
34108207|NCT00220077|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34108208|NCT06142097|||COHORT||PROSPECTIVE|||||||
34108209|NCT06641921|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34108210|NCT05833542|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34108211|NCT05810467|||COHORT||PROSPECTIVE|||||||
34108212|NCT04857281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108213|NCT06642948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34108214|NCT04049214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108215|NCT02248233|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33806863|NCT06454929|RANDOMIZED|PARALLEL||OTHER||SINGLE|no masking|operative by k-wires or screws or non-operative by cast immobilisation treatment (using randomization tables/software|f|f|f|t
33806864|NCT03549949|||COHORT||PROSPECTIVE|||||||
33806865|NCT03440086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial (no blinded)||||
34108216|NCT02236897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108217|NCT06122909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and outcome assessors will be blinded to the groups|Left ventricular outflow tract-velocity time integral (LVOT-VTI) resuscitation based group Inferior vena cava (IVC) diameter variation resuscitation based group|t|f|f|t
34108218|NCT06347978|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34108219|NCT00721110|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34108220|NCT04458194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34108221|NCT04508530|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34149587|NCT02299076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149588|NCT04358159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and staff responsible for the postoperative care of the patient are masked to the acollcation.|Randomised controlled trial of Vantralex versus Progrip for repair of midline incisional hernias|t|f|f|t
34149589|NCT02633553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149590|NCT05529004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Double Blind study.|t|f|f|t
34149591|NCT01778920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149592|NCT03079726|||CASE_CONTROL||PROSPECTIVE|||||||
34149593|NCT01969721|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34149594|NCT02349490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149595|NCT03016923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149596|NCT00053547|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34149597|NCT05568550|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1||||
34149598|NCT03002311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||SMS text messaging to prompt adherence with follow-up appointment.||||
34149599|NCT00140842|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34149600|NCT04123613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149601|NCT00885794|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34149602|NCT04140981|||COHORT||PROSPECTIVE|||||||
34149603|NCT00805064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149604|NCT04889482|||COHORT||CROSS_SECTIONAL|||||||
34149605|NCT04702815|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34149606|NCT04465812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34149607|NCT03530085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149608|NCT02882386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34149609|NCT05266560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34149610|NCT02947399|NA|SINGLE_GROUP||OTHER||NONE||||||
34149611|NCT03599323|||COHORT||PROSPECTIVE|||||||
34149612|NCT01198509|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34152681|NCT05523375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34152682|NCT01230138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724751|NCT04690543|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two or more groups in parallel for the duration of the study||||
33724752|NCT02320500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724753|NCT00002259||||TREATMENT||||||||
33724754|NCT01689129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034706|NCT05553821|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There are two groups in the study. The control group is the normal pressure applied group, the application group is the cold pressure applied group.|f|f|f|t
34034707|NCT02413892|||COHORT||PROSPECTIVE|||||||
34034708|NCT03618251|||OTHER||PROSPECTIVE|||||||
34034709|NCT00381979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034710|NCT03665740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Randomized Double-blind Placebo controlled, intent-to-treat|t|t|t|t
34034711|NCT03606785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034712|NCT00485264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034713|NCT01130532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34034714|NCT03015246|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Medication conditions blinded using different-sized buprenorphine/naloxone sublingual tablets including placebo. Stress conditions blinded using encapsulation of yohimbine/placebo and hydrocortisone/placebo. Only pharmacy aware of drug codes.|4x2 within-subject crossover design: 4 medication conditions (morphine first, then 3 doses of buprenorphine/naloxone), crossed with 2 stress conditions (placebo vs. stress \[yohimbine + hydrocortisone\], nested within medication conditions)|t|f|f|t
34034715|NCT00631215|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034716|NCT04165746|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Children will be randomized to either enhanced institutional care or enhanced foster care. Both arms of the RCT will participate in an intervention. Children randomized to foster care will receive 2 forms of intervention.||||
34034717|NCT02530502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034718|NCT04239755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034719|NCT01552109|||||PROSPECTIVE|||||||
34034720|NCT05411757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034721|NCT04347720|||COHORT||PROSPECTIVE|||||||
34034722|NCT02321995|||COHORT||PROSPECTIVE|||||||
34034723|NCT04403724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108222|NCT06638931|NA|SINGLE_GROUP||TREATMENT||NONE||The study aims to evaluate the efficacy of the anti-PD1 monoclonal antibody, nivolumab, in the treatment of patients with advanced or metastatic rare malignant neoplasms. This study will be conducted as a single-arm trial, including patients who have a Combined Positive Score (CPS) of 10 or greater and who have demonstrated progression on standard treatment. Participants will be monitored to determine their response to treatment and any adverse effects associated with the use of nivolumab. The expectation is to provide evidence regarding the efficacy of this immunotherapeutic agent in a difficult-to-treat population, contributing to the advancement of therapeutic options available for these patients.||||
34108223|NCT02543385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34108224|NCT02960893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108225|NCT03439072|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34108226|NCT06640556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The statistician will be blinded in the study. The researcher will not be blinded because he/she is the implementer. However, the researcher will open the envelope created by the statistician just before the application and learn which group the mother is in. In order to prevent bias in the evaluation of the data, the groups will be coded as A and B, and the data will be analysed by an independent statistician. After the analysis and interpretation of the data is completed, the codes of the intervention and control groups will be revealed.|The group that watched the animation and the group that did not watch it|t|f|f|t
34108227|NCT03863574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724755|NCT01176266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724756|NCT03221803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724757|NCT03380585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded (Participant)||t|f|f|f
33724758|NCT05657691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||placebo-controlled, parallel-group, double-blind, proof-of-concept trial|t|f|t|t
33724759|NCT03476291|||OTHER||CROSS_SECTIONAL|||||||
33724760|NCT06497114|||OTHER||CROSS_SECTIONAL|||||||
33724761|NCT05150262|||CASE_ONLY||RETROSPECTIVE|||||||
33724762|NCT02128191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724763|NCT04148950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724764|NCT01768351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724765|NCT04245384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724766|NCT01220258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724767|NCT01482793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724768|NCT01290666|||CASE_ONLY||PROSPECTIVE|||||||
33724769|NCT02490722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724770|NCT01525147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724771|NCT00005955||||TREATMENT||||||||
33724772|NCT01085097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33724773|NCT04582110|||CASE_CONTROL||PROSPECTIVE|||||||
33724774|NCT02735551|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724775|NCT02342340|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33724776|NCT03302013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724777|NCT03551912|||COHORT||PROSPECTIVE|||||||
33724778|NCT04369794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724779|NCT01207518|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33724780|NCT06320574|||COHORT||PROSPECTIVE|||||||
33724781|NCT02013167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724782|NCT01318031|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33724783|NCT01142973|||COHORT||CROSS_SECTIONAL|||||||
33724784|NCT03181854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724785|NCT01191580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724786|NCT04404738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724787|NCT00089349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724788|NCT04643262|||COHORT||RETROSPECTIVE|||||||
34108228|NCT01652157|||COHORT||PROSPECTIVE|||||||
33806866|NCT03618758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108229|NCT06563687|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34108230|NCT06638047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108231|NCT03794635|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33724789|NCT03942354|||OTHER||PROSPECTIVE|||||||
33724790|NCT02067910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724791|NCT04231786|||COHORT||PROSPECTIVE|||||||
33724792|NCT02064881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806867|NCT04420078|||COHORT||RETROSPECTIVE|||||||
33806868|NCT05620979|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|no blinding|This is a multi-site, three-arm, financial navigation intervention||||
33806869|NCT01143142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33806870|NCT04473703|||COHORT||PROSPECTIVE|||||||
33806871|NCT00547066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806872|NCT03908606|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33806873|NCT06699706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806874|NCT05902936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* The participant will be blinded to the materials will be used during the pulpotomy process.~* The outcome assessors will be blinded.~* The operator will not be blinded for both materials during pulpotomy procedure as the two materials having different colors and different handling techniques."||t|f|f|t
33806875|NCT00010088||||TREATMENT||||||||
34034724|NCT05447104|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double blind|prospectively planned, double-blind, single center cross-over study|t|t|t|t
34034725|NCT02901938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034726|NCT03329339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034727|NCT05445102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034728|NCT02902224|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34034729|NCT04594681|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34034730|NCT03256604|||COHORT||RETROSPECTIVE|||||||
34034731|NCT00967330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034732|NCT02387840|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34034733|NCT05850325|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34034734|NCT04521881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking will be done by an independent clinical trials supply company. It will involve the removal of the original manufacturer's label and replacement with the clinical trial label bearing the randomisation number, which will be used as the pack identification. Apart from the randomisation number, all pack label texts will be identical for tranexamic acid and placebo.|A randomised, double blind, placebo controlled trial among 10,000 older adults with mild traumatic brain injury.|t|t|t|t
34034735|NCT02665793|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34034736|NCT04082897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034737|NCT01434095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034738|NCT04747470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34034739|NCT02060305|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34034740|NCT03231163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34034741|NCT03460002|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The RECAMP trials test two separate hypotheses relating to the potential beneficial non-specific effects of providing live vaccines in general vaccination campaigns.~The RECAMP-MV trial tests the effect of a Measles Vaccination campaign among children aged 9-59 months The RECAMP-OPV trial tests the effect of an Oral Polio Vaccination campaign in children aged 0-8 months"|f|t|f|f
34034742|NCT01891864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034743|NCT01235754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034744|NCT02548156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34034745|NCT00293787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034746|NCT01715961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34034747|NCT02365987|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34034748|NCT01523652|||COHORT||PROSPECTIVE|||||||
34034749|NCT04897854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034750|NCT05148221|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34034751|NCT04761315|||CASE_ONLY||PROSPECTIVE|||||||
34034752|NCT01071915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034753|NCT02904772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034754|NCT00842673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034755|NCT03123744|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, open-label, non-randomized Phase II study of palbociclib in adult subjects with recurrent or refractory advanced cancers with aberration(s) in cyclin (CCN/CDK) signaling. Treatment will consist of daily oral administration of palbociclib in 28-day cycles.||||
34034756|NCT05767658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34034757|NCT02664181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034758|NCT01495650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108232|NCT02415114|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108233|NCT06475300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108234|NCT06321029|NA|SINGLE_GROUP||TREATMENT||NONE||Single group waitlist control||||
34108235|NCT03538457|||CASE_ONLY||PROSPECTIVE|||||||
34034759|NCT02154867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034760|NCT02968576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34034761|NCT01437293|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34108236|NCT04598087|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108237|NCT01275079|||COHORT||PROSPECTIVE|||||||
34108238|NCT03026777|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724793|NCT02232581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724794|NCT01263301|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724795|NCT02120950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724796|NCT00006101|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33724797|NCT02548520|||COHORT||PROSPECTIVE|||||||
33724798|NCT02605603|||COHORT||PROSPECTIVE|||||||
33724799|NCT05975086|||COHORT||PROSPECTIVE|||||||
33724800|NCT05796674|||COHORT||RETROSPECTIVE|||||||
33806876|NCT06411041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be informed about the group of the participants|The experimental group will receive regular care and a 12-week program of pelvic floor muscle training (PFMT) and yoga. The control group will receive regular care.|f|f|f|t
34034762|NCT06401135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be not informed about their groups and they will be evaluated and trained at different places and times|Patients will be randomized to the following groups: Group 1 (10% MIP), Group 2 (30% MIP), or Group 3 (60% MIP).|t|f|f|f
34034763|NCT01869933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034764|NCT06237946|||COHORT||RETROSPECTIVE|||||||
34034765|NCT05111782|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034766|NCT02254980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034767|NCT02535403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034768|NCT02801253|||COHORT||PROSPECTIVE|||||||
34034769|NCT04877119|||COHORT||PROSPECTIVE|||||||
34034770|NCT00741000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034771|NCT02955212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034772|NCT01705795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034773|NCT00927589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034774|NCT04809532|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled Trial||||
34034775|NCT02144714|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34034776|NCT02015728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034777|NCT00073164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034778|NCT02668575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34034779|NCT00324077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034780|NCT00263822|RANDOMIZED|||TREATMENT||NONE||||||
34034781|NCT05754489|||CASE_ONLY||PROSPECTIVE|||||||
34034782|NCT06378515|||COHORT||PROSPECTIVE|||||||
34034783|NCT00610129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034784|NCT03690050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Ophthalmologists undertaking laser treatments for DMO at each of the participating centres will also deliver the treatment for the trial. Although, for obvious reasons, ophthalmologists delivering the treatment will not be masked with regards to the laser used, every effort will be made to ensure that participants and outcome assessors (e.g. optometrists measuring visual function, photographers/technicians/nurses obtaining OCT images and ophthalmic technicians obtaining visual fields) will be masked to the allocated treatment. Patients will not be informed before, during, and after the laser treatment about which technology of laser was used for their treatment.~Similarly, the investigators obtaining outcome measures will only have access to the CRF booklet (but not to the notes of the patients) which will contain no information with regards to the type of laser the patient had been allocated or received"||t|t|f|t
34034785|NCT02696291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034786|NCT02909686|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34034787|NCT04207658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The data of the study is collected by using Baseline Obstetric Data Form in which demographic, obstetric, and first stage features of labour with features of 2nd, 3rd and 4th stages of pregnancy are registered, and Visual Analogue Fatigue Scale (VAFS).~.Management of Data Collection Tools and Forms Randomization of gravitas participated in the study is done with the help of computers. The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour.~The pushing is initiated; when the servical dilatation is 10cm along with strong uterus contractions until foetal head rotation is over and when the foetal head is at least +1 in the pelvis. In addition, at the onset of pushing in spontaneous group, woman's desire to push is not ignored."|t|f|f|f
34034788|NCT00567008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034789|NCT04463758|||COHORT||PROSPECTIVE|||||||
34034790|NCT02120638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034791|NCT05328739|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34034792|NCT02082015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034793|NCT05252299|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Statistical power is not the goal for this pilot study; rather, we wish to obtain estimates of feasibility as a basis for a future randomized controlled trial. As such, we plan to enroll 30 caregivers in each group.||||
34034794|NCT04000139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized into two treatment arms, active ingredient or placebo with the ratio 2:1.|t|t|t|t
34034795|NCT00172718|||||PROSPECTIVE|||||||
34034796|NCT02744872|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34034797|NCT00870844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034798|NCT01296087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034799|NCT03606616|||COHORT||PROSPECTIVE|||||||
34034800|NCT00839358|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34034801|NCT05268562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34034802|NCT03228888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants were randomly assigned to one of the two groups (artificial or ecological RAS) and were evaluated in three moments: before the rehabilitative treatment (T0), at the end of the 5 week rehabilitative treatment (T5), and 3 months after the end of the treatment, namely 17 weeks after the first assessment (T17).|t|t|t|t
34034803|NCT03782168|||CASE_CONTROL||PROSPECTIVE|||||||
34034804|NCT01807403|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34034805|NCT02932462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034806|NCT00268450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034807|NCT01324778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034808|NCT06306248|||COHORT||PROSPECTIVE|||||||
34034809|NCT06577818|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34034810|NCT04197804|||CASE_CONTROL||PROSPECTIVE|||||||
34034811|NCT06583226|NA|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034812|NCT04160650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are blinded after assignment to interventions, those in intervention and control groups are not aware which treatment they get.|A two-arm, single center, patient blinded superiority trial with stratified randomization (1:1) and with repeated measures|t|f|f|f
34034813|NCT05977192|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806877|NCT03170050|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||The Subjects are injected investigational devide(YYD701-2 or Restylane Perlane Lidocaine) in right or left nasolabial folds|t|f|f|t
33806878|NCT04878159|||COHORT||PROSPECTIVE|||||||
33806879|NCT00686465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806880|NCT06085989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33806881|NCT05099419|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Two different intervention protocols will be administered in a crossover design.||||
33806882|NCT06336590|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33806883|NCT02994407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806884|NCT03491540|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both participants and investigators are unaware of the intervention assignment||t|f|t|f
33806885|NCT02963571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806886|NCT06509646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated.||f|f|f|t
33806887|NCT02803749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034814|NCT05045287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034815|NCT00634946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034816|NCT02026050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034817|NCT01530464|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34034818|NCT03298204|||CASE_CONTROL||RETROSPECTIVE|||||||
34034819|NCT01403051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034820|NCT03367819|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment used only for allocation to Cohort A-1 or A-2||||
34034821|NCT00259181|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34034822|NCT00001850|||COHORT||PROSPECTIVE|||||||
34034823|NCT04931693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An online randomization program (http://www.randomizer.org) will be used to generate random list and to allocate patients into two study groups: Random allocation numbers will be concealed in opaque closed envelops. The patient and investigator performing the block and assessing study outcomes will all be blinded to the study group allocation.|The patient will be randomly assigned to two equal groups. conventional control group(C) (n=20) where20 children will receive IV paracetamol 20 mg / kg . and Pectoral nerves blocks group (P) (n=20) where 20 children will have PECs Block .|t|t|f|f
34034824|NCT01467297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034825|NCT03139474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034826|NCT00516659|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
34034827|NCT03920514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Women will be randomly divided in to four groups the first Group will undergo IUI after 24 H of hCG administration the second g will undergo IUI after 36 h after hCG the third Group will undergo IUI after 48h of hCG administration the last Group will undergo IUI at the time of hCG adminstration|f|f|t|f
34034828|NCT00479999|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034829|NCT02811965|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Each research subject will have pressure mapping performed on his or her right foot in the 7 conditions described for each study arm to determine the contact forces experienced by the heel in each off-loading condition. Each intervention will be randomly applied.|f|f|f|t
34034830|NCT02368964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034831|NCT01299675|||COHORT||PROSPECTIVE|||||||
34034832|NCT05334524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034833|NCT03208686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108239|NCT00778401|RANDOMIZED|CROSSOVER||||NONE||||||
34108240|NCT06454188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108241|NCT05002309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806888|NCT05901532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806889|NCT02457741|||COHORT||PROSPECTIVE|||||||
33806890|NCT06544499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806891|NCT04486820|||COHORT||RETROSPECTIVE|||||||
33806892|NCT00713752|||COHORT||PROSPECTIVE|||||||
33806893|NCT06694441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33806894|NCT01640951|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806895|NCT05554549|||COHORT||PROSPECTIVE|||||||
33838062|NCT03689751|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients were block randomised in groups of 10 participants to either control (no video) or intervention (video), using opaque envelopes. Both control and intervention arms received standard pre-operative face to face counseling and written information. Clinicians were blinded to allocation. A research nurse blinded to allocation performed data entry.|Two RSAV were created explaining LSCS and TVT/TOT. Participants were block-randomised in groups of 10 to either control (no video) or intervention (video). Target recruitment was 60 patients per group; 30 patients per arm.|f|t|f|t
33838063|NCT04318457|||OTHER||PROSPECTIVE|||||||
34108242|NCT06340360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to 1 of 3 groups (low dose, high dose, or placebo).|t|t|t|t
34108243|NCT05479981|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will receive one blinded treatment at Day 43. Treatment assignment on this day will be based on treatment received in AOC 1001-CS1 so that participants who did not receive active drug on Day 43 in AOC 1001-CS1 will received active drug on Day 43 in AOC 1001-CS2.|||||
34108244|NCT01208766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806896|NCT05930106|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The research will involve 50 female patients who have undergone liposuction and will be divided into two groups.~Group Intraoperative Fluid Ratio: Fluid administration will be determined by the intraoperative fluid ratio. This ratio is calculated by dividing the sum of subcutaneous infiltration and intravenous fluid by the total aspirate volume. Depending on the aspiration volume, it will be maintained at 1-1.4.~Group Carotid Artery Peak Velocity Variation: Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA."||||
33806897|NCT04492475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034834|NCT00416390|RANDOMIZED|||TREATMENT||DOUBLE||||||
34034835|NCT04989543|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34034836|NCT03385889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors of joint position sense, balance, and cervical spine range of motion via the Cervical Flexion Rotation Test will be blinded to group allocation|Pre-test, Post-test, control group design 3 groups - mobilization, manipulation, control|f|f|f|t
34034837|NCT03759548|||COHORT||PROSPECTIVE|||||||
34034838|NCT03903302|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Safety, pharmacokinetics and pharmacodynamics of CS1||||
34034839|NCT06155201|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Collect blood samples from more than 5,000 patients with depression, more than 5,000 patients with anxiety disorders, more than1000 patients with autism spectrum disorder, and more than1000 patients with attention deficit hyperactivity disorder, and complete different intervention for a total of more than 12,000 patients. Based on the CCBT theory Moca system and systematic aerobic exercise system and other projects, personalized functional training intervention for children can be achieved. Use wearable diagnostic and treatment equipment, such as brain imaging, brain functional imaging, and neuromodulation technology to assist diagnosis and treatment; use structured psychological behavioral therapy and artificial intelligence technology to improve management.||||
34034840|NCT05667090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034841|NCT02226523|||COHORT||PROSPECTIVE|||||||
34034842|NCT04314453|||COHORT||RETROSPECTIVE|||||||
34034843|NCT04756947|||COHORT||RETROSPECTIVE|||||||
34034844|NCT03358927|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio||||
34034845|NCT02711202|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34034846|NCT00677521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034847|NCT04785872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34034848|NCT06209580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034849|NCT05850611|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34034850|NCT01495299|||COHORT||PROSPECTIVE|||||||
34034851|NCT06267898|||CASE_ONLY||PROSPECTIVE|||||||
34034852|NCT06464484|RANDOMIZED|PARALLEL||TREATMENT||NONE||This intervention was a randomized, controlled trial. The participants were randomized using lottery method either to the probiotic group (PG) and the control group (CG). The probiotic group received a daily (Lactobacillus rhamnosus GG 6x10\^9 cpu) supplement for 30 days||||
34034853|NCT00096629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34034854|NCT05823285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034855|NCT01215136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034856|NCT06511843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34034857|NCT04709562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034858|NCT06512753|||COHORT||PROSPECTIVE|||||||
34034859|NCT05038878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034860|NCT02548169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034861|NCT03877900|||CASE_ONLY||PROSPECTIVE|||||||
34034862|NCT06320184|||CASE_CONTROL||RETROSPECTIVE|||||||
34034863|NCT04929327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034864|NCT02943980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034865|NCT02691234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034866|NCT00879086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034867|NCT03367195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034868|NCT03860974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034869|NCT02969252|NA|SINGLE_GROUP||OTHER||NONE||||||
34034870|NCT03982511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Behavioral observation coders are masked.|Parent-child dyads will be randomly assigned to PCIT-Health or a waitlist control.|f|f|f|t
34034871|NCT02500589|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34034872|NCT00508599|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34034873|NCT05950672|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034874|NCT06156995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034875|NCT04790903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34034876|NCT03928483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This single-armed trial will have one condition: the modified WW Food program.||||
34034877|NCT03036826|||COHORT||PROSPECTIVE|||||||
34034878|NCT06551155|||OTHER||CROSS_SECTIONAL|||||||
34034879|NCT02943837|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34034880|NCT04683861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034881|NCT06331481|||COHORT||PROSPECTIVE|||||||
34034882|NCT01541085|||||RETROSPECTIVE|||||||
33806898|NCT02252822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034883|NCT01366820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034884|NCT04512664|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, 2-group, Single-blind, Randomized clinical trial|t|f|f|f
34034885|NCT04074005|||COHORT||PROSPECTIVE|||||||
34034886|NCT05391373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34034887|NCT04902001|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There is no need for masking here.|One group of adolescents with obesity||||
34034888|NCT01214655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034889|NCT00186732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034890|NCT01483443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034891|NCT02068274|||COHORT||PROSPECTIVE|||||||
34034892|NCT01916525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034893|NCT03348332|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34108245|NCT03502200|RANDOMIZED|PARALLEL||PREVENTION||NONE|This study is a comparative randomized study.|Participants will be assigned to one of two conditions randomly.||||
34108246|NCT04692597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108247|NCT04818229|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34108248|NCT05855746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a prospective, two arms, randomized (1:1), double blind, superiority study evaluating colchicine versus placebo administrated during six months among participants with acute myocarditis.|t|t|t|t
34108249|NCT05988229|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Block randomization stratified by language and level of care (observation unit versus inpatient floor)||||
34108250|NCT02446457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108251|NCT04585035|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase Ia dose escalation portion of the study followed by a Phase Ib dose combination portion. Phase 2 will consist of 5 treatment arms.||||
34149613|NCT03976284|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will participate in 10 weekly health promotion sessions featuring cooking instruction, brief didactic nutrition instruction and 10-minute bouts of physical activity all taking place in the church kitchen/meeting room.||||
34149614|NCT03545997|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Montelukast will be crushed and coated in a capsule, Mannitol is into a capsule too.|It's a prospective, randomized, comparative vs placebo, double blind, multicenter, national study.|t|t|t|t
34149615|NCT04459364|||COHORT||OTHER|||||||
34149616|NCT04870541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34149617|NCT02030288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149618|NCT03131739|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34149619|NCT01640665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149620|NCT03106129|||COHORT||PROSPECTIVE|||||||
34149621|NCT05294458|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149622|NCT00318331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149623|NCT02739516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149624|NCT04397965|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33806899|NCT02646774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806900|NCT02513043|||CASE_ONLY||PROSPECTIVE|||||||
33806901|NCT05532501|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|t
33806902|NCT01733615|||CASE_ONLY||PROSPECTIVE|||||||
33806903|NCT05139784|||CASE_CONTROL||PROSPECTIVE|||||||
34034894|NCT02392117|||COHORT||PROSPECTIVE|||||||
34034895|NCT01772290|RANDOMIZED|PARALLEL||||NONE||||||
34034896|NCT03142737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34034897|NCT04015973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded randomised controlled trial||||
34034898|NCT01668745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034899|NCT01849965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034900|NCT03977948|||OTHER||PROSPECTIVE|||||||
34034901|NCT00809562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034902|NCT03575208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034903|NCT03684850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034904|NCT03827889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034905|NCT03274193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034906|NCT05809648|||COHORT||PROSPECTIVE|||||||
34034907|NCT05280392|||OTHER||PROSPECTIVE|||||||
34034908|NCT01328184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149625|NCT01572272|||COHORT||PROSPECTIVE|||||||
34149626|NCT01820052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149627|NCT04631653|NA|SINGLE_GROUP||SCREENING||NONE||Examine the diagnostic accuracy in referred participants||||
34149628|NCT04150692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149629|NCT04906057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group allocation will be concealed to the individual obtaining all outcomes of interest|rater-blind, prospective randomized trial|f|f|f|t
34149630|NCT01800318|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34149631|NCT05623111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2-armed active/placebo 1:1 ratio|t|t|t|f
34149632|NCT01110798|RANDOMIZED|||TREATMENT||NONE||||||
33806904|NCT02180724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149633|NCT00002254||||TREATMENT||||||||
34149634|NCT00026377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806905|NCT01809275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33806906|NCT00982072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806907|NCT06098118|NA|SINGLE_GROUP||OTHER||NONE||||||
33806908|NCT06696508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806909|NCT06427590|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33806910|NCT06238934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33806911|NCT06430021|||COHORT||PROSPECTIVE|||||||
33806912|NCT03964740|RANDOMIZED|PARALLEL||OTHER||NONE||Single-center open-label controlled pilot study. The interventional group receive a mobile device with an installed application for asthma and obesity control and have protocolized in-person ambulatory visits for asthma and nutrition parameters control while the control study follows a pattern of visits based on the usual clinical practice in the study site.||||
33806913|NCT02546531|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806914|NCT05657470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806915|NCT00900900|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33806916|NCT01310166|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33806917|NCT05062291|||COHORT||PROSPECTIVE|||||||
33806918|NCT05055063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806919|NCT04346914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806920|NCT00000852||||TREATMENT||||||||
33806921|NCT02958696|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806922|NCT00152672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33806923|NCT02867956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806924|NCT05964907|NA|SINGLE_GROUP||OTHER||NONE||||||
33806925|NCT03835559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, prospective randomized controlled trial||||
34034909|NCT03097627|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|There is no masking in this study.|||||
34034910|NCT05415163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The photobiomodulation application devices are identical in both groups and in the placebo group the device will not emit light, only the sound signal. Both participant and researcher will wear protective eyewear and will not know which equipment is the active or placebo. Only a researcher external to the procedure will know which equipment is in each group||t|f|t|f
34034911|NCT06128161|||CASE_ONLY||CROSS_SECTIONAL|||||||
34034912|NCT03871543|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34034913|NCT05924724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective randomized controlled trial||||
34034914|NCT01088477|||CASE_ONLY||PROSPECTIVE|||||||
34034915|NCT01416519|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034916|NCT00835393|RANDOMIZED|CROSSOVER||||NONE||||||
34034917|NCT01551771|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34034918|NCT01644682|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34034919|NCT04069819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034920|NCT04908592|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34034921|NCT00056927|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34034922|NCT01213966|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034923|NCT03487471|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34034924|NCT05509387|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34034925|NCT03039114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034926|NCT01397357|||||PROSPECTIVE|||||||
34034927|NCT00980486|||COHORT||PROSPECTIVE|||||||
34034928|NCT00260559|||CASE_ONLY||PROSPECTIVE|||||||
34034929|NCT06165276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034930|NCT06455215|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Randomization will occur at the garden level. Three gardens will be randomized to the intervention and three gardens to the control group. The participants assigned to the three gardens in the intervention group will receive an 8-week intervention that includes 1) educational materials, 2) healthy cooking demonstrations, 3) food and transportation support and 4) garden social activities. The control garden group will not receive an intervention during this time period which allows us to evaluate differences in the primary and secondary outcomes in the intervention and control groups at 8 weeks and 6 months.~The control group will receive the delayed 8-week intervention one year after the intervention group."||||
34034931|NCT04935541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The surgeon who performed the surgery, the participants included in the study, and the technician who collected the study data were unaware of the study groups and the type of drugs used for sedation.||t|t|f|t
34034932|NCT03701893|NA|SINGLE_GROUP||SCREENING||NONE||Open label intervention study.||||
34034933|NCT06424548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034934|NCT03236467|NA|SINGLE_GROUP||TREATMENT||NONE||Using an innovative translational research approach to study whether a 12 week-progressive - exercise program will reduce FM pain in patients with PTSD and to elucidate and modify potential PTSD-related deficiencies in neurobiological and psychological responses to exercise||||
34034935|NCT00001284|||COHORT||PROSPECTIVE|||||||
34034936|NCT03832686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34034937|NCT01981902|||CASE_ONLY||CROSS_SECTIONAL|||||||
34034938|NCT01390610|||CASE_CONTROL||PROSPECTIVE|||||||
34034939|NCT04293874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034940|NCT05630846|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single-blind study. recipients and care providers will be unaware of vaccine administered.||t|t|f|f
34034941|NCT00421161|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34034942|NCT01197534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149635|NCT05547789|||COHORT||PROSPECTIVE|||||||
34149636|NCT06234215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149637|NCT02900170|||COHORT||PROSPECTIVE|||||||
34149638|NCT04713332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34149639|NCT04167072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806926|NCT02824198|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|An observer-blind procedure was followed for the injection of CYD dengue vaccine or placebo. Neither the blind-observer Investigator nor the participants (and/or participants' parent(s)/legally acceptable representative(s) for participants aged \< 21 years) knew which product was administered.||t|f|t|f
33806927|NCT03382470|||COHORT||PROSPECTIVE|||||||
33806928|NCT04502381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806929|NCT01724996|||COHORT||PROSPECTIVE|||||||
34034943|NCT00962897|||CASE_CONTROL||RETROSPECTIVE|||||||
34034944|NCT03517410|||CASE_ONLY||CROSS_SECTIONAL|||||||
34034945|NCT05244694|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034946|NCT01364012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034947|NCT00266279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034948|NCT05990829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034949|NCT05708534|||COHORT||PROSPECTIVE|||||||
34034950|NCT04965805|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a double-center, two-armed, randomized, prospective, non-inferiority, clinical comparative trial.||||
34034951|NCT00051948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34034952|NCT00608101|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
34034953|NCT01873352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034954|NCT06352021|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34034955|NCT03207776|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34034956|NCT02828293|||CASE_CONTROL||PROSPECTIVE|||||||
34034957|NCT00202371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34034958|NCT01692626|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34034959|NCT05565989|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1 control condition implying a Motivational Interview (MI)~1 experimental condition implying a Motivational Interview (MI) + Mindfulness-Based Meditation practices (MBM) + Intention Implementation (II)"||||
34034960|NCT00269646|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34034961|NCT04885309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34034962|NCT03813173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034963|NCT06581510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34034964|NCT02655731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034965|NCT02205463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034966|NCT05785182|||COHORT||PROSPECTIVE|||||||
34034967|NCT06201767|||OTHER||CROSS_SECTIONAL|||||||
34034968|NCT04388956|||CASE_ONLY||PROSPECTIVE|||||||
34034969|NCT04362228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034970|NCT05575973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34034971|NCT04113473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34034972|NCT06582875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034973|NCT04662879|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Post-enrollment consent|t|f|f|t
34034974|NCT03443349|NA|SINGLE_GROUP||OTHER||NONE||"The medical device will be used according to its market authorization, i.e. CE-Certification. Because it will be used for the first time in pregnant women, a vulnerable population, the following three step application procedure has been determined:~* First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.~* Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife in agreement with the woman.~* All the remaining pregnant women (35) use the device for 30 minutes. Position and module proposed by the midwife with the agreement of the woman.~During the intervention period, position and module might be changed once if required.~There will be a safety review board meeting after each group of the pregnant women having used the device, checking the safety criteria according to predefined Adverse Device Effects and Adverse Events."||||
34034975|NCT03936205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34034976|NCT05902286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The testing sessions will be completed by research assistants who are blinded to the participant's condition as not to influence testing results. All participants will be randomized into a condition (e.g., Osc+ or Osc-) by a graduate student so research assistants doing the assessments are blinded to condition.|The investigators plan to collect a sample of 50 older adult participants (25 per group) for the current study. Participants who meet the inclusion and exclusion criteria will then be randomized into the Osc+ or Osc- group for the five-week condition. All randomization in this study will be completed using a quasi-random number generator constrained so there are equal numbers of participants in each condition.|t|f|f|t
34034977|NCT03478943|||OTHER||PROSPECTIVE|||||||
34034978|NCT05791097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034979|NCT00238017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034980|NCT02852954|||CASE_CONTROL||RETROSPECTIVE|||||||
34034981|NCT05137392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34034982|NCT03566030|||CASE_CONTROL||PROSPECTIVE|||||||
34034983|NCT06107569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034984|NCT03700762|||CASE_ONLY||PROSPECTIVE|||||||
34034985|NCT01937221|||CASE_CONTROL||PROSPECTIVE|||||||
34149640|NCT01410812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149641|NCT01365806|||COHORT||PROSPECTIVE|||||||
34149642|NCT02337166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149643|NCT05391308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149644|NCT03668990|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149645|NCT05245877|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34149646|NCT05553275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806930|NCT04939909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806931|NCT04633148|NA|SEQUENTIAL||TREATMENT||NONE||Initial dose escalation followed an adaptive design. Further dose escalation includes 2 additional TMpPSMA dose levels and follows a 3+3 design.||||
33806932|NCT04693741|RANDOMIZED|PARALLEL||OTHER||NONE||"Patients will be randomized into two groups according to the surgical procedure performed as follows:~Group A: the autogenous iliac bone graft will be used to fill the alveolar defect.~Group B : Xenograft with PRF will be used to fill the alveolar defect."||||
33806933|NCT03781349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33806934|NCT05657821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33806935|NCT02404441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Although the study had 2 'arms', the phase I part of the study had 5 dosing cohorts and the phase ll part had 5 treatment groups for a total of 10 reporting groups.||||
33806936|NCT01837602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806937|NCT03042741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind study in two groups of patients assigned randomly into experimental and placebo arms|Group on experimental drug compared against group receiving placebo in randomized, blinded phase III study to evaluate effect on lipid profile, i.e., LDL, HDL, triglycerides and total cholesterol|t|t|t|f
33806938|NCT02660294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806939|NCT00463229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806940|NCT02371395|||COHORT||CROSS_SECTIONAL|||||||
33806941|NCT01064999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806942|NCT06699108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34034986|NCT00711295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34034987|NCT00674739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34034988|NCT04282109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034989|NCT00766740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034990|NCT06582082|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34034991|NCT03472781|||OTHER||RETROSPECTIVE|||||||
34034992|NCT05637372|||COHORT||CROSS_SECTIONAL|||||||
34034993|NCT00300924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34034994|NCT01909856|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34034995|NCT02246751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34034996|NCT04768192|||COHORT||PROSPECTIVE|||||||
34034997|NCT01739465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34034998|NCT03557112|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34034999|NCT04617457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035000|NCT05204212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035001|NCT04115319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|A Randomized, Double-blind, Active Comparator-Controlled Study|t|t|t|t
34035002|NCT04505657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomized controlled trial|randomized controlled trial|t|f|f|f
34035003|NCT06302673|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Double blinded randomized controlled trial (RCT)|t|f|f|t
34035004|NCT06483009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035005|NCT01134250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035006|NCT02692859|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34035007|NCT04365010|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective cluster-randomized, multiple-crossover trial||||
34035008|NCT05755880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035009|NCT00118157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035010|NCT03503604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035011|NCT05840458|||CASE_ONLY||PROSPECTIVE|||||||
34035012|NCT00295113|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34035013|NCT00017693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035014|NCT05158673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized Clinical Trial only the principal investigator is not blinded|Randomized Clinical Trial|t|t|t|t
34035015|NCT05157412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035016|NCT05098652|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34035017|NCT03177525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035018|NCT00392366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035019|NCT00944060||||PREVENTION||||||||
34035020|NCT04311294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study team, medical personnel, and participants will be blind to drug condition.|Randomized, triple-blind, placebo-controlled, parallel-group study of ANS-6637 (200mg, 600mg, 0mg \[palcebo\])|t|t|t|f
34035021|NCT00452244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035022|NCT06060561|||CASE_ONLY||CROSS_SECTIONAL|||||||
34035023|NCT06230445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035024|NCT02969382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035025|NCT03365362|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34035026|NCT03908450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|angiographies blinded to treatment groups|1:1 randomization|f|f|f|t
34035027|NCT01499095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035028|NCT05190445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Group Assignment Drug Cinrebafusp Alfa (PRS-343) Combination Therapy||||
34035029|NCT04254848|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34035030|NCT04785547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035031|NCT02764593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33806943|NCT00418652|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34035032|NCT06156397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three groups with a conventional therapy control group|t|f|f|t
34035033|NCT06582290|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The two clinicians completing and coding the OVAATs will be blind to which group the participant is.|The study will use a correlational design. An online autism assessment tool (the Oxford Virtual Autism Assessment Tool (OVAAT)) will be (a) compared to an existing standardised autism observation tool (the ADOS-2) and developmental history (gathered from parents) in terms of it's ability to identify features of ASD and (b) evaluated to determine whether it can distinguish between 13-18 year old young people with ASD and 13-18 year old young people with no neurodevelopmental conditions or mental health problems.|f|f|f|t
34035034|NCT04338932|||COHORT||RETROSPECTIVE|||||||
34035035|NCT03707626|||COHORT||RETROSPECTIVE|||||||
34035036|NCT03203317|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34035037|NCT05908877|||COHORT||PROSPECTIVE|||||||
34035038|NCT04459936|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a randomised, open label, blinded endpoint trial, with balanced randomisation (1:1)||||
34035039|NCT01258140|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34035040|NCT05491902|||COHORT||CROSS_SECTIONAL|||||||
34035041|NCT05204667|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase IV, randomized, open-label, parallel-group, multicentre study.||||
34035042|NCT05758870|||CASE_CONTROL||PROSPECTIVE|||||||
34035043|NCT04952961|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035044|NCT04527510|||CASE_ONLY||PROSPECTIVE|||||||
34035045|NCT01298232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34035046|NCT01022840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035047|NCT05744167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34035048|NCT02105987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035049|NCT01777503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035050|NCT05192239|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Coded envelope.|Participants will be randomized to either placebo or intervention separated by a 4 day wash-out period.|t|f|f|f
34035051|NCT00308178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035052|NCT05894707|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34035053|NCT06058702|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34035054|NCT01868802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035055|NCT01866826|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34035056|NCT04751487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035057|NCT04214834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacy will track dose levels to know where an infant is within a rapid- or slow-wean intervention arm. The clinical team will be blinded to the dose level and will only be aware of the study steps. Both the rapid- and slow-wean intervention arms are depicted to indicate that if each intervention arm has the same number of escalations, the study steps will be identical. This is critical to maintaining the clinical team blinding.|The study will have two intervention arms (rapid-wean and slow-wean) with 251 morphine/methadone treated infants per intervention arm, for a total of 502 morphine/methadone treated infants.|t|t|t|t
34035058|NCT05929404|||COHORT||PROSPECTIVE|||||||
34035059|NCT02152137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035060|NCT05832632|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34035061|NCT04190992|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34035062|NCT00439985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035063|NCT00203333|||COHORT||PROSPECTIVE|||||||
34035064|NCT01875978|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34035065|NCT02721381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035066|NCT03759392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035067|NCT04017806|||COHORT||PROSPECTIVE|||||||
34035068|NCT05702983|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035069|NCT04737941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035070|NCT06107257|||CASE_ONLY||RETROSPECTIVE|||||||
34035071|NCT06058546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035072|NCT02197819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035073|NCT02142608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035074|NCT06551597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34035075|NCT02304471|||CASE_CONTROL||PROSPECTIVE|||||||
34035076|NCT05012046|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34035077|NCT03934346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Subjects are not informed of the amount of zinc in each test diet, or the order of the diets. The basic foods making up the test diets are identical in appearance and amount on each of the oral zinc stable isotope tracer days, so there is no way for the subject to distinguish any differences in the amount or form of zinc given.|Nonlinear regression of fractional zinc absorption from 3 test diets using the Hill transport equation, and determination of an unknown amount of zinc based on fractional absorption from a single test diet. Order of the four test diets is randomized, with the constraint that the same oral zinc stable isotope tracer is not given on consecutive days.||||
34035078|NCT02978638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035079|NCT02440464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035080|NCT05100056|||COHORT||PROSPECTIVE|||||||
34035081|NCT01059656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035082|NCT05027204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035083|NCT00150735|NON_RANDOMIZED|PARALLEL||||DOUBLE||||||
34149647|NCT03386409|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Participants are not informed about their group allocation.|In the first phase of the study, all participants are assigned to an observational baseline group. Once the enrollment milestone is met, the second phase of the study will open. In this phase, participants all receive the intervention of safe firearm storage device distribution. Participants are randomized to either the free device group, or the low cost ($5) device group.|t|f|f|f
34149648|NCT02207257|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34149649|NCT01651091|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33806944|NCT05869734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33806945|NCT00714207|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149650|NCT02725190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34035084|NCT06451757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trial personnel and subjects will be blinded to treatment until the database is locked. Investigators will contact the Sponsor prior to unblinding any subject's treatment unless in the instance of a medical emergency.|The study will be a double-blind, randomised, placebo-controlled, multi-centre, parallel-group study. 150 subjects, with a confirmed mitochondrial DNA tRNALeu(UUR) 3243A\>G mutation will be randomised in a 1:1 ratio to receive bid oral administration of 100 mg sonlicromanol or placebo.|t|t|t|t
34035085|NCT05369754|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34035086|NCT00240721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34035087|NCT02983019|||COHORT||PROSPECTIVE|||||||
34035088|NCT03457181|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34035089|NCT04305743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are randomized into one of two treatment arms (receiving 5 versus 20 injections per treatment with intradetrusor onabotulinumtoxin A) and are not notified of which arm they are participating in.|Single-blinded randomized controlled trial|t|f|f|f
34035090|NCT00251329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035091|NCT05725239|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34035092|NCT03327844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035093|NCT02611908||SEQUENTIAL||TREATMENT||NONE||||||
34035094|NCT03674736|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 4 levels of methionine or lysine provided as free amino acids, Rice, Wheat, Chickpeas or Lentils for a total of 7 studies x 3 days per study.||||
34035095|NCT05933954|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Computer assisted randomisation of exposure vs non exposure side||t|t|t|t
34035096|NCT06014060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and study investigators were aware of the study-group assignments, but outcome adjudicators were not. All potential events were adjudicated according to prespecified criteria by an independent clinical events committee whose members were unaware of the trial-group assignments.||f|f|f|t
34035097|NCT01330303|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34035098|NCT04762667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035099|NCT03334929|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34035100|NCT02783495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035101|NCT06573931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035102|NCT00107627|RANDOMIZED|PARALLEL||||NONE||||||
34035103|NCT03715920|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035104|NCT05317312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind, placebo controlled||t|f|t|f
34035105|NCT03154125|RANDOMIZED|PARALLEL||OTHER||SINGLE|Neither participants nor site staff will be blinded to SC injection sites. However, laboratory staff analyzing serum MPA specimens and staff at FHI 360 responsible for adjudicating pregnancy outcomes and coding adverse events will be blinded to individual participant injection site assignments for the duration of each participant's follow up.|All participants will receive the same study drug, Sayana® Press. However, women will be randomized to receive their injections in the abdomen, back of the upper arm, or upper thigh to control for potential confounding when assessing relationships between SC injection site, efficacy, and PK. One cohort of N=630 women will be randomized 1:1 to receive their injections in the abdomen or thigh, and a separate PK cohort of N=120 women agreeing to MPA testing will be randomized 1:1:1 to receive their injections in the abdomen, upper thigh, or back of the upper arm. Randomization will be stratified by cohort and site using appropriate randomly permuted block sizes.|f|f|f|t
34035106|NCT01894087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035107|NCT06300190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Aim of this study is comparing outcome results of Biceps Tenodesis Alone Versus Biceps Tenodesis and labrum Repair in Superior Labrum Anteroposterior (SLAP) Lesion Type IV|2 parallel groups selected by Randomisation|f|f|f|t
34035108|NCT00696215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035109|NCT04908514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035110|NCT01497028|||COHORT||PROSPECTIVE|||||||
34035111|NCT00954759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035112|NCT03644342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035113|NCT00752128|||COHORT||PROSPECTIVE|||||||
34035114|NCT00806429|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035115|NCT00156403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035116|NCT02287181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035117|NCT01006278|||COHORT||PROSPECTIVE|||||||
34035118|NCT06581289|||COHORT||PROSPECTIVE|||||||
34035119|NCT00199017|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035120|NCT02390947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149651|NCT02057809|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34149652|NCT04343014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149653|NCT00086099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149654|NCT00544622|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34149655|NCT02096263|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149656|NCT04083755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34149657|NCT01409369|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34149658|NCT05518526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149659|NCT06411496|||COHORT||OTHER|||||||
34149660|NCT00238914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149661|NCT04476394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149662|NCT06262256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Echocardiography evaluators will be masked about participant allocation.|Randomized clinical trial with control group|f|f|f|t
34149663|NCT03087526|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149664|NCT05013970|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with mild to moderate knee osteoarthritis||||
34149665|NCT00359723|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34149666|NCT00468988|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34149667|NCT00081133||||TREATMENT||||||||
34149668|NCT02259985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152683|NCT03650790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||40 obese preeclamptic pregnant women 40 non-obese preeclamptic pregnant women 40 normal pregnant women|f|f|t|f
34152684|NCT00975663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108252|NCT06206837|NA|SEQUENTIAL||TREATMENT||NONE||"Phase 1b will use an escalation/de-escalation approach to determine the recommended phase 2 dose (RP2D) of vepdegestrant when administered in combination with PF-07220060. The decision to escalate the starting dose level of vepdegestrant will be using mTPI-2 decision criteria based on the number of dose limiting toxicity (DLT)-evaluable participants and the number of DLTs in those participants during the DLT observation period (Cycle 1).~Phase 2 will further evaluate the preliminary antitumor activity and safety of the combination RP2D."||||
34108253|NCT02075684|NA|SINGLE_GROUP||OTHER||NONE||||||
34108254|NCT04797481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34108255|NCT05249660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108256|NCT02522273|||COHORT||PROSPECTIVE|||||||
34108257|NCT01653314|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34108258|NCT05335057|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will experience all four conditions, in a random order||||
34108259|NCT06549335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108260|NCT01160718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34108261|NCT05015049|||COHORT||RETROSPECTIVE|||||||
34108262|NCT04023058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108263|NCT02825563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108264|NCT05638217|||COHORT||PROSPECTIVE|||||||
34108265|NCT00467493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34108266|NCT06555081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34108267|NCT03242031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108268|NCT04016610|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single Group Assignment||||
34108269|NCT04709393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34108270|NCT06640283|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||84 to150 patients will be tested for HPV in their tumor samples 68 patients with negative ctDNA after CRT will be monitored with ctDNA plus routine image 16 patients with positive ctDNA after CRT will receive anti-PD1||||
34108271|NCT05500521|||CASE_CONTROL||RETROSPECTIVE|||||||
34108272|NCT02781558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108273|NCT05552573|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34108274|NCT04627103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108275|NCT04478890|||COHORT||PROSPECTIVE|||||||
34108276|NCT05832541|||CASE_CONTROL||PROSPECTIVE|||||||
34108277|NCT03517358|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108278|NCT05677347|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participants and investigators will be blinded.|The same cohort of participants will move from Part 1 (single ascending doses treatment periods 1 and 2) to Part 2 (repeat dose treatment period 3)|t|f|t|f
34108279|NCT06067139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34108280|NCT06569472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108281|NCT06469242|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34108282|NCT06641752|||CASE_ONLY||PROSPECTIVE|||||||
34035121|NCT05125640|RANDOMIZED|CROSSOVER||OTHER||NONE||Comparative, Randomized, Two-Sequence, Two-Treatment, Four-Period, Open-Label, Single oral Dose, Fully Replicated, Crossover bioequivalence Study||||
34035122|NCT05575882|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|white plastic bottles and automatized randomization in eCRF.|Multicentric, double blind, randomized, comparative study with two parallel group: study group vs placebo group.|t|t|t|f
34108283|NCT01212692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108284|NCT06641375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108285|NCT04556006|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blinded|Single blinded, randomised-control study|t|f|f|f
34108286|NCT04132427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 is double-blind Parts 2 and 3 are single-blind (outcomes assessor is blinded)|Part 1: Randomized, double-blind, placebo-controlled Part 2: Treatment group enters observation, placebo group switched to treatment Part 3: Long-term observation|t|t|t|t
34108287|NCT03193138|||CASE_ONLY||RETROSPECTIVE|||||||
34108288|NCT00404911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035123|NCT00485511|RANDOMIZED|PARALLEL||||DOUBLE||||||
34035124|NCT01287806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035125|NCT04982861|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, single-blind, two-period, single dose, cross-over design in 22 healthy subjects under fasting condition.|t|f|t|f
34035126|NCT03805386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035127|NCT05232760|||COHORT||PROSPECTIVE|||||||
34035128|NCT03461523|||COHORT||PROSPECTIVE|||||||
34108289|NCT06082843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152685|NCT02156336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152686|NCT01349764|||COHORT||PROSPECTIVE|||||||
34152687|NCT00242593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152688|NCT06259890|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152689|NCT03579173|||COHORT||PROSPECTIVE|||||||
34152690|NCT03822000|||CASE_CONTROL||RETROSPECTIVE|||||||
34152691|NCT05713539|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Metal placed onto skin at -2 degrees celsius for 30 seconds, and then timed on how long it takes for the skin to return to normal levels, measured using a thermal imaging camera||||
34152692|NCT04706000|||CASE_CONTROL||PROSPECTIVE|||||||
34152693|NCT01014039|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33806946|NCT04334317|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33806947|NCT03567616|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33806948|NCT03039296|||COHORT||PROSPECTIVE|||||||
33806949|NCT04471441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806950|NCT02301806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806951|NCT01476241|||COHORT||RETROSPECTIVE|||||||
33806952|NCT01948024|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33806953|NCT06511908|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33806954|NCT05323032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multifocal electroretinogram in normal population||||
33806955|NCT01223274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806956|NCT01137916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806957|NCT06232681|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33806958|NCT04747418|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33806959|NCT06207617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33806960|NCT03222934|||OTHER||CROSS_SECTIONAL|||||||
33806961|NCT04865718|||CASE_ONLY||CROSS_SECTIONAL|||||||
33806962|NCT02945059|NA|SINGLE_GROUP||TREATMENT||NONE|Single-arm feasibility study|Reversible Portal vein embolization (PVE) using curaspon® (Absorbable Gelatin Hemostats)||||
33806963|NCT01256242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035129|NCT00137176|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34035130|NCT04478877|||OTHER||PROSPECTIVE|||||||
34035131|NCT02201537|NA|SINGLE_GROUP||SCREENING||NONE||||||
34035132|NCT06213376|NA|SINGLE_GROUP||TREATMENT||NONE|Independent Raters will be used to examine non-standardized outcomes at benchmark time points.|Single-subject experimental design||||
34035133|NCT01152073|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34035134|NCT03881293|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Double Blinded Randomized Control Trial|t|t|t|t
34035135|NCT00550511|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34035136|NCT02847260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035137|NCT03086655|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34035138|NCT01250210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035139|NCT05868369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035140|NCT05765864|||OTHER||OTHER|||||||
34035141|NCT06045013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035142|NCT03571828|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035143|NCT02961595|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035144|NCT05106179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035145|NCT01000155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035146|NCT06581159|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blind, Placebo controlled||t|f|f|t
34035147|NCT01688219|||COHORT||PROSPECTIVE|||||||
34035148|NCT01132729|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035149|NCT00469924|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34035150|NCT00998504|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035151|NCT03411863|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34035152|NCT06230042|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The participant, the investigator and the outcomes assessor were all masked. Only the care provider who performed the anaesthesia were not blinded but they were not involved in the subsequent prostate biopsy, pain assessment, data collection and data analysis.||t|f|t|t
34035153|NCT06385678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035154|NCT04492228|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a controlled, randomized, open-label, clinical trial designed to determine whether a ketogenic diet,in comparison with a standard diet, improves mortality and reduces ventilator requirements or ICU access in patients with coronavirus disease.~The study team will prospectively enroll 50 patients with COVID-19 infection administering a 4:1 ratio ketogenic formula (both enteral or parenteral) and 50 with standard diet"||||
34035155|NCT03479398|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34035156|NCT04395482|||COHORT||RETROSPECTIVE|||||||
34035157|NCT04218318|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective open labeled randomized control trial||||
34035158|NCT01405547|||COHORT||PROSPECTIVE|||||||
34035159|NCT04540809|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035160|NCT00449904|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035161|NCT00065156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035162|NCT05662176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34035163|NCT01458665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035164|NCT02463370|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34035165|NCT04412356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the randomization outcome.|Randomized, single blinded, controlled trial|t|f|f|f
34035166|NCT06084299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035167|NCT05528211|||COHORT||PROSPECTIVE|||||||
34035168|NCT02810873|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035169|NCT06535516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants will be blind to which arm the participant has been randomly assigned to and to study hypotheses.|Trauma-Focused Cognitive Behavioral Therapy and Racial Socialization|f|f|f|t
34035170|NCT04579354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34035171|NCT06509802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34035172|NCT01934439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035173|NCT01473264|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34035174|NCT04823065|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"All recruited patients will undergo a 4FMFES-PET after biopsy confirmation of a ER+ endometrial cancer or suspicion of ovarian cancer. All patients are scanned prior to surgery.~Patients are then randomly distributed for 3 different interventions aiming to reduce the intestinal peristalsis in order to diminish abdominal background generated by 4FMFES radio-metabolites.~1. Control group: no intervention other than standard 4FMFES injection;~2. 4 mg loperamide, per os, 15 minutes prior to 4FMFES injection;~3. Repeated i.v. injection of 20 mg hyoscine-N-butylbromide at 0, 20 and 40 minutes after 4FMFES injection."||||
34035175|NCT03046732|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035176|NCT04147364|||CASE_ONLY||RETROSPECTIVE|||||||
34035177|NCT04067050|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035178|NCT01988181|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34035179|NCT00014430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035180|NCT02380339|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035181|NCT05747105|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm pilot intervention study to assess the efficacy of a 16-week sleep extension protocol.||||
34035182|NCT00000714||||TREATMENT||NONE||||||
34035183|NCT04335955|||CASE_ONLY||PROSPECTIVE|||||||
34035184|NCT04238078|||CASE_CONTROL||PROSPECTIVE|||||||
34035185|NCT02971774|||OTHER||PROSPECTIVE|||||||
34035186|NCT03668808|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will begin in Honolulu, HI (HNL), fly to Newark (EWR) where they will stay for up to 72 hours followed by a return long-haul flight back to Honolulu with up to 72 hours at this destination. This journey will be repeated after a 2 week period when subjects return to their original insulin treatment regimen and then switch to the alternative basal insulin.||||
34035187|NCT04600947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035188|NCT03631589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035189|NCT00793455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34035190|NCT03829605|||COHORT||PROSPECTIVE|||||||
34035191|NCT02250625|||COHORT||PROSPECTIVE|||||||
34035192|NCT06150248|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||Cluster randomized controlled trial (RCT) design|t|f|f|f
34035193|NCT06281964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035194|NCT00320203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035195|NCT05429125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724801|NCT04076735|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized controlled trial comparing acute distal femoral replacement versus surgical fixation as a treatment for geriatric comminuted bi-condylar distal femur fractures||||
34108290|NCT05200338|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective observational cohort study. Six SCD patients per cohort will be vaccinated with a recombinant HBV vaccine before allogeneic MSD HSCT (cohort 1a) and haploidentical HSCT (cohort 1b). Six SCD patients not undergoing allogeneic HSCT will be vaccinated as controls (cohort 2). Six haploidentical donors and six matched sibling donors of unvaccinated receivers will be vaccinated against HBV before stem cell donation (cohort 3a and 3b, respectively). All vaccinated patients and the receivers of stem cells of vaccinated donors will receive a booster vaccination at 12 months post-transplantation. Follow-up will be until 2 years post-transplantation.||||
34108291|NCT06075277|RANDOMIZED|CROSSOVER||TREATMENT||NONE||two-way crossover||||
34108292|NCT06644872|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single-arm repeated measurement study||||
34108293|NCT04037644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108294|NCT05402332|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34108295|NCT06640231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34108296|NCT03856918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34108297|NCT05081609|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108298|NCT06643910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108299|NCT05598788|||COHORT||PROSPECTIVE|||||||
34108300|NCT06570330|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34108301|NCT04670484|NA|SINGLE_GROUP||SCREENING||NONE||||||
34108302|NCT01500135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108303|NCT06106568|||COHORT||RETROSPECTIVE|||||||
34108304|NCT04357470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who diagnosed diagnosed with isolated DRF or DRF accompanied with ulnar styloid fracture and applied to hand rehabilitation unit were included in the study. The patients were divided into two groups according to the ulnar styloid fracture presence. USF Group was DRF with ulnar styloid fracture; NON-USF Group was DRF without ulnar styloid fracture.||||
34108305|NCT02133872|NA|SEQUENTIAL||TREATMENT||NONE||Open label, dose effectiveness trial||||
34108306|NCT06643585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108307|NCT06357377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108308|NCT05199844|||OTHER||CROSS_SECTIONAL|||||||
34108309|NCT01282398|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34108310|NCT03891446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108311|NCT06569940|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Annotators of capnography data were blinded to the values provided by the investigational device|||||
34108312|NCT03223987|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|First letter of prename, second and third letter of name.|Before-after intervention, open label study||||
34108313|NCT06641024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108314|NCT06571916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108315|NCT04155632|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34108316|NCT04573881|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a single arm, non-randomized, multicenter, prospective trial.||||
34108317|NCT05960201|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108318|NCT00834197|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34108319|NCT05533437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108320|NCT04175184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding of participants: participants will be unaware about the specificities of the group allocation. The inclusion of a sham mobilisation with movement (MWM) procedure has the aim to mask the manual therapy procedure. For a naive participant, it is unlikely that he/she might be able to discern the real MWM from the sham MWM. In addition, participants will be requested to avoid discussing the interventions received with the outcome assessor.~A scale ranging from treatment under investigation to I don´t know will be used to assess blinding of participants.~Blinding of outcome assessor: this research assistant will only be responsible for conducting the outcome assessments. He/she will be unaware of group allocation and will also be requested not to discuss any specifics about the treatment programmes with the participants"|Randomized clinical trial, placebo-controlled, with a parallel group design|t|f|f|t
33806964|NCT03408028|||COHORT||RETROSPECTIVE|||||||
33806965|NCT05523869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108321|NCT00974272|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34108322|NCT05497206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806966|NCT05088421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized in a 3:1 ratio of BWC0977 and Placebo. The following controls will be employed to maintain the double-blind status of the study Infusion solution containing active drug and placebo will be indistinguishable in appearance Randomization list will be provided to the study center pharmacist for dispensing purposes and kept in the pharmacy, accessible to the pharmacist and authorized personnel only PK results for the interim analyses between cohorts will be presented in a blinded fashion.|Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose (SAD and MAD) trial|t|f|t|f
34108323|NCT02260232|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34108324|NCT02268656|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34108325|NCT06641960|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34108326|NCT06640153|||COHORT||PROSPECTIVE|||||||
34108327|NCT04700800|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34108328|NCT01342120|||COHORT||RETROSPECTIVE|||||||
34108329|NCT05720351|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34108330|NCT02957019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108331|NCT05299671|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33806967|NCT04089930|||CASE_CONTROL||PROSPECTIVE|||||||
34108332|NCT06638476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108333|NCT06015438|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108334|NCT00303407|||DEFINED_POPULATION||PROSPECTIVE|||||||
34108335|NCT04205812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108336|NCT06642064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"Intervention group and Control group (2 groups):~• Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes.~• Control group:~Participants only received a logbook to record their physical activity every week and participated in regular physical exercise activities at school."|t|f|f|f
34108337|NCT06380270|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34108338|NCT06640270|NA|SINGLE_GROUP||SCREENING||NONE||||||
34108339|NCT05453539|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34108340|NCT05410314|||CASE_CONTROL||OTHER|||||||
34108341|NCT06639867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108342|NCT06344247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108343|NCT04639726|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34108344|NCT02126891|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34108345|NCT04653376|||CASE_CONTROL||PROSPECTIVE|||||||
34108346|NCT03862417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Baseline exams will occur before randomization. Participants and therapists will be reminded not to discuss their group allocation. Evaluators will be blinded to group allocation. The statistician will also complete analyses blinded to which group received therapy or when they did.|"Participants will be randomized to the observation (control) group or the Schroth exercise treatment group using REDCAP.~All outcomes will be measured at baseline and at a 3-month follow-up. Longer term effects will be assessed 3 months after the exercise program.~The control group will be under observation for 3 months. The Schroth group will participate in weekly supervised sessions and a daily home program for 3 months. After 3 months, controls will undergo the same exercise protocol. This will allow examining exercise effects using these patients as their own controls and improve willingness for randomization."|f|f|f|t
34108347|NCT06643819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108348|NCT03982810|||COHORT||RETROSPECTIVE|||||||
34108349|NCT04730960|||CASE_CROSSOVER||PROSPECTIVE|||||||
34108350|NCT05520307|||COHORT||CROSS_SECTIONAL|||||||
34108351|NCT06641661|||CASE_ONLY||PROSPECTIVE|||||||
34108352|NCT06639282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The clinical research coordinator, the psychometrist, the co-investigators (Dr. Boris Decourt and Dr. Karl Golnik) will be masked. Everyone who is patient-facing will be masked.|The study will have 105 participants with a 2:1 ratio of drug:placebo.|t|t|t|t
34108353|NCT00967252|||CASE_ONLY||PROSPECTIVE|||||||
34108354|NCT06308211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient would be allocated.||f|f|f|t
34108355|NCT04629196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108356|NCT05613946|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34108357|NCT01251055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108358|NCT05937243|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2\*2 factorial design|t|f|f|f
34108359|NCT04904549|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"For initial, double-blind, primary series design of study: participants, outcome assessors, Investigators, laboratory personnel, and sponsor trial staff are blinded to intervention group; and those preparing the study interventions are unblinded to vaccine assignment group.~For crossover / booster design of study (Stage 1 and Stage 2): unblinded"|The study is designed to demonstrate clinical efficacy of each of the two SARS-CoV-2 adjuvanted recombinant protein vaccines (monovalent and bivalent). In Stage 1, the monovalent vaccine will be evaluated against a placebo control. In Stage 2, the bivalent vaccine will be assessed against a placebo control.|t|t|t|t
34108360|NCT05418426|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108361|NCT06196034|||CASE_CONTROL||PROSPECTIVE|||||||
34108362|NCT06643221|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"This trial has two main approaches:~1. Single Group - Blood samples collected from healthy participants during and after an acute exercise bout (or isoproterenol infusion) are compared to the 'resting' sample of the donor.~2. Crossover - Blood samples collected from healthy participants during and after an acute bout of exercise (or isoproterenol infusion) are compared across different conditions involving a placebo, selective beta-antagonists, non-selective beta-antagonists and phosphodiesterase inhibitors. In this model, all participants act as their own controls and a wash out period of at least 7-days is interspersed between each trial."|t|f|t|f
34108363|NCT06550128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108364|NCT02447406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108365|NCT00928720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34108366|NCT04855435|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, single arm, multinational, multicenter Phase I trial||||
34108367|NCT06442891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients are blinded to intervention.||t|f|f|f
34108368|NCT06571240|||CASE_ONLY||CROSS_SECTIONAL|||||||
34108369|NCT01339091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108370|NCT06645093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Safety and feasibility study,-pilot study||||
34108371|NCT06569810|||COHORT||OTHER|||||||
34108372|NCT03849144|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34108373|NCT02274675|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34108374|NCT06518655|||COHORT||PROSPECTIVE|||||||
34108375|NCT05852340|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34108376|NCT06638554|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||This study uses a sequential randomization design in which all eligible participants will be randomized into one of two interventions at Stage 1 and then participants that do not respond to Stage 1 interventions will be randomized to receive Stage 2 interventions|f|f|f|t
33838064|NCT04531722|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||We will establish intraoperative microdialysis in patients undergoing anterior temporal lobectomy for drug-resistant temporal lobe epilepsy. The human measurements will yield hypothesis-generating data and establish a methodological/logistical paradigm for future large-scale application of microdialysis in patients with drug refractory epilepsy.||||
34108377|NCT01458457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108378|NCT00280488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108379|NCT01613885|||OTHER||OTHER|||||||
34108380|NCT03716973|NA|SINGLE_GROUP||TREATMENT||NONE||Open label pilot study||||
34108381|NCT00970710|NA|SINGLE_GROUP||PREVENTION||NONE||Pragmatic controlled trial||||
34108382|NCT06429072|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108383|NCT04849273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108384|NCT05974787|||CASE_ONLY||CROSS_SECTIONAL|||||||
34108385|NCT05864469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34108386|NCT06638424|||CASE_ONLY||RETROSPECTIVE|||||||
34108387|NCT05317936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108388|NCT06310759|||COHORT||PROSPECTIVE|||||||
34108389|NCT05529602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108390|NCT06434350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108391|NCT05883787|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34108392|NCT06646679|||OTHER||CROSS_SECTIONAL|||||||
34108393|NCT03894462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|We do not inform providers giving usual care whether their patients are receiving ASSIP. However, providers may find out through ordinary course of usual care being provided.|Randomized controlled trial|f|t|f|f
34108394|NCT06493084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108395|NCT01145183|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34108396|NCT03469960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108397|NCT02719509|||COHORT||PROSPECTIVE|||||||
34108398|NCT04785820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108399|NCT03290677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108400|NCT04595201|||COHORT||PROSPECTIVE|||||||
34108401|NCT06191445|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34108402|NCT06636695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108403|NCT01003327|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34108404|NCT06635122|||CASE_CONTROL||RETROSPECTIVE|||||||
34108405|NCT04659343|||COHORT||PROSPECTIVE|||||||
34108406|NCT06642597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicentre, prospective, adaptive, randomised, open-label, parallel group, non-inferiority trial|f|f|f|t
34108407|NCT05600751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108408|NCT06644508|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multicentre prospective study (clinical implementation evaluation) with a before-after design with continuous recruitment and single measurements||||
34108409|NCT01904279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108410|NCT02180542|||COHORT||PROSPECTIVE|||||||
34108411|NCT06645301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108412|NCT06253767|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34108413|NCT06639321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108414|NCT05363930|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34108415|NCT01675440|||COHORT||PROSPECTIVE|||||||
34108416|NCT05006040|NA|SINGLE_GROUP||TREATMENT||NONE||This is a non-randomized prospective cohort study about the safety and feasibility of a commercially available hybrid closed loop insulin delivery system in children and young adults with high-risk ALL who are at high risk of hyperglycemia due to an intensive chemotherapy regimen containing steroids and asparaginase||||
34108417|NCT04441138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108418|NCT03829501|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108419|NCT01881958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108420|NCT06478693|NA|SEQUENTIAL||TREATMENT||NONE||||||
34108421|NCT01321580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108422|NCT05498870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the patient will be blinded to the treatment group.||t|f|f|f
34108423|NCT05153317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108424|NCT03308474|||COHORT||PROSPECTIVE|||||||
34108425|NCT01048853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108426|NCT05383898|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108427|NCT06641050|||COHORT||PROSPECTIVE|||||||
34108428|NCT00581919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108429|NCT05988281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessor will be blinded regarding group allocation as patients' ID and group will be anonimysed|"This is a prospective, parallel-group, randomized study. This study will include three groups:~i. Immediate dental implant placement with autogenous connective tissue graft (type I).~ii. Early dental implant placement (type II). iii. Delayed/late dental implant placement in socket-preserved sites (type III/IV)."|f|f|t|t
34108430|NCT06644859|||OTHER||RETROSPECTIVE|||||||
34108431|NCT04105283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108432|NCT06468826|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108433|NCT03748472|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34108434|NCT05779956|||COHORT||PROSPECTIVE|||||||
34108435|NCT06640907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data analysts will also be masked.|Cluster randomized controlled trial|f|f|f|t
34108436|NCT06124404|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34108437|NCT06211517|||OTHER||PROSPECTIVE|||||||
34108438|NCT05051228|||COHORT||PROSPECTIVE|||||||
34108439|NCT01381679|||COHORT||PROSPECTIVE|||||||
34108440|NCT00666042|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34108441|NCT04472468|RANDOMIZED|PARALLEL||TREATMENT||NONE||multi-center, randomized, prospective, open label controlled pragmatic trial||||
34108442|NCT02371187|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34108443|NCT03612531|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108444|NCT02621944|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108445|NCT05013138|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Cluster randomized controlled trial. Randomization occurs at the provider level.||||
34108446|NCT00756509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108447|NCT03503331|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Brain amyloid PET levels will be measured with the PET tracer \[C-11\]PiB in all study participants.||||
34108448|NCT00130390|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33724802|NCT00205426|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34035196|NCT04911517|NA|SINGLE_GROUP||TREATMENT||NONE||The enrolled patients in this NCRT-PD-1-LARC trial will receive long course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day8), followed by total mesorecta excision 6-8 week after the end of radiotherapy.||||
34035197|NCT01390025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724803|NCT05106192|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724804|NCT03010111|NA|SINGLE_GROUP||SCREENING||NONE||||||
34035198|NCT04813484|NA|SINGLE_GROUP||PREVENTION||NONE|No masking|One-arm pilot||||
33724805|NCT01218074|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34035199|NCT00097097|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724806|NCT06030882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33724807|NCT00060931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724808|NCT01339728|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33724809|NCT01149447|||COHORT||PROSPECTIVE|||||||
33724810|NCT04211701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724811|NCT06504199|NA|SINGLE_GROUP||TREATMENT||NONE||reated with 6 cycles of ZGR followed by a short cycle (3 cycles) of cytarabine + Obinutuzumab induction therapy. The maintenance regimen was selected according to patient risk stratification. Zanubrutinib in combination with lenalidomide was used for maintenance treatment in non-high-risk patients; maintenance treatment with zanubrutinib in combination with lenalidomide was allowed in high-risk patients after recovery of hemogram 2 months after treatment with chimeric antigen receptor T cells (CAR-T), with lenalidomide maintained for 1 year and zanubrutinib maintained for 2 years.||||
33724812|NCT04930848|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33724813|NCT04918212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724814|NCT03309189|||COHORT||CROSS_SECTIONAL|||||||
33724815|NCT05778396|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants, managing clinicians, outcome assessors, data analysts, and investigators will be blinded to intervention assigned. Only treating clinicians will not be blinded to the interventions but will be trained and asked not to disclose the intervention, nature of the interventions, nor trial objectives to trial participants or other members of the trial team.|Two-parallel-group, single-centre, sham-controlled, methodological blinding feasibility randomised trial.|t|f|t|t
33724816|NCT06069479|||COHORT||PROSPECTIVE|||||||
33724817|NCT04714996|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind, placebo-controlled||t|t|t|t
33724818|NCT05988398|NA|SINGLE_GROUP||PREVENTION||NONE||Two Schools will receive the intervention in addition to pre- and post- surveys. There is no control group.||||
33724819|NCT05669820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Eggyolk powder with same smell, texture and colour in identical packages.|Randomized, prospective, double blinded|t|t|t|t
33724820|NCT03004066|||COHORT||PROSPECTIVE|||||||
34035200|NCT03022370|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035201|NCT06499402|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34035202|NCT05871814|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34035203|NCT01814943|||COHORT||RETROSPECTIVE|||||||
34035204|NCT03793608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035205|NCT01576354|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34035206|NCT04076930|||COHORT||RETROSPECTIVE|||||||
34035207|NCT01202175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035208|NCT00627159|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34035209|NCT00748592|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035210|NCT03103087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035211|NCT02414958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34035212|NCT01125917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035213|NCT03593837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035214|NCT00578474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035215|NCT05519748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035216|NCT02115269|||OTHER||PROSPECTIVE|||||||
34035217|NCT02166580|||CASE_CONTROL||PROSPECTIVE|||||||
34035218|NCT05824624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental model|t|f|f|f
33724821|NCT01016444|||CASE_CONTROL||PROSPECTIVE|||||||
34035219|NCT05332301|NA|SINGLE_GROUP||OTHER||NONE||||||
34108449|NCT03539614|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|During the portion of the study where participants are receiving either placebo or blinded prazosin, the participants, care providers, and outcomes assessors will all be blinded as to whether the participant is at that time receiving prazosin or placebo.|This study is a modified cross-over study, also called an aggregated N-of-1 study. Each participant who meets criteria for participation in and completes the treatment portion of the study will spend time on open-label prazosin, blinded prazosin, and placebo.|t|t|f|t
34108450|NCT05874960|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33724822|NCT02930421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724823|NCT03849742|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34035220|NCT01107691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035221|NCT01683396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035222|NCT00513240|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34035223|NCT04233294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035224|NCT04891757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035225|NCT00716391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035226|NCT00523939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035227|NCT03559972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035228|NCT00470470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035229|NCT00004667||||TREATMENT||||||||
34035230|NCT03839069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035231|NCT04712214|NA|SINGLE_GROUP||OTHER||NONE||||||
34035232|NCT00075816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035233|NCT00782054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035234|NCT05861518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|collecting data and continuing treatment||f|t|f|t
34035235|NCT04200820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035236|NCT01304056|||COHORT||PROSPECTIVE|||||||
34035237|NCT03527069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035238|NCT03885986|||CASE_ONLY||OTHER|||||||
34035239|NCT01977417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035240|NCT01009814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035241|NCT06084793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed opaque envelopes will be employed within the 7 days preceding the embryo transfer (for fresh transfers, it will be done on the day of fertilization, and, for frozen transfers, it will be done once the endometrium is prepared and it is ready to start the progesterone supplementation). Both the participants and the attending physician will be aware of the assigned allocation group. The researcher responsible for outcome assessment will remain blinded to the allocation.|The process of randomization and allocation concealment will be implemented through a block random computer-generated list.|f|f|t|t
34035242|NCT04821726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035243|NCT00004981||||TREATMENT||||||||
34035244|NCT04105673|||COHORT||PROSPECTIVE|||||||
34035245|NCT04042506|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-institution, single-arm phase II study. SBRT will be given to a single extracranial metastatic site in combination with nivolumab.||||
34035246|NCT04571853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Single-blind, parallel-group, randomized controlled trial|f|f|t|t
34035247|NCT04119362|||COHORT||PROSPECTIVE|||||||
34035248|NCT00739713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035249|NCT04164004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035250|NCT03726060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035251|NCT00218946|RANDOMIZED|FACTORIAL||||SINGLE|||f|t|f|f
34035252|NCT05814731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035253|NCT04045769|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34035254|NCT02382211|||OTHER||PROSPECTIVE|||||||
34035255|NCT03283527|||CASE_ONLY||PROSPECTIVE|||||||
34035256|NCT00116506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035257|NCT01280643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035258|NCT06313710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035259|NCT06531837|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035260|NCT04540991|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34035261|NCT04688671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind|Placebo-Controlled, Parallel-Group|t|f|t|f
34035262|NCT02812524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035263|NCT05957601|||OTHER||CROSS_SECTIONAL|||||||
34035264|NCT02640482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035265|NCT03064204|||COHORT||PROSPECTIVE|||||||
34035266|NCT02366169|||COHORT||PROSPECTIVE|||||||
34035267|NCT00574002|||COHORT||PROSPECTIVE|||||||
34035268|NCT01851252|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34035269|NCT04047992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035270|NCT05638464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035271|NCT00578591|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035272|NCT06086106|||CASE_CONTROL||PROSPECTIVE|||||||
34035273|NCT00280735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035274|NCT01371604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035275|NCT05935410|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34035276|NCT02199964|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34035277|NCT04937140|||CASE_CONTROL||PROSPECTIVE|||||||
34035278|NCT01809912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035279|NCT03170544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035280|NCT00974116|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035281|NCT01153828|||||RETROSPECTIVE|||||||
34035282|NCT02532686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035283|NCT02765997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035284|NCT02389283|||COHORT||PROSPECTIVE|||||||
34035285|NCT05196113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34035286|NCT03347682|||OTHER||CROSS_SECTIONAL|||||||
34035287|NCT02279966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035288|NCT01308203|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035289|NCT05050565|||COHORT||OTHER|||||||
34035290|NCT01800747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Antibiotic treatment versus delayed antibiotic treatment||||
34108451|NCT01751425|NA|SINGLE_GROUP||TREATMENT||NONE||This study was stopped early and did not go on to phase II.||||
34108452|NCT05835323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108453|NCT06592001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108454|NCT06505395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035291|NCT06152432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective comparative study||||
34035292|NCT06350981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study subjects will be randomized to either Group 1 or Group 2 in a 1:1 ratio based on the randomization scheme in sealed envelopes maintained by the study coordinator.||t|f|t|f
34035293|NCT03222310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035294|NCT02147977|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34035295|NCT05760963|||COHORT||PROSPECTIVE|||||||
34035296|NCT00612131|||COHORT||PROSPECTIVE|||||||
34035297|NCT02573597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34035298|NCT03317418|||COHORT||PROSPECTIVE|||||||
34035299|NCT04551690|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035300|NCT04992078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035301|NCT03843060|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035302|NCT04525534|||CASE_CONTROL||PROSPECTIVE|||||||
34035303|NCT01012895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035304|NCT02687451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035305|NCT05268653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a randomized controlled study in a quasi-experimental design in the pre-test post-test design.|t|f|f|f
34035306|NCT05825183|||COHORT||PROSPECTIVE|||||||
34108455|NCT03085290|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34108456|NCT05078437|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33724824|NCT00112658|RANDOMIZED|PARALLEL||TREATMENT||||||||
33724825|NCT03536403|NA|SINGLE_GROUP||OTHER||NONE||||||
33724826|NCT06404632|NA|SINGLE_GROUP||PREVENTION||NONE||Feasibility trial with pre, peri, post and follow-up measurements||||
33724827|NCT03961542|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33724828|NCT06308809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Single (Participant)~- Page 2 of 5 \[DRAFT\] -In order to avoid mutual interference between the experimental group and the control group, a blinding method needs to be used in the study. In this study, a single blind experiment will be conducted to blind the participating athletes.~During the sample grouping process, participating athletes will not know the specific grouping situation."||t|f|f|f
33724829|NCT01869296|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33724830|NCT06358105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724831|NCT01393405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724832|NCT02473315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838065|NCT06179147|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Simple Random Numbers Table was used as the randomization method for sample selection. In this method; Randomly sorted algorithm was created at the maximum allowed percentage and 10% deviation in total 100 samples. In the algorithm, 100 sample (female) groups for both groups; Up to 200 randomly sorted as A and B. Intervention group: A, Control group: B. The sample taken according to the order in the list on the data collection days; It was accepted as group A or B (Piantdosi S, 2005; Pocock SJ, 1983; Rosenberger WF, 2002). The primary outcome measure of the RCT study was the difference between the cervical traction group and the control group.|There are two groups: the cervical traction group (intervention group) and the control group.|t|f|f|f
33838066|NCT01882413|||CASE_ONLY||PROSPECTIVE|||||||
34035307|NCT03884361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035308|NCT00920439|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035309|NCT04842071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Every patient in need and/or eligible for a standard 99mTc-biphosphonate bone scintigraphy is eligible to participate to this study. Patient data and examination results will be compiled and monitored. The safety profile of 18F-NaF produced in the primary site will be determined.||||
34035310|NCT02401152|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34035311|NCT02677753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035312|NCT03469232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035313|NCT00596531|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035314|NCT00595621|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34035315|NCT01629511||SEQUENTIAL||TREATMENT||NONE||||||
34035316|NCT00592306|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34035317|NCT00776841|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34035318|NCT03080025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035319|NCT04281329|||COHORT||PROSPECTIVE|||||||
34035320|NCT02510443|||COHORT||PROSPECTIVE|||||||
34035321|NCT05848193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34035322|NCT05398328|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|statistician will not be aware of group affiliation||f|f|f|t
34035323|NCT05317039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108457|NCT05250934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108458|NCT05101551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724833|NCT03837873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035324|NCT01963546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035325|NCT05395260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035326|NCT00184886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108459|NCT01174966|||COHORT||PROSPECTIVE|||||||
34108460|NCT06637683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind study, while both patients and care providers know clearly which product is being tested, the assessor in the study is a blind assessor to ensure objectivity in the assessment.|A randomized, single-blind, controlled clinical trial|f|f|t|f
34108461|NCT05528939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, randomized, active-control trial using a 1:1 randomization (stratified by diagnosis) to the intervention or a comparison digital activity.|f|f|f|t
34108462|NCT03077061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individuals assessing radiographic parameters will be masked to the intervention.|The study is designed as a two-arm randomized clinical trial.|f|f|f|t
34108463|NCT06675292|||OTHER||CROSS_SECTIONAL|||||||
34108464|NCT06284304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108465|NCT04886856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108466|NCT06183541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients who underwent PENG block and those who did not undergo PENG block are randomly divided into two groups using the sealed envelope method. They are grouped as Group I: Those who received PENG block (n: 35) and Group II: Those who did not receive PENG block (control group) (n: 35).|This prospective randomised controlled study included a total of 70 patients aged 30-85 years who underwent hip fracture surgery under spinal anaesthesia. Patients were divided into two groups as PENG block and non-PENG block (control group).|t|f|f|f
34108467|NCT06642285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108468|NCT06445595|||CASE_CONTROL||PROSPECTIVE|||||||
34035327|NCT06551532|RANDOMIZED|PARALLEL||PREVENTION||NONE|In this study, both participants and researchers are aware of the group assignment. Participants know whether they are receiving the multicomponent intervention or are part of the control group. The researchers who administer the intervention and collect data are also aware of the group assignments.|Participants are randomly assigned to either an intervention group receiving the multicomponent intervention or a control group with no intervention, with both groups being monitored concurrently throughout the 6-week period.||||
34108469|NCT05683977|||COHORT||PROSPECTIVE|||||||
34108470|NCT06464640|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||"Experimental group: The Online Interactive Podcast Program\&amp;#34;Living with Type 1 Diabetes to Grown-Up\&amp;#34; will be used for intervention in the experimental group.~active control group:E-book.According to the research results from the project Healthcare CEO app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled\&amp;#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&amp;#34;"|t|f|t|f
34108471|NCT06324461|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open-labelled, superiority randomized controlled trial||||
34108472|NCT06396325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33724834|NCT05354128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||non-randomized control||||
34108473|NCT02431871|||COHORT||CROSS_SECTIONAL|||||||
34108474|NCT03409770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|MR spectroscopy analysis will be masked to the allocation|Therapeutic hypothermia (33 to 34 C) for 2 different durations (48, or 72 h) and usual care (normothermia)|f|f|f|t
34108475|NCT05749094|||COHORT||PROSPECTIVE|||||||
34035328|NCT02426502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035329|NCT04332315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035330|NCT04413513|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34108476|NCT03809351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035331|NCT02790164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035332|NCT04324424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035333|NCT02676882|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A pilot study of EnBrace HR in two groups of women with major depressive disorder (MDD). Group 1 includes women who are well at time of enrollment and are not experiencing clinically significant depressive symptoms. In this group, EnBrace HR is studied for depressive relapse prevention during the perinatal period. Group 2 includes women who are depressed at time of enrollment and who are currently experiencing clinically significant depressive symptoms. In this group, EnBrace HR is assessed for acute treatment of MDD.||||
34035334|NCT06225219|||OTHER||RETROSPECTIVE|||||||
34035335|NCT00063024|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34035336|NCT06325826|||COHORT||PROSPECTIVE|||||||
34035337|NCT05641298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035338|NCT02508623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035339|NCT03248687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor will not know if the patient was followed at home or by a primary care provider.|Enrolled patients will be randomized to one of two follow up arms|f|f|f|t
34035340|NCT06134310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035341|NCT03428243|||CASE_ONLY||RETROSPECTIVE|||||||
34035342|NCT05513482|||COHORT||PROSPECTIVE|||||||
34035343|NCT01121614|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34108477|NCT06332352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108478|NCT06625931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108479|NCT06562946|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34108480|NCT04547075|||OTHER||PROSPECTIVE|||||||
34108481|NCT05272280|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|triple||t|t|t|f
34108482|NCT03066180|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108483|NCT05826626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Stroke and MCI patients will be recruited in the IRCCS San Camillo Hospital. The selection will be based on diagnosis made by an expert neurologist and on a neuropsychological evaluation. Enrolled patients will be randomized in three groups and by using a block randomization sequence (Random.org), to receive MindLenses combines treatment (prism adaptation+serious games(PA+SG), n=20), treatment with MindLenses's serious games (SG without prism adaptation, n=20), or conventional treatment (CT, n=20). The PA+SG and the SG groups will perform 5 daily sessions, 30 min each, per 2 weeks. The CT group will undergo the standard cognitive training offered by the Hospital for the same duration as the other two groups.|t|f|f|f
34108484|NCT05971173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108485|NCT04304300|||COHORT||PROSPECTIVE|||||||
34108486|NCT04304248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108487|NCT05604703|||COHORT||RETROSPECTIVE|||||||
34108488|NCT06354049|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108489|NCT06089317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A total of 200 subjects with mild to moderate DED will be recruited. Only one eye of recruited subjects with the shorter NIBUT will be selected and analyzed as the study eye. The subjects will be randomly divided into TCM compound decoction (CD) group, dendrobium caulis (DC) group, houttuynia cordata (HC) group, placebo atomization (PA) group, and artificial tears (AT) group equally. An online-based clinical trial randomization tool with a permuted block and stratification randomization method is applied for the randomization, and block sizes are randomly chosen. Stratification variances is sex and age.|t|t|t|t
34108490|NCT06337305|||COHORT||PROSPECTIVE|||||||
34108491|NCT05056818|||CASE_CONTROL||RETROSPECTIVE|||||||
34108492|NCT01141764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108493|NCT06647888|||CASE_ONLY||PROSPECTIVE|||||||
34108494|NCT06041139|||CASE_CONTROL||PROSPECTIVE|||||||
33724835|NCT02506504|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33724836|NCT04009655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33724837|NCT04260737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724838|NCT04255355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33724839|NCT04959968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724840|NCT01242956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724841|NCT05409781|||CASE_CROSSOVER||PROSPECTIVE|||||||
33724842|NCT00625976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724843|NCT01923454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724844|NCT06112028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724845|NCT01315756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724846|NCT03535428|||COHORT||PROSPECTIVE|||||||
33724847|NCT02520011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108495|NCT03163667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded, placebo-controlled|This is a double blinded placebo-controlled study where participants will be randomized 2:1 to either CB-839 plus everolimus (CBE) or placebo plus everolimus (PboE)|t|t|t|t
34108496|NCT02088086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108497|NCT06638437|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34108498|NCT06640946|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Cream will be applied by a clinician not involved in the laser procedure and will be removed prior to the procedure. Laser technicians will assess patient pain and will be blinded, as will the patient, to the study arm.|Placebo versus agent crossover per patient|t|t|f|t
34108499|NCT04375826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34108500|NCT06672809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The evaluators were blinded to the intervention details of the participants.||f|f|f|t
34108501|NCT03578172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108502|NCT00307580||||TREATMENT||||||||
34035344|NCT00782782|||CASE_CONTROL||PROSPECTIVE|||||||
34035345|NCT00839488|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035346|NCT04037280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the randomization participants will be assigned to the 4 groups. The investigator will be blinded to group allocation. Moreover, the assessor will be blinded.|"120 subjects on the list for RALP surgery will be recruited and randomized into 4 groups. Subjects will be evaluated during the preoperative session (T0) and about 45-55 days before the surgery (T1). The initial assessment shall provide for the compilation of two self-assessment questionnaires concerning urinary symptoms: IPSS (International Prostatic Symptoms Score) and ICIQ-SF (International Consultation on Incontinence Questionnaire- Short Form). Furthermore, the impact of quality of life of patient (index of quality of life 0-6) will be evaluated, in order to give a numerical indicator to the patient's perception about its condition.~The same questionnaires will be given by a physiotherapist during follow-up session (T1) before 45-55 days post-surgery, when the amount of urinary incontinence through PAD test 48h will be evaluated, that provides for the weighing of used pad by patient during 48 hours before the session."|f|f|t|t
34035347|NCT03034980|||CASE_CONTROL||RETROSPECTIVE|||||||
34035348|NCT05610215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724848|NCT02603835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035349|NCT00610428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035350|NCT05506618|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Subject are asked to provide nasal swab or nasopharyngeal swab samples||||
34035351|NCT02038010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035352|NCT06005662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and study team will be masked/blinded to intervention.|The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction|t|t|t|t
34035353|NCT02486146|||OTHER||PROSPECTIVE|||||||
34035354|NCT02902588|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34035355|NCT02851017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34035356|NCT03442114|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Randomized Clinical Trial||||
34035357|NCT00811044|||OTHER||CROSS_SECTIONAL|||||||
34035358|NCT03218020|||COHORT||PROSPECTIVE|||||||
34108503|NCT02209675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108504|NCT05020769|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108505|NCT01198691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108506|NCT06572020|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34035359|NCT04279431|||COHORT||PROSPECTIVE|||||||
34108507|NCT06545903|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34108508|NCT05916937|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, open-label, non-inferiority trial.||||
34108509|NCT06011655|||OTHER||OTHER|||||||
34108510|NCT06284122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108511|NCT05255666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108512|NCT04733495|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108513|NCT04528186|||CASE_CONTROL||OTHER|||||||
34108514|NCT00530257|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34108515|NCT05317481|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a randomized control trial (RCT) with subjects randomized 2:1 (using block randomization) to BE-SMART-DR or a psychoeducational control comparator condition (CC).|t|f|f|f
34108516|NCT06571331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind|Randomized, Double Blind, Parallel Group, Placebo-Controlled Trial|t|f|t|f
34108517|NCT06638138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108518|NCT03551119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, participants cannot be blinded to group assignment; however, the primary outcome is objectively measured (24-hour ambulatory blood pressure measurement). For main trial secondary outcomes, assessors will be blinded to allocation status.|In this parallel arm control trial, participants recruited from outpatient CKD clinics in Alberta Kidney Care North, Edmonton, Alberta, Canada will be randomized (1:1) to enhanced usual care (measurement of physical activity levels) or an exercise intervention.|f|f|f|t
34108519|NCT06637085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34108520|NCT05596812|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34035360|NCT02881398|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34035361|NCT01512017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108521|NCT00236665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34108522|NCT06640660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108523|NCT04774666|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34108524|NCT05530304|||OTHER||PROSPECTIVE|||||||
34108525|NCT04743232|RANDOMIZED|PARALLEL||SCREENING||NONE||stepped-wedge cluster randomized trial||||
34108526|NCT06559007|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108527|NCT05893732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study, both the participants and the outcomes assessor will be blinded. Participants will be unaware of whether they are receiving active HILT or sham HILT, while the outcomes assessor will not know the treatment allocation while assessing the outcomes.||t|f|f|t
34035362|NCT05860738|||OTHER||PROSPECTIVE|||||||
34108528|NCT06015516|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34108529|NCT06636110|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 selection of pregnant women with and without criminal justice oversight. There will be further random selection of a sub-sample (n=20) (n=10 with and n=10 without criminal justice oversight to interview using Health Belief Model (HBM)||||
34108530|NCT06644339|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108531|NCT02940119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108532|NCT04031677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108533|NCT02346279|||COHORT||PROSPECTIVE|||||||
34108534|NCT00844220|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34108535|NCT00949039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108536|NCT03939065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108537|NCT05197387|||CASE_CONTROL||PROSPECTIVE|||||||
34108538|NCT06568172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A central review of 40% of patients who experience a recurrence or progression that is considered a primary endpoint event will be conducted once the number of events for the primary endpoint has been reached. Each case will be reviewed by two independent reviewers who are blinded to the patient's assigned treatment arm.||f|f|f|t
34108539|NCT06497673|||OTHER||OTHER|||||||
34108540|NCT03906084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind Endpoint Classification: Efficacy Study||f|f|f|t
34108541|NCT05715827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108542|NCT06640218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34108543|NCT04904913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108544|NCT03302468|||COHORT||PROSPECTIVE|||||||
34108545|NCT06183528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This prospective randomised controlled study included a total of 60 patients aged 40-85 years who underwent THA surgery under spinal anaesthesia. Patients were divided into two groups as PENG block and non-PENG block (control group).|t|f|f|f
34108546|NCT06445127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will undergo a MRI (1-4). This is a non-invasive test. No radiation. No contrast. No IV catheter.||||
34108547|NCT03107182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108548|NCT03183947|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108549|NCT05280860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035363|NCT03975673|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective two-arms consecutive patients study|t|f|f|t
34108550|NCT02732444|||OTHER||PROSPECTIVE|||||||
34108551|NCT04557124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108552|NCT02007460|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34108553|NCT04441515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108554|NCT05247398|NA|SINGLE_GROUP||TREATMENT||NONE||prospective pre-postinterventional study||||
34108555|NCT03376282|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33838067|NCT04494204|RANDOMIZED|PARALLEL||TREATMENT||NONE||After obtaining the informed consent, patients will be screened by undergoing various assessments and after confirming eligibility, eligible patients will be randomized in the study and assigned either to the test group or control group with Best standard of care as per institutional practice, for 10 days treatment period. Patient will be hospitalized during the treatment period.||||
33838068|NCT06541626|||COHORT||PROSPECTIVE|||||||
33838069|NCT03889847|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33838070|NCT02565524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838071|NCT02225262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838072|NCT04646356|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
34035364|NCT03859167|||CASE_ONLY||PROSPECTIVE|||||||
34035365|NCT00821743|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035366|NCT04997330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
34035367|NCT04526028|||CASE_CONTROL||PROSPECTIVE|||||||
34035368|NCT05383131|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035369|NCT03631706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035370|NCT03519412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035371|NCT00000814||||TREATMENT||||||||
34108556|NCT06092346|||COHORT||PROSPECTIVE|||||||
34108557|NCT06587230|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not be blinded; children must assent, and parents consent, to receive mental health care and teachers will be aware they are delivering care. One research assistant (RA) and staff mental health clinician will not be blinded to observe teachers' fidelity. Otherwise, personnel are blinded.|The study will be conducted as a two-arm, clustered trial evaluating the program implementation of the intervention (Tealeaf) that will be compared to an active comparator (RE-SEED). Schools will be randomized into either the full intervention or a lower-resourced version of the intervention. It is noted that schools are more willing to participate in an intervention trial if they will receive some benefit from their participation, leading to having a lower-resourced comparator rather than a true control comparator. Additionally, the active comparator ethically allows for identified children in need of care to have more resources than if no intervention occurred. Schools, teachers, and students will be followed prospectively with data collection at regular intervals.|f|f|f|t
34108558|NCT05085756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108559|NCT04476147|||COHORT||PROSPECTIVE|||||||
34108560|NCT06207435|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34108561|NCT04543786|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34108562|NCT06643143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108563|NCT00216385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108564|NCT02679274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34108565|NCT05245175|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Patients are blinded to the sequence of exposures. Within the 2 blocks, the order of challenge atmospheres will be randomized.|18 patients will be exposed 5 times in the Allergen Challenge Chamber. The 5 exposures are divided into 2 blocks. The first block consists of 3 challenges with sodium chloride particles, lactose particles, and clean air to address the primary and secondary objectives. The second block consists of 2 further challenges with D. pteronyssinus coupled with either sodium chloride particles or lactose particles to address exploratory objectives.|t|f|f|f
34108566|NCT00855335|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108567|NCT01987999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108568|NCT04953026|||CASE_CONTROL||RETROSPECTIVE|||||||
34108569|NCT05211466|||COHORT||OTHER|||||||
34108570|NCT06642220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108571|NCT06643988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108572|NCT02070211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108573|NCT03886636|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34108574|NCT06018519|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108575|NCT05399212|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|"The number of infertile people after recruitment was divided into 2 groups.~* Spermatogenesis.~* Male infertility group due to lack of sperm."|"The number of infertile people after recruitment was divided into 2 groups.~* Spermatogenesis.~* Male infertility group due to lack of sperm."||||
34108576|NCT06644209|||COHORT||PROSPECTIVE|||||||
34108577|NCT04096677|||COHORT||PROSPECTIVE|||||||
34108578|NCT01405664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108579|NCT06643325|||CASE_ONLY||PROSPECTIVE|||||||
34108580|NCT05525520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108581|NCT04966169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108582|NCT06637657|||COHORT||PROSPECTIVE|||||||
34108583|NCT06563869|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects who meet the inclusion criteria will receive sintilimab combined with platinum-containing chemotherapy for 2 cycles (21 days for 1 cycle) as neoadjuvant therapy according to the research plan. Polyethylene glycolylated recombinant human granulocyte stimulating factor will be given 24 hours after the end of chemotherapy. Radical surgical treatment will be received within 3-6 weeks after the completion of the last neoadjuvant treatment.||||
33724849|NCT05463510|||CASE_ONLY||RETROSPECTIVE|||||||
33724850|NCT00138944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108584|NCT04705233|RANDOMIZED|PARALLEL||OTHER||NONE||A 2 arm, multi-centre, open label, parallel-group randomised designed trial||||
34108585|NCT06487936|||COHORT||OTHER|||||||
34108586|NCT06643572|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33724851|NCT03398031|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724852|NCT00116051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724853|NCT00800228|||COHORT||PROSPECTIVE|||||||
33724854|NCT03444922|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Double-blinded study; Study statistician computer generated randomization||f|f|f|t
33724855|NCT02245256|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724856|NCT03084887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724857|NCT00528723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108587|NCT06643923|RANDOMIZED|PARALLEL||TREATMENT||NONE||Children and their families who have scored 8.5 or higher on the DVSS will be invited for further evaluation. Participants will be divided into two groups (Treatment and Active Control) using a 6-way block randomization method among the volunteer families.||||
34108588|NCT05939544|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34108589|NCT06571201|||COHORT||CROSS_SECTIONAL|||||||
34108590|NCT06610903|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34108591|NCT04962113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34108592|NCT02095457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108593|NCT02386072|||COHORT||PROSPECTIVE|||||||
34108594|NCT05442879|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108595|NCT04701710|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled 1:1. Experimental Group and Control Group.||||
33724858|NCT03089203|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33724859|NCT02621242|||COHORT||PROSPECTIVE|||||||
33724860|NCT03171454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33724861|NCT05957796|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33724862|NCT06325956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724863|NCT06463951|||COHORT||PROSPECTIVE|||||||
33724864|NCT03608579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724865|NCT00931749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724866|NCT00001437||||TREATMENT||||||||
33724867|NCT01488331|||COHORT||PROSPECTIVE|||||||
34108596|NCT03314584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blinded study where only the statistician is aware of the randomization.||t|t|t|f
34108597|NCT05289544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34108598|NCT00745355|||COHORT||PROSPECTIVE|||||||
34108599|NCT06645405|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34108600|NCT02998320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108601|NCT03368144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108602|NCT05208437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108603|NCT04280783|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will randomize 30 participants to either the PATH treatment group or wait-list control group.||||
34108604|NCT05313373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108605|NCT06352073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108606|NCT06639269|RANDOMIZED|PARALLEL||OTHER||NONE||In our study, we will have two groups: control and intervention. A 3-session fertility health education program will be applied to the students in the intervention group.||||
34108607|NCT06258382|||CASE_CONTROL||PROSPECTIVE|||||||
34108608|NCT05670756|||COHORT||PROSPECTIVE|||||||
33838073|NCT00256022|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34108609|NCT03272334|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pembrolizumab administered in combination with HER2 Bispecific Antibody Armed Activated T-Cell (BATs) infusions||||
34108610|NCT06642246|NA|SINGLE_GROUP||OTHER||NONE||The study conditions are as follows: sleep goal, digital sleep guidance, loss-framed financial incentive, and personalized feedback. All participants need to self-monitor their sleep duration by wearing the sleep tracker to allow for daily capture of sleep duration and goal achievement status.||||
34108611|NCT05983809|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Interventional, randomised, controlled, cross-over pilot study.|f|f|f|t
34108612|NCT01228032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108613|NCT01711099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108614|NCT06565182|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33838074|NCT02337153|||COHORT||PROSPECTIVE|||||||
33838075|NCT00636415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838076|NCT02470689|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33838077|NCT00500968|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838078|NCT06044246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838079|NCT01517997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108615|NCT03653819|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||All participants complete a baseline assessment followed by the randomisation to HIIT + compression or HIIT - compression.||||
34108616|NCT05614869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108617|NCT06600971|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The information indicating that the patients included in the research sample were assigned to groups A and B according to the randomization table was placed in an opaque envelope. This envelope was kept by the neurology clinic secretariat. When the researcher went to the patient selected for acupressure application, he first applied a pre-test and then contacted the neurology clinic secretariat to learn which group the patient was in. In this way, the participants were blinded in terms of groups.|The intervention and control groups were selected by drawing lots|t|f|t|f
34108618|NCT02082379|RANDOMIZED|PARALLEL||||NONE||||||
34108619|NCT02321514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108620|NCT06642883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|"This is a double-blind, placebo-controlled, randomized trial in which the enrolled subjects will be included in one year. After the written informed consent collection, subjects will be randomized in a 1:1 ratio to the Group 1 or Group 2:~* Group 1 will take Treatment A: 1 vial/day of PROLIFE 10 FORTE for 60 days.~* Group 2 will take the Treatment B: 1 vial/day of placebo for 60 days.~We will enroll 70 UC patients in the remission phase, both males and females, with a diagnosis of Ulcerative Colitis for at least three months. The therapy undertaken could not be changed nor stopped during the probiotic administration"|t|t|t|f
34108621|NCT01752179|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108622|NCT03988205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108623|NCT05213221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108624|NCT04794504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All sponsors and collaborators will be blinded, and randomization and mixing of solutions will be done by an assistant not involved in the study. Half way through the study, one of the members of the research team will be unblinded to ensure confounders are appropriately matched in each of the two arms.|We will have two independent groups, one receiving botox injection, and another receiving saline injection.|t|t|t|f
34108625|NCT04806399|RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be randomly selected for assignment to the Outreach Contact with Decision Counseling Group or randomly selected for assignment to a Usual Care Control Group||||
34108626|NCT05611775|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108627|NCT03376386|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
34108628|NCT06519994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108629|NCT04877041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysts will also be blinded to study group||f|f|f|t
34108630|NCT01782274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838080|NCT00992342|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33838081|NCT00137410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33838082|NCT01250795|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34108631|NCT02843425|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34108632|NCT06643754|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of SHR-3276||||
34108633|NCT03413072|||OTHER||CROSS_SECTIONAL|||||||
34108634|NCT05621837|||CASE_CONTROL||PROSPECTIVE|||||||
34108635|NCT03573089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108636|NCT01380080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108637|NCT05399511|||OTHER||PROSPECTIVE|||||||
34108638|NCT04767048|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|tonsillectomy +/- bilateral mucosectomy|||||
34108639|NCT01489137|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108640|NCT00572819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34108641|NCT03847519|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Safety phase:~* Part A: ADXS-503 monotherapy dose escalation~* Part B: ADXS-503 + pembrolizumab dose escalation~Efficacy phase:~• Part C: ADXS-503 + pembrolizumab"||||
34108642|NCT05903989|||COHORT||RETROSPECTIVE|||||||
34108643|NCT05473715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108644|NCT01734122|||COHORT||PROSPECTIVE|||||||
34108645|NCT00605189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108646|NCT06300528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108647|NCT06048042|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A non-randomized Clinical Trial|f|f|f|t
34108648|NCT04388345|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34108649|NCT05583721|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34108650|NCT06317909|NA|SINGLE_GROUP||OTHER||NONE||||||
34108651|NCT05918042|||COHORT||PROSPECTIVE|||||||
34108652|NCT04482920|||COHORT||PROSPECTIVE|||||||
34108653|NCT02730169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108654|NCT02959463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108655|NCT04862403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34108656|NCT02446509|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34108657|NCT05334940|||CASE_ONLY||PROSPECTIVE|||||||
33806968|NCT05430555|NA|SEQUENTIAL||TREATMENT||NONE||This 2-part trial consists of Phase 1 dose-escalation and expansion and Phase 2. In escalation, 6-18 subjects will receive TK-8001 across 3 dose levels (DL). In expansion, subjects will be treated with the DL selected in escalation. Subjects without brain metastasis (Cohort 1) and subjects with brain metastases (Cohort 2) will both be included in expansion if DL3 is declared safe. Cohort 1 will include melanoma \[skin or uveal\], NSCLC, urothelial, breast, gastric esophageal, sarcoma, HNSCC, HCC, biliary tract, cervical, and salivary gland cancer subjects. Cohort 2 will only include melanoma \[skin or uveal\], NSCLC, urothelial, or breast cancer. In expansion, up to 20 additional subjects may be treated on DL3 if cleared during escalation. Up to 10 additional Cohort 2 subjects may be treated on DL3 if cleared during escalation. 33 subjects maximum may be treated on DL3 during Phase 1. If DL2 was safely completed the maximum total number of subjects to be treated on DL2 would be 12.||||
33806969|NCT06700096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108658|NCT04692779|||COHORT||PROSPECTIVE|||||||
34108659|NCT02457546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34108660|NCT03408262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34108661|NCT05143411|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Evaluating pre-test and post-test (pre and post glucose levels)||||
34108662|NCT05200481|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, phase II, randomized, open-labelled, non-comparative multicenter study with two parallel arms||||
34108663|NCT03126630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34108664|NCT04600973|RANDOMIZED|FACTORIAL||PREVENTION||NONE||2x2 Factorial||||
34108665|NCT06440577|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Men and women with OUD receiving medications for OUD treatment will complete both the Consumer Items Willingness-to-Pay Task and Snack Foods Willingness-to-Pay Task at two separate task sessions. Non-psychiatric community control participants will complete the Snack Foods Willingness-to-Pay Task.||||
34108666|NCT06373068|||COHORT||RETROSPECTIVE|||||||
34108667|NCT04293432|||CASE_ONLY||CROSS_SECTIONAL|||||||
34108668|NCT05824728|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34108669|NCT06120842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108670|NCT03526666|||CASE_ONLY||PROSPECTIVE|||||||
34108671|NCT06639126|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34108672|NCT05745246|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Since this study is a Cluster Randomized Trial (CRT), first, Departments will be recruited and randomized to the treatment arm or the control arm, with a 1:1 allocation ratio stratified by region. The randomization sequence will be generated by a trained person that is not related to the study participants in any way. The investigators and study staff will be blinded to the randomization sequence until the end of the study. Participant randomization will be performed in REDCap. REDCap maintains an automated audit trail which includes the assigned study identification number, treatment allocation, and date and time of the allocation assignment.~Once a department is recruited and assigned to a study group, all the members in that department will be assigned to the same group."|This study is a two-arm, feasibility, Cluster Randomized Trial (CRT).|f|f|t|t
34108673|NCT06094803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108674|NCT03427619|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible participants receive the actual drug.||||
34108675|NCT06325410|||COHORT||RETROSPECTIVE|||||||
34108676|NCT06639724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108677|NCT02937571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108678|NCT03395093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108679|NCT02157545|||CASE_CONTROL||PROSPECTIVE|||||||
34108680|NCT04369209|||COHORT||PROSPECTIVE|||||||
34108681|NCT05472870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108682|NCT06021613|NA|SINGLE_GROUP||OTHER||NONE||||||
34108683|NCT03721289|||COHORT||RETROSPECTIVE|||||||
34108684|NCT05319197|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34108685|NCT05079373|||CASE_CONTROL||RETROSPECTIVE|||||||
34108686|NCT00656695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34108687|NCT05972772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806970|NCT00406887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34108688|NCT06569524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806971|NCT03567785|||COHORT||PROSPECTIVE|||||||
33806972|NCT05986994|||COHORT||PROSPECTIVE|||||||
34108689|NCT05553236|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34108690|NCT04353492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108691|NCT02758730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108692|NCT04952571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||glioblastoma at first relapse, glioblastoma at second relapse||||
34108693|NCT06638190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Test beverages will be served cold in opaque containers with lids.|"Participants will complete four tests at least 2-3 day apart. They will arrive at the laboratory at 8:00 am following a 10-12 h fast, except for a small amount of water permitted up to 1 h before arriving. Foods rich in polyphenols (particularly citrus fruits) will be forbidden on the day before the studies. On the day before to each test session, the participants will complete a food diary to verify adherence to the polyphenol-free diet and fasting protocol and to estimate the amount of nutrients consumed (carbohydrates, fibre, water).~The sequence of beverages intake will be randomized. Participants will consume one of the three beverages, including (1) 100% orange juice (AMC Murcia, Spain), (2) orange beverage with 50% orange juice and 50% water with added sugars to match the content of the 100% juice, and (3) 100% water with added sugars to match the content of the 100% juice. The study will be repeated to evaluate intra and inter-individual variability."|t|f|t|t
34108694|NCT06126900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34108695|NCT01044719|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34108696|NCT03164993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed using the eCRF. The subject will allocated to a randomization number and the randomization number will be sent to the hospital pharmacy. The pharmacy keeps the randomization listing and prepares the infusion according to the given randomization number. The pharmacy will keep a log of all infusions prepared. All other study personell will be blinded to the treatment code.|Randomized, double-blind, placebo-controlled|t|f|t|f
34108697|NCT06283160|||CASE_ONLY||PROSPECTIVE|||||||
34108698|NCT05277532|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized crossover design (comparing morning vs afternoon exercise) in parallel groups (Type 1 diabetes and control subjects)||||
34108699|NCT03951480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108700|NCT01287208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34108701|NCT06644079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108702|NCT06575868|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34108703|NCT04726527|||CASE_ONLY||PROSPECTIVE|||||||
34108704|NCT00000307||||TREATMENT||||||||
34108705|NCT02759809|||COHORT||PROSPECTIVE|||||||
34108706|NCT02926846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108707|NCT05767086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108708|NCT01822379|NA|SINGLE_GROUP||TREATMENT||TRIPLE|Will perform cell separation using either diaspase or trypsin|diaspase versus trypsin for cell separation|t|f|t|t
34108709|NCT05917145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A - Dose Escalation Phase Group B - Dose Expansion Group C - Tumor Penetrance Cohort||||
34108710|NCT03713450|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108711|NCT03599713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108712|NCT03058887|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34108713|NCT06564363|||CASE_ONLY||PROSPECTIVE|||||||
34108714|NCT06641531|||OTHER||CROSS_SECTIONAL|||||||
34108715|NCT03599076|||CASE_CONTROL||PROSPECTIVE|||||||
34108716|NCT00839930|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34108717|NCT03649503|||COHORT||PROSPECTIVE|||||||
34108718|NCT02324244|||COHORT||PROSPECTIVE|||||||
34108719|NCT03913130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108720|NCT06476548|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34108721|NCT03687671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108722|NCT01926509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108723|NCT06642116|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34108724|NCT03868280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Pilot cluster randomized crossover trial design|t|f|t|t
34108725|NCT01277185|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34108726|NCT03708510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108727|NCT03872115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Investigators and outcomes assessors will be blinded to the dose of vibration randomly assigned to participants.||t|f|t|t
34108728|NCT02507934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The packaging used for the comparator in the present investigation aimed at ensuring a complete masking of the test IMD.||t|f|t|f
34108729|NCT05998564|||COHORT||PROSPECTIVE|||||||
34108730|NCT04381806|NA|SEQUENTIAL||TREATMENT||NONE||This is a phase 1, open label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study to determine the maximum tolerated doses (MTD) or recommended phase 2 doses (RP2D) of both ALA and RT. Once the MTDs are identified, the cohort providing the highest dose intensity at or below the MTD (if supported by emerging PK and biomarker data) will be selected for an expansion phase for the purpose of refining the safety assessment and assessing preliminary efficacy. The initial dose escalation phase will enroll at least 20 patients across a variety of tumor types, after which concurrent disease site-specific expansion cohorts will accrue, each consisting of 20 patients. Anatomic site-specific cohorts will include patients with symptomatic metastatic disease to specific anatomic regions, where varying toxicity may be expected (Head and Neck, Thorax and Abdomen/Pelvis).||||
34108731|NCT00202241|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34108732|NCT06541119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sixty mild to moderate Hallux valgus patients will be evaluated for eligibility ; participants will be randomized in 1:1 ratio using computer generated block randomization , followed by concealed allocation by opening quantity numbered sealed envelopes , a card inside will reveal the group assignment as either group A, or group B.||t|f|t|f
34108733|NCT05012124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34108734|NCT05157698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108735|NCT05453968|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|This is a sequential, three-part, open-label study. Minimum participation in this study is expected to be 24 weeks in the SOC treatment period through Part 1 of the study and up to an additional 132 weeks in Parts 2 and 3.||||
34108736|NCT06114472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108737|NCT06539000|||COHORT||RETROSPECTIVE|||||||
34108738|NCT06140316|||COHORT||PROSPECTIVE|||||||
34108739|NCT05190666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34108740|NCT05497687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked for the study arms allocation||f|f|f|t
33806973|NCT06678243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blind, remote, randomized clinical trial|t|f|f|f
34108741|NCT01356940|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34108742|NCT06640179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108743|NCT06650566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108744|NCT06397040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108745|NCT06674330|||OTHER||PROSPECTIVE|||||||
34108746|NCT05941780|||COHORT||CROSS_SECTIONAL|||||||
34108747|NCT03858244|||COHORT||PROSPECTIVE|||||||
34108748|NCT05754996|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The recruited patients will be randomly allocated in one of two groups:~Group I (The study group): patients will receive oral nifuroxazide: 800 mg daily in 4 divided doses for maximum 7 days and lactulose 30 to 60 mL peroral (PO) three times daily (TID) according to bowel movement (to produce 2 to 3 semisoft stools per day) plus rifaximin 550 mg twice daily.~Group II (The control group): patients will receive the standard treatment : lactulose 30 to 60 mL PO TID according to bowel movement (to produce 2 to 3 semisoft stools per day) plus rifaximin 550 mg twice daily.."||||
34108749|NCT06564038|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108750|NCT05570162|NA|SINGLE_GROUP||TREATMENT||NONE||"30 minutes diabetes educational program:~* 10-minute talk about Flash measurements and importance of diabetes control.~* 10-minute practic exercises with Flash values and tendencies.~* 10-minute talk about recomendations for increasing daily Flash scanning."||||
34108751|NCT06367101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108752|NCT03274466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108753|NCT05937802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108754|NCT01557244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108755|NCT02800785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108756|NCT03543423|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"12 healthy male individuals will each be studied on two occasions in random order.~* oral glucose tolerance test~* liquid mixed meal test"||||
34108757|NCT01586715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806974|NCT03406169|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33806975|NCT03438409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33806976|NCT02922010|||OTHER||CROSS_SECTIONAL|||||||
33806977|NCT01100151|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33806978|NCT06699186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Prior to and following the interventions, all assessments were evaluated by a researcher who was blinded to the groups.|"The study was designed as a randomised, single-blind, controlled trial. The patients were divided into two groups, designated as the sleep group and the non-sleep group, through the implementation of a matched randomization method that considered both gender and age as variables."|f|f|t|f
33806979|NCT01462799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33806980|NCT05174520|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34108758|NCT02276040|||CASE_ONLY||PROSPECTIVE|||||||
34108759|NCT04289493|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A psychologist blinded to the patient´s clinical characteristics and study groups performs the outcome questionnaires three times for each patient during the study period.|Two groups with 27 patients in each one. Group 1 starts therapy in the first 3 months since study inclusion and from months 3-6 is group 2 control. Group 2 starts language therapy from months 3-6, serving previously as group 1 control.|f|f|f|t
34108760|NCT05612945|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Monocentric randomized controlled trial (2 groups):~Group 1 (n=30): high-intensity interval training group (HIIT) Group 2 (n=30): low-to-moderate intensity training group (LowMod)"||||
34108761|NCT00781898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806981|NCT02628626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33806982|NCT01999036|||COHORT||PROSPECTIVE|||||||
34108762|NCT01893086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108763|NCT06258512|RANDOMIZED|PARALLEL||TREATMENT||NONE||The interventions of the health social workers rely on listening in the clinical interview, They give space to the patient's subjective complaint, they locate the understanding of the discomfort and the symbolic meaning of the symptoms. The difficulties are focused as elements of the relationship between the professional and the user and does not refer to pharmacological treatments. Since social work identifies discomfort psychosocial as an object of study, we would like to demonstrate that, establishing locally an intervention with a narrative approach implemented in the area of primary health care with the aim of improving the perception of emotional support of users with excessive use of self-initiated consultation, we can reduce the use of medical consultations, and, most importantly, the suffering and discontent of said users who do not find an answer appropriate to your discomforts.||||
34108764|NCT04025320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34108765|NCT03725592|RANDOMIZED|PARALLEL||PREVENTION||NONE||Recruit and prospectively follow 300 households and 600 participants (2 per household) to one of 2 study arms (150 households per arm). Each arm will receive arsenic removal devices. However the Standard Arm will only be provided with written instructions on how to use the arsenic removal device and follow-up phone calls, while the Intensive Education Arm will receive up to 5 additional in-visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.||||
33806983|NCT05381519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33806984|NCT06267300|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled trial comparing HBOT to standard care alone, with a cross-over from standard care to HBOT in case primary outcome is positive after 6 months follow-up.||||
33806985|NCT00081913|RANDOMIZED|||TREATMENT||DOUBLE||||||
33806986|NCT06698432|||COHORT||RETROSPECTIVE|||||||
34108766|NCT06323083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was designed to be randomly controlled.|f|f|f|t
34108767|NCT04573738|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108768|NCT00339287|||OTHER||OTHER|||||||
34108769|NCT04832698|||COHORT||PROSPECTIVE|||||||
34108770|NCT06642129|||CASE_ONLY||PROSPECTIVE|||||||
34108771|NCT03900650|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34108772|NCT06557811|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study will be double-blind, meaning both the research participants and the outcome assessors will be blinded.|Diabetic patients who suffered acute myocardial infarction will be divided into 2 groups, an arm that will receive medication and another arm placebo (control population).|t|t|t|t
34108773|NCT04704648|NA|SINGLE_GROUP||TREATMENT||NONE||Using an exact binomial one-sample test for proportions, 90% power and one-sided 0.0167 significance level (0.05/3 = 0.0167), the number of study participants required to test the hypotheses shown above, respectively, are 28, 28 and 68. Thus, this study will require 68 evaluable participants using a one-sample test of proportions. We define evaluable as participants with suspected OSSN lesions who are shown to have OSSN on biopsy. We estimate that 20% of participants will be found to have lesions that are histopathologically not OSSN and will therefore, not be evaluable. As a result, we are recruiting 84 individuals (21 per clinical site) to get 68 evaluable participants.||||
34108774|NCT06645119|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34108775|NCT05819801|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly divided into two groups and told whether to eat or fast prior to their procedure||||
34108776|NCT05555329|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34108777|NCT05989269|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Ordering care providers will not be aware if the test results are eligible for modified reporting or not.|This is a pragmatic cluster-randomized crossover trial in 6 adult ICUs (1 medical and 1 surgical ICU each at 3 hospitals). ICUs (clusters) will be randomized at the hospital-level (1:1) to a sequence of intervention (6 months) followed by control (6 months), or vice-versa. The study population is ventilated patients with respiratory culture orders but not meeting clinical pneumonia criteria, and organism(s) growing in respiratory culture. A research physician will evaluate likelihood of pneumonia using a standard clinical algorithm, within 24 hours of the order Mon-Fri. If pneumonia criteria are not met AND there is growth of organism(s) (except normal respiratory flora), during the intervention period, the culture report will be modified to reflect the likelihood of asymptomatic colonization instead of reporting bacterial identification. Clinicians may call the lab for identification and susceptibilities if necessary. During the control period, no modification to reporting will occur.|f|t|f|f
34108778|NCT04456673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108779|NCT01957384|RANDOMIZED|CROSSOVER||||NONE||||||
34108780|NCT02249949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108781|NCT06598761|||COHORT||PROSPECTIVE|||||||
34108782|NCT04076709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724868|NCT01526265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33724869|NCT03976063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33724870|NCT04849806|||CASE_CONTROL||PROSPECTIVE|||||||
33724871|NCT03809520|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33724872|NCT02381808|||CASE_ONLY||PROSPECTIVE|||||||
33724873|NCT00436228|||||PROSPECTIVE|||||||
34108783|NCT06571812|||COHORT||PROSPECTIVE|||||||
33724874|NCT01436981|||COHORT||PROSPECTIVE|||||||
33724875|NCT06134479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724876|NCT04064918|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33724877|NCT06353880|||COHORT||CROSS_SECTIONAL|||||||
33724878|NCT05383079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724879|NCT00151320|NA|SINGLE_GROUP||TREATMENT||NONE||"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the dose escalation schedule."||||
33724880|NCT00005926||||TREATMENT||||||||
34108784|NCT00409656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108785|NCT06517966|||COHORT||OTHER|||||||
34108786|NCT06211374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108787|NCT03890094|||CASE_ONLY||RETROSPECTIVE|||||||
34108788|NCT02003703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34108789|NCT04756232|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34108790|NCT02383823|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34108791|NCT06674850|||CASE_CONTROL||RETROSPECTIVE|||||||
34108792|NCT06642428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724881|NCT00912990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108793|NCT06641791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806987|NCT05054270|||OTHER||PROSPECTIVE|||||||
33806988|NCT04788524|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Case-Control Design||||
33806989|NCT01286636|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33806990|NCT02852252|||COHORT||PROSPECTIVE|||||||
33806991|NCT01617369|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects completed mucociliary clearance measurements (via gamma scintigraphy) at baseline, 30 minutes after inhaling 2.8% NaCl, and 4 hours after inhaling 2.8% NaCl at separate study visits to characterize acute vs. sustained effects of inhaled 2.8% NaCl on this physiologic process.||||
34108794|NCT05176665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108795|NCT00989495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108796|NCT06264154|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34108797|NCT02184286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108798|NCT05660187|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34108799|NCT06200441|||COHORT||PROSPECTIVE|||||||
34108800|NCT06297902|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2||||
34108801|NCT00661180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108802|NCT06639776|||COHORT||CROSS_SECTIONAL|||||||
34108803|NCT01915446|||COHORT||PROSPECTIVE|||||||
34108804|NCT04665245|||COHORT||PROSPECTIVE|||||||
34108805|NCT02416544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34108806|NCT03673982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108807|NCT05961735|||CASE_CONTROL||PROSPECTIVE|||||||
34108808|NCT06154525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo Preg - Mom, LiveSpo KIDS, and RO water are indistinguishable regarding smell and taste. Because the three liquid products are packed in opaque plastic ampoules, the color and turbidity of the suspension are unrecognizable to investigators, trainers, the patient's parents, and patients except for the Principal Investigator (PI) and final data analysis|A randomized, double-blind, controlled clinical trial|t|t|t|f
34108809|NCT05059665|||CASE_CONTROL||PROSPECTIVE|||||||
34108810|NCT06639750|||COHORT||PROSPECTIVE|||||||
34108811|NCT06064617|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know what lens they are in|This study will be an observational single-center investigation using a cross sectional design and each subject will undergo two test sessions and will wear two different contact lenses.|t|f|f|f
34108812|NCT05406401|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108813|NCT06531018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108814|NCT06640686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blind to their group and outcomes assessor will be blind to groups.|randomized controlled study|t|f|f|t
34108815|NCT04751357|||CASE_ONLY||PROSPECTIVE|||||||
34108816|NCT05634811|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34108817|NCT06631391|NA|SINGLE_GROUP||TREATMENT||NONE||To evaluate the safety, tolerability and efficacy of umbilical cord blood natural killer cell injection in the treatment of high-risk, recurrent/refractory neuroblastoma in children||||
34108818|NCT04548219|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34108819|NCT05883709|||COHORT||RETROSPECTIVE|||||||
34108820|NCT04447222|||COHORT||CROSS_SECTIONAL|||||||
34108821|NCT03811119|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized trial||||
34108822|NCT05551117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108823|NCT04738266|||COHORT||CROSS_SECTIONAL|||||||
34108824|NCT06643494|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|Both the active compactor and the placebo will be in unlabeled foil packets. The contents will be the same weight and color.|The study consists of a single group of subjects included in the study design, in which all subjects receive a single intervention, N-111, and the outcomes are assessed over time.|t|t|t|f
34108825|NCT04777916|||COHORT||PROSPECTIVE|||||||
34108826|NCT06638320|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34108827|NCT04054180|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, open, multicentric, national and uncontrolled study.||||
34108828|NCT04813120|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34108829|NCT01435356|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108830|NCT06637124|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108831|NCT05507853|||COHORT||PROSPECTIVE|||||||
34108832|NCT01549015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035372|NCT00466700|||CASE_ONLY||PROSPECTIVE|||||||
34108833|NCT01950494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035373|NCT01254643|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035374|NCT06314243|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Design: Prospective, randomized, Open label - controlled clinical trial.~Patients: A total of 56 patients on regular hemodialysis (HD) will be enrolled in the study. These patients will be randomly allocated into two equal groups:~* Group 1 (PSO group): consists of 28 patients who will receive one capsule containing 1010 mg PSO once daily for 12 weeks,  Ronkin®, KMT PHARMA, Egypt. ~* Group 2 (Control group): consists of 28 patients who will not receive the intervention."||||
34035375|NCT02446041|||COHORT||RETROSPECTIVE|||||||
34035376|NCT03312244|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All participants will be blinded. The steering committee will have the authority to open the blinding in case of adverse effects|12x12 weeks of pyridostigmine or placebo followed by crossing-over to the other arm of intervention|t|t|t|t
34035377|NCT00624429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035378|NCT03599817|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035379|NCT03650699|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035380|NCT03784638|RANDOMIZED|PARALLEL||TREATMENT||NONE||lingually-based triangle flap design buccaly-based triangular flap design||||
34035381|NCT00750425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035382|NCT01321879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035383|NCT02818101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34035384|NCT05961956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035385|NCT01823861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34035386|NCT03707405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035387|NCT01786993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035388|NCT02046044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035389|NCT01796678|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34035390|NCT01818882|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035391|NCT04077593|||OTHER||PROSPECTIVE|||||||
34035392|NCT03691857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035393|NCT05736354|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035394|NCT06453083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035395|NCT03788850|||COHORT||RETROSPECTIVE|||||||
34035396|NCT01390636|||CASE_CONTROL||PROSPECTIVE|||||||
34035397|NCT00383253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035398|NCT03830333|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035399|NCT06092801|||COHORT||CROSS_SECTIONAL|||||||
34035400|NCT04563663|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
34035401|NCT05257200|||COHORT||PROSPECTIVE|||||||
34035402|NCT06076993|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a parallel two-arm cluster randomized controlled effectiveness trial. This pragmatic trial will be conducted in settings similar to the real world which will include use of a school setting, teacher-led delivery during classroom time, no strict exclusion criteria for students and comparison to routine lessons-as-usual."||||
34035403|NCT05854004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035404|NCT00185289|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34035405|NCT01396668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035406|NCT04085211|||COHORT||PROSPECTIVE|||||||
34035407|NCT03797911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind||t|t|t|f
34035408|NCT05229094|||COHORT||PROSPECTIVE|||||||
34035409|NCT02585908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34035410|NCT06043401|||COHORT||PROSPECTIVE|||||||
34035411|NCT00634868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34035412|NCT04736147|NA|SINGLE_GROUP||OTHER||NONE||||||
34035413|NCT01744301|||COHORT||RETROSPECTIVE|||||||
34035414|NCT03906799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035415|NCT01561716|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035416|NCT04328090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||parallel||||
34035417|NCT03143283|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||We will use a stepped wedge sample design, a type of cluster randomized crossover design in which different clusters (in our case, hospitals) switch permanently from a control to an intervention state at different time points (steps) (Woertman, 2013). We chose a cluster-randomized design to prevent contamination that would likely occur were providers or patients randomized to receive different interventions within hospitals. All clusters start in the control condition (usual care), with hospitals switching to the intervention at consecutive 3- month time points, where the time of the switch is randomized for every hospital. At the end of the study period, all clusters will have switched from a control to an intervention condition.||||
34035418|NCT00107029|||COHORT||OTHER|||||||
34035419|NCT05754268|||COHORT||RETROSPECTIVE|||||||
34035420|NCT01195311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035421|NCT03818113|||COHORT||RETROSPECTIVE|||||||
34035422|NCT03479580|||COHORT||PROSPECTIVE|||||||
34035423|NCT01482416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035424|NCT00129883|RANDOMIZED|PARALLEL||ECT||NONE||||||
34035425|NCT06511635|||COHORT||RETROSPECTIVE|||||||
34035426|NCT02614924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035427|NCT02719886|RANDOMIZED|PARALLEL||||NONE||||||
34035428|NCT02381847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035429|NCT05163483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035430|NCT04242810|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34035431|NCT00570063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035432|NCT03176069|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34108834|NCT03369808|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108835|NCT06638502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108836|NCT01678833|||||OTHER|||||||
34108837|NCT03383874|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108838|NCT04987775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants enrolled will be randomized into one of two arms: NAC or Placebo.|t|t|t|f
34108839|NCT04232553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108840|NCT05393427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108841|NCT05811949|||COHORT||PROSPECTIVE|||||||
34108842|NCT01489553|||CASE_ONLY||PROSPECTIVE|||||||
34108843|NCT06639256|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108844|NCT04089111|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Patients will not be aware of the procedure or ventilation modes that will be performed. Outcomes will be analyzed by an independent statistician.|Patients will be ventilated for two different minute volume targets in two sets. 'Adapted support ventilation' and 'volume control (VC)' modes will be used consecutively in each set. Every patient will be ventilated 1.1. ASV with minute volume target of % 100; 1.2. VC with same MV target; 2.1 ASV with MV target associated with PaCo2 less than 45 mmHg; 2.2 VC with same MV target. Sequence of ventilation modes wıll be randomized within each group.|t|f|f|t
33724882|NCT05140031|NON_RANDOMIZED|CROSSOVER||OTHER||NONE|This study is designed as a cross-over study. As such, all participants will receive usual care before being introduced to the PNE4Adults board.|"After a period of usual care for 2-4 weeks, we want to cross-over and add the pain education intervention.~The pain education intervention is an add-on to usual care and consists of an individualized pain education program in the form of Danish PNE4Adults. The education program consists of two session of +/- 1 hour each tailored individually to the needs of the patient. After the pain education, the patient will continue the planned rehabilitation program, but will integrate the knowledge obtained through the pain education, as an integrated part of the PNE4Adults program."||||
34108845|NCT06638515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34108846|NCT06641700|||CASE_CONTROL||PROSPECTIVE|||||||
34108847|NCT01150279|||COHORT||PROSPECTIVE|||||||
34108848|NCT04874194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108849|NCT06637046|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34108850|NCT04600089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108851|NCT06174220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized in a 1:1 ratio using an automated central, web-based system within 30 days of completing their baseline Holter. Randomization will be stratified by TMEM43-p.S358L variant status.|t|t|t|t
34108852|NCT06638242|||CASE_ONLY||RETROSPECTIVE|||||||
34108853|NCT05927298|||COHORT||PROSPECTIVE|||||||
34108854|NCT05022654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108855|NCT06277219|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108856|NCT03334955|NA|SINGLE_GROUP||TREATMENT||NONE||Laparoscopic ovarian drilling was performed under general anesthesia with good muscle relaxation and endotracheal intubation using the three-punctures technique (one puncture 10mm at the umbilicus and the other two punctures 5mm at both iliac fossa) in the early follicular phase. A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points (regardless of the size of the ovary), with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds. The ovary was then cooled using 200 ml crystalloid solution before releasing the ligament.||||
33724883|NCT01047956|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33724884|NCT03226262|||COHORT||PROSPECTIVE|||||||
33724885|NCT04131634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724886|NCT01224847|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34108857|NCT06493526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724887|NCT01829776|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108858|NCT03235804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108859|NCT04876456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108860|NCT06460662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33724888|NCT01357265|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33724889|NCT06061627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33724890|NCT03860428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806992|NCT05357820|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33806993|NCT03647358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33806994|NCT01767467|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34108861|NCT03732794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108862|NCT02913846|||COHORT||PROSPECTIVE|||||||
34108863|NCT03140969|NA|SEQUENTIAL||TREATMENT||NONE||||||
34108864|NCT06642038|||COHORT||PROSPECTIVE|||||||
34108865|NCT05728242|||COHORT||PROSPECTIVE|||||||
34108866|NCT03701074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108867|NCT05719246|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108868|NCT01166646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34108869|NCT05208762|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108870|NCT00336063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108871|NCT06643520|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34108872|NCT05359562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study hypotheses will be masked to participant, therapist, and outcome assessor. Assignment of women participants to groups will be masked to therapist, investigator, and outcome assessor.||t|t|t|t
34108873|NCT04978467|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will experience all controller conditions.||||
34108874|NCT02768246|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34108875|NCT01275300|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34108876|NCT06565091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108877|NCT06275958|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase III, open-label, non-inferiority, randomized controlled clinical trial comparing dose-reduced chemotherapy versus standard dose chemotherapy in older adults with metastasized colorectal cancer||||
34108878|NCT06609096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to prevent outcome reporting bias, the data obtained from the study will be coded as A, B and C by an independent researcher and transferred to the SPSS program. Group assignment will be concealed from the researchers during the data analysis and reporting process.||f|f|f|t
34108879|NCT01756742|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34108880|NCT06569316|NA|SINGLE_GROUP||SCREENING||NONE||||||
34108881|NCT03941184|||CASE_CONTROL||RETROSPECTIVE|||||||
34108882|NCT06644911|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34108883|NCT06639230|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* group 1: This group was made up of ten patients treated using diode lasers with an output power of 3 W in the contact mode, the tip will be moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.~* group 2: This group was made up of ten patients who were treated with sclerosing agent after anaesthetizing the surgical site with a local anesthetic agent, the lesion will be injected with the sclerosing agent, diluted in distilled water, the solution is injected slowly into the lesion using a 23-gauge needle until it leaks out from the surface."||||
34108884|NCT03914833|||CASE_CONTROL||PROSPECTIVE|||||||
34108885|NCT02185768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108886|NCT05031897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108887|NCT05023018|NA|SINGLE_GROUP||TREATMENT||NONE||This multi-site, Phase 2 clinical trial is an open label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed residual, progressive or recurrent high-grade meningioma. There will be up to 30 patients enrolled into the study to enroll 28 evaluable patients. NEO100 will be self-administered four times daily for a 28-day treatment cycle until disease progression, death or patient withdraw for any reason, whichever occurs first.||||
34035433|NCT04935333|||CASE_CONTROL||PROSPECTIVE|||||||
34035434|NCT06034106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34035435|NCT04192643|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||PROSPECTİVELY DOUBLE-BLİND RANDOMİSED CONTROLLED TRİAL|f|f|t|f
34035436|NCT01153100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035437|NCT01996930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035438|NCT03627117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34035439|NCT03629262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34035440|NCT04371289|||COHORT||PROSPECTIVE|||||||
34035441|NCT06403176|||COHORT||PROSPECTIVE|||||||
34035442|NCT02420925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035443|NCT06214910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Household-level randomization -- all individuals in a household will be randomized to the same study arm of medication delivery.||||
34035444|NCT06258083|||COHORT||RETROSPECTIVE|||||||
34035445|NCT00155311|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34035446|NCT03054233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035447|NCT01795404|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035448|NCT00607321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108888|NCT05422482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108889|NCT04625660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108890|NCT00273585|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34108891|NCT04593745|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108892|NCT02208167|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108893|NCT06639828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108894|NCT01879826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34108895|NCT05845580|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to receive either atorvastatin therapy or red yeast rice extract and then atorvastatin. The two arms will be run concurrently, and patients in each arm will be assessed for adherence and outcomes over the same period of time.||||
34108896|NCT03941561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108897|NCT03757715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34108898|NCT04893811|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035449|NCT02292693|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035450|NCT01210534|||CASE_ONLY||PROSPECTIVE|||||||
34035451|NCT01753570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035452|NCT05353465|||COHORT||RETROSPECTIVE|||||||
34035453|NCT05058079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34035454|NCT02688543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035455|NCT06551207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035456|NCT00004310|RANDOMIZED|||TREATMENT||DOUBLE||||||
34035457|NCT01455662|||COHORT||PROSPECTIVE|||||||
34035458|NCT06305117|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34035459|NCT01068639|||CASE_ONLY||CROSS_SECTIONAL|||||||
34035460|NCT01956578|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108899|NCT03186820|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective monocentric comparative study||||
34108900|NCT05374603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108901|NCT06024538|||COHORT||PROSPECTIVE|||||||
34108902|NCT05935085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108903|NCT06303453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated.||f|f|f|t
34108904|NCT05082909|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomised, cross-over study||||
34108905|NCT05744063|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm, multi-centre study to collect safety and efficacy data on emapalumab in treatment experienced male and female patients diagnosed with pHLH. The study will be performed in China.||||
34108906|NCT05983133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108907|NCT03079999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In the Randomized Treatment Phase, patients aged 12 years or older with VSs will be identified and recruited into one of two randomized groups who receive either 1) 325 mg aspirin twice daily (81 mg aspirin twice daily for pediatric patients \<50 kg); or 2) a placebo. Patients will stay on aspirin/placebo as long as there is no more than 20% increase in VS volume. At tumor progression, patients will enter the Open Label Follow Up Phase. Patients who progress on placebo will receive unblinded aspirin. Patients who progress on aspirin (either blinded or unblinded) will be taken off study drug and followed. All patients will be followed for at least 3.5 years after randomization.|t|t|t|t
34108908|NCT06643806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|We will attempt to enforce community level blinding/masking in this study, but other forms of blinding/masking are not entirely possible in a cluster randomized trial|Cluster randomized trial of 12 week intervention.|t|f|f|f
34108909|NCT06641986|||COHORT||PROSPECTIVE|||||||
34108910|NCT03044054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108911|NCT04070040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108912|NCT03312114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108913|NCT05651490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly allocated to one of the two arms: intervention group (PST-D) and attention control group. The random assignment will be based on a code generated by R statistical software, contained within sequential sealed envelopes. The random number sequence will be password protected and available to a statistician external to the study team who will conduct the randomisation process. The randomisation process is designed to yield an expected assignment ratio of 1:1|f|f|f|t
34108914|NCT02881216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108915|NCT06637514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108916|NCT06642909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108917|NCT01955551|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34108918|NCT06024226|||COHORT||PROSPECTIVE|||||||
34108919|NCT06113289|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108920|NCT04632862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108921|NCT03743519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34108922|NCT06438731|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single blinding (participants) will be used in the study. Participants will not be informed about which group they are in.|Breast Mılk, Knıtted Octopus And Control Group|t|f|f|f
34108923|NCT03076151|NA|SINGLE_GROUP||OTHER||NONE||||||
34108924|NCT06645483|RANDOMIZED|PARALLEL||OTHER||SINGLE||Branch A and Branch B will be randomly assigned as the experimental and control groups via a draw conducted through the randomizer.org website. At the beginning of the study, a pre-test will be administered to both groups. The lessons for the experimental group will be conducted using ChatGPT during the first two weeks, while the control group will receive instruction through the traditional teaching method (presentation-based instruction). At the end of the two weeks, a post-test will be administered to both groups. To ensure that the students receive the same course under the same conditions and opportunities, the teaching methods will be crossed between the groups during the following two weeks, with the experimental group receiving traditional education and the control group being taught with ChatGPT. At the end of the total four-week implementation, a follow-up test will be administered to both groups.|t|f|f|f
34108925|NCT03517800|||OTHER||RETROSPECTIVE|||||||
34108926|NCT05142293|||OTHER||PROSPECTIVE|||||||
34108927|NCT06405412|||COHORT||RETROSPECTIVE|||||||
34108928|NCT06572397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108929|NCT03938740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806995|NCT02449785|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33806996|NCT05299034|||COHORT||RETROSPECTIVE|||||||
33806997|NCT02470169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806998|NCT01745965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33806999|NCT05198674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807000|NCT02568215|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108930|NCT05737680|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108931|NCT06201611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained outcomes assessor unaware of the treatment arm to which the patient has been allocated to will perform all outcomes assessments|We will use a 3 center, 3-arm, parallel group, open label, stratified randomized controlled trial design with a 1:1:1 allocation ratio and blinding of outcome assessors.|f|f|f|t
34108932|NCT02918942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108933|NCT03982173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108934|NCT06020079|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|who had undergone bariatric surgery in the general surgery ward of the university hospital 6-24 months ago. Sample size was determined using power analysis. The analysis revealed that the sample should consist of a total of 62 patients (31 intervention, 31 control),|A Guasi-experimental Study with a Pretest-Posttest Control Group Design.|t|f|f|f
34108935|NCT06327165|||COHORT||PROSPECTIVE|||||||
34108936|NCT06639802|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34108937|NCT06340269|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, national, monocentric, single-arm, open label, feasibility pilot clinical trial.||||
34108938|NCT05345158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108939|NCT05309226|||COHORT||PROSPECTIVE|||||||
34108940|NCT06636955|||COHORT||PROSPECTIVE|||||||
33807001|NCT02966249|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33807002|NCT06671353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838083|NCT00895557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34108941|NCT05603780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Follow-up of one group of healthy participant to 40days in a contraint underground environment||||
34108942|NCT05919498|||COHORT||CROSS_SECTIONAL|||||||
34108943|NCT04661358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-masked, placebo-controlled clinical trial|t|t|t|f
34108944|NCT03327129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34108945|NCT00330733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108946|NCT06507644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the researcher responsible for performing the treatments (who will open the randomization envelopes) will know which treatment is assigned to each participant. The group identification will be revealed only after statistical data analysis to all involved in the study by this researcher. Therefore, the researcher responsible for data collection and their assistant will be blinded to the treatments assigned to the groups. The participant will be blinded to the type of treatment performed, as will the statistician.|A Double-Blind Randomized Controlled Clinical Protocol|t|f|t|t
34108947|NCT06636760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34108948|NCT05715320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108949|NCT06635850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108950|NCT01179555|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34108951|NCT00804583|||COHORT||PROSPECTIVE|||||||
34108952|NCT06643468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108953|NCT03435107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108954|NCT06303518|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The anesthesiologist will be blinded to the BIS reading and will continue to provide anesthesia according to the protocol. The BIS numerical value in the OR will be covered, but the waveform will be visible to assess signal quality. The anesthesiologist providing care to the patient will not be involved in data collection or analysis|"The investigators plan to conduct a randomized, prospective, crossover trial. The six arms will be as below:~1. Normal ETCO2 -\> High Normal ETCO2 -\> Low Normal ETCO2~2. Normal ETCO2 -\> Low Normal ETCO2 -\> High Normal ETCO2~3. High Normal ETCO2 -\> Low Normal ETCO2 -\> Normal ETCO2~4. High Normal ETCO2 -\> Normal ETCO2 -\> Low Normal ETCO2~5. Low Normal ETCO2 -\> High Normal ETCO2 -\> Normal ETCO2~6. Low Normal ETCO2 -\> Normal ETCO2 -\> High Normal ETCO2"|f|t|f|f
34108955|NCT04473196|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34108956|NCT03100461|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34108957|NCT05395338|||COHORT||RETROSPECTIVE|||||||
33807003|NCT05999682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single(Participant)|"Treatment group: Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 days or ICU discharge.~Control group: Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 days or ICU discharge."|t|f|f|f
33807004|NCT00894257|||COHORT||RETROSPECTIVE|||||||
33807005|NCT02432066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807006|NCT05964023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807007|NCT00449774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807008|NCT03212638|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33807009|NCT06698861|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33807010|NCT06550401|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807011|NCT02595346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807012|NCT01448941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807013|NCT03592797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham laser acupuncture group|Randomized, sham control, double blind pilot study|t|f|t|t
33807014|NCT06207578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807015|NCT00076115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807016|NCT02738307|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108958|NCT03482232|||COHORT||RETROSPECTIVE|||||||
34108959|NCT05498909|||COHORT||PROSPECTIVE|||||||
34108960|NCT06645080|||OTHER||OTHER|||||||
34108961|NCT06439810|||CASE_CONTROL||PROSPECTIVE|||||||
34108962|NCT03287492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33724891|NCT03155074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34108963|NCT01851798|||COHORT||PROSPECTIVE|||||||
34149669|NCT02684188|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Patients were recruited from those admitted from one of four rural counties. In the initial phase, all patients enrolled from any county were assigned to a baseline condition. After enrollment stabilized, patients from one county were enrolled in the intervention while patients from the other three counties remained in baseline. Subsequently the intervention was introduced to the other counties sequentially while others remained in baseline. A return to baseline conditions followed a period after the intervention had been introduced in all counties.|t|f|f|f
33724892|NCT00481195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724893|NCT05673642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724894|NCT01197131|||COHORT||PROSPECTIVE|||||||
33724895|NCT00704028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724896|NCT06388395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Block randomization will be used to randomly assign participants. The sequences will be concealed in opaque, consecutively numbered envelopes for each block. One envelope will be obtained for each participant, corresponding to the assignment of the protocol (conventional versus PEEK). The outcome assessor will be independent and not involved in any treatment procedure|Two groups will be provided with two types of implant-supported prostheses|f|t|f|t
33724897|NCT02143609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33724898|NCT02154555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33724899|NCT03063476|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724900|NCT01458158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33724901|NCT02647086|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33724902|NCT00187460|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33724903|NCT02177448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724904|NCT00370253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724905|NCT02014363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724906|NCT01011842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724907|NCT02383953|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34108964|NCT06466642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization to study arm. Participants will be randomized into one of two study arms after the baseline assessment: an active experimental group receiving the CR, or an attention-matched control group. Because our sample size (N=43) is smaller than 100, investigators will use block randomization to assign participant numbers equally across each arm. To prevent the executer (the neuropsychology technician) from predicting the next assignment, they will be kept ignorant of the block size. Concealing the allocation sequence from those assigning participants, will prevent selection bias. Allocation numbers will be placed in individually sealed brown envelopes by the project manager prior to study commencement.|Recruited participants will first be screened for eligibility and required to provide informed consent. After the baseline assessment, participants will be randomized into one of two study arms: an active experimental group receiving CR (CogSMART and BrainHQ©) or an attention-matched control group. Measures, both subjective and objective, will evaluate participants' cognition, behavior, and functional abilities. Exit focus groups will gather participant feedback. The study aims to inform a larger RCT to enhance cognitive functioning and well-being among PWH in South Africa.|f|f|f|t
34108965|NCT06637007|NA|SEQUENTIAL||TREATMENT||NONE||||||
34108966|NCT04737265|RANDOMIZED|PARALLEL||PREVENTION||NONE||Serial monitoring of NTproBNP during chemotherapy will be used to identify high-risk patients in the intervention arm; patients who experience elevations in NTproBNP will be initiated and titrated on a personalized regimen of neurohormonal antagonists. Patients in the usual care arm will not have serial NTproBNP monitoring and will be managed according to usual care.||||
34108967|NCT05805189|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This is a prospective, single-center, randomized study, designed to evaluate the acute achievement of pulmonary vein isolation with HELIOSTAR Balloon catheter. In this study, patients will be treat using prospectively the pre-ablation indicators of optimal electrode positioning in comparison with standard positioning evaluated by fluoroscopy visualization and contrast injection and the optimized biophysical parameters as predictors of long-term efficacy.|t|f|f|f
34108968|NCT04938427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108969|NCT00219414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34035461|NCT06458517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34108970|NCT03407950|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34108971|NCT04336969|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34108972|NCT02877446|||CASE_ONLY||PROSPECTIVE|||||||
34108973|NCT03295942|NA|SINGLE_GROUP||TREATMENT||NONE||OMP-336B11||||
34108974|NCT06638762|||CASE_ONLY||RETROSPECTIVE|||||||
33807017|NCT05605613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807018|NCT04480385|NA|SINGLE_GROUP||OTHER||NONE||||||
34035462|NCT04348877|NA|SINGLE_GROUP||TREATMENT||NONE||Antibody-Rich Plasma from COVID-19 recovered patients||||
34035463|NCT04240392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will use a matched-pair cluster randomized trail design. The investigators will match clinical centers in pairs. The participants in each pair will be randomly assigned to either CC or ECHO using computer generated random numbers.|f|f|f|t
34035464|NCT01668615|||CASE_ONLY||PROSPECTIVE|||||||
34108975|NCT04672616|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34108976|NCT06642194|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34108977|NCT03034044|||CASE_ONLY||RETROSPECTIVE|||||||
34108978|NCT05558267|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34108979|NCT00934180|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34108980|NCT06637241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108981|NCT05044481|||OTHER||PROSPECTIVE|||||||
34108982|NCT02999659|||CASE_CONTROL||PROSPECTIVE|||||||
34108983|NCT06638008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34108984|NCT02097225|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34108985|NCT02956148|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34108986|NCT06210893|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34108987|NCT06373120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded and independent clinical event adjudication committee will adjudicate all primary and secondary outcomes|Prospective, 1:1 randomized, controlled, multicenter trial to assess effectiveness and safety of CorVad compared to VA-ECMO in complicated and high-risk patient with indications for PCI|f|f|f|t
34108988|NCT03559556|NA|SINGLE_GROUP||OTHER||NONE|Neurosurgeon who contoured AVM nidus using interventional cerebral arteriography.|The study proposes to evaluate whether a target volume based on CT angiography can serve as a reliable substitute for a target based on interventional cerebral arteriography. Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography. If the target volume based on CT angiography are adequate compared to their invasive counterpart, future investigators may selectively omit performing interventional cerebral arteriography in the treatment planning for SRS of AVM. Use of CT angiography may lead to reduction in the risk from the procedure and cost, improve the efficiency of the treatment process ideally without compromising the success of the procedure, with greater patient comfort and satisfaction.||||
34108989|NCT04576754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34108990|NCT03876821|||OTHER||PROSPECTIVE|||||||
34108991|NCT00088699|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34108992|NCT05430438|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34108993|NCT06157593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34108994|NCT01522872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149670|NCT06325319|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34149671|NCT03130296|||COHORT||PROSPECTIVE|||||||
34149672|NCT00877721|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33807019|NCT00779194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035465|NCT03617094|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34035466|NCT01780701|||CASE_CROSSOVER||PROSPECTIVE|||||||
33807020|NCT06513507|NA|SINGLE_GROUP||TREATMENT||NONE|No blinding will be performed in this study. All participants and investigators will know the treatment being administered.|This is a single-group study with an exploratory longitudinal prospective design aimed at measuring the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis.||||
34035467|NCT01350882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34108995|NCT04603560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This was a cluster-randomized trial randomized at the provider level. Primary care providers were invited to participate and consented into the study. Patients accrued into the study were study-eligible patients cared for by each enrolled primary care provider. The number of participants listed below includes both patients and providers (466 patients and 45 providers).|f|f|t|t
33807021|NCT02280031|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34108996|NCT06635642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34108997|NCT06596187|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34108998|NCT04182334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Only the unblinded study coordinator is aware of randomization. Outcomes assessors are blinded|Slow Tempo Music vs Attention Control|f|t|t|t
34108999|NCT02055339|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34109000|NCT02050399|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34149673|NCT01727791|NON_RANDOMIZED|||OTHER||NONE||||||
34149674|NCT01447160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807022|NCT04478487|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a non-controlled observational trial using objective measures (body weight) to assess the support of growth and tolerance of a new fortifier based on human milk, thereby enabling an exclusive human milk diet for VLBW infants in the NICU.||||
33807023|NCT00619554|||OTHER||PROSPECTIVE|||||||
33807024|NCT04636138|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34035468|NCT02436928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149675|NCT04356079|||FAMILY_BASED||RETROSPECTIVE|||||||
33807025|NCT06161987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035469|NCT01091194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035470|NCT03926299|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, active-controlled||||
33807026|NCT06381700|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33807027|NCT03855293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807028|NCT00012259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807029|NCT01162772|||||PROSPECTIVE|||||||
33807030|NCT03098589|||CASE_ONLY||PROSPECTIVE|||||||
33807031|NCT06239532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035471|NCT01976026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035472|NCT03154905|||COHORT||PROSPECTIVE|||||||
34035473|NCT06213077|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|IRB approved, double blind placebo-controlled crossover study. Control product (Tadalafil) open label. Nitric Oxide and placebo products labelled Sample 1 and Sample 2.|IRB approved, double blind placebo-controlled crossover study|t|f|t|f
33807032|NCT04278066|||CASE_ONLY||RETROSPECTIVE|||||||
33807033|NCT01532999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807034|NCT01719874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035474|NCT04800081|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 264 cases of perimenopausal patients with essential hypertension who were admitted to Department of Cardiology, Second Hospital of Lanzhou University,from January, 2020 to March,2021 will be enrolled and randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan or 80-320 mg of Valsartan.||||
34035475|NCT00683865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035476|NCT06416943|NA|SINGLE_GROUP||OTHER||NONE||||||
34035477|NCT05579964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035478|NCT00728455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035479|NCT01387659|NA|SINGLE_GROUP||OTHER||NONE||Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations||||
34035480|NCT00931411|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34035481|NCT01547429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035482|NCT02832011|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34035483|NCT01302743|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34035484|NCT04664322|||CASE_CROSSOVER||PROSPECTIVE|||||||
34035485|NCT02841137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035486|NCT02603016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34035487|NCT03447639|RANDOMIZED|PARALLEL||PREVENTION||NONE||2 arm parallel study with 1 to 1 randomization||||
34035488|NCT02493153|||COHORT||PROSPECTIVE|||||||
34035489|NCT02974686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035490|NCT01733550|||COHORT||PROSPECTIVE|||||||
34035491|NCT04960371|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035492|NCT06106204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two-arm, parallel, cluster-randomized trial of 40 hospitals randomized to an implementation intervention designed to support antibiotic stewardship interventions vs. usual care control.||||
34035493|NCT05580874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035494|NCT01299103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035495|NCT06025071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open-lable study. But while the study is in progress, the grouping information is masked from outcome assessors.|Open-label, Two-arm, Randomized, Superiority Trial|f|f|f|t
34035496|NCT00713024|||COHORT||CROSS_SECTIONAL|||||||
34035497|NCT02352467|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035498|NCT01383720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035499|NCT04378972|||OTHER||OTHER|||||||
34035500|NCT02671838|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34035501|NCT05872789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The main objective of this study was to evaluate the efficacy of Diazepam 1% oral gel over placebo in the management of BMS|t|f|t|f
34035502|NCT05060536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded RCT||t|t|t|t
34035503|NCT02289599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035504|NCT04406428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34035505|NCT01473914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035506|NCT03111940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035507|NCT01383174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34035508|NCT02342678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035509|NCT03010228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33724908|NCT04558931|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After confirmation of the eligibility criteria, patients will be randomly assigned in a 1:1 ratio to one of the two treatment arms:~Isatuximab in combination with CellProtect (ISA/CellProtect experimental arm), or Isatuximab (ISA, control arm).~Randomization will be at diagnosis and before the start of the treatment for patients eligible for SCT. Treatment administration will start within 100 days from AST date.~Patients will be treated until disease progression (max 3 years), unacceptable adverse event (AE), patient's decision to stop the study treatment, death or any other reasons, whichever occurs first.~Closing of randomization will occur after a total of approximately 60 patients have been randomized.~After randomisation, patients in experimental arm will donate starting material for the production of the IMP.~Manufacturing of CellProtect is promptly initiated for patients randomised to the active IMP arm A."||||
33724909|NCT05141721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807035|NCT05184062|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33807036|NCT06226155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33807037|NCT02358005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035510|NCT04163614|RANDOMIZED|PARALLEL||TREATMENT||NONE||Active Control Participants will be managed in entirety by their treating nephrologists The intradialytic blood pressure slope (IBPS) group will have their target weight adjusted each month by study investigator based on recent intradialytic blood pressure slopes||||
34035511|NCT01768377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34035512|NCT03936036|||COHORT||RETROSPECTIVE|||||||
34035513|NCT00183547|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035514|NCT01186237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035515|NCT02522689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035516|NCT04777227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34035517|NCT06313541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035518|NCT05318027|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035519|NCT04713605|||COHORT||PROSPECTIVE|||||||
34035520|NCT04820725|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34035521|NCT00450437|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34035522|NCT05951413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035523|NCT05030792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035524|NCT04455867|||COHORT||PROSPECTIVE|||||||
34035525|NCT03347110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035526|NCT02813915|||COHORT||PROSPECTIVE|||||||
34035527|NCT02700217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035528|NCT00578201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035529|NCT00200863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035530|NCT06295172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Randomized, Evaluator-blind, Matched pairs, Prospective, Non inferiority, Confirmatory Study|f|f|f|t
34035531|NCT05140044|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|t|t|f
34035532|NCT01585090||PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34035533|NCT00451373|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34035534|NCT02044263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035535|NCT04840381|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34035536|NCT05521581|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||"Single Group Assignment~Women who had cesarean section in the institution were evaluated in terms of sample.~They were divided into two groups as criteria and random sampling. be an order obtained a random number table, capable of random sampling automatically by means of programs on websites by specifying a number. samples. Selection of intervention and control groups determined by tossing a coin. The sample number was determined as 83 women who had a total of 166 cesarean section in each of the intervention and control groups. Considering the data losses, 10% more was calculated and it was planned to conduct the research with a total of 182 women (91 women in the intervention group, 91 women in the control group)."|t|f|f|f
34035537|NCT05671341|||CASE_CONTROL||PROSPECTIVE|||||||
34035538|NCT04670328|||CASE_ONLY||RETROSPECTIVE|||||||
34035539|NCT04395820|||COHORT||PROSPECTIVE|||||||
34035540|NCT04535141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34035541|NCT06172868|||OTHER||CROSS_SECTIONAL|||||||
34035542|NCT01195896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035543|NCT02885779|||COHORT||PROSPECTIVE|||||||
34035544|NCT03816423|RANDOMIZED|PARALLEL||OTHER||NONE||"Primary purpose: assess and compare patient knowledge on prenatal genetic screening before and after a standard prenatal care visit compared to the addition of a pre-appointment educational video.~All participants will complete a 15-item questionnaire on prenatal genetic screening options at baseline and after routine prenatal care visit.~Participants randomized to the control group, will have a routine prenatal care appoinment, while the intervention group will watch a pre-appointment 4.5 minute educational video entitled How to decide about prenatal genetic testing."||||
34035545|NCT02236260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035546|NCT00352742|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035547|NCT04298944|||OTHER||CROSS_SECTIONAL|||||||
34035548|NCT03883321|||CASE_CONTROL||PROSPECTIVE|||||||
34035549|NCT00626353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109001|NCT05402072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessors, those performing data entry and analysis, and patients will be blinded to the treatment allocation.|All patients presenting to each clinical site's out-patient fracture clinics and/or sports medicine subspecialty clinics between ages of 18 and 5 years with a symptomatic chondral injury of the hip will be screened. There will be a Research Coordinator on hand during the initial phase of the surgery for each consented patient, where the surgeon will assess the final aspects of eligibility. If eligibility is confirmed, the Research Coordinator will randomize the patient using a centralized 24-hour online randomization system that will follow a randomization schedule in random block sizes of 4 and 8. The secure online randomization system will ensure concealment of the treatment allocation. If the surgeon deems intra-operatively that the subject does not meet the inclusion criteria, the surgeon will manage the lesion as per the normal standard of care and the subject's ineligibility will be recorded on the screening form.|t|f|f|t
34109002|NCT03598829|||COHORT||PROSPECTIVE|||||||
34109003|NCT05938946|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|This is a double-blinded, single ascending dose escalation design. After confirmation of eligibility, subjects will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for rest of the cohorts to receive the assigned dose of L608 or placebo|Randomized, Placebo-controlled, double-blinded, single ascending dose escalation|t|f|t|f
34109004|NCT00347971|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109005|NCT05870124|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035550|NCT03426111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multicenter, randomized,controlled and double-blind study with two parallel arms, placebo (normal endoscopy and lifestyle modification) or endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) and lifestyle modification.|t|f|t|f
34109006|NCT01245023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109007|NCT03888287|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The WatchRx is a smartwatch worn on the patient's wrist which receives alerts and notifications for medication administration scheduling as well as intervention messages from a App to the caregiver||||
34109008|NCT06023264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109009|NCT01978301|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109010|NCT03272321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34109011|NCT00085735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109012|NCT04720807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109013|NCT04512378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109014|NCT06267729|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
34109015|NCT05135754|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109016|NCT04649749|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109017|NCT04129021|NA|SINGLE_GROUP||OTHER||NONE||||||
33724910|NCT04914845|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||During dose escalation, patients will receive oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle, and the first dose cohort will be 30 mg. Subsequent dose escalation cohorts, as well as a de-escalation cohort, will be administered. Dose escalation will continue until the MTD is determined. The MTD is defined as the highest dose at which ≤1 patient experiences a DLT in Cycle 1. A RP2D equal to or less than the MTD will be declared and used for the Dose Expansion Phase, if conducted.||||
34035551|NCT02514486|||COHORT||PROSPECTIVE|||||||
34035552|NCT01199939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035553|NCT00596791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035554|NCT05717972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035555|NCT03352674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035556|NCT03498612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035557|NCT06498518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149676|NCT03031067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A matched-case analysis was developed: 10 HOPE-ECD livers and kidneys, HOPE-L and -K groups, were matched 1:3 with livers and kidneys preserved with static cold storage (SCS), SCS-L and -K groups respectively.||||
33724911|NCT03599050|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33724912|NCT03031093|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33724913|NCT02203487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33724914|NCT00942396|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724915|NCT06114147|NA|SINGLE_GROUP||OTHER||NONE||prospective cross sectional study||||
33724916|NCT05845879|||COHORT||RETROSPECTIVE|||||||
33724917|NCT01540708|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724918|NCT02270164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33724919|NCT00549562||SEQUENTIAL||TREATMENT||NONE||||||
34109018|NCT03403179|NA|SINGLE_GROUP||OTHER||NONE||This study is a single center, open-label, outpatient clinical trial with no randomization or blinding. The Barcelona Functional Remediation for Bipolar Disorder (FR) Program will be tested over a 21-week period using 30 participants split into two equal cohorts. The study will evaluate the feasibility and preliminary efficacy of the intervention.||||
34109019|NCT03845036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized controlled clinical trial|f|f|f|t
34109020|NCT05000788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109021|NCT04362644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109022|NCT02790736|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34109023|NCT06637293|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||stepped wedge randomization|f|f|f|t
34109024|NCT05328622|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will receive daily text messages and incentives for medical adherence. Recruitment will occur on a rolling basis, with participants completing the protocol in multiple waves.||||
34109025|NCT05050669|||CASE_ONLY||PROSPECTIVE|||||||
34109026|NCT06589934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109027|NCT06640010|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109028|NCT02248493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109029|NCT06259812|||OTHER||RETROSPECTIVE|||||||
34109030|NCT06230341|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Descriptive study||||
34109031|NCT00830336|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34109032|NCT01673919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109033|NCT02955082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109034|NCT06132204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807038|NCT00885313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807039|NCT02788994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807040|NCT05765331|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33807041|NCT01478594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807042|NCT02508441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109035|NCT05085847|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34109036|NCT06225544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomised controlled trial with parallel arms of placebo versus study drug (lumasiran). With a 1:1 ratio between the two groups.|t|t|t|t
34109037|NCT01661387|||CASE_ONLY||PROSPECTIVE|||||||
34109038|NCT05910554|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Metformin capsules will be encapsulated by the Investigational Drug Services to blind study participants and providers, as well study personnel.||t|t|t|t
34109039|NCT05426083|||OTHER||PROSPECTIVE|||||||
34109040|NCT02233569|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109041|NCT05771155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109042|NCT04501120|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109043|NCT02614248|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109044|NCT04812483|RANDOMIZED|PARALLEL||TREATMENT||NONE|The laboratory team will be kept blinded regarding information about response or non-response of patients.|Randomized study evaluating the immunomodulatory effects of eltrombopag versus standard high-dose (HD) DXM therapy (1:1) in newly diagnosed ITP.||||
33807043|NCT00001349|||OTHER||OTHER|||||||
33807044|NCT03944694|||COHORT||PROSPECTIVE|||||||
33807045|NCT01808352|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807046|NCT04366024|||CASE_ONLY||RETROSPECTIVE|||||||
33807047|NCT04065399|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1 will employ an accelerated titration design. The dose escalation will follow a modified Fibonacci sequence.||||
33807048|NCT02944123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-labeled||f|f|f|t
33807049|NCT01439906|||COHORT||PROSPECTIVE|||||||
33807050|NCT02432898|||COHORT||PROSPECTIVE|||||||
33807051|NCT03510052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807052|NCT03369457|||CASE_CONTROL||PROSPECTIVE|||||||
33807053|NCT03629171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807054|NCT04276506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807055|NCT02561195|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33807056|NCT02195232|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33807057|NCT01534546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807058|NCT04125641|||COHORT||PROSPECTIVE|||||||
33807059|NCT03041233|||CASE_ONLY||PROSPECTIVE|||||||
33807060|NCT06117891|||COHORT||PROSPECTIVE|||||||
33807061|NCT06038747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial design. Allocation ratio of 1:1.||||
33807062|NCT03214172|||COHORT||RETROSPECTIVE|||||||
33807063|NCT00739934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807064|NCT04896736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33807065|NCT06687148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109045|NCT06038175|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|"The clinician performing the vHIT will be blinded to the result of the CT scan before entering their report.~The neurotologist reviewing the results of vHIT testing will be blinded to the patient's presentation, neurologic testing, and CT scan results.~the clinician performing the vHIT and the neurotologist reviewing the results of vHIT testing are both members of the Study Team."||f|f|t|f
34109046|NCT05521269|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE||This study consists of single-ascending dose (SAD), food effect, and multiple-ascending dose (MAD) parts.|t|f|t|f
34109047|NCT06426394|||COHORT||PROSPECTIVE|||||||
34109048|NCT05312658|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||1:1 randomized controlled trial|f|f|t|t
34109049|NCT06645041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109050|NCT00864279|RANDOMIZED|CROSSOVER||||NONE||||||
34109051|NCT04418154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109052|NCT04540471|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Block randomisation was implemented (block size = 4). A random number generator was used to generate random numbers, and all participants were subsequently given an MP3 player.|an assessor blinded, randomized, controlled, parallel group trial.|t|t|t|t
34109053|NCT03661021|||CASE_CONTROL||PROSPECTIVE|||||||
34109054|NCT06638489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109055|NCT06114628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109056|NCT05392751|NA|SINGLE_GROUP||TREATMENT||NONE||EA-2353 will be administered to all subjects during this study. It will be administered as 4 weekly intravitreal injections in the Study Eye.||||
34109057|NCT01565759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34109058|NCT00511199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33724920|NCT03409926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724921|NCT06047353|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33724922|NCT03539523|||OTHER||OTHER|||||||
33724923|NCT05577676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients of CTS for at least 04 weeks will be selected. Informed written consent will be taken. Data will be collected by face-to-face interview. Total 62 samples will then be randomly allocated into two groups. One group will receive 5 ml of normal saline and another group will receive 5 ml combination of triamcinolone, lidocaine \& normal saline. Both group will also receive Gabapentin, B vitamin, static wrist splint overnight, tendon gliding exercises and ADL advices. After taking all aseptic measures, a 23-gauze needle will be placed between transverse carpal ligament \& median nerve where 3 ml fluid is given and then, at below the median nerve where another 2 ml fluid is injected. The patients will be kept in a sitting position and observed for 10 to 15 minutes before discharge.|t|f|f|f
34109059|NCT00044785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109060|NCT05662722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|triple (care provider, evaluator and outcome assessor)|clinical random assignment|t|f|t|t
34109061|NCT06244823|NA|SINGLE_GROUP||TREATMENT||NONE|Given that the efficacy of Fremanezumab has been established in the pivotal trials and due to sample-size reasons, we chose an open-label study. However, in order to avoid biases as much as possible, we will blind clinical data to the imaging analysts. Patients, clinicians involved in the Fremanezumab administration and data analysts cannot be blind to the information.|The present study is an open-label, controlled-trial, single-blind trial analyzing brain changes measured by dMRI and fMRI in patients with high frequency episodic migraine and chronic migraine will be treated with Fremanezumab, 12 weeks after treatment.||||
34109062|NCT03558126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149677|NCT02447809|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33724924|NCT02732483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724925|NCT00435877|||||PROSPECTIVE|||||||
33724926|NCT06363656|||COHORT||PROSPECTIVE|||||||
33724927|NCT03355586|||COHORT||PROSPECTIVE|||||||
33724928|NCT05468437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a wait-list control study. Individuals in the immediate treatment group will receive the intervention in the first 3 months, followed by a 3 month durability phase. The delayed treatment group will receive the intervention in the second 3 month period.||||
33724929|NCT03899376|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomized open-label clinical trial||||
33724930|NCT01960946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33724931|NCT02319031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724932|NCT05896553|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|f
33724933|NCT02234414|||COHORT||PROSPECTIVE|||||||
33724934|NCT01016535|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33724935|NCT03841734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724936|NCT01569958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724937|NCT02646176|||COHORT||PROSPECTIVE|||||||
33724938|NCT02680028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724939|NCT01012011|||COHORT||PROSPECTIVE|||||||
33724940|NCT04630951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724941|NCT02979145|||CASE_ONLY||PROSPECTIVE|||||||
33724942|NCT05840146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109063|NCT06232954|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|In exception of the data management personnel responsible for coordinating the manufacture and distribution of the Mossie-GO and independent statistician preparing the Data Safety and Monitoring Board (DSMB) report, all study staff will remain blinded to the household treatment allocation, until the completion of data collection and the locking of the database at the end of the study. Unblinded study staff will have no role in study implementation or outcome assessment.|Cluster-randomised placebo-controlled trial|t|t|t|f
34109064|NCT00003053|RANDOMIZED|||TREATMENT||||||||
34109065|NCT06643273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34109066|NCT04419987|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109067|NCT06569914|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109068|NCT04606290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109069|NCT02652052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109070|NCT03991728|||COHORT||PROSPECTIVE|||||||
34109071|NCT04770285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109072|NCT00174629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724943|NCT04338048|||OTHER||OTHER|||||||
33724944|NCT03455660|||COHORT||RETROSPECTIVE|||||||
33724945|NCT02578654|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33724946|NCT01324349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33724947|NCT06047912|||OTHER||PROSPECTIVE|||||||
33724948|NCT02374645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724949|NCT06067945|||OTHER||PROSPECTIVE|||||||
33724950|NCT05173649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither subjects nor the investigator who is assessing the patient are aware of the treatment assignment until the end of the study||t|f|f|t
33807066|NCT04456413|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807067|NCT05078775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838084|NCT00446888|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33838085|NCT03444896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109073|NCT03174067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109074|NCT03648892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34109075|NCT06498648|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109076|NCT05149872|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34109077|NCT04017208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34109078|NCT05507047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109079|NCT04639791|||CASE_ONLY||PROSPECTIVE|||||||
34109080|NCT01231945|||||PROSPECTIVE|||||||
34109081|NCT04139304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724951|NCT00539578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724952|NCT02311439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838086|NCT02693197|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33838087|NCT01762904|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33838088|NCT05757557|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33838089|NCT05304455|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33838090|NCT00364377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838091|NCT03581604|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient group consisting of patients labeled as penicillin allergic.||||
34109082|NCT03315026|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II study investigating the symptomatic and cytokine response to an anti-IL-6 chimeric monoclonal antibody (siltuximab) during the acute phase of autologous stem cell transplantation (ASCT) in older individuals with multiple myeloma (MM) and systemic AL amyloidosis (AL).||||
34109083|NCT05488795|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped Wedge Cluster Randomized Design. Each practice suite represents a cluster. All eight suites begin in the control group and then cross over (one-way) to the intervention group at one of three randomly assigned time periods, ensuring that all suites eventually receive implementation of TB-HBPM.||||
34109084|NCT02599831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109085|NCT05399433|NA|SINGLE_GROUP||OTHER||NONE||||||
34109086|NCT05462262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|blinded endpoint||f|f|f|t
34109087|NCT04868357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34109088|NCT04201873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109089|NCT05721079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109090|NCT05848817|||COHORT||PROSPECTIVE|||||||
34109091|NCT03770611|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|"Patient Blinding: Patients in automated peritoneal dialysis will be blinded to the intervention they will receive. Evaluator Blinding: The principal investigator and the Doctorate program student will be blinded to the intervention that patients will receive (probiotic, prebiotic, symbiotic or placebo).~Care providers will be blinded to the intervention groups."|Parallel assignment, patients in automated peritoneal dialysis will be randomly assigned to one of the four intervention groups: probiotic, prebiotic, symbiotic and placebo|t|t|t|f
34109092|NCT04972604|||COHORT||PROSPECTIVE|||||||
34109093|NCT06644664|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blinded to their randomization category (absolute risks, relative risks, or control)||t|f|f|f
34109094|NCT06351371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109095|NCT06186518|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The study will be conducted in the pediatric clinic of a training and research hospital. Initially, control group data will be gathered through the routine peripheral intravenous catheter placement practices within the service. Subsequently, data for the experimental group will be collected using the PİKSEÇ application.||||
34109096|NCT00432965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109097|NCT06639334|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109098|NCT06266351|||OTHER||PROSPECTIVE|||||||
34109099|NCT02251041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109100|NCT01163942|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109101|NCT06639919|||CASE_CONTROL||PROSPECTIVE|||||||
34109102|NCT06268249|||COHORT||RETROSPECTIVE|||||||
34109103|NCT06043011|||COHORT||PROSPECTIVE|||||||
34109104|NCT04345354|||CASE_CONTROL||PROSPECTIVE|||||||
34109105|NCT06112275|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109106|NCT05119335|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose escalation sequential; Phase 2 dose expansion randomized to 2 dosage levels||||
34109107|NCT06571097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109108|NCT02249520|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109109|NCT04869527|||CASE_CONTROL||PROSPECTIVE|||||||
34109110|NCT03413995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724953|NCT02449174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|frozen intestinal bacteria from a healthy donor given by retention enema or lyophilized intestinal bacteria given orally in capsules for therapy in subjects with recurrent C. difficile associated diarrhea (RCDAD)|Allocation: Randomized Endpoints: Safety, preliminary efficacy in preventing future bouts of CDAD and improvement in intestinal flora diversity Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment|f|f|f|t
33724954|NCT00004078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724955|NCT00387478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33724956|NCT03448185|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Subjects and investigative team (except for statistician) are blinded to omega-3 vs olive oil placebo. Subjects and investigators are aware of exercise modality. Outcomes assessors are blinded to all aspects of subject randomization.|2x2 factorial design. Subjects are randomized to aerobic exercise or yoga as well as high dose omega-3 fatty acids or olive oil placebo.|t|f|t|t
33724957|NCT02066467|||COHORT||PROSPECTIVE|||||||
34109111|NCT05299320|||CASE_CONTROL||PROSPECTIVE|||||||
34109112|NCT04427189|||COHORT||PROSPECTIVE|||||||
34109113|NCT06675669|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33724958|NCT05451979|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Randomized crossover study design.||||
33724959|NCT04773444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33724960|NCT03829748|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33724961|NCT04901494|||COHORT||RETROSPECTIVE|||||||
33724962|NCT03511612|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33724963|NCT03626714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724964|NCT00537381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724965|NCT01860755|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33724966|NCT00998543|||COHORT||PROSPECTIVE|||||||
33724967|NCT00149916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724968|NCT04848935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724969|NCT00070265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724970|NCT01316276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724971|NCT01216475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109114|NCT05860985|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109115|NCT05774041|||COHORT||PROSPECTIVE|||||||
34149678|NCT05088668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researchers involved in measuring outcomes will not be aware of treatment allocation.||f|f|f|t
34149679|NCT06267638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149680|NCT03847909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149681|NCT05591716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149682|NCT00189501|||||PROSPECTIVE|||||||
34149683|NCT03764267|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34149684|NCT05565768|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34149685|NCT00530920||PARALLEL||TREATMENT||||||||
34109116|NCT05615883|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Pre/post intervention, two-arms, sequential study. Patients with newly diagnose of melanoma are eligible.The study will enroll a total of 20 patients (10 in the AEP and 10 in the CEP), who will be enrolled approximately in 12-13 months.The first series of patients will be assigned to the Acute Exercise Program (AEP group), the second series to the Chronic Exercise Program (CEP group). The final endpoint is to verify whether short-term physical exercise can represent a feasible and safe tool for re-setting antitumor immunity in early melanoma patients. Investigators will analyze how the acute physical exercise modifies systemic immunity and biochemical/metabolic parameters. Specifically, Investigators will verify whether the exercise will modify:1 the immunological profiling of blood including frequency and function of MDSC, together with the concomitant status of antitumor immunity; 2 blood concentration of biochemical and metabolic parameters related to physical exercise and immunity||||
34109117|NCT05902442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109118|NCT05231915|NA|SINGLE_GROUP||SCREENING||NONE||||||
34109119|NCT05148338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109120|NCT00400322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34109121|NCT06638697|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34109122|NCT06296225|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109123|NCT06630130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109124|NCT05687578|||COHORT||PROSPECTIVE|||||||
34109125|NCT04026737|||COHORT||PROSPECTIVE|||||||
34109126|NCT02556047|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
34109127|NCT03751982|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|The phase alignment of the treatment is set in software and not revealed to participant or experimenter. Order of treatment is randomized and counterbalanced.|Within subjects comparison of two effective treatments. Order of treatment is randomized and counterbalanced.|t|t|t|t
34109128|NCT04933708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Those that provide care for patients on the labor floor will not know if they have had access to labor podcasts or not.|"Pregnant patients between 28w0d - 36w0d will be randomized to one of the following study arms upon enrollment. Patients will be approached after 20 weeks for consent and randomized after they reach 28 weeks. The study will be done in an intent-to-treat fashion. Due to the nature of the study, blinding will not be possible.~Study Arms~1. Labor Podcast Group~2. Usual Teaching"|f|t|f|f
34109129|NCT05115773|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Randomization was performed by a computer-generated random sorting sequence|randomized controlled, single-blind, split-mouth clinical trial|t|f|f|f
34109130|NCT00238329||||TREATMENT||NONE||||||
34109131|NCT04714255|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34109132|NCT05549622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||24 older adults (\> 65y) will be randomized to consume a high- or low-soluble fiber diet|t|t|t|t
34109133|NCT06633991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants did not know whether they were allocated to the control or the experimental condition|control vs experiemntal condition|t|f|f|f
34109134|NCT00000709||||TREATMENT||NONE||||||
34109135|NCT05821205|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Providers or staff (n=240) participating in screening (e.g., nurses) and/or intervention delivery (e.g., social workers, child life, community health workers) will be consented/enrolled in the MRT, each person randomized weekly with equal probability to one of three ES or control and also randomized monthly to receive personalized feedback or no personalized feedback.||||
34109136|NCT03282994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109137|NCT06546618|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34109138|NCT06335212|||COHORT||CROSS_SECTIONAL|||||||
34109139|NCT04731597|||CASE_CONTROL||RETROSPECTIVE|||||||
34109140|NCT06637800|NA|SINGLE_GROUP||TREATMENT||NONE|Unblinded|||||
34109141|NCT02615613|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34109142|NCT01969058|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|Participants were randomized 2:1 to Isotretinoin arm and no study treatment arm. The primary endpoints were compared between the 2 study arms.||||
34109143|NCT04516434|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34109144|NCT06252584|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Treatment||||
34109145|NCT06540976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34109146|NCT06160167|||COHORT||RETROSPECTIVE|||||||
34109147|NCT01283672|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34109148|NCT04347109|||CASE_CONTROL||PROSPECTIVE|||||||
34109149|NCT05974176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109150|NCT06639399|||CASE_CONTROL||RETROSPECTIVE|||||||
34109151|NCT06621277|||OTHER||OTHER|||||||
34109152|NCT06644365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34109153|NCT03934619|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study will be a prospective study using a convenient cohort of 55 adult patients, who was using NIV, to pilot the effectiveness of the Dolores One to improve verbal communication. There will be no randomization and no control group. The design is a pretest / posttest mixed method in which the Easy of Communication Scale and the Intelligibility section of the Frenchay Dysarthria Assessment will be administered at base line and repeated once the Dolores One has been set up on the patient.||||
34109154|NCT01311258|||COHORT||PROSPECTIVE|||||||
34109155|NCT06639191|NA|SEQUENTIAL||TREATMENT||NONE||This is a prospective, open-label, first-in-human Phase 1 dose-finding trial. Patients will be included in consective dosing cohorts, with both increasing doses of radioactivitity (Lutetium-177) and the CD44v6-targeted antibody (AKIR001)||||
34109156|NCT05670704|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34109157|NCT05815498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33838092|NCT05722639|||COHORT||CROSS_SECTIONAL|||||||
33838093|NCT03832218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838094|NCT03263247|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33838095|NCT02178930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838096|NCT03255005|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Group A: treatment J0 + Diet 1 year Group B: Diet 6 months - Treatment - Diet 1 year||||
34109158|NCT03578315|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149686|NCT05792306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open label, two arm clinical study||||
34149687|NCT02189707|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34149688|NCT02145871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109159|NCT05781503|RANDOMIZED|PARALLEL||TREATMENT||NONE||This pilot study will employ a convergent mixed methods (quantitative and qualitative data collected concurrently and the findings combined), two-arm parallel RCT (participants randomly assigned to either one intervention or control group), open-label (participants and research team aware of random assignment) design with 1:1 allocation (roughly equal number of participants in each study arm) embedded within a Community Based Participatory Action Research framework. Twenty young people will be allocated to the intervention group (portable rent subsidies + identity capital intervention), while 20 will be allocated to the control group (portable rent subsidies only). Participants in the intervention group (n = 20) will receive 12 months of: portable rent subsidies, engage in a co-designed (with youth who have experienced homelessness) leadership guide, and be assigned a coach (one coach/10 youth).||||
34109160|NCT00000884|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34109161|NCT00179686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109162|NCT06342609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Double blind Placebo controlled|t|t|t|f
34109163|NCT04974476|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109164|NCT00809588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109165|NCT05398848|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34109166|NCT06560892|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109167|NCT06325631|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34109168|NCT03464201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109169|NCT02103179|||CASE_CONTROL||RETROSPECTIVE|||||||
34109170|NCT05007132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open, multicenter Phase II trial with two parallel arms||||
34109171|NCT01092650|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34109172|NCT04147286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, randomized, placebo-controlled trial|This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.|t|t|t|t
34109173|NCT04048837|||COHORT||PROSPECTIVE|||||||
34109174|NCT03190954|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34109175|NCT06611306|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomised interventional multi-centre feasibility trial in patients with brain metastases from breast cancer receiving dose escalated internal PTV (DE-iPTV) radiotherapy||||
33838097|NCT04593953|RANDOMIZED|PARALLEL||OTHER||TRIPLE|To minimize assessment bias, patients and evaluators (nurse and physiotherapist) will be unaware of the intervention group. Only the investigator, who will include the patient and will realize the procedure, will know the arm of randomization.||t|t|f|t
34109176|NCT05607576|NA|SINGLE_GROUP||OTHER||NONE|This study is not blinded|||||
33838098|NCT05590442|||COHORT||PROSPECTIVE|||||||
34109177|NCT04632654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34109178|NCT06638814|||COHORT||PROSPECTIVE|||||||
34109179|NCT06643104|||OTHER||PROSPECTIVE|||||||
34109180|NCT06240286|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34109181|NCT03630679|||COHORT||PROSPECTIVE|||||||
34109182|NCT02990767|||COHORT||PROSPECTIVE|||||||
34109183|NCT06640621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109184|NCT06539195|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109185|NCT06639984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109186|NCT04630769|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is conducted in two consecutive stages with 5 cohorts. A minimum of 28 days must separate each cohort. Within a 3 patient cohort, a minimum of 14 days must separate the first and second patient. Stage 1 Step 1 uses a fast-track design (1 patient per cohort) with a minimum of 28 days between each patient until one of the following: a) 1st occurrence of a pre-defined adverse event at which point the study moves to Step 2. The cohort size increases from 1 to 3 patients with 2 additional patients added. Escalation in Step 2 continues until the 1st DLT at which point Stage 2 continual reassessment method (CRM) is activated. If Cohort 5 is completed with 10 patients enrolled at the MTD without a DLT, Stage 2 (CRM) is not used. b) The 1st occurrence of a DLT the study moves directly to Stage 2 (CRM) and Step 2 is not used. c) Cohort 5 is completed without a pre-defined AE or a DLT - neither Step 2 nor Stage 2 is used if a total of 10 patients are enrolled in Cohort 5.||||
34109187|NCT05450978|||COHORT||PROSPECTIVE|||||||
34109188|NCT04981912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109189|NCT04046419|||OTHER||PROSPECTIVE|||||||
34109190|NCT00060775|||COHORT||PROSPECTIVE|||||||
34109191|NCT01519479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109192|NCT06476509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109193|NCT03420820|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34109194|NCT02586194|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109195|NCT06639243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109196|NCT02184013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109197|NCT05727501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109198|NCT06131112|||CASE_CONTROL||PROSPECTIVE|||||||
34109199|NCT06512558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109200|NCT05908760|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Male and female NOH patients (n=28) will be recruited from the Calgary Autonomic Clinic. Participants will complete the following two randomized head-up tilt tests (HUT):~* Room Air: Participants will breathe room air while supine and during a 5-min HUT test~* CO2 rebreathing: Participants will breathe with the rebreather in the supine position until CO2 levels increase between 5-10mmHg. Once CO2 levels are increased, participants will be tilted upright, and will continue to breathe with the rebreather during a 5-min HUT test"||||
34109201|NCT02738619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109202|NCT06535100|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109203|NCT06550388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109204|NCT05059327|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is a multi-center, randomized, double-blind, placebo-controlled, 30-week, cross-over (Part A) followed by a 52-week open-label extension (OLE) (Part B) study.|t|f|t|f
34109205|NCT02941055|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34109206|NCT02264756|||COHORT||PROSPECTIVE|||||||
34109207|NCT06568575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807068|NCT03658109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible patients will undergo current standard enhanced recovery protocol (ERP) gyn-oncology protocol. All patients will receive intrathecal morphine as part of the existing ERP. They will then be randomized to receive; either lidocaine infusion, regional anesthesia truncal block (quadratus lumborum block), or intrathecal morphine alone. Patients will be randomized into either lidocaine (group 1), QL block (group 2), or intrathecal opioid alone (group 3) groups. There will be blinding of the patient and personnel involved in data collection, and patients will undergo either a posterior QL block with local anesthetic (group 2) or simulated QL block (groups 1 and 3; subcutaneous local anesthetic only) pre-operatively. All patients will also undergo a loading dose of lidocaine (groups 1) or saline (group 2 and 3) followed by continuous lidocaine infusion in the lidocaine group (group 1). Primary and secondary endpoints will be measured post-operatively.||t|f|f|t
34109208|NCT04467255|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are assigned to two groups in parallel for the duration of the study||||
34035558|NCT03757819|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This study employed a double-blind, sham-controlled, parallel-randomized crossover design. Each participant attended three sessions. In the first session, participants were consented and completed the Patient-Determined Disease State and Fatigue Severity Scale questionnaires. Then, after a counter-balanced randomization into BEFORE or DURING groups, the participants completed a 6-Minute Walk Test for baseline/familiarization purposes. The second and third sessions involved brain stimulation or sham stimulation either before or during a 6-Minute Walk Test, depending on group assignment. The brain stimulation was randomly assigned to either session two or three, and sham stimulation was performed in the other session.|t|f|t|f
34109209|NCT05723263|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||hybrid effectiveness-implementation study design||||
33807069|NCT06637358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807070|NCT01214759|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807071|NCT00765544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035559|NCT02689765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807072|NCT01082900|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|t|f|f
33807073|NCT00326196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807074|NCT02659124|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109210|NCT06519526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807075|NCT06699537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double(Participant,Investigator)||t|f|t|f
33807076|NCT05590559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807077|NCT01943305|RANDOMIZED|PARALLEL||||NONE||||||
33807078|NCT02720432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807079|NCT06699485|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807080|NCT01915914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807081|NCT00753545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807082|NCT03177941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||2 Group Random Clinical Trial|f|f|t|f
33807083|NCT04300764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33807084|NCT00143286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807085|NCT05909449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807086|NCT06698497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035560|NCT00102219|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035561|NCT00853008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035562|NCT06316544|||COHORT||OTHER|||||||
34035563|NCT04636476|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential Assignment Prospective cohort study||||
34035564|NCT04671589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34035565|NCT01777282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035566|NCT05589077|NA|SINGLE_GROUP||OTHER||NONE||All participants will complete the same survey and engage in the same intervention.||||
34035567|NCT05834556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035568|NCT04680169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035569|NCT04122521|||COHORT||PROSPECTIVE|||||||
34035570|NCT03867240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035571|NCT06196437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035572|NCT05740111|NA|SINGLE_GROUP||SCREENING||NONE||||||
34035573|NCT02138877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035574|NCT00991887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035575|NCT02639715|||COHORT||RETROSPECTIVE|||||||
34035576|NCT06139146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035577|NCT06362954|||OTHER||CROSS_SECTIONAL|||||||
34035578|NCT00005095|||OTHER||PROSPECTIVE|||||||
34035579|NCT02165449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035580|NCT04293393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035581|NCT05754255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035582|NCT05609513|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped wedge cluster randomized trial. Sixteen clinics will be randomized to the order in which they will begin intervention, with two clinics initiating the intervention every 2 months after a 2-month run-in period. Sites will be additionally randomized to receive the HTN-BASIC package only or the enhanced HTN-PLUS intervention. We will collect clinic data during the control period, run-in period and the intervention phase.||||
34035583|NCT00002881|RANDOMIZED|||TREATMENT||||||||
34035584|NCT01665001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035585|NCT06443489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035586|NCT03526068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035587|NCT01809353|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035588|NCT04526015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34035589|NCT01445782|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34035590|NCT03230578|||OTHER||CROSS_SECTIONAL|||||||
34035591|NCT00086229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035592|NCT04703153|||COHORT||PROSPECTIVE|||||||
34035593|NCT05289505|||OTHER||PROSPECTIVE|||||||
34035594|NCT01803698|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34035595|NCT03238521|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035596|NCT01834833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109211|NCT00153933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035597|NCT02976129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807087|NCT02397707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807088|NCT04358107|||COHORT||RETROSPECTIVE|||||||
33807089|NCT01913093|||CASE_CONTROL||PROSPECTIVE|||||||
33807090|NCT02992652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035598|NCT04807920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035599|NCT02291237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035600|NCT02623725|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|An observer-blind procedure was followed for the injection of the CYD Dengue Vaccine booster or placebo. Neither the observer Investigator, nor the Sponsor, nor the participant/participants' parent(s)/legally acceptable representative(s) knew which product was administered.||t|t|t|t
34035601|NCT01433471|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34035602|NCT01755533|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035603|NCT02569879|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34035604|NCT01776827|||COHORT||RETROSPECTIVE|||||||
34035605|NCT02026401|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34035606|NCT01121861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34035607|NCT03477006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035608|NCT04654273|||COHORT||PROSPECTIVE|||||||
34035609|NCT01480869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035610|NCT03035188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035611|NCT00210028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035612|NCT05496439|||COHORT||PROSPECTIVE|||||||
34035613|NCT03523520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each participant will be receiving one injection and tablets which have been randomly assigned.|Participants will be assigned to one of three groups i. Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection ii. Methylnaltrexone 12mg subcutaneous injection + placebo sugar tablets iii. Naloxegol oral tablets (total 25 mg) + subcutaneous water injection|t|t|t|f
34035614|NCT02772133|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035615|NCT02445716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035616|NCT06155344|||COHORT||PROSPECTIVE|||||||
34035617|NCT03058627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035618|NCT06000657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035619|NCT05435261|||COHORT||PROSPECTIVE|||||||
34035620|NCT01184651|||COHORT||CROSS_SECTIONAL|||||||
34035621|NCT04241588|||CASE_CONTROL||PROSPECTIVE|||||||
34035622|NCT02409927|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participant underwent 7 metabolic day (1-day visit), each visit separate by a minimum of 3 day||||
34035623|NCT03398564|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34035624|NCT01938638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035625|NCT00226577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035626|NCT00300807|RANDOMIZED|||TREATMENT||DOUBLE||||||
34035627|NCT03236090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo (we evaluate the probiotic Vivomixx® vs placebo as adjunctive in addition to the standard of care)|"Decompensated patients with cirrhosis:~1. Outpatients with refractory ascites (substudy 1) (n=20)~2. Patients hospitalized because bacterial infection (substudy 2) (n=30)"|t|f|f|f
34035628|NCT03295292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035629|NCT05554601|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE||behavioral economics approach (gamification with social incentives)|f|f|t|t
34035630|NCT00458744||||TREATMENT||||||||
34035631|NCT03433573|NA|SINGLE_GROUP||OTHER||NONE||||||
34035632|NCT03657797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035633|NCT06206304|||COHORT||PROSPECTIVE|||||||
34035634|NCT03370640|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035635|NCT00218712|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34035636|NCT00245518|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34035637|NCT01742312|||COHORT||PROSPECTIVE|||||||
34035638|NCT00254592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035639|NCT03036657|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34035640|NCT04753216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035641|NCT06145841|||CASE_CONTROL||PROSPECTIVE|||||||
34035642|NCT01012726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035643|NCT00001000||||TREATMENT||DOUBLE||||||
34035644|NCT03011086|||COHORT||PROSPECTIVE|||||||
34035645|NCT00699816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035646|NCT01736592|NA|SINGLE_GROUP||OTHER||NONE||||||
34035647|NCT02018419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109212|NCT05495126|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33807091|NCT05141513|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single institution, single arm pilot study to evaluate the safety and feasibility of implementing IORT in patients with non-metastatic Pancreatic adenocarcinoma (PDAC) who have been treated with neoadjuvant chemotherapy and SBRT and who are undergoing surgical resection.||||
34109213|NCT06474013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109214|NCT01218321|||CASE_CONTROL||PROSPECTIVE|||||||
34109215|NCT03960177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109216|NCT05087342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109217|NCT01112956|||COHORT||PROSPECTIVE|||||||
34109218|NCT04933422|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109219|NCT06570616|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|CPAP device screen is taped to hide CPAP level and mode|Crossover Assignment|t|f|f|f
34109220|NCT03774121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109221|NCT06100731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Randomization (stratified by PTSD status and medication use) into active or shame tDCS. Double blind software will be used to ensure that the experimenter and the subject remain blind during task administration.|Subjects will be randomly assigned to receive Active (real) or Sham (placebo) transcranial direct current stimulation.|t|f|t|f
34109222|NCT06077279|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109223|NCT06645015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33807092|NCT04784585|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Participants and investigators will not need to be masked to condition, as conditions are randomized sequentially according to a pre-established algorithm.|The interventional model is a micro-randomized trial, which involves sequential (within-subjects) randomization at individual moments of high lapse risk as determined by the investigators' previously-validated predictive machine learning algorithm. In prior work, participants are at high lapse risk \~7x/week and so the investigators anticipate that randomization will occur \>100 times for each participant over the 6-month study period.||||
33807093|NCT04250636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109224|NCT05694611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807094|NCT05106842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Medical history, demographics, and clinical scores will be collected by the selected and blinded investigator (on corresponding case reporting forms). Patients will be informed of the blinding procedure. They should not unblind investigator during the whole follow-up.|This prospective case-control clinical study is randomized 1:1 between rehabilitation with hydrotherapy and land-based rehabilitation.|f|f|f|t
33807095|NCT04097535|||COHORT||PROSPECTIVE|||||||
33807096|NCT03946956|RANDOMIZED|FACTORIAL||SCREENING||NONE||2 x factorial design regarding attendance rate to cardiovacular screening||||
33807097|NCT05144659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|2 (Participant, Investigator) 2 masking (Participant, Investigator)|68 pediatric patients will be randomly divided (using non-transparent closed envelope randomization method) into two equal groups, each will include 34 patients; Group A will undergo double-faced preputial onlay island flap and Group B will undergo transverse inner preputial onlay island flap.|t|f|t|f
33807098|NCT04842253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807099|NCT06699966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807100|NCT03769415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807101|NCT01439685|||CASE_CONTROL|||||||||
33807102|NCT06357299|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2 factorial design||||
33807103|NCT05150873|||CASE_ONLY||RETROSPECTIVE|||||||
34109225|NCT05970367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised controlled trial (RCT)|f|f|f|t
34109226|NCT03901365|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34109227|NCT03189719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109228|NCT05881291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109229|NCT06637956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109230|NCT05702450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109231|NCT04720001|||CASE_ONLY||PROSPECTIVE|||||||
34109232|NCT03812848|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Quasi experimental study (separate sample pre-test post-test design)||||
34109233|NCT06570486|||COHORT||CROSS_SECTIONAL|||||||
34109234|NCT06008795|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Sequential Parallel Comparison Design|t|t|t|t
34109235|NCT04606472|NA|SEQUENTIAL||TREATMENT||NONE||||||
34109236|NCT03449576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34109237|NCT03162211|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34109238|NCT06119477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109239|NCT06642636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109240|NCT06223269|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, interventional, controlled, randomized, multicenter clinical trial. Each patient represents both the experimental and control group, to be evaluated in isolated but comparable settings. The use of an intra-patient comparator allows for a matched control to eliminate significant underlying differences. Treatment assignment will be randomized to receive either realSKIN or a surgically harvested autograft.||||
34109241|NCT04134936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109242|NCT04025957|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109243|NCT05268367|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109244|NCT00833703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109245|NCT06641427|||OTHER||CROSS_SECTIONAL|||||||
34109246|NCT04254627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109247|NCT06008080|||COHORT||PROSPECTIVE|||||||
34109248|NCT02322840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109249|NCT06569407|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"According to the randomization table, nurses who volunteered to participate in the study will be assigned to the experimental and control groups by the single-blinding method. Nurses will be assigned to the experimental and control groups. The randomization process was performed by a statistician other than the researcher and communicated to the researcher. A computer-aided simple randomization method was used to ensure a homogeneous distribution of the gro. For this purpose, 70 sets were created using the functions on the internet address https://www.random.org/integer-sets."|The study is planned as an open-label, randomized and controlled experimental research.|t|f|f|f
34035648|NCT05717569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34035649|NCT06240078|||OTHER||CROSS_SECTIONAL|||||||
34035650|NCT03692715|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients will undergo central randomization, which will be accessed by phone or internet. Un-blinding will occur only once statistical analysis is complete.||t|t|t|t
34035651|NCT01487967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035652|NCT04376658|||COHORT||PROSPECTIVE|||||||
34035653|NCT03855774|NA|SINGLE_GROUP||SCREENING||NONE||Epidemiological and genetic screening of a population||||
34035654|NCT01291355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035655|NCT04965311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035656|NCT03262428|||OTHER||PROSPECTIVE|||||||
34035657|NCT05405816|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|Due to the double-blind nature of the study, the outcome of the impedance procedure will not be known by the surgeon and the patient until the end of the study. Only the researcher will know the result of the impedance process.|Measurement of the change in gastroesophageal reflux disease after laparoscopic sleeve gastrectomy with 24-hour multichannel intraluminal impedance and pH-meter. It is aimed to determine the effect of surgery in a single group.|t|t|f|f
34035658|NCT05307783|||COHORT||PROSPECTIVE|||||||
33807104|NCT06014372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035659|NCT02205073|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33807105|NCT03069391|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover RCT: participants are randomly assigned to start with one form of intervention and then crossover to another form of the intervention.||||
33807106|NCT04539015|||COHORT||PROSPECTIVE|||||||
33838099|NCT01930097|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838100|NCT04830553|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838101|NCT05071586|NA|SINGLE_GROUP||OTHER||NONE||||||
33838102|NCT05416047|||COHORT||PROSPECTIVE|||||||
34035660|NCT01062425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035661|NCT03975894|RANDOMIZED|PARALLEL||TREATMENT||NONE||Regular prophylactic blood transfusion given every 6-10 weeks during pregnancy to maintain a HbS% of \<30%||||
34035662|NCT06346301|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple baseline case series design: Patients wil be randomized to different lengths of baseline period and the effectiveness of the treatment is tested by comparing means and slopes of daily reported schema- or core beliefs and OCD and BDD severity,||||
34035663|NCT02385474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035664|NCT00190762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035665|NCT00942084|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035666|NCT00503698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035667|NCT04810208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035668|NCT00004919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035669|NCT02101125||PARALLEL||||NONE||||||
34035670|NCT01103180|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035671|NCT04717752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035672|NCT01987778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035673|NCT04256772|||COHORT||RETROSPECTIVE|||||||
34035674|NCT06570694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will be allocated to condition via a random number generator and will be provided with trial instructions pertaining only to their allocated condition. Trial participants will not be provided with any information relating to the remaining three conditions in the trial until the 1-month follow-up period has elapsed.~The member of the research team responsible for analysing the data will additionally be blinded to the allocation of participants. This will be anonymised for them in the dataset without accompanying explanatory label."|"Four arm parallel-group trial:~(1) intervention condition (therapist support); (2) intervention condition (no therapist support); (3) Partial intervention (daily sampling and emotion valuation questions); (4) Control group (only daily sampling questions)."|t|f|f|f
34035675|NCT02959125|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035676|NCT03307252|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34035677|NCT03766295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035678|NCT02613247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035679|NCT04731727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035680|NCT02367469|||CASE_CONTROL||PROSPECTIVE|||||||
34035681|NCT03304405|||COHORT||PROSPECTIVE|||||||
34035682|NCT01381965|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34035683|NCT03667040|RANDOMIZED|PARALLEL||TREATMENT||NONE||150 participants will be recruited; 75 participants into the intervention group and 75 into the control group. There will three visits, baseline and follow-up at 30 days and 60 days.||||
34035684|NCT01838369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035685|NCT03093259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind Treatment|Double-blind, placebo-controlled, randomized study|t|t|t|t
34035686|NCT02162277|||COHORT||PROSPECTIVE|||||||
34109250|NCT06564480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109251|NCT06643429|||CASE_CONTROL||PROSPECTIVE|||||||
34109252|NCT04144517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109253|NCT03009292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109254|NCT06637397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109255|NCT06101485|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33807107|NCT03451422|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||This phase 1b study is a double-blind, placebo controlled multiple ascending dose (MAD) study to evaluate the safety and tolerability of Efavaleukin Alfa in participants with systemic lupus erythematosus (SLE) and to determine the recommended phase 2 dose(s). Participants will be treated for a total of 12 weeks followed by a 6 week follow-up period. Five dosing cohorts are planned for the study.|t|t|t|f
33807108|NCT01507675|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33807109|NCT00009932||||TREATMENT||||||||
34109256|NCT06643091|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter open label and single-arm phase II trial||||
34109257|NCT05947903|||OTHER||CROSS_SECTIONAL|||||||
34109258|NCT06013852|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109259|NCT06644781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109260|NCT06589999|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109261|NCT02188056|||COHORT||PROSPECTIVE|||||||
34109262|NCT06640972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Sponsor||t|t|t|f
34109263|NCT01166698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34109264|NCT03592264|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109265|NCT04236154|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The investigator will incrementally increase the exercise prescription for groups of patients.||||
34109266|NCT01352455|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109267|NCT04387669|||COHORT||PROSPECTIVE|||||||
34109268|NCT05417906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109269|NCT04593277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34109270|NCT02364284|||COHORT||RETROSPECTIVE|||||||
34109271|NCT05385978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Parallel Assignment Randomized, double-blind, placebo-controlled, parallel-group proof-of-concept efficacy and safety study|t|t|t|t
34109272|NCT03889535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109273|NCT05546866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109274|NCT02871440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34109275|NCT00088946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807110|NCT00528216|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33807111|NCT02079649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807112|NCT01203943|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33807113|NCT06698718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807114|NCT06698809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109276|NCT00684294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109277|NCT02722785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109278|NCT06053372|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109279|NCT06570564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109280|NCT02683993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109281|NCT06640309|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective randomized controlled interventional parallel open label study.||||
34109282|NCT05848297|||COHORT||PROSPECTIVE|||||||
34109283|NCT04280380|||COHORT||PROSPECTIVE|||||||
34109284|NCT05860244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109285|NCT03409198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label||||
34109286|NCT04469686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109287|NCT02170519|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109288|NCT06399094|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109289|NCT04787809|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to a treatment (digital ACT-informed intervention) or control group.||||
34109290|NCT06154265|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||(1) Default TEE: Where the TEE probe is placed after going under general anesthesia and a breathing tube is placed. TEE issued to take pictures of your heart before and after the CABG surgery. The TEE probe will remain in place throughout the surgery. (2) As-Needed TEE: Where the TEE probe is placed only in situations where a surgeon requires information that can only be obtained by ultrasound imaging of the heart.||||
34109291|NCT06461494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109292|NCT04925024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109293|NCT05631119|||COHORT||PROSPECTIVE|||||||
34109294|NCT04035486|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34109295|NCT03287986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109296|NCT04491344|||COHORT||CROSS_SECTIONAL|||||||
34109297|NCT05581511|||COHORT||PROSPECTIVE|||||||
34109298|NCT01950520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34109299|NCT00835042|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34109300|NCT06643390|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Double blinded||f|f|f|t
34149689|NCT01595191|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807115|NCT05808205|||CASE_ONLY||PROSPECTIVE|||||||
33807116|NCT01084941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807117|NCT00729209|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33807118|NCT02897206|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33807119|NCT02669173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807120|NCT03875313|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33807121|NCT00864006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035687|NCT04290364|||COHORT||OTHER|||||||
34035688|NCT05324657|||COHORT||RETROSPECTIVE|||||||
34035689|NCT01735461|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34035690|NCT02767167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035691|NCT05782933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035692|NCT04647084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34035693|NCT04821076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Energy balance group vs. energy restriction|t|t|t|f
34035694|NCT04843917|||COHORT||PROSPECTIVE|||||||
34035695|NCT04427761|||COHORT||PROSPECTIVE|||||||
34035696|NCT02345980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035697|NCT03820128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34035698|NCT04482764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035699|NCT02005289|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035700|NCT00107848|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34035701|NCT06143280|||COHORT||RETROSPECTIVE|||||||
34035702|NCT03209271|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Unblinded (unable to blind subjects)|Crossover study of 2 different temperatures of crystalloid fluid bolus.||||
34035703|NCT04549350|||OTHER||CROSS_SECTIONAL|||||||
34035704|NCT02432638|||CASE_ONLY||PROSPECTIVE|||||||
34035705|NCT05203770|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035706|NCT04261946|||CASE_ONLY||RETROSPECTIVE|||||||
34035707|NCT00304252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34035708|NCT02284477|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34035709|NCT06269991|||COHORT||CROSS_SECTIONAL|||||||
34035710|NCT05339633|NA|SINGLE_GROUP||OTHER||NONE||||||
34035711|NCT02300064|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34035712|NCT01639417|||COHORT||CROSS_SECTIONAL|||||||
34035713|NCT06110273|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34035714|NCT03261414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035715|NCT05444452|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035716|NCT05368324|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|All participants will be evaluated by an independent evaluator who will be blinded. The statistician will also be blinded, will not participate in the evaluation or intervention. For analysis it will only be revealed as group A or group B. Only when the analyzes have been completed will the exact nature of the groups be revealed.|Randomized clinical trial, with a control group on the waiting list.|f|f|t|t
34035717|NCT03120182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded study|randomized, placebo controlled, double blinded study|t|t|t|t
34035718|NCT01690117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035719|NCT01236716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035720|NCT02977715|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34035721|NCT02398266|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34035722|NCT01133730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035723|NCT04867005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035724|NCT04924192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035725|NCT02658253|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34035726|NCT01276340|||COHORT||PROSPECTIVE|||||||
34035727|NCT05370625|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34035728|NCT00631046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34035729|NCT03130972|||COHORT||RETROSPECTIVE|||||||
34035730|NCT04090125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035731|NCT06196892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035732|NCT00542633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035733|NCT00521794|||COHORT||PROSPECTIVE|||||||
34035734|NCT05409729|||COHORT||RETROSPECTIVE|||||||
34035735|NCT00695344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035736|NCT01881477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035737|NCT00535210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035738|NCT01057511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035739|NCT00282646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intraarterial administration of BM-MNC or placebo|t|f|t|f
34035740|NCT00347646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109301|NCT05020808|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blind (participant)|Block randomized control trial, parallel group design|t|f|f|f
34109302|NCT03960736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and the patient will be blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for VATS under general anesthesia will be included in the study. Patients with a history of bleeding diathesis, receiving anticoagulant treatment, known local anesthetics and opioid allergy, infection of the skin at the site of the needle puncture, pregnancy or lactation, and patients who do not accept the procedure will be excluded from the study. Randomization will be achieved using a randomizing computer program. Patients will be randomly divided into two groups (Group A = ESP group, Group B = TEA group) including 25 patients each, before entering the operating room.|t|f|f|t
34109303|NCT04278924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807122|NCT05362942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109304|NCT04697823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|t|f|f
34109305|NCT04161482|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"The initial cohort (Cohort 1) will receive 80 mg (10 mL) with a bi-phasic delivery profile over 5 hours.~Cohort 2a will evaluate a 2-hour infusion and Cohort 2b will be a bi-phasic delivery over 2 hours.~Cohorts 3 and 4 will deliver the Furoscix over one hour and 30 minutes, respectively."||||
34109306|NCT05636176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109307|NCT02304159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109308|NCT05077072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109309|NCT04003519|||COHORT||PROSPECTIVE|||||||
34109310|NCT02284893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109311|NCT06289764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34109312|NCT05498090|NON_RANDOMIZED|PARALLEL||OTHER||NONE||2 arms in study: cross-sectional (cases v. controls); interventional (cases only: pre and post fenofibrate intervention)||||
34109313|NCT05616910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109314|NCT03847012|NA|SINGLE_GROUP||OTHER||NONE||||||
34109315|NCT06585384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109316|NCT05996471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109317|NCT03439449|||COHORT||PROSPECTIVE|||||||
34109318|NCT01790191|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34109319|NCT06331949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34109320|NCT01066910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109321|NCT06362629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109322|NCT06105255|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109323|NCT00086515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109324|NCT02072057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109325|NCT05110261|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34109326|NCT05689099|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109327|NCT04118920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-arm prospective open-label interventional study|t|f|t|f
33724972|NCT03096327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"To ensure double-blind allocation, the sponsor, who is not directly involved in clinical team will use a random number sequence generated by a computer software to allocate the participant to either the treatment or placebo group. Patients who will be randomized to the treatment group will receive 10 mg montelukast. Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.~Both products will be packaged in identical plastic bottles identifiable only by the patient allocation number. Patient will be asked to take one montelukast each day. Acceptable compliance will be defined as at least taking medication at least 21 days. The patients will be instructed to leave the remaining tablets in bottle so that they would be counted later."|Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Two arm Parallel Assignment Masking: Double Blind Primary Purpose: Prevention|t|t|f|f
34109328|NCT05836909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34109329|NCT05143814|||COHORT||PROSPECTIVE|||||||
34109330|NCT06561087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109331|NCT03331354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blinded to conditions|Patients will be randomly assigned to either a distance learning program (COMPASS) or basic vocational services.|f|f|f|t
34109332|NCT01189760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109333|NCT04958096|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33724973|NCT02149173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33724974|NCT04623918|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Masking description: The study was a double-blind, randomized controlled trial of; (1) iron-biofortified rice (IR68144-2B-2-2-3), compared to (2) a commercially available variety of rice (C4), with the intervention randomized at the individual level. Administrators, participants, research staff (i.e. responsible for daily data collection and preparation of rice for all meals, assessment of outcomes), and laboratory staff were blinded to the intervention group.||t|f|t|t
33724975|NCT01204476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724976|NCT03993197|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33724977|NCT00399009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724978|NCT06406673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33724979|NCT02292290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724980|NCT01170806|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34109334|NCT06589128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33807123|NCT06550804|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group receives intervention and one groups receives routine care only.||||
33724981|NCT05164237|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33807124|NCT05599815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807125|NCT01617707|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33807126|NCT00003984||||TREATMENT||||||||
33807127|NCT02025504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33807128|NCT01566890|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34035741|NCT05011838|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are kept unaware of the intervention implementation and its assignment in one commune or another. Furthermore, participants will be randomly recruited in both communes.|Two deprived Communes of the city have been selected as intervention and control arms. All the intervention components will be implemented in Commune 2, located in the northeast of Medellin. Commune 6, located northwest of Medellin, has been selected as the control area to deliver routine care. Two representative population surveys of adults aged 35 years or older will be undertaken in the intervention and the control Communes two years apart, one before the intervention implementation and the other after. The surveys will randomly include different individuals. The main outcomes assessed will be the gaps in hypertension diagnosis, treatment, follow-up and control.|t|f|f|f
33724982|NCT04902755|||COHORT||PROSPECTIVE|||||||
33724983|NCT01433679|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33724984|NCT05064605|||COHORT||PROSPECTIVE|||||||
33724985|NCT02695745|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33724986|NCT06167109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035742|NCT06286501|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data will be collected using individual study codes for participants. Study codes do not reveal which group the participant has belonged to.|Randomized clinical study on a CE-approved medical device|f|f|f|t
34035743|NCT06067841|NA|SEQUENTIAL||TREATMENT||NONE||||||
34035744|NCT00474890|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34035745|NCT03754010|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34035746|NCT01881061|||CASE_CONTROL||PROSPECTIVE|||||||
34035747|NCT02690831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035748|NCT01987440|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34035749|NCT01416636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035750|NCT04990453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34035751|NCT04185155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34035752|NCT03632499|||COHORT||PROSPECTIVE|||||||
34035753|NCT02566772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035754|NCT05383495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III, multicentre, open-label, randomized, three-arm, adaptive trial||||
34035755|NCT00029003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035756|NCT05757128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035757|NCT03937362|||COHORT||PROSPECTIVE|||||||
34035758|NCT00768586|||COHORT||PROSPECTIVE|||||||
34035759|NCT00697632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035760|NCT00673699|||CASE_CONTROL||PROSPECTIVE|||||||
34035761|NCT03926429|||COHORT||RETROSPECTIVE|||||||
34035762|NCT02521883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035763|NCT02023983|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035764|NCT01983267|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035765|NCT01769248|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34035766|NCT00469430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035767|NCT01436240|||CASE_ONLY||PROSPECTIVE|||||||
34035768|NCT05354037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035769|NCT03160378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035770|NCT03000231|||CASE_CONTROL||PROSPECTIVE|||||||
34035771|NCT02348736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035772|NCT04154683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035773|NCT01342471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035774|NCT03063008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035775|NCT00122382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035776|NCT04430062|||CASE_ONLY||RETROSPECTIVE|||||||
34035777|NCT00477737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34035778|NCT03585569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035779|NCT04845867|||COHORT||PROSPECTIVE|||||||
34035780|NCT03103438|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34109335|NCT05166499|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109336|NCT06645002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109337|NCT06437366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33724987|NCT01170182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33724988|NCT02443142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724989|NCT01424423|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33724990|NCT00588822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724991|NCT00477672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33724992|NCT00138307|||||PROSPECTIVE|||||||
33724993|NCT03610659|||OTHER||PROSPECTIVE|||||||
33724994|NCT03168152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33724995|NCT05805787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized, pretest-posttest control group study.|t|f|f|f
33724996|NCT01442415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33724997|NCT03720912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor will be masked to the participant's assignment. Others (participant, care provider, investigator) cannot be masked to assignment because one group will be receiving the behavioral health intervention and the other will not be receiving anything additional.||f|f|f|t
33724998|NCT04486846|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33724999|NCT04699682|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33725000|NCT04421911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725001|NCT05184374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725002|NCT03869450|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035781|NCT03710408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To achieve assessor/care provider blinding, all participants will receive a sham needle (opposite of the randomization). This will not pierce the skin but just lay on top of the skin. Both the randomized and the sham needle will be covered by non-woven swabs before placement of the dressing. Both the active and the sham device is connected to an infusion set. The infusion tubes will be tangled at the top, just below the roller ball and drop counter. The entanglement will be covered by opaque dressing. This way it cannot be know which infusions tube is connected to the fluid bag, while it is still possible to control the infusion speed.||f|t|t|t
34035782|NCT02691923|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33807129|NCT00238485|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807130|NCT06685809|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33807131|NCT01883193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109338|NCT06638255|RANDOMIZED|CROSSOVER||OTHER||SINGLE||To test the hypothesis, a crossover clinical-experimental protocol has been designed. Clinical and physiological data will be collected from patients with ARDS undergoing protective mechanical ventilation. Patients will be randomly allocated to two clinical protocols validated for setting PEEP levels: ARDSNet (low PEEP) and LOV (high PEEP), each for a duration of 12 hours. Clinical and physiological data, advanced ultrasound assessments, organ dysfunction markers, and a complete respiratory and hemodynamic assessment will be collected. Both PEEP strategies (Low vs High PEEP) will be applied to each patient included in the study. The PEEP setting will be selected through a computerized randomization system at the beginning of the study.|f|f|f|t
34035783|NCT06575205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34109339|NCT04309682|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34109340|NCT06069713|NA|SINGLE_GROUP||PREVENTION||NONE||Conduct a cross-sectional online survey with a nationally representative probability-based sample of adults, ages 18-65 to assess consumer perceptions of 55 documented advertisements about CBD. Participants will be randomly assigned to 1 of 11 panels that each contain 5 advertisements about CBD.||||
34109341|NCT04588883|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109342|NCT05576337|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34109343|NCT00500331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807132|NCT01186224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109344|NCT00901914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109345|NCT05918029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109346|NCT06641518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109347|NCT06213480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a triple-blind study. Participants, the research staff, the PI, and the biostatistician will be all blinded. A university staff person who does not belong to the research team or the funding agency but has been CITI certified and approved by the IRB will hold the key of the assignment key.|Sixty participants will be randomized into one of two groups: 1) 3-day antibiotic plus placebo for 3 months, or 2) 3-day antibiotic plus symbiotic for 3 months.|t|t|t|t
33807133|NCT04157894|||COHORT||PROSPECTIVE|||||||
33807134|NCT02491489|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807135|NCT02663804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33807136|NCT04839809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807137|NCT01500200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807138|NCT06533865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807139|NCT05717140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807140|NCT02310581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807141|NCT04130932|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34109348|NCT02376010|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial, with blinded randomization to one of two groups.||||
34109349|NCT01220583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109350|NCT06541678|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|No masking|This is a Phase 1, open-label, fixed-sequence, 3-period study||||
34109351|NCT06571227|||CASE_ONLY||PROSPECTIVE|||||||
34109352|NCT04822883|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participants will not be informed of their dose cohort or of the sequence of placebo or active capsules.|Four dose cohorts will be enrolled sequentially.|t|f|f|f
34109353|NCT05090865|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109354|NCT03984578|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109355|NCT05309291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109356|NCT06644677|||COHORT||PROSPECTIVE|||||||
34109357|NCT06407232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109358|NCT00159445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109359|NCT06027905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109360|NCT05360303|||COHORT||PROSPECTIVE|||||||
34109361|NCT03921567|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34109362|NCT06099002|||COHORT||CROSS_SECTIONAL|||||||
33807142|NCT03435367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807143|NCT02620449|NA|SINGLE_GROUP||OTHER||NONE||||||
33807144|NCT03725020|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34109363|NCT00780598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109364|NCT04799535|||CASE_CONTROL||PROSPECTIVE|||||||
34109365|NCT06280989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||kinesio taping and myofascial release technique|t|f|f|t
34109366|NCT06116123|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34109367|NCT06309628|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109368|NCT06644326|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34109369|NCT06640829|||COHORT||CROSS_SECTIONAL|||||||
34109370|NCT05964699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigators, and outcome assessors are unaware of the assigned interventions. The care provider will know at this time of procedure what site will receive the intervention and what site will be the control site.|Split mouth study|t|t|t|t
34109371|NCT00200746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109372|NCT04130347|||CASE_ONLY||RETROSPECTIVE|||||||
34109373|NCT06498479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109374|NCT00835354|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34109375|NCT04331522|||COHORT||PROSPECTIVE|||||||
34109376|NCT06051357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109377|NCT06343974|||CASE_CONTROL||PROSPECTIVE|||||||
34109378|NCT05919563|||COHORT||PROSPECTIVE|||||||
34109379|NCT06641830|||COHORT||PROSPECTIVE|||||||
34109380|NCT05195840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109381|NCT00748605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109382|NCT06320782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data analysis and interpretation stage will be carried out by the study coordinator, who will not have knowledge about the allocation of participants among the intervention groups|4 interventions distributed in a randomized manner among 4 different groups|f|f|f|t
34109383|NCT03374956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109384|NCT03329131|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34109385|NCT06641414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807145|NCT05376982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33807146|NCT06648785|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot/feasibility design with tolerability and toxicity as primary endpoints and response as exploratory endpoint. Standard drug dosages utilized with no dose finding component to this study.||||
33807147|NCT04516226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807148|NCT01428869|||||RETROSPECTIVE|||||||
33807149|NCT03407144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807150|NCT04698382|||COHORT||RETROSPECTIVE|||||||
33807151|NCT01801800|||COHORT||PROSPECTIVE|||||||
33807152|NCT06133530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33807153|NCT00289666|||CASE_ONLY||PROSPECTIVE|||||||
33807154|NCT01644032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807155|NCT00127582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807156|NCT00937287|||||PROSPECTIVE|||||||
33807157|NCT00653172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807158|NCT00073372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807159|NCT03356236|||COHORT||PROSPECTIVE|||||||
33807160|NCT02198300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109386|NCT04709523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34109387|NCT03196778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109388|NCT01275378|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34109389|NCT05818254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109390|NCT05263167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109391|NCT05311423|||COHORT||PROSPECTIVE|||||||
34109392|NCT04116489|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109393|NCT02033408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34109394|NCT04991142|||COHORT||CROSS_SECTIONAL|||||||
34109395|NCT00980798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109396|NCT03266783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109397|NCT06253312|||COHORT||RETROSPECTIVE|||||||
34109398|NCT00879398|||CASE_ONLY||PROSPECTIVE|||||||
34109399|NCT02048540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807161|NCT06509607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807162|NCT05803109|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Double-blind study||f|f|f|t
33807163|NCT02861820|||CASE_CONTROL||PROSPECTIVE|||||||
33807164|NCT02842957|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807165|NCT01782105|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807166|NCT00738400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807167|NCT03454256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807168|NCT02912247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035784|NCT03492515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807169|NCT06475521|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||"Randomised, controlled, double-blinded, multi-country, multi-center~Including Breastfed reference group"|t|t|t|t
34035785|NCT05810532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33807170|NCT00759798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807171|NCT03646266|RANDOMIZED|PARALLEL||TREATMENT||NONE||pilot randomized controlled trial (RCT)||||
33807172|NCT03601715|RANDOMIZED|CROSSOVER||OTHER||SINGLE||A randomized single blind, crossover experimental study.|f|f|f|t
34035786|NCT01290588|||COHORT||OTHER|||||||
34035787|NCT01853215|NA|SINGLE_GROUP||||NONE||||||
34035788|NCT00322712|||COHORT||RETROSPECTIVE|||||||
34035789|NCT02864576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34035790|NCT02069639|||CASE_ONLY||RETROSPECTIVE|||||||
34035791|NCT05144529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035792|NCT04947592|||CASE_CONTROL||PROSPECTIVE|||||||
34035793|NCT01274702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035794|NCT04061174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035795|NCT02308930|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34035796|NCT05346198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035797|NCT04633005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035798|NCT00220389|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34035799|NCT05173181|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators have only one group of patients, (Adult with isolated fracture distal ulna). The investigators will do a single intervention, (Fixation with flexible intramedullary nail).||||
34035800|NCT01349192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Although this is an open-label study, the PIs and operational study team will remain blinded to the study arm assignments of the aggregate study population and will not view aggregate study results by study arm until after database lock.||f|f|t|f
34035801|NCT02353286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035802|NCT00326391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34035803|NCT00837837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035804|NCT00959478|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34035805|NCT05723094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34035806|NCT03473444|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34035807|NCT02579473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035808|NCT01588067|||COHORT||PROSPECTIVE|||||||
34109400|NCT00037765|||COHORT||PROSPECTIVE|||||||
34109401|NCT06022705|||CASE_ONLY||PROSPECTIVE|||||||
34109402|NCT01889251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109403|NCT05613127|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34109404|NCT03499743|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The investigators who will insert the IUDs and will collect important data, the patients and the statistician who will perform the final data analysis will be blinded to the group allocations||t|t|t|t
34109405|NCT06385353|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34109406|NCT04947098|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34109407|NCT03082547|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109408|NCT04501718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109409|NCT06639906|||CASE_CONTROL||PROSPECTIVE|||||||
34149690|NCT03459053|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Research coordinator will conduct the randomization and all information will be deidentified. Investigator will not know who is in which group.||f|f|t|t
34149691|NCT05644275|||COHORT||RETROSPECTIVE|||||||
34149692|NCT03442296|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34149693|NCT05632783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study. Matching placebo tablets, indistinguishable from the test drug 800 mg chondroitin sulfate tablets|Multicenter, Randomized, Double-blind|t|t|t|t
34035809|NCT01075789|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34035810|NCT01845441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34035811|NCT03733769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035812|NCT00128635||||TREATMENT||NONE||||||
34035813|NCT00459563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035814|NCT02826629|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34035815|NCT03194919|RANDOMIZED|PARALLEL||PREVENTION||NONE|"The recruitment procedure and the treatment is fully automated and delivered by web, e-mail and SMS-textmessages - i.e., the participant is not contacted by any care providers, investigators or assessors during recruitment or treatment~- and data are collected by means of web-based questionnaires."|Participants receive one out of two versions of a web-based smoking cessation program. Either with or without the option of negotiating and re-negotiating the quit date.||||
34035816|NCT00764205|||CASE_CONTROL||PROSPECTIVE|||||||
34035817|NCT03613181|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization to experimental arm and comparator arm||||
34035818|NCT02436343|||COHORT||PROSPECTIVE|||||||
34035819|NCT04830631|||COHORT||PROSPECTIVE|||||||
34035820|NCT03569410|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label prospective clinical trial.||||
34035821|NCT01946828|NA|SINGLE_GROUP||||NONE||||||
34035822|NCT03627975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035823|NCT01417793|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035824|NCT01910493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34035825|NCT01750801|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34149694|NCT05618418|||COHORT||PROSPECTIVE|||||||
34109410|NCT03517605|NA|SINGLE_GROUP||TREATMENT||NONE||An exercise program was performed by the Specialist Nurses in Rehabilitation Nursing, comprising the combination of the various components of the exercise: aerobic and recovery/stretching. The program will start in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. The evaluations will be performed during hospitalization, in phase I of cardiac rehabilitation, and one-month post-discharge, in the Nursing visits of follow-up (phase II of cardiac rehabilitation). Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min).||||
34109411|NCT02835105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109412|NCT03583294|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109413|NCT03884257|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|a single-blind masking will be implemented. The patient won't know which DCB he/she received.|The patients will be assigned at random to one of two treatment groups namely the Passeo-18 Lux or the IN.PACT Admiral treatment group.|t|f|f|f
34109414|NCT01383876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34109415|NCT02689557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109416|NCT04404153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109417|NCT06637722|||COHORT||PROSPECTIVE|||||||
34109418|NCT02624856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109419|NCT03085953|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34109420|NCT01128517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109421|NCT03840889|||COHORT||PROSPECTIVE|||||||
34109422|NCT06638775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34109423|NCT04463355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open-label, parallel trial with a control group and an intervention group.||||
34109424|NCT06645379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109425|NCT03087045|||COHORT||PROSPECTIVE|||||||
34109426|NCT04388228|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34109427|NCT04873557|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34109428|NCT06492928|||OTHER||PROSPECTIVE|||||||
34109429|NCT03579316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109430|NCT06193239|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants with and without suspicion of having lung cancer will all receive the same IMP||||
34109431|NCT05709327|NA|SINGLE_GROUP||OTHER||NONE||Single-arm observational study||||
34109432|NCT05158699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Masking will be achieved as much as possible. As there is an objective primary outcome, it will not be necessary to replace medicines by sham injections or placebo eye drops. Moreover, the ophthalmologist who performs the cataract surgery will not be blinded for treatment allocation of the subject. The study statistician, the data safety monitoring group, optometrists who perform the examinations (especially visual acuity) and observers who evaluate the examinations and OCTs will be masked when possible for treatment allocation.|A block randomization procedure will be followed to acquire equal number of subjects in every treatment group. Patients are randomly allocated to 1 of 4 treatment groups in a 1:1:1:1 ratio. The various study centres will be taken into account during randomization.|f|t|f|t
34109433|NCT05963984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109434|NCT02054728|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34109435|NCT05763641|||COHORT||PROSPECTIVE|||||||
34109436|NCT06640530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109437|NCT03073512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109438|NCT00400140|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34109439|NCT04925804|||COHORT||PROSPECTIVE|||||||
34109440|NCT06440837|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"To ensure allocation concealment, an external party using a third-party allocation approach will be employed. This involves using a research assistant to maintain allocation concealment. The list of eligible dormitories will be sent to a second research assistant, who will then carry out the sequence generation described above. Neither the researchers nor other research personnel will be aware of the specific dormitory group assignments."|The random sequence generation will be implemented at the cluster level rather than the individual level to prevent sample contamination. Dormitories meeting the eligibility criteria will be coded and randomly assigned to either the intervention group or the control group. The random assignment will be executed using computer-generated software on a research randomization website, with a 1:1 allocation ratio.|f|f|t|t
34109441|NCT06014801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807173|NCT04775810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838103|NCT05133492|NA|SINGLE_GROUP||TREATMENT||NONE||Population diagnosed with small to medium-sized (3.5-5.0cm) abdominal aortic aneurym.||||
33838104|NCT01614353|||COHORT||PROSPECTIVE|||||||
33838105|NCT03635203|||OTHER||RETROSPECTIVE|||||||
33838106|NCT03911934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcome assessor of the 13 months follow-up EQ5D data is blinded to participant allocation.|Randomized, parallel clinical trial with two arms. The participants are randomized to usual care or usual care plus polypharmacy intervention when they are referred to the geriatric outpatient clinic before the first visit. They stay in the assigned group until end of trial (after 13 months follow-up). Randomization is performed by the medical secretaries in the outpatient clinic in REDCap's randomization module and randomization is stratified on gender, age group (65-70 years, 71-80 years, \>80 years) and number of drugs (9-11 drugs, 12-16 drugs, \>16 drugs).|f|f|f|t
34109442|NCT01146821|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109443|NCT01931410|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34109444|NCT06626516|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1A: Single-arm combination therapy (tebentafusp-tebn with hepatic IE with GM-CSF), with the first cohort of six patients being enrolled in a safety lead in.~Part 1B: If the safety and preliminary efficacy in Part 1A are met, we will then proceed with a randomized phase II trial. 52 patients will be randomized in a 2:1 ratio to receive tebentafusp-tebn in combination with hepatic IE or tebentafusp-tebn alone Part 2: Single-arm, two-stage phase II trial of sequential TACE with BCNU followed by tebentafusp-tebn in 39 patients with higher liver tumor burden"||||
34109445|NCT01250327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109446|NCT06298058|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open, multi-dose increasing single and multiple dose study.||||
34109447|NCT04416958|||COHORT||PROSPECTIVE|||||||
34109448|NCT05050279|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34109449|NCT05583864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blinded|Two types of spinal cages will be evaluated against one another for patient outcomes. It is possible that a single patient may receive both cages, but outcomes will be radiographically assessed individually by cage.|t|t|t|f
34109450|NCT06594770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109451|NCT06569732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109452|NCT05316545|||OTHER||RETROSPECTIVE|||||||
34109453|NCT03379870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109454|NCT03170986|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109455|NCT00011635||||TREATMENT||||||||
34109456|NCT03809000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109457|NCT05987813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||FGID group, non-FGID group. Assigned to 2 hours of daily TENS usage||||
34109458|NCT00811850|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34109459|NCT03336606|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be stratified by tumor type and randomly assigned to a MEDI0562 administration schedule; initially 5 patients will enroll to each of two cohorts.||||
34109460|NCT01285232|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34109461|NCT06316570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109462|NCT06185751|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109463|NCT02721732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109464|NCT06270056|||CASE_ONLY||PROSPECTIVE|||||||
34109465|NCT05634174|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34109466|NCT04977349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34109467|NCT06298708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109468|NCT02135133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109469|NCT02852837|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109470|NCT06644131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
34109471|NCT00137449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109472|NCT06238973|RANDOMIZED|PARALLEL||SCREENING||SINGLE||The group to be designated as Group A will aim to maintain an average arterial pressure in the range of 50-57 mmHg. For Group B, the target is to keep the average arterial pressure within the range of 58-65 mmHg.|t|f|f|f
34109473|NCT06003504|RANDOMIZED|PARALLEL||OTHER||DOUBLE||This is a randomised controlled trial in which the allocation is done at the level of the individual participant.|f|f|t|t
34109474|NCT00111735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34109475|NCT04050839|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34109476|NCT03741855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109477|NCT06207019|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34109478|NCT04957472|||CASE_CROSSOVER||PROSPECTIVE|||||||
34109479|NCT05648812|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34109480|NCT00522379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109481|NCT05095285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34109482|NCT04946370|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the phase I portion of the study, patients will receive 225Ac-J591 at either 65 or 90 KBq/kg, in addition to pembrolizumab and ARPI. In the subsequent phase II portion of the study, patients will be randomized to receive 225Ac-J591 (at the dose determined in phase I) + ARPI and pembrolizumab or ARPI and pembrolizumab alone in a 1:1 ratio. Randomization will take into account prior receipt of ARPI, baseline PSMA imaging intensity, and presence of visceral metastasis.||||
34109483|NCT02154230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109484|NCT05691829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109485|NCT00240266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34109486|NCT01374854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109487|NCT03967600|||COHORT||PROSPECTIVE|||||||
34109488|NCT01143441|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109489|NCT04845347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomized using the minimization method. The study team will balance assignment to group based on the following baseline characteristics: baseline Structured Interview Guide For The Hamilton Depression Rating Scale (SIGH-SAD) score, maternal age, parity, and infant age.|t|f|t|t
34109490|NCT05516121|NA|SINGLE_GROUP||OTHER||NONE||||||
34109491|NCT00938574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109492|NCT05192070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which groups they belongs to||t|f|f|f
34109493|NCT05689112|||CASE_CONTROL||PROSPECTIVE|||||||
34109494|NCT02053155|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34109495|NCT00433186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109496|NCT06188741|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID||||
34109497|NCT04878185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109498|NCT06637748|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34109499|NCT05374798|NA|SINGLE_GROUP||OTHER||NONE||Participants will wear activity trackers (Garmin smartwatch) equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed The investigative team is not testing the Garmin smartwatch, but the use of EMA and HRV biofeedback as a mechanism to modulate alcohol use and IPV among couples.||||
34109500|NCT00738660||CROSSOVER||TREATMENT||NONE||||||
34109501|NCT04511494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Blinded randomisation process after a positive baseline peanut challenge (for both participants, care provider and investigator) by opaque envelops.~After the child is randomised to treatment or avoidance, everyone (particpant, care provider and investigator) know if the child is in the treatment or avoidance group."||t|t|t|f
34109502|NCT05810597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34109503|NCT03479528|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34109504|NCT06637631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109505|NCT03424733|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||Patients in both arms first take Tylenol and then take Tylenol in combination with Prednisone.||||
34109506|NCT04166747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention study with 2 parallel arms||||
34109507|NCT06028412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109508|NCT02117076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109509|NCT06565039|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a prospective, non-randomized, single-arm, multicenter study||||
34109510|NCT00245479|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109511|NCT04474873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109512|NCT01092897|||COHORT||PROSPECTIVE|||||||
34109513|NCT02553733|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34109514|NCT03662451|RANDOMIZED|PARALLEL||TREATMENT||NONE||Women are randomized to either robotic single site or multi site hysterectomy||||
34109515|NCT03966313|||COHORT||PROSPECTIVE|||||||
34109516|NCT06153108|||COHORT||PROSPECTIVE|||||||
33838107|NCT06224777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838108|NCT04697134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838109|NCT04286633|||COHORT||PROSPECTIVE|||||||
33838110|NCT04487470|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized cross-over study||||
33838111|NCT02794181|||COHORT||PROSPECTIVE|||||||
33838112|NCT00243906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838113|NCT00648999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035826|NCT00897650|||COHORT||PROSPECTIVE|||||||
33838114|NCT03143647|||CASE_CONTROL||PROSPECTIVE|||||||
34035827|NCT02286713|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34035828|NCT04629040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035829|NCT00876889|||OTHER||PROSPECTIVE|||||||
34035830|NCT00281281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035831|NCT01169350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035832|NCT01949415|||COHORT||PROSPECTIVE|||||||
34035833|NCT05577559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035834|NCT03646383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035835|NCT03573180|||CASE_ONLY||CROSS_SECTIONAL|||||||
34035836|NCT04720105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035837|NCT00402077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035838|NCT02545582|||COHORT||PROSPECTIVE|||||||
34035839|NCT00273182|||COHORT||PROSPECTIVE|||||||
34035840|NCT04573322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Lead-in: no masking. Randomized pilot: The participants, care providers, investigators, and outcomes assessors are masked. The pharmacist, unblinded clinical research associate, and unblinded study drug administrator are not masked.|Open-label, pharmacokinetic, pharmacodynamic, ascending dose, safety and tolerability lead-in Single-center, randomized, placebo-controlled, double-blind, adaptive, safety and efficacy pilot|t|t|t|t
34035841|NCT06331325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be unaware of the recruitment group. The allocation sequence will be contained within sequentially numbered, opaque, sealed packets that the patients will pull. According to the randomization table, the written number on the paper will allocate the patient to the intervention or control group.|Randomized clinical trial. Allocation Ratio: 1:1|t|f|f|t
34035842|NCT03608163|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|The subject and investigator will be blinded as to which study drug(s) participant is receiving first (Drug, Drug and Placebo combination, or Placebo).|This study is a combination of model types. In phase 1 of the study, non-diabetic participants who are susceptible to hypoglycemia-associated autonomic failure (HAAF) are identified. Only participants who are susceptible to HAAF are studied in the second and third phases. Thus, continuation of subjects identified in phase one into phase two and/or three studies follows a sequential model. The second phase follows a crossover design in which subjects receive naloxone or placebo nasal sprays in a randomized, double blinded fashion. In the third phase, subjects will receive either oral diazoxide or oral placebo (for diazoxide), in combination with naloxone nasal spray or placebo (for naloxone) nasal spray in a randomized, double blinded crossover design.|t|f|t|f
34035843|NCT01368653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035844|NCT05552820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34035845|NCT00020631||||SUPPORTIVE_CARE||||||||
34035846|NCT02475473|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34035847|NCT05410665|||CASE_ONLY||PROSPECTIVE|||||||
34035848|NCT02003404|||COHORT||PROSPECTIVE|||||||
34035849|NCT00908570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34035850|NCT00618111|RANDOMIZED|||TREATMENT||NONE||||||
34035851|NCT05845801|||OTHER||PROSPECTIVE|||||||
34035852|NCT05989464|||COHORT||PROSPECTIVE|||||||
34035853|NCT03258411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035854|NCT01550237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035855|NCT01558960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035856|NCT00955617|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34035857|NCT02526667|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34035858|NCT02163044|||OTHER||PROSPECTIVE|||||||
34035859|NCT06582654|||COHORT||PROSPECTIVE|||||||
34035860|NCT04358081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035861|NCT00197847|||DEFINED_POPULATION||PROSPECTIVE|||||||
34035862|NCT03751176|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned in a 3:2 ratio to receive FOLFIRI + panitumumab (Group A) or FOLFIRI alone (Group B). Randomization will be stratified by primary tumour location (left vs right).||||
34035863|NCT02876809|||COHORT||CROSS_SECTIONAL|||||||
34035864|NCT00882518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035865|NCT03246451|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34035866|NCT04135937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035867|NCT01477346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109517|NCT06587659|NA|SINGLE_GROUP||TREATMENT||NONE||Nonrandomized, open-label trial||||
34109518|NCT05975450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109519|NCT06134401|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34035868|NCT02273388|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34035869|NCT00834691|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34035870|NCT01366417|NA|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34035871|NCT01007305|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34035872|NCT01483703|||CASE_ONLY||CROSS_SECTIONAL|||||||
34035873|NCT06582004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34035874|NCT02126514|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34035875|NCT02009189|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34035876|NCT05241340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035877|NCT04711993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34035878|NCT01153815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035879|NCT03440229|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This is a randomized double-blind controlled feeding experiment.||t|t|t|t
34035880|NCT02763046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34035881|NCT00911833|||||PROSPECTIVE|||||||
34035882|NCT04504968|RANDOMIZED|PARALLEL||TREATMENT||NONE||he DIABFRAIL-LATAM is an open randomized clinical trial, with random allocation 1:1 by participants to Usual Care Group (UCG) or Intervention Group (IG)||||
34035883|NCT03359850|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34035884|NCT06468592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035885|NCT03173209|NA|SINGLE_GROUP||PREVENTION||NONE||A one-group (N 93) mixed-methods design using a pretest-posttest survey and qualitative analysis of written reﬂections was used to explore the meaning and outcomes of the Calm Moments Cards program.||||
34035886|NCT01506505|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34035887|NCT03648099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to avoid bias in assessing pain and fear, three midwives who were not involved in the study team, who worked in the hospital where the study was carried out and who did not know the groups of the participants administered the scales. The midwives who were involved in data collection during the study were trained by the researchers on the use of data collection tools.|a single-blind randomized controlled intervention trial|f|t|f|f
34035888|NCT00289848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035889|NCT05081037|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants randomized to both the control (Scheduled Care Group) and the intervention group (Wearable Care Group).||||
34035890|NCT01432067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035891|NCT04857528|||CASE_ONLY||PROSPECTIVE|||||||
34035892|NCT05486039|||COHORT||PROSPECTIVE|||||||
34035893|NCT03875508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035894|NCT03104192|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Two Arm Pilot Study||||
34035895|NCT05878275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single Blind|Longitudinal experimental design|f|f|t|t
34035896|NCT01200446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34035897|NCT01075438|||CASE_ONLY||PROSPECTIVE|||||||
34035898|NCT01813617|||COHORT||PROSPECTIVE|||||||
34035899|NCT02452606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035900|NCT04751812|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participant will be blinded to allocation arm. The anesthesia nurses, the anesthesiologist and the PACU-nurse will not be blinded to the intervention. The assistant nurse performing the postoperative pain assessments will be blinded to allocation group. Once the assistant nurse has performed the assessment the PACU-nurse will decide on treatment depending on allocation and specific instructions.||t|f|t|t
34035901|NCT02764255|||CASE_CONTROL||PROSPECTIVE|||||||
34035902|NCT04823325|||COHORT||PROSPECTIVE|||||||
34035903|NCT03364101|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34035904|NCT04242277|||COHORT||PROSPECTIVE|||||||
34035905|NCT02260661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035906|NCT03877380|||COHORT||OTHER|||||||
34035907|NCT03134248|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34035908|NCT03857477|||CASE_CONTROL||PROSPECTIVE|||||||
34035909|NCT02905058|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34035910|NCT03037593|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This will be a randomized single-center study with a target study group of 300 women. Women will be followed from enrollment through the remainder of their pregnancy||||
34035911|NCT02892045|||CASE_ONLY||PROSPECTIVE|||||||
34035912|NCT04593615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035913|NCT05610540|||COHORT||PROSPECTIVE|||||||
34035914|NCT05840055|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34035915|NCT03504319|||CASE_CONTROL||PROSPECTIVE|||||||
34035916|NCT04382729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34035917|NCT03266146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035918|NCT01269918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34035919|NCT00366431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34035920|NCT03497741|||COHORT||RETROSPECTIVE|||||||
34035921|NCT03309761|||COHORT||PROSPECTIVE|||||||
34035922|NCT04686955|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34035923|NCT02303457|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34035924|NCT04827693|||COHORT||PROSPECTIVE|||||||
34035925|NCT05719428|NA|SINGLE_GROUP||TREATMENT||NONE||"Patients NGS profile will be analysed with DRUID system to generate recommendations based on predicted efficacy. Patients with available archival tissue will have gene expression analysis performed to optimise DRUID recommendation. Patients will subsequently receive single agent therapy based on DRUID recommendations and criteria for therapy choice.~Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion."||||
34035926|NCT01138202|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34035927|NCT03076632|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Raw electromyography data assessed while masked to specific conditions.|Each subject will receive combinations of brain stimulation, cervical stimulation, or peripheral nerve stimulation, either with or without performing simultaneous hand exercises.|f|f|f|t
34109520|NCT01517152|||COHORT||PROSPECTIVE|||||||
34109521|NCT06526429|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34109522|NCT00032513|||FAMILY_BASED||PROSPECTIVE|||||||
34109523|NCT03631511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109524|NCT03979001|||COHORT||PROSPECTIVE|||||||
34035928|NCT05294679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In this study, evaluation researchers and drug administration researchers were set up. The whole process of the experiment was blind not only to the subjects, but also to the evaluation researchers.|Participants were randomly assigned 1:1 to receive intravenous ciprofol or propofol 1 hour before the start of treatment.|t|f|f|t
34109525|NCT06638853|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109526|NCT00525863|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34109527|NCT06557863|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34109528|NCT06625372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34109529|NCT06324409|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||There is an intervention group and a comparison group in the study.||||
34109530|NCT06674447|||OTHER||CROSS_SECTIONAL|||||||
34109531|NCT03267849|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109532|NCT01775345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109533|NCT06402162|NA|SINGLE_GROUP||TREATMENT||NONE||The study will include 40 tennis players diagnosed with rotator sheath lesions who meet the inclusion criteria. Groups will be randomly divided into 2. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week, for 8 weeks. In both groups, pain will be assessed by Visual Analog Scale (VAS), muscle strength by isokinetic dynamometer and supraspinatus muscle architecture by ultrasonography and dynamic tendon imaging.||||
34109534|NCT03592758|||COHORT||PROSPECTIVE|||||||
34109535|NCT02331303|||COHORT||OTHER|||||||
34109536|NCT05360784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109537|NCT06645288|||COHORT||PROSPECTIVE|||||||
34109538|NCT00932607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109539|NCT05256537|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label safety trial||||
34109540|NCT04212923|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109541|NCT05656040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109542|NCT06570746|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34035929|NCT00764881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109543|NCT04824677|||CASE_ONLY||PROSPECTIVE|||||||
34109544|NCT06434727|||OTHER||RETROSPECTIVE|||||||
34109545|NCT04392622|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34109546|NCT06644066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109547|NCT03462745|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109548|NCT06462456|||COHORT||OTHER|||||||
34109549|NCT06641557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109550|NCT03507725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34035930|NCT06275373|||COHORT||RETROSPECTIVE|||||||
34035931|NCT03604224|||CASE_ONLY||RETROSPECTIVE|||||||
34035932|NCT01766076|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34109551|NCT02494492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109552|NCT06179446|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34109553|NCT05614882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Individuals in this study will be based from a convenience sample from the Rehabilitation and Wellness Center in Milford, Connecticut. Participants will be admitted post-stroke after being diagnosed with stroke of mild to moderate severity. Individuals will be over 18 years of age with no history of prior stroke who are able to read basic information, having no more than a mild aphasia with intact language comprehension skills who speak English or Spanish (assessment materials are available in these two languages).~All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization. Anticipated enrollment of 20 for pilot and 200 for larger study."||||
34109554|NCT04206683|||COHORT||PROSPECTIVE|||||||
34109555|NCT06152172|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be enrolled based on their disease.||||
34109556|NCT06489431|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Participants will be aware of the two options, however will be randomly selected to receive only one of the two treatments. Investigators will be aware of the treatment as they are administering it|Non inferiority trial|t|f|f|f
34109557|NCT03520114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and will be masked during the one-year follow-up period.Precautions will be taken to minimize unmasking the study groups: Since RP slings require two suprapubic stab incisions, identical sham incision will also be performed in the SIS group.||t|f|f|f
34109558|NCT01629498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109559|NCT06636006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035933|NCT06139822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035934|NCT04234308|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34109560|NCT05708521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants will be masked to which group they are assigned to avoid the placebo effect.~Given the nature of the study in which opioid prescription quantities are controlled and questionnaires provide a detailed schedule of opioid dosage and frequency, providers and investigators cannot be masked."|Participants will be randomly allocated to one of 2 parallel study arms and followed longitudinally. Their allocation to the study arms will be performed by using a random number generator, whereby if the number 0 arises, they are allocated to the control group, and if the number 1 arises, they are assigned to the experimental group.|t|f|f|f
34149695|NCT01458028|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34035935|NCT05821816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807174|NCT03398798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Neither subjects nor the treating orthodontists will know whether a .014 or 0.16 dimension wire is being used. The investigator will assign wire dimensions using a random number generator and distribute the wires to the treating orthodontists with the archwire dimension number removed from the package. The outcomes assessor will be blinded as to which patients were treated with which archwires while analyzing the digital models of the teeth.~Because there is a clear visual difference between twin and self-ligating brackets, there will be no blinding with regard to ligation method (bracket type)."|"There will be four different groups in this study, with each planned to consist of 20 patients (40 dental arches).~In the twin bracket cohort, 40 dental arches are planned to be treated with .014 dimension wire, and 40 dental arches are planned to be treated with .016 dimension wire.~In the self-ligating bracket cohort, 40 dental arches are planned to be treated with .014 dimension wire, and 40 dental arches are planned to be treated with .016 dimension wire."|t|t|f|t
33807175|NCT00415688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807176|NCT02170259|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33807177|NCT04018222|||CASE_CONTROL||PROSPECTIVE|||||||
33807178|NCT02762201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807179|NCT01809457|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33807180|NCT05023434|||COHORT||PROSPECTIVE|||||||
33807181|NCT00077935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807182|NCT06699628|NA|PARALLEL||TREATMENT||NONE||Ascending doses||||
34035936|NCT06100523|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34035937|NCT03405831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a prospective single-center, double-blinded, placebo controlled, randomized study in long-term heart transplant recipients.~Patients who meet the eligibility criteria will be randomized 1:1 at inclusion for one of two treatment groups: (i) treatment with ivabradine 5 mg bid or (ii) treatment with placebo bid for a period of 12 weeks. 35 participants will be enrolled."|t|t|t|t
34035938|NCT03402295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Retrospectively compared two different groups of treatments||||
34035939|NCT03383965|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
34035940|NCT05828498|||CASE_ONLY||PROSPECTIVE|||||||
34035941|NCT00720551|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34035942|NCT02368990|||COHORT||PROSPECTIVE|||||||
34035943|NCT04658966|||CASE_CONTROL||PROSPECTIVE|||||||
34035944|NCT03849924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The questionnaire administrator/investigator and participants are blind to the condition, as participants are not informed of the questionnaires being different from one another, and participants should return their questionnaires in sealed envelopes.|Participants are randomly assigned to an intervention group, intervention 'booster' group (receive the intervention twice) or a control group via a web-based randomiser.|t|t|t|t
34035945|NCT02657486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035946|NCT02090088|||CASE_CONTROL||PROSPECTIVE|||||||
34035947|NCT06147882|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34035948|NCT01451450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035949|NCT00124189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035950|NCT03179670|||OTHER||PROSPECTIVE|||||||
34035951|NCT02748746|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34035952|NCT00581750|||COHORT||PROSPECTIVE|||||||
34035953|NCT02192463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035954|NCT00948272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34035955|NCT06510699|RANDOMIZED|PARALLEL||TREATMENT||NONE||PRAGMATIC is a parallel-group randomised (1:1) clinical trial aiming to recruit at least 104 patients. A hybrid feasibility sub-study will assess the scalability of genotype directed dosing to ensure a sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost effectiveness of genotype-directed testing compared to standard care.||||
34035956|NCT05425212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035957|NCT02736552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035958|NCT05348759|||COHORT||PROSPECTIVE|||||||
34035959|NCT05286177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A double-blinded strategy is not feasible for this study because the medical team cannot remain adequately blinded to study arms after randomization. Bedside nurses delivering EN support need to know which feeding algorithm to follow. The medical team (including PICU physicians, nurse practitioners, and dietitians) have access to patients' medical records which include current hourly infusion rates of enteral feeds so they will be able to deduce the patients' allocations. The team uses current hourly infusion rates to assess fluid balance and to make clinical decisions.~To minimize bias, the research assistant tasked with data collection will remain blinded to study allocation throughout data collection and will enter the data into the REDCap Database in a blinded fashion. After data collection and prior to data analysis, all identifying information will be saved in a separate file to ensure the Study Coordinator will be re-blinded to participant allocation during data analysis."|The investigators will conduct a single-center parallel partially blinded 1:1 randomized feasibility trial of 20 children admitted to the Alberta Children's Hospital (ACH) PICU.|f|f|t|t
34035960|NCT03281252|||COHORT||PROSPECTIVE|||||||
34035961|NCT02722031|||COHORT||PROSPECTIVE|||||||
34035962|NCT00314704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34035963|NCT05804214|||COHORT||PROSPECTIVE|||||||
34035964|NCT04882813|||COHORT||RETROSPECTIVE|||||||
34035965|NCT01959633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035966|NCT05976880|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will get separate tretment protocols and possible efforts will be put to mask the both groups about their treatment|Its a randomized control trial,used to measure the grip strength of visually impared children by powerball.Subjects with visual impairment meeting the predetermined inclusion and exclusion criteria will be divided into two groups using random sampling technique|t|f|f|f
34035967|NCT02735902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34035968|NCT03732664|NA|SINGLE_GROUP||TREATMENT||NONE||"Anti-PD-1 or anti-PD-L1 antibody administration:~One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."||||
34035969|NCT00659191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34109561|NCT06644534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, investigator and sponsor will be blinded to active:placebo assignment and to PK measurements during the study.|Multi-center, Randomized, Double-Blind, Placebo-Controlled Twelve (12) patients will be randomized on a 2:1 (active:placebo) ratio, with 8 receiving TTI-0102 and 4 receiving a placebo|t|t|t|t
34109562|NCT01795157|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109563|NCT04874480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109564|NCT01587196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109565|NCT06564324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109566|NCT06637137|||CASE_CONTROL||PROSPECTIVE|||||||
34109567|NCT03340506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109568|NCT02236910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109569|NCT02740998|||COHORT||PROSPECTIVE|||||||
34109570|NCT02337556|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34109571|NCT03757663|NA|SINGLE_GROUP||PREVENTION||NONE||Each participant will self-report skin protective behaviors and attitudes before wearing a UV dosimeter for 3 weeks. After the wear period, the study team provides feedback based on UV exposure. The participant will then wear the device again for 3 weeks.||||
34109572|NCT05424276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109573|NCT05887401|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||This study uses a full factorial experimental design testing the efficacy of four intervention components, each with two levels|t|f|f|f
34109574|NCT06122597|NA|SINGLE_GROUP||OTHER||NONE||||||
34109575|NCT04581083|||OTHER||CROSS_SECTIONAL|||||||
34109576|NCT04715581|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This is a randomized controlled trial.|f|t|t|t
34109577|NCT02398799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109578|NCT05078411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The examiner responsible for administrating psychological questionnaires will be kept blinded as to patient allocation to treatment (the examiner will leave the operating room when treatment allocation is disclosed and when the operator delivers the assigned treatment).|The study is designed as a multicenter, single-blind, parallel-arm, randomized trial.|f|f|f|t
34109579|NCT04316143|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109580|NCT05226052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|: The person delegated to assigns treatment is the nurse of the medical office. Assignment will be done using a simple excel algorithm. The cans are numbered sequentially. The blindness will be broken until the statistical analysis is completed|Randomized, double-blind clinical trial|t|t|t|t
34109581|NCT06010251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109582|NCT01577407|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34109583|NCT06066333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109584|NCT05940272|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109585|NCT03832985|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No one is prevented from having knowledge of this project.|"The study sample will be drawn from all pediatric MyCode participants (ages 0-17 years). At least one parent will be enrolled for each pediatric participant. Parents of children ages 0-10 years at enrollment will participate in data collection; parents of children ages 11-17 years at enrollment and their children will participate in data collection. Group 3 participants will be frequency matched to Groups 1 and 2 participants on age and sex.~Individuals who have already had genetic counseling for any of the MyCode target conditions as part of their routine clinical care will be excluded to avoid confounding study findings.~Quantitative data collection will be on 705 (530 parents and 175 adolescents)."||||
34109586|NCT00780585|||COHORT||PROSPECTIVE|||||||
34109587|NCT03526172|||COHORT||PROSPECTIVE|||||||
34109588|NCT02796911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109589|NCT04169009|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34109590|NCT04198545|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109591|NCT01556334|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34109592|NCT01761149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34109593|NCT02133079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109594|NCT05135260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34109595|NCT00811837|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34109596|NCT04479709|||COHORT||PROSPECTIVE|||||||
34109597|NCT06643871|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109598|NCT06212817|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized controlled trial with three parallel arms consisting of two intervention arms and one control arm.||||
34109599|NCT04891198|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open, single-arm study, without randomization and blinding||||
34109600|NCT02295865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34109601|NCT04803565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109602|NCT05879029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807183|NCT02328144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807184|NCT00776009|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33807185|NCT02824926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807186|NCT01561300|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33807187|NCT02711332|||CASE_ONLY|||||||||
33838115|NCT02273258|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33838116|NCT01655303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34109603|NCT05204485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109604|NCT04979143|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34149696|NCT02984449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blinding (researcher and participants) is not possible because of logistic reasons. However, the primary endpoint is evaluated by an independent end-point committee, blinded for group allocation.||f|f|f|t
34149697|NCT03959787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149698|NCT00038779|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149699|NCT06547060|||COHORT||PROSPECTIVE|||||||
34149700|NCT00828789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149701|NCT01662947|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34149702|NCT04705948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149703|NCT04759365|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34149704|NCT02822976|||COHORT||PROSPECTIVE|||||||
34109605|NCT05385289|RANDOMIZED|PARALLEL||TREATMENT||NONE|"A computerized version of the Autobiographical Memory Test (AMT; Williams et Broadbent, 1986) will be used to assess the overgeneral processing. This task focused on retrieving past memories of personal events.~AMT raters will be not involved in any other aspect of the study procedures. The memories will also be presented to the raters in a randomized order, so that there was no possibility of guessing who completed them or when."|"The final sample will comprise 12 participants.~The initial sample size was based on Shadish \& Sullivan's (2011) study reporting that the median and modal number of participants in single-case designs is three. Therefore, recruiting 6 participants allowed for a direct intrasubject replication (i.e., a replication of the experimental effect within the design) while ensuring that three participants were retained despite possible dropout. Moreover, using two waves of six participants (resulting in a total sample of 12 participants) allowed for a direct inter-subject replication (i.e., repeating the same study but with additional individuals). Those two replications were used to demonstrate that changes on target behaviors systematically arrives after the intervention introduction, hence controlling for external variables."||||
34109606|NCT06640725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109607|NCT05535569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807188|NCT03878966|NA|SINGLE_GROUP||TREATMENT||NONE||• Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .||||
33807189|NCT04415775|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||One experimental group and other control group receiving control intervention.|f|f|f|t
33807190|NCT00567073|||OTHER||OTHER|||||||
33807191|NCT05106049|||CASE_CONTROL||RETROSPECTIVE|||||||
33807192|NCT01480349|||COHORT||PROSPECTIVE|||||||
34109608|NCT02600650|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34109609|NCT05183984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109610|NCT03514940|||COHORT||PROSPECTIVE|||||||
34109611|NCT06398249|||OTHER||CROSS_SECTIONAL|||||||
34109612|NCT04103814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Enrolled patients will receive either active Mg-CBDa (magnesium-cannabidiolic acid) cream or placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus.|t|t|t|t
34109613|NCT06040827|||COHORT||PROSPECTIVE|||||||
33807193|NCT01553526|||||PROSPECTIVE|||||||
33807194|NCT05400161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Video coders will be blinded to intervention assignment.||f|f|f|t
33807195|NCT04809376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33807196|NCT00562094|||COHORT||PROSPECTIVE|||||||
33807197|NCT04746807|||COHORT||PROSPECTIVE|||||||
33807198|NCT04528498|||COHORT||PROSPECTIVE|||||||
33807199|NCT01143935|||COHORT||PROSPECTIVE|||||||
33807200|NCT06432257|||COHORT||RETROSPECTIVE|||||||
33807201|NCT06522061|NA|SINGLE_GROUP||OTHER||NONE|The investigators, care providers, participants, and outcome assessors will be blinded to the anastomotic leak risk-score generated by Stream Platform. This will ensure that subject care is not influenced by use of the device and postoperative monitoring is conducted as per the standard of care.|||||
33807202|NCT06699394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807203|NCT02029443|NA|SEQUENTIAL||TREATMENT||NONE||||||
34109614|NCT01481285|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109615|NCT04979000|||CASE_CONTROL||RETROSPECTIVE|||||||
34109616|NCT03546439|||CASE_ONLY||PROSPECTIVE|||||||
34109617|NCT05599165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A single group of bimodal cochlear implant users will be tested with three different signal processing for consonant enhancement in noise.||||
34109618|NCT06094296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109619|NCT04774445|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109620|NCT05383482|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109621|NCT04503616|NA|SINGLE_GROUP||PREVENTION||NONE||Interventional, non-randomized open label, 2- stage optimal Simon design with interim futility analysis.||||
34109622|NCT06640127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34109623|NCT03533283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109624|NCT04205786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a randomized controlled trial. Participants will be randomly assigned 1:1 to treatment or control arm.||||
34109625|NCT01342315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109626|NCT04418245|||CASE_ONLY||RETROSPECTIVE|||||||
34109627|NCT05620329|||COHORT||PROSPECTIVE|||||||
34109628|NCT02245659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109629|NCT01798225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109630|NCT06643130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109631|NCT05085834|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients, study staff, and the study statistician will be blinded to treatment allocation (zinc gluconate or placebo capsules). The research staff as well as the principle investigator will remain blinded to treatment assignment.|This is a double-blind randomized placebo-controlled trial 2:1 Patients will be given zinc gluconate capsules at a dose of 90 mg elemental zinc daily or matching placebo for 24 weeks.|t|t|t|t
34109632|NCT05773469|||COHORT||CROSS_SECTIONAL|||||||
34109633|NCT05982678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109634|NCT06381102|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34109635|NCT00706173|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34109636|NCT02618941|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109637|NCT05207839|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34109638|NCT03852420|NA|SINGLE_GROUP||TREATMENT||NONE||"The LUMINIZE RF Balloon Catheter is a multi-electrode, irrigated, over-the-wire balloon catheter designed to facilitate cardiac electrophysiological mapping and ablation. The catheter interfaces with the LUMINIZE Console and is designed to localize potentials and create lesions using multi-polar RF energy.~The System consists of the following devices and components:~* LUMINIZE RF Balloon Catheter~* LUMINIZE Steerable Sheath~* LUMINIZE Console~* LUMINIZE System Accessories"||||
34109639|NCT05227326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807204|NCT00349206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838117|NCT01931098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838118|NCT06248437|||OTHER||PROSPECTIVE|||||||
33838119|NCT01211301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109640|NCT03537508|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study was conducted modified double blind for the infant part of the study, with everyone involved in the study (participants/parents, investigators, safety outcome assessor, Sponsor) blinded to the meningococcal vaccine received, except the personnel administering the vaccine.||t|t|t|t
34109641|NCT05071326|NA|SINGLE_GROUP||OTHER||NONE||||||
34109642|NCT06641388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109643|NCT04175015|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single - Participant||t|f|f|f
34109644|NCT03452345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109645|NCT01809769|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34109646|NCT06176586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109647|NCT06001749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109648|NCT03917615|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will not know the aim of study|2 groups according to the year of physiotherapy school.|t|f|f|f
34109649|NCT06160791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109650|NCT06644586|||COHORT||PROSPECTIVE|||||||
34109651|NCT06638983|NA|SINGLE_GROUP||OTHER||NONE||Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention, SNA, SNB, ANB, SN_GoGn, SN_Occplane, U1_NAmm, U1_NA, L1_NBmm, L1_NB, U1_L1, U1_Mp, Ls_E, Li_E, and Nasolabial_angle. Intervention was MBT (MBT System, 3M Unitek, USA) non-extraction fixed orthodontic treatment. One experienced researcher analyzed and interpreted all of the cephalometric images used in the study using the WedCeph (https://webceph.com/). Data were analyzed by linear regression and T-Test statistical test using R software version 4.3.0 (R Foundation for Statistical Computing, Vienna, Austria) by a blinded statistician.||||
34109652|NCT01394185|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34109653|NCT05665127|||COHORT||PROSPECTIVE|||||||
34109654|NCT06221007|||CASE_CONTROL||RETROSPECTIVE|||||||
34109655|NCT06115954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109656|NCT06090799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-3032 for dose escalation|t|t|t|t
34109657|NCT05998759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109658|NCT06365463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109659|NCT05809700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109660|NCT00952692|NA|SINGLE_GROUP||OTHER||NONE||||||
34109661|NCT01117246|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109662|NCT00963638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109663|NCT04810624|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34109664|NCT03246412|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34109665|NCT03213405|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34149705|NCT00658307|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34149706|NCT00673881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149707|NCT00499902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149708|NCT03250572|||CASE_CONTROL||PROSPECTIVE|||||||
34149709|NCT03000036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109666|NCT06039514|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants that meet the inclusion criteria will complete the web-based baseline assessment (pre), with questionnaires relating to maladaptive beliefs, emotional symptomatology, self-esteem, body satisfaction and eating symptomatology. After, experimental group will use the GGTCA-AD, and control group will use the GGNeutra for 14 days. Then, both groups will complete again the above-mentioned assessment (post use the app). Finally, all participants will complete the follow-up measures at one month.|t|f|f|f
34109667|NCT06334796|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The model of this Phase 1 interventional study involves evaluating the diagnostic accuracy and utility of an AI-powered virtual assistant in the triage of emergency neurological conditions. Patients and healthcare professionals interacted with the assistant, providing real-world clinical scenarios to assess its effectiveness. The study's design aimed to demonstrate the assistant's potential to enhance emergency neurological care by comparing its performance with established diagnostic tools and patient outcomes.||||
34109668|NCT03411187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a prospective randomized controlled study to select a continuous case of thyroid surgery in the fujian medical university union hospital from January 2017 to June 2017.|t|t|t|t
34109669|NCT05966714|||COHORT||PROSPECTIVE|||||||
34109670|NCT03777605|NA|SINGLE_GROUP||TREATMENT||NONE|All tablets are processed, marked and coded by a pharmacist,|A randomized, cross over design||||
34109671|NCT01355627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109672|NCT02527512|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34109673|NCT04428580|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109674|NCT05509127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109675|NCT01019915|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109676|NCT04877366|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34109677|NCT05634200|||CASE_ONLY||PROSPECTIVE|||||||
34109678|NCT06456671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will complete seven Experimental Tobacco Marketplace conditions. Conventional cigarette price will be parametrically increased, and the purchasing of alternative products measured. Alternative products (i.e. nicotine vaping products, heated tobacco products and nicotine pouches) will be available at different prices in separate conditions (i.e., ½ market price and market price).||||
34109679|NCT00860769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109680|NCT04268147|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109681|NCT00341679|||COHORT||RETROSPECTIVE|||||||
34109682|NCT06642493|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||In this model, participants are randomly assigned to one of two or more groups (arms) simultaneously, with each group receiving a different intervention or control treatment. The outcomes of each group are then compared to assess the efficacy and safety of the interventions.|t|f|f|t
34109683|NCT06644599|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|The randomization list will be maintained with a research coordinator who is not involved in this trial, and the ward allocation will remain concealed from the research and clinical teams throughout the study and will be revealed for a given sequence only 1 month before the implementation of the intervention to allow training.||f|t|t|t
34109684|NCT06303427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single-blinded as the assessor of the study would be kept blind to the treatment groups to which patients will be allocated.||f|f|f|t
34109685|NCT04756531|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34109686|NCT03421353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109687|NCT05518045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109688|NCT06035887|||OTHER||PROSPECTIVE|||||||
34109689|NCT04605666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109690|NCT06570005|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Stepped-wedge Randomized Controlled Trial||||
34109691|NCT00543127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109692|NCT06206720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109693|NCT04111354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109694|NCT03773419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109695|NCT04612192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34109696|NCT01080235|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34109697|NCT06583655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807205|NCT06523478|RANDOMIZED|PARALLEL||TREATMENT||NONE|This experiment is a comparative study of two treatment methods, and there are obvious differences between the treatment methods of the experimental group and the control group, so it is difficult to blind the subjects, researchers and evaluators, and only the experiment design without blindness can be adopted.|||||
33807206|NCT00003593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838120|NCT05722886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838121|NCT02546297|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34109698|NCT05731245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109699|NCT05213234|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34109700|NCT04011241|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109701|NCT05368519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109702|NCT06638034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807207|NCT04108403|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Participants will be masked to the type of instructional set received during the intervention. However, participants will be notified of this upon completion of the study.||t|f|f|f
34109703|NCT02758626|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34109704|NCT01254214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109705|NCT06424262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34109706|NCT05866640|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34109707|NCT05508126|||COHORT||PROSPECTIVE|||||||
34109708|NCT05410223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34109709|NCT05202782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109710|NCT05019079|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34109711|NCT04912518|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34109712|NCT05653206|||COHORT||PROSPECTIVE|||||||
34109713|NCT01078532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33807208|NCT04390724|||COHORT||PROSPECTIVE|||||||
33807209|NCT00006350||||TREATMENT||||||||
33807210|NCT02813954|||CASE_CONTROL||PROSPECTIVE|||||||
33807211|NCT02115659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838122|NCT05452551|||OTHER||CROSS_SECTIONAL|||||||
33838123|NCT00507403|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838124|NCT00037206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109714|NCT04647357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109715|NCT03298737|||COHORT||PROSPECTIVE|||||||
34109716|NCT04171960|||COHORT||PROSPECTIVE|||||||
34109717|NCT03802396|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Participants will be randomized to receive either CN-105 or placebo after they consent to participate in the trial. Participants will be enrolled in 1 of 3 dose cohorts of 67 subjects each. An independent statistician will prepare dose stratified mixed block size randomization lists in a 3 to 1 ratio to achieve the desired distribution of drug and placebo. In each block of 67 trial participants, 50 will receive CN-105 and 17 will receive placebo, in a double-blind fashion.~CN-105 and placebo will be prepared in identical bags labelled simply with the trial participant's number (1-201) to keep all trial staff and clinicians blinded to randomization. Only the investigational pharmacist will have the randomization list for each participant showing what dose of CN-105 or placebo will be administered. To minimize bias, investigators conducting the laboratory assays on the CSF and blood samples will be blinded to trial group assignment during the course of the trial."|Investigators will enroll 201 patients total in this phase 2 escalating dose study, with escalating CN-105 doses occurring in three successive groups of 67 patients each. In each group of 67 patients, 50 will receive a given dose of CN-105 and 17 will receive placebo.|t|t|t|t
34109718|NCT03340779|RANDOMIZED|CROSSOVER||TREATMENT||NONE||3 first hours : strategy 1, norepinephrine alone with increased dose or norepinephrine + dobutamine 0.5 hour : wash-out (decrease of norepinephrine dose or weaning of dobutamine) 3 last hours : strategy 2, crossover, norepinephrine alone with increased dose or norepinephrine + dobutamine||||
34109719|NCT05789290|||COHORT||PROSPECTIVE|||||||
34109720|NCT03457662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109721|NCT03611686|||COHORT||PROSPECTIVE|||||||
34109722|NCT06385028|NA|SINGLE_GROUP||PREVENTION||NONE||pilot feasibility study||||
34109723|NCT00279695|||CASE_CONTROL||PROSPECTIVE|||||||
34109724|NCT06263803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single||t|f|f|f
34109725|NCT06637943|||CASE_CONTROL||PROSPECTIVE|||||||
34109726|NCT04635774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigational pharmacist will use randomization software to randomize numbers 1-30. Each number will be randomized to either active drug (regular insulin) or placebo (normal saline).The investigational pharmacist will have the randomization table should un-blinding be required.|"The study is double-blind, randomized, placebo controlled. Neither the physician, patient, nor investigator will be aware of which patient is receiving insulin and which is receiving placebo. The treatment group will receive 40 IU via four activations of an intranasal spray. The placebo group will receive four activations of an intranasal spray containing placebo (normal saline).~Both groups of patients receiving the insulin or placebo as intervention will be assessed with the CAM assessment at 10 min, 30min, and 60 min, and 6hr."|t|t|t|f
34109727|NCT06274840|||COHORT||PROSPECTIVE|||||||
34109728|NCT02572648|||CASE_CONTROL||PROSPECTIVE|||||||
34109729|NCT01980147|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34109730|NCT05548556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109731|NCT03318627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109732|NCT06629103|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34109733|NCT04535297|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109734|NCT06642740|||COHORT||PROSPECTIVE|||||||
34109735|NCT04907084|RANDOMIZED|FACTORIAL||OTHER||NONE|This is an open-label study. Participants will be told if they are taking serine and/or fenofibrate, or if they are participating as a control (no treatment).|The randomization model will stratify patients by diabetes status, ensuring equal treatment of diabetics / non-diabetics in the study. A permuted block design will be used to randomize participants in a 1:1:1:1:1:1 ratio to either 1) serine 200 mg/kg/day, 2) serine 400 mg/kg/day, 3) fenofibrate 200 mg/day, 4) serine 200 mg/kg/day AND fenofibrate 200 mg/day, 5) serine 400 mg/kg/day AND fenofibrate 200 mg/day, or 6) no treatment (control group).||||
34109736|NCT05704803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109737|NCT05338736|||CASE_CONTROL||PROSPECTIVE|||||||
34109738|NCT06279182|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The experimental group will receive the Barre stretching intervention. The control group will not receive any intervention.|f|f|f|t
34109739|NCT06642714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109740|NCT02174237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109741|NCT05003856|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109742|NCT03603808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109743|NCT06501196|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109744|NCT00492050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109745|NCT06592079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109746|NCT01516372|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34109747|NCT04618276|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Intervention group with PDT~* Arm A will receive the photosensitizer 5-ALA~* Arm B will receive Methylene blue as photosensitizer for the PDT."||||
34109748|NCT06412146|NA|SINGLE_GROUP||OTHER||NONE||||||
33807212|NCT03986359|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|While subjects receive Sham therapy, the machine turning on but the energy is zero.|We prospectively assessed the clinical outcome of LI-ESWT for the treatment of ED of organic origin. This study was approved by the institutional review board at National Taiwan University Hospital (NTUH, No. T-NTUH-57401).|t|f|f|f
34109749|NCT00798408|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34109750|NCT06643442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109751|NCT04831229|RANDOMIZED|PARALLEL||OTHER||SINGLE|Randomization will be carried out by means of a simple drawing where an independent researcher, not involved in the intervention or evaluation of the participants, will allocate the participants and it will be hidden using opaque and closed envelopes.|We propose an RCT with 64 children aged 24 to 36 months and their parents. Measures of cognitive, motor and language development through the Bayley III Scale and Auditory Vocabulary Test. For follow-up purposes, parents will be asked to complete the Daily Record Board. Children will be randomly randomized into two groups: Active Interactive Media Group: children will use the media actively (games) and Passive Interactive Media Group: children will use the media passively (content viewing). Both groups will participate in the intervention for 30 minutes, three times a week, for 16 weeks. After this period, children will be reassessed for cognitive, language and fine motor development, receptive vocabulary and analysis of the Daily Record Board.|t|f|f|f
34109752|NCT06469021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109753|NCT02705963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109754|NCT02760342|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807213|NCT00745875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807214|NCT05935969|||COHORT||RETROSPECTIVE|||||||
33807215|NCT01122914|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838125|NCT03016351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838126|NCT01458054|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34035970|NCT04066452|||COHORT||PROSPECTIVE|||||||
34035971|NCT03983980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The Investigator, study center staff, subject, and Sponsor will be blinded to treatment assignment.|Following a 34-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily treatment with tapinarof cream, 1% or vehicle cream.|t|t|t|f
34035972|NCT05030740|||COHORT||PROSPECTIVE|||||||
34035973|NCT00459355|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34035974|NCT06195137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035975|NCT02044380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035976|NCT05285423|NA|SINGLE_GROUP||TREATMENT||NONE|Patients in othe only arm are provided with vocal cord lateralization with prolene suture technique, and this is known by the patient, health care provider and the assessor.|The single group will be offered vocal cord lateralization with prolene suture and mesh implant technique.||||
34035977|NCT04637503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035978|NCT03905798|||CASE_ONLY||PROSPECTIVE|||||||
34035979|NCT06511466|||OTHER||PROSPECTIVE|||||||
34109755|NCT03275987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34109756|NCT03709667|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34109757|NCT01356147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34109758|NCT06636747|||CASE_ONLY||PROSPECTIVE|||||||
34109759|NCT00740675|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34109760|NCT04906512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109761|NCT00443014|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34109762|NCT02474173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109763|NCT05868811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34109764|NCT06645223|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109765|NCT01765413|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34035980|NCT06265454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035981|NCT02817763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34035982|NCT03866577|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"Part A: Double (Subject, Investigator);~Part B, C, and D: Open Label Investigations"|||||
34035983|NCT02433132|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34035984|NCT04805905|||COHORT||PROSPECTIVE|||||||
34035985|NCT01008566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035986|NCT03248115|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34035987|NCT01403402|||COHORT||PROSPECTIVE|||||||
34035988|NCT03286153|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Subjects are randomized to receive factor based either on ideal body weight or actual body weight first followed by receiving factor based on the other category next||||
34035989|NCT04114682|||COHORT||PROSPECTIVE|||||||
34035990|NCT04057742|||COHORT||PROSPECTIVE|||||||
34035991|NCT02836522|||COHORT||PROSPECTIVE|||||||
34035992|NCT00755742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34035993|NCT00987337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34035994|NCT01452243|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34035995|NCT00173329|||DEFINED_POPULATION||OTHER|||||||
34035996|NCT03746847|||COHORT||PROSPECTIVE|||||||
34035997|NCT05659199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||fascia trigger point release group extracorporeal shock wave group extracorporeal shock wave and fascial trigger point release treatment group|t|f|f|t
34035998|NCT02773147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109766|NCT02989857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients randomized in a 2:1 allocation (AG-120 vs Placebo)|t|f|t|f
34109767|NCT02748798|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34109768|NCT03215160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109769|NCT00712283|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34109770|NCT05838248|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT prospective patients randomized to two duration groups for simple appendicitis and two duration groups for complex appendicitis. Also age \< or \> 65 will undergo separate randomization.||||
34109771|NCT02801578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109772|NCT05236023|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34109773|NCT01923038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109774|NCT02244398|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109775|NCT06294587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109776|NCT05137158|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Sixty participants are randomly and equally divided into intervention group or sham stimulation group according to the predetermined random number list.|t|t|t|t
34109777|NCT05548283|RANDOMIZED|PARALLEL||TREATMENT||NONE||The aminoglycoside study will compare treatment of an IV β-lactam and aminoglycoside (AG) versus an IV β-lactam only (non-AG). Individuals will be randomly assigned in a 1:1 fashion to receive either the AG or non-AG intervention for a planned 14 day course of IV antibiotics. IV antibiotic treatments for each intervention arm will be selected by the treating physician following standard of care.||||
34109778|NCT06639763|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34109779|NCT05163639|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants with chronic SCI, participants with spondylotic radiculopathy or myelopathy scheduled to undergo elective cervical decompression surgery, and volunteers without neural injury will be prospectively enrolled in this interventional experimental study.||||
34109780|NCT06459804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109781|NCT02886962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109782|NCT05967169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-cohort||||
34109783|NCT00396370|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34109784|NCT05605197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34035999|NCT02922920|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34109785|NCT06644703|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34109786|NCT03686657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109787|NCT04591080|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The participants will not know which intervention is on which side of their mouth, but will know that they are getting both types of interventions simultaneously, given the split-mouth design of the study.|Split mouth design where one side of the mouth will be receiving the intervention and the other side of the mouth the control treatment.|t|f|f|f
34109788|NCT01096251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109789|NCT04705766|||COHORT||PROSPECTIVE|||||||
34109790|NCT06271057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109791|NCT02987140|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
34109792|NCT05298618|||CASE_ONLY||PROSPECTIVE|||||||
34109793|NCT06161493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109794|NCT05847153|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||MASC is an intervention that includes evidence based skills of: 1) mindfulness; 2) compassion toward others and self; 3) behavioral management skills. MASC has 6 sessions delivered in a group format over secure live video with Zoom. Each session includes psychoeducation on program skills, skill practice, strategies to incorporate the skill into the caregiver experience, and strategies for sustained practice.||||
34109795|NCT06563817|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients receive treatment with sirolimus (rapamycin), administered in capsule form at a dosage of 0.5 mg per capsule. The capsules, provided by North China Pharmaceutical under the trade name Yixinke, were stored at room temperature. The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.||||
34109796|NCT03167060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Controls will undergo same treatment with the medical device, but it will be a sham treatment|Post-market clinical study of one or more CE marked devices within intended purposes, involving a change to standard care or randomisation between groups|t|f|f|f
34109797|NCT00386581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34109798|NCT06564012|||COHORT||PROSPECTIVE|||||||
34109799|NCT01017432|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34109800|NCT02971839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036000|NCT05927012|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||2 parts: Part 1 Initial Titration Strategy and Part 2 Cohort Expansion or Alternate Titration Strategy||||
34109801|NCT06644092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036001|NCT00129389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036002|NCT02923232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109802|NCT06088667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.|Parallel Assignment|t|f|t|f
34109803|NCT04300894|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34109804|NCT05745844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, longitudinal, open-label, comparative (two arms), randomized study||||
34109805|NCT05175664|||COHORT||PROSPECTIVE|||||||
34109806|NCT06192550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109807|NCT04452916|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Waiting list control group||||
34109808|NCT04258631|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109809|NCT05845255|||CASE_CONTROL||PROSPECTIVE|||||||
34109810|NCT04614337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109811|NCT06640036|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Meals identical in apperance and taste will be prepared, and blinded.||t|t|t|t
34109812|NCT06638372|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34109813|NCT02711098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109814|NCT02443857|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109815|NCT05660642|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34109816|NCT05925400|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109817|NCT05492045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34036003|NCT04937413|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036004|NCT03514459|RANDOMIZED|PARALLEL||SCREENING||NONE||Cluster randomized trial of family planning clinics||||
34109818|NCT00381641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109819|NCT05712109|||COHORT||PROSPECTIVE|||||||
34109820|NCT02678377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109821|NCT06241352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109822|NCT05271383|||COHORT||PROSPECTIVE|||||||
34109823|NCT01648933|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109824|NCT05516875|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34109825|NCT05021848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109826|NCT06016244|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial, parallel group, block randomized and stratified by age and centre.||||
34109827|NCT05044767|||COHORT||PROSPECTIVE|||||||
34109828|NCT05718531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109829|NCT06545617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109830|NCT05748769|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized control trial (RCT)|t|f|f|f
34109831|NCT06571877|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The meals are adjusted in energy density without noticeable changes in appearance or taste. These meals have identical ingredients, but the macronutrient proportions are modified. It can be not ruled out that some participants may recognize differences of the meals.|"This is a repeated measures randomized controlled cross-over design with an additional randomization on block:~1) Randomized controlled cross-over experiments are conducted at the end of the first week of the bedrest (days 6-8) and at the end of the bed rest (days 51-53). In total, every participant is tested on 4 days, receiving either the control test meal or the meal with increased fat content in a 1000 ml bowl. 2) Additionally, the 4 campaigns are randomized on block so that either the breakfast or the lunch will be manipulated."|t|f|f|t
34109832|NCT04171895|||COHORT||PROSPECTIVE|||||||
34109833|NCT01055340|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34109834|NCT02033941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109835|NCT00302822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109836|NCT05843604|||CASE_CONTROL||PROSPECTIVE|||||||
34109837|NCT04197583|||COHORT||PROSPECTIVE|||||||
34109838|NCT06642090|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This interventional study follows a randomized controlled trial (RCT) design, comparing the effectiveness of an educational intervention against standard care in patients undergoing hemodialysis. Participants will be randomly assigned to one of two groups: the intervention group, which will receive targeted educational sessions focused on chronic kidney disease management. The control group didn't receive any intervention.~The educational program aims to enhance patient knowledge, improve self-management skills, and optimize clinical outcomes such as medication adherence and weight management. Assessments will be conducted at baseline and after the intervention to evaluate changes in knowledge, self-care behaviors, and clinical parameters.~The study will be conducted in a public hemodialysis center in the Marrakech-Safi region, and aims to provide insights into the impact of educational interventions on patient outcomes in this population"||||
34109839|NCT06637813|||COHORT||OTHER|||||||
34109840|NCT05562388|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled open label clinical trial. Data gathers from recruitment until appliance delivery will be used allowing each participant to also be their own control, as wait list type of study.||||
34109841|NCT04846946|RANDOMIZED|PARALLEL||PREVENTION||NONE||In Aim 3 of our study, our goal is to complete the MOST preparation phase wherein we collect acceptability, feasibility, and some effectiveness data on each module prior to combining them to test the effects of the full intervention package.||||
34109842|NCT05920252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109843|NCT02215473|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34109844|NCT01334879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109845|NCT06642805|||COHORT||RETROSPECTIVE|||||||
34109846|NCT01064726|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34109847|NCT03999424|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34109848|NCT03622983|||COHORT||PROSPECTIVE|||||||
34109849|NCT00757016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109850|NCT06595290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109851|NCT06565325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant group|There are 2 groups in the current study including exercise with and without audible cues.|t|f|f|f
34109852|NCT01738412|||CASE_ONLY||PROSPECTIVE|||||||
34109853|NCT06637891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34109854|NCT00420537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109855|NCT06073067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109856|NCT05463341|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109857|NCT06421350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109858|NCT02538809|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109859|NCT00943137|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109860|NCT05960604|||COHORT||PROSPECTIVE|||||||
34109861|NCT01550510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109862|NCT04518228|||COHORT||PROSPECTIVE|||||||
34109863|NCT01751880|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34109864|NCT05175157|||OTHER||PROSPECTIVE|||||||
34109865|NCT00023595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109866|NCT06057090|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34109867|NCT04281940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109868|NCT01969409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109869|NCT01728896|RANDOMIZED|PARALLEL||PREVENTION||||||||
34109870|NCT05368935|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34109871|NCT01505088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109872|NCT01403480|||COHORT||RETROSPECTIVE|||||||
34109873|NCT03032029|||COHORT||PROSPECTIVE|||||||
34109874|NCT06554639|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109875|NCT06062485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109876|NCT06644105|NA|SINGLE_GROUP||OTHER||NONE||||||
34109877|NCT05628480|||CASE_CONTROL||PROSPECTIVE|||||||
34109878|NCT05713487|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34109879|NCT01838733|||COHORT||PROSPECTIVE|||||||
33838127|NCT01175304|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34109880|NCT05161195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109881|NCT05896371|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34109882|NCT05974800|||COHORT||CROSS_SECTIONAL|||||||
34109883|NCT01405196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109884|NCT03440411|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This is a 2x2 factorial randomized study.||||
34109885|NCT02137343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109886|NCT03275337|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34109887|NCT00133432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34109888|NCT04183712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109889|NCT03097640|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34109890|NCT06564064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and investigator both are masked|study group (abdominal binders) and control group|t|f|t|f
34109891|NCT02341274|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34109892|NCT06415084|||OTHER||OTHER|||||||
34109893|NCT00224549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109894|NCT03981510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109895|NCT05946551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109896|NCT05977439|||CASE_ONLY||PROSPECTIVE|||||||
34109897|NCT01554904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109898|NCT00582296|||COHORT||PROSPECTIVE|||||||
34109899|NCT02756585|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109900|NCT04788693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure masking, the raters physiotherapist, and data analysis researcher, will be blinded to the participant's allocation. Although participants and treating physiotherapists cannot be totally blinded to the intervention performed, the hypothesis and objectives of the study will be hidden from them. At the same time, all participants will be instructed not to disclose information regarding their intervention to the raters' physiotherapists.||f|f|t|t
34109901|NCT06641739|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group 1: Ten patients will be treated with simplified papilla preservation flap with platelet-rich fibrin grafted into the defect site.~Group 2: Ten patients will be treated the simplified papilla preservation flap with laser therapy performed into the defect site. The laser used in the study is diode lasers (940nm), with an output power of 3 W in the contact mode."||||
34109902|NCT06361173|||OTHER||CROSS_SECTIONAL|||||||
34109903|NCT06639841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Only the Outcomes Assessor will be blinded to the group assignments in this study. This masking is employed to avoid measurement bias when comparing the primary and secondary outcomes such that the assessor does not know whether the subject had a Virtual Reality (VR) intervention or Yoga. This approach improves the validity of data collection and measure outcomes.~Because of the distinct and participatory nature of the interventions, VR and Yoga respectively, it is impossible to mask participants, care providers and researchers. This selective blinding approach of masking the Outcomes Assessor aims at an unbiased measure of outcome, despite the practical impossibility of full masking during behavioral and physical interventions."|This study follows a parallel assignment model, where participants are divided into two distinct groups (arms). Each group will receive a different intervention simultaneously, without crossing over to the other group. The two arms will be independently assessed throughout the study period to compare the effects of the assigned interventions on the participants. This design allows for the direct evaluation of each intervention's impact, ensuring that comparisons can be made between the groups without overlap in treatment or intervention|f|f|f|t
34109904|NCT02695277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109905|NCT05702112|||COHORT||PROSPECTIVE|||||||
34109906|NCT01014312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109907|NCT05901207|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109908|NCT04978415|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34109909|NCT02168556|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34109910|NCT06640088|||COHORT||PROSPECTIVE|||||||
34109911|NCT04805593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109912|NCT06541951|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Cluster-randomized stepped wedge design|f|t|f|f
33807216|NCT03530631|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.|2 X 2, within-subjects, balanced placebo design|t|f|t|f
33807217|NCT01660659|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33807218|NCT05230966|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33807219|NCT00555503|||COHORT||PROSPECTIVE|||||||
34109913|NCT06643156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109914|NCT03562156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109915|NCT06418308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be assigned a group by picking from a stack of envelopes. The interventional drug which the envelope contains will be assigned by a random number generator. The interventional drug will be drawn up by an anesthesiologist not involved in the patient's care and the syringe given to the anesthesiologist performing the spinal anesthetic.|Patients will be randomized to either receiving the addition of epinephrine or dexmedetomidine to the standard spinal medication mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.|t|t|t|t
33807220|NCT00949117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807221|NCT02816398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807222|NCT04864782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807223|NCT03163563|||OTHER||PROSPECTIVE|||||||
33807224|NCT04125901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807225|NCT02937493|||COHORT||PROSPECTIVE|||||||
34109916|NCT02774694|||COHORT||PROSPECTIVE|||||||
34109917|NCT04821310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind|t|t|t|t
34109918|NCT00835172|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33807226|NCT01218659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807227|NCT03520036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807228|NCT00002235||||TREATMENT||NONE||||||
33807229|NCT01182649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807230|NCT03948295|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807231|NCT03363945|RANDOMIZED|PARALLEL||PREVENTION||NONE||Total lymphoid irradiation and anti-thymocyte globulin||||
34109919|NCT05840250|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34109920|NCT03988218|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109921|NCT03731429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study was designed as a double-blind randomized controlled trial|t|f|t|t
34109922|NCT04049474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109923|NCT05866302|||COHORT||PROSPECTIVE|||||||
34109924|NCT00001854||||TREATMENT||||||||
34109925|NCT05172297|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a non-randomized controlled experiment (i.e., quasi-experiment) with a wait-list comparison group||||
34109926|NCT01427478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109927|NCT06528418|||COHORT||PROSPECTIVE|||||||
34109928|NCT05022719|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"Single-center, prospective, non-randomized clinical trial designed to evaluate the technical feasibility during CCE procedure, when using MB-MMX as a contrast- enhancement technique of mucosal staining in CRC high risk population.~Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.~The technical feasibility will be evaluated by:~1. The percent of colonic polyps which have a visible contrast to the healthy colonic mucosa during CCE.~2. The interference level of detrimental effects on the visualization of the colonic mucosa during CCE, due to use of MB-MMX per colonic segment."||||
34109929|NCT04943757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109930|NCT06048029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109931|NCT04531579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In addition to the individuals listed above, Sponsor's representatives such as clinical research associates who will perform site monitoring, the pharmacovigilance medical monitor, and all staff at the research sites other than the pharmacist of record will be masked.|A phase 2, single-dose, multicenter, double-blind, randomized, placebo-controlled study|t|t|t|f
34109932|NCT05411900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To maintain the blinding of the study drug (BoNT-A or placebo), all study personnel will be blinded to subjects' treatment assignment. Physicians, nurses, subjects, and any study personnel performing assessments must NOT be informed of the subject's treatment assignment except in the event of a medical emergency or as required by regulatory authorities. The injection syringes will be prepared by pharmacy personnel not involved in the study to ensure that the clinical site staff responsible for administering the study drug and conducting assessments per the protocol, and the subject, remain blinded to study treatment. Moreover, the BoNT-A and placebo solution will be limpid and indistinguishable, to maintain blindness. Both subjects, investigators and study personnel will maintain blindness to the treatments throughout the study.|Interventional prospective, multicenter, randomized, double-blind, placebo-controlled study.|t|t|t|f
34109933|NCT06192420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|CRO (including CRAs)|Randomized, double-blind, active- and placebo-controlled confirmatory clinical trial|t|t|t|t
34109934|NCT04941885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109935|NCT00966667|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34109936|NCT00751231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109937|NCT04595292|||OTHER||PROSPECTIVE|||||||
34109938|NCT05664529|||COHORT||CROSS_SECTIONAL|||||||
34109939|NCT04728230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109940|NCT06274177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109941|NCT02759133|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34109942|NCT06500585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34109943|NCT04932772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109944|NCT00723632|||CASE_ONLY||PROSPECTIVE|||||||
34109945|NCT05103332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109946|NCT06645444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109947|NCT06638684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34109948|NCT05018507|||CASE_CONTROL||RETROSPECTIVE|||||||
34109949|NCT02496000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109950|NCT06424002|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109951|NCT06189573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The selection of the graft to be used will be carried out randomly with a box with a closed envelope, which contains the same number of envelopes with one or another type of graft, and the resulting option will be the way in which the type of graft is assigned. graft, which will not be disclosed to the patient during the period of the study.~Subjective and objective clinical evaluations with KT-1000 will be carried out preoperatively and postoperatively at 3, 6, 12 and 24 months by 2 evaluators who will be blinded to the type of graft used in each patient, for which the anterior part of his knee will be covered with a 20cm long micropore band, so that the type of graft cannot be identified by the evaluator based on the area of the knee and surgical scar."|Controlled, longitudinal, prospective, randomized, double-blind clinical trial that will include patients from the Luis Guillermo Ibarra-Ibarra National Rehabilitation Institute (INRLGII) of the Sports Orthopedics and Arthroscopy service, with primary ACL injury who undergo surgery with a consistent procedure in ACL reconstruction either with the use of bone tendon bone graft or quadriceps tendon with bone pad in the period from October 2023 to October 2025.|t|t|f|t
34109952|NCT04621877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34109953|NCT05024162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109954|NCT06607770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109955|NCT05697380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109956|NCT05603637|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34109957|NCT05507333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109958|NCT05052684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109959|NCT05497024|||CASE_ONLY||CROSS_SECTIONAL|||||||
34109960|NCT05765175|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Varian CRA trial is a multicenter, international, pivotal, 2-arm randomized controlled trial (RCT). Subjects will be randomized 1:1 to CRA or repeat CA. Randomization will be stratified by (1) enrolling institution and (2) NYHA class I/II vs. III/IV. Blinding will not be used in this trial, as the different interventions cannot be blinded.||||
34109961|NCT06645171|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34149710|NCT02128945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149711|NCT00792532|||COHORT||PROSPECTIVE|||||||
34109962|NCT06077214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not be told the group to which they were assigned and will have been under anesthesia for administration. The surgeon, other clinical team members, and the study staff will not be blinded to the study group assignment.|Patients will randomly be treated with either liposomal bupivacaine (study drug) or standard bupivacaine after undergoing bariatric surgery.|t|f|f|f
34109963|NCT06610890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109964|NCT05588323|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34109965|NCT03044795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34109966|NCT05234216|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, prospective, interventional, randomized cluster study.||||
34109967|NCT06163404|NA|SINGLE_GROUP||TREATMENT||NONE||Device: Spirair NSD system for minimally invasive correction of nasal septal deviation.||||
34109968|NCT06637202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109969|NCT04331249|||COHORT||PROSPECTIVE|||||||
34109970|NCT00655655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34109971|NCT04239703|||COHORT||PROSPECTIVE|||||||
34109972|NCT06636942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34109973|NCT04023110|RANDOMIZED|PARALLEL||PREVENTION||NONE||An internally validated CV risk score will be used to determine an individual patient's risk. Low risk patients will be observed and managed according to usual care. Elevated risk patients will be randomized to open label, individually dosed carvedilol for 1 year or usual care.||||
34109974|NCT05214573|||COHORT||RETROSPECTIVE|||||||
34109975|NCT05668624|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34109976|NCT05585294|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessor unaware of what care was provided, and care was provided by other providers. Possibility of sequential trail is considered. The value of p will be adjusted depending the number of analysis made and stopping rule will be followed.|pre and post outcomes comparison after clinical intervention|f|t|f|t
34109977|NCT03332056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109978|NCT05750784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34109979|NCT04906343|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients selected for the study will be randomised in two groups for the surveillance: group 1, surveillance with colonoscopy in two years; group 2, surveillance with colonoscopy in three years.||||
34109980|NCT03969030|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||PEBRA study is a cluster randomized, open-label, superiority trial in a resource-limited setting||||
34109981|NCT05618925|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4 week cycle of the CD19 t haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab (cohort A) or in combination with rituximab and N-803 (cohort B). Following a second 1-week rest period, subjects will receive up to 4 repeated 4 week cycles of CD19 t haNK in combination with rituximab (cohort A) or in combination with rituximab and N 803 (cohort B) without lymphodepleting chemotherapy.||||
34109982|NCT05797623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34109983|NCT06571162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34109984|NCT04190472|||COHORT||PROSPECTIVE|||||||
34109985|NCT04905407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34109986|NCT00541424|||CASE_ONLY||PROSPECTIVE|||||||
34109987|NCT01344226|||CASE_ONLY||PROSPECTIVE|||||||
34109988|NCT06603493|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34109989|NCT04695366|||COHORT||PROSPECTIVE|||||||
34109990|NCT06386107|NA|SINGLE_GROUP||OTHER||NONE||"Prospective cohort of consecutive patients initiating full-dose anticoagulant therapy for an episode of CAT, followed up until the 6th month of treatment to assess the risk of clinically relevant adjunctive bleeding events and any other adverse event during anticoagulant therapy (recurrence of CAT, death).~TGT measurement is fully automated and calibrated with quality control."||||
34109991|NCT01506726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34109992|NCT05755269|||COHORT||PROSPECTIVE|||||||
34109993|NCT06100120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34109994|NCT05427929|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34109995|NCT04115566|||COHORT||PROSPECTIVE|||||||
34109996|NCT00271180|||COHORT||PROSPECTIVE|||||||
34109997|NCT00233246|RANDOMIZED|||PREVENTION||NONE||||||
34109998|NCT05128903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34109999|NCT06640374|||OTHER||CROSS_SECTIONAL|||||||
34110000|NCT06063876|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34110001|NCT06483113|||COHORT||OTHER|||||||
34110002|NCT04280588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110003|NCT03286361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110004|NCT04708847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110005|NCT04943848|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I, open label, plus expansion clinical trial||||
33807232|NCT03704519|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34110006|NCT00642759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807233|NCT01748864|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110007|NCT00936650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807234|NCT01658345|||COHORT||PROSPECTIVE|||||||
33807235|NCT06452173|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807236|NCT04969666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807237|NCT05049941|||CASE_ONLY||PROSPECTIVE|||||||
33807238|NCT05319041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807239|NCT01160887|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807240|NCT00973999|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33807241|NCT05842265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33807242|NCT00123409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807243|NCT03543631|||OTHER||CROSS_SECTIONAL|||||||
33807244|NCT04596488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807245|NCT00283205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807246|NCT03958773|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, single-arm feasibility clinical study.||||
33807247|NCT04825379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110008|NCT00539500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110009|NCT06471010|||COHORT||PROSPECTIVE|||||||
34110010|NCT04666740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a phase 2, open-label, non-randomized study.||||
34110011|NCT03162627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110012|NCT05914129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110013|NCT06602011|||COHORT||PROSPECTIVE|||||||
34110014|NCT05787041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807248|NCT00949364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807249|NCT02470806|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33807250|NCT05798065|||COHORT||RETROSPECTIVE|||||||
33807251|NCT04696900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807252|NCT02741505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807253|NCT03643224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807254|NCT06700057|||COHORT||OTHER|||||||
33807255|NCT03142490|RANDOMIZED|PARALLEL||TREATMENT||NONE||In vitro fertilization patients will be randomized into two groups: treatment group (with complementary acupuncture) and control group (without complementary acupuncture).||||
33807256|NCT00044603|||COHORT||PROSPECTIVE|||||||
33807257|NCT02349516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036005|NCT04727385|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an adaptative-design, interventional, open-label, single-arm trial performed at a single centre in France.~3 cohorts will be sequentially initiated according to the DSMB review of the safety parameters :~The safety primary endpoints of each cohort will be assessed by an independent Data Safety Monitoring Board (DSMB) at Day 42 post-injection to provide safety oversight on the patients and guidance on initiating the study on the next cohort.~Patients will be injected at day 0 and will be followed-up for a variable period according to the cohort.~* As the first enrolled cohort, the 1L cohort will have the longest follow-up (48 weeks) and will attend 9 visits.~* The second cohort (2L) will have a shorter follow-up period (36 weeks) attend the same visits except for V9, which will not be done.~* The third cohort (1-2L) will will have the shorter follow-up period (24 weeks) and will attend visits 1 to 7 except for V4, which will not be done."||||
34036006|NCT05352230|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34036007|NCT01431079|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34036008|NCT01608100|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036009|NCT04827095|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34036010|NCT05362071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking Description: Blinding will be implemented for the outcome assessors. All tests and questionnaires will be supervised by an evaluator blinded to the participant's group. Due to the type of intervention, the investigator conducting exercise sessions and participants will not be blinded.|This is a randomized, single-blinded, parallel, superiority, controlled trial. Participants males and females with type 2 diabetes mellitus will be allocated to experimental and control groups based on a randomization sequence created in blocks by an independent research assistant with a 1:1 ratio. Allocation concealment will be implemented through a central randomization routine conducted by the same investigator to generate the sequence. The allocation of participants will occur after the completion of baseline outcomes evaluations.|f|f|f|t
34036011|NCT06212531|NA|SINGLE_GROUP||PREVENTION||NONE||Observational study of recruitment of young Papuan men who volunteer for medical male circumcision.||||
34036012|NCT02123784|||COHORT||PROSPECTIVE|||||||
34036013|NCT05405751|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pilot, prospective, single-centre, single-arm, single-treatment study.||||
34036014|NCT02333058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036015|NCT00204490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Research pharmacist dispensed study pills according to a pre-generated randomization list and were blinded to all other aspects of the study protocol.~Subjects, research staff, investigators, and statistician all were blinded to treatment assignment."|One group received soy isoflavones (60 mg daidzein, 60 mg gensitein and 16.6 mg glycitein, all as aglycone equivalent) Another group, carbohydrate filler|t|t|t|t
34036016|NCT06168461|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|double blind||t|t|t|t
34036017|NCT05592171|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open-label interventional study on a medical device.||||
34036018|NCT02336321|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34036019|NCT04818125|NA|SINGLE_GROUP||OTHER||NONE||||||
34036020|NCT02090725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036021|NCT00995124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036022|NCT04098341|NA|SINGLE_GROUP||SCREENING||NONE|as above|Observational study assessing the feasibility and acceptability of opt-out screening for latent Tuberculosis infection amongst pregnant migrants in antenatal clinics. All pregnant migrants who meet the inclusion criteria will be offered an opt-out IGRA blood test as screening for latent TB infection||||
34036023|NCT00115076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036024|NCT03991234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036025|NCT01161511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036026|NCT00646490|||COHORT||PROSPECTIVE|||||||
34036027|NCT03808181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036028|NCT04939298|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036029|NCT03979625|||COHORT||RETROSPECTIVE|||||||
34036030|NCT06052293|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|||||
34036031|NCT05934630|||COHORT||PROSPECTIVE|||||||
34036032|NCT05761314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036033|NCT04444024|||CASE_ONLY||RETROSPECTIVE|||||||
34036034|NCT06430164|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34036035|NCT01257269|||CASE_ONLY||OTHER|||||||
34036036|NCT03035591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036037|NCT02621866|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34036038|NCT03055624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036039|NCT04055740|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort of patients undergoing transvenous lead extraction||||
34036040|NCT03485144|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036041|NCT01105897|||COHORT||PROSPECTIVE|||||||
34036042|NCT06447532|||COHORT||RETROSPECTIVE|||||||
34036043|NCT03765372|||OTHER||PROSPECTIVE|||||||
34036044|NCT04933344|||CASE_CONTROL||RETROSPECTIVE|||||||
34110015|NCT06241846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110016|NCT06634498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|single blind: both participants and experiment won't know the stimulation condition|within-subject, sham-controlled design: all subjects will receive active and sham rTMS in a randomized order|t|f|t|f
34110017|NCT06272890|RANDOMIZED|PARALLEL||OTHER||SINGLE|In order to prevent detection bias in the study, all measurements will be made using an online survey form. In order to prevent reporting bias, the data obtained from the research will be coded as A and B by an independent statistician, transferred to the SPSS program and analyzed.|The research was planned as a randomized controlled experimental study in a two-center parallel group pretest-posttest design.|f|f|f|t
34110018|NCT02478281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110019|NCT06449118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110020|NCT05905146|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110021|NCT06209619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110022|NCT05487391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110023|NCT05386472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|(Open Label)|||||
34110024|NCT06040255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because corticosteroids cause significant behavioral effects in children, the local study investigators cannot be effectively blinded to the treatment; however, one of the study biostatisticians and all personnel reviewing neuroimaging as a part of the neuroimaging core will be blinded to Study Arm assignment.||f|f|f|t
34110025|NCT04172220|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single center, open label randomised controlled trial||||
34110026|NCT05836701|||CASE_ONLY||RETROSPECTIVE|||||||
34110027|NCT06498258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||In this study, positive psychotherapy balance model applied to individuals caring for oncology patients the effect of psychoeducation intervention on balanced life, psychological well-being and self-efficacy. It will be carried out as a randomised control group experimental research with pretest-posttest follow-up.|t|f|f|f
34110028|NCT06125405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110029|NCT00610220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110030|NCT00443456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110031|NCT04873908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110032|NCT02438969|||COHORT||PROSPECTIVE|||||||
34110033|NCT00336206|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110034|NCT04466007|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110035|NCT06564194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded study||t|t|t|t
34110036|NCT05656664|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study randomization will be performed by using a randomization scheme provided by the Investigational Drug Service (IDS). The randomization scheme will be held by IDS and concealed to investigators until the completion of the study.|Study procedures will consist of recruitment of 100 subjects, 50 each in the treatment (Folic Acid, 800 mcg) and placebo groups respectively. Folic Acid 800 mcg or placebo pill bottles will be provided to the participants with instructions to take one pill orally daily. Both the investigators and subjects will be blinded. Compliance will be measured via pill count.|t|t|t|t
34110037|NCT06642025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110038|NCT02971163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34110039|NCT06000787|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two non-randomized cohorts with assignment based on tumor type||||
34110040|NCT06365502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110041|NCT00850330|||COHORT||PROSPECTIVE|||||||
34110042|NCT04130191|||COHORT||PROSPECTIVE|||||||
34149712|NCT03624452|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34149713|NCT04407104|||COHORT||RETROSPECTIVE|||||||
34149714|NCT04196673|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination, fibrosis, posterior capsule opacification (PCO) score and YAG capsulotomy rate.|t|f|t|f
33807258|NCT00367653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807259|NCT02334215|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149715|NCT06266104|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34149716|NCT00604617|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34149717|NCT01162668|||OTHER||PROSPECTIVE|||||||
34149718|NCT03695965|||OTHER||CROSS_SECTIONAL|||||||
34149719|NCT05356338|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study staff collecting data on the primary outcome of beverage consumption at 3 and 6 month follow-up will be blinded to group allocation of participants.||f|f|f|t
34149720|NCT03158350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807260|NCT01307800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807261|NCT03937765|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage.||||
33807262|NCT05705323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807263|NCT04890899|||COHORT||RETROSPECTIVE|||||||
33807264|NCT04239768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149721|NCT01342614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149722|NCT00003709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149723|NCT00861016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149724|NCT06438796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149725|NCT00851994|||CASE_CONTROL||PROSPECTIVE|||||||
34149726|NCT06160830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149727|NCT04570189|||COHORT||RETROSPECTIVE|||||||
34149728|NCT03561935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110043|NCT05322005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatment A (augmentation-to-surgery): subjects surgically treated with partial meniscectomy combined with an intraarticular and intra-meniscal injection of polynucleotide gel.~Treatment B (conservative): subjects treated with three injections session of polynucleotide gel."||||
34110044|NCT05708859|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Double blind Placebo controlled|t|t|t|t
34110045|NCT05878795|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110046|NCT06626126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110047|NCT06640816|||OTHER||OTHER|||||||
34110048|NCT02706392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110049|NCT05136495|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34110050|NCT06460155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study is a prospective diagnostic accuracy study. All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.||||
34110051|NCT05409794|||COHORT||CROSS_SECTIONAL|||||||
34110052|NCT05549362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34110053|NCT06418061|NA|SEQUENTIAL||TREATMENT||NONE||||||
34110054|NCT06637930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34110055|NCT03947463|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Registered pain nurse||f|f|f|t
34110056|NCT02239237|||COHORT||PROSPECTIVE|||||||
34110057|NCT05706350|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34110058|NCT02322385|||COHORT||PROSPECTIVE|||||||
34110059|NCT06493253|||COHORT||RETROSPECTIVE|||||||
34110060|NCT04907955|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110061|NCT00301860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110062|NCT06043154|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110063|NCT05470686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110064|NCT01172392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110065|NCT00672035|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110066|NCT03471845|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34110067|NCT03624075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The volunteers will be recruited from the waiting list of the Clinic School of Physiotherapy of the Faculty of Health Sciences of Rio Grande do Norte, as well as the community in general. Initially, a signature will be requested from the TCLE and the next series of personal data. When we are already included, how should participants assess pain, muscular strength, edema and physical function (T0). Then all of them must be allocated to one of the three groups, where due intervention is required for each group. After one session, muscle strength and pain were again assessed (T1) and 72 hours later (T2), all outcomes assessed at time T0 were retested, including the global rating of change.|f|f|f|t
34110068|NCT04278781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110069|NCT01210781|||COHORT||PROSPECTIVE|||||||
34110070|NCT04925284|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalation followed by cohort-expansion in tumor-specific expansion cohorts||||
34110071|NCT05976633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||crossover randomized clinical trial.|t|f|f|f
34110072|NCT03618407|||CASE_ONLY||RETROSPECTIVE|||||||
34110073|NCT05810480|||CASE_CONTROL||PROSPECTIVE|||||||
34110074|NCT06468137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110075|NCT06625710|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||"There are two sequential arms plus one extra cohort:~Part A: 2.24 mg and 4.48 mg Part B: 0.56 mg, 1.12 mg, 2.24 mg, and 4.48 mg Extra cohort: 1.12 mg, 8 Caucasian, after completion of dose group 1.12 in Part B.~All dose groups will recruit participants at a ratio of 6:2 for the study drug to placebo.~All dose escalation between dose groups and from Part A to Part B will be determined by the SRC's review and must be carried out sequentially."|t|t|t|t
34110076|NCT04077502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants in control group were stimulated by sham repetitive transcranial magnetic stimulation coil. The investigator did not know if the participants were stimulated by real or sham coil. Stimulation was provided by other member of invetigation group.|randomized double blinde and placebo controlled|t|f|t|t
34110077|NCT01649869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110078|NCT05650866|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110079|NCT03193580|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants will be assigned to one of three groups (sham, tDCS, HD-tDCS) throughout the duration of the study.|t|f|f|t
34110080|NCT06602830|||COHORT||PROSPECTIVE|||||||
34110081|NCT06317597|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
34110082|NCT05827341|||COHORT||RETROSPECTIVE|||||||
34110083|NCT02116335|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34110084|NCT03923335|||COHORT||PROSPECTIVE|||||||
34110085|NCT02891356|||COHORT||PROSPECTIVE|||||||
34110086|NCT04199390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34110087|NCT04965363|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34110088|NCT06496724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110089|NCT05703295|||COHORT||PROSPECTIVE|||||||
34110090|NCT00163293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110091|NCT06640205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110092|NCT06355297|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A quasiexperimental controlled trial is designed, with two arms: an experimental group and a control group.||||
34110093|NCT05990491|||COHORT||PROSPECTIVE|||||||
34110094|NCT02631785|NON_RANDOMIZED|PARALLEL||||NONE||||||
34110095|NCT00553254|NON_RANDOMIZED|||TREATMENT||NONE||||||
34110096|NCT01156350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110097|NCT06645275|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110098|NCT05131256|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34110099|NCT06631534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110100|NCT06616155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110101|NCT04198012|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label rollover study.||||
34110102|NCT05671666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110103|NCT06277284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110104|NCT04662450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34110105|NCT06637345|||COHORT||PROSPECTIVE|||||||
34110106|NCT00761137|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34110107|NCT03796104|||CASE_CONTROL||PROSPECTIVE|||||||
34110108|NCT00319007|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34110109|NCT03231267|||CASE_CONTROL||PROSPECTIVE|||||||
34110110|NCT04480866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110111|NCT04204915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110112|NCT02831049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110113|NCT03826472|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34110114|NCT01830803|||OTHER||PROSPECTIVE|||||||
34110115|NCT06119204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the intervention, participants will not be blinded, thus they will be aware of the group allocation. However, the statistician will be blinded to participant allocation.|This study is a single centre, parallel-group, randomised controlled trial,||||
34110116|NCT03662607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110117|NCT04227379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All participants will receive a texting intervention but they will not be told whether their intervention is part of the experimental or comparison arm.|Once consented by project coordinators, patients will be asked to complete the baseline survey instruments. Participants will then be randomized with stratification by gender, using a separate randomization table per site. The investigators will first recruit women, with the goal of achieving 10-20% of the sample at each site. The investigators will then recruit male Veterans until the investigators obtain 200 to DD-TXT and 200 to DSE, for a total of 400 enrolled across sites.|t|f|f|f
34110118|NCT04779008|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental Group 1:The patient underwent one RIPC (Four five-minute cycles of upper limb ischaemia and Four five-minute pauses using a blood pressure cuff air vehicle to 200 mmHg) 4 hours before surgery, then normal surgery, and RIPC was performed on the second day after surgery and every day after surgery, which lasted for 1 year.~Experiment Group 2: Patients underwent once RIPC 4 hours before surgery, and then normal medical procedures were performed with no additional intervention.~Control group: Patients did not receive any additional intervention."||||
34110119|NCT03682484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110120|NCT01323374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110121|NCT03452202|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34110122|NCT06643338|||COHORT||PROSPECTIVE|||||||
34110123|NCT06094621|||COHORT||OTHER|||||||
34110124|NCT04950439|NA|SINGLE_GROUP||OTHER||NONE||||||
34110125|NCT02290912|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33807265|NCT06566339|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807266|NCT01316705|||CASE_CONTROL||PROSPECTIVE|||||||
33807267|NCT03041961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34110126|NCT05022316|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A randomized quasi-experimental design will be used to assess the impact of the newly developed CDS tools designed to support social-risk informed care.||||
34110127|NCT04623593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded until one-year after allocation.|Prospective Single-blind Randomised Controlled Trial with computer randomization in a 1:1 ratio|t|f|f|f
34110128|NCT00951639|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34110129|NCT03982316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110130|NCT03985527|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an acute, prospective, non-randomized, single arm IDE feasibility study.||||
34110131|NCT05580042|NA|SINGLE_GROUP||TREATMENT||NONE||patients with Granuloma Annulare||||
34110132|NCT03462602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110133|NCT04379830|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single center, single-arm prospective cohort pilot study.||||
34110134|NCT05349604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110135|NCT03508674|NA|SINGLE_GROUP||OTHER||NONE||||||
34110136|NCT04100018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blinded||t|t|t|t
34110137|NCT04789941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110138|NCT03976596|||COHORT||CROSS_SECTIONAL|||||||
34110139|NCT06624995|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34110140|NCT01283984|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34110141|NCT04850456|||COHORT||RETROSPECTIVE|||||||
34110142|NCT05929313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110143|NCT02825667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110144|NCT03750019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34110145|NCT02602145|||OTHER||PROSPECTIVE|||||||
34110146|NCT00001055||||PREVENTION||DOUBLE||||||
34110147|NCT04318938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110148|NCT02903147|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110149|NCT02592863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110150|NCT06377319|||COHORT||PROSPECTIVE|||||||
34110151|NCT05179577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110152|NCT01542203|||COHORT||PROSPECTIVE|||||||
34110153|NCT05787249|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34110154|NCT01202084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110155|NCT05385107|||COHORT||RETROSPECTIVE|||||||
34110156|NCT00939185|||||PROSPECTIVE|||||||
33807268|NCT02892019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807269|NCT01588054|||CASE_ONLY||PROSPECTIVE|||||||
33807270|NCT01201837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807271|NCT01413659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33838128|NCT03683537|||CASE_CONTROL||PROSPECTIVE|||||||
33838129|NCT01024153|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33838130|NCT01889576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838131|NCT02215564|||COHORT||PROSPECTIVE|||||||
33838132|NCT00148668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838133|NCT05292053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838134|NCT04276259|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||This is a mechanistic trial.|t|f|t|f
33838135|NCT04634474|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34036045|NCT05579431|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34036046|NCT03203967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34036047|NCT00738179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036048|NCT04478929|||CASE_CONTROL||PROSPECTIVE|||||||
34036049|NCT05385653|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Cross-sectional, single-center comparative study||||
34036050|NCT04088812|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34036051|NCT04678518|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE||"The study will be conducted in the Heart Hospital to be conducted from the time of ethical approval for 24 months.~The clinical characterization of post decannulation SIRS when patient fulfill 2 out of 3 criteria, fever (temperature \>38.3 Celsius), leukocytosis (white blood cell \[WBC\] \>12,000, or \> 25% increase from pre-procedure baseline), and need for escalation of vasopressors post decannulation. The rest of SIRS criteria will not be used as it is subjected to changes due to contribution from the inotropes, sedation, pain level and ventilation settings. \[12\] Patients will be grouped according to the presence or absence of SIRS criteria into group I (SIRS) and group II (no-SIRS). Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF 1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours) both groups will be compared."|t|f|f|f
34036052|NCT05362604|||COHORT||RETROSPECTIVE|||||||
34036053|NCT01357499|||CASE_CONTROL||PROSPECTIVE|||||||
34036054|NCT03627546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036055|NCT01388959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036056|NCT06347224|NON_RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34036057|NCT04074187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036058|NCT05050812|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||An interventional, single-group method that lacks random assignment and has no control group but does provide baseline and post-intervention testing.||||
34036059|NCT01880892|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036060|NCT02552446|||||PROSPECTIVE|||||||
34036061|NCT03196583|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric, prospective, open-label, interventional, exploratory pilot study.||||
34036062|NCT04196569|||COHORT||PROSPECTIVE|||||||
34036063|NCT03640312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036064|NCT02928289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036065|NCT03902665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036066|NCT01487525|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34036067|NCT01288807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036068|NCT01622647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34036069|NCT05819970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||patients and assessors involved in the study from randomization, allocation, bacteriological outcome, and data analysis will be blinded to which medicament group the patients belonged as all data will be coded.|t|f|f|t
34036070|NCT02492373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34036071|NCT01568567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34036072|NCT02142790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036073|NCT00897715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036074|NCT01622673|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036075|NCT04898686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double blind, randomized, placebo controlled|t|f|t|t
34036076|NCT04587154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group will be asked to stay on their usual diet.|One arm, the intervention group, has been randomly assigned to be on a low-fat vegan diet while consuming 1/2 cup of cooked soybeans each day. The other arm, the control group, will maintain their pre-study diet for the duration of the study.|f|f|t|f
34036077|NCT01560975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036078|NCT00955929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036079|NCT04363580|||CASE_ONLY||PROSPECTIVE|||||||
34036080|NCT01706406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036081|NCT04991246|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34036082|NCT04159389|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34036083|NCT05830786|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|Investigators and outcome assessors will be blinded to participant group allocation. Participants will also be blinded to group assignment up to the point of study initiation.||t|f|t|t
34036084|NCT03726372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Muscle relaxant will be given by a specific investigator that is not involved in anesthesia and outcome assessment||t|t|f|t
34036085|NCT05274178|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be told they are wearing either a prescriptive hearing aid or an OTC (Over-The-Counter) hearing device based on the labeling of the hearing aids. Both sets of devices will actually be the same. The investigator that is scoring the objective speech in noise test will not know which device the participant is wearing at the time of the test (i.e., the set that is labeled as prescriptive or the set that is labeled as OTC).|A single group of participants will be involved in this study. All participants will be evaluated with both hearing devices.|f|f|t|f
34036086|NCT03825354|RANDOMIZED|PARALLEL||OTHER||NONE||a randomized study with 1:1 parallel design||||
34036087|NCT05587010|||CASE_ONLY||CROSS_SECTIONAL|||||||
34036088|NCT04018378|RANDOMIZED|CROSSOVER||TREATMENT||NONE||an open-label, randomized, single-dose crossover clinical trial||||
34110157|NCT06527274|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The lenses used in this study are daily disposable. This means that for each type of lens worn, participants will receive 7 lenses of each type. Lenses will be delivered one type at a time for the next week. The lenses will be packaged with a neutral label with a lot number. It is impossible for the participant to know which type this lot number corresponds to. Therefore, they do not know what type of lens they will receive.|Prospective, randomized, crossover masked study. Participants are randomly assigned to wear one type of soft lens for one week, then washed out for a few days, and then the second type of soft lens for the same period of time. Participants are masked to the type of lens provided|t|f|f|f
34110158|NCT02923167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807272|NCT05624138|RANDOMIZED|PARALLEL||PREVENTION||NONE||"- Study design This study will be a Randomized placebo controlled parallel study Group one (Placebo group or code A; n=32)~Patients will receive 12 cycles of modified FOLFOX-6 regiment plus placebo tablets daily throughout the twelve chemotherapy cycles. The chemotherapy cycles will be received every 2 weeks and will be as follows:~Day 1: Oxaliplatin 85 mg/m2 intravenous infusion in 250-500 mL 5% dextrose solution and leucovorin 400 mg/m2 intravenous infusion in 5% dextrose solution both were given over 120 minutes at the same time in separate bags using a Y-line access, followed by 5-fluorouracil 400 mg/m2 intravenous bolus given over 2-4 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenous infusion in 500 mL 5% dextrose solution as a 46-hour infusion.~Group two (Ketotifen group or code B; n=32) Patients will receive the same chemotherapy regimen as group one in addition to oral ketotifen 2 mg daily throughout the twelve chemotherapy cycles."||||
34110159|NCT05697588|||COHORT||PROSPECTIVE|||||||
34110160|NCT00830531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110161|NCT06468553|NA|SINGLE_GROUP||PREVENTION||NONE||"The impact of the intervention on the change in weight and glycated hemoglobin will be determined, secondarily the change in quality of life will also be measured, using a before and after design. Subjects who attend the Specialized Diabetes Management Clinic and meet the selection criteria will be included in this study. Once their admission to the study has been decided, subjects will be able to participate in the recruitment and intervention stage and then in the annual follow-up stage"||||
34110162|NCT03333187|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatment A (only with a suitable stem cell donor):~Allogeneic SCT after 3 months of Ruxolitinib induction therapy~Treatment B:~Ruxolitinib continuous therapy"||||
34110163|NCT05006755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110164|NCT00835367|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34110165|NCT02671292|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110166|NCT04951193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110167|NCT04392076|||COHORT||PROSPECTIVE|||||||
34110168|NCT03131479|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110169|NCT05829044|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will have the same study conditions and schedule except for the order combinations of light stimuli within the pupillometer testing. There are 8 different order combinations of light stimuli. Participants will be randomized to one of those combinations.||||
34110170|NCT05377411|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Procedures for tDCS will be identical for both arms with the exception of the amount of current delivered. Neither the participant nor the experimenter will know the amount of current delivered during tDCS sessions. Web-based permuted block randomization to randomly divide participants into the two groups.|Arm 1 will receive optimized tDCS paired with cognitive training. Arm 2 will receive sham tDCS paired with cognitive training.|t|t|t|t
34110171|NCT05299424|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110172|NCT00167037|||CASE_CONTROL||OTHER|||||||
34110173|NCT03323255|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34110174|NCT06396559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34110175|NCT06414031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110176|NCT06639685|||CASE_ONLY||PROSPECTIVE|||||||
34110177|NCT06223152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110178|NCT04138355|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients' burn scars had re-epithelialized after aseptic care or skin graft. We included patients aged ≥18 years with a deep partial-thickness (second-degree) burn or a full thickness (third-degree) burn to their hands, with joint contracture(hand and wrist), having been transferred to the rehabilitation department after acute burn treatment, and less than 6 months since the onset of the burn injury. Selected patients had a history of hand surgery resulting in painful, retracting scarring on hands.||||
34110179|NCT05748210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34110180|NCT05497934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will undergo OCT and conventional endoscopic imaging before topical application of glycerol to the tympanic membrane, after topical application of glycerol to the tympanic membrane and after rinsing the tympanic membrane with saline.||||
33807273|NCT02191670|||COHORT||PROSPECTIVE|||||||
34110181|NCT03716596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110182|NCT03070665|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34110183|NCT01542944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110184|NCT03782493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors and data coders will be blind to experimental condition|A stratified randomized clinical trial design will be used with site (Vanderbilt, Northwestern) and biological sex (boys, girls) as stratification factors and EMT-SF or business-as-usual (BAU) control as a randomization factor.|f|f|f|t
34110185|NCT02929732|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34110186|NCT04652297|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34110187|NCT05229705|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both participants and accessors will be blinded to group allocation|Experimental group versus control group|t|f|f|t
34110188|NCT02956473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110189|NCT00843960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34110190|NCT04795219|||CASE_ONLY||CROSS_SECTIONAL|||||||
34110191|NCT06527677|NA|SINGLE_GROUP||OTHER||NONE||||||
34110192|NCT06096363|||COHORT||PROSPECTIVE|||||||
34110193|NCT03584490|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The study is a two-group, three time-point experimental design. The two study groups are paper-and-pencil questionnaires versus a computerized talking touchscreen interface. The three time points are baseline, 3-month follow-up, and 6-month follow-up.~Additionally, due to the COVID-19 pandemic, participants can optionally enroll in a phone-based assessment that includes 3 time-points over 6 months."||||
34110194|NCT05380947|RANDOMIZED|CROSSOVER||TREATMENT||NONE||4-way crossover||||
34110195|NCT06395935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34110196|NCT00839579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110197|NCT02772302|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Arm 1: patients Arm 2: healthy controls||||
34110198|NCT02892279|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110199|NCT06511778|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patient will not know whether they had the hemostatic agent applied during scheduled on pump sternotomy surgery as an additional adjunct to control bleeding.|Patients undergoing on pump sternotomy surgery|t|f|f|f
34110200|NCT01676870|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110201|NCT05197842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110202|NCT04347967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110203|NCT02699411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34110204|NCT06548724|||COHORT||PROSPECTIVE|||||||
34110205|NCT01533987|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34110206|NCT06368206|NA|SINGLE_GROUP||OTHER||NONE||1 study cohort that will test investigational device (Aktiia G2C) and Blood Pressure and Pulse Rate references.||||
34110207|NCT01483170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807274|NCT03712150|||COHORT||CROSS_SECTIONAL|||||||
34110208|NCT06405269|||COHORT||PROSPECTIVE|||||||
33807275|NCT05018156|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33807276|NCT03347396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807277|NCT03477214|||COHORT||CROSS_SECTIONAL|||||||
34110209|NCT04164927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110210|NCT01415947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110211|NCT06095050|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center prospective randomized controlled study||||
34110212|NCT01865032|||CASE_ONLY||PROSPECTIVE|||||||
34110213|NCT06265415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110214|NCT01404247|NA|SINGLE_GROUP||SCREENING||NONE||||||
34110215|NCT06639971|||COHORT||RETROSPECTIVE|||||||
34110216|NCT00829465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110217|NCT00296712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110218|NCT04083027|||CASE_ONLY||CROSS_SECTIONAL|||||||
34110219|NCT06564766|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33807278|NCT00887224|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807279|NCT05153681|||COHORT||PROSPECTIVE|||||||
33807280|NCT02507869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807281|NCT05343494|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807282|NCT01638897|||OTHER||PROSPECTIVE|||||||
33807283|NCT05728996|||COHORT||PROSPECTIVE|||||||
34110220|NCT02758028|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34110221|NCT01324973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110222|NCT03456076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110223|NCT04012450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110224|NCT05038839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110225|NCT02943161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807284|NCT01779050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838136|NCT03525470|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Cross-over design where on one occasion subjects lost 0.5% body weight,and drank 300ml water and on another occasion nothing was consumed||||
34036089|NCT05899777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036090|NCT03538145|||COHORT||CROSS_SECTIONAL|||||||
34036091|NCT02380612|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participant and blinded evaluator will be not be told which treatment area received which treatment (RECELL or Control).|||||
34036092|NCT02843321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036093|NCT00489866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036094|NCT01207687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036095|NCT05976958|||COHORT||PROSPECTIVE|||||||
34036096|NCT05074368|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036097|NCT02817581|||COHORT||PROSPECTIVE|||||||
34036098|NCT01022476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036099|NCT00134823|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34036100|NCT02656303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036101|NCT02597764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036102|NCT03359148|||OTHER||PROSPECTIVE|||||||
34036103|NCT03110237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036104|NCT05514015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036105|NCT01149863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036106|NCT03859427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036107|NCT03342378|||COHORT||PROSPECTIVE|||||||
34036108|NCT05533619|||OTHER||RETROSPECTIVE|||||||
33725003|NCT05210166|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"For blinding of participants:~The protocol will be the same in the active tSCS and sham tSCS groups. The sham stimulation will consist of the same stimulation parameters used for active tSCS, except for the stimulus intensity, which will be set at the sensory threshold, maintained for 30 s and then slowly decreased to zero. The participants will receive the same instructions that given to the active tSCS session.~For blinding of outcomes assessor:~Two blinded assessors will perform the evaluations before, after and a follow-up at 4 weeks post-intervention.~The operator of the Lokomat will be also masked to the group allocation. To ensure this, the same stimulator and electrode location will be used for both groups and the screen of the device will be covered. Only the investigator who applies spinal stimulation will know which group belongs the patient."|"It is a double-blind, randomized, controlled clinical trial.~There will be two groups:~Group A (n=15): tSCS combined with Lokomat Group B (n=15): Sham-tSCS combined with Lokomat"|t|f|f|t
33725004|NCT02800291|||OTHER||PROSPECTIVE|||||||
33725005|NCT00139828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725006|NCT03930888|||COHORT||PROSPECTIVE|||||||
33725007|NCT01630512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725008|NCT05659810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A physician assessing outcomes blinded to the nature of the study and will monitor the block density and regression time. Drugs will be given to the patient by an anesthesiologist unaware of the study|Randomization by concealed envelope method|t|f|f|t
33725009|NCT01321125|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33725010|NCT02859051|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33725011|NCT00437593|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725012|NCT01060033|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33725013|NCT05188092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725014|NCT03318315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725015|NCT00258453||||DIAGNOSTIC||NONE||||||
33725016|NCT05707117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725017|NCT00816075|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|t|f|f
33725018|NCT05086887|||COHORT||PROSPECTIVE|||||||
33725019|NCT03568357|||COHORT||PROSPECTIVE|||||||
33725020|NCT02618434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725021|NCT02871388|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33725022|NCT03635255|||CASE_ONLY||PROSPECTIVE|||||||
34036109|NCT01709500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036110|NCT04176250|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34036111|NCT02315911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036112|NCT06394310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036113|NCT04876638|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34036114|NCT06583174|||COHORT||PROSPECTIVE|||||||
34036115|NCT01316081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34036116|NCT03856411|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34036117|NCT03957044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036118|NCT04878029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036119|NCT04072081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036120|NCT03572686|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34036121|NCT01708577|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34036122|NCT05383183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036123|NCT00474500||CROSSOVER||BASIC_SCIENCE||NONE||||||
34036124|NCT04495829|||CASE_ONLY||PROSPECTIVE|||||||
34036125|NCT02005380|||COHORT||CROSS_SECTIONAL|||||||
34036126|NCT01894919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036127|NCT02555579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036128|NCT00584324|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34036129|NCT05359263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725023|NCT04945629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807285|NCT06223373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"patients who will be recruited into randomized into 1 of 2 study arms: 1) those undergoing rehabilitation using Blood Flow Restriction (BFR) pressurized per standard protocols in addition to our institutional rehabilitation protocol or 2) those undergoing rehabilitation using sham BFR as well as our institutional rehabilitation protocol."||||
34036130|NCT06318520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036131|NCT03224312|||COHORT||PROSPECTIVE|||||||
34036132|NCT03992521|||OTHER||OTHER|||||||
34036133|NCT02021981|||||RETROSPECTIVE|||||||
34036134|NCT01878357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036135|NCT00499005|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34036136|NCT00613769|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34036137|NCT03982732|||COHORT||PROSPECTIVE|||||||
34036138|NCT00794768|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34036139|NCT00002578||||TREATMENT||||||||
34036140|NCT01332487|||COHORT||RETROSPECTIVE|||||||
34036141|NCT05981690|NA|SINGLE_GROUP||TREATMENT||NONE||Non concurrent multiple baseline design||||
34036142|NCT03028428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|A Randomized, Double Blind, Phase-II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients with Osteoarthritis of Knee|t|t|t|t
34036143|NCT04305132|||COHORT||PROSPECTIVE|||||||
34036144|NCT05832203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036145|NCT02642172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036146|NCT02201004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036147|NCT02565680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036148|NCT04575337|||COHORT||PROSPECTIVE|||||||
34036149|NCT02873793|||COHORT||PROSPECTIVE|||||||
34036150|NCT03289091|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34036151|NCT02298127|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34036152|NCT02308150|||COHORT||PROSPECTIVE|||||||
34036153|NCT02963779|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34036154|NCT05457504|RANDOMIZED|PARALLEL||OTHER||SINGLE||"In this study, we are testing different strategies to help women decrease issues with hypertension in the postpartum period. Participants may or may not undergo some of the following study procedures:~* Frequent blood pressure monitoring and feedback~* Receive information related to blood pressure measurement, heart disease prevention, etc.~* Regular blood pressure monitoring and advice regarding changes in medications."|t|f|f|f
34036155|NCT00208442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036156|NCT05359744|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||3 groups undergoing intervention, 1 control group||||
34036157|NCT05354167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036158|NCT00720213|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34036159|NCT00772863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036160|NCT02254382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036161|NCT03671161|NA|SINGLE_GROUP||TREATMENT||||19 patients with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day.||||
34036162|NCT01307332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036163|NCT04846400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036164|NCT02441010|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036165|NCT06581744|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036166|NCT03916718|||COHORT||PROSPECTIVE|||||||
34036167|NCT04099745|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34036168|NCT04359394|||COHORT||PROSPECTIVE|||||||
34036169|NCT01025882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036170|NCT04229862|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34036171|NCT03304691|||COHORT||PROSPECTIVE|||||||
34036172|NCT04753008|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036173|NCT03997812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036174|NCT03839420|RANDOMIZED|PARALLEL||TREATMENT||NONE||comparative randomized trial||||
34036175|NCT03485560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036176|NCT06581393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036177|NCT05066425|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34036178|NCT04744025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, clinical providers, investigators and Outcome assessors will be blinded to outcomes.|Sibling oocyte study: Participants will have their oocytes (eggs) divided into two groups. Half of the eggs will be injected with sperm processed in the normal way, and half will be injected with sperm processed via a microfluidics chamber.|t|t|t|t
34036179|NCT03739281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036180|NCT03164876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036181|NCT05264662|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||open label phase IV clinical trial||||
34036182|NCT01946750|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036183|NCT01899339|||CASE_ONLY||PROSPECTIVE|||||||
34036184|NCT00731835|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036185|NCT02070965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036186|NCT05051852|||COHORT||PROSPECTIVE|||||||
34036187|NCT04696224|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"For randomization, the computer generated random sequence (BIOESTAT 5.0) will be used. The allocation concealment will be guaranteed by the consecutive opening of numbered, opaque sealed envelopes, after anesthetic induction, opened by the anesthetist, who will be responsible for the intravenous administration and for instructing the nurse of the room about what should be placed in a vat for topical use: saline or tranexamic acid. The orthopedic medical team and the patient will not be aware of which of these will be used intravenously or topically (double blind). The envelopes opened by the anesthetist will have a card written: intravenous or local or placebo."|Primary, analytical, prospective, interventional, double-blind, controlled, randomized study in humans.|t|f|t|f
34036188|NCT01797874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036189|NCT00753038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036190|NCT05889650|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Unaware of randomisation arm|2-stage randomization|f|f|f|t
34110226|NCT04984200|||CASE_ONLY||CROSS_SECTIONAL|||||||
34110227|NCT06639035|||CASE_CONTROL||PROSPECTIVE|||||||
34110228|NCT06477692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are blinded to their treatment.|radiation ENI versus INRT|t|f|f|f
34110229|NCT05026801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded|Approximately 200 patients with symptoms of a RTI who test positive for SARS-CoV-2 by polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and chloroquine 500 mg or matching placebos for six consecutive days. There will be two treatment regimens into which patients are randomized so that all patients will receive some active therapy. A sequential probability ratio test will be employed in which comparisons between each regimen will be made with every Day 3 PCR endpoint; if the p value crosses a p=0.001 threshold for any pairwise comparison, the less efficacious arm will be closed to further enrollment and superiority will be declared.|t|t|t|f
34110230|NCT06564870|||OTHER||RETROSPECTIVE|||||||
34110231|NCT05575440|||COHORT||PROSPECTIVE|||||||
34110232|NCT05524012|||COHORT||PROSPECTIVE|||||||
34110233|NCT00283166|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34110234|NCT02022202|||CASE_ONLY||PROSPECTIVE|||||||
34110235|NCT04678258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are blinded to the treatment group. During FU the physician is blinded to the treatment group.|2 groups, randomized|t|f|f|t
34110236|NCT01847014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110237|NCT02310269|||COHORT||PROSPECTIVE|||||||
34110238|NCT06004037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110239|NCT01758120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110240|NCT06098573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110241|NCT03663023|||COHORT||RETROSPECTIVE|||||||
34110242|NCT04039347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110243|NCT03578055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110244|NCT06637150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110245|NCT00042263|||||OTHER|||||||
34110246|NCT02494115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110247|NCT06059898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110248|NCT00685295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34110249|NCT00960245|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34110250|NCT03962647|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110251|NCT06160245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110252|NCT06637163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110253|NCT03934294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized to one of two groups: Acu/ Con in a 1:1 ratio. The random number and patient name will be written down on an non transparent envelope by a study nurse. The study nurse will provide an envelope containing a sheet depicting the acupoint name, location and picture (Acu / Con) to the acupuncture doctor. Acupuncture doctor (blind) will preform acupuncture on the points. 30 minutes after needle insertion, acupuncture doctor will withdraw the needles. Acupuncturists, ICU nurses, ICU doctors, researchers and statisticians will all be blind to group allocation and to the meaning of the random numbers until all acupuncture treatments have been completed.|two groups, randomized, pre-post intervention study|t|t|t|t
34110254|NCT04357925|||COHORT||PROSPECTIVE|||||||
34110255|NCT00887887|||COHORT||PROSPECTIVE|||||||
34110256|NCT06571864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110257|NCT06419504|||CASE_ONLY||PROSPECTIVE|||||||
34110258|NCT02266771|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110259|NCT06509035|||OTHER||CROSS_SECTIONAL|||||||
34110260|NCT01434940|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34110261|NCT06570369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110262|NCT00937105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34110263|NCT01215331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110264|NCT05382130|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110265|NCT05752487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110266|NCT03619356|||OTHER||PROSPECTIVE|||||||
34110267|NCT06316765|||COHORT||RETROSPECTIVE|||||||
34110268|NCT06637020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110269|NCT05911165|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34110270|NCT03074669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110271|NCT05478837|NA|SEQUENTIAL||TREATMENT||NONE||||||
34110272|NCT04578041|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725024|NCT06011018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Participants were randomly assigned treatment groups:~1. Mirror Therapy~2. Mirror Therapy + Electrical Stimulation~3. Mirror Therapy + Binaural Beat"|f|f|f|t
33725025|NCT03131336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, interventional, randomized, controlled, double-blind, parallel group|t|f|t|f
33725026|NCT05339620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||f|f|t|t
33725027|NCT00623727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725028|NCT02338765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725029|NCT01527682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725030|NCT01127308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725031|NCT02228642|||CASE_CONTROL||PROSPECTIVE|||||||
33725032|NCT01453283||||TREATMENT||||||||
33725033|NCT03266991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725034|NCT04184531|||COHORT||RETROSPECTIVE|||||||
33725035|NCT03862274|||CASE_CONTROL||OTHER|||||||
33725036|NCT04409743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725037|NCT02782533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725038|NCT00844272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807286|NCT01443000|||COHORT||OTHER|||||||
34110273|NCT06541132|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110274|NCT03384966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinding will apply to treatment (ACT-246475 vs placebo). The dose (8 mg vs 16 mg) will be single blinded (subject blinded). The site for the sub-cutaneous injection (thigh vs abdomen) will not be blinded.||t|t|t|t
34110275|NCT03211624|||CASE_CONTROL||PROSPECTIVE|||||||
34110276|NCT04733079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110277|NCT00321932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807287|NCT03624283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33807288|NCT01354782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807289|NCT04786275|||COHORT||PROSPECTIVE|||||||
34036191|NCT04430959|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34036192|NCT00651833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036193|NCT05032300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Test group (shock wave) chronic plantar fasciitis; Control group patients with chronic plantar fasciitis;|f|f|f|t
34036194|NCT01381211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036195|NCT04252651|||CASE_ONLY||PROSPECTIVE|||||||
34036196|NCT00432926|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036197|NCT04522440|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34036198|NCT00494637|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036199|NCT03452670|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded by study ID# during data collection and management.|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in the mindfulness app at the end of the study.|f|f|t|t
34036200|NCT01863667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036201|NCT02735759|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34036202|NCT04851977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study is double-blinded. Sealed participant-specific code break envelopes will be produced by the unblinded statistician so that the treatment assigned to each participant can be obtained if required, in an emergency only, where knowledge of the randomisation code is required to provide appropriate treatment. The code break envelopes will be retained at the clinical unit in a secure, accessible location. Those blinded to study drug assignment include the sponsor, the PI, clinical study personnel participating in participants' care or clinical evaluations, and the study participants.|"A total of up to 60 eligible participants will be enrolled and randomised in a 4:1 ratio (investigational vaccine versus placebo) to receive one of the following treatments:~* BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo \[saline/mannitol\] by IM injection to the deltoid region of the other arm, given sequentially).~* BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm \[one injection of 10 μg rRSV-G protein/10 μg CsA per arm\], given sequentially). The high dose is twice the strength of the low dose.~* Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially)."|t|f|t|f
34036203|NCT04601766|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036204|NCT03582462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036205|NCT05460767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036206|NCT03125967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two-arm randomized placebo-controlled study with pre-exposure and post-exposure assessments|t|f|f|f
34036207|NCT01675934|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34036208|NCT02060331|||COHORT||PROSPECTIVE|||||||
34036209|NCT06079411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036210|NCT05120986|||COHORT||PROSPECTIVE|||||||
34036211|NCT03591874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All subjects, investigators, and study personnel involved in the conduct of the study, including data management and statistics, will be masked to treatment assignment except for a specified staff member from the designated packaging vendor who will do the package labeling.~Unmasking will be permitted in a medical emergency that requires immediate knowledge of the subject's treatment assignment."|This will be a randomized, placebo-controlled, double-masked, multicenter phase 3 study.|t|t|t|t
34036212|NCT01023009|||CASE_ONLY||PROSPECTIVE|||||||
34036213|NCT03388151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34036214|NCT04019977|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"As described above, the nurse home visiting program is being provided on a random-assignment basis according to child birthdate. Nurse home visitors will enroll new mothers into the nurse home visiting program every other day only (on odd dates). The new mothers who give birth on an even date will not be offered the nurse home visiting program. They will be considered the control group and are expected to access community services as they normally would."||t|f|f|f
34036215|NCT01631760|||COHORT||PROSPECTIVE|||||||
34036216|NCT02764892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036217|NCT01735084|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34036218|NCT01593397|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036219|NCT02515331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036220|NCT01031329|||CASE_ONLY||PROSPECTIVE|||||||
34036221|NCT03439241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The trial starts with a baseline period. After 4 baseplate changes the subjects is randomised into two arms.||||
34036222|NCT01110018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036223|NCT03159390|NA|SINGLE_GROUP||OTHER||NONE||||||
34036224|NCT00044408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34036225|NCT04795037|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A Single Ascending Dose(SAD) study with 7 Cohorts including 1 Cohorts for Food effect (FE) assessment with 8 subjects each (6 active and 2 placebo) and A Multiple Ascending Dose(MAD) study with 3 Cohorts with 8 subjects each (6 active and 2 placebo).|t|t|t|t
34036226|NCT05271175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036227|NCT00692692|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34036228|NCT04991441|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment Observational control followed by dietary intervention||||
34036229|NCT00743925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036230|NCT00659711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036231|NCT03468218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036232|NCT00893880|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036233|NCT00942357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036234|NCT02010957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036235|NCT06033937|||COHORT||PROSPECTIVE|||||||
34036236|NCT01352195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838137|NCT05223218|||COHORT||PROSPECTIVE|||||||
34036237|NCT01252095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036238|NCT00655993|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34110278|NCT05006248|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The purpose of this study is to compare 1) conventional robotic continuous passive movement (CPM) training to 2) training with visual biofeedback and 3) training with both visual and haptic biofeedback.||||
34110279|NCT04605250|NA|SINGLE_GROUP||OTHER||NONE||||||
34110280|NCT06001255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110281|NCT00583154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110282|NCT06640673|||COHORT||OTHER|||||||
34110283|NCT03220633|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110284|NCT06062472|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34110285|NCT03960944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807290|NCT04071106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients do not know whether they are receiving the drugs with active ingredients or negative control. The pathologist will be masked regarding the groups and the point of time before or after therapy.|"Five groups will be included in the study Group 1: 10 Psoriatic patients receive turmeric extract based ointment . Group 2: 10 psoriatic patients will receive turmeric extract + olive oil based ointment.~Group 3: 10 psoriatic patients will receive petrolatum base as negative control.~Group 4: 10 psoriatic patients will receive NBUVB as positive control. Group 5: 10 psoriatic patients will receive established topical treatment serving as 2nd positive control."|t|f|f|t
33807291|NCT04671875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807292|NCT00452114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807293|NCT05953805|||COHORT||CROSS_SECTIONAL|||||||
33807294|NCT00198419|NA|SINGLE_GROUP||SCREENING||NONE||||||
33807295|NCT03528213|RANDOMIZED|PARALLEL||TREATMENT||NONE||bolus then continuous infusion of molar sodium lactate (2 doses) or normal saline||||
33807296|NCT05137600|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33807297|NCT00621673|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807298|NCT01830049|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110286|NCT06420336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110287|NCT02078726|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34110288|NCT05506111|||COHORT||PROSPECTIVE|||||||
34110289|NCT05989997|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110290|NCT02697448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110291|NCT06637969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110292|NCT03000881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110293|NCT04598425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110294|NCT00319761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110295|NCT01422382|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34110296|NCT06638151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110297|NCT05591365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110298|NCT04275284|||COHORT||PROSPECTIVE|||||||
34110299|NCT04053504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110300|NCT06435221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110301|NCT06529627|NA|SINGLE_GROUP||TREATMENT||NONE||Single group of infertile couple undergoing ICSI-ET with the standard long GnRH agonist protocol||||
34110302|NCT01889446|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34110303|NCT06640296|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34110304|NCT06175832|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34110305|NCT03537794|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110306|NCT06313359|||OTHER||CROSS_SECTIONAL|||||||
34110307|NCT04781894|||COHORT||PROSPECTIVE|||||||
34110308|NCT05259098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110309|NCT05541718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110310|NCT05962736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34110311|NCT05488483|||COHORT||PROSPECTIVE|||||||
34110312|NCT05482451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110313|NCT00071032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110314|NCT02516813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110315|NCT03132987|NA|SINGLE_GROUP||TREATMENT||NONE||Physical therapy exercises (progressive strengthening program)||||
34110316|NCT01598155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34110317|NCT05838287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the participant nor the investigator knows what treatment is given|double-blind placebo controlled, randomized clinical trial|t|t|t|f
34110318|NCT05044468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34110319|NCT01712373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110320|NCT05168293|||CASE_ONLY||PROSPECTIVE|||||||
34110321|NCT05987423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110322|NCT05463419|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|double blind||t|t|t|f
34110323|NCT03610698|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34110324|NCT05997901|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will conduct a non-randomized single arm feasibility study. It will only have an intervention group, and is designed to examine important study procedures (e.g., patient recruitment, retention, missing data), in advance of a larger randomized controlled trial (RCT) testing the effectiveness of the healthbot.||||
34110325|NCT02499237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110326|NCT01657188|||COHORT||PROSPECTIVE|||||||
34110327|NCT05996120|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, open label, statistician blinded, multicentre, randomised controlled feasibility trial.||||
34110328|NCT04021745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110329|NCT05326295|||COHORT||RETROSPECTIVE|||||||
34110330|NCT05681481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110331|NCT00977444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110332|NCT05640427|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34110333|NCT05536791|||COHORT||PROSPECTIVE|||||||
34110334|NCT04240509|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34110335|NCT02889874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110336|NCT00643656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110337|NCT03684980|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, non-randomized, pilot study of Voraxaze administered following standard of care MTX and rituximab in patients with CNS lymphoma.||||
34110338|NCT01356368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807299|NCT02325349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807300|NCT00463502|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33807301|NCT00195403|||CASE_ONLY||PROSPECTIVE|||||||
34110339|NCT04943796|||COHORT||PROSPECTIVE|||||||
33807302|NCT01600482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807303|NCT01961466|||CASE_ONLY||PROSPECTIVE|||||||
33807304|NCT05519852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807305|NCT05850793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and the researcher who evaluated the analysis are blind to the study|A randomized controlled trial|t|f|f|t
33807306|NCT00399685|NON_RANDOMIZED|PARALLEL||||NONE||||||
33807307|NCT06466616|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34036239|NCT03796325|||COHORT||PROSPECTIVE|||||||
34036240|NCT03074578|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The analysis of heart signal, polysomnography and dream reports analysis will be performed by assessors masked to the group and type of video.|Watching two different videos (one violent, one non-violent), re-exposure after 11h daytime (wake period) or 11h nighttime (sleep period). The order of videos is balanced, in a cross over fashion|f|f|f|t
34036241|NCT04537884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036242|NCT04977011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||30 minutes music intervention for 3 days on bedside|f|f|f|t
34036243|NCT05029817|||COHORT||CROSS_SECTIONAL|||||||
34036244|NCT05869591|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110340|NCT04892277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110341|NCT01765387|NON_RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34110342|NCT00143845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110343|NCT06402305|||CASE_CONTROL||PROSPECTIVE|||||||
34110344|NCT05888922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110345|NCT06197724|||COHORT||PROSPECTIVE|||||||
34110346|NCT06583720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110347|NCT05167708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded, the assessor of the out comes did not participate in the study|single-center, prospective, single blinded, with 3 parallel arms, randomized clinical trial that had a 1:1:1 allocation.|f|f|f|t
34110348|NCT05396404|||COHORT||RETROSPECTIVE|||||||
34110349|NCT02085863|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34110350|NCT03925467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Three groups, pre-post intervention study|t|f|f|f
34110351|NCT06092892|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm||||
34110352|NCT02852707|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110353|NCT05826054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110354|NCT06166433|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, investigators, and outcomes assessors will blind to assignment.|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.|t|f|t|t
34110355|NCT05878067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110356|NCT02853292|||COHORT||PROSPECTIVE|||||||
34110357|NCT04649905|||COHORT||PROSPECTIVE|||||||
34110358|NCT05274477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34110359|NCT04345328|||COHORT||PROSPECTIVE|||||||
34110360|NCT06591741|NA|SINGLE_GROUP||OTHER||NONE||||||
34110361|NCT01108874|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34110362|NCT05630456|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE||In the intervention group, the researcher provided feedback on the participants' exercise amount through telephone contact every two weeks during the 12-week study period. It includes recommendations for continuing exercise therapy based on the recommendations for physical activity. Through phone consultations, they answered questions about exercise or discussed problems, were encouraged to continue exercising, answered questions or discussed problems related to wearable devices and apps, and encouraged for continuous data transmission.|t|f|t|f
34110363|NCT06132789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110364|NCT04083378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110365|NCT06571435|||COHORT||PROSPECTIVE|||||||
34110366|NCT06570421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110367|NCT01965457|||COHORT||PROSPECTIVE|||||||
34110368|NCT00587912|||CASE_ONLY||PROSPECTIVE|||||||
34110369|NCT00997763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110370|NCT05321602|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Approximately 80 eligible patients will be randomized in a 1:1:1:1 ratio to 1 of 4 treatment groups as shown below.~Treatment Group Treatment (LY03010) Injection Site~1. 156 mg Deltoid~2. 156 mg Gluteal~3. 351 mg Deltoid~4. 351 mg Gluteal"||||
34110371|NCT06548438|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomised controlled trial. Randomization will be stratified based on the dedicated surgeon performing the procedure. Allocation will be at a 1:1 ratio between the two arms||||
34110372|NCT03636022|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomly assigned to home exposure practice with or without the VR system, i.e., intervention or control||||
34110373|NCT06177704|||OTHER||PROSPECTIVE|||||||
34110374|NCT03096431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All participants will be blinded to the study design and will be randomized into one of three treatment arms. Research assistant is blinded to both the study design and to which arm the participants are randomized.||t|f|t|f
34110375|NCT06363708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110376|NCT05583955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110377|NCT06640790|||COHORT||PROSPECTIVE|||||||
34110378|NCT01573429|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110379|NCT02329587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110380|NCT00005479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110381|NCT05852431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110382|NCT03709017|||CASE_ONLY||PROSPECTIVE|||||||
34110383|NCT03862950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110384|NCT05660538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110385|NCT06482034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study is a randomized, controlled, interventional clinical trial conducted at Mansoura University Oncology Hospital. Fifty head and neck cancer patients receiving radiotherapy will be randomized into five groups of ten each. Group I will receive N-acetylcysteine (NAC) sachets (600mg) twice daily, Group II will receive zinc sulfate capsules (25mg) thrice daily, Group III will receive both NAC and zinc sulfate, and Group IV will receive NAC and zinc sulfate after mucositis onset. Group V, the control group, will receive standard care with normal saline mouthwash. The study aims to evaluate the efficacy of NAC, zinc sulfate, and their combination in treating radiotherapy-induced oral mucositis. Mucositis severity will be assessed using the WHO criteria for grading oral mucositis. Patients' consent and ethical approval will be obtained.|t|f|f|t
34110386|NCT05882370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110387|NCT05130801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110388|NCT00781261|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110389|NCT03109457|||COHORT||RETROSPECTIVE|||||||
34110390|NCT00221858|||||OTHER|||||||
33807308|NCT02873533|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807309|NCT01488656|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33807310|NCT00036140||||TREATMENT||||||||
33807311|NCT00382941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33807312|NCT03473717|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33807313|NCT02821299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807314|NCT01565187|||COHORT||PROSPECTIVE|||||||
33807315|NCT00130182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807316|NCT06352905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807317|NCT04847258|||COHORT||PROSPECTIVE|||||||
33807318|NCT05866536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807319|NCT00989742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807320|NCT05671484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients will be divided randomly by a computer-generated randomization table into two equal groups.|f|t|f|t
33807321|NCT00794300|||COHORT||PROSPECTIVE|||||||
33807322|NCT02605174|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34036245|NCT03511430|||COHORT||PROSPECTIVE|||||||
34036246|NCT03805412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807323|NCT02061124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33807324|NCT04535999|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Intervention-Secukinumab||||
33807325|NCT00385606|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33807326|NCT05461235|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33807327|NCT03842605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807328|NCT03443999|||OTHER||PROSPECTIVE|||||||
33807329|NCT03989388|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807330|NCT06322121|||CASE_CONTROL||PROSPECTIVE|||||||
33807331|NCT05464498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807332|NCT01074242|||OTHER||PROSPECTIVE|||||||
33807333|NCT04011930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All eligible patients were randomly assigned to either study (A) control(B) group||||
33807334|NCT03068988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807335|NCT03117400|||COHORT||PROSPECTIVE|||||||
33807336|NCT05886972|||COHORT||PROSPECTIVE|||||||
33807337|NCT01105975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807338|NCT05435859|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036247|NCT00815880|NA|SINGLE_GROUP||TREATMENT||NONE||The C-Pulse System is indicated for use in subjects with moderate to severe heart failure who are refractory to optimal medical therapy||||
34036248|NCT00653627|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34036249|NCT00238472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036250|NCT06016647|||COHORT||PROSPECTIVE|||||||
34036251|NCT06581419|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34036252|NCT05154175|||CASE_ONLY||RETROSPECTIVE|||||||
34036253|NCT06377774|||COHORT||PROSPECTIVE|||||||
34036254|NCT02596360|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34036255|NCT06582355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be unaware of which condition the participant is in.||f|f|f|t
34036256|NCT02727803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036257|NCT02607046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036258|NCT00048386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036259|NCT00634036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036260|NCT04298398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|only the investigator responsible for the eligibility assessment would be blind (in the recruitment, in order to assess eligibility to enter the study), before the randomization.|||||
34036261|NCT02047695|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036262|NCT01368497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036263|NCT00446693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036264|NCT06461806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are provided with unlabelled protein containers in this single-blind study.|Participant are randomized to a plant or animal protein based ketogenic diet for a 12 week period. They are provided with the plant or animal proteins which they consume in the form of a smoothie twice a day. The remaining meal comprises of self selected foods.|t|f|f|f
34036265|NCT05418842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34036266|NCT05459961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|double blind|randomised double blind placebo controlled|t|f|t|t
34036267|NCT02542007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036268|NCT00521105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34036269|NCT00192582|RANDOMIZED|CROSSOVER||||NONE||||||
34036270|NCT00757796|||COHORT||PROSPECTIVE|||||||
34036271|NCT00218595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036272|NCT03196453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double blind, placebo controlled,|t|f|t|t
34036273|NCT02960009|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34036274|NCT01930682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036275|NCT04416282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036276|NCT04629495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple-blind|placebo controlled study|t|t|t|t
34036277|NCT01163838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036278|NCT05920304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Masking of participants is not possible due to the nature of the study|This study is a randomized clinical trial. Participants will be randomized in the ratio 1:2 (for each participant randomized to vHaH, there will be two participants randomized to continued conventional in-hospital admission)||||
34036279|NCT04163601|||COHORT||RETROSPECTIVE|||||||
34036280|NCT03746132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sham devices are not involved in this study. The surgeon will remain blinded to the subject's group assignment until after the wound is surgically closed in the operating room, and just prior to application of the dressing. A clinical professional, experienced in care of surgical wounds, will be appointed at the end of the study as a masked independent evaluator. This clinical professional will be blinded as to the treatment group of the subject.|Subjects who meet the inclusion/exclusion criteria will be randomized to receive the treatment device with Standard of Care or Standard of Care alone (1:1).|f|f|t|t
34036281|NCT05293704|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036282|NCT01279824|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34036283|NCT01737047|||COHORT||PROSPECTIVE|||||||
34036284|NCT00886080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036285|NCT02952144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036286|NCT02045446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036287|NCT02248844|||CASE_ONLY||PROSPECTIVE|||||||
34036288|NCT04237376|||COHORT||PROSPECTIVE|||||||
34036289|NCT00659308|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036290|NCT05059613|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036291|NCT04020887|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The first phase is an observation phase and the next phase is an interaction phase.||||
34036292|NCT01662492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036293|NCT00224367|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34036294|NCT01019902|||CASE_ONLY||CROSS_SECTIONAL|||||||
34036295|NCT01129557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036296|NCT03817125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomly assigned in a 2:1 ratio to oral microbiome study intervention or matching placebo. Nivolumab will be administered open-label as standard of care to all groups. Investigators, site personnel, and participants will remain blinded to the assignment of microbiome study intervention throughout the course of the study. Select Sponsor personnel, including but not limited to the Medical Monitor, Clinical Scientists, Biostatistician, and Patient Safety, will be unblinded to treatment assignment for ongoing safety monitoring.||t|t|t|f
34036297|NCT03093142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036298|NCT05487950|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a phase III prospective superiority randomized open-label multicenter study with 2 parallel groups (control vs. experimental group).~Our study will test the superiority of anticoagulation treatment with Rixaroxaban (experimental group) compared to SOC (control group).~This is a phase III prospective superiority randomized, open-label multicenter study with 2 parallel groups (control vs. experimental group).~Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% PAC /24 hours or any atrial runs ≥ 20 PACs on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3"||||
34036299|NCT00204906|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34036300|NCT04965597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036301|NCT00199420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34036302|NCT04038905|||COHORT||PROSPECTIVE|||||||
34036303|NCT04658134|NA|SINGLE_GROUP||OTHER||NONE||||||
34036304|NCT00170105|||||PROSPECTIVE|||||||
34036305|NCT01785082|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34036306|NCT06053346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036307|NCT01372618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036308|NCT03695900|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a prospective crossover study to compare the within-subject effect of the two target ranges of arterial oxygen saturation (SpO2, 93-95% vs 90-92%) on ventilatory stability in premature infants.||||
34036309|NCT03689829|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Part 1 - randomized open label. Part 2 and Part 3 - randomized double blind.|||||
34036310|NCT01928264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036311|NCT03700060|||OTHER||PROSPECTIVE|||||||
34036312|NCT05411185|||COHORT||PROSPECTIVE|||||||
34036313|NCT04433208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34036314|NCT00162981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036315|NCT01228682|||COHORT||PROSPECTIVE|||||||
34036316|NCT02234908|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036317|NCT06262763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036318|NCT00413699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036319|NCT01425489|||COHORT||PROSPECTIVE|||||||
34036320|NCT00455884|||COHORT||PROSPECTIVE|||||||
34036321|NCT03802526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807339|NCT04399772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This study has ethical approval that the patients involved are not aware that there is a difference between the two treatment strategies in the study. Patient masking in this study is done to ensure that included patients are as representative as possible.~The randomization sequence is distributed and stored in sealed opaque envelopes handled only by an independent study secretary who has no other involvement in the trial. All outcome measurements are completed via an electronic questionnaire system sent via personal links to the patients' official digital inbox, e-Boks (used by public hospitals, municipalities and other institutions to send official documents to citizens of Denmark). The researcher responsible for the statistical analyzes are blinded to group allocation."|This study is a patient-blinded 2-arm randomized controlled trial with a parallel group design and 1:1 group allocation.|t|f|t|t
34036322|NCT03340597|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34036323|NCT03144908|||OTHER||PROSPECTIVE|||||||
34036324|NCT02614677|||CASE_ONLY||PROSPECTIVE|||||||
34036325|NCT01446302|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34036326|NCT04505670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036327|NCT01293916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036328|NCT03718988|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||SWAP-MEAT is a randomized, cross-over design among 30 adults randomly assigned to one of two diet sequences. Each diet sequence will consist of two phases: the Meat phase, which will consist of participants consuming their typical diet, and the Plant Alternative phase, which will consist of participants consuming plant-based meat alternatives instead of their typical meat products, for a predominantly vegetarian diet.|f|f|t|t
34036329|NCT03660930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036330|NCT00991393|||COHORT||PROSPECTIVE|||||||
34036331|NCT03067727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036332|NCT01234350|||COHORT||PROSPECTIVE|||||||
34036333|NCT01136941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036334|NCT03942757|||CASE_CONTROL||PROSPECTIVE|||||||
34036335|NCT05223400|||OTHER||RETROSPECTIVE|||||||
34036336|NCT03413462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036337|NCT00397462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036338|NCT04881474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34036339|NCT02771977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036340|NCT03239093|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34036341|NCT05172206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blinded||f|f|f|t
34036342|NCT03273101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036343|NCT01965860|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Initially 39 participants were enrolled, 7 excluded because they declined to participate. 32 people were randomized.|f|f|f|t
34036344|NCT05374031|||CASE_ONLY||PROSPECTIVE|||||||
34036345|NCT01502319|||OTHER||OTHER|||||||
34036346|NCT04956744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34036347|NCT04118387|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Specific Aim (1) is to determine the effect of combination therapy aiming to dampen chemoreceptor sensitivity AND decreasing plant gain. We hypothesize that combined therapy with PAP, acetazolamide and oxygen will be superior to each intervention alone in reducing CAHI and the CO2 reserve during sleep in patients with central sleep apnea. Specific Aim (2) is to determine the effect of decreasing respiratory-related arousals on the propensity to develop central apnea. We hypothesize that administration of PAP and zolpidem, will decrease respiratory-related arousals, CAHI and the CO2 reserve during sleep in patients with CSA compared to placebo. Specific Aim (3) is to determine the effect of augmenting serotonin A1 receptor activity on breathing during sleep. We hypothesize that administration of PAP and buspirone, a serotonin A1 receptor agonist; will reduce the propensity to central apnea during sleep in Veterans with central sleep apnea.|t|f|f|t
34036348|NCT03655171|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036349|NCT02453932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036350|NCT03585023|||COHORT||PROSPECTIVE|||||||
34036351|NCT00920868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036352|NCT04649008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036353|NCT03807427|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036354|NCT05382273|||COHORT||PROSPECTIVE|||||||
34036355|NCT04773340|||COHORT||PROSPECTIVE|||||||
34036356|NCT02548143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036357|NCT01329055|||COHORT||RETROSPECTIVE|||||||
34036358|NCT05430373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036359|NCT03749876|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The research staff performing the statistical analyses of the outcomes of interest will be masked from knowing the individuals' randomized treatment assignments, as will the principal investigator.|Participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study.|f|f|t|t
34036360|NCT03098212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036361|NCT01511042|||COHORT||CROSS_SECTIONAL|||||||
34036362|NCT01856725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036363|NCT05899738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036364|NCT00431470|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34036365|NCT02135523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036366|NCT03771092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036367|NCT00944099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036368|NCT06354881|||COHORT||CROSS_SECTIONAL|||||||
34036369|NCT03004651|||CASE_CONTROL||PROSPECTIVE|||||||
34036370|NCT02655614|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34036371|NCT00425243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036372|NCT00210769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036373|NCT06257654|||CASE_CONTROL||RETROSPECTIVE|||||||
34036374|NCT03194828|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34036375|NCT00139451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036376|NCT05245136|||COHORT||PROSPECTIVE|||||||
34110391|NCT06194656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Ⅱa is an open-label study and Ⅱb is a randomized, double-blind study.|t|t|t|t
34110392|NCT04967456|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||a randomized, split-mouth, controlled, clinical trial||||
34110393|NCT00496119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110394|NCT06436781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110395|NCT03483701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This randomized controlled trial will use a single-blind study design with two treatment arms. The research team that assesses participants at baseline and follow-up will have no knowledge of their assigned treatment arm. The participants, however, will know which treatment arm they have been assigned.||f|f|f|t
34110396|NCT06585605|||COHORT||RETROSPECTIVE|||||||
34110397|NCT01661595|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"Subjects were assigned to one of 4 arms:~1. Sildenafil (50mg/day) for weeks 0-4. Placebo for weeks 5-8.~2. Tadalafil (10mg/day) for weeks 0-4. Placebo for weeks 5-8.~3. Placebo for weeks 0-4. Sildenafil (50mg/day) for weeks 5-8.~4. Placebo for weeks 0-4. Tadalafil (10mg/day) for weeks 5-8."|t|t|t|f
34110398|NCT05286619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110399|NCT01991873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110400|NCT05841667|||COHORT||PROSPECTIVE|||||||
34110401|NCT05726968|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Patients will be randomly allocated to one of the 3 groups by sealed closed envelop technique|The purpose of this study is to determine the least sufficient dose of intrathecal hyperbaric prilocaine 2% combined with fentanyl 25 µg required for day-case lower abdominal and urologic surgeries , fewer adverse effects, faster recovery time, and shorter stay in post anesthesia care unit (PACU) in the geriatric patient population, as a previous study has investigated hyperbaric prilocaine (30 mg) when combined with fentanyl (20 µg) for a day-case perianal surgery, achieving a spinal anaesthesia with a mean sensory level of T9|t|f|t|f
34110402|NCT02678533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110403|NCT01448642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110404|NCT01161966|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34110405|NCT00784017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110406|NCT03753516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725039|NCT03800927|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Participants will receive active and sham devices for the first 12-weeks. Responders to treatment will continue with 12 weeks of additional active treatment.|t|t|f|t
33725040|NCT02602587|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725041|NCT03676322|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33725042|NCT00935870|||COHORT||CROSS_SECTIONAL|||||||
33725043|NCT04529590|||COHORT||PROSPECTIVE|||||||
33725044|NCT01087086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725045|NCT04026607|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and the investigators will be blinded to the supplement type, only the Lead Principal Investigator will have the codes to decipher the supplement type. Supplements are referred to as A, B and C.|The study will be a double blind, randomized parallel group controlled trial.|t|f|t|t
33725046|NCT04757636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725047|NCT03433924|||COHORT||PROSPECTIVE|||||||
33725048|NCT01132547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33725049|NCT01793727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725050|NCT02075138|||||PROSPECTIVE|||||||
33725051|NCT03605797|||COHORT||RETROSPECTIVE|||||||
33807340|NCT01581216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807341|NCT05040828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110407|NCT03056469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In one randomization arm the participants submit patient-reported outcomes, and the care providers have access to the patient-reported outcomes. In another randomization arm the participants submit patient-reported outcomes, but the care providers do not have access to the patient-reported outcomes. In the last randomization arm the participants are randomized to standard follow-up, do not complete PRO questionnaires and are thus controls.||f|t|f|f
34110408|NCT01651208|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34110409|NCT00928772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110410|NCT01437189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110411|NCT02888340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110412|NCT02489279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110413|NCT01702298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110414|NCT05845749|NA|SINGLE_GROUP||OTHER||NONE||This is a 24 week natural history study followed by a 48 week open label single arm intervention with vosoritide||||
34110415|NCT01462747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110416|NCT02287779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110417|NCT05715021|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial with Embedded Non-randomized Cohort||||
34110418|NCT06554821|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110419|NCT00375232|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34110420|NCT06427980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators in charge of the recruitment and follow-up evaluation and participants will be blinded, along with the outcome assessors and data analysts.||t|t|t|t
34110421|NCT05997953|||OTHER||CROSS_SECTIONAL|||||||
34110422|NCT05432609|||COHORT||OTHER|||||||
34110423|NCT04104789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110424|NCT06225349|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34110425|NCT04983030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110426|NCT03303729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34110427|NCT01661543|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Investigators and data analysts were blinded to participant group assignment.||f|f|t|t
34110428|NCT03508583|||CASE_ONLY||PROSPECTIVE|||||||
34110429|NCT01192074|||COHORT||PROSPECTIVE|||||||
34110430|NCT05961527|NA|SINGLE_GROUP||TREATMENT||NONE|Independent raters for the primary clinical outcome will be blinded to study design and timepoint.|Open-label study examining safety and feasibility of MDMA-assisted group therapy||||
34110431|NCT03770286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluator of the x-rays will be blinded.|Silver diamine fluoride is a medicament that can be used to remineralize and treat demineralized tooth structure. This studies Silver Diamine Fluoride application as a treatment for interproximal caries. It also compares Super Floss and Microbrush as ways in which to apply the medicament.|f|f|f|t
34110432|NCT02921256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110433|NCT06456892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110434|NCT03940248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110435|NCT06643403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110436|NCT00538447|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34110437|NCT06028464|NA|SEQUENTIAL||TREATMENT||NONE||||||
34110438|NCT03078868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110439|NCT05470166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34110440|NCT00835549|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34110441|NCT04716725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110442|NCT03282916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807342|NCT01763359|||COHORT||PROSPECTIVE|||||||
33807343|NCT01753011|||COHORT||PROSPECTIVE|||||||
33807344|NCT02810600|||COHORT||PROSPECTIVE|||||||
33807345|NCT02813525|||COHORT||PROSPECTIVE|||||||
33807346|NCT02765594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807347|NCT04780074|RANDOMIZED|CROSSOVER||OTHER||NONE||Five-period crossover bioavailability study will include 30 subjects who will test five CoQ10 formulations. Subjects will test 5 formulations of single dose CoQ10 with 2 week wash-out. to assess bioavailability.||||
33807348|NCT03777566|||COHORT||CROSS_SECTIONAL|||||||
34110443|NCT04742023|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34110444|NCT05337189|||COHORT||PROSPECTIVE|||||||
34110445|NCT05258292|||COHORT||OTHER|||||||
34110446|NCT04740567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110447|NCT06563986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110448|NCT06496477|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110449|NCT02609594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110450|NCT06194838|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will take home three interventional devices for data collection and feedback. One of the interventions will be the commercially available Ossur OFM-2, a passive mechanical knee, and the most commonly used knee for K2 users. The two other interventional devices will be commercially available powered knees: (1) the Ossur Power Knee and (2) the Reboocon Intuy Knee. Participants will be trained on the interventional knees during the first month of at-home use. Functional outcome measures and self-report surveys will also be completed in-lab before and after each take-home intervention, as well as at the last training visit, in order to form a detailed comparison between the three interventions.||||
34110451|NCT06022887|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807349|NCT04657341|||OTHER||PROSPECTIVE|||||||
33807350|NCT00309751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110452|NCT06188806|RANDOMIZED|PARALLEL||TREATMENT||NONE||three groups Group 1: proximal ACB (n:26) Group 2: distal ACB(n:26) Group 3: Control group (n:26)||||
34110453|NCT06565130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110454|NCT01990040|||OTHER||PROSPECTIVE|||||||
34110455|NCT01230411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110456|NCT00938626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110457|NCT06036368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110458|NCT01117779|||CASE_ONLY||PROSPECTIVE|||||||
33807351|NCT03088800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807352|NCT04589975|||COHORT||RETROSPECTIVE|||||||
33807353|NCT04566172|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will receive the same intervention.||||
34110459|NCT06563167|||COHORT||PROSPECTIVE|||||||
33807354|NCT04784390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Part A: Single-masked by outcome assessor only~Part B: Open-label"||f|f|f|t
33807355|NCT06047535|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807356|NCT03865004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807357|NCT00013715|||||PROSPECTIVE|||||||
33807358|NCT02746107|RANDOMIZED|FACTORIAL||||NONE||||||
33807359|NCT01641900|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33807360|NCT02132520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807361|NCT01575015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807362|NCT03113409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036377|NCT02004418|NA|SINGLE_GROUP||TREATMENT||NONE||"Subjects will receive a fixed dose (400 MBq +/-10%) of 11C-Choline and PET/CT imaging with co-registration 3T MRI imaging prior to Enhanced EBRT and two further doses of 11C-Choline at two intervals (3 and 6 months) thereafter.~Subjects with suitable intraprostatic lesion delineation with 11C-Choline will proceed to Enhanced EBRT, consisting of a dose prescription of 78 Gy in 25 fractions to the intraprostatic lesions and 68 Gy in 25 fractions (simultaneously) to the prostate gland. Subjects without suitable intraprostatic lesion delineation will be treated with Cross Cancer Institute standard of care EBRT and undergo follow-up for biochemical recurrence per protocol to determine the prognostic value of the baseline PET findings"||||
34036378|NCT04748640|NA|SINGLE_GROUP||TREATMENT||NONE|All assessments filmed on video and scored by a blinded evaluator.|||||
34036379|NCT00517881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036380|NCT02633007|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34036381|NCT03361306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036382|NCT04030299|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34036383|NCT02499731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036384|NCT01111773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110460|NCT04935593|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34110461|NCT06005948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The dynamic neuromuscular stabilization exercises|f|f|f|t
34110462|NCT04861701|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34110463|NCT03659825|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Study drinks will be matched for taste and appearance. Investigator preparing and administering the drink will not carry out the testing.|Young healthy adults.|t|f|t|f
34110464|NCT05573308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34110465|NCT03559530|||CASE_ONLY||RETROSPECTIVE|||||||
34110466|NCT04409431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in the Intervention group will be treated with endovascular chemical ablation of adrenal gland by endovascular injection of dehydrated alcohol. Patients in the Control group will be treated with spironolactone||||
34110467|NCT00091975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34110468|NCT01047865|||COHORT||OTHER|||||||
34110469|NCT06482996|||COHORT||PROSPECTIVE|||||||
34110470|NCT04855799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110471|NCT06564259|||COHORT||PROSPECTIVE|||||||
34110472|NCT04714177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110473|NCT03664544|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34110474|NCT06172023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807363|NCT06696690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807364|NCT04477707|||COHORT||RETROSPECTIVE|||||||
33807365|NCT03473041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807366|NCT02003859|||COHORT||PROSPECTIVE|||||||
33807367|NCT03418610|NA|SINGLE_GROUP||TREATMENT||NONE||Single Site, Single Arm Open Label Study||||
33807368|NCT04955951|||CASE_ONLY||PROSPECTIVE|||||||
33807369|NCT06407804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807370|NCT01028287|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807371|NCT02961634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33807372|NCT02163148|||CASE_ONLY||CROSS_SECTIONAL|||||||
33807373|NCT02987218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33807374|NCT03089255|||COHORT||PROSPECTIVE|||||||
33807375|NCT04048746|||COHORT||PROSPECTIVE|||||||
33807376|NCT04198467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Hyaluronic acid as placebo both patient and investigator blinded|"182 patients screened, 100 were considered eligible for the study and were randomized. The most common reason for exclusion was either the lack of radio graphic evidence of knee OA or the presence of severe disease with JSW less than 2 mm at the narrowest point.~Out of the 100 randomized patients, roughly equal numbers, six patients in PRP and 7 in placebo, did not complete the study. Reasons for withdrawal were personal,inefficacy, or adverse event as an increase in pain."|t|f|t|f
34036385|NCT01227473|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34036386|NCT05806385|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Since proposed intervention ( cryoablation and immune therapy infusion) cannot be masked with placebo, only the data analyst will be masked.|Randomized controlled trial|f|f|f|t
34110475|NCT04752826|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1/2a, dose escalation, consecutive-cohort, open-label study trial of BI-1808 as a Single Agent and in Combination with Pembrolizumab||||
34110476|NCT01587560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110477|NCT06640140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded only for the evaluator of primary and secondary endpoints.|This is a prospective study, blinded for the evaluator, randomized (1:1) to receive standard management alone or combined with a training program (aerobic combined with strength exercises) that will be carried out in a single center.|f|f|t|f
34110478|NCT05229666|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110479|NCT05406713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110480|NCT03880019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110481|NCT04391569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110482|NCT01497730|||COHORT||PROSPECTIVE|||||||
33807377|NCT04842916|||COHORT||OTHER|||||||
33807378|NCT01722409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807379|NCT01419808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110483|NCT05902741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Self-identified African American women will be randomized to either the race-based stress reduction intervention group (Resilience, Stress, and Ethnicity \[RiSE\]) or the HEP.|f|f|f|t
34110484|NCT06011733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110485|NCT04430010|NA|SINGLE_GROUP||OTHER||NONE||||||
33807380|NCT04521907|||CASE_ONLY||RETROSPECTIVE|||||||
33807381|NCT01835639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036387|NCT01305421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036388|NCT03699332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
34036389|NCT03214224|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A self-controlled validation study of experimental remote PFT assessment vs standard of care (non-randomized)||||
34036390|NCT02885220|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036391|NCT03896022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"A designated investigator (auriculotherapy provider) will apply the intervention prior to the aspiration abortion; thus the care provider (abortion provider) will not be aware of the treatment arm.~Participant will wear a surgical hat that covers their ears and the adhesive disks appear similar for the treatments and the placebo arm; thus the participants will be unaware of their treatment assignment.~The research assistant collecting the outcomes data will not know which treatment arm the participant belongs to.~Finally, treatment assignment will be coded in the study database until analysis is complete, so that the investigator will be unaware of the treatment assignment until analysis is complete and then un-blinding will occur."|This 3-arm randomized trial will assign participants 1:1:1 to receive either of two active treatments (acupressure or acupuncture) or placebo (inert adhesive disks applied to ears).|t|t|f|t
34036392|NCT06177873|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34036393|NCT05507814|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The experimental group will compare episodic future thinking (EFT) to the control group, control episodic thinking (CET).|t|f|f|f
34036394|NCT04746287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Drug: CKD-510 Drug: Placebo|t|f|t|f
34036395|NCT00144820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34036396|NCT02554682|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34036397|NCT04110015|||COHORT||PROSPECTIVE|||||||
34036398|NCT02641327|||CASE_CONTROL||RETROSPECTIVE|||||||
34036399|NCT01139775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036400|NCT06563453|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34036401|NCT02323412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036402|NCT02747108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34036403|NCT05557929|||OTHER||OTHER|||||||
34036404|NCT04024670|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036405|NCT01119859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036406|NCT05302817|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Phase 1: open trial for establishing safety and methodology. Phase 1, Part 1: 10 subjects enrolled for establishing methodology for guiding radiation therapy using HXe MRI. Radiation treatment will follow standard-of-care.~Phase 1, Part 2: 10 subjects enrolled for studying safety and efficacy of HXe MRI guided radiation therapy. Radiation therapy will follow lung functional avoidance maps."||||
34036407|NCT03534687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036408|NCT04747158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036409|NCT02626091|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036410|NCT05584618|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized controlled trial|f|f|f|t
34036411|NCT02631642|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34036412|NCT03901794|||COHORT||PROSPECTIVE|||||||
34036413|NCT04321746|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34036414|NCT00594867|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34036415|NCT00478062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036416|NCT06497608|||CASE_CONTROL||OTHER|||||||
34036417|NCT02681861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34036418|NCT01701011|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34036419|NCT01827111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036420|NCT00711087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036421|NCT01228058|||CASE_ONLY||PROSPECTIVE|||||||
34036422|NCT05098717|||CASE_CONTROL||PROSPECTIVE|||||||
34036423|NCT06525350|RANDOMIZED|FACTORIAL||TREATMENT||NONE||In stage 2, participants who meet the eligibility criteria are randomly assigned to the experimental group (glumetinib tablets+HB1801), factorial group (glumetinib tablets), and control group (docetaxel) in a 2:1:1 ratio.||||
34036424|NCT01578239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036425|NCT04220515|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036426|NCT06582953|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34036427|NCT05091333|||CASE_ONLY||PROSPECTIVE|||||||
34036428|NCT05335486|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled study||||
34036429|NCT03971396|||COHORT||PROSPECTIVE|||||||
34036430|NCT01915030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036431|NCT06225791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"MMS will be implemented across 13 districts in Indonesia. In each of the 8 high-intensity evaluation districts and 5 moderate-intensity evaluation districts, 3 study arms/sub-districts have been purposively selected (total n = 24 sub-districts).~* Arm/sub-district 1: Provision of 90-count bottles x 2, with standard MMS delivery strategies and MMS orientation~* Arm/sub-district 2: Provision of 90-count bottles x 2, with enhanced MMS deliveries strategy (3 with MMS orientation with BCC; 5 with MMS orientation with expanded BCC)~* Arm/sub-district 3: Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (3 with MMS orientation with BCC; 5 with MMS orientation with expanded BCC)"||||
34036432|NCT01774760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036433|NCT03591848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34036434|NCT04650269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036435|NCT02339168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807382|NCT00091988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807383|NCT06699225|||CASE_ONLY||CROSS_SECTIONAL|||||||
33807384|NCT01766206|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807385|NCT05085418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110486|NCT05094609|RANDOMIZED|PARALLEL||PREVENTION||NONE||Dose escalation: Assuming no safety signal, the dose for each vaccine (Ad5-triCoV/Mac and ChAd-triCoV/Mac) will be escalated from a dose of 10e5 TCID50/dose (n=3/vaccine group), to a dose of 10e6 (n=3/vaccine group) and then further increased for each vaccine group to 1x10e7 (n=3 per group) and 3x10e7 (n=3 per group) assuming no safety signal. Based on poor immune responses to Ad5-triCoV/Mac the dose of Ad5-triCoV/Mac will not be further escalated. Since immunogenicity endpoints were not met at 3x10e7 for ChAd-triCoV/Mac and there was no safety signal, the dose will be further escalated to 6x10e7 and 1x10e8 (n=3 per dose level). Participants with a history of COVID infection will be enrolled to receive ChAd-triCoV/Mac, beginning with a dose of 3x10e7 (n=3) and, in the absence of any safety signal, escalated to 6x10e7 and, if required, 1x10e8 and, once the optimal dose has been determined, participants enrolled at this dose level to complete enrolment of the cohort (n=6).||||
34110487|NCT06638788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be completing loads of 20, 40, and 60% 1RM at 18,12, and 6 reps respectively on the standard knee extension (varying torque) and biodex dynamometer machine (constant torque). The muscle oxygenation of the vastus laterals muscle will be assessed throughout its range of motion in both conditions and compared to torque (standard knee extension) or knee angle (Biodex dynamometer).||||
34110488|NCT02583815|||CASE_CONTROL||PROSPECTIVE|||||||
34110489|NCT00323622|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110490|NCT06571526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110491|NCT06443632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110492|NCT05220202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research staff conducting outcome assessments will be blinded to whether the subject is in active or waitlist group.|This Randomized Clinical Trial will randomize to either MOTIVATE or a waitlist control|f|f|f|t
33807386|NCT06380309|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33807387|NCT03941106|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33807388|NCT01462175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807389|NCT03506945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807390|NCT04630509|||CASE_ONLY||RETROSPECTIVE|||||||
33807391|NCT02725697|||CASE_ONLY||PROSPECTIVE|||||||
33807392|NCT02481856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807393|NCT00609869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110493|NCT06645197|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110494|NCT04567251|||COHORT||PROSPECTIVE|||||||
34110495|NCT03005002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110496|NCT02956564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110497|NCT05812859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiner in the post-operative setting will be blinded to intervention during examination and survey.||f|f|f|t
34110498|NCT04255381|NA|SINGLE_GROUP||TREATMENT||NONE||SIngle arm cohort study||||
34110499|NCT04789317|||COHORT||PROSPECTIVE|||||||
34110500|NCT06207942|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Participants (out of hospital cardiac arrest survivors and caregivers) will be blinded. Assessors of neurological prognosis will be blinded. Outcome assessors and investigators will be blinded.|2X2X2 factorial., with all participants taking part in each factor|t|f|t|t
34110501|NCT06205069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34110502|NCT04584723|||CASE_ONLY||RETROSPECTIVE|||||||
34110503|NCT05264402|||COHORT||PROSPECTIVE|||||||
34110504|NCT00572559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110505|NCT06135064|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34110506|NCT02670291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110507|NCT02304185|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34110508|NCT06398197|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34110509|NCT01631500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807394|NCT02563119|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34036436|NCT05811130|||OTHER||CROSS_SECTIONAL|||||||
34036437|NCT02360241|NA|SINGLE_GROUP||||NONE||||||
33807395|NCT00663819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807396|NCT02440438|NA|SINGLE_GROUP||||NONE||||||
33807397|NCT03991416|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807398|NCT04574206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study will be single-blinded at the participant level, however if further funding is obtained then the study will be double-blinded to include blinding at the researcher level.|This is a two-arm, randomised pilot study to compare a caregiver-delivered elaborative reminiscence intervention against a control intervention for children with autism spectrum disorder, aged 7-11 years. Randomisation will occur at the participant level and participants will be allocated to the trial arms using a 1:1 ratio.|t|f|f|f
33807399|NCT04243200|||COHORT||RETROSPECTIVE|||||||
34036438|NCT04666948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"participants and parents or legal representatives are blinded for the allocation to the intervention or standard-of-care arm until the end of study.~the statistician is kept blinded until after data analysis."||t|f|f|t
34036439|NCT00955370|||||RETROSPECTIVE|||||||
34036440|NCT03797170|||COHORT||PROSPECTIVE|||||||
34036441|NCT05915247|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Part 1: single ascending doses of up to six dosing cohorts Part 2: single dose defined based on the Part 1 data|t|t|t|t
34036442|NCT02462590|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33807400|NCT03528603|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Extra Virgin Olive Oils will be stored and provided to the study investigators in coded single serving bottles|controlled, randomized, double-blind, with 2 interventions|t|f|t|f
34036443|NCT02284776|NON_RANDOMIZED|PARALLEL||||NONE||||||
34036444|NCT00401648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34036445|NCT04121559|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036446|NCT02162056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036447|NCT01936844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036448|NCT04133701|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The interventional study model used will consist of a time-restricted feeding intervention.||||
34036449|NCT03113812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036450|NCT02600975|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036451|NCT01938092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036452|NCT00364767|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34036453|NCT02084862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036454|NCT04078594|RANDOMIZED|PARALLEL||SCREENING||NONE|The electronic alert will be masked on the control wards.|Stepped-wedge Cluster Randomized Controlled Trial||||
34036455|NCT00146302|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036456|NCT03852654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036457|NCT03847025|||COHORT||PROSPECTIVE|||||||
34036458|NCT00731354|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34036459|NCT03304925|NA|SINGLE_GROUP||OTHER||NONE||||||
34036460|NCT01234168|||COHORT||CROSS_SECTIONAL|||||||
34036461|NCT02508337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036462|NCT04509076|RANDOMIZED|PARALLEL||PREVENTION||NONE||2-arm RCT with 1:1 randomization to PrEP iT! group or the usual care control group||||
34036463|NCT01228201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036464|NCT06368492|NA|SINGLE_GROUP||TREATMENT||NONE|Blinding will be handled by one of the study pharmacies and order and allocation of the treatment to each participant will be completely randomized. This setup ensures that neither the participant nor the experimenter running the test day will be aware of the contents of the capsule.|double-blind, randomized, within-subjects, placebo-controlled design.||||
34036465|NCT03945305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036466|NCT04386850|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All subjects in a stratified random sampling method based on age, sex, BMI and serum level of 25(OH)D (\<10 ng/dL vs 10 to \<20 ng/dL) with serum calcium \<=10.6 mg/dL will be recruited in the 25(OH)D3 or placebo group. The clinical coordinator will determine this with a computer-generated randomization program. Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.|This is a multicenter randomized double-blinded placebo-controlled clinical trial with parallel groups and allocation 1:1.|t|t|t|t
34036467|NCT04069650|||COHORT||RETROSPECTIVE|||||||
34036468|NCT00639301|||COHORT||RETROSPECTIVE|||||||
34036469|NCT05652673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036470|NCT03175536|||COHORT||RETROSPECTIVE|||||||
34036471|NCT04460911|||COHORT||RETROSPECTIVE|||||||
34036472|NCT00308204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036473|NCT02473627|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34036474|NCT03807570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34036475|NCT06042595|||COHORT||RETROSPECTIVE|||||||
34036476|NCT00318773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036477|NCT05839444|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Stratified block randomization, Sequentially numbered, sealed, opaque envelopes|randomized, double-blind, placebo-controlled, parallel-group|t|t|t|f
34036478|NCT00151931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036479|NCT02673177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036480|NCT05474014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036481|NCT03101631|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Cases and Contols Study||||
34036482|NCT02845648|||COHORT||RETROSPECTIVE|||||||
34036483|NCT05227391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036484|NCT01028963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036485|NCT03908996|NA|SINGLE_GROUP||TREATMENT||NONE|A participant will not be informed of the analysis done on their stool samples. The results of the testing done on a participants stool sample will not be entered into the participants medical record.|All enrolled patients will participate in the Profile weight management program||||
34036486|NCT00134680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036487|NCT05681091|||COHORT||PROSPECTIVE|||||||
34036488|NCT01362335|||OTHER||PROSPECTIVE|||||||
34036489|NCT02946476|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34036490|NCT04357769|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036491|NCT05479786|||CASE_CONTROL||RETROSPECTIVE|||||||
34036492|NCT04310202|||COHORT||PROSPECTIVE|||||||
34036493|NCT06490848|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In this study, all consecutive patients referred for diagnostic cerebral angiography at a large academic tertiary care medical center were randomly assigned to two groups: right radial access versus femoral access for diagnostic cerebral angiography.||||
34036494|NCT00004115|RANDOMIZED|||TREATMENT||||||||
34036495|NCT03288155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind randomized controlled feasibility trial with assessors and participant blinded to intervention||t|f|f|t
34036496|NCT01753999|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34036497|NCT01839708|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34036498|NCT05082818|||OTHER||RETROSPECTIVE|||||||
34036499|NCT03721523|||COHORT||PROSPECTIVE|||||||
34036500|NCT02266784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036501|NCT04117438|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34036502|NCT01629628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036503|NCT03427242|NA|SINGLE_GROUP||TREATMENT||NONE||apatinib||||
34036504|NCT05550233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036505|NCT02347813|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34036506|NCT00929370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036507|NCT02191774|||COHORT||PROSPECTIVE|||||||
34036508|NCT03514732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036509|NCT03525704|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Randomized, Double-Masked|One-month, approximately 36 subjects enrolled (\~12/site), randomized, double-masked crossover trial.|t|f|t|f
34036510|NCT03606343|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial||||
34036511|NCT04153461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807401|NCT00750477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33807402|NCT01438034|NA|SINGLE_GROUP||OTHER||NONE||||||
33807403|NCT06625684|||CASE_ONLY||PROSPECTIVE|||||||
34036512|NCT00452764|||||PROSPECTIVE|||||||
34036513|NCT01131169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036514|NCT00407134|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036515|NCT03694509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The ultrasound assessor will be blinded to group allocation. The statistician will be blinded to group allocation.|Two groups - Tea with milk group and water control group.|f|f|t|t
34036516|NCT01831635|||CASE_CONTROL||RETROSPECTIVE|||||||
34036517|NCT03380065|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomised controlled trial||||
34036518|NCT02051582|||COHORT||PROSPECTIVE|||||||
34036519|NCT06254443|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34036520|NCT02252835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036521|NCT03645473|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34036522|NCT02111798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036523|NCT05452460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036524|NCT04745533|||COHORT||PROSPECTIVE|||||||
34036525|NCT02185196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036526|NCT05800470|RANDOMIZED|PARALLEL||OTHER||SINGLE|Assessor will be blinded to the allocation until the last assessment (4-week follow-up).|Part 1: A cross-sectional study aims to investigate the influence of fatigue on the MI ability in PD compared to healthy controls Part 2: A randomized controlled trial compare the effect of fNIRS-based NFB-MI on balance and gait performance versus MI only in people with PD.|f|f|f|t
34036527|NCT01312376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036528|NCT06583109|||CASE_ONLY||RETROSPECTIVE|||||||
34036529|NCT02534051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34036530|NCT00595894|||COHORT||PROSPECTIVE|||||||
34036531|NCT03440242|||COHORT||PROSPECTIVE|||||||
34036532|NCT04633317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036533|NCT01637116|||||PROSPECTIVE|||||||
34036534|NCT04806737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036535|NCT05495945|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34036536|NCT05664360|||COHORT||RETROSPECTIVE|||||||
34036537|NCT03649672|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Neuromuscular monitoring by TOF Watch SX on the dominant and on the non dominant arm||||
34036538|NCT04775160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34036539|NCT06298422|||COHORT||PROSPECTIVE|||||||
34036540|NCT01161069|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34036541|NCT04584801|||COHORT||PROSPECTIVE|||||||
34036542|NCT05341219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation concealment was implemented through the use of numbered containers. The allocation sequence was concealed from the researcher enrolling and assessing participants in sequentially numbered, opaque, sealed, and stapled envelopes. The trial participants, outcome assessors, and data analysts will be blinded after assignment to interventions using label A and B for the two groups.|Subjects recruited from the two institutions are being randomly allocated to the experimental group (light needle plus methadone maintenance treatment, n = 50, expected), or the control group (light needle without laser output plus methadone maintenance treatment, n = 50, expected). The study participants will receive 12 sessions of light needle therapy within 4 weeks.|t|f|f|t
34036543|NCT03995641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34036544|NCT00450879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036545|NCT06208917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036546|NCT04054765|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||non-equivalent control groups design with 285 teens ages 12-15 comparing the Invite Only VR intervention vs. treatment as usual|t|f|f|f
34036547|NCT02034929|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
34036548|NCT00155597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036549|NCT01366924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34036550|NCT05822570|||CASE_ONLY||PROSPECTIVE|||||||
34036551|NCT00740636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036552|NCT01761903|||CASE_CONTROL||PROSPECTIVE|||||||
34036553|NCT06245473|||OTHER||PROSPECTIVE|||||||
34036554|NCT03380429|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI. Clip-on sensors will be attached to both inhalers which will provide data on maintenance therapy and rescue medication use to the subjects and their HCP. Subjects will be randomized into five treatment arms in a ratio of 1:1:1:1:1 depending on whether the data, from RELVAR/BREO ELLIPTA or RELVAR/BREO ELLIPTA and salbutamol MDI, is fed back to the subject or subject and HCP, or not at all.||||
34036555|NCT05415176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized clinical trial.|t|f|t|t
34036556|NCT00033085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34036557|NCT05377749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Biostatistician||f|f|t|f
34110510|NCT05897775|NA|CROSSOVER||TREATMENT||DOUBLE|The participants will be blinded to the order of interventions they receive. The investigators assessing the severity of tremor and side effects through videos will also be blinded to the intervention condition.|Each participant will receive both the new intervention which is a new stimulation pattern and the standard of care intervention, each for a week.|t|f|f|t
34110511|NCT06323421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34110512|NCT06121752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110513|NCT06641609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110514|NCT06042491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group allocation will not be indicated in data analyzed by the outcome assessors.||f|f|f|t
34110515|NCT06116175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110516|NCT00205322|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110517|NCT06054308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110518|NCT04514835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110519|NCT04578379|||COHORT||RETROSPECTIVE|||||||
34110520|NCT05817786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomisation at month 1|t|f|f|f
34110521|NCT03123679|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110522|NCT06101420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110523|NCT06500156|||COHORT||PROSPECTIVE|||||||
34110524|NCT02657343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110525|NCT02102945|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110526|NCT04070703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34110527|NCT04084366|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110528|NCT06222684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The evaluation was made by the participants in the study.|The study is a randomized controlled trial.|t|f|f|f
34110529|NCT05814159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34110530|NCT02458729|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110531|NCT03729609|||COHORT||PROSPECTIVE|||||||
33807404|NCT02766296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807405|NCT04282759|||CASE_ONLY||PROSPECTIVE|||||||
33807406|NCT02389049|||COHORT||CROSS_SECTIONAL|||||||
33807407|NCT02617693|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807408|NCT01752699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807409|NCT01534091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807410|NCT01453959|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33807411|NCT02447666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807412|NCT05836103|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigators propose to test tailored smartphone-based messages to support young adults in quitting smoking. This study addresses 3 specific aims.~For Aim 1, a micro-randomized trial (within-subject randomization) with 80 young adult smokers will investigate the efficacy of smoking cessation messages based on CBT and mindfulness/ACT for reducing smoking urge 15 minutes after message delivery.~In Aim 2, a built-in and conventionally randomized EMA-only control group will allow us to test if intervention messages result in changes in smoking behavior over time. The primary outcome will be self-reported number of cigarettes per day at end of treatment, as well as 3- and 6-month follow-up.~Aim 3 will explore moderation effects of substance co-use (cannabis, alcohol, other drugs) and exposure to specific locations (home, work, bars) on urge reduction message efficacy among intervention group participants."||||
33807413|NCT02224469|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807414|NCT01072045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807415|NCT01238874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807416|NCT01006538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110532|NCT03463681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110533|NCT03779620|NA|SINGLE_GROUP||TREATMENT||NONE||Ultrasound treatment of calcified aortic valve stenosis||||
34110534|NCT04724837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110535|NCT02843399|||COHORT||RETROSPECTIVE|||||||
34110536|NCT05545059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34110537|NCT05855694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34110538|NCT00091156|RANDOMIZED|||TREATMENT||DOUBLE||||||
34110539|NCT06196905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110540|NCT05260242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34110541|NCT05158010|NA|SINGLE_GROUP||OTHER||NONE||||||
34110542|NCT00461890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110543|NCT02208765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110544|NCT04165109|||COHORT||PROSPECTIVE|||||||
34110545|NCT05309629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110546|NCT03246880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110547|NCT00668642|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34110548|NCT05712681|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34110549|NCT03242447|RANDOMIZED|PARALLEL||PREVENTION||NONE||participants are assigned to one of two or more groups in parallel for the duration of the study||||
34110550|NCT02015130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110551|NCT02714751|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34110552|NCT00480727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34110553|NCT04200963|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and expansion using the revised modified Toxicity Probability Interval (mTPI-2) design||||
34110554|NCT02979990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34110555|NCT04660344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110556|NCT05704088|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Randomized, controlled trial that will include 100 patients with LN with an estimated glomerular filtration rate (eGFR) of 25-75 ml/min/1.73m2. Diagnosis of LN was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center.~The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.~Control group: will be maintained on their medication."|t|t|t|f
34110557|NCT06052358|||COHORT||PROSPECTIVE|||||||
34110558|NCT02394067|||COHORT||PROSPECTIVE|||||||
34110559|NCT03896581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110560|NCT02019849|||COHORT||PROSPECTIVE|||||||
34110561|NCT03409809|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34110562|NCT06415240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As participants are neonates, they are not able to judge any intervention. Data is being collected by an independent data collector and pain scoring is also planned to be done by an independent Research Assistant. So, an investigator is masked.|Randomized Control Trial|t|f|t|f
34110563|NCT01715766|||COHORT||PROSPECTIVE|||||||
34110564|NCT06563414|||CASE_ONLY||PROSPECTIVE|||||||
34110565|NCT06616610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34110566|NCT01542788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110567|NCT06638450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807417|NCT03089359|||COHORT||PROSPECTIVE|||||||
33807418|NCT02540031|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33807419|NCT03784469|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33807420|NCT00512252|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807421|NCT01235520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807422|NCT04546776|||COHORT||PROSPECTIVE|||||||
33807423|NCT00154609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807424|NCT06308406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807425|NCT01499849|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33807426|NCT05381324|||COHORT||RETROSPECTIVE|||||||
33807427|NCT00689455|||||CROSS_SECTIONAL|||||||
33807428|NCT00698867|||COHORT||PROSPECTIVE|||||||
33807429|NCT05811273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036558|NCT00777387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036559|NCT01435850|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34110568|NCT04344912|||COHORT||OTHER|||||||
34110569|NCT03131193|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34110570|NCT06236646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110571|NCT00219726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110572|NCT04252664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110573|NCT03970031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110574|NCT06511024|||COHORT||CROSS_SECTIONAL|||||||
34110575|NCT04648085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, open, single-arm pilot study without randomization.||||
34110576|NCT02081703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110577|NCT05530733|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34110578|NCT06642259|||COHORT||PROSPECTIVE|||||||
34110579|NCT06443814|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigators, data collectors and usual medical providers were blinded to participant treatment status. Participants in both intervention groups were given similar expectations of positive outcomes.|This was a phase 2 randomized controlled trial of two behavioral interventions-Meditation and Health Education.|f|t|t|t
34036560|NCT00265187|||COHORT||PROSPECTIVE|||||||
34036561|NCT04010565|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|The consumption of SANE and placebo will be in the form of tablets with the same appearance, of 550 mg / tablet, guaranteeing that the study is blind both for the researchers of the project and for the participants (double blind).||t|t|t|t
34036562|NCT01377701|||COHORT||PROSPECTIVE|||||||
34036563|NCT05583435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036564|NCT00435331|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036565|NCT02016534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149729|NCT04427852|RANDOMIZED|PARALLEL||TREATMENT||NONE|"note on masking: The title of the study presented to participants is IONsport: Women and Protein and the funding source is withheld to mask from participants our underlying hypothesis. It is open label in the sense that they know what they are eating."|"Study participants will be randomized to either one serving of beef or a macronutrient equivalent veggie patty per day for 30 days."||||
34036566|NCT01365871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036567|NCT00800267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036568|NCT04421599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34036569|NCT00708461|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149730|NCT06530888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149731|NCT05823272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149732|NCT06276790|||CASE_CONTROL||RETROSPECTIVE|||||||
34149733|NCT02182765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149734|NCT03639506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036570|NCT06251440|||COHORT||RETROSPECTIVE|||||||
34036571|NCT04113161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Youth and their families will receive 1) standard care or 2) the cbhN intervention.||||
34149735|NCT00086645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149736|NCT01608451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149737|NCT06428812|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34149738|NCT00167388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33807430|NCT03779672|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blinded Placebo vs Memantine|Monocentric, Off-Label Use, Randomized, crossover, Double-blinded Placebo vs Memantine.|t|t|t|t
33807431|NCT01388413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807432|NCT00836498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33807433|NCT04022421|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807434|NCT00086359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807435|NCT06017700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study design is a parallel two-arm realist pilot cluster-randomised controlled trial. The trial will be conducted in eight schools (four intervention and four control). We will assess participants in intervention and control arms at baseline (week 0), after the first group session (week 5), after the sixth group session (week 12), at endline (weeks 20-21) and at follow-up (weeks 45-46). A caregiver survey will be administered at baseline and endline. Focus groups and interviews will be conducted with patients, caregivers, teachers, nurses, school principals.|f|f|f|t
33807436|NCT03813472|||COHORT||PROSPECTIVE|||||||
33807437|NCT01299194|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33807438|NCT02103166|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33807439|NCT02108704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807440|NCT02108574|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33807441|NCT00057499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036572|NCT01459133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807442|NCT02599025|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33807443|NCT01971112|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33807444|NCT03440645|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807445|NCT04639999|||CASE_ONLY||PROSPECTIVE|||||||
33807446|NCT01823224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33807447|NCT02722434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807448|NCT06502132|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Three groups with two experimental groups and one control group, including patient education and therapeutic touch||||
34036573|NCT06545851|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant and investigator is blinded to the type of oxygen supply (constant flow or automatic titrating flow).||t|f|t|f
34036574|NCT02802410|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34036575|NCT02653625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036576|NCT03309137|RANDOMIZED|PARALLEL||PREVENTION||NONE||An Open Label Randomized Feasibility Pilot Study||||
34036577|NCT01334229|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34036578|NCT01288703|||COHORT||PROSPECTIVE|||||||
34036579|NCT04850339|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34036580|NCT00047450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036581|NCT04835324|||CASE_ONLY||RETROSPECTIVE|||||||
34036582|NCT05562570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34036583|NCT04138901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|We plan to perform TAPB in patients under general anesthesia. Physicians not involved in this study will investigate the outcomes.|A prospective randomized double-blinded study|t|f|f|t
34036584|NCT01641640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036585|NCT06207721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34036586|NCT02312167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036587|NCT03531775|NA|SINGLE_GROUP||OTHER||NONE||Clinical trial to study a novel intervention (upright MRI) to compare interventions in clinical practice||||
34036588|NCT01295749|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34036589|NCT06305806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|In each Appendix trial, each participant will be assigned with equal probability to one of the factorial combinations based on two factors: (1) a study intervention/control and (2) non-pharmacologic intervention/control if the participant is eligible for the study intervention.|t|t|t|f
34036590|NCT02584101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036591|NCT04337398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036592|NCT06266325|||COHORT||RETROSPECTIVE|||||||
34036593|NCT02134431|||COHORT||CROSS_SECTIONAL|||||||
34036594|NCT05702333|||COHORT||RETROSPECTIVE|||||||
34036595|NCT03051451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34036596|NCT00663936|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036597|NCT05089383|||COHORT||PROSPECTIVE|||||||
34036598|NCT02890173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036599|NCT05214625|||COHORT||PROSPECTIVE|||||||
34036600|NCT04588701|||COHORT||RETROSPECTIVE|||||||
33807449|NCT03492021|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33807450|NCT01212913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807451|NCT06699355|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807452|NCT03773549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807453|NCT05743426|||COHORT||PROSPECTIVE|||||||
33807454|NCT03580551|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036601|NCT00882752|||CASE_ONLY||RETROSPECTIVE|||||||
34036602|NCT03243110|||CASE_ONLY||PROSPECTIVE|||||||
34036603|NCT05653479|RANDOMIZED|PARALLEL||TREATMENT||NONE||All treatment groups will enroll and run in parallel. Japanese participants will be enrolled and randomly assigned, on Day 1, to treatment groups 1, 2 or 3. NJNEA participants will be assigned to treatment group 4.||||
34036604|NCT05132062|||COHORT||RETROSPECTIVE|||||||
34036605|NCT06119776|||CASE_CONTROL||PROSPECTIVE|||||||
34149739|NCT05265507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149740|NCT03842683|||OTHER||RETROSPECTIVE|||||||
34149741|NCT04763187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149742|NCT02616770|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|f|t
34036606|NCT01982682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149743|NCT03409510|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is single-centre, open and non-blinded clinical trial. Enrolled participants were allocated into two groups, light-skinned group and darker-skinned group, based on their Fitzpatrick Skin Type and ethnic origin. As both groups received identical intervention no masking was used. The main purpose was to include participants representing a broad variation in skin pigmentation for common analysis. To ensure this, participants were allocated into two groups and firstly analysed as such to determine if a common analysis was possible.||||
34149744|NCT01117935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149745|NCT01232153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807455|NCT00210275|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725052|NCT04067128|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly assigned to receive health coaching or usual care. For the health coaching arm, an unlicensed, trained health coach called patients three times to identify and resolve barriers to adherence, including lack of understanding of their condition or the treatment, discomfort in acclimating to treatment, technical difficulties in mask fit or device settings, and challenges in navigating durable medical equipment providers. Patients assigned to usual care had access to all other available resources, including technical support from durable medical equipment providers, respiratory therapist visits with the Sleep Clinic, group visits, or visits with their primary care provider.||||
33807456|NCT04724265|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807457|NCT06195306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807458|NCT04359069|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, Randomized, Non-inferiority Trial||||
33807459|NCT06231316|||COHORT||PROSPECTIVE|||||||
33807460|NCT00518206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort 1 was enrolled first, in which subjects received the NY-ESO-1 ISCOM vaccine. Enrollment then proceeded to Cohort 2, in which subjects received the NY-ESO-1 ISCOM vaccine and low-dose cyclophosphamide.||||
33807461|NCT00040105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036607|NCT04760899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34036608|NCT02942017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036609|NCT03343925|||COHORT||PROSPECTIVE|||||||
34036610|NCT01518322|||CASE_ONLY||PROSPECTIVE|||||||
34036611|NCT00537173|||OTHER||PROSPECTIVE|||||||
34036612|NCT01744769|||CASE_ONLY||PROSPECTIVE|||||||
34036613|NCT00865761|RANDOMIZED|CROSSOVER||||NONE||||||
34036614|NCT03876951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036615|NCT01472861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036616|NCT03047187|||CASE_ONLY||CROSS_SECTIONAL|||||||
34036617|NCT05410249|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036618|NCT05881629|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention group (side-lying position with peanut ball) versus control group (free position choice, no peanut ball)||||
34036619|NCT05221762|||CASE_ONLY||PROSPECTIVE|||||||
34036620|NCT00256178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036621|NCT01417871|||CASE_CONTROL||PROSPECTIVE|||||||
34036622|NCT04382547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036623|NCT01078935|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34036624|NCT06349525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036625|NCT03600389|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interviewer and chart abstractor is blinded to the nature of the intervention and to the group assignment.||f|f|f|t
34036626|NCT04460872|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34036627|NCT05263908|||CASE_ONLY||PROSPECTIVE|||||||
34036628|NCT01522911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036629|NCT03154541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, non-blinded single arm cohort study||||
34036630|NCT00266942|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34036631|NCT01545648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036632|NCT00733005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036633|NCT01060241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34036634|NCT03936010|||COHORT||RETROSPECTIVE|||||||
34036635|NCT03336736|||COHORT||PROSPECTIVE|||||||
34036636|NCT02913911|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34036637|NCT02771067|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036638|NCT04879992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036639|NCT05129501|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036640|NCT05063422|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34036641|NCT02302417|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036642|NCT04899674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036643|NCT01707173|RANDOMIZED|PARALLEL||||NONE||||||
34036644|NCT03835923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036645|NCT02330497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036646|NCT00626002|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036647|NCT03257540|||CASE_ONLY||PROSPECTIVE|||||||
34036648|NCT00856492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036649|NCT01825473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34036650|NCT01516281|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036651|NCT01226160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036652|NCT05001893|||CASE_CONTROL||OTHER|||||||
34036653|NCT03481972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036654|NCT00180661|||COHORT||CROSS_SECTIONAL|||||||
34036655|NCT04842331|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients are randomised to 1 of 2 arms.||||
34036656|NCT04786002|||COHORT||PROSPECTIVE|||||||
34036657|NCT02215655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036658|NCT05486130|||COHORT||RETROSPECTIVE|||||||
34036659|NCT04394403|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized trial to either immediate or delayed access to the internet guided self-help program||||
34036660|NCT02655913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036661|NCT04719442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807462|NCT06086067|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Two interventions will be carried out in a single group, being two aerobic sessions, one in luteal phase and another in follicular phase. Because we want to observe both phases in the same menstruation cycle, both aerobic training sessions cannot be randomized.|f|f|f|t
33807463|NCT02631668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807464|NCT03075683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised controlled trial|t|f|f|f
33807465|NCT01841671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110580|NCT04010344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Other staff will conduct the evaluations using established protocols. They will remain blinded as to patients' group status throughout the study (i.e., pre-intervention, 1, 3, 6 \& 9-month evaluations).|Two-arm pilot cluster randomized control trial involving 240 participants with uncontrolled hypertension. The healthcare setting is the unit of randomization and patients are the unit of analysis. Each of the four healthcare settings will be recruited and randomly assigned to the multilevel intervention or control group. Randomization will be performed using a computer-generated random sequence program with a 1:1 allocation and a block size of 6 (to assure equal numbers in each arm). After meeting the study criteria for enrollment, 60 eligible patients for each setting will be assigned to either control or intervention arm according to their healthcare setting's intervention assignment by the study coordinator. The intervention will be administered for six months following which it will be withdrawn, and patients will be followed for six more months to assess outcomes.|t|f|f|t
34110581|NCT04402216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807466|NCT01051271|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34110582|NCT04363892|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34110583|NCT01600651|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34110584|NCT03238547|||OTHER||CROSS_SECTIONAL|||||||
34110585|NCT00601445|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34110586|NCT03158246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110587|NCT00265499|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34110588|NCT04148209|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This study is a double-blinded (investigator- and participant-blinded), sponsor-open, randomized, single-ascending oral dose, 4-period crossover, placebo substitution design in 2 interleaving cohorts of healthy adult participants. An additional cohort, enrolling healthy adult participants in up to 4 crossover periods, may be included to permit assessment of any of the following: repeat of a previously administered dose level; studying additional dose levels as dictated by the evaluated safety, tolerability or PK of earlier dose levels; or any other assessment needed to meet the objectives of this study. A cohort enrolling Japanese participants to receive PF-07081532 or placebo in up to 3 periods, may be included.|t|f|t|f
34110589|NCT06634069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110590|NCT01232140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110591|NCT02444247|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110592|NCT02531256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110593|NCT06643676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant will be masked by using the autoclaved guides of other patients with the guide tubes cut down and conventional surgery done in control group through the guide.||t|f|f|t
34110594|NCT04412746|||COHORT||PROSPECTIVE|||||||
34110595|NCT02578251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110596|NCT01364831|RANDOMIZED|CROSSOVER||||NONE||||||
34110597|NCT05704647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110598|NCT04017312|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be a non-blinded prospective Randomized Control Trial (RCT) pilot study with subjects requiring airway clearance therapy randomized to Oscillating Positive Expiratory Pressure (OPEP) therapy as the control group and High Frequency Chest Wall Oscillation (HFCWO) therapy as the intervention group||||
34110599|NCT06564220|||OTHER||PROSPECTIVE|||||||
34110600|NCT05505500|||COHORT||PROSPECTIVE|||||||
34110601|NCT05745961|||COHORT||PROSPECTIVE|||||||
34110602|NCT02881554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110603|NCT03509779|||COHORT||OTHER|||||||
34110604|NCT05301764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110605|NCT01796847|||CASE_ONLY||CROSS_SECTIONAL|||||||
34110606|NCT02317419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110607|NCT05834738|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blind||t|t|t|f
34110608|NCT00849992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110609|NCT04198402|||CASE_CONTROL||PROSPECTIVE|||||||
33807467|NCT00605306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807468|NCT04874259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807469|NCT03360032|||COHORT||PROSPECTIVE|||||||
33807470|NCT06510608|||OTHER||CROSS_SECTIONAL|||||||
33807471|NCT00677209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807472|NCT04425980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|by concealing the other allocated intervention from participants / unaware of the presence of a second intervention approach|a total of 30 children met inclusion criteria (grades 1-4) were randomly assigned to one of two groups (modified constraint-induced movement therapy or Bimanual training), at an equal number and probability|t|f|f|f
33807473|NCT00399828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807474|NCT00859300|||CASE_CONTROL||PROSPECTIVE|||||||
34110610|NCT03014115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110611|NCT03755427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110612|NCT04223271|||COHORT||PROSPECTIVE|||||||
33807475|NCT03126604|||COHORT||PROSPECTIVE|||||||
33807476|NCT04197037|||CASE_ONLY||PROSPECTIVE|||||||
33807477|NCT05467943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"All patients will be enrolled to Cohort 1 and 2 based on the EZH2 mutations, respectively:~* Cohort 1: MT patients with R/R FL; planned enrollment number: 19;~* Cohort 2: WT patients with R/R FL; planned enrollment number: 20; Both cohorts have same dose administered: 800 mg, twice per day (BID), continuously, at a suggested interval of 12 hours between two doses."||||
33807478|NCT00557284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807479|NCT03710252|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase IV, open label, single arm study.||||
33807480|NCT00861003|||CASE_ONLY||PROSPECTIVE|||||||
33807481|NCT02958566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807482|NCT01507506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807483|NCT03738384|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33807484|NCT01012063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807485|NCT05919680|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33807486|NCT02423005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807487|NCT00787709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807488|NCT00031941||||TREATMENT||||||||
33807489|NCT03476772|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33807490|NCT04990388|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The SAD and OL-RD cohorts will be open-label, while the DB-RD dose cohorts will be randomized, double-blind, and placebo-controlled.||t|t|t|t
33807491|NCT02401932|||COHORT||RETROSPECTIVE|||||||
33807492|NCT02983266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33807493|NCT03697603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807494|NCT02555306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807495|NCT05298371|||CASE_ONLY||PROSPECTIVE|||||||
33807496|NCT01267617|||CASE_ONLY||PROSPECTIVE|||||||
33807497|NCT01433185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807498|NCT02432300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807499|NCT03272412|||COHORT||PROSPECTIVE|||||||
33807500|NCT00293410||||TREATMENT||||||||
33807501|NCT03950206|NA|SINGLE_GROUP||OTHER||NONE||||||
33807502|NCT03926624|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, controlled||||
33807503|NCT03795688|||COHORT||PROSPECTIVE|||||||
33807504|NCT04912401|||OTHER||PROSPECTIVE|||||||
33807505|NCT00843050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807506|NCT05333367|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807507|NCT00960206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807508|NCT02909959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807509|NCT01579318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807510|NCT03693807|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot non- randomized safety study.||||
33807511|NCT05314049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807512|NCT05064631|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Parents or guardians will be blind to treatment allocation, as will the entire site study team involved in the management of the study, including the Chief Investigator (CI), PIs, sub-investigators, study nurses, and site coordinators. Trial Steering Committee (TSC) members will remain blind. The progress and safety of the study will be assessed by the Data Monitoring Committee (DMC). The DMC will therefore not be blinded. The main study trial manager (PCTU) and trial monitors will be blinded. The Sponsor's Joint Research Management Office (JRMO) including the JRMO monitor(s) will unblind themselves to specific patients in order to report SUSARs to the Medicines and Healthcare products Regulatory Agency (MHRA). The study pharmacist will be blinded, and the study pharmacy file will contain blinded documents, please see pharmacy manual. The treatment allocation list will be available from the PCTU or their designate (Sealed Envelope) on request should the need arise.|Children will be allocated into two arms (oral BV and placebo) in a 1:1 ratio. Randomisation will be stratified by site and parental asthma and the lists generated using random blocks of size 4 and 6.|t|t|t|t
33807513|NCT02201888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110613|NCT03524157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Blinding It will consist in the elimination of the primary label (commercial) in the case of Xyel Ofteno® and Systane Ultra® and the placement of a label identical to the other interventions. Because the bottle in which Systane Ultra® is packaged differs in the color and shape of the lid used by Xyel Ofteno® and PRO-087, a masking will be carried out on the primary packaging which will be identical for the three interventions.The allocation sequence will be generated by personnel assigned. The research center will receive a set of envelopes which will contain the intervention number individually. The envelopes will be identical on the outside. Each of these envelopes will be shown to the participants for their election by the principal investigator or by a designated member of their team.~The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the all analysis."|Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory.|t|f|t|t
33807514|NCT05851014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807515|NCT00738959|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33807516|NCT04140643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33807517|NCT06699563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The data analyse is going to be completed by a independent researcher.|The research will be conducted using randomized controlled, experimental type and single-blind research methods. For this purpose, after the data are collected, they will be coded as A and B groups, so the researcher who will make the research statistics will analyze the data without knowing the study and control groups. Randomization method will be used to determine the groups. For this, the patients who meet the study criteria and volunteer will be assigned to the groups using the randomization program 'Random Allocation Software 2.0' according to the order of hospitalization.||||
34110614|NCT00329420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149746|NCT03095820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, we were unable to blind the nurses performing the intervention. However, to achieve double blinding as rigorously as possible, group allocation was not divulged to participants, and symptoms were rated by independent psychologists unaware of the randomization status.|Randomized controlled parallel-design study|f|f|f|t
34149747|NCT05059977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33807518|NCT06698757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807519|NCT01738698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807520|NCT05290090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807521|NCT06249165|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, controlled, multicenter, open-label two arm trial||||
33807522|NCT03776760|||COHORT||PROSPECTIVE|||||||
33807523|NCT00064870|||COHORT||PROSPECTIVE|||||||
33807524|NCT02821936|NA|SINGLE_GROUP||OTHER||NONE||||||
33807525|NCT04300244|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|randomized, multi-center, open-label, proof of concept study comparing the efficacy and safety of nivolumab and ipilimumab with or without UV1 in patients with inoperable malignant pleural mesothelioma after first-line platinum-based chemotherapy.||||
33807526|NCT01193205|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807527|NCT03232398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary efficacy endpoint will be the presence of LV thrombus as assessed be echocardiography after 3 months of treatment. Echocardiography images will be reviewed for the presence of LV thrombus by two experts who will be blinded to the study drug.||f|f|f|t
33807528|NCT03293238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blindfolded for the duration of their procedure. Investigator will always place ultrasound probe on patient's knee regardless of group assignment to eliminate bias. To further enhance blinding, the ultrasound screen will placed on freeze for the patients randomized into the groups without ultrasound guidance. Radiologist will be blinded to patient's group assignment.|Patients will be randomized into one of four intervention arms for the purpose of obtaining patient reported outcomes as it relates to the accuracy of injections into the knee joint with or without ultrasound guidance.|t|f|f|t
33807529|NCT03314324|RANDOMIZED|CROSSOVER||OTHER||NONE||Prospective, randomized, open-label, multicenter, cross-over phase II trial||||
33807530|NCT03551600|||COHORT||PROSPECTIVE|||||||
34036662|NCT03938883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masked images will be sent to a central reading center|"All subjects (all eyes) who receive any study treatment will be evaluable for safety analysis. All treatment assignments are assigned through 1:1 randomization with one eye designated as the study eye for statistical purposes. The final subject evaluability will be determined prior to breaking the code for masked treatment assignment and locking the database."|f|f|f|t
34036663|NCT01961986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036664|NCT02401269|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34036665|NCT03213808|||OTHER||RETROSPECTIVE|||||||
34036666|NCT00314327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036667|NCT01921608|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036668|NCT00569972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036669|NCT04719572|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036670|NCT00241397|||DEFINED_POPULATION||OTHER|||||||
34036671|NCT04085237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Research Pharmacy will provide randomization/allocation.|Feasibility pilot study|t|t|t|t
34036672|NCT00950118|||CASE_ONLY||PROSPECTIVE|||||||
34036673|NCT03280238|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036674|NCT00728234|||COHORT||PROSPECTIVE|||||||
34036675|NCT03717155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036676|NCT00894972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036677|NCT03160937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One single evaluator who was blinded to the group assignments performed all tests that occurred 5 minutes prior to and 5 minutes after the intervention.|a single NM treatment session on Delayed Onset Muscle pain (DOMS) and to compare them with those of one foam roller (FR) session|f|f|f|t
34036678|NCT02509819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036679|NCT03379402|||CASE_ONLY||PROSPECTIVE|||||||
34036680|NCT03082859|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036681|NCT01848418|||OTHER||PROSPECTIVE|||||||
34036682|NCT01099592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036683|NCT05308511|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||"The trial is a prospective, multi-center,randomized, self-controlled,and non-inferiority design clinical trial. Subjects included in the research were subject to capsule endoscopy in one swallowing order (two in total), which was determined by the pre-generated random number.~Swallowing order I: First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.~Swallowing order II: First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h."||||
34036684|NCT00879255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036685|NCT00234637|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036686|NCT02090972|||CASE_CONTROL||PROSPECTIVE|||||||
34036687|NCT03687320|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham control|Single center, Prospective, Double Blind, Randomized, Sham-Controlled, Parallel Group, Superiority comparison|t|t|t|f
34036688|NCT03807544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036689|NCT00576719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036690|NCT02902523|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036691|NCT03198962|||COHORT||PROSPECTIVE|||||||
34036692|NCT06181773|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the study, only the research members who collect and analyze the data from participants can be masked to the randomization.|The participants will be randomly allocated to two arms: the intervention group and the control group.|f|f|f|t
34036693|NCT00338676|||COHORT||PROSPECTIVE|||||||
34036694|NCT00708890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036695|NCT02052024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036696|NCT04871360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The selection of which group each adolescent will belong to will be made by randomization by simple lottery by a researcher from the Department of Medical Sciences of the University of Guanajuato who is not involved in the treatment and follow-up of the participants and will be designated to a Placebo group and to the Citrulline group. The participants and the researcher will not know which group each adolescent belongs to.|"The intervention consists of the oral administration of placebo or l-citrulline as follows:~Group Placebo: Carboxymethyl cellulose will be used for the placebo group. Four capsules will be taken in the morning before the first meal and four capsules at night before going to sleep for eight weeks.~Group Citrulline: a dose of 6 g of citrulline will be used per day, distributed as 3 g (4 capsules) in the morning before the first meal and 3 g (4 capsules) in the evening before sleep, for eight weeks. Each capsule contains 750 mg of pure citrulline."|t|f|t|t
34036697|NCT01653535|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34036698|NCT05211570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, multi-centre, non-randomized, 2-part study||||
34110615|NCT04416711|RANDOMIZED|PARALLEL||PREVENTION||NONE||This two-site prevention trial will be conducted at Arizona State University (ASU) and the University of Iowa (Iowa). Participants will be 190 college men aged 18-19 (50% at each site). Scientific rigor will be ensured by (a) examining the feasibility of the intervention components in Phase I (n = 10); (b) evaluating the acceptability and preliminary efficacy of the intervention components in a Phase II open trial (n = 40); and (c) conducting a small randomized controlled trial (RCT; n = 140) in which participants will be randomly assigned (stratified by rape-supportive attitudes, frequency of HED, and frequency of sexual behavior) to either the treatment or services as usual (Phase III).||||
34110616|NCT04894864|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Laboratory data analysis collaborators|Implementation of a multimodal anesthetic opioid-free strategy, that includes the administration of pregabalin, ketamine, dexmedetomidine, lidocaine, dexamethasone, magnesium sulphate, paracetamol and dexketoprofen is anticipated to modulate the inflammatory and stress response, as measured by levels of inflammatory markers and haemodynamic stability, compared to conventional anesthetic opioid-based techniques. Furthermore, a decreased inflammatory and stress response, as expressed by reduced levels of inflammatory biomarkers and hemodynamic stability, is expected to decrease peripheral and central sensitization, contributing to better postoperative analgesia.|t|f|t|f
34110617|NCT02510924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34110618|NCT03604744|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34110619|NCT02085980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110620|NCT03685149|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is double-blinded trial with all participants, investigators, and outcome assessors being blinded with except for the Data and Safety Monitoring Board (DSMB) members.|This is a randomized double-blinded placebo-controlled crossover trial on the effect of flecainide on the frequency of ventricular arrhythmias of 38 ARVC patients. The crossover design requires a 10-week treatment with each patient receiving flecainide 100 mg bid and placebo for 4 weeks in a blinded randomized order.|t|t|t|t
34110621|NCT02878863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110622|NCT01313676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110623|NCT00480532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110624|NCT02976805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34110625|NCT00732888|RANDOMIZED|CROSSOVER||||NONE||||||
34110626|NCT06177184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who are conducting the microbial analysis and statistical analysis will not be aware of which group is intervention and which is control. These groups will be assigned a number (Group1; Group 2).|An experimental study design in which each participant will be randomized to one of two groups (intervention \[DHM\] or standard care/control \[formula\]).|f|f|f|t
34110627|NCT05650996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34110628|NCT02772692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110629|NCT02314923|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||The study comprised two separate cohorts. Cohort 1 consisted of the 4 lower V920 dose groups (3x10\^3 pfu, 3x10\^4 pfu, 3x10\^5 pfu, and 3x10\^6 pfu). Cohort 2 consisted of the 3 higher V920 dose groups (9x10\^6 pfu, 2x10\^7 pfu, 1x10\^8 pfu) plus a bridging group that received vaccine at the highest dose evaluated in Cohort 1 (i.e. 3x10\^6 pfu). Both Cohorts 1 and 2 had a placebo group.|t|f|t|t
34110630|NCT05617885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110631|NCT04892589|||COHORT||PROSPECTIVE|||||||
34110632|NCT03592017|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34110633|NCT00217802|RANDOMIZED|||TREATMENT||||||||
34110634|NCT05364502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110635|NCT01920113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110636|NCT02692534|||COHORT||PROSPECTIVE|||||||
34110637|NCT06583343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One group receiving conventional physical therapy as the control group, along with another experimental group||||
34110638|NCT01807884|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34110639|NCT05446207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be single blinded study in which the outcome assessor will be unaware of the treatment intervention.||f|f|f|t
34110640|NCT05905302|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Fifteen Parkinson's disease patients who have undergone DBS surgery and utilize the Percept system will complete a FE and VE exercise session on a stationary cycle while OFF antiparkinsonian medication. Bilateral neural activity of the STN will be continuously recorded.||||
33807531|NCT02708394|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33807532|NCT00434694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807533|NCT03881046|||CASE_CONTROL||PROSPECTIVE|||||||
33807534|NCT03667833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807535|NCT02168309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036699|NCT05670808|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34036700|NCT01015534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036701|NCT06261762|||COHORT||PROSPECTIVE|||||||
33807536|NCT00668798|||||PROSPECTIVE|||||||
33807537|NCT02767674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807538|NCT02794363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807539|NCT06698991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807540|NCT00824408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807541|NCT06509165|||COHORT||RETROSPECTIVE|||||||
34036702|NCT00179907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036703|NCT03727074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036704|NCT03198442|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Small cohort.||||
34036705|NCT03288961|||CASE_ONLY||CROSS_SECTIONAL|||||||
34036706|NCT00988416|||CASE_ONLY||PROSPECTIVE|||||||
34036707|NCT03521388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34036708|NCT00419614|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34036709|NCT06323837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036710|NCT06439160|||CASE_ONLY||PROSPECTIVE|||||||
34036711|NCT05725941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036712|NCT04962295|||COHORT||PROSPECTIVE|||||||
34036713|NCT02364765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036714|NCT04314037|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34036715|NCT03981107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Because of the inherent logistical problems with blinding of CPR techniques for dispatchers, the trial is considered as an open labeled trial. Treatment allocation will, however, be blinded in data management and at follow-up, for personnel treating the patients at the hospitals and for all responsible researchers. Allocation concealment will be preserved."|Randomized, 1:1, open label, multicenter trial|f|f|t|t
34036716|NCT06035965|||COHORT||PROSPECTIVE|||||||
34036717|NCT04688437|||COHORT||PROSPECTIVE|||||||
34036718|NCT00095446|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036719|NCT04904211|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34036720|NCT02568072|||COHORT||PROSPECTIVE|||||||
34036721|NCT00380874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036722|NCT00682786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036723|NCT05669950|NA|SEQUENTIAL||TREATMENT||NONE||||||
34036724|NCT03630497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036725|NCT02265094|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34036726|NCT02329028|||COHORT||PROSPECTIVE|||||||
34036727|NCT01185327|||CASE_CONTROL||RETROSPECTIVE|||||||
34036728|NCT02352571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036729|NCT02013063|||CASE_ONLY||PROSPECTIVE|||||||
34036730|NCT00116779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036731|NCT05266053|RANDOMIZED|PARALLEL||PREVENTION||NONE||Women will be randomized to placement of a PICO 7 dressing or a standard abdominal dressing at the time of cesarean. The standard abdominal dressing will be removed approximately on postoperative day (POD) 1-2 and the PICO 7 dressing will be removed approximately on POD 3-4 (prior to discharge). If the patient with a PICO dressing remains inpatient for longer than 7 postoperative days, the PICO dressing will be removed prior to POD 7, in accordance with device instructions. Participants in both groups will be sent POSAS surveys at the two, four and six week visit window with primary outcome being aesthetic appearance (cosmesis) at six weeks. Observers (healthcare providers) will complete a POSAS survey at the postpartum visit (\~4-6 weeks postoperative) to rate scar quality.||||
34036732|NCT03539302|NA|SEQUENTIAL||TREATMENT||NONE|"Part A was open-label however subjects were randomized to either a single dose or a double dose. There was no masking and this was a single-arm study.~Part B was an open-label, multicenter design to confirm the safety (including tolerability) and efficacy of the optimal dose from Part A.~Part C was an open-label, multicenter design study to assess the feasibility of self-administration of FlecIH-103 under medical supervision. Part C also included a sub-study to evaluate a hand-held echocardiogram device to assess the feasibility of its use in an emergent setting."|The 3 parts of the study were performed sequentially. Only Part A was randomized to assign subjects to either the 30 mg dose or 60 mg. Parts B and C were not randomized. There were no comparators in this study and no masking.||||
34036733|NCT05151237|||COHORT||PROSPECTIVE|||||||
34036734|NCT03839628|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be tested before and 2-weeks after they have reduced their level of physical activity||||
34036735|NCT03376893|||COHORT||PROSPECTIVE|||||||
34036736|NCT06320340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036737|NCT04700241|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34036738|NCT03466450|NA|SEQUENTIAL||TREATMENT||NONE||Phase Ib/II, multicentric, non-randomized, open label||||
34036739|NCT05125471|NA|SINGLE_GROUP||TREATMENT||NONE||Cobimetinib will be given orally at the recommended phase 2 dose (RP2D).||||
34036740|NCT02641015|||COHORT||RETROSPECTIVE|||||||
34036741|NCT05417841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036742|NCT05179889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036743|NCT02200055|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036744|NCT00422916|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34036745|NCT05442229|||CASE_CONTROL||PROSPECTIVE|||||||
34036746|NCT04347577|||CASE_ONLY||PROSPECTIVE|||||||
34036747|NCT00348127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036748|NCT05628610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036749|NCT02246400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34036750|NCT04648267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators evaluating the skin grafts with adobe photoshop will be masked and will not know which skin graft belonged to which patient||f|f|f|t
34036751|NCT06377124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor was not aware of which groups the patients belonged to.|"The 3S intervention includes an individual session, messaging and phone contact related to lung cancer self-management, and hotline services.~The general health information includes an individual session, messaging and phone contact related to general health information, and hotline services."|f|f|f|t
34036752|NCT02492828|||COHORT||RETROSPECTIVE|||||||
34036753|NCT01992172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036754|NCT00287586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036755|NCT02242253|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34036756|NCT05699343|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study will be a parallel, randomized single center clinical trial where participants will be randomized in to 2 groups: treatment with or without resorbable collagen membrane.||||
34036757|NCT04636788|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036758|NCT04471493|||COHORT||PROSPECTIVE|||||||
34036759|NCT06381206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036760|NCT01357837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036761|NCT02382042||PARALLEL||TREATMENT||||||||
34036762|NCT05807490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34036763|NCT00665405|||CASE_CONTROL||PROSPECTIVE|||||||
34110641|NCT04139291|NA|SINGLE_GROUP||OTHER||NONE|The physiatrist who perform ultrasonographic assessments will be blind to other assessments.|Patients with postmastectomy lymphedema||||
34110642|NCT04432623|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each higher dose level cohort will be enrolled after 2 weeks of treatment in the lower dose level. Additional doses or regimens may be added or expanded.||||
34110643|NCT05250908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects and investigator/site personnel are blinded until the Month 3 visit.|All eligible subjects will be implanted with the INTIBIA device. Subjects will be randomized to either INTIBIA therapeutic or INTIBIA non-therapeutic in a 2:1 ratio for the first 3 months of the study, at which point all subjects will receive therapeutic stimulation.|t|t|t|t
34036764|NCT03694080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110644|NCT05793502|||CASE_ONLY||PROSPECTIVE|||||||
34036765|NCT00017810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036766|NCT01676207|||COHORT||CROSS_SECTIONAL|||||||
34036767|NCT03480490|||CASE_ONLY||CROSS_SECTIONAL|||||||
34036768|NCT05116501|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036769|NCT00063011|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34036770|NCT05374655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036771|NCT05674032|||CASE_CONTROL||PROSPECTIVE|||||||
34036772|NCT05392842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind masking||t|f|t|f
34036773|NCT05961696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036774|NCT04263311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036775|NCT00993538|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110645|NCT05755958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110646|NCT02177162|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34110647|NCT05769036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110648|NCT00356187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110649|NCT00526799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110650|NCT04452877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110651|NCT01828060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34110652|NCT03227549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34110653|NCT02876614|||COHORT||RETROSPECTIVE|||||||
34110654|NCT00815633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110655|NCT06408233|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study is a stepped wedge design where clinics are randomized to onset of intervention in one of five time periods over the three years of the intervention rollout (years 2-4 of the phase) and tracked using administrative data. Data for all clinic clients during each of the seven six-month periods will be drawn from administrative data. All clinics will be in the control condition for the first six-month period. Seven clinics will be assigned randomly to one of five time periods for onset of intervention.||||
34110656|NCT03926013|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110657|NCT04621188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110658|NCT05214118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34110659|NCT05849467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110660|NCT06003712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110661|NCT06352463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34110662|NCT06634771|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The study team will be provided a numeric code to enter into the XCSITE 100 tACS system, which will conceal the stimulation parameters from the study team, ensuring double blinding. The XSCITE 100 device allows for the programming of stimulation codes corresponding to sham or active stimulation, both of which are set to a total duration of 30 minutes, allowing for reliable double-blinding.|"Study design consists of 3 groups of participants:~1. Control (CON): no adolescent binge drinking (AIE) and current (past month) World Health Organization (WHO) risk drinking levels of either 0 or 1 (abstinent or low-risk)~2. (RISK): no AIE and current WHO level 2, 3, or 4 (medium risk, high risk, or very high risk)~3. (RISK+AIE): history of adolescent binge drinking and current WHO risk level 2, 3, or 4.~Within each group (n=22), participants will be randomly assigned to either the 10Hz tACS (stim) group or the sham tACS (sham) group.~Study design requires randomly assigning individuals to a stimulation group after completing Session 1. Prior to study onset, Dr. Boettiger will create a randomization table in which stimulation type (true or sham) is pseudo randomly ordered within groups, stratified by sex. Dr. Boettiger will provide assignment to the study team based on this predefined randomization table in order to ensure balanced sex and group for each stimulation type."|t|f|t|t
34110663|NCT00005978||||TREATMENT||||||||
34110664|NCT04414943|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725053|NCT05387317|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A unblinded vaccinator will administer the dose and will not be involved in outcome assessment. Unblinding will occur for each participant at approximately 28 days after the study vaccine||t|t|t|t
33725054|NCT04749953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are blinded to the used grafting material.|A single-blinded randomized controlled study. No drug or device is tested. Different grafting materials for bone augmentation is compared. Autogenous bone graft is golden standard, which is compared with two different mixtures of alternative grafting materials.|t|f|f|f
33725055|NCT03050073|||COHORT||PROSPECTIVE|||||||
34036776|NCT05895448|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||PWID arm and non-PWID arm prospective, parallel observational cohorts||||
34036777|NCT01370629|||COHORT||PROSPECTIVE|||||||
34036778|NCT00663793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036779|NCT01422213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036780|NCT00254787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34036781|NCT03919656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Dapagliflozin 10 mg, Green, plain, diamond shaped, film coated tablet (orally); Matching placebo for dapagliflozin Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient|Patients will be randomized in a 1:1 ratio|t|f|t|f
34110665|NCT06296498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the intervention which they are randomized to.|The proposed study is a split-mouth design, randomized, prospective clinical trial in which we will use either OFD alone or OFD + L-PRF for periodontal surgery. Both procedures are standard of care|t|f|f|f
34110666|NCT05034081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110667|NCT05396014|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Sequential Multiple Assignment Randomized Trial (SMART)|f|f|f|t
34110668|NCT06109324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34110669|NCT05937698|||COHORT||PROSPECTIVE|||||||
34110670|NCT00912717|||CASE_CONTROL||PROSPECTIVE|||||||
34110671|NCT04344873|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective placebo controlled crossover design||||
34110672|NCT02041273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110673|NCT06558578|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34110674|NCT06275867|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34110675|NCT00240019|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34110676|NCT06484881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110677|NCT05949957|RANDOMIZED|PARALLEL||PREVENTION||NONE||A parallel 2-arm, single-Centre Randomized Control Trial based on 1:1 allocation ratio. Eligible women will be randomized at baseline to either Group 1 (Intervention) or Group 2 (Control). Participants will receive the assigned intervention from baseline to 1 year, followed by 3 years follow-up period.||||
34110678|NCT00159016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110679|NCT01661673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110680|NCT02408874|||COHORT||PROSPECTIVE|||||||
34110681|NCT00476645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036782|NCT04010851|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention is delivered in a group format, which takes the form of a full day's training, focusing on ADHD diagnosis, its treatment, how to cope with the challenges related to living with ADHD, as well as coping with challenges of parenting a child with chronic health conditions. After this one day-intervention, the participants can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence. Participants are encouraged to adopt an active role in order to achieve a positive parent/provider partnership.||||
34036783|NCT01595880|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036784|NCT02769507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34036785|NCT02620995|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34036786|NCT03678246|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Images are reviewed by two senior anaesthetists who is not directly involved in the study.|Ramped vs Supine position||||
34036787|NCT05662371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34036788|NCT04274933|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34036789|NCT01731639|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
34036790|NCT00745901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036791|NCT03472014|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036792|NCT06121323|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34110682|NCT05154734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110683|NCT05408780|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||"This is a two-part study.~Part A (Food Effect Assessment): It is a randomized, double-blind (to IMP received), placebo-controlled, four-period, single-dose design. Subjects will be dosed in the fed state or the fasted state depending on the regimen.~Part B (Titration Tolerability): Participants will be administered to either tricaprilin or a matching placebo."|t|t|t|t
34110684|NCT01631266|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34110685|NCT06639425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110686|NCT02558868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110687|NCT06632171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110688|NCT06570161|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Randomized crossover design||||
34110689|NCT05175729|||CASE_CONTROL||PROSPECTIVE|||||||
34110690|NCT01422577|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34110691|NCT06645418|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34110692|NCT05837481|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The proceduralists that will be performing the peripheral vascular interventions will be blinded to the group allocation.||f|t|f|f
34110693|NCT06138418|NA|SINGLE_GROUP||OTHER||NONE||Longitudinal evaluation waking ability within activity devices||||
34110694|NCT04197232|||CASE_CONTROL||PROSPECTIVE|||||||
34110695|NCT06547632|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34110696|NCT06643065|||COHORT||PROSPECTIVE|||||||
34110697|NCT05488522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110698|NCT06230913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110699|NCT04723719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Stratified permuted block randomization, controlling for ADHD medication use (yes/no), is done by a masked/independent researcher.|Randomized Controlled Trial with training group and control group.|f|f|t|f
34110700|NCT06565013|||COHORT||PROSPECTIVE|||||||
34110701|NCT06516198|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A random number card will be drawn in sequence from a box. Even numbered cards will assign the patient to the experimental group, odd numbered cards will assign the patient to the control group. For the sham intervention (Sham Type II, same intervention with seeding and intermittent pressing) the seeds are placed at nonacupressure points for the control group.||t|f|f|f
34110702|NCT01334255|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110703|NCT06312930|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34110704|NCT02743741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110705|NCT02381587|||CASE_ONLY||RETROSPECTIVE|||||||
34110706|NCT04073420|||COHORT||OTHER|||||||
34110707|NCT00002673||||SUPPORTIVE_CARE||||||||
34110708|NCT01531335|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34110709|NCT00600496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110710|NCT05493657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110711|NCT05025865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33807542|NCT04789759|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Person who does the volumetric analysis is blinded, Person who makes data treatment is blinded|Case Series of 10 consecutive cases , with one extraction (at least ) with a type 2 socket, Control group, 10 consecutive dental extractions.|f|f|f|t
33807543|NCT02551224|RANDOMIZED|CROSSOVER||OTHER||NONE||open-label, cross-over study comparing the preference on the feedback mechanisms of dose delivery confirmation with the Breezhaler® device compared to the Ellipta® device||||
33807544|NCT03071354|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807545|NCT05508854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment Prospective, parallel, two arm, randomized controlled clinical trial||||
33807546|NCT03908164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807547|NCT02969200|||COHORT||RETROSPECTIVE|||||||
33807548|NCT01911559|||CASE_ONLY||PROSPECTIVE|||||||
33807549|NCT05758584|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled study||||
33807550|NCT05667311|||COHORT||CROSS_SECTIONAL|||||||
34036793|NCT03285347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Before and after the intervention period, the patients are tested in a neuropsychological battery to asses their executive functioning. The tester is blinded to the Group allocation of the patients.|Two intervention Groups training with each their computer-based cognitive programme, one control Group receiving no intervention except for the same amount of follow-ups as the two intervention Groups.|f|f|f|t
34036794|NCT06520618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34036795|NCT00684372|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036796|NCT05164692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|LiveSpo Navax and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax suspension is unrecognizable to investigators except the PI and analyzer, nurses, patient's parents, and patients due to opaque plastic container.|Blind, randomized, and controlled clinical trial|t|t|t|f
34036797|NCT04558073|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants and the collaborators performing the interventions will not be blinded to the conditions. In order to minimize bias, the main statistical analyses aimed at evaluating the hypotheses will be performed by a statistician blinded to the participants' allocation.||f|f|f|t
34036798|NCT05774067|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34036799|NCT01832064|NA|SINGLE_GROUP||||NONE||||||
34036800|NCT00962819|||OTHER||CROSS_SECTIONAL|||||||
34036801|NCT04949217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036802|NCT00004012||||TREATMENT||||||||
34036803|NCT04343040|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34036804|NCT02816736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036805|NCT03023072|||CASE_CONTROL||PROSPECTIVE|||||||
34036806|NCT03257280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036807|NCT03866213|||COHORT||PROSPECTIVE|||||||
34036808|NCT05360810|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Single (Participant) closed envelope technique||t|f|f|f
34036809|NCT04131088|||CASE_ONLY||PROSPECTIVE|||||||
34036810|NCT00007631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036811|NCT04999059|||COHORT||PROSPECTIVE|||||||
34036812|NCT01004354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036813|NCT02813408|||COHORT||PROSPECTIVE|||||||
34036814|NCT03987282|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pre- versus post-implementation evaluation||||
34036815|NCT01779440|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036816|NCT04542473|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|"Sequential study numbers will be computer generated according to a blocked randomization list of random block sizes allocated to each site before the study begins.~Identical study investigation medical product (IMP) packs will be labelled with sequential study numbers according to a prepared blocked randomization list before the trial begins. An independent off-site trial-pharmacist will implement labeling of the IMP with unique study numbers according to the randomization list.~Study numbers will be issued in consecutive order at each site."|"Double-blind, randomized clinical trial 2x2 factorial design in 3 stages:~In stage 1, (200 participants). Then the Data \& Safety Monitoring Committee (DSMC) will review data for likelihood major safety signals/harm (non-inferior to placebo) based on a composite endpoint of toxicity, serious adverse events (SAEs) and deaths.~In stage 2, (200 more participants, total 400 participants). Then the DSMC will review data on a composite endpoint of SAEs and deaths and results of modeled simulations for the likelihood of superiority over placebo for mortality. Interventions with less than 80% probability of efficacy will be discontinued. Sample size for stage 3 may be adjusted.~In stage 3, (800 more participants, total target sample size 1,200) across all sites, based on a hazard ratio of 0.66 (a 33% reduction in mortality) from a baseline mortality of 24% to 16% with 90% power, 20% inflation for the factorial design and 5% loss to follow up."|t|t|t|t
34036817|NCT01113723|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34036818|NCT00371579|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036819|NCT00837148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036820|NCT03322202|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patient participants will be blinded as will an assessor measuring participation during sessions. Therapist participants will be aware of the arm in which they will be placed.|Patients in the experimental group will be exposed to a Physical or Occupational Therapist trained in Motivational Interviewing. The control group will receive standard therapy communication.|t|f|f|t
34036821|NCT03929978|||OTHER||RETROSPECTIVE|||||||
34036822|NCT02851628|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036823|NCT05021900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036824|NCT01601418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34036825|NCT05828381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036826|NCT03866889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33838138|NCT04955977|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Unique masking when study participants, who will not know:~1. Assignment to research groups, for which the measurement of the severity of the disease will be developed individually.~2. Treatment to receive, for which the intervention will be carried out individually and at the home of each participant."|Quasi-experimental study with assignment to groups by convenience by severity of the disease. Group 1: COPD GOLD1-2, Group 2: COPD GOLD3-4, Group 3: Control. Study with intra- and inter-group comparison before and after intervention with an external control group|t|f|f|f
34036827|NCT04466280|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34036828|NCT02603289|||COHORT||PROSPECTIVE|||||||
34036829|NCT03612245|||CASE_CONTROL||PROSPECTIVE|||||||
34036830|NCT04507724|||COHORT||PROSPECTIVE|||||||
34110712|NCT02985944|||COHORT||PROSPECTIVE|||||||
33807551|NCT05095740|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants will be randomly assigned to one of two arms of this study (real rTMS or sham). Only the study personnel tasked with setup of the rTMS equipment will know to which group each participant has been randomized so that they can adjust the machine parameters for each participant.|Participants will be randomly assigned to receive 5 consecutive days of either rTMS or sham rTMS. Day 1, baseline (Pre) acoustic, perceptual and patient-reported assessments of voice production and TMS-measured neurophysiology will be performed. Participants will then receive the first rTMS intervention. Day 2, 3 and 4, participants will receive rTMS intervention solely, with no testing. Day 5, the same acoustic, perceptual, patient-reported and assessments will be performed after rTMS intervention. At least 3 months after Post1, participants will cross-over to receive the other intervention. Assessments in Pre2 and Post2, will mirror the timing of Pre1 and Post1 in phase 1. Following treatments, acoustic measures and a global rating of change in vocal function will be evaluated to understand the longevity of our treatment approach. Follow up voice recordings will be obtained using a portable voice recorder given to and returned by participants at their initial visit.|t|t|t|t
33807552|NCT02179359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807553|NCT00262015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807554|NCT03130894|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807555|NCT06135220|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807556|NCT04082507|||COHORT||PROSPECTIVE|||||||
33807557|NCT06154330|||OTHER||CROSS_SECTIONAL|||||||
33807558|NCT00005869|RANDOMIZED|||TREATMENT||||||||
33807559|NCT00275444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807560|NCT00834379|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33807561|NCT01536093|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33807562|NCT04707170|||COHORT||PROSPECTIVE|||||||
33807563|NCT00811512|||CASE_ONLY||RETROSPECTIVE|||||||
33807564|NCT01075750|||COHORT||PROSPECTIVE|||||||
33807565|NCT00926159|||CASE_ONLY|||||||||
33807566|NCT05570617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807567|NCT03392194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807568|NCT05538572|NA|SEQUENTIAL||TREATMENT||NONE||||||
33807569|NCT06466083|||COHORT||PROSPECTIVE|||||||
33807570|NCT03830151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807571|NCT06511089|RANDOMIZED|PARALLEL||TREATMENT||NONE|PROBE design|||||
33807572|NCT05150093|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807573|NCT06470386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807574|NCT06009666|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807575|NCT05610566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807576|NCT01229904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807577|NCT02132676|||COHORT||RETROSPECTIVE|||||||
33807578|NCT02134171|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807579|NCT00447837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807580|NCT00001968||||TREATMENT||||||||
33807581|NCT05077475|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807582|NCT01220115|||COHORT||PROSPECTIVE|||||||
33807583|NCT00741650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807584|NCT05372224|NA|SINGLE_GROUP||TREATMENT||NONE||"76 participants were considered from the climacteric clinic of the regional hospital 1o de Octubre of the Institute of Security and Social Services for State Workers (ISSSTE), of which 23 presented elimination criteria, and 55 were included in the study."||||
34036831|NCT00002019||||TREATMENT||||||||
33807585|NCT04805736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036832|NCT03403673|||COHORT||PROSPECTIVE|||||||
34036833|NCT02721342|||COHORT||PROSPECTIVE|||||||
34036834|NCT04711538|||COHORT||PROSPECTIVE|||||||
34036835|NCT01942993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036836|NCT05138861|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking procedure is required as this is an open-label study.|This is a single-center, open-label, single-arm study.||||
34036837|NCT02012322|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34036838|NCT05327400|||CASE_CONTROL||PROSPECTIVE|||||||
34036839|NCT03526328|||OTHER||PROSPECTIVE|||||||
34036840|NCT05494996|||COHORT||CROSS_SECTIONAL|||||||
34036841|NCT02041819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036842|NCT03142477|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into tree different groups: control, placebo, treatment.||||
34036843|NCT05714592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036844|NCT00089804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036845|NCT03412721|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Allocation: Randomized Intervention Model: Split-mouth assignment with two-way repeated measures design Masking: Double (Participant, Outcomes Assessor)|t|f|f|t
34036846|NCT02789774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036847|NCT04492982|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34036848|NCT01880866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036849|NCT06382818|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"* COHORT A = Low risk of recurrence / Low risk of breast toxicity~* COHORT B = Low risk of recurrence / High risk of breast toxicity~* COHORT C = High risk of recurrence / Low risk of breast toxicity~* COHORT D = High risk of recurrence / High risk of breast toxicity"||||
34036850|NCT03203473|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036851|NCT00505908|||OTHER||PROSPECTIVE|||||||
34036852|NCT04654195|||COHORT||PROSPECTIVE|||||||
34036853|NCT01656460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110713|NCT04272034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of 2 parts. Part 1 is a dose-escalation design to identify the maximum tolerated dose and/or pharmacologically active dose for INCB099318. Part 2 is an expansion at 1 or more dose levels to further explore safety, preliminary efficacy, pharmacoketics, and pharmacodynamic effects.||||
34110714|NCT03746210|||COHORT||PROSPECTIVE|||||||
34110715|NCT02626884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725056|NCT04939415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725057|NCT04745403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725058|NCT05048121|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|"Randomized, double blind, placebo controlled. All products will be packed in the identical packaging and will be labeled in accordance to randomization technique.~Label will contain: 4 digit, randomization code of the sample and visible sign LEFT or RIGHT.~Visible sign ''Left'' or ''Right'' will indicate the side of the face the product will be applied."|Infra-subject comparisons study. As the study is intraindividual, every subject will apply study product on the one side of the face and placebo on the other side of the face at the same time. Subject will not be aware what product is the study product and application is indicated only by the side of the face products are applied.|t|t|t|t
33725059|NCT03402009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33725060|NCT01024049|||CASE_CONTROL|||||||||
33807586|NCT05716425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807587|NCT00306475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807588|NCT04999007|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33807589|NCT06296407|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34036854|NCT00810212|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized to one of four (4) parallel treatment arms; autograft standard of care control, or one of three (3) doses of mesenchymal precursor cells (MPCs) combined with MasterGraft Granules. Subjects randomized to receive investigational product will be treated with one of the following three doses of allogeneic MPCs in 4 milliliters (mLs) per posterolateral lumbar fusion (PLF) level (204 mLs per side): 25 million (M), 50M or 75M MPCs per PLF level (or a total dose of 50 million, 100 million or 150 million MPCs if subject undergoes fusion at two levels). Each of the four treatment groups will include six (6) evaluable subjects.||||
34036855|NCT04644523|||COHORT||PROSPECTIVE|||||||
34036856|NCT00979654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036857|NCT02767557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036858|NCT03558581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036859|NCT01714830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34036860|NCT04735510|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive study drug||||
34036861|NCT06494475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34036862|NCT03507868|||COHORT||PROSPECTIVE|||||||
34036863|NCT04390776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34036864|NCT03393923|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34036865|NCT01375062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036866|NCT00616265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34036867|NCT02738918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036868|NCT05674539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to one of two reduced intensity conditioning (RIC) regimens (fludarabine plus busulfan and fludarabine plus melphalan)||||
34036869|NCT01628731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036870|NCT02125682|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34036871|NCT04377204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will be consented to participate, but will be blinded to which preoperative local anesthetic regimen they will receive for their rhinoplasty procedure.|Single blinded cohort intervention|t|f|f|f
34036872|NCT04623619|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open-label, controlled study||||
34036873|NCT01894386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036874|NCT05071599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036875|NCT03973606|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A 4-sessions workshop to improve health literacy among Arab women in Israel, with pre-post evaluation.||||
34036876|NCT05541367|||CASE_ONLY||PROSPECTIVE|||||||
34036877|NCT03065855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036878|NCT03456102|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34036879|NCT03006601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036880|NCT02442947|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036881|NCT01160705|||COHORT||PROSPECTIVE|||||||
34036882|NCT00637845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036883|NCT00483015|||||RETROSPECTIVE|||||||
34036884|NCT05754905|||CASE_CONTROL||PROSPECTIVE|||||||
34036885|NCT05564156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34036886|NCT01395147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036887|NCT04812444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34036888|NCT03671967|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label randomized controlled trial||||
34036889|NCT00671112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036890|NCT05302960|||COHORT||PROSPECTIVE|||||||
34036891|NCT02563054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036892|NCT05549843|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34036893|NCT02672917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110716|NCT06642727|RANDOMIZED|PARALLEL||OTHER||NONE||There will be two groups: an experimental group and a control group. The experimental group will undergo laughter yoga, while the control group will not receive any intervention.||||
34110717|NCT02985723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110718|NCT04112992|||CASE_ONLY||PROSPECTIVE|||||||
33807590|NCT00592891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036894|NCT00786786|||CASE_ONLY||CROSS_SECTIONAL|||||||
34036895|NCT03076892|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Split Face intra individual comparison||||
34036896|NCT05561387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036897|NCT02727478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036898|NCT02729298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036899|NCT02264769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036900|NCT01116167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036901|NCT04589156|||COHORT||CROSS_SECTIONAL|||||||
34036902|NCT04827823|||OTHER||RETROSPECTIVE|||||||
34036903|NCT03203382|||COHORT||PROSPECTIVE|||||||
34036904|NCT06187129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036905|NCT05966584|NA|SINGLE_GROUP||TREATMENT||NONE||A multi-center, open-label, phase 2 trial||||
34036906|NCT04220788|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34036907|NCT00529373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036908|NCT03943693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34036909|NCT02841839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036910|NCT06115135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036911|NCT02883972|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34036912|NCT02696343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34036913|NCT03330561|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|Drug PRS-343 Monotherapy||||
34036914|NCT06211309|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036915|NCT01341275|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34036916|NCT04319471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036917|NCT00221338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036918|NCT02832232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036919|NCT05230381|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110719|NCT03599765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110720|NCT03374306|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|Randomized clinical trial|t|f|t|f
34110721|NCT04839640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||split mouth technique|t|t|t|t
34110722|NCT02729415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110723|NCT06564857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment, multicenter|t|t|t|t
34110724|NCT02629107|||COHORT||PROSPECTIVE|||||||
34110725|NCT04961255|||COHORT||PROSPECTIVE|||||||
34110726|NCT06638411|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to the study hypotheses and treatment arms, and to the type of intervention they are receiving. Outcome assessors will be blinded to participants' treatment arm assignment and the type of intervention they are receiving.||t|f|t|f
34110727|NCT06312059|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|RP Over stickered TP in blank packaging.||t|t|t|t
34110728|NCT01827020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110729|NCT04432779|||COHORT||PROSPECTIVE|||||||
34110730|NCT06637709|||CASE_CONTROL||PROSPECTIVE|||||||
34110731|NCT06541197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110732|NCT06507618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110733|NCT03738228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110734|NCT06361836|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential escalating dose cohorts||||
34110735|NCT02026167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110736|NCT04921865|||CASE_ONLY||PROSPECTIVE|||||||
34110737|NCT05479370|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110738|NCT00925574|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34110739|NCT06099665|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34110740|NCT03453229|||COHORT||PROSPECTIVE|||||||
34110741|NCT06570252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34110742|NCT03563001|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with diagnosis of simple chronic obstructive pulmonary disease(COPD) and asthma-chronic obstructive pulmonary disease overlap(ACO) are recruited.Small airways function of subjects in both group(chronic obstructive pulmonary disease and asthma-chronic obstructive pulmonary disease overlap) is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.||||
34110743|NCT03671226|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110744|NCT00391716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110745|NCT06268847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34110746|NCT05781308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110747|NCT03888027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Patients will be randomized via REDCap (Research Electronic Data Capture), a secure, centralized web-based randomization module to:~1. Standard of care; or~2. WalkMORE Ambulation program + Standard of care. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge. Patients randomized to the WalkMORE intervention will be assessed daily by the Research Coordinator to ensure patients remain fit for independent ambulation. The duration of each walking session will be determined daily by the RC and the medical team."|f|f|f|t
34110748|NCT05437419|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34110749|NCT03014258|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110750|NCT06139354|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110751|NCT06459778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110752|NCT02552264|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34110753|NCT00375713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110754|NCT03404713|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each eligible participant receives the same standard group treatment for the first four weeks. Early responders continue in that treatment for an additional 12 weeks. Early weak responders are assigned to a higher intensity individualized treatment for the next 12 weeks.||||
34110755|NCT00220662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110756|NCT05039307|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not possible due to the nature of this research.|A cluster randomized controlled trial (cRCT) with a hierarchical design will be conducted whereby 2 groups of 3 healthcare centers (in total 6 healthcare centers) will be randomized to an intervention group or comparison group.||||
34110757|NCT05053061|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110758|NCT03586531|||CASE_ONLY||CROSS_SECTIONAL|||||||
33807591|NCT06030817|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807592|NCT02227706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110759|NCT06637579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110760|NCT02071589|RANDOMIZED|CROSSOVER||||NONE||||||
34110761|NCT06526273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110762|NCT04581395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be performed using Research Randomizer in blocks of 30. The primary investigator will inform the person doing the case as to what group the participants are randomized. Both the participants and the research staff doing assessments will be blinded.||t|f|f|t
34110763|NCT05388487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110764|NCT02160808|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110765|NCT01979185|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34110766|NCT04198428|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110767|NCT00553085|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110768|NCT00095576|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34110769|NCT05414799|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study included two groups i.e. experimental and control group.||||
34110770|NCT04921267|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant doesn't know what condition they are in.|2 groups. One group is trained to listening through simulated hearing protection. The other receives no such training.|t|f|f|f
34110771|NCT03141437|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34110772|NCT06077357|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Two groups consisting of a COPD group and an Asymptomatic group.||||
34110773|NCT02676180|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34110774|NCT06638528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34110775|NCT00437788|||||PROSPECTIVE|||||||
34110776|NCT05456087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110777|NCT06563934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a prospective, single-center, randomized, double-blind controlled trial.|This is a prospective, single-center, randomized, double-blind controlled trial. The clinical study is divided into 2 groups: Group 1) Patients in the control group were given lenvatinib 8mg (≤ 60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day, combined with PD-1 monoclonal antibody 200mg intravenously once every 3 weeks until disease progression, intolerable toxicity or death, and patients in the control group were given intestinal bacteria capsules placebo. Group 2) Patients in the study group were given lenvatinib 8 mg (≤ 60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day in combination with PD-1 monoclonal antibody 200 mg intravenously every 3 weeks until disease progression, intolerable toxicity, or death, and patients in this study group were given intestinal bacteria capsules.|t|f|t|f
34110778|NCT06570980|||OTHER||RETROSPECTIVE|||||||
34110779|NCT03986892|||COHORT||CROSS_SECTIONAL|||||||
34110780|NCT03232567|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE||Single ascending dose study|t|t|t|f
34110781|NCT03810807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110782|NCT06068621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110783|NCT05329831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled||||
34110784|NCT06283212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110785|NCT03747367|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Experiment 1 - none Experiment 2 - double-blind|Experiment 1 - Single group, repeated assessment Experiment 2 - Double-blind, randomized, cross-over design|t|f|t|f
34110786|NCT06560736|RANDOMIZED|PARALLEL||TREATMENT||NONE||Wait-list Control Design||||
34110787|NCT06055751|||COHORT||PROSPECTIVE|||||||
34110788|NCT03236883|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110789|NCT03552029|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 Single Group 1 Arm, Part 2 Parallel, 2 Cohorts||||
34110790|NCT05991713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110791|NCT02729519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110792|NCT05530525|||COHORT||RETROSPECTIVE|||||||
34110793|NCT04160832|||COHORT||PROSPECTIVE|||||||
34110794|NCT03388827|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded||t|t|f|t
34110795|NCT04344795|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||open-label dose escalation, schedule and dose optimization, and dose expansion||||
34110796|NCT01417767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110797|NCT04674085|||COHORT||RETROSPECTIVE|||||||
34110798|NCT04458857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110799|NCT00875446|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34110800|NCT06061757|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34110801|NCT06645236|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807593|NCT00229970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807594|NCT00308035|||COHORT||PROSPECTIVE|||||||
33807595|NCT01878305|||CASE_ONLY||PROSPECTIVE|||||||
33807596|NCT02808234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807597|NCT01827839|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807598|NCT05670821|||COHORT||PROSPECTIVE|||||||
33807599|NCT03537326|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Healthy women, aged between 18 and 45 years old, weighing between 50 and 75 kg and with BMI included between 19 and 27 kg/m².||||
33807600|NCT03479918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Factorial Assignment||||
33807601|NCT00241800|||COHORT||RETROSPECTIVE|||||||
33807602|NCT02168998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807603|NCT05733559|||OTHER||PROSPECTIVE|||||||
34110802|NCT05828173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110803|NCT04492384|||COHORT||OTHER|||||||
34110804|NCT04037137|||FAMILY_BASED||RETROSPECTIVE|||||||
34110805|NCT06424743|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients will be allocated to 1 of three groups: 1 set, 2 sets, or 3 sets of resistance exercise. In the next sessions they will be allocated to the series he has not performed yet.|f|f|t|t
34110806|NCT02712203|||COHORT||RETROSPECTIVE|||||||
34110807|NCT04605276|||COHORT||PROSPECTIVE|||||||
33807604|NCT00000215||||TREATMENT||||||||
34110808|NCT01596023|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34110809|NCT05991453|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34110810|NCT01052779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110811|NCT02267447|||COHORT||PROSPECTIVE|||||||
34110812|NCT05105620|||CASE_ONLY||RETROSPECTIVE|||||||
34110813|NCT03018873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110814|NCT06503185|||COHORT||RETROSPECTIVE|||||||
34110815|NCT00618787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110816|NCT00506766|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34110817|NCT05339555|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110818|NCT03632044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"During the block placement the surgical team will be asked to leave the operating room briefly to remain blinded to the group assignment of all patients as the surgical team will manage the subjects post-operative care and determine discharge readiness.~ICU nursing staff and parents will be informed of participation in the study but will not be informed as to group assignment to remain blinded."|This randomized, double-blinded study. Subjects will be randomly assigned to one of two different protocols by a designated study team member based on a computer generated randomization table. Randomization will occur following consent. Randomization will be 1:1.|t|t|f|t
34110819|NCT01993732|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34110820|NCT06637787|||OTHER||PROSPECTIVE|||||||
34110821|NCT00505687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110822|NCT03563079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants selected to participate in this research will be randomly drawn and randomly allocated using sealed opaque envelopes, and therefore included randomly in one of the two groups present in this study. A collaborative researcher blind to the groups will be assigned to conduct the pre- and post-intervention evaluation process of all individuals.|Randomized clinical trial|f|f|f|t
34110823|NCT04342702|||COHORT||PROSPECTIVE|||||||
34110824|NCT01107496|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34110825|NCT06215378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The members of the endpoint committee will evaluate events related to both primary and secondary outcomes in a blinded manner, ensuring they are unaware of patient identities and the groups to which they were allocated through randomization.|Phase III, national, multicenter, controlled, randomized open label study in 2 parallel groups at a 1:1 ratio|f|f|f|t
34110826|NCT05713292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110827|NCT06457087|||COHORT||PROSPECTIVE|||||||
34110828|NCT05601869|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pretest-Posttest Design||||
34110829|NCT06467188|||OTHER||CROSS_SECTIONAL|||||||
34110830|NCT05629520|||COHORT||PROSPECTIVE|||||||
34110831|NCT03592355|RANDOMIZED|PARALLEL||OTHER||NONE||Clinicians slated for virtual visit rollout will be randomized (stratified by department) to either receive immediate virtual visit on-boarding (intervention arm) or delayed (3-months later) virtual visit on-boarding (control arm).||||
34110832|NCT03506360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110833|NCT00867152|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34110834|NCT05316844|||CASE_ONLY||CROSS_SECTIONAL|||||||
34110835|NCT03512730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110836|NCT05011383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||3 cohort phase II study||||
34110837|NCT05692089|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110838|NCT04641026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|participant is blinded to the presence or absence of deuterium label||t|f|f|f
34110839|NCT02951481|||COHORT||OTHER|||||||
34110840|NCT01980264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110841|NCT01683812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110842|NCT06107699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34110843|NCT04950153|RANDOMIZED|PARALLEL||PREVENTION||NONE||Stepped wedge (cluster) randomized trial||||
34110844|NCT03454347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110845|NCT01716000|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34110846|NCT02382146|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34110847|NCT03864328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomization stratified by background IPF therapy use and FVC % predicted at baseline|t|t|t|t
34110848|NCT06459440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be randomized control trial in which non probability convenient sampling will be used. Two groups of 4-8 age will be formed in which participants will be randomly divided.Group A will be receive Group-Task-Oriented Training. Group B will be receive routine therapy.|t|f|f|f
34110849|NCT05544682|||CASE_ONLY||RETROSPECTIVE|||||||
34110850|NCT05703763|||COHORT||PROSPECTIVE|||||||
34110851|NCT04558736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110852|NCT03815344|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34110853|NCT04063202|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34149748|NCT03328858|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Ketogenic Diet will be initiated as inpatient, once all necessary studies are obtained and reviewed. The classic ketogenic diet will be initiated, and once ketosis is reached and patient demonstrates tolerance to diet he/she will be discharged home. Follow-up visits will be necessary up to 1 year."||||
34110854|NCT04998942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|In order to enable us to conduct a placebo-controlled study, we will not disclose to participants which intervention they have been assigned to. In order to obtain blinded data, incomplete disclosure is necessary to make the research scientifically valid and feasible. Unblinding subjects increases the risk that a favorable outcome is associated with the intervention simply because subjects are aware that they received an intervention and thus performing a placebo-controlled trial is necessary to determine the true effect of the intervention.|"In this study, we are testing different strategies to help women keep their heart healthy after a pregnancy complicated by hypertension.~Participants may or may not undergo some of the following study procedures:~* Complete surveys which could include topics related to activity, stress, nutrition, heart disease etc. with study staff via telephone or a secure online platform~* Be contacted by study staff once monthly to collect subjects' weight, blood pressure, whether they are breastfeeding, exercise routine, smoking status, and stress levels~* Meet with a nutritionist~* Meet with an exercise physiologist~* Participate in optional group sessions~* Receive infographics which could include topics such as mindful living and lifestyle, prevention of heart disease, nutrition, heart disease, etc.~Arm assignment and a description of the arms will be disclosed to participants after study completion."|t|f|f|f
34110855|NCT04164719|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34110856|NCT05121090|||COHORT||PROSPECTIVE|||||||
34110857|NCT04641351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34110858|NCT03870633|||CASE_ONLY||PROSPECTIVE|||||||
34110859|NCT05206370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110860|NCT03484104|||COHORT||PROSPECTIVE|||||||
34110861|NCT00633958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34110862|NCT04617860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110863|NCT04980157|||CASE_ONLY||PROSPECTIVE|||||||
33838139|NCT00452140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838140|NCT03423810|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110864|NCT01797250|||CASE_ONLY|||||||||
34110865|NCT02568319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110866|NCT06037811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110867|NCT00726583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110868|NCT04980209|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34036920|NCT04705792|NA|SINGLE_GROUP||TREATMENT||NONE||After a physical therapy evaluation, the patient underwent a booklet-guided physical exercise program that lasted three months (3 times per week with a duration of 60 minutes per session). Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit. The patient was evaluated at 2 different timepoints (baseline and after 12 weeks of training); thus, he served as his own control. The physiotherapist contacted the patient by phone weekly to follow the progression of the treatment. Throughout the application of the protocol, the patient regularly maintained his follow-up visits with the multidisciplinary team. Moreover, there was no change in pharmacological treatment throughout this period.||||
34036921|NCT01026753|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34110869|NCT02007343|||OTHER||PROSPECTIVE|||||||
34110870|NCT02239003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34110871|NCT00667121|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110872|NCT03430999|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34110873|NCT04028258|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34110874|NCT04319809|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a small sample open label feasibility study for an object recognition and localization system based on machine learning||||
34110875|NCT05014919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110876|NCT04785638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110877|NCT06228937|||COHORT||PROSPECTIVE|||||||
34110878|NCT04109300|RANDOMIZED|PARALLEL||OTHER||DOUBLE|This will be a single-blinded study. The treating gastroenterologist will be unblinded to the participant's allocation, while the assessor seeing the patient at the initial visit (PM Clinic) and at the subsequent follow up visits (week 14, week 26, week 52) will be blinded to the intervention (preemptive screening versus standard do care).|Participants will be randomized 1:1 to prospective HLADQA1\*05A\>G screening and targeted administration of combination therapy or standard of care (administration of combination therapy is at the discretion of the treating physician) and followed up to one year or until infliximab discontinuation. HLADQA1\*05A\>G genotyping will be performed in the standard of care group; however, investigators will remain blinded to this outcome until study completion.|t|f|f|t
34110879|NCT00113373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110880|NCT04440774|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
34110881|NCT04139408|NA|SINGLE_GROUP||OTHER||NONE||||||
34110882|NCT00374179|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110883|NCT06040398|||COHORT||PROSPECTIVE|||||||
34110884|NCT05102370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110885|NCT05918354|||COHORT||PROSPECTIVE|||||||
34110886|NCT03974061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to which intervention is hypothesized to be superior and produce the intended effects. Outcome assessors will be blinded to which intervention participants received.|Participants will be randomized (stratified by gender and interventionist) to a treatment condition (brief acceptance and commitment therapy or a brief alcohol intervention) and an interventionist.|t|f|f|t
34110887|NCT06563726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||multi-centre, non-blinded, non-randomized prospective interventional pilot study||||
34110888|NCT04729439|RANDOMIZED|PARALLEL||TREATMENT||NONE||A preliminary feasibility effectiveness trial comparing two groups: (1) organizational/behavioral skills intervention augmented with digital health application and (2) organizational/behavioral skills intervention only||||
34110889|NCT03850067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110890|NCT05514288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110891|NCT03249649|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34110892|NCT00363298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110893|NCT04998513|RANDOMIZED|PARALLEL||OTHER||SINGLE|Analysts will be masked as to the study arm participants are randomized to.|The proposed trial is designed as a randomised, controlled, analyst blinded, multi-institutional, pragmatic superiority trial with two parallel groups.|f|f|f|t
34110894|NCT01073293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110895|NCT06569979|||COHORT||PROSPECTIVE|||||||
34110896|NCT04037215|NA|SINGLE_GROUP||OTHER||NONE||"All assessments in patients with AM are performed as part of routine care and do not require additional monitoring modalities added by research.~For controls, phenotypic exploration will require a consultation with clinical examination including the search for psychiatric comorbidities and the completion of standardized questionnaires, exploration of the neuropsychological profile (with eye tracking, overall cognitive exploration, executive functions, social cognition and self-esteem).~Test results will not be returned except for screening requiring specific management. The information will then be returned to the child's parents by the investigating doctor, who will be responsible for organizing specific care whenever it is necessary."||||
34110897|NCT02587455|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34110898|NCT05504434|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center prospective consecutive observational cases series study||||
34110899|NCT03242434|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34110900|NCT00172367|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110901|NCT00725855|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34110902|NCT03248752|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34110903|NCT06564103|||COHORT||RETROSPECTIVE|||||||
34110904|NCT05565456|||COHORT||PROSPECTIVE|||||||
34110905|NCT03004079|||CASE_ONLY||PROSPECTIVE|||||||
34036922|NCT03578224|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036923|NCT02639845|||COHORT||PROSPECTIVE|||||||
34110906|NCT06630767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725061|NCT03627819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The margarine is provided in white but colour-coded tubs and it is not known to the participant and the researcher which colour coded margarine is placebo, plant sterol or stanol ester margarine.|This study is a randomized, placebo-controlled, double blinded pilot study with a run-period of 2 weeks, an intervention period of 12 months and a wash-out period of 1 month.|t|f|t|t
33725062|NCT03283423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725063|NCT05270655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single-blind, multi-center, randomised controlled trial|f|f|f|t
33725064|NCT06145360|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||An adaptive research design was judiciously employed to navigate the complexities of this research. Leveraging a secondary dataset, the study engaged data from registered diabetic patients who had been consistently monitored by SINA over the past six months. These existing datasets formed the foundation for analysis, enabling informed decision-making. Based on rigorous analytical evaluations, a standardized treatment protocol was established, with patients prescribed Empagliflozin 10mg for a duration of three months|t|t|f|f
33725065|NCT06460064|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Subjects, Investigator staff, assessors, clinical operations personnel, data analysts, and personnel at central laboratories will remain blinded to the identity of the treatment from the time of randomization until clinical database lock and study unblinding.||t|t|t|t
33725066|NCT00492310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725067|NCT04230837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The surgeon was unaware of the abutment height until after the insertion of the implant. Patients were unknown the abutment group. The examiner, independent to the study, carried out the radiographic analysis.|Randomized controlled prospective study|t|f|f|f
34036924|NCT01685918|||COHORT||PROSPECTIVE|||||||
34036925|NCT05510037|||COHORT||RETROSPECTIVE|||||||
34036926|NCT06486155|||OTHER||PROSPECTIVE|||||||
34036927|NCT04704310|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A convenience sample of adults living with COPD (N=4-6) will be recruited to participate an 8- week online exercise intervention.The objective is to conduct a proof-of-concept online exercise intervention for individuals living with COPD, using functional tasks, and incorporating peer support.||||
34036928|NCT03077477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|If subject is given active drug or placebo is masked|"The study is comprised of a total of 8 cohorts; 4 single ascending dose (SAD) cohorts, 1 Food Effect (FE) Crossover cohort, and 3 multiple ascending dose (MAD) cohorts. Tablets will be administered after an overnight fast (10 hours) with at least 250 mL water. No food will be administered (exception for fed subjects, see below) for one hour thereafter.~Each cohort will have a total 6 subjects: SAD and MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); and FE crossover (6 subjects receiving active AMXT 1501 dicaprate)."|t|t|t|f
34036929|NCT04396808|RANDOMIZED|CROSSOVER||OTHER||NONE||1:1 cluster-crossover in 3 month blocks||||
34036930|NCT01859338|||COHORT||PROSPECTIVE|||||||
34036931|NCT01861743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34036932|NCT04383548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036933|NCT03915132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036934|NCT05421819|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036935|NCT02598635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036936|NCT01941615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036937|NCT03217864|||COHORT||PROSPECTIVE|||||||
34110907|NCT01833078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110908|NCT06637306|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label, Single Arm Trial.||||
34110909|NCT00246103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110910|NCT05072379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"1. mobile health app group~2. control group"|t|t|f|t
33725068|NCT03445819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysts will be blinded to the study treatment.Wherever possible, outcome assessors will be blinded to the study treatment.||f|f|f|t
33725069|NCT02098109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725070|NCT04758377|NA|SINGLE_GROUP||OTHER||NONE||||||
33725071|NCT01184274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725072|NCT02807350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725073|NCT02971267|||COHORT||PROSPECTIVE|||||||
33725074|NCT06146946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725075|NCT02522208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34036938|NCT06144138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34036939|NCT00005575|RANDOMIZED|||TREATMENT||SINGLE||||||
34036940|NCT04699929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036941|NCT01144611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036942|NCT03166722|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||investigator-initiated randomised multi-centre multinational clinical trial|f|f|f|t
34036943|NCT01924689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036944|NCT01436097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34036945|NCT02827461|||COHORT||PROSPECTIVE|||||||
34036946|NCT01831115|||COHORT||PROSPECTIVE|||||||
34036947|NCT01654640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036948|NCT02353182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036949|NCT05590611|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34110911|NCT00889330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34110912|NCT02602652|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34110913|NCT00376103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110914|NCT04174586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110915|NCT00556114|||CASE_CONTROL||PROSPECTIVE|||||||
34110916|NCT01346904|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34110917|NCT03567265|||COHORT||PROSPECTIVE|||||||
34110918|NCT05770570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110919|NCT00437073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110920|NCT01504360|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110921|NCT04977232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110922|NCT01836757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33807605|NCT00146172|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This trial was an open-label, phase 1, ascending single and multiple oral dose study of HKI-272 administered to subjects with erbB-2- or erbB-1-positive tumors. Each subject participated in only 1 dose group and received a single dose of test article, followed by a 1-week observation period, and then received the test article administered once daily by mouth for up to 6 months (6 cycles). Daily dose administration could continue beyond 6 cycles at the same dose level if HKI-272 was well tolerated and there was no evidence of progressive disease.||||
33807606|NCT06699784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34110923|NCT04219020|||COHORT||PROSPECTIVE|||||||
33807607|NCT04181099|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807608|NCT05561491|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 part dose escalation and multiple expansion phase 2 trial.||||
34110924|NCT01942369|||CASE_ONLY||PROSPECTIVE|||||||
34110925|NCT01477684|||||RETROSPECTIVE|||||||
34110926|NCT02764138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34110927|NCT01384487|||CASE_CONTROL||PROSPECTIVE|||||||
34110928|NCT06172088|NA|SINGLE_GROUP||TREATMENT||NONE||Bicenter, single-arm, prospective intervention study including qualitative accompanying study||||
34110929|NCT05075174|||COHORT||RETROSPECTIVE|||||||
34110930|NCT06416475|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 3-month Randomized Controlled pilot Trial among 104 patients with T2D, who will be randomly allocated to consume comparable bottle volumes of either crude plant Mankai beverage (60ml Mankai) or water (60ml) on top of a standardized MediterraneanT2D-recommended healthy diet, after morning, lunch, and dinner over 3 months.||||
34110931|NCT05001737|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|2 cohorts||||
34110932|NCT04501822|||COHORT||PROSPECTIVE|||||||
34110933|NCT05294302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Investigators who are not delivering the intervention and the study biostatistician will be blinded to participant assignment.|Participants will be assigned to the intervention group (eSCCIP/eSCCIP-SP) or an education control condition.|f|f|f|t
34110934|NCT06145646|NA|SINGLE_GROUP||OTHER||NONE||||||
34110935|NCT05389072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110936|NCT03923868|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34110937|NCT06019676|||COHORT||PROSPECTIVE|||||||
34110938|NCT06451146|||CASE_ONLY||PROSPECTIVE|||||||
34110939|NCT04638309|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110940|NCT04541927|||COHORT||OTHER|||||||
34110941|NCT01771354|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34110942|NCT04797884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110943|NCT06183021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment|t|f|f|t
34110944|NCT05501899|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110945|NCT04398225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110946|NCT02526290|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34110947|NCT04808596|||COHORT||PROSPECTIVE|||||||
34110948|NCT01520441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807609|NCT04801706|||COHORT||PROSPECTIVE|||||||
33807610|NCT00372476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807611|NCT02377193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110949|NCT06528080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110950|NCT03770702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110951|NCT04831346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants as well as The assessor, who took the measurements for both the intervention and control groups, was blinded to the subject's group, while the treating therapist was not blinded to the treatment intervention.|Parallel Assignment A prospective, parallel-group, randomized clinical trial participants will be randomly assigned to the control group or one of the 2 intervention groups. One group received low level laser therapy (gallium arsenide diode ) while the other received the soft occusive splint. The control group was considered as a wait list for laser treatment aand did not recieve any treatment during the intervention period.|t|f|f|t
34110952|NCT06294990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multi-center, national, randomized, double-blind, placebo-controlled intervention study|t|t|t|f
34110953|NCT01148771|RANDOMIZED|CROSSOVER||||NONE||||||
34110954|NCT01245608|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34110955|NCT04945837|NA|SINGLE_GROUP||OTHER||NONE|"Data anonymisation:~Participant timepoints data are identified and followed up through a token number"|Prospective Longitudinal Study by Self-administered Questionnaires||||
34110956|NCT01878448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110957|NCT01952977|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34110958|NCT00003451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110959|NCT05348122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34110960|NCT06195007|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34110961|NCT04438824|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II study of palbociclib plus INCMGA00012 in patients with advanced WD/DD liposarcoma.||||
34110962|NCT05734066|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34110963|NCT02704884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110964|NCT00561379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110965|NCT03801993|||COHORT||PROSPECTIVE|||||||
34110966|NCT05617079|||OTHER||PROSPECTIVE|||||||
34110967|NCT04482283|||OTHER||PROSPECTIVE|||||||
34110968|NCT04458766|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pre-post study design. The intervention group will have medication adherence measured prior to receiving incentives, medication adherence while receiving incentives, and medication adherence after discontinuation of the incentives.||||
34110969|NCT06554587|||OTHER||PROSPECTIVE|||||||
34110970|NCT04830085|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807612|NCT00451711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807613|NCT06699407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807614|NCT01894399|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110971|NCT06639659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34110972|NCT01516476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34110973|NCT03490565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34110974|NCT05913687|||CASE_CONTROL||PROSPECTIVE|||||||
34110975|NCT01230060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34110976|NCT04936555|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Self-Acupressure and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
34110977|NCT05902559|||COHORT||PROSPECTIVE|||||||
34110978|NCT04694287|||COHORT||PROSPECTIVE|||||||
34110979|NCT05301127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110980|NCT05536115|||COHORT||PROSPECTIVE|||||||
34110981|NCT04450550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110982|NCT06253650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110983|NCT05786326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34110984|NCT05921786|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34110985|NCT01568879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110986|NCT00737789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34110987|NCT04608058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34110988|NCT00001382||||TREATMENT||||||||
34110989|NCT04372953|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The clinical team within the Delivery Room managing enrolled and randomised infants will not be masked/blinded to the intervention.~Members of the Research Team at participating sites will also not be masked/blinded to the intervention.~Research staff based at the central Trial Coordinating Centre (TCC), the Data Coordinating Centre (DCCe) and the Trial Statistician will be blinded to assigned treatment."|Two parallel group, non-blinded, 1:1 randomised controlled, multi-national, multi-centre, trial comparing dynamic PEEP ( dynamic group) with standard PEEP strategy (static group).|f|f|f|t
34110990|NCT03088033|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34110991|NCT00890760|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34110992|NCT04849897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110993|NCT00461318|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34110994|NCT00105066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34110995|NCT03794466|||OTHER||PROSPECTIVE|||||||
34110996|NCT05935137|||CASE_CONTROL||PROSPECTIVE|||||||
34110997|NCT06095011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be recruited through occupational hand therapy clinics throughout the Yale New Haven Hospital system||||
34110998|NCT05177380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34110999|NCT05617196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34111000|NCT00037882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111001|NCT05595668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111002|NCT02583841|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34111003|NCT06419881|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomly assigned to eight tele-drama therapy treatment groups or eight usual care groups. Participants in the experiment group received a 12-week tele-drama therapy intervention, with each session lasting 75 minutes via the Uniper Care platform. Participants in the usual care groups continued to receive the routine activities provided by Uniper Care. As a token of gratitude for their participation, participants in the control groups were offered a 3-session online playback theater workshop, in addition to a gift card.||||
34111004|NCT00652834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111005|NCT02194179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111006|NCT04728425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111007|NCT02156947|||CASE_CONTROL||PROSPECTIVE|||||||
34111008|NCT05106725|||CASE_CONTROL||PROSPECTIVE|||||||
34111009|NCT04354233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||At the first visit of the study, participants will be randomly assigned (1:1 ratio), with minimization based on the presence of visceral metastases (presence vs. absence of visceral metastases), the method of administration of chemotherapy (intravenous vs. per os) and the 6-minute walking distance (6MWD) (\<455 versus ≥ 455m based on the median of the pilot ABLE study) to: (i) the intervention arm to receive PA recommendations and benefit from a 6-month APA program (ii) the control arm to receive PA recommendations only.||||
34111010|NCT05414045|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible patients for the study will have the same treatment: autologous testicular tissue transplantation with testicular tissue containing spermatogonial stem cells frozen at pre-pubertal age. Transplantation will be performed subcutaneously in the scrotum and intra-testicular.||||
34111011|NCT03289039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111012|NCT04273061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Simon 2-stage design; 8 tumour-defined cohorts consisting of 8 to 24 participants each.||||
34111013|NCT04454333|||COHORT||RETROSPECTIVE|||||||
34111014|NCT02150629|||COHORT||PROSPECTIVE|||||||
34111015|NCT00508456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111016|NCT00153231|RANDOMIZED|PARALLEL||||NONE||||||
34111017|NCT03261804|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34111018|NCT04881565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical measures of balance, strength and proprioception will be administered by a physical therapist blind to group allocation. The physical therapist will not work at the facility where the research is being conducted, therefore reducing the likelihood of a breach of allocation concealment. If a breach occurs, it will be reported in the final publication.||f|f|f|t
34111019|NCT05169853|||COHORT||CROSS_SECTIONAL|||||||
34111020|NCT02995200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111021|NCT05851547|NA|SINGLE_GROUP||TREATMENT||NONE||Prostate radiotherapy of 27 Gy in 3 fractions to uninvolved regions, up to 39 Gy in 3 fractions to mpMRI-defined intraprostatic lesions, with concurrent/adjuvant androgen deprivation therapy (6 months intermediate risk, 24 months for high risk)||||
34111022|NCT02136992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725076|NCT01814501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725077|NCT00709774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725078|NCT04702477|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single-arm, paired-sample pilot intervention study.||||
33725079|NCT01625143|||CASE_ONLY||RETROSPECTIVE|||||||
33725080|NCT01025310|||COHORT||CROSS_SECTIONAL|||||||
33725081|NCT01045109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725082|NCT00032643||||||DOUBLE||||||
33725083|NCT04070131|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled parallel clinical trial, randomised, not-masked, with Control Group and Intervention Group.||||
33725084|NCT03020823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807615|NCT03827200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807616|NCT01937494|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807617|NCT05302882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33838141|NCT05051969|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838142|NCT02594787|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33807618|NCT04301206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||The parents of children aged 6 months to 11.9 years who calls 1813 about a medical condition will be offered to participate in the study. They will hear a recorded instruction, explaining the study. If they accept to participate they will be allocated to the intervention group and the control group 1:1.|f|t|t|f
33807619|NCT04604652|NA|SINGLE_GROUP||TREATMENT||NONE||Single group open label||||
33807620|NCT02734355|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33807621|NCT04045652|||COHORT||PROSPECTIVE|||||||
33807622|NCT00010049||PARALLEL||TREATMENT||||||||
33807623|NCT03408041|||COHORT||RETROSPECTIVE|||||||
33807624|NCT01662388|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807625|NCT00083590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33807626|NCT04390516|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807627|NCT00365885|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33807628|NCT02499601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807629|NCT00990600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807630|NCT05622097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807631|NCT05566444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807632|NCT06439667|||CASE_ONLY||PROSPECTIVE|||||||
34036950|NCT00498147|||COHORT|||||||||
33725085|NCT05224505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding for Stage 2 will be ensured until the last subject has received all treatments|Stage 1: single administration of GNT0006, open label Stage 2: randomized, placebo-controlled, double blind. One cohort will receive single administration of GNT0006 followed by a single administration of placebo one year after. The second cohort will receive single administration of placebo followed by a single administration of GNT0006 one year after|t|t|t|t
34036951|NCT05712499|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study was designed as a quasi-experimental study with a control group.||||
34036952|NCT02810457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34036953|NCT04784091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment assignment will be unknown to the study participant, investigators and site staff performing study assessments.|Active arm: TP-03, 0.25% Control arm: Vehicle of TP-03|t|t|t|t
34036954|NCT04765930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34036955|NCT05825638|||CASE_CROSSOVER||PROSPECTIVE|||||||
34036956|NCT02222922|NON_RANDOMIZED|||TREATMENT||NONE||||||
34036957|NCT05988827|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant is not aware about the light exposure used during the surgery (NGenuity or SOM)|Prospective, randomized, 2-arm controlled, parallel, single-masked, single-center study|t|f|f|f
34036958|NCT01615367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036959|NCT02720666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807633|NCT01584466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807634|NCT06029140|||COHORT||RETROSPECTIVE|||||||
33807635|NCT01543893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34036960|NCT02570789|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34036961|NCT02780037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34036962|NCT04296318|||COHORT||PROSPECTIVE|||||||
34036963|NCT03723850|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Neither the participant, nor the research assistant administering tDCS will know if the participant is receiving active tDCS or sham tDCS.||t|f|t|f
34036964|NCT05748743|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, investigators, and outcomes assessor are blind to the intervention group assignment.The only people that were unmasked were the surgical team.|The study is a parallel-group randomized control trial with 2 arms. Arm 1 includes patients who will have glove changed prior to abdominal closure during cesarean surgery. Aim 2 includes patients who will not have glove changed prior to abdominal closure during cesarean surgery. All patients are randomized using computer-generated sequences with allocation ratio 1:1. Clinic visits are performed at 2 time points. Visit 1 is at 2-3 days post-surgery and visit 2 is at 30 ± 2 days post-surgery where primary and secondary outcomes are measured. The primary outcomes of interest are any wound complications occurring after the surgery, including seroma, hematoma, wound separation, and wound infection. Secondary outcomes are any signs of SSI, including fever, swelling, redness, and pain surrounding the incisional area. The outcomes will be evaluated during clinic visits by qualified medical practitioners who are blind to the intervention group assignment.|t|f|t|t
34036965|NCT02686307|||||PROSPECTIVE|||||||
34036966|NCT03977467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036967|NCT05471999|NA|SINGLE_GROUP||TREATMENT||NONE||Retrospective data analysis||||
34036968|NCT04571372|||COHORT||PROSPECTIVE|||||||
34036969|NCT00012792|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34036970|NCT01693016|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036971|NCT06469554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants or their caregivers/legal guardians will be informed of their random inclusion in one of the three groups, but they will not be aware of the specific group to which they have been assigned.||t|f|f|f
34036972|NCT02143128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective randomized trial||||
34036973|NCT02869243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036974|NCT00213109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036975|NCT03126773|||COHORT||PROSPECTIVE|||||||
34036976|NCT06513078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants did not know whether they were receiving actual cupping treatment or a sham treatment.||t|f|f|f
34036977|NCT02511418||||TREATMENT||||||||
34036978|NCT01170988|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34036979|NCT02933164|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036980|NCT02931864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34036981|NCT00519116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036982|NCT01219816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036983|NCT05882825|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34036984|NCT00918866|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34036985|NCT00935116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34036986|NCT04757974|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study|This is a two-part study, where Part 1 will be conducted as a randomized three period, three treatment crossover study and Part 2 will have a randomized two period, two treatment crossover design.||||
34036987|NCT01267019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036988|NCT02251093|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34036989|NCT04032015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34036990|NCT05477069|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34036991|NCT02462603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036992|NCT04162743|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34036993|NCT00586703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34036994|NCT06150586|||COHORT||PROSPECTIVE|||||||
34036995|NCT04355078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34036996|NCT01087918|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33725086|NCT03704961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33725087|NCT02049333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725088|NCT02612428|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725089|NCT05533047|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33725090|NCT06284226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725091|NCT01165138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725092|NCT02820012|NA|SINGLE_GROUP||OTHER||NONE||||||
33725093|NCT00304356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725094|NCT04751149|RANDOMIZED|PARALLEL||PREVENTION||NONE||Early removal of urinary catheter Medial removal of urinary catheter Late removal of urinary catheter||||
33725095|NCT00590109|||COHORT||PROSPECTIVE|||||||
33725096|NCT05096858|||COHORT||PROSPECTIVE|||||||
33725097|NCT00862186|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725098|NCT03676881|||COHORT||PROSPECTIVE|||||||
33725099|NCT04347382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33725100|NCT04139967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725101|NCT06233487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The radiologist will be blinded to each others measurements, until all examinations have been performed.|||||
33725102|NCT03239730|||COHORT||PROSPECTIVE|||||||
33725103|NCT03254186|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33807636|NCT05120336|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33807637|NCT03281603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Principal investigator, main supervisors and co-supervisor cannot be blinded as the trial will include digital designing of complete dentures on the CAD software and in the steps of the manufacturing techniques.||t|f|f|f
33807638|NCT06031116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||split mouth (dental arches)|t|f|f|f
33807639|NCT02265354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807640|NCT00552253|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807641|NCT04497337|NA|SINGLE_GROUP||TREATMENT||NONE||Data included in this descriptive retrospective study were collected from records of 70 patients with superficial lesions around the auricle, i.e., periauricular (preauricular, auricular, and postauricular) during the period extending between 2017 and 2019, who were primarily diagnosed and operated||||
33807642|NCT05161000|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33807643|NCT03744026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807644|NCT01069666|||||PROSPECTIVE|||||||
33807645|NCT05866575|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization and introduction of the new antidepressant will occur immediately after V1. Patients will receive an antidepressant as monotherapy after randomization between two strategies: escitalopram and vortioxetine. To maximize acceptability by referring psychiatrists, dosage and co-prescriptions will be at the discretion of the psychiatrist in charge, but the allocated treatment will not be changed for 4 weeks (until V3).~After 4 weeks, the treatment can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial."||||
33807646|NCT01683188|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33807647|NCT03385759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807648|NCT05474404|||OTHER||PROSPECTIVE|||||||
34111023|NCT04144920|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants were blinded on what protocol they will be performing until after their first standardized meal.|The study design is a crossover randomized trial with three conditions: (i) uninterrupted sitting, (ii) high-frequency and low duration (HFLD) standing breaks, and (iii) low-frequency and high duration (LFHD) standing breaks. We utilized a balanced and uniform with 6 randomization blocks (ABC, ACB, BAC,BCA, CAB, CBA) design.|t|f|f|f
34111024|NCT01706185|||COHORT||RETROSPECTIVE|||||||
34111025|NCT00421564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34111026|NCT00863590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111027|NCT01312298|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34111028|NCT04637061|||COHORT||PROSPECTIVE|||||||
34111029|NCT05029388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A total of 78 participants with low SES who are aged between 12 and 15 and studying in secondary one to three from local secondary schools will be recruited for this study. They will be randomly assigned to either an aerobic exercise group, an HIIT group, or a no-exercise control group. Participants in the first two groups will partake in a 10-week training program period, which will be conducted thrice a week on non-consecutive days.|f|f|f|t
34111030|NCT06563076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111031|NCT03224884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34111032|NCT00000222||CROSSOVER||TREATMENT||||||||
34111033|NCT00104884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111034|NCT02147327|||COHORT||PROSPECTIVE|||||||
34111035|NCT03257657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pilot, randomized controlled trial. The investigators will pilot a multi-component intervention delivered in a WIC (Women, Infants, children) setting.||||
34111036|NCT00518076|||DEFINED_POPULATION||PROSPECTIVE|||||||
34111037|NCT06560190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111038|NCT06301022|||CASE_ONLY||RETROSPECTIVE|||||||
34111039|NCT04354857|||COHORT||PROSPECTIVE|||||||
34111040|NCT03317873|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34111041|NCT03092518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111042|NCT02955290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111043|NCT05035108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111044|NCT05870072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111045|NCT03715907|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34111046|NCT02818192|||COHORT||PROSPECTIVE|||||||
34111047|NCT02758821|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34111048|NCT04576455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111049|NCT01481012|||COHORT||PROSPECTIVE|||||||
34111050|NCT06597656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111051|NCT01189851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111052|NCT02343185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111053|NCT06108947|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111054|NCT04704193|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34111055|NCT06211296|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111056|NCT06061185|||COHORT||PROSPECTIVE|||||||
34111057|NCT03728478|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a a 12-month open label, randomised, actively controlled, multi-centre, prospective, superiority trial of two different treatment strategies (Step-down versus Step-up).~After signature of informed consent/assent patients will be randomized into two therapeutic arms: Step-up or Step-down. Patients in the Step-up arm will be treated according to a conventional strategy based on treatment escalation and driven by the treat-to-target strategy. Patients in the Step-Down arm will be treated with an early, combined, aggressive therapy for 6 months.~After the conclusion of the 12-month observation period of the trial, patients will be followed for up to 5 years for the evaluation of disease course, medication requirements, adverse events, and long-term disease-related morbidity."||||
34111058|NCT04781179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111059|NCT05962775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111060|NCT06197581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111061|NCT06183970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111062|NCT05198934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111063|NCT05962489|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34111064|NCT01274208|||COHORT||PROSPECTIVE|||||||
34111065|NCT00122473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111066|NCT03347799|||COHORT||RETROSPECTIVE|||||||
34111067|NCT06006286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807649|NCT05501652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807650|NCT04810390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807651|NCT00779805|RANDOMIZED|CROSSOVER||||NONE||||||
33807652|NCT04872296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807653|NCT04786197|||COHORT||PROSPECTIVE|||||||
33807654|NCT00374959|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807655|NCT05829109|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a pilot study of 16-18 patients who will each receive FMT.||||
34036997|NCT01741038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34036998|NCT02994849|||COHORT||OTHER|||||||
34036999|NCT02550561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037000|NCT06292039|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34037001|NCT01583140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037002|NCT00182546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037003|NCT02123264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34037004|NCT04125147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037005|NCT05576688|NON_RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34037006|NCT03644641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34037007|NCT03564119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037008|NCT06118476|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037009|NCT06407323|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037010|NCT02695446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037011|NCT05524389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037012|NCT00472563|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34037013|NCT03083327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessment of bone marrow biopsy to determine transplant success will be undertaken independent of the knowledge of treatment assignment.||f|f|f|t
34037014|NCT05568069|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Eligible patients will be randomised in a controlled fashion into two arms (n=1252):~Arm A: ICD implantation Arm B: No ICD implantation Patients with no scar on CMR will be followed up in a registry (n=1252)"||||
34037015|NCT00006105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037016|NCT00578045|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34037017|NCT00663416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037018|NCT03691519|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"This study will be a double-blind trial. The packaging, presentation, and labelling of products will ensure the blinding of both the medical team and the patient. The treatment arms in this study will be differentiated only by treatment numbers. Treatment arms will be allocated treatment numbers according to the previously established randomisation table.~Neither the investigating doctors nor the patients will be aware of the treatment arm to which the patients have been allocated until the end of the study."|Subjects will be randomly assigned in a 1:1 ratio to one of the following 2 groups: (i) DHA+EPA supplement or (ii) placebo. A computer-generated randomisation procedure will be used with stratification by centre. A centralised Interactive Voice Response System will be used to identify which group to allocate and which lot number to administrate|t|t|t|f
34037019|NCT00001042||||PREVENTION||DOUBLE||||||
34037020|NCT05864248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037021|NCT01772589|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34037022|NCT04781426|||COHORT||PROSPECTIVE|||||||
34037023|NCT02320305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037024|NCT01058473|||COHORT||PROSPECTIVE|||||||
34037025|NCT00015964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037026|NCT03870815|||COHORT||RETROSPECTIVE|||||||
34037027|NCT03970577|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will be a single stage phase IIb, randomized, open-label, parallel group, in a 1:1 ratio, active controlled, multicenter trial testing the efficacy and safety of two injections of Rituximab separated by one week (375mg/m2) from initial episode of MCNS in adults.~The control arm is a standard regimen of oral steroid alone (progressively tapered within 24 weeks).~At inclusion, all patients will receive oral steroid therapy (Prednisone, 1mg/kg/day, maximum 80 mg/day). For patients without complete remission after 4 weeks of treatment, prednisone will be continued at the same dose until the 8th week. For patients with complete remission after 4 weeks of treatment, doses of prednisone will be progressively reduced between the 4th and the 8th week (0.06 mg/kg by week).~Patients who reach complete remission by 8 weeks after inclusion will be randomized at this time to receive either Rituximab (experimental group) or the standard steroid regimen (control group)."||||
34037028|NCT02389478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34037029|NCT03026634|||COHORT||PROSPECTIVE|||||||
34037030|NCT06201988|||CASE_CROSSOVER||PROSPECTIVE|||||||
34037031|NCT03514524|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037032|NCT06303804|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34037033|NCT00383318|||||PROSPECTIVE|||||||
34037034|NCT02925962|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34037035|NCT02391922|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34037036|NCT03017768|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34037037|NCT06574529|NA|SINGLE_GROUP||OTHER||NONE||All patients with active tuberculosis were invited to participate in the study and followed during the duration of their treatment until treatment completion||||
34037038|NCT05744518|||COHORT||PROSPECTIVE|||||||
34037039|NCT03253614|||COHORT||PROSPECTIVE|||||||
34037040|NCT00004008||||TREATMENT||||||||
34037041|NCT03830489|RANDOMIZED|PARALLEL||OTHER||SINGLE|Only the endoscopists in charge of rating the bowel cleansing during the colonoscopy will be masked||f|f|t|f
34037042|NCT05032781|NA|SEQUENTIAL||TREATMENT||NONE||See study design||||
34037043|NCT00259870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34037044|NCT03775616|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037045|NCT03468660|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Experimental group Active control group Passive control group||||
34037046|NCT05543616|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33807656|NCT05028933|NA|SEQUENTIAL||TREATMENT||NONE||"single dose escalation The classic 3+3 dose escalation test. The starting dose refers to the results of the previous test of subsequent subjects. In this study, 3 increasing dose levels were set up, with 3 to 6 cases per dose."||||
33807657|NCT00724126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037047|NCT00956501|||OTHER||PROSPECTIVE|||||||
34037048|NCT05935228|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a mixed (quantitative and qualitative), multicentre, non-randomised, quasi-experimental, before-and-after, open, cross-sectional study, with control and experimental groups and comprising three phases. This division into three data collection phases allows detailed analysis of the targeted care procedure and avoids errors of assessment of the impact of the different tools introduced in the interventional phase (the vascular access difficulty score \[VAD\] in phase 2, then the algorithm \[composed of the VAD score and the graded decision tree for management\] in phase 3).||||
34037049|NCT00300235|||COHORT||RETROSPECTIVE|||||||
34037050|NCT01901640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037051|NCT04468425|NA|SEQUENTIAL||OTHER||NONE||||||
34037052|NCT06326346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037053|NCT00468819|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037054|NCT00970346|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34037055|NCT02105467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037056|NCT05206123|||CASE_ONLY||PROSPECTIVE|||||||
34037057|NCT05605418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037058|NCT01589458|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34037059|NCT02863796|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34037060|NCT02282540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037061|NCT03321682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037062|NCT05505591|||COHORT||RETROSPECTIVE|||||||
34037063|NCT04390607|||COHORT||PROSPECTIVE|||||||
34037064|NCT03808948|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037065|NCT00459862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037066|NCT06463990|||CASE_CONTROL||PROSPECTIVE|||||||
34037067|NCT00697463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037068|NCT01242293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037069|NCT02633293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037070|NCT01277926|||CASE_ONLY||PROSPECTIVE|||||||
34037071|NCT03012997|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34037072|NCT03004274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037073|NCT03202082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34037074|NCT02483676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037075|NCT05820204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* Outcome assessment will be completed via automated transmission of a redCAP link, and as such is inherently blinded.~* Fidelity assessment will be conducted by blinded fidelity assessors who are otherwise not involved in the study."|Three-arm randomized control trial|f|f|f|t
34037076|NCT06035692|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|In this study, participants, data recorders(investigators), and outcome assessor were unaware of group assignments.|This is a multicenter prospective randomized controlled study.Patients were assigned to the two groups with the use of central randomization and competitive enrollment.|t|f|t|t
34037077|NCT05479825|NA|SINGLE_GROUP||OTHER||NONE||||||
34037078|NCT02031861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037079|NCT03509064|||OTHER||PROSPECTIVE|||||||
34037080|NCT02783924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34037081|NCT01582529|||COHORT||PROSPECTIVE|||||||
33807658|NCT04205669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807659|NCT06515873|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807660|NCT03897699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807661|NCT01824225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807662|NCT05716438|||COHORT||PROSPECTIVE|||||||
33807663|NCT01673399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33807664|NCT05142774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807665|NCT00564421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807666|NCT00384514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807667|NCT05316259|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33807668|NCT00845520|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 2 medical device study||||
33807669|NCT01060800|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33807670|NCT01009424|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33807671|NCT03843606|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open interventional study to investigate the effects of 3 different ketogenic diet regimes||||
33807672|NCT04603300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind is controlled by IWRS||t|t|t|t
33807673|NCT02446106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33807674|NCT04230941|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Usability||||
33807675|NCT02498145|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33807676|NCT04063332|||CASE_CONTROL||PROSPECTIVE|||||||
33807677|NCT02910999|||COHORT||PROSPECTIVE|||||||
33807678|NCT01697683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807679|NCT04443400|||COHORT||PROSPECTIVE|||||||
33807680|NCT03056066|||COHORT||PROSPECTIVE|||||||
33807681|NCT04047407|||OTHER||PROSPECTIVE|||||||
34037082|NCT03678610|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34037083|NCT03349021|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group interventional study||||
34111068|NCT05112640|RANDOMIZED|PARALLEL||OTHER||SINGLE|Reviewers of wound cosmetics during the post operative time will be blind to the intervention. However, surgeon at the time skin closure and patient will not be blinded to the intervention.|Subjects who agree to participate in the study will be randomized to one of the two groups below in a 1/1 allocation|f|f|f|t
34111069|NCT03321942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807682|NCT02106884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807683|NCT05715684|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807684|NCT06466512|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34111070|NCT01940055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111071|NCT04898179|||CASE_CONTROL||PROSPECTIVE|||||||
34111072|NCT05643404|||CASE_CONTROL||PROSPECTIVE|||||||
33807685|NCT03132298|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants (N=96), ages 12-15 will be randomized to receive one of two a 30-minute, computer-based programs: (1) a 'growth mindset' program, teaching that personal traits and characteristics are malleable; or (2) a control program, designed to mimic 'supportive therapy,' teaching the value of sharing one's feelings with close others.|t|f|t|t
33807686|NCT00981552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807687|NCT01969916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725104|NCT02706509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725105|NCT06414967|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725106|NCT01428180|||COHORT||PROSPECTIVE|||||||
33725107|NCT03030079|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33725108|NCT00802399|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725109|NCT00535548|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33725110|NCT02293226|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725111|NCT03211949|NA|SINGLE_GROUP||OTHER||NONE||||||
33725112|NCT03213821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study design A randomized, parallel-arm, controlled pilot study is designed. Sample size is determined 50 participants per treatment arm using the stepped rules of thumb, with standardized effect sizes of 0.1 or less and power 80% for main trial (n=100). After baseline assessments, balanced permuted block method will be used for randomization. Concealment of the randomization sequence will be performed by the RCT center of Rajaie Cardiovascular, Medical and Research Center. Intervention will be according to the randomization sequence.|t|t|f|t
33725113|NCT00035854|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725114|NCT01524861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33725115|NCT00885339|||COHORT||PROSPECTIVE|||||||
33725116|NCT00003733||||TREATMENT||||||||
33725117|NCT06183996|||OTHER||PROSPECTIVE|||||||
33725118|NCT05694728|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The Sponsor, investigators and biostatisticians will remain blinded to subject allocation.|Healthy women ages 20-45 eligible for the trial will be stratified at a 1: 1 ratio into 2 age subgroups (20-30 years of age and 31-45 years of age), and each subgroup will be randomized at a 1: 1: 1 ratio to receive the mid-dosage investigational vaccine, high-dosage investigational vaccine or the positive control, respectively.|t|f|t|f
33807688|NCT01942915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111073|NCT05600517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participant is not informed about if they are in the control or intervention group Outcome assessor are not aware of group allocation Both dentist/nurse and patient do not know the genotype or risk group. Caries registration at start and end will be performed by a dentist not involved in giving the orthodontic treatment or prevention to each patient|Randomized controlled study|t|t|t|t
34111074|NCT01447784|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111075|NCT01088906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111076|NCT05827679|||COHORT||PROSPECTIVE|||||||
34111077|NCT06564597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111078|NCT04388631|||COHORT||PROSPECTIVE|||||||
34111079|NCT00589524|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111080|NCT06421649|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluative commissioning study. This is a single arm, non-randomised study.||||
34111081|NCT01880463|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34111082|NCT02648360|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34111083|NCT06341647|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"* Safety: incidence and severity of AE and SAE \[Time Frame: From the time of consent through End of Study (up to 18 months per patient)\]~* Determination of Recommended Phase 2 Dose (RP2D)"||||
34111084|NCT05718739|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34111085|NCT04925427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111086|NCT01973192|||COHORT||PROSPECTIVE|||||||
34111087|NCT06564909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111088|NCT04692506|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This is a double-blind study and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.|Adouble-blind, randomised, placebo-controlled, parallel-group|t|t|t|t
34111089|NCT02959346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34111090|NCT02038036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111091|NCT03566732|||CASE_ONLY||PROSPECTIVE|||||||
34111092|NCT02853136|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111093|NCT03528733|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111094|NCT03817229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI will not be notified of group status or details of participants. The healthcare provider will also not know which group participants are randomized to.|This a 2-stage, sequential, multiple assignment, randomized trial (SMART) . In Stage 1 (three months long), non-adherent caregivers (\< 95%) will be randomized to a mHealth education module and automated digital reminders (control) or the mHealth education module, automated digital reminders, and individualized adherence feedback based on real-time adherence monitoring (treatment) to address the primary barrier of forgetting. At the beginning of Stage 2 (two months long), caregivers randomized to treatment who do not achieve adherence \> 95% (response) by the end of Stage 1 will be re-randomized to either continued individualized adherence feedback or individualized adherence feedback augmented with three mHealth problem-solving modules (translated from the PIs existing RCTs) with a therapist.|f|t|t|f
34111095|NCT04946214|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34111096|NCT02998307|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111097|NCT05264454|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|intervention will be blinded to those assessing the size of the IVC||f|f|f|t
34111098|NCT06593951|||COHORT||PROSPECTIVE|||||||
34111099|NCT02649309|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34111100|NCT06563739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111101|NCT06637566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111102|NCT01964261|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34111103|NCT01132885|||COHORT||PROSPECTIVE|||||||
34111104|NCT01446523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111105|NCT01190527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111106|NCT05729087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34111107|NCT06645314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111108|NCT05641116|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111109|NCT01597700|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34111110|NCT05152823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111111|NCT06052553|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34111112|NCT06288828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34111113|NCT00853684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111114|NCT01336699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34111115|NCT06198400|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111116|NCT02367456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807689|NCT01214031|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|f|f|t
33807690|NCT05527808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111117|NCT05036109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111118|NCT03801590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111119|NCT04884802|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parallel group randomized trial.|t|f|f|t
34111120|NCT05512338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111121|NCT03740113|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized design of schools||||
34111122|NCT06283966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a Phase III randomized, double-blind, parallel group, multi-center event-driven study comparing BGF MDI 320/14.4/9.6 μg BID with GFF MDI 14.4/9.6 μg BID in participants with COPD who are at risk of a cardiopulmonary event.|t|t|t|t
34111123|NCT05539547|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"This study consists of the enrolment of two groups concurrently both receiving the usual physiotherapy treatment with the addition of NMES to the experimental group.~Control Group: Effect of usual physiotherapy care, including chest and mobility physiotherapy on quadriceps strength and endurance during hospital admission on patients with severe acute exacerbation COPD.~Experimental Group: Effect of NMES on quadriceps strength and endurance as an adjunct to usual physiotherapy care (chest physiotherapy and mobility) during hospital admission in patients with severe acute exacerbation COPD."|f|f|t|f
34111124|NCT04110145|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||There are 3 cohorts with ascending doses and an additional final cohort to repeat the highest dose determined to be safe|t|t|t|f
34111125|NCT00468494|||||PROSPECTIVE|||||||
34037084|NCT04099472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All study data will be collected, de-identified and managed using REDCap electronic data capture tools hosted and supported by the University of Calgary. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies.The data will be coded according to group assignment for the individual conducting the data analyses.|All consecutively enrolled dyads (patient and caregiver) will be randomly assigned to either the control or intervention group. Both groups will receive standard care. The intervention group will receive additional ICU delirium education.|f|f|f|t
34037085|NCT02092870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037086|NCT00246818||||TREATMENT||||||||
34037087|NCT03402061|||OTHER||PROSPECTIVE|||||||
33807691|NCT03559205|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Before and after comparative study||||
33807692|NCT03773471|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33807693|NCT03955926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33807694|NCT01895114|||||PROSPECTIVE|||||||
33807695|NCT00082836||||TREATMENT||||||||
33807696|NCT03606551|||CASE_ONLY||PROSPECTIVE|||||||
33807697|NCT05473806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838143|NCT03321253||SEQUENTIAL||TREATMENT||NONE||sequential self-controlled clinical trial||||
33838144|NCT00484081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807698|NCT05900466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||We will conduct a proof of concept pilot study, a single site, randomized, double-blinded, phase 2 clinical trial with 2 parallel dosing arms comparing the effects of placebo, and 500mg of once a day metformin on improving hyperalgesia and other symptoms in 72 patients with FMS.|t|f|t|f
33807699|NCT04061759|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33807700|NCT03397823|||OTHER||PROSPECTIVE|||||||
33807701|NCT01335867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807702|NCT04221659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807703|NCT04153838|||COHORT||PROSPECTIVE|||||||
33807704|NCT05673551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807705|NCT00168415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807706|NCT04332094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807707|NCT03926702|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will undergo the same evaluation, which includes screening, cognitive assessment, magnetic resonance imaging scanning (MRI) of the brain, and genetic testing for Apolipoprotein E. Subsequently all subjects will undergo positron-emission tomography (PET) scanning with C-11 PIB (Pittsburgh compound B) for amyloid detection, and JNJ067 for tau detection.||||
33807708|NCT04779853|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33807709|NCT01097811|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33807710|NCT01562184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807711|NCT02159352|RANDOMIZED|PARALLEL||||NONE||||||
33807712|NCT05112913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33807713|NCT05031923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807714|NCT05413200|||COHORT||PROSPECTIVE|||||||
33807715|NCT04756271|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33807716|NCT02509715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807717|NCT04224415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807718|NCT01602185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807719|NCT00766909|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33807720|NCT01315977|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33807721|NCT00180232|||||PROSPECTIVE|||||||
33807722|NCT03529994|||COHORT||PROSPECTIVE|||||||
33807723|NCT04454476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807724|NCT05240794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807725|NCT04769141|||OTHER||PROSPECTIVE|||||||
33807726|NCT04936386|||COHORT||PROSPECTIVE|||||||
33807727|NCT02807857|NA|SINGLE_GROUP||OTHER||NONE||||||
33807728|NCT04359017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807729|NCT05948774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be double-blinded for MT200605/matching placebo. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (MT200605 or placebo).Blinding will be maintained until at least the clinical phase of the study is completed. Since the outward appearance of MT200605 and Placebo is not totally same after preparations, the unblinded study nurses and Pharmacists were set up to avoid the effects of blinding.||t|f|t|f
33807730|NCT05194696|||COHORT||PROSPECTIVE|||||||
33807731|NCT01953679|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33807732|NCT02653794|||||CROSS_SECTIONAL|||||||
33807733|NCT02576691|||CASE_CONTROL||RETROSPECTIVE|||||||
34111126|NCT06308315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient would be allocated.||f|f|f|t
34111127|NCT06256900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded to the participant|Randomized, controlled, single-center study|t|f|f|f
33807734|NCT03192501|||CASE_CONTROL||PROSPECTIVE|||||||
33807735|NCT02093169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807736|NCT00877305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33807737|NCT01833455|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33807738|NCT01765374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807739|NCT02241785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807740|NCT01613417|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33807741|NCT03912909|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33807742|NCT00110669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807743|NCT06293066|||COHORT||RETROSPECTIVE|||||||
33807744|NCT02429115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33807745|NCT04124887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807746|NCT06700122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807747|NCT04988542|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients will be in the control group for 1 month and in the intervention group for one month||||
33807748|NCT02553889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34111128|NCT02326584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111129|NCT02474498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33807749|NCT05626374|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||2x2 factorial design, cluster-randomized, multicentre trial||||
33807750|NCT03926026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-masked|sequential dose-escalating cohorts -- Cohort 1 (2 parallel groups) and Cohort 2 (2 parallel groups)|t|f|t|f
33807751|NCT03661463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of radiological outcomes will be blinded to which arm of the trial patients were randomised to.|2 Parallel Arms - one with the intervention (Aspirin 300mg OD), and one with no treatment. 29 patients each arm.|f|f|f|t
33807752|NCT02405702|||||RETROSPECTIVE|||||||
33807753|NCT04378894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The mothers in the control group will take a special awareness program but not MOCEP and the participant, the care providers and the investigators are masked.|Randomized wait-list controlled trial|t|t|t|f
33807754|NCT05449366|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open-label, single-center, phase-1/2 study with a classic three-plus-three dose escalation design.||||
33838145|NCT00852605|RANDOMIZED|||||NONE||||||
34037088|NCT00968747|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34037089|NCT00349973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037090|NCT03961737|NA|SINGLE_GROUP||OTHER||NONE||||||
34037091|NCT00972374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34037092|NCT05344599|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037093|NCT00453739|||COHORT||PROSPECTIVE|||||||
34037094|NCT02419534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037095|NCT06303141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the assessor who take the reading is blind||f|f|f|t
34037096|NCT04032405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037097|NCT03918629|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34037098|NCT03101956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037099|NCT01941017|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34037100|NCT04977895|||COHORT||PROSPECTIVE|||||||
34037101|NCT01025414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037102|NCT02743325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037103|NCT02077140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037104|NCT01723800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037105|NCT04163003|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Among those with insufficient sleep, after participants are screened and receive universal education about sleep, those with insufficient sleep will be offered to participate in the randomized pilot trial. There are two arms in the randomized trial: TAPAS intervention, and wait-list control (monitoring only). The study will enroll n=50 participants in the Randomized Control Trial (RCT) to obtain full data on n=40 participants after attrition.~Participants who obtain sufficient sleep will not be randomized, but will obtain the universal education only. Investigators anticipate enrolling n=35 adolescents with sufficient sleep."||||
34037106|NCT06294717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34037107|NCT06072274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34037108|NCT03686605|||OTHER||CROSS_SECTIONAL|||||||
34037109|NCT00562848|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34037110|NCT04221490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037111|NCT05460338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34037112|NCT01323517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037113|NCT02811510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34037114|NCT00666328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037115|NCT04089579|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Blinded infusion|This study is a phase II, prospective, randomized, blinded, cross over, clinical trial designed to assess the efficacy of intravenous dosing of hCT-MSC for improving social communication abilities in young children with ASD. All participants will ultimately be treated with hCT-MSC. Participants randomized to arm A will each receive a single intravenous dose of 6x106 hCT-MSC per kilogram at baseline, followed by a placebo infusion at six months. Participants randomized to arm B will each receive a placebo infusion at baseline, followed by an intravenous dose of 6x106 hCT-MSC per kilogram at six months.|t|t|t|t
34037116|NCT04577560|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037117|NCT01109693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037118|NCT01468714|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34037119|NCT00632060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037120|NCT05361590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The subjects will be randomized into the study group and the control group by using a sealed envelope system.|20 participants in the treatment (Lumoral) group and 20 participants in the control group.|t|f|t|t
34037121|NCT02858791|||CASE_CONTROL||PROSPECTIVE|||||||
34037122|NCT00563329|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34037123|NCT01400477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The pharmacist places the treatment or placebo into identical coded vials. Only the pharmacist and the statistician have the code to identify of the treatment.|Random allocation to a treatment and placebo group.|t|f|t|t
34037124|NCT04959721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037125|NCT05993364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037126|NCT02000492|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037127|NCT04477720|||COHORT||RETROSPECTIVE|||||||
34037128|NCT04653038|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||① Cohort 1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy; ② Cohort 2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma.||||
34037129|NCT03182231|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Patients will receive an 68Ga-NODAGA-exendin-4 PET/CT scan before RYGB and 1 year after RYGB||||
34037130|NCT01240759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037131|NCT05630573|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34037132|NCT04785378|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34037133|NCT02716961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34037134|NCT03908125|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037135|NCT04933383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037136|NCT06571110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34037137|NCT01404767|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34037138|NCT02338648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037139|NCT03359655|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Double blind masking|Three group parallel design|t|t|t|t
34037140|NCT06078124|RANDOMIZED|PARALLEL||PREVENTION||NONE||A hybrid type 1 effectiveness-implementation pilot randomized-controlled trial with one treatment arm and one control arm.||||
34037141|NCT02749188|NA|SINGLE_GROUP||OTHER||NONE||||||
34037142|NCT04413786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34037143|NCT04619511|||COHORT||PROSPECTIVE|||||||
34037144|NCT02957383|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34037145|NCT04780893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34111130|NCT03171948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet Nut Free group (NFG), as control group, who continue their diet without any nut consumption.|t|f|f|f
34111131|NCT06639048|||CASE_ONLY||CROSS_SECTIONAL|||||||
34111132|NCT03531580|NA|SINGLE_GROUP||OTHER||NONE||||||
33807755|NCT00387075|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|Participants and Investigators were not provided results of the University of Pennsylvania Smell Identification Test (UPSIT).||t|f|t|f
33807756|NCT05437666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807757|NCT06379516|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Proof of science/concept||||
33807758|NCT05964426|||OTHER||CROSS_SECTIONAL|||||||
33807759|NCT00000492|RANDOMIZED|||PREVENTION||DOUBLE||||||
34037146|NCT04259671|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Given that MAP's use is to assist parents in communication and service navigation, clinicians will be informed by the study team which family has been allocated to the MAP group. For children allocated to the control group, clinicians will be instructed to continue with usual clinical care. In the Developmental Passport Pilot study, clinicians were blinded to the intervention and the study team found this was a limitation as families were not able to share aspects of their service navigation with their health care providers (Young et al, 2019). As such, we will not blind members of the clinical team to intervention but allow both the intervention and usual care to co-occur within the pragmatic, real life setting.|Families of children between 0-6 years of age with a new ASD diagnosis who have consented to the study will be randomly assigned to either the control group (standard of care) or the intervention group (provided the MAP app). They will be in their randomly assigned group for the entire duration of the study.|f|f|t|t
33807760|NCT06274099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||pretest posttest randomized controlled trial|f|f|t|t
33807761|NCT05782699|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037147|NCT05628597|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|"The investigators and study participants will be blinded to treatment assignments. Each of the two patch products (Fos Biomedical product and placebo) will be provided to the study team by the study funder (Fos Biomedical). The products will have a similar appearance and texture. One will be described to study participants and study team members as Product A and the other as Product B. The description of products A and B will be sent by Fos Biomedical in a sealed envelope that will be kept in locked cabinet at the PRC. The envelope will be opened at the conclusion of the statistical analyses. Therefore all members of the investigative team will be blinded to the study interventions."|To provide a sound basis for the statistical comparison of outcome measures for treatment assignments, participants will be randomized to 1 of 2 sequence permutations of the Fos Biomedical patch product and a placebo patch product, which will begin after randomization. Each permutation will include a 12-week treatment phase, followed by a 2-month washout phase, followed by a 12-week treatment phase (8 months total for each study participant, including the washout phase).|t|f|t|t
33807762|NCT00775866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807763|NCT02113267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037148|NCT02227563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037149|NCT02276248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037150|NCT04760080|||CASE_CONTROL||RETROSPECTIVE|||||||
34037151|NCT03295071|||COHORT||CROSS_SECTIONAL|||||||
34037152|NCT00402909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34037153|NCT03783767|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34037154|NCT06160609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037155|NCT06282939|||OTHER||PROSPECTIVE|||||||
34037156|NCT01101828|||||CROSS_SECTIONAL|||||||
34037157|NCT00149682|RANDOMIZED|PARALLEL||||NONE||||||
34111133|NCT00836706|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34111134|NCT00693147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807764|NCT00094952|||||PROSPECTIVE|||||||
33807765|NCT04163237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807766|NCT02615132|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33807767|NCT01589341|||COHORT||RETROSPECTIVE|||||||
33807768|NCT06071052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807769|NCT01212822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807770|NCT06153745|||COHORT||RETROSPECTIVE|||||||
33807771|NCT01760226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807772|NCT02219659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807773|NCT05406947|||COHORT||PROSPECTIVE|||||||
33807774|NCT01455766|||COHORT||PROSPECTIVE|||||||
33807775|NCT02950883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807776|NCT02398786|||COHORT||PROSPECTIVE|||||||
33807777|NCT03297138|||COHORT||RETROSPECTIVE|||||||
33807778|NCT01411566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33807779|NCT06700213|||COHORT||PROSPECTIVE|||||||
33807780|NCT01892176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807781|NCT00219466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33807782|NCT04547660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes will be analyzed by blinded investigators. Group allocation will not be disclosed during statistical analysis.|Randomized, open-label, phase 3, comparing best supportive care (BSC, no investigational drugs allowed) and convalescent plasma, along BSC.|f|f|f|t
33807783|NCT00405184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037158|NCT04136314|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Primary/blinded investigator will be blinded to randomization of subject to either group A (gain-framed) or group B (loss-framed) arms. Blinded party will create the randomization master list and provide a given subject's arm allocation to the primary/unblinded investigator once that subject has been enrolled.||f|f|t|f
34037159|NCT06445998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|traditional physical therapy|task oriented training|t|f|f|f
34037160|NCT01615458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34037161|NCT01741987|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34037162|NCT00048373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111135|NCT00020683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111136|NCT03697447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34111137|NCT04154878|||COHORT||RETROSPECTIVE|||||||
33807784|NCT02363049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807785|NCT01560494|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33807786|NCT01379651|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807787|NCT06387966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807788|NCT03085407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037163|NCT04062669|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"In Part 1 of the study, only data during the primary vaccination phase (from study start to Day 91) will be collected in an observer-blind manner. By observer-blind, it is meant that the vaccines recipient and those responsible for the evaluation of any study endpoint will all be unaware of which vaccine was administered.~For Part 1, the study will be observer-blind until Day 91. When the Day 91 analysis will result in unblinding of all the subjects to the sponsor. Therefore, the study cannot be considered observer-blind beyond Day 91 and will be conducted in a single-blind\* manner thereafter; with all subjects remaining blinded up to study conclusion (Month 14).~For Part 2, the study will be conducted in open-label manner from study start to study conclusion.~\*Due to the recent COVID-19 pandemic, the study will be fully unblinded from study start to study conclusion to allow all subject treatments to be known to the team and investigators, thereby facilitating rapid safety assessment."||t|t|t|t
34037164|NCT00322829|||CASE_ONLY||PROSPECTIVE|||||||
34037165|NCT03390608|||COHORT||RETROSPECTIVE|||||||
34037166|NCT00818077|||COHORT||PROSPECTIVE|||||||
34037167|NCT02256618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037168|NCT03575052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037169|NCT02892630|||COHORT||PROSPECTIVE|||||||
34037170|NCT04731805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial, longitudinal and prospective||||
34037171|NCT04777942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037172|NCT03642262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||2-Way Crossover||||
34037173|NCT01950455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037174|NCT06230744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037175|NCT04178460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037176|NCT03660319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants randomized into two groups: Music Therapy Intervention (Environmental Music Therapy) and Control arm with no Music Therapy.||||
34037177|NCT04551456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Physicians and other clinical personnel remained blind to the treatment assignment throughout the study.|Parallel Assignment Arms Placebo Comparator: WANICAD Trial are as a 3 arm trial comparing standard of care plus placebo to either standard of care plus WJMSC one or three times infusion with participants allocated to each study arm in a 1:1:1 ratio|t|f|t|f
34037178|NCT01163201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037179|NCT05845437|||COHORT||RETROSPECTIVE|||||||
34037180|NCT05801705|||COHORT||CROSS_SECTIONAL|||||||
34037181|NCT00022594||||TREATMENT||||||||
34037182|NCT02877901|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34037183|NCT04119297|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The random allocation cards was developed using a computer generated random number by a biostatistician who was not associated with the study. Group allocation was concealed using individual sealed opaque envelopes. As patients were enrolled in the study, the next envelope was extracted and the patients was assigned to the groups accordingly. When the patient was transferred from the operating theatre to the NICU or clinic, the nurse in the study (NA) assigned the patient to one of the groups according to the list in the envelope. Other investigator nurse (SY), two observer nurses (DG, YT), and all patients were blinded from group assignment. Also, all patients were blinded to all measurements and, the investigator and two observers were blinded to each other's measurements.|This study was conducted as a prospective, parallel, three arm (1:1:1), randomized controlled clinical trial at neurosurgical intensive care units (NICU) and neurosurgical clinics in two medical faculty hospital of a university in Istanbul, Turkey.|t|f|t|f
34037184|NCT05430243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34037185|NCT02289066|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037186|NCT03359408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037187|NCT05191290|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037188|NCT01644851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34037189|NCT01788826|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037190|NCT00716599|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037191|NCT01116271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037192|NCT01385137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34037193|NCT02862236|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34037194|NCT00352872|||COHORT||PROSPECTIVE|||||||
34037195|NCT03695783|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Given the study design and intervention, it is not possible to ensure the blinding of patients and physicians. However, we will attempt to address the limitations resulting from a lack of blinding:~* Patients and the physicians will be informed of the study protocol, but will not be provided accurate information about the specific primary outcome (i.e. comparison between IBD\&me and the Crohn's \& Colitis Foundation of America (CCFA) resource). The informed consent document will keep participants blind to the study goals.~* Physicians will be kept blinded of the patient's assignment group until the clinic visit.~* Data will be collected by an independent researcher. Study investigators and the data analyst will remain blinded until all follow-up data is obtained and the primary analysis is finalized."|Parallel Assignment|f|f|t|f
34037196|NCT06162598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Two group with conventional therapy control group|t|t|f|t
34037197|NCT00922077|NA|SINGLE_GROUP||TREATMENT||||||||
34037198|NCT03345771|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037199|NCT05159947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037200|NCT01664637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037201|NCT01628497|||OTHER||CROSS_SECTIONAL|||||||
34037202|NCT03075371|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34037203|NCT03686059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037204|NCT00263354|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037205|NCT02498197|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34037206|NCT00995917|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34037207|NCT06414941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037208|NCT01983566|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037209|NCT00816998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037210|NCT03194542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037211|NCT01615419|||COHORT||PROSPECTIVE|||||||
34037212|NCT03669510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||atrophic posterior mandible requiring nerve lateralization|f|f|f|t
33807789|NCT00297349|||||PROSPECTIVE|||||||
33807790|NCT05637905|||CASE_CONTROL||OTHER|||||||
33807791|NCT01674998|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037213|NCT00363233|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33725119|NCT01682590|RANDOMIZED|PARALLEL||OTHER||NONE||"To investigate whether early initiation of RRT (within 12 hours after a diagnosis of acute renal insufficiency at thefailure stage according to the RIFLE Criteria), will reduce 90-day mortality as compared to deferred initiation of RRT(48 to 60 hours after diagnosis), in intensive care unit (ICU) patients with septic shock who develop acute renal failure"||||
33725120|NCT03693079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725121|NCT01059370|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34037214|NCT01621334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037215|NCT05867030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037216|NCT00729664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037217|NCT00338416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037218|NCT05202314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037219|NCT02519686|||CASE_CONTROL||PROSPECTIVE|||||||
34037220|NCT01757093|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34037221|NCT06174727|||COHORT||RETROSPECTIVE|||||||
34037222|NCT01095276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037223|NCT06087848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037224|NCT04269369|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is not blinded (not for the patients participating in the trial and not for the treating physicians).|"In a subgroup of patients, a parallel study model will be used. In the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature. After obtaining written informed consent, patients will be randomized in a 1:1 ratio to one of the two study groups."||||
34037225|NCT05278312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037226|NCT05791435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037227|NCT02279875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037228|NCT01618175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037229|NCT05634421|||COHORT||RETROSPECTIVE|||||||
34037230|NCT02158156|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037231|NCT04276181|||CASE_CONTROL||PROSPECTIVE|||||||
34037232|NCT06266182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This trial is enhanced by a single-case experimental design (SCED), in which all study participants will receive the same intervention (i.e., intervention study model: single group). In SCED, there is no masking. The estimated total number of participants to be enrolled in SCED is 6-9.|t|t|f|t
34037233|NCT04037787|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A stepped-wedge cluster randomized clinical trial. Each center starts as control group (usual care) and switch to experimental group (ERAS protocol implementation) according to a randomized order.||||
34037234|NCT00702767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037235|NCT01125189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037236|NCT03093194|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The study is not double blind, therefore is subjected to the care provider bias. Outcomes assessment might also be over or under evaluated by the physician following the patients outside the hospital.|"Patients will be randomaly assigned into two groups. The experiment group will not undergo vaginal preparation. The control will undergo perioperative vaginal preparation with antiseptic soap and chlorohexidine-alcohol.~All patients participating in this trail will sign a written informed consent. All patients will receive preventative antibiotics peri-operatively according to the our hospital protocol.~Exclusion criteria are a known allergy to antiseptic soap, chlorohexidine-alcohol or shellfish, or patients who had any infection in the perioperative period.~Inclusion criteria: an elective or emergent CS in a woman who did not report having a fever or skin infection signs in the 5 days prior to surgery.~Once a patient is admitted to the delivery room, approximately 7 days to several hours before CS each patient will be assigned randomly to a group using a computerized randomization software."|f|t|f|t
34037237|NCT04797104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind to treatment (LIB003 or placebo) and lipid data|Randomized double blind placebo controlled|t|t|t|t
34037238|NCT02416063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037239|NCT02615782|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037240|NCT03458078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34037241|NCT00317343|||CASE_ONLY||PROSPECTIVE|||||||
34037242|NCT01094704|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037243|NCT05169801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||BP102 in combination with paclitaxel/carboplatin compared with Avastin® in combination with paclitaxel/carboplatin|t|t|t|t
34037244|NCT04898699|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34037245|NCT02236039|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34037246|NCT03324568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34037247|NCT02119312|||OTHER||PROSPECTIVE|||||||
34037248|NCT00000914||||TREATMENT||NONE||||||
34037249|NCT06516068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037250|NCT06443528|||COHORT||PROSPECTIVE|||||||
34037251|NCT04535492|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34037252|NCT02438423|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34037253|NCT01742546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037254|NCT04578873|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|matched oral placebo capsule|Double-blind, placebo-controlled, sequential, ascending single-and multiple-dose design|t|t|t|t
34037255|NCT02949973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037256|NCT06575634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037257|NCT05611866|NA|SINGLE_GROUP||TREATMENT||NONE||All recruited patients will receive FMT.||||
34037258|NCT01444339|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725122|NCT03451318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725123|NCT01232920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33725124|NCT03274986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111138|NCT05467410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study personnel evaluating cognitive function outcomes will use standardized cognitive measures and will be blinded to participants' group assignments.|Prospective, randomized, experimental design|f|f|f|t
34111139|NCT04164901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants randomized in a 1:1 allocation (vorasidenib vs Placebo)|t|t|t|t
34111140|NCT04586257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* The patients will be blinded to their groups.~* An anesthesia resident who will not participate in the study and have no subsequent rule in it will help in the preparation of local anesthetic mixtures under strict aseptic precautions.~* An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in the collection of the data of measurements."||t|f|t|t
34111141|NCT06221449|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||comparison|t|f|t|f
34111142|NCT02305992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111143|NCT06365749|||COHORT||PROSPECTIVE|||||||
34111144|NCT06641843|||COHORT||PROSPECTIVE|||||||
34111145|NCT02495883|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34111146|NCT05337566|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|single blinded - the placebo tablets slightly differ from the azithromycin tablets, therefore they are sealed in package which is given straight to the participant||f|t|t|t
34111147|NCT03639935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111148|NCT05416814|NA|SINGLE_GROUP||OTHER||NONE||||||
34111149|NCT05645380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111150|NCT06200948|RANDOMIZED|PARALLEL||TREATMENT||NONE||While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks.||||
34111151|NCT05840913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111152|NCT01623947|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34111153|NCT03661099|||CASE_ONLY||PROSPECTIVE|||||||
34111154|NCT02731560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111155|NCT05889091|NA|SINGLE_GROUP||TREATMENT||NONE||This is a descriptive, single-arm pilot study.||||
34111156|NCT02128035|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34111157|NCT01370551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111158|NCT01606241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111159|NCT02645799|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34111160|NCT01044069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111161|NCT06564129|||COHORT||PROSPECTIVE|||||||
34111162|NCT05995626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111163|NCT02686775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111164|NCT03834740|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111165|NCT05353608|||COHORT||RETROSPECTIVE|||||||
34111166|NCT00663156|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34111167|NCT06141733|||COHORT||RETROSPECTIVE|||||||
34111168|NCT04434729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111169|NCT06563648|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34111170|NCT00455702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111171|NCT03473587|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34111172|NCT04854304|||OTHER||PROSPECTIVE|||||||
33725125|NCT03889769|||CASE_ONLY||PROSPECTIVE|||||||
33725126|NCT04178746|||CASE_CONTROL||PROSPECTIVE|||||||
33725127|NCT05934877|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Two randomly assigned arms (3:1) into ASK-PrEP Stepped Care (PrEP navigation) or Standard of Care (SOC).||||
33725128|NCT03528720|||OTHER||OTHER|||||||
33725129|NCT00000751||PARALLEL||TREATMENT||||||||
33725130|NCT02146573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725131|NCT04238351|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, care giver and outcome assessor can not know the group assingment.|Applying Transnasal humidified rapid insufflation ventilator exchange|t|t|f|t
33807792|NCT00476736|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34111173|NCT06109727|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34111174|NCT03707392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34111175|NCT02510586|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
34111176|NCT00336726|||||PROSPECTIVE|||||||
34111177|NCT01770704|||COHORT|||||||||
34111178|NCT05222711|RANDOMIZED|PARALLEL||OTHER||NONE|Open label|pragmatic randomised controlled trial||||
34111179|NCT01377402|||COHORT||PROSPECTIVE|||||||
34111180|NCT02943473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111181|NCT02710032|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111182|NCT03408353|||COHORT||PROSPECTIVE|||||||
34111183|NCT04770584|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037259|NCT05748067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037260|NCT05150301|||CASE_CONTROL||RETROSPECTIVE|||||||
34037261|NCT00002943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037262|NCT03743415|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|Follow-up data collectors will be blind to the arm of the study.|This project will determine which dyads require which intervention sequence: Handbook alone, Handbook alone stepped up with Telephone Interpersonal Counseling (TIP-C) based on demonstrated needs after giving Handbook alone 4 weeks of time, or an combined TIP-C+Handbook for the first 8 weeks then Handbook alone for 4 weeks. Dyads will be initially randomized to either Handbook alone or TIP-C+Handbook. If the survivor's depression or anxiety does not respond to Handbook alone at week 4, dyads will be re-randomized to the TIPC+Handbook or continue with Handbook alone. Outcome data will be collected at baseline, weeks 13 (post-intervention) and 17 (follow-up). Total duration is 17 weeks.|f|f|f|t
34037263|NCT02881684|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111184|NCT05231980|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized controlled open label study||||
34111185|NCT03769155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725132|NCT04318496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study nurse 1 will be responsible to randomize and prepare the needles in the envelopes. Outside the envelopes, there will be a number belonged to one patient, and inside the envelopes, there will 14 separate sterile needle which can be either placebo or true press tack needles. The envelopes and the pouches of needle will look the same. The acupuncturist will be asked not to check the needles when they insert them. At the time of acupuncture, a nurse will accompany the acupuncturist and will verify that he is not examining the needles closely. Study nurse 2 will do the measurement. The acupuncturist, patients and study nurse 2 will be blinded.|Double Blinded Randomized Control Trial|t|t|t|t
33725133|NCT01976442|||COHORT||RETROSPECTIVE|||||||
33807793|NCT02331485|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807794|NCT03058757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807795|NCT00104949||||TREATMENT||||||||
33807796|NCT01232166|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34037264|NCT03802825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligibility criteria for all study participants is a diagnosis of diabetes with A1C ≥ 8.||||
34037265|NCT05816629|||COHORT||PROSPECTIVE|||||||
34037266|NCT05793164|||CASE_CONTROL||RETROSPECTIVE|||||||
34037267|NCT05135065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34037268|NCT02734277|||COHORT||PROSPECTIVE|||||||
34037269|NCT02814604|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34037270|NCT05821933|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34037271|NCT03271801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037272|NCT06066268|||CASE_CONTROL||RETROSPECTIVE|||||||
34037273|NCT05628831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In one group of patients vaginal hysterectomy will be done with anterior and/or posterior repair depending on the judgment of the surgeon at the time of the operation. Second group will be treated with minimally invasive technique (vNOTES-vaginal natural orifice transluminal surgery) in which we will remove uterus and support pelvic floor with autologous tissue. Tissue graft will be isolated from abdominal rectus muscle. Fixation will be done using vNOTES aproach.|t|f|f|f
34037274|NCT03743532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037275|NCT03084653|||OTHER||OTHER|||||||
34037276|NCT00780338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037277|NCT02350101|||||RETROSPECTIVE|||||||
34037278|NCT04816734|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34037279|NCT03667222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Vehicle control is identical to the active product in appearance||t|f|t|t
34037280|NCT01608750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037281|NCT03596957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The endpoint blinding will be assured since all the MRI scans will be forwarded to the Comparative Medicine Laboratory in Aarhus for evaluation|Patients will be randomised in a 1:1 ration either to treatment with tolvaptan for six weeks followed by six weeks observation without trial medicaion or to the Control group receiving no tolvaptan treatment for 12 weeks|f|f|f|t
34037282|NCT02447211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34037283|NCT01864993|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34037284|NCT00075205||||TREATMENT||||||||
34037285|NCT00886015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037286|NCT03449732|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037287|NCT05738733|RANDOMIZED|PARALLEL||PREVENTION||NONE|The study is open-label.|A proof-of-science, open-label, single-centre, four-arm, In-Use tolerance, safety, efficacy clinical study||||
34037288|NCT05875402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037289|NCT04255576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037290|NCT00005754|||COHORT||PROSPECTIVE|||||||
34037291|NCT02280837|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037292|NCT03215212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111186|NCT03064009|||CASE_ONLY||PROSPECTIVE|||||||
34111187|NCT01869673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111188|NCT02507726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111189|NCT01971918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037293|NCT00606112|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34037294|NCT02743624|NA|SINGLE_GROUP||||NONE||||||
34037295|NCT04268771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, parallel group, multicenter study to assess the immunogenicity and safety of transitioning subjects with rheumatoid arthritis to biosimilar rituximab (DRL_RI) or continued treatment with Rituxan® or MabThera®|t|t|t|t
34037296|NCT01585974|||COHORT||PROSPECTIVE|||||||
34037297|NCT01221870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037298|NCT03197480|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective observational clinical trial with only the use of a standard care of drug, aflibercept. All study eyes will receive intravitreal aflibercept at the initial injection and x 4 monthly injections including at month 3.||||
34037299|NCT03053752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037300|NCT01805089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037301|NCT05303610|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34037302|NCT00880412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111190|NCT04433195|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|both care providers and participants will be informed of positive results of Xpert MTB/RIF test|pragmatic trial||||
34111191|NCT05429411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34111192|NCT00404248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111193|NCT01051661|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34111194|NCT04075695|||COHORT||PROSPECTIVE|||||||
34111195|NCT02395276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111196|NCT00864357|RANDOMIZED|CROSSOVER||||NONE||||||
34111197|NCT02860403|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111198|NCT01502527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111199|NCT01467557|||COHORT||PROSPECTIVE|||||||
34111200|NCT04539288|||CASE_ONLY||PROSPECTIVE|||||||
34111201|NCT03272932|||CASE_ONLY||PROSPECTIVE|||||||
34111202|NCT05205837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment|t|f|t|f
34111203|NCT02639988|||COHORT||PROSPECTIVE|||||||
34111204|NCT06548048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111205|NCT01659294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111206|NCT04419519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter clinical stopping trial for venetoclax-treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.||||
34149925|NCT06344260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In order to blind also the statistician that will analyse the results the protocol has been designed as a triple-blinded protocol. This means that both the researchers, which include neurologist, neurosurgeon and biologist, as well as the patients and the statisticians are unaware of whether the participant received the treatment or the placebo (only IMP Manufacturer QP is unblinded since release the cell drug to the use in the surgery room)|"This is an approximate 24-months triple-blinded, randomized, controlled vs placebo, in three arms study (PHASE B). A preliminary 3+3 dose-escalation open-label phase (PHASE A) will be performed in order to test the toxicity of the two proposed cell doses.~In the phase B three arms will be: 1) hNSCs 20 milion cells 2) hNSCs 40 milion cells 3) Saline (comparator)"|t|f|t|t
34149926|NCT01278082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807797|NCT00716300|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33807798|NCT03705663|||COHORT||PROSPECTIVE|||||||
33807799|NCT00002236||||TREATMENT||NONE||||||
33725134|NCT06287983|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||A total of 44 patients were randomly divided into 2 groups using the sealed envelope randomization method. The exercise program will be applied to both groups 3 sessions a week for 60 minutes for 6 weeks. Inspiratory muscle training will also be added to the intervention group. Patients included in the study; At weeks 0, 6, 12 and 24, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), BASFI (Bath Ankylosing Spondylitis Functional Index), ASQoL (The Ankylosing Spondylitis Quality of Life), Modified Borg Scale, Visual Analog scale (VAS) and maximum Dyspnea measurement during exercise, 6-minute walk test, chest expansion measurement and respiratory function test (spirometry) will be evaluated.|t|f|f|f
34037303|NCT06550999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Following informed consent, patients will be randomized to either the adhesive strip repair group or the suture repair group for their facial laceration. The patient and care provider will therefore know which group they are part of. Randomization and allocation concealment will be managed by a nominated independent individual(s) not involved in patient care or data extraction/analysis. A password-protected randomization database that is only accessible to the study team will be utilized. The investigator and outcomes assessor will be blinded to the group assignments.|This is a prospective, single-blinded, randomized controlled trial taking place in a single center. Patients will be identified in the emergency room as they present to the hospital and meet eligibility criteria. Following informed consent, patients will be randomized in a 1:1 ratio to either the adhesive strip repair or the suture repair group. Randomization will be dictated by a validated online software utilizing the Wichmann-Hill random number generator. Randomization and allocation concealment will be managed by a nominated independent individual(s) not involved in patient care or data extraction/analysis. A password-protected randomization database that is only accessible to the study team will be utilized.|f|f|t|t
34037304|NCT02600936|||CASE_ONLY||OTHER|||||||
34037305|NCT03834922|||COHORT||PROSPECTIVE|||||||
34037306|NCT01086137|||CASE_ONLY||CROSS_SECTIONAL|||||||
33725135|NCT02790970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037307|NCT02081027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34037308|NCT06150937|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot RCT of a 4-session intervention. Participants will be randomized in a 2:1 intervention to control ratio and followed up for 12 months.||||
34037309|NCT04231617|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Randomized, double-blind, cross-over, placebo-controlled design in healthy volunteers.|t|t|t|t
34037310|NCT00002303||||TREATMENT||DOUBLE||||||
34037311|NCT02750618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037312|NCT01384474|||COHORT||PROSPECTIVE|||||||
34037313|NCT03662087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037314|NCT00933907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037315|NCT04924400|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34037316|NCT04587687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037317|NCT06280859|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Students enrolled in physical education (PE) class will be eligible to enroll in the study, and serve as the intervention group. Those not enrolled in PE that semester will be recruited as the control group.||||
34037318|NCT02500095|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34037319|NCT00447174|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037320|NCT03193684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|the study is placebo controlled double blinded. randomization will be made by pharmacist and the randomization code will be kept in the pharmacy|subjects will receive in parallel a treatment with empagliflozin or placebo for 3 months hepatic glucose metabolism and norepinephrine turnover will be studied before and after treatment|t|f|t|f
34037321|NCT00659451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037322|NCT03501823|||COHORT||CROSS_SECTIONAL|||||||
34037323|NCT03244306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037324|NCT02932501|||CASE_ONLY||PROSPECTIVE|||||||
34037325|NCT00486785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037326|NCT05214651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037327|NCT00811733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037328|NCT02308969||CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34037329|NCT06344195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037330|NCT03432143|RANDOMIZED|PARALLEL||OTHER||NONE||24 community members will receive training and mentoring in reviewing manuscripts. The trial will involve 568 manuscripts that will be randomly assigned to two groups using a random number generator.||||
34037331|NCT03875053|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037332|NCT04092868|||COHORT||PROSPECTIVE|||||||
34037333|NCT01389050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037334|NCT05469893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037335|NCT00985504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037336|NCT02174419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037337|NCT00181727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037338|NCT04341363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037339|NCT01646372|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34037340|NCT01808066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037341|NCT03837054|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037342|NCT01294176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037343|NCT00238966|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34037344|NCT03918824|||COHORT||RETROSPECTIVE|||||||
34037345|NCT03517540|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037346|NCT01052480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037347|NCT04517409|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Prospective randomized trial||||
34037348|NCT05928065|||COHORT||PROSPECTIVE|||||||
33807800|NCT00002095||||TREATMENT||DOUBLE||||||
33807801|NCT01011101|||CASE_CONTROL||PROSPECTIVE|||||||
33838146|NCT00484029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838147|NCT05916703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037349|NCT03200990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037350|NCT03949218|||OTHER||RETROSPECTIVE|||||||
34037351|NCT03350282|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34037352|NCT06310343|||COHORT||PROSPECTIVE|||||||
34037353|NCT00279435|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34037354|NCT02689154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037355|NCT04861077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037356|NCT01585415|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037357|NCT01344421|||COHORT||PROSPECTIVE|||||||
34037358|NCT01629251|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037359|NCT01837264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037360|NCT01626482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34037361|NCT04982575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037362|NCT06068062|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34037363|NCT05595967|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34037364|NCT03113864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All parties involved in the study are blinded|Randomized, Double-Blind, Placebo-Controlled, Parallel Intervention Trial|t|t|t|t
34037365|NCT01422200|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant, care provider, and investigator are not masked. The outcomes assessor (personnel determining the HI titers) is masked.||f|f|f|t
33725136|NCT05279820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant will not be informed whether the treatment performed was partial or full pulpotomy the outcome assessor will be blinded to the type of treatment performed, and evaluation of the radiographs will include masking the crown so that the procedure cannot be identified.|The study will run concurrently and the participants will randomly distributed between the two interventions using a block randomization procedure|t|f|f|t
33725137|NCT02153255|||COHORT||PROSPECTIVE|||||||
33725138|NCT02912234|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725139|NCT03561623|||CASE_CONTROL||PROSPECTIVE|||||||
33725140|NCT02233244|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725141|NCT03362281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037366|NCT05452044|||CASE_ONLY||PROSPECTIVE|||||||
34037367|NCT02383979|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037368|NCT05086705|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34037369|NCT05900518|||CASE_ONLY||RETROSPECTIVE|||||||
34037370|NCT04390113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037371|NCT02996409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037372|NCT01499264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037373|NCT00765102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037374|NCT05946993|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34037375|NCT00940628|NON_RANDOMIZED|||TREATMENT||NONE||||||
34037376|NCT02125383|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34037377|NCT01580852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037378|NCT03989102|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34037379|NCT02894645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037380|NCT04696302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were blinded from whether they were in control or experimental group and statistician was blinded.|Two independent groups measured at 4 timepoints, baseline, acquisition, short-term, and long-term retention.|t|f|f|t
34037381|NCT05020860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037382|NCT01323400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037383|NCT00780377|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34037384|NCT04907097|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34037385|NCT04405882|||COHORT||RETROSPECTIVE|||||||
34037386|NCT00413582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037387|NCT03117153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34037388|NCT05331001|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037389|NCT04811872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037390|NCT00160823|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE||||||
34037391|NCT03630926|||COHORT||PROSPECTIVE|||||||
34037392|NCT02206854|NA|SINGLE_GROUP||||NONE||||||
34037393|NCT04348552|||COHORT||PROSPECTIVE|||||||
34037394|NCT01071642|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037395|NCT01974518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34037396|NCT02344667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037397|NCT00039559|NA|SINGLE_GROUP||SCREENING||NONE||||||
34037398|NCT05584033|||CASE_ONLY||RETROSPECTIVE|||||||
34037399|NCT04570332|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|This is a phase 2 study with one single treatment arm (BO-112 in combination with pembrolizumab)||||
34037400|NCT00712192|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34037401|NCT00004330||||PREVENTION||||||||
34037402|NCT06509932|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037403|NCT04427540|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single IM injection of Oxytocin 17 micrograms||||
34149927|NCT03685006|||COHORT||PROSPECTIVE|||||||
33725142|NCT01863992|||OTHER||PROSPECTIVE|||||||
33725143|NCT00298207|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Single Blind||f|f|t|f
33725144|NCT05796011|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725145|NCT06457841|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33725146|NCT00076011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725147|NCT04510779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725148|NCT01770561|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725149|NCT00271947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725150|NCT02424929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Randomized parallel assignment, unblinded|||||
33725151|NCT03200899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Care providers are not informed of the participant's participation in a particular arm. Staff collecting outcome data are not aware of the participant's assignment to intervention or usual care.||f|t|f|t
33725152|NCT02325011|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33725153|NCT04581642|||COHORT||PROSPECTIVE|||||||
33725154|NCT03143699|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33725155|NCT05109663|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33725156|NCT03214159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725157|NCT03322488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||20 patients with Crohn's disease and 20 patients without Crohn's disease will be recruited||||
34037404|NCT05160116|||COHORT||RETROSPECTIVE|||||||
34037405|NCT02914912|||COHORT||PROSPECTIVE|||||||
34037406|NCT01831661|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037407|NCT02839538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037408|NCT02249975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037409|NCT02302469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037410|NCT03690700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Prior to the first training session, participants will be block-randomized to either active BFRE (n=12) or sham BFRE (n=12), (control for gender). The participants will be blinded from the randomization|randomized placebo controlled parallel group study|t|f|f|f
34037411|NCT00051051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037412|NCT05682456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34037413|NCT00884117|||CASE_ONLY||PROSPECTIVE|||||||
34037414|NCT04231526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037415|NCT03877835|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome measures will be performed by an independent assessor|Single intervention||||
34037416|NCT03154983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037417|NCT00000377|RANDOMIZED|||TREATMENT||||||||
34037418|NCT02954432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Phase II|t|f|t|t
34037419|NCT00581672|||COHORT||PROSPECTIVE|||||||
34037420|NCT05479864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037421|NCT00382122|||COHORT||CROSS_SECTIONAL|||||||
34037422|NCT05775965|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037423|NCT02535026|||CASE_ONLY||PROSPECTIVE|||||||
34037424|NCT00005055|RANDOMIZED|||TREATMENT||||||||
34037425|NCT00828360|||COHORT||PROSPECTIVE|||||||
34037426|NCT03395288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants in the RCT treatment and RCT control arm will not be told the name of the nutraceutical being studied. Participants in the observational arm will be aware of the nutraceutical being studied.|There will be a RCT portion of the study with a treatment arm and a control arm and an additional observational arm of the study.|t|f|f|f
34037427|NCT05910281|||COHORT||PROSPECTIVE|||||||
34037428|NCT02431611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037429|NCT02547012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037430|NCT04886583|||COHORT||PROSPECTIVE|||||||
34037431|NCT04535934|||COHORT||PROSPECTIVE|||||||
34037432|NCT05596110|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34037433|NCT02860156|||COHORT||CROSS_SECTIONAL|||||||
33838148|NCT06311903|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037434|NCT06098781|||COHORT||PROSPECTIVE|||||||
34037435|NCT02822937|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34037436|NCT03617237|||CASE_ONLY||RETROSPECTIVE|||||||
34149928|NCT04494308|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34149929|NCT00850941|||COHORT||RETROSPECTIVE|||||||
34149930|NCT05764174|RANDOMIZED|PARALLEL||OTHER||NONE||Three treatment arms and one control will be deployed.||||
34037437|NCT06030297|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Unblinded team member will dispense patch masked to patient and investigator|"Response biomarker set-up and optimization in Healthy Subjects Examination of the relationship between Response Biomarker measures and severity of neuropathic pain in patients with peripheral neuropathy.~Evaluate the the Response Biomarker using lidocaine patch as a peripherally acting neuropathic pain agents"|t|f|t|f
34037438|NCT05166083|||COHORT||PROSPECTIVE|||||||
34037439|NCT02847949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037440|NCT04652115|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, two cohort clinical trial.||||
34037441|NCT00725868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037442|NCT02741076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037443|NCT02329015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34037444|NCT02028897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037445|NCT01037218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037446|NCT04828278|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Double Blind|Crossover Intervention Trial|t|f|t|f
34037447|NCT01342380|||OTHER||RETROSPECTIVE|||||||
34037448|NCT00794690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037449|NCT03760432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149931|NCT06184958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149932|NCT01120925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149933|NCT04454593|||CASE_CONTROL||RETROSPECTIVE|||||||
34149934|NCT04730427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||t|f|f|f
34149935|NCT03234491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149936|NCT02767739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149937|NCT02266875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149938|NCT05571774|||CASE_ONLY||CROSS_SECTIONAL|||||||
34149939|NCT02555605|||CASE_ONLY||RETROSPECTIVE|||||||
34149940|NCT05093803|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
34149941|NCT00275756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34149942|NCT00885482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149943|NCT00235950|RANDOMIZED|PARALLEL||||DOUBLE||||||
34149944|NCT02680470|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34149945|NCT01725243|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149946|NCT01054521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037450|NCT01674881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037451|NCT05494944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111207|NCT05454514|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This is a randomized, unblinded, Phase 1 study of the HiDO automated medication adherence platform in patients ages 18 to 65 with HIV/AIDS who are currently taking ART. For this single-site device study, clinical collaborators will recruit 24 subjects into a single study group. After a screening period of up to 14 days, subjects will receive the 90-day intervention that consists of using of an automated medication adherence platform. Medication adherence will be assessed through observed therapy using front-facing cameras on the device. Corroborating data will be drawn from viral load data.|HiDO is an automated Artificial Intelligence driven direct observation medication adherence platform. The platform is a 510K exempt Class I medical device that integrates medication dispensing, dose administration time, pill count and front facing video cameras to validate the right medications, at right time to the right patient. The device dispenses up to 7 different types of medications simultaneously. The camera logs every dose using facial recognition and provides real time consumption logs. Investigators have access to video observation logs, patient dose time, adherence trends, and study level adherence measures.||||
33807802|NCT06699719|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Only one intervention arm is available to study participants (i.e., an online EW intervention), and participants are randomized to one of two arms: 1) the intervention, which is to complete four sessions of writing online or 2) no intervention (i.e., control).|t|f|f|f
33807803|NCT06699641|||CASE_ONLY||CROSS_SECTIONAL|||||||
33807804|NCT05555901|RANDOMIZED|PARALLEL||TREATMENT||NONE||fruquintinib plus chemotherapy vs bevacizumab plus chemotherapy||||
33807805|NCT06509763|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807806|NCT05879276|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, interregional, randomised, controlled, open-label clinical trial evaluating the effect of early initiation of a SGLT2 inhibitor i.e Empaglifozin, in cardiogenic shock.||||
33838149|NCT02090023|||COHORT||RETROSPECTIVE|||||||
33838150|NCT05241353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be concealed from outcome assessors. The allocation sequence will also be blinded in advance from individuals involved in the randomization process. However, it will not be fully possible to blind participants due to the nature of the trial (i.e., assignments will be evident to participants).|Randomized controlled trial with two arms (standard versus reduced-frequency). Participants will be assigned in a one-to-one fashion at baseline to one of the two groups.|f|f|f|t
34037452|NCT02853877|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037453|NCT01200771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037454|NCT03983525|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized paralleled arm clinical trial||||
34037455|NCT03649035|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment||||
34037456|NCT05815212|||COHORT||RETROSPECTIVE|||||||
34037457|NCT01769573|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34037458|NCT01828723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037459|NCT04152135|||CASE_CONTROL||PROSPECTIVE|||||||
34037460|NCT03812835|||OTHER||PROSPECTIVE|||||||
34037461|NCT05938023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, placebo controlled treatment periods followed by open labelled treatment period|t|t|t|t
34037462|NCT02536092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037463|NCT05913752|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Parts C and D are randomized, double-blind, placebo-controlled.|Single and repeated doses of CMND-100. Parts A and B are open-label, non-controlled parts, in which HVs and subjects with binge drinking/AUD respectively will be treated with single, ascending dose cohorts of CMND-100, for evaluation of tolerability, safety and PK/PD. Parts C and D are randomized, double-blind, placebo-controlled parts, in which HVs and subjects with binge drinking/AUD respectively will be treated with repeated doses of CMND-100, for evaluation of safety, PK/PD and preliminary efficacy.|t|t|t|t
34037464|NCT01953302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037465|NCT03581864|||CASE_ONLY||RETROSPECTIVE|||||||
34037466|NCT05679375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34037467|NCT03441412|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study is an experimental observational study in ten healthy volunteers. Volunteers fulfilling all of the inclusion and none of the exclusion criteria will be included. Enrollment will be continued until the required sample size is achieved (10 subjects).||||
34037468|NCT03146806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037469|NCT03929133|||COHORT||CROSS_SECTIONAL|||||||
34037470|NCT02419989|||CASE_ONLY||PROSPECTIVE|||||||
33725158|NCT05877092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037471|NCT01836471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037472|NCT06506396|||COHORT||PROSPECTIVE|||||||
34037473|NCT02544620|||COHORT||PROSPECTIVE|||||||
34037474|NCT02100462|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34037475|NCT02151227|||COHORT||CROSS_SECTIONAL|||||||
34037476|NCT01239810|||COHORT||PROSPECTIVE|||||||
34037477|NCT06469905|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34037478|NCT06498778|||COHORT||RETROSPECTIVE|||||||
34037479|NCT03495557|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Control will have simple closure while experimental group will have simple closure+mesh|t|f|t|f
34037480|NCT02976857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037481|NCT02123004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037482|NCT04327544|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037483|NCT01441024|RANDOMIZED|PARALLEL||TREATMENT||||||||
34037484|NCT06205862|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037485|NCT00454337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037486|NCT05102682|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective, open label, single arm, non-randomized, non-comparative feasibility study.||||
34037487|NCT02288325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037488|NCT02614326|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34037489|NCT04868695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037490|NCT02556320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037491|NCT01985243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725159|NCT04579042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725160|NCT05021367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725161|NCT03320564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Reader will not be informed which scan was infiltrated.|All patients with a moderate or greater infiltration on a routine F-18 FDG PET will be invited to return for a repeat scan.||||
33725162|NCT04227821|||COHORT||PROSPECTIVE|||||||
33725163|NCT02298881|||CASE_CONTROL||PROSPECTIVE|||||||
33725164|NCT06160063|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||randomized control||||
33725165|NCT04490447|||CASE_CONTROL||PROSPECTIVE|||||||
33725166|NCT00234988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725167|NCT01148511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725168|NCT01673035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725169|NCT05104515|NA|SEQUENTIAL||TREATMENT||NONE||"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."||||
33725170|NCT03360370|||COHORT||PROSPECTIVE|||||||
33725171|NCT00002052||||TREATMENT||||||||
33725172|NCT03338426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725173|NCT01023646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33725174|NCT02741700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807807|NCT04433091|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participant, care provider and investigator will all be blinded to the assigned treatment arm.|This will be a double-blind, randomized study. Eligible subjects will be randomized according to a permuted block scheme with a block size of balancing interval, varying randomly according to the outcome of a computer-generated random number. This ensures that the cumulative number of assignments to each treatment (2-HOBA or placebo) will be in balance after each block of assignments had been made. A statistician will design the randomization table and enable the randomization tool within REDCap. After a patient enrolls for the study, the study nurse will determine the treatment assignment using the randomization tool in REDCap.|t|t|t|f
33807808|NCT06294249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807809|NCT04189822|||FAMILY_BASED||PROSPECTIVE|||||||
33807810|NCT06397196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807811|NCT04318834|NA|SINGLE_GROUP||OTHER||NONE||||||
33807812|NCT02777541|RANDOMIZED|PARALLEL||||NONE||||||
33807813|NCT06041165|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33807814|NCT01160588|||CASE_CONTROL||PROSPECTIVE|||||||
33807815|NCT01218009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807816|NCT06507345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807817|NCT01170845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807818|NCT01397006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807819|NCT00980213|||COHORT||PROSPECTIVE|||||||
33807820|NCT06698913|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Sample 1, intervention group patients had ventilator settings adjusted with PEEP based on BMI, followed by a 2 cmH2O increase and 20 minutes in a lateral position at 30 degrees for lung recruitment, monitored by plethysmogram. PEEP was increased up to 4 cmH2O as needed. Afterward, patients returned to supine, and the process was repeated on the other side. The control group had similar ventilator settings but stayed supine. Both groups had an alveolar recruitment maneuver with increased pressures. In Sample 2, all patients underwent a 2-minute recruitment maneuver, followed by a 5-minute PEEP titration. The EIT-PEEP was identified and selected as the first PEEP above the crossing point of collapse and hyperdistension curves. Patients were then randomized, and PEEP was increased progressively based on randomization. The intervention group avoided traditional recruitment maneuvers, increasing PEEP gradually. This was followed by 4 hours of observation and a 24-hour follow-up||||
33838151|NCT01162486|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838152|NCT01002716|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34037492|NCT01960257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34037493|NCT03000192|||COHORT||PROSPECTIVE|||||||
34037494|NCT01636271|||COHORT||PROSPECTIVE|||||||
34037495|NCT04174274|||CASE_CONTROL||PROSPECTIVE|||||||
34037496|NCT05651594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111208|NCT02374255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149947|NCT04276974|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34149948|NCT01017445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037497|NCT00428701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037498|NCT06497907|NA|SINGLE_GROUP||TREATMENT||NONE||Patient with growth faltering whose weight still below -2 SD for age and sex on the WHO scores after 12 weeks of nutritional rehabilitation with polymeric formula, underwent upper gastrointestinal endoscopy and who were diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula and probiotics||||
34037499|NCT05395117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037500|NCT03164551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037501|NCT00128232|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037502|NCT01129297|||COHORT||PROSPECTIVE|||||||
34037503|NCT02069015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037504|NCT04368546|||CASE_CROSSOVER||PROSPECTIVE|||||||
34037505|NCT06357897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The intervention and control were prepared in the similar sachet and was blinded to investigatiors, participants and guardians|Intervention group received PEG-Chula Control group received Forlax|t|t|t|f
34037506|NCT05890651|||CASE_ONLY||PROSPECTIVE|||||||
34037507|NCT00685100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037508|NCT04086056|||OTHER||PROSPECTIVE|||||||
34037509|NCT02832687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34037510|NCT03224728|||COHORT||PROSPECTIVE|||||||
34037511|NCT05418933|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention group||||
34037512|NCT04833751|||COHORT||PROSPECTIVE|||||||
34037513|NCT03473925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037514|NCT01468142|||COHORT||PROSPECTIVE|||||||
34037515|NCT00554385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037516|NCT05178615|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34037517|NCT05972993|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Data will be collected in an observer-blind manner.|Dose escalation with sentinel dosing|t|t|t|f
34037518|NCT00949858|||COHORT||PROSPECTIVE|||||||
34037519|NCT01320995|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037520|NCT04574713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses|t|t|f|t
34037521|NCT00861640|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037522|NCT00026988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34037523|NCT01991743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34037524|NCT01226082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037525|NCT01041924|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34037526|NCT05173155|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will either receive a hemiarthroplasty in the direct anterior approach or the lateral approach.||||
34149949|NCT04018742|||COHORT||PROSPECTIVE|||||||
34037527|NCT05992012|||COHORT||PROSPECTIVE|||||||
34037528|NCT04122963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037529|NCT04918017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037530|NCT05653557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037531|NCT02279654|||COHORT||PROSPECTIVE|||||||
34037532|NCT05832268|||COHORT||PROSPECTIVE|||||||
33807821|NCT04920253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Prescribing Physician will be blinded. A site blinded physician will confirm the Prescribing Physician's initial assessment of wound healing and a final blinded Independent Adjudicator will review baseline and final images to assess and provide confirmation of healing.|Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT). Control and Treatment Arms|f|t|t|t
33807822|NCT01847859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807823|NCT04798378|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807824|NCT05486494|||COHORT||PROSPECTIVE|||||||
33807825|NCT01005849|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33807826|NCT03664882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807827|NCT05771857|||COHORT||OTHER|||||||
33807828|NCT02386332|||||PROSPECTIVE|||||||
33807829|NCT06452069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double Blind|Multicenter, Randomized, Prospective Study|f|f|f|t
33807830|NCT03267537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Observers will be blinded to subjects group assignment|Randomized Controlled Trial|f|f|t|t
33807831|NCT00485693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807832|NCT02043041|||||CROSS_SECTIONAL|||||||
33807833|NCT03244800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807834|NCT05701579|||COHORT||PROSPECTIVE|||||||
33807835|NCT00526994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111209|NCT03490240|RANDOMIZED|PARALLEL||OTHER||SINGLE|The investigators will advertise the study as comparing two approaches delivered through the Internet for managing consequences of MS and improving health indicators. On randomization, the investigators will again reaffirm this position with the participant. The participant will not be informed about which condition is the control or the intervention.||t|f|f|f
34111210|NCT03255473|RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare hearing outcomes between treatment with dexamethasone versus prednisone in participants who have been diagnosed with unilateral SSNHL within six weeks, and compare side effect profiles between the two treatment regimens of either dexamethasone or prednisone.||||
34111211|NCT04743011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The clinical trial will be triple-blind. Participants, researchers, and the data/statistical analysis team will not have access to the research data. Only one member of the team will produce the test product and assist a external physician (not part of the research team), with the adverse events that may occur with the participants during the execution of the research.|Participants allocated to Group 1 (control) will receive inhalation with 0.9% saline solution applied 4/4 hours, for 7 days. Participants allocated to Group 2 (intervention) will receive high molecular weight inhaled heparin (2,5mg / mL 0.9% SF), at a 4/4 hour dose, for 7 days.|t|t|t|t
34111212|NCT06571890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111213|NCT01537432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111214|NCT00933478|||COHORT||RETROSPECTIVE|||||||
34111215|NCT01387867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34111216|NCT00453492|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111217|NCT01929694|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34111218|NCT04564820|||OTHER||PROSPECTIVE|||||||
34111219|NCT02644304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111220|NCT02171728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111221|NCT05560113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111222|NCT06262399|||CASE_ONLY||PROSPECTIVE|||||||
34111223|NCT06549348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111224|NCT03761550|||CASE_ONLY||PROSPECTIVE|||||||
34111225|NCT03359161|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, open-label, descriptive two-phase study to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration. Participants with mild to moderate signs of fluid overload will be included in the study. The study involves at home treatment with a novel formulation of subcutaneous furosemide. In the Pilot Phase (20 patients) will undergo 3 days of at home treatment for fluid overload. If determined to require more, will undergo an extra 4 days of treatment. The Investigator and her team will review the results for the first cohort and depending on the results will proceed to the Evaluation phase (40 patients).||||
34111226|NCT01266980|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34111227|NCT03596554|||COHORT||CROSS_SECTIONAL|||||||
34111228|NCT01300689|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34111229|NCT03255395|NA|SINGLE_GROUP||TREATMENT||NONE||A single group feasibility study||||
34111230|NCT01048957|RANDOMIZED|SINGLE_GROUP||OTHER||||||||
34111231|NCT03257501|||COHORT||PROSPECTIVE|||||||
33807836|NCT03336892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34111232|NCT01001689|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34111233|NCT03253237|||COHORT||PROSPECTIVE|||||||
34111234|NCT06140225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
34111235|NCT00804232|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111236|NCT03256487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The provider, nurse administering the medication, patient, and research assistant will be masked to the randomization and the drug provided. We will ensure masking by the following mechanisms: drugs will be prepared by the pharmacy staff in identical 10mL syringes; the medication will be diluted to a volume of 10mL with normal saline (NS); and both medications are clear so the syringes will appear identical. Both drugs will be administered over the same period of time, 3-5 minutes.||t|t|t|t
34111237|NCT03308279|||OTHER||CROSS_SECTIONAL|||||||
34111238|NCT05665283|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34111239|NCT01436227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111240|NCT02264366|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33807837|NCT01786876|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807838|NCT06699953|||COHORT||PROSPECTIVE|||||||
33807839|NCT04620096|||COHORT||PROSPECTIVE|||||||
33807840|NCT04811508|||COHORT||RETROSPECTIVE|||||||
33807841|NCT03511144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33807842|NCT04055818|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 Randomization||||
33807843|NCT02466958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807844|NCT05635357|||COHORT||RETROSPECTIVE|||||||
34111241|NCT00146822|RANDOMIZED|PARALLEL||||SINGLE||||||
34111242|NCT03532347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will receive both interventions the order i.e. FNB first or FNA first will be randomised. The pathologists reporting the samples will be blinded to the results with the alternative device||||
34111243|NCT00168376|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
34111244|NCT03702309|||COHORT||PROSPECTIVE|||||||
34111245|NCT00044174|||CASE_CONTROL||PROSPECTIVE|||||||
34111246|NCT02735460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111247|NCT02798887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111248|NCT03129906|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE||All participants received placebo capsules and, after that, gluten capsules.|t|f|f|f
34111249|NCT04451798|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111250|NCT03434730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111251|NCT03961672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111252|NCT05212207|||CASE_ONLY||PROSPECTIVE|||||||
34111253|NCT05812690|||CASE_CONTROL||PROSPECTIVE|||||||
34111254|NCT02061826|||CASE_CONTROL|||||||||
34111255|NCT02784587|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111256|NCT05196620|||COHORT||PROSPECTIVE|||||||
34111257|NCT00770679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111258|NCT03423979|NA|SINGLE_GROUP||TREATMENT||NONE||treatment group - treated with Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter||||
34111259|NCT05059275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111260|NCT02921867|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34111261|NCT00839501|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34111262|NCT03942744|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||prospective randomized crossover study||||
34111263|NCT03027596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34111264|NCT04481841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Each of the three centers has a researcher responsible for the treatment and interpretation of the subjects. The head of the research center trained the researcher to unify the standards. Three researchers were not involved in the evaluation of efficacy. Another researcher was responsible for recording pain and emotional nature and degree score, pain index, pain multi-dimensional characteristics score, depression index, Pittsburgh sleep quality index, Kupperman menopause score, dry mouth subjective symptoms questionnaire, saliva flow, and recording laboratory results, and collecting records. Data, analysis of efficacy, the researchers do not know the specific grouping, in order to minimize the subjective impact of the researchers on the test results.|1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.|f|f|f|t
34111265|NCT00057148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111266|NCT04110132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, care provider and outcomes assessors will not be aware of the used intervention.|"After approval of local ethical committee and patient consent, this double blinded randomized study will be done on 60 patients undergoing hemorrhoidectomy surgery in Alexandria University hospital.~After standard general anesthesia with Propofol 1-2mg/kg LMA for airway management and maintenance with Isoflurane 1%. The patient will be randomized into two groups.~Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml"|t|t|f|t
34111267|NCT02997202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111268|NCT04863404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|3 arm parallel clinical trial||f|f|f|t
34111269|NCT06434493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111270|NCT03741673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111271|NCT01362179|||COHORT||OTHER|||||||
34111272|NCT03797937|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111273|NCT01464606|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34111274|NCT06482983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group I: Volume control mode (VC) n: 40 Group II: Pressure-controlled volume guaranteed mode (PC-VG) n:40 Group III: Pressure control mode (PC) n:40|Group I: Volume control mode (VC) n: 40 Group II: Pressure-controlled volume guaranteed mode (PC-VG) n:40 Group III: Pressure control mode (PC) n:40|t|f|f|f
34111275|NCT06570850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111276|NCT06042816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"The drugs were administered in 10 mL and 50 mL syringes labeled as ''loading'' or ''infusion'' respectively. All the drugs delivered in loading dose (intravenous lidocaine and ketamine, epidural levobupivacaine in FOA group; fentanyl and normal saline in OA group) were diluted in normal saline to 10 ml volume labeled indistinguishably as ''loading-1'' and ''loading-2'', loading-3.... Because the number of loading drugs in the FOA group was greater than in OA group, investigators added some 10 ml normal saline syringes in the OA group to make the number of loading syringes in the two groups equal, thereby ensuring complete blinding. The infusion drugs (lidocaine, ketamine and levobupivacaine in FOA group or normal saline in OA group) were prepared in 50 mL syringes and labeled as ''infusion-1'' and''infusion-2'' respectively. The patients and the anesthetists taking part in the procedures were not informed of the study protocol."|Patients were randomized into 2 groups: Group OA - Opioid anesthesia (n = 49): Intraoperative pain control by fentanyl; FOA group - Free-opioid anesthesia (n = 49): Intraoperative pain control by continuous infusion of lidocaine, bolus doses of ketamine combined with epidural levobupivacaine.|t|t|f|t
34111277|NCT00448513|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34111278|NCT01085214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111279|NCT03524066|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34111280|NCT04918082|||COHORT||PROSPECTIVE|||||||
34111281|NCT06456164|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cook Cervical Ripening Balloon||||
34111282|NCT00789711|||COHORT||PROSPECTIVE|||||||
34111283|NCT04683653|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34111284|NCT00200239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111285|NCT06129955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111286|NCT06535373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized controlled study where participants will be randomly assigned to one of two groups.|f|f|t|t
34111287|NCT05114174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding will be done in a single-blind fashion. The care provider will be blinded to the randomization of the subjects to avoid bias in routine care.|Classic randomized clinical trial (RCT).|f|t|f|f
34111288|NCT06268106|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Graphic novel will be visualized by interventional group before EUS-FNB|f|t|f|f
34111289|NCT00212602|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34111290|NCT04527432|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34111291|NCT04853121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111292|NCT03847584|||OTHER||CROSS_SECTIONAL|||||||
34111293|NCT02263547|NA|SINGLE_GROUP||OTHER||NONE||||||
34111294|NCT06269315|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"1. Skin Cleansing and Testing Patch Preparation:~   Prepare a test set of patch testing tapes, each containing a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution. The safety dose of the tested products and agents will be defined beforehand.~   Before exposure, selected areas of forearm skin will be cleaned and moistened. Electrical impedance will be measured by electrical impedance spectroscopy (EIS) to assess skin barrier integrity.~2. Patch Application:~Apply the prepared patches on the skin of the forearm. Patches will be removed after 5 minutes of exposure.~During the exposure period, subjects will be instructed not to touch, wash, or wet the exposed area to avoid interfering with the action of the testing reagents. 3. Patch Removal and Post-Exposure Monitoring:~The patch will be gently removed from the skin. Exposed areas of skin will be evaluated by EIS at specific times up to 24 hours after the treatment."||||
34111295|NCT06350110|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group.|"Single Group Assignment~Patients enrolled in this clinical trial will receive a carefully designed treatment regimen. Prior to the infusion of CD19 and BCMA CAR-T cells, participants will undergo preconditioning chemotherapy. This chemotherapy serves to create an optimal environment for the CAR-T cell therapy to effectively target and eliminate malignant B cells. Following chemotherapy, participants will receive the infusion of CD19 and BCMA CAR-T cells.~Monitoring and Follow-up:~Following the CAR-T cell infusion, patients will be subjected to rigorous monitoring to assess safety and treatment response."||||
34111296|NCT06642415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham piezoelectric setup for patients undergoing conventional surgery.||t|f|f|f
34111297|NCT03412955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111298|NCT04957589|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is infeasible, as the participants will know which intervention they are partaking in.|This is a proof-of-concept, single centre, randomised, non-blinded control trial.||||
34111299|NCT03594474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111300|NCT05769062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111301|NCT05169502|||COHORT||PROSPECTIVE|||||||
34111302|NCT04614532|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111303|NCT06445777|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The researchers involved in data collection after the intervention will be masked.|Children will be randomly assigned to either the control or intervention group after the baseline assessment. Participants in the control group will receive the intervention at a later stage.|f|f|t|f
34111304|NCT04057157|||COHORT||PROSPECTIVE|||||||
34111305|NCT05713266|||COHORT||PROSPECTIVE|||||||
34111306|NCT02296125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34111307|NCT00516308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111308|NCT03873545|||COHORT||PROSPECTIVE|||||||
34111309|NCT01129206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111310|NCT03828604|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Acute Psychosocial stress vs. Non-stress active control|t|f|f|f
34111311|NCT01136720|||CASE_ONLY||PROSPECTIVE|||||||
34111312|NCT06069570|NA|SEQUENTIAL||TREATMENT||NONE||The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) or the maximum administered dose (MAD) will be determined based on isotonic regression in Part 1 Dose Escalation. If the MTD/MAD shows an acceptable safety and tolerability profile, an additional 12 participants in Part 2 expansion will be enrolled. Three dose levels of KB-GDT-01 will be evaluated and will follow a Bayesian Optimal Interval (BOIN) design rule based on a targeting rate of 25% for dose limiting toxicity (DLT) occurring between the first KB-GDT-01 infusion and Day 40. Depending on observed DLT rate, the safety monitoring committee will assess whether to escalate to the next dose, de-escalate (not applicable for the first dose), hold at current dose or stop the study if at the first dose.||||
34111313|NCT05611164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111314|NCT05674955|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 groups of ischemic cardiomyopathy patients. 1st group receive circuit weight training. 2nd group receive aerobic. 3rd group receive medications||||
34111315|NCT03504709|||COHORT||PROSPECTIVE|||||||
34111316|NCT06564662|||COHORT||RETROSPECTIVE|||||||
34111317|NCT00567502|||COHORT||PROSPECTIVE|||||||
34111318|NCT05086380|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34111319|NCT05129306|||CASE_ONLY||PROSPECTIVE|||||||
34111320|NCT05944692|||COHORT||PROSPECTIVE|||||||
34111321|NCT04129398|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111322|NCT01596270|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111323|NCT00679614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111324|NCT02129621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111325|NCT02144532|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34111326|NCT04258748|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111327|NCT03410160|||CASE_CONTROL||PROSPECTIVE|||||||
34111328|NCT03135860|NA|SINGLE_GROUP||TREATMENT||NONE||Exploratory Single Arm Study||||
34149950|NCT03032445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149951|NCT01742065|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34149952|NCT01270152|RANDOMIZED|PARALLEL||||NONE||||||
34149953|NCT02438345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149954|NCT03304067|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149955|NCT00500708|||COHORT||PROSPECTIVE|||||||
34149956|NCT02754960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33807845|NCT06465550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807846|NCT00367874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807847|NCT00192959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33807848|NCT05179265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
34037533|NCT04253418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807849|NCT03905278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||The effectiveness of the parental support intervention is assessed through a longitudinal two arms, randomized controlled trial and the experimental condition, the two significant caregivers of the children or the individual caregiver receive the intervention composed of an informational booklet and a psychological intervention. In the control condition, the participants receive the informational booklet before being registered in a waiting list for the psychological intervention. The intervention should ideally last two months. Assessments are conducted at two periods : before and after the intervention for the experimental group and at 9 weeks of interval for the control group.|t|t|t|t
33807850|NCT03597087|RANDOMIZED|PARALLEL||TREATMENT||NONE|Using a web site, and creating a randomized list at Sealedenvalop.com. Patients are randomly assigned to receive an anesthetic consent, and no masking is performed.|After randomization, they were divided into two parallel groups 289 patients were randomly assigned to a spinal anesthesia group and a general anesthesia group 1: 1.||||
34037534|NCT06172270|||COHORT||PROSPECTIVE|||||||
34037535|NCT05220852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|all the research subjects were masked and enrolled by picking up one of two sealed envelope to take place in one of the groups|RTC single-blind|t|f|f|f
34037536|NCT02291510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34037537|NCT04533737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Brodalumab (1.5 mL) and guselkumab (1.0 mL) are in pre-filled syringes and packaged open-label. Dummy injections are used for blinding.||t|f|f|t
34037538|NCT01998919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037539|NCT03162250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037540|NCT03707223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037541|NCT03992365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After bowel preparation, independent evaluator who is blinded to subject's treatment will evaluate the overall colon cleansing based on Aronchick and Ottawa scale.|randomized, evaluator blind, active-controlled, parallel study|f|f|f|t
34037542|NCT01069198|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34037543|NCT04370132|||CASE_CONTROL||RETROSPECTIVE|||||||
34037544|NCT04326361|||OTHER||CROSS_SECTIONAL|||||||
34037545|NCT01470924|||COHORT||PROSPECTIVE|||||||
34037546|NCT02629315|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Randomization occurred after surgery, the surgeon was blind during the procedure||f|t|f|f
34037547|NCT03836690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037548|NCT00479986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34037549|NCT00170781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34037550|NCT01270568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037551|NCT02742662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037552|NCT00518271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037553|NCT00063726|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037554|NCT03000010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037555|NCT04038463|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037556|NCT04675099|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34037557|NCT03691701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037558|NCT04283240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Treatment was blinded by the institutional pharmacy embedding the placebo or treatment pill in a gelatinous cap||t|t|t|t
34037559|NCT04756882|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037560|NCT01486446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037561|NCT00749450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037562|NCT05264038|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34037563|NCT01275846|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037564|NCT01365819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037565|NCT02651701|||CASE_CONTROL||PROSPECTIVE|||||||
34037566|NCT06478498|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Two groups who will follow similar study procedures up until week 5. After this, one group receives direct treatment after which the study will end in week 13. The other group receives top-up inoculations to receive patent infection and remains chronically infected for approximately two years, therefore their follow-up scheme looks different compared to the other group.||||
34037567|NCT04442789|||COHORT||PROSPECTIVE|||||||
34037568|NCT02201693|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037569|NCT05046262|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037570|NCT04930289|||COHORT||CROSS_SECTIONAL|||||||
34037571|NCT01700972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037572|NCT02001311|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34037573|NCT00860795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34037574|NCT02972619|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34037575|NCT03354351|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34037576|NCT06427746|||COHORT||PROSPECTIVE|||||||
34037577|NCT00677664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037578|NCT03781908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037579|NCT03187613|||COHORT||PROSPECTIVE|||||||
34149957|NCT00343707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149958|NCT02925728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149959|NCT04957758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149960|NCT05503888|RANDOMIZED|FACTORIAL||TREATMENT||NONE||This study is a multicenter, open-label, dose-exploring, and efficacy expansion phase Ib/II study. The first phase explored two doses of SHR-1701 plus fixed dose of almonertinib to confirm RP2D. The second phase is for efficacy expansion through randomization.||||
34111329|NCT04365855|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We will invite adult Olmsted County residents with research authorization, identified based on a random search of the Rochester Epidemiology Project database. We plan to accrue 800 participants. Based on literature estimates, approximately 25-30% of adults will be at risk for NAFLD due to overweight/obese status. Participants will undergo tests for NAFLD screening: blood tests, Magnetic Resonance Imaging/Elastography and electrocardiogram. Those identified with fatty liver will undergo Transient elastography and liver biopsy for disease severity assessment. These results will be used to validate a machine learning model of NAFLD diagnosis and liver disease severity which uses the participants clinical and laboratory data (noninvasive electronic health records). The cohort will be followed for 5 years, when they will return for repeat imaging and blood tests to monitor for incident NAFLD, liver disease progression and outcomes.||||
34111330|NCT06518928|||CASE_CONTROL||PROSPECTIVE|||||||
34111331|NCT04026802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111332|NCT05993884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34111333|NCT00209131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111334|NCT06220084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Groups: live DfPD® vs remote DfPD® vs Control. The experimental period will be of 10 months, including 3 periods of two months intervention for each group (live DfPD® vs remote DfPD®) versus control group (non-intervention group) and 2 washout periods of two months between.||||
34111335|NCT06387953|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34111336|NCT05147142|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single blind administration||t|f|f|f
34111337|NCT06447103|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111338|NCT06477770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both the patients and 3 researchers will know the intervention, however, the groups will be listed and during the analysis phase, the analyst researcher will not know which group each patient corresponds to.|randomized, single-blind clinical trial, whose population to be studied will be randomized patients with a diagnosis of dehiscence and infection of a cesarean surgical wound who meet the inclusion and exclusion criteria.|f|f|f|t
34111339|NCT04226261|||COHORT||PROSPECTIVE|||||||
34111340|NCT00642044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34111341|NCT00912886|||CASE_CONTROL||PROSPECTIVE|||||||
34111342|NCT06135090|NA|SINGLE_GROUP||TREATMENT||NONE|This is a single arm, uncontrolled design. Thus, no masking to intervention allocation is possible.|The trauma recovery program (TRP) is a seven-session, peer-led, group program for family members/significant others of people with borderline personality disorder (BPD) and emotion dysregulation. It draws on principles of cognitive processing therapy for PTSD and cognitive behavioural conjoint therapy for PTSD to target PTSD symptoms in these individuals that are related to having a loved one with BPD or emotion dysregulation. As a peer-support model, it is not a psychotherapy. The TRP involves learning about common reactions to trauma and learning methods of challenging trauma-related beliefs that inhibit trauma recovery. Group members are asked to practice exercises outside of sessions that focus on challenging beliefs that fall into several key trauma-related themes.||||
34111343|NCT05385822|RANDOMIZED|PARALLEL||TREATMENT||NONE||Men who meet all inclusion criteria will be randomized 1:1 for either pelvic floor training or control. Stratified randomization with correction for IIEF-EF category is used (mild 17-25, moderate 11-16, severe 0-10)||||
34111344|NCT06637605|||CASE_CONTROL||PROSPECTIVE|||||||
34111345|NCT03999476|RANDOMIZED|PARALLEL||OTHER||SINGLE|patient will be under general anesthesia|parallel assignment|t|f|f|f
34111346|NCT03152201|||CASE_ONLY||PROSPECTIVE|||||||
34111347|NCT00552045|||CASE_CONTROL||PROSPECTIVE|||||||
34111348|NCT00863304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111349|NCT05356715|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Patients aged from 18-70 years old, who will undergo open heart surgery procedure through sternotomy will be included in the study. Patients will be randomly allocated into one of two groups:~* Group A (n=110): will receive Ultrasound guided bilateral ESBP after induction of general anesthesia.~* Group B (n=110): will receive fentanyl IV infusion 2mic/kg/hr after induction of General anesthesia"|t|t|f|t
34111350|NCT06645210|||COHORT||RETROSPECTIVE|||||||
34111351|NCT06638905|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be treated with a combination therapy of Babor Ultimate ECM Repair Serum and the Babor Cure Cream to their entire face.||||
34111352|NCT06558604|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 cohorts||||
34111353|NCT06301373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111354|NCT03391882|RANDOMIZED|CROSSOVER||TREATMENT||NONE|"Open label: APL-130277 and Subcutaneous Apomorphine~Single-Blinded Rater for MDS-UPDRS Part III Motor Examination assessment in Part B."|||||
33807851|NCT06700304|NA|SINGLE_GROUP||OTHER||NONE||The study is a prospective, longitudinal, non-randomized, open-label, single-arm early feasibility study (EFS)||||
33807852|NCT00140491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34111355|NCT01199393|||CASE_ONLY||PROSPECTIVE|||||||
34111356|NCT03254784|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111357|NCT05946044|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|assessor-blinded||f|f|f|t
34111358|NCT00895505|RANDOMIZED|PARALLEL||||NONE||||||
34111359|NCT02570438|||OTHER||PROSPECTIVE|||||||
34111360|NCT06639087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|t|t|f
34111361|NCT06200246|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34111362|NCT06545552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111363|NCT04523025|||CASE_CONTROL||PROSPECTIVE|||||||
34111364|NCT06460376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111365|NCT05577741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111366|NCT06152926|||COHORT||PROSPECTIVE|||||||
34111367|NCT03790189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111368|NCT03459222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111369|NCT04722354|RANDOMIZED|CROSSOVER||OTHER||SINGLE||a randomized, cross-over, placebo-controlled trial will be employed to evaluate the effects of ABA (95ug) twice a day (190ug total per day) for 14 days on tolerability and insulin sensitivity during a hyperinsulinemic euglycemic clamp.|t|f|f|f
34111370|NCT04661488|||COHORT||PROSPECTIVE|||||||
34111371|NCT02227355|||COHORT||PROSPECTIVE|||||||
34037580|NCT05685147|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The embryologist will grade the morphology of blastocysts according to Gardner's criteria stated above and enter the grading of blastocysts into an online database, which will be managed by an IT technician. The laboratory staff in the PGT laboratory will enter the PGT result into a local database when the NIPGT results are available. The IT technician will collect the database from the PGT laboratory and enter it into the online software to compile the sequence of embryo transfer according to a pre-determined algorithm which depends on the day of blastocyst development (day 5 better than day 6), blastocyst morphology and niPGT-A result. The IT technician will issue the sequence of embryo transfer which does not contain information on the grading of the blastocyst and the NIPGT result to the embryologists in the IVF laboratory. Therefore, the subjects recruited, the clinicians and the embryologists will be blinded to the group allocation.||t|t|f|f
34037581|NCT02939677|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33807853|NCT06270524|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33807854|NCT03496558|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33807855|NCT03347409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807856|NCT05726526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Given the nature of the intervention, patients and care providers will not be blinded; outcome assessment and statistical analysis will be blinded|Eligible participants will be randomly allocated to the intervention group (usual care + the VIEWER virtual care platform) or the control group (usual care).|f|f|f|t
33807857|NCT02461979|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34037582|NCT00475267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037583|NCT02705365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037584|NCT05379413|||COHORT||PROSPECTIVE|||||||
34037585|NCT00286104|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037586|NCT04468568|||COHORT||RETROSPECTIVE|||||||
34037587|NCT02816346|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037588|NCT04231825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34037589|NCT01598363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037590|NCT03610204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Since the patient are prone during the low back massage, the patient will not know what treatment they receive, as the two treatments are similar and only different in the pressure force.~The primary outcome is assessed by a self-reported questionnaire. The assessor who performs the clinical assessments will be blinded to the treatment assignment."|The patients are randomly assigned into two treatment arms.|t|f|f|t
34037591|NCT02930499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037592|NCT04369391|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Blinded|"Subjects will be randomized using a double Williams design in equal ratio to six possible sequences of receiving the three treatments being studied:~SEP-363856 150mg, Matched Placebo, moxifloxacin 400mg."|t|f|t|t
34037593|NCT00691444|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037594|NCT01493518|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34037595|NCT02912702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037596|NCT00725283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037597|NCT03883997|||OTHER||CROSS_SECTIONAL|||||||
34037598|NCT03657875|||OTHER||RETROSPECTIVE|||||||
34037599|NCT00718874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037600|NCT01808846|||CASE_CONTROL||PROSPECTIVE|||||||
34037601|NCT00333320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037602|NCT00194441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037603|NCT00707239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037604|NCT03523741|||CASE_ONLY||PROSPECTIVE|||||||
34037605|NCT02013817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807858|NCT06522919|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open-label, multicenter phase 2 clinical trial||||
33807859|NCT05424666|NA|SINGLE_GROUP||OTHER||NONE||||||
33807860|NCT05371951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807861|NCT02304757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with OS were divided into 99Tc-MDP and fosamax treatment groups.||||
33807862|NCT04263051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807863|NCT01799200|||||CROSS_SECTIONAL|||||||
33807864|NCT04806841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33807865|NCT04205799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807866|NCT04236700|||CASE_CONTROL||RETROSPECTIVE|||||||
33807867|NCT04720612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807868|NCT00087022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807869|NCT03764020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple blinding is planned. All participants, medical providers and outcome evaluators will be blinded about treatment arms.~The THC pharmacy will dispense the medication and perform the randomization. Melatonin capsule and placebo will be completely identical."|Melatonin 3 Mg or placebo associated with life style modification according to 2013ACC/ AHA guideline has been planned in parallel fashion for three weeks of follow up. Participants allocated to each group will stay at the same interventional group for entire follow up period of three weeks.|t|t|f|t
33807870|NCT05121142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807871|NCT02579915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807872|NCT00894894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807873|NCT02959385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33807874|NCT01530334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807875|NCT05957510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807876|NCT05193799|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33807877|NCT00678925|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33807878|NCT00570388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807879|NCT05822752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807880|NCT04684095|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33807881|NCT03224806|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33807882|NCT06699147|||CASE_CONTROL||PROSPECTIVE|||||||
33807883|NCT00419874|||DEFINED_POPULATION||OTHER|||||||
33807884|NCT01994057|||CASE_ONLY||RETROSPECTIVE|||||||
34037606|NCT04899180|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037607|NCT00556946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037608|NCT01173484|||COHORT||PROSPECTIVE|||||||
34037609|NCT00791609|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037610|NCT04587869|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessor does not randomize participant until after the baseline assessment||f|f|f|t
34037611|NCT02968602|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34037612|NCT02824120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34037613|NCT02166333|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34037614|NCT04846569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037615|NCT05183139|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037616|NCT03491293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037617|NCT05566899|NA|SINGLE_GROUP||PREVENTION||NONE||A single-center, open label pilot study that will evaluate the acceptability and feasibility of EGD at time of routine screening colonoscopy (EGD-SC). The Pre-Study Screening is day -30 to day 0; EDG at time of routine screening colonoscopy and follow-up day five to seven.||||
34037618|NCT01461694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037619|NCT01935141|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34037620|NCT05650112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Part 1 is double blind. Part 2 is open label|Part 1 - randomized, placebo-controlled. Part 2 - open label.|t|t|t|f
34037621|NCT06476990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037622|NCT03842319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Non-intervention or MedDiet intensive intervention group assignment will be made through an automated system. Each patient will be assigned a patient identification number that should appear on all eCRF pages (electronic case report), source documents and laboratory data. All researchers involved in the measurement of data, analysis and allocation of results will be blind. The MedDiet intensive intervention will be blind to the evaluation of the endpoints (the research team in charge of the measurement, analysis and awarding of the results will be blind). The samples will be coded and anonymously analyzed by each research team"|Intervention Group: High intensity Mediterranean diet in secondary prevention after acute coronary syndrome. Control Group: recommendation of a standard of care, standard Mediterranean diet. Duration of the intervention per participant: 12 months. Follow-up period per participant: 12 months.|f|f|t|f
34037623|NCT01110590|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34037624|NCT00000807||||TREATMENT||NONE||||||
34037625|NCT06480838|||CASE_CONTROL||PROSPECTIVE|||||||
34037626|NCT05106491|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34037627|NCT04166786|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"Placebo treatments are administered in the same posology as active treatments (testosterone and ethanol).~Ethanol is diluted in placebo (lemon-flavoured water) to prevent differentiation."|Subjects receive 4 different treatment conditions (testosterone+ethanol placebo, ethanol+testosterone placebo, testosterone+ethanol, and placebo testosterone+placebo ethanol), separated by a wash-out period of 15 days. The order of the treatment conditions is randomly assigned.|t|f|f|f
34037628|NCT06288451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors are blinded to the assigned interventions.||f|f|f|t
34037629|NCT04127227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037630|NCT01298804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34037631|NCT06250296|||CASE_CONTROL||PROSPECTIVE|||||||
34037632|NCT05043480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037633|NCT05962723|||COHORT||PROSPECTIVE|||||||
34037634|NCT06040710|||CASE_ONLY||PROSPECTIVE|||||||
34037635|NCT06041451|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34037636|NCT05221944|||CASE_CONTROL||RETROSPECTIVE|||||||
34037637|NCT02925481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037638|NCT06012344|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This triple-blinded randomized clinical trial ensured masking of participants, physiotherapists, assessors, and the principal investigator. Participants were unaware of their assigned treatment, as treatments were standardized and shared similar characteristics. Physiotherapists were trained to deliver treatments without disclosing specific interventions. Assessors remained blinded to treatment assignments, conducting outcome assessments independently. The principal investigator had no knowledge of treatment allocations to maintain objectivity. Implementing triple-blinding enhanced the study's internal validity, minimizing biases and improving the reliability of the results.|This triple-blinded, randomized clinical trial employed a five-phase crossover design to evaluate the effects of post-isometric relaxation, post-facilitation stretch, and hamstring Nordic lower exercises on hamstring function and athletic performance in young athletes. Participants were randomly assigned to treatment groups in Phase I, followed by washout periods in Phases II and IV. In Phase III, participants switched treatments to ensure exposure to all interventions. Outcome measures included hamstring flexibility, lower limb power, speed and acceleration, hamstring strength, and agility. The study utilized triple-blinding and randomization to minimize biases. The findings will guide practitioners and coaches in optimizing training and rehabilitation strategies for young athletes. In conclusion, this trial provides valuable insights into the effects of different treatments on hamstring function and athletic performance, benefiting athletes and enhancing performance outcomes.|t|t|t|t
34037639|NCT06498856|||COHORT||PROSPECTIVE|||||||
34037640|NCT01125397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111372|NCT04349969|NA|SEQUENTIAL||TREATMENT||NONE||||||
34111373|NCT06274957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111374|NCT03068000|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator and the evaluators will be blind as well as the allocation.|Judo training and Ball games|f|f|t|t
34111375|NCT05246566|||COHORT||PROSPECTIVE|||||||
34111376|NCT04993196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111377|NCT00492544|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111378|NCT06569719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111379|NCT03375242|||CASE_ONLY||PROSPECTIVE|||||||
34111380|NCT06645184|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Participating subjects are blinded and will not know which of the 4 study products they will consume||t|t|f|f
33725175|NCT00407563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037641|NCT01622257|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34037642|NCT00564850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037643|NCT02884362|||||PROSPECTIVE|||||||
34037644|NCT01265862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037645|NCT03516695|||OTHER||PROSPECTIVE|||||||
34037646|NCT03410576|||COHORT||PROSPECTIVE|||||||
34037647|NCT01801943|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34037648|NCT03587402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind||f|f|f|t
34037649|NCT02380586|||CASE_ONLY||PROSPECTIVE|||||||
34037650|NCT00997841|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34037651|NCT05316207|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intervention group and control group||t|f|f|f
34037652|NCT00100672|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037653|NCT01110460|||COHORT||PROSPECTIVE|||||||
34037654|NCT05716308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34111381|NCT02766855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111382|NCT04769869|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"Part 1a: Healthy volunteers will be blinded to treatment allocation (single-blind design) to minimize bias.~Part 1b: This part of the study is open-label and blinding is not applicable.~Part 2: Healthy volunteers will be blinded to treatment allocation (single-blind design) to minimize bias.~Part 3: Patients will be blinded to treatment allocation (single-blind design) to minimize bias"||t|f|f|f
34111383|NCT03319251|||CASE_ONLY||PROSPECTIVE|||||||
34111384|NCT02458014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111385|NCT04331275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111386|NCT04395547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111387|NCT04237584|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Masking of Radium-223 or placebo only|12 week lead-in open-label androgen-receptor blocker (ARB) followed by up to 6 cycles of double-blind Radium-223 or placebo.|t|f|t|f
34111388|NCT05073588|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized, Single centre Open label study||||
34111389|NCT05126303|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomized, double-blind, adaptive, parallel group|t|t|t|t
34111390|NCT02106806|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34111391|NCT02457065|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34111392|NCT02908217|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34111393|NCT03602508|||COHORT||RETROSPECTIVE|||||||
34111394|NCT01927913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111395|NCT03178682|||COHORT||PROSPECTIVE|||||||
34111396|NCT01817400|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34111397|NCT01900184|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34111398|NCT05707260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111399|NCT02371356|||COHORT||PROSPECTIVE|||||||
34111400|NCT02811887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111401|NCT05041504|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a 2-arm pragmatic randomized controlled trial with an active wait-list control, and an embedded process evaluation. Participants in the intervention group will receive the True North Peer Navigation intervention. Participants in the active control group will receive access to an online health resource library and will be offered the True North Peer Navigation intervention after study completion.|f|f|f|t
34111402|NCT00190957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34111403|NCT06455904|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an interventional, randomized controlled, prospective, multicenter and adaptive study aimed at investigating the effect of a concentric pedaling training program carried out during (neo)adjuvant chemotherapy in addition to usual care.||||
34111404|NCT02160431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111405|NCT05177536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111406|NCT04168125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111407|NCT04568148|||OTHER||OTHER|||||||
34111408|NCT05844618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intra-individual|t|t|t|t
34111409|NCT02749916|||CASE_CONTROL||PROSPECTIVE|||||||
33725176|NCT03094845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725177|NCT00625677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725178|NCT03902951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725179|NCT01319877|||COHORT||PROSPECTIVE|||||||
33725180|NCT00620438|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725181|NCT04413084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725182|NCT03338062|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725183|NCT01384396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725184|NCT00003120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725185|NCT04452617|||COHORT||RETROSPECTIVE|||||||
34037655|NCT01255488|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34037656|NCT06361680|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34037657|NCT05603169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of this study will be kept blind of the participants treatment group|Parallel assignment into two groups|f|f|f|t
34037658|NCT02220764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037659|NCT06146465|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037660|NCT00998920|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34037661|NCT04412616|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34111410|NCT05547984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111411|NCT06230198|RANDOMIZED|CROSSOVER||OTHER||NONE||a multiple period vanguard cluster crossover trial||||
34111412|NCT06644742|||COHORT||PROSPECTIVE|||||||
34111413|NCT03301584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, controlled, intervention study. Evaluation of a modified model of in-patient rehabilitation compared to standard care, with follow-up at 1 month post-discharge.||||
34111414|NCT00005038|RANDOMIZED|||TREATMENT||NONE||||||
34037662|NCT01057706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037663|NCT06286683|||COHORT||PROSPECTIVE|||||||
34037664|NCT04429945|NA|SINGLE_GROUP||TREATMENT||NONE||"Once patients are enrolled, baseline data and pre-intervention outcome measures will be collected. APPs will be selected from the VR Toolkit that best address the individual patient's treatment goals.~Patients will be instructed in the use of the head mounted display with VR APPs. VR dosage will be two one-half hour sessions per therapy day. Patients can initiate use of a more challenging APPs that gradually includes hand/arm movement."||||
34037665|NCT05643937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037666|NCT03521011|||COHORT||PROSPECTIVE|||||||
34037667|NCT04515147|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|f|t|t
34037668|NCT01515423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037669|NCT01308125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037670|NCT01778855|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34037671|NCT03551990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037672|NCT05699941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037673|NCT01281397|||COHORT||PROSPECTIVE|||||||
34037674|NCT05482698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel-group, Randomized, Double-blind|t|f|t|t
34037675|NCT03726697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Parents and Statistician are blinded||f|f|f|t
34037676|NCT00249301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037677|NCT03898791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037678|NCT00311948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34037679|NCT01159808|RANDOMIZED|FACTORIAL||||TRIPLE|||t|t|t|f
34037680|NCT01341288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037681|NCT00489632|||CASE_ONLY||PROSPECTIVE|||||||
34037682|NCT05136781|||CASE_ONLY||RETROSPECTIVE|||||||
34037683|NCT02066844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037684|NCT04700670|||CASE_ONLY||PROSPECTIVE|||||||
34037685|NCT04003883|||CASE_ONLY||PROSPECTIVE|||||||
34037686|NCT00789048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34037687|NCT02471729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037688|NCT04069273|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34037689|NCT00154661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037690|NCT03885661|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Reference therapy is usual care, so the subject and coordinators are unblinded to assignment, but investigators and outcomes assessors are blinded to assignment.|Parallel, randomized, controlled mechanistic pilot/feasibility experiment focused on elucidating detailed mechanism of action for apolipoprotein turnover kinetics changes using intravenous infusions of stable isotopes in a clinical/translational metabolic unit.|f|f|t|t
34037691|NCT04383561|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34037692|NCT01857908|||CASE_CONTROL||PROSPECTIVE|||||||
34037693|NCT00571324|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34037694|NCT05845424|RANDOMIZED|PARALLEL||TREATMENT||NONE|A prospective, open label, multicenter randomized controlled trial|standard treatment vs. aggressive treatment||||
34037695|NCT04207606|||COHORT||PROSPECTIVE|||||||
34037696|NCT01050829|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34037697|NCT03518008|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34037698|NCT05630885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||At study entry, participants were randomized 2:1 to oral CVC (Arm A) or oral placebo for CVC (Arm B) once a day. The study treatment was added to the participants' pre-existing ARV regimens.|t|f|t|f
34037699|NCT05343780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Double blinded||t|t|t|f
34037700|NCT05045391|||CASE_CONTROL||PROSPECTIVE|||||||
34037701|NCT05219760|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance."|t|f|f|f
33807885|NCT01473069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807886|NCT03876886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037702|NCT00270946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037703|NCT00274300|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037704|NCT05155904|||CASE_ONLY||PROSPECTIVE|||||||
34037705|NCT01904695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037706|NCT02462798|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34037707|NCT01809405|||COHORT||PROSPECTIVE|||||||
34037708|NCT05862623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037709|NCT04902027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037710|NCT00751699|RANDOMIZED|PARALLEL||||NONE||||||
34037711|NCT04454255|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Cross-over, repeated-measures, open without masking.||||
34037712|NCT02675036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111415|NCT02001792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150017|NCT01805388|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150018|NCT02635997|||COHORT||RETROSPECTIVE|||||||
34150019|NCT06464523|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|They did not know if they were in the control and intervention group at the time of randomization.|||||
34150020|NCT05307432|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Stepped-wedge cluster-randomized controlled design|f|f|f|t
34150021|NCT03255564|||OTHER||PROSPECTIVE|||||||
34150022|NCT01341717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150023|NCT01194622|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150024|NCT01295970|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150025|NCT02177838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150026|NCT02796885|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34150027|NCT00007267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807887|NCT01828671|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33807888|NCT02022657|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33807889|NCT05381090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33807890|NCT06342700|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33807891|NCT02873559|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33807892|NCT06311266|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Due to the surgical workflow (using the robotic guided device or not) the performing surgical team will not be blinded to the allocated group. However, investigators will be blinded to the allocation of the patients.|prospective, randomized, single center cohort trial|t|f|f|f
33807893|NCT04880018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807894|NCT01282957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33807895|NCT00378391|||DEFINED_POPULATION||OTHER|||||||
33807896|NCT00038636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807897|NCT03488550||SEQUENTIAL||TREATMENT||NONE||||||
33807898|NCT00002294||||TREATMENT||DOUBLE||||||
33807899|NCT06699602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807900|NCT03978676|||COHORT||RETROSPECTIVE|||||||
33807901|NCT00822900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807902|NCT01935063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807903|NCT01083732|NA|SINGLE_GROUP||||NONE||||||
33807904|NCT01692769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33807905|NCT05856656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34037713|NCT06405984|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|Although it is known what devices are used, all personnel on the investigative team will be masked to fetal oxygenation levels during data collection.|This is a single-arm, device feasibility study, based on convenience sampling.||||
34037714|NCT03454334|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037715|NCT04079218|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to receive treatment with estradiol vaginal tablets or no treatment.||||
34037716|NCT04764747|||COHORT||RETROSPECTIVE|||||||
34037717|NCT02088177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037718|NCT05708248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037719|NCT02265393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037720|NCT04333160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037721|NCT01332344|||COHORT||RETROSPECTIVE|||||||
34037722|NCT01480323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037723|NCT05382208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participant and site personnel will not know which study treatment the participant is receiving.||t|t|t|t
34037724|NCT01626001|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037725|NCT02406690|||CASE_CONTROL||PROSPECTIVE|||||||
34037726|NCT02685228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037727|NCT02926443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34037728|NCT03654612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037729|NCT05018182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037730|NCT04691362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double blinded randomized controlled trial. Patient, anesthesiologist and surgeon are blinded.||t|t|t|t
34037731|NCT03692286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150028|NCT05389189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34150029|NCT01655147||CROSSOVER||TREATMENT||NONE||||||
34150030|NCT06522971|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34150031|NCT00685373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150032|NCT05650671|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150033|NCT03102567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150034|NCT03570346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150035|NCT03623061|||COHORT||PROSPECTIVE|||||||
34150036|NCT05218226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150037|NCT01916850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150038|NCT04133714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150039|NCT04736134|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34150040|NCT05275790|NA|SINGLE_GROUP||TREATMENT||NONE||Bilateral electrical vestibular nerve stimulation will be administered using a battery-powered vestibular nerve stimulator (ML 1000). Participants will act as their own self-control.||||
34150041|NCT05661396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150042|NCT03612050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34150043|NCT04384627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicentre, Non-inferiority, Randomised controlled trial|f|f|f|t
34150044|NCT01761773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150045|NCT05219669|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34150046|NCT00196053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150047|NCT05018741|||COHORT||RETROSPECTIVE|||||||
34150048|NCT03076346|||COHORT||PROSPECTIVE|||||||
34150049|NCT02618551|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34150050|NCT03042260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150051|NCT01345552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150052|NCT05363826|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a phase I Drug study of the photochemotherapy drug Methyl bacteriopurpurinimide Bacteriopurpurinimide-methyl ester (registered trade name Photobac®) in adult subjects with recurrent diagnosed glioblastoma or gliosarcoma.~We are evaluating the safety of this photosensitizing drug in an 8 step dose escalation with 3 patients per step and a fixed light dose (50 joules / square centimeter) by way of intraoperative cavitary photodynamic therapy using a balloon and spherical diffuser to deliver the light."||||
34150053|NCT01510899|NON_RANDOMIZED|PARALLEL||||NONE||||||
34150054|NCT03917550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Folow-up interviews will be carried out by a different team of assessors (blinded to the treatment condition)||f|f|f|t
34150055|NCT00324233|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34150056|NCT04386876|RANDOMIZED|CROSSOVER||OTHER||NONE||Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over||||
34150057|NCT04430647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33807906|NCT01128595|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33807907|NCT01357057|||COHORT||RETROSPECTIVE|||||||
33807908|NCT05066022|NA|SINGLE_GROUP||TREATMENT||NONE||CAR T||||
33807909|NCT04006834|||CASE_CONTROL||PROSPECTIVE|||||||
33807910|NCT05443698|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Independent Readers reviewing Imaging Exams will be fully blinded to participant health history and exam setting.|Prospective, interventional, single arm clinical trial||||
34037732|NCT04029025|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||Double-blinded double-randomized controlled trial (RCT) with crossover design|t|f|f|t
34037733|NCT00121914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037734|NCT04181021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34037735|NCT02707484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037736|NCT02881853|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037737|NCT04815070|||COHORT||PROSPECTIVE|||||||
34037738|NCT03858751|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34037739|NCT05221541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Parallel group study design||||
34037740|NCT03815500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037741|NCT03444662|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34037742|NCT02745431|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34037743|NCT01325363|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037744|NCT05064397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037745|NCT00748839|||COHORT||PROSPECTIVE|||||||
34037746|NCT05973188|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized and open label. We will randomly assign first patient into group A that is control group (warfarin group) then next patient to group B (rivaroxaban group) and then next patient into group C (Apixaban group). We will repeat the cycle to achieve the target sample size in each group. Patients will be randomized in group A, B and C in a ratio of 1:1:1, to either control group A (Warfarin group with dose adjusted, target INR 2-3), group B (Rivaroxaban 20mg QD) and group C (Apixaban 5mg BD or 2.5mg BD if having two or more of the following, patients with age ≥80years and/or creatinin≥1.5 and/or body weight ≤60kg). LVT resolution will be assessed by blinded cardiologist via transthoracic echocardiogram at 1, 3 and 6 months' interval after starting on the respective regimen.||||
34037747|NCT05804851|||COHORT||PROSPECTIVE|||||||
34037748|NCT00411983|||COHORT||PROSPECTIVE|||||||
34037749|NCT05715229|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized 2:1 and patients in both arms will begin treatment with nivolumab 360 mg intravenously every 3 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks. At five weeks of treatment, subjects will have ctDNA response evaluation with Guardant360 Response assay. At the next cycle of treatment (+/- 2 days), patients in the arm A will receive treatment based on the Guardant360 Response assay results, as described below. Arm B will continue the immunotherapy only.||||
34037750|NCT04595188|NA|SINGLE_GROUP||OTHER||NONE||||||
34037751|NCT00765505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037752|NCT03275493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037753|NCT03088202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking, the randomization applies to institutions, not patients|||||
34037754|NCT00824200|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Main outcome measure was 7-day bladder diary derived count of nocturia episodes. Assessor was blinded to randomization|Factorial design with no true placebo arm- drug alone versus behavior alone versus drug + behavior|f|f|f|t
34037755|NCT05882019|NA|SINGLE_GROUP||SCREENING||NONE||300 women presenting for screening mammograms and 400 women presenting for diagnostic mammography will undergo the Bexa Breast exam (BBE). Bexa examiners will be blinded regarding each subject's origin (screening vs. diagnostic mammogram). Each woman will receive digital breast tomosynthesis and a BBE exam on the same day. All women with a positive finding on either digital breast tomosynthesis or BBE will have an ultrasound examination of all positive findings. Up to six Bexa Certified examiners will rotate, performing the BBE's on roughly equal proportions of the subjects at a location designated within the Breast Center so as to minimally disrupt patient workflow within the site and also provide minimal inconvenience to the trial participant.||||
34037756|NCT05730933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037757|NCT03786588|||CASE_CONTROL||PROSPECTIVE|||||||
34037758|NCT04249102|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Subjects will be randomized in a 1:1 ratio either in the control group (Flash Glucose Monitoring system) or in the investigational group (Continuous Glucose Monitoring system).~Randomization will be stratified according to the subject impaired hypoglycaemia awareness score (\< 4 vs ≥ 4)"||||
34037759|NCT04242940|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The participants are however blinded to the Ponto 4 setting (OpenSound Navigator ON/OFF in Ponto 4) activated for each list of sentences.|||||
34037760|NCT05606640|||COHORT||PROSPECTIVE|||||||
34037761|NCT00677937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037762|NCT00795899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037763|NCT04039841|NA|SINGLE_GROUP||SCREENING||NONE||Non-interventional Monocentric Prospective Non-intervention Research||||
34037764|NCT02503540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111416|NCT06571539|NA|SINGLE_GROUP||OTHER||NONE||"Prospective clinical pilot study with the goal to assess feasibility, safety and clinical performance of high-accuracy AR-guided EVD placement using a standalone head-worn navigation system in critical care settings at the Universitair Ziekenhuis Brussel over the course of one year.~Consecutive sample (n=11) of adult patients requiring EVD placement, performed with AR guidance; compared to a matched (for quantity, intervention, performing surgeons, and timeframe), non-concurrent freehand control group (n=11, retrospective outcome analysis without active enrollment to receive study treatment)."||||
34111417|NCT01149694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111418|NCT05576649|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34111419|NCT06644807|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111420|NCT04827914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111421|NCT04433182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111422|NCT02699307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807911|NCT01849107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807912|NCT03353636|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||Five period crossover study|t|t|t|t
34111423|NCT03063502|||COHORT||CROSS_SECTIONAL|||||||
34037765|NCT04898283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.~The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.~So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance."|Randomized, double-blind, placebo-controlled, multicentre, parallel-group study|t|t|t|t
34111424|NCT02499926|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33807913|NCT04165018|||COHORT||PROSPECTIVE|||||||
33807914|NCT02798900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33807915|NCT02298556|||CASE_ONLY||PROSPECTIVE|||||||
33807916|NCT03944200|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33807917|NCT00705406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807918|NCT06698380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037766|NCT01514981|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34037767|NCT00354913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111425|NCT03282266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sham operation||t|f|f|f
34111426|NCT04696003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neonatal outcome will be evaluated one year after the delivery by the stuff of the University Center of the Clinical Studies.|randomized multicenter controlled trial; two-arm parallel design.|f|f|f|t
34111427|NCT04219072|||COHORT||CROSS_SECTIONAL|||||||
34111428|NCT06557161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111429|NCT03413800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111430|NCT00297791|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111431|NCT06641011|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Randomization of molar teeth into six groups according to the restoration time, dental restorative material type, and conditions:~Group 1: Restoration one week after silver fluoride application (n=72) Subgroup 1: Resin-based fissure sealant (n=36) Subgroup 2: Glass ionomer-based fissure sealant (n=36) Group 2: Immediate restoration after silver fluoride application (n=144) Subgroup 1: Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant (n=36) Subgroup 2: Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant (n=36) Subgroup 3: Rinsing silver fluoride off and air-drying of fissures followed by resin-based fissure sealant (n=36) Subgroup 4: Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant (n=36)"||||
34111432|NCT02939885|||COHORT||PROSPECTIVE|||||||
34111433|NCT03050333|||CASE_ONLY||PROSPECTIVE|||||||
34111434|NCT03527667|RANDOMIZED|PARALLEL||TREATMENT||NONE||3-arm randomized controlled trial||||
34111435|NCT05507242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111436|NCT06464991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037768|NCT00006186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34037769|NCT03019861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037770|NCT06231329|||CASE_ONLY||PROSPECTIVE|||||||
34037771|NCT00140387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037772|NCT04604756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34037773|NCT03014154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037774|NCT04011722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Devices under investigation in this clinical study include the Portico™ (Navitor) Valve (23mm, 25mm, 27mm and 29mm sizes), Navitor Titan Valve (35 mm), FlexNav™ Delivery System (small and large) and Portico™ NG (Navitor) Loading System(s) (small and large), and Navitor Loading System - LG+, all of which are currently approved for investigational use only.||||
34037775|NCT01293695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037776|NCT01205269|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34037777|NCT00038402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037778|NCT06488586|||CASE_ONLY||PROSPECTIVE|||||||
34037779|NCT04259164|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blind, randomized, two-way cross-over study with two treatment periods.|t|t|t|f
34037780|NCT02116270|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34037781|NCT02154607|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111437|NCT04192708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33807919|NCT01054859|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33807920|NCT01836159|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33807921|NCT04263714|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Aerobic and resistance exercise||||
33807922|NCT04638738|||COHORT||PROSPECTIVE|||||||
33807923|NCT01829646|NA|SINGLE_GROUP||OTHER||NONE||||||
33807924|NCT00964236|||CASE_CONTROL||PROSPECTIVE|||||||
34037782|NCT03939702|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33807925|NCT06621771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental study involving a repeated-measure designed of two groups of participants with stroke, i.e., those receiving piano training sessions and those receiving additional conventional occupational therapy sessions.|f|f|f|t
33807926|NCT05168397|||OTHER||OTHER|||||||
33807927|NCT06211595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807928|NCT03407976|NA|SINGLE_GROUP||TREATMENT||NONE||open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab||||
33807929|NCT05690230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two interventions will be trialed, each in parallel with a control group. The two phases will be done in sequence.||||
34037783|NCT00363207|||CASE_CROSSOVER||PROSPECTIVE|||||||
34037784|NCT02179762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34037785|NCT03971032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037786|NCT02350023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037787|NCT02155127|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037788|NCT06491303|||COHORT||PROSPECTIVE|||||||
34037789|NCT06001216|||CASE_ONLY||OTHER|||||||
34037790|NCT04275011|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Using a computer-generated random selection process, participants will be randomized in a 1:1 allocation ratio in blocks which will be randomly determined. Allocation will be concealed from all but the person performing the randomization, the participants, and the exercise trainers. Although the participants cannot be blinded to the assigned exercise group, they will simply be informed that the purpose of the study is to compare two different exercise programs with no indication regarding the study hypothesis. Research staff blinded to group allocation will have access to the assessment forms. An alternate research staff member will collect or enter data that may cause unblinding (e.g., randomization, exercise adherence logs). Exercise trainers who are unblinded to group allocation will have access to the exercise training manual. Completed outcome assessments and exercise training data will be stored in separate password protected files to avoid exposing group allocation.|This is a single-blinded RCT comparing moderate-high progressive resistance training and impact exercise to an attention control who will be performing static posture and balance exercises.|f|f|t|t
34037791|NCT06191289|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|double-blind|Crossover 2-condition placebo-controlled trial|t|f|t|t
34037792|NCT00357981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037793|NCT00848718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037794|NCT00384618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34111438|NCT05215145|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The clinician administering the Preschool Language Scales will be blind to group assignment.|The investigators are using a multiphase optimization strategy (MOST) as a framework for development, optimization, and evaluation of the feasibility and effects of our dynamic web intervention platform. The investigators will recruit 80 children (parent-child dyads) with communication delays (below the 10th percentile) at 12-18 months of age. Families will be invited to the Social Communication Growth Charts bundled with the Baby Navigator Webinar. At 18-21 months, slow responders (communication delay still below the 10th percentile) will be randomized to continue the bundle or add Mobile Coaching, and responders will continue the bundle.|f|f|f|t
34111439|NCT05750407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111440|NCT02082977|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|Subjects will receive escalating doses of GSK2816126 in Part 1 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D) based on Part 1 of the study.||||
34111441|NCT05005533|||OTHER||PROSPECTIVE|||||||
34111442|NCT00284128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111443|NCT03519880|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|There is no masking.|All trial enrollees will receive the custom-designed 3D printed non-invasive ventilation mask interface.||||
34111444|NCT06047470|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||This study is a mixed methods study comprising of a randomized, crossover interventional trial of Kangaroo Care vs Control and milk expression, study of implementation of scheduled Kangaroo Care in the UC Davis NICU, and qualitative interviews of providers and parents to understand their attitudes and experiences with Kangaroo Care.||||
34111445|NCT06640101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111446|NCT00867139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111447|NCT06373679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037795|NCT00864630|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34037796|NCT01681446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037797|NCT05359354|NA|SINGLE_GROUP||TREATMENT||NONE||The traditional 3+3 design will be used in dose escalation.||||
34037798|NCT05399472|||COHORT||CROSS_SECTIONAL|||||||
34111448|NCT06167148|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34111449|NCT04847882|||COHORT||CROSS_SECTIONAL|||||||
34111450|NCT04124757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34111451|NCT04003038|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111452|NCT06154590|||CASE_CONTROL||PROSPECTIVE|||||||
34111453|NCT04434755|||OTHER||CROSS_SECTIONAL|||||||
34111454|NCT04947189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111455|NCT03064607|||COHORT||PROSPECTIVE|||||||
33807930|NCT06324344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double|"Participants who satisfy the inclusion and exclusion criteria and sign the informed consent form will be randomly assigned into two groups in a 1:1 ratio. One group will utilize high-dose TENS therapy (Intervention group, AG); the other group will utilize low-dose TENS devices (Placebo group, PG).~Both groups will receive their respective devices at the initial visit (Baseline) and will be asked to return in 4 weeks and 8 weeks for follow-up assessment.~Throughout this 8-week period the participants may receive follow-up phone calls assessing their compliance. All subjects will keep their active device after completion of the 8-week study."|t|t|f|f
33807931|NCT06356532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes Assessor is blinded to the group assignments of the patients. She is tasked with collecting the measured outcomes from the patients. Data collection will be conducted by co-principal investigator of the research team. She will distribute the questionnaires at enrollment, and on the 7th and 14th days post-operation. Once notified by the researchers, data collector will distribute and collect the questionnaires. Upon completion, the questionnaires will be sealed in envelopes by the data collectors.|"The participants in the control group received the routine care including communication and companionship provided by the nurses of the intensive care unit.~The participants in the intervention group received the intensive care unit diary writing and reading. Participants are required to write at least one sentence daily. The primary writers will be the patients themselves, and in cases where patients are unable to write, their family members will write on their behalf. After completion, the diary will be handed over to the patients to review its contents for at least 10 minutes before bedtime, allowing them to write down their immediate reflections and thoughts on when they read. This process will continue until the 14th day post-operation."|f|f|f|t
33807932|NCT00054938|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33807933|NCT00942344|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33807934|NCT01351376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807935|NCT01475266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807936|NCT03124472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33807937|NCT02525822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33807938|NCT05377918|RANDOMIZED|PARALLEL||SCREENING||NONE||"There will be three groups in the study. Spiritual Diary Group will be asked to keep a spiritual diary What Did You Feel Today? The children in Diary Gruop will be asked to keep a diary of What did You do today? 3 days a week for 4 weeks, and Control Group will be the control group."||||
33807939|NCT03087318|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|open, proof of concept study in overweight or moderate obese OSA patients,|"Prospective, open, proof of concept study in overweight or moderate obese OSA patients, comparing 3 different programs of sport prescription: patient's referred to a rehabilitation medical center, to a private sport club or to a sport association."||||
33807940|NCT01588093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33807941|NCT02089295|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33807942|NCT02231736|||COHORT||CROSS_SECTIONAL|||||||
33807943|NCT06681350|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33807944|NCT04256148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Participants randomized in 1:1:1:1 ratio to 1 of 4 study arms.|t|t|t|f
33807945|NCT04164446|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33807946|NCT06150417|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II non-blinded randomized study evaluating men with de novo oligometastatic prostate cancer randomized (1:1) to standard of care (SOC) versus SOC plus MDRT.||||
33807947|NCT02683174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807948|NCT00955162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807949|NCT02117310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33807950|NCT00692913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807951|NCT03884842|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34037799|NCT05581277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will know the baseline condition they have been assigned to: 6, 8 or 10 evaluation days before the intervention.|In the present investigation, all consecutive patients presenting post covid-19 condition and symptoms of anxiety or depression are requested to participate. Once inclusion criteria are accomplished, each patient will be randomly assigned to one of the multiple baseline groups: 6, 8 or 10 days of assessment before the intervention. The study includes seven assessment points (baseline, pre-treatment, post-treatment and four follow-ups, at one, three, six and twelve months after completion of treatment).|t|f|f|f
34037800|NCT04848155|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34037801|NCT03898453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two groups assignment - One group will receive EMDR psychotherapy the other one support psychotherapy.||||
34037802|NCT02170220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111456|NCT00581100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037803|NCT01582776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037804|NCT00180882|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037805|NCT04771572|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study will start at lower doses (20 mg) and adopt an accelerated titration design for these cohorts. Once the safety of the 20 mg dose level is established, we will continue dose escalation using a classic 3+3 design to establish DLT, MTD, and RP2D, starting also with an accelerated step-up dosing schedule."||||
34037806|NCT02129231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037807|NCT04798625|||COHORT||PROSPECTIVE|||||||
34037808|NCT01185678|||COHORT||PROSPECTIVE|||||||
34111457|NCT05581225|||COHORT||PROSPECTIVE|||||||
34111458|NCT04039464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34111459|NCT02221726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111460|NCT06332157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111461|NCT03463655|||COHORT||PROSPECTIVE|||||||
34111462|NCT03896763|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Two-by-two factorial, response-adaptive, randomized controlled clinical trial||||
34111463|NCT03132142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33807952|NCT01596413|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807953|NCT02593760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807954|NCT01856569|||COHORT||OTHER|||||||
33807955|NCT01683409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807956|NCT04149132|||COHORT||PROSPECTIVE|||||||
33807957|NCT02701296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33807958|NCT04129099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807959|NCT06051799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The selection of participants and the randomisation sequence will be carried out by the principal investigator using the patient's unique identity number in the centre's programme as a code. After randomisation, participants will be sent by another therapist in the centre to each intervention room without knowing which treatment they will receive. The therapists in charge of delivering the interventions will not know which patient has been assigned to them.~Although both therapists and patients will not know which group they are assigned to, obviously the therapist, given the nature of the intervention and the need to know and master the technique, knows which treatment to apply to each subject."|"Randomised, controlled, clinical trial with blinded assessment of response variables. The guidelines of the CONSORT guide will be followed.~A follow-up of the participants will be carried out, where measurements will be taken prior to the intervention (baseline), after the protocol of four treatment sessions and fifteen days after the last session."|t|f|f|t
33807960|NCT02667366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807961|NCT05725694|||COHORT||RETROSPECTIVE|||||||
34037809|NCT00695461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34037810|NCT05831878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037811|NCT03558802|||COHORT||PROSPECTIVE|||||||
34037812|NCT04117360|||COHORT||PROSPECTIVE|||||||
34037813|NCT01566188|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34037814|NCT02347982|||COHORT||CROSS_SECTIONAL|||||||
33807962|NCT03998098|||COHORT||PROSPECTIVE|||||||
33807963|NCT02203032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725186|NCT02088983|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34037815|NCT03563430|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||neuromuscular electrical stimulation, low intensity aerobic exercise, self massage with foam roller methods|t|f|t|t
34037816|NCT01567462|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34037817|NCT03458117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037818|NCT02837731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037819|NCT03973736|||COHORT||RETROSPECTIVE|||||||
34037820|NCT02284581|||COHORT||OTHER|||||||
34037821|NCT02620293|NA|SINGLE_GROUP||||NONE||||||
34037822|NCT03238560|||OTHER||PROSPECTIVE|||||||
34037823|NCT06469229|||COHORT||PROSPECTIVE|||||||
34037824|NCT06283381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037825|NCT01971528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037826|NCT03469700|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34037827|NCT03327701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be conducted under double-blind conditions. Neither the subject nor the investigator and clinical site personnel will know which medication is administered. The medication given will be determined according to a randomization table handled by a collaborating IUCPQ-UL pharmacist. Only the pharmacist responsible for preparing the medication for the randomized patients will have access to information on treatment allocations (unblended). Benralizumab and placebo solutions for injection in an accessorized pre-filled syringe (PFS) will have the same packaging.|This study is a parallel study, double-blind, placebo controlled randomized trial, with a ratio placebo-active drug 1:2.|t|t|t|f
34037828|NCT03525405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037829|NCT00395629|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037830|NCT02321657|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34037831|NCT00496717|||COHORT||PROSPECTIVE|||||||
34037832|NCT06578039|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34037833|NCT05827003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not know which participant received which intervention.|There will be an equal number of participants in the three groups randomized by the computer.|f|f|t|f
34037834|NCT01862978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037835|NCT05017792|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||"5 blood samples will be taken: Each one is 5 cm as following~1- Before vaccination:~To detect:~* COVID-19 IgG/IgM Rapid Test~* COVID-19 IgG/IgM by quantitative method(ELISA).~* D-dimer~* COVID-19 IgM detection~* COVID-19 IgG detection D-dimer Measuring D-dimer 3-Before the second dose: To detect IgG and IgM To detect the level of Covid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.~  4-After 3 months from the second dose: To detect the level ofCovid-19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine.~  5-After 6 months from the second dose: To detect the level ofCovid 19 Ig G antibodies titer in the blood, Quantitative Ig G titer should be measured. To detect the response of the immune system to the vaccine."||||
34037836|NCT02757053|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34037837|NCT00038181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037838|NCT03743051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This was a double-blind study. The blinding of the study drugs was guaranteed by the use of anamorelin HCl film-coated tablets and matching placebo tablets. Patients were randomized using the Interactive Web Response System (IWRS). Any unblinding of the study treatment was performed using the IWRS.|Randomized, Double-Blind, Placebo-Controlled, Multicenter Study|t|t|t|t
34037839|NCT04521062|NA|SINGLE_GROUP||OTHER||NONE||||||
34037840|NCT01628432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037841|NCT02452944|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34037842|NCT05691127|||CASE_CONTROL||PROSPECTIVE|||||||
34037843|NCT01890122|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34037844|NCT02253511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037845|NCT04444011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725187|NCT05151263|||COHORT||PROSPECTIVE|||||||
33725188|NCT06429501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study team members and the participants will be blinded to the assignment of participants in the study groups. Only the pharmacist will prepare the study syringes and the unblinded statistician will have access to the study group assignments.|Double-blinded, placebo-controlled randomized clinical trial|t|t|t|t
33725189|NCT00102700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725190|NCT06271733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725191|NCT02021747|||COHORT||PROSPECTIVE|||||||
33725192|NCT02110576|||COHORT||PROSPECTIVE|||||||
33807964|NCT02031809|||COHORT||RETROSPECTIVE|||||||
33807965|NCT05001659|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33807966|NCT05062343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physician performing the cervical exams will be blinded to the patient's study arm|Randomized Controlled Trial|f|t|f|f
33807967|NCT06509386|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33807968|NCT05969600|||COHORT||RETROSPECTIVE|||||||
33807969|NCT06387810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807970|NCT05249153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33807971|NCT01190852|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33807972|NCT05483088|||COHORT||PROSPECTIVE|||||||
33725193|NCT04166838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037846|NCT03525561|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-blind use of acetazolamide where participant is not informed. Goal is to evaluate effect (or lack thereof) on exercise performance.|Subjects will serve as their own controls. Will exercise during simulated altitude exposure twice, once with acetazolamide and once with placebo.|t|f|f|f
34037847|NCT02394600|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34037848|NCT03806114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34037849|NCT00350207||PARALLEL||TREATMENT||||||||
34037850|NCT02045264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037851|NCT06067256|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34037852|NCT00093912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037853|NCT04321629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037854|NCT01616836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037855|NCT05277883|||COHORT||PROSPECTIVE|||||||
34037856|NCT03915301|||COHORT||PROSPECTIVE|||||||
34037857|NCT06504134|||COHORT||PROSPECTIVE|||||||
34037858|NCT05481853|||COHORT||RETROSPECTIVE|||||||
34037859|NCT06578702|||CASE_ONLY||RETROSPECTIVE|||||||
34037860|NCT04755114|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|t|f|f|f
34037861|NCT02763930|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34037862|NCT03382236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037863|NCT02137252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34037864|NCT01860365|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34037865|NCT00195143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037866|NCT01922037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037867|NCT04801303|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluate the effects of Calcitriol 0.25mcg/24h administered during a year in the neurological symptoms of patients with Friedreich's Ataxia||||
34037868|NCT06013007|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will be implanted with DES by Joint Inflation with Nominal-pressure and Stability (JINS) approach, which is described as inflating a stent balloon with nominal-pressure without decay for at least 30 seconds.||||
34037869|NCT00225615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037870|NCT05972902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037871|NCT00582101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037872|NCT02729259|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34037873|NCT01156779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037874|NCT01212237|||CASE_CONTROL||PROSPECTIVE|||||||
34037875|NCT06354868|||COHORT||PROSPECTIVE|||||||
34037876|NCT02418949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037877|NCT04197466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037878|NCT01217112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037879|NCT05922566|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34037880|NCT01282684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34037881|NCT02544438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037882|NCT04527133|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A non-comparative study of the efficacy and safety||||
34037883|NCT01494675||PARALLEL||||TRIPLE|||t|t|t|f
34037884|NCT01875523|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037885|NCT00299325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34037886|NCT05273528|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34037887|NCT00615550|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34037888|NCT03655405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037889|NCT00400374|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34037890|NCT06031740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037891|NCT02505217|||COHORT||PROSPECTIVE|||||||
34037892|NCT03620708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual conducting the outcomes assessment is blind to study condition.|Randomized clinical trial in which participants are randomized to one of three groups.|f|f|f|t
34037893|NCT03253900|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The investigator who processed the acquired data was blinded for rowing interventions and subject information.|All participants in the study will complete the measurements for all the three rowing interventions; in a random order.||||
34037894|NCT03877068|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34037895|NCT02828579|||COHORT||PROSPECTIVE|||||||
34037896|NCT00654095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037897|NCT02989220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34037898|NCT00316732|||||PROSPECTIVE|||||||
34037899|NCT05454319|NA|SINGLE_GROUP||OTHER||NONE||||||
34037900|NCT02841761|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34037901|NCT03948516|||COHORT||PROSPECTIVE|||||||
34037902|NCT04900428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725194|NCT00918515|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725195|NCT04216927|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE||• This pilot study is a single center, double-blind, randomized controlled trial.|t|t|t|f
33725196|NCT01706003|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33725197|NCT02459028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725198|NCT00934960|||CASE_ONLY||RETROSPECTIVE|||||||
33725199|NCT05165615|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037903|NCT02549781|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34037904|NCT05031312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective comparative simple randomized study of 30 cases of superior oblique palsy divided in to two groups (A) and (B) Group A will include 15 cases who will undergo inferior oblique anterior and nasal transposition and group B will include 15 cases who will undergo inferior oblique myectomy .|t|f|f|f
34037905|NCT00317616|||COHORT||PROSPECTIVE|||||||
34037906|NCT04227431|||COHORT||RETROSPECTIVE|||||||
34037907|NCT01965743|NA|SINGLE_GROUP||||NONE||||||
34037908|NCT00512681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037909|NCT05103930|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34037910|NCT00333827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037911|NCT00009204|RANDOMIZED|||TREATMENT||DOUBLE||||||
34037912|NCT01593670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037913|NCT03023215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34037914|NCT01408290|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34037915|NCT06139900|||OTHER||CROSS_SECTIONAL|||||||
34037916|NCT01194232|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037917|NCT03268083|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34037918|NCT04993716|||COHORT||PROSPECTIVE|||||||
34037919|NCT05488743|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34037920|NCT02629939|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34037921|NCT04302415|||CASE_CONTROL||PROSPECTIVE|||||||
34037922|NCT02591277|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34037923|NCT03696212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037924|NCT01051310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037925|NCT05653830|||COHORT||RETROSPECTIVE|||||||
34037926|NCT05684874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34037927|NCT05756595|NA|SINGLE_GROUP||TREATMENT||NONE|A self-controlled an open label clinical study(An investigator-initiated off-label use clinical study)|A self-controlled an open label clinical study(An investigator-initiated off-label use clinical study)||||
34037928|NCT06209190|NA|SINGLE_GROUP||TREATMENT||NONE||"Our study will enroll 14 patients in an estimated period of 2 years, with non-probabilistic sampling based on consecutive cases from January 2022 to January 2024 based on prior local transplant data. The study will be done according with the Declaration of Helsinki, and with Good Clinical Practice guidelines and the protocol will be approved by local Institutional Review Board after external review and will be locally funded.~Descriptive statistics will be used to report the baseline variables of the patients. Groups will be compared with hypothesis tests through deductive statistics using Student's t test or Mann Whitney U test accordingly, to determine significant differences between two groups and their means; and the Chi square test as a verification test and comparison of hypotheses of categorical data, in addition, survival analysis will be carried out by the Kaplan-Meier method and competing risk analysis as appropriate."||||
34037929|NCT02371538|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037930|NCT02680704|NA|SINGLE_GROUP||OTHER||NONE||||||
34037931|NCT05669404|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Due to the nature of this study, which was a dietary intervention evaluating the effect of certain dietary strategies on blood pressure levels and cardiometabolic risk factors, masking of the trial participants and the clinical dietician (sub-investigator), who provided the dietary education and was solely responsible for the assignment of patients to the study groups was not possible. However, patients were completely unaware of the other groups of the study and were treated according to strict criteria, preventing deviations from the intended intervention. Moreover, the principal investigator, care providers, and all members of the medical team, who conducted the office and the ambulatory BP measurements (outcomes assessors) were blinded to patients' allocations.|Enrolled patients were blindly randomized with a 1:1:1:1 allocation to one of the four study groups, i.e., control group (CG), salt restriction group (SRG), DASH diet combined with salt restriction group (DDG), or MedDiet combined with salt restriction group (MDG).|f|t|t|t
34037932|NCT01418378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34037933|NCT03798015|||COHORT||RETROSPECTIVE|||||||
34037934|NCT05118919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037935|NCT00147875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037936|NCT01945814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037937|NCT06415929|||CASE_ONLY||RETROSPECTIVE|||||||
34037938|NCT01553552|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34037939|NCT05182853|||CASE_CONTROL||RETROSPECTIVE|||||||
34037940|NCT03277443|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||SM and VSM|t|f|t|f
34037941|NCT06188715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The trial will be double blinded (i.e. study participants and the trial team/researchers conducting the treatment and assessing the outcomes will be blinded) using appearance-matching placebos.||t|t|t|t
34037942|NCT03688724|||COHORT||PROSPECTIVE|||||||
34037943|NCT00795093|||COHORT|||||||||
34037944|NCT05477264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037945|NCT03711188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807973|NCT03627637|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Participants will receive, in random order, daily 70 g of soy nuts (soy treatment) or no food products (control treatment) for sixteen weeks, separated by a wash-out period of at least 8 weeks.|f|f|t|t
33807974|NCT05328466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807975|NCT03577106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807976|NCT06075082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33807977|NCT06318559|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients will be randomized using an Excel® macro in 2 group: 3D and no3D, stratifying them by age, PSA, cT, PSA density, prostate volume, lesion volume, extracapsular extension (ECE), seminal vesicle invasion (SVI), biopsy ISUP.||||
33807978|NCT05075499|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33807979|NCT05462067|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807980|NCT00948168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33807981|NCT01550952|||COHORT||PROSPECTIVE|||||||
34037946|NCT04056260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037947|NCT05709418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34037948|NCT05786560|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037949|NCT00869102|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34037950|NCT04350892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort||||
34037951|NCT01976962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111464|NCT06122948|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The drug will be prepared by an anesthesia nurse who will not be involved in the study. The active drug will be administered by a fully trained anesthesiologist and Clear definitions of the respiratory adverse events will be provided to the involved anesthetist. All researchers directly involved in the study will be blinded to the drug which will be administered|Children will be randomly assigned to 2 groups: the midazolam group will receive intranasal midazolam (0.1 mg/kg), and the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg) for premedication|t|t|t|t
34111465|NCT06608589|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"This study employs a mixed-methods, multilevel, quasi-experimental design with a pre-post evaluation to assess the impact of the CoMPAS+ MNCD Program intervention.~Micro level: Quantitative and qualitative assessment of the impact of the CoMPAS+ MNCD Program on the patient reported experience in care transitions.~Meso level (behaviour): Quantitative assessment of the intention of participating health care professionals to apply best practices in care transitions of patients living with a MNCD.~Meso level (organisational): Quantitative and qualitative assessment of the implementation process, sustainability factors and scaling potential of the Program.~Macro level: Comparison of administrative performance indicators between the arms and the control population (non participating LSNs in the greater Chaudière-Appalaches region and other socio-sanitary regions in the province of Quebec)"||||
34037952|NCT00821561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34037953|NCT02094352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34037954|NCT03981835|||COHORT||PROSPECTIVE|||||||
34037955|NCT06031090|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|triple blinded||t|t|f|t
34037956|NCT06129448|||CASE_CONTROL||PROSPECTIVE|||||||
34037957|NCT01017536|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34037958|NCT05383430|||COHORT||CROSS_SECTIONAL|||||||
34037959|NCT02920762|||COHORT||RETROSPECTIVE|||||||
34037960|NCT01350362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34037961|NCT06578299|NA|SINGLE_GROUP||TREATMENT||NONE||"Inetetamab and Paclitaxel ± Pertuzumab Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously on the first day of every three weeks, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination."||||
34037962|NCT03993847|||COHORT||PROSPECTIVE|||||||
34037963|NCT01861223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111466|NCT03204812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111467|NCT01150032|||COHORT||PROSPECTIVE|||||||
34037964|NCT04556682|||COHORT||RETROSPECTIVE|||||||
34037965|NCT04798833|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111468|NCT06565247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111469|NCT05166902|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34111470|NCT00973128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33807982|NCT01201772|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33807983|NCT02903875|||COHORT||PROSPECTIVE|||||||
33807984|NCT05820763|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will initially receive 4 cycles of consolidation triplet therapy followed by 8 cycles of maintenance doublet therapy.||||
33807985|NCT06412094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled study||||
33807986|NCT01673594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33807987|NCT00188305|RANDOMIZED|PARALLEL||||NONE||||||
33807988|NCT06046196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807989|NCT00065182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33807990|NCT06640855|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33807991|NCT04050956|||COHORT||PROSPECTIVE|||||||
33807992|NCT01353274|||CASE_ONLY||PROSPECTIVE|||||||
33807993|NCT01987518|||COHORT||RETROSPECTIVE|||||||
34037966|NCT03601013|||COHORT||PROSPECTIVE|||||||
33807994|NCT00804219|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33807995|NCT02804256|||CASE_ONLY||PROSPECTIVE|||||||
33807996|NCT04909619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33807997|NCT05815628|||COHORT||PROSPECTIVE|||||||
33807998|NCT01389921|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33807999|NCT03805672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037967|NCT06521996|NA|SINGLE_GROUP||TREATMENT||NONE||"Induction Phase:~Cycles 1-2: Step-up Phase: Weekly step-up dosing of mosunetuzumab IV (4-hour infusions) in 21-day cycles. Doses: 1/2/30 mg on C1D8/C1D15/C2D1, with C2D1 and subsequent doses fixed at 30 mg. Safety monitored by an Independent Medical Committee (IMC). First five patients at each dose hospitalized for 48 hours.~Cycles 3-6: Fixed Dose Phase: Mosunetuzumab (30 mg) combined with CHOP (M-CHOP) every 21 days. Disease evaluated by PET/CT after cycles 3 and 6. Patients with PD are withdrawn.~Maintenance Phase:~Cycles 7-17: Mosunetuzumab monotherapy starts 3 weeks (+2 weeks) after EoI. Administered over eleven 21-day cycles (approx. 10 months) for patients with stable disease (SD), partial response (PR), or complete response (CR) not eligible for cellular therapy until disease progression or unacceptable toxicity.~Final Evaluation:~Post-Treatment: Tumor response by PET/CT 8-12 weeks after last dose at Cycle 17 or early discontinuation to confirm disease progression."||||
33808000|NCT05804825|RANDOMIZED|PARALLEL||OTHER||NONE||randomized discrete choice modeling experiment design||||
34037968|NCT02481089|||COHORT||PROSPECTIVE|||||||
34037969|NCT04722432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037970|NCT03710135|||CASE_ONLY||PROSPECTIVE|||||||
34037971|NCT03490110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||training in brain state regulation compared to treatment-as-usual|f|f|t|t
34037972|NCT01402570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037973|NCT01465412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037974|NCT02223546|||OTHER||PROSPECTIVE|||||||
34037975|NCT00025025|||CASE_ONLY||PROSPECTIVE|||||||
34037976|NCT02332629|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34037977|NCT03011827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34037978|NCT01962103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037979|NCT00471679|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34037980|NCT01780519|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34037981|NCT03517163|||CASE_ONLY||PROSPECTIVE|||||||
34037982|NCT02647710|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34037983|NCT01221519|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34037984|NCT00533481|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34037985|NCT05322772|||CASE_ONLY||CROSS_SECTIONAL|||||||
34037986|NCT02198170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34037987|NCT04323163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34037988|NCT03822091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037989|NCT02731430|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34037990|NCT03427294|||COHORT||PROSPECTIVE|||||||
34037991|NCT04534530|||COHORT||RETROSPECTIVE|||||||
34037992|NCT04398004|NA|SINGLE_GROUP||PREVENTION||NONE||Treatment with clarithromycin||||
34037993|NCT06080269|RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding was done hence its a open label study|Intervention and control group||||
34037994|NCT03915925|||COHORT||PROSPECTIVE|||||||
34037995|NCT00435669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34037996|NCT02571478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34037997|NCT03760692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, multicenter, randomized|f|f|t|t
34037998|NCT03943043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111471|NCT06564714|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Both investigators and trial participants will be fully aware of which treatment group the participants are in and what treatments are assigned to them.~Participants will be randomized into the early baclofen treatment or control group using computer-generated random treatment assignment."|55 recruited participants will be randomized into the early baclofen treatment group or the control group.||||
34037999|NCT01134939|||COHORT|||||||||
34111472|NCT06511401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111473|NCT03308357|||COHORT||PROSPECTIVE|||||||
34111474|NCT03741270|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111475|NCT05276856|||COHORT||PROSPECTIVE|||||||
34111476|NCT04102566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111477|NCT06625437|NA|SINGLE_GROUP||TREATMENT||NONE||Small-n design with single group of participants who will each receive the treatment||||
34111478|NCT05229744|||COHORT||PROSPECTIVE|||||||
34111479|NCT06641713|||COHORT||RETROSPECTIVE|||||||
34111480|NCT00509288|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038000|NCT04980807|||CASE_CONTROL||PROSPECTIVE|||||||
33808001|NCT04288167|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The laboratories will analyze the samples blinded, without knowing whether the sample was from an injured patient or a healthy control.||f|f|f|t
33808002|NCT04688684|NA|SINGLE_GROUP||PREVENTION||NONE||Stepped wedge cluster randomized trial||||
33808003|NCT00898521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038001|NCT05236335|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34038002|NCT03974867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111481|NCT06565286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Inlay inner preputial graft versus Transverse preputial island flap in management of proximal penile hypospadias|t|t|f|f
34111482|NCT03924895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111483|NCT04345614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo||t|t|t|t
34111484|NCT01401673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111485|NCT05280054|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||AV-101 alone followed by AV-101 + Probenecid||||
34111486|NCT02040909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111487|NCT06455033|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111488|NCT04961593|||CASE_ONLY||PROSPECTIVE|||||||
34111489|NCT05537376|RANDOMIZED|PARALLEL||TREATMENT||NONE||Veterans receiving SUPPORT will be offered all modules of the intervention via weekly, 50-minute sessions with a Peer Specialist. Following the completion of a mental health evaluation by a licensed professional, the Peer Specialist leads the Veteran who is at risk for suicide through recovery planning that is tailored to the Veteran's suicidal experiences with cognitive learning strategies to enhance recall of the Veteran's safety plan and improve recovery.||||
34111490|NCT01441492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111491|NCT03514576|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111492|NCT06034340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111493|NCT05558579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111494|NCT06633393|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34111495|NCT06641635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038003|NCT00000292||||TREATMENT||DOUBLE||||||
34038004|NCT04537078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038005|NCT00515970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038006|NCT06475547|||COHORT||PROSPECTIVE|||||||
34038007|NCT00101270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038008|NCT04223336|RANDOMIZED|PARALLEL||PREVENTION||NONE||Individuals enrolling into the STOP program at a primary care organization (Family Health Team, Community Health Centre, or Nurse Practitioner-led Clinic) will be randomly allocated in a 1:1 allocation ratio to control or intervention group.||||
33808004|NCT06698445|RANDOMIZED|PARALLEL||OTHER||NONE||Patients who meet the sample selection criteria will be randomly and equally distributed into 2 groups (1st experimental group, 2nd control group) using a computer program according to gender, age and whether or not KIA has been applied for the first time, thus providing simple stratified randomization.||||
33808005|NCT04252157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808006|NCT02340013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33808007|NCT03276585|||COHORT||CROSS_SECTIONAL|||||||
34038009|NCT05311683|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34111496|NCT01353729|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34111497|NCT00004128|RANDOMIZED|||TREATMENT||||||||
34111498|NCT06327425|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34111499|NCT00835055|||CASE_ONLY||PROSPECTIVE|||||||
33808008|NCT01320800|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34038010|NCT04409145|NA|SINGLE_GROUP||TREATMENT||NONE|Part 1: Open label Part 2: Double blind|Part 1: Open-label, 4-sequence, escalating repeat-application cohort study, with intra-subject and inter-cohort dose escalation to determine safety and tolerability, and maximum feasible dose/maximum tolerable dose Part 2: Randomized, placebo-controlled, double-blind, safety and exploratory efficacy study||||
34038011|NCT04760977|||COHORT||PROSPECTIVE|||||||
34038012|NCT03016507|||||CROSS_SECTIONAL|||||||
34038013|NCT01115244|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038014|NCT04886843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
34038015|NCT04988269|||CASE_CONTROL||PROSPECTIVE|||||||
34038016|NCT02165163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038017|NCT01900769|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038018|NCT04503148|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A prospective randomized controlled study|t|f|f|t
34038019|NCT03857646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038020|NCT00489957|||CASE_CONTROL||PROSPECTIVE|||||||
34038021|NCT05435027|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038022|NCT01699009|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34038023|NCT02705794|||CASE_CROSSOVER||PROSPECTIVE|||||||
34038024|NCT04781803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038025|NCT05143060|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34038026|NCT05522192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038027|NCT05794100|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|"Products have been produced with different shapes and with very close texture, colors and taste. They are packaged in individual portion bags labeled Product 1 to Product 10."|Each subject will be allocated to a sequence of consumption of the 10 different products|t|f|t|t
34038028|NCT05990374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038029|NCT06478121|||CASE_CONTROL||PROSPECTIVE|||||||
34038030|NCT03778346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038031|NCT01164020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34038032|NCT03447587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized to two groups in 1:1 ratio.|t|f|f|t
34038033|NCT01329380|||COHORT||PROSPECTIVE|||||||
34038034|NCT02905240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038035|NCT06301542|||COHORT||PROSPECTIVE|||||||
34111500|NCT01532739|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111501|NCT03601026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible participants who are randomized to not be offered the intervention will not be aware of the presence of a potential intervention. Study staff who are assessing outcomes (i.e., psychopathology, cannabis use) will not know who did and did not receive the intervention.|Trial-within-cohort|f|f|f|t
34111502|NCT05206929|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 randomization||||
34111503|NCT01580787|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111504|NCT03247101|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34111505|NCT04210960|||CASE_CONTROL||RETROSPECTIVE|||||||
34111506|NCT05328648|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34111507|NCT04846998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111508|NCT03622606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111509|NCT05633927|||COHORT||PROSPECTIVE|||||||
34111510|NCT05145010|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111511|NCT06402487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111512|NCT06477601|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and investigators will be blind during randomization. Participants will be randomly assigned to their arm, but once assigned, participants and investigators will know which product they have been assigned to.|Participants will be 20 adult current menthol smokers. Participants will be randomized to continued menthol smoking (n = 4), WS-3 synthetic cooling agent cigarette smoking (n = 8), or traditional non-menthol cigarette smoking (n = 8).||||
33808009|NCT00178204|||||PROSPECTIVE|||||||
33808010|NCT03750682|RANDOMIZED|SINGLE_GROUP||OTHER||NONE|No one is blinded during this study.|The ENGAGE for Brain Health is designed as a single blind, randomized-controlled, parallel group pilot study. This study plans to enroll up to 40 participants to be randomized into the PA or HE intervention group.||||
33808011|NCT03324724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808012|NCT02276599|||CASE_ONLY||PROSPECTIVE|||||||
33808013|NCT02163200|||CASE_CROSSOVER||PROSPECTIVE|||||||
33808014|NCT00838461|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33808015|NCT05913791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34038036|NCT06436976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038037|NCT02593695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038038|NCT02166515|||CASE_CONTROL||PROSPECTIVE|||||||
34111513|NCT01771497|||CASE_ONLY||PROSPECTIVE|||||||
34111514|NCT06640738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34111515|NCT05044897|NA|SEQUENTIAL||TREATMENT||NONE||||||
34111516|NCT06572293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111517|NCT03589833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111518|NCT06239558|||OTHER||CROSS_SECTIONAL|||||||
34111519|NCT06070376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038039|NCT03816020|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All participants and investigators will be masked.|After initial assessment at baseline, the participants will be randomly assigned (1:1) to one of two study groups (n = 15 per group): NR 500 mg x 2/day, or placebo. Participants and investigators will be masked to treatment group.|t|t|t|f
34111520|NCT03699865|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Participants will be informed that they will be supplied cigarettes with low nicotine content but will be blinded to exact nicotine content and unaware that within-subject, all packages will contain the same type of low nicotine cigarette|Randomized, single-blind, 2 x 4 mixed factorial design laboratory-based study manipulating: (1) cigarette pack color (4-level within-subjects factor: own brand vs. white vs. purple vs. black color), and (2) nicotine content (2-level between-subjects factor: moderate vs. very low nicotine content). All participants will provide and smoke their preferred brand for an initial 5-day baseline period, receiver their own brand free-of-charge for 5-days, and then will be randomly assigned to smoke either intermediate or very low LNC cigarettes for the study duration. We will supply participants with LNC cigarettes in three pack colors; each color will be used for a 10-day period, in counter-balanced order.|t|f|f|f
34111521|NCT03286699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111522|NCT03073577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111523|NCT04602845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34111524|NCT00141011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111525|NCT04282915|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|There are two types of study participants: primary care providers and primary care patients. Based on the municipality of randomization, primary care providers will either participate in RESHAPE training or implementation as usual training. Patients will not be randomized because the health facilities they attend are already assigned to either having the primary care providers trained through RESHAPE or implementation as usual. The providers and patients will be masked to the implementation, i.e., they will not be given information on the differences in the two different implementation strategies. Research assistants and research psychiatrists who conduct the assessments will be masked to whether the provider or patients are in the RESHAPE or implementation-as-usual arms.|This is a cluster randomized controlled trial with municipalities being the unit of randomization. 24 municipalities will be randomized to either RESHAPE or implementation as usual. Three health facilities in each municipality will participate in the study. All primary care providers with prescribing rights will be trained based on their municipality randomization arm.|t|t|f|t
34111526|NCT04183686|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||Single-center, double-blind, randomized, placebo-controlled Phase 1 study|t|t|t|t
34111527|NCT05295472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34111528|NCT05951101|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Implantation of Zenith LAA Occlusion System||||
34111529|NCT06271915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111530|NCT01322152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111531|NCT01498809|||CASE_ONLY||PROSPECTIVE|||||||
34111532|NCT01969929|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34111533|NCT01076699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111534|NCT04512690|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, non-randomized, open-label, descriptive, experimental||||
34111535|NCT00894881|||COHORT||PROSPECTIVE|||||||
34111536|NCT02330003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111537|NCT05193708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111538|NCT00633685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111539|NCT02946697|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111540|NCT02464748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111541|NCT03163771|||COHORT||PROSPECTIVE|||||||
34111542|NCT05266495|||COHORT||OTHER|||||||
34111543|NCT04261985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A research assistant not working on any other aspect of the study, and therefore having no knowledge of whether participants are in the control or intervention group, will measure child and caregiver height and weight. A 2nd research assistant, who is not blinded to participants, will be responsible for making appointments with participants for height and weight measures.|a prospective control group design|f|f|f|t
34111544|NCT05366751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111545|NCT06411938|NA|SINGLE_GROUP||PREVENTION||NONE||Community-based, non-randomized||||
34111546|NCT03815552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111547|NCT04824911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111548|NCT04227002|||COHORT||PROSPECTIVE|||||||
33725200|NCT04330742|||COHORT||PROSPECTIVE|||||||
33725201|NCT01301495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038040|NCT04608318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725202|NCT03483675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725203|NCT02649660|||COHORT||CROSS_SECTIONAL|||||||
33725204|NCT04264910|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34038041|NCT02017210|||COHORT||CROSS_SECTIONAL|||||||
34038042|NCT01962610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34038043|NCT02915718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038044|NCT03453775|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled, open trial||||
34038045|NCT00546533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038046|NCT03990467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038047|NCT04127279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038048|NCT00104780||||TREATMENT||NONE||||||
33725205|NCT05261867|||COHORT||RETROSPECTIVE|||||||
33725206|NCT05667922|||COHORT||PROSPECTIVE|||||||
33725207|NCT02646033|||COHORT||PROSPECTIVE|||||||
33725208|NCT03733288|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33725209|NCT06092099|NA|SINGLE_GROUP||OTHER||NONE||All subjects in the study will use the device||||
33725210|NCT04782856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038049|NCT01123811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038050|NCT00793871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808016|NCT01822756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808017|NCT00294736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808018|NCT03298490|||CASE_ONLY||PROSPECTIVE|||||||
34038051|NCT00949637|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038052|NCT00571142|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038053|NCT03313180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038054|NCT06084325|||CASE_CONTROL||PROSPECTIVE|||||||
34038055|NCT03751033|NA|SINGLE_GROUP||OTHER||NONE||||||
34038056|NCT03767153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Blinded assessment of photographs taken at baseline and 6, 12 weeks post final treatment by independent evaluators.||f|f|f|t
34038057|NCT04944043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038058|NCT00722137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038059|NCT00000122|RANDOMIZED|||TREATMENT||DOUBLE||||||
34038060|NCT06219811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34038061|NCT03351608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34038062|NCT04579952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant blinding: sham tDCS is provided by a 15 second activation (to perform initial sensation) and then no stimulation in the same areas and with the same cadence of the real tDCS.~Outcomes assessor blinding: the assessor who evaluates the participants doesn't know if the tDCS or sham tDCS will be or were performed."|Single center, double blinded randomized controlled trial|t|f|f|t
34038063|NCT01268631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038064|NCT05457686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study was designed as blinded, randomized and controlled.the person who evaluates the patients before and after the treatment is blind.In other words,the person evaluating the patients and the person giving the treatment are different.|randomized controlled study|t|f|f|t
34038065|NCT03977064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes assessor will receive pseudonymous data||f|f|f|t
34038066|NCT04752852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34038067|NCT03953976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038068|NCT03870880|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is an open label extension|||||
34038069|NCT04291313|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Treatment is blinded for participants and for the caretakers including nurses, midwifes and obstetricians.~The investigators do not participate in diagnosing patients and are not blinded."||t|t|f|f
34038070|NCT05845632|||COHORT||RETROSPECTIVE|||||||
34038071|NCT02250898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038072|NCT06576973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038073|NCT04538781|||COHORT||RETROSPECTIVE|||||||
34038074|NCT06545539|NA|SINGLE_GROUP||OTHER||NONE||||||
34038075|NCT02842710|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038076|NCT04369274|NA|SINGLE_GROUP||TREATMENT||NONE||The design is a case series with repeated measures analysis. All patients will receive the experimental treatment as well as conventional ventilation and unassisted oxygenation as observed prior to initiation of mechanical ventilation.||||
34038077|NCT06456775|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking|Single Group: Clinical trials with a single arm||||
34038078|NCT03979482|||CASE_CONTROL||PROSPECTIVE|||||||
34038079|NCT01882959|||||PROSPECTIVE|||||||
34038080|NCT04698044|||COHORT||CROSS_SECTIONAL|||||||
34038081|NCT02355639|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34038082|NCT01807754|||COHORT||PROSPECTIVE|||||||
34038083|NCT05393167|||OTHER||CROSS_SECTIONAL|||||||
34038084|NCT00563693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038085|NCT00879307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038086|NCT02996227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038087|NCT04158167|NA|SINGLE_GROUP||OTHER||NONE||After completion of clinical and cognitive assessments, all subjects will undergo a baseline fMRI scan. Later subjects will receive24IU oxytocin and saline placebo in counterbalanced order on two separate days and undergo repeat fMRI scans.||||
34038088|NCT02857816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038089|NCT02247778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038090|NCT00391768|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038091|NCT02042157|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038092|NCT03751098|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|There were no differences in the presentation of study treatment administered and all study personnel conducting ophthalmic assessments after study treatment administration were masked to treatment assignment.|This trial was a double-masked, placebo-controlled, cross-over superiority study evaluating the efficacy of the fixed combination drug vs. placebo. All participants in the trial were to receive each treatment.|t|f|f|t
34038093|NCT01011816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34038094|NCT01294774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038095|NCT00552968|||COHORT||PROSPECTIVE|||||||
34038096|NCT01699373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038097|NCT02359955|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34038098|NCT05292235|||COHORT||PROSPECTIVE|||||||
34038099|NCT04104503|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038100|NCT03700983|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Head and neck cancer survivors - patients who had been diagnosed with cancer of lip, oral cavity, oropharynx and nasopharynx, received treatment and the oncologists had defined them as complete remission, and having normal physical exam and blood biochemistry"||||
34038101|NCT04456777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038102|NCT05457023|||COHORT||PROSPECTIVE|||||||
34038103|NCT06307886|||CASE_CONTROL||PROSPECTIVE|||||||
34038104|NCT03842917|||COHORT||PROSPECTIVE|||||||
34038105|NCT04487613|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33808019|NCT06510751|||COHORT||PROSPECTIVE|||||||
33808020|NCT01960738|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34038106|NCT01946620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038107|NCT05206513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038108|NCT02670226|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34038109|NCT01047566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038110|NCT02913677|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33808021|NCT05033327|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33808022|NCT03936192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and Investigator|"glucosamine sulphate 1500mg + meloxicam 15mg, produced by Eurofarma Laboratories S.A., administered once a day for 12 weeks.~Glucosamine sulfate 1500mg + Chondroitin sulfate 1200mg, produced by Zodiac Pharmaceutical Products S.A. (Condroflex®), given once daily for 12 weeks.~Placebo administered once daily for 12 weeks."|t|f|t|f
34038111|NCT00349219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038112|NCT04667637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038113|NCT05066503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34038114|NCT04687969|||COHORT||PROSPECTIVE|||||||
34038115|NCT05889754|||COHORT||PROSPECTIVE|||||||
34038116|NCT00852059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038117|NCT02056223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038118|NCT05058482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038119|NCT02188147|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038120|NCT01045187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038121|NCT03563599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038122|NCT01787292|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.~B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.~C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer"||||
34038123|NCT01146119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038124|NCT06039501|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038125|NCT03507634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34038126|NCT03306745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The medications are unlabeled for both groups and will be dispensed in unlabeled blisteres. However, patients could search for the actual look of the PROfertil ® female soft capsules and the pills (for example on the internet). Since they differ from the folic acid capsules, patients could identify the control medications. We are aware of the fact that this kind of blinding is not according to standards and could introduce some kind of bias.||t|f|t|f
34038127|NCT04871776|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34038128|NCT04273113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038129|NCT01925729|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34038130|NCT03295838|NA|SINGLE_GROUP||TREATMENT||NONE||Patients were selected using a research protocol with defined criteria, all patients that were intended to treat in the Mentalization-based Treatment program were followed over 18 months and assessed for primary and secondary outcomes.||||
34038131|NCT04182178|||OTHER||RETROSPECTIVE|||||||
34038132|NCT02691052|||COHORT||OTHER|||||||
34038133|NCT00192231|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34038134|NCT03228979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded end-point clinical trial|Study is a multicenter, randomized, parallel-design, adaptive and blinded end-point clinical trial of sub-acute stroke patients|f|f|f|t
34038135|NCT04464174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038136|NCT05265286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038137|NCT00602251|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34038138|NCT05238298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038139|NCT02242812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34038140|NCT01198470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038141|NCT05002634|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038142|NCT03035617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation will be done by the staff at clinical trial unit which will be kept undisclosed to the investigators, patients and outcome assessors. Clinical Trial Unit will provide the solution for soaking mesh in coded form according to treatment arm allocation.|We propose a parallel design having two arms. In both the arms operative procedure of laparoscopic ventral hernia repair will be the same except solution used to soak the mesh before application. In control arm mesh will be soaked in normal saline solution as is routinely done. In intervention arm mesh will be soaked in .5% bupivacaine solution before application. Twenty ml of .5% bupivacaine will be provided by Institutional Clinical Trial Unit in coded form. Record of the codes will be kept by the clinical trial unit. Soaking will be done for one minute. Participants, investigators and outcome assessors will be blinded of the treatment allocation.|t|t|t|t
34038143|NCT01109212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038144|NCT03195829|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled pilot study, single blind|t|f|f|t
34038145|NCT05439096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038146|NCT04135677|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34038147|NCT01791894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038148|NCT04149821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038149|NCT03903289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038150|NCT00052572||||TREATMENT||NONE||||||
34038151|NCT04018131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038152|NCT06070519|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038153|NCT01710865|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038154|NCT02062125|||COHORT||PROSPECTIVE|||||||
34038155|NCT04743544|||COHORT||PROSPECTIVE|||||||
34038156|NCT05140200|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label study.|||||
34038157|NCT04114929|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will randomised either to threshold-based training or standard care||||
34038158|NCT05561868|||COHORT||PROSPECTIVE|||||||
34038159|NCT04485442|||COHORT||PROSPECTIVE|||||||
34038160|NCT04646265|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||prospective single center comparative clinical trial to investigate the biomechanical properties of periodontal tissues||||
34038161|NCT02701465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038162|NCT01999816|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34038163|NCT03725488|||OTHER||PROSPECTIVE|||||||
34038164|NCT00620945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038165|NCT04024046|||COHORT||RETROSPECTIVE|||||||
34038166|NCT05335837|||COHORT||RETROSPECTIVE|||||||
34038167|NCT00840957|||COHORT||PROSPECTIVE|||||||
34038168|NCT00117273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038169|NCT06261307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A dedicated member of the research team will be in charge of randomization of the participants to the two intervention arms, to ensure blindness of other team members. This member will not act as an outcomes assessor or a care provider.~The study will be presented to the caregivers as evaluating the effect of hobbies on language development. Therefore, the caregivers should not consider either intervention as the control arm. Both arms are expected to be potentially beneficial for the children's development.~Outcomes assessors will be unaware of the intervention arm and risk status (dyslexia risk vs no risk) of the children; caregivers will be reminded not to mention these to the researcher. Person in charge of randomization keeps track of violations of outcome assessor blindness."|The experimental arm will receive music training and the control arm will receive circus training.|t|f|f|t
34038170|NCT01786161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038171|NCT04093310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038172|NCT04417452|||COHORT||PROSPECTIVE|||||||
34038173|NCT02694159|||CASE_ONLY||RETROSPECTIVE|||||||
34038174|NCT05231811|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34038175|NCT03631680|||COHORT||CROSS_SECTIONAL|||||||
34038176|NCT01931436|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038177|NCT02391688|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34038178|NCT03327259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038179|NCT01805063|||CASE_CROSSOVER||PROSPECTIVE|||||||
34038180|NCT04948346|||OTHER||CROSS_SECTIONAL|||||||
34038181|NCT02946463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038182|NCT06323681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038183|NCT00656656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038184|NCT04178902|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038185|NCT04122300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038186|NCT03120780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The subject and the research personnel will be blinded to the arm to which they are randomized. Only the clinician assessing the patient and administering epidural doses will be not be blinded to the study group.|Subjects will be randomly assigned to one of two groups: one group will receive lower dose epidural fentanyl (20 micrograms) combined with local anesthetic; and one group will receive higher-dose epidural fentanyl (100micrograms) combined with the same amount of local anesthetic.|t|f|f|f
34038187|NCT03525080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038188|NCT00152061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038189|NCT01033903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038190|NCT02666937|||COHORT||OTHER|||||||
34038191|NCT03669211|NA|SINGLE_GROUP||OTHER||NONE||||||
34038192|NCT04423991|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038193|NCT06299891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Eligible subjects will be assigned treatment using a sex-stratified permuted-block randomization (1:1) to drug vs. placebo for 27 weeks with varying block sizes constructed by the study statistician.|Two-center, double-blind (participant and assessor), randomized, parallel-arm placebo-controlled 28-week clinical trial, comparing changes related to active drug (Qsymia®) vs. placebo (matched capsules).|t|t|t|t
34038194|NCT06304987|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: Neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor Control: Neoadjuvant chemoradiotherapy combined with PD-1 inhibitor||||
34038195|NCT02597439|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038196|NCT02655822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038197|NCT04148326|||CASE_ONLY||PROSPECTIVE|||||||
34038198|NCT01628900|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038199|NCT00006429|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34038200|NCT01445730|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038201|NCT06095921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Our employee's statistical analysis was conducted by a biostatistician unrelated to her work.||f|f|f|t
34038202|NCT03676608|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038203|NCT04850417|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Factorial 2x2 design (a) beta-blockers yes/no; b) Antiplatelets short/long)|f|f|f|t
34038204|NCT04614519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038205|NCT06231225|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038206|NCT05481632|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34038207|NCT03741868|||COHORT||PROSPECTIVE|||||||
34038208|NCT04146441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038209|NCT03649568|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
34038210|NCT02261272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038211|NCT05661474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038212|NCT04044989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038213|NCT02035371|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34038214|NCT01036282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Raters were blind to the type of interventions|Two arm, parallel group, randomized, blinded 12 -week intervention study of two forms of cognitive remediation in patients with chronic schizophrenia|f|f|f|t
34038215|NCT05818228|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34038216|NCT00360282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34038217|NCT05029037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038218|NCT01570790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038219|NCT06370169|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038220|NCT01437436|||COHORT||PROSPECTIVE|||||||
34038221|NCT02523755|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038222|NCT04969406|NA|SINGLE_GROUP||OTHER||NONE||||||
34038223|NCT04776629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038224|NCT04100343|||CASE_ONLY||CROSS_SECTIONAL|||||||
34038225|NCT04345237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038226|NCT02021929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038227|NCT02350283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038228|NCT02570308|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038229|NCT04012021|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Three single groups to be included||||
34038230|NCT05982470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038231|NCT05689320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038232|NCT04089631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038233|NCT02009553|||CASE_CONTROL||PROSPECTIVE|||||||
34038234|NCT02545569|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34038235|NCT00180531|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038236|NCT01059838|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038237|NCT00799890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038238|NCT02899182|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34038239|NCT04004442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038240|NCT03618693|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, parallel group, single centre, interventional, active controlled trial||||
34038241|NCT00365794|NA|SINGLE_GROUP||TREATMENT||NONE|No masking. This was an open label (un-blinded)|||||
34038242|NCT02271334|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34038243|NCT01803672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038244|NCT01724710|||CASE_CONTROL||PROSPECTIVE|||||||
34038245|NCT02263560|||COHORT||OTHER|||||||
34038246|NCT00485719|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038247|NCT00520065|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34038248|NCT00372684|||||PROSPECTIVE|||||||
34038249|NCT02335437|||COHORT||PROSPECTIVE|||||||
34038250|NCT02725554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038251|NCT01580124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038252|NCT01310062|||||CROSS_SECTIONAL|||||||
34038253|NCT02640261|||CASE_CONTROL||PROSPECTIVE|||||||
34038254|NCT04396262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34038255|NCT06479538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038256|NCT01200693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038257|NCT00304850|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34038258|NCT04362592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038259|NCT04760431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038260|NCT01411150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038261|NCT06033911|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be allocated into one of 3 groups: (i) no App control; (ii) App without 'high-in' nutrition symbol; (iii) App with Canada's 'high-in' nutrition symbol|2-week long, single-blinded randomized controlled trial with a 3-parallel arm.|t|f|f|f
34038262|NCT01546818|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34038263|NCT02573051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038264|NCT03910400|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34038265|NCT06127342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038266|NCT04749485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038267|NCT03507361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34038268|NCT03529513|||COHORT||CROSS_SECTIONAL|||||||
34038269|NCT04073537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038270|NCT03191383|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34038271|NCT02712320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038272|NCT02074241|||COHORT||PROSPECTIVE|||||||
34038273|NCT04230551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Technicians and/or imaging cardiologists involved in image analysis will not be informed about the procedure in order to have an unbiased analysis at baseline. At follow-up, treated patients will have akinetic/infarcted proximal septum that will be noticed during image acquisition. However, the pre-PTSMA status (symptomatic vs. asymptomatic) will be blinded for the analysis.||f|f|f|t
34038274|NCT03550677|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34038275|NCT03059017|RANDOMIZED|PARALLEL||TREATMENT||NONE||Volunteers will be divided into two groups; each group contained 10 volunteers who will receive one formula of the selected formulae.||||
34038276|NCT02309320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038277|NCT02120118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038278|NCT00907361|||COHORT||PROSPECTIVE|||||||
34038279|NCT00523848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038280|NCT02283424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038281|NCT01038986|||||PROSPECTIVE|||||||
34038282|NCT05423288|||CASE_ONLY||RETROSPECTIVE|||||||
34038283|NCT05610397|||CASE_ONLY||RETROSPECTIVE|||||||
34038284|NCT03482518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be informed that they will be drawn to participate in one of the two groups (intervention group or control group). Allocation in the groups will be done randomly, by lot, following the order of randomization, keeping the confidentiality, ie, one should not know to which group the participant will be sent before he / she agrees to be evaluated and sign the TCLE.|A randomized controlled trial|t|f|t|f
34038285|NCT05774561|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038286|NCT02702128|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038287|NCT01038336|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34038288|NCT03972904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The diet will be administered by a professional physician (intervention group:Light-Fat Rice® combined with Active Peptide®; control group: staple food of equal energy containing a small amount of dietary fiber combined with comparable energy maltodextrin) with a lifestyle guidance,same in both groups, to assist in diabetes management. The method of taking the product can be divided into two parts.And a dynamic blood glucose transient monitor would be worn for all patients at the 3rd week to record the patients's dynamic blood glucose changes including preprandial, postprandial (every 15 minutes), before and after exercise (every 30 minutes).Besides these,the patients would be asked to record dietary and exercise diary for 3 days(including one weekend at least) each week also.|t|f|f|t
34038289|NCT03638804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038290|NCT00480168|||COHORT||PROSPECTIVE|||||||
34038291|NCT03817853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038292|NCT02389829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038293|NCT03170362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study intervention is the provision of pharmacogenetic test results which can then be used to choice appropriate medication.|f|f|f|t
34111549|NCT05054101|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34111550|NCT03468998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34111551|NCT01445275|||OTHER||RETROSPECTIVE|||||||
34111552|NCT00392574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111553|NCT04838288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111554|NCT00663078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111555|NCT05632393|NA|SINGLE_GROUP||OTHER||NONE||||||
34111556|NCT01970709|||COHORT|||||||||
34111557|NCT03058874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111558|NCT05438121|||COHORT||PROSPECTIVE|||||||
34111559|NCT06029647|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study will follow a randomized, controlled, crossover design with two 16-week dietary interventions separated by 4-week washout periods.||||
34111560|NCT02644070|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34111561|NCT04053387|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects in this study completed treatment with tapinarof or vehicle in 1 of 2 parent Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). The study will consist of up to 40 weeks of tapinarof cream, 1%, and a 4-week safety follow-up period.||||
34111562|NCT05694494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111563|NCT05819528|||COHORT||RETROSPECTIVE|||||||
34111564|NCT00950521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111565|NCT04634435|NA|SEQUENTIAL||TREATMENT||NONE||||||
34111566|NCT02259595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111567|NCT02311504|||COHORT||PROSPECTIVE|||||||
34111568|NCT01535378|||CASE_ONLY||PROSPECTIVE|||||||
34111569|NCT04323046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111570|NCT03886857|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34111571|NCT03510689|||COHORT||PROSPECTIVE|||||||
34111572|NCT05840263|||CASE_ONLY||PROSPECTIVE|||||||
34111573|NCT05586776|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34111574|NCT03298893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111575|NCT05620940|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34111576|NCT02947048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111577|NCT04931017|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a partial crossover model whereby the no-treatment subjects will receive the drug after being controls.||||
34111578|NCT04482127|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Group A will receive atraumatic extraction and soft tissue augmentation using SCTG harvested from palatal tissue by single line incision technique (Hürzeler and Weng, 1999) blade will be oriented perpendicular to the palatal tissue surface. A single incision will be made down to the bone in a horizontal direction approximately 2 to 3 mm apical to the gingival margin of the maxillary teeth. A partial thickness dissection will then be made within the single incision, leaving an adequate thickness of the palatal flap intact to minimize the chance of sloughing of the overlying tissue. Careful manipulation of the graft with tissue forceps will be required and care must be taken to prevent compression or tearing of the graft.~Group B will receive atraumatic extraction with no soft tissue augmentation."|f|f|f|t
34111579|NCT05371379|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34111580|NCT05627921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The person performing the examinations and evaluating the data was blind to the treatment administered.|"Patients will be randomized into two equal groups using the closed envelope system. The patients in the first group will be injected with Botulinum Toxin-A with the Stumplex device into the spastic muscle.~The patients in the second group will be injected with Botulinum toxin with the same procedure. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used."|f|f|t|t
34111581|NCT00750399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111582|NCT04860466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111583|NCT03923088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111584|NCT03285360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|Dentin Hypersensitivity|t|f|f|t
34111585|NCT03405350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111586|NCT05462704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will receive matching ferrous sulfate or placebo formulate to appear and taste similar. They will also each receive an infusion of 1000mg ferric derisomaltose in 250ml of normal saline or 250ml of normal saline only, camouflaged in an opaque intravenous bag and tubing covers.||t|t|f|t
34111587|NCT06632080|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||The present trial has a randomized, double-blind, placebo-controlled, 2-way crossover design and will be conducted at a single site.|t|t|t|t
34111588|NCT04468360|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|In this double-blind, placebo controlled, randomized trial, active drug and matching placebo will be supplied by the research pharmacy. Participants, assessors, and the investigators will be blind to treatment condition.|Active drug vs. placebo will be administered in two separate experiments to a population of medically healthy, non-medicated patients with PTSD stratified by sex and by menstrual phase within female sex.|t|f|t|t
34111589|NCT03346837|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111590|NCT00004682|RANDOMIZED|||TREATMENT||||||||
34111591|NCT06114368|||COHORT||RETROSPECTIVE|||||||
34111592|NCT06252415|||COHORT||PROSPECTIVE|||||||
33838153|NCT04017338|NA|SINGLE_GROUP||TREATMENT||NONE||Investigators aim to transplant 40 recipients (20 lung; 20 other organs) on the transplant wait-list. Donor organs will be selected based on usual donor selection criteria. Recipients will be selected based on usual hospital protocol for selecting suitable recipients. After transplantation, recipients will receive highly effective antiviral prophylaxis using approved direct-acting antivirals (DAAs) Glecaprevir/Pibrentasvir (G/P) and they will also receive ezetimibe, a cholesterol-lowering medication. Additionally, lung transplant recipients will receive donor lungs treated with normothermic ex vivo lung perfusion (EVLP) prior to transplant.||||
33838154|NCT01249495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111593|NCT05249270|||COHORT||PROSPECTIVE|||||||
34111594|NCT01854450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111595|NCT06565117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111596|NCT05994846|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, unblinded, feasibility study where participants will serve as their own controls.||||
34111597|NCT01924819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111598|NCT04695665|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111599|NCT05270863|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34111600|NCT03190876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111601|NCT05595239|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34111602|NCT04305210|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111603|NCT06564883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111604|NCT05861843|||CASE_ONLY||PROSPECTIVE|||||||
34111605|NCT04956887|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the patient or authorized surrogate provides informed consent, the cognitive training and rehabilitation intervention versus usual care will be randomly assigned at a 1:1 allocation ratio. Computerized randomization will occur after informed consent has been obtained using a permuted-block randomization scheme with varying block size. We will use adequate allocation concealment using a computer-generated, permuted-block randomization scheme with varying block size. The block size and randomization list will only be known to the independent biostatistician creating the randomization list and will not be shared with trial investigators or any other study personnel, as this information could make it easier to correctly guess the next treatment allocation. This list will be directly uploaded into REDCap's randomization module.16||||
34111606|NCT01344356|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111607|NCT02354573|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34111608|NCT04055012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111609|NCT06601179|NA|SINGLE_GROUP||TREATMENT||NONE||"Phase 1 aims to determine the minimum effective dose for BPH treatment. It will include 10 patients receiving 50% of the standard shooting power. If, after a 3-month follow-up, there are no serious adverse events (SAEs) and good efficacy, Phase 2 will begin.~If Phase 1 results indicate that 50% power is insufficient, power levels will be increased by 10% increments (60%, 70%, 80%, 90%) with similar follow-up until the minimum effective dose is determined.~Phase 2 aims to validate the effocacy of the minimum effective dose. It will include 90 new patients treated with the same 50% power. They will be monitored regularly after 1 and 3 months, every 6 months up to 24 months, and finally at 36 months."||||
34111610|NCT00823797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111611|NCT03130049|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study||||
34111612|NCT05452668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The outcome evaluator will be a single personnel from the oncology team following up with the case.||t|f|f|t
34111613|NCT00499447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111614|NCT03463187|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"PartA is a multiple dose escalating design in 3 sequential cohorts at 3 dose levels (80mg, 160mg, and 240mg) in plaque psoriasis subjects.~Part B is a multiple dose, parallel-group design consisting of 4 treatment arms and 1 placebo arm to assess the efficacy and safety of s.c. injections of SHR-1314 in plaque psoriasis subjects."|t|t|t|t
34111615|NCT06567392|NA|SINGLE_GROUP||OTHER||NONE||Single oral dose of \[14C\] HRS-5965||||
34111616|NCT02096354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111617|NCT04870515|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34111618|NCT02798757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111619|NCT05196776|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34111620|NCT04430738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33838155|NCT02764268|NA|SINGLE_GROUP||TREATMENT||||||||
34111621|NCT06305429|NA|SINGLE_GROUP||TREATMENT||NONE||Open, single-group trial||||
34111622|NCT01714674|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34111623|NCT06014983|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34111624|NCT06602817|||COHORT||PROSPECTIVE|||||||
34111625|NCT02779231|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34111626|NCT05116280|||COHORT||RETROSPECTIVE|||||||
34111627|NCT02720458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111628|NCT06399224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study group will be treated with both plantar vibration and Otago exercise whereas the control group will receive Otago exercise only. Both groups will receive a 50 minutes of otago exercise program except for the study group will take 15 minutes of plantar vibration with frequency of 80 Hz, with 10 seconds of vibration and 5 seconds of rest with total time 15 min before the Otago exercise. The frequency of the exercise will be 3 times a week for 12 weeks.|t|f|f|t
34111629|NCT06634875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111630|NCT04233892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111631|NCT06044571|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This trial will have a single-masked design, so the team assessing study outcomes is masked to intervention assignment. Participants will be asked not to reveal their assignment. Arm assignment cannot be blinded due to the study's design. The assessment team will schedule assessments to minimize contact with the intervention team to maintain separation. Data entry and analysis will be blinded to the study investigators, besides Kosorok and team. Assessments will be done at different times and in separate areas at the study site. The intervention setting for participants will be in their homes. To enhance continued masking, participants will be asked not to disclose their assigned group and not to discuss their intervention arms during assessment sessions. Assessment of compliance to the intervention will be performed by the intervention team and not by the outcome assessment team. The investigators will be blinded to data analysis, collection, and study arms.|A single site two-stage, Phase III clinical trial using a SMART design, will assess the superiority between two first-line strategies (prescriptive, behavioral) on percent weight loss at 52 weeks|t|t|f|f
34111632|NCT02373657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34111633|NCT02247921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111634|NCT01189565|||CASE_ONLY||PROSPECTIVE|||||||
33838156|NCT03242343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838157|NCT04508855|||COHORT||PROSPECTIVE|||||||
33838158|NCT01819142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838159|NCT01405651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838160|NCT05497544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33838161|NCT04920266|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Each subject will serve as his or her own control. We will compare the Test and Reference methods during moderate intensity self-paced training runs, coach-led fitness sessions, and/or group outdoor cycling rides.||||
33838162|NCT01451502|NA|SINGLE_GROUP||OTHER||NONE||||||
33808023|NCT05454059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 102 (n=102) individuals were included in the study and were divided into 6 groups. The control groups of our study were Group 1 (HH), which included 17 both systemically healthy and periodontally healthy normoglycemic individuals, Group 2 (HP), which included 17 systemic healthy with Grade A periodontitis. Periodontally healthy T2DM patients were divided into two groups according to their HbA1c levels, and 17 patients with HbA1c levels below 7% were grouped as Group 3 (T2D+H), and 17 patients with HbA1c above 7% and 7% were grouped as Group 5 (T2D-H). 17 patients with T2DM with Grade B periodontitis with an HbA1c below 7% in the last three months were included in Group 4 (T2D+P), and 17 patients T2DM and periodontitis with an HbA1C value above 7% were included in Group 6 (T2D-P).|t|f|f|t
33808024|NCT06699914|||COHORT||RETROSPECTIVE|||||||
33808025|NCT04242212|||COHORT||PROSPECTIVE|||||||
33808026|NCT00999596|||||PROSPECTIVE|||||||
33808027|NCT01772212|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33808028|NCT06698627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prior to randomization participants will be sent the Poise Impressa sizing kit via mail. They will then be asked what size of device works best for them based on the sizing kit. After this information is obtained they will then be sent both Revive and correct size of Poise Impressa. They will be randomized at this time regarding which device they will start with. If participants are menstruating, they will be asked to start this study after their last day of bleeding as this study will last approximately 20 days. They will then begin using the device they were randomized to use first for 7 days. There will be a three day wash out period and them they will use the remaining device for 7 days.||||
33808029|NCT02260154|||COHORT||PROSPECTIVE|||||||
33808030|NCT01241526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33808031|NCT03653364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038294|NCT04378725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The schoolchildren in the intervention and control schools were not aware of the differed treatment. The dentist involved in delivery the content of the KOTAK program were aware of the allocation of the schools.|The study design is a cluster (cluster = school) randomized trial of schoolchildren participating in the school-based smoking prevention and cessation program (The KOTAK) . Randomization were done at the school level,after the schools were paired and matched base on the schools' overall academic achievement.The matched pairs were randomly selected.The selected pairs were then randomly allocated to either Intervention or Control schools. The Advance Intervention section of the KOTAK program will be assigned to the Intervention Schools.The cluster size will be treated as balancing factors in stratified allocation or as covariate in the statistical analysis.|t|f|f|f
34038295|NCT05017337|||COHORT||PROSPECTIVE|||||||
34038296|NCT03389932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34038297|NCT00802048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808032|NCT01753167||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808033|NCT00989118||PARALLEL||||||||||
33808034|NCT00145145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038298|NCT04620746|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038299|NCT00663390|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038300|NCT06449729|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34038301|NCT02992249|||CASE_ONLY||PROSPECTIVE|||||||
34038302|NCT01943214|||COHORT||PROSPECTIVE|||||||
34038303|NCT03984500|NA|SINGLE_GROUP||OTHER||NONE||||||
34038304|NCT04154254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038305|NCT06578611|||COHORT||PROSPECTIVE|||||||
34038306|NCT00636519|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34038307|NCT00063934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038308|NCT02571673|||COHORT||PROSPECTIVE|||||||
34038309|NCT00160849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038310|NCT04945395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to the patients´ allocation in terms of intervention|Randomized controlled trial|f|f|f|t
34038311|NCT06151873|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34038312|NCT05330117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34038313|NCT02945241|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038314|NCT02859766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038315|NCT01984320|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038316|NCT02653963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34038317|NCT03776266|||COHORT||RETROSPECTIVE|||||||
34038318|NCT02375971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038319|NCT03079986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038320|NCT04084067|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038321|NCT05928078|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34038322|NCT00157846|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34038323|NCT05446701|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34038324|NCT01537601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038325|NCT01114035|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038326|NCT03661359|NA|SINGLE_GROUP||OTHER||NONE||Each patient who consents will be given the community resource interventions which apply to them based on the results of the Social Determinants of Health Screening Tool.||||
34038327|NCT03242408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038328|NCT03577080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Differents groups received differents training protocoles during the same duration|f|t|t|f
34038329|NCT00901550|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038330|NCT01170429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038331|NCT05566522|||OTHER||PROSPECTIVE|||||||
34038332|NCT00570154|||||PROSPECTIVE|||||||
34038333|NCT05584956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038334|NCT01882985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038335|NCT06012188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33808035|NCT06167434|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808036|NCT04954885|||COHORT||PROSPECTIVE|||||||
33808037|NCT01449760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808038|NCT06269731|||OTHER||CROSS_SECTIONAL|||||||
33808039|NCT06700252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808040|NCT02656147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808041|NCT04257799|||COHORT||PROSPECTIVE|||||||
33808042|NCT01920932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808043|NCT04274530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants with operatively managed extremity fractures 2-12 weeks post-fracture fixation will be randomized to receive either cognitive behavioural therapy (CBT) delivered through a mobile application or standard of care (control). Outcomes will be assessed at 3 months, 6 months, 9 months, and 12 months' post-fracture.|f|f|f|t
33808044|NCT00145587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808045|NCT03594305|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster randomized trial in which villages are randomized to receive or not to receive the intervention.|t|f|f|f
33808046|NCT06487702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808047|NCT03611088|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33808048|NCT01180231|NON_RANDOMIZED|||||SINGLE|||t|f|f|f
33808049|NCT02684435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808050|NCT01263496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808051|NCT03225625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"There will be 3 Arms:~Arm 1: BMSC Paraspinal, IV, Intranasal . Arm 2: BMSC Paraspinal,IV,Intranasal + exoskeleton or equivalent . Arm 3: BMSC Paraspinal, IV, Intranasal + virtual reality or equivalent ."||||
33808052|NCT04031794|||COHORT||OTHER|||||||
33808053|NCT01709006|NA|SINGLE_GROUP||TREATMENT||NONE||IMRT by helical tomotherapy with concomitant chemotherapy at 70 Gy in 33 fractions on GTV, 59.4 Gy in 33 fractions on CTV1 and 43.2 Gy in 24 fractions on CTV 2, where CTV 2 would include only level 2 and 3 contralateral and ipsilateral level 4.||||
33808054|NCT05775159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808055|NCT02479672|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33808056|NCT04350294|||CASE_CONTROL||PROSPECTIVE|||||||
33808057|NCT01015872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808058|NCT02575365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808059|NCT00000170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808060|NCT05985408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808061|NCT02841449|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33808062|NCT01714076|||COHORT||PROSPECTIVE|||||||
33808063|NCT00893334|||CASE_CONTROL||PROSPECTIVE|||||||
33808064|NCT02919748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808065|NCT06497699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study group:Dexycu interventional group~External control group;without intervention"||||
33808066|NCT01502813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808067|NCT06430424|||COHORT||RETROSPECTIVE|||||||
33808068|NCT01163981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838163|NCT04004689|||COHORT||PROSPECTIVE|||||||
33838164|NCT05456906|||OTHER||RETROSPECTIVE|||||||
34038336|NCT02661880|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038337|NCT04060667|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||describe time blocks, include description of time allotment||||
34038338|NCT01473823|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038339|NCT06136533|||CASE_CONTROL||PROSPECTIVE|||||||
34038340|NCT01555749|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34038341|NCT05159531|RANDOMIZED|CROSSOVER||PREVENTION||NONE||1:1 open-label RCT using a AB:BA crossover design, comparing the standard of care to an mHealth-based model of care for TAF/FTC PrEP delivery over 72 weeks.||||
34038342|NCT01167140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038343|NCT06021405|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038344|NCT05526638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective cohort study||||
34038345|NCT05928507|||OTHER||PROSPECTIVE|||||||
34038346|NCT02641262|||COHORT||PROSPECTIVE|||||||
34038347|NCT05885425|||CASE_CONTROL||PROSPECTIVE|||||||
34038348|NCT00444002|||CASE_ONLY||CROSS_SECTIONAL|||||||
34038349|NCT02179892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34038350|NCT01080482|RANDOMIZED|CROSSOVER||||NONE||||||
34038351|NCT05565248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038352|NCT02686931|||COHORT||PROSPECTIVE|||||||
34038353|NCT03303313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038354|NCT04169269|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomized to one of two medications.||||
34038355|NCT01449656|||CASE_CONTROL||PROSPECTIVE|||||||
34038356|NCT05943756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Both groups will participate in a different intervention program meant to improve well-being in individuals who have sustained a brain injury.|t|f|f|t
34038357|NCT01821235|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34038358|NCT03608033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible patients will be randomized 1:1 to receive OMS721 or placebo|t|t|t|t
34038359|NCT04570839|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation, followed by an expansion cohort upon determination of the recommended dose for expansion (RDFE) of COM701 in combination with BMS-986207 and nivolumab.||||
34038360|NCT01014546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038361|NCT00502242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038362|NCT03373877|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038363|NCT02514499|NA|SINGLE_GROUP||SCREENING||||||||
34038364|NCT02866305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038365|NCT02613793|||CASE_CONTROL||PROSPECTIVE|||||||
34038366|NCT01754155|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038367|NCT04483830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|placebo control|prospective, single centre, randomized, placebo-control trial|t|f|f|f
34038368|NCT04885881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038369|NCT01955928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038370|NCT05494710|NA|SINGLE_GROUP||TREATMENT||NONE||single group of patients receiving same treatment||||
33808069|NCT04237909|NA|SINGLE_GROUP||TREATMENT||NONE||After the couples are recruited for the study, Antral follicle count (AFC), serum anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) levels will be determined at baseline and will be repeated beginning with the first menstrual cycle. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary Ovarian reserve (AFC, FSH, AMH), and IVF laboratory outcome parameters (number of MII oocytes, 2PN embryos, cleavage stage embryos) will be followed for six sequential months. Spontaneous pregnancies will also be recorded.||||
33808070|NCT03397459|||COHORT||PROSPECTIVE|||||||
33808071|NCT03472352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808072|NCT03732807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808073|NCT03512782|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33808074|NCT00263757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808075|NCT05841407|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Both isotonic drinks (high nitrate or no nitrate) are deidentified and labelled (coded) by a third party not involved with the research. Randomisation is completed by a third party not involved in the testing.||t|f|t|f
33808076|NCT01394276|||COHORT||PROSPECTIVE|||||||
33808077|NCT00233714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038371|NCT04936763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038372|NCT04672577|||COHORT||PROSPECTIVE|||||||
34038373|NCT03063437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808078|NCT03678792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808079|NCT06301867|||COHORT||PROSPECTIVE|||||||
34038374|NCT04826081|||OTHER||PROSPECTIVE|||||||
34038375|NCT00712712|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038376|NCT02571491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038377|NCT01070368||PARALLEL||DIAGNOSTIC||NONE||||||
34038378|NCT05202197|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34038379|NCT02793869|||COHORT||PROSPECTIVE|||||||
34038380|NCT01479075|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34038381|NCT00491283|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34038382|NCT00240708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038383|NCT05733169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038384|NCT01082328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038385|NCT01532934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34038386|NCT02257073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808080|NCT03258866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111635|NCT06565676|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The order of bread types to be consumed by the participants will be determined by a person who is not a researcher in the study by simple randomization method using Microsoft Excel program. A researcher who does not interact with the participants will provide the participants with breakfast containing the test breads every day. Due to the difference in bread types, the comparison of breads will be double-blind. An investigator who does not know the type of bread consumed will be assigned for glucose measurement and will be blinded to the assigned bread.|All volunteer participants were randomly assigned to a breakfast meal containing all types of bread (white flour bread, white flour bread with whey powder added, whole wheat flour bread and whole wheat flour bread with whey powder added) for four days.|t|f|t|f
34111636|NCT02957240|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34111637|NCT04016714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111638|NCT06216288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||participants will be assigned to one of the 2 groups: either the control group receiving McKenzie repeated back extension exercise or the experimental group receiving combined McKenzie and Lumbar traction|t|f|f|t
34111639|NCT02114034|||COHORT||PROSPECTIVE|||||||
34111640|NCT00182650|NON_RANDOMIZED|||TREATMENT||NONE||||||
34111641|NCT03091855|||COHORT||PROSPECTIVE|||||||
34111642|NCT05670184|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Random allocation of couples to a the treatment order will be done using Sealedenvelope software, by one experimenter who does not come in direct contact with the participants. The study will be double blind to the subject and the testing experimenter. One experimenter will be responsible for preparing the LSD. This experimenter will not be the one testing the participants. If a subject is withdrawn from the study they will be replaced, for a maximum of n=60 participants (n=30 couples). Following completion of all data collection the study will be fully unblinded.|LSD and placebo will be administered in an AB or BA sequence, with half of the couples following sequence AB and the other half following sequence BA. Couples will receive an oral dose of either 50 µg of LSD or placebo. All couples will receive both the LSD and the placebo solution on separate dosing days with follow-ups 2 days later (in the lab), and 4 days later (at home). There will be a 14-day washout period between drug administrations.|t|f|t|f
34111643|NCT00853853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111644|NCT00195728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111645|NCT01844596|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34111646|NCT02500108|||COHORT||RETROSPECTIVE|||||||
34111647|NCT04150445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111648|NCT05053685|||CASE_CONTROL||PROSPECTIVE|||||||
34111649|NCT05696119|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An independent statistician, blinded to group allocation, will analyze data|Cluster-randomized study|f|f|f|t
34111650|NCT06558435|||OTHER||RETROSPECTIVE|||||||
34111651|NCT02410187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111652|NCT05323344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded video rating for primary endpoint|Feasibility study|f|f|f|t
34111653|NCT01955863|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34111654|NCT03309202|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34111655|NCT04900298|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This will be a prospective, single center, unmasked, controlled before and after study. Two patients (case-pair) having surgery in a serial manner in a randomly selected operating room will be evaluated for the detection of pathogenic bacteria. The first twenty patients (10 case-pairs) will be enrolled in the control (standard care) arm followed by 20 patients (10 case-pairs) being enrolled in the intervention (SafeHaven) arm.||||
34111656|NCT03108898|||CASE_ONLY||PROSPECTIVE|||||||
34111657|NCT02845414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111658|NCT05299580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111659|NCT06569355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111660|NCT06460532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111661|NCT04118101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded control study|After skin sterilization and draping, a high-frequency linear array ultrasound probe will be placed on the back in a transversly to identify the tip of the T7 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will be rotated into a longitudinally to produce a para-sagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin and subcutaneous tissue, trapezius and erector spinae muscle. An echogenic 22-G block needle will be inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T7 transverse process. Correct location oft he needle tip in the fascial plane deep to erector spinae muscle will confirmed by injecting 0.5-1 ml normal saline and seeing the fluid lifting the erector spinae muscle off the transverse process without distending the muscle.|t|t|t|t
34111662|NCT00737360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111663|NCT04897568|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A type II effectiveness implementation hybrid trial will be conducted using a pre-post design to evaluate the effectiveness (co-primary outcomes of LCS and decision quality) and implementation at four rural clinics.||||
34111664|NCT03638375|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The ACTME trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe.~Phase 1, Cohort 1: Adding TIL therapy to anti-PD1 immunotherapy. Phase 1, Cohort 2: Adding IFN-alpha to the treatment with TIL and anti-PD1 immunotherapy.~Phase 2: Patients will be treated with TIL, IFN-alpha and anti-PD1 according to the same schedule as used in phase 1 cohort 2."||||
33808081|NCT02851134|||FAMILY_BASED||PROSPECTIVE|||||||
33808082|NCT03653897|NA|SINGLE_GROUP||OTHER||NONE||This study is a prospective, open label, clinical study evaluating the safety and effectiveness of the ID-Cap System under direct observation in the clinical setting.||||
33808083|NCT00733174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808084|NCT05794841|||COHORT||PROSPECTIVE|||||||
33808085|NCT05445557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Each of the subject's flanks will be randomized for RZL-012 and placebo injections.|t|t|t|f
33808086|NCT03511794|||COHORT||RETROSPECTIVE|||||||
33808087|NCT02234141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808088|NCT00439686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808089|NCT01580306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808090|NCT04396210|||OTHER||PROSPECTIVE|||||||
33808091|NCT02557230|||COHORT||RETROSPECTIVE|||||||
33808092|NCT04796844|||COHORT||PROSPECTIVE|||||||
33808093|NCT04972526|||COHORT||PROSPECTIVE|||||||
33808094|NCT02923479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808095|NCT03877783|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33808096|NCT03589768|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33808097|NCT03860454|||CASE_CONTROL||PROSPECTIVE|||||||
34038387|NCT00253435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038388|NCT00151879|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038389|NCT02313311|||COHORT|||||||||
34038390|NCT06485102|||COHORT||RETROSPECTIVE|||||||
34038391|NCT01667718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038392|NCT05707273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038393|NCT01647386|||CASE_ONLY||PROSPECTIVE|||||||
34038394|NCT01042353|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038395|NCT02954484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038396|NCT01966757|||||CROSS_SECTIONAL|||||||
34038397|NCT02566213|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038398|NCT04733066|||COHORT||PROSPECTIVE|||||||
34038399|NCT05496205|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34038400|NCT01231451|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038401|NCT03205878|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34038402|NCT02448485|||COHORT||RETROSPECTIVE|||||||
34038403|NCT06127316|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded, to the greatest extent possible, to the different CDO heel distraction heights.|In this study, forces acting under the foot (hindfoot, midfoot, forefoot, and total foot) will be measured using wireless Loadsol insoles (Novel GMBH, St. Paul, MN) as participants walk without an orthosis (NoCDO) and with a CDO with three different posterior strut lengths resulting in three different levels of heel distraction (0cm, 1cm, 2cm) at self-selected and controlled speeds. Gait kinematics and kinetics will be measured using infra-red motion capture cameras (Vicon Motion Systems Ltd., Denver, CO) and force plates (AMTI, Watertown, MA). Testing order of the CDO conditions will be randomized to prevent influence of testing order.|t|f|f|f
34038404|NCT00778817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038405|NCT00002382||||TREATMENT||NONE||||||
34038406|NCT02386267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038407|NCT02097329|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34038408|NCT01108172|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34038409|NCT05888220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34038410|NCT01169064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038411|NCT00987818|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34038412|NCT05663112|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|not necessary|This research is a prospective randomized study. Patients will be randomized by number-drawing method. Patients with BMI\>30 and age\>65 will be equally distributed to the experimental and active comparator arms. Under general anesthesia patients will be injected with 5 ml of isosulfan blue into the subareolar region. In one group, breast massage will be applied for 5 minutes. In the other group no massage will be applied. Surgical team will wait for a duration of 5 minutes for the self distribution of the blue dye.||||
34038413|NCT03901677|NA|SINGLE_GROUP||TREATMENT||NONE|All assessments done by masked therapist to avoid bias who have no idea about intervention before and 12 weeks after the tai chi exercise.|||||
34038414|NCT05240898|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038415|NCT06391307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038416|NCT02714218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038417|NCT03827499|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34038418|NCT00141492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34038419|NCT03125954|||COHORT||PROSPECTIVE|||||||
34038420|NCT05733429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|eye cervical re-education and motor imagery therapy|f|f|t|t
34038421|NCT00922064|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038422|NCT04872686|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34038423|NCT04083885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will not know which arm the participants are in. Group allocation will be provided to the research staff member providing the intervention, through use of an online randomization program.|Multi-site Prospective randomized open blinded end-point (PROBE) study|f|f|f|t
34038424|NCT02157376|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34038425|NCT01343043|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
34038426|NCT05771077|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038427|NCT01611883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038428|NCT00488956|||COHORT||RETROSPECTIVE|||||||
34038429|NCT03771911|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038430|NCT01624571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038431|NCT05643703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34038432|NCT02182843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038433|NCT04064138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|- Single blind (participant) study||t|f|f|f
34038434|NCT06409845|||CASE_ONLY||PROSPECTIVE|||||||
34038435|NCT02992041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038436|NCT01952392|||COHORT||PROSPECTIVE|||||||
34038437|NCT02944539|||CASE_CONTROL||RETROSPECTIVE|||||||
34038438|NCT04205643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038439|NCT00014495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038440|NCT04020666|||COHORT||PROSPECTIVE|||||||
34038441|NCT02964481|||CASE_CONTROL||PROSPECTIVE|||||||
34038442|NCT02819024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038443|NCT05306028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808098|NCT03876184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants will select only one sealed envelope containing the archwires which has been labelled and coded without looking at other archwires. Both operators and participants are not informed of the brands of the coated archwires. The statistician will analyse the data based on the assigned codes. The codes will be broken by the principal investigator after the results have been produced.||t|t|t|t
34111665|NCT06254833|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34111666|NCT04602260|||COHORT||OTHER|||||||
34111667|NCT05849207|NA|SEQUENTIAL||TREATMENT||NONE||"Open-label trial~De-escalation of post-transplant cyclophosphamide dosing"||||
34111668|NCT03616340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111669|NCT06251310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will be conducted in two sequential parts: Part 1 dose escalation and Part 2 dose expansion.||||
33808099|NCT00139165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33808100|NCT03987074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111670|NCT06344416|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|A minimum of 50 and a maximum of 200 patient charts are expected to be reviewed for the control study group.|Study groups|t|f|f|f
34111671|NCT03690245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111672|NCT06153264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111673|NCT05077384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111674|NCT03477422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111675|NCT06317987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All study outcomes are extracted from secondary data including electronic health record and healthcare claims databases|Care coordinators will be randomized to two parallel groups: usual care (UC; i.e., the comparator group) and usual care plus care navigation (UC + CN; i.e., the experimental group). All care coordinators will continue offering substance use resources and treatment options to patients as usual. Clinicians randomized to UC + CN will be able to offer and refer patients to a care navigator.|f|f|f|t
34111676|NCT02927964|NA|SEQUENTIAL||TREATMENT||NONE||||||
34111677|NCT00019448||||TREATMENT||||||||
34111678|NCT05393492|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded analysis of linguistic markers of emotional regulation and free will by an independent laboratory|DBT for patients|f|f|f|t
34111679|NCT04132297|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111680|NCT04721717|||COHORT||PROSPECTIVE|||||||
34111681|NCT04031508|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The attendant gastroenterologist has a randomized allocation and will indicate the type of emulsion during the recruitment. Each emulsion will be designed as a code A or B. The code for each patient is stored into an opaque envelop, which is opened once the parents have given their written informed consent.|Use of a parenteral emulsion that is used as routine nutrition for newborns but not evaluated for persistent pulmonary hypertension.|t|t|f|t
34111682|NCT04203576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111683|NCT06298734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111684|NCT00689884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111685|NCT06638658|||COHORT||PROSPECTIVE|||||||
34111686|NCT02085720|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111687|NCT00734032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111688|NCT03931330|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the same electro auricular device||||
34111689|NCT04823026|||CASE_CONTROL||PROSPECTIVE|||||||
34111690|NCT02075060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111691|NCT02836249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111692|NCT04029779|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups were made one test and control. All the subjects were treated with immediate implants. In the test group subjects, injectable platelet-rich fibrin was coated around dental implants and was also injected in the socket. The control group received only dental implants.||||
34111693|NCT06634524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111694|NCT06132464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111695|NCT06151483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111696|NCT02686944|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34111697|NCT06549231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111698|NCT03003663|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111699|NCT04089358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34111700|NCT05230277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111701|NCT06055231|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34111702|NCT05745922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The personnel who will be analysing the milk samples will be blinded to which condition the samples were obtained from and the time-point.|Sequential assignment|f|f|f|t
34111703|NCT05078112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111704|NCT05677971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111705|NCT03039868|||CASE_CONTROL||PROSPECTIVE|||||||
34111706|NCT06645431|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34111707|NCT06630156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician and the assessor were blinded, but the operator was not because of the nature of the study|"The patients selected in this study were randomly divided into 2 groups:~1. Group A: 14 teeth were disinfected by triple paste and treated by Bio-MTA.~2. Group A: 14 teeth were disinfected by triple paste and treated by a Total Fill biocearmic root repair."|t|f|f|t
34111708|NCT05826665|||COHORT||PROSPECTIVE|||||||
34111709|NCT05145569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111710|NCT01421420|||COHORT||PROSPECTIVE|||||||
34111711|NCT02875418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111712|NCT03113344|||COHORT||PROSPECTIVE|||||||
34111713|NCT05724030|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33808101|NCT03184987|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111714|NCT03466151|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 Randomization||||
34111715|NCT03645460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111716|NCT06644053|||CASE_CONTROL||PROSPECTIVE|||||||
33808102|NCT06075030|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808103|NCT00291694|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34038444|NCT01351649|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038445|NCT00455403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038446|NCT00179972|||COHORT||PROSPECTIVE|||||||
34038447|NCT00856193|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34111717|NCT06261255|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical investigation is a single-center, prospective case series study and is reported in compliance with the Preferred Reporting of Case Series in Surgery (PROCESS) guidelines. The study was conducted at the Department of Periodontology of the University Complutense of Madrid between March 2021 and September 2023.||||
34111718|NCT01630109|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34111719|NCT01859013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111720|NCT00936936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111721|NCT03730350|RANDOMIZED|PARALLEL||TREATMENT||NONE|Random assignment to group will take place after baseline assessment. Patients who are randomly assigned to the clinical hypnosis group will immediately undergo their first in-person hypnosis session focused on preparing for surgery. Masking is not employed as patients will know if they are randomized to the intervention arm.|This study will conduct a 2-arm (intervention vs. treatment-as-usual) pilot RCT with patients currently undergoing oncology surgery at Toronto General Hospital. This study will recruit N = 92 patients (n = 46 psychology intervention, n = 46 control). The psychology intervention will be delivered by the TPS pain psychology team, under the supervision of Transitional Pain Service lead pain psychologist Dr. Aliza Weinrib. In addition, audio recordings developed by Dr. Weinrib will be provided to patients||||
34111722|NCT05888064|||COHORT||PROSPECTIVE|||||||
34111723|NCT01532154|||COHORT||PROSPECTIVE|||||||
34111724|NCT04855890|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The present study is a mono-center prospective randomized study enrolling 170 patients with PAF and no prior Ablation for AF.~Patients will be randomized to one of the following groups. Group A: Cryo-Ablation PVI will be performed using a Cryo-balloon. Group B: High-Power-Short-Duration PVI will be performed using HPSD RF-ablation. (70W over 5s posterior and 7s anterior) Catheter ablation procedures will be performed with commercially available devices including 3D mapping systems (EnSite, Abbott) and irrigated radiofrequency current (RFC) ablation or cryothermal balloon ablation (Arctic Front Advance Pro, Medtronic)."||||
34111725|NCT05543317|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111726|NCT05136560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111727|NCT05943678|||CASE_CONTROL||PROSPECTIVE|||||||
34111728|NCT02919618|NA|SINGLE_GROUP||TREATMENT||NONE||Noninvasive Cardiac Radioablation, all subjects||||
34111729|NCT05525390|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to receive either XR-enhanced behavioral activation or traditional behavioral activation.||||
34111730|NCT04245189|||OTHER||CROSS_SECTIONAL|||||||
34111731|NCT05932498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will not know which group they are in. Care provider, investigator, and outcomes assessor does not know which block participants will receive. The anesthesiologists who perform the blocks are not care provider, investigator, or outcomes assessor.|one group is that participants receive PENG block and another group is that participants receive QL block for postoperative pain control.|t|t|t|t
34111732|NCT06000696|||COHORT||PROSPECTIVE|||||||
34111733|NCT05548114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111734|NCT05731557|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34111735|NCT06067698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111736|NCT06267846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111737|NCT06201845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34111738|NCT00319189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111739|NCT05652569|||COHORT||PROSPECTIVE|||||||
34111740|NCT05750368|||COHORT||RETROSPECTIVE|||||||
34111741|NCT01585025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111742|NCT00867035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111743|NCT02663076|||COHORT||PROSPECTIVE|||||||
34111744|NCT02314195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111745|NCT04199026|NA|SINGLE_GROUP||OTHER||NONE||||||
34111746|NCT01508767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111747|NCT05706740|||OTHER||OTHER|||||||
34111748|NCT02771301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808104|NCT05987774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808105|NCT04682457|||CASE_CONTROL||PROSPECTIVE|||||||
33808106|NCT02610322|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808107|NCT04968509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808108|NCT04852757|||COHORT||CROSS_SECTIONAL|||||||
34038448|NCT00722228|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038449|NCT03849911|||COHORT||PROSPECTIVE|||||||
34038450|NCT00707629|||COHORT||CROSS_SECTIONAL|||||||
34038451|NCT01901458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038452|NCT03357068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split mouth design - one side of mouth is test group, other side is control group|t|f|f|t
34111749|NCT05585320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111750|NCT04636073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111751|NCT03868696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Sham ultrasound will be conducted in control group with screen off and facing away from participant.~Active US screen will also be turned away from participant in the US allocated group and no discussion allowed about the image."|1:1 randomised stratified by centre|t|f|t|t
34111752|NCT06581237|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111753|NCT02089269|||COHORT||PROSPECTIVE|||||||
34111754|NCT06627049|||OTHER||PROSPECTIVE|||||||
34111755|NCT00661856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34111756|NCT06010979|||COHORT||OTHER|||||||
34111757|NCT04322279|||COHORT||PROSPECTIVE|||||||
34111758|NCT05627037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|either the operator or the patient will be blinded for the primary outcome|Split-Mouth Study Model|f|t|f|t
34111759|NCT02439957|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34111760|NCT05651711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038453|NCT02835547|||COHORT||PROSPECTIVE|||||||
34111761|NCT01172782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34111762|NCT04429919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||placebo controlled, Phase IIa clinical trial|t|f|t|f
34038454|NCT03173898|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The method of anesthesia used for the left or right sides was blinded to the patient and determined randomly by the same surgeon (MA) who was not involved in the extraction. the extraction procedure was randomly commenced by the same resident who was blinded to the anesthetic technique administered randomly by the surgeon.participiants were also blinded to the type of technique applied on each side.|a prospective randomized double blinded, split mouth study|t|t|t|t
34038455|NCT02839603|||COHORT||PROSPECTIVE|||||||
34038456|NCT05888363|||COHORT||RETROSPECTIVE|||||||
34111763|NCT03758846|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34111764|NCT04087642|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111765|NCT02278003|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34111766|NCT01821755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111767|NCT05018481|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34111768|NCT05720104|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants in two groups (Study group and Control group) shall receive instructions for standard oral hygiene. The same assessments are done for participants in both groups, and within the same time periods.|Participants in two groups (Study group and Control group) shall receive instructions for standard oral hygiene. The same assessments are done for participants in both groups, and within the same time periods. The Study group will also be using the Lumoral Treatment device.||||
34111769|NCT06473688|||CASE_ONLY||PROSPECTIVE|||||||
34111770|NCT00184392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34111771|NCT04701242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will receive blinded drug containers. Care providers and investigators assessing study end-points will be blinded to group allocation of the patients Steering committee will be the only who have the key table for study-ID of the patient and allocation groups.|Double blinded, randomized controlled trial 1:1 randomization|t|t|t|f
34111772|NCT04707209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111773|NCT00619866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111774|NCT03966547|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34111775|NCT06634719|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Women with HMB||||
34111776|NCT04964700|||COHORT||RETROSPECTIVE|||||||
34111777|NCT06081920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111778|NCT06333561|||COHORT||RETROSPECTIVE|||||||
34111779|NCT02693639|||COHORT||PROSPECTIVE|||||||
34111780|NCT06296680|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|In order to prevent assessment bias, blinding was implemented throughout the collection of data from patients, evaluation of the effectiveness and reliability of the applied dependent variables, data processing, reporting, and statistical analysis. The researcher was provided with a randomization list by a statistical expert. The researcher was included in the study without knowing which group the patients would be assigned to, and the patients were also enrolled without knowledge of their group assignment. Therefore, this study was conducted as a three-arm, double-blind, randomized follow-up study in the experimental research model, with intervention, placebo, and control groups.|This study is a three-arm intervention trial. Reiki was applied to the intervention group, Sham Reiki to the placebo group, and Progressive Relaxation Exercise to the control group. The effects of these three methods applied to cancer patients on their levels of pain, anxiety, and cortisol were examined.|t|f|t|f
34111781|NCT06000683|NA|SINGLE_GROUP||SCREENING||NONE||||||
34111782|NCT04835259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111783|NCT03199079|||CASE_CONTROL||PROSPECTIVE|||||||
34111784|NCT03238573|||COHORT||PROSPECTIVE|||||||
34111785|NCT02445911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038457|NCT00070031||||TREATMENT||NONE||||||
34111786|NCT06565351|||COHORT||RETROSPECTIVE|||||||
34111787|NCT04942145|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34111788|NCT06547320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111789|NCT01809431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34111790|NCT02427932|||COHORT||PROSPECTIVE|||||||
34111791|NCT01269775|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34038458|NCT05495282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigator and outcomes assessor will be masked|Single-center cross over design|f|f|t|t
34038459|NCT05961046|||COHORT||PROSPECTIVE|||||||
34038460|NCT06301438|||COHORT||PROSPECTIVE|||||||
34038461|NCT01013272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038462|NCT05790681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038463|NCT02285101|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038464|NCT03832569|NA|SINGLE_GROUP||TREATMENT||NONE||This is a randomized, double-blind study of adjuvant pembrolizumab or placebo in patients with MSI-H solid tumors with persistent circulating tumor DNA (ctDNA) despite curative surgery and completion of standard perioperative and/or adjuvant therapy||||
34038465|NCT04012736|||CASE_CONTROL||PROSPECTIVE|||||||
34111792|NCT03859011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Control Trial||||
34111793|NCT06048458|||COHORT||PROSPECTIVE|||||||
34111794|NCT01621100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111795|NCT04910867|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||A non-randomized, pre-post design. Data will be collected from participants at both sites during a control period, prior to implementing the intervention, and during an intervention period, under the proposed APOL1 genetic testing program.||||
34111796|NCT06250673|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A total of 48 people, 16-16-16.|t|f|t|t
34111797|NCT06422676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34111798|NCT03549325|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Group 1: Nasal inoculation with Neisseria lactamica with eradication on day 4 - up to 22 volunteers or until 11 colonised on day 4 Group 2: Nasal inoculation with Neisseria lactamica with eradication on day 14 - up to 22 volunteers or until 11 colonised on day 4||||
34111799|NCT03033784|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34111800|NCT03931551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111801|NCT01537328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34111802|NCT05532800|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34038466|NCT01352572|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34111803|NCT05593289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34111804|NCT06570304|||COHORT||RETROSPECTIVE|||||||
34111805|NCT05628571|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Randomization lists will be kept confidential by the Investigator, inside a locked cabinet. As patients are included by the Examiner at the first visit (T0), the Investigator will make the allocation. The Examiner and other team members, including the Laboratory Technician, will not know the group to which the patient belongs.~Toothpastes will be covered with white paper to disguise the identity of the product.~Participants will also not know which group they belong to and which investigational product they are using. To this end, the products will be distributed in a separate area of the exam room by the Assistant, without the other participants being present.~The samples will also be labeled with the information of the participant's first and last name initials, the randomization code and the sample collection data (type, intraoral location and collection date). The Laboratory Technician will not know which group the sample belongs to."||t|t|f|t
34111806|NCT01296204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111807|NCT01224314|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34111808|NCT00005315|||COHORT||PROSPECTIVE|||||||
34111809|NCT05213741|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34111810|NCT03225404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assesor|A specialist physician will be diagnosed the epicondylitis|t|f|f|f
34111811|NCT06040788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111812|NCT06142591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34111813|NCT03045952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038467|NCT02716714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111814|NCT01784484|||||PROSPECTIVE|||||||
34111815|NCT00427037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111816|NCT00236041|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34111817|NCT00433485||||PREVENTION||NONE||||||
34111818|NCT00924274|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111819|NCT06564571|||COHORT||PROSPECTIVE|||||||
34038468|NCT04703972|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038469|NCT02365441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038470|NCT05768711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038471|NCT01186068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038472|NCT02530723|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Functional testers are masked to what group the participants are in (control, Exercise Group I, II, or III). All testers are masked during baseline testing.|With 3 groups and a wait-control group, our general design will include 4 (group) x 2 (baseline and post-study) and 4 (group) x 3 (baseline, midpoint, and post-study) analyses. We may also conduct one-way ANOVA analyses as problems with normality in the data are apparent.|f|f|f|t
34038473|NCT03484962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,non-intervention therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.|This is a phase II clinical trial of single-center, and it will divide into three groups.|t|t|t|t
34038474|NCT02458144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34038475|NCT00958828|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34038476|NCT06348069|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Groups (sites/clusters) are randomized to either the intervention (pharmacy-based PrEP refills plus gift card incentives) or the control (standard of care) and are followed and compared over time.||||
34038477|NCT06101966|||COHORT||PROSPECTIVE|||||||
34038478|NCT05663125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038479|NCT05958043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038480|NCT03801005|||OTHER||PROSPECTIVE|||||||
34038481|NCT01977105|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038482|NCT03573973|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Natural experiment with prospective matched controlled cluster design. The setting is a UK discount supermarket chain.||||
34038483|NCT01164293|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038484|NCT01127997|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34038485|NCT03726827|||OTHER||OTHER|||||||
34038486|NCT00574704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038487|NCT01421979|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34111820|NCT04826302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients will be assigned to two groups:~* Experimental group: who will receive myofascial intervention~* Control / placebo group: who will receive sham myofascial intervention~Neither the participants assigned to the groups nor the evaluators who measure the variables know to which group the subjects belong.~Participants will be randomly assigned through the GraphPad software."|"A randomized double blind clinical trial controlled with placebo in which neither the participants assigned to the groups nor the evaluators who measure the variables know to which group the subjects belong.~To be part of the study, participants must obtain high scores in anxiety (STAI questionnaire).~The calculation estimates a sample of 36 participants: 18 for the experimental group and 18 for the placebo group.~Participants will be randomly assigned to the experimental group or the placebo group.~In addition to anxiety levels before and after treatment, variables such as chronic pain, central sensitization, general health, somatization and depression will be measured."|t|f|f|t
34111821|NCT02843633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111822|NCT06349213|||CASE_CONTROL||PROSPECTIVE|||||||
34111823|NCT03901430|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants are given ID numbers and all data is coded with ID number|||||
34111824|NCT03634384|||COHORT||PROSPECTIVE|||||||
34111825|NCT04759287|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The patients will be randomly assigned into two equal groups using computer-generated randomization technique. The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS. The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.|t|f|t|f
33808109|NCT04824625|||COHORT||PROSPECTIVE|||||||
34038488|NCT04861753|||CASE_CONTROL||PROSPECTIVE|||||||
33808110|NCT01116206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808111|NCT05113134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808112|NCT05329519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 parallel group randomized controlled||||
33808113|NCT04495140|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33808114|NCT01945320|||COHORT||PROSPECTIVE|||||||
33808115|NCT04923022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808116|NCT02285218|||COHORT||PROSPECTIVE|||||||
33808117|NCT00764582|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33808118|NCT01292213|||CASE_CONTROL||PROSPECTIVE|||||||
33808119|NCT03905642|NA|SINGLE_GROUP||TREATMENT||NONE||Extension phase for evaluation of safety, tolerability and efficacy. Single dose group of 560 mg of Arikase TM||||
33808120|NCT00687869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34111826|NCT03577457|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34111827|NCT03223675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111828|NCT05188014|NA|SINGLE_GROUP||OTHER||NONE||||||
34111829|NCT02009267|||COHORT||RETROSPECTIVE|||||||
34111830|NCT00741377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111831|NCT04835129|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34111832|NCT02946203|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34111833|NCT03322566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111834|NCT03439488|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
34111835|NCT04450953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"* Arm A in which they will receive eplerenone 50mg/day taken orally for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period without eplerenone, until the end of the study.~* arm B where they will be eplerenone-free for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period in which they will receive eplerenone 50 mg/day as a single dose taken orally."||||
34111836|NCT03277599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective,randomized,single blind|f|f|f|t
34111837|NCT00441324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111838|NCT04890509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111839|NCT04997850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111840|NCT00654602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111841|NCT02615288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111842|NCT02978495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111843|NCT03765931|RANDOMIZED|PARALLEL||TREATMENT||NONE||We aimed to determine the efficacy of a single dose of doxycycline compared to a 5-day amoxicillin course for the treatment of fever.||||
34111844|NCT05728554|||OTHER||RETROSPECTIVE|||||||
34111845|NCT03014089|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34111846|NCT01691911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34111847|NCT02259803|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34111848|NCT04778566|||COHORT||PROSPECTIVE|||||||
34111849|NCT06563882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111850|NCT04943679|||COHORT||PROSPECTIVE|||||||
34111851|NCT02247128|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111852|NCT00478257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33808121|NCT05995795|||COHORT||PROSPECTIVE|||||||
33808122|NCT00786864|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33808123|NCT05608070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Blinding will be performed by the Investigational Research Pharmacy. The Investigational Research Pharmacy will have the randomization key and prepare medication or placebo. The study medication or placebo in 500 ml bag of labeled as Oxytocin Study Drug for IV infusion."||t|t|t|t
33808124|NCT02124252|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33808125|NCT04000399|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|"Outcomes assessors will be masked to the intervention condition at follow-up assessment timepoints.~See notes on pre-assignment details in participant flow related to study model single arm vs. multi arm."|"Ultimately, this study design was an open trial after unsuccessful attempts to maintain initial recruitment sites in the study.~This study initially attempted to use a stepped wedge design, which involves the sequential random rollout of an intervention over 2 time periods. Following a baseline period in which no clusters (= practices) are exposed to the intervention, the crossover is typically in one direction, from control to intervention and continues until both of the clusters have crossed-over to receive the intervention, with observations taken from each cluster and at each time period."||||
34111853|NCT06240676|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be given the option of two envelopes, one of which is experiment and the other is control. Participants will be asked to choose one of the two envelopes when applying to the obstetrics clinic of the hospital.|THE FEMALE MILK OF TWO GROUPS WILL BE COMPARED WITH EDUCATIONAL AND NON-EDUCATIONAL|t|f|f|f
34111854|NCT03781063|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label, randomized, parallel-group, multicenter study||||
34111855|NCT04430998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111856|NCT01542892|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34111857|NCT04194827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During every study visit the joints of all patients will be examined for pain and swelling by a blinded nurse or physician. The number of painful and swollen joints will be used to calculate the DAS28 score, the primary outcome of the study|Rheumatoid arthritis patients treated with adalimumab will be randomly assigned to a dose reduction strategy using disease activity scores or to a dose reduction strategy using serum drug concentrations|f|f|f|t
34111858|NCT04408612|||CASE_ONLY||PROSPECTIVE|||||||
34111859|NCT04236076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808126|NCT01121328|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808127|NCT00772902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808128|NCT04828109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33808129|NCT02351791|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33808130|NCT05950607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33808131|NCT03040856|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33808132|NCT06509204|NA|SINGLE_GROUP||OTHER||NONE||||||
33808133|NCT00777894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808134|NCT02430766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33808135|NCT04192357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808136|NCT01023542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808137|NCT05977985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808138|NCT01343797|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33808139|NCT03062072|||COHORT||PROSPECTIVE|||||||
33808140|NCT03428438|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects recruited will be randomized into two groups: one group of subjects (the study group) A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E. The second group (the control group) will be given a routine training in the ward by a nurse and you will receive a weekly SMS message||||
33808141|NCT01595451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808142|NCT03090711|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33808143|NCT01030237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808144|NCT06140550|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ratio of control group to test group 1:1||||
33808145|NCT02795884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808146|NCT01513616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808147|NCT05190172|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Experimental treatment arm with proton radiationtherapy~* Standard treatment arm with photon radiationtherapy"||||
34038489|NCT01401764|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34038490|NCT00669669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038491|NCT01342523|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34038492|NCT00594165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038493|NCT05523102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient does not know what analgetics are given, investigator also do not evaluate pain therefore is masked from the intervention given|Computer generated, randomized selection of patients with 50% probability of assignment into either group Treatment group : paracetamol group Control Group: ketorolac|t|f|t|f
34038494|NCT04200651|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This prospective study enrolled 29 eyes from 25 total patients. The protocol permitted some binocular enrollment from patients who met eligibility criteria in both eyes.~All eligible eyes received concomitant cataract and MIGS surgery. Each eye was randomized to receive either DEXTENZA® insertion at the end of the surgery or to a standard of care prednisolone acetate 1% eye drop regimen via block randomization. All eyes received the standard of care topical ofloxacin antibiotic regimen. The experimental group consisted of the eyes receiving DEXTENZA® insertion. The control group consisted of the eyes placed on the prednisolone eye drop regimen."||||
34038495|NCT03077737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038496|NCT02337335|||CASE_CROSSOVER||PROSPECTIVE|||||||
34038497|NCT03045263|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34038498|NCT04909853|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34038499|NCT02152904|||COHORT||PROSPECTIVE|||||||
34111860|NCT06588582|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111861|NCT04441502|||COHORT||PROSPECTIVE|||||||
34111862|NCT01910454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111863|NCT00834574|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34111864|NCT03049644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111865|NCT01930500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111866|NCT04507204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111867|NCT04765397|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to the resectoscopes used during the operation, patients will be divided into 2 groups as Monopolar one (Group M) and Bipolar one (Group B).||||
34111868|NCT05095922|RANDOMIZED|PARALLEL||TREATMENT||NONE||The type 2 diabetes subjects with diabetic microangiopathy||||
34111869|NCT06572137|||OTHER||CROSS_SECTIONAL|||||||
34111870|NCT00754572|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111871|NCT06539481|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34111872|NCT01188967|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34111873|NCT02209987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111874|NCT04214509|||OTHER||CROSS_SECTIONAL|||||||
34111875|NCT03539679|RANDOMIZED|PARALLEL||OTHER||SINGLE|Exclusion criteria is that a volunteer must be health enough to have permission to take part in the military fitness tests.|Intervention group and control group.|t|f|f|f
34111876|NCT00645658|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111877|NCT06562829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||From May 2020 to May 2021, children requiring PICC were recruited by convenience sampling and divided into three groups: A, B and C. Group A was implanted with PICC under ultrasound guidance. Group B and group C all used VR intervention and used VR equipment 5 minutes before the operation began. Group B was anesthetized afterthe puncture needle was sent into the guide wire, and group C was anesthetized before the puncture needle was sent into the guide wire. The success rate of one puncture, pain, fear, compliance and catheterization time were compared among the three group||||
34111878|NCT04306926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111879|NCT00651287||PARALLEL||TREATMENT||NONE||||||
34111880|NCT02003313|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34111881|NCT06642649|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, controlled, prospective, multi-center||||
34111882|NCT03773484|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34111883|NCT01370044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111884|NCT05128747|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||diabetic patients type2 with dyslipidemia|t|f|f|f
34111885|NCT02009787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111886|NCT04089696|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Intervention study||||
34111887|NCT00000720||||TREATMENT||DOUBLE||||||
34111888|NCT01040247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111889|NCT01734044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150058|NCT03562468|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"The study site will be provided placebo and TRU NIAGEN capsules, each labeled with the protocol number, blinded product code, expiration date, batch number, the statement For Investigational Use Only and a space to write the subject's initials, screen and date dispensed."|Treatments will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design.|t|t|t|t
34150059|NCT02434328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808148|NCT06261437|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33808149|NCT03789357|||COHORT||PROSPECTIVE|||||||
33808150|NCT03136822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The wound will be assessed by Pathologists who are masked for treatment|Open label, controlled, randomised, parallel arm study|f|f|f|t
33808151|NCT00780806|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33808152|NCT05559645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808153|NCT05897905|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33808154|NCT05913700|||COHORT||PROSPECTIVE|||||||
33808155|NCT03770520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|QFR will be masked to care providers and participants, and open to investigators, the allocation will be based on QFR.||t|t|f|f
33808156|NCT06509282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The concealment of allocation will be conducted by a researcher not involved in the clinical procedures of the intervention using the method of opaque, sealed, and consecutively numbered envelopes. The random sequence and allocation concealment allow for the control of selection bias.~For enhanced bias control, the data analysis will be performed by a researcher blinded to the intervention groups."||f|t|t|t
34111890|NCT03802019|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be informed that they will be supplied with study cigarettes with a low nicotine content, but will be blinded to the exact nicotine content and unaware that all packages will contain the same type of low nicotine content cigarette.|This project will recruit current, daily cigarette smokers to a 35-day, randomized, controlled, parallel design protocol. After a 5-day period of smoking their own preferred brand cigarettes, participants will be randomized to a 30-day experimental period when they will receive either their own preferred brand (control group), or LNC cigarettes in one of four types of packaging: standard investigational (current gray packaging); red, or blue (tobacco industry strategy); or plain packaging (tobacco control strategy), for 30 days.|t|f|f|f
34111891|NCT05856396|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Researchers analyzing the immunological outcomes will be blinded to the groups of the subjects (pregnant vs non pregnant ; infants)|"* Non pregnant and pregnant women will be recruited in parallel~* Infants born to Tdap vaccinated-mothers (enrolled or not in the study) or not vaccinated mothers will be recruited"|f|f|f|t
34111892|NCT05642338|||COHORT||PROSPECTIVE|||||||
34111893|NCT00244985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111894|NCT01395082|||COHORT||PROSPECTIVE|||||||
34111895|NCT03231553|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34111896|NCT05759767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111897|NCT02878785|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34111898|NCT02647502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111899|NCT05386966|||OTHER||PROSPECTIVE|||||||
34111900|NCT05977296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111901|NCT04610515|||COHORT||PROSPECTIVE|||||||
34111902|NCT03903783|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34111903|NCT05994287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111904|NCT02987387|||COHORT||PROSPECTIVE|||||||
34111905|NCT02020226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111906|NCT00175500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111907|NCT06150430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111908|NCT05098821|||CASE_CONTROL||PROSPECTIVE|||||||
34111909|NCT02662751|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34111910|NCT06571058|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111911|NCT05444387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34111912|NCT04932148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34111913|NCT05704387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Principal investigator, the patient, the surgeon and the outcome assessor will not know the study group allocation|prospective randomized controlled parallel superiority trial|t|f|t|t
34111914|NCT05765721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research assistants are trained for being outcomes assessors in this study who did not know the allocation of participants.|Patients in the intervention group will receive an 8-week family-based frailty self-management program including:individual consultation, teaching how to do self-management by family-based frailty self-management video.|f|f|f|t
34111915|NCT06564935|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34111916|NCT02227745|||COHORT||PROSPECTIVE|||||||
34111917|NCT04611243|||COHORT||PROSPECTIVE|||||||
34111918|NCT03110562|RANDOMIZED|PARALLEL||TREATMENT||NONE||Primary part is parallel (SVd vs Vd treatment arm). Participants who received Vd were allowed to cross-over to receive either SVd or SdX treatment arm.||||
34111919|NCT05007704|||COHORT||CROSS_SECTIONAL|||||||
34111920|NCT04377373|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34111921|NCT05603676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded means that participants will not be inform than a half will follow a placebo intervention.|This project is a single center national study. It is designed as a randomized single-blinded parallel group control study. Single-blinded means that participants will not be inform than a half will follow a placebo intervention. Parallel group means that the design serves to compare different experimental conditions. Randomized means that the participants are assigned to the two different conditions randomly (by chance alone). Control means that one of the group/conditions is the standard of comparison (control participant achieving placebo and IHHC interventions). A follow-up, one month after the intervention will be done.|t|f|f|f
34111922|NCT05478876|NA|SINGLE_GROUP||TREATMENT||NONE||"cohort of 9 patients with primary gynecological melanoma. The intervention consists in carbon ion radiation therapy.~The expected duration of treatment is 4 weeks, 4 fractions per week."||||
34111923|NCT01442610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111924|NCT05781451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111925|NCT03416894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111926|NCT05923723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34111927|NCT02006511|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111928|NCT00520338|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34111929|NCT03172767|||CASE_CONTROL||PROSPECTIVE|||||||
34111930|NCT00285194|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111931|NCT04389060|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double blind, cross-over design||t|f|t|f
33808157|NCT02170532|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808158|NCT02792855|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33808159|NCT01034488|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33808160|NCT04203966|||OTHER||CROSS_SECTIONAL|||||||
33808161|NCT00527267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808162|NCT02994524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808163|NCT02646618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038500|NCT05006287|RANDOMIZED|PARALLEL||TREATMENT||NONE||a multi-center, prospective, randomized, open-label, blinded-endpoint (PROBE) pilot study||||
34038501|NCT02628808|||CASE_CONTROL||PROSPECTIVE|||||||
34038502|NCT04823468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808164|NCT04715815|||COHORT||PROSPECTIVE|||||||
33808165|NCT06509854|||COHORT||RETROSPECTIVE|||||||
33808166|NCT05389618|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33808167|NCT01372085|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33808168|NCT00610558|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Three different Groups in this study: Juvenile Myoclonic Epilepsy, Frontal Lobe Epilepsy, Normal Controls||||
33808169|NCT00760591|||COHORT||PROSPECTIVE|||||||
34038503|NCT04421131|NA|SINGLE_GROUP||SCREENING||NONE||||||
34038504|NCT03809975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038505|NCT02913118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34038506|NCT05370040|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Open label 6 Cohort Phase 1 Study leading to Randomized 4 Cohort Phase 2 Study|t|t|t|f
34038507|NCT01380912|||CASE_CONTROL||PROSPECTIVE|||||||
34038508|NCT01933074|||CASE_ONLY||PROSPECTIVE|||||||
34111932|NCT00129974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111933|NCT00166920|||DEFINED_POPULATION||OTHER|||||||
33808170|NCT05364840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111934|NCT00571714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111935|NCT03723473|||COHORT||PROSPECTIVE|||||||
33725211|NCT06485063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to which group they will belong, as they never had contact to the technique investigated. The statistical analysis will be blinded as well, and the statistical will not know which is the experimental or the placebo group.|Two-arm Randomized Clinical Trial, presenting a placebo and a experimental group.|t|f|f|t
33725212|NCT03710655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|randomization and blinded personnel at site|1-1 in two studies of 468 patients total patients 936|t|f|t|t
33725213|NCT03474887|||COHORT||PROSPECTIVE|||||||
33808171|NCT01642719|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33808172|NCT03489785|||OTHER||RETROSPECTIVE|||||||
33808173|NCT04092322|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808174|NCT04136990|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will be blinded to the patient group|Non-randomized 1:1 allocation|f|f|f|t
33808175|NCT06194695|||COHORT||PROSPECTIVE|||||||
33808176|NCT04666181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038509|NCT06162364|RANDOMIZED|PARALLEL||OTHER||SINGLE||A sample of 79 voluntary students was divided into three groups through simple randomization: VR group (N=27), theoretical education group (N=27), and video education group (N=25). The VR group received education using VR goggles, the theoretical group underwent traditional theoretical education, and the video group was educated through video content on surgical handwashing and sterile dressing. For the VR group, 3D videos were presented using VR goggles, while the video group experienced 2D video content. The theoretical group was allocated self-study time. Subsequent to the educational interventions, student performance, self-confidence, and satisfaction were evaluated. Data collection involved various forms assessing skills, knowledge, technology usage, method satisfaction, and self-confidence.|f|f|f|t
33808177|NCT01933997|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808178|NCT05188144|||COHORT||PROSPECTIVE|||||||
34038510|NCT03798028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038511|NCT05669625|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34038512|NCT00923741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038513|NCT03490552|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||A double blind, randomized, controlled investigational study|t|t|t|f
34038514|NCT04168268|||COHORT||PROSPECTIVE|||||||
34038515|NCT01960413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038516|NCT02389309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038517|NCT02239731|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038518|NCT05112081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For randomization the research coordinator will place an information sheet containing the randomization in sealed envelopes (1:1 block randomization). At first treatment the research coordinator will open a sealed envelope revealing the randomization and prepare the solution needed. The patient and physician will be blinded for the treatment.|"This study is a prospective, randomized, placebo-controlled, double-blinded multi-center trial. Patients are included from the whole region of Southern Denmark.~In case of successful spermatic cord block patients will be randomized to either BTX cord block or injection with sterile saline. Patients will be followed up according to the questionnaires. After three months, patients in the control arm will have the option to cross-over to the intervention arm."|t|f|t|f
34038519|NCT03397589|RANDOMIZED|PARALLEL||OTHER||SINGLE|Because of the nature of the intervention, participants will know after randomization which arm they are in. Outcomes assessors and data analysts will be masked to study arm. Most investigators will be masked to study arm.|cluster-randomized two arm trial with wait list control|f|f|f|t
34038520|NCT00295581||||TREATMENT||||||||
34038521|NCT01272050|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34038522|NCT02418884|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038523|NCT05989061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038524|NCT01842438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34038525|NCT06201923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||0.2% thyme honey mouth rinse as intervention|t|t|f|f
34038526|NCT03376724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038527|NCT05338164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038528|NCT00660517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038529|NCT03850483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038530|NCT04727905|NON_RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
34038531|NCT05029518|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34038532|NCT01310842|||COHORT||PROSPECTIVE|||||||
34038533|NCT06128330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038534|NCT02843048|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038535|NCT01731119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038536|NCT04006639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34038537|NCT06359223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111936|NCT05586295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111937|NCT05770973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized for compression dressing or none|f|f|t|f
34111938|NCT01358734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111939|NCT01911260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34111940|NCT02323048|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34111941|NCT01285102|NA|SINGLE_GROUP||TREATMENT||NONE||The first cohort of patients will receive a dose of 50 mg of irinotecan per DEBIRI treatment. We will escalate by 25 mg with subsequent cohorts up to a dose of 100 mg of irinotecan per DEBIRI treatment.||||
34111942|NCT05288192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111943|NCT04717466|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34111944|NCT01640080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34111945|NCT02663362|||COHORT||CROSS_SECTIONAL|||||||
34150060|NCT05989659|||COHORT||PROSPECTIVE|||||||
34150061|NCT06437912|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33808179|NCT01448109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808180|NCT01233934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038538|NCT05227859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038539|NCT02092376|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038540|NCT01368601|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150062|NCT01277315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808181|NCT02368041|||CASE_CONTROL||PROSPECTIVE|||||||
34038541|NCT00840164|||||PROSPECTIVE|||||||
33808182|NCT02070809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808183|NCT05499663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038542|NCT01524159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038543|NCT02720718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038544|NCT06091813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34038545|NCT05933733|||COHORT||PROSPECTIVE|||||||
34038546|NCT02627313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038547|NCT01874808|||OTHER||OTHER|||||||
34038548|NCT00360061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038549|NCT03332355|NA|SINGLE_GROUP||TREATMENT||NONE||PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1) and 150 mg/m2 dose of temozolomide given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.||||
34038550|NCT02394210|||COHORT||PROSPECTIVE|||||||
34038551|NCT04949815|||CASE_ONLY||RETROSPECTIVE|||||||
34038552|NCT06250582|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34038553|NCT04311866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038554|NCT02094482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038555|NCT05000151|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34038556|NCT05338840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038557|NCT01160692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808184|NCT02934932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808185|NCT05949866|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors (outcome assessors) collecting cognition outcome variables will be masked.|Childcare centers will be randomized to either the treatment or the control intervention.|f|f|f|t
33808186|NCT03963466|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33808187|NCT04148560|NA|SINGLE_GROUP||OTHER||NONE||||||
33808188|NCT04973306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808189|NCT04919395|RANDOMIZED|PARALLEL||TREATMENT||NONE||Information regarding the planned intervention study model was removed, as the trial did not meet its recruitment goals.||||
33808190|NCT06002035|||CASE_CONTROL||PROSPECTIVE|||||||
33808191|NCT01608113|||COHORT||PROSPECTIVE|||||||
33808192|NCT04436016|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"Single center, randomized, placebo-controlled, double-blind, parallel group, feasibility pilot trial.~Patients will be randomized to receive ivabradine or placebo."|t|t|t|t
33808193|NCT05201599|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with upper urinary stones ≤ 2cm in diameter will be assigned to intervention group (FURL-ICP group) or control group (f-URL) by a simple random sampling technique with a rate of 1:1.||||
34111946|NCT04093453|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators will be masked to the contents of the capsules (sodium propionate or sodium chloride). They will not be masked to whether it is a resting or exercise or fasting condition as this is not possible.|This protocol consisted of three individual trials.|t|f|t|f
34111947|NCT03048682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34111948|NCT06639646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111949|NCT05424588|||CASE_ONLY||PROSPECTIVE|||||||
34111950|NCT03864848|NA|SINGLE_GROUP||TREATMENT||NONE||Registry||||
34038558|NCT06444919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038559|NCT03493191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038560|NCT03926117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo||t|t|t|t
34111951|NCT01524744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34038561|NCT01277601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111952|NCT04827030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB)|t|f|t|t
34038562|NCT01804946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038563|NCT00739323|||CASE_CONTROL||PROSPECTIVE|||||||
34038564|NCT03665220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038565|NCT04166474|NA|SEQUENTIAL||TREATMENT||NONE||||||
34038566|NCT05518851|||COHORT||PROSPECTIVE|||||||
34038567|NCT01976182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038568|NCT03648320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038569|NCT03589417|||OTHER||PROSPECTIVE|||||||
34038570|NCT04868708|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038571|NCT01759472|||CASE_CONTROL||PROSPECTIVE|||||||
34038572|NCT02694822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038573|NCT05244057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038574|NCT00165464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038575|NCT03858972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038576|NCT00857675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34038577|NCT01837901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038578|NCT04181086|||OTHER||CROSS_SECTIONAL|||||||
34038579|NCT03096860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34038580|NCT00520377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038581|NCT05035290|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Critically ill paediatric patients scheduled for weaning from mechanical ventilation will be randomized to interventional group (negative pressure ventilation) and control group (standard approach)||||
34038582|NCT00461877|||COHORT||PROSPECTIVE|||||||
34038583|NCT00843765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038584|NCT05783063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled clinical trial testing iTBS versus sham|t|t|t|t
34038585|NCT05680519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038586|NCT05682209|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients scheduled for modified radical mastectomy (MRM) were randomized into a treatment group that received 100µg of octreotide and a control group that received 1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day|t|f|t|t
34038587|NCT00520312|||COHORT||PROSPECTIVE|||||||
34038588|NCT05629858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038589|NCT06283329|||COHORT||PROSPECTIVE|||||||
34038590|NCT02446067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038591|NCT04682808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038592|NCT01244438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038593|NCT04527692|||CASE_ONLY||PROSPECTIVE|||||||
34038594|NCT01378728|||COHORT||PROSPECTIVE|||||||
34038595|NCT04457908|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34038596|NCT04097054|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A single centre randomized open label trial.||||
34038597|NCT00000115|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34038598|NCT05922722|||CASE_ONLY||PROSPECTIVE|||||||
34038599|NCT04593485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34111953|NCT06122168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients, within the database, will be identified as group A and B; Once the study and the compilation of the database have been completed, this will be delivered to the results evaluation team which will therefore be blinded, not being able to recognize whether group A and B belong to control or intervention.|single center, prospective, randomized trial|f|f|f|t
34111954|NCT06317844|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34111955|NCT05336695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will receive the same injection of 64Cu-FBP8 and undergo PET/MR imaging.||||
34111956|NCT00414154|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111957|NCT03870568|||COHORT||PROSPECTIVE|||||||
34111958|NCT04466839|||CASE_ONLY||PROSPECTIVE|||||||
34111959|NCT05432167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34111960|NCT06089603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111961|NCT01890031|RANDOMIZED|PARALLEL||||NONE||||||
34111962|NCT06308237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated.||f|f|f|t
34038600|NCT04686799|NA|SINGLE_GROUP||OTHER||NONE||The plan for achieving the specific aims is to first assess patient receptiveness by screening patients with symptomatic lateral or medial elbow tendinopathy for eligibility and tracking the proportion of eligible patients who decline participation in the study due to not wanting to take an extended course of SD-doxycycline. 25 subjects will given SD-doxycycline and have the tendinopathy grade measured by ultrasound. The medication will be prescribed for 12 weeks during which time logs will be used to track compliance and monitor side effects. This will be done in combination with usual care, which includes a home exercise program, a counterforce brace, and over-the-counter pain medication to use as needed. Clinical effectiveness outcomes will include patient reported outcomes, ultrasound tendinopathy grade, grip strength, and markers of MMP activity and collagen production/connective tissue anabolism.||||
34038601|NCT01205776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111963|NCT05379530|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Thromboelastography (TEG) analysis will be done on all subjects who consent to participate in the study. TEG results will be made available to the anesthesiologist caring for the subject and may be used to help guide their care.||||
34111964|NCT05540483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111965|NCT04406454|||CASE_ONLY||PROSPECTIVE|||||||
34111966|NCT01328600|||||OTHER|||||||
34111967|NCT01616147|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34111968|NCT03766672|||COHORT||PROSPECTIVE|||||||
34111969|NCT01107886|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038602|NCT01984333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34111970|NCT05534126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34111971|NCT04922216|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||This study uses a full factorial experimental design testing the efficacy of five intervention components, each with two levels|f|f|t|t
34111972|NCT06559332|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Clinical event adjudication committee will be blinded to group allocation.||f|f|f|t
34111973|NCT05904483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34111974|NCT01927614|||COHORT||PROSPECTIVE|||||||
34111975|NCT04382092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective interventional study||||
34111976|NCT01772654|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34111977|NCT03487133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111978|NCT05613231|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111979|NCT04958603|||CASE_ONLY||RETROSPECTIVE|||||||
34111980|NCT04017858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111981|NCT05857241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111982|NCT01229566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111983|NCT01656122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808194|NCT03490032|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Phase I: characterize PK and dosimetry Phase II: diagnostic potential in 2 groups~1. Prostate Cancer in biochemical relapse, and~2. Metastatic Prostate Cancer"||||
33808195|NCT06079736|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808196|NCT00431054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808197|NCT02971969|||COHORT||PROSPECTIVE|||||||
34038603|NCT05000164|NA|SINGLE_GROUP||TREATMENT||NONE|Subjects will be unaware of the identity of the investigational product to help reduce potential bias|||||
34038604|NCT00174304|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038605|NCT03145844|||COHORT||RETROSPECTIVE|||||||
34038606|NCT04488341|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34111984|NCT04282785|||COHORT||PROSPECTIVE|||||||
34111985|NCT01194037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808198|NCT01020266|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34111986|NCT00601731|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34111987|NCT02935036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34111988|NCT02329808|||COHORT||PROSPECTIVE|||||||
34111989|NCT03642613|||COHORT||CROSS_SECTIONAL|||||||
33808199|NCT01354145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808200|NCT04760678|||COHORT||PROSPECTIVE|||||||
33808201|NCT03488459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33808202|NCT03932214|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects will be divided into two groups with a 1: 1 ratio. Each patient will be assigned to one of the following 2 arms:~- Usual technique : Visualization of the vein to be catheterized will be done directly. without infrared illumination.~or~-Use of the Accuvein® device: Visualization of the vein to be catheterized will be done with infrared illumination.~In both groups, catheterization will be carried out according to the usual technique in accordance with the recommendations."||||
33808203|NCT01555138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808204|NCT01472406|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33808205|NCT01286532|||COHORT||PROSPECTIVE|||||||
33808206|NCT02140879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33808207|NCT06116968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038607|NCT05902884|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038608|NCT05933018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038609|NCT01268553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038610|NCT03029286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34038611|NCT01978132|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038612|NCT05079672|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34038613|NCT04336280|||CASE_ONLY||RETROSPECTIVE|||||||
34038614|NCT02445261|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038615|NCT06431724|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34038616|NCT04445025|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Test group will receive Elagolix 60 days prior to initiating frozen embryo transfer preparation.~Control group will receive depot leuprolide twice (once every 28 days) prior to initiation frozen embryo transfer preparation."||||
34111990|NCT00003680|RANDOMIZED|||TREATMENT||||||||
34111991|NCT04337970|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34111992|NCT01312831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111993|NCT03935347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111994|NCT02101463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111995|NCT05371327|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34111996|NCT06501898|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34111997|NCT01715116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34111998|NCT01495013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34111999|NCT00291837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112000|NCT05607472|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112001|NCT02642757|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34112002|NCT02294864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112003|NCT00806130|||OTHER||CROSS_SECTIONAL|||||||
34112004|NCT03572283|NA|SINGLE_GROUP||OTHER||NONE||Phase 0 study to assess the impact of bethanechol on pancreatic cancer biomarkers||||
34112005|NCT05727332|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group and negative control group||||
34112006|NCT04734392|||CASE_CONTROL||PROSPECTIVE|||||||
34112007|NCT03682744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112008|NCT05626712|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a two-arm, open label, randomized trial. Subjects who meet eligibility criteria will be randomized to treatment or control groups in a 2:1 ratio.||||
34112009|NCT02659241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112010|NCT01561469|||COHORT||RETROSPECTIVE|||||||
34112011|NCT01007955|||COHORT||PROSPECTIVE|||||||
34112012|NCT05121350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112013|NCT02553096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2-block randomised trial||||
34112014|NCT06327438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled study|t|f|f|f
34112015|NCT05400564|RANDOMIZED|PARALLEL||PREVENTION||NONE||Families will be assigned to treatment vs. a school as usual control. The investigators will assess families at baseline and at 3-, 6-, 12- and 24- month follow ups. Families in the treatment condition will receive the intervention between baseline and the 3-month follow-up.||||
34112016|NCT00659425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112017|NCT03088683|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112018|NCT04429763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||It will be included 30 patients, randomly assigned by centralized electronic sequence of assignation, for the application of a single dosis of 1\*10\^6 cells/Kg or placebo|t|t|t|f
34112019|NCT03236545|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34112020|NCT05341843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|a double blinded study as participants, health care providers as well as the outcome assessor will be unaware about the type of treatment each patient receive.|"This research is a double-blinded randomized multicentric clinical trial in which 50 haemodialysis patients will be randomly assigned to one of the study groups using block randomization with a ratio of 1:1.~* Group A: 25 patients will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.~* Group B: 25 patients will receive a placebo."|t|t|f|t
34112021|NCT01512576|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34038617|NCT03984864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34038618|NCT05531630|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The study will be designed as a blinded trial, in which nor the investigator, nor the patient will know the sequence of the treatments (AB or BA). The patients will receive a box with sachets for treatment period 1 at the screening visit. The box will have a number from 1 to 76 and the sachets from both treatment groups will not contain any information regarding the content.|Patients will be asked to perform nasal irrigations with both Xylitol (treatment A) and saline (treatment B) once daily for six weeks, with a washout period of one week before the start of the treatment and one week between the two treatment periods. Washout periods are included to reduce the risk for a carryover effect. Patients will be randomized in two treatment arms: AB and BA. Patients in the AB arm will first receive Xylitol, followed by saline, and vice versa in the BA group.|t|f|t|f
34038619|NCT01686373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038620|NCT00126750|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34038621|NCT03764774|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34038622|NCT05023915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038623|NCT02240056|||COHORT||PROSPECTIVE|||||||
34038624|NCT01973439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038625|NCT03709199|||COHORT||PROSPECTIVE|||||||
34038626|NCT00571740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038627|NCT05645848|||OTHER||CROSS_SECTIONAL|||||||
34038628|NCT02834520|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34038629|NCT05154045|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34038630|NCT00808210|NA|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038631|NCT06189664|||COHORT||RETROSPECTIVE|||||||
34038632|NCT00961103|||COHORT||RETROSPECTIVE|||||||
34112022|NCT03446690|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||33 subjects were prospectively recruited for the project in the MI Varnish group. These subjects were studied against a control group of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham.|f|f|f|t
34112023|NCT00271245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112024|NCT01704157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112025|NCT02692027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112026|NCT06126159|NA|SINGLE_GROUP||OTHER||NONE||||||
34112027|NCT06569823|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34112028|NCT04631692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Masking investigator, research assistants and data analyst|We will use a two-arm randomized controlled cluster trial design trial with 8 clusters in total (2 clusters per region) and 4 general practitioners per cluster (i.e. 32 doctors in total). We will target disadvantaged areas in the following regions: Marseille, Lyon, Toulouse and Paris. We will use two ecological indexes of disadvantage: the European Deprivation Index (EDI) and the French Deprivation Index (FDEP). A community-based participatory research approach will be privileged throughout this project as well as focus groups and interviews|f|f|t|t
34112029|NCT06563908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112030|NCT02593630|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34112031|NCT05031832|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34112032|NCT00160563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112033|NCT02145884|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34112034|NCT04023045|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Crossover clinical trial||||
34038633|NCT06189196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038634|NCT04050761|||COHORT||PROSPECTIVE|||||||
34038635|NCT05306002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038636|NCT03841864|RANDOMIZED|PARALLEL||OTHER||NONE||This study will partition all CSMC elective pre-operative patients into grade 1, 2a, 2b and 3 classifications to better assess the patient population distribution. Grade 2A vein classification cohort 2nd IV insertion attempt success rate comparison of traditional vs ultrasound guided technique, IV insertion pain scores and patient satisfaction, will be compared amongst the 2 different modalities for peripheral IV insertion.||||
34038637|NCT05800717|NA|SINGLE_GROUP||TREATMENT||NONE||single group, successive cohort design||||
33808208|NCT06497920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent assistant external to the project will manage the randomization of subjects. The clinician, investigators, participant and technician will all be blinded. To ensure blinding during treatment, either the active or sham adapter will be connected to the Magstim Horizon, the coil will remain the same. To ensure blinding of the technician and the participant an independent study assistant will connect the active or sham adapter for the Magstim Horizon. Both heads have identical external appearances, and stimulation of either coil generates identical auditory and somatosensory (vibration) stimuli. All raters obtaining outcome measures will also be blinded to treatment assignment.|This project has a randomized controlled trial. We will use a randomized, double- blind, sham-controlled design comparing the efficacy of active vs. sham rTMS (6000 pulses at 20 Hz/session) delivered to the motor cortex using bilaterally, 1 session/day for 5 days (5 sessions). The pulses will be delivered first to one side (right or left), which will be then followed by the pulses being delivered to the opposite side. The sequence will be randomized per participants.|t|t|t|t
33808209|NCT00598390|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808210|NCT01812759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808211|NCT04869605|||CASE_CONTROL||PROSPECTIVE|||||||
33808212|NCT01391767|||CASE_CONTROL||PROSPECTIVE|||||||
33808213|NCT06285409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808214|NCT04694066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The care providers, though cannot be blinded, will not have knowledge about the aims of the study. The research assistants responsible for assessing the outcomes and entering the data will be blinded to the group.~allocation."||f|f|f|t
34038638|NCT01967862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038639|NCT00443066|||CASE_ONLY||PROSPECTIVE|||||||
34038640|NCT04852744|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34038641|NCT00660244|||CASE_ONLY||PROSPECTIVE|||||||
34038642|NCT05569681|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Local quality control approval to mask injections of Bemiparin (3500 and 5000 IU), it could not be read by the surgeon, patients, and health care provider.|Two groups of orthopedic and non-orthopedic morbidly obese patients will be randomized to receive 2 different doses of Bemiparin|t|t|t|f
34038643|NCT01120587|||COHORT||PROSPECTIVE|||||||
34038644|NCT04924387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The groups will be arranged randomly and the masking technique to be used will the double blind procedure. The subjects will be randomly selected through the GPower 3.1 programme. The random allocation to each group will be made just by one external researcher, this way, neither the main researcher, nor the participants, will know their allocation. Furthermore, the inspector who will collect the evaluation data won't know either the allocation of each subject.||t|t|f|f
34038645|NCT03688308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not know if they received the surgical intervention that includes BMAC administration||t|f|f|t
34038646|NCT04084951|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038647|NCT06399380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34038648|NCT04080427|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34038649|NCT00493597|||COHORT||PROSPECTIVE|||||||
34038650|NCT03442751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomization was by eye (active or sham). However an individual participant could receive active/active, active/untreated, sham/sham, sham/untreated or active/sham|t|f|f|t
34038651|NCT05986604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Participants will be randomly allocated to TranS-C plus the MSI (TranS-C+MSI) or TranS-C alone"|t|t|f|t
34038652|NCT05533593|||OTHER||RETROSPECTIVE|||||||
34038653|NCT01283464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34038654|NCT04320225|||COHORT||PROSPECTIVE|||||||
34038655|NCT02079623|||COHORT||PROSPECTIVE|||||||
34038656|NCT04074733|||CASE_ONLY||PROSPECTIVE|||||||
34038657|NCT06356714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038658|NCT06581341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study employs a single-blind, randomized clinical trial design, with participants assigned to one of three groups: Group 1 receives repetitive transcranial magnetic stimulation (rTMS) combined with posterior tibial nerve percutaneous neuromodulation, Group 2 receives only rTMS, and Group 3 receives only posterior tibial nerve percutaneous neuromodulation. To prevent allocation bias, sealed, opaque, numbered envelopes containing color-coded cards (red for Group 1, green for Group 2, yellow for Group 3) will be used. These envelopes will be selected sequentially at the time of inclusion, ensuring that neither participants nor investigators can predict the assignments. The principal investigator will oversee randomization and administer the treatments, while the collaborating investigator, who is blinded to group assignments, will evaluate the participants. This methodology preserves the study's randomized integrity and ensures unbiased group assignments.|clínical Trials with 3 arms|f|f|t|f
34038659|NCT00133419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34038660|NCT02182492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038661|NCT01410097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808215|NCT06151340|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34038662|NCT04931732|||CASE_ONLY||PROSPECTIVE|||||||
34038663|NCT02598232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038664|NCT00707148|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34038665|NCT02075567|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34038666|NCT00482768|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34038667|NCT00937976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038668|NCT02291042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33808216|NCT05136794|||CASE_CONTROL||RETROSPECTIVE|||||||
34038669|NCT02063477|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34038670|NCT00736697|RANDOMIZED|PARALLEL||||NONE||||||
34038671|NCT04610190|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34038672|NCT05638126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038673|NCT05232383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34038674|NCT00933023|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038675|NCT04798794|||COHORT||RETROSPECTIVE|||||||
34038676|NCT00004990||||TREATMENT||||||||
34038677|NCT04857658|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038678|NCT01707394|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038679|NCT04032483|||COHORT||PROSPECTIVE|||||||
34038680|NCT03709186|||COHORT||PROSPECTIVE|||||||
34038681|NCT03848260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038682|NCT02471170|||COHORT||PROSPECTIVE|||||||
34038683|NCT06490471|||COHORT||PROSPECTIVE|||||||
34038684|NCT02162537|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038685|NCT03392948|||COHORT||PROSPECTIVE|||||||
34038686|NCT00576589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34038687|NCT02972879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038688|NCT02473172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038689|NCT01598844|||COHORT||PROSPECTIVE|||||||
34038690|NCT02585947|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038691|NCT02464007|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34038692|NCT03920124|NA|SINGLE_GROUP||OTHER||NONE||This will be a pragmatic feasibility study of a single case group. However, examination of acute responses to different step and walk-based interval exercise types will follow a randomised, counter-balanced (repeated-measures) design.||||
34038693|NCT01928472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34038694|NCT02174692|RANDOMIZED|PARALLEL||||NONE||||||
34038695|NCT04965038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038696|NCT00444535|NA|||TREATMENT||NONE||||||
33808217|NCT04778813|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, randomized, open-label, three-arm study involving three sites representing the three different epidemiological facies of malaria in Burkina Faso.The three therapeutic combinations (AL, DHA-PPQ and As-Pyr) will be tested in different sites with different characteristics of transmission and resistance of malaria. Participants will be treated for 3 days then followed during by 28-days (AL arm) and 42-days (DHA-PPQ and Pas-Pyr). There will be no comparision between study arms, but the for each arm, the efficacy will be measured and compared to WHO critical value.||||
33808218|NCT03890484|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to one of two conditions, which will run in parallel.||||
33808219|NCT02110381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038697|NCT01593774|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038698|NCT00755027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038699|NCT02711475|||COHORT||PROSPECTIVE|||||||
34038700|NCT03102996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038701|NCT05953051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are blinded. As well, staff conducting and evaluating MRI, clinical evaluation, CT and functional tests are blinded.|Patients will be allocated 1:1 on experimental and control arm using block randomization within both genders with random block sizes (randomly chosen from the set \[2,4,6,8\]).|t|f|f|t
34038702|NCT05932537|||COHORT||RETROSPECTIVE|||||||
34038703|NCT01545167|||CASE_CONTROL||PROSPECTIVE|||||||
34038704|NCT04361773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers who will carry out the application of PBM will not carry out any type of evaluation. The evaluations (initial and after application of the FBM) will be made by the field researchers, who will not be informed of the group in which each participant is allocated. Participants will not be aware of whether or not they have received PBM, as the applicator researchers will position the equipment at the irradiation sites in all participants, cover the limb with fabric that does not allow visualization, and will only activate the light when and where provided in the specific experimental group. A sound recorded on a cell phone will be played when the participant is allocated to the sham group.||t|f|f|t
34038705|NCT00722969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038706|NCT05712083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038707|NCT03266861|||COHORT||PROSPECTIVE|||||||
34038708|NCT02618291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34038709|NCT02259010|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34038710|NCT01842230|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34038711|NCT06250621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34038712|NCT02253589|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038713|NCT04092556|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34038714|NCT04425057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34038715|NCT04615273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once-weekly lonapegsomatropin and once-weekly placebo treatment arms will be double-blinded, daily somatropin product will be open-label.|Double-blind, placebo-controlled, parallel group with subjects randomized into 3 treatment groups (1:1:1); lonapegsomatropin once-weekly, placebo for lonapegsomatropin once-weekly, somatropin daily.|t|f|t|f
34038716|NCT06214195|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Label|The risk exposure factors for the experimental group and the control group are the same||||
34038717|NCT00600730|RANDOMIZED|PARALLEL||||NONE||||||
34038718|NCT04596774|||COHORT||RETROSPECTIVE|||||||
34038719|NCT01730053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038720|NCT02754804|||COHORT||PROSPECTIVE|||||||
33808220|NCT00324948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33808221|NCT01747304|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112035|NCT00203606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112036|NCT05119582|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is a multicenter (two-center) open-label study with high-intensity focused ultrasound (HIFU) treatment of patients with the genetic disease Neurofibromatosis Type1.~The study is not comparative or randomized. The investigation is performed prior to CE mark to confirm safety and performance of the System ONE-M device when used as intended, i.e. as an non-invasive method to remove cutaneous neurofibromas by 20 MHz high intensity focused ultrasound."||||
34112037|NCT05020457|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112038|NCT00019825||||TREATMENT||||||||
34112039|NCT03424343|||COHORT||PROSPECTIVE|||||||
34112040|NCT01622478|||COHORT||PROSPECTIVE|||||||
34112041|NCT00567554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112042|NCT03505060|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112043|NCT01413009|||COHORT||PROSPECTIVE|||||||
34112044|NCT05176067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized Controlled Clinical Study|Randomized Controlled Clinical Study|f|f|t|f
34112045|NCT03367104|||CASE_CONTROL||PROSPECTIVE|||||||
34112046|NCT05417178|||OTHER||PROSPECTIVE|||||||
34112047|NCT04368208|||COHORT||PROSPECTIVE|||||||
34112048|NCT04843592|||OTHER||CROSS_SECTIONAL|||||||
34112049|NCT04669795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34112050|NCT04194242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112051|NCT04597801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112052|NCT01798602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34112053|NCT02115529|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112054|NCT02106429|||CASE_ONLY||PROSPECTIVE|||||||
34112055|NCT03205267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112056|NCT04033640|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112057|NCT04375358|||COHORT||PROSPECTIVE|||||||
34112058|NCT02652247|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112059|NCT02769104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112060|NCT03185026|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34112061|NCT00822094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112062|NCT04763109|NA|SINGLE_GROUP||OTHER||NONE||||||
34112063|NCT03639402|RANDOMIZED|PARALLEL||PREVENTION||NONE||one community is randomized as intervention arm, another community as control arm||||
34112064|NCT00422487|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34112065|NCT06234514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34112066|NCT00287560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34112067|NCT02480049|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112068|NCT00425555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112069|NCT02576626|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34112070|NCT05589025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinding of assessor of clinical outcomes|split mouth|t|f|f|t
33808222|NCT00637104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112071|NCT03220009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112072|NCT06389032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112073|NCT06022640|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study included 75 patients in the intervention group who received an educational and supportive program designed by a clinical pharmacist. The intervention group received support through five visits: at admission, monitoring medication, monitoring ovulation, monitoring harmful effects, providing emotional support, and following up after egg retrieval during embryo transfer.||||
34038721|NCT01706341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34038722|NCT03085537|||COHORT||PROSPECTIVE|||||||
34038723|NCT01004497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038724|NCT04280692|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34038725|NCT00498394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038726|NCT05520073|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038727|NCT02083744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34038728|NCT01068860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038729|NCT02663869|||CASE_CONTROL||RETROSPECTIVE|||||||
34038730|NCT05969184|NA|SINGLE_GROUP||TREATMENT||NONE|we have only one single center participant and none of the roles in research needed to be mask|||||
34038731|NCT02949596|||COHORT||PROSPECTIVE|||||||
34038732|NCT04083638|||CASE_CONTROL||PROSPECTIVE|||||||
34038733|NCT04145154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34038734|NCT01890681|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34038735|NCT03588403|||CASE_CONTROL||PROSPECTIVE|||||||
34038736|NCT05002231|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Randomized, single-dose, cross-over study|Open-label, 3-period, 6-sequence, randomized, single-dose, crossover study designed to assess the relative bioavailability of a 15 mg tablet of losmapimod versus two 7.5 mg tablets of losmapimod under fasted conditions and to assess the effect of food on the pharmacokinetics of a 15 mg tablet of losmapimod under fasted and fed conditions|t|t|t|t
34038737|NCT00256074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038738|NCT00739882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038739|NCT02990741|||COHORT||PROSPECTIVE|||||||
34038740|NCT00110396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038741|NCT06302439|||CASE_ONLY||PROSPECTIVE|||||||
34038742|NCT06077578|||COHORT||CROSS_SECTIONAL|||||||
34038743|NCT01040572|||COHORT||RETROSPECTIVE|||||||
34038744|NCT05602168|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||the study is interventional because there are blood samples taken outside the scope of routine care||||
34038745|NCT03114605|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34038746|NCT01552395|||||PROSPECTIVE|||||||
34038747|NCT00160303|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34038748|NCT06123637|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038749|NCT01696123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808223|NCT03057600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of 4 arms depending on the number of prior lines of therapy they have received and whether or not they have African ancestry||||
33808224|NCT01957163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808225|NCT06162182|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The assessors will not be blind about the type of intervention/control assessment methods due to different application methods. However it will not be allowed amongst the examiners to exchange any information throughout the entire study period||f|f|f|t
33808226|NCT00855426|||COHORT||PROSPECTIVE|||||||
33808227|NCT03192189|||CASE_ONLY||PROSPECTIVE|||||||
33808228|NCT05136066|NA|SINGLE_GROUP||TREATMENT||NONE||Two groups with mint oil control group||||
33808229|NCT01237067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808230|NCT01691677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808231|NCT04237857|||COHORT||RETROSPECTIVE|||||||
33808232|NCT06195813|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants were randomly divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups.|t|f|t|t
33808233|NCT00649857|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33808234|NCT05618041|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Single Group Assignment||||
33808235|NCT02009020|||||PROSPECTIVE|||||||
33808236|NCT01296230|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808237|NCT00154115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808238|NCT01989689|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33808239|NCT00780494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808240|NCT03958526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808241|NCT06159959|||CASE_CONTROL||RETROSPECTIVE|||||||
33808242|NCT00495144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808243|NCT03965949|||COHORT||RETROSPECTIVE|||||||
33808244|NCT04508777|||COHORT||PROSPECTIVE|||||||
33808245|NCT04248868|NA|SINGLE_GROUP||TREATMENT||NONE||Pulse Spray and Infusion of r-tPA||||
33808246|NCT02562937|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33808247|NCT06304051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808248|NCT01479010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808249|NCT04996225|RANDOMIZED|PARALLEL||TREATMENT||NONE||Finally, it could be concluded that aerobic exercise and balancing exercise with relaxation exercises decrease anxiety and dizziness in patients with COVID-19. So, it considered as effective, safe, cheap and successful adjunct treatment methods in reducing anxiety and dizziness in patients with COVID-19.||||
33808250|NCT01736449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808251|NCT01115140|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33808252|NCT01746576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808253|NCT05443516|||COHORT||PROSPECTIVE|||||||
33808254|NCT00930475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808255|NCT04226456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808256|NCT05224986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not be blinded to the intervention or purpose of the study but will be told that rest-activity patterns will be examined in the context of well-being and that we will test the influence of these lifestyle patterns on glucose control and body composition. Although the investigators and research assistant directly involved in the conduct of the study cannot be blinded to participant assignment to the intervention or control group, the technicians involved in sample processing and the biostatistician (Dr. Cheng) will be blinded to this information to reduce the risk of bias.|A randomized, parallel-arm clinical intervention study to assess the role of variability in lifestyle behaviors on glucose control and body composition in adults with pre-diabetes. The goal is to test whether following a fixed schedule improves glucose control and insulin sensitivity and reduces adiposity compared to those who maintain a variable schedule.|f|f|f|t
33808257|NCT01077700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808258|NCT02430454|RANDOMIZED|PARALLEL||||NONE||||||
33808259|NCT02630966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112074|NCT06495606|||COHORT||PROSPECTIVE|||||||
34112075|NCT01524406|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34112076|NCT03719131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112077|NCT01851902|||COHORT||PROSPECTIVE|||||||
34112078|NCT03100279|NA|SINGLE_GROUP||TREATMENT||NONE||This study will employ a quasi-experimental open-trial design that includes a comprehensive diagnostic assessments at pre- and post-treatment (diagnostic interview, symptom and functioning measures, and prospective mediators) and continuous assessment throughout an active treatment phase. Anxiety/depression symptoms will be assessed each session and prospective mediators (cognitive, behavioral, and affective variables) will be assessed every four sessions. A two-week baseline period will separate the initial intake from the first treatment session. The traditional ABAB experimental single-case design will not be used because it is not appropriate in clinical situations where the removal of treatment intervention could be harmful to clinical patients (Kazdin, 1992). Each youth who meets inclusion criteria will complete a two-week baseline phase that includes three assessments (intake, phone follow-up, and first session).||||
34112079|NCT06343623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112080|NCT06217263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34112081|NCT03419819|NA|SINGLE_GROUP||TREATMENT||NONE||Two phase study consisting of a 1 week taste introduction period followed by a 4 week period assessing acceptability and metabolic control.||||
34112082|NCT05287373|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112083|NCT05956483|||COHORT||PROSPECTIVE|||||||
34112084|NCT05534867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled clinical trial|t|f|f|t
34112085|NCT06114745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||SHR-1707 injection compared with placebo|t|t|t|f
34112086|NCT06315998|||COHORT||PROSPECTIVE|||||||
34112087|NCT06256055|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration design and 3+3 design||||
34112088|NCT03316430|||COHORT||PROSPECTIVE|||||||
34112089|NCT02665377|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112090|NCT00710619|||CASE_ONLY||PROSPECTIVE|||||||
34112091|NCT05595005|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112092|NCT01186757|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34112093|NCT01688804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112094|NCT01061788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112095|NCT04120467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112096|NCT01690273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112097|NCT06539182|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112098|NCT02014376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112099|NCT03352947|RANDOMIZED|PARALLEL||TREATMENT||NONE||INTERIM is a multi-centre, open label, two arm, randomised phase II feasibility trial||||
34112100|NCT04442009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is superficial cervical plexus block group. The second one is no intervention control group|t|f|f|t
34112101|NCT02538796|RANDOMIZED|PARALLEL||||NONE||||||
34112102|NCT00208338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112103|NCT04998630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112104|NCT02191618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808260|NCT02233556|NA|SINGLE_GROUP||||NONE||||||
33808261|NCT02374736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808262|NCT02317172|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808263|NCT02666404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808264|NCT05885516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33808265|NCT02263105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808266|NCT00147667|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33808267|NCT03637036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants receive one of four types of communications inviting them to take up the influenza vaccination in a randomized fashion. Participants will not be explicitly told that alternative versions of the communications are being sent.||t|f|f|f
33808268|NCT01619059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112105|NCT05930639|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34112106|NCT02895555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112107|NCT00654355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112108|NCT03148002|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Patients will be randomized to received the Current Bowel Protocol or the PEG Bowel Protocol||||
34112109|NCT05910346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to prevent statistical bias, data analysis will be performed by an independent statistician, and the experimental and control groups specified as A and B during the analysis will not be shared with the statistician. Intention-to-treat analysis-ITT will be performed at the end of the study in order to prevent the reduction bias.||f|f|f|t
34112110|NCT03802916|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33808269|NCT05576103|||COHORT||PROSPECTIVE|||||||
33808270|NCT03418545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808271|NCT01217866|||COHORT||RETROSPECTIVE|||||||
33808272|NCT01450007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33808273|NCT00369902|||CASE_ONLY||PROSPECTIVE|||||||
33808274|NCT03491566|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34112111|NCT03749239|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808275|NCT05770609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038750|NCT00657072|||CASE_ONLY||PROSPECTIVE|||||||
34038751|NCT03207815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038752|NCT03801135|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038753|NCT03215680|||COHORT||PROSPECTIVE|||||||
34038754|NCT01662635|||COHORT||CROSS_SECTIONAL|||||||
34038755|NCT00180843|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34038756|NCT04588168|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038757|NCT01278186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725214|NCT05851183|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is designed as an open-label trial to investigate the efficacy of vitis vinifera extract compared to a group undergoing lifestyle modification alone.|The investigators aim to compare and evaluate the improvement effects on venous reflux time in patients with lower extremity varicose veins between lifestyle modifications and the combined treatment of Vitis Vinifera seed extract (Entelon®) administration and lifestyle modifications.||||
33725215|NCT01277523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725216|NCT01933854|||COHORT||PROSPECTIVE|||||||
33725217|NCT05534178|||COHORT||PROSPECTIVE|||||||
33725218|NCT04713475|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, multi-center, dose escalation||||
33725219|NCT02580357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33725220|NCT04888546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725221|NCT05860283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34038758|NCT04087759|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34038759|NCT02221336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038760|NCT06329570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038761|NCT06220851|||COHORT||CROSS_SECTIONAL|||||||
34038762|NCT00357292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34038763|NCT01577212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038764|NCT02850146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038765|NCT03137550|||COHORT||PROSPECTIVE|||||||
34038766|NCT02104674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038767|NCT01223118|NA|SINGLE_GROUP||||NONE||||||
34038768|NCT04047667|||COHORT||PROSPECTIVE|||||||
34038769|NCT05368844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study aims to test the feasibility, safety and acceptability of a new form of TMS, intermittent theta-burst stimulation (iTBS), in anorexia nervosa and to test whether iTBS can reduce body image distortion and facilitate eating in anorexia nervosa.|t|f|f|f
34038770|NCT01097889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038771|NCT06455566|||COHORT||PROSPECTIVE|||||||
33725222|NCT01447290|||COHORT||PROSPECTIVE|||||||
33725223|NCT05463185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725224|NCT05904457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038772|NCT04478383|||CASE_ONLY||RETROSPECTIVE|||||||
34038773|NCT04400383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038774|NCT01801865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038775|NCT00632268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038776|NCT01003873|||CASE_CONTROL||PROSPECTIVE|||||||
33725225|NCT03878914|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.||||
33725226|NCT05046041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725227|NCT04500184|||CASE_CONTROL||RETROSPECTIVE|||||||
33725228|NCT03407742|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data manager was in charge of conducting randomization and allocating parents to treatment conditions.|Participants were randomized to one of two conditions: (a) intervention consisting of parenting program, or (b) wait-list control group|t|f|f|f
33725229|NCT03657355|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|For blinding purposes, suvorexant and zolpidem will be over-encapsulated, whereas a matching-placebo will be used for ACT-541468.|Single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 6-way cross-over study|t|t|t|t
33725230|NCT02881645|||CASE_CONTROL||PROSPECTIVE|||||||
33725231|NCT02053181|NA|SINGLE_GROUP||||NONE||||||
33808276|NCT04160559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Control group: chemotherapy plus water, test group: chemotherapy plus green tea.||||
34038777|NCT00001041||PARALLEL||PREVENTION||||||||
33808277|NCT00128973|||OTHER||CROSS_SECTIONAL|||||||
33808278|NCT05611385|||COHORT||RETROSPECTIVE|||||||
33808279|NCT03510195|NA|SINGLE_GROUP||OTHER||NONE||||||
33808280|NCT06067776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808281|NCT04105387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725232|NCT01625247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725233|NCT02947308|||CASE_CONTROL||PROSPECTIVE|||||||
33725234|NCT02691299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725235|NCT02598180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112112|NCT03814044|||CASE_ONLY||RETROSPECTIVE|||||||
33725236|NCT04206774|||OTHER||PROSPECTIVE|||||||
33725237|NCT02793518||PARALLEL||||NONE||||||
34112113|NCT00855101|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112114|NCT02746055|||||CROSS_SECTIONAL|||||||
34112115|NCT00542178|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34112116|NCT06377501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112117|NCT06564428|||COHORT||PROSPECTIVE|||||||
34112118|NCT00867334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112119|NCT03436667|||COHORT||PROSPECTIVE|||||||
34112120|NCT02129972|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34112121|NCT00877656|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112122|NCT05218707|||OTHER||CROSS_SECTIONAL|||||||
33725238|NCT03155802|||COHORT||PROSPECTIVE|||||||
33725239|NCT02418195|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33725240|NCT02224911|||CASE_ONLY||PROSPECTIVE|||||||
33725241|NCT04121260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725242|NCT04706130|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will be an open-labelled randomized clinical trial to determine therapeutic efficacy.||||
33725243|NCT05541549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double- blinded, Phase 2 trial in patients with PML due to JCPyV.|t|t|t|f
33725244|NCT06055855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725245|NCT06160466|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725246|NCT01827657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725247|NCT03507712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and outcome assessor (the orthoptist) will be blinded regarding the type of surgery|"Group I: Symmetrical IO weakening surgery - Bilateral IO Myectomy / Bilateral equal graded IO Recession (Same surgery in both eyes).~Group II: Asymmetrical IO weakening surgery - IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye."|t|f|f|t
33725248|NCT01556828|||||PROSPECTIVE|||||||
33725249|NCT02261636|||COHORT||PROSPECTIVE|||||||
33725250|NCT04444596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725251|NCT01289847|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725252|NCT05316831|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112123|NCT06536426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112124|NCT00158093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725253|NCT04694677|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33725254|NCT05920421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112125|NCT03112902|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
33725255|NCT03330431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725256|NCT02486042|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34112126|NCT00416507|RANDOMIZED|||TREATMENT||||||||
34112127|NCT04770896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112128|NCT06465238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112129|NCT05338307|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34112130|NCT00249626|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33725257|NCT04366167|||COHORT||PROSPECTIVE|||||||
33725258|NCT05705284|NA|SINGLE_GROUP||OTHER||NONE||Multidisciplinary process for medication review/deprescribing: The intervention will be a structured process for performing a shared-decision, person-centred medication review among those living with frailty involving GPs, PCN-pharmacist and ANPs.||||
34112131|NCT02899403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112132|NCT05367947|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|"Participants are people with multiple sclerosis according inclusion/exclusion criteria.~Investigators are health professionals (i.e., physiotherapist, sports scientist, neuropsychologist, neurologist, biostastician)."|The study follows a concurrent multiple baseline design across subjects, which involves five people with RRMS that will be managed as five different case studies. The specific design has the advantage to verify the cause-effect inference clearly by the staggered duration through separate baseline phases||||
33808282|NCT03082313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112133|NCT04992273|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808283|NCT04154007|||COHORT||PROSPECTIVE|||||||
33808284|NCT00004474|RANDOMIZED|PARALLEL||TREATMENT||||||||
33808285|NCT02294500|||COHORT||PROSPECTIVE|||||||
33808286|NCT02644122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808287|NCT01264172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808288|NCT03737487|||COHORT||PROSPECTIVE|||||||
33808289|NCT00144235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34038778|NCT05052957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038779|NCT04849403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||61 patients who underwent Laparoscopic Sleeve Gastrectomy are included. USG was performed (Figure I,II) by a clinician who had previously received superficial USG evaluation training for trocar site hernia and abdominal incision sites were investigated for the presence of hernias.||||
34038780|NCT04766892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038781|NCT02151747|||CASE_CONTROL||PROSPECTIVE|||||||
34038782|NCT04831021|NA|SINGLE_GROUP||OTHER||NONE||All patients will be assigned to one dialysis session without physical exercise, one dialysis session with pre-dialytic physical exercise and one dialysis session with per-dialytic physical exercise in random order.||||
34038783|NCT00460811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038784|NCT01955278|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34038785|NCT05698901|||COHORT||OTHER|||||||
34038786|NCT02630251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038787|NCT00272077|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34038788|NCT00648791|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34038789|NCT01702623|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34038790|NCT02257346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038791|NCT05582889|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34038792|NCT02343653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038793|NCT05643014|||CASE_ONLY||PROSPECTIVE|||||||
34038794|NCT00489918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038795|NCT02635594|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34038796|NCT03976271|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|All subjects will undergo a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp (nadir 2.8 mmol/L), during and after which blood and urine will be sampled for further examination for up to one week.|||||
34038797|NCT04598061|||COHORT||RETROSPECTIVE|||||||
34038798|NCT03232359|||COHORT||PROSPECTIVE|||||||
34038799|NCT01210560|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34038800|NCT01803451|NON_RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34038801|NCT05867251|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose-escalation Phase 2 dose-expansion||||
34038802|NCT01899482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34038803|NCT00519857|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34038804|NCT05992337|||CASE_CONTROL||PROSPECTIVE|||||||
34038805|NCT06205771|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34038806|NCT01358435|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34038807|NCT05535777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Pragmatic comparative effectiveness trial with a standard-of-care control group|t|f|f|f
34038808|NCT01244568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038809|NCT02146937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038810|NCT05394818|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34038811|NCT01884246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34038812|NCT02478944|NA|SINGLE_GROUP||SCREENING||NONE||||||
34038813|NCT02300831|||COHORT||PROSPECTIVE|||||||
34038814|NCT02724319|||COHORT||PROSPECTIVE|||||||
34112134|NCT04503369|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33808290|NCT01489774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038815|NCT01129063||CROSSOVER||BASIC_SCIENCE||NONE||||||
34038816|NCT01812109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"The probe will be laid on the exposed testis (intraoperative testicular tissue). Each measurement is painless and takes \<15 seconds each. The NIRS probe will be placed on the anterior testis to obtain the three sets of three measurements. Thus, the unaffected testis will serve as the patient's own control. NIRS #2-4 will not delay detorsion of the affected testis. Surgeons will be blinded to these NIRS results, thus the decision during the operation will not be affected.~All participants' NIRS results will be blinded to the surgeons."|Those that accept study participation after informed consent will receive standard of care therapy for the acute scrotum and will be evaluated by NIRS. The NIRS measurements will not bias the treatments performed or not performed on the study patients, permitting standard of care treatment unbiased. The clinical data will be collected prospectively for each patient utilizing REDCap Data Collection Management and stored in the REDCap databases and the photographic database. Photographs will be taken of the scrotum. In addition, select participants will be asked if they will allow us to videotape the NIRS measurements.||||
34038817|NCT04268225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038818|NCT03652051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038819|NCT06404398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This clinical study was double-blind study as the evaluators who were not included in the restorative procedures and the patients were blinded to tested groups, but the operator wasn't blinded to these groups|randomized controlled clinical study|t|f|f|t
34038820|NCT05514561|||COHORT||PROSPECTIVE|||||||
33808291|NCT05774626|||COHORT||PROSPECTIVE|||||||
33808292|NCT01825850|RANDOMIZED|CROSSOVER||||NONE||||||
33808293|NCT01959958|||COHORT||PROSPECTIVE|||||||
33808294|NCT03004625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112135|NCT05156528|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725259|NCT02063347|||COHORT||PROSPECTIVE|||||||
33725260|NCT05616858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized, open-label, case-control study||||
33725261|NCT05864911|NA|SINGLE_GROUP||TREATMENT||NONE||placement of the Gastric Bypass Stent System||||
33725262|NCT02372851|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725263|NCT03448315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725264|NCT01880112|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33725265|NCT02684643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725266|NCT01623596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725267|NCT04911283|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725268|NCT04891900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725269|NCT04829773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study had two components. One component evaluated the effect of food and the effect of swallowing capsule whole versus sprinkling on apple sauce on the PK/bioavailability of palovarotene, and the other component evaluated the effect of palovarotene on the PK of the CYP3A4 substrate midazolam. The PK of palovarotene after single and multiple doses was also evaluated as part of the DDI component. Two cohorts of healthy adult subjects were enrolled, one for each component.||||
33725270|NCT02658136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808295|NCT05270460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808296|NCT03844698|||COHORT||RETROSPECTIVE|||||||
33808297|NCT03658252|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33808298|NCT02955199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112136|NCT06560788|||CASE_CONTROL||PROSPECTIVE|||||||
34112137|NCT01953250|||COHORT||PROSPECTIVE|||||||
34112138|NCT03453216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112139|NCT03757494|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Using Alpha Stim||||
34112140|NCT01380665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112141|NCT05205863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112142|NCT02181920|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34112143|NCT01705392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112144|NCT01534559|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112145|NCT06168344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There are two groups in the study. Web-based education was provided to mothers in the intervention group (n=30). No intervention was applied to the mothers in the control group (n=30) other than the outpatient clinic routine of the hospital.||||
34112146|NCT03344484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112147|NCT03270995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34112148|NCT05494086|RANDOMIZED|PARALLEL||TREATMENT||NONE||DPLDG group :Reduced Port Laparoscopic Distal Gastrectomy LDG group: Laparoscopic Distal Gastrectomy||||
34112149|NCT05404009|||COHORT||PROSPECTIVE|||||||
34112150|NCT04928547|||COHORT||PROSPECTIVE|||||||
34112151|NCT06026579|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112152|NCT04838067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112153|NCT02399852|||OTHER||PROSPECTIVE|||||||
34112154|NCT03777228|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112155|NCT03748550|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinicians interpreting the echocardiograms and stress test results will not know whether the participant is in the control group or the exercise intervention.|Participants will be randomly allocated to either the standard of care group (control) or the intervention group (standard of care + 12-weeks aerobic exercise).|f|f|f|t
34112156|NCT04647760|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Hybrid-implementation effectiveness design incorporating a delayed-treatment design for treatment group assignment|f|f|f|t
34112157|NCT00444405|||OTHER||PROSPECTIVE|||||||
34112158|NCT02753972|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112159|NCT03325231|||COHORT||RETROSPECTIVE|||||||
34112160|NCT05032586|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|randomized|parallel assigment||||
34112161|NCT00645502|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112162|NCT06090552|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||1:1 randomized block design stratified by enrollment site; within enrollment site, further stratified by surgical clinic||||
34112163|NCT02157610|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112164|NCT02834364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112165|NCT03815188|||COHORT||RETROSPECTIVE|||||||
34112166|NCT01082939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112167|NCT04587492|||COHORT||PROSPECTIVE|||||||
34112168|NCT03898427|||CASE_ONLY||PROSPECTIVE|||||||
34112169|NCT00226356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112170|NCT05616442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112171|NCT04839887|||COHORT||PROSPECTIVE|||||||
34112172|NCT06530459|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34112173|NCT05293717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112174|NCT03884673|||CASE_ONLY||PROSPECTIVE|||||||
33725271|NCT06299774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33725272|NCT04461782|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725273|NCT04980677|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33725274|NCT00684476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725275|NCT03086603|||COHORT||PROSPECTIVE|||||||
33725276|NCT05235334|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No masking will be used|All enrolled participants will use the SOLIUS home device.||||
33725277|NCT01964274|||COHORT||PROSPECTIVE|||||||
33725278|NCT00983268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112175|NCT00569179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112176|NCT05423613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725279|NCT04149600|||COHORT||PROSPECTIVE|||||||
33725280|NCT00367952|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725281|NCT01340092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33725282|NCT01530295|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34112177|NCT00497497|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112178|NCT04619602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725283|NCT06218407|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33725284|NCT02916563|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725285|NCT01524627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725286|NCT01044602|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725287|NCT04799899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725288|NCT04462809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725289|NCT05122065|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725290|NCT05497492|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33725291|NCT05098145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725292|NCT03679871|NA|SINGLE_GROUP||OTHER||NONE||||||
34112179|NCT00086437|||CASE_CONTROL||PROSPECTIVE|||||||
34112180|NCT02306252|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112181|NCT03868501|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33725293|NCT00719836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038821|NCT01412567|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34038822|NCT01981460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808299|NCT03504787|||OTHER||CROSS_SECTIONAL|||||||
33808300|NCT02797587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808301|NCT03844685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient and personnel involved in trial masked to treatment vs. placebo|Prospective, randomized, double-blind clinical trial|t|t|t|f
34038823|NCT00419991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038824|NCT04524793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038825|NCT01129427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34038826|NCT01131455|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038827|NCT02482688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038828|NCT06271148|||CASE_CONTROL||PROSPECTIVE|||||||
34038829|NCT01508611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038830|NCT01456754|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34038831|NCT01253902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34038832|NCT01571323|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34038833|NCT05005507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038834|NCT04625049|||COHORT||PROSPECTIVE|||||||
34038835|NCT03114930|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038836|NCT03048708|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038837|NCT04742400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038838|NCT01954576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038839|NCT02064816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038840|NCT04463407|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725294|NCT04401696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725295|NCT03678467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725296|NCT03202264|||COHORT||PROSPECTIVE|||||||
33725297|NCT00783445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725298|NCT05595889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725299|NCT02539381|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33725300|NCT05956912|||OTHER||PROSPECTIVE|||||||
33725301|NCT05983770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725302|NCT03205059|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725303|NCT03883932|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33725304|NCT05346263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808302|NCT01898767|||COHORT||PROSPECTIVE|||||||
33808303|NCT05402566|||COHORT||CROSS_SECTIONAL|||||||
33808304|NCT04433780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808305|NCT05116098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808306|NCT01275859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808307|NCT02071316|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34038841|NCT02647008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038842|NCT05357521|||CASE_CONTROL||PROSPECTIVE|||||||
34038843|NCT03494712|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33808308|NCT01079806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038844|NCT04751552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Randomized controlled double blind trial|t|t|t|t
34038845|NCT03048214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34038846|NCT03592238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34038847|NCT00608777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038848|NCT02314026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038849|NCT04656756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants didn't know which group they were allocated. The participants will be blind when they take personalized care from investigators.|The study was conducted as a single blind, prospective, and simple randomized controlled trial. The sample was calculated through Power analysis. Consequently, the sample size calculated for α:0.05 and 1-β= 0.95 was 48.Considering the possibility that participants of the sample might be lost or abandon the study, 120 mothers who met the criteria of inclusion to experimental (E) (n=60) and control (C) (n=60) groups were included and assigned to both groups using the permuted block randomization method. The size and number of blocks divided into two groups as E and C was calculated as 20 (3E and 3C) with six mothers in each block. Using Microsoft Office Excel 2013, numbers ranging from 1 to 20 were randomly generated.A total of 120 mothers were evenly and homogeneously assigned to both groups.|t|f|f|f
34038850|NCT05809869|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Immune checkpoint inhibitors and radioembolisation for previously untreated metastatic hepatocellular carcinoma||||
34038851|NCT06007001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038852|NCT01268670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038853|NCT03292666|||COHORT||RETROSPECTIVE|||||||
34038854|NCT02028663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038855|NCT00261209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038856|NCT05603871|||CASE_ONLY||PROSPECTIVE|||||||
34038857|NCT00867529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038858|NCT01935609|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34038859|NCT05823233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34038860|NCT05308953|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34038861|NCT04344483|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients will be recruited in the study by closed envelope technique and the study will be single blinded.|Patients with non healing wound who will otherwise be healthy will be recruited in the study and will randomly assign groups. One group will receive Adrenaline and Lidocaine soaked gauze and the second group will be a control group who will receive normal saline soaked gauze.|t|f|f|f
34038862|NCT04802486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038863|NCT01422889|||COHORT||PROSPECTIVE|||||||
34038864|NCT05280444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038865|NCT02588898|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34038866|NCT03312036|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038867|NCT03098719|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34038868|NCT05433818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled study||||
34038869|NCT05027659|RANDOMIZED|PARALLEL||OTHER||SINGLE|The data of the study were entered by a person other than the researcher. Statistical analysis was performed by a person other than the researcher. In the study, virtual reality glasses were worn on the participants of experimental group. For this reason, blinding could not be done for the participants. The researcher herself collected all data because the hospital restricted traffic in and out of the unit due to the pandemic. Therefore, the evaluator was not blinded to the study.|A randomized controlled trial|f|f|f|t
34038870|NCT04969328|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study has a RCT design and consist of a intervention- and a control group (1:1).~The study is part of a complex intervention design consisting of four phases: development, pilot testing, evaluation and implementation. The RCT study is together with a qualitative process evaluation part of the evaluation phase."||||
34038871|NCT00255463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34038872|NCT01819233|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038873|NCT00396071|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34038874|NCT04295408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808309|NCT06143007|NA|SEQUENTIAL||TREATMENT||NONE||||||
33808310|NCT01888484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808311|NCT02245529|||COHORT||PROSPECTIVE|||||||
33808312|NCT04762914|||OTHER||RETROSPECTIVE|||||||
34038875|NCT03016884|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038876|NCT05104437|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Serum testing technicians will be masked.||f|f|f|t
33808313|NCT03029299|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34038877|NCT01429948|||CASE_CONTROL||PROSPECTIVE|||||||
34038878|NCT04947007|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34038879|NCT02009852|||CASE_ONLY|||||||||
34038880|NCT01997476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038881|NCT00113763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038882|NCT01564693|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34038883|NCT01270438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038884|NCT02648139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038885|NCT00155064|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038886|NCT04261803|||COHORT||PROSPECTIVE|||||||
34038887|NCT04530188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038888|NCT04026490|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33808314|NCT01702376|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33808315|NCT00890591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808316|NCT03488043|||COHORT||OTHER|||||||
33808317|NCT02116075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808318|NCT00773500|||COHORT||PROSPECTIVE|||||||
33808319|NCT02879942|||COHORT||PROSPECTIVE|||||||
33808320|NCT01158248||||TREATMENT||NONE||||||
33808321|NCT01171053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038889|NCT03869619|||COHORT||PROSPECTIVE|||||||
34038890|NCT02760108|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34112182|NCT04540367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants were randomized to either perform exercises with blood flow restriction therapy or without||||
33808322|NCT05616494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808323|NCT06294834|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"For therapists, we will use a randomized, single-blinded, two-period cross-over study design for Groups 1 and 2. Participants will complete baseline assessments and then be randomized to either Group 1 or Group 2. After we have completed enrollment for Groups 1 and 2 we will enroll participants into Group 3.~Rehabilitation professionals who are not therapists will be enrolled in Group 4."|Randomized, single-blinded, two-period cross-over study design for Groups 1 and 2. Participants will complete baseline assessments and then be randomized to either Group 1 or Group 2. After enrollment for Groups 1 and 2 is complete, participants will be enrolled into Group 3.|t|f|f|f
33808324|NCT03765749|||COHORT||PROSPECTIVE|||||||
33808325|NCT01513733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038891|NCT04904497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"In this study, researchers, recruiters, evaluators, control group team and data analyst will be masked. These teams will not have contact with the interventionists of the experimental group. Evaluators who have contact with the patients of both groups, they will be professionals from other medical units, who do not know the ICU team, and will only be able to maintain their dialog, according to the guideline of each evaluation.~It is not possible to mask the treating occupational therapist and patient receiving OT."|A control group (standard ASDM measures) or an intervention group (early and intensive occupational therapy + ASDM) will be randomized. The intervention group will receive 20 occupational therapy sessions. The interventions will be organized on the basis of i) level of sedation, ii) presence or absence of delirium (according to CAM ICU +/- (Confusion Assessment Method Intensive Care Unit)), iii) movement with or without gravity (cut-off point 3 points in elbow flexion movement in Medical Research Council(MRC)). The areas of intervention implemented by occupational therapist will be: i) Polysensory stimulation, ii) Cognitive stimulation, iii) Basic activities of daily living, iv) Motor function stimulation, v) Education|f|t|t|t
34038892|NCT01956773|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34038893|NCT04674215|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||While the patients receiving control treatment received routine clinical care, the patients in the intervention group received in- bed rotation and mobilization training with planned training with planned training one day before the operation.|t|t|f|f
34038894|NCT02124655||CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34112183|NCT02011412|||CASE_CONTROL||PROSPECTIVE|||||||
34112184|NCT04217317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725305|NCT05990400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Investigator, Outcomes Assessor) The allocation sequence was generated with a computer by an analyst. The allocation sequence was concealed from the investigators, outcomes assessor, and subjects.|Eligible subjects were randomized to receive either combination of minoxidil 5% topical and finasteride 0,1% topical or minoxidil 5% topical. The allocation sequence was generated with a computer by an analyst.|t|f|t|t
33725306|NCT03437109|||COHORT||PROSPECTIVE|||||||
33725307|NCT02132767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725308|NCT01136096|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33725309|NCT05578287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725310|NCT05339451|||COHORT||PROSPECTIVE|||||||
33725311|NCT03062956|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Subjects will be randomized 6:2 to MYK-491:placebo within each cohort.||t|t|t|t
33725312|NCT05231590|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725313|NCT03725189|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33725314|NCT04611763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725315|NCT03488979|||COHORT||PROSPECTIVE|||||||
33808326|NCT02067819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808327|NCT01399450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808328|NCT01847534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725316|NCT03930446|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33725317|NCT01514760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725318|NCT03476083|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808329|NCT01904097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725319|NCT02242708|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34112185|NCT03586921|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients received enhanced primary care, which included: (1) The nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety, including diagnosis, appropriate medication interventions, psycho-education, and cognitive and problem solving therapy. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants.||||
34112186|NCT01784302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112187|NCT04426474|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34112188|NCT05425121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomly allocated to control Group A (Core stability training protocol ) or Interventional Group B(core stability training protocol with surface electromyography biofeedback protocol) for the whole duration of the study.|f|f|f|t
34112189|NCT03037749|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Both distressed violent and distressed nonviolent partners participated in two experimental sessions and were counter-balanced to receive either an alcohol beverage or a placebo beverage in the first or second experimental session.|This is a within subjects design where distressed violent and distressed nonviolent partners participated in a placebo-controlled alcohol administration study with an emotion-regulation task.|t|f|f|f
34112190|NCT02363166|||CASE_ONLY||CROSS_SECTIONAL|||||||
34112191|NCT04881058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112192|NCT03251989|||COHORT||PROSPECTIVE|||||||
34112193|NCT03464773|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34112194|NCT06513247|||COHORT||PROSPECTIVE|||||||
34112195|NCT05870631|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112196|NCT05963126|||COHORT||PROSPECTIVE|||||||
34112197|NCT02371889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112198|NCT00967499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112199|NCT05575102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112200|NCT06571682|||COHORT||PROSPECTIVE|||||||
34112201|NCT00005980|RANDOMIZED|||TREATMENT||||||||
34112202|NCT05443321|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||pre-post interrupted time series analysis||||
34112203|NCT03494829|||COHORT||PROSPECTIVE|||||||
34112204|NCT06015009|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112205|NCT00889005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112206|NCT06397092|||COHORT||RETROSPECTIVE|||||||
34112207|NCT05170802|||OTHER||PROSPECTIVE|||||||
34112208|NCT03643237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34112209|NCT00654732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112210|NCT03924414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's Disease or parkinsonism with at least 2 years of follow-up.|t|f|t|t
34112211|NCT03032484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112212|NCT03290521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients will therefore be divided into two groups:~A - Yes Washing (SL) B - No Washing (NL)"|t|f|t|f
34112213|NCT06638827|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34112214|NCT03341936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112215|NCT01146002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112216|NCT05438329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112217|NCT04923672|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to either control group or one of two exercise groups: moderate continuous or high intensity interval training||||
34112218|NCT02754297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112219|NCT06563518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112220|NCT03038087|NA|SINGLE_GROUP||OTHER||NONE||||||
34112221|NCT03637348|NA|SINGLE_GROUP||OTHER||NONE||||||
34112222|NCT06336304|||COHORT||PROSPECTIVE|||||||
34112223|NCT02845882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112224|NCT01527032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112225|NCT03615638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The orthopedic surgeons, outcomes assessor and statistician will be blinded.|Single-blinded 3-arm randomized controlled trial|f|t|t|t
34112226|NCT00009178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34112227|NCT02116023|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34112228|NCT05880524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Monocentric, randomised, placebo-controlled single-blinded, Phase 2 trial|t|f|f|f
34112229|NCT03629704|||COHORT||PROSPECTIVE|||||||
34112230|NCT02755350|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34112231|NCT06379100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Alzheimer's disease patients were enrolled by expert neurol ogists who were blinded to treatment allocation. rTMS sessions were performed by dedicated technicians. The Cognitive evaluations and analysis of neuro physiological data were performed by expert neurophysiologists blinded to treatment allocation.||t|f|t|t
34112232|NCT05194995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33725320|NCT05264194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Given the nature of the suturing techniques, it would be impossible to blind the study to the investigators and the participants.|Patients will be randomly assigned to receive sutures that will either be hidden underneath their skin (subcuticular) or on your skin (transcutaneous) at the time of skin closure post-surgery.||||
34112233|NCT01142570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112234|NCT06563778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112235|NCT05801887|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||test group - application of shockwave on osteoblast control group - No shockwave on osteoblast||||
34112236|NCT02992730|||COHORT||CROSS_SECTIONAL|||||||
34112237|NCT00982280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112238|NCT01480830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112239|NCT04910620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34112240|NCT00149357|||COHORT||OTHER|||||||
34112241|NCT05828108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112242|NCT06472856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725321|NCT01460433|||COHORT||PROSPECTIVE|||||||
33725322|NCT00160095|||COHORT||PROSPECTIVE|||||||
33725323|NCT05717010|||CASE_CROSSOVER||PROSPECTIVE|||||||
33725324|NCT03645655|||COHORT||PROSPECTIVE|||||||
33725325|NCT01380184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038895|NCT06181188|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Envelops with pre-randomized and documents will be sealed and placed in a locked cabinet. Once a patient has been enrolled an envelop will be obtained indicating which arm the patient will be enrolled into. The study drugs will be labeled A (ketamine), B (midazolam), and C (fentanyl) and will be referred to as A, B, or C during the procedure to as to maintain anonymity from the patient.|Single blinded randomized control trial. The control arm will receive a combination of midazolam and fentanyl. The study arm will receive a combination of midazolam and ketamine.|t|f|f|f
33725326|NCT01720914|||COHORT||PROSPECTIVE|||||||
33725327|NCT02984566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038896|NCT04846712|||COHORT||RETROSPECTIVE|||||||
34038897|NCT01925430|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34038898|NCT02822014|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038899|NCT05021393|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34038900|NCT05492604|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038901|NCT05396027|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants do not know which study group they are in.|The crossover study design is implemented whereby healthy participants are assigned to the control group whereas visually impaired participants are assigned to the intervention group initially. After 14 days, the same participants cross over from the first session to the second session during the experiment.|t|f|f|f
34038902|NCT01506115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038903|NCT02809729|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34038904|NCT03886610|||COHORT||PROSPECTIVE|||||||
34038905|NCT01094574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34038906|NCT02000960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038907|NCT06371924|RANDOMIZED|PARALLEL||OTHER||NONE||"The investigators propose to conduct a randomised clinical trial in which 36 DCD human livers will be allocated to 1 of 3 treatment arms:~i) SCS; ii)NRP; and iii) HOPE. This will be followed by a period of time in NMP in order to study the IRI response and determine if the quality of the livers is good enough to proceed to transplantation. This study will allow the doctors to decipher the mechanisms of liver IRI in humans in a much better way than what has been achieved to date."||||
34038908|NCT05511870|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|JX02001 is a double blind phase 1 study.|A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study|t|f|t|f
34038909|NCT06449482|NA|SINGLE_GROUP||TREATMENT||NONE||selinexor venetoclax and azacitidine||||
34038910|NCT00124501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038911|NCT01724697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038912|NCT01607515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038913|NCT02760537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038914|NCT02355392|||COHORT||CROSS_SECTIONAL|||||||
34038915|NCT06490224|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34038916|NCT01124994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038917|NCT05755919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038918|NCT02088762|||COHORT||RETROSPECTIVE|||||||
34038919|NCT04016675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34038920|NCT05401617|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34038921|NCT05711108|||CASE_ONLY||PROSPECTIVE|||||||
34038922|NCT04578301|||COHORT||PROSPECTIVE|||||||
34038923|NCT05576142|||COHORT||PROSPECTIVE|||||||
34038924|NCT02978118|||COHORT||PROSPECTIVE|||||||
34038925|NCT03214601|NA|SINGLE_GROUP||TREATMENT||NONE||The Relay Branch System is intended for treating thoracic aortic arch pathologies requiring coverage of the innominate and left common carotid arteries. The system includes a graft with a proximal landing zone in the proximal aorta and branch grafts that extend into the innominate and left common carotid arteries. The arch graft and branch grafts are composed of self-expanding nitinol stents sutured to polyester vascular graft fabric, creating an exoskeleton||||
34038926|NCT05434988|||COHORT||PROSPECTIVE|||||||
34038927|NCT04323410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Non-inferiority randomized controlled trial|f|f|t|t
34038928|NCT02539940|||COHORT||PROSPECTIVE|||||||
34038929|NCT06575478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038930|NCT01089400|||CASE_CONTROL||PROSPECTIVE|||||||
34038931|NCT02094274|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34038932|NCT04829968|||CASE_ONLY||OTHER|||||||
34038933|NCT01431716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038934|NCT05225272|||COHORT||OTHER|||||||
34038935|NCT04404543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038936|NCT04526288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038937|NCT03533517|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34038938|NCT05344560|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34038939|NCT01332669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038940|NCT00964067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038941|NCT00644215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038942|NCT03749330|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34038943|NCT03719469|||OTHER||RETROSPECTIVE|||||||
34038944|NCT03711786|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|"As randomization is at the clinic level and cannot be masked, participants, care providers, and investigators will not be masked to allocation.~Outcome assessors do not need to know study arm, but it will be operationally difficult to blind them to whether a clinic is receiving the basic or enhanced implementation package."|10 clinics will be randomized 1:1 to either a basic or enhanced implementation package to support integration of evidence-based depression treatment.||||
33725328|NCT02776150|||CASE_ONLY||PROSPECTIVE|||||||
33725329|NCT04985812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33725330|NCT06003010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725331|NCT05552872|||CASE_CONTROL||PROSPECTIVE|||||||
33725332|NCT01347541|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33725333|NCT01489072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33725334|NCT00973479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725335|NCT02225522|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33725336|NCT02589782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725337|NCT01283126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34038945|NCT03869320|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Single-center, double-blind, randomized, placebo-controlled, single-ascending dose, Phase 1 study. The food effect will be assessed using a two-period, fixed-sequence design.|t|f|t|t
34038946|NCT05420038|||COHORT||PROSPECTIVE|||||||
34038947|NCT03298386|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038948|NCT06055205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The statistician performing the data analyses will be masked for group status. The participants, study nurses and study coordinator will not be masked.|The study will use a prospective randomized controlled trial design. Participants will be assigned randomly to study conditions (1:1) through permuted block randomization with various sizes of the blocks (4, 6, 8, 10) in random order. The randomization will be performed manually by the principle investigator (PI). Sealed, opaque, numbered envelopes will be used, and will be opened after consent from the patient. For the intervention group, the study coordinator will contact the patient's general practitioner (GP) by calling the doctor's office to obtain consent for participation. For the control group, the GP will not be asked for consent. To ensure that no GPs are included in both groups, the GPs retain their initial allocation if they have additional patients in the project. In practice, this corresponds to cluster-randomization at the GP level (and will be treated as such in the statistical analyzes).|f|f|f|t
34038949|NCT00850057|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038950|NCT06574607|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34038951|NCT03428152|||COHORT||PROSPECTIVE|||||||
34038952|NCT05863663|||OTHER||CROSS_SECTIONAL|||||||
34038953|NCT06015724|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038954|NCT01905761|||COHORT||PROSPECTIVE|||||||
34038955|NCT02812797|||COHORT||PROSPECTIVE|||||||
34038956|NCT00133016|RANDOMIZED|PARALLEL||||NONE||||||
34038957|NCT02950415|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
34038958|NCT05364866|||COHORT||PROSPECTIVE|||||||
34038959|NCT01537042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34038960|NCT04606212|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34038961|NCT03560401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients eligible for the study were selected by an independent research assistant. The study was explained, and informed consent was obtained from patients before the surgery. Using a randomization sequence, the patients were assigned to the brace or no brace group.|Patients in the brace group were instructed to wear a rigid brace (Knight-Taylor \[chairback\] brace) full-time for 12 weeks, except when bathing or lying in bed. Patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off. All patients started wearing the brace or corset during their first ambulation out of bed following drainage tube removal after the surgery.|f|f|t|f
34038962|NCT04517305|||COHORT||RETROSPECTIVE|||||||
34038963|NCT01606358|||COHORT||PROSPECTIVE|||||||
34038964|NCT02361099|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34038965|NCT03725306|NA|SINGLE_GROUP||TREATMENT||NONE||Objective Performance Criterion||||
33725338|NCT00731887|||CASE_ONLY||CROSS_SECTIONAL|||||||
33725339|NCT03343483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725340|NCT03767920|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participating patients, surgeons, anesthesiologists and medical investigators who will be involved in the data collection will be all blinded to the patient's group assignment until the collection of data for all cases will be complete.|A prospective Randomized Interventional double-blind study.|t|t|t|t
34112243|NCT03134209|RANDOMIZED|PARALLEL||TREATMENT||NONE||Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty will be compared to two groups: 1) Monocryl + Dermabond 2) Polyester mesh + Dermabond||||
34112244|NCT06564545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112245|NCT05903235|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34112246|NCT01965847|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34112247|NCT03544463|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33725341|NCT04759872|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Participants will be asked to complete 1 screening visit to determine eligibility.~If participants remain eligible, they will be asked to complete 1 metabolic study visit."||||
33725342|NCT01702701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33725343|NCT05048446|||OTHER||CROSS_SECTIONAL|||||||
33725344|NCT00805974|NA|SINGLE_GROUP||SCREENING||NONE||||||
33725345|NCT03733171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808330|NCT04913103|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single arm, combination - polatuzumab vedotine + rituximab+bendamustin||||
33808331|NCT00529009|NON_RANDOMIZED|PARALLEL||||NONE||||||
33808332|NCT06132659|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All staff present during the MRI session, as well as the participant, will be blinded to group assignment. The Study Coordinator will remain unblinded during the duration of the study.||t|t|f|f
33808333|NCT01156454|||||PROSPECTIVE|||||||
34038966|NCT02844413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038967|NCT03972189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038968|NCT03161470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038969|NCT04967820|||OTHER||CROSS_SECTIONAL|||||||
34038970|NCT00656422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038971|NCT06133608|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34038972|NCT00762710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34038973|NCT00161226|||CASE_ONLY||PROSPECTIVE|||||||
34038974|NCT03550495|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective, single institution, controlled, pilot study of patients admitted to the 7W ICU which will compare the incidence and delirium rates among patients undergoing routine care before intervention (no routine psychiatric involvement) (control group) and patients after the intervention (psychiatry team rounding with the ICU team daily) (intervention group) . Randomization is not possible for this study; although block randomization was considered, it will result in sub-optimal data subject to bias.||||
34038975|NCT03131752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038976|NCT00706459|||CASE_CONTROL||PROSPECTIVE|||||||
34038977|NCT03328507|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038978|NCT02502149|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34038979|NCT00661557|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34038980|NCT01886677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038981|NCT04958213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34038982|NCT02150226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038983|NCT05304130|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open-label study.|Eligible participants will receive treatment with otilimab.||||
33725346|NCT02065232|||COHORT||PROSPECTIVE|||||||
33725347|NCT06131008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725348|NCT02174458|||CASE_CONTROL||PROSPECTIVE|||||||
33725349|NCT04252989|||COHORT||RETROSPECTIVE|||||||
33725350|NCT02444572|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33725351|NCT06481527|||FAMILY_BASED||PROSPECTIVE|||||||
34038984|NCT02528877|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34038985|NCT00405561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34038986|NCT00513695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112248|NCT06251115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112249|NCT03841799|||COHORT||PROSPECTIVE|||||||
34112250|NCT04411992|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|All the measurement scores were obtained by another researcher blinded to group allocation.|Two groups were formed according to crossover design. The groups of the patients were determined according to the randomization list formed by using the following website; www.randomization.com.All the measurement scores were obtained by another researcher blinded to group allocation.|f|f|t|f
34112251|NCT04862780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112252|NCT00103844|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112253|NCT04339062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112254|NCT02248571|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34112255|NCT06418282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112256|NCT04773379|||COHORT||CROSS_SECTIONAL|||||||
34112257|NCT00552136|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112258|NCT06186310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups with a conventional physical therapy control group||||
34112259|NCT03318094|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34112260|NCT02656056|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34112261|NCT04431063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112262|NCT03132467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112263|NCT01427673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34112264|NCT00741728|||COHORT||PROSPECTIVE|||||||
33725352|NCT00730782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725353|NCT01356654|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33725354|NCT03823053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725355|NCT04697693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725356|NCT03095066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725357|NCT00668486|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725358|NCT00644969|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33725359|NCT00225381|||CASE_ONLY||OTHER|||||||
33725360|NCT00105703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725361|NCT00316199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725362|NCT01589757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725363|NCT05024500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|trial participants, data collectors and outcome assessors or committees will remain blinded to the patient assigned group of treatment.|three groups of treatments (A, B and C) are given so that one group receives only A while another group receives only B and the third group receives only C. All volunteers will be randomized to one of the three groups of treatment.|t|f|t|t
33725364|NCT01454921|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33725365|NCT03254095|||COHORT||PROSPECTIVE|||||||
33725366|NCT02562651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725367|NCT05602415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112265|NCT02169596|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112266|NCT06291779|||CASE_CONTROL||PROSPECTIVE|||||||
33725368|NCT05200754|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725369|NCT05261984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725370|NCT03304847|NA|SINGLE_GROUP||TREATMENT||NONE||single group assignment||||
33725371|NCT04272528|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33808334|NCT05416476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|In this double-blind clinical trial, Anisodine Hydrobromide was identical in appearance to the Anisodine Hydrobromide placebo.Patients, investigators (persons who screen patients, assess endpoints, and assess protocol compliance), and sponsor personnel associated with clinical research should be blinded.|All subjects were randomly assigned to group A (Anisodine Hydrobromide 1 mg bid) and group B (placebo 1 mg bid) according to 1:1 ratio.|t|t|t|t
33808335|NCT01687920|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33808336|NCT01130870|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34112267|NCT01992757|||COHORT||PROSPECTIVE|||||||
33808337|NCT02760654|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33808338|NCT03208465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808339|NCT02410278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808340|NCT03056378|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808341|NCT00695188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038987|NCT04910100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is observer masked. The study medication will be provided in foil pouches contained in identical-appearing boxes. An unmasked staff member not involved in performing study endpoint-related procedures (i.e., IOP measurement) will be responsible for providing dosing instructions, dispensing study medication, and conducting study medication accountability and dosing compliance assessment. The identity of the study medications will be masked to the Investigator and study personnel responsible for study endpoint-related procedures. IOP measurements will be performed by the Investigator/designee who will be masked to the readout of the tonometer, which will be read and entered into the source documentation (whether electronic or paper) by a second staff member once the Investigator/designee reaches the correct applanation effect in the slit lamp.|Eligible participants will be randomized in a 1:1:1:1 ratio to 4 treatment arms: nebivolol 0.5% ophthalmic suspension; nebivolol 1.0% ophthalmic suspension; timolol 0.5% ophthalmic suspension; and timolol 0.5% ophthalmic solution.|f|t|t|t
34038988|NCT00550355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038989|NCT04217096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038990|NCT00127231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038991|NCT02534805|||COHORT||PROSPECTIVE|||||||
34038992|NCT02595918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34038993|NCT00080912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34038994|NCT04432766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34038995|NCT05984199|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34038996|NCT02768818|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34038997|NCT02586974|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34038998|NCT03432104|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34038999|NCT00400023|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039000|NCT02727946|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34039001|NCT03729167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039002|NCT01650688|||CASE_ONLY||RETROSPECTIVE|||||||
34039003|NCT05850481|||OTHER||PROSPECTIVE|||||||
34112268|NCT04408885|||COHORT||PROSPECTIVE|||||||
33808342|NCT06006572|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808343|NCT02669576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808344|NCT00016107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808345|NCT00713596|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33808346|NCT01989052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808347|NCT02994667|||COHORT||PROSPECTIVE|||||||
33808348|NCT00747006|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808349|NCT03152435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808350|NCT00078156||||TREATMENT||||||||
34039004|NCT04529629|||OTHER||PROSPECTIVE|||||||
34039005|NCT01772173|||COHORT||RETROSPECTIVE|||||||
34039006|NCT05237167|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective randomized diagnostic comparison study||||
34039007|NCT06025357|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Parallel Assignment Double (Participant, Investigator) Randomized, double-blind, placebo-controlled, parallel study design|t|f|t|f
34039008|NCT02590497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039009|NCT05693259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|"* Control group (PW): purified water-drinking group~* Experimental group (EARW): Electrolyzed alkaline reduced water drinking group"|t|f|t|f
34039010|NCT00977093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039011|NCT04667325|||COHORT||PROSPECTIVE|||||||
34039012|NCT00877045|||CASE_ONLY||RETROSPECTIVE|||||||
34039013|NCT02858804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039014|NCT02435693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039015|NCT01597323|||CASE_CONTROL||PROSPECTIVE|||||||
34039016|NCT05313503|NA|SINGLE_GROUP||TREATMENT||NONE||interventional, monocentric, open label||||
33808351|NCT04597866|||COHORT||RETROSPECTIVE|||||||
34039017|NCT06136273|||CASE_CONTROL||PROSPECTIVE|||||||
34039018|NCT00310999|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34039019|NCT06360172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34112269|NCT02567903|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34112270|NCT03518151|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||WRAPPED1 is a natural experiment with a prospective matched controlled cluster design||||
34112271|NCT00573768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112272|NCT05840302|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112273|NCT01538199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112274|NCT02010502|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34112275|NCT03230214|||COHORT||PROSPECTIVE|||||||
34112276|NCT05132491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808352|NCT04983615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808353|NCT03011047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112277|NCT01930448|||CASE_CONTROL||PROSPECTIVE|||||||
33808354|NCT05741450|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All participants received Lens 1 and then Lens 2 in fixed-sequence order.|t|f|f|f
33808355|NCT03019341|||COHORT||PROSPECTIVE|||||||
33808356|NCT05511545|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808357|NCT03701906|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This is an interventional, randomized, double-blind, placebo-controlled, parallel-group study.|t|t|t|f
34039020|NCT05115851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The interventions were performed by trained physical therapist and the data was collected by independent assessor. Therapists, assessors and participants were blinded to group allocation throughout the duration of the trial.||t|t|f|t
34039021|NCT03392727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039022|NCT02418182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34039023|NCT00376649|RANDOMIZED|PARALLEL||||NONE||||||
34039024|NCT00184327|||COHORT||PROSPECTIVE|||||||
34039025|NCT02726009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039026|NCT02930772|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039027|NCT00315458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112278|NCT06565312|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34039028|NCT05208190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded raters and a blinded adjudication committee to ensure that the outcome is valid|single-blind, open-label, randomized, active comparator (TAU) controlled clinical trial|f|f|f|t
34039029|NCT03922321|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
34039030|NCT03192449|NA|SINGLE_GROUP||OTHER||NONE||Pharmacokinetics||||
34039031|NCT03458442|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34039032|NCT05399784|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039033|NCT02807129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039034|NCT05531812|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34039035|NCT03055676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039036|NCT04015271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The care provider completing intervention and the outcomes assessor are members of the research team and blinded to group assignment.|A pilot randomized controlled single blinded, parallel-group study design|f|t|f|t
34039037|NCT04983472|||OTHER||PROSPECTIVE|||||||
34039038|NCT03583580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039039|NCT05545722|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34039040|NCT01415518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039041|NCT01779843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039042|NCT00000876||||TREATMENT||NONE||||||
34112279|NCT05699109|||COHORT||PROSPECTIVE|||||||
34112280|NCT01678742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112281|NCT05068583|||COHORT||PROSPECTIVE|||||||
34112282|NCT05954884|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34112283|NCT04298073|||CASE_CONTROL||PROSPECTIVE|||||||
34112284|NCT02115087|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34112285|NCT05817110|||COHORT||PROSPECTIVE|||||||
34112286|NCT03403686|||COHORT||OTHER|||||||
34112287|NCT00514189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808358|NCT02311621|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808359|NCT01887275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808360|NCT01144520|||OTHER||OTHER|||||||
33808361|NCT05845970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808362|NCT02718339|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33808363|NCT03591588|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, in the same individuals with randomized crossover design.|f|f|f|t
33808364|NCT06360978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112288|NCT00339352|||OTHER||RETROSPECTIVE|||||||
34112289|NCT00599092|||OTHER||PROSPECTIVE|||||||
34112290|NCT01483560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112291|NCT05853965|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I: 3+3 Fibonacci design Phase II: single group||||
34112292|NCT05210543|||CASE_ONLY||PROSPECTIVE|||||||
34112293|NCT06255769|||OTHER||PROSPECTIVE|||||||
34112294|NCT03514134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112295|NCT05790876|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-center, non-controlled, non-randomized, open-label study (pilot study)||||
34112296|NCT02898688|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112297|NCT02275195|||OTHER||PROSPECTIVE|||||||
34112298|NCT01779960|||||PROSPECTIVE|||||||
34112299|NCT00760760|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34112300|NCT05077969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Participants randomized 1:1, study drug:placebo|t|t|t|f
34112301|NCT02077608|||COHORT||PROSPECTIVE|||||||
34112302|NCT04023487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725372|NCT01661712|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725373|NCT04278521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725374|NCT05213923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725375|NCT01374685|||||OTHER|||||||
33725376|NCT02233322|NA|SINGLE_GROUP||OTHER||NONE||||||
33725377|NCT05929183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039043|NCT05183841|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|All the measurements will be performed by a blinded professional, who will be masked from randomization and other results. The randomization sequence will be generated by computer, and put in sealed and opaque envelopes by a volunteer not involved in the study. The bronchodilator (BD) or placebo will be administered by a professional not involved in the study, according to the randomization. The evaluator will not have access to information on which intervention (BD or placebo) was given prior to each CLET.|On the first day, anamnesis, anthropometric evaluation and lung function will be performed, followed by: Quality of Life Questionnaire-Bronchiectasis, Saint George questionnaire, modified Medical Research Council scale and social and economic status. Then, a cardiopulmonary exercise test (CPET) will be performed and after rest, a bronchodilator (BD) or placebo randomization will precede a constant load exercise test (CLET) with the respiratory mechanics assessment (OEP). Finally, the accelerometer will be coupled to the patient for 7 consecutive days, aiming to assess the PAL. On the second day, after at least one-week washout, the accelerometer will be collected and the patient will repeat the CLET with the respiratory mechanics assessment, at the opposite condition to randomization.|t|f|f|t
33725378|NCT04931433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The medications will be prepared before induction by a nurse or doctor who is neither a member of the trial team and later handed to the anaesthetist in charge of the administration according to the trial protocol. The trial drugs are prepared in a 10-ml syringe for the bolus injection and a 50-ml syringe for continuous infusion. For the bolus injection, IV lignocaine 1% will be drawn into the 10-ml syringe will lignocaine 1% solution according to the weight of the patient (0.15ml/kg) or an equal amount of 0.9% saline. The 50-ml syringe contained either 50ml of lignocaine 1% solution or 0.9% normal saline solution.|Group A, Lignocaine and Group B, placebo. Group A will receive 1.5 mg/kg IV lignocaine bolus prior to induction followed by 2mg/kg/hour of lignocaine infusion throughout surgery until wound closure in which the infusion rate will be halved to 1 mg/kg/hour until the end of surgery. This same rate will be infused in the recovery room for another half an hour before patient discharge. Group B will receive saline of similar volume and rate as for Group A.|t|f|f|t
34039044|NCT04277013|||COHORT||PROSPECTIVE|||||||
34039045|NCT02768480|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34039046|NCT05849727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039047|NCT02820974|||||PROSPECTIVE|||||||
34039048|NCT06549842|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34039049|NCT00452296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039050|NCT01289470|||COHORT||PROSPECTIVE|||||||
34039051|NCT03218995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039052|NCT04553731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039053|NCT03853174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34039054|NCT04229693|||COHORT||PROSPECTIVE|||||||
34112303|NCT06534775|||COHORT||PROSPECTIVE|||||||
33725379|NCT03462550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725380|NCT01336075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725381|NCT04145778|||CASE_CONTROL||PROSPECTIVE|||||||
33725382|NCT06036576|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725383|NCT00643422|||COHORT||PROSPECTIVE|||||||
33725384|NCT01052207|||COHORT||PROSPECTIVE|||||||
34150063|NCT04065633|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a Phase 1 randomized, open label, single-dose, crossover study in healthy participants to estimate the rBA of the commercial formulation of PF-04965842 (Test formulation 1) and the variant formulation with slower dissolution (Test formulation 2) compared to the Phase 3 formulation (Reference formulation), to demonstrate the BE of the commercial formulation relative to the Phase 3 formulation, and to estimate the effect of food on the rBA of the commercial formulation after a single 200 mg oral dose.||||
34150064|NCT05099159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808365|NCT03760653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The probiotic and the placebo will be encapsulated in identical capsules and in identical cans that will only be identified with the letters A and B||t|f|t|f
33808366|NCT04033250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33808367|NCT05108363|NA|SINGLE_GROUP||TREATMENT||NONE||And lifestyle modification program for 6 months of therapy||||
33808368|NCT06142838|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33808369|NCT00637858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808370|NCT01536366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808371|NCT05537532|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization scheme||||
33808372|NCT01209195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112304|NCT04066959|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The outcomes assessor/data collector will be kept blind to treatment assignments to the extent possible in a behavioral trial.|The study will use an 8-arm full factorial design. In arms 1-3 participants will receive 1 of the 3 intervention components, arms 4-6 receive a combination of 2 components, arm 7 receives all 3 components, and arm 8 is the standard care control. The study will use the mixed effects linear model for the ANOVA of a factorial design powered on the main effects to identify the intervention components that significantly contribute to a clinically significant improvement in HbA1c. Each model will include a random intercept and slope and fixed effects for treatment combinations and time, as well as the stratification variable. The component selection experiment will result in empirical evidence supporting the efficacy of an autonomy support intervention composed of one or more components to improve metabolic control.|f|f|f|t
34112305|NCT06644820|||CASE_ONLY||PROSPECTIVE|||||||
34112306|NCT03127930|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants and outcomes assessors were not blind to the intervention by nature o the protocol. Investigators and analysts were blinded to study group assignment.|Social Cognitive and Self Efficacy Theory drove the problem-solving tailored intervention delivered via face to face and telephone by either a master's prepared social worker or nurse.|f|f|t|f
34112307|NCT03360344|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants do not know which group they will be randomly assigned|prospective randomized controlled trial|t|f|f|f
34112308|NCT03331887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|no masking||t|f|f|t
34112309|NCT03575598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112310|NCT06278324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessment of viral load analyses|Randomized Controlled Trial, parallel arms (1:1 allocation ratio), single center, with a blind assessment for primary outcome|f|f|f|t
34112311|NCT06293781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112312|NCT02741050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34112313|NCT04198649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112314|NCT01379690|||CASE_CONTROL||RETROSPECTIVE|||||||
34112315|NCT00294749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112316|NCT03874559|||COHORT||PROSPECTIVE|||||||
34112317|NCT04565730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is general anesthesia group. The second one is spinal anesthesia group|f|f|f|t
34112318|NCT05380700|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive the intervention||||
34112319|NCT06564558|RANDOMIZED|FACTORIAL||OTHER||DOUBLE||The study will follow a randomized controlled clinical trial design. Participants will be recruited from the physical therapy outpatient clinic at Beirut Arab University as well as several outpatient and private physical therapy clinics around Beirut, Lebanon. After recruitment and screening for eligibility, the participants will be divided randomly using a computer randomization program into a control and experimental group. After the completion of the program, the two groups will be compared based on selected outcome measures.|t|f|f|t
34112320|NCT03361449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34112321|NCT06045078|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|Research staff (i.e. research assistants, coordinators, etc.)|A pilot randomized controlled trial|t|f|t|f
34112322|NCT00574015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112323|NCT01257750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112324|NCT04557423|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34112325|NCT01081392|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34112326|NCT06558773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112327|NCT00189137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112328|NCT05197764|||COHORT||PROSPECTIVE|||||||
34112329|NCT00183248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112330|NCT02970565|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34112331|NCT01748656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112332|NCT02076711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34112333|NCT00371124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34112334|NCT02478541|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34112335|NCT04952714|||COHORT||PROSPECTIVE|||||||
34112336|NCT01613651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34112337|NCT05588167|||COHORT||RETROSPECTIVE|||||||
34112338|NCT04890184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112339|NCT02228928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112340|NCT04417530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112341|NCT04992130|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34112342|NCT00347269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112343|NCT03889379|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112344|NCT05348421|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112345|NCT02465008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112346|NCT06473675|||CASE_ONLY||PROSPECTIVE|||||||
34112347|NCT05852327|||COHORT||PROSPECTIVE|||||||
34112348|NCT02383784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112349|NCT01799902|||CASE_ONLY||PROSPECTIVE|||||||
34112350|NCT02485886|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150065|NCT01248871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34150066|NCT04715009|||COHORT||PROSPECTIVE|||||||
34150067|NCT05339282|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150068|NCT04185506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150069|NCT00002020||||TREATMENT||||||||
34150070|NCT04516551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150071|NCT03708874|||OTHER||PROSPECTIVE|||||||
33725385|NCT04330560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The masking will be imposed on the investigator who will be involved with the recruitment of the participant to prevent selection bias. The allocation of the participant to a group will be randomised using computer-generated random numbers by the other investigator who did not involve in recruiting the participant.||f|f|t|f
33725386|NCT01859494|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725387|NCT05928585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725388|NCT04014075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725389|NCT02719132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725390|NCT03573986|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725391|NCT04914390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725392|NCT04819555|||COHORT||PROSPECTIVE|||||||
33725393|NCT03136003|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The randomization of the participant to a study arm will be done prior to the study visit by the pharmacy at the hospital. The Investigator and study team will know the arm each participant is in before the patient's visit. This information will also be provided to the participant before the visit.|||||
33725394|NCT04045496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725395|NCT00859235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725396|NCT03121092|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33725397|NCT00847288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838165|NCT00581477|NA|SINGLE_GROUP||TREATMENT||NONE||Although the study was designed as a potential trial of multiple medications, plus placebo, in actuality it served as a means of safely determining the optimal dose of Droxidopa for our patients with Dopamine beta-Hydroxylase Deficiency to take at home. Before each dose of Droxidopa, blood pressure and heart rate were measured for 30 minutes. At 60 or 120 minutes after dosing, blood pressure was also measured after 5 minutes of lying down and 5 minutes of sitting or standing. These measurements were used to calculate the orthostatic change in systolic blood pressure, the primary outcome.||||
33838166|NCT01909297|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039055|NCT04316429|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||To provide a sound basis for the statistical comparison of outcome measures for treatment assignments, participants will be randomized to 1 of 2 sequence permutations of an egg-included vegan diet and a vegan diet, which will begin after a 4-week run in phase. Each permutation will include a 6-week treatment phase, followed by a 4-week washout phase, followed by 6-week treatment phase (20 weeks total for each study participant, including the run-in phase).|f|f|t|t
34039056|NCT00980863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039057|NCT00114140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039058|NCT00964574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039059|NCT02810626|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039060|NCT06534762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039061|NCT03808649|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
34039062|NCT02851563|||COHORT||PROSPECTIVE|||||||
34039063|NCT03517072|||COHORT||PROSPECTIVE|||||||
34039064|NCT04848064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039065|NCT06019546|||COHORT||PROSPECTIVE|||||||
34039066|NCT03911232|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34039067|NCT06287385|NA|SINGLE_GROUP||OTHER||NONE||||||
34039068|NCT02154568|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039069|NCT01969149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039070|NCT05375357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725398|NCT03548402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725399|NCT03234660|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34039071|NCT00865228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039072|NCT03014583|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34039073|NCT01441648|||COHORT||PROSPECTIVE|||||||
34039074|NCT01478412|||CASE_ONLY||RETROSPECTIVE|||||||
34039075|NCT03486808|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34112351|NCT05807594|RANDOMIZED|PARALLEL||PREVENTION||NONE|All investigators and the outcomes assessor(s) will be masked from the randomization scheme, and what study groups each participant will be/was randomized to. The randomization scheme will be developed and programmed into REDCap by the biostatistician. The team of investigators will not have knowledge of the randomization scheme or be able to view the programming. The programming will be password protected and only be able to be accessed by the biostatistician.|A staff member will request randomization after the pre-intervention measures by unique subject ID number. The study biostatistician will develop the randomization scheme using variable-size, random permuted blocks to ensure the number of subjects in each group is balanced after each set of B randomized subjects where B is block size. Randomization to control (n=72) and intervention (n=72) groups will use 1:1 allocation; subjects will be entered consecutively. Randomization will be stratified by pre-pregnancy BMI status (\< 29.9 kg/m2 vs. greater than or equal to 30 kg/m2). A staff member will call each woman to inform her of study assignment and schedule her for the first session (attention control or HMZ 2.0 intervention).||||
34112352|NCT05509348|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Sequential multiple assignment randomization trial|f|f|t|t
34112353|NCT00829244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112354|NCT00797303|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34112355|NCT02640300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112356|NCT06564090|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Outcome measurements, and data analysis were performed by trained and blinded outcome assessor who was not involved in the intervention. The outcome measures were evaluated before training and immediately after 8 weeks of training.||f|f|f|t
34112357|NCT02643485|||CASE_CONTROL||PROSPECTIVE|||||||
34112358|NCT00659022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112359|NCT04372485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039076|NCT02935712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039077|NCT02715193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039078|NCT02385773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039079|NCT04867226|RANDOMIZED|PARALLEL||TREATMENT||NONE||100 Patients will participate for eligibility and enroll in the study, an open labell randomize control clinical trial will held among patients who will infect with COVID-19 in whom they met the inclusion criteria, either treat at home with healthcare advises and follow up or at centres of COVID-19 in ERBIL city ( Rozhawa emergency hospital, Erbil international private hospital) .||||
34039080|NCT00226499|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039081|NCT05642871|||OTHER||PROSPECTIVE|||||||
34039082|NCT01994148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039083|NCT04955353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34039084|NCT01554527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725400|NCT01548131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725401|NCT04991181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725402|NCT03638310|RANDOMIZED|PARALLEL||TREATMENT||NONE||two groups of patients, one group prehabituated by chemical labyrintectomy, the second control group without prehabituation before the surgery||||
33725403|NCT05928052|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725404|NCT00624806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33725405|NCT03042052|||COHORT||RETROSPECTIVE|||||||
34039085|NCT06485921|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three groups with conventional therapy control group||||
33725406|NCT01335230|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725407|NCT04196946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725408|NCT01839552|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725409|NCT02599155|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33838167|NCT00003768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838168|NCT02167919|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34039086|NCT03302169|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||This is a prospective randomized controlled trial to assess early urinary continence recovery rates after robotic assisted radical prostatectomy when a posterior rhabdosphincter reconstruction is performed or not.|t|t|t|f
34039087|NCT06490055|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112360|NCT05093621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039088|NCT04036695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039089|NCT05469737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039090|NCT01820143|RANDOMIZED|CROSSOVER||||NONE||||||
34112361|NCT02449187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112362|NCT02055508|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725410|NCT03772847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725411|NCT05513885|||COHORT||RETROSPECTIVE|||||||
33725412|NCT01441674|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33838169|NCT03066882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838170|NCT01367847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838171|NCT00463164|||CASE_CONTROL||OTHER|||||||
33838172|NCT02142153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33725413|NCT01906710|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33725414|NCT00885066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725415|NCT03350074|||COHORT||RETROSPECTIVE|||||||
33725416|NCT00049439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838173|NCT04835454|||CASE_CONTROL||RETROSPECTIVE|||||||
34112363|NCT00636779|||COHORT||CROSS_SECTIONAL|||||||
34112364|NCT00000340||||TREATMENT||||||||
34112365|NCT06407011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112366|NCT00283192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34112367|NCT01432444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112368|NCT00155129|||DEFINED_POPULATION||OTHER|||||||
34112369|NCT00913822|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112370|NCT02476227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725417|NCT01625455|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33725418|NCT02436421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33725419|NCT02808130|||CASE_CONTROL||PROSPECTIVE|||||||
33725420|NCT00145665|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33725421|NCT06080386|||COHORT||RETROSPECTIVE|||||||
33725422|NCT00369551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725423|NCT00846937|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725424|NCT05720156|||CASE_CONTROL||PROSPECTIVE|||||||
34112371|NCT05876520|NA|SINGLE_GROUP||TREATMENT||NONE||Total Pulpotomy in mature permanent teeth treated with Nano-bioactive glass mixed with I-PRF||||
34112372|NCT03488615|||COHORT||RETROSPECTIVE|||||||
33725425|NCT04083807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725426|NCT01455012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112373|NCT04098588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725427|NCT01817725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725428|NCT00521196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725429|NCT02167503|||COHORT|||||||||
33725430|NCT02290106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725431|NCT05398679|RANDOMIZED|PARALLEL||TREATMENT||NONE||National multi-center study, open, controlled, and randomized||||
33725432|NCT03293732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725433|NCT04309656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each panel of 24 subjects will be randomized according to the same 4-sequence, 4-period Williams design, in which each participant will receive four single-dose treatments. Subjects in Panel 1 will receive all treatments after consuming an FDA standard high-fat, high-calorie breakfast following an overnight fast of at least 10 hours. Subjects in Panel 2 will receive all treatments directly following an overnight fast of at least 10 hours. The two panels will be investigated concurrently.||||
33725434|NCT01653769|||COHORT||OTHER|||||||
33725435|NCT05020340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725436|NCT01429883|||COHORT||PROSPECTIVE|||||||
33725437|NCT05129488|NA|SINGLE_GROUP||TREATMENT||NONE|The participant and investigator were masked and randomized allocation.|Approximately 30 habitual soft contact lens wearing subjects will be enrolled in this two-hour randomized, contralateral, double-masked (subject and investigator masked), repeated measures dispensing study.||||
34112374|NCT00100425|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
33725438|NCT03147547|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single-blind masking|Participants were randomly assigned to one of two conditions: 1) promotional brochure plus an attention-control research interview or 2) Package Engagement Package|t|f|f|f
33725439|NCT03131440|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33725440|NCT00300859|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33725441|NCT02234375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725442|NCT05334901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725443|NCT04479956|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Computer Based|Randomized controlled Prospective study|t|t|f|t
33725444|NCT06386835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725445|NCT04227106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725446|NCT06238076|NA|SINGLE_GROUP||OTHER||NONE||Feasibility pilot study, monocentric, non-comparative||||
33725447|NCT03342742|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33725448|NCT04075487|NA|SINGLE_GROUP||OTHER||NONE||Pilot study of feasibility and user experience of minimal risk App for pain self-management intervention.||||
33725449|NCT04935242|||COHORT||RETROSPECTIVE|||||||
33725450|NCT01957462|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33725451|NCT04226066|NA|SEQUENTIAL||TREATMENT||NONE||||||
33725452|NCT04109664|||COHORT||RETROSPECTIVE|||||||
33725453|NCT01464658|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725454|NCT00265343|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725455|NCT04898751|||OTHER||CROSS_SECTIONAL|||||||
33838174|NCT03659162|||OTHER||CROSS_SECTIONAL|||||||
33838175|NCT03160846|||COHORT||PROSPECTIVE|||||||
33838176|NCT05613153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838177|NCT03533842|||CASE_CROSSOVER||PROSPECTIVE|||||||
33838178|NCT00580060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838179|NCT05108753|||COHORT||RETROSPECTIVE|||||||
34112375|NCT05605249|NA|SINGLE_GROUP||TREATMENT||NONE||The study consists of four visits to the gait laboratory and four contact moments by telephone divided over 13 weeks. In between visits 1 and 2 (period of 6 weeks), participants do not receive any training or instructions and will carry out their activities as normal. In between laboratory visits 2 and 4, participants will use Cue X to train their gait and balance with gamified AR gait-and-balance exercises in their own home environment as intervention above usual care (6 weeks for a minimum of 30 minutes per day and 5 days a week to comply with World Health Organization \[2020\] movement guidelines). Two different state-of-the-art AR headsets will be used for Cue X training, namely Microsoft's HoloLens 2 and Magic Leap's 2 headsets, randomized over participants using covariate adaptive randomization with age, gender and disease duration as covariates. Half of the participants will train with HoloLens 2 and the other half with Magic Leap 2.||||
34112376|NCT05634005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34112377|NCT02296099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112378|NCT01137084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34112379|NCT01558167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112380|NCT02360085|||COHORT||PROSPECTIVE|||||||
33725456|NCT06256042|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Stabilizing interocclusal plate (IOP): a stabilizing maxillary acrylic occlusal plate was made, flat, total and adjusted in central relation (RC). Advice and guidance on the disease.~Arthrocentesis: Delimitation of a corner-tragus line to mark points A (10mm in front of the tragus and 2mm below the CT line) and B (20mm in front of the tragus and 10mm below the CT line); Local intra- and extra-oral antisepsis with aqueous chlorhexidine 0.12% and 0.2%, respectively; Local anesthesia of the auriculotemporal and intra-capsular nerve with mepivacaine 2% + Epinephrine 1:100,000; Insertion of the first 30x0.8 mm needle at point A and injection of 2-3 mL of Lactated Ringer; Insert the second 30x0.8 mm needle into point B Wash with 100-200mL of Ringer Lactate; Removal of the second needle; Injection of 1mL of 20mg Triamcinolone diluted in 0.9% saline solution (1:1) through the needle at point A."||||
34039091|NCT05331378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects (and their parents/guardians) will be masked to the lens assignment. Sibling of subjects must be excluded due to the noticeable differences between the test and control spectacle lenses Only the statistician will be unmasked when comparing the two lenses. The investigator who is responsible for randomization and allocation will also be unmasked. However, the primary outcome variables (spherical equivalent refraction \& axial length) will be taken by masked investigators. To facilitate this, the subject will be led into the room(s) containing a biometer without their study spectacles by the unmasked investigator.|This is a randomized, controlled, 2-armed, double-masked, monocenter, clinical trial, which consists of 6 visits across 1 year. The test myopia control lens will be compared with a single vision control lens in evaluating study objectives. After obtaining informed consent and assent, a comprehensive eye examination for screening will be done among approximately 80 myopic children between the age of 8-13 years old for eligibility. After randomization, the subjects will be back for dispensing of study spectacles and for baseline visit, where assessment of study spectacles, biometry, and instructions to use study spectacles were done. A follow up visit will be conducted in 3, 6 and 12 months time, in which the latter visit will also be the end of visit. All of which are non-contact and non-invasive to the eyes.|t|f|t|f
34039092|NCT05587595|||CASE_CONTROL||PROSPECTIVE|||||||
34039093|NCT04905901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34039094|NCT03956979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, double-dummy.||t|t|t|t
34039095|NCT05583461|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|"Being sedated and paralyzed, included patients will not be aware of the study phase.~The investigators performing the echocardiographic exams will be blinded to the experimental setting because the PEEP level set at the ventilator will be covered.~The echocardiographic measurement will be performed offline with no information on the experimental settings."|Randomized sequence of application of four levels of positive end-expiratory pressure in adult patients requiring invasive controlled mechanical ventilation for acute respiratory distress syndrome|t|f|t|t
34039096|NCT04405037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039097|NCT01842360|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34039098|NCT04469595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, masked, active-controlled, multi-center study|t|f|f|t
34039099|NCT05529550|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34039100|NCT04090229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind, Placebo-controlled, Randomized|t|t|t|t
34039101|NCT06220825|||COHORT||PROSPECTIVE|||||||
34039102|NCT05570240|||CASE_CONTROL||PROSPECTIVE|||||||
34039103|NCT02568189|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34039104|NCT03305965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patient navigation vs. care as usual||||
34039105|NCT01543438|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34039106|NCT01853813|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34039107|NCT06116188|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34039108|NCT05201287|NA|SINGLE_GROUP||TREATMENT||NONE||Up to 35 patients at 7 sites will receive treatment.||||
34039109|NCT01707160|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34039110|NCT06000150|||CASE_CONTROL||PROSPECTIVE|||||||
34039111|NCT02597504|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34039112|NCT02157935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039113|NCT03603912|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34039114|NCT04814381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|infusion will be prepared by a nurse that is not blinded to the treatment and will not take part to patient evaluation. Active and control treatments are of transparent colour and will not be recognisable.|patients will be randomised with 1:1 ratio|t|f|t|f
34039115|NCT04636775|||COHORT||PROSPECTIVE|||||||
34039116|NCT06147193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039117|NCT04931277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039118|NCT02204072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039119|NCT03478215|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34039120|NCT05786950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||the responds of the neural respiratory drive of the chronic obstructive pulmonary disease patients after inhaling bronchodilator(3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany).||||
34039121|NCT00937573|||COHORT||PROSPECTIVE|||||||
34039122|NCT02140151|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34039123|NCT04398043|||COHORT||PROSPECTIVE|||||||
34039124|NCT02461433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34039125|NCT06008652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039126|NCT03832764|||COHORT||PROSPECTIVE|||||||
34039127|NCT00527774|||COHORT||PROSPECTIVE|||||||
34112381|NCT05192278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34112382|NCT00398814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112383|NCT06482385|||COHORT||PROSPECTIVE|||||||
34112384|NCT00460122|||||OTHER|||||||
34112385|NCT05643378|||COHORT||PROSPECTIVE|||||||
33725457|NCT02213393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725458|NCT04552587|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725459|NCT04008446|||COHORT||PROSPECTIVE|||||||
33725460|NCT00721786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725461|NCT01133184|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33725462|NCT00698581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112386|NCT05980702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725463|NCT03503903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725464|NCT00006181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838180|NCT02047162|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33838181|NCT00514579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039128|NCT05079542|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the first phase, participants are randomized to receive implants either immediately or 8 weeks after tooth extraction. In a second phase, participants receive either a restoration out of one material or another, this also being randomized.||||
34039129|NCT02540382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34039130|NCT02546375|||CASE_ONLY||RETROSPECTIVE|||||||
34039131|NCT01958437|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blinded|Transcranial Direct Current Stimulation|t|f|t|f
34039132|NCT04146792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039133|NCT02583451|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34039134|NCT03408938|||COHORT||CROSS_SECTIONAL|||||||
34039135|NCT03856125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039136|NCT02965573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039137|NCT00070005|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34039138|NCT01930162|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039139|NCT02079129|||COHORT||PROSPECTIVE|||||||
34039140|NCT01044407|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34039141|NCT02040129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039142|NCT03187301|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind period||t|t|t|t
34039143|NCT02829320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039144|NCT05463796|||COHORT||PROSPECTIVE|||||||
34039145|NCT03005587|||COHORT||PROSPECTIVE|||||||
34039146|NCT05126290|||COHORT||PROSPECTIVE|||||||
34039147|NCT03038542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039148|NCT05481892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34039149|NCT01703260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039150|NCT04714424|||OTHER||CROSS_SECTIONAL|||||||
34039151|NCT06427668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Double blinded|Phase 2 randomized, double-blind, placebo-controlled safety and tolerability study in adult participants with Alzheimer's Disease|t|t|t|t
34039152|NCT05748925|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blind|"randomized controlled trial, It will include 100 patients with lupus nephritis, Diagnosis of glomerulonephritis was performed by renal biopsy, and all of the renal biopsies were carried out at urology and nephrology center.~Patients with an estimated glomerular filtration rate (eGFR) \>30 ml/min/1.73m2 will be randomized into two groups Study group will receive SGLT2i inhibitor as add on drug or replace another drug according to patient clinical situation, Dapagliflozin 10 mg and 25 mg will be used once daily with or without food.~Control group will be maintained on placebo."|t|t|f|f
34039153|NCT05393037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34039154|NCT06517602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039155|NCT05310682|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34039156|NCT06122792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039157|NCT03005704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039158|NCT00662584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112387|NCT05061212|||CASE_ONLY||PROSPECTIVE|||||||
34112388|NCT03896308|||OTHER||PROSPECTIVE|||||||
34112389|NCT03919162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112390|NCT00759395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112391|NCT04311307|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34112392|NCT02399228|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34112393|NCT03768687|||COHORT||PROSPECTIVE|||||||
34112394|NCT02880319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112395|NCT01160185|||||RETROSPECTIVE|||||||
33725465|NCT01758653|||COHORT||PROSPECTIVE|||||||
33725466|NCT01425879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725467|NCT02295995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725468|NCT02812316|NA|SINGLE_GROUP||OTHER||NONE||||||
34039159|NCT01077778|||COHORT||PROSPECTIVE|||||||
34039160|NCT01858844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039161|NCT00767611|||||PROSPECTIVE|||||||
34039162|NCT05769504|||CASE_CROSSOVER||PROSPECTIVE|||||||
34039163|NCT04858646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039164|NCT02965001|NA|SINGLE_GROUP||OTHER||NONE||||||
33725469|NCT04898933|||COHORT||PROSPECTIVE|||||||
33725470|NCT02280590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725471|NCT01969903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33725472|NCT05251376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725473|NCT04646499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725474|NCT02486380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039165|NCT04025099|RANDOMIZED|PARALLEL||PREVENTION||NONE||This three-armed randomized, controlled trial will assess the effects of a novel internal cues intervention (treatment group; intuitive eating and body positive yoga) compared to an active control group consisting of traditional healthy weight sessions, following standardized government recommendations for eating and activity, and a no-treatment control group completing assessments only.||||
34039166|NCT06071364|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34039167|NCT02182115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039168|NCT03260556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo controlled|Double blind placebo controlled trial|t|t|t|f
34039169|NCT03053037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Similar instrumentation method is used for both groups, therefore participants cannot be aware of the allocation. Data will be de-identified prior to outcome assessment.|randomized clinical trial 2 arms|t|f|f|t
34039170|NCT03558425|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34039171|NCT05047692|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34039172|NCT06205160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112396|NCT01896973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112397|NCT06481631|NA|SINGLE_GROUP||PREVENTION||NONE||Clinical trial with one arm.||||
33725475|NCT03342664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|180 day mRS is blinded|Subjects will be randomized to either minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device with medical management (MIS group) or best medical management alone (2:1) (MM).|f|f|f|t
33725476|NCT04666428|||COHORT||PROSPECTIVE|||||||
33725477|NCT03995914|||COHORT||PROSPECTIVE|||||||
33725478|NCT03265249|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups where randomization is either to device or SOC (standard of care)||||
33725479|NCT02560337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725480|NCT00417092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33725481|NCT00954382|||||RETROSPECTIVE|||||||
33725482|NCT01867450|||OTHER||CROSS_SECTIONAL|||||||
34112398|NCT06384963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725483|NCT00649896|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33725484|NCT00116441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725485|NCT01602250|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33725486|NCT02846207|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33725487|NCT03821493|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725488|NCT02453763|||COHORT||PROSPECTIVE|||||||
33725489|NCT04098107|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||a wearable prototype device for monitoring upper extremity sports related forces translated to the body during activity. The system will track exposure to injurious forces and monitor adherence to sport specific overuse standards and prescribed rehab regimens.||||
33725490|NCT00142675|RANDOMIZED|||PREVENTION||||||||
33725491|NCT05735301|RANDOMIZED|PARALLEL||SCREENING||NONE|The investigators will know nothing about the patient's image result until randomization. Outcome analysis was performed by an independent statistician, and results were reported directly to the data and safety regulatory committee, the investigator being aware of the results at this time.|"In this study, Patients will be screened, and image modality seletion be randomizied by a dedicated Clinical coordinator who is a non-treatment and non-follow-up participant. The randomization procedure will be computer- and web-based. Randomization is allowed when the occlusion has been established by MRA or CTA. All eligible subjects will be assigned to one of the following two treatment arms in the ratio of 1:1 after randomization:~1. None-Perfusion group.~2. Perfusion group."||||
33725492|NCT01938911|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33725493|NCT05138679|||COHORT||PROSPECTIVE|||||||
33725494|NCT01816828|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34039173|NCT06121817|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All subjects will have both durian and banana interventions, with a wash-out period of at least 5 days between interventions.||||
34039174|NCT05651048|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34039175|NCT05889117|NA|SINGLE_GROUP||TREATMENT||NONE||Single group waitlist-control||||
34039176|NCT01966120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039177|NCT00497068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039178|NCT02592577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039179|NCT01507792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039180|NCT06415708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039181|NCT00636246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039182|NCT00271063|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112399|NCT03014804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112400|NCT03105323|||COHORT||PROSPECTIVE|||||||
34112401|NCT06039696|||COHORT||PROSPECTIVE|||||||
34112402|NCT01514357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725495|NCT02220244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725496|NCT00063869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725497|NCT05939492|RANDOMIZED|PARALLEL||TREATMENT||NONE||After a 2-week wash-in period, study participants will be randomly assigned to either the standard of care control group or the mindfulness-based intervention group.||||
33725498|NCT02053753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838182|NCT04276051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838183|NCT01063998|||||PROSPECTIVE|||||||
33838184|NCT00739258|||COHORT|||||||||
33838185|NCT03554720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838186|NCT03128580|||COHORT||PROSPECTIVE|||||||
34039183|NCT00641992|||CASE_CONTROL||PROSPECTIVE|||||||
34039184|NCT01730989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039185|NCT00717912|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34039186|NCT04853472|||COHORT||PROSPECTIVE|||||||
34039187|NCT01664663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039188|NCT03338582|||COHORT||PROSPECTIVE|||||||
34039189|NCT06448923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112403|NCT04746898|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34112404|NCT02511288|||COHORT||PROSPECTIVE|||||||
34112405|NCT06500507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112406|NCT00212004|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112407|NCT02035657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112408|NCT06301113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||30 Participants were randomly assigned to groups A (experimental group)and B (Control group).||||
34112409|NCT06029790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||The study was planned as a prospective, single-blind, parallel-group, randomized controlled study.|t|t|t|t
34112410|NCT00829868|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34112411|NCT06564233|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are assigned to one of two groups in parallel for the duration of the study.||||
34112412|NCT06288893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Randomized 2:1 to experimental and placebo arms|t|t|t|t
34112413|NCT01716702|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112414|NCT01120353|||COHORT||RETROSPECTIVE|||||||
34112415|NCT00809822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112416|NCT00275717|||COHORT||PROSPECTIVE|||||||
34112417|NCT04649099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112418|NCT03060889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34112419|NCT01490021|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34112420|NCT01362790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725499|NCT01094691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725500|NCT04912934|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725501|NCT04557228|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, double-blinded design with 34 subjects|t|f|t|t
33725502|NCT02455271|||COHORT||PROSPECTIVE|||||||
33725503|NCT03054857|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33725504|NCT06095791|||COHORT||RETROSPECTIVE|||||||
33725505|NCT01237158|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725506|NCT06125288|||COHORT||PROSPECTIVE|||||||
33725507|NCT00324467|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725508|NCT04917055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider and investigator will know if patient received SHAM or bupivacaine iPACK, but everyone else will be blinded|Randomized|t|f|f|t
33725509|NCT04099160|||OTHER||PROSPECTIVE|||||||
33725510|NCT01526889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725511|NCT00371254|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725512|NCT02363725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725513|NCT05644704|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725514|NCT04982055|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725515|NCT01516944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725516|NCT05837936|||COHORT||PROSPECTIVE|||||||
33838187|NCT04567381|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized into two separate groups, treatment as usual and enhanced services. Groups will be followed concurrently for one year for the outcomes of interest.||||
33838188|NCT02808975|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838189|NCT02400775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039190|NCT03828721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Families enrolled in the study will be blinded to its specific aims, other than We are looking at ways to make reading with children at home more fun and interactive."|"This is a prospective, randomized controlled trial involving 2 age categories of low-SES caregiver-child dyads served by the ROR program, each followed for 6 months. For each category, a baseline assessment (pre-) and an outcomes assessment (post-) will be conducted. Category 1 will involve 6 month-old infants, followed until they are 12 months old. Category 2 will involve 18 month-old toddlers, followed until they are 24 months old.~Families assigned to the control arm in each age category will receive customary ROR, and reading-related developmental surveillance and anticipatory guidance. Control families will also receive a new children's book reinforcing AAP screen-based media recommendations. Families in the intervention arm will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively)."|t|f|f|f
34039191|NCT01416454|||COHORT||PROSPECTIVE|||||||
34039192|NCT02659423|||OTHER||PROSPECTIVE|||||||
34039193|NCT02767011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039194|NCT06487832|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||In a randomized, single-blinded, within subject cross-over design, we will compare cerebral response from before to after intranasal insulin or placebo administration after a single dose of 0.25 mg semaglutide administration versus placebo administration|t|f|f|f
34039195|NCT06273319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|2||t|f|t|t
34039196|NCT06498193|||CASE_ONLY||CROSS_SECTIONAL|||||||
34039197|NCT03658785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039198|NCT05945940|||COHORT||RETROSPECTIVE|||||||
34039199|NCT06577961|NA|SINGLE_GROUP||TREATMENT||NONE||Vorolanib combined with cadonilimab||||
34039200|NCT05340764|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34039201|NCT04131660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The ventilator used in both arms will be similar in appareance.|"The patients are randomized in 2 arms at their admission :~* S/T mode arm : the patient is ventilated as the standard procedure of the ICU, with settings defined by the pratician.~* AVAPS-AE mode arm : the pratician sets NIV with a positive expiratory pressure set between 4 and 14 cmH2O, an inspiratory support between 14 and 24 cmH2O and a target tidal volume between 8 and 10 mL/kg of an ideal weight (Size (m) \* Size (m) \* 23)."|t|f|f|f
34039202|NCT01811342|||CASE_ONLY||RETROSPECTIVE|||||||
34039203|NCT03241849|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039204|NCT04693208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039205|NCT05491551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Control Trial|f|f|t|t
34039206|NCT04680000|RANDOMIZED|PARALLEL||TREATMENT||NONE|Pragmatic trial using a behavioral intervention. Treatment condition cannot be masked to the provider, patient or booster contact personnel. Assessments are self-report.|Pragmatic trial randomizing to two conditions (standard BCBT-CP and BCBT-CP + Booster) in a 1:1 ratio at the level of the individual||||
34039207|NCT01650480|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34039208|NCT01106560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039209|NCT03686943|||CASE_ONLY||PROSPECTIVE|||||||
34039210|NCT01557504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039211|NCT01027520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725517|NCT01923415|||CASE_ONLY||CROSS_SECTIONAL|||||||
33725518|NCT01167231|||COHORT||PROSPECTIVE|||||||
33725519|NCT02856633|||OTHER||PROSPECTIVE|||||||
33725520|NCT06516276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33725521|NCT00951028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725522|NCT05542875|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial Study||||
33725523|NCT02717481|||CASE_ONLY||PROSPECTIVE|||||||
33725524|NCT03904407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Probiotic study drug and identical appearing placebo tablet|Randomized double blind placebo controlled trial|t|t|t|t
33725525|NCT04254978|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, open-label||||
34039212|NCT00571727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039213|NCT00573690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039214|NCT02872714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039215|NCT00425932|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34039216|NCT03999242|||CASE_ONLY||RETROSPECTIVE|||||||
34039217|NCT01739205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039218|NCT00373230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112421|NCT03226691|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112422|NCT04409444|||COHORT||PROSPECTIVE|||||||
33808373|NCT03261466|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The study is a triple blind study in which the treatment or intervention is unknown to the research participant, the individuals who administer the treatment or intervention, and the researchers who assess the outcomes.|In the first part of the study (Study 1, V0-V1) patients will be randomized in a open-label, into two groups homogeneous for number and sex of the subjects. One group will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) and one group will receive a placebo for a total of 2 months of treatment. For patients who wants to continue the study there will be a cross-over study (study 2, V2-V3) after one month of wash-out.|t|t|t|t
33808374|NCT00005962|RANDOMIZED|||TREATMENT||||||||
33808375|NCT00022672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808376|NCT03690557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808377|NCT02727634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808378|NCT02966652|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808379|NCT05656066|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not know which group in. Researcher and nurse will know.|Randomized, controlled, and experimental design|t|f|f|f
33808380|NCT03120026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808381|NCT04909333|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Prospective, single-center, cross-over, placebo controlled pilot, proof of principle clinical study|t|f|t|f
33808382|NCT04405310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|parallel design 3:2:3|Parallel assignment, relationship 3.2.3|t|t|f|f
33808383|NCT03846037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808384|NCT06700161|||OTHER||CROSS_SECTIONAL|||||||
33808385|NCT02261805|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808386|NCT05088200|||OTHER||RETROSPECTIVE|||||||
33808387|NCT05500352|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The present echocardiographic study includes participants from three experimental clamp studies; the Hypo-Heart 1 (Study 1), Hypo-Heart 2 (Study 2) and Rapid-Heart (Study 3).|f|f|t|f
33808388|NCT04275960|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33808389|NCT03041155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808390|NCT04730206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be masked for camostat or placebo, molnupiravir is open label||t|t|t|t
33808391|NCT00881296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808392|NCT04757194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Analyst masked to treatment group allocation in final analysis. Outcomes extracted algorithmically from databases.|Groups of patients experiencing a resource constrained situation randomized 1:1 at time of inclusion to control/intervention arms|f|f|t|f
33808393|NCT00606216|||COHORT||PROSPECTIVE|||||||
33808394|NCT05313412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33808395|NCT00665015|||COHORT||RETROSPECTIVE|||||||
33808396|NCT02590094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33808397|NCT03960957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808398|NCT01184885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039219|NCT05953935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single-center, prospective, randomized, interventional, pre-post clinical study with control group and seamless adaptive design. It will be conducted in two phases: 1) exploratory phase (E) and 2) confirmatory phase (C), depending on the results obtained in the exploratory phase. Patients will be randomized to control group (standard clinical procedures) and experimental group (OKTO medical device)|f|f|f|t
34039220|NCT05754892|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34039221|NCT01592786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039222|NCT00308191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039223|NCT00328497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039224|NCT02268916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039225|NCT03500068|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039226|NCT04181294|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Pre- and post study design||||
34039227|NCT04034810|||COHORT||PROSPECTIVE|||||||
34039228|NCT05206006|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Stepped wedged design||||
33838190|NCT00463905|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33838191|NCT00534170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33838192|NCT00390520|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33838193|NCT01943942|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33838194|NCT00719329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838195|NCT04267068|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34039229|NCT05418881|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34039230|NCT05798975|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||AE= Aerobic Exercise RE= Resistance Exercise CT= Control (no exercise)|t|t|f|f
34039231|NCT04209452|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34039232|NCT02162134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039233|NCT00982787|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34039234|NCT05695612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039235|NCT00505713|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039236|NCT01521832|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34039237|NCT03131817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039238|NCT06506916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039239|NCT01808417|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|There is no masking in this study as all study subjects receive the same intervention.|||||
34039240|NCT01333592|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039241|NCT03216122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039242|NCT01474174|||OTHER||PROSPECTIVE|||||||
34039243|NCT02361411|||COHORT||PROSPECTIVE|||||||
34039244|NCT00302380|||CASE_CONTROL||PROSPECTIVE|||||||
34039245|NCT00000668||||TREATMENT||NONE||||||
34039246|NCT02056210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039247|NCT03669380|||COHORT||RETROSPECTIVE|||||||
34039248|NCT06577428|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34039249|NCT05441787|||COHORT||PROSPECTIVE|||||||
34039250|NCT00502931|||CASE_CONTROL||RETROSPECTIVE|||||||
34039251|NCT00323453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039252|NCT04667923|||CASE_ONLY||PROSPECTIVE|||||||
34039253|NCT04025060|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34039254|NCT03540888|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||In order to compare the effects of DTFM to static and dynamic stretching techniques, participants were randomly assigned to one of three groups (a) DTFM group, (b) Dynamic stretching group, and (c) Static stretching group, and were followed- up over four weeks period.|f|f|t|t
34039255|NCT03252535|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study drugs will be provided in identical packages to maintain the study masking. Neither the Investigator nor the study team will know which drug the subject is receiving. In addition, the external outcome evaluator will receive the results in a codified manner (concealed).||t|f|t|t
34039256|NCT01481948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725526|NCT03035955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator is blinded to which side of face is using the azelaeic acid treatetment|This is a split face, randomized, single blind, single center study. Male and female (non-pregnant, non-nursing) subjects, age 18 or greater, with mild to moderate papulopustular (based on Investigator Global Assessment) facial rosacea, with bilateral facial involvement, and no more than two nodules will be enrolled. Subjects will be randomized 1:1 by the study coordinator using a standard randomization table to receive azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face.|f|f|t|f
33725527|NCT04930679|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 diabetes type 2 patients are recruited, in which 14 took part in the study, randomly divided into 2 arms.||||
33725528|NCT00963261|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725529|NCT00003463||||TREATMENT||||||||
33725530|NCT04444609|||COHORT||PROSPECTIVE|||||||
33725531|NCT05114135|NA|SINGLE_GROUP||TREATMENT||NONE||40-65-year-old adults requiring one level instrumented spine fusion||||
33725532|NCT04922203|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33725533|NCT05876273|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover: Participants will be randomized to two groups differing by the order of controller use: Group A: NAP, followed by UMPC; Group B: UMPC, followed by NAP.||||
33725534|NCT03889821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725535|NCT06524310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33725536|NCT03828812|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725537|NCT00174915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33725538|NCT02939560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725539|NCT02822989|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33725540|NCT00843921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725541|NCT05738941|||COHORT||PROSPECTIVE|||||||
33725542|NCT04839094|||CASE_ONLY||PROSPECTIVE|||||||
33725543|NCT03102931|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33725544|NCT01457625|||COHORT||PROSPECTIVE|||||||
33725545|NCT01343563|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33725546|NCT04203628|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Enrolment will have 2 stages. During stage 1 (prospective cohort stage), all consecutive children with presumptive TB enrolled in the TB-Speed HIV or TB-Speed SAM or seen in routine care if ineligible for those two studies will be proposed to participate in the study until we reach the number needed for the evaluation of specificity. All children with presumptive TB will have at least two respiratory samples collected (ES or GA) tested with Ultra and mycobacterial culture. The cohort will be closed once the sample size of presumptive TB children with two negative Ultra results from respiratory samples will be reached.~During the 2nd phase (enrichment phase), only children with presumptive TB who are Xpert positive on at least one respiratory sample will be proposed to participate in the study in order to complement the number of confirmed TB cases required for the evaluation of the sensitivity."||||
33725547|NCT00828191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725548|NCT01613521|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725549|NCT02327858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33725550|NCT04391387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725551|NCT01771146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725552|NCT04735120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725553|NCT00210054|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725554|NCT06546904|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33725555|NCT01233674|||OTHER||PROSPECTIVE|||||||
33725556|NCT01367574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725557|NCT03395158|||COHORT||PROSPECTIVE|||||||
33725558|NCT00000514|RANDOMIZED|||PREVENTION||DOUBLE||||||
33725559|NCT02723968|NA|SINGLE_GROUP||SCREENING||NONE||||||
33725560|NCT00979888||||SUPPORTIVE_CARE||NONE||||||
33725561|NCT00961935|||||CROSS_SECTIONAL|||||||
33725562|NCT06267079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039257|NCT01238159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039258|NCT06575322|||CASE_CONTROL||PROSPECTIVE|||||||
34039259|NCT02128854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039260|NCT01092234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34112423|NCT04756479|||CASE_ONLY||RETROSPECTIVE|||||||
34112424|NCT01948427|||COHORT||PROSPECTIVE|||||||
34112425|NCT05185622|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112426|NCT00317122|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112427|NCT06628986|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|double blind|randomized controlled trial|t|t|t|t
34112428|NCT05039281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725563|NCT02360163|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725564|NCT05606042|||COHORT||PROSPECTIVE|||||||
33725565|NCT04898673|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||prospective, pre-market, Multi-site, non-randomized.||||
33725566|NCT02007876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725567|NCT04252755|NA|SINGLE_GROUP||OTHER||NONE||This study will utilize a pre-post within-subjects design. All participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of neurofeedback, and finish with another session (post) after completion of all neurofeedback sessions.||||
33725568|NCT00071565|||FAMILY_BASED||PROSPECTIVE|||||||
33725569|NCT04484454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838196|NCT04434326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808399|NCT04018300|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Treatments will be randomized to A or B. Investigators will be blinded to the corresponding treatment, in addition to the subjects being randomized to follow the sequence of supplements as ACB or BCA.|Three armed, cross-over, double blinded design. Fifteen subjects will be randomized to treatment FeSO4, ASP or placebo for two week per treatment. Following each treatment, will be a two week washout period whereby subjects will not consume a supplement. Baseline and final blood draws of each treatment will be collected, in addition to serum collection at 0h, 1h, 2h, 3h, 4h following one dose to determine NTBI concentration curve.|t|f|t|f
33808400|NCT04174079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808401|NCT00162253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33808402|NCT04510324|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Patients will be randomized in a 1:1 ratio. Randomization will be performed within the electronic database system at the time of enrollment using a random number generator, an approach we have used successfully in other clinical trials. The participants will be blinded to the intervention assignment (single blinded study).|Single-center, randomized, single-blinded cross-over trial including healthy adult participants (N=40, omnivores, aged between 25 and 65 years, and with a body mass index (BMI) between 20 and 40 kg/m2 (see participation criteria below). Following one week of a meat, egg, and seafood free diet ('washout'), participants will be randomized to either red meat (cow burger) or plant meat (plant-based burger) for one week. Following this, participants will under go another week of diet washout and will then be crossed over to the other meat burger for one week. The primary outcome will be the within-group change in the TMAO levels.|t|f|f|f
33808403|NCT04105751|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33808404|NCT01435785|||CASE_CONTROL||PROSPECTIVE|||||||
33808405|NCT02118922|||COHORT||CROSS_SECTIONAL|||||||
33808406|NCT02455427|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33808407|NCT02305511|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808408|NCT06618976|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33808409|NCT03906279|||CASE_CROSSOVER||PROSPECTIVE|||||||
33808410|NCT01796691|||CASE_CONTROL||RETROSPECTIVE|||||||
33808411|NCT02268240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808412|NCT02329691|||CASE_ONLY||PROSPECTIVE|||||||
33808413|NCT01928875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808414|NCT04436432|||COHORT||PROSPECTIVE|||||||
33808415|NCT01691716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808416|NCT00830856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33808417|NCT02104349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33808418|NCT03498365|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33808419|NCT04758949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Cohort 2 will be randomized. The investigator and participants will be masked.||t|t|t|t
33808420|NCT01800305|RANDOMIZED|PARALLEL||||NONE||||||
33808421|NCT01567787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808422|NCT01600378|||CASE_ONLY||PROSPECTIVE|||||||
33808423|NCT00853580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808424|NCT04263740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding the physical therapist (the principal investigator) who provided interventions to both groups in the study to the type of intervention was not feasible. Blinding the principal investigator to the assessment process was possible by using another physical therapist who conducted all measurements. Blinding the assessor to subject's group assignment was done to ensure unbiased ascertainment of outcomes. Randomization also served to reduce the risk of selection bias by the principal investigator.|This study followed a prospective experimental pretest-posttest control group randomized design with repeated measures. Two groups were included in this study, an experimental group and a control group.|t|t|t|t
33808425|NCT02905292|||||PROSPECTIVE|||||||
33808426|NCT03673566|RANDOMIZED|PARALLEL||OTHER||NONE||The NICU is divided into two floors. One floor will have the Dashboard installed and serve as the intervention floor, while the other will not have the Dashboard and thus serves as the Control floor. As patients are admitted, they are randomly assigned to a room based on availability. Therefore, intervention and control arms will run in parallel in a quasi-randomized fashion.||||
33808427|NCT03034278|||COHORT||PROSPECTIVE|||||||
33808428|NCT03919851|||COHORT||RETROSPECTIVE|||||||
33808429|NCT03389919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808430|NCT03351400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808431|NCT04465721|RANDOMIZED|PARALLEL||OTHER||SINGLE||Metabolically unhealthy mid-life adults with overweight or obesity who habitually eat for more than 13h/day, will be randomized to a restricted eating window to 10h/d (TRE group) or to their habitual eating window (≥ 13h, HABIT group), and followed up to 12 months.|f|f|f|t
34112429|NCT00123630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112430|NCT00337168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112431|NCT04872439|||COHORT||PROSPECTIVE|||||||
34112432|NCT00331721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112433|NCT06565234|||COHORT||PROSPECTIVE|||||||
34112434|NCT05657847|||COHORT||PROSPECTIVE|||||||
34112435|NCT05707559|||OTHER||CROSS_SECTIONAL|||||||
34112436|NCT04763343|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind, Placebo Controlled||t|t|t|f
33808432|NCT00236652|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808433|NCT04464031|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33808434|NCT02797132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808435|NCT01323790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838197|NCT01920477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838198|NCT01607476|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33838199|NCT04212351|||COHORT||PROSPECTIVE|||||||
34112437|NCT00540631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112438|NCT02124408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34112439|NCT02987738|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34112440|NCT03656354|||COHORT||PROSPECTIVE|||||||
34112441|NCT01316666|||||PROSPECTIVE|||||||
34112442|NCT04908228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112443|NCT02784340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112444|NCT04505800|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33725570|NCT05818579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the proposed study, only the outcome assessor will be blinded to the group labels. Participants and interventionists are impossible to be blinded in this study. The group labels will not be known to the outcome assessors and will not appear on any documents that the outcome assessors can access. The participants, family members, and staff members of the LTCF are prohibited to disclose the group labels of the participants to the outcome assessors.||f|f|f|t
33725571|NCT01153412|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33725572|NCT01275898|||COHORT|||||||||
33725573|NCT04149951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Parallel Assignment in 1:1 active to control allocation|t|t|t|t
33725574|NCT05450887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725575|NCT03193411|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725576|NCT00199355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725577|NCT05293756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial (RCT)||||
33725578|NCT00100243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725579|NCT05595512|||OTHER||RETROSPECTIVE|||||||
33725580|NCT02180412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725581|NCT03854422|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||this study includes 3 different groups. left, left supine,dynamıc|t|f|t|f
33725582|NCT03263208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725583|NCT01187043|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33725584|NCT05686213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725585|NCT03295708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725586|NCT03387163|||COHORT||OTHER|||||||
33725587|NCT00772499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725588|NCT05568654|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||To accomplish these two aims, we will perform a, pragmatic, multicenter 2 X 2 factorial cluster randomized controlled trial with four arms:||||
33725589|NCT04865354|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725590|NCT03302988|RANDOMIZED|FACTORIAL||OTHER||NONE||Each wound will have 2 treatments. The type of treatment (Type of suturing) will be chosen by random assignment||||
33725591|NCT01248507|||COHORT||PROSPECTIVE|||||||
33725592|NCT01708174|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725593|NCT04792632|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33725594|NCT03163745|||OTHER||PROSPECTIVE|||||||
33725595|NCT06259240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725596|NCT05834517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The eligible participants will be randomly allocated for one of the two groups; test and control group using computer generated random tables.|topical application of hyaluronic acid in patients with periodontitis 1 day after scaling|f|f|f|t
33725597|NCT02820896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725598|NCT02038582|RANDOMIZED|PARALLEL||||NONE||||||
33725599|NCT04910009|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33725600|NCT04780763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"The study Test and Control products have been developed in order to guarantee the blinding, they will be similar by their taste, texture, color, packaging, nutritional content and flavor.~The blinding of study products will be performed by assigning a study product number corresponding to the randomization list. Then blinded study product packages will then be carried to the investigational site for assignment to the subject.~Product allocation will be performed by randomized method (IWRS validated system) as a Randomized Controlled Trial. The participants are thus assigned to intervention groups randomly."|A proof-of-efficacy, randomized, controlled, double-blind, monocentric, parallel arms design|t|t|t|t
33725601|NCT03647228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725602|NCT03691064|||COHORT||OTHER|||||||
33725603|NCT03034720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725604|NCT02836899|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33725605|NCT05749198|||COHORT||PROSPECTIVE|||||||
33725606|NCT04143139|||COHORT||CROSS_SECTIONAL|||||||
33725607|NCT00230698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725608|NCT02901535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33808436|NCT04867382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Methods for concealment of allocation. PCCs were blind to their randomized MyLearning training assignment. The study statistician generated the randomization assignment, and a study team member submitted that list to HealthPartners (HP) MyLearning staff. Study team members collecting outcome data from surveys, Opioid Wizard, and Epic (including use rates, buprenorphine prescriptions) also were blinded to treatment assignment.|This study used a randomized controlled trial (RCT) design embedded in a larger, multisite trial of a clinical decision support (CDS) tool to help PCCs identify, diagnose, and treat patients with OUD. PCCs in clinics randomized to Opioid Wizard were randomized 1:1 to the intervention or comparison training and stratified by clinic.|t|f|f|f
33725609|NCT03095456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725610|NCT00352846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725611|NCT05794178|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33725612|NCT05760287|||COHORT||CROSS_SECTIONAL|||||||
33725613|NCT03175328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725614|NCT03522766|||COHORT||PROSPECTIVE|||||||
33725615|NCT01885533|||COHORT||RETROSPECTIVE|||||||
33725616|NCT06265116|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725617|NCT03897400|||CASE_CONTROL||PROSPECTIVE|||||||
33725618|NCT02515409|||COHORT||PROSPECTIVE|||||||
33725619|NCT03760146|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33725620|NCT05199454|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Clinical Trial||||
33725621|NCT04567875|||CASE_ONLY||PROSPECTIVE|||||||
33725622|NCT02953379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33725623|NCT05883904|||CASE_ONLY||PROSPECTIVE|||||||
33725624|NCT01869283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725625|NCT00142870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725626|NCT05951530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725627|NCT05658965|||COHORT||PROSPECTIVE|||||||
33725628|NCT00841529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112445|NCT04227587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112446|NCT02644551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112447|NCT06398184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112448|NCT00189475|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34112449|NCT05818462|||COHORT||PROSPECTIVE|||||||
34112450|NCT00899301|||COHORT||PROSPECTIVE|||||||
34112451|NCT01139515|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34112452|NCT04321655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112453|NCT06400082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 parallel groups, one treated with conventional povidone iodine 10% and the other is treated with topical insulin|t|f|f|f
34112454|NCT05450211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patient will not know which study group he is in. The anesthetist, who will perform the regional block, will give the block to be applied in a sealed envelope by an assistant staff outside the study, and at the same time, the patient will not know which block has been made. The anesthesiologist who made the block will not participate in the pain follow-up of the patients. Postoperative pain assessment and data collection will be performed by another investigator blinded to the study.||t|t|t|f
34112455|NCT02008643|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34112456|NCT00779909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112457|NCT05593939|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112458|NCT05751304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112459|NCT02796651|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34112460|NCT05539677|||COHORT||PROSPECTIVE|||||||
34112461|NCT01332916|NON_RANDOMIZED|PARALLEL||||NONE||||||
34112462|NCT01019941|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112463|NCT06375148|||OTHER||CROSS_SECTIONAL|||||||
34112464|NCT05849558|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: with non-cirrhosis, F0, F1 and F2 Group 2: with advanced fibrosis and cirrhosis, F3 and F4||||
34112465|NCT01399853|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34112466|NCT04656561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112467|NCT06281457|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will typically be unaware of the conditions presented, though because these involve manipulations of stimuli or task demands, they may be aware of the manipulation. This is not expected to impact the primary outcome measures (e.g., BOLD signal activation patterns).|This is a basic science study in which all participants will participate in all task conditions within each experiment (repeated-measures design).||||
34112468|NCT03598348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112469|NCT00767780|||COHORT||RETROSPECTIVE|||||||
34112470|NCT00378092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112471|NCT06517290|||COHORT||RETROSPECTIVE|||||||
34112472|NCT02385071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112473|NCT04994977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112474|NCT06495567|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112475|NCT03386162|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In the randomized treatment phase, patients will be randomized 2:1 to receive:~• Experimental arm (Arm A3): fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive luteinizing hormone-releasing hormone (LH-RH) analogs in addition every 28 days ± 3 days.~OR~• Control arm (Arm B3): maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.~A total of approximately 90 patients will be enrolled"||||
34112476|NCT03087071|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112477|NCT02056769|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112478|NCT00829998|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34112479|NCT01113684|||COHORT||PROSPECTIVE|||||||
34112480|NCT00066040|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34112481|NCT06266546|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The study will be a prospective, single-arm, non-randomized trial||||
34112482|NCT06328712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112483|NCT05575466|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112484|NCT06168773|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|prospective randomized double-blind placebo-controlled study|"Group I (number of patients = 45): will receive 1 mg haloperidol intravenously 3 times daily and magnesium sulfate 4 g intravenous infusion (IVI) in 1st day (diluted in 50 ml D5W over 24 hours) then 2g IVI over 24 hours (diluted in 50 ml D5W over 24 hours) for 3 days postoperatively starting the first dose 2- 4 hours after surgery. If the first prophylactic dose is delayed for more than 4 hours post admission, patient is excluded from the study.~Group II (number of patients= 45): will receive 1 mg haloperidol intravenously 3 times daily and 50 ml of D5W IVI infusion over 24 hours for 4 days postoperatively starting the first dose 2- 4 hours after surgery.~Group III (number of patients = 45): will receive 1 mL 0.9% of sodium chloride intravenously 3 times daily and 50 ml of D5W IVI infusion for 4 days postoperatively starting the first dose 2- 4 hours after surgery."|t|f|t|f
34112485|NCT06336564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|f|f|f|t
34112486|NCT03375437|NA|SINGLE_GROUP||SCREENING||NONE||||||
34112487|NCT01741129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112488|NCT04466358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112489|NCT03893357|||COHORT||RETROSPECTIVE|||||||
33725629|NCT01980043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725630|NCT01508975|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33725631|NCT06202781|||COHORT||OTHER|||||||
33725632|NCT02259309|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33725633|NCT00262509|RANDOMIZED|CROSSOVER||||NONE||||||
34112490|NCT00621283|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112491|NCT05761756|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34112492|NCT03038620|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112493|NCT00995514|||COHORT||PROSPECTIVE|||||||
34112494|NCT06461507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112495|NCT04990583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112496|NCT02695836|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and outcome assessors are blinded to study arm assignment||t|f|f|t
33808437|NCT04828096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808438|NCT04921709|||COHORT||PROSPECTIVE|||||||
33808439|NCT04388865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34039261|NCT06385652|NA|SEQUENTIAL||DIAGNOSTIC||NONE|All PET/CT images are jointly interpreted by at least two imaging and nuclear medicine physicians, each with several years of diagnostic experience and at least at the attending physician level. They compare and record the number of lesions detected and the SUVs (Standard Uptake Values) for both 18F-FDG and 68Ga-NB381 PET/CT scans. After consultation, they provide a unified diagnostic opinion.|"In this sequential assignment clinical trial, we aim to evaluate and compare the diagnostic performance of two PET imaging agents, 68Ga-NB381 and 18F-FDG, in patients diagnosed with multiple myeloma (MM). The study will enroll MM patients who meet the inclusion criteria and are scheduled for routine diagnostic imaging.~Each participant will undergo PET imaging with 18F-FDG first, followed by a second PET scan using 68Ga-NB381 (or reversed). To minimize potential interference between the two imaging sessions and ensure patient safety, a minimum interval of one day will be maintained between the two scans, with all imaging completed within one week. This sequential imaging approach allows for direct comparison of the imaging agents in the same patient, thus controlling for inter-patient variability and providing a more accurate assessment of the relative merits of each imaging agent in the same metabolic and pathological condition."||||
34039262|NCT06341751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039263|NCT00848913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039264|NCT00175123|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34039265|NCT03549078|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039266|NCT03666130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039267|NCT06142604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039268|NCT04204109|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34039269|NCT06080243|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039270|NCT01790984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34039271|NCT00869622|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039272|NCT00004642||||TREATMENT||||||||
34039273|NCT01066832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039274|NCT03391219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34039275|NCT03513237|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The women will be blinded to the intervention, but the investigator will not be blinded to the procedure allocation (due to the nature of the intervention).||t|f|f|t
34039276|NCT03451890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039277|NCT01016951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34039278|NCT00516841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039279|NCT03525223|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34039280|NCT02450201|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039281|NCT05706272|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will include 26 intervention primary care practices and 25 matched control practices.||||
34039282|NCT05441488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039283|NCT00688350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039284|NCT06439550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039285|NCT03017404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039286|NCT03977896|NA|SINGLE_GROUP||OTHER||NONE||||||
34039287|NCT04181892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039288|NCT00708383|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34039289|NCT05613205|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind (Day 1 to Day 197) and in a partially observer-blind (Day 197 to Day 337) manner.||t|t|t|t
34039290|NCT01322243|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34039291|NCT01617993|||COHORT||PROSPECTIVE|||||||
34039292|NCT06143917|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34039293|NCT04249960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34039294|NCT05124808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039295|NCT01444664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039296|NCT04817124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039297|NCT02845024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039298|NCT02859337|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039299|NCT02940262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039300|NCT03836235|||COHORT||PROSPECTIVE|||||||
34039301|NCT03861390|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||The randomization schedule will be generated by using permuted block randomization with a block size of 4 (2 prednisone, 2 placebo for the first treatment period of the protocol).|t|t|t|f
34039302|NCT00252291|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
34039303|NCT01074268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039304|NCT04287075|||CASE_CONTROL||PROSPECTIVE|||||||
34039305|NCT00375414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039306|NCT05434156|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Open label in Part 2||t|f|t|t
34039307|NCT02748304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039308|NCT05356000|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039309|NCT02455206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039310|NCT05442502|||COHORT||RETROSPECTIVE|||||||
34039311|NCT04969679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039312|NCT01171144|||OTHER||RETROSPECTIVE|||||||
34039313|NCT04073927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039314|NCT00387335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039315|NCT01692860|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34039316|NCT03838536|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants will be given a jar of egg powder without labeling and they will not be aware of which they receive (egg white or whole egg).|Participants will be randomized to whole egg or egg white powder to consume throughout the study.|t|f|f|f
34039317|NCT00915018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039318|NCT04247113|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-post design||||
34039319|NCT00046137||||TREATMENT||||||||
34039320|NCT03891251|||COHORT||PROSPECTIVE|||||||
34039321|NCT02119013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808440|NCT02442037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112497|NCT06158152|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33808441|NCT00979459|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039322|NCT01671228|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33808442|NCT01331772|RANDOMIZED|PARALLEL||||NONE||||||
33808443|NCT02972424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808444|NCT03455985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808445|NCT03158506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808446|NCT03800368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808447|NCT00920985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33808448|NCT05951972|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808449|NCT03464955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808450|NCT00712413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838200|NCT00158704|NON_RANDOMIZED|||TREATMENT||NONE||||||
33838201|NCT05510050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Conditions will be provided in blinded containers (e.g. A,B,C).|Randomized, double-blind, placebo controlled|t|f|t|f
34039323|NCT02327871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039324|NCT03754335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"This procedure is to be able to easily randomize half of the patients into a sham LP arm passed by independent practitioners of the investigators in charge of the patient, which allows a good double-blind study."|Randomized, double blind, prospective monocentric trial evaluating in parallel groups|t|f|t|f
34039325|NCT03945227|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039326|NCT01983540|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039327|NCT05720741|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants (anticipated N=1,625), ages 10-16 years, will be randomized to complete one 30-minute, digital programs: (1) Project THINK: a program designed to teach adolescents how to identify and modify unhelpful thoughts; or (2) Project SHARE: a control program designed to teach adolescents to identify and share emotions with trusted adults. A priori power analyses revealed that N=788 participants are needed to detect a small effect size (.2, the approximate effect size found in recent brief digital intervention RCTs) using two-tailed tests with α = .05. In line with findings from similar studies, attrition in online survey studies with students is high; a recent meta-analysis of \~1,000 studies that used online assessments found a mean attrition rate of 51.5%. Assuming this level of attrition, to achieve the desired sample (N=788), the most conservative estimate of the minimum number of participants needed is 1,625 students at baseline.|t|f|t|t
34039328|NCT00279071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039329|NCT01776437|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34039330|NCT03242473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039331|NCT06438029|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Randomisation method will be used to determine how the experimental and control groups will be separated at the beginning of the study (13). As the randomisation method, simple randomisation method was chosen in order to provide equal number of samples in two groups. Randomisation will be performed using https://www.randomizer.org/ website in computer environment. According to the randomisation outputs, the individuals to be included in the experimental and control groups will be listed. Columns between 1-90 will be created in the system. Patients will be randomly assigned to the groups by considering the numbers 1 and 2 in the columns (nursing education group 1 and control group 2)."|This research is a randomised control study with pretest-posttest design.|t|f|t|f
34039332|NCT06577779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039333|NCT04617743|||COHORT||PROSPECTIVE|||||||
34039334|NCT05467020|||COHORT||PROSPECTIVE|||||||
34039335|NCT04212325|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who will be operated due to diabetic foot will be randomized to 3 groups with continuous sciatic nerve block (Group C), single injection sciatic nerve block (Group S)||||
34039336|NCT01230086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039337|NCT05010538|||COHORT||PROSPECTIVE|||||||
34039338|NCT04748562|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34039339|NCT05233553|||COHORT||RETROSPECTIVE|||||||
34039340|NCT04430556|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34039341|NCT00216580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039342|NCT03548818|||COHORT||PROSPECTIVE|||||||
34039343|NCT02237469|||CASE_ONLY||RETROSPECTIVE|||||||
34039344|NCT01532856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039345|NCT01446536||||||SINGLE|||f|f|t|f
34039346|NCT03176303|||COHORT||PROSPECTIVE|||||||
34039347|NCT05209867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039348|NCT05408130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective randomized control trial with blinded end-point. 1:2 randomization to sham or intervention arm. We will use sealed envelope randomization.|t|f|f|t
34039349|NCT01468337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039350|NCT05788172|||COHORT||PROSPECTIVE|||||||
34039351|NCT01283451|||OTHER||CROSS_SECTIONAL|||||||
34039352|NCT03858153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessor and investigator will be masked of Arms to the extent possible (i.e., for some outcomes e.g., biomarkers but not others e.g. symptom tests).||f|f|f|t
34039353|NCT05871281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes were measured by gynecologists, intervention done by physiotherapist, who did not know measurements' results|This study is a four week, single blinded randomized controlled trial with pre-post design comparing PFM training group with PFM electrostimulation|f|f|f|t
34039354|NCT02531308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039355|NCT05261542|||OTHER||PROSPECTIVE|||||||
34039356|NCT06032208|NA|SINGLE_GROUP||TREATMENT||NONE||"Study visits take place within the patients usual hemodialysis unit consistent with their routinely scheduled dialysis sessions. Beginning week 5 participants will use the Theranova dialyzer until the end of dialysis week 28. Participants will answer 9 questions at least (1-3 times weekly) - weeks 1 through 28 (entire length of study) using the LEVIL application.~Furthermore, participants answer a single Time-to-Recovery question between weeks 1-4 and repeated at week 28 to get more information on recovery time after dialysis in addition to completing Creyos (cognitive testing formally Cambridge Brain Sciences), as well as Sexual Desire Inventory-2 testing."||||
33725634|NCT00729027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725635|NCT05702593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study was designed as a randomized, double-blind, controlled trial. The participants were randomly (randomisation was performed using the website www.randomiser.org ) allocated to one of two groups|f|f|t|t
33725636|NCT03673163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725637|NCT05372263|||COHORT||PROSPECTIVE|||||||
33725638|NCT02196792|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34112498|NCT00713973|||COHORT||PROSPECTIVE|||||||
33725639|NCT02893072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725640|NCT00433056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725641|NCT05044455|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants are assigned an identification number and data is de-identified during analysis phase|"Randomized Control Trial - Treatment group receives a 9 week on-line CBT treatment delivered by Peer facilitators as well as accessing treatment as usual for new mothers experiencing postpartum depression.~Control Group accesses treatment as usual or typical treatment for new mothers in participant's communities and does not receive the CBT group."||||
33725642|NCT02508493|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725643|NCT05563753|||CASE_CONTROL||PROSPECTIVE|||||||
34112499|NCT05605860|||COHORT||RETROSPECTIVE|||||||
34112500|NCT06625528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician and the evaluator were blinded, but the operator was not because of the nature of the study|"The patients selected in this study will be randomly divided into 3 groups:~Group I: Periodontitis patients with an intra-bony defect will be treated by open flap debridement.~Group II: Periodontitis patients with an intra-bony defect will be treated by open flap debridement combined with the application of lyophilized platelet-rich fibrin.~Group III: Periodontitis patients with an intra-bony defect will be treated by open flap debridement and lyophilized platelet-rich fibrin combined with nanocrystalline hydroxyapatite bone substitute.~All patients will be evaluated clinically, radiographically and biochemically"|f|f|f|t
34112501|NCT06569550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The TMS stimulation machine (MagPro XP orange edition, MagVenture A/S, Farum, Denmark), in combination with an A/P-coil with a separate active and placebo (sham) side. The sham side is designed to deliver \<5% of the magnetic field of the active side, with similar tactile and auditory input.~The coil is designed to be reversible, with no markings as to which side is which. There is an internal sensor that allows the device to determine which side is up. Masking is ensured by a pre-programmed code, unique to each participant, which is input in the device whereafter the device will indicate if the wrong side is being used for stimulation."|Randomized (1:1) parallel group study to either active treatment or sham|t|t|t|t
34112502|NCT03257891|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, non-randomized, multicentre, open label, single arm, phase II study will be conducted in patients with advanced ACC treated with Cabazitaxel||||
34112503|NCT00195780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112504|NCT03114865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112505|NCT04282148|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center, global (US and OUS)||||
34112506|NCT06507540|||COHORT||RETROSPECTIVE|||||||
34112507|NCT04049513|NA|SEQUENTIAL||TREATMENT||NONE||Modified 3+3 dose escalation scheme.||||
34112508|NCT05012579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112509|NCT05985239|||OTHER||RETROSPECTIVE|||||||
34112510|NCT04434183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112511|NCT05580705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be a single blinded study and the outcome assessor will be blinded to the treatment group||f|f|f|t
34112512|NCT01233947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112513|NCT06174571|||CASE_CONTROL||RETROSPECTIVE|||||||
34112514|NCT04940078|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial consists of a Part A with multiple weekly dosings at site and a Part B with a single dose (SD) part of the first dose step in Part A.||||
34112515|NCT05878704|NA|PARALLEL||TREATMENT||NONE||||||
34112516|NCT06637098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112517|NCT03538847|||OTHER||RETROSPECTIVE|||||||
34112518|NCT05599100|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112519|NCT04975620|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The pathologists who assess the FNB specimens are blinded on the needle type||f|f|f|t
34112520|NCT01349478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725644|NCT04400838|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
33725645|NCT05251220|||CASE_CONTROL||RETROSPECTIVE|||||||
33725646|NCT01280552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725647|NCT05350033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Care providers communicate to the PI for participants' availability each week. PI assigns an anonymization code that serves to activate the stimulation device in active or sham-mode, blinded to investigators or participants.|"* Group 1: Active-stimulation in Phase 1 and Phase 2~* Group 2: Active-stimulation in Phase 1 and Sham-stimulation in Phase 2~* Group 3: Sham-stimulation in Phase 1 and Active-stimulation in Phase 2~* Group 4: Sham-stimulation in Phase 1 and Phase 2"|t|t|t|t
33725648|NCT03791216|||CASE_CONTROL||PROSPECTIVE|||||||
33725649|NCT00752882|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33725650|NCT06484998|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725651|NCT00181012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725652|NCT06304090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725653|NCT03285971|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33725654|NCT05268159|||CASE_ONLY||RETROSPECTIVE|||||||
33725655|NCT00733746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725656|NCT05624346|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental research|f|f|t|f
34112521|NCT01829451|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34112522|NCT05453084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112523|NCT04682847|||COHORT||PROSPECTIVE|||||||
34112524|NCT04876287|||COHORT||PROSPECTIVE|||||||
34112525|NCT04564508|||COHORT||PROSPECTIVE|||||||
34112526|NCT02531191|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34112527|NCT05016271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34112528|NCT04643379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112529|NCT00070304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725657|NCT03741556|||CASE_ONLY||PROSPECTIVE|||||||
33725658|NCT04152720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808451|NCT04813224|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The patients are not aware that there is another intervention and that they will receive both of them. The participants are not related and do not know each other. The conditions of the study are only known by the researcher, the therapists, and the Committee for the Evaluation and Monitoring of Research with Human Beings of the Universidad Internacional de Valencia|Parallel Assignment|t|f|f|f
33808452|NCT02571868|||COHORT||PROSPECTIVE|||||||
33808453|NCT04230434|NA|SINGLE_GROUP||PREVENTION||NONE||Interventional cohort (Safety Plan Intervention)||||
33808454|NCT02032836|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808455|NCT02587052|||CASE_CONTROL||RETROSPECTIVE|||||||
33808456|NCT00821288|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33808457|NCT03374254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039357|NCT03412136|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The experimental beverages contained either 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) or 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight. A non-calorie drink was used as control. All beverages were flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water. The whey protein and control beverages were sweetened with 0.2g sucralose (Tate \& Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.|In a randomized, crossover study, sixteen 9-18 y old males were given beverages containing either: 1) whey protein (1g/kg bodyweight), 2) glucose (1g/kg bodyweight) or a calorie-free control (C). Serum testosterone, appetite biomarkers and subjective appetite were measured prior (0) and at 20, 35 and 65 minutes after the consumption of the beverage. Food intake at an ad libitum pizza meal was assessed 20 min later (65-85min).|t|f|f|f
34039358|NCT05885503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725659|NCT01315704|||COHORT||CROSS_SECTIONAL|||||||
33725660|NCT02912026|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33725661|NCT04377360|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center feasibility trial with DaRT for the treatment of malignant skin and superficial soft tissue tumors.||||
33725662|NCT03349216|RANDOMIZED|PARALLEL||TREATMENT||NONE|not blinded|Bier's Block with Lidocaine versus Conscous Sedation with ketamine||||
33725663|NCT03745937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725664|NCT01852812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039359|NCT01353430|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34039360|NCT00965211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039361|NCT02835625|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34039362|NCT05756660|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Three strata are identified for this study:~Stratum 1: Cisplatin sensitive/no progression on cisplatin (when given at first diagnosis): Regimen Cisplatin/STS (CS)~Stratum 2A: Cisplatin resistant or progressed on cisplatin after initial response (when given at first diagnosis): Regimen Cisplatin/STS/SAHA (CSS)~Stratum 2B: Wilms tumor, Germ Cell tumor, Neuroblastoma: Regimen CSS~Within each of the 3 eligible strata, patients will be enrolled and directly assigned to their respective protocol therapy, yielding 3 independent single-arm cohorts. Patients will receive protocol therapy for up to 6 3-week cycles before moving to follow-up."||||
34039363|NCT01699672|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039364|NCT00942578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039365|NCT00733421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34039366|NCT04494386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039367|NCT01671007|||COHORT||PROSPECTIVE|||||||
34039368|NCT05030883|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34039369|NCT02621359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039370|NCT02567123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039371|NCT03421951|||COHORT||PROSPECTIVE|||||||
34039372|NCT06301763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039373|NCT02095548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039374|NCT02764671|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039375|NCT00697905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039376|NCT05797181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039377|NCT04762017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039378|NCT00739661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039379|NCT00762255|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039380|NCT04576286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to the type of intervention as well as the data collector and the statistician.|After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.|t|f|f|t
34039381|NCT03790501|||COHORT||PROSPECTIVE|||||||
33725665|NCT03341195|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized trial, four intervention arm and one control arm||||
33725666|NCT02022839|||COHORT||PROSPECTIVE|||||||
33808458|NCT04855747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808459|NCT02413138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808460|NCT00548444|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039382|NCT01135355|||COHORT||PROSPECTIVE|||||||
34039383|NCT00938769|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725667|NCT02345967|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725668|NCT00729183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725669|NCT02771483|||COHORT||PROSPECTIVE|||||||
33725670|NCT03642717|||CASE_ONLY||PROSPECTIVE|||||||
33725671|NCT01541137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808461|NCT00827385|||CASE_CONTROL||PROSPECTIVE|||||||
33808462|NCT03076853|||OTHER||PROSPECTIVE|||||||
33808463|NCT02118311|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808464|NCT01974258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808465|NCT01717066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33808466|NCT05522023|RANDOMIZED|PARALLEL||PREVENTION||NONE||3 group randomized||||
33808467|NCT04338451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33808468|NCT05199506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808469|NCT00390884|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808470|NCT01046292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808471|NCT03470805|NA|SINGLE_GROUP||TREATMENT||NONE||Olaparib as maintenance therapy||||
33808472|NCT02915432|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34039384|NCT00021385||||TREATMENT||||||||
34039385|NCT02992353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039386|NCT06258538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039387|NCT01683435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039388|NCT04356547|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will be a controlled, cross-sectional, randomized, non-blind, superiority trial and will be realized in a simulation center, with pediatric manikins. It includes 41 anesthesiologists or anesthesiology residents, who will be randomized to start their participation in the clinical trial in the intervention or control group. Subsequently, they will become part of the opposing group.||||
34039389|NCT06068543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Patients in the intervention Arm will receive 800 mg Epigallocatechin-3-Gallate (EGCG) + 250mg Ascorbic Acid|t|t|t|f
34039390|NCT01358929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039391|NCT04647331|||CASE_ONLY||PROSPECTIVE|||||||
34039392|NCT05455541|||COHORT||PROSPECTIVE|||||||
34039393|NCT02044120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039394|NCT02913183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039395|NCT01750775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039396|NCT02240212|NON_RANDOMIZED|||TREATMENT||NONE||||||
34039397|NCT03175263|||COHORT||RETROSPECTIVE|||||||
34039398|NCT04069039|||COHORT||CROSS_SECTIONAL|||||||
34039399|NCT06573463|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Blinding will not be feasible neither for the operator nor the patient. As there are some differences in the clinical steps, the form of the appliances and number of needed visits.~Outcome assessor and Statistician will be blinded from the intervention and control not knowing which group represents which procedure."|A randomized controlled clinical trial, parallel group, allocation ratio 1:1 Framework superiority|f|f|f|t
34039400|NCT06244329|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|A blinded assessor, who is not aware of the condition order, conducts all behavioral assessments.||f|f|f|t
34039401|NCT02580110|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34039402|NCT05505435|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039403|NCT03640533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039404|NCT00736164|RANDOMIZED|||TREATMENT||DOUBLE||||||
34039405|NCT05949346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039406|NCT02645240|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039407|NCT00294866|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34039408|NCT04322994|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039409|NCT04191174|||OTHER||PROSPECTIVE|||||||
34039410|NCT04261829|||COHORT||PROSPECTIVE|||||||
34039411|NCT00189124|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34039412|NCT01915602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039413|NCT02445248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039414|NCT04933019|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34039415|NCT04030442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34039416|NCT02042508|NA|SINGLE_GROUP||||NONE||||||
34039417|NCT04771208|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"There are 2 different study designs included:~1. Pre-post study: NH participants from Homestead and Group Assisted Living (N=110) will partake in a pre-post study design. Participants will receive a baseline survey (as described below), view the ACP video intervention, and receive a post-intervention survey, which includes the same items as the baseline survey.~2. RCT: In the ambulatory clinics we will conduct a randomized controlled trial (N=110), and randomize (1:1) in blocks of 2 and 4 to either the video (intervention) or usual care (control) arm. The intervention group will use the ACP video decision aid and participants in the control group will receive usual care. All participants will have a baseline survey, be randomized to intervention or control, and receive a post-intervention survey, which includes the same items as the baseline survey."||||
34039418|NCT01096719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039419|NCT04434339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34039420|NCT01839890|RANDOMIZED|PARALLEL||||NONE||||||
34039421|NCT00000520|RANDOMIZED|PARALLEL||PREVENTION||||||||
34039422|NCT00804310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039423|NCT05311059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039424|NCT04651933|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34039425|NCT05834725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039426|NCT06388083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039427|NCT03321318|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039428|NCT00776035|||OTHER||PROSPECTIVE|||||||
34039429|NCT06534879|||CASE_ONLY||PROSPECTIVE|||||||
34039430|NCT01529333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039431|NCT04947865|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039432|NCT01809080|||COHORT||PROSPECTIVE|||||||
33808473|NCT00845364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808474|NCT01481974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808475|NCT04017611|NA|SINGLE_GROUP||OTHER||NONE||||||
33808476|NCT00369460|||COHORT||PROSPECTIVE|||||||
33808477|NCT05400759|||COHORT||RETROSPECTIVE|||||||
33808478|NCT06509529|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34039433|NCT04855760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039434|NCT01879384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039435|NCT00337701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039436|NCT01972191|||COHORT||RETROSPECTIVE|||||||
34039437|NCT00188474|||CASE_ONLY||PROSPECTIVE|||||||
34039438|NCT00105547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039439|NCT04931030|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, unblinded, dietary intervention||||
34039440|NCT05532111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039441|NCT00128882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039442|NCT04815889|NON_RANDOMIZED|FACTORIAL||SCREENING||SINGLE|"Children who are referred to a Child Health psychologist at the age of 1.5-4 (mostly after 2.5 years of supervision at the Child Health Nurse).~Informants are parents, preschool teachers, child health care psychologists and nurses."|All families receive the first interventions, which are PRIMUS parent education and teacher education. Then the families receive different interventions based on need. The control group receives treatment as usual.|t|f|f|f
34039443|NCT01058642|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34039444|NCT01864902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039445|NCT01544985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112530|NCT05508347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112531|NCT03278561|||COHORT||CROSS_SECTIONAL|||||||
34112532|NCT06172140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112533|NCT05527769|||COHORT||PROSPECTIVE|||||||
34112534|NCT01217892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112535|NCT05062525|||COHORT||OTHER|||||||
34112536|NCT05078957|||COHORT||PROSPECTIVE|||||||
34112537|NCT02318433|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34112538|NCT00643279|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34112539|NCT05586750|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039446|NCT01915407|||COHORT||CROSS_SECTIONAL|||||||
34039447|NCT02838732|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants received L-carnitine supplementation (500 mg per tablet per day, GNC) for one month. Oral carnitine challenge tests and fecal sampling were conducted both before and after the intervention.||||
34112540|NCT03198403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot Study||||
34112541|NCT00208676|||||PROSPECTIVE|||||||
34112542|NCT01140204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112543|NCT03781479|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34112544|NCT00003249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112545|NCT03370315|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112546|NCT01505855|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34112547|NCT02386241|||FAMILY_BASED||PROSPECTIVE|||||||
34112548|NCT04189614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112549|NCT04701554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A ramdomized controlled trial.|f|f|t|f
34112550|NCT06066086|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34112551|NCT06191146|||COHORT||RETROSPECTIVE|||||||
34039448|NCT06363344|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34039449|NCT03270657|NA|SINGLE_GROUP||OTHER||NONE||||||
34039450|NCT03447925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039451|NCT00083382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039452|NCT00000162|RANDOMIZED|||TREATMENT||||||||
34039453|NCT05286450|||OTHER||CROSS_SECTIONAL|||||||
34039454|NCT04169893|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34039455|NCT02962583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039456|NCT05729360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039457|NCT05272111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112552|NCT04573985|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112553|NCT05338073|||CASE_ONLY||PROSPECTIVE|||||||
34112554|NCT01434784|||COHORT||PROSPECTIVE|||||||
34112555|NCT02903862||PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112556|NCT03965923|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33725672|NCT04927936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Participants will be randomised per cohort in 1:1:1:1 fashion using block randomisation.~The study will be single-blind. Staff involved in study will be aware of which vaccine the participant is receiving (arm allocation); the participants will remain blinded to their vaccine allocation.~Seven days (after filling in the questionnaires regarding side-effects) after the boost (2nd vaccination) the vaccination strategy will be unblinded. Directly after the boost (2nd vaccination) a letter will be given in which the study is explained and a statement is given that a second vaccination is given.~Those participants receiving only one shot with Janssen will only be told on the day of planned boost (2nd vaccination). They will not be vaccinated with placebo."|"A multicenter, randomised, single-blind, controlled trial to determine reactogenicity and immunogenicity of different prime-boost COVID-19 vaccine schedules.~Setting Multicenter study conducted through 4 academic trial sites (Amsterdam UMC, Erasmus MC, Leiden UMC, and UMC Groningen).~Trial duration Total duration of each participant will be 12 months from the administration of the boost vaccine dose."|t|f|f|f
33725673|NCT01776788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725674|NCT01750164|||CASE_ONLY||PROSPECTIVE|||||||
33725675|NCT01028157|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725676|NCT01792947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725677|NCT00817895|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725678|NCT00037921|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33725679|NCT06468709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725680|NCT02724904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725681|NCT06301711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725682|NCT02367703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725683|NCT02897674|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34112557|NCT05725031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34112558|NCT05095467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112559|NCT05775939|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112560|NCT02423694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112561|NCT01418456|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
34112562|NCT00269659|||||PROSPECTIVE|||||||
34112563|NCT02007473|||CASE_ONLY||PROSPECTIVE|||||||
34112564|NCT04890262|||COHORT||PROSPECTIVE|||||||
34112565|NCT02733094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112566|NCT05697224|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34112567|NCT03774381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112568|NCT03401866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725684|NCT01527396|||COHORT||PROSPECTIVE|||||||
33725685|NCT00868933|RANDOMIZED|PARALLEL||||NONE||||||
33725686|NCT05465564|||COHORT||PROSPECTIVE|||||||
33725687|NCT05505513|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33808479|NCT05305391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33808480|NCT04934033|NA|SINGLE_GROUP||OTHER||NONE||||||
33808481|NCT03857321|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Neither participants or site personnel will know whether insulin or saline is being administered. Exceptions will be the study nurse who is directly involved in preparing the insulin or placebo, as well as preparing DSMB reports.|At study entry, participants will be randomized to receive either an acute dose of insulin or of placebo first and the other substance on a second visit.|t|t|t|t
34112569|NCT06486064|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34112570|NCT04962516|||CASE_CONTROL||PROSPECTIVE|||||||
34112571|NCT01096004|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34112572|NCT03573050|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34112573|NCT05892107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
34112574|NCT00565747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112575|NCT00341484|||OTHER||CROSS_SECTIONAL|||||||
34112576|NCT05871060|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Out of three treatments, the investigator is blinded for two of them (pre-labelled as A and B).~The participant is fully blinded, i.e. treatments will be served in black cups and vanilla-flavoured."|All participants undertake all three experimental conditions in a random order.|t|f|t|f
34112577|NCT04871620|||COHORT||PROSPECTIVE|||||||
34112578|NCT03007433|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112579|NCT02532101|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112580|NCT01146197|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112581|NCT05126420|||CASE_CONTROL||RETROSPECTIVE|||||||
34112582|NCT01202162|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34112583|NCT02477748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112584|NCT04754490|||COHORT||PROSPECTIVE|||||||
34112585|NCT04817956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Simon 2-stage Basket-Umbrella||||
34112586|NCT05640557|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||There will be two groups: study group (taking a part in the exercise program) and control (no intervention).||||
34112587|NCT05399173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34112588|NCT04046744|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112589|NCT04818710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34112590|NCT04987814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112591|NCT04918459|||COHORT||RETROSPECTIVE|||||||
34112592|NCT06101459|||COHORT||PROSPECTIVE|||||||
34112593|NCT05534646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112594|NCT04628806|||COHORT||PROSPECTIVE|||||||
34112595|NCT03787615|NA|SINGLE_GROUP||PREVENTION||NONE||A variety of technologies (e.g., wrist-worn sensors, smart water bottles, mobile applications) can be utilized to engage participants over time and support compliance with increasing fluid consumption.||||
34112596|NCT06532188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112597|NCT00748774|||CASE_CONTROL||PROSPECTIVE|||||||
34112598|NCT06291987|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112599|NCT00916487|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34112600|NCT05305651|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective cohort study which will enroll IC non-hospitalized participants receiving sotrovimab treatment as per standard of clinical care for COVID-19 in sentinel sites.||||
34112601|NCT02534922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112602|NCT04502914|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental group will consist of wounds treated with the open-to-air strategy. The control group will consist of wounds treated with traditional closed-wound management with dressings soaked in topical antimicrobial solutions.||||
34112603|NCT05849766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112604|NCT02852330|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34112605|NCT05984290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112606|NCT01852981|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112607|NCT04883463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725688|NCT02817165|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725689|NCT01342510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725690|NCT02704078|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33725691|NCT04739007|||COHORT||PROSPECTIVE|||||||
33725692|NCT02291055|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33725693|NCT01275274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725694|NCT03209063|||CASE_CONTROL||PROSPECTIVE|||||||
33808482|NCT02193932|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33808483|NCT05461755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary outcome assessment is blinded|A single-center, prospective, randomized and intra-individual clinical trial comparing untreated striae (controls) to striae treated with topical tretinoin and radiofrequency, respectively, and to combination therapy.|f|f|f|t
34112608|NCT05945225|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34112609|NCT02577809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112610|NCT06254261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112611|NCT03906409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants will be randomised to one of two parallel trial arms: constant feed or bolus feed|t|f|f|f
34112612|NCT02149966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112613|NCT04656912|||COHORT||RETROSPECTIVE|||||||
34112614|NCT04250792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112615|NCT06409260|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized study||||
34112616|NCT00397540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112617|NCT03955978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112618|NCT01156844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112619|NCT03484897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112620|NCT06537687|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112621|NCT03626766|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34039458|NCT02050386|||COHORT||CROSS_SECTIONAL|||||||
34039459|NCT05598112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039460|NCT05570682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants undergoing intervention will be unaware of the intervetion Outcomes assessor will be not involted in the other study of the study and will be not aware of the intervention||t|f|f|t
34039461|NCT02174640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34039462|NCT00677547|||CASE_CONTROL||PROSPECTIVE|||||||
34039463|NCT05400447|||OTHER||PROSPECTIVE|||||||
34039464|NCT02613832|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34112622|NCT01392157|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112623|NCT01174563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039465|NCT00929968|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34039466|NCT05315037|NA|SINGLE_GROUP||OTHER||NONE||Blood glucose and lactate measurements will be collected prior to any physical activity, post workout, and then 10- and 20-minutes post workout. Using a standard lancet device, capillary blood glucose values will be obtained using a Contour Next Glucometer.||||
34039467|NCT02827825|||COHORT||RETROSPECTIVE|||||||
34039468|NCT03264183|||CASE_ONLY||PROSPECTIVE|||||||
34039469|NCT03283566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be single-blinded. The PI, biostatistician who will analyze the data, consultants, and technicians running assays will be blinded to the study arm into which the subjects have been randomized. An alphanumeric identifier that refers to the study subject without any indicators of study arm allocation will be used. Only the surgeons and the research coordinator, but not the personnel conducting the metabolic studies, will be un-blinded as to the study arm randomization.|open label, randomized, two-arm, single-blinded, placebo-controlled, parallel|t|f|t|t
34039470|NCT03762265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039471|NCT05259332|||COHORT||RETROSPECTIVE|||||||
34039472|NCT03175705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039473|NCT04741750|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Allocation is concealed until intervention is assigned. The PI and those analyzing the outcome of the trial will remain blinded throughout the entirety of the study. Only the patients and those delivering the intervention will be aware of the allocation.|A pragmatic quality improvement randomized controlled trial will be conducted among 200 people who inject drugs (PWID) with chronic hepatitis C virus (HCV), age ≥18 years, recruited from Family Health Centers of San Diego's mobile clean syringe exchange program (CSEP). Patients will be recruited to undergo HCV testing. Patients with a positive HCV Ab rapid finger stick test will be randomly allocated (ratio 1:1) to receiving treatment immediately in a mobile medical clinic (n=100) or in a community clinic (n=100, this will serve as a concurrent control group).|f|f|t|t
34039474|NCT02712554|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34039475|NCT00292734|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34039476|NCT06476301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039477|NCT06061120|||COHORT||PROSPECTIVE|||||||
34039478|NCT05468294|NA|SEQUENTIAL||TREATMENT||NONE||||||
34039479|NCT01702220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039480|NCT03004638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039481|NCT06020911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039482|NCT06507410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039483|NCT01846364|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039484|NCT05919797|NA|SINGLE_GROUP||OTHER||NONE||||||
34039485|NCT02124915|||CASE_CROSSOVER||PROSPECTIVE|||||||
34039486|NCT06016205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34039487|NCT00429325|||||PROSPECTIVE|||||||
34039488|NCT05823935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039489|NCT06576921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|During the study, the subjects, the investigator, the sponsor, and the designees are not aware of the randomized allocation, except in the event of emergency unblinding. During the course of treatment with the study drug, if the investigator determines that the study drug is related to a life-threatening situation of the subject, and the investigator considers that knowing the medication of the subject is conducive to the handling of adverse events, an emergency unblinding is allowed. Two sets of sealed blind envelopes were prepared. In the event of an emergency unblinding, the identification number will be used to open the retained envelope to complete the unblinding process.|This study employed block randomization to allocate subjects in a 1:1 ratio to either the experimental or control group. To ensure balance in sample size between the groups, the randomization sequence was generated using SAS 9.4 software. The randomization list was generated by an independent statistician and securely stored in a password-protected computer system, with corresponding envelopes prepared.|t|f|t|t
34039490|NCT04309396|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039491|NCT02999750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039492|NCT00972790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039493|NCT05626296|||CASE_CONTROL||OTHER|||||||
34039494|NCT00961675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039495|NCT05632861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725695|NCT03637465|RANDOMIZED|PARALLEL||PREVENTION||NONE||This cluster RCT involves 14 matched pairs; study recruitment and randomization occurs at the recreation center-level. Participating sites are matched based on center size, summer program enrollment, presence of indoor gym, neighborhood income \& race/ethnicity. Then, an intervention site and control site are randomly determined by a coin flip within each pair.||||
33725696|NCT02451410||SEQUENTIAL||PREVENTION||NONE||||||
33808484|NCT05689606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33808485|NCT01798498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039496|NCT00200447|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039497|NCT06534970|||COHORT||PROSPECTIVE|||||||
34039498|NCT04103125|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open-label, non-randomized, single group clinical investigation||||
34039499|NCT06447961|||CASE_ONLY||CROSS_SECTIONAL|||||||
34039500|NCT03364725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039501|NCT05013710|||COHORT||PROSPECTIVE|||||||
34112624|NCT06247748|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112625|NCT00693758|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725697|NCT06042309|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The forearm randomized to SLS and the order in which the different concentrations of thiurams and carbamates and the control solution are applied to the skin, will be blinded for the reader of the skin reactions and the latter also for the participant.|The participants are assigned to either the SLS-group or NON-SLS-group.|t|f|f|t
33808486|NCT00968903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33808487|NCT03258398|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Part 1, subjects will receive eFT508 in combination with a fixed dose of avelumab. Once the recommended dose of eFT508 in combination with avelumab is determined in Part 1, enrollment in Part 2 will begin. Subjects will be randomized in approximately a 2:1 ratio to receive eFT508 in combination with avelumab or eFT508 monotherapy.||||
33808488|NCT06698796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808489|NCT06402552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808490|NCT00862030|||COHORT||CROSS_SECTIONAL|||||||
33808491|NCT02298998|||COHORT||PROSPECTIVE|||||||
33808492|NCT04668729|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals are randomly allocated into control and chiropractic groups.||||
33808493|NCT03376659|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808494|NCT03378791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808495|NCT03177707|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Couples will be randomized to an immediate or delayed treatment group; the delayed treatment couples will be considered the waitlist control group in this study.||||
33808496|NCT06062641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808497|NCT06477679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808498|NCT00715351|||||PROSPECTIVE|||||||
33808499|NCT00808834|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33808500|NCT06642402|||CASE_CONTROL||PROSPECTIVE|||||||
33808501|NCT05926674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not have knowledge of each participant's intervention.|This study is a double-arm repeated measures study performed in a single session lasting approximately 30-40 minutes.|f|f|f|t
33808502|NCT04746404|||COHORT||PROSPECTIVE|||||||
33808503|NCT02428556|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33808504|NCT03684993|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33808505|NCT01579799|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34039502|NCT06534320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039503|NCT01799629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039504|NCT02874625|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34039505|NCT00385047|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039506|NCT00568451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808506|NCT03288688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039507|NCT01207024|||COHORT||PROSPECTIVE|||||||
34039508|NCT04232865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039509|NCT04390919|||COHORT||RETROSPECTIVE|||||||
34112626|NCT06244589|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study aims to compare cases of laparoscopic cholecystectomy with those undergoing open-conversion cholecystectomy to assess factors influencing the conversion to open surgery.||||
34112627|NCT00213382|||||PROSPECTIVE|||||||
34112628|NCT01928056|RANDOMIZED|||TREATMENT||NONE||||||
34112629|NCT03022721|||COHORT||PROSPECTIVE|||||||
34112630|NCT05161468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Bayesian regression model|t|f|t|t
34112631|NCT01203397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112632|NCT01292031|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112633|NCT00425620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112634|NCT00255502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34112635|NCT01085903|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725698|NCT00919399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808507|NCT00293761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33808508|NCT02021396|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33808509|NCT04378205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Psarticipants did not know which size is allocated/side.|A split mouth study design was applied. Each patient received 2 archwire sizes at one time joined in the midline by crimpable hook and applied in the lower arch. Patients were assigned into one of 2 groups based on archwire sizes used. Group 1:- 0.014-inch and 0.018-inch NiTi Group 2:- 0.016-inch and 0.018-inch NiTi.|t|f|f|t
33808510|NCT05197127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039510|NCT06578221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039511|NCT04955405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039512|NCT04571905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039513|NCT06114381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112636|NCT01644331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112637|NCT02966548|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112638|NCT05913674|NA|SINGLE_GROUP||OTHER||NONE||||||
34112639|NCT03469895|||COHORT||RETROSPECTIVE|||||||
33725699|NCT03592147|NA|SINGLE_GROUP||TREATMENT||NONE||"Within-subject pilot study, where each participant will undergo five different relaxation therapies (guided imagery meditation, music listening, relaxation lighting, combination of light and meditation, and a combination of light and music) and one silence/control state."||||
33725700|NCT03886558|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.||t|f|f|f
33725701|NCT04761068|||COHORT||PROSPECTIVE|||||||
33725702|NCT02799758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725703|NCT02859233|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33725704|NCT02620514|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33725705|NCT05169788|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Outcomes assessors and participants are blinded with respect to group assignment, as both Group 1 and Group 2 use the TOPS program platform, even though with different contents.|Group 1 performs the regular TOPS intervention on problem-solving and executive function-related behaviors, while Group 2, serving as active control group, performs a modified version of the TOPS including only sessions on health and wellness but no contents on problem-solving and executive function-related behaviors.|f|t|f|t
33725706|NCT04807192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725707|NCT03893838|||COHORT||PROSPECTIVE|||||||
33725708|NCT01150123|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33725709|NCT04430777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients were randomly assigned to three groups: Placebo group, intravenous group and subcutaneous group according to the administration route of tranexamic acid|t|f|t|f
33725710|NCT03075917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725711|NCT03027895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725712|NCT01840293|||COHORT||OTHER|||||||
33725713|NCT00022828|||||PROSPECTIVE|||||||
33725714|NCT02518867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725715|NCT01066988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725716|NCT02763852|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725717|NCT06122142|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The study design will be a prospective cluster Randomized Control Trial (cRCT)|t|t|t|t
33725718|NCT01213979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725719|NCT00885599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725720|NCT05518968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725721|NCT06108505|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Neither participant nor site investigator is aware for the product|A 1:1 randomization will be used in the study to allocate subjects into two groups. A group will receive the strain of Lacticaseibacillus with oats and the other group will receive only plain oats.|t|f|t|f
33725722|NCT04663581|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33725723|NCT00915369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725724|NCT04721912|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Healthy pregnant participants will be randomly assigned to one of two groups (Probiotic vs No Probiotic (standard of care)). The Probiotic group will take one capsule daily and have the same study measures at the same times.||||
33725725|NCT03486093|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Patients have been randomized into two groups:~1. patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.~2. Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices."|t|f|f|f
33725726|NCT02417688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725727|NCT03357692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725728|NCT03096652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725729|NCT02902510|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725730|NCT01816893|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33725731|NCT06244355|||COHORT||PROSPECTIVE|||||||
33725732|NCT04821206|||COHORT||PROSPECTIVE|||||||
33725733|NCT03567837|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33725734|NCT01254435|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33725735|NCT00486694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725736|NCT04641611|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Patient will be blinded with regards to type of venous cannulation performed intra-operatively.~Measurement of outcome will be performed by an independent cardiologist, who is blinded to treatment allocation."||t|f|f|t
33725737|NCT00005731|||NATURAL_HISTORY|||||||||
33725738|NCT03025061|||OTHER||PROSPECTIVE|||||||
33725739|NCT00873509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725740|NCT04029714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725741|NCT00331175|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33725742|NCT00076687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725743|NCT02037542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725744|NCT01995799|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725745|NCT01035944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725746|NCT03156478|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized in 3 groups: 1) control group, 2) digital lifestyle intervention group and 3) combined digital and face-to-face lifestyle intervention group. Environmental changes will be done within some work places.Part of the participants in each group may be exposed to environmental modification that are aimed for lifestyle changes at work places.||||
33725747|NCT04045678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725748|NCT03752307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be randomized 1:1 according to a computer-generated allocation scheme to receive either Isoxsuprine HCL 1 capsule 3 times daily for 5 days or matching placebo.|This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse|t|f|t|f
33725749|NCT03535766|||COHORT||RETROSPECTIVE|||||||
33725750|NCT00419198|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725751|NCT03967834|NA|SINGLE_GROUP||OTHER||NONE||||||
33725752|NCT00612053|||COHORT||PROSPECTIVE|||||||
33725753|NCT01459965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725754|NCT01492322|||COHORT|||||||||
33725755|NCT04754347|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33808511|NCT03650465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808512|NCT06272188|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||We do not use a model|t|f|f|f
33808513|NCT05122026|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized 1:1 to receive either 1HP or 3HP||||
33808514|NCT04486703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725756|NCT02801942|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33725757|NCT02570061|RANDOMIZED|PARALLEL||||NONE||||||
33725758|NCT03624712|||CASE_ONLY||PROSPECTIVE|||||||
33725759|NCT00982813|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725760|NCT00831532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725761|NCT00174655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725762|NCT01145768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725763|NCT06159140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725764|NCT02325336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112640|NCT01021527|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33725765|NCT01222975|RANDOMIZED|CROSSOVER||||NONE||||||
33725766|NCT04123353|||COHORT||RETROSPECTIVE|||||||
34039514|NCT04807764|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a mechanistic randomized clinical trial. We will enroll 45 individuals with SCI. We will use blocked randomization into three groups with a block size of nine, with stratification according to severity of SCI (ambulatory with assistive device, or not ambulatory).1 We will check after completion of intervention by all subjects in each group whether the groups are balanced or not regarding baseline motor function and perform tests of association accordingly.||||
33725767|NCT04382131|RANDOMIZED|PARALLEL||TREATMENT||NONE||ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected or confirmed COVID-19 being managed at home. Participants from Scotland will be self-recruiting via web based system which will randomise in a 1:1 ratio to perform HSNIG or not.||||
33725768|NCT06007040|||COHORT||RETROSPECTIVE|||||||
34039515|NCT02508350|NA|SINGLE_GROUP||||NONE||||||
33725769|NCT00511693|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||||||
33725770|NCT04588649|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||"* GroupA (Stroke/TIA patients), n=300~* Group (healthy elderly controls), n=30"|f|f|t|f
33808515|NCT03141918|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33808516|NCT05259800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039516|NCT00086619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039517|NCT01616797|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34039518|NCT02871011|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34039519|NCT05889897|||OTHER||PROSPECTIVE|||||||
33725771|NCT05832333|||OTHER||PROSPECTIVE|||||||
33808517|NCT02431767|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33808518|NCT03288012|||COHORT||PROSPECTIVE|||||||
33808519|NCT06094166|||COHORT||PROSPECTIVE|||||||
33808520|NCT00783952|NA|SINGLE_GROUP||OTHER||NONE||||||
33808521|NCT05252468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Double blind.||f|f|f|t
33808522|NCT00790569|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33808523|NCT01231178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039520|NCT00464282|||DEFINED_POPULATION||PROSPECTIVE|||||||
34039521|NCT00967239|||CASE_CONTROL||RETROSPECTIVE|||||||
34039522|NCT01494883|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039523|NCT02290756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039524|NCT00522730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039525|NCT00603473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039526|NCT02422446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34039527|NCT00020787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039528|NCT03697343|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, Open-Label, randomized||||
34039529|NCT00004208|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34039530|NCT01422837|||OTHER||PROSPECTIVE|||||||
34039531|NCT03489642|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34039532|NCT03139851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039533|NCT04309383|||COHORT||CROSS_SECTIONAL|||||||
34039534|NCT05714865|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort||||
34039535|NCT01360905|||COHORT||CROSS_SECTIONAL|||||||
34039536|NCT01823328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039537|NCT01193777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039538|NCT02996968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039539|NCT05703737|||COHORT||CROSS_SECTIONAL|||||||
34039540|NCT06368297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34039541|NCT01408511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039542|NCT04468022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups divided in 40 eyes|t|f|f|f
34039543|NCT06306898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover design||||
34039544|NCT01461486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039545|NCT01982513|||CASE_ONLY||PROSPECTIVE|||||||
34039546|NCT05307874|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34039547|NCT00714857|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34039548|NCT04111289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039549|NCT02730910|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34039550|NCT00639756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039551|NCT03239535|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039552|NCT04124731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039553|NCT06118801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|f|f|f|t
34039554|NCT04710654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039555|NCT04585256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039556|NCT01796392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039557|NCT01780012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039558|NCT06017258|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34039559|NCT01044615|||COHORT||CROSS_SECTIONAL|||||||
34039560|NCT06181604|||CASE_ONLY||PROSPECTIVE|||||||
34039561|NCT06270576|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34039562|NCT02880670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039563|NCT03566199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039564|NCT04208451|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34039565|NCT06007287|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34039566|NCT02640664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039567|NCT05023447|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomized||t|f|f|t
34039568|NCT00616213|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039569|NCT01120808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039570|NCT02092298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112641|NCT03145220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112642|NCT00601367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112643|NCT00775658|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34112644|NCT05764772|||COHORT||PROSPECTIVE|||||||
34112645|NCT05212909|||OTHER||CROSS_SECTIONAL|||||||
34112646|NCT00427830|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34112647|NCT04167735|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34112648|NCT05573672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Collection of height and weight data will be completed by an individual blind to participant allocation. The statistician completing data analysis will be blind to allocation.|This study will be wait-list controlled. Participants will be randomized to one of two groups. One group will begin the intervention immediately. The other will wait 12 weeks and then complete the intervention.|f|f|f|t
34112649|NCT04118764|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34112650|NCT04986150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34112651|NCT00800644|||CASE_ONLY||PROSPECTIVE|||||||
34112652|NCT03524599|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112653|NCT00756340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112654|NCT01868412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725772|NCT05509699|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study consists of two parts, i.e., a single-arm Phase IIa study and a randomized (1:1), controlled Phase IIb study.~Phase IIa:~It is planned that 20 patients will be enrolled to receive treatment with Surufatinib plus anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy .~Phase IIb:~It is planned that 40 patients will be enrolled to receive the following treatments:~Group A: Patients will receive treatment with Surufatinib plus anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy.~Group B: Patients will receive treatment with anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy."||||
33725773|NCT01341600|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725774|NCT03622346|NA|SINGLE_GROUP||TREATMENT||NONE||Just one patient, subject to two surgeries: curettage and external fixation; subsequently the patient underwent total knee arthroplasty||||
33725775|NCT00804518|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725776|NCT02410382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725777|NCT00272571|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725778|NCT03161431|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In this sequential model initially participant groups will enroll to receive SX-682 monotherapy for 21 days in a dose escalation phase. A 3 + 3 participant design will be used to determine the safe dose. After 21 days, at the specified dose of SX-682 monotherapy, subjects are administered combination therapy consisting of SX-682 at the same dose as used in monotherapy and standard pembrolizumab therapy. Again, a 3 + 3 participant design will be used to determine the safe dose of SX-682 in combination therapy with pembrolizumab. The next higher dose level will be enrolled only after subjects have received the current dose level safely for at least 6 weeks.~Once the safe dose level of SX-682 in combination with pembrolizumab is determined, then participants will be enrolled at the highest safe dose level of SX-682, in combination with pembrolizumab, in an expansion phase."||||
33725779|NCT01757119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725780|NCT04650477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725781|NCT05331118|||COHORT||PROSPECTIVE|||||||
33725782|NCT02437955|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33725783|NCT03005821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725784|NCT01586819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725785|NCT02711423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725786|NCT06142721|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33725787|NCT04972019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will not be told which group the participant is part of, so not be biased in evaluations.|"Feasibility Sham comparison study:~Participants are randomized equally into the experimental group and a sham control group. Randomization will be based on a randomization table prepared by a contracted bio-statistician."|f|f|f|t
33725788|NCT03929848|||COHORT||PROSPECTIVE|||||||
33725789|NCT03152539|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Methodological development of new MRI approaches||||
33725790|NCT04430933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725791|NCT00735878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725792|NCT00209677|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725793|NCT02230865|||COHORT||PROSPECTIVE|||||||
33725794|NCT01206179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725795|NCT03539835|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725796|NCT03864874|||OTHER||CROSS_SECTIONAL|||||||
33725797|NCT03329690|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two randomized investigative arms will run in parallel (DS-8201a and Physician's Choice), with participants who have disease progression after two previous regimens.~Two non-randomized exploratory arms will run with HER2 treatment-naive participants."||||
33725798|NCT03103789|||CASE_CONTROL||PROSPECTIVE|||||||
33725799|NCT03462316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725800|NCT04048642|NA|CROSSOVER||TREATMENT||NONE||||||
33725801|NCT01152463|||COHORT||PROSPECTIVE|||||||
33725802|NCT04318782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725803|NCT00754754|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725804|NCT01261182|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725805|NCT04606576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In this randomized, double-blind, double dummy, placebo-controlled study, approximately 675 eligible subjects with type 2 diabetes and inadequate control on at least one and up to 3 oral glucose-lowering agents will undergo an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period and a 26-week Double-Blind Treatment Extension Period.|t|t|t|t
34150072|NCT06201351|||COHORT||PROSPECTIVE|||||||
34150073|NCT05285306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150074|NCT01065311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150075|NCT02759536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150076|NCT05790980|||CASE_CONTROL||RETROSPECTIVE|||||||
34150077|NCT05999110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are being assigned for two groups in parallel and a pre and post-test analysis is being performed.|f|f|f|t
33808524|NCT03307044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808525|NCT04624139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808526|NCT05662436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808527|NCT02027350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808528|NCT04003324|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725806|NCT00089570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808529|NCT00705159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808530|NCT01888991|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33808531|NCT01522638|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33725807|NCT05033639|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Once the mother is admitted for labor, she or the father will be asked to sign consent. However, if the mother was admitted as an emergency delivery, the parents would be ask immediately after delivery. No one would know what group the patient will be. Enrolled infants will be randomized by a 1:1 block scheme to provide a comparable subject in each group.|This is a double-blind Randomized Control trial where melatonin would be the interventions given to preterm infants admitted at the Neonatal Intensive Care Unit of Ilocos Training and Regional Medical Center.|t|t|t|t
33725808|NCT01758380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725809|NCT02134132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725810|NCT05401955|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725811|NCT04818190|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33725812|NCT01360658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725813|NCT00146874|||COHORT||PROSPECTIVE|||||||
33725814|NCT03365310|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label study|Parallel follow up of two treatment groups randomly allocated through a central randomization process||||
33725815|NCT06297174|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33725816|NCT04706143|||COHORT||PROSPECTIVE|||||||
33725817|NCT05301088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33725818|NCT01825382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725819|NCT04093388|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|Pathologist (outcomes assessor) will be blinded|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.|f|f|f|t
33725820|NCT03864952|||CASE_ONLY||CROSS_SECTIONAL|||||||
33725821|NCT00544258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725822|NCT06072651|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33725823|NCT02467556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725824|NCT01889784|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33808532|NCT05585632|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All participants will be unblinded at Day 29 (1 month following study injection) to seek immunization with licensed influenza and/or SARS-CoV-2 vaccines, outside of the study, per local standard of care.||t|f|t|t
34039571|NCT03102606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Plinabulin and pegfilgrastim are each masked using a double-dummy design in phase 3.~Docetaxel administration is not masked."||t|t|t|f
34039572|NCT01069601|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039573|NCT05541003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039574|NCT06532578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725825|NCT00669812||||TREATMENT||NONE||||||
33725826|NCT04458753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not know in which group they assigned|Two groups; group A will be treated with exercises directed to lumbar and knee, group B will receive exercises directed to knee only. 3 sessions/ week for 4 weeks|t|f|f|f
33725827|NCT00299260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725828|NCT04419038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725829|NCT05192746|RANDOMIZED|PARALLEL||TREATMENT||NONE||pre post intervention study||||
33725830|NCT03006913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725831|NCT01089088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725832|NCT02487212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33725833|NCT05053529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725834|NCT04459312|||COHORT||PROSPECTIVE|||||||
33725835|NCT05063110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725836|NCT02657525|||CASE_ONLY||PROSPECTIVE|||||||
33725837|NCT03276689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All personnel and patients will be blinded to the given treatment (double-blind design). The person conducting the immediate and the long term follow up will not know what the results were of the pre-treatment assessments.|Treatments The patients will take 2 tab/d of either (i) duloxetine 60mg or (ii) pregabaline 150mg x 2/day or (iii) placebo for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. In line, the initial 7-days dose of pregabaline will 75mg x 2. For duloxetine, the morning dose will be a sham pill. Study nurse will be available for the patients regarding any side effects or issues arising, and communicate the relevant data to the PI. All personnel and patients will be blinded to the given treatment (double-blind design). The person conducting the immediate and the long term follow up will not know what the results were of the pre-treatment assessments.|t|t|t|t
33838202|NCT03259477|RANDOMIZED|PARALLEL||PREVENTION||NONE||Some participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental during laparoscopic partial nephrectomy and the others undergo complete renal arterial clamping.||||
34039575|NCT00108459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039576|NCT06055361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039577|NCT01833481|||CASE_CONTROL||RETROSPECTIVE|||||||
34039578|NCT01602211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34039579|NCT01099618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039580|NCT01057316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039581|NCT00672724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039582|NCT04501237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725838|NCT03666923|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33725839|NCT03379649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the treatment they received, but providers and investigators will be aware.||f|t|f|f
33725840|NCT00827255|||CASE_ONLY||RETROSPECTIVE|||||||
33808533|NCT05252832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to the anesthesia route selected until after they report their pain scale report. Care provider cannot be blinded in order to complete.|Participant blinded block randomization of the control local infitrate (Arm 1) and the experimental SCPB (Arm 2).|t|f|f|f
33808534|NCT02142946|||CASE_CONTROL||RETROSPECTIVE|||||||
33808535|NCT03372694|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808536|NCT06387550|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pre-post quasi experimental study having one group analysis.Participants will be selected through inclusion and exclusion criteria then pre assessment would be done that include HBA1C and EQ5DL QOL tool, followed by intervention and post assessment.||||
33808537|NCT00237120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808538|NCT03643809|||COHORT||RETROSPECTIVE|||||||
33808539|NCT03700554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Method of closed envelopes|Randomised, non-blinded, actively controlled clinical trial.|f|f|t|f
33808540|NCT05040152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808541|NCT05499767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34112655|NCT05005416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants conducting all assessments and biostatisticians conducting the analyses will be masked to treatment group. Participants, physical therapist providers, investigators, recruitment coordinators, and project managers will not be masked. Physical therapists who provide the Usual Care intervention will be naïve to the purpose of the study and details of the GOALS intervention.|The primary purpose of this interventional study is to determine the efficacy of a culturally adapted cognitive behavioral based tele-rehabilitation program compared to usual care for Hispanics/Latinos with chronic neck or low back pain. The main objective of the GOALS intervention is to improve pain-related disability in Hispanics/Latinos with chronic spine pain. The interventional study model is a single site, 2-arm parallel assignment randomized clinical trial with blinded assessors. After completing the baseline assessment, enrolled participants will be stratified by sex (male, female) and diagnosis (low back pain/neck pain) and randomized into either the GOALS intervention arm or the Usual Care control arm.|f|f|f|t
34112656|NCT03990987|||OTHER||PROSPECTIVE|||||||
34112657|NCT02979119|||COHORT||PROSPECTIVE|||||||
34112658|NCT03290027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112659|NCT03137823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112660|NCT00955578|||CASE_ONLY||PROSPECTIVE|||||||
34112661|NCT03347656|||COHORT||PROSPECTIVE|||||||
34112662|NCT01280669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112663|NCT06259019|NA|SINGLE_GROUP||OTHER||NONE||||||
34112664|NCT05089916|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, explorative, multi-center parallel cohort study||||
34112665|NCT02997085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112666|NCT06486220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112667|NCT05734196|NA|SINGLE_GROUP||TREATMENT||NONE||Study INZ701-104 is a Phase 1b, open-label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of INZ-701 in infant study participants with ENPP1 Deficiency or with ABCC6 Deficiency.||||
34112668|NCT02256748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112669|NCT06033560|||COHORT||RETROSPECTIVE|||||||
34112670|NCT03495414|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112671|NCT02806661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112672|NCT01331590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112673|NCT04125602|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34112674|NCT06187909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112675|NCT04580550|NA|SINGLE_GROUP||OTHER||NONE||||||
34112676|NCT03683433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112677|NCT01951391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112678|NCT06489015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112679|NCT03910595|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"All patients will receive the Mepitel film intervention. This film will be given to patients in one of three patient populations:~1. Patients with large breasts~2. Patients with small or medium sized breasts~3. Patients with chest wall radiation"||||
34112680|NCT05291910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112681|NCT05872412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a double-blinded randomized controlled trial to explore the efficacy and toxicity of platinum-based versus non-platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.|t|f|f|t
34112682|NCT04185779|||COHORT||CROSS_SECTIONAL|||||||
34112683|NCT04636996|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34112684|NCT01179373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34112685|NCT01221116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112686|NCT06243770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34112687|NCT04252079|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cross sectional study||||
34112688|NCT05478317|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects' matching inclusion criteria will be randomly assigned to control (OF) or tested (PZ) groups. After eligibility has been ascertained and consent has been obtained, subjects planned for ECL will be enrolled in the study and assigned to the group in 1:1 ratio using computer-generated block randomization scheme.||||
34112689|NCT01993550|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34112690|NCT03286868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
34112691|NCT05663684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomization will be performed by a secondary investigator who will have no participant interaction during the performance of the procedure and obtainment of the survey responses. A random number generator will be used to obtain either an even or odd number. Odd numbers mean the left eye receives Proparacaine hydrochloride 0.5% ophthalmic solution, even numbers mean the right eye does. The secondary investigator will then label each syringe L or R depending on randomization results. Two identical 1 ml syringes will be prepared. One syringe containing control BSS, and the other containing Proparacaine hydrochloride 0.5% ophthalmic solution. Each syringe will be labeled with either left (L) or right (R) as randomized."||t|t|f|f
34112692|NCT00694863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112693|NCT05552404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112694|NCT03274778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112695|NCT02663193|||COHORT||PROSPECTIVE|||||||
33725841|NCT04535791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To ensure that participants are unaware of the intervention they are receiving, both the capsules containing vitamin D3 and the placebo will be the same. Cholecalciferol (Vitamin D3), 4000UI tablets will be purchased from the MEDIX laboratory (trade name HISTOFIL). The placebo will consist of corn starch, which will be purchased from a supplier, who packages it in a 25 kg bag. As it is a dry product, the supplier guarantees that the corn starch maintains its characteristics for 3 years, as long as it is stored in closed container, in a cool and dry place, free of moisture, dust, insects and rodents. The encapsulation of the placebo and vitamin D3 will be carried out by an external supplier with capsules of the capsugel brand, maintaining quality control to avoid contamination of the product during storage and encapsulation. An external researcher will have a list to which group each subject belongs, without being in contact with the research.|Blinded randomized clinical trial|t|t|t|f
33725842|NCT00988507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725843|NCT02181062|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725844|NCT03774277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725845|NCT01385475|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33725846|NCT00644293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725847|NCT00165893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33725848|NCT03903354|||COHORT||PROSPECTIVE|||||||
33725849|NCT02533336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33725850|NCT05375552|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33725851|NCT02867540|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725852|NCT00127712|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808542|NCT02157948|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808543|NCT03930940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808544|NCT05404997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|t|f
33808545|NCT02015767|||CASE_ONLY||PROSPECTIVE|||||||
33808546|NCT03451695|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33808547|NCT00874588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808548|NCT05481346|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to an experimental group that will perform the physical exercise program and a control group that will perform nothing and continue with their normal lifestyle routines, without any physical activity.||||
33808549|NCT00716170|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808550|NCT00326183|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039583|NCT02437773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34039584|NCT03321500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039585|NCT04209790|NA|SINGLE_GROUP||TREATMENT||NONE||"After standard treatment of Glioblastoma multiforme (GBM) with resection and adjuvant therapy, local failure the dominant pattern of failure. Neo adjuvant therapy consistently provides the potential for improved local control and removal of residual stem cell niches. The hypothesis is that earlier institution of neo adjuvant chemo radiation therapy in GBM would improve local control and potentially overall survival.~Involved field radiation is often employed to treat unresectable or sub totally resected GBM. Radiating native GBM is not uncommon as many tumors are not safely resectable due to its location in eloquent brain. Planned neoadjuvant chemo radiation prior to immediate surgical resection in glioblastoma is a novel approach in resectable tumors."||||
34039586|NCT01460238|||COHORT||PROSPECTIVE|||||||
34039587|NCT05098522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039588|NCT06180096|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34039589|NCT01290068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039590|NCT05654376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039591|NCT05374122|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial||||
34112696|NCT05099315|||CASE_ONLY||PROSPECTIVE|||||||
34112697|NCT06489509|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||The regional distribution of pulmonary ventilation was measured in the supine, right, and left lateral positions while alternating the sides to ensure randomization.|t|f|f|t
33725853|NCT04073758|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725854|NCT01983579|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725855|NCT02948491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33808551|NCT05982366|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, single-center, randomized trial||||
33808552|NCT04642898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808553|NCT00002232||||PREVENTION||DOUBLE||||||
33808554|NCT02426255|||COHORT||PROSPECTIVE|||||||
33808555|NCT06146634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808556|NCT06082115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Selected Physical Therapy Program, Mirror Therapy, Task Oriented Training|t|f|f|t
33808557|NCT04326478|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded|Each household will be randomized to either receive a single-dose of azithromycin or receive non-antibiotic placebo. All study visits after the drug administration, which occurs during the first visit, are equal for both groups.|t|t|t|t
33808558|NCT02871661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33808559|NCT03765658|NA|SINGLE_GROUP||TREATMENT||DOUBLE||During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.|t|f|t|f
33808560|NCT02139241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33808561|NCT04352517|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33808562|NCT05467566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808563|NCT00237224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039592|NCT03197142|||CASE_ONLY||PROSPECTIVE|||||||
34039593|NCT00598455|||COHORT||PROSPECTIVE|||||||
34039594|NCT05695001|||COHORT||PROSPECTIVE|||||||
34112698|NCT05107076|||CASE_ONLY||PROSPECTIVE|||||||
34112699|NCT05892900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112700|NCT00216190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34112701|NCT02988076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject is masked as to assignment to Control or Treatment Group. The subject acts as the blinded rater - providing the primary outcome measure - the Quick Inventory of Depressive Symptomatology - 16 Item Self report||t|f|f|t
34112702|NCT06307457|||COHORT||RETROSPECTIVE|||||||
34039595|NCT01590225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039596|NCT00529503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039597|NCT02017158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039598|NCT02931344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039599|NCT00890383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039600|NCT00593723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039601|NCT03285516|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34039602|NCT02821026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039603|NCT05122182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039604|NCT05829083|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039605|NCT00181857|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34039606|NCT02779920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039607|NCT03045211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34039608|NCT04998565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039609|NCT02498704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039610|NCT00474084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039611|NCT03902262|||CASE_ONLY||RETROSPECTIVE|||||||
34039612|NCT00253825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34039613|NCT02178657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039614|NCT01198223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039615|NCT04142372|||CASE_ONLY||RETROSPECTIVE|||||||
34039616|NCT00116818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039617|NCT00216125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039618|NCT03035825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34039619|NCT02897778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039620|NCT02538575|NA|SINGLE_GROUP||OTHER||NONE||||||
34039621|NCT00326274|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34039622|NCT03389204|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were blinded to physical support or not|RCT intervention and not intervention|t|f|f|f
34039623|NCT06136091|||COHORT||PROSPECTIVE|||||||
34039624|NCT00874575|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34039625|NCT01422564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039626|NCT03628664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039627|NCT02147834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039628|NCT05844293|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34039629|NCT01053715|||COHORT||PROSPECTIVE|||||||
34039630|NCT06179914|||CASE_ONLY||CROSS_SECTIONAL|||||||
34039631|NCT02114424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039632|NCT02356588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039633|NCT01006122|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34039634|NCT05231473|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This study is designed as a quasi-experimental study with a control group, an intervention group, without random assignment and multicenter trial; which is carried out at two centers in Barcelona, Spain: Bellvitge University Hospital (BUH) and Hospital Germans Trias i Pujol (HGTiP), between December 2021 and November 2023. The participants are assigned according to the implanted and functioning program of each center, to one of two arms: a control arm, in which they join the ERAS program without NEC (group I), and an intervention arm, in which the participants will be included in the ERAS program with NEC (group II).~In HGTiP, the ERAS program without NEC is carried out in a standardized way, and in BUH it is carried out with NEC for all patients. The study directly compares both programs and their compliance in patients who are candidates for elective colorectal surgery."||||
34039635|NCT03207269|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039636|NCT06410482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34039637|NCT04747119|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group received the conventional selected exercise program and the study group received the same exercise training program in addition to muscle energy technique||||
34039638|NCT01707810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039639|NCT00380133|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34039640|NCT06459219|||CASE_CONTROL||PROSPECTIVE|||||||
34039641|NCT03825796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039642|NCT00745862|||COHORT||PROSPECTIVE|||||||
34039643|NCT00718614|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34039644|NCT00004872||||TREATMENT||||||||
34039645|NCT04502654|||COHORT||PROSPECTIVE|||||||
34039646|NCT00950014|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34039647|NCT06323824|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The comparative effectiveness of two strategies to address retention in medication for opioid use disorder (MOUD) treatment will be tested over a 168-day period. Behavioral treatments offered to patients are designed to be similar across the two medication conditions.~Office-based methadone where the clinician prescribes methadone and oral methadone is administered and/or dispensed at a pharmacy. Providers and Randomized Control Trial (RCT) participants will have flexibility to use behavioral and pharmacological services as clinically indicated.~Office-based buprenorphine (BUP) where the clinician prescribes BUP formulations that are dispensed at a pharmacy or administered in the office (e.g., extended-release formulations). Providers and RCT participants will have flexibility to use behavioral and pharmacological services as clinically indicated."||||
34039648|NCT03277287|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Prospective comparative study|t|f|f|f
34039649|NCT01554462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34039650|NCT04994210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039651|NCT01568892|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34039652|NCT00762814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039653|NCT02756143|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808564|NCT03263611|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33808565|NCT02717819|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33808566|NCT00969241|||CASE_CONTROL||PROSPECTIVE|||||||
34039654|NCT02348086|||COHORT||PROSPECTIVE|||||||
34039655|NCT02805153|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039656|NCT03173118|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112703|NCT05164653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725856|NCT05735223|NA|SINGLE_GROUP||PREVENTION||NONE|Stretched flaccid penile length (SFPL) was measured by a single male assessor at preoperative visit, and at the time of catheter removal (10 days post-surgery). The subjects were blinded to the measurements to prevent bias.|In an IRB approved study, we prospectively evaluated the stretched flaccid penile length (SFPL) pre and post robot assisted laparoscopic radical prostatectomy (RALP) in subjects with a diagnosis of prostate cancer. The multiparametric MRI (MP-MRI) was utilized for surgical planning if available preoperatively. Repeated measures t-test, linear regression and 2-way ANOVA analyses were performed.||||
33725857|NCT01787175|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725858|NCT02863133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725859|NCT04950569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725860|NCT00763165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725861|NCT02816060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725862|NCT03217786|||COHORT||PROSPECTIVE|||||||
33725863|NCT00864877||||TREATMENT||||||||
33725864|NCT02098590|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725865|NCT01220479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725866|NCT03463564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725867|NCT06400433|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, the administering physician, the physician conducting the clinical and ultrasonographic evaluation, and the physician performing the electrophysiological examination will not be informed about the injection materials assigned to the patients.||t|t|t|f
33725868|NCT01832025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725869|NCT02395796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725870|NCT01430013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725871|NCT01478321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725872|NCT05542927|||COHORT||PROSPECTIVE|||||||
33725873|NCT03080259|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33725874|NCT03998553|NA|SINGLE_GROUP||OTHER||NONE||Prospective and unicentric cohort pilot study||||
33725875|NCT04116138|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1-2, open label, single arm, single center.||||
33725876|NCT05263700|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective single arm cohort study.||||
33725877|NCT02477995|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33725878|NCT05457374|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Partial hepatectomy+PVE Partial hepatectomy+LVD|t|t|f|f
33725879|NCT03608774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725880|NCT04877938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be awared of he group they belong. However, Invesitgators and Outcome assessors will not know the group each single participant belogns to.|"1 group echological intervention~1 group standard physical activity intervention~1 control group"|f|f|t|t
33725881|NCT04000204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725882|NCT04908670|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|Participant and clinician providing the manipulation on the spine were blinded to the EEG measures|Half of the group was assigned randomly to receive intervention 1 and during the second visit intervention 2. The other half received intervention 2 first followed by intervention 1 on subsequent visit|t|f|t|f
33725883|NCT03759561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725884|NCT03646838|||COHORT||PROSPECTIVE|||||||
33725885|NCT01684371|||COHORT||PROSPECTIVE|||||||
33725886|NCT04130243|||COHORT||PROSPECTIVE|||||||
33725887|NCT04882527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33725888|NCT03293251|||COHORT||RETROSPECTIVE|||||||
33725889|NCT03506750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33725890|NCT05067296|||CASE_CONTROL||PROSPECTIVE|||||||
33725891|NCT04680689|||COHORT||PROSPECTIVE|||||||
33725892|NCT03087968|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33725893|NCT01527279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725894|NCT01362842|||CASE_ONLY||OTHER|||||||
33725895|NCT04049851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725896|NCT02162342|||CASE_CONTROL|||||||||
33725897|NCT04839159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725898|NCT05512507|||COHORT||PROSPECTIVE|||||||
33725899|NCT02131402|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33725900|NCT00379496|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33725901|NCT02251795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725902|NCT00860782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725903|NCT02200848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725904|NCT04664933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808567|NCT01776320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808568|NCT01436175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808569|NCT03429816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725905|NCT03745092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33725906|NCT06029699|RANDOMIZED|PARALLEL||TREATMENT||NONE||When the patient become weanable from mechanical ventilation, the subjects were extubated immediately and randomly divided into two groups, with one group receiving HFNC (called HFNC group), the other group receiving NIPPV (called NIPPV group)||||
33725907|NCT05452395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725908|NCT02999256|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33725909|NCT05093296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725910|NCT02945410|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33725911|NCT01806896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725912|NCT05446883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725913|NCT02407769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725914|NCT04173026|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized cluster controlled implementation study||||
33725915|NCT03779711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725916|NCT01566955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725917|NCT01528072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725918|NCT00002130||||TREATMENT||NONE||||||
33725919|NCT03022760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808570|NCT01281436|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725920|NCT00086749|||COHORT||PROSPECTIVE|||||||
33725921|NCT04988256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725922|NCT04390594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725923|NCT04944901|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725924|NCT00030563||||TREATMENT||||||||
33725925|NCT06312878|||COHORT||RETROSPECTIVE|||||||
33725926|NCT00017303||||TREATMENT||||||||
33725927|NCT02078154|||CASE_ONLY||PROSPECTIVE|||||||
33725928|NCT04327999|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33725929|NCT00006478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725930|NCT00312494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725931|NCT05826899|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33725932|NCT00271349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33725933|NCT01408121|||COHORT||PROSPECTIVE|||||||
33725934|NCT02933177|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33725935|NCT02374879|NA|SINGLE_GROUP||OTHER||NONE||||||
33725936|NCT03662984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33725937|NCT03127657|NA|SINGLE_GROUP||TREATMENT||NONE||Topical application of cock's comb extract in the treatment of palmar arsenical keratosis||||
33725938|NCT00533533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725939|NCT00731770|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33725940|NCT04130295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725941|NCT04171037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33725942|NCT04078685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725943|NCT02786628|||COHORT||PROSPECTIVE|||||||
33725944|NCT01712256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725945|NCT02284646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725946|NCT04538703|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33725947|NCT02532296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33725948|NCT06323460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725949|NCT04682626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
33725950|NCT03685084|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33725951|NCT03823248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33725952|NCT03454984|NA|SINGLE_GROUP||PREVENTION||NONE||all patients eligible to receive SGI-110 at day 40 to day130 after transplantation, will be treated||||
33725953|NCT00178841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725954|NCT02410499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725955|NCT03170973|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Will be included 66 women, randomly divided into two groups, control and experiment, overweight, sedentary and aged 18-30 years. After a 12-hour fast, baseline blood collection will be performed in both groups. The experiment group, 12 hours after the first collection, will be submitted to a physical exercise session with energy expenditure of 250Kcal. The volunteers in the control and experiment group will make a second blood collection 24 hours after the first one.||||
33725956|NCT01986868|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725957|NCT05413252|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study is conducting a stepped-wedge design RCT trial. Practices will be randomized into the study into one of three waves.||||
33725958|NCT01110746|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33725959|NCT06386614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33725960|NCT06528704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725961|NCT02895958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725962|NCT00129363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808571|NCT05710757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group will receive a sham intervention.|The control group will receive a sham myofascial release pectoralis minor release intervention. The experimental group will receive a myofascial release pectoralis minor release intervention. Both groups will receive blood flow restriction exercise to strength the scapula retractors.|t|f|f|f
33725963|NCT01284283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725964|NCT02932865|||CASE_CONTROL||PROSPECTIVE|||||||
33725965|NCT04851899|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33725966|NCT05081856|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Interventional study with posttest control group|t|f|f|f
33725967|NCT00852709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33725968|NCT01769040|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33725969|NCT05817136|||COHORT||PROSPECTIVE|||||||
33725970|NCT00605046|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33725971|NCT01261871|||CASE_CONTROL||PROSPECTIVE|||||||
33725972|NCT01093911|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33725973|NCT02120794|NA|SINGLE_GROUP||TREATMENT||NONE||single group||||
33808572|NCT04255316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808573|NCT04515992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808574|NCT01441284|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33838203|NCT00000416|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33838204|NCT02708407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838205|NCT05812742|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33838206|NCT01276808|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33838207|NCT04278170|||OTHER||CROSS_SECTIONAL|||||||
33838208|NCT03149042|||COHORT||PROSPECTIVE|||||||
34112704|NCT00000600|RANDOMIZED|||PREVENTION||||||||
33725974|NCT02857478|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33725975|NCT04990960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725976|NCT03057938|NA|SINGLE_GROUP||PREVENTION||NONE||Phase II, open-label clinical trial with a medicinal product.||||
33725977|NCT06237790|||COHORT||OTHER|||||||
33725978|NCT00971347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33725979|NCT01002755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33725980|NCT01973985|||COHORT||PROSPECTIVE|||||||
33725981|NCT00181961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725982|NCT02850458|||COHORT||RETROSPECTIVE|||||||
33725983|NCT05820347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33725984|NCT01069133|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808575|NCT05632666|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The lung function analyst is blinded for treatment allocation. A data analyst will design and sign the data analysis plan in advance. The data will be analyzed according to the analysis plan by a physiotherapist who is not blinded for treatment allocation. The physiotherapists who will perform the two-weekly telephone calls are not blinded for treatment allocation. Patients will know that there are two treatment groups, and they are informed that it is not yet known which treatment is most effective.|"In the first four months of the study, the active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax). The sham-control group will receive the same training protocol but with a low (10% of PImax and PEmax) non-therapeutic intensity.~After four months, the sham-control group will also be provided with a supervised RMT at a therapeutic intensity of 30% of PImax and PEmax."|f|f|f|t
33808576|NCT02522598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808577|NCT00829400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808578|NCT01006057|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808579|NCT05937269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808580|NCT03734978|||COHORT||RETROSPECTIVE|||||||
33808581|NCT05474963|||COHORT||PROSPECTIVE|||||||
33808582|NCT04732611|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33808583|NCT01052974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039657|NCT03299660|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive standard LCCRT treatment followed by 4 cycles of Avelumab followed by surgical resection||||
34039658|NCT02285361|||COHORT||PROSPECTIVE|||||||
34039659|NCT00420420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039660|NCT05473832|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34039661|NCT00488644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039662|NCT02491866|NA|SINGLE_GROUP||OTHER||NONE||||||
34039663|NCT01063738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039664|NCT00319137|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34039665|NCT01555632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039666|NCT06516237|NA|SINGLE_GROUP||OTHER||NONE|Ultrasound and endoscopy will be performed within 7 days in blinded fashion, where the ultrasound operators will be blinded to clinical and endoscopic findings and the endoscopist will be blinded of the clinical and ultrasound findings.|50 Consecutive adult (18 years of age and older) patients with an established diagnosis (\> 3 months) of ulcerative colitis irrespective to state of disease and treatment, undergoing routine investigations by colonoscopy or sigmoidoscopy(according to the current standard of care indications and ECCO guidelines), will be enrolled and undergone routine biopsies in the distal colon and intestinal ultrasound with Shear wave elastography measurements. In addition, up to 8 biopsies will be performed, at clinical judgment, in distal colon to determine molecular and epigenetic biomarkers. Any medication will be kept stable in the interval between the two procedures.||||
34039667|NCT01086631|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039668|NCT06327139|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a phase III, randomized, single-centre, multiple arm trial of immobilization methods for head and neck cancer patients receiving radical radiation therapy. A faceless three point head and neck mask in conjunction with intra fraction surface guided monitoring, a faceless five point mask in conjunction with intra fraction surface guided monitoring and a conventional closed face five point mask without the use of intra fraction surface guided monitoring are being investigated in this study. The set-up accuracy will be based on the magnitude of the translational corrections measured prior to delivery of each radiation therapy fraction.||||
34039669|NCT03611647|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34039670|NCT02334878|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039671|NCT00784329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039672|NCT03307772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039673|NCT04513496|||COHORT||PROSPECTIVE|||||||
34039674|NCT02869347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039675|NCT06343415|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"Assessors are blinded to allocation for the following exploratory clinical outcome scales: Disability Rating Scale and Coma Recovery Scale-Revised.~Data analyses are blinded by coding and blinding the groups (groups A and B) for the statistical analyses. After the analysis, two separate conclusions will be written before lifting the blinding and revealing the results."|AB - BA|f|f|f|t
34039676|NCT02696668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039677|NCT03827681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039678|NCT00328601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039679|NCT01591096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039680|NCT01554670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039681|NCT00194402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039682|NCT02828774|||COHORT||PROSPECTIVE|||||||
34039683|NCT00553839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039684|NCT01795391|||COHORT||PROSPECTIVE|||||||
34039685|NCT00834509|||CASE_CONTROL||PROSPECTIVE|||||||
34039686|NCT03077815|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34039687|NCT04873947|||CASE_ONLY||PROSPECTIVE|||||||
34039688|NCT00965029|||COHORT||PROSPECTIVE|||||||
34039689|NCT01822730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039690|NCT06210243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039691|NCT01315392||PARALLEL||TREATMENT||||||||
34112705|NCT04391335|||CASE_CONTROL||PROSPECTIVE|||||||
34112706|NCT01427439|||COHORT||PROSPECTIVE|||||||
34112707|NCT01657357|||COHORT||PROSPECTIVE|||||||
34112708|NCT01831908|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112709|NCT04994613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The random allocation, block sizes, and block sequences will be concealed from study personnel and each patient until the time a patient is assigned to a group.|The control group will be standard practice with no sensory adaptive environment and the intervention group with be a sensory adaptive environment. Patients will be randomized in varying block sizes using a random number generator to ensure equal numbers in each group.|t|t|t|t
34112710|NCT05032378|||OTHER||PROSPECTIVE|||||||
33725985|NCT01389180|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33725986|NCT01736696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33725987|NCT04120532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33725988|NCT03569332|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33725989|NCT05727228|||COHORT||PROSPECTIVE|||||||
33808584|NCT00866619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33725990|NCT04384302|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33725991|NCT01824186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33725992|NCT01559012|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33725993|NCT01452412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33725994|NCT05255770|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Each condom will be contained within an individual foil packet on which all branding will be masked. All the condom types will be masked in the same manner and identical secondary packaging boxes will be used.|The condom types will be tested in a 3-way cross-over design where subjects will be randomised to use each of the 3 condom types in a defined order, according to the randomisation schedule.|t|f|t|t
33725995|NCT00112502|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33725996|NCT00264355|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33725997|NCT05543486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes are assessed by a blinded examiner|Prospective, randomized, parallel arm|f|f|f|t
33725998|NCT02073279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33725999|NCT02255370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726000|NCT05465551|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726001|NCT01972737|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33726002|NCT05742451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A Randomized Controlled Trial|f|f|f|t
33726003|NCT01249612|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33726004|NCT00481546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726005|NCT03397082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726006|NCT00632333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726007|NCT02775344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726008|NCT03205618|||COHORT||RETROSPECTIVE|||||||
33726009|NCT00778700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726010|NCT04306874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel, non-blinded, randomized controlled two-arm trial: supplement vs. placebo||||
33726011|NCT01810029|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33726012|NCT02761707|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33808585|NCT06326788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33808586|NCT01918176||CROSSOVER||BASIC_SCIENCE||NONE||||||
33808587|NCT01366742|||COHORT||PROSPECTIVE|||||||
34039692|NCT05966077|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trials||||
34039693|NCT04499144|NA|SINGLE_GROUP||TREATMENT||NONE||case series of a new surgical design||||
34039694|NCT05194826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039695|NCT00191477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039696|NCT04395456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039697|NCT06149975|NA|SINGLE_GROUP||OTHER||NONE||||||
34039698|NCT04455308|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34039699|NCT01067105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808588|NCT03838549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039700|NCT04340037|||CASE_CONTROL||RETROSPECTIVE|||||||
34039701|NCT04435418|||COHORT||PROSPECTIVE|||||||
34039702|NCT00298272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039703|NCT04335123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||30 patients with COVID-19 and respiratory failure who meet criteria and agree to participation in the study will be placed on losartan 25 mg once daily on study day 0. If parameters are met the dose of losartan will be increased to 50 mg once daily on study day 3. Patients and/or surrogate decision maker who do not give consent to treatment will be asked to allow collection of data from their medical record for use as a control group. We will also collect medical information relating to safety criteria on historical controls treated at the University of Kansas Hospital in the 30 days prior to the study start date and during the study period.||||
34039704|NCT03388684|||COHORT||RETROSPECTIVE|||||||
34039705|NCT02929771|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33726013|NCT01442870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808589|NCT06479889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33808590|NCT05134103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a waitlist-controlled, randomized controlled trial.||||
34039706|NCT04059835|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Not blinded but randomized|Randomized controlled trial two Groups||||
34039707|NCT06131814|RANDOMIZED|PARALLEL||OTHER||SINGLE|Assessor who will take the resdings is blind|Randomized Clinical Trail|f|f|f|t
34039708|NCT01156181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039709|NCT04454203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34039710|NCT03153904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34039711|NCT02450149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726014|NCT00842660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726015|NCT02906774|||COHORT||PROSPECTIVE|||||||
33726016|NCT01865279|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33726017|NCT00433563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726018|NCT00746941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726019|NCT01838642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726020|NCT03344939|||COHORT||PROSPECTIVE|||||||
33726021|NCT03322215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726022|NCT05465265|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Cases : Navigation into PrEP~Control group: Provision of pamphlets with information on PrEP."|"The study may have two arms: Cases will be navigated into PrEP services and the Control group will just be given PrEP information pamphlets"|f|t|f|f
33726023|NCT04434690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726024|NCT03684915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808591|NCT02988713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039712|NCT06521060|||COHORT||PROSPECTIVE|||||||
33808592|NCT03578965|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The principal investigator along with all members of the study team involved in data analysis as well as the patients will be blinded to the randomization group. The research assistant will disclose the randomization group to the anesthesiologist who will screen the patient for allergies and then obtain the appropriate antibiotics from the pharmacy and administer the antibiotics as appropriate. These will be administered prior to the procedure and so the surgeon will remain blinded to the administration||t|t|t|t
33808593|NCT02350400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808594|NCT04727294|||COHORT||PROSPECTIVE|||||||
33726025|NCT04220411|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I: conventional 3+3 design of dose escalation Phase IIa: single-arm||||
33808595|NCT00507767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039713|NCT00152334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039714|NCT02922751|||CASE_ONLY||CROSS_SECTIONAL|||||||
33726026|NCT03917420|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039715|NCT04341493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients won´t know whether the treatment they receive is hydroxychloroquine or nitazoxanide + hydroxychloroquine.|In this study all patients with a COVID-19 positive result attended at the Health Institute of the State of Mexico (ISEM), will be invited to participate and offered one of two options that try to reduce the complications of this disease.|t|f|f|f
34039716|NCT05084027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039717|NCT02233387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112711|NCT02090764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112712|NCT01943227|||COHORT||PROSPECTIVE|||||||
34112713|NCT01241123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34112714|NCT06526234|||CASE_ONLY||RETROSPECTIVE|||||||
33726027|NCT03810274|||COHORT||RETROSPECTIVE|||||||
33726028|NCT06136663|||COHORT||RETROSPECTIVE|||||||
33726029|NCT01886807|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33726030|NCT03144882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33726031|NCT03125434|NA|SINGLE_GROUP||OTHER||NONE||||||
33726032|NCT03330938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation measures|Prospective, parallel, randomized clinical trial|f|f|t|f
33726033|NCT04336891|||COHORT||RETROSPECTIVE|||||||
33726034|NCT05612685|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33726035|NCT03220217|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|All the primary and secondary imaging endpoints are read by third-party independent readers. Most of the reading will be conducted in blinded manner.||f|f|f|t
33726036|NCT05735561|||COHORT||RETROSPECTIVE|||||||
33726037|NCT02479711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33726038|NCT02669368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33726039|NCT02998801|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726040|NCT02942355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726041|NCT03179150|||COHORT||RETROSPECTIVE|||||||
33726042|NCT04961034|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33726043|NCT02514356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726044|NCT02159664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726045|NCT04085198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33726046|NCT02862431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726047|NCT04838249|||CASE_CONTROL||PROSPECTIVE|||||||
33726048|NCT04259957|||OTHER||RETROSPECTIVE|||||||
33726049|NCT01068509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726050|NCT00821470|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808596|NCT06212661|||COHORT||PROSPECTIVE|||||||
34039718|NCT00815932|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34039719|NCT00827008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039720|NCT05161260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34039721|NCT05561673|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039722|NCT00426946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039723|NCT02301013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039724|NCT00801385||||TREATMENT||NONE||||||
34039725|NCT06461325|||COHORT||RETROSPECTIVE|||||||
34039726|NCT04714879|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||7 experimental stimulation conditions (including sham stimulation) are tested in a randomized, counterbalanced, within-subject design|t|f|t|f
34039727|NCT00806403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039728|NCT03747523|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726051|NCT01413360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039729|NCT06396117|||COHORT||PROSPECTIVE|||||||
34039730|NCT01945658|||COHORT||PROSPECTIVE|||||||
34039731|NCT04939831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039732|NCT00513981||||TREATMENT||NONE||||||
34039733|NCT00717392|||||PROSPECTIVE|||||||
34039734|NCT04519372|||OTHER||RETROSPECTIVE|||||||
34039735|NCT01317407|||CASE_ONLY||PROSPECTIVE|||||||
34039736|NCT02454608|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34039737|NCT02367651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039738|NCT01079468|||COHORT||PROSPECTIVE|||||||
34039739|NCT01963104|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34039740|NCT01279317|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34039741|NCT01408303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039742|NCT03673969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not know the arm prior to surgery, but will be made aware of it afterward||t|f|f|f
34039743|NCT04293471|||COHORT||PROSPECTIVE|||||||
34039744|NCT03634969|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112715|NCT01715558|||OTHER||PROSPECTIVE|||||||
34112716|NCT00758563|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34112717|NCT03622151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention group (housing first model program) and control group (treatment as usual).||||
34112718|NCT02299999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112719|NCT01827189|||CASE_CONTROL||PROSPECTIVE|||||||
34112720|NCT06639529|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150078|NCT05938036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726052|NCT00896558|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33726053|NCT00581568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726054|NCT04338295|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33726055|NCT00772356|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33726056|NCT03849885|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Group 1 - 4 %Chlorohexidine Wipe Group 2 - 4 % Chlorohexidine Wipe with 5% benzoyl peroxide (BPO) application||||
33726057|NCT02070835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726058|NCT00978068|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726059|NCT06224842|NA|SEQUENTIAL||TREATMENT||NONE||||||
33726060|NCT06140095|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33726061|NCT01496092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726062|NCT03327610|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33726063|NCT01616485|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33726064|NCT06483035|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a 2-arm randomized controlled trial with a parallel group design and 1:1 allocation.||||
33726065|NCT02731872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726066|NCT04694313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726067|NCT01376609|||COHORT||PROSPECTIVE|||||||
33726068|NCT04164979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726069|NCT02940327|||CASE_CONTROL||PROSPECTIVE|||||||
33726070|NCT06126757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726071|NCT01971853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726072|NCT04829487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised controlled study|t|t|t|t
33726073|NCT03946735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726074|NCT01650207|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33726075|NCT01498952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726076|NCT06078033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was conducted by single randomization. Allocation of the selected patients to different groups (A, intervention; B, placebo) was implemented by opaque envelopes. The randomization was performed by personnel not involved in the trial, such as clinics receptionist. The personnel placed the random characters into sealed opaque envelopes and provided the group allocation to patients. The envelopes were opened only by the manual therapist, without letting the patient know to which group they were assigned to. Additionally, outcomes assessor was blinded to which group patients were assigned to.||t|f|f|t
33726077|NCT01978028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726078|NCT00702403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726079|NCT01886183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726080|NCT03244865|||OTHER||OTHER|||||||
33726081|NCT05616156|||COHORT||RETROSPECTIVE|||||||
33726082|NCT03141281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Assessors will be blinded to study condition when administering the tests to participants|Random assignment to one of four treatment groups at study entry|f|f|f|t
33726083|NCT06428227|||CASE_CONTROL||RETROSPECTIVE|||||||
33726084|NCT00149942|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726085|NCT01865903|||COHORT||PROSPECTIVE|||||||
33726086|NCT03526458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726087|NCT03291210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33726088|NCT05111691|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive the same dry needling intervention.||||
33726089|NCT03390881|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33726090|NCT00798369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808597|NCT04932018|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
33808598|NCT01026805|||COHORT||RETROSPECTIVE|||||||
33726091|NCT02918149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726092|NCT05930730|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33726093|NCT04568590|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33726094|NCT01811927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726095|NCT06427356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726096|NCT01262482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726097|NCT02970279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726098|NCT04976842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the investigator assessing outcome did not know the kind of anesthesia the patient received|2 groups of patients assigned to either opioid-free anesthesia or opioid-based anesthesia were studied in a randomized manner as for postoperative pain and cognitive dysfunction|t|f|f|t
33726099|NCT01064492|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726100|NCT03792672|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The study is double blind in Treatment Periods 1, 2, and 3 and open-label in Treatment Period 4.|The study is a randomized, crossover 6 sequence study in Treatment Periods 1, 2, and 3.|t|f|t|f
33726101|NCT02270827|||COHORT||PROSPECTIVE|||||||
33726102|NCT05039710|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33726103|NCT01596348|||CASE_ONLY||CROSS_SECTIONAL|||||||
33726104|NCT03054662|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||monocentric prospective study with longitudinal data collection of a single group||||
33726105|NCT06340438|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will be blinded about application of pruritogens.|The participants will randomly receive applications of cowhage and histamine.|t|f|f|f
33726106|NCT04526483|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, one-arm, single-center, single-set target value clinical trial to investigate the clinical value of the Intelligent Navigation 4K UHD 3D Endoscopic Imaging System on laparoscopic gastric surgery. The trial will recruit a total of 67 participants.||||
33726107|NCT03616288|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blinded|Randomized placebo controlled, double-blinded, four-parallel arm, multicentre trial|t|f|t|f
33726108|NCT01266213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726109|NCT04069156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Investigator, site, patient, CEC, and core lab are blinded.|Double-blinded, randomized 1:1, active arm versus placebo arm|t|t|t|t
33726110|NCT05049993|||COHORT||PROSPECTIVE|||||||
33726111|NCT04783805|||COHORT||PROSPECTIVE|||||||
33808599|NCT06510140|||COHORT||PROSPECTIVE|||||||
33808600|NCT05277285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039745|NCT04851301|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The UM Pharmacy will assign de-identified study IDs to participants and provide the study drug (Naloxone or Saline) so that participants, the person conducting the experiment, and the investigator will be blind to the participant's group.|AIM 1: This is a double-blinded, randomized, between- and within-subjects design (3 X 3) with TMD participants randomly assigned to one of three groups. The three groups are 1. Naloxone group 2. Saline group 3. Natural history group, in which participants will not be given any drugs. Within-subjects factor: All three groups will go through the following 3 conditions:1. Active VR (theBlu); 2. Sham VR; 3. No-VR.|t|f|t|t
34039746|NCT05914597|NA|SINGLE_GROUP||OTHER||NONE||Assessing the acceptance of remote colon capsule endoscopy||||
34039747|NCT05370599|RANDOMIZED|FACTORIAL||TREATMENT||NONE||3x3 by BP agent and BP monitoring approach||||
34112721|NCT01766687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research staff and participants were aware of the randomized group assignment; however, outcome assessors (technicians performing the laboratory measurements for the primary and secondary outcomes) are blinded to the random allocation, and the trial statistician will be blinded to patient allocation for the primary analysis||f|f|f|t
34112722|NCT01313533|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34112723|NCT05495568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Interchangeability study|t|t|t|t
34112724|NCT05299190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The MINI will be administered at 6-months post-partum by a blind assessor|Participants will be randomly assigned to the yoga intervention plus treatment as usual (TAU) or TAU plus biweekly clinical monitoring|f|f|f|t
34112725|NCT04548960|NA|SINGLE_GROUP||OTHER||NONE||In this study a part of samples (blood and biopsies) will be collected specifically for this study. This is why the study is therefore interventional||||
34112726|NCT06363292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Single-blind|Phase I, controlled, comparative, parallel-group, single-blind, single-center, controlled clinical trial.|t|t|t|t
34112727|NCT06044792|||COHORT||RETROSPECTIVE|||||||
34112728|NCT00002487||||TREATMENT||||||||
34112729|NCT06376825|NA|SINGLE_GROUP||TREATMENT||NONE|In this study participants will be randomized to different baseline durations and randomization will be done by one of the investigators who are blind to participants assessments.|The study will be a concurrent multiple-baseline single-case experimental study with participiants randomized to baseline durations.||||
34112730|NCT06303310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blinded. Assessor will be the person having 10 years experience in neuromuscular rehabilitation.|Group A (Gaze Stability Exercises + Balance Exercises) Group B (Optokinetic Exercises + Balance Exercises)|f|f|f|t
34112731|NCT04725838|||OTHER||PROSPECTIVE|||||||
34112732|NCT02313038|||COHORT||PROSPECTIVE|||||||
34112733|NCT02569606|||COHORT||RETROSPECTIVE|||||||
34112734|NCT01763762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112735|NCT01655056|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34112736|NCT04206696|||OTHER||RETROSPECTIVE|||||||
34112737|NCT05586373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112738|NCT01539031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112739|NCT02014467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112740|NCT05500534|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Study participants will be scheduled for laser lithotripsy using the investigational device. A comparator arm will also be included, being composed of retrospective, anonymised and non-study related data of patients who underwent laser lithotripsy with a device used in routine lithotripsy interventions at the investigational site.||||
34112741|NCT03682367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All staff involved including nursing, surgeons, pain management, participants and PI will be blinded. Unmasked personnel only include research pharmacy staff.||t|t|t|f
34112742|NCT03161873|||COHORT||PROSPECTIVE|||||||
33726112|NCT03465878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33726113|NCT02727920|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33726114|NCT01177540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726115|NCT01363596|||COHORT||PROSPECTIVE|||||||
33726116|NCT00002137||||TREATMENT||||||||
33726117|NCT02381912|||CASE_CONTROL||PROSPECTIVE|||||||
33726118|NCT02208609|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33726119|NCT00702117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726120|NCT00134212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33726121|NCT00199290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33726122|NCT06376240|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33808601|NCT00792337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808602|NCT02195856|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34039748|NCT03481673|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group, pre-experimental, intervention pilot study.||||
34039749|NCT02066701|||CASE_CONTROL||PROSPECTIVE|||||||
34039750|NCT04473222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants conducting outcome assessments will be blinded to study condition.|Caregiver-child dyads (child ages 1-5 years with a sleep problem) will be recruited from CHOP urban primary care sites and randomly assigned either to the intervention or to an enhanced usual care condition (sleep education handout).|f|f|f|t
34039751|NCT05507073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Individual/s carrying out assessment post-intervention are not aware of the intervention allocation|This will be a two-arm, single blind (assessor blind), randomised controlled group study. It will take place in the NHS hospital setting. Stratification will be performed for age and sex by means of a minimisation technique during randomisation for each subject entering the trial. Any participant that withdraws from the study will be replaced.|f|f|f|t
34039752|NCT05760196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726123|NCT04425746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726124|NCT06338592|RANDOMIZED|PARALLEL||SCREENING||NONE||This is a patient randomized trial that includes two sub-studies, with 2 arms each.||||
33726125|NCT00275951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112743|NCT05950321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112744|NCT04277130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34112745|NCT03084445|||COHORT||CROSS_SECTIONAL|||||||
34112746|NCT01853280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726126|NCT03413059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"1. Group (m): which will receive morphine dose 0.1mg /kg with 9 ml of 0.125 % bupivacaine with through epidural catheter in T 7-T10 .on admission. Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h)~2. Group (s) : will receive mixture consisting of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) .through epidural catheter in-T7- T10 .on admission"|t|t|f|f
33726127|NCT00355186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726128|NCT04128163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726129|NCT01034449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726130|NCT03196011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective, randomised controlled trial with 2 intervention arms|t|f|f|t
33726131|NCT04384965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726132|NCT03263416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33726133|NCT02519712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726134|NCT05096936|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726135|NCT01885312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726136|NCT02313025|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726137|NCT06368232|||CASE_ONLY||RETROSPECTIVE|||||||
33726138|NCT01065519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726139|NCT04307628|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34150079|NCT02006069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726140|NCT03303404|NA|SINGLE_GROUP||OTHER||NONE||||||
33726141|NCT02679859|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33726142|NCT02853240|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33726143|NCT03891654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patient will receive the standard of care, with the intervention, DCE-CT perfusion, occurring pre-treatment and post-treatment||||
33726144|NCT02293070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726145|NCT02155023|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33726146|NCT00718328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726147|NCT00080743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726148|NCT03721419|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Crossover study between 2 medical ICUs and 1 Surgical ICU. Patients in one unit will start off with Low Flow (LF) while the other unit will start off with High Flow (HF). After one half of the required sample size is accrued we will crossover the Medicine ICUs with the Surgical ICU.|f|f|f|t
33726149|NCT05413135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726150|NCT00496847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726151|NCT03733821|||COHORT||RETROSPECTIVE|||||||
34150080|NCT04752345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726152|NCT02567006|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33726153|NCT04525950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded as the Navio system will be switched on at all operations, the outcomes assessors, statisticians and co-researchers will not get access to the randomization information.|Randomized, blinded (patient and outcomes assessor), clinical and radiostereometric trial|t|f|t|t
33726154|NCT03581656|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, multi-center, prospective, non-randomized study. The study is conducted in accordance with the guidelines of the Mitral Valve Academic Research Consortium (MVARC) regarding study design and endpoint definition as well as International Standards Organization 5840-3.||||
33726155|NCT05568784|||COHORT||PROSPECTIVE|||||||
33726156|NCT05683119|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|The experimenter will be blind to the intended testing timepoint. Experimenter blinding will be achieved by having an independent party schedule the testing session, based on the participant's hormonal profile, without disclosing this to the experimenter who will conduct the testing session. On completion of the study, the blinded experimenters will be asked to comment if blinding was achieved and maintained.|This study will conduct the same outcome measures in two populations (i.e., eumenorrheic women and OCP users).|f|f|f|t
33726157|NCT01080898|||COHORT||CROSS_SECTIONAL|||||||
33726158|NCT03938194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726159|NCT04190082|||COHORT||PROSPECTIVE|||||||
33726160|NCT00116831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726161|NCT02466555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726162|NCT05912699|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both participant groups and the study coordinators will be blinded to the allocation.|Randomized Controlled Trial. Participants will be randomized into the intervention group (SlimBiotics Postbiotic) or into a placebo product control group|t|f|t|f
33726163|NCT00655967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726164|NCT01663415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150081|NCT00921453|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33808603|NCT05469165|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33808604|NCT00509756|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33808605|NCT04404894|||COHORT||PROSPECTIVE|||||||
33808606|NCT00831948|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808607|NCT03259568|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participant is not informed about TMS intensity.|"The study is a within-subjects design focused on estimating the fMRI BOLD response to different levels of TMS intensity. The conditions in the study (arms) are repeated within each participant (20%, 40%, 80%, or 120% of an individual's titrated resting motor threshold)."|t|f|f|f
33808608|NCT03807596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808609|NCT00875706|NON_RANDOMIZED|||HEALTH_SERVICES_RESEARCH||NONE||||||
33808610|NCT06227988|||CASE_CONTROL||PROSPECTIVE|||||||
33808611|NCT01092416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808612|NCT03154775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838209|NCT03564353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomly assigned to one of four groups: (1) tDCS targeting location 1 paired with memory task (2) tDCS targeting location 2 with memory task (3) tDCS targeting location 3 paired with memory task (4) tDCS targeting location 4 paired with memory task|t|f|f|t
34150082|NCT02504931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150083|NCT05039658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726165|NCT04248933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726166|NCT01203592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726167|NCT05629013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33726168|NCT05324540|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33726169|NCT03589612|||OTHER||OTHER|||||||
33726170|NCT02478242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726171|NCT00748215|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33726172|NCT03620565|||COHORT||PROSPECTIVE|||||||
33726173|NCT00040885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33726174|NCT00263068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726175|NCT01276093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726176|NCT04146064|||COHORT||PROSPECTIVE|||||||
33726177|NCT05993611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726178|NCT05439408|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33726179|NCT06372288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|One study personnel not involved in participant interventions will be unblinded and will randomize participants and confirm the set up of the device for the session prior to the blinded study personnel interacting with the participant. Both the participant and the blinded study personnel will not know which group the participant will be part of throughout the study sessions.|Participants will be randomized to either receive 5 transcranial magnetic stimulations or 5 sham transcranial magnetic stimulation (no therapeutic levels of stimulation) sessions.|t|t|t|f
33726180|NCT02182362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33726181|NCT02236429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726182|NCT01411163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726183|NCT06544811|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-condition, parallel group, RCT design, will examine the efficacy of a culturally aligned digital quit resource versus a general audience version of the resource. This is a multi-site study that will involve participants engaging with their assigned quit resource, and following up with them during months 1, 3 and 6.||||
33726184|NCT01120951|||COHORT||PROSPECTIVE|||||||
33726185|NCT06436846|||COHORT||PROSPECTIVE|||||||
33726186|NCT05768152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726187|NCT00017433||||TREATMENT||||||||
33726188|NCT02456610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726189|NCT02511470|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33726190|NCT05064956|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33726191|NCT05595317|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Study group will take Non-immersive Virtual reality (VR) exercise, sham controlled group will take sham VR.|t|t|f|t
33726192|NCT03379207|||CASE_CONTROL||PROSPECTIVE|||||||
33726193|NCT03088176|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Phase 1b single arm single dose level||||
33726194|NCT02231346|||COHORT||PROSPECTIVE|||||||
33726195|NCT05873231|||COHORT||PROSPECTIVE|||||||
33726196|NCT03803280|||COHORT||OTHER|||||||
33726197|NCT06370156|||CASE_CONTROL||PROSPECTIVE|||||||
33726198|NCT00696137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726199|NCT02029651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726200|NCT01417481|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33726201|NCT00880347|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33726202|NCT02228915|||COHORT||PROSPECTIVE|||||||
33726203|NCT04352751|NA|SINGLE_GROUP||OTHER||NONE||Single arm, open label, clinical trial employing WHO recognized monitored emergency use of unregistered and experimental interventions (MEURI) study.||||
33726204|NCT02090517|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33726205|NCT03639766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind placebo-controlled trial.|This is a two-arm parallel assignment involves two groups of participants. One group/hand receives the abobotulinum toxin A, and the other group/hand receives a saline solution (control).|t|f|t|f
33726206|NCT02474095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726207|NCT00210821|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33726208|NCT01267396|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726209|NCT03615807|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two prospected-randomized protocols||||
33726210|NCT00115973|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726211|NCT03552575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Prospective, randomised, active-comparator, double-blinded study.|t|t|t|t
33726212|NCT00803881|||COHORT||PROSPECTIVE|||||||
33726213|NCT01995695|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726214|NCT02522390|||COHORT||PROSPECTIVE|||||||
33726215|NCT02661360|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33726216|NCT03231787|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33726217|NCT05345639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization takes place during surgery. Bilateral parasternal block or transverse thoracic block are performed ultrasound-guided, under general anesthesia.|Study phase III, superiority study, monocentric, comparative, with three parallel groups, randomized with a ratio (1:1:1), controlled versus standard care, single-blind|t|f|f|f
33726218|NCT03000699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726219|NCT04631679|||COHORT||PROSPECTIVE|||||||
33726220|NCT02576028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33726221|NCT06361823|RANDOMIZED|PARALLEL||TREATMENT||NONE||The researchers are tasked with adhering to the protocol requirements when selecting participants, and consistently enrolling eligible patients who are then randomly assigned to either the experimental or control group in a 1:1 ratio. The randomization process is overseen by expert statisticians and executed by specialized clinical researchers in an independent manner.||||
33726222|NCT04338438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726223|NCT04059146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to type of education program Outcomes assessor will be blinded to treatment group allocation||t|f|f|t
33726224|NCT00680082|||COHORT||CROSS_SECTIONAL|||||||
33726225|NCT01766869|||CASE_ONLY||PROSPECTIVE|||||||
33726226|NCT00510354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838210|NCT02385058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838211|NCT01195623|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33726227|NCT03811795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The study is a randomized, prospective multicenter pilot study to assess the utility and efficacy of high-density mapping with the Rhythmia mapping system to guide PV re-isolation in subjects with recurrent AF after an initial cryoballoon PVI compared to repeat cryoballoon PVI.~After obtaining informed consent to participate in the study, subjects will undergo baseline data collection. Subjects will then be randomized to undergo repeat PVI with either cryoballoon ablation or repeat PVI with an IntellaNav Open-Irrigated or other approved ablation catheters for atrial fibrillation under guidance of the Rhythmia mapping system and IntellaMap Orion mapping catheter. The performance of repeat AF ablation, use either the cryoballoon or Rhythmia mapping system, mapping catheter, and ablation catheters are in accordance with standard clinical indications and practice, regardless of participation in the study."|t|f|f|f
33726228|NCT02032147|||COHORT||PROSPECTIVE|||||||
33726229|NCT00484237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33726230|NCT02550847|||CASE_ONLY||PROSPECTIVE|||||||
33726231|NCT04459117|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The active product is a 10 ml polyethylene ampoule of acetaminophen containing 100 mg of acetaminophen, solution for infusion, B BRAUN. The placebo product is a polyethylene ampoule of 10ml of NaCL 0.9%, B BRAUN. Polyethylene ampoule of active and placebo products are with the same appearance, in accordance with Good Manufacturing Practices Drugs for Clinical Trials|Phase II is a dose finding phase Phase III is a randomized, multicenter, double-blind, placebo-controlled superiority trial, two arms in a 1:1 ratio, evaluating an increasing of 10% of the percentage of survival without severe morbidity at 36 weeks of post menstrual age|t|t|t|t
33726232|NCT06114758|||CASE_CONTROL||PROSPECTIVE|||||||
33726233|NCT00685243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726234|NCT02146638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726235|NCT06281041|||COHORT||PROSPECTIVE|||||||
33726236|NCT03647540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726237|NCT04585087|NA|SINGLE_GROUP||OTHER||NONE||Single Group Assignment||||
33726238|NCT01210365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726239|NCT01050985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726240|NCT00568828|||CASE_ONLY||PROSPECTIVE|||||||
33726241|NCT06300164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will not know which type of cookies to eat.|The study will conduct by using a prospective randomized double-blind clinical trial model.|t|t|f|f
33726242|NCT03257631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726243|NCT04196478|||COHORT||CROSS_SECTIONAL|||||||
33726244|NCT01381133|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33726245|NCT04380987|||COHORT||PROSPECTIVE|||||||
33726246|NCT05047081|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33726247|NCT02474108|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33726248|NCT03034785|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33726249|NCT01749579|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726250|NCT05507983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726251|NCT04374890|NA|SINGLE_GROUP||OTHER||NONE||||||
33726252|NCT02504567|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33726253|NCT03597633|||COHORT||PROSPECTIVE|||||||
33726254|NCT03624660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be assigned to treatment group according to their lymph node risk or seminal vesicle invasion.~2 treatment groups:~* HR-A: Patients with \<15% risk of positive pelvic nodes, without posterior extracapsular extension and negative for seminal vesicle invasion on exam pretreatment diagnostic MRI.~* HR-B: Patient with ≥ 15% risk of positive pelvic nodes or with seminal vesicle invasion, without posterior extracapsular extension."||||
33726255|NCT01599273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726256|NCT00176592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726257|NCT04457609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726258|NCT04153500|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Principal investigator and the statistician will remain blind to group allocation. Outcome assessments will only be conducted by principal investigator blind to the intervention and control groups.~Second researcher and professor will remain blind to questions included in both questionnaires: anatomy and satisfaction."||t|f|f|t
33726259|NCT01430845|||CASE_ONLY||RETROSPECTIVE|||||||
33726260|NCT04094467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726261|NCT02444091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726262|NCT05150535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726263|NCT04129788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The study is a double blind study with a randomization ratio 1:1. The subjects, the investigator and the Sanofi team will be blinded to the treatment sequences allocation until the database lock. The medicinal product and placebo are indistinguishable using exactly the same packing and form.|Phase IV, single center, double blind, randomized (1:1 ratio), two arms (bisacodyl and placebo), multiple doses, and crossover clinical trial.|t|f|t|t
33726264|NCT03051542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726265|NCT06040021|||COHORT||RETROSPECTIVE|||||||
33726266|NCT01892696|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33726267|NCT06255951|RANDOMIZED|PARALLEL||TREATMENT||NONE||PartA is the itraconazole study sequence,PartB was the rifampin study sequence.||||
33726268|NCT02492529|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33726269|NCT04113499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|During follow up, the coordinators that are contacting the subjects will be blinded to the randomization assignment.||f|f|f|t
33726270|NCT04361162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726271|NCT05305872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726272|NCT00944151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726273|NCT04941508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33726274|NCT01514968|RANDOMIZED|CROSSOVER||||NONE||||||
33726275|NCT05227950|||COHORT||PROSPECTIVE|||||||
33726276|NCT02925546|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726277|NCT01264458|||CASE_CONTROL||PROSPECTIVE|||||||
33726278|NCT00656630|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33726279|NCT01925404|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33726280|NCT00045747||||TREATMENT||NONE||||||
33726281|NCT01380743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726282|NCT01542216|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726283|NCT02759666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726284|NCT00624533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33726285|NCT05010889|||COHORT||PROSPECTIVE|||||||
33726286|NCT04690504|||CASE_ONLY||PROSPECTIVE|||||||
33726287|NCT04952870|||CASE_CONTROL||PROSPECTIVE|||||||
33726288|NCT01874496|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33726289|NCT04608500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study, with limited access to the randomization code. The randomization code will be held in confidence until after the study database is locked and a memo documenting the database lock has been issued. Every effort will be made to retain the integrity of the blind. When issued to the sites, the study drug will be identical in appearance for all participants, regardless of treatment assignment.||t|f|t|f
33726290|NCT00723281|||CASE_ONLY||PROSPECTIVE|||||||
33726291|NCT01840774|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33726292|NCT04695860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726293|NCT00930995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726294|NCT02692092|||CASE_ONLY||PROSPECTIVE|||||||
33726295|NCT05102786|||COHORT||PROSPECTIVE|||||||
33726296|NCT06443762|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726297|NCT03336216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726298|NCT00044954||||TREATMENT||NONE||||||
33726299|NCT03562039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726300|NCT05828251|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized controlled trial in the first part om of the study, 28 patients in each arm.~Prospective study in second part of the study with 28 patients."||||
33726301|NCT01531296|||COHORT||CROSS_SECTIONAL|||||||
33726302|NCT04475588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726303|NCT06034613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726304|NCT03023033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33726305|NCT06537349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726306|NCT03639337|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33726307|NCT04073381|NA|SINGLE_GROUP||PREVENTION||NONE||100 subjects between the ages of 18 and 90, who have GI cancer and will undergo surgery will be recruited for this study. 100 is an arbitrary number of participants. Due to this study design not being previously use before power analysis calculations were unable to made for key variables. All subjects will participate in the study design.||||
33726308|NCT02495311|||CASE_CONTROL||PROSPECTIVE|||||||
33726309|NCT01729312|||CASE_CONTROL||PROSPECTIVE|||||||
33726310|NCT02572466|||COHORT||CROSS_SECTIONAL|||||||
33726311|NCT02046148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33726312|NCT02113956|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33726313|NCT00975533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726314|NCT05972538|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants don't know which treatment type they received.|two groups.Group I received ball and socket retained mandibular implant overdenture while Group II received cement retained implant supported fixed bridges|t|f|f|f
33726315|NCT05952622|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients are randomly assigend, masking is not possible.|Patients are assigned to one of two rehabilitation protocols consisting of either A: initial immobilization followed by physiotherapy or B: initial immobilization followed by physiotherapy and additional continuous passive motion therapy||||
33726316|NCT02079688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33726317|NCT05965856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726318|NCT00343733|RANDOMIZED|||TREATMENT||DOUBLE||||||
33726319|NCT01074164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726320|NCT06284785|||COHORT||PROSPECTIVE|||||||
33726321|NCT04922918|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33726322|NCT05277246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group 1; 2 ml of 1% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.~Group 2: 2 ml of 2.5% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length.~Group 3; 2 ml of 5.25% NaOCl solution will be used as irrigation solution at every file change during root canal preperation .2 ml dental injector and 27 gauge thickness dental needle tip will be used for irrigation . The tip of the cannula will be adjusted to reach two-thirds of the working length."|t|f|f|f
33726323|NCT01271868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726324|NCT06109584|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||We propose a prospective diagnostic validity study in which the correct location of the central venous catheter will be verified by ultrasound and then verified by radiography in the same patient, without modifying the usual clinical practice criteria.|t|f|f|f
33726325|NCT02699203|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33726326|NCT03462238|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33726327|NCT01083095|RANDOMIZED|PARALLEL||||NONE||||||
33726328|NCT01049321|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33726329|NCT02952014|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33726330|NCT00729339|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33726331|NCT02180334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33726332|NCT04079478|||COHORT||PROSPECTIVE|||||||
33726333|NCT03001258|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33726334|NCT03037528|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33838212|NCT00750295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838213|NCT00292968|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838214|NCT04186104|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33838215|NCT03929705|||COHORT||PROSPECTIVE|||||||
33726335|NCT03899948|RANDOMIZED|PARALLEL||OTHER||SINGLE|Independent Evaluators (IEs) conduct all post and follow-up assessments. These IEs are blind to the condition of all participants.|This study uses a parallel Randomized Controlled Trial Design. Following teacher enrollment, randomization occurs at the teacher level with a 1:1 (20 TAPES condition: 20 TAT condition) ratio. Teachers in each condition complete the training and intervention concurrently.|f|f|f|t
33726336|NCT01395329|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33726337|NCT05978154|||COHORT||PROSPECTIVE|||||||
33726338|NCT05687435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726339|NCT03921931|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33726340|NCT03546751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators will randomize two groups of patients with OSA to receive either CPAP or intensive exercise. The study biostatistician will ensure that matching results in equal distributions of patients based on sex, age, race, severity of OSA, and obesity status.|Comparative Effectiveness Trial|f|f|f|t
33726341|NCT03943563|NA|SINGLE_GROUP||OTHER||NONE|"None at the time of intervention. At the end of the study, Blind reading without knowledge of the type: Dixon or classic sequences."|||||
33726342|NCT02276872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726343|NCT05492669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, the anesthesiologist, data collectors, the physicians performing the follow-up, and data analysts will be blinded to the group allocation. Blinding will maintain until the completion of the final analyses.|The experimental group received lidocaine and the control group received the same amount of saline.|t|t|t|t
33726344|NCT02071355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808613|NCT05655000|NA|SINGLE_GROUP||OTHER||NONE||Single-subject study of a supermicrosurgical technique for neonatal thymus transplantation in an adult with acute myeloid leukemia who is not candidate for bone marrow transplant, nor intensive chemotherapy. The participant will receive multidisciplinary supportive care before, during and after the procedure. The safety and adverse event profile will be assessed throughout the study. The graft will be explanted 14-21 days after the procedure. Thymopoiesis will be measured at baseline and at postoperatve day 14-21, before explantation.||||
33808614|NCT03736980|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Four independent study groups|t|f|t|f
33836962|NCT03597984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For each patient the following variables for balancing the study arms will be considered: Gender, age, performance status, histology, site and primary tumor and presence of visceral metastases; Randomization will be performed at the Gemelli ART of the Gemelli Polyclinic Foundation and will be done by e-mail. Patients will be randomized after verification of inclusion and exclusion criteria. Randomization will be performed according to a random list generated by the computer.|"The study is a randomized, controlled superiority trial. The study will appear as an interventionist without medicinal, multicentric, spontaneous. Randomization will take place in a 1: 1 ratio. The study involves the enrollment of 330 patients divided into two groups of 165 patients for each of the two study arms (arm A (gold standard): 4 Gy x 5 fractions (fr); arm B: 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the Gross Tumor Volume - GTV). The expected difference between the two treatments in terms of three-month pain control rates is 15% more in the experimental arm compared to the standard arm.~The calculation of the sample size took into account a 95% CI with a coefficient α of 0.05 and a drop-out rate of 10%."|t|f|f|f
34112747|NCT05763667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The pharmacy will prepare the solutions for groups 2 and 3, reflecting the usual practice of this PI and his mentees. No solution will be prepared for group 1, as this is a form of standard care for patients undergoing minimally invasive hysterectomy. As the liposomal bupivacaine has a cloudy appearance whereas plain bupivacaine and saline are clear, the surgeon will not be blinded.|"Potential subjects will be identified in the GYN specialty clinics at Tufts Medical Center and approached for possible study participation. Eligibility criteria will be assessed by the PI or co-I. Eligible subjects who wish to participate in the study will be consented for the study by the PI or co-I. Informed consent for the study may be obtained up to the day of the surgery, prior to anesthesia induction. The following demographics will be collected from the medical record and de-identified: age, race, ethnicity, height, weight, ASA class.~On the day of surgery, the subject will be randomized using a random number generator to one of 3 groups:~1. No TAP block~2. TAP block with liposomal and plain bupivacaine: 20 mL liposomal bupivacaine, 30 mL 0.25% bupivacaine, 150 mL normal saline (200 mL total)~3. TAP block with plain bupivacaine alone: 60 mL of 0.25% bupivacaine, 140 mL of normal saline (200 mL total)"|t|f|f|t
34112748|NCT06052592|||COHORT||PROSPECTIVE|||||||
34112749|NCT03179033|||COHORT||PROSPECTIVE|||||||
34112750|NCT04886531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112751|NCT02798341|||COHORT||PROSPECTIVE|||||||
33726345|NCT02212587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726346|NCT02245789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726347|NCT05603923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33726348|NCT01485562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726349|NCT02107599|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33726350|NCT05310110|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|t|f
33726351|NCT05628077|||COHORT||CROSS_SECTIONAL|||||||
33726352|NCT06372847|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Before-and-after study||||
33726353|NCT05795426|||OTHER||PROSPECTIVE|||||||
33726354|NCT03664752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) As a double-blinded study, the investigators, the site staff, the sponsor, and the clinical monitors will not be aware of the treatment assigned to the individual study subjects|Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study|t|t|t|t
33726355|NCT02417012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726356|NCT00386867|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726357|NCT02251951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726358|NCT05442528|||CASE_ONLY||PROSPECTIVE|||||||
33726359|NCT03046199|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33726360|NCT01575184|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33726361|NCT02932904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726362|NCT05014022|||COHORT||PROSPECTIVE|||||||
33726363|NCT04344314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomised, controlled||||
33836963|NCT03571399|||COHORT||CROSS_SECTIONAL|||||||
33726364|NCT01166828|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33726365|NCT06333327|||COHORT||PROSPECTIVE|||||||
33726366|NCT01120613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726367|NCT01388075|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33726368|NCT05836207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726369|NCT01652664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726370|NCT00006294|||COHORT||PROSPECTIVE|||||||
33726371|NCT05378620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726372|NCT04172441|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33726373|NCT01609920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726374|NCT04287504|||CASE_CONTROL||PROSPECTIVE|||||||
33726375|NCT05216874|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Although it will be explained to the patients that they would be included in a study determining the joint positions and that a bite record would be taken from them during the operation for this purpose, they will not informed about whether they are included in the splint treatment group or the control group.|Preoperative occlusal splint treatment Cl III Laterognathia patients|t|f|f|f
33726376|NCT05066971|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants follow the same intervention||||
33726377|NCT00079924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726378|NCT01571206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726379|NCT03146442|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Double-blind, the PI and outcomes assessor will be blinded to the intervention arms (which will be designated with code words). The participants in the high protein and normal protein intervention arms will be blinded to the protein content within the breakfast meals (which will be designated with code words).|Participants will be randomly assigned to the following breakfast groups: high protein breakfast (350kcal; 34% protein (30g protein), 40% CHO, and 26% fat); normal protein breakfast (350kcal; 11% protein (10g protein), 63% CHO, and 26% fat); or breakfast skipping (0 kcal)|t|f|t|t
33726380|NCT03827278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726381|NCT00001731||||TREATMENT||||||||
33726382|NCT03531216|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726383|NCT01005004|NA|SINGLE_GROUP||||NONE||||||
33726384|NCT03806920|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|participants were unaware of selected sugar intake prior to second meal|Comparison of sucrose vs. palatinose (isomaltulose) on second meal effect (high-GI meal vs. high-protein meal) in subjects with T2DM or metabolic Syndrome without T2DM|t|f|f|f
33726385|NCT04174911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726386|NCT01743287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726387|NCT06396832|||COHORT||CROSS_SECTIONAL|||||||
33726388|NCT01777204|||COHORT||PROSPECTIVE|||||||
33726389|NCT00802412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726390|NCT05296785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726391|NCT04241497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726392|NCT04932785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726393|NCT00642668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726394|NCT02541071|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33726395|NCT04872036|||OTHER||RETROSPECTIVE|||||||
33726396|NCT03935633|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33726397|NCT02723149|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33726398|NCT03780842|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, interventional, exploratory study in a convenience sample||||
33726399|NCT02621814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33726400|NCT00903617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726401|NCT02855749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726402|NCT00699556|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33726403|NCT05277844|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, parallel-group RCT||||
33726404|NCT05180136|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726405|NCT03501095|||COHORT||PROSPECTIVE|||||||
33726406|NCT04906785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726407|NCT01076504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808615|NCT03087890|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients in one study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme. Participants in arm 2 will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo|Patients with newly diagnosed hiv-1 infection and good immunological status defined as CD4 counts of \>350 pr microliter, will be randomised to receive cotrimoxazole (160mg/800mg) daily or placebo for 48 weeks. Rectal and nasal swabs will be collected on day 0, 14, week 24 and week 48. The swabs will be analysed for the presence of bacterial species with focus on certain multidrug-resistant bacteria such as ESBL (extended spectrum beta-lactamase)-producing Gram negative bacteria, MRSA (methicillin-resistant Staphylococcus aureus) and VRE (Vancomycin-resistant enterococci). Patients will also be monitored closely on monthly visits to assess for any adverse events.|t|t|t|t
33808616|NCT02680262|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33808617|NCT02329704|||CASE_CONTROL||PROSPECTIVE|||||||
33808618|NCT05701059|||COHORT||PROSPECTIVE|||||||
33808619|NCT04681794|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808620|NCT02153970|||COHORT||PROSPECTIVE|||||||
33808621|NCT02379000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808622|NCT06692998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726408|NCT01785576|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33726409|NCT05588102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726410|NCT01388842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726411|NCT01883427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726412|NCT01341561|||COHORT||PROSPECTIVE|||||||
33726413|NCT05038995|||CASE_CONTROL||OTHER|||||||
33726414|NCT03392116|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33808623|NCT01812226|||CASE_CONTROL||PROSPECTIVE|||||||
33836964|NCT00597051|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33836965|NCT01535651|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836966|NCT01833208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836967|NCT06020599|||COHORT||PROSPECTIVE|||||||
33836968|NCT00350727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836969|NCT02489734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34039753|NCT02610660|||COHORT||PROSPECTIVE|||||||
34039754|NCT05679739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039755|NCT00047073|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039756|NCT04632186|NA|SINGLE_GROUP||TREATMENT||NONE|The outcome assessor will be blinded to the type of intervention provided at each session.|Explorative study||||
34039757|NCT06140537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039758|NCT05944471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||randomized controlled experimental|t|f|f|t
34039759|NCT04180020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039760|NCT02644954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039761|NCT01436513|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34039762|NCT06488430|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed-Methods study Phase 1: Quantitative design to assess the burden of mild cognitive impairment (MCI) Phase 2: Development of multidomain intervention (DONE) Phase 3: Qualitative design to explore the barriers and facilitators for adherence to intervention||||
34039763|NCT05325177|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||The investigators are equipped with unique and complementary expertise that will propel this promising work forward. We will recruit 30 preterm infants less than (\<)29 weeks gestation at birth with echocardiographic evidence of hsPDA that require pharmacologic treatment. We will examine renal, cerebral, intestinal blood flow and tissue oxygenation in high-risk preterm infants receiving high dose or standard-dose Ibuprofen treatment for hsPDA. Successful completion of this study will establish feasibility and provide proof-of-concept for a future multi-center trial. We will use descriptive statistics to compare patients' characteristics. To compare NIRS and Doppler data between the two groups, we will use paired t-test if data is normally distributed or Wilcoxon signed-rank test if not normally distributed|t|t|t|f
34039764|NCT00198718|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34039765|NCT01677468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726415|NCT03981081|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized, open-label, parallel groups||||
33726416|NCT03184051|||COHORT||PROSPECTIVE|||||||
34039766|NCT00928291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039767|NCT01775111|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34039768|NCT04630002|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label study.|This is an open-label, single-sequence, multiple-dose and 3-cohort study.||||
34039769|NCT05261087|||COHORT||PROSPECTIVE|||||||
34039770|NCT03941808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039771|NCT03735277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039772|NCT03970629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039773|NCT05008744|||COHORT||PROSPECTIVE|||||||
34039774|NCT01313897|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039775|NCT04608396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
34039776|NCT00529087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039777|NCT02774941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039778|NCT00449865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039779|NCT06471049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726417|NCT00001086||||TREATMENT||NONE||||||
33726418|NCT04750837|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups one group managed by conventional dressing and the other by platelet rich plasma||||
33726419|NCT03818165|NA|SINGLE_GROUP||TREATMENT||NONE||Three doses of CAR2 Anti-CEA CAR T Cells 1 x 10e10 cells by hepatic artery infusion (on Days 1, 8, and 15) of each 28-day cycle in the Treatment Period using the HITM method and Surefire device, with IL-2 systemic infusion. Patient may receive up to three 28-day cycles of CAR-T therapy in the Treatment Period.||||
33726420|NCT05300490|||COHORT||PROSPECTIVE|||||||
33726421|NCT04098276|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||The study will use a sequential, multiple assignment, randomized (SMART) design|t|f|f|f
33726422|NCT01274624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726423|NCT02453958|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33726424|NCT04869072|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT).||||
33726425|NCT01108536|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33726426|NCT01076712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726427|NCT00297037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726428|NCT01894152|||COHORT||PROSPECTIVE|||||||
33726429|NCT02477501|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33726430|NCT05871359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized into 2 groups, using REDCap (Research Electronic Data Capture) software (Harris et al, 2009): 15 / group and will carry out activities in Dual Task (DT) associated with transcranial Direct Current Stimulation (tDCS) real (test group) or sham (control group).|t|t|t|t
33726431|NCT05773547|||COHORT||PROSPECTIVE|||||||
33726432|NCT03187457|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33726433|NCT01512953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726434|NCT05638685|||COHORT||RETROSPECTIVE|||||||
33726435|NCT00504218|||||OTHER|||||||
33726436|NCT00004159||||TREATMENT||||||||
33726437|NCT00409045|||||PROSPECTIVE|||||||
33726438|NCT05936866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726439|NCT06038201|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A controlled, non-inferiority prospective trial|f|f|t|f
33726440|NCT02803307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726441|NCT04733651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726442|NCT00624494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808624|NCT04148170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|all will be know the surgical procedure but participant will know only that he will be treated but cant understand type of procedure done|"Group (I): 80 eyes of children suffer from congenital nasolacrimal duct obstruction will have probing with metal probe and then intubation with bicanlicular silicon tube.~Group (II): 80 eyes of children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube."|t|f|f|f
33808625|NCT04886349|||COHORT||RETROSPECTIVE|||||||
34112752|NCT05432973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112753|NCT06529484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112754|NCT01220687|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112755|NCT02265133|||CASE_CONTROL||PROSPECTIVE|||||||
34112756|NCT06750939|||COHORT||PROSPECTIVE|||||||
34112757|NCT06748339|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112758|NCT05035030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112759|NCT06749925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34112760|NCT06749639|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112761|NCT03311503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||open labeled, multi-center, phase I/II, cohort study||||
34112762|NCT06748248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be randomized control trial in which non probability convenient sampling will be used. two groups of 3-6 age will be formed in which participants will be randomly divided. Group A will be receive Suspension Therapy. Group B will be receive routine therapy.|t|f|f|f
34112763|NCT06751030|||COHORT||PROSPECTIVE|||||||
34112764|NCT06748430|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The group of subjects will go through the three visits of the study in the same order. All subjects will consume the same variety at the same time.||||
34112765|NCT06750926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112766|NCT06750965|||COHORT||PROSPECTIVE|||||||
34112767|NCT06750822|||COHORT||RETROSPECTIVE|||||||
34112768|NCT06748157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient and investigator are blinded, as is the statistician|1:1 randomization|t|f|t|f
34112769|NCT06749574|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34112770|NCT06750757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112771|NCT06749730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112772|NCT06748586|NA|SINGLE_GROUP||TREATMENT||NONE||hyperbaric oxygen therapy (2ATA, 100% oxygen)||||
34112773|NCT04869761|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112774|NCT06748482|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112775|NCT06748131|||COHORT||PROSPECTIVE|||||||
34112776|NCT06747520|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112777|NCT05728489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808626|NCT04009291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo controlled, parallel group with subjects randomized into 4 treatment groups (1:1:1:1): Transcon PTH 15 mcg/day, TransCon PTH 18 mcg/day, TransCon PTH 21 mcg/day, placebo|t|t|t|t
33808627|NCT04338113|||CASE_ONLY||PROSPECTIVE|||||||
33808628|NCT02554006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112778|NCT06750731|||OTHER||PROSPECTIVE|||||||
34112779|NCT03937817|||OTHER||PROSPECTIVE|||||||
34112780|NCT02720445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112781|NCT06749860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112782|NCT06749327|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34112783|NCT06748274|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The participants will be held uninformed about the interventional condition undertaking. TMS will be single-blinded, as the stimulation is applied over three active control spots, while tDCS will be double-blinded, with protocols initiated remotely.|"For this bicentric (Bern and Berlin), cross-over, single-blind, controlled trial with partial randomization, we will recruit n=32 healthy participants (Study Arm 1, Bern and Berlin) and n=32 participants expressing predefined elevated scores in depressive and autonomic symptoms, including functional dyspepsia (Study Arm 2, Bern). Notably, sample sizes of Study Arms 1 and 2 are estimates and will be adjusted using Bayesian updating (see Power considerations and key analysis plan). Before starting any of the study arms, n=10 participants (n=5 in Bern, n=5 in Berlin) will be invited to undergo the protocol for Study Arm 1 to ensure technical feasibility and high data quality (Pilot Phase)."|t|f|t|t
34112784|NCT06750991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112785|NCT06748391|||COHORT||RETROSPECTIVE|||||||
34112786|NCT06750627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|f|f|t|t
34112787|NCT05743621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112788|NCT00314119|||COHORT||PROSPECTIVE|||||||
34112789|NCT04486716|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34112790|NCT04969471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112791|NCT05673148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112792|NCT05334069|||CASE_CONTROL||PROSPECTIVE|||||||
34112793|NCT02327884|||COHORT||CROSS_SECTIONAL|||||||
34112794|NCT05176223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112795|NCT06275022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34112796|NCT06749886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112797|NCT03049462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34112798|NCT06750874|NA|SINGLE_GROUP||PREVENTION||NONE||Non-randomized, non-controlled pilot trial||||
34112799|NCT05523973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 1:1 into either the Lingual Endurance Training only (Group 1) or Lingual Endurance + Transference Exercise (Group 2)||||
34112800|NCT01375530|||OTHER||OTHER|||||||
34112801|NCT05400486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The principal investigator will not be part of any assessment or treatment process.~Two researchers will be solely responsible for evaluating the outcomes. These will not participate in any other process. And they did not know the allocation of participants in their respective groups."||f|f|t|t
34112802|NCT00404560|||COHORT||PROSPECTIVE|||||||
34112803|NCT05976763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112804|NCT05237986|||COHORT||PROSPECTIVE|||||||
34112805|NCT05773274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726443|NCT04644614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726444|NCT03770650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will remain blinded until the final study results are released.|Patients will undergo 1:1 randomization to either IVUS-guided DKCrush stenting which will be the treatment group or Angio-guided DKCrush stenting which will be the control group based on an online Clinical Research Data Management Platform provided by King Yee,,Beijing CN. The initiation of the trial is defined as the time of randomization. After study subjects' enrollment and randomization, the study intervention will take place immediately. The follow-up visits for the primary endpoint are scheduled at 1, 6, and 12 months after the index procedure. Angiographic follow-up is scheduled at 13 months.|f|f|f|t
33726445|NCT03229265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726446|NCT05174910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multicenter, prospective, randomized, single-blind|t|f|f|f
33726447|NCT01936116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726448|NCT05409872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized (1:1) double-blind, single-center controlled trial|t|t|t|t
33726449|NCT03031808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33726450|NCT02086669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726451|NCT01241903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726452|NCT05360953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled study (double-blind)|t|t|t|t
33726453|NCT03732885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726454|NCT02141997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112806|NCT03895658|NA|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33726455|NCT05683288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112807|NCT02211768|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34112808|NCT06092333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112809|NCT00794352|||CASE_CONTROL||PROSPECTIVE|||||||
34112810|NCT03254914|||COHORT||PROSPECTIVE|||||||
34112811|NCT06043609|||CASE_ONLY||PROSPECTIVE|||||||
34112812|NCT06247774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112813|NCT03412435|||COHORT||PROSPECTIVE|||||||
34112814|NCT04172532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112815|NCT04129450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34112816|NCT03534245|||COHORT||PROSPECTIVE|||||||
34112817|NCT04627285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112818|NCT04708470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112819|NCT06170619|||COHORT||PROSPECTIVE|||||||
34112820|NCT04079712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112821|NCT04902443|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112822|NCT04268277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112823|NCT05887908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112824|NCT03739814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112825|NCT00042614|||COHORT||PROSPECTIVE|||||||
34112826|NCT01087294|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112827|NCT05277519|||CASE_ONLY||PROSPECTIVE|||||||
34112828|NCT06749080|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34112829|NCT03974854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112830|NCT06063967|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33726456|NCT06301893|||OTHER||CROSS_SECTIONAL|||||||
33726457|NCT06352450|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33726458|NCT00965822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726459|NCT02599753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726460|NCT01214707|||||PROSPECTIVE|||||||
33726461|NCT03790527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double blind: both participants and experimenters won't know which group is training group or sham control group.|The investigators assigned subjects to two training groups and collected pre - and post-test data|t|f|t|f
33726462|NCT02253212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726463|NCT01044082|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726464|NCT02843035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726465|NCT01617057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726466|NCT05392361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726467|NCT03556423|||COHORT||PROSPECTIVE|||||||
33726468|NCT03467087|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33726469|NCT02361710|||COHORT||PROSPECTIVE|||||||
33726470|NCT01296295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726471|NCT04909775|NA|SINGLE_GROUP||TREATMENT||NONE||Cisplatin-based chemotherapy combined with tislelizumab||||
33726472|NCT00001877||||TREATMENT||||||||
33726473|NCT04078828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726474|NCT00862173|||COHORT||PROSPECTIVE|||||||
33726475|NCT05453942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726476|NCT02445690|||COHORT||PROSPECTIVE|||||||
33726477|NCT04850014|||COHORT||RETROSPECTIVE|||||||
33726478|NCT06049121|||COHORT||PROSPECTIVE|||||||
34112831|NCT02788227|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112832|NCT00001406|||COHORT||PROSPECTIVE|||||||
34112833|NCT06751277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112834|NCT06750198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112835|NCT06750354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients will be included:~1. 40 patients from both genders.~2. Participants between the age 12 and 18 years~3. Oriented, medically stable and taking their medical treatment~4. Mild and moderate asthma~5. All patients are diagnosed as iron deficiency anemia~6. Body mass index between 18.5 -24.9~While excluded if:~1. Have any serious chest diseases, Patients with heart diseases.~2. Patients with neurological disease affecting respiratory muscles or any muscular dystrophy~3. Patients with kidney diseases~4. Patients with liver diseases~5. Other types of anaemia Chest deformities"|f|f|t|f
34112836|NCT06750861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112837|NCT06750211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112838|NCT06748261|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112839|NCT06751433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Clinical trial, double arm, double blind, randomized|t|f|t|f
34112840|NCT06749678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836970|NCT01686139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039780|NCT05428774|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33726479|NCT03832374|||OTHER||PROSPECTIVE|||||||
33726480|NCT05117411|||CASE_CONTROL||RETROSPECTIVE|||||||
33726481|NCT01139736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726482|NCT06253065|||COHORT||PROSPECTIVE|||||||
34039781|NCT00114075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039782|NCT04316338|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label design.||||
34039783|NCT03892642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039784|NCT00958958|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34039785|NCT06509633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039786|NCT03239249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Students and guardians are masked for experimental condition, teachers and collaborating professionals are not.|Of all schools (42) in four counties, 20 have been randomized to experimental and 22 have been randomized to control condition. Schools randomized to experimental condition implement the IKO-model, while schools randomized to control condition work with drop-out as previously.|t|f|f|f
34039787|NCT01598272|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34039788|NCT04540744|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039789|NCT00316238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039790|NCT05948150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Quantitative|t|f|f|t
34039791|NCT03895008|||COHORT||PROSPECTIVE|||||||
34039792|NCT01977755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039793|NCT02682303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34039794|NCT03538860|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34039795|NCT05541081|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34039796|NCT06035523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039797|NCT06499051|||OTHER||OTHER|||||||
34039798|NCT01113892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind study. The surgeon and study site staff knew which vascular graft each subject received, but the subject did not.|This was a prospective, randomized, single-blind (subject), parallel group, multicenter study in subjects with peripheral arterial occlusive disease (PAOD) who were scheduled to undergo femoral popliteal peripheral bypass surgery. Eligible subjects were randomly assigned in a 1:1 ratio to receive either FUSION Bioline or EXXCEL vascular graft.|t|f|f|f
34039799|NCT02933385|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||5 options are offered, however one option was not chosen by the companies so 4 will be analyzed in future studies|t|f|t|t
34039800|NCT04767841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039801|NCT00758901|||COHORT||PROSPECTIVE|||||||
34039802|NCT02360969|||CASE_ONLY||PROSPECTIVE|||||||
34039803|NCT01237171|||COHORT||PROSPECTIVE|||||||
34039804|NCT01026519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039805|NCT01812460|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34039806|NCT02059512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization into three observation groups was carried out according to the table of random numbers.|Potential participants in this study were all patients admitted for planned coronary artery bypass grafting under extracorporeal circulation and who, according to angiographic examination, had 3 or more stenotic coronary arteries. The final decision on the inclusion of each individual patient in this study was determined taking into account the inclusion criteria. The study was conducted according to the approved protocol as a randomized, blind, placebo controlled.|f|f|t|f
34039807|NCT03855657|||CASE_CONTROL||PROSPECTIVE|||||||
34039808|NCT05238727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34039809|NCT01598064|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34039810|NCT03458585|||OTHER||CROSS_SECTIONAL|||||||
34039811|NCT05560568|||CASE_CONTROL||PROSPECTIVE|||||||
34039812|NCT05109533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039813|NCT02231567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039814|NCT00580151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039815|NCT06566131|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants will get the same mobile health intervention.||||
34039816|NCT06328205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039817|NCT03268980|||COHORT||PROSPECTIVE|||||||
34039818|NCT02318446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34039819|NCT00197782|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039820|NCT04861727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Control Group will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment. The Intervention Group, in addition to the control group procedures, will also perform the MRPA, the result of which will guide the pharmaceutical suggestions, when necessary, they also received a Letter of Referral to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.||||
34039821|NCT05399875|NA|SINGLE_GROUP||OTHER||NONE||||||
34039822|NCT03374865|||CASE_CONTROL||PROSPECTIVE|||||||
34039823|NCT01631539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039824|NCT05089513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039825|NCT02044302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039826|NCT00818350|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33726483|NCT01104636|||COHORT||PROSPECTIVE|||||||
34039827|NCT01182012|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34039828|NCT05925647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Mesenchymal stem cell placebo and secretome using injections that are similar in shape and color|This study was divided into two groups, namely, control and treatment. Both received intervention in the form of a 1.5 cc injection on the scheduled day|t|t|t|t
34112841|NCT06748209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112842|NCT06750393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726484|NCT05514158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726485|NCT04720196|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Sham stimulation will be provided by holding the stimulating coil perpendicularly to the scalp, which assures similar impression as during active stimulation but prevents significant magnetic field to reach the brain tissue.|Patients will be randomly assigned to active and then sham stimulation or to sham and then active stimulation.|t|f|t|t
33726486|NCT02431754|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33726487|NCT02316483|||COHORT||PROSPECTIVE|||||||
33726488|NCT01742338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726489|NCT06371742|||OTHER||CROSS_SECTIONAL|||||||
33726490|NCT01163409|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33726491|NCT01148602|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33726492|NCT03656419|RANDOMIZED|PARALLEL||TREATMENT||NONE||A controlled, quantitative cross-sectional clinical study.||||
33726493|NCT01478126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33726494|NCT02518477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33726495|NCT03087656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|subjects to be randomized into two arms: antibiotic arm and no antibiotic arm||t|f|t|f
33726496|NCT03571919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Immediate care providers (nurses, primary teams) will be blinded; however, lidocaine levels will be monitored by the acute pain service, a consulting team providing direct care to the patient, who will not be blinded.||t|t|t|f
33726497|NCT05584696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726498|NCT06003556|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34112843|NCT06748456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Due to the nature of the intervention, it will not be possible to blind the GP's or members of the research team after the allocation. The primary outcome is blinded to the statistician and data manager is blinded until outcomes are analyzed|"The study design is a cluster randomized trial. The quality clusters are the participants (clusters) and randomization will take place at quality cluster level. Each cluster includes on average 13 GP clinics.~The control group will be offered the intervention at the end of the intervention period."|f|f|f|t
34112844|NCT06751329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112845|NCT06750809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112846|NCT06749093|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34112847|NCT06748833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112848|NCT06749275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Fluoridated products and the different concentrations of toothpastes will be camouflaged and labeled by a member of the research team that does not participate in the clinical study who will keep them in separate boxes prior to delivery. The principal investigator and the outcomes assessor will not know the treatment received.|The total sample (132 individuals) will be divided randomly into 3 groups (44 per group) by means of a listing and using the online software http://www.random.org/ following a simple 1: 1: 1 assignment procedure in each group.|f|f|t|t
34112849|NCT06748170|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The trial will be designed as a randomized, two-arm, single-blind parallel group study.|f|f|f|t
34112850|NCT06750159|||COHORT||PROSPECTIVE|||||||
34112851|NCT06751342|||CASE_ONLY||PROSPECTIVE|||||||
34112852|NCT06751017|NA|SINGLE_GROUP||TREATMENT||NONE||1-sequence, drug-drug interaction study||||
34112853|NCT06750770|||COHORT||RETROSPECTIVE|||||||
34112854|NCT06751459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112855|NCT06750263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112856|NCT06748859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112857|NCT06749262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Interventional longitudinal study||||
34112858|NCT06750224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112859|NCT06750133|NA|SEQUENTIAL||TREATMENT||NONE||||||
34112860|NCT03647163|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Safety run-in with dose escalation to be used to identify the optimum dose for expansion. Dose expansion will recruit patients in parallel into 3 groups, NSCLC, NEC and RCC.||||
34112861|NCT04367506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This project has three phases. Phase 1: Adapt BecomeAnEX, conduct usability testing (n=10), and train digital coaches. Phase 2: Conduct a 1-arm pilot trial of the adapted BecomeAnEX (n=20). Phase 3: Conduct a pilot randomized controlled trial (n=90) to examine indicators of feasibility, acceptability, target mechanisms, and preliminary efficacy.|f|f|f|t
34112862|NCT03811015|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34112863|NCT06401798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112864|NCT06749067|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Women will be divided into three experimental and one control group by lottery method from the selected family health centre. All participants will first be informed about the intervention application and informed consent will be obtained. Afterwards, all participants will be asked to fill out the Personal Information Form, Psychological Well-Being Scale, Menopause Symptoms Assessment Scale as a pre-test application.~As an intervention programme, no treatment will be applied to the women in the control group, Mindfulness-Based Practices for the women in the experimental 1 group, Engagement Practice for the experimental 2 group, and Mindfulness-Based Occupational Practice for the experimental 3 group were planned as 2 sessions per week for 8 weeks and 16 sessions of 45-60 minutes."||||
34112865|NCT06749340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the first evaluation, participants will determine their groups by choosing closed and opaque envelopes. One of the researchers will perform all outcome measurements and will not know which group the participant falls into.|Participants with liver cirrhosis will be randomly assigned to 3 groups: face-to-face exercise group, home-based exercise group and control group.|f|f|f|t
34112866|NCT03968822|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Patients will be blinded to which treatment they are receiving both times they come in for the study.||t|f|f|t
34112867|NCT06749301|||OTHER||PROSPECTIVE|||||||
34112868|NCT06750601|||COHORT||RETROSPECTIVE|||||||
34112869|NCT06750744|||COHORT||PROSPECTIVE|||||||
34112870|NCT06749158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This trial is considered a randomized single blind clinical trial due to the following:~* The participants will be blinded to the technique that will be used during the surgical procedure.~* The operator will not be blinded for both techniques during the surgical procedure as the two techniques are different.~* The outcome assessor cannot be blinded."||t|f|f|f
34112871|NCT06748196|||OTHER||CROSS_SECTIONAL|||||||
34112872|NCT05605444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112873|NCT06749613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112874|NCT06749535|||COHORT||CROSS_SECTIONAL|||||||
34112875|NCT06749249|||COHORT||PROSPECTIVE|||||||
34112876|NCT06748625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34112877|NCT06749522|||CASE_CONTROL||PROSPECTIVE|||||||
34112878|NCT05757570|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34112879|NCT06748326|NA|SINGLE_GROUP||TREATMENT||NONE||Children with intussusception that failed non surgical procedures and whose with recurrence||||
34112880|NCT06750666|||COHORT||PROSPECTIVE|||||||
34112881|NCT06749457|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34112882|NCT06749665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112883|NCT06750848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112884|NCT06750913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112885|NCT05663320|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34112886|NCT06182163|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34112887|NCT06748573|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study is single-center, observational, case-controlled, randomized and prospective trail conducted at the ZAS heart center. Before CIED implantation, patients were randomly assigned in a 1:1 ratio to the study group (SafeGuard FocusTM compression device) or control group (standard care with compressive bandage) using a sealed envelope system.~Inclusion criteria were all patients above 18 years of age undergoing primo CIED implantation (pacemaker, internal cardiac defibrillator or cardiac resynchronization therapy) with a high bleeding risk (as defined by at least 1 of the following risk factors: age \> 75 years, heart failure, kidney failure, antithrombotic use (double antiaggregant therapy or anticoagulation). Exclusion criteria were refusal to participate or mental illness."||||
34112888|NCT06751420|||CASE_ONLY||RETROSPECTIVE|||||||
34112889|NCT06748820|||CASE_ONLY||PROSPECTIVE|||||||
34112890|NCT06748560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112891|NCT06749691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112892|NCT06748976|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34112893|NCT06215664|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-armed parallel randomized controlled trial||||
34112894|NCT06750562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34112895|NCT06750341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112896|NCT06748989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112897|NCT06749119|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112898|NCT05713799|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34112899|NCT06749444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sleep laboratory employees||f|f|f|t
34112900|NCT06749704|RANDOMIZED|PARALLEL||TREATMENT||NONE|As it is a nutritional intervention study masking either the participant or the investigator is not possible|Open Label||||
34112901|NCT06748144|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34112902|NCT06750068|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double blinded|3D printed band and loop space maintainer Conventions band and loop space maintainer|t|f|f|t
34112903|NCT06749912|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34112904|NCT06750172|||COHORT||PROSPECTIVE|||||||
34112905|NCT06748092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigator cannot see the measurement results.|||||
34112906|NCT06748495|||COHORT||OTHER|||||||
34112907|NCT06750081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34112908|NCT06750692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-Blinded Prospective Randomized Trial||f|f|t|t
34112909|NCT06749210|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34112910|NCT06748365|||CASE_ONLY||PROSPECTIVE|||||||
34112911|NCT06750016|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34112912|NCT05564390|NA|SINGLE_GROUP||SCREENING||NONE||||||
34112913|NCT04830410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After a low FODMAP diet, patients will have to reintroduce fructan or placebo powder. Patients will be randomized by a web-mail randomization.The powder bags were prepared and named A or B by the firms Beneo, and the participants and the staff involved in the study will be blinded.||t|t|t|t
34112914|NCT06136559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112915|NCT04609046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726499|NCT02844296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33726500|NCT01972269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726501|NCT04562896|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded to the different design variations of each device, and will only be introduced to each device as CDO-A, CDO-B or CDO-C.|All participants will be cast and fit with three carbon fiber custom dynamic orthoses (CDOs). Each CDO will differ from the others in design and will be labeled as CDO-A, CDO-B and CDO-C. Participants will be randomly assigned to one of six CDO testing sequences (ABC, ACB, BCA, BAC, CAB, CBA) to prevent testing order from influencing study results. Multiple rounds of evaluation (\~5 rounds) with small groups of participants in each round (n=\~6) will be used.|t|f|f|f
33726502|NCT03119155|||CASE_ONLY||CROSS_SECTIONAL|||||||
33726503|NCT03496688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Investigator, Outcome Assessor|A randomized,controlled, double-blind clinical trial|t|f|t|t
33726504|NCT02220270|||COHORT||PROSPECTIVE|||||||
34112916|NCT05712200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112917|NCT03271151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112918|NCT02153957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34112919|NCT06246643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150084|NCT05025696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators who scraped the skin and did the transepidermal water loss examination were blinded on which arm the subjects were allocated.|A random cluster sampling was done on the population member diagnosed with scabies based on the boarding school building location into the intervention group and control group. The intervention group was receiving permethrin 5% cream and Blacksoap®, while the control group was receiving permethrin 5% cream and baby soap.|f|f|t|f
34150085|NCT03631420|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150086|NCT01013363|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150087|NCT05738720|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled clinical trial||||
34039829|NCT01021462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039830|NCT05430750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The patient will be blinded to the type of anesthesia intervention. The attending anesthesiologist will however not be blinded to the technique utilized to administer GA and recovery immediately after extubation inside the OR. The postoperative patient profile will be evaluated by an independent assessor blinded to the technique of GA.|"One hundred and two patients of either sex, and schedule for elective surgery under general anesthesia (GA) will be randomly divided into three groups of 34-each.~Group 1('Conventional' N2O carrier gas group) Ventilation will be initiated with 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min to MAC 0.5. Once MAC reaches 0.5, the FGF will be decreased to 1.0L/min.~Group 2 ('Streamed-in' N2O carrier gas group) Ventilation will be initiated with 2% Sevoflurane in O2 -Air (60 % FiO2) @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.~Group 3 (Non-N2O group) Ventilation will be initiated with 2% Sevoflurane in O2-Air (60 % FiO2 @ 3.0L/min) till the time it reaches MAC 0.5. Once MAC 0.5 reached, the FGF is decreased to 1.0L (Low-flow)."|t|f|f|t
34039831|NCT06377813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assignment|f|f|f|t
34039832|NCT03600961|||COHORT||PROSPECTIVE|||||||
34039833|NCT06010953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039834|NCT05183542|NA|SINGLE_GROUP||PREVENTION||NONE||Persons to be operated on for lumbar arthrodesis by the neurosurgery team of the Nancy CHRU and respecting the eligibility criteria (including neuropathic pain scale score \< 4, see non-inclusion criteria), will be proposed to participate in the study||||
34039835|NCT05224128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34039836|NCT05289336|NA|SEQUENTIAL||TREATMENT||NONE||Phase 2 prospective non-inferiority trial comparing with previous prospective collected national cohort||||
34039837|NCT04796532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participants will be randomized and alllocated in one of the three groups (control or experimental HIIT Homebased or experimental HIIT traditional)|3 arm parallel groups|t|f|f|f
34039838|NCT02702830|||CASE_CONTROL||PROSPECTIVE|||||||
34039839|NCT05184205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The placebo control arm will include the application of saline isotonic solution and the introduction of the PDT device with no powering on. Due to the characteristics of the device, and the need for the investigator to deliberately not switching it on, it is clear that there cannot be a blind scheme in this trial.|This is a single-center open-label study to evaluate antimicrobial photodynamic therapy (PDT) for upper airway decolonization in patients presenting with SARS-CoV-2 positive antigen test with mild or no symptoms of COVID-19.|t|f|f|f
34039840|NCT03870750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34039841|NCT05897281|RANDOMIZED|PARALLEL||OTHER||SINGLE|the control group will continue their routine training, outcome assesstments will be performed by an investigator who was blinded to group allocation.|two groups, one control and one exercise group|f|f|f|t
34039842|NCT01788631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34039843|NCT03359993|||COHORT||RETROSPECTIVE|||||||
34039844|NCT05553990|||COHORT||PROSPECTIVE|||||||
34039845|NCT04942626|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 design||||
34039846|NCT04151186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039847|NCT03076840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039848|NCT02284074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34039849|NCT00772876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039850|NCT00404391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039851|NCT05021133|NA|SINGLE_GROUP||SCREENING||NONE||||||
34039852|NCT01229995|RANDOMIZED|||||||||||
34039853|NCT04446338|||COHORT||PROSPECTIVE|||||||
34039854|NCT04500197|||CASE_ONLY||PROSPECTIVE|||||||
34039855|NCT04628247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039856|NCT01994408|NA|SINGLE_GROUP||OTHER||NONE||default drug escalation||||
34039857|NCT00828217|RANDOMIZED|PARALLEL||||NONE||||||
34039858|NCT02254317|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34039859|NCT04562168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039860|NCT06117839|||COHORT||PROSPECTIVE|||||||
34039861|NCT02647957|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34039862|NCT04845750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039863|NCT00170027|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
34039864|NCT00320710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039865|NCT02021344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34039866|NCT06577077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039867|NCT03450317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34039868|NCT01535417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039869|NCT02060838|||CASE_ONLY||PROSPECTIVE|||||||
34039870|NCT04398238|||COHORT||RETROSPECTIVE|||||||
34039871|NCT03552978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34039872|NCT03758664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039873|NCT06576804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039874|NCT06139471|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34039875|NCT05602220|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34039876|NCT04687137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039877|NCT04553601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with advanced NSCLC underwent 18F-FDG PET/CT and PET/CT-guided synchronous targeted biopsy of primary and distant metastatic tumors.||||
34039878|NCT06402318|||CASE_CONTROL||PROSPECTIVE|||||||
34039879|NCT05045443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039880|NCT01982617|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34039881|NCT02062450|||COHORT||RETROSPECTIVE|||||||
33726505|NCT05718232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039882|NCT00634803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039883|NCT06392022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34039884|NCT00239265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039885|NCT01579097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039886|NCT01491568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039887|NCT02598050|||OTHER||PROSPECTIVE|||||||
34039888|NCT00316511|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112920|NCT06584799|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Sealed envelope principle|Clinical trials with a single arm. The study will include 150 consecutive female patients with symptomatic PeVD. All patients will undergo a clinical examination, transabdominal and transvaginal DUS of the pelvic veins to verify the diagnosis and to determine the diameters of the pelvic veins and the duration of reflux in them. The CPP intensity will be assessed using a visual analogue scale (VAS). For randomization procedure, the sealed envelope principle will be used. Three groups of 50 patients each will be formed depending on the recommended VAD usage: group 1 (n=50) with MPFF1000; group 2 (n=50) with Diosmin 600; and group 3 (n=50) with Hesperidin + Diosmin 1000. After the start of VAD intake, the patients will be self-rating the pain intensity on VAS on the weekly basis. Based on the repeated examination data and the VAS results, a comparative analysis of the clinical efficacy of VADs will be carried out.||||
33838216|NCT02288169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34039889|NCT02501122|||COHORT||RETROSPECTIVE|||||||
34039890|NCT00463372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34039891|NCT04968730|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The routine group was given routine nursing, and the control group was given early rehabilitation nursing|f|t|f|t
34039892|NCT02509507|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34039893|NCT02641743|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34039894|NCT01286467|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34039895|NCT03015337|NA|SINGLE_GROUP||||NONE||||||
34039896|NCT05923801|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants treated with ECT for depression, showing no 'response' (≥50 percent decrease in depressive symptom severity compared to baseline) after 4 treatment sessions will be randomized into 2 treatment groups: either continuation with RUL ECT or switch to BT ECT.|t|f|t|t
34039897|NCT04750499|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional (Clinical Trial)||||
34039898|NCT02153177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039899|NCT03379727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039900|NCT01492829|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34039901|NCT06370546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial, single blinded.||||
34039902|NCT02354677|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34039903|NCT03190993|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized parallel arm design trial examining solid sugar vs. SSB treatments will be performed.|f|f|t|f
34039904|NCT05348460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind masking|Randomized, double-blind, placebo-controlled cross-over design|t|t|t|t
34039905|NCT02374970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34039906|NCT03526861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the subject nor any of the investigator or LEO staff who are involved in the treatment or clinical evaluation and monitoring of the subjects will be aware of the treatment received. The packaging and labelling of the investigational medicinal products (IMPs) will contain no evidence of their identity. Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded healthcare professional at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments.||t|f|t|f
34039907|NCT04412031|||COHORT||RETROSPECTIVE|||||||
34039908|NCT00696423|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34039909|NCT03068377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|randomized double blind|Single-phase, randomized, parallel, double blind , comparative study of LYC-001e versus placebo on ocular blood vessels in healthy individuals|t|t|t|t
34039910|NCT02746250|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34039911|NCT01105169|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34039912|NCT05102357|||CASE_ONLY||RETROSPECTIVE|||||||
34039913|NCT06033027|RANDOMIZED|CROSSOVER||OTHER||NONE|Masking is not possible|Single case experimental design with multiple baselines||||
34112921|NCT04439253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112922|NCT02167867|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34112923|NCT06191549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be blinded to their assigned brain stimulation protocols.|Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Young and older healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.|t|f|f|t
34112924|NCT05695339|NA|SEQUENTIAL||TREATMENT||NONE||||||
34112925|NCT05879757|||COHORT||PROSPECTIVE|||||||
34112926|NCT06413706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112927|NCT06748508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112928|NCT06750055|||COHORT||PROSPECTIVE|||||||
34112929|NCT04468399|||COHORT||RETROSPECTIVE|||||||
34112930|NCT03407079|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34112931|NCT05828069|NA|SEQUENTIAL||TREATMENT||NONE||||||
34112932|NCT06748703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112933|NCT06749964|NA|SINGLE_GROUP||TREATMENT||NONE||Multiple Baseline Single Case Design||||
34150088|NCT04788862|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34150089|NCT01030874|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33726506|NCT02488681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726507|NCT02416427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726508|NCT02578927|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33726509|NCT04874974|NA|SINGLE_GROUP||TREATMENT||NONE||Incoming patients from the clinic of Max Planck Institute of Psychiatry are continuously screened for study eligibility and - after they have given informed consent - are assigned to the experimental treatment condition.||||
33726510|NCT02229942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726511|NCT05699083|NA|SINGLE_GROUP||OTHER||NONE||Pre-post interventional study||||
33726512|NCT00615056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726513|NCT00858442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33726514|NCT03620006|||COHORT||OTHER|||||||
33726515|NCT03247166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726516|NCT02063737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726517|NCT01881659|||OTHER||PROSPECTIVE|||||||
33726518|NCT02504697|||COHORT||PROSPECTIVE|||||||
33726519|NCT02103283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838217|NCT00942864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112934|NCT06751303|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a pragmatic trial which offers HRD testing and for patients HRProficient, a patient decision aid to help them decide whether niraparib is right for them. Whatever they decide, we followup with QoL questionnaires and assessment of time to progression.||||
34112935|NCT06748664|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34112936|NCT06749587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded-Live evaluator||f|f|f|t
34112937|NCT06748443|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Type 3 hybrid cluster randomised controlled trial|f|f|f|t
34112938|NCT06047444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34112939|NCT06487481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34112940|NCT03094663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112941|NCT05907746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112942|NCT04450797|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The primary outcome is the surgical intervention time, recorded by blinded anaesthesiologists. Some of the secondary outcomes (catheter placement (optimal vs. not optimal, grade I to IV), volumetry of side ventricles, Evans' Index) are measured by a blinded neuroradiologist.||t|f|f|t
34112943|NCT06749743|||OTHER||CROSS_SECTIONAL|||||||
34112944|NCT06330493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112945|NCT00114101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112946|NCT05509582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112947|NCT06748677|||COHORT||PROSPECTIVE|||||||
34112948|NCT06749977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34112949|NCT01934660|||COHORT||PROSPECTIVE|||||||
34112950|NCT02361723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112951|NCT06255782|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation with dose staggering. Dose selection will be based on an assessment of the totality of the safety and efficacy.||||
34112952|NCT04907929|NA|SINGLE_GROUP||OTHER||NONE||||||
34112953|NCT06163157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112954|NCT03537586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34112955|NCT03433339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent operator (trained personnel from the research team) will prepare the tsDCS device parameters for each session, but will not participate in the rest of the assessments. Patients and raters will remain blinded to spinal stimulation protocol assigned to each participant throughout the study.|8-week, double blinded, randomized, sham controlled, parallel group, pilot clinical trial study design.|t|t|t|t
34112956|NCT06246916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112957|NCT06467084|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112958|NCT03767348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112959|NCT05237973|||COHORT||PROSPECTIVE|||||||
34112960|NCT06237855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comparison of control group (drain removal in clinic via provider) versus intervention group self-removing drain at home.||||
34112961|NCT06460168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34112962|NCT06325696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112963|NCT05223036|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34112964|NCT05830929|NA|SINGLE_GROUP||OTHER||NONE||||||
34112965|NCT03370276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112966|NCT01563341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112967|NCT05600972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Embryologists are blinded to individual clinical treatment allocation||f|f|t|f
34112968|NCT02911129|||COHORT||PROSPECTIVE|||||||
34112969|NCT06750783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112970|NCT05998395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112971|NCT05008848|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34112972|NCT03701282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112973|NCT06748183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment|It will be a randomized control trial employing nonprobability convenient sampling. Two groups, comprising participants aged 6 to 12, will be formed and randomly divided. Group A will undergo Functional Power Training (FPT) alongside Routine Physical Therapy (RPT), while Group B will receive only Routine Physical Therapy (RPT). This intervention aims to compare the effects of combined functional training and routine therapy against routine therapy alone, focusing on improvements in gait parameters and mobility among children with Cerebral Palsy.|t|f|f|f
34112974|NCT03244384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112975|NCT06748378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Allocation Randomized Interventional Model Parallel Assignment Masking Double (Participant Outcomes Assessor) Primary Purpose Treatment|t|f|f|t
34112976|NCT06469970|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, observational, single-centre phase II (exploratory) cohort study aiming to describe changes in initial distribution volume of glucose (IDVG) during the first 4 days of care for patients with severe burns. Patients will be included on admission to the Burn Treatment Centre and IDVG will be measured on admission, then every 8 hours for the first 24 hours of the stay, then every 24 hours until the fourth day. The rest of the evaluation criteria correspond to standard practice in the management of severely burned patients according to the department's procedure.||||
34112977|NCT01176006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112978|NCT06489522|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Approximately 10 high-risk mother-child dyads (defined as a mother having an episode of relapse in the past two years) and approximately 10 low-risk mother-child dyads (defined as mother not having any episodes of relapse in the past two-years) will be enrolled. There will be 1 therapist and 9 clinical stakeholders (Patient Navigators, program manager, pediatricians, peer recovery coaches involved in the care of mother-child dyads in the SOFAR Program).||||
34150090|NCT01927055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838218|NCT04525599|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
33838219|NCT00723619|||COHORT||PROSPECTIVE|||||||
33838220|NCT05524090|||COHORT||PROSPECTIVE|||||||
33726520|NCT05284838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726521|NCT04536727|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants are randomized to the intervention or wait-list group.||||
33726522|NCT00753116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726523|NCT02008448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726524|NCT04779255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726525|NCT04368975|||COHORT||PROSPECTIVE|||||||
33726526|NCT06301100|||COHORT||PROSPECTIVE|||||||
33726527|NCT05372692|NA|SEQUENTIAL||TREATMENT||NONE||||||
33726528|NCT01613781|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33726529|NCT03500133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Initial disease risk assignment defines three arms: low, intermediate and high risk. After early disease response assessment 7 Arms are defined, treated with more intense chemotherapy according to initial risk and therapy response. Finally radiotherapy is delivered only to patients who do not achieve complete remission after chemotherapy at late disease response assessment.||||
33726530|NCT02234921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726531|NCT05352828|NA|SINGLE_GROUP||TREATMENT||NONE||Upon successful leukapheresis to produce CD30.CAR-T cells, patients will enter the treatment phase of the study. Treatments will include 4 cycles of nivolumab and CD30.CAR-T infusion (preceded by lymphodepletion chemotherapy). Patients will then enter the post-treatment follow-up phase of the study, whereby patients will undergo either autologous stem cell transplant or continue to receive up to 6 additional treatment cycles of nivolumab. Patients will be followed for response assessments and safety monitoring until end of study (EOS); approximately 3 years after leukapheresis. Long-term follow-up will continue with additional safety monitoring and survival for up to 15 years after Leukapheresis.||||
33726532|NCT01039896|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33726533|NCT00619879|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726534|NCT02603042|||COHORT||PROSPECTIVE|||||||
33726535|NCT02138461|||COHORT||RETROSPECTIVE|||||||
33726536|NCT02396836|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33808629|NCT06341959|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"The intervention group will be provided with tools to facilitate dental contact and will be informed about the importance of regular dental visits. Participants are given the opportunity to receive an oral examination. Afterwards, each participant will receive brochures with oral hygiene instructions to take home. Participants will receive information about any identified oral pathology. A referral letter for the dentist and a report for the general practitioner will also be prepared to increase social influence. If the participant doesn't have a dentist, the participant will receive a list of contact information for dentists in the area.~In the control group, no oral examination will be performed. However, participants will be given a list of nearby dentists and flyers with oral hygiene instructions."|f|f|f|t
33808630|NCT02831699|||COHORT||PROSPECTIVE|||||||
33726537|NCT03960151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726538|NCT04640519|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"Multidisciplinary Team Nursing: transitions of care, motivational interview w/ tailored infographics~Pharmacy: medication education, adherence and titration~Physician: patient tailored risk factor control, post stroke complications~Integrated Approach: Home BP monitoring with remote support, Telehealth visits by each discipline, Tailored BP infographics, Patient Reported Outcomes (PROs)"|f|f|f|t
33726539|NCT04706845|||COHORT||PROSPECTIVE|||||||
33726540|NCT04147065|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase I study Tailored therapy (Clar S: 7 vs. 14 d triple therapy, Clar R: 7 vs. 14d BQT) vs. empirical therapy (7 or 14 d triple therapy) for H. pylori eradication~Phase 2 study Tailored therapy (Clar S: 7d triple therapy, Clar R: 7d BQT vs. empirical therapy (14d triple therapy)"||||
33726541|NCT02910167|||COHORT||PROSPECTIVE|||||||
33726542|NCT03393156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726543|NCT04592965|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33726544|NCT05172661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726545|NCT04047264|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33726546|NCT03642392|||COHORT||PROSPECTIVE|||||||
33726547|NCT04859868|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Subjects attend four visits of the experiment on four separate days. Each visit will be an hour and a half long. In the first visit, subjects will perform batteries of tests that involve balance, cognition, and determine motion perception at different current levels using a rotating chair. In the next three visits, researchers will test the Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair be either turning stimulation ON from beginning, or middle or by not turning ON (the order will be randomized).||||
33726548|NCT05617768|||OTHER||OTHER|||||||
33726549|NCT03042390|||CASE_CONTROL||RETROSPECTIVE|||||||
33726550|NCT05902039|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33808631|NCT03043443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects with Alcohol use disorder and sleep problems will be recruited and assigned randomly to the active treatment Melatonin or Placebo arms.|t|f|t|f
33808632|NCT03709849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808633|NCT01355172|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33808634|NCT04169776|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE|This study design was chosen as it is the most realistic and practical design for this pilot study. There is no blinding or masking in this pilot study.|This study is a prospective cohort pilot study not formally classified as a specific trial phase. The study will involve two Arms, with 15 participants in each Arm of the study. Arm 1 will recruit patients with steroid-sensitive frequently-relapsing idiopathic nephrotic syndrome. Arm 2 will recruit patients with steroid-resistant idiopathic nephrotic syndrome. All participants in both Arms of the study will perform daily transcutaneous auricular vagus nerve stimulation (taVNS) therapy for 5 minutes each day. The study period will be 6 months. The participants will be monitored for labwork and clinical evidence of nephrotic syndrome relapse, comparing the number of relapses and level or proteinuria in the 6 months before starting taVNS therapy to number of relapses and level of proteinuria in the 6 month study period.||||
33808635|NCT05162339|||COHORT||PROSPECTIVE|||||||
33808636|NCT06455059|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33808637|NCT04114019|||COHORT||PROSPECTIVE|||||||
33808638|NCT05069792|||COHORT||PROSPECTIVE|||||||
33808639|NCT02284607|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34112979|NCT05097430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This is not a double-blind study. Participants in the intervention arm will be aware that they are receiving the intervention but the investigators will not know as the randomization will take place within the software program.|Participants will be randomly assigned to either the intervention condition or treatment as usual (TAU) based on a 2:1 intervention:TAU ratio.|f|f|t|f
34112980|NCT06751056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112981|NCT04930432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34112982|NCT01875588|||COHORT||PROSPECTIVE|||||||
34112983|NCT04120766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, placebo controlled, randomized 1:1, single center study of nicorandil (20 mg by mouth daily) or placebo for 96 weeks.|Double-blind, placebo controlled, randomized 1:1, single center study of nicorandil (20 mg by mouth daily) or placebo for 96 weeks.|t|t|t|t
34112984|NCT06751407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34112985|NCT06055933|||COHORT||CROSS_SECTIONAL|||||||
34112986|NCT04692831|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This protocol will perform a first-in-human imaging trial of 89Zr-ss-pertuzumab.||||
34112987|NCT06601998|||OTHER||CROSS_SECTIONAL|||||||
34112988|NCT05647265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112989|NCT06750107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34112990|NCT05872932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112991|NCT04731467|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Parts A and C are non-randomized parts, part D is a randomized part.|||||
34112992|NCT03517917|||CASE_ONLY||PROSPECTIVE|||||||
34112993|NCT06748352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34112994|NCT06750952|NA|SINGLE_GROUP||TREATMENT||NONE||Ivonescimab combined with chemotherapy||||
34112995|NCT06749652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel model has been used. The randomization allocation sequence (1:1) has been generated using asymptomatic maximal randomization. Patients, data collectors and data analysts were blinded to the allocation. As blinding the surgeons during procedure was not possible, they were not involved in either data collection or analysis.|t|f|t|t
34112996|NCT06750432|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double bind|There will be 3 sequential escalating dose cohort groups. Dose groups are 350 mg, 700 mg, and 1400 mg administered as a single 60-minute infusion.|t|f|t|f
34112997|NCT06748898|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34112998|NCT04206319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34112999|NCT06749015|||COHORT||RETROSPECTIVE|||||||
34113000|NCT06748937|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113001|NCT06750237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113002|NCT06750185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113003|NCT06749509|||COHORT||PROSPECTIVE|||||||
34113004|NCT06748885|||COHORT||PROSPECTIVE|||||||
34113005|NCT06749756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113006|NCT06748105|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Protocol Design:~Participants will be randomized 1:1, with group assignments known to all. Dapagliflozin (10 mg/day) will be administered orally within 12 hours of glucocorticoid dosing. Adherence will be ensured through patient/family training and nursing reports.~Intervention Monitoring:~Daily glucose levels will be assessed via preprandial capillary measurements (three shifts) and fasting central glucose (6-8 hours fasting). Standard glycemic monitoring (SGM) will also be performed.~Definitions for Objectives:~Hyperglycemia (HIG): ≥2 readings ≥140 mg/dL (7.8 mmol/L) in 24 hours. Hyperglycemic Crisis (HC): ≥2 readings ≥180 mg/dL (\>10 mmol/L) in 24 hours. If insulin or other antidiabetic treatments are initiated, they will be allowed alongside dapagliflozin in the intervention arm, with their use documented.~Safety Monitoring:~Adverse events will be recorded for all groups. Follow-up will continue until discharge, 10 days, or whichever occurs first."||||
34113007|NCT06750978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized controlled trial with repeated measures design will be used. The study consists of three phases. (1) Baseline phase (2 weeks): Following eligibility screening and consent, all participants will install an app developed by the research team. The app will track and report participants daily smartphone usage and establish a baseline pattern of PSU. (2) Experimental phase (4 weeks): After the baseline data collection, participants will be randomized on a rolling basis into one of the four conditions (12 participants in each condition): Self-Reflection, Self-Reflection + Alternative Activity Engagement, Self-Reflection + Contingency Management, and Control. Participants daily smartphone usage, review of usage data, and/or evidence of alternative activity engagement will be recorded by the app and reported to the researcher. (3) Follow-up phase (2 weeks): The three intervention conditions will be withdrawn in this phase.||||
34113008|NCT06748807|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34113009|NCT06750588|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113010|NCT06750471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113011|NCT06749171|||COHORT||OTHER|||||||
34113012|NCT06749483|||COHORT||PROSPECTIVE|||||||
34113013|NCT06749561|||CASE_CONTROL||RETROSPECTIVE|||||||
34113014|NCT03189524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113015|NCT04369053|||COHORT||PROSPECTIVE|||||||
34113016|NCT06749405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"* Intervention Group: Patients managed using a transfusion algorithm based on Quantra®~* Control Group: Patients managed using a conventional transfusion algorithm"|t|f|f|f
34113017|NCT04989803|NA|SEQUENTIAL||TREATMENT||NONE||||||
33808640|NCT00259116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808641|NCT04176952|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are registered to receive either FOLFOX-A or AG depending on their age and performance status||||
33808642|NCT03483649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808643|NCT01265693|||COHORT||PROSPECTIVE|||||||
34113018|NCT06750497|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34113019|NCT06749197|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33808644|NCT05276999|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pragmatic public health study to test an integrated strep education and treatment program to reduce echo-detected burden of RHD||||
33808645|NCT02434276|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33726551|NCT05657665|||CASE_ONLY||PROSPECTIVE|||||||
33726552|NCT06302192|||COHORT||PROSPECTIVE|||||||
33726553|NCT01051128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726554|NCT00817167|RANDOMIZED|PARALLEL||||NONE||||||
33726555|NCT02063516|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33726556|NCT01506518|||COHORT||PROSPECTIVE|||||||
33726557|NCT05591014|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The sensitivity/specificity and diagnostic accuracy of clinicians will be compared before and after the use of novel ROTEM app. The performance of more experienced clinicians will be compared to those with little to no experience in ROTEM. Analysis will be done using a mixed effects model to account for clustering of measurements within clinician groups. Inter-rater reliability analysis will be done to assess the similarity within clinician groups using the ICC.||||
33726558|NCT03476304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726559|NCT05263154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
33726560|NCT04356963|NA|SINGLE_GROUP||TREATMENT||NONE|Interventions will take place in patient rooms with curtain pulled and sign to mask active intervention vs. control intervention from care providers.|Within-Subjects Design. All participants (single group, 1 arm) intended to complete all three sessions (interventions) in randomized order. At least 4 hours were required to pass between each session to allow for washout.||||
33726561|NCT02140658|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726562|NCT01317238|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33726563|NCT02319005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726564|NCT05102110|||CASE_CONTROL||PROSPECTIVE|||||||
33726565|NCT03510156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726566|NCT02187588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33726567|NCT05348382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726568|NCT03304171|||COHORT||PROSPECTIVE|||||||
33726569|NCT04190134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33808646|NCT02208843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808647|NCT04121715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808648|NCT02282254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808649|NCT02661958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808650|NCT03951259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113020|NCT06477107|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||"For the Phase I portion of the study subjects the order of the stimulation (active vs sham stimulation) in a single session will be randomized and counterbalanced across subjects.~For the Phase II portion of the study a cross-over design will be used and the subjects will be randomly assigned either to active or sham tDCS first, then they will cross over to the other treatment arm after 4-week period of washout."|t|f|f|t
34113021|NCT06486779|||COHORT||PROSPECTIVE|||||||
34113022|NCT06193928|||COHORT||PROSPECTIVE|||||||
34113023|NCT02749955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113024|NCT06749899|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|||||
34113025|NCT06750042|||OTHER||CROSS_SECTIONAL|||||||
34113026|NCT06749808|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34113027|NCT06749353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||PRE POST INTERVENTION STUDY||||
34113028|NCT06748755|||CASE_CONTROL||RETROSPECTIVE|||||||
34113029|NCT06748716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113030|NCT06750653|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Access to the randomization code will be strictly controlled.~The moisturizing products will be placed in identical cardboard boxes by a staff member not involved in the disease assessments so that investigators taking assessments will not be aware of which study arm participants were randomized to. Participants will be asked not to open the cardboard packaging until they leave the study site."|Subjects will act as their own control - they will be asked to apply the study moisturizer they are randomized to for one intervention period (4 weeks) and not to apply topical moisturizers for the other 4- week intervention period).|f|t|t|t
34113031|NCT04752774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113032|NCT05833789|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34113033|NCT03465865|||CASE_CONTROL||RETROSPECTIVE|||||||
34113034|NCT06748963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pre vs post, 2 group parallel study design|f|f|f|t
34113035|NCT06750289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Benralizumab and placebo will be supplied in identical Accessorised pre-filled syringe (APFS). Medium and high dose ICS-LABA will be supplied in identical inhalers, as appropriate for US and ex-US markets, and the maximum daily dose is the same for the 2 Investigational products (IPs) (2 doses/day).~Participants are not aware of the dose levels to which they are assigned. The Interactive Response Technology / Randomisation and Trial Supply Management (IRT/RTSM) will provide to the investigator(s) or pharmacist(s) the kit identification number to be allocated to the participant at the dispensing visit.~Routines for this will be described in the IRT/RTSM user manual that will be provided to each centre."|"Participants will be randomised 1:1 to one of the following arms:~* Medium-dose ICS-LABA + benralizumab~* High-dose ICS-LABA + placebo (benralizumab)"|t|t|t|t
34113036|NCT06751147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836971|NCT05534724|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The surgical operation will be the modified Lapidus arthrodesis of hallux valgus with/without an Akin or a Weil/Hohmann surgery fusion.~Post-operatively, patients will be randomized into one of the two groups:~* Group A (control intervention): immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO for 6 weeks, crutches and antithrombotic prophylaxis.~* Group B (experimental intervention): immediate post-operative complete weight-bearing with a VACOPASO for 6 weeks and antithrombotic prophylaxis."||||
33836972|NCT01979575|||COHORT||PROSPECTIVE|||||||
33726570|NCT02142127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726571|NCT05915767|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be divided into two groups. One group will take olive leaf tea, and the other group will receives no tea.||||
33726572|NCT01373749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836973|NCT00196469|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33836974|NCT05758467|||COHORT||CROSS_SECTIONAL|||||||
33836975|NCT06052527|||COHORT||PROSPECTIVE|||||||
33836976|NCT03826524|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836977|NCT03322839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808651|NCT04748341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The data will be collected at two points in time. 1st-time data will be collected as a pre-test before the educational intervention. The 2nd-time data will be collected after 6 weeks of educational intervention. Two facilitator evaluators will be trained regarding the scoring of each scale in a two-hour workshop before data collection. All the students were allotted code after allocation. Only the principal investigator knows the allocation status of each student code. The skill was tested through simulation scenarios in the skill lab. The facilitators, who assessed the student's skills, endure uninformed regarding the student's allocation status and sequence of the scenario in the pre-and post-data collection.|The study design is a Single-blind randomized control trial conducted in the College of Nursing, Allama Iqbal Medical College, Lahore, Pakistan. A sample size of 72 nursing students (36 in each group) will be taken through simple random sampling. The students allocated from each professional in group A and group B through the Lottery method. Allocation of participants was concealed using envelop method. A total of 6 weeks of intervention will be provided to both groups. Group A will be taught through the two steps traditional method (2 lectures/week + 1 skill lab/week). On the contrary Group B will learn through the 6-step method constituted 2 lecture/week + video + 2skill lab/week (1 session under instructor + 1 session for skill maintenance).|f|f|f|t
33808652|NCT00002090||||TREATMENT||||||||
33808653|NCT02980588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808654|NCT06348875|||COHORT||PROSPECTIVE|||||||
33808655|NCT02223728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113037|NCT06749847|RANDOMIZED|PARALLEL||SCREENING||NONE||This is a three-arm study||||
33808656|NCT03221881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808657|NCT04218084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind, Placebo-Controlled||t|t|t|t
33808658|NCT02629666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808659|NCT05215249|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized crossover study||||
33808660|NCT04295642|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808661|NCT02602548|||COHORT||PROSPECTIVE|||||||
33808662|NCT00084435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808663|NCT03510416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808664|NCT01752959|RANDOMIZED|PARALLEL||||NONE||||||
34039914|NCT03211676|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34039915|NCT04450992|||COHORT||PROSPECTIVE|||||||
34113038|NCT06750887|||COHORT||CROSS_SECTIONAL|||||||
34113039|NCT06748599|||COHORT||PROSPECTIVE|||||||
34113040|NCT06751251|||COHORT||PROSPECTIVE|||||||
34113041|NCT06749951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113042|NCT06749054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113043|NCT04667949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113044|NCT06748651|NA|SINGLE_GROUP||TREATMENT||NONE||The study will consist of two stages, during which a single treatment of Allocetra, will be administered via intra-articular injection into the target temporomandibular joint .||||
34113045|NCT02987530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113046|NCT06748742|||COHORT||PROSPECTIVE|||||||
34113047|NCT06749132|||COHORT||PROSPECTIVE|||||||
34113048|NCT06749821|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34113049|NCT06750679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113050|NCT06749600|||COHORT||OTHER|||||||
34113051|NCT06751264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113052|NCT06750900|||COHORT||CROSS_SECTIONAL|||||||
34113053|NCT06749145|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34113054|NCT06388954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients participated will be masked about the type of intervention, where (GA) patients will receive physical therapy program + sham transcutaneous auricular Vagus nerve stimulation, while patients in (GB) will receive true transcutaneous auricular Vagus nerve stimulation in addition to the same physical therapy program as (GA).|Single-blind, randomized controlled study.|t|f|f|f
34113055|NCT02143414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113056|NCT05390762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluations will be performed by blind operators of the program.||f|f|f|t
34113057|NCT06750718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded researcher will assess the patients during the trial, blinding will not be feasible for participants or therapists due to the layout of the VR therapy.|Fifty patients with mechanical neck pain patients will be randomly allocated into 2 equal groups; group (A) received VR neck-based sensorimotor training only, group (B) received comprehensive sensorimotor training only. (Parallel Group Two-Armed Comparative Randomized Controlled Trial)|f|f|f|t
34113058|NCT06750419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113059|NCT06749418|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113060|NCT06749041|||COHORT||OTHER|||||||
34113061|NCT06748313|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34113062|NCT06749236|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34113063|NCT06751134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039916|NCT04924361|||COHORT||PROSPECTIVE|||||||
34039917|NCT05799833|||CASE_CONTROL||PROSPECTIVE|||||||
34039918|NCT01582490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039919|NCT02512302|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039920|NCT00985387|||COHORT||PROSPECTIVE|||||||
34039921|NCT03138213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34039922|NCT05175404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039923|NCT06123091|||COHORT||PROSPECTIVE|||||||
34039924|NCT02433184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039925|NCT02611895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34039926|NCT05607784|||COHORT||OTHER|||||||
34039927|NCT04964050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039928|NCT00966992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039929|NCT01542242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113064|NCT06748534|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34113065|NCT06749834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34113066|NCT06751316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113067|NCT06748924|||COHORT||PROSPECTIVE|||||||
34039930|NCT03909230|||COHORT||PROSPECTIVE|||||||
33726573|NCT02689258|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33726574|NCT05698966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33726575|NCT03146988|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33726576|NCT00891137|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726577|NCT05993065|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33726578|NCT05017610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726579|NCT02858219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726580|NCT01243359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726581|NCT01068938|||COHORT||PROSPECTIVE|||||||
33726582|NCT06546254|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The investigators will employ a two provider system to ensure a double-blinded set-up. The first provider (Provider A) will open the allocation envelopes without the presence of the participant or second provider (Provider B).~Provider A will then enter the patient's room and introduce themselves. Provider A will place the speculum, and administer either the intervention, placebo, or control and then leave the room after injection-related bleeding has stopped. After 3 minutes, the second provider (Provider B) will enter the room to place the tenaculum and perform the endometrial biopsy and will be unaware of the participant's treatment arm.~A standardized script will be used with all participants: You may or not may feel a poke.~Both lidocaine and the control (normal saline) are odorless and clear, minimizing the risk of unblinding. All data will remain blinded until data analysis."|"The proposed study is a double-blind, triple arm, placebo-controlled randomized clinical trial. Participants will be recruited from Mount Sinai Hospital outpatient gynecology clinics. Recruitment, consent, randomization, procedure, and post-procedure survey will occur during the same visit. Each participant will be randomly assigned to one of three arms:~Each participant will be randomly assigned to one of three arms:~1. intervention (paracervical block - 10 cc 1% lidocaine with epinephrine)~2. placebo (10 cc paracervical injection of normal saline)~3. control (gently tapping the cervicovaginal junction with a capped needle)"|t|t|t|f
33726583|NCT03469479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726584|NCT04738110|||COHORT||RETROSPECTIVE|||||||
33726585|NCT02050282|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33726586|NCT00531232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726587|NCT00925418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726588|NCT05813158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients will be randomly allocated to one of the two groups by sealed closed envelop technique|We hypothesize that high volume low concentration ultrasound-guided Erector Spinae Plane block is going to be more effective than low volume high concentration in patients undergoing MRM. Many authors advocate increasing the volume of injection in fascial plane blocks to allow better spread of local anesthetic according to multiple studies|t|f|t|f
33726589|NCT03689166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded RCT|"Definition and design. Prospective, double-blind randomised study.~Population Pregnant women admitted for TPL between weeks 24.0 and 34.6 of gestation at the participating centre."|t|t|t|t
33726590|NCT03496142|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who will have prostate biopsy will be randomized 1:1 among transperineal or transrecal approach||||
33726591|NCT00233051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726592|NCT05202847|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Medical staff performing patient care, including pain management, and investigators who investigate and record observations and evaluations, and participants are kept unaware of group assignments.||t|t|t|t
33726593|NCT06383663|RANDOMIZED|PARALLEL||TREATMENT||NONE||Supraclavicular lymph node dissection combined with radiotherapy versus radiotherapy alone||||
33726594|NCT00164346|RANDOMIZED|PARALLEL||||SINGLE||||||
33726595|NCT01903304|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33726596|NCT04882007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|During the Double-blind phase all participants will be blinded to treatment assignment.||t|t|t|t
33726597|NCT05930665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726598|NCT04016545|||CASE_ONLY||OTHER|||||||
33726599|NCT02753699|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33726600|NCT00776646|RANDOMIZED|CROSSOVER||||NONE||||||
33726601|NCT04130399|NA|SINGLE_GROUP||TREATMENT||NONE||preoperative chemotherapy with FOLFIRINOX followed by SBRT in patients with resectable pancreatic cancer.||||
33726602|NCT02586896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726603|NCT00741481|||||PROSPECTIVE|||||||
33726604|NCT02124863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726605|NCT06197594|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Controlled trial||||
33726606|NCT00575055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726607|NCT00648596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726608|NCT05403879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808665|NCT02185794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808666|NCT06700070|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This substudy is not blinded.||||
33726609|NCT05111977|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33726610|NCT05744349|NA|SINGLE_GROUP||TREATMENT||NONE||After administration of anesthesia, surgery will be performed with the patient supine on the operating table and fracture will be analyzed with an image intensifier. In radius, the wire will be inserted by surgical drilling through Lister's tubercle or the radial styloid while in ulna, the wire will be inserted through the tip of the olecranon.||||
33726611|NCT04414709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726612|NCT00422266|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33726613|NCT05096507|||COHORT||PROSPECTIVE|||||||
33726614|NCT05252039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective, randomized, controlled, parallel-group, two-armed|f|f|f|t
33808667|NCT01217099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808668|NCT05100797|||OTHER||OTHER|||||||
33808669|NCT03213028|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33808670|NCT02326506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808671|NCT00252005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34113068|NCT06749717|||OTHER||CROSS_SECTIONAL|||||||
34113069|NCT06750536|||OTHER||PROSPECTIVE|||||||
34113070|NCT06700330|||COHORT||RETROSPECTIVE|||||||
33808672|NCT00223756|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33726615|NCT01113879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study used a single-subject, multiple-baseline design across behaviors. Following assessment and baseline procedures, participants completed 2 therapy periods: Block 1 was aphasia therapy alone, and Block 2 was aphasia therapy plus aerobic exercise or stretching.||||
33726616|NCT02869490|||COHORT||PROSPECTIVE|||||||
33726617|NCT01814735|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33726618|NCT03669120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726619|NCT01871610|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33726620|NCT03924258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726621|NCT02717988|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33726622|NCT04020133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113071|NCT06750250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726623|NCT01862887|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33726624|NCT04006665|||CASE_ONLY||PROSPECTIVE|||||||
33726625|NCT03022292|NA|SINGLE_GROUP||OTHER||NONE||||||
33726626|NCT04564612|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33726627|NCT02442778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113072|NCT06701357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113073|NCT06751446|RANDOMIZED|PARALLEL||OTHER||NONE||Intervention Group Control Group||||
33726628|NCT01419548|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726629|NCT04049942|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33726630|NCT04602637|||CASE_ONLY||RETROSPECTIVE|||||||
33726631|NCT02599181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726632|NCT06088433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726633|NCT03795675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726634|NCT03913091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726635|NCT05019924|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726636|NCT01015586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726637|NCT02860715|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33726638|NCT01274403|RANDOMIZED|||||NONE||||||
33726639|NCT00000644||||TREATMENT||DOUBLE||||||
33726640|NCT06122090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33726641|NCT00629785|||||RETROSPECTIVE|||||||
33726642|NCT05580341|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33726643|NCT03419728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113074|NCT06700616|||COHORT||PROSPECTIVE|||||||
34113075|NCT06700980|||OTHER||OTHER|||||||
34113076|NCT06748846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34113077|NCT06749496|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33726644|NCT02507635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726645|NCT02876900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726646|NCT02134873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726647|NCT05276245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726648|NCT04037319|||COHORT||PROSPECTIVE|||||||
33726649|NCT00805428|||CASE_CONTROL|||||||||
33726650|NCT02106728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726651|NCT04390581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726652|NCT01238614|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||f|f|f|t
33726653|NCT01716013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726654|NCT00291668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726655|NCT00243178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726656|NCT04112017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726657|NCT02758392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726658|NCT01542385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726659|NCT04707261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33726660|NCT02922270|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33726661|NCT05434806|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Jarlsberg cheese|Between-patients Response Surface Pathway (RSP)|f|f|t|f
33726662|NCT00199784|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33726663|NCT01484574|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726664|NCT04134780|||COHORT||PROSPECTIVE|||||||
33726665|NCT02818777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726666|NCT04329312|||COHORT||RETROSPECTIVE|||||||
33726667|NCT03371901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726668|NCT06030778|||OTHER||CROSS_SECTIONAL|||||||
33726669|NCT04527861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726670|NCT01212575|||CASE_CONTROL||RETROSPECTIVE|||||||
33726671|NCT05462028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome data will be collected by a research assistant who was blinded in group assignment.||f|f|f|t
33726672|NCT03911440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726673|NCT02076828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726674|NCT01611987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726675|NCT01644175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726676|NCT00001487||||TREATMENT||||||||
33726677|NCT05040581|NA|SINGLE_GROUP||PREVENTION||NONE||Objective 2 will be addressed using a single-group pre-post design (n=15).||||
33726678|NCT02372669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726679|NCT01859507|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33726680|NCT02159521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726681|NCT00870623|||COHORT||PROSPECTIVE|||||||
33726682|NCT04346472|||COHORT||RETROSPECTIVE|||||||
33726683|NCT02780804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726684|NCT01041872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726685|NCT05667623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726686|NCT02127359|||COHORT||PROSPECTIVE|||||||
33726687|NCT04368481|||OTHER||OTHER|||||||
33726688|NCT06274541|||COHORT||PROSPECTIVE|||||||
33726689|NCT01549964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808673|NCT04197791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33808674|NCT04373967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726690|NCT04426565|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The motivational enhancement interview, the individual psychotherapy, the group psychotherapy, the family therapy will be provided by our team members.||||
33726691|NCT02665208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33726692|NCT03897452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726693|NCT06186778|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33726694|NCT06321133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726695|NCT05540834|RANDOMIZED|PARALLEL||TREATMENT||NONE||A two stage study evaluating (1) safety and dose-finding of escalating Actilyse (tPA) doses, followed by (2) a randomised, controlled efficacy study of VET-guided Actilyse treatment + standard care VERSUS standard care alone.||||
33726696|NCT01500707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726697|NCT04800003|||CASE_ONLY||CROSS_SECTIONAL|||||||
33726698|NCT02631863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726699|NCT01900028|NA|SINGLE_GROUP||||NONE||||||
33726700|NCT04659746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726701|NCT00357188|NON_RANDOMIZED|PARALLEL||||NONE||||||
33726702|NCT01347138|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33726703|NCT00128921|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33726704|NCT02488603|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33726705|NCT05793463|||OTHER||PROSPECTIVE|||||||
33726706|NCT05129878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33726707|NCT04156568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726708|NCT04924036|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and investigators in the trial will be blinded.|This is a Prospective, Double Blinded, Placebo Controlled, Randomized, Cross-over trial.|t|f|t|f
33726709|NCT01297907|||COHORT||PROSPECTIVE|||||||
33726710|NCT01894789|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33808675|NCT01199991|||COHORT||CROSS_SECTIONAL|||||||
34113078|NCT06696716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808676|NCT01152229|||CASE_CONTROL||RETROSPECTIVE|||||||
33808677|NCT04767815|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808678|NCT01333449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808679|NCT06268782|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33808680|NCT03715985|NA|SEQUENTIAL||TREATMENT||NONE||Not a randomized study. 25 patients to be included. Group A) has not yet started standard treatment Group B) has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo.||||
33808681|NCT01503099|||CASE_CONTROL||PROSPECTIVE|||||||
34113079|NCT06697678|||COHORT||PROSPECTIVE|||||||
34113080|NCT06696781|||COHORT||PROSPECTIVE|||||||
34113081|NCT06749223|||CASE_ONLY||PROSPECTIVE|||||||
34113082|NCT06700044|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113083|NCT06750523|NA|SINGLE_GROUP||SCREENING||NONE||||||
34113084|NCT06566820|NA|SINGLE_GROUP||OTHER||NONE||||||
34113085|NCT02839161|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33726711|NCT03466476|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who meet enrollment criteria will be randomized to either the treatment group where they will receive their consensus tracpatch or be assigned to the control group where no wearable technology will be employed.||||
33726712|NCT00206869|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33726713|NCT02771990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808682|NCT03705572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33808683|NCT05538000|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808684|NCT03871439|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33836978|NCT03909490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836979|NCT06418321|||COHORT||PROSPECTIVE|||||||
34113086|NCT06750146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113087|NCT06749769|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34113088|NCT06750796|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||In this study, n=128 (64=control, 64=half swaddling group) mothers and infants who volunteered to participate in the study will be conducted in two groups as case and control, randomly.||||
34113089|NCT03956745|||OTHER||PROSPECTIVE|||||||
34113090|NCT06630650|||COHORT||PROSPECTIVE|||||||
34113091|NCT06750614|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34113092|NCT06749795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34113093|NCT06751095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34113094|NCT06694948|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33726714|NCT00265512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726715|NCT01701115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33726716|NCT03559712|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Using a collaborative care approach with the aid of telemedicine to treat children with ADHD||||
33726717|NCT03314727|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33726718|NCT03877627|RANDOMIZED|PARALLEL||TREATMENT||NONE||60 patients who were assessed negative by sentinel lymph node imaging combined with imaging were randomized to undergo pelvic and peritoneal lymphadenectomy.||||
33726719|NCT01124604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726720|NCT00370474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726721|NCT01571895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726722|NCT01909908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726723|NCT00732810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726724|NCT05777031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726725|NCT05963087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726726|NCT04975555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726727|NCT04127916|||CASE_ONLY||OTHER|||||||
33726728|NCT01909349|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33726729|NCT04398069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726730|NCT04477343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836980|NCT00224744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113095|NCT06751212|||COHORT||PROSPECTIVE|||||||
34113096|NCT06751069|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized waitlist control||||
34113097|NCT06748469|||CASE_CONTROL||PROSPECTIVE|||||||
34039931|NCT01391858|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34039932|NCT02338323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039933|NCT04145128||SEQUENTIAL||TREATMENT||NONE||||||
34039934|NCT00701584|||COHORT||PROSPECTIVE|||||||
34039935|NCT04513444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34039936|NCT06353373|||COHORT||RETROSPECTIVE|||||||
34039937|NCT06242431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"SPSIPB; The procedure will be carried out with the patient in the lateral decubitus position. After gently shifting the scapula laterally, the US probe is held sagittally at the upper corner of the scapula, and the 3rd rib and serratus posterior superior muscle are visualized. The block needle will be advanced in the cranio-caudal direction to enter between the serratus posterior superior and the 3rd rib. After confirming the block site, 30 ml of 0.25% concentration of marcaine (bupivacaine) will be used.~PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied."|t|f|f|f
34039938|NCT00629356|||CASE_CONTROL||RETROSPECTIVE|||||||
34039939|NCT00558948|||CASE_ONLY||CROSS_SECTIONAL|||||||
34039940|NCT00156780|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
34039941|NCT05941507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039942|NCT02604043|NA|SINGLE_GROUP||OTHER||NONE||||||
34039943|NCT05078892|||COHORT||PROSPECTIVE|||||||
34039944|NCT05531123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039945|NCT00371410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34039946|NCT04465669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||About 50 patients with clinical evidence of ischemic heart disease and / or a positive functional study and documented stable angina pectoris (Canadian cardiovascular society classification (CCS)1, 2, 3 or 4), or documented silent ischemia in de-novo, native, previously unstented vessel in Tyumen Cardiology Center,will be randomly assigned undergoing implantation of Orsiro stent or Resolute Integrity stent (in a 1:1 ratio).|t|f|f|f
34039947|NCT03776357|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34039948|NCT02441738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039949|NCT04142073|||COHORT||PROSPECTIVE|||||||
34039950|NCT00379717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039951|NCT00266292|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34039952|NCT03785522|||COHORT||PROSPECTIVE|||||||
34039953|NCT03930485|||COHORT||RETROSPECTIVE|||||||
34039954|NCT02641795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039955|NCT04655560|||OTHER||PROSPECTIVE|||||||
34039956|NCT06088680|||CASE_ONLY||RETROSPECTIVE|||||||
34039957|NCT00840749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039958|NCT03364660|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34039959|NCT02382575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039960|NCT03622125|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34039961|NCT02755103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039962|NCT02896634|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34039963|NCT06524050|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34039964|NCT03535792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, care provider and outcome assessor will not be informed with the medication used.|"Group F:~25 Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg).~Group N:~25 Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt)."|t|t|f|t
34039965|NCT00142831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34039966|NCT03892798|||COHORT||OTHER|||||||
34039967|NCT04785482|||COHORT||OTHER|||||||
34039968|NCT04698395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Allocation|f|t|f|t
34113098|NCT05645172|||COHORT||PROSPECTIVE|||||||
34113099|NCT06748872|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open label, multicenter, phase I study following a Bayesian optimal interval (BOIN) design for dose escalation||||
34113100|NCT06750367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113101|NCT06750640|||COHORT||CROSS_SECTIONAL|||||||
34039969|NCT06351891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039970|NCT06059287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039971|NCT01326260|||COHORT||RETROSPECTIVE|||||||
34039972|NCT05391347|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34039973|NCT02757001|||COHORT||PROSPECTIVE|||||||
34039974|NCT02444208|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34039975|NCT01731132|||COHORT||PROSPECTIVE|||||||
34113102|NCT03777657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113103|NCT06694454|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113104|NCT06124664|||COHORT||PROSPECTIVE|||||||
34113105|NCT04014348|||OTHER||PROSPECTIVE|||||||
34113106|NCT04743973|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113107|NCT06692192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113108|NCT05410145|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113109|NCT06697405|||CASE_CONTROL||RETROSPECTIVE|||||||
34113110|NCT03716739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34039976|NCT01768026|||COHORT||PROSPECTIVE|||||||
34039977|NCT05171504|||CASE_CONTROL||RETROSPECTIVE|||||||
34039978|NCT03274388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"Masking is not possible, since the intervention group receives exercise intervention in addition to protein-rich nutritional therapy."|parallel group, controlled pilot study||||
34039979|NCT01999920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113111|NCT06748118|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||The research is multicentric and randomized. The study intervention will be implemented in a stepped-wedge design with 10 steps, 10 healthcare facilities (clusters), 12 2-month periods, 1 2-month period including wash-out and training of healthcare professionals (intervention). The wash-out will prevent contamination between the two periods.|f|f|f|t
33808685|NCT06372340|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments regarding pelvic floor muscle strength will be conducted by an assessor blind to treatment allocation. The assessor will go through a profound assessment training program. Due to the nature of the intervention neither participants nor care providers can be blinded to allocation, but are strongly inculcated not to disclose the allocation status of the participant at the follow up assessments. An employee outside the research team will feed data into the computer in separate datasets so that the researchers can analyse data without having access to information about the allocation.|The participants will be allocated to experimental group(EG) or the control group(CG). Subjects in the experimental group (EG) will receive personalized pelvic floor muscle training guidance provided by the system, whereas subjects in the control group(CG) will exercise according to the handbook or oral guidance.|f|f|t|t
33808686|NCT04484376|||OTHER||RETROSPECTIVE|||||||
33808687|NCT05096182|||OTHER||PROSPECTIVE|||||||
33808688|NCT03485287|NA|SINGLE_GROUP||TREATMENT||NONE||Three sessions of MDMA-assisted therapy with flexible dose of MDMA (100 to 125 mg with optional supplemental half-dose)||||
33808689|NCT04559633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808690|NCT02106078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34039980|NCT04211688|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34039981|NCT03993626|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, phase 1b/2 safety; and efficacy using Simon Two-Stage analysis||||
34039982|NCT06254716|||COHORT||RETROSPECTIVE|||||||
34039983|NCT01872312|NA|SINGLE_GROUP||OTHER||NONE||||||
34039984|NCT00730483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039985|NCT01211834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34039986|NCT05519917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039987|NCT00486746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039988|NCT03775525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34039989|NCT05888662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039990|NCT02805920|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34039991|NCT02604992|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34039992|NCT00209261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34039993|NCT05503537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor does not know that the participant receives which treatment.|This study is randomized controlled trial which consist of three group. One group will be given generalized cardiac rehabilitation protocol. Second group will be given post-isometric relaxation technique along with generalized cardiac protocol and third group will be given static stretching along with generalized cardiac protocol. All the groups will be recruited concurrently.|f|f|f|t
34039994|NCT03506191|||COHORT||RETROSPECTIVE|||||||
34039995|NCT04622605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34039996|NCT01660633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113112|NCT06751394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113113|NCT06748794|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113114|NCT06698042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113115|NCT06749782|||COHORT||RETROSPECTIVE|||||||
34113116|NCT06750276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a single-blind, randomized, placebo-controlled study with up to 2 study intervention cohorts that are participant and investigator-blinded.|"The total duration of study participation for each participant in Cohorts A and B will be approximately 63 days (9 weeks) and will include an up to 28-day screening period, a 28-day treatment period, and a follow-up visit seven days following completion of treatment.~Assessments will be conducted as described in the SoA."|t|f|t|f
34113117|NCT06749873|||CASE_CROSSOVER||PROSPECTIVE|||||||
34113118|NCT06002113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34113119|NCT03698669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113120|NCT06750549|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization by site||||
34113121|NCT06749392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized controlled trial|f|f|t|t
34113122|NCT05083481|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113123|NCT03970057|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A randomisation algorithm on the HappyMUM website automatically assigned women to either the intervention (MoodUP) group or the control (HealthyMum) group in a 1:1 allocation ratio. A computer-generated message notified women of their group assignment. We aimed to blind women to use the active nature of the control condition. Due to the computer-based randomisation, the researchers and research assistants were unaware of the group assignment before allocation and remained blinded to the participants' group allocation throughout the trial, which ensured allocation concealment. We also blinded the group assignment to data collectors and analysts.||t|t|t|t
34113124|NCT06624657|||OTHER||RETROSPECTIVE|||||||
34113125|NCT06749626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113126|NCT01019343|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34113127|NCT06303297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113128|NCT06749548|||CASE_CONTROL||PROSPECTIVE|||||||
34113129|NCT06751225|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be fit into the one week replacement soft contact lens to wear for 3 weeks.||||
34113130|NCT05938296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113131|NCT06748222|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113132|NCT06748235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant will get separate treatment protocol and possible efforts will be put to mask the both group about the treatment|It will be randomized control trial in which non probability convenient sampling will be used. Two groups of 6-12 age will be formed in which participants will be randomly divided. Group A will be receive Group-Task-Oriented Training. Group B will be receive routine therapy|t|f|f|f
34113133|NCT06751186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113134|NCT02520791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113135|NCT06690294|||COHORT||PROSPECTIVE|||||||
34039997|NCT00916669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34039998|NCT05669105|||COHORT||PROSPECTIVE|||||||
34039999|NCT01321749|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34040000|NCT00514215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040001|NCT04980430|||OTHER||PROSPECTIVE|||||||
34040002|NCT06070467|||COHORT||PROSPECTIVE|||||||
34113136|NCT06628310|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34113137|NCT06072924|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Sham Controlled||||
34113138|NCT06751368|||COHORT||RETROSPECTIVE|||||||
34113139|NCT06299826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113140|NCT04071223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113141|NCT04153136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113142|NCT06626269|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113143|NCT06623630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113144|NCT06625320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113145|NCT06685783|||COHORT||PROSPECTIVE|||||||
34113146|NCT05319730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113147|NCT06685757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a 2-part trial; Part A will be randomized and placebo-controlled, and Part B will be open-label.||t|t|t|t
34113148|NCT06015529|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|blinded adjudication committee assessing endpoints|Pragmatic cluster-randomized trial||||
34113149|NCT06149481|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113150|NCT01799538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113151|NCT03141684|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113152|NCT06750029|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34113153|NCT03422848|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel-group RCT with two arms during 12 months. Subjects will be randomized to the water-intervention (in total 1.5 L increment daily on the top of habitual intake) and control groups (1:1) by computer-generated block randomization. Both groups will receive general life style advice (general oral and written advice on diet and physical activity).||||
34113154|NCT04339777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113155|NCT06444451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113156|NCT01829724|||COHORT||CROSS_SECTIONAL|||||||
34113157|NCT06547346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113158|NCT06748417|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
34113159|NCT06750406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34113160|NCT06751199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113161|NCT06679985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113162|NCT06749470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, placebo-controlled, multicenter clinical study.|t|t|t|t
34113163|NCT04767568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113164|NCT06750575|||CASE_ONLY||PROSPECTIVE|||||||
34113165|NCT02790931|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34113166|NCT06681766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113167|NCT06748300|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34113168|NCT06750315|||OTHER||CROSS_SECTIONAL|||||||
34113169|NCT06141473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-dummy||t|t|t|t
34113170|NCT05034952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113171|NCT02320435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113172|NCT06749288|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' assigned study products. Participants are blinded to the study product they received.|Participants will be stratified then randomized to one of the study arms. Each participant will have an equal chance of being assigned to each study arm.|t|f|t|f
34113173|NCT05997082|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking since there is only 1 group.|||||
34113174|NCT06748911|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34113175|NCT06749028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In addition to the parties commonly masked in this clinical trial(e.g., participants, investigators, and outcome assessors), other parties be masked include:~1. Data Analysts: If feasible, data analysts will be blinded to the intervention groups during data analysis to reduce bias in interpreting results.~2. Study Coordinators or Site Staff: Those responsible for enrolling participants or managing study logistics will be masked to intervention assignments to prevent unintentional influence on participant behavior.~3. Pharmacists or Treatment Preparers: Pharmacists will be blinded to the allocation of active versus placebo treatments~4. Regulatory Reviewers or Monitors: External reviewers or monitors who audit the study will be masked to treatment allocation to ensure unbiased oversight.~5. Statistical Reviewers for Interim Analyses: the statisticians conducting these will be masked to group allocations to preserve trial integrity."|"PICOT~* Population:Adult patients ≥ 18 years old diagnosed with hypertriglyceridemia, defined as triglycerides \>150 mg/dL.~* Intervention: Omega-3 + phospholipids.~* Comparator: Omega-3.~* Outcome: Reduction in triglyceride levels and inflammatory markers, improvement in HOMA-IR index, and Omega Index.~* Time:12 weeks."|t|t|t|t
34113176|NCT06750328|||COHORT||RETROSPECTIVE|||||||
34113177|NCT05825469|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113178|NCT06750705|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34113179|NCT06751004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113180|NCT06683846|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, multi-cohort||||
34113181|NCT06750835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113182|NCT05245032|||COHORT||PROSPECTIVE|||||||
34113183|NCT06748287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113184|NCT05652504|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34113185|NCT03117946|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113186|NCT03253172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113187|NCT04751370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113188|NCT00001975|||COHORT||PROSPECTIVE|||||||
34113189|NCT03896503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113190|NCT04181060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113191|NCT00039676|||FAMILY_BASED||PROSPECTIVE|||||||
34113192|NCT05751668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34113193|NCT02339012|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113194|NCT02014246|||CASE_CONTROL||OTHER|||||||
34113195|NCT03964532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113196|NCT02723955|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33726731|NCT00987116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726732|NCT05868070|RANDOMIZED|PARALLEL||OTHER||SINGLE|The group allocation will be performed by an independent researcher who is not involved in the evaluation of treatment outcomes and be concealed to physiotherapists who are involved in the evaluation of treatment outcomes. The participants and in-bed cycling/stepping intervention provider will be instructed not to disclose the allocation to the evaluator.||f|f|f|t
33726733|NCT00099125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726734|NCT01999595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The group allocation for each participant was sealed in an envelope prepared by an investigator. Just before the start of the second visit, a second investigator opened the envelope to confirm the allocation of TENS groups for individual participants and applied the TENS. For better blinding, a third investigator assessed the blunt pressure pain threshold (BPPT) for the baseline value.|"One hundred eighty participants (equal number of females and males, Fig. 1) were randomly assigned into six groups with the following TENS characteristics. (1) Group 1:~control group, (2) group 2: sham group, (3) group 3: high frequency (80 pps)/large pad (5 cm x 10 cm) group, (4) group 4: low frequency (3 pps)/large pad (5 cm x 10 cm) group, (5) group 5: high frequency (80 pps)/small pad (5 cm x 2.5 cm) group, and (6) group 6: low frequency (3 pps)/small pad (5 cm x 2.5 cm) group."|t|f|t|f
33726735|NCT03167879|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This 3-arm cluster RCT will compare (1) a multi-component intervention that integrates safer conception counseling (SCC) into existing family planning (FP) services and provides intensive training and supervision (SCC1), (2) the integration of the same intervention as in (1) into FP services but with a less intensive training and supervision model that mimics the Ministry of Health approach, and (3) usual care FP services, at 6 HIV clinics (2 per arm) operated by TASO Uganda. The model is factorial because the two active intervention arms will be combined and compared to usual care in some analyses.||||
34113197|NCT04470726|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects will be treated once, twice or three times at 21 days interval and lesions examined at the end of the study investigators will evaluate the lesion surface area for clearance and excise the original lesion area for histological assessment.||||
33726736|NCT04116918|||COHORT||PROSPECTIVE|||||||
33726737|NCT05719012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808691|NCT06272591|||COHORT||PROSPECTIVE|||||||
33808692|NCT00573105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808693|NCT01123174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33808694|NCT00703391|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34113198|NCT06750380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113199|NCT05063565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113200|NCT05554393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113201|NCT06362226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113202|NCT05702060|RANDOMIZED|PARALLEL||OTHER||NONE||Conventional Right Radial Artery Approach and Left Distal Radial Artery Approach for Coronary Angiography and Interventions||||
34113203|NCT06750445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113204|NCT00942981|||COHORT||CROSS_SECTIONAL|||||||
34113205|NCT04847453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113206|NCT04038957|NA|SINGLE_GROUP||TREATMENT||NONE|open label|This is a single-site, open-label, flexibly-dosed study||||
34113207|NCT06748768|||CASE_CONTROL||PROSPECTIVE|||||||
34113208|NCT02843191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113209|NCT06684483|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113210|NCT06750458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113211|NCT06749106|||OTHER||PROSPECTIVE|||||||
34113212|NCT05231018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113213|NCT05569967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113214|NCT06306014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A: None (Open-label). Part B: Double-blind.|Part A = Single Arm open label. Part B = Randomised, placebo-controlled, double-blind.|t|t|t|t
34113215|NCT05421325|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||A randomized, double-blind, placebo-controlled trial|t|t|t|t
33808695|NCT01648803|||CASE_ONLY||PROSPECTIVE|||||||
33808696|NCT04881305|||CASE_CONTROL||RETROSPECTIVE|||||||
34113216|NCT05282121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113217|NCT05593341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34113218|NCT04736199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808697|NCT02441374|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34113219|NCT04366310|||COHORT||PROSPECTIVE|||||||
33808698|NCT05715632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808699|NCT04675684|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be 1:1 randomized into either a recovery group (experimental) or a control group (no intervention).||||
33808700|NCT02879136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33808701|NCT03227510|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33808702|NCT02565966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34113220|NCT05908773|NA|SINGLE_GROUP||OTHER||NONE||||||
34113221|NCT06315543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113222|NCT05948709|RANDOMIZED|PARALLEL||OTHER||NONE||The investigators will recruit 200 older adults and randomize half of them to receive additional incentives. The other half will not receive additional incentives. The investigators will track step count of these two groups for 6 weeks using Fitbits and Fitabase software.||||
34113223|NCT05016882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomised, double-blind, active and placebo-controlled, double-dummy, parallel group, multinational trial investigating NNC0194-0499 at 3 different dose levels when co administered with semaglutide|t|t|t|t
34113224|NCT05693935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113225|NCT06137170|||COHORT||RETROSPECTIVE|||||||
34113226|NCT04514107|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33808703|NCT02027259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808704|NCT02915783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808705|NCT00764166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808706|NCT01052935|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34113227|NCT00837369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113228|NCT05112601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808707|NCT02509858|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808708|NCT02158806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical placebo with only difference being unique code on bottle containing product.||t|t|t|t
33808709|NCT02634307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808710|NCT02265107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33808711|NCT03723031|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33808712|NCT03065400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808713|NCT03567278|NA|SINGLE_GROUP||TREATMENT||NONE||Medical Device Study||||
33808714|NCT03072888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808715|NCT02040870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150135|NCT05792566|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"There are 3 phases of this study:~1. Participants will be shown features from the ATOMIC app and asked to discuss what features they like and what additional content, features and functionalities they would want for a specific PA app focused on pediatric cancer survivors. This information will be used to adapt the app.~2. Use a talking aloud approach as they encounter issues with completing a series of tasks related to using the app. The design team and the research team will develop a new iteration of the platform that will then be vetted by our app creation committee and the next interview participants.~3. Real Life Usability Testing. 6 pediatric cancer survivors. Individualized aerobic and resistance exercise intervention. The social-cognitive-theory-based mobile app will support the exercise intervention. One-on-one messaging chats with a PA coach through the mobile app will facilitate exercise goal establishment and attainment."||||
33808716|NCT00775892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808717|NCT00344916|RANDOMIZED|CROSSOVER||||SINGLE||||||
33808718|NCT05127902|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040003|NCT01109537|||CASE_CONTROL||PROSPECTIVE|||||||
34040004|NCT00204776|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34040005|NCT03386552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040006|NCT05673980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040007|NCT02130362|||COHORT||PROSPECTIVE|||||||
34040008|NCT02775682|||COHORT||PROSPECTIVE|||||||
34040009|NCT03468517|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34040010|NCT01729390|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34040011|NCT05067413|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34040012|NCT05118672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Group 1: Eurofarma Laboratórios SA paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg FDC (experimental drug).~Group 2: Placebo."|"Adult participants (aged ≥ 18 years) of both sexes with common cold or flu will be randomized in a 1:1 ratio to receive the experimental drug (paracetamol 500 mg / fexofenadine 60 mg / phenylephrine 20 mg) or placebo, in the dosage of one (01) film-coated tablet every eight (08) hours, for 3 to 7 days.~Randomized participants will be instructed to use the study treatment uninterruptedly, every eight (08) hours, for three (03) days, and may, after that, discontinue treatment at any time if they experience no more symptoms."|t|f|t|f
34040013|NCT00803608|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34040014|NCT01620138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040015|NCT03131843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, parents, care providers and outcomes assessors will not be aware of whether the participant was swabbed in the location of the vaccine injection. Only the investigator will know where alcohol was applied on the skin relative to the vaccine injection site.|Parallel randomized controlled trial|t|t|f|t
34040016|NCT03596801|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040017|NCT03225469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The patients and the associated family members know which group they are assigned，while the colonoscopist, information collector are blinded to group assignment.|reinforced family member education group, regular education (control) group|f|f|t|t
34040018|NCT04744194|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34040019|NCT02303795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040020|NCT02127151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040021|NCT05536973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040022|NCT01669863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040023|NCT00356382|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34040024|NCT02673736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040025|NCT02172443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040026|NCT05488977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040027|NCT02269137|||COHORT|||||||||
34040028|NCT02413905|||CASE_CONTROL||PROSPECTIVE|||||||
34040029|NCT04302870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040030|NCT00288535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040031|NCT01694160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040032|NCT02183324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040033|NCT05694780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34040034|NCT00191581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040035|NCT06575712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040036|NCT04868825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the graft performing sub-investigator and the study coordinator are un-blinded to subjects allocation - semi double blinded study.|prospective, randomized, semi double blinded with blinded assessments study comparing patients grafted with Ivory Dentin Graft (study arm) and patients grafted with OsteoBiol Gen Os (control arm) for alveolar ridge preservation following tooth extraction.|t|f|f|t
34040037|NCT03765489|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34040038|NCT03231072|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808719|NCT06152718|||CASE_ONLY||PROSPECTIVE|||||||
33808720|NCT02417285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808721|NCT03331536|||COHORT||PROSPECTIVE|||||||
33808722|NCT06466759|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33808723|NCT02725138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808724|NCT01437410|||CASE_CONTROL||RETROSPECTIVE|||||||
33808725|NCT00087256|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33808726|NCT04696016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808727|NCT02325466|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33836981|NCT01246999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113229|NCT05946109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A computer algorithm will be used to generate the random allocation sequence. Participants will be randomized in a 1:1 ratio, using permuted block randomization into one of the three parallel groups. Randomization will be done centrally by an interactive web response system. Once the participants are found eligible for the trial, they can be randomized. This will generate a unique study randomization number and the treatment arm label (A professionals, B volunteers, C control) to which the participant is randomized. An accountability log with the corresponding label will be kept by the PI or delegated person to ensure that allocation was successfully performed. Participants will be scheduled to receive their randomisation within one week of eligibility assessment.|This project aims to investigate the effect on physical functioning, cognition, loneliness, self-management, subjective health and meaningful activities of frail older adults, provided by professionals (study condition 1) or provided by trained volunteers (study condition 2) or when not provided (controls, study condition 3). Since it is hypothesized that volunteers will reduce health care cost, the investigators will assess health care utilization in the three groups. Therefore, a RCT will be used.. The duration of the intervention is 24 weeks and assessments will be done before, after and at 48 weeks follow-up. The trial is designed in line with The Geriatric ICF Core Set reflecting health-related problems in community-living older adults aged 75 years and older without dementia. To limit possible bias due to non-specific treatment effects, all participants allocated to both intervention arms will receive an identical amount of treatment, securing balanced treatment arms.|f|t|t|t
34113230|NCT06049212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113231|NCT06362265|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113232|NCT06193863|||COHORT||PROSPECTIVE|||||||
34113233|NCT05610163|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113234|NCT05559580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, investigators, central reviewers, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial will remain blinded regarding the randomised treatment assignments until the database is declared ready for analysis according to the sponsor's Standard Operating Procedures (SOPs).||t|t|t|t
34113235|NCT00084305|||COHORT||CROSS_SECTIONAL|||||||
34113236|NCT02803437|||COHORT||PROSPECTIVE|||||||
34113237|NCT05832151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113238|NCT05911841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113239|NCT05977322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113240|NCT01744782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113241|NCT04071236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113242|NCT06748547|||CASE_CONTROL||PROSPECTIVE|||||||
34113243|NCT01036581|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113244|NCT06407830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113245|NCT05458297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113246|NCT02926859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113247|NCT05548881|||COHORT||PROSPECTIVE|||||||
34113248|NCT01333969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34113249|NCT03737981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113250|NCT05612971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113251|NCT02281747|||COHORT||RETROSPECTIVE|||||||
34113252|NCT00397111|||COHORT||OTHER|||||||
34113253|NCT05196035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113254|NCT04103346|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|filtration units with or without filters. filters are placed by research assistant from the environmental college and researchers performing the health outcomes are blinded to the condition (sham or active filtration) along with the subject.|crossover of active filtration in subject's residence with a home filtration unit (Holmes air filtration unit Model HAP8650B-NU-1) versus an inactive sham filtration|t|f|t|t
34113255|NCT06128499|||OTHER||CROSS_SECTIONAL|||||||
34113256|NCT06478459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726738|NCT05215743|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Combined antioxidant therapy (CAT) and placebo|t|f|t|t
33726739|NCT05516082|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||All participants received Lens A and then Lens B in fixed-sequence order.|t|f|f|f
33726740|NCT01453244|||COHORT|||||||||
33726741|NCT00546611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726742|NCT01957748|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33726743|NCT04014257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726744|NCT01577667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33726745|NCT00152581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726746|NCT02018458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726747|NCT04328974|||COHORT||PROSPECTIVE|||||||
33726748|NCT06207539|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33726749|NCT00719004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726750|NCT00084669|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33726751|NCT01567397|||COHORT||PROSPECTIVE|||||||
33726752|NCT00181207|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33726753|NCT01755923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726754|NCT02750891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726755|NCT06083350|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Triple blind, the unique codes of the intervention and placebo are known only to the person in charge of the intervention manufacturer (Anginute), not to the study implementors, investigators, subjects, data collectors and analysts, and are only unblinded by the manufacturer after the study is completed.||t|t|t|t
33726756|NCT01531387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726757|NCT02978742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726758|NCT06414174|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This study involves two group of participants to receive specific intervention. One of the group will be using split septum mechanism for their needleless connector, while the other group will use mechanical valve mechanism for their needleless connector. Both group will be assessed and monitored closely for the incidence of infection|t|f|t|f
33726759|NCT00563953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726760|NCT03741036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726761|NCT03045965|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking of the intervention is planned to include the one-year follow-up of menopausal symptoms.||t|f|f|f
33726762|NCT05278429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726763|NCT03434041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726764|NCT00208195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726765|NCT00453999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726766|NCT02302651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726767|NCT03898349|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Patients and providers did not know which facilitation group they were in|Four facilities were randomized to serve as intervention sites and receive our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance. An additional three comparison sites received usual implementation of Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls run by the Office of Connected Care. Two control sites did not receive Annie.|t|t|f|f
33726768|NCT05805761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726769|NCT05464654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The pathologist and colposcopists were blinded to the treatment the participants received.|"A randomised clinical trial was conducted in 136 postmenopausal women with GSM from the peri-postmenopause and bone metabolism clinic of the Regional Hospital October 1st  of ISSSTE, Mexico, from June to December 2021. The control group (n=64) received local estrogen-based hormonal therapy, applied to the vagina mucosa on Monday, Wednesday, and Friday of each week, for 3 months, while the experimental group (n=72) received local salmon PDRNs on vaginal suppositories, applied solely for six days every night in the first week. The follow-up assessment was done after 3 months."|f|f|f|t
33726770|NCT02138903|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33726771|NCT01936935|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33726772|NCT01884610|||COHORT||PROSPECTIVE|||||||
33726773|NCT02017314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726774|NCT03412084|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726775|NCT02508025|||COHORT||RETROSPECTIVE|||||||
33726776|NCT03561415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726777|NCT06169280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Both groups will receive up to 6 doses of NSC-CRAd-S-pk7 in addition to standard of care radiation and temozolomide. Every other patient enrolled (beginning with the first patient) will undergo oral administration of N-acetylcysteine amide (NACA).||||
33726778|NCT00313612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726779|NCT02791620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726780|NCT02391103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33726781|NCT03278964|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and investigators do not know which orbital decompression technique will be done until 6 months of postoperative period.|Patients with Graves orbitopathy will be randomly divided in two groups. One group will be submmited to orbital decompression by antro-ethmoidal technique. The other group will be treated by lateral wall technique.|t|f|t|t
33726782|NCT00161707|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33726783|NCT06363565|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33726784|NCT03375541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized control trial||||
33726785|NCT03414463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726786|NCT02417051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726787|NCT01308450|||CASE_ONLY||CROSS_SECTIONAL|||||||
33726788|NCT01164449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726789|NCT00573755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726790|NCT01561352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726791|NCT04903327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726792|NCT06097208|||COHORT||RETROSPECTIVE|||||||
33726793|NCT02331225|||COHORT||CROSS_SECTIONAL|||||||
33726794|NCT04248595|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726795|NCT03464006|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single centre, randomized controlled trial.||||
33808728|NCT03609099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind treatment||t|t|t|f
33726796|NCT00117559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726797|NCT05993676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726798|NCT04270916|||COHORT||CROSS_SECTIONAL|||||||
33726799|NCT00067678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33726800|NCT03025828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726801|NCT02811224|||CASE_CONTROL||PROSPECTIVE|||||||
33726802|NCT00603746|RANDOMIZED|PARALLEL||TREATMENT||||||||
33726803|NCT00811577|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33726804|NCT05252611|||OTHER||CROSS_SECTIONAL|||||||
33726805|NCT05433779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726806|NCT02653651|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33726807|NCT05563064|NA|SINGLE_GROUP||TREATMENT||NONE||A randomized, open, prospective, multicenter clinical trial to evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets)||||
33726808|NCT01948739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726809|NCT00378066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726810|NCT02918851|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33726811|NCT05369858|NA|SINGLE_GROUP||OTHER||NONE||||||
33726812|NCT04820790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33726813|NCT03468907|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|The care provider, participant, investigator and outcomes assessor all konw the process.|Pregnant mothers who opt for antiviral therapy will start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy will be discontinued in intrapartum or at postpartum 6 weeks.||||
33726814|NCT05128175|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726815|NCT00624962|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33726816|NCT02529137|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808729|NCT00162318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808730|NCT02765126|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33808731|NCT03690804|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808732|NCT03254472|||CASE_ONLY||RETROSPECTIVE|||||||
34113257|NCT06273241|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This study will be an open label study. Participants will be selected from an existing database of the Institute of Pharmacology Greifswald.|This is an unblinded, randomized, prospective study comparing berberine intake in fasted condition and after a high or low caloric meal in a cross-over design.||||
34113258|NCT05889182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113259|NCT05391893|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A treatment protocol using oral and IV diltiazem has been implemented. We will compare admission rates, time to heart rate control, and hypotension between the protocol group and patients receiving traditional treatments for atrial fibrillation with rapid ventricular response||||
34113260|NCT05116709|NA|SEQUENTIAL||TREATMENT||NONE||||||
34113261|NCT06523621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113262|NCT01841736|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34113263|NCT06750094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113264|NCT06055439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113265|NCT04579224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113266|NCT05966519|||CASE_ONLY||PROSPECTIVE|||||||
34113267|NCT05894694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113268|NCT06160986|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113269|NCT06561165|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Participants will be randomized and counterbalanced to arm 1 or arm 2.|t|f|f|f
34113270|NCT03513614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113271|NCT06749366|||CASE_ONLY||CROSS_SECTIONAL|||||||
34113272|NCT06323161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113273|NCT04305431|NA|SEQUENTIAL||PREVENTION||NONE||||||
34113274|NCT04360941|NA|SINGLE_GROUP||OTHER||NONE||"This is a two-part phase 1b trial of induction palbociclib with the addition of avelumab. In Part A of the study, the MTD of the study will be determined using a 3+3 design. There will be a 1-week interval between the first and second patients started at each dose level.~In Part B, the MTD dose level will be expanded."||||
34113275|NCT00715819|||||PROSPECTIVE|||||||
34113276|NCT05999799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigator are blinded to study intervention.|This is a dose finding, placebo-controlled study where participants will be randomized to receive either GSK1070806 or placebo.|t|f|t|f
34113277|NCT00601900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113278|NCT05161481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34113279|NCT02752035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113280|NCT03667196|||COHORT||PROSPECTIVE|||||||
34113281|NCT05827926|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34113282|NCT03056040|NA|PARALLEL||TREATMENT||NONE||||||
34113283|NCT03253705|||OTHER||OTHER|||||||
34113284|NCT06456762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113285|NCT05372627|||CASE_ONLY||PROSPECTIVE|||||||
34113286|NCT04899661|||COHORT||PROSPECTIVE|||||||
34113287|NCT06130683|||OTHER||PROSPECTIVE|||||||
34113288|NCT01712672|||CASE_ONLY||OTHER|||||||
34113289|NCT05225922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808733|NCT05018143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes evaluator will be blinded to randomization.|"The investigators will adapt a life skills intervention to increase the desire to live and reduce suicide ideation among at-risk emerging adult sexual minorities (EASM). STARS will embed components of the Safety Plan Intervention and modules to promote coping with discrimination, social support, and positive affect. We will pilot test STARS in a racially/ethnically diverse sample of 60 EASM who report past-month suicidal ideation. Eligible participants will provide informed consent and complete a Safety Planning Intervention with a licensed clinician. They then will be randomized to the control condition (CC, n = 30) or STARS (n = 30). The investigators will follow participants for 6 months, with evaluations at 2, 4, and 6 months. Primary outcomes will be preliminary efficacy outcomes of suicidal ideation and behavior and hypothesized mechanisms of change (improved coping with discrimination, social support, positive affect) to estimate critical parameters for a future trial."|f|f|f|t
33808734|NCT00355745|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808735|NCT06297057|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808736|NCT04740944|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33808737|NCT03154736|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33808738|NCT04343898|||COHORT||OTHER|||||||
33808739|NCT00349232|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33836982|NCT03715777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113290|NCT06479811|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113291|NCT05089630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113292|NCT01148381|||COHORT||CROSS_SECTIONAL|||||||
34113293|NCT01306084|||OTHER||PROSPECTIVE|||||||
34113294|NCT06048120|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE||This study will be conducted in a single-center, single-blind, randomized, placebo-controlled, group-comparison, dose escalation design|t|f|f|f
34113295|NCT04392037|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be treated with iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd)||||
34113296|NCT05858593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be masked to which study condition they are assigned to.||t|f|f|f
33838221|NCT05222594|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113297|NCT00334815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113298|NCT01362803|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113299|NCT03191149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113300|NCT06010914|||COHORT||PROSPECTIVE|||||||
33838222|NCT03622970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838223|NCT02673632|||COHORT||PROSPECTIVE|||||||
34113301|NCT06226883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113302|NCT06484868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113303|NCT05479812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113304|NCT04708418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathologists||f|f|f|t
34113305|NCT05291091|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34113306|NCT06749431|||COHORT||PROSPECTIVE|||||||
34113307|NCT06751173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808740|NCT04874649|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Thirty school-age children with asthma aged 7 - 12 years old who were admitted at the outpatient examination room, Phramongkutklao Hospital, divided into 2 groups. The first group was 15 individuals trained with sustained maximal inspiration (SMI) breathing exercise while the second group was 15 individuals training with balloon-blowing breathing exercise. Participants were required to complete breathing exercise 5 times per week for 8 weeks. Physiological characteristics data and pulmonary function variables were comparatively analyzed before and after training. The dependent variables between pre-test and post-test were analyzed by a paired t-test. Independent t-test was used to compare the variables between groups. Differences were considered to be significant at p \< .05.||||
33808741|NCT06298266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808742|NCT04441775|||COHORT||OTHER|||||||
33808743|NCT03098199|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113308|NCT06161116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34113309|NCT04242095|||COHORT||PROSPECTIVE|||||||
34113310|NCT06750120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113311|NCT06383676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study participants are unaware of their assigned group|The study was planned as a randomized controlled study|t|f|f|f
34113312|NCT00001778|||COHORT||PROSPECTIVE|||||||
34113313|NCT04822181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Sponsor staff involved in the clinical trial is masked according to company standard procedures~The trial has two parts, a part 1 and a part 2, in part 2 sponsor will be unblinded"||t|f|t|f
34113314|NCT06287801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcomes assessor team will be blinded to the intervention assignments of participants. Due to the nature of the intervention, the participants, the investigator, and the care providers are unable to be blinded to the participant assignments.|Feasibility of a clinical comparative effectiveness trial|f|f|f|t
34113315|NCT04770909|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||2 (incentives for dietary self-monitoring: yes vs. no) x 2 (incentives for weight loss: yes vs. no)|f|f|f|t
34113316|NCT04256941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113317|NCT05950945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113318|NCT05549258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113319|NCT06152003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent assessors will be used to measure study outcomes of the RCT at follow-up assessments.||f|f|f|t
34113320|NCT04741542|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113321|NCT06748404|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a phase 2, randomized, open-label, single-center clinical trial that will assess the efficacy of TriCalm Hydrogel® in treating pruritus related to ICIs. Patients will be randomized 1:1 to receive 2 cycles of TriCalm Hydrogel® versus one cycle of topical corticosteroid followed by one cycle of TriCalm Hydrogel®. A randomized comparison of the change in mean NRS scores between each treatment arm will be performed. Patients will be stratified by 3-week and 4-week ICI cycles. Efficacy and safety outcomes will be assessed over a period of 2 cycles of ICI therapy ranging 6-8 weeks.||||
34113322|NCT06751160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113323|NCT06751082|||COHORT||PROSPECTIVE|||||||
34113324|NCT06410534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113325|NCT00001373|||COHORT||PROSPECTIVE|||||||
34113326|NCT00902044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113327|NCT04418466|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113328|NCT05627362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113329|NCT05777889|||COHORT||PROSPECTIVE|||||||
34113330|NCT04340141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113331|NCT06389942|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34113332|NCT05918211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active and matching placebo tablets will be identical in appearance.|Randomized, double-blind, placebo-controlled safety and efficacy study of udenafil versus placebo of approximately 436 subjects enrolled equally between the two arms (udenafil and placebo)|t|t|t|t
34113333|NCT04781309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113334|NCT05171387|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment period: The start of the treatment period is defined by the first administration of the study treatment (Day 1). The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally BID at about 12- hour intervals. All participants must also continue ADT treatment if they have not had bilateral orchiectomy. Doses of study treatment may be modified in case of clinically significant toxicities. Participants will receive study treatment until any of the discontinuation criteria are met.||||
34113335|NCT02116764|||COHORT||PROSPECTIVE|||||||
34113336|NCT05982015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113337|NCT04530565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34113338|NCT05794581|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34113339|NCT04976634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113340|NCT05574946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113341|NCT05753306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113342|NCT04927741|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Participant will remain blinded until completion of their study activities|1:1:1 Randomization|t|f|f|f
33808744|NCT04998552|RANDOMIZED|PARALLEL||OTHER||NONE||The study is an open-label, longitudinal, prospective randomized, superiority clinical trial.||||
33808745|NCT02436694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113343|NCT04898777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113344|NCT04963803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34113345|NCT02325154|NA|SINGLE_GROUP||OTHER||NONE||||||
34113346|NCT05674240|||COHORT||PROSPECTIVE|||||||
34113347|NCT04028687|||COHORT||PROSPECTIVE|||||||
34113348|NCT02522611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113349|NCT05473429|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34113350|NCT05925582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|None of the participants knows the group they are in.|Two groups: Interventional (study) group and Control group|t|f|f|f
34150136|NCT00013728|||DEFINED_POPULATION||PROSPECTIVE|||||||
34150137|NCT04825067|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150138|NCT06050798|||COHORT||PROSPECTIVE|||||||
34150139|NCT00574548|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33808746|NCT03301870|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"the assignment of the test articles to the test sites will be randomized. Each arm is a different patch of skin on the same study participant"|t|f|f|t
34113351|NCT06480487|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The data analysis will be done by a team and those team members will be masked on the intervention provided.|A 2×2×2 factorial design will be conducted, with three two-level components making up a total of 8 groups of AnF interventions. The sample population will be randomly assigned to these 8 intervention groups.|f|f|f|t
34113352|NCT06389656|NA|SINGLE_GROUP||TREATMENT||NONE||Open trial||||
34113353|NCT05466825|||COHORT||PROSPECTIVE|||||||
34113354|NCT04130854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113355|NCT03250377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113356|NCT06379360|NA|SINGLE_GROUP||TREATMENT||NONE||Apply hypomethylating agent, azacitidine or decitabine as maintenance therapy.||||
34113357|NCT05440617|||CASE_ONLY||PROSPECTIVE|||||||
34113358|NCT06356571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113359|NCT04163523|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34113360|NCT06406881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113361|NCT01316783|||COHORT||CROSS_SECTIONAL|||||||
34113362|NCT05807841|||CASE_ONLY||PROSPECTIVE|||||||
34113363|NCT04083235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113364|NCT06448429|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113365|NCT05285982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113366|NCT06141486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113367|NCT05616650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113368|NCT04828486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113369|NCT05112198|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34113370|NCT06300411|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34113371|NCT05674617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial (RCT)|f|f|f|t
34113372|NCT05703685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113373|NCT06503952|||CASE_CONTROL||RETROSPECTIVE|||||||
34113374|NCT00977977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113375|NCT05797376|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113376|NCT04744116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113377|NCT06548542|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808747|NCT02785159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808748|NCT02604693|||COHORT||PROSPECTIVE|||||||
34040039|NCT05182060|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34040040|NCT00605618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040041|NCT02224651|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34040042|NCT06578793|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34040043|NCT04825691|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040044|NCT00274274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040045|NCT04888793|||COHORT||PROSPECTIVE|||||||
34040046|NCT05820815|RANDOMIZED|PARALLEL||OTHER||SINGLE|An outcome assessor will be blinded after assignment to interventions by blocking access to the web randomization table operated on the website.||f|f|f|t
34040047|NCT01672502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040048|NCT02863185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040049|NCT04491825|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040050|NCT04305327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind until Week 12, where the primary endpoint is assessed. Open-label active comparator treatment from Week 0 to Week 52, but with blinded outcomes assessor throughout the study.||t|f|t|f
34040051|NCT04656821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040052|NCT04087993|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:2:1 distribution Polyglucoferron, Ferric Carboxymaltose i.v., or oral iron substitution with Ferrous sulfate. After safety assessment of first 35 patients treated with Polyglucoferron or Ferric Carboxymaltose i.v. respectively, Ferric Carboxymaltose arm will be closed.||||
34040053|NCT04994769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040054|NCT01236508|NA|SINGLE_GROUP||SCREENING||NONE||||||
34040055|NCT00686608|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will receive infusions of glucose, fructose, and saline in a randomized order.|t|f|t|f
34040056|NCT06574659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040057|NCT05339373|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34040058|NCT06307535|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34040059|NCT00937079|||CASE_ONLY||PROSPECTIVE|||||||
34113378|NCT06548269|||COHORT||PROSPECTIVE|||||||
34113379|NCT05669846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113380|NCT06047457|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34113381|NCT03366129|||COHORT||PROSPECTIVE|||||||
34113382|NCT02875548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113383|NCT05843643|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34113384|NCT00581763|||COHORT||PROSPECTIVE|||||||
34113385|NCT02023866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113386|NCT00001352|||COHORT||PROSPECTIVE|||||||
34113387|NCT05825014|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34113388|NCT00001360|||COHORT||CROSS_SECTIONAL|||||||
34113389|NCT04802967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be double-blinded (Investigator- and subject-blinded).|In the Part B of the study the Intradermal (ID) Capsaicin Model is used.|t|f|t|f
34113390|NCT05303792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113391|NCT00542230|||COHORT||PROSPECTIVE|||||||
34113392|NCT04939090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113393|NCT05508737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113394|NCT05092958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113395|NCT03955445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113396|NCT06503146|NA|PARALLEL||DIAGNOSTIC||NONE||||||
34113397|NCT06271187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113398|NCT04738942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113399|NCT03289403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113400|NCT06451354|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34113401|NCT04716634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113402|NCT04314401|||OTHER||OTHER|||||||
34113403|NCT01352962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113404|NCT04150718|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34113405|NCT05760313|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34113406|NCT00246857|||OTHER||PROSPECTIVE|||||||
34040060|NCT02045069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040061|NCT00792051|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34040062|NCT05644054|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Neither the participants nor the investigators will be aware of the drug being administered.|A Cross-Over, Double-Blind Placebo-Controlled Study|t|f|t|f
34040063|NCT02547792|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34040064|NCT00003909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040065|NCT05689346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34040066|NCT04439942|||CASE_ONLY||PROSPECTIVE|||||||
34040067|NCT02461966|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|No Masking|||||
34040068|NCT05813873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040069|NCT05666635|NA|SEQUENTIAL||TREATMENT||NONE||Participants will be assigned to sequentially escalating dose cohorts of LTC004||||
34040070|NCT02059135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040071|NCT03972748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040072|NCT00004043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040073|NCT04720456|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A prospective randomized cohort study with a longitudinal arm. There will be 2 cohorts.||||
34040074|NCT04082026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The research study compared the EASE treatment (7 weekly sessions for adolescents and 3 for their caregivers) against an Enhanced Treatment as Usual (ETAU) consisting of a single psychoeducation individual session, jointly for eligible adolescents and their caregivers. ETAU included information on: (i) the results of the screening; (ii) self-care strategies; and, (iii) seeking services from local health or community services offering psychosocial / mental health care support.|t|f|t|f
34040075|NCT00623168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040076|NCT02972905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040077|NCT05465629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once enrolled, participants are randomized into one of the three arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.|Randomized, blinded, cohort study divided into three arms: 1) control group (placebo), 2) condition-based supplement, 3) precision-supplement|t|f|f|f
34040078|NCT03416205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040079|NCT05496647|RANDOMIZED|PARALLEL||PREVENTION||NONE|"Criteria for Inclusion in the Research~* Over 18 years old,~* Can speak Turkish,~* Subjected to daily gynecological surgery for the first time,~* Does not have any psychiatric disease and mental perception problems,~* Having no vision, hearing, and perception problems,~* Having no physical problems squeezing a stress ball,~* There will be women who agree to participate in the research verbally and in writing."|||||
34040080|NCT06162949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040081|NCT05348772|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Cohorts||||
34040082|NCT06487923|||COHORT||CROSS_SECTIONAL|||||||
34040083|NCT01088763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040084|NCT04557579|||CASE_ONLY||RETROSPECTIVE|||||||
34040085|NCT01789112|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040086|NCT05057130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040087|NCT00155506|||DEFINED_POPULATION||OTHER|||||||
34040088|NCT01783990|||COHORT||PROSPECTIVE|||||||
34040089|NCT04528667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040090|NCT01155934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040091|NCT05306912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040092|NCT01188031|RANDOMIZED|CROSSOVER||||NONE||||||
34040093|NCT06214663|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE||"Patients in active labor (6 cm cervical dilatation) will be randomly divided into 3 groups. For each patient, first, VAS score (visual analogue scale: patients were asked to evaluate their own pain on a vertical, unnumbered scale. Then, the patient's evaluation was graded with the help of a scale divided into 1/10 sections of the same length as the scale: 0: no pain and 10: unbearable pain) will be measured for labor pain and repeated at 10, 30, 60 and 90 minutes after injection. Injections will be administered over the sacral area (both posterior iliac spines and 2 cm downward and medial), and this technique was described by Lytzen et al in 1989 and later standardized. The results will be compared between the three groups."|t|f|f|f
34040094|NCT02852174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040095|NCT04107545|NA|SINGLE_GROUP||OTHER||NONE||||||
34040096|NCT03497104|||COHORT||PROSPECTIVE|||||||
34040097|NCT03925948|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The investigators used a single-arm pre- and post-test design for this pilot study in which the investigators assessed the feasibility, acceptability, and preliminary efficacy of the PLAN 4 Success-Diabetes in inner-city AAs in Baltimore, Maryland. Community-dwelling AAs were recruited via referrals from inner-city federally-qualified health clinics. Nineteen of 30 participants who completed the baseline survey received the study intervention which consisted of four-week health literacy training and disease knowledge education followed by two home visits and monthly phone counseling for over 6 months.||||
34040098|NCT00984542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040099|NCT02829619|||COHORT||PROSPECTIVE|||||||
34040100|NCT01061112|||COHORT||PROSPECTIVE|||||||
34040101|NCT00616837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34040102|NCT00828568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040103|NCT06359769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040104|NCT02116933|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113407|NCT05683756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113408|NCT05751967|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113409|NCT04422899|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113410|NCT05768906|||COHORT||PROSPECTIVE|||||||
34113411|NCT06459518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113412|NCT01524276|||COHORT||PROSPECTIVE|||||||
33808749|NCT03879538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and other involved providers will be blinded to the treatment type. Research investigators administering the treatments will not be blinded.|The nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, and the control group will receive 50% oxygen (oxygen plus air mixture). Both groups will undergo inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit. Vital signs (blood pressure, respiratory rate, heart rate) will be monitored every 30 minutes.|t|f|f|t
34113413|NCT03062319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113414|NCT05613673|||OTHER||PROSPECTIVE|||||||
34113415|NCT03650764|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113416|NCT04971733|NA|SEQUENTIAL||TREATMENT||NONE||||||
34113417|NCT04336722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113418|NCT00004571|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113419|NCT05758077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113420|NCT05650632|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113421|NCT01784068|NA|SINGLE_GROUP||OTHER||NONE||||||
34113422|NCT01961557|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34113423|NCT05170399|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34113424|NCT06201728|RANDOMIZED|PARALLEL||PREVENTION||NONE||"For inclusion, each week, all patients that were discharged from the hospital an adhere to the inclusion criteria will be identified using an electronic medical records software (Chameleon) and a list with their details will be created. The diagnosis of asthma and of the exacerbation will be verified by senior pulmonologist. Following that, the research coordinator will contact each subject with details on the study and a preliminary acceptance for inclusion. After acceptance, the randomization will be performed manually by randomly choosing from 200 identical envelops (100 with printed intervention and 100 with control)."||||
34113425|NCT06548217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113426|NCT05947851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In Part 1, Dose Confirmation will be determined by modified toxicity probability interval (mTPI) design, where participants will be assigned to two treatment groups, Nemtabrutinib + Venetoclax in parallel with Nemtabrutinib + Venetoclax. Part 2 will be an Efficacy Expansion where all participants will be randomized 1:1 to Nemtabrutinib Part 1 Dose Selection plus Venetoclax or Venetoclax plus Rituximab (VR) (or Rituximab biosimilar) for the duration of the study.|f|f|f|t
34113427|NCT06573801|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34113428|NCT05540860|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34113429|NCT04373330|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34113430|NCT06428409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113431|NCT00001620|||OTHER||CROSS_SECTIONAL|||||||
34113432|NCT05564403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113433|NCT03687528|||CASE_ONLY||PROSPECTIVE|||||||
34113434|NCT06486844|||COHORT||RETROSPECTIVE|||||||
34113435|NCT04284787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113436|NCT05606965|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study design for Part A and Prt C is randomized and Part B is non-randomized.||||
34113437|NCT06100744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113438|NCT04035005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113439|NCT05949060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113440|NCT05964452|||CASE_ONLY||PROSPECTIVE|||||||
34113441|NCT01319565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113442|NCT06269653|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808750|NCT03650543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The mean masking was the treating Gastroenterologist doctor.|A randomized single - blinded Clinical Trial conducted from 2012 to 2015 in Bogotá, Colombia. The aim was studying the effectiveness of triple therapy for H. pylori with amoxicillin, clarithromycin and standard dose of omeprazole versus amoxicillin, clarithromycin with dose of omeprazole according to CYP2C19 polymorphisms was studied, the subjects were allocated to a treatment regimen according to a randomized crossover sequence, provided by a computer-generated randomization list. Patients were contacted by telephone for assigned an appointment for treatment delivery according to the assigned group.|f|t|f|f
33808751|NCT03096470|||CASE_CONTROL||PROSPECTIVE|||||||
33808752|NCT03987698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808753|NCT01971255|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808754|NCT00774059||PARALLEL||PREVENTION||NONE||||||
34113443|NCT05877014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113444|NCT06310577|NA|SINGLE_GROUP||TREATMENT||NONE||Self-controlled||||
34113445|NCT06479837|||COHORT||PROSPECTIVE|||||||
34113446|NCT02965716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113447|NCT00001645|||OTHER||PROSPECTIVE|||||||
34113448|NCT04339751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113449|NCT06115499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113450|NCT06487910|NA|SINGLE_GROUP||OTHER||NONE||||||
34113451|NCT04573062|||CASE_ONLY||PROSPECTIVE|||||||
34113452|NCT05421390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34113453|NCT03667820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113454|NCT03973320|||COHORT||RETROSPECTIVE|||||||
34113455|NCT05779748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34113456|NCT03221036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113457|NCT05593029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113458|NCT02610439|||CASE_CONTROL||RETROSPECTIVE|||||||
34113459|NCT05505643|RANDOMIZED|PARALLEL||TREATMENT||NONE||The initial 20 participants will be enrolled to a safety lead-in arm receiving cryoablation. The next 236 participants will be randomized in a 1:1 manner to either cryoablation or lumpectomy. Patients initially treated with cryoablation who have evidence of residual or recurrent tumor on follow-up imaging will be crossed over to receive a rescue lumpectomy.||||
34113460|NCT03090152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34113461|NCT05763407|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113462|NCT06430658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113463|NCT00594672|||COHORT||PROSPECTIVE|||||||
34113464|NCT06408051|||CASE_CONTROL||RETROSPECTIVE|||||||
34113465|NCT02839291|NA|SINGLE_GROUP||OTHER||NONE||||||
34150140|NCT01751139|NA|SINGLE_GROUP||OTHER||NONE||||||
33808755|NCT01608685|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808756|NCT06697808|||COHORT||PROSPECTIVE|||||||
33808757|NCT00317395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808758|NCT03292692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808759|NCT02075723|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33808760|NCT05925335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808761|NCT01376674|||CASE_ONLY||PROSPECTIVE|||||||
33808762|NCT03339466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808763|NCT03032198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040105|NCT01672554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040106|NCT00348777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040107|NCT04937777|||COHORT||RETROSPECTIVE|||||||
34040108|NCT04289441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled double-blind trial|t|f|t|f
34040109|NCT02481206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040110|NCT04771286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040111|NCT02323542|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34040112|NCT03070236|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34040113|NCT03229837|||COHORT||PROSPECTIVE|||||||
34040114|NCT01772810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040115|NCT01898507|NA|SINGLE_GROUP||OTHER||SINGLE|All subjects were blinded to the nicotine content of the study cigarettes.||t|f|f|f
34040116|NCT06217705|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Assessments will be completed independently by participants online. Investigators will be blinded to condition throughout the study.|Participants will be randomized to receive the intervention condition (Project Calm) immediately or after two months. Participants in the delayed Calm condition will complete a typical school activity instead (i.e., treatment as usual). All participants will complete survey measures online at baseline, immediately after receiving the intervention, and 1-, 2, 3-, and 4-months after baseline.|f|f|t|t
34040117|NCT03247231|||COHORT||PROSPECTIVE|||||||
34040118|NCT04363320|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||The proposed study will implement a cluster randomized block design where staff are nested within sites. The community-based provider sites and jails will be grouped into homogeneous blocks and then randomly assigned into 2x2 factorial design for each block. The forty-eights sites will be assigned to one of four study arms using a matching strategy within the blocks that groups four jail-clinic combination together prior to randomization. Each jail and cognitive behavioral (CB) treatment provider (or clinic) in these combinations will be treated as a site.||||
34040119|NCT03162653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040120|NCT05648773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34040121|NCT02060058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040122|NCT05270577|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
34040123|NCT01253629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040124|NCT01826331|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34040125|NCT01641458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040126|NCT05688566|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The subject already knows the angle of the pedal when he steps on the pedal, because there are only three angles.|Then the pedal angle are inversion 10 ˚,0 ˚, eversion 10˚. Participants stepped on the Pinnacle trainer under three angle levels, namely inversion 10 ˚,0 ˚, eversion 10˚.||||
34040127|NCT00687726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040128|NCT02252224|||CASE_ONLY||PROSPECTIVE|||||||
34040129|NCT01870973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040130|NCT02263430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34040131|NCT06181214|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, Double-Blind, Placebo Controlled Design|t|f|t|t
34040132|NCT05337280|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||This is a single center sequential design||||
34040133|NCT01063192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040134|NCT01862926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040135|NCT00475488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040136|NCT01035294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040137|NCT04762160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040138|NCT05032027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The random assignment of patients was performed by Nanchang Medical University with a computer-generated random number code. Patients were randomly distributed in a 1:1 ratio to receive probiotics or a placebo (the block size was known only to the statistician). The drug was distributed and packaged in accordance with random numbers, and the documents stating the parameters, such as the blinding codes for the seeds of the random numbers, the block length, and the random numbers, were sealed in envelopes||t|t|t|t
34040139|NCT05577988|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Members of the Endpoint Adjudication Committee (AEC) are blinded to randomization group, treatments and characteristics.~The Committee will assess all endpoints according to the definitions stated in the protocol. This will be a blinded evaluation. Clinical endpoint adjudication will be performed using blinded source data that are provided by CRAs to the committee."|National, multicentre, comparative, controlled, randomized, open label trial using the PROBE study design (Prospective Randomized Open Blinded End-point)|f|f|f|t
34040140|NCT00314340|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34040141|NCT03588910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treating provider and the patient know their prescription. The outcomes assessor will be blinded when administering the postoperative surveys.|Patients are randomized to receive one of two prescription regimens.|f|f|f|t
34040142|NCT01868737|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040143|NCT05281029|||COHORT||PROSPECTIVE|||||||
34040144|NCT01420068|||OTHER||PROSPECTIVE|||||||
34040145|NCT02174263|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34040146|NCT02560922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040147|NCT04185220|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040148|NCT04987320|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34040149|NCT00471224|||CASE_ONLY||PROSPECTIVE|||||||
33808764|NCT06463145|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Both the placebo (0 mg) and Botanical extract capsules (50mg, 100mg and 150mg) were identical in appearance to maintain the blindness of the study treatment. Only an unblinded research assistant will have knowledge of which label corresponds to Vanizem doses or placebo. That research assistant will be in charge of: (1) Before each appointment, distributing appropriate treatments or placebo pills into closable pots with a number corresponding to each participant. Care-providers will give closed pots to participants at the time of assessment. (2) Re-labeling all collected data and samples with a participant code number, and sorting into appropriate groups for analysis by blinded researchers.The investigators, study staff, subjects, and statisticians were blinded to the study.||t|t|t|t
33726817|NCT03510117|NA|SINGLE_GROUP||OTHER||NONE||To evaluate different forms of validity (e.g., construct, criterion), responsiveness to change over time, and estimation of minimally important differences, we will administer new mindfulness short forms, legacy measures, and an experiential measure of focused attention to \~250 mindfulness students at baseline, 8-weeks, and 16 weeks in multiple, on-going 8-week Mindfulness-Based Stress Reduction (MBSR) courses and similar MBI programs at Pittsburgh and Chicago sites, as well as at member sites from the Academic Consortium for Integrative Medicine and Health and the BraveNet Practice-Based Research Network.||||
33726818|NCT01867593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726819|NCT00783029|||CASE_ONLY||PROSPECTIVE|||||||
33726820|NCT00188019|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726821|NCT03606954|NON_RANDOMIZED|PARALLEL||OTHER||TRIPLE|double-blind controlled comparative study||t|f|t|t
33726822|NCT05594394|||CASE_ONLY||PROSPECTIVE|||||||
33726823|NCT00641095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726824|NCT00959842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726825|NCT02117375|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33726826|NCT02869594|||COHORT||PROSPECTIVE|||||||
33726827|NCT00962104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726828|NCT01251380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113466|NCT03237702|NA|SINGLE_GROUP||SCREENING||NONE||"A total of 1,980 male patients who are planning to have prostate biopsy will be enrolled in the first stage of this study for measuring urine metabolomics. Only the patients who have non-metastatic significant prostate cancer, insignificant prostate cancer, ASAP/PIN, or benign prostate proved by prostate biopsy are enrolled into the second stage in which MCS supplementation will be used for 8 weeks.~In addition, 20 men and 20 women will be enrolled as a healthy control without any further medication."||||
33726829|NCT02641379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726830|NCT03471533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, controlled clinical trial, with two parallel branches, (experimental product and placebo), double blind and unicentric.|t|f|t|f
33726831|NCT03439371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726832|NCT03532620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726833|NCT03974815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Active stimulation group: 2mA, 30min (1min ramping up/down) Sham stimulation group: 0mA, 30min (1min ramping up/down)|t|t|t|t
33726834|NCT03726008|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33726835|NCT01024712|NON_RANDOMIZED|||TREATMENT||NONE||||||
33726836|NCT01860456|||COHORT||PROSPECTIVE|||||||
33726837|NCT03858946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In the TI group, two shame incisions will be performed to mimic those, incisions made during FCR tendon harvesting in the LRTI group. Hence, blinding to treatment allocation of patients, physiotherapists and health care providers will be possible. Furthermore, independent data collectors will be responsible for baseline and follow-up assessments, while all self-reported outcome questionnaires are made available to the patients electronically, and responses entered into a database identified by identification numbers only. The data analyst will be unaware of the treatment allocation as data will be analyzed using recoded identification numbers. An independent person will perform the recoding||t|t|t|t
33808765|NCT01484743|||COHORT||PROSPECTIVE|||||||
33808766|NCT05696405|||CASE_ONLY||RETROSPECTIVE|||||||
33808767|NCT00236847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33808768|NCT02510573|||CASE_ONLY||PROSPECTIVE|||||||
33808769|NCT03829553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040150|NCT05759741|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group was given probiotics: 4 tablets of MIYAIRI 588, inserted into the distal ileostomy, once a week. The control group was not given drugs, only monthly outpatient follow-up of the anastomosis stoma.||||
34040151|NCT02062060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040152|NCT02721277|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113467|NCT05447325|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participants will be prevented from having knowledge of the interventions assigned to them.|In the PSA exposure conditions, half of the participants will receive regular PSA exposure during the first 6 months and then switch to receiving flavor PSA exposure during the second 6 months; the other half will first receive flavor PSAs, and then the regular PSAs.|t|f|f|f
33808770|NCT02597699|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33808771|NCT00689351|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33808772|NCT05585710|RANDOMIZED|PARALLEL||PREVENTION||NONE|Pulsed Lavage is a surgical technique that cannot be masked from the investigators performing the operation.|Two cohorts will be established. One cohort will include patients who undergo pulsed lavage to wash out the mastectomy pocket. The other cohort will include patients who do not receive pulsed lavage.||||
33808773|NCT00872248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040153|NCT00746148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34040154|NCT06577909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040155|NCT00428246|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34040156|NCT04454801|||COHORT||PROSPECTIVE|||||||
34040157|NCT00107861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040158|NCT00634361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040159|NCT06198153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808774|NCT05996315|||COHORT||PROSPECTIVE|||||||
33808775|NCT05080257|||CASE_ONLY||PROSPECTIVE|||||||
34040160|NCT01496677|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34113468|NCT06297447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be stratified by cite. Block randomization in random concealed block sizes of 4 to 6 (1:1) into two parallel groups is used to avoid imbalance in the randomization between intervention groups. A person not otherwise affiliated with the study will generate the randomization sequence.The randomization will be coded (Group 1 or 2), thus the primary investigator (BE) will not know the code to the groups.|Multicenter randomized controlled, superiority trial with a 2-group parallel design.|f|f|t|t
34113469|NCT06311357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34113470|NCT03691883|||COHORT||PROSPECTIVE|||||||
34113471|NCT04008797|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The Dose Optimization part and HCC subpart of Expansion part of the study are randomized. The Dose Escalation part, and CRC/EC subparts of Dose Escalation part are non-randomized.||||
34113472|NCT04821154|||COHORT||OTHER|||||||
34113473|NCT03866382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113474|NCT06335303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113475|NCT05669755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113476|NCT05534971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34113477|NCT05431803|||COHORT||PROSPECTIVE|||||||
34113478|NCT03321643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113479|NCT03155620|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34113480|NCT06579872|||CASE_CONTROL||PROSPECTIVE|||||||
34113481|NCT04128566|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|Blinding to the experimental condition is not possible because of the obvious differences between conditions (partial weight bearing and additional load). However, the person processing the data will be blinded to the condition.|||||
34113482|NCT06359782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A prospective, multicenter, randomized, double-blind, placebo-controlled, phase II trial.|t|t|t|t
34113483|NCT04111458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113484|NCT06554951|||COHORT||PROSPECTIVE|||||||
34113485|NCT06569303|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34113486|NCT06173375|RANDOMIZED|PARALLEL||SCREENING||NONE||Two-arm intervention trial comparing mailed Cologuard outreach (intervention) to mailed FIT outreach (control)||||
34113487|NCT04896073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113488|NCT04844606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113489|NCT04936542|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34113490|NCT00001160|||CASE_ONLY||PROSPECTIVE|||||||
34113491|NCT00943514|||OTHER||PROSPECTIVE|||||||
34113492|NCT00410241|||OTHER||PROSPECTIVE|||||||
34113493|NCT04214990|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113494|NCT05666713|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34113495|NCT01676805|||COHORT||PROSPECTIVE|||||||
34113496|NCT00001316|||COHORT||PROSPECTIVE|||||||
34113497|NCT04111692|||CASE_ONLY||PROSPECTIVE|||||||
34113498|NCT06493422|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34113499|NCT04929041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113500|NCT03606642|NA|SINGLE_GROUP||TREATMENT||NONE||DAPT or Dual Antiplatelet Therapy is a combination of two medications given after a percutaneous coronary intervention (PCI) with a drug eluting stent. The medications used for DAPT are low dose Aspirin (81mg) and one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient). Because the patients are considered to be at a high risk for bleeding due to one or a combination of reasons this study is trying to determine if a shorter use of DAPT in combination with the Synergy® stent and an imaging tool called IVUS used during your PCI procedure is safe and effective to reduce the potential for serious bleeding events and early stent thrombosis. The Synergy® stent was chosen because of its enhanced method of healing and reduced inflammation of the artery after placement. The Synergy stent may be a better choice for patients who are at high risk for bleeding and could benefit from a shortened period of DAPT.||||
34113501|NCT00001252|||CASE_CONTROL||OTHER|||||||
34113502|NCT04870788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113503|NCT01231932|||COHORT||PROSPECTIVE|||||||
34113504|NCT06303193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113505|NCT01150721|||COHORT||PROSPECTIVE|||||||
33726838|NCT00154583|||DEFINED_POPULATION||OTHER|||||||
33726839|NCT03050619|||OTHER||RETROSPECTIVE|||||||
33726840|NCT06083506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726841|NCT03079323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726842|NCT04534764|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33726843|NCT02710890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726844|NCT05762146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a Prospective Randomized Open-label Blinded End-point (PROBE) trial|This is a Prospective Randomized Open-label Blinded End-point (PROBE) trial evaluating safety and efficacy of a triple combination therapy of riociguat, propylthiouracil, and perphenazine, administered orally in addition to standard of care treatment in patients with disabling acute ischemic stroke. Patients will be randomly assigned to the triple combination therapy group or the control group in a 3:1 ratio:|f|f|f|t
33726845|NCT03762382|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33726846|NCT03232385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726847|NCT04794790|RANDOMIZED|PARALLEL||TREATMENT||NONE||We are attempting to characterize the particular problem of prolonged precipitated withdrawal in individuals with fentanyl dependence through a quasi-experimental study, which will enroll 20 to 30 individuals at the PPI OTP, who are using fentanyl and/or combination of fentanyl and opioids but desiring buprenorphine naloxone induction. There will be a standard treatment arm, then a micro dose and macro dose arm.||||
33726848|NCT00211458|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726849|NCT00239707|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33726850|NCT02445495|||||RETROSPECTIVE|||||||
33726851|NCT00368264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726852|NCT06039033|||CASE_CROSSOVER||PROSPECTIVE|||||||
33726853|NCT04750031|||CASE_CONTROL||PROSPECTIVE|||||||
33726854|NCT05080452|||OTHER||PROSPECTIVE|||||||
33726855|NCT01674231|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33726856|NCT01160068|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726857|NCT00924872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726858|NCT03384121|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 1 pilot study whereby all participants start the study at a starting dose 5mg/kg/day (at study visit 2) for two months, and those that do not respond to 5mg/kg/day, otherwise known as non-responders, will receive a higher dose of 10 mg/kg/day (at study visit 4) for another two months. Recruited patients will be followed prospectively for a total of 6-11 months. This will include 2 months of observation, 2 months of receiving the starting dose of rifampin of 5mg/kg/day with a maximum dose of 600mg/day followed by a 2 month washout phase. The efficacy of the starting dose of rifampin will be determined prior to proceeding only in non-responders to the higher dose of 10 mg/kg/day with a maximum dose of 600 mg/day.||||
33726859|NCT04620083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Allocation concealment was done to avoid selection bias while blinding was done to research assistant who performed data collection.|The research team randomly allocated the elderly to the control group (Con), Experimental 3-day normal group (Exp-N) and Experimental 5-day intensive group (Exp-I). For the control group, the participants received conventional therapy which included group activities for reality orientation, reminiscence therapy and activities organized by occupational therapists one hour a day, five days a week. In addition to conventional therapy, the two experimental groups also joined the integrative learning program. For consistency, Day 1 and 3 of the 3-day protocol were replicated as Day 4 and Day 5 of the 5-day protocol.|f|f|t|f
33726860|NCT03073590|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"To determine the impact of Hot lunch, iron -folate tablet and behaviour change communications program on the main outcome (i.e., prevalence of anemia) we used a quasi-experimental, controlled, pre-post design for both sets of interventions.~Intervention Description Two types of interventions was tested against controls in a total of 4 factories. Among factories that already provide a hot lunch to workers, one intervention and one control factory was selected, and among factories that do not provide hot lunches, one intervention and one control factory was selected."||||
33726861|NCT03463889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726862|NCT04667039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Throughout the study, until the end of the comparative treatment study period, neither the investigators nor the patients knew which drug was being administered|Interventional|f|f|t|f
33726863|NCT02848677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726864|NCT01452464|||COHORT||PROSPECTIVE|||||||
33726865|NCT02476968|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33726866|NCT04762134|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization with a 1:1 ratio||||
33726867|NCT05517499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726868|NCT05486221|||OTHER||PROSPECTIVE|||||||
33726869|NCT05669456|||CASE_ONLY||PROSPECTIVE|||||||
33726870|NCT01124643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726871|NCT05096416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33726872|NCT02306135|||CASE_ONLY||PROSPECTIVE|||||||
33726873|NCT04222712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808776|NCT04703907|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Prospective investigation during 15 weeks of treatment for each participant with waiting list control group (no intervention). Waiting group will receive the intervention (auricular stimulation) after 15 weeks of investigation."||||
33726874|NCT03232658|||COHORT||RETROSPECTIVE|||||||
33726875|NCT00449644|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33808777|NCT03250793|NA|SINGLE_GROUP||OTHER||NONE||||||
33808778|NCT02895659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808779|NCT03173625|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33808780|NCT03486509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808781|NCT03611556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808782|NCT00797056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808783|NCT04353050|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Ambispective study with two retrospective cohorts and one prospective cohort||||
34040161|NCT05732571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Randomisation will be completed in a 1:1 ratio (Intervention: Usual Care) using a sealed envelope block randomisation process.~The study will be single blinded and controlled through the use of a distinct intervention team and an outcomes team.~The intervention team will manage the randomisation and intervention session and planning. The outcomes team will be blinded to the intervention or usual care."|A single site, pilot RCT of intervention compared to usual care|f|f|f|t
34040162|NCT01049256|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040163|NCT01292512|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040164|NCT04750395|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, open-label, randomized controlled trial. Patients will be randomly assigned to one of two groups as part of follow-up management.||||
34040165|NCT00359424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040166|NCT04961385|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040167|NCT04501887|||COHORT||PROSPECTIVE|||||||
34040168|NCT06349291|||CASE_ONLY||PROSPECTIVE|||||||
34040169|NCT01472692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040170|NCT01697748|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34040171|NCT03039504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040172|NCT00410540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040173|NCT05651321|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34040174|NCT05601739|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040175|NCT05164770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040176|NCT03244761|||CASE_CROSSOVER||PROSPECTIVE|||||||
34040177|NCT04451551|||COHORT||PROSPECTIVE|||||||
34040178|NCT01818271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040179|NCT04577404|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Open Label||||
34040180|NCT00765687|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34040181|NCT04051671|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34113506|NCT05839548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective, randomized, clinical trial with two parallel arms, to evaluate the safety and efficacy of 4% Articaine, 2% Mepivacaine on vital and non-vital primary teeth that needs restorative, pulp therapy, or dental extraction by using buccal infiltration technique. The effect will be assessed by measuring the pain experience during injection and treatment procedures, and by assessing the child's behavior during the procedure, and postoperative pain and complications. The study consisted of a screening period for up to 6 months. A Qualified participants through the screening assessments will be assigned randomly to receive either 4% Articaine, or 2% Mepivacaine.|f|f|f|t
34113507|NCT05761366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040182|NCT04116840|NA|SEQUENTIAL||TREATMENT||NONE||||||
34040183|NCT02729025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040184|NCT05208931|||CASE_CONTROL||RETROSPECTIVE|||||||
34040185|NCT02229760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040186|NCT05302401|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34040187|NCT05799508|||COHORT||PROSPECTIVE|||||||
34040188|NCT02779010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34040189|NCT05710835|||COHORT||RETROSPECTIVE|||||||
34040190|NCT05002218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care providers and outcome assessor will not know which group individuals are assigned. In addition, the primary outcome will be video-recorded and the videos will be scrambled so that outcome assessor will not know if the test was done pre- or post-training.|This is a single-blinded randomized control trial.|f|t|f|t
34040191|NCT05808374|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34040192|NCT05445713|||COHORT||CROSS_SECTIONAL|||||||
34040193|NCT01817868|||COHORT||PROSPECTIVE|||||||
34040194|NCT02036073||PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34040195|NCT02593838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040196|NCT01374555|||COHORT||PROSPECTIVE|||||||
34040197|NCT00058929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040198|NCT00105079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040199|NCT01534338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040200|NCT04672837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor) The assessors who receive participants and do the measurement are masked|Parallel assignment|f|f|t|t
34040201|NCT00105859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040202|NCT01285362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040203|NCT05506046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040204|NCT03626402|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial comparing an intervention group to usual care||||
34040205|NCT01591538|||COHORT||PROSPECTIVE|||||||
34040206|NCT05453227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040207|NCT03308890|RANDOMIZED|PARALLEL||OTHER||NONE||Arm 1：0.5mg Entecavir QD for 6 months after cessation of TDF. Arm 2：0.5mg Entecavir QD for 12 months after cessation of TDF. Arm 3：No consolidation arm and observation only. Clinical observation for up to 6 months after the end of study follow-up for all arms.||||
34040208|NCT05526677|||COHORT||PROSPECTIVE|||||||
34040209|NCT02927951|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34040210|NCT03850743|||OTHER||PROSPECTIVE|||||||
34040211|NCT02055924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040212|NCT03454061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040213|NCT02206282|||COHORT||PROSPECTIVE|||||||
34040214|NCT00031590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040215|NCT03378518|||OTHER||RETROSPECTIVE|||||||
34040216|NCT04769193|NA|SINGLE_GROUP||TREATMENT||NONE|The evaluation of skin volume will be masked as the assessors will not known which scans are from what time period.|||||
34040217|NCT00813072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040218|NCT03033992|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label single-arm study within each stratum|The study includes two independent strata. Stratum 1 is a single-arm safety and feasibility study. While stratum 2 is a phase I/II study which consists of two parts: a phase I component to evaluate the safety and tolerability of concurrent Optune and RT, and a phase II component to evaluate the feasibility of concurrent Optune and RT and the efficacy associated with this approach compared to historical controls.||||
34040219|NCT02851121|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040220|NCT03538288|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34040221|NCT04831853|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized sequence of supervised self-swabbing and conventional swabbing for SARS-CoV-2 screening||||
34040222|NCT02220738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040223|NCT00506415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040224|NCT00000594|RANDOMIZED|||PREVENTION||DOUBLE||||||
34040225|NCT04267809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a randomized, double-blind, placebo-controlled clinical trial of metformin in 44 healthy adults.|Enrolled subjects will be randomized into one of two groups in the same ratio (1:1). As this is an open-label study, random block sizes will be used to avoid selection bias yet ensure balance over time. Randomization will be performed via a web-based randomization system: http://www.randomization.com by an independent person who has no direct contact with the subjects. Randomization opaque envelopes will be prepared by an independent team in accordance to the Master Randomization List generated. The randomization envelopes are to be opened sequentially for each enrollment by the study team and will determine the subject's allocation to one of the two groups.|t|f|t|f
34040226|NCT05527535|||OTHER||PROSPECTIVE|||||||
34040227|NCT01852448|||COHORT||PROSPECTIVE|||||||
34040228|NCT04940273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040229|NCT01683318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040230|NCT04663529|||CASE_CONTROL||PROSPECTIVE|||||||
34040231|NCT05798182|||CASE_ONLY||PROSPECTIVE|||||||
34040232|NCT05774938|||COHORT||PROSPECTIVE|||||||
34040233|NCT04040140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040234|NCT06348355|NA|SINGLE_GROUP||OTHER||NONE||||||
34040235|NCT01001273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040236|NCT01478776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113508|NCT06535854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Masking only applies to the subjects in the ISR Cohort, subjects will be randomized at a 1:1 ratio to treatment with the Prevail DCB or the Agent DCB.~Subjects in DNSV Cohort will be prospectively enrolled in the study and treated with Prevail DCB."||t|f|f|f
34040237|NCT00597610|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040238|NCT02678793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040239|NCT03437863|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Participants will be recruited to a pre-post design study.||||
34040240|NCT00838903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040241|NCT00288626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040242|NCT06224556|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The General Practitioners (GPs) involved will be randomised in clusters in a 1:1 ratio, therefore one group of GPs will enrol patients for the Intervention Group and a second group of GPs will include patients for the Control Group.~Therefore, the role of GPs are masked."|"The Intervention Group will receive the Personlized Prevention Program (PPP)~be evaluated by a Comprehensive Geriatric Assessment thanks to the Multidimensional Prognostic Index (MPI) questionnaire."|f|t|f|f
34040243|NCT04653012|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040244|NCT00991237|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34040245|NCT00155012|||DEFINED_POPULATION||PROSPECTIVE|||||||
34040246|NCT02694172|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34040247|NCT04936750|||CASE_ONLY||PROSPECTIVE|||||||
34040248|NCT03641014|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34040249|NCT00287534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040250|NCT03923023|||COHORT||PROSPECTIVE|||||||
34040251|NCT06125652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040252|NCT06267924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The proposed clinical trial for the study device will be a randomized, sham-controlled, double-blind study with two-parallel arms (active/sham device).|t|f|t|f
34040253|NCT04744649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34040254|NCT06043674|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040255|NCT03515005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040256|NCT05867602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040257|NCT01775813|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040258|NCT04245137|||COHORT||CROSS_SECTIONAL|||||||
34040259|NCT05618704|NA|SINGLE_GROUP||OTHER||NONE||single arm, open label, interventional, multi-centre study||||
34040260|NCT06187012|||COHORT||OTHER|||||||
34040261|NCT03027635|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040262|NCT02984865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The first group was designed to observe the advantage of transversus abdominis plane (TAP) block combined with rectus sheath (RS) block in PD catheter placement surgery, which is independent from other 4 groups.|t|t|f|t
34040263|NCT00364923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040264|NCT05912881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study team members and study participants are blinded as to which olfactory training kit (treatment vs placebo) the participants received.|Participants are enrolled into treatment or placebo groups for the entirety of the study.|t|t|t|t
34040265|NCT05962333|NA|SINGLE_GROUP||TREATMENT||NONE||Intra-subjected controlled clinical study. Treatment is performed in left arm of the subjects and right arm (no intervention), measurements are performed before the first and after the last administration.||||
34040266|NCT03171805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040267|NCT05284786|||OTHER||PROSPECTIVE|||||||
34040268|NCT04407182|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34040269|NCT02762942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040270|NCT01024504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040271|NCT03181633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040272|NCT04152837|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single treatment group||||
34040273|NCT01534442|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34040274|NCT03827993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040275|NCT01146639|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040276|NCT01330823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040277|NCT03035383|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Non-randomized controlled study||||
34040278|NCT05333120|||COHORT||PROSPECTIVE|||||||
34040279|NCT01653821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040280|NCT02101944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040281|NCT01487395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040282|NCT00438581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040283|NCT02104219|||OTHER||RETROSPECTIVE|||||||
34040284|NCT04539184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040285|NCT01397877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040286|NCT01851122|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040287|NCT00710450|||CASE_ONLY||PROSPECTIVE|||||||
34040288|NCT04335851|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040289|NCT05810012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040290|NCT05872269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040291|NCT04328038|||COHORT||CROSS_SECTIONAL|||||||
34040292|NCT04614909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040293|NCT06576336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040294|NCT04943146|||CASE_ONLY||RETROSPECTIVE|||||||
34040295|NCT03866681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040296|NCT02375360|||CASE_CONTROL||PROSPECTIVE|||||||
34040297|NCT04665219|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34040298|NCT02309476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040299|NCT05893823|||CASE_CONTROL||RETROSPECTIVE|||||||
34040300|NCT00059930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040301|NCT04303689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects are blinded and randomized to receive either colchicine-treatment or placebo|Single blinded randomized placebo-controlled intervention|t|f|f|f
34040302|NCT01700062|RANDOMIZED|PARALLEL||||NONE||||||
34040303|NCT02348918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040304|NCT02549326|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34040305|NCT04852419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040306|NCT02166931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040307|NCT03137641|||COHORT||PROSPECTIVE|||||||
34040308|NCT00403481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040309|NCT03144661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040310|NCT00566241|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34040311|NCT00313196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040312|NCT00304798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040313|NCT01585051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040314|NCT00916851|||CASE_CONTROL||OTHER|||||||
34040315|NCT01051960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040316|NCT00230659|||CASE_CONTROL||PROSPECTIVE|||||||
34040317|NCT01414582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040318|NCT06280911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was designed to be randomly controlled.|f|f|f|t
34040319|NCT00971438|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040320|NCT00243126|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34040321|NCT00551239|RANDOMIZED|PARALLEL||TREATMENT||||||||
34040322|NCT00287040|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34040323|NCT05896865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040324|NCT01268982|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040325|NCT03493854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040326|NCT02825017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040327|NCT04367181|NA|SINGLE_GROUP||SCREENING||NONE||Approximately 1.5% of infants born every year in the United States are born at an extremely low gestational age (ELGA \<29 weeks GA). As reported in the 2015 VON database, the risk for developing any grade of intraventricular hemorrhage (IVH) in ELGA infants is about 20% and in more than 90% of these cases it occurs during the first three postnatal days. The major risk factor for IVH is the gestational age of the infant with greater immaturity being associated with the highest risk. The degree of prematurity of the infant relates to the immaturity of the vascular bed within the germinal matrix as well as challenges in the regulation of the cerebrovascular circulation. Specifically, increases, decreases and significant fluctuations in cerebral blood flow (CBF) have been shown to play important pathogenic roles in IVH. We are investigating the possibility of using a novel optical method to quantify cerebral perfusion, continuously, at the bedside in the NICU preterm population.||||
34040328|NCT02124200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040329|NCT02547428|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040330|NCT06537362|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34040331|NCT06116279|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The investigators will adhere to the internationally accepted five-stage Idea, Development, Evaluation, Assessment, Long-term study (IDEAL) framework for novel surgical device innovation. An IDEAL Stage 1 study requires a highly-selected patient group (n=6) and focuses on novel device innovation feasibility and safety. Adhering to the IDEAL framework will facilitate the development and evaluation of the novel device in a logical manner that balances innovation and safety.||||
34040332|NCT01269216|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34040333|NCT03472430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34040334|NCT04722068|NA|SINGLE_GROUP||OTHER||NONE||||||
34040335|NCT01247584|||CASE_ONLY||RETROSPECTIVE|||||||
34040336|NCT01753310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040337|NCT02818452|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34040338|NCT05989256|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34040339|NCT00754104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040340|NCT06453668|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040341|NCT02641093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040342|NCT03859596|||COHORT||OTHER|||||||
34040343|NCT05059873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040344|NCT03863782|||COHORT||PROSPECTIVE|||||||
34040345|NCT01017874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040346|NCT02141880|||COHORT||PROSPECTIVE|||||||
34040347|NCT03948529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040348|NCT04186793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040349|NCT03189095|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators opted to use a wait-list control group to serve as an untreated comparison for the experimental group. From the investigators' perspective, people calling about an exercise trial want to receive an intervention, and thus, they believe it would be unethical to deny access to the intervention. Control group participants will be asked to continue their current activity level over the 16 weeks and following their posttest, they will be invited to participate in the WOWii program in full. The investigators will examine whether differential dropouts occur between those assigned to the experimental and wait-list control groups. The investigators previous exercise study conducted among women with mobility impairment indicated slightly lower attrition in the wait list control group, with no significant differences between those who withdrew and those who remained in the study by six months.||||
34040350|NCT03995485|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, external (historic) control||||
34040351|NCT05087264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental group, control group||||
34040352|NCT06390904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040353|NCT02219880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040354|NCT03194633|||COHORT||PROSPECTIVE|||||||
34040355|NCT03864224|||COHORT||PROSPECTIVE|||||||
34040356|NCT03512769|||OTHER||CROSS_SECTIONAL|||||||
34040357|NCT03390023|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040358|NCT04088916|||OTHER||PROSPECTIVE|||||||
34040359|NCT05222932|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single arm, dose escalation||||
34040360|NCT01074801|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040361|NCT02356939|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808784|NCT04649645|RANDOMIZED|PARALLEL||SCREENING||NONE||"Smokers participants who were eligible and consent to take part will be randomized to either continuing smoking their own cigarette brand (Arm A) or switching to using C-F NDS (Arm B). Never-smokers participants who were eligible and consent to take part will be assigned to Arm C.~The randomization sequence will be computer generated, with an allocation ratio of 1:4 (Study Arm A : Study Arm B; Smokers : N-C NDS users) to compensate for an estimated 25% success rate (combined smoking abstinence rate + \>90% smoking reduction rate) in the long term. The randomization scheme will be provided to clinical sites via a web-based application set up by the CRO. The staff randomizing the participant will access the web-based application when the participant is with them, entering their participant identification number, date of birth and initials into the program. The allocation will be immediately provided by the program/software."||||
33808785|NCT02399449|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33808786|NCT01281657|||COHORT||PROSPECTIVE|||||||
33808787|NCT04652869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113509|NCT06293339|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113510|NCT05629286|||COHORT||PROSPECTIVE|||||||
34113511|NCT04436835|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113512|NCT05688410|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||2\^1 x 3\^1 factorial randomized clinical trial|f|t|f|t
34113513|NCT05286801|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113514|NCT05372367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113515|NCT05383352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34113516|NCT01780142|||CASE_CONTROL||PROSPECTIVE|||||||
34113517|NCT04835805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113518|NCT04260698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113519|NCT00408005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113520|NCT04826341|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113521|NCT03096262|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113522|NCT06029972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113523|NCT06289257|||COHORT||PROSPECTIVE|||||||
34113524|NCT05424237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34113525|NCT06627231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113526|NCT06750003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113527|NCT06581432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113528|NCT05675436|||COHORT||PROSPECTIVE|||||||
34113529|NCT06704919|||CASE_ONLY||PROSPECTIVE|||||||
34113530|NCT06687785|||CASE_CONTROL||RETROSPECTIVE|||||||
34113531|NCT06693362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113532|NCT05279690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113533|NCT06136897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113534|NCT00977574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113535|NCT06714461|||COHORT||CROSS_SECTIONAL|||||||
34113536|NCT06748612|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34113537|NCT05723601|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34113538|NCT06714448|||OTHER||CROSS_SECTIONAL|||||||
34113539|NCT04474353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113540|NCT06643832|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|open label for rubbing distraction group which is the novel approach to be tested in this trial (obviously, participant and pain assessor in the rubbing distraction group can not be blinded). however, lidocaine group and control group patients and their pain assessors are blinded to group assignment. so a final description of (partially blinded study) can be adopted.||t|f|f|t
34113541|NCT04356612|||COHORT||RETROSPECTIVE|||||||
34113542|NCT03575897|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113543|NCT06746493|||CASE_CONTROL||PROSPECTIVE|||||||
34113544|NCT06750484|NA|SINGLE_GROUP||TREATMENT||NONE||All people enrolled in the study will receive the same treatment and no one will receive a placebo or alternate treatment.||||
34113545|NCT06479824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113546|NCT06743828|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34113547|NCT06736041|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Modified double-blind~* Blinding for vaccine group assignment: participants and participant's parent(s) / legally acceptable representative(s) (LARs), outcome assessors, Investigators, laboratory personnel, and Sponsor study staff~* No blinding for vaccine group assignment: those preparing and administering the study interventions"||t|t|t|t
34113548|NCT06744868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113549|NCT06747923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113550|NCT06746285|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34113551|NCT04749615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34113552|NCT05308446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113553|NCT02838381|NA|SINGLE_GROUP||OTHER||NONE||||||
34113554|NCT05677594|||COHORT||PROSPECTIVE|||||||
34113555|NCT06746779|||COHORT||RETROSPECTIVE|||||||
34113556|NCT04310007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113557|NCT06747286|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two groups with an experiment control group||||
34113558|NCT06722664|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34113559|NCT06704191|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34113560|NCT02936752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113561|NCT06727331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The IDS will perform both the randomization and blinding and will be the only unblinded research staff. The study investigators will obtain placebo injectors from the manufacturer for the trial. All other research staff will remain blinded for the duration of the trial.||t|f|t|t
34113562|NCT06733155|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study follows a parallel assignment model where participants are randomly assigned to one of five distinct arms: a control arm or one of four intervention arms. Each arm receives a different intervention, and the effects are compared to assess the impact on the uptake of surveillance mammography.||||
34113563|NCT00018044|||COHORT||CROSS_SECTIONAL|||||||
34113564|NCT06748781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113565|NCT05308004|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre-post design where control data will be collected prior to intervention being implemented||||
34040362|NCT05736757|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomly divided into control group (without tissue fibrinogen activator) or drug group (injection of 50 ug tissue fibrinogen activator into the suprachoroidal cavity or subretinal space ).||||
34113566|NCT05090371|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open label, multi-center, active-comparator study||||
34113567|NCT01212003|||COHORT||PROSPECTIVE|||||||
34113568|NCT05587296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113569|NCT03557697|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34113570|NCT05927090|||COHORT||PROSPECTIVE|||||||
34113571|NCT05923073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113572|NCT05280652|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113573|NCT05104476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113574|NCT06744153|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34113575|NCT06732687|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34113576|NCT06747598|||CASE_ONLY||CROSS_SECTIONAL|||||||
34113577|NCT06707025|||COHORT||PROSPECTIVE|||||||
34113578|NCT06750302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34113579|NCT06706440|||CASE_ONLY||RETROSPECTIVE|||||||
34113580|NCT06739629|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Data collectors assessing anthropometric measures, dietary records and questionnaires were masked|Two-arm randomized intervention|f|t|t|t
34113581|NCT03952585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113582|NCT06717659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113583|NCT06722365|||COHORT||PROSPECTIVE|||||||
34113584|NCT06726122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113585|NCT06740864|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34113586|NCT06741176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Triple (Participant, Investigator, Outcomes Assessor)|It is a randomized controlled trial in experimental design.|t|f|f|t
34113587|NCT06743516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113588|NCT06746051|||COHORT||PROSPECTIVE|||||||
34113589|NCT06747078|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were divided into 3 groups. Group 1 (study group) received neurodevelopmental therapy (NDT) combined with core stabilization exercises (CSE). Group 2 (study group) received NDT combined with balance exercises (BE). The control group received only NDT||||
34113590|NCT05829460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and pathologist|Patients will be randomized on a 1:1 basis to either progestin + semaglutide 2.4 mg or progestin + placebo. Randomization will be stratified by previous progestin and metformin use.|t|t|f|f
34040363|NCT00548301|RANDOMIZED|PARALLEL||||DOUBLE||||||
34040364|NCT00937274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040365|NCT01311271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34040366|NCT03283657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34040367|NCT04408729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040368|NCT04384003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|a single-blinded randomized controlled trial will be conducted, in which patients will be randomized into groups by sealed envelope method.||t|f|f|f
34040369|NCT03981367|||OTHER||CROSS_SECTIONAL|||||||
34040370|NCT00751062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040371|NCT05639049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040372|NCT00473317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040373|NCT04471194|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34040374|NCT01120184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040375|NCT04273347|||COHORT||PROSPECTIVE|||||||
34040376|NCT05776784|||COHORT||PROSPECTIVE|||||||
34040377|NCT02637882|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34040378|NCT00392340||||TREATMENT||NONE||||||
34040379|NCT01240681|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040380|NCT01080638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040381|NCT05760989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040382|NCT06574854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040383|NCT01954056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040384|NCT05851807|||COHORT||PROSPECTIVE|||||||
34040385|NCT04996914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040386|NCT00086177|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040387|NCT01734005|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34040388|NCT00749073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040389|NCT00864929|||COHORT||RETROSPECTIVE|||||||
34040390|NCT06536270|||OTHER||CROSS_SECTIONAL|||||||
34040391|NCT06576817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be told exercise stations may vary within-session and week to week but will not be informed that only one group has UE exercise interventions.~Assessors are blinded to group allocation."|Single center, two arm, pre-test post-test parallel design with up to 4 cohorts of class participants.|t|f|f|t
34040392|NCT06262737|||COHORT||PROSPECTIVE|||||||
34040393|NCT03068234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040394|NCT04104763|||CASE_ONLY||RETROSPECTIVE|||||||
34040395|NCT02376712|||COHORT||PROSPECTIVE|||||||
34113591|NCT06715696|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113592|NCT00005902|||COHORT||PROSPECTIVE|||||||
34113593|NCT06744881|NA|SINGLE_GROUP||TREATMENT||NONE||A pilot study (in blocks of 5 participants per cohort and 4 cohorts in total)||||
34113594|NCT06751355|||COHORT||PROSPECTIVE|||||||
34113595|NCT06748521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113596|NCT00186368|||OTHER||PROSPECTIVE|||||||
34113597|NCT05618028|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040396|NCT06574152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040397|NCT04735523|||COHORT||RETROSPECTIVE|||||||
34040398|NCT01297517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040399|NCT06424613|||COHORT||RETROSPECTIVE|||||||
34113598|NCT06471829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113599|NCT06747130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113600|NCT06749938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113601|NCT06744283|||CASE_ONLY||OTHER|||||||
34113602|NCT06744036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator will only participate in the evaluation process.||f|f|f|t
34113603|NCT04806282|||COHORT||PROSPECTIVE|||||||
34113604|NCT06735768|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34113605|NCT06717776|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The therapist who conducted the assessment tests was unaware of the participants' group assignments (interventon or control)|Two groups with an intervention group and a control group|f|f|f|t
34113606|NCT06705426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113607|NCT06747689|||COHORT||PROSPECTIVE|||||||
34113608|NCT06577467|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113609|NCT06748950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113610|NCT06066138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113611|NCT06736379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Cohort A and B are nonrandomized. Cohort C subjects will be randomized into 3 different treatment groups. Both investigator and subject will not be blinded to treatment group assigned.|Dose de-escalation Model||||
34113612|NCT06734351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113613|NCT05303467|NA|SINGLE_GROUP||TREATMENT||NONE||The TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients||||
34113614|NCT03520660|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113615|NCT06722430|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113616|NCT06704906|||CASE_ONLY||PROSPECTIVE|||||||
34113617|NCT06722417|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34113618|NCT06707207|||COHORT||PROSPECTIVE|||||||
34113619|NCT06725706|||COHORT||PROSPECTIVE|||||||
34113620|NCT06263101|||CASE_ONLY||PROSPECTIVE|||||||
34113621|NCT06707142|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34113622|NCT06751108|||COHORT||RETROSPECTIVE|||||||
34113623|NCT06701461|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This preliminary study will look at the predictive effectiveness of the measured biomarker across a small group of patients with osteoarthritis and a small control group of patients without osteoarthritis.||||
34113624|NCT06750510|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34113625|NCT06471257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113626|NCT05562934|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigator staff, persons performing the assessments will remain blinded to the identity of the treatment from the time of randomization until database lock. The study site pharmacist/nurse or other designated qualified site personnel who prepares the study drug and the unblinded CRA will remain unblinded.|The planned duration of treatment is 12 weeks per participant. Participants may be discontinued from treatment earlier due to unacceptable adverse events, disease progression and/or if treatment is discontinued at the discretion of the investigator or the participant. Following the conclusion of the 12-week Randomized Treatment Period, participants will enter an 8-week Safety Follow-up Period in which participants may be treated at the discretion of the investigator taking into account that their blood pressure may still be affected by the study treatment for some time after its discontinuation, especially those who were randomized to XXB750.|t|t|t|f
34113627|NCT05904093|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113628|NCT02242968|||COHORT||PROSPECTIVE|||||||
34113629|NCT03106779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113630|NCT05276973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113631|NCT06129149|NA|SINGLE_GROUP||OTHER||NONE||||||
34113632|NCT05932641|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a Phase I, randomised, double-blind, placebo controlled study evaluating the safety, tolerability, PK and PD of AZD3152 in healthy Japanese adult participants, 18 to 55 years of age. Approximately 24 healthy participants will be randomised at up to 2 study sites in a ratio of 6:2 in each cohort to either AZD3152 or placebo administered IM or IV, across 3 fixed-dose cohorts. To participants who will receive the IMP via IM injection (Cohorts 1 and 2), the IMP will be given as a direct anterolateral thigh IM administration of AZD3152 or placebo. To participants who will receive the IMP via IV infusion (Cohort 3), the IMP will be administered as an IV infusion containing AZD3152 or placebo. The randomisation of Cohort 2 and 3 should be performed sequentially.|t|t|t|t
34113633|NCT06746675|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113634|NCT05690581|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113635|NCT05426733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113636|NCT06408207|RANDOMIZED|PARALLEL||TREATMENT||NONE|Everyone will know their assigned intervention.|Simple randomization||||
34113637|NCT00104325|||CASE_ONLY||RETROSPECTIVE|||||||
34113638|NCT01087281|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113639|NCT05377684|||COHORT||PROSPECTIVE|||||||
34113640|NCT04153292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113641|NCT06459180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113642|NCT04049669|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34113643|NCT06096844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113644|NCT03434080|||COHORT||PROSPECTIVE|||||||
34113645|NCT04033445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113646|NCT05564377|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34113647|NCT06639620|||COHORT||PROSPECTIVE|||||||
34113648|NCT06577454|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34113649|NCT06751121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113650|NCT06712329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"1. Inceler Medical, Modus Focused ESWT~2. 15% dextrose solution injection"|t|f|t|t
34113651|NCT06702553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The intervention gas tanks and the gas delivery systems or the intervention gas generator system in the OR and at the bedside when patients in ICU are covered with drapes and masked that cannot be distinguished on the basis of appearance. This allows to keep participants, clinicians and investigators blind to the assignment group. For safety and gas monitoring, the clinician (or respiratory therapist) administering the test gas remains unblinded to the treatment. This unblinded clinician(or respiratory therapist) is solely responsible for gas tank preparation and test gas delivery and monitoring.||t|t|t|t
34113652|NCT06713005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: 4 mins suprascapular pulsed RF Group 2: 9 mins suprascapular pulsed RF||||
34113653|NCT06719856|||CASE_ONLY||PROSPECTIVE|||||||
33808788|NCT05413993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||QUASI-EXPERIMENTAL CLINICAL TRIAL||||
33808789|NCT04958720|||COHORT||RETROSPECTIVE|||||||
33808790|NCT04559698|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33808791|NCT04069806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808792|NCT00806767|NON_RANDOMIZED|||TREATMENT||NONE||||||
33808793|NCT03560271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigator, sponsor, and subject will be blinded to study treatment.|Subject will be assigned to either 6 mg Cyclo-Z, 15 mg Cyclo-Z or placebo for the duration of study treatment.|t|t|t|t
34040400|NCT03102346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040401|NCT05697497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A delayed treatment control group will be used to compare the effects of the intervention to a control group. Both groups will complete their study visits at baseline, week 6, and week 12, with the intervention group starting their exercises immediately after the baseline visit and the delayed treatment control group starting their exercise intervention after their week 12 visit.|f|f|f|t
34040402|NCT03693131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040403|NCT01149239|||CASE_ONLY||PROSPECTIVE|||||||
34040404|NCT05258305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-randomized open-label study with a patient population consisting of up to 200 subjects divided in 2 cohorts with 100 patients each: reconstruction and augmentation.||||
34040405|NCT06509737|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Dependent Variables: The dependent variables of the study are the knowledge scores of the parents in the groups on the Life with Food Allergy Education Data Collection Form.~Independent Variables: The independent variables of the research are the Food Allergy Life Education application given face to face and via social media, and the sociodemographic characteristics of the child and mother.~Data Collection Techniques and Tools:Parental Data Collection Form and Life with Food Allergy Education Parent Evaluation Form prepared by the researcher will be used to collect research data.~The Parent Data Collection Form consists of questions to inquire about the sociodemographic characteristics of the participants, their children's food allergy processes and social media usage characteristics.~In the study, participants were randomised into two experimental groups. A digital programme was used for block randomisation."||||
34040406|NCT01050933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040407|NCT02042989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040408|NCT00483444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040409|NCT03425591|||COHORT||PROSPECTIVE|||||||
34040410|NCT04856267|||COHORT||PROSPECTIVE|||||||
34040411|NCT00290953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040412|NCT02792712|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34040413|NCT01496001|NA|SINGLE_GROUP||||NONE||||||
34040414|NCT05876676|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040415|NCT01992627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040416|NCT00396656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040417|NCT03089723|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34040418|NCT03448419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040419|NCT04903015|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34040420|NCT02169271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34040421|NCT00771576|||OTHER||RETROSPECTIVE|||||||
34040422|NCT04148586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040423|NCT04119869|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34040424|NCT02630173|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040425|NCT03208166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040426|NCT03280524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To ensure the blinding, the study included an interventionist enabled for application of foot reflexology.|The patients will be taken to a room reserved for the procedure. First, the patients answer the research instruments and then they will be asked to lie supine on a stretcher. The feet of the patients will be cleaned with water (37ºC) and mild soap and then will be dry with paper towels. The next phase consists in the application of foot massage, that will follow the Lourenço's Protocol (2012), which consists of 14 steps of relaxation massage. Each step will have duration of 1 minute, 3 procedures by week, by 4 consecutive weeks. The research instruments, SF-36 and Stanford Health Assessment Questionnarie will be applied before the first and after the last procedure.|t|f|t|f
34040427|NCT06047730|||CASE_ONLY||RETROSPECTIVE|||||||
34040428|NCT04291183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040429|NCT00318474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040430|NCT05251896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040431|NCT02809313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040432|NCT03444311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040433|NCT00954811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34040434|NCT00305019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040435|NCT01888172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34113654|NCT06716983|||COHORT||PROSPECTIVE|||||||
34113655|NCT06731530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113656|NCT06741254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808794|NCT03555812|NON_RANDOMIZED|PARALLEL||OTHER||NONE||measurements of pelvic inclination||||
34040436|NCT05042999|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34040437|NCT04393519|||COHORT||PROSPECTIVE|||||||
34040438|NCT06118931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040439|NCT02646995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34040440|NCT01770769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34040441|NCT04494490|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34040442|NCT01296776|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34040443|NCT01737632|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34040444|NCT00824772|||CASE_ONLY||PROSPECTIVE|||||||
34040445|NCT04005404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Differentiated analysis for the subgroups subtrochanteric femoral fractures, intertrochanteric femoral fractures and neck femur fractures"||||
34040446|NCT05020158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-post effectiveness-implementation hybrid design||||
34113657|NCT05298423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808795|NCT02718196|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808796|NCT00600353|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808797|NCT06157645|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040447|NCT02154451|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|f|t|f
34040448|NCT01665560|||COHORT||PROSPECTIVE|||||||
34040449|NCT00002659|RANDOMIZED|||TREATMENT||||||||
34040450|NCT01660750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040451|NCT02409199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040452|NCT00306020|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34040453|NCT04350125|NA|SEQUENTIAL||TREATMENT||NONE||Subjects treated in this study will be divided into 3 cohorts of 5. After the first cohort of 5 subjects have been treated and evaluated for safety, the second cohort of 5 subjects will proceed with treatment followed by review of events for safety. If determined safe to proceed the third cohort of 5 subjects will proceed with treatment.||||
34040454|NCT03584334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective non-randomized, multi-center, diagnostic performance study of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells||||
34040455|NCT04740710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040456|NCT03174535|||COHORT||PROSPECTIVE|||||||
34040457|NCT06536387|NA|SINGLE_GROUP||OTHER||NONE||||||
34040458|NCT03466684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040459|NCT04121819|NA|SINGLE_GROUP||TREATMENT||NONE||AraC||||
34040460|NCT01043627|||CASE_ONLY|||||||||
34040461|NCT04451057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind .Participants and their legal representatives are blinded.|control group:conventional oxygen therapy interventional group:high flow nasal cannula|t|f|f|f
34040462|NCT05903469|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34040463|NCT04100980|||CASE_ONLY||PROSPECTIVE|||||||
34040464|NCT03739086|||CASE_ONLY||RETROSPECTIVE|||||||
34040465|NCT02632929|||COHORT||PROSPECTIVE|||||||
34040466|NCT00642564|||COHORT||PROSPECTIVE|||||||
34040467|NCT02572570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040468|NCT03126968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040469|NCT00089687||||TREATMENT||||||||
34040470|NCT03070600|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||We will select 20 clinics from Western Kenya. Ten clinics will be randomized to universal PrEP and ten to targeted PrEP (Table 2). To ensure balance between study arms in terms of key site characteristics, sites will be categorized on HIV prevalence and ANC volume, and restricted randomization will be used for site (cluster) allocation to intervention and control arms (68).||||
34040471|NCT06400368|||COHORT||PROSPECTIVE|||||||
34040472|NCT00778219|||CASE_CONTROL||PROSPECTIVE|||||||
34040473|NCT00543322|||||PROSPECTIVE|||||||
34040474|NCT03609385|||COHORT||PROSPECTIVE|||||||
34040475|NCT04968535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was performed using a Computer based randomization program. The physician regulating the electrotherapy device was the only one who was unmasked. The others (physician recruiting the patients, physician investigating the patients at the beginning and in the end of the enrollment, nurses) as well as the patients were blinded. The team was instructed to keep conversations to a minimum required.|randomized controlled double blinded pilot study|t|f|t|f
34040476|NCT00300560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040477|NCT06189300|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34040478|NCT04298970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040479|NCT02755467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040480|NCT04385212|||COHORT||RETROSPECTIVE|||||||
34040481|NCT01729078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34040482|NCT01576679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040483|NCT04347369|||CASE_ONLY||RETROSPECTIVE|||||||
34040484|NCT04332900|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Due to the nature of the study only the person that will process and analyze the data could be blinded regarding the procedures and interventions of the study.|randomised cross-over desing|f|f|f|t
34040485|NCT01854190|||CASE_CONTROL||PROSPECTIVE|||||||
34040486|NCT00891059|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040487|NCT05787717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34040488|NCT05470699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040489|NCT00080756|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34040490|NCT00351195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040491|NCT04565145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040492|NCT06255119|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|Subjects were blinded to study condition.||t|f|f|f
34040493|NCT00384462|||COHORT||PROSPECTIVE|||||||
34040494|NCT01878552|||COHORT||PROSPECTIVE|||||||
34040495|NCT06069219|||COHORT||PROSPECTIVE|||||||
34040496|NCT01873846|NA|SINGLE_GROUP||SCREENING||NONE||||||
34040497|NCT04812041|||COHORT||CROSS_SECTIONAL|||||||
34040498|NCT01400490|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34040499|NCT06481293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study included two groups. One group receives dual wavelength laser diode therapy and the other group receives topical aveogyl dressing.|t|f|t|t
34040500|NCT05428683|NA|SINGLE_GROUP||TREATMENT||NONE||cataract surgery followed by intravitreal injection of triamcinolone and moxifloxacin combination as a prophylaxis against endophthalmitis||||
34040501|NCT05258318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040502|NCT05224739|||CASE_CONTROL||RETROSPECTIVE|||||||
34040503|NCT03602378|||OTHER||CROSS_SECTIONAL|||||||
34040504|NCT03252977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040505|NCT02617160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040506|NCT06126913|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34040507|NCT05516485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040508|NCT02109627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040509|NCT02801617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040510|NCT02533440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040511|NCT03326570|||COHORT||PROSPECTIVE|||||||
34040512|NCT05350618|||CASE_CONTROL||PROSPECTIVE|||||||
34113658|NCT06483282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113659|NCT06739616|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single case research design||||
34113660|NCT06744530|||COHORT||PROSPECTIVE|||||||
34113661|NCT06745284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113662|NCT06751043|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Phase III pragmatic multicenter parallel-group randomized controlled non-inferiority trial with patient-level randomization and assessor blinding. If non-inferiority is demonstrated, we will perform a pre-specified superiority test.|f|f|f|t
34113663|NCT06749314|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants were randomized into two group with computer generated block-of-four randomization with allocation 1:1 into two groups. The control group recieved MIS TLIF while the experimental group recieved endoscopic decompression.||||
34113664|NCT06748690|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34113665|NCT06749379|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34113666|NCT06749184|||COHORT||PROSPECTIVE|||||||
34113667|NCT06747767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113668|NCT06720350|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Each of treatment options will randomized in patients with postmenopausal women.||||
34113669|NCT01621594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808798|NCT05123079|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a Phase 1, single-center trial in healthy participants. The trial is an open-label, randomized, 3-period, 6-sequence, crossover design to investigate the relative bioavailability and effect of food of Darigabat from a single oral.||||
33808799|NCT03528291|||COHORT||PROSPECTIVE|||||||
33808800|NCT00336505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808801|NCT04627896|NA|SINGLE_GROUP||TREATMENT||NONE||Targeted microwave ablation||||
33808802|NCT04422288|||COHORT||RETROSPECTIVE|||||||
33808803|NCT04419779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808804|NCT03340415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Surgeon blinded||f|f|t|f
33808805|NCT03905512|RANDOMIZED|PARALLEL||TREATMENT||NONE|Assessments of qualitative endpoints will be conducted on an assessor-blinded basis.|||||
33808806|NCT05460910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808807|NCT00427440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808808|NCT05870085|NA|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33808809|NCT02956109|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33808810|NCT01616537|NA|SINGLE_GROUP||||NONE||||||
33808811|NCT03497052|||OTHER||PROSPECTIVE|||||||
33808812|NCT05473325|||COHORT||OTHER|||||||
33808813|NCT06698328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808814|NCT02161458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33808815|NCT02167451|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33808816|NCT03067857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808817|NCT06061900|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Individuals completing pre and post-testing will be blinded to if the participate received the intervention or not.||f|f|f|t
33808818|NCT00877019|RANDOMIZED|||TREATMENT||SINGLE|||f|f|t|f
33808819|NCT02108171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808820|NCT03176056|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33808821|NCT01263132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808822|NCT02444845|||COHORT||CROSS_SECTIONAL|||||||
33808823|NCT06124170|||CASE_CONTROL||RETROSPECTIVE|||||||
33808824|NCT00426205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113670|NCT06717347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113671|NCT06716580|NA|SINGLE_GROUP||SCREENING||NONE||||||
34113672|NCT06746948|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34113673|NCT06749002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113674|NCT06746363|||COHORT||PROSPECTIVE|||||||
34113675|NCT06746636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34113676|NCT06743945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808825|NCT06509581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808826|NCT04112810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808827|NCT04318483|||CASE_CONTROL||RETROSPECTIVE|||||||
33808828|NCT01164488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808829|NCT05775432|||COHORT||OTHER|||||||
33808830|NCT01064466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|No-placebo and random and double blind|"* The usual approach group (injection)~* The study approach group (oral)"|t|t|t|t
33808831|NCT00681837|||COHORT||CROSS_SECTIONAL|||||||
33808832|NCT04806100|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the stiffness of each brace. Braces will be labeled A and B, with stiffness only known by research staff.|All participants will be tested wearing no brace and two braces of differing stiffness's. The testing order will be randomized for each participant to prevent testing order from influencing study results.|t|f|f|f
33808833|NCT01818466|||COHORT||RETROSPECTIVE|||||||
33808834|NCT04815720|NA|SINGLE_GROUP||TREATMENT||NONE||"This study will be conducted in 2 parts: a Safety Run-in phase and a Dose Expansion phase.~The Safety Run-in phase will be based on the starting dose of 20 mg/kg pepinemab and a fixed dose of pembrolizumab (200 mg Q3W); 3 to 6 subjects will be treated at this pepinemab dose level. If the initial 20-mg/kg dose of pepinemab in combination with pembrolizumab is determined not to be well tolerated, the dose of pepinemab will be reduced to 15 mg/kg for an additional 3 subjects and a maximum of 6 subjects and then, potentially, to 10 mg/kg for a third group of 3 subjects and a maximum of 6 subjects.~Once the recommended Dose Expansion phase dose is determined, a maximum of approximately 62 subjects will be treated with that dose of pepinemab combined with pembrolizumab."||||
33808835|NCT04012970|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cross-over study design, within-subject repeated measures (intervention versus no intervention).||||
33808836|NCT00570999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113677|NCT03065335|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34113678|NCT06747169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113679|NCT06751238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113680|NCT05100251|NA|SEQUENTIAL||TREATMENT||NONE||||||
34113681|NCT03038672|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808837|NCT00198185|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33808838|NCT00570505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040513|NCT04640428|||COHORT||PROSPECTIVE|||||||
34040514|NCT04021914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040515|NCT05858788|NA|SEQUENTIAL||TREATMENT||NONE||||||
34040516|NCT00813150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040517|NCT03708328|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040518|NCT01537926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150141|NCT05274360|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to either an experimental group or a control group. In the experimental group the participants will receive mobile-based aphasia therapy for two weeks. In the control group participants will receive no additional therapy apart from the conventional aphasia therapy that they are already receiving.||||
34150142|NCT00909597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150143|NCT02488993|||CASE_ONLY||OTHER|||||||
33808839|NCT05785728|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808840|NCT03041090|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All participants are included in the static imaging arm. Some participants were also included in the dynamic imaging arm||||
33808841|NCT02018549|NA|SINGLE_GROUP||OTHER||NONE||||||
33808842|NCT04165772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase II study investigating the efficacy of PD1 blockade with TSR-042 in patients with locally advanced MMRd or MSI rectal adenocarcinoma.||||
33808843|NCT04598594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040519|NCT05220982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34040520|NCT00722358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040521|NCT05880875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Classroom observations will be conducted by study staff who are not aware of which study condition (i.e., experimental or waitlist control) participants are enrolled in.|Participants (i.e., early learning supervisors) will be randomized to the experimental condition (i.e., the Reflective Supervision enhancement) or the waitlist control condition (i.e., business-as-usual).|f|f|f|t
34040522|NCT06349993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34040523|NCT00379418|||COHORT||PROSPECTIVE|||||||
34040524|NCT06288698|||CASE_CROSSOVER||PROSPECTIVE|||||||
34040525|NCT02711696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040526|NCT01575951|NA|SINGLE_GROUP||SCREENING||NONE||||||
34040527|NCT05872204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040528|NCT03690128|RANDOMIZED|PARALLEL||PREVENTION||NONE||A prospective, cluster randomized, cross-over, non-inferiority study||||
34040529|NCT04711590|||COHORT||PROSPECTIVE|||||||
34040530|NCT00765336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040531|NCT05461664|||CASE_ONLY||PROSPECTIVE|||||||
34040532|NCT04572958|||COHORT||PROSPECTIVE|||||||
34040533|NCT02703467|||COHORT||PROSPECTIVE|||||||
34040534|NCT03845660|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||"Subjects will be recruited when electronically identified. The inclusion criteria will be all adults ≥18 years who have an NTproBNP levels of \>500 pg/mL and received intravenous diuretics within 24 hours of admission within the YNHS. Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when providers accesses a patient record to enter a progress note."|t|f|t|t
34040535|NCT00140868|RANDOMIZED|PARALLEL||||NONE||||||
34040536|NCT03165461|||CASE_ONLY||PROSPECTIVE|||||||
34040537|NCT02513160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040538|NCT03538730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Group allocation will be revealed to one investigator at the outset of the lab visit. Other investigators and participants will remain masked until the end of the memory interview. Outcome assessors will remain masked for the duration of the study.|At 2-weeks post-surgery, parent-child dyads will participate in a lab visit during which time they will be randomized into an intervention or control group. Randomization will be conducted by an external statistician using a computer random number generator. Allocation concealment will be achieved using sequentially numbered, opaque, and sealed envelopes.|t|f|f|t
34040539|NCT06163664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34040540|NCT02639624|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040541|NCT00841113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040542|NCT01173523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040543|NCT03096938|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34040544|NCT04424043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040545|NCT03894826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040546|NCT00770783|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34040547|NCT05006079|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|drug doses will be encapsulated, and placebo is included in the design|Repeated measures, placebo-controlled, randomized crossover|t|f|f|t
34040548|NCT00490750|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34040549|NCT00111605|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34040550|NCT05048901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040551|NCT04102267|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040552|NCT03376789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040553|NCT02116127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040554|NCT06378905|||COHORT||PROSPECTIVE|||||||
34040555|NCT03507517|||COHORT||PROSPECTIVE|||||||
34040556|NCT05482113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34040557|NCT00317785||||TREATMENT||NONE||||||
34040558|NCT03963492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors blinded to experimental condition|Randomized controlled pre-post study|f|f|f|t
34040559|NCT02632266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34040560|NCT04351919|NA|SINGLE_GROUP||TREATMENT||NONE||open, interventional, multicentric study||||
34040561|NCT04903639|||OTHER||CROSS_SECTIONAL|||||||
34040562|NCT02915770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040563|NCT05670665|||COHORT||PROSPECTIVE|||||||
34040564|NCT00187980|||DEFINED_POPULATION||PROSPECTIVE|||||||
33726876|NCT03984786|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|"Participants will be blinded to randomization, i.e. will not know which groups they can be randomized to. Health educators providing guidance to participants will be blinded to whether the client has been randomized to Assessment Interview factor (condition 1) or No assessment interview (condition 3). All outcomes are collected online, so there is no need to blind any outcomes assessor."|"Factor 1: Guidance (yes or no)~Factor 2: Assessment interview (yes or no)~Each client will be randomized to one of four conditions:~Condition 1: Assessment interview and Guidance Condition 2: Assessment Interview and No Guidance Condition 3: No Assessment Interview and Guidance Condition 4: No Assessment Interview and No Guidance"|t|t|f|t
33726877|NCT00749320|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726878|NCT03188861|||COHORT||PROSPECTIVE|||||||
33726879|NCT04407130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, Double-Blind, Placebo-Controlled Trial|t|f|t|f
33726880|NCT06050551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726881|NCT03237728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33726882|NCT05148481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726883|NCT03357484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Independent Outcomes Assessor were blinded to study groups. Names of participants were coded and known to Principal investigator only.|Patients who met the inclusion criteria for this split-mouth study underwent bilateral IMTM surgical extractions. Following extraction, randomization was done. One socket received L-PRF, and the other socket served as a regular blood clot control.|t|f|f|t
33726884|NCT01904604|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33726885|NCT01514396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726886|NCT00311896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33726887|NCT06045091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726888|NCT02276612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726889|NCT05739851|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726890|NCT04091503|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
33726891|NCT05777681|||COHORT||RETROSPECTIVE|||||||
33726892|NCT02381223|||COHORT||PROSPECTIVE|||||||
33726893|NCT00916474|||COHORT||PROSPECTIVE|||||||
33726894|NCT00004065||||TREATMENT||||||||
33726895|NCT05408416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726896|NCT02680639|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33726897|NCT00892567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726898|NCT00003814|RANDOMIZED|||TREATMENT||||||||
33726899|NCT03224702|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726900|NCT03858491|NA|SINGLE_GROUP||TREATMENT||NONE||In this study a group of patients will receive cobicistat as add-on on their regular treatment with osimertinib. All patients experience low osimertinib trough concentration levels when treated with the regular osimertinib dose (80 mg per day).||||
33726901|NCT01750580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726902|NCT04738773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33726903|NCT03480997|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726904|NCT01119989|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33726905|NCT02290821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726906|NCT05228392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33726907|NCT04602858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Statistician blinded||f|f|f|t
33808844|NCT06509867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All clinical measurements will be measured and recorded by the blinded researcher. Treatment assignment and surgeries will have been unknown to this examiner. For statistically analysis, groups will be anonymized.|"A total of 15 patients were surgically treated with coronally advanced flap (CAF) associated with de-epithelialized gingival graft. Groups were defined as DGG and DGG+PRF:~DGG Group (n=15): de-epithelialized subepithelial connective tissue grafts + coronally advanced flap DGG+PRF Group (n=15): de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap"|f|f|t|t
33808845|NCT00978588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808846|NCT00467090|||||PROSPECTIVE|||||||
33808847|NCT01925144|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808848|NCT04487249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726908|NCT01025427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726909|NCT04079153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to the intervention allocation and intervention group. A single orthodontic resident will treat all the patients, and one dental technician will construct all the appliances. The clinician, however, is unable to be blinded due to the need to prescribe the MAA as being randomized. Data collection and analysis will be done by the orthodontic resident. Blinding during data collection will not possible but after data collection, all the data will be coded before being processed and analysed, ensuring blinding of this stage of study. Sleep technician and physician who respectively carried out and analysed the polysomnography will be blinded to the treatment assignment. Statistician who analysed the data will also blinded to the group of treatment.|Group A will be assigned for intervention group, whereby patients will receive their MAA set at 25% of mandibular maximal protrusion while Group B will be assigned for control group, whereby patients will receive their MAA set at 50% of mandibular maximal protrusion.|t|f|f|t
33726910|NCT00145873|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33726911|NCT02357940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726912|NCT00954642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726913|NCT02935790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726914|NCT04626869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Diaphragm Measurements will be done by an expert unaware of the working groups.|The patients will be divided into two groups as patients who underwent suprascapular nerve block with the supraclavicular approach and patients who underwent conventional interscalene nerve block. 5 ml of 0.5% Bupivacaine will be injected into both groups. Diaphragmatic movement will be evaluated with ultrasound at the right and left subcostal border with the patients in a semi-sitting position. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block.|f|f|f|t
33726915|NCT05585970|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33726916|NCT00280579|||||PROSPECTIVE|||||||
33726917|NCT04485338|||COHORT||RETROSPECTIVE|||||||
33808849|NCT01278030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808850|NCT05208034|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33808851|NCT05825274|RANDOMIZED|PARALLEL||TREATMENT||NONE|we use in half of patient cathodal tDCS or Brain noninvasive stimulation|Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment||||
33808852|NCT04306419|||OTHER||PROSPECTIVE|||||||
33808853|NCT02733159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808854|NCT01681485|||CASE_ONLY||PROSPECTIVE|||||||
33808855|NCT04016207|||CASE_ONLY||PROSPECTIVE|||||||
33808856|NCT00744952|||COHORT||PROSPECTIVE|||||||
33808857|NCT05202366|||CASE_ONLY||PROSPECTIVE|||||||
33808858|NCT02324790|NA|SINGLE_GROUP||TREATMENT||NONE|evaluator blind|||||
33808859|NCT02343666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808860|NCT05132049|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808861|NCT04318691|||CASE_CONTROL||PROSPECTIVE|||||||
33808862|NCT01596231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808863|NCT03239704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33808864|NCT04440800|||COHORT||PROSPECTIVE|||||||
33808865|NCT03066921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized placebo controlled trial|t|t|t|t
34040565|NCT02172664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040566|NCT02907177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040567|NCT05061693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040568|NCT03543748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040569|NCT05616195|||OTHER||PROSPECTIVE|||||||
34040570|NCT00302848|||COHORT||PROSPECTIVE|||||||
34040571|NCT01643577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040572|NCT02818933|||||PROSPECTIVE|||||||
34040573|NCT04084223|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040574|NCT04446169|||COHORT||PROSPECTIVE|||||||
34113682|NCT05608018|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomly assigned to the intervention/Bluetooth group, intervention/non-Bluetooth group, control/Bluetooth group, or control/non-Bluetooth group upon enrollment in the study. Assignment status will not be concealed from the research assistants enrolling the participant, the participants themselves, or the rest of the study team.|This study is a randomized control trial with 2 arms, and 4 possible randomization groups (intervention/Bluetooth, intervention/non-Bluetooth, control/Bluetooth, and control/non-Bluetooth). The control group will receive the control condition, during which the app monitors driving but the intervention feature is not enabled, and the intervention group will receive the intervention condition during which the intervention feature is enabled. Both groups will self-report their smartphone communication while driving via periodic surveys. Participants randomized to receive a Bluetooth device will keep the device in their primary vehicle for the duration of the study. This device will collect outgoing text date and time from their dyad partner enrolled in the study. Non-Bluetooth participants will not receive the device.|t|f|f|f
34113683|NCT06746922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113684|NCT02769962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113685|NCT05505916|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113686|NCT06193954|NA|SINGLE_GROUP||TREATMENT||NONE||Participants may be enrolled in the trial if an attempt to cross the target lesion with a standard wire fails.||||
34113687|NCT06747338|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this randomized, controlled, open-label, multicenter phase 3 study, treatment-naive with HER2-positive breast cancer were randomly assigned (1:1) centrally and stratified by early (T2-3, N0-1, M0), locally advanced (T2-3, N2-3, M0; T4, any N, M0) breast cancer, and by hormone receptor expression to receive six neoadjuvant cycles of: KN026 plus HB1801 (Experimental) or pertuzumab and trastuzumab plus docetaxel (Active Comparator).||||
34113688|NCT06745804|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34113689|NCT06315374|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34150144|NCT00586976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150145|NCT03042130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150146|NCT00001410||||TREATMENT||||||||
33726918|NCT02386696|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33726919|NCT02184221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33726920|NCT01176227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726921|NCT00884299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726922|NCT02891707|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33726923|NCT06362135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Telephone support or virtual meeting during the research process will be provided by an independent interviewer.|Parallel Assignment Virtual visit with stroke patient and their caregiver|f|f|f|t
33726924|NCT02872779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726925|NCT01734564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726926|NCT06460896|NA|SINGLE_GROUP||OTHER||NONE||||||
33808866|NCT05069818|||COHORT||RETROSPECTIVE|||||||
33808867|NCT04147637|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized crossover study||||
33808868|NCT05528692|||COHORT||PROSPECTIVE|||||||
33808869|NCT00360269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808870|NCT01529632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33808871|NCT03578978|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33808872|NCT06510673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808873|NCT01113736|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33808874|NCT03389789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33808875|NCT05192382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808876|NCT02322424|||COHORT||PROSPECTIVE|||||||
33808877|NCT04953975|||COHORT||PROSPECTIVE|||||||
34040575|NCT02644668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040576|NCT05416528|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040577|NCT03950414|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose-escalation, open label, non-randomized, non-placebo controlled, single group assignment study||||
34040578|NCT03320343|||COHORT||PROSPECTIVE|||||||
34040579|NCT05917535|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||RCT|t|f|f|f
33726927|NCT05322174|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants are randomly assigned to one of two online, behavioral interventions. Because the participants will know which behaviors are promoted to their group, and study staff will be interacting with the participants in their groups, masking is not possible. However, which group is considered the main intervention versus the attention control will not be known to participants.|||||
33726928|NCT05165212|NA|SINGLE_GROUP||OTHER||NONE||||||
33726929|NCT05312229|RANDOMIZED|PARALLEL||OTHER||NONE||The investigators are implementing Critical Time Intervention (CTI), an evidence-based, time limited case management practice for individuals experiencing homelessness. The investigators will be randomizing sites receiving CTI into one of two levels of implementation support (low vs. high intensity support).||||
33726930|NCT06308068|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33726931|NCT00031538|||COHORT||PROSPECTIVE|||||||
33726932|NCT03794037|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33726933|NCT00260754|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33726934|NCT05935007|||COHORT||PROSPECTIVE|||||||
33726935|NCT04991571|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726936|NCT01492452|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33726937|NCT05682131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726938|NCT04104009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The sample is suitable, pregnant women in the second and third trimester of pregnancy who will give birth in a maternity ward County Hospital Dr. Mihovil Sucic Livno from February 2019 to the beginning of September 2019.~By randomization, the respondents will be divided into two groups:~1. Interventional group- a group where group education, breathing exercise and listening to classical music will be conducted.~2. Control group - a group who will spend the pregnancy without education, listening to classical music and breathing exercises.~Both groups are subject to inclusion and exclusion criteria."||||
33726939|NCT06488482|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33726940|NCT00733863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113690|NCT04966481|RANDOMIZED|PARALLEL||TREATMENT||NONE||"These patients will be randomized on a 2:1 basis to Arm 1 (palbociclib + cetuximab, n=54) or Arm 2 (cetuximab alone, n=27). Patients will be stratified at randomization to balance the proportion of patients in each arm with:~1. previous exposure to a platinum agent (cisplatin or carboplatin given to treat recurrent or metastatic disease, or as a component of multimodality therapy for newly diagnosed locally advanced, non-metastatic HNSCC),~2. previous exposure to cetuximab (given as a component of multimodality therapy for newly diagnosed locally advanced, non-metastatic HNSCC)."||||
34113691|NCT06740448|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||A randomised, single blind, crossover design with a 3 week washout period between conditions investigating the acute effects (over 2 and 8 hours) of green tea on blood viscosity|f|f|t|t
34113692|NCT05027802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113693|NCT06745037|||COHORT||PROSPECTIVE|||||||
34113694|NCT06747546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113695|NCT06238531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113696|NCT06492460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34113697|NCT06746935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were randomly allocated into two groups utilizing Random Allocation Software version 2.0. then the allocation was concealed in opaque sealed envelopes. In both groups. The allocation was revealed to the operator just before the surgery. On the other hand, the patients, outcome assessor and the statistician who analyzed the collected data and performed the statistical analysis were blinded.||f|f|f|t
34113698|NCT06730126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113699|NCT06727552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113700|NCT06719609|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34113701|NCT06702618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113702|NCT06716190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34113703|NCT06714318|||COHORT||PROSPECTIVE|||||||
34113704|NCT06732258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113705|NCT06280833|||COHORT||PROSPECTIVE|||||||
34113706|NCT06749990|||COHORT||OTHER|||||||
34113707|NCT04827875|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Excisions of existing keloid scar, treatment of incisional area followed by evaluation of scar formation overtime.||||
34113708|NCT06751381|||COHORT||RETROSPECTIVE|||||||
34113709|NCT06058377|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33726941|NCT06427278|||CASE_CONTROL||RETROSPECTIVE|||||||
33726942|NCT00506155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726943|NCT06025630|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blinded to which condition they are randomly assigned (placebo vs TUDCA ingestion)|This study uses a single-blind, placebo-controlled model.|t|f|f|f
33726944|NCT05712408|NA|SINGLE_GROUP||OTHER||NONE||||||
33726945|NCT03728894|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Outcomes Assessor) Each of the children/parents, the dentist and the outcomes assessors were blinded. To ensure the blindness of the dentist, the inhalation sedation machine was placed in a way that he could not see the flow rate panel or the type of the administered gases.|blinded, randomized controlled trial, comparing two groups.|t|t|f|t
33726946|NCT02852096|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33726947|NCT00344773|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33726948|NCT04710706|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34113710|NCT06745232|||COHORT||PROSPECTIVE|||||||
34113711|NCT06468228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113712|NCT02890342|||COHORT||PROSPECTIVE|||||||
34113713|NCT05812807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113714|NCT06257485|||COHORT||RETROSPECTIVE|||||||
34113715|NCT06233591|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113716|NCT06740981|||COHORT||PROSPECTIVE|||||||
34113717|NCT06751290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113718|NCT06740916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113719|NCT06740890|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34113720|NCT06736236|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34113721|NCT06738225|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113722|NCT06737380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726949|NCT03463746|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Only assessors of the primary outcomes will be blinded to group assignment|Monocentric, randomised-controlled, single-blind trial.|f|f|f|t
33726950|NCT06041412|||CASE_CONTROL||RETROSPECTIVE|||||||
33726951|NCT00690391|||COHORT||PROSPECTIVE|||||||
33726952|NCT02712944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726953|NCT03215329|||COHORT||PROSPECTIVE|||||||
33726954|NCT02338869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33726955|NCT01115595|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33726956|NCT03012113|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33726957|NCT06330922|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33726958|NCT03777293|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33726959|NCT01649375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726960|NCT05721274|RANDOMIZED|PARALLEL||PREVENTION||NONE|Project team will keep liaison with key stakeholders, committee members, polio workers/supervisors and other relevant persons. Influential community members will conduct awareness and motivation activities. The messages would address reasons for OPV and routine vaccine refusals in the community and will be disseminated via health promotion materials and support groups organized by committees.|The intervention is based on behaviour change theory||||
33726961|NCT02342483|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34113723|NCT06726941|NA|SINGLE_GROUP||TREATMENT||NONE||All participants enrolled will receive the same treatment. Gene analysis, histone acetylation levels, motor function and quality of life changes will be assessed.||||
33726962|NCT01053286|||COHORT||CROSS_SECTIONAL|||||||
33726963|NCT00106782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33726964|NCT03237767|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The present study will be a pilot, counter-balanced, cross-over trial in individuals with CF.|The present study will be a pilot, counter-balanced, cross-over trial in individuals with CF.||||
33726965|NCT03766854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33726966|NCT01462357|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33726967|NCT00048542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726968|NCT05223855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant is presented a numbered, opaque, sealed envelope. The outcomes assessor will be presented with data masked from group participations.|Intervention group receives intervention twice a week for 8 weeks. Control group receives usual care through GP for 8 weeks, and are then offered participation in de-stress class twice a week for 8 weeks.|f|f|t|t
33726969|NCT03023865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726970|NCT05830474|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33726971|NCT02510378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726972|NCT03199027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33726973|NCT01527292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726974|NCT02189564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33726975|NCT06385587|||COHORT||PROSPECTIVE|||||||
33726976|NCT03873987|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33726977|NCT01475630|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33726978|NCT05344898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33726979|NCT04774978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33726980|NCT04382248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33726981|NCT00353405|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33726982|NCT06193746|||COHORT||CROSS_SECTIONAL|||||||
33726983|NCT04732559|||OTHER||CROSS_SECTIONAL|||||||
33726984|NCT05415696|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33726985|NCT00665600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33726986|NCT01398956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726987|NCT01430481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33726988|NCT03057028|NA|SINGLE_GROUP||TREATMENT||NONE||Open label treatment with Anakinra||||
33726989|NCT03340337|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||"Thirty male subjects, right leg dominant, will receive 3 types of electrical stimulation in a randomized order. Aussie current will be delivered by Aussie Sport (Ibramed) device, Neo-Russian by Neurodyn III (Ibramed) device and RBS by a Genesy (Globus) device.~MVIC and MEIC will be measured with an isometric dynamometer (3 reps x 5 sec work x 120 sec rest). The best rep will be used. Whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum. MVIC will be used for data normalization.~The VAS will be used to assess tolerance to each treatment. A ratio between MEIC and VAS will be calculated.~One week later, subjects will receive, ramdomly, a fatigue protocol with the three types of electrical stimulation that consists in 21 reps (5 sec work x 5 sec rest). The data will be normalized with the MVIC and the reps equal or below 50 % of the first rep will be considered as a fatigue rep."|t|t|t|t
34113724|NCT06743854|||OTHER||CROSS_SECTIONAL|||||||
34113725|NCT06727734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113726|NCT06269627|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34113727|NCT06707389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33726990|NCT03662542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808878|NCT05458752|||COHORT||RETROSPECTIVE|||||||
33808879|NCT03078205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808880|NCT00336349|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33808881|NCT00914641|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33808882|NCT01961609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808883|NCT02356055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34113728|NCT06720298|||CASE_ONLY||PROSPECTIVE|||||||
33726991|NCT05826782|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33726992|NCT00409812|||||PROSPECTIVE|||||||
33726993|NCT02307851|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33726994|NCT06481306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33726995|NCT01932827|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33726996|NCT00277069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726997|NCT04684147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726998|NCT06244862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113729|NCT06710990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040580|NCT01709487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040581|NCT05552248|||CASE_CONTROL||PROSPECTIVE|||||||
34040582|NCT06286774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|PI Miller and study therapists will be blinded to assessment outcomes, and assessment RAs will be blinded to participant condition.|Subjects will be randomized to Cognitive Behavioral Therapy for Insomnia (CBT-I) or waitlist control.|f|f|t|t
34040583|NCT06230926|||CASE_ONLY||PROSPECTIVE|||||||
34040584|NCT05565118|NA|SINGLE_GROUP||TREATMENT||NONE||Participants undergoing surgical resection will have a regional recording of neuronal electrical activity that will be measured in a minimum of 4 peritumoral anatomic zones via depth electrodes, overlying the cortex of the lesion via a subdural grid, within the presumed tumor, and in adjacent presumed normal brain. Recording findings specific to these anatomo-electro-clinical zones will be correlated with the presence/degree of contrast-enhancing tumor on MRI at recurrence. Additionally, biopsies will be obtained in these depth electrode regions for correlative studies.||||
34040585|NCT03335475|RANDOMIZED|PARALLEL||PREVENTION||NONE|Investigator, research assistants, coaches (interventionists), and participants do not know which condition a participant is in until the condition is revealed (opening an envelope with the condition listed) after the participant assents/consents to Phase 2. Envelopes with the conditions were prepared by the study statistician.|Study includes 2 possible conditions to which participants are randomized: (1) Fitbit only and (2) Fitbit + coaching sessions.||||
34040586|NCT01999556|||OTHER||PROSPECTIVE|||||||
34040587|NCT03389074|||CASE_ONLY||PROSPECTIVE|||||||
34040588|NCT03187730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34040589|NCT02742493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040590|NCT03489668|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34040591|NCT02746965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34040592|NCT05894005|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The outcomes assessor will not be aware of which video format will be viewed by the participants.|Participants will be asked to complete 2 navigation tasks within Sunnybrook Hospital. Prior to each task, video instructions will be provided using either 2D video or immersive 360-degree VR video. Participants will be randomized to two groups with different task orders and for which each task is matched with a different form of instruction (2D or VR).|f|f|f|t
34040593|NCT04432610|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34113730|NCT06704867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34113731|NCT06707077|||COHORT||PROSPECTIVE|||||||
34113732|NCT06698939|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34113733|NCT06703398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113734|NCT06699030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double (Investigator, Participant)|Parallel Assignment|t|t|t|t
34113735|NCT06705764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113736|NCT06744647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113737|NCT04711109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34113738|NCT06203600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113739|NCT05189925|NA|SEQUENTIAL||TREATMENT||NONE||||||
34113740|NCT06709534|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113741|NCT05642468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113742|NCT06427798|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113743|NCT04439266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113744|NCT03895645|||CASE_ONLY||OTHER|||||||
34113745|NCT05730335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33726999|NCT00235872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727000|NCT04504383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||12-week randomized, double-blind, placebo-controlled, parallel design study in patients with moderate to severe active UC. It will be followed by 40 weeks of Extended Active Treatment.|t|f|t|t
33727001|NCT05262634|||COHORT||RETROSPECTIVE|||||||
33808884|NCT00995644|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33727002|NCT00448162|||COHORT||CROSS_SECTIONAL|||||||
33727003|NCT04990752|||CASE_CONTROL||PROSPECTIVE|||||||
33727004|NCT05533853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The treating therapist, for both the control and intervention groups, was unblinded to the treatment method but the assessor who conducted the measurements were blinded. Assessor blinding was obtained through an independent research assist; not knowing the study design and not specifically involved in any aspect of the trial|A prospective, double blinded, parallel-group, randomized clinical trial was conducted at one of our university's research departments,|f|f|f|t
33727005|NCT01068457|||COHORT||RETROSPECTIVE|||||||
33727006|NCT02033421|||CASE_ONLY||PROSPECTIVE|||||||
33727007|NCT04959838|NA|SINGLE_GROUP||SCREENING||NONE||||||
33727008|NCT01966965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727009|NCT04358887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727010|NCT04988217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727011|NCT01100242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727012|NCT03238911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727013|NCT02493738|RANDOMIZED|CROSSOVER||||NONE||||||
33727014|NCT01250587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727015|NCT06438042|||COHORT||PROSPECTIVE|||||||
33727016|NCT02400723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727017|NCT04210635|||COHORT||PROSPECTIVE|||||||
33727018|NCT01083212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33727019|NCT03519568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33727020|NCT00360464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727021|NCT00621881|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727022|NCT01814254|||COHORT||PROSPECTIVE|||||||
33727023|NCT00094939|||||PROSPECTIVE|||||||
33727024|NCT00000560|RANDOMIZED|||||DOUBLE||||||
33727025|NCT04656210|||COHORT||PROSPECTIVE|||||||
33727026|NCT02280135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727027|NCT03561493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727028|NCT03488316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727029|NCT02786485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808885|NCT01847768|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33808886|NCT01632956|||COHORT||PROSPECTIVE|||||||
33808887|NCT01276743|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113746|NCT03150693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113747|NCT03002207|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34113748|NCT03641092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113749|NCT05689021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113750|NCT04554953|||COHORT||PROSPECTIVE|||||||
34113751|NCT05710406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113752|NCT06748638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33808888|NCT00391170|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34113753|NCT06427967|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||One-group pretest-posttest||||
34113754|NCT06518057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113755|NCT03826030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808889|NCT04103099|NA|SINGLE_GROUP||OTHER||NONE||The present study will be a single site, prospective, single arm observational study of minimal risk consisting of at least 200 participants who suffer from cold symptoms||||
34113756|NCT06066736|||COHORT||RETROSPECTIVE|||||||
34113757|NCT04379570|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34113758|NCT06670287|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE||Type I hybrid effectiveness-implementation trial with two steps. Step 1: In-lab trial (with a sample of participants balanced on degree of technological literacy) comparing data processing using legacy actigraphy to multi-sensor machine learning. Step 2: At-home implementation of multi-sensor machine learning approach (balanced by technological literacy).|t|f|t|f
34113759|NCT06542653|||CASE_CONTROL||RETROSPECTIVE|||||||
34113760|NCT06676059|||OTHER||PROSPECTIVE|||||||
34113761|NCT06433752|||CASE_ONLY||PROSPECTIVE|||||||
34113762|NCT05870865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|At all times, treatment and randomization information will be kept confidential and will not be released to the Sponsor's trial team until database lock is completed. Investigators, participants, and clinical staff will remain blinded throughout the trial.|Eligible participants will be randomized to 1 of 4 cohorts: ASN008 gel 1.25 percent, 2.5 percent, 5 percent, or matching vehicle.|t|t|t|t
34113763|NCT04873934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113764|NCT05752474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113765|NCT06517017|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase 2 study.||||
33808890|NCT05123859|||COHORT||CROSS_SECTIONAL|||||||
33808891|NCT01981213|||CASE_ONLY|||||||||
33808892|NCT00395759|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE||||||
33808893|NCT06193655|||CASE_ONLY||CROSS_SECTIONAL|||||||
33808894|NCT01727570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33808895|NCT06181656|||COHORT||PROSPECTIVE|||||||
33808896|NCT03840096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808897|NCT06475079|||COHORT||CROSS_SECTIONAL|||||||
34113766|NCT05081219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither participants nor site personnel involved in assessing participants will know which dose of insulin is being administered. Exceptions will be the study nurse who is directly involved in preparing the insulin.||t|t|t|t
34113767|NCT06409130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34113768|NCT02506673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113769|NCT06664814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113770|NCT06609616|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34113771|NCT06457958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||There will be 2 parallel study arms where sevoflurane and desflurane are administered.|t|f|f|t
33808898|NCT06699589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113772|NCT06253871|NA|SINGLE_GROUP||TREATMENT||NONE||Dose-escalation and dose optimization||||
34113773|NCT04628585|||CASE_ONLY||PROSPECTIVE|||||||
34113774|NCT04387656|||COHORT||PROSPECTIVE|||||||
34113775|NCT06594263|||OTHER||CROSS_SECTIONAL|||||||
34113776|NCT05934526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113777|NCT03601897|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113778|NCT05954091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113779|NCT06656494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113780|NCT06607406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113781|NCT06615973|||COHORT||PROSPECTIVE|||||||
34113782|NCT06616987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113783|NCT05394857|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-1314 s.c in the treatment group, no placebo||||
34113784|NCT03427996|||COHORT||PROSPECTIVE|||||||
33808899|NCT05017454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808900|NCT06322368|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808901|NCT02408913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808902|NCT03247595|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The endoscopist who reports colon cleanliness is blinded to the subject's assignment.|One arm receives Polyethelyne Glycol colonoscopy preparation and the other arm receives magnesium citrate capsules colonoscopy preparation.|f|f|t|f
33808903|NCT03444415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33808904|NCT02501694|||COHORT||PROSPECTIVE|||||||
33808905|NCT01354574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33808906|NCT05156307|||OTHER||PROSPECTIVE|||||||
33808907|NCT01583166|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33808908|NCT04275167|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33808909|NCT02540369|||COHORT||PROSPECTIVE|||||||
33808910|NCT02542943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808911|NCT04463394|NA|SEQUENTIAL||TREATMENT||NONE||Using Minimal Sample size estimation based on the primary outcome (PVR/SVR ratio) based on paired means for decreases in PVR/SVR ratio after vasopressin administration from a prior study at our institution. We calculated a minimum sample size of 28 for a power of 0.8 and and 0.05 significant difference.||||
33808912|NCT03104530|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33808913|NCT01427413|||CASE_ONLY||RETROSPECTIVE|||||||
34040594|NCT03308097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34040595|NCT03025529|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE|In the single group pilot study, there is no intervention and no masking-- just obtaining an MRI and a cerebellocortical inhibition measure. There were 8 subjects in this phase of the study. There were no subjects enrolled in the crossover design phase of this study.|This is a crossover design with two groups, preceded by a separate single group of healthy controls in a pilot study to assess feasibility of obtaining the cerebellocortical inhibition measure||||
34040596|NCT04565197|NA|SINGLE_GROUP||TREATMENT||NONE||Qausi-experimental||||
34040597|NCT00365404|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34040598|NCT00716781|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34113785|NCT05691465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113786|NCT06668922|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113787|NCT04464707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113788|NCT05757193|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants stratified based on use of background use of SGLT2 inhibitors||||
34113789|NCT06661369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be randomized control trial in which non probability convenient sampling will be used. Two groups of 4-12 age will be formed in which participants will be randomly divided. Group A: individually SPM training will be given, Group B: Grouped SPM training given|t|f|f|f
34113790|NCT06597019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked (Year 1) to No Masking (Year 2)|Parallel (Year 1) to single-group (Year 2)|t|f|t|f
33727030|NCT06528392|NA|SINGLE_GROUP||TREATMENT||NONE||This is an exploratory, single arm treatment, non-inferiority trial.||||
33727031|NCT06496841|||COHORT||RETROSPECTIVE|||||||
33727032|NCT03444974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Symptom reduction in the treatment group (adolescent patients with substance abuse and dependency) in comparison to age and gender matched waiting-list and healthy controls. Changes in parental stress levels and parenting skills in the treatment group parents in comparison to waiting-list parents.||||
33727033|NCT01566448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727034|NCT01726738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727035|NCT05811546|||OTHER||CROSS_SECTIONAL|||||||
33727036|NCT01026051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727037|NCT00793338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727038|NCT03864315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040599|NCT03357523|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34040600|NCT03662802|||COHORT||OTHER|||||||
34040601|NCT02790099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34040602|NCT01720862|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040603|NCT03004781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040604|NCT00782626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040605|NCT00675051|||CASE_ONLY||PROSPECTIVE|||||||
34040606|NCT04126538|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34040607|NCT05352620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040608|NCT04709146|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040609|NCT03889418|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||This proposal is a 4-year type 2 effectiveness-implementation hybrid stepped wedge cluster randomized control (cRCT) trial to evaluate a multi-component intervention to: electronic medical recorded (EMR)clinical decision support (CDS) guided care; and stepped opioid collaborative care model (CCM) to improve opioid management of primary care patients with chronic non-cancer pain. The stepped wedge cRCT design will allow us to examine the clinical impact of the intervention as the two components are implemented in a stepwise fashion across the health system. The EMR CDS guided care component went live in all primary care clinics as the health system's standard of practice in October 2017. The stepped opioid CCM component will require 15 months to scale up in 3-month intervals across five geographic regions of the health system in the state of Louisiana. We will randomize the order in which stepped opioid CCM becomes available in each region|f|f|f|t
34040610|NCT04756726|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040611|NCT02007681|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34040612|NCT06080035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040613|NCT03019237|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34040614|NCT04079647|||CASE_ONLY||RETROSPECTIVE|||||||
34040615|NCT02594553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34040616|NCT02838823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040617|NCT05386459|||COHORT||PROSPECTIVE|||||||
34040618|NCT03411031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040619|NCT05408299|||COHORT||PROSPECTIVE|||||||
34040620|NCT01387087|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34040621|NCT04005430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040622|NCT03074825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040623|NCT03578432|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34040624|NCT03155464|RANDOMIZED|PARALLEL||OTHER||NONE||This study will enroll participants in a 1:1 randomized study design. Participants will serve as their own controls. A consecutive series of patients will be randomized to either Group 1 or 2. Randomization will occur through 40 sealed, opaque sequentially numbered envelopes containing the randomization. Those that qualify and sign consent will be randomized 24hrs prior to surgery. The randomization envelopes will be stored in a locked filing cabinet within the clinical research coordinators office. The subject will know what treatment arm they are in prior to surgery.||||
34150147|NCT01424228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727039|NCT01121692|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33727040|NCT05379439|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727041|NCT00006347||||TREATMENT||||||||
33727042|NCT00506090|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33727043|NCT01169506|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727044|NCT00943228|NA|SINGLE_GROUP||||NONE||||||
33727045|NCT05838131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727046|NCT01030562|||COHORT||OTHER|||||||
33727047|NCT02600637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727048|NCT01667978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808914|NCT03395600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808915|NCT02124356|||COHORT||PROSPECTIVE|||||||
34040625|NCT01945840|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34040626|NCT02856932|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|f|t
34040627|NCT05596929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040628|NCT01144702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040629|NCT01109485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040630|NCT03757065|||COHORT||CROSS_SECTIONAL|||||||
34040631|NCT01376999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040632|NCT00536146|||||PROSPECTIVE|||||||
34040633|NCT05212610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040634|NCT05046912|RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical and non-clinical participants will be assigned to either a yoga or mindfulness condition.||||
34040635|NCT01697072|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040636|NCT00347958|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33727049|NCT03398720|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040637|NCT02985580|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34040638|NCT02943954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040639|NCT00223041|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040640|NCT01411800|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040641|NCT04029584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|No masking will be employed because it is very difficult to mask the effects of rifampin (range discoloration) on subjects.|This study is a two arm, randomized, open label, crossover, clinical trial. Arm 1 will be conducted in normal healthy volunteers; Arm 2 will be conducted in hepatically induced (by oral rifampin) healthy volunteers.||||
34040642|NCT02323425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040643|NCT03898167|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34040644|NCT00994383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040645|NCT04677777|NA|SINGLE_GROUP||TREATMENT||NONE||Contemporaneously controlled, open-label safety study||||
34040646|NCT04841395|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040647|NCT01611727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040648|NCT02507739|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34040649|NCT04723446|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34040650|NCT04692311|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Mixed-method pilot study in which persons with central nervous system diseases and occupational therapists were included|f|f|f|t
34040651|NCT04227223|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The serum measurements were performed in total group of 50 adult patients: Study Group - 36 patients with chronic Low-Back Pain with opioids pharmacotherapy and Control Group - 14 patients, healthy volunteers. I||||
34040652|NCT06155929|NA|SINGLE_GROUP||PREVENTION||NONE||The investigators are investigating wether a flight abroad is causing a decrease in stools.||||
34040653|NCT06461026|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
34040654|NCT01287559|||CASE_CONTROL||PROSPECTIVE|||||||
34040655|NCT04191525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Single-centre, randomized, double-blind clinical trial|t|f|t|f
34040656|NCT02627664|||OTHER||PROSPECTIVE|||||||
34040657|NCT01353599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040658|NCT03904251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040659|NCT05510479|||CASE_ONLY||PROSPECTIVE|||||||
34040660|NCT05037201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34040661|NCT00155168|||CASE_CONTROL||PROSPECTIVE|||||||
34040662|NCT03278223|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34040663|NCT02839304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040664|NCT00507455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040665|NCT01265108|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34113791|NCT06663345|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Prospective Randomized||||
34113792|NCT05106036|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34113793|NCT06566378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This prospective, randomised controlled study.|f|f|f|t
33727050|NCT02361255|||CASE_CONTROL||PROSPECTIVE|||||||
33727051|NCT00593307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727052|NCT00001893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33727053|NCT00281203|||CASE_ONLY||PROSPECTIVE|||||||
33727054|NCT03488212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33727055|NCT05075226|||COHORT||PROSPECTIVE|||||||
33727056|NCT04834479|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33727057|NCT05017194|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727058|NCT00676299|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727059|NCT06225726|||CASE_ONLY||PROSPECTIVE|||||||
33727060|NCT06327399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33727061|NCT03729336|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Patient spontaneously voids in the bathroom using PEEZY (research sample). Within 10 minutes, patient is catheterized during physical exam (control sample) for post-void residual.||||
33727062|NCT03987893|RANDOMIZED|PARALLEL||TREATMENT||NONE|participant is randomised using a table of random numbers.|Open Label, randomized control trial||||
33727063|NCT02666183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study personnel administering questionnaire and follow-up questions with participants will be blinded to the arm assignment of the participant||f|t|f|f
33727064|NCT00165412|||CASE_ONLY||PROSPECTIVE|||||||
33727065|NCT01736319|||||PROSPECTIVE|||||||
33727066|NCT02143908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727067|NCT05863299|||COHORT||PROSPECTIVE|||||||
33727068|NCT01450410|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33727069|NCT05810090|||COHORT||RETROSPECTIVE|||||||
33727070|NCT01334203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727071|NCT00877695|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33727072|NCT00244712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727073|NCT01658423|||COHORT||CROSS_SECTIONAL|||||||
33727074|NCT06045234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727075|NCT06115265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be recruited to participate in either KDDP or NDPP. The lifestyle interventions are identical with the exception of dietary recommendations. Groups will be matched according to age, sex, and HbA1c.||||
34113794|NCT05238922|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1a and 2a will be dose escalation using a statistical hybrid design to identify the RDE(s). Parts 1b and 2b will consist of dose expansion to better characterize the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of INCB123667 as monotherapy or in combination with anticancer therapies.||||
34113795|NCT06654050|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113796|NCT06472622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113797|NCT03609216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113798|NCT03992404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113799|NCT03998202|||COHORT||PROSPECTIVE|||||||
34113800|NCT06407297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113801|NCT06595953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113802|NCT05707598|||CASE_CONTROL||RETROSPECTIVE|||||||
34113803|NCT05871970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113804|NCT04130997|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, single-arm, extension study||||
34113805|NCT05814055|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34113806|NCT03388606|||CASE_CONTROL||PROSPECTIVE|||||||
34113807|NCT05057013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113808|NCT05488340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 - open label, Part 2 - blinded.||t|t|t|t
34113809|NCT05454839|||COHORT||PROSPECTIVE|||||||
34113810|NCT05500417|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34113811|NCT05673759|||COHORT||CROSS_SECTIONAL|||||||
34113812|NCT06562595|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The participant will be randomly assigned to one of the four experimental groups by a computerised randomisation software.|"The training methods employed comprise four arms:~1. Video-based training,~2. Classical lecturing,~3. Brochure,~4. Voice recording (Radio broadcast)."|t|f|f|f
34113813|NCT06174402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113814|NCT02052882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113815|NCT02828358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113816|NCT06589154|||COHORT||PROSPECTIVE|||||||
34113817|NCT06477653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113818|NCT06016608|||COHORT||PROSPECTIVE|||||||
34113819|NCT06223542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113820|NCT02626533|||COHORT||PROSPECTIVE|||||||
34113821|NCT06643481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded placebo for infusion|Double-blind, Randomized 2:1 ratio|t|f|t|t
34113822|NCT04990167|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective, randomized, open-label crossover pilot feasibility trial.||||
34113823|NCT00029445|||CASE_ONLY||OTHER|||||||
34113824|NCT06015893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113825|NCT05722210|||COHORT||PROSPECTIVE|||||||
34113826|NCT06074588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113827|NCT02413970|NA|SINGLE_GROUP||TREATMENT||NONE||Inspire UAS||||
34113828|NCT04704544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Providers will be masked to the random assignment of participant visits.|We will conduct an open label, two-period, multi-center, non-inferiority, patient-level randomized controlled trial comparing tele-rheumatology (audio +/- video) with usual care (in-person) visits. Patients will be randomized to the sequence of care for their next two visits (V1 and V2): i) tele-rheumatology (V1) + usual care (V2), OR ii) usual care (V1) + tele-rheumatology (V2). Primary outcome will be ascertained after the first visit (V1).|f|t|f|f
33727076|NCT05700552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727077|NCT03356249|||COHORT||PROSPECTIVE|||||||
33727078|NCT01692236|||||PROSPECTIVE|||||||
33727079|NCT03364296|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727080|NCT05988112|||COHORT||RETROSPECTIVE|||||||
33727081|NCT01856790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727082|NCT05898295|||OTHER||PROSPECTIVE|||||||
33727083|NCT00017134|RANDOMIZED|||PREVENTION||||||||
33727084|NCT00449956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727085|NCT06350175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33808916|NCT01375699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113829|NCT04933539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113830|NCT06019481|||COHORT||PROSPECTIVE|||||||
34113831|NCT06640478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Sub-investigators, research assistants||f|f|t|f
34113832|NCT04982419|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Eligible patients will be randomized to RIPC or sham-RIPC.|f|f|f|t
34113833|NCT06291246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113834|NCT04021108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113835|NCT06269640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113836|NCT06274749|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34113837|NCT03680092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113838|NCT04117347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to study arm. The PI, study coordinator and research assistants will remain unblinded to perform safety assessments and provide feedback on intervention adherence. Blinded staff will wear buttons as an upfront visual cue to remind participants not to talk about their treatment.||f|f|f|t
34113839|NCT06552754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34113840|NCT05253131|NA|SINGLE_GROUP||TREATMENT||NONE||"Part A will be a phase 1 dose escalation study of the combination with selumetinib and BI.~Part B will be phase 1 study combining the determined dose of selumetinib and BI from Part A with durvalumab.~Part C will be a phase 2 study combining selumetinib, BI with durvalumab in MPNST patients at the recommended doses from part B. A Simon's two-stage design will be used in the phase 2 trial to determine the clinical benefit in patients with unresectable or metastatic NF associated MPNST."||||
34113841|NCT01432847|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113842|NCT00026754|||COHORT||PROSPECTIVE|||||||
34113843|NCT04470011|||COHORT||RETROSPECTIVE|||||||
34113844|NCT05653336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808917|NCT00470782|||CASE_ONLY|||||||||
34040666|NCT06236789|||COHORT||RETROSPECTIVE|||||||
34150148|NCT02728531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040667|NCT02791919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040668|NCT03249012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040669|NCT03977870|||COHORT||PROSPECTIVE|||||||
34040670|NCT01610089|NA|SINGLE_GROUP||||NONE||||||
34040671|NCT02149979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040672|NCT03699618|||CASE_ONLY||PROSPECTIVE|||||||
34040673|NCT04562350|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040674|NCT01199627|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34040675|NCT05885763|NA|SINGLE_GROUP||TREATMENT||NONE||A Single-arm, Open-label Study||||
34040676|NCT01648868|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040677|NCT01778530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040678|NCT04016129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040679|NCT05953519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor is blinded to the group assignment||f|f|f|t
34040680|NCT00698633|||COHORT||PROSPECTIVE|||||||
34040681|NCT04677725|||COHORT||PROSPECTIVE|||||||
34040682|NCT01018927|||OTHER||PROSPECTIVE|||||||
34040683|NCT01583062|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040684|NCT02892955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040685|NCT02439918|||||CROSS_SECTIONAL|||||||
34040686|NCT05984901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"All participants fulfilling the eligibility criteria and providing consent will wear the CAVA device for 30 days. The CAVA algorithm will then diagnose each patient based only on the data recorded from the device. The accuracy of the system will be tested by comparing the CAVA system's diagnosis with each patient's known diagnosis. The results of the algorithm work (the diagnosis) will not be available until the end of the trial and will not be made available to clinicians or patients during the trial."||||
34040687|NCT03355274|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with thoracic outlet syndrom (patients) Healthy asymptomatic patients (controls)||||
34040688|NCT04025242|||COHORT||PROSPECTIVE|||||||
34040689|NCT05044611|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||"Two-phased study:~1st phase: Double blind, placebo-controlled, randomized trial to demonstrate the efficacy of 2 months treatment with amiloride 5mg twice a day to increase urine osmolality in patients with BD treated with lithium for at least 5 years and with a urine concentration defect.~This double-blinded phase is followed by an open label phase (2nd phase) during 10 months to evaluate the long-term safety profile of the investigated drug and its potential nephroprotective role."|t|t|t|t
34040690|NCT06465862|NA|SINGLE_GROUP||OTHER||NONE||Single arm pilot demonstration||||
34040691|NCT05504980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040692|NCT05999201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelope|Craniocervical Neural Mobilization and selected physiotherapy program|f|f|t|t
34040693|NCT05721014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040694|NCT00266435|||COHORT||PROSPECTIVE|||||||
34040695|NCT04403230|NA|SINGLE_GROUP||TREATMENT||NONE||This prospective study included 149 teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).||||
34040696|NCT02720328|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34040697|NCT00917748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040698|NCT02537613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040699|NCT05846100|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Fictional ultrasound identification Screen device shut down Intervertebral space identified using the standard palpation|"All eligible participants scheduled for cesarean delivery were prospectively randomized to 2 groups using computer-generated random numbers:~A standard manual palpation group (standard group, n=45) and a pre-puncture ultrasound-guided neuraxial anesthesia group (ultrasound group, n=45)."|t|f|f|f
34040700|NCT04024969|||OTHER||PROSPECTIVE|||||||
34040701|NCT01047059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040702|NCT00932308|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34040703|NCT03768908|RANDOMIZED|||TREATMENT||NONE|No blinding was done due to the different drug formulations and regimens.|A multicentre randomised comparative clinical trial of the efficacy of ASAQ versus AL for the treatment of uncomplicated childhood Plasmodium falciparum malaria.||||
34040704|NCT06400186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34040705|NCT00094731|RANDOMIZED|||||||||||
34040706|NCT06104020|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040707|NCT02332226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040708|NCT06576180|||CASE_CONTROL||PROSPECTIVE|||||||
34040709|NCT03711708|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34040710|NCT03524417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040711|NCT00248742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040712|NCT00855894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040713|NCT00925444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040714|NCT02699346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040715|NCT02562001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040716|NCT01889329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040717|NCT00030901|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34040718|NCT03801369|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040719|NCT01193933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040720|NCT06081647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040721|NCT00073203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040722|NCT04977427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unable to fully mask to investigator in order to maintain safety (must assess the investigational Dextenza insert and its position in the lower punctum at each office visit).|Randomized Fellow-Eye study design, in which one randomized eye in each patient undergoing bilateral cataract surgery receives standard prednisolone therapy, the other eye receiving the investigational Dextenza treatment.|f|f|f|t
33727086|NCT05804383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Placebo capsules||t|t|t|f
33727087|NCT06168487|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727088|NCT06212219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33727089|NCT01172951|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727090|NCT02755376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727091|NCT02506335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727092|NCT04693390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33727093|NCT05751330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727094|NCT04649164|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33727095|NCT02597556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727096|NCT05372796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727097|NCT02886390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727098|NCT04157595|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33727099|NCT00180024|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33727100|NCT00323154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727101|NCT01536431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727102|NCT04427969|||COHORT||RETROSPECTIVE|||||||
33727103|NCT05522413|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727104|NCT01246947|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727105|NCT02876419|||COHORT||OTHER|||||||
33727106|NCT06304142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727107|NCT02622828|NA|SINGLE_GROUP||OTHER||NONE||||||
33727108|NCT02550496|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727109|NCT02993003|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727110|NCT05620576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727111|NCT01200628|||COHORT||PROSPECTIVE|||||||
33727112|NCT02888548|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33727113|NCT00934739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727114|NCT04497779|||COHORT||PROSPECTIVE|||||||
33727115|NCT05622279|NA|SINGLE_GROUP||TREATMENT||NONE||The VAS pain data will be compared between before the procedure and 6 months after using a Wilcoxon ranks test for paired data.||||
33727116|NCT05723016|||COHORT||CROSS_SECTIONAL|||||||
33727117|NCT04785274|||COHORT||PROSPECTIVE|||||||
33727118|NCT01024907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727119|NCT03695731|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727120|NCT00914810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727121|NCT05970315|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33727122|NCT04437966|RANDOMIZED|PARALLEL||TREATMENT||NONE|Data collectors will be blinded to church randomization status until the end of the six-week recruitment period.|Twelve faith based organizations will be chosen from an organization known as New Testament Church of God Assemblies (a Pentecostal religion). Of the 12 organizations selected to participate in the study, six will be randomized to receive the intervention and six will receive usual care. the study statistician will randomly assign each church to either intervention or control groups based on a 1:1 ratio, using a pre-specified random number generator (Stata statistical software version 16). Using a 3-church block, we will assign 2 churches to intervention and 2 churches to control in each randomization block. Block randomization will be used to ensure balanced distribution of intervention and control churches.||||
33727123|NCT05471050|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators are undertaking a randomized controlled trial of 120 adults with steroid-resistant/ relapse ITP in China. Patients were randomized to tacrolimus plus danazol and danazol monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.||||
33727124|NCT04995016|NA|SINGLE_GROUP||TREATMENT||NONE||simon's two stage design||||
33727125|NCT00319826|||CASE_CONTROL||RETROSPECTIVE|||||||
33727126|NCT00550095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727127|NCT02578784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040723|NCT05820529|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||We will do Adenotonsillectomy by three different technique||||
34040724|NCT04633967|||COHORT||RETROSPECTIVE|||||||
34040725|NCT04712344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040726|NCT02956018|||COHORT||PROSPECTIVE|||||||
34113845|NCT06237335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and investigator masking only applies to Part 1 which is randomized. For Part 2, there is no masking, and this part is Open Label.||t|f|t|f
34040727|NCT00995228|||||PROSPECTIVE|||||||
34113846|NCT04235777|NA|SEQUENTIAL||TREATMENT||NONE||||||
33727128|NCT01391481|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33727129|NCT05256121|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727130|NCT00264641|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727131|NCT03558815|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727132|NCT01212718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727133|NCT00273572|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727134|NCT05625035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727135|NCT02626143|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33727136|NCT03451877|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33727137|NCT00218673|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727138|NCT06404151|||CASE_CONTROL||PROSPECTIVE|||||||
33727139|NCT03951246|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727140|NCT04653779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727141|NCT02519920|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33727142|NCT04566419|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Interventional, prospective, randomized (with standard and experimental groups) monocentric study||||
33727143|NCT03034954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727144|NCT01553006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33727145|NCT02889640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727146|NCT01909037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727147|NCT03373383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040728|NCT04735562|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33808918|NCT05646407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is impossible to blind the participants or the investigators for the intervention, as they will be able to see whether they have been allocated to the fan-to-face group or the no fan group. However, participants will complete the supervised exercise-training sessions alone (with the study coordinator) with no other participants in the room, therefore they will be unaware of who has been allocated to the fan-to-face group or the no fan group. They will also be kept relatively unaware of the study hypothesis.|Parallel assignment|t|f|f|f
33808919|NCT04929600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients in ARNI group will take sacubitril/valsartan + matching placebo of amlodipine; Patients in amlodipine group will take amlodipine + matching placebo of sacubitril/valsartan. Any markers that can identify placebo or active drugs will be removed.|After screening and run-in period, eligible patients will be randomly assigned into ARNI group (sacubitril/valsartan 200-400mg QD) or amlodipine group (amlodipine 5-10mg QD).|t|t|t|t
33808920|NCT04037020|||COHORT||OTHER|||||||
34040729|NCT03319238|||COHORT||PROSPECTIVE|||||||
34040730|NCT00004656||||DIAGNOSTIC||||||||
34040731|NCT00789945|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
34040732|NCT05776264|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participant is masked to which condition is the experimental intervention of the study.|Participants will listen to either self-selected music and then a podcast or podcast and then self-selected music on two consecutive sessions, based on a randomized order.|t|f|f|f
34040733|NCT00228436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040734|NCT05138705|NA|SINGLE_GROUP||PREVENTION||NONE|Open Label|Subjects in one group received a first and a second dose of the vaccine at different time points.||||
34040735|NCT03279822|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34040736|NCT01164579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040737|NCT02075931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040738|NCT01937611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040739|NCT05068180|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040740|NCT01166620|||COHORT||RETROSPECTIVE|||||||
34040741|NCT00937365|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040742|NCT05973539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34040743|NCT06222164|||COHORT||PROSPECTIVE|||||||
34040744|NCT01976429|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040745|NCT00012376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040746|NCT04306731|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040747|NCT04627649|||OTHER||PROSPECTIVE|||||||
34040748|NCT03125252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040749|NCT01034202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040750|NCT06065163|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Experimental, randomized, double-blind, and prospective study|t|t|f|f
34040751|NCT00261586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34040752|NCT01045811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040753|NCT05879289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34040754|NCT04996901|||CASE_ONLY||RETROSPECTIVE|||||||
34040755|NCT05661890|||CASE_CONTROL||RETROSPECTIVE|||||||
34040756|NCT02907723|NA|SINGLE_GROUP||OTHER||NONE||||||
34040757|NCT03870932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040758|NCT00648882|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34040759|NCT02479620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040760|NCT04722042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and testing audiologist were blinded to the randomized map|Subjects will be randomized to one of two groups.|t|f|f|t
34040761|NCT05994339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040762|NCT05644626|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040763|NCT05505734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040764|NCT05362188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040765|NCT00907543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040766|NCT00789854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040767|NCT03547375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040768|NCT06344884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized||||
34040769|NCT02921685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040770|NCT05182684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040771|NCT05578261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113847|NCT06352658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113848|NCT06483334|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part 1 is non-randomized open-label. Part 2 is randomized open-label.||||
34113849|NCT05149638|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A prospective, cross-sectional study design consisting of one study visit during which the study participant will undergo cosyntropin stimulation test. The three groups in the study are healthy volunteers (HV; n = 30), patients with known primary or central adrenal insufficiency (n = 30), and patients suspected to have primary or central adrenal insufficiency (n = 30).||||
34113850|NCT01810913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113851|NCT06561828|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34113852|NCT06171178|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34150149|NCT04958226|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040772|NCT00735813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040773|NCT06576492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040774|NCT06048744|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34040775|NCT05799638|||COHORT||PROSPECTIVE|||||||
34040776|NCT02344238|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34040777|NCT01277627|NON_RANDOMIZED|PARALLEL||||NONE||||||
34040778|NCT02199431|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040779|NCT02588612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040780|NCT03903432|NA|SINGLE_GROUP||OTHER||NONE||||||
34040781|NCT01630187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040782|NCT02363543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150150|NCT03417934|||CASE_ONLY||PROSPECTIVE|||||||
34150151|NCT02790814|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34150152|NCT01062061|||||PROSPECTIVE|||||||
34150153|NCT01954316|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34040783|NCT00351468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040784|NCT02298153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040785|NCT03078764|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34040786|NCT04104633|NA|SINGLE_GROUP||OTHER||NONE||||||
34040787|NCT00279461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040788|NCT05630833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040789|NCT01476839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040790|NCT06338501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040791|NCT00474071|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040792|NCT06468085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double Blind study, where participants will be blinded to the study groups they are randomized to, statisticians will be blinded while performing statistical analysis. On the other hand, the operator/primary investigator cannot be blinded as she is already familiar with the tooth and materials used and their different application. Also, the outcome assessor is not blinded due to the difference between the used materials.|two study groups and one control group|t|f|f|f
34040793|NCT02045342|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040794|NCT06297330|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All volunteers will receive an intervention program based on sleep improvement and fatigue reduction.||||
34040795|NCT03574285|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34040796|NCT04863001|||COHORT||RETROSPECTIVE|||||||
34040797|NCT03328013|||COHORT||PROSPECTIVE|||||||
34040798|NCT03648736|||CASE_ONLY||PROSPECTIVE|||||||
34040799|NCT02463903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040800|NCT01076673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040801|NCT02802787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040802|NCT03894657|NA|SINGLE_GROUP||OTHER||NONE||||||
34040803|NCT00832455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040804|NCT02323373|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34040805|NCT02687568|||CASE_CONTROL||PROSPECTIVE|||||||
34040806|NCT06471621|||COHORT||PROSPECTIVE|||||||
34040807|NCT06578429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be completed and stored with staff in the Biostatistic Core. Treatment assignments will be recorded on a USB drive read by the device in order to ensure treaters and study investigators remain blinded. In the instance that a serious adverse event (SAE) occur, consultation with the Data Safety and Monitoring Board and the Institutional Review Board will occur to determine the appropriateness of breaking the blind. The blind may be broken for a specific individual in order to determine whether the SAE is related to the treatment.|Randomized, double-blind, sham-controlled|t|t|t|t
34040808|NCT04911777|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||In the first phase, 45 subjects will be randomized at 2:1 ratio to Pentarlandir™ UPPTA low dose or placebo. After interim analysis and evaluate by DSMB, 45 subjects will be randomized to 2:1 ratio to Pentarlandir™ UPPTA high dose or placebo in second phase. The final sample will be high-dose, low-dose, and placebo group at 1:1:1 ratio.|t|f|t|f
34040809|NCT05056259|||CASE_ONLY||PROSPECTIVE|||||||
34040810|NCT05984524|RANDOMIZED|PARALLEL||OTHER||SINGLE|Sham placebo control intervention|Randomized Control Trial|t|f|f|f
34040811|NCT06396871|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040812|NCT00077207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040813|NCT03105908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040814|NCT03618394|||CASE_CONTROL||PROSPECTIVE|||||||
34040815|NCT03432637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040816|NCT01047384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34040817|NCT01357317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040818|NCT04511013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040819|NCT04417855|||COHORT||CROSS_SECTIONAL|||||||
34040820|NCT01294241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Blinded comparison of wound photo series by two independent experts||f|f|f|t
34040821|NCT04387565|||CASE_CONTROL||PROSPECTIVE|||||||
34040822|NCT06397690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040823|NCT05715411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040824|NCT04830969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34040825|NCT02340429|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34040826|NCT01847586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040827|NCT00583765|||COHORT||PROSPECTIVE|||||||
34040828|NCT03922308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040829|NCT00734994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040830|NCT03426618|||CASE_ONLY||PROSPECTIVE|||||||
34040831|NCT05017675|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34040832|NCT06541457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040833|NCT00902772|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34040834|NCT00637312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040835|NCT03452761|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Supplemental packets were not labeled except with the code A or B - placed by the supplement laboratory. PI notified of groups after completion.|Randomized, double-blinded, 2-groups (condition and placebo)|t|f|t|f
34040836|NCT02431676|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34040837|NCT01987089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040838|NCT04299568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor who will be responsible for collecting the data from the participants in the study will be unaware to the allocation of the participants to the group.||f|f|f|t
34040839|NCT06198231|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomised control trial||||
34040840|NCT03418688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040841|NCT00764660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040842|NCT05587322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040843|NCT02894372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040844|NCT00766012|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34040845|NCT01965756|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This pilot study used a randomized, double-blinded, placebo-controlled 16 week crossover design to examine the effects of metformin on biochemical, neurophysiological, and cognitive biomarkers of AD.|t|t|t|t
33808921|NCT03466983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded||t|t|t|t
33808922|NCT04845386|||CASE_CONTROL||PROSPECTIVE|||||||
33808923|NCT01535898|||COHORT||PROSPECTIVE|||||||
33808924|NCT06375759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808925|NCT01401218|||CASE_ONLY||RETROSPECTIVE|||||||
33808926|NCT06332326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||40 patients diagnosed with UHV were included. Patients were randomized into 2 separate groups (20 people in the vestibular rehabilitation group, 20 people in the vagus nerve stimulation group in addition to vestibular rehabilitation).|t|f|t|t
33808927|NCT05237999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessments will be performed by allocation-blind assessors. The randomization procedure is carried out by a research assistant not involved in assessments, and outcomes are not visible for assessors. Participants are reminded immediately at each contact with an assessor that they are not allowed to discuss whether or not they were in the intervention group.|A randomized controlled trial comparing KopOpOuders-PTSD to control (no intervention). In the intervention group, participants complete 8 sessions over 9 weeks (5 individual online self-help modules, 3 in-person sessions with a prevention professional) of KopOpOuders-PTSD. In the control group, participants do not receive an intervention (but do get access to the online self-help modules after their participation). In both conditions, PTSD treatment (and other therapies if applicable) continue as normal during and after participation.|f|f|t|t
33808928|NCT02911961|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33808929|NCT02022865|||CASE_CONTROL||PROSPECTIVE|||||||
34040846|NCT01836731|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040847|NCT02143505|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34040848|NCT01104805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040849|NCT00595920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040850|NCT04086953|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040851|NCT03570619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040852|NCT03920839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040853|NCT02936297|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
34040854|NCT00511745|||COHORT||PROSPECTIVE|||||||
34040855|NCT05389137|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This clinical trial was designed as a self-controlled trial to observe the immunogenicity and safety. This study was an exploratory study.||||
34040856|NCT01303172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150154|NCT04665531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The method of treatment is obvious and cannot be masked for care providers and investigators. Data will be non-labelled and therefore concealed before the outcomes assessor.|Prospective, randomised, controlled|t|f|f|t
34150155|NCT01528761|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150156|NCT00252616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150157|NCT03597061|RANDOMIZED|PARALLEL||PREVENTION||NONE||Infants will be assigned to either the treatment or control condition.||||
33808930|NCT04346875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single-blind|f|f|f|t
33808931|NCT03421301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"PD and placebo interventions were packaged identically in appearance, both the researcher and the participant did not know what type of maneuver was assigned. The envelopes were distributed by a person outside the study who was the same who performed the randomization.~Study staff and participants were blinded during the assignment and execution of interventions in the study. The packages given to the participants were 2 per day, the placebo packages were matched in grams, calories, color, appearance, flavor to the PD."|In the first stage, the participants with type 2 diabetes consumed a reduced-energy diet tailored to provide a 500-kcal/d deficit as recommended by NIH (8) the with respect to their habitual diet for 15 days. In the second stage the participants continued to consume the reduced energy diet with the addition of a combination of functional foods (dietary portfolio; DP). The DP provided 200 kcal that were subtracted from the diet. The DP consisted of a mi The kcal, appearance and flavor were similar in DP and P. The DP and P was given in a package in dehydrated form ready to be dissolved in water. The DP was divided into two packages, the first package contained 17.3 g of DP or P given in the breakfast and dissolved in 250 ml and the second package was given at the dinner time (15:00-16:00 h) and contained 34.7g of P and DP dissolved in 300 mL of water.|t|f|t|f
33808932|NCT03170882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808933|NCT00336791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808934|NCT03094546|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33808935|NCT01793779|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33808936|NCT01669356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808937|NCT02318810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808938|NCT06510569|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808939|NCT06274203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808940|NCT01825720|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33808941|NCT04284085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33808942|NCT00895245|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33808943|NCT01676454|||COHORT||PROSPECTIVE|||||||
33808944|NCT04256395|||OTHER||PROSPECTIVE|||||||
33808945|NCT05011955|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33808946|NCT00880074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808947|NCT05219526|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808948|NCT04251923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|those who will be filling questionnaires before and after the surgery are masked|"If patient gives consent and falls on selection criteria (inclusion and exclusion), she will be enrolled for randomization. Written informed consent will be taken. Computer generated simple randomization will be done.filled. POP-Q, Occult SUI and ESST will be checked and noted. This will be done by one of the researcher. Surgery will be performed by one of the researcher. Both Group I and Group II patients will undergo vaginal hysterectomy with McCall's culdoplasty and anterior repair with or without posterior repair according to the need. Patient who falls in Group I will undergo midurethral sling with tension free vaginal tape (TVT).~Patient will be followed up at 3 and 6 months. The primary outcome of the study will be the difference in SUI. Secondary outcomes will be BFLUTS AND udi-6 SCORE, voiding dysfunction, dyspareunia, patient satisfaction and complications during surgery."|f|f|f|t
33808949|NCT04755504|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each patient will be evaluated with routine polysomnography and additionally 2 EEG signals will be recorded behind each air.||||
33808950|NCT02594709|NA|SINGLE_GROUP||TREATMENT||NONE||Radiosurgery||||
33808951|NCT01703546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808952|NCT03183349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33808953|NCT06427239|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33808954|NCT02631655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33808955|NCT05958966|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33808956|NCT04658667|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33808957|NCT03020498|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33808958|NCT06172504|||COHORT||CROSS_SECTIONAL|||||||
33808959|NCT06004557|||OTHER||OTHER|||||||
33808960|NCT00698737|||CASE_ONLY||PROSPECTIVE|||||||
33808961|NCT00003654||||DIAGNOSTIC||||||||
33808962|NCT03605732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33808963|NCT00076674||||TREATMENT||||||||
33808964|NCT02676011|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33808965|NCT05106621|||COHORT||PROSPECTIVE|||||||
33808966|NCT01711294|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33808967|NCT06327282|||COHORT||PROSPECTIVE|||||||
33808968|NCT04809623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808969|NCT03412266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808970|NCT04609735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33808971|NCT00028548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808972|NCT04196309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808973|NCT04851665|||OTHER||RETROSPECTIVE|||||||
34040857|NCT06353464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants consume two preloads one at each visit, but are not informed which preload is being consumed on which test visit.|individuals consume two distinct preloads at separate sessions||||
34040858|NCT05931380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040859|NCT03377231|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study involved the use of Stratamark® in prevention and treatment of stretch marks in 2 study arms.||||
34040860|NCT01663961|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34040861|NCT00075907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040862|NCT01093287|||CASE_ONLY||PROSPECTIVE|||||||
34040863|NCT03103152|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34040864|NCT04786678|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be passively monitored for 4 weeks, and all will undergo cell phone based intervention which will notify participants if they are using the cell phone past their latest bedtime for adequate sleep (e.g. if a participant habitually wakes at 8am, and are using their phone past midnight, they will receive a notification).||||
34040865|NCT06418022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a single-center, minimal risk study that will include a total of 400 critically ill patients, aged 18 and older, that require fluid administration.~In prior studies, fluid responsiveness has been shown after an IV fluid bolus with ≥15% increase in VTI or after a passive leg raise (PLR) with ≥ 15% increase in VTI. Similar to the other maneuvers such as the PLR maneuver, we hope to find an optimal cutoff in the increase in VTI after Trendelenburg positioning based on ROC analysis, with an increase of VTI \>15% in patients after receiving IV fluids as the gold standard. There will be no intervention arm and patients will serve as their own control."||||
34040866|NCT04319263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040867|NCT06577324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040868|NCT06199700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040869|NCT02110082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040870|NCT03359616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040871|NCT06352788|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Study participants, investigators, and outcome assessors will be blinded to the condition being tested and will only be introduced to each condition as A, B, or C. Only study coordinators, who will verify adherence with the study protocol (CDO configuration), will not be blinded.|Participants will be cast and fit with either a carbon fiber custom dynamic orthosis (CDO) with a modular or mono design. After being fit with the CDO they will complete testing with the CDO in three different configurations (A, B, C) in a randomized order and without the CDO.|t|f|t|t
34040872|NCT06119893|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34040873|NCT02431286|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34040874|NCT04518241|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Factorial design with 3 components and 8 conditions||||
34040875|NCT05496270|||COHORT||RETROSPECTIVE|||||||
34040876|NCT03451253|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Single (physician) blinded.|4 week randomized into 2 arms, followed by 4 weeks of open label non-randomized follow-up.|f|t|t|t
34040877|NCT02931682|||COHORT||PROSPECTIVE|||||||
34040878|NCT02861807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
34040879|NCT01472042|||COHORT||PROSPECTIVE|||||||
34040880|NCT01659983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040881|NCT02311127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34040882|NCT02146014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040883|NCT06441604|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Only the participant will be masked.|Single-blind, fixed-order, dose-escalation design. All participants (n=10) will first receive XR-BUP 16mg in single-blind fashion. If at least 90% successfully complete induction (success defined as experiencing no BPOW) with the 16mg dose, then we will proceed to the 24mg dose. If at least 90% successfully complete induction the 24mg dose, then we will proceed to the 32mg dose.|t|f|f|f
34040884|NCT02897102|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34040885|NCT03197389|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33808974|NCT00595959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808975|NCT00357916|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33808976|NCT00430599|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33808977|NCT00536120|RANDOMIZED|PARALLEL||||NONE||||||
33808978|NCT02888821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808979|NCT05671445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808980|NCT00089791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33808981|NCT06015256|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33808982|NCT03572894|||COHORT||PROSPECTIVE|||||||
33808983|NCT00728104|||FAMILY_BASED||PROSPECTIVE|||||||
34040886|NCT04603872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040887|NCT03137160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150158|NCT05969132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The current investigation will be a single-blinded clinical trial. Blinding included the assessor, and the statistician. Its impossible for the operator who performed the surgical procedure to be blinded as the interventions will be completely different and the patient also.||f|f|f|t
33808984|NCT05827185|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Because of the experimental nature of the study methodology, it was not feasible to blind the treating therapist as well as the participants included in the study. The therapists who assessed the outcome variables at baseline, 4-weeks, 8-weeks, and 6-months were blinded. Therefore, the therapist providing the treatment and the therapist measuring the data were different individuals. In addition, the outcome-measuring therapist continued to be masked to the participant's groups at all-time intervals. Also, participants were asked not to discuss their treatment details with their peers or the outcome-measuring therapist.|The study includes ergonomic modifications group (EMG; n=24), physiotherapy group (PTG; n=24), and ergonomic modifications combined with physiotherapy group (EPG; n=24) and, control group (CNG; n=24)|f|f|f|t
33808985|NCT06140875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33808986|NCT03868878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33808987|NCT02085772|NA|SINGLE_GROUP||OTHER||||||||
33808988|NCT04614805|||COHORT||PROSPECTIVE|||||||
33808989|NCT03072303|||COHORT||PROSPECTIVE|||||||
33808990|NCT02481804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33808991|NCT03929198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808992|NCT00831506|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33808993|NCT04873206|||CASE_CONTROL||PROSPECTIVE|||||||
34040888|NCT04055701|NA|SINGLE_GROUP||SCREENING||NONE||||||
33808994|NCT00647400|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040889|NCT05280938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34040890|NCT04050852|NA|SINGLE_GROUP||TREATMENT||NONE||5-10 patients with spinal muscular atrophy (SMA), ages 5 years old and above, who have already consented to nusinersen treatment, or have already initiated nusinersen (spinraza) treatments at NYU Winthrop Hospital.||||
34040891|NCT04752956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040892|NCT02773901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040893|NCT02209350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040894|NCT04163120|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
34040895|NCT03989128|||CASE_ONLY||PROSPECTIVE|||||||
34040896|NCT03204994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040897|NCT05047315|||COHORT||PROSPECTIVE|||||||
34040898|NCT06578819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pre-test and post-test case control||||
34040899|NCT00169572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040900|NCT01155856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040901|NCT02841995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040902|NCT03519503|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040903|NCT02119403|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34040904|NCT03779230|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.||||
34040905|NCT04973150|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34040906|NCT02588794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040907|NCT02099890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040908|NCT00172198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34040909|NCT03134144|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34040910|NCT05201872|||COHORT||PROSPECTIVE|||||||
34040911|NCT04052217|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Masking of female participant|Single Case Experimental Design|t|f|f|f
34040912|NCT06526741|||COHORT||OTHER|||||||
34040913|NCT02259374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34040914|NCT05859919|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"The study will be a series of comparisons with two groups. The main group will receive the drug Rutan 0.1.~The control group will not be given the study drug."||||
34040915|NCT06360198|||CASE_ONLY||CROSS_SECTIONAL|||||||
34040916|NCT02522884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040917|NCT04595045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040918|NCT03930355|||OTHER||PROSPECTIVE|||||||
34040919|NCT02555228|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34040920|NCT05272293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150159|NCT04200326|||OTHER||PROSPECTIVE|||||||
34150160|NCT01692665|||CASE_ONLY||PROSPECTIVE|||||||
34150161|NCT05494372|||COHORT||PROSPECTIVE|||||||
34150162|NCT00235287|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33808995|NCT03024021|||COHORT||PROSPECTIVE|||||||
34040921|NCT02133560|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34040922|NCT01492907|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34040923|NCT02479451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040924|NCT06575803|NA|SINGLE_GROUP||TREATMENT||NONE||clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics||||
34040925|NCT02174601|||||PROSPECTIVE|||||||
34040926|NCT03340012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34040927|NCT02015611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34040928|NCT02027454|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34040929|NCT00921609|||CASE_ONLY||PROSPECTIVE|||||||
34040930|NCT03740646|||COHORT||PROSPECTIVE|||||||
34040931|NCT00044018|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040932|NCT05794893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The independent assessors are blind to conditions.|All participants in the intervention group receive the same GBG intervention. The control condition consists of service-as-usual (SAU).|f|f|f|t
34040933|NCT03468491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040934|NCT01317888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34040935|NCT04021030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150163|NCT01021098|||COHORT||PROSPECTIVE|||||||
34150164|NCT01416428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808996|NCT03035942|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Group assignments will be sealed in sequentially numbered opaque envelopes that were opened after patient inclusion in the study. All care providers, researchers, and patients will be blinded to group assignments. Study 5-mL syringes will be prepared by a nurse independent of the study. Normal saline (5 mL total volume), dexamethasone (made up to 5 mL with normal saline), or ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened.|Prospective, randomized, controlled, double-blinded|t|t|t|t
33808997|NCT00266656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33808998|NCT02697968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040936|NCT01006304|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34040937|NCT03722563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040938|NCT06090825|||COHORT||CROSS_SECTIONAL|||||||
33808999|NCT03636854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809000|NCT02705976|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33809001|NCT00974805|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33809002|NCT03400579|NA|SINGLE_GROUP||OTHER||NONE||Prospective, single center, single arm pilot study evaluating the feasibility of delivering remote ischemic conditioning by emergency medical services during ground ambulance transport of patients experiencing chest pain or anginal equivalent symptom||||
33809003|NCT06690242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809004|NCT05325099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809005|NCT06341946|NA|SINGLE_GROUP||TREATMENT||NONE||All patients with malfunctioning VP shunt will be included in this study||||
33809006|NCT02725372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809007|NCT06440213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, parallel group study|t|f|t|f
33809008|NCT02136654|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33809009|NCT04886466|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809010|NCT06152900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809011|NCT03294967|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Participants will not see the label of the capsule.|This will be a crossover study. Each subject is required to consume 200mg caffeine capsule and 200IU vitamin E control capsule, as control, in two different visits. The two visits will be randomized, with a washout period of at least one week.|t|f|f|f
34040939|NCT03187418|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional and monocentric study based in a university hospital setting||||
34040940|NCT01462760|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34040941|NCT05598424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040942|NCT04812223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective randomized||||
34040943|NCT03353714|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040944|NCT01203163|||||PROSPECTIVE|||||||
34040945|NCT00035711|||||RETROSPECTIVE|||||||
34040946|NCT05906381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34040947|NCT05697172|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|A sound proof material will be employed to deliver sham stimulation. The operator of the device will be unblinded to the type of intervention (verum vs sham). Participant, assessment team including raters, and staff responsible for evaluation of psychiatric and neurological status will be blind to the intervention.|An exploratory hypothesis is that stimulation of anteromedial structures of the telencephalic cortex of the right hemisphere and their connections with subcortical structures will lead to detectable attenuation of RNT in high RNT depressed individuals. In this study, the investigators will use a double-blind, randomized cross-over design employing either tfUS or sham stimulation. The proposed design parsimoniously follows the approved pilot study supported by the Center of Biomedical Research Excellence grant NeuroMAP (P20GM121312), in which the investigators will characterize neural circuits associated to RNT.|t|t|f|t
34040948|NCT04997252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040949|NCT04823273|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34040950|NCT00246194|||COHORT||PROSPECTIVE|||||||
34040951|NCT03691454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040952|NCT06009315|||COHORT||PROSPECTIVE|||||||
34040953|NCT01075269|||CASE_CONTROL||PROSPECTIVE|||||||
34040954|NCT05637853|||CASE_CONTROL||PROSPECTIVE|||||||
34040955|NCT00954941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040956|NCT01511978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This was a multicenter, randomized, double-blind, placebo-controlled withdrawal study to assess the safety and efficacy of 3,4-DAP in subjects on a stable regimen of all LEMS-related treatments, including 3,4-DAP, for a minimum of 3 months prior to study entry. Subjects who met all study entry criteria were randomized in a 1:1 ratio to continue their current treatment regimen (Group A, continuous 3,4-DAP) or tapered withdrawal from 3,4-DAP (Group B, taper to placebo).|t|t|t|t
34040957|NCT02863094|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34040958|NCT04394234|||COHORT||RETROSPECTIVE|||||||
34040959|NCT01545531|||COHORT||PROSPECTIVE|||||||
34040960|NCT02504918|||COHORT||PROSPECTIVE|||||||
34040961|NCT06578754|||COHORT||PROSPECTIVE|||||||
34040962|NCT03747380|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34040963|NCT06142487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040964|NCT01198769|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34040965|NCT05228223|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||Prospective randomized controlled double blind study|t|f|t|t
34040966|NCT03063788|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34040967|NCT02737488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34040968|NCT03995537|||CASE_CONTROL||PROSPECTIVE|||||||
34040969|NCT02363218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040970|NCT03911063|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34040971|NCT04295083|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Without knowing that participants are in the experimental or control group||t|f|f|f
34040972|NCT01654185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040973|NCT03055780|||COHORT||RETROSPECTIVE|||||||
33727148|NCT03801564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There are five investigators in this study. N.Fusun Toraman is project manager and blind for the study groups. Yasemin Karaman and Sevim Yıldız are radiologists and blind for the study groups. Meral Bilgilisoy Filiz and Aslı Karadag Ozdemir know the groups, they will select the participants, and Meral Bilgilisoy Filiz will apply intraarticular injections via ultrasound. The participants of the groups do not know each other.|The volunteer, sedanter patients with Kellgren Lawrence (KL) radiological grade II-III knee OA, unilateral knee pain, aged 50-70 years will be selected. Exclusion criterias are; KL radiological grade ≥2 of contrlateral knee, thrombocytopenia, coagulopathy, OA of multiple joints, acute exacerbation of any joint, intraarticular steroid, PRP or HA injection within 6 months, non-steroidal anti inflammatory drugs or steroid use within 6 weeks; diabetes and cancer; severe anemia (Hb \<10), presence of heart and lung disease that can not perform physical function tests, secondary inflammatory arthritis; knee surgery or knee injury; planning for joint replacement within the next 3 months, difficulty in answering the questionnaires, limitation in joint range of motion, presence of genu varum/valgum \>50. Patients will be divided into two groups: Group 1: HA group, Group 2: PRP group, using covariate adaptive randomization as age and osteoarthritis severity covariate.|t|f|t|t
33727149|NCT01438320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33727150|NCT05706688|||COHORT||RETROSPECTIVE|||||||
33727151|NCT03102281|||COHORT||PROSPECTIVE|||||||
33727152|NCT01740596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727153|NCT00571506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727154|NCT02051530|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34113853|NCT05384860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and research assistants (RAs)collecting data from the patients will be blinded.|"Subjects were randomly assigned to receive Acupuncture, or No Acupuncture based on a 1:1 schedule with blocks of four created prior to study initiation using SAS version 9.4 (SAS Institute; Cary, NC) by a member of the biostatistics core not otherwise involved in the trial.~Treatment assignments were transcribed onto notecards and sealed in opaque, consecutively numbered envelopes by a research assistant not otherwise involved in the trial.~After patient consent and prior to anesthesia start, the research assistant involved in the trial handed the randomization envelope to the medical acupuncturist. All patients and research assistants involved with data collection will be blinded to the group allocation.~Randomization lists will be accessed by an intra-op monitor RA who is not otherwise involved in the study in any other aspect."|t|f|f|t
33727155|NCT03394768|||COHORT||PROSPECTIVE|||||||
33727156|NCT02357147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727157|NCT05839210|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727158|NCT03774940|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727159|NCT01378793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727160|NCT01784783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727161|NCT02048553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727162|NCT03228004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727163|NCT02558790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727164|NCT00177892|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33727165|NCT04027738|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trials with a single arm||||
33727166|NCT00204620|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727167|NCT02552316|NA|SINGLE_GROUP||OTHER||NONE||||||
33727168|NCT04843709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040974|NCT03966300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Students will not be aware of whether they are in the intervention or control group. Care providers who are trained in the intervention are aware of the group allocation. They will not communicate with care providers not trained in the intervention. Care providers that are trained in the intervention will not deliver care to participants in the control group and care providers that are not trained will not deliver care to participants in the intervention group|Randomized controlled trial; schools will be randomized to CARD or usual care and all students attending the schools will receive the allocated treatment|t|f|f|f
34113854|NCT01247597|||FAMILY_BASED||OTHER|||||||
34113855|NCT06479148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113856|NCT00843882|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34113857|NCT00644228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113858|NCT02610465|||CASE_CONTROL||PROSPECTIVE|||||||
34113859|NCT04106349|||COHORT||PROSPECTIVE|||||||
33727169|NCT04488965|NA|SINGLE_GROUP||TREATMENT||NONE||monocentric, non-randomized, open-label with single-arm design||||
33727170|NCT05289609|||COHORT||OTHER|||||||
33727171|NCT00855491|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33809012|NCT00357019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809013|NCT01014299|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33809014|NCT04571437|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are assigned into two arms of treatment, arm A contains Letrozole and metronomic Capecitabine while arm B contains Letrozole alone.||||
34040975|NCT03097757|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The orthopedic surgeon reading the x-rays and determining the degree of angulation and displacement will be blinded to all patient characteristics and to the patient's group assignment.|Prospective randomized, controlled, single blinded study|f|f|f|t
34040976|NCT03916237|RANDOMIZED|PARALLEL||TREATMENT||NONE||Students enrolled in the School Health Program with a diagnosis of asthma will be randomized into two groups. The first group will receive regular School Health asthma care. The second group will receive the Asthma Home Assessment Intervention. Based on results of the screening tool and home assessments, participants will be placed into one of four groups: GROUP A (no referral) GROUP B (home assessment only) GROUP C (home assessment and remediation) and GROUP D (medical legal partnership referral only) Home assessment and remediation follows Environmental Health Watch Healthy Homes model previously described. Medical Legal partnership referrals follow protocols consistent with medical legal partnerships previously prescribed.||||
34040977|NCT02019472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34040978|NCT01383707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040979|NCT03413982|||COHORT||PROSPECTIVE|||||||
34113860|NCT01273168|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113861|NCT05877963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727172|NCT03439969|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researcher was blind to the patients||f|f|t|f
33727173|NCT00640705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727174|NCT06061393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727175|NCT02140437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727176|NCT01275495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727177|NCT00138489|||||PROSPECTIVE|||||||
33727178|NCT03947749|||COHORT||PROSPECTIVE|||||||
33727179|NCT06366880|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727180|NCT01845285|||CASE_ONLY||PROSPECTIVE|||||||
33727181|NCT00937417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727182|NCT01600924|||COHORT||PROSPECTIVE|||||||
34040980|NCT03511105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double blind study where investigator, sub-investigators, other site staff and the subject will be blinded. Selected sponsor study team members will be unblinded to perform the interim analysis. This may include the medical monitor, study statistician, study programmer (and delegates) and study pharmacokineticist.|This is a randomised, placebo-controlled, parallel-group study wherein, subjects will be randomised in a ratio of 1:1 to receive 2 single doses of either 4.8 milligrams GSK2798745, then 2.4 milligrams GSK2798745 12 hours later; or a dose of placebo, then another dose of placebo 12 hours later.|t|t|t|f
34040981|NCT00304096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040982|NCT02590744|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34040983|NCT05287035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient and surgeon will be masked. Anesthesiologist will not be masked.|The study will be a double blinded (patient, surgeon) prospective randomized controlled trial.|t|t|t|f
34040984|NCT00218023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113862|NCT05574062|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Run-in Phase: training on the MiniMed 780G system in Manual Mode with SBL activated to collect 2 weeks of baseline data.~Study Phase:~Sequence A: subjects MiniMed 780G system in Auto Mode for 12 weeks (Treatment). The washout phase of 2 weeks will be followed by a 12-week phase where subjects will use 780G system in Manual Mode with SBL activated (Control). Sequence B: subjects 780G system in Manual Mode with SBL activated (Control). After a washout phase of 2 weeks, subjects will use t MiniMed 780G system in Auto Mode for 12 weeks (Treatment).~Continuation Phase:~Period 1: subjects will use MiniMed 780G system in Auto Mode for 18 weeks +/- 6 weeks.~Period 2:~Arm A2: subjects will start using the MiniMed 780G BLE 2.0 system (treatment) for 12 weeks (Treatment).~Arm B2: subjects will continue to use MiniMed™ 780G system in Auto Mode for 12 weeks (Control)."||||
34113863|NCT01498263|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34113864|NCT06406465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040985|NCT02074358|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34113865|NCT02912949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113866|NCT04685200|||COHORT||PROSPECTIVE|||||||
34113867|NCT06375512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113868|NCT04728893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113869|NCT05644951|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34113870|NCT00013559|||COHORT||PROSPECTIVE|||||||
34113871|NCT00001403|||COHORT||PROSPECTIVE|||||||
34113872|NCT05749822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727183|NCT05090761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33727184|NCT04372602|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Blocks of 10 patients will be used to allocate patients to duvelisib or placebo||t|t|t|f
33727185|NCT05420246|||CASE_ONLY||PROSPECTIVE|||||||
33809015|NCT03978065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, single-center pilot study||||
33809016|NCT04127552|||CASE_CONTROL||PROSPECTIVE|||||||
33809017|NCT03139526|||COHORT||CROSS_SECTIONAL|||||||
33809018|NCT01746966|||CASE_CONTROL||PROSPECTIVE|||||||
34040986|NCT01251419|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34040987|NCT01547260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34040988|NCT00224861|RANDOMIZED|||TREATMENT||||||||
34040989|NCT06426732|||COHORT||PROSPECTIVE|||||||
34040990|NCT03010384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113873|NCT05778162|||COHORT||CROSS_SECTIONAL|||||||
33809019|NCT01939249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809020|NCT00770874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809021|NCT03156738|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33809022|NCT05856682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded study : participants and person assessing the post operative pain will be blinded to both the control and intervention group, person performing TAP block will not be assessing the outcome|randomized, prospective, double blinded|t|f|f|t
33809023|NCT05387018|||CASE_CONTROL||PROSPECTIVE|||||||
33809024|NCT02342652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33809025|NCT06238830|||COHORT||PROSPECTIVE|||||||
33809026|NCT06250868|||COHORT||PROSPECTIVE|||||||
33809027|NCT00849485|RANDOMIZED|CROSSOVER||||NONE||||||
33809028|NCT02661932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809029|NCT03365232|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33809030|NCT00569439|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33809031|NCT03622710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809032|NCT02448069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809033|NCT03642834|NA|SEQUENTIAL||TREATMENT||NONE||||||
34040991|NCT02662010|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34040992|NCT06578377|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34040993|NCT01256450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113874|NCT06448299|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34113875|NCT05726864|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113876|NCT04101344|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113877|NCT06101095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34113878|NCT00182858|||CASE_ONLY||RETROSPECTIVE|||||||
34113879|NCT00001465|||COHORT||PROSPECTIVE|||||||
34113880|NCT04972201|||CASE_CONTROL||PROSPECTIVE|||||||
34113881|NCT06484088|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113882|NCT06019182|||COHORT||OTHER|||||||
33727186|NCT05400616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"A biostatistician, not involved in assignment or care of the trial participants, will generate the randomisation sequence with a computerised random number generator. A research assistant, not involved in any other aspect of this study, will place the assigned treatments into sealed envelopes.~Participants (Patients and donors) will be blinded from knowing if they are in the intervention group or the control group. The nurse and doctors attending to the participants will also be blinded. A member of the study team who will prepare the Nasal Microbiota Transplant therapy will not be masked. The person doing the analysis will be masked."|"Eligible patient participants will be randomly assigned to intervention or control group (1:1 ratio) as per a computer-generated randomisation schedule using permuted blocks of random sizes. The block sizes will not be disclosed, to ensure concealment.~Both groups will receive two weeks of antibiotic treatment between recruitment and allocation to a study arm. The study team will work with each patient participant to find a suitable donor. Some patient participants will prefer a donor that is known to them other patients will prefer a donor that is an unknown volunteer. Potential donors who consent to participating in this study will be screened and be classified as donor-participants in the study."|t|t|t|t
33727187|NCT00113659|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727188|NCT00868712|||COHORT||PROSPECTIVE|||||||
33727189|NCT05311371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All of the participants were blinded to the randomization procedure.|Randomized controlled trial|t|f|f|f
33727190|NCT01467999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727191|NCT04953533|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727192|NCT04916795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727193|NCT06219460|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33809034|NCT02727205|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33727194|NCT03491618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective comparative study.||||
33727195|NCT00165425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727196|NCT06229015|||COHORT||PROSPECTIVE|||||||
33727197|NCT00733044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33727198|NCT04342104|||COHORT||PROSPECTIVE|||||||
33727199|NCT00044343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727200|NCT01371097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727201|NCT02286193|||OTHER||PROSPECTIVE|||||||
33727202|NCT01302912|||COHORT||RETROSPECTIVE|||||||
33727203|NCT04483024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||A Randomized, Double-blind, Four-arm Pilot Study to Evaluate the Effects of Brands Chicken Extract and Collagen on Joint, Bone, and Muscle Functions|t|f|t|f
33727204|NCT05022758|||COHORT||RETROSPECTIVE|||||||
33727205|NCT01391975|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33727206|NCT06063486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727207|NCT00189228|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33727208|NCT01865162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727209|NCT05133999|||COHORT||PROSPECTIVE|||||||
33727210|NCT06495918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727211|NCT01720433|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33727212|NCT03255343|NA|SINGLE_GROUP||TREATMENT||NONE||10 patients with liver tumor non operable, with resistance to other classical chemotherapy, injected a single dose of IMDENDRIM 10 mCi per 1 cm²||||
33727213|NCT05546684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33727214|NCT05360563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727215|NCT04726254|||COHORT||PROSPECTIVE|||||||
33727216|NCT00462319|RANDOMIZED|PARALLEL||ECT||NONE||||||
33727217|NCT02596854|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|None used for this single group study.|A single group will be enrolled from the general imaging population using the scanner available at the investigational site (either 1.5T or 3.0T, based on site determination and not specified per protocol). All participants are assigned to a single group.||||
33727218|NCT03198377|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33727219|NCT03893552|NA|SINGLE_GROUP||OTHER||NONE||||||
33727220|NCT06071455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blinded limited to the outcome assessment|split-mouth, prospective, single-center, single-blinded, two-arm randomized clinical trial with a 1:1 allocation ratio.|f|f|f|t
33727221|NCT03932396|||OTHER||PROSPECTIVE|||||||
33727222|NCT04931056|||COHORT||RETROSPECTIVE|||||||
33809035|NCT03543059|||COHORT||PROSPECTIVE|||||||
33727223|NCT03621228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727224|NCT06249282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727225|NCT03714048|||COHORT||PROSPECTIVE|||||||
33727226|NCT00543764|||COHORT||RETROSPECTIVE|||||||
33727227|NCT03667352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33727228|NCT02242851|||COHORT||PROSPECTIVE|||||||
33727229|NCT06458894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33727230|NCT04991961|||COHORT||PROSPECTIVE|||||||
33727231|NCT00598754|||COHORT||PROSPECTIVE|||||||
33727232|NCT00066066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727233|NCT01437007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727234|NCT04656132|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727235|NCT01484769|||COHORT||CROSS_SECTIONAL|||||||
33727236|NCT03317171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727237|NCT04280367|||CASE_CONTROL||PROSPECTIVE|||||||
33727238|NCT04547062|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Continual Reassessment Method for MTD||||
33727239|NCT01446965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809036|NCT05912374|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind|randomized controlled pilot trial|t|f|f|f
33809037|NCT01584596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809038|NCT01018550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809039|NCT02506452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded wound core lab||f|f|f|t
33809040|NCT00000127|RANDOMIZED|||TREATMENT||||||||
33809041|NCT03620955|||CASE_CONTROL||PROSPECTIVE|||||||
33809042|NCT04559074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809043|NCT04255225|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34040994|NCT00941135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34040995|NCT01918488|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34040996|NCT05807295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34040997|NCT03285828|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||A pilot pre-post study investigating the effects of a training programme, by comparing performance before and after its implementation|t|f|f|f
34040998|NCT03839004|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34040999|NCT05208463|||COHORT||RETROSPECTIVE|||||||
34041000|NCT04346797|RANDOMIZED|PARALLEL||TREATMENT||NONE||Bayesian open labelled randomized clinical trial||||
34041001|NCT04380831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041002|NCT03993054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041003|NCT02066480|||COHORT||PROSPECTIVE|||||||
34041004|NCT04387435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041005|NCT01171027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041006|NCT04405492|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041007|NCT00510211|||COHORT||PROSPECTIVE|||||||
34041008|NCT04774627|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041009|NCT04671420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041010|NCT03981250|RANDOMIZED|PARALLEL||PREVENTION||NONE|There is no masking due to intervention characteristics (exercise training programme).|Randomized controlled trial.||||
34041011|NCT05877118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized clinical trial||||
34041012|NCT03680378|NA|SINGLE_GROUP||OTHER||NONE||||||
34041013|NCT06111014|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label continuation study|Open-label||||
34041014|NCT01610882|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34041015|NCT01216241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041016|NCT00001298||||TREATMENT||||||||
34041017|NCT01158235|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34041018|NCT05556954|||COHORT||PROSPECTIVE|||||||
34041019|NCT04615403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041020|NCT05967013|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||An open-label single-dose, 4-period cross-over, randomized, non-comparative mono-centric study where 0.625 mL of a saline solution will be injected in the thigh (on bare skin or through clothing) with the ZENEO® injector to healthy subjects.||||
34041021|NCT02064998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34041022|NCT06504979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041023|NCT00256412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041024|NCT03096314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041025|NCT06319989|RANDOMIZED|PARALLEL||OTHER||NONE|The intervention group will receive caudal epidural block under the guidance of biplane ultrasound. The procedures for patients in the control group will be guided by conventional single-plane ultrasound.|This is a prospective, randomized, parallel study to assess the efficacy of biplane ultrasound-guided caudal epidural anesthesia in pediatric patients.||||
34041026|NCT05031611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041027|NCT03683875|||CASE_CONTROL||PROSPECTIVE|||||||
34041028|NCT02989870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041029|NCT03964675|NA|SINGLE_GROUP||OTHER||NONE||||||
34041030|NCT00591565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041031|NCT02564653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041032|NCT01870011|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041033|NCT05150483|||COHORT||PROSPECTIVE|||||||
34041034|NCT02547220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041035|NCT04150978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator is blinded from any information regarding the treatment allocation of participants during the intervention.|Within 24-48 hours, Intensive care patients are allocated into three treatment, Enteral High-Protein Formulas, Oligomeric Formula, and 5% Dextrose Solution as control|f|f|t|f
34041036|NCT02053766|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34041037|NCT00952965|||||PROSPECTIVE|||||||
34041038|NCT05003804|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind, placebo-controlled|Participants will be enrolled in a three-part sequential approach (Parts A1, A2, and B). Part A will enroll at risk participants of 1 year to less than 6 years of age; after safety review, Part A2 will enroll at risk participants of 1 month to less than 12 months of age; and after safety review, Part B will enroll at -risk participants between 0 and 14 days of life.|t|t|t|t
34041039|NCT06256601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041040|NCT02025725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809044|NCT05885620|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33809045|NCT03383848|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33809046|NCT01855165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34041041|NCT06133517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041042|NCT02368535|||COHORT||PROSPECTIVE|||||||
34041043|NCT03906760|||COHORT||RETROSPECTIVE|||||||
34041044|NCT00862004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041045|NCT06337149|||COHORT||PROSPECTIVE|||||||
34041046|NCT05641805|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041047|NCT05643469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041048|NCT04492176|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34041049|NCT04439929|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34041050|NCT02746718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041051|NCT02553018|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34041052|NCT00717301|||COHORT||PROSPECTIVE|||||||
34041053|NCT01463189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041054|NCT02545959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041055|NCT05333068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind||t|f|f|f
34041056|NCT02173691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041057|NCT01276756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041058|NCT03778892|RANDOMIZED|PARALLEL||PREVENTION||NONE||half of study participants will receive the intervention||||
34041059|NCT00698672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041060|NCT01182051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809047|NCT06199115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809048|NCT01963598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809049|NCT04569188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809050|NCT03442777|RANDOMIZED|PARALLEL||PREVENTION||NONE||patients will be allocated to 1 of the 3 study arms based on a 1:1:1 allocation||||
33809051|NCT04829552|||COHORT||RETROSPECTIVE|||||||
33809052|NCT01003366|RANDOMIZED|PARALLEL||||NONE||||||
33809053|NCT01869049|||COHORT||PROSPECTIVE|||||||
33809054|NCT05307952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809055|NCT03773497|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33809056|NCT02906137|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33809057|NCT04348357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809058|NCT02441569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809059|NCT03709797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809060|NCT04913506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, Randomized, Controlled, Single-Blinded Study|f|f|f|t
34041061|NCT00629252|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34041062|NCT05040425|RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants selected at screening who provide written informed consent will be randomly allocated to two groups. One will be submitted to Chinese herbal medicine group, and the other to control group.||||
34041063|NCT03907761|||CASE_CONTROL||RETROSPECTIVE|||||||
34041064|NCT02113462|||COHORT||PROSPECTIVE|||||||
34041065|NCT04711551|||COHORT||OTHER|||||||
34113883|NCT00044304|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041066|NCT04022057|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blinded, randomized controlled, prospective|t|t|t|f
33809061|NCT02624830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809062|NCT05292118|||COHORT||PROSPECTIVE|||||||
34041067|NCT00418860|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809063|NCT00233610|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809064|NCT01385800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809065|NCT02767999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809066|NCT01958385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113884|NCT02115282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041068|NCT04947215|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041069|NCT01808963|||CASE_ONLY||PROSPECTIVE|||||||
34041070|NCT00131612|||CASE_ONLY||PROSPECTIVE|||||||
34041071|NCT03831009|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two-arm parallel assignment. Based on stability evaluation using weight-bearing adiographs one group recieves surgery, one group recieves non-surgical treatment.||||
34041072|NCT04618523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041073|NCT05091580|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Since this is a stepped wedge design, masking will not be possible. Clinics will be randomized in terms of the order in which they're trained to deliver the behavioral intervention over time, but it will be obvious whether or not a clinic is implementing the intervention.|Stepped-wedge cluster-randomized hybrid type I effectiveness-implementation trial||||
34113885|NCT00055172|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34113886|NCT03996291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113887|NCT04370795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113888|NCT05328154|RANDOMIZED|PARALLEL||TREATMENT||NONE||Following the inclusion visit, patients will be assigned to one of the two groups (bisphosphonates alone or bisphosphonate associated with magnesium). Treatment assignment will follow a predefined randomization list and will be performed by a Clinical Research Associate who is totally independent from the protocol. The randomization list and a copy will be edited and given to the Clermont-Ferrand University Hospital Pharmacy and to the Rheumatology Department of the Gabriel Montpied University Hospital.||||
34113889|NCT05657405|||COHORT||PROSPECTIVE|||||||
34113890|NCT03294460|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113891|NCT04069468|||COHORT||PROSPECTIVE|||||||
34113892|NCT06161558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113893|NCT00055055|||CASE_CONTROL||OTHER|||||||
34113894|NCT06238622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113895|NCT06287762|||COHORT||PROSPECTIVE|||||||
34113896|NCT01132937|||CASE_ONLY||PROSPECTIVE|||||||
34113897|NCT01271465|||COHORT||PROSPECTIVE|||||||
34113898|NCT06052618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113899|NCT06322940|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participant's study group will be coded.|Three treatment groups|f|f|t|t
34113900|NCT06557772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113901|NCT05968430|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Eligible subjects participating in the RTW will receive double-blind treatment with matching placebo. Upon completion, subjects will return to open-label treatment|||||
34113902|NCT06161545|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809067|NCT03543904|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants were blinded towards which group they were allocated. If participants know that they were belonging to the experimental group 1 then they will be performing better than the participants in allocated in the experimental group 2.|Parallel||||
33809068|NCT00714402|||CASE_ONLY||PROSPECTIVE|||||||
33809069|NCT01667003|||OTHER||PROSPECTIVE|||||||
33809070|NCT04266496|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809071|NCT02066155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809072|NCT06216704|||CASE_CONTROL||PROSPECTIVE|||||||
33809073|NCT04041726|||COHORT||PROSPECTIVE|||||||
33809074|NCT03067337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809075|NCT06543797|NA|SINGLE_GROUP||OTHER||NONE||||||
33809076|NCT00300404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33809077|NCT04459572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809078|NCT05899699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33809079|NCT04363112|NA|SINGLE_GROUP||OTHER||NONE||The study is an monocentric, interventional, comparative uncontrolled study||||
34041074|NCT01030289|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34041075|NCT00516022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041076|NCT00793962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809080|NCT01779700|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34113903|NCT06567847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not know which participant received which intervention.|There will be an equal number of participants in the two groups randomized by the computer.|f|f|f|t
34113904|NCT04431024|||CASE_ONLY||PROSPECTIVE|||||||
34113905|NCT06312137|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a multi site study|f|f|f|t
34113906|NCT06052631|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34113907|NCT04402788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809081|NCT03471013|||OTHER||CROSS_SECTIONAL|||||||
33809082|NCT01847456|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33809083|NCT02431741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041077|NCT06370676|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|The participant is blinded for the location of the oesophageal temperature probe tip.||t|f|f|f
34041078|NCT01464593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041079|NCT02716168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34041080|NCT04972552|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|Randomization will be performed by a pharmacy and investigators will not know the assignment until trial completion.|2x2 placebo-controlled factorial trial|t|f|t|t
34041081|NCT01850238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041082|NCT03192488|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34041083|NCT00056238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34041084|NCT06578663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The sample will be randomly divided into three groups: A, B, and C. Group A: The control group (n=20) Group B: The study group (n=20) will receive conventional physical therapy plus electrical dry needling.~Group C: The study group (n=20) will receive conventional physical therapy plus glucosamine sulfate iontophoresis."|Randomized controlled trail, repeated measured; pre and post-test experimental design will be conducted|t|f|f|f
34041085|NCT00204698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041086|NCT03387371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041087|NCT03862313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041088|NCT02156011|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041089|NCT00558467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041090|NCT05149456|||CASE_ONLY||RETROSPECTIVE|||||||
34041091|NCT05215977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041092|NCT06509087|||COHORT||PROSPECTIVE|||||||
34041093|NCT00163956|||DEFINED_POPULATION||OTHER|||||||
34041094|NCT01354002|||CASE_CONTROL||PROSPECTIVE|||||||
34041095|NCT02962648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041096|NCT01822639|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041097|NCT06091956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041098|NCT03104140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34041099|NCT03688867|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041100|NCT01510210|||CASE_ONLY||PROSPECTIVE|||||||
34041101|NCT04412967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041102|NCT00113581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041103|NCT04939987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041104|NCT06576856|||COHORT||CROSS_SECTIONAL|||||||
34041105|NCT06216132|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The surgeon and the team performing the subcutaneous implant and removal will be unmasked. All other staff and subjects will be masked.|Determine naltrexone and 6b-naltrexole pharmacokinetic parameters in subjects administered a single dose of BIOPIN 6 \[BIOPIN 6 implants containing 4.8g (dose-level #1), 9.6g (dose-level #2), or 14.4g (dose-level #3) naltrexone\]. Each of the three dose groups will be compared to a placebo implant group.|t|t|t|t
34041106|NCT03517176|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041107|NCT02151851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34113908|NCT05382559|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113909|NCT06344130|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113910|NCT06312176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113911|NCT06517654|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three parallel treatment groups.||||
34113912|NCT04616326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113913|NCT06354257|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Open-label|Fixed sequence||||
34113914|NCT04267848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809084|NCT01519557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809085|NCT00489879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809086|NCT05420584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809087|NCT00893698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809088|NCT04163432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer.||||
33809089|NCT02113826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809090|NCT00364988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041108|NCT04798911|||OTHER||OTHER|||||||
34041109|NCT00317187|RANDOMIZED|PARALLEL||PREVENTION||||||||
34041110|NCT00779896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041111|NCT01913548|||CASE_CONTROL||PROSPECTIVE|||||||
34041112|NCT00462709|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041113|NCT05509907|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34041114|NCT06096168|||COHORT||PROSPECTIVE|||||||
34041115|NCT05148676|||OTHER||CROSS_SECTIONAL|||||||
34041116|NCT03811548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34041117|NCT01573832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34041118|NCT06209723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041119|NCT06491537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727240|NCT04797260|NA|SINGLE_GROUP||TREATMENT||NONE||CD34+ HSC from patient will be obtained by leukapheresis or from bone marrow. After purification, CD34+ cells will be transduced with the SIN-LV-RAG1 vector. Transduced cells will be cryopreserved. Upon confirmation of successful transduction and meeting the release criteria as RAG1 LV CD34+ cells, patient conditioning will be allowed to start. After patient conditioning, cryopreserved RAG1 LV CD34+ cells will be thawed and administered to the patient. In case of failure of hematopoietic reconstitution after infusion of the RAG1 LV CD34+ cells the autologous backup graft will be infused to rescue the patient from aplasia. In addition, a conventional allogeneic HSCT procedure will be scheduled. Patients included in this study will be monitored on protocol during the first two years after infusion of the RAG1 LV CD34+ cells as per study protocol. Follow up as part of the routine clinical care for post-transplant patients will be annual after this, for at least 15 years after infusion.||||
33727241|NCT01946399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727242|NCT05847530|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization is not requires, as the group to which a subject is assigned to will be at the discretion of the investigator.||||
33727243|NCT02806050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727244|NCT00969787|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33727245|NCT03161483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041120|NCT05219591|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participant Masking: on steps 2, 3 and 4 Investigator Masking: on step 2|"The study will be carried out in 4 steps:~1. During Polysomnography exam: Intermittent application of expiratory pressure relief (EPR), when the peak inspiratory flow will be measured with and without the application of EPR, on sleep stage called N2~2. During Polysomnography exam: After the intermittent application of EPR, manual CPAP pressure titration will be performed with (CPAP-EPRon) and without EPR on (CPAP-EPRoff), under random order and a blinded observer.~3. Use of outpatient CPAP, in random order, for a total of 3 weeks:~   i. adjusted to the previously titrated pressure CPAP-EPRoff, without the addition of EPR technology (1 week) and with the addition of EPR technology(1 week).~   ii. adjusted to the previously titrated pressure CPAP-EPRon, with the addition of EPR technology, for 1 week.~4. Use of outpatient CPAP, in random order, for a total of 2 weeks:~   i. adjusted in automatic mode with adding EPR technology on (1 week) and off (1 week)."|t|f|t|f
33727246|NCT05640570|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33727247|NCT04274647|NA|SINGLE_GROUP||TREATMENT||NONE||NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUE||||
33809091|NCT01501825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809092|NCT01240785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809093|NCT02721407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809094|NCT01556594|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809095|NCT00148122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041121|NCT02525783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041122|NCT05818501|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The trial is a single group pre-post test study at elderly residential settings and rehabilitation settings. During the 12-day or 13-day trial period, the participants will use conventional cups in the first 5 days of the trial, receive 2-3 days of training on using the one of the two models of dysphagia cups, and use the dysphagia cups for 5 days.||||
34113915|NCT06373731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trial personnel and subjects will be masked to treatment until the database is locked at the end of the trial, unless noted below. The Investigator will contact the Sponsor Medical Monitor prior to unmasking any subject's treatment sequence unless in the instance of a medical emergency. In case of an immediate medical emergency, or if directed by the Sponsor, and only if the information is required by the Investigator to manage a subject's AE, a subject's treatment assignment may be unmasked prematurely using the computerized system. The Sponsor must be notified as soon as possible regarding the reason for unmasking.|Subjects will be randomized (2:1) to once daily 40 mg SC of elamipretide or placebo for 96 weeks of treatment by a central randomization|t|t|t|t
33809096|NCT05328258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects are randomised to triptorelin (active arm) or placebo (control) given in parallel to the chemotherapy treatment for the cancer diagnosis. All personnel involved in the study, and subjects, except personnel preparing triptorelin/placebo at the local site and an unblinded monitor, will be blinded during the study. Unblinded research nurse at each site will prepare blinded triptorelin/placebo to subjects and a web-based randomisation system will be used to allocate of blinded triptorelin/placebo to subjects at randomisation and drug dispense during the treatment period.|Prospective, randomised, double-blinded, placebo-controlled, phase 3 study|t|t|t|f
33809097|NCT04290052|||COHORT||PROSPECTIVE|||||||
33809098|NCT01402518|||COHORT||PROSPECTIVE|||||||
33809099|NCT00598949|||CASE_CONTROL||PROSPECTIVE|||||||
33809100|NCT04056754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809101|NCT05957770|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809102|NCT05377476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809103|NCT05235685|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients masked from intervention (gas mixture being delivered). Non-randomized (air medical condition tested first).|2 parralel study groups: patients with COPD (N=20); patients with COPD-HF overlap (N=20) Between-group comparison (COPD vs COPD-HF) under medical air Only patients with COPD-HF overlap exposed to intervention (hyperoxia)|t|f|f|f
33809104|NCT02011360|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33809105|NCT01696500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809106|NCT03774849|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041123|NCT03786328|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34041124|NCT03123393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041125|NCT04166942|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open-label, non-randomized, parallel-group study with the following subject treatment arms:~Group 1: normal hepatic function; Group 2: mild hepatic impairment; Group 3: moderate hepatic impairment; Group 4: severe hepatic impairment"||||
34041126|NCT05660161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041127|NCT05749744|||CASE_CONTROL||RETROSPECTIVE|||||||
34041128|NCT01051791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041129|NCT00598741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34113916|NCT05715125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study has a double-blind design, meaning that the participant, care provider, and investigator will not know what treatment group each participant has been assigned to. This blinding will last from randomization until the end of the study.|Participants are randomly assigned at the beginning of the study to either Dose A, Dose B, or placebo group, where they stay for the remainder of the study.|t|t|t|t
34113917|NCT05102019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34113918|NCT04444921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113919|NCT06203834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113920|NCT04971109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An oral dose of placebo (3 capsules identical to TPOXX)||t|f|t|f
34113921|NCT06274632|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34113922|NCT05268276|RANDOMIZED|PARALLEL||TREATMENT||NONE||after obtaining the primary and official permission data collection will be carried out through five steps in each group: Recruitment \& randomization; interviewing; initial assessment; intervention; follow up and monitoring. : For the study group the intervention will be according to a designed protocol of care that entails; 1) Application of ice gel pad on perineal trauma for the first 24 hours post partum; 2) Performance of pelvic floor exercises (Kegel exercises) from six hours till one week postpartum; 3) Application of warm compresses after 48 hours and through the first week postpartum. The investigator will perform demonstration and then redemonstration by the women on each intervention will be done. A designed booklet (developed previously) that explains each intervention will be given to each woman.The control group will receive the routine hospital care only||||
34113923|NCT03980340|||OTHER||PROSPECTIVE|||||||
34113924|NCT06429956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will not be known to participants that we are testing combinatory and sequencing effects and that participants are randomly allocated to receive the treatment modules in a specific order.|Participants will be randomized to receive either 1) the mindful emotion awareness module followed by the cognitive flexibility module or 2) the cognitive flexibility module followed by the mindful emotion awareness module. All participants will undergo a three-week waiting period before starting treatment.|t|f|f|f
34113925|NCT06500702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113926|NCT06445023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113927|NCT06504394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113928|NCT02286089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113929|NCT05604547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113930|NCT02473445|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label extension study||||
34113931|NCT04459468|||CASE_CONTROL||PROSPECTIVE|||||||
34113932|NCT06589440|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1 will follow a traditional 3+3 dose escalation scheme. Approximately 6-12 subjects will be treated in Part 1.~Part 2 Approximately up to 58 subjects will be enrolled:~Cohort A: MSS-CRC subject with no active liver metastases Cohort B: MSS-CRC subject with active liver metastases"||||
34113933|NCT03717753|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34113934|NCT06652503|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34113935|NCT03988621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator was blinded to the assignment of participant to the two different arms in the study.|"The study was based on the Transactional Model of Stress and Coping. Stressful experiences such as caregiving demand - circumstances that give rise to real or perceived stress - are construed as person-environment transactions. Primary appraisal of demand involves assessment of its significance, which results in perceived burden. Secondary appraisal involves assessment of the resources available to cope with it. These appraisals lead to the coping effort. Without successful coping, self-care is poor, which decreases health status in caregivers. The virtual support intervention \[ViCCY (Vicky) - Virtual Caregiver Coach for You\] addressed both appraisal and coping."|f|f|t|f
34113936|NCT03484819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113937|NCT06592703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113938|NCT04592211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113939|NCT06602453|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34113940|NCT06586112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113941|NCT06591455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113942|NCT05698745|||COHORT||PROSPECTIVE|||||||
34113943|NCT06603246|NA|SEQUENTIAL||TREATMENT||NONE||||||
34113944|NCT06660355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113945|NCT06661304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33809107|NCT01640340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809108|NCT04565652|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Each patient will knowingly wear the ICD Smartband|A single group of patients will wear the LOIS ICD smartband during elective ICD defibrillation||||
33809109|NCT03269500|||COHORT||PROSPECTIVE|||||||
33809110|NCT06147466|||COHORT||PROSPECTIVE|||||||
33809111|NCT05097638|||COHORT||PROSPECTIVE|||||||
33809112|NCT04958837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will be a single blinded study. Only the participants will be masked.|Participants will be randomly allocated to Interventional Group A (FIFA 11+ with dynamic core stability training protocol) or Interventional Group B/ Control Group (FIFA 11+ protocol) for the whole duration of the study.|t|f|f|f
33809113|NCT02829398|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33809114|NCT05188066|||COHORT||PROSPECTIVE|||||||
33809115|NCT01087437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33809116|NCT05103891|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33809117|NCT00201045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809118|NCT02764970|||COHORT||RETROSPECTIVE|||||||
33809119|NCT03507244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809120|NCT05118100|||COHORT||PROSPECTIVE|||||||
33809121|NCT04439825|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33809122|NCT00286325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809123|NCT04819698|||COHORT||PROSPECTIVE|||||||
34113946|NCT06660667|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part I is an open-label study. Part II is partially masked in which participants, Investigators, and outcomes assessors including reading center (RC) are masked to study intervention. The Sponsor is not masked. Masking will be maintained until all participants reach 52 weeks of follow up after SAR402663 dose.|Part I is nonrandomized sequential dose escalation and Part II is randomized parallel assignment|t|t|t|t
33727248|NCT05026684|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33727249|NCT00952107|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33727250|NCT03094754|||COHORT||PROSPECTIVE|||||||
33727251|NCT00962507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809124|NCT01837368|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809125|NCT00359203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809126|NCT05686499|RANDOMIZED|CROSSOVER||OTHER||NONE||Trainees will be selected from among resident doctors and consultants working in teaching hospitals and federal medical centres that have facilities for colonoscopy. These will be randomized into two arms - high fidelity (HF) and low fidelity (LF) arms. Baseline test will then be carried out by the trainees after which they will be exposed to colonoscopy lectures and demonstrations using respective fidelity type to which they are randomized. Simulation examination will then be carried out after which trainees will be cross-overed to alternate arms for further simulation on different fidelity types. They will then all have opportunity to perform colonoscopy on live patients which will be supervised and accessed by trainers.||||
33809127|NCT05037305|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||All individuals in study will be undergo pharmacogenetic testing, which will be performed in our CLIA-CAP certified clinical laboratory using the panel-based clinical pharmacogenetic assay used at Vanderbilt University Medical Center. Upon completion of the pharmacogenetic testing, participants will be randomized to view an educational video immediately (intervention group), or after completion of a follow up survey (delayed intervention).||||
33809128|NCT01590134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809129|NCT01788371|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809130|NCT02414594|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33809131|NCT04179565|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33809132|NCT04345627|||CASE_CONTROL||PROSPECTIVE|||||||
33809133|NCT05143125|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041130|NCT06385574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessors do not know which patient is in which group.|There are three groups in the study. First group is leap motion interventional group, second group is hand exercises group and the third group is waiting list.|f|f|t|t
34041131|NCT03253653||PARALLEL||OTHER||NONE||The investigators will employ a repeated measures design. A sample of 50 adult male and female exclusive WP smokers and a control sample of 25 male and female non-smokers will be recruited. Over a 3-week study, WP smokers will smoke one WP tobacco head during each of 3 separate WP smoking sessions with a 7-day washout period before each session. Session 1, WP smokers will smoke using 1 quick-light charcoal and room temperature water in the WP jar; Session 2, WP smokers will smoke using 1 quick-light charcoal but adding ice cubes to the water in the WP jar; Session 3, WP smokers will smoke WP tobacco without charcoal using an electric WP head and room temperature water. Physiological effects, carbon monoxide exposure and biomarkers of toxicants and carcinogens related to WP tobacco smoking practices will be compared.||||
34041132|NCT02118116|RANDOMIZED|PARALLEL||||NONE||||||
34041133|NCT03195621|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||2 groups||||
33727252|NCT01476943|||COHORT||OTHER|||||||
33727253|NCT05385419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727254|NCT05947136|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727255|NCT05528237|NA|SINGLE_GROUP||SCREENING||NONE||||||
33727256|NCT02264002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33727257|NCT03314350|||COHORT||CROSS_SECTIONAL|||||||
33727258|NCT05613621|||COHORT||PROSPECTIVE|||||||
33727259|NCT00443586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors were masked to original treatment assignments.||f|f|f|t
33727260|NCT04305795|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727261|NCT06118112|||OTHER||PROSPECTIVE|||||||
34041134|NCT01924832|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041135|NCT05709678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34041136|NCT06209528|||COHORT||CROSS_SECTIONAL|||||||
34041137|NCT03944668|NA|SINGLE_GROUP||OTHER||NONE||single arm, non-randomized||||
34041138|NCT04735601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041139|NCT02395250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041140|NCT03375268|||OTHER||RETROSPECTIVE|||||||
34041141|NCT05334693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041142|NCT04515654|NA|SINGLE_GROUP||OTHER||NONE||||||
34041143|NCT05903404|||OTHER||CROSS_SECTIONAL|||||||
34041144|NCT05879536|||COHORT||PROSPECTIVE|||||||
34041145|NCT00005606||||TREATMENT||||||||
34041146|NCT02506868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041147|NCT02594982|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041148|NCT05726071|||OTHER||CROSS_SECTIONAL|||||||
34041149|NCT03088072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041150|NCT01837511|||COHORT||RETROSPECTIVE|||||||
34041151|NCT05522998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041152|NCT02564601|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34041153|NCT00683722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041154|NCT00896792|NA|SINGLE_GROUP||OTHER||||||||
34041155|NCT02887183|NA|SINGLE_GROUP||OTHER||NONE||||||
34041156|NCT00010335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041157|NCT04276246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041158|NCT03340454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041159|NCT06577753|||COHORT||PROSPECTIVE|||||||
34041160|NCT06577012|||OTHER||OTHER|||||||
34041161|NCT05769387|||COHORT||PROSPECTIVE|||||||
34041162|NCT02480673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041163|NCT04236492|||COHORT||PROSPECTIVE|||||||
34041164|NCT01603693|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727262|NCT03588221|RANDOMIZED|CROSSOVER||SCREENING||NONE||"Randomized crossover trial, comparing the following four sets of hand hygiene measurements per participant:~1. Six-step hand hygiene technique with an application time of 30 seconds~2. Six-step hand hygiene technique with an application time of 15 seconds~3. Three-step hand hygiene technique with an application time of 30 seconds~4. Three-step hand hygiene technique with an application time of 15 seconds"||||
33727263|NCT03947151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33727264|NCT05618262|||CASE_CONTROL||RETROSPECTIVE|||||||
33727265|NCT02596646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727266|NCT01982253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727267|NCT01147991||||TREATMENT||||||||
33727268|NCT02678676|||COHORT||PROSPECTIVE|||||||
33727269|NCT04578249|RANDOMIZED|PARALLEL||PREVENTION||NONE||Study participants at the Heart and Vascular Institute (HVI) will be randomly assigned to the control group (goggles that allow through the full spectrum of light), or to the experimental group (goggles that filter out light in the blue range) using block randomization. With a sample size of 40 participants per group (i.e., N = 80 total).||||
33727270|NCT05455983|||COHORT||PROSPECTIVE|||||||
33727271|NCT00206453|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727272|NCT02865915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727273|NCT01677091|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33727274|NCT00162565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727275|NCT04382001|||OTHER||PROSPECTIVE|||||||
33727276|NCT04877275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809134|NCT04711291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"BIDMC kidney transplant patients currently taking immediate release tacrolimus (IR-Tac) will be screened for enrollment into the trial. Eligible patients will be randomized to one of three treatment arms in a 1:1:1 fashion. We aim to randomize seventy-five (75) patients into one of three treatment arms (1:1:1) as described.~Arm 1: Remain on tacrolimus immediate release (IR-Tac) prescribed doses every 12 hours; Arm 2: Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours; OR Arm 3: Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAxTM."|t|t|t|f
33727277|NCT03583996|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects receive HepQuant SHUNT test and DSI measurement prior to a SOC EGD, to be done within 42 days of the SHUNT test. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test||||
33727278|NCT06342843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicenter, prospective, double blinded, randomized controlled intervention study|t|f|t|f
33727279|NCT00902564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727280|NCT03610243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727281|NCT06021561|||COHORT||RETROSPECTIVE|||||||
33727282|NCT03957512|||COHORT||OTHER|||||||
33727283|NCT00682188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727284|NCT01959152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727285|NCT03067805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33727286|NCT05292560|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33727287|NCT00864747|RANDOMIZED|CROSSOVER||||NONE||||||
33727288|NCT03669835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727289|NCT01895738|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33727290|NCT04657497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809135|NCT00239512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33809136|NCT03282253|||COHORT||PROSPECTIVE|||||||
33809137|NCT00986752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809138|NCT02260973|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33809139|NCT00776139|RANDOMIZED|CROSSOVER||||NONE||||||
33809140|NCT04903080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study includes two groups: a safety cohort and a surgical cohort.||||
33809141|NCT06510985|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33809142|NCT04555668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809143|NCT00307216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809144|NCT02695199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33727291|NCT06394869|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809145|NCT04707807|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809146|NCT01138384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809147|NCT01524497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33809148|NCT01661972|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809149|NCT04284878|||CASE_CONTROL||RETROSPECTIVE|||||||
33809150|NCT05749237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized placebo controlled|t|f|f|f
33809151|NCT03398668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809152|NCT03031743|||CASE_CONTROL||PROSPECTIVE|||||||
33727292|NCT05210686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809153|NCT04580004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809154|NCT02226159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809155|NCT00109031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33809156|NCT05522309|NA|SEQUENTIAL||TREATMENT||NONE||||||
33809157|NCT05945316|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33809158|NCT04913532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809159|NCT01087710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113947|NCT06587204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34113948|NCT06660342|||COHORT||PROSPECTIVE|||||||
33727293|NCT02061969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727294|NCT00779103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727295|NCT03048396|NA|SINGLE_GROUP||OTHER||NONE||||||
33727296|NCT05159245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727297|NCT04334499|||COHORT||PROSPECTIVE|||||||
33727298|NCT01928862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727299|NCT02734810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727300|NCT05347316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727301|NCT01251588|||OTHER||PROSPECTIVE|||||||
33727302|NCT04508270|||COHORT||PROSPECTIVE|||||||
33727303|NCT01461772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727304|NCT06250062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel|t|t|t|t
33727305|NCT02260284|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727306|NCT06072937|NA|SINGLE_GROUP||TREATMENT||NONE||Single Arm Early Feasibility Trial||||
33727307|NCT00004888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727308|NCT02871739|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33727309|NCT00314236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809160|NCT05478096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent researcher who is not involved in the study will generate the random sequence using a computer random sequence generator. Randomisation will take place at an individual level, stratified by gender and the university where students study. Participants will be randomised into two groups (web-based intervention vs. WL) with allocation ratio of 1:1. We will conduct block randomisation with randomly varied block sizes (6 to 12 allocations per block) to prevent foreknowledge of intervention assignment. Allocation will be concealed from the study's researchers. It is not possible to mask personnel and participants to the treatment allocation because of the nature of the intervention.|The present study is a two-arm randomized control superiority trial. This trial will be conducted in a university setting. A guided web-based anti-procrastination programme (GetStarted) will be compared to a waiting list condition.|f|f|t|t
33727310|NCT01865981|||OTHER||OTHER|||||||
33727311|NCT03500146|||COHORT||PROSPECTIVE|||||||
33727312|NCT01054638|||COHORT||RETROSPECTIVE|||||||
33727313|NCT01787578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727314|NCT01182493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727315|NCT00456716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727316|NCT00448071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33727317|NCT01582997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727318|NCT04092166|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 Randomization||||
33727319|NCT04377282|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized crossover||||
33727320|NCT02876965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727321|NCT02419118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727322|NCT02187328|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33727323|NCT02886377|||CASE_CONTROL||RETROSPECTIVE|||||||
33727324|NCT01667640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727325|NCT01770288|NA|SINGLE_GROUP||SCREENING||NONE||||||
33727326|NCT00882258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727327|NCT03880851|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, Intervention: Plan adaption in case of significant changes of organ at risk or target volumes measured in weekly MRIs||||
33727328|NCT05407246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33727329|NCT05776654|||COHORT||PROSPECTIVE|||||||
33727330|NCT04277754|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33727331|NCT01498640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727332|NCT05766332|||COHORT||PROSPECTIVE|||||||
33727333|NCT02418858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727334|NCT05086796|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727335|NCT06060626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The endoscopist performing the procedure will not be informed which group the patient belongs to.|The study will be performed on a sample of patients undergoing an endoscopic procedure requiring sedation. Patients will be divided into two groups, one group will be sedated with propofol only, the other will be premedicated with the opioid analgesic fentanyl before the procedure.|f|t|f|f
33727336|NCT04210752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727337|NCT02357069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809161|NCT01329406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809162|NCT01627314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113949|NCT06662383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727338|NCT03422120|||COHORT||PROSPECTIVE|||||||
33727339|NCT02701972|NA|SINGLE_GROUP||TREATMENT||NONE||BACE device implant||||
33727340|NCT04301765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||randomized, double-blind, placebo-controlled, parallel group, trial of daily transdermal testosterone gel or placebo gel for 6-months|t|t|t|t
33727341|NCT04031833|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I: Persons in Uganda without meningitis or active infections Phase II: HIV-infected persons in Uganda with cryptococcal meningitis||||
33727342|NCT06062966|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study designed to treat 20 subjects to provide the preliminary data necessary to inform the design of subsequent hypothesis-driven studies.||||
33727343|NCT02893410|||COHORT||PROSPECTIVE|||||||
33727344|NCT04328831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727345|NCT02515942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727346|NCT04052542|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727347|NCT01112631|||CASE_CONTROL||PROSPECTIVE|||||||
33727348|NCT01583972|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727349|NCT02629692|NA|SINGLE_GROUP||TREATMENT||NONE|"Part B and C: Single arm (Open-label)~Part A: 2 arms: Investigational agent arm and Placebo arm (Double-blind)."|"Part A: Single ascending dose in healthy volunteers.~Part B: Multiple ascending dose safety and tolerability study in subjects with CML or Ph + ALL.~Part C: Efficacy and safety study in subjects with treatment-resistant CML"||||
33809163|NCT03466970|||OTHER||PROSPECTIVE|||||||
33809164|NCT04843449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727350|NCT03533387|RANDOMIZED|CROSSOVER||OTHER||NONE||"Subjects will receive the following three treatments in a crossover fashion, administered one week apart:~* ER1: Single dose (50mg) of ER Prototype 1 (one 50mg ER1 tablet),~* ER2: Single dose (50mg) of ER Prototype 2 (one 50mg ER2 tablet), and~* IR: Two doses of intermediate-release capsules (50mg Pinatos® capsules in two divided doses 12 hours apart, i.e., 25mg for each dose)."||||
33727351|NCT03435965|||CASE_CONTROL||PROSPECTIVE|||||||
33727352|NCT01334866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727353|NCT00621218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727354|NCT05769959|NA|SEQUENTIAL||TREATMENT||NONE||||||
33727355|NCT02556684|||COHORT||PROSPECTIVE|||||||
33727356|NCT06065761|||COHORT||PROSPECTIVE|||||||
33727357|NCT02653742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727358|NCT01976832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727359|NCT03239470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33727360|NCT02685631|||COHORT||PROSPECTIVE|||||||
33727361|NCT02782416|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33727362|NCT04434885|||COHORT||CROSS_SECTIONAL|||||||
33727363|NCT04929652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727364|NCT02174835|RANDOMIZED|CROSSOVER||||NONE||||||
33727365|NCT05132764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor and the investigator will have no knowledge of the intervention in the digital models.|Two parallel arm randomized controlled clinical trial|f|f|t|t
33727366|NCT02865031|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727367|NCT03072966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727368|NCT03141411|||CASE_CONTROL||PROSPECTIVE|||||||
33727369|NCT05511142|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727370|NCT04903405|||COHORT||CROSS_SECTIONAL|||||||
33727371|NCT05077943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727372|NCT05525845|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33727373|NCT05725512|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|None of the personnel with patient contact will have knowledge to the patient's allocation to prednisolone or placebo group.||t|t|t|t
33809165|NCT04067609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|double blind|a pilot double blind, placebo controlled randomized control trial using 40 subjects|t|f|f|f
33809166|NCT03692845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809167|NCT05659394|RANDOMIZED|PARALLEL||TREATMENT||NONE||The IPCOTT study is a parallel global multicentre, pragmatic, open, randomised controlled trial of IPC (2hrs daily) plus standard wound care vs. standard wound care alone.||||
33809168|NCT01276275|||COHORT||RETROSPECTIVE|||||||
33809169|NCT04701372|||CASE_ONLY||RETROSPECTIVE|||||||
33809170|NCT03251456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809171|NCT00389454|||||PROSPECTIVE|||||||
33809172|NCT01579032|||COHORT||CROSS_SECTIONAL|||||||
33809173|NCT03673605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809174|NCT01360918|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809175|NCT00003041||||TREATMENT||||||||
33809176|NCT04338178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33809177|NCT03534349|||OTHER||OTHER|||||||
33727374|NCT02265055|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33809178|NCT05732727|RANDOMIZED|PARALLEL||TREATMENT||NONE|"The very nature of the intervention assessed prevents any form of blinding, neither for care providers, nor for patients.~However, the primary outcome is a composite outcome of events which we plan to adjudicate. As a consequence, the primary outcome will be blindly assessed."|Cluster randomized controlled||||
33809179|NCT00360191|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33809180|NCT02591056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809181|NCT00838994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809182|NCT03352713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33727375|NCT01188408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727376|NCT05159895|NA|SINGLE_GROUP||OTHER||NONE||||||
33727377|NCT04096118|||COHORT||RETROSPECTIVE|||||||
33727378|NCT03075670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33727379|NCT05659173|||CASE_CONTROL||PROSPECTIVE|||||||
33727380|NCT05619276|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The study will be advertised as research on practical strategies to facilitate a balanced and healthy diet.|The study involves two stages. During stage 1 (control condition) all participants will use conventional kitchen utensils to self-serve and condiment a laboratory meal. During stage 2 (experimental condition) all participants will use an experimental set of tools to self-serve and condiment the same meal as in stage 1. The two stages will always follow the same order, control first and then experimental. The before and after design was chosen as the study aims to explore the acute effect of the implementation of portion control utensils in the same individual, avoiding carry-over effects due to learning from using the experimental tool.|t|f|f|f
33727381|NCT03047109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727382|NCT02411487|||CASE_ONLY||PROSPECTIVE|||||||
33809183|NCT00035048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809184|NCT00042926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809185|NCT01469585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809186|NCT02298166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33727383|NCT00212953|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33727384|NCT03088254|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33727385|NCT03782428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|both probiotic and placebo product were labelled as either A or B and was given to the patients through simple randomization.|A randomized double-blind placebo controlled trial was performed in patients who were diagnosed with colorectal cancer and planned for colorectal resection. Four weeks postoperative, patients were randomized to receive either placebo or 3g X 1010 probiotic containing six viable microorganism of Lactobacillus and Bifidobacterium strains for six months.|t|f|t|f
33727386|NCT00853554|RANDOMIZED|CROSSOVER||||NONE||||||
33727387|NCT01853033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33727388|NCT02323854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33809187|NCT00946972|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33809188|NCT04813991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple Blinded|Randomized Double-Blind Intervention Trial|t|t|t|t
33809189|NCT01031056|||||PROSPECTIVE|||||||
33809190|NCT06180226|||COHORT||PROSPECTIVE|||||||
33809191|NCT03140670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809192|NCT00895596|NON_RANDOMIZED|||TREATMENT||NONE||||||
33809193|NCT02790632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809194|NCT01650051|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809195|NCT04404465|||COHORT||PROSPECTIVE|||||||
33809196|NCT06317623|||COHORT||PROSPECTIVE|||||||
33727389|NCT00324831|RANDOMIZED|||TREATMENT||DOUBLE||||||
33727390|NCT00581776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727391|NCT01851720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727392|NCT00283933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727393|NCT06481722|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33727394|NCT00360074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33727395|NCT01044914|||COHORT||PROSPECTIVE|||||||
33727396|NCT04924829|||COHORT||RETROSPECTIVE|||||||
33727397|NCT03690388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study treatment assignment will be unknown to the subjects, investigators, study centers, Sponsor, and any Contract Research Organization affiliated with the study other than those authorized to access treatment assignment for regulatory safety reporting and submission processes, interactive response technology (IRT) system administration, and drug supply management. Cabozantinib-matched placebo will be packaged and color-, size-, and shape-matched to be indistinguishable from cabozantinib. Individual study treatment assignment will be unblinded and information provided to the Investigators upon request for subjects with radiographic progressive disease (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 confirmed by the blinded independent radiology committee (BIRC).|This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of cabozantinib in subjects with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) after prior vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) therapy. Cabozantinib-matched placebo will be given in the control arm to blind (mask) study treatment. Approximately 300 eligible subjects will be randomized in a 2:1 ratio to receive either cabozantinib or placebo. After the primary efficacy endpoints have been analyzed and sufficient data have been collected to adequately evaluate all study endpoints to establish, for regulatory purposes, the safety and efficacy profile of the experimental drug within this study, the study will transition to an open label Maintenance Phase.|t|t|t|f
33727398|NCT03843879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727399|NCT02527954|||COHORT||PROSPECTIVE|||||||
33727400|NCT01364428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727401|NCT04732975|||COHORT||PROSPECTIVE|||||||
33727402|NCT05282719|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727403|NCT01791738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727404|NCT02768675|NA|SINGLE_GROUP||OTHER||NONE||||||
33727405|NCT05764187|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|It was not possible to mask nether the participants nor the care provider|Two parallel arm randomized clinical trial|f|f|f|t
33727406|NCT04095507|NA|SINGLE_GROUP||SCREENING||NONE||Single Group Assignment||||
33727407|NCT04865237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Adaptive design||||
33727408|NCT01440738|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33727409|NCT03301194|||COHORT||RETROSPECTIVE|||||||
33727410|NCT00451035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727411|NCT05783635|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The proposed study will achieve this using a Sequential Multiple Assignment Randomized Trial (SMART) design.|f|f|f|t
33727412|NCT01835743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33727413|NCT05102188|||COHORT||CROSS_SECTIONAL|||||||
33727414|NCT03873870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727415|NCT02381418|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727416|NCT01224639|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33727417|NCT02574871|||CASE_ONLY||CROSS_SECTIONAL|||||||
34113950|NCT06606847|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive durvalumab and oleclumab as an IV infusions||||
33727418|NCT00748267|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33727419|NCT04943731|NA|SEQUENTIAL||OTHER||NONE||Multi-center, prospective, two-phase clinical study. The end of Phase 1 serves as the baseline for Phase 2.||||
33727420|NCT06244264|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized parallel controlled study||||
33727421|NCT02676531|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727422|NCT03549702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727423|NCT03970863|||COHORT||PROSPECTIVE|||||||
33727424|NCT01889680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727425|NCT00922766|||CASE_ONLY||PROSPECTIVE|||||||
33727426|NCT03250546|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective Phase II Clinical Trial||||
33727427|NCT03325686|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33727428|NCT05553015|||COHORT||PROSPECTIVE|||||||
33727429|NCT06343064|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33727430|NCT02883296|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727431|NCT01716728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727432|NCT00405548|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33727433|NCT00150046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34113951|NCT06603818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113952|NCT06663072|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs. It will involve two stages: Stage 1, a safety run-in stage (enrolling 6-12 patients), and Stage 2, a dose-expansion stage (enrolling 13 patients).||||
33727434|NCT03282292|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33727435|NCT00180375|||COHORT||PROSPECTIVE|||||||
34113953|NCT06065345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727436|NCT05695222|||COHORT||RETROSPECTIVE|||||||
33727437|NCT04152889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727438|NCT00922883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809197|NCT01787032|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809198|NCT00780741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809199|NCT01874366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809200|NCT04329598|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Comparative Study||||
33809201|NCT00815100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113954|NCT03604991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809202|NCT05847699|||COHORT||PROSPECTIVE|||||||
34113955|NCT06608849|||OTHER||CROSS_SECTIONAL|||||||
34113956|NCT04823689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113957|NCT06589804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727439|NCT03155009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727440|NCT04100707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727441|NCT02265822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33727442|NCT01027481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727443|NCT02174848|NA|SINGLE_GROUP||TREATMENT||NONE||All participants in this study received the same intervention.||||
33727444|NCT01820416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33727445|NCT04362631|||COHORT||PROSPECTIVE|||||||
33727446|NCT04721249|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727447|NCT01926080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727448|NCT03317431|||COHORT||PROSPECTIVE|||||||
33727449|NCT04115943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33727450|NCT05276492|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33727451|NCT01280292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727452|NCT01834807|||COHORT||RETROSPECTIVE|||||||
33727453|NCT01340157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33727454|NCT03044132|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter post market product evaluation of study product for deep wounds of the lower extremity||||
33727455|NCT05844852|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727456|NCT05850169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33727457|NCT03121326|||COHORT||PROSPECTIVE|||||||
33727458|NCT01517516|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727459|NCT02164227|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33727460|NCT00880529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727461|NCT05091268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727462|NCT03422393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727463|NCT03425929|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33809203|NCT06368999|NA|SINGLE_GROUP||SCREENING||NONE||study of brain EEG activity||||
33809204|NCT03403036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809205|NCT02142725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809206|NCT01211106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809207|NCT00506844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809208|NCT01573338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809209|NCT04406532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727464|NCT04998591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to mask a fasting intervention for the participant or the study personel. Therefore only outcome assessors are masked.|This explorative study is conducted in form of a randomized, controlled trial design with a fasting intervention and a waiting list, which continues the usual diet.|f|f|f|t
33727465|NCT03462797|||OTHER||PROSPECTIVE|||||||
33727466|NCT01203072|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727467|NCT01215227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727468|NCT04480255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727469|NCT02404350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727470|NCT05913895|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727471|NCT04619524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727472|NCT05540964|||CASE_CONTROL||PROSPECTIVE|||||||
33727473|NCT05791474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727474|NCT01279408|||COHORT||PROSPECTIVE|||||||
33727475|NCT00338910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727476|NCT01344096|||CASE_CONTROL||PROSPECTIVE|||||||
33727477|NCT06163248|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Chrono nutrition intervention:~Participants will be asked to fast for 12 hours each day. During the fasting period, they may consume non-caloric beverages such as plain water, coffee or unsweetened tea. They will be asked to follow a dietary plan in which the total daily calorie intake will be calculated using indirect calorimetry, subtracting 500 calories from the total calorie amount. The dietary plan will have the following macronutrient distribution: 40% carbohydrates (\<10% simple carbohydrates), 20% protein, and 40% fats (6-11% polyunsaturated, 15-20% monounsaturated, and \<10% saturated). The plan will consist of 3 meals: breakfast will account for 40% of the total calories. Dinner will include only 10% of the total grams of carbohydrates. The order of food consumption should be: 1) vegetables, 2) proteins, 3) complex carbohydrates, and 4) simple carbohydrates (fruits)."||||
33727478|NCT01527188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727479|NCT04724954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Number of subjects: The Investigators expect to enroll up to 40 subjects, inpatients and then outpatients at a research hospital and its outpatient clinic at Kessler Foundation: 20 stroke patients, and 20 will be their spouses/caregivers of subjects participating in the randomized control trials component of this study.|t|f|f|f
33727480|NCT02311491|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33727481|NCT02439320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727482|NCT05604768|||COHORT||PROSPECTIVE|||||||
33727483|NCT01828372|NA|SINGLE_GROUP||SCREENING||NONE||||||
33727484|NCT03893656|||COHORT||RETROSPECTIVE|||||||
33809210|NCT03069209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809211|NCT03346733|||OTHER||PROSPECTIVE|||||||
33727485|NCT05050058|||COHORT||PROSPECTIVE|||||||
33727486|NCT00733109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727487|NCT05699590|||OTHER||RETROSPECTIVE|||||||
33809212|NCT06055491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent nurse uses a random sequence generator and allocates the participants into the two groups. Participant, investigator and outcomes assessor were blinded of participants' information|Study group: Vitamin D3 injection at ilsilateral deltoid muscle and extensor muscle strengthening exercise with counterforce brace for lateral epicondylitis of elbow Control group: Saline injection at ilsilateral deltoid muscle and extensor muscle strengthening exercise with counterforce brace for lateral epicondylitis of elbow|t|t|t|t
33809213|NCT05302115|||COHORT||RETROSPECTIVE|||||||
33809214|NCT04085952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809215|NCT01326455|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33809216|NCT05089487|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33809217|NCT01705756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727488|NCT05678556|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Experimental Arm:~all2GETHER is an HIV prevention and relationship education program designed for young MSM. all2GEHTER consists of 3 online didactic skills modules and 2 videoconference-based skills coaching sessions The 3 online modules focus on developmental skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.~Control Arm:~Participants will receive no intervention, but have access to HIV prevention resources from the CDC website and national databases. We will also assess exposure to other interventions that may be naturally occurring in participants' local context, which can be used to describe the sample and as a covariate (as necessary)."|f|f|t|t
33727489|NCT06539117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open labeled equivalence randomized control trial||||
33727490|NCT05768477|||COHORT||PROSPECTIVE|||||||
33727491|NCT05798416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727492|NCT01063764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727493|NCT00046332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33727494|NCT03545061|||COHORT||PROSPECTIVE|||||||
33727495|NCT04189458|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727496|NCT01814306|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33727497|NCT01463371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727498|NCT00605774|RANDOMIZED|CROSSOVER||||NONE||||||
33727499|NCT03462212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727500|NCT04884711|||OTHER||PROSPECTIVE|||||||
33727501|NCT00255593|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33727502|NCT04381845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727503|NCT00129129|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33727504|NCT03168464|NA|SINGLE_GROUP||TREATMENT||NONE||Eligible patients will receive on Day 1 ipilimumab 3mg/kg concurrently with Radiation therapy (6GY x 5 fractions). On Day 22, patients will receive nivolumab 240mg (every 2 weeks) in addition to ipilimumab (1mg/kg). Patients will be evaluated for response at Day 70 (+/- 7 days) for progression.||||
33727505|NCT02067377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727506|NCT01209442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727507|NCT04681482|||COHORT||RETROSPECTIVE|||||||
33727508|NCT06481540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the whole study protocol, patients did not receive information about testing the SpiroGym app. They will receive information that we are testing two types of expiratory muscle strength training programs.|Participants are randomly assigned to either the experimental or the active control group.|t|f|f|t
33727509|NCT02093598|NA|SINGLE_GROUP||OTHER||NONE||||||
33727510|NCT03828799|NA|SEQUENTIAL||OTHER||NONE||||||
33727511|NCT04666064|||CASE_ONLY||PROSPECTIVE|||||||
33727512|NCT02482025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33727513|NCT00542581|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33727514|NCT03898596|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33727515|NCT03442738|||CASE_ONLY||PROSPECTIVE|||||||
33809218|NCT03650166|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessor will be blinded to group assignment||f|f|f|t
33809219|NCT04967118|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Two research assistants (NICU nurses) who are blinded to the intervention condition (30% oral glucose and combination of 30% oral glucose and the mother's heartbeat intervention) will be perform calculation of infant PIPP-R and NIAPAS scores independently. Calculating NIAPAS scores will requires observation of the neonate's body, so during the skin-to-skin contact the intervention condition cannot be blinded. NIRS signals will be analyzed by researchers who are unaware of the nature of intervention and whether they are analyzing a noxious or non-noxious stimulation. To minimize observer bias, research assistants and researchers analyzing the NIRS signal will not be permitted to attend data collection sessions and will not share datasets or communicate with each other regarding the study.|A crossover design with each child as his or her own control will be used to minimize interchild variability. Order of interventions will be randomly assigned by computer-generated program.|f|f|f|t
33809220|NCT06117215|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809221|NCT05689073|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33809222|NCT01995214|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33727516|NCT03905785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727517|NCT01746212|||COHORT||PROSPECTIVE|||||||
33809223|NCT02169414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809224|NCT04349319|NA|SINGLE_GROUP||TREATMENT||NONE||A case control study||||
33809225|NCT01989104|||OTHER||CROSS_SECTIONAL|||||||
33809226|NCT02390206|||COHORT||PROSPECTIVE|||||||
33727518|NCT01175733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727519|NCT03762655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Subjects will be randomized in a blinded manner to one of two study arms, the Treatment or Scaffold Arm and the Standard of Care or Comparator Arm. Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery. Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold. The subjects will be blinded to their study arm for the duration of the study."|"Subjects will be randomized in a blinded manner to one of two study arms, the Treatment or Scaffold Arm and the Standard of Care or Comparator Arm. Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery. Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold."|t|f|f|f
33727520|NCT00233623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727521|NCT01516957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33727522|NCT01675882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727523|NCT00454090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727524|NCT05375734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727525|NCT03145896|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727526|NCT05677620|||CASE_CONTROL||PROSPECTIVE|||||||
34113958|NCT06592768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is designed as a double-blind, placebo-controlled, parallel-group, randomized, study to evaluate the safety and efficacy of briquilimab on allergen-induced asthmatic airway responses.|t|t|t|t
33809227|NCT01084525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809228|NCT01052766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809229|NCT00464893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809230|NCT05769491|||CASE_CROSSOVER||PROSPECTIVE|||||||
33809231|NCT03937609|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open-label, Multicenter Study||||
34041165|NCT03718637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study participant will not have knowledge of which treatment group he/she is randomized into for the duration of the study. Because the care provider/investigator will be required to implant the bioinductive patch, the physician will know into which treatment group each patient falls.|"Patients will be randomized into one of two groups. In the control group, patients will receive the current surgical treatment for lateral epicondylitis: tendon debridement and repair. Patients in the experimental group will receive a bio-inductive patch following the same surgical treatment. Both groups of patients will participate in preoperative and postoperative ultrasound imaging studies."|t|f|f|f
34041166|NCT01287169|||||PROSPECTIVE|||||||
34041167|NCT00113048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34113959|NCT06606990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809232|NCT03212885|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33809233|NCT06323369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809234|NCT02761499|||COHORT||PROSPECTIVE|||||||
33809235|NCT05850624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041168|NCT05974878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041169|NCT01767766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041170|NCT05043974|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34041171|NCT04981002|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041172|NCT06080997|||COHORT||PROSPECTIVE|||||||
34041173|NCT01719367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041174|NCT01871844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041175|NCT00660257|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34041176|NCT00536939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041177|NCT06576011|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study conditions are randomly assigned and the intervention delivery is automated through digital advertisements on social media. Senior members of the research team will have a record of the participants randomized to each condition, but the delivery of intervention content is automated. Junior members of the research team responsible for sending follow-up survey reminders will not be aware of participant condition assignment.||t|f|f|f
34041178|NCT06308458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masking (Investigator, Outcomes assessor|Prospective pre/ posttreatment, randomized controlled study|f|f|t|t
34041179|NCT05063279|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Study conditions (exercise volume) and age groups identifiers are omitted from outcome assessments whenever possible. Assessment of the primary (and selected secondary) outcome(s) will be performed in a blinded fashion by assessors/investigators.|Study conditions (exercise volume) are randomized to either leg/arm for within-participant comparisons. The effect of age is assessed from two parallel age groups.|f|f|t|t
34041180|NCT04730596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* The patients will be blinded to their groups.~* An anesthesia resident who will not participate in the study and have no the subsequent rule in it will help in the preparation of local anesthetic mixtures under strict aseptic precautions.~* An assistant nurse who will be blinded to the study groups and will have no the subsequent rule in it will help in the collection of the data of measurements"||t|t|f|t
34041181|NCT04726696|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will be conducted in the province of Navarra (Spain), in the primary health care service. The study will follow a cluster randomised design with primary care teams (PCT) as sampling units. A PCT consists of a group of family physicians who work in close cooperation with nurses and social workers to offer primary care services to registered individuals in the area. Each cluster will be randomly assigned to one of the two groups, control or intervention. The main reason for using a cluster design is to avoid contamination, which could occur among nurses working in the same PCT. This is more likely given the particular characteristics of this complex intervention in which masking is not possible. The R software (version 3.3.0) will be used to choose an allocation at random. The randomisation of the study groups will be stratified according to the scope of work (rural / urban), to guarantee the representativeness of the different segments of the study population.||||
34041182|NCT04161469|RANDOMIZED|PARALLEL||TREATMENT||NONE||The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s (2). We planned to randomized patients in two groups. Group 1) FiLaC closure of the tract, group 2) FiLaC closure of the tract with an additional surgical technique as the closure of the internal orifice with a purse-string suture using 2-0 polyglactin (VicrylR).||||
34041183|NCT00386360|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041184|NCT04267198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments will be conducted by study staff blind to treatment condition|Delayed-start controlled trial with stratification across two groups (massed-INT, distributed-INT) based on severity of word retrieval deficits.|f|f|f|t
34041185|NCT04962919|||COHORT||RETROSPECTIVE|||||||
34041186|NCT01002989|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041187|NCT03426592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041188|NCT06293560|||COHORT||PROSPECTIVE|||||||
34041189|NCT01056783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041190|NCT02175511|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34041191|NCT03485963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041192|NCT02492204|||COHORT||PROSPECTIVE|||||||
34113960|NCT06661122|||COHORT||PROSPECTIVE|||||||
33809236|NCT00433628|||||PROSPECTIVE|||||||
33809237|NCT03686839|NA|SINGLE_GROUP||PREVENTION||NONE||no randomized, no controlled.||||
33809238|NCT00463944|||DEFINED_POPULATION||PROSPECTIVE|||||||
33727527|NCT04133493|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized controlled trial (RCT) with two arms.||||
33727528|NCT01183169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727529|NCT03903627|NA|SINGLE_GROUP||TREATMENT||NONE||all participants will receive the same verbal instruction||||
33727530|NCT00339326|||CASE_CONTROL||OTHER|||||||
33727531|NCT01998451|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33727532|NCT04783506|||CASE_CONTROL||PROSPECTIVE|||||||
33727533|NCT05243095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809239|NCT04700202|||COHORT||RETROSPECTIVE|||||||
33809240|NCT00143806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809241|NCT02954289|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809242|NCT01860300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809243|NCT04255498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.||||
33809244|NCT00386685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809245|NCT01855399|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33809246|NCT03775252|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33809247|NCT01051843|||||CROSS_SECTIONAL|||||||
33809248|NCT03128099|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants are assigned to low or high dose randomly. They do not know which condition they are in. The research staff who assess symptoms before and after training do not know which condition the participant is assigned to.|"Half the participants play the virtual reality video game for one hour per session (low dose).~The other half play the virtual reality video game for 2 hours per session (high dose).~Both groups visit the lab 10 times ( twice a week for 5 weeks)"|t|f|f|t
33809249|NCT01606098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809250|NCT03547154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809251|NCT04305496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind Randomised Study|t|t|t|t
33809252|NCT03683641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809253|NCT03735849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809254|NCT01030315|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33809255|NCT00894218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34113961|NCT06591468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113962|NCT06660732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113963|NCT06609330|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon enrollment into the study, participants will begin with a minimal contact wait condition followed by randomization to different wait times (2-, 3-, or 4-weeks)||||
34113964|NCT04170374|||COHORT||RETROSPECTIVE|||||||
34113965|NCT06669572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113966|NCT06669416|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment/Control (usual care)||||
34113967|NCT06658301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34113968|NCT04758533|NA|SINGLE_GROUP||TREATMENT||NONE||Open, non-randomized, single-center Phase I clinical trial.||||
34113969|NCT04526665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind (DB), randomized, placebo-controlled study followed by an open-label long term extension (LTE)|t|t|t|t
34113970|NCT05432804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113971|NCT04585958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113972|NCT06596694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113973|NCT01286766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113974|NCT05505942|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization procedures to the two groups will apply sex at birth (male/female) and body mass index (greater than or equal to 30 or less than 30) as blocking variables.||||
34113975|NCT05181748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental: Group of participants receiving PRP treatment Women presenting with POR, treated with autologous PRP intraovarian infusion in the mid-luteal phase of the menstrual cycle, undergoing a subsequent stimulated fresh Embryo Transfer-Intracytoplasmic Sperm Injection (ET-ICSI) cycle on the first menstrual cycle following PRP treatment.~Control Group: Group of participants receiving standard management Women presenting with POR undergoing a stimulated fresh ET-ICSI cycle"||||
34113976|NCT06402825|||COHORT||CROSS_SECTIONAL|||||||
34113977|NCT06017973|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34113978|NCT06595940|||FAMILY_BASED||PROSPECTIVE|||||||
34113979|NCT05197855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113980|NCT06592742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"In our study participants are randomly assigned to one of two groups:~Intervention Group: receives the pulmonary rehabilitation program with PMR. Control Group: receives the standard PR program only, without PMR."|f|f|f|t
34113981|NCT05470777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113982|NCT06617325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113983|NCT05545449|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34113984|NCT04548752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113985|NCT05347485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113986|NCT06676033|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34113987|NCT00687115|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34113988|NCT00024622|||COHORT||CROSS_SECTIONAL|||||||
34113989|NCT06455202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34113990|NCT06676046|||OTHER||PROSPECTIVE|||||||
34113991|NCT05256290|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34113992|NCT00923104|||COHORT||PROSPECTIVE|||||||
34113993|NCT01143454|||CASE_CONTROL||PROSPECTIVE|||||||
34113994|NCT06132958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809256|NCT04426266|||COHORT||CROSS_SECTIONAL|||||||
34113995|NCT03481829|||COHORT||PROSPECTIVE|||||||
33727534|NCT04509843|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33727535|NCT02110316|NA|SINGLE_GROUP||||NONE||||||
33727536|NCT04860102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727537|NCT02052921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727538|NCT03216447|RANDOMIZED|PARALLEL||TREATMENT||NONE|open labeled|||||
34113996|NCT06225258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients are randomised in a double-blind, placebo-controlled manner to two groups using sealed envelopes. In the intervention group, all patients receive Xanthohumol as adjunctive therapy as recommended by the Surviving Sepsis Campaign. In the control group, patients are treated without Xanthohumol as recommended by the Surviving Sepsis Campaign and are treated as recommended by Surviving Sepsis.~Bioavailability, clinical and possible side effects are monitored."|f|f|t|f
33727539|NCT02996864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33727540|NCT04196933|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33727541|NCT00578175|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33727542|NCT04849156|||COHORT||PROSPECTIVE|||||||
34113997|NCT00903110|||CASE_ONLY||OTHER|||||||
33727543|NCT06216431|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727544|NCT01106209|||COHORT||PROSPECTIVE|||||||
33727545|NCT02659020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727546|NCT05687279|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Observer-blind:~* Blinding for vaccine group assignment: participants, parents or legally acceptable representative (LAR), outcome assessors, investigators, laboratory personnel, Sponsor study staff~* No blinding for study staff who prepare and administer the study interventions"||t|t|t|t
33727547|NCT00586183|NA|SINGLE_GROUP||||NONE||||||
33727548|NCT04093778|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-post study of effect of training intervention on perinatal and neonatal survival and health workers skills and knowledge||||
33727549|NCT06456281|||CASE_CONTROL||PROSPECTIVE|||||||
33727550|NCT01988142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727551|NCT05128851|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33727552|NCT01500642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727553|NCT01667666|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727554|NCT00615277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33727555|NCT01794091|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33727556|NCT01637740|||CASE_CONTROL||RETROSPECTIVE|||||||
33727557|NCT02028988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34113998|NCT05206500|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Patients with Urinary Tract Infection (UTI) symptoms and Colony-forming Units (CFU) \<10,000 have clinically significant UTIs. Characterizing the species of bacteria growing in low numbers and treating the patients based on bacterial sensitivity will help in resolving patients' symptoms.||||
34113999|NCT05139017|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In Part 1, Dose Confirmation will be determined by modified toxicity probability interval (mTPI) design, where participants will be assigned to two treatment groups, cohort: A (zilovertamab vedotin in combinatio with R-GemOx) in parallel with cohort B (zilovertamab vedotin in combination with BR). Part 2 will be an Efficacy Expansion (cohorts A \& B) where all participants in each cohort will be assigned to 2 treatment groups for the duration of the study.||||
34114000|NCT03782207|||COHORT||PROSPECTIVE|||||||
34114001|NCT05320367|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||In this crossover design, participants will be administered both dosages of CBD and placebo during participation in the study. Participant will be randomly assigned to one of ten pre-determined sequences with a CBD or placebo product at 5 dosages (0 mg, 5 mg, 20 mg, 50 mg and 100 mg). Participants will be randomized based on a completely balanced 5 by 5 latin square|t|t|t|t
34114002|NCT05718817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114003|NCT05844137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114004|NCT03627923|||COHORT||PROSPECTIVE|||||||
34114005|NCT06013475|||COHORT||RETROSPECTIVE|||||||
34114006|NCT04659408|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized controlled trial with within-participants crossover||||
34114007|NCT04689828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|No masking.|Patients randomized to ARDT treatment have an option to crossover to 177Lu-PSMA-617 treatment after rPFS.|f|f|f|t
34114008|NCT06481319|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||One group intervention with age-matched historical controls||||
34114009|NCT04002947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041193|NCT04063553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessor will be blinded from the group allocation. Research coordinator will be the the only person handling randomization, group allocation, arrange for volunteers to attend to the patient or not, and arrange for assessor to assess the patients.|This is a randomised controlled trial, eligible subjects will be randomised by research coordinator to either control or intervention group based on block randomisation with sealed envelop.|f|f|t|t
33727558|NCT04523233|||CASE_CONTROL||PROSPECTIVE|||||||
33727559|NCT05812014|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727560|NCT00666757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727561|NCT03272919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727562|NCT06003530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be allocated to one of the following arms: Low dose single administration of hOMSC200, High dose single administration of hOMSC200 or Placebo (control) all in addition to SOC treatment|t|f|f|t
33727563|NCT01018199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34041194|NCT03859479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded||t|f|f|f
34041195|NCT02443714|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34041196|NCT02898597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041197|NCT03313557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041198|NCT02029066|NA|SINGLE_GROUP||||NONE||||||
33727564|NCT02663635|NA|SINGLE_GROUP||||NONE||||||
33727565|NCT02122536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33727566|NCT03427359|NA|SINGLE_GROUP||TREATMENT||NONE||All patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.||||
34041199|NCT00954031|||CASE_CONTROL||PROSPECTIVE|||||||
34041200|NCT06577246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34041201|NCT02214329|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34041202|NCT04299815|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34041203|NCT03270683|||CASE_CONTROL||PROSPECTIVE|||||||
34041204|NCT00033722||||TREATMENT||||||||
33809257|NCT03735459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809258|NCT01396629|||||PROSPECTIVE|||||||
33809259|NCT01179802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33809260|NCT00240175|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33809261|NCT00647335|||CASE_ONLY||PROSPECTIVE|||||||
33809262|NCT03413826|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Baseline demographic and physical characteristics will be reported as means and standard errors. Baseline group (6 days/week, 2 days per week exercise, sedentary control) differences will be tested with one-way ANOVA. Alterations in accumulated negative energy balance, body composition, RRVfood, RRVexercise, dietary intake, energy expenditure, exercise discomfort, hunger/satiety hormones, and fitness will be tested with two-way repeated measures analysis of variance (RMANOVA) with group treated as a between-subjects variable and time treated as a within subjects variable.||||
33809263|NCT01493128|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809264|NCT04274790|||CASE_ONLY||PROSPECTIVE|||||||
33809265|NCT02446275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809266|NCT01293292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809267|NCT01784107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809268|NCT02622698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809269|NCT01802619|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809270|NCT06243432|||OTHER||RETROSPECTIVE|||||||
34114010|NCT06123312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114011|NCT01861106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114012|NCT05719584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114013|NCT03878589|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This trial will be a double-blinded, randomized crossover group design that will randomize older adults with symptomatic knee Osteoarthritis pain to four weeks of intranasal self-administration of either oxytocin (OT) or placebo (P) (48 IUs daily) followed by a four-week washout period and a second four weeks of intervention (either OT or P).|t|t|t|t
34114014|NCT01496599|||COHORT||PROSPECTIVE|||||||
34114015|NCT03687957|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Phase II only: This study is triple-blinded (participant, physician, and study coordinator are all blinded; pharmacist and study statistician are not blinded)|-Phase I enrollment will be a sequential enrollment (patients will be stratified by concomitant use of steroids (yes/no). Phase II randomized portion will open with 2 arms being enrolled to in parallel. Phase II expansion cohort will not be randomized.|t|t|t|f
34114016|NCT01200680|||CASE_ONLY||OTHER|||||||
34114017|NCT05993442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114018|NCT05559359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114019|NCT05947760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34114020|NCT06428396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114021|NCT03650114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114022|NCT05267054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114023|NCT04305054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114024|NCT06534411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114025|NCT06481462|||OTHER||PROSPECTIVE|||||||
34114026|NCT00026884|||COHORT||PROSPECTIVE|||||||
33809271|NCT04315766|||COHORT||PROSPECTIVE|||||||
33809272|NCT02433444|||CASE_ONLY||PROSPECTIVE|||||||
33809273|NCT04181385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single-blinded study with participant blinded to treatment|Participants receive either placebo, olanzapine or olanzapine plus bromocriptine, in random order on 3 separate study visits, with blood samples taken before and after treatment and intake of a high-fat drink|t|f|f|f
33809274|NCT01331408|NA|SINGLE_GROUP||OTHER||NONE||||||
33809275|NCT03794219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33809276|NCT03803150|RANDOMIZED|PARALLEL||PREVENTION||NONE|Senior supervisor Prof. Dr. Hairy El mossy will generate the allocation sequence.|Block, consecutive, 1:1 Consecutive because patients with subcondylar fracture need immediate surgical intervention, that is why investigators can not wait to collect the whole sample size and make computer generated randomization .||||
33809277|NCT03003104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809278|NCT01934036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809279|NCT00259792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809280|NCT06346652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809281|NCT05678725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809282|NCT00005799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809283|NCT04417075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809284|NCT02114515|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33809285|NCT01972906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809286|NCT00927706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114027|NCT03793166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114028|NCT02190266|||COHORT||CROSS_SECTIONAL|||||||
34114029|NCT03854474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114030|NCT05024760|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a 3 arm study with 1 arm receiving no treatment and 2 arms receiving treatments.||||
34114031|NCT06558123|||CASE_CONTROL||PROSPECTIVE|||||||
34114032|NCT00720785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114033|NCT04085887|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33809287|NCT00540111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809288|NCT05474313|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled study||||
33809289|NCT05266300|||OTHER||CROSS_SECTIONAL|||||||
33809290|NCT03918096|||COHORT||PROSPECTIVE|||||||
34114034|NCT03602599|||COHORT||PROSPECTIVE|||||||
34114035|NCT05286879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114036|NCT03916978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114037|NCT03984448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114038|NCT01594723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114039|NCT05982964|||OTHER||OTHER|||||||
34114040|NCT02332668|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114041|NCT03366116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809291|NCT03372252|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33809292|NCT05093894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809293|NCT04320966|||COHORT||PROSPECTIVE|||||||
34114042|NCT04421768|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The total number of exams per hour of labor or triage stay and exam discrepancy between 2 examiners will be compared between the 6 month time period before training and 6 months after all nurses have completed the training||||
34114043|NCT03152773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114044|NCT02431845|NA|SINGLE_GROUP||TREATMENT||NONE|Open label study|Open naturalistic treatment||||
34114045|NCT02954874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114046|NCT06035874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114047|NCT04399941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114048|NCT02583646|||COHORT||PROSPECTIVE|||||||
34114049|NCT05281562|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive 6 weeks of oral immunonutrition supplementation, consisting of L-Arginine, Vitamin C, and Omega-3 fatty acids, in addition to standard of care for wound treatment or standard of care alone.||||
34114050|NCT05376111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114051|NCT03711734|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34114052|NCT02450851|||CASE_ONLY||PROSPECTIVE|||||||
34114053|NCT02270814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114054|NCT00324805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114055|NCT06429059|RANDOMIZED|PARALLEL||TREATMENT||NONE||At month 3, DIGAP classification will be revealed to each participant and based on this, they will receive 1 of 4 treatments. They will take their assigned treatment for 6 months.||||
34114056|NCT06356311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114057|NCT05563220|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114058|NCT01145196|||COHORT||CROSS_SECTIONAL|||||||
34114059|NCT05030428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|randomized, double-blind, parallel group, placebo-controlled, multi-center, event-driven study|t|f|t|f
34114060|NCT06487442|||OTHER||PROSPECTIVE|||||||
34114061|NCT05763719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114062|NCT03432286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114063|NCT03855995|||COHORT||PROSPECTIVE|||||||
34114064|NCT04159259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114065|NCT05042505|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will be randomized to one of the following intervention groups: Sita group (n = 50): patients with diabetes mellitus receiving multiple doses of insulin plus metformin 500 mg twice daily plus sitagliptin 100 mg once daily and Dapa group (n = 50): patients with diabetes mellitus receiving multiple doses of insulin plus metformin 500 mg daily plus dapagliflozin 10 mg once daily. Glycemic equipoise will be maintained between the two groups by adjusting insulin doses and maintaining target fasting glucose, post-prandial glucose and glycated hemoglobin (HbA1c) in accordance with the ADA 2021.||||
34114066|NCT06502639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant will get seperate treatment protocols and possible efforts will be put to mask the both group about the treatment|it will randomized controlled trial in which non probability convenient sampling will be used. Two groups of 6-12 years will be performed in which participant will randomly divided. Group A will recieve conventional therapy and Group B will recieve conventional therapy with theraplay program.|t|f|f|f
34114067|NCT03739827|||COHORT||PROSPECTIVE|||||||
34114068|NCT04074135|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34114069|NCT06583512|||CASE_ONLY||PROSPECTIVE|||||||
34114070|NCT06109311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114071|NCT02233868|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
34114072|NCT05775497|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Participants (anticipated n=88) will receive the 12-week online weight loss treatment and will be randomized to receive 0-3 novel intervention components (targeting minority stress, negative body image, and social support). The primary outcome (weight loss) will be assessed at baseline, post-treatment (12 weeks), and follow-up (24 weeks).|f|f|f|t
34114073|NCT04145115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114074|NCT05228158|||COHORT||PROSPECTIVE|||||||
34114075|NCT06192758|NA|SINGLE_GROUP||OTHER||NONE||"Subjects will be treated in cohorts at three sequential target absorbed radiation dose levels, where the dose level for the next cohort will be determined by a prespecified decision tree for escalation/de-escalation, according to the accelerated Time-to-Event Bayesian Optimal Interval Design (TITE-BOIN) approach.~* Cohort size = 3 subjects~* ≤15 subjects (or 5 cohorts) will be treated at any single dose level. ≤ 36 subjects (or 12 cohorts) will be treated in total across all doses. If no dose limiting toxicities are observed at any dose level, a minimum of 21 subjects will be treated"||||
33809294|NCT02707952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809295|NCT03450642|||COHORT||PROSPECTIVE|||||||
33809296|NCT00853528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase I study with 2 parallel groups of dose escalation using a 3 +3 design to determine the maximum tolerated dose of the radiation with the FDA approved device. There are three dose cohorts in each group, thus 6 arms.||||
33809297|NCT04798534|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809298|NCT03211988|NA|SINGLE_GROUP||TREATMENT||NONE||Simon 2-stage design (optimum version)||||
33809299|NCT01767688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809300|NCT03246750|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escaltion design||||
33809301|NCT05162352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809302|NCT04877756|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||2 parallel arms and then a 3rd arm will be enrolled if the endpoints for the first 2 arms aren't met.|t|t|t|t
33809303|NCT00388726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809304|NCT00043589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33809305|NCT01307254|||COHORT||PROSPECTIVE|||||||
33809306|NCT04446156|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809307|NCT01688505|||COHORT||RETROSPECTIVE|||||||
33809308|NCT00018512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809309|NCT04365959|||CASE_ONLY||PROSPECTIVE|||||||
34114076|NCT06122701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This study is an opel-label study.|"The study is designed as a 4-arm cross-over, open-label, randomized single oral dose comparison (5 mg, 10 mg, 50 mg, and 200 mg thiamin).~A fifth arm applying thiamin intravenously with a dose selected based on results from the four oral arms is also planned."||||
34114077|NCT04084288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114078|NCT03584633|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114079|NCT04360018|NA|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34114080|NCT01631617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34114081|NCT01928394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114082|NCT04821089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114083|NCT03831958|||COHORT||PROSPECTIVE|||||||
34114084|NCT02460458|||COHORT||OTHER|||||||
34114085|NCT06285318|||COHORT||RETROSPECTIVE|||||||
34114086|NCT01733316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114087|NCT03986021|||COHORT||PROSPECTIVE|||||||
34114088|NCT06060392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114089|NCT02587403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114090|NCT06503497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114091|NCT05886049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114092|NCT01730131|||COHORT||PROSPECTIVE|||||||
34114093|NCT05455684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114094|NCT05858034|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Persons with HIV age ≥50 years followed in the Atrium Health Wake Forest Baptist Health Infectious Diseases Specialty Clinic (AHWFB IDSC), The study will take place at in the outpatient clinics of Atrium Health Wake Forest Baptist Health IDSC in Winston-Salem, NC, High Point Medical Center in High Point, NC, and Lexington Memorial Hospital (Lexington, NC).||||
34114095|NCT06154252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114096|NCT06145334|NA|SINGLE_GROUP||OTHER||NONE||Twenty Veterans aged 65 or older with depression will engage in the intervention, Veterans Socials (VS). Veterans will receive 90-minutes of weekly social engagement in a community-setting in accordance with the VS manual. Each week will focus on social connections, engagement in social activities, and reinforcing behaviors that give individuals meaning and purpose. Each VS will be held in a community setting across 4 months. The investigators will evaluate the feasibility of VS including fidelity, retention, acceptability of the intervention and preliminary outcomes around social functioning.||||
34114097|NCT05974280|||COHORT||PROSPECTIVE|||||||
34114098|NCT06135792|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE||Split-mouth design|t|t|t|t
34114099|NCT06492616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114100|NCT03825757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The IMP producer (Galena Pharma Ltd., Kuopio, Finland) has packed the IMP according to study protocol and provides a code of each product. The IMP is used double-blinded in their numbered order. The key of the codes are stored in closed envelopes in Hospital´s locked closet. HYKS-institute performs regular study monitoring|Randomized double-blinded controlled trial|f|t|f|f
33727567|NCT05697887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Children with drug-resistant epilepsy followed at Children's Hospital No.2, Viet Nam treated by KD were included in a prospective study from June 2019 to October 2021. Side-effects, retention rate, number, and duration of seizures were recorded after 1, 3, 6, 9 and 12 months of KD. Patients were considered as responder when a 50% seizure frequency was reached. Tolerance and acceptability of the KD were closely monitored.||||
33727568|NCT03227887|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727569|NCT05404061|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33727570|NCT04389125|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34114101|NCT01621581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114102|NCT01143519|||COHORT||CROSS_SECTIONAL|||||||
34114103|NCT01674140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114104|NCT01197378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114105|NCT05590351|RANDOMIZED|PARALLEL||PREVENTION||NONE||m-health coaching application||||
34114106|NCT06390163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34114107|NCT03896750|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114108|NCT06454838|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114109|NCT00862433|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34114110|NCT04512716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114111|NCT01581554|||COHORT||PROSPECTIVE|||||||
34114112|NCT01629108|||COHORT||CROSS_SECTIONAL|||||||
34114113|NCT05172258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114114|NCT00098475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114115|NCT05124769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (investigator, outcome assessor)|Randomized controlled trial with parallel assignment|f|f|t|t
34114116|NCT01875601|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114117|NCT06105918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114118|NCT05508789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114119|NCT06082167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114120|NCT02610361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114121|NCT06011239|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The study will recruit all staff except the clinic managers at each of five family medicine clinics within our academic family medicine department.||||
34114122|NCT06332534|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34114123|NCT01352975|||COHORT||PROSPECTIVE|||||||
34114124|NCT06143514|||COHORT||PROSPECTIVE|||||||
34114125|NCT05950191|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomised trial to evaluate the impact of LLINs distributed in Uganda through the 2023 national universal coverage campaign. A cluster has been defined as the target area surrounding an MRC. A total of 24 clusters will be included in the study, covering 20 moderate-high malaria burden districts in Uganda. Clusters have been randomised in a 1:1 ratio to receive one of two types of LLINs: (1) chlorfenapyr-pyrethroid LLINs (PermaNet Dual, n=12) or (2) PBO-pyrethroid LLINs (PermaNet 3.0, n=12).||||
34114126|NCT05961436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114127|NCT03814759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114128|NCT06333951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114129|NCT01925196|||COHORT||PROSPECTIVE|||||||
34114130|NCT01927783|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33809310|NCT04888052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809311|NCT06186349|||COHORT||PROSPECTIVE|||||||
33809312|NCT02699099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809313|NCT02113449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809314|NCT02714777|||COHORT||PROSPECTIVE|||||||
33809315|NCT04705649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809316|NCT04498780|||COHORT||PROSPECTIVE|||||||
34114131|NCT05369611|||COHORT||PROSPECTIVE|||||||
34114132|NCT04623944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114133|NCT05432427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Controlled prospectiv cohort study. Patients in the trial get a 64Cu-DOTATATEPET/ CT and/or 18F-FDG-PET/CT||||
34114134|NCT04339738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809317|NCT04126577|||COHORT||PROSPECTIVE|||||||
33809318|NCT00718120|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809319|NCT02326220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809320|NCT00513318|||CASE_ONLY||PROSPECTIVE|||||||
33809321|NCT04755972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809322|NCT05966272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A multi-center, randomized, double-blind, placebo- parallel controlled Phase II clinical study|t|t|t|f
33809323|NCT06028308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33809324|NCT01634165|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809325|NCT02455557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809326|NCT03938272|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study in which all patients will receive Oxabact OC5||||
33809327|NCT04497545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809328|NCT01179100|RANDOMIZED|FACTORIAL||||DOUBLE|||t|t|f|f
33809329|NCT00361907|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809330|NCT04810832|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||"Open and prospective study.~Evoked related potentials are recorded on the scalp and with intracranial electrodes for each participant while they listen 3 paradigms successively and in a random order:~i) their own name uttered by a smiling voice ii) their own name uttered by a neutral voice iii) their own name uttered by a rough voice"||||
33809331|NCT01840722|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809332|NCT03915678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"6 independent single-arm, multicenter, phase II trials, based on 2-stage Simon's optimal design (Simon R, Controlled Clinical Trials 1989):~* Population 1: pancreatic cancer~* Population 2: virus-associated tumors~* Population 3: non-small lung cancer~* Population 4: soft-tissue sarcoma~* Population 5: bladder cancer~* Population 6: triple negative breast cancer"||||
33809333|NCT03480815|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomized, controlled study||||
33809334|NCT04659382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809335|NCT02541318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809336|NCT03292406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809337|NCT04726657|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cross-over||||
33809338|NCT04653688|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33809339|NCT02176577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809340|NCT04565717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Parts A\&B: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Part C: Open label||t|t|t|t
33809341|NCT03678454|||OTHER||PROSPECTIVE|||||||
33809342|NCT00553332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809343|NCT05453630|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33809344|NCT04382313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33809345|NCT03295409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809346|NCT00808496|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33809347|NCT00343083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041205|NCT01051596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041206|NCT04494503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041207|NCT00245466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041208|NCT05990322|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|f|t|t
34041209|NCT00599118|||CASE_CONTROL||PROSPECTIVE|||||||
34041210|NCT04880395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041211|NCT00167011|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041212|NCT02679417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041213|NCT01609296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041214|NCT06574932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and investigators will be blinded|Two-arm parallel design randomized control trial|t|f|t|f
34041215|NCT03872206|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041216|NCT05463757|||COHORT||PROSPECTIVE|||||||
34041217|NCT03986307|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Subjects are a priori randomized to one of both conditions. Both groups undergo an identical intervention, but receive different supplements (although appearance-matched). The investigators do not know in which condition the subjects are randomized. One researcher, who is not involved in the intervention/data collection/data analyses, holds the code.|Elderly humans (\>65y) are randomized to a placebo or omega-3 group (interventions, tests, analyses etc. are executed in parallel).|t|f|t|f
34041218|NCT02485262|||COHORT||PROSPECTIVE|||||||
34041219|NCT01538277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041220|NCT02796222|||COHORT||PROSPECTIVE|||||||
34041221|NCT02198664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041222|NCT04696822|NA|SEQUENTIAL||TREATMENT||NONE||Open-label, single-dose, two-period, three-treatment, fixed-sequence, comparative bioavailability study||||
34041223|NCT00975182|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041224|NCT01464333|||COHORT||PROSPECTIVE|||||||
34041225|NCT04544241|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041226|NCT01608802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041227|NCT04610801|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Masking to care providers||f|t|f|f
34041228|NCT04835610|||CASE_ONLY||PROSPECTIVE|||||||
34041229|NCT00932048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041230|NCT02982681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041231|NCT06575361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114135|NCT05980234|||COHORT||OTHER|||||||
34114136|NCT05039515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114137|NCT04803201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114138|NCT06019260|||CASE_CONTROL||PROSPECTIVE|||||||
34114139|NCT04094298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114140|NCT05651022|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects will receive a single dose of Decoy20 at one of up to seven assigned dose levels on Week 1 Day 1. Subjects will be observed for 28 days for dose-limiting toxicity in the single ascending dose Part 1. Subjects enrolled in Part 2 will receive continuous weekly doses of Decoy20 at the dose determined from Part 1. Safety and preliminary anti-tumor activity will be assessed.||||
34114141|NCT06584656|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34114142|NCT04704674|||COHORT||PROSPECTIVE|||||||
34114143|NCT06232044|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114144|NCT02709161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114145|NCT05912608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114146|NCT04426591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114147|NCT04858009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114148|NCT03952624|||COHORT||PROSPECTIVE|||||||
34114149|NCT00342732|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34114150|NCT03736226|||OTHER||PROSPECTIVE|||||||
34114151|NCT05230667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114152|NCT00001727|||CASE_ONLY||PROSPECTIVE|||||||
34114153|NCT02466971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114154|NCT05496036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114155|NCT05652465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114156|NCT06430801|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114157|NCT02911077|||COHORT||PROSPECTIVE|||||||
34114158|NCT06566534|RANDOMIZED|PARALLEL||PREVENTION||NONE|Although patients will not be explicitly informed of which arm they were randomized to, they will be aware of the messages they receive. The care provider will be provided an information sheet describing the intervention, but they will not be explicitly told which patients are enrolled or their randomized arm assignment.|||||
34114159|NCT06271317|||CASE_CONTROL||PROSPECTIVE|||||||
34114160|NCT02891603|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34114161|NCT04164082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114162|NCT06159764|||COHORT||PROSPECTIVE|||||||
34114163|NCT04269902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114164|NCT06004479|||CASE_CONTROL||PROSPECTIVE|||||||
34114165|NCT06340958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114166|NCT05967247|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Difficult to blind study caregivers and study outcome assessors due to the nature of the mindfulness-based stress reduction intervention||t|f|f|f
34114167|NCT00077909|||COHORT||CROSS_SECTIONAL|||||||
34114168|NCT05322031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114169|NCT03049475|||CASE_CONTROL||PROSPECTIVE|||||||
34114170|NCT04164069|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34114171|NCT02610426|||CASE_CONTROL||RETROSPECTIVE|||||||
34114172|NCT06397846|NA|SINGLE_GROUP||OTHER||NONE||||||
34114173|NCT06407713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114174|NCT06567548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34114175|NCT05784246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114176|NCT04280848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114177|NCT05064085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114178|NCT05946070|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34114179|NCT04468607|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Open Label|||||
34114180|NCT05675410|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114181|NCT04980248|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||Study participants will be enrolled into 3 cohorts in a sequential fashion.||||
34114182|NCT00867269|||COHORT||PROSPECTIVE|||||||
34114183|NCT00001539|||OTHER||OTHER|||||||
34114184|NCT04136171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114185|NCT06408688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114186|NCT06503159|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34114187|NCT05199870|||COHORT||PROSPECTIVE|||||||
34114188|NCT06250608|NA|SINGLE_GROUP||SCREENING||NONE||||||
34114189|NCT06302816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114190|NCT03048331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114191|NCT06254950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114192|NCT06346392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is an open-label study; however, it will be conducted 'sponsor-blind' and the specific treatment to be taken by a participant will be assigned using an IRT/RTSM. To maintain the integrity of the study, sponsor access to treatment records will be restricted, and, in particular, under no circumstances will the sponsor undertake any efficacy analysis by treatment arm during the study. A Study Integrity Plan will be generated in which nominated individuals who will be granted access to any treatment-revealing data will be pre-specified, with their reason for requiring access detailed.|"Participants will be randomized in a 1:1:1 ratio to one of the following intervention arms until the dose selection decision is made:~Arm 1: AZD0901 arm 1 IV, Q3W Arm 2: AZD0901 arm 2 IV, Q3W Arm 3: Participants in the Investigator's choice arm, including regionally accepted chemotherapies or targeted therapies 2L: Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W 2L: Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only) 2L: Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only) 3L+: Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W 3L+: TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China) 3L+: Apatinib 500-850 mg, orally once daily, Q4W (China only)"|f|f|f|t
34114193|NCT05135390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114194|NCT05306938|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Statisticians will be blinded to the intervention status of individuals and schools.|This is a cluster randomized control trial, with randomization occurring at the school level into one of two arms: intervention or control.|f|f|f|t
34114195|NCT06442514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809348|NCT04905784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The information and instructions for the two groups will be placed in 70 envelopes, each group has 35 envelopes, and then these envelopes will be mixed randomly (as in playing cards) and at the end these envelopes will be placed in a box. Patients will be asked to randomly select an envelope from the box. The investigator assesses oral hygiene in check-up appointments without knowledge of group allocation.|Parallel group, single-blind randomized controlled clinical trial.|f|f|t|f
34114196|NCT04908410|||CASE_ONLY||OTHER|||||||
34114197|NCT00102544|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33809349|NCT02191540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114198|NCT03314454|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are aware of the interventions, but are not aware of the assigned arm.||t|f|f|f
34114199|NCT02503722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114200|NCT06052059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Induction and maintenance treatments will be blinded. Reinduction will not be blinded.||t|t|t|t
34114201|NCT06528821|||COHORT||PROSPECTIVE|||||||
34114202|NCT05256225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114203|NCT04811560|NA|SEQUENTIAL||TREATMENT||NONE||||||
34114204|NCT03762733|||COHORT||PROSPECTIVE|||||||
34114205|NCT04924075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114206|NCT06016062|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114207|NCT02573493|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114208|NCT02194738|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34114209|NCT00005909|||COHORT||PROSPECTIVE|||||||
34114210|NCT06113237|||COHORT||PROSPECTIVE|||||||
34114211|NCT03647878|||COHORT||PROSPECTIVE|||||||
34114212|NCT05390268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor is not involved in the treatment of the patient||f|f|f|t
34114213|NCT06407687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114214|NCT06193070|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34114215|NCT04997902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114216|NCT04626635|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114217|NCT02154035|||COHORT||CROSS_SECTIONAL|||||||
34114218|NCT02133196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114219|NCT06491745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34114220|NCT06280820|||COHORT||PROSPECTIVE|||||||
34114221|NCT06020508|||OTHER||PROSPECTIVE|||||||
34114222|NCT05642195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114223|NCT00450788|||COHORT||PROSPECTIVE|||||||
34114224|NCT05382299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114225|NCT04847063|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34114226|NCT04977466|||COHORT||OTHER|||||||
34114227|NCT01812694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809350|NCT00729898|||COHORT||PROSPECTIVE|||||||
33809351|NCT05535959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809352|NCT02978183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809353|NCT02541305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809354|NCT02776826|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33809355|NCT02930317|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809356|NCT00315848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33809357|NCT00856687|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33809358|NCT04862598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809359|NCT04895670|||COHORT||PROSPECTIVE|||||||
33809360|NCT02586467|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33809361|NCT03742622|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|||||
33809362|NCT05606900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomisation of patients to one of the study arms will be carried out by another researcher other than the researcher who will practice the intervention. With this masking method, it is planned to assign the patients to the groups without any bias of the psychotherapist.|This study was designed as an open-label randomized controlled trial.|f|f|t|f
33809363|NCT01240590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809364|NCT00846222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809365|NCT06417372|||COHORT||PROSPECTIVE|||||||
33809366|NCT00620854|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34114228|NCT05696717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Open Label followed by Randomized Parallel Assignment|t|t|t|t
34114229|NCT06507748|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34114230|NCT06469944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114231|NCT05333458|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114232|NCT01568658|||FAMILY_BASED||PROSPECTIVE|||||||
34114233|NCT05601544|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34114234|NCT04577755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114235|NCT04241835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114236|NCT04813055|||CASE_CONTROL||PROSPECTIVE|||||||
34114237|NCT03994796|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114238|NCT02523014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114239|NCT06575296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114240|NCT01264055|||COHORT||CROSS_SECTIONAL|||||||
34114241|NCT06454461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114242|NCT06646549|||CASE_ONLY||CROSS_SECTIONAL|||||||
34114243|NCT06075667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114244|NCT04628767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114245|NCT06534008|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Outcomes assessor will be blinded to exercise status of participant but all participants will receive treatment|||||
34114246|NCT05440786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114247|NCT06172296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114248|NCT06498596|||CASE_CONTROL||PROSPECTIVE|||||||
34114249|NCT05044845|||COHORT||PROSPECTIVE|||||||
34114250|NCT06003985|||COHORT||CROSS_SECTIONAL|||||||
34114251|NCT05974644|||COHORT||PROSPECTIVE|||||||
34114252|NCT06021353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114253|NCT06340451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114254|NCT03538600|||COHORT||PROSPECTIVE|||||||
33809367|NCT00524797|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809368|NCT06148636|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3 + 3 dose escalation||||
33809369|NCT01227746|||COHORT||RETROSPECTIVE|||||||
33809370|NCT02751710|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809371|NCT02183272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809372|NCT05581251|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809373|NCT01885559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809374|NCT02323945|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33809375|NCT02590198|||CASE_CONTROL||PROSPECTIVE|||||||
34041232|NCT06234839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical evaluators of the results were unaware that each patient belonged to one of the 2 study groups.|Both study groups underwent conventional mechanical periodontal therapy/oral anti-plaque hygiene. However, the experimental group additionally received the administration of two daily tablets, containing both L. reuteri strains, for 30 days, while the control group did not.|f|f|f|t
34041233|NCT02871154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114255|NCT02610413|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114256|NCT06393595|||COHORT||PROSPECTIVE|||||||
34114257|NCT06386419|NA|SINGLE_GROUP||TREATMENT||NONE||open label assignment||||
34114258|NCT06016842|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114259|NCT06153966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114260|NCT05361434|||COHORT||PROSPECTIVE|||||||
34114261|NCT00086567|||CASE_ONLY||PROSPECTIVE|||||||
34114262|NCT05987241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727571|NCT00382811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727572|NCT01452308|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727573|NCT01056809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727574|NCT01188603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727575|NCT01894269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727576|NCT01272830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727577|NCT05423821|||CASE_ONLY||RETROSPECTIVE|||||||
33727578|NCT01302574|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33727579|NCT05695716|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This is a prospective, single-arm, single-site study.||||
33727580|NCT01852266|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727581|NCT03266120|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727582|NCT05400928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809376|NCT05208294|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants will be blinded to the actual substance groups. In order to carry out the expectation manipulation, the clinician scientists will provide participants with substance information that is unrelated to the actual substance that is received by the participants. Hence the clinician scientists are blind to the actual substance (double blind design). Other than providing (invalid) substance information (i.e. the expectation manipulation) and drawing blood samples, the study clinicians do not take part in the remaining experimental procedure. The investigators who accompany participants throughout the experimental procedure are not aware of participants' true substance and expectation allocation.|A fully crossed 2x2 placebo design will be employed by giving participants either a placebo or a sulpiride capsule in combination with a low vs. high expectation manipulation.|t|f|t|t
33809377|NCT01934322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33809378|NCT05674981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Parallel Assignment, Randomized Controlled Trial|t|f|t|f
33809379|NCT05433441|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33809380|NCT03371316|NA|SINGLE_GROUP||TREATMENT||NONE||All patients requiring a hemicraniectomy will also receive the amnion patch as an anti-adhesive barrier||||
33809381|NCT02773862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809382|NCT02142595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33809383|NCT06176014|RANDOMIZED|PARALLEL||OTHER||SINGLE|all the selected patients were rehabilitated with lower single denture then divided by computer randomization using random allocation software|to compare PEKK framework for hybrid prostheses ( fixed detachable ) versus PFM framework|f|f|t|f
33809384|NCT02052687|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33809385|NCT04932954|||OTHER||RETROSPECTIVE|||||||
33809386|NCT00113308|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33809387|NCT00513071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809388|NCT04348669|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group intervention study of adults (18-80 years-old) with cervical dystonia undergoing a 6-week intervention of 30-minute yoga classes delivered remotely through videoconferencing 2 times per week. There will be baseline testing (0-weeks), post-intervention testing (6-weeks), and follow-up testing (12-weeks).||||
33809389|NCT05038215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After recruitment and informed consent are complete, subjects will be randomized to the control or experimental group using Random.org. This is a true random number service that generates randomness via atmospheric noise.|To determine if the interventions increase adherence in the experimental group compared with a control group receiving the standard protocol.|t|t|t|t
33809390|NCT00623337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809391|NCT06403410|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The study will utilize single-blind masking|randomized controlled quasi-experimental study|t|t|t|f
33809392|NCT06510244|||OTHER||OTHER|||||||
33809393|NCT04413526|||COHORT||RETROSPECTIVE|||||||
33809394|NCT00001004||||TREATMENT||DOUBLE||||||
33809395|NCT02759575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809396|NCT01542255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809397|NCT05077670|||COHORT||PROSPECTIVE|||||||
34114263|NCT00067054|||OTHER||PROSPECTIVE|||||||
34114264|NCT00923065|||COHORT||PROSPECTIVE|||||||
34114265|NCT04530799|||COHORT||PROSPECTIVE|||||||
34114266|NCT00001529|||CASE_ONLY||PROSPECTIVE|||||||
34114267|NCT03937661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114268|NCT04595760|||COHORT||PROSPECTIVE|||||||
34114269|NCT00713492|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34114270|NCT04629248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114271|NCT05646355|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33727583|NCT03091608|||COHORT||PROSPECTIVE|||||||
33727584|NCT00980395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809398|NCT02848625|RANDOMIZED|CROSSOVER||||NONE||||||
33809399|NCT01271244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727585|NCT01449526|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33809400|NCT04567459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33809401|NCT03075878|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809402|NCT01249638|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809403|NCT05331872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809404|NCT01409837|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33809405|NCT01487837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809406|NCT06156800|||COHORT||PROSPECTIVE|||||||
33809407|NCT01595269|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809408|NCT02082990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809409|NCT01496339|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809410|NCT02039999|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809411|NCT02997410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809412|NCT04817345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33809413|NCT05059106|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33809414|NCT04594525|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding to data entry means a unique code will be allocated to each subject before entering the data for the analysis.|"The design of the study: Two-arm randomized controlled trial. One Arm (Intervention): Will receive baseline assessment (personal characteristics) and standard psychological distress screening tools Plus WHO-low psychological intervention.~One Arm (Control): baseline assessment (personal characteristics) and standard psychological distress screening tools without the WHO-low psychological intervention."|f|f|f|t
33809415|NCT03698383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041234|NCT05413213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The experimental plan is that of therapeutic research. This is a multicenter, prospective, comparative, randomized patient study in 2 parallel arms (ratio 1: 1) in single blind, providing for 134 participants.~They can provide an unbiased evaluation of the effect of this intervention, randomisation having the effect of eliminating any influence of the patient or the doctor on the allocation of the intervention and therefore of not guiding the selection of patients according to the intervention they will receive. Conducting a double-blind trial would be impossible here. The patient and the physiotherapist will be aware of the treatment arm to which the patient belongs. However, the evaluator (who is not the therapist) will not know the treatment arm and the patient will not know the hypothesis tested (effectiveness of the rehabilitation received by the experimental group)."|"Experimental group: Ambulatory rehabilitation program based on mobilizations and muscular solicitations (muscle strengthening and dynamic humeral recentering), supervised by a physiotherapist, consisting of 15 individual sessions of 30 minutes each, spread over 8 weeks, according to a standardized program .~Control group: Ambulatoryrehabilitation program, consisting of ultrasound physiotherapy, supervised by a physiotherapist, consisting of 15 individual sessions of 30 minutes each, spread over 8 weeks."|f|f|t|t
34041235|NCT06041360|||CASE_CROSSOVER||PROSPECTIVE|||||||
34041236|NCT04642833|||COHORT||RETROSPECTIVE|||||||
34041237|NCT02935127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041238|NCT00963300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041239|NCT05642897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041240|NCT04001725|RANDOMIZED|PARALLEL||PREVENTION||NONE||Eligible patients will be randomized in a 1:1 ratio. Randomization will be stratified by means of minimization technique according to the following factors: primary tumor (melanoma versus lung versus breast cancer), dexamethasone dosage (8-12 mg vs \>12 mg daily), baseline (pre-enrollment) fasting glycemia (\< 100 versus 100-125 mg/dl). Patients randomized to the experimental arm will discontinue metformin after 30 days, unless diabetes has developed in the meanwhile and the physician believes that metformin is still required for its management. Patients randomized to the control arm who develop steroid-induced diabetes will be prescribed metformin, unless contraindicated, as the preferred therapy option for the management of hyperglycemia. In both treatment arms, dexamethasone will be administered until necessary and at the required dosage in the judgment of the treating physician.||||
33809416|NCT03604809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All investigators, with the exception of the occupational therapist, will be blinded to participant randomization.||f|f|t|t
33727586|NCT06353490|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727587|NCT00907374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727588|NCT06105385|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33727589|NCT04407910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind participant|We have two groups applied to split-mouth experimental units. Left side of maxillary have received rubber-cup and right side of maxillary of each subject.have APD prophylaxis respectively.|t|f|f|f
33727590|NCT03578081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33727591|NCT04434131|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809417|NCT01726998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809418|NCT01266369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809419|NCT03967015|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33809420|NCT03547167|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809421|NCT04320914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809422|NCT03973515|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33809423|NCT00002437||||TREATMENT||||||||
33809424|NCT05173220|||COHORT||PROSPECTIVE|||||||
33809425|NCT00481572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809426|NCT04017104|||COHORT||PROSPECTIVE|||||||
33809427|NCT05445349|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809428|NCT05847452|||COHORT||PROSPECTIVE|||||||
33838224|NCT03587766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|As the study is double-blinded, the patient, investigators, pharmacist(s) and DNDi study team members involved with the clinical trial implementation will remain blinded to treatment allocation for the duration of the clinical trial.|This study is designed as a double-blind, randomized, prospective, comparative, pharmacokinetic-pharmacodynamic, and proof-of-concept trial design, with three-parallel groups and historical placebo control in patients with chronic indeterminate Chagas Disease.|t|f|t|f
33727592|NCT03348696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838225|NCT04071301|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33838226|NCT06470477|||COHORT||PROSPECTIVE|||||||
33838227|NCT02539459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114272|NCT04531917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34114273|NCT04224493|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||"3 stages study:~Stage 1:~Open-Label (Phase 1b: Safety run-in): All participants will receive Tazemetostat in combination with Lenalidomide and Rituximab~Stage 2:~Double-blinded (Phase 3):~* Study drug arm: Tazemetostat in combination with Lenalidomide and Rituximab~* Placebo arm: Placebo in combination with Lenalidomide and Rituximab~Stage 3:~Long-term Follow-up of participants in Stage 2 after treatment for response, when applicable, and overall survival for up to 5 years after the enrollment of the last patient in the study."|t|t|t|t
34114274|NCT05195281|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114275|NCT06337318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114276|NCT05663801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"this is a randomized double-blinded study All patients included will be divided randomly into three groups Preoperative data will be recorded by anesthesiologist who will be blinded to the study .~The studied drugs will be prepared by anesthetist ( who will be blinded to the study and will not involved in the technique) in labeled syringes .~Randomization will be done using a computer-generated sequence. The randomly assigned numbers in each group will be hidden in sealed and opaque envelopes"|Ultrasound guided pectoral nerve block will be performed after induction of general anaesthesia . Starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line. The needle will be inserted in plane with ultrasound probe between 2 pectoralis muscles and 10 mL of bupivacaine 0.25% alone or with ketamine or magnesium will be injected between the 2 pectoral after negative aspiration for blood (PECS I) then the ultrasound probe will be moved towards axilla until identification of the serratus anterior then the needle will be inserted between pectoralis minor and serratus anterior muscles and 20 mL of bupivacaine 0.25% alone or with ketamine or magnesium will be injected after negative aspiration. Skin incision will be performed 15 minutes after the block will be given . After extubation , all patients will be transferred to the post anesthesia care unit for postoperative monitoring and observation|f|t|f|t
34114277|NCT06531083|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective surveillance with early intervention||||
34114278|NCT00028080|||COHORT||PROSPECTIVE|||||||
34114279|NCT03811002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114280|NCT04920890|NA|SINGLE_GROUP||TREATMENT||NONE|Los pacientes no conocerán sin van a ser sometidos a tratamiento o si se les administrará placebo.|||||
34114281|NCT06554912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34114282|NCT05388669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114283|NCT06470243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114284|NCT06431763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114285|NCT03685721|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114286|NCT02867592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114287|NCT06439225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114288|NCT04717375|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114289|NCT04731376|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114290|NCT05332769|||COHORT||PROSPECTIVE|||||||
34114291|NCT06041503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114292|NCT02108041|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114293|NCT02543996|||CASE_ONLY||CROSS_SECTIONAL|||||||
34114294|NCT00442195|||OTHER||PROSPECTIVE|||||||
34114295|NCT02196181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114296|NCT06020716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a Phase 4, randomized controlled, parallel group, multicenter, double blind study of amoxicillin-clavulanate in children 9-36 months of age with chronic wet cough. A total of 300 children will be included in the study in two different RCTs; AMIC 1 and AMIC 2.AMIC 1 will be performed before AMIC 2.There is no randomization between AMIC 1 and AMIC 2.~To study the role of respiratory pathogens, microbiome and inflammation, 50 healthy controls will be included for comparison."|t|t|t|t
34114297|NCT06407934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114298|NCT06459726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114299|NCT03478956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114300|NCT03762590|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34114301|NCT03926130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114302|NCT05621291|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114303|NCT01866852|||COHORT||PROSPECTIVE|||||||
34114304|NCT04241276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114305|NCT00012545|||CASE_ONLY||CROSS_SECTIONAL|||||||
34114306|NCT06079359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded||t|t|t|t
33727593|NCT00398853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34041241|NCT04189978|||COHORT||PROSPECTIVE|||||||
34041242|NCT01098773|||||CROSS_SECTIONAL|||||||
34041243|NCT02569801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041244|NCT00762437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041245|NCT04872751|||COHORT||PROSPECTIVE|||||||
34114307|NCT00001372|||COHORT||PROSPECTIVE|||||||
33727594|NCT05677542|||COHORT||RETROSPECTIVE|||||||
33727595|NCT01540058|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727596|NCT03712033|||COHORT||PROSPECTIVE|||||||
33727597|NCT01938274|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34041246|NCT02923011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041247|NCT04039568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34041248|NCT02176655|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34041249|NCT06409481|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041250|NCT02892773|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant and Care Provider will be masked from electrical impedance tomography distribution of ventilation recording during lung expansion therapy to reduce risk of performance bias.||t|t|f|f
34041251|NCT01020630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041252|NCT02227498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041253|NCT05697354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34114308|NCT05662241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114309|NCT05300035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114310|NCT05836584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114311|NCT04633252|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114312|NCT05746442|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34114313|NCT05826652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34114314|NCT03223610|NA|SEQUENTIAL||TREATMENT||NONE||||||
34114315|NCT05879484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114316|NCT04089865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114317|NCT05477420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34114318|NCT05461027|||COHORT||RETROSPECTIVE|||||||
34114319|NCT01498276|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34114320|NCT01572506|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114321|NCT00071526|||COHORT||PROSPECTIVE|||||||
34114322|NCT05247905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114323|NCT04858334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114324|NCT05295030|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34114325|NCT04558983|||COHORT||PROSPECTIVE|||||||
34114326|NCT05232929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114327|NCT00001721|||COHORT||PROSPECTIVE|||||||
34114328|NCT04660539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114329|NCT06108687|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114330|NCT04802161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114331|NCT05017012|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|None (Open-label)|||||
34114332|NCT04569591|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114333|NCT04388839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114334|NCT04025554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114335|NCT00814827|||COHORT||PROSPECTIVE|||||||
34114336|NCT03261089|||COHORT||PROSPECTIVE|||||||
34114337|NCT06571994|RANDOMIZED|PARALLEL||PREVENTION||NONE|Laboratory scientists will be blinded to the participant status|||||
34114338|NCT06422143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are allocated to a single induction arm, then assigned randomly to one of 2 maintenance arms.||||
34114339|NCT04500613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114340|NCT04545736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114341|NCT06043817|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114342|NCT06460389|||COHORT||PROSPECTIVE|||||||
34114343|NCT05807789|||COHORT||PROSPECTIVE|||||||
34114344|NCT06406699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114345|NCT06393374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114346|NCT06565793|||COHORT||PROSPECTIVE|||||||
34114347|NCT05417594|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114348|NCT06104605|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped-wedge design. CHCs will be randomized to receive the intervention either first, second, or third two months apart.||||
34114349|NCT05304377|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114350|NCT06444360|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The study is a two-arm, multisite, and multiformat randomized controlled trial (RCT). IMPACT is a status-neutral intervention that uses behavioral activation (BA)-an evidence-based, cognitive behavior therapy-as a treatment for stimulant use and sexual risk reduction (RR) counseling for young gay/bisexual sexual minority men.~The IMPACT intervention includes 10 sessions: 2 intervention sessions of HIV RR, 1 session focused on orienting and rationale of BA, 6 sessions integrating BA and RR-including pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) and HIV care-and 1 final session on relapse prevention.~The enhanced Standard of Care (eSOC) group includes two HIV risk reduction intervention sessions."||||
34114351|NCT00340132|||COHORT||PROSPECTIVE|||||||
34114352|NCT03912428|NA|PARALLEL||DIAGNOSTIC||NONE||||||
34114353|NCT06439602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114354|NCT02070549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114355|NCT05536804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114356|NCT00018057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114357|NCT04252235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sham air purifiers will be indistinguishable from real air purifiers. Only the research assistant installing the purifiers and the data coordinating center will have knowledge of assignment to real or sham purifiers.|Participants will be randomized to receive real or sham HEPA filters in the bedroom and living room for a total of 12 months.|t|t|t|t
33727598|NCT04968899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727599|NCT01180309|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727600|NCT05953662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727601|NCT03240133|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33727602|NCT00834210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34114358|NCT03299049|RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study and therefore no blinding is required|Two groups of subjects will be randomized to receive CAB LA + RPV LA Q4W, or CAB LA + RPV LA Q8W regimen||||
34114359|NCT00980538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114360|NCT06320743|RANDOMIZED|CROSSOVER||OTHER||NONE||Cerebral NIRS probe will be attached to the right and left frontotemporal region, and a peripheral NIRS probe will be attached to the inner surface of the forearm and the values will be noted.||||
33727603|NCT04563091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727604|NCT04145258|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment||t|t|t|t
33727605|NCT04126395|||CASE_CONTROL||RETROSPECTIVE|||||||
33727606|NCT01023581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727607|NCT02051036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727608|NCT02889094|||COHORT||OTHER|||||||
33727609|NCT02120976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727610|NCT00267722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727611|NCT00913744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727612|NCT06158191|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group and control group||||
33727613|NCT04836299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants, care providers and also investigator will be blinded for this study design.|"Randomized, double-blind, Placebo-controlled parallel clinical trial to Study the efficacy and therapeutic safety of Ivermectin associated with standard of care treatment versus placebo with standard of care treatment in the early phase of coronavirus infection (COVID19).~A PHASE II pilot study."|t|t|f|f
34114361|NCT04570956|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects with be randomized by MedidataRave and Pharmacy.|"Subjects will be randomized 2:2:1 with either Oral Tamoxifen 10 mg/day~* gel placebo, Topical 4-OHT gel 4 mg/each breast/day~* oral placebo, or Control Oral and gel placebo for 4 weeks of treatment."|t|t|t|f
34114362|NCT06170788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727614|NCT01930292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727615|NCT03137888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727616|NCT00404950|||CASE_ONLY||PROSPECTIVE|||||||
33727617|NCT05861791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33727618|NCT05279586|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727619|NCT00363454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727620|NCT02583932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigators and care providers are masked as to group assignment||f|t|t|f
33727621|NCT02897128|||COHORT||PROSPECTIVE|||||||
33727622|NCT03194451|||CASE_ONLY||PROSPECTIVE|||||||
33727623|NCT03646110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727624|NCT02735161|NA|SINGLE_GROUP||OTHER||NONE||||||
33727625|NCT04935021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727626|NCT04263974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727627|NCT00385528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33727628|NCT00256919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727629|NCT03072485|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33727630|NCT02813603|||CASE_CONTROL||PROSPECTIVE|||||||
33727631|NCT02253810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727632|NCT01253252|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727633|NCT00001749||||TREATMENT||||||||
34114363|NCT00046202|||OTHER||OTHER|||||||
33727634|NCT01120756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727635|NCT03160053|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant served as his/hers own control.||||
33727636|NCT05929547|||CASE_CROSSOVER||PROSPECTIVE|||||||
33727637|NCT06423911|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part A 2:1 ratio Part B: control||||
33727638|NCT05543512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded|Targeted elimination diet therapy versus sham diet elimination therapy|t|t|t|f
33727639|NCT01988116|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33727640|NCT03591237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114364|NCT06044935|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33727641|NCT04846725|||COHORT||RETROSPECTIVE|||||||
33727642|NCT03530579|NON_RANDOMIZED|PARALLEL||PREVENTION||||||||
33727643|NCT03225911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727644|NCT05326165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33727645|NCT02403245|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34114365|NCT00071786|||FAMILY_BASED||RETROSPECTIVE|||||||
33727646|NCT00258076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33727647|NCT02856542|||COHORT||PROSPECTIVE|||||||
33727648|NCT05092555|||CASE_ONLY||PROSPECTIVE|||||||
33727649|NCT00138437|||COHORT||CROSS_SECTIONAL|||||||
33727650|NCT03173716|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727651|NCT06310850|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study was designed as a randomized, prospective study|t|f|f|f
33727652|NCT02105337|||CASE_ONLY||PROSPECTIVE|||||||
33727653|NCT02523846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727654|NCT02762175|||COHORT||PROSPECTIVE|||||||
33727655|NCT04398758|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, randomized, non-treatment-controlled, investigator-blinded, multicenter, 2-arm parallel group study (main phase: from inclusion until 6 months of age with treatment group and control group (without treatment) according to 1:1 randomisation; follow-up phase: 6-12 months of age in which only half of the children from the treatment group is treated according to initial 1:1 randomisation)|f|f|t|f
33809429|NCT05332613|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a single-site, randomized, controlled pilot study. The investigators hypothesize that time-restricted eating (TRE) will lead to an additional improvement in hepatic steatosis as compared to standard of care lifestyle recommendations alone measured by MRI-PDFF. The investigators plan to enroll 40 participants to two arms between the years of 18 and 65 with NAFLD as defined by MRI-PDFF score of greater or equal to 10%. Participants on the experimental arm (TRE plus SOC) will be required to fast for 16 hours each day for 12 weeks. Counseling will involve instructing the participant to choose an 8-hour eating window. During the fasting window, the participant is able to drink water and black coffee or tea. Participants in both arms will be given lifestyle recommendations with respect to diet and exercise. The RD will instruct participants regarding standard of care lifestyle recommendations, which includes education of a low-calorie diet and moderate-intensity exercise.||||
33809430|NCT04808024|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33809431|NCT05350670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114366|NCT06208306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114367|NCT01581580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114368|NCT02594202|||CASE_ONLY||PROSPECTIVE|||||||
34114369|NCT05652478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34114370|NCT06328036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114371|NCT01174108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114372|NCT02146170|||COHORT||PROSPECTIVE|||||||
34114373|NCT06575153|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||This study will include up to 5 cohorts in Part 1 (SAD) and up to 3 cohorts in Part 2 (MAD). Each cohort will consist of 8 participants who will receive a single IV dose of either ART5803 or placebo (6 active \[ART5803\], 2 placebo) based on the individual participant's randomly assigned treatment.|t|t|t|t
33727656|NCT01913366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727657|NCT00118807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809432|NCT02394054|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809433|NCT01685268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809434|NCT04943445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809435|NCT04216641|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33809436|NCT04880837|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809437|NCT00403494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809438|NCT05341037|||COHORT||RETROSPECTIVE|||||||
33809439|NCT04723615|||OTHER||PROSPECTIVE|||||||
33809440|NCT02286869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33809441|NCT05906966|||COHORT||RETROSPECTIVE|||||||
33809442|NCT02336802|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809443|NCT02698956|||COHORT||PROSPECTIVE|||||||
33809444|NCT02293551|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809445|NCT02753998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809446|NCT06269068|||COHORT||CROSS_SECTIONAL|||||||
33809447|NCT04860999|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants underwent an osteopathic structural examination and osteopathic manipulation. Participants completed a biomechanical assessment prior to and following the osteopathic manipulation to evaluate the effect of osteopathic manipulation on gait asymmetry.||||
33809448|NCT04885673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33809449|NCT06019052|||OTHER||PROSPECTIVE|||||||
33809450|NCT04620252|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33809451|NCT04494399|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label randomised controlled trial||||
33809452|NCT01769716|NA|SINGLE_GROUP||TREATMENT||NONE||allogeneic cord blood transplantation for children with developmental delay||||
33809453|NCT01138969|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809454|NCT01267552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041254|NCT03142009|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to factors that make the randomization of participants to either an intervention or usual and customary treatment group not feasible, the investigators do not use randomization or masking.|The investigators use a two arm non-equivalent control group design with pretest, immediate post- test, and 12 month follow-up assessment points. Among quasi-experimental designs that could be employed, this design carries several advantages over other designs in being able to infer causality. One advantage of this design is that it allows for a more meaningful analysis of the impact of the FL/CP intervention by a comparison of the intervention group with the usual and customary comparison group, an advantage not possible with single-group over time designs. Second, the design provides an analysis of diffusion effects (i.e. the potential influence of the intervention on the comparison group over time). Given the tight social networks and small number of interconnected families in the three participating communities, the investigators expect some degree of program diffusion in the comparison group families.||||
34041255|NCT05113550|||CASE_CONTROL||RETROSPECTIVE|||||||
34041256|NCT02942797|||COHORT||PROSPECTIVE|||||||
34041257|NCT05370950|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single-center, random, parallel, open-label||||
34041258|NCT04394780|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Every patient underwent peritoneal dialysis at 37 C and then at 32 C one week after.||||
34041259|NCT06358547|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041260|NCT04948502|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041261|NCT00774163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041262|NCT04699474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041263|NCT01808599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041264|NCT05419219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The Multi-domain Tai Chi-DTx will be provided via a tablet or smart phone. The traditional Tai Chi exercise with background music and respiratory control exercise with 18 BPM metronome, and 40 Hz sound stimulation will be comprised in a 4-week therapeutic session.~A control arm will be designed in this study, which will use the same way to deliver traditional Tai Chi exercise with plain music background only."|To evaluate the effectiveness of Multi-domain Tai Chi Digital Therapy for treating the long term sequalae symptoms among COVID-19 survivors compared with traditional Tai Chi exercise only as control.|t|f|f|f
34041265|NCT00289419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041266|NCT03415932|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||baseline and follow up in one population||||
34041267|NCT00818766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041268|NCT04548193|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041269|NCT04031846|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34041270|NCT03051100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041271|NCT02110212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041272|NCT05094271|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|If subjects have been randomized to receive room air, subjects will have a nasal cannula with pressurized room air to avoid unblinding.||t|f|f|f
34041273|NCT00857987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041274|NCT06530550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041275|NCT00684411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041276|NCT05055479|||CASE_ONLY||RETROSPECTIVE|||||||
34041277|NCT04737629|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041278|NCT03508219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041279|NCT03478566|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041280|NCT05663073|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34041281|NCT04860973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041282|NCT05110417|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study so all 10 participants will be assigned to the pyridostigmine (Mestinon) treatment arm.||||
34041283|NCT01707966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041284|NCT06045676|||CASE_CONTROL||PROSPECTIVE|||||||
34041285|NCT04934813|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041286|NCT03673813|||COHORT||PROSPECTIVE|||||||
34041287|NCT04816617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34041288|NCT00618592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041289|NCT03604133|||CASE_ONLY||PROSPECTIVE|||||||
34041290|NCT02576080|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041291|NCT00619450|||CASE_ONLY||PROSPECTIVE|||||||
34041292|NCT05884736|||COHORT||PROSPECTIVE|||||||
33809455|NCT00327730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809456|NCT00681941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809457|NCT00001686|||COHORT||PROSPECTIVE|||||||
33809458|NCT04039776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809459|NCT04813666|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33809460|NCT01057082|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33809461|NCT00284466|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809462|NCT04180943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809463|NCT06195345|||COHORT||PROSPECTIVE|||||||
33809464|NCT06511310|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33809465|NCT01792401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809466|NCT02384382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809467|NCT01604824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809468|NCT01451359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809469|NCT00002801||||TREATMENT||||||||
33809470|NCT01262456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809471|NCT03999788|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809472|NCT01102790|||COHORT||PROSPECTIVE|||||||
33809473|NCT02427516|||COHORT||RETROSPECTIVE|||||||
33809474|NCT04180683|||OTHER||CROSS_SECTIONAL|||||||
33809475|NCT04701645|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809476|NCT00456339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809477|NCT00746759|||COHORT||PROSPECTIVE|||||||
33809478|NCT02060487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809479|NCT03739606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809480|NCT02640703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809481|NCT03328637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a Randomized Controlled Trial (RCT) with single blind rating. The randomization of participants is across two groups (1) one provided with intervention of CBT and (2) the other group will be on Treatment As Usual (TAU)|f|f|f|t
33809482|NCT02322372|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33809483|NCT01833598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809484|NCT05491291|NA|SINGLE_GROUP||OTHER||NONE||The rating scale will be passed at three different times, day 1, day 15 and day 75.||||
34114374|NCT01851447|||COHORT||PROSPECTIVE|||||||
34114375|NCT01976715|||COHORT||PROSPECTIVE|||||||
34114376|NCT03519945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114377|NCT06181994|||COHORT||RETROSPECTIVE|||||||
34114378|NCT05965700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
34114379|NCT04180202|||CASE_ONLY||RETROSPECTIVE|||||||
34114380|NCT06220669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114381|NCT00040352|||FAMILY_BASED||OTHER|||||||
34114382|NCT03746431|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114383|NCT00001594|||COHORT||PROSPECTIVE|||||||
34114384|NCT00065676|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34114385|NCT04204941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Phase 1b is open label, phase 3 is not open label||t|t|t|t
34114386|NCT05772520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114387|NCT04394858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114388|NCT04115163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114389|NCT02625428|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34114390|NCT02958865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114391|NCT02415556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"289 signed ICF.~244 were randomized (115 T2DM adults and 129 non-DM controls).~79 T2DM adults and 90 non-DM controls completed intervention (as of 4/23/2020)"|t|t|t|t
34114392|NCT05199753|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114393|NCT05687370|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34114394|NCT01342848|||COHORT|||||||||
34114395|NCT05325684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809485|NCT01597674|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34114396|NCT04613388|||COHORT||PROSPECTIVE|||||||
34114397|NCT02357303|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34114398|NCT03551093|NA|SINGLE_GROUP||TREATMENT||NONE||"This will be a multi-center, adjunctive to Standard of Care, single arm study, which includes the following steps:~1. Screening (day 1)~2. Implantation (day 1)~3. Treatment and symptom assessment (days 1-5)~4. Device Positioning and Removal (day 5)~5. Discharge/Final Visit (day 7-10)"||||
34114399|NCT05503277|RANDOMIZED|CROSSOVER||OTHER||NONE||observational||||
33809486|NCT03998059|||CASE_CONTROL||PROSPECTIVE|||||||
33809487|NCT03100188|NA|SINGLE_GROUP||TREATMENT||NONE||one cohort of patients who meet inclusion criteria had intervention and followed for 12 months||||
33809488|NCT05376397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809489|NCT04252638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809490|NCT06074744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomization by sealed envelopes||t|t|t|t
33809491|NCT01911156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809492|NCT05973175|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809493|NCT00168246|||NATURAL_HISTORY||OTHER|||||||
33809494|NCT00944359|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33809495|NCT04743388|||COHORT||PROSPECTIVE|||||||
33809496|NCT01706666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809497|NCT02650505|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33809498|NCT01147471|RANDOMIZED|PARALLEL||||NONE||||||
33809499|NCT03367832|||COHORT||PROSPECTIVE|||||||
33809500|NCT03281928|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33809501|NCT02548299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809502|NCT05004909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33809503|NCT06021275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809504|NCT04718285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809505|NCT00366470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809506|NCT04254549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809507|NCT01582321|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727658|NCT04122859|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized, controlled post-market clinical investigation that will enroll pediatric subjects requiring laceration repair. The investigation population will consist of 30 pediatric subjects fulfilling the eligibility criteria for the clinical investigation. The subjects will be randomly assigned at a 1:1 ratio to either the Zip 4 Surgical Skin Closure Device group or the Standard of Care sutures group.||||
33727659|NCT00594061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727660|NCT00394212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727661|NCT00694369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727662|NCT03090100|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727663|NCT01718756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727664|NCT03160833|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, Multi-center, Dose Escalation Study||||
33727665|NCT03979638|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Two-arm, Two-Period, crossover assignment|t|t|t|t
33809508|NCT03496545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data analyst who will analyze the data from each patient will be masked to what medication(s) the patients received.|open label, blinded endpoint, randomized (1:1) controlled trial with two arms: control - acetaminophen and intervention - acetaminophen and bromocriptine.|f|f|f|t
33809509|NCT04644887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and investigators are blinded with the genotype, but not with the dietary groups.||t|f|t|f
33809510|NCT05625230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors are blind to the conditions.||t|f|f|t
33809511|NCT05892445|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33809512|NCT03119740|||COHORT||RETROSPECTIVE|||||||
33809513|NCT06343493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809514|NCT01553266|||COHORT||RETROSPECTIVE|||||||
34114400|NCT04078867|||CASE_CONTROL||PROSPECTIVE|||||||
34114401|NCT03419182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual administering the WOMAC or SF-36 will be blinded to the patient's treatment arm.|Patients will be randomized t wo treatment groups : 1. Open reduction internal fixation (ORIF) 2. Acute primary total hip athroplasty (THA) +ORIF. These are both two standard accepted treatments for this injury. Participants who do not consent to being randomized will be asked if they would consent to participating in an observational arm. In this case, type of surgery would be planned and chosen by clinical decision making from the surgeon and patient. As these procedures are both standard of care, partipants could end up in either group as well. All follow up will be the same.|f|f|f|t
34114402|NCT05284643|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114403|NCT02104193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114404|NCT01888016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114405|NCT03795142|RANDOMIZED|SEQUENTIAL||SCREENING||QUADRUPLE|The clinical study will be performed in a double-blinded manner for all cohorts.||t|t|t|t
34114406|NCT06639178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34114407|NCT04169763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114408|NCT00856557|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34114409|NCT02216526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34114410|NCT04547556|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34114411|NCT03643081|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34114412|NCT05493410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding in the distribution of participants will be guaranteed, as it will be carried out by a different researcher from the one who will treat the patients. In addition, the researchers who will collect and analyze the data will be different and blind to the experimental groups and types of intervention.|"Participants were split into two experimental groups:~CONTROL GROUP (CG): Pulmonary rehabilitation protocol comprising muscle strengthening and aerobic training; TREATMENT GROUP (TG): Pulmonary rehabilitation protocol comprising muscle strengthening, aerobic training, and inspiratory muscle training using the POWERbreathe Classic Medic® device."|t|t|t|t
34114413|NCT05533840|||COHORT||PROSPECTIVE|||||||
34114414|NCT04474132|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||subjects are recruited continuously and being tested with the study device as well as with the standard cleared test for the presence of Toxoplasma gondii antibody.||||
34114415|NCT03213067|||COHORT||CROSS_SECTIONAL|||||||
34114416|NCT02164110|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34114417|NCT02339051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727666|NCT04916730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809515|NCT01232101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809516|NCT01562964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809517|NCT00532766|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33809518|NCT00963924|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809519|NCT01548703|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33809520|NCT01154504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809521|NCT00622700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809522|NCT05548049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33809523|NCT04388137|||CASE_ONLY||PROSPECTIVE|||||||
33809524|NCT03585400|||OTHER||RETROSPECTIVE|||||||
33809525|NCT01827761|||COHORT||PROSPECTIVE|||||||
33809526|NCT04256044|||COHORT||PROSPECTIVE|||||||
33727667|NCT02609334|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33727668|NCT00500292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727669|NCT03587935|||COHORT||PROSPECTIVE|||||||
33727670|NCT05767632|RANDOMIZED|CROSSOVER||OTHER||NONE||An open label randomized, single dose, three-way, partial replicate crossover design||||
33727671|NCT01299922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727672|NCT02164799|||COHORT||PROSPECTIVE|||||||
33727673|NCT00261742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727674|NCT02319538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727675|NCT05134207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||randomized controlled clinical trial|t|f|f|t
33727676|NCT05888129|||COHORT||RETROSPECTIVE|||||||
33727677|NCT05151211|||COHORT||CROSS_SECTIONAL|||||||
33809527|NCT01289600|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809528|NCT02045498|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33809529|NCT03758248|||COHORT||OTHER|||||||
33727678|NCT03509727|||COHORT||PROSPECTIVE|||||||
33727679|NCT04355000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727680|NCT04553432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will not be aware whether bandage contact lens has an amniotic membrane beneath in periphery or not Masked investigator will perform the clinical examinations|1 month baseline followed by randomisation into treatment or control and 6 months follow-up|t|f|t|f
33727681|NCT00314574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727682|NCT03881137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The present study is a controlled cluster-randomized pilot study. Cluster-randomization is chosen to avoid contamination of the control group. Before patient recruitment commences, a selection of 32 municipalities and city districts (= clusters) will be stratified into blocks in accordance with number of inhabitants. The selection will include city districts, large and smaller municipalities to ensure sample size and representativity. Clusters within each block will be randomly assigned to intervention or control by using a computer-generated code, 1:1, i.e. 16 in each group~Eligible, consenting patients from municipalities/city districts randomized to control will enter the control group. Eligible, consenting patients from municipalities randomized to intervention will enter the intervention group"||||
33727683|NCT06428604|||COHORT||PROSPECTIVE|||||||
33727684|NCT01911130|||COHORT||PROSPECTIVE|||||||
33727685|NCT02094001|NA|SINGLE_GROUP||OTHER||NONE||||||
33727686|NCT05083988|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||parallel-group and allocation ratio (1:1) Intervention: virtual reality glasses. Control: audiodistraction using music||||
33727687|NCT04537858|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33727688|NCT01965288|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33727689|NCT03562819|||COHORT||CROSS_SECTIONAL|||||||
33809530|NCT03028285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809531|NCT00252382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809532|NCT05505227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33809533|NCT03652493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809534|NCT01332552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809535|NCT04598139|||OTHER||CROSS_SECTIONAL|||||||
33809536|NCT06324552|||COHORT||PROSPECTIVE|||||||
33809537|NCT05985265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809538|NCT01814605|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33809539|NCT01170936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809540|NCT02444962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809541|NCT03186248|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double blind randomized clinical trial|Double blind randomized clinical trial|t|f|t|f
34114418|NCT02867137|||COHORT||PROSPECTIVE|||||||
33809542|NCT04432155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809543|NCT06509308|||COHORT||PROSPECTIVE|||||||
33809544|NCT03954860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114419|NCT02308514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34114420|NCT04183348|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34114421|NCT03849261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114422|NCT06042946|||CASE_CONTROL||RETROSPECTIVE|||||||
34114423|NCT03728335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114424|NCT02333448|||CASE_ONLY||PROSPECTIVE|||||||
34114425|NCT00006167||||TREATMENT||DOUBLE||||||
34114426|NCT05313581|RANDOMIZED|PARALLEL||PREVENTION||NONE|open|1) Web-based group training guided by a trained START NOW facilitator(either face-to-face or through videoconferencing)2) Web-based self-help without guidance 3) Treatment as usual (TAU)||||
34114427|NCT02487511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114428|NCT00005830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809545|NCT05819294|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Laboratory personnel responsible for the cytological and biochemical analysis will be blinded to the identity of the paired samples|All participants will undergo both thoracentesis techniques; the standard and the experimental pre-aspiration agitated fluid techniques||||
33809546|NCT05137366|||CASE_CONTROL||PROSPECTIVE|||||||
33809547|NCT01828021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809548|NCT00142246|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33809549|NCT02971215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809550|NCT00075998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809551|NCT03649191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Once the data is collected from all participating nursing homes, anonymized and and electronically encoded, the study arm will also be encoded and the person analyzing the data will be blinded to which group is which.|Cluster-randomized study|f|f|f|t
33809552|NCT02869802|||COHORT||PROSPECTIVE|||||||
33809553|NCT06271850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809554|NCT00108589|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33809555|NCT00666705|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33809556|NCT00586755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809557|NCT05488405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809558|NCT05026970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809559|NCT02573129|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33809560|NCT02206815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041293|NCT05186805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041294|NCT04988932|NA|SINGLE_GROUP||TREATMENT||NONE||Administration of iNO in SAH patients with severe vasospasm||||
34041295|NCT05302531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041296|NCT03693638|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041297|NCT06382701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Pre-cannulation spray application to the intervention and placebo groups will be provided by an interviewer trained by the researchers. Cannulations will be performed by nurses in the institution where the study is conducted. Data will be collected by the responsible nurses in the institutions.~Patients participating in the study, researchers, and the nurse in charge will not know who is in the intervention and placebo groups.~The research will be completed in twelve sessions over four weeks."|The study was designed as a randomized controlled and double-blind study to evaluate the effect of clove oil applied to arterio-venous fistula on pain and anxiety caused by cannulation and to determine the effect of the application on satisfaction.|t|t|t|f
33727690|NCT06266455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the nutritional interventions, the clinical and research teams will not be blinded to study intervention. The radiologist and research team members performing MRI interpretation, post-acquisition processing, and quantitative analysis will be blinded to study nutritional intervention arm. Similarly, teams performing neurodevelopmental follow-up will also be blinded to study nutritional intervention arm.|Prospective, randomized-controlled trial comparing the impact of individualized human milk fortification on somatic growth and neurodevelopment in preterm infants randomized to receive one of three nutritional interventions: standardized (control), adjustable, or targeted human milk fortification.|f|f|f|t
33727691|NCT03758742|NA|SINGLE_GROUP||TREATMENT||NONE|Week 0, 4, and 12 endpoints are assessed blinded by individuals not affiliated with the protocol. Also, data cleaning will be performed while being blinded to the timepoint.|||||
33727692|NCT02321462|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33727693|NCT05581316|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727694|NCT03999892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727695|NCT04951934|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since this is an experiment with a medical device that emits blue light, in this case the masking of the assignment to one of the two groups cannot be carried out.|Multi-centric prospective, randomized controlled study||||
33727696|NCT02732106|||||PROSPECTIVE|||||||
33727697|NCT00744575|||CASE_CONTROL||PROSPECTIVE|||||||
33727698|NCT02151526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727699|NCT04055597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727700|NCT06297707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727701|NCT01483105|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33727702|NCT04884685|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727703|NCT00022321||||TREATMENT||||||||
33727704|NCT03610932|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33727705|NCT02509065|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Some of the study arms are double blinded: the 110 mg/dl and 130 mg/dl set point configurations of the bionic pancreas are double blinded, so neither the patient nor the study team know if they are using the bihormonal bionic pancreas or insulin only bionic pancreas|||||
33727706|NCT00132418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727707|NCT00558103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727708|NCT03365596|||COHORT||RETROSPECTIVE|||||||
33809561|NCT06020300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Tablet Pyridoxine used as placebo in view of tablet colchicine look alike|Block randomization method will be used for sampling. Patients recruited will be randomly assigned to colchicine \& placebo group with 1:1 ratio|t|t|t|t
33727709|NCT02903186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727710|NCT01992731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727711|NCT04200807|||CASE_CONTROL||PROSPECTIVE|||||||
33727712|NCT01197690|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727713|NCT05728346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809562|NCT03842332|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This project utilizes an intention to treat, wait-list cross over design of individuals who agree to participate.||||
33809563|NCT05688605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809564|NCT03305172|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33809565|NCT01858324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809566|NCT02596061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809567|NCT01253798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809568|NCT02656199|||COHORT||PROSPECTIVE|||||||
33809569|NCT04864899|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809570|NCT04627168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned to 1 of 2 groups. The first subject group will include spinal cord injured persons presenting with constipation, the second group - able-bodied persons with chronic constipation. In both groups, subjects will receive transcutaneous abdominal electrical stimulation that will be delivered through commercially available equipment.||||
33809571|NCT01965990|||CASE_ONLY||PROSPECTIVE|||||||
33809572|NCT04412005|||OTHER||PROSPECTIVE|||||||
33809573|NCT01128959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809574|NCT05454943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809575|NCT01593644|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33809576|NCT04541199|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33809577|NCT02773732|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809578|NCT04012905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114429|NCT02884102|||OTHER||PROSPECTIVE|||||||
34114430|NCT05150626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114431|NCT01108887|||COHORT||PROSPECTIVE|||||||
34114432|NCT06449820|||COHORT||RETROSPECTIVE|||||||
34114433|NCT04695990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727714|NCT00563238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727715|NCT00909948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727716|NCT03503721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727717|NCT02694146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727718|NCT04287738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727719|NCT02838264||||BASIC_SCIENCE||NONE||||||
33727720|NCT02271191|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727721|NCT06182644|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727722|NCT00116558|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727723|NCT04264468|||OTHER||RETROSPECTIVE|||||||
33727724|NCT02614911|||COHORT||PROSPECTIVE|||||||
33727725|NCT01554618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809579|NCT01119651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33809580|NCT04019067|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809581|NCT04817059|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809582|NCT01603836||PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809583|NCT00006045||||TREATMENT||||||||
33809584|NCT02220959|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33809585|NCT04773145|||COHORT||RETROSPECTIVE|||||||
34114434|NCT00085527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727726|NCT05016388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, Principal Investigator will not receive information about the assigned group (intervention/control). The Outcome assessor will be blinded to the assigned group (intervention/control) for data analysis.|The collaborative multidimensional model (CMD) for depression incorporates to the current knowledge for the treatment of depression in primary care (PHC) teams in Chile, competences for the management of clinical, functional, psycho-biographical dimensions. These dimensions are prevalent in patients consulting PHC in Chile, associated to a complex depression sub-type, for which the current clinical guide does not provide recommendations. The implementation of this model entails a 22-hour training consisting of lectures and workshops through a virtual platform, followed by the application of the CMD in the PHC teams. In brief, the application of the model involves the creation of a case manager that prioritizes participants according to their complexity and collaboration sessions with the participation of specialists and the PHC team every 15 days for at least 3 months after the training.|t|f|t|t
33727727|NCT02206412|||CASE_ONLY||PROSPECTIVE|||||||
33727728|NCT04396093|||COHORT||PROSPECTIVE|||||||
33727729|NCT01687491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33727730|NCT06155591|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727731|NCT03246113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727732|NCT05179421|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each participant will receive 2 IV infusions separated by 1 hour One study day: saline (placebo) then oxytocin 1.3 micrograms Another study day: oxytocin 0.3 micrograms then oxytocin 7 micrograms|t|f|t|t
33727733|NCT03981133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33727734|NCT02363465|||COHORT||CROSS_SECTIONAL|||||||
33727735|NCT06416696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809586|NCT05826496|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||HLA-A2 positive participants complete one acute bout of supervised aerobic high-intensity exercise||||
33727736|NCT05403242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727737|NCT01794052|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33727738|NCT00647127|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33727739|NCT02705677|||COHORT||PROSPECTIVE|||||||
33727740|NCT03547388|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I feasibility study||||
33727741|NCT02860520|||COHORT||PROSPECTIVE|||||||
33727742|NCT03411876|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33727743|NCT00208936|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727744|NCT03634787|||CASE_CONTROL||PROSPECTIVE|||||||
33727745|NCT04512248|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-group, parallel-randomized controlled trial||||
33727746|NCT03612206|||COHORT||PROSPECTIVE|||||||
33727747|NCT06065826|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727748|NCT04470999|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33727749|NCT05269693|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-blinded, pilot randomized controlled trial with two-armed repeated measures||||
33727750|NCT05316012|NA|SINGLE_GROUP||OTHER||NONE||||||
33727751|NCT06298175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pre-post test, randomized controlled study||||
33727752|NCT01087047|||COHORT||PROSPECTIVE|||||||
33727753|NCT04605328|||COHORT||PROSPECTIVE|||||||
33727754|NCT00322192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33727755|NCT01998048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727756|NCT01100099|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727757|NCT04118309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114435|NCT06545006|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Main Investigator will be be blinded from the group intervention. The Main Investigator will record the outcomes.|Single-center, controlled, randomized, stratified on time to activation of cervical spine extensor muscles, open-label study with blinded evaluation.|f|f|t|f
33727758|NCT04454372|||COHORT||RETROSPECTIVE|||||||
33727759|NCT01779193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727760|NCT06404827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727761|NCT00111969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33727762|NCT03719313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809587|NCT03014037|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33809588|NCT03926806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment|t|t|f|f
33809589|NCT04208035|||COHORT||OTHER|||||||
33809590|NCT01324076|RANDOMIZED|||TREATMENT||DOUBLE||||||
33809591|NCT00454194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114436|NCT01722669|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727763|NCT00762398|||CASE_ONLY||PROSPECTIVE|||||||
33727764|NCT03318991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727765|NCT01727141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727766|NCT03773731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33727767|NCT05110911|||COHORT||PROSPECTIVE|||||||
33727768|NCT00366990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727769|NCT02261376|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33809592|NCT02427191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809593|NCT03138499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809594|NCT01708278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809595|NCT02740426|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33809596|NCT00211549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33809597|NCT05032716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809598|NCT03631966|NA|SINGLE_GROUP||TREATMENT||NONE||All patient's recruited to this study will have failed prior conservative treatment, and therefore any improvements seen in symptoms from the BTX-A injection will be considered above and beyond what was provided by conservative care. As such, each patient in this study design acts as their own case control (i.e. there is no appropriate intervention and/or placebo control group for these patients).||||
33809599|NCT00070486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809600|NCT00840775|NA|SINGLE_GROUP||OTHER||NONE||||||
33809601|NCT04026256|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33809602|NCT01044446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809603|NCT00213278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809604|NCT00093353||||TREATMENT||||||||
33809605|NCT00309439|RANDOMIZED|PARALLEL||||SINGLE||||||
33809606|NCT01522014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809607|NCT03314636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809608|NCT01942954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809609|NCT05830279|||COHORT||PROSPECTIVE|||||||
33809610|NCT04723979|||COHORT||RETROSPECTIVE|||||||
33809611|NCT00679406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809612|NCT01211509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809613|NCT05563571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809614|NCT03313726|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809615|NCT01719172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809616|NCT04597931|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label||||
34041298|NCT06119620|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The participant won't be told if they receive sham or active stimulation.|This is a single case experimental design. All participants will receive both sham and active stimulation. The order of stimulation (sham, active, sham active OR active, sham, active, sham) will be randomised. Also the length of the N-back task is randomised between 8, 10, and 12 minutes).||||
34041299|NCT00564642|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34041300|NCT01961219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34041301|NCT06300203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041302|NCT04370873|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part 1 enrolled immediately. Part 2 enrolled following review of Part 1 pharmacokinetic data. A third part was planned but did not enroll because Part 2 yielded sufficient data and Part 3 was optional per protocol.|t|f|t|f
34041303|NCT04129489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041304|NCT04043494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041305|NCT02037178|||COHORT||CROSS_SECTIONAL|||||||
34041306|NCT06578052|NA|SINGLE_GROUP||TREATMENT||NONE||"Irinotecan liposome: intravenous infusion, day 1, every 2 weeks (Q2W). Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs"||||
34041307|NCT05944744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041308|NCT06205914|NA|SINGLE_GROUP||OTHER||NONE||||||
34041309|NCT05958199|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation and dose expansion||||
34041310|NCT01454323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041311|NCT01075165|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34041312|NCT06390150|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants will be randomly assigned into treatment groups known only to the care provider. The baseline and follow-up assessments will be conducted by blinded assessors minimizing bias. Patients will be blinded for stimulation 'On' or 'Off'. Current stimulation programs do not generate any perceptible sensation, which allows for the blinded cross-over design.|This study will be conducted as a placebo-controlled, crossover, randomized clinical trial of the intervention spinal cord stimulation for the indication neuropathic pain following intra-thoracic surgery. Following a 4-week recovery period post-surgery, participants will be randomly assigned to Group A (stimulation on, treatment) or Group B (stimulation off, placebo). After 6 weeks, participants will cross-over into the other treatment arm for another 6 weeks (Group A, stimulation off, placebo; Group B, stimulation on, treatment). All participants will then have stimulation turned on for the remainder of the study.|t|f|f|t
34041313|NCT05107609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be aware that they are randomized into one of two intervention conditions.||t|f|f|f
34041314|NCT05487001|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34041315|NCT01174381|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041316|NCT04736498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34041317|NCT02213172|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34041318|NCT01996241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34041319|NCT06071910|NA|SEQUENTIAL||TREATMENT||NONE||Sequential patients with OHCA in air ambulance operational area||||
34041320|NCT05628935|||COHORT||RETROSPECTIVE|||||||
34041321|NCT05745818|||COHORT||PROSPECTIVE|||||||
34041322|NCT06576297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator, Outcomes assessor|Parallel assignment|f|f|t|t
34041323|NCT01100086|RANDOMIZED|CROSSOVER||||NONE||||||
34041324|NCT01479465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041325|NCT05918120|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34041326|NCT02865967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34041327|NCT05345392|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The final study visit will include a Kiddie Schedule for Affective Disorders and Schizophrenia: Present and Lifetime (KSADS-PL) administered by an assessor who will be blind to group assignment. Consensus will also occur with a psychiatrist/psychologist who is blind to group assignment.||f|f|t|t
34041328|NCT01871623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041329|NCT04071912|||CASE_ONLY||RETROSPECTIVE|||||||
34041330|NCT06455553|NA|SINGLE_GROUP||SCREENING||NONE||||||
34041331|NCT03150719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041332|NCT03540316|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34041333|NCT06024174|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041334|NCT06222138|NA|SINGLE_GROUP||OTHER||NONE||||||
34041335|NCT04803344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34041336|NCT03682848|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|All participants will receive the FDC of DTG/3TC (50/300 milligrams) for once daily dosing in this single arm study.||||
34041337|NCT00640120|||CASE_CONTROL||PROSPECTIVE|||||||
34041338|NCT04134533|||COHORT||PROSPECTIVE|||||||
34041339|NCT03242850|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041340|NCT00774501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041341|NCT01149980|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041342|NCT02593097|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34041343|NCT05300581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041344|NCT04545671|||CASE_ONLY||OTHER|||||||
33809617|NCT04129372|NA|SINGLE_GROUP||PREVENTION||NONE||"Classrooms will receive New Foods Take Time, a series of 5 interactive lessons. Children, parents, and teachers will participate in the research"||||
33809618|NCT05953909|||CASE_CONTROL||RETROSPECTIVE|||||||
33809619|NCT01992965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809620|NCT00912171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809621|NCT06463301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809622|NCT02515123|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33809623|NCT02662816|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809624|NCT01205633|||||PROSPECTIVE|||||||
34114437|NCT06387342|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study||||
34114438|NCT03525847|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34114439|NCT02482311|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114440|NCT03271515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114441|NCT06167239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33809625|NCT02053298|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33809626|NCT00884026|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809627|NCT01529944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809628|NCT01314066|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33809629|NCT00541996|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33809630|NCT00130091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809631|NCT01857076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809632|NCT00222092|||COHORT||PROSPECTIVE|||||||
33809633|NCT04812249|||COHORT||PROSPECTIVE|||||||
33809634|NCT00001930||||TREATMENT||||||||
33809635|NCT05773235|||COHORT||PROSPECTIVE|||||||
33809636|NCT04347941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33809637|NCT01755559|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33809638|NCT04275583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809639|NCT00857766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809640|NCT03735381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants know they will be selected for either a pedometer group or a not pedometer group. They wil not know if the intervention is minimum (pedometer only) or maximum (pedometer and a goal of 11000 steps/day)||t|f|f|f
33809641|NCT03536845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809642|NCT00598234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809643|NCT00000418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33809644|NCT01846715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809645|NCT02246699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809646|NCT03883828|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809647|NCT05748184|||CASE_CROSSOVER||PROSPECTIVE|||||||
33809648|NCT01558908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809649|NCT01313884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809650|NCT06246903|||CASE_ONLY||RETROSPECTIVE|||||||
34041345|NCT01059214|||||PROSPECTIVE|||||||
34041346|NCT00917852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041347|NCT05131841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041348|NCT03906617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041349|NCT03098277|NA|SINGLE_GROUP||OTHER||NONE||||||
34041350|NCT06182111|||COHORT||RETROSPECTIVE|||||||
34041351|NCT06261489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041352|NCT02084810|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34041353|NCT06099522|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be assigned to either standard iCBT and Spelpaus (treatment condition), or Spelpaus only (control condition)."||||
34041354|NCT00319579|||COHORT||PROSPECTIVE|||||||
34041355|NCT01464424|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34041356|NCT00031629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041357|NCT05137782|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34041358|NCT01286610|NA|SINGLE_GROUP||OTHER||NONE||||||
34041359|NCT02518048|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34041360|NCT00611923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041361|NCT04791722|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34041362|NCT05352464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041363|NCT04110626|||OTHER||PROSPECTIVE|||||||
34041364|NCT03550755|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|Single group assignment to receive one pill of vaccine once per day for 3 months||||
34041365|NCT03999151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041366|NCT03260660|||COHORT||PROSPECTIVE|||||||
34041367|NCT00746889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34041368|NCT05567653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a Randomized, Double-blind, Placebo-controlled Study|t|f|t|t
34041369|NCT06282328|||OTHER||CROSS_SECTIONAL|||||||
34041370|NCT05484999|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized controlled trial|t|f|f|t
34041371|NCT01504464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041372|NCT00757042|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"Escalating dose cohorts will be enrolled sequentially based on a blinded review of safety data up to day 15 of the previous dose cohort with consideration of predefined stopping rules.~The first 2 participants in Cohort 1 will be a sentinel pair, randomized at a 1:1 ratio to receive either tezepelumab or placebo and monitored for safety and tolerability. Once the safety in the sentinel pair is confirmed the subsequent six participants will be randomized at a 5:1 ratio for tezepelumab or placebo treatment. In cohorts 2 through 8 (escalating doses, healthy subjects), participants will be randomized to receive tezepelumab or placebo at a 6:2 ratio. In cohort 9 (700 mg IV, atopic dermatitis subjects),a sentinel pair will again be used to first establish safety, and the subsequent 10 participants will be randomized to receive tezepelumab or placebo at a ratio of 8:2, for a total of 12 evaluable participants in this cohort."|t|f|t|f
34041373|NCT04457232|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34041374|NCT04084418|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041375|NCT03773029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041376|NCT06182202|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114442|NCT02974192|||CASE_CONTROL||PROSPECTIVE|||||||
33809651|NCT03831698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809652|NCT05072002|||CASE_ONLY||PROSPECTIVE|||||||
33809653|NCT03806309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809654|NCT04914585|||OTHER||PROSPECTIVE|||||||
33809655|NCT00055991|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33809656|NCT03386500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809657|NCT00000388|RANDOMIZED|||TREATMENT||||||||
33809658|NCT01510197|||CASE_ONLY||PROSPECTIVE|||||||
33809659|NCT02120807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809660|NCT00229034|||COHORT||PROSPECTIVE|||||||
33809661|NCT01463475|NA|SINGLE_GROUP||||NONE||||||
33809662|NCT00868894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809663|NCT02305498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809664|NCT03836651|RANDOMIZED|PARALLEL||TREATMENT||NONE||The design is that of a two-group randomized controlled intervention study. Subjects (N=100) will be randomized to 1 of 2 groups (intervention group or usual care/control group). Subjects will be recruited from outpatient cardiology clinics. The intervention group will be given one 11.5 ounce can of V8® 100% vegetable juice to drink each day for 30 days in addition to their normal diet. The usual care group will continue to consume their normal diet. Data collection for both groups will occur at baseline, and at one-month post-baseline. Data will include sociodemographic and clinical information, 24-hr dietary recalls, carotenoid levels and biomarkers of inflammation and oxidative stress.||||
33809665|NCT04213807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809666|NCT05119699|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm, open-label, feasibility trial for the assessment of the clinical effects of a course of accelerated bilateral sequential TBS for LLD||||
33809667|NCT01349270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809668|NCT01332266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809669|NCT06064591|||COHORT||PROSPECTIVE|||||||
33809670|NCT05864196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809671|NCT01049516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041377|NCT05820633|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized phase 3 study||||
34041378|NCT00251238|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34041379|NCT01640119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041380|NCT01295827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041381|NCT04153760|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041382|NCT01447550|||COHORT||PROSPECTIVE|||||||
34041383|NCT00780130|||CASE_ONLY|||||||||
34041384|NCT03260829|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041385|NCT05189652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041386|NCT04923360|||COHORT||PROSPECTIVE|||||||
34041387|NCT05890274|NA|SINGLE_GROUP||OTHER||NONE||||||
34041388|NCT06405113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041389|NCT06478966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041390|NCT00959114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041391|NCT03876535|||OTHER||CROSS_SECTIONAL|||||||
34041392|NCT02877004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041393|NCT02737254|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34041394|NCT04141241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34041395|NCT04689620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041396|NCT01762644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041397|NCT04853082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded|Exploratory Clinical Trial；Randomized Controlled Trial|t|f|t|t
34041398|NCT02671799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041399|NCT02019264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041400|NCT01632293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041401|NCT01659827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041402|NCT05500885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041403|NCT01029548|||COHORT||PROSPECTIVE|||||||
34041404|NCT02293512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041405|NCT01691560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041406|NCT02884050|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34041407|NCT06366451|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an exploratory clinical trial to evaluate intratumoral mechanistic effects of novel and approved agents on intact human tumors. This is a cohort substudy of a Master Protocol (PBI-MST-01, NCT04541108) framework, under which comparisons will not be made between substudy cohorts.||||
34041408|NCT04476693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Two experimental trials will be completed in a randomised counterbalanced order: BC and BO. A standardised lunch will be provided three hours after breakfast consumption (BC) or after water consumption during breakfast omission (BO). Finger prick blood samples for the analysis of plasma glucose, insulin and triaclglycerol and expired gas samples for the analysis of substrate oxidation will be taken throughout the trials. An incremental cycling exercise test with 4 minute stages will be performed 2 h after lunch for the determination of maximum fat oxidation (MFO) and intensity at which MFO occurred (i.e., Fatmax). The OMNI scale will be used to evaluate the perceived exertion at the end of each cycling stage. PA enjoyment will be evaluated using Physical Activity Enjoyment Scale (PACES).||||
34041409|NCT02494258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041410|NCT01305382|||COHORT||CROSS_SECTIONAL|||||||
34041411|NCT04903158|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34041412|NCT05046080|||CASE_ONLY||RETROSPECTIVE|||||||
34041413|NCT02581280|||COHORT||PROSPECTIVE|||||||
34041414|NCT03062930|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041415|NCT03919552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34041416|NCT04389164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041417|NCT00791778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041418|NCT03657420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041419|NCT05306691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041420|NCT01710579|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041421|NCT03107039|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2 group||||
33809672|NCT04242797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator uses Bluetooth to control the output of a switching box for each patient from outside the treatment room. The box controls whether the inputs from the Calamare device or two traditional dual-channel TENS devices are connected to the output. The stimulus amplitude knobs for the TENS units are ganged to those of the Calmare using O-rings. When the therapist increases the stimulus amplitude on Calmare, that of the corresponding TENS unit is increased to about the same extent simultaneously.|Equal numbers of participants are randomly assigned to either the Calmare or traditional TENS group. Using skin electrodes positioned by the therapist proximal to the limb pain, each participant is given the assigned stimulation mode for 30-minute therapy sessions. One therapy is used in the pilot study and ten therapies on consecutive weekdays in the extended study.|t|t|f|f
33809673|NCT06356285|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study arm that they have been assigned to.|This study has been designed as a four-armed online randomised control trial (RCT). This will be conducted using Predictiv, an online platform for running behavioural experiments built by the Behavioural Insights Team The 4,000 participants will be randomised in a 1:1:1:1 ratio to one of four trial arms.|t|f|f|f
33809674|NCT01328496|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809675|NCT01801007|NA|SINGLE_GROUP||TREATMENT||NONE||FRED||||
33809676|NCT03196869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809677|NCT00690404|RANDOMIZED|CROSSOVER||||NONE||||||
33809678|NCT02089529|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33809679|NCT00777049|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809680|NCT01517503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041422|NCT01588769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041423|NCT06576999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised clinical trial|t|f|f|t
34114443|NCT06092437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114444|NCT00538850||CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34114445|NCT04218981|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34114446|NCT03896191|||COHORT||PROSPECTIVE|||||||
34114447|NCT04331639|||CASE_ONLY||PROSPECTIVE|||||||
34114448|NCT05766605|RANDOMIZED|PARALLEL||TREATMENT||NONE||The test group received postoperative conventional treatment combined with precise transarterial chemoembolization based on PDOX results, and the control group received postoperative conventional treatment combined with empirical transarterial chemoembolization with Doxorubicin.||||
34114449|NCT05693376|||COHORT||PROSPECTIVE|||||||
34114450|NCT04293614|||COHORT||PROSPECTIVE|||||||
34114451|NCT03485157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041424|NCT02421705|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114452|NCT01006148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114453|NCT04162834|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34114454|NCT05478278|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34114455|NCT00622726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114456|NCT03503409|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects enrolled will receive continuous 28-day cycles of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle||||
34114457|NCT00862940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114458|NCT02489084|||COHORT||PROSPECTIVE|||||||
34114459|NCT03527784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Subject is blinded of the mesh used. Outcome at 12 month follow-up is assessed by surgeon who was not involved in the operation.|Prestoma is a prospective randomized controlled multicenter trial.|t|f|f|f
34114460|NCT06634784|||OTHER||OTHER|||||||
34114461|NCT01203345|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041425|NCT04369144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blinded Randomized Controlled study|t|t|t|t
34041426|NCT05214690|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041427|NCT05429801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041428|NCT01772914|||CASE_ONLY||PROSPECTIVE|||||||
34041429|NCT01225198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041430|NCT00505219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041431|NCT06050629|||COHORT||RETROSPECTIVE|||||||
34041432|NCT00461630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041433|NCT06379997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both study groups will undergo assessment using pain and functional scales by a clinician who is blinded to the treatment group|The enrolled patients will be randomized in two groups: treated with oral supplements (Group 1 - G1) or with intra-articular hyaluronic acid (Group 2 - G2)|f|f|t|f
34041434|NCT00504712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114462|NCT04595435|||COHORT||PROSPECTIVE|||||||
34114463|NCT04542928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114464|NCT00934921|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34114465|NCT00497835|||||PROSPECTIVE|||||||
34114466|NCT00614224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114467|NCT03787654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants in electroacupuncture and sham electroacupuncture groups are blinded, and solifenacin group is open.||f|f|t|t
34114468|NCT01088685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34114469|NCT04962854|||COHORT||PROSPECTIVE|||||||
34114470|NCT00157872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114471|NCT01655277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114472|NCT06537388|||COHORT||RETROSPECTIVE|||||||
34114473|NCT00470522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114474|NCT05815888|||COHORT||PROSPECTIVE|||||||
34150165|NCT03731260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In Part 1 of the study, patients will be randomly assigned to 1 of 3 doses of avapritinib or to placebo + BSC. Once the recommended phase 2 dose (RP2D) of avapritinib is identified in Part 1, patients in Part 2 will be randomly assigned to receive avapritinib at the RP2D + BSC or matching placebo + BSC. In Part 3, patients who have completed treatment in Part 1 or Part 2 of the study (including those initially randomized to placebo) may participate in a long-term open-label extension, receiving avapritinib at the RP2D + BSC.|t|t|t|t
34150166|NCT03712111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150167|NCT02442258|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33809681|NCT01827982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809682|NCT01728324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33809683|NCT02173288|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809684|NCT00655109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809685|NCT04007705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809686|NCT03319836|||OTHER||RETROSPECTIVE|||||||
33809687|NCT03540524|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809688|NCT04262115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809689|NCT02028091|||CASE_CONTROL||PROSPECTIVE|||||||
33809690|NCT05292066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809691|NCT04660799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809692|NCT00686257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809693|NCT00944541|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809694|NCT01934452|||CASE_CONTROL||PROSPECTIVE|||||||
33809695|NCT01374152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809696|NCT01935375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809697|NCT01513707|||COHORT||PROSPECTIVE|||||||
33809698|NCT04783766|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809699|NCT01962597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809700|NCT01990625|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33809701|NCT02736422|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809702|NCT05794594|||COHORT||RETROSPECTIVE|||||||
33809703|NCT04648670|RANDOMIZED|PARALLEL||TREATMENT||NONE||An intervention group and a control group with the same characteristics are included.||||
33809704|NCT02123940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809705|NCT00661206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809706|NCT00850915|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041435|NCT04504448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041436|NCT02734966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041437|NCT05002790|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group assignment Controlled trial without randomisation||||
34041438|NCT06525831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The participants will undergo a Magnetic Resonance-elastography and Ultrasound exams for the research.||||
34114475|NCT03386773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Recruited participants will be randomized to one of two arms, intervention or control. Both intervention and control groups will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis. If intervention patients do not have a fitness tracker, a low-cost option will be provided for them. Both iOS and Android phone options will be supported. The app will be selected from a limited set of well-established options such as LoseIt!, MyFitnessPal, Apple Health, or Google Fit.||||
34114476|NCT03509402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114477|NCT02092129|||COHORT||RETROSPECTIVE|||||||
34114478|NCT00460213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114479|NCT04193735|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114480|NCT02285478|||COHORT||PROSPECTIVE|||||||
34114481|NCT03249818|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34114482|NCT05775250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114483|NCT05892341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114484|NCT03197519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114485|NCT05294887|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Subjects will be randomly assigned to 1 of 6 possible treatment sequences. All treatment sequences will include the consecutive treatment with bisoprolol, diltiazem, and placebo.||t|t|t|t
33809707|NCT03393390|||CASE_CONTROL||PROSPECTIVE|||||||
33809708|NCT00897858|||COHORT||PROSPECTIVE|||||||
33809709|NCT05518214|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind study where both the Participant and Investigator are blind to the supplement given.||t|f|t|f
33809710|NCT01259570|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33809711|NCT03241810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 Study.|Patients will be randomized in a 1:1 ratio (experimental arm versus active comparator arm) using an Interactive Web Response System (IWRS). Randomization will be stratified based on bone-only disease (yes, no) and geographic region (US, non-US).|t|t|t|f
33809712|NCT03115099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809713|NCT06207981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809714|NCT01334840|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33809715|NCT06269029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809716|NCT01915888|||COHORT||RETROSPECTIVE|||||||
33809717|NCT02266927|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809718|NCT01085513|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33809719|NCT03340259|||CASE_ONLY||PROSPECTIVE|||||||
33809720|NCT06466681|||COHORT||PROSPECTIVE|||||||
34041439|NCT03199560|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|A double-blind study. Study compound will be masked before dispensing to care team.|double-blinded randomized control trial|t|t|t|f
34041440|NCT05856331|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, randomized, active-control, parallel group interventional study|t|t|t|t
34041441|NCT05998187|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
34041442|NCT06577129|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34041443|NCT01567774|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34041444|NCT06219356|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34150168|NCT06301750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150169|NCT00430937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809721|NCT00825344|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041445|NCT02685176|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114486|NCT04616898|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||For this study, there will be three treatment groups in total. Details of each treatment are depicted in the addendum below. Groups 1 (laser only- 6 visits) and 2 (laser plus radiofrequency- 4 visits) will each consist of one patient. Group 3 (multiple vs. single laser treatments - 5 visits) will consist of three patients.||||
34114487|NCT04425239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809722|NCT05213182|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A quasi-experimental design was used, and the research tested differential changes over base-, mid-, and end-line in mental health and social support outcomes among adolescent mothers (14-18 years) in the intervention and control arms.||||
33809723|NCT06510088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33809724|NCT02054429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041446|NCT00806897|||CASE_ONLY||PROSPECTIVE|||||||
34041447|NCT03227289|||COHORT||PROSPECTIVE|||||||
34041448|NCT02810366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34041449|NCT04022538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041450|NCT05013320|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041451|NCT04767945|||COHORT||PROSPECTIVE|||||||
34041452|NCT05881343|||COHORT||RETROSPECTIVE|||||||
34041453|NCT01467713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041454|NCT04215627|||COHORT||RETROSPECTIVE|||||||
34041455|NCT05713890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors (neurologists, physiotherapists and neuropsychologists) will be blinded to treatment allocation.|This is a randomized, controlled, single-blinded, parallel study. A total sample size of 60 PwMS is planned, with 30 participants randomly assigned to each of the treatment arms (ratio 1:1) through a computer-generated list managed by a physician external to the study.|f|f|f|t
34041456|NCT01965366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041457|NCT00703586|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041458|NCT04653181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041459|NCT06183307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34041460|NCT05340088|||CASE_ONLY||RETROSPECTIVE|||||||
34041461|NCT01314339|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041462|NCT00248274|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041463|NCT03043326|||COHORT||PROSPECTIVE|||||||
34041464|NCT03786848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041465|NCT01627574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041466|NCT02646540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041467|NCT04900818|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041468|NCT06440239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041469|NCT05440045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041470|NCT02163096|||CASE_CONTROL||PROSPECTIVE|||||||
34041471|NCT01353365|||COHORT||PROSPECTIVE|||||||
34041472|NCT03353168|||COHORT||PROSPECTIVE|||||||
34041473|NCT06012396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||rct|t|f|f|f
34041474|NCT02151305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34041475|NCT06156033|||COHORT||PROSPECTIVE|||||||
34041476|NCT03955705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34041477|NCT06438614|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive 2 cycles of HITS. Each cycle of HITS (4 doses of hu3F8, 5 doses of irinotecan and temozolomide and 5 doses of GM-CSF). Patients with CR after 2 or 4 cycles of HITS will receive 5 cycles of Naxitamab + GM-CSF cycles. Patients that do not have an objective response (CR/PR) will receive NICE within 3 weeks from last dose. Each cycle of NICE consists of 4 doses of hu3F8, 5 doses of GM-CSF, 1 dose of carboplatin, and 3 doses each of ifosfamide and etoposide. Patients with less than CR response (PR/SD) will receive 2 more cycles of NICE and evaluated after 4th cycle. Patients with no objective response at these timepoints will be removed from the study. Patients with CR will receive 5 cycles of Naxitamab consolidation cycles consisting of GM-CSF250mcg/m2/day SC administered from day -4 to day 0 and GM-CSF500mcg/m2/day SC administered from day 1 to day 5. Three doses of hu3F83 mg/kg IVwill be administrated, specifically on days 1, 3 and 5.||||
34041478|NCT00961350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041479|NCT05511324|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041480|NCT03727919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded assessor will be allocated to a certain participant when she/he was succesfully enrolled. This means that the same assessor will perform the clinical assessments (i.e., FAC, 10-m Walk Test, FM, MI) at the different measurement occasions for this participant to avoid inter-assessor variability effects on longitudinal recovery trajectories.|"Participants will be randomly assigned to either the early group or delayed group. Both groups will be provided a dose- and content-controlled intervention in addition to usual care. The early group will receive this intervention at approximately 2 weeks post-stroke and the delayed group at 8 weeks post-stroke. As such, this study is explicitly designed to investigate the effects of time to initiate rehabilitation on recovery outcomes."|f|f|f|t
34041481|NCT04989946|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a randomized, open-label, single-institution phase 1/2 trial designed to evaluate the immunological and clinical effect of pTVG-AR, a DNA vaccine encoding AR, given with or without T-cell checkpoint blockade in combination with standard androgen deprivation for patients with newly diagnosed high-risk prostate cancer.||||
34041482|NCT01747473|||||PROSPECTIVE|||||||
34041483|NCT05390333|NA|SINGLE_GROUP||OTHER||NONE||||||
34041484|NCT00090714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34041485|NCT02996825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041486|NCT04242472|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants and providers will not be blind to the study intervention. Nutrition and tuberculosis treatment outcomes will be assessed by two independent reviewers without knowledge of each participant's treatment allocation.|A Cluster Randomized Trial (CRT) with parallel design will be employed.|f|f|f|t
34041487|NCT05860192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041488|NCT02523183|||COHORT||PROSPECTIVE|||||||
34041489|NCT06574776|||COHORT||PROSPECTIVE|||||||
34041490|NCT06022315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041491|NCT01314872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041492|NCT00630825|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041493|NCT00661128|||CASE_CONTROL||OTHER|||||||
33809725|NCT04235205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114488|NCT05466383|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114489|NCT00498628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114490|NCT01180127|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34114491|NCT00220090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114492|NCT05062421|||CASE_ONLY||PROSPECTIVE|||||||
34114493|NCT02340195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114494|NCT06341335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114495|NCT03470025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114496|NCT00054262||||TREATMENT||NONE||||||
34114497|NCT04165837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114498|NCT01331655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114499|NCT00239915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114500|NCT03822611|RANDOMIZED|PARALLEL||OTHER||NONE||cluster Randomized controlled trial (c-RCT)||||
34114501|NCT06179264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized wait list control trial. Parallel assignment of participants to treatment and wait list groups. Wait list participants receive treatment after 10 weeks of waiting. Treatment participants receive treatment immediately.||||
34114502|NCT01055951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114503|NCT03364504|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114504|NCT00304161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114505|NCT05096130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parameters such as questionnaires' scores, polysomnography outcomes, indices of health, and other data will be masked and coded for blind analysis by the main investigator.|This is a randomized controlled trial. The study is composed of two groups. Group 1 is the control group and Group 2 is the experimental one. The trial period will last for 6 months for both groups. Intervention includes lifestyle changes targeting physical activity, diet, stress and sleep quality. The design is parallel.|f|f|f|t
34114506|NCT01058746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114507|NCT05538728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114508|NCT06247137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114509|NCT02179034|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
34114510|NCT05391555|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|The investigator determining the PUAL will be blinded to the opioid level concurrent with the measurement.|||||
34114511|NCT03224845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34114512|NCT00619775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114513|NCT04883944|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||a prospective, randomized controlled trial with a 2x2 crossover design||||
34114514|NCT01280331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114515|NCT00410683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114516|NCT06080555|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114517|NCT04281667|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34114518|NCT02444754|||OTHER||CROSS_SECTIONAL|||||||
34114519|NCT06424639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114520|NCT06505460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34114521|NCT01238887|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34114522|NCT00223145|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114523|NCT02676037|||OTHER||CROSS_SECTIONAL|||||||
34114524|NCT02448381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114525|NCT04417985|NA|SINGLE_GROUP||OTHER||NONE||||||
34114526|NCT05342168|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Each sample type is read by a pathologist blinded to the traditional ly obtained biopsy|cross sectional study comparing to tissue sampling methods||||
34114527|NCT04881084|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two-armed, parallel-design, individually randomized trial.|f|f|t|t
34114528|NCT02714348|||COHORT||PROSPECTIVE|||||||
34114529|NCT02957838|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34114530|NCT06564792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114531|NCT02551185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114532|NCT03254810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114533|NCT06134882|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"Investigators who have no direct contact with study participants will communicate directly with information technology (IT) staff to assign participants to one of the two study groups. Participants will be blind to hypothesis, and outcome assessors will be completely blind. Care providers (i.e., Contingency Management \[CM\] Guides) cannot be blind because modified scripts are required for their interactions with participants depending on group assignment."||t|f|f|t
34114534|NCT06163339|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114535|NCT04537650|||COHORT||PROSPECTIVE|||||||
34114536|NCT05428644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||A double-blind randomised controlled clinical trial.|t|f|t|t
34114537|NCT02490189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114538|NCT04123704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114539|NCT04336826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114540|NCT05374616|||CASE_ONLY||OTHER|||||||
34114541|NCT03140111|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34114542|NCT04726501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114543|NCT06249464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34114544|NCT02150746|||CASE_ONLY||PROSPECTIVE|||||||
34114545|NCT03984240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114546|NCT04633330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114547|NCT02665091|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34114548|NCT05162248|||OTHER||RETROSPECTIVE|||||||
34114549|NCT00020748||||TREATMENT||||||||
34114550|NCT04629430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114551|NCT00666263|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34114552|NCT00954447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114553|NCT01259011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34114554|NCT05858814|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150170|NCT06020443|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Low Dose chest CT Scan for Lung Cancer Screening||||
33809726|NCT05707494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A multicenter prospective observational study with a control group to evaluate the efficacy and safety of LPS Adsorption using the Efferon LPS NEO device in children with SepSis (LASSO NEO).||||
33727770|NCT05662579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluations of the participants and the analysis of the data will be carried out by a researcher blind to the allocation of the subjects in each group.|This is a randomized blind clinical trial, with a longitudinal characteristic in the area of physiotherapy, orthopedics, postural control and biomechanics. The intervention will consist of 4 weeks, 2 times a week, and the variables of interest will be measured in the pre-treatment period, after 4 weeks (immediately after the end of the protocol) and in the follow up of 12 weeks after the end of the protocol.|f|f|t|t
33727771|NCT06300333|||OTHER||PROSPECTIVE|||||||
33727772|NCT01878539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727773|NCT01306370|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727774|NCT00747435|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727775|NCT05866861|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33727776|NCT00663052|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33727777|NCT03848923|||CASE_ONLY||PROSPECTIVE|||||||
33727778|NCT06357611|RANDOMIZED|PARALLEL||OTHER||SINGLE||In order to allocate each participant to an intervention group, each voluntary participation questionnaire was assigned a number. Subsequently, all the numbers of the participants in the sample were randomly distributed among the 3 groups by the principal investigator.|t|f|f|f
33809727|NCT02611869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809728|NCT04534738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809729|NCT04329585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|It's double-blind study. We make every participant an envelope in which a randomized result of GABA antagonist or normal saline is declared to the care provider during the colonoscopy. The participant and the investigator are not aware of the medication.||t|f|t|f
33809730|NCT03278977|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blood sample analysis will be blinded||f|f|f|t
33809731|NCT05643521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment Randomized diet intervention study in a cross over design||||
33809732|NCT02177825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809733|NCT01409772|||OTHER||PROSPECTIVE|||||||
33809734|NCT01585623|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809735|NCT00416975|NA|SINGLE_GROUP||SCREENING||NONE||||||
33809736|NCT00346320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809737|NCT03584074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809738|NCT02867982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809739|NCT04074252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809740|NCT03848975|RANDOMIZED|PARALLEL||OTHER||NONE|The person who generate the randomization list and prepare the envelopes will not be involved later in the study. The subject of this study necessarily involves the fact that the participants know the group to which they are assigned. They will be asked to avoid to reveal their allocation to the other care providers (midwives and other colleagues) involved in the care of the patients delivering under their supervision. The investigator responsible for collecting and coding the data will not know to which group belongs the person being evaluated. In some cases, the midwife in charge of the patient will collect the data. She will not know to which group belongs to the person being evaluated. The patient will not know to which group belongs the doctor practicing the obstetric maneuver. However the study taking place within a hospital, it can not be excluded that a care provider or an outcome assessor learns informally the allocation of one or more participants, despite these precautions.|"For the intervention (trained) group, training sessions will be conducted over six months. The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). The groups will cross-over for the next 6 months.~After six months the success rate and secondary outcomes will be analyzed. The comparison will be, first, between the intervention (trained) group and the control group and, second, for each subject, between its success rate reported before and its success rate after the observation period.~Some aspects of our study design can be those of a cross over trial, or a stepped wedge design : the participants will have intervention ECV followed, after 6 months, by intervention VE, or intervention VE followed, after 6 months, by intervention ECV. However as some aspects are not those of the above designs, the investigators believe that the best category is a parallel trial."||||
33809741|NCT05983861|||COHORT||PROSPECTIVE|||||||
33809742|NCT03960359|||COHORT||PROSPECTIVE|||||||
33809743|NCT00624637|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33838228|NCT06380452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|The SKABUP study is a prospective, randomized, double-blind, 2-arm superiority study in a group sequential design with recruitment stop and interim analysis after 172 patients. If there is no evidence of superiority in the interim analysis, the study will be continued unchanged up to the planned number of 220 patients and will be terminated and analyzed regularly.|t|t|t|t
33838229|NCT06320132|||COHORT||CROSS_SECTIONAL|||||||
34041494|NCT03777267|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This will be a single site, open label, pilot clinical trial, enrolling people aged 11 or older, who have self-reported symptoms of stress, anxiety, or insomnia, and meet a threshold score on self-reported inventories. Up to 100 participants will be enrolled so as to gather pilot data that will help inform regarding effect size, and dosing to support future cohort-specific randomized trials. Participants will receive between 6 and 12 intervention sessions of Cereset Research consisting of audible tones echoing current brainwave activity.||||
34041495|NCT03699111|||COHORT||PROSPECTIVE|||||||
34041496|NCT02368223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041497|NCT00726856|||COHORT||RETROSPECTIVE|||||||
34041498|NCT04090060|RANDOMIZED|PARALLEL||SCREENING||NONE||Subjects will be randomly assigned to groups encouraged to practice anal examination (Experimental) or not encouraged to practice anal examinations (Control).||||
34041499|NCT05930054|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eighteen patients were divided into 2 groups: TBB group (n = 9, 16.11 ± 0.59 years of age) and BB group (n = 9, 15.33 ± 1.22 years of age). CBCT scans were obtained before treatment and after 3 months of expansion. Transverse skeletal and dental expansion, alveolar and tooth inclination, and buccal alveolar bone thickness were evaluated in maxillary first premolars and molars. Paired t tests and independent-sample t tests were used to compare the expansion appliances.||||
34041500|NCT00866281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041501|NCT01396135|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33727779|NCT03659305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809744|NCT05160779|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking of groups|"The allocation of participants in the two research groups will happen in a stratified random way, so that individuals who were diagnosed and presented the mild or asymptomatic form of the disease (with treatment and monitoring carried out by primary care) will be gathered in the study group called  mild/asymptomatic cases, and individuals who were diagnosed and presented with severe forms of the disease, and who required hospitalization in the Intensive Care Unit (ICU) (with or without invasive mechanical ventilation) will be grouped in the group called severe cases ."||||
33809745|NCT00220649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809746|NCT05955443|||COHORT||PROSPECTIVE|||||||
33809747|NCT01204996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809748|NCT03131713|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33809749|NCT02434783|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809750|NCT05075200|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The main objective of this prospective observational study is to assess TXA blood concentrations in patients requiring major arthroplasty surgery with varied preoperative renal function. We will use this information to create new dosing guidelines for patients undergoing major arthroplasty surgery.||||
33809751|NCT04759794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The conventional staining method and new staining method will be performed in cytology specimens obtained from the same patient.||||
33809752|NCT02704052|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809753|NCT00258115|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34114555|NCT03641196|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The analyses will be blinded regarding treatment received and time.|This study will be a stratified, parallel randomized controlled, single-blinded, with an allocation ratio of 1:1:1.|f|f|f|t
34114556|NCT02141009|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114557|NCT01696643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114558|NCT00518180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114559|NCT05714982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114560|NCT03119220|RANDOMIZED|PARALLEL||OTHER||NONE||The overall behavior change goal is defined as increasing physical activity by 15% every other week over 10 weeks based on an initial one week of activity recording establishing an individual's baseline. This will result in a doubling of the initial steps by weeks 10-11, while keeping the demands and goals comparable between individuals. After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only. The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.||||
34114561|NCT02796456|||CASE_CONTROL||PROSPECTIVE|||||||
34114562|NCT02188966|NA|SINGLE_GROUP||||NONE||||||
34114563|NCT00121979|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34114564|NCT06263699|||COHORT||PROSPECTIVE|||||||
34114565|NCT06254625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114566|NCT02540421|||CASE_CONTROL||RETROSPECTIVE|||||||
34114567|NCT06391268|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||"1. Determination of Subjective Units of Discomfort (SUD) (The researcher scores the distress felt on a scale between zero and ten points).~2. Setup (The general structure of the setup sentence is Despite this .........., I deeply and completely accept myself.)~3. Clicking the meridian points in sequence~4. Nine Gamut procedure (some eye movements, mumbling and counting while clicking on the Gamut point in the hand)."|t|f|f|t
33809754|NCT02878616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809755|NCT01005693||||SUPPORTIVE_CARE||||||||
33809756|NCT05851898|NA|SINGLE_GROUP||PREVENTION||NONE||geriatric patients with operative lower extremity fragility fractures that will be started on Serotonin-norepinephrine reuptake inhibitor (SNRI) medication immediately after obtaining consent at index hospitalization or first post operative clinic appointment||||
33809757|NCT00262691|||CASE_CONTROL||PROSPECTIVE|||||||
33809758|NCT04634851|RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot study comparing intervention (virtual dietary counselling) versus standard of care||||
33809759|NCT05309057|||OTHER||PROSPECTIVE|||||||
33809760|NCT00630357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809761|NCT00479375|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||||||
33809762|NCT00613756|||COHORT||PROSPECTIVE|||||||
33809763|NCT01270282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809764|NCT05589337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessors were blinded to the group allocation of the participants.|This study is a 16-week, randomized controlled trial. Patients with depression and anxiety symptoms are randomized to either Baduanjin intervention group or health education control group.|f|f|f|t
33809765|NCT03412903|||COHORT||PROSPECTIVE|||||||
34114568|NCT00690339|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34114569|NCT01811420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809766|NCT03763968|||COHORT||RETROSPECTIVE|||||||
33809767|NCT05185167|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33809768|NCT04580433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809769|NCT02311062|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809770|NCT05772338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809771|NCT03233152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809772|NCT01866800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809773|NCT05267093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809774|NCT03470597|||CASE_ONLY||PROSPECTIVE|||||||
33809775|NCT06455306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809776|NCT02604771|||OTHER||CROSS_SECTIONAL|||||||
33809777|NCT01584674|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809778|NCT02499094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33809779|NCT00019604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809780|NCT01545583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838230|NCT05017051|||CASE_CONTROL||PROSPECTIVE|||||||
34114570|NCT00000438|RANDOMIZED|||TREATMENT||||||||
34114571|NCT02422108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114572|NCT01151267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114573|NCT00833690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114574|NCT05152602|||COHORT||PROSPECTIVE|||||||
34114575|NCT03324841|||COHORT||PROSPECTIVE|||||||
34114576|NCT02648945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114577|NCT05296161|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter randomized controlled non-inferiority trial in The Netherlands||||
34114578|NCT04233021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114579|NCT04015388|||COHORT||PROSPECTIVE|||||||
34114580|NCT01435343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114581|NCT02501421|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34114582|NCT01296308|||COHORT||PROSPECTIVE|||||||
34114583|NCT00205959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114584|NCT01777477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114585|NCT01939145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114586|NCT00563732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114587|NCT04196621|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Which eye as well as the order of artificial eye drops will be randomized. Randomization information will be put in a sealed envelope on screening date and opened in operating theatre right before procedure start.|Biometry will be performed in individuals with age related cataract. Patients will be classified as dry eye or normal eye. Two different artificial tears will be instilled at two time points in a randomized order with a time-lag of at least 24 hours.|t|t|t|t
34114588|NCT01459627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114589|NCT04118660|||CASE_ONLY||PROSPECTIVE|||||||
34114590|NCT03381326|||CASE_ONLY||PROSPECTIVE|||||||
34114591|NCT05442697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114592|NCT00925275|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114593|NCT04023019|||COHORT||PROSPECTIVE|||||||
34114594|NCT06306183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Double-blind randomized placebo-controlled trial|t|t|t|f
34114595|NCT02460276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114596|NCT06563557|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34114597|NCT05803785|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114598|NCT01342666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114599|NCT06635785|NA|SEQUENTIAL||TREATMENT||NONE||||||
34114600|NCT05010473|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114601|NCT00674102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114602|NCT00280202|||COHORT||PROSPECTIVE|||||||
34114603|NCT04313582|NA|SINGLE_GROUP||OTHER||NONE||||||
34114604|NCT04750083|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Phase II is open-labelled with one arm, and phase III is single-blinded for the participants with 2 arms.||t|f|f|f
33809781|NCT05396001|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants randomized to the App+JITAI will receive push notifications throughout the study, while those in the App alone group will not. The participants will not be told the group in which they are randomized, but they may know the group because of the number of push notifications.||t|f|f|f
34114605|NCT02071615|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809782|NCT02109913|NA|SINGLE_GROUP||OTHER||NONE||||||
33809783|NCT00004805||||ECT||||||||
33809784|NCT00385866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809785|NCT04718259|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33809786|NCT05230316|||COHORT||CROSS_SECTIONAL|||||||
33809787|NCT06196164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809788|NCT06239519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the nature of this trial, it will not be possible to blind participants to their allocation. As measures are self report, blinding of outcome measures is also not possible. Protect against bias will occur by blinding investigators to condition (i.e., only staff directly managing participants will be unblinded).|A pragmatic, parallel arm randomized controlled superiority trial will be used. Participants will be randomly allocated in a 1:1 ratio to the control (usual practice; UP) or intervention (UP + JoyPop) condition. Stratified block randomization (block size of 10) will be used to randomly assign participants to each condition.|f|f|t|f
33809789|NCT02850939|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33809790|NCT03721562|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809791|NCT06340984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809792|NCT02442622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809793|NCT02404844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809794|NCT01695291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809795|NCT06050941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114606|NCT04738006|||COHORT||PROSPECTIVE|||||||
34114607|NCT02735200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||assignment|t|f|t|f
34114608|NCT03531255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114609|NCT00557440|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34114610|NCT00164281|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34114611|NCT01027676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114612|NCT03624725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114613|NCT00420706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114614|NCT04748237|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Before adjudication, all documents will be masked regarding previous coronary computed tomographic angiography.|Patients presenting to the ED with chest pain or other symptoms suggestive of ACS, without acute MI but with an intermediate risk (HEART-score \>3) will after written informed consent be randomized to either a strategy with an initial coronary computed tomographic angiography or not.|f|f|f|t
34114615|NCT01602484|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34114616|NCT05486507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114617|NCT01370473|||COHORT||PROSPECTIVE|||||||
34114618|NCT04743648|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34114619|NCT05646082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114620|NCT01577316|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114621|NCT04063696|||COHORT||PROSPECTIVE|||||||
33809796|NCT06360224|||OTHER||PROSPECTIVE|||||||
33809797|NCT02589457|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809798|NCT00667017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809799|NCT02149511|||COHORT||PROSPECTIVE|||||||
33809800|NCT02844959|||COHORT||PROSPECTIVE|||||||
33809801|NCT03854565|||COHORT||PROSPECTIVE|||||||
34114622|NCT04152239|||COHORT||PROSPECTIVE|||||||
34114623|NCT01409408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34114624|NCT00251992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114625|NCT03144401|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34114626|NCT05902897|||COHORT||RETROSPECTIVE|||||||
34114627|NCT02882347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114628|NCT06417060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and outcome assessor||t|f|f|t
34114629|NCT05136755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114630|NCT02988908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114631|NCT03457792|||COHORT||PROSPECTIVE|||||||
34114632|NCT04717401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients will be assigned randomly to the 2 groups by using opaque, sealed envelopes, containing the name of one of each groups (SCS or MET). A colleague who will be not participating in recruiting, treating or evaluating participants will select the envelopes. After the initial assessment but before the first therapy session, group allocation will be carried out.||t|f|f|f
34114633|NCT01793389|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34114634|NCT02525198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114635|NCT01186276|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34114636|NCT03477812|||CASE_CONTROL||PROSPECTIVE|||||||
34114637|NCT03557190|||COHORT||PROSPECTIVE|||||||
34114638|NCT06563856|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34114639|NCT03116126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114640|NCT05755581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Patients will be randomized into two groups:~The first group (Arm A) will receive NCT; (Any approved Chemotherapy protocol by guidelines.~The second group(Arm B) will receive NET; GnRH analog Goserelin acetate 3.6 mg every 4 weeks with tamoxifen 20 mg daily for premenopausal patients or an aromatase inhibitor for postmenopausal patients."||||
34114641|NCT04744103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114642|NCT06486402|||COHORT||PROSPECTIVE|||||||
33809802|NCT06028659|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|f|t|t
33809803|NCT01308684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809804|NCT01213940|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33809805|NCT04493359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809806|NCT03900988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33809807|NCT05991882|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Participants in the factorial trial will be informed generally of the assigned condition (i.e., introduction module + no daily messages or introduction module + daily messages), but not given detailed content.|Participants will be randomly assigned to one of eight conditions|t|f|f|f
34041502|NCT06475911|||COHORT||PROSPECTIVE|||||||
34041503|NCT06314438|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041504|NCT05975619|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, single-arm, single-site feasibility study designed to generate data describing the quality and applicability of on-couch high-performance CBCT imaging technology.||||
34041505|NCT06010017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041506|NCT03524625|||OTHER||OTHER|||||||
34041507|NCT04620837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041508|NCT00240448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34041509|NCT02362360|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34041510|NCT03498430|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34041511|NCT01087125|||COHORT||PROSPECTIVE|||||||
34041512|NCT06578312|||COHORT||RETROSPECTIVE|||||||
34041513|NCT00618644|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34041514|NCT04553939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041515|NCT00369954||||TREATMENT||||||||
34041516|NCT02386319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041517|NCT02333526|||CASE_CONTROL||PROSPECTIVE|||||||
34041518|NCT04399018|||COHORT||CROSS_SECTIONAL|||||||
34041519|NCT02957253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041520|NCT01498796|RANDOMIZED|PARALLEL||TREATMENT||||||||
34041521|NCT06274190|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041522|NCT06295965|||COHORT||PROSPECTIVE|||||||
34041523|NCT00700219|||CASE_ONLY||PROSPECTIVE|||||||
34041524|NCT01374204|||COHORT||PROSPECTIVE|||||||
34114643|NCT02502552|||COHORT||PROSPECTIVE|||||||
34114644|NCT05851963|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel Assignment This trial is designed as an four-arm parallel cluster randomized controlled trial and an allocation ratio of 1:1:1:1|f|f|f|t
34041525|NCT01354652|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041526|NCT01912092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041527|NCT05455203|NA|SINGLE_GROUP||PREVENTION||NONE||Black parents and youth between the ages of 11-17 years from (n=40) parent-child dyads will be recruited for this study. The study is a formative qualitative study design with the intention of using findings for the adaptation and evidence-based intervention.||||
34041528|NCT01916096|||CASE_ONLY||PROSPECTIVE|||||||
34041529|NCT03911726|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All study participants will undergo a single PET/MR-measurement.||||
34041530|NCT04629911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041531|NCT02946554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041532|NCT05705739|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34041533|NCT01907490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041534|NCT00607620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041535|NCT03863535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041536|NCT01877642|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34041537|NCT05302596|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center, prospective, controlled, randomized and open label study||||
33727780|NCT04589676|RANDOMIZED|PARALLEL||PREVENTION||NONE||An unblinded, two-arm, parallel group cluster-randomized trial with non-random cluster sampling will be conducted in two Indiana counties to establish the usability and feasibility of ORRS and its recruitment and training components.||||
33727781|NCT03283020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33727782|NCT00736801|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33727783|NCT02670044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727784|NCT02635464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727785|NCT04529889|||COHORT||PROSPECTIVE|||||||
33727786|NCT01485211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727787|NCT03127891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33727788|NCT05627882|||CASE_CROSSOVER||PROSPECTIVE|||||||
33727789|NCT00624676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727790|NCT04796246|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The proposed work will be characterized as a Randomized Clinical Trial, with evaluators outside the experimental groups (single-blind). The sample will be probabilistic, from individuals diagnosed with Parkinson's disease.|t|t|t|t
33727791|NCT04298996|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727792|NCT03302728|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a single arm dose escalation study. There are four dose levels for the combination of Brentuximab vedotin and Lenalidomide considered during the dose escalation.~Starting Dose Level 1: Brentuximab vedotin 1.8mg/kg q21 days \& Lenalidomide 15 mg daily (D1-14)~The dose can be decreased as follows:~Level -2 Brentuximab vedotin 1.2mg/kg q21 days \& Lenalidomide 5 mg daily (D1-14)~Level -1 Brentuximab vedotin 1.2mg/kg q21 days \& Lenalidomide 10 mg daily (D1-14)~or the dose can be escalated as follows:~Level 2 Brentuximab vedotin 1.8mg/kg q21 days \& Lenalidomide 25 mg daily (D1-14)~Patients will be assigned a starting dose by the safety committee; this will be communicated by the PI and/or their designated sub-investigator prior to planned Cycle1 Day 1 for each patient."||||
33727793|NCT01672476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727794|NCT03576248|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Study will be double-blind : neither participant nor the investigator will know which stimulation type (in-phase active, anti-phase active or sham) is on.|This study is composed of two independent sub-studies, one exploring the effects of tACS and the other the effects of tDCS, with different participants assigned to the two sub-studies. There will be 2 arms in tACS group and 2 arms in tDCS group. Among each sub-study, all participants will participate in all arms (hence the cross-over design).|t|t|t|t
33727795|NCT04428892|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33809808|NCT05554445|||COHORT||PROSPECTIVE|||||||
33809809|NCT01539252|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809810|NCT00005379|||CASE_CONTROL|||||||||
33809811|NCT05640505|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Experimental research design with randomized control trial with difference of 4 weeks were be applied. Pretest post-test was done to compare the difference in the scores of academic stress and emotional experiences among adolescents before and after the intervention. Two experimental conditions will be used: (1) Gratitude (individuals assigned with daily gratitude-inducing activity) and (2) Control (no-assigned activity). Both groups were measured at (a) Pre-test (prior to the intervention); (b) Post-test (immediately after intervention).||||
33809812|NCT01868061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809813|NCT04366193|||OTHER||PROSPECTIVE|||||||
33809814|NCT03375424|||COHORT||PROSPECTIVE|||||||
33809815|NCT01670799|NA|SINGLE_GROUP||OTHER||NONE||||||
33809816|NCT04171674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809817|NCT04103164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809818|NCT00241826|||COHORT||PROSPECTIVE|||||||
33809819|NCT04198441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809820|NCT05162469|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation (non randomized， 6 arms); Dose-expansion and efficacy-expansion(non-randomized,1-3 arms)||||
33809821|NCT02399605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809822|NCT05476900|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open-label, multicenter, parallel groups, Phase II clinical trial||||
33809823|NCT05785325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809824|NCT02744066|NA|SINGLE_GROUP||OTHER||NONE||||||
33809825|NCT03862898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809826|NCT02892591|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33809827|NCT01136512|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809828|NCT02516709|||COHORT||PROSPECTIVE|||||||
33809829|NCT01128322|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33809830|NCT00841711|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33809831|NCT03942575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A prospective cohort will be compared to a historical control group.||||
33809832|NCT05734690|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||One group of patients, upon randomization, will immediately begin participation in a remote, pharmacist-driven heart failure clinic that will initiate and titrate medications according to a standardized medical algorithm. The comparator group will first receive curated patient education, an alert to providers, and provider education, and then after 3 months begin participation in the remote heart failure clinic.||||
33809833|NCT01187706|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809834|NCT06061978|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33809835|NCT06287957|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are going to be 4 treatment groups. Group 1: Mini Implant Platform treated with Labrida Bioclean Group 2: Regular Implant Platform treated with Labrida Bioclean Group 3: Mini Implant Platform treated with Air-Flow Device Group 4: Regular Implant Platform treated with Air-Flow Device||||
33809836|NCT00914771|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33809837|NCT02281266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809838|NCT01554267|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809839|NCT04128670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not know if they are in the experimental taping condition or the placebo taping condition.|Randomized single-blind controlled trial|t|f|f|f
33809840|NCT04183023|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34041538|NCT04218656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two single clinical cohorts will be studied.||||
34041539|NCT04062929|||COHORT||RETROSPECTIVE|||||||
33809841|NCT02046304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809842|NCT03540329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort prospective study model comparing two different techniques for distraction osteogenesis in 4 different subgroups||||
34114645|NCT02783833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114646|NCT04500405|||COHORT||RETROSPECTIVE|||||||
34114647|NCT00688740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114648|NCT01003223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114649|NCT05743309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants did not know which group they were assigned to.|In this study, there are two groups (one experimental and one control group). While experimental group patients received telemedicine practices related to Family planning, control group patients received only routine health services provided by primary health care setting.|t|f|f|f
34114650|NCT01416337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114651|NCT02850341|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114652|NCT01891929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114653|NCT03094052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114654|NCT03682965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114655|NCT05370092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114656|NCT05303883|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled children will receive the intervention.||||
34114657|NCT03747692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|group 1 will be subjected to intracervical injection of mepicaine hydrochloride 3%iof a local anasthetic as Carbocaine3% and group 2 will be subjected to intracervical injection of 5 ml of normal saline|two groups will be used , 1st study group using intracervical anasthesia of a local anasthetic as Carbocaine3%,and 2nd group using NSAIDs and intracervical injection of a placebo ( saline ).Ask the patient to tell about any sense of nausea or vomiting or drowsiness.|t|f|f|f
34114658|NCT02515318|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34114659|NCT06308224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single-blinded as the assessor of the study would be kept blind of the treatment groups to which the patient would be allocated.||f|f|f|t
34114660|NCT00711373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114661|NCT06479356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114662|NCT01069757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114663|NCT05267496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114664|NCT02902614|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34114665|NCT05638828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114666|NCT06563635|||COHORT||RETROSPECTIVE|||||||
34114667|NCT03358082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114668|NCT06489002|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A stepped-wedge cluster randomization design will be used to assess the impact of implementation support strategies to support social needs screening and referrals for patients in care management.||||
34114669|NCT04815174|||COHORT||PROSPECTIVE|||||||
34114670|NCT03594708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34114671|NCT01881256|||COHORT||PROSPECTIVE|||||||
34114672|NCT02892370|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114673|NCT02996929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114674|NCT01520181|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114675|NCT01342055|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114676|NCT05207384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be evaluated by an independent physiatrist, blinded for the assigned treatment.||f|f|f|t
34114677|NCT00496171|||||PROSPECTIVE|||||||
33809843|NCT01920126|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33809844|NCT03353610|||COHORT||PROSPECTIVE|||||||
33809845|NCT01989416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33809846|NCT04796792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809847|NCT05300594|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33809848|NCT02483468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809849|NCT05918107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809850|NCT04799366|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33809851|NCT03044457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|neither the participant nor the outcome assessor know the group. The surgeon of course knows.|"Two groups: reversed gap technique vs. gap technique, randomized"|t|f|f|t
33809852|NCT05575505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|t|f|f
33809853|NCT06494566|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be randomized in blocks of two participants, at a 1:1 ratio, for the two groups of treatment. For every two participants, there will be one block. The number of each block will be hold in a nontransparent, seriated, sealed envelope. Intervention capsules will be opaque and stored in identical containers by a single investigator, who will not take part in data collection or analysis.|Randomized, Double-blind, Placebo-controlled, Multicenter, CONSORT oriented study|t|t|t|t
34114678|NCT05687344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114679|NCT02816814|RANDOMIZED|PARALLEL||||NONE||||||
34114680|NCT05526729|||COHORT||PROSPECTIVE|||||||
34114681|NCT03058952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114682|NCT03817580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Samples are blinded to the participant and technical team.||t|f|f|f
34114683|NCT05242939|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34114684|NCT00648414|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34114685|NCT00031733|RANDOMIZED|||TREATMENT||||||||
34114686|NCT06454656|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Study||||
34114687|NCT05452473|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33809854|NCT04009772|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33809855|NCT01883609|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33809856|NCT00597376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33809857|NCT03925389|||COHORT||PROSPECTIVE|||||||
34114688|NCT01204957|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34114689|NCT00267176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114690|NCT01972659|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34114691|NCT03464318|||OTHER||PROSPECTIVE|||||||
34114692|NCT00629603|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114693|NCT00238394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727796|NCT06054373|||CASE_ONLY||RETROSPECTIVE|||||||
33727797|NCT04010942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727798|NCT03439566|||COHORT||PROSPECTIVE|||||||
33727799|NCT00889954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727800|NCT02984358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33727801|NCT01350128|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33727802|NCT05422781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727803|NCT00870363|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727804|NCT00001445||||TREATMENT||||||||
33727805|NCT01728025|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727806|NCT05107258|||CASE_ONLY||PROSPECTIVE|||||||
33727807|NCT05820971|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33727808|NCT00579111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727809|NCT01436812|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727810|NCT05748340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727811|NCT03513484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727812|NCT05715203|||COHORT||CROSS_SECTIONAL|||||||
33727813|NCT02963649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727814|NCT06045039|||COHORT||PROSPECTIVE|||||||
33727815|NCT05217550|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single-centre interventional cluster randomised controlled trial||||
33727816|NCT01615471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727817|NCT06377397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Project staff, nurses and resident doctors looking after the neonate will not be blinded. The assessment of the primary outcome will be performed by a blinded adjudicator, who is not involved in the recruitment and monitoring of subjects. A part of the case report form (CRF) containing relevant details of all episodes of sickness in the 1st week of life will be detached from the main form and will be sent to the blinded adjudicator. This part will be linked to the main form only by a unique identification number. No patient identifiers or allocation group will be mentioned on the part sent to the blinded adjudicator.|"Neonates will be randomized to 1 of the following groups:~1. Group 1: Intervention group (Selective antibiotic group)~2. Group 2: Comparison group (Universal antibiotic group)"|f|f|f|t
33727818|NCT01268111|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33727819|NCT04448210|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33727820|NCT05352295|||COHORT||OTHER|||||||
33727821|NCT02180282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727822|NCT05382117|||COHORT||PROSPECTIVE|||||||
33727823|NCT04205760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|functional outcome assessor will be blinded to study group allocation|National multicenter two-group randomized-controlled, blinded to assessor clinical pilot trial|f|f|f|t
33727824|NCT01940926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727825|NCT01399242|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33727826|NCT06254053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|statistician|last decade has seen several innovative additions to enhance the properties of GIC whilst simplifying its usage. Unlike the early glass-ionomers, these newer systems are easy and more practical to use as a dental restorative and luting material for preschoolers, children and teenagers alike. These new varieties are composed of ceramic and zirconia reinforced glass ionomer cements were introduced to provide better drawbacks of amalgam as well as tooth-colored restorative materials exhibiting the strength of amalgam and at the same time maintain the fluoride releasing capacity of GIC providing better mechanical properties.|t|t|t|t
33727827|NCT03459664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Individuals who evaluate the outcomes of interest will remain blinded regarding a participant's condition (RECOVER/TAU) over the course of the study. Randomization will be conducted after baseline assessment and communicated to the participant by a person that is not the outcome assessor. During follow-up assessments after 6 and 12 month the outcome assessor will remain blinded regarding a participant's condition.|Randomized controlled study with two arms (RECOVER or treatment as usual)|f|f|f|t
33727828|NCT00490516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727829|NCT04692961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727830|NCT00006481||||SUPPORTIVE_CARE||||||||
33727831|NCT02204748|||CASE_ONLY||CROSS_SECTIONAL|||||||
33727832|NCT02165319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33727833|NCT04087122|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727834|NCT00819715|||COHORT||PROSPECTIVE|||||||
33727835|NCT00868621|||OTHER||PROSPECTIVE|||||||
33727836|NCT04629287|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|blind|Randomized, blind, dose-incrementing, placebo controlled|t|t|t|f
33727837|NCT00245284|||DEFINED_POPULATION||OTHER|||||||
33727838|NCT01378338|||CASE_ONLY||PROSPECTIVE|||||||
33727839|NCT06332716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727840|NCT03322228|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study plans to enroll 20 subjects. All subjects will receive 1 music therapy intervention lasting approximately 1 hour.||||
33727841|NCT04471636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727842|NCT03320772|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727843|NCT03221920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Care provider are not told whether the patient belongs to intervention or control group|Patients were randomized in to two groups, with very low carbohydrate diet and with normal diet|f|t|f|f
33727844|NCT03681457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727845|NCT05473312|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33727846|NCT04420156|||COHORT||PROSPECTIVE|||||||
33809858|NCT00059826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809859|NCT04784650|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809860|NCT06229769|||CASE_ONLY||CROSS_SECTIONAL|||||||
33809861|NCT00386399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809862|NCT03494413|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33809863|NCT01794299|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809864|NCT03332875|RANDOMIZED|PARALLEL||TREATMENT||NONE||Couples are randomized to receive either one call with a coach or four calls with a coach.||||
33727847|NCT01126996|||COHORT||PROSPECTIVE|||||||
33809865|NCT02955966|NA|SINGLE_GROUP||OTHER||NONE||||||
33809866|NCT04364230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809867|NCT02233998|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33727848|NCT06211725|||COHORT||PROSPECTIVE|||||||
33727849|NCT00819416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727850|NCT05858827|||OTHER||PROSPECTIVE|||||||
33727851|NCT06545370|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33727852|NCT06133231|NA|SINGLE_GROUP||OTHER||NONE||Feasibility of using multinutrient intervention with previously under-represented populations||||
33809868|NCT05044416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|device for intubation may not be blinded for provider or investigator|randomized 1:1|t|f|f|f
33809869|NCT01792557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809870|NCT01042184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809871|NCT02542696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809872|NCT01399606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809873|NCT05383989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"1. A personality-matched wellness program condition in face-to-face format (i.e., high AS student receives face-to-face AS program; high HOP student receives face-to-face HOP workshop: high SS student receives face-to-face SS workshop; high IMP student receives face-to-face IMP workshop)~2. A personality-matched wellness program condition in distance-delivery format (i.e., high AS student receives distance-delivered AS workshop; etc. as per the face-to-face format).~3. Services-as-usual offered by the respective university"|f|f|f|t
33809874|NCT05211596|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809875|NCT04529928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809876|NCT02662205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809877|NCT00316797|NA|SINGLE_GROUP||||NONE||||||
33809878|NCT04817293|||CASE_CONTROL||PROSPECTIVE|||||||
33809879|NCT02196337|||||CROSS_SECTIONAL|||||||
33809880|NCT01080404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809881|NCT02941094|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33809882|NCT02085941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809883|NCT02736188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809884|NCT04144088|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33809885|NCT04338919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809886|NCT04377724|||COHORT||PROSPECTIVE|||||||
33809887|NCT04378413|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809888|NCT01939288|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33809889|NCT02659540|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809890|NCT01229176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33809891|NCT03411382|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33809892|NCT04573218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809893|NCT03153306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809894|NCT02251301|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33809895|NCT01291212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33809896|NCT01873898|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33809897|NCT01159236|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33809898|NCT01335100|||CASE_CONTROL||PROSPECTIVE|||||||
33809899|NCT00115674|||COHORT||PROSPECTIVE|||||||
33809900|NCT02454959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809901|NCT03862469|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33809902|NCT05387863|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33809903|NCT02240472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809904|NCT01341769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33809905|NCT01420757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809906|NCT03172975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants and investigators will be blinded to study product allocation.||t|t|t|t
33809907|NCT01228734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809908|NCT00775398|||COHORT||PROSPECTIVE|||||||
34041540|NCT02503124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041541|NCT01567917|||COHORT||PROSPECTIVE|||||||
33809909|NCT03192709|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33809910|NCT03177226|NON_RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33809911|NCT04986371|||OTHER||PROSPECTIVE|||||||
33809912|NCT01182532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809913|NCT03794232|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34041542|NCT02278445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150171|NCT00641082|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809914|NCT03477266|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Color coded active tablets backed in red while identical dummy tablets coded in blue,both tablets are physically identical and usually no anticipated noticed side effects from mosapride||t|t|f|t
33809915|NCT04530370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809916|NCT02633982|||COHORT||PROSPECTIVE|||||||
33809917|NCT05494658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809918|NCT05224232|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33809919|NCT06294145|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All 20 participants will be assigned to the same 7-week savoring intervention.||||
33809920|NCT05125224|||COHORT||RETROSPECTIVE|||||||
33809921|NCT02165202|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33809922|NCT04419207|||CASE_CONTROL||PROSPECTIVE|||||||
33809923|NCT03765385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcome assessors will be masked to group allocation. The participants will be given repeated instructions not to reveal their group allocation to the outcome assessors. Data set will be blinded regarding group allocation (and the code for the groups will be held by a researcher not involved in the study) when performing analyses for main outcomes.||f|f|t|t
33809924|NCT01772199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809925|NCT04899557|||CASE_ONLY||RETROSPECTIVE|||||||
33809926|NCT01411137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809927|NCT05155358|||CASE_CONTROL||PROSPECTIVE|||||||
33809928|NCT02881229|||COHORT||OTHER|||||||
33809929|NCT00669474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809930|NCT01040312|||COHORT||PROSPECTIVE|||||||
33809931|NCT03731767|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pretest post test study design||||
34150172|NCT05364762|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727853|NCT00805935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727854|NCT00606892|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33809932|NCT02050555|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33809933|NCT02265120|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34114694|NCT05006495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Using a generator of www.randomization.com, 100 subjects randomized into blocks of 50 and 50. To reproduce this plan, use the seed 3169 along with the number of subjects per block/number of blocks and (case-sensitive) treatment labels as entered originally.~and (case-sensitive) treatment labels as entered originally. After randomization of 100 subjects, additional 26 subjects randomized into blocks of 13 and13. To reproduce this plan, use the seed 5134 along with the number of subjects per block/number of blocks and (case-sensitive) treatment labels as entered originally."|A randomized controlled trial, assigning subjects to two groups: C3 laminectomy with laminoplasty and C3-6 laminoplasty|t|f|f|f
33809934|NCT03217123||SEQUENTIAL||TREATMENT||TRIPLE|Patients were blind to the study phase (contact and parameters of stimulation).|The study meets a double-blind, longitudinal design. Stimulation contact was set following a random series known only by the neurosurgeon, with patient, psychiatry and neuropsychology teams blind. Psychiatric assessment was conducted each month, and neuropsychological testing was performed after each activation and washout period|t|t|t|f
33809935|NCT00234000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809936|NCT06196853|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114695|NCT01777867|||CASE_CONTROL||PROSPECTIVE|||||||
34114696|NCT04669067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114697|NCT03895372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114698|NCT06559319|||OTHER||PROSPECTIVE|||||||
34114699|NCT04958057|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group prenatal care with a focus on preeclampsia prevention||||
34114700|NCT03369158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114701|NCT06063655|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects will be assigned conditions via a code (A, B, C)|A Randomized, Placebo Controlled, Semi-Blind, Crossover Study|t|f|f|f
34114702|NCT04604431|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114703|NCT03371212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will not have information about the treatment group they've been assigned to until after surgery.|Patients will be randomized to 1 of 2 treatment groups, which they will be in for the duration of the study. Because of the nature of the study, there will be no crossover.|t|f|f|f
34114704|NCT06059950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114705|NCT01121757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114706|NCT05329220|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34114707|NCT04746755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, single-centre, parallel-group clinical investigation||||
34114708|NCT03560388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participant, care provider, and investigator are blind to allocation to control vs. intervention groups. Participant is also blind to the 2nd allocation to the two intervention group sub-arms.|Two main arms of control and intervention. Intervention arm include two sub-arms of integrative treatment plus acupuncture vs. integrative treatment with no acupuncture|t|t|t|f
34114709|NCT00867607|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34114710|NCT04772794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114711|NCT01262105|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34114712|NCT01058850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114713|NCT06242795|NA|SINGLE_GROUP||TREATMENT||NONE||This will be an open label, single arm pilot study of 7% hypertonic saline (HS) in patients with non-cystic fibrosis bronchiectasis (NCFB).||||
34114714|NCT04035226|||COHORT||PROSPECTIVE|||||||
34114715|NCT02305186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114716|NCT02001168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114717|NCT05601882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114718|NCT00895921|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34114719|NCT04995341|NON_RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|While all participants have the investigational imaging, throughout image grading, the principal investigator and image analysts are masked to all health data (including retinopathy of prematurity examination findings) except age at time of imaging. The visual acuity and neurodevelopmental outcome assessors are masked to all OCT image and fundus photograph grading data.||f|f|t|t
34114720|NCT06565052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Investigators blinded to block size||f|f|t|f
34114721|NCT05744479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded RCT|Metformin vs Placebo|t|t|t|t
34114722|NCT06337448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114723|NCT02037529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114724|NCT02298725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34114725|NCT05762354|||CASE_ONLY||CROSS_SECTIONAL|||||||
34114726|NCT01936831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114727|NCT01626742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114728|NCT02234193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114729|NCT03798210|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Pre-masked randomized tablet vials with Lactobacillus reuteri, or corresponding placebo|Lactobacillus reuteri versus placebo on prevention of flare in ulcerative colitis/proctosgmoiditis|t|t|t|f
34114730|NCT05587127|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34114731|NCT04312802|||COHORT||PROSPECTIVE|||||||
34114732|NCT04466891|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, open-label, multi-cohort, multicenter study||||
33727855|NCT04010721|NA|SINGLE_GROUP||OTHER||NONE||||||
33727856|NCT03454074|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727857|NCT06482008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727858|NCT03026257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33727859|NCT03523546|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33727860|NCT04439032|||COHORT||PROSPECTIVE|||||||
33727861|NCT01112527|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727862|NCT05472558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727863|NCT02901951|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33727864|NCT00711737|||CASE_ONLY||PROSPECTIVE|||||||
33727865|NCT03011359|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33727866|NCT01622452|||||PROSPECTIVE|||||||
33727867|NCT00046735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809937|NCT05671211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041543|NCT05710653|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|According to availability and the feasibility of the enrolment's requirements, patients will be allocated to an arterial hypertension group (HTN), an elevated blood pressure (Ele), and a last normotensive (NT) experimental group, and thus randomly allocated to an experimental (HTNex, Eleex, NTex) or control group (HTNcg, Elecg, NTcg) in where subjetcs will not do HIIT exercise.|We will compare three different exercise training experimental groups categories, such as; an arterial hypertension group (HTN), an elevated blood pressure (Ele), and a last normotensive (NT) experimental group in their physiological adaptations versus other three control groups of HTN, Ele, and NT control peers, after 3 months of training, and other 3 months od detraining y several health-related outcomes.|t|f|t|f
34041544|NCT04122742|||CASE_ONLY||PROSPECTIVE|||||||
34041545|NCT02606916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114733|NCT04388826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind Randomized Placebo-Controlled|Randomized Placebo-Controlled|t|t|t|t
33727868|NCT06520709|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727869|NCT00457938|NA|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33727870|NCT01810666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727871|NCT04914910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727872|NCT00542919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809938|NCT03406325|||COHORT||CROSS_SECTIONAL|||||||
33809939|NCT00774709|||CASE_ONLY||PROSPECTIVE|||||||
34041546|NCT05534295|||CASE_ONLY||RETROSPECTIVE|||||||
34041547|NCT00212550|||||PROSPECTIVE|||||||
34041548|NCT04311333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients will be examined with endostomal three-dimensional ultrasonography, clinical examination and computerized tomography before undergoing laparotomy or laparoscopy||||
34041549|NCT02684864|||COHORT||PROSPECTIVE|||||||
34041550|NCT01749826|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34041551|NCT06569199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and parents are blinded until after study has been explained and consent obtained. Participants then are randomized into either the spica cast or functional bracing group.||t|f|f|f
34041552|NCT02295826|RANDOMIZED|PARALLEL||TREATMENT||||||||
34041553|NCT03048747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041554|NCT06152562|||COHORT||CROSS_SECTIONAL|||||||
34041555|NCT05043207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The HA fitting procedure will be blinded, so neither the participant, the audiologist, nor the follow up test examiner knows which group the participant belongs to.|randomised control trial|t|t|f|f
34041556|NCT05874128|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041557|NCT01307865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041558|NCT02599285|||COHORT||PROSPECTIVE|||||||
34041559|NCT03208335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041560|NCT06278935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041561|NCT00053716|NON_RANDOMIZED|||TREATMENT||NONE||||||
34041562|NCT01806051|NON_RANDOMIZED|PARALLEL||||NONE||||||
34041563|NCT03464188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34041564|NCT03964857|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34041565|NCT02387671|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041566|NCT01105689|||COHORT||CROSS_SECTIONAL|||||||
34041567|NCT02473939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041568|NCT05915663|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomised cluster and cross-over study||||
34041569|NCT01394731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041570|NCT01950468|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34041571|NCT01764360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041572|NCT03852472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041573|NCT02909712|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34041574|NCT06574646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041575|NCT04915313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041576|NCT02680808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041577|NCT06174103|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34041578|NCT05655364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34041579|NCT06577844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114734|NCT02769793|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114735|NCT05992974|||COHORT||PROSPECTIVE|||||||
34114736|NCT05884125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114737|NCT00468663|||||PROSPECTIVE|||||||
34114738|NCT04767321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomised, Double-blind, Placebo-controlled Randomization 3:1, active to placebo|t|t|t|f
33727873|NCT05190120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727874|NCT00217360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33727875|NCT05982535|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33727876|NCT02535741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727877|NCT01959620|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727878|NCT02746562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041580|NCT06578000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients will be assigned randomly into 2 groups:~Group (A): Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + traditional therapy (Splint + Stretch + strength).~Group (B): conventional therapy (Splint + Stretch + strength) twice a week for six weeks"|t|f|t|f
34041581|NCT02549404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041582|NCT02772926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34041583|NCT01446861|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041584|NCT00023855||||TREATMENT||||||||
34041585|NCT01512004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114739|NCT01661283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114740|NCT04982796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical interviewers will be blinded to condition and study timepoint.||f|f|f|t
34114741|NCT01659502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041586|NCT06272539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|By doing so, we will aim to eliminate or reduce potential biases due to the order of patients and any transference effects that might occur if one profile clinical patients will influence the performance in several evaluations. Specifically, each patient will complete a sequence of allocation in the order of A, B, B, A, where 'A' represents SCS treatment isolated and 'B' denotes combined treatment. Subsequently, the average of the two 'A' conditions was calculated, and the same process was applied for the 'B' conditions||f|t|t|t
34041587|NCT06533800|||COHORT||PROSPECTIVE|||||||
34041588|NCT04874870|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Controlled||||
34041589|NCT00353509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041590|NCT02550782|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34114742|NCT02105129|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114743|NCT03326908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34114744|NCT06467409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114745|NCT05057507|||COHORT||PROSPECTIVE|||||||
34114746|NCT05684302|||OTHER||PROSPECTIVE|||||||
34114747|NCT04085250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114748|NCT04179344|||OTHER||CROSS_SECTIONAL|||||||
34114749|NCT04243486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114750|NCT05775445|||CASE_CONTROL||OTHER|||||||
34114751|NCT02666560|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34114752|NCT01645202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114753|NCT04149743|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33809940|NCT02517385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809941|NCT06510855|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33809942|NCT02838459|||COHORT||PROSPECTIVE|||||||
33809943|NCT01380145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809944|NCT05738785|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33809945|NCT04672174|NA|SINGLE_GROUP||SCREENING||NONE||||||
33809946|NCT02978248|||COHORT||PROSPECTIVE|||||||
33809947|NCT03353961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809948|NCT03418922|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33809949|NCT03579407|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33809950|NCT04063124|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open-label pilot study of intermittent D+Q to measure its target engagement in CSF and blood, and to establish the feasibility and safety of D+Q treatment in older adults with early stage AD as initial proof-of-concept for a larger Phase 2 clinical trial.||||
33809951|NCT01131546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809952|NCT04084522|RANDOMIZED|PARALLEL||TREATMENT||NONE|As it is a nutritional intervention masking of the either of participants or investigator or other investigator is not possible|||||
33809953|NCT04334252|||COHORT||PROSPECTIVE|||||||
33809954|NCT00337610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33809955|NCT05997563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809956|NCT04353583|||COHORT||PROSPECTIVE|||||||
33809957|NCT04864834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33809958|NCT05643222|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Only the principal investigator knows the identity of each of the lenses.|6 colour defect subjects eye were inserted with 4 different types of red tinted contact lenses at different times and then tested with Ishihara Test and 100 Hue Test to obtain the score values. This was done only on one non dominant eye of subject.|f|f|f|t
33809959|NCT00860457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809960|NCT02162082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809961|NCT05410106|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the nature of the interventional device it is not possible to blind the care providers or outcome assessors to the intervention group. The trial participants will be unconscious/sedated for the duration of the period that the PneuX device or standard ETT is in place and therefore will be unaware of their allocation. Samples sent to the laboratory for analysis will be anonymised using individual deidentified numbers for each participant.|Feasibility, 2-arm, parallel, randomised controlled trial|t|f|f|f
33809962|NCT06178380|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Masking is a technique used to keep treatment information indisclosed to the study participants while allowing researchers and treatment administration to know this information: study participants are not informed about the treatment they are receiving, they do not know whether they are receiving the experimental treatment under investigation or if they are in the control group , which may receive a placebo or standard treatment .~This helps reduce potential bias related to participant expectations"|"A randomized single blind clinical trial is a research study design used to evaluate the effectiveness of a medical intervention or treatment. In this type of trial, participants are randomly assigned to one of two a more groups, one groupe receives the experimental treatment, while the other group may receive a placebo or standard treatment, depending on the study's design~- the term single blind refers to the fact that , in this trial the participants do not know whether they are receiving the experimental treatment or a control treatment this is done to minimize the potential for bias in reporting their symptoms or outcomes"|t|f|f|f
33809963|NCT01620788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809964|NCT05873205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838231|NCT01292148|||CASE_ONLY||PROSPECTIVE|||||||
33838232|NCT05597813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838233|NCT03153150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|PROBE design|1:1 allocation of intervention: comparator, using a minimisation algorithm|f|f|f|t
33838234|NCT04435964|||COHORT||PROSPECTIVE|||||||
33838235|NCT00335140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114754|NCT04794933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients who met the inclusion criteria and agreed to participate were randomly allocated to Group 1 \[Conventional therapy (CT)\], Group 2 \[CT+ PNF in extremity pattern\] and Group 3 \[CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns\].|t|f|f|f
34114755|NCT00277901|||COHORT||RETROSPECTIVE|||||||
34114756|NCT04694911|||COHORT||PROSPECTIVE|||||||
34114757|NCT00861887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114758|NCT00451737|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114759|NCT01974284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150173|NCT03688568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114760|NCT06564753|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, double-blind, placebo-controlled, parallel arm study|t|t|t|f
34114761|NCT03561311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114762|NCT05789251|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34114763|NCT01333436|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34114764|NCT03455686|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114765|NCT05539482|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All the participants will be blind to the allocation. Participants in the intervention group will receive intervention based on core package, while participants in the control will receive health information which are collected and provided by collaborators. The collaborator also will be told to avoid discussing allocation with the participants.|The participants recruited by one collaborator will be considered as one cluster. A research assistant will randomly assign the clusters from the NGOs, Schools, and Companies to either the intervention group or the active control group, respectively. After allocation, there will be four clusters in both the intervention and control groups from the NGOs, schools and companies, respectively. This will result in 3 × 4 = 12 clusters for each group (intervention/control). A active control group will be used instead of a standard control group to help motivate the collaborators to implement the program and to avoid a high participant dropout rate.|t|f|f|f
34114766|NCT01047540|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34114767|NCT05809947|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34114768|NCT02018211|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114769|NCT03735914|NA|SINGLE_GROUP||OTHER||NONE||||||
34114770|NCT05970328|||COHORT||PROSPECTIVE|||||||
34114771|NCT04342247|||CASE_CONTROL||PROSPECTIVE|||||||
34114772|NCT00900614|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114773|NCT05765474|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Research participants will be blinded to the overall purpose of the study and will not be informed of the difference between the groups. They will be debriefed after the completion of all study procedures in accordance with IRB policies. Outcomes assessors will be blinded to group allocation.||t|f|f|t
34114774|NCT06227949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients will be randomly assigned in a 1:1 ratio to either treatment or control group. Treatments in each of the trial arms will be as follows:~1. Treatment arm: Patients will self-administer a subcutaneous injection of Gonal-F (FSH) in addition to Luveris daily until a pre-set criteria to trigger ovulation is reached.~2. Control arm: Patients will self-administer a subcutaneous injection of Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached."|f|f|t|t
34114775|NCT02884453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114776|NCT00668759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114777|NCT02743962|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|||||
34114778|NCT00681070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114779|NCT00615888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114780|NCT04329767|||COHORT||PROSPECTIVE|||||||
34114781|NCT03107845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114782|NCT05847166|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The expected duration of participation for each subject is approximately 17 weeks. This includes up to 1 week for screening, 4 weeks for diagnostic procedures, and 12 weeks for safety evaluation.||||
34114783|NCT00833521|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34114784|NCT00062257||||TREATMENT||NONE||||||
34114785|NCT01998477|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34114786|NCT00242151|||DEFINED_POPULATION||PROSPECTIVE|||||||
34114787|NCT05751109|||CASE_CONTROL||PROSPECTIVE|||||||
34114788|NCT01533623|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34114789|NCT01404234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114790|NCT01013571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114791|NCT00529048|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114792|NCT04113889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34114793|NCT00883597|||COHORT||PROSPECTIVE|||||||
34114794|NCT03378960||SEQUENTIAL||OTHER||NONE||This was a single-dose, open-label, bioavailability study of surgical group and controls.||||
34114795|NCT05482022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114796|NCT05784012|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Two cohorts:~Cohort A: Patients who are candidates for definitive radiotherapy plus cisplatin (eligible for platinum).~Cohort B: Patients who are ineligible for cisplatin."||||
34114797|NCT01995097|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114798|NCT03405012|||CASE_CONTROL||PROSPECTIVE|||||||
34114799|NCT00851084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114800|NCT04696029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114801|NCT03674281|NA|SEQUENTIAL||TREATMENT||NONE||||||
34114802|NCT02435030|||CASE_ONLY||PROSPECTIVE|||||||
34114803|NCT01138722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114804|NCT04243148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114805|NCT01901692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838236|NCT00911651|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114806|NCT06378840|||COHORT||PROSPECTIVE|||||||
34114807|NCT03057756|||COHORT||PROSPECTIVE|||||||
34114808|NCT04533945|NA|SINGLE_GROUP||OTHER||NONE||||||
34114809|NCT01272427|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34114810|NCT05434468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114811|NCT05204121|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114812|NCT05691920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
34114813|NCT00467441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114814|NCT01721720|||COHORT||PROSPECTIVE|||||||
34114815|NCT04770207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Drug-eluting beads loaded with various drugs including IL2, kytruda, imfinzi, yevoy, bevacizumag, or/and ramucirumab, doxorubicin/idarubicin are injected into solid tumors under CT guidance according to appropriate treatment strategy, once per 3-6 weeks, and the safety and efficacy will be evaluated by guidelines.||||
34114816|NCT06288438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to group allocation.|Participants will be randomized into 1 of 2 groups. Group 1 will receive the intervention for 24 weeks. Group 2 will receive the control condition for 24 weeks.|f|f|f|t
33727879|NCT03583424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727880|NCT06361628|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33727881|NCT04384757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727882|NCT00464828|||||PROSPECTIVE|||||||
33727883|NCT03383328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33727884|NCT05798572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727885|NCT00365196|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33727886|NCT04076800|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33727887|NCT05209022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33727888|NCT01217970|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33727889|NCT02130063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727890|NCT00328913|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33727891|NCT03303833|||COHORT||OTHER|||||||
33727892|NCT06149416|NA|SINGLE_GROUP||OTHER||NONE||||||
33727893|NCT01136304|||COHORT|||||||||
33727894|NCT02660320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727895|NCT05336058|||COHORT||PROSPECTIVE|||||||
33727896|NCT02531412|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727897|NCT03243812|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727898|NCT01495585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33727899|NCT02020005|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33727900|NCT05773430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Testers will be unaware of which training condition participants are assigned.|A pre-post two-group experimental design will be used. One group will receive the experimental targeted neurocognitive training and the other group will not receive anything (no-contact control group)|f|f|t|f
33809965|NCT03314259|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double blind, placebo- controlled trial. After establishing the eligibility of the patients and obtaining the necessary informed consent, the research assistant (third party) will provide them with pre-assigned sealed envelopes that contain information with regards to their designated arm. The patients in the intervention arm will then be provided with Tamsulosin, while the rest will be given the placebo in a similar packaging. Blinded personnel would include the study participants and doctors/nurses involved in the surgery and peri-operative care. As such, participants, care providers and outcome assessors would all be blinded in our study. There will be no unmasking in our trial.||t|t|t|t
33727901|NCT04262453|||COHORT||PROSPECTIVE|||||||
33727902|NCT05504629|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33727903|NCT06286462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Matched, cluster randomized controlled design||||
33727904|NCT01535703|||COHORT||PROSPECTIVE|||||||
33727905|NCT01217060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727906|NCT04716023|||CASE_ONLY||PROSPECTIVE|||||||
33727907|NCT04999046|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33727908|NCT03500328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33809966|NCT05370378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Opaque Sealed Envelops will be provided to participants by investigator, with mentioned treatment group. A separate therapist serving as outcome assessor will be unaware of treatment group provided.|Group A: Hold Relax with Agonist Contraction with Routine Physical Therapy Group B: Active Release Therapy with Routine Physical Therapy|f|f|f|t
33809967|NCT05318963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809968|NCT04518709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809969|NCT04751981|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33809970|NCT03183050|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33809971|NCT01252420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809972|NCT03754660|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33809973|NCT04042298|||CASE_CONTROL||PROSPECTIVE|||||||
33809974|NCT04365205|||CASE_CONTROL||PROSPECTIVE|||||||
33809975|NCT05110794|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33727909|NCT03629782|||COHORT||RETROSPECTIVE|||||||
33727910|NCT05754606|||COHORT||PROSPECTIVE|||||||
33727911|NCT00589953|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33727912|NCT05410470|||CASE_ONLY||RETROSPECTIVE|||||||
33727913|NCT00854243|||||PROSPECTIVE|||||||
34114817|NCT04893733|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34114818|NCT01350076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34114819|NCT00978848|||CASE_ONLY||CROSS_SECTIONAL|||||||
33727914|NCT01748253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727915|NCT00446147|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33727916|NCT05946538|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective accuracy observational study||||
33727917|NCT03050879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727918|NCT02877628|||CASE_ONLY||PROSPECTIVE|||||||
33727919|NCT05929092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727920|NCT00628602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727921|NCT03326011|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33727922|NCT02670655|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33727923|NCT03146234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727924|NCT03778151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727925|NCT06351579|||OTHER||PROSPECTIVE|||||||
33727926|NCT02956733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33727927|NCT00764621|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727928|NCT00102232|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33727929|NCT04327986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33727930|NCT01611181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33727931|NCT00006489|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
33727932|NCT05044806|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33727933|NCT01150929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33727934|NCT06047275|||OTHER||OTHER|||||||
33727935|NCT06208436|||COHORT||RETROSPECTIVE|||||||
33727936|NCT00872703|||CASE_CONTROL||RETROSPECTIVE|||||||
33727937|NCT05832671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33727938|NCT03323658|NA|SEQUENTIAL||PREVENTION||NONE||||||
33727939|NCT03716297|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727940|NCT00256152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727941|NCT05457569|||COHORT||PROSPECTIVE|||||||
33727942|NCT03829046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The identity of the treatments will be concealed by the use of matching placebo to the study drug that are identical in packaging, labeling, appearance and schedule of administration.|A multi-center, double-blind, randomized, placebo-controlled, parallel group Phase IV study with two treatment arms: evolocumab SC 420 mg/dL QM or matching placebo. The identity of the treatments will be concealed by the use of matching placebo to the study drug that are identical in packaging, labeling, appearance and schedule of administration.|t|t|t|f
33727943|NCT03135041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727944|NCT05775107|||COHORT||PROSPECTIVE|||||||
33727945|NCT02985632|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727946|NCT00358085|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33727947|NCT04624321|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study has an initial 3-month randomization phase with two parallel arms, one randomized to access the lifestyle tool and one randomized to a wait list on usual care. After that 3-month period, all participants will get access to the tool, independent of previous randomization assignment, and are followed over three years in an open-label observation period where changes to HbA1c and secondary variables are compared against matched controls on usual care.||||
33727948|NCT04056559|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single||||
33727949|NCT06215963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727950|NCT00347724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33727951|NCT02579265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33727952|NCT03632278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Participants referred to the study will be assessed at a screening examination to ensure eligibility and obtain written consent from a research assistant.~Eligible participants will be randomly assigned to receive Mindfulness psychoeducation programme (MBPP) plus TAU or TAU."|f|f|f|t
33727953|NCT02639104|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34114820|NCT05334836|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33727954|NCT01449578|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33727955|NCT00191828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727956|NCT02307006|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33727957|NCT01293240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727958|NCT01451307|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33727959|NCT04617691|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33727960|NCT03068975|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Will create a double blind, randomized, parallel design study to evaluate the effectiveness of Alvimopan(post operative dose) in preventing post-operative ileus in poly-traumatized patients|t|t|t|f
33727961|NCT05366439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33809976|NCT02568306|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33809977|NCT04895774|||COHORT||PROSPECTIVE|||||||
34114821|NCT00567580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114822|NCT01101126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114823|NCT03005886|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34114824|NCT05023109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114825|NCT00517790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114826|NCT02467270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114827|NCT06170684|||COHORT||RETROSPECTIVE|||||||
34114828|NCT01910155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114829|NCT03663582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114830|NCT03106714|||COHORT||PROSPECTIVE|||||||
34114831|NCT05482295|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Experimental, randomized, double blind, four arm parallel group study, lot to lot consistency|t|t|t|t
34114832|NCT05537727|||CASE_ONLY||PROSPECTIVE|||||||
34114833|NCT05120804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114834|NCT03154957|||COHORT||RETROSPECTIVE|||||||
34114835|NCT03714516|NA|SINGLE_GROUP||PREVENTION||NONE||non-controlled evaluation pilot study with pre-, post- and follow-up assessments||||
34114836|NCT00242606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114837|NCT02101255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114838|NCT00883155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114839|NCT04217434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114840|NCT00388609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34114841|NCT01948102|||OTHER||PROSPECTIVE|||||||
34114842|NCT02106832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114843|NCT00023335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114844|NCT06420700|||COHORT||PROSPECTIVE|||||||
34114845|NCT04509258|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34114846|NCT05006664|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single arm, combination - brentuximab vedotin+cyclophosphamide+doxorubicin+etoposide+prednison||||
34114847|NCT04448379|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114848|NCT05819957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727962|NCT02165046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33727963|NCT03305510|||COHORT||RETROSPECTIVE|||||||
33809978|NCT00725959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809979|NCT05071677|||COHORT||PROSPECTIVE|||||||
33809980|NCT04250623|NA|SINGLE_GROUP||OTHER||NONE||Clinical trial, single-arm||||
33809981|NCT02024217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809982|NCT02409043|||CASE_CONTROL||PROSPECTIVE|||||||
33809983|NCT02198417|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33809984|NCT03940339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded participants will be recruited|Two group pretest posttest randomized control design|t|f|f|f
34114849|NCT03699202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114850|NCT02898038|NA|SINGLE_GROUP||||NONE||||||
34114851|NCT02786056|NA|SINGLE_GROUP||OTHER||NONE||||||
34114852|NCT00629928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34114853|NCT04470414|||COHORT||PROSPECTIVE|||||||
34150174|NCT06066073|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34150175|NCT04039152|||OTHER||PROSPECTIVE|||||||
33809985|NCT02832128|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33809986|NCT03775213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33809987|NCT06233552|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33809988|NCT02675322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809989|NCT02747537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33809990|NCT03839550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33809991|NCT03270709|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 44 subjects (11 per group, smokers and non-smokers, HIV+, HIV-) will be enrolled.||||
33809992|NCT00635700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809993|NCT01667198|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33809994|NCT00569634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33809995|NCT00262366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33809996|NCT00357994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33809997|NCT02941692|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33809998|NCT04866160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33809999|NCT04246866|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810000|NCT01317966|||COHORT||PROSPECTIVE|||||||
33810001|NCT05514184|RANDOMIZED|PARALLEL||TREATMENT||NONE|Meal plans in both arms will be administrated by the study dietitians over 6-months among 120 patients with non-dialysis CKD/DM stages 3-5 for 6-months to examine dietary, nutritional, and glycemic endpoints.|This is a pilot/feasibility, two-center (UCI and VA Long Beach), unblinded, randomized controlled trial, conducted in parallel with patients' routine CKD clinic visits, to test feasibility and safety of a patient-centered Plant-Focused Nutrition in CKD/DM (PLAFOND) comprised of \>2/3 plant proteins compared to the standard-of-care renal diet, i.e., low K content with \<1/3 plant protein.||||
33810002|NCT02434705|||CASE_CONTROL||PROSPECTIVE|||||||
33810003|NCT05818852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810004|NCT02394613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810005|NCT06510829|||COHORT||PROSPECTIVE|||||||
33810006|NCT04300270|||COHORT||PROSPECTIVE|||||||
33810007|NCT05764057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810008|NCT03135782|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33810009|NCT02076594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810010|NCT00220805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810011|NCT02814409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810012|NCT05774262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||multicenter, noncommercial, physician-initiated, proof-of-concept, prospective, randomized, controlled trial and registry|f|f|f|t
33810013|NCT01064609|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810014|NCT01038934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810015|NCT03005106|NA|SINGLE_GROUP||TREATMENT||NONE||See detailed description||||
33810016|NCT03338166|||COHORT||PROSPECTIVE|||||||
33810017|NCT04803045|||COHORT||PROSPECTIVE|||||||
33810018|NCT06148441|||OTHER||CROSS_SECTIONAL|||||||
33810019|NCT06041932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810020|NCT06365905|||CASE_ONLY||PROSPECTIVE|||||||
33810021|NCT05932303|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810022|NCT04161716|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||NIRS module recording||||
33810023|NCT02502019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810024|NCT02906657|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33810025|NCT05149963|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The researcher who completes the assessments will be blinded to baseline allocation length|Randomised multiple-baseline Single Case Experimental Design (SCED)|f|f|t|f
33810026|NCT01564498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810027|NCT01619319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810028|NCT01404000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810029|NCT05831566|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized controlled trial with a superiority design. Patients will be randomly assigned to one of two groups in parallel for the duration of the study. They will either recieve biologics directly or they will undergo an in-dept assessment to map the asthma diagnosis in more detail.||||
33810030|NCT02751957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810031|NCT00997750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810032|NCT00470483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810033|NCT06325228|||COHORT||CROSS_SECTIONAL|||||||
33810034|NCT02013804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810035|NCT04377542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810036|NCT01540500|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34150176|NCT05587166|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34150177|NCT01422668|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33810037|NCT04648215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized three group design : lavender aromatherapy (intervention); grapeseed oil aromatherapy (placebo) ; standard of care for night time (control)||||
33810038|NCT01528683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810039|NCT04569526|||COHORT||PROSPECTIVE|||||||
33810040|NCT00681109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810041|NCT00761267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810042|NCT06305143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810043|NCT00951132|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810044|NCT03592407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810045|NCT04637100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810046|NCT00003088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810047|NCT00530036|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33810048|NCT05017909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33810049|NCT04630119|||COHORT||CROSS_SECTIONAL|||||||
33810050|NCT04336618|||COHORT||PROSPECTIVE|||||||
33810051|NCT05544305|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No blinding will be possible in the study.|||||
33810052|NCT04153851|NA|SINGLE_GROUP||SCREENING||NONE||||||
33727964|NCT02485028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33727965|NCT05377528|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33727966|NCT04895384|||COHORT||PROSPECTIVE|||||||
33727967|NCT01660854|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727968|NCT03367377|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33727969|NCT03099551|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33727970|NCT04422145|RANDOMIZED|PARALLEL||PREVENTION||NONE|Due to the nature of the intervention 9a nurse led education programme) it was not possible to mask participant or trial team to the intervention|||||
33727971|NCT05112692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33727972|NCT03272451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727973|NCT02038595|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33727974|NCT01018082|||COHORT||PROSPECTIVE|||||||
33727975|NCT01412866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727976|NCT05180903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33727977|NCT03002168|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33727978|NCT02637219|||COHORT||CROSS_SECTIONAL|||||||
33727979|NCT00175890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33727980|NCT02114879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33727981|NCT01846975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727982|NCT01730183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727983|NCT01110694|||COHORT||PROSPECTIVE|||||||
33727984|NCT02152410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727985|NCT06276959|||CASE_ONLY||CROSS_SECTIONAL|||||||
33727986|NCT06256770|||CASE_CONTROL||PROSPECTIVE|||||||
33727987|NCT05058521|||OTHER||CROSS_SECTIONAL|||||||
33727988|NCT03805022|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a multicenter trial with:~* An open randomized two-arm phase III trial for high-risk CINSARC patients assessing whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management (3 cycles of neoadjuvant anthracycline based chemotherapy + surgery +/- radiotherapy) improves the outcome of patients~* a prospective cohort for low-risk CINSARC patients."||||
33727989|NCT00469482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727990|NCT01364090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33727991|NCT00002115||||TREATMENT||||||||
33727992|NCT05300295|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33727993|NCT03249779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33727994|NCT05603416|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33727995|NCT05041933|||COHORT||PROSPECTIVE|||||||
33727996|NCT03995212|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810053|NCT02351674|||COHORT||RETROSPECTIVE|||||||
33810054|NCT05392972|||OTHER||PROSPECTIVE|||||||
33810055|NCT05015699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810056|NCT03683849|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33727997|NCT05749796|||CASE_ONLY||PROSPECTIVE|||||||
33727998|NCT03700697|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomized quality improvement intervention trial||||
33727999|NCT01001442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728000|NCT04193475|||COHORT||PROSPECTIVE|||||||
33728001|NCT03411512|||CASE_CONTROL||PROSPECTIVE|||||||
33728002|NCT03098342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728003|NCT00485446|||DEFINED_POPULATION||OTHER|||||||
33728004|NCT04618120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728005|NCT02423863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728006|NCT02155335|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728007|NCT04216875|||COHORT||PROSPECTIVE|||||||
33728008|NCT00855036|||CASE_CONTROL||PROSPECTIVE|||||||
33728009|NCT01781442|||COHORT||PROSPECTIVE|||||||
33728010|NCT02927379|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33810057|NCT04069455|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33728011|NCT03302585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masked randomization and allocation, only data safety monitor will know allocation if adverse event requires unblinding|A double-blind randomized placebo/standard therapy phase II trial|t|t|t|t
33728012|NCT05009810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33728013|NCT04033159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Trial consisting of pre-screening consent, screening period, run-in period (if applicable), SAD part with 4 weeks follow-up after IMP and washout period of ≥ 12 weeks, MAD part of 12 weeks and MAD extension part of 12 weeks. All subjects to participate in SAD, MAD, and MAD extension unless they withdraw. Subjects to receive DYN101 in a low (1.5 mg/kg), middle (4.5 mg/kg) or high (9 mg/kg) dose in Cohorts 1, 2 and 3 respectively, and remain on assigned dose throughout the trial (unless IDMC advises otherwise). Each cohort will have 3-4 subjects with a DNM2 mutation and 2-3 subjects with a MTM1 mutation. Cohorts will enroll in a sequential staggered approach with an interval of ≥7 days between dosing of the first and the next subject in a cohort (after Medical Monitor 48hr safety data review).||||
33728014|NCT03437785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728015|NCT01660412|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33728016|NCT00176553|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33728017|NCT02586493|NA|SINGLE_GROUP||OTHER||NONE||||||
33728018|NCT04779684|NA|SINGLE_GROUP||OTHER||NONE||Pilot study of acceptability and fesability||||
33728019|NCT03249285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728020|NCT00801125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728021|NCT03413553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728022|NCT03712410|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728023|NCT02986620|||CASE_ONLY||PROSPECTIVE|||||||
33728024|NCT02196324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728025|NCT01878201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728026|NCT06269081|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33810058|NCT02177292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810059|NCT06140888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810060|NCT00869856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810061|NCT06031714|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728027|NCT00592566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728028|NCT05091008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728029|NCT01277354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728030|NCT05625763|||CASE_CONTROL||RETROSPECTIVE|||||||
33728031|NCT00554437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728032|NCT04076774|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The two devices in the trial are distinctly different and so device specific training is required and so cannot be blinded. The statistician analysing the data will be blinded to female condom type.|This research study will be a two-period, cross-over randomized controlled trial to compare the functional performance, safety and acceptability of two FC types (FC2 and Wondaleaf).|f|f|f|t
33728033|NCT02800330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728034|NCT00002524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728035|NCT04145895|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, nonrandomized, parallel||||
33728036|NCT03072134|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A Phase I study of neural stem cell based virotherapy in combination with standard radiation and chemotherapy for patients with newly diagnosed malignant glioma||||
33728037|NCT02283515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728038|NCT02156765|||||PROSPECTIVE|||||||
33728039|NCT05424536|||COHORT||PROSPECTIVE|||||||
33728040|NCT05909592|||COHORT||PROSPECTIVE|||||||
33728041|NCT03214809|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||When the MET team arrives first assessment will be done according to the abcde algorithm. If immediate interventions are needed (intubation, CPR etc) this will be done first (and noted). After the abcde assessment an initial diagnosis is noted. In the even weeks the thoracic ultrasound protocol will be done, in the uneven weeks not. After the use of ultrasound various variables are noted.||||
33728042|NCT03402438|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33728043|NCT05655611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728044|NCT02045511|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728045|NCT04090554|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Healthy community volunteers will be invited to participate in the study , complete and questionnaire and swallow the cytosponge. Participation rates and acceptability of device administration will be assess in this single group.||||
33728046|NCT02739269|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33728047|NCT00096512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728048|NCT03569228|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study 1. Participants obtaining replacement in-the-ear (ITE) or behind-the ear (BTE) hearing aids will be assigned to the ITE or BTE coupler-based fitting groups.~Study 2: Participants will be fitted with open-fit hearing aids using simulated audiograms.~Study 3. Participants obtaining replacement open fit or receiver-in-the canal hearing aids will be randomly assigned to the standard of care fitting groups (open or closed) or the coupler-based fitting groups (open or closed)."||||
33728049|NCT00423969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33728050|NCT01234233|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33728051|NCT00797082|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33728052|NCT03928951|||COHORT||PROSPECTIVE|||||||
33728053|NCT00461695|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33728054|NCT03741764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728055|NCT04905056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728056|NCT01414335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728057|NCT04656067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728058|NCT00903812|||OTHER||OTHER|||||||
33728059|NCT00963573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728060|NCT03675490|NA|SINGLE_GROUP||TREATMENT||NONE||pre-post pilot feasibility||||
33728061|NCT06200675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not know prior to their study participation that there are three different study conditions, and they will not find out which condition they were randomized to until the end of their study participation.|1/3 of the study participants (anticipated n=116) will be randomly assigned to the self-compassion intervention group, 1/3 of the participants (anticipated n=116) will be placed into the logic-based intervention group, and 1/3 of the study participants (anticipated n=116) will be placed into the control group.|t|f|f|f
33728062|NCT04832464|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor and participants.|Parallel assignment|t|f|f|t
33728063|NCT02592746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728064|NCT01879228|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33728065|NCT01468506|||COHORT||PROSPECTIVE|||||||
33728066|NCT01200797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728067|NCT03184181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A specialist physician will be diagnosed the supraspinatus tendinopathy.|f|f|f|t
33728068|NCT03619109|||OTHER||CROSS_SECTIONAL|||||||
33810062|NCT02684656|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33810063|NCT04431128|||CASE_CONTROL||RETROSPECTIVE|||||||
33810064|NCT06459544|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33810065|NCT04794244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810066|NCT02499497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33810067|NCT04121741|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33810068|NCT04663256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled trial|f|t|t|t
33810069|NCT03755115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810070|NCT04386538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810071|NCT05483166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810072|NCT04996407|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810073|NCT05483985|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial, 1:1 allocation in treatment and control group.||||
33810074|NCT03137784|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33810075|NCT05181735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810076|NCT04043988|||CASE_ONLY||PROSPECTIVE|||||||
33810077|NCT00090415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150178|NCT01043588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150179|NCT05671796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810078|NCT04081532|RANDOMIZED|PARALLEL||OTHER||SINGLE|General Practitioner||t|f|f|f
34150180|NCT04427449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150181|NCT04784468|||CASE_CONTROL||PROSPECTIVE|||||||
34150182|NCT00428207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838237|NCT00905905|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34041591|NCT06536361|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding: Participant blinding was implemented in the study. Participants were recruited without being informed of their group assignments, and different teaching techniques were applied to each group sequentially. The participants' skills were assessed by a field expert who was unaware of their group allocation. During the data collection phase, data were entered into the system by an individual other than the researcher and subsequently shared with an independent statistical expert without revealing group assignments. This expert conducted the data analysis without knowledge of which group was assigned to the experimental condition and which to the control condition. Blinding of outcome assessment was ensured, thereby minimizing bias. The blinding of evaluators, participants, and statisticians was employed to control for detection and statistical biases.|This study is a single-blind, pre-test-post-test, parallel group randomized controlled trial. Participants will first receive theoretical training, followed by demonstration videos one week later. Skills training in the simulation lab will be conducted two weeks after the theoretical training. At the semester's end, participants will be assigned to groups based on gender and course achievement scores. Two weeks before the intervention, pre-reading materials and demonstration videos for thorax and lung physical examination will be distributed. Knowledge and skill levels will be assessed seven days before the intervention. The control group will receive skills training in small groups using a manual and practice on each other. The experimental group will use a VR-based learning tool for training. Final assessments will take place seven days after the intervention, with experimental group students providing feedback on the VR tool's usability.|t|f|f|t
34041592|NCT05014659|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34041593|NCT05372835|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants have no idea in the usage of mouthwash or water. Participant with and without periodontal disease was blinded for the laboratory determining total oral bacterial count in saliva samples.|The volunteers of patients with and without periodontal disease were recruited in the same day. Patients with periodontal disease were randomized into mouthwash group and mouthwash plus periodontal flosser group. Patients without periodontal disease were recruited as the control group.|t|f|f|t
34041594|NCT03809663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe AD. This study consists of Part A (the main study evaluating tezepelumab as a monotherapy) and Part B (a study evaluating tezepelumab as adjunctive therapy when combined with a topical corticosteroid regimen|t|t|t|t
34041595|NCT04248114|||CASE_ONLY||RETROSPECTIVE|||||||
34041596|NCT04509336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041597|NCT00602459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041598|NCT06368466|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|t|f|f
34041599|NCT05636696|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This is a 1-arm pilot trial. All eligible and consenting couples will be allocated to the couple eMBCT named 'COMPANION' (Dutch name: 'Samen Minder Moe'). No randomization takes place.~The couple eMBCT was developed based on the evidence-based eMBCT directed (only) at patients. The couple eMBCT entails nine sessions, takes 15-20 weeks, can be followed from home and will be supervised remotely by a trained psychotherapist. Consistent with the original (patient only) eMBCT, the couple eMBCT aims to change the patient's behavioral and cognitive reactions to fatigue and other cancer-related stressors. Couple eMBCT includes extra information for partners each session, the possibility for partners to perform exercises and one extra session dedicated to the couple's mutual relationship and mindful communication about CCRF. Couples can determine themselves to which degree the partner is involved in the therapy."||||
34041600|NCT03495531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041601|NCT04367545|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041602|NCT01003860|||COHORT||PROSPECTIVE|||||||
34041603|NCT06150066|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041604|NCT00390871|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34041605|NCT05750212|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041606|NCT04712162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041607|NCT04226547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041608|NCT05971784|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Two groups as exercise group and control group|t|f|f|t
34041609|NCT06089564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34041610|NCT02596204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041611|NCT00171210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041612|NCT02478424|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041613|NCT04798053|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34041614|NCT02623062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041615|NCT04659954|NA|SINGLE_GROUP||OTHER||NONE||||||
34041616|NCT05916417|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding Procedures The participants, PI, Research Staff involved in TMS treatment, and staff performing the study procedures will be blinded to the participant's dl-PFC protocol assignment throughout the study.|"A total of 60 participants will be recruited and assigned to one of the two arms (active or sham TMS) at a 4:1 ratio (i.e., 48 participants for the active TMS group and 12 for the sham group).~The primary outcome is the MC or dl-PFC fNIRS signal, and a total of 12 comparisons will be conducted (i.e., one test for Aim 1; one for Aim 2; and 10 for Aim 3, considering the comparisons of CNR and TDR for the four longer paradigms as well as the shorter paradigm)."|t|f|t|f
34041617|NCT02626026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041618|NCT02892669|||CASE_ONLY||PROSPECTIVE|||||||
34041619|NCT00466245|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34041620|NCT03349060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150183|NCT05696574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150184|NCT02886559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150185|NCT04807387|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33838238|NCT04038918|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33838239|NCT02221557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728069|NCT04695132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to one of two arms: Active treatment arm (recipients of Illness Management and Recovery) and Control condition (TAU). Participants in the Control condition will be offered Illness Management and Recovery after study completion, conditional on them still being treated at the forensic inpatient treatment sites that are part of the study. Participants will be recruited in clusters (consisting of wards at inpatient treatment sites) and enrollment of new clusters will take place continually during data collection.||||
33728070|NCT00600756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728071|NCT02235376|||||PROSPECTIVE|||||||
33728072|NCT03183414|||COHORT||PROSPECTIVE|||||||
33728073|NCT00788827|NA|SINGLE_GROUP||TREATMENT||NONE||Autologous stem cells||||
33810079|NCT06088576|NA|SINGLE_GROUP||OTHER||NONE||The group consists of teenagers between 11 and 18 years old, recruited by professionals of medical-psychological center, Child Protection, school medicine college and high school as well as pediatric emergencies. The group will have access to the digital mental health application for 6 months. Assessments will take place at different times.||||
33728074|NCT05633706|||COHORT||CROSS_SECTIONAL|||||||
33728075|NCT01433107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728076|NCT03414346|RANDOMIZED|CROSSOVER||OTHER||SINGLE||A randomized single blind, crossover experimental study.|f|f|f|t
33728077|NCT04702490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728078|NCT01358604|||CASE_ONLY||RETROSPECTIVE|||||||
33728079|NCT02972632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728080|NCT01510119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728081|NCT01695785|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728082|NCT01314209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728083|NCT02857777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728084|NCT00981006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728085|NCT03507218|||CASE_CONTROL||PROSPECTIVE|||||||
33728086|NCT01340378|||CASE_ONLY||PROSPECTIVE|||||||
33728087|NCT00003268||||TREATMENT||||||||
33810080|NCT00703352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810081|NCT04201314|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33810082|NCT01779141|||COHORT||PROSPECTIVE|||||||
33810083|NCT00173706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810084|NCT00240994|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33810085|NCT00336882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810086|NCT06472713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810087|NCT01946594|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33810088|NCT06465537|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041621|NCT05067608|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This is a phase 1b/2a single centre clinical trial. Eligible hypoproliferative thrombocytopenic adult patients enrolled in the study will be randomised into two arms. One arm is the treatment arm using cryopreserved platelets and the second is the control arm using liquid platelets. A recruitment period of two years is expected for 17 subjects in each arm. Subjects will automatically be crossed over to the other treatment arm once they have completed the first treatment arm and there is at least a 5-days interval without platelet transfusion. Subjects can be both inpatient and outpatient. During the thrombocytopenic period of 28 days, subjects may be required to have multiple platelet transfusions during this period."||||
33728088|NCT02795728|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33728089|NCT01907828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728090|NCT03190070|NA|SINGLE_GROUP||OTHER||NONE||Physiological study to measure the change in glomerular filtration rate after an oral protein load||||
33810089|NCT03072862|||COHORT||PROSPECTIVE|||||||
33810090|NCT00353691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33810091|NCT00254124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810092|NCT04187482|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants are undergoing 12-weeks of aerobic exercise training||||
33810093|NCT06509685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810094|NCT03651934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810095|NCT03719547|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomized controlled trial||||
33810096|NCT02431442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810097|NCT04674553|||OTHER||CROSS_SECTIONAL|||||||
33810098|NCT00849446|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041622|NCT01844154|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041623|NCT05977660|||OTHER||CROSS_SECTIONAL|||||||
33728091|NCT02693509|||COHORT||OTHER|||||||
33728092|NCT03307733|RANDOMIZED|PARALLEL||PREVENTION||NONE|It is difficult to mask in these type of interventions.|Feasibility Randomized Control Trial||||
33728093|NCT02849548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728094|NCT02506816|||CASE_ONLY||PROSPECTIVE|||||||
33728095|NCT04802265|||COHORT||PROSPECTIVE|||||||
33728096|NCT02680821|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33728097|NCT01967602|||COHORT||PROSPECTIVE|||||||
33728098|NCT00613509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728099|NCT01465646|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33810099|NCT01366456|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|f|t
33810100|NCT00105170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810101|NCT01706159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810102|NCT05330000|RANDOMIZED|CROSSOVER||OTHER||NONE||A total of 48 healthy adult subjects were enrolled; Intravenous drip Voriconazole (T) for injection or reference preparation vfend ® （R）in fasting state per cycle； After a 7-day cleaning period, the second cycle of cross administration.||||
33810103|NCT01090258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810104|NCT04186377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810105|NCT06272032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810106|NCT03014791|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810107|NCT02424968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810108|NCT05139615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810109|NCT03849066|||COHORT||PROSPECTIVE|||||||
33810110|NCT01697228|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33728100|NCT04809909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, outcome assessors and data analysts will be kept blinded to the allocation status to avoid information bias. Patients who have no knowledge in acupuncture are told that the leads would be implanted at the acupuncture points that can be at or outside the painful sites. Only the pain physician administering the allocated intervention is unblinded, whereas he/she is not involved in data collection or analysis.|The randomization sequence will be generated by Microsoft Excel software. Blocked randomization will be done with an allocation ratio of 1:1 under block randomization (patients with lower back pain only or patient having low back pain with radicular pain). The assigned intervention group is stated in sequentially numbered, opaque, sealed envelopes, which will be opened by the attending therapist treating the patient. The investigator who is involved in sequence generation or allocation concealment will not be involved in enrolling participants or administering the intervention.|t|f|t|t
33728101|NCT02766244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728102|NCT05992506|||COHORT||PROSPECTIVE|||||||
33728103|NCT00684853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728104|NCT01125111|||CASE_CONTROL||RETROSPECTIVE|||||||
33728105|NCT01640366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728106|NCT02871947|||COHORT||PROSPECTIVE|||||||
33728107|NCT00925483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728108|NCT02800356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728109|NCT03254238|||COHORT||PROSPECTIVE|||||||
33728110|NCT00548704|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728111|NCT01530321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728112|NCT02233010|||CASE_ONLY||PROSPECTIVE|||||||
33728113|NCT05698264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728114|NCT00966238|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728115|NCT01921179|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33728116|NCT02918695|||COHORT||PROSPECTIVE|||||||
33728117|NCT03920631|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33728118|NCT02606591|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728119|NCT02356783|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728120|NCT06450548|NA|SINGLE_GROUP||OTHER||NONE||||||
33728121|NCT05001243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|While in office the care provider took a number out of a closed container. Number 1 was designated for the Brimonidine, Number 2 was designated for the PBOHB compound, Number 3 was designated for de Pilocarpine compound|Single Group Assignment To determine safety and efficacy of a Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic Acid, Bromfenac compound compared to Brimonidine and Pilocarpine to improve near uncorrected vision in healthy presbyopic patients|t|t|f|f
33728122|NCT01321775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728123|NCT05121883|||COHORT||PROSPECTIVE|||||||
33728124|NCT06028945|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, Randomized, Pilot, Pragmatic, Open label||||
33728125|NCT02975921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728126|NCT06049056|||COHORT||PROSPECTIVE|||||||
33728127|NCT06092515|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"This clinical trial will be conducted with a double-blind design~Participant Blinding:~Participants will not be informed about which specific type of flatbread they are receiving. Each participant will receive their assigned flatbread without knowledge of whether it falls into the fermented high zinc, unfermented high zinc, post-harvest fortified, or low zinc category.~Investigator and outcomes assessor Blinding:~The investigators and research staff responsible for data collection and assessment will also be unaware of the treatment assignments. They will not be involved in the preparation of the flatbreads to ensure that their observations and assessments are unbiased."|"This clinical trial investigates the health impact of consuming various types of wheat flour flatbreads among adolescent and adult females. The primary focus is on assessing zinc status and metabolic health in individuals at high risk of zinc deficiency and Type 2 Diabetes (T2DM). The study encompasses both fermented and unfermented flatbreads made from wheat variants with different zinc content and post-harvest fortified wheat flour."|t|f|t|t
33728128|NCT00710320|||COHORT||PROSPECTIVE|||||||
33728129|NCT03559075|||CASE_ONLY||CROSS_SECTIONAL|||||||
33728130|NCT00302133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728131|NCT00594464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728132|NCT02577796|||COHORT||PROSPECTIVE|||||||
33728133|NCT04745897|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33728134|NCT00500422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728135|NCT05478070|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33728136|NCT02990169|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810111|NCT02311413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810112|NCT02269852|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33810113|NCT03802409|||COHORT||PROSPECTIVE|||||||
33810114|NCT06190444|||OTHER||CROSS_SECTIONAL|||||||
33810115|NCT01486459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810116|NCT03681132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810117|NCT01701141|||CASE_CONTROL||PROSPECTIVE|||||||
33810118|NCT00420368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33810119|NCT04252950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810120|NCT01857999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810121|NCT03851094|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will consist of an allocation ratio of 2:1 (control:treatment).||||
33810122|NCT00407888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810123|NCT02981329|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810124|NCT02693288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810125|NCT05149950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810126|NCT02808832|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810127|NCT02359916|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33810128|NCT06270732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, parallel group, randomized controlled trial|t|f|f|t
33810129|NCT01320124|||COHORT||RETROSPECTIVE|||||||
33810130|NCT01021748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810131|NCT05320094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810132|NCT02381132|RANDOMIZED|PARALLEL||||NONE||||||
33728137|NCT04489706|NA|SINGLE_GROUP||TREATMENT||NONE||Histologically confirmed ovarian cancer and endometrial cancer patients with P53 mutation who had relapsed or metastasized after at least one line of standard system therapy. 20 subjects will be enrolled in this study.||||
33728138|NCT01589081|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33728139|NCT01901003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728140|NCT04375410|||COHORT||CROSS_SECTIONAL|||||||
33728141|NCT02269462|||COHORT||PROSPECTIVE|||||||
33728142|NCT01139333|||CASE_ONLY||RETROSPECTIVE|||||||
33728143|NCT04401891|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728144|NCT03087812|||COHORT||PROSPECTIVE|||||||
33728145|NCT00386412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728146|NCT04760158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728147|NCT05834296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each cohort will have 10 total subjects randomized in a 7:3 ratio (active:placebo). Subjects will be randomly allocated to treatment groups based on a central computer-generated randomization scheme.||t|f|t|t
33728148|NCT01772641|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33728149|NCT03551210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All eligible patients will be randomized to receive either treatment with Nemonoxacin or Tavanic® in a ratio of 1:1.|t|f|t|f
33728150|NCT03289507|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33728151|NCT04664504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728152|NCT03007511|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728153|NCT03804112|||COHORT||PROSPECTIVE|||||||
33728154|NCT04585516|||COHORT||OTHER|||||||
33728155|NCT06241027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728156|NCT05339139|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open label, prospective, single-arm, multicenter study with adult patients requiring CRRT. In this study, the subjects will receive CRRT on the mFTPRO system with RCA.~RCA treatment should be used until the end of CRRT. The circuit needs to be replaced after 72 hours of running time."||||
33728157|NCT01666756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728158|NCT06176950|||OTHER||OTHER|||||||
33728159|NCT01649258|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728160|NCT00348556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728161|NCT04947332|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm study||||
33728162|NCT04242888|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|participant and outcome assessor does not know the purpose of the trial|Four trial of a single group quasi experimental design on healthy subjects through individual intervention followed by similar trial on subject with shoulder pathology through combination of all intervention.|t|f|f|t
33728163|NCT04471753|||COHORT||PROSPECTIVE|||||||
33728164|NCT04105621|||COHORT||PROSPECTIVE|||||||
33728165|NCT01341886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728166|NCT00426283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728167|NCT02020083|||COHORT||PROSPECTIVE|||||||
33728168|NCT02445027|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33728169|NCT02153411|||CASE_ONLY||PROSPECTIVE|||||||
33728170|NCT06221033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728171|NCT04098458|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33728172|NCT06104501|||COHORT||PROSPECTIVE|||||||
33728173|NCT00632554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810133|NCT06143124|RANDOMIZED|PARALLEL||TREATMENT||NONE||one group (control) the classical eradication treatment therapy (14 days), second group (therapeutic) shorter duration of therapy (7 days) with the same drugs including Bismuth||||
33810134|NCT00630500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810135|NCT01053650|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33810136|NCT05395299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810137|NCT00364455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810138|NCT01707303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810139|NCT02296593|||COHORT||PROSPECTIVE|||||||
33810140|NCT03434600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810141|NCT01429454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810142|NCT02481167|||COHORT||CROSS_SECTIONAL|||||||
33810143|NCT03727672|||COHORT||PROSPECTIVE|||||||
34041624|NCT02245399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34041625|NCT06577311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728174|NCT05664724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728175|NCT01955070|RANDOMIZED|PARALLEL||||NONE||||||
33728176|NCT03569371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728177|NCT02450227|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33728178|NCT04499586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728179|NCT04891848|||CASE_CONTROL||PROSPECTIVE|||||||
33728180|NCT00017264||||TREATMENT||||||||
33728181|NCT02244580|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728182|NCT01530971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728183|NCT02304224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33728184|NCT03802448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728185|NCT00677807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728186|NCT02904057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728187|NCT03417388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Clinical Events Committee (CEC) will be masked to all treatment assignment.|This will be a PROBE design, that will evaluate an intensive statin/ACE-I (or ARB) treatment strategy (IMT) vs. primary prevention risk factor therapy treatment strategy (UC) in symptomatic (chronic angina or equivalent) women with non-obstructive CAD.|f|f|f|t
33728188|NCT00294164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728189|NCT03786757|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728190|NCT02189421|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33728191|NCT03037788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810144|NCT02994004|||||PROSPECTIVE|||||||
33810145|NCT01989793|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33810146|NCT02684032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810147|NCT04497415|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33728192|NCT05398978|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The pregnant mothers will be registered in the electronic database, they will be called by the midwives to motivate them for facility delivery and they will receive a text message regarding this.||||
33728193|NCT05513378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher who will review the documented ultrasound movies and assess the secondary outcomes will be blinded. However, given the nature of the study neither the Care Provider or Investigators will be blinded for the group affiliation or the primary outcome||f|f|f|t
33728194|NCT01388634|||COHORT||RETROSPECTIVE|||||||
33728195|NCT05423067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728196|NCT01874262|RANDOMIZED|PARALLEL||||NONE||||||
33728197|NCT05771181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728198|NCT02739191|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728199|NCT01968642|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33728200|NCT06210425|||CASE_CONTROL||PROSPECTIVE|||||||
33728201|NCT06310512|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33728202|NCT05539807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728203|NCT00117858||||TREATMENT||||||||
33728204|NCT00871390|||COHORT||PROSPECTIVE|||||||
33728205|NCT03222843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728206|NCT00951093|||COHORT||PROSPECTIVE|||||||
33728207|NCT01902446|||COHORT||PROSPECTIVE|||||||
33728208|NCT04300569|||COHORT||PROSPECTIVE|||||||
33728209|NCT02243878|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33728210|NCT02166190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728211|NCT00143702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728212|NCT05669079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728213|NCT06175143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728214|NCT03221595|RANDOMIZED|PARALLEL||OTHER||NONE||randomized, controlled trial||||
33728215|NCT01876069|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728216|NCT05449730|||COHORT||CROSS_SECTIONAL|||||||
33728217|NCT06088966|||CASE_ONLY||CROSS_SECTIONAL|||||||
33728218|NCT01166685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728219|NCT02882555|NON_RANDOMIZED|PARALLEL||||NONE||||||
33728220|NCT01751607|||COHORT||PROSPECTIVE|||||||
33810148|NCT02581904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728221|NCT05768854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728222|NCT03034993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33728223|NCT00353743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728224|NCT00402675|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810149|NCT00020527||||SUPPORTIVE_CARE||||||||
33810150|NCT00529204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810151|NCT00235937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810152|NCT03441490|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Design is a two-by-two factorial randomized trial with four intervention groups: 1, ICBT with therapeutic guidance through mail. 2, ICBT with therapeutic guidance through chat. 3, ICBT with learning support and terapeutic guidance through mail. 4. ICBT with learning support and terapeutic guidance through chat.||||
33810153|NCT05955807|||OTHER||PROSPECTIVE|||||||
33810154|NCT00000269||||TREATMENT||||||||
33810155|NCT02659982|||COHORT||RETROSPECTIVE|||||||
33810156|NCT05086874|||COHORT||RETROSPECTIVE|||||||
33810157|NCT02553148|||||RETROSPECTIVE|||||||
33810158|NCT03335488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Controlled, Open-Label Parallel Arm study||||
33810159|NCT02941549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33728225|NCT02676570|||CASE_ONLY||RETROSPECTIVE|||||||
33728226|NCT05987865|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33728227|NCT04583930|||COHORT||PROSPECTIVE|||||||
33728228|NCT05328830|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728229|NCT01627938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728230|NCT06432530|||CASE_ONLY||RETROSPECTIVE|||||||
33728231|NCT01188694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810160|NCT03333824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728232|NCT03595878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33728233|NCT00956124|||CASE_CONTROL||PROSPECTIVE|||||||
33728234|NCT04056195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728235|NCT01933048|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728236|NCT03200678|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33728237|NCT00228592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728238|NCT00695838|||COHORT||PROSPECTIVE|||||||
33728239|NCT00891358|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728240|NCT00136149|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728241|NCT03678155|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients will be informed of the condition they have been assigned to.|Two conditions. Patients will be randomly assigned to one of the two conditions.||||
33728242|NCT06019156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33728243|NCT02767427|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33728244|NCT02802280|NA|SINGLE_GROUP||||NONE||||||
33728245|NCT03846258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728246|NCT02928510|||CASE_ONLY||PROSPECTIVE|||||||
33728247|NCT03767218|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, phase 3 pilot randomized trial using a two-arm design with 1:1 allocation ratio||||
33728248|NCT06258148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810161|NCT03392805|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810162|NCT02234700|||CASE_CONTROL||PROSPECTIVE|||||||
33810163|NCT04815135|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810164|NCT01774240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810165|NCT01051869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810166|NCT03438565|||CASE_ONLY||OTHER|||||||
33810167|NCT01335061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838240|NCT02294526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838241|NCT00527761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810168|NCT04034966|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|750 Patients will be cluster randomized.|"The Project will consist in the conventional clinical treatment of the APD patient cared for in IMSS regarding the kind of dialysis solution, handling of laboratory and office procedures, as well as the handling of complications. One arm will utilize the Claria device, and the other will utilize normal treatment procedures.~The APD device in the control group will be called Claria® (Baxter, S.A. de C.V.) without the telemedicine device, and in the intervention group it will be the same device with the telemedicine module. Handling will be done according to the basic operating instructions established by the manufacturer.~According to the preliminary analysis of the flow of patients in PD indicated in the above paragraphs, recruitment of the sample size will not represent a problem. Infrastructure available in both technical and experienced human resources makes the study feasible."||||
33810169|NCT02383693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810170|NCT02064283|NA|SINGLE_GROUP||||NONE||||||
33810171|NCT04686617|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33810172|NCT00539084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810173|NCT02424474|NA|SINGLE_GROUP||SCREENING||NONE||||||
33810174|NCT03672032|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33810175|NCT01579071|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33810176|NCT05649891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810177|NCT06482528|NA|SINGLE_GROUP||SCREENING||NONE||||||
33810178|NCT03929471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150186|NCT02967939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150187|NCT02929082|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810179|NCT05549466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810180|NCT03676504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810181|NCT06435481|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810182|NCT00157794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810183|NCT04907617|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The participants will be blinded to the trial hypothesis and design to avoid being affected by the warming intervention.|The participants in the study will be allocated to one of four groups. In the trial, the participants will be assigned to the interventions and registered by the first author of this study.After the induction of anaesthesia, forced-air warming as well as warmed IV and irrigation fluids will be applied to the first group, the second group will be heated with only forced-air warming device, the third group will receive only warmed IV and irrigation fluids, and the fourth group will be the control group without any intervention.|t|f|f|f
33810184|NCT00134186|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810185|NCT03002194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810186|NCT03195998|||CASE_ONLY||PROSPECTIVE|||||||
33810187|NCT04907383|||COHORT||PROSPECTIVE|||||||
33810188|NCT00614614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33810189|NCT02697552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810190|NCT05441293|||COHORT||RETROSPECTIVE|||||||
33810191|NCT02399956|||CASE_CONTROL||PROSPECTIVE|||||||
33810192|NCT02364648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810193|NCT03485105|||COHORT||RETROSPECTIVE|||||||
33810194|NCT03663920|||COHORT||PROSPECTIVE|||||||
33810195|NCT05641857|||CASE_CONTROL||PROSPECTIVE|||||||
33810196|NCT06389266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The study is not sham-controlled, as both arms are active TMS treatments. The type of TMS is not masked from the participant or the investigator. Statistician will be blinded to intervention.|All participants receive five days of DMN-targeted cTBS and five days of L DLPFC-targeted iTBS. The order in which participants receive the two types of TMS is randomized.||||
33838242|NCT00682032|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33838243|NCT02771379|||COHORT||PROSPECTIVE|||||||
34041626|NCT02551562|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34041627|NCT01237574|||COHORT||PROSPECTIVE|||||||
34041628|NCT05501821|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part A will consist of multiple cohorts, each at an escalated dose level of KBA1412.~Part B will consist of disease specific cohorts, each cohort treated with KBA1412 at a fixed dose level.~Part C will consist of disease specific cohorts, each cohort treated with KBA1412 at a fixed dose in combination with pembrolizumab at a fixed dose."||||
34041629|NCT01467102|||COHORT||PROSPECTIVE|||||||
34041630|NCT01536340|||COHORT||PROSPECTIVE|||||||
34041631|NCT02328313|NA|SINGLE_GROUP||OTHER||NONE||||||
34041632|NCT02289248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041633|NCT01867125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041634|NCT03649932|RANDOMIZED|PARALLEL||TREATMENT||NONE||Previous studies in patients undergoing cardiac surgery have shown that post-operative pulmonary hypertension did not develop in patients with citrulline level \> 37 micromol/L. A cross-sectional study reported that citrulline levels \< 29 micromol/L was associated with BPD_PH (100% sensitivity and 75% specificity) hence this may be used as a screening tool for BPD_PH2. The investigators will use the higher levels of citrulline of the reported levels as our goal (\>37µmol/L). The investigators will supplement infants with 3 different dosages and check serum levels to see what dose is required to achieve the optimal plasma level of citrulline (\>37µmol/L).||||
34041635|NCT05486182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041636|NCT00628212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041637|NCT04670549|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-post design||||
34041638|NCT03136237|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 parallel treatment assessments||||
34041639|NCT03857529|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34041640|NCT02806908|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34041641|NCT03480542|||OTHER||RETROSPECTIVE|||||||
34041642|NCT05586347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041643|NCT04076293|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34041644|NCT01346566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041645|NCT00703157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150188|NCT00757692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150189|NCT06089941|||COHORT||PROSPECTIVE|||||||
34150190|NCT03046979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150191|NCT03909828|||CASE_ONLY||PROSPECTIVE|||||||
33810197|NCT03673618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A study pharmacist will provide soluble corn fiber or a placebo (malodextrin) in identical packets to be dispensed in identical fruit-flavored beverage||t|t|t|t
34114854|NCT03855904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Due to the nature of the intervention and control arms, blinding of the endoscopist is not possible (visual clues as to the nature of endoscopic treatment are evident and no sham procedure can be delivered since both are active treatment groups). However, in order to minimize possible patient/observer bias, any research team member or investigator assessing the patient after the initial endoscopy and involved in data collection or analysis, as well as the patient, and research nurse will be blinded to treatment allocation.|At the time of initial early endoscopy, following fulfillment of patient and bleeding lesion eligibility, central randomization is carried out in a 1:1 ratio, in blocks of 4. The confidential centralized random numbers allocation is obtained by using REDCap (https://www.project-redcap.org/), a web based platform available to all participating centres. An independent staff member maintained the randomization numbers in sealed opaque envelopes. After obtaining a written informed from an eligible patient, the gastroenterologists who were blinded to the sequence of treatment opened the next numbered sealed envelope with treatment allocation.Randomization is stratified by location of bleed (upper versus lower GI tract), considering the lack of comparative outcomes data in the literature, thus balancing known and unknown confounding more completely|t|f|t|t
34114855|NCT04848194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34114856|NCT04380142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114857|NCT00601744|||FAMILY_BASED||PROSPECTIVE|||||||
34114858|NCT06209866|||COHORT||PROSPECTIVE|||||||
34114859|NCT00060125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114860|NCT00718185|||COHORT||PROSPECTIVE|||||||
34114861|NCT01972126|||COHORT||PROSPECTIVE|||||||
34114862|NCT03685942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114863|NCT00793520|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34114864|NCT06363760|||OTHER||PROSPECTIVE|||||||
34114865|NCT06351514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114866|NCT06551649|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34114867|NCT04641832|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Dr. Kawata (PI) will only know subjects' group assignment and ensure blinded experiment and data processing. They will assign participants into two groups, chronic cannabis users and non-users. Group assignment will be based on self-reported cannabis use history and confirmed on 1st day of the study, with a saliva test ensuring no recent (24h-prior) use and a urine test to confirm history of chronic cannabis use or no use. Under the strict supervision of Dr. Kawata, experienced research assistants will perform soccer heading protocol, blood draws, neurocognitive and ocular-motor testing. Statistician will be blinded from group assignment. These processes will ensure single blind method||f|f|f|t
34114868|NCT01781988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114869|NCT03222570|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34114870|NCT03192436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34114871|NCT06442982|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"This study aims to explore the usefulness of collected data and does not establish a control group. Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined."||||
34114872|NCT04548908|||COHORT||PROSPECTIVE|||||||
34114873|NCT04940169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114874|NCT04815447|||COHORT||RETROSPECTIVE|||||||
34114875|NCT04936438|||COHORT||PROSPECTIVE|||||||
34114876|NCT01290991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114877|NCT00506623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114878|NCT04373200|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Comparative study with 3 cohorts of 25 adult patients:~* Cohort A: 25 COVID-19 associated ARDS~* Cohort B: 25 COVID-19 without ARDS~* Cohort C: 25 ARDS from other causes"||||
34114879|NCT02625779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114880|NCT01389687|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34114881|NCT05298930|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34114882|NCT05839925|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114883|NCT01296165|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34114884|NCT03322904|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114885|NCT05072899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34114886|NCT01144650|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34114887|NCT03841409|||COHORT||PROSPECTIVE|||||||
34114888|NCT05737979|||COHORT||RETROSPECTIVE|||||||
34114889|NCT05189678|||COHORT||PROSPECTIVE|||||||
34114890|NCT04284111|||CASE_ONLY||PROSPECTIVE|||||||
34114891|NCT02421757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114892|NCT01644435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114893|NCT06559449|||COHORT||RETROSPECTIVE|||||||
34114894|NCT00817609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114895|NCT06508619|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34114896|NCT01329133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114897|NCT05594186|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114898|NCT04277260|||CASE_CONTROL||OTHER|||||||
34114899|NCT03558217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to which group they have been assigned to until the final study visit at which point study personnel will reveal the group allocation.|Participants will be randomized to have either the collared or collarless Corail femoral implant used during surgery and randomization will be stratified by surgical approach (determined by surgeon expertise).|t|f|f|f
33810198|NCT05889494|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, intensive care unit physician, and outcome assessors will be blinded to study arm. The intraoperative anesthesiologist will not be blinded to study arm.||t|t|f|t
33810199|NCT05264285|||COHORT||PROSPECTIVE|||||||
33810200|NCT00647075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810201|NCT03617575|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33810202|NCT04834804|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838244|NCT03591484|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33838245|NCT02985359|||OTHER||CROSS_SECTIONAL|||||||
34041646|NCT01339260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041647|NCT04666987|||COHORT||PROSPECTIVE|||||||
34041648|NCT00090025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041649|NCT04439474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041650|NCT00758290|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34041651|NCT00879905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041652|NCT03390751|||COHORT||PROSPECTIVE|||||||
34114900|NCT05524233|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants will be part of the intervention group||||
34114901|NCT04856280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor was blinded regarding group allocation.||f|f|f|t
34041653|NCT03256032|||OTHER||CROSS_SECTIONAL|||||||
34041654|NCT05468112|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group design in which participants participants are assigned to a SKY meditation treatment intervention.||||
34041655|NCT03324750|||OTHER||PROSPECTIVE|||||||
34041656|NCT03396653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041657|NCT05284331|NA|SINGLE_GROUP||OTHER||NONE||||||
34041658|NCT00000971||||TREATMENT||||||||
34041659|NCT01164189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041660|NCT03622684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041661|NCT03803007|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The phase Ib of the study with a sequential design has been achieved (5 arms). The second phase IIa is ongoing. The selected dose (1000mg) for this second part will be compared to placebo (2 arms) with a parallel design.|t|t|t|f
34041662|NCT03392246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041663|NCT01761604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041664|NCT05051189|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The participant will be unaware of the arm|"2 groups will be identified-~1. patients with sleep study O2 nadir \>85%~2. patients with sleep study O2 nadir \<85%"|t|f|f|f
34041665|NCT06302556|||COHORT||OTHER|||||||
34041666|NCT01581437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041667|NCT01532518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041668|NCT05107908|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34041669|NCT04876326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041670|NCT01886209|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041671|NCT04838522|||COHORT||PROSPECTIVE|||||||
34041672|NCT06142500|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041673|NCT00167583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041674|NCT06224647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator conducting the analyses will be blinded to group assignments, remaining unaware of which data corresponds to the control group and which to the intervention group.|This study is a 12-week superiority parallel-group randomized controlled trial including three follow-up assessments at weeks 3, 8, and 12. Eligible participants are randomized to either an intervention condition (i.e., full access to the app) or to the waitlist control condition (i.e., receives access upon completion of the study).|f|f|t|f
34041675|NCT01611935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041676|NCT04939272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041677|NCT06298448|||CASE_CONTROL||PROSPECTIVE|||||||
34041678|NCT00408642|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34041679|NCT05028790|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants were masked to the order in which they wore contact lenses||t|f|f|f
34041680|NCT06416774|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041681|NCT03554733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, waitlist-control|f|f|f|t
34041682|NCT03822585|NA|SINGLE_GROUP||PREVENTION||NONE||Close Relatives Of β-Thalassemia Will Do Laboratory Tests||||
34041683|NCT01328990|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041684|NCT04380935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041685|NCT04272944|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||MSB2311 IV at 10 mg/kg Q2W, 20 mg/kg 3QW||||
34041686|NCT01760031|||CASE_CONTROL||PROSPECTIVE|||||||
34041687|NCT00118339||||SUPPORTIVE_CARE||||||||
34041688|NCT05505669|||CASE_CONTROL||PROSPECTIVE|||||||
34041689|NCT04276961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041690|NCT00368667|||||PROSPECTIVE|||||||
34041691|NCT05382819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041692|NCT01812954|||OTHER||RETROSPECTIVE|||||||
34041693|NCT03291184|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|The participant will still be under sedation at the moment of measuring neuromuscular blockade. The care provider will perform measurements, while the investigator is blinded.|Patients admitted to the ICU after elective cardiac surgery and ready for weaning from the ventilator.|t|f|t|f
34041694|NCT02367118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114902|NCT02666053|RANDOMIZED|CROSSOVER||OTHER||||||||
34114903|NCT01769027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114904|NCT04446052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114905|NCT04544280|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, interventional, multi-centre, open-labeled study.||||
34114906|NCT04943861|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34114907|NCT01160406|||COHORT||PROSPECTIVE|||||||
34114908|NCT00744744|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34041695|NCT04382495|||OTHER||CROSS_SECTIONAL|||||||
34041696|NCT05307640|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34041697|NCT04008719|NA|SINGLE_GROUP||SCREENING||NONE||||||
34114909|NCT06490159|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34114910|NCT01683942|||CASE_ONLY||RETROSPECTIVE|||||||
34114911|NCT05450562|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114912|NCT05862155|||COHORT||PROSPECTIVE|||||||
34114913|NCT04312022|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Neither the subject nor the investigators were aware of the study assignments, which were assigned by a lab member not directly involved in the measurements of the research.|Randomized, placebo-controlled, crossover design (1:1)|t|f|t|f
34114914|NCT04163757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114915|NCT06450743|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114916|NCT06204783|||COHORT||PROSPECTIVE|||||||
34114917|NCT01959932|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728249|NCT03197532|||COHORT||PROSPECTIVE|||||||
33728250|NCT00861107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728251|NCT03509675|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blinded crossover study|Non Steroidal anti-inflammatory topical rinse|t|t|t|f
33728252|NCT03539653|||OTHER||PROSPECTIVE|||||||
33728253|NCT01172652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728254|NCT04446065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The study will use 2 parallel groups in each center to compare the effects of an oral formulation of EGCG (Previfenon®, patent pending) with those of placebo (starch) in the prevention of respiratory disease caused by SARS-CoV-2 (COVID-19) in health care workers directly exposed to clinical care, daily contact, or traffic of individuals with suspected for COVID-19 during the epidemic outbreak.|t|t|t|t
33728255|NCT04015934|||COHORT||RETROSPECTIVE|||||||
33728256|NCT06195397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||parallel group (experimental-control)||||
33728257|NCT01955057|||CASE_CONTROL||PROSPECTIVE|||||||
33728258|NCT04884269|||OTHER||PROSPECTIVE|||||||
33728259|NCT01895673|||COHORT||PROSPECTIVE|||||||
33728260|NCT02983071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728261|NCT01168024|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33728262|NCT00132015||||TREATMENT||NONE||||||
33728263|NCT02990611|||COHORT||PROSPECTIVE|||||||
33728264|NCT04925011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728265|NCT01735656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728266|NCT04060407|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
33728267|NCT04657133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728268|NCT05714111|||COHORT||OTHER|||||||
33728269|NCT00454168|RANDOMIZED|||TREATMENT||||||||
33728270|NCT04278534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728271|NCT00179985|||COHORT||PROSPECTIVE|||||||
33728272|NCT04682821|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33728273|NCT05273268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A randomised control trial with two parallel arms.||||
33728274|NCT04623827|||COHORT||RETROSPECTIVE|||||||
33728275|NCT01747083|RANDOMIZED|CROSSOVER||||NONE||||||
33728276|NCT00062465||||TREATMENT||||||||
33728277|NCT00161993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728278|NCT05544838|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Each novice resident will place ten times LMA insertion with each insertion technique in randomised cross over manner by dividing the residents in two groups (5 residents in each group), by draw method. The one group will place LMA with standard insertion technique and other group will place by rotational LMA insertion technique, then after, the groups will switch over with concerned insertion techniques||||
33728279|NCT02049242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728280|NCT06437210|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33728281|NCT06276257|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728282|NCT05504655|||COHORT||RETROSPECTIVE|||||||
33728283|NCT00218374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33728284|NCT05516576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728285|NCT05824806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients will be randomized in block by simple drawing of opaque envelopes before application, in 3 experimental groups.~During infiltration, patients will be sitting on the stretcher in a comfortable position, with knees flexed and blindfolded (blinding as to the treatment performed).~Patients will be evaluated by an observer independent of the one who applied the selected treatment."|"Patients will be randomized in blocks by simple drawing of opaque envelopes before application, in 3 experimental groups, and identified as described below:~GROUP A: Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP A), once a week, for three consecutive weeks; GROUP B: Composed of 30 patients who will receive an intra-articular injection of platelet-rich plasma (PRP B), once a week, for three consecutive weeks; GROUP C: Composed of 30 patients who will receive an intra-articular injection of 2 mL of intra-articular hyaluronic acid (AHI), once a week, for three consecutive weeks."|t|t|t|f
33728286|NCT01289769|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33728287|NCT02603432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728288|NCT02656108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728289|NCT00080171|||COHORT||PROSPECTIVE|||||||
33810203|NCT05405244|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||Participants are randomly assigned to one of two possible intervention arms (active drug vs. placebo) at baseline. Following a 2-week washout period, participants receive the other intervention.|t|f|t|t
33728290|NCT02478138|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810204|NCT02730091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810205|NCT04269694|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking|In control group, no dressing material will be applied to donor site. While in test group, an antibacterial honey dressing material (Medihoney, http://www.medihoney.com) will be applied to donor site.||||
33810206|NCT03656198|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded to their study arm allocation. The intervention procedure will be identical for both arms (intramuscular injections at Student Health Services on days 0, 7 and 21). Participants allocated to the control group will receive an intramuscular injection of sterile water for injection using identical syringes and needles as for the vaccine group. The injection will be prepared in a separate room to maintain participant blinding.|The trial design is a single-site, two-arm, parallel-group, participant-blinded, randomized, placebo-controlled, two-sided comparative study, with an internal pilot study for blinded sample size re-estimation. Allocation to study arm will be by block randomization stratified by sex within cohort (semester) with a 1:1 allocation ratio.|t|f|f|f
33728291|NCT03780153|||COHORT||CROSS_SECTIONAL|||||||
33728292|NCT00190801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728293|NCT02382081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728294|NCT04782908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Outcome assessors will be blinded whether they are analysing pre or post transcatheter tricuspid valve edge-to-edge repair data.|Patients undergoing transcatheter tricuspid valve edge-to-edge repair will undergo multimodal cardiovascular diagnostics before and after tricuspid valve repair including pressure volume loop analysis and cardiac magnetic resonance imaging||||
33810207|NCT05230433|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33810208|NCT01929161|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33810209|NCT03009344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810210|NCT01683669|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33810211|NCT00774878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114918|NCT05678465|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded (surgeon/patient)|Patients in both arms will recieve intervention. First arm (mesh + fixation) serves also as control. Patients in second arm will be operated with mesh without fixation.|t|f|t|t
34114919|NCT06184802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114920|NCT00951314|||||PROSPECTIVE|||||||
34114921|NCT01855984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114922|NCT04836533|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34114923|NCT04164277|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors and interviewers will be blinded to the randomization.|From the eligible 13 Head Start centers with at least three classrooms in one Head Start organization, six Head Start centers will be randomly selected and assigned to the intervention (n = 3) or control (n = 3) group with usual Head Start activities. Three to five classes will be randomly selected from each selected Head Start center to be involved in the study. In each class, six caregiver-preschooler dyads will be randomly selected from the eligible participants, and total 24 caregiver-preschooler dyads will be recruited from each center, yielding a total of 144 dyads.|f|f|f|t
34114924|NCT02445209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114925|NCT01461460|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
34114926|NCT00078260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114927|NCT03123575|||OTHER||RETROSPECTIVE|||||||
34114928|NCT03102086|||CASE_ONLY||CROSS_SECTIONAL|||||||
34114929|NCT02400684|||CASE_ONLY||PROSPECTIVE|||||||
34114930|NCT04980560|||COHORT||PROSPECTIVE|||||||
34114931|NCT06564116|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34114932|NCT06563921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114933|NCT03226041|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34114934|NCT01535482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34114935|NCT00995787|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34114936|NCT01073969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34114937|NCT01596920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114938|NCT02279056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114939|NCT05019209|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects are exposed to house dust mite and allergen-free air in the same sequence. Subjects are blinded to the sequence of house dust mite and allergen-free air exposures||||
34114940|NCT04902872|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Parts B, C \& Modified Part B will follow a 3 + 3 design, enrolling 3 subjects in each cohort. (De)escalation rules: DLT period for each subject in Phase 1 Part B \& Modified Part B will be 3 weeks \& 4 weeks in Part C (i.e., 1 cycle). If none of the 3 subjects experience a DLT, dose will be escalated to next highest dose level. If 1 of 3 subjects in cohort experiences a DLT, up to 3 additional subjects will be enrolled/treated at same dose. If none of the additional 3 subjects experience a DLT (i.e., only 1 of 6 subjects in cohort has a DLT), dose will be escalated to next highest level. If 2 or more of up to 6 subjects at dose level have DLTs, enrollment to that cohort will stop, dose will be considered above MTD. Dose will be decreased to previous dose level or to a level intermediate to those previously evaluated. MTD will be highest dose evaluated at which ≤ 1 of 6 have a DLT. A minimum of 6 DLT-evaluable subjects will be enrolled to any dose level being evaluated as possible MTD.||||
34114941|NCT04038879|||COHORT||PROSPECTIVE|||||||
34114942|NCT05041829|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Investigator will be masked for assigned amount of dietary sodium intake of participants.|There are two 4-week experimental periods, each participant will received low and high sodium diet during one of the periods and the order of the amount of sodium diet will be determined by randomization.|f|f|t|f
34114943|NCT05755750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114944|NCT04225767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114945|NCT01276951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34114946|NCT00940147|||COHORT||PROSPECTIVE|||||||
34114947|NCT05606107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114948|NCT04437576|||COHORT||PROSPECTIVE|||||||
34114949|NCT03940755|||COHORT||PROSPECTIVE|||||||
34114950|NCT05965219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114951|NCT05790447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114952|NCT06249919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Phase 1b/2a, prospective, randomized, double-blind, placebo-controlled, multicenter, dose-escalation, exploratory study evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and efficacy of multiple doses of NS101 in healthy adults and patients with sudden Sensorineural Hearing Loss|t|f|t|t
34114953|NCT06030635|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114954|NCT01008826|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34114955|NCT06145412|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase II.||||
33810212|NCT04337593|NA|SINGLE_GROUP||TREATMENT||NONE||all patients enrolled will received basiliximab and pegaspargase.||||
33810213|NCT02105571|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810214|NCT00048932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810215|NCT02574286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810216|NCT05357677|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33810217|NCT02442557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810218|NCT01264107|||||PROSPECTIVE|||||||
33810219|NCT05815420|||COHORT||PROSPECTIVE|||||||
33810220|NCT00221065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810221|NCT00077558||||TREATMENT||||||||
33810222|NCT03398980|||CASE_ONLY||RETROSPECTIVE|||||||
34114956|NCT00426686|||CASE_ONLY|||||||||
34114957|NCT03212729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34114958|NCT04754464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo products are identical with verum in smell, flavour, color, texture, appearance, packaging (sachets) and labelling.|Randomised, controlled, double-blind|t|t|t|t
34150192|NCT03385330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728295|NCT02526407|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728296|NCT05652296|||COHORT||OTHER|||||||
33728297|NCT02166489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728298|NCT03202862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728299|NCT01695811|||CASE_CONTROL||PROSPECTIVE|||||||
33728300|NCT00749983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728301|NCT03114137|||COHORT||PROSPECTIVE|||||||
33728302|NCT00524446|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728303|NCT04925063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728304|NCT00816699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728305|NCT05142761|||CASE_ONLY||CROSS_SECTIONAL|||||||
33728306|NCT01822132|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33728307|NCT03493828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization sheet was given to someone who is not involved in the study, also the person who prepare the medicine is not involved in the study.|Arm 1: Bupivacaine 05%, arm 2: Bupivacaine 0.25%, and arm 3: placebo (Normal saline)|t|t|t|t
33728308|NCT03751410|||COHORT||PROSPECTIVE|||||||
33728309|NCT04974658|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization assignments will be kept in sealed envelopes until all preprocedural measurements will be completed, and then they are opened by the research anesthesiologist immediately prior to the nerve block.|This study will be performed in neurosurgical operating rooms at Zagazig University Hospitals and included 52 patients allocated randomly into two groups: 26 patients recruited in the block group (I) for the Inter-semispinal plane block and 26 patients recruited in the (C) control group.|f|t|f|t
33728310|NCT05225558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind with placebo|Placebo-controlled|t|f|t|f
33728311|NCT03950518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728312|NCT04488120|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, controlled, multi-centre trial of the efficacy and safety of the Occlutech septal occluder (Figulla Flex II) compared to the AGA septal occluder (Amplatzer ASO) for transcatheter closure of secundum atrial septal defects in patients.||||
33728313|NCT01945489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728314|NCT04248816|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33728315|NCT02731729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728316|NCT04019743|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728317|NCT01224249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33728318|NCT04702295|||COHORT||PROSPECTIVE|||||||
33728319|NCT04693585|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The three intervention modalities to be tested include: real-time live voice calls versus audio/video recording; text-based, asynchronous, on-demand social support; and standard of postnatal care (3 visits in first 7 days).||||
33810223|NCT05793866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
33810224|NCT00701259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810225|NCT05156606|NA|SINGLE_GROUP||TREATMENT||NONE||Male patients with metastatic BC (n=6)||||
33810226|NCT02133625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810227|NCT04654390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810228|NCT05626907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33810229|NCT03643484|||COHORT||PROSPECTIVE|||||||
33810230|NCT00490789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150193|NCT00228865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150194|NCT02759224|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34150195|NCT01985763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728320|NCT02908113|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728321|NCT04157946|||COHORT||PROSPECTIVE|||||||
33728322|NCT02528162|||COHORT||PROSPECTIVE|||||||
33728323|NCT01325779|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728324|NCT00021268||||TREATMENT||||||||
33728325|NCT00692770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728326|NCT03453450|||COHORT||OTHER|||||||
33728327|NCT02311465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728328|NCT04081948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are two models for this study. The first group is erector spinae plane block group. The second one is sham block group.|t|f|f|t
33728329|NCT04889742|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive additional hyperthermia according to physicians´choice as a radiosensitizer to standard of care re-irradiation or re-chemoradiation.||||
33728330|NCT03507556|NA|SINGLE_GROUP||TREATMENT||NONE||Revascularization for immature necrotic permanent teeth with apical periodontitis.||||
33728331|NCT02199405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728332|NCT04992221|||COHORT||RETROSPECTIVE|||||||
33728333|NCT06255535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728334|NCT00681499|||COHORT||PROSPECTIVE|||||||
33728335|NCT03837548|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33728336|NCT00254007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728337|NCT01256112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728338|NCT01301222|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728339|NCT05013983|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33728340|NCT02852031|||CASE_ONLY||PROSPECTIVE|||||||
33728341|NCT03408015|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Three groups of individuals will be recruited: asymptomatic non-contact lens wearers; symptomatic non-contact lens wearers, with dry eye disease; symptomatic contact lens wearers, with contact lens discomfort. All three groups will receive the same Xiidra treatment for the complete study duration.||||
33810231|NCT02531126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810232|NCT02258178|||COHORT||OTHER|||||||
34150196|NCT03850002|||COHORT||PROSPECTIVE|||||||
33810233|NCT05407051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810234|NCT03895567|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33838246|NCT00416364|||CASE_CONTROL||PROSPECTIVE|||||||
33838247|NCT00448487|||COHORT||PROSPECTIVE|||||||
33838248|NCT01180504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728342|NCT00005833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728343|NCT02601352|||COHORT||PROSPECTIVE|||||||
33728344|NCT02155738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728345|NCT03356496|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33728346|NCT05438069|||COHORT||RETROSPECTIVE|||||||
33728347|NCT02179996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728348|NCT01519856|||||PROSPECTIVE|||||||
33728349|NCT04611074|||COHORT||PROSPECTIVE|||||||
33728350|NCT06184425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33728351|NCT02283112|||CASE_ONLY||PROSPECTIVE|||||||
33728352|NCT05188859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728353|NCT00784511|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728354|NCT05124665|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|There are 3 teams of community health workers (CHWs) in total: one intervention, one standard of care, and one clinic-based that will always carry out initial enrollment and record clinic follow-up for both arms. Blinding of the CHWs is not feasible because it is a behavioral intervention that is easily recognized and CHWs must be trained to deliver either the standard of care or the intervention strategy. CHWs will collect data for the outcomes. CHWs will be separated into two teams and will only have electronic permissions to access training, procedures, forms, and contact information related to their assigned allocation within the electronic case record forms. They will be blinded to randomization procedures and outcomes. Participants will be blinded to their randomization assignment. Investigators and study staff will be blinded to study outcomes until the database is locked at the end of the trial. The onsite study coordinator who manages randomization will not be blinded.||t|f|t|f
33728355|NCT04721990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728356|NCT04296981|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33728357|NCT03504358|||COHORT||RETROSPECTIVE|||||||
33728358|NCT01749722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728359|NCT05503719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The participants are divided into two groups. The first group will get an absorbable suture and the second a non-absorbable suture.|f|f|f|t
33728360|NCT05437978|NA|SINGLE_GROUP||OTHER||NONE||||||
33728361|NCT05772533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation, perform the block, and administer bupivacaine solution.|Prospective, randomized, double blind study|t|f|f|t
33728362|NCT04049656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigators administering anesthesia will be informed as to whether or not HFVI information will be unmasked to help guide analgesic administration. However, subjects who participate in the trial and the PACU assessors of pain levels will be blinded to study group assignment.|A Prospective, Randomized, PACU Blinded, Clinical Utility Study to Confirm the Safety and Efficacy of HFVI-Guided Analgesic Administration in Surgical Subjects Receiving Balanced Sevoflurane-Fentanyl Anesthesia|t|t|f|f
33728363|NCT03523117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728364|NCT05781438|NA|SINGLE_GROUP||OTHER||NONE||Single-subject research design||||
33728365|NCT01165866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728366|NCT06262841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33728367|NCT01262885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728368|NCT02282956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728369|NCT03999411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728370|NCT02440386|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33810235|NCT05300672|RANDOMIZED|PARALLEL||TREATMENT||NONE|blinded-endpoint (PROBE)|This is a pilot, phase 3, prospective randomized open label, blinded-endpoint (PROBE) controlled trial on the effect of fibrinogen infusion in acute ischemic stroke patients treated with i.v. rtPA who develop hypofibrinogenemia (fibrinogen\<2 g/L or decrease rate \>50% after 2 and 6 hours from iv rtPA, compared to baseline values||||
33810236|NCT01450397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041698|NCT04663633|RANDOMIZED|PARALLEL||OTHER||SINGLE|The assessment of the test is conducted by masked assessors (judges and physiotherapists)|Pre-test, intervention and post-test. The Experimental Group performs an eight-week Core Stability Training 3 days a week and the Control Group performs the traditional Rhythmic Gymnastics Training during that period of time.|f|f|f|t
34041699|NCT02369965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041700|NCT06068101|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041701|NCT04900259|||CASE_CONTROL||RETROSPECTIVE|||||||
34041702|NCT06557642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041703|NCT06526481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded study, only the participant is blinded to the group he is going to be in.||t|f|f|f
34041704|NCT03010800|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34041705|NCT05676606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||a group of chemotherapy-naive patients with first time diagnosed various kinds of tumors, planned for the first cycle polychemotherapy treatment.||||
34041706|NCT05171842|||COHORT||PROSPECTIVE|||||||
34041707|NCT04216836|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34041708|NCT03337113|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The participant will be prevented from having knowledge of the interventions assigned.|A 2x2 factorial model will include four groups (Working Memory Training \[WMT\] + repetitive Transcranial Magnetic Stimulation \]rTMS\], sham WMT+rTMS, WMT+sham TMS, and sham WMT+sham rTMS) capable of isolating independent and combined effects of WMT and rTMS on the primary outcome variables.|t|t|f|f
34041709|NCT05951829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041710|NCT04520542|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34041711|NCT06465173|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041712|NCT01501539|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041713|NCT03500731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041714|NCT02825628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041715|NCT05831501|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041716|NCT00000468||||TREATMENT||||||||
34041717|NCT03142139|||COHORT||RETROSPECTIVE|||||||
34150197|NCT01435967|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34150198|NCT02992535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150199|NCT00209898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041718|NCT06311916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041719|NCT04120259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114959|NCT06547606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were allocated to either the intervention group or the control group using a concealed lottery method. Assessors were blinded to the treatments received by participants, ensuring impartial evaluation of outcomes.|This study is a double-blinded randomized controlled trial (RCT), where both participants and assessors were blinded. Participants were randomly allocated to either the experimental group, receiving resistive inspiratory muscle training, or the control group, receiving usual care, allocated using a lottery method.|t|f|f|t
34114960|NCT01842659|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114961|NCT05931731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|mechanical interference and neural mobilization|f|f|t|t
34114962|NCT06293183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34114963|NCT01567722|||CASE_ONLY||PROSPECTIVE|||||||
34041720|NCT00204009|||CASE_ONLY|||||||||
34114964|NCT03089294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114965|NCT05036135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114966|NCT00213070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34114967|NCT04509388|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Double-blind, randomised, crossover design|t|f|t|f
34114968|NCT04899687|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Symptom rating will be done by independent evaluators blind to treatment allocation.|After signing consent and baseline assessments, participants will be randomized 1:1 to Group A or Group B for the purposes of sequencing fluoxetine vs combined fluoxetine/dextromethorphan treatment periods.|f|f|f|t
34114969|NCT02740270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34114970|NCT01636284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114971|NCT01072084|||CASE_CONTROL||PROSPECTIVE|||||||
34114972|NCT01681914|||COHORT||PROSPECTIVE|||||||
34114973|NCT03552016|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|"The researchers involved, the project investigator, and the patients will be blinded from knowing which patient will get which treatment by assigning a number to each patient and having that patient take that number to the pharmacy where they will pick up their riboflavin. The dosage of riboflavin given to the patient will be chosen by the number that the patient gives to the pharmacy. There will be no labels revealing the dose of riboflavin that the patient receives. There will be placebo dose which contains a small dose of riboflavin that has been shown to not reach therapeutic levels."|This is a 1:1:1 double-blinded randomized study for children ages 6-12 year old with axial myopia who will be treated with one of three different doses of oral riboflavin. Expected number of participants is 100.|t|t|t|f
34114974|NCT01481610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114975|NCT01993082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34114976|NCT01676233|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34114977|NCT04570202|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Trials Within Cohort (TWIC) :~Participants are included within a cohort. They are screened using an online self-administered questionnaire for psychological distress (Post-Traumatic Stress Disorder, Burnout, Depression) every three months for one year.~People who are positive after screening (at M0 or M3 or M6) will be eligible for the trial and some of them will be randomly assigned to the treatment group. The rest of the cohort will be the second arm (control group)."||||
34114978|NCT02551783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114979|NCT00003561||||TREATMENT||||||||
34114980|NCT00502918|||COHORT||CROSS_SECTIONAL|||||||
34114981|NCT02446002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114982|NCT02321475|||CASE_ONLY||PROSPECTIVE|||||||
34114983|NCT05949593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Eligible subjects will be randomly assigned to begin treatment in 2:1 ratio to receive the study drug (either Tinlarebant 5 mg or matching placebo)||t|f|t|f
34114984|NCT03633006|||COHORT||PROSPECTIVE|||||||
34114985|NCT00027599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114986|NCT01006733|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34114987|NCT02757430|||COHORT||PROSPECTIVE|||||||
34114988|NCT02143882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34114989|NCT00637351|||CASE_ONLY||PROSPECTIVE|||||||
34114990|NCT01006395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34114991|NCT02595515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34114992|NCT01452945|||COHORT||PROSPECTIVE|||||||
34114993|NCT05557396|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34114994|NCT04581811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34114995|NCT05701826|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||HRS3797 for dose escalation||||
34114996|NCT04862312|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive the VideoDining intervention.||||
34041721|NCT05344157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041722|NCT04486937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041723|NCT05274243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041724|NCT01942577|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34114997|NCT05901272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This is a two-arm randomized controlled trial (RCT) with four VA HIV clinics in each arm. Arm 1 receives a learning collaborative and clinical champions at each site Arm 2 receives these plus external facilitation. Learning collaboratives will be hosted separately for sites in Arm 1 and sites in Arm 2 to avoid contamination. Across all aims, there are research activities proposed to evaluate the quality improvement (referred to as implementation strategy bundles). All implementation strategy bundles are supported by educational materials about HITIDES and tools to engage Veterans in implementation activities."||||
34114998|NCT00966459|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34114999|NCT06289374|||CASE_ONLY||PROSPECTIVE|||||||
34041725|NCT04600765|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34041726|NCT02040103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041727|NCT00969930|||CASE_CONTROL||PROSPECTIVE|||||||
34041728|NCT02464592|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041729|NCT00001030||||TREATMENT||||||||
34041730|NCT02673931|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34041731|NCT03825939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728371|NCT06213402|||COHORT||PROSPECTIVE|||||||
33728372|NCT05394675|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation and dose expansion study model||||
33728373|NCT01856751|||COHORT||PROSPECTIVE|||||||
33728374|NCT01379118|||CASE_CONTROL||PROSPECTIVE|||||||
33728375|NCT04046185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33728376|NCT03575884|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728377|NCT02218333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728378|NCT01847391|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33728379|NCT05967962|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will be blind to group allocation|A randomized controlled trial with an experimental group and a control group: Specifically participants will be screened for SMD, thereafter randomization will be applied within each group: with and without SMD, separately.|f|f|f|t
33728380|NCT05464004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Effects of Nintendo Wii balance board in combination with conventional physical therapy in children with CP|f|f|t|f
33728381|NCT03653936|||COHORT||PROSPECTIVE|||||||
33728382|NCT03467633|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33728383|NCT00886431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33728384|NCT00895791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728385|NCT00006916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728386|NCT05940974|||COHORT||PROSPECTIVE|||||||
33728387|NCT06391866|||COHORT||PROSPECTIVE|||||||
33728388|NCT02353247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728389|NCT05381584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728390|NCT06100666|||CASE_ONLY||CROSS_SECTIONAL|||||||
33728391|NCT01547416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728392|NCT03409471|||OTHER||CROSS_SECTIONAL|||||||
33728393|NCT00184262|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728394|NCT01977586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728395|NCT05696834|||CASE_ONLY||PROSPECTIVE|||||||
33728396|NCT04695938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728397|NCT02065648|||CASE_ONLY||PROSPECTIVE|||||||
33728398|NCT01257373|||COHORT||PROSPECTIVE|||||||
33728399|NCT00581074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33728400|NCT03492190|||CASE_ONLY||CROSS_SECTIONAL|||||||
33728401|NCT06338345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728402|NCT04686864|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||We studied the implementation of a virtual parent-led peer support group.||||
34115000|NCT04965584|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728403|NCT01941446|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33728404|NCT03978364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728405|NCT00002188||||TREATMENT||||||||
33728406|NCT04601545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728407|NCT04297930|||COHORT||PROSPECTIVE|||||||
33728408|NCT02636465|||||PROSPECTIVE|||||||
33728409|NCT03532997|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728410|NCT00824863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728411|NCT01858012|||COHORT||PROSPECTIVE|||||||
33728412|NCT04952194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728413|NCT02250196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33728414|NCT06031974|||COHORT||PROSPECTIVE|||||||
33728415|NCT03145441|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728416|NCT01709695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728417|NCT03168672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728418|NCT04895592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728419|NCT01869192|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized sequence of therapy.||||
33728420|NCT03250468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33728421|NCT04368884|||COHORT||PROSPECTIVE|||||||
33728422|NCT02733536|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810237|NCT01617811|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33810238|NCT00462072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728423|NCT02469116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810239|NCT02443909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810240|NCT06353620|||COHORT||RETROSPECTIVE|||||||
33810241|NCT05414825|||OTHER||PROSPECTIVE|||||||
33810242|NCT01058018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810243|NCT03719352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant, outcomes Assessor||t|f|f|t
33838249|NCT02649205|||COHORT||PROSPECTIVE|||||||
33838250|NCT03120468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33728424|NCT03848845|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|Subjects will receive GSK2857916 at escalating doses along with pembrolizumab on Day 1 of each 21-day Cycle to establish RP2D during the Part 1 of the study. Subjects will receive GSK2857916 at RP2D along with pembrolizumab on Day 1 of each 21-day Cycle in Part 2 of the study.||||
33728425|NCT02534831|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33728426|NCT01831232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728427|NCT05520008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants who satisfy the inclusion and exclusion criteria and sign the informed consent form will be randomly assigned with a ratio of 1:1 into two groups. Both groups will be given a compression garment (CompreCares, Medline, IL, USA) to wear for the 4 weeks of the study. The Active group (AG) will also be allocated a tablet and foot sensor so that they can play game-based foot \& ankle exercises during the same time period. The other group (Control group, CG) will only use the compression garment.||||
33728428|NCT03179176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33728429|NCT05402995|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be enrolled and randomized into one of four groups:~1. Standard operative debridement and spanning external fixator (reference/control group)~2. Spanning external fixator with Irrisept irrigation (treatment group 1)~3. Antibiotic-coated medullary nail with saline irrigation (treatment group 2) or~4. Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)"||||
33728430|NCT05393557|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33728431|NCT02635191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041732|NCT06345859|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34041733|NCT06574451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041734|NCT00664768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041735|NCT05147415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041736|NCT03561714|||CASE_CONTROL||PROSPECTIVE|||||||
34041737|NCT03548961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041738|NCT04455087|||COHORT||PROSPECTIVE|||||||
34041739|NCT02764762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041740|NCT04033354|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34041741|NCT03721796|||COHORT||PROSPECTIVE|||||||
34041742|NCT06331897|||OTHER||PROSPECTIVE|||||||
34041743|NCT03721874|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study|t|f|t|f
34041744|NCT05111912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041745|NCT00802230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041746|NCT05565833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041747|NCT04050163|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Single/participant blinded|Sequential dose escalating|t|f|f|f
34041748|NCT02364830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041749|NCT05709574|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041750|NCT05951803|NA|SINGLE_GROUP||TREATMENT||NONE|in data analysis, an external investigator will be asked to perform randomization and data processing.|Randomized controlled trial of equivalence with two groups in parallel (1:1) with repeated measures in pretreatment, posttreatment and follow-up at 3 months||||
34041751|NCT05090436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34041752|NCT04287257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041753|NCT03268226|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34041754|NCT00780884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041755|NCT05459246|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Virtual reality glasses and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
34041756|NCT03445741|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to three groups in parallel for the duration of the study.||||
34041757|NCT06159842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041758|NCT00874874|NON_RANDOMIZED|||TREATMENT||||||||
34041759|NCT02962492|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34041760|NCT02678169|||COHORT||PROSPECTIVE|||||||
34041761|NCT04613921|||CASE_CONTROL||PROSPECTIVE|||||||
34041762|NCT01137149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041763|NCT06170476|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041764|NCT02954601|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34041765|NCT01209520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041766|NCT04821180|||OTHER||PROSPECTIVE|||||||
34041767|NCT05519826|||COHORT||RETROSPECTIVE|||||||
34041768|NCT04227197|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34041769|NCT01829100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041770|NCT02550379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34041771|NCT00470717|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041772|NCT04402762|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, open-label, 2-way cross-over, single-dose study with at least 7 days wash-out period.||||
34041773|NCT04553822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)|Single-blind randomized controlled trial|f|f|f|t
34041774|NCT01073605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041775|NCT00126828|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041776|NCT00643474|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041777|NCT06292845|NA|SINGLE_GROUP||OTHER||NONE||||||
34041778|NCT02594293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041779|NCT01323387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041780|NCT03793205|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF.||||
34041781|NCT05486195|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34041782|NCT00092118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041783|NCT00312689|||DEFINED_POPULATION||PROSPECTIVE|||||||
34041784|NCT05914662|NA|SINGLE_GROUP||TREATMENT||NONE||Patients were treated with ZBR regimen for 6 cycles, followed by Zanubrutinib monotherapy for 6 months.||||
34041785|NCT04138537|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|OB measurements were done in a single-blinded method.||f|f|t|f
34041786|NCT02927236|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34041787|NCT00321698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041788|NCT06578481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041789|NCT04921826|||OTHER||PROSPECTIVE|||||||
34041790|NCT05741801|||COHORT||CROSS_SECTIONAL|||||||
34041791|NCT01657721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041792|NCT00577746|||COHORT||PROSPECTIVE|||||||
34041793|NCT00683618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041794|NCT04968080|||COHORT||PROSPECTIVE|||||||
34041795|NCT00425750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041796|NCT00753285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041797|NCT04528940|||COHORT||PROSPECTIVE|||||||
34041798|NCT04390490|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34041799|NCT04916054|||COHORT||RETROSPECTIVE|||||||
34041800|NCT02883205|||||PROSPECTIVE|||||||
34115001|NCT04856878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115002|NCT03195569|||CASE_CONTROL||PROSPECTIVE|||||||
34115003|NCT02143284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115004|NCT03332030|||COHORT||OTHER|||||||
34150200|NCT00000713||||TREATMENT||||||||
34150201|NCT02066129|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150202|NCT00812903|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34150203|NCT04455945|||COHORT||PROSPECTIVE|||||||
34150204|NCT04337008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34115005|NCT05332704|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"This is a double-blind study.~The pharmacist will be unblinded and is responsible for preparing blinded drug for administration."|"This is a phase I, multi-centre study to assess the safety, tolerability, PK \& PD of ONO-4685. This study consists of: Part A single ascending dose, Part B an assessment of multiple doses \& Part C to undertake initial assessment of efficacy with multiple doses.~The study will recruit patients, male \& female, with mild or moderate psoriasis diagnosed for at least 6 months. Following screening activities, patients are admitted to a clinical unit 1 day ahead of dosing and will stay at the unit for 4 nights. For patients receiving multiple doses, they will attend the clinic on the day of dosing and will stay for 3 nights. All patients will be followed up, for up to 24 weeks from 1st dose.~The study will recruit 6 patients per cohort for part A \& B and 18 patients per cohort for part C. The overall active to placebo ratio will be 2:1."|t|f|t|f
34115006|NCT05458531|||OTHER||CROSS_SECTIONAL|||||||
34115007|NCT00058747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115008|NCT01021800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115009|NCT05744414|||COHORT||PROSPECTIVE|||||||
34115010|NCT05114928|||COHORT||RETROSPECTIVE|||||||
34115011|NCT04588610|||COHORT||PROSPECTIVE|||||||
34115012|NCT01511302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115013|NCT01649193|||COHORT||PROSPECTIVE|||||||
34115014|NCT06505226|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Screening prior to the consent process will include assessing the age and relevant medical history of each prospective participant.||||
34115015|NCT04658485|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|The subjects are pseudo randomly allocated to either the active stimulation group or the sham stimulation group (placebo), ensuring equal weighting of male and female in the two groups. The care provider is handed the tDCS device which is preprogrammed by a third party either deliver the active or the sham stimulation based on the participation ID-number, effectively blinding the care provider. The outcome assessor and investigator is similarly blinded to the protocol administered to the participants.||t|t|t|t
34115016|NCT00642291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115017|NCT02196350|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34115018|NCT05957627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115019|NCT01474109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115020|NCT01198626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115021|NCT02690142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115022|NCT03372616|||COHORT||CROSS_SECTIONAL|||||||
34115023|NCT03474276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728432|NCT03862664|||COHORT||RETROSPECTIVE|||||||
33728433|NCT03365206|||CASE_ONLY||PROSPECTIVE|||||||
33728434|NCT02062307|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728435|NCT00006012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728436|NCT01564303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33728437|NCT06308991|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"The order of the 2 different touching methods and routine care practices to be applied to the infants in the research group was determined by randomized method and 3 groups were created. Considering the order of application in each group, it was decided which touch method and routine care would be applied to the infants. Both touch techniques and routine care practices were applied once to each infant.~Group 1: Yakson touch, Routine care, Gentle HumanTouch Group 2: Routine care, Gentle HumanTouch, Yakson touch Group 3: Gentle HumanTouch, Yakson touch, Routine care"|t|f|f|t
33728438|NCT01468766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728439|NCT06162754|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33728440|NCT00978328|||COHORT||PROSPECTIVE|||||||
33728441|NCT01876485|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33728442|NCT02245243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728443|NCT04468932|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The subjects will be blinded to the order of intervention, but the PI will not be blinded in order to perform the TMS intervention. The outcome evaluators will be blinded to the intervention, however.|The investigators will use a single-blind crossover design with a 4 week TMS washout period. The subjects will serve as their own controls, thus limiting confounding variables such as medication or cognitive effect.|t|t|f|t
33728444|NCT02581696|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
33728445|NCT05420558|||COHORT||PROSPECTIVE|||||||
33728446|NCT03919461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728447|NCT04675216|||COHORT||PROSPECTIVE|||||||
33728448|NCT00081614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33728449|NCT03622892|||COHORT||PROSPECTIVE|||||||
33728450|NCT00649675|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33728451|NCT03688412|||COHORT||PROSPECTIVE|||||||
33728452|NCT01596764|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33728453|NCT05349149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and investigators will be blinded to the infusion of saline or tocilizumab|Randomized, placebo-controlled, double-blind|t|f|t|f
33728454|NCT02310139|||COHORT||PROSPECTIVE|||||||
33728455|NCT00560690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728456|NCT01515683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728457|NCT05678062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728458|NCT00323973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728459|NCT01503827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728460|NCT01552239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728461|NCT03203902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants receiving sham and authentic therapeutic touch will be masked.|Three arm, randomized controlled design|t|f|f|f
33728462|NCT04049539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728463|NCT04409288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728464|NCT01220271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728465|NCT01127750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728466|NCT03389464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728467|NCT03323489|NA|SINGLE_GROUP||TREATMENT||NONE||all of the patients will be treated.||||
33728468|NCT02835274|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33728469|NCT00914030|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728470|NCT02903667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810244|NCT06032689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||participants had at least four class II cavities in a split-mouth design and randomly each cavity was restored using one of four strategies( groups applied)|t|f|t|f
33810245|NCT00012688|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||||||
33810246|NCT04751097|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810247|NCT00392197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115024|NCT00062764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115025|NCT02146378|||CASE_ONLY||OTHER|||||||
34115026|NCT03207347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in both cohorts will receive niraparib.||||
34115027|NCT00763828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115028|NCT06304415|||COHORT||PROSPECTIVE|||||||
34115029|NCT05938686|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115030|NCT06281418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115031|NCT01259258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115032|NCT06518304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115033|NCT04844333|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34115034|NCT05815602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115035|NCT00789555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115036|NCT02786407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115037|NCT01416350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34115038|NCT00640003|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34115039|NCT01891955|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115040|NCT02552225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115041|NCT03350945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34115042|NCT01937065|||COHORT||RETROSPECTIVE|||||||
34115043|NCT04600284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115044|NCT02518529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115045|NCT02897336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115046|NCT00794430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115047|NCT00243035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115048|NCT03017001|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34115049|NCT04806152|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34115050|NCT03651206|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 2 :~Arm A - Niraparib~Arm B - Niraparib plus TSR-042~Arm C - Chemotherapy drugs~Peak the winner between the Arm A or the arm B~Phase 3:~Arm A: The best arm of the phase 2~Arm B: Chemotherapy drugs"||||
34115051|NCT03573674|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Cluster randomization with stratification allocated groups selected by participating organizations to treatment and control groups. Primary stratification was by the organization. Within-organization stratification took into account the size, the type of work tasks and the response rate in the first survey of cluster. Participating organizations entered all together to 36 clusters, each with individuals for the intervention and active control groups (N=638 individuals). The intervention (and active control) receive different types of workshops, individual tasks and team tasks. Additional information is available from non-randomized passive control group (N=289 individuals).~Participating organizations were recruited by informing about the study. Participating units included knowledge workers, whose work tasks are cognitively rather than physically demanding."||||
34115052|NCT02724839|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115053|NCT03620396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be equally divided into two test groups.Group A consists of Gingivitis patients and Group B consists of Periodontitis patients. Both the group patients have been evaluated for Serum Trefoil factor 3 at baseline and treated with non surgical periodontal therapy. After three months both the group patients were again assessed for serum trefoil factor 3.|f|f|f|t
34115054|NCT01726764|NA|SINGLE_GROUP||||NONE||||||
34115055|NCT03707821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115056|NCT04013178|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups in parallel for the duration of the study||||
34115057|NCT03342560|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810248|NCT03260998|||CASE_CONTROL||PROSPECTIVE|||||||
33810249|NCT05445050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810250|NCT02381028|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33810251|NCT03167008|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810252|NCT01068977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810253|NCT06315868|||COHORT||PROSPECTIVE|||||||
33810254|NCT04214457|||COHORT||PROSPECTIVE|||||||
33810255|NCT03026166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810256|NCT00390845|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33810257|NCT00315185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810258|NCT03210324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33810259|NCT00446368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810260|NCT04057261|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Single center, prospective, placebo-controlled, double-blind, randomized, 2 arm parallel, interventional, exploratory pilot study|t|t|t|t
33810261|NCT05352737|||CASE_CONTROL||RETROSPECTIVE|||||||
33810262|NCT01841515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115058|NCT00710099|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115059|NCT00004419||||TREATMENT||NONE||||||
34115060|NCT00718432|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34115061|NCT06388629|NA|SINGLE_GROUP||OTHER||NONE||Prospective, non-randomized||||
34115062|NCT01923922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115063|NCT03657121|||COHORT||PROSPECTIVE|||||||
34115064|NCT00719368|||COHORT|||||||||
34115065|NCT04186832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115066|NCT05678140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researcher will not know which treatment is applied to the patients. The physiotherapist who gives the treatment will not know the results of the research.|randomızed controlled trıal|f|t|t|f
34115067|NCT02437318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115068|NCT04778202|||CASE_CONTROL||PROSPECTIVE|||||||
34115069|NCT01300637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150205|NCT05980338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33810263|NCT02082002|||CASE_CONTROL||PROSPECTIVE|||||||
33810264|NCT01951703|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33810265|NCT05865366|||COHORT||PROSPECTIVE|||||||
33810266|NCT05594732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants were randomly divided into two groups without knowing the exposing mode.|"The participants were randomly divided into the following two groups:~1. 4000Lux natural light exposure;~2. 10000Lux natural light exposure."|t|f|f|f
33810267|NCT06170125|||OTHER||PROSPECTIVE|||||||
33810268|NCT06272526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33810269|NCT03717207|||COHORT||RETROSPECTIVE|||||||
33810270|NCT01844401|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810271|NCT00879632|||COHORT||PROSPECTIVE|||||||
33810272|NCT01480375|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115070|NCT06639789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||A randomized crossover study will be conducted in which 18 subjects will perform the following conditions: B12) 1 mg/d vitamin B12; PLA) 200 mg/d placebo (microcrystalline cellulose) 3 days before physical and cognitive performance tests.|t|f|t|f
34115071|NCT02302287|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115072|NCT03281213|||OTHER||RETROSPECTIVE|||||||
34115073|NCT02167776|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34115074|NCT03952845|NA|SINGLE_GROUP||OTHER||NONE||In brief, three consecutive patients will receive the initial intervention dose, and complete a post-intervention assessment. Subsequent cohorts receive escalating doses that are determined in advance (see below). If no patients in the initial cohort experience a dose limiting toxicity, three new patients will be recruited into the subsequent cohort and each will receive the escalated dose. This process continues on until at least one patient in a cohort experiences a dose limiting toxicity. When this occurs, three new patients will be recruited but will receive the same dose as the patient who experienced a dose limiting toxicity. If no patients in this new cohort experience a dose limiting toxicity, three additional patients will be recruited and will receive the next predetermined escalated dose. However, if two of six patients experience a dose limiting toxicity, the trial is considered complete and the dose these six patients received is considered the maximum tolerated dose.||||
34115075|NCT05308810|||COHORT||RETROSPECTIVE|||||||
34115076|NCT00616720|RANDOMIZED|||TREATMENT||||||||
34115077|NCT00145730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34115078|NCT06564415|||COHORT||PROSPECTIVE|||||||
34115079|NCT05819359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115080|NCT06431880|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34115081|NCT06026098|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34115082|NCT05558904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115083|NCT01737905|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34115084|NCT06060535|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Clinics are the unit of randomization, all behavioral health clinics will be randomized, over the course of three waves, to cross over from usual care to intervention (implementation of the suicide risk model).||||
34115085|NCT05438147|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Active Intervention Device vs. Care-as-Usual Control||||
34115086|NCT00808873|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34115087|NCT00928668|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34115088|NCT03093714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115089|NCT00486096|||||RETROSPECTIVE|||||||
34115090|NCT01731782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34115091|NCT03360994|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115092|NCT05577156|||OTHER||PROSPECTIVE|||||||
34115093|NCT03534492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115094|NCT00415636|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115095|NCT00419744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115096|NCT04868422|RANDOMIZED|PARALLEL||TREATMENT||NONE||The Ethics Committee approval was not required, since this study was part of our quality assurance procedure to revise the treatment protocol.||||
34115097|NCT06187389|||CASE_ONLY||RETROSPECTIVE|||||||
34115098|NCT00475098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115099|NCT04687930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115100|NCT01358162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115101|NCT04822103|||COHORT||RETROSPECTIVE|||||||
34115102|NCT05151926|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial||||
34115103|NCT05014984|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study staff, investigators, and outcome assessors will be blinded to the intervention arm. The lay health coach interventionist and the participant will not be blinded.|This is a randomized controlled trial|f|t|t|t
34115104|NCT06055283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115105|NCT02693756|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115106|NCT04064905|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Observer blind||t|t|t|f
34115107|NCT06075784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34115108|NCT00003888|RANDOMIZED|||TREATMENT||||||||
34115109|NCT01463033|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810273|NCT05693194|||COHORT||PROSPECTIVE|||||||
33810274|NCT03385291|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810275|NCT05019859|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33810276|NCT03138720|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|There will be two treatment groups: those who are deemed resectable and those that are deemed borderline resectable and with locally advanced pancreas cancer.||||
33810277|NCT03138005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810278|NCT05766943|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33810279|NCT03001635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810280|NCT00987324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810281|NCT06459167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810282|NCT01279707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810283|NCT02950961|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33810284|NCT00856362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810285|NCT03150758|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33810286|NCT02188602|||COHORT||RETROSPECTIVE|||||||
34115110|NCT02494414|||COHORT||PROSPECTIVE|||||||
34115111|NCT03901040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115112|NCT05903079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The researcher will receive equipment already programmed by a research assistant, so the researcher who will deliver the tDCS to perform stimulation will not know the programed stimulation. Patients will be instructed to discuss aspects of treatment with the respective investigator. Two independent evaluators who will not participate in the consultations where guidance on the use of tDCS will be provided will be trained to make outcome assessments in follow-up. Patients will not be aware of the type of intervention received, since the sham condition produces a stimulus, but no expected effects. In order to study the level of the blinding, at each moment of evaluation, the patient will be asked about the type of intervention that he / she believes to have received (active or simulated), and about the degree of safety in the response, using a standardized questionnaire. The blinding will be evaluated at the end of each treatment week by means of a standardized instrument.|Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial|t|t|t|t
34115113|NCT00800826|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34115114|NCT03947957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Infants will be included between the 2nd visit to the CRCM (about 2 months of age) and the 6th month then they will be followed until the age of 36 months. The pace of visits will be based on the usual follow-up rate of CF infants.||||
34115115|NCT04513236|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomized to one of three airtime incentive timings: 1) no incentive; 2) 0.1X incentive received before the IVR noncommunicable disease risk factor survey is sent, followed by 1X incentive upon completing the survey; or 3) 1X incentive received upon completing the survey.|f|f|f|t
34115116|NCT03537703|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Sham tDCS|Parallel Assignment|t|f|f|f
34115117|NCT06164054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115118|NCT04870983|||COHORT||PROSPECTIVE|||||||
34115119|NCT04390282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115120|NCT04902612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115121|NCT04798677|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Ramdomized, double-blinded and placebo-controlled|Single-center, randomized, double-blinded, placebo-controlled clinical study. Multicomponent intervention (clinical and nutritional) resulting from the administration of influenza or Covid-19 vaccine and supplementation with ABBC-1.|t|t|t|f
34115122|NCT05434923|||OTHER||CROSS_SECTIONAL|||||||
34115123|NCT05459662|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34115124|NCT02692573|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34115125|NCT04271293|||COHORT||PROSPECTIVE|||||||
34115126|NCT01931644|||COHORT||CROSS_SECTIONAL|||||||
34115127|NCT01153516|||CASE_CROSSOVER||PROSPECTIVE|||||||
34115128|NCT04747301|RANDOMIZED|PARALLEL||TREATMENT||NONE||Low-risk pregnant women eligible for study will be asked to sign the informed consent form. Then, they will be randomly assigned in a 1:1 ratio to receive either double balloon insertion or vaginal prostaglandin E2||||
34115129|NCT06028750|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34115130|NCT04927221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant, Investigator|Participants are assigned to one of 5 groups in parallel for the duration of the study|t|f|f|f
34115131|NCT00924092|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115132|NCT00696605|||OTHER||PROSPECTIVE|||||||
34115133|NCT05569317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT||||
34115134|NCT02327169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115135|NCT00600340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115136|NCT05159050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115137|NCT02675400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115138|NCT01651988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34115139|NCT04448951|||CASE_CONTROL||PROSPECTIVE|||||||
34115140|NCT03680521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115141|NCT04885621|||CASE_ONLY||PROSPECTIVE|||||||
34115142|NCT03755193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115143|NCT04253600|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34115144|NCT05405270|||COHORT||PROSPECTIVE|||||||
34115145|NCT02006927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115146|NCT00286286|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34115147|NCT04618094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34115148|NCT01969214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115149|NCT06569862|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34115150|NCT06594705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115151|NCT01155050|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study randomized consenting subjects to four arms for evaluation of different weight loss strategies.||||
34115152|NCT02544048|||COHORT||PROSPECTIVE|||||||
34115153|NCT04081285|||COHORT||CROSS_SECTIONAL|||||||
34115154|NCT05433142|NA|SEQUENTIAL||TREATMENT||NONE||||||
34115155|NCT06032182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115156|NCT05253378|||COHORT||PROSPECTIVE|||||||
34115157|NCT02935764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115158|NCT00568009|||COHORT||PROSPECTIVE|||||||
34115159|NCT06547931|||COHORT||RETROSPECTIVE|||||||
34115160|NCT01194596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34115161|NCT01139151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115162|NCT04809337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115163|NCT05119816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728471|NCT01398111|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33728472|NCT01892930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810287|NCT00986869|||CASE_ONLY||PROSPECTIVE|||||||
33810288|NCT00380250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115164|NCT06572072|||OTHER||OTHER|||||||
33728473|NCT06111365|||COHORT||PROSPECTIVE|||||||
33728474|NCT05461131|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728475|NCT04497233|||CASE_ONLY||OTHER|||||||
33728476|NCT05082077|||COHORT||CROSS_SECTIONAL|||||||
33728477|NCT00984854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728478|NCT01991171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810289|NCT00927966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810290|NCT01112800|||COHORT||PROSPECTIVE|||||||
34115165|NCT05568862|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115166|NCT01135966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115167|NCT00922857||PARALLEL||BASIC_SCIENCE||NONE||||||
34115168|NCT03808571|||CASE_CONTROL||PROSPECTIVE|||||||
34115169|NCT01823055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115170|NCT04436744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115171|NCT04311450|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34115172|NCT02578901|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115173|NCT04821167|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective study conducted to evaluate the safety and efficiency of laparoscopic orchiopexy of intra-canalicular (emergent/peeping) testis.||||
34115174|NCT05629871|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115175|NCT03146260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115176|NCT00785720|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34115177|NCT02767076|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34115178|NCT03899415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115179|NCT00966108|||COHORT||PROSPECTIVE|||||||
34115180|NCT00002193||PARALLEL||TREATMENT||||||||
34115181|NCT04942002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants won't be aware to which group they were assigned. Investigator in charge of assessing outcomes and analyzing data won't be aware to which group participants were assigned.|"Randomized groups (2)~1. Standard treatment + placebo~2. Standard treatment + intervention"|t|f|f|t
34115182|NCT00647088|||CASE_CONTROL||PROSPECTIVE|||||||
34115183|NCT04648020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34115184|NCT01891279|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34115185|NCT02558166|||COHORT||PROSPECTIVE|||||||
34115186|NCT00406926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115187|NCT00004157||||TREATMENT||||||||
34115188|NCT06165055|||COHORT||PROSPECTIVE|||||||
34115189|NCT05383742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115190|NCT01786122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115191|NCT02894398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115192|NCT02447692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115193|NCT01195974|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
34115194|NCT00799565|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34115195|NCT01295047|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34115196|NCT01731145|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115197|NCT04730388|||COHORT||PROSPECTIVE|||||||
34115198|NCT01302886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115199|NCT02133573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115200|NCT03229538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115201|NCT00822952|||CASE_ONLY||PROSPECTIVE|||||||
34115202|NCT03869112|RANDOMIZED|PARALLEL||OTHER||NONE||A feasibility study with three groups. two interventional groups and one control.||||
34115203|NCT04908293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115204|NCT02279927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115205|NCT03152448|||COHORT||PROSPECTIVE|||||||
34115206|NCT02501447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115207|NCT04316416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34115208|NCT01291589|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115209|NCT04756453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115210|NCT03144284|||COHORT||CROSS_SECTIONAL|||||||
34115211|NCT05165472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, sham-controlled, patient- and evaluator-blind, two-centre, parallel group study|t|f|f|t
33728479|NCT01997268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115212|NCT05216133|||COHORT||PROSPECTIVE|||||||
34115213|NCT01693367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115214|NCT00773188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115215|NCT03164161|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34115216|NCT00439114|||DEFINED_POPULATION||OTHER|||||||
34115217|NCT00004200|RANDOMIZED|||TREATMENT||||||||
34115218|NCT02878382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115219|NCT04361279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115220|NCT03499756|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34115221|NCT00664222|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34115222|NCT05140421|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Stepped-wedge design: To isolate the effects of D2S on viral suppression, the investigators will randomize (within matched pairs and one trio) 27 RWPA-funded behavioral health and housing services provider agencies to immediate or delayed implementation of D2S (12 months apart).||||
34115223|NCT01090596|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34115224|NCT01150357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115225|NCT04970914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728480|NCT03028818|||COHORT||PROSPECTIVE|||||||
33728481|NCT06392243|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33728482|NCT02857452|||COHORT||PROSPECTIVE|||||||
33728483|NCT05410626|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
33810291|NCT05582824|||COHORT||PROSPECTIVE|||||||
34115226|NCT02083757|||||PROSPECTIVE|||||||
34115227|NCT01170663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115228|NCT04103450|NA|SINGLE_GROUP||TREATMENT||NONE||Long-term extension||||
34115229|NCT04555759|NA|SINGLE_GROUP||OTHER||NONE||||||
34115230|NCT03758183|||COHORT||RETROSPECTIVE|||||||
34115231|NCT05014152|NA|SINGLE_GROUP||OTHER||NONE||||||
34115232|NCT05802901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Three groups of participants receive one of three different interventions. One group receives spinal manipulation only, another group receives dry needling only, and the last group receives the combination of spinal manipulation and dry needling. Participants in each group receive their respective treatment in parallel with the other groups.|f|f|t|t
33810292|NCT02597166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810293|NCT00998517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33810294|NCT04572867|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Controlled Trial with two arms (aquapheresis and IV diuretics/Control), but there is the potential for cross-over to aquapheresis if a patient receiving diuretics is refractory to maximum doses of IV diuretics.||||
33810295|NCT01523392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810296|NCT02604251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810297|NCT01097954|||CASE_ONLY||PROSPECTIVE|||||||
33810298|NCT02067663|||COHORT||PROSPECTIVE|||||||
33810299|NCT01653652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810300|NCT04490694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810301|NCT04566185|||COHORT||PROSPECTIVE|||||||
33810302|NCT03004989|||||RETROSPECTIVE|||||||
33810303|NCT06478979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115233|NCT01695603|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34115234|NCT00312286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115235|NCT04399421|||COHORT||PROSPECTIVE|||||||
34115236|NCT06564805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34115237|NCT04267445|||CASE_ONLY||PROSPECTIVE|||||||
34115238|NCT01270529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115239|NCT02946996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115240|NCT00953628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34115241|NCT01128478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115242|NCT02815163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34115243|NCT03841279|||COHORT||PROSPECTIVE|||||||
34115244|NCT02428829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115245|NCT00006427|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34115246|NCT02051192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115247|NCT01055028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115248|NCT05458739|||COHORT||PROSPECTIVE|||||||
34115249|NCT03896633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34115250|NCT05523908|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two parallel group with each of 18 patients. One group would receive high-dose hypofraction radiotherapy of 60Gy/15f and the other group would receive low-dose hypofraction radiotherapy of 48Gy/12f.||||
34115251|NCT05504499|NA|SINGLE_GROUP||TREATMENT||NONE||This clinical investigation is a prospective, open-label, non-randomized, multi-center study. It is designed to collect clinical follow-up data on patients undergoing interspinous interlaminar fusion with bone graft performed on an ambulatory basis by interventional pain physicians, orthopedic, and neurosurgeons, as normally performed in the real-world setting.||||
34115252|NCT03556891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115253|NCT02587910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115254|NCT04781491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115255|NCT00687076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34115256|NCT04498546|||OTHER||PROSPECTIVE|||||||
34115257|NCT05513963|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized-Control Trial||||
34115258|NCT00760552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34115259|NCT02429960|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115260|NCT00730327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33810304|NCT00726505|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810305|NCT03179046|||CASE_ONLY||CROSS_SECTIONAL|||||||
33810306|NCT00003259||||TREATMENT||||||||
33810307|NCT01427517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810308|NCT04816305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810309|NCT00105846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810310|NCT00348361|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33810311|NCT01246804|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33810312|NCT02843100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810313|NCT05858359|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized waitlist controlled trial||||
34115261|NCT00738127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33810314|NCT03608111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810315|NCT04290741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33810316|NCT00220532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33810317|NCT00667732|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33810318|NCT04422392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810319|NCT04741009|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33810320|NCT00253266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810321|NCT01829711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115262|NCT02012634|||CASE_CONTROL||PROSPECTIVE|||||||
34115263|NCT02733757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115264|NCT02972307|||CASE_ONLY||CROSS_SECTIONAL|||||||
34115265|NCT04476784|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34115266|NCT01071161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115267|NCT03820076|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double blind||t|t|t|t
34115268|NCT02641184|||COHORT||PROSPECTIVE|||||||
34115269|NCT04473560|||CASE_CONTROL||PROSPECTIVE|||||||
34115270|NCT02083367|||CASE_CONTROL||PROSPECTIVE|||||||
34115271|NCT03426527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34115272|NCT06561282|||COHORT||PROSPECTIVE|||||||
34115273|NCT05772871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115274|NCT01605097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115275|NCT01109433|||CASE_CONTROL||PROSPECTIVE|||||||
34115276|NCT02789982|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115277|NCT04044157|||COHORT||PROSPECTIVE|||||||
34115278|NCT03735355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115279|NCT02128776|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34115280|NCT04389697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34115281|NCT01397253|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33728484|NCT00275210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728485|NCT01567761|||||PROSPECTIVE|||||||
33728486|NCT00112242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728487|NCT03585452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients were not aware of the fact into which group they were divided|Patients were randomly divided into two groups by simple 1:1 randomisation using opaque envelopes: the control group (group CON; patients with typical anaesthetic regimens) and the dexmedetomidine group (group DEX; those with additional dexmedetomidine infusion).|t|f|f|f
33728488|NCT01719185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728489|NCT00578942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728490|NCT01139528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728491|NCT02957175|||COHORT||PROSPECTIVE|||||||
33728492|NCT05230212|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Involved researchers and participants are blinded to which breakfast shake they are administering and/or receiving.|This trial will be a double-blinded, randomized, cross-over design. There will be 2 testing visits in which each participant will be randomized to receive either the control (cream) shake or the pecan shake at visit 1; they will receive the opposing shake at visit 2. There will be a 6-8 day washout period between visit 1 and visit 2.|t|f|t|f
33728493|NCT02502266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728494|NCT03532464|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, multicenter||||
33728495|NCT04484324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treating therapist, for both the control and intervention groups, was unblinded to the treatment method but the subjects and assessor who conducted the measurements were blinded. Assessor blinding was obtained through an independent research assist; not knowing the study design and not specifically involved in any aspect of the tria|A prospective, double blinded, parallel-group, randomized clinical trial was conducted at one of our university's research departments,|t|f|f|t
33728496|NCT03740425|||COHORT||RETROSPECTIVE|||||||
33728497|NCT03756610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728498|NCT02945527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728499|NCT06424054|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is a open label study since blinding is not possible as healthcare professionals will receive the CTC gradation based on the reported side effects in the intervention group and are obligated to act on these reports.|A clinical randomized controlled trial will be performed in 746 breast cancer patients treated with (neo-)adjuvant chemotherapy. Patients will be randomized to the intervention group, using the eChemoCoach in addition to standard of care monitoring to manage side effects or are randomized to solely standard of care monitoring.||||
33728500|NCT04862156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728501|NCT05506202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728502|NCT00420524|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728503|NCT05676957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728504|NCT03729531|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728505|NCT06209736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728506|NCT04152512|||COHORT||PROSPECTIVE|||||||
33728507|NCT00367068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728508|NCT02658890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728509|NCT02148172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728510|NCT06166810|||COHORT||PROSPECTIVE|||||||
33728511|NCT05250024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728512|NCT02237170|||COHORT||PROSPECTIVE|||||||
33728513|NCT03489395|NA|SINGLE_GROUP||TREATMENT||NONE||Non-controlled, open-label pilot study.||||
33728514|NCT03575546|||COHORT||RETROSPECTIVE|||||||
33728515|NCT06156592|||COHORT||PROSPECTIVE|||||||
33728516|NCT03606525|||COHORT||PROSPECTIVE|||||||
33728517|NCT02843945|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation Phase I followed by a feasibility trial in Phase II||||
33728518|NCT03784573|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Subjects will be randomized per dog and handler availability, but subjects that are excluded due to an aversion or dogs or per the Child Life staff member, can be in the control group.||||
33728519|NCT04448899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind study||t|f|t|f
33810322|NCT00064883|||COHORT||PROSPECTIVE|||||||
33810323|NCT04171011|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33810324|NCT01229332|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33810325|NCT04346784|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728520|NCT03898661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810326|NCT06275594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810327|NCT04878679|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33810328|NCT05200624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810329|NCT03046706|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research group is the group of patients who do not keep voice rest and talk without restrictions or special instructions after surgery.||||
33810330|NCT00925561|||COHORT||CROSS_SECTIONAL|||||||
33810331|NCT02314975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810332|NCT06154161|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||6-month prospective interventional clinical trial||||
33810333|NCT04914702|||OTHER||PROSPECTIVE|||||||
33810334|NCT06303128|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||"- Low-risk penicillin allergic patients (low-risk determined by a PEN-FAST score of 2 or less) will be recruited. Clinically stable patients will be randomly assigned in a double-blinded manner to receive either a one-dose or graded two-dose direct oral challenge with amoxicillin in an outpatient setting. Those assigned to receive one dose of amoxicillin will receive a placebo in place of a second dose of amoxicillin. Both groups will receive the same cumulative dose of amoxicillin (250mg) by the end of the trial. Baseline vital signs will be obtained and tracked throughout the trial. Patients will also be monitored for development of signs of allergic reactions during the trial, with administration of appropriate treatment should the need arise."|t|t|t|t
33810335|NCT00724009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810336|NCT01436214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838251|NCT00453024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838252|NCT01747551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33838253|NCT00916708|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838254|NCT00154687|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810337|NCT03726593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label clinical trial to evaluate the tolerability and clinical and parasitological responses after treatment of Pf and/or mixed infections (Pf/Pv) in volunteers with uncomplicated malaria. The assignment of volunteers will be 1:1:1 for ASPY (Pyramax), AP+ASPY (AP+Pyramax), and AP+ASMQ. All study drug administration will be by directly observed therapy (DOT).||||
33810338|NCT05396365|||COHORT||CROSS_SECTIONAL|||||||
33810339|NCT04413994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The NEO-VASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial.|f|f|f|t
33810340|NCT05536869|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33810341|NCT04970732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33810342|NCT01976507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115282|NCT01263210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34115283|NCT01943747|||CASE_ONLY||PROSPECTIVE|||||||
34115284|NCT03296982|||COHORT||PROSPECTIVE|||||||
34115285|NCT04462575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115286|NCT03283241|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The devices are delivered single packed and sterile to distributor. The distributor performs blinding, randomization and distribution. The labels are, after blinding of lot number, identical for both the Active and the placebo device.|Parallel groups ration 1;1|t|t|t|f
34115287|NCT02232360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115288|NCT02551588|||CASE_CONTROL||PROSPECTIVE|||||||
34115289|NCT03454035|NA|SINGLE_GROUP||TREATMENT||NONE||This is a standard 3+3 dose escalation design.||||
34115290|NCT00529295|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34115291|NCT05454865|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|double-blind setting|Patients with advanced cancer and moderate to severe cancer-related fatigue were randomized to receive either Jin Si Herbal Tea or a placebo (mimic fluid) for the first treatment cycle (three weeks) in a double-blind manner. On the next cycle (three weeks), all patients received open-label treatment with Jin Si Herbal Tea.|t|t|t|t
34115292|NCT05074914|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115293|NCT03320005|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115294|NCT03842397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115295|NCT04033692|||COHORT||RETROSPECTIVE|||||||
34115296|NCT04028830|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115297|NCT06564584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115298|NCT05554679|RANDOMIZED|PARALLEL||PREVENTION||NONE||metformin effect on prevention of macrosomia in obese pregnant women||||
34115299|NCT03379974|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The randomization of the participant to a study arm will be done prior to the study visit by the pharmacy at the hospital. The Investigator and study team will know the arm each participant is in before the patient's visit. This information will also be provided to the participant before the visit.|||||
34115300|NCT03958331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is 2-arm randomized controlled clinical trial to improve adherence in adolescents with epilepsy|f|f|t|f
34115301|NCT00457626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115302|NCT03469739|||OTHER||CROSS_SECTIONAL|||||||
34115303|NCT04991948|NA|SEQUENTIAL||TREATMENT||NONE||||||
34115304|NCT02568657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115305|NCT04069988|RANDOMIZED|PARALLEL||OTHER||SINGLE|The data of the five metabolic indexes, height, and bodyweight were collected by a research assistant.|The participants were divided into experimental and control groups through block randomization.|t|f|f|f
34115306|NCT00355043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115307|NCT04626934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and the team that assess the patients do not know to which group the patients have been assigned|Randomized double blinded study|t|f|f|t
34115308|NCT00420186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728521|NCT06042036|||COHORT||PROSPECTIVE|||||||
33728522|NCT06307275|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33810343|NCT02405000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810344|NCT06167421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810345|NCT00410748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810346|NCT00362960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810347|NCT01217736|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33810348|NCT03559959|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33810349|NCT02516085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810350|NCT00668226|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33810351|NCT06501950|||COHORT||PROSPECTIVE|||||||
33810352|NCT01355445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838255|NCT00769600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838256|NCT03984513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Coordinator who is assessing goals of participants is masked from knowing which group each participant was randomized to.|Randomized Clinical Trial - A study in which the participants are divided by chance into separate groups that compare different treatments or other interventions.|f|f|f|t
33838257|NCT01475747|||COHORT||PROSPECTIVE|||||||
33838258|NCT01287325|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34115309|NCT04697927|||COHORT||PROSPECTIVE|||||||
34115310|NCT02873728|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34115311|NCT01734902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115312|NCT06544460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115313|NCT05826509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728523|NCT06343844|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728524|NCT02832310|||CASE_ONLY||PROSPECTIVE|||||||
33728525|NCT03447665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individuals coding videosomnography are blinded to the participant's condition.|Families are randomly assigned to one of three groups: control, bedtime only (intervention), or all night (intervention).|f|f|f|t
33728526|NCT02076412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728527|NCT02732834|||COHORT||CROSS_SECTIONAL|||||||
33728528|NCT05605665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728529|NCT00816725|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33728530|NCT02531321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115314|NCT00841815|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34115315|NCT02092714|||COHORT||CROSS_SECTIONAL|||||||
34115316|NCT04272801|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, 1 arm||||
34115317|NCT03859219|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115318|NCT05900752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34115319|NCT01015950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115320|NCT03732755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115321|NCT01895192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115322|NCT05002725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This will be a double blinded study where patients and assessors are blinded to the technique used. The operator performing the block cannot be blinded. It will not be possible to tell from the appearance of the catheter whether it is a femoral nerve catheter or PENG catheter||t|f|t|t
34115323|NCT02000102|||COHORT||RETROSPECTIVE|||||||
34115324|NCT00855361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115325|NCT06032130|||CASE_CONTROL||PROSPECTIVE|||||||
34115326|NCT01837355|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34115327|NCT04450732|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Modified 3+3 Design||||
34115328|NCT05368883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34115329|NCT06642077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This randomized controlled experimental study was conducted with a total of 60 patients, with 30 patients in the experimental group and 30 patients in the control group.|t|t|t|t
34115330|NCT03532360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized to one of three groups: a control group that will receive no treatment, a low-dose group and a high dose group. Participants in the latter two groups will be blinded as to what group they have been assigned|Randomized controlled trial|t|f|f|f
34115331|NCT03498716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115332|NCT01350323|NON_RANDOMIZED|PARALLEL||||NONE||||||
34115333|NCT06564493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115334|NCT03612570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115335|NCT01226108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115336|NCT00001066||||TREATMENT||DOUBLE||||||
34115337|NCT03278522|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34115338|NCT06189794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pregnant women won't be introduced which essential oil would be used.||t|f|f|f
34115339|NCT03910075|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34115340|NCT03362671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115341|NCT05245903|||CASE_ONLY||CROSS_SECTIONAL|||||||
34115342|NCT02947971|NA|SINGLE_GROUP||OTHER||NONE||||||
34115343|NCT05975424|||COHORT||PROSPECTIVE|||||||
34115344|NCT05903703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115345|NCT02193529|||CASE_ONLY||RETROSPECTIVE|||||||
34115346|NCT02094391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115347|NCT01418521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115348|NCT06232616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115349|NCT04786964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115350|NCT06015932|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115351|NCT04870866|NA|SINGLE_GROUP||TREATMENT||NONE||Open label proof of concept||||
34115352|NCT03237884|||COHORT||PROSPECTIVE|||||||
34115353|NCT06014762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115354|NCT01675947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115355|NCT03950856|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34115356|NCT01395745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115357|NCT02224339|||COHORT||PROSPECTIVE|||||||
34115358|NCT03158831|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective interventional study whereby each eligible patient undergoes a placebo-controlled graded challenge. Each patient receives a placebo prior to undergoing a graded challenge to 1/10 the treatment dose of the challenge drug followed by a full treatment dose of the challenge drug.||||
34115359|NCT02822664|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115360|NCT01359124|||COHORT||PROSPECTIVE|||||||
34115361|NCT05326737|||COHORT||PROSPECTIVE|||||||
34115362|NCT01606618|||COHORT||PROSPECTIVE|||||||
34115363|NCT04765098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115364|NCT02164409|||COHORT||PROSPECTIVE|||||||
34115365|NCT01405430|NA|SINGLE_GROUP||||NONE||||||
34115366|NCT04924348|RANDOMIZED|PARALLEL||PREVENTION||NONE||Interventional, prospective, therapeutic, comparative, randomized controlled open-label, non-inferiority, single-center, national study.||||
34115367|NCT04882943|||COHORT||PROSPECTIVE|||||||
34115368|NCT00247546|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34115369|NCT00846157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115370|NCT04275804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115371|NCT06267417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The outcome evaluator will be a single personnel from the oncology team following up with the case||t|f|f|t
34115372|NCT05006066|||COHORT||PROSPECTIVE|||||||
34115373|NCT01107132|||COHORT|||||||||
34115374|NCT03014635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115375|NCT05731609|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33728531|NCT01571661|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34115376|NCT06412887|RANDOMIZED|CROSSOVER||PREVENTION||NONE|The subjects were informed regarding which input system was to be used|Subjects play the virtual reality game using the wfc input system followed by the wofc input system||||
34115377|NCT04461886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115378|NCT01239940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115379|NCT01966146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115380|NCT04989361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115381|NCT02102009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115382|NCT02150707|||COHORT||PROSPECTIVE|||||||
34115383|NCT00270387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115384|NCT02354521|||COHORT||PROSPECTIVE|||||||
34115385|NCT03404180|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pilot clinical trial with a single arm||||
33728532|NCT00366847|||COHORT||RETROSPECTIVE|||||||
33728533|NCT05206474|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open-Label, non-comparative||||
33728534|NCT05548192|||COHORT||PROSPECTIVE|||||||
33728535|NCT04907032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728536|NCT03528746|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded to the study hypothesis|The proposed study is a participant blinded, randomised crossover superiority trial, to examine acute effect of isometric versus isotonic resistance exercise on pain in patients with patellar tendinopathy.|t|f|f|f
33728537|NCT00894335|||COHORT||PROSPECTIVE|||||||
33728538|NCT01339351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728539|NCT04400396|||COHORT||OTHER|||||||
34115386|NCT01958749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728540|NCT02027844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728541|NCT01723163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728542|NCT00445510|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33728543|NCT02691286|||CASE_CONTROL||PROSPECTIVE|||||||
33728544|NCT04606979|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||sham-controlled, counterbalanced study|t|t|f|f
33728545|NCT04332289|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728546|NCT04827043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After approval of The InstitutionalEthics Committee of The National Cancer Institute ,Cairo University, 50 patients scheduled for gynacological cancer surgery will be enrolled in this study|A prospective randomized comparative study|t|t|t|t
33728547|NCT04357210|||COHORT||RETROSPECTIVE|||||||
33728548|NCT05686265|||CASE_CONTROL||PROSPECTIVE|||||||
33728549|NCT02935465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728550|NCT05886959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33728551|NCT00153400|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Low income uninsured and underinsured participants.|Provide Health coaching and Lifestyle programs||||
33728552|NCT01116232|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728553|NCT01520363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728554|NCT02492139||SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33728555|NCT01889316|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728556|NCT01556204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728557|NCT00476450|||OTHER||PROSPECTIVE|||||||
33728558|NCT01301872|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33728559|NCT03601754|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728560|NCT02838212|||COHORT||RETROSPECTIVE|||||||
33728561|NCT01581463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728562|NCT02281552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728563|NCT03530475|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33728564|NCT03894878|||COHORT||RETROSPECTIVE|||||||
33728565|NCT00136084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728566|NCT04296552|NA|SINGLE_GROUP||TREATMENT||NONE||The study is an open, single-centre, case-control characterisation study, followed by open label dietary intervention for a subgroup of subjects with IBS-D. Exploratory trial.||||
33728567|NCT00000796||||TREATMENT||||||||
33728568|NCT00422032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728569|NCT03062475|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728570|NCT04395937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728571|NCT05729334|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33728572|NCT04830527|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33728573|NCT05094934|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728574|NCT05143970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728575|NCT02795390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728576|NCT01199211|||OTHER||PROSPECTIVE|||||||
33728577|NCT04715399|||COHORT||OTHER|||||||
33728578|NCT06273345|||COHORT||PROSPECTIVE|||||||
33728579|NCT05705063|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33728580|NCT01933867|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33728581|NCT02347748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33728582|NCT00854581|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33728583|NCT03921710|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized Clinical Trial~Patients are randomized to either CAPA-IVM or STANDARD-IVM using block randomization by an independent study coordinator using a computer-generated random list (block size 4) on the second day of their periods."||||
33728584|NCT02246803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728585|NCT06255652|||CASE_CONTROL||RETROSPECTIVE|||||||
33838259|NCT04446611|RANDOMIZED|PARALLEL||SCREENING||NONE|The allocation of study arm is concealed to study staff during randomization|The intervention will incorporate diagnostic testing using the Xpert® platform with same-day treatment for Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis infection at first ANC (aim 1 and 2) with either a test-of-cure (arm 1) or 30 weeks repeat testing as follow-up (arm 2) compared to the standard of care (arm 3), i.e. syndromic management as per the South African guidelines. It is thus a 3-arm (1:1:1) control trial with additional components of vaginal microbiome analysis, economic evaluation and qualitative insights.||||
33728586|NCT00094965|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728587|NCT00999024|||COHORT||PROSPECTIVE|||||||
33728588|NCT03748199|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33728589|NCT05272982|||COHORT||PROSPECTIVE|||||||
33728590|NCT00486265|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728591|NCT01185795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728592|NCT02062762|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33728593|NCT01752855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728594|NCT00249470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728595|NCT02382016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728596|NCT06145009|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728597|NCT02888847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33728598|NCT02933242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728599|NCT00401765|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728600|NCT00058825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810353|NCT05840185|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a mono-centre, prospective, one-arm, unmasked clinical trial, which consists of 6 visits, across 12 months. The objective of this clinical trial is to compare the test myopia control spectacle lens to the single vision control spectacle lens from the previous clinical trial, otherwise termed as historical control group.~After obtaining informed consent and assent, a comprehensive eye examination will be conducted during the screening visit on all 40 myopic children between the age of 8 to 13 years old. Eligible children will return in a separate visit (baseline visit) to collect the study spectacles and the assessment of study spectacles, biometry and instructions to use study spectacles are established in the same visit. A follow up visit will be conducted in 3, 6 and 12 months time, where 12 months is the end of study. All of the eye examinations and assessments are non-contact and non-invasive to the eyes."||||
33810354|NCT01738997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810355|NCT02467985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810356|NCT05206994|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Close to Home (C2H) is a primary prevention community mobilization model that engages community members across multiple sectors and social networks to strengthen community connections and shift social norms regarding SV, but has never been rigorously evaluated. C2H moves beyond criminal justice, lobbying, or school-based curricular approaches, taking a true community-level and community-led approach.||||
33810357|NCT03728452|||COHORT||PROSPECTIVE|||||||
33810358|NCT04705051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115387|NCT04588142|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34115388|NCT01164826|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115389|NCT06176547|||COHORT||PROSPECTIVE|||||||
34115390|NCT02903485|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34115391|NCT05305469|||COHORT||PROSPECTIVE|||||||
34115392|NCT02630641|||CASE_ONLY||PROSPECTIVE|||||||
34115393|NCT04277247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Upon entry to the study, all subjects will be assigned to a subject number. Eligible subjects will be randomized to receive either BTXA injections or placebo on VISIT 1 in a double-blind manner according to a randomization schedule using computerized randomization tables as prepared by a blinded clinical nurse. All patients will receive BTXA injections on VISIT 4 in an open-label phase. The specific type of randomization used will be block randomization to ensure equal sample sizes of the BTXA and placebo groups.|We will perform a double-blind, randomized, parallel group study evaluating the safety and efficacy of BTXA injections vs. placebo injections, targeted at painful muscles, followed by an open-label phase when all participants will receive BTXA. Subjects, caregivers, and the investigators will be blinded to assignment.|t|t|t|f
34115394|NCT06545435|||COHORT||RETROSPECTIVE|||||||
34115395|NCT00930124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115396|NCT04801576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115397|NCT02727608|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115398|NCT04120207|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The principal investigator was blinded to participant allocation, and the analyses were performed blinded to the group. Participants' individual identification numbers assigned at baseline were used during the course of the trial. Following full data extraction from SurveyMonkey.com, identifying information were removed, such that no participant could be identified in the working dataset through one, or a combination of different variables.|Randomized controlled trial|f|f|t|t
34115399|NCT02433938|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34115400|NCT02950259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115401|NCT01968980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115402|NCT05557708|NA|SEQUENTIAL||TREATMENT||NONE||||||
34115403|NCT00400101|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34115404|NCT01701882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115405|NCT02298621|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34115406|NCT03100526|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34115407|NCT02350452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115408|NCT03243084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This is a double-blind study, meaning that neither the participant nor the experimenter knows what kind of stimulation the participant is receiving. An unblinded monitor (separate from the staff that interacts with the participant) is responsible for creating the stimulation codes that run each session and for ensuring that these codes worked correctly.|Each participant will receive sham stimulation and 10Hz tACS stimulation at two separate sessions. The order will be randomized (ie, half the participants will receive sham stimulation at the first session and 10Hz tACS stimulation at the second session, and the other half will receive 10Hz tACS stimulation at the first session and sham stimulation at the second session).|t|f|t|f
34115409|NCT03499678|||CASE_CONTROL||RETROSPECTIVE|||||||
34115410|NCT03335878|||COHORT||CROSS_SECTIONAL|||||||
34115411|NCT01920243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115412|NCT01990690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115413|NCT00637910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115414|NCT00708357|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34115415|NCT03304366|||COHORT||PROSPECTIVE|||||||
34115416|NCT05597384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115417|NCT06387862|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34115418|NCT05003414|||COHORT||PROSPECTIVE|||||||
34115419|NCT02906111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810359|NCT00885625|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810360|NCT02079259|||CASE_ONLY||PROSPECTIVE|||||||
33810361|NCT04039646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810362|NCT01351259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810363|NCT00701415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810364|NCT02436070|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33838260|NCT03882086|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34115420|NCT04653792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115421|NCT01190319|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34115422|NCT05978934|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34115423|NCT01378195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115424|NCT06350279|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34115425|NCT01507740|||CASE_ONLY||PROSPECTIVE|||||||
33728601|NCT05761379|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Low lever red light therapy with Model : Sky-n1201c at the wavelength of 650nm; 3 minutes illumination for both eyes, administered twice daily at the interview of 4 hours.~Children in the red light therapy group wore single vision spectacles the entire day and under red light therapy (power, 0.6mW; wavelength, 650nm; Beijing Airdoc MPC Co. Ltd, Beijing, China) twice per day for 3 minutes each session, with at least a 4-hour interval between sessions. There were no specific guidelines for room illumination. After the first measurement session, each child returned for follow-up examinations at 1, 3, and 6 months and completed all the aforementioned examinations."||||
33728602|NCT00573027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728603|NCT04804462|NA|SINGLE_GROUP||OTHER||NONE||This study will employ a convergent mixed-methods design with quantitative and qualitative data collection occurring concurrently throughout the study||||
33728604|NCT04537728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810365|NCT05260944|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The participants are the patients who undergoing coronary artery bypass graft surgery.~The care providers are the cardiothoraci surgeon and the nursing staff. The investigator is the physical Therapy ( my self)"|"In the study three groups of patients will participated first, group A. Will receive acapella device.~Second, group B. Will receive power lung device. Third, group C. Will receive only routine physical Therapy program."|t|t|t|f
33810366|NCT04787198|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34115426|NCT06563947|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single-center, single-arm clinical study. For those who meet the enrollment conditions, the original regimen of immune checkpoint inhibitors combined with anti-angiogenic targeted drugs will remain unchanged after enrollment.On this basis, the study subjects started oral enterobacterial capsules to see whther enterobacterial capsules could improve the efficacy of patients receiving the above treatment regimens.||||
33728605|NCT00752583|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115427|NCT05378802|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34115428|NCT05923684|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33728606|NCT05427396|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
33728607|NCT03592433|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33728608|NCT00588445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728609|NCT02122588|||COHORT||PROSPECTIVE|||||||
33728610|NCT00709371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728611|NCT03549247|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728612|NCT00928928|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33728613|NCT01978314|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This pilot study was a prospective, open-label, single site study designed to evaluate the safety of the FAST mGFR Test™ in healthy adult volunteers, patients with varying degrees of renal impairment and hemodynamically stable AKI.||||
33728614|NCT02280980|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728615|NCT02258204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728616|NCT00458653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728617|NCT00265824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728618|NCT04350151|||OTHER||RETROSPECTIVE|||||||
33728619|NCT02481895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33728620|NCT01950429|||COHORT||PROSPECTIVE|||||||
33728621|NCT01811095|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33728622|NCT00218348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33728623|NCT00308711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728624|NCT01539187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728625|NCT01162382|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33728626|NCT00660348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728627|NCT02313753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810367|NCT03516071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810368|NCT01536704|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33810369|NCT00568425|||COHORT||PROSPECTIVE|||||||
33810370|NCT02522104|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33810371|NCT04689932|NA|SEQUENTIAL||TREATMENT||NONE||||||
33810372|NCT02309892|NA|SEQUENTIAL||TREATMENT||NONE||Single arm, dose escalation where patients are recruited into cohorts of escalating doses of L-DOS47 (0.59 up to 12.0 µg/kg) in combination with pemetrexed and carboplatin.||||
33810373|NCT01443156|||COHORT||PROSPECTIVE|||||||
34115429|NCT03257384|||COHORT||PROSPECTIVE|||||||
33728628|NCT02534766|||COHORT||RETROSPECTIVE|||||||
33728629|NCT01063595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728630|NCT04390633|||COHORT||CROSS_SECTIONAL|||||||
33728631|NCT02178384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810374|NCT02068053|NA|SINGLE_GROUP||||NONE||||||
33728632|NCT04628312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728633|NCT02753062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728634|NCT02245542|||COHORT||PROSPECTIVE|||||||
33728635|NCT01132495|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33728636|NCT05638373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33728637|NCT03942978|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||Stepped Wedge Randomized Control Trial|t|f|f|f
33728638|NCT00802022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728639|NCT05551143|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728640|NCT02984410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728641|NCT01556529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728642|NCT00955266|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728643|NCT02064907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810375|NCT05333666|||COHORT||RETROSPECTIVE|||||||
33810376|NCT02476929|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33810377|NCT05294185|||COHORT||PROSPECTIVE|||||||
33810378|NCT01883063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810379|NCT03031509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810380|NCT06309355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810381|NCT03658603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810382|NCT03864159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33810383|NCT02893800|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33810384|NCT03836885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115430|NCT00344981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115431|NCT06563765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115432|NCT05238792|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34115433|NCT02660229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115434|NCT00895804|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115435|NCT00318682|||COHORT||PROSPECTIVE|||||||
34115436|NCT00006163|RANDOMIZED|FACTORIAL||||||||||
34115437|NCT04543851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115438|NCT03801525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115439|NCT01605994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115440|NCT02725684|||COHORT||PROSPECTIVE|||||||
34115441|NCT03369353|||COHORT||PROSPECTIVE|||||||
34115442|NCT02229357|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115443|NCT02740985|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115444|NCT02320188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115445|NCT06109935|||COHORT||PROSPECTIVE|||||||
34115446|NCT04047485|||COHORT||PROSPECTIVE|||||||
34115447|NCT00969020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34115448|NCT06262542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115449|NCT03240328|NA|SINGLE_GROUP||TREATMENT||NONE||No control.||||
34115450|NCT04586933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The study will be twofold and consist of Intervention 1 and Intervention 2.~Intervention 1: Dietary guidance (12 weeks). All participants will receive individual dietary guidance, as well as an intensive dietary course with 4 sessions. Participants will receive contact information to the clinical dietitian, and the opportunity to ask questions throughout the intervention period. Patients will be asked to not use other omega-3 supplement during the intervention period 1.~Intervention 2: Omega-3 vs. placebo (24 weeks). After intervention 1, patients will be randomized to take either 3 grams of omega-3 or placebo daily, divided into 4 capsules. Patients will be asked not to use other omega-3 supplements in the period from 2 months until after intervention period 2."|t|t|t|t
34115451|NCT01987414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115452|NCT02225535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34115453|NCT00922961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115454|NCT02065284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115455|NCT00163189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115456|NCT05610735|NA|SINGLE_GROUP||TREATMENT||NONE||Recurrent Ovarian Cancer Participants treated with combination of DOXIL and Ashwagandha||||
34115457|NCT00940602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients, investigator staff, persons performing the assessments, and data analysts remained blind to the identity of the study treatment from the time of randomization until database lock.||t|f|t|f
34115458|NCT02468583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115459|NCT06073522|||CASE_CONTROL||PROSPECTIVE|||||||
34115460|NCT01417884|||COHORT||PROSPECTIVE|||||||
34115461|NCT05928988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115462|NCT00718315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115463|NCT00969423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115464|NCT00647647|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34115465|NCT06149182|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115466|NCT05924802|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Both participant and investigators will be blinded. A representative in the center will be in charge of maintaining encrypted key.|Placebo vs intervention group. Ketone ester is NOT a drug and only used to see the physiological effects on the heart.|t|f|t|f
34115467|NCT04106778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115468|NCT05222685|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"This randomized controlled trial will offer the intervention group the intervention of BT coaching during the first 6-months while the control group, or waitlist group will receive no intervention aside from the usual wellness activities of their institution."||||
34115469|NCT06331377|||CASE_ONLY||OTHER|||||||
34115470|NCT01469247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115471|NCT04485702|RANDOMIZED|CROSSOVER||OTHER||SINGLE|randomization|Randomized, Single-Dose, 6-Sequence, 3-Period, Crossover|t|f|f|f
34115472|NCT04882865|||CASE_ONLY||PROSPECTIVE|||||||
34115473|NCT03124186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115474|NCT02347605|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34115475|NCT02578082|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34115476|NCT03781986|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Part 1 -- Parallel assignment \[terminated early\]:~* Arm A: APG-115 Monotherapy~* Arm B: APG-115 + Carboplatin~Part 2 -- Single arm (Arm A only): APG-115 Monotherapy"||||
34115477|NCT05512624|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-armed randomized waitlisted control trial||||
34115478|NCT03483948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115479|NCT02300545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115480|NCT04190264|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will complete three trials under three different body cooling conditions/interventions; passive cooling using the body's natural body cooling mechanisms, body cooling using cold water immersion, and cooling using the investigational thermal rehab machine.||||
33728644|NCT02795559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33728645|NCT00213837|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33728646|NCT01508780|NA|SINGLE_GROUP||||NONE||||||
33728647|NCT00941083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728648|NCT06151236|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, single centre clinical trial||||
33728649|NCT03861260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728650|NCT03372213|||COHORT||CROSS_SECTIONAL|||||||
33728651|NCT02427321|||COHORT||PROSPECTIVE|||||||
33810385|NCT05222100|||COHORT||PROSPECTIVE|||||||
33810386|NCT05652907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115481|NCT02538614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1b: sequential assignment, Phase 2: parallel assignment||||
34115482|NCT02621892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115483|NCT01066845|||COHORT||PROSPECTIVE|||||||
34115484|NCT06272604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33728652|NCT04663555|RANDOMIZED|PARALLEL||TREATMENT||NONE||"REMED is a prospective phase II open-label randomized controlled trial testing superiority of dexamethasone 20 mg vs 6 mg. The study is multi-centre and will be conducted in intensive care units (ICUs) of university hospitals in the Czech Republic. The trial aims to be pragmatic, i.e. designed to evaluate the effectiveness of the intervention in conditions that are very close to the real-life routine clinical practice. Dexamethasone will be administered once daily intravenously for 10 days. 300 participants will be enrolled and followed up for 360 days after randomization.~Following stratification factors will be applied:~* Age \< 65 and ≥ 65 (12);~* Charlson Comorbidity index (CCI; APPENDIX B Assessment tools, scores, and scales, Chapter 14.2) \< 3 and ≥ 3;~* CRP \< 150 mg/L and ≥ 150 mg/L~* Trial centre. Patients will be randomized in 1 : 1 ratio in one of the two treatment arms. Randomization through eCRF will be available 24 hours every day."||||
33728653|NCT00620594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115485|NCT01185717|||||CROSS_SECTIONAL|||||||
33728654|NCT03521986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33728655|NCT01312584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34115486|NCT01596114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115487|NCT05876156|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33728656|NCT05203263|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33728657|NCT01127334|||||PROSPECTIVE|||||||
33810387|NCT03340961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Each subject will be allocated to one of the following treatment groups, receiving 1 capsule once daily in the morning for 16 weeks:~1. DFD-29 Extended Release Capsules (40 mg)~2. DFD-29 Extended Release Capsules (20 mg)~3. Doxycycline Modified Release Hard Capsules (40 mg)~4. Placebo Capsules"|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study|t|t|t|t
33810388|NCT02779426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810389|NCT04082598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810390|NCT01698918|NA|SINGLE_GROUP||TREATMENT||NONE||The main study was an open-label single-arm study. The stomatitis sub-study was a randomized open-label study with two arms: dexamethasone and standard of care.||||
33810391|NCT04343417|||OTHER||PROSPECTIVE|||||||
33810392|NCT06300294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Since block randomization will be used in the study, the research director and the individuals who meet the study inclusion criteria will not know which group they will be in during the preliminary evaluation process of the study. However, the person analyzing the data will not know which group the data belongs to.|experimental and control|t|t|f|t
33810393|NCT00706888|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33810394|NCT03732456|||OTHER||PROSPECTIVE|||||||
33810395|NCT01584648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810396|NCT06509009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810397|NCT01446718|||COHORT||PROSPECTIVE|||||||
33810398|NCT06343181|||CASE_ONLY||PROSPECTIVE|||||||
33810399|NCT02202317|NA|SINGLE_GROUP||SCREENING||NONE||||||
33810400|NCT03535636|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810401|NCT00927849|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34115488|NCT06183398|NA|SINGLE_GROUP||OTHER||NONE||||||
34115489|NCT02756052|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34115490|NCT00049543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115491|NCT03526211|NA|SINGLE_GROUP||OTHER||NONE||||||
34115492|NCT02225184|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34115493|NCT04290624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115494|NCT02523950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115495|NCT00716157|||CASE_ONLY||PROSPECTIVE|||||||
34115496|NCT01103414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115497|NCT01518413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115498|NCT04378868|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomized into two arms according to urgency and simultaneously each patient is randomized into two arms according to antibiotic treatment||||
34115499|NCT00135083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115500|NCT05599724|||COHORT||PROSPECTIVE|||||||
34115501|NCT02646410|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34115502|NCT04803279|||COHORT||RETROSPECTIVE|||||||
34115503|NCT03914690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115504|NCT06022926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34115505|NCT03134040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115506|NCT02443636|||COHORT||PROSPECTIVE|||||||
34115507|NCT04816032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115508|NCT06079983|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial||||
34115509|NCT01593540|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34115510|NCT05320276|||COHORT||CROSS_SECTIONAL|||||||
34115511|NCT02684461|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34115512|NCT02151240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115513|NCT01966627|||COHORT||PROSPECTIVE|||||||
34115514|NCT01192880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115515|NCT05503082|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IV prospective open label randomized clinical study evaluating safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality).||||
34115516|NCT03904485|||CASE_CONTROL||PROSPECTIVE|||||||
34115517|NCT03381599|NA|SINGLE_GROUP||OTHER||NONE||||||
34115518|NCT01014871|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34115519|NCT04606927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115520|NCT01409096|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115521|NCT04573972|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The primary outcome is steps walked, as assessed via the Fitbit app, which is blind to study condition.|Two group, between-subjects design|f|f|f|t
34115522|NCT02542618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115523|NCT04507763|||COHORT||RETROSPECTIVE|||||||
34115524|NCT02586584|||CASE_ONLY||PROSPECTIVE|||||||
34115525|NCT05943821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115526|NCT01209767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115527|NCT00107575|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34115528|NCT01599884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115529|NCT00907621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115530|NCT02940548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115531|NCT06126692|||COHORT||PROSPECTIVE|||||||
34115532|NCT01138514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115533|NCT04510207|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115534|NCT03983421|||COHORT||CROSS_SECTIONAL|||||||
34115535|NCT04713189|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34115536|NCT00000621||||TREATMENT||||||||
34115537|NCT02781363|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34115538|NCT05829837|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115539|NCT06062693|NA|SINGLE_GROUP||TREATMENT||NONE||sensor-home-based hand training for MS, PD, stroke or control group||||
34115540|NCT02979418|||COHORT||PROSPECTIVE|||||||
34115541|NCT02428790|||COHORT||CROSS_SECTIONAL|||||||
34115542|NCT02969135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34115543|NCT01162759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115544|NCT03713801|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34115545|NCT01363102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115546|NCT00646230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115547|NCT01133847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115548|NCT04277312|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Masking was not possible due to the nature of the interventions.|Project Daire is a randomised-controlled, factorial design trial evaluating two interventions||||
34115549|NCT00725985|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115550|NCT04116255|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomized prospective study||||
34115551|NCT05480007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115552|NCT05835648|NA|SINGLE_GROUP||OTHER||NONE||||||
34115553|NCT00468091|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
34115554|NCT02673021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115555|NCT05960214|||CASE_CONTROL||RETROSPECTIVE|||||||
34115556|NCT06295419|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115557|NCT04069442|||COHORT||RETROSPECTIVE|||||||
34115558|NCT03113279|||COHORT||CROSS_SECTIONAL|||||||
34115559|NCT04501432|||COHORT||OTHER|||||||
34115560|NCT04955041|||CASE_CONTROL||RETROSPECTIVE|||||||
34115561|NCT00415090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728658|NCT03876327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"3 groups were included in the study:~1. PD patients that will undergo FMT tretment and a half of year follow-up-15 patients.~2. PD patients that will not undergo FMT procedure and will donate stool sample only once-35 patients.~3. healthy PD relatives, that live with them and have similiar life styling and which will donate stool sample only once-50 participants."||||
33728659|NCT05009394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728660|NCT00743652|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728661|NCT04625608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728662|NCT00915512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728663|NCT06167395|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33728664|NCT01193491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728665|NCT06148922|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33728666|NCT05297539|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728667|NCT02221310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728668|NCT05685290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be blinded to group allocation and randomization process. Additionally they will be blinded for interventions.|Randomized controlled trial||||
33728669|NCT04732637|||COHORT||PROSPECTIVE|||||||
33728670|NCT05402683|||COHORT||PROSPECTIVE|||||||
33728671|NCT01802957|NA|SINGLE_GROUP||||NONE||||||
33728672|NCT01221961|||||PROSPECTIVE|||||||
33728673|NCT04283643|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Within subjects design of real and control stimulation, pain measures and behavioral assessments may be compared between healthy subjects and pain groups.|t|f|f|f
33728674|NCT05651464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728675|NCT02347527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The MRI sample and Behavioral-only sample involve separate participants who complete the same intervention (assigned to either active or control groups), but the MRI sample also completed MRI outcomes and a food intake outcome that the Behavioral-only sample did not."|t|f|t|t
33728676|NCT01991002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728677|NCT04445558|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33728678|NCT02086110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33728679|NCT00144365|RANDOMIZED|PARALLEL||||NONE||||||
33728680|NCT02508636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115562|NCT00543985|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115563|NCT04264000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115564|NCT03898011|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participants and the investigator will not be blinded towards the identity of the study products. However, bioanalytical laboratory will be blinded towards identity of the study products administered.||f|f|f|t
34115565|NCT05617027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and team members, also referred to as evaluator members above (researchers, analysts, physical therapists, and research assistants) will all be blinded to the intervention, except for those not involved in data collection and analysis: a) the statistician who will generate the randomization list, b) the computer team who will program the randomization system, and c) the interventionist who will apply the tDCS power.|Multicenter randomized controlled trial (RCT) with placebo that includes two parallel groups (real tDCS and placebo tDCS), with random assignment|t|f|t|t
34115566|NCT01690533|||CASE_ONLY||PROSPECTIVE|||||||
34115567|NCT03076684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There are three arms of this study: a diet-treated group, a drug-treated group and a control group.||||
34115568|NCT03447873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041801|NCT04729829|RANDOMIZED|PARALLEL||OTHER||SINGLE|Partially masked. Participation is randomised to the community level. Participants will be aware they are participating in a project/study, but not the particular study design or which treatment arm they are assigned to. Statistical analysts will be masked until the analysis is complete.|"The main treatment variable is a dummy variable that indicates to which of the four treatment arms a village was assigned. Our primary model is an unadjusted model. However, if we find that after unmasking, there are variables in the dataset that appear different by treatment arm, we may consider adjusting for confounders in the model.~We will first estimate a parsimonious model with only the treatment dummies and the municipality fixed effects. Then we will control for additional baseline covariates. The control group is the no-FAD and no-SBC group. Intent to treat (ITT) will be estimated separately for midline and end line subsamples. However, we will compare the magnitude of impacts at midline and endline."|f|f|f|t
34041802|NCT05252572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728681|NCT04541875|||COHORT||PROSPECTIVE|||||||
33728682|NCT02433236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728683|NCT00856908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728684|NCT00873548|||CASE_ONLY||PROSPECTIVE|||||||
34041803|NCT04399616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34041804|NCT05730075|||COHORT||OTHER|||||||
34041805|NCT00961571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041806|NCT01010529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728685|NCT00265473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041807|NCT00301119|||COHORT||PROSPECTIVE|||||||
34041808|NCT00670358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041809|NCT06119815|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041810|NCT03225105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subsequent cohorts of patients treated at different dose levels.||||
34041811|NCT04251481|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34041812|NCT01735916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041813|NCT02262520|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34041814|NCT01482637|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041815|NCT04892329|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34041816|NCT04244552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041817|NCT02660567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34041818|NCT06354036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041819|NCT01703572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041820|NCT05891093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041821|NCT00957801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041822|NCT05154669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041823|NCT01069042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041824|NCT05321043|NA|SINGLE_GROUP||OTHER||NONE||||||
34041825|NCT06571721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041826|NCT05015634|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A total of 338 patients will be randomised 1:1 to the 2 trial arms over 9 months.||||
34041827|NCT03980145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34041828|NCT03386591|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This will be an inpatient open-label, randomized, 5-period, 5-treatment, 5-sequence, crossover study involving approximately 30 healthy subjects.||||
34041829|NCT06539403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041830|NCT04566614|||COHORT||PROSPECTIVE|||||||
34041831|NCT00703651|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041832|NCT02536079|||COHORT||PROSPECTIVE|||||||
34041833|NCT02242682|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
34041834|NCT03325816|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041835|NCT00925951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041836|NCT04589377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041837|NCT04409223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041838|NCT01622218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041839|NCT01367886|NA|SINGLE_GROUP||||NONE||||||
34041840|NCT00730535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041841|NCT06576609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041842|NCT03960008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041843|NCT04679766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041844|NCT00596232|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041845|NCT00952835|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041846|NCT01679782|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041847|NCT02158585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041848|NCT03992963|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34041849|NCT06336928|||COHORT||PROSPECTIVE|||||||
33728686|NCT02822469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728687|NCT00665184|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33728688|NCT02310919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34041850|NCT03710967|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||single-blinded, randomized controlled cross-over design trial|t|f|f|t
34041851|NCT03403140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041852|NCT01662141|||||PROSPECTIVE|||||||
34041853|NCT02529657|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34041854|NCT04289025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041855|NCT01739231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A of the study was masked to the participant, care provider, investigator, and outcomes assessor. Part B was open label.||t|t|t|t
34041856|NCT01559077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041857|NCT05814263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the staff performing and evaluating echocardiography and hall-walk tests are blinded to the treatment arm||t|f|f|t
34041858|NCT06575504|||CASE_CONTROL||PROSPECTIVE|||||||
34041859|NCT04839302|||COHORT||PROSPECTIVE|||||||
34041860|NCT05865860|||OTHER||PROSPECTIVE|||||||
34041861|NCT01419756|||CASE_ONLY||PROSPECTIVE|||||||
34041862|NCT06331351|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34041863|NCT06348238|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728689|NCT00437684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728690|NCT02581384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728691|NCT00187746|NON_RANDOMIZED|PARALLEL||||NONE||||||
33728692|NCT03134066|||COHORT||PROSPECTIVE|||||||
33728693|NCT03736850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728694|NCT02978287|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33728695|NCT02995785|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33728696|NCT04759625|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33728697|NCT03010878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33728698|NCT06167018|||OTHER||PROSPECTIVE|||||||
33728699|NCT02734888|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33728700|NCT04977323|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33728701|NCT04079985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Single-centre, two-arm randomized, controlled, open-label clinical trial||||
33728702|NCT00358202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33728703|NCT04633096|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|||f|f|t|t
33728704|NCT00712465|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728705|NCT01607983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728706|NCT03060746|||CASE_ONLY||PROSPECTIVE|||||||
33728707|NCT01598792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728708|NCT05862064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728709|NCT00758628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728710|NCT01250470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728711|NCT06367465|||COHORT||PROSPECTIVE|||||||
33728712|NCT00768729|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33728713|NCT01855295|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728714|NCT01071928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728715|NCT00012558|RANDOMIZED|||TREATMENT||DOUBLE||||||
33728716|NCT03324763|||COHORT||PROSPECTIVE|||||||
33728717|NCT02721316|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33728718|NCT03594097|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33728719|NCT00714064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728720|NCT02459977|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728721|NCT02457403|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33728722|NCT04090593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator will determine patient eligibility and recruit participants, team will randomize patients to receive intervention vs. current practice. Outcome assessor(s) will be blinded from patient intervention status.|Study is randomized controlled trial.|f|f|t|t
33728723|NCT02268409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728724|NCT00889083|||CASE_CONTROL||PROSPECTIVE|||||||
33728725|NCT00684606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728726|NCT01331616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728727|NCT00504686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728728|NCT05764213|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33728729|NCT05155384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810402|NCT05543109|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33810403|NCT05466786|||COHORT||PROSPECTIVE|||||||
33728730|NCT03164967|NA|SINGLE_GROUP||OTHER||NONE||||||
33728731|NCT02016625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728732|NCT03547713|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33728733|NCT02086942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728734|NCT05522465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728735|NCT04736797|||COHORT||PROSPECTIVE|||||||
33728736|NCT06440031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728737|NCT00819988|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728738|NCT01939587|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33810404|NCT00005921||||TREATMENT||NONE||||||
33810405|NCT04427124|||COHORT||PROSPECTIVE|||||||
33810406|NCT06200090|||OTHER||CROSS_SECTIONAL|||||||
33810407|NCT05028465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810408|NCT00004784|RANDOMIZED|||TREATMENT||DOUBLE||||||
33810409|NCT04924296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1314 subcutaneous administration, a multicentre, randomized, double-blind, parallel, placebo-controlled study|t|t|t|t
33810410|NCT04957277|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants are exposed to all conditions in a randomized order.||||
33810411|NCT01849536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810412|NCT01677832|||OTHER||OTHER|||||||
33810413|NCT04592926|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The patient and observer who collects the outcome data will be blinded to group allocation. The anesthesiologist caring for the patient and the resident/fellow performing the spinal anesthetic will be unblinded.|randomized controlled trial|t|f|f|t
33810414|NCT06234020|||COHORT||PROSPECTIVE|||||||
33810415|NCT02757911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810416|NCT03288506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810417|NCT02418689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728739|NCT02180516|||COHORT||PROSPECTIVE|||||||
33728740|NCT01871363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728741|NCT01538862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728742|NCT01997619|||CASE_ONLY||RETROSPECTIVE|||||||
33728743|NCT04781634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728744|NCT05905484|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33728745|NCT06391788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728746|NCT04116645|||COHORT||PROSPECTIVE|||||||
33728747|NCT00984581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728748|NCT04918602|||OTHER||PROSPECTIVE|||||||
33728749|NCT02561975|NA|SINGLE_GROUP||OTHER||NONE||||||
33728750|NCT02630784|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33728751|NCT00805766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728752|NCT01520116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33728753|NCT02501980|||COHORT||PROSPECTIVE|||||||
33728754|NCT00806884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33728755|NCT02380651|||COHORT||PROSPECTIVE|||||||
33728756|NCT02787473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728757|NCT05894642|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728758|NCT02858245|||COHORT||PROSPECTIVE|||||||
33728759|NCT02972216|||CASE_CONTROL||RETROSPECTIVE|||||||
33728760|NCT05180461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking applies to Parts 1a/b and Part 2. Part 0 (Pilot Group) is Open Label||t|t|t|t
33728761|NCT01515800|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33728762|NCT06032312|||CASE_CONTROL||PROSPECTIVE|||||||
33728763|NCT03023085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728764|NCT04779866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double|Participants will be randomized and either be assigned to the self-hypnosis group or a self-administered white noise hypnosis group.|f|f|t|t
33728765|NCT06146036|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728766|NCT02101502|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33728767|NCT06137443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728768|NCT03759756|||OTHER||RETROSPECTIVE|||||||
33728769|NCT04766242|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33728770|NCT02084628|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728771|NCT04134247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728772|NCT01633320|||COHORT||PROSPECTIVE|||||||
33728773|NCT02211469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33728774|NCT06034509|||CASE_CONTROL||OTHER|||||||
33728775|NCT01236755|NA|SINGLE_GROUP||TREATMENT||SINGLE|The outcome assessor was responsible for measuring the axial length and was unaware of the intervention (i.e. spectacles or orthokeratology) used by the subjects|All subjects were prescribed with a pair of glasses for seven months and switched to orthokeratology for another seven months||||
33728776|NCT05727709|||COHORT||PROSPECTIVE|||||||
33728777|NCT04911738|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"Participants know the intervention condition but not the effect expected. Assessor knows the intervention condition for the primary outcome change in PV, and the secondary outcomes, changes in VV, body orientation, and weight bearing asymmetry.~Assessor blind of the intervention condition for the assessment of the secondary criteria lateropulsion (SCALA) and balance in daily life (PASS)"|"* 20 stroke participants perform the experiment over 4 weeks (W0, W1, W2, W3). W0 and W1 are devoted to clinical assessments of lateropulsion, balance disorders and other clinical deficits post-stroke. W2 is devoted to the intervention over 4 consecutive half days: 2 for the verticality perception assessments (PV, VV), and 2 for concomitant assessments of lateral body orientation (by inertial captors) and weight-bearing asymmetry (by posturography). These 4 tests are performed before and during virtual reality. A post-effect is investigated only for PV and VV. Each patient is randomly assigned to one of the two following planes: plane A (PV/VV assessment on days 1 and 3 and postural assessment on days 2 and 4) or plane B (postural assessment on days 1 and 3 and PV/VV assessment on days 2 and 4).The W3 is devoted to conventional rehabilitation with only assessment of lateropulsion and balance on Friday (as each week of this protocol).~* 20 controls perform the same experiment on 2 days."|f|f|f|t
33728778|NCT04632251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728779|NCT00107211||||TREATMENT||||||||
33728780|NCT05825898|||CASE_ONLY||RETROSPECTIVE|||||||
33728781|NCT01763775|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33728782|NCT06058195|||COHORT||PROSPECTIVE|||||||
33728783|NCT00440882|||COHORT||PROSPECTIVE|||||||
33728784|NCT05771259|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33728785|NCT04865432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728786|NCT00311337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728787|NCT02071524|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33728788|NCT01230931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728789|NCT06190808|NA|SINGLE_GROUP||OTHER||NONE||Hyperglycemic patients admitted to an intensive care unit will have blood glucose concentration measured using current standard-of-care tests (fingerstick determinations and laboratory assays). Study participants will bel be asked to volunteer to permit concurrent glucose measurement using a Dexcom G7 continuous glucose monitor in order to determine the accuracy and feasibility of the latter. Only standard glucose measurements will be used for patient management.||||
33810418|NCT02038049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810419|NCT03377049|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810420|NCT04275544|||COHORT||RETROSPECTIVE|||||||
33810421|NCT01327014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810422|NCT00004939|RANDOMIZED|||TREATMENT||DOUBLE||||||
33810423|NCT02085512|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33810424|NCT02865785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810425|NCT00291941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810426|NCT05891405|||COHORT||PROSPECTIVE|||||||
33810427|NCT04440540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33810428|NCT02761317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33810429|NCT04730726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810430|NCT05308589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810431|NCT00664599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810432|NCT03776604|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.||||
33810433|NCT00281905||||TREATMENT||NONE||||||
33810434|NCT01472159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33810435|NCT04072627|||OTHER||CROSS_SECTIONAL|||||||
33810436|NCT03542747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810437|NCT02387606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810438|NCT00569166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33810439|NCT03311880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810440|NCT02444195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33810441|NCT03210298|||COHORT||PROSPECTIVE|||||||
33810442|NCT05944094|||COHORT||PROSPECTIVE|||||||
33810443|NCT01630304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041864|NCT02862665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041865|NCT05952843|||CASE_CONTROL||RETROSPECTIVE|||||||
34041866|NCT06322732|||COHORT||PROSPECTIVE|||||||
34041867|NCT00206271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34115569|NCT05241366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masking (Trial Participant/Outcomes Assessor)|Single-blind randomized controlled clinical trial. Non-probabilistic sampling of consecutive cases randomized to each arm of the study. The study will consist of a control group and a study group. The study group will receive a therapeutic scheme with Transcranial Magnetic Stimulation (TMS) + usual pharmacological treatment and the control group will receive an identical scheme with TMS simulated with a sham coil + usual pharmacological treatment.|t|f|f|t
34041868|NCT04735679|||COHORT||PROSPECTIVE|||||||
34041869|NCT02838797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041870|NCT05462938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041871|NCT06178211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041872|NCT06279442|||COHORT||OTHER|||||||
34041873|NCT05300815|||COHORT||PROSPECTIVE|||||||
34041874|NCT02701829|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34041875|NCT05448274|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double blinded study where both the investigator (the physician), care provider (nurse) and the participants are blinded.|A crossover study where subjects recieve placebo or Ruminococcus torques on two different study days with three to six weeks of wash-out between the study days.|t|t|t|t
34041876|NCT06314113|||COHORT||RETROSPECTIVE|||||||
34115570|NCT00654108|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34115571|NCT01994876|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34115572|NCT06193707|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34115573|NCT00811460|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34115574|NCT06449560|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized, single-blinded, two parallel-groups trial|f|f|t|t
34115575|NCT02095106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115576|NCT00492557|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115577|NCT01582750|||COHORT||PROSPECTIVE|||||||
34115578|NCT06511583|||CASE_CONTROL||PROSPECTIVE|||||||
34041877|NCT05590793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041878|NCT04873921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Group 1 and 2 will be assessed and treated by two different experienced physiotherapists for each group.|Patients are randomized into 2 groups; Group 1: Sterile Kinesio tape application (n=28), Group 2: Control group (n=28). Group 1 will receive Sterile Kinesio Taping application within 72 hours applied with Sterile Web Cut Kinesio Tape without tension additional to standard postoperative care. Group 2 will receive only standard postoperative care.|t|f|f|t
34041879|NCT04287660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041880|NCT01114802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041881|NCT04142736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041882|NCT00725153|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34041883|NCT03522012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041884|NCT05527171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041885|NCT01510301|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34041886|NCT01969773|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|The attending doctors, patients, and study nurses did not know which solution was injected to their bladders, to keep the study in a double-blind condition.|The patients were allocated to the treatment or control group by permuted block randomization code in a 2:1 ratio|t|t|t|t
34041887|NCT04578457|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34041888|NCT04468178|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized controlled mono-centric study||||
34041889|NCT02802124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041890|NCT06371235|NA|SINGLE_GROUP||OTHER||NONE||||||
34041891|NCT04009525|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34041892|NCT06468059|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The control prosthesis and the experimental prosthesis are covered by a sock to prevent the participant from knowing which has been fit.||t|f|f|f
34041893|NCT03092856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041894|NCT00202124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34041895|NCT02609815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115579|NCT02748447|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34115580|NCT00473174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115581|NCT01173744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34115582|NCT01593371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34115583|NCT03067636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115584|NCT00315406|||COHORT||PROSPECTIVE|||||||
33728790|NCT05179733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728791|NCT03850873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728792|NCT02127632|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33728793|NCT00500370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728794|NCT02696369|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33728795|NCT04362917|||COHORT||OTHER|||||||
33728796|NCT00217542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728797|NCT00091299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728798|NCT02612532|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728799|NCT04237428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728800|NCT05155228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The Attachment, Regulation and Competency (ARC) Framework is an attachment focused model designed specifically for trauma-impacted children that incorporates principles of the following theoretical orientations: 1) developmental theory; 2) family systems theory; and 3) strengths-based approaches. The central goals of the ARC framework are to (a) support caregiving systems and enhance caregiver-child relationships (Attachment), (b) support children in developing the skills and tolerance for connecting to, identifying, and sharing internal experience and managing emotional and physiological states (Regulation), (c) build key capacities associated with resilience including the ability to engage in problem-solving and a positive / effective sense of self (Competency), and (d) process traumatic experiences."|f|f|f|t
33728801|NCT00228345|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115585|NCT05548426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115586|NCT00832013|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115587|NCT05636839|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34115588|NCT06005402|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Single ascending dose study|t|f|t|t
34115589|NCT00693550|||COHORT||PROSPECTIVE|||||||
34115590|NCT00173719|NON_RANDOMIZED|CROSSOVER||||NONE||||||
34115591|NCT05420571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115592|NCT03064373|||FAMILY_BASED||PROSPECTIVE|||||||
34115593|NCT03956160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34115594|NCT05994352|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomized controlled|t|f|f|f
34115595|NCT02862093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115596|NCT03057184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is an experimental design using random assignment to select 130 family members responsible for the preparation and transfer of the care-recipient from their home to the ADCC: was randomized to an intervention group or control group (care as usual).|f|t|f|f
34115597|NCT03230188|||COHORT||PROSPECTIVE|||||||
34115598|NCT03498209|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34115599|NCT03830879|||COHORT||PROSPECTIVE|||||||
34115600|NCT03772535|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||t|f|f|f
34115601|NCT05354219|||COHORT||PROSPECTIVE|||||||
34115602|NCT05747248|||COHORT||CROSS_SECTIONAL|||||||
34115603|NCT04927702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115604|NCT02852915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115605|NCT00038935|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34115606|NCT05443828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115607|NCT02194413|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115608|NCT05432310|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized Phase I/II clinical trial to assess the safety and efficacy of gene therapy for ADA SCID by transplantation of autologous mPB CD34+ hematopoietic stem and progenitor cells (HSPC) transduced by the EFS-ADA lentiviral vector.||||
34115609|NCT02164864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115610|NCT02399293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115611|NCT05209035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115612|NCT05578066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A two-arm, cluster-randomized controlled trial with CESFAMs being the unit of randomization.||||
34115613|NCT01822925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115614|NCT01241630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115615|NCT03271775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"After the initial test, subjects will randomly distribute into three different research groups.~Each subgroup will include 30 patients."|f|f|f|t
34115616|NCT06392425|||CASE_CONTROL||RETROSPECTIVE|||||||
34115617|NCT02077127|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115618|NCT02104934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115619|NCT02665260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115620|NCT04946058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115621|NCT02386956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115622|NCT01862003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115623|NCT00656370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115624|NCT05482061|||COHORT||OTHER|||||||
34115625|NCT05160883|||COHORT||PROSPECTIVE|||||||
34115626|NCT04667156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33728802|NCT00397800|NON_RANDOMIZED|||TREATMENT||NONE||||||
34115627|NCT01958086|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33728803|NCT00009048||||TREATMENT||||||||
33728804|NCT05756686|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33728805|NCT00005669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728806|NCT03602937|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Open label prospective acceptability study.||||
33728807|NCT05085977|NA|SEQUENTIAL||TREATMENT||NONE||First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.||||
33728808|NCT02078583|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33728809|NCT00277212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728810|NCT04743661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728811|NCT05873465|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33728812|NCT02776228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33728813|NCT04249258|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33728814|NCT00862784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728815|NCT01505127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728816|NCT01485523|||CASE_CONTROL||PROSPECTIVE|||||||
34115628|NCT05327647|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The study started with cohort A (open-label study) for around 40 participants. Then the recruitment in cohort A will stop and the recruitment in cohort B (double-blind, with placebo) will start.|t|f|f|f
34115629|NCT04153487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single (participant)|Randomized Controlled Trial|t|f|f|f
34115630|NCT05494892|||OTHER||OTHER|||||||
34115631|NCT03981276|||COHORT||PROSPECTIVE|||||||
34115632|NCT03035630|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open-Label|||||
34115633|NCT00906763|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34115634|NCT04194450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Placebo masked with flavouring and participants consume in opaque containers.||t|f|t|t
34115635|NCT00588432|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115636|NCT03235050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will be conducted in a double-blind fashion for MEDI0382 and placebo. The sponsor staff, the subjects, and the Investigators involved in the treatment of subjects or in the clinical evaluation of subjects will not be aware of the treatment received. Liraglutide will be provided in an open-label active comparator arm.|Randomised, parallel, double-blind, placebo-controlled study with an open-label active comparator.|t|t|t|f
34115637|NCT06179537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728817|NCT04760210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728818|NCT03051048|||COHORT||PROSPECTIVE|||||||
33728819|NCT04244786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|tDCS device programmed with codes to deliver active vs. sham tDCS in a blinded manner. Individual independent of study team managed randomization and provided codes for blinded tDCS administration.|Double-blind, randomized, sham-controlled trial. 2 arms of clinical trial. Listing 3 arms to include an arm for individuals who signed consent but discontinued prior to randomization and clinical intervention, to describe available data and adverse events in this group.|t|t|t|t
33728820|NCT02182375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728821|NCT00232310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728822|NCT01418937|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33728823|NCT06484608|RANDOMIZED|PARALLEL||OTHER||SINGLE|In this study, masking is implemented at the participant level. This means that the neonates (participants) and their caregivers are unaware of whether the neonate is receiving isotonic or hypotonic fluids. However, the clinical staff administering the fluids and assessing outcomes are not blinded to the intervention group. This approach helps reduce bias in the perception and reporting of outcomes by those caring for the neonates while ensuring accurate administration and monitoring by the healthcare providers.|In this study, participants (neonates post-surgery) are randomly assigned to one of two groups, with each group receiving a different type of intervention (isotonic or hypotonic fluids). The parallel assignment model means that all participants in each group receive the same intervention throughout the study period, and the outcomes of these groups are compared to evaluate the effectiveness and safety of the interventions.|t|f|f|f
33728824|NCT04147312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33728825|NCT00586469|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33728826|NCT01157533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728827|NCT00483964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728828|NCT02558998|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728829|NCT02205593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728830|NCT01725191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728831|NCT01482260|||COHORT||PROSPECTIVE|||||||
33728832|NCT01837628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33728833|NCT05719363|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|All patients will have the nasal cannula in place during both 6MWTs, but the POC will be activated only during the test conducted with oxygen supplementation||t|f|f|f
33728834|NCT04845607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728835|NCT03594383|||CASE_ONLY||PROSPECTIVE|||||||
33728836|NCT02340299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728837|NCT05167162|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"80 patients divided into 4 groups of equal size and randomly selected. The 4 treatment methods used will be as follows:~Group 1: Compression techniques (n=20). Group 2: Massage techniques (n=20) Group 3: Hydrotherapy (n=20) Group 4: Active recovery technique (n=20)"|t|t|t|f
33728838|NCT03033472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment||t|t|t|t
33728839|NCT00850031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728840|NCT04584710|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33728841|NCT04700748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728842|NCT06485271|||COHORT||PROSPECTIVE|||||||
33728843|NCT03856437|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728844|NCT02039609|||OTHER||CROSS_SECTIONAL|||||||
33728845|NCT02881996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33728846|NCT00082433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728847|NCT04076969|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The pregnant women were blinded to the intervention.|there are two groups, the study group and the control group|t|f|f|f
33728848|NCT01010048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728849|NCT06291558|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants will be informed that the study was carried out for scientific purposes and the information will not be shared with third parties. Randomization of exercise groups will be performed according to the closed envelope procedure. The student who selects one of the envelopes with the names of the 3 groups will be included in the group written in the envelope he selected. Information about other groups will not be shared.||t|f|f|f
33728850|NCT03262194|||CASE_ONLY||PROSPECTIVE|||||||
33728851|NCT01365273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728852|NCT06188442|RANDOMIZED|PARALLEL||PREVENTION||NONE||With a 3:1 intervention-to-control allocation ratio (198 and 66 participants would receive intervention and control, respectively), a total of 264 participants would be recruited.||||
33728853|NCT01622855|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33728854|NCT00193882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728855|NCT00490165|||COHORT||RETROSPECTIVE|||||||
33728856|NCT02808286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728857|NCT06287346|||COHORT||PROSPECTIVE|||||||
33728858|NCT00590954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810444|NCT05532553|||CASE_CONTROL||RETROSPECTIVE|||||||
33810445|NCT03626194|||OTHER||PROSPECTIVE|||||||
33728859|NCT02674620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728860|NCT04292730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728861|NCT02825836|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33728862|NCT04473651|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33810446|NCT03015220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810447|NCT02337114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810448|NCT01228565|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33810449|NCT02729246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810450|NCT00579839|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810451|NCT06377137|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33810452|NCT02417350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33810453|NCT01536964|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33810454|NCT03564106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810455|NCT04111159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810456|NCT02010866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810457|NCT01394302|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041896|NCT00205023|NA|SINGLE_GROUP||OTHER||NONE||||||
34041897|NCT01686672|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34041898|NCT05773105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728863|NCT01944995|RANDOMIZED|CROSSOVER||||NONE||||||
33728864|NCT01000675|||OTHER||PROSPECTIVE|||||||
33728865|NCT04067362|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33728866|NCT01520129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041899|NCT05587530|NA|SINGLE_GROUP||TREATMENT||NONE|N/A - Open pilot trial|Informed by data from qualitative participatory interviews and secondary data analysis of administrative databases and based on client and staff stakeholder preferences, the investigators will develop a manualized treatment engagement and retention protocol for suicidal outpatient clients. To determine feasibility and acceptability of the manualized treatment engagement and retention protocol for suicidal outpatient clients, the investigators will conduct a small pilot study with 15 clients across 1-2 clinics (single arm intervention pilot).||||
33728867|NCT03871127|||COHORT||RETROSPECTIVE|||||||
33728868|NCT03251573|||COHORT||PROSPECTIVE|||||||
33728869|NCT03366064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728870|NCT00829881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728871|NCT06159972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728872|NCT00806546|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728873|NCT06072547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study involves two randomizations, one at the beginning of the study and another at the end of week 3.||||
33728874|NCT04209179|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33728875|NCT06517147|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33728876|NCT03880903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728877|NCT00138983|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33728878|NCT04963582|RANDOMIZED|PARALLEL||TREATMENT||NONE||Case-controlled||||
33728879|NCT02394938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728880|NCT03870152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728881|NCT02781103|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33728882|NCT05994716|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33728883|NCT05788458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728884|NCT03808168|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810458|NCT05704192|||COHORT||RETROSPECTIVE|||||||
33810459|NCT00893009|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33810460|NCT00089609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810461|NCT02362386|||CASE_ONLY||PROSPECTIVE|||||||
33810462|NCT05579184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810463|NCT01026207|||COHORT||PROSPECTIVE|||||||
34041900|NCT00655408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115638|NCT04787315|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34115639|NCT01394159|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34115640|NCT04337047|||COHORT||PROSPECTIVE|||||||
34115641|NCT06408376|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34115642|NCT03601299|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810464|NCT04863339|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The only staff with access to randomization codes will be our study statistician who created the randomization table and our investigational drug services pharmacy who is preparing the investigational product.|Participants randomized to receive the investigational product vs placebo during a single study encounter.|t|t|t|t
34115643|NCT02554955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728885|NCT01219725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33728886|NCT05881473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33728887|NCT04406064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728888|NCT02608112|||CASE_ONLY||PROSPECTIVE|||||||
33728889|NCT06452940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33810465|NCT03679299|||COHORT||PROSPECTIVE|||||||
33810466|NCT01474382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810467|NCT05654285|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|"Triple masking was applied, as described below. Participants: The drinks were offered in standardized disposable cups so that the participants could not visually identify the test drink. All beverages were offered at approximately 4°C and participants were asked to consume them within 10 minutes.~Investigator: All participants received the mineral water (control) in the first study session. Allocation to the remaining 3 interventions was randomized for each participant, and members of the research team who administered the beverages, performed blood sampling, processed samples in the laboratory, or followed participants during the study sessions were unaware of the allocation, that is, the type of drink that was administered to each participant.~Outcomes Assessor: The investigator who performed the statistical analysis did not have access to the identity of the participants or the allocation of interventions."||t|f|t|t
33728890|NCT04430439|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will be first randomized in a parallel design to meal type (low vs high GI). Within the meal arms, participants will be randomized in a cross-over design to undergo the lab-based stress and non-stress tasks.|t|f|t|f
33728891|NCT05534763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study 1 is a feasibility study with pre- and post-assessments evaluating feasibility, acceptability and satisfaction of the study protocol and the preliminary efficacy of I-ER. Study 1 consists of IERGD (a behavioral intervention for individuals with GD) and IER SUPPORT (a parallell behavioral course for a support person to the person with GD).||||
33728892|NCT03812965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728893|NCT00222547|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33728894|NCT03335982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33728895|NCT04154228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728896|NCT03342976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33728897|NCT06441383|||COHORT||CROSS_SECTIONAL|||||||
33728898|NCT00097721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728899|NCT03946397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33728900|NCT04262037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33728901|NCT04160793|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective unblinded interventional study||||
33810468|NCT01894737|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33810469|NCT00708266|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33810470|NCT03676088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Computer generated randomization sequence was obtained by the assistant. Allocation concealment was achieved using a sealed coded opaque envelope containing the treatment of the specific subject The sealed envelope containing treatment assignment was opened immediately prior to surgery to prevent surgeon bias|The patients were assigned into two treatment groups (test and control). The test group was treated with recombinant human Platelet Derived Growth Factor-BB and Modified Coronally Advanced Tunnel +Connective Tissue Graft whereas the control group was treated by Modified Coronally Advanced Tunnel +Connective Tissue Graft alone.|f|f|f|t
33810471|NCT00736502|||COHORT||PROSPECTIVE|||||||
33810472|NCT03451461|||COHORT||PROSPECTIVE|||||||
33810473|NCT02327442|||||PROSPECTIVE|||||||
33810474|NCT04927078|||CASE_CONTROL||RETROSPECTIVE|||||||
33810475|NCT02280759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810476|NCT00038038|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041901|NCT06576778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is based on different technical procedures of framework fabrication. Since these differences are visible, the operator and the patients involved in the study cannot be blinded. But the outcome assessor and the statistician will be blinded.|"Group I, (control): patients obtained an Implant-supported, full arch maxillary definitive prosthesis utilizing 6 implants, for constructing PEKKTON framework without provisionalization.~Group II, (intervention): Patients obtained an Implant-supported full arch maxillary provisional prosthesis protocol utilizing 6 implants for constructing a resin glass fiber composite framework followed by a definitive PEKKTON framework."|f|f|f|t
33810477|NCT02225171|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041902|NCT00119249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041903|NCT00872911|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34041904|NCT01090778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34041905|NCT03238664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041906|NCT01573182|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041907|NCT05890924|||COHORT||RETROSPECTIVE|||||||
34041908|NCT06577298|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34041909|NCT04297748|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will enroll into two sequential cohorts A and B||||
34041910|NCT04343495|||COHORT||PROSPECTIVE|||||||
34041911|NCT00777296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041912|NCT02091089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041913|NCT03099837|||COHORT||PROSPECTIVE|||||||
34041914|NCT02818946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041915|NCT02093780|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34041916|NCT06512285|||COHORT||PROSPECTIVE|||||||
34041917|NCT03830697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34041918|NCT05445466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041919|NCT06286137|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the study and the music intervention, it is not possible to blind participants and investigators. However, participants will not be informed of the study arm to which they are randomized in advance.|The randomized controlled trial will have four study arms. Subjects will be assigned to one of the four arms: control without music and music groups with 1 minute, 5 minutes and 20 minutes. All subjects will receive electric stimuli in three phases. In each phase, subject will be exposed to three consecutive stimuli. First a detection threshold will be measured. Secondly a baseline test will be performed in order to assess basic levels of pain endurance. Hereafter, the intervention phase starts. Subjects in the music groups will listen to 1, 5 and 20 minutes of their own preferred music through headphones. Directly after, all subjects will again receive three electric stimuli.||||
34041920|NCT02718833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041921|NCT05103982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041922|NCT02208193|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34041923|NCT05509790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041924|NCT05739422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to treatment allocation|Randomised feasibility study|f|f|f|t
34041925|NCT02591160|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041926|NCT02641418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041927|NCT02523976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041928|NCT01626196|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34041929|NCT04381728|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34041930|NCT01757184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041931|NCT01922232|||COHORT||PROSPECTIVE|||||||
34041932|NCT05784233|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants receive each level of task (easy singleton detection task, hard feature search task) and salient item presence (present, absent during search). Groups differ based on the likelihood of the salient item being the search target when present(0%-100%, in 25% increments).||||
34041933|NCT05790395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34041934|NCT02288403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041935|NCT01144065|||CASE_CONTROL||PROSPECTIVE|||||||
34041936|NCT04580940|||COHORT||PROSPECTIVE|||||||
34041937|NCT02619630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041938|NCT01050582||PARALLEL||TREATMENT||NONE||||||
34041939|NCT02619357|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34041940|NCT06081842|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Three-arm, single-blinded, parallel cluster randomized-controlled trial will compare routine care (arm 1) with the contraceptive counseling package (arm 2) and the same package combined with wider method availability (arm 3). Only data analysts will be masked to trial-arm allocation.|The research entails a complex multi-site, two-stage and 5-phase: STAGE 1 is formative and will comprise of a pre-formative (phase 1) and a formative (phase 2). While the STAGE 2 is experimental and will include intervention design (phase 3), experimental (phase 4), and reflective (phase 5).|f|f|f|t
34041941|NCT02840539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041942|NCT04179838|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34041943|NCT01346696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041944|NCT02929589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728902|NCT04538066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor, investigators and staff, and the clinical research organization are all blinded to study treatment assignment.|Study subjects will be randomized 1:1 to receive either the active treatment, bryostatin-1, or placebo.|t|t|t|t
33728903|NCT04092335|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728904|NCT04400721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Single-blinded, single-center, randomized, prospective study|t|f|f|f
33728905|NCT06441734|||CASE_CONTROL||OTHER|||||||
33728906|NCT01365390|||COHORT|||||||||
33728907|NCT03961100|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728908|NCT01192971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728909|NCT02308735|||CASE_CONTROL||PROSPECTIVE|||||||
33728910|NCT00691496|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728911|NCT05129072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728912|NCT00476021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33728913|NCT03033407|RANDOMIZED|CROSSOVER||TREATMENT||NONE|It was open label study.|||||
33728914|NCT00838227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728915|NCT04062916|||COHORT||RETROSPECTIVE|||||||
33728916|NCT02094716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728917|NCT03321669|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33728918|NCT02850003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728919|NCT01959542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728920|NCT05591326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728921|NCT06468150|||COHORT||RETROSPECTIVE|||||||
33728922|NCT05113186|NA|SINGLE_GROUP||TREATMENT||NONE||a pilot interventional study||||
33728923|NCT04200248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728924|NCT03476096|||CASE_ONLY||PROSPECTIVE|||||||
33728925|NCT00579826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33728926|NCT06146530|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The randomization scheme will be derived using random allocation software by the Cerina technical lead who is not involved in the study. Randomization will take place in blocks of 6, and will take place in a 1:1 ratio. All participants will be informed about the condition they are assigned to. Please see below for the study design.|The study is a single-blind pilot RCT with two conditions: Treatment (i.e., access to Cerina for 6 weeks) and a waitlist control group (i.e., optional campus-based wellbeing services for 6 weeks)|f|f|t|f
33728927|NCT01256593|||CASE_ONLY||PROSPECTIVE|||||||
33728928|NCT01760148|||COHORT||PROSPECTIVE|||||||
33728929|NCT01438970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728930|NCT03169946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33728931|NCT05244629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33728932|NCT03674060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728933|NCT00911703|||COHORT||PROSPECTIVE|||||||
33728934|NCT03012100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33728935|NCT01076907|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33728936|NCT02302196|||CASE_CONTROL||PROSPECTIVE|||||||
33728937|NCT05525221|||COHORT||PROSPECTIVE|||||||
33728938|NCT00614913|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728939|NCT03172936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study was comprised of two treatment arms.~Group A included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 intravenous on day 1 of every 28 day cycle and intratumoral injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle.~Group B included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 intravenous on day 1 of every 28 day cycle and an intratumoral injection of MIW815 (ADU-S100) on day 1 of every 28 day cycle.~Once the maximum tolerated dose and/or recommended dose for expansion had been determined, the plan was to open the expansion part of the study. However, the dose expansion phase of the study was not opened to enrollment due to the program's early termination."||||
33728940|NCT04037553|||COHORT||PROSPECTIVE|||||||
34041945|NCT06070142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728941|NCT01581632|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33728942|NCT01755416|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33728943|NCT00046033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728944|NCT06115538|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"randomized controlled trial~Our study is a randomized controlled study. After two different Levodopa preparations (drugs or biologic products) are given to the patients, blood will be taken from the patients at regular intervals (intervention) and the changes in blood dopamine levels between the 2 groups will be examined."||||
33728945|NCT05489315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33728946|NCT01554891|||COHORT||PROSPECTIVE|||||||
33728947|NCT06231303|||COHORT||PROSPECTIVE|||||||
33728948|NCT00661700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728949|NCT02150564|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33728950|NCT04964453|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33728951|NCT00363974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728952|NCT04697979|||COHORT||PROSPECTIVE|||||||
33728953|NCT01542853|||COHORT||PROSPECTIVE|||||||
33728954|NCT05369351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33728955|NCT02479737|||COHORT||PROSPECTIVE|||||||
33728956|NCT05263492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728957|NCT03266328|||CASE_ONLY||PROSPECTIVE|||||||
33728958|NCT03013543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728959|NCT04566237|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33728960|NCT00748475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728961|NCT02270866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728962|NCT04561401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728963|NCT05742880|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33728964|NCT01529424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728965|NCT00576277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33728966|NCT02656641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728967|NCT02885155|||COHORT|||||||||
34041946|NCT01643343|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041947|NCT05643742|NA|SEQUENTIAL||TREATMENT||NONE||||||
33810478|NCT05905549|||COHORT||RETROSPECTIVE|||||||
33810479|NCT02962024|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33810480|NCT00269022|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34115644|NCT03350464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115645|NCT01347060|||COHORT||RETROSPECTIVE|||||||
34115646|NCT04101773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the comparison of outpatient-based and surgical treatment strategies in this study, blinding to the treatment allocation for patients and medical staff is not possible. The trial statistician will be blinded for the treatment allocation.|Prospective multicentre randomized controlled trial.|f|f|f|t
34115647|NCT02002325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115648|NCT04745091|||CASE_ONLY||PROSPECTIVE|||||||
34115649|NCT02862886|NA|SINGLE_GROUP||||NONE||||||
34115650|NCT03120845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To compare incidence of post-operative pain and apical healing after single-visit versus two-visit root canal treatment of teeth with necrotic pulp and apical periodontitis. Each participant received a root canal treatment (RTC)|Ibuprofen for post operative pain. after RCT in one visit|t|f|f|f
34115651|NCT06458569|||CASE_CONTROL||PROSPECTIVE|||||||
34115652|NCT04864691|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34115653|NCT06029231|||CASE_ONLY||PROSPECTIVE|||||||
34115654|NCT05471921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized to SBIRT or treatment as usual (TAU) control. The Research Assistant (RA) will allocate participants to study conditions using a series of sealed, opaque envelopes. RAs and data analysts will be blinded. Participants will be notified immediately about the result of the randomization.||f|f|f|t
34115655|NCT03489694|||COHORT||PROSPECTIVE|||||||
34115656|NCT02429011|||CASE_CONTROL||PROSPECTIVE|||||||
34115657|NCT01533415|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115658|NCT00650507|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34115659|NCT03175107|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34115660|NCT00772759|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115661|NCT05990686|||CASE_CONTROL||PROSPECTIVE|||||||
34115662|NCT06537869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115663|NCT03314090|NA|SINGLE_GROUP||TREATMENT||NONE||Testing silicone gel in the treatment of upper lip scar||||
34115664|NCT05270993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34115665|NCT01969734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115666|NCT02230449|||COHORT||PROSPECTIVE|||||||
34115667|NCT02688439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115668|NCT01197547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115669|NCT00034814||||TREATMENT||||||||
34115670|NCT00400686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34115671|NCT01051245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115672|NCT00127439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115673|NCT00746811|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34115674|NCT05748002|||OTHER||PROSPECTIVE|||||||
34115675|NCT05472792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115676|NCT04629742|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Nobody (unless the principal investigator) knows the types of pizza and their coding system|Twelve healthy volunteers were recruited for a Randomized Controlled Trial, with the consumption of one Standard Pizza and one seawater pizza using a balanced crossover design, with 1 week wash out|t|t|t|f
34115677|NCT02964364|||CASE_ONLY||CROSS_SECTIONAL|||||||
34115678|NCT00909701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115679|NCT00601341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115680|NCT02796716|||OTHER||PROSPECTIVE|||||||
34115681|NCT02236091|||CASE_ONLY||CROSS_SECTIONAL|||||||
34115682|NCT04983784|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The experiment group is composed of home walking, which contained walking guidance and telephone consultation, the control group without any intervention.||||
33728968|NCT02340533|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33728969|NCT02882321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728970|NCT02584504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728971|NCT01515332|||COHORT||PROSPECTIVE|||||||
33728972|NCT01733914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728973|NCT04146727|||CASE_ONLY||PROSPECTIVE|||||||
33728974|NCT05601310|||CASE_CONTROL||RETROSPECTIVE|||||||
33728975|NCT02803918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33728976|NCT00233727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810481|NCT06510413|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810482|NCT02993926|||COHORT||RETROSPECTIVE|||||||
33810483|NCT02761356|||CASE_ONLY||RETROSPECTIVE|||||||
34115683|NCT00543192|||CASE_ONLY||CROSS_SECTIONAL|||||||
34115684|NCT04800692|NON_RANDOMIZED|PARALLEL||OTHER||NONE||All subjects will receive the same starting dose of the 3 components which will be escalated at day 45.||||
34115685|NCT05092750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115686|NCT01010464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115687|NCT00085748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115688|NCT05683366|||OTHER||PROSPECTIVE|||||||
34115689|NCT02023437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115690|NCT05310253|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
34115691|NCT01508364|||COHORT||PROSPECTIVE|||||||
34115692|NCT03606577|NA|SINGLE_GROUP||TREATMENT||NONE||One group of subjects who must have documented Multiple Myeloma High Risk satisfying the CRAB and measurable disease.||||
34150206|NCT03051594|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|The side to which interventions or control is assigned to will be recorded and all records of all patients will be kept with the main supervisor . The operator will not be blinded as the difference in application protocol of the restorative materials prohibited blinding of the operator; however, the patient, Statisticians and Outcome assessors will be blinded to the material assignment||f|f|f|t
34150207|NCT01329744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150208|NCT05011799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34150209|NCT00629798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728977|NCT03557320|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33728978|NCT02012595|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728979|NCT05198570|||CASE_ONLY||RETROSPECTIVE|||||||
33728980|NCT06287892|||CASE_CONTROL||RETROSPECTIVE|||||||
33728981|NCT02204891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728982|NCT05248516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33728983|NCT03015051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33728984|NCT02582099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728985|NCT03388138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33728986|NCT03387449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33728987|NCT05893420|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|In control hospitals, eCART will be scoring silently in the background and not visible to the care provider or the patient. Because this is administrative data, the outcomes assessor will similarly be blinded to the score. In the intervention hospitals, care providers will be aware of the score and trained to it. Patients may be aware as a result.|This a parallel study with an intervention group of medical-surgical patients where the tool will be used by providers, and a control group wherein the tool will run silently in the background. The primary analysis will utilize a delta-delta design comparing the intervention hospitals' pre vs. post results to the control hospitals' pre vs. post results. The primary analysis will be limited to patients who ever had an elevated eCARTv5 as those are the ones who would have been eligible for intervention (viewing of the eCARTv5 trend and following the clinical pathway).|t|t|f|t
33728988|NCT04360564|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33728989|NCT01323075|||COHORT||PROSPECTIVE|||||||
33728990|NCT02643654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728991|NCT04685304|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, prospective, randomized trial design||||
33728992|NCT03660696|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33728993|NCT02132585|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33728994|NCT01147185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33728995|NCT03389711|||COHORT||PROSPECTIVE|||||||
33728996|NCT01845792|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33728997|NCT00741884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33728998|NCT06276816|||COHORT||PROSPECTIVE|||||||
33728999|NCT04180696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Eligible subjects will be randomized after baseline assessment and implant of a CRT system containing the aCRT algorithm. Randomization will be done in a 1:1 ratio to either treatment (aCRT ON, Adaptive Bi-V and LV) or control (aCRT OFF, Nonadaptive CRT) groups. All subjects, independent of randomization assignment, will have a CRT system.|t|f|f|f
33729000|NCT05508412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729001|NCT02097355|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33729002|NCT00445328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729003|NCT00902642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729004|NCT02263066|||CASE_ONLY||RETROSPECTIVE|||||||
33729005|NCT01554566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810484|NCT02102724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All gelcaps were overencapsulated to mask their contents|"Participants were randomized to one of two arms:~Intervention arm = fish oil Control arm = placebo."|t|f|t|f
33810485|NCT02343094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810486|NCT00943969|NA|SINGLE_GROUP||||NONE||||||
33810487|NCT00905294|||COHORT||PROSPECTIVE|||||||
33810488|NCT06511219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The buccal segmental distalizer will take the anchorage from infrazygomatic miniscrews (IZC).~the palatal distalizer take anchorage from palate"|t|f|f|t
33810489|NCT01394198|||OTHER||PROSPECTIVE|||||||
33810490|NCT01214200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810491|NCT03051568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810492|NCT06488742|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33810493|NCT01604122|||OTHER||CROSS_SECTIONAL|||||||
33810494|NCT05283018|||COHORT||PROSPECTIVE|||||||
33810495|NCT02644265|||COHORT||PROSPECTIVE|||||||
33810496|NCT06002867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"Grup SAPB~Grup Control"|f|t|t|f
33810497|NCT02504801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810498|NCT03153176|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Allocation, and those who evaluate the outcomes of the main outcome (physical activity, sedentary behavior, dietary intake and body composition) will be blind to baseline group assignment|physical activity and lifestyle intervention|f|f|t|t
33810499|NCT00347061|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729006|NCT02597010|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33729007|NCT05547269|||COHORT||PROSPECTIVE|||||||
33729008|NCT05564663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33729009|NCT04741165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729010|NCT04649775|RANDOMIZED|PARALLEL||TREATMENT||NONE||Unblinded, randomized, controlled trial with two arms.||||
33729011|NCT05923203|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be four groups of study participants including two experimental groups (pediatric and adult EAS) as well as two control groups \[pediatric and adult listeners with normal hearing (NH).||||
33729012|NCT02136667|||COHORT||RETROSPECTIVE|||||||
33729013|NCT04734496|||COHORT||PROSPECTIVE|||||||
33729014|NCT00031174|||CASE_CONTROL||PROSPECTIVE|||||||
33729015|NCT01466699|||COHORT||CROSS_SECTIONAL|||||||
33729016|NCT06420154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729017|NCT02188485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729018|NCT02342704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810500|NCT02203656|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33810501|NCT04148378|||CASE_ONLY||PROSPECTIVE|||||||
33810502|NCT00800176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810503|NCT03155022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810504|NCT04901416|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, unblinded, non-randomized Phase 1 dose-finding study of DVX201.||||
33810505|NCT04920968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810506|NCT04131257|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33810507|NCT04317885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810508|NCT02567591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729019|NCT03369938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810509|NCT03845699|||COHORT||PROSPECTIVE|||||||
33810510|NCT00886834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810511|NCT04895085|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a single site study taking place over 24 months and involving (50) caregivers and their children with medical complexity. Additionally, (20) of these caregivers will be invited to participate in an hour-long, virtual contextual inquiry session.||||
33810512|NCT01802424|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33810513|NCT00552591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810514|NCT00176319|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33810515|NCT03985397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The patients were randomly assigned to the intervention (50 patients) and control groups (50 patients) by lot according to the protocol numbers that are even and odd numbers (even numbers; the intervention group, odd numbers; the control group).|f|f|t|f
33810516|NCT00903864|||||PROSPECTIVE|||||||
33810517|NCT03080805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810518|NCT04976829|||OTHER||OTHER|||||||
33810519|NCT05379166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810520|NCT06501027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150210|NCT04229836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810521|NCT02111551|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34150211|NCT01494519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150212|NCT03346577|||CASE_ONLY||PROSPECTIVE|||||||
33810522|NCT00822432|||||CROSS_SECTIONAL|||||||
33810523|NCT00022165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33810524|NCT04665583|||CASE_ONLY||PROSPECTIVE|||||||
33810525|NCT03042767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041948|NCT04651855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041949|NCT04021238|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041950|NCT00913263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041951|NCT02332057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150213|NCT01086852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729020|NCT03592615|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Cataract group: participants undergo cataract surgery for vision correction Refractive error group: participants undergo corneal refractive surgery for vision correction||||
33729021|NCT00911261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810526|NCT01961076|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810527|NCT03847727|||CASE_CONTROL||PROSPECTIVE|||||||
33810528|NCT05371821|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810529|NCT04070105|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will walk with their standard prosthesis, a commercial high activity foot, and then the new design of CAESAR foot||||
33810530|NCT04820491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33810531|NCT04852237|||COHORT||RETROSPECTIVE|||||||
33810532|NCT00239967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810533|NCT00126958|||||PROSPECTIVE|||||||
33810534|NCT06261905|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||This is primarily a within-subject, two scan, randomized, double-blind, placebo-controlled study design. Healthy control subjects will only complete one scan to serve as a baseline comparison for subjects with OUD.|t|f|t|f
33810535|NCT00950456|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33729022|NCT00714259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729023|NCT03425812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729024|NCT02759120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729025|NCT04939727|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33729026|NCT00423891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729027|NCT01466192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729028|NCT04116164|NA|SINGLE_GROUP||OTHER||NONE||3-6 patients will be studied in each of 3 sub-cohorts to determine the most favorable mass amount of h11B6 (2 mg, 10 mg, 20 mg). An additional 6 patients will be imaged at the most favorable mass amount to assess tumor targeting.||||
33729029|NCT04638465|||COHORT||PROSPECTIVE|||||||
33729030|NCT02385175|||CASE_CONTROL||PROSPECTIVE|||||||
33729031|NCT02850536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810536|NCT01698541|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810537|NCT03176407|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||There is only one patient group. The one that swallow the sensor capsule.||||
34041952|NCT06521697|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|"This study employs a triple-blinding approach to ensure unbiased results. The participants, care providers (including anesthesiologists and nurses), and investigators are all blinded to the group assignments. Randomization envelopes containing the treatment allocation will be prepared and sealed by a research assistant who is not involved in patient care or data collection.~At the time of surgery, the envelope will be opened by a designated anesthesia nurse who will prepare the study medication (either the dexmedetomidine-ketamine-lidocaine mixture or normal saline) according to the randomization. The medication will be labeled identically to maintain blinding and administered via continuous infusion during anesthesia. Fresh gas flow settings will be adjusted according to the randomization and indicated by a concealed flow meter display."|"This study is a single-center, prospective, 2x2 factorial randomized controlled trial designed to evaluate the anesthetic-sparing and renal protection effects of minimal-flow (intervention 1) sevoflurane anesthesia combined with multimodal analgesia (intervention 2) in head and neck cancer patients undergoing free flap microvascular surgery. Participants will be randomly assigned to one of four groups:~Fresh gas flow at 0.5 L/min with dexmedetomidine-ketamine-lidocaine mixture. Fresh gas flow at 0.5 L/min with normal saline. Fresh gas flow at 1.0 L/min with dexmedetomidine-ketamine-lidocaine mixture. Fresh gas flow at 1.0 L/min with normal saline.~The study uses triple blinding (participant, care provider, investigator) to ensure unbiased results. The primary purpose of the study is treatment, aiming to reduce anesthetic usage and assess renal protection."|t|t|t|t
34041953|NCT02350491|||OTHER||PROSPECTIVE|||||||
34041954|NCT00427648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041955|NCT01275365|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34041956|NCT01930032|||OTHER||PROSPECTIVE|||||||
34041957|NCT04976010|||COHORT||PROSPECTIVE|||||||
34041958|NCT06574672|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Stepped Wedge Intervention||||
34041959|NCT01438905|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34041960|NCT04824430|||COHORT||PROSPECTIVE|||||||
34041961|NCT05547139|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Infants will be randomized to the usual care group or the protocol care group.||||
34041962|NCT04849468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The studied drugs will be prepared immediately before injection by an anesthesiologist blinded to the study methodology and will be administered by a second blinded anesthesiologist patients and assessor also will be unaware of the type of group|patients will be randomly allocated into two groups; Diclofenac (D) group which will receive 75 mg (3ml) IM Diclofenac in a 5ml syringe and Saline (S) group which will receive 3ml IM saline in a similar 5ml syringe|t|f|f|t
34041963|NCT02351414|||COHORT||PROSPECTIVE|||||||
34041964|NCT00813384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041965|NCT03503669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34041966|NCT00330993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041967|NCT04340947|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34041968|NCT00291070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34041969|NCT03946319|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|All relevant participant research data is stored separate from protected health information and potentially identifiable information, including into which study arm the participant has been randomized.|Participants are randomized either into a control group assigned to the standard of care diagnostic assessments once daily or into an experimental group assigned to the novel, personalized assessment system. The content of both assessment systems is the same, but the approach to delivering the assessments differs based on the arm. Each arm will have 25 participants, and any additional participants who register will be assigned to a waitlist.|t|t|t|t
34115693|NCT04106505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The randomization number will be drawn sequentially from a list of 40 numbers where one random in every four numbers results in downloading a sham-version of the app. Both versions of the app look alike and no pattern in the 5-digit number or the randomization list can reveal which version of the app is given. This will ensure blinding of both participants and study personnel. Breaking of the randomization will be made after follow-up of the last participant. The software developers will at this point reveal what 5-digit numbers corresponded to the biofeedback or sham version of the app.|The study will begin with a one-month baseline period, followed by a two-month treatment period. Participants will randomly be assigned to one of two groups by a computer-generated block-randomization list. In each block of four, participants will have a 75% chance of being allocated to the biofeedback group and 25% chance of being allocated to the sham group, to ensure 30 participants in the biofeedback group and 10 in the sham group. The randomization list will remain inaccessible to the investigators until end of follow-up of the last participant. Both participants and personnel will be blinded to the intervention given. It should be noted that this study is intended as a pilot study, and not a randomized controlled trial. Still, we wish to use randomization and blinding to ensure that the group receiving sham treatment is a random subset of the study population.|t|t|t|f
34115694|NCT00373542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115695|NCT06206590|||COHORT||PROSPECTIVE|||||||
34115696|NCT00305396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115697|NCT04145596|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34115698|NCT05093608|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115699|NCT01871376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115700|NCT04799795|||CASE_CONTROL||PROSPECTIVE|||||||
34115701|NCT04063813|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Five parallel groups, matched for age and BMI, where exercise was applied at 6o uphill or 6o downhill either as one 40-min morning bout or as two 20-min half bouts distributed 7 h apart. A sedentary group served as a control for the four exercise groups.||||
34041970|NCT03105180|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34041971|NCT06384404|||COHORT||PROSPECTIVE|||||||
34041972|NCT01866462|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34041973|NCT02448394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Study investigators (except statistician and data manager) blinded to interim outcome results by study arm.|Randomized community trial|f|f|t|f
34041974|NCT00263705|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041975|NCT00687544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041976|NCT03455088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34041977|NCT02596555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041978|NCT01441765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041979|NCT01523782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
34041980|NCT05424848|||OTHER||PROSPECTIVE|||||||
34041981|NCT03059043|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34041982|NCT05822076|||COHORT||PROSPECTIVE|||||||
34041983|NCT04201574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041984|NCT03454308|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34041985|NCT02195869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041986|NCT05693064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729032|NCT03267862|||COHORT||CROSS_SECTIONAL|||||||
33729033|NCT02958839|||CASE_CONTROL||PROSPECTIVE|||||||
33729034|NCT05691231|||CASE_ONLY||PROSPECTIVE|||||||
33729035|NCT02306512|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729036|NCT04338711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729037|NCT02627612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33729038|NCT01020058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729039|NCT05145829|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729040|NCT02549508|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729041|NCT04111094|||COHORT||PROSPECTIVE|||||||
33729042|NCT04607993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729043|NCT00855088|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729044|NCT05892848|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729045|NCT02803112|||CASE_ONLY||RETROSPECTIVE|||||||
33729046|NCT02112825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729047|NCT01354496|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33810538|NCT01806207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810539|NCT06058130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33810540|NCT02255474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33810541|NCT05785650|||CASE_CONTROL||PROSPECTIVE|||||||
33810542|NCT00424957|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115702|NCT03498573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115703|NCT01940419|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34115704|NCT00980044|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115705|NCT04487509|||COHORT||PROSPECTIVE|||||||
34115706|NCT00766987|||COHORT||PROSPECTIVE|||||||
34115707|NCT02328495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34115708|NCT02746809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115709|NCT02134184|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34115710|NCT03026179|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34115711|NCT06060873|||COHORT||PROSPECTIVE|||||||
34115712|NCT01662206|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115713|NCT01818778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115714|NCT05106556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1: Inspiratory Muscle Training (IMT) Group Group 2: Control Group|t|f|f|t
34115715|NCT03837509|RANDOMIZED|PARALLEL||TREATMENT||NONE||An initial equal randomization of participants between INCB001158 in combination with daratumumab SC (Treatment Group A), daratumumab SC monotherapy (Treatment Group B), and INCB001158 monotherapy (Treatment Group C) will be conducted. Participants in the treatment groups B and C at confirmed disease progression will be crossed over to INCB001158 + daratumumab SC. After the equal randomization period, a response adaptive randomization design will be used to compare the objective response rate of Treatment Groups A and B with adjustments to the randomization rate based on the observed objective response rate.||||
34115716|NCT01585727|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34115717|NCT02107612|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115718|NCT03715790|||OTHER||PROSPECTIVE|||||||
34115719|NCT01596426|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115720|NCT06344091|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm study of liposomal bupivacaine injection||||
34115721|NCT04812327|||CASE_ONLY||PROSPECTIVE|||||||
34150214|NCT01586455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150215|NCT01633190|||COHORT||OTHER|||||||
34150216|NCT01300988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810543|NCT01124552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810544|NCT04106739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized (permuted block randomization, fixed), Parallel Group, Placebo Controlled Trial.|t|f|f|t
33810545|NCT06397586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33810546|NCT01596686|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33810547|NCT04987528|||COHORT||RETROSPECTIVE|||||||
33810548|NCT04693169|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34041987|NCT02307942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34041988|NCT04793711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041989|NCT05969041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34041990|NCT00521820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041991|NCT00586820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34041992|NCT02752113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34041993|NCT06480539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34041994|NCT00894270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34041995|NCT03291080|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34041996|NCT05885646|||COHORT||PROSPECTIVE|||||||
34041997|NCT02118571|||CASE_ONLY||CROSS_SECTIONAL|||||||
34041998|NCT06577168|||COHORT||PROSPECTIVE|||||||
34041999|NCT05990712|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients will be assigned to either the omega-3 group or no omega-3 group.|f|f|f|t
34042000|NCT04137081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042001|NCT00002691||||TREATMENT||||||||
34042002|NCT04090671|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||multicenter prospective cohort study||||
34042003|NCT05904873|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The researcher who performs the ice test and the researcher who performs the surgical procedures are different from each other. The researcher performing the surgical procedure cannot know the ice test results of the participants.||f|f|t|f
34042004|NCT03261778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042005|NCT01636193|||COHORT||PROSPECTIVE|||||||
34042006|NCT05739838|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||ten patients with periodontally affected teeth subjected to low level laser therapy||||
34042007|NCT00588133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042008|NCT06577831|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042009|NCT05574218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial|f|f|t|f
34042010|NCT06059261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042011|NCT03911128|||COHORT||PROSPECTIVE|||||||
34042012|NCT06578676|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||2 sequence||||
34042013|NCT06163430|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34042014|NCT02472106|||CASE_ONLY||PROSPECTIVE|||||||
34042015|NCT04535869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042016|NCT03560284|||COHORT||RETROSPECTIVE|||||||
34042017|NCT05519930|||OTHER||PROSPECTIVE|||||||
34042018|NCT04303806|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"computer generated randomization will be conducted in a Women's Health Hospital, Assuit University. Neither the doctor investigator nor the participant parturient will be aware of the group allocation or the drug used. The study drugs will be prepared by one of the supervisor anesthesia (not included in the procedure, observation or in data collection)"|". They will be randomly allocated into two equal groups of 40 parturient each: Group 1: 40 preeclamptic parturient receive 20 mg rosuvastatin orally once daily.~Group 2: 40 preeclamptic parturient receive 40 mg rosuvastatin orally once daily"|t|f|t|f
34042019|NCT03914716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729048|NCT05371353|||OTHER||PROSPECTIVE|||||||
33729049|NCT00094874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810549|NCT06254976|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The evaluations were conducted by a physical therapy and rehabilitation specialist who was blinded to the patient's treatment protocol, ensuring unbiased assessments.|Thirty patients were evaluated at three different time points: before treatment (day 0), after exercise treatment (day 14), and after two doses of LP-PRP treatment combined with exercise treatment once a week (day 28). The assessment included the Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), cartilage thickness measurement by ultrasonography (USG), 6-minute walk test (6MWT) parameters, and measurements of serum YKL-40 and nesfatin-1 levels.|f|f|f|t
33810550|NCT00005826||||TREATMENT||||||||
34115722|NCT03404882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to treatment group allocation by not involving them in discussions about study participants and not granting them access to the database which contains the randomization code. In addition, study participants will be asked not to reveal their treatment allocation to their assessor. Moreover, these assessors will not be involved in data analysis. To test the success of blinding we will ask the assessor to guess the treatment group for each participant at six and 12-month follow-up. After data collection is complete all data will undergo a blind review for the purposes of finalizing the planned analysis.|This will be a longitudinal, prospective, parallel design, three arm, rater-blinded randomized clinical trial with a recruitment period of six months and an observation period of 12 months for each participant.|f|f|f|t
33810551|NCT06499142|NA|SINGLE_GROUP||OTHER||NONE||||||
33810552|NCT03629366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33810553|NCT00519207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810554|NCT02827201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810555|NCT05109598|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33810556|NCT05243459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810557|NCT01061307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810558|NCT06474039|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33810559|NCT01429285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810560|NCT05845398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and site study staff will be blinded to the randomization. Some members of the Sponsor team will be unblinded.|Participants will be randomized 3 to 1 to DCR-AUD or placebo.|t|f|t|f
33838261|NCT03997175|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Participants nor their parents did not know the arm. Care providers did not know the group as they did not know the content of the sand box. Investigators and field assistants knew the content in each sand box but they did not know the coding of the arms when they analyzed the differences in cytokine levels. Outcomes assessors i.e. nurses who took blood samples did not know the arms nor the contents of the sand boxes.|One arm received biodiversity sand and the other arm normal sand.|t|t|t|t
34115723|NCT05120492|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33838262|NCT04746105|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33838263|NCT01128270|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33838264|NCT04837339|NA|SINGLE_GROUP||OTHER||NONE||||||
33838265|NCT03572881|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115724|NCT02891226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115725|NCT05511948|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The open label sub-cohort will not have masking.|Randomized 3-arm tranche of main cohorts, to be followed by open-label Solar Lentigo sub-cohort|t|f|t|t
34115726|NCT00189423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34115727|NCT01527994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115728|NCT00468247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115729|NCT00293176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115730|NCT06074432|||COHORT||RETROSPECTIVE|||||||
34115731|NCT06264635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The provider and patient are both blinded to which treatment (PRP vs saline) the patient is receiving||t|t|f|f
34115732|NCT06071676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115733|NCT04880421|||COHORT||RETROSPECTIVE|||||||
34115734|NCT02196922|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|||||
34115735|NCT00590317|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115736|NCT01086527|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34115737|NCT02348190|NON_RANDOMIZED|PARALLEL||||NONE||||||
34115738|NCT01418859|||COHORT||PROSPECTIVE|||||||
34115739|NCT01202695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34115740|NCT03690778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115741|NCT01621646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729050|NCT00253578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729051|NCT06496802|||COHORT||RETROSPECTIVE|||||||
33729052|NCT03751085|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729053|NCT00747968|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33729054|NCT04035304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Waitlist control group, which will receive same intervention 8 weeks after baseline.|||||
33729055|NCT04475289|||CASE_ONLY||PROSPECTIVE|||||||
33729056|NCT05254262|||COHORT||PROSPECTIVE|||||||
33729057|NCT05210790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Randomized, Double-blind (Part 1a):~Subjects will be randomized in a blinded fashion to 32 weeks of rusfertide or placebo added-on to each subject's ongoing treatment for polycythemia vera.~Open-label (Part 1b + Part 2):~Open-label treatment phase during which all subjects who complete Part 1a successfully will receive rusfertide for 124 weeks."|t|f|t|t
33729058|NCT00362999|||OTHER||PROSPECTIVE|||||||
34115742|NCT00624858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115743|NCT05447403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34115744|NCT01736917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115745|NCT04621578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115746|NCT05967754|NA|SINGLE_GROUP||SCREENING||NONE||||||
34115747|NCT05964686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115748|NCT01493414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115749|NCT06531681|||COHORT||PROSPECTIVE|||||||
34115750|NCT00922363|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729059|NCT01269697|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33729060|NCT04209309|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33729061|NCT01767922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33729062|NCT00443313|||||OTHER|||||||
33729063|NCT05316662|||COHORT||PROSPECTIVE|||||||
33729064|NCT05371600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33729065|NCT03144492|||CASE_ONLY||PROSPECTIVE|||||||
33729066|NCT02051465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729067|NCT04723212|||COHORT||CROSS_SECTIONAL|||||||
33729068|NCT05932446|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33729069|NCT01344447|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729070|NCT05618106|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cross-over of 3 variations of the low FODMAP diet excluding 1 of the 3 components in every period||||
33729071|NCT05225896|||COHORT||RETROSPECTIVE|||||||
33729072|NCT02984384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33729073|NCT04990934|||CASE_ONLY||RETROSPECTIVE|||||||
33729074|NCT05072353|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33729075|NCT03606681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729076|NCT01726699|||CASE_ONLY||PROSPECTIVE|||||||
33729077|NCT01904708|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33729078|NCT02479152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729079|NCT00721695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729080|NCT04300972|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33729081|NCT03591575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo solution will have the same appearance and flavor as deferiprone oral solution, and will be administered at a volume matching that required for the dose of active product.||t|t|t|t
33729082|NCT00534235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729083|NCT02726633|||CASE_ONLY||PROSPECTIVE|||||||
33729084|NCT01474642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729085|NCT01147653|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33729086|NCT04516083|||COHORT||PROSPECTIVE|||||||
33729087|NCT00703547|RANDOMIZED|CROSSOVER||PREVENTION||||||||
33729088|NCT02202928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729089|NCT05209685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729090|NCT02290288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729091|NCT00972803|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33729092|NCT00832403|||CASE_ONLY||RETROSPECTIVE|||||||
33729093|NCT04552366|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729094|NCT02413827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729095|NCT04935476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, study staff and data analyst)|"This is a randomized, triple-blind, placebo-controlled, multi-center study.~Following e-signature of the informed consent form, approximately 3000 participants meeting all inclusion criteria and no exclusion criteria will be randomized to receive either Dapsone or placebo (1:1 allocation ratio) for 21 days. Screening blood-work and confirmatory tests are made available to participants at their residence by the study. Study interventions (drugs or placebo) will be delivered directly to participants by courier .~Participants are remotely followed-up through e-daily diary during 21 days of treatment along with virtual visits (phone) at 1, 7, 14, 21, 28 and 51 days following randomization for evaluation of the occurrence of any trial endpoints or other adverse events. During study enrollment patients are linked to the study through their participant account on the study virtual care platform."|t|f|t|t
33729096|NCT04514575|||COHORT||RETROSPECTIVE|||||||
33729097|NCT01071512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729098|NCT04637958|||COHORT||RETROSPECTIVE|||||||
33729099|NCT05799092|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Clinical outcome assessment will be performed under blinded assessment about the allocated treatment group.|Pragmatic, prospective, multi-center, open label, randomized controlled, superiority trial.|f|f|f|t
33729100|NCT02239809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729101|NCT05920434|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33729102|NCT01606046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33729103|NCT04289116|RANDOMIZED|PARALLEL||OTHER||NONE||At baseline participants will be randomized to one of two conditions: Condition 1: MI-CST + observation of ACT videos + CHTC, and Condition 2: Individual HIV Testing (IHTC) as usual. Youth have the choice of attending the baseline visit alone or with their partner and have the option to bring their partner in later after completing the baseline alone. Youth in this CET will complete follow-up assessments at 1, 3, and 6 months.||||
33729104|NCT00169143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729105|NCT03041012|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33729106|NCT05961774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33729107|NCT01970683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33729108|NCT00380393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33729109|NCT05111132|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33729110|NCT03999307|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115751|NCT00670644|||COHORT||PROSPECTIVE|||||||
33729111|NCT02135224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33729112|NCT00755066|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33729113|NCT00983580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33729114|NCT00062569|RANDOMIZED|PARALLEL||||NONE||||||
33729115|NCT01171716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33729116|NCT01427088|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729117|NCT04288622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729118|NCT03442075|||COHORT||RETROSPECTIVE|||||||
33729119|NCT04226482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to allocation and instrument used for surgery, with the same clinical treatment and postoperative follow-up.|Participants will be randomized to laparoscopic appendectomy with new ultrasonic shears versus laparoscopic appendectomy with reused ultrasonic shears. Randomization sequence will be issued by independent statistician and the participants will be blinded to the surgical instrument used for laparoscopic appendectomy.|t|f|f|f
33729120|NCT03298750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729121|NCT02588924|||CASE_CONTROL||RETROSPECTIVE|||||||
33729122|NCT05349162|||COHORT||RETROSPECTIVE|||||||
33729123|NCT02188615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729124|NCT00876304|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33729125|NCT03331692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"During the anesthesia, in all the participants an AAI-A line ARX index was continuously monitored. The electrodes were placed after the induction of anesthesia.~Intraoperatively, both auditory evoked potentials with AAI index and electroencephalogram with burst suppression analysis was recorded. Recorded data were blinded for anesthesiologists, so were not used for analysis of level of anesthesia during surgery."|Participants are assigned to intravenous or volatile anesthesia. In both groups both the clinical and instrumental monitoring of the proper level of anesthesia was analyzed.|t|t|f|f
33729126|NCT05371314|||CASE_CONTROL||RETROSPECTIVE|||||||
33729127|NCT02452151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33729128|NCT06000865|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
33729129|NCT02462967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729130|NCT01734551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729131|NCT00011089||||TREATMENT||||||||
33729132|NCT03221933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729133|NCT00795743|||COHORT||PROSPECTIVE|||||||
33729134|NCT03258827|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assistant who doesn't know the group which patients belong to will evaluate the functional performance of the patients three times, such as before training, after training, post-training 3 months.|We randomize these 60 older adults into 2 groups (experimental group and control group) and there are 30 older adults in each group. Those older adults are age above 65 year-old, have lower grip strength and slower walking speed. Experimental group receive this exercise program training, 60 minutes/time, 3 times/week, total duration: 3 months. Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times, would be assigned for Control group. Total duration is 3 months.|f|f|f|t
33729135|NCT05326503|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33729136|NCT01327404|||CASE_CONTROL||PROSPECTIVE|||||||
33729137|NCT02389504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729138|NCT05926167|||CASE_ONLY||PROSPECTIVE|||||||
33729139|NCT02513524|||COHORT||PROSPECTIVE|||||||
33729140|NCT01963390|||COHORT||PROSPECTIVE|||||||
33729141|NCT03080558|NA|SINGLE_GROUP||TREATMENT||NONE|open|||||
33729142|NCT00099463||||TREATMENT||||||||
33729143|NCT04659785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729144|NCT00253383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729145|NCT03645668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810561|NCT04183491|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.~Subjects and staff will be blinded to treatment assignment during confinement, but route of administration will not be blinded. The blind will be maintained through a randomization schedule held by the dispensing pharmacist. Subjects and staff will be informed of a subject's end of study day when discharged from confinement. Subjects and staff will not be informed of the specific treatment arm assignment. The clinical research nurse will administer the subcutaneous study drug in unit dose containers that are not transparent."|Subjects will be randomized to one of three dose groups (low, intermediate, and high) of each drug (interferon beta-1a and peginterferon beta-1a) or placebo|t|f|t|f
33810562|NCT02084615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810563|NCT05485493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The research is a randomized controlled experimental model with a pretest posttest control group.|t|f|f|f
33810564|NCT06246890|||CASE_ONLY||PROSPECTIVE|||||||
33729146|NCT02355327|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33729147|NCT03909542|||COHORT||RETROSPECTIVE|||||||
33729148|NCT05252533|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33810565|NCT02166632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810566|NCT03822806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810567|NCT03360617|RANDOMIZED|PARALLEL||OTHER||DOUBLE|When the pharmacist prepares the medication he/she will refer to the randomization form to select the correct study arm. The pharmacist will place a protective cover over the syringe and over the piggyback bag before it is provided to the nurse administering the medication.|Single-center, prospective, double-blinded, double-dummy, randomized controlled trial|t|t|f|f
33810568|NCT05636397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective dose-escalation study.~Arm 1: BPD-PH Total of 12-24 infants; 6-12 at each dose level. (300 or 500 mg/kg/day divided q6 hours)~Arm 2: sNEC A total of 18-36 infants with Stage III NEC; 6-12 at each dose level. (75, 150 or 225 mg/kg/day divided q6 hours)"||||
33810569|NCT02123953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810570|NCT00199056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810571|NCT06226441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810572|NCT02647333|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33810573|NCT03021616|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
33810574|NCT00911404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810575|NCT02412904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810576|NCT01939509|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33810577|NCT05519306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A feasibility study with pretest/posttest design will be deployed to address the research aims. A feasibility study is considered the most appropriate design due to the lack of MP research with this population. Acceptability and limited efficacy will be the specific areas of focus of feasibility. The findings from this study can be used to indicate if a larger, randomized controlled trial with individuals with severe UE hemiparesis is necessary.||||
33810578|NCT04999072|||COHORT||RETROSPECTIVE|||||||
33810579|NCT01386372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810580|NCT02060084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810581|NCT01115036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810582|NCT04614129|NA|SINGLE_GROUP||SCREENING||NONE||||||
33810583|NCT06151106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810584|NCT04931303|||COHORT||PROSPECTIVE|||||||
33729149|NCT05853133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the postoperative period, the effectiveness and safety of the block will be evaluated by another researcher (blind) who does not know which group the patient is in.|"Group E: Before the operation, the ESP block will be applied to the patients bilaterally, in the prone position under sedation by same anesthesiologist. Group E (ESP block) will be applied 20 ml of %0.25 bupivacaine between the erector spina muscle and transverse process at the 11th thoracic level.~Group W: At the end of the operation,wound infiltration will be administered under general anesthesia in supine position by surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each)~In the postoperative period, the patient was evaluated to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life."|f|f|t|t
33729150|NCT00962130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729151|NCT03689556|||CASE_ONLY||PROSPECTIVE|||||||
33729152|NCT03863028|||COHORT||PROSPECTIVE|||||||
33729153|NCT06106971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810585|NCT02333318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33810586|NCT04305340|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33810587|NCT04780152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In addition some of the personnel (evaluators, data analyst, result analyst) will be blinded in order to increase the internal validity of our study. A blind person is considered by the person that apply the intervention.|A multicentric, randomized, clinical trial, phase 2/3 of superiority, with two parallel arms, comparative, controlled with placebo, in which changes in a major depressive disorder scale will be assessed (change in CDI score measured at week 10 compared with initial score) comparing with basal score and between the two groups (\>40% measured at 2 weeks, 1,2, 3 months of treatment).|t|t|t|t
33810588|NCT03784105|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Double-blind, preparation and administration of codeine or placebo conducted by an independent researcher.|Double-blind, placebo-controlled, randomized, cross-over study in healthy volunteers|t|f|t|t
33810589|NCT00778856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810590|NCT03691441|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, two-arm, open label, multicenter, randomized, controlled comparative effectiveness study.~The trial is based on an event-driven design: the final analysis will be performed when all events have been observed or the study was terminated at one of the interim analyses."||||
33810591|NCT02005172|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810592|NCT01354509|||CASE_CONTROL||PROSPECTIVE|||||||
34115752|NCT01170351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115753|NCT01428635|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34115754|NCT01368614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115755|NCT03825705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115756|NCT02041793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115757|NCT04987372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115758|NCT01188187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115759|NCT03435380|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned, in a ratio of 1:1:1, to one of the three groups: control, patient activation (PA), or patient activation + primary care provider activation (PA+PCP). Participants will remain in the group they are randomized to with no crossover throughout the study.||||
34115760|NCT01650402|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34115761|NCT01090947|||CASE_ONLY||CROSS_SECTIONAL|||||||
34115762|NCT01936558|||CASE_CONTROL|||||||||
34115763|NCT05973955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115764|NCT01357681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115765|NCT02702050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115766|NCT00198900|||DEFINED_POPULATION||OTHER|||||||
34115767|NCT03070626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34115768|NCT02052973|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115769|NCT05629988|||COHORT||PROSPECTIVE|||||||
33729154|NCT05233436|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33729155|NCT01192152|RANDOMIZED|CROSSOVER||||NONE||||||
33729156|NCT02927028|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33810593|NCT05778409|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33810594|NCT06407648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized parallel clinical trial|f|f|f|t
33810595|NCT01271894|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33810596|NCT01319058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810597|NCT01966705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810598|NCT03553225|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33810599|NCT00250770|||CASE_CONTROL||PROSPECTIVE|||||||
33810600|NCT00003412||||TREATMENT||||||||
34115770|NCT01988753|||OTHER||PROSPECTIVE|||||||
34115771|NCT05149729|NA|SINGLE_GROUP||TREATMENT||NONE||Patients over the age of 18 who underwent Crowe Type 3 and Type 4 shortened hip prosthesis||||
34115772|NCT01959685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115773|NCT05132972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115774|NCT05201807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115775|NCT03243864|||CASE_ONLY||PROSPECTIVE|||||||
34115776|NCT00427700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115777|NCT05347342|||COHORT||PROSPECTIVE|||||||
34115778|NCT00152438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729157|NCT01665274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729158|NCT02872636|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729159|NCT01347437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729160|NCT06076694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729161|NCT01650363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33729162|NCT04753164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept study|t|t|t|t
33729163|NCT03666078|||CASE_ONLY||CROSS_SECTIONAL|||||||
33729164|NCT03164798|||CASE_ONLY||PROSPECTIVE|||||||
33729165|NCT03650907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729166|NCT04371380|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study|Eligible participants will receive orally, tablets of cabotegravir plus rilpivirine for 28 days. There will be 10 to 14 days wash out period followed by an IM injection of cabotegravir long-acting plus rilpivirine long-acting.||||
33729167|NCT05358496|||COHORT||PROSPECTIVE|||||||
34042020|NCT04495972|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Double-blind, randomized, placebo-controlled study|t|t|t|t
33729168|NCT05894681|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||THE EFFECT OF WATSON MODEL-BASED PSYCOEDUCATIONAL INTERVENTIONS ON PREVENTION OF POSTPARTITION DEPRESS|f|f|t|f
33729169|NCT06057688|||COHORT||PROSPECTIVE|||||||
33729170|NCT02665416|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729171|NCT01015352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729172|NCT01431703|||COHORT||PROSPECTIVE|||||||
33729173|NCT03437122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729174|NCT02679911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intra-individual study|f|f|t|f
33729175|NCT02455310|||OTHER||RETROSPECTIVE|||||||
33729176|NCT01591473|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33729177|NCT00259090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729178|NCT05548023|NA|SINGLE_GROUP||OTHER||NONE||||||
33729179|NCT00555984|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33729180|NCT02863835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729181|NCT00816868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729182|NCT05595993|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33729183|NCT00203528|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33729184|NCT05324163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Assignment|t|t|t|t
33729185|NCT04043312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33729186|NCT01275066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729187|NCT00937690|||CASE_CONTROL||PROSPECTIVE|||||||
34042021|NCT03917446|||CASE_CONTROL||PROSPECTIVE|||||||
34042022|NCT01107522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042023|NCT04597177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042024|NCT02464423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042025|NCT00951743|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34042026|NCT03196115|||COHORT||PROSPECTIVE|||||||
34042027|NCT03267082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042028|NCT02677571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042029|NCT01706939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042030|NCT06040515|||CASE_ONLY||PROSPECTIVE|||||||
34042031|NCT01805518|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34042032|NCT03742661|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Participating physicians will recruit patients meeting the inclusion and exclusion criteria. Upon completion of screening and enrollment procedures study participants will be randomly assigned to one of two groups using a randomized call-in system: treatment or standard of care.~Demographics will be obtained for both groups during this initial clinic visit. The treatment group will be prescribed the Brain Sentinel® SPEAC System for use in the home environment. Study Participants in the standard of care group will be given standard care."||||
34042033|NCT00873743|||||PROSPECTIVE|||||||
34042034|NCT00027066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34042035|NCT02391012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042036|NCT06548386|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042037|NCT01605240|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33729188|NCT05098353|NA|SINGLE_GROUP||TREATMENT||NONE||Open label study||||
33729189|NCT01572038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729190|NCT05767333|||COHORT||PROSPECTIVE|||||||
33729191|NCT05962411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729192|NCT00262067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729193|NCT01161329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729194|NCT05062265|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33729195|NCT02610699|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33729196|NCT04804709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042038|NCT04927780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729197|NCT03925727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729198|NCT04654533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants are randomized into intervention group or a waitlist|f|f|f|t
33810601|NCT01496794|||CASE_ONLY||PROSPECTIVE|||||||
33810602|NCT04154085|NA|SINGLE_GROUP||TREATMENT||NONE||A group consisting of 12-15 participants will be recruited for this initial exploratory study.||||
33810603|NCT05870163|||COHORT||PROSPECTIVE|||||||
33810604|NCT04568213|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33810605|NCT01226888|||CASE_ONLY||PROSPECTIVE|||||||
33810606|NCT04072133|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial with single arm||||
33810607|NCT04530032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810608|NCT06037707|||COHORT||RETROSPECTIVE|||||||
33810609|NCT06475534|||COHORT||PROSPECTIVE|||||||
33810610|NCT02050815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810611|NCT03357237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo."|t|t|t|f
34042039|NCT00404001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042040|NCT00777270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042041|NCT04570670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects were randomized to 1 of 2 treatment sequences prior to the first dose.||||
34042042|NCT02510664|NA|SINGLE_GROUP||OTHER||NONE||||||
34042043|NCT02881515|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34042044|NCT00598312|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042045|NCT06303401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042046|NCT04412109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042047|NCT01117922|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042048|NCT02425592|||COHORT||PROSPECTIVE|||||||
33729199|NCT05775978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Investigator: researchers have no information on participants' allocation in the groups; a research assistant from the Cognitive Neuroscience Group of the CIMCYC is designated for this purpose. None of the participants are students of any of the researchers. For the purpose of communicating with the participants over group allocation, another lecturer from the UGR is appointed. Outcome Assessors: all measures are collected online via the UGR LimeSurvey platform and no recording of group assignment is introduced in the system. Care providers: they are not informed about the outcome measures or specific research hypothesis regarding expected effects for each program. Participants: although it is not possible to blind their assignment to the groups in this type of study, they are not informed about the specific hypothesis regarding the expected outcomes of the programs.|Students are randomly assigned to three groups: the MBSR group that receives an adapted version of the MBSR program, the Más Presente group that receives training on transversal competences following the EU framework, LifeComp, and a third group that receives a neuro-muscular stimulation-based program. All participants are asked to fill in an informed consent and a demographic questionnaire to determine eligibility. Eligible participants are randomly assigned to either group. The three programs are given simultaneously.|t|t|t|t
33729200|NCT04501614|NA|SEQUENTIAL||TREATMENT||NONE||||||
33729201|NCT02194868|||COHORT||PROSPECTIVE|||||||
33729202|NCT03382106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Subject and study team are masked to which arm subject is assigned (study drug or placebo). Investigational pharmacy will not be masked. For the non-smoker groups, both subjects and the study team will know which group they are assigned to (study drug or no medication).||t|f|t|f
33729203|NCT03214627|NA|SINGLE_GROUP||OTHER||NONE||The trial will consist of a retrospective control period and a prospective period. During the prospective period, the ACM will be used to facilitate the Investigators' decision making and will help the Investigators to administer a personalised IV iron and ESA therapy, whereas treatment according to standard of care will be documented retrospectively for the same patients during the retrospective (historical) period of the trial. Thus, patients can serve as their own control.||||
33729204|NCT00881946|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729205|NCT00834912|RANDOMIZED|CROSSOVER||||NONE||||||
33729206|NCT02861950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729207|NCT03341988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729208|NCT03616912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729209|NCT05071703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729210|NCT01839448|||COHORT||PROSPECTIVE|||||||
33729211|NCT00951431|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729212|NCT01865825|||CASE_CONTROL||PROSPECTIVE|||||||
33729213|NCT05667233|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be randomly assigned to one of two parallel groups (train to failure OR train to non-failure) and stratified according to their recent training experience (beginner \[3-9 months experience\], intermediate \[9-18 months experience\], advanced \[\>18 months experience\]).||||
33729214|NCT02838277|||COHORT||PROSPECTIVE|||||||
34115779|NCT04736355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729215|NCT00424151|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115780|NCT04881760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729216|NCT02825303|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33729217|NCT04228796|||CASE_ONLY||RETROSPECTIVE|||||||
33729218|NCT04985630|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729219|NCT03715608|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33729220|NCT06242210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729221|NCT04489030|||COHORT||PROSPECTIVE|||||||
33729222|NCT05016232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729223|NCT03179085|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Participants randomized to control group will receive standard care for 12 months before entering into the delayed intervention. Participants randomized to the intervention will receive the intervention during the first 12 months.||||
33810612|NCT04185818|RANDOMIZED|PARALLEL||OTHER||SINGLE||The People's Trial is an online pragmatic, randomised controlled trial.|f|f|f|t
33810613|NCT01544907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810614|NCT01124045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810615|NCT04108104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810616|NCT03287232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810617|NCT01192555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810618|NCT04217252|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The participants from the department of hematology and intensive care unit who meet the inclusion criteria are randomly divided into the control group and the experimental group. Both the participants of the control group and the experimental group undergo routine clinical diagnosis methods and treatment. In addition, the participants of the experimental group are collected the samples including whole blood, cerebrospinal fluid or alveolar lavage fluid required for high throughput sequencing of infectious pathogens during sample collection for routine pathogenic examination of infection.|t|f|f|f
33810619|NCT00653185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810620|NCT01929291|||COHORT||PROSPECTIVE|||||||
33810621|NCT05606185|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33810622|NCT01338506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810623|NCT03205488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810624|NCT00985582|||CASE_ONLY||PROSPECTIVE|||||||
33810625|NCT03102892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810626|NCT01487954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33838266|NCT04011488|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33729224|NCT03325907|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||single-armed feasibility trial||||
33729225|NCT04213456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729226|NCT05281614|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||open label study with 2 treatment arms||||
33838267|NCT02792595|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33838268|NCT00569543|||COHORT||PROSPECTIVE|||||||
33838269|NCT04530578|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controled, prospective, randomized, comparative against standard treatment.||||
34042049|NCT00979316|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33729227|NCT01334658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729228|NCT01194947|||CASE_ONLY||PROSPECTIVE|||||||
33729229|NCT01802775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729230|NCT02121587|||COHORT||PROSPECTIVE|||||||
33729231|NCT02214277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33729232|NCT05854875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729233|NCT04735497|||COHORT||PROSPECTIVE|||||||
33729234|NCT00994448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33729235|NCT03023566|||COHORT||PROSPECTIVE|||||||
33729236|NCT05433454|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The nature of the intervention will be randomized to participants.||||
33729237|NCT04306809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729238|NCT03616353|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Care provider is performing a specific type of injection and therefore cannot be blinded. Those investigators responsible for collecting, managing, and analyzing data will be blinded to treatment randomization.||t|f|t|t
33729239|NCT02499393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729240|NCT04892576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment|A prospective pre-test post-test randomized controlled trial|f|f|f|t
33729241|NCT03367143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729242|NCT03661814|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two cohorts. Experimental group receives the study device and the control group receives the standard of care (No device). Patients are randomized to either group.||||
33729243|NCT03204513|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own microprocessor (MP) knee prosthesis and the powered knee-ankle (PKA) prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions per device. The device participants begin with will be randomly selected but there will be equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."||||
33729244|NCT03859895|||COHORT||PROSPECTIVE|||||||
33729245|NCT06082466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729246|NCT06167616|||CASE_CONTROL||PROSPECTIVE|||||||
33729247|NCT05819164|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729248|NCT01489969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729249|NCT04010266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33729250|NCT02129803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729251|NCT00659867|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33729252|NCT00518804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33729253|NCT02751177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729254|NCT05785364|||COHORT||PROSPECTIVE|||||||
33810627|NCT03417700|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Participants will receive vitamin D supplementation, but the dose will be known only to one investigator, who will be not be participating in any other assessment.|"Model I~Women and men over 65 years old will participate in the training programme. All subjects will undergo a medical check-up before being subject to exercise. All procedures will be performed with the approval from the Bioethical Committee of the Regional Medical Society in Gdansk. One week prior to the beginning of the experiment, a battery of physiological and psychological tests will be performed. The same procedure will be repeated after the training period.~In addtition to training, supplementation of vitamin D (800IU and 4000IU) will be administered.~Model II~Young women will participate in the training programme. They will perform a high-intensity circuit training according to the ACSM. They will perform a single session of HICT and 12 units of HICT regularly. One week prior to the beginning of the experiment, a battery of physiological and psychological test will be performed. The same procedure will be repeated after the training period."|f|f|t|f
33810628|NCT00797550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810629|NCT04383392|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33810630|NCT02302157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810631|NCT05056194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810632|NCT03121885|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33810633|NCT01138657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810634|NCT01703598|NA|SINGLE_GROUP||TREATMENT||NONE||Asleep Deep Brain Stimulation||||
33810635|NCT04588207|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810636|NCT01159600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810637|NCT02469025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33810638|NCT00443274|||COHORT||PROSPECTIVE|||||||
33729255|NCT06447844|RANDOMIZED|PARALLEL||TREATMENT||NONE||a multi-site, randomized, two-arm, controlled clinical trial using OsteoGen® Plug (Test) vs Freeze-dried Bone Allograft with collagen barrier||||
33729256|NCT00494572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729257|NCT00813358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729258|NCT01263548|||||PROSPECTIVE|||||||
33729259|NCT02119546|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33810639|NCT03838757|||CASE_CONTROL||OTHER|||||||
33810640|NCT05787236|||COHORT||RETROSPECTIVE|||||||
33729260|NCT05148858|||CASE_CONTROL||RETROSPECTIVE|||||||
33810641|NCT02819999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810642|NCT01404338|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE||||||
33810643|NCT00794807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810644|NCT01686152|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33810645|NCT01295099|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810646|NCT02792907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810647|NCT05829668|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810648|NCT00186563|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33810649|NCT01829594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33810650|NCT00506896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810651|NCT00706160|||||PROSPECTIVE|||||||
33810652|NCT04704440|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33810653|NCT00249405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810654|NCT03541525|||COHORT||PROSPECTIVE|||||||
33810655|NCT05171426|||OTHER||RETROSPECTIVE|||||||
33810656|NCT06466551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042050|NCT05432765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients who meet eligibility criteria will be randomized (1:1) into one of two treatment arms using balanced-permuted block randomization with a block size of 4, stratified by transplant number (first versus second). The random allocation sequence will be prepared by the study statistician and implemented automatically by the randomization procedure in REDCap||t|f|t|f
34115781|NCT03178409|||CASE_CONTROL||RETROSPECTIVE|||||||
33810657|NCT04053699|||COHORT||PROSPECTIVE|||||||
33810658|NCT01750788|||COHORT||PROSPECTIVE|||||||
33810659|NCT02677766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810660|NCT06031818|||COHORT||RETROSPECTIVE|||||||
33810661|NCT00491101|||COHORT||PROSPECTIVE|||||||
33810662|NCT02530892|||COHORT||PROSPECTIVE|||||||
33810663|NCT04970602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810664|NCT01303471|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33810665|NCT02715388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810666|NCT00266383|||CASE_CONTROL||OTHER|||||||
34042051|NCT04105166|NA|SEQUENTIAL||TREATMENT||NONE||Initial safety evaluation will occur in an adult cohort (n=2) patients, followed by pediatric patients ages 8-17 (n=2-3).||||
34042052|NCT05940181|NA|SEQUENTIAL||TREATMENT||NONE||single-center, open-label, single-arm, dose escalation exploratory study||||
34042053|NCT04894825|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34042054|NCT06491173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042055|NCT06079723|||CASE_CROSSOVER||PROSPECTIVE|||||||
34042056|NCT06576154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34042057|NCT05496712|||COHORT||PROSPECTIVE|||||||
34042058|NCT05827718|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Patients, investigators, and outcomes assessors will all be blinded to who arm each patient is enrolled into.|RCT #1: three-arm trial of three methods to contact patients (text v. email v. email+text) / RCT #2: three-arm trial of two sources of contact (personal physician v. research team) / RCT #3: two-arm trial of framing methods (appeal to altruism vs. no appeal) / RCT #4: three-arm trial of framing methods (social proof v. perceived scarcity v. neither) / RCT #5: two-arm trial of framing methods (opt-in v. opt-out) / RCT #6: four-arm trial of incentive structure (gain-framed v. loss-framed; guarantee v. lottery)|t|f|t|t
34042059|NCT00941486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042060|NCT05864703|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blind to intervention|Randomized, sham-controlled trial|t|f|f|f
34042061|NCT01315938|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Delayed start design|f|f|f|t
34042062|NCT00916084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34042063|NCT04722705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042064|NCT03704025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042065|NCT04177095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective single-center, single-arm pilot study||||
34042066|NCT06445712|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042067|NCT00612274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042068|NCT01602367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042069|NCT02175693|||COHORT||PROSPECTIVE|||||||
34042070|NCT01506401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042071|NCT06461962|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34042072|NCT05527275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042073|NCT00086684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042074|NCT03533153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042075|NCT05609760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Participants, clinical investigators, outcome assessors, analysts and sponsors will be kept unaware of treatment allocation. The masking of the participating patients will be carried out through an informative brochure on bronchial asthma delivered as part of the usual education, albeit without using pictograms.|Randomized clinical trial of parallel groups with triple masking amongst patients with a recent diagnosis of asthma (\<=15 days) in primary care.|t|t|t|t
34042076|NCT00778869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042077|NCT02823665|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34042078|NCT04482361|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34042079|NCT05809960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115782|NCT04768244|||CASE_CONTROL||PROSPECTIVE|||||||
34115783|NCT04626726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115784|NCT02604511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115785|NCT00594750|||COHORT||CROSS_SECTIONAL|||||||
34115786|NCT03081104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115787|NCT02317627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115788|NCT03488771|||COHORT||PROSPECTIVE|||||||
34115789|NCT00791648|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150217|NCT04233944|||COHORT||PROSPECTIVE|||||||
34150218|NCT04971941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150219|NCT01934309|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34150220|NCT03880344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34150221|NCT01624090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810667|NCT04325425|RANDOMIZED|PARALLEL||TREATMENT||NONE||mFOLFIRINOX (experimental arm) vs Platinum - Etoposide (standard arm)||||
33810668|NCT01403285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810669|NCT03100370|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Each participant will receive active anodal spinal stimulation, active cathodal spinal stimulation, and sham spinal stimulation. The order that each participant receives anodal, cathodal, and sham stimulation will be randomized.|t|f|t|t
33810670|NCT01662193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810671|NCT01595867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33810672|NCT01014559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810673|NCT05960669|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort Study||||
33810674|NCT05552105|NA|SINGLE_GROUP||SCREENING||NONE||||||
33810675|NCT03279367|||COHORT||PROSPECTIVE|||||||
34042080|NCT05508048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34042081|NCT01117038|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34042082|NCT03719781|||CASE_ONLY||PROSPECTIVE|||||||
34042083|NCT05666037|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042084|NCT03293992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042085|NCT00771719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042086|NCT05631717|RANDOMIZED|PARALLEL||TREATMENT||NONE||The test will be divided into two groups. One group of subjects will receive intravenous injection of human umbilical cord mesenchymal stem cells (2 × 106 cells/kg body weight, suspended in 30ml of normal saline); the other group will receive IL-2 (1 × 106 IU) every other day. Subcutaneous injection for 2 weeks (a total of 7 injections), with an interval of 2 weeks, such that 4 weeks is a cycle, and three consecutive cycles of treatment for a total of 12 weeks.||||
34042087|NCT00485251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042088|NCT04663997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042089|NCT05684991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042090|NCT02522364|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34042091|NCT00930280|||CASE_CONTROL||PROSPECTIVE|||||||
34042092|NCT04304430|||COHORT||RETROSPECTIVE|||||||
34042093|NCT02262715|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34042094|NCT02807038|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34042095|NCT00005777|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34042096|NCT05421182|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Case-Control Study||||
34042097|NCT04023032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042098|NCT03929120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042099|NCT04595799|||OTHER||PROSPECTIVE|||||||
34042100|NCT04806893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participants, study staff, investigator and sponsor blinded to treatment and lipid levels|Placebo-controlled, randomized 2:1 to Active or placebo|t|t|t|t
34042101|NCT04459325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042102|NCT03418233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Data and Safety Monitoring Board (DSMB) will be blinded at project start, but may request unblinding if necessary to accommodate effective review of data.~Other than the DSMB (if necessary), the only other un-blinded parties, meaning that they will have knowledge as to the patient's treatment assignment, will be the PBTiK UJ CM employee who participates in randomization utilizing randomization lists and investigational medication preparation."|"The CIHF trial will enroll 105 patients with randomization into active and placebo therapy with 2:1 ratio.~Additional 5-10 subjects meeting inclusion/exclusion criteria will receive, in a non-blinded fashion, labelled CardioCell to determine the early myocardial uptake and retention of IMP."|t|t|t|t
34042103|NCT06152289|||COHORT||PROSPECTIVE|||||||
34042104|NCT02400918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042105|NCT03900169|||CASE_CONTROL||PROSPECTIVE|||||||
34042106|NCT01155180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042107|NCT06576258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042108|NCT03278678|||OTHER||PROSPECTIVE|||||||
34042109|NCT05234125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34042110|NCT04932655|RANDOMIZED|CROSSOVER||OTHER||NONE||Four-way crossover of Phase 3 tablets under fasted or high-fat or low-fat conditions and the Phase 2 tablet under fasted conditions. Subjects are randomized to a sequence.||||
34042111|NCT02215369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042112|NCT01964222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042113|NCT04438837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042114|NCT04668079|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042115|NCT02070263|||OTHER||PROSPECTIVE|||||||
34042116|NCT01247051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042117|NCT03742518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042118|NCT03213002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042119|NCT04399213|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized, double-blind study|t|f|f|t
34042120|NCT03258918|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042121|NCT02138487|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042122|NCT06296771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042123|NCT05914493|||COHORT||PROSPECTIVE|||||||
34042124|NCT03505684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34042125|NCT03283787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042126|NCT03677284|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The assessments at three and six months (for intervention group t2, for control group t2 and t3) will be performed by research assistants to avoid bias from the care providers (occupational therapists giving intervention). It is anticipated that the research assistant will not be informed of what group the PwD was allocated to.|"Assessments at baseline (t1) is done for each person with dementia (PwD) with informed consent. The coding of each PwD is determined by the memory clinic (first two digits in the code, 10 - 70) and consecutive starting with 01 and on.~A stratified randomization will be prepared in advance by the researchers, in closed envelopes, for each memory clinic. When the assessment is done, the occupational therapist opens the top envelope marked with the code of the PwD to find out allocation to intervention or control.~Intervention will be provided by the occupational therapist at the memory clinic or at other out-patient service during three months. The second data collection (t2) will be done by research assistants. After the assessment (t2), the control group will be offered intervention with prescribed time assistive products, followed by a third assessment (t3) after another three months (6 months after baseline)."|f|t|f|t
34042127|NCT00108264|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34042128|NCT01704495|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042129|NCT04957251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042130|NCT05028582|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042131|NCT06571149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042132|NCT04585074|||COHORT||PROSPECTIVE|||||||
34042133|NCT04394949|RANDOMIZED|PARALLEL||OTHER||NONE||Randomize at the participant level (individual level block) for larger centers that have multiple Independent Living (IL) Specialists. Participant will be randomly assigned to work with a staff who is trained in the experimental services or usual care. CILs that cannot accommodate both the experimental services and usual care, cluster randomization will be used.||||
33810676|NCT06193499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blind fold on participants. No infomration about given treatment to outcome assessors.|Randomized controlled trial|t|f|f|t
33810677|NCT04990856|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33810678|NCT03528304|RANDOMIZED|FACTORIAL||PREVENTION||NONE||We used a 2x2 factorial design to evaluate contingency management (CM) for weight loss and smoking abstinence among women who were both overweight/obese and current smokers. Participants were accordingly randomized in equal numbers into one of four groups: 1) women receiving CM for weight loss, 2) women receiving CM for smoking abstinence, 3) women receiving CM for both weight loss and smoking abstinence, or 4) a non-contingent control group.||||
33810679|NCT00748982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810680|NCT04101045|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33810681|NCT06172036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810682|NCT02074228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042134|NCT00376155|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042135|NCT00442897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042136|NCT01372995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042137|NCT06254118|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|an independent researcher not directly involved in the study, utilized a computer generated random number sequence to assign participants to either the control or study group. this randomization was executed before the commencement of the treatment phase.||t|t|t|t
34042138|NCT03981380|||COHORT||PROSPECTIVE|||||||
34042139|NCT04189315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042140|NCT02576847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042141|NCT03016429|||COHORT||PROSPECTIVE|||||||
34115790|NCT04549454|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intervention condition is randomly assigned and the intervention delivery is digital, through a web app. Senior members of the research team will have a record of the participants randomized to each condition but the delivery of all intervention content is automated within the app. Junior members of the research team responsible for tracking participants and sending follow-up survey reminders will not be aware of participant condition assignment.||t|f|f|f
34115791|NCT01195597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042142|NCT01139957|||CASE_ONLY||PROSPECTIVE|||||||
34042143|NCT05406479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042144|NCT00136929|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042145|NCT06368336|||COHORT||OTHER|||||||
34042146|NCT01278004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34042147|NCT04203342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug will be randomised, packaged and blinded by an independent packaging company.||t|t|t|t
34042148|NCT02734537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042149|NCT00651261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042150|NCT03309943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double-blind|Participants will be randomly assigned to receive propranolol (40 mg) or placebo|t|f|t|t
34042151|NCT03452280|||CASE_ONLY||OTHER|||||||
34042152|NCT06104254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single||t|f|f|f
34042153|NCT06253000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized double-blind controlled trial in two groups|t|f|f|f
34042154|NCT04538833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042155|NCT02921724|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34042156|NCT05388279|NA|SEQUENTIAL||TREATMENT||NONE||Sequential||||
34042157|NCT06578832|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34042158|NCT02312323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042159|NCT05063513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042160|NCT06205043|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||Patients will be randomized to receive either an algorithm based program vs standard of care program. After a period each group will cross over to the other side. UPDRS assessments will be done at each time.|t|f|f|t
34042161|NCT02159053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042162|NCT02463851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042163|NCT03395145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042164|NCT05358054|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34042165|NCT06313619|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042166|NCT02836002|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042167|NCT01401361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042168|NCT03890432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042169|NCT01077297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042170|NCT00016432|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34042171|NCT02848144|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042172|NCT04273529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042173|NCT00566020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042174|NCT04938180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042175|NCT06368271|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study is a randomized, double-blinded crossover design. Participants ingest Medium-chain-fatty acids (MCT) or Long-chain fatty acids (LCT) oil on two test days with one-week period between the experimental days. The day prior to the experimental days, the participants consume a eucaloric control diet, and abstain from alcohol and vigorous physical activity to ensure similar conditions on experimental days.||||
34042176|NCT02075203|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34042177|NCT05374317|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042178|NCT06163885|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34042179|NCT02215395|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042180|NCT06261346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34115792|NCT00024934||||TREATMENT||||||||
33838270|NCT03406078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously|t|t|t|f
33838271|NCT00078338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838272|NCT00555529|||OTHER||OTHER|||||||
33838273|NCT03430544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042181|NCT05392205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042182|NCT03325634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729261|NCT00472134|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33729262|NCT01248858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729263|NCT01381861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729264|NCT05596760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33729265|NCT04906642|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Due to the double-blinded nature of the study, neither the participant, treating physician, site staff, or site study team will be aware of the treatment assignment (XPERIENCE No-Rinse Antimicrobial Solution or blinded saline) of each subject.|Prospective, randomized, controlled, double-blinded clinical study|t|t|t|t
33729266|NCT04917276|||COHORT||PROSPECTIVE|||||||
33729267|NCT05037838|||COHORT||PROSPECTIVE|||||||
33729268|NCT04566796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|via the closed envelope method||t|f|t|f
33729269|NCT03769272|||CASE_CONTROL||PROSPECTIVE|||||||
33729270|NCT05937048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729271|NCT03162601|||COHORT||PROSPECTIVE|||||||
33810683|NCT03652610|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner. By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity and immunogenicity) will all be unaware of which vaccine was administered. To do so, vaccine preparation and administration will be done by authorized medical personnel who will not participate in any of the study clinical evaluations.||t|t|t|t
33810684|NCT02095678|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810685|NCT02809755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33810686|NCT00724737|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810687|NCT01558349|||COHORT||PROSPECTIVE|||||||
33810688|NCT00294021|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33810689|NCT01106885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810690|NCT01000467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33810691|NCT00310037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810692|NCT03230084|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33810693|NCT02052167|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33810694|NCT01812330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810695|NCT00878189|NON_RANDOMIZED|||TREATMENT||NONE||||||
33810696|NCT02323776|||COHORT||RETROSPECTIVE|||||||
33810697|NCT06082219|||COHORT||PROSPECTIVE|||||||
33810698|NCT00341991|||OTHER||RETROSPECTIVE|||||||
34042183|NCT02454686|||COHORT||PROSPECTIVE|||||||
34042184|NCT01565603|||CASE_ONLY||CROSS_SECTIONAL|||||||
34042185|NCT03741192|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Participating physicians will recruit patients meeting the inclusion and exclusion criteria. Upon completion of screening and enrollment procedures study participants will be randomly assigned to one of two groups using a randomized call-in system: treatment or standard of care.~Demographics will be obtained for both groups during this initial clinic visit. The treatment group will be prescribed the Brain Sentinel® SPEAC System for use in the home environment. Study Participants in the standard of care group will be given standard care."||||
34042186|NCT01213732|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042187|NCT06176274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the experimental group will receive care through the prehabilitation program, while the control group will receive standard nursing care. participants will not know which group they are in.|a randomized trial with experimental design with pre-test post-test control group|t|t|f|f
34042188|NCT05472025|||CASE_ONLY||PROSPECTIVE|||||||
34042189|NCT06576544|||COHORT||PROSPECTIVE|||||||
34042190|NCT00773825|||||PROSPECTIVE|||||||
34042191|NCT04195204|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34042192|NCT05809232|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042193|NCT03321968|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Observer-blind||t|t|t|t
34042194|NCT02155283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042195|NCT00597662|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34042196|NCT06018675|||OTHER||RETROSPECTIVE|||||||
34042197|NCT06166446|RANDOMIZED|PARALLEL||OTHER||SINGLE||15 completely edentulous patients, divided into two groups, received two implants in the mandibular canine area with ball attachment. The first group received a CAD/CAM-milled mandibular overdenture and a maxillary acrylic conventional complete denture, while the second group received a 3D-printed mandibular overdenture and a maxillary acrylic complete denture. Peri-implant soft tissue was evaluated using clinical parameters including the gingival index, plaque index, bleeding index, and probing depth at the time of mandibular complete overdenture insertion (T0), six months (T6), and twelve months (T12) of denture use.|f|f|t|f
34042198|NCT06041854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Test group will receive EMD mixed with freeze-dried bone allograft, Control group will receive freeze-dried bone allograft|t|f|f|t
34042199|NCT03259464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042200|NCT06292741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042201|NCT02283268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042202|NCT03324620|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|86 patients in experimental group. 104 patients retrospectively collected from the inclusion of the first patient of the intervention group.|Mixed study. Retrospective control group.||||
34042203|NCT02764281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042204|NCT02986022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042205|NCT06392659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042206|NCT05282537|||OTHER||PROSPECTIVE|||||||
34042207|NCT01831076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042208|NCT03577496|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042209|NCT04033731|||CASE_ONLY||PROSPECTIVE|||||||
34042210|NCT01921101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042211|NCT05260567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042212|NCT04643977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042213|NCT04485325|RANDOMIZED|PARALLEL||TREATMENT||NONE||two arm, randomized, open-label, parallel group||||
34042214|NCT05411055|||CASE_ONLY||PROSPECTIVE|||||||
34042215|NCT00656825|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34042216|NCT04572503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042217|NCT03481868|NA|SINGLE_GROUP||OTHER||NONE||||||
33729272|NCT01841814|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729273|NCT00654277|RANDOMIZED|CROSSOVER||||NONE||||||
33729274|NCT02397330|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729275|NCT01040585|||COHORT||PROSPECTIVE|||||||
33729276|NCT06497049|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open randomized study of comparative pharmacokinetics and biosimilarity of GP40221, solution for subcutaneous administration, 1.34 mg/ml and Ozempic®, solution for subcutaneous administration, 1.34 mg/ml in parallel groups in healthy volunteers||||
33729277|NCT02703636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729278|NCT04007172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729279|NCT00024089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729280|NCT02284503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729281|NCT01061086|||CASE_ONLY||PROSPECTIVE|||||||
33729282|NCT06190561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729283|NCT01737567|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33729284|NCT05855564|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33729285|NCT04813770|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will not be blinded to the assigned intervention but will not be informed of the purpose of the study until they have completed the follow-up survey, at which point they will be debriefed. Investigators will be blinded to allocation because all procedures will be undertaken digitally and remotely without any investigator contact with participants.||f|f|t|f
33729286|NCT04060329|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||In Phase 1, participants receive usual care only. In Phase 2, a different group of participants receive the coopeRATE Prompt intervention in addition to usual care.||||
33729287|NCT06481202|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Neither the investigators nor the patients knew which drug was being administered||t|f|t|f
33729288|NCT00726570|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33729289|NCT00324064|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729290|NCT00189046|||CASE_CONTROL||OTHER|||||||
33729291|NCT03139890|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33729292|NCT00544076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729293|NCT01883336|||CASE_ONLY||RETROSPECTIVE|||||||
33729294|NCT01885091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729295|NCT04784286|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The randomized assignments (2 arms) will be generated by an analyst/statistician using a Mayo Clinic statistical application. The research assistant/coordinator will issue the next in a series of sequentially numbered, sealed, opaque envelopes containing the group assignment. The envelope will have information regarding the treatment assignment and will be entered into a database by the study coordinator.|Randomized clinical trial|f|t|t|f
33729296|NCT02638142|||CASE_CONTROL||PROSPECTIVE|||||||
33729297|NCT01223144|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33729298|NCT05210127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729299|NCT02550457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729300|NCT02667483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729301|NCT00916175|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33729302|NCT03382483|||OTHER||OTHER|||||||
33729303|NCT00013663||||TREATMENT||DOUBLE||||||
33729304|NCT05932186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded||t|f|f|f
33729305|NCT02296112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729306|NCT06115928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33729307|NCT03926234|||COHORT||RETROSPECTIVE|||||||
33729308|NCT02312726|||CASE_ONLY||CROSS_SECTIONAL|||||||
33810699|NCT05366478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810700|NCT03942094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810701|NCT01039610|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33810702|NCT03682003|||COHORT||PROSPECTIVE|||||||
33810703|NCT04514562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729309|NCT03734471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729310|NCT02330796|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33729311|NCT03063996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This will be a randomized control trial comparing peripheral IJ to standard care of difficult access patients.||||
33729312|NCT02940171|||CASE_ONLY||PROSPECTIVE|||||||
33729313|NCT02259153|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729314|NCT01728493|||CASE_CONTROL||PROSPECTIVE|||||||
33729315|NCT03628911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729316|NCT00587379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729317|NCT06110988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729318|NCT04366622|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33729319|NCT00113256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729320|NCT05530369|||COHORT||PROSPECTIVE|||||||
33729321|NCT02242357|||COHORT||PROSPECTIVE|||||||
33729322|NCT00403000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729323|NCT03543319|||COHORT||PROSPECTIVE|||||||
33729324|NCT03118128|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33729325|NCT06251856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33729326|NCT02086929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33729327|NCT05451771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729328|NCT01664572|||||PROSPECTIVE|||||||
33729329|NCT02979743|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33810704|NCT05048485|||COHORT||PROSPECTIVE|||||||
33810705|NCT04078607|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized controlled crossover study where participants were assigned to begin in the distracted or control condition. One week later, participants completed the opposite condition.||||
33810706|NCT04370561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810707|NCT06238310|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810708|NCT03820024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33810709|NCT01199315|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33810710|NCT03683615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810711|NCT01824849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810712|NCT00678002|||COHORT||PROSPECTIVE|||||||
33810713|NCT04928937|||COHORT||PROSPECTIVE|||||||
33810714|NCT05991804|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot study||||
33810715|NCT05832593|||COHORT||CROSS_SECTIONAL|||||||
33810716|NCT04257916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115793|NCT03159182|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33810717|NCT00068107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810718|NCT01617785|||COHORT||PROSPECTIVE|||||||
33810719|NCT01981746|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33810720|NCT00826826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810721|NCT01852045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810722|NCT02231970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810723|NCT02496559|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810724|NCT00853593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810725|NCT00539812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810726|NCT02161354|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33810727|NCT06253299|||COHORT||PROSPECTIVE|||||||
34115794|NCT04955548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115795|NCT02334657|||COHORT||PROSPECTIVE|||||||
34115796|NCT01741961|||CASE_CONTROL||RETROSPECTIVE|||||||
34115797|NCT04614324|NA|SINGLE_GROUP||TREATMENT||NONE||Active treatment for all subject enrolling prospectively||||
34115798|NCT02064478|||CASE_CONTROL||PROSPECTIVE|||||||
34115799|NCT00360139|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115800|NCT01782157|||COHORT||PROSPECTIVE|||||||
34115801|NCT05249959|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, phase II single arm study||||
34115802|NCT04386018|||COHORT||PROSPECTIVE|||||||
34115803|NCT02285881|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115804|NCT01047995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115805|NCT03999489|||COHORT||PROSPECTIVE|||||||
34115806|NCT04847687|||OTHER||RETROSPECTIVE|||||||
34115807|NCT01679184|||CASE_ONLY||PROSPECTIVE|||||||
34115808|NCT01651468|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34115809|NCT03255616|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34115810|NCT04445103|||COHORT||PROSPECTIVE|||||||
34115811|NCT04546789|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810728|NCT00645411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810729|NCT02322489|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33810730|NCT01439854|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34115812|NCT04403932|||COHORT||PROSPECTIVE|||||||
34115813|NCT06565299|||OTHER||PROSPECTIVE|||||||
34115814|NCT04931381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115815|NCT05719220|||COHORT||PROSPECTIVE|||||||
34115816|NCT02331758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34115817|NCT02191163|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34115818|NCT03053609|||CASE_ONLY||RETROSPECTIVE|||||||
34115819|NCT06443853|||CASE_CONTROL||PROSPECTIVE|||||||
34115820|NCT02339077|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34115821|NCT02347384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115822|NCT05105724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115823|NCT04039243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115824|NCT00575224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115825|NCT04017234|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34115826|NCT03890510|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients will be randomly assigned to the limited fluid infusion group and the loose fluid infusion group.|t|f|t|t
34115827|NCT05790291|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"First, the participants were blinded. Participants were randomized after the pretest and divided into two groups. No explanation was given to the participants about how many groups there were and which group they belonged to.~Second, the observer was blinded. Video recording was taken by the researcher during the administration in calculating the error rates.~The video recordings were watched one by one by an assistant researcher who did not know the groups, and the administration steps were marked on the observation form as true/false.~Third, the statistician was blinded."|randomized control|t|f|t|t
34115828|NCT01441960|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
34115829|NCT02561962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810731|NCT03936166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind study|Single and multiple-dose cohorts are placebo-controlled.|t|t|t|t
33810732|NCT00487045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810733|NCT03845881|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The oxycodone and placebo tablets will be encapsulated by the research pharmacy prior to dispensing for blinding purposes.|Multi-Modal Pain Protocol with and without Opioids Following Total Joint Arthroplasty|t|f|t|f
33810734|NCT05794074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810735|NCT01823406|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810736|NCT05064072|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115830|NCT03448328|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, parallel group||||
34115831|NCT00002325||PARALLEL||TREATMENT||||||||
34115832|NCT02152748|||CASE_ONLY||RETROSPECTIVE|||||||
34115833|NCT05992272|||CASE_CONTROL||RETROSPECTIVE|||||||
34115834|NCT03186547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind||f|f|f|t
34115835|NCT03838835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115836|NCT01634152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115837|NCT00116571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115838|NCT05253040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33810737|NCT03879265|||OTHER||CROSS_SECTIONAL|||||||
33810738|NCT04942288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Double Blind|It consists of 3 Different Groups.||||
33838274|NCT06277505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838275|NCT01031628|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838276|NCT00209404|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838277|NCT03567629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838278|NCT00597090|||CASE_CONTROL||PROSPECTIVE|||||||
33838279|NCT01362504|||CASE_CONTROL||PROSPECTIVE|||||||
33729330|NCT01514695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729331|NCT02657811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729332|NCT00178191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729333|NCT06127082|||COHORT||PROSPECTIVE|||||||
33729334|NCT05325567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be scheduled and added to the operative list of the day by the PI's primary nurse. The primary nurse is not a part of the study and will not be present in the operating room. On the day of surgery, all enrolled patients who happen to be in the list in an odd number will undergo 1 incision technique while those on the list who are in an even number will undergo 2 incision technique.|On the day of surgery, all enrolled patients who happen to be in the list in an odd number will undergo 1 incision technique while those on the list who are in an even number will undergo 2 incision technique.|f|f|t|f
33729335|NCT00885547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115839|NCT00949533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729336|NCT05645822|||COHORT||PROSPECTIVE|||||||
33729337|NCT00144586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729338|NCT00688480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115840|NCT00531778|||COHORT||PROSPECTIVE|||||||
33729339|NCT06418386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The children will be randomly divided into 2 main groups according to type of file used in root canal preparation:~Group I with manual file. Group II with rotary file.~Then the children will be randomly sub grouped according to irrigant that will be used:~Group IA and group II A with normal saline. Group IB and group II B with neem . Group IC and group II C with NaOCl"|f|f|f|t
33729340|NCT01138280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810739|NCT05919732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The statistician for the study will generate a randomization table. An unblinded research coordinator will prepare randomization envelopes which will be numbered sequentially and placed in a bin located in the secure medication room in the peri-operative suite.Intra-operatively, neither the anesthesiologist nor the surgeon will be blinded since they are present from the induction of anesthesia until the conclusion of the operation for patient safety. The doctors, nurses and others caring for the infant postoperatively will be blinded.|A prospective, blinded, randomized controlled trial|t|t|f|f
33810740|NCT01750424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810741|NCT03163472|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33810742|NCT02322645|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810743|NCT00798863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810744|NCT02142309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115841|NCT05069519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33810745|NCT02874391|||OTHER||PROSPECTIVE|||||||
34042218|NCT04768816|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34042219|NCT03601598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042220|NCT05009693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34115842|NCT03060837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34042221|NCT05460351|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|A third party not involved with the conduct of the study provided research staff with the beetroot juice in participant specific coded bottles. The research staff then distributed these coded bottles to the participant. At the end of the trial, the code was revealed for intervention assignment.|Participants will be randomized into one of two groups. The first group will consume daily beetroot juice containing 380 mg of nitrate and the second group will consume daily beetroot juice with nitrate removed. Both groups will undergo resistance exercise training and consume a protein supplement|t|f|t|t
34042222|NCT01104974|||COHORT||CROSS_SECTIONAL|||||||
34042223|NCT00511914|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115843|NCT01574950|||COHORT||PROSPECTIVE|||||||
34115844|NCT00047034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115845|NCT06192563|||COHORT||PROSPECTIVE|||||||
33729341|NCT04004728|NA|SINGLE_GROUP||TREATMENT||NONE|Blind photo evaluation.|One leg laser ando the other sclerotherapy.||||
33729342|NCT05008991|||OTHER||PROSPECTIVE|||||||
33729343|NCT03119415|RANDOMIZED|PARALLEL||PREVENTION||NONE||This research is a comparison between the Cooperative Learning program and services as usual. Approximately twelve middle schools will be randomized to a waitlist-control condition. The intervention group will receive training in Cooperative Learning immediately and the waitlist-control group will receive training at the end fo the project. Teachers will be given training on the basics of Cooperative Learning and will be supported in their efforts to implement it in their classrooms. No curricular changes will be required. The initial training will last two or three days and will confirm to the professional development calendar of the intervention schools (selected at random). The implementation of Cooperative Learning is expected to be on-going for the full duration of the project (two years).||||
33729344|NCT00006095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729345|NCT04217486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33729346|NCT05935579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729347|NCT02273219|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33729348|NCT06358456|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The investigator and patient knew which device they were tested on|one arm for each diagnostic device (three in total)||||
33729349|NCT04685564|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33729350|NCT01919658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810746|NCT01404637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810747|NCT01065532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810748|NCT01961232|||COHORT||PROSPECTIVE|||||||
33810749|NCT01005615|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33810750|NCT01347294|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33810751|NCT06510868|||COHORT||PROSPECTIVE|||||||
33810752|NCT05918549|||CASE_ONLY||PROSPECTIVE|||||||
34042224|NCT05978050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042225|NCT02099110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042226|NCT04891146|||CASE_CONTROL||PROSPECTIVE|||||||
34042227|NCT06001710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042228|NCT06213584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115846|NCT04630483|||COHORT||PROSPECTIVE|||||||
33729351|NCT01488097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729352|NCT00003294||||TREATMENT||||||||
33729353|NCT06116331|||COHORT||PROSPECTIVE|||||||
33729354|NCT01352494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729355|NCT06368453|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||f|t|f|f
33729356|NCT03670810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729357|NCT06212102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729358|NCT00302003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729359|NCT03799484|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization will only be known by the principal investigator performing the injections and will not be disclosed to the participants or the brow excursion examiner.||t|f|f|t
33729360|NCT02151448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729361|NCT02627599|||COHORT||PROSPECTIVE|||||||
33729362|NCT05164900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729363|NCT05087654|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33729364|NCT03424031|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33810753|NCT05035563|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"Pre-intervention: The practices of each ICU will be maintained, until the moment that according to randomization corresponds to the beginning of the intervention, in each center~Post-intervention: Integral and early strategy to facilitate communication between the family, patient and health team. For this it will be implemented written material, via the web (tablet and webmaster) and by telephone.~It also includes strategies to support health teams, weekly multidisciplinary virtual meetings with the family, ICU diaries for family members."|f|f|f|t
34150222|NCT04989647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729365|NCT00532285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729366|NCT04431037|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Patients admitted in the emergency department were randomly assigned into treatment group or control group in postoperative period.Neither the researcher nor the patient were aware of the patient allocation.Patients were management by the oncall surgical team irrespective of the researcher.|This randomized controlled trial was conducted in Surgical Unit 1 BBH from August 2018 to December 2019 with a total sample size of 36 patients with the diagnosis of perforated duodenal ulcer. Patients were randomly divided in two groups. Group A consisted of early oral feeding group and group B consisted of traditional postoperative care group. Outcome results studied were the length of hospital stay, duodenal repair site leak, severity of pain (VAS score) and duration of post-operative ileus. Results were analysed on SPSS version 20 and chi-square and independent t-test were applied.|t|f|t|f
33729367|NCT02526069|NA|SINGLE_GROUP||||NONE||||||
33729368|NCT05851729|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729369|NCT02611492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729370|NCT02376946|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33729371|NCT00751816|||COHORT||PROSPECTIVE|||||||
33729372|NCT03040635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729373|NCT02242838|||COHORT||PROSPECTIVE|||||||
33729374|NCT04780386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729375|NCT00154453|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33729376|NCT01943149|||COHORT||PROSPECTIVE|||||||
33729377|NCT05312671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729378|NCT03890679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729379|NCT05309603|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33810754|NCT06464302|||CASE_CONTROL||RETROSPECTIVE|||||||
33810755|NCT00161122|RANDOMIZED|PARALLEL||||DOUBLE||||||
33810756|NCT04602949|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810757|NCT00770250|||COHORT||CROSS_SECTIONAL|||||||
33810758|NCT01947114|RANDOMIZED|||TREATMENT||SINGLE|||t|f|f|f
33810759|NCT04037033|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, pre-post design||||
33810760|NCT01205763|||CASE_ONLY||PROSPECTIVE|||||||
33810761|NCT05556369|||COHORT||PROSPECTIVE|||||||
33810762|NCT04169802|||OTHER||CROSS_SECTIONAL|||||||
33810763|NCT06210152|||OTHER||PROSPECTIVE|||||||
33810764|NCT05062070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810765|NCT03863405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded||t|f|f|f
33810766|NCT04001777|NA|SEQUENTIAL||TREATMENT||NONE||||||
34042229|NCT03259425|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open label, Phase II||||
33810767|NCT02802488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33810768|NCT02387385|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810769|NCT00853411|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810770|NCT04514081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042230|NCT06444776|||OTHER||PROSPECTIVE|||||||
33810771|NCT03675321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, investigators and study team members blinded|Randomized, double blind placebo-controlled trial|t|t|t|t
33810772|NCT01560429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810773|NCT01959776|NA|SINGLE_GROUP||TREATMENT||||||||
33810774|NCT01815359|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||After the initial 212 patients are accrued, the final 70 patients will be accrued to only the appendiceal cohorts||||
33810775|NCT04921540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810776|NCT03032757|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810777|NCT01567852|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33810778|NCT02535221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810779|NCT00851513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810780|NCT00268333|NON_RANDOMIZED|||TREATMENT||NONE||||||
34042231|NCT04856007|RANDOMIZED|CROSSOVER||OTHER||NONE||There will be two independent cohorts of subjects who will each receive two treatments in a randomized order, and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability. In each cohort approximately 40 healthy subjects will be randomized to receive treatment with IP in order to complete at least 36 evaluable subjects.||||
34042232|NCT00648115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042233|NCT04536974|||COHORT||PROSPECTIVE|||||||
34042234|NCT01615406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042235|NCT02108548|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34042236|NCT05738057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115847|NCT06564285|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized, Double-Blind, Placebo Controlled Design|t|f|t|t
34115848|NCT01581424|||COHORT||PROSPECTIVE|||||||
34115849|NCT06453577|||CASE_CONTROL||PROSPECTIVE|||||||
34115850|NCT00248924|||||PROSPECTIVE|||||||
34115851|NCT01624324|||COHORT||PROSPECTIVE|||||||
34115852|NCT04414787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All masking done via differential user accesses allowed by a mobile app platform.|Randomized clinical trial comparing intervention to usual care control.|t|f|f|t
34115853|NCT01478425|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34115854|NCT04154722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115855|NCT02347410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115856|NCT04958486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115857|NCT01646827|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34115858|NCT02157909|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34115859|NCT02940925|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental: Drug: Taxol,cisplatin and capecitabine Active Comparator: Drug: Cisplatin and 5-Fluorouracil||||
34115860|NCT02154061|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115861|NCT04269954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115862|NCT02297516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115863|NCT02546323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115864|NCT02826187|||COHORT||PROSPECTIVE|||||||
34115865|NCT05201209|||COHORT||RETROSPECTIVE|||||||
34115866|NCT04782921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115867|NCT02474810|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115868|NCT00185341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115869|NCT01435161|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115870|NCT06216977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34115871|NCT01515371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115872|NCT00261833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115873|NCT02009566|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115874|NCT00557193|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115875|NCT01785030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115876|NCT01668680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115877|NCT00309283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34115878|NCT03906526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115879|NCT06489067|||CASE_ONLY||OTHER|||||||
34115880|NCT00267930|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115881|NCT02862119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115882|NCT03061890|||COHORT||PROSPECTIVE|||||||
34115883|NCT00584857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115884|NCT01752049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115885|NCT04161924|||COHORT||PROSPECTIVE|||||||
34115886|NCT05657158|||COHORT||RETROSPECTIVE|||||||
34115887|NCT06250465|||OTHER||OTHER|||||||
34115888|NCT03447392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115889|NCT03182855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial. No blinding||||
34115890|NCT05787015|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34115891|NCT05754125|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Neither participants, investigators, or data analysts will be aware of the supplement assignment (labelled A-C) until data analysis for the primary outcome is complete.|Cross over study design; Block randomized.|t|f|t|t
34115892|NCT05589454|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115893|NCT02406417|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115894|NCT00814255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115895|NCT04242680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33729380|NCT03553732|||COHORT||PROSPECTIVE|||||||
33729381|NCT05409027|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729382|NCT04176003|||OTHER||OTHER|||||||
33729383|NCT00738972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115896|NCT01313455|||||PROSPECTIVE|||||||
34115897|NCT04519333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115898|NCT04878224|||COHORT||PROSPECTIVE|||||||
34115899|NCT02373592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34115900|NCT02498366|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34115901|NCT01409954|||CASE_ONLY||PROSPECTIVE|||||||
33729384|NCT03299192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research Specialists will be unaware of study group.|Comparison of Tai Chi to Health Education and to Usual Medical Care|f|f|f|t
33729385|NCT05211128|||COHORT||RETROSPECTIVE|||||||
33729386|NCT05207020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single group with a device||||
33729387|NCT05928910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115902|NCT03150264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115903|NCT06131190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Effect Mindfulness Based Training on Attention|t|f|f|f
33729388|NCT03970785|||CASE_ONLY||RETROSPECTIVE|||||||
33729389|NCT04270838|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33729390|NCT04765358|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33729391|NCT00375843|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729392|NCT03909009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729393|NCT06259331|NA|SINGLE_GROUP||OTHER||NONE||||||
33729394|NCT04930887|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729395|NCT03348358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729396|NCT00787774|NA|SINGLE_GROUP||SCREENING||NONE||||||
33729397|NCT03862391|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
33729398|NCT03433664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and treating clinician were aware of which scar half had been treated, however investigator and assessor were blinded|Scar area (10x10cm square) randomly assigned a square vector 'map' which split the scar into a control and treatment half along one of 4 vectors: vertical, horizontal, and along both diagonals. The envelope revealing the vector map and treatment zones was opened by the treating laser clinician immediately prior to the first treatment. The same treating clinician performed all laser treatments to minimise inter-user variability.|f|f|t|t
34042237|NCT00162110|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729399|NCT01011517|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33729400|NCT03738943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will be assigned to one of three arms of the study. The arms of the study are based on the vasodilators being tested in order to determine the effect of pyridoxine or PLP on vasodilation in response to intra-arterial administration of the vasodilators.||||
33729401|NCT01225445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729402|NCT05181111|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33729403|NCT00000833||||TREATMENT||||||||
33729404|NCT04616807|||OTHER||PROSPECTIVE|||||||
33729405|NCT04853225|||COHORT||PROSPECTIVE|||||||
33729406|NCT01742793|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729407|NCT00215046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729408|NCT02188238|||OTHER||OTHER|||||||
33729409|NCT01331694|||COHORT||RETROSPECTIVE|||||||
33729410|NCT04813796|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants who are offered an opportunity to receive an additional injection of mRNA-1273, will participate in an open-label part of the study.||t|t|t|t
33729411|NCT03411473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729412|NCT04625751|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729413|NCT05846620|||CASE_ONLY||PROSPECTIVE|||||||
33729414|NCT02953990|NA|SINGLE_GROUP||OTHER||NONE||||||
33729415|NCT04155008|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729416|NCT03098511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"1. Participant will be comatose~2. Care providers, investigators and outcome assessors will be blinded from the results of the CT-Perfusion scan result (for the clinical assessment) and from the clinical assessment results (for the CT-Perfusion scan interpretation)"|||||
33729417|NCT01522066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729418|NCT03759067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729419|NCT00079833|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729420|NCT03718442|||CASE_ONLY||PROSPECTIVE|||||||
33729421|NCT02206516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729422|NCT02280174|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33729423|NCT00720681|||COHORT||CROSS_SECTIONAL|||||||
33729424|NCT03492333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Intervention GFD in IBS and HV(controls)||||
33729425|NCT01499888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729426|NCT01933906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729427|NCT04724850|||COHORT||OTHER|||||||
33729428|NCT01045564|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729429|NCT04601051|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33729430|NCT01185873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810781|NCT02232737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This study was one of three multi-site clinical trials conducted in three different vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder or additional assessments related to disadvantaged women of reproductive age. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by- condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment. Please see Statistical Analysis Plan for more details.|t|f|t|f
33810782|NCT05260866|||COHORT||RETROSPECTIVE|||||||
33810783|NCT03118206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042238|NCT03055299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042239|NCT00424619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042240|NCT03286556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled trial.||||
34042241|NCT03241862|NA|SINGLE_GROUP||OTHER||NONE||||||
34042242|NCT00269373|||COHORT||PROSPECTIVE|||||||
34042243|NCT04967482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042244|NCT04720924|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34042245|NCT03364465|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34042246|NCT04108468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042247|NCT05217810|||COHORT||PROSPECTIVE|||||||
34042248|NCT05304728|||COHORT||RETROSPECTIVE|||||||
33729431|NCT06237166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729432|NCT00326664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729433|NCT00847444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729434|NCT02501096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729435|NCT03671291|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33729436|NCT00539838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729437|NCT03129516|||OTHER||PROSPECTIVE|||||||
33729438|NCT02752932|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729439|NCT03189628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729440|NCT04183556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729441|NCT01023165|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729442|NCT00892164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729443|NCT02299531|RANDOMIZED|CROSSOVER||||NONE||||||
33729444|NCT03127969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33729445|NCT01471548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729446|NCT05500365|||OTHER||PROSPECTIVE|||||||
33729447|NCT01138228|||CASE_CROSSOVER||PROSPECTIVE|||||||
33729448|NCT02165930|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33729449|NCT00184015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729450|NCT04705285|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33729451|NCT03149250|||COHORT||PROSPECTIVE|||||||
33729452|NCT04055688|||COHORT||PROSPECTIVE|||||||
33729453|NCT01024296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729454|NCT03688672|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33729455|NCT03348085|||CASE_CONTROL||PROSPECTIVE|||||||
33729456|NCT03217227|||COHORT||PROSPECTIVE|||||||
33729457|NCT06273228|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Parents will be recruited in pediatric primary care settings and will be assessed at baseline and at a 3-month follow-up. Parents will receive the intervention between baseline and follow-up. Nine parents will be randomly selected for an additional follow-up interview.||||
33729458|NCT02237846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729459|NCT00075335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729460|NCT05859295|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33729461|NCT00006890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729462|NCT05112666|||COHORT||RETROSPECTIVE|||||||
33729463|NCT00607282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729464|NCT01100411|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729465|NCT00404352|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33729466|NCT04413578|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients were either randomized to the Dexcom G6 Device or the Contour NextOne a Standard of Care glucometer. Both subjects knew what they received after they were randomized.|Parallel Randomized Control Trial||||
33729467|NCT05372120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729468|NCT05274256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729469|NCT03941522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729470|NCT02757079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729471|NCT04889625|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729472|NCT04915391|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729473|NCT03200925|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Patients will not know which arm of the trial they will be apart of until after they have consented to participate||t|f|f|f
33729474|NCT05175066|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33729475|NCT05466019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729476|NCT02040610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729477|NCT05605340|NA|SINGLE_GROUP||PREVENTION||NONE|All participants enrolled will receive the study intervention, so blinding is not possible.|All participants enrolled will receive the study intervention. A quasi-experimental design will be used to investigate the preliminary efficacy of the meal delivery intervention on gestational weight gain and estimate the effect size of the intervention relative to a non-randomized standard care but weighted control group derived from de-identified hospital records.||||
33729478|NCT01027091|||COHORT||PROSPECTIVE|||||||
33729479|NCT03976427|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be assigned to a guided imagery exercise||||
33729480|NCT06066762|||COHORT||PROSPECTIVE|||||||
33729481|NCT06227507|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33729482|NCT00053794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729483|NCT04233970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The study will be conducted as an investigator blinded trial and participating physicians as well as MS centres in general will not be provided with any information about group assignment. Randomization will take place only after baseline documentation. Blinding of the trial participants is pursued, but only possible to a limited extent. Furthermore, it cannot be prevented that patients discuss the intervention contents with their physician. Thus participants and neurologists might realize their group assignment. While blinding in complex educational interventions including a webinar is virtually not possible, the only strategy to increase similarity of groups is to have an active control group, which we aim for with the optimized standard care group. Furthermore, the outcome assessors are blinded.||t|t|t|t
33729484|NCT01861496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729485|NCT04501731|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729486|NCT00547703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729487|NCT04223726|||COHORT||PROSPECTIVE|||||||
33729488|NCT00422331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33729489|NCT03149237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The 12 clinics randomly assigned to the intervention arm will receive a combination of community and clinical services, including: (1) ANC-based couples HIV testing, couples-based treatment enrollment, and clinical care for sero-concordant HIV+ expectant couples; (2) couple-centered treatment in the post-partum period; (3) couples-based education and skills building during the ANC and post-partum period; and (4) treatment continuity support by expert-patient (peer) navigators selected among couples who have successfully navigated EMTCT. The 12 clinics randomized to the control arm will continue to provide standard of care EMTCT services that include: standard HoPS male engagement (male invitation to ANC services and couples HIV testing), opt-out rapid HIV testing of all pregnant women attending ANC, HIV-specific counseling and support for all women who test positive, provision of cotrimoxazole prophylaxis, and universal ART, as per option B+ guidelines.||||
33810784|NCT01597856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810785|NCT03560804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810786|NCT01142895|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810787|NCT03035526|||COHORT||CROSS_SECTIONAL|||||||
33810788|NCT01681823|NA|SINGLE_GROUP||TREATMENT||NONE||Dietary Supplement: PectaSol-C Modified Citrus Pectin (MCP) Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).||||
33810789|NCT00407498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042249|NCT00076726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34042250|NCT03023618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042251|NCT06378593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34042252|NCT03852953|||OTHER||RETROSPECTIVE|||||||
34042253|NCT06578442|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups with a conventional therapy||||
34042254|NCT02390921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042255|NCT03033368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042256|NCT01056471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042257|NCT02343939|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34042258|NCT02910206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participants were anesthetized and were unaware of the grouping. Care providers did not know the grouping. Specific investigators who did the intervention were aware of the grouping. The outcome assessors and the data analyzers did not know the grouping.||t|t|f|t
34042259|NCT01031680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042260|NCT06367504|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, parallel group, double-blind, placebo-controlled trial|t|t|t|t
33729490|NCT03331796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115904|NCT04785209|||COHORT||CROSS_SECTIONAL|||||||
34115905|NCT00158587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115906|NCT04506684|||COHORT||PROSPECTIVE|||||||
34115907|NCT01198665|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115908|NCT02014987|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115909|NCT00140686|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115910|NCT00406796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115911|NCT01332656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34115912|NCT00375180|||||PROSPECTIVE|||||||
34115913|NCT03626233|||COHORT||PROSPECTIVE|||||||
34115914|NCT04748887|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115915|NCT05388578|||COHORT||PROSPECTIVE|||||||
34115916|NCT02009579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115917|NCT00626041|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34115918|NCT00824954|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34115919|NCT05790655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient and PI will not know which arm the patient is in. This will not be unblinded until study completion|Prospective, double-blinded placebo controlled|t|t|t|t
34115920|NCT04820023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115921|NCT04096066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115922|NCT02185183|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34115923|NCT01344733|||||PROSPECTIVE|||||||
34115924|NCT02951507|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34115925|NCT01647854|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34115926|NCT06352346|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The target behavior (i.e. performance on an untrained shopping task) will be measured repeatedly, on a minimum of six occasions in each phase where possible, in accordance with the recommendations of the What Works Clearinghouse and RoBiNT criteria. Repeated measures of target behavior will be assessed via the OxMET-NL task and is scored automatically: no assessor input is required to either save or score the main outcome data. The secondary outcome measure(s) are scored by an outcome assessor who is blind to the order in which the secondary outcome measure(s) were taken.|"A randomized Single-case Experimental Design (SCED) with a follow-up period of 6 weeks. Participants will be first assigned to a baseline phase (phase A). The start of the treatment phase (phase B) is determined randomly for each participant, given the restriction that the baseline phase (phase A) should last for at least three weeks (21 days) and at most five weeks (30 days). This means that the treatment phase can start on any day between the 21th and the 30th days. So, in the first three weeks, all participants are in the baseline condition. The duration of baseline will thus be different for each subject. Nonspecific effects, such as linear trends, retesting or non-specific recovery, can be controlled by this approach, since expected changes in level of performance due to treatment should parallel this stepwise onset of therapy procedure.~Phase A acts as a control and is therefore compared with phase B."|f|f|f|t
34115927|NCT04846179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115928|NCT02857972|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34115929|NCT05059886|||COHORT||PROSPECTIVE|||||||
34115930|NCT06009302|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115931|NCT02873156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34115932|NCT01447992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115933|NCT01335607|RANDOMIZED|CROSSOVER||||NONE||||||
34115934|NCT01471184|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34115935|NCT04077840|||CASE_CONTROL||PROSPECTIVE|||||||
34115936|NCT05574881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729491|NCT00382538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33729492|NCT01879566|||CASE_ONLY||PROSPECTIVE|||||||
33729493|NCT02769702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729494|NCT04568122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Enrollment is to a single group. Specific eligibility criteria apply depending on whether the participant is a hospitalized patient, in high-risk or infected population, or low-risk population||||
33729495|NCT03250702|||COHORT||PROSPECTIVE|||||||
33729496|NCT06407466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34115937|NCT00787150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115938|NCT01343472|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34115939|NCT05085132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized in a 1:1 allocation to use the MindFi app or receive a dummy version of the app (containing music tracks for relaxation).|f|f|t|t
34115940|NCT01728103|||COHORT||PROSPECTIVE|||||||
34115941|NCT05334797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33729497|NCT00414804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729498|NCT06087965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729499|NCT01800617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729500|NCT00436943|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33729501|NCT05763888|||CASE_CROSSOVER||PROSPECTIVE|||||||
33729502|NCT00820001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729503|NCT02559869|||CASE_CONTROL||PROSPECTIVE|||||||
33729504|NCT02697162|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33729505|NCT04892238|||COHORT||PROSPECTIVE|||||||
34115942|NCT02244515|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34115943|NCT05630131|||COHORT||PROSPECTIVE|||||||
34115944|NCT04362735|||COHORT||RETROSPECTIVE|||||||
34115945|NCT04179422|||OTHER||PROSPECTIVE|||||||
34115946|NCT05077423|NA|SEQUENTIAL||TREATMENT||NONE||open-label, single-arm, dose-escalation consisting of up to 12 cycles||||
34115947|NCT02083978|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34115948|NCT01908010|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34115949|NCT01482715|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34115950|NCT01168596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115951|NCT00205127|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115952|NCT00931281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729506|NCT04382911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729507|NCT05583396|NA|SINGLE_GROUP||OTHER||NONE||||||
33729508|NCT02366832|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34115953|NCT06228378|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, single-centre, open-label study of patients undergoing ankle stabilisation surgery.||||
34115954|NCT00399529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115955|NCT04609982|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34115956|NCT01935453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115957|NCT05615064|||COHORT||CROSS_SECTIONAL|||||||
34115958|NCT05383261|||COHORT||CROSS_SECTIONAL|||||||
34115959|NCT01323608|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34115960|NCT05467657|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The experimental group will recive conventional therapy and repetitive transcranial magnetic stimulation over somatosensory cortex, and control group will receive conventional therapy and sham repetitive transcranial stimulation|t|f|t|t
34115961|NCT02458235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115962|NCT03190421|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Expanded Quantitative Urinary Culture (EQUC) versus Standard Culture (SUC) Techniques||||
34115963|NCT04079738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34115964|NCT03808935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34115965|NCT05363592|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34115966|NCT01175122|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34115967|NCT02271880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115968|NCT01074346|||COHORT||PROSPECTIVE|||||||
34115969|NCT01528592|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34115970|NCT04541615|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants do not know in which group they will be assigned and they will not know the study design. The investigators know which study group is training in the skills lab.|48 subjects will be randomized in 4 different groups of 12 subjects each. The first group will receive information on how to optimally perform the anastomosis task and the material will be delivered via an e-learning platform. Group 1 will be required to study the material to a pre-defined proficiency level. The second group will receive the exact same information as Group 1 on how to optimally perform the anastomosis task but they are not required to study the material to a pre-defined proficiency benchmark. The third group will receivelectures on how to perform the chicken anastomosis task. It will not differ from what they would normally receive during a traditional surgery training course when they arrive at the ORSI Academy for their training. The fourth group will not receive lectures or e-learning on how to perform the anastomosis task. They will however receive practical one-to-one training during a traditional surgical training course, with deliberate practice.|t|f|f|f
34115971|NCT05572294|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34115972|NCT06565143|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34115973|NCT00105898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115974|NCT02965781|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115975|NCT05477888|||COHORT||CROSS_SECTIONAL|||||||
34115976|NCT01862354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115977|NCT01775384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34115978|NCT02485184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729509|NCT03461224|||OTHER||RETROSPECTIVE|||||||
33729510|NCT01067404|||COHORT||PROSPECTIVE|||||||
33729511|NCT00287664|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729512|NCT01395056|||COHORT||PROSPECTIVE|||||||
33729513|NCT05949190|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|In the food comparison, while the 2 study foods taste similar, full masking cannot be guaranteed. In the CBT comparison, participants and therapists will not be masked. In all cases, outcomes assessors will be masked.|2x2 factorial design|f|t|t|t
33729514|NCT03100708|||CASE_ONLY||PROSPECTIVE|||||||
33729515|NCT00072150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729516|NCT04431791|||COHORT||OTHER|||||||
33729517|NCT02727348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33729518|NCT06390228|||CASE_CONTROL||RETROSPECTIVE|||||||
33729519|NCT05351346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729520|NCT01619670|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729521|NCT06447090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729522|NCT02438748|||COHORT||PROSPECTIVE|||||||
33729523|NCT03934528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729524|NCT02165358|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729525|NCT00898976|||CASE_ONLY||PROSPECTIVE|||||||
33729526|NCT00981032|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33729527|NCT03666169|||COHORT||CROSS_SECTIONAL|||||||
33729528|NCT04517916|||CASE_ONLY||PROSPECTIVE|||||||
33729529|NCT01664013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729530|NCT00735371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729531|NCT02385799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729532|NCT01422499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729533|NCT03948373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is an open-label, parallel, prospective, randomized and controlled trial.|f|f|t|f
33729534|NCT01574703|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34115979|NCT04254406|||CASE_ONLY||RETROSPECTIVE|||||||
34115980|NCT02958345|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34115981|NCT01466088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115982|NCT06521268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled study|t|f|f|f
34115983|NCT04993261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34115984|NCT04189484|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.~Subjects and staff will be blinded to treatment assignment during confinement. The blind will be maintained through a randomization schedule held by the dispensing pharmacist. Subjects and staff will be informed of a subject's end of study day when discharged from confinement. Subjects and staff will not be informed of the specific treatment arm assignment. The clinical research nurse will administer the subcutaneous study drug in unit dose containers that are not transparent."|Subjects will be randomized to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (evolocumab or alirocumab) or placebo|t|f|t|f
34115985|NCT05703399|||COHORT||PROSPECTIVE|||||||
33729535|NCT05339607|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33729536|NCT04061200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded||t|t|t|t
33729537|NCT01660893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33729538|NCT04415606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subject will not know which arm they were randomized to.||t|f|f|f
34115986|NCT03069716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Investigators are blinded.~Study personnel conducting 6MWT and echo will be blinded."|Randomization will occur after a two-week run-in period to improve ability to identify a true baseline step count and account for potential dropout. Participants will be assigned to either the smartphone text messaging or no smartphone text messaging arms in a random manner until 25 participants are enrolled into each arm. Permuted block randomization stratified by functional class (I/II vs. III) will be used to ensure approximate balance of treatment groups within each stratum over time. Randomization will be performed in small blocks, which vary in size. Investigators will be unaware of the size or order of the blocks. Randomization will occur through REDCap by a study coordinator. Although the texting intervention will end after Week 12, subjects in both groups will be asked to continue wearing the Fitbit Charge HR device for an additional 3 weeks to determine whether withdrawal of the texting intervention results in a reduction in step counts.|f|t|t|t
33729539|NCT06264388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729540|NCT01914666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729541|NCT06165796|||CASE_CONTROL||RETROSPECTIVE|||||||
33729542|NCT04488029|RANDOMIZED|PARALLEL||TREATMENT||NONE||Final study eligibility will be assessed after administration of the Western Aphasia Battery, Revised (WAB-R). Eligible subjects will be pseudorandomly assigned to the experimental group OR the control group, while trying to balance for aphasia severity (WAB-R Aphasia Quotient, WAB-AQ). Subjects in the experimental group will receive therapy via the PCT app during the treatment period. Subjects in the control arm will receive conventional workbook therapy. Subjects in both groups will be asked to refrain from obtaining one-on-one individual aphasia or cognitive therapy. Subjects may participate in organized social groups, such as community aphasia groups.||||
33729543|NCT04150224|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33729544|NCT02644707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729545|NCT01261858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729546|NCT02174081|||COHORT|||||||||
34115987|NCT02890875|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34115988|NCT02369536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34115989|NCT02530255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34115990|NCT06120205|NA|SINGLE_GROUP||SCREENING||NONE||||||
34115991|NCT02803905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34115992|NCT03580954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34115993|NCT01669512|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115994|NCT03901586|NA|SINGLE_GROUP||OTHER||NONE||||||
34115995|NCT00094276|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34115996|NCT05495022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34115997|NCT00265798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34115998|NCT03202394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized in a 1:1 ratio to either BIO 11006 125 mg twice daily (intervention) plus standard of care ventilation or placebo BID plus standard of care ventilation. Patients randomized to receive BIO 11006 or placebo will start dosing at the time of ventilation and continue for up to 30 days or length of ventilation (if shorter).|t|t|t|t
34115999|NCT05994430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116000|NCT00178009|||CASE_CONTROL||PROSPECTIVE|||||||
34116001|NCT05313490|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34116002|NCT03220438|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34116003|NCT03064308|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34116004|NCT04574336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116005|NCT06173089|||COHORT||PROSPECTIVE|||||||
34116006|NCT04706988|||COHORT||PROSPECTIVE|||||||
34116007|NCT06205121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116008|NCT02027792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116009|NCT04116684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||50 patients will be randomly assigned to standard of care home blood pressure monitoring while the other 50 patients will be randomized to Withings home digital blood pressure monitoring.||||
34116010|NCT01983111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116011|NCT01280968|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34116012|NCT02128022|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33729547|NCT03892811|||CASE_CROSSOVER||PROSPECTIVE|||||||
33729548|NCT05054738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and research staff providing follow up assessments will be blinded to participants study condition|Between groups randomized controlled trial|f|f|t|t
33729549|NCT01790334|||CASE_CROSSOVER||PROSPECTIVE|||||||
33729550|NCT00323414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729551|NCT02530424|NA|SINGLE_GROUP||OTHER||NONE||||||
33810790|NCT05076825|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33810791|NCT06122025|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33810792|NCT04393402|||COHORT||PROSPECTIVE|||||||
33810793|NCT00415649|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33810794|NCT01167998|||COHORT||PROSPECTIVE|||||||
34116013|NCT02983409|||CASE_ONLY||RETROSPECTIVE|||||||
34116014|NCT04269421|||COHORT||OTHER|||||||
34116015|NCT01533545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34116016|NCT00893802|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34116017|NCT06452992|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116018|NCT06034626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients receiving IPL treatment were masked.|The trial aimed to assess therapeutic effectiveness of the study treatment arm (OPL-I with the dual filter system; Miracle Laser systems, Wuhan, China) to the control treatment arm (M22 with a single filter; Lumenis, Yokneam, Israel). Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.|t|f|f|f
34116019|NCT02148848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116020|NCT02456129|NA|SINGLE_GROUP||||NONE||||||
33729552|NCT04904185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"12 Patients will be indluced in two steps.~* Part A (6 patients): Lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0. If the production of the MASE-T cell product was feasible for the majority (\>50%) of patients intended to treat in Arm A and the toxicity was acceptable, six patients will further be included in part B.~* Part B (6 patients): Lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21."||||
33729553|NCT04069403|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Analyze baseline concurrent opioid prescribing metrics at the individual prescriber level in the Duke Health System on the identified three main outcome measures.~Test the impact of reports on opioid prescriber behaviors with the following primary measures: number of prescriptions with concurrent or benzo within reporting period, number of prescriptions with concurrent muscle relaxants within reporting period, and number of encounters with naloxone prescriptions for patients with any opioid-related diagnosis within reporting period.~Create a blueprint to implement the concurrent opioid prescribing nudge intervention in other settings."||||
33729554|NCT06306456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729555|NCT05222061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729556|NCT05417932|NA|SINGLE_GROUP||TREATMENT||NONE||SCG101 in the Treatment of Subjects with Hepatitis B Virus-Related Hepatocellular Carcinoma||||
33729557|NCT01404091|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33729558|NCT05527431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729559|NCT02485106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729560|NCT02812758|||COHORT||PROSPECTIVE|||||||
33729561|NCT01358227|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729562|NCT02394080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729563|NCT05304260|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33729564|NCT03657888|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and volunteers cannot be blinded but data analyst will be blinded.|The study is a prospective controlled trial with two conditions: (1) intervention group participating in Family Club Denmark and (2) wait-list control group.|f|f|f|t
33729565|NCT04594850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729566|NCT05242081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33729567|NCT04699331|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33729568|NCT05865288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729569|NCT02149342|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33729570|NCT05876026|||COHORT||PROSPECTIVE|||||||
33729571|NCT04728269|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33729572|NCT03995381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33729573|NCT05817929|NA|SINGLE_GROUP||OTHER||NONE||||||
33729574|NCT04308317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729575|NCT02421133|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33729576|NCT01574352|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33729577|NCT03750981|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33729578|NCT00189735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33729579|NCT01630330|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33729580|NCT03588364|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Only the study coordinator and the participants are privy to the assigned treatment arm (immediate vs. delayed) until the study is complete and the database is locked.|This is a 30-week prospective, randomized delayed treatment control group design in which 20 participants from the community will be randomized 1:1 into (a) an immediate treatment group that will receive 12 weeks of osteopathic manipulation (OMT) treatment plus standard of care right away or (b) delayed treatment group that will receive 12 weeks of OMT plus standard of care after a 6-week waiting period. The delayed treatment group initially serves as a control condition but then receives the experimental treatment.|f|t|t|t
33729581|NCT02108821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729582|NCT03633981|||COHORT||PROSPECTIVE|||||||
33729583|NCT00210314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729584|NCT04122573|||COHORT||PROSPECTIVE|||||||
33810795|NCT02732990|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33729585|NCT00722319|||COHORT||PROSPECTIVE|||||||
33729586|NCT03316833|||COHORT||PROSPECTIVE|||||||
33729587|NCT01133769|||CASE_CROSSOVER||PROSPECTIVE|||||||
33729588|NCT00763074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729589|NCT00922571|NA|SINGLE_GROUP||||NONE||||||
33729590|NCT04549220|||COHORT||PROSPECTIVE|||||||
33729591|NCT00786695|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33729592|NCT03424837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729593|NCT00508742|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33729594|NCT04411433|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label, multicenter, parallel-group, randomized, phase III trial that evaluates the efficacy and safety of hydroxychloroquine and favipiravir in the treatment of patients with possible or confirmed COVID-19 observed within the last 5 days. 1000 patients will be randomized in 2:1:2:2:2:1 ratio and divided into six groups.||||
33729595|NCT04472936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729596|NCT03821012|||COHORT||PROSPECTIVE|||||||
33729597|NCT00960518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729598|NCT05058313|NA|SINGLE_GROUP||OTHER||NONE||||||
33729599|NCT03385252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not be masked. Data collectors will not be informed of the participant's group assignments. Data analysis will be conducted on blinded datasets until the primary analysis is complete.||f|f|t|t
33810796|NCT03316690|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33810797|NCT05098405|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810798|NCT05794295|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not be aware of whether they have acoustic stimulation or sham stimulation. They will be asleep while they are monitored.|The study is a parallel design with FE patients and healthy controls.|t|f|f|f
33810799|NCT00958048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729600|NCT04953403|||COHORT||RETROSPECTIVE|||||||
34116021|NCT06395558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessor will be unaware about the study arm allocation of the patient||f|f|f|t
34116022|NCT00884780|||COHORT||PROSPECTIVE|||||||
34116023|NCT02752542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116024|NCT06116097|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A total of 83 adolescent female elite athletes from 3 different sport clubs (football n=34, basketball n=16 and volleyball n=33) between 15 and 18 years(mean 17.2 ± 2.0) were included in the study.They were divided into either the intervention or the control groupby simple randomization. Fortyfem participants took 6 physical nutrition education lectures and the other group (n=38) didn't have any nutrition education. All of them filled the LEAF-Q (Low energy availability in athletes questionnaire),EAT-26(Eating Attitude Test)and SNKQ (Sports Nutrition Knowledge Questionnaire).Energy and nutrient intakes were assessed based on 3-day food records. Activity logs were analysed to measure exercise energy expenditure. All of the tests have been repeated after 6 months. Nutrition education was comprised of 6 physical 60 minutes sessions given every week in a school class. Each session was consisted of a different subject. Participants got written information as a printed booklet.||||
34116025|NCT02378480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116026|NCT06008444|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116027|NCT03396159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116028|NCT02499887|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116029|NCT02001519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116030|NCT02874092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116031|NCT04336189|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo or SP and DP) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. A randomization list will be computer generated by a member of the project who will not be directly involved in the conduct of the study. The randomization list will include consecutive treatment numbers with corresponding random treatment assignments. Randomized codes will correspond to the 3 treatment arms using permuted variable sized blocks of 6 and 9.|Double blinded randomized controlled trial|t|t|t|f
34116032|NCT02257320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116033|NCT00156195|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34116034|NCT04570384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind Clinical Trial|Placebo controlled and Active Drug|t|t|t|t
34116035|NCT04856527|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34116036|NCT05241678|||COHORT||PROSPECTIVE|||||||
34116037|NCT06224023|||COHORT||PROSPECTIVE|||||||
34116038|NCT06203223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|use of placebo, masked randomisation list|randomised controlled trial|t|t|t|t
34116039|NCT02327377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116040|NCT05267782|||CASE_ONLY||PROSPECTIVE|||||||
34116041|NCT04858373|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single (Investigator)|Crossover Assignment|f|f|t|f
34116042|NCT02881827|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34116043|NCT04597749|NA|SINGLE_GROUP||SCREENING||NONE||||||
34116044|NCT06225206|||OTHER||OTHER|||||||
34116045|NCT05958602|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116046|NCT05571293|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116047|NCT03217617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116048|NCT00490711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116049|NCT00890500|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33729601|NCT02946060|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33729602|NCT04671810|||COHORT||PROSPECTIVE|||||||
33729603|NCT03867513|||CASE_CONTROL||PROSPECTIVE|||||||
33729604|NCT05677165|||OTHER||RETROSPECTIVE|||||||
33729605|NCT05320991|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|All investigators (except anesthesiologists) are blinded until fMRI data has been preprocessed||t|f|t|t
33729606|NCT02617550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116050|NCT04829513|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
34116051|NCT00196898|||COHORT||PROSPECTIVE|||||||
34116052|NCT01365455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116053|NCT05026164|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Double-blind, randomized|t|t|t|f
34116054|NCT02390076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116055|NCT00970398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34116056|NCT05269186|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34116057|NCT02212860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116058|NCT06032611|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116059|NCT01836354|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116060|NCT05638113|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomized Controlled Trial||||
33729607|NCT04021264|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Double-blinded, randomized controlled, prospective|t|t|t|f
33729608|NCT01358617|||CASE_CONTROL||RETROSPECTIVE|||||||
33729609|NCT01410396|||CASE_CONTROL||PROSPECTIVE|||||||
33810800|NCT00715182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116061|NCT01318681|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33729610|NCT00231881|||DEFINED_POPULATION||PROSPECTIVE|||||||
33729611|NCT04871295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116062|NCT04041193|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34116063|NCT03767868|||CASE_ONLY||PROSPECTIVE|||||||
34116064|NCT05024084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34116065|NCT01297855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116066|NCT06478862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be 2 cohorts with up to 10 patients per cohort indication (ovarian/pancreatic). Eligible patients will be assigned in parallel to receive 6 cycles of Promitil treatment.||||
34116067|NCT04435626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116068|NCT02635295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34116069|NCT02073474|||OTHER||PROSPECTIVE|||||||
34116070|NCT05700409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116071|NCT06561139|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial, and subsequently a qualitative study||||
34116072|NCT05745714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116073|NCT03014466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116074|NCT06220110|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34116075|NCT03393104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to participants' treatment allocation.||f|f|f|t
34116076|NCT03402841|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open|Single arm study||||
34116077|NCT04622592|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Observer-blind||t|t|t|t
34116078|NCT00485173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116079|NCT01468155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116080|NCT01502384|||COHORT|||||||||
34116081|NCT00064857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116082|NCT01778413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116083|NCT05933811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116084|NCT04204824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent investigator will set the parameters with the machine outside the treatment area and not in sight of the principal investigator or participant. The face of the machine will then be covered so neither the principal investigator nor the participant can see the settings.The principal investigator and the participants will not be aware of their group assignments until conclusion of the study.|Two groups: Control vs. experimental|t|f|t|f
34116085|NCT01098422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116086|NCT03836404|NA|SINGLE_GROUP||OTHER||NONE||||||
34116087|NCT05429606|||CASE_ONLY||CROSS_SECTIONAL|||||||
34116088|NCT02048202|||FAMILY_BASED||PROSPECTIVE|||||||
34116089|NCT06571942|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study comparing the effect of 3 inhaled triple therapies and 1 inhaled double therapy in small airway in COPD and pre-COPD patients for three months||||
34116090|NCT06537791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116091|NCT05358327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116092|NCT00158106|RANDOMIZED|PARALLEL||ECT||NONE||||||
34116093|NCT02260037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116094|NCT03279952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116095|NCT06460272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The PI and the study statistician will be masked to treatment condition when conducting initial data analysis.|"This study is a human-centered three-arm design implementation trial to compare MTM only vs. MTM + SMA (weekly culinary and nutrition education and practice for 10 weeks) vs. a wait-list control group (MTM-Later). Meals will be provided at a frequency of 14 meals/week for 10 weeks. All intervention components will be designed and intended to be culturally congruent. Primary outcomes will be implementation (recruitment and retention rates) and feasibility (engagement and satisfaction).~This study aims to distinguish an effective treatment (e.g., MTM only or MTM + SMAs) from a less effective or ineffective treatment. For this study, the investigators propose a three-arm (1:1:1) parallel-group randomized controlled trial (n = 75) powered to detect threshold levels of implementation and engagement. Intervention arms include, 1) MTM (only), 2) MTM +SMA, and a 3) Wait-list Control."|f|f|t|t
34116096|NCT00906061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116097|NCT03688971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116098|NCT04612426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116099|NCT04729790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|An independent statistician will develop a randomization list using SAS. Randomization in permuted blocks will be used to achieve balance across treatment groups. The randomization scheme consists of a sequence of blocks such that each block contains a pre-specified number of treatment assignments in random order. The purpose of this is to balance the randomization scheme at the completion of each block. The target sample size is 200 evaluable subjects or as many as can be done up to that number.|This is a double-blinded study for the groups randomized to receive FMT products either from single or three healthy donors|t|t|t|t
34116100|NCT02407119|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116101|NCT00749346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116102|NCT04052165|NA|SINGLE_GROUP||TREATMENT||NONE||GDD in glaucoma patient||||
34116103|NCT04840511|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34116104|NCT05936658|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116105|NCT02323711|RANDOMIZED|PARALLEL||||NONE||||||
34116106|NCT02183584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116107|NCT01427491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116108|NCT01264185|||COHORT||PROSPECTIVE|||||||
34116109|NCT01600287|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34116110|NCT05309655|NA|SINGLE_GROUP||TREATMENT||NONE||Investigators will recruit 90 women, 67 who will be in the near-complete estrogen deprivation (NCED) group and 23 in the triple-negative breast cancer (TNBC) group. This will allow for approximately a 10% loss-to-follow-up rate and will allow investigators to have 60 participants in the NCED group and 20 in the TNBC with 2-year of data. There are 2 primary types of statistical analyses to address the study questions. The first includes testing hypotheses concerning between group (NCED vs TNBC) and within group (i.e. longitudinal changes within the NCED group) comparisons (Aims 1 and 2). The second analyses involve developing predictive equations among the NCED patients to determine if patient demographics including age, race, ethnicity, social determinants of health, clinical parameters, serum biomarkers and/or markers of inflammation are associated with cardiovascular changes over time.||||
34116111|NCT03429140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once it has been determined that a subject meets the entry requirements of the study they will be randomized, like the flipping of coin into one of two treatment groups. Neither the subject nor the investigator will be told which of the two treatments that the subject is assigned to. However, the investigator can find out in the case of emergency. Treatment assignment will be released to the subject after they have completed all study visits.||t|f|t|f
34116112|NCT03739619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116113|NCT06123299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34116114|NCT06344507|||COHORT||OTHER|||||||
34116115|NCT00498212|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116116|NCT01846312|||COHORT||PROSPECTIVE|||||||
34116117|NCT00767026|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34116118|NCT00649584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810801|NCT02579109|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33810802|NCT00151866|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34042261|NCT00324818|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34042262|NCT06443957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34042263|NCT03019133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042264|NCT04126980|||COHORT||RETROSPECTIVE|||||||
34042265|NCT05217134|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34042266|NCT00815542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042267|NCT02689193|||CASE_CONTROL||PROSPECTIVE|||||||
34042268|NCT06578806|||OTHER||RETROSPECTIVE|||||||
34042269|NCT05529901|||CASE_ONLY||PROSPECTIVE|||||||
34042270|NCT04498182|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042271|NCT05234905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042272|NCT00845221|NA|SINGLE_GROUP||||NONE||||||
34042273|NCT06464718|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group A comprised of 15 subject who were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA). Group B (control) consisted of 15 subjects who consumed a sweet formed from a chewable tablet with 1. A calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily, these are potent supplements that are often used in practice, as per the researchers' recommendations||||
34042274|NCT00386451|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042275|NCT05696990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042276|NCT02865304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042277|NCT02882581|NA|SINGLE_GROUP||OTHER||NONE||11C-metformin uptake in breast cancer. Single center, single dose, open-label.||||
34042278|NCT04970147|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34042279|NCT04864119|||CASE_ONLY||PROSPECTIVE|||||||
34042280|NCT05480072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042281|NCT02069041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042282|NCT03383289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research Assistants||t|f|f|f
34042283|NCT02920502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042284|NCT00810667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042285|NCT05795543|RANDOMIZED|PARALLEL||TREATMENT||NONE||participant divide to 2 groups first group subtalar arthrodesis by single screw second group subtalar arthrodesis by double screws||||
34042286|NCT04415164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042287|NCT06577701|||COHORT||PROSPECTIVE|||||||
34042288|NCT06295874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized controlled single blind study||||
34042289|NCT04374123|||COHORT||PROSPECTIVE|||||||
34042290|NCT01540201|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34042291|NCT02761772|||COHORT||PROSPECTIVE|||||||
34042292|NCT04850352|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34042293|NCT02408835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042294|NCT00322270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042295|NCT02687061|||COHORT|||||||||
34042296|NCT00891020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042297|NCT02819037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042298|NCT03215290|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042299|NCT04132323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34042300|NCT04156711|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Outcomes assessor are partly blinded and data analysis will be blinded||f|t|f|t
34042301|NCT04576520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042302|NCT05251961|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34042303|NCT00002234||||TREATMENT||||||||
34042304|NCT02903940|||COHORT||PROSPECTIVE|||||||
34042305|NCT05190770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042306|NCT03063060|||COHORT||RETROSPECTIVE|||||||
34042307|NCT00448266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042308|NCT03863639|||CASE_CONTROL||PROSPECTIVE|||||||
34042309|NCT03095326|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant are divided into two different groups, which are assigned with either zinc or placebo|All splenectomized thalassemia major subjects were provided with PCV pneumococcal vaccine (Prevenar 13®) at the start of the trial. The subjects were then randomly assigned into one of 2 groups (the zinc group and the placebo group). Zinc was provided in the form of syrup at a dose of 1.5 mg/kg/day, with a maximum of 50 mg/day. The placebo was also provided in the form of syrup, with similar shape and flavor.|f|f|t|f
34042310|NCT03023917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34042311|NCT05101889|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||phase II randomized, double-blind study|t|f|t|t
34042312|NCT05495100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042313|NCT04900441|||OTHER||CROSS_SECTIONAL|||||||
34042314|NCT02695966|||CASE_ONLY||PROSPECTIVE|||||||
34042315|NCT06574685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To maintain blinding, placebo supplements were identical in appearance to the intervention supplements, and investigators remained unaware of the participants' group assignments.|One group intervention and one group placebo, consumption of supplements for 20 days.|t|f|t|f
34042316|NCT03710837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Participant information is pseudonymised using student numbers only. As soon is data is generated data will be fully anonymised.|Multi disciplinary randomised controlled trial|t|f|t|t
34042317|NCT06123169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042318|NCT04917003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042319|NCT02923323|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042320|NCT05691582|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34042321|NCT00315133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042322|NCT02861105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042323|NCT04505930|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34042324|NCT03726047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33729612|NCT03495882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729613|NCT05358275|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Randomized clinical trial with 1:1 allocation ratio|t|f|f|t
33729614|NCT00829296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33729615|NCT01459172|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33729616|NCT03055000|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33729617|NCT05833620|||COHORT||CROSS_SECTIONAL|||||||
33729618|NCT05409235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729619|NCT03093675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729620|NCT01819805|||COHORT||PROSPECTIVE|||||||
33729621|NCT03768115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Autologous crimped plasma segments||||
33729622|NCT05199480|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33729623|NCT02181556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729624|NCT04484272|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729625|NCT02605668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729626|NCT00337103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729627|NCT04814290|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729628|NCT00945984|||CASE_CONTROL||RETROSPECTIVE|||||||
33729629|NCT05604560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729630|NCT02006459|||CASE_CONTROL||PROSPECTIVE|||||||
33729631|NCT04175093|||CASE_ONLY||CROSS_SECTIONAL|||||||
33729632|NCT03350503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729633|NCT00769847|||COHORT||PROSPECTIVE|||||||
33729634|NCT02829593|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729635|NCT00283439||PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729636|NCT00706641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729637|NCT00908960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729638|NCT04321304|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33729639|NCT00107458|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33729640|NCT05318144|||CASE_CONTROL||PROSPECTIVE|||||||
33729641|NCT02609022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729642|NCT01297868|||COHORT||PROSPECTIVE|||||||
33729643|NCT02075944|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33729644|NCT05130203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33729645|NCT04138875|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open label, sequential, risk stratified study.||||
33729646|NCT02611622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33729647|NCT03219697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Control Trial|f|f|f|t
33729648|NCT02009410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729649|NCT03412916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729650|NCT04914728|NA|SINGLE_GROUP||OTHER||NONE||Single-centre, pilot study evaluating the feasibility, difficulties and morbidity of ambulatory lumbar arthrodesis||||
33729651|NCT02042924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729652|NCT04268420|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729653|NCT00254995|||COHORT|||||||||
33729654|NCT05268861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33729655|NCT03202004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator, study center staff, subject, and sponsor will be blinded to randomized study treatment assignments.||t|f|t|f
33729656|NCT03175094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729657|NCT01466946|||CASE_ONLY||PROSPECTIVE|||||||
33729658|NCT03676530|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pro-Tec Shin Splints Compression Wrap||||
33729659|NCT01991119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729660|NCT05530122|||OTHER||OTHER|||||||
33729661|NCT03445624|||CASE_CONTROL||PROSPECTIVE|||||||
33729662|NCT04188262|NA|SINGLE_GROUP||TREATMENT||NONE||NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease||||
33729663|NCT00639834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729664|NCT02294877|||COHORT||PROSPECTIVE|||||||
33729665|NCT01578928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729666|NCT01315769|||CASE_CONTROL||PROSPECTIVE|||||||
34116119|NCT01728246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116120|NCT03481439|||COHORT||PROSPECTIVE|||||||
34116121|NCT02563015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729667|NCT01180270|||||PROSPECTIVE|||||||
33729668|NCT04498793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729669|NCT03601221|||OTHER||PROSPECTIVE|||||||
33729670|NCT02581774|||CASE_CONTROL||PROSPECTIVE|||||||
33729671|NCT01908569|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33729672|NCT00754416|||COHORT||PROSPECTIVE|||||||
33729673|NCT04332328|||COHORT||CROSS_SECTIONAL|||||||
33729674|NCT00779012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810803|NCT04908930|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"All interested football players on the 2 teams will be enrolled; of those enrolled, 15-20 per team (n=30-40 total) will be randomly selected for instrumentation with head impact sensors using a random numbers table. Athletes on these teams will follow their coach prescribed practice structure.~Two additional youth football teams at the middle school level will be recruited to pilot test the intervention developed in this study. All interested athletes on these teams will be enrolled; of those enrolled, 15-20 per team (n=30-40 total) will be randomly selected for instrumentation with head impact sensors using a random numbers table.~Enrolled athletes will wear head impact sensors embedded in a custom mouthpiece that will be used to collect head impact exposure in conjunction with on-field video data for the season."||||
33729675|NCT06183359|RANDOMIZED|PARALLEL||PREVENTION||NONE||The group Self-Identification Program (SIP) versus The group Acceptance and Commitment Therapy (ACT)||||
33729676|NCT06415643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810804|NCT06352554|||COHORT||CROSS_SECTIONAL|||||||
33810805|NCT04277156|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33810806|NCT05786378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810807|NCT00297466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810808|NCT06313632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blind study||t|t|f|t
33810809|NCT04890457|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33810810|NCT00532350|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33810811|NCT00953355|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33810812|NCT04976764|||CASE_CONTROL||RETROSPECTIVE|||||||
33810813|NCT02797743|||FAMILY_BASED||PROSPECTIVE|||||||
33810814|NCT00074425|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33810815|NCT01218594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810816|NCT04156048|||COHORT||PROSPECTIVE|||||||
33810817|NCT05227898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33810818|NCT00969007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810819|NCT04638049|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33810820|NCT03674788|||COHORT||PROSPECTIVE|||||||
33810821|NCT02431169|||CASE_ONLY||PROSPECTIVE|||||||
33810822|NCT03306498|||COHORT||PROSPECTIVE|||||||
33810823|NCT03849937|RANDOMIZED|CROSSOVER||OTHER||NONE||The research design is a randomized clinical trial. An initial nursing home will be used to test feasibility. Six nursing homes will be randomly assigned to intervention or wait-list control groups.||||
33810824|NCT01379885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810825|NCT04093609|||CASE_CONTROL||PROSPECTIVE|||||||
33810826|NCT04335149|||COHORT||RETROSPECTIVE|||||||
33810827|NCT02680015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34116122|NCT00784615|||COHORT||CROSS_SECTIONAL|||||||
34116123|NCT00002035||||TREATMENT||DOUBLE||||||
34116124|NCT02697357|||COHORT||PROSPECTIVE|||||||
34116125|NCT03840967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116126|NCT06186232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116127|NCT02114645|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34116128|NCT05790356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participants or the investigator will know which treatment arms participants have been assigned to. This information can be obtained quickly from pharmacy if needed.|Randomized, double-blind, placebo-controlled proof-of-concept study.|t|f|t|f
34116129|NCT04946604|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant is given the intervention, and they are measured at pre, post and 6 month follow-up.||||
34116130|NCT03526263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116131|NCT06314945|||OTHER||CROSS_SECTIONAL|||||||
34116132|NCT01988077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116133|NCT03558529|||COHORT||PROSPECTIVE|||||||
34116134|NCT02361892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116135|NCT05595109|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116136|NCT04442269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116137|NCT02878434|||COHORT||PROSPECTIVE|||||||
34116138|NCT01448616|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34116139|NCT05155111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116140|NCT02683447|||COHORT||PROSPECTIVE|||||||
34116141|NCT05287451|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116142|NCT00180284|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116143|NCT04260477|RANDOMIZED|PARALLEL||TREATMENT||NONE|Providers in the TB clinics and lab technicians in the Niger clinics and labs will not be blinded to the prescribed regimen. However, lab technicians working in the Institute of Tropical Medicine (ITM) lab will be blinded to the prescribed regimen. Also the statistician will be blinded to the prescribed regimen until the first interim analysis is completed.|||||
34116144|NCT02614820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116145|NCT02908711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116146|NCT01435590|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34116147|NCT00948350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116148|NCT01115504|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34116149|NCT02715284|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810828|NCT03713476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810829|NCT04373655|||COHORT||PROSPECTIVE|||||||
33810830|NCT00428714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810831|NCT03393559|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized controlled trial|t|f|f|t
33810832|NCT02179203|||CASE_ONLY||CROSS_SECTIONAL|||||||
33810833|NCT04620642|||COHORT||PROSPECTIVE|||||||
33810834|NCT04852471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116150|NCT03670472|||CASE_CONTROL||PROSPECTIVE|||||||
34116151|NCT05664373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116152|NCT03518021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The whole study team, including the statistician, will be blinded until after database lock and the primary analysis are done. The allocation list will be stored by by the Hospital Pharmacy Trondheim. There will not be automatic unblinding of SAEs. Study personnel do not have any access to the allocation list. An emergency option for individual unblinding is available to medical monitor in case of SAE/ SUSAR Study workers are blinded to the different preparations. This is carefully performed by covering the vials with neutral and opaque labels for study drug. The risk of for unintentional unblinding is very small. The procedure for securing credible blinding is described in the study protocol and approved by the Norwegian Medicines Agency."|Double blinded, double dummy, randomized controlled trial|t|t|t|t
34116153|NCT01067807|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116154|NCT00222820|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116155|NCT03271333|||COHORT||PROSPECTIVE|||||||
34116156|NCT01604317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810835|NCT03909100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810836|NCT05114993|NA|SEQUENTIAL||SCREENING||NONE||"Participants will be observed and monitored for 5 minutes without any intervention. After 5 minutes of observation and monitoring, participants will don a disposable surgical mask. Participants will then be observed and monitored for 15 minutes while under the intervention of mask-wearing. Only one type of mask will be used for all participants."||||
33810837|NCT00893100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33810838|NCT05081726|||CASE_CONTROL||PROSPECTIVE|||||||
33810839|NCT03576092|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810840|NCT01603108|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33810841|NCT05605132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810842|NCT02243800|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33810843|NCT04377191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116157|NCT05159674|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34116158|NCT01664624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116159|NCT02695654|||COHORT||PROSPECTIVE|||||||
34116160|NCT05021939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are blind to the treatment methods|Randomized Controlled Study|t|f|f|f
34116161|NCT02623244|||CASE_CONTROL||PROSPECTIVE|||||||
34116162|NCT02408744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116163|NCT05481684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116164|NCT04394494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be assigned in an alternating order to either the experimental or control group.|This is an Randomized Control Trial. Subjects with LBP will be allocated to one of 2 study groups.|t|f|f|f
34116165|NCT01365754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116166|NCT01451021|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34116167|NCT03673176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116168|NCT05391776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116169|NCT04501926|||CASE_CONTROL||RETROSPECTIVE|||||||
34116170|NCT01923376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116171|NCT00090376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116172|NCT00754884|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34116173|NCT04585178|NA|SINGLE_GROUP||OTHER||NONE||Single group assignment||||
34116174|NCT02716441|||COHORT||PROSPECTIVE|||||||
34116175|NCT02622061|||COHORT||PROSPECTIVE|||||||
34116176|NCT03373435|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34116177|NCT05547035|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34116178|NCT00571883|RANDOMIZED|||TREATMENT||||||||
34116179|NCT01685684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116180|NCT02434861|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116181|NCT05641766|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This proof-of-concept study will use a double-blind, randomized, cross-over (within-subject), placebo-controlled, counterbalanced study design in which participants will receive 0 (placebo) or 0.03 mg/kg intravenous THC over 20 minutes while undergoing simultaneous MEG/EEG data collection.|t|f|t|f
34116182|NCT03939390|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116183|NCT02698384|||COHORT||PROSPECTIVE|||||||
34116184|NCT00208130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116185|NCT06565364|||COHORT||PROSPECTIVE|||||||
34116186|NCT01493544|||COHORT||CROSS_SECTIONAL|||||||
34116187|NCT05890209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116188|NCT04942847|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116189|NCT04049773|||CASE_ONLY||PROSPECTIVE|||||||
34116190|NCT03297658|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"All subjects will have electro-acupuncture pads applied at four points bilaterally: pericardial 4 (PC 4), pericardial 6 (PC 6), large intestine 4 (LI 4) and stomach 36 (ST 36). No needles will be used. (Appendix A; 1)~Group 1: Receive electro-acupuncture (EA) (treatment) frequency will be at 2Hz and 100 Hz the amplitude will be microA.~Group 2: Receive sham (control) will not have stimulation."|t|t|t|f
34116191|NCT02234362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116192|NCT06171061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34116193|NCT04363346|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study starts with a fast-track design by proceeding in cohorts of one patient until the first DLT is observed. If no DLT is observed, escalation continues by one patient per cohort until Dose Strategy 3 is reached. If the MTD is not yet established by Dose Strategy 3, Dose Strategy 3 is expanded to 6 patients using the final stage of a 3+3 design. An extension of 4 additional patients is planned if FT516 continues to be safe for a total of 10 patients treated at the MTD."||||
34116194|NCT04259216|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34116195|NCT02418091|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34116196|NCT04670796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116197|NCT05004415|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Single-Dose pharmacokinetic (PK) study.||||
34116198|NCT01772940|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34116199|NCT02281045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116200|NCT05229614|NA|SINGLE_GROUP||TREATMENT||NONE||Patient with solid cancer (NSCLC, HNSCC, melanoma, urothelial carcinoma) and a stable disease will be enrolled in the study.||||
33810844|NCT03941509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Stepped-wedge design will see a staggered roll out of the intervention over 16 months. Each cluster of two facilities will commence in the control phase (2 months) and transition to the intervention phase until all facilities receive the intervention. A transition phase of 2 months between the control and intervention phase will occur to allow for education and integration of the intervention.||||
33810845|NCT03122548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810846|NCT05825404|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33810847|NCT05283876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810848|NCT04027985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116201|NCT00068289||||TREATMENT||NONE||||||
34116202|NCT01400711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116203|NCT06546332|||COHORT||PROSPECTIVE|||||||
34116204|NCT05781789|||COHORT||PROSPECTIVE|||||||
34116205|NCT02793960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116206|NCT04146155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116207|NCT01697644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150223|NCT00154128|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34150224|NCT00495378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150225|NCT06492473|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150226|NCT04399915|||CASE_CONTROL||PROSPECTIVE|||||||
34150227|NCT02980627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150228|NCT01455220|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150229|NCT03417986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810849|NCT04460066|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810850|NCT01597882|||COHORT|||||||||
33810851|NCT05277454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810852|NCT02364024|||COHORT||PROSPECTIVE|||||||
33810853|NCT00591136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810854|NCT00814749|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33810855|NCT06470633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810856|NCT04948736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810857|NCT04536766|RANDOMIZED|PARALLEL||TREATMENT||NONE||100 Caregiver-child dyads (children ages 8-12 years) will be recruited from the Beds for Kids program.||||
33810858|NCT03566901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A multisite single blind randomized controlled trial involving the 3 clinical sites (Verona, Bolzano, Monza) will be performed, according to the CONSORT Statement (www.consort-statement.org). The PIs will be responsible for the randomization procedures. If eligible, patients will be randomly allocated (allocation ratio 1:1) to the experimental (EG) or conventional physiotherapy (CP) using computer-generated random numbers (www.randomization.com). In each site, one examiner blinded to group assignment will be responsible for assessments.~Prior to the start of the study the EG and CP protocols will be designed. To ensure uniformity in the delivery of treatments, one therapist from each center will be taught to training protocols by the research collaborators. Participants will receive 50-min, individual treatment sessions as outpatients 2 days a week for 5 consecutive weeks, for a total of 10 sessions. For each Unit one physiotherapist will be assigned to the EG and one to the CP."|f|f|f|t
33810859|NCT01318850|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33810860|NCT02367794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810861|NCT04529824|||COHORT||PROSPECTIVE|||||||
33810862|NCT04121234|||COHORT||RETROSPECTIVE|||||||
34042325|NCT01666626|||COHORT||PROSPECTIVE|||||||
34042326|NCT02945475|||COHORT||PROSPECTIVE|||||||
34042327|NCT06576440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34042328|NCT01113372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34042329|NCT04275739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042330|NCT06535334|||CASE_CONTROL||RETROSPECTIVE|||||||
34042331|NCT00982332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042332|NCT06578104|||COHORT||PROSPECTIVE|||||||
34042333|NCT02494869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042334|NCT05027451|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34042335|NCT06574711|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Forty-seven subjects were randomized and assigned to one of the three intervention groups supplemented daily with 200g of: Sacha Inchi Oil (SIO)-containing yogurt (Group-A), Hybrid palm oil (HPO)-containing yogurt (Group-B), and plain yogurt (Group-C).|A pilot randomized; double-blind, parallel-controlled pragmatic trial was performed|t|f|t|t
34042336|NCT02185326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042337|NCT03225209|NA|SINGLE_GROUP||TREATMENT||NONE||"Proof of concept study"||||
34042338|NCT02158325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042339|NCT05737524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042340|NCT05520723|NA|SINGLE_GROUP||TREATMENT||NONE|Open label, single-arm|||||
34042341|NCT01701817|||COHORT||RETROSPECTIVE|||||||
34042342|NCT01343810|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34042343|NCT06574581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042344|NCT05602844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessment will be performed by orthopaedic surgeons from the Foot and Ankle team; the patient and the outcome assessor will be blinded while the surgeon will not.|single-blinded, parallel-group, randomised controlled trial will be conducted to compare the outcome of the 3D-Printed PSI Assisted Lapidus Fusion (n=27) vs Conventional Lapidus Fusion (n=27) for Surgical Correction of HV Deformity|t|f|f|t
34042345|NCT00531115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042346|NCT06382064|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will be fit into Acuvue Oasys contact lenses at the first visit to wear for 2 weeks. Subjects will then be fit into PRECISION7 lenses at the second visit to wear for 2 weeks.||||
34042347|NCT03793842|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042348|NCT02875613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042349|NCT06497530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042350|NCT05331131|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Simon 2-stage||||
34042351|NCT05519904|||CASE_ONLY||PROSPECTIVE|||||||
34042352|NCT01531621|||COHORT||PROSPECTIVE|||||||
34042353|NCT01695174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042354|NCT00266201|||CASE_CONTROL||PROSPECTIVE|||||||
34042355|NCT05184595|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042356|NCT01316003|||CASE_CONTROL||PROSPECTIVE|||||||
34042357|NCT05457855|||COHORT||RETROSPECTIVE|||||||
34042358|NCT00288405|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042359|NCT05433987|||COHORT||PROSPECTIVE|||||||
34042360|NCT00466362|||COHORT||PROSPECTIVE|||||||
34042361|NCT03211884|RANDOMIZED|PARALLEL||TREATMENT||NONE|Self-administered on-line surveys which preclude the need for a masked outcomes assessor.|Randomized Clinical Trail.||||
34042362|NCT04417010|||COHORT||PROSPECTIVE|||||||
34042363|NCT06532721|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34042364|NCT00509951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042365|NCT01253005|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34042366|NCT01149564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34042367|NCT03510039|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Mono-centric pilot comparative study like  Before /After . It will be necessary to recruit at first 35 thirds benefiting from the in current load, Before phase, then to set up our intervention, and recruit another 35 different thirds for the After."||||
34042368|NCT01722825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042369|NCT00789373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042370|NCT04144894|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34042371|NCT00987129|||COHORT||PROSPECTIVE|||||||
34042372|NCT06229561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116208|NCT06564025|NA|SINGLE_GROUP||PREVENTION||NONE||To assess program feasibility, acceptability, and preliminary efficacy, the investigators will pilot the intervention with a purposive sample of 50 father-teen pairs. All participants will receive the intervention. An online screener, pre- and post-intervention surveys, and brief module feedback will assess feasibility and acceptability. Pre- and post-intervention surveys will provide initial data on directionality for correlates of teens' sexual risk behaviors to determine whether a full-scale R01 is warranted. Debrief interviews with a purposive sample of pilot participants (5 fathers, 5 teens) will obtain in-depth intervention feedback and conduct member checks on module feedback. The investigators will revise the intervention prototype based on feasibility, acceptability, and preliminary efficacy data, then write up and distribute findings for dissemination.||||
34116209|NCT01413815|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34116210|NCT02892292|||COHORT||RETROSPECTIVE|||||||
34116211|NCT02103465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116212|NCT05769114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116213|NCT04039932|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomized trial assigning facility catchment areas to intervention vs. standard of care||||
34116214|NCT05959525|||OTHER||CROSS_SECTIONAL|||||||
34116215|NCT00143884|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34116216|NCT03336229|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34116217|NCT02119273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34116218|NCT03610048|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label||||
34116219|NCT01583907|||COHORT||PROSPECTIVE|||||||
34116220|NCT03650023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116221|NCT01233544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116222|NCT06413914|NA|SINGLE_GROUP||TREATMENT||NONE||200 patients with long-term pain and rheumtic disease, participate in cognitive behavioral therapy individually or in a group. The treatment consists of 8 sessions, 7 weekly sessions and a booster session 2 months after the end of treatment.||||
34116223|NCT06137248|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34116224|NCT03703557|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||TRIPLE||Interventional, prospective, open, monocentric study with risks and minimal constraints|t|f|t|t
34116225|NCT05694247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116226|NCT01240057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116227|NCT02969577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116228|NCT00548886|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34116229|NCT03209258|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Stepped-wedge Cluster Randomised Trial|f|f|f|t
34116230|NCT02424162|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116231|NCT03663543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study|t|t|t|f
34116232|NCT04931576|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34116233|NCT02048007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116234|NCT05287321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116235|NCT05894603|||COHORT||PROSPECTIVE|||||||
34116236|NCT00641264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116237|NCT04627129|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116238|NCT00441025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116239|NCT01280942|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Random allocation of study wards to intervention and control, with washout period and crossover of assignment.||||
34116240|NCT06399055|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116241|NCT02829372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116242|NCT06128057|||COHORT||CROSS_SECTIONAL|||||||
34116243|NCT03676387|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34116244|NCT01987557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116245|NCT00317811||||TREATMENT||NONE||||||
34116246|NCT02348021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116247|NCT02264314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116248|NCT02004626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116249|NCT02636010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116250|NCT00128999|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116251|NCT04556253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810863|NCT04768569|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Subjects will be randomized in a balanced fashion into one of 3 arms: Zonisamide 100 mg pre-op, Placebo, or Zonisamide 100 mg post-op.~To ensure double-blinding of the trial, each subject will be assigned a previously prepared envelope with one package labeled 1 and designated to be taken 4 hours prior to surgery and another package labeled 2 designated to be taken within 4-12 hours after surgery or when the patient is released clinically to oral medication."|This study is a randomized, double-blinded placebo-control trial with three parallel groups, to make use of a common control group.|t|f|t|f
33810864|NCT01720706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810865|NCT00608699|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34116252|NCT03961126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116253|NCT04494789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116254|NCT06563622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34116255|NCT03588754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116256|NCT01011608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116257|NCT06546124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116258|NCT02661750|||CASE_ONLY||PROSPECTIVE|||||||
34116259|NCT00309582|||DEFINED_POPULATION||PROSPECTIVE|||||||
34116260|NCT01916473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116261|NCT05349734|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34116262|NCT01907282|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34116263|NCT04462289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Patient-level randomized pilot|f|f|f|t
34116264|NCT00358878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116265|NCT02051426|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34116266|NCT03747055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116267|NCT03589742|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34150230|NCT00896441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33810866|NCT00082966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810867|NCT01903902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810868|NCT05972252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810869|NCT00655499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810870|NCT02504762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810871|NCT01402804|||COHORT||PROSPECTIVE|||||||
33810872|NCT04847180|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33810873|NCT00029588|||COHORT||CROSS_SECTIONAL|||||||
33810874|NCT01337752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810875|NCT05492513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810876|NCT06035354|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)||t|t|t|t
33810877|NCT00610961|||CASE_CONTROL|||||||||
33810878|NCT02494037|||CASE_ONLY||PROSPECTIVE|||||||
33810879|NCT04705389|NA|SINGLE_GROUP||OTHER||NONE||||||
33810880|NCT04402476|NA|SINGLE_GROUP||TREATMENT||NONE||Powder Free Polychloroprene Surgical Glove, Sterile. Low Dermatitis Potential, tested for use with chemotherapy drugs||||
33810881|NCT02309294|NA|SINGLE_GROUP||||NONE||||||
33810882|NCT03055988|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34042373|NCT06198309|||CASE_CONTROL||PROSPECTIVE|||||||
34042374|NCT04640454|||COHORT||PROSPECTIVE|||||||
34042375|NCT05702931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blinded|An investigator-initiated, placebo-controlled, double-blinded, parallel-group, randomised trial.|t|f|f|f
34042376|NCT01050036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042377|NCT01903330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042378|NCT03864757|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34042379|NCT05935397|||CASE_ONLY||PROSPECTIVE|||||||
34042380|NCT04757025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042381|NCT03034447|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Sleep study and spirometric evaluation of children with asthma||||
34042382|NCT05525013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|After the participant is confirmed eligible for the study, the participant will drag an envelope and will be given a number. Based on this number the patient will be allocated to either intervention or control group after contacting the co- supervisor to reveal the assigned group of the current patient according to the generated random sequence.|A Computerized random sequence will be generated using computer software (http://www.random.org/). The sequence generation will be done for the patients' numbers which results in a sequence of random numbers divided in two columns (A \& B), where one column assigned for the intervention groups and one for the control group and kept with the co- supervisor. The patients will be allocated into either of the two groups with allocation ratio 1:1|t|f|f|t
34042383|NCT03411499|RANDOMIZED|PARALLEL||TREATMENT||NONE||Partially Randomized Preference Trial||||
34042384|NCT01155908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042385|NCT03855527|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The operator will not be blinded to the type of treatment as each antibacterial agent has different consistency, color and application technique. However the expert assessing the microbiologic sample and statistician will be blinded to the treatment groups.|This study is a three arm randomized controlled clinical trial, where children indicated for Atraumatic Restorative Treatment (ART) will be selected.|t|t|f|t
34042386|NCT06312644|||OTHER||OTHER|||||||
34042387|NCT03469856|NA|SINGLE_GROUP||TREATMENT||NONE||The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values.||||
34042388|NCT06148792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042389|NCT04471688|||OTHER||PROSPECTIVE|||||||
34042390|NCT06188078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042391|NCT05749705|||COHORT||CROSS_SECTIONAL|||||||
34042392|NCT01248598|||CASE_ONLY||CROSS_SECTIONAL|||||||
34042393|NCT03885895|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34042394|NCT03168711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042395|NCT02322112|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34042396|NCT06577740|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34042397|NCT03038360|||COHORT||PROSPECTIVE|||||||
34042398|NCT02137213|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34042399|NCT06449430|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open randomized clinical trial has been designed comparing sedation with propofol versus spinal analgesia.||||
34042400|NCT04723927|||CASE_ONLY||CROSS_SECTIONAL|||||||
34042401|NCT00550043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042402|NCT05106296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042403|NCT00838656|RANDOMIZED|||TREATMENT||NONE||||||
34042404|NCT05737745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042405|NCT04181476|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042406|NCT01882660|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042407|NCT01574365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810883|NCT05667441|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label, randomized, clinical trial with 3 arms. Total study duration 2 years: intervention period for 1 year and a follow-up period of 1 year with no intervention for all study arms.||||
33810884|NCT03430427|||COHORT||PROSPECTIVE|||||||
33810885|NCT03682614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810886|NCT06132009|||COHORT||RETROSPECTIVE|||||||
33810887|NCT03696056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810888|NCT02022293|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33810889|NCT06072742|||COHORT||CROSS_SECTIONAL|||||||
33810890|NCT03658915|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34042408|NCT06161467|||COHORT||CROSS_SECTIONAL|||||||
34042409|NCT02767024|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042410|NCT05487443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042411|NCT00133848|RANDOMIZED|||TREATMENT||DOUBLE||||||
34042412|NCT06325735|||COHORT||PROSPECTIVE|||||||
34042413|NCT00944931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34042414|NCT05917184|||COHORT||PROSPECTIVE|||||||
34042415|NCT02484846|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33810891|NCT05573217|||CASE_ONLY||PROSPECTIVE|||||||
33810892|NCT00424502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810893|NCT01344980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116268|NCT03332147|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||The reference device and Patient Monitor are used to monitor the heart rate (HR) and respiratory rate (RR) of the same participant at the same time in Test 1. The RHEA device and patient monitor are used to monitor the heart rate and respiratory rate of the same participant at the same time in Test 2. The two tests results will be compared and evaluated for the accuracy of the two devices. The RHEA device is used alone to evaluate the accuracy of motion or no motion alarm in Test 3.||||
34116269|NCT00726908|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34116270|NCT04133415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116271|NCT03972527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"The sponsor, clinical research organization (CRO), subjects, research staff and Investigators performing the weekly OM evaluations for the study will be blinded to the treatment assignments. Subjects will be mandated to use light-blocking eyewear.~Only the research staff delivering treatment will be unblinded. No other personnel or visitors will be allowed in the treatment room during active/sham treatment.~The Investigators will not administer the daily treatment and will not visit or observe the patient during device use in order to remain blinded. The Investigators will also remain blinded to the patients' responses to the weekly Self-Assessments."|A prospective, multi-center, randomized, double-blind, placebo controlled, adaptive sample size, two-treatment parallel, pivotal clinical study.|t|f|t|t
34116272|NCT00133705|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116273|NCT02995590|NA|SINGLE_GROUP||OTHER||NONE||||||
34116274|NCT03185221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116275|NCT01342094||PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116276|NCT04345393|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"1. Smartphone, and inform them about the DTN program through a description and embedded video.~2. Including SDH, behavioral health, lack of knowledge of quality metrics, or lack of Smartphone access or connectivity.~3. The IBD home or to IBDTx care pathways. RxUniverse platform allows the creation of adaptive pathways based on feedback loops that provide relevant on-demand resources based on patient care touch-points.~4. Digitally enabled population, or an Interactive Voice Response \[IVR\] for those who are not"||||
34116277|NCT01005290|RANDOMIZED|CROSSOVER||||NONE||||||
34116278|NCT02284191|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34116279|NCT01817387|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34116280|NCT01214837|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116281|NCT01681147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116282|NCT04961905|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116283|NCT05453461|NA|SINGLE_GROUP||OTHER||NONE||||||
34116284|NCT04692922|||COHORT||PROSPECTIVE|||||||
34116285|NCT00309218|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116286|NCT01468064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116287|NCT01588327|||CASE_CONTROL||PROSPECTIVE|||||||
34116288|NCT01710566|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116289|NCT05822310|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116290|NCT00448448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor(s) are blinded to the treatment assignment.||f|f|f|t
34116291|NCT05821946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In the research, the participants will be blinded; the researcher cannot be blinded because he is practicing. To avoid statistical evaluator bias, statistical evaluations will be made on a data file where the intervention or control group is not explicitly stated by the researcher.|The study is a single-center, parallel-group, single-blind, pretest, and posttest randomized controlled experimental study.|t|f|f|t
34116292|NCT02876731|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116293|NCT02639689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116294|NCT05130593|||COHORT||PROSPECTIVE|||||||
34116295|NCT03695445|||COHORT||PROSPECTIVE|||||||
34116296|NCT02791243|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34116297|NCT03232788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34116298|NCT04749914|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34116299|NCT04329884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116300|NCT00143832|||CASE_CONTROL||OTHER|||||||
34116301|NCT02135484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116302|NCT04879407|||COHORT||RETROSPECTIVE|||||||
34116303|NCT02356237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116304|NCT03157947|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34116305|NCT02573064|||COHORT||RETROSPECTIVE|||||||
34116306|NCT00298376|||CASE_CONTROL||PROSPECTIVE|||||||
34116307|NCT00416741|||COHORT||PROSPECTIVE|||||||
34116308|NCT00775957|||CASE_CONTROL||PROSPECTIVE|||||||
34116309|NCT01057979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116310|NCT04661527|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, one-arm, open label, multicentric study, to evaluate treatment of severe COVID-19 with sarilumab prior to entry into the intensive care unit (ICU)||||
34116311|NCT01498861|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34116312|NCT02900014|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33810894|NCT06282926|||COHORT||PROSPECTIVE|||||||
33810895|NCT05796141|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33810896|NCT01247155|||CASE_CONTROL||PROSPECTIVE|||||||
33810897|NCT00738348|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33810898|NCT02236611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810899|NCT03294187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116313|NCT02724202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116314|NCT03412929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116315|NCT04056247|||COHORT||PROSPECTIVE|||||||
34116316|NCT00314977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116317|NCT01832727|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116318|NCT02657148|||CASE_CONTROL||PROSPECTIVE|||||||
34116319|NCT05756322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116320|NCT01480687|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34116321|NCT05556902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116322|NCT05549544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116323|NCT01999530|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116324|NCT02288130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34116325|NCT06458556|NA|SINGLE_GROUP||TREATMENT||NONE||Non-blinded non-comparative pilot trial in which a total of 20 subjects with OAB are included. Subjects may include individuals with overactive balder and contraindications to alternative first- and second-line treatments, OAB and do not desire pursuing alternative first- and second-line treatments, refractory overactive balder, and urge predominate mixed urinary incontinence. Subjects will undergo treatment with the Morpheus system every 4 weeks for a total of 3 treatments. Follow up will occur at 3- month and 6-month intervals after the subjects first treatment.||||
34116326|NCT04928378|||COHORT||RETROSPECTIVE|||||||
34116327|NCT05081830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded: The initial interview by the evaluator will be recorded and the video / audio will be shared with an independent evaluator who does not know the case for evaluation. Once the evaluation is completed, users will be randomly assigned to one of the study conditions. The randomization will be carried out by an independent researcher through the random.stg software in a 1: 1: 1 ratio by saturation of blocks of 12 per condition. The coordinator will inform the participant of the condition in which he / she will participate in the study (experimental or control waiting list) and, depending on the characteristics of said condition, he / she will be discharged from the study and will put him / her in contact with the advisor who has been assigned to you.|A randomized controlled study will be carried out, following the guidelines set forth in the CONSORT statement (http://www.consort-statement.org) and CONSORT EHealth ( https://www.jmir.org/2011/4/e126/ ). An experimental design between subjects with three independent groups will be used, with within-subject measurements at four evaluation moments: pretest, posttest, follow-up at 3 and 6 months (Solomon Solomon, Cavanaugh \& Draine, 2009). Participants will be randomly assigned to one of three conditions: (a) transdiagnostic intervention via the Internet; (b) Cognitive-Behavior Therapy via the Internet; (c) waiting list control.|t|t|t|t
34116328|NCT02200601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116329|NCT00916448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116330|NCT01659060|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34116331|NCT00769054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34116332|NCT01876498|||COHORT||PROSPECTIVE|||||||
34116333|NCT02993263|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116334|NCT00175279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34116335|NCT01093014|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116336|NCT00633841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116337|NCT02824679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116338|NCT00914576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34116339|NCT03381989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116340|NCT01350726|||CASE_CONTROL||PROSPECTIVE|||||||
34116341|NCT01903746|||COHORT||PROSPECTIVE|||||||
34116342|NCT00854360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116343|NCT06095895|||COHORT||PROSPECTIVE|||||||
34116344|NCT03306550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116345|NCT06461780|NA|SINGLE_GROUP||SCREENING||NONE||||||
34116346|NCT04968483|||COHORT||PROSPECTIVE|||||||
34116347|NCT03969173|RANDOMIZED|PARALLEL||PREVENTION||NONE|The physician who directly anesthetize the patient should not be aware of the patient's placement due to the nature of the study design and maintenance of anesthesia. The ultrasound examination of the patient's degree of atelectasis and data collection of cardiac index data was limited to a single anesthesiologist without knowing which group the patient is in. Blind cancellation is performed after data analysis is completed.|"It is divided into the following three groups according to PEEP to be applied during anesthesia.~Test group: PEEP6 group (6 cmH2O), PEEP9 group (9 cmH2O) control group: PEEP3 group (PEEP 3 cmH2O)"||||
34116348|NCT04722666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116349|NCT01656161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116350|NCT02514655|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116351|NCT04138056|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner. In an observer-blind study, the subject and the site and sponsor personnel involved in the clinical evaluation of the subjects are blinded while other study personnel may be aware of the treatment assignment. By observer-blind, it is meant that during the course of the study, the vaccine(s) recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity) will all be unaware of which vaccines were administered.||t|t|t|t
34116352|NCT04863742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116353|NCT05928169|||COHORT||PROSPECTIVE|||||||
34116354|NCT01627886|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116355|NCT04834921|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Blinding procedure was limited to the doctors who collected the data and the external statistician who performed the analysis|All patients received two consecutive RRT (MCO-CVVHD and HFF-CVVHDF); in a controlled randomized (1:1) blinded manner. Each RRT treatment lasted 24 hours Crossover randomized to sequence (A+B or B+A) for 48 h total without washout|f|f|t|f
34116356|NCT03051191|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116357|NCT04636632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116358|NCT04715035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116359|NCT03986957|||CASE_ONLY||PROSPECTIVE|||||||
34116360|NCT04050384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Personnel who code the video recording for behavioral measures and analysis of the electroencephalographic readings will be done in a blinded and/or independent fashion.||t|f|f|t
34116361|NCT00929266|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34116362|NCT00560417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116363|NCT05521932|||CASE_ONLY||PROSPECTIVE|||||||
34116364|NCT00004466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150231|NCT04487171|NA|SINGLE_GROUP||OTHER||NONE||||||
34150232|NCT00000480|RANDOMIZED|||TREATMENT||||||||
34150233|NCT05547165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150234|NCT03668834|RANDOMIZED|PARALLEL||TREATMENT||NONE||All 3 methods of recipient site preparation will be done in all 36 patients.||||
34150235|NCT04924478|||COHORT||PROSPECTIVE|||||||
34116365|NCT06306001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The random allocation will be concealed using serially numbered opaque sealed envelopes. After opening the envelope, a research nurse will administer a bolus of the study drug or placebo behind a screen, shielded from other staff. The infusion will be drawn up in an opaque syringe by the research nurse and infused through an intravenous tubing covered completely with aluminum foil. The research nurses will not be masked to the study drug. The parents of the subject, the regular staff nurses and doctors working in the unit and the project coordinator will be masked.|Subjects will be randomly allocated to an intervention arm and a placebo arm. The 2 arms of the trial will run concurrently.|t|t|f|t
34116366|NCT02016521|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34116367|NCT05173779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116368|NCT00678522|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34116369|NCT01183351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116370|NCT02243358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116371|NCT05612230|||OTHER||RETROSPECTIVE|||||||
34116372|NCT02966483|RANDOMIZED|PARALLEL||TREATMENT||NONE||Transanal or Laparoscopic Total Mesorectal Excision treat rectal cancer||||
34116373|NCT03243461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116374|NCT04484857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116375|NCT00470015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116376|NCT04278404|||OTHER||PROSPECTIVE|||||||
34116377|NCT03953807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116378|NCT00191711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116379|NCT05703230|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||cross-sectional stepped wedge cluster randomized trial||||
34116380|NCT02055846|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116381|NCT00285571|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34116382|NCT02908178|||COHORT||RETROSPECTIVE|||||||
34116383|NCT05017558|||COHORT||PROSPECTIVE|||||||
34116384|NCT03605693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors that assess PTSD symptoms 1 month after discharge (primary outcome) will be blinded to treatment assignment.||f|f|f|t
34116385|NCT05762432|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Subjects will be randomised 1:1 to RTD Wound Dressing or standard of care dressing. Randomisation will be in blocks of four.|Combination of normal standard of care and study device||||
34116386|NCT03516721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34116387|NCT04747288|||COHORT||PROSPECTIVE|||||||
34116388|NCT00773084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116389|NCT05782348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Three arm parallel group single blind study|f|f|f|t
34116390|NCT01069549|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116391|NCT02089204|||CASE_CONTROL||PROSPECTIVE|||||||
34116392|NCT05058326|||CASE_ONLY||PROSPECTIVE|||||||
34116393|NCT04172675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116394|NCT03502681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116395|NCT00000395|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34116396|NCT05958186|||OTHER||PROSPECTIVE|||||||
34116397|NCT01083602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116398|NCT02696135|||COHORT||PROSPECTIVE|||||||
34116399|NCT00741078||CROSSOVER||TREATMENT||||||||
34116400|NCT00261339|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116401|NCT04164381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116402|NCT05709847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34116403|NCT01471613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116404|NCT06544915|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Actives and placebos made by 3rd party in discreet containers inconspicuously labeled.|Randomized placebo-controlled double-blind parallel study|t|f|t|t
34116405|NCT02210676|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34116406|NCT05364398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116407|NCT04470765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A third party will be assigned to label the devices prior to distribution to the study center. The 3rd party will maintain blinding of the device labelling/ assignment codes until the trial completion.|"The study is a prospective, randomized, single-blind, placebo-controlled study of 50 subjects divided into two groups, with one group having the active ZIDA device treatment once weekly at home, and one group having a sham ZIDA device (non-treatment) once weekly at home, for a duration of 12 weeks for both groups. Subjects will be called by a research member weekly to report their weekly treatment and any complications during the 12-week treatment period. A phone call assessment will be conducted during week-6 period. Subjects will complete a final phone-call assessment at the end of the week-12 period.~This clinical investigation is being conducted in accordance with 21 CFR Parts 50, 54, 56, and abbreviated 21 CFR 812 regulations, International Conference on Harmonization Good Clinical Practice (ICH GCPs), applicable local regulations and Institutional Review Board (IRB) requirements."|t|t|t|f
34116408|NCT04120987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116409|NCT03021096|||COHORT||PROSPECTIVE|||||||
34116410|NCT05181228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The participants were unaware of which group they were assigned to. The data will be entered using A and B codes, and the researcher doing the statistical analysis will be blind to the participants' groups.|The research has a randomized controlled interventional study design. An impartial investigator who is not participating in the study will conduct the randomization. Six alternative combinations with a block size of four (ABAB(1), ABBA(2),...) containing codes A and B will be constructed using the block randomization method. From 1 to 6, combinations will be numbered. By sorting the integers (1-6) via randomizer.org 21 times in a random order, a random assignment sequence will be formed. By drawing lots with coins, it will be established which of the A and B codes is the intervention group and which is the control group. Participants who meet the inclusion criteria will be asked to sign an informed consent form, and their group will be shared with the researcher after the pre-tests (T1) are completed. In the intervention group, participants will get a web-based training based on the family-centered approach.|t|f|f|t
34116411|NCT00458549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34116412|NCT03748914|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34116413|NCT01348893|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150236|NCT01123824|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33729677|NCT05040633|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization codes will be generated by a member of the trial team who is not involved in the day-to-day running of the trial, nor will they be involved in future data analysis. Each participant's randomized code will be kept in a sealed envelope to be opened only by the assessor during the first trial visit. The assessor and patients will be blinded to treatment allocation but physiotherapists offering treatment will not be blinded to treatment allocation.|"Participants will be allocated to three groups and provided with one of the following interventions: (i) Low Level Laser Therapy (LLLT) therapy in combination with standard exercise therapy (Arm 1), (ii) sham LLLT therapy in combination with standard exercise therapy (Arm 2), or (iii) exercise therapy alone (Arm 3).~Participants will receive treatment three times per week for four consecutive weeks (i.e., each participant will receive a total of 12 treatment sessions; see section 2, Trial Design)."|t|f|t|t
33729678|NCT01039181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729679|NCT04505891|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33729680|NCT02022228|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729681|NCT00836875|NON_RANDOMIZED|||TREATMENT||NONE||||||
33729682|NCT05235191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33729683|NCT03438890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Allocation information was hidden from the participants and outcome assessor.||t|f|f|t
33729684|NCT04642729|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33729685|NCT00489853|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33729686|NCT01453842|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33729687|NCT02150655|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33729688|NCT02102633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33729689|NCT02265978|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729690|NCT04518007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||hyperbaric oxygen therapy (2ATA, 100% oxygen) vs. sham (1.1ATA, 21% oxygen)|t|t|t|t
33729691|NCT05766306|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, placebo-controlled, double-blinded.|t|t|t|t
33729692|NCT03499392|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33729693|NCT01070316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729694|NCT01418209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729695|NCT03950284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729696|NCT01090726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729697|NCT03356548|||CASE_ONLY||PROSPECTIVE|||||||
33729698|NCT02694419|||CASE_CONTROL||PROSPECTIVE|||||||
33729699|NCT04977258|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33729700|NCT03019692|||COHORT||RETROSPECTIVE|||||||
33729701|NCT05888168|||CASE_CONTROL||RETROSPECTIVE|||||||
33729702|NCT04818359|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to undergo either a lifestyle recommendations and supervised exercise program or only lifestyle recommendations||||
33729703|NCT00541827|||COHORT||PROSPECTIVE|||||||
33729704|NCT02595853|||COHORT||PROSPECTIVE|||||||
33729705|NCT02811939|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33729706|NCT01421784|NA|SINGLE_GROUP||OTHER||NONE||||||
33729707|NCT00165490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729708|NCT02752191|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33729709|NCT03002051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810900|NCT02402270|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33729710|NCT01443247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729711|NCT03764670|||CASE_ONLY||RETROSPECTIVE|||||||
33729712|NCT04054687|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33729713|NCT03464864|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33729714|NCT04211337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729715|NCT04139928|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33810901|NCT00191542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810902|NCT03622957|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839223|NCT04480775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blinded|"Patient will be evaluated pre operative and full lab will be done In the Pre Anaesthesia Room ,a 20 gauge venous catheter will be inserted in the upper limb , and monitoring included heart rate, electrocardiogram, noninvasiveblood pressure, and peripheral oxygen saturation.Oxygen at the rate of 6 L/min will beadministered through oxygen mask to all patients.~The anesthesiologist who performed the block will be blinded to drug solution and not involved in data collection, another anesthesiologist will prepare drug solution and other anesthesiologist collect the data."|t|f|t|f
33839224|NCT04391543|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33729716|NCT02821962|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33729717|NCT00004258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729718|NCT00545857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729719|NCT01326819|||COHORT||PROSPECTIVE|||||||
33729720|NCT04950777|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33729721|NCT04842539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729722|NCT01625975|||CASE_ONLY||RETROSPECTIVE|||||||
33729723|NCT04965194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33729724|NCT04595864|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729725|NCT02327923|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33729726|NCT02279186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33729727|NCT03718611|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33729728|NCT04982666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729729|NCT02082210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729730|NCT01268384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729731|NCT00017706|RANDOMIZED|||TREATMENT||||||||
33729732|NCT00310908|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729733|NCT05747144|||COHORT||PROSPECTIVE|||||||
33729734|NCT00649337|NA|SINGLE_GROUP||SCREENING||NONE||||||
33729735|NCT02702401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33729736|NCT05365438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729737|NCT02048020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729738|NCT00554671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729739|NCT04208906|NA|SINGLE_GROUP||OTHER||NONE||||||
34116414|NCT06486883|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm A: T-DXd; Arm B CDK4/6i plus endocrine therapy (ET). The physician's choice of CDK4/6i plus ET will be limited to one CDK4/6i plus fulvestrant or an aromatase inhibitor (AI). The options for CDK4/6i are palbociclib, ribociclib, and abemaciclib, the options for ET are fulvestrant, letrozole, anastrozole, and exemestane.||||
34116415|NCT01879007|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116416|NCT01883921|||COHORT||PROSPECTIVE|||||||
34116417|NCT02893891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116418|NCT00963872|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116419|NCT06163131|||COHORT||PROSPECTIVE|||||||
34116420|NCT00164580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116421|NCT02059447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116422|NCT01307449|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34116423|NCT04497714|||COHORT||RETROSPECTIVE|||||||
34116424|NCT04817150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes are assessed by 2 independent blinded coloproctologists|a prospective randomized comparative study in parallel groups|t|f|f|t
34116425|NCT05334238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116426|NCT01582217|||CASE_ONLY||PROSPECTIVE|||||||
34116427|NCT00435448|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34116428|NCT03507595|||COHORT||PROSPECTIVE|||||||
34116429|NCT01916031|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116430|NCT01450345|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116431|NCT02746315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116432|NCT05185362|||COHORT||RETROSPECTIVE|||||||
34116433|NCT03400423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34116434|NCT06513208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34116435|NCT01821183|||||CROSS_SECTIONAL|||||||
34116436|NCT05042921|||COHORT||PROSPECTIVE|||||||
34116437|NCT00882089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116438|NCT04766567|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116439|NCT00508521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116440|NCT03944395|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||A non-randomized, pragmatic, stepped-wedge study to be implemented in 80 Sites. The stepped wedge portion of the study will last 10 months (May - March 2018). Once all 80 sites are implementing standard of care (SOC) plus VAPN, the study will be extended an additional 3 months to assess any trends in declining yield from SOC plus VAPN index case testing services.||||
34116441|NCT02461186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116442|NCT03968874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116443|NCT04247438|NA|SINGLE_GROUP||OTHER||NONE||Single group, prospective, longitudinal, interventional pilot study to test the feasibility of study design, protocol, and methods for evaluating the artificial dentures biofilm equivalent. This pilot study is intended to provide initial data and insights into the development and establishment of an artificial dentures biofilm equivalent. According to the current state of research, no data, therefore, are available.||||
34116444|NCT04626102|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were informed that they are invited to attend a group intervention aiming to improve healthy eating attitudes and behaviours. However, they were not informed that they were invited because they had higher levels of disordered eating attitudes and behaviours than the others who were not invited. Also, they did not know that the real aim was to prevent development of eating disorders.|Eligible participants were randomly assigned to 6-session Healthy Eating Attitudes and Behaviours Group Program (experimental group condition), single session Eating Disorders and Body Dissatisfaction: A Group Work (active control group condition) or wait-list control group condition.|f|f|f|t
34116445|NCT05448456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116446|NCT02599116|NA|SINGLE_GROUP||OTHER||NONE||||||
34116447|NCT00646386|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116448|NCT01101776|||COHORT||PROSPECTIVE|||||||
34116449|NCT04768153|||COHORT||PROSPECTIVE|||||||
34116450|NCT02112084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116451|NCT04899765|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|BCG is given intradermally and typically results in a local skin reaction that heals leaving a small scar. Measles vaccine is given subcutaneously and typically does not leave any sign of vaccination. Though we do not believe women will be able to distinguish between intradermal and subcutaneous injections, complete blinding on the recipient side will not be possible; those who get a skin reaction after BCG will most likely be able to guess what they received, whereas MV and placebo recipients will not. We do not believe this will influence the results of the blood testing or their treatment of their offspring.|We plan a trail randomising non-pregnant women of fertile age 1:1:1 to MV, BCG or placebo. The first children to be born will also be randomised to early MV or no early MV at 20 weeks of age. All children will get the recommended MV by 9 months of age.|t|t|f|t
34116452|NCT05155982|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34116453|NCT02665910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116454|NCT01276626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116455|NCT04454515|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized study|one group is going to receive precedex and another is placebo.|t|t|t|t
34116456|NCT01604460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116457|NCT01078727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116458|NCT05677880|||CASE_CONTROL||PROSPECTIVE|||||||
34116459|NCT03295344|||OTHER||PROSPECTIVE|||||||
34116460|NCT05639959|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116461|NCT00744861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116462|NCT02254291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116463|NCT02172794|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34116464|NCT04756830|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34116465|NCT01484249|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34116466|NCT03949517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116467|NCT00006004|RANDOMIZED|||TREATMENT||||||||
34116468|NCT01876381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116469|NCT01918137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34116470|NCT06222021|NA|SINGLE_GROUP||SCREENING||NONE||Participants will undergo preoperative genomic assay testing||||
34116471|NCT01503320|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|f|t
34116472|NCT03193541|||COHORT||PROSPECTIVE|||||||
34116473|NCT02682056|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34116474|NCT05871957|||COHORT||PROSPECTIVE|||||||
34116475|NCT02441218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116476|NCT03768037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116477|NCT02398019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116478|NCT05790694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116479|NCT04015258|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34116480|NCT05333926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116481|NCT02525679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116482|NCT04147273|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116483|NCT00822276|||CASE_CONTROL||PROSPECTIVE|||||||
34116484|NCT01006161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116485|NCT05425160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116486|NCT01444781|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34116487|NCT03315585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116488|NCT00536289|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34116489|NCT05182918|||COHORT||PROSPECTIVE|||||||
34116490|NCT05732064|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116491|NCT05302778|||COHORT||CROSS_SECTIONAL|||||||
34116492|NCT04603183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116493|NCT03312647|||CASE_CONTROL||PROSPECTIVE|||||||
34042416|NCT03800199|NA|SINGLE_GROUP||OTHER||NONE||"Questionnaire: Combined Index of Severity of Fibromyalgia (ICAF)~Intervention: Perceptive rehabilitation~Procedure: Assessment of reliability, acceptability, validity and responsiveness."||||
34042417|NCT01571219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042418|NCT03792399|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042419|NCT04508257|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34042420|NCT06478472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042421|NCT04291287|||COHORT||RETROSPECTIVE|||||||
34042422|NCT01964482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042423|NCT06370689|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34042424|NCT03240068|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34042425|NCT01692041|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34042426|NCT02203461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042427|NCT05858281|||COHORT||PROSPECTIVE|||||||
34042428|NCT03404037|||COHORT||PROSPECTIVE|||||||
34042429|NCT05169242|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34042430|NCT00745342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042431|NCT02462772|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34042432|NCT02913443|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34042433|NCT05743829|||COHORT||PROSPECTIVE|||||||
34042434|NCT03068390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||2 group randomized controlled trial|t|f|f|f
34042435|NCT01168232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042436|NCT05376774|||COHORT||RETROSPECTIVE|||||||
34042437|NCT01592175|||COHORT||CROSS_SECTIONAL|||||||
34042438|NCT01610674|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042439|NCT01733940|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34042440|NCT06574438|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042441|NCT05107817|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34042442|NCT03231813|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34042443|NCT05350657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042444|NCT01591278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042445|NCT04790890|||COHORT||PROSPECTIVE|||||||
34042446|NCT05609773|||OTHER||PROSPECTIVE|||||||
34042447|NCT06265129|||CASE_CONTROL||PROSPECTIVE|||||||
34042448|NCT02556775|||COHORT||PROSPECTIVE|||||||
34042449|NCT02307422|||CASE_CONTROL||RETROSPECTIVE|||||||
34042450|NCT06534853|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
34042451|NCT05565781|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34042452|NCT03289026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042453|NCT02067845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042454|NCT00471822|||COHORT||PROSPECTIVE|||||||
34042455|NCT02182921|||CASE_CONTROL||PROSPECTIVE|||||||
34042456|NCT01067781|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34042457|NCT05060276|NA|SEQUENTIAL||TREATMENT||NONE||To determine DLT and MTD, the design uses a 3+3 ascending dose cohort design evaluating up to five dose cohorts including: 8 mg/kg, 12 mg/kg, 16 mg/kg, 20 mg/kg, 24 mg/kg.||||
34042458|NCT06575283|||COHORT||PROSPECTIVE|||||||
34042459|NCT06022432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042460|NCT01450306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34042461|NCT03046589|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34042462|NCT01905202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042463|NCT04412655|||COHORT||RETROSPECTIVE|||||||
34042464|NCT06368479|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34042465|NCT01215396|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34042466|NCT04596410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042467|NCT06380114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116494|NCT03694028|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34116495|NCT00991640|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34116496|NCT05314660|RANDOMIZED|PARALLEL||PREVENTION||NONE|The operator must know the group in which the participant is enrolled so as to provide and carry out the intended treatment protocol. Randomization was preformed by block randomization by the nurse.|3 equal groups receiving 3 different protocols||||
34116497|NCT00790673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116498|NCT05949450|||COHORT||OTHER|||||||
34150237|NCT02710942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150238|NCT01862861|||COHORT||PROSPECTIVE|||||||
34150239|NCT03753399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116499|NCT05185076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Subjects will be seen at follow-up visits. A Masked Examiner must complete distance VA, near VA and stereoacuity testing at these visits. All procedures will be performed with the subject's current spectacle correction. If a subject currently wears spectacles but is not wearing them at the follow-up examination for whatever reason, testing must be performed in trial frames except for Visit 1 and Visit 5 visual acuity must ONLY be performed in current refractive correction glasses (not trial frames).~Prior to the Masked Examiner entering the room, subjects and parents should be instructed not to discuss their treatment with the Masked Examiner."|Parallel Assignment The EDC and data management will construct a Master Randomization List using a permutated block design stratified by initial visual acuity in the amblyopic eye and age which will specify the order of treatment group assignments. Randomization will be managed directly by the eCRF platform.|f|t|f|f
34116500|NCT05458960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116501|NCT00338637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116502|NCT00516282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116503|NCT02305121|||CASE_ONLY||PROSPECTIVE|||||||
34116504|NCT01735526|||COHORT||PROSPECTIVE|||||||
34116505|NCT05951907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Case-Control|t|f|f|f
34116506|NCT03790748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34116507|NCT01287299|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116508|NCT06032039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34116509|NCT01078948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116510|NCT01217034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116511|NCT04235309|||COHORT||PROSPECTIVE|||||||
34116512|NCT06058091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116513|NCT03950232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116514|NCT01216488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116515|NCT01907893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116516|NCT02012517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116517|NCT00992550|RANDOMIZED|CROSSOVER||||NONE||||||
34116518|NCT00133445|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34116519|NCT02629861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116520|NCT01352429|||COHORT||PROSPECTIVE|||||||
34116521|NCT04322461|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34116522|NCT01639989|||COHORT||PROSPECTIVE|||||||
34116523|NCT04068805|RANDOMIZED|PARALLEL||OTHER||NONE||Users are randomly assigned between arms after completing baseline assessment and stay in that arm for the duration of the study.||||
34116524|NCT02030626|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116525|NCT02628535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116526|NCT02100826|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34116527|NCT01373281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116528|NCT00844506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116529|NCT01677988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116530|NCT02896205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116531|NCT00025415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116532|NCT01300026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116533|NCT02692196|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34116534|NCT01475721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34116535|NCT06164158|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34116536|NCT02976181|||COHORT||PROSPECTIVE|||||||
34116537|NCT01575574|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116538|NCT02434081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116539|NCT05683379|||COHORT||PROSPECTIVE|||||||
34116540|NCT03416816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116541|NCT04955288|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34116542|NCT01352884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116543|NCT06195852|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116544|NCT03981874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116545|NCT04256655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind study||t|t|t|f
34116546|NCT06456840|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34116547|NCT02972645|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34116548|NCT00524563|||COHORT||RETROSPECTIVE|||||||
34116549|NCT03429088|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34116550|NCT01072526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116551|NCT01038323|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34116552|NCT06091904|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34116553|NCT02551315|||COHORT||PROSPECTIVE|||||||
34116554|NCT04405531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116555|NCT05759403|||COHORT||CROSS_SECTIONAL|||||||
34116556|NCT02031614|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34116557|NCT01142180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116558|NCT05637632|||OTHER||PROSPECTIVE|||||||
34116559|NCT00582907|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34116560|NCT04999267|NA|SINGLE_GROUP||OTHER||NONE||||||
34116561|NCT05548699|||COHORT||PROSPECTIVE|||||||
33839225|NCT03659357|||CASE_CROSSOVER||PROSPECTIVE|||||||
33839226|NCT01168947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116562|NCT06557304|||COHORT||RETROSPECTIVE|||||||
34116563|NCT00788112|NA|SINGLE_GROUP||OTHER||NONE||||||
34116564|NCT04604990|||COHORT||PROSPECTIVE|||||||
34150240|NCT00468403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150241|NCT02471638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150242|NCT02393053|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150243|NCT03031119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34150244|NCT05770661|||COHORT||PROSPECTIVE|||||||
34150245|NCT01030614|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150246|NCT06383468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150247|NCT00096330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34150248|NCT02231268|||COHORT||PROSPECTIVE|||||||
34150249|NCT06264284|||CASE_ONLY||RETROSPECTIVE|||||||
33729740|NCT06325150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"This study will test the effect of light emitting glasses, vs placebo, vs no-glasses to attention in college students. This is a crossover study, where participants will be randomly assigned to one of three groups, and tested in random order. The students will be tested on 2 or 3 different conditions (no glasses, placebo or light emitting glasses). The assignment to each of the groups, and the order of the intervention (+/- glasses) will be randomized.~Note-light emitting glasses are not FDA regulated. Because light emitting glasses can change physiology, this is considered a phase 1 clinical trial."|f|f|t|f
33729741|NCT00273728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729742|NCT03366350|NA|SINGLE_GROUP||TREATMENT||NONE||Patients receive consolidative allo-HSCT following CAR-T therapy.||||
33729743|NCT00371943|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729744|NCT00314366|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33729745|NCT00717769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729746|NCT04262895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Doses of drug and placebo will be prepared in identical sachets, with group assignment known only to the research pharmacist.|In Phase 1, the investigators will determine whether TTI-0102 2 mg/day or 4 mg/day is more tolerated and/or more effective compared with placebo in Veterans with mild to moderate TBI and PTSD. In Phase 2, the investigators will determine the feasibility and acceptability of trial procedures involving TTI-0102 (dose determined in Phase 1) vs placebo in Veteran participants receiving Compensatory Cognitive Training.|t|f|t|t
33729747|NCT01232296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729748|NCT05377021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective and randomized comparison|t|f|f|f
33729749|NCT05886595|||COHORT||PROSPECTIVE|||||||
33729750|NCT06095466|||COHORT||PROSPECTIVE|||||||
33729751|NCT05180435|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33729752|NCT04903236|||COHORT||PROSPECTIVE|||||||
33729753|NCT04492891|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IIa clinical trial in which 75 non-ICU hospital inpatients will be randomized 2:1 to 7 days of Neoral (2.5mg/kg PO BID) + standard of care (SOC) or no CSA + SOC.||||
33729754|NCT00869739|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33729755|NCT02312232|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729756|NCT00480779|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729757|NCT05472688|||COHORT||PROSPECTIVE|||||||
33729758|NCT00218517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729759|NCT03662438|NA|SINGLE_GROUP||TREATMENT||NONE||This is a self-controlled study where participants will serve as their own controls. Physical activity levels and quality of life will be measured before and after a 10 week home-based exercise program.||||
33836983|NCT05845541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A person not involved in the data collection or analysis of the findings will be responsible for generating the randomization sequence (to start with treatment or to start with standard care), and will be blinded to which participants are allocated to which group. Since it is impossible to mask the study participants, we will request they not discuss their group allocation with the coordinator who is collecting the outcome measure data, but it is possible they may inadvertently reveal this to the coordinator. Consequently, this will serve to inform the feasibility of masking the study staff for a future trial. If the staff becomes unmasked, we will make a note and the coordinator will continue to collect data. However, the person analyzing the survey data will be masked to group allocation (group 1 versus group 2) only.|Pilot Study using an RCT design will be employed whereby participants are randomly assigned to either a treatment arm (iom2 - technology supported meditation) or control arm (standard care).|f|t|f|t
33729760|NCT00577512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729761|NCT06096415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729762|NCT00344383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729763|NCT01102413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729764|NCT05374265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729765|NCT02418468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729766|NCT05233566|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33729767|NCT04134000|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, non-randomized, dose de-escalation clinical trial with atezolizumab administered by IV infusion in combination with intravesical BCG.||||
33729768|NCT03430804|||COHORT||PROSPECTIVE|||||||
33729769|NCT00016952|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729770|NCT01393769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729771|NCT04742569|||COHORT||PROSPECTIVE|||||||
33729772|NCT02583581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729773|NCT01924169|NA|SINGLE_GROUP||OTHER||NONE||||||
33729774|NCT03709537|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Data collection and analysis will occur without knowledge of participant intervention condition.|The study will draw participants from mental health sites where one or more peer supervisors and peer workers are located. These sites will be randomized to either the treatment or standard practice control group. The treatment group will receive the intervention, which consists of a Co-Learning Collaborative, several trainings, and the creation of Implementation Teams. The sites assigned as part of control group will not receive any training or additional technical assistance that is part of the intervention.|f|f|f|t
33729775|NCT02845752|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33729776|NCT04339400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729777|NCT03468881|||COHORT||PROSPECTIVE|||||||
33729778|NCT02533271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729779|NCT02346084|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33729780|NCT04082988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729781|NCT02781636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729782|NCT02000375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729783|NCT03696433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33729784|NCT00582933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836984|NCT06502743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836985|NCT01246505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729785|NCT02167256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836986|NCT03532503|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33836987|NCT02019186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836988|NCT04676789|NA|SINGLE_GROUP||TREATMENT||NONE||treatment with sintilimab and pegaspargase combined with intensity-modulated radiotherapy (IMRT)||||
34116565|NCT04104347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After the baseline (Time 0) assessment participants are randomised to either MCT or the control group through a computerized plan (no stratification factors) in blocks of 10 subjects (maximum number of each group) and assessor-patient blind. Only one co-principal investigator of the project (EBG) has access to the randomisation plan, but the assessor (JDLM) is not informed of the patient's allocation arm. Also, big efforts will be made on the ground to reduce the risk that the assessor (JDLM) may become accidentally unblinded and patients are reminded that they should not disclose their group assignment at any time. At the end of the baseline assessment, participants receive an envelope with the intervention assignment from an independent administrator who is not involved in the research team. Hence, assessor-blindness is guaranteed at all times throughout the study period since the assessor (JDLM) is not involved in the randomization plan or the active interventions.|This single-center, assessor-blind, parallel-group, randomised clinical trial (RCT) aims to investigate the efficacy of MCT for improving insight (primary outcome), including clinical and cognitive insight, which will be measured by the Schedule for Assessment of Insight (Expanded version) (SAI-E) and the Beck Cognitive Insight Scale (BCIS), respectively, in (at least) n=126 outpatients with SSD at three points in time: i) at baseline (Time 0); ii) after treatment (Time 1) and iii) at 1-year follow-up (Time 2). SSD patients receiving MCT and controls attending a non-intervention support group will be compared on insight level changes and several clinical and cognitive secondary outcomes at Time 1 and at Time T2, whilst adjusting for baseline data. Ecological momentary assessment (EMA) will be piloted to assess functioning in a subsample of participants.|f|f|f|t
34116566|NCT02683902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116567|NCT01219257|||CASE_ONLY||PROSPECTIVE|||||||
34116568|NCT05875961|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Eligible subjects are randomized in an equal ratio to one of the 6 different treatment groups (formulations) and will receive two doses of the allocated H2N3c vaccine (adjuvanted or non-adjuvanted) at 3 weeks apart, ie, at Day 1 and Day 22.|t|f|t|t
34116569|NCT04293198|||CASE_ONLY||PROSPECTIVE|||||||
34116570|NCT04666792|NA|SINGLE_GROUP||PREVENTION||NONE||This a programmatic stepped-Wedge cluster randomized trial||||
34116571|NCT03830437|||CASE_CONTROL||PROSPECTIVE|||||||
34116572|NCT01447537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116573|NCT05465304|||CASE_CONTROL||PROSPECTIVE|||||||
34116574|NCT02491879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116575|NCT05489328|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel Assignment||||
34116576|NCT03817684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116577|NCT00005989||||TREATMENT||||||||
34116578|NCT04089020|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34116579|NCT00093509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116580|NCT05406583|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34116581|NCT04326738|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116582|NCT03563547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116583|NCT01145950|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34116584|NCT03616821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Global, multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study|t|t|t|f
34116585|NCT05170971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116586|NCT04252209|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Trial participants will be blinded as the two interventions will have the same properties in the same container. The investigator will be blinded as he will not know the treatment assigned for the participants. Also the outcome assessor and the statistician will be blinded.|50% of patients will start with intervention (A) for 2 weeks then wash out periods for 7 days then control for 2 weeks and the other 50% will start with control for 2 weeks then wash out periods for 7 days then intervention (B) for 2 weeks.|t|t|t|t
34116587|NCT02803684|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116588|NCT03997721|||COHORT||PROSPECTIVE|||||||
34116589|NCT06133023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116590|NCT04620161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind, placebo-controlled|Randomized, double-blind and placebo-controlled study|t|t|t|t
34116591|NCT01664884|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34116592|NCT03448211||SEQUENTIAL||TREATMENT||NONE||||||
34116593|NCT02256995|||COHORT||PROSPECTIVE|||||||
34116594|NCT03904160|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116595|NCT01744015|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34116596|NCT05539326|||COHORT||PROSPECTIVE|||||||
34116597|NCT00918619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116598|NCT03906643|NA|SINGLE_GROUP||OTHER||NONE||Open label phase I study||||
34116599|NCT04517435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116600|NCT05671250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34116601|NCT04206761|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single site, two arm, randomized, open-label study||||
34116602|NCT03140618|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34116603|NCT05168761|||OTHER||RETROSPECTIVE|||||||
34116604|NCT00549159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116605|NCT04487405|||CASE_CONTROL||PROSPECTIVE|||||||
34116606|NCT06047938|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34116607|NCT05164471|NA|SINGLE_GROUP||OTHER||NONE||||||
34116608|NCT03639610|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arms differed based on patients' level of renal function (moderate or severe impairment) and starting dose of melflufen.||||
34116609|NCT03929679|||COHORT||PROSPECTIVE|||||||
33729786|NCT05970432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729787|NCT02239536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836989|NCT04683003|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729788|NCT02660918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729789|NCT06296667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729790|NCT04249804|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The patients will be randomly allocated to Groups (\[T\], Intrathecal MgSo4 and \[M\], IV infusion MgSo4 groups) on the basis of computer-generated random numbers. Patients belonging to Group T (n = 45) will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine \[131\],while those belonging to Group M (group, n = 45) will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia.~Axillary temperature and grades of shivering will be noted every 10 min by the same anesthesiologist who performed the spinal anesthesia using Crossley and Mahajan scale,\[8\] If grade III, IV shivering persisted for \>10 min pethidine 25 mg IV will be administered as a rescue drug and number of patients required rescue drug will be recorded."|t|f|f|f
33729791|NCT00012051|RANDOMIZED|||TREATMENT||||||||
33729792|NCT00417794|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34116610|NCT04883138|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase 1, first in human (FIH) study utilizing a 3+3 design to assess the safety and pharmacology of single ascending doses (SAD) of GIGA-2050 in patients hospitalized with confirmed COVID-19.||||
33729793|NCT04275596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729794|NCT04729166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following recruitment, the pregnant women were divided into a study and a control group by randomization (1:1 randomization)||||
33729795|NCT05503433|||COHORT||PROSPECTIVE|||||||
33729796|NCT05296603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729797|NCT02371707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729798|NCT01466270|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729799|NCT04165668|||COHORT||PROSPECTIVE|||||||
33729800|NCT00367172|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33729801|NCT06182358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment assignment will be unknown to the study participants, investigators, and site staff performing study assessments|Active arm: XDEMVY 0.25% Control arm: Vehicle of XDEMVY|t|t|t|t
33729802|NCT05692661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729803|NCT02123199|||COHORT||PROSPECTIVE|||||||
33729804|NCT00004238||||TREATMENT||||||||
33729805|NCT06325033|||COHORT||PROSPECTIVE|||||||
33729806|NCT05149417|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Included patients were randomized to one of the 3 groups:~1. Usual care (control) group Patients enrolled in this group were discharged and they didn't undergo any intervention within the treatment period.~2. SMS group Or short message service (SMS) group: patients received SMS at day 2 every day to remind them to take their treatment .~3. Telemonitoring group:~Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed according to an algorithm:~At each call (day 2 and day 4), the VAS was assessed. If VAS ≥ 3 we looked for a medication discontinuation, inadequate dose or change of the prescribed treatment and the patient was instructed to take action accordingly . If the problem is related to side effects, the analgesic treatment was changed or associated to another analgesic"||||
33729807|NCT03621878|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|both the examiner and the outcomes assessor where blinded to the participants groups. the primary investigator was also blind to the outcomes of each participant during the study period.||f|t|f|t
33729808|NCT06311890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729809|NCT02420028|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729810|NCT05984355|||CASE_ONLY||PROSPECTIVE|||||||
33729811|NCT05808712|||COHORT||PROSPECTIVE|||||||
33729812|NCT04912921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Palmitoylethanolamide and placebo tablets are identical in appearance and presented to participant in unlabeled opaque containers by investigators blinded to container content. Curcumin and control tablets are identical in appearance and presented to participant in unlabeled opaque containers by investigators blinded to container content|double-blind, randomized, controlled trial|t|f|t|f
33729813|NCT00280254|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729814|NCT00938028|||||PROSPECTIVE|||||||
33729815|NCT02738125|||COHORT||PROSPECTIVE|||||||
33729816|NCT03212625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729817|NCT00154596|||CASE_CONTROL||PROSPECTIVE|||||||
33729818|NCT05583903|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33729819|NCT02851537|||COHORT||RETROSPECTIVE|||||||
33729820|NCT01893424|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33729821|NCT01457495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729822|NCT02018289|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34116611|NCT04371848|||COHORT||PROSPECTIVE|||||||
34116612|NCT02681393|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34116613|NCT03289754|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116614|NCT01561976|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34116615|NCT03733548|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot trial to finish developing and refining the intervention||||
33729823|NCT03818516|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116616|NCT01708044|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34116617|NCT03085901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116618|NCT00317837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116619|NCT01738243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116620|NCT02060981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116621|NCT00545779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116622|NCT02431156|||COHORT||RETROSPECTIVE|||||||
34116623|NCT06146816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, single-blinded, two arms, pilot study. We will recruit 40 CD patients suffering from an active disease based on clinical score and fecal calprotectin level. Thirty patients will be allocated to the experimental group and receive high intensity fIR therapy, while 10 patients will be allocated to the control group and receive the lowest intensity fIR therapy (placebo). Another 10 patients will be recruited in case there is a drop-out. Rate of patients with mild disease (HBI 5-7) will be similar between the two groups.|t|f|t|f
34116624|NCT03290352|||COHORT||PROSPECTIVE|||||||
34116625|NCT00805389|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34116626|NCT01374360|||OTHER||PROSPECTIVE|||||||
34116627|NCT00673920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116628|NCT02943694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116629|NCT02348203|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116630|NCT05896241|||OTHER||PROSPECTIVE|||||||
34116631|NCT05875857|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34116632|NCT00237042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116633|NCT02466919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116634|NCT04592809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The investigator, patient, and study staff will be blinded. Packaging and labeling of the study drugs will be performed by the research pharmacy in a way to ensure blinding throughout the study.~No members of the study team will have access to the randomization scheme during the conduct of the study. The Research Pharmacist and the CDRC (Center for Depression Research and Clinical Care) Program Manager will have access to the treatment assignment in the event of an emergency. The treatment code must not be broken except in medical emergencies when the appropriate management of the patient necessitates knowledge of the treatment randomization. The investigator retains the right to break the code for serious adverse events (SAEs) that are unexpected and are suspected to be causally related to a study drug and that potentially require expedited reporting to regulatory authorities."|Youth will be randomized in 1:1 fashion to either intravenous ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg) twice weekly for 2 weeks followed by weekly visits for 10 weeks (for a total of 12-week post-randomization observation period).|t|t|t|f
34116635|NCT00413114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116636|NCT05104060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116637|NCT02031406|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116638|NCT03126487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116639|NCT05475808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116640|NCT04544306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116641|NCT03554655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Given the nature of the intervention, patients and healthcare providers cannot be kept blinded. Investigators responsible for data collection and data entry will be blinded as to patient allocation until all outcomes have been collected.|A two-arm, observer-blinded, parallel group randomised controlled superiority trial will be used for this intervention. Participants will be placed in one of two groups: Intervention group: treatment as usual (TAU) together with the Momentum app or (2) Control group: TAU without the Momentum app.|f|f|t|t
34116642|NCT05320978|||COHORT||PROSPECTIVE|||||||
34116643|NCT03034889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116644|NCT05375630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Parallel Group Randomised Controlled Trial|t|t|t|t
34116645|NCT05558969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|It will be evaluated by another investigator (blind) who does not know in which group the patient is using magnesium sulfate during the intraoperative period.|A total of 30 pregnant women, who are taking magnesium and not taking magnesium, will be included in the study to be taken by cesarean section under general anesthesia.At the end of surgery, whether sugammadex reverses the effect of NMBA will be evaluated. The time up to TOF 0.9 will be recorded.A blood sample will be taken to measure simultaneous calcium and magnesium values.|t|f|t|f
34116646|NCT00114491|||DEFINED_POPULATION||PROSPECTIVE|||||||
34116647|NCT01468480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116648|NCT01734525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116649|NCT03015285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116650|NCT03383666|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116651|NCT00404807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34116652|NCT00484263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116653|NCT02176915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116654|NCT00674921|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34116655|NCT01937702|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34116656|NCT04542681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is designed in 2 cycles. The first cycle subjects will receive Placebo (n=10) or MANP 2.5 ug/kg (n=20). In the second cycle subjects will receive MANP 5 ug/kg/ (n=10).||||
34116657|NCT02184533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116658|NCT02257684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116659|NCT01527565|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34116660|NCT00050804||||TREATMENT||||||||
34116661|NCT02872038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116662|NCT01221506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116663|NCT03827317|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Non-randomised cohort||||
34116664|NCT05688085|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34116665|NCT02009826|||CASE_CONTROL||PROSPECTIVE|||||||
34116666|NCT01480167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116667|NCT04278248|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116668|NCT00698841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116669|NCT00700206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116670|NCT00129857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116671|NCT03461718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116672|NCT02478151|NA|SINGLE_GROUP||OTHER||NONE||||||
34116673|NCT00314457|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34116674|NCT03732989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be aware of the other condition, i.e., that the device could be interactive/non-interactive.||t|f|f|f
34116675|NCT04373304|NA|SINGLE_GROUP||TREATMENT||NONE|Patients are blinded during reintroduction.|||||
34116676|NCT04862494|||COHORT||RETROSPECTIVE|||||||
34116677|NCT03942081|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34116678|NCT05034926|||COHORT||PROSPECTIVE|||||||
34116679|NCT05270525|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34116680|NCT03823326|||COHORT||PROSPECTIVE|||||||
34116681|NCT05640089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116682|NCT03963284|||COHORT||PROSPECTIVE|||||||
34116683|NCT03234634|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Patients will be dichotomized into good collateral (group 1) and poor collateral group (group 2) according to collateral status assessed on multiphase CT angiography.|f|f|f|t
33729824|NCT03508856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729825|NCT00006211||||TREATMENT||||||||
33729826|NCT00651027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729827|NCT05161130|||COHORT||RETROSPECTIVE|||||||
33729828|NCT00189748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729829|NCT05157932|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33729830|NCT01617603|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33836990|NCT00257114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836991|NCT04574817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116684|NCT03659578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116685|NCT02865174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116686|NCT04857554|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single (Investigator)|Crossover Assignment|f|f|t|f
34116687|NCT06222112|||COHORT||PROSPECTIVE|||||||
34116688|NCT00977210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116689|NCT06345885|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116690|NCT00738296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116691|NCT03825627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116692|NCT03625076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116693|NCT01347814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34116694|NCT05951426|||COHORT||PROSPECTIVE|||||||
34116695|NCT03173937|NA|SEQUENTIAL||TREATMENT||NONE||||||
34116696|NCT03089814|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34116697|NCT05288556|NA|SINGLE_GROUP||TREATMENT||NONE||Single Site, Prospective, Phase I Study, Safety and Efficacy||||
34116698|NCT02466828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116699|NCT06357104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116700|NCT03542617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116701|NCT04843280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116702|NCT05455892|||COHORT||RETROSPECTIVE|||||||
34116703|NCT06477627|RANDOMIZED|PARALLEL||PREVENTION||NONE||three groups: one group that lives at the coast all year round, one group that lives inland all year round and one group that live inland but in the month August lives at the coast (to investigate the change in environment) The participants will not get any treatment, they just have to give samples.||||
34116704|NCT06560944|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Random number generator, via technicians, concealed allocation|Randomised-controlled crossover trial|t|f|t|f
34116705|NCT05644873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The patients were randomly divided into two groups according to a 1:1 randomization ratio using opaque sealed envelopes before surgery. Study randomization was performed using computer generated randomization codes by SPSS v23.0 (IBM, New York, USA). Each patient was asked to choose an envelope and the patients were assigned to the study according to the group specified in the envelope. The drugs to be used were prepared 30 minutes before the surgery by the nurse who did not participate in the study in the drug preparation room. Everyone involved in this study, including patients, researchers, the anesthesiologist responsible for anesthesia management, and the surgeon, remained blind to group distribution during the study.|t|f|f|t
34116706|NCT02526914|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34116707|NCT02647671|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34116708|NCT06571344|||CASE_CONTROL||PROSPECTIVE|||||||
34116709|NCT02898948|||COHORT||PROSPECTIVE|||||||
33729831|NCT03416400|||CASE_CONTROL||PROSPECTIVE|||||||
33729832|NCT00358462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729833|NCT00259506|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729834|NCT03522181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836992|NCT02108002|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116710|NCT05206903|||OTHER||CROSS_SECTIONAL|||||||
34116711|NCT01731925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729835|NCT01561066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729836|NCT00210704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33729837|NCT05612906|||OTHER||PROSPECTIVE|||||||
33729838|NCT00301249|||OTHER||CROSS_SECTIONAL|||||||
33729839|NCT03951922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729840|NCT01034410|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729841|NCT03672435|||COHORT||PROSPECTIVE|||||||
33729842|NCT06402188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729843|NCT04240145|||COHORT||PROSPECTIVE|||||||
33729844|NCT01746784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729845|NCT02544529|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33729846|NCT03865329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729847|NCT03299842|NA|SINGLE_GROUP||TREATMENT||NONE||ZX008-1503 Fenfluramine, open-label||||
33729848|NCT01076829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33729849|NCT02212821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33836993|NCT04358432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33836994|NCT02686619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836995|NCT01439867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836996|NCT01293942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836997|NCT00501657|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33836998|NCT04478253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized prospective monocentric open-label study on two parallel groups based on the use or non-use of a virtual reality device coupled with hypnosis software (HYPNO-VR) during the insertion of a chest tube.||||
33839227|NCT03813277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116712|NCT06325215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|After providing information about the study to the parents of preterm newborns who met the inclusion criteria, informed consent forms were obtained without disclosing which group their babies would be assigned to. The research outcome measurements were recorded by two nurses working at NICU. Prior to the study, necessary training and information about the form and process were provided to the nurses. The data analysis was conducted by an independent statistician.|Randomized Controlled Experimantal|f|t|t|f
34116713|NCT03621280|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Extension Study||||
34116714|NCT03819309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836999|NCT05986422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind.|Double-blind, randomized, placebo-controlled trial.|t|f|t|t
33837000|NCT00703495|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33837001|NCT03107637|||OTHER||PROSPECTIVE|||||||
33837002|NCT02489240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33837003|NCT06378723|||OTHER||OTHER|||||||
34042468|NCT00755599|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Randomization into one of two arms|f|f|f|t
34042469|NCT03512613|||OTHER||PROSPECTIVE|||||||
34042470|NCT02686463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042471|NCT00244114|||||PROSPECTIVE|||||||
34042472|NCT02223962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042473|NCT00485199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34042474|NCT03966417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042475|NCT03799640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Tests will not be performed by the investigators providing the interventions..|Comparison of Yoga Interventions|f|f|t|f
34042476|NCT03637881|||OTHER||CROSS_SECTIONAL|||||||
34042477|NCT04679532|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subject serves as their own control. Both devices are worn during the same exercise session.||||
34116715|NCT00380926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116716|NCT04894682|||COHORT||PROSPECTIVE|||||||
34116717|NCT06376955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116718|NCT05176587|||CASE_CONTROL||PROSPECTIVE|||||||
34116719|NCT05656157|||COHORT||RETROSPECTIVE|||||||
34116720|NCT03683979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116721|NCT02249078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116722|NCT03618537|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II open-label study.||||
34116723|NCT00902330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34116724|NCT04445948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116725|NCT06469983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blind could not be applicable since a physical therapist could be blinded due to the nature of the intervention (RV or SR). However, clinical evaluation will be performed by an examiner blind to the patient' group of treatment.||f|f|f|t
34116726|NCT00603681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116727|NCT00197821|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34116728|NCT00000305||||TREATMENT||||||||
34116729|NCT05160389|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single-dose, open-label, randomized, three-way crossover design||||
34116730|NCT06544720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116731|NCT03585387|||COHORT||PROSPECTIVE|||||||
34116732|NCT05115266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116733|NCT00734552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116734|NCT04908644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34116735|NCT01564017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116736|NCT00775255|RANDOMIZED|CROSSOVER||||NONE||||||
34116737|NCT05873088|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116738|NCT03041220|||COHORT||RETROSPECTIVE|||||||
34116739|NCT01126073|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116740|NCT03152578|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34116741|NCT04994171|||COHORT||PROSPECTIVE|||||||
34116742|NCT00474903|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34116743|NCT04046939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Four-arm parallel assignment|t|t|t|f
34116744|NCT01067430|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116745|NCT06157073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects who meet all criteria for enrolment will be randomized in a 1:1 allocation ratio to receive either open-loop ventilator (OLV) or closed-loop ventilator (CLV). Randomization will be stratified by the respiratory pathology present: normal lung, hypercapnic respiratory failure and decreased lung compliance. Randomization sequence will be generated using a web-based randomisation software.||||
34116746|NCT04951349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two part study with four total arms. Parts: Health care providers and CV-19 infected patients. Arms: Interventional and placebo in each of the two groups.|t|t|t|t
34116747|NCT02179073|||COHORT||PROSPECTIVE|||||||
34116748|NCT04809194|||COHORT||PROSPECTIVE|||||||
34116749|NCT01074931|||||PROSPECTIVE|||||||
34116750|NCT03434834|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116751|NCT05086484|||COHORT||OTHER|||||||
34116752|NCT01076114|||COHORT||PROSPECTIVE|||||||
34116753|NCT02136784|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34116754|NCT00160953|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34116755|NCT05517408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116756|NCT06113861|||CASE_CONTROL||PROSPECTIVE|||||||
34116757|NCT02040389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116758|NCT03890211|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116759|NCT01099488|NA|SINGLE_GROUP||OTHER||NONE||||||
34116760|NCT05119530|||COHORT||CROSS_SECTIONAL|||||||
34116761|NCT00499044|RANDOMIZED|CROSSOVER||||NONE||||||
33837004|NCT01275781|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33837005|NCT05569213|||CASE_CONTROL||PROSPECTIVE|||||||
34116762|NCT02982226|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34116763|NCT03044145|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||This study follows an NIMH model known as the Stage Model of Intervention Development. The first project is creating a cross-cultural communication intervention designed to improve patient adherence in mental health services through patient and clinician feedback at JHMC and expert consensus with my K23 mentoring team. The second project is testing the intervention in a trial that compares the CFI-EA to treatment as usual.|t|f|f|f
34116764|NCT01206127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837006|NCT06117553|||CASE_CONTROL||PROSPECTIVE|||||||
33837007|NCT00322244|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33839228|NCT06122922|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116765|NCT04618471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116766|NCT00272181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729850|NCT01567969|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33729851|NCT00697346|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729852|NCT01188577|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33729853|NCT01996566|||CASE_CROSSOVER||PROSPECTIVE|||||||
33729854|NCT05098535|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants will be masked to the primary purpose of the study during their preoperative consultation. Upon receiving and completing the survey responses participants will be asked to recall their individualized risk of myocardial injury and provide feedback on the risk discussion they had with the anesthesiologist.|A block randomized approach will be used to generate 2 groups of patients who will have their preoperative risk discussion guided by the use of a structured script or have the risk discussion guided by the use of a structured script and the display of a visual aid outlining the risk of myocardial injury.|t|f|t|t
33729855|NCT04847674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729856|NCT04388943|||CASE_CONTROL||RETROSPECTIVE|||||||
33729857|NCT01434524|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33729858|NCT00782262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729859|NCT03880721|||COHORT||PROSPECTIVE|||||||
33729860|NCT01434290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729861|NCT01339390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729862|NCT05680922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729863|NCT02072967|||CASE_ONLY||PROSPECTIVE|||||||
33729864|NCT02857010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729865|NCT00654069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33729866|NCT02254330|||COHORT||CROSS_SECTIONAL|||||||
33729867|NCT02528916|||CASE_ONLY||PROSPECTIVE|||||||
33729868|NCT05550051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729869|NCT04187196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729870|NCT01159964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729871|NCT06406127|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729872|NCT05126927|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729873|NCT02006277||CROSSOVER||BASIC_SCIENCE||NONE||||||
33729874|NCT03863613|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Participants will be randomised to either cerclage, pessary, cerclage plus progesterone or pessary plus progesterone in a 1:1:1:1 ratio with a variable block size of 4 or 8.||||
33729875|NCT03126994|NA|SINGLE_GROUP||OTHER||NONE||Prospective validation study to evaluate PWV, PR, and BW accuracy in a sample of subjects representing the US general adult population.||||
33729876|NCT02540954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729877|NCT04036942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator in charge of capturing the data will only know if the patients received an A or B treatment without knowing the meaning of these letters; the endoscopist who carries out the procedure and the patient will be aware that group A corresponds to management with ARAT and group B to management with ARMS|A simple randomized, comparative (pretreatment and posttreatment), prospective clinical trial will be carried out among the group of patients managed with ARAT and ARMS|f|f|t|f
33729878|NCT01064557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729879|NCT02633956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729880|NCT03766178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729881|NCT02771262|||COHORT||PROSPECTIVE|||||||
33729882|NCT03764722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729883|NCT02385604|||COHORT||PROSPECTIVE|||||||
33729884|NCT03929965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729885|NCT00177437|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33729886|NCT01408186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729887|NCT01206985|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33729888|NCT04498962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729889|NCT01891851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729890|NCT05510869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729891|NCT03516669|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||20 participants receive intraluminal eradication of H. pylori. Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.||||
33729892|NCT00007033||||TREATMENT||||||||
33837008|NCT00879775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33837009|NCT04678531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837010|NCT02002377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837011|NCT00708318|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837012|NCT04593823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042478|NCT03039764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729893|NCT01358318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33729894|NCT05626946|||CASE_CONTROL||RETROSPECTIVE|||||||
33729895|NCT04648865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33729896|NCT00794196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33729897|NCT06290310|||COHORT||PROSPECTIVE|||||||
33729898|NCT02623803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729899|NCT05092893|||CASE_ONLY||CROSS_SECTIONAL|||||||
33729900|NCT02920983|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729901|NCT00004296|||||OTHER|||||||
33729902|NCT03296306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729903|NCT03561857|NA|SINGLE_GROUP||OTHER||NONE||||||
33729904|NCT01485315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729905|NCT02170584|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33837013|NCT00806481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837014|NCT02272504|||CASE_CONTROL||PROSPECTIVE|||||||
33837015|NCT05202054|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE||PRETEST POSTTEST EXPERIMENTAL RANDOMIZED STUDY|t|f|f|t
34042479|NCT02514720|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042480|NCT05630261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042481|NCT03787784|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34042482|NCT02189031|||CASE_ONLY||PROSPECTIVE|||||||
34116767|NCT03122184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and treating study staff will be aware of the patient's treatment condition. However, follow-up assessments will be performed by a study staff member that is masked to the participant's treatment condition.|Randomized, single-blinded, controlled trial|f|f|f|t
34116768|NCT05309525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116769|NCT06030518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116770|NCT00151177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116771|NCT00320606|NA|SINGLE_GROUP||TREATMENT||NONE||Recipients of parental living-donor liver allografts will undergo gradual withdrawal as tolerated of immunosuppression with the goal of complete withdrawal.||||
34116772|NCT04005300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34116773|NCT04422496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116774|NCT04740151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116775|NCT00922129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116776|NCT03791879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34116777|NCT02109276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116778|NCT01144819|||CASE_ONLY||PROSPECTIVE|||||||
34116779|NCT01502735|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116780|NCT06365281|||OTHER||CROSS_SECTIONAL|||||||
34116781|NCT04954664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The calibrated, trained, masked-examiner (who is unaware of which Group the patient is randomized), will be masked and available during the entire duration of the study.||f|f|f|t
34116782|NCT05437991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116783|NCT03156114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116784|NCT00226005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116785|NCT06561802|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34116786|NCT00729950|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116787|NCT05383287|||COHORT||PROSPECTIVE|||||||
34116788|NCT01382108|||CASE_CONTROL||PROSPECTIVE|||||||
34116789|NCT02441894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116790|NCT05098392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be informed of the group status of the children.|Children in the US and China will be randomized into the two groups at each location.|f|f|f|t
34116791|NCT03769350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116792|NCT01570387|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116793|NCT00399087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116794|NCT00273884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116795|NCT04541524|||COHORT||PROSPECTIVE|||||||
34116796|NCT06570122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116797|NCT03906214|||OTHER||OTHER|||||||
34116798|NCT04862754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116799|NCT03464825|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||One intervention group receiving Specific and progressive balance training One control group|f|f|t|f
34116800|NCT04866719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116801|NCT01854528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116802|NCT03048370|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participant will be blinded to the order of experimental conditions, as well as the person conducting specific ratings assessments.|Each participant will successively receive 6 vestibular stimulation conditions. Side of stimulation will be randomized.|t|f|f|t
34116803|NCT02825108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116804|NCT05023161|||CASE_ONLY||PROSPECTIVE|||||||
34116805|NCT01657981|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116806|NCT03268564|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34116807|NCT06021041|||COHORT||RETROSPECTIVE|||||||
34116808|NCT03493139|RANDOMIZED|PARALLEL||PREVENTION||NONE||Classroom Physical Activity Breaks Delivered by Teacher vs. Classroom Physical Activity Breaks Delivered by Video||||
34116809|NCT04435158|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34116810|NCT05699200|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116811|NCT01481792|||COHORT||PROSPECTIVE|||||||
34116812|NCT06006104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837016|NCT01605682|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33837017|NCT00662597|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116813|NCT06546527|NA|SEQUENTIAL||TREATMENT||NONE||||||
34116814|NCT00226083|||||PROSPECTIVE|||||||
34116815|NCT03615885|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34116816|NCT02519842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116817|NCT01459120|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116818|NCT04167943|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34116819|NCT01627184|||COHORT||PROSPECTIVE|||||||
34116820|NCT04353687|||COHORT||PROSPECTIVE|||||||
34116821|NCT04228458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116822|NCT00724763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34116823|NCT04314622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116824|NCT01914588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34116825|NCT01368094|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116826|NCT00688714|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34116827|NCT04850326|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34116828|NCT01872884|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34116829|NCT01257685|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116830|NCT05124730|RANDOMIZED|CROSSOVER||OTHER||NONE|The study was open-labelled; however, analysts did not have access to the randomization scheme to prevent bias during analyses.|||||
34116831|NCT04719156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Operating surgeon will be blinded to ICG Images.|Patients with suspected sarcoma tumors.||||
34116832|NCT00587119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116833|NCT00221767|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116834|NCT00004264||||TREATMENT||||||||
34116835|NCT01374425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116836|NCT05825040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116837|NCT00137592|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34116838|NCT00073125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33729906|NCT05961566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Individuals computing the statistical analysis will be masked for which outcome was used. Surgeons and patients will only know which outcome will be used at time of surgery.|Individuals will be randomly assigned to be in the control group of the intervention group (Collagen matrix soft tissue augmentation).|f|f|f|t
33729907|NCT02467101|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33729908|NCT03876730|||CASE_ONLY||PROSPECTIVE|||||||
33729909|NCT02393963|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33729910|NCT03984695|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized clinical trial.||||
33729911|NCT04441333|NA|SINGLE_GROUP||OTHER||NONE||Pilot study: single-arm non-comparative study||||
33729912|NCT02146482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810903|NCT05185973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization scheme will be generated by an independent Statistician using a computer-generated block randomization scheme, with randomly selected block lengths of 4. Each of the two study arms will be identified by a unique 1-digit code (1, 2). The Institut Pasteur du Laos (IPL) member, unaffiliated with the study, will be responsible for assigning each of the two study codes to an intervention product and communicating this information directly to the product manufacturers. The identity of the treatment codes is stored in sealed envelopes held by the co-principal investigators (PIs) and the statistician. The envelopes will be opened only after statistical analyses of primary outcomes are completed and consensus on the interpretation of results is reached, unless required by one of the IRBs or the Project Steering Committee.|The LaoBiome Study is a community-based double blinded randomized controlled trial. Approximately 1,200 infants and young children 6-23 months of age will be enrolled, and individually-randomized to one of two intervention groups of 600 children: 1) daily administration of For-Baby supplement (Intervention Group); 2) daily administration of micronutrient Placebo (Control Group). In both groups, children will remain under observation and receive their assigned supplements for a period of 12 months.|t|f|t|f
33810904|NCT04912765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810905|NCT01275911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33810906|NCT05647538|||CASE_CONTROL||RETROSPECTIVE|||||||
33810907|NCT06365892|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding of patients and providers will not be feasible due to the nature of the study.|Both arms - Open-label Placebo (COLP) and Treatment As Usual (TAU)||||
33810908|NCT00458094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33810909|NCT00673088|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116839|NCT01720368|||||PROSPECTIVE|||||||
34116840|NCT02497105|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116841|NCT02612246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116842|NCT00431964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116843|NCT03829592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||3 paralle groups|t|f|f|t
34116844|NCT00753532|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116845|NCT02645864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116846|NCT01928433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116847|NCT00285051|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Group 1 cycle 1 - Ondansetron; cycle 2 - 300 mcg of delta-8-THC per dose Group 2 cycle 1 - Ondansetron; cycle 2 - 600 mcg of delta-8-THC per dose Group 3 cycle 1 - 300 mcg of delta-8-THC per dose cycle 2 - Ondansetron Group 4 cycle 1 - 600 mcg of delta-8-THC per dose cycle 2 - Ondansetron|t|t|t|f
34116848|NCT06312215|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34116849|NCT00575666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116850|NCT03410654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116851|NCT03505333|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomized to two groups according to a two-blocked randomization list which was coded (a) or (b) at 1:1 ratio. The two parallel groups were prepared using a Computer-generated randomization system. The allocated groups were concealed in serially numbered sealed opaque envelopes that were opened only after recruitment. Patient allocation was performed prior to the induction of anesthesia by an independent researcher, who was not otherwise being involved in this study. The trial was appropriately single-blinded. The participants were blinded to the procedure performed.|single-blinded randomized trials|t|f|f|f
34116852|NCT06029205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34116853|NCT00822380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116854|NCT04143776|||COHORT||PROSPECTIVE|||||||
34116855|NCT05229016|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are masked from knowing the purpose of the study's hypothesis, which is that patient-related factors may influence scores of patient related outcome measures.|"Patients will be assigned randomly to complete one of six patient reported outcome measures.~Prior to completion of the patient reported outcome measures, patients will be randomly assigned to one of three groups: Group A where patients will be asked to reflect on positive health-related experiences, Group B where patients will be asked to reflect on negative health-related experiences, Group C where patients will not be asked to reflect on health-related experiences (Control)."|t|f|f|f
34116856|NCT05136716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116857|NCT02507986|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34116858|NCT05960578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116859|NCT02250989|||COHORT||PROSPECTIVE|||||||
34116860|NCT04955821|||CASE_ONLY||PROSPECTIVE|||||||
34116861|NCT02738463|||CASE_CONTROL||PROSPECTIVE|||||||
34116862|NCT01346124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116863|NCT04708522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729913|NCT00855309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729914|NCT00231101|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34116864|NCT05619237|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants and researchers will be aware of the phases of the study.|Patients will receive the standard of care for the first 4 weeks. If the chronic wound has healed less than 50%, then the patient will receive the intervention for 4 weeks.||||
34116865|NCT00417755|||DEFINED_POPULATION||PROSPECTIVE|||||||
34116866|NCT00346723|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34116867|NCT02428426|||CASE_CONTROL||PROSPECTIVE|||||||
34116868|NCT01858727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116869|NCT00000628||PARALLEL||TREATMENT||||||||
33729915|NCT06267235|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Longitudinal study changing diet during the intervention 5 weeks restricted dietary protein + 5 weeks habitual dietary protein consumption||||
33729916|NCT03395366|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The study will be designed as a 16-week randomized controlled trial in which 40 subjects on hemodialysis with below average HrQOL will be assigned to one of two educational interventions.|t|f|f|t
33729917|NCT04725435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant, Outcomes Assessor)|"First sub purpose was designed as a single blind, parallel group, randomized controlled pre-test post-test order.~Second sub purpose was designed as a single blind, parallel group, two intervention groups in pre-test and post-test order, and a randomized controlled control group."|t|f|f|f
33729918|NCT01076985|||COHORT||PROSPECTIVE|||||||
33810910|NCT02372318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33810911|NCT00560339|||COHORT||PROSPECTIVE|||||||
33810912|NCT02695004|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33810913|NCT03810170|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial||||
33810914|NCT01760005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One arm is Open-label as noted in the arm descriptions|Interventional with a non-interventional run-in component (Future interventions to be added)|t|t|t|t
33810915|NCT00594282|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33810916|NCT05904210|||COHORT||RETROSPECTIVE|||||||
33810917|NCT02332889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810918|NCT01286311|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33810919|NCT03690466|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE||"This will be a controlled, randomized, double-blinded trial of short-term (14 days) treatment with ultrasound stimulation (therapeutic energy dose) or sham (no energy dose) delivered to the spleen.~Participants will be provided a portable ultrasound device or sham device for at home use. Participants will be trained on how to use the device and will be instructed to use it for 30 minutes per day, at approximately the same time each day for 14 days.~Participants will be assessed at several time points before, during and at the end of treatment as well as a one-week follow-up visit."|t|t|t|t
33810920|NCT06498609|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33810921|NCT05247307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Treatment in the intervention group:~Infusion of 300 cc of convalescent donor plasma from COVID 19, administered within more than 168 hours from the onset of symptoms~Treatment in the control group:~For the study to be blind, the infusion of non-convalescent donor plasma, obtained before the start of the epidemic, is required to guarantee the absence of anti-COVID antibodies in the plasma of the control group."|"Prospective, randomized (1:1; experimental group: control group), double-blind study, in which the doctors who prescribe the treatments and those who assess the results do not know the treatment received by the patient.~The convalescent plasma will be contrasted with fresh frozen plasma, available at the Basque Transfusion and Tissue Center of the Basque Autonomous Community (CVTTH), obtained before 12/31/2019."|t|t|t|f
33810922|NCT02999139|||COHORT||PROSPECTIVE|||||||
33810923|NCT02752984|||COHORT||PROSPECTIVE|||||||
33810924|NCT01933100|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810925|NCT02791295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33810926|NCT01933945|||COHORT||PROSPECTIVE|||||||
33810927|NCT02359929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810928|NCT04924166|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a double-blind, randomized, placebo-controlled trial in which trauma victims are randomized to receive a single oral dose of HCORT or placebo within the first six hours following trauma exposure. This design permits testing of the primary study hypothesis that HCORT administration within hours post-trauma facilitates physiological recovery, thereby promoting resilience.|t|t|t|t
33810929|NCT05392881|||COHORT||PROSPECTIVE|||||||
33810930|NCT00799409|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33810931|NCT03833752|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33810932|NCT02216084|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810933|NCT00491400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33810934|NCT05770115|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33810935|NCT02570100|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33810936|NCT04997798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810937|NCT00074607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810938|NCT05376839|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33810939|NCT03068312|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33810940|NCT01570894|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33810941|NCT00435006|||DEFINED_POPULATION||OTHER|||||||
33810942|NCT01721356|||COHORT||CROSS_SECTIONAL|||||||
33810943|NCT00097409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729919|NCT01482767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729920|NCT05111366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729921|NCT03996200|NA|SINGLE_GROUP||TREATMENT||NONE||MINIject SO627||||
33729922|NCT02353767|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33810944|NCT05147155|||COHORT||PROSPECTIVE|||||||
33810945|NCT00128765|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33810946|NCT05893615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33810947|NCT02638506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810948|NCT03854734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Following collection of baseline data, schools will be randomized. Study staff measuring the primary outcome will be blinded to school group assignment. Given the intervention, it is not possible to blind participants to group assignment.||f|f|t|f
33810949|NCT00120549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33810950|NCT01672684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33810951|NCT00000872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810952|NCT02584257|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33810953|NCT06505993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33810954|NCT03985566|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Fibre Grains have similar appearance to normal Jasmine white rice. It is made up of functional fibre extruded into grain-shaped food particles .|This study is a within-subject cross-over trial design to assess the glycemic response of fibre enriched rice consumer by human subjects as compared to normal non-enriched rice in a mixed meal setting.|t|f|f|f
33810955|NCT02334605|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33810956|NCT05351697|NA|SEQUENTIAL||OTHER||NONE||||||
33810957|NCT01538498|||CASE_ONLY||PROSPECTIVE|||||||
33810958|NCT05681611|||COHORT||PROSPECTIVE|||||||
33810959|NCT01375790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042483|NCT01072773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042484|NCT00554515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042485|NCT03474185|||COHORT||PROSPECTIVE|||||||
34042486|NCT01610817|||||PROSPECTIVE|||||||
34042487|NCT03789760|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042488|NCT03038867|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participant, investigator, and outcomes assessor are all blinded to participant's assigned group.|Blinded, placebo-controlled, randomized controlled trial|t|f|t|t
34042489|NCT02647190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042490|NCT05662072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042491|NCT01208675|||COHORT||PROSPECTIVE|||||||
34042492|NCT00523471|||CASE_ONLY||PROSPECTIVE|||||||
34042493|NCT02011685|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042494|NCT00754130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116870|NCT01354093|||OTHER||PROSPECTIVE|||||||
34116871|NCT02398331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34116872|NCT01765400|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34116873|NCT03037970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One component of the study drug will be blinded as the study employs a placebo-controlled arm. More specifically, vials containing rhPDGF or saline will be the same Type I, sodium borosilicate vials with rubber stopper, and plastic cap. Each vial will contain 3 ml of clear liquid. The vials will have blinded labels. Type I collagen wound dressings, on the other hand, will all be the same and are not part of the blinding.|This is a randomized, blinded, two-arm, clinical study|t|f|t|f
34116874|NCT00030264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116875|NCT02980640|||COHORT||PROSPECTIVE|||||||
34116876|NCT06317935|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE||"Two groups, intervention (A) and control (B), will be created from the target research group using the randomization method.~Intervention group (A) will receive virtual reality application for 30 minutes, 5 days a week for 3 weeks, in addition to traditional occupational therapy and physiotherapy approaches for the first 3 weeks, and will receive only traditional treatments between 3-6 weeks.~The control group (B) will receive only traditional occupational therapy and physiotherapy approaches for the first 3 weeks, and between 3-6 weeks, they will receive virtual reality application in addition to traditional approaches for 30 minutes, 5 days a week for 3 weeks."|t|f|f|t
34116877|NCT04552054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116878|NCT01849276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116879|NCT01203007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116880|NCT04825743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116881|NCT03763630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116882|NCT05410730|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group .Dose escalation and expansion of SHR-1501 alone or in combination with intravesical BCG in the treatment of NMIBC||||
34116883|NCT01442987|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34116884|NCT03057704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant is not told which group they are randomized to. However, a tourniquet is applied in the experimental group, thus some subjects may reason that they are in the experimental group. The study coordinator is aware which group the subject is in.|A randomized, controlled trial of two methods of administering lidocaine prior to propofol injection|t|f|f|f
34116885|NCT04824833|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34116886|NCT03944148|||CASE_ONLY||PROSPECTIVE|||||||
34116887|NCT01374009|||CASE_CONTROL||RETROSPECTIVE|||||||
34116888|NCT02510456|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34116889|NCT01646411|||CASE_ONLY||CROSS_SECTIONAL|||||||
34116890|NCT05210816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Experimental: Intervention group ''Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group Intervention: Behavioral: Acceptance and Commitment Therapy No Intervention: Control group Only data collection was carried out. No attempt was made by the researcher during the study.|Intervention and control group|t|f|f|f
34116891|NCT05323656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116892|NCT04641091|||OTHER||CROSS_SECTIONAL|||||||
34116893|NCT04500145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116894|NCT01158859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116895|NCT00872300|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34116896|NCT00691626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized controlled trial comparing two forms of psychotherapy.|f|f|f|t
34116897|NCT01005173|||CASE_CONTROL||PROSPECTIVE|||||||
34116898|NCT05520684|||COHORT||PROSPECTIVE|||||||
34116899|NCT05233839|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
34116900|NCT02150161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116901|NCT01530958|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34116902|NCT01938729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042495|NCT00639704|||CASE_ONLY||PROSPECTIVE|||||||
34042496|NCT04742361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042497|NCT01508091|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042498|NCT01689454|||COHORT||PROSPECTIVE|||||||
34042499|NCT02968173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810960|NCT01135121|||COHORT||PROSPECTIVE|||||||
33810961|NCT00500604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810962|NCT01835652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33810963|NCT05995730|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33810964|NCT02504411|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34042500|NCT01091506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34042501|NCT05484206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042502|NCT02490371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042503|NCT01045382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33729923|NCT04213898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729924|NCT01909661|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729925|NCT01110421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729926|NCT03844126|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33729927|NCT05411822|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729928|NCT06382233|||CASE_CONTROL||PROSPECTIVE|||||||
33729929|NCT04276103|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33810965|NCT02333565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042504|NCT05648422|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The outcomes assessors and care providers had no access to any information about the treatment administered to each child, which ensured compliance with the blinded portion of the study.|Randomized, controlled clinical trial with blinding.|f|t|f|t
34042505|NCT00357799|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042506|NCT02161640|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34042507|NCT01317095|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042508|NCT02004366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042509|NCT03334344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042510|NCT05661539|||COHORT||PROSPECTIVE|||||||
34042511|NCT01981707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042512|NCT02449486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042513|NCT03334240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|A total of 48 subjects are planned to be enrolled within one of the following three groups: a.) Immunocompetent patients with anogenital warts, b.) Immunocompromised with anogenital warts and c.) Immunocompromised with vulvar HSIL \[3:1, active/vehicle\]. Eligible subjects may enroll in an (up to) 8-week open-label Part 2 of study|t|f|t|f
34042514|NCT06068673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All enrolled 44 patients will be divided into two groups; Group I are patients who will receive clindamycin added-on therapy. Group II patients will be managed with the standard regimen.||||
34042515|NCT04353713|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The intervention in this study will consist of oral administration of either Dextrose 40% gel or placebo (2% carboxymethylcellulose) gel immediately after stabilisation of the preterm infant in the delivery room.These intervention products will be identically labelled pre-filled syringes. No person involved in either the trial or clinical care of the newborn will ever know the identity of whether dextrose gel or placebo was ever administered to the newborn.|"This will be a randomised, double-blinded (using masking), placebo controlled clinical trial. It will involve multiple study sites.~The study population will consist of infants born at ≤32 weeks gestation. These may include singleton or multiples births.~Randomisation will be stratified into two groups using gestational age at birth:~≤29 weeks~29+1 to ≤32 weeks~Randomisation will also be stratified by multi-centre site."|t|t|t|t
34042516|NCT02042755|||CASE_ONLY||PROSPECTIVE|||||||
34042517|NCT02588768|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34042518|NCT01760304|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34042519|NCT02019316|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34042520|NCT05127317|||CASE_ONLY||PROSPECTIVE|||||||
34042521|NCT04019782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind masking.|"Participants in one group receive drug A (Hylan G-F20) in parallel to participants in the other group, who receive drug B (Collagen-PVP)."|t|f|f|t
34042522|NCT05801783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042523|NCT03780439|||COHORT||PROSPECTIVE|||||||
34042524|NCT04283630|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover double blinded crossover study|t|f|t|f
34042525|NCT00003646||||TREATMENT||NONE||||||
34042526|NCT05029375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||two parallel intervention groups differing in parental involvement|t|t|f|t
33729930|NCT00009919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729931|NCT01234545|||COHORT||PROSPECTIVE|||||||
33729932|NCT04985851|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|This is an open-label, randomised, multicenter, Phase II study. This study is planned to enroll 90 eligible patients to receive durvalumab combined with up to 4 cycles of etoposide and platinum-based chemotherapy (EP). And approximately 64 patients who complete the 4 cycles of durvalumab + EP treatment and don't have progressive diseases (Non-PD patients) will be randomized in a 1:1 ratio to receive maintenance treatment durvalumab + anlotinib (Arm 1) or durvalumab (Arm 2) until confirmed progressive disease. Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab||||
33729933|NCT01332942|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33729934|NCT00364780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33729935|NCT01638962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33729936|NCT00526058|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33810966|NCT03180476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810967|NCT06369844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The information about which group (intervention or control) the nurses who volunteered to participate in the study would belong to was provided after the pre-test data were collected. Blinding of the researcher was not performed because the researcher conducted the educational phase of the study. The determination of the study groups was carried out randomly by a person not associated with the study using a random draw method. The statistical analysis of the study data was conducted by someone not related to the study.|The study design will be two-group and pretest-posttest design.|t|f|f|t
33810968|NCT01079104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810969|NCT02309515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810970|NCT05777772|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33810971|NCT00561249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810972|NCT04495153|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a phase II prospective study to evaluate the safety and potential efficacy of CAN-2409 plus prodrug added to standard of care immune checkpoint inhibitor (ICI) therapy in stage III/IV NSCLC||||
33810973|NCT04555057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729937|NCT03388190|RANDOMIZED|PARALLEL||TREATMENT||NONE||The METIMMOX study is a multicenter open-label randomized phase 2 trial in first-line treatment of MSS/pMMR-mCRC using the standard-of-care Nordic FLOX regimen (control arm) or sequential therapy with the Nordic FLOX regimen and nivolumab (experimental arm), to investigate whether the experimental arm shows superiority in PFS, safety, tolerability, and QoL.||||
33729938|NCT02815748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729939|NCT04246385|RANDOMIZED|PARALLEL||TREATMENT||NONE|The principle investigator (PI) will be providing the intervention and therefore will not be blinded to the COPM of the intervention group as the COPM not only provides the objective data of the participant's' performance and satisfaction of goals but the goals themselves to be addressed within the intervention. However, the PI will not be providing the intervention of the control group, the AMPS assessments, and CPI evaluations.|This randomized control pilot study will estimate for 22 participants, 11 for the CO-OP group and 11 for the control group, expecting 8 for each to complete the study. Each individual CO-OP group will be expected to include three to six participants to remain consistent with the literature (Chan, 2007; Green, Chambers, \& Sugden, 2008).||||
33729940|NCT06469255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729941|NCT00679575|||CASE_CONTROL||PROSPECTIVE|||||||
33729942|NCT03898765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33729943|NCT00397982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729944|NCT05492396|||COHORT||PROSPECTIVE|||||||
33729945|NCT01504321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729946|NCT03377777|||COHORT||CROSS_SECTIONAL|||||||
33729947|NCT01552772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729948|NCT06406738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33729949|NCT04270981|NA|SINGLE_GROUP||TREATMENT||NONE||single centre, open-label, single group, non-randomised, single oral dose study in healthy male subjects||||
33729950|NCT02362165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729951|NCT02789176|||COHORT||PROSPECTIVE|||||||
33729952|NCT01129141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729953|NCT02121691|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729954|NCT01436279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729955|NCT03852797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729956|NCT03302481|NA|SINGLE_GROUP||OTHER||NONE||patients with obesity surgery with a laparoscopic approach scheduled in the department of digestive surgery of the CHU de Nantes||||
33729957|NCT04667403|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33729958|NCT02188576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729959|NCT02464202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729960|NCT05716828|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33729961|NCT03060434|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The assessor and the investigator are unaware of the sequence of the 15 days treatment with pentoxifylline|Each patient will receive for 1 month: Ibuprofen 600 mg bid; Paracetamol 1g tid if needed; pregabalin 75 mg bid pentoxifylline 400 mg bid will be added for either the first or second 15 days (randomization)|f|f|t|t
33729962|NCT01552538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729963|NCT04126291|NA|SINGLE_GROUP||OTHER||NONE||The recruited group of health care professionals (HCPs) will answer a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, the participants will re-rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For participants who consent to do a follow up questionnaire four-six months later, investigators will send an email link for HCPs to complete a satisfaction questionnaire and re-rate their perceived self-efficacy and knowledge to help elucidate outstanding educational gaps.||||
33729964|NCT03164070|||COHORT||PROSPECTIVE|||||||
33810974|NCT00299676|||COHORT||PROSPECTIVE|||||||
33729965|NCT03339609|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729966|NCT03703635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729967|NCT00694967|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33729968|NCT00482495||||TREATMENT||NONE||||||
33729969|NCT05414643|||COHORT||PROSPECTIVE|||||||
33729970|NCT01524770|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33729971|NCT04582851|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33729972|NCT06022016|NA|SINGLE_GROUP||OTHER||NONE||||||
33810975|NCT03964974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33810976|NCT02577939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810977|NCT03108430|||COHORT||PROSPECTIVE|||||||
33810978|NCT00610337|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33810979|NCT02445404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729973|NCT01467232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33729974|NCT00439556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810980|NCT02459860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810981|NCT03795532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33810982|NCT01228500|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33810983|NCT02589613|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33810984|NCT02601859|NA|SINGLE_GROUP||OTHER||NONE||||||
33810985|NCT04903067|||OTHER||PROSPECTIVE|||||||
33810986|NCT04640584|||COHORT||PROSPECTIVE|||||||
33810987|NCT04661774|RANDOMIZED|CROSSOVER||OTHER||SINGLE|each participant has reflexology and placebo massage, he is his own comparator|monocentric, interventional, comparative, randomized cross-over study in healthy individuals, with minimal risk and constraints|t|f|f|f
33810988|NCT02580799|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33729975|NCT02965612|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33729976|NCT05909371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33810989|NCT00978718|RANDOMIZED|||PREVENTION||DOUBLE||||||
33837018|NCT02171299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042527|NCT03348007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This is a multicenter, randomized (2-arm), double-blind, comparative study versus weakly mineralized water (placebo) in women with functional constipation (Rome Criteria III).~During the selection visit functional constipation will be evaluated by retrospective examination over the previous 3 months according to the diagnostic criteria for functional constipation in Rome III. During the 7 to 9 days prior to randomization, the patients selected by the investigators will observe a period of Wash out and will have to drink 1.5l of Nestlé PureLife® (low mineral water) water per day and inform them daily about their symptomatology ( stool frequency, abdominal pain aspect), their water intake and rescue laxative treatment.~Wash-out period concerned previous taking of laxatif drugs"|t|f|t|f
34042528|NCT01562782|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34042529|NCT00415818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116903|NCT03313934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject will not be aware of which tear trough has the PRF condition. Additionally, the blind observer, who is going to evaluate improvement based on before/after photos, will also be blind to to which tear trough as treated with the PRF condition.|10 subjects will receive treatment with hyaluronic acid fillers for tear trough rejuvenation. Each subject with have one tear trough treated with HA filler mixed with Platelet Rich Fibrin, and the other tear trough injected with HA filler mixed with saline. The subject with be blind as to which tear trough contains the PRF. This will be randomly assigned for each subject and documented by the CRC.|t|f|f|t
34116904|NCT02362685|||COHORT||PROSPECTIVE|||||||
34116905|NCT03377751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116906|NCT01293331|||COHORT||PROSPECTIVE|||||||
34116907|NCT00713011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116908|NCT01775540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34116909|NCT01689948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34116910|NCT02092181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116911|NCT03744390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116912|NCT02803385|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34116913|NCT05353439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116914|NCT00772057|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34116915|NCT06488755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116916|NCT00626236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116917|NCT02854163|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116918|NCT00778427|RANDOMIZED|CROSSOVER||||NONE||||||
34116919|NCT01152437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116920|NCT00108381|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34116921|NCT01542970|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34116922|NCT00437749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116923|NCT03520270|||COHORT||PROSPECTIVE|||||||
34116924|NCT01159834|||COHORT||PROSPECTIVE|||||||
34116925|NCT05654584|||COHORT||PROSPECTIVE|||||||
34116926|NCT05406973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116927|NCT00630617|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34116928|NCT01390623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34116929|NCT00101348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116930|NCT05486767|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34116931|NCT06277440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measurements will be performed by a researcher who is blind to the groups' allocation.|Twenty preschool children with Attention Deficit Hyperactivity Disorder and developmental delays under rehabilitation therapy will be collected. They will be randomly assigned to the experimental group (receiving rehabilitation therapy and three times per week for 15 minutes, a total of 12 weeks of interactive cognitive training) and the control group (receiving rehabilitation therapy only). Therapeutic effects will be evaluated by an investigator blinded to the group's allocation before and after 12 weeks of treatment.|f|f|f|t
34116932|NCT02806414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116933|NCT06156150|||OTHER||OTHER|||||||
34042530|NCT02011633|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042531|NCT01188330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042532|NCT05976321|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042533|NCT02767466|||CASE_CROSSOVER||PROSPECTIVE|||||||
34042534|NCT00934336|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34042535|NCT01767246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042536|NCT03423173|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A double-blind study.||t|t|t|t
34116934|NCT05858931|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34116935|NCT06655740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116936|NCT05779930|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, unblinded, pilot treatment study||||
34116937|NCT00000684||||TREATMENT||NONE||||||
34116938|NCT04471311|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||THIS IS A CONTROLLED RANDOMIZED STUDY OF BINARY SUPERIORITY OUTCOME IN PARALLEL GROUPS. 302 PATIENTS ARE REQUIRED TO HAVE A 95% CHANCE OF DETECTING, AS SIGNIFICANT AT THE 5% LEVEL, A DECREASE IN THE PRIMARY OUTCOME MEASURE FROM 18% (INCISIONAL HERNIA RATE) IN THE CONTROL GROUP TO 5%(INCISIONAL HERNIA RATE) IN THE EXPERIMENTAL GROUP.|t|t|f|f
34116939|NCT02192957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116940|NCT02001246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116941|NCT02303262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116942|NCT03490994|RANDOMIZED|PARALLEL||TREATMENT||NONE||warfarin vs. rivaroxaban||||
34116943|NCT03880357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116944|NCT03249363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34116945|NCT04846595|NA|SINGLE_GROUP||OTHER||NONE||||||
33837019|NCT03445533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042537|NCT03478644|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|The dental examiner and dermatologist blinded for both treatment arms.||f|f|t|t
34042538|NCT02815332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34116946|NCT02266160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116947|NCT06146647|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Masking is not possible for the investigator due to the trial design and protocol for data collection.||t|t|f|t
34116948|NCT02750969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33729977|NCT05724849|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33729978|NCT03696524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The subjects and providers will not be blinded, since it will be apparent which patients received a pleurx catheter. Outcomes measured by survey and chart review will be scored and analyzed in a blinded fashion.|There will be an intervention group (receiving the tunneled pleural catheter) and a usual care group.|f|f|f|t
33729979|NCT06162286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33729980|NCT00446433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33729981|NCT03003975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33729982|NCT00479908|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33729983|NCT03974230|||COHORT||PROSPECTIVE|||||||
33729984|NCT04027166|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This within-subject study design will assess pain and cognitive performance in individuals with OUD engaged in MMT. Participants will be asked to complete two separate 4 hours sessions that will be spaced approximately 2-15 days apart. The two sessions will differ based on methadone administration to evaluate study variables in methadone peak (immediately after dose) and trough (20-24 hour after last dose) states.||||
33729985|NCT00881192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33729986|NCT03689361|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33729987|NCT05067933|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Double-Blind, Randomized (Part 2)|Open-label dose and age escalation lead in phase in naive and prior vaccinated subjects, followed by a multi-center, placebo-controlled efficacy phase.|t|t|t|f
33729988|NCT03624621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Codification of participants, assessor will never know what treatment arm participant was allocated|Randomized single-blind and controlled clinical trial|f|f|f|t
33729989|NCT06031571|RANDOMIZED|PARALLEL||TREATMENT||NONE||38 participants will be assigned at random into 2 equal groups: group A (will receive dry cupping massage technique in addition to traditional exercises for 3 sessions per week for 12 sessions), and group B (will receive myofascial release technique in addition to traditional exercises for 3 sessions per week for 12 sessions.||||
33729990|NCT00386256||PARALLEL||||NONE||||||
33729991|NCT04890392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729992|NCT00571129|RANDOMIZED|PARALLEL||TREATMENT||NONE||DCR with/ without tubes Revision DCR with/ without mitomycin||||
33729993|NCT02315235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33729994|NCT00131586|||CASE_ONLY||PROSPECTIVE|||||||
33729995|NCT03851016|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||A switching replication design was employed to examine the effects of the Life Story Book (LSB). Two comparable nursing homes were allocated to each intervention. Participants in each nursing home received the same intervention at the same time.||||
33729996|NCT06221228|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33729997|NCT04156815|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33729998|NCT01541930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33729999|NCT01307566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730000|NCT04078776|||COHORT||CROSS_SECTIONAL|||||||
33730001|NCT05668065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Simple-Blinded|Randomized simple-blinded comparative phase III clinical trial|t|f|f|f
33730002|NCT00874068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33730003|NCT04123496|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33730004|NCT03669445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730005|NCT02871128|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33730006|NCT02448875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730007|NCT01990677|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33730008|NCT02248090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730009|NCT01332136|||COHORT||PROSPECTIVE|||||||
33730010|NCT05992792|RANDOMIZED|PARALLEL||PREVENTION||NONE||Controlled Clinical Trial||||
33730011|NCT05715567|||COHORT||RETROSPECTIVE|||||||
33730012|NCT04503564|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This study is designed as a single arm device feasibility evaluation||||
33730013|NCT05735288|||COHORT||PROSPECTIVE|||||||
33730014|NCT00774631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730015|NCT04055727|||COHORT||RETROSPECTIVE|||||||
33730016|NCT02911675|||COHORT||PROSPECTIVE|||||||
33730017|NCT02072291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33730018|NCT05388942|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33730019|NCT00003256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730020|NCT04460222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730021|NCT01143090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730022|NCT02959281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730023|NCT03125512|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Research staff assessing the outcomes of the study, the scoring of the sleep studies, and data analyses will be blinded.|8-week randomized crossover trial with a 1 week washout period.|f|f|f|t
33730024|NCT04552938|||CASE_CONTROL||PROSPECTIVE|||||||
33730025|NCT02908724|||COHORT||RETROSPECTIVE|||||||
33730026|NCT00698269|||||PROSPECTIVE|||||||
33730027|NCT01384435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33730028|NCT04334460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730029|NCT01073865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810990|NCT02321956|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Sealed envelops were used. Ultrasonographers were masked with the group of patients. Participants were masked with the techniques of selecting endotracheal tubes. Care providers and outcome assessors were masked with the techniques of selecting. endotracheal tubes|randomized controlled trial|t|t|t|t
34116949|NCT06058416|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34116950|NCT05904717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810991|NCT06357455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33810992|NCT02188459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33810993|NCT04277494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116951|NCT00133133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116952|NCT02691156|||COHORT||PROSPECTIVE|||||||
33730030|NCT03266068|||CASE_CONTROL||PROSPECTIVE|||||||
33730031|NCT05321862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730032|NCT01108367|||COHORT||RETROSPECTIVE|||||||
33810994|NCT00578344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810995|NCT06301620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837020|NCT01855711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116953|NCT04883268|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are randomised to group by the online research system. The investigator does not know what group participants have been assigned to. Participants are aware whether they have been assigned to the intervention or comparison (waitlist) group.||f|f|t|f
34116954|NCT00003525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116955|NCT03276442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|In the crossover subgroup condition, participants will not be briefed about what diet they will receive before the actual onset of the dietary intervention|"Participants will be studied in a crossover design both after a healthy diet, and after an unhealthy diet"||||
34116956|NCT05046587|||COHORT||PROSPECTIVE|||||||
34116957|NCT04201535|||CASE_CONTROL||PROSPECTIVE|||||||
34116958|NCT04203472|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||In all patients cough severity and tolerance of therapy will be analyzed during therapy with budesonide and/ or formoterol administered by DPI and MDI used in turn. Order of using different types of inhalers will be accidental||||
34116959|NCT04214249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116960|NCT01329861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116961|NCT00399022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116962|NCT02953769|||COHORT||PROSPECTIVE|||||||
34116963|NCT04755647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Packaging will be generic, coded and indistinguishable from placebo.|This is a single-center, randomized, placebo controlled parallel group,clinical safety study comparing an investigational drug add-on to a placebo control. Up to 40 participants with mildly infected neuropathic or non-neuropathic or neuro-ischemic diabetic foot ulcers will be enrolled.|t|t|t|t
34116964|NCT06451588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A person will be responsible for the Randomization and Allocation (RAP) procedure, and will be the only person not blinded to randomization and treatment. This person will, however, be blinded for the patient´s identity.|A blinded, randomized, placebo-controlled, parallel-group, single-center, superiority, phase III clinical trial. Participants randomized til active treatment will receive FMT from one of three donors. Allocation will be random in blocks of 9 (Donor A: Donor B : Donor C : Placebo 2:2:2:3).|t|t|t|t
34116965|NCT06104345|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116966|NCT03136055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116967|NCT05013814|||CASE_CONTROL||PROSPECTIVE|||||||
34116968|NCT05093972|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116969|NCT01196715|RANDOMIZED|FACTORIAL||||NONE||||||
34116970|NCT00579644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116971|NCT04234893|||COHORT||PROSPECTIVE|||||||
34116972|NCT04252014|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention consists of brief hookah tobacco public education messages delivered online through 4 brief study communications. Messages will communicate about the risks of hookah tobacco use in the following theme areas: 1) Health Harms; 2) Addictiveness; 3) Social Use; 4) Flavorings. The order of message themes delivered in each study communication will be randomized.||||
34116973|NCT06635863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116974|NCT01563055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116975|NCT01599286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116976|NCT05982093|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study||||
34116977|NCT02017184|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34116978|NCT00699595|||COHORT||PROSPECTIVE|||||||
34116979|NCT01730430|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34116980|NCT00163098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34116981|NCT03891888|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient will not know if they are randomized to the control or intervention group|Participants will be randomized to either a treatment or control group.|t|f|f|f
34116982|NCT00786422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116983|NCT05470400|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34116984|NCT00043602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34116985|NCT04534673|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open label, 2 arm, pilot trial||||
34116986|NCT02112656|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34116987|NCT03304964|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|MAD part (Part 1) - double-blind; FE part (Part 2) - open-label|MAD part (Part 1) - sequential multiple ascending doses; FE part (Part 2) - crossover food effect after single dose administration|t|f|t|f
34116988|NCT04301830|||COHORT||PROSPECTIVE|||||||
34116989|NCT04076033|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34116990|NCT06081894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34116991|NCT02004158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116992|NCT05770284|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34116993|NCT05631847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34116994|NCT04017130|NA|SEQUENTIAL||OTHER||NONE||||||
34116995|NCT05472493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34116996|NCT04035031|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomised, placebo-controlled, open-label, cross over intervention study||||
33837021|NCT01054378||||TREATMENT||||||||
33837022|NCT02772939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34116997|NCT01084889|||OTHER||PROSPECTIVE|||||||
34116998|NCT02250248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34116999|NCT00359268|||OTHER||PROSPECTIVE|||||||
34117000|NCT03537443|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151104|NCT05643586|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Randomization assignment for each patient was kept in a sealed envelope. At least 12 hours before PCI, a study nurse not involved in the procedure was responsible of opening the sealed envelope and administering study drugs according to treatment allocation. Both the patient and the catheterization laboratory team (operator and scrubbed nurse) were blinded to the assigned treatment. The PCI procedures were performed by standard technique.|Patients were randomly assigned to receive loading doses of either ticagrelor (180 mg) or prasugrel (60 mg) at least 12 hours before intervention. Assignment to one of the two treatments was determined by a computer-based randomization system.|t|t|t|t
33730033|NCT06080152|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patient who is using a walker is randomized into two groups:~1. 12 patients get an A-linker 3 months before surgery (knee arthroplasty)~2. 12 patients use a walker 3 months before surgery (knee arthroplasty)~All 24 patients will undergo a total knee Arthroplasty surgery.~Questionnaires at:~0 week from randomization into two groups 6 weeks 12 weeks (surgery) 18 weeks"||||
33730034|NCT01088646|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE||To evaluate the safety and efficacy of an endoscopic capsule placement device.|f|f|t|f
33730035|NCT05927753|RANDOMIZED|PARALLEL||OTHER||NONE|Open label randomization assignment between test and control intervention.|Comparison of a test contact lens performance to a known, cleared for market contact lens.||||
33730036|NCT02809430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730037|NCT06226727|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730038|NCT02825069|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730039|NCT00075166||||TREATMENT||||||||
33730040|NCT04219865|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE||Factorial Assignment|t|t|t|f
33730041|NCT03726177|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|both participants and researchers will be blinded to the intervention given.|This will be a randomized control trial to estimate the efficacy of two doses (80 mg versus 160 mg) of aspirin for prevention of preeclampsia in High-Risk Pregnant Women identified in the first trimester to be at high risk.|t|t|t|t
33730042|NCT00247728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730043|NCT05039346|||CASE_ONLY||PROSPECTIVE|||||||
33730044|NCT04223882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33730045|NCT03950128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730046|NCT02103829|RANDOMIZED|FACTORIAL||||NONE||||||
33837023|NCT04490577|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The 36 healthy participants divided into three groups.||||
33837024|NCT04393311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117001|NCT03985202|NA|SINGLE_GROUP||TREATMENT||NONE||"Non-randomised interventional observational study. Pilot study. 60 patients to be recruited from the Torbay AAA screening programme and AAA surveillance group over a two-year period.~Cardiopulmonary exercise test and survival prediction when AAA reaches 4.5 cm. (Current clinical practice).~9 week structured exercise programme. 3 sessions per week. (Intervention). Repeat cardiopulmonary exercise test and survival prediction after structured exercise programme. Advice given for on going exercise and maintenance of fitness. (Intervention).~Repeat cardiopulmonary exercise test and survival prediction after 3 months after structured exercise programme. (Intervention).~Pateitns are asked to complete the following questionnaires:- EQ-5D-5L and Hospital Anxiety and Depression Scale (HADS) before, after the last exercise session and 3 months after the exercise programme. Change in medical or drug history. Change in weight or smoking."||||
34117002|NCT01468545|||CASE_CONTROL||PROSPECTIVE|||||||
34117003|NCT05111067|||COHORT||PROSPECTIVE|||||||
34117004|NCT01855386|||CASE_CONTROL||PROSPECTIVE|||||||
34117005|NCT02020161|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117006|NCT05189665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117007|NCT04635852|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117008|NCT00973440|||CASE_ONLY||PROSPECTIVE|||||||
34117009|NCT02190500|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Alternating week assignment to groups. Entry criteria adjudicated by masked investigator. Primary outcome also by masked investigator.||f|f|f|t
34117010|NCT05401981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will randomly be assigned to 2 groups of intervention (The clinician receives the check list) and control (The clinician doesn't receive a checklist). After the visit patients will answer to questionnaires .|Parallel Assignment|t|f|f|t
34117011|NCT04931238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117012|NCT00952926|||CASE_ONLY||PROSPECTIVE|||||||
34117013|NCT01871649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117014|NCT05617261|||COHORT||PROSPECTIVE|||||||
34117015|NCT03549962|||CASE_ONLY||RETROSPECTIVE|||||||
34117016|NCT02036346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34117017|NCT01761578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117018|NCT04539171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Quasi-experimental, controlled, non-randomized study||||
34117019|NCT00876447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117020|NCT01179230|||COHORT||PROSPECTIVE|||||||
34117021|NCT05387746|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34117022|NCT01752803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117023|NCT01814982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117024|NCT00365807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117025|NCT03047135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117026|NCT00365950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117027|NCT01061528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117028|NCT03666390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||0.5mg/kg vs. active placebo (0.045mg/kg Midazolam)|t|t|t|t
34117029|NCT02220634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117030|NCT05135728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117031|NCT06405633|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117032|NCT03162432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117033|NCT02108288|RANDOMIZED|PARALLEL||||NONE||||||
34117034|NCT05768594|||CASE_CONTROL||PROSPECTIVE|||||||
34117035|NCT00665834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117036|NCT04897022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117037|NCT06278493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117038|NCT02725463|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34117039|NCT02651545|||CASE_CONTROL||PROSPECTIVE|||||||
34117040|NCT03319576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117041|NCT01942109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117042|NCT00114348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117043|NCT01395134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117044|NCT05955339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients will be randomly allocated to NOTES or NOTES+AUDIO using a block randomization technique with the clinician acting as the blocking variable. This strategy will ensure an equal number of patients per clinician will be randomly assigned to each study arm.||||
33730047|NCT04257812|||CASE_ONLY||PROSPECTIVE|||||||
33730048|NCT02318693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730049|NCT02794272|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33730050|NCT01112293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730051|NCT04022135|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33730052|NCT04377607|||OTHER||RETROSPECTIVE|||||||
33730053|NCT03921060|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33730054|NCT02412592|||COHORT||PROSPECTIVE|||||||
33730055|NCT01095588|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33730056|NCT02866838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730057|NCT04792112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Controlled before and after study||||
33730058|NCT01195805|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33730059|NCT03584269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730060|NCT00271479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33730061|NCT05958485|||CASE_CROSSOVER||PROSPECTIVE|||||||
33730062|NCT00706836|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33730063|NCT03711162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730064|NCT04124107|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730065|NCT04066426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730066|NCT03650010|||CASE_CONTROL||OTHER|||||||
33730067|NCT02437565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730068|NCT01336686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730069|NCT01335958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730070|NCT04874337|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33730071|NCT00262548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33730072|NCT04345952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730073|NCT03534856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730074|NCT02012127|||COHORT||RETROSPECTIVE|||||||
33810996|NCT03956407|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|An amendment for performance of a minimization procedure in order to enhance the probability of comparable characteristics between the groups was approved. The researcher responsible for minimization is not involved in data collection or analysis.||t|t|f|t
33810997|NCT03310255|||COHORT||PROSPECTIVE|||||||
33810998|NCT02159794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33810999|NCT01056159|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33811000|NCT01419184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811001|NCT05615285|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Implementation study designed to operate closely to clinical practice: no masking appropriate or required.|A feasibility and implementation study of the PERCS triage and referral system. Participants are triaged into one of three groups, but the outcomes of the groups will not be compared from an intervention perspective. The system will be evaluated as a whole.||||
33811002|NCT04195789|||CASE_ONLY||PROSPECTIVE|||||||
33811003|NCT02439099|||CASE_CONTROL||PROSPECTIVE|||||||
33811004|NCT01648114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811005|NCT02016144|||CASE_ONLY||PROSPECTIVE|||||||
33811006|NCT05967845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811007|NCT00135278|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811008|NCT02614157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811009|NCT03187548|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811010|NCT03191448|NA|SINGLE_GROUP||OTHER||NONE||This study will document the use of standard care treatment using FDA approved material used in an FDA approved fashion.||||
33811011|NCT04994093|||CASE_ONLY||CROSS_SECTIONAL|||||||
33811012|NCT01269307|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33811013|NCT05894291|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811014|NCT01728298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730075|NCT01857063|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33730076|NCT00882531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730077|NCT00556855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730078|NCT05973916|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33730079|NCT03742141|NA|SINGLE_GROUP||OTHER||NONE||All patients enrolled in the study will be in a single group.||||
33730080|NCT04116710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730081|NCT03167762|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33730082|NCT02705690|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730083|NCT00651521|||COHORT||RETROSPECTIVE|||||||
33730084|NCT06267612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730085|NCT00994331|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730086|NCT02213211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730087|NCT04594395|||COHORT||PROSPECTIVE|||||||
33730088|NCT01403038|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33730089|NCT02153866|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33730090|NCT02980965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730091|NCT02449239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730092|NCT01920815|||COHORT||PROSPECTIVE|||||||
33730093|NCT02848976|||COHORT||PROSPECTIVE|||||||
33730094|NCT00515307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730095|NCT05370664|||COHORT||PROSPECTIVE|||||||
33730096|NCT00832351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730097|NCT03301324|||COHORT||PROSPECTIVE|||||||
33730098|NCT02777125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730099|NCT04985981|||OTHER||OTHER|||||||
33730100|NCT04242108|||OTHER||RETROSPECTIVE|||||||
33811015|NCT02099409|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811016|NCT06153784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811017|NCT01999335|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33811018|NCT06434584|||OTHER||OTHER|||||||
33811019|NCT05819268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The PI, statistician and data manger will be blinded to treatment.|Children with FS will be enrolled and randomized to either ReACT or CATCH-IT therapies|f|f|t|f
33837025|NCT00540033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33839229|NCT00214695|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33730101|NCT01050738|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730102|NCT06344819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811020|NCT04024982|RANDOMIZED|CROSSOVER||OTHER||NONE||"The TEE session will consist of a 1-hour lecture and a 2-hour simulation session. Participants for the TEE session are divided into 2 groups. Trainee participants are randomly divided into groups A and B. The specialists are also randomly divided into groups C and D. Groups A and C undergo lecture first then simulation, whereas B and D undergo simulation first then lecture.~Prior to the teaching session (lecture or simulation), the participants will take a MCQ pre-test with 30 questions relating to TEE safety, probe manipulation and basic views in TEE. There is no pre-test on technical skill, as all of them are novices to TEE (i.e. with no skill on TEE). A post-test consisting of 30 MCQs (same as pre-test but in a different sequence) and a technical skill test is held at the completion of both lecture and simulation sessions."||||
33811021|NCT05397509|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|olive leaf tea and placebo tea were offered in a opaque mug|"Each participant will test one beverage on the first visit and the other one on the second visit. A wash-out period of two weeks will be done.~Allocation of the first beverage to each participant is made by randomization."|t|t|f|t
33811022|NCT04707820|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33837026|NCT05397847|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33839230|NCT00132899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117045|NCT02712788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117046|NCT04976777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117047|NCT04627714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117048|NCT04549467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117049|NCT04490681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Due to the nature of randomized study, it will be masked to all participants, care providers, investigators, and outcomes assessors.||t|t|t|t
34117050|NCT00251433|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117051|NCT02394561|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arms represent stratification of Cw6 positive and Cw6 negative patients||||
34117052|NCT04876911|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Multiple Baseline Single Case Experimental Design (SCED) of two phases.||||
34117053|NCT04423432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34117054|NCT04518137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117055|NCT02007629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117056|NCT03281057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cluster randomization Clinical trial with 3 arms - individual, group, and self-help intervention.|t|f|f|f
34117057|NCT05392816|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Meals are served from identical plastic boxes. Participants are served the meals in a separate room from preparation||t|f|f|f
34117058|NCT01078077|||CASE_CONTROL||PROSPECTIVE|||||||
34117059|NCT03067181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117060|NCT04476992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117061|NCT05223673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117062|NCT02146157|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34117063|NCT03730519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a post-marketing open label twin arm, single centre clinical trial of electrical carotid sinus stimulation with the Barostim Neo device to target sub-optimally controlled arterial hypertension or highly variable blood pressure in patients for whom no alternative therapies are available.||||
34117064|NCT02998190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117065|NCT05973643|NA|SINGLE_GROUP||TREATMENT||NONE||simple-blind, any adult patient presenting a characterized depressive episode in the context of unipolar major depressive disorder or bipolar disorder who consents and requires an ECT treatment. study including 50 patients.||||
34117066|NCT00056823|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117067|NCT01617902|||COHORT||PROSPECTIVE|||||||
34117068|NCT03641287|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34117069|NCT01256255|||COHORT||PROSPECTIVE|||||||
34117070|NCT05739448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117071|NCT04415554|||CASE_CONTROL||PROSPECTIVE|||||||
34117072|NCT00668629|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117073|NCT04212663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117074|NCT04972279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34117075|NCT06228950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind, neither the participant nor the investigator know what they are getting|A randomized controlled trial (RCT) design will be used in this interventional study to evaluate the effectiveness of mindfulness-based intervention for emotional and behavioral problems of students with visual impairment. Participants in RCT will be randomized in the intervention and the control group. Urdu-translated and adaptive mindfulness-based intervention that is MBSR designed specifically to meet the needs of students with visual impairment will be given to the intervention group. The MBSR training program consisted of 8-week group sessions with a duration of 50 to 90 minutes each for a group of 5-8 members. The intervention will include a body scan, sitting meditation, yoga, breathing exercises, guided mindfulness exercises, loving kindness etc to improve emotional and behavioral problems. Standardized measures will be used to evaluate changes in pre and post-intervention.|t|f|t|f
34117076|NCT03213509|||COHORT||RETROSPECTIVE|||||||
34117077|NCT02299245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117078|NCT04419246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117079|NCT04224519|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117080|NCT00462826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117081|NCT05751577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|TRACS is an all-comer, prospective, randomized, multicenter, open-label trial with blinded adjudicated evaluation of outcomes (PROBE)||f|f|f|t
33730103|NCT01435291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730104|NCT03907683|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33730105|NCT00842348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730106|NCT00164242|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33730107|NCT01914224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730108|NCT01505686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730109|NCT01544530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730110|NCT00003681||||TREATMENT||||||||
34042539|NCT03115437|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be stratified according to their sex since body mass depends on sex. Two pre-established randomization list (block size = 40) will be prepared by a statistician not involved in any other part of the study before the beginning of the study. To ensure allocation concealment, the study groups as well as the shoes will be coded and the randomization lists will be uploaded in the TIPPS system by an IT specialist who will not be involved in any other part of the study. The TIPPS system will provide the investigator with a study group code for each participant, according to the randomization lists. The investigator will upload the shoe ID according to shoe size and study group so that a cross validation will be performed by the TIPPS system. The investigators in charge of the recruitment, follow-up and data validity check, as well as the participants, will be blinded regarding the shoe version distributed. The shoe code will be broken after completion of data analysis.||t|t|t|t
34042540|NCT04075214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042541|NCT01741688|||COHORT||PROSPECTIVE|||||||
34042542|NCT05220449|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Double (Participant \& Investigator)||f|f|t|f
34042543|NCT02821754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042544|NCT05958628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessment will be performed by a investigator who was blinded to group allocation.|Two groups; one group will receive conventional physiotherapy and one group will be operated with robotic hand exoskeleton system in addition to conventional physiotherapy.|f|f|f|t
34042545|NCT06155955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042546|NCT00457197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042547|NCT03834688|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Single-Arm Study, Cycle 1 Dose Escalation||||
34042548|NCT06297018|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Experimental|Interventional Crossover Assignment|t|t|t|t
34042549|NCT06576518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042550|NCT00542009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042551|NCT02110303|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042552|NCT05647564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34042553|NCT05284318|||COHORT||PROSPECTIVE|||||||
34042554|NCT06231888|||OTHER||CROSS_SECTIONAL|||||||
34042555|NCT01405339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042556|NCT06576245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042557|NCT06578208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||The study included 62 people diagnosed with mechanical low back pain. These 62 people were divided into two groups as male group (n=31) and female group (n=32). Spinal manipulation was performed in the side lying position twice a week for a total of 4 weeks. The evaluation methods were repeated 3 times: at the beginning, at the end and 1 month after the end of the treatment. The study used various statistical techniques to evaluate data, including Shapiro-Wilks test, Student's t test, Mann Whitney U test, repeated measures analysis of variance, Bonferroni test, Friedman's test, Wilcoxon sign test, Wilcoxon Signed Ranks test, and Chi-square test. These tests were used to compare normally distributed and non-normally distributed parameters, as well as within-group comparisons of parameters, and to determine the period causing the difference. Significance was evaluated at a p\<0.05 level.|t|f|f|t
34042558|NCT02391415|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34042559|NCT04668495|||COHORT||PROSPECTIVE|||||||
34042560|NCT03337087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042561|NCT03782753|||CASE_CONTROL||OTHER|||||||
34042562|NCT02682693|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34042563|NCT06485050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042564|NCT02170974|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042565|NCT01489436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34042566|NCT05753020|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34042567|NCT06067906|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042568|NCT05747326|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|This study was a prospective, single-arm, open-label phase II clinical trial conducted at National cancer center in China. The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.||||
34042569|NCT01690858|||CASE_CONTROL||PROSPECTIVE|||||||
34042570|NCT03194971|||OTHER||RETROSPECTIVE|||||||
34042571|NCT00904358|||COHORT||PROSPECTIVE|||||||
34042572|NCT00156585|||CASE_ONLY||PROSPECTIVE|||||||
34042573|NCT04305457|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study includes a randomized, parallel arm clinical trial in which subjects will be randomized to receive either inhaled nitric oxide (in addition to the standard of care) or the standard of care alone.~In a third arm, COVID-19 subjects will be enrolled at Providence HealthCare Network, Anchorage (AK). Subjects in this arm will not be randomized and will all receive nitric oxide gas either as an inpatient or outpatient."||||
34042574|NCT03469635|||COHORT||RETROSPECTIVE|||||||
34042575|NCT03793114|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34042576|NCT00927862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042577|NCT05034211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042578|NCT06393309|||COHORT||RETROSPECTIVE|||||||
34042579|NCT06578403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1:1|f|f|f|t
34042580|NCT02541513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117082|NCT06173869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151105|NCT06104956|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33730111|NCT04185233|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized clinical trial|f|f|t|t
34151106|NCT02526251|||COHORT||PROSPECTIVE|||||||
33730112|NCT00739752|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||2 X 3 Factorial Design|t|f|t|t
33730113|NCT04733963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730114|NCT00983216|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730115|NCT02347566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730116|NCT05702164|||COHORT||PROSPECTIVE|||||||
33730117|NCT00664716|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33730118|NCT01397175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||BES EES ZES-R|t|f|f|f
33730119|NCT01515969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730120|NCT03323528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|investigation: participant, care provider and investigator blinded assessment: participant, care provider and investigator blinded outcome analysis: statistician blinded|randomized allocation of participants to verum or placebo (1:1)|t|t|t|t
33811023|NCT05904652|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants will be randomised in a 1:1 manner using a computer-generated 30 number sequence of '1s' and '2s' from https://www.random.org/ between 1) SAFEx treatment and 2) standard care. A clinician, not involved in the study, will obtain this 30 number sequence and conceal its order within 30 sealed, opaque, numbered envelopes. The investigators will be blinded to the participant's allocation until they have been enrolled in the study, after which the next envelope in the sequence will be opened and treatment allocation will be unblinded.|Participants will be randomised in a 1:1 manner between two treatments at time of extubation: SAFEx treatment or standard care.||||
34042581|NCT06574750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042582|NCT00175149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730121|NCT05357872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730122|NCT02040181|||||RETROSPECTIVE|||||||
33730123|NCT01679275|||COHORT||PROSPECTIVE|||||||
33730124|NCT03080961|NA|SINGLE_GROUP||PREVENTION||NONE|Vials with the sample will be coded. The assessor does not know the coding.|Trial participants take extra-genital swabs before and after application of the barrier cream.||||
33730125|NCT04322396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042583|NCT03512054|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34042584|NCT02840123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042585|NCT03355131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042586|NCT05390775|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34042587|NCT02203227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042588|NCT05832684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042589|NCT05772949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessor(s) of the follow-up outcomes and the research analysts will not be involved in the recruitment and intervention delivery and will be blinded to the group allocation (single blindness).|Participants will be individually randomized to experimental group to use the smart hearing aids from week 1 to week 6, or wait-list control group to follow existing practice (i.e. using no hearing aids or using hearing aids other than the smart hearing aids) from week 1 to week 6 and use the smart hearing aids from week 8 to week 14. A list of random numbers will be generated to create a list of random group allocation (either experimental or wait-list control; allocation ratio 1:1), using the rand function of Excel. The research staff will perform the randomization procedure, by assigning consenting participants who meet all eligibility criteria to the two groups using the list.|f|f|f|t
34042590|NCT04786860|||CASE_ONLY||RETROSPECTIVE|||||||
34042591|NCT05905315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042592|NCT01541332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042593|NCT06336902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042594|NCT03497520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042595|NCT01371695|||CASE_CONTROL||PROSPECTIVE|||||||
34042596|NCT05172284|||CASE_ONLY||PROSPECTIVE|||||||
34042597|NCT02483650|||OTHER||PROSPECTIVE|||||||
34042598|NCT02012361|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042599|NCT00931528|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34042600|NCT03653962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042601|NCT02915731|||COHORT||PROSPECTIVE|||||||
34042602|NCT03693183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042603|NCT00997373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042604|NCT04445038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042605|NCT05858580|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data collectors will be blinded to the participant's assigned group.|Participants will be randomized 1:1 in blocks of 6 to the intervention or control groups with the Randomization Module of the Research Data Capture (REDCap).|f|f|f|t
34042606|NCT00343044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042607|NCT03617380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042608|NCT06335381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The Principal Investigator and Biostatistician will be masked.|Participants will be assigned to one of two groups in parallel for the duration of the study.|f|f|t|f
34042609|NCT02034734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042610|NCT00011141|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34042611|NCT05129865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Parts 1, 2 and 3 are double blind during the data collection. Determination for dose escalation may be made under unblinded conditions by assessors.~Part 4 consists of 2 groups. Group 1 (the validation group) will be single-arm placebo. Group 2 (the test group) will be double blind during data collection."|Part 1 consists of 1 Arm with crossover of active treatment and placebo; Part 2 consists of 1 Arm with active treatment; Part 3 consists of 4 Arms with active treatment or placebo; Part 4 consists of 2 arms with active or placebo.|t|f|t|f
34042612|NCT04390503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 150 eligible subjects will be randomized in a 2:1 ratio to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%)|t|f|f|t
34042613|NCT03367182|||COHORT||RETROSPECTIVE|||||||
34042614|NCT01623310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042615|NCT04301869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042616|NCT05481697|NA|SINGLE_GROUP||SCREENING||NONE||||||
34042617|NCT06048861|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34042618|NCT02380833|RANDOMIZED|FACTORIAL||||NONE||||||
34117083|NCT03822026|NA|SINGLE_GROUP||TREATMENT||NONE||several parameters are collected at different time points: at baseline conditions, during moderate hyperventilation, and after return to baseline||||
34117084|NCT01212900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33730126|NCT03618264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33730127|NCT02692677|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33811024|NCT03400007|||COHORT||PROSPECTIVE|||||||
33811025|NCT04202822|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33811026|NCT06114290|||OTHER||PROSPECTIVE|||||||
34042619|NCT06101797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be implemented by the outcome assessor. All measurements (PROMs, muscle architecture, and functional outcomes) will be conducted by an evaluator blinded to the participant's group. Due to the nature of the intervention, investigators conducting the exercise intervention and participants will not be able to be blinded.|This study is a non-inferiority randomized clinical trial with two parallel groups in a single center with blinding of outcome assessors. Patients, males, and females with symptomatic and radiographic knee OA will be allocated to supervised in-person or remote exercise groups based on a stratified randomization method, considering the baseline outcome age (in the categories of participants aged 45 to 54 years old or 55 to 80 years old). A single independent researcher assistant will carry out randomization with a 1:1 ratio.|f|f|f|t
34042620|NCT03461484|||COHORT||PROSPECTIVE|||||||
34117085|NCT04561856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34042621|NCT02892890|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042622|NCT03963232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042623|NCT01599260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042624|NCT05796219|NA|SINGLE_GROUP||SCREENING||NONE||The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.||||
34042625|NCT00735969|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042626|NCT00264719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042627|NCT02412163|||CASE_ONLY||PROSPECTIVE|||||||
34042628|NCT05976997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042629|NCT00684320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042630|NCT04124211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042631|NCT05836727|||COHORT||RETROSPECTIVE|||||||
34042632|NCT05446857|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
34042633|NCT02890576|||COHORT||PROSPECTIVE|||||||
34042634|NCT00940615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042635|NCT01346059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34042636|NCT00552643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117086|NCT05598814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Nasal Polyp Score (NPS) evaluation will be performed by a third surgeon (blinded evaluation) who will not know the results of the screening visit and FESS/non-FESS randomisation.|The study is a randomized clinical trial with two arms. Arm 1: Biologic treatment with Mepolizumab every month combined with Arm 2: Only biologic treatment with Mepolizumab every month combined with Functional Endoscopic Sinus Surgery (FESS) 2 weeks after the first injection of Mepolizumab.|f|f|f|t
34117087|NCT04443114|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34117088|NCT03782415|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 1b/2a Single-center, Open-label, Dose-escalation study followed by a fixed-dose study to evaluate the safety, tolerability, and preliminary efficacy of MN-166 plus temozolomide in patients with newly diagnosed or recurrent glioblastoma.||||
34117089|NCT02563327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117090|NCT01020357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117091|NCT04667689|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117092|NCT00410579|||COHORT|||||||||
34117093|NCT00158678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117094|NCT01862757|||||PROSPECTIVE|||||||
34117095|NCT03218969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|placebo||t|f|t|f
34117096|NCT01263119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117097|NCT00740181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117098|NCT05903534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both groups about their treatment|Its a randomized control trial, used to evaluate the comparative effects of pediatric endurance and limb strengthening program with lower limb strength training in diplegic cerebral palsy. Subjects with diplegic cerebral palsy (GMFCS level 1-11) meeting the predetermined inclusion and exclusion criteria will be divided into two groups using simple random sampling technique|t|f|f|f
34117099|NCT00138684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117100|NCT01766102|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34117101|NCT04348474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117102|NCT06438289|||COHORT||PROSPECTIVE|||||||
34117103|NCT02145936|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34117104|NCT01762865|||CASE_ONLY||PROSPECTIVE|||||||
34117105|NCT06278454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117106|NCT04577781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117107|NCT06544070|||CASE_ONLY||CROSS_SECTIONAL|||||||
33730128|NCT04270825|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive a novel treatment for hoarding disorder.||||
33730129|NCT04065789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042637|NCT00395005|||NATURAL_HISTORY||RETROSPECTIVE|||||||
33730130|NCT05245422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33730131|NCT00499096|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33730132|NCT01052545|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33730133|NCT04269967|||CASE_CONTROL||PROSPECTIVE|||||||
33730134|NCT04560634|||CASE_CONTROL||PROSPECTIVE|||||||
33730135|NCT05983497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Due to the nature of the study educational intervention, the subjects and investigators are not masked. However, the outcome assessors are marked for analysis.|"This study uses a prospective, parallel group, randomized control group design to compare those received self-care skill educational intervention and the control group (no kind of intervention) among clinical nurses.~The samples will be divided into experimental and control groups by randomly assigning the subjects to each group."|f|f|f|t
33730136|NCT01637350|||CASE_CONTROL||PROSPECTIVE|||||||
33730137|NCT04206293|NA|SINGLE_GROUP||OTHER||NONE||||||
33730138|NCT02203812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730139|NCT03026621|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33730140|NCT02620098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730141|NCT00799968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730142|NCT05193474|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33730143|NCT02334228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34117108|NCT01688297|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730144|NCT04023877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042638|NCT04689035|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33730145|NCT01569529|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33730146|NCT05878548|NA|SINGLE_GROUP||TREATMENT||NONE||fixation with Wagner technique||||
33730147|NCT01433432|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730148|NCT04254614|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This is a cohort study with assessments at baseline and after implementation of the mobile application. The study period will cover 6-12 months.||||
33811027|NCT05370924|||COHORT||RETROSPECTIVE|||||||
33811028|NCT03971552|||OTHER||RETROSPECTIVE|||||||
33811029|NCT02070172|||||PROSPECTIVE|||||||
33811030|NCT02279732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042639|NCT04848051|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34042640|NCT00083759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34042641|NCT06266195|||COHORT||PROSPECTIVE|||||||
34042642|NCT05831163|||CASE_CROSSOVER||PROSPECTIVE|||||||
34042643|NCT02909335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042644|NCT06172712|||COHORT||PROSPECTIVE|||||||
34042645|NCT04305639|||COHORT||PROSPECTIVE|||||||
34042646|NCT02264626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042647|NCT05235412|||COHORT||PROSPECTIVE|||||||
34042648|NCT00912743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042649|NCT04290221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34117109|NCT02895217|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34117110|NCT02672995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117111|NCT00006379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117112|NCT00730886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117113|NCT01526200|||COHORT||RETROSPECTIVE|||||||
34117114|NCT04179617|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34117115|NCT00006021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117116|NCT01252680|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34117117|NCT05442645|||OTHER||OTHER|||||||
34117118|NCT02235324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117119|NCT05792748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117120|NCT00048984|||||PROSPECTIVE|||||||
34117121|NCT02081586|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117122|NCT01092221|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117123|NCT02180789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117124|NCT03508050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"Just before induction of anesthesia and according to the computerized randomization list generated by the statistical department, each of the 30 patients is allocated to one of the following groups:~Control group : OLV with the specific lumen of the NVL opened to ambient air. Experimental group : OLV with a clamp on the specific lumen of the NVL"|t|t|f|t
34117125|NCT01425814|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34117126|NCT01428791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117127|NCT01967745|||COHORT||CROSS_SECTIONAL|||||||
34117128|NCT05532969|||COHORT||PROSPECTIVE|||||||
34117129|NCT03767049|||COHORT||PROSPECTIVE|||||||
34117130|NCT00251108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34117131|NCT04705805|||COHORT||PROSPECTIVE|||||||
34117132|NCT03559270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117133|NCT03825679|||COHORT||PROSPECTIVE|||||||
34117134|NCT03857776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117135|NCT04068922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117136|NCT04312633|||COHORT||PROSPECTIVE|||||||
34117137|NCT02916264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34117138|NCT00865748|RANDOMIZED|CROSSOVER||||NONE||||||
34117139|NCT06426979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were divided into 2 Groups as the group titles were printed into cards that were enclosed in sealed envelopes and patients were asked to choose a closed envelop.||t|f|f|f
34117140|NCT03040206|||COHORT||RETROSPECTIVE|||||||
34117141|NCT01912014|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34117142|NCT01673126|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34117143|NCT06560333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730149|NCT06331793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|Randomization 1:1|t|f|t|f
33730150|NCT00950534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730151|NCT03365674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730152|NCT04655716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730153|NCT03904706|RANDOMIZED|PARALLEL||OTHER||SINGLE|Health facilities (clusters) will be the units of randomization. Within each stratum, health facilities will be randomly allocated to one of the three arms. Arm 1: includes morbidity and mortality health facility audits-only; arm 2: includes morbidity and mortality health facility audits in addition to community-engagement; and arm 3: will serve as the control arm and collect outcome data only.|This will be a three-arm cluster randomized controlled study to evaluate a novel intervention. Each facility is a cluster and includes all deliveries (including stillbirths and live births) in health facilities and respective catchment areas that provide obstetric and post-natal services.|t|f|f|f
33730154|NCT01914484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730155|NCT02409836|RANDOMIZED|CROSSOVER||||NONE||||||
33730156|NCT03007394|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730157|NCT00014365||||TREATMENT||||||||
33730158|NCT02818595|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33730159|NCT03023488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730160|NCT05572619|||CASE_CROSSOVER||OTHER|||||||
33730161|NCT00002882|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730162|NCT01233336|||COHORT||PROSPECTIVE|||||||
33730163|NCT00838565|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34117144|NCT03778801|||COHORT||CROSS_SECTIONAL|||||||
34117145|NCT00529633|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34117146|NCT00284635|RANDOMIZED|PARALLEL||||NONE||||||
33730164|NCT01387321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730165|NCT01346267|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33730166|NCT03884777|||COHORT||RETROSPECTIVE|||||||
33730167|NCT04415099|NA|SINGLE_GROUP||SCREENING||NONE||||||
33730168|NCT06442735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042650|NCT06092788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730169|NCT05005390|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33730170|NCT03010410|||COHORT||PROSPECTIVE|||||||
33730171|NCT05658744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinding of patient||t|f|f|f
33730172|NCT04106310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The dialyzer used will be covered||t|f|f|f
34042651|NCT05245526|NA|SINGLE_GROUP||OTHER||NONE||||||
33730173|NCT00581958|||COHORT||PROSPECTIVE|||||||
33730174|NCT02346136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33730175|NCT06197568|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is open-label. Randomization and blinding procedures will not be used.|Subjects will be enrolled into five cohorts (n=7/cohort).||||
33730176|NCT02994862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730177|NCT03166280|||OTHER||CROSS_SECTIONAL|||||||
33730178|NCT00041431|RANDOMIZED|||||DOUBLE||||||
33730179|NCT04844554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730180|NCT00414388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042652|NCT05841563|NA|SEQUENTIAL||TREATMENT||NONE||||||
33730181|NCT01091792|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730182|NCT04952220|||COHORT||PROSPECTIVE|||||||
33730183|NCT04499079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811031|NCT03453645|||CASE_ONLY||PROSPECTIVE|||||||
33811032|NCT03183804|||CASE_ONLY||PROSPECTIVE|||||||
33811033|NCT00126867|||COHORT||PROSPECTIVE|||||||
33811034|NCT02024503|||CASE_CONTROL||PROSPECTIVE|||||||
33811035|NCT04789174|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33811036|NCT02086461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811037|NCT05799534|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after intervention program||||
33811038|NCT06358794|||COHORT||RETROSPECTIVE|||||||
33811039|NCT01095536|||COHORT||PROSPECTIVE|||||||
33811040|NCT02072109|||CASE_CROSSOVER||PROSPECTIVE|||||||
33811041|NCT05469516|NA|SEQUENTIAL||TREATMENT||NONE|• Blinded assessment of aesthetic improvement at each visit as follows: Blinded reviewer to make qualitative comparisons of images of treated arms vs. baseline at each follow-up visit. If the reviewer perceived an improvement, he/she ask will be asked to select the correct post-treatment photograph|"This is a single centre prospective pilot study to evaluate the efficacy of combining MFU-V and diluted CaHA for improving skin quality on the lower face.~Treatment protocols are as follows:~1. MFU-V delivered to the lower face areas as drawn using a single transducer with a focal depth of 1.5mm (following a previously published paper (Lowe, 2021) but with extension of the lower treatment area to the two-ruler width (Ulthera marking ruler) as treatment zones. Application will be delivered through a cross-hatching technique.~2. Immediately following MFU-V or up to a week after, diluted CaHA will be administered following the Global Consensus Guidelines published in 2018 by de Almeida et al as follows 1) 1 syringe or 1.5ml of CaHA diluted 1:1 with saline for a total of 3ml of solution or 1.5 diluted CaHA per side will be injected in the subdermal plane with a cannula using a retrograde fanning technique."||||
33811042|NCT04307056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811043|NCT05866354|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811044|NCT04249440|||CASE_CONTROL||PROSPECTIVE|||||||
33811045|NCT04728191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811046|NCT01573559|||||CROSS_SECTIONAL|||||||
33811047|NCT02929758|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34042653|NCT03160690|||COHORT||PROSPECTIVE|||||||
34042654|NCT02901210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042655|NCT01591135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042656|NCT04335890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042657|NCT00529620|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811048|NCT01274507|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042658|NCT05106140|||COHORT||PROSPECTIVE|||||||
34042659|NCT04607564|NA|SINGLE_GROUP||OTHER||NONE||This is a pilot and feasibility study where sites are conveniently selected and the recruitment of participants is by invitation and non-randomised. All participants will receive the Ntombi Vimbela intervention.||||
34042660|NCT04010760|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34042661|NCT02557282|||CASE_ONLY||RETROSPECTIVE|||||||
34042662|NCT00873392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042663|NCT00674648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042664|NCT00880113|||COHORT||PROSPECTIVE|||||||
33730184|NCT02190799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730185|NCT01469286|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33730186|NCT04736238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33730187|NCT01290848|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730188|NCT00531843|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730189|NCT00180856|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730190|NCT00157378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33730191|NCT01538186|||COHORT||RETROSPECTIVE|||||||
33730192|NCT04675320|||COHORT||PROSPECTIVE|||||||
33730193|NCT04796831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730194|NCT02976896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730195|NCT04400279|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|PI will be blind to the allocation to the groups. Person sending out emails to participants to complete surveys will be blind to group allocation.||f|f|t|t
33730196|NCT02423941|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33730197|NCT05918367|||COHORT||PROSPECTIVE|||||||
33730198|NCT00393679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730199|NCT03455465|||COHORT||PROSPECTIVE|||||||
33811049|NCT00980616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811050|NCT03994809|||CASE_ONLY||CROSS_SECTIONAL|||||||
33811051|NCT01571947|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33811052|NCT00690079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811053|NCT01111812|||COHORT||PROSPECTIVE|||||||
33811054|NCT05559697|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Clinician research performing skin assessment masked from knee assignment to two interventions. Before the assessment, a separate clinician will remove the dressings and perform other measurements. The investigator performing data analysis will not know group assignment until unblinding.|Healthy human knees are prepped as if for total knee replacement. Incisional negative pressure dressings are applied to both knees.|f|f|t|t
33811055|NCT05474950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811056|NCT03770897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117147|NCT03262961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|- It's a double blinded, randomized, placebo-controlled trial.|- Double blinded, randomized, placebo-controlled trial.|t|t|t|t
33811057|NCT03102632|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The radiologist measuring kidney volumes will be masked to the study condition.|Participants will have a period of usual fluid intake and a period of increased water intake over the course of the study.|f|f|f|t
34117148|NCT04857060|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33811058|NCT05694832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811059|NCT02279485|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34117149|NCT04304560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||RCT|t|t|f|f
33811060|NCT02766361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33811061|NCT05371899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117150|NCT00097630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34117151|NCT03398330|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34117152|NCT04009148|||FAMILY_BASED||PROSPECTIVE|||||||
34117153|NCT06087380|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34117154|NCT00943644|||CASE_ONLY||PROSPECTIVE|||||||
34117155|NCT02286063|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34117156|NCT00492453|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34117157|NCT01349114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34117158|NCT02063256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117159|NCT04999410|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Employ software to monitor intervention and outcomes. Intervention groups will be coded and the investigators will not be aware of intervention group assignment.|"Participants will be randomly assigned to one of four training intervention groups.~Before to after changes will be contrasted."|f|t|t|f
34117160|NCT05231863|||COHORT||RETROSPECTIVE|||||||
34117161|NCT02188329|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34117162|NCT00806585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117163|NCT02590107|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117164|NCT00951392|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34117165|NCT03716648|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, crossover study||||
34117166|NCT06324656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34117167|NCT05173090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117168|NCT04891029|NA|SINGLE_GROUP||SCREENING||NONE||||||
34117169|NCT02549066|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117170|NCT06297148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117171|NCT01832610|||CASE_ONLY||OTHER|||||||
34117172|NCT02455739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34117173|NCT00016354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117174|NCT01813383|||CASE_ONLY||PROSPECTIVE|||||||
34117175|NCT05201651|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind. Individual without other involvement in study has study codes and prepares and distributes study kits containing creatine and placebo (similar appearance).|Participants assigned to receive creatine supplementation or placebo.|t|t|t|t
34117176|NCT01617473|RANDOMIZED|PARALLEL||||NONE||||||
34117177|NCT01854684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117178|NCT02427490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117179|NCT06518967|||OTHER||PROSPECTIVE|||||||
33811062|NCT02067689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33811063|NCT05477407|NA|SINGLE_GROUP||OTHER||NONE||ADDORE is a pilot, open, single arm pathogenesis study to evaluate the impact on adipose tissue (AT) of a switch to TDF/FTC/DOR at week 48 in 20 patients with a body-weight gain under an INSTI-based regimen (RAL or DTG or BIC) Each patient will be evaluated with an adipose tissue biopsy performed just prior (D0) and after week 48 (W48) of switching from an INSTI-based regimen to a non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®).||||
33811064|NCT02539576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811065|NCT04806906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811066|NCT01047709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811067|NCT03559296|||OTHER||PROSPECTIVE|||||||
33811068|NCT05021198|||COHORT||OTHER|||||||
33811069|NCT01234584|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33811070|NCT04328467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811071|NCT04131556|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811072|NCT04680988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811073|NCT06308354|||COHORT||PROSPECTIVE|||||||
33811074|NCT04083209|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Patients will be randomized into a treatment and control group.||||
33811075|NCT01208506|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33811076|NCT03942107|RANDOMIZED|PARALLEL||SCREENING||NONE||after root canal treatment, post and core application in the first group and only root canal treatment in the second group post operative pain intensity will be assessed at 24, 48, and 72-h; 7-day follow-up.||||
33811077|NCT01631409|||COHORT||PROSPECTIVE|||||||
34117180|NCT02944890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117181|NCT03588702|NA|SINGLE_GROUP||TREATMENT||NONE|Independent blinded reviewers to view photographs to assess improvement of skin appearance of the treated side at 1 month post-treatment using the General Aesthetic Improvement Scale (GAIS) compared to the non-treated side|Subjects act as their own control.||||
34117182|NCT04201704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151107|NCT01112111|||COHORT||PROSPECTIVE|||||||
34151108|NCT00002112||PARALLEL||TREATMENT||||||||
33811078|NCT00362284|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33811079|NCT03146026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33811080|NCT00259766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117183|NCT06118658|NA|SINGLE_GROUP||TREATMENT||NONE||About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment||||
33811081|NCT02745756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811082|NCT01968824|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811083|NCT03479892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33811084|NCT01705366|||COHORT||PROSPECTIVE|||||||
33811085|NCT04326894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811086|NCT05914532|||COHORT||RETROSPECTIVE|||||||
33811087|NCT02636114|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34117184|NCT02470702|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34117185|NCT00187109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117186|NCT06490692|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||A randomized controlled clinical trial.|t|f|f|t
34117187|NCT02896946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117188|NCT02840630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117189|NCT03028701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117190|NCT06300775|RANDOMIZED|PARALLEL||TREATMENT||NONE|no Masking|Modified Hyrax Versus Quad Helix||||
34117191|NCT02520778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042665|NCT03426306|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117192|NCT00626080|RANDOMIZED|CROSSOVER||||NONE||||||
33811088|NCT02393976|RANDOMIZED|PARALLEL||||NONE||||||
33811089|NCT05729126|||COHORT||CROSS_SECTIONAL|||||||
33811090|NCT04094207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811091|NCT03444597|||COHORT||PROSPECTIVE|||||||
33811092|NCT04237792|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33811093|NCT00002086|RANDOMIZED|||TREATMENT||||||||
33811094|NCT04389658|||OTHER||RETROSPECTIVE|||||||
33811095|NCT04598646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811096|NCT00807599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811097|NCT00799838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811098|NCT06115798|||COHORT||PROSPECTIVE|||||||
33839757|NCT02661191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839758|NCT02812095|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33839759|NCT03037203|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33839760|NCT05756270|||COHORT||PROSPECTIVE|||||||
34042666|NCT00351702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042667|NCT00019929||||TREATMENT||||||||
34042668|NCT03809338|||COHORT||CROSS_SECTIONAL|||||||
34042669|NCT06428279|||COHORT||CROSS_SECTIONAL|||||||
34042670|NCT00954772|||COHORT||PROSPECTIVE|||||||
34042671|NCT02318680|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042672|NCT01028014|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34042673|NCT01065337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042674|NCT02273063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042675|NCT05189977|NON_RANDOMIZED|CROSSOVER||OTHER||NONE|• Open: no masking is used. All involved know the identity of the intervention assignment.|• Cross-over: participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study||||
34042676|NCT00093314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042677|NCT04016389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042678|NCT03055455|||COHORT||PROSPECTIVE|||||||
34042679|NCT06023381|||COHORT||PROSPECTIVE|||||||
34042680|NCT04408339|||COHORT||PROSPECTIVE|||||||
34042681|NCT04124601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042682|NCT03685253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042683|NCT06482398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042684|NCT05943093|||CASE_CONTROL||RETROSPECTIVE|||||||
34042685|NCT06049563|||CASE_ONLY||PROSPECTIVE|||||||
34042686|NCT01715532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042687|NCT02042014|NA|SINGLE_GROUP||TREATMENT||NONE||This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study (A2301E1) and were judged by the investigator to benefit from continued QTI571 treatment||||
34042688|NCT02366689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042689|NCT02649491|||COHORT||PROSPECTIVE|||||||
34042690|NCT00131313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042691|NCT04410107|||COHORT||PROSPECTIVE|||||||
34042692|NCT00463047|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34042693|NCT05573022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study is designed as a randomised, controlled trial, in which patients are allocated to either a digital pre-consultation patient decision aid or a paper-based in-consultation patient decision aid. A total estimate of 204 patients with breast and 70 patients with colorectal cancer are included in the study including 10% to compensate for missing data and dropouts.||||
34042694|NCT04835662|NA|SINGLE_GROUP||OTHER||NONE||||||
34042695|NCT03056638|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients with intermediate risk disease will be randomized to ADT with SBRT versus SBRT alone. PSA and testosterone testing every 6 months, Biopsy 24-30 months after SBRT||||
34042696|NCT02028767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33811099|NCT03885544|RANDOMIZED|CROSSOVER||OTHER||SINGLE||This is a 24-week randomized controlled, crossover, single-blind study. Following a 5-wk pre-intervention baseline period, subjects will be randomly assigned to consume a controlled diet that either does not contain any red meat (lacto-ovo vegetarian, LOV), or contains unprocessed lean red meat, or contains processed lean red meat, for 3 weeks. After a 5-week dietary 'washout' period, they will consume one of the alternative diets for 3 weeks. After the second 5-week dietary 'washout' period, they will consume the remaining alternative diet for 3 weeks. Stool and fasting-state blood samples will be obtained at the end of study weeks 3, 4, 7, 8, 11, 12, 15, 16, 19, 20, 23, and 24, which correspond to before and during the last 2 weeks of the three 3-wk controlled diet periods. Consecutive 4-day 24-hour urine samples will be collected within the assessment weeks of each dietary 'washout' period and control diet period (study weeks 4, 8, 12, 16, 20, 24).|f|f|f|t
33811100|NCT00163358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811101|NCT03772132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811102|NCT05671549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811103|NCT05642806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study pharmacist and one of the research coordinators will be unblinded|Randomized, double-blind, placebo-controlled, parallel-group study|t|t|t|f
33811104|NCT06428656|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|"The randomization of the participants to the supplement or placebo condition will be performed via a random integer set generator (Random.org) available online.~Neither the participants, nor the care provider, nor the investigator will be aware of whether participants receive the postbiotic supplement or the placebo. Additionally, blood samples will be masked during the biochemical analysis, and during the statistical analysis."||t|t|t|t
33811105|NCT05630859|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Data will be collected in an observer-blind manner.||t|t|t|t
33811106|NCT02696200|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117193|NCT05036343|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34117194|NCT06563843|||CASE_CROSSOVER||PROSPECTIVE|||||||
34117195|NCT00946595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117196|NCT01574144|||COHORT||PROSPECTIVE|||||||
34117197|NCT00523978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117198|NCT01340456|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34117199|NCT04546100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34117200|NCT01594242|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who are planned to start a bortezomib-containing regimen (whether for newly diagnosed or relapsed myeloma) will begin with one week off therapy and then one week of single agent bortezomib to allow investigation of its effects on cellular metabolism. Patients may then go on to receive bortezomib in whatever combination is planned by their treating oncologist.||||
34117201|NCT02728024|||COHORT||PROSPECTIVE|||||||
34117202|NCT03497377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117203|NCT00734448|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117204|NCT00444106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117205|NCT04519970|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117206|NCT06338163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of the primary outcome will be masked concerning arm allocation|Randomized controlled prospective multicenter|f|f|f|t
34117207|NCT02550002|||COHORT||PROSPECTIVE|||||||
34117208|NCT02782910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34117209|NCT03515421|NA|SINGLE_GROUP||OTHER||NONE||||||
34117210|NCT01784029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117211|NCT04119713|||COHORT||PROSPECTIVE|||||||
34117212|NCT03852030|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were not told to which weekly text messaging group they were being assigned, or about the other groups.|Following participation in the 8-week course, participants will be randomized to either 4 months of: 1) weekly MBSR specific text or email messages related to course teachings, 2) weekly general/informational texts or emails about healthy living and lifestyle, or 3) no texts or emails.|t|f|f|f
34117213|NCT01658059|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34117214|NCT00010478|RANDOMIZED|||TREATMENT||DOUBLE||||||
34117215|NCT03800355|||CASE_ONLY||RETROSPECTIVE|||||||
34117216|NCT03982160|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects will receive systemic intravenous infusion of L-arginine or saline for 30 minutes in a randomized order. The randomization will be carried out by research personnel.|This will be a randomize, saline-controlled crossover design study|t|f|f|f
34117217|NCT06565273|NA|SINGLE_GROUP||OTHER||NONE||||||
34117218|NCT04337151|||CASE_CONTROL||RETROSPECTIVE|||||||
34117219|NCT05578014|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||A pilot study|t|f|f|f
34117220|NCT00558818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117221|NCT03576235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117222|NCT01204788|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117223|NCT02541591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117224|NCT04844125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Background Lipolowering therapy in combination with SHR-1209/ placebo|t|t|t|t
34117225|NCT05975242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will be single site, prospective data collection, with pre- and post-intervention comparison. A total of 30 people with T2D will be randomly allocated (2:1 randomization) to the interventional group (n = 20) that will use the digital self-management application during the 12-week study period or the control group (n = 10) without the app.||||
34117226|NCT05358002|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34117227|NCT03053128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117228|NCT03997032|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117229|NCT03260712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117230|NCT02272127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117231|NCT02471144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117232|NCT03944850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117233|NCT04516278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117234|NCT00151840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117235|NCT05641610|NA|SINGLE_GROUP||TREATMENT||NONE||Hemophilia B patients||||
34117236|NCT05090787|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34117237|NCT01343212|||CASE_ONLY||PROSPECTIVE|||||||
34117238|NCT05427292|||COHORT||PROSPECTIVE|||||||
33811107|NCT01122134|||||PROSPECTIVE|||||||
33811108|NCT01319032|||COHORT||PROSPECTIVE|||||||
34117239|NCT00125788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117240|NCT04232852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34117241|NCT05453214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811109|NCT00651326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117242|NCT01119638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117243|NCT05235165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117244|NCT04284137|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34117245|NCT04505488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117246|NCT01788878|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117247|NCT01115907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117248|NCT05035888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34117249|NCT06528405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117250|NCT00335881|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117251|NCT05767281|||COHORT||PROSPECTIVE|||||||
34117252|NCT03361878|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two arms - metformin tolerant and metformin intolerant. All participants given single dose of metformin.||||
34117253|NCT05321290|NA|SINGLE_GROUP||TREATMENT||NONE||A multiple SSRD study using an ABA design and follow-up will be conducted with up to 10 participants. This study design focuses on within-participant comparisons of repeated performance outcome measurements over time, which will be critical for determining the clinical efficacy of the therapy program for individual participants (Graham et al, 2012). The SSRD will be supplemented with questionnaires, and survey and open-ended interview questions.||||
34117254|NCT04127318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117255|NCT06645795|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover clinical trial.||||
34117256|NCT04504955|||COHORT||PROSPECTIVE|||||||
34117257|NCT06370390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117258|NCT01876212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117259|NCT01985230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730200|NCT00409383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730201|NCT04856033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2 group RCT|f|f|t|t
33730202|NCT02569671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730203|NCT00712296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730204|NCT04453917|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients with neurological symptoms (\< 3 months) with brain MRI lesions suggestive of PML and positive PCR in cerebrospinal fluid for JCV||||
33730205|NCT04619056|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an open label, first-in-human clinical trial that will be conducted in 3 dose-escalation cohorts (3-6 patients each) and in an expansion cohort, at the highest dose determined to be safe and tolerable.~CEB-01 loaded with a SN-38 dose between 9 and 36 mg will be allocated to each patient."||||
33811110|NCT04240197|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811111|NCT02394912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811112|NCT01355809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811113|NCT01884207|||COHORT||PROSPECTIVE|||||||
33811114|NCT03838575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"ROSSINI 2 is a double blind trial; both the patient and outcome assessor will be blinded to the intraoperative intervention(s). It is not possible to blind the operating surgeon to the intervention allocation.~The following measures will be taken to ensure concealment of the chosen intervention(s) (blinding):~* Randomisation in theatre after induction of anaesthesia~* The intraoperative interventions used will not be documented in the operation notes or in the patient's notes.~* The skin around the closed wound will be wiped clean using a wet sterile towel at the end of the procedure to prevent unblinding.~* Clinical follow-up will be conducted by a trained surgeon or a trained member of the local research team who did not participate in the index procedure or surgery."|"This major, multicentre, multi-arm, multi-stage (MAMS) trial with the opportunity to cease (and introduce) arms would be the first of its kind in a surgical setting. In addition to generating new knowledge in our primary research area, by utilising this advanced design in the context of our relatively simple primary endpoint of SSI, it will also pave the way for future efficient and rapid trials in other aspects of surgical care.~Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment. This means that only 3 interventional arms (4 including the control arm) remain in the trial."|t|f|f|t
33811115|NCT02339402|||COHORT||PROSPECTIVE|||||||
33811116|NCT00753259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811117|NCT06144437|||CASE_ONLY||CROSS_SECTIONAL|||||||
33811118|NCT03973021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Different patients receive different numbers of cell for treatment per time|In this group, the patients will receive intracavernous injection of autologous VSELs. The check indexes are International Index of Erectile Function 5(IIEF-5), Erection Hardness Score(EHS) and penile vascularization assessed using color duplex Doppler ultrasound (CDDU), mainly including erectile function, stretched penile length, sexual drive, intercourse satisfaction, and overall satisfaction.|f|f|t|f
33811119|NCT00466037|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117260|NCT01151657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117261|NCT06274658|||CASE_CONTROL||PROSPECTIVE|||||||
34117262|NCT02455167|NA|SINGLE_GROUP||OTHER||NONE||||||
34117263|NCT00127855|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34117264|NCT00097279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117265|NCT02071901|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117266|NCT06021132|||COHORT||PROSPECTIVE|||||||
33730206|NCT00231348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730207|NCT02201303|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33811120|NCT02042092|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811121|NCT01333709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117267|NCT01617876|||CASE_ONLY||PROSPECTIVE|||||||
34117268|NCT03895073|||OTHER||PROSPECTIVE|||||||
34117269|NCT00375258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117270|NCT05344534|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge||||
34117271|NCT03405740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730208|NCT03696654|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The control system of measurements will be before and after treatment on the same group of patients (children with SDB and indication for adeno-tonsillectomy). For the analysis of the main variable (mean systolic blood pressure-BP), baseline values will be obtained through ambulatory blood pressure monitoring (ABPM) and pulse transit time (PTT) in the basal visit. In order to evaluate the impact of treatment of SDB (adeno-tonsillar surgery) on BP, the measurement will be repeated just before the surgical intervention (ABPM and PTT) and six months after surgery (ABPM and PTT) in the same group. In this way, a control group will be available (measurements just before the surgery / control group) that will be compared with the measurements of those same patients six months after the surgery (treatment group). This measure allows having control values without preventing the treatment of any patient and without causing delays in the application of the same linked to the study||||
33730209|NCT05558293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and clinicians were blinded to group and treatment assignment|Patients undergo non-surgical quadrant scaling and root planing|t|f|t|f
33730210|NCT00991575|||COHORT||PROSPECTIVE|||||||
33730211|NCT06330194|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Design: Prospective, open-label, two-stage randomised-crossover study.~Population: Patients with type 1 or type 2 diabetes undergoing hemodialysis (n=5), peritoneal dialysis (n=5) or chronic kidney disease stage 3b to stage 5 (n=5).~Methods: Participants entering the study will have a four-to-six-week run-in phase with diabetes education. During the run-in phase three weeks of unblinded continous glucose monitoring (CGM) will be performed to assess baseline glucose levels.~All participants will be randomized to receive either eight weeks with an advanced insulin delivery (AID) System or eight weeks of control (usual care) with cross over at the end of the first eight weeks.~CGM study outcome data will be collected by identical methods, using unblinded-CGM devices, for participants in both intervention and control study arms."||||
33730212|NCT04295291|||COHORT||OTHER|||||||
33730213|NCT00004881||||TREATMENT||||||||
34042697|NCT05057598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Before and after study online based on community-based participatory research (CBPR): CBPR approach which has been defined as 'a process that involves community members or recipients of interventions in all phases of the research process'. Over the past two decades, there has been an increasing presence of community-based research and participatory methods in health research, and involving patients at various stages of the research process has been shown to improve the ethical nature of research and the appropriateness of methods.||||
33730214|NCT03012386|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730215|NCT00347152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730216|NCT06328790|||COHORT||PROSPECTIVE|||||||
33730217|NCT00006412||||TREATMENT||||||||
33730218|NCT03069625|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33730219|NCT06321874|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The belonging to one group or the other was blinded to the laboratory staff.|Randomization was conducted post-surgery in a 1:1 ratio across groups: Normobaric Oxygen Paradox (NOP) group, and a control (CTR) group. The NOP group received 60% oxygen for two hours on days 1, 3, and 5 post-surgery using a venti-mask. The CTR group did not receive oxygen therapy during the post-operatory period starting from day 1. All patients could receive oxygen during the surgery and the first 24 hours post-surgery (day 0) as needed. The belonging to one group or the other was blinded to the laboratory staff.|f|t|f|f
33730220|NCT02196285|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33730221|NCT03585075|||CASE_CONTROL||PROSPECTIVE|||||||
33730222|NCT06474494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Two blinded, experienced, and calibrated dentists (who specialized in esthetic dentistry with more than 15 years of clinical practice), will perform the clinical evaluation. Patients will be also blinded to group assignment. An inter-examiner and inter-examiner agreement of at least 85% will be necessary before beginning the evaluation|"This is a four-arm, double-blind, randomized controlled clinical trial. Experimental group 1: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying a double layer of Scotchbond Universal Plus adhesive applied as etch-and-rinse mode.~Experimental group 2: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying a double layer of Scotchbond Universal Plus adhesive applied as selective enamel etching mode.~Control group 1: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive applied as etch-and-rinse mode.~Control group 2: 35 non-carious cervical lesions (NCCL) will receive composite resin restorations applying one layer of Scotchbond Universal Plus adhesive applied as selective enamel etching mode.~LCNCs will be randomized to application mode and number of layers"|t|f|f|t
33730223|NCT01660828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811122|NCT01273298|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33811123|NCT01157195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811124|NCT05119192|||COHORT||CROSS_SECTIONAL|||||||
33811125|NCT06240351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811126|NCT03133572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The neonatologists assessing the Thompson score will be blinded to the intervention arm. Other staff members will know about the arm allocation.|Day by day, infants will be randomized to either of the arms.|f|f|f|t
33811127|NCT00446576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811128|NCT00519935|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811129|NCT04784988|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811130|NCT04693637|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811131|NCT00861874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811132|NCT01349998|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33811133|NCT03396445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811134|NCT03368274|NA|SINGLE_GROUP||TREATMENT||NONE||To compare IgG4-RD responder index, serum parameters and blood lymphocytes subpopulations at baseline and after treatment of 12 weeks and 24 weeks||||
33811135|NCT05533905|||COHORT||PROSPECTIVE|||||||
33811136|NCT01477866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811137|NCT01337388|||COHORT||PROSPECTIVE|||||||
33811138|NCT05208788|||CASE_CONTROL||PROSPECTIVE|||||||
33811139|NCT04549688|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single-arm, case-control cohort study with consecutive patients with intermediate-risk, MRI-visible prostate cancer treated focally with HIFU. Study patients will be compared to historical controls (patients observed with AS at SiV 2009-2017).||||
33730224|NCT05148312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study drug will be administered by nebulization. The subjects will adhere to the following therapeutic scheme at each treatment period of 3 days, for 4 treatment periods:~* One single dose of study medication on the first day of the treatment period, followed by~* Minimum washout period of 3 days, i.e. minimum 72 hours between two drug administrations~The pharmacokinetics profile of budesonide in plasma, will be evaluated through pharmacokinetics parameters, calculated for each single dose, and based on 17 timepoints from 0 to 24h."||||
33730225|NCT01744327|||CASE_CONTROL||PROSPECTIVE|||||||
33730226|NCT02142686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33730227|NCT05057416|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study will be include females aged 20-49, 3 exercise conditions analyzed for exercise enjoyment and adherence. It will involve 30 women assigned randomly to one of three exercise groups with a specific exercise protocol with various intensities. The study will be 8 weeks in duration.||||
33730228|NCT01935765|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33730229|NCT04689256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730230|NCT03437200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730231|NCT03215134|NA|SINGLE_GROUP||OTHER||NONE||uncontrolled pilot study of 1 intervention||||
33730232|NCT02664324|||COHORT||PROSPECTIVE|||||||
33730233|NCT05009758|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Subjects attending the outpatient clinic of the Department of Othorrinolaringology or Pulmonology of the Medical University of Vienna for symptoms of asthma or CRS with nasal polyposis will be recruited during their routine visit. After informing patients about the scopes of the study, they will be invited for a screening visit. During this visit, patients will be informed about the nature of the study and asked whether they are willing to participate. After signing the informed consent, they will undergo a screening visit to determine their eligibility for the study and group allotment. The following parameters will be recorded at the screening visit: medical history including concomitant medication, nasal examination (endoscopy), lung function and FeNO measurement, blood draw (eosinophil levels and for exploratory parameters). Thereafter, eligible patients will attend a single study visit for the collection of all clinical parameters and samples.||||
33730234|NCT02703571|NA|SINGLE_GROUP||TREATMENT||NONE||single group for phase 1b parallel group for phase 2||||
33730235|NCT04594096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||2 telehealth visits with a medical provider (either an MD or NP) after last chemotherapy administration in the cycle, or as otherwise indicated||||
33730236|NCT00064246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730237|NCT01465464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730238|NCT02643251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730239|NCT00086580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730240|NCT00630968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730241|NCT05091528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730242|NCT04409821|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility study||||
33730243|NCT03451656|||COHORT||PROSPECTIVE|||||||
33730244|NCT00578500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730245|NCT05207124|||CASE_ONLY||PROSPECTIVE|||||||
33730246|NCT02924077|||COHORT||PROSPECTIVE|||||||
33730247|NCT01652716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730248|NCT02884089|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33730249|NCT04055857|||COHORT||PROSPECTIVE|||||||
33730250|NCT06430619|||CASE_CONTROL||RETROSPECTIVE|||||||
33730251|NCT01624909|||COHORT||PROSPECTIVE|||||||
33730252|NCT03925324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730253|NCT03784833|||COHORT||RETROSPECTIVE|||||||
33730254|NCT02953899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730255|NCT02619409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730256|NCT03450707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization list was prepared by an independent statistician using 1:1 randomization in blocks of four. This list will be provided to the research pharmacy, and the research pharmacy will be the only unblinded people involved with the study, and will have no patient contact or role in the analysis or other aspects of the study. Thiamine is colorless and odorless, and the 500mg dose is mixed in 100mL of normal saline. Placebo will be 100mL of normal saline and is indistinguishable in appearance from thiamine. Study team, clinical team and patient and family will all be blind to the allocation.||t|t|t|t
33811140|NCT02954783|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33811141|NCT05110378|||OTHER||PROSPECTIVE|||||||
33811142|NCT05870995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811143|NCT02525185|||COHORT||PROSPECTIVE|||||||
33811144|NCT05479708|||COHORT||PROSPECTIVE|||||||
33811145|NCT00004496||||TREATMENT||DOUBLE||||||
33811146|NCT01186809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811147|NCT00837044|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33811148|NCT05583656|||OTHER||PROSPECTIVE|||||||
33811149|NCT03223688|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811150|NCT04288388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study group being 178 and the control group being 169 with 347 women. Immediately before the episiotomy repair was started (after exit of placenta and applying local anesthetic agent), women assigned to the study (massage) group were asked to place plastic gloves filled with ice pieces in the LI4 point on hand. This application was made for 5 minutes to the right hand and for 5 minutes to the left hand. Women were asked to mark the perceived pain level before the application and at the end of the application using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair). In the control group women were not excluded from routine practice; women were asked to mark the perceived pain level before episiotomy repair begin and at the end the repair using the VAS (Visual Analog Scale) (perceived pain level during episiotomy repair) like the study (massage) group.||||
33811151|NCT05068232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811152|NCT00160758|||CASE_ONLY||PROSPECTIVE|||||||
33811153|NCT05488990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811154|NCT01945372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811155|NCT02409407|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33811156|NCT02377544|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33839761|NCT05817240|NA|SINGLE_GROUP||OTHER||NONE||||||
33730257|NCT03761732|NA|SINGLE_GROUP||TREATMENT||NONE||This is an active intervention feasibility study, using a pre-post clinical trial design; there is no randomization and no control intervention.||||
33730258|NCT02150668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730259|NCT05826964|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The study will have the following 3 steps:~1. Step 1: All patients (N=450 to 500) will be receiving standard of care (SOC) frontline treatment regimens.~2. Step 2: A subset of patients in Step 1 (N=160) will be randomized to continue same treatment (Arm 1) or switch to new treatment (Arm 2).~3. Step 3: A subset of patients in Arm 1 will be switched to new treatment at time of clinical disease progression (number to be determined)."||||
33730260|NCT05137873|||COHORT||PROSPECTIVE|||||||
33730261|NCT02557009|||COHORT||PROSPECTIVE|||||||
33730262|NCT02995291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730263|NCT01262716|||CASE_ONLY||PROSPECTIVE|||||||
33730264|NCT01538212|||CASE_ONLY||RETROSPECTIVE|||||||
33730265|NCT00917891|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33730266|NCT01266668|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33730267|NCT03640676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-blinded randomized sham-controlled trial|t|t|t|f
33730268|NCT01583010|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33730269|NCT01587781|||COHORT||PROSPECTIVE|||||||
33730270|NCT04915404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730271|NCT05314686|||OTHER||PROSPECTIVE|||||||
33730272|NCT01024543|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33730273|NCT02690675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33730274|NCT00418691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730275|NCT03839589|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The outcome assessor will be blinded to the intervention assignment. Within the resources available to this study, intervention staff will not be engaged in evaluating participants.|We will use a wait-listed design versus a standard parallel group RCT because the wait-listed design allows all participants to (eventually) receive the intervention, and maximizes the overall amount of information obtained. A wait-listed design has been previously used by the primary mentor of this award, Dr. Lenze; successfully increasing recruitment, retention and adherence of the intervention and control groups. This design also allows us to get participant feedback in the whole sample and get preliminary estimates of outcomes, which will be crucial to inform the proposed R01 to be submitted by year 4 of the current award.|f|f|f|t
33730276|NCT03525197|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Each subject's supplement is coded with a different number, and neither the researchers nor the subjects are aware of the condition the subject is placed in.|Parallel group design (with repeated measurements within each group)|t|f|t|f
33730277|NCT02806726|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730278|NCT01110993|||COHORT||PROSPECTIVE|||||||
33730279|NCT00850395|||||PROSPECTIVE|||||||
33730280|NCT02197390|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33811157|NCT05687214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will not know which group the participants were assigned (experimental or control group) at any study stage.|Single-blind parallel group-randomized design.|f|f|f|t
33811158|NCT00224835|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33730281|NCT03509038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811159|NCT06380959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised Controlled||||
33730282|NCT04571112|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"* The post-surgical double-blind cross-over phase with randomization will follow once programming settings are determined. Under constant GPi DBS, patients will receive NBM DBS active or sham for 8 weeks followed by an 8-week cross-over. Then, patients will enter a post-surgical open-label follow-up phase during which they will receive GPi+NBM DBS.~* The outcomes assessor is blinded to the whether the NBM DBS is active to avoid bias while analyzing the data"|To target both the NBM and GPi in a single trajectory, using the Vercise system (Boston Scientific, Marlborough, Massachusetts, US) which is now approved for human use in Canada. This system includes a novel 8-contact electrode and an IPG system with 16 independent power sources allowing the so-called 'Multiple Independent Current Control' (MICC) that permits concurrent high- and low-frequency stimulation, as well as a variety of amplitudes and pulse widths independently controlled at each stimulated region.|t|f|f|t
33730283|NCT01226719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811160|NCT00476294|||CASE_CONTROL||PROSPECTIVE|||||||
33811161|NCT00236509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811162|NCT01840085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811163|NCT00165048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811164|NCT04373291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be blinded to treatment. The physicians administering the BCG vaccine or placebo will not be blinded. In case of serious adverse events, the participant can be unblinded after consultation with the coordinating PI or sponsor.|A multi-center randomized placebo-controlled trial|t|f|f|t
33811165|NCT04865744|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||Blinded Randomised Single-group Crossover|t|t|f|f
33811166|NCT06456359|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm prospective, open label, multi-centre phase II study of pasireoide maintenance therapy in patients with advanced/metastatic DSRCT and SySa. According to the staggered approach during a run-in phase feasibility is assessed in 3 (or, if necessary, more) adult patients before initiating recruitment in adolescents. Adults receive 60 mg via intragluteal depot injection every 28±3 days, adolescents 60 mg (body surface area \[BSA\] \>1.6 m²) or 40 mg (BSA 1.1-1.6 m2) via intragluteal depot injection every 28±3 days.||||
33811167|NCT06001515|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple blinded|one experimental group and one active comparator group|t|f|t|t
33811168|NCT03713580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811169|NCT02078518|||CASE_ONLY||PROSPECTIVE|||||||
33811170|NCT00917098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811171|NCT01177449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811172|NCT03162614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811173|NCT03609450|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms, intervention and low-dose comparator, which are randomly assigned at the same time and are implemented in parallel.||||
33811174|NCT05352854|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33811175|NCT02156180|||COHORT||PROSPECTIVE|||||||
34042698|NCT00003853||||TREATMENT||||||||
33730284|NCT01637610|||COHORT||PROSPECTIVE|||||||
34117272|NCT06326021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730285|NCT03420703|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33730286|NCT04203550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Due to the nature of the treatment, it is not possible to blind the surgeon and OR staff from the treatment allocation. Measures to minimize bias include:~* The patient will not be informed of treatment allocation~* Treatment allocation will not be documented in medical records i.e. all the personnel participating in patient care after operation will be blinded to allocation~* The study group members collecting postoperative data and performing the statistical analyses will be blinded to treatment arm until the analyses are finished."|Prospective, randomized, controlled, parallel group non-inferiority trial.|t|t|t|t
33730287|NCT06476223|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33730288|NCT00853177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730289|NCT00412165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730290|NCT03758911|||CASE_ONLY||PROSPECTIVE|||||||
33730291|NCT04201561|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients enrolled in this study will be randomized into two groups. Patients in the control group will receive paclitaxel chemotherapy every 3 weeks for a total of 6 cycles and a dose of normal saline 40 ml every cycle before chemotherapy begins. Patients in the experimental group will receive a dose of selenium 2000 μg/40 ml instead every cycle before chemotherapy.|t|t|t|f
33730292|NCT03289104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730293|NCT02153775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730294|NCT05160428|||OTHER||CROSS_SECTIONAL|||||||
33730295|NCT02832869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33730296|NCT02983006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730297|NCT01313429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730298|NCT01462669|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730299|NCT00207181|||||PROSPECTIVE|||||||
33730300|NCT02144740|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33730301|NCT00389116|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33730302|NCT00052845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730303|NCT05949138|||COHORT||PROSPECTIVE|||||||
33730304|NCT01652391|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33730305|NCT06164132|||OTHER||CROSS_SECTIONAL|||||||
33730306|NCT05263427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730307|NCT00004144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730308|NCT01211028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730309|NCT03152370|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will investigate two neoadjuvant radiotherapy/chemoradiotherapy schedules in combination with E7046 in parallel.||||
33730310|NCT05132621|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33730311|NCT02646579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730312|NCT03292081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730313|NCT06062043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcomes assessors will be blinded to randomization assignments.||t|f|f|t
33730314|NCT03160963|||COHORT||CROSS_SECTIONAL|||||||
33730315|NCT06323252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730316|NCT04141280|||OTHER||CROSS_SECTIONAL|||||||
33730317|NCT01654965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730318|NCT05164458|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33730319|NCT02953821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730320|NCT05709184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome will be assessed by an observer blinded to study group assignment||f|f|f|t
33730321|NCT00938483|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33730322|NCT01332617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730323|NCT04679077|NA|SINGLE_GROUP||OTHER||NONE||Patients will be split into two groups after data collection. They will receive the same treatment during the clinical trial.||||
33730324|NCT04110483|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730325|NCT03123159|||COHORT||PROSPECTIVE|||||||
33730326|NCT01248299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730327|NCT05440292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33730328|NCT04426617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730329|NCT03377712|||COHORT||PROSPECTIVE|||||||
33730330|NCT01105507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730331|NCT00292357|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730332|NCT06347081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||one treatment one control group|t|f|f|t
33730333|NCT06014073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730334|NCT02350309|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33730335|NCT01387204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730336|NCT02143570|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730337|NCT00849368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730338|NCT01081366|||COHORT||PROSPECTIVE|||||||
33730339|NCT03033017|||COHORT||PROSPECTIVE|||||||
33730340|NCT04317248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811176|NCT05816707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled clinical trial.|t|t|f|t
33811177|NCT02637063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811178|NCT01020578|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33811179|NCT00147615|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811180|NCT06269497|NA|SINGLE_GROUP||OTHER||NONE||Observational study / clinical trial||||
33811181|NCT03692871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33811182|NCT05503407|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811183|NCT03142932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811184|NCT01255800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811185|NCT01489683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811186|NCT03701607|||COHORT||PROSPECTIVE|||||||
33811187|NCT00651703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811188|NCT05361356|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811189|NCT03597152|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33730341|NCT02915653|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33730342|NCT05626036|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33730343|NCT01590407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730344|NCT04143451|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double-blind randomization will be performed. Only the study nurse has knowledge of the type of topical treatment applied. Subjects and investigators remain blinded to the route and type of vaccination.|Double blind randomised controlled trial|t|f|t|f
33730345|NCT02961699|RANDOMIZED|PARALLEL||TREATMENT||NONE||this study utilizes a medical device||||
33730346|NCT06039241|||OTHER||PROSPECTIVE|||||||
33730347|NCT01009099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730348|NCT05243212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The treatment dose is 6 or 9 x 10\^6 CAR+ T cells/kg of recipient bodyweight.||||
33730349|NCT00724516|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33730350|NCT02235779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117273|NCT03973957|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Randomized and controlled trial||||
33730351|NCT02366078|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33730352|NCT00000403|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33730353|NCT01113125|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730354|NCT06132607|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33730355|NCT01549210|||COHORT||PROSPECTIVE|||||||
33811190|NCT01794273|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33811191|NCT04117100|||COHORT||PROSPECTIVE|||||||
33811192|NCT00010868||PARALLEL||TREATMENT||DOUBLE||||||
33811193|NCT03116191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811194|NCT03114215|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"The primary objective of the study is to evaluate the safety of biotin at 300 mg/day over placebo in patients with amyotrophic lateral sclerosis.~This is a 6-month double blind randomized 2:1 placebo-controlled study with two arms (placebo, biotin 300 mg/day). The study will be followed by a 6-month extension phase during which all patients will receive biotin 300 mg/day."|t|t|t|t
33811195|NCT04827849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following recruitment, the pregnant women were divided into a study and a control group by randomization (1:2 randomization)||||
33811196|NCT04003558|||COHORT||RETROSPECTIVE|||||||
33811197|NCT01181232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811198|NCT00154544|||DEFINED_POPULATION||OTHER|||||||
33811199|NCT06216002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Train of four nerve stimulation||||
33811200|NCT03230448|||OTHER||PROSPECTIVE|||||||
33811201|NCT00131404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811202|NCT03516877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730356|NCT00615563|||COHORT||PROSPECTIVE|||||||
33811203|NCT00729547|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33811204|NCT03711279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811205|NCT01666821|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33811206|NCT01221532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811207|NCT00647465|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33811208|NCT05534230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||This Study will be consist of two arms one treatment arm and one control arm.|t|t|f|t
33811209|NCT06165978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33811210|NCT04393571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811211|NCT01947491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811212|NCT01630486|||COHORT||PROSPECTIVE|||||||
33730357|NCT03195959|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33730358|NCT05418452|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33730359|NCT01231581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730360|NCT02310178|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730361|NCT01158222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730362|NCT00208377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730363|NCT04709666|||COHORT||RETROSPECTIVE|||||||
33730364|NCT01556672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730365|NCT04618055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730366|NCT05705622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|This study will be conducted by a researcher. Patients will be assigned to the experimental and control groups after the randomization process. Patients will not know which group they are in. In this study, only the researcher will know which group the patients are in.|This is a randomized controlled trial. Oral mucositis levels of patients treated in hospital for bone marrow transplantation will be examined. Before starting the research, permission will be obtained from the patients, and after the necessary randomization, they will be assigned to the experimental and control groups. The patients in the experimental group will be trained for oral mucositis. Oral diagnosis of the patients will be made once a week for four weeks and the effectiveness of the nursing education given to the patients will be evaluated.|t|f|f|f
33730367|NCT05653960|||COHORT||OTHER|||||||
33730368|NCT02990793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33811213|NCT04033653|||CASE_ONLY||PROSPECTIVE|||||||
33811214|NCT00071500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33811215|NCT00879827|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811216|NCT00681915|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33811217|NCT04680598|||COHORT||PROSPECTIVE|||||||
33811218|NCT04871555|||OTHER||RETROSPECTIVE|||||||
33811219|NCT02565589|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33811220|NCT01316913|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811221|NCT00458185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811222|NCT06012409|||COHORT||PROSPECTIVE|||||||
33811223|NCT04493411|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811224|NCT00599196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811225|NCT04929509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33811226|NCT03720249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33811227|NCT06229756|||COHORT||PROSPECTIVE|||||||
33811228|NCT00351026|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811229|NCT05435105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of three groups as 2 intervention (virtual reality, local cold-vibration) and control group (routine application)||||
33730369|NCT05595629|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants who consent will be unaware of the existence of the other remote blood pressure monitoring program. The nurse practitioner who manages postpartum hypertension for all participants will be aware of randomization group but will manage each participant per a standard treatment algorithm regardless of randomization group. The research team and outcomes assessors will be blinded to the randomization group.||t|f|t|t
33730370|NCT01627613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730371|NCT04708717|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33730372|NCT03608488|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33730373|NCT05254795|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33730374|NCT01557400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730375|NCT00002183||||TREATMENT||||||||
33730376|NCT00333684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730377|NCT04138615|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33730378|NCT01849211|NA|SINGLE_GROUP||OTHER||NONE||||||
33730379|NCT05190042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind study where patients were not informed about their randomization allocation.||t|f|f|f
33730380|NCT06391879|||COHORT||PROSPECTIVE|||||||
33730381|NCT02607514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730382|NCT00656006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730383|NCT03212963|NA|SINGLE_GROUP||OTHER||NONE||Open label study to evaluate adrenal suppression potential and pharmacokinetics of halobetasol lotion 0.05%||||
33730384|NCT05585814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730385|NCT05901727|||COHORT||PROSPECTIVE|||||||
33730386|NCT01303575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730387|NCT06483971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33730388|NCT06022185|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A total of 70 people, 35 in the experimental group and 35 in the control group, will be included in the study.|t|f|t|t
33730389|NCT03031171|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33730390|NCT03346122|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33730391|NCT00914615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730392|NCT03674866|||COHORT||RETROSPECTIVE|||||||
33730393|NCT01451775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730394|NCT01172743|||COHORT||PROSPECTIVE|||||||
33730395|NCT04694807|RANDOMIZED|PARALLEL||TREATMENT||NONE|However, the investigator, therapists, and participants are masked in terms of not knowing which treatment the participants will be randomized to until after the completion of baseline assessment (T1).|Block randomization with a 1:1 allocation ratio to individually delivered versus group-based CBTgrief at the clinic in Copenhagen, and with a 1:2 allocation ratio to individually delivered versus group-based CBTgrief at the clinic in Odense. Randomization is conducted by an independent employee at the Danish National Center for Grief (DNCG). The allocation will take place after completion of baseline questionnaire (T1).||||
33730396|NCT04887662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730397|NCT00793364|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33730398|NCT02282696|NA|SINGLE_GROUP||OTHER||NONE||||||
33730399|NCT00003491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730400|NCT02774681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730401|NCT03856762|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730402|NCT04590495|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A randomized, parallel-group, double-blind, exploratory two-arm trial.|t|f|t|f
33730403|NCT04419116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730404|NCT00232908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730405|NCT02603809|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730406|NCT05410327|NA|SINGLE_GROUP||OTHER||NONE||||||
33730407|NCT03108846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Over-encapsulation||t|t|t|t
33730408|NCT05906862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811230|NCT05295706|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33811231|NCT05760950|||COHORT||RETROSPECTIVE|||||||
33811232|NCT00114452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811233|NCT03262714|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811234|NCT01762397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730409|NCT03517709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811235|NCT03944889|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants and investigators will be blinded to the delivered dose; however, the type of capsaicin delivery cannot be blinded from either participants or investigators. The member of the research team conducting the randomization schedule and concealing allocation will have knowledge of and keep track of the doses contained in the containers and vials of the topical and injectable capsaicin, respectively. They will deliver the appropriate dose to the team member implementing the experimental protocol to ensure there is blinding with respect to dose.|A single-centered, factorial, randomized, placebo-controlled trial with two independent variables (dosage and depth of application).|t|f|f|f
33811236|NCT03286907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811237|NCT05722626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811238|NCT05051826|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||In this experiment, the combination of water and land resistance training method was used to intervene the teenagers' turning and starting, and compared with the traditional strength training method|t|f|t|t
33811239|NCT06077305|||COHORT||PROSPECTIVE|||||||
34042699|NCT01257334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042700|NCT02484456|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34042701|NCT04171336|NA|SINGLE_GROUP||TREATMENT||NONE||Pragmatic trial||||
34042702|NCT01022307|||CASE_CONTROL||RETROSPECTIVE|||||||
33730410|NCT02047799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730411|NCT06296303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730412|NCT01346384|||COHORT||PROSPECTIVE|||||||
33730413|NCT02214121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730414|NCT04163744|||COHORT||PROSPECTIVE|||||||
33730415|NCT02030171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730416|NCT01006382|||||CROSS_SECTIONAL|||||||
33730417|NCT05093699|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33730418|NCT05142683|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"The evaluator of the primary outcome will be blind to treatment arm as well as blind to the stepped wedge design.~Edited March 7th, 2024: The evaluator of the primary outcome will be blind to treatment arm as well as blind to the quasi-experimental cluster controlled design."|"The study uses a Type 1 Hybrid Implementation Effectiveness design that focuses on the effectiveness of the clinical intervention (ICP) while exploring the implementation effectiveness of the intervention.~A stepped wedge, cluster randomized controlled trial is indicated as the intervention is applied at the clinic level.~Edited on March 7th, 2024: The study uses a Type 1 Hybrid Implementation Effectiveness design that focuses on the effectiveness of the clinical intervention (ICP) while exploring the implementation effectiveness of the intervention.~A cluster controlled trial is indicated as the intervention is applied at the clinic-level."|f|f|f|t
33730419|NCT00804336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730420|NCT04028011|||COHORT||PROSPECTIVE|||||||
33730421|NCT01467076|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33730422|NCT02227485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730423|NCT05547321|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33730424|NCT03561181|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730425|NCT03912727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||"36 patients with end-stage renal disease (ESRD) receiving hemodialysis treatment will be enrolled in the study and the patients will be identified by coded numbers to maintain the privacy.~Patients will be randomized into two groups each group includes 18 patients:~Control Group: 18 patients will receive their standard therapy only. Tested Group: 18 patients will receive alpha lipoic acid (thiotacidR) product with their standard therapy."|t|t|f|f
33730426|NCT03367312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The outcomes assessor, the radiologist who is reading the imaging will be blinded to treatment.|This will be a single-blinded open-label study enrolling 15 patients (accrued 12 subjects total) with Pulmonary Hypertension who are currently on a stable dose of Inhaled Prostacyclin for treatment of PH.||||
34042703|NCT00558701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730427|NCT02153944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33730428|NCT01423448|RANDOMIZED|PARALLEL||||NONE||||||
33730429|NCT02311751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730430|NCT05960396|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730431|NCT02936960|||COHORT||PROSPECTIVE|||||||
33730432|NCT00463359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730433|NCT01504724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730434|NCT01064895|||CASE_ONLY||PROSPECTIVE|||||||
33730435|NCT00924911|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730436|NCT02437682|||COHORT||CROSS_SECTIONAL|||||||
33730437|NCT00843713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730438|NCT04601688|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730439|NCT03998007|||CASE_ONLY||PROSPECTIVE|||||||
33730440|NCT04916184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730441|NCT06275295|||OTHER||RETROSPECTIVE|||||||
33730442|NCT03083496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730443|NCT02202447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730444|NCT02579746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33730445|NCT03108248|||COHORT||RETROSPECTIVE|||||||
33730446|NCT00238277||||TREATMENT||NONE||||||
33730447|NCT00684424|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33730448|NCT00872846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730449|NCT03922568|||COHORT||RETROSPECTIVE|||||||
33730450|NCT01968018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730451|NCT01064791|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730452|NCT00001249||||TREATMENT||||||||
33730453|NCT04360577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730454|NCT00411619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730455|NCT03087370|||COHORT||OTHER|||||||
33811240|NCT05068050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants do not know the direction of the hypotheses~The assessors are blinded to the assignment of the participants to the experimental group or the control group.~The investigators treating the data are blinded to the allocation of participants to the experimental group or the control group."|Two groups of participants: i) experimental group, ii) active control group|t|f|t|t
33811241|NCT00524069||||TREATMENT||NONE||||||
33811242|NCT02040701|||COHORT||PROSPECTIVE|||||||
33811243|NCT02068157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811244|NCT03792178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||bulk fill resin composite placement techqniues versus nano resin composite at postoperative hypersensitivity|t|f|f|t
33811245|NCT01095848|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811246|NCT00278928|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34042704|NCT00001997||||TREATMENT||||||||
34042705|NCT00210418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042706|NCT01598493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730456|NCT00005770|||NATURAL_HISTORY||CROSS_SECTIONAL|||||||
33730457|NCT04974775|||COHORT||OTHER|||||||
33730458|NCT06362148|||COHORT||PROSPECTIVE|||||||
33811247|NCT01297595|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33811248|NCT04892745|||COHORT||PROSPECTIVE|||||||
33811249|NCT05074212|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33811250|NCT02399241|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33811251|NCT00247507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811252|NCT00644306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811253|NCT00001627|||COHORT||PROSPECTIVE|||||||
33811254|NCT00444743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811255|NCT01372475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33811256|NCT05364515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042707|NCT04200989|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects receive the study intervention: Peanut ILIT.||||
34042708|NCT02589626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34042709|NCT02019199|||COHORT||PROSPECTIVE|||||||
34042710|NCT04055441|||CASE_CROSSOVER||PROSPECTIVE|||||||
33730459|NCT03790826|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730460|NCT06174324|||COHORT||PROSPECTIVE|||||||
33730461|NCT06457594|||COHORT||PROSPECTIVE|||||||
33730462|NCT02967250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730463|NCT04817228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730464|NCT03821558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730465|NCT01863472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730466|NCT04640948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, the participants , care provider and investigator cannot be blinded but the outcome is objective and data will be analyzed by statistician independent of the study team.|Randomized controlled parallel group trial|f|f|f|t
33730467|NCT05983718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
33730468|NCT03395314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730469|NCT03467425|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized in a ratio of 1:1 to receive one of the following study treatment regimens: TRELEGY ELLIPTA once daily in the morning or Non-ELLIPTA MITT twice-daily treatment.||||
33730470|NCT00327704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730471|NCT04845126|||COHORT||PROSPECTIVE|||||||
33730472|NCT04503057|||CASE_CONTROL||PROSPECTIVE|||||||
33730473|NCT01565330|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33730474|NCT01588912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730475|NCT03320681|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Double-blind|t|f|t|f
33730476|NCT04369248|||CASE_CONTROL||PROSPECTIVE|||||||
33730477|NCT05140577|||OTHER||CROSS_SECTIONAL|||||||
33730478|NCT06225089|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33730479|NCT01456442|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33730480|NCT03811756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730481|NCT02256891|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33730482|NCT02365636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730483|NCT03595410|||COHORT||RETROSPECTIVE|||||||
33730484|NCT00992810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730485|NCT04222738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730486|NCT05675566|||CASE_ONLY||PROSPECTIVE|||||||
33730487|NCT06189456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||profit, multicentric, prospective, open-label, non-pharmacological clinical investigation||||
33730488|NCT05713123|NA|SINGLE_GROUP||OTHER||NONE||Patients received Iode 131 for thyroid cancer and 72 hours after taking iodine capsule,||||
33730489|NCT06228430|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33730490|NCT00225836|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730491|NCT02510794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730492|NCT06305533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sites will randomly be assigned to test or control groups according to a computer-generated list. Allocation concealment will be assured by opaque, sealed envelopes prepared and sequentially numbered by a person not otherwise involved in the study. The person responsible for delivering treatment will be aware about allocation of the groups, while the assessor will be blinded.|This study is 3 arm, split-mouth, double blinded, randomized clinical trial. The first group will receive RSD only, the second group will be treated with RSD + aPDT with ICG as a PS, and the last group will receive RSD + Laser disinfection.|f|f|f|t
33730493|NCT03440671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730494|NCT01642238|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730495|NCT04578847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730496|NCT03734120|||COHORT||PROSPECTIVE|||||||
33730497|NCT06049472|||CASE_CROSSOVER||PROSPECTIVE|||||||
33730498|NCT03377946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730499|NCT03751215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811257|NCT03690609|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33730500|NCT02646696|||CASE_CONTROL||PROSPECTIVE|||||||
33730501|NCT00807534|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33730502|NCT01242657|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730503|NCT02281136|NA|SINGLE_GROUP||||NONE||||||
33730504|NCT01067768|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730505|NCT03098069|||OTHER||PROSPECTIVE|||||||
33811258|NCT00278499|||COHORT||PROSPECTIVE|||||||
33730506|NCT01622946|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33730507|NCT01458327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730508|NCT03925766|||CASE_ONLY||RETROSPECTIVE|||||||
33730509|NCT04044417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730510|NCT00633191|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33730511|NCT06178172|NA|SINGLE_GROUP||OTHER||NONE||||||
33730512|NCT04114253|||COHORT||PROSPECTIVE|||||||
33730513|NCT02272413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730514|NCT00002510|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730515|NCT03159728|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33730516|NCT02928328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33730517|NCT04464681|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33730518|NCT03580603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33730519|NCT05005858|NA|SINGLE_GROUP||TREATMENT||NONE|The specialis tasked with histomorphometric, micro-CT analysis has no knowledge on the intervention method|"* Procedure: alveolar ridge splitting~* Procedure: bone core biopsy After 3 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.~* Device: dental implant placement During reentry after bone biopsy dental implants were placed.~* Clinical measurements:~Measurements were carried out using Williams probe~* Histomorphometric measurements~* Micro-CT analysis"||||
33730520|NCT03142880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730521|NCT02547129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811259|NCT00620139|||COHORT||PROSPECTIVE|||||||
33811260|NCT01754584|||CASE_ONLY||PROSPECTIVE|||||||
33811261|NCT00861315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117274|NCT00172809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117275|NCT03098095|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-Label, Randomized, Multicenter, Pilot Study||||
34117276|NCT03198390|||CASE_CONTROL||PROSPECTIVE|||||||
34117277|NCT05648708|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34117278|NCT06503731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117279|NCT04582214|RANDOMIZED|PARALLEL||TREATMENT||NONE||The active treatment group will consist of patients who are treated OLE therapy while on heated high-flow oxygen therapy. Results from subjects in the active treatment group will be compared to retrospectively collected results from patients treated with standard care with no OLE therapy.||||
34117280|NCT00730054|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34117281|NCT03377660|||COHORT||PROSPECTIVE|||||||
34117282|NCT06173466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient were performed TPVB in preoperative room before surgery. And the patient, care provider, anesthesiologist in OR, investigator and outcome assessor were blind to the study group.||t|t|t|t
34117283|NCT02107885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34117284|NCT02481557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117285|NCT05466305|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34117286|NCT01116284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117287|NCT01265485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117288|NCT05878574|||COHORT||PROSPECTIVE|||||||
34117289|NCT04518501|NA|SEQUENTIAL||TREATMENT||NONE||||||
34117290|NCT02639390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117291|NCT04790500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117292|NCT05381480|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster Randomized Controlled Trial, buildings randomized to one of two interventions||||
34117293|NCT05539651|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|double-blinded||t|t|t|t
34117294|NCT00186459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117295|NCT03671811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117296|NCT04490278|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117297|NCT05966480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117298|NCT05072483|||CASE_CONTROL||OTHER|||||||
34117299|NCT03025126|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117300|NCT01031888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117301|NCT05157360|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A randomization list will be used to show whether patients will be in group A or B. Only the Research Scientist who made the randomization list and the Pharmacy will know what group patients are in. The Burn Program Coordinator will get consent and enroll patients to the study. After that, the Burn Program Coordinator will call the pharmacy and report what group the patient is enrolled in, A or B. Then, the pharmacy will order the respective medications.~The doctors and nurses providing care for the patients will not know who is in what treatment group, and neither will the patients."||t|t|t|f
34117302|NCT05631444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117303|NCT00314613|NON_RANDOMIZED|||TREATMENT||NONE||||||
34117304|NCT06119217|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Parallel Group Study||||
34117305|NCT05419245|||CASE_ONLY||CROSS_SECTIONAL|||||||
34117306|NCT00831389|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34117307|NCT01968343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117308|NCT02588014|||COHORT||PROSPECTIVE|||||||
34117309|NCT00151021|RANDOMIZED|CROSSOVER||||NONE||||||
34117310|NCT06004622|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34117311|NCT02199041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117312|NCT01517984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117313|NCT06095037|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34117314|NCT06343805|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This dose escalation study will follow a 3+3 cohort design until the RP2D and/or MTD is determined.||||
34117315|NCT05511779|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117316|NCT00987350|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
34117317|NCT06041321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The Biostatistics Unit will develop and implement the randomization procedure using the Biostatistics Randomization Management System (BRMS). The Biostatistics Randomization Management System (BRMS) is a secure, HIPAA-compliant, web-based application that allows investigators to randomize subjects into randomized clinical trials (RCTs) using their personal computer. The BRMS allows for multi-center, stratified, and single/double blinded RCTs, using permuted blocks. Randomization notifications (respectful of blinding status) are automatically sent to the PI and other authorized personnel. BRMS includes a feature that allows for medically indicated breaking of the blind, with requirement for justification. BRMS includes an audit trail of all transactions.|This is a phase IV, parallel designed, placebo controlled, randomized clinical trial|t|f|t|f
34117318|NCT01359956|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34117319|NCT06315933|||COHORT||OTHER|||||||
34117320|NCT05716945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117321|NCT00525421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117322|NCT05415904|||COHORT||RETROSPECTIVE|||||||
34117323|NCT03198156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This is a 5 week randomized, sham-controlled, parallel group study involving subjects with any of the following diagnoses: Idiopathic Hypersomnia, Narcolepsy without Cataplexy, Hypersomnia in OSA patients adequately treated with PAP therapy or dental device, Posttraumatic hypersomnia, Hypersomnia, unspecified. Subjects with idiopathic hypersomnia with an MSLT mean sleep latency of \>8 minutes will undergo actigraphy and those with an average sleep time of \>10 hours per day will continue with the study while those with \<10 hours sleep time will be excluded. OSA subjects with complaints of hypersomnia with an ESS score \<10 will be excluded. Female subjects of child bearing age and not menopausal will have a pregnancy test performed.~Subjects will receive either active tDCS or sham stimulation for 30 minutes daily for 4 sessions. Subjects will be blinded as to whether they are receiving sham or active tDCS treatments."|t|t|t|f
34117324|NCT03589274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117325|NCT00875914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117326|NCT06547736|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117327|NCT05927987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will know to which group they are to be allocated. The PM+ supervisors, PM+ helpers, and two principal researchers will know which participants are randomised in a specific group. Involved research assistants (the outcome assessors) and the two other involved researchers will not know.|The RCT is a parallel-group, two-arm trial with a 1:1 allocation ratio. Participants are imprisoned adults in Dutch remand prisons with elevated levels of psychological distress (K10 \> 15). Participants will be stratified by gender. A total of 60 participants will be included.|f|f|f|t
34117328|NCT05719116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||As the main aim of the study is to investigate feasibility, no randomisation is done at this stage. The participants with psychotic disorder will be compared with participants with a psychiatric disorder (but no psychotic disorder).||||
34117329|NCT01933893|||CASE_CONTROL||PROSPECTIVE|||||||
34117330|NCT01434004|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34117331|NCT03430167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|post operative assessor obtaining range of motion and performing physical exam will be blinded to participant's group.||f|f|f|t
34117332|NCT04321408|||COHORT||PROSPECTIVE|||||||
34117333|NCT00735657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117334|NCT02900430|||COHORT|||||||||
34117335|NCT00490581|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34117336|NCT01793116|||COHORT||PROSPECTIVE|||||||
34117337|NCT03708367|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117338|NCT03965845|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117339|NCT01846026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117340|NCT06718322|NA|SINGLE_GROUP||OTHER||NONE||This study evaluates an implementation intervention targeting professionals implementing a cancer prevention program. The intervention is an online toolkit that supports implementers in selecting and adapting an evidence-based cancer prevention program and developing a tailored implementation plan.||||
34117341|NCT06563960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117342|NCT01511133|||OTHER||RETROSPECTIVE|||||||
34117343|NCT05956002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34117344|NCT05862688|||COHORT||PROSPECTIVE|||||||
34117345|NCT06124222|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|There will be double-blind blinding, since neither the participant nor the principal investigator will be aware of which group (A/B) each patient belongs to.|"* Group A: patients who have not received radiotherapy (RT) in their oncologic treatment (non-irradiated).~* Group B: patients who have received radiotherapy (RT) in their oncologic treatment (irradiated)."|t|f|t|f
34117346|NCT03378102|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117347|NCT06389175|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34117348|NCT06715228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117349|NCT03175029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117350|NCT03186638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34117351|NCT04328389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34117352|NCT05645757|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|All investigative site personnel, study volunteers, DMID, Wockhardt and DVC personnel will remain blinded through database lock, with the exception of an unblinded pharmacist/verifier at the research site, an unblinded SDCC biostatistician, and a DMID/CMS manager responsible for PK sample storage.||t|f|t|t
34117353|NCT01887717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117354|NCT03201120|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34117355|NCT02180828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117356|NCT04256525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117357|NCT04655157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117358|NCT05024513|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117359|NCT06410209|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Investigators and participating site staff are blinded.||f|t|t|t
34117360|NCT01885988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117361|NCT05965310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a parallel arm prospective randomized-controlled trial.|f|t|f|f
34117362|NCT06382051|NA|SINGLE_GROUP||SCREENING||NONE||||||
34117363|NCT02795039|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34117364|NCT01039389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117365|NCT04486040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117366|NCT00105625|||||PROSPECTIVE|||||||
34117367|NCT03577899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117368|NCT01415752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117369|NCT03560492|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Postural assessment is performed by a blinded investigator with a device for computerized measurement of surface curvature in the upright position (SpinalMouse®).|Participants are randomised to receive one intervention during the initial 3 month phase of the study and receive the other intervention during the second 3 month phase of the study, after a wash out 3 month period.|f|f|t|t
34117370|NCT06230809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117371|NCT04696146|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Once eligible patients are identified, consented, and have an acceptable kidney transplant offer, they will be randomized by the Cedars-Sinai Research Pharmacy to receive study drug vs. placebo. Drug and placebo will be prepared by the Cedars-Sinai Research Pharmacy and conveyed to the operating room in a blinded manner. The drug will be administered by the transplant surgeon in the OR in a blinded manner.|Intraoperative C1INH (500U/kidney) vs. Placebo administered into the graft renal artery 1-2 hours prior to implantation in adult subjects receiving a deceased donor kidney allograft considered high-risk for development of DGF (KDPI\>80). Patients will be randomized in a 1:1 manner|t|t|t|t
34117372|NCT02483364|NA|SINGLE_GROUP||TREATMENT||NONE||Cell therapy||||
34151109|NCT04659694|NA|SINGLE_GROUP||OTHER||NONE||A mixed method design is an integrative methodology in understanding the social inquiry into the implementation of an intervention(Greene,2008). The whole system wellness intervention will be applied to care home residents by (intervention-trained) care home staff.||||
34151110|NCT00828152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811262|NCT05503485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A psychology student will monitor participants self-reported scores for safety reasons.||f|f|t|f
33811263|NCT02315118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730522|NCT04365699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All subjects hospitalized with COVID-19 infection hospitalized will be enrolled in the registry; a subgroup meeting specific entry criteria listed below will be enrolled in the open-label interventional trial||||
33730523|NCT01492634|NA|SINGLE_GROUP||||NONE||||||
33730524|NCT06237153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study coordinator holds randomization code.|30 patients randomly assigned to drug treatment or saline placebo injection (15 patients in each arm)|t|f|t|f
33730525|NCT01577758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811264|NCT04926259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811265|NCT01673256|||COHORT||PROSPECTIVE|||||||
33811266|NCT06371950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811267|NCT04738214|||COHORT||PROSPECTIVE|||||||
33811268|NCT01869465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811269|NCT02253966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34042711|NCT03368092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042712|NCT01826513|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34042713|NCT06295458|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34042714|NCT00775801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042715|NCT01962012|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34042716|NCT01159041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042717|NCT00005235|||COHORT||PROSPECTIVE|||||||
34042718|NCT01760135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042719|NCT00255866|RANDOMIZED|PARALLEL||||NONE||||||
34042720|NCT02068508|||COHORT||PROSPECTIVE|||||||
34042721|NCT02449798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042722|NCT06534593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||the study will consist of 2 arms.|f|f|t|t
34042723|NCT00450099|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34042724|NCT00808912|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34042725|NCT06171984|||CASE_ONLY||OTHER|||||||
34042726|NCT04697446|||COHORT||RETROSPECTIVE|||||||
34042727|NCT04687839|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34042728|NCT01256489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042729|NCT02435537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042730|NCT03978663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042731|NCT02073929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042732|NCT01288677|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34042733|NCT05344443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This will be a 4-week double blinded placebo controlled trial (2 weeks of baseline assessment followed by 2-weeks of treatment/placebo). The trial design is based on a recent successful study of the treatment of sleep problems in shift workers with a hypocretin/orexin receptor antagonist|t|t|t|t
34042734|NCT03747133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042735|NCT05780125|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|A computerized system generated a randomization sequence, and then sealed envelopes containing the drug assigned was prepared. The randomization ratio of the treatment arms was 1:1. An unblinded biologist (E.B.) was in charge of running the ROTEM® tests, randomization, drug preparation, and masking, and its delivery to the operating room. The attending anesthesiologist, the surgical staff, and the medical staff in the ICU and ward were blinded.|Prospective, double-blind, randomized|t|t|t|t
34042736|NCT03028207|||COHORT||CROSS_SECTIONAL|||||||
34042737|NCT03996005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042738|NCT03235713|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34042739|NCT00562172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042740|NCT05576935|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are not informed as to what condition they are subjected.|R randomized, single-blinded, placebo controlled, counter-balanced, cross-over design|t|f|f|f
34042741|NCT01906216|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042742|NCT06055517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042743|NCT06564675|||COHORT||PROSPECTIVE|||||||
34042744|NCT06572059|||CASE_CONTROL||OTHER|||||||
34042745|NCT03347305|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking|||||
34042746|NCT05729789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042747|NCT05633160|NA|SINGLE_GROUP||TREATMENT||NONE||This study is to be conducted in 2 phases, a dose escalation phase and a cohort expansion phase||||
34042748|NCT02134054|||COHORT||PROSPECTIVE|||||||
34042749|NCT03738436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042750|NCT05740566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042751|NCT02206919|||COHORT||PROSPECTIVE|||||||
34042752|NCT02194283|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34042753|NCT02097745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042754|NCT05939960|||COHORT||PROSPECTIVE|||||||
34042755|NCT03444181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042756|NCT06314672|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34042757|NCT01548040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042758|NCT00674960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042759|NCT00381862|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34042760|NCT00068120|||||PROSPECTIVE|||||||
34042761|NCT06369454|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042762|NCT04027530|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34042763|NCT05176821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042764|NCT00928096|||COHORT||PROSPECTIVE|||||||
34042765|NCT01438398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042766|NCT06573684|||CASE_ONLY||CROSS_SECTIONAL|||||||
34042767|NCT04754932|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34042768|NCT04871048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* active tDCS stimulation. Patients will receive 10 sessions of tDCS over 5 consecutive days, at a frequency of 2 sessions per day spaced at least two hours apart, at an intensity of 2mA, for 20 minutes each.~* tDCS placebo stimulation. Patients will receive 10 sessions of tDCS over 5 consecutive days, at a frequency of 2 sessions per day spaced at least two hours apart, following an identical procedure (tracking, then wearing the device for 20 minutes) but with actual stimulation provided during the first 40 seconds."|"Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.~The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures."|t|t|f|f
34042769|NCT03596112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34042770|NCT06576986|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34042771|NCT02112383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042772|NCT01095562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042773|NCT01749475|||||PROSPECTIVE|||||||
34042774|NCT05921578|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34042775|NCT00060242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042776|NCT06576531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042777|NCT05881564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042778|NCT03349879|||FAMILY_BASED||RETROSPECTIVE|||||||
34042779|NCT00002837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042780|NCT04992806|||OTHER||RETROSPECTIVE|||||||
34042781|NCT02989038|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34042782|NCT06329349|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomized cross-over||||
34042783|NCT04936100|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34042784|NCT04634344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042785|NCT01435460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34042786|NCT02283684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042787|NCT04944914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042788|NCT06578260|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster Randomized Controlled trial (CRCT)|t|f|f|f
34042789|NCT01379768|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34042790|NCT04740671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042791|NCT02200172|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34042792|NCT04079179|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of 4 groups in parallel for the duration of the study. All 4 groups receive the same intervention.||||
34042793|NCT01920412|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042794|NCT02361463|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042795|NCT04519268|||COHORT||PROSPECTIVE|||||||
34042796|NCT03807479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042797|NCT03058562|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34042798|NCT06575985|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Considering that the heat acclimation condition will be easily perceptible to the participants, it will not be possible to blind them from their group assignment. The investigators will also be required to set the environmental conditions for each exercise session, so they will also be aware of group assignment during the intervention. However, efforts will be made to blind outcomes assessors to group assignment, by reassigning unique participant identifier codes with the random assignment of A and B to the experimental and control groups by a third party. The experimental and control group can therefore be compared, without knowledge of which label corresponds to which group until after data processing and statistical analyses have been performed."||f|f|f|t
34042799|NCT03792100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation to the treatment arms will not be known to the patient||t|f|f|f
34042800|NCT02830503|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042801|NCT00199810|||COHORT||PROSPECTIVE|||||||
34042802|NCT01580605|||COHORT||PROSPECTIVE|||||||
34042803|NCT03616574|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1 (dose escalation) of the study will use a conventional 3+3 design (3 subjects per dose cohort, with the potential to add an additional 3 subjects if dose limiting toxicity \[DLT\] is observed at the same dose level at which the toxicity occurred). Enrollment will occur in 2 groups, CA102N monotherapy (Group A) and CA102N combination therapy (Group B).~Subjects will be enrolled in Group A first. Once enrollment in Group A has been completed, subsequent subjects will be enrolled in Group B.~In Part 2 of the study, the safety and tolerability of the preliminary RP2D of CA102N combined with trifluridine/tipiracil (LONSURF) will be further evaluated in up to 12 additional subjects with relapsed or refractory locally advanced or metastatic colorectal cancer who have previously received oxaliplatin and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy."||||
34042804|NCT05707468|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio between arm A (hormone) and arm B (neoadjuvant hormone and RT).||||
34042805|NCT06576700|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot,open label, single-treatment trial in which the enrolled subjects will be included in a one-year period, after the written informed consent collection. 25 UC patients in remission phase, both males and females, will be included in a one-year period, after the written informed consent collection. Patients will be treated with the Ecovitis extract. Patients will be asked to take 2 capsules per day, away from meals, for 8 weeks. The therapy undertaken could not be changed nor stopped during the supplement administration.||||
34042806|NCT00640757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042807|NCT04856306|||COHORT||PROSPECTIVE|||||||
34042808|NCT03871751|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking.|All participants will receive the auditory intervention.||||
33730526|NCT05693610|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Since the portable and cloud-based versions of the device are visibly different, it is not possible to mask the participant.|Within-subjects design; Different levels of intervention outcomes are compared||||
34117373|NCT03183310|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Sessions will run in a double-blind randomized-controlled way. The order of placebo and chlorpromazine administration will be randomized by an online randomization tool (http://www.randomization.com/). The randomization scheme will be carried out by an experienced independent researcher or study nurse, this person will prepare and inject chlorpromazine or placebo. In this way, the investigator performing the actual study and data analysis will be blinded until termination of the study.|a randomized, double-blind, placebo-controlled study|t|f|t|t
34117374|NCT00011544|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34117375|NCT06205693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigators will mask the allocation for the outcome assessors and trial statistician who will conduct the analyses, and the author group while writing the abstract for the trial report with the two intervention groups coded as 0 and 1. Due to the nature of the intervention and control, the trial will not be blinded for the surgeons performing the interventions|prospective, randomized, blinded clinical superiority trial|t|f|f|t
34117376|NCT04272697|||COHORT||PROSPECTIVE|||||||
34117377|NCT05007964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117378|NCT03580044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117379|NCT01198587|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117380|NCT03719014|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, multi-center, prospective, supplemental study in which the device, NovaCross™ CTO micro-catheter, will be tested in up to 60 patients scheduled to undergo CTO-PCI using an anterograde approach||||
34117381|NCT03044444|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34117382|NCT06089993|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34117383|NCT02749747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117384|NCT02736071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117385|NCT06631638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117386|NCT06027606|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34117387|NCT05818566|||COHORT||RETROSPECTIVE|||||||
34117388|NCT06477198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for lumbar disc herniation surgery will be included in the study. Patients will be randomly divided into two groups (Group QLB = QLB group, Group ESPB = ESPB group) including 30 patients each, before entering the operating room.|t|f|f|t
34117389|NCT05678946|||COHORT||PROSPECTIVE|||||||
34117390|NCT01960491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117391|NCT04747379|||COHORT||PROSPECTIVE|||||||
34117392|NCT01276704|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34117393|NCT04079660|||CASE_ONLY||PROSPECTIVE|||||||
34117394|NCT00286637|||OTHER||OTHER|||||||
34117395|NCT01935388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117396|NCT05685303|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34117397|NCT00619996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117398|NCT05489471|||CASE_ONLY||PROSPECTIVE|||||||
34117399|NCT04464668|||CASE_ONLY||PROSPECTIVE|||||||
34117400|NCT05276674|||COHORT||PROSPECTIVE|||||||
34117401|NCT06037564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multi-stage, randomized, multicenter, open-label non-inferiority trial with active control|f|f|f|t
34117402|NCT02203643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117403|NCT01906268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117404|NCT06476678|||CASE_ONLY||PROSPECTIVE|||||||
34117405|NCT04841408|NA|SINGLE_GROUP||OTHER||NONE||Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks||||
34117406|NCT01990742|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34117407|NCT04101097|||COHORT||PROSPECTIVE|||||||
34117408|NCT02346669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117409|NCT00000276||||TREATMENT||||||||
34117410|NCT05077410|||CASE_ONLY||PROSPECTIVE|||||||
34117411|NCT05201131|||COHORT||PROSPECTIVE|||||||
34117412|NCT01424800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117413|NCT02359656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117414|NCT06716476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117415|NCT03030378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117416|NCT01220661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117417|NCT00214565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34117418|NCT04550364|||OTHER||OTHER|||||||
34117419|NCT02526784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730527|NCT01889017|||COHORT||RETROSPECTIVE|||||||
33730528|NCT01618357|NA|SINGLE_GROUP||TREATMENT||NONE||A dose finding trial to assess the acute and late toxicity of pre-operative PARPi and concurrent radiation in women with stage II-IV invasive breast cancer who have had an incomplete response to NAC. Our primary goal is to assess the acute toxicity a dose finding trial to assess the acute and late toxicity of pre-operative of this combined modality therapy.||||
33730529|NCT03984422|||CASE_ONLY||PROSPECTIVE|||||||
33730530|NCT00907634|||||PROSPECTIVE|||||||
33730531|NCT03915249|||CASE_CONTROL||RETROSPECTIVE|||||||
33730532|NCT00757835|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33730533|NCT05827497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730534|NCT02431208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730535|NCT02619695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730536|NCT04751591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730537|NCT06103006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730538|NCT02241499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730539|NCT02489175|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730540|NCT05630027|||COHORT||PROSPECTIVE|||||||
33730541|NCT02315638|||CASE_ONLY||PROSPECTIVE|||||||
33730542|NCT01069055|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117420|NCT02433964|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34117421|NCT03501628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117422|NCT01819740|||CASE_ONLY||PROSPECTIVE|||||||
34117423|NCT00586157|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34117424|NCT06433583|NA|SINGLE_GROUP||OTHER||NONE||||||
34117425|NCT05603260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Four single case series A-B-A within subject designs|f|f|f|t
34117426|NCT01880957|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34117427|NCT00678704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117428|NCT06710080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117429|NCT03984279|||COHORT||RETROSPECTIVE|||||||
34117430|NCT05853601|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34117431|NCT04964947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117432|NCT04807738|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All participants of the study will undergo a clinical examination including a questionnaire survey, led by a blinded independent examiner, who will not have access to intervention documentation. The examiner will see each patient twice, before the first intervention and in follow-up examination in a week following the last therapy. The examiner will be prohibited to talk about the therapy attended. The patients will be informed about the character of the examination and the importance of the most objectivity possible. All therapists can apply both interventions, therefore masking is more efficient.|"A randomized controlled trial. 110 outpatients will be randomized into two interventional groups, one with face-to-face individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The second arm will place the same therapy, but virtual reality environment. Participants of both groups - active comparator and virtual reality interventional group will undergo 15 hourly therapies, twice a week in a time range of two months. Before and in a week following the last therapy, all participants will be examined by a blinded independent clinician."|f|f|f|t
34117433|NCT03976336|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34117434|NCT05300477|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants and Investigators will be blinded to who receives erythropoietin and placebo. Medical providers and a subset of staff will be aware of participants receiving erythropoietin and placebo. Participants, Investigators, and Medical Providers will all be aware of participants administered acetazolamide.|This study will use a double-blind randomized study design in which one group will receive erythropoietin and the other group will receive the placebo for 4 weeks. After the 4 weeks, both groups will receive acetazolamide.|t|f|t|f
34117435|NCT06529432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A multicenter, randomized, double-blind, dose-finding, positive control, phase Ⅱ clinical trial of liposomal bupivacaine injection|t|t|t|f
34117436|NCT03081689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117437|NCT06297876|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Participants will view either storytelling videos or learn more videos. They will not know which video they will get ahead of time nor will they know that they may get one or the other.||t|f|f|f
34117438|NCT03440385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117439|NCT04827706|||COHORT||OTHER|||||||
34117440|NCT06712602|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34117441|NCT02468830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117442|NCT06717880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117443|NCT01464879|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117444|NCT03181867|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34117445|NCT05185843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117446|NCT04960670|||COHORT||PROSPECTIVE|||||||
34117447|NCT05053191|NA|SINGLE_GROUP||OTHER||NONE||||||
34117448|NCT03768323|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomized to one of three airtime incentive amounts: 1) no incentive; 2) 1X incentive; or 3) 2x incentive where X was equal to 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018). Airtime incentives were sent if participants completed the noncommunicable disease risk factor survey|f|f|f|t
34117449|NCT03754322|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34117450|NCT02383316|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117451|NCT00095550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117452|NCT00444314|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149749|NCT03710304|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used.|"participants will be randomized via a computer-generated random number sequence into one of two groups: one group received a pre-prepared sealed and opaque packet containing 400 μg of misoprostol (2 tablets of 200 μg), 2 ampoules of TA (1 gm for infusion) and separate placebo ampoule (distilled water). The other group received similar packets containing two placebo tablets, two placebo ampoules (distilled water) and separate 2 ampoules of oxytocin (syntocinon; 10 IU in each ampoule for infusion) for slow intravenous injection. The misoprostol and placebo tablets were similar in size, shape, and color, and ampoules of oxytocin was also similar to placebo. Randomization was done by the resident doctors immediately before transfer to theater, whereas preparation of packets and confidential record maintenance was done by the labor room nursing staff.~Study drug administration"|t|t|t|t
34149750|NCT01454349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149751|NCT02391961|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34149752|NCT05248503|||COHORT||PROSPECTIVE|||||||
33730543|NCT06496126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730544|NCT04712604|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33730545|NCT02484495|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730546|NCT03148743|||CASE_ONLY||PROSPECTIVE|||||||
33730547|NCT03588637|||OTHER||OTHER|||||||
33730548|NCT03298828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730549|NCT05363735|||COHORT||RETROSPECTIVE|||||||
33730550|NCT06311383|||COHORT||PROSPECTIVE|||||||
33730551|NCT05827627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study was conducted in two groups: a pelvic simulator group (PSG) and a computer-based simulator group (CBSG).||||
33730552|NCT03646773|||COHORT||PROSPECTIVE|||||||
33730553|NCT04935268|||OTHER||PROSPECTIVE|||||||
33730554|NCT01886248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730555|NCT00952341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730556|NCT00125866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33730557|NCT03566628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811270|NCT05948995|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|On the follow up date , both groups will be removed sling / brace before receiving by outcome assessor|The participants were randomly divided into two groups. The control group received arm sling post operative arthroscopic rotator cuff repair. The experimental group received abduction external rotation brace post operative arthroscopic rotator cuff repair.|f|f|f|t
33811271|NCT05479565|||COHORT||PROSPECTIVE|||||||
33811272|NCT03756545|||COHORT||PROSPECTIVE|||||||
33811273|NCT06510959|NA|SINGLE_GROUP||OTHER||NONE||||||
33811274|NCT06552351|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to receive either needle-free jet injection or traditional lidocaine needle infiltration for local anesthesia during infant lumbar puncture||||
33811275|NCT03507504|||COHORT||PROSPECTIVE|||||||
33811276|NCT03593785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This study is single-blind with regard to treatment (AZD8233 or placebo) at each dose level.~AZD8233 and placebo will be matched for formulation, appearance and amount. Subjects randomized to placebo will receive the same volume of injection as subjects on active drug."||t|f|f|f
33811277|NCT01519882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811278|NCT02488798|||COHORT||PROSPECTIVE|||||||
33811279|NCT01078051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811280|NCT02340806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811281|NCT02798653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811282|NCT05073393|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Computerized randomization only known to the principal investigator, who are not directly involved in data collection or data analysis|Double blinded randomized clinical trial with a test and placebo group|t|t|t|t
33811283|NCT03481985|||COHORT||PROSPECTIVE|||||||
33811284|NCT02353507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811285|NCT02915211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811286|NCT06452121|||COHORT||PROSPECTIVE|||||||
33811287|NCT01116609|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33811288|NCT00635635|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33811289|NCT04090502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33811290|NCT04269044|||COHORT||PROSPECTIVE|||||||
33811291|NCT01487460|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33811292|NCT00655785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811293|NCT02562274|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33811294|NCT01745666|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33811295|NCT02398955|||CASE_ONLY||PROSPECTIVE|||||||
33811296|NCT04848532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811297|NCT04454112|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||to compare the results of pre- and postoperative 24-hour pH monitoring in patients who underwent gastrostomy only and who underwent fundoplication concurrently with gastrostomy and to evaluate influence of gastrostomy/ LNF+ gastrostomy on GER.||||
33811298|NCT02732132|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33811299|NCT02845609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811300|NCT01444404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811301|NCT01784809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33730558|NCT01890772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730559|NCT06486571|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730560|NCT00301405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730561|NCT04269759|||COHORT||PROSPECTIVE|||||||
33730562|NCT05981638|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33730563|NCT04174313|||OTHER||PROSPECTIVE|||||||
33730564|NCT03904771|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33730565|NCT04212585|||COHORT||CROSS_SECTIONAL|||||||
33730566|NCT01402362|||COHORT||PROSPECTIVE|||||||
33730567|NCT05277311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730568|NCT01686412|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33730569|NCT04238728|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Silverlon dressing||||
33730570|NCT01190254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811302|NCT01338532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811303|NCT06205836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811304|NCT01407874|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811305|NCT04272385|||COHORT||PROSPECTIVE|||||||
33811306|NCT04336709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participant or the care provider cannot be masked due to difference in colors of the medicaments, Metapex being yellow. The investigator (lab technician) and outcome assessor will be masked regarding the groups.|First visit: After chemomechanical preparation, irrigation and drying, a sterile paper point (size 20; EZ Endo, USA) will be inserted to the confirmed working length of the canal, and retained in position for 60 seconds for sampling (S1). Afterwards, the paperpoint will be gently removed and placed in an eppendorf tube (5 ml) containing Brain Heart Infusion Broth and sent directly to the microbiology laboratory for microbial cultivation. Respective intracanal medicament will be placed by means of lentulo spiral fillers and packed with a cotton pellet at the level of canal entrance. Access cavity will be filled with a temporary filling, Cavit-G. Second visit after 7 day, medicament will be removed. In case of Metapex (oil based medicament) either Protaper rotary or ultrasonic activation of file will be used for removal and radiograph obtained to ensure removal and sample will be obtained(S2). The canals will be then obturated. A definitive restoration will be placed subsequently.|f|f|t|t
33811307|NCT04130490|||COHORT||PROSPECTIVE|||||||
33811308|NCT05662930|||CASE_CONTROL||PROSPECTIVE|||||||
33811309|NCT00607607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811310|NCT03949257|NA|SINGLE_GROUP||OTHER||NONE||||||
33811311|NCT03137446|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Trial||||
33811312|NCT02368652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811313|NCT04916704|||COHORT||PROSPECTIVE|||||||
33730571|NCT01801787|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33730572|NCT01918527|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730573|NCT02210429|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33730574|NCT03483935|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, internally controlled trial||||
33730575|NCT00906191|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34149753|NCT02565810|NA|SINGLE_GROUP||OTHER||NONE||||||
33730576|NCT03850145|||CASE_ONLY||RETROSPECTIVE|||||||
33730577|NCT04516265|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with cerebral palsy will be divided into 3 groups in a randomized controlled manner. Each group will continue and follow routine physiotherapy and rehabilitation treatments for 8 weeks. Then, structured trunk training will begin. NGT-based trunk training (45 minutes) to the first group, video-based trunk training (45 minutes) to the second group, and Video-based trunk training (45 minutes) will apply with Theratogs to the third group. Treatments will be applied two days a week for 8 weeks.||||
33730578|NCT01353378||SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34149754|NCT00951756|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33730579|NCT05872009|||COHORT||PROSPECTIVE|||||||
33730580|NCT01262014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730581|NCT05196919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled, double blind||t|t|t|t
33730582|NCT04050111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149755|NCT03070821|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Healthy subjects in the sham feedback condition were not aware of their group membership, but were debriefed at the end of the study.|The design is a pre-test/post-test study with an intervention of three parallel groups. The groups are a healthy elderly experimental group, a patient group and a healthy elderly sham-feedback group.|t|f|f|f
33730583|NCT01106456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730584|NCT02091791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33730585|NCT01783951|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730586|NCT03640065|RANDOMIZED|PARALLEL||TREATMENT||NONE|only statistician was blind known participants only by codes|||||
33730587|NCT01072695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730588|NCT02972528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33730589|NCT00849966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730590|NCT03080103|||COHORT||PROSPECTIVE|||||||
33730591|NCT03479866|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730592|NCT01843244|||COHORT||PROSPECTIVE|||||||
33811314|NCT03055598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811315|NCT03979937|||COHORT||PROSPECTIVE|||||||
33811316|NCT02795741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811317|NCT02312544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811318|NCT03595670|||COHORT||PROSPECTIVE|||||||
33811319|NCT02689011|RANDOMIZED|PARALLEL||||NONE||||||
33811320|NCT05756569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811321|NCT03450811|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The control group consisted of volunteer participitants who were admitted to the outpatient clinics with various reasons or healthy persons|The patients who underwent elective open or laparoscopic inguinal hernia repair were treated by a single general surgeon.|t|f|f|f
33811322|NCT04918394|||COHORT||PROSPECTIVE|||||||
34149756|NCT04395287|||COHORT||PROSPECTIVE|||||||
34149757|NCT00102713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149758|NCT04996082|||CASE_CONTROL||PROSPECTIVE|||||||
34149759|NCT06371534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149760|NCT01058590|||COHORT||PROSPECTIVE|||||||
33730593|NCT00285506|||||OTHER|||||||
33730594|NCT05076643|||OTHER||CROSS_SECTIONAL|||||||
33730595|NCT02423616|NA|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
33730596|NCT02507414|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730597|NCT01285648|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33730598|NCT04966338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730599|NCT03132051|NA|SINGLE_GROUP||TREATMENT||NONE||All patients received steroid injection for carpel tunnel syndrome (CTS) and ultrasonographic evaluation before and after steroid injection||||
33730600|NCT00974714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730601|NCT04019041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomized to every week bermekimab injections, every other week bermekimab injections, or every week placebo injections.|t|t|t|t
33811323|NCT00712179|||||CROSS_SECTIONAL|||||||
34149761|NCT04722757|RANDOMIZED|PARALLEL||TREATMENT||NONE||The FUNCTIon trial is designed as a multicenter, open-label, 2-arm parallel-group, non-inferiority randomized multicenter international trial. Randomization will be stratified by center, with permuted blocks and balanced allocation (1:1). Neither participants nor treating physicians will be blinded to treatment allocation.||||
33730602|NCT00913094|||COHORT||PROSPECTIVE|||||||
33730603|NCT02189057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Subject and study staff will be blind to randomization.|Subjects will be randomized to either genotyping intervention or treatment as usual.|t|f|t|f
33730604|NCT01752478|||CASE_ONLY||PROSPECTIVE|||||||
33730605|NCT05010928|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33730606|NCT02460770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730607|NCT03464903|||CASE_CONTROL||OTHER|||||||
33730608|NCT04152122|||COHORT||PROSPECTIVE|||||||
33730609|NCT00025883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730610|NCT04576533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33730611|NCT00390975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811324|NCT01303744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811325|NCT05672485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811326|NCT00955565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839762|NCT04467918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A total of 104 patients with SARS-CoV-2 infection will be included in the study (i.e., 52 cases in the CBD group plus pharmacological and clinical measures and 52 in the placebo group plus pharmacological and clinical measures). All patients will receive the clinical and pharmacological measures standardized by the Brazilian Ministry of Health's practical guidelines for diagnosis and treatment for mild and moderate cases for SARS-CoV-2|t|t|t|t
33839763|NCT04383353|||CASE_CONTROL||PROSPECTIVE|||||||
33730612|NCT01464515|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34042809|NCT06204263|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33730613|NCT01247090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730614|NCT04333810|||COHORT||PROSPECTIVE|||||||
33730615|NCT00423306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730616|NCT00542152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730617|NCT05222113|||CASE_ONLY||RETROSPECTIVE|||||||
33730618|NCT06109428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In each cohort, subjects will be randomized in a 2:1 ratio to HTX-011 or bupivacaine HCl, respectively. All subjects will receive a scheduled postoperative non opioid multimodal analgesic (MMA) regimen.|t|f|f|t
34042810|NCT00649922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042811|NCT03066713|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33730619|NCT00191503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730620|NCT05115383|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33730621|NCT05145166|||CASE_ONLY||PROSPECTIVE|||||||
33730622|NCT04975464|||COHORT||CROSS_SECTIONAL|||||||
33730623|NCT00356551|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730624|NCT01972672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730625|NCT05938361|||COHORT||PROSPECTIVE|||||||
33730626|NCT00186004|||COHORT||PROSPECTIVE|||||||
33730627|NCT01659112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730628|NCT00122343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730629|NCT05687240|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042812|NCT02402387|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33730630|NCT04808050|||COHORT||RETROSPECTIVE|||||||
33730631|NCT00749775|||CASE_ONLY||PROSPECTIVE|||||||
33730632|NCT00202618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730633|NCT03225612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730634|NCT04561076|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|Double-Blind, Placebo-Controlled||t|t|t|t
33730635|NCT02439112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33730636|NCT01411306|||COHORT||PROSPECTIVE|||||||
33730637|NCT05897879|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730638|NCT04364529|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|"The partisipants are unknown of the study design. They are told that they have been randomized in two groups who receive ALS education in two different ways.~Two senior anesthetists analyse the ALS-performance of the video recordings. They are unaware of the study design. They analyze the videos independently and in random order."|The students are divided into 26 four-person resuscitation teams: one medical student, one student paramedic and two student nurses. These 26 teams are randomidez in two study arms: intervention (pit-crew group) and the control Group.|t|f|t|t
34042813|NCT03111680|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|people collecting data were unaware of study condition|this was a cluster randomized trial, with housing developments randomized to intervention or control|f|t|t|f
33730639|NCT02888899||||TREATMENT||||||||
33730640|NCT03730948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730641|NCT01619033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730642|NCT05905588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730643|NCT06068569|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33730644|NCT02143115|||CASE_ONLY||PROSPECTIVE|||||||
33730645|NCT01308190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730646|NCT01221974|NA|SINGLE_GROUP||TREATMENT||||||||
33730647|NCT00151814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730648|NCT03521258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730649|NCT02296814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730650|NCT03634553|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730651|NCT06423235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811327|NCT05073822|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The investigators propose to conduct the study in two phases. Phase I will randomise renal transplant recipients over the age of 60yrs to either standard of care Immunosuppression (SOC-IS) or minimised immunosuppression (Min-IS) therapy, with monitoring of plasma dd-cfDNA levels over the first post-transplant year.~There will be different target drug levels for tacrolimus: SOC-IS target levels of 8-12ng/ml in the first 3 months, 6-8ng/ml in months 4-12 and 4-8ng/ml after the 1st year; Min-IS levels 6-8ng/ml for first 3 months and 4-8ng/ml in months 4-12, For mycophenolate there will be two doses used: SOC-IS dose starting at 2g/day for 1 month, then 1.5mg/day between months 2-12, and then 1g/day after the 1st year; for Min-IS 1.5g/day in the first month and then 1g/day until 1 year post-transplantation. Outcomes will be assessed by the end of year 1"||||
33811328|NCT00241618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811329|NCT02345551|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811330|NCT00204399|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
33811331|NCT03738592|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33811332|NCT00162006|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811333|NCT01799603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730652|NCT04412330|NA|SINGLE_GROUP||TREATMENT||NONE|Prospective study with one-treatment arm|||||
33730653|NCT06210087|RANDOMIZED|PARALLEL||OTHER||SINGLE||Spontaneous pushing-Experimental Group Valsalva-type pushing-Control Group|t|f|f|f
33730654|NCT05232604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assessors (assessing clinician assessed outcomes) and the statistician will be blinded to group allocation. Participants will be unaware of the hypothesis of this study to decrease performance biases.|Two groups (aerobic exercise group and neck motor control exercise group) will receive the protocol at the same time period.|t|f|t|t
33730655|NCT01228630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839764|NCT00036348||||TREATMENT||||||||
33839765|NCT04219995|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33839766|NCT01466218|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839767|NCT05337553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839768|NCT05231525|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33839769|NCT05619497|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33839770|NCT03112915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind randomized controlled trail|Double-blind randomized controlled trail|t|f|t|t
33730656|NCT04262336|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind|"Part A: DB-020 12% right ear/placebo left ear; DB-020 12% left ear/placebo right ear; DB-020 25% right ear/placebo left ear; DB-020 25% left ear/placebo right ear on Day 1 of every 21 or 28 day cisplatin cycle for up to 6 cycles until cisplatin administration is discontinued~Part B: DB-020 12% both ears or DB-020-25% both ears on Day 1 of every 21 or 28 day cisplatin cycle for up to 6 cycles until cisplatin administration is discontinued"|t|t|t|t
33730657|NCT01495845|NA|SINGLE_GROUP||||NONE||||||
33730658|NCT00136292|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33730659|NCT00003196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730660|NCT00157599|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042814|NCT03813680|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
33730661|NCT01399593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730662|NCT03857087|||COHORT||PROSPECTIVE|||||||
33730663|NCT01277939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730664|NCT03001921|||COHORT||PROSPECTIVE|||||||
33730665|NCT03143270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730666|NCT03050905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730667|NCT01120210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730668|NCT04872855|||COHORT||OTHER|||||||
33730669|NCT00885833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730670|NCT05718635|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33730671|NCT01327352|NA|SINGLE_GROUP||||NONE||||||
33730672|NCT05675553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730673|NCT05479578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730674|NCT05761275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730675|NCT03073096|NA|SINGLE_GROUP||PREVENTION||NONE||All melanoma and other skin cancers (merkel cell carcinoma, squamous cell carcinoma as well as sarcoma patients requiring a nodal dissection (groin or axillary) will be offered to have a LVA at time of nodal dissection to prevent lymphedema.||||
33730676|NCT01365780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730677|NCT00000540|RANDOMIZED|||TREATMENT||||||||
33730678|NCT03672695|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33730679|NCT04091646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730680|NCT03810066|NA|SINGLE_GROUP||TREATMENT||NONE||Simon 2 step design||||
33730681|NCT04466475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730682|NCT00222456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730683|NCT04780425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Persons delivering the intervention are not involved in patient care||f|t|f|f
33730684|NCT02069522|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33730685|NCT04169867|||CASE_ONLY||CROSS_SECTIONAL|||||||
33730686|NCT05512676|||CASE_ONLY||PROSPECTIVE|||||||
33730687|NCT00234195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730688|NCT04001569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730689|NCT03570866|||COHORT||PROSPECTIVE|||||||
34042815|NCT04644432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730690|NCT02487394|||COHORT||PROSPECTIVE|||||||
33730691|NCT05076266|||COHORT||PROSPECTIVE|||||||
33730692|NCT03026465|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730693|NCT00000946||||PREVENTION||DOUBLE||||||
33730694|NCT04347304|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, open-labelled, parallel controlled trial will be conducted in Universiti Putra Malaysia from October 2021 until December 2022 involving obese adult aged 18 - 45 years.||||
33839771|NCT03496077|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized cross-over study||||
33839772|NCT04715438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839773|NCT05028972|RANDOMIZED|PARALLEL||TREATMENT||NONE||Consenting participants will be randomly assigned to the control or intervention arm of the study. Participants in the intervention arm will receive PockeTalkers (personal amplifiers) for the duration of their time in the emergency department. Participants in the control group will not receive personal amplifiers during their time in the emergency department, but will receive one upon discharge from the emergency department. In later stages, there will be no control group and all participants will receive a personal amplifier during their time in the emergency department.||||
33839774|NCT02720120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730695|NCT06329102|||COHORT||PROSPECTIVE|||||||
33730696|NCT03111420|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Platelet function test results are not provided to the participant, care provider, or investigator||t|t|t|f
33730697|NCT04854915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||pilot, parallel group, randomised controlled trial||||
33730698|NCT04966676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730699|NCT00204256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730700|NCT04623333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730701|NCT04019691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730702|NCT01344369|RANDOMIZED|CROSSOVER||||NONE||||||
33730703|NCT04155515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The non-cirrhotic, HCV genotype 1 infected subjects will be assigned to Group 1. The cirrhotic, HCV genotype 1 infected subjects will be assigned to Group 2. The subjects in Group 1 and 2 will be treated with TG-2349 400mg combined with DAG181 200mg and Ribaverin 1000mg/1200mg for 12 weeks.||||
33730704|NCT03941210|||CASE_CONTROL||OTHER|||||||
33730705|NCT02367599|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33839775|NCT01612273|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33730706|NCT00630071|||COHORT||PROSPECTIVE|||||||
33730707|NCT01813318|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33730708|NCT01725568|||CASE_ONLY||PROSPECTIVE|||||||
33730709|NCT00628290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839776|NCT03597373|||COHORT||RETROSPECTIVE|||||||
33839777|NCT03429777|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||For this study the investigators will test at least 50 subjects with some form or hearing loss and 50 control subjects between the ages of 18-80. The subjects will be invited to take the app. The approach for this study is to characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the app in both subject groups.|f|f|f|t
33839778|NCT00040287|RANDOMIZED|||TREATMENT||||||||
33730710|NCT05638646|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The intervention was delivered at the hospital level. The intervention group will receive QS implementation, including QS training for physicians of respiratory department every 12 weeks; QS implementation check every 12 weeks, and follow-up every 12 weeks, QS-related written COPD clinical procedures will be also suggested to established key QS training requirements are:1) COPD diagnosis and assessment; 2)Therapy prescribed in accordance with national guideline 3)Non-pharmacological interventions; 4)An appropriate follow-up according to QS.~The control group will maintain current practice and follow up every 12 weeks."||||
33730711|NCT04752501|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This research study is a blinded randomized controlled trial. The participants will not be made aware which education video series they watch is the control and which is the intervention. The study staff will be blinded to group allocation until after measurements are completed.||t|t|t|t
33730712|NCT04865796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730713|NCT01202825|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33730714|NCT04067284|RANDOMIZED|PARALLEL||PREVENTION||NONE||A three-arm randomized controlled trial in Dhaka's slum area is proposed. Infants at risk of stunting (-1 SD length-for-age z-score, LAZ) aged around 5 months are eligible for the study. Eligible children will be randomised to receive: 1) nutrition education on dietary diversity; 2) a combination of similar education plus daily supplementation of homemade yogurt; 3) a 'usual care' (control) group. We will recruit 120 children (40 per arm).||||
33730715|NCT06143475|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Clinicians involved in the measurements and researchers that worked with data results did not know which group each patient was in.|Parallel-group, single-blinded controlled clinical trial|t|t|f|t
33730716|NCT02889354|NA|SINGLE_GROUP||TREATMENT||||||||
34042816|NCT05149625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730717|NCT03680274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811334|NCT05569382|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"The trial will be performed and analyzed in three phases, and each phase may be unblinded and analyzed separately.~Phase one: More than 26 patients must have completed all three treatment periods. Functional analyses of VO2 max from CPX tests and secondary functional effect parameters (KCCQ, NYHA, CCS), echocardiographic parameters, biomarkers (TNI/TNT, pro-BNP/BNP).~Phase two: Between 30 to 50 patients must have completed all three treatment periods and have CMR performed in each period. Structural and hemodynamic analyses of cardiac dimensions and hemodynamic effect parameters (CMR). Sex specific analyses of functional, structural and hemodynamic effect parameters will be performed.~Phase three (n \> 82): Arrhythmic effect parameters will be analyzed from ambulatory ECG monitoring."|t|t|t|f
34042817|NCT01019759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042818|NCT03952273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042819|NCT05617157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042820|NCT02934581|||COHORT||PROSPECTIVE|||||||
34042821|NCT05654961|||COHORT||PROSPECTIVE|||||||
34042822|NCT01549587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34042823|NCT02192996|NA|SINGLE_GROUP||||NONE||||||
34042824|NCT01353560|||OTHER||CROSS_SECTIONAL|||||||
34042825|NCT02407925|||COHORT||PROSPECTIVE|||||||
34042826|NCT01796535|||CASE_ONLY|||||||||
33811335|NCT03185793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811336|NCT00836537|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33811337|NCT06318377|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Individual will be randomly assigned either an experimental or a control condittion||||
33811338|NCT05210309|||COHORT||PROSPECTIVE|||||||
34042827|NCT04953442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042828|NCT02752243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042829|NCT02095639|||COHORT||PROSPECTIVE|||||||
34042830|NCT02087540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149762|NCT03495791|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34042831|NCT05675592|||COHORT||OTHER|||||||
34042832|NCT03278327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042833|NCT02134015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042834|NCT04145180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34042835|NCT04644302|||COHORT||PROSPECTIVE|||||||
34042836|NCT03431831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Statistician will make random assignment envelopes, clerical staff will collect intake forms and make envelope assignments according to randomization schedule. Participants will see different providers based on trial arm assigned to.||f|t|t|f
34042837|NCT03957200|||OTHER||PROSPECTIVE|||||||
34042838|NCT00226460|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34042839|NCT03297645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34042840|NCT01686464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042841|NCT00381082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34042842|NCT04725162|||CASE_CONTROL||RETROSPECTIVE|||||||
34042843|NCT06018324|||COHORT||PROSPECTIVE|||||||
34042844|NCT02589639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042845|NCT00640913|||CASE_ONLY||PROSPECTIVE|||||||
34149763|NCT05314933|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34149764|NCT00028886|RANDOMIZED|||TREATMENT||||||||
34149765|NCT05978635|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Once an adequate seal with consistent end tidal carbon dioxide on capnography is achieved, time starts. Patients are divided into two groups:~Group A: Anesthesia provider encourages patient to breathe deeply by intermittently stating take as deep a breath as you can. No goal directed numeric coaching is given. End point is 80% expired oxygen. The time it takes to achieve this end point and breath volumes are recorded.~Group B: Anesthesia provider gives goal directed numeric coaching. For example, if the initial tidal volume achieved by the patient is 500mL, the provider states, that was a 500mL breath, now try to achieve a 1000mL breath. The numeric goal should continue to increase above the patient's actual tidal volume (volume moved in and out of lungs during normal, quiet breathing) until an end point of 80% is reached. The time it takes to achieve this end point and breath volumes are recorded."||||
34149766|NCT04033068|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34149767|NCT02107872|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34149768|NCT05818514|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34042846|NCT06577233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subject will be told that the study is regarding postoperative pain control and superior hypogastric nerve plexus blocks with bupivacaine hydrochloride and that they will be randomized into the placebo group or the intervention group, but will be blinded to their assignment. They will be informed they have a 50% chance of being randomized to the investigative treatment group and a 50% chance of being chance of being randomized to the placebo group. Risks and benefits of the procedure as well as consent for the procedure will be obtained. The subject will be assigned a number to de-identify the data and then be randomized using a computer generator and RedCap. The practitioner will be aware of the group that is assigned.|This study will be a randomized single blind clinical trial where the participant will be blinded to whether they received a superior hypogastric nerve block with 0.25% Bupivacaine Hydrochloride (investigative treatment) or 0.9% normal saline (placebo). The researcher will not be blinded and will know which arm the participant has been randomized to. Randomization will be performed by a computer generator in RedCap.|t|f|f|f
33730718|NCT02127502|||COHORT||PROSPECTIVE|||||||
33730719|NCT06113952|||COHORT||PROSPECTIVE|||||||
33730720|NCT04596150|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730721|NCT05779813|||FAMILY_BASED||PROSPECTIVE|||||||
33730722|NCT02815228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730723|NCT02029534|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730724|NCT03800719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730725|NCT01200875|||CASE_ONLY||PROSPECTIVE|||||||
33811339|NCT01008787|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811340|NCT02346357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811341|NCT00368394|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34042847|NCT02761421|||COHORT||PROSPECTIVE|||||||
33811342|NCT04271865|NA|SINGLE_GROUP||TREATMENT||NONE||providing Dates fruits as a potential palliative remedy to mitigate anaemia combined with nutritional education||||
33811343|NCT05015842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042848|NCT06534099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042849|NCT05253469|||COHORT||RETROSPECTIVE|||||||
34042850|NCT03532425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042851|NCT04222998|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Sub-villages (dusun) will be randomly assigned to control and treatment group with around 740 caregiver-child (9-14 months) dyads in each group."||||
34042852|NCT01822093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042853|NCT03459560|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34042854|NCT04071210|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|PI are the only one aware of participant status.|Randomized double blind clinical trial|t|t|t|t
34042855|NCT03684707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized clinical trials|f|f|f|t
34042856|NCT04558801|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34042857|NCT05720338|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042858|NCT03510845|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042859|NCT05236205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical evaluations of the carious tissue removal, as well as the microbiological and radiographic analyses, will be performed by examiners blinded to the treatments performed on each tooth.||f|f|f|t
34042860|NCT06120426|||COHORT||PROSPECTIVE|||||||
34042861|NCT02645474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042862|NCT00600912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34042863|NCT02980068|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042864|NCT04759560|||COHORT||PROSPECTIVE|||||||
34042865|NCT01174823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042866|NCT02491840|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042867|NCT02043444|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34042868|NCT00767455|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
34042869|NCT00433394|NA|SINGLE_GROUP||||NONE||||||
34042870|NCT06575673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34042871|NCT02866292|||||CROSS_SECTIONAL|||||||
34042872|NCT03188289|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34042873|NCT04445272|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, one-arm, open label, multicentre study||||
34042874|NCT06159231|||COHORT||RETROSPECTIVE|||||||
34042875|NCT00053690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042876|NCT00204919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042877|NCT03935139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042878|NCT06273514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042879|NCT05373732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was stratified by age, gender, mean arterial pressure, left ventricular mass index (LVMI), and antihypertensive medication. Investigators, data collectors and data management staff were blinded to group assignment. The biostatistician concealed the allocation by conveying the group assignment to the project manager who then informed each participant and instructed them not to reveal it to the research and data collection staff during the course of the study.|A randomized, controlled, single-blinded, clinical trial was conducted to compare the effect of Transcendental Meditation (TM) and health education (HE) on left ventricular mass in adult hypertensive African-Americans|f|t|t|t
34149769|NCT06383104|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34149770|NCT01291277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149771|NCT05241925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34149772|NCT03163368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730726|NCT00000537|RANDOMIZED|||PREVENTION||||||||
33730727|NCT01331031|||||CROSS_SECTIONAL|||||||
33730728|NCT04204018|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The study will enroll practicing OB/GYNs in the US. All eligible and consented participants will complete 4 patient simulations. The intervention arm only will receive educational material about Progenity's test prior to these simulations, and be provided simulated Progenity test results in the simulated cases.||||
33730729|NCT04287907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811344|NCT05409170|||CASE_ONLY||RETROSPECTIVE|||||||
33811345|NCT03093064|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||This is an experimental medicine study, the purpose of which is provide a mechanistic understanding of neuroinflammation in schizophrenia by investigating response to natalizumab (phase 1b).|t|t|t|t
34042880|NCT05887440|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Due to the nature of the intervention neither subjects nor staff can be blinded to allocation. The outcome assessors and data analyst will be blinded to research aims and randomization (multiple baseline design before introducing isokinetic strength training)|Single Case Experimental Design (SCED)|f|f|f|t
34042881|NCT04160234|||COHORT||PROSPECTIVE|||||||
34042882|NCT05261516|RANDOMIZED|PARALLEL||OTHER||SINGLE|"For practical reasons it is impossible to blind the investigator who conducts the anesthesia. However, the parameters of neuromuscular block are standardized, and study outcomes will be evaluated using the data stored and displayed in theTetraGraph Viewer software. All neuromuscular measurements of the study outcomes are reproducible and objective.~In contrast, the investigator evaluating the patient in the postanesthetic care unit and for the 24 h postoperative visit will be blinded to the study group allocation.~The patient will also be blinded to the study group allocation."|This study is a three centers prospective randomized, electrophysiological, single blinded study that will include 96 patients allocated to one of four arms: one arm with propofol anesthesia and three arms with volatile anesthetics (one arm with isoflurane, one with sevoflurane and one with desflurane). Each arm will have 24 patients.|t|f|f|f
34042883|NCT01289860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33811346|NCT02290548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33811347|NCT03967197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33811348|NCT01111006|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811349|NCT00230906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042884|NCT05024188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34042885|NCT05668416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant, Outcomes Assessor)|It is a randomized controlled trial. In this parallel group study, intervention group and control group will take place.|t|f|f|f
34042886|NCT03193853|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin.||||
34042887|NCT03084120|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||a prospective monocentric study, not therapeutic, and physiopathological||||
34042888|NCT04986345|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A semi-randomized (experimental conditions) crossover design will be used with a population of elderly women with T2D, and with three experimental conditions (1- rest, 2-HIIT-10: 10x 1 min, 3- HIIT-4: 4 x 4 min).||||
34042889|NCT02535767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042890|NCT06510270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34042891|NCT05372432|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34042892|NCT02254590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042893|NCT04912908|||CASE_CROSSOVER||PROSPECTIVE|||||||
34042894|NCT04800328|||OTHER||OTHER|||||||
34042895|NCT03956563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34042896|NCT01672541|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34042897|NCT05868330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective Randomized Control||||
34042898|NCT00799474|||COHORT||CROSS_SECTIONAL|||||||
34042899|NCT06296758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be conducted through blocked randomization with blocks of 4 according to a schedule not known to the investigators using a computerized algorithm. The attending surgeon, anesthetist, and nursing team will be blinded to the randomization assignment.|A concealed-allocation parallel-group blinded randomized controlled clinical|t|t|t|t
34042900|NCT00728260|||COHORT|||||||||
34042901|NCT03152877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34042902|NCT06439875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042903|NCT04994340|||COHORT||CROSS_SECTIONAL|||||||
34042904|NCT04547985|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34042905|NCT03866512|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind study design||t|f|t|f
34042906|NCT01215591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042907|NCT03384030|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Subjects will be kept naïve with respect to the fact that stress responses are the primary responses of interest.|All participants receive the same intervention. 30 healthy males are subjected to the adapted STMST to induce emotional sweating.||||
34042908|NCT01945723|||CASE_ONLY||CROSS_SECTIONAL|||||||
34042909|NCT03823170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher who will evaluate the treatments through the syringe test will be masked as to the type of treatment performed in each patient. The investigator responsible for the treatment and the patient will not be masked.|Groups: treatment with laser therapy (Group 1); treatment with fluorotherapy (Group 2) and treatment with laser therapy and fluorotherapy (Group 3).|f|f|f|t
34042910|NCT02174510|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34042911|NCT02714439|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34042912|NCT04582539|NA|SEQUENTIAL||TREATMENT||NONE||||||
34042913|NCT04316871|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"This randomized, double blinded, clinical trial was approved by the local ethics committee of faculty of medicine, Assuit University, Assuit, Egypt. The maximum total PCA morphine consumption was 12 ± 16 mg while in healthy controls was 70± 35 mg. We aim to enroll at least 60-80 participants considering the following assumptions:~* Main statistical test is ANOVA\\t-test to detect the difference of the difference of PCA morphine consumption between the four groups.~* Main outcome variable is total PCA morphine consumption after lower abdominal cancer surgery in elderly patients receiving three different doses of epidural morphine in comparison with its consumption in healthy controls not receiving epidural morphine.~* Effect size = 0.75, Alpha = 0.05, Power = 0.80~* Allocation ratio N4/N3/N2/N1 = 1/1/1/1.~* 22 patients should be enrolled in each group to account for dropouts."|f|f|f|t
34042914|NCT06573385|||COHORT||PROSPECTIVE|||||||
34042915|NCT04168723|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Double-Blind, Randomized, Placebo- and Positive Controlled, Double-Dummy, Parallel-Group, Repeated-Dose Study with a Nested Cross-Over Comparison Between Moxifloxacin and Placebo|t|t|t|t
34042916|NCT02189005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042917|NCT01218087|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811350|NCT03064256|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117453|NCT03567694|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The participants, principal investigator, and all other study personnel involved with participant assessments will remain blinded to the actual treatment assignments of the participants. The principal investigator will be ultimately responsible for ensuring that the integrity of the blind is maintained throughout the study and will be required to notify the sponsor in the event of any breaking of the blind for any reason. An unblinded pharmacist staff will be required at the Clinical Site to comply with the study's randomization and blinding requirements. At the Clinical Site, prior to study initiation, the principal investigator will be responsible for designating a qualified pharmacy staff to serve as the unblinded pharmacy staff in the study. Unblinded pharmacy staff may not participate in any participant assessments.|The study consists of 2 parts, Part A (SAD, including fed/fasted comparison) and Part B (MAD). Part A will include an assessment of the effect of a high-fat breakfast on the absorption and PK profile of HA115, performed in 10 participants at a single dose to be selected based on SAD results and predicted to be associated with therapeutic plasma concentrations. Part B will be a randomized, double-blind, placebo controlled parallel group study of up to 3 dose levels of HA115 given once daily. The number of days of dosing will be based on the results of the PK analysis from Part A. In each cohort, 8 participants will receive active compound fasted and 2 will receive placebo in a randomized, double blind fashion. Safety observations and PK evaluations will be made. Safety data will be reviewed with the SRC prior to each dose escalation.|t|t|t|t
33811351|NCT03731741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042918|NCT01040637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042919|NCT05361577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Phase 1: randomized sham controlled crossover study (active versus sham condition)~Phase 2: Open label study (active condition)"|t|f|f|t
34042920|NCT03924180|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Multicenter randomized controlled trial performed in open and 2 parallel groups: GMP versus amino acids group"||||
34117454|NCT00743470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117455|NCT05003193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117456|NCT04034888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117457|NCT04341623|RANDOMIZED|SEQUENTIAL||OTHER||NONE||All three arms will be done at one time||||
34117458|NCT05040776|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Open Label, Single Dose Escalation Study||||
34117459|NCT01968122|||COHORT||PROSPECTIVE|||||||
34117460|NCT00003156||||TREATMENT||||||||
34117461|NCT02797821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117462|NCT01713439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117463|NCT02096107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117464|NCT04784156|||CASE_CONTROL||PROSPECTIVE|||||||
34117465|NCT06644378|NA|PARALLEL||BASIC_SCIENCE||NONE||||||
34117466|NCT01246882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117467|NCT01132859|||OTHER||PROSPECTIVE|||||||
34117468|NCT04817189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||interventional, open label, randomized, active controlled, parallel arms, multicenter and multinational study||||
34117469|NCT06586398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and investigators and outcomes assessors will be blind to the assignment to active or sham rTMS||t|t|t|t
34117470|NCT05730842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117471|NCT05271357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117472|NCT00897026|||CASE_ONLY||PROSPECTIVE|||||||
34117473|NCT04268238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants and the outcome assessor of sensitivity will be blind to the procedure. However, the researcher who will apply the products is not blind, due to the different forms of clinical manipulation of products.||t|f|f|t
34117474|NCT06140693|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117475|NCT05552365|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The clinical interview (ADIS) will be administered by assessors who will not be told which arm participants are. Participants will be told not to mention intervention arm status to assessors.||f|f|f|t
34117476|NCT05879978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117477|NCT06062303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||comparative multicentre, open-label, investigator-led randomized controlled trial.||||
34117478|NCT03253081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117479|NCT05321563|RANDOMIZED|PARALLEL||OTHER||SINGLE|Individuals collecting longitudinal student-level data for the primary aims will be blind to group assignment. Initial implementation of analyses for primary aims will also be 'analyst-blind.' Analyses for primary aims will first be implemented on data where the key factor of interest (whether the 45-day and 90-day follow-ups occurred post-intervention) has been randomly shuffled. Only once data exclusion criteria have been finalized, models have been properly specified, and any other unforeseen circumstances addressed, will the un-shuffled data be provided to the analyst for the final analysis implementation.|This is a type 1, hybrid effectiveness-implementation trial using a stepped wedge design with stratified, clustered randomization. Investigators will randomly allocate the timing of implementation of the iDECIDE curriculum compared to standard disciplinary response, over approximately 24 months. Schools will cross over from control (i.e., standard disciplinary response) to intervention (i.e., iDECIDE curriculum) with all schools exposed to iDECIDE by the end of the trial.|f|f|f|t
34117480|NCT06396676|||CASE_ONLY||CROSS_SECTIONAL|||||||
34117481|NCT01924780|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34117482|NCT05136170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This was a double-blind study.The vials containing cenegermin (20 mcg/mL) or vehicle were identical in appearance, and the contents of the vials were indistinguishable. All staff directly involved in the analysis of study results remained masked to treatment assignments while the study was in progress. The blind was not broken for any patient during the study before the database lock.|multicenter, double-masked, vehicle-controlled study|t|t|t|t
34117483|NCT02398214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34149773|NCT02184429|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34149774|NCT02796508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34042921|NCT05775393|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34042922|NCT00000918||||TREATMENT||||||||
33811352|NCT03150589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042923|NCT04458402|NA|SEQUENTIAL||TREATMENT||NONE||Dose allocation will be based upon a Bayesian continual reassessment method that incorporates patient-reported outcomes (PRO-CRM17), which uses separate models for the probability of C-DLT and the probability of P-DLT, as well as the accumulated C-DLT and P-DLT data at each dose level, to sequentially allocate each new patient cohort.||||
34042924|NCT05005195|NA|SINGLE_GROUP||SCREENING||NONE|There is no randomisation in this study.|"A non-randomised feasibility study of adding non-contrast CT scanning of the abdomen to the CT chest undertaken in the T2 round of YLST.~YLST is a two-arm, (1:1) implementation study using a single-consent Zelen's randomised controlled design. Participants have already been randomised to intervention (invitation to an initial telephone-based riskassessment and then, if eligible, for a Lung Health Check (LHC) which is carried out on a mobile van and incorporates LDCT scanning for lung cancer) or usual care (no invitation)."||||
34117484|NCT03643835|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Participants will complete three trials under three different body cooling conditions/interventions; passive cooling using the body's natural body cooling mechanisms, body cooling using forearm ice towels, and cooling using the investigational thermal rehab machine.||||
34117485|NCT01019265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117486|NCT04843631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is double-blinded. Sealed participant-specific code break envelopes will be produced by the unblinded statistician so that the treatment assigned to each participant can be obtained if required, in an emergency only, where knowledge of the randomisation code is required to provide appropriate treatment. The code break envelopes will be retained at the clinical unit in a secure, accessible location. Those blinded to study drug assignment include the sponsor, the PI, clinical study personnel participating in participants' care or clinical evaluations, and the study participants.|Double blinded, randomized, parallel group|t|f|t|t
34117487|NCT03339596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117488|NCT06380543|||COHORT||PROSPECTIVE|||||||
34117489|NCT02918448|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34117490|NCT03136120|||COHORT||PROSPECTIVE|||||||
34117491|NCT03540680|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34117492|NCT06715813|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive SNAGs and the second will receive Sternocleidomastoid Release along with SNAGS. Both groups will be recruited concurrently.||||
34117493|NCT06544629|||COHORT||PROSPECTIVE|||||||
34042925|NCT01015365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117494|NCT03564236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Paralell-group randomised controlled trial|f|f|f|t
34117495|NCT06657001|||COHORT||PROSPECTIVE|||||||
34117496|NCT03062943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117497|NCT06149169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117498|NCT04221893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117499|NCT05442736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Fifty-five patients having single rooted teeth with signs and/or symptoms of post treatment disease that were indicated for non-surgical root canal retreatment were participated in this study|f|f|f|t
34117500|NCT03992950|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34117501|NCT02659085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117502|NCT00897884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117503|NCT03586973|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117504|NCT02185300|RANDOMIZED|CROSSOVER||||NONE||||||
34117505|NCT04255771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117506|NCT05544721|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117507|NCT06310382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042926|NCT01563042|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34042927|NCT02770794|NA|SINGLE_GROUP||TREATMENT||NONE|Investigators were masked for ultrasound results|||||
34042928|NCT02407613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042929|NCT02276755|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel assignment|t|t|t|t
34042930|NCT05736120|||COHORT||CROSS_SECTIONAL|||||||
34042931|NCT04440215|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||An interrupted time series design. It consists of observing the same dependent variable over time, with a break in the series of observations corresponding to the introduction of an intervention.||||
34042932|NCT05369065|NA|PARALLEL||TREATMENT||DOUBLE|The participant and follow-up investigators in the randomized cohort will be blinded to the intervention. Subjects in the single-arm treatment non-randomized cohort are not blinded.|Prospective, multicenter safety and performance study including two groups: a double-blind, randomized, sham controlled cohort and a single-arm treatment non-randomized cohort.|t|f|f|t
34042933|NCT00715273|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34042934|NCT01775059|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34042935|NCT04439877|||COHORT||CROSS_SECTIONAL|||||||
34042936|NCT02056184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34042937|NCT02043795|NA|SINGLE_GROUP||OTHER||NONE||||||
34117508|NCT01402310|||COHORT||PROSPECTIVE|||||||
34117509|NCT04863794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117510|NCT05219643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117511|NCT05635006|||OTHER||RETROSPECTIVE|||||||
34117512|NCT00874601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117513|NCT01985789|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34117514|NCT00822302|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34117515|NCT04293562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117516|NCT00188916|||||PROSPECTIVE|||||||
34117517|NCT06393751|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117518|NCT02930148|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117519|NCT04330976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34117520|NCT05221892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117521|NCT06082453|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117522|NCT03302767|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective study||||
34117523|NCT06329219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149775|NCT00987493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149776|NCT01131741|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33730730|NCT04700696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730731|NCT06355869|||OTHER||PROSPECTIVE|||||||
33730732|NCT06416865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811353|NCT03265132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811354|NCT05148052|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34117524|NCT05669222|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|This is a blinded clinical trial. Subjects and clinical assessor (including the follow-up research personnel, clinical events committee (CEC) members, and angiographic core laboratory analysts) will be blinded to the assignment results. All the study site personnel will receive training for the blinding measures before the trial initiating. In addition to standard procedural sedation, music-playing headphones will be worn by the patient during the whole procedure, and patients in both groups will be preset a 10-minute delay for μQFR+RWS or sham calculation before the PCI procedure, a lesion/device evaluation form is required to fill in during the period in both groups, to reduce the possibility of unblinding. All the study site personnel will be trained not to disclose the treatment assignment to the subject in any unplanned time. Blinding to the subjects will maintain until 5-year follow-up completed.||t|f|f|t
34117525|NCT03545672|||COHORT||PROSPECTIVE|||||||
34117526|NCT04400825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single-blind|randomized clinical trial|f|f|f|t
34117527|NCT05595928|||CASE_CONTROL||PROSPECTIVE|||||||
34117528|NCT04027296|||COHORT||PROSPECTIVE|||||||
34117529|NCT05838742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117530|NCT06377150|||COHORT||CROSS_SECTIONAL|||||||
34117531|NCT02146443|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34117532|NCT01163188|||COHORT||RETROSPECTIVE|||||||
34117533|NCT01331759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34117534|NCT06718686|NA|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|f|t
34117535|NCT03773809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Both the patients and the principal investigator will remain blind to the intervention given. After the end of follow up, at the time of data analysis principal investigator will be provided with the information about which patient isgoven placebo and which patient isgivev drug.|"Baseline group:~This group will include 60 vitamin D3 deficient ACO patients.~Group A:~Group A0: Vitamin D3 deficient ACO patients with placebo at day 0. Group A90: Vitamin D3 deficient ACO patients with placebo at day 90~Group B:~Group B0: Vitamin D3 deficient ACO patients with vitamin D3 at day 0. Group B90: Vitamin D3 deficient ACO patients with vitamin D3 at day 90.~All the patients will be similar by age, sex and BMI"|t|f|t|f
34117536|NCT01295710|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117537|NCT01034722|||ECOLOGIC_OR_COMMUNITY|||||||||
34117538|NCT03166748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117539|NCT05899829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117540|NCT02543775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117541|NCT05547672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117542|NCT01480778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117543|NCT03549520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117544|NCT03227042|||OTHER||PROSPECTIVE|||||||
34117545|NCT03781414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117546|NCT05384314|||COHORT||RETROSPECTIVE|||||||
34117547|NCT06639633|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome assessors will be blinded to group allocation|Prospective parallel group with single-blinded design|f|f|f|t
34117548|NCT04325308|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Caregivers and primary outcome evaluators will be masked. Nutrition room staff not involved in patient care will be responsible for determining participant allocation to one of the supplementation groups by opening sequentially numbered sealed envelopes, dispensing feeding syringes with the allocated human milk diet (protein-enriched or usual), and masking caregivers administering the assigned dietary intervention.||t|t|t|t
34117549|NCT00005267|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34117550|NCT06707922|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34117551|NCT06120244|||COHORT||CROSS_SECTIONAL|||||||
34117552|NCT01912235|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117553|NCT04594746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Drug and placebo will be encapsulated and blinded by the investigational pharmacy.||t|t|t|t
34117554|NCT00548535|||||PROSPECTIVE|||||||
34117555|NCT05111756|||COHORT||PROSPECTIVE|||||||
34117556|NCT05027828|||COHORT||PROSPECTIVE|||||||
33811355|NCT03070548|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811356|NCT02132039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33811357|NCT04008953|||COHORT||PROSPECTIVE|||||||
33811358|NCT03351504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization will be performed using dummy codes to represent intervention and control groups by an independent statistician; blinding of the intervention to the participants and field team is not possible, but data analysis will take place prior to unblinding.||f|f|f|t
33811359|NCT03382704|||CASE_ONLY||PROSPECTIVE|||||||
33811360|NCT06134193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811361|NCT02764905|||OTHER||PROSPECTIVE|||||||
33811362|NCT01353872|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
33811363|NCT05813990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811364|NCT06506357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811365|NCT00585793|||COHORT||PROSPECTIVE|||||||
33811366|NCT00378898|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33811367|NCT00004807||||TREATMENT||||||||
33811368|NCT05841342|||CASE_CONTROL||PROSPECTIVE|||||||
33811369|NCT00509509|||||PROSPECTIVE|||||||
33839779|NCT01367470|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34117557|NCT01137890|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33730733|NCT02322554|||OTHER||PROSPECTIVE|||||||
33730734|NCT00485316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730735|NCT03612037|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33730736|NCT05328492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730737|NCT01965808|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33730738|NCT00952094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730739|NCT04013620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839780|NCT04198389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811370|NCT04885140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The methods were based on previous research on the feedback method of health education. A cluster randomized controlled trial design was used. From March 2019 to January 2020, patients who underwent spinal surgery at Tianjin Hospital were enrolled, and 76 met the inclusion criteria for lumbar disc disease (lumbar disc herniation, LDH). Patients were divided into an experimental group and a control group, with 38 patients in each group. Feedback-based health education was conducted for the experimental group, and routine health education was provided for the control group.|t|f|f|t
33811371|NCT03848962|||COHORT||PROSPECTIVE|||||||
34042938|NCT04537234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The study was modified double-blind. The designated vaccine prepare(s)/administrator(s) would be unblinded given that the QIV-HD and QIV-SD vaccines had different dose volumes. Neither the participant nor the investigator nor the study staff in charge of vaccination was aware of which vaccine was administered (the syringes was masked to maintained the blinding of the participants and other members of the clinical site). The unblinded designated vaccine preparer(s)/administrator(s) was not involved in any of the blinded study assessments (eg, immunogenicity, safety).||t|t|t|t
33811372|NCT02016365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811373|NCT00392652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33811374|NCT05779696|||COHORT||CROSS_SECTIONAL|||||||
33811375|NCT06177561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811376|NCT03874949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subject will be randomized in a 1:1 allocation ratio between the two treatment groups.|t|f|t|f
33811377|NCT02160600|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34042939|NCT03319732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042940|NCT04707521|RANDOMIZED|PARALLEL||OTHER||TRIPLE||3M tape ship-shaped combined with strap fixing method|t|t|t|f
34042941|NCT06574906|||OTHER||PROSPECTIVE|||||||
34042942|NCT06210113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||MBSR intervention|t|f|f|f
34149777|NCT05047575|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730740|NCT00532896|||COHORT||PROSPECTIVE|||||||
33730741|NCT03145779|||CASE_ONLY||PROSPECTIVE|||||||
33730742|NCT02752009|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730743|NCT00245765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730744|NCT04413929|||COHORT||RETROSPECTIVE|||||||
33730745|NCT05753059|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Randomized placebo-controlled, double-blind, double-dummy, crossover design|t|t|t|f
33730746|NCT05203471|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is an adaptive study design where recruitment and retention protocols are modified to improve involvement of rural study participants over three waves. Actively enrolled participants receive/ provide care for diabetic foot ulcers using a care algorithm and referral checklist. Results are compared to historical controls.||||
33730747|NCT05943912|||COHORT||PROSPECTIVE|||||||
33811378|NCT01488084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811379|NCT03441009|||COHORT||PROSPECTIVE|||||||
33811380|NCT01853384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811381|NCT03744052|NA|SINGLE_GROUP||OTHER||NONE||||||
33811382|NCT05621902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042943|NCT00203619|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34042944|NCT03279432|||COHORT||PROSPECTIVE|||||||
34042945|NCT02090348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042946|NCT05944848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042947|NCT06096779|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042948|NCT06556433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042949|NCT02921984|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042950|NCT04164966|||OTHER||PROSPECTIVE|||||||
34042951|NCT02914613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34042952|NCT02353546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042953|NCT04028609|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research interviewers were blinded to study condition.|The intervention includes 4 components: development of a personal health plan; review and support for medication adherence; connection with primary care provider within 30 days; and education about clinical indicators that call for immediate intervention.|f|f|f|t
34042954|NCT03557619|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042955|NCT06235021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical outcome assessor (A.A) will not be aware of which treatment will be being administered, thus yielding a single-blind controlled study.|The experimental group will receive scaling and root debridement and will be instructed to use a mouthwash containing aqueous extract of saffron twice a day for 6 weeks.|f|f|f|t
34042956|NCT00841386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34042957|NCT00152802|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34042958|NCT04832594|RANDOMIZED|PARALLEL||SCREENING||NONE||For each screening mammography examination, the AI tool will produce an AI Joint Score and an AI Masking Score. Women having an AI Masking Score above the threshold and an AI Joint Score above the threshold will be invited to the study unless they met exclusion criteria. Women who decide to participate, will be randomized to MRI or no-MRI (standard-of-care).||||
34042959|NCT03217890|||OTHER||OTHER|||||||
34042960|NCT04477148|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34042961|NCT00827216|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34042962|NCT05835440|||OTHER||PROSPECTIVE|||||||
34042963|NCT05516680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34042964|NCT00000412|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34042965|NCT03926832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042966|NCT02898428|||CASE_CONTROL||PROSPECTIVE|||||||
34042967|NCT03382834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042968|NCT04013672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042969|NCT00410813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042970|NCT01709682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34042971|NCT02748213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042972|NCT03254745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Investigator will be blinded. Outcome assessor would be blinded. Patients in the control group would be blinded.||f|f|t|t
34042973|NCT05096364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811383|NCT00481611|||OTHER||CROSS_SECTIONAL|||||||
34117558|NCT04946630|NON_RANDOMIZED|FACTORIAL||DEVICE_FEASIBILITY||NONE||The 4 treatment periods will include 4 inhalation sessions. The 12 included subjects will participate in all 4 treatment periods and the same order of treatment periods will be followed for all included subjects. There will be a wash-out period of at least 1 week between treatments.||||
34117559|NCT01429688|RANDOMIZED|CROSSOVER||||NONE||||||
34117560|NCT05299164|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 dose-escalation||||
34117561|NCT06605209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117562|NCT05526417|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Masking of treatment assignment to the surgeon and radiation oncologist.||f|t|f|f
34117563|NCT05504122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117564|NCT01042314|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34117565|NCT00688597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117566|NCT00617864|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34117567|NCT06715748|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34117568|NCT05739266|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34117569|NCT01680211|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34117570|NCT02008617|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117571|NCT03012750|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34117572|NCT05905562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117573|NCT06333496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117574|NCT01923636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117575|NCT01385579|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117576|NCT06527807|||OTHER||RETROSPECTIVE|||||||
34117577|NCT02407431|||COHORT||PROSPECTIVE|||||||
34117578|NCT06264167|RANDOMIZED|PARALLEL||OTHER||NONE||"Feasibility trial, open label, three-group, randomised clinical trial~30 eligible females aged 18 or older with clinically stage 1b or 2 vulvar cancer will receive a bilateral groin node ultrasound up to 30 days prior to planned surgery:~Participants with normal/negative baseline groin ultrasounds will be randomly assigned to two groups (2:1 randomisation): one group undergoing radical procedures (groin lymph nodes are not removed) with bilateral groin ultrasound surveillance in conjunction with clinical examinations every 2 months, and the other group undergoing upfront full groin LND or sentinel node biopsy (SNB) based on clinician choice (according to local clinical practice management guidelines).~Participants with suspicious/indeterminate baseline groin ultrasound (third group) will receive an upfront full groin LND or SNB, consistent with the current standard treatment, according to local clinical practice management guidelines."||||
34117579|NCT00005935||||TREATMENT||||||||
34117580|NCT04637529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117581|NCT05099263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117582|NCT04372914|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117583|NCT05029752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117584|NCT06029088|||COHORT||RETROSPECTIVE|||||||
34117585|NCT03479983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment|t|f|t|f
34117586|NCT05485558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117587|NCT00278161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117588|NCT06400667|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34117589|NCT03870048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117590|NCT04120870|RANDOMIZED|PARALLEL||OTHER||NONE|open label|ketamine group: ketamine 2 mg/kg iv as induction agent etomidate group: etomidate 0.2 mg/kg iv as induction agent||||
34117591|NCT04919512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117592|NCT04289480|||COHORT||PROSPECTIVE|||||||
34117593|NCT01889914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117594|NCT01421056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117595|NCT06710925|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33730748|NCT06156254|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33730749|NCT03806582|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|open label study|||||
33730750|NCT05736679|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Given the nature of the intervention, it is impossible to conduct this study in a fully blinded manner but those parts of the data collection that can be blinded will be. Observer bias will be reduced where feasible. All laboratory work will be blinded. Mosquito collector bias will be reduced by using standard light traps which do not rely on the ability of the fieldworker to collect specimens. Trap catches will not be examined and analyzed by those who collected them but by different technicians who will not know the trap location. We will use codes to identify any clinical samples. Electronic records will not carry the name of the research participants, only an alphanumeric code. Primary analysis by the project statistician will be conducted on blinded data (e.g. arms designated as treatment A \& B or something similar). Datasets will only be unblinded once they have been locked.||f|f|f|t
33730751|NCT05595915|NA|SINGLE_GROUP||PREVENTION||NONE||The investigators plan to recruit 35 young men and women ages 18-40. All subjects will take COMP-4 twice a day for a total of 14 days, and FMD and senescence associated markers of PAI-1 and IL-8 will be measured on day 0 and again on day 14.||||
33730752|NCT03581110|||COHORT||RETROSPECTIVE|||||||
33730753|NCT02353091|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730754|NCT05147896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730755|NCT02378766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730756|NCT00257517|||COHORT||PROSPECTIVE|||||||
33730757|NCT03010787|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33730758|NCT03949829|||CASE_CONTROL||PROSPECTIVE|||||||
33730759|NCT00159588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730760|NCT05395962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730761|NCT01391065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730762|NCT05703529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The intervention provider, investigator, and outcomes assessor have not been informed of the group allocation, but the participants may be aware of the group allocation because of the nature of the research design.||f|t|t|t
33730763|NCT05221853|||CASE_ONLY||PROSPECTIVE|||||||
34117596|NCT05457595|NA|SINGLE_GROUP||TREATMENT||NONE||Enrolled subjects will undergo to carbon ion radiation therapy. It is a monocentric, prospective II study.||||
34117597|NCT05015231|||COHORT||PROSPECTIVE|||||||
34117598|NCT06677892|||COHORT||PROSPECTIVE|||||||
33730764|NCT03553628|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Allocation of mouthwash and times of applications to groups will be done through sealed opaque sequentially numbered containers to ensure absolute concealment.|A total of 64 patients will be assigned in this study. Patients will be randomly divided into two groups according to type of mouthwash (A) where group A1 patients will use chlorhexidine mouthwash as control group while group A2 patients will use chlorhexidine with propolis and clove oil mouthwash as intervention group with 32 patients in each group. Each group will be further divided into two groups according to times of application (T) where T1 represents patients using the mouthwash once daily for one week every month for 6 months and T2 where patients will use the mouthwash twice daily for one week every month for 6 months with 16 patients in each subgroup.|t|t|t|t
33730765|NCT00430092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730766|NCT03663595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730767|NCT02459392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730768|NCT01579942|||CASE_CONTROL||PROSPECTIVE|||||||
33730769|NCT06363487|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34117599|NCT04350684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.|t|t|t|f
34117600|NCT02675829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117601|NCT05365776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the study hypotheses and treatment arms, but not to the type of intervention they are receiving. Outcome assessors will be blinded to participants' treatment assignments.||t|f|f|t
34117602|NCT05210725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117603|NCT02605902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117604|NCT01987076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117605|NCT03333603|NA|SINGLE_GROUP||TREATMENT||NONE||Investigators will give 40 mg/day esomeprazole in the first two weeks and 80 mg/day from the third week to the end of the trial. Investigators will check the area under the concentration of metabolites of esomeprazoleon Day 1, Day 14 and Day 56 and the genotype of CYP2C19. The GI symptoms and related drug side effects will be evaluated.||||
34117606|NCT03700177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117607|NCT05141695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117608|NCT06719336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117609|NCT02892240|||COHORT||RETROSPECTIVE|||||||
34117610|NCT04088903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117611|NCT04582591|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117612|NCT02449525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117613|NCT02499744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117614|NCT00618761|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34117615|NCT06716892|||COHORT||PROSPECTIVE|||||||
34117616|NCT05619393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117617|NCT06338111|||CASE_CONTROL||PROSPECTIVE|||||||
34117618|NCT04242147|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117619|NCT03700229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117620|NCT03586947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117621|NCT05638074|||CASE_CONTROL||PROSPECTIVE|||||||
34117622|NCT01510574|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117623|NCT01146145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117624|NCT01138410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730770|NCT05321394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730771|NCT02809703|||COHORT||OTHER|||||||
33730772|NCT04999111|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33730773|NCT00701129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730774|NCT03554291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730775|NCT01911507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811384|NCT05608772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A single-blind randomization procedure, in which patients and outpatient clinic nurses will be blinded to the study period p|t|f|f|f
33811385|NCT01078272|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33811386|NCT03097549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811387|NCT04483102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||To successfully transplant NMP-treated livers to patients that would otherwise have been discarded.||||
33811388|NCT00520663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811389|NCT04927715|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33811390|NCT02936544|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117625|NCT00374647|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117626|NCT01917318|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34117627|NCT00099255|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149778|NCT01818440|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149779|NCT01547091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811391|NCT02205255|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811392|NCT05585398|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Intra-individual comparison||||
33811393|NCT00003167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811394|NCT02160301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811395|NCT04130282|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811396|NCT00044759||||TREATMENT||||||||
33811397|NCT01180959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811398|NCT03340922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective, randomized, controlled and international multicenter study. All patients who fulfill the inclusion criteria will be consecutively enrolled and randomized on a 1:1 basis to each of the LAT annotation systems (WF vs. M-method) before the ablation procedure. Ablation will be directed to the earliest activation site identified with the assigned annotation system. Any change of the assigned annotation system during the procedure won't be allowed, thus being a reason for justifying study exclusion.|t|f|f|f
33811399|NCT03190148|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730776|NCT05850650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants (patients) will not be informed about which side will recieve the collagen|The patients will have surgical extraction of impacted 3rd molars for both sides with a gap of 3 weeks. The study side will receive a collage sponge after extraction followed by sutures. The controlled side will have sutures without a collagen sponge.|t|f|f|f
33730777|NCT03189030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730778|NCT06216392|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33730779|NCT00699010|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33730780|NCT01037946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730781|NCT04703452|||CASE_ONLY||CROSS_SECTIONAL|||||||
33730782|NCT05874180|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730783|NCT03993938|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33730784|NCT03755141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730785|NCT00957203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730786|NCT04685876|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33730787|NCT03216850|||COHORT||PROSPECTIVE|||||||
33730788|NCT00866632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730789|NCT05754177|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33730790|NCT00322010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730791|NCT03887039|||OTHER||CROSS_SECTIONAL|||||||
33730792|NCT05584293|||COHORT||OTHER|||||||
33730793|NCT03857633|||COHORT||PROSPECTIVE|||||||
34042974|NCT05385263|NA|SINGLE_GROUP||TREATMENT||NONE||All patients enrolled to this study with DLBCL in SD/PD at time of lymphodepletion will be given nivolumab ( 3mg/kg IV) on day +5 Patients with CAR-T expansion\<100 cells/microL on day +7 will be given 1 additional dose of nivolumab (3mg/kg IV) on day +19 (two weeks after first dose of nivolumab).||||
33730794|NCT02682316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730795|NCT00637195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730796|NCT06235528|||OTHER||CROSS_SECTIONAL|||||||
33730797|NCT03071796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blind||t|f|t|f
33730798|NCT03854916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33730799|NCT04103528|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33730800|NCT00590148|||COHORT||PROSPECTIVE|||||||
33730801|NCT02909556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730802|NCT02826356|||COHORT||RETROSPECTIVE|||||||
33730803|NCT03435549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33730804|NCT01807052|||CASE_ONLY||RETROSPECTIVE|||||||
33730805|NCT04059848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730806|NCT00733720|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33730807|NCT05154448|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The sham procedure would be done using the same system and setup. Randomization would be done using an EDC system and no person at the room would know if the procedure is a treat or sham procedure.|Double arm randomized study|t|t|t|t
33730808|NCT02171481|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33730809|NCT03569670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811400|NCT03917186|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34042975|NCT05668208|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34042976|NCT01661335|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34042977|NCT00802035|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34042978|NCT02425566|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34117628|NCT03582176|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks)|t|f|t|t
33730810|NCT05137795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the study pharmacist will be aware of treatment assignment|Multicenter Randomized Placebo-controlled Trial|t|t|t|t
33730811|NCT02166983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730812|NCT02383667|||COHORT||PROSPECTIVE|||||||
33730813|NCT01989351|||COHORT||PROSPECTIVE|||||||
33730814|NCT00196950|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33730815|NCT05421208|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The POTS patients will be randomized to chronic transcutaneous vagus nerve stimulation (tVNS) in any of the two sites on ear, and there will 50% change to be allocated to one of the sites that may have less stimulation.|Case-control study|t|f|f|f
33730816|NCT03467269|||COHORT||RETROSPECTIVE|||||||
33730817|NCT06375005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730818|NCT06457334|||COHORT||PROSPECTIVE|||||||
33730819|NCT01446731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730820|NCT00152217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730821|NCT00219674|RANDOMIZED|PARALLEL||||NONE||||||
33730822|NCT02839616|||COHORT||PROSPECTIVE|||||||
33730823|NCT03422341|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730824|NCT02617316|RANDOMIZED|CROSSOVER||||NONE||||||
33730825|NCT00096044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730826|NCT03735862|||COHORT||RETROSPECTIVE|||||||
33730827|NCT00004918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730828|NCT00737516|NA|SINGLE_GROUP||||NONE||||||
33730829|NCT03385239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730830|NCT04086264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730831|NCT06221696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33730832|NCT00945022|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33730833|NCT03517527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33811401|NCT01613599|||COHORT||PROSPECTIVE|||||||
33811402|NCT05766202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811403|NCT03080350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811404|NCT02172898|||CASE_CONTROL||PROSPECTIVE|||||||
33730834|NCT01984138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730835|NCT05794256|||COHORT||PROSPECTIVE|||||||
34042979|NCT06577194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042980|NCT02801513|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34042981|NCT03661619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730836|NCT01856816|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33730837|NCT03616158|||OTHER||OTHER|||||||
33730838|NCT05449028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sampling: Consecutive sampling of incident cases of patients with H. pylori gastric infection and clinical indication for its eradication; Patients will be continuously monitored throughout the study. Regarding the evaluation of oral and gut microbiota and immunological changes, the study will be blinded, since the researchers responsible for sequencing and immunological analysis will not know the therapeutic scheme applied.|An interventional study is proposed to compare the efficacy and safety of the different approved H. pylori eradication quadruple regimens. Patients will be randomly assigned to the five quadruple regimens arms (A, B, C D and E). All patients will be followed during 12 months. A standardized protocol will be applied for all the groups, differing only in type of quadruple regimen used.|t|f|t|f
33730839|NCT03738371|||OTHER||PROSPECTIVE|||||||
33730840|NCT00690963|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730841|NCT01957475|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33730842|NCT03793907|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730843|NCT05390203|||COHORT||PROSPECTIVE|||||||
33730844|NCT04436523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730845|NCT04380311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730846|NCT02333916|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730847|NCT03663283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacist will prepare, and dispense the medication sequentially. Medication syringes will be blinded utilizing black tape. Patients, care team in recovery, study team members collecting and recording data, and statisticians will be blinded to randomization assignment. All patients will be documented in EMR as receiving liposomal bupivacaine to ensure the blind is maintained and to ensure that safety features in the EMR for all patients receiving liposomal bupivacaine are activated. Further, all additional standard precautionary measures (e.g. wrist band) will be similarly implemented for both patient groups.||t|t|t|t
33730848|NCT01407913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730849|NCT04855643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730850|NCT04361526|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-branch randomized, controlled, uni-center study. Eligible patients will be randomly assigned in a 1:1 ratio to receive cytokine filtration plus standard intensive care, or standard intensive care alone||||
33730851|NCT05952648|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled, multicenter, open-label trial||||
33730852|NCT05548608|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33730853|NCT06493630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730854|NCT06223646|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33730855|NCT05069922|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730856|NCT03053895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730857|NCT04727658|NA|SINGLE_GROUP||TREATMENT||NONE||"The study will be carried out according to a design by Simon in two stages (Simon, 1989).~First step: 14 patients will be included in the study. When the 14th patient has been treated, the inclusions will be suspended for 1 year until analysis of the primary endpoint.~• Second stage: 34 additional patients will be recruited for a total of 48 patients."||||
33730858|NCT03277261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded, active-controlled study|Randomized, multi-center, double-blinded, active-controlled study|t|t|t|t
33730859|NCT03938142|||CASE_ONLY||CROSS_SECTIONAL|||||||
33730860|NCT02501603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730861|NCT01600586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33730862|NCT01489046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730863|NCT05156580|||COHORT||OTHER|||||||
33730864|NCT05428475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730865|NCT05933681|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33730866|NCT04698356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730867|NCT01041625|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730868|NCT06407089|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33730869|NCT03615950|||CASE_CONTROL||PROSPECTIVE|||||||
33730870|NCT02388984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730871|NCT06263335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730872|NCT04763499|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|both the control and freeze dried strawberry powders are package with only a code as the identifier|A randomized, double-blind, crossover dietary intervention trial.|t|f|t|f
33811405|NCT04373772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, due to the nature of the intervention, only the patient was blinded. The researchers involved in the running of the study were not blinded.|prospective, parallel, two arm (1:1), randomized controlled clinical trial|t|f|f|f
33811406|NCT02709044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811407|NCT05688891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||prospective randomized controlled clinical trial||||
33811408|NCT06422715|||COHORT||RETROSPECTIVE|||||||
33811409|NCT04901585|||COHORT||RETROSPECTIVE|||||||
33811410|NCT03345979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811411|NCT01000649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811412|NCT02671266|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33811413|NCT00304642|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33811414|NCT05891392|||COHORT||OTHER|||||||
33811415|NCT03605147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811416|NCT01431118|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33811417|NCT04150016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811418|NCT03610620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Compare accuracy and speed of the Vivascope 2500 to frozen sections.||||
33839781|NCT02963662|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33839782|NCT00589303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839783|NCT03399851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839784|NCT02271984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33839785|NCT04577001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34042982|NCT01569971|||COHORT||PROSPECTIVE|||||||
33730873|NCT06008613|NA|SINGLE_GROUP||OTHER||NONE||||||
33730874|NCT02547662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730875|NCT01209910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33730876|NCT05940935|||CASE_CONTROL||RETROSPECTIVE|||||||
33730877|NCT03671902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34042983|NCT00680485|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730878|NCT04900077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730879|NCT00934544|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33730880|NCT01179971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730881|NCT00658281|||CASE_ONLY||PROSPECTIVE|||||||
33730882|NCT03000582|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33730883|NCT06197789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730884|NCT05750303|||CASE_CONTROL||PROSPECTIVE|||||||
33730885|NCT03897790|||COHORT||PROSPECTIVE|||||||
33730886|NCT02736656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117629|NCT02866747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730887|NCT03211169|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized prospective study||||
33730888|NCT01170728|||COHORT||PROSPECTIVE|||||||
33730889|NCT04672005|NA|SINGLE_GROUP||TREATMENT||NONE||single group assignment||||
33730890|NCT01248026|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33811419|NCT04097509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patient and investigator were blinded to the applications|This study was designed as a randomized, controlled clinical trial. Three groups were randomly assigned as one control and two test groups. A total of 36 patients (12 patients in each group) were included in the study. In the control group, only moist sterile tamponade was applied following graft removal to the palatinal donor area. In the test groups, polymerized AFG or polymerized i-PRF were applied to the donor area. After these procedures, donor palate was closed with sterile aluminum foil and periodontal pat in all 3 groups.|t|f|t|f
33811420|NCT02558205|||COHORT||PROSPECTIVE|||||||
33811421|NCT01073761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811422|NCT04472715|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33811423|NCT03950661|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross over design. Repeated measures.||||
33811424|NCT04699578|||COHORT||PROSPECTIVE|||||||
33811425|NCT01955499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811426|NCT01197924|||CASE_CONTROL|||||||||
33811427|NCT00047385|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33811428|NCT00564798|||CASE_CONTROL||PROSPECTIVE|||||||
33811429|NCT06405906|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33811430|NCT00184743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730891|NCT01897103|||COHORT||PROSPECTIVE|||||||
34042984|NCT05029791|NA|SINGLE_GROUP||OTHER||NONE||||||
34042985|NCT02664831|||COHORT||PROSPECTIVE|||||||
34042986|NCT02790567|||||PROSPECTIVE|||||||
34042987|NCT06113419|RANDOMIZED|PARALLEL||TREATMENT||NONE||CHISPA is a randomized controlled, parallel-group, superiority clinical trial. Patients will be randomly allocated to receive early laparoscopic cholecystectomy (within 72 hours after randomization) or interval laparoscopic cholecystectomy (30 +/- 5 days after randomization).||||
34042988|NCT00326716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042989|NCT00650013|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34042990|NCT03456804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042991|NCT05557162|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33811431|NCT04218877|||COHORT||RETROSPECTIVE|||||||
33811432|NCT03788811|||CASE_CONTROL||PROSPECTIVE|||||||
33811433|NCT06121765|||COHORT||CROSS_SECTIONAL|||||||
33811434|NCT01623609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33811435|NCT01009359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33811436|NCT02791204|||CASE_CONTROL||PROSPECTIVE|||||||
33811437|NCT05760508|||COHORT||PROSPECTIVE|||||||
33811438|NCT06533046|||COHORT||PROSPECTIVE|||||||
33811439|NCT02983721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811440|NCT06305078|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|None (open-label)|Open Label Trial||||
33730892|NCT03001570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730893|NCT05934292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730894|NCT04583813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730895|NCT02023151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730896|NCT06173206|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Fully placebo controlled|Groups 1-2 will receive a 7-day course of placebo artesunate; Group 3 will be given a 7-day course of active artesunate. This will span Day -7, -6, -5, -4, -3, -2, and -1. Then, on Day 0, children in Groups 1-2 will receive a single course of malaria chemoprevention, whereas Group 3, having completed a 7-day course of AS will receive placebo SP.|t|t|t|t
33730897|NCT02155413|||||RETROSPECTIVE|||||||
33730898|NCT00136487|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33730899|NCT01112384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811441|NCT02992145|||CASE_CONTROL||RETROSPECTIVE|||||||
33811442|NCT01394835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811443|NCT00916110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811444|NCT05025813|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-centre, open-labelled, non-randomised, single-arm phase 2 study of Pembrolizumab in participants aged 18 years or older with locally advanced (LA) Stage II-IV resectable cSCC.||||
33811445|NCT01553617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811446|NCT03868774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Project collaborators examining the degree of depression during intervention are blinded to the type of treatment|comparing the antidepressant effect of a standard rTMS model with an accelerated treatment model|f|f|t|t
33840142|NCT00168389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840143|NCT04912830|||CASE_ONLY||CROSS_SECTIONAL|||||||
33840144|NCT02593877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840145|NCT05630729|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33840146|NCT06530927|||COHORT||PROSPECTIVE|||||||
33840147|NCT04089189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840148|NCT04508127|||CASE_ONLY||RETROSPECTIVE|||||||
33840149|NCT04651790|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840150|NCT00156442|||||PROSPECTIVE|||||||
33730900|NCT03445416|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We will employ an experimental design with pre/posttest measures to determine changes in vaccination awareness, intention and status, as well as engagement in health care. A total of 20 POLs will be identified and randomized to either the intervention or comparison arm. Regardless of assignment, POLs will be asked to diffuse information to at least 5 YBMSM network recruits; either the intervention (comprised of vaccination messaging developed in partnership with YBMSM) or comparison group health messaging. The comparison group content will be developed by the investigative team and consist of general, non-tailored health-related messaging (e.g., no vaccination messaging, will not address stigma or medical mistrust). Outcome analysis will compare the 50 intervention recruits to the 50 SOC recruits at 3 months post intervention.||||
33730901|NCT02273843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730902|NCT04033003|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33730903|NCT02550327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730904|NCT05556707|||OTHER||CROSS_SECTIONAL|||||||
33730905|NCT04167774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730906|NCT00378703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730907|NCT03038464|||COHORT||RETROSPECTIVE|||||||
33730908|NCT05411796|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|menstrual cups distributed in unmarked packaging; participants and investigator blinded||t|f|t|f
33730909|NCT05797506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730910|NCT02787252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730911|NCT02005978|||CASE_CONTROL||PROSPECTIVE|||||||
33730912|NCT06021067|NA|SINGLE_GROUP||TREATMENT||NONE||one-arm study||||
33730913|NCT05828277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730914|NCT05098639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be unaware of the condition they are in. As the initial session requires a brief individual session using BASICS, DRT, or DRT+BASICS, investigators will be aware of study condition.|This study will randomly assign participants to one of three conditions: Active Control (BASICS), DRT, or DRT+Active Control|t|f|f|f
33730915|NCT00518908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730916|NCT04984655|NA|SINGLE_GROUP||OTHER||NONE||Pilot Study (uncontrolled)||||
33730917|NCT01289808|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|t|f
33730918|NCT02696551|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33730919|NCT05425758|||OTHER||PROSPECTIVE|||||||
33730920|NCT04222179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730921|NCT03494036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33730922|NCT06224530|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"Participants and investigators will be blinded to the randomised order of administration of levetiracetam and placebo.~Once screening procedures have confirmed the subject's eligibility to enter the study, a random list (i.e., of A B B A A A B B) will be created using an automated online random generator. A researcher that is not involved in the study will be responsible for randomisation and documentation. This information will then be given to the South London and Maudsley NHS Foundation Trust Pharmacy where the levetiracetam / placebo capsules will be dispensed from in visually identical capsules for blinding to the A's or B's. Only the SLaM Pharmacy contact will know what capsules were allocated to A's or B's and will keep the enrolment log blinded from the enrolment log kept by the study researcher."|Basic science study involving procedures with human participants. Randomised, double-blind, placebo-paired, levetiracetam versus placebo challenge before scanning.|t|t|t|t
33730923|NCT00748644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730924|NCT00000252|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33730925|NCT02267629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730926|NCT05012605|||COHORT||PROSPECTIVE|||||||
33730927|NCT03945812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730928|NCT05094297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730929|NCT06247033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33730930|NCT01701167|||CASE_ONLY||CROSS_SECTIONAL|||||||
33730931|NCT05028504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730932|NCT00486122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33730933|NCT00963339|||COHORT||PROSPECTIVE|||||||
33730934|NCT00424905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730935|NCT03044197|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients will be randomly assigned to arm A or arm B following a 1:1 simple randomization procedure according to a computer-generated randomization list.||||
33730936|NCT00844792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730937|NCT03261583|||COHORT||PROSPECTIVE|||||||
33730938|NCT00963690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33730939|NCT00123188|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730940|NCT02944318|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811447|NCT05488509|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participants and the RAs who administer the drug and the memory tests (and other outcomes) will be blinded to drug condition. The PI Dr. McLaughlin will be unblinded and will handle the drug, weigh the drug and pre-load it into the Volcano Vaporizer prior to each testing session.|Double-blind placebo-controlled clinical trial|t|f|f|t
33811448|NCT02502136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33811449|NCT04108858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811450|NCT05596916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811451|NCT00637663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811452|NCT05135234|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33730941|NCT00715793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730942|NCT02619890|||COHORT||PROSPECTIVE|||||||
33730943|NCT02881294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730944|NCT02271308|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33730945|NCT00482079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730946|NCT01385124|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33811453|NCT02941744|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811454|NCT04675268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811455|NCT01596985|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811456|NCT04577326|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I dose-escalation trial.||||
33811457|NCT02129751|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33730947|NCT04949269|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33730948|NCT04936958|||COHORT||RETROSPECTIVE|||||||
33730949|NCT03848546|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Two groups: one receives general advice (control), the other personalized advice (intervention). Subjects are followed over time.|t|f|f|f
33730950|NCT05187416|||OTHER||OTHER|||||||
33730951|NCT03135197|||COHORT||PROSPECTIVE|||||||
33730952|NCT04765007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33730953|NCT04101266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33730954|NCT03469921|||COHORT||RETROSPECTIVE|||||||
33730955|NCT05371964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730956|NCT05926999|||CASE_ONLY||CROSS_SECTIONAL|||||||
33730957|NCT02025101|||CASE_ONLY|||||||||
33730958|NCT03165708|||OTHER||PROSPECTIVE|||||||
33730959|NCT06332521|||COHORT||PROSPECTIVE|||||||
33730960|NCT05374499|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|An envelope, which is identified by the patient specific study ID, will contain Exparel and standard bupivacaine syringes. The syringes will be masked and labeled left or right, depending on the randomization results. Designated dental assistants not associated with the study will receive the corresponding envelope to prepare the syringes. Syringes containing the solutions will be masked so that the operator would not be able to detect which solution is being infiltrated.||t|t|t|t
33730961|NCT05241886|||CASE_ONLY||PROSPECTIVE|||||||
33730962|NCT06297356|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||randomized controlled trial|t|f|f|f
33730963|NCT00222287|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33730964|NCT02011048|||CASE_CONTROL||PROSPECTIVE|||||||
33730965|NCT04702087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33730966|NCT06179082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730967|NCT03072212|||COHORT||PROSPECTIVE|||||||
33730968|NCT02126969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730969|NCT03612167|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A quasi-experimental design with nonequivalent control was adopted in a senior center. Experimental variable was a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives. Participants were allocated into intervention group (cognitive intervention group) and control group (nutrition education group). The group assignment depended on what group they signed up for participate.||||
33730970|NCT00643370|||CASE_ONLY||RETROSPECTIVE|||||||
33811458|NCT02734706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811459|NCT02198898|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33811460|NCT04685395|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel group, two arm, superiority randomized controlled clinical trial|t|t|t|t
33811461|NCT03457558|||OTHER||CROSS_SECTIONAL|||||||
33811462|NCT01905566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811463|NCT00375388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811464|NCT03917732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33811465|NCT03871075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Group assignment regarding the intermittent pneumatic compression device is double-blinded and neither investigators nor participants in the study will know which intermittent pneumatic compression device each participant has (therapeutic intervention vs. sham). Participants will be aware of their exercise group assignment after randomization, but the study coordinators collecting follow-up data will be unaware of each participant's group assignment.||t|f|t|t
33811466|NCT03500406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811467|NCT00734682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811468|NCT05158426|||COHORT||PROSPECTIVE|||||||
33811469|NCT02924051|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Control/Intervention Groups (3 sites in each group)|t|f|f|f
33811470|NCT03590496|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33811471|NCT01672242|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33811472|NCT06073587|||COHORT||PROSPECTIVE|||||||
33811473|NCT03711058|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33811474|NCT04153357|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
33811475|NCT03200574|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-center trial||||
33811476|NCT01224574|||COHORT||PROSPECTIVE|||||||
34042992|NCT02846181|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34042993|NCT05924789|||COHORT||OTHER|||||||
34042994|NCT04657588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||multicenter randomized controlled open-label superiority trial with adaptive design in ambulatory patients with FI with two parallel treatment arms: anal inserts and care as usual (incontinence pads).||||
34042995|NCT01514292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042996|NCT02940756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34042997|NCT04386330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34042998|NCT04446013|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34042999|NCT02858583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043000|NCT02917382|||COHORT||PROSPECTIVE|||||||
34043001|NCT04431258|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Double blind, randomized, placebo-controlled, multicenter study|f|t|f|f
34043002|NCT04257344|||COHORT||PROSPECTIVE|||||||
34043003|NCT03146455|||OTHER||CROSS_SECTIONAL|||||||
34043004|NCT00836225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043005|NCT06362915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Group (A): will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1% (9).~* Group (B): will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist."||t|t|t|t
34043006|NCT06348459|||COHORT||PROSPECTIVE|||||||
34043007|NCT05577013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043008|NCT04827953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043009|NCT01450553|||COHORT||PROSPECTIVE|||||||
34043010|NCT04573049|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043011|NCT00149344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043012|NCT03476187|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043013|NCT04454047|||COHORT||RETROSPECTIVE|||||||
33730971|NCT05884697|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|Qualtrics is an online survey software used by researchers. It can randomly assign participants to different groups without revealing the assignments to participants or researchers, blinding them to the assignment. This ensures unbiased treatment and assessment of participants.|Participants will be randomized to one of four experimental conditions using a 2x2 factorial design with two factors (Storytelling and Chatbot) and two levels (Yes/On and No/Off). Acceptability and feasibility outcomes include recruitment/retention rates, obtaining photographic documentation, and perceived satisfaction with the intervention.|t|t|t|t
33730972|NCT02140034|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33730973|NCT00155818|||DEFINED_POPULATION||OTHER|||||||
33730974|NCT03815162|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Opaque capsules of equal size and appearance presented in similar bottles labelled only by a code. Code to product information is held by the manufacturer and un-blinding of the PI will only occur once the study analysis has been completed or in the event of a serious adverse event occurring.|Double-blinded, placebo controlled study. Block randomised with equal allocation of participants between groups.|t|t|t|t
33730975|NCT00178945|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33730976|NCT01080313|||||PROSPECTIVE|||||||
33730977|NCT03151356|||COHORT||PROSPECTIVE|||||||
33730978|NCT06146166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33730979|NCT04648930|||COHORT||PROSPECTIVE|||||||
33730980|NCT05656547|||CASE_CONTROL||RETROSPECTIVE|||||||
33730981|NCT01158794|||CASE_ONLY||PROSPECTIVE|||||||
33730982|NCT02003625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730983|NCT03578510|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33730984|NCT00859170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33730985|NCT00843869|||CASE_ONLY||PROSPECTIVE|||||||
33730986|NCT01243346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730987|NCT03159884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33730988|NCT00983554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33730989|NCT05374811|||CASE_ONLY||PROSPECTIVE|||||||
33730990|NCT02404311|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33730991|NCT03019276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730992|NCT05399524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants are blinded|FUTURE-GB is a 2-Stage trial: Stage 1 is a non-randomised multicentre learning and evaluation Stage (IDEAL IIB study), and Stage 2 a prospective, multicentre definitive randomised controlled trial.|t|f|f|t
33730993|NCT04270500|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a randomized controlled pilot trial of patients with colorectal cancer scheduled for major abdominal surgery. The prehabilitation intervention group will be compared with the usual care for an average of 4 weeks before planned surgery. All participants will wear an actigraphy to objectively assess their daily physical activity and their sleep behavior.~The intervention will last for 4 weeks pre- and 8 weeks post-surgery, for a total of 12 weeks. Site visits will occur weekly before surgery and every 4 weeks after surgery. In that period, weekly phone calls will reinforce compliance and provide tips to help patients adhere to the treatment protocol. A dedicated and specially trained research team lead by a physician, a kinesiologist, a nutritionist and a psychologist will perform the measurements and collect the demographic and surgical details of all the patients, recording daily detailed information of clinical outcomes up to 8 weeks after surgery."||||
33730994|NCT02553746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811477|NCT04788407|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Prospective, Cluster-Randomized, double-blind, placebo-controlled clinical trial.|t|f|t|f
33811478|NCT03456856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811479|NCT00539955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811480|NCT05828407|||COHORT||PROSPECTIVE|||||||
33811481|NCT00910962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811482|NCT05197452|NA|SINGLE_GROUP||PREVENTION||NONE||"We established a network of testing sites in African American churches and community sites located in testing deserts in Chicago. Individuals of all ages were eligible for testing. Individuals with a confirmed COVID-19 infection within the past 3 months were ineligible. Testing was open to the public and no appointments were necessary. Testing was offered 5 days per week (at 1 or 2 locations each day) with varying hours of operation to accommodate community member's work and school schedules. There was no limit to the number of times an individual could be tested.~Testing was administered by experienced mobile clinical teams of community health workers and registered nurses from Rush University Medical Center. Participants received COVID-19 education, social determinants of health screening, and free SARS-CoV-2 polymerase chain reaction (PCR) testing."||||
33811483|NCT00615368|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33811484|NCT05178706|||CASE_CONTROL||PROSPECTIVE|||||||
33811485|NCT04892251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33811486|NCT02646098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811487|NCT02851498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33811488|NCT00900302|||COHORT||RETROSPECTIVE|||||||
33811489|NCT01856062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811490|NCT06204653|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33811491|NCT04546555|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33811492|NCT00643409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811493|NCT01008917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811494|NCT02243449|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33811495|NCT01204502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811496|NCT00446095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811497|NCT06477549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811498|NCT06451159|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33811499|NCT03733951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811500|NCT01455948|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33811501|NCT04834830|||COHORT||PROSPECTIVE|||||||
33811502|NCT02166684|NA|SINGLE_GROUP||||NONE||||||
33811503|NCT05026541|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33811504|NCT01497184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811505|NCT00442507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811506|NCT00502684|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34043014|NCT02333344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811507|NCT02003872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117630|NCT04190368|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34117631|NCT03170440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34117632|NCT05964894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33811508|NCT03644082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811509|NCT02000752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33811510|NCT05647759|NA|SINGLE_GROUP||OTHER||NONE|If consent is obtained in person, study personnel will be in a private room with both parties masked, eye protection, and social distancing guidelines in place. Baseline data collection will occur in a private room with masks, eye protection, and social distancing guidelines in place. Hospital-based facilities and staff are in compliance with local health department guidance on masks and social distancing.|This study is a prospective, single-group, repeated measures feasibility study.||||
33811511|NCT00926107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811512|NCT03964779|||CASE_CONTROL||PROSPECTIVE|||||||
34043015|NCT01985841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043016|NCT06535945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043017|NCT06369363|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34043018|NCT04917822|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|At the recruitment phase, the participants and the social workers who lead the intervention group will not know which intervention arm the participants will be assigned. A cluster of approximately 10 participants formed a group based on their attendance date in the intervention program. This group will be randomly assigned to one of the two intervention arms through pre-prepared randomization list calculated by random allocation software.|Both parents and children will be included in the intervention. The research team will conduct parallel intevention to parents and children in separate groups at the same time.|t|f|f|f
34043019|NCT01692925|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043020|NCT04070001|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34043021|NCT03424811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34043022|NCT05498129|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34043023|NCT01840514|||COHORT||PROSPECTIVE|||||||
34043024|NCT02653781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34043025|NCT00918411|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34043026|NCT04956601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043027|NCT01705613|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34043028|NCT05047211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded placebo controlled clinical trial. We will be using intravenous and oral placebos for each interventions|Randomized control trial|t|t|t|t
34043029|NCT01453270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043030|NCT05627505|||COHORT||PROSPECTIVE|||||||
34043031|NCT03444428|||COHORT||PROSPECTIVE|||||||
34043032|NCT05185037|||OTHER||PROSPECTIVE|||||||
34043033|NCT04901247|||COHORT||PROSPECTIVE|||||||
34043034|NCT03549728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|: Eighty eight envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside into group A or B|The aim of this study is to evaluate the effect of granulocyte colony-stimulating factor on clinical pregnancy rate in patients with endometriosis undergoing in-vitro fertilization after recurrent implantation failure.|t|t|t|f
34043035|NCT05664152|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043036|NCT05528796|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043037|NCT01288937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043038|NCT01736644|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34043039|NCT03346135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043040|NCT04601077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Placebo Control|t|t|t|f
34043041|NCT06578169|||COHORT||PROSPECTIVE|||||||
34043042|NCT01680536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043043|NCT04054115|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with a bidirectional Glenn in their Pre-Fontan evaluation.||||
34043044|NCT00602836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043045|NCT03657992|||COHORT||RETROSPECTIVE|||||||
34043046|NCT04429789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistant administering the telephone assessments is blinded to participant treatment intervention while the clinician conducting the treatment sessions is blinded to participant responses provided during telephone assessments. The only instance where we may unblind staff members to assessment or treatment data (depending on what the staff member is responsible for) will be at the end of the study, after data collection has been completed. At that point, the staff member conducting telephone assessments may be allowed to know which interventions participants were assigned to, and the clinician conducting treatment sessions may be allowed to access assessment data if a staff member were to assist in data cleaning or data analysis. Participants are blind to study hypotheses and will not be told which intervention is expected to yield what results. Participants may be unblinded if/when we disseminate findings (e.g., in a published manuscript) related to this study.|Single-center, single-blind three-group randomized (1:1:1) controlled trial (RCT) comparing two hypnosis interventions to waitlist control efficacy for MS-related fatigue.|f|f|f|t
34043047|NCT04670952|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|It will be single blinded. Operator, first assistant and data collector could not be blinded. Whereas patients, nurses, data analyzer, and those who have the access to the primary predictor will be blinded.||t|f|f|t
34043048|NCT05333302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043049|NCT04769089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043050|NCT03147690|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043051|NCT03090334|RANDOMIZED|PARALLEL||OTHER||SINGLE|Care provider will be blinded to result of BG in patients enrolled in the standard of care arm||f|t|f|f
34043052|NCT00454246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043053|NCT03726970|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34043054|NCT00468351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34043055|NCT06576453|||FAMILY_BASED||PROSPECTIVE|||||||
33811513|NCT02188355|||OTHER||PROSPECTIVE|||||||
34117633|NCT00946933|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34117634|NCT03817398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811514|NCT03678688|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This will be a multiple-dose trial of OPC-167832 with 2 stages.~Stage 1 is a multiple ascending dose trial planned to be conducted in 4 sequential cohorts of 18 participants each. There will be 2 arms (OPC-167832, combination of rifampicin, isoniazid, ethambutol, and pyrazinamide (RHEZ)) in each cohort.~Stage 2 will be a parallel group comparison of 4 treatment regimens: 1) OPC-167832 plus Delamanid 2) OPC-167832 plus Bedaquiline 3) OPC-167832 plus Delamanid plus Bedaquiline 4) RHEZ."||||
33811515|NCT05866432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811516|NCT02054208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Stage 1: 9 subjects (3 subjects for low dose and 6 subjects for high dose) Stage 2: 36 subjects ( 24 subjects for high dose and 12 subjects for placebo) A total of 45 subjects to be enrolled|t|t|t|t
33811517|NCT04020172|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34117635|NCT06654232|||COHORT||CROSS_SECTIONAL|||||||
34117636|NCT05181488|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention: intraoperative radiotherapy||||
34117637|NCT04826198|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open label, phase Ib/II||||
34117638|NCT03732469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34117639|NCT04065321|||COHORT||PROSPECTIVE|||||||
34117640|NCT00147329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34117641|NCT01225952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117642|NCT04052373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117643|NCT06304857|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117644|NCT02259114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117645|NCT06639464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The IDS will perform both the randomization and blinding, and will be the only research staff that will remain unblinded, the study investigators will obtain placebo injectors from the manufacturer for the trial. All other research staff will remain blinded for the duration of the trial.||t|t|t|t
34117646|NCT00759343|||CASE_CONTROL||OTHER|||||||
34117647|NCT02096978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117648|NCT04249180|||CASE_CONTROL||OTHER|||||||
34117649|NCT04457024|||CASE_ONLY||OTHER|||||||
34117650|NCT02979587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117651|NCT05067101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117652|NCT00784602|||OTHER||OTHER|||||||
34117653|NCT03200470|||COHORT||PROSPECTIVE|||||||
34117654|NCT06490146|||COHORT||PROSPECTIVE|||||||
34117655|NCT05849129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34117656|NCT00153660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117657|NCT00269581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117658|NCT00481936|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34117659|NCT01465009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117660|NCT03913351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117661|NCT00640302|||COHORT||PROSPECTIVE|||||||
34117662|NCT05047042|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117663|NCT02320656|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117664|NCT05950841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811518|NCT05697536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811519|NCT01130298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811520|NCT00162409|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811521|NCT02390778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811522|NCT02219607|||COHORT||PROSPECTIVE|||||||
33811523|NCT05641220|||COHORT||PROSPECTIVE|||||||
33811524|NCT01785056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117665|NCT00714948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117666|NCT00317265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117667|NCT00655096|||COHORT||CROSS_SECTIONAL|||||||
34117668|NCT02919592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117669|NCT03199183|||COHORT||OTHER|||||||
34117670|NCT03733327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117671|NCT04268914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117672|NCT06211712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double-blind, placebo-controlled study|t|f|t|f
34117673|NCT01077063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117674|NCT01682330|||COHORT||CROSS_SECTIONAL|||||||
34117675|NCT03622047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117676|NCT05564637|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117677|NCT03193151|||COHORT||PROSPECTIVE|||||||
34117678|NCT00401076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117679|NCT05233397|NA|SINGLE_GROUP||TREATMENT||NONE||ACTEMRA® (tocilizumab)||||
34117680|NCT01591629|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34117681|NCT05308121|||OTHER||CROSS_SECTIONAL|||||||
34117682|NCT02699229|||COHORT||PROSPECTIVE|||||||
34117683|NCT06398873|||COHORT||PROSPECTIVE|||||||
34117684|NCT04698304|||CASE_CROSSOVER||PROSPECTIVE|||||||
34117685|NCT00176748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117686|NCT05544253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117687|NCT00002414||||TREATMENT||DOUBLE||||||
34117688|NCT05568329|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117689|NCT00461708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117690|NCT06345404|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Blinded Placebo-Controlled|Sequential Dose Escalation|t|t|t|t
34117691|NCT05364814|||COHORT||PROSPECTIVE|||||||
34117692|NCT04068168|||CASE_ONLY||PROSPECTIVE|||||||
34117693|NCT03152669|||OTHER||OTHER|||||||
34117694|NCT00279214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117695|NCT00570843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117696|NCT05662657|||OTHER||PROSPECTIVE|||||||
34117697|NCT02971501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117698|NCT02301897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811525|NCT01742494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811526|NCT00972920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811527|NCT00725972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants undergo anesthesia and are unaware of the arm they are in. Outcomes Assessors are only given data on results and are kept unaware of the peri-operative management.|A protocol group receiving augmented Oxygen Delivery will be compared to a usual care group.|t|f|f|t
33811528|NCT03737110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043056|NCT05091905|RANDOMIZED|PARALLEL||TREATMENT||NONE|It will be impossible to mask investigators as they program the infusion pumps based on treatment group assignment; it will be impossible to mask participants as they will either be told how to titrate the bolus doses or not; and it will be impossible to mask the outcome assessor as we need to query patients on their daily bolus dose volume to track changes.|Randomized, Unmasked, Active-Controlled Human Subjects Clinical Trial||||
33811529|NCT04159545|||OTHER||PROSPECTIVE|||||||
33811530|NCT01070537|NA|SINGLE_GROUP||||||||||
33811531|NCT00688415|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33811532|NCT01037868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043057|NCT02458248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043058|NCT02473250|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043059|NCT03496896|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Given the nature of the intervention, it will be not possible to blind patients and nurses providing the TARGET intervention. However, treatment allocation in the database will be coded and the study nurses collecting the outcomes or working on data cleaning and the statistician performing the analysis will be blinded to the group allocation.||f|f|f|t
34043060|NCT03482453|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|t|t|f
34043061|NCT06539156|||COHORT||CROSS_SECTIONAL|||||||
34043062|NCT05907564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043063|NCT04253483|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043064|NCT01934582|NA|SINGLE_GROUP||OTHER||NONE||||||
34043065|NCT02014311|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34043066|NCT01019694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043067|NCT05033717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043068|NCT01566539|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34043069|NCT01131364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043070|NCT02445638|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34043071|NCT00880854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043072|NCT04028050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043073|NCT05664022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043074|NCT00781729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34043075|NCT04568915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043076|NCT04917159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34043077|NCT00302328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043078|NCT04129957|||COHORT||RETROSPECTIVE|||||||
34043079|NCT02156037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043080|NCT03938350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043081|NCT06488456|||CASE_ONLY||PROSPECTIVE|||||||
34043082|NCT03618160|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34043083|NCT01644071|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34043084|NCT01527656|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34043085|NCT02006589|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043086|NCT03137238|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34043087|NCT01009450|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34043088|NCT00409487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043089|NCT03907748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome measures will be collected by researchers who are not aware of the whether the participants' are allocated to the music, reading or standard care groups. The participants will be reminded not to reveal the group they are in to the person collecting the data. The participants themselves cannot be blinded due to the active nature of the intervention.|Participants (people with dementia and their cohabiting family caregivers) will be allocated to either (1) the music intervention group, (2) the reading intervention group or (3) the standard care group.|f|f|f|t
34043090|NCT05802524|||OTHER||PROSPECTIVE|||||||
34043091|NCT01908075|||COHORT||RETROSPECTIVE|||||||
34043092|NCT05131217|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The individual analyzing study data will be blind to subject allocation.|This is a repeated measures cross-over design, in which all subjects will complete all acute exercise intensity conditions: HIIT, continuous moderate intensity at lactate threshold (LT), and rest (control). The order of the acute treatment bouts will be randomized for each subject over three experimental visits (not counting the screening visit).|f|f|f|t
34043093|NCT04183296|RANDOMIZED|PARALLEL||PREVENTION||NONE|triple (Participant, Care Provider, investigator)|A Randomized Trial||||
34043094|NCT06322641|||COHORT||CROSS_SECTIONAL|||||||
34043095|NCT01631643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811533|NCT03349944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33811534|NCT00540956||||TREATMENT||NONE||||||
33811535|NCT00525122|||COHORT||PROSPECTIVE|||||||
33811536|NCT04898582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811537|NCT00286039|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811538|NCT01651507|||CASE_ONLY||RETROSPECTIVE|||||||
33811539|NCT01970878|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811540|NCT00236535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811541|NCT05172232|||OTHER||PROSPECTIVE|||||||
33811542|NCT04235998|||COHORT||PROSPECTIVE|||||||
33811543|NCT02434991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811544|NCT03637075|RANDOMIZED|CROSSOVER||OTHER||SINGLE||single-blinded, monocentric, prospective crossover study|t|f|f|f
33811545|NCT06195449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Statistician||t|t|t|t
33811546|NCT04938453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811547|NCT02282215|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811548|NCT03626376|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811549|NCT05890404|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34043096|NCT04138953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043097|NCT02089373|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34043098|NCT00459277|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34043099|NCT03969823|NA|SINGLE_GROUP||OTHER||NONE||||||
34043100|NCT04795648|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The study design will be a prospective cluster Randomized Control Trial (cRCT)|t|t|t|t
34043101|NCT00726973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34117699|NCT05067335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117700|NCT05016635|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34117701|NCT05663060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117702|NCT05792020|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Device stimulation will be blinded by the outcomes assessor to maintain the blinding of the participants and care provider|Within-subject, each participant will receive one excitatory course of stimulation and one inhibitory course of stimulation of the motor cortex.|t|t|f|f
34117703|NCT02209467|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34117704|NCT04219410|||COHORT||RETROSPECTIVE|||||||
34117705|NCT02951780|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34117706|NCT04378153|||OTHER||PROSPECTIVE|||||||
34117707|NCT06474871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blind could not be applicable since neither the participants nor the cognitive rehabilitation therapists could be blinded due to the nature of the intervention. However, clinical evaluation will be performed by an examiner blind to the patient' group of treatment.||f|f|f|t
34117708|NCT00796458|RANDOMIZED|||TREATMENT||NONE||||||
34117709|NCT02411461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34117710|NCT01918189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117711|NCT04744584|||COHORT||PROSPECTIVE|||||||
34117712|NCT04915716|||COHORT||PROSPECTIVE|||||||
34117713|NCT04885959|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34043102|NCT01398969|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants received either FMT or placebo to prevent further episode of CDI following FMT|t|f|t|t
34117714|NCT02022540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117715|NCT03655847|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117716|NCT01179815|||COHORT||PROSPECTIVE|||||||
34117717|NCT05503329|||CASE_ONLY||PROSPECTIVE|||||||
34117718|NCT01218269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117719|NCT03254121|||COHORT||OTHER|||||||
34117720|NCT02894411|||OTHER||PROSPECTIVE|||||||
34117721|NCT02236676|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117722|NCT03555058|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34117723|NCT03728933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117724|NCT06304155|||CASE_ONLY||PROSPECTIVE|||||||
34117725|NCT03929692|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The Intervention Group (mean age 15-16 years at the baseline and 17-18 years at follow-up) will be compared to a Control Group (mean age 17-18 years) that did not participate in the health promotion program.||||
34043103|NCT05369897|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The participants will be randomly assigned to either the experimental or the control group, and will be blind to the group assignment.~The data gathered before and after the intervention will be sent to an external statistical analyst blinded to group assignment."||t|f|f|t
34043104|NCT02476578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043105|NCT03594981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117726|NCT01935947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117727|NCT02177383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34117728|NCT04670861|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34117729|NCT04692389|NA|SINGLE_GROUP||TREATMENT||NONE||"The investigators would like to involve 30 oncology patients with 2 or 3 grade radiodermatitis (based on RTOG score).~All oncology diagnosis will be included."||||
34117730|NCT01991860|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117731|NCT06446570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117732|NCT01229124|||CASE_ONLY||RETROSPECTIVE|||||||
34117733|NCT05089292|NA|SINGLE_GROUP||SCREENING||NONE||Pre/Post-test design||||
34117734|NCT01846702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34117735|NCT04769284|||OTHER||PROSPECTIVE|||||||
33730995|NCT03277846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and investigators are blind to condition.|A 2x2 factor Randomized Controlled Trial with block randomization|t|t|t|t
33730996|NCT01989013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33730997|NCT01578044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33730998|NCT02555995|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33730999|NCT03732053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Controlled Trial|f|f|f|t
33731000|NCT01715818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731001|NCT03633838|||OTHER||RETROSPECTIVE|||||||
33731002|NCT04565054|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, interventional, prospective, two-arm, randomized, open-label, controlled adjuvant, phase-III trial evaluating the efficacy and safety of abemaciclib with endocrine therapy (ET) versus standard-of-care endocrine therapy in early breast cancer (EBC) patients with molecular HR+/HER2- subtype.||||
33731003|NCT06202742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731004|NCT00648219|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33731005|NCT02659215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731006|NCT06269471|||COHORT||RETROSPECTIVE|||||||
33731007|NCT05958212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731008|NCT02371499|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33731009|NCT01352390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731010|NCT00002816||||TREATMENT||||||||
33811550|NCT05888740|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm, open-label, feasibility acute phase study||||
33811551|NCT01052272|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33811552|NCT01005914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811553|NCT05765526|NA|SINGLE_GROUP||TREATMENT||NONE||An open label, single arm and before and after treatment||||
34043106|NCT03220269|||COHORT||PROSPECTIVE|||||||
34043107|NCT05002257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117736|NCT02450825|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34117737|NCT01573117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840151|NCT05063877|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|All parties are blinded for the initial two week safety period. A sponsor study physician and statistician (not an outcomes assessor) will be unblinded after the initial two week period to monitor ongoing safety, PK and concomitant drug levels|4:1 treatment to placebo|t|t|t|t
33840152|NCT04225572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34043108|NCT00383760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043109|NCT01701440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117738|NCT02870426|||OTHER||OTHER|||||||
34117739|NCT04541667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blinded, prospective, randomized study|Eligible study participants will be randomized 1:1 into two study arms; one receiving air and the other receiving carbon dioxide for luminal inflation.|t|f|t|f
34117740|NCT02834819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117741|NCT05464602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34117742|NCT04244734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34117743|NCT01656577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34117744|NCT03199833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117745|NCT04259593|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117746|NCT01606150|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34117747|NCT02332811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117748|NCT00451230|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
34117749|NCT00916227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117750|NCT00060944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117751|NCT02827721|||COHORT||PROSPECTIVE|||||||
34117752|NCT00706147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117753|NCT00960089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117754|NCT05857397|||OTHER||OTHER|||||||
34117755|NCT05863455|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117756|NCT02045602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34117757|NCT05338138|||COHORT||PROSPECTIVE|||||||
34117758|NCT02950337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117759|NCT01623063|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34117760|NCT05104827|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective non-controlled study||||
34117761|NCT01205516|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34117762|NCT02536664|||COHORT||PROSPECTIVE|||||||
34117763|NCT04161664|NA|SINGLE_GROUP||TREATMENT||NONE||a prospective, phase II trial to investigate the response rate of carboplatin and paclitaxel in patients with vulvar carcinoma||||
34117764|NCT00876941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117765|NCT04033458|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34117766|NCT02835690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117767|NCT00716274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117768|NCT03525509|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|At enrollment, each participant will be assigned a study number, which will match a previously prepared computer-generated list of randomization numbers to determine the interventions. Pharmacy staff who prepares blinded syringes of medications for administration will not be involved in medication administration, outcomes assessment, or statistical analysis. The participants and all other study personnel will be blinded to the treatment allocation.|Randomized, double-blinded, crossover design in healthy volunteers|t|f|t|t
34117769|NCT03218865|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective multicenter controlled and randomized protocol study||||
34117770|NCT01729039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117771|NCT06341894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117772|NCT05702307|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|double blind (participant and outcome assessor)|Crossover assignment|f|f|t|t
34117773|NCT02951260|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34117774|NCT01114984|||||PROSPECTIVE|||||||
34117775|NCT05918848|||COHORT||RETROSPECTIVE|||||||
34117776|NCT03189732|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34117777|NCT01326442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117778|NCT03149978|||COHORT||PROSPECTIVE|||||||
34117779|NCT05975658|||COHORT||PROSPECTIVE|||||||
34117780|NCT04700150|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34117781|NCT02553629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117782|NCT05702034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117783|NCT00928967|||COHORT||PROSPECTIVE|||||||
34117784|NCT01018602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117785|NCT02018120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117786|NCT03259295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117787|NCT06161584|||COHORT||PROSPECTIVE|||||||
34117788|NCT05375422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34117789|NCT03985735|||CASE_CONTROL||PROSPECTIVE|||||||
34043110|NCT01509313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043111|NCT00833105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117790|NCT00578097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043112|NCT01935232|||COHORT||CROSS_SECTIONAL|||||||
34043113|NCT06307132|||OTHER||PROSPECTIVE|||||||
34043114|NCT02946372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043115|NCT02933554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043116|NCT04545008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043117|NCT02920008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043118|NCT01157104|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34043119|NCT01534039|RANDOMIZED|CROSSOVER||||NONE||||||
34117791|NCT06716619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117792|NCT03916146|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34117793|NCT00544206|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117794|NCT05962944|||CASE_ONLY||PROSPECTIVE|||||||
34117795|NCT06332131|||COHORT||PROSPECTIVE|||||||
34117796|NCT02228057|||COHORT||PROSPECTIVE|||||||
34117797|NCT03943277|||COHORT||PROSPECTIVE|||||||
34117798|NCT02464982|||COHORT||PROSPECTIVE|||||||
33811554|NCT06207006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The investigator, care provider, and outcomes assessor are masked in terms of not knowing to which condition the participants will be randomized until after the completion of the baseline assessment. The outcomes assessor will break the envelope for the next eligible participant indicating if that participant is to be allocated to the intervention or control arms.~The participants are masked in terms of not knowing that the intervention, eConquerFear-HK are hypothesized to yield larger effects than the other (i.e. control)."|A prospective, parallel RCT design will be used to assess the impact of the eConquerFear-HK intervention on FCR improvement among Chinese cancer survivors in Hong Kong. Participants will be randomly assigned to an intervention group or a control group at a 1:1 ratio, using a computer-generated block randomization sequence generated by a statistician who is blinded to the identity of participants. This allocation concealment approach minimizes risk of selection and assessment bias. The serially labelled opaque sealed envelope method will be used for randomization. Block randomization structure with randomly permuted blocks sizes of 2 and 4 will be used to ensure close balance of numbers in each arm.|t|t|t|t
33811555|NCT03388957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Three groups, with 20 children in each group|t|t|t|t
33811556|NCT05484297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Following recommendations for blinding in behavioral interventions, participants will be blinded by limiting details about the study hypotheses and differences between the study arms. Furthermore, research staff involved in outcome assessment and study biostatisticians involved in data analysis will be blinded to study arms.|"Participants will be randomized 1:1 to either the intervention or the control group. Block-randomization schemes using random block sizes to assign the two study arms will be created in R using the blockrand package before study start. Randomization will be stratified by study site. The intervention will consist of a series of post cards with Crisis Caring Contacts content sent over 10 months. The control group will receive similar post cards intended to control for attention received but not including elements thought to be active ingredients in the intervention."|t|f|t|t
33811557|NCT06093490|||OTHER||PROSPECTIVE|||||||
33811558|NCT03794388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multicenter, open, randomized study||||
33811559|NCT00309673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33811560|NCT02823340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811561|NCT02283086|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33811562|NCT02320097|NA|SINGLE_GROUP||||NONE||||||
33811563|NCT02051218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811564|NCT04514978|RANDOMIZED|PARALLEL||OTHER||TRIPLE|An algorithm was created using randomizer.org|Explorative|t|t|t|f
33811565|NCT00141232|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33811566|NCT06230588|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811567|NCT05588739|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Blinded randomization into 2 groups: Treatment \& Waitlist Control. Treatment group receives treatment right away. Waitlist group receives treatment after a 5 week wait.|f|f|f|t
33811568|NCT05165420|||COHORT||OTHER|||||||
33811569|NCT05498051|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-centre, open-label, non-randomized cohort safety and feasibility study.||||
33811570|NCT00655824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811571|NCT00995683|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811572|NCT00362219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33811573|NCT05424328|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study consists of 2 groups A and B each contains 10 patients of total 20 patients. Where group A (control group) where Alt flap harvest for tongue reconstruction after hemi glossectomy is done with the conventional method where flap design and volume depends on surgeon's own experience while group B (study group) the Alt flap design and volume will be harvested by the aid of a guide that is virtually planned before the operation.||||
33811574|NCT00231699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33811575|NCT03938207|||COHORT||RETROSPECTIVE|||||||
33811576|NCT01124942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811577|NCT00964171||||TREATMENT||NONE||||||
33811578|NCT04918719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sylvia Youn, Pharm.D., the ED Pharmacist will maintain drug accountability logs in compliance with FDA regulations. She will instruct other ED pharmacists about the study and the randomization log which will be kept in the pharmacy room in the ED. She will also create study drug labels to keep the nurses, physicians and patients blinded to the study medication.|Randomized double blinded clinical trial|t|t|t|t
33811579|NCT04995198|||COHORT||PROSPECTIVE|||||||
33811580|NCT01049152|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34117799|NCT01731561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117800|NCT02622269|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34117801|NCT01093131|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34117802|NCT03687281|||OTHER||PROSPECTIVE|||||||
33811581|NCT02089906|||||PROSPECTIVE|||||||
33811582|NCT03367299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811583|NCT05924113|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811584|NCT03918005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811585|NCT01735214|||CASE_ONLY||PROSPECTIVE|||||||
33811586|NCT00482911|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811587|NCT05750719|||COHORT||RETROSPECTIVE|||||||
33811588|NCT04612218|||COHORT||PROSPECTIVE|||||||
33811589|NCT05927259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811590|NCT05038202|RANDOMIZED|PARALLEL||TREATMENT||NONE||450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatment.||||
33811591|NCT04552015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811592|NCT04920799|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33811593|NCT00555932|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33811594|NCT00523900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811595|NCT05168280|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811596|NCT03335059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117803|NCT03401294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149780|NCT05130476|NA|SINGLE_GROUP||PREVENTION||NONE||Matched cohort study||||
34149781|NCT02077543|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149782|NCT03506919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811597|NCT01279694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149783|NCT02488460|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34149784|NCT00784485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811598|NCT00780793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811599|NCT04635657|||COHORT||PROSPECTIVE|||||||
33811600|NCT03136159|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811601|NCT05013398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33811602|NCT00825318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043120|NCT06401473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients remained blinded to their assigned intervention until after all study procedures were complete.~Injecting provider was technically blinded but was functionally unblinded at the time of the injection itself due to the visible and audible differences between each group throughout the course of the injection.~Outcome assessor was blinded while instructing patients how to denote their pain level after the procedure, but was unblinded at the time of the injection. No input was given by the outcome assessor after they were unblinded."|Random assignment into one of three parallel groups: control, distraction, or experimental|t|f|f|f
34043121|NCT06285864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of their assigned treatment.||t|f|f|f
34043122|NCT06577142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043123|NCT03629938|||CASE_CONTROL||PROSPECTIVE|||||||
34043124|NCT02743936|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34043125|NCT06431932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The trial consists of:~* a single-arm open-label study, in which healthy volunteers (n=20) will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.~* a 2-arm triple-blind randomized placebo-controlled study, in which older patients with multimorbidity (n=40) will receive either:~  * 20 mg/kg/day fisetin for two consecutive days, or~ * placebo for two consecutive days."|t|t|t|t
34043126|NCT04349228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"As the trial is open-label and to preserve the validity of the trial, the measurement of the endpoint must be blinded by a third party (i.e., an evaluator who is not aware of the arm to which the patient has been assigned or the treatment the patient is receiving) using the PROBE (Prospective Randomized Open Blinded Endpoint) method."|"Arm1:Hydroxychloroquine (HCQ) (200 mg / day) for at least 2 months or until potential contamination\*\*.~Arm2:Placebo (1 tablet/day) for at least 2 months or until potential contamination\*\*.~\*\* If the participant is contaminated (COVID19+), he or she will be followed up by telephone according to the study schedule."|f|f|f|t
34043127|NCT01519375|||COHORT||RETROSPECTIVE|||||||
34043128|NCT02362802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043129|NCT02129166|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043130|NCT02218047|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043131|NCT02299232|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34043132|NCT00669097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043133|NCT00676364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043134|NCT01470248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043135|NCT02694926|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043136|NCT01168414|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043137|NCT06072469|||OTHER||CROSS_SECTIONAL|||||||
34043138|NCT05434195|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34043139|NCT03683225|NA|SINGLE_GROUP||TREATMENT||NONE||"Pramipexole ER tablets will be administered with or without aprepitant, orally once daily in the morning.~During Part 1 and Part 2, pramipexole ER dosage will be adjusted in twice-weekly increments of 0.75 mg/day as guided by efficacy and tolerability (see table above).~Aprepitant:~From study Part 2 onwards, participants will also receive one 80 mg capsule of aprepitant co-administered once daily with pramipexole ER."||||
34043140|NCT06565494|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, proof-of-concept with single group assignment.||||
34043141|NCT03819712|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043142|NCT06240936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043143|NCT00719485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043144|NCT05822323|RANDOMIZED|PARALLEL||OTHER||NONE||"The study was carried out on 40 lower incisors of 40 patients who applied to the Fırat University Faculty of Dentistry Department of Periodontology between the years of 2019 and 2021, who had Miller class III gingival recession in their lower 1st incisors, and were treated with FGG operation due to insufficient amount of keratinized gingiva. The patients were divided into 2 groups as randomized controlled.~Control group (FGG) (n:20): The patients in this group only underwent the FGG operation.~Study group (FGG+BTX) (n:20): The patients in this group received 5 U BTX-A injection into the mental muscle immediately after the FGG operation."||||
34043145|NCT04557215|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34043146|NCT05540847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043147|NCT04057482|||COHORT||RETROSPECTIVE|||||||
34043148|NCT04534920|||OTHER||RETROSPECTIVE|||||||
34043149|NCT05944497|||COHORT||PROSPECTIVE|||||||
34043150|NCT00245089||||TREATMENT||NONE||||||
34043151|NCT01130441|||COHORT||CROSS_SECTIONAL|||||||
34043152|NCT01519219|||CASE_ONLY||PROSPECTIVE|||||||
34043153|NCT03416426|||COHORT||RETROSPECTIVE|||||||
34043154|NCT04851808|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34043155|NCT04631601|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043156|NCT01961739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043157|NCT02644993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043158|NCT02915705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043159|NCT04867122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The randomized portion of the trial will enroll 500 family caregivers. An additional portion of the trial will enroll 30 key stakeholders to participate in individual interviews focused on potential barriers and facilitators to adoption of the problem-solving therapy (PST) intervention into clinical practice.|f|f|f|t
34043160|NCT02844933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043161|NCT01757002|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043162|NCT02215200|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043163|NCT01209949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043164|NCT00406341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34043165|NCT06575387|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33811603|NCT03410420|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a prospective study designed to determine the safety and value of pimonidazole hydrochloride to detect levels of tissue hypoxia in patients presenting with ascending aortic aneurysm||||
33731011|NCT03073278|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|no masking|Group 1 will receive 36 grays (radiation dose unit Gy) in 6 treatments. Group 2 will receive 38 grays (Gy) in 6 treatments and Group 3 will receive 40 grays (Gy) in 6 treatments. If the first group of participants tolerate the treatment well and with minimal side effects, then the next group of participants will be given the same treatment but at the higher dose (38 Gy). If the second group tolerates this higher dose, then the third group of patients will be given a higher dose (40 Gy). This will be the final dose being tested in this investigation.||||
33731012|NCT01536496|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731013|NCT04546958|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Laboratory technicians who assess the study outcomes will be masked|A randomized, active-controlled trial with cross-over design|f|f|f|t
33731014|NCT01296516|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
33731015|NCT02348528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731016|NCT04548674|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33731017|NCT04534842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731018|NCT03571087|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731019|NCT01720069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731020|NCT02134457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731021|NCT00006374||||TREATMENT||||||||
33731022|NCT03102918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study.|In this randomized, double-blind, placebo-controlled trial, cannabis-dependent subjects ages 18-65 will receive medical management over a 6-week period, with half receiving Epidiolex treatment and half receiving placebo.|t|f|t|f
33731023|NCT02299050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731024|NCT06135662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043166|NCT02527733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043167|NCT06576869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33731025|NCT02173197|||COHORT||PROSPECTIVE|||||||
34043168|NCT01723085|||COHORT||PROSPECTIVE|||||||
34043169|NCT01747031|NA|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34043170|NCT06575556|||COHORT||CROSS_SECTIONAL|||||||
34043171|NCT03794648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731026|NCT01092247|NON_RANDOMIZED|PARALLEL||||NONE||||||
34043172|NCT00508014|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33731027|NCT02103751|||CASE_CONTROL||PROSPECTIVE|||||||
33731028|NCT03791658|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Cross-sectional, single center, single visit study.~1 group of 70 asthmatics, 1 group of 70 COPD-patients"||||
33731029|NCT02788734|||COHORT||PROSPECTIVE|||||||
33731030|NCT02813343|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34043173|NCT06128772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043174|NCT05629780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All patients are included and analyzed for outcomes in the CLASSIC trial. The allocation and amount of fluids received for the included subjects are blinded for the investigator at the time point of analysis.|This is a retrospective analysis of patients recruited to an interventional multicenter trial.|f|f|t|f
34043175|NCT00658723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043176|NCT00002205||||TREATMENT||||||||
34043177|NCT06128239|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are aware of their own treatment condition but masked to the other two treatment conditions. Most investigators, including the senior statistician, are masked to treatment conditions.|Participants randomized 1:1:1 to three treatment conditions|t|f|t|f
34043178|NCT00108017|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34043179|NCT02430519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The eligible samples were screened and randomly assigned by lottery method by investigator KRR into PRF (Group A) and GTR + Allograft (Group B). The treatment was performed by investigator SA who was blinded to the randomization process|Prospective, randomized, parallel arm, interventional trial|t|f|t|f
34043180|NCT06578572|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043181|NCT00242138|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34043182|NCT05252325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The products will be administered by the Investigator/Co-Investigator (Treating Investigator), while the evaluations will be done by a Co-Investigator not aware of the side type treatment (Blinded Evaluator)|pre-CE mark controlled, prospective, randomized, blinded evaluator, single centre, split-face clinical investigation|f|f|f|t
34043183|NCT02158013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34043184|NCT05270616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34043185|NCT04467567|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34043186|NCT00061997||||PREVENTION||||||||
34043187|NCT02817295|||COHORT||RETROSPECTIVE|||||||
34043188|NCT05679947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participant: the researcher learned the study and control groups after the pre-test data. The study group was trained with the mobilization protocol. The control group received training on the current mobilization procedure of the clinic. Participants did not know which group they were in.~Outcomes Assessor. Study and control groups data were coded into the SPSS programme as group one and group two. Analysis of data was done by an independent statistician. The statistician has no information about which group the patients belong to."|Prospective, parallel group single blinded, randomized controlled clinical trial|t|f|f|t
34043189|NCT03182504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043190|NCT03589144|||CASE_ONLY||PROSPECTIVE|||||||
34043191|NCT04858776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043192|NCT04152070|||COHORT||CROSS_SECTIONAL|||||||
34043193|NCT03124368|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34043194|NCT00291876|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043195|NCT00172172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043196|NCT00356603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043197|NCT03067532|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043198|NCT01941849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043199|NCT00492648|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149785|NCT02383771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731031|NCT01816464|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731032|NCT00820612|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33731033|NCT03816631|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731034|NCT02637843|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33731035|NCT03789201|NA|SINGLE_GROUP||OTHER||NONE||||||
33731036|NCT05256238|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731037|NCT04182035|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33731038|NCT00001996||||TREATMENT||NONE||||||
33731039|NCT00148603|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33731040|NCT00122720|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33731041|NCT05262205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups, each is 50 child randomly allocated.||||
34043200|NCT05533268|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor will not know about grouping of the participants.||f|f|f|t
34043201|NCT04509193|||COHORT||RETROSPECTIVE|||||||
34043202|NCT04940793|||COHORT||PROSPECTIVE|||||||
34043203|NCT00713908|||COHORT||PROSPECTIVE|||||||
34043204|NCT00002435||||TREATMENT||DOUBLE||||||
34043205|NCT04286685|||COHORT||PROSPECTIVE|||||||
34043206|NCT06183385|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043207|NCT01184820|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043208|NCT02309762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043209|NCT04033861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043210|NCT05022940|||COHORT||PROSPECTIVE|||||||
34043211|NCT03809754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043212|NCT01227590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043213|NCT03709303|||CASE_ONLY||CROSS_SECTIONAL|||||||
34043214|NCT04245436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||t|f|t|f
34043215|NCT02439541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043216|NCT02499211|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043217|NCT02518282|||COHORT||PROSPECTIVE|||||||
34043218|NCT02955095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043219|NCT03612596|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34043220|NCT00180804|||||OTHER|||||||
34043221|NCT05704998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 26 patients with temporomandibular disorder, aged between 18-70 years, 13 of whom were in the Posterior Edentulous Group (PDG) and 13 were in the Fully Toothed Group (TDG), received same treatment.||||
34043222|NCT00578019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043223|NCT02594033|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34043224|NCT02404636|||COHORT||PROSPECTIVE|||||||
34043225|NCT05017350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043226|NCT06576141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be done via random.org.|There are three groups. Kaleidoscope ,Virtual Reality Glasses and control group|t|f|f|t
34043227|NCT00232362|RANDOMIZED|PARALLEL||||NONE||||||
34043228|NCT03397498|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are not told which group they are assigned to, and the investigator (PI) and coordinators completing the cognitive evaluation are not told which group the participants are assigned to.||t|f|t|f
34043229|NCT00350090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043230|NCT04210401|||COHORT||PROSPECTIVE|||||||
34043231|NCT06457802|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind; The participants and the interventionists will be aware of the treatment assignments, but the data collectors will be blinded to the group assignments to reduce bias in data collection and analysis.|This study employs a parallel assignment interventional model, wherein participants are randomly allocated to one of two groups: the intervention group or the control group. The intervention group will receive a comprehensive sedentary behavior (SB) reduction program over 8 weeks, utilizing wearable technology, including Fitbit devices and smart water bottles, combined with personalized text message prompts. The control group will receive standard care, consisting of educational materials provided by the American Heart Association, without additional prompts or interventions. The primary goal is to compare the outcomes between these two groups to assess the feasibility, acceptability, and preliminary efficacy of the SB reduction intervention in reducing SB and improving cardiometabolic health and patient-centered outcomes in individuals with type 2 diabetes.|f|f|f|t
34043232|NCT05708872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34043233|NCT04947384|||COHORT||PROSPECTIVE|||||||
34043234|NCT05866705|||COHORT||PROSPECTIVE|||||||
34043235|NCT06575608|||OTHER||CROSS_SECTIONAL|||||||
34043236|NCT04632069|NA|SINGLE_GROUP||TREATMENT||NONE|Co-investigator analyzing MRI data will be blinded to timing of MRI scan and dose|We will obtain parental consent, and then administer NAC 100mg/kg loading dose, followed by 75mg/kg q 6h via nasogastric tube, started 4 days prior to taVNS-paired feeding and continued for a total of 14 days. We will perform pharmacokinetics of oral NAC, and MRIs prior to, after 3-4 days of NAC, and after taVNS treatment period.||||
34043237|NCT00058656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043238|NCT04604613|||COHORT||PROSPECTIVE|||||||
34043239|NCT05501418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043240|NCT00018941||||TREATMENT||||||||
34043241|NCT05168631|||COHORT||RETROSPECTIVE|||||||
34043242|NCT00540150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043243|NCT04167033|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a bicentric case-control study: 60 patients with POI followed in the endocrinology department, and 60 healthy volunteers matched with POI's patients on age (+/- 5 years), on BMI classes (BMI\<18, 18-25, 25-30, 30-35, 35-40, \>40) and with regular cycles (26 to 32 days).||||
34043244|NCT04031040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043245|NCT01385969|||CASE_CONTROL||PROSPECTIVE|||||||
34043246|NCT03227744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043247|NCT01219829|||COHORT||RETROSPECTIVE|||||||
34043248|NCT02744729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043249|NCT02607774|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043250|NCT00002596|RANDOMIZED|||TREATMENT||||||||
34043251|NCT06575062|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34043252|NCT01483027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043253|NCT04074941|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study staff involved in administering the dietary intervention and assessing compliance will be masked to participants' outcome assessments (e.g. BP).|Participants will be randomized to either a low sodium diet or a usual sodium diet for a period of two weeks.|t|f|t|t
34043254|NCT06062628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043255|NCT05457036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research staff will not change any study procedures based on the subject's group placement. Blinding assessment will be done during the study visits 2 and 3. We will use an established blinding assessment.33 Subjects will be asked if they believe they are receiving the real treatment, sham/placebo treatment, or if they are uncertain. Answers will be asked and recorded by the research staff on the case report forms.|After signing the Study consent form, the subject will be randomized (1:1, block randomization with a block size of 10 stratified by site and race (Caucasian or non-Caucasian)) to one treatment group (Active or Sham treatment, see below) and be considered part of the intent-to-treat (ITT) cohort.|t|t|f|f
34043256|NCT03534518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043257|NCT02573181|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731042|NCT06082999|||COHORT||PROSPECTIVE|||||||
33731043|NCT04196166|||COHORT||RETROSPECTIVE|||||||
33731044|NCT04073316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33731045|NCT04107480|RANDOMIZED|PARALLEL||TREATMENT||NONE||This partially randomized, preference trial design, comprises three unblinded randomized controlled trials (RCTs) and an observational study arm (PRolaCT-O) that compare neurosurgical counselling and potentially subsequent endoscopic transsphenoidal adenoma resection with current standard care (DA treatment). Patients with a non-invasive prolactinoma of limited size (\<2.5 cm) will be divided over the three RCTs based on duration of pre-treatment with DA: PRolaCT-1: newly diagnosed, treatment naive patients; PRolaCT-2: patients with limited duration of DA treatment (4-6 months); and PRolaCT-3: patients with persisting prolactinoma after DA treatment for \>2 years. PRolaCT-O will include patients who decline randomization or those with a clear treatment preference. After study inclusion and treatment allocation, all study procedures and follow up are equal for the three RCTs and PRolaCT-O and are therefore discussed as one.||||
33731046|NCT03777969|||COHORT||OTHER|||||||
33731047|NCT03192839|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33731048|NCT04618718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731049|NCT02321696|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33731050|NCT00482391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043258|NCT03555318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043259|NCT00249340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043260|NCT00887575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043261|NCT01010412|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34043262|NCT02449031|||COHORT||PROSPECTIVE|||||||
34043263|NCT05456178|||COHORT||PROSPECTIVE|||||||
34043264|NCT05368818|||COHORT||RETROSPECTIVE|||||||
34043265|NCT04103892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Part A - 15 patients, 2 arms, parallel; Part B - 122 patients, 2 arms, parallel|t|f|t|f
34043266|NCT03084107|NA|SINGLE_GROUP||OTHER||NONE||||||
34043267|NCT02183883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043268|NCT04668248|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34043269|NCT05358288|||COHORT||PROSPECTIVE|||||||
34043270|NCT06577480|||CASE_ONLY||CROSS_SECTIONAL|||||||
34043271|NCT04781283|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043272|NCT06256952|RANDOMIZED|PARALLEL||OTHER||SINGLE||The study employs a within-group design. The participants of each group (AUD and HC) attend two consecutive sessions (one a day), and on each of these days, they engage in the Cyberball Experiment before undertaking the PIT Task. Within the Cyberball Experiment, participants are randomly assigned to either partial exclusion or inclusion on the first day. On the second consecutive day, they undergo the condition they did not experience previously.|t|f|f|f
34043273|NCT00161005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043274|NCT06043505|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043275|NCT03550222|||COHORT||PROSPECTIVE|||||||
34043276|NCT03568292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043277|NCT04614025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043278|NCT00234975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043279|NCT06164561|||OTHER||PROSPECTIVE|||||||
34043280|NCT04426721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043281|NCT03408769|||COHORT||PROSPECTIVE|||||||
34043282|NCT02406027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043283|NCT00382200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043284|NCT03485417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|treatment group randomised to each participant is masked to the outcome assessors|prospective randomised single-blinded|f|f|f|t
34043285|NCT06537427|||COHORT||CROSS_SECTIONAL|||||||
34043286|NCT00464958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043287|NCT01506037|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043288|NCT03668444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessors are blinded to conditions|Randomized Control Trial|f|f|f|t
34043289|NCT04463251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043290|NCT01624740|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34043291|NCT06194240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149786|NCT00237380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149787|NCT03124212|||FAMILY_BASED||PROSPECTIVE|||||||
34149788|NCT03412383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043292|NCT04501497|||COHORT||PROSPECTIVE|||||||
34043293|NCT05360147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043294|NCT03291431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043295|NCT02281435|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043296|NCT05268224|||COHORT||PROSPECTIVE|||||||
34043297|NCT04883242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043298|NCT00321295|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34043299|NCT04143854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043300|NCT06524362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34043301|NCT06445803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33811604|NCT06505525|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Blinding after the assignment of patients to their group will be done as follows:~* Participants: No blinding.~* Investigators: No blinding.~* Intervention providers: No blinding.~* Data recorders: Partial blinding.~* Outcome assessors: No blinding.~* Data analysts, statisticians: Blinding. The statistician will only know the group of each patient after the statistical analysis is complete.~* Care providers: No blinding."|Prospective Multicenter Randomized Clinical Trial||||
33811605|NCT02417324|||COHORT||PROSPECTIVE|||||||
33811606|NCT04946734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117804|NCT03314428|NA|SINGLE_GROUP||TREATMENT||NONE|Data will be analyzed by an assessor blinded to date of data collection for each testing session. Following data collection, a researcher not involved with data collection or analysis will re-code data timepoints to ensure that the assessor is unaware of the timepoint each datapoint was obtained.|Single Group cohort study||||
33811607|NCT05145348|||COHORT||PROSPECTIVE|||||||
34117805|NCT06717334|||COHORT||PROSPECTIVE|||||||
34117806|NCT01882465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34043302|NCT04828018|||COHORT||CROSS_SECTIONAL|||||||
34117807|NCT01194362|||CASE_CONTROL||PROSPECTIVE|||||||
34117808|NCT03425955|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043303|NCT00274612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34117809|NCT01486888|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34043304|NCT05296083|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043305|NCT01921868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043306|NCT04881864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117810|NCT02162706|||COHORT||OTHER|||||||
34117811|NCT02499614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043307|NCT06355076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients in the experimental or control group, as well as their family members, are unaware|The experimental group received a new urethral reconstruction technique, which involves suturing the levator ani muscle with the lateral striated muscle of the urethra, the dorsal median ridge (MDR), and the Di's fascia together for continuous suturing before performing bladder urethral anastomosis. After the reconstruction is completed, the end to end anastomosis of the bladder urethra is performed|t|f|f|f
34117812|NCT06368648|||CASE_ONLY||PROSPECTIVE|||||||
34043308|NCT01167933|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043309|NCT01605552|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34117813|NCT04858581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117814|NCT01737892|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34117815|NCT04142489|NA|SINGLE_GROUP||OTHER||NONE||||||
34117816|NCT03265184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34117817|NCT05181345|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34117818|NCT06143189|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34117819|NCT04907630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34117820|NCT05613556|||COHORT||PROSPECTIVE|||||||
34117821|NCT04675827|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Eligible subjects will first receive neoadjuvant treatment then surgery. After surgery, subjects who achieve a pCR (RCB score at surgery = 0) will receive adjuvant pertuzumab and trastuzumab FDC SC for additional 14 cycles. Those with residual invasive disease (RCB score at surgery ≥ 1) will receive salvage adjuvant T-DM1 for 14 cycles. In subjects with RCB score as ≥2, 3 to 4 cycles of anthracycline-based chemotherapy may be administered, at the investigator's discretion, before the administration of T-DM1.||||
34117822|NCT04015804|NA|SINGLE_GROUP||OTHER||NONE||||||
34117823|NCT00285779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117824|NCT05193448|||COHORT||CROSS_SECTIONAL|||||||
34117825|NCT05042011|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34117826|NCT02328872|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34117827|NCT05811325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117828|NCT05752500|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Data analyst will be masked to intervention component assignment labels.|2x2x2 factorial design|f|f|t|f
34117829|NCT06280209|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117830|NCT01877304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117831|NCT05910658|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117832|NCT02286895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117833|NCT00723567|||COHORT||PROSPECTIVE|||||||
34117834|NCT00842621|||COHORT||PROSPECTIVE|||||||
34117835|NCT05441514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117836|NCT04986631|NA|SINGLE_GROUP||TREATMENT||NONE||Individuals in this pilot study will be 12-\<18 years of age at enrollment. All participants will receive topiramate for 3.5 months.||||
34117837|NCT04256850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731051|NCT01302821|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731052|NCT02915744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731053|NCT01088009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731054|NCT03493334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731055|NCT05379296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731056|NCT03900299|NA|SINGLE_GROUP||TREATMENT||NONE||All operable(don't require neoadjuvant therapy or inflammatory carcinoma) female patients diagnosed as multifocal breast cancer will receive oncoplastic breast surgery as a surgical treatment.||||
33731057|NCT03822728|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731058|NCT06399146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731059|NCT03641352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731060|NCT03609541|||COHORT||PROSPECTIVE|||||||
33731061|NCT02346240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731062|NCT00572507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731063|NCT00098111|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33731064|NCT05448482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731065|NCT00003739|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33731066|NCT04978792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731067|NCT02840877|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731068|NCT05385939|||COHORT||PROSPECTIVE|||||||
34043310|NCT01068678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811608|NCT02356874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33811609|NCT01145313|||COHORT||RETROSPECTIVE|||||||
33811610|NCT04374981|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811611|NCT04221711|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since blinding is not possible for patients, only the statistician will be blinded with respect to the treatment group.|The study design was chosen to be a randomized, controlled trial.||||
33811612|NCT03033056|||CASE_CONTROL||PROSPECTIVE|||||||
33811613|NCT02382172|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33811614|NCT04995315|||COHORT||PROSPECTIVE|||||||
33811615|NCT03146845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043311|NCT01214291|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34043312|NCT02127840|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043313|NCT01356823|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043314|NCT03182244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043315|NCT04082923|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34043316|NCT05202067|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patients assigned to the intervention group will receive from the research pharmacist, a didactic talk (of at least 10 and up to 20 minutes), where they will be provided information about type 2 diabetes mellitus and Systemic Arterial Hypertension, causes of the disease and consequences of poor control, on its pharmacological treatments, changes in lifestyle and diet. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.~Patients assigned to the control group will receive only standard care, represented by regular consultation with their prescribing physician."||||
33811616|NCT01196364|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34043317|NCT03780881|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The investigator randomly assigns participants to one of the experimental conditions. Participants are not aware which experimental condition they are allocated to.|Participants are assigned to one of two experimental groups in parallel for the duration of the study|f|f|t|f
34043318|NCT05961943|NA|SINGLE_GROUP||PREVENTION||NONE||Study recruitment will be conducted at the vascular outpatient clinic at Galway University Hospitals (GUH), Ireland. Those who consent will then be invited to attend a baseline assessment. All participants will be provided with an activPAL accelerometer device to use for seven consecutive days. Patients will also complete the six-minute walk test (6-MWT) using timed walk application. Participants will then commence the 12-week tailored intervention to empower participants to reduce/interrupt their sedentary time. Participants will have access to an online education session via the RESPONSE-2-PAD link. The researcher will support and motivate participants to reduce/interrupt their sitting time by contacting them through phone or video coaching calls once a week, on average lasting 10-15 minutes. an activity tracker will be used as a sedentary reminder. Participants will be followed up at 12-weeks and again at six months.||||
33811617|NCT03339544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811618|NCT01230970|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33811619|NCT06309862|||COHORT||PROSPECTIVE|||||||
33811620|NCT00125723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811621|NCT04038190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The purpose of the study is to conduct a cluster randomized trial testing BA administered in a semester-long (16 week) freshman orientation course, compared to a standard orientation course in 540 freshmen spread over 36 course sections (18 sections each of the BA and standard orientation format). A 5-month post-treatment assessment will measure durability of effects. Mediation analyses will test mechanisms of action. A random sample of 20% of participants will complete a 17 month follow up to examine long term effects.|t|f|f|f
33811622|NCT00853606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811623|NCT03160976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33811624|NCT01219127|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811625|NCT04084262|||CASE_ONLY||PROSPECTIVE|||||||
33811626|NCT00987272|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33811627|NCT03142867|||OTHER||PROSPECTIVE|||||||
33811628|NCT05346588|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33811629|NCT04220983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811630|NCT06092177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811631|NCT05575687|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|With the exception of the water treatment, treatment type will be blind for the participants and the researchers. The primary analysis will be performed completely blinded.||t|f|t|t
33811632|NCT05528809|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This a single-center prospective comparative non-randomized cohort pilot study, with 2 parallel groups (experimental group : patients with Gougerot-Sjögren's syndrome and positive control group : patients with diffuse systemic scleroderma).||||
33811633|NCT00001397|||CASE_ONLY||PROSPECTIVE|||||||
33811634|NCT06301048|||COHORT||RETROSPECTIVE|||||||
33811635|NCT00916656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811636|NCT00704340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811637|NCT03111706|||COHORT||PROSPECTIVE|||||||
33811638|NCT00876005|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33811639|NCT00531037|||COHORT||PROSPECTIVE|||||||
33811640|NCT06129981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811641|NCT01457755|||COHORT||PROSPECTIVE|||||||
33811642|NCT03265756|||COHORT||PROSPECTIVE|||||||
33811643|NCT03541226|||COHORT||PROSPECTIVE|||||||
33811644|NCT04190485|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33811645|NCT04501744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811646|NCT00989755|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33811647|NCT05588388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811648|NCT02435485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33811649|NCT03615833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811650|NCT00006200||||TREATMENT||||||||
33811651|NCT01199185|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811652|NCT01867307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811653|NCT02237937|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||f|f|t|t
33811654|NCT05448521|||COHORT||PROSPECTIVE|||||||
33811655|NCT04317430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731069|NCT03343691|||COHORT||PROSPECTIVE|||||||
33731070|NCT01424553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731071|NCT05954481|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731072|NCT03019627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The identity of the treatments was concealed from the patient, Investigator, site staff, and Dompé's clinical research personnel until the study was unmasked for the final statistical analysis (after data base lock) except in case of specific events that required unmasking of the patient.||t|f|t|f
33731073|NCT02927457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731074|NCT00934206|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731075|NCT05157594|||COHORT||PROSPECTIVE|||||||
33731076|NCT03960502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731077|NCT00854503|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33731078|NCT01040481|||COHORT||RETROSPECTIVE|||||||
33731079|NCT00004903||||TREATMENT||||||||
33731080|NCT00542750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731081|NCT05498558|||OTHER||PROSPECTIVE|||||||
33731082|NCT06099262|||COHORT||PROSPECTIVE|||||||
33731083|NCT02639481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731084|NCT03945981|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive 50 mg DTG + 300 mg 3TC FDC, participants will administer one tablet once daily (OD) orally with or without food.||||
33731085|NCT04295603|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Monocentric study with a design of non-randomized cluster trial. The treatment is assigned to one of two care units and subjects are allocated to the care unit not according to a randomization process but based on administrative basis.|t|f|f|f
33731086|NCT04168177|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|the data collector will be unaware of the nature of the study|patients will be randomly assigned into one of two groups, control group will receive patient controlled analgesia, and intervention group will receive ESP Block .|f|t|f|t
33731087|NCT04931901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomization per dominant and nondominant hand. So that there is an even share of number of patients with Stimpod NMX450X on dominant hand and Datex-Ohmeda E-NMT.||||
33731088|NCT01393743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731089|NCT02126540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731090|NCT01762943|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731091|NCT01765127|||COHORT||RETROSPECTIVE|||||||
33731092|NCT00742313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731093|NCT04487327|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Study investigators collecting outcome assessments will be blinded to group allocation. Participants will be asked not to reveal what group they believe they were randomized to.|"Specific Aim 1: To evaluate if DN has an effect on muscle stiffness, gait, pain pressure threshold, and balance in individuals with injuries to the ankle and/or hindfoot.~The dependent variables for Aim1 are: muscle stiffness, plantar pressure, PPT, and balance. The independent variables for Aim1 are Group (MTrP needling versus away from the MTrP site) and Time. The primary aim will be examined using linear mixed modeling with any baseline differences between groups used as a co-variate. A separate model will be created for each dependent variable.~Specific Aim 2: To determine the validity of dry needling specific muscles of the lower extremity based upon needle placement, location relative to anatomical structures and accuracy of needle placement in muscle with in vivo ultrasound imaging."|t|f|f|t
33731094|NCT04210154|||CASE_CROSSOVER||PROSPECTIVE|||||||
33731095|NCT02759068|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731096|NCT00655564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731097|NCT03085589|||OTHER||CROSS_SECTIONAL|||||||
33731098|NCT03817619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Open-label, 2-period, randomised, cross-over, single-centre, phase I, single-dose trial in 14 healthy adult subjects.~Intrasubject comparison of PK parameters after different administrations of Zepatier"||||
33731099|NCT00003585||||TREATMENT||||||||
33731100|NCT01125215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811656|NCT05703659|RANDOMIZED|PARALLEL||OTHER||NONE||"Primary Purpose of this study is epidemiological, and to determine if probiotic species can transmit between infants whose microbiomes are still developing.~Mothers and infant dyads will be enrolled and attend 5 weekly lactation support group sessions. After the first session, infants will be randomized to receive 1 of 2 probiotics. Both probiotics are marketed in the US as dietary supplements for infants. At the first support group session and at the final session, infant fecal samples and mother's milk samples will be collected and tested for detectable levels of both probiotics to determine if horizontal transmission of the probiotic species occurred in the setting of a lactation support group."||||
33811657|NCT03883724|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
34043319|NCT01208779|||||PROSPECTIVE|||||||
34043320|NCT01619267|||CASE_CONTROL||PROSPECTIVE|||||||
34117838|NCT00006384||||TREATMENT||||||||
34043321|NCT05121311|||COHORT||PROSPECTIVE|||||||
34043322|NCT06363331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043323|NCT03208998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043324|NCT01448473|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34043325|NCT05801536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731101|NCT06218082|||COHORT||PROSPECTIVE|||||||
33731102|NCT04076644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731103|NCT04019158|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731104|NCT01883401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731105|NCT04415541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731106|NCT01752205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731107|NCT05019222|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33731108|NCT00400647|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043326|NCT04210063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043327|NCT06575426|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase I/IIa, Single site, Open-Label, Ascending Dose Study||||
34043328|NCT06346444|||COHORT||PROSPECTIVE|||||||
34043329|NCT05600231|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34043330|NCT00840567|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043331|NCT01754129|||COHORT||PROSPECTIVE|||||||
34043332|NCT04806243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731109|NCT03973242|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Study group: Dual Focus with Narrow band imaging Control group: White light endoscopy|t|f|f|f
34117839|NCT05784857|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34117840|NCT00152126|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043333|NCT06572644|||COHORT||CROSS_SECTIONAL|||||||
33731110|NCT00046124|||DEFINED_POPULATION||PROSPECTIVE|||||||
33731111|NCT02002494|||COHORT||PROSPECTIVE|||||||
34043334|NCT06369168|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|t|f|f|f
34043335|NCT04277364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043336|NCT02802202|||||PROSPECTIVE|||||||
34043337|NCT00347009|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043338|NCT01245959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043339|NCT05244070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731112|NCT01470391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731113|NCT05686512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors conducting 12 weeks-assessments will be blind to treatment allocation. The outcome measure (PARS) is identical for both groups, ensuring that the assessors remain blind. At the 12 week-assessment, participants will be reminded to not reveal their arm allocation. To measure blinding integrity, all assessors will record whether the participating families inadvertently reveal their group allocation, and subsequently guess each participant's treatment allocation.|Single-blind parallel-group pilot randomised controlled feasibility trial|f|f|f|t
33731114|NCT01391728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731115|NCT04551846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients and the legal guardians will be blinded|Monocentric randomized controlled trial with 2 groups: interventional (oligomeric formula) and control (polymeric)|t|f|f|f
33731116|NCT04605757|||COHORT||OTHER|||||||
33731117|NCT05325463|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731118|NCT05256433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-Blinded||t|f|f|f
33731119|NCT04509544|||CASE_ONLY||CROSS_SECTIONAL|||||||
33731120|NCT02965443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811658|NCT05485025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811659|NCT04955054|||CASE_CONTROL||PROSPECTIVE|||||||
33811660|NCT04396938|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33811661|NCT01702259|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33811662|NCT00546156|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043340|NCT04563910|||CASE_ONLY||CROSS_SECTIONAL|||||||
34043341|NCT06578533|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase III multicenter, randomized, open-label, parallel-group non-inferiority trial||||
34043342|NCT02529046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043343|NCT05904834|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigators on charge of the test do not know the group they are measuring|Single intervention group and single control group|f|f|t|f
34043344|NCT00013338|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34043345|NCT06176404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34043346|NCT00183859||PARALLEL||TREATMENT||NONE||||||
34043347|NCT06022510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043348|NCT05618678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessor will not be aware of the randomization arm of the NH they are collecting data in.|Nursing homes are randomized to one of two groups: 1.) DIGNITY Intervention (Protocol Manual, Baseline Education, ECHO Coaching) or 2.) Control Arm - (Infection Control Training - CDC Guidelines, Baseline Education, ECHO Coaching)|f|f|f|t
34043349|NCT01208974|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1 dose-escalation/de-escalation.||||
34043350|NCT06486558|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043351|NCT02739789|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||within-subjects crossover design|t|f|t|f
34043352|NCT01448772|RANDOMIZED|CROSSOVER||||NONE||||||
34043353|NCT00259948|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34043354|NCT05399940|||COHORT||OTHER|||||||
34043355|NCT02713932|||COHORT||PROSPECTIVE|||||||
34043356|NCT05059808|||OTHER||CROSS_SECTIONAL|||||||
34043357|NCT06576024|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This study aims to evaluate the immunogenicity and safety of hepatitis A vaccine in HIV-infected people, thus the vaccine is considered to be a kind of intervention. We divided HIV-infected people into different groups according to their HIV virus loads to make comparison||||
34043358|NCT00282113|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34043359|NCT05458999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, single-center, prospective, open-label study.||||
34043360|NCT02074423|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34043361|NCT03635515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which study arm/intervention group they will be assigned to.|Patients will be asked to indicate their peak pain level in the twenty-four hours prior to the appointment using a visual analog scale (VAS). The VAS scale will consist of a 100mm line where 0 equals 'no pain' and 100 equals the 'worst pain imaginable'. Patients will be divided into one of two treatment groups, either standard cleaning protocol or Gentlewave irrigation. Patient demographics, anesthesia, cleaning and shaping instruments, irrigation technique, and obturation method and material will be recorded, along with the number of appointments, extent of treatment rendered, and the occurrence of over-instrumentation or overfill of obturation material. Once obturation is completed, patients will be given the same VAS scale to take home and asked to record their level of pain at 6, 24, 72, and 168 hours post-treatment.|t|f|f|f
34043362|NCT04751955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043363|NCT00406367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043364|NCT00365157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043365|NCT06110494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043366|NCT03393325|||COHORT||PROSPECTIVE|||||||
34043367|NCT01203514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34043368|NCT00775229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117841|NCT02569853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117842|NCT03892317|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34117843|NCT02004301|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117844|NCT00220506|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811663|NCT02680145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811664|NCT02798016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811665|NCT01045057|NA|SINGLE_GROUP||TREATMENT||NONE||Provox Vega Puncture Set||||
34043369|NCT00740792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043370|NCT05829629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043371|NCT03525275|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 x 5 Mixed model ANOVA||||
34043372|NCT05573932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized into the two separate groups using a random number generator and allocation will be concealed in opaque envelopes prior to data collection.||f|f|f|t
34043373|NCT04299646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized 2:1 phase II trial|t|f|f|f
34043374|NCT03317314|||CASE_ONLY||PROSPECTIVE|||||||
34043375|NCT05917457|RANDOMIZED|PARALLEL||TREATMENT||NONE|they knew which groups they were in and the researcher knew where they were too.|"Criteria for Inclusion of Volunteers in the Study and Control Group in the Research:~to be in the age of 7-14, Except for visual impairment (neurological and systemic diseases, hearing impairment, etc. ) not having an additional disease October, Having been diagnosed with low vision, To be able to establish cooperation, Volunteering to participate in the study The 25 individuals who met the inclusion criteria were divided into 2 groups, including 13 in the study group and 12 in the control group"||||
34043376|NCT05781711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|t|f
34043377|NCT01136902|||CASE_ONLY||PROSPECTIVE|||||||
34043378|NCT05455814|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE||This is a prospective cohort study with 40 intervention and 40 matched controls to be followed up for 6 months. Both cohorts will be recruited from meditation-Naïve healthy individuals. The intervention group will learn a 21 minute meditation to practice daily. Various outcomes related to brain health and brain age will be collected over a period of 6 months.|f|f|f|t
34043379|NCT02593279|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043380|NCT03005496|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043381|NCT02967315|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043382|NCT06210035|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043383|NCT02748642|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
34043384|NCT02554617|||CASE_ONLY||CROSS_SECTIONAL|||||||
34043385|NCT01746186|||COHORT||PROSPECTIVE|||||||
34043386|NCT06575491|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34043387|NCT06407115|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility phase to prepare for randomized controlled trial.||||
34043388|NCT01994941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043389|NCT03349073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043390|NCT00026117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34043391|NCT01424410|||COHORT||PROSPECTIVE|||||||
34043392|NCT00224068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043393|NCT04099992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A third-party investigator outside of the research team will label both real and sham devices with a coded number so that both participants and investigators can remain double-masked during the clinical trial.|"Protocol 1 (R61): 50 CKD participants will be randomized to MBSR (N=25) versus an active control intervention (health enhancement program, HEP; N=25).~Protocol 2 (R33): 75 CKD participants will be randomized to MBSR+tVNS (n=25), MBSR+sham-tVNS (n=25), HEP+tVNS (n=25), and HEP+sham-tVNS (n=25)."|t|f|t|t
34043394|NCT03998384|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two eyes of one patient with RP will be divided into two groups. One eye with more serious retinal atrophy will receive retrobulbar injection of autoserum, and the other eye will receive retrobulbar injection of saline solution.|t|t|f|t
34043395|NCT05436665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study, the treating surgeons will be unblinded to the graft type. The outcomes will be assess by a blinded assessor and the quality of life questionnaires will be completed by the patient themselves, with assistance from the blinded assessor as needed.|"After the patient has been screened and deemed eligible for participation, and the informed consent of the patient has been obtained, the patients will be included in the study. Once the inclusion data is entered by a member of the study personnel into the trial software, allocation of the patient to a treatment arm will take place using minimisation.~The allocation will be performed with an equal 1:1 allocation to DSAEK or DMEK with minimisation using the following stratification of participant factors:~* Surgical Indication (i.e., Fuchs' endothelial dystrophy and non Fuch's endothelial dystrophy);~* Surgical site;~* Preoperative visual acuity (Patients with 0.6 LogMAR BCVA or lower (i.e., better vision) and patients with LogMAR BCVA higher than 0.6 LogMAR (i.e., worse vision).~The minimisation will be performed by the study team using the online allocation software QMinim."|f|f|f|t
34043396|NCT03973125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043397|NCT06577506|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34043398|NCT03788993|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-centre, unblinded, two-arm, parallel-group, pragmatic effectiveness RCT of differences in the mean duration of acute psychiatric hospitalization in days for individuals exposed to experimental lighting compared with normal lighting conditions.||||
33811666|NCT05005351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811667|NCT02877524|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33811668|NCT00540566|||CASE_ONLY||PROSPECTIVE|||||||
33811669|NCT05731206|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|double-blind|Crossover assignment and an observational, single-arm, follow-up.|t|t|t|t
33811670|NCT02789488|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811671|NCT01564472|||CASE_ONLY||RETROSPECTIVE|||||||
33811672|NCT06461585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811673|NCT03630549|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel cluster-randomized||||
33811674|NCT00488267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811675|NCT05380115|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811676|NCT01782209|||CASE_ONLY||PROSPECTIVE|||||||
33811677|NCT01777932|||COHORT||PROSPECTIVE|||||||
33811678|NCT03234010|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33811679|NCT03608436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33811680|NCT02538094|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33811681|NCT03600207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043399|NCT00957320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811682|NCT04150809|||CASE_ONLY||PROSPECTIVE|||||||
33811683|NCT06231680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811684|NCT00135018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811685|NCT05570227|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33811686|NCT00054197|RANDOMIZED|||TREATMENT||NONE||||||
33811687|NCT01854866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811688|NCT00837291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811689|NCT01697826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811690|NCT00163501|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33811691|NCT00195819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811692|NCT02206867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811693|NCT04027452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33811694|NCT01494766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811695|NCT00001615||||TREATMENT||||||||
33811696|NCT05631236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Bright light therapy devices include two sets: intervention that emit blue light and the control that emits light at a non-therapeutic intensity.|Randomized placebo control trial.|t|f|f|f
34043400|NCT06577974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811697|NCT01368484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811698|NCT00982527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34043401|NCT01689805|||CASE_CONTROL||PROSPECTIVE|||||||
34043402|NCT02684097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043403|NCT06014190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043404|NCT02243722|||COHORT||CROSS_SECTIONAL|||||||
34043405|NCT05608915|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive all interventions in a crossover fashion, on the same day. All participants will first experience the conventional cue intervention. The order of the remaining interventions will be randomized. All conditions will be performed after participants hold (do not take) their morning dopaminergic medications.||||
34043406|NCT02659410|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043407|NCT00409136|||CASE_CONTROL||PROSPECTIVE|||||||
34043408|NCT00407238|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34043409|NCT04325568|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE|Masking will not be used. Again, the 27 participants will be assigned to the clinician manual and the next 27 participants will be assigned to Autotutor. The investigators are doing this in order to prevent contamination.|This is a pre-post design (N=54) in which the first 27 participants will take part in the clinician manual intervention and the next 27 participants will be assigned to the AutoTutor. Participants will only complete either the clinical manual intervention or the AutoTutor intervention, but not both. These groups will not be compared to one another. Each participant will be assessed on all outcomes before and after the intervention and will only take part in either the clinician manual or Autotutor. Since each participant is only getting one intervention and the clinician manual and AutoTutor are not being compared to each other the most appropriate study design is single group (and cannot be considered factorial, crossover, parallel, or sequential).||||
34043410|NCT03633123|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Subject will be blinded to the treatment arm assignment. Physicians which were not part of the team in the surgery room, or from the hospital's infectious diseases dept. will remain blinded to the study arm, and will be those assessing the incisional wound for the study primary endpoint at each follow-up visit post the index surgery.~On top, for each suspicion of infection, an external, independent and blinded adjudication committee will be the one making the final decision whether an infection occured or not."|"Males and females, \>18 years old, undergoing scheduled abdominal colon surgery involving resection and anastomosis or a stoma, who meet the inclusion criteria and none of the exclusion criteria and provide signed informed consent will be enrolled in the study.~Subjects will be randomized to either the investigational arm (SOC + D-PLEX) or to the control arm (SOC only) in a 1:1 ratio.~Subjects will be blinded to the study arm."|t|f|f|f
34043411|NCT04820465|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34043412|NCT06282016|||CASE_CONTROL||RETROSPECTIVE|||||||
34043413|NCT04228679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043414|NCT02810041|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34043415|NCT01771562|||COHORT||PROSPECTIVE|||||||
34043416|NCT03595514|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will not be allowed to see the ultrasound screen. Outcome assessors will not be present during the performance of the block.|Randomized|t|f|f|t
34043417|NCT04694599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34043418|NCT05312463|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043419|NCT00606385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043420|NCT05402189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Randomization will be performed using a computer-generated random number table in opaque sealed envelopes with 1:1 allocation ratio by an anesthesiologist not directly involved in the trial or patient care.~- Patients will be subsequently followed up by a researcher who will be unaware of the group allocation. Thus effectively, the patient and the outcome assessor will be blinded to the group allocation."|prospective interventional randomized study|t|t|t|f
34043421|NCT02912975|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043422|NCT05792033|||COHORT||PROSPECTIVE|||||||
34043423|NCT03585933|||COHORT||PROSPECTIVE|||||||
34043424|NCT00333983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043425|NCT00763425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043426|NCT04007120|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34043427|NCT05936060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043428|NCT00779935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043429|NCT02861222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043430|NCT03385993|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34043431|NCT00478777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043432|NCT02165917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043433|NCT06044415|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34043434|NCT01541761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811699|NCT00838409|||||CROSS_SECTIONAL|||||||
33811700|NCT01890954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811701|NCT00234676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811702|NCT01483885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811703|NCT05386537|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34117845|NCT05109793|||OTHER||PROSPECTIVE|||||||
34117846|NCT04194424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117847|NCT05000710|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34117848|NCT00360945|NON_RANDOMIZED|||TREATMENT||NONE||||||
34117849|NCT01750853|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34117850|NCT06004232|RANDOMIZED|PARALLEL||PREVENTION||NONE||PRY-D intervention vs treatment as usual (TAU)||||
34117851|NCT02804620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117852|NCT05423184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Knowledge that which exercises are structured for research will keep from participants.|Prospective Randomize Controlled Study|t|f|f|f
34117853|NCT02070653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117854|NCT00904371|||COHORT||PROSPECTIVE|||||||
34117855|NCT05188989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117856|NCT01489280|||COHORT||RETROSPECTIVE|||||||
34117857|NCT00140140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117858|NCT00451529|||COHORT||PROSPECTIVE|||||||
34117859|NCT05238116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34117860|NCT04349683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117861|NCT00307957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34117862|NCT06078566|NA|SINGLE_GROUP||TREATMENT||NONE|eyes are blacked out in photos|||||
34117863|NCT02196532|||CASE_CONTROL||RETROSPECTIVE|||||||
34117864|NCT05732038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117865|NCT06449651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117866|NCT01706484|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34117867|NCT05786287|||COHORT||RETROSPECTIVE|||||||
34117868|NCT04951427|||COHORT||PROSPECTIVE|||||||
34117869|NCT05947006|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, controlled, non-randomized single-center pilot study.||||
34117870|NCT03419494|||CASE_CONTROL||PROSPECTIVE|||||||
34117871|NCT00382226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34117872|NCT05228418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117873|NCT04250701|||CASE_ONLY||CROSS_SECTIONAL|||||||
34117874|NCT00104702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117875|NCT06469801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117876|NCT06487520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34117877|NCT02862574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117878|NCT04052009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors are blinded since the testing assessor is not conducting the randomization. Patients and the physiotherapists conducting the training are not blinded. This is not due to the training location.|CT - Group: The conventional training EET: end-effector-based training CETcomb: combined training with CT and EET|f|f|f|t
34117879|NCT02566863|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34117880|NCT04084379|||COHORT||PROSPECTIVE|||||||
34117881|NCT06282341|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Prospective study on healthy volunteers, comparing the neurophysiological, physiological and biomechanical effects at the end of a marathon compared with an equivalent effort trail in the open air, or simulated on a treadmill, in runners specialising in each of the 2 disciplines||||
34117882|NCT02141321|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34117883|NCT04089410|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34117884|NCT00276419|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34117885|NCT01510093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117886|NCT06516406|||COHORT||CROSS_SECTIONAL|||||||
33811704|NCT01729767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811705|NCT03346590|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking|||||
33811706|NCT01459952|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811707|NCT02254902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811708|NCT06352307|||COHORT||OTHER|||||||
33811709|NCT01049490|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811710|NCT02180932|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33811711|NCT00515242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811712|NCT02099058|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33811713|NCT04943640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117887|NCT02411409|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117888|NCT03035747|||OTHER||PROSPECTIVE|||||||
34117889|NCT03868358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117890|NCT05239078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117891|NCT04678401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117892|NCT03545048|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34117893|NCT04863430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117894|NCT03331380|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34117895|NCT04848506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117896|NCT00871026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34117897|NCT05753176|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and the research coordinator cannot be blinded to group condition though the research assistants sending out 1, 2, and 3 month postpartum follow questionnaires and data analysts will not be aware of group status.|A parallel-group Ontario-wide RCT with experimental (workshop) and TAU (control) groups will address our objectives. Participants will be randomly assigned in a 1:1 ratio to the treatment or control group.|f|f|f|t
34117898|NCT05835843|||COHORT||PROSPECTIVE|||||||
34117899|NCT01480102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34117900|NCT01321814|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34117901|NCT06717386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34117902|NCT04608708|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34117903|NCT00005835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117904|NCT02007941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811714|NCT06510972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811715|NCT04482556|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811716|NCT01924585|||COHORT||PROSPECTIVE|||||||
33811717|NCT01331174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811718|NCT00396487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117905|NCT05317130|||COHORT||PROSPECTIVE|||||||
33811719|NCT03936699|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, adaptive parallel arm study.||||
34117906|NCT00442702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117907|NCT02457338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117908|NCT00818194|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34117909|NCT06712342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34117910|NCT04971577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117911|NCT02932410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117912|NCT05173597|||COHORT||PROSPECTIVE|||||||
34117913|NCT01746290|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34117914|NCT05776758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117915|NCT05471375|||COHORT||CROSS_SECTIONAL|||||||
34117916|NCT03007147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117917|NCT03548129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117918|NCT05262569|||CASE_CONTROL||RETROSPECTIVE|||||||
34117919|NCT00004103||||TREATMENT||||||||
34117920|NCT06590038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117921|NCT01182350|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is not a randomized trial rather participants are classified and therapy is directed based on molecular profile obtained from surgical biopsy.||||
34117922|NCT03478605|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II randomized trial||||
34117923|NCT06375681|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|"All researchers that have contact with participants will be unaware of the tested hypothesis of the study.~Participants will be unaware of the experimental conditions.~Researchers and participants will be unaware (blinded) to the game conditions assigned to the participant, except for researchers in charge of supervising the training part of the study who will be aware what training the participant is undergoing.~More information on how this was achieved will be registered after data collection is completed to preserve the scientific integrity of the study."|"Following Pre-testing, participants randomly assigned into the full study will be further randomly assigned to a total of 9 unique experimental conditions for the full 2x2x2+1 factorial design.~The full description of the study's 9 arms will be registered after data collection is completed to preserve the scientific integrity of the study."|t|f|f|t
34117924|NCT04662164|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34117925|NCT06324032|||CASE_ONLY||PROSPECTIVE|||||||
34117926|NCT06194799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117927|NCT00001204|||COHORT||PROSPECTIVE|||||||
34117928|NCT02903472|||COHORT||PROSPECTIVE|||||||
34117929|NCT03957382|||CASE_ONLY||PROSPECTIVE|||||||
34117930|NCT06446492|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34117931|NCT02947984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117932|NCT04464980|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Retention Phase: 3x2 for BUP; 1x2 for XR-NTX; Discontinuation Phase: 2x2 for SL-BUP; 1x2 for XR-BUP; 1x2 for XR-NTX||||
34117933|NCT05242289|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The model consists of a randomized controlled pilot in human patients using a cytokine adsorption device.~Lung transplant recipients are randomized to either the treatment group which undergoes cytokine adsorption using the medical device compared to the control group which has not received the cytokine adsorber."||||
34117934|NCT04826380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117935|NCT04650581|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149789|NCT06421272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental group (emotion recognition); control group (memory training)|f|f|t|t
33811720|NCT02514824|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811721|NCT00799331|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33811722|NCT05751733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811723|NCT01181115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811724|NCT06445140|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811725|NCT00559572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34043435|NCT02079350|||CASE_CONTROL||PROSPECTIVE|||||||
34043436|NCT04735627|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants will receive oral carbidopa and levodopa and the minimally invasive experimental device will measure levodopa levels in capillary blood, sweat, and/or interstitial fluid (separate experiments and consents), which will be compared to plasma levodopa levels measured using high-performance liquid chromotography.||||
34043437|NCT00439283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043438|NCT01406379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043439|NCT02739009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043440|NCT03001492|||COHORT||PROSPECTIVE|||||||
34043441|NCT02271646|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043442|NCT01367678|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34043443|NCT03569930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043444|NCT03864679|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043445|NCT03145454|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043446|NCT00447343|||CASE_CONTROL||PROSPECTIVE|||||||
34043447|NCT04862169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Allocation concealment will use sealed envelopes. Randomization will be done by concealing a piece of paper that has the phrase Intervention (SPARK) or Control (MODULE only) which will be placed inside a thick envelope. The outside of the envelopes will be labelled with the sequence number. After a participant has been enrolled into the study and consented, the next sequence numbered envelope on the stack will be opened to determine the study group that the subject will enter."|The intervention on this RCT is SPARK (Sinau PAlliative Rame-rame bareng eLOK) OR Strengthening PAlliative caRe in the community by enhancing nurses' Knowledge). This is an educational intervention using an online method with learning method system (LMS) eLOK hosted by Universitas Gadjah Mada Yogyakarta (Affiliation of authors' team). The intervention includes online discussions and access to eLOK for study materials (modules and videos).|t|f|t|f
33731121|NCT04425330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"* Participants will not know whether which group they are participating in, that is, treatment group or placebo with photobiomodulation.~* The evaluator and who will perform the exercises will not know which group the participant is participating in relation to photobiomodulation.~* A therapist who will not participate in assessments and physiotherapy sessions will perform the application of photobiomodulation.~* The microtubes with the saliva samples will be marked with numbers corresponding to each participant, so the evaluator will not know which group the sample corresponds to. A therapist will be responsible for the assessment and electromyography scales."||t|t|t|t
33731122|NCT05508529|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|randomized, placebo-controlled, with coded bottles for each group|treatment (5 dietary supplement blends) versus placebo (control)|t|t|t|t
33731123|NCT02064452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731124|NCT02016963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731125|NCT02994537|||COHORT||PROSPECTIVE|||||||
33731126|NCT00499603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731127|NCT05130411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731128|NCT04720365|RANDOMIZED|PARALLEL||OTHER||NONE||Experimental, prospective, controlled, open randomized, multicenter, national research.||||
33731129|NCT00876473|||COHORT||PROSPECTIVE|||||||
33731130|NCT03771833|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731131|NCT02281851|||CASE_CONTROL||OTHER|||||||
33731132|NCT00015275||||DIAGNOSTIC||NONE||||||
33731133|NCT06123546|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Months 1-4: recruitment/data collection of the control group Month 5: implementation of the intervention Month 5-8: recruitment/data collection of the intervention group||||
33731134|NCT05501106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Maternity hospital allocation will be concealed from the research assistant who will enroll and assign the hospitals. Because the quality improvement plans proposed by the NCHQMO are publicly released, it will not be possible to blind the hospital staff to the allocation. The investigators collecting information of invention implementation and acceptability will not be masked to the allocation, while the investigators assessing clinical practices and health outcomes and data statistical analysts will be blinded.|"Recruited hospitals will be randomly assigned in a 1:1 ratio to either the experimental or comparison arms.~All hospitals will receive general interventions, including: recommendation for implementing quality improvement programs to reduce vaginal delivery complications; trainings on obstetric quality management and clinical skills (3 times a year); and monitoring postpartum hemorrhage rate every month.~The hospitals in the experimental group will additionally implement integrated improvement strategies which include postpartum hemorrhage risk screening, hierarchical management and preparedness, rescue recording, and case review."|f|f|f|t
33731135|NCT04020302|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group: Clinical trials with a single arm||||
33731136|NCT02457325|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33731137|NCT05361681|NA|SINGLE_GROUP||OTHER||NONE|Assessor is blinded regarding patient and details of intervention (i.e. which charging column and which electric cars were used)|Exposure of patients with pacemaker or ICD to the electromagnetic fields of high power charging systems||||
33731138|NCT00003694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731139|NCT06037746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731140|NCT06265402|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33731141|NCT01478217|||CASE_CONTROL|||||||||
33731142|NCT00002417||||PREVENTION||||||||
33731143|NCT01971346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731144|NCT05283252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind|Parallel Assignment|t|f|f|t
33731145|NCT04135638|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33731146|NCT05052424|||COHORT||PROSPECTIVE|||||||
33731147|NCT05213858|||COHORT||PROSPECTIVE|||||||
33731148|NCT02285231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731149|NCT02733510|||COHORT||PROSPECTIVE|||||||
33731150|NCT05605262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33731151|NCT05146856|||CASE_CROSSOVER||PROSPECTIVE|||||||
33731152|NCT02561130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731153|NCT01753453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731154|NCT01691027|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible subjects trained on three computer-based training modules. SLO assessment of changes in fine manual task performance and in retinal functional geography was done before and after each training module.||||
33731155|NCT05091307|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731156|NCT04586803|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33731157|NCT01542515|||COHORT||PROSPECTIVE|||||||
33731158|NCT04025528|||CASE_CONTROL||PROSPECTIVE|||||||
33731159|NCT03651791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731160|NCT00990483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043448|NCT02020538|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Investigator-initiated, prospective, open-label, 4-period sequential study||||
34043449|NCT06578494|NON_RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||This is a before and after study, where the patients pre-implementation stage receive intravenous access via the traditional palpation technique and in the post-implementation stage receive ultrsound-guided intravenous cannulation.|f|f|t|f
33731161|NCT06290401|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Investigator and Outcomes assessors will not know the condition to which participants have been randomized.|Participants will be allocated to SCThrive or SCHealthED (uniform standard care) using a randomized block design for age group (13-17 years of age or 18-21 years of age) with a predefined block size of 4.|f|f|t|t
33731162|NCT06158802|||CASE_CONTROL||PROSPECTIVE|||||||
33731163|NCT03405142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731164|NCT00838201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731165|NCT04657536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731166|NCT02014675|||CASE_ONLY||PROSPECTIVE|||||||
33731167|NCT05305599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043450|NCT05056324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043451|NCT04067167|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment parallel-group, randomized-controlled study||||
34043452|NCT00764829|||CASE_ONLY||PROSPECTIVE|||||||
34043453|NCT00497523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731168|NCT02100007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731169|NCT01282593|NA|SINGLE_GROUP||OTHER||NONE||||||
33731170|NCT06255691|||COHORT||PROSPECTIVE|||||||
33731171|NCT02273648|||OTHER||PROSPECTIVE|||||||
33731172|NCT03454555|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two intervention arms for the duration of the study. The study will use real-time 1:1 ratio randomization to limit participant loss prior to treatment. Eligible patients will be randomized using a stratified, permuted-block design, as this constrained randomization approach ensures balance between treatment groups within each of the 3 clinical institutions (our only stratification factor) at the completion of each block. Consequently, throughout the trial, the intervention arms are expected to have approximately equal sample sizes both within an institution and across the study.||||
33731173|NCT05819034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731174|NCT06125821|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33731175|NCT03164499|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731176|NCT02151708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731177|NCT03577431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731178|NCT04630093|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811726|NCT03995394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33731179|NCT00265616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731180|NCT02269891|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33731181|NCT03379116|||CASE_ONLY||RETROSPECTIVE|||||||
33731182|NCT03196752|NA|SINGLE_GROUP||OTHER||NONE||||||
33731183|NCT04035421|||COHORT||CROSS_SECTIONAL|||||||
33731184|NCT03271879|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients will receive study drug: empagliflozin or placebo for an exposure period of up to 16 weeks - at the two treatment periods in a crossover design.|t|f|t|f
33731185|NCT05886569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731186|NCT01974193|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33731187|NCT03688321|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Labels with CMUH REC No. plus serial numbers on each bottle been completed by manufacturer and deliver to participants followed by random grouping order.|Study Group: take 2 probiotics capsules before sleep for 12 weeks after being confirmed as GBS positive on 28th gestation Placebo Group: take 2 placebo capsules before sleep for 12 weeks after being confirmed as GBS positive on 28th gestation|t|t|t|f
33731188|NCT04586179|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Care provider will not be aware of group assignment; participant will be aware of intervention assessment||f|t|f|f
33731189|NCT01849588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731190|NCT05018715|||COHORT||PROSPECTIVE|||||||
33731191|NCT00354172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731192|NCT01812928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33731193|NCT05565911|||COHORT||PROSPECTIVE|||||||
33731194|NCT00186667|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731195|NCT01457599|||COHORT||PROSPECTIVE|||||||
33731196|NCT04670991|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, category 2 study according to Jardé Law (minimal risks and constraints) of three prospective cohorts: Tumors located at the oropharynx, the oral cavity and the larynx-hypopharynx||||
33731197|NCT00205712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731198|NCT01524562|||COHORT||OTHER|||||||
33731199|NCT01573780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811727|NCT04288869|||COHORT||PROSPECTIVE|||||||
33811728|NCT03132636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811729|NCT05770492|||CASE_CONTROL||PROSPECTIVE|||||||
33811730|NCT05097105|||COHORT||PROSPECTIVE|||||||
33811731|NCT02799849|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33811732|NCT02757378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811733|NCT01535352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811734|NCT04154891|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The results of the different strategies will be interpreted blindly, each participating laboratory being in charge for a given investigation center, either of 1) the trio or 2) the 44GPS (part of the reference strategy) and, for the randomized sub-population of the overall population coming for a first genetic advice, simplex analyses. Fra-X and chromosomal microarray analysis corresponding to the reference strategy will follow the routine circuit, which is mainly independent from the WGS circuit.|Prospective multicenter diagnostic study comparing the percentage of Intellectual Deficiency (ID) causal diagnosis obtained using 2 main different strategies (Whole Genome Sequencing using a trio strategy (WGST), and reference strategy) applied blindly to consecutive patients with no obvious diagnosis. Each included patient will be his own control; he will benefit from the two main strategies compared, in parallel. The diagnostic yield of Whole Genome Sequencing using a simplex strategy (WGSs) will be also investigated in parallel to the two main strategies but only in a randomized subgroup of the overall population coming for a first genetic advice.|f|f|f|t
33811735|NCT04482413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811736|NCT02137785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811737|NCT04803734|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33811738|NCT04997408|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective randomized study||||
33811739|NCT01209156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811740|NCT03390166|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double blinded|non-inferiority double-blinded, randomized, controlled trial|t|f|t|f
33811741|NCT04251988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043454|NCT03668119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731200|NCT01440348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731201|NCT03732911|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731202|NCT03490370|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of concept study.||||
33811742|NCT03342261|||COHORT||RETROSPECTIVE|||||||
33811743|NCT01499979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811744|NCT03587415|||CASE_CONTROL||PROSPECTIVE|||||||
33811745|NCT02426931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043455|NCT00116974|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34043456|NCT00839800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043457|NCT01154114|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811746|NCT00486304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33811747|NCT06390449|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33811748|NCT04894942|||COHORT||PROSPECTIVE|||||||
33811749|NCT05440240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811750|NCT05556304|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The study design includes a consultation during pregnancy between 36 and 38 weeks of gestation and an assessment in the delivery room during childbirth|prospective, longitudinal and single-center study||||
33811751|NCT01061580|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811752|NCT03661398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043458|NCT04604392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|3-arm parallel trial|t|f|f|t
34043459|NCT04423744|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34043460|NCT02461069|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33811753|NCT02065609|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811754|NCT06441357|||CASE_ONLY||PROSPECTIVE|||||||
33811755|NCT05484336|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind|Crossover Assignment|t|f|t|f
34043461|NCT02131285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811756|NCT01868230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33811757|NCT00287404|||||PROSPECTIVE|||||||
33811758|NCT03605420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33811759|NCT06486233|||COHORT||PROSPECTIVE|||||||
33811760|NCT01918033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811761|NCT04090476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043462|NCT01437254|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The Nuclear Medicine physicians interpreting the whole body biodistribution pattern of CPERT and GPERT scans were blinded.||f|f|f|t
34043463|NCT01710202|||CASE_CONTROL|||||||||
34043464|NCT05598450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043465|NCT00497393|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34043466|NCT05362877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomised controlled clinical trial|f|t|f|f
34117936|NCT03941132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There will be a total of 60 patients enrolled in the study. The study participants will be enrolled at 2 centers (Vancouver and Toronto), and will be referred by adult or pediatric endocrinologists. This sample size estimation is based on results from week 52 C-peptide AUC values observed in the pilot UST1D study and the expected 1-year C-peptide decline in adult-onset T1D patients. Using a 2:1 Ustekinumab vs. placebo randomized assignment, a sample size of 60 yields 85% power to detect improvement in C-peptide function (alpha = 0.05) in the Ustekinumab group for an unstratified analysis at 12 months. Sixty-six participants (44 active: 22 placebo) will be recruited to allow for an approximate 10% loss to follow-up.|t|t|t|t
34117937|NCT03849209|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Randomization was performed using random sequences generated by a computer and then closed in consecutive numbered envelopes.||f|f|t|f
34117938|NCT03984825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117939|NCT02981628|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34117940|NCT00002366||||TREATMENT||||||||
34117941|NCT04191226|||COHORT||PROSPECTIVE|||||||
34117942|NCT00002529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117943|NCT03784248|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34117944|NCT02229617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117945|NCT01255280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117946|NCT04117633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The study included two equal groups. one group underwent laparoscopic mesh rectopexy and the other underwent suture rectopexy.|t|t|f|f
34117947|NCT01968928|||CASE_ONLY||CROSS_SECTIONAL|||||||
34117948|NCT06330701|NA|SINGLE_GROUP||OTHER||NONE||||||
34117949|NCT02152189|||CASE_ONLY||CROSS_SECTIONAL|||||||
34117950|NCT01589614|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34117951|NCT02286609|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34117952|NCT03627702|||COHORT||PROSPECTIVE|||||||
34117953|NCT00968409|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811762|NCT05237869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For patients enrolled in the control group, the participants will undergo calibration of the Delfi Personalized Tourniquet System to measure limb occlusion pressure and will wear the cuff during completion of the exercises with minimal inflation (approximately 5%), to hold the cuff in place during treatment. This will act as a sham.||t|f|f|t
33811763|NCT05991518|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33811764|NCT00310609|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811765|NCT02356198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811766|NCT04002349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811767|NCT06509594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811768|NCT03762278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33811769|NCT01850342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043467|NCT02937987|||COHORT||PROSPECTIVE|||||||
34043468|NCT06192862|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There will no masking|Patient will be randomized into either Text reminder (control) group or Chatbot outreach group||||
34043469|NCT01659606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043470|NCT05468905|||COHORT||PROSPECTIVE|||||||
34043471|NCT05847374|||COHORT||PROSPECTIVE|||||||
34043472|NCT01236274|||||RETROSPECTIVE|||||||
34043473|NCT03227081|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34043474|NCT04310670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043475|NCT05622838|||CASE_CONTROL||PROSPECTIVE|||||||
34043476|NCT05478161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117954|NCT01926860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34117955|NCT05290532|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The study participants will be randomized ( ww. randomizer.org) into an intervention group and a control group. the assessment staff will be blinded to the participant randomization assignment, as well as to the main study design ant to what changes we expect to occur in the study outcomes in either group.~It will not be possible to conceal the group assignment from the staff involved in the training of the intervention group."|This is a randomized clinical trial,patient who meet the inclusion criteria will be randomly assigned to the intervention or control group|f|f|t|f
33811770|NCT04511286|NA|SINGLE_GROUP||TREATMENT||NONE|Psychological intervention, patient-reported outcomes|Prospective single-group cohort study||||
33811771|NCT01475110|||CASE_ONLY||PROSPECTIVE|||||||
33811772|NCT01319344|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043477|NCT06468345|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33811773|NCT00105222||||TREATMENT||||||||
33811774|NCT06231667|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043478|NCT04815811|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043479|NCT04889443|||CASE_ONLY||PROSPECTIVE|||||||
34043480|NCT03738670|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33811775|NCT02562612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811776|NCT03049332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The same group of individuals will be measured pre and post intervention.||||
33811777|NCT01498614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811778|NCT04851782|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants either have Braun Infusomat Pump with ivEAD tubing or standard pump OR another pump with or without ivEAD tubing or standard tubing||||
33811779|NCT06360276|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33811780|NCT00788606|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811781|NCT00729794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811782|NCT02932124|||COHORT||PROSPECTIVE|||||||
33811783|NCT01567007|RANDOMIZED|PARALLEL||||NONE||||||
33811784|NCT01020097|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811785|NCT01110096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043481|NCT04787913|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|This will be a single-blinded study because we cannot mask participants to the fact that they have been randomized to a visualization e.g., about measles. However, participants will not necessarily know the purpose of the study arm to which they are assigned,and investigators will be blinded to study arm during data analysis (investigators are not aware of whether the next eligible participant will be receiving treatment or control intervention.)|"This study will be a multi-armed factorial randomized controlled trial. Each participant will be randomly allocated to focus on one of four possible vaccine-preventable diseases: measles, pertussis, flu (influenza), or a generic vaccine-preventable disease (hereby referred to as generic). All aspects of the study (visualization, questionnaire) will be focused on that one disease for that participant. The primary and secondary outcomes of the study which are risk perception, emotion, knowledge, trust in information provided, attitudes and a validated scale about vaccination (Betsch et al. 2018) will be assessed in an online questionnaire.~Because three online visualizations are available only in English whereas our study will be conducted in both English and French, we will use slightly different randomization patterns for English- and French-speaking participants."|f|f|t|f
34043482|NCT01883726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043483|NCT00644917|RANDOMIZED|SINGLE_GROUP||||QUADRUPLE|||t|t|t|t
34043484|NCT02423395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043485|NCT00297440|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043486|NCT06404970|RANDOMIZED|CROSSOVER||SCREENING||NONE||Hybrid type 2 implementation-effectiveness cluster-randomized adaptive trial||||
34043487|NCT01628198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043488|NCT03371862|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
34043489|NCT02569125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043490|NCT05258357|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients will opt to enroll in the study without knowing which arm they will be assigned, Ultrasound-assisted or landmark group.||t|f|f|f
34043491|NCT04988555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Bayesian Regression Model for Phase 1 dose escalation||||
34043492|NCT02976740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043493|NCT04228614|||COHORT||OTHER|||||||
34043494|NCT03647618|||COHORT||PROSPECTIVE|||||||
34043495|NCT02523508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34043496|NCT02260336|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34043497|NCT03718208|NA|SINGLE_GROUP||OTHER||NONE||||||
34043498|NCT00444756|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34043499|NCT02324504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043500|NCT02706431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043501|NCT04823481|||COHORT||RETROSPECTIVE|||||||
34043502|NCT01708382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043503|NCT04202120|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043504|NCT04213885|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Randomized at outset|Treatment of patients with disease|f|f|f|t
34043505|NCT03061695|||COHORT||PROSPECTIVE|||||||
34043506|NCT00445497|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34043507|NCT05994872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Surgical doctor team, patient, outcome assessor, data analyst and image reviewer are masked.||t|t|t|t
34043508|NCT06578689|||CASE_CONTROL||PROSPECTIVE|||||||
34043509|NCT06534619|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trail, having two groups. One group will receive Maitland joint mobilization along with rocabado exercises and the second will receive rocabado exercises only. Both groups will be recruited concurrently.||||
34043510|NCT04073004|NA|SINGLE_GROUP||TREATMENT||NONE||all participants will receive the same treatment. The investigators will compare their results to data reported by Rothbaum et al (2005) which includes 2 treatment groups and a control group.||||
34043511|NCT04047836|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment||||
34043512|NCT05163925|||CASE_ONLY||PROSPECTIVE|||||||
34043513|NCT00002875|RANDOMIZED|||TREATMENT||SINGLE||||||
34043514|NCT06578520|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized, open-label, crossover study, parallel, 2-sequence, 2-period, 2-treatment.||||
34043515|NCT04122313|||COHORT||PROSPECTIVE|||||||
34043516|NCT01597570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043517|NCT06575257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043518|NCT05319925|||OTHER||PROSPECTIVE|||||||
34043519|NCT01304511|||CASE_ONLY||PROSPECTIVE|||||||
34043520|NCT02667704|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043521|NCT05999071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34117956|NCT01082302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731203|NCT01483196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043522|NCT05268081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking description of intervention status, i.e., outcomes assessor will not know who received the intervention.|Pragmatic randomized controlled trial|f|f|f|t
33731204|NCT00360334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731205|NCT02082873|||COHORT||PROSPECTIVE|||||||
33731206|NCT04013191|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731207|NCT01587495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731208|NCT04216082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731209|NCT00038922||||TREATMENT||||||||
33731210|NCT02886052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731211|NCT04408846|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731212|NCT04385784|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The study is interventional, consisting of three arms with parallel monitoring. The first two arms perform an intervention based on physical exercise guided by physiotherapists, in order to improve their balance and postural control. These two arms are differentiated by the level of daily physical activity that their participants have (sedentary and active people). In addition to the guided exercise sessions, they are offered an exercise book to perform at home. The third arm of the study only performs the home-based program and is made up of sedentary people.|t|t|f|f
33731213|NCT02239250|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731214|NCT05355844|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731215|NCT04970758|||CASE_CONTROL||PROSPECTIVE|||||||
33731216|NCT05114304|||OTHER||CROSS_SECTIONAL|||||||
33731217|NCT01603875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731218|NCT02456324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731219|NCT02930850|NA|SINGLE_GROUP||OTHER||NONE||||||
33731220|NCT02812667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043523|NCT04044040|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731221|NCT01926795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731222|NCT00720941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731223|NCT01653522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731224|NCT01760083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731225|NCT05697042|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731226|NCT04573036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|The study consists of 2 parts: single dose escalation (Part 1) with four cohorts and food effect on HRS4800 PK (Part 2) with one cohort. All cohorts can enroll healthy male subjects|t|t|t|f
33731227|NCT03964298|||COHORT||CROSS_SECTIONAL|||||||
34043524|NCT02180529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731228|NCT00632697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731229|NCT02649881|||COHORT||PROSPECTIVE|||||||
33731230|NCT04495114|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33731231|NCT01218516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731232|NCT01139281|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731233|NCT00645333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731234|NCT03676361|NA|SINGLE_GROUP||OTHER||NONE||||||
33731235|NCT03826758|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic randomized clinical parallel trial with two arms||||
33731236|NCT03597516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US). The study is comprised of 4 study periods.|t|t|t|t
33731237|NCT05426837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized to receive either control or intervention condition and they will be blind to which condition they are receiving.|"Following the production of the refined/modified CSI, a RCT will be initiated to assess the efficacy of the CSI intervention relative to a Health Education Training (HET) control group.~Approximately 50 participants will be randomly assigned to one of two conditions (1) CSI or (2) HET Control. Consistent with the rationale of an Indicated clinical trial, the primary entry criteria will be age (\>65) as well as above average levels of loneliness (primary outcome). Participants will be assessed on a range of relevant outcome measures at pretreatment, post-treatment, and 1-month follow-ups. There are three interrelated study hypotheses (see Aim 2 above):~1. CSI will significantly reduce loneliness relative to control.~2. CSI will positively impact other outcomes such as quality of life during the follow-up period relative to control.~3. Intervention related changes in risk (PB/TB) will mediate the relationship between CSI and outcomes (loneliness) at follow-up."|t|f|f|f
33731238|NCT01971658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731239|NCT01633697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731240|NCT05090020|||COHORT||RETROSPECTIVE|||||||
33811786|NCT01862159|||COHORT||PROSPECTIVE|||||||
33811787|NCT06401590|||COHORT||PROSPECTIVE|||||||
34043525|NCT06096077|||COHORT||RETROSPECTIVE|||||||
34043526|NCT02719717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043527|NCT01056237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043528|NCT06111378|||CASE_CROSSOVER||PROSPECTIVE|||||||
34043529|NCT06044636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34043530|NCT00981812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811788|NCT00659373|RANDOMIZED|PARALLEL||||NONE||||||
33811789|NCT05188378|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33811790|NCT02291406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811791|NCT02673359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33811792|NCT03266419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers who evaluate postoperative pain will be blinded to the patient's allocation|This study is investigator-initiated, randomized, double blinded clinical trial.|t|f|f|t
33811793|NCT00803985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043531|NCT02325388|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34043532|NCT02220036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043533|NCT04167319|||COHORT||PROSPECTIVE|||||||
34043534|NCT03950830|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).||||
34117957|NCT00366457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117958|NCT04615819|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34117959|NCT00672997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117960|NCT01597817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117961|NCT01603654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34117962|NCT06102395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117963|NCT02916485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117964|NCT02205424|||COHORT||PROSPECTIVE|||||||
34117965|NCT00633126|NA|SINGLE_GROUP||OTHER||NONE||||||
34117966|NCT04242069|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34117967|NCT05213806|RANDOMIZED|PARALLEL||OTHER||NONE||The WHEAT trial is a pragmatic, randomized, controlled, unblinded, international, multicentre, parallel-group superiority trial comparing two clinical care pathways.||||
34117968|NCT04272164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34117969|NCT05361174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117970|NCT06716125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117971|NCT03780257|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34117972|NCT04456907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34117973|NCT06625242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117974|NCT05617326|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34117975|NCT02412670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117976|NCT03323164|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34117977|NCT02213250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117978|NCT02114086|||CASE_CONTROL||PROSPECTIVE|||||||
34117979|NCT05177250|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34117980|NCT03571490|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Double blind|Double blind placebo Controlled Trial|t|t|t|f
34117981|NCT04470024|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial will have a run-in safety phase for each of the 2 arms, starting with arm 1 using a standard 3+3 design. If arm 1 is deemed safe, the safety run-in for arm 2 will begin enrollment, using the same 3+3 design. If arm 2 is deemed safe, enrollment will continue to 15 in each arm (total n = 30). Patients enrolling after the safety run-in will be randomly assigned to either arm 1 or arm 2.||||
34117982|NCT01131052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117983|NCT00313560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34117984|NCT01889693|||CASE_CONTROL||PROSPECTIVE|||||||
34117985|NCT03763578|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34117986|NCT03198871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, care provider, outcomes assessor and investigator are all blinded to the treatment allocation||t|t|t|t
34117987|NCT01227057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34117988|NCT06187857|NA|SINGLE_GROUP||TREATMENT||NONE||A feasibility study of twenty-five older adults completing the same virtual procedures.||||
34117989|NCT05558384|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm feasibility pilot||||
34117990|NCT04118205|||CASE_ONLY||PROSPECTIVE|||||||
33731241|NCT05832645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33731242|NCT03611569|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Cohort|t|f|t|f
33731243|NCT00365326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731244|NCT01357629|||COHORT||RETROSPECTIVE|||||||
33731245|NCT05330650|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33731246|NCT00197327|RANDOMIZED|PARALLEL||||DOUBLE||||||
33731247|NCT02135575|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731248|NCT04619706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731249|NCT00637039|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731250|NCT06391463|||COHORT||RETROSPECTIVE|||||||
33731251|NCT04173143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be single blinded randomized control trail, participants will be unaware of treatment groups, they will be randomly allocated through sealed envelope method.|Both experimental and control groups will be treated simultaneously with different modes of endurance training|t|f|f|f
33731252|NCT02480556|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731253|NCT00165971|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33731254|NCT01838005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33731255|NCT00997503|||COHORT||PROSPECTIVE|||||||
33731256|NCT00003075|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33731257|NCT04338464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731258|NCT00446719|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811794|NCT06003244|RANDOMIZED|CROSSOVER||OTHER||NONE||Each participant works as its own perfect control||||
33811795|NCT04781868|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811796|NCT00445757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811797|NCT06208605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811798|NCT00926094|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33811799|NCT03110809|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33811800|NCT01342497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811801|NCT01567150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34117991|NCT06174675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34117992|NCT04565457|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
34117993|NCT05481736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34117994|NCT06361537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34117995|NCT06243029|||OTHER||PROSPECTIVE|||||||
34117996|NCT01803633|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34117997|NCT06216574|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Local NCORP site staff and study investigators will be blinded to the treatment assignment|Factorial trial using the multiphase optimization strategy (MOST) framework, in which participants will be randomized to one of 16 conditions (2\^4) to receive access to a combination of one to four SHINE components.|f|f|t|f
34117998|NCT00414375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149790|NCT05505526|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149791|NCT06265623|||COHORT||PROSPECTIVE|||||||
34149792|NCT00007020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149793|NCT00261508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149794|NCT00885781|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811802|NCT00264888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811803|NCT04003792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811804|NCT01995981|||CASE_ONLY||PROSPECTIVE|||||||
33811805|NCT05837806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811806|NCT03125148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811807|NCT01572805|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811808|NCT05253092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811809|NCT03044652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811810|NCT03000725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811811|NCT06099444|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Assessors who do not know subject group assignments will perform the assessments.||f|f|f|t
33811812|NCT00418119|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811813|NCT05205213|||COHORT||RETROSPECTIVE|||||||
33811814|NCT00296790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811815|NCT04389788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Both patients and the outcome assessors were blinded to the type of treatment which was done in each eye|Patients with periorbital hyperpigmentation will be treated using Carboxy theraby method at right side of face followed by microneedling using dermapen will be at left side of face.|t|f|f|t
33811816|NCT04449094|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33811817|NCT02239614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043535|NCT03870269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043536|NCT02525120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043537|NCT04521179|NA|SEQUENTIAL||TREATMENT||NONE||||||
34043538|NCT02608216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043539|NCT05715905|||CASE_CROSSOVER||PROSPECTIVE|||||||
34043540|NCT01226784|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043541|NCT03248999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043542|NCT05970510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043543|NCT03358069|||COHORT||PROSPECTIVE|||||||
34043544|NCT02211209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043545|NCT06409754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34043546|NCT03146949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Primary outcome assessor is masked. The primary outcome involves the analysis of blood concentrations of isoflurane, and the laboratory will not be given information on allocation.||t|f|f|t
34043547|NCT00389311|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34043548|NCT05912647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043549|NCT02275819|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized case control study with two groups. One group received exercise and the controls did not.||||
34043550|NCT03850470|||COHORT||PROSPECTIVE|||||||
34043551|NCT06188871|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043552|NCT06329856|||OTHER||RETROSPECTIVE|||||||
34043553|NCT04059614|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043554|NCT04699318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043555|NCT05931042|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34043556|NCT06576349|NA|SINGLE_GROUP||PREVENTION||NONE||single-arm, multiple-methods, pilot and feasibility study||||
34043557|NCT04758468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043558|NCT01935726|||OTHER||PROSPECTIVE|||||||
34043559|NCT05770141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043560|NCT05139212|||COHORT||PROSPECTIVE|||||||
34043561|NCT02741726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043562|NCT05353257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043563|NCT06154824|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Participant will be blinded about application of pruritogens.|The participants will randomly receive 3 consecutive applications of cowhage and histamine.|t|f|f|f
34043564|NCT06577038|||COHORT||PROSPECTIVE|||||||
34043565|NCT05369338|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The subjects are blinded to the irradiation side by audiovisual masking (swimming goggles with blackened lenses, hearing protection). The subjects do not have access to the randomisation list and are not in the same room during the irradiation. This means that they are also blinded to the irradiation side.|Prospective, double-blind, randomised, sham-controlled|t|f|t|t
34043566|NCT03669926|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043567|NCT01434160|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043568|NCT05349656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043569|NCT05727839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043570|NCT01174706|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34043571|NCT02649842|NA|SINGLE_GROUP||OTHER||NONE||||||
34043572|NCT04234490|||COHORT||PROSPECTIVE|||||||
34043573|NCT06577064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||andomized controlled trial.|f|t|t|f
34043574|NCT00984893|||COHORT||PROSPECTIVE|||||||
34043575|NCT01156623|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34043576|NCT01779128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043577|NCT00436189|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043578|NCT06309160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent observer evaluating goal attainment outcomes|Pre-post; randomized control|f|f|f|t
34043579|NCT01735825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|iopromide coated paclitaxel-eluting balloon catheter|t|f|f|t
34043580|NCT01809301|RANDOMIZED|CROSSOVER||||NONE||||||
34043581|NCT04452214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043582|NCT02904460|||COHORT||RETROSPECTIVE|||||||
34043583|NCT00220610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34043584|NCT03121846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043585|NCT00241709|||FAMILY_BASED||RETROSPECTIVE|||||||
34043586|NCT00516230|||DEFINED_POPULATION||PROSPECTIVE|||||||
34043587|NCT03236961|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|||||
34043588|NCT00123760|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043589|NCT04689191|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043590|NCT00789698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811818|NCT03315338|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||The 5 study parts may not be conducted entirely sequentially provided that this is justified by PK and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from at least 2 SAD levels using the same formulation.|t|t|t|f
33811819|NCT01995292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33811820|NCT01411657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811821|NCT01967394|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
33811822|NCT00515892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811823|NCT02630186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811824|NCT05421572|||OTHER||CROSS_SECTIONAL|||||||
33811825|NCT00590759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811826|NCT02817386|||CASE_ONLY||PROSPECTIVE|||||||
33811827|NCT03507179|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33811828|NCT02196610|||CASE_CONTROL||PROSPECTIVE|||||||
33811829|NCT04463004|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33811830|NCT01763307|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33811831|NCT01676298|||||PROSPECTIVE|||||||
33811832|NCT05396885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811833|NCT04842006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811834|NCT00971555|||COHORT||PROSPECTIVE|||||||
33811835|NCT00254241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33811836|NCT05749120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The care provider knows the surgical intervention and the randomized participant doesn´t know the recipient vessel performed|Parallel group trial design with allocation ratio of 1:1 and permuted block randomization|t|f|f|f
33811837|NCT04949113|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label two-arm randomized phase 3 trial||||
33811838|NCT02944981|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811839|NCT01858688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluation of accuracy of the MRI relative to biopsy||||
33811840|NCT06306937|||CASE_CONTROL||PROSPECTIVE|||||||
33811841|NCT03137849|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|All participants will be told they are attending to a yoga protocol. All outcomes assessments will be taken by blind investigators to the interventions.||t|f|f|t
33811842|NCT04226118|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33811843|NCT04738149|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811844|NCT05020067|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811845|NCT01137682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811846|NCT05146635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811847|NCT05729386|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label, randomized, fed, single-dose, 2-group, 2-period, crossover design||||
33811848|NCT06149299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811849|NCT00641537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811850|NCT03977805|NA|SINGLE_GROUP||OTHER||NONE||||||
33811851|NCT04265235|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm Exercise Intervention study||||
33811852|NCT04704856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811853|NCT05862402|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective study compare historical controlled study||||
33811854|NCT00663780|||CASE_ONLY||PROSPECTIVE|||||||
34117999|NCT05401838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Co-I Gunn (statistician) will be blinded to intervention condition during primary data analyses; the dataset will be cleaned by other project staff and intervention condition will be referred to only as intervention A or B.|Investigators will conduct parallel 2-arm randomized controlled trial of G-BCBT compared to a DBT skills group. G-BCBT is a new adaptation of the existing BCBT protocol administered in a group format. Because DBT's efficacy in a group format is already supported and investigators anticipate G-BCBT to be at least as equally effective, investigators propose a 2-arm non-inferiority design.|f|f|f|t
34118000|NCT05024552|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118001|NCT06314009|||COHORT||PROSPECTIVE|||||||
34118002|NCT02877017|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||pre-post intervention study||||
34118003|NCT00512070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118004|NCT06718556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118005|NCT06586281|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34118006|NCT05318508|||CASE_ONLY||PROSPECTIVE|||||||
34118007|NCT02161536|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Bowel cleansing level was evaluated by using the Boston Bowel Preparation Score (BBPS) at baseline and after the use of the Motus Cleansing System.||||
34118008|NCT02479191|||COHORT||PROSPECTIVE|||||||
34118009|NCT02493764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118010|NCT05655767|||COHORT||PROSPECTIVE|||||||
34118011|NCT05179876|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, open-label, extension study, with a platform-study design for long-term safety follow-up of participants using study intervention as in their respective pulmonary hypertension (PH) parent study (that is, pulmonary arterial hypertension \[PAH\] or chronic thromboembolic pulmonary hypertension \[CTEPH\]). Participants who have completed a parent study, that benefit from their study intervention maintenance and have no adequate alternative local treatment option (access to the study intervention or an equivalent approved therapy) will be enrolled in this study.||||
34118012|NCT04734457|||COHORT||RETROSPECTIVE|||||||
34118013|NCT02167321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118014|NCT06648993|||OTHER||CROSS_SECTIONAL|||||||
34118015|NCT00677794|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34118016|NCT05816954|||COHORT||PROSPECTIVE|||||||
34118017|NCT02407964|||||RETROSPECTIVE|||||||
34118018|NCT06712017|||COHORT||RETROSPECTIVE|||||||
34118019|NCT01332981|||COHORT||RETROSPECTIVE|||||||
34118020|NCT03139448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118021|NCT06186609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118022|NCT05980130|NA|SINGLE_GROUP||PREVENTION||NONE|This is a Single subject design study. Thus, as all participants receive the intervention, there is no masking possible.|Single subject design||||
34118023|NCT06561347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118024|NCT02911727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33811855|NCT01581099|||CASE_CONTROL||PROSPECTIVE|||||||
33811856|NCT05888844|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of 2 parts. In Part 1, participants with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC will be randomized 1:1:1 to INCB099280 Dose 1, Dose 2, or Dose 3. In Part 2, one dose level identified from Part 1 will be expanded to enroll additional participants with metastatic cSCC and locally advanced cSCC.||||
34118025|NCT06639438|||COHORT||PROSPECTIVE|||||||
34118026|NCT06018987|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34118027|NCT00652548|||OTHER||PROSPECTIVE|||||||
34118028|NCT00639457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118029|NCT05796752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118030|NCT06073678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be masked by using a sham laser. Outcomes assessor will not be able to identify the experimental groups||t|f|f|t
34118031|NCT05020574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118032|NCT05109741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118033|NCT00982384|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34118034|NCT04156139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118035|NCT01603017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118036|NCT05881798|||COHORT||PROSPECTIVE|||||||
34118037|NCT05558111|||COHORT||CROSS_SECTIONAL|||||||
34118038|NCT01306695|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118039|NCT06406933|||COHORT||PROSPECTIVE|||||||
34118040|NCT02217969|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34118041|NCT04410861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34118042|NCT04196530|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118043|NCT03839914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a single blinded trial as patients will not know their treatment allocation until the termination of study. Operating surgeons cannot be blinded to allocation. However, all clinical and radiological outcomes will be evaluated by an independent researcher who is blinded to the allocation. This researcher will be blinded to the study treatment throughout the study period.|Single-blinded open-label randomized controlled trial|f|f|t|t
34118044|NCT05962021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were divided into the 19del and L858R groups according to their EGFR mutation status.||||
34118045|NCT04983043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118046|NCT02351089|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118047|NCT00271544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118048|NCT03005340|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118049|NCT00716820|||CASE_ONLY||PROSPECTIVE|||||||
34118050|NCT05010590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118051|NCT03655067|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized at the baseline visit to the CATCH-IT Intervention or Control group||||
34118052|NCT04562415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34149082|NCT03139799|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"This study will include outcome assessor blinding as recommended in a publication on methodological quality criteria for cognitive rehabilitation research and computer game training in older adults (Bleakley et al., 2015; Cicerone, Azulay, \& Trott, 2009).~This will ensure that the person conducting the assessment of outcome measures will be unaware of the participant's treatment condition. For this purpose, a central randomization procedure will be used where a designated staff member not involved in the study will conduct and securely maintain the randomization, contact and allocate participants and use central methods (e.g. phone or secure computer) after the patient is enrolled. This way the treatment assignments are not revealed to the assessors when conducting the outcome assessments. The assessors will also be excluded from any activity pertaining to the intervention activities (e.g. instructing participants, distributing the tablet-computers)."|This study uses a 16-week, assessor blinded, randomized crossover design with two phases of treatment and three waves of measurement. Participants are randomly allocated to either the experimental (group T) or control intervention (group C). Group T will first receive the experimental and then the control intervention (T-C) while group C is given the opposite order of intervention (C-T). In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention) while group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task) while the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.|f|f|f|t
34149083|NCT02759315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149084|NCT03130452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149085|NCT03105648|||CASE_CONTROL||RETROSPECTIVE|||||||
34149086|NCT04191785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149087|NCT02048410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149088|NCT02191605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149089|NCT02599623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149090|NCT02642965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149091|NCT00185601|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34149092|NCT01325714|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34149093|NCT01407796|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149094|NCT05118802|||CASE_ONLY||CROSS_SECTIONAL|||||||
33811857|NCT00668057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811858|NCT04669366|||COHORT||RETROSPECTIVE|||||||
33811859|NCT02095145|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33811860|NCT00110032|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33811861|NCT04775732|RANDOMIZED|PARALLEL||TREATMENT||NONE||pragmatic cluster trial||||
33811862|NCT05939505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will not know which group they are in. The person who analyzes the data obtained at the end of the study will not know the groups.|randomized-controlled,placebo|t|f|f|t
34149095|NCT00547040|||COHORT||PROSPECTIVE|||||||
34149096|NCT02515201|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149795|NCT03891914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149796|NCT05373693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34118053|NCT04951531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33811863|NCT05574309|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Case-control study from the clinical gerontology service and the PROOF cohort. Cases: patients who fell (= at least one fall in the last 12 months) mainly from the clinical from the clinical gerontology department.~Controls: patients/subjects who have not fallen, mainly from the PROOF cohort."||||
33811864|NCT05878106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33811865|NCT02471872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34118054|NCT01076010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118055|NCT05364450|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|An external statistician will create the randomization sequence. An unblinded research manager will maintain the randomization sequence and randomization assignment for each participant in password-protected databases not accessible by the study team. All study personnel, including the study's principal investigator (PI), biostatistician, data manager, research coordinator (RC), and research assistants (RAs), will be blind to the randomization sequence. The PI, research manager, interventionists, and intervention supervisors will be the only individuals privy to participants' randomization assignments. The study RC, RAs (including outcome assessors), and the study biostatistician and data manager will remain blind to participants' random assignments for the trial's duration to enhance rigor and reduce the risk of outcome expectancy and other biases. Participants will be blind to study hypotheses, yet will be aware of their assignment to a 6-session versus single-session intervention.||t|f|f|t
34118056|NCT00839969|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118057|NCT02210078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118058|NCT03454789|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Patients, the operating team, nurses, and observers involved in the quality assessment of blocks and the follow-up data collection were unaware of group allocation. The research coordinator after the BPB was not present in the operating theatre at the time of tourniquet inflation and the beginning of the surgery. The intra- and postoperative parameters, drug consumptions and VNR values were collected and matched retrospectively, the list of cases was provided in the form of a spreadsheet program by an observer-blinded assistant and was statistically evaluated by an independent analyst.|LB= 15 ml lidocaine 1% + 15 ml bupivacaine 0.5%; BS= 20 ml bupivacaine 0.5% + 10 ml normal saline; LS=20 ml lidocaine 1% + 10 ml normal saline; and BL=20 ml bupivacaine 0.5% + 10 ml lidocaine 1%.|t|f|t|t
34118059|NCT03190122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118060|NCT00967616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118061|NCT03537638|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34118062|NCT05085522|||CASE_ONLY||RETROSPECTIVE|||||||
34118063|NCT02916316|||COHORT||PROSPECTIVE|||||||
34118064|NCT00986882|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118065|NCT05805163|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34118066|NCT03669887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In the pilot study that preceded a similar postpartum intervention trial, in which the intervention included telephone counselling (Ferrara et al. 2011). The proportion of women from the control arm who reached the postpartum weight goal was 30%, with the absolute difference in percentage of women meeting the postpartum weight goals being 16% between the intervention and control arms. Assuming a larger between group difference of 20% based on our more intensive individual-level intervention, and a similar 30% of women in the control arm reaching postpartum weight goal, a sample size of 220 (110 in each arm) would give 90% power to detect the between group difference of 20%. Allowing for up to 30% drop-out at 12 months, we planned to recruit 157 subjects in each arm (total sample size n=314).|f|f|t|f
34118067|NCT03243721|NON_RANDOMIZED|PARALLEL||OTHER||NONE|There is no masking in this study.|There will be two groups running in parallel. One will be MS patients (15) and the other will be control patients (5). Both groups will receive the same interventions.||||
34118068|NCT03573492|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34118069|NCT04741906|||COHORT||PROSPECTIVE|||||||
34118070|NCT06484582|||OTHER||CROSS_SECTIONAL|||||||
34118071|NCT01561833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118072|NCT05324241|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118073|NCT05542888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a another person who will be unaware of the group the particpant belong to.|This study is a randomized controlled trial which will consist of two groups. Once will recieve conventional physcial therapy and the sencond will recieve conventional physcial therapy with sacroiliac joint mobilization.Both groups will be recruited concurrently.|f|f|f|t
34118074|NCT00353002|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118075|NCT02838667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118076|NCT03743493|||OTHER||RETROSPECTIVE|||||||
34118077|NCT01544673|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118078|NCT04108273|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118079|NCT04400435|||COHORT||CROSS_SECTIONAL|||||||
34118080|NCT04811690|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34118081|NCT01101529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118082|NCT06113757|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The clinical study is designed on a comparative control basis, comparing treatment interventions applied to patients. As there are no medical devices with antiviral effects, the comparison is structured to evaluate the progression and effects of the disease. It is specifically designed to compare the change between the group receiving only liquid serum support and supportive treatment and the group receiving Dr. Biolyse® treatment, with the aim of demonstrating the development and impact of the disease.|f|f|f|t
34118083|NCT05325203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118084|NCT01798797|||OTHER||PROSPECTIVE|||||||
34118085|NCT04136145|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized in a 1:2 ratio to receive one treatment of either IV or SC administration of belimumab 200 mg.||||
34118086|NCT06509373|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34118087|NCT00744614|||COHORT||PROSPECTIVE|||||||
34118088|NCT01943760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811866|NCT05673109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811867|NCT01670877|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811868|NCT03020433|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33811869|NCT00478127|||||OTHER|||||||
34043591|NCT04955314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The patients will be divided into two groups and a different physiotherapist from the one who will subsequently perform the intervention will assess and determine which is the most painful segment in each of them.~In the first of the groups, the intervention to be carried out will be through posteroanterior vertebral mobilizations in the most painful lumbar segment. The members of the second group will undergo this same technique on a painful segment of the region adjacent to the one they have referred as the main source of pain."|f|t|f|f
33731259|NCT06502288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The surgeon, patients and the outcome assessor will be blind for the duration of the study.~Participants: After teeth extraction, participants receive either the antibiotic or not without knowing which one they take.~Surgeon: The clinicians who prescribe and administer the medication will not know whether they are giving the antibiotic or not. This can be achieved by having a third-party individual prescribe and distribute the medications according to the randomization schedule.~Outcome Assessor: The individual assessing the outcomes (e.g., infection rates, healing times) will also be blinded to which treatment the participant received. This prevents bias in the evaluation of the treatment effects."|"Intervention Group-A: Administration of a specific antibiotic regimen post-extraction.~Control Group-B: Administration of no antibiotic.~For group A, patients will be prescribed 625 mg of amoxicillin with combined clavulanic acid tablets three times a day after meals for 7 days following extraction. For group B, no post-operative antibiotics will be administered. Both groups will be given a non-steroidal anti-inflammatory drug, 400 mg ibuprofen, and an H2 receptor blocker, 20 mg omeprazole, twice daily before meals."|t|f|t|t
33731260|NCT00557791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731261|NCT04248569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731262|NCT03325166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731263|NCT04061603|NA|SINGLE_GROUP||TREATMENT||NONE||Symptomatic persistent atrial fibrillation that failed at least one class I or Class III AAD with no prior history of ablation||||
33731264|NCT00354445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731265|NCT05291364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731266|NCT05069012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization maintained in the research pharmacy. Blinded syringe delivered to the investigator for the study.|Prospective randomized|t|t|t|t
33731267|NCT04689087|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731268|NCT01319149|||COHORT||RETROSPECTIVE|||||||
33731269|NCT00381420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731270|NCT02453295|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33731271|NCT05599035|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Out of 45 PD patients, 30 patients had sleep disturbance and 6 out of them refused to be participated in the study . Group allocations (active or vs sham with ratio 2 (16 cases):1(8 cases) were placed in serially numbered closed envelopes.|This study included 30 PD patients and 20 normal volunteers' age and sex matched that were recruited .The diagnosis of PD was done according to UK Brain bank Criteria for diagnosis of PD. Out of them we selected only patients with sleep disturbance according to Self-reported questionnaire for non-motor symptoms (sleep disturbance section; Question 23, 24, 25, 26 as follow 23-Difficulty getting to sleep at night or staying asleep at night 24. Intense, vivid dreams or frightening dreams. 25. Talking or moving about in your sleep as if you are 'acting out' a dream 26. Unpleasant sensations in your legs at night or while resting, and a feeling that you need to move.,) (NMSQuest) or frightening dreams All patients fulfilled by Parkinson's disease sleep scale (PDSS). Treatment was maintained constant during the trial. Each patient under levodopa (Sinemet 250/25; ½ table 3 times per day) and anticholinergic (cogenitol ½ table 3 times per day).|t|f|t|t
33731272|NCT01451346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731273|NCT01032135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731274|NCT00613028|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731275|NCT05071092|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The nature of the intervention does not allow for blinding of the participants or researchers. After data collection, the database will be coded by an independent researcher to ensure that data analysis is conducted in a blinded way.||f|f|f|t
33731276|NCT05891938|NA|SINGLE_GROUP||PREVENTION||NONE|Before and after of treatment in single group|Single Group Assignment||||
33731277|NCT01398891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811870|NCT03830320|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811871|NCT05771688|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33811872|NCT04468191|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|During the experimental condition, expiratory muscle strength training (EMST) devices will be set to 50% of patients with ALS' highest maximum expiratory pressure from their baseline pulmonary function test assessment. During the control condition, no resistance will be added, and the loaded spring will be removed from the device. For both experimental conditions, patients with ALS will be blinded to condition.|This study will be a prospective study with randomized experimental and control conditions. Patients with ALS will undergo the experimental and control conditions in random order on two separate days within a two-week time frame.|t|t|f|f
33811873|NCT03543332|||COHORT||PROSPECTIVE|||||||
33811874|NCT04150965|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The trial is designed for patients with functionally high-risk MM (early relapse after initial therapy as defined above), who will be assigned to a targeted agent in the presence of an actionable mutation or an agent in the absence of an actionable genetic alteration, both in combination with a common backbone. This is a MMRC Sponsored multicenter, open label Phase 1/2 study of several different drugs in patients with relapsed myeloma, with treatment assignment guided by genomic studies.||||
33811875|NCT06169345|||COHORT||RETROSPECTIVE|||||||
34043592|NCT00921557|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34043593|NCT04985292|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The investigator will be provided with numbered boxes containing study products with identical probiotic and placebo capsules. The numbers have been generated using a block randomization (investigator blinded to length of block). Participants in each of the race will be allocated to receive one of the study product boxes depending on 1. Race order (all participants in the first race receive study product before any participant in the second race), and 2. Time of recruitment into study.~There is no care provider in this study of healthy individuals."|Before each run (each study participant may only be included in one run) approximately half runners are randomized to receive a probiotic supplement and the other half to receive placebo|t|f|t|t
34043594|NCT04400851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731278|NCT00004412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731279|NCT04486456|||COHORT||PROSPECTIVE|||||||
33731280|NCT05060393|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731281|NCT00111228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731282|NCT02271633|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33731283|NCT04888975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731284|NCT05322187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731285|NCT03879889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research study personnel who will conduct the data collection on outcome measures will be blinded to the group assignment. The researchers who will conduct the data analysis will also be blinded the group assignment.|A single blinded randomized controlled trial aiming to evaluate the effectiveness of smoking reduction interventions for smoking parents in paediatric hospital setting in Hong Kong. This trial consists of a 24-week intervention period. Eligible families will be randomly assigned to either intervention group or control group. Smoking parent(s) in intervention group will be given face-to-face counselling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of NRT and monthly phone follow-up for counselling and support. Smoking parent(s) in control group will be given standard advice and information on smoking cessation.|f|f|t|t
34118089|NCT05849597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731286|NCT05157152|||CASE_ONLY||PROSPECTIVE|||||||
33731287|NCT00350766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Control group received injection of saline with 5% autologous serum without the suspension of mononuclear cells.|Double Blind Randomized Controlled Trial|t|t|t|t
33731288|NCT01371656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
33731289|NCT01539226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731290|NCT02045771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731291|NCT03376178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All investigators, patients, and other clinical staff were blinded to the treatment group. The investigator in charge of the patient was unaware of patient allocation. He did not perform the block or open the sealed and opaque envelope, but followed the patient in the ward. An opaque skin dressing was used in order to blind the type of catheter used. End-hole catheter Vygon is white and stiff whereas six-hole catheter contiplex is yellow and flexible.|Eighty adult patients (aged ≥18 years) scheduled to undergo primary total knee arthroplasty under a combination of CFNB, sciatic nerve block and general anesthesia were randomized to CFNB using either a 3-pair micro-hole (Contiplex, BRAUN®, 20G - 400 mm) or an end-hole (Silverstim VYGON®, 20G - 500 mm) catheter. Once the femoral catheter was sited, a bolus of 20 mL lidocaine 1% was injected. An electronic pump then delivered an automated 5 mL bolus of ropivacaine 0.2% hourly, with 10 mL self-administered patient controlled analgesia boluses.|t|f|t|t
33731292|NCT01485458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731293|NCT01411878|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731294|NCT01120431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731295|NCT00820742|||||PROSPECTIVE|||||||
33731296|NCT02915029|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33731297|NCT03397290|NA|SINGLE_GROUP||SCREENING||NONE||||||
33731298|NCT04275128|||COHORT||PROSPECTIVE|||||||
33731299|NCT02567071|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33731300|NCT01004367|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33731301|NCT01197469|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33731302|NCT02051049|||COHORT||PROSPECTIVE|||||||
33731303|NCT00694980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731304|NCT02567396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731305|NCT00062582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731306|NCT03431116|||COHORT||PROSPECTIVE|||||||
33731307|NCT01061138|||COHORT||PROSPECTIVE|||||||
33731308|NCT01823874|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33731309|NCT03247439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731310|NCT03151759|||COHORT||PROSPECTIVE|||||||
33731311|NCT04185168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731312|NCT02829749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731313|NCT06290856|||COHORT||PROSPECTIVE|||||||
33731314|NCT02728479|||COHORT||PROSPECTIVE|||||||
33731315|NCT06130722|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, Multicenter, Dose escalation Clinical Study||||
33731316|NCT05749081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731317|NCT02686346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731318|NCT01156285|||COHORT||PROSPECTIVE|||||||
33731319|NCT03940365|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study will use a single group for the intervention as detailed above.||||
33731320|NCT04074317|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33811876|NCT04658888|RANDOMIZED|PARALLEL||SCREENING||NONE||This study will use a two armed model: an intervention and a control arm. The control arm will use a standard of care letter reminding the participant to schedule their screening with their primary care provider. The intervention arm will consist of a modified letter with a postcard giving the participant the option to request a self-sampling kit.||||
33731321|NCT04385602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)||t|t|t|t
33731322|NCT04089540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731323|NCT01069289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811877|NCT04528524|||COHORT||PROSPECTIVE|||||||
33811878|NCT02378376|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33811879|NCT03030365|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33811880|NCT03441256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811881|NCT05550441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043595|NCT04496804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34043596|NCT05087511|||CASE_CONTROL||RETROSPECTIVE|||||||
34043597|NCT02741661|||CASE_CONTROL||RETROSPECTIVE|||||||
34118090|NCT02588885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118091|NCT02363530|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34118092|NCT06400784|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel group, 2-arm, superiority trial.||||
34118093|NCT02078869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118094|NCT00003562||||TREATMENT||||||||
33811882|NCT06363604|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study used a single-blind design for the subjects. A statistician created a random sequence of numbers using a randomization scheme. The sequence was then placed in opaque coded envelopes and sealed in numerical order. When a patient met the inclusion and exclusion criteria and was assigned a number, the researcher notified the manager to obtain the corresponding envelope and perform the intervention according to the grouping plan inside the envelope. Group 0 correspond to the control group not receiving PWI isolation, while group 1 correspond to the experimental group for PWI isolation.|"A total of 260 participants with persistent AF who undergo radiofrequency catheter ablation and received VOMEI + PVI will be randomized assigned to two groups at 1:1 ratio.~Group 0 (Control): VOMEI + PVI + linear ablation of mitral isthmus. Group 1 (Experimental): VOMEI + PVI + linear ablation of mitral isthmus + PWI"|t|f|f|f
33811883|NCT00787475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33811884|NCT04780607|||COHORT||PROSPECTIVE|||||||
33811885|NCT06310707|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multi-center, prospective, randomized, unblinded, two-arm study, to include approximately 128 subjects treated with the ePatch Extended Wear Holter (worn for 7 days) and approximately 128 subjects treated with a Standard Wear Holter (worn for 24 hours). Randomization will be balanced for gender.||||
33811886|NCT03302091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118095|NCT05193006|||COHORT||RETROSPECTIVE|||||||
33811887|NCT01368874|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33811888|NCT02099188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811889|NCT02633085|||COHORT||RETROSPECTIVE|||||||
33811890|NCT01811615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33811891|NCT06509555|||CASE_CONTROL||PROSPECTIVE|||||||
33811892|NCT03492853|||CASE_CONTROL||PROSPECTIVE|||||||
33811893|NCT06358599|||COHORT||RETROSPECTIVE|||||||
34118096|NCT05395936|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33811894|NCT05087407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043598|NCT04337905|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The investigator blind to the ADHD-VR diagnostic test results The care provider blind to the ADHD-VR diagnostic test results The ADHD-VR assessor blind to the ADHD diagnosis|"There is two group of children:~1. Group 1: Children with ADHD~2. Group 2: Children without ADHD as a control group~Both group will running the ADHD-VR diagnostic test and goes to diagnosis by child psychiatrist. The outcomes that were analyzed:~1. The sensitivity, specificity and Likelihood ratio of the ADHD-VR diagnostic test in detecting the ADHD clinical symptoms and executive function~2. Content validity of the ADHD-VR diagnostic test"|f|t|t|t
34043599|NCT03303690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118097|NCT04815863|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34043600|NCT00746564|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043601|NCT00557544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043602|NCT02094170|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34043603|NCT00575172|||COHORT||PROSPECTIVE|||||||
34043604|NCT05082675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with an HLA-identical sibling donor were allocated to the auto-allo arm (n = 108) and patients without a matched sibling donor were allocated to the auto arm (n = 249)||||
34043605|NCT06129916|||COHORT||PROSPECTIVE|||||||
34043606|NCT02729051|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118098|NCT00841139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118099|NCT03085680|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded|Randomized placebo-controlled design.|t|f|t|f
34118100|NCT06325787|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118101|NCT02007304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118102|NCT01599039|||||PROSPECTIVE|||||||
34118103|NCT05235984|||OTHER||OTHER|||||||
34118104|NCT05971095|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is an analytical study (with hypothesis testing) of a single-center, unblinded, randomized clinical trial. The patients will be separated between the intervention group and the control group.~To carry out the assignment of interventions, a methodology by blocks of 2 without stratification will be used. To obtain the sequence of random numbers, the official Clinical Trial Randomization Tool of the National Cancer Institute (USA) will be used."||||
34118105|NCT00938301|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118106|NCT05139537|||OTHER||CROSS_SECTIONAL|||||||
34118107|NCT03652155|||OTHER||PROSPECTIVE|||||||
34118108|NCT02937155|||COHORT||PROSPECTIVE|||||||
34118109|NCT00264017|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34118110|NCT03547427|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34118111|NCT04313465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34118112|NCT00077974|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33811895|NCT01693471|||COHORT||PROSPECTIVE|||||||
33811896|NCT02991118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043607|NCT06272968|||COHORT||PROSPECTIVE|||||||
34043608|NCT00216619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043609|NCT03563963|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The anesthesia provider will be blinded to the intervention group allocation as the two solutions are clear, however they will not be blinded if their patient is in the control group. All patients will be anesthetized when the medium is placed in the ETT, thus patients will be blinded. The primary investigator will be blinded. The resident researcher who will be the outcome assessor will also be blinded.|The two intervention groups will be: 1) lidocaine 2% in the ETT cuff and 2) ropivacaine 0.5%in the ETT cuff. The control group will be air in the ETT cuff.|t|f|t|t
34043610|NCT05320315|NA|SINGLE_GROUP||TREATMENT||NONE|The study was Investigator evaluator blinded. The products were dispensed according to the randomization list by a responsible designated person other than the Investigator evaluator and/or evaluators. The randomization list was masked to the Investigator evaluator during the whole study.|Monocentric, single-blind, randomized, controlled, study with intra-individual comparisons||||
34043611|NCT04684537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043612|NCT00792883|||COHORT||PROSPECTIVE|||||||
34043613|NCT00817349|||CASE_ONLY||PROSPECTIVE|||||||
34043614|NCT00776438|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118113|NCT00057161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811897|NCT03482102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731324|NCT00448422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731325|NCT00275158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731326|NCT00419562|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33731327|NCT00846924|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731328|NCT01013233|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731329|NCT03171350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731330|NCT02386943|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731331|NCT00810953|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731332|NCT01367769|||CASE_CONTROL||PROSPECTIVE|||||||
33731333|NCT02158416|||COHORT||PROSPECTIVE|||||||
33731334|NCT02694315|||COHORT||PROSPECTIVE|||||||
33731335|NCT04349722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and care provider are blinded from the treatment|Comparison between participants who receive hyoscine and those who do not.|t|t|f|f
33811898|NCT01682928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811899|NCT02065999|||COHORT||PROSPECTIVE|||||||
33811900|NCT03686345|NA|SINGLE_GROUP||TREATMENT||NONE||Core binding factor acute myeloid leukemia (CBF-AML) patients||||
33811901|NCT00337402|||DEFINED_POPULATION||PROSPECTIVE|||||||
33811902|NCT03028805|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33811903|NCT05576558|||CASE_CONTROL||PROSPECTIVE|||||||
34118114|NCT05187299|RANDOMIZED|PARALLEL||OTHER||DOUBLE||randomized|t|f|f|t
34118115|NCT06078826|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients who meet the research criteria will be numbered after they are determined by the researcher. It will be determined and recorded by the researcher in the digital randomization environment (https://www.randomizer.org/ internet address), which is a simple randomization method, where the enumerated patients will be assigned to the intervention or control group. After randomization, passive music therapy and foot massage will be applied to the patients in the intervention group, and no treatment will be given to the control group.|The research is planned as a prospective, randomized controlled, single-blind, experimental study. The research will be carried out in the 3rd Level Intensive Care Units of Ömer Halisdemir University Training and Research Hospital located in Niğde City Center. The population of this study will consist of patients receiving mechanical ventilator support, who are intubated in the 3rd Level Intensive Care Units of Ömer Halisdemir University Training and Research Hospital in the city center of Niğde. The sample of the study was 'The Effect of Foot Massage on Pain of the Intensive Care Patients:A Parallel Randomized Single-Blind Controlled' study by Momeni et al. (2020), based on pain, power :0.90, type II- error 10%, confidence When the range of 1.96 is taken as a reference, the experimental groups that should be taken as a minimum were calculated as 25 and the control group 25 as a total of 75 patients.|t|f|f|f
34118116|NCT03722810|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomised controlled trial, with sham control.|t|f|f|f
34118117|NCT04256447|||CASE_ONLY||PROSPECTIVE|||||||
34118118|NCT06524544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118119|NCT02751814|||CASE_ONLY||PROSPECTIVE|||||||
34118120|NCT02589821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118121|NCT03586960|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34118122|NCT06064487|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The current study will include 80 patients with sepsis associated AKI stage~1 or 2 according to KDIGO definition admitted to Alexandria Main University Hospital. Urinary TIMP2 and IGFBP7: will be measured by the ELISA technique. Urinary KIM-1: will be measured by the ELISA technique. Examination of urine sediment from fresh urine sample."||||
34118123|NCT04088396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118124|NCT01882816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118125|NCT06240650|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34118126|NCT00413348|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34118127|NCT01150292|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34118128|NCT06483399|||CASE_CONTROL||RETROSPECTIVE|||||||
34118129|NCT03564886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34118130|NCT06628843|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34118131|NCT00926614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118132|NCT02128737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118133|NCT05901610|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be informed whether they are receiving the control behavioral intervention and Sham LIFU.|Each participant will receive all interventions throughout the study. Their pain response will be compared after episodic future thinking (EFT) with the control, episodic recent thinking (ERT) and low-intensity focused ultrasound (LIFU) with the control, Sham LIFU.|t|f|f|f
34118134|NCT01499537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118135|NCT03156218|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||In both groups FiO2 will be modulated: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.||||
34118136|NCT00710593|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118137|NCT00487916|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118138|NCT03121521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118139|NCT01474980|||COHORT||RETROSPECTIVE|||||||
34118140|NCT03433560|||COHORT||PROSPECTIVE|||||||
34118141|NCT05130073|||COHORT||PROSPECTIVE|||||||
34118142|NCT01161771|||CASE_ONLY||PROSPECTIVE|||||||
34149097|NCT04445623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|use of placebo tablets of the same shape, colour of the investigational drug. Identical time and route of administration.|Experimental phase 3 drug trial, randomized 1:1, double-blind, multicentre in patients treated with prasugrel vs placebo.|t|t|f|f
34149797|NCT00179036|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731336|NCT00945503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731337|NCT04124575|||OTHER||CROSS_SECTIONAL|||||||
33731338|NCT02693574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731339|NCT01538693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33731340|NCT00774033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731341|NCT06277804|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33731342|NCT02150174|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731343|NCT01194206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731344|NCT05652166|||COHORT||PROSPECTIVE|||||||
34118143|NCT03796910|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Subjects will be randomized in a 3:1 ratio to receive SPR720 or placebo. The randomization code will produced by Simbec using the PROC PLAN procedure of SAS® version 9.3 or higher. The randomization code will include 2 dose-leaders (1 active:1 placebo) in each cohort who will be randomized prior to the remainder of the cohort. The allocation to SPR720 or placebo will be performed using a block randomization algorithm.|Randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD and MAD) trial|t|t|t|t
34118144|NCT05932485|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34118145|NCT01663792|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34118146|NCT02297412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34118147|NCT06356155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118148|NCT02108886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118149|NCT05469178|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118150|NCT00003486||||TREATMENT||||||||
34118151|NCT04108650|RANDOMIZED|PARALLEL||OTHER||SINGLE|Experimental and control group had no interaction to each other during the study. For data collection was used an individual interview in a place that guarantee privacy. None participant were aware about the group that they will be allocated before the baseline assessment.||t|f|f|f
34118152|NCT00002930||||DIAGNOSTIC||||||||
34118153|NCT05129956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118154|NCT05669365|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34118155|NCT04001400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118156|NCT01370148|NON_RANDOMIZED|PARALLEL||||NONE||||||
34118157|NCT02760914|||COHORT||PROSPECTIVE|||||||
34118158|NCT01615783|||COHORT||RETROSPECTIVE|||||||
34118159|NCT03202160|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118160|NCT02622789|||CASE_CONTROL||PROSPECTIVE|||||||
34118161|NCT03533582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118162|NCT03681756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118163|NCT00090506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118164|NCT06387082|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118165|NCT05831943|||COHORT||PROSPECTIVE|||||||
34118166|NCT06101810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118167|NCT04260958|RANDOMIZED|CROSSOVER||TREATMENT||NONE||CR centers will be cluster randomized and start as either the intervention or control center. Patients at intervention centers will be offered remote video exCR (first-hand option), usual care centre-based exCR or a combination of these two exercise modes. At control centers, patients will be offered usual care centre-based exCR only. The duration of each time period for each center will be 15 months and then cross-over will occur, so that intervention centers become control centers and the other way around. At intervention centers, patients participating in remote exCR will finish their 3-month exercise period, but no new patients will be offered remote exCR after the cross-over has occurred.||||
34118168|NCT05557877|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34118169|NCT05940350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be divided into groups according to the randomization list created to assign each patient to a group. Two independent researchers will conduct the assigned participants to the intervention and control groups and the evaluated the outcome measurement data. Researchers will not be blinded because they will perform these interventions. However, the participants will be blinded because they do not know which group they are in.|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."|t|f|f|f
34118170|NCT01658046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118171|NCT06099769|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This phase II study will randomize.||||
34118172|NCT05602194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118173|NCT06581042|||COHORT||PROSPECTIVE|||||||
34118174|NCT05160415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118175|NCT01641575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118176|NCT02307630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118177|NCT05826600|NA|SEQUENTIAL||TREATMENT||NONE||||||
34118178|NCT03037398|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34118179|NCT06050980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118180|NCT00046072|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34118181|NCT05695976|||COHORT||PROSPECTIVE|||||||
34118182|NCT01645176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118183|NCT06204484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118184|NCT05613816|||CASE_CONTROL||PROSPECTIVE|||||||
34118185|NCT04225858|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective non-inferiority cohort, single-arm registration trial||||
34118186|NCT05740514|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Study subjects will participate in a twelve-week exercise program. Following this time, a one-week detraining period will ensue. Following this detraining period, study subjects will re-engage in a four-week exercise program.||||
34118187|NCT05544487|||CASE_ONLY||PROSPECTIVE|||||||
33731345|NCT00003002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731346|NCT01308307|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|f|t
33731347|NCT04277091|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33731348|NCT05437289|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33731349|NCT00573716|||CASE_CONTROL||RETROSPECTIVE|||||||
33731350|NCT03042234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731351|NCT01565291|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731352|NCT00417443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34118188|NCT06262659|||CASE_ONLY||PROSPECTIVE|||||||
34118189|NCT02189109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118190|NCT00613106|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118191|NCT01470157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118192|NCT05446714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118193|NCT06089083|||COHORT||PROSPECTIVE|||||||
34118194|NCT00240877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34118195|NCT02972996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118196|NCT04843059|NA|SINGLE_GROUP||OTHER||NONE|"To compare the resident memory T-cell infiltrate in perilesional vitiligo skin after 6 months of treatment with OMP and UVB, between three groups of patients suffering from non-segmental vitiligo, using flow cytometric analysis.~* First group will include patients with a long-lasting disease (more than 2 years) and no new or growing lesions for at least 2 years: Old vitiligo with Old lesions~* The second group will include patients with a long-lasting disease (more than 2 years) and with at least one new lesion developed in the last 6 months: Old vitiligo with new lesions~* The third one will include patients developing, for the first-time, vitiligo lesions with all the lesions no older than 6 months: New vitiligo"|"To compare the resident memory T-cell infiltrate in perilesional vitiligo skin after 6 months of treatment with OMP and UVB, between three groups of patients suffering from non-segmental vitiligo, using flow cytometric analysis.~* First group will include patients with a long-lasting disease (more than 2 years) and no new or growing lesions for at least 2 years: Old vitiligo with Old lesions~* The second group will include patients with a long-lasting disease (more than 2 years) and with at least one new lesion developed in the last 6 months: Old vitiligo with new lesions~* The third one will include patients developing, for the first-time, vitiligo lesions with all the lesions no older than 6 months: New vitiligo"||||
34118197|NCT03248323|||CASE_ONLY||PROSPECTIVE|||||||
34118198|NCT01416025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118199|NCT05244161|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34118200|NCT03810976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118201|NCT05298475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118202|NCT02261961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34118203|NCT06120322|||CASE_ONLY||OTHER|||||||
34118204|NCT03112876|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118205|NCT00342134||||TREATMENT||||||||
34043615|NCT02027545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A cluster-randomized (by provider) pragmatic trial of the patient-centered intervention versus pragmatic control.||||
34043616|NCT01228890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043617|NCT02565628|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34043618|NCT00065754|RANDOMIZED|FACTORIAL||||DOUBLE||||||
34043619|NCT02127411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043620|NCT05752019|||COHORT||PROSPECTIVE|||||||
34043621|NCT06310733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34043622|NCT01086189|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34043623|NCT00589758|||COHORT||PROSPECTIVE|||||||
34043624|NCT03616873|||COHORT||PROSPECTIVE|||||||
34043625|NCT00020072||||DIAGNOSTIC||||||||
34043626|NCT02919319|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34043627|NCT03219814|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be unaware until completion of study as to which group they were assigned to (all participants who sign up are only given the information that they will be engaging in an eyetracking task and discussions about the media). The assessments consist of self-report questionnaires (which will be scores by a masked assessor), and eye-tracking, which is an objective measure of time spent gazing at various stimuli.||t|f|f|t
34043628|NCT02908165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043629|NCT00708552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043630|NCT02069808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043631|NCT06215950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043632|NCT00955409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043633|NCT00409435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043634|NCT01326104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043635|NCT06578624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 of the study will start with dose escalation by 2-fold (i.e., 2x preceding dose level) in cohorts of a single participant until Grade 2 or greater toxicity is observed. When a single Grade 2 or higher toxicity is observed, 3+3 multi-participant cohorts will be treated at the dose in which the Grade 2 or higher toxicity was observed by enrolling another 2 participants at this dose. The 3+3 multi-participant cohorts will follow the standard 3+3 paradigm based on occurrence of any DLT with 50% dose escalation until the MTD is identified. In phase 2 of the study, the MTD will be administered to 2 cohorts of 20 participants each: Cohort A) with known MDM2 amplified DD LPS; Cohort B) p53 wild-type solid tumors.||||
34043636|NCT05708118|||CASE_ONLY||PROSPECTIVE|||||||
34043637|NCT01039480|||COHORT||CROSS_SECTIONAL|||||||
34043638|NCT01268826|||CASE_ONLY||PROSPECTIVE|||||||
34043639|NCT06291038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double blind|Multicentric; prospective; randomized; double blind; interregional|t|f|f|f
34043640|NCT02063061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043641|NCT01014364|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043642|NCT06339944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34043643|NCT02772211|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118206|NCT05829876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be assigned to either the treatment (HF-ECG guided LV pacing site optimisation) or control (Q-LV guided LV pacing site optimisation) arm, employing a 1:1 randomization.|t|f|f|f
34118207|NCT03735732|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118208|NCT04676100|||COHORT||PROSPECTIVE|||||||
34118209|NCT04031729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118210|NCT04391920|||COHORT||OTHER|||||||
34118211|NCT00658268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118212|NCT00823173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118213|NCT05795907|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part 1b with open label study design|t|f|t|f
33731353|NCT04709575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811904|NCT02751294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118214|NCT01246960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33811905|NCT02451072|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34118215|NCT06351618|||COHORT||PROSPECTIVE|||||||
33811906|NCT02648555|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33811907|NCT01141257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811908|NCT04697615|||COHORT||CROSS_SECTIONAL|||||||
33811909|NCT06113393|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33811910|NCT05466630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118216|NCT01855893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118217|NCT01877174|||||PROSPECTIVE|||||||
34118218|NCT05969951|||CASE_CONTROL||PROSPECTIVE|||||||
34118219|NCT01378143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118220|NCT05597176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118221|NCT05407701|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigators and study participants will be blind to treatment allocation, with the cranberry and placebo beverages of the same taste and color, and contained in identical looking bottles.|Randomized treatment, double blinded procedures, crossover|t|f|t|f
34118222|NCT05217173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the maneuver, the collaborator who will invite and enter the study subject cannot be blinded to the group assignment. Subsequent evaluations (weekly) where the response variables will be measured will be carried out by a different collaborator, who will be blinded from the group to which each study subject corresponds. The data analyst will remain blinded and will not know to which groups each study subject belongs. The circumstances that may unmask the data of the study subjects for both the evaluator and the data analyst, will be when the study subject is removed from the study for any reason.|A controlled, randomized, pragmatic, single-blind and parallel clinical trial will be conducted. The independent variable will be the type of intervention (tele-rehabilitation vs usual care).|f|f|t|t
34118223|NCT06484075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34118224|NCT03831620|||COHORT||PROSPECTIVE|||||||
34118225|NCT03023345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118226|NCT03763747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118227|NCT06185452|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 12-months prospective, hybrid type (implementation-effectiveness), phase IV, randomized (1:1), open label, multicentric study.||||
34118228|NCT00852111|||COHORT||PROSPECTIVE|||||||
34118229|NCT01892566|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118230|NCT02226302|||COHORT||PROSPECTIVE|||||||
34118231|NCT04781582|RANDOMIZED|PARALLEL||TREATMENT||NONE||single center, 1:1 randomized, open label, controlled||||
34118232|NCT00651222|||COHORT||RETROSPECTIVE|||||||
34118233|NCT04043286|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, prospective, randomized modified split mouth clinical trial||||
34118234|NCT03954431|||COHORT||PROSPECTIVE|||||||
34118235|NCT06482567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34118236|NCT03168139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118237|NCT01893710|||OTHER||PROSPECTIVE|||||||
34118238|NCT02345733|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118239|NCT01816295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118240|NCT05949879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blinded to which group they are in and what oil they are receiving.|Four groups of 28-day parallel feeding trials with three groups receiving different amounts of pecans (low, mid, high) and one group serving as control (instructed to maintain their current habitual diet and avoid any nut consumption for the 28-day intervention).|t|f|f|f
34118241|NCT05818644|||COHORT||RETROSPECTIVE|||||||
34118242|NCT04358406|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|Treatment blinded to all but unblinded pharmacist|Randomized, blinded, placebo controlled interventional|t|t|t|t
34118243|NCT03223753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118244|NCT06486909|||COHORT||PROSPECTIVE|||||||
34118245|NCT06311760|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34118246|NCT00671086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118247|NCT03789708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The placebo and the Gum Arabic are provided to patients in similar unlabeled packages|Randomized and controlled clinical trial with parallel design|t|t|f|f
33731354|NCT00473720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731355|NCT00481442|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731356|NCT04507932|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731357|NCT04036656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33731358|NCT01529359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731359|NCT00218543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731360|NCT05558228|||COHORT||PROSPECTIVE|||||||
33731361|NCT00654381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731362|NCT05118841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33811911|NCT01941576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811912|NCT05884515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811913|NCT02151084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811914|NCT04235920|||CASE_ONLY||PROSPECTIVE|||||||
33731363|NCT02254707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33811915|NCT05596006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811916|NCT04658784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811917|NCT00909909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118248|NCT00328172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34118249|NCT00598507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118250|NCT06432465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118251|NCT03340714|||CASE_ONLY||PROSPECTIVE|||||||
34118252|NCT06176209|||COHORT||PROSPECTIVE|||||||
34118253|NCT01900366|||CASE_CONTROL||PROSPECTIVE|||||||
34118254|NCT01195454|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118255|NCT02647684|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34118256|NCT01999192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149098|NCT04798209|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE||Single-center, double-blind, randomized, placebo-controlled Phase 1 study|t|t|t|t
33811918|NCT02369328|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34043644|NCT03136640|NA|SINGLE_GROUP||TREATMENT||NONE||Three patients will start at the starting dose level. If none of these patients experiences a DLT, another three patients will be added at the same dose level. The dose will be escalated or de-escalated based on safety and pharmacokinetic parameters. The recommended dose level, defined as the maximum tolerated dose (MTD) of docetaxel (as ModraDoc006 10 mg tablets) that can safely be administered in combination with ritonavir to patients with metastatic castration-resistant prostate cancer in a bi-daily weekly schedule without interruption and results in an adequate systemic exposure to docetaxel, will be expanded to at least 20 for toxicity evaluable patients.||||
34043645|NCT05069220|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043646|NCT01994434|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34043647|NCT02284061|RANDOMIZED|PARALLEL||||NONE||||||
34043648|NCT00921531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043649|NCT04306965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043650|NCT04089904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043651|NCT01863199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043652|NCT02598661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043653|NCT02590549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043654|NCT00998647|||COHORT||PROSPECTIVE|||||||
34043655|NCT05645640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34043656|NCT04928612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043657|NCT01024140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043658|NCT06577584|||COHORT||RETROSPECTIVE|||||||
34043659|NCT02088905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118257|NCT03493646|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase II open label multicentre study. All participants will commence with Vidaza for 6 cycles, followed by 6 cycles of CC 486 regardless of response to Vidaza||||
34118258|NCT00840333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118259|NCT05424601|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34118260|NCT04273360|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118261|NCT02040714|||COHORT||PROSPECTIVE|||||||
34118262|NCT04594187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118263|NCT06060210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118264|NCT03721822|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118265|NCT06327711|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||2 groups, non-crossover|t|t|t|t
34118266|NCT06234982|||OTHER||CROSS_SECTIONAL|||||||
34118267|NCT02160821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34118268|NCT03528902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Single-center, randomized, double-blind, placebo-controlled Phase II study of 24 subjects with PAH. Eligible subjects will be randomized to treatment with a 1:1 ratio using a permuted-block randomization algorithm.|t|t|t|t
34118269|NCT06322134|||COHORT||RETROSPECTIVE|||||||
34118270|NCT04551495|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, muti-center, phase 2 trial||||
33811919|NCT06046807|||COHORT||PROSPECTIVE|||||||
34118271|NCT04574856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118272|NCT06717711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118273|NCT03108196|RANDOMIZED|PARALLEL||TREATMENT||NONE||Superiority verification based on the ileal neobladder||||
34118274|NCT05266547|||CASE_CONTROL||RETROSPECTIVE|||||||
34118275|NCT03949023|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118276|NCT06719479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118277|NCT05579652|||COHORT||PROSPECTIVE|||||||
34118278|NCT03261921|RANDOMIZED|FACTORIAL||DIAGNOSTIC||TRIPLE|The Patients allocated to study groups using computer generated random list \& group assignment was sealed in sequentially numbered opaque envelopes that opened after induction of anesthesia.|"Sixty-three patients with ASA I-II aged from 1-6 years scheduled for hypospadias surgery in Abu El-Resh pediatric Hospital-Cairo university, were included in this prospective randomized double-blinded clinical study. Patients with contraindication to caudal anesthesia, cardiovascular diseases, drug allergy, type I diabetes, clotting disorders, mentally retarded children or those whose families did not approve inclusion in the study were excluded from the study.~Patients were randomly divided on the morning of surgery into three groups group I( dexamethasone 21 patients), Group II ( Dexmedetomidine 21 patients) and group III(Dexmedetomidine and dexamethasone 21 patients)."|t|t|t|f
34118279|NCT04746417|||COHORT||PROSPECTIVE|||||||
34118280|NCT05455320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118281|NCT05968846|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34118282|NCT04996667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118283|NCT04538157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33811920|NCT02782260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811921|NCT03605082|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34149099|NCT03869333|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33811922|NCT04455282|||COHORT||PROSPECTIVE|||||||
33811923|NCT01656512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811924|NCT05432518|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, pilot, umbrella trial||||
33811925|NCT01083706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811926|NCT03270384|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34043660|NCT02464163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043661|NCT00277225|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34043662|NCT04943328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043663|NCT00734162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043664|NCT00806273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043665|NCT01006187|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043666|NCT05757206|||COHORT||CROSS_SECTIONAL|||||||
34043667|NCT00874627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043668|NCT04682717|||COHORT||PROSPECTIVE|||||||
34043669|NCT01081769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043670|NCT06035458|||COHORT||PROSPECTIVE|||||||
34043671|NCT05445505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149100|NCT02421926|||COHORT||PROSPECTIVE|||||||
33811927|NCT02027584|||COHORT||PROSPECTIVE|||||||
33811928|NCT00003152||||TREATMENT||||||||
33811929|NCT03927794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded trial where patients won't know to which group they are assigned and where the outcome assessor will be blinded.|2 Groups where group A will receive self-assembling peptide P11-4 and group B will receive topical fluoride varnish.|t|f|f|t
33811930|NCT03556410|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33811931|NCT00861991|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33811932|NCT00952640|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33811933|NCT00211926|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118284|NCT05041985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were presented with a sealed opaque envelope which contained a piece of A4 paper with inscriptions Group A or Group B. After choosing one envelope they would tell the nurse which letter they got without the assessor's knowing the group.|Study group will get the recommendation to use one Diazepam 5 mg pill per day (bedtime) for 7 days after whiplash injury.|f|f|t|f
34118285|NCT06464770|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Randomization Option 1: Right shoulder, Test Group ; Left shoulder, Control Group Randomization Option 2: Right shoulder, Control Group ; Left shoulder, Test Group||||
34118286|NCT04864392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118287|NCT05462899|||OTHER||CROSS_SECTIONAL|||||||
34118288|NCT06446128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118289|NCT04585750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"During Phase 2 Monotherapy the Recommended Phase 2 Dose (RP2D) selected at the end of Phase 1 Monotherapy and in Phase 2 (Dose Expansion) the RP2D will be assigned to all participants. Participants will be assigned to one of five cohorts: ovarian cancer, lung cancer, breast cancer, endometrial cancer, or other solid tumors. Enrollment ongoing.~During Phase 1 Monotherapy (Dose Escalation), participants will be assigned a dose level using an accelerated titration design in the initial dose cohorts, followed by a modified toxicity probability interval (mTPI) design in subsequent dose cohorts. Enrollment closed.~During Part 1 of the Ph 1b Combination Therapy, patients will be assigned a dose level using mTPI design. A recommended PC14586 (INN: rezatapopt) Phase 2 Dose (RP2D) when administered in combination with pembrolizumab will be selected at the end of Phase 1b Part 1, and the RP2D will be assigned to all participants in Part 2."||||
34118290|NCT06368401|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34118291|NCT06154603|||COHORT||RETROSPECTIVE|||||||
34118292|NCT05500989|||COHORT||PROSPECTIVE|||||||
34118293|NCT06717633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34118294|NCT02031302|||COHORT||PROSPECTIVE|||||||
34118295|NCT00203190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34118296|NCT05178784|||CASE_CONTROL||PROSPECTIVE|||||||
34118297|NCT06607523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118298|NCT05212103|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118299|NCT05309616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118300|NCT05476081|||COHORT||PROSPECTIVE|||||||
34118301|NCT06715670|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118302|NCT06122610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118303|NCT06652295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An independent assessor who is unaware of the group of participants going to perform all evaluations.||f|f|f|t
34118304|NCT05682937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118305|NCT06658366|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118306|NCT05165706|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118307|NCT04288089|NA|SEQUENTIAL||TREATMENT||NONE||||||
34118308|NCT05592548|NA|SINGLE_GROUP||TREATMENT||NONE||split face study||||
34118309|NCT04881682|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118310|NCT01333319|||COHORT||PROSPECTIVE|||||||
34118311|NCT01758029|||COHORT||PROSPECTIVE|||||||
34118312|NCT06719076|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|"To maintain internal validity and minimize bias, randomization will be employed to allocate participants to either the control group or the Diabetes Healthcare Program group. A series of individually concealed envelopes will be prepared by an assistant not involved in the trial (Clark et al., 2021). Each bearing a randomly assigned indication of either Control group or Diabetes Healthcare Program group and sequentially numbered. Once a participant provides informed consent and meets the inclusion criteria, the next envelope in line will be opened to determine the group allocation, ensuring that randomization remains blinded to the research team until allocation is revealed. This approach adheres to the CONSORT guidelines, which recommend randomization in trials to avoid confounding variables and ensure comparability between groups (Schulz et al., 2010)."|In single group arm design the Type-II Diabetics randomized in two arms the first arm receive 3 months of DHCP intervention and other arm receive 3 month usual care. The allocation of groups assigned after the randomization either for intervention arm or control arm and the result will be compared and interpreted and disseminated.||||
34118313|NCT06016283|||COHORT||RETROSPECTIVE|||||||
34118314|NCT01911468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118315|NCT06099704|||COHORT||PROSPECTIVE|||||||
34118316|NCT04127162|||OTHER||OTHER|||||||
34118317|NCT05523323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study was unblinded on August 16, 2023||t|f|t|f
34118318|NCT05943262|||CASE_ONLY||RETROSPECTIVE|||||||
33731364|NCT00829322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731365|NCT04933591|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731366|NCT01442363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731367|NCT05863741|||CASE_CONTROL||PROSPECTIVE|||||||
33731368|NCT00640510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33811934|NCT01083966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811935|NCT05584748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33811936|NCT04152824|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34118319|NCT02149459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118320|NCT04552223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118321|NCT04231448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118322|NCT05641935|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118323|NCT02379520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118324|NCT06168240|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118325|NCT06716736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118326|NCT05075161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731369|NCT04087291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Doctors of Chiropractic (DCs), site study coordinators (SCs), participants and interviewers will not be blinded to treatment group assignment; DCs will not see research outcome measures; statisticians will be blinded to treatment group assignment during data analysis; and research personnel conducting Computerized Adaptive Testing Interviews (CATIs) will be blinded to study group.|This pragmatic, parallel groups, multisite randomized trial will include Veterans with cLBP who will be randomly allocated to undergo a course of a low dose (1-5 visits) or a higher dose (8-12 visits) of multimodal, evidence-based chiropractic care for 10 weeks (Phase 1). Group allocation will occur through a 1:1 ratio by a predetermined, computer-generated, restricted randomization scheme with random block sizes, stratified by site and sex. After Phase 1, participants within each treatment arm will be randomly allocated again to receive either chiropractic chronic pain management (CCPM) consisting of scheduled monthly chiropractic care or no CCPM for 10 months. This second group allocation will also occur through a 1:1 ratio to Phase 2 within low dose or higher dose in Phase 1 by a predetermined, computer-generated, restricted randomization scheme with random block sizes, stratified by site and sex.|f|f|t|t
33731370|NCT01401933|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731371|NCT03287388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Each patient wil serve as its own control:~Each patient will start without neuromuscular blockade (phase 1), followed by moderate neuromuscular blockade (phase 2) and deep neuromuscular blockade (phase 3)."||||
33731372|NCT00616850|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33731373|NCT04974970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731374|NCT03090256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731375|NCT01176292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731376|NCT02743572|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33731377|NCT02484703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731378|NCT05782595|NA|SINGLE_GROUP||TREATMENT||NONE|Randome generator|Aquatic therapy||||
33731379|NCT06319326|||COHORT||PROSPECTIVE|||||||
33731380|NCT04433468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33731381|NCT04411342|||OTHER||CROSS_SECTIONAL|||||||
33731382|NCT06424080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731383|NCT06375057|||COHORT||PROSPECTIVE|||||||
33731384|NCT03407326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33731385|NCT01521611||SEQUENTIAL||TREATMENT||NONE||||||
33731386|NCT05882682|||COHORT||CROSS_SECTIONAL|||||||
33731387|NCT06207058|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33731388|NCT00580424|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731389|NCT01690390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731390|NCT03193606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||split mouth randomized clinical trial|t|f|f|t
33731391|NCT01456325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731392|NCT01469468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731393|NCT03077165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731394|NCT05561972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811937|NCT04321109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Results were sent to Outcome Assessor masked , so he was not able to know results belong to which group|"Group (1): Seven extraction sockets that received the collagen matrix (Collacone) for alveolar ridge preservation.~Group (2): Seven extraction sockets that were treated with mineralized cortico-cancellous bone allograft (Maxgraft) for alveolar ridge preservation"|f|f|f|t
33811938|NCT05211726|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||A single-blind, randomized-crossover, controlled feeding study. Participants will be provided with 10-days each of a research diet containing low sugar (LS; 5% of energy from added sugars) vs. high sugar (HS; 25% of energy from added sugars) in a random order, separated by a 2-week washout.|f|f|t|f
33811939|NCT03188484|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33811940|NCT01106807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33811941|NCT04698694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subjects and investigators will remain blind with respect to the voltage strength received.|"Twenty (20) subjects will be randomized 1:1 to one of the following EP conditions:~1. voltage amplitude of 40 V (10 subjects)~2. voltage amplitude of 60 V (10 subjects)."|t|f|t|f
33811942|NCT02527694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811943|NCT02709200|||CASE_ONLY||PROSPECTIVE|||||||
33811944|NCT02731066|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34118327|NCT06681272|||COHORT||PROSPECTIVE|||||||
34118328|NCT04585308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118329|NCT06214403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118330|NCT02920320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118331|NCT06716398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34118332|NCT02953912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118333|NCT05702645|||COHORT||PROSPECTIVE|||||||
34118334|NCT03722979|NA|SINGLE_GROUP||OTHER||NONE||||||
34118335|NCT02466724|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34118336|NCT03464266|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34118337|NCT04405817|||COHORT||PROSPECTIVE|||||||
33731395|NCT04122729|||CASE_ONLY||CROSS_SECTIONAL|||||||
33811945|NCT05389202|NA|SINGLE_GROUP||TREATMENT||NONE|The infusion scans will be interpreted by a radiologist who does not know the patient's clinical result in order to avoid a classification bias.|||||
34118338|NCT03807089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118339|NCT06011083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118340|NCT00794092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118341|NCT01737866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118342|NCT04322318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118343|NCT00027560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118344|NCT02383160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118345|NCT00691392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118346|NCT02096211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118347|NCT05880212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Participants will be blinded to the trial hypothesis and knowledge of the fact that two treatment options are being compared.||t|f|f|t
34118348|NCT01991379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118349|NCT05064228|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to either the m-ReACT intervention condition or an active control condition.||||
34118350|NCT05228275|||OTHER||OTHER|||||||
34118351|NCT03325504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118352|NCT02353962|NA|SINGLE_GROUP||OTHER||NONE||||||
34118353|NCT02421094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118354|NCT04287413|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the new model of care and comparison, it is not possible to blind the patients or health care providers. Since the primary outcomes are self-reported outcome measures, the assessor is also not blind to the intervention.|This is a cluster randomized controlled trial randomizing 20 sites to the PT-led primary care model for back pain or to the usual care model||||
34118355|NCT00086073|||COHORT||PROSPECTIVE|||||||
34118356|NCT03501368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118357|NCT00213642|||||PROSPECTIVE|||||||
34118358|NCT06642675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||32 participants will be randomly divided into intervention group or sham group|t|t|t|t
34118359|NCT03848780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34118360|NCT05271006|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|PI will be blind to the allocation to the groups. Person sending out emails to participants to complete surveys will be blind to group allocation.|"Power analysis with three different effect sizes δ: .30, .40, and .50.~Using Optimal Design Software, to detect a small effect size δ= .30 based on a two-level (non)linear growth model (six time points; level-1 residual variability = 8.798; level-1 coefficient variability = 22.548) with Power (1 - b) = .80 and alpha = .05 for 7 time points repeated measures design, 357 participants required across the four arms. With an additional 10 recruitment sites, investigators require an additional 90 participants (for the possibility of nesting or for creation of 9 dummy variables to covary locations). With a 20% expected attrition, a total of 560 HCWs will be randomized. Investigators will be employing this conservative target for this study.~In order to detect a small effect size δ= .40 and a 20% expected attrition, a total of 366 HCWs will be randomized.~In order to detect a small effect size δ= .50 and a 20% expected attrition, a total of 276 HCWs will be randomized."|f|f|t|t
34118361|NCT04240561|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are randomly assigned to Hearing Aid fitting order A or B. One group will have the higher level of signal manipulation for the first session while the other group will start with the lower level of signal manipulation. Each group will then be given the other signal manipulation strategy. Outcome data will be collected by individuals blinded to which signal modification strategy the participant is using.|Randomized cross-over Trial|t|f|f|t
34118362|NCT03486353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"open-label, Simon 2-stage clinical study of the combination of FF-10501-01 and azacitidine in MDS patients. The Phase 2 portion of the trial will be preceded by a Phase 1 run-in to evaluate the safety of the combination of FF-10501-01 plus azacitidine."||||
34118363|NCT02808780|||COHORT||PROSPECTIVE|||||||
34118364|NCT02483429|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34118365|NCT03738917|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, pragmatic, parallel group, open randomized trial.||||
34118366|NCT06360107|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34118367|NCT04513808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||As usual with time-to-event outcomes, enrollment will be based on the number of outcome events, not the number of patients enrolled. We anticipate that about 1614 patients will be required to generate 579 recurrences and/or deaths, but this is only a rough estimate since follow-up duration is a function of when patients are enrolled, not just their number.|t|t|f|f
33731396|NCT01250613|||FAMILY_BASED||RETROSPECTIVE|||||||
33731397|NCT02306356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731398|NCT04525612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731399|NCT00207142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731400|NCT01067352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731401|NCT00378313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731402|NCT01988870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731403|NCT02963493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731404|NCT00515827|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33731405|NCT06116422|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparative effectiveness study.||||
33731406|NCT06292715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731407|NCT00647621|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33731408|NCT04737538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731409|NCT03872180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731410|NCT02099214|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731411|NCT02586012|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731412|NCT06278597|NA|SINGLE_GROUP||SCREENING||NONE||||||
33731413|NCT06077188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731414|NCT00935428|||COHORT||RETROSPECTIVE|||||||
33731415|NCT03423732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Data and Safety Monitoring Board (DSMB) will be blinded at project start, but may request unblinding if necessary to accommodate effective review of data.~Other than the DSMB (if necessary), the only other un-blinded parties, meaning that they will have knowledge as to the patient's treatment assignment, will be the PBTiK UJ CM employee who participates in randomization utilizing randomization lists and investigational medication preparation."|"The N-O CLI trial will enroll 105 patients with randomization into active and sham therapy with 2:1 ratio.~Additional 5-10 subjects meeting inclusion/exclusion criteria will receive, in a non-blinded fashion, labelled CardioCell to determine the early uptake and retention of IMP in the target ischemic tissues."|t|t|t|t
33731416|NCT03521453|||CASE_CONTROL||PROSPECTIVE|||||||
33731417|NCT03689764|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33731418|NCT02722928|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33731419|NCT03369639|||CASE_ONLY||PROSPECTIVE|||||||
33731420|NCT01624428|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33731421|NCT04939285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731422|NCT05996263|||COHORT||RETROSPECTIVE|||||||
33731423|NCT04615559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731424|NCT05439356|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33731425|NCT01150214|||COHORT||PROSPECTIVE|||||||
33731426|NCT01256710|||COHORT||PROSPECTIVE|||||||
33731427|NCT04347486|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731428|NCT05529212|||COHORT||PROSPECTIVE|||||||
33731429|NCT03314467|||CASE_CONTROL||PROSPECTIVE|||||||
33731430|NCT05583968|||COHORT||RETROSPECTIVE|||||||
33731431|NCT04249128|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study is done completely online. Supplements are fulfilled at a central fulfillment center. The study sponsor, nor any care provider, or investigator know what formulation a participant receives until the end of the study|Participants are randomized into one of eight arms. The arms include four combinations of dietary supplements for skin, hair \& nail health (Keratin, collagen peptides, pro-berry powder, vegan Keratin, and Astaxanthin). Each supplement formation is included in two arms - one arm is paid, the other arm is free.|t|t|t|t
33731432|NCT04777539|||OTHER||PROSPECTIVE|||||||
33731433|NCT05908279|||CASE_CONTROL||PROSPECTIVE|||||||
33731434|NCT00276718||||TREATMENT||NONE||||||
33731435|NCT00947492|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33731436|NCT02900820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731437|NCT01122667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731438|NCT03425617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33731439|NCT00146718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731440|NCT02262481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33731441|NCT02313610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731442|NCT02567461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731443|NCT03678142|||COHORT||PROSPECTIVE|||||||
33731444|NCT03548584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731445|NCT00675116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33731446|NCT04132557|||COHORT||RETROSPECTIVE|||||||
33731447|NCT02095769|||COHORT|||||||||
33731448|NCT03643562|NA|SINGLE_GROUP||TREATMENT||NONE||Continued treatment for children at least 4 years of age||||
33731449|NCT05336903|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Participants will be invited to participate in the study with an understanding that they will be assigned to either a model of care in which they see the physician or nurse practitioner first or a model of care in which they see a physiotherapist first, even though this is a single arm feasibility study and all participants will be assigned to the APP model of care. This partial masking at the time of consent and initial assessment was determined to be important to provide accurate estimates of feasibility (e.g. consent rate, percentage of consenting participants who see the physiotherapist first who also request to see the physician or nurse practitioner). Due to the nature of the intervention, participants and healthcare providers will not be blinded to the intervention received in this or the fully powered trial. Since the primary outcome measures are self-report measures (ie. the participant is the assessor), the outcome assessor is similarly not planned to be blinded.|This is a single-arm feasibility study at the one chronic pain clinic in Kingston, Ontario, Canada. The intervention is the integration of an APP as the first point of contact in this interprofessional setting.||||
33731450|NCT00565279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731451|NCT06137456|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731452|NCT02807181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731453|NCT02934230|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33731454|NCT02989207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731455|NCT01458899|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33731456|NCT00243308|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33731457|NCT04117126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731458|NCT00127322|||DEFINED_POPULATION||PROSPECTIVE|||||||
33731459|NCT03234738|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|IV bags and lines are covered to prevent unblinding.|Five Multiple-Ascending Doses|t|t|t|t
33811946|NCT03648749|NA|SINGLE_GROUP||TREATMENT||NONE||A single group will be studied during no intervention (no feedback about speech) and intervention (feedback about speech) phases.||||
33811947|NCT06030739|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33811948|NCT05123755|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This is a double-blind, placebo-controlled study. All sponsor, vendor and site study staff will be blinded to treatment assignment, with the exception of the unblinded biostatistician, unblinded site pharmacist, and unblinded site monitor.|This is a randomized (1:1 ratio) placebo controlled trial.|t|t|t|t
33811949|NCT05080348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient will not know which group they are in as they will be injected with either SHAM or Intervention group, which the pharmacy will create. As a result, the anesthesiologist performing the injection and the intraoperative anesthesiologist will also not know if the patient received a SHAM or intervention injection. This will also apply to the PACU nurse. The person performing the data analysis will know which patients received the intervention, as this is required for data analysis.|Randomized double blind placebo controlled|t|t|t|f
33811950|NCT02407899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811951|NCT02064933|||COHORT||OTHER|||||||
33811952|NCT02596737|NA|SINGLE_GROUP||||NONE||||||
33811953|NCT04867772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2 arm RCT|t|f|t|t
33811954|NCT03841994|||COHORT||PROSPECTIVE|||||||
33811955|NCT04210830|||CASE_ONLY||PROSPECTIVE|||||||
33811956|NCT05207397|||OTHER||CROSS_SECTIONAL|||||||
33811957|NCT06169566|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33811958|NCT04951791|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial||||
33811959|NCT01297088|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33811960|NCT05051072|NA|SINGLE_GROUP||OTHER||NONE||||||
33811961|NCT01529866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33811962|NCT01333215|||COHORT||CROSS_SECTIONAL|||||||
33811963|NCT00002977||||TREATMENT||||||||
33811964|NCT01211015|||CASE_CONTROL||PROSPECTIVE|||||||
33811965|NCT00211640|||||OTHER|||||||
34043672|NCT06321406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043673|NCT02724657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043674|NCT02162251|||COHORT||PROSPECTIVE|||||||
34118368|NCT03066206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118369|NCT05247203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118370|NCT03064074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731460|NCT05466227|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a mixed-methods study that uses realist evaluation as the overall conceptual framework to examine a quality improvement program to improve the care for patients with paroxysmal supraventricular tachycardia in the emergency department.~A realist evaluation is methods-neutral, and the use of a mixed-methods approach employing a case note review, interviews, and focus groups with patients and staff will generate and analyse both qualitative and quantitative data to achieve the goal of the evaluation. Analysis of qualitative and quantitative data will be carried out using a convergent mixed-methods approach to ensure continuous triangulation of multiple data, which will provide a greater understanding of the findings in relation to policy and practice. Broadly, the evaluation could also be considered a process and outcome evaluation."||||
33731461|NCT01096784|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731462|NCT04294004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the different technical procedures between the control and the intervention arms (KUR-113 Bone Graft versus local autograft), investigators cannot be blinded to the treatment. However, all stage 1 patients will remain blinded for the duration of their participation in the study. All stage 2 patients will receive the same treatment and will be unblinded.||t|f|f|f
33731463|NCT03460587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731464|NCT00838266|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33731465|NCT02403908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731466|NCT05709171|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731467|NCT03029624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731468|NCT00685152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731469|NCT02888327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731470|NCT06481956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731471|NCT01057043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731472|NCT02735070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731473|NCT01782781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731474|NCT06021392|||CASE_ONLY||PROSPECTIVE|||||||
33811966|NCT04998266|RANDOMIZED|PARALLEL||OTHER||NONE||"After first session evaluation, employees will be randomly assigned to one of the 2 followings groups: (1) group with traditional exercise (CLA) and group with adapted and personalized exercises (IND). The CLA group will perform exercises following World Health Organization (WHO) prescription while the IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.~Note that all session evaluations are investigated within the company of the participant"||||
33811967|NCT05858606|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Our trial aims to evaluate the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size (taking child gender into account), after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. We propose to perform a two-step study. The first one consists in a standardized multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of ISS is confirmed.||||
33811968|NCT03054506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811969|NCT06372899|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33811970|NCT04985903|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|We will mask the intervention arms during the coding process.||t|f|f|t
33811971|NCT06463626|||COHORT||RETROSPECTIVE|||||||
33811972|NCT05255744|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a randomized, open label, cross over study to evaluate the Whitsundays nasal mask system (prototype mask) against a released mask system, the ResMed AirFit N30i Quiet mask system.|t|f|f|f
33811973|NCT01799005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811974|NCT01444365|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811975|NCT00848094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811976|NCT03032965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811977|NCT02871245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811978|NCT02958553|NA|SINGLE_GROUP||TREATMENT||NONE||First the patient data is gathered with the subject's own passive prosthetic. Then switched over to the emPOWER Ankle. Third, the patient's prosthetic is switched back to test for carry-over benefits. Then they are put on the emPOWER for a final series of tests.||||
33811979|NCT03528915|||CASE_CONTROL||PROSPECTIVE|||||||
33811980|NCT05458466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33811981|NCT00383383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33811982|NCT02501369|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33811983|NCT00709787|||CASE_ONLY||PROSPECTIVE|||||||
33731475|NCT02985294|||COHORT||PROSPECTIVE|||||||
33731476|NCT05697900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This was a double-blinded clinical trial since participants and those assessing the outcomes were blinded to the intervention. All groups were given small metallic plastic bags with five grams of powder identical in size, shape, and color but the placebo contained maltodextrin (Tecnas S.A., Medellín, Colombia).|This was a double-blinded placebo-controlled repeated-measures randomized clinical trial in elite team-sport athletes with three arms in parallel.|t|f|t|f
33731477|NCT02773043|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731478|NCT00771433|NON_RANDOMIZED|||SUPPORTIVE_CARE||||||||
33731479|NCT02615951|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731480|NCT01321788|||COHORT||PROSPECTIVE|||||||
33731481|NCT05795894|||COHORT||PROSPECTIVE|||||||
33811984|NCT01544894|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33811985|NCT04862988|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33811986|NCT02973932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811987|NCT06338384|||CASE_CROSSOVER||PROSPECTIVE|||||||
33811988|NCT05764395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811989|NCT04338568|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with the diagnosis of COVID-19 pneumonia will undergo a lung ultrasound, by two observers each. The findings will be compared with findings on chest x-ray and/or CT thorax. Accuracy and inter-observer variability will be calculated.||||
34118371|NCT05180968|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33731482|NCT01664143|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33811990|NCT04890626|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Main randomization. Patients will be randomized to Emtricitabine / Tenofovir disoproxil fumarate or no treatment.~Rescue randomization: patients with oxygen requirements, O2 Sat \<95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms:~* dexamethasone + Baricitinib~* dexamethasone"||||
34118372|NCT04052061|NA|SEQUENTIAL||TREATMENT||NONE||||||
34118373|NCT05101070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118374|NCT04009980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, interventional, randomized, double-masked, monocentric pilot study|t|f|t|t
34118375|NCT06174740|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The order of the allocation for new inclusions will be concealed from the assessors. Researchers administering assessments at the two time points will be masked and concealed from the randomization and participant allocation. Researchers involved in the MRI acquisition and analysis will collect the data under a different participant identifier (ID) than the ID used to conduct MRI analysis, and will follow an analysis script designed before data collection is completed, where applicable. Participants, and researchers may not be masked from the conditions due to practical reasons relating to the presence of auditory stimuli in the same or nearby vicinity, or interacting with the participants regarding the presence of auditory stimuli, which is the main intervention being investigated.|Participants will be randomized into either the audiovisual condition (Experimental Group) or visual cues only condition (Control Group). A randomization list stratified by gender will be generated before commencing data collection.|f|f|f|t
34118376|NCT01789190|||COHORT||PROSPECTIVE|||||||
34118377|NCT05098314|||OTHER||PROSPECTIVE|||||||
34118378|NCT05024344|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34118379|NCT03981328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118380|NCT06710288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118381|NCT04722783|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The DPICS rating - as part of the primary outcome - is the only measure that is masked|This is a pilot, practical clinical trial with a single-blind, mixed randomized and non-randomized controlled factorial design within a monocentric setup|f|f|f|t
34118382|NCT00361712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118383|NCT03326245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34118384|NCT00082121|RANDOMIZED|PARALLEL||||DOUBLE||||||
34118385|NCT04726241|NA|SINGLE_GROUP||SCREENING||NONE||||||
34118386|NCT00332696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118387|NCT00534001|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118388|NCT00557037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118389|NCT03861338|NA|SINGLE_GROUP||TREATMENT||NONE||open label pilot for sublocade||||
34118390|NCT01864434|||CASE_CONTROL||RETROSPECTIVE|||||||
34118391|NCT05697718|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118392|NCT01593917|||COHORT||PROSPECTIVE|||||||
34118393|NCT05988138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34118394|NCT04911426|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The two-arm randomization has been discontinued with new consented participants joining the study in 2023.||||
34118395|NCT03894085|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118396|NCT01470105|||COHORT||PROSPECTIVE|||||||
34118397|NCT06254066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118398|NCT05330975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Parts A and B are randomized, observer blind studies and Part C is a single-arm, open-label study.||t|t|t|t
34118399|NCT00863161|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34118400|NCT03960840|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118401|NCT04906694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118402|NCT05626491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118403|NCT01597739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118404|NCT04925141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118405|NCT04551300|RANDOMIZED|PARALLEL||TREATMENT||NONE||4 different dosages of VS-505 in Comparison with Sevelamer Carbonate||||
34118406|NCT06451497|NA|SINGLE_GROUP||OTHER||NONE||||||
34118407|NCT03590886|||OTHER||CROSS_SECTIONAL|||||||
34118408|NCT01337570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34118409|NCT03679949|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, cross-over, double-blind, placebo-controlled study. All participants will partake in each arm and receive all interventions.|t|f|t|f
34118410|NCT06313203|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118411|NCT04796584|||COHORT||PROSPECTIVE|||||||
34149101|NCT02428413|RANDOMIZED|PARALLEL||||NONE||||||
34149102|NCT00478309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149103|NCT00444977|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34149104|NCT00829491|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149105|NCT03730545|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Eligible patients were randomly assigned in equal numbers to undergo SEN or EIN according to a computer-generated randomization list managed by a dietary nurse not involved in the study. The study was double-blind: SEN and EIN feeds were identical in color and type of container, so treatment assignments were not revealed to patients or to any staff members.|Patients were randomized to receive enteral immunonutrition or standard enteral nutrition in postoperative day 1 by enteral feeding.|t|f|t|f
33811991|NCT00703092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811992|NCT05454332|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33811993|NCT00504205||||TREATMENT||||||||
33811994|NCT04779463|||COHORT||PROSPECTIVE|||||||
33811995|NCT02802111|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33811996|NCT00838045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33811997|NCT06041438|NA|SEQUENTIAL||TREATMENT||NONE||||||
33811998|NCT03430440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33811999|NCT02124044|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812000|NCT05521256|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33812001|NCT03982797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812002|NCT06244914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812003|NCT01505309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812004|NCT06364514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812005|NCT00458783|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33812006|NCT00213759|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33812007|NCT01221402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Original plan was to enroll 138 subjects, but trial was terminated early and total randomized was 38.|t|t|t|t
33812008|NCT00149409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812009|NCT01697605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812010|NCT03610685|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33812011|NCT00655213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812012|NCT04330612|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33812013|NCT01482325|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118412|NCT06226610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study sponsor will supply all study drug (including placebo) as blinded kits. Study staff, investigators, and participants will be blinded to which treatment condition a participant has been randomized to. Note that the drug manufacturer will email codes to the pharmacists (who are unblinded) identifying the appropriate study drug for a particular participant. It is possible that participants may become unblinded to the obvious physical effects related to receiving Dupixent or placebo (pruritus improves or does not improve). Study staff will not discuss or speculate potential treatment arm allocation with participants based on participants' comments, questions, daily itch diary data, or physical observation. Study staff will encourage participants expressing resentful demoralization to remain in the study through their final visit.|This is a dual-arm, two-site, randomized, placebo-controlled interventional Phase 2 randomized controlled clinical trial to estimate the potential effect size of Dupixent on improving post-burn pruritus symptoms. N=46 participants will be enrolled at a 1:1 intervention:control ratio.|t|t|t|f
34118413|NCT00294034|||DEFINED_POPULATION||PROSPECTIVE|||||||
34118414|NCT06598332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118415|NCT04846335|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The protocol provided that in the trial were included carriers and non-carriers, members of the FFI family, who followed exactly the same procedures with the only difference that non-carriers received the placebo instead of the DOXY, since we could not exclude that a participant, by accidentally discovering that he/she received DOXY, automatically would realize to belong to the carrier group, we decided that also the non-carrier people will receive DOXY with a random schedule for a limited period of time so to eliminate any possible association. Only study coordinator will be informed about the presence of the mutation and will perform drug allocation.||t|t|t|t
34118416|NCT06437834|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34118417|NCT00332618|||DEFINED_POPULATION||OTHER|||||||
34118418|NCT04466969|||OTHER||PROSPECTIVE|||||||
34118419|NCT01287494|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34118420|NCT01040156|||COHORT||RETROSPECTIVE|||||||
34118421|NCT03844308|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||It is a waitlisted controlled study where the control group will receive the intervention after the intervention arm completes the study.|t|f|f|f
34118422|NCT04573855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118423|NCT06662279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118424|NCT05626634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118425|NCT06290388|NA|SEQUENTIAL||TREATMENT||NONE||||||
34118426|NCT05537389|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34118427|NCT00784121|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34118428|NCT05799274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118429|NCT06362005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118430|NCT04326179|||COHORT||RETROSPECTIVE|||||||
34118431|NCT05589298|||COHORT||CROSS_SECTIONAL|||||||
34118432|NCT03838744|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled, parallel, two arm study||||
34118433|NCT01769924|||COHORT||PROSPECTIVE|||||||
34118434|NCT06229119|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118435|NCT05061030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118436|NCT05488054|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be enrolled in one of two arms: surgical patients undergoing physical therapy or healthy volunteers. Data from patients including O2 and hemoglobin levels in injured tissue will be collected to determine safe return to sport.||||
34118437|NCT05318781|||COHORT||PROSPECTIVE|||||||
34118438|NCT06233448|||COHORT||PROSPECTIVE|||||||
34118439|NCT02550145|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34118440|NCT05192915|NA|SINGLE_GROUP||SCREENING||NONE||This study is a prospective, cross-sectional within-subjects comparison||||
34118441|NCT03701243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118442|NCT01060943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118443|NCT01323192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118444|NCT05891899|||CASE_ONLY||PROSPECTIVE|||||||
34118445|NCT06026813|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34118446|NCT00995852|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118447|NCT05515744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149106|NCT01480011|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149107|NCT04773990|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"Fifty subjects (power analysis) of both gender diagnosed with recurrent lateral ankle sprain patients will be assigned randomly into 2 groups.~* Group (A) will receive biodex balance training~* Group (B)will receive a physical therapy exercise protocol only"|t|f|f|f
34149108|NCT03522831|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34149798|NCT05323071|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149799|NCT02774304|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812014|NCT03086226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812015|NCT05575349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33812016|NCT01960972|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812017|NCT05569343|||COHORT||RETROSPECTIVE|||||||
33812018|NCT00486954|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812019|NCT06275802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812020|NCT01533194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812021|NCT05758207|||COHORT||CROSS_SECTIONAL|||||||
33812022|NCT05912049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731483|NCT03026712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812023|NCT04078217|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|One of the investigator (the research assistant) will not know the type of intervention (technology or booklet), until the last week of testing when the investigator takes back the equipment for intervention.||f|f|t|f
33731484|NCT06484777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731485|NCT03065556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731486|NCT00060996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731487|NCT04256616|||CASE_CONTROL||PROSPECTIVE|||||||
33731488|NCT00127140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731489|NCT02563028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731490|NCT04405609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731491|NCT01167062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731492|NCT00727714|||COHORT||PROSPECTIVE|||||||
33731493|NCT05976919|||COHORT||PROSPECTIVE|||||||
33731494|NCT00482755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731495|NCT05880433|||COHORT||PROSPECTIVE|||||||
33731496|NCT02696096|NA|SINGLE_GROUP||OTHER||NONE||||||
33731497|NCT01428193|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812024|NCT00308308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731498|NCT00743171|||CASE_CONTROL||PROSPECTIVE|||||||
33731499|NCT01265446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731500|NCT05577039|||COHORT||RETROSPECTIVE|||||||
33731501|NCT06413199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731502|NCT00968591|NA|SINGLE_GROUP||OTHER||NONE||||||
33731503|NCT00969553|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731504|NCT02977234|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731505|NCT02129075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731506|NCT04940845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731507|NCT03106207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731508|NCT00324779||||TREATMENT||NONE||||||
33731509|NCT05582330|||OTHER||PROSPECTIVE|||||||
33731510|NCT00816101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731511|NCT01233375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731512|NCT03254134|||COHORT||RETROSPECTIVE|||||||
33731513|NCT03645629|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||"Perform skin prick test and atopy patch test of lyophilized foods (cow milk, egg white, egg yolk, wheat, soy and shrimp) stored at different time; 0, 3 and 6 months after preparation.~Then compare the results."|t|t|t|t
33731514|NCT01550419|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731515|NCT03078946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731516|NCT03221985|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731517|NCT05425420|NA|SINGLE_GROUP||OTHER||NONE||Subjects will be studied on one occasion in the Early Phase Research Unit at Duke University Medical Center for administration of drug, collection of blood samples, and measurements of drug effect. Study drug is intravenous methadone hydrochloride Plasma samples collections are obtained up to 96 hr after dosing. Dark-adapted pupil diameter is measured by infrared camera. Responses to thermal skin stimulation are recorded. Respiratory rate and end-tidal carbon dioxide concentrations are measured. Subject self-assessment of methadone effect is performed using verbal analog scales. Blood samples obtained during the study will be analyzed for plasma concentrations of methadone.||||
33731518|NCT04499768|||CASE_CONTROL||PROSPECTIVE|||||||
33731519|NCT05047991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731520|NCT04259190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731521|NCT05630352|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Phase 1 open label sequential dose escalation study||||
33812025|NCT01680432|RANDOMIZED|CROSSOVER||||NONE||||||
33812026|NCT01685476|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33812027|NCT06100354|||OTHER||OTHER|||||||
33812028|NCT02135315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessments of outcome is conducted by aninvestigator who did not participate in the randomization, protocol treatment or in-hospital clinical treatment of the patient.||f|f|t|f
33812029|NCT02110407|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33812030|NCT06037044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blinded to group allocation||f|f|f|t
33731522|NCT00223106|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33812031|NCT00787176|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33812032|NCT03675789|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812033|NCT00053118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812034|NCT05020236|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33812035|NCT05304676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812036|NCT06118008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812037|NCT03367416|||COHORT||CROSS_SECTIONAL|||||||
33812038|NCT03960645|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Study model 'single group' is selected as the Neonates group was only followed up but not treated.||||
33812039|NCT05050032|||COHORT||PROSPECTIVE|||||||
33731523|NCT05714488|NA|SINGLE_GROUP||TREATMENT||NONE||The Investigators are conducting a single-arm study with one-group posttest only design.Although this study is a non-randomized control trial, the one-arm design avoids selection and treatment diffusion (among other things). The comparator for the coil catheter is inferior and known to cause injury and infection. Therefore, researchers could not ethically randomly assign subjects to a control group that would receive the alternative device for the sake of comparison.||||
33731524|NCT00358527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731525|NCT06278675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731526|NCT06288516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Benralizumab (30mg) administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks||||
33731527|NCT05660694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group 1: Triamcinolone Group 2: Pentoxifylline|t|f|f|f
33812040|NCT01448928|||CASE_ONLY||PROSPECTIVE|||||||
33812041|NCT03136861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812042|NCT03015688|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812043|NCT02064686|NA|SINGLE_GROUP||SCREENING||SINGLE|||f|f|t|f
33731528|NCT03702478|||OTHER||CROSS_SECTIONAL|||||||
33731529|NCT03746821|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812044|NCT00439218|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731530|NCT04916327|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33731531|NCT03765736|||COHORT||PROSPECTIVE|||||||
33731532|NCT06122207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731533|NCT03270917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient, ward physician and research investigator are blinded to the treatment intervention. A large abdominal dressing will be used to cover the incision(s) until postoperative day 4. Obviously, the surgeon and anaesthesiology team can not be blinded.|Patients will be randomised to either the open or the laparoscopic treatment arm.|t|f|t|f
33731534|NCT05706363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"1. Standard: Gracillis graft~2. Intervention: Quadriceps graft"|f|f|f|t
33731535|NCT03189394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be aware that there are online and in-person aspects of the study as seen in the consent form, but will be randomized to a group and unaware of which arm they are in.|On completion of the baseline survey and testing, couples will be randomized to one of the three arms of the study (PRIDE, ePRIDE, or Men's Health). Couples will be randomized in blocks with the block size randomly permuted via a SAS computer program based on a pseudo-random number generator. Each arm of the intervention will begin on the same date and run for two weeks. Couples randomized to ePRIDE will be sent a link on the same day that PRIDE and Men's Health sessions are scheduled and will have two weeks to complete the program.|t|f|f|f
33731536|NCT02805335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731537|NCT02500069|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33731538|NCT06243133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731539|NCT03732066|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|The patients (but not their care providers), research personnel, and investigators will be unaware of their allocation. Study coordinators and research assistants conducting the assessments and statisticians will also be blinded.|Randomization will be performed using a centralized, computerized randomization program in a uniform 1:1 allocation ratio.|t|f|t|t
33731540|NCT04569045|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subject's two sides of nasolabial folds (NLF) were randomized to receive FACILLE® Light (contains Lidocaine) or FACILLE® (without Lidocaine).|t|f|t|t
33731541|NCT02164552|||||PROSPECTIVE|||||||
33731542|NCT06210529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731543|NCT01209897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731544|NCT02338752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731545|NCT04199429|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731546|NCT04347265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731547|NCT03424538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The single-arm, 5-week intervention is monitor every day on the effect of postural control on walking performance, balance and quality of life. The intervention team (n = 15) takes 25 training sessions for 5 weeks. Every move takes 60 minutes to continuously increase the load intensity of the X-box program. Before each intervention started, the patients perform a 10 minute warm-up and the drainage exercises are 15 minutes stretching exercises. The MStp group (n=14) participated in a 5-week physiotherapy course. The general treatment consisted of strengthening, stretching and walking correction. During the 5-week period, 25 patients attended training. One treatment takes 60 minutes. The control group (n = 14) did not receive physiotherapeutic treatment outside the medication.|f|f|t|f
33731548|NCT05360836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731549|NCT00004028||||TREATMENT||||||||
33731550|NCT02784301|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731551|NCT01627990|||COHORT||PROSPECTIVE|||||||
33731552|NCT04908254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Single Crossover||||
33731553|NCT03981224|||COHORT||RETROSPECTIVE|||||||
33731554|NCT03535220|||COHORT||PROSPECTIVE|||||||
33731555|NCT00019474||||TREATMENT||||||||
33731556|NCT00964392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731557|NCT03066765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731558|NCT03781076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention explicitly involves behavior change, so the participant cannot be blinded. The outcomes assessment involves objective monitors, and therefore can be considered blind.|Note that the intervention portion of the study involves only a subset of participants. The larger bulk (planned n=108) will undergo only initial observation of sleep and concussion symptoms. The investigators plan to have 24 (those still symptomatic at 4 weeks post-concussion who do not get recommended sleep) undergo a pilot trial of a sleep intervention.|f|f|f|t
33812045|NCT04677309|||COHORT||PROSPECTIVE|||||||
33812046|NCT04166084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812047|NCT02260726|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33812048|NCT06248255|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The test pads is to both forearms of the participants. Participants will be blinded to the test pad type. In total 4 pads are applied per participant. The test pads are either Dry (control), 50% or at 100% capacity. Dry and 50% pads are applied once, 100% capacity twice. This to allow one pad for recovery measurement and one for water profile measurement. Pad location will be randomized.||||
33812049|NCT05600439|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33812050|NCT03229291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812051|NCT04313699|||COHORT||PROSPECTIVE|||||||
33812052|NCT00983294|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33812053|NCT04823910|||OTHER||RETROSPECTIVE|||||||
33812054|NCT00813709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812055|NCT01924117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33812056|NCT03530644|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33812057|NCT03443206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33812058|NCT01282645|||COHORT||RETROSPECTIVE|||||||
33812059|NCT05702788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812060|NCT05116306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812061|NCT04896567|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Consecutive patients will be consented to obtain kidney biopsy material.||||
33812062|NCT04070937|||CASE_CONTROL||PROSPECTIVE|||||||
33812063|NCT02439892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812064|NCT01507142|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812065|NCT04433052|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812066|NCT02647411|||||RETROSPECTIVE|||||||
34118448|NCT06583733|RANDOMIZED|PARALLEL||TREATMENT||NONE|Usually, in physiotherapist studies it is very difficult to do blinding, because the patients can do some physical activity or exercise. In this trial, participants blinding will not be possible because the patients know what treatment they do, they should do the different exercises with app or with a HB information. Also, it is necessary to do face-to-face assessment for the physiotherapist.|120 individuals will be simple randomised to a control (recommendations for self- managing urinary symptoms) or intervention (KOKU Bladder) group. It is anticipated that the multicomponent intervention will last 12 weeks and consist of health education, pelvic floor muscle exercises and BC techniques but this may vary according to the co-creation process. Measures will be assessed at baseline and end of intervention.||||
33812067|NCT00100009||||TREATMENT||||||||
34118449|NCT06295679|||COHORT||PROSPECTIVE|||||||
34118450|NCT00288145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118451|NCT04850599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118452|NCT02503423|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118453|NCT05207098|||COHORT||PROSPECTIVE|||||||
34118454|NCT05200559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118455|NCT06441279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118456|NCT05075759|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
34118457|NCT05393700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34118458|NCT01501357|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34118459|NCT01258673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118460|NCT05624268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118461|NCT02059421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118462|NCT05189262|||COHORT||PROSPECTIVE|||||||
34118463|NCT06378957|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|place controlled, double-blind|Within-subjects design where participants are randomly assigned to dose conditions|t|f|f|t
34118464|NCT00499837|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118465|NCT05430061|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants were not aware of the treatment recieved|treatment (21 days of consumption of 30 g of raw corn starch) and control (21 days of consumption of maltodextrin)|t|f|f|f
34118466|NCT04487444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118467|NCT05422261|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118468|NCT00003287|RANDOMIZED|||TREATMENT||||||||
34118469|NCT02472249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118470|NCT04975997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118471|NCT00626496|||FAMILY_BASED||PROSPECTIVE|||||||
34118472|NCT02957630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118473|NCT06414291|RANDOMIZED|CROSSOVER||OTHER||SINGLE|non labeled bottles||t|f|f|f
34118474|NCT05419232|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34118475|NCT02835469|||CASE_ONLY||PROSPECTIVE|||||||
34118476|NCT03663855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118477|NCT02565329|||COHORT||RETROSPECTIVE|||||||
34118478|NCT02066649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118479|NCT03800550|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34118480|NCT03440008|||COHORT||OTHER|||||||
34118481|NCT01554098|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34118482|NCT04548973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118483|NCT00157118|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118484|NCT00078221|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34118485|NCT02971371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34118486|NCT04427293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118487|NCT03823989|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose-escalation study will begin with a dose of 1.25 mg/kg, to be followed by an increase to 1.5 mg/kg PROMITIL and a further increase 1.8 mg/kg in the absence of DLTs after two treatment cycles, with an interluding 10-fraction course of radiotherapy. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third confirmatory cohort (n=6) will be recruited and will be treated with the same dose as that administered to Cohort 2||||
34118488|NCT06127238|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment Escalation followed by Dose Expansion||||
34118489|NCT01110538|||CASE_ONLY||PROSPECTIVE|||||||
34118490|NCT05035160|||COHORT||PROSPECTIVE|||||||
34118491|NCT04870944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812068|NCT05344209|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|Randomized Phase II, Open-label, Multicenter Study||||
33838411|NCT06299735|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The anesthesia method applied for both patient groups is the same. However, the airway maintenance device used will vary between two different patient groups. Group BB: A bronchial blocker will be used for this patient group, Group DLT: A double-lumen tube will be used for this patient group. The parameters to be recorded for both patient groups include: preoperative smoking history, ARISCAT score, systolic arterial pressure, diastolic arterial pressure, saturation, pulse, and the duration of airway device insertion following anesthesia induction and intubation. For the assessment of postoperative pulmonary complications in both patient groups, arterial blood gas analysis, chest X-ray, respiratory sounds, and the patient's oxygen requirement will be monitored every 6 hours for 24 hours.|t|f|f|f
34118492|NCT04435691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118493|NCT00873275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118494|NCT06497309|||OTHER||PROSPECTIVE|||||||
34118495|NCT03759496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118496|NCT01465841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118497|NCT04632017|||CASE_CONTROL||PROSPECTIVE|||||||
34118498|NCT02875470|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118499|NCT04155398|||COHORT||PROSPECTIVE|||||||
34118500|NCT05565586|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118501|NCT04129307|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34118502|NCT05469919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118503|NCT06258005|||COHORT||PROSPECTIVE|||||||
34118504|NCT00165828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118505|NCT06284759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the study, the statistician was blinded using the blind technique.||f|f|f|t
34118506|NCT04001842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118507|NCT00776230|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34118508|NCT04812925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118509|NCT06631144|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A single-arm feasibility study to test a non-medical digital health intervention||||
34118510|NCT06059300|NA|SINGLE_GROUP||SCREENING||NONE||||||
34118511|NCT02025790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118512|NCT04092634|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial with two groups: THA with dual mobility components vs THA with single-bearing designs.||||
34118513|NCT05776524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118514|NCT05886036|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118515|NCT04949009|||COHORT||PROSPECTIVE|||||||
34118516|NCT03720366|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118517|NCT03346993|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34118518|NCT05071053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118519|NCT05236166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118520|NCT06715865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118521|NCT06400615|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A total of approximately 40 participants will be enrolled in the 2 arms:~20 subjects taking GLP-1+ AD109 20 subjects taking AD109 without any GLP-1 Therapy"||||
34118522|NCT06717919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118523|NCT06715683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118524|NCT04643015|||COHORT||PROSPECTIVE|||||||
34118525|NCT04447755|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34118526|NCT03834896|NA|SINGLE_GROUP||OTHER||NONE||||||
34118527|NCT05611242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Independent Investigator-initiated, designed and conducted non-industry study. A prospective, phase III, randomized, open-label, blinded-endpoint controlled trial (PROBE Design).|f|f|f|t
34118528|NCT06666231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34118529|NCT04874948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118530|NCT03279926|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118531|NCT05678426|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118532|NCT05373472|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118533|NCT06123481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be blinded as to group assignment. Both groups will undergo a core decompression. One group will undergo a bone marrow aspiration and the other group will undergo a sham procedure. This sham procedure consists of a small incision and placing a needle up to the iliac bone but with no bone penetration or aspiration.~The study radiologists will be blinded as to patient treatment assignment; images will be assigned the patient study number and date only."|A 1:1 randomized, parallel design with two treatment arms: 1) core decompression (percutaneous drilling) alone, or 2) core decompression augmented with autogenous bone marrow aspirate. Cluster randomization will be performed at each participating institution.|t|f|f|t
34118534|NCT03941483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118535|NCT04887532|NA|SINGLE_GROUP||OTHER||NONE||Single center, open, three-period, sequential design||||
34118536|NCT05400174|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118537|NCT05919940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34118538|NCT04077177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118539|NCT06719427|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118540|NCT06702059|||COHORT||PROSPECTIVE|||||||
34118541|NCT04174196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118542|NCT00287924||||TREATMENT||NONE||||||
34118543|NCT01313871|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118544|NCT04995172|||COHORT||PROSPECTIVE|||||||
34118545|NCT01668004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118546|NCT01128569|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118547|NCT00148356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118548|NCT01707537|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34118549|NCT02202564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118550|NCT04397380|||COHORT||PROSPECTIVE|||||||
34118551|NCT03323957|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118552|NCT02975960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118553|NCT01561911||||||NONE||||||
34118554|NCT05119010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be included sequentially in each arm from arm A to arm D. When the first inclusion arm A will be full with 15 patients who passed the screening, then next patients will be enrolled in arm B, then it will be the same process with arm C and last patients will be included in arm D.~However, the clinician has the option of including the patient in the standard diet arms with or without BHB (arm C or D), instead of the ketogenic diet arms (arm A or B), if the patient's organizational constraints do not allow for a strict ketogenic diet."||||
34118555|NCT06518915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118556|NCT04276805|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34118557|NCT01507025|||CASE_CONTROL||RETROSPECTIVE|||||||
34118558|NCT04972838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118559|NCT00491478|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34118560|NCT03064828|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34118561|NCT06400498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study will be performed as a single center, pragmatic, randomized clinical trial.||||
34118562|NCT06311799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34118563|NCT06546839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesiologist who performs postoperative pain evaluation and the patient will not know the group.|There are two models for this study. The first group is the SPSIPB group. The second one is the SAPB group.|t|f|f|t
34118564|NCT05547113|||CASE_CROSSOVER||PROSPECTIVE|||||||
34118565|NCT00642486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118566|NCT06527885|||OTHER||PROSPECTIVE|||||||
34118567|NCT03366337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118568|NCT02724371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118569|NCT06217302|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043675|NCT04516343|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study has four experiments. In experiment I, participants will be recruited to complete user-centric device testing. In experiment 2, participants will be recruited to complete a study to determine effectiveness of the device during clinical gait therapy. In experiment three, participants will be recruited to complete gait training with the RAAD under assistance.In experiment four, participants will be recruited to complete gait training with the RAAD under resistance either (1) always under therapist supervision, or (2) with one therapist-supervised and two parent- supervised sessions per week.||||
33731559|NCT05136729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Care providers and investigators are blinded to outcome assessment. The de-identified data will be provided to the biostatistician for analysis. Analyzed data will be submitted to the PI for analysis.|A single-blind randomized controlled trial (RCT) design with a wait-list control group|f|f|f|t
33731560|NCT01176552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812069|NCT04411771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be informed only that they will be randomised between two different types of extended assessments, both of which are more extensive than regular healthcare. They will receive no information about the nature of the extended assessments or about different treatments following the assessments to avoid nocebo effects.|"Patients are randomised between an extended assessment and a screening assessment. Patients in the screening assessment arm can only be treated with brief interventions whereas patients in the extended assessment arm are offered guided self-help if deemed appropriate and otherwise gets brief interventions.~Patients are thus randomized to two arms, however we have included four arms in order to be able to describe the primary and secondary analysis. The primary is performed on all patients treated with shCBT in the arm where an extended assessment is made, compared to patients in the screening assessment arm that is found suitable for shCBT (base on screening data), but treated with brief interventions."|t|f|f|f
33812070|NCT00208884|||||RETROSPECTIVE|||||||
33812071|NCT00006084||||TREATMENT||||||||
34043676|NCT06223594|||COHORT||RETROSPECTIVE|||||||
34043677|NCT00002772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118570|NCT05466032|||COHORT||PROSPECTIVE|||||||
34118571|NCT06315309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118572|NCT00001295|||COHORT||PROSPECTIVE|||||||
34118573|NCT04963777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The prebiotic and placebo are both white powders with similar sweet taste and dissolve in water.|Multi-centre placebo controlled double-blind randomized clinical trial|t|t|t|t
34118574|NCT05589987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the masking will be of the evaluator. The assessments will be passed by a study evaluator and scored by an evaluator external to the study to ensure blinding of the groups.|2 groups: experimental and control groups.|f|f|f|t
34118575|NCT04773665|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|This is an observer-blinded study. Both participants and the study center staff performing outcome measurement are blinded; vaccines will be administered by qualified unblinded study personnel who have no other role in the study.||t|f|t|t
34118576|NCT05811091|||COHORT||CROSS_SECTIONAL|||||||
34118577|NCT00593229|||CASE_ONLY||PROSPECTIVE|||||||
34118578|NCT03399448|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118579|NCT02189889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118580|NCT00516724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118581|NCT06663449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118582|NCT05282667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized clinical trial|f|t|f|t
34118583|NCT06229691|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118584|NCT05250037|||COHORT||PROSPECTIVE|||||||
34118585|NCT06716450|NA|SINGLE_GROUP||SCREENING||NONE||Screening for HIV and syphilis infection at point of care settings as a self-test in the presence of a trained, silent observer. The embedded study will involve participants interacting with a peer navigator following the self-test to discuss prevention and care options for HIV and syphilis.||||
34118586|NCT04551729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The members of the event adjudication committee will be blinded for treatment allocation. Moreover, the statistician who performs the primary analysis will be blinded for treatment allocation.||f|f|f|t
34118587|NCT06473051|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34118588|NCT06484413|||COHORT||PROSPECTIVE|||||||
34118589|NCT04464239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731561|NCT00610493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731562|NCT06030414|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33731563|NCT01384084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731564|NCT06293846|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33731565|NCT02674412|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33812072|NCT03823703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812073|NCT05120674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812074|NCT02602691|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812075|NCT05871905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812076|NCT00488969|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33812077|NCT05792852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838412|NCT00258752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33838413|NCT03248544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838414|NCT04829097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838415|NCT00234598|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|t|f|t
33838416|NCT04126252|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33838417|NCT02807883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838418|NCT03057847|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single arm, open-label, prospective cohort study||||
34118590|NCT05000983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118591|NCT05090826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118592|NCT03358693|||CASE_ONLY||PROSPECTIVE|||||||
34118593|NCT06194578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118594|NCT05642819|||OTHER||PROSPECTIVE|||||||
34118595|NCT00335829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118596|NCT06629389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled|t|t|t|t
34118597|NCT01310972|||COHORT||PROSPECTIVE|||||||
34043678|NCT01118195|||COHORT||CROSS_SECTIONAL|||||||
34043679|NCT02203721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34043680|NCT00751920|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043681|NCT05008432|||COHORT||PROSPECTIVE|||||||
34043682|NCT05984940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043683|NCT02374268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043684|NCT00771342|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34043685|NCT02888041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043686|NCT02143973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043687|NCT03095144|||COHORT||RETROSPECTIVE|||||||
34043688|NCT03670342|||CASE_ONLY||PROSPECTIVE|||||||
34043689|NCT03962777|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34043690|NCT01031511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043691|NCT06244953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34043692|NCT00444522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34043693|NCT02400996|||COHORT||PROSPECTIVE|||||||
34043694|NCT00072280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043695|NCT06577688|||OTHER||PROSPECTIVE|||||||
34043696|NCT02336568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043697|NCT00785070|||||PROSPECTIVE|||||||
34043698|NCT06252571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043699|NCT06480799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blinded study|Controlled intervention|t|f|f|f
34043700|NCT01417156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043701|NCT06010004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043702|NCT06524570|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase 1 trial, monocenter||||
34043703|NCT02928653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34043704|NCT01637428||CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34043705|NCT04681690|||OTHER||PROSPECTIVE|||||||
34043706|NCT02024802|||COHORT||PROSPECTIVE|||||||
34043707|NCT03417557|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This will be, prospective, single-masked, randomized, bilateral, cross-over, non-dispensing study comparing the test lens against the control lens.|t|f|f|f
34043708|NCT03221816|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34043709|NCT00760916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043710|NCT05631418|||COHORT||OTHER|||||||
34043711|NCT01470404|||COHORT||PROSPECTIVE|||||||
34043712|NCT03364400|NA|SEQUENTIAL||TREATMENT||NONE||||||
34043713|NCT05396040|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will enrol 440 classes (around 8800 students, teachers and other personnel) from 2 countries, randomised to Lolli-Methode or SoC. Samples from pools will be regularly collected and tested using PCR-based techniques.||||
34043714|NCT00232297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043715|NCT02187198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043716|NCT04756973|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043717|NCT01777906|||COHORT||PROSPECTIVE|||||||
34043718|NCT04676477|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043719|NCT02203435|||||RETROSPECTIVE|||||||
34043720|NCT04583774|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34043721|NCT04382781|||COHORT||RETROSPECTIVE|||||||
34043722|NCT05002608|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Intervention and Usual care||||
34043723|NCT01757535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043724|NCT01871129|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043725|NCT01139125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043726|NCT05136885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043727|NCT03783819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34043728|NCT01732640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043729|NCT06578325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043730|NCT03838289|||COHORT||PROSPECTIVE|||||||
34043731|NCT06174766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043732|NCT00003624||||SUPPORTIVE_CARE||||||||
34043733|NCT00679211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043734|NCT00415727|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
34043735|NCT02240940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043736|NCT02792062|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34043737|NCT03053791|NA|SINGLE_GROUP||TREATMENT||NONE||Single group of patients with spinal cord injury and spared fibers.||||
34043738|NCT03843489|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Hospital staff will place the pulse oximeter sensor(s) on one or both hand or feet of the neonate/infant and start the pulse oximeter data collection computer to record continuously. Each time an arterial CO-Oximeter sample is collected the data collection file will be marked by pressing the file marker key on the data collection computer. Information from each arterial CO-Oximeter sample will be written on the CRF. The arterial sample will always be measured in the reference co-oximeter. The sample may also be measured in the currently used AVOX 1000E.~This study will only use arterial blood samples that are taken in the normal course of care; the sample size of the blood draw will not be altered for this study (sample size will not be increased from the normal course of care for any portion of this study)."||||
34043739|NCT00502385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043740|NCT05099497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster randomized-control trial|f|f|t|f
34043741|NCT03902873|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||f|f|f|t
34043742|NCT05658770|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34043743|NCT02274012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043744|NCT03582163|||COHORT||RETROSPECTIVE|||||||
34043745|NCT02653144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34043746|NCT03476889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043747|NCT02420561|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34043748|NCT01736345|||COHORT||PROSPECTIVE|||||||
34043749|NCT00123838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043750|NCT06352112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043751|NCT01178749|||COHORT||PROSPECTIVE|||||||
34043752|NCT02000635|||OTHER||PROSPECTIVE|||||||
33838419|NCT02393742|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33838420|NCT02879786|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838421|NCT00487825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838422|NCT04988789|||COHORT||OTHER|||||||
33838423|NCT05789576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838424|NCT04765878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118598|NCT05926583|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118599|NCT02983240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118600|NCT04586270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118601|NCT06708598|||COHORT||PROSPECTIVE|||||||
34118602|NCT00285844|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118603|NCT06141928|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34118604|NCT06112301|||OTHER||RETROSPECTIVE|||||||
34118605|NCT06715319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118606|NCT03943901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118607|NCT03767881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118608|NCT04270643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118609|NCT04335071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and study personnel involved in patient enrolment, treatment, and follow-up will be masked to group assignment until the final report will be completed and a first interpretation of the results has been done.|A multicenter, double-blind, randomized controlled phase II trial|t|t|t|t
34118610|NCT06716606|NA|SINGLE_GROUP||TREATMENT||NONE|This will be a Open Label Extension study.|||||
34118611|NCT05444764|||COHORT||OTHER|||||||
34118612|NCT06148246|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34118613|NCT03745950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Olaparib vs placebo|t|t|t|f
34118614|NCT06488664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118615|NCT03351348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment assignments can be viewed only by the hospital pharmacists who are dispensing the study drugs.|A prospective, double-blind, randomized, placebo-controlled trial|t|f|t|f
34118616|NCT06717997|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118617|NCT03939585|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase I, pilot study designed to treat 10 participants with the donor NK/γδ T cell-enriched product on transplant Day 28.||||
34118618|NCT05542823|||COHORT||PROSPECTIVE|||||||
34118619|NCT01463527|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34118620|NCT06664801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118621|NCT04209556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118622|NCT05462912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Each participant will be evaluated at baseline, when the customized foot orthoses will be made, and the corresponding tests will be conducted||||
34118623|NCT03801512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34118624|NCT05124912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118625|NCT01752218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118626|NCT01061684|||COHORT||PROSPECTIVE|||||||
34118627|NCT06145919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118628|NCT03888560|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of either patient or clinician is not possible during allocation, treatment and data collection. However, blinding can be ensured during data processing, analysing stages and data collection for secondary outcomes on total volume of root resorption from CBCT, formation of black triangle and gingiva recession|The start date of lower labial segment alignment (T1) was recorded after insertion of the lower 0.014'' NiTi archwire. Participants were reviewed every 6 weeks and repeated MOPs were performed for the MOP group until the completion of lower labial segment alignment (LLS), which is when the LII scores one, indicating a minimum irregularity of ≤ 2 mm contact point displacement, based on the contact point displacements of the mandibular anterior segment, from canine to canine. At the end of alignment stage, the date for completion of alignment was recorded (T2), from which the overall alignment time (OAT) in days, required to complete LLS alignment, were calculated. Measurements were done clinically using an electric digital caliper. At this point, perforations were stopped. Gingival recession and black triangle were then recorded and measured. Patients were referred for CBCT images to evaluate for root resorption.|f|f|f|t
34118629|NCT02948439|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118630|NCT05819762|||COHORT||PROSPECTIVE|||||||
34118631|NCT05317637|||COHORT||CROSS_SECTIONAL|||||||
34118632|NCT05287750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118633|NCT02755961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118634|NCT06403449|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization was conducted by an independent research assistant, and the random sequence was concealed from the investigator until the process was completed.|||||
34118635|NCT05859113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118636|NCT05101720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118637|NCT05443529|||COHORT||CROSS_SECTIONAL|||||||
34118638|NCT05123326|||COHORT||PROSPECTIVE|||||||
34118639|NCT03619564|||COHORT||PROSPECTIVE|||||||
34118640|NCT06088173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118641|NCT04778592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo Controlled|t|f|t|f
33731566|NCT04928326|||CASE_ONLY||PROSPECTIVE|||||||
33731567|NCT00839293|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731568|NCT05289596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731569|NCT01942629|||COHORT||RETROSPECTIVE|||||||
33731570|NCT02021682|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731571|NCT01163994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731572|NCT03101904|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33731573|NCT04568252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomization : intervention group and control group|t|t|t|f
33731574|NCT00748956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33731575|NCT06452524|||OTHER||CROSS_SECTIONAL|||||||
33731576|NCT01826162|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33731577|NCT00431171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731578|NCT01505192|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33812078|NCT05990556|NA|SINGLE_GROUP||TREATMENT||NONE|Blinding and unblinding This is a real-world study that intends to include three patients as case studies without blinding prior to intervention and therefore does not involve blinding.|"Interventional single-arm studies, no grouping.~1 Randomize groupings 1.1 Method for generating random sequence assignments This study is a real-world study, it is planned to include 20 patients as a case, there is no need for random sequence and blinded allocation before intervention, the patient's condition, experimental purpose, experimental method and possible risks are informed before surgery, and the patient chooses whether to undergo preoperative interventional surgery to block bilateral meningeal blood supply.~1.2 Randomly assigned hiding This is a real-world study that intends to include three patients as individual cases without random sequencing prior to intervention and therefore does not involve allocation concealment."||||
34118642|NCT06519565|NA|SINGLE_GROUP||TREATMENT||NONE||PRG-1801 Injection||||
33812079|NCT02873897|RANDOMIZED|CROSSOVER||||NONE||||||
34118643|NCT03916809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Subjects will not know whether the device that they are given has a functioning valve spring or whether the valve spring has been removed.~Researchers assessing the outcomes will not know the arm to which the subject was randomized."|Subjects will be randomized to an 8-week program of either Active Expiratory Muscle Strength Training (EMST) + Standard Care or Sham EMST + Standard Care in order to examine the impact of EMST on swallowing function.|t|f|f|t
33812080|NCT03311997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Personell assessing functional performance of patients are blinded.||f|f|f|t
33812081|NCT00455715|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33812082|NCT06030037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812083|NCT03406390|||CASE_CONTROL||PROSPECTIVE|||||||
33812084|NCT03948958|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34118644|NCT05497375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118645|NCT05112614|||COHORT||PROSPECTIVE|||||||
34118646|NCT06180603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118647|NCT05429619|||COHORT||PROSPECTIVE|||||||
34118648|NCT02455869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34118649|NCT06677307|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34118650|NCT03522064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118651|NCT05700825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34118652|NCT05843461|||COHORT||PROSPECTIVE|||||||
34118653|NCT06715774|||OTHER||RETROSPECTIVE|||||||
34118654|NCT05631249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118655|NCT04672135|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"An independent statistician will provide the randomization list to an unblinded person at the site. The unblinded person prepares the medication for the subjects. The ready medication is handed over to the blinded investigator and the investigator will dose the blinded subjects.~Randomization numbers will be kept secret until data base lock. After data base lock the results will be unblinded for final analysis."|A Single Ascending Dose study with 6 Cohorts with 8 young male subjects each and 1 cohort with 4 male and 4 female subjects A Multiple Ascending Dose MAD study with 2 Cohorts: (Cohort 1: 10 young male subjects, Cohort 2: 6 elderly male and 6 elderly female (not of CBP) subjects.|t|f|t|f
34118656|NCT06235502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are anonymised with a participant identification|Randomized Controlled Trial|t|f|f|f
34118657|NCT00581516|||COHORT||PROSPECTIVE|||||||
34118658|NCT04038073|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118659|NCT05309954|||COHORT||PROSPECTIVE|||||||
34118660|NCT05164315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118661|NCT05212792|||CASE_CONTROL||PROSPECTIVE|||||||
34118662|NCT00663611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118663|NCT03192098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be blinded for dilation strategy.|randomized controlled patient groups|t|f|f|f
34118664|NCT06217081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118665|NCT05980598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118666|NCT03005392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118667|NCT01426802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118668|NCT05393245|||COHORT||RETROSPECTIVE|||||||
34118669|NCT06528626|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34118670|NCT02805790|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34118671|NCT05761171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118672|NCT01059747|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812085|NCT00831194|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33812086|NCT06511180|||OTHER||OTHER|||||||
33812087|NCT05953025|||CASE_CONTROL||PROSPECTIVE|||||||
33812088|NCT02135666|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812089|NCT05328817|RANDOMIZED|PARALLEL||TREATMENT||NONE||In order to maintain balanced groups, block randomization will be used. Pregnant women will be randomized in blocks of 6 with a total number of blocks to be 40. This will be conducted using STATA16 software, which will generate random permutations of sequential IDs of eligible study participants and their assignment to the treatment arms. This will be transferred to the REDCap in which a database will be created to facilitate random assignment during recruitment while maintaining concealment of randomization.||||
33812090|NCT02192632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34118673|NCT01282541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118674|NCT00800735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118675|NCT01430390|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I trial designed to identify tolerable and clinically active doses of allogeneic Epstein - Barr virus specific cytotoxic T lymphocytes (EBV-CTLs) genetically modified to target the B-cell antigen CD19 when administered to patients with CD19+||||
34118676|NCT00002219||||TREATMENT||||||||
34118677|NCT01746524|||COHORT||PROSPECTIVE|||||||
34118678|NCT04885101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator won't be aware where participants will be allocated.|The study will be conducted men diagnosed with Erectile Dysfunction alocated in three groups: Non-Ablative Radiofrequency Therapy (NARFT), Low Intensity Shockwave Therapy (LISWT) or Sham.|f|f|t|f
34118679|NCT06424223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118680|NCT06680921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149800|NCT00399100|||CASE_CONTROL||PROSPECTIVE|||||||
33812091|NCT00000532|RANDOMIZED|||PREVENTION||||||||
33812092|NCT05455632|||COHORT||RETROSPECTIVE|||||||
33812093|NCT01737398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812094|NCT01491815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118681|NCT01554748|NA|SINGLE_GROUP||TREATMENT||NONE||Implantation of TMC total joint arthroplasty in a patient cohort||||
34118682|NCT06047743|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33812095|NCT05260437|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34118683|NCT06717204|||COHORT||OTHER|||||||
33812096|NCT01450774|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33812097|NCT02330900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118684|NCT03291756|||COHORT||PROSPECTIVE|||||||
33812098|NCT02813304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812099|NCT02544191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812100|NCT02741557|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812101|NCT04867044|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812102|NCT02204202|||COHORT||CROSS_SECTIONAL|||||||
34118685|NCT03181191|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812103|NCT05557695|||COHORT||RETROSPECTIVE|||||||
33812104|NCT01019967|||||PROSPECTIVE|||||||
33812105|NCT04139486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label study with blinded evaluation (PROBE)||f|f|f|t
33812106|NCT05177432|NA|SEQUENTIAL||TREATMENT||NONE||"This is a single-centre study based on the Simon 2-stage optimal design: 9 patients will be enrolled initially. The study will be expanded to a further 14 patients (Stage II) if 2 or more patients enrolled in stage I of the study achieve an objective response (of \>35% ) with the chemotherapeutic agent selected by the drug screen assay. Accounting for 10% attrition rate, a total of 26 evaluable patients will be included in both stages of study.~QPOP-based drug screen assay will be used as a clinical decision platform to identify patient-specific drug combinations across a range of breast cancer patients."||||
33812107|NCT05727111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary aim, the FMA, will be videotaped and the scoring will be done by a blind evaluator. In secondary outcomes, the WMFT will be blind scored.|The trial will be a single-blind, randomized, monocentric controlled trial. The trial start with a division in two arms HABIT-ILE therapy classic or at home then half of each group will benefit from a HABIT-ILE follow-up while the other will have usual care. That means that participants will be divided into four groups.|t|f|f|t
33812108|NCT06192459|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33812109|NCT02959411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118686|NCT03848455|||CASE_CONTROL||RETROSPECTIVE|||||||
34118687|NCT06230965|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34118688|NCT04548180|||COHORT||CROSS_SECTIONAL|||||||
34118689|NCT06695117|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The study will be performed in a modified double-blind fashion.~Modified double-blind:~* Investigator, participants, and laboratory personnel will be blinded~* Clinical site staff preparing/administering the study vaccines will be unblinded~* Sponsor study staff will be blinded, except for dedicated staff involved in interim analysis, who will be unblinded at the time of interim analysis, and for dedicated staff involved in assessing criteria for safety surveillance"||t|t|t|t
34118690|NCT06706622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118691|NCT01932684|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34118692|NCT04682665|||COHORT||PROSPECTIVE|||||||
34118693|NCT06450106|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34118694|NCT05202262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Open Label for Symbicort TBH||t|t|t|t
34118695|NCT06540170|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-group pre-intervention and post-intervention comparison||||
34118696|NCT06441006|RANDOMIZED|PARALLEL||TREATMENT||NONE|PRISM-TB will not include any placebo. Participants, providers, and pharmacists will be aware of strategy and treatment allocation. Masking of participants to treatment allocation would obscure differences in durations and affect behavior in shortened regimens that would not be reflective of future use and is therefore not included as a feature of this trial.|||||
33812110|NCT06065930|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812111|NCT02170207|||COHORT||PROSPECTIVE|||||||
33812112|NCT01127737|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33731579|NCT05483491|NA|SEQUENTIAL||TREATMENT||NONE||This is a phase I clinical trial that will determine the maximum tolerated dose and clinical tumor responses for escalating doses of KK-LC-1 TCR-T cells.||||
33731580|NCT01488643|||CASE_CONTROL||PROSPECTIVE|||||||
33731581|NCT02577237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731582|NCT03086174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731583|NCT02084771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731584|NCT05487729|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731585|NCT02139566|RANDOMIZED|PARALLEL||||NONE||||||
33731586|NCT03340129|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomised trial.||||
33731587|NCT03869593|||CASE_ONLY||PROSPECTIVE|||||||
33731588|NCT01077960|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731589|NCT00274599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731590|NCT01239368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731591|NCT01768611|||CASE_ONLY||CROSS_SECTIONAL|||||||
33731592|NCT00989833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731593|NCT01925846|||COHORT||RETROSPECTIVE|||||||
33731594|NCT03978975|RANDOMIZED|CROSSOVER||PREVENTION||NONE||participants may receive different interventions sequentially during the protocol||||
33731595|NCT03878134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Enrolled patients may be scanned on the investigational Photon Counting CT scanner. Conventional images also obtained for comparison using the same scanner at the same time.||||
33812113|NCT04927468|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812114|NCT01690000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838425|NCT03273842|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838426|NCT06276010|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838427|NCT00241488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838428|NCT01722279|||CASE_ONLY||CROSS_SECTIONAL|||||||
33838429|NCT00903500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118697|NCT05815914|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34118698|NCT03477604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118699|NCT06157021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding to the child participants and legal guardian of each participating child, inter examiner and statistician. The operator and the child were blinded to the intervention from the beginning till finishing the procedure of caries removal and access cavity. Blinding cannot be done during root canal instrumentation because of visual differences between manual and rotary files.|Randomized controlled parallel double blinded study|f|f|t|t
34118700|NCT02410772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118701|NCT04982952|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization into one of 2 groups will be stratified by recruiter and a binary nicotine dependency code||||
34118702|NCT06463184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118703|NCT05666830|||CASE_ONLY||PROSPECTIVE|||||||
34118704|NCT02443935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118705|NCT05807126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118706|NCT05070858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118707|NCT05982561|||COHORT||PROSPECTIVE|||||||
34118708|NCT01282073|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118709|NCT04542122|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34118710|NCT02224170|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118711|NCT00523627|||COHORT||PROSPECTIVE|||||||
34118712|NCT01697111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118713|NCT06292819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118714|NCT01346176|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34118715|NCT05359237|||COHORT||PROSPECTIVE|||||||
34118716|NCT01171911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118717|NCT03885700|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118718|NCT01820000|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118719|NCT05522686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Clinical Trial||||
34118720|NCT06053164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blind investigation, investigator and assessors will be blinded to the condition/treatment arm|Single-blind open-label randomized control|f|f|t|t
34118721|NCT05746988|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34118722|NCT02205320|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118723|NCT02750930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118724|NCT05580614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118725|NCT05285891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34118726|NCT04790786|RANDOMIZED|PARALLEL||OTHER||NONE||The study is an adaptive platform and as such is intended to study multiple interventions simultaneously, does not have a defined sample size, and is intended to move forward in perpetual fashion with domains and interventions being added and subtracted over time. For example, interventions will be added and subtracted depending on federal decisions regarding monoclonal antibodies, such as granting or revoking authorization for use.||||
34118727|NCT04998851|NA|SINGLE_GROUP||OTHER||NONE||||||
34118728|NCT06137365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only investigator-level study personnel will have access to group assignment.|Placebo and active cannabis groups|t|f|f|t
34118729|NCT04803006|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118730|NCT05961098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118731|NCT04559893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-arm randomized control trial (RCT) where participants are randomly assigned to intervention or control.|f|f|f|t
34118732|NCT04234828|||OTHER||PROSPECTIVE|||||||
34118733|NCT06663501|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single-site exploratory, unrandomized, the first arm is persons with stroke, the second arm is uninjured controls. Both Cohorts receive the same intervention||||
34118734|NCT05990244|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731596|NCT06108817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||randomized controlled study||||
33731597|NCT05138939|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded by the type of beverages (control, red wine1, and red wine2).|Three-way crossover randomized controlled trial|t|f|f|f
33731598|NCT04233281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33731599|NCT02089061|NON_RANDOMIZED|PARALLEL||||NONE||||||
33731600|NCT01494610|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33731601|NCT01416168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731602|NCT03658083|||CASE_CONTROL||PROSPECTIVE|||||||
33731603|NCT01556542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731604|NCT04943965|||COHORT||PROSPECTIVE|||||||
33731605|NCT05300165|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731606|NCT04212468|||COHORT||PROSPECTIVE|||||||
33731607|NCT01400867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731608|NCT04259112|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The patients, surgeons and the ones who collect data will be masked.||t|t|f|t
33731609|NCT01551342|||COHORT||PROSPECTIVE|||||||
33731610|NCT01497210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731611|NCT06408467|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731612|NCT00882791|||COHORT||PROSPECTIVE|||||||
33731613|NCT03548766|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838430|NCT02389764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838431|NCT02003677|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118735|NCT00384943|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118736|NCT03928925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118737|NCT05127941|||COHORT||PROSPECTIVE|||||||
34118738|NCT00185094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118739|NCT04095234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-arm parallel (Acupuncture vs. Massage) randomized controlled trial|f|f|f|t
34118740|NCT04445909|||COHORT||CROSS_SECTIONAL|||||||
34118741|NCT00003616||||TREATMENT||||||||
34118742|NCT05373485|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118743|NCT05270876|NA|SINGLE_GROUP||OTHER||NONE|Participants were masked to which fitting method they had at any point in the study|Interrupted time series||||
34043753|NCT06343467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients underwent the standard surgical consent, however the specific plate vendor that was used, was not specified by the physician.|Surgeons alternated between using generic implants and conventional implants in their distal radius fracture patients over the course of six months.|t|f|f|f
34043754|NCT04411901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043755|NCT02695667|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34043756|NCT02434146|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838432|NCT06198972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043757|NCT03632928|||COHORT||PROSPECTIVE|||||||
34043758|NCT05841680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043759|NCT01249053|||||RETROSPECTIVE|||||||
34043760|NCT03656068|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043761|NCT06362538|NA|SEQUENTIAL||PREVENTION||NONE||||||
34043762|NCT02549859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043763|NCT01553422|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34043764|NCT01580670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043765|NCT02906501|||CASE_CONTROL||PROSPECTIVE|||||||
34043766|NCT05389774|||COHORT||PROSPECTIVE|||||||
34043767|NCT00766636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043768|NCT04014205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043769|NCT03446027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043770|NCT02209051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043771|NCT03068195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043772|NCT05893940|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34043773|NCT04962412|||COHORT||PROSPECTIVE|||||||
34043774|NCT04769518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label study - patients and staff are aware of whether treatment is provided by the ARRC model or standard recovery room then ward care.|Patients are allocated to ARRC or standard care. Allocation is based on bed availability, which has not produced group bias in the past. Matching techniques will be used if needed.||||
34043775|NCT00833495|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34043776|NCT06575127|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II single arm study||||
34043777|NCT00247429|||CASE_ONLY||PROSPECTIVE|||||||
34043778|NCT00572936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043779|NCT05779683|||CASE_CONTROL||PROSPECTIVE|||||||
34043780|NCT01906853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34043781|NCT01470274|||COHORT||PROSPECTIVE|||||||
34043782|NCT00179075|||CASE_ONLY||PROSPECTIVE|||||||
34043783|NCT06134284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043784|NCT02017431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34043785|NCT04603066|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Prospective, randomized, double blind, crossover study|t|f|t|t
34043786|NCT05677464|||OTHER||PROSPECTIVE|||||||
34043787|NCT05884385|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Surgeons will perform 3 surgical procedures under 3 randomized conditions: no intervention, simulated exercises, and mental visualization. EMG and EEG monitoring will be performed to collect data at predefined POIs. Condition 1 involves no changes to their regular robotic procedure, while Condition 2 has surgeons perform simulated tasks before surgery. In Condition 3, surgeons undergo mental training scripts before performing surgery, which involves guided mental visualization. The study aims to investigate the effects of these conditions on surgical performance.||||
34043788|NCT02708628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043789|NCT03066648|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043790|NCT03645395|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043791|NCT00546377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043792|NCT04342611|||COHORT||PROSPECTIVE|||||||
34043793|NCT06574594|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34043794|NCT04941651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043795|NCT03002948|||COHORT||CROSS_SECTIONAL|||||||
34043796|NCT01616238|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043797|NCT03000998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34043798|NCT00795002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043799|NCT00751504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043800|NCT02420080|||CASE_CONTROL||RETROSPECTIVE|||||||
34043801|NCT05500612|||CASE_ONLY||PROSPECTIVE|||||||
34043802|NCT03773250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043803|NCT04399135|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All patients who need root canal treatment would be screened to determine the periodontal condition for possible involvement in this study. They would be grouped into two groups, normal and periodontitis Group.||||
34043804|NCT05539456|||COHORT||PROSPECTIVE|||||||
34043805|NCT05162417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043806|NCT03627663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043807|NCT00053196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043808|NCT03903991|||COHORT||PROSPECTIVE|||||||
34043809|NCT02436096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043810|NCT03324386|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||TRIPLE|Individual Orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);|VLE Group use the technology in a virtual learning environment(VLE) for distance learning (DL), HYBRID Group use the educational technology in the E-blended mode leraning, A Group he use of embracement strategy (relational strategies).|t|t|t|f
34043811|NCT04925882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043812|NCT05443880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043813|NCT00006339||||TREATMENT||||||||
34043814|NCT04974996|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043815|NCT02631122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34043816|NCT05143346|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043817|NCT00730860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043818|NCT06577350|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118744|NCT00427193|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|all lab based assays were masked due to de-identified person and time interval measured. All physical measures were masked to intervention group status.||f|f|f|t
34118745|NCT03612024|||COHORT||PROSPECTIVE|||||||
34118746|NCT05460182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two examiners, blinded with respect to the surgical procedures, assessed all the clinical and aesthetic outcomes of treatments.||f|f|f|t
34118747|NCT03889652|||CASE_CONTROL||PROSPECTIVE|||||||
34118748|NCT05812885|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover Assignment|t|f|f|t
34118749|NCT01166035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118750|NCT06112015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118751|NCT00300014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118752|NCT00512564|||COHORT||PROSPECTIVE|||||||
34118753|NCT05339945|||COHORT||PROSPECTIVE|||||||
34118754|NCT05796687|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34118755|NCT02914938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a three-arm study of ME-401 alone, of ME-401 in combination with rituximab, and of ME-401 in combination with zanubrutinib in subjects with relapsed/refractory CLL/SLL or B cell NHL. The 3 arms of the study will be conducted in parallel, with subject allocation to ME 401 alone, ME-401 plus rituximab, or ME 401 plus zanubrutinib based on disease type and availability of an open enrollment slot.||||
34118756|NCT05140343|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118757|NCT02782962|||COHORT||PROSPECTIVE|||||||
34118758|NCT02847897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118759|NCT00145626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118760|NCT00805051|||COHORT||PROSPECTIVE|||||||
34118761|NCT06684704|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34118762|NCT01141530|||CASE_ONLY||RETROSPECTIVE|||||||
34118763|NCT04483778|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118764|NCT04660734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Clinical and radiographic results at the last follow-up were evaluated by one surgeon who did not participate in the surgical management of the patients|Two techniques for treatment of posterior structure of acetabular fracture|t|f|f|t
34118765|NCT03473743|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118766|NCT04070209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118767|NCT05551468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34118768|NCT02384421|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34118769|NCT06117059|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm Phase II study of 3 fractions of prostate SBRT||||
34118770|NCT02638909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118771|NCT04189445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of independent 3 cohorts (Cohorts A, B and C) and there is no difference in the treatment regimen between the cohorts||||
34118772|NCT02117102|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118773|NCT05785208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118774|NCT06206863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34118775|NCT06719362|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118776|NCT01402921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118777|NCT01276574|||COHORT||PROSPECTIVE|||||||
34118778|NCT02219152|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34118779|NCT05311397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This 2-part, open-label, PhaseⅠstudy will administer A166 by IV infusion once every 3 weeks. Sequential dose-escalation cohorts are planned using a 3+3 design. An expansion study will be conducted based on the RS2D with comprehensive analysis of safety, tolerability, and pharmacokinetic data in the first phase||||
34118780|NCT06447909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118781|NCT04376593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118782|NCT04089514|||COHORT||PROSPECTIVE|||||||
34118783|NCT00028340|||COHORT||PROSPECTIVE|||||||
34118784|NCT06715384|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|Randomization will be concealed. The patient will be blind to the assigned groups. The endoscopist will be blind to the allocated groups until the polyp is identified.|prospective, multi-endoscopist, single-center or multi- centers|t|f|f|f
34118785|NCT01959529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731614|NCT04198727|NA|SINGLE_GROUP||OTHER||NONE||This is an open-label multi-center prospective cohort study to compare the response of patients with high phenotype to patients with normal phenotype. The analyzes performed will focus on clinical and biological criteria.||||
33731615|NCT04979585|NA|SINGLE_GROUP||TREATMENT||NONE||camrelizumab combined with anlotinib and nab-paclitaxel||||
33731616|NCT04603729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731617|NCT02262351|NA|SINGLE_GROUP||SCREENING||NONE||||||
33731618|NCT06007014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Metformin and insulin glargine combined with Chiglitazar sodium tablets 48mg/ day group；Metformin and insulin glargine combined with placebo group.|t|t|t|t
33731619|NCT04027218|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|For hemolysis analysis in blood samples, the responsible of analysis by spectrophotometry is blinded from the intervention or comparator used for blood sample performed, using two different departments: one for interventions and comparator applications and other for spectrophotometer.|Experimental, randomized and controlled study with the usual technique of inserting a venipuncture catheter until now. Incomplete clinical trial, blind to third parties, in healthy volunteers, which consists of three arms, in which they are intervened and the comparator is applied.|f|f|t|f
33731620|NCT00330291|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731621|NCT03724201|||OTHER||CROSS_SECTIONAL|||||||
33731622|NCT05845788|||CASE_ONLY||PROSPECTIVE|||||||
33731623|NCT01791361|||OTHER||RETROSPECTIVE|||||||
33731624|NCT03254901|||OTHER||CROSS_SECTIONAL|||||||
33731625|NCT05425290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731626|NCT01782651|||COHORT||RETROSPECTIVE|||||||
33731627|NCT06492811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731628|NCT06323642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients and their parents/attendants will be kept blind to the fact that they are receiving either probiotic or placebo|randomized control trial|t|f|f|f
33731629|NCT06054048|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled non-inferiority trial||||
34118786|NCT05759780|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118787|NCT05069649|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118788|NCT06719258|||COHORT||RETROSPECTIVE|||||||
34118789|NCT04319757|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118790|NCT03313973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34118791|NCT04966637|||COHORT||RETROSPECTIVE|||||||
34118792|NCT06622044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118793|NCT06477783|||COHORT||PROSPECTIVE|||||||
34118794|NCT06068504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118795|NCT05354024|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|An electronic central randomization system will be used to designate the investigational product (IP) that each participant must receive. A team study non-blind, qualified member (nurse/pharmacist) will obtain the corresponding randomization, will separate the respective IP, will blind the product and deliver it to blind staff. The product will be in a syringe that is in a blister labeled with the sponsor's name, IP code, administration route, IP dose and expiration date. The study non-blind staff will not have contact with the participants, will not have access to identification data or any other involvement with the study, besides randomizing the participant, separating the syringe containing active control or vaccine, checking if the information on the blister label corresponds the information on the cartridge label and the syringe is labeled with the clinical trial code, ID, corresponding visit and investigator's name.|Parallel Assignment in Phase II (1:1), that aims to evaluate safety and immunogenicity in 400 subjects. Phase III (3:1), that aims to evaluate safety in total population (n=4.000, 3000 in arm of NDV-HXP-S 10μg, 1000 subjects per each consecutive batch, and 1000 subjects in the active control arm), immunogenicity in a subcohort (n=1000) and consistency of three consecutive batches in part of the subcohort of immunogenicity correspondent only to the NDV-HXP-S 10μg arms (n=750).|t|t|t|f
34118796|NCT06419452|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118797|NCT05927311|||CASE_ONLY||PROSPECTIVE|||||||
34118798|NCT03705234|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118799|NCT04490798|||COHORT||RETROSPECTIVE|||||||
34118800|NCT06010680|NA|SINGLE_GROUP||OTHER||NONE||Single oral dose of \[14C\]SHR2554||||
34118801|NCT05420948|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118802|NCT06656637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118803|NCT04224701|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34118804|NCT05207813|||COHORT||PROSPECTIVE|||||||
34118805|NCT03060902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118806|NCT06348095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118807|NCT04804527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a pragmatic, randomized, controlled, unblinded feasibility trial with two parallel groups: an intervention group receiving intensified acute in-hospital physiotherapy (n=40) and a control group receiving usual care acute in-hospital physiotherapy (n=20).||||
34118808|NCT05187234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118809|NCT04715126|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34118810|NCT01497756|NA|SINGLE_GROUP||OTHER||NONE||||||
34118811|NCT03979300|||COHORT||PROSPECTIVE|||||||
34118812|NCT00657267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118813|NCT05714202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118814|NCT03401320|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Phase I, open label, sequential, single ascending dose||||
34118815|NCT03261830|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Randomization envelops will be created. Attending surgeons/Investigators will be blinded. Participant will be blinded.|Patients will be randomized in that one group receives one dose of pre-operative antibiotics or one that does not.|t|f|t|t
34118816|NCT03836443|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."||||
34118817|NCT00020254|RANDOMIZED|||TREATMENT||||||||
34118818|NCT03814135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Duble-blind and double-dummy||t|f|t|f
34118819|NCT06392308|||COHORT||PROSPECTIVE|||||||
34118820|NCT06101173|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34118821|NCT05028530|||CASE_ONLY||CROSS_SECTIONAL|||||||
34118822|NCT00660218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118823|NCT05030467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118824|NCT03292237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||multicentre, prospective, parallel, randomised controlled trial||||
34118825|NCT06716359|||OTHER||PROSPECTIVE|||||||
34118826|NCT05961371|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and outcome assessors will be masked to the group allocation of participants.|Participants will be randomized 1:1 to the exercise or waitlist control group.|f|f|t|t
34118827|NCT04576494|NA|SINGLE_GROUP||OTHER||NONE||||||
34118828|NCT06714916|||COHORT||PROSPECTIVE|||||||
34118829|NCT06717815|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118830|NCT05876923|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34118831|NCT04770493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118832|NCT06410521|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design will comprise three evaluation moments: initial evaluation (M0 - 0 week), mid-term evaluation (M1 - 12 weeks after) and final evaluation (M2 - 24 weeks after). After M0 patients will be randomised into the intervention arm (experimental group) and comparator arm (usual care group). The intervention arm will perform supervised exercise (cardiovascular and resistance training) three times a week for 12 weeks and the comparator arm will receive information regarding standard lifestyle modification but without specific recommendations about the exercise programme. After the 12 weeks, both groups will transit to the intervention arm (home-based exercise) where they will perform regular walking at least three times week for 12 weeks.||||
34118833|NCT06150157|NA|SEQUENTIAL||TREATMENT||NONE||||||
33731630|NCT06306443|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label randomized controlled trial||||
33731631|NCT00949624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838433|NCT05778942|||CASE_ONLY||PROSPECTIVE|||||||
33838434|NCT01721889|||CASE_ONLY||PROSPECTIVE|||||||
33838435|NCT03402698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33838436|NCT02191306|||COHORT||PROSPECTIVE|||||||
33731632|NCT03077503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After written informed consents were obtained, all participant was blinded from the study drug. The study drugs (dexmedetomidine and fentanyl) were prepared by anesthetist nurse who not involved in the study. Dexmedetomidine was labeled with group A whereas fentanyl was labeled with group B. The study drug was administrated by the blinded anesthiologist. Blood pressure, mean arterial pressure, and heart rate were recorded by same blinded anesthesiologist|A randomized, double-blinded controlled trial was conducted from September 2015 to September 2016 in Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Thailand. Sixty patients who underwent craniotomy with insertion of skull pin were randomly allocated into group A and B. After patients entered the operative room, blood pressure and heart rate were measured (T1) then repeated measurement again (T2) when started induction, intubation and infusion dexmedetomidine 1 µg/kg over 10 min infusion in group A whereas group B received normal saline. At 3 minutes before skull pin insertion (T3), patient in group B received a single bolus of fentanyl 1 µg/kg whereas group A received normal saline. Then hemodynamic responses were recorded and repeated again at one minute before skull pin insertion (T4). Blood pressure and heart rate were observed at the time of skull pin insertion (T5) then repeated every 1 minutes after skull pin application until 5 minutes (T6 - T10).|t|t|f|t
33731633|NCT00980551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731634|NCT02673775|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33731635|NCT03707769|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731636|NCT02738684|||CASE_ONLY||PROSPECTIVE|||||||
33731637|NCT04218058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731638|NCT04070300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731639|NCT01339975|||COHORT||PROSPECTIVE|||||||
33731640|NCT05097131|||COHORT||PROSPECTIVE|||||||
33731641|NCT02462577|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118834|NCT03864068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo Group; Active Treatment with Inositol 1gm/bid; Active Treatment with Inositol 2gm/bid; Active Treatment with Inositol 3gm/ bid|t|t|t|t
34118835|NCT00624845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118836|NCT00859833|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34118837|NCT06024291|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|As the randomisation will take place after the baseline examination, participants, exercise scientists, and physicians supervising the intervention will be blinded for group allocation at baseline but not post-intervention.||t|f|t|f
34118838|NCT05658575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118839|NCT01127620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118840|NCT04240054|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118841|NCT03593148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118842|NCT05952050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34118843|NCT03582579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118844|NCT02182518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34118845|NCT04174352|NA|SINGLE_GROUP||TREATMENT||NONE||a single-arm, open-label, pilot study of escalating doses of tamoxifen||||
34118846|NCT01344343|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34118847|NCT04882098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118848|NCT01045369|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118849|NCT06281743|||COHORT||PROSPECTIVE|||||||
34118850|NCT01957865|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34118851|NCT05941286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34118852|NCT02327767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118853|NCT05175014|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Vaccinators will not be blinded, but participants will not know vaccine dosage allocation. Laboratory staff (outcome assessors) will be blinded to their group allocation.|A Phase IV, 3-arm, observer-blinded, cluster-randomized controlled trial|t|f|t|t
34118854|NCT01071460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118855|NCT03811470|||COHORT||PROSPECTIVE|||||||
34118856|NCT05757869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118857|NCT04750161|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118858|NCT04999735|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118859|NCT00953706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731642|NCT02969928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731643|NCT02410720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731644|NCT03393793|||COHORT||RETROSPECTIVE|||||||
33731645|NCT01109082|||COHORT||PROSPECTIVE|||||||
33812115|NCT05543005|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The study designs a two-arm, double blind randomized control trial (RCT) experiment in terms of a block randomization for allocating participants in experimental and control groups respectively. In the experimental group maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time, and totally three times a day over a 14-days intervention duration. Meanwhile a standard care treats premature infants in the control group.|t|f|t|f
33812116|NCT06462248|NA|SINGLE_GROUP||TREATMENT||NONE||single arm prospective study||||
33812117|NCT03971344|||COHORT||RETROSPECTIVE|||||||
33812118|NCT04919668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33812119|NCT02393456|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33812120|NCT06299748|||OTHER||OTHER|||||||
33812121|NCT03742297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812122|NCT05008003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118860|NCT02398812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118861|NCT06128876|||COHORT||PROSPECTIVE|||||||
34118862|NCT01523938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118863|NCT06703944|||COHORT||RETROSPECTIVE|||||||
34118864|NCT06434558|||CASE_ONLY||PROSPECTIVE|||||||
34118865|NCT04859192|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118866|NCT04249375|||OTHER||OTHER|||||||
34118867|NCT01816984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118868|NCT03522402|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34118869|NCT04098263|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Part B: Identical-appearing placebo|Part A: Open Label Part B: Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
34118870|NCT01172028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731646|NCT01133691|||CASE_ONLY||PROSPECTIVE|||||||
33731647|NCT03219060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731648|NCT04528446|||CASE_CONTROL||PROSPECTIVE|||||||
33731649|NCT03458130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, doubleblind, placebo-controlled, dose-ranging design is considered to be the most appropriate study design for meeting this objective. On the basis of information gained from previous clinical experience with AG10, the doses used in this study will be selected to determine the dose with the better safety and tolerability profile.|t|t|t|t
33731650|NCT02941679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731651|NCT04230148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731652|NCT03470337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Double-Blinded||t|t|t|t
33731653|NCT01899599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731654|NCT01530126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731655|NCT01787084|||COHORT||PROSPECTIVE|||||||
33731656|NCT04248296|||OTHER||RETROSPECTIVE|||||||
33731657|NCT05856838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731658|NCT02377089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731659|NCT02131480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731660|NCT03941535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center, prospective interventional study to compare a decreasing dose of daily Vitamin K to a matched retrospective cohort||||
33731661|NCT03357458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33731662|NCT01743261|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33731663|NCT01870622|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33731664|NCT01140425|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34118871|NCT05754866|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731665|NCT01194024|||COHORT||PROSPECTIVE|||||||
33731666|NCT02244203|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33731667|NCT03791866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33731668|NCT03291613|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731669|NCT02859649|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731670|NCT03284216|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33731671|NCT05041790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731672|NCT06114264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731673|NCT01786629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731674|NCT04281381|||COHORT||PROSPECTIVE|||||||
33731675|NCT01533610|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731676|NCT03096665|||CASE_ONLY||PROSPECTIVE|||||||
33731677|NCT02142166|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812123|NCT06103877|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33812124|NCT01502839|||COHORT||RETROSPECTIVE|||||||
33812125|NCT06019767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812126|NCT04945538|||COHORT||PROSPECTIVE|||||||
34118872|NCT01786590|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118873|NCT04972825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118874|NCT01215851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118875|NCT05390788|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731678|NCT04253717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731679|NCT00436748|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731680|NCT03331068|||COHORT||PROSPECTIVE|||||||
33731681|NCT01276314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731682|NCT00326612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731683|NCT00696956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731684|NCT01885390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731685|NCT01103934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731686|NCT02355132|||CASE_CONTROL||RETROSPECTIVE|||||||
33731687|NCT05713032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731688|NCT02203864||PARALLEL||TREATMENT||NONE||||||
33731689|NCT01703793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731690|NCT01254799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731691|NCT05830630|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open Label|||||
33731692|NCT04307485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731693|NCT02148328|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731694|NCT03855735|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parallel design for Phase 2 and sequential design in Phase 3|f|t|t|f
33731695|NCT01153581|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33731696|NCT01537783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731697|NCT04145570|RANDOMIZED|CROSSOVER||OTHER||NONE||"Based on the log-transformed parameters, the following criteria were used to evaluate the bioequivalence between the test and reference products:~* The 90% confidence interval of the relative mean AUCt of the test to reference products should be between80% and125%.~* TherelativemeanCmaxofthetesttoreferenceproductsshouldbebetween80% and125%"||||
33731698|NCT05338190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind controlled trial||t|t|t|t
33731699|NCT00733343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731700|NCT04063033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two cardiologists will examine the participants after 12 and 24 weeks and evaluate functional status and volume status.|Randomisation to two groups, One receiving IV Iron on top of standard therapy while admitted to the hospital and the other receiving only standard therapy for acute heart failure.|f|f|f|t
33812127|NCT00762866|||COHORT||CROSS_SECTIONAL|||||||
33812128|NCT02412540|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812129|NCT00078832|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33812130|NCT06500403|||COHORT||PROSPECTIVE|||||||
33812131|NCT00937014|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33812132|NCT03189303|||COHORT||PROSPECTIVE|||||||
33812133|NCT06506409|RANDOMIZED|PARALLEL||TREATMENT||NONE||We have three parallel groups: Two treatment groups and one control group||||
33812134|NCT01431157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118876|NCT05721950|||CASE_ONLY||OTHER|||||||
34118877|NCT04996329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731701|NCT02940691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118878|NCT04019002|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118879|NCT06716229|||COHORT||PROSPECTIVE|||||||
34118880|NCT06507306|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118881|NCT05688969|RANDOMIZED|PARALLEL||OTHER||SINGLE||1:1 allocation|f|f|f|t
34118882|NCT06138171|||COHORT||CROSS_SECTIONAL|||||||
34118883|NCT06563479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34118884|NCT04273945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118885|NCT05062018|||COHORT||PROSPECTIVE|||||||
34118886|NCT06268470|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Identical capsules|Patients diagnosed with chronic urticaria will be assigned to 2 treatment arms. 1. high dose antihistamine with antiplatelets; and 2. high dose antihistamine alone.|t|t|t|f
34118887|NCT02144467|||COHORT||CROSS_SECTIONAL|||||||
34118888|NCT02915497|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34118889|NCT01092884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34118890|NCT01847443|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118891|NCT03276182|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118892|NCT04651530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118893|NCT05922930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118894|NCT01650454|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118895|NCT06492759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118896|NCT03276273|||COHORT||PROSPECTIVE|||||||
34118897|NCT03547440|||CASE_CONTROL||PROSPECTIVE|||||||
34118898|NCT06677957|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34118899|NCT04239248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34118900|NCT02921789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118901|NCT02167711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118902|NCT05495581|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34118903|NCT03940716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118904|NCT05886478|||COHORT||RETROSPECTIVE|||||||
34118905|NCT05820503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118906|NCT04999566|||COHORT||RETROSPECTIVE|||||||
34118907|NCT05794607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Patients who will undergo lung surgery for lung cancer|f|f|t|f
34118908|NCT00976456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118909|NCT01931917|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34118910|NCT02801786|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34118911|NCT06493734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118912|NCT04273269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118913|NCT05015504|NA|SINGLE_GROUP||TREATMENT||NONE||Single group self comparison||||
34118914|NCT01298323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118915|NCT03543865|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34118916|NCT01624753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118917|NCT06719180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34118918|NCT05992129|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||After initial measurements of dependent variables (electromyographic activity amplitude of core muscles, static stability, dynamic stability, ergospirometry, countermovement jump, and 40m sprint test), athletes are divided into two groups: 1) Case group, which is further classified into (a) athletes with high arched feet and (b) athletes with flat feet, and 2) Control group, consisting of athletes with neutral feet. The case group performs intrinsic and extrinsic foot muscle strengthening exercises for 12 weeks, while the control group does not engage in these exercises. Following intervention, both case and control groups are re-evaluated in dependent variables to conduct pre-post intervention variable comparisons.||||
34118919|NCT04516603|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34118920|NCT06248151|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34118921|NCT04451161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The care provider is not masked to the intervention condition they are in (ie, TF-CBT vs TAU), but will be masked to the implementation strategy (ie, Attention Control vs. BASIS).||f|t|f|f
34118922|NCT05574556|||COHORT||PROSPECTIVE|||||||
34118923|NCT03769688|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34118924|NCT05916040|||CASE_ONLY||PROSPECTIVE|||||||
34118925|NCT00731484|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34118926|NCT04591574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118927|NCT05427695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|At the beginning of the study patients will be provided enough study product to complete 2 nasal sinus irrigations/day for a period of 14 days. There will be 1 packet for each nasal irrigation procedure (a total of 28 vials for 2 weeks). The packets will be distributed by the University's Investigational Drug Service (IDS) and will be labeled in a way that neither the patient nor the investigator will know the contents of the packet. Only IDS personnel will have the product/patient code link.|Adult patients of the PI's or co-investigator's with a diagnosis of active CRS and who meet the inclusion and exclusion criteria will be eligible to participate. A total of 60 subjects will be randomize evenly into 2 study groups: 30 patients in the saline group (SAL) and 30 patient in the Lactobacillus sakei group (LAC). Patients will asked to do nasal irrigations 2 times/day for 14 days. Patient history, sinus exams, culture swabs, surveys (SNOT-22) and pain scale will access pre and post treatment results. Patients will be assessed and compared prior to beginning sinus irrigations, the week after irrigations are completed, and 6 weeks after initial assessment.|t|f|t|f
34118928|NCT00863876|||COHORT||CROSS_SECTIONAL|||||||
34118929|NCT04326452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118930|NCT05130840|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This represents a two-cohort feasibility study to establish the feasibility of a multi-modality central nervous system (CNS) disease detection platform in patients with HER2+ breast cancer with no known CNS metastatic disease. Patients will enroll into one of 2 cohorts. Cohort A will be open to patients with Stage IV HER2+ breast cancer and Cohort B will include patients with Stage II-III HER2+ breast cancer.||||
34118931|NCT05225714|||COHORT||PROSPECTIVE|||||||
34118932|NCT02723734|||COHORT||PROSPECTIVE|||||||
34118933|NCT01997164|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34118934|NCT06376175|||CASE_ONLY||PROSPECTIVE|||||||
34118935|NCT05921344|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
27403739|NCT06687642|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study includes three different experiment circuits. Circuit A comprises a single experiment, carried out online on a computer. Circuits B and C comprise four experiments, identical between circuits B and C, which take place at the ICM in Paris, on the Pitié-Salpêtrière hospital site. A participant on a circuit performs only one experiment on the circuit. In circuit C, some of the experiments take place under fMRI.||||
33812135|NCT00687297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812136|NCT02203799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812137|NCT02174978|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812138|NCT02765867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812139|NCT05637242|||COHORT||OTHER|||||||
33812140|NCT02055079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812141|NCT05814809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812142|NCT02040038|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118936|NCT03961308|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118937|NCT06049914|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||12-week combined exercise-nutrition intervention|t|f|t|f
34118938|NCT06555770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34118939|NCT06705140|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* Blinding for vaccine group assignment: participants, parents or legally acceptable representatives (LARs), outcome assessors, investigators, laboratory personnel, Sponsor study staff~* No blinding for study staff who prepare and administer the study interventions"||t|f|t|t
34118940|NCT04406987|||COHORT||PROSPECTIVE|||||||
34118941|NCT00770393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118942|NCT02131766|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34118943|NCT04524988|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34118944|NCT05506254|||COHORT||PROSPECTIVE|||||||
34118945|NCT06633757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118946|NCT03920891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118947|NCT02700438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118948|NCT00011583|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118949|NCT02789852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34118950|NCT03139058|NA|SINGLE_GROUP||OTHER||NONE||||||
34118951|NCT04624178|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II open label study evaluating the combination of rucaparib and nivolumab in patients with refractory LMS.||||
34118952|NCT05066412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118953|NCT04945460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Each eligible participant will be randomly assigned in a 1:1:1 ratio to 1 of the 3 treatment groups during the Treatment Period:~Arm 1: Treatment Group 1: Placebo delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks~Arm 2: Treatment Group 2: Sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks~Arm 3: Treatment Group 3: Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week Treatment Period"|t|t|t|f
34118954|NCT03914625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118955|NCT06277115|NA|SINGLE_GROUP||TREATMENT||NONE||Two-phase intervention: several weeks of CPAP therapy followed by two weeks CPAP therapy withdrawal||||
34118956|NCT00071955||||TREATMENT||NONE||||||
34118957|NCT03251521|||CASE_ONLY||RETROSPECTIVE|||||||
34118958|NCT03158064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118959|NCT05186740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subject will have noise cancelling headphones on during the treatment. A drape will be placed preventing subjects from observing implant procedure. The follow-up clinic coordinator will not have access to enrolled subjects' medical records including the randomization scheme and treatment procedure.|Prospective, multi-center, randomized, double-blind, sham-controlled safety and effectiveness study|t|f|f|t
34118960|NCT03436342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118961|NCT06626230|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34118962|NCT02847403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118963|NCT03307382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cohort study||||
34118964|NCT04279743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither the participant nor the research nurse will know the randomization of the different treatments administered. All plasma samples collected during the research project will be anonymized i.e. it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.|Double-blind controlled randomized study with a parallel study design (40 men and 40 women, ApoE4 carriers and non carriers)|t|t|t|t
34118965|NCT04261777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118966|NCT06320990|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34118967|NCT01224886|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118968|NCT01528579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812143|NCT05360537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Care Provider)|Parallel Assignment|t|t|f|f
33812144|NCT01029704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812145|NCT03630653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812146|NCT01500070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812147|NCT04140526|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label||||
33812148|NCT05224245|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The protocol allows for up to 20 patients to be enrolled.||||
33812149|NCT02065297|||OTHER||PROSPECTIVE|||||||
33812150|NCT04179526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812151|NCT01506700|||COHORT||PROSPECTIVE|||||||
33812152|NCT05670561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812153|NCT00691340|||CASE_ONLY||PROSPECTIVE|||||||
33812154|NCT06413888|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of patients. Group 1 patients will have NGT placed in the operating room and continued in the immediate postoperative recovery period. Group 2 patients will have oropharyngeal gastric tube inserted in the operating room and removed at the end of the procedure.||||
34118969|NCT05857748|||COHORT||PROSPECTIVE|||||||
34118970|NCT04287972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118971|NCT03186339|||COHORT||PROSPECTIVE|||||||
34149801|NCT01750359|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33731702|NCT00783042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33731703|NCT00847275|RANDOMIZED|PARALLEL||||NONE||||||
33731704|NCT06121271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731705|NCT00213148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731706|NCT04061694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731707|NCT01388829|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33731708|NCT03181542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, controlled trial||||
33731709|NCT02643524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731710|NCT06036069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (outcomes Assessor)|Randomized control study|f|f|f|t
33731711|NCT04524312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant will not be informed which type of prosthesis was used in their particular case.~Outcomes Assessor will not be informed which type of prosthesis was used in particular patient."||t|f|f|t
33731712|NCT04347395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731713|NCT01586468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812155|NCT00691691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812156|NCT00824850|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812157|NCT01714908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812158|NCT03152214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812159|NCT01575704|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812160|NCT02264847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812161|NCT06245564|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The participant will be blinded about which cream is applied.|In each participant, the four different creams will be applied in a randomized position. After the cream removal, itch will be induced using histamine in one session and cowhage in the other session.||||
33812162|NCT04755309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812163|NCT05326685|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33812164|NCT05205083|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812165|NCT05272202|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812166|NCT06517576|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33731714|NCT03548012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A stepped wedge cluster randomized controlled trial. All clusters (i.e., municipalities) will start as controls and will change to intervention at various times determined by randomization. In this way, all municipalities will contribute to control and intervention groups, thus accounting for variation between municipalities.||||
33812167|NCT04112563|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||the patient will be randomized and included in one of two groups: WLI-LCI group: a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI LCI-WLI group: a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)||||
33812168|NCT02789514|||OTHER||CROSS_SECTIONAL|||||||
33812169|NCT06134557|||COHORT||RETROSPECTIVE|||||||
33812170|NCT02174146|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33812171|NCT02826954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812172|NCT01759966|||CASE_CONTROL||PROSPECTIVE|||||||
33812173|NCT03072706|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|The patient assessor will be blinded to the patients' group allocation|Single-centre, patient-assessor blinded, parallel-group, randomised-controlled trial|f|f|f|t
33812174|NCT01084772|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33731715|NCT03765294|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||2-way cross-over|t|t|t|t
33812175|NCT04540926|NA|SEQUENTIAL||TREATMENT||NONE||Consecutive patients with suspected or confirmed diagnosis of COVID-19 were assigned, in an unblinded and non-randomized fashion, to receive either steroids plus CsA (intervention group) or steroids only (standard of treatment in this hospital, control group), as per individual clinical judgment||||
33812176|NCT01062438|||COHORT||RETROSPECTIVE|||||||
33812177|NCT04388748|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812178|NCT00265902||||DIAGNOSTIC||||||||
33812179|NCT04555226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812180|NCT02932176|||COHORT||PROSPECTIVE|||||||
33812181|NCT06312592|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812182|NCT01198314|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812183|NCT01602302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812184|NCT00299507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812185|NCT00296309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812186|NCT01762982|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33812187|NCT02125292|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33812188|NCT01555944|||COHORT||PROSPECTIVE|||||||
33812189|NCT05474326|NA|SINGLE_GROUP||OTHER||NONE||The Kendall SCD™ 700 Smart Compression™ Controller is an intermittent pneumatic compression (IPC) device application of this intermittent pneumatic pressure device on lower limbs in women with oligohydramnios and its effect on maternal uterine artery doppler, fetal umbilical artery doppler, middle cerebral artery doppler||||
33812190|NCT01622140|||COHORT||PROSPECTIVE|||||||
33812191|NCT00000617|RANDOMIZED|||PREVENTION||DOUBLE||||||
33812192|NCT05667935|||COHORT||PROSPECTIVE|||||||
33812193|NCT03947853|||OTHER||PROSPECTIVE|||||||
33812194|NCT04976946|||OTHER||PROSPECTIVE|||||||
33812195|NCT01884571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812196|NCT03477084|||COHORT||PROSPECTIVE|||||||
33812197|NCT05615337|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33812198|NCT01836523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812199|NCT00786188|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33812200|NCT02372799|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812201|NCT00303537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33812202|NCT05281081|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33812203|NCT04131036|||COHORT||OTHER|||||||
33812204|NCT02773082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812205|NCT00493688|||COHORT||PROSPECTIVE|||||||
33812206|NCT06473363|||COHORT||RETROSPECTIVE|||||||
33812207|NCT02489357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812208|NCT04976556|||OTHER||PROSPECTIVE|||||||
34118972|NCT05380687|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Randomized crossover of 2 trainings (A and B)||||
34118973|NCT03377517|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.||||
34118974|NCT03899350|||COHORT||PROSPECTIVE|||||||
34118975|NCT06392906|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this study, both participants and researchers are aware of the treatment administered due to the necessity for close monitoring of treatment outcomes and side effects by radiation oncologists and ophthalmologists.|Phase 2 randomized control trial comparing between standard radiation therapy arm (20 Gy in 10 fractions) and experimental radiation therapy arm (10 Gy in 5 fractions)||||
34118976|NCT04897945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34118977|NCT00002429||PARALLEL||TREATMENT||||||||
33812209|NCT00551421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812210|NCT06177821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812211|NCT03488498|||CASE_CONTROL||PROSPECTIVE|||||||
33812212|NCT03233542|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants meeting study criteria for Panic Disorder will be randomized to an intervention arm (CBT) or waiting list arm (which is followed by CBT after completion of the study procedures); participants meeting study criteria for the anxious control group will be allocated to an intervention (CBT) arm. The study aims to have equal numbers of participants in each of the 3 arms.||||
33812213|NCT03693989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding and masking The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner in the case of a partial and final analysis.~The masking will be carried out using boxes in the identical primary packaging in the two groups and re-labeling the bottles of both interventions.~Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the assignment number."|double-blind, controlled, parallel group, multicentre, randomized|t|f|t|f
33812214|NCT00217152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812215|NCT01894503|NA|SINGLE_GROUP||TREATMENT||NONE||Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses||||
33812216|NCT04740541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812217|NCT05733494|||CASE_ONLY||PROSPECTIVE|||||||
33812218|NCT05438875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812219|NCT03072810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Participants will be aware that they are partaking in the programme and the researcher will see which arm each participant is in. However, participants will be allocated an anonymous code that will be used for storing and analysing outcome data.|Randomised wait-list control study||||
33812220|NCT04613284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812221|NCT03019289|NA|SINGLE_GROUP||OTHER||NONE||||||
33812222|NCT04520815|||COHORT||OTHER|||||||
34118978|NCT06657365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34118979|NCT03467516|NA|SINGLE_GROUP||TREATMENT||NONE||The Phase 2 study will follow the Simon's optimal two-stage design. Fifteen patients will be included in the first stage; if there are 1 or fewer patients responding to therapy the trial will be terminated. If at least 2 responses are observed, expansion into Stage 2 to a total of 47 patients will occur. If at least 6 patients respond to therapy, the study therapy would be considered to have met its primary study goal.||||
34118980|NCT03816176|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34118981|NCT02065219|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34118982|NCT06372795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34118983|NCT02234349|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34118984|NCT06236516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34118985|NCT06382844|||COHORT||PROSPECTIVE|||||||
34118986|NCT00188214|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34118987|NCT01564342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34118988|NCT05166668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118989|NCT05340413|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34118990|NCT06218979|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34118991|NCT03291522|||CASE_ONLY||PROSPECTIVE|||||||
34118992|NCT03549780|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34118993|NCT06289465|||COHORT||CROSS_SECTIONAL|||||||
34118994|NCT06566014|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34118995|NCT02771405|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118996|NCT04276441|||COHORT||PROSPECTIVE|||||||
34118997|NCT06551220|||COHORT||RETROSPECTIVE|||||||
34118998|NCT01444820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34118999|NCT02965963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34119000|NCT04843488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34119001|NCT05431595|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119002|NCT03279107|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single Participant|randomized|t|f|f|f
34119003|NCT06235580|||CASE_CONTROL||PROSPECTIVE|||||||
34119004|NCT01527630|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34119005|NCT04991220|NA|SINGLE_GROUP||SCREENING||NONE||||||
34119006|NCT04972851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119007|NCT06120140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119008|NCT06547918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119009|NCT04186585|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Within-patient, 3-level Response Surface Pathway (RSP) design||||
34119010|NCT05286333|||COHORT||PROSPECTIVE|||||||
34119011|NCT01455480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149109|NCT05027984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All events included in the study endpoints will be adjudicated by a blinded Clinical Event Adjudication Committee.|Two groups: one group receiving functional assessment of intermediate coronary lesions and the other group undergoing OCT assessment.|f|f|f|t
34149110|NCT01877889|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34149111|NCT00710242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149112|NCT03474692|||CASE_ONLY||OTHER|||||||
33731716|NCT06571188|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The random sequence will be sealed in consecutively numbered opaque envelopes and kept by the study coordinator.~Participants will be randomly divided into two groups . The coordinator will open the envelopes for allocation according to the order of enrolment and prepare the study drug.~The participants will be blinded to the allocation.Anaesthesiologists who perform the nerve block and take charge of intraoperative management and surgeons are independent individuals.Researchers who do not take part in the nerve block and intraoperative management are designated to postoperative follow-up. Besides, trained anaesthesiologist who do not perform the block will be designated to evaluate the clinical features of the block objectively"|Participants will be randomly divided into two groups according to the 1:1 ratio of ESPB group and TEB group. A research coordinator is designated to distribute and preserve randomization result. The coordinator will open the envelopes for allocation according to the order of enrolment and prepare the study drug|t|t|f|t
33731717|NCT00052728||||TREATMENT||NONE||||||
33731718|NCT03140202|RANDOMIZED|CROSSOVER||OTHER||NONE||"In Guide group, participants have a real time feedback (and record) on chest compression quality performed by means of the visuals informations profided by the feedback device.~In Blind group, participants have a real time record of chest compression quality performed by means of the feedback device without feedback information of the performance."||||
33731719|NCT00757445|||CASE_ONLY||RETROSPECTIVE|||||||
33731720|NCT00113737||||PREVENTION||DOUBLE||||||
33731721|NCT04765488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33731722|NCT05092659|NA|SINGLE_GROUP||OTHER||NONE||||||
33731723|NCT04593030|||COHORT||RETROSPECTIVE|||||||
34149113|NCT00050674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149114|NCT02545816|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731724|NCT03607916|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731725|NCT02734316|||COHORT||CROSS_SECTIONAL|||||||
34149115|NCT00238459|||CASE_CONTROL||PROSPECTIVE|||||||
33731726|NCT03466502|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731727|NCT04403321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731728|NCT05030142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731729|NCT05830253|||COHORT||PROSPECTIVE|||||||
33731730|NCT00839839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731731|NCT02997033|||COHORT||PROSPECTIVE|||||||
33731732|NCT00394030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731733|NCT01966926|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731734|NCT04138407|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33731735|NCT01595360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731736|NCT05483946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Investigators will be blinded to the measurement results|||||
33731737|NCT01148004|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33731738|NCT01726010|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731739|NCT04514601|||COHORT||RETROSPECTIVE|||||||
33731740|NCT05326139|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33731741|NCT01368575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731742|NCT01127503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731743|NCT04521491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731744|NCT01944059|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33731745|NCT00811564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731746|NCT04126928|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731747|NCT05435378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Trial medication will be dispensed in similar colored capsules, prepacked in similar opaque white plastic jars of 30 capsules each so that neither patient nor investigator (whom is also the care provider) will know whether patient was receiving vitamin B3, B9 or placebo. the outcome assessor will be given the data coded without knowing the data for the group of patients corresponding to which intervention group.||t|t|t|t
33731748|NCT00330551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731749|NCT04462705|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33812223|NCT01929902|||COHORT||PROSPECTIVE|||||||
33812224|NCT01778803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812225|NCT04158206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33812226|NCT04454723|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33812227|NCT03953079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Visual examiner-masked|Parallel-arm design|f|f|f|t
33812228|NCT02840045|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812229|NCT04725032|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33812230|NCT01532609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812231|NCT06509230|||COHORT||CROSS_SECTIONAL|||||||
33812232|NCT02613052|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33812233|NCT04164407|||COHORT||RETROSPECTIVE|||||||
34149116|NCT00921310|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149117|NCT04610736|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomized, international, multi-centre, open-label, single arm study||||
33731750|NCT03364088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731751|NCT03288597|||COHORT||PROSPECTIVE|||||||
33812234|NCT01997866|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33812235|NCT05851157|NA|CROSSOVER||TREATMENT||NONE||||||
33731752|NCT01247766|||COHORT||PROSPECTIVE|||||||
33731753|NCT04625738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase IIa double-blind randomized controlled trial|t|t|t|t
33731754|NCT03416309|||COHORT||PROSPECTIVE|||||||
33731755|NCT03583671|||CASE_ONLY||CROSS_SECTIONAL|||||||
33731756|NCT03270046|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||In this study, participants will be randomised 1:1 to water enema group or no water enema group using blocked randomization with random block sizes.|f|f|t|f
33812236|NCT01684540|||CASE_ONLY||PROSPECTIVE|||||||
33812237|NCT04804202|NA|SINGLE_GROUP||OTHER||NONE||Repeated Measures Design||||
33812238|NCT01157624|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33812239|NCT00667953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812240|NCT00871715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded to treatment allocation||f|f|f|t
33812241|NCT02991573|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33812242|NCT00579306|||COHORT||PROSPECTIVE|||||||
34119012|NCT04567524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Although treatment assignment was blinded; the dose level was not blinded. The dose of LYN-005 (14 or 28 mg)/IR risperidone (2 or 4 mg/day) administered was based on the subject's current antipsychotic medication dose. Randomization was stratified by risperidone dose (LYN-005 14 mg/IR risperidone 2 mg/day \[low dose\] and LYN-005 28 mg/IR risperidone 4 mg/day \[high dose\], with a maximum of 16 subjects enrolled in each stratum. Within each stratum, subjects were randomized on a 3:1 basis to either LYN-005 or risperidone, respectively.|LYN-005-C-004 was a blinded, multiple-dose, randomized, parallel group, safety, tolerability and PK study of LYN-005 in subjects with a primary diagnosis of schizophrenia or schizoaffective disorder in general good health. Eligible subjects were clinically stable and receiving a therapeutic dose of an approved oral antipsychotic drug for a minimum of 6 weeks at the time of Screening. Enrolled subjects were evaluated under steady-state conditions on commercially-available IR risperidone tablets and then assigned in blinded fashion either to LYN-005 weekly or continued encapsulated IR risperidone daily for 3 weeks to attain (or continue) steady-state exposure.|t|t|f|f
34119013|NCT04170920|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119014|NCT06145594|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, 2 parallel groups (EMA or EMA+mTMS) with longitudinal follow-up (with EMA monitoring) over 1 year. open-label mTMS and other concurrent treatment as usual (TAU) for bother groups; Adjunct mTMS is offered if/when determined by software algorithm for EMA+mTMS group only.||||
34119015|NCT06245434|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34119016|NCT00605059|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119017|NCT04554303|||CASE_CONTROL||PROSPECTIVE|||||||
34119018|NCT06716788|||CASE_ONLY||PROSPECTIVE|||||||
34119019|NCT02685397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119020|NCT06541808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119021|NCT05377060|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34119022|NCT02083224|||COHORT||PROSPECTIVE|||||||
34119023|NCT06314178|||COHORT||PROSPECTIVE|||||||
34119024|NCT06718179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119025|NCT03753048|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119026|NCT04936191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119027|NCT02154022|||CASE_ONLY||PROSPECTIVE|||||||
34119028|NCT06373666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119029|NCT06546462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119030|NCT00956891|||CASE_CONTROL||RETROSPECTIVE|||||||
34119031|NCT06716216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119032|NCT05907811|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The cases were divided into 2 groups by the envelope method, and 30 subjects were included in the general anesthesia group (GA), and 30 subjects were included in the general anesthesia and thoracic epidural anesthesia group (GAE).|Randomized prospective, controlled study|t|f|f|t
34119033|NCT05833217|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119034|NCT06698003|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119035|NCT03093116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119036|NCT02708680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119037|NCT02906943|||COHORT||PROSPECTIVE|||||||
34119038|NCT04939597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34119039|NCT05251649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119040|NCT06264609|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34119041|NCT01578161|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34119042|NCT02568553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119043|NCT01905540|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34119044|NCT06247787|NA|SEQUENTIAL||TREATMENT||NONE||||||
34119045|NCT02146924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119046|NCT06225466|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients/families, treating teams (except for the anesthesia team), and research staff/investigators responsible for measuring and adjudicating outcomes will be blinded to allocation.|randomized, patient- and assessor-blinded, parallel arm, controlled trial|t|t|f|t
34119047|NCT04733534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119048|NCT01071954|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119049|NCT03824158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34119050|NCT02821780|||COHORT||PROSPECTIVE|||||||
34119051|NCT05448950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119052|NCT03218917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119053|NCT06427395|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, Open-Label, phase III, safety and efficacy study||||
34119054|NCT06591780|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119055|NCT06604429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812243|NCT00811239||PARALLEL||TREATMENT||NONE||||||
33812244|NCT06500546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||comparison of restoration success|t|f|f|f
33812245|NCT06505577|||COHORT||PROSPECTIVE|||||||
33812246|NCT00330785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812247|NCT01727167|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33812248|NCT01214070|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33812249|NCT00768755|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812250|NCT01296100|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33812251|NCT00754325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812252|NCT00638456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812253|NCT04633200|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized Controlled Trial||||
33812254|NCT01549951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812255|NCT02833948|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33812256|NCT02162394|||COHORT||PROSPECTIVE|||||||
33812257|NCT03556332|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, Simon two-stage phase II trial of combination therapy||||
33812258|NCT01713491|||COHORT||PROSPECTIVE|||||||
33812259|NCT01466569|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812260|NCT01189552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812261|NCT02358304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812262|NCT01230359|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119056|NCT01126957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731757|NCT05720325|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The designated unblinded biostatisticians will allocate dupilumab or placebo for dupilumab to each participant. The designated unblinded biostatisticians will develop the final unblinded randomization key for coding of study drug that will be filed in a secure location in the event that unblinding is necessary at any point during the study.|"This is a prospective, double-blind, randomized placebo-controlled mechanistic clinical trial to test the effects of an 18-week course of dupilumab on HDM allergen challenge-induced nasal mucosa and peripheral blood traits and symptoms in persons with HDM-associated perennial allergic rhinoconjunctivitis (PARC) with allergic asthma (HDM+PARC+AA+) participants. For each yearly cohort, participants of each phenotype will be randomly selected, resulting in two groups classified as the (i) adaptive, and (ii) maladaptive phenotypes.~Using the R package SeqAlloc, a covariate-adjusted randomization will be employed to randomize each of these two groups into two subgroups; the subgroups within each group (phenotype) will be balanced by age and gender. Thus, this will result in the generation of four groups:~(i) adaptive-A (ii) adaptive-B (iii) maladaptive-A (iv) maladaptive-B"|t|f|t|f
33731758|NCT00846118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731759|NCT05544617|||FAMILY_BASED||PROSPECTIVE|||||||
33731760|NCT02008500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731761|NCT01882270|||CASE_ONLY||PROSPECTIVE|||||||
33731762|NCT01686646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731763|NCT02457533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731764|NCT04874506|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Three dosing regimens will be explored and represented by Cohort 1, Cohort 2, and Cohort 3.~The first 6 patients (Cohort 1) will begin with a total daily dose (TDD) of 1000 mg of MBM-02."||||
33731765|NCT01227512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731766|NCT03592121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731767|NCT02677792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731768|NCT01536639|||COHORT||PROSPECTIVE|||||||
33731769|NCT04125316|||CASE_CONTROL||PROSPECTIVE|||||||
33731770|NCT03296228|||COHORT||PROSPECTIVE|||||||
33731771|NCT01027793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731772|NCT01482520|||COHORT||RETROSPECTIVE|||||||
33731773|NCT04860310|||CASE_ONLY||PROSPECTIVE|||||||
33731774|NCT03309280|||COHORT||PROSPECTIVE|||||||
33812263|NCT02362789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119057|NCT06168396|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34119058|NCT06568419|NA|SINGLE_GROUP||TREATMENT||NONE||a non-randomized, single arm, multi-center mixed methods clinical trial in a naturalistic setting||||
34119059|NCT01913327|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119060|NCT06711627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119061|NCT00506142|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients were enrolled into the study in two cohorts. After completion of enrollment in Cohort 1, enrollment in Cohort 2 has commenced.||||
34119062|NCT03531736|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study to assess engraftment of a T cell depleted (TCD) graft following a reduced intensity conditioning regimen (RIC). The conditioning regimen will include total body irradiation (TBI), Fludarabine, anti-thymocyte globulin (ATG) and post transplant cyclophosphamide (PT-Cy). The graft will be TCD and will be composed of a TCR-α/β+ lymphocyte depletion stem cells and CD34+ selected stem cells.||||
34119063|NCT06715033|||CASE_ONLY||CROSS_SECTIONAL|||||||
34119064|NCT05076045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34119065|NCT05456256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119066|NCT01901536|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34119067|NCT03009461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119068|NCT04889924|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized, multicenter study.||||
34119069|NCT06718218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119070|NCT04779099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34119071|NCT02531087|||COHORT||PROSPECTIVE|||||||
34119072|NCT04700423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open Label with masked outcomes assessors||f|f|f|t
34119073|NCT06431711|||OTHER||PROSPECTIVE|||||||
34119074|NCT01871441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119075|NCT05026723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Owing to the nature of the intervention, participants, providers, and many study staff will know to which group individual participants have been randomized. However, efforts will be made to keep the study statistician and outcome assessors blinded to randomization group during the course of the trial.|Participants will be assigned in 1:1 ratio to one of two intervention arms|f|f|f|t
34119076|NCT02791464|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34119077|NCT05958589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731775|NCT06440070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731776|NCT04197570|RANDOMIZED|PARALLEL||OTHER||SINGLE||The investigators plan to enroll 158 subjects at Virginia Mason Medical Center that are undergoing open cardiac surgery. Subjects who volunteer to be involved in the study will be randomized to either the opioid free or traditional anesthetic arm. Subjects will be blinded to the assigned arm.|t|f|f|f
33731777|NCT03156010|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All participants undergo testing with the same three devices. The order of devices will be semi-randomized to eliminate order effects.||||
33731778|NCT01281748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731779|NCT00403273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731780|NCT02554656|||COHORT||PROSPECTIVE|||||||
33731781|NCT06464042|||CASE_CONTROL||RETROSPECTIVE|||||||
33812264|NCT01065779|||OTHER||PROSPECTIVE|||||||
33812265|NCT06402292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812266|NCT02355106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812267|NCT01425398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812268|NCT02341222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33812269|NCT03695185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812270|NCT02002689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812271|NCT01109979|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33731782|NCT00193401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731783|NCT03825289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731784|NCT04510935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731785|NCT01079871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731786|NCT00112203|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731787|NCT02852265|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33731788|NCT04397536|||COHORT||PROSPECTIVE|||||||
33731789|NCT02718638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731790|NCT03076424|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731791|NCT03309683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731792|NCT05737472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients, investigators, care providers, and data analysts will be blinded from the treatment allocation until data analysis is complete, thus quadruple blinding. The two RUTFs will be packaged in identical 92g sachets. The RUTFs will be as similar as possible in colour, texture, and smell. The two packages/sachets of the two types of RUTF will differ by colour, and the number code will be either grey-88 or purple-99 (the colour code will be unique to each RUTF type). An independent statistician will perform the colour allocation.||t|t|t|t
33731793|NCT01072201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731794|NCT05393375|||COHORT||RETROSPECTIVE|||||||
33731795|NCT04002414|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be stratified into groups: active or insufficiently active based on current average physical activity. Randomization will be into one of two parallel arms, maintenance of current activity during ovarian stimulation, or modify activity level during ovarian stimulation."||||
33731796|NCT02611258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731797|NCT01481116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731798|NCT04570293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731799|NCT04352140|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731800|NCT02398552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731801|NCT01397695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731802|NCT04607226|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33731803|NCT00353678|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33731804|NCT04147442|NA|SINGLE_GROUP||TREATMENT||NONE|The allotted program position for the music programs will be randomized. Half of the participants will have the fine-tuned program in slot 2 and half will have it in slot 3. They will not know in which position the fine-tuned program is versus the standard program.|The participants will have access to both music programs for 10 +/- 7 days. During this time they will use both programs and switch between them during music playing situations.||||
33731805|NCT02895399|||||PROSPECTIVE|||||||
33731806|NCT04566328|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33731807|NCT04435327|||COHORT||PROSPECTIVE|||||||
33731808|NCT03265626|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Community based three arm quasi-experimental design will be employed using mixed methods (quantitative and qualitative). Study participants will be allocated to the intervention and control groups to piloting the feasibility and effectiveness of community based intervention to avert domestic violence against women (15-49 years). Married or cohabited women, husbands/partner, community representatives (such as leaders/local politicians, religious leaders and elders), health care providers, police, women association and women affair office representatives will be involved in this implementation research.||||
33731809|NCT00019435||||TREATMENT||||||||
33731810|NCT06009952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||•Pre/ posttest randomized controlled trial design.|f|f|f|t
33731811|NCT05703061|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be assigned to either a control group or an increased time in bed (10 hours/night) group.||||
33731812|NCT04999631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded on what area received the study cream and what area received the placebo ethanol solution.|Two areas of the subject's nevus will be marked. Study medication will be applied to one area. Placebo ethanol solution will be applied to the other area. Area to be treated will be randomized among subjects. Both areas will be monitored and following surgery, samples will be obtained. Area to be treated vs area that will serve as control will be randomized.|f|f|f|t
33731813|NCT05957133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind masking with blinded assessor.|Longitudinal prospective, controlled, single-blind study|f|f|t|t
33731814|NCT00003217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731815|NCT00706966|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731816|NCT03139916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731817|NCT05974904|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731818|NCT04466163|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this study a single case experimental design (n = 8) with multiple measures will be used, to determine the effects of the ST-HA protocol on self-compassion, well-being, positive affect and Healthy Adult functioning. For each participant a no-treatment randomized baseline period (2-5 weeks) will be compared with treatment (ST-HA, 10 weekly sessions) and post-treatment follow-up (at 1- and 3-months).||||
33731819|NCT05279521|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33731820|NCT04817826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase II, multicentre, single-arm, multi-cohort trial.||||
33731821|NCT00649064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731822|NCT03061539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Two-arm non-randomised, non-comparative phase II trial||||
33731823|NCT02613533|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731824|NCT05833503|RANDOMIZED|PARALLEL||TREATMENT||NONE|These are two behavioral treatments.It is therefore impossible to mask the allocation of participants to either treatment, for both participants and clinicians.|Participants will be randomized to either Integrative Couple Therapy for Addiction (ICT-A, experimental group) or the usual individual treatment (control group).||||
33731825|NCT03070353|NA|SINGLE_GROUP||TREATMENT||NONE||Focus on clinical response after receiving treatment||||
33731826|NCT05296694|||COHORT||CROSS_SECTIONAL|||||||
33812272|NCT05118152|||COHORT||CROSS_SECTIONAL|||||||
33812273|NCT02144194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812274|NCT04432415|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not know which type of fluoride they are getting. Outcome assesor will not know the type of fluoride or placebo assigned to each group|Participants will be assigned randomly into treatment and control group using a randomization protocol.|t|f|f|t
34119078|NCT01164007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119079|NCT05760274|||COHORT||RETROSPECTIVE|||||||
34119080|NCT06694233|||OTHER||PROSPECTIVE|||||||
34119081|NCT05343988|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective unblinded pilot study to evaluate the feasibility of use of a peripheral neurostimulator for treatment of paroxysmal sympathetic hyperactivity in children with acute severe brain injury||||
34119082|NCT05357040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient and assessor blinded to study group assigned.|Parallel-group, controlled trial; randomized participants (1:1) to nitrous oxide (Nitrous group) or oxygen-air mixture (FiO2 ≈0.3, Control group). The Nitrous group will be further randomly assigned to either 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75).|t|f|f|t
34119083|NCT02987608|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119084|NCT05039021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119085|NCT02393859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119086|NCT06421740|||COHORT||PROSPECTIVE|||||||
34119087|NCT03991585|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are six classroom assignments. Classrooms will be randomized to either of the treatment arms.||||
34119088|NCT05018364|||OTHER||CROSS_SECTIONAL|||||||
34119089|NCT04856462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and group facilitators in the control group will made aware that they are part of the control gropu|Participants will be randomly assigned to an intervention group where they will receive structured education and support or to control group where they will participate in a group call.|t|t|f|f
34119090|NCT06158022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34119091|NCT06153056|||COHORT||PROSPECTIVE|||||||
34119092|NCT05969275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Randomized Controlled Trial|t|t|t|t
34119093|NCT04438967|||COHORT||OTHER|||||||
34119094|NCT05283889|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Triple blinding will be accomplished as follows: operator (RF generator operated by assistant out of sight of operator); participant (local anesthetic administration and cannula placement identical; RF generator makes the same beeping sound for the same duration); assessor (only the study coordinator is aware of group assignment).||t|t|f|t
34119095|NCT03361215|||CASE_CONTROL||PROSPECTIVE|||||||
34119096|NCT03170518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119097|NCT03375099|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Participants will not be informed of the nature of the conditions other than the one they are randomly assigned to receive|2 (Lethal Means Counseling vs Health and Stress Reduction) x 2 (Provision of free gun locks vs No gun locks)|t|f|f|f
34119098|NCT06016075|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34119099|NCT04691388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119100|NCT04083417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randmization to antibiotic treatment or no antibiotic treatment|f|f|t|f
34119101|NCT04714593|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||According to the sequence from the low dose group to the high dose group||||
34119102|NCT06142864|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34119103|NCT05311514|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119104|NCT05775900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119105|NCT06378437|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119106|NCT04177355|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34119107|NCT05525741|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Patients with non segmental vitiligo compared to healthy volunteers (1st degree family of vitiligo patients) atopic dermatitis, psoriasis and alopecia areata patients||||
34119108|NCT02118155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119109|NCT06499129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trials|f|f|f|t
34119110|NCT02317692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34119111|NCT04564989|||COHORT||PROSPECTIVE|||||||
34119112|NCT03515161|NA|SINGLE_GROUP||TREATMENT||NONE||SINGLE GROUP ASSIGNMENT||||
34119113|NCT04347421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119114|NCT04515888|||COHORT||PROSPECTIVE|||||||
34119115|NCT06716463|||COHORT||PROSPECTIVE|||||||
34119116|NCT06309667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119117|NCT01911351|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34119118|NCT00387088||PARALLEL||TREATMENT||||||||
34119119|NCT03962855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Single center, prospectively randomized, double-blinded, placebo-controlled clinical trial.|t|t|t|t
34119120|NCT06124768|||COHORT||OTHER|||||||
34119121|NCT02217943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119122|NCT04182685|||COHORT||PROSPECTIVE|||||||
34119123|NCT04933149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34119124|NCT04284709|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34119125|NCT01903005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119126|NCT06222203|||COHORT||PROSPECTIVE|||||||
34119127|NCT04055974|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blind - the investigator is unaware of the intervention assignment||f|f|t|f
34119128|NCT05947838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812275|NCT01329107|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812276|NCT02359071|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34119129|NCT03833921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119130|NCT05049863|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119131|NCT02068144|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34119132|NCT04994717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119133|NCT06396936|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34119134|NCT00390377|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34119135|NCT05738408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34119136|NCT03481348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119137|NCT05175846|||COHORT||PROSPECTIVE|||||||
34119138|NCT01306292|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34119139|NCT05644002|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34149118|NCT00689754|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149802|NCT01055483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149803|NCT01908166|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119140|NCT06544408|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Blinding Procedures The participants, PI, Research Staff involved in TMS treatment, and staff performing the study procedures will be blinded to the participant's dl-PFC protocol assignment throughout the study.||t|f|t|f
34119141|NCT01695941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119142|NCT04624984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119143|NCT02228538|||COHORT||PROSPECTIVE|||||||
34119144|NCT02637986|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34119145|NCT02834455|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34119146|NCT05701787|||CASE_ONLY||PROSPECTIVE|||||||
34119147|NCT05111288|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34119148|NCT01726374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119149|NCT05625217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119150|NCT03232073|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-group open-label extension study to investigate long-term safety, tolerability and control of disease of ponesimod 20 mg in subjects with RMS. Statistical analyses will be descriptive and therefore all endpoints are exploratory in nature. All exploratory endpoints are listed under primary outcomes.||||
34119151|NCT06434870|||CASE_CONTROL||PROSPECTIVE|||||||
34119152|NCT05836272|RANDOMIZED|PARALLEL||TREATMENT||NONE||This involves randomizing 2 independent groups according to a succession of six blocks of random permutations and this will be carried out using a computer-generated tool: the NE group (early noradrenaline group) which will receive NA at start for correction of hypotension and Placebo group (standard treatment group).||||
34119153|NCT06061692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119154|NCT06714812|||COHORT||OTHER|||||||
34119155|NCT02170064||PARALLEL||TREATMENT||NONE||||||
34119156|NCT05361460|||COHORT||PROSPECTIVE|||||||
34119157|NCT00241150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34119158|NCT05820035|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single-group target value, interventional, non-inferiority study||||
34119159|NCT06206941|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34119160|NCT03555877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119161|NCT05050903|||CASE_CONTROL||PROSPECTIVE|||||||
34119162|NCT06716749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Patients, care team, and research team are all blinded to their respective group until the study is concluded.|43 patients receiving placebo. 43 patients receiving experimental.|t|t|t|t
34119163|NCT06335966|||COHORT||PROSPECTIVE|||||||
34119164|NCT05661552|RANDOMIZED|PARALLEL||TREATMENT||NONE||The experimental and control groups consist of patients undergoing stenting for acute coronary syndrome and will be randomized to receive early evolocumab along with statin/ezetimibe use or no evolocumab. Rosuvastatin 5 mg and Ezetimibe 10 mg are administered to both the experimental group and the control group.||||
34119165|NCT04947722|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34119166|NCT02359903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119167|NCT04381312|||COHORT||PROSPECTIVE|||||||
34119168|NCT03628209|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib lead-in with extension to Phase II||||
34119169|NCT03160625|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Subjects' principal investigator and study team will be blinded to the randomization assignment. However clinical site personnel performing the device programming will not be blinded. Site personnel performing the CPET and 6-min hall walk assessments will be blinded to the randomization assignment.|"To assess whether rate adaptive pacing provides benefit to HFpEF patients, a pool of up to 60 qualifying subjects with pre-existing pacemaker and established diagnosis of HFpEF who demonstrate chronotropic incompetence (CI) with RAP turned off will be enrolled.~Subjects who meet CI criterion during Visit 2 will be randomized. Subjects' principal investigator and study team will be blinded to the randomization assignment. However clinical site personnel performing the device programming will not be blinded. Site personnel performing the CPET and 6-min hall walk assessments will be blinded to the randomization assignment.~Crossover of study subjects will occur during Visit 3, which will occur 12 weeks after subject enrollment. Subjects who were randomized with RAP ON first will have the device programmed to RAP OFF and conversely, subjects who were randomized to RAP OFF first will have the device programmed to RAP ON."|t|f|t|t
34119170|NCT06381336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized two-group design with pretest-posttest assessment was used to analyse the effectiveness of the TRAK-SILVER application. Seventy-two adults aged 65 and above were stratified by gender and physical functioning capacity (SPBB) and then randomly assigned to either the experimental (EG) or control group (CG). EG received the TRAK-SILVER platform as a treatment methodology. The CG did not have access to the platform and was instructed to continue with the standard care program through exercise sheets.|f|f|f|t
34149804|NCT02552862|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731827|NCT04037202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The researcher prepared the mother for foot massage (foot care, proper position, etc.) and gave a total of 20-minute massage of foot massage, 10 minutes for each foot. VAS was repeated immediately after the first session (in the 20th minute) and after 30 minutes (in the 50th minute). The second session was performed on the second day, 20-24 hours after the first session (before the discharge). The VAS was analyzed before the second (last) session (0th minute), and the VAS was repeated immediately after the application (20th minute) and 30 minutes (50th minute), and the PCS was administered for the last time. Administered analgesics were recorded in the DFC and the administration made with package leaflet was supported.||||
33731828|NCT00958776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731829|NCT00996762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731830|NCT00861211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731831|NCT02915549|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731832|NCT02485912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731833|NCT01559311|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731834|NCT01637688|||COHORT||PROSPECTIVE|||||||
33731835|NCT02064179|||CASE_ONLY||PROSPECTIVE|||||||
33731836|NCT01302392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731837|NCT03706235|||CASE_CONTROL||PROSPECTIVE|||||||
33731838|NCT00594828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812277|NCT02481011|||CASE_ONLY||RETROSPECTIVE|||||||
33812278|NCT05659836|||COHORT||PROSPECTIVE|||||||
33731839|NCT04787939|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The study is a single arm non-inferiority study evaluating wound healing outcomes (orocutaneous fistula, salivary leak, wound dehiscence) in subjects undergoing free tissue transfer for oral cavity reconstruction who are permitted to drink liquids by mouth on postoperative day 1. Outcomes are tracked and assessed over a 30 day period postoperatively.||||
33731840|NCT06075680|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731841|NCT04623580|||COHORT||PROSPECTIVE|||||||
33731842|NCT01778166|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33731843|NCT03717038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731844|NCT03200782|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33731845|NCT06404203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33731846|NCT04723433|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||In the post-anesthesia care unit (PACU), participants will be randomized to receive conservative (titrated to an SpO2 between 90 and 94%) versus liberal (titrated to SpO2 \> 96%) oxygen supplementation, via a non-rebreather mask.|t|t|f|f
33731847|NCT06019416|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Intervention group will receive the virtual reality-based culturally tailored mindfulness and positive psychological intervention, whereas the control group will not receive any intervention as a waitlist group.|t|f|f|f
33731848|NCT04886011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Methylcellulose gel|t|f|t|t
33731849|NCT05404269|||COHORT||PROSPECTIVE|||||||
33731850|NCT01790464|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33731851|NCT01563068|NA|SINGLE_GROUP||OTHER||NONE||||||
33731852|NCT04449367|||COHORT||PROSPECTIVE|||||||
33731853|NCT02761811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731854|NCT00413725|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33731855|NCT00993096|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33731856|NCT06336369|||CASE_CONTROL||PROSPECTIVE|||||||
33731857|NCT05857124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This trial utilizes a completely remote and virtual design. It is a double blind randomized controlled trial that is expected to involve 36 participants who are confirmed to have Post- COVID cognitive impairment.|t|t|t|f
33731858|NCT02627859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731859|NCT06439979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking will only be used for participants in the study. Investigators will know which arm of the study each participant has been randomized to.|RAYS uses a 2-arm cluster-randomized trial in 2 rural US states (Utah and West Virginia) matched for high skin cancer burden and rurality. This parallel model includes an intervention arm, which will include sun-safety education and skin cancer prevention, and the control arm which will focus on general sports-related injury prevention. Leagues enrolled in the study will be randomized to one of the two arms.|t|f|f|f
33731860|NCT06466174|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Placebo crossover to probiotic A Probiotic A crossover to Placebo Placebo crossover to probiotic B Probiotic B crossover to Placebo|t|f|t|t
33731861|NCT04383821|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33731862|NCT06131515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731863|NCT03086785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731864|NCT02696356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731865|NCT02066012|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731866|NCT03884621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34119171|NCT03994016|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"WiseGuyz' integrated and sequential curriculum is comprised of four core modules and 20 sessions per module. Sessions are a mix of targeted education, group discussion, and skills development (e.g., role play). The sequence of the modules is critical as each module builds into the next. The modules are:~Module 1: Healthy Relationships (6 sessions) Module 2: Sexual Health (5 sessions) Module 3: Gender, Sexuality and the Media (5 sessions) Module 4: Advocacy and Leadership (4 sessions)"||||
34119172|NCT06710210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119173|NCT05359250|||COHORT||PROSPECTIVE|||||||
34119174|NCT01074125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119175|NCT06250829|||COHORT||PROSPECTIVE|||||||
34119176|NCT04883476|||COHORT||PROSPECTIVE|||||||
34119177|NCT05556434|||COHORT||PROSPECTIVE|||||||
34119178|NCT02113319|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119179|NCT00656682|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34119180|NCT03593590|||COHORT||PROSPECTIVE|||||||
34119181|NCT02230345|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34119182|NCT05788445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There are two stimulating colis with the same shape, color and touch. The one is able to stimulate, the other is able to sham-stimulate. All patients are randomly assigned to use one of the two coils for treatment. Except for the designer, all participant, care provider, investigator, and outcomes assessorthey don not know who used which coil to treatment.|There are two groups in this study. One group includes patients who receive nrTMS stimulation with high frequency on the contralateral Broca's area on the right hemisphere. The second group includes patients who receive nrTMS sham stimulation with high frequency on the contralateral Broca's area on the right hemishere.|t|t|t|t
34119183|NCT06717932|||OTHER||PROSPECTIVE|||||||
34119184|NCT04074564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119185|NCT02208219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149805|NCT02560298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731867|NCT00898703|||CASE_ONLY||PROSPECTIVE|||||||
33812279|NCT01366352|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33812280|NCT03060785|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812281|NCT01584167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812282|NCT02404298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812283|NCT03462966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812284|NCT00405834|||||PROSPECTIVE|||||||
33812285|NCT06324097|||CASE_ONLY||RETROSPECTIVE|||||||
33812286|NCT03442998|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33812287|NCT02006641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812288|NCT05899348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812289|NCT03749005|||COHORT||RETROSPECTIVE|||||||
34149806|NCT01906112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731868|NCT04838314|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled prospective trial||||
33731869|NCT00886210|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33731870|NCT01940120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731871|NCT03712475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731872|NCT00833924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731873|NCT02790346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731874|NCT05811624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Study participants will be randomized (1/1) into one of the two treatment arms (control or intervention)|t|f|t|t
33731875|NCT05430828|||CASE_ONLY||OTHER|||||||
33731876|NCT00617682|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33731877|NCT00789282|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33731878|NCT01448018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731879|NCT03775668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731880|NCT04683185|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33731881|NCT02489747|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731882|NCT00569686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33731883|NCT00534690|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33731884|NCT06424886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization will be done by sealed envelope method.|a randomized, controlled, single-blind, prospective study|f|f|f|t
33731885|NCT00370526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731886|NCT05811611|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33731887|NCT04488328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731888|NCT01828034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731889|NCT03800498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731890|NCT03304899|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731891|NCT01410734|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731892|NCT00425399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731893|NCT03060772|RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals with alcohol use disorder will be randomized to receive the study medication, pioglitazone, or no medication (12 in each group). A third group of healthy individuals who do not have an alcohol use disorder will also be enrolled to serve as an additional comparison group.||||
33731894|NCT01620580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33731895|NCT01392950|RANDOMIZED|PARALLEL||||NONE||||||
33731896|NCT05103124|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33731897|NCT00120432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731898|NCT00638703|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731899|NCT01610128|||||PROSPECTIVE|||||||
33731900|NCT02332551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731901|NCT04834934|||COHORT||RETROSPECTIVE|||||||
33731902|NCT05525182|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, investigator staff and all site personnel will remain blinded to group allocation from randomization until database lock; randomization data will not be accessible by anyone involved in the study unless knowledge of the study treatment is relevant to the safety of the patient|"Phase II -Dose-finding Phase II will be enrolled 424 patients (1:1:1:1 ratio) randomly assigned to one of the four treatment groups as follows.~* ES16001 480 mg /day~* ES16001 720 mg /day~* ES16001 960 mg /day~* Placebo~Phase III In the phase III, safety and efficacy with the dose selected in the phase II will be compared with placebo. In the phase III, about 706 patients will be randomized in 1:1 ratio to test drug or placebo. Randomization will be stratified depending on the well-known risk factors for progression and disease severity of a patient. Final Endpoints and the sample size may be different depending on the results of the phase II."|t|t|t|f
33731903|NCT00607763|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33731904|NCT05828017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731905|NCT06008964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33731906|NCT04718935|||COHORT||PROSPECTIVE|||||||
33812290|NCT06278194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812291|NCT01415206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33731907|NCT02923518|||CASE_CONTROL||PROSPECTIVE|||||||
33731908|NCT06381869|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33731909|NCT02616211|||CASE_ONLY||PROSPECTIVE|||||||
33731910|NCT03972839|||COHORT||PROSPECTIVE|||||||
33731911|NCT00670228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731912|NCT01541826|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33812292|NCT01135719|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33731913|NCT02171598|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731914|NCT02450214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731915|NCT05037565|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731916|NCT00998634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731917|NCT04399161|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33731918|NCT01299831|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33731919|NCT04124172|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants received rTMS vs simulated stimulation without information of their status. Physical therapy and clinical evaluation will be carried out blindly with respect to the status of brain stimulation. Only the researcher who performs the rTMS knows the intervention condition.|It is a randomized design (rTMS vs simulated stimulation before upper limb rehabilitation session) in patients with a single stroke (\< 6 months) and unilateral involvement with upper limb paresis (Fugl Meyer \> 22).Patients received 15 consecutive rTMS (real or not) plus rehabilitation. Clinical evaluation will be performed before, at the end and one month after the intervention. A neurophysiological exam will be performed before and after the intervention also.|t|f|t|t
33812293|NCT03547206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All clinic staff and participants will be masked to group assignments. Only the Data and Safety Monitoring Board (DSMB) and designated unmasked staff at the Coordinating Center will have access to the group assignments.||t|t|t|t
33812294|NCT05391867|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open label randomized clinical trial||||
33812295|NCT00923169||||TREATMENT||||||||
33812296|NCT05325983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33812297|NCT03052517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731920|NCT06340035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In the study, blinding will be implemented to minimize bias. The evaluating clinician will be blinded to participant group assignments, ensuring assessments are unbiased. Similarly, the data analyst will also be blinded, analyzing data without knowledge of group allocations to maintain impartiality. Data will be handled objectively, with statistical methods applied blindly to compare treatment groups. Despite challenges in completely blinding participants due to the distinct nature of interventions, every effort will be made to minimize potential bias.|This pilot study utilizes a randomized parallel-group design, focusing on procedure feasibility for future clinical trials, in line with extended CONSORT guidelines for pilot studies. Participants, selected through a convenience sampling method due to their chronic knee pain, received pre- and post-treatment evaluations to assess the effect on gluteal muscle function. Post-informed consent, participants were allocated to either TENS or ultrasound-guided percutaneous nerve stimulation via a computer-generated randomization process executed with GraphPad Software (San Diego, CA, USA), ensuring a balanced 1:1 ratio.|f|t|t|t
33731921|NCT03759912|||COHORT||PROSPECTIVE|||||||
33731922|NCT03636750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731923|NCT04107571|||COHORT||PROSPECTIVE|||||||
33731924|NCT05286190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731925|NCT04776967|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33812298|NCT05504447|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"1. Parallel study design.~2. There is a control group (placebo).~3. Blinding method: non-blind.~4. Random assignment: yes"|t|f|f|t
33812299|NCT01470209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812300|NCT02976272|||OTHER||PROSPECTIVE|||||||
33812301|NCT00004085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812302|NCT06506552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812303|NCT00039884|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33812304|NCT03847545|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort Study||||
34119186|NCT04750421|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The operator will guarantee the confidentiality of the part of facial where the trasillumination was used, the assessors will not be aware of the part of the face where the transillumination was used.|"The random assignment of the right or left side of the face on which the trasnillumination will be used will be done by numbered and sealed envelope.~Envelopes will be prepared before the start of inclusion. Each envelope will contain a sheet of paper whose contents cannot be guessed when the envelope is closed. Each sheet will be marked either Left+TL or Right+TL. Each envelope will contain a unique code number that will be randomly assigned to each patient after inclusion."|f|f|f|t
33812305|NCT05606796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both preserved and preservative-free drugs would be masked from the patient and the principal researcher. The pharmacist would remove actual labels, and mask them with new labels, coded ''X'' and ''Y'' latanoprost 0.005%, representing either preserved or preservative free medications, known to only the pharmacist.|Randomized clinical control trial.|t|f|t|f
33812306|NCT01307306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812307|NCT06052943|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812308|NCT04131855|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The procedures, data collection and data analysis will be done by the orthodontic post-graduate student who is the main investigator in this study, and will not be blinded.The patients will be blinded. This will be done by pumicing the occlusal surfaces of the teeth that are in the study quadrant, and the labial surfaces of the teeth in the control quadrant. The trial is hence a single-blinded study.|Participants will be placed in two different groups based on the randomization and will receive, or not receive the intervention, which is pumicing prior to bond-up, for the duration of the study.|t|f|f|f
33812309|NCT00184444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812310|NCT04931966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812311|NCT00330499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812312|NCT05159427|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a crossover study design. Subjects are asked to complete the study events/procedures in two phases (G.I intubation phase and no intubation phase) with a washout period of at least 5 days between phases.||||
34119187|NCT06068517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119188|NCT06719063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119189|NCT01740687|||COHORT||PROSPECTIVE|||||||
34119190|NCT02987257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119191|NCT04155476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119192|NCT04234568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119193|NCT01143220|||COHORT||PROSPECTIVE|||||||
34119194|NCT00736983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119195|NCT05772325|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34119196|NCT01750125|||COHORT||PROSPECTIVE|||||||
34119197|NCT03875638|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Subjects will be provided with identical-appearing tablets containing either placebo, levetiracetam 125 mg, or levetiracetam 500 mg.|Participants will be tested in a double-blind crossover design with twice daily, low-dose levetiracetam (125 mg twice daily) or high-dose levetiracetam (500mg twice daily) or placebo. Each dose and placebo will be administered for a four week period.The order of interventions will be counterbalanced across subjects, with randomization occurring in blocks of 6. There will be a 4 week washout period between each treatment period.|t|t|t|t
34119198|NCT06717724|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are divided into an experimental group that receives the basic treatment combined with the intervention and one control group that receives the basic treatment||||
34119199|NCT01678521|||CASE_ONLY||PROSPECTIVE|||||||
34119200|NCT02893020|||COHORT||PROSPECTIVE|||||||
33812313|NCT05934175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors are used|Prolonged exposure will be offered in a massed format with a total of nine 60 minutes sessions of imaginal exposure and processing and five 2 hour group session with psychoeducation, rationales and in vivo exposure during one treatment week followed by three individual 60 minutes sessions 1, 2 and 4 weeks afterwards.|f|f|f|t
33812314|NCT03165305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812315|NCT02100098|||COHORT||PROSPECTIVE|||||||
33812316|NCT03051074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||On the 2nd session, participants will be randomly assigned to start in the pool condition or comparison condition. Following a 1-week washout period, they will crossover to the other condition.||||
34119201|NCT04192591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731926|NCT03973346|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Multiple observation, pre-post with a secondary data source comparison group design, and a difference-in-difference modeling approach.||||
33731927|NCT03434756|NA|SINGLE_GROUP||SCREENING||NONE||||||
33731928|NCT03441906|||COHORT||PROSPECTIVE|||||||
33731929|NCT02075320|NA|SINGLE_GROUP||SCREENING||NONE||||||
33812317|NCT00783146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812318|NCT00639418|||||PROSPECTIVE|||||||
33812319|NCT00652600|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33812320|NCT02926118|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33812321|NCT04709185|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33812322|NCT06486428|||COHORT||PROSPECTIVE|||||||
33812323|NCT03197831|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33812324|NCT04119947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel ，Placebo control|t|t|t|t
34119202|NCT03929913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812325|NCT01256359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812326|NCT00321672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119203|NCT05139316|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34119204|NCT00956384|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119205|NCT05409066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119206|NCT05889286|||COHORT||PROSPECTIVE|||||||
34119207|NCT06095960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34119208|NCT04056403|||CASE_CONTROL||PROSPECTIVE|||||||
34119209|NCT03911297|||COHORT||PROSPECTIVE|||||||
34119210|NCT00749437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119211|NCT01607281|||||PROSPECTIVE|||||||
34119212|NCT03220022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119213|NCT02704208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119214|NCT06717750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119215|NCT01029535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119216|NCT06399536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical investigators, the responsible anesthesiologists and surgeons, the research assistants, and the participants will not be blinded to the treatment assignment, and the statisticians responsible for outcome analysis will be blinded.||f|f|f|t
34119217|NCT01796743|||CASE_CONTROL||PROSPECTIVE|||||||
34119218|NCT04841590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluator will be blinded. Parents will be blinded to the allocation group to which each subject belongs until the end of the study|A randomized controlled experimental clinical trial will be conducted where the evaluator and parents will be blinded to the allocation group for each subject|f|t|f|t
34119219|NCT03352765|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase I single arm, open label trial||||
34119220|NCT03721250|||OTHER||PROSPECTIVE|||||||
34119221|NCT05817461|NA|SEQUENTIAL||TREATMENT||NONE||||||
34119222|NCT03703388|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33812327|NCT02790788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812328|NCT00211276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812329|NCT05637684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled trial|t|t|f|t
33812330|NCT01597089|||CASE_ONLY||PROSPECTIVE|||||||
33812331|NCT05539118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812332|NCT02138838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119223|NCT00899912|||CASE_ONLY||PROSPECTIVE|||||||
34119224|NCT05659849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119225|NCT05716451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812333|NCT00635609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812334|NCT04433039|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33812335|NCT05493488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812336|NCT05637944|||COHORT||PROSPECTIVE|||||||
33812337|NCT04208828|||CASE_ONLY||RETROSPECTIVE|||||||
33812338|NCT02926313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812339|NCT03006393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812340|NCT00854594|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812341|NCT02580227|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33812342|NCT05870761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119226|NCT06328127|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119227|NCT02552797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119228|NCT01361984|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34119229|NCT05170412|||COHORT||CROSS_SECTIONAL|||||||
34119230|NCT05246514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119231|NCT05701917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812343|NCT03345706|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119232|NCT01849653|||COHORT||PROSPECTIVE|||||||
34119233|NCT04351594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119234|NCT03487094|RANDOMIZED|PARALLEL||OTHER||NONE|Eligible infants are randomized to commercial control or experimental product.|Multi-Investigator, Prospective, Randomized Clinical Trial||||
34119235|NCT03495401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intervention group given fortified synbiotic milk, control group given non-fortified synbiotic milk|t|t|t|t
34119236|NCT00342927|||COHORT||PROSPECTIVE|||||||
34119237|NCT01595477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731930|NCT02665871|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33731931|NCT00000102||PARALLEL||TREATMENT||DOUBLE||||||
33731932|NCT04767009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731933|NCT00858871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731934|NCT01485861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In Phase II participants and investigators were blinded with regard to treatment status (i.e., ipatasertib vs. placebo). Phase Ib and the safety cohort were open-label.||t|f|t|f
33812344|NCT02168855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812345|NCT05041894|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812346|NCT01427400|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33812347|NCT01586416|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33731935|NCT04131101|NA|SINGLE_GROUP||OTHER||NONE||||||
33731936|NCT03018392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731937|NCT04512911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the ablation procedures and medications treatment assignment, physicians and patients cannot be blinded to the randomization.|A total of 100 patients will be randomized in 1:1 fashion to investigation arms Endocardial - Epicardial (20 patients) or Endocardial ablation (20 patients) if patients have previously failed AAD and in 1:1:1 fashion randomization to Endocardial - Epicardial ablation (20 patients), Endocardial ablation (20 patients) and AAD (20 patients) if patients have not failed AAD previously. If during follow up VT recurrence occurs, treatment method that patient was assigned to will be considered failed and patients will undergo redo ablation (same as previously assigned to) or if AAD failed patient will be added a second AAD or changed to another AAD. If during follow up after second procedure or adjustment of AAD patient experiences VT recurrence the treatment method will be considered failed.|f|f|f|t
33731938|NCT00862407|||COHORT||RETROSPECTIVE|||||||
33731939|NCT01641562|||CASE_ONLY||PROSPECTIVE|||||||
33731940|NCT04688164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731941|NCT05408481|||COHORT||PROSPECTIVE|||||||
33731942|NCT02159547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33731943|NCT03627728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731944|NCT06021236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a randomized clinical trial design (randomized clinical trial) with qualitative analysis, which is a mixed-methods research. Research objects were randomly assigned to the experimental and control groups in a 1:1 manner. The experimental group received the mindfulness-based intervention designed and routine care, and the control group received usual care. A total of four questionnaires were filled in the pretest (T0), the first month of discharge (T1), the 3rd month of discharge(T2), and the 6th month of discharge (T3), including anxiety, depression, mental toughness, and stress perception. Qualitative interviews were conducted at T2 and T3 to understand the improvement of psychological problems.|t|f|f|f
33731945|NCT03072173|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|t|t|f
33731946|NCT02832674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731947|NCT03282552|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731948|NCT04026919|NA|SINGLE_GROUP||TREATMENT||NONE|"The random assignment of the participants was carried out according to the following criteria: 1) Prepare an unpredictable sequence of random numbers; and, 2) Keep this sequence hidden until the assignment was carried out. To hide the sequence, the person in charge of the random assignment was maintained out of the recruitment and pre-treatment evaluation.~The assignment was carried out controlling the following variables: sex, age (over or under 60 years), burden (score\> 17 in the Reduced Zarit caregiver burden interview), attendance or not to the SENDIAN program (psychological support users) and / or support groups or non-users) of the primary caregiver and the level of dependence of the elderly person with dementia (mild / moderate or severe)."|||||
33731949|NCT02699944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731950|NCT00931307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731951|NCT05848310|||CASE_CONTROL||RETROSPECTIVE|||||||
33731952|NCT00286416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33731953|NCT01922024|||COHORT||PROSPECTIVE|||||||
33731954|NCT01585480|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33731955|NCT00261716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731956|NCT02096458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731957|NCT01604343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731958|NCT03533062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731959|NCT05914727|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study comprises a cross-sectional case-control part and a prospective cohort part. In the cross-sectional part, exhaled breath samples with volatile and non-volatile compounds of ASMD patients and healthy controls will be collected. After potential biomarkers are identified in the cross-sectional part, patients will enter the longitudinal part in which the prognostic and monitoring value of these markers will be evaluated using clinical parameters.||||
33731960|NCT00075829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812348|NCT03353285|||COHORT||PROSPECTIVE|||||||
34119238|NCT00685061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812349|NCT03507699|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||a phase I inter-patient dose-escalation study.||||
33812350|NCT02815865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33812351|NCT06098833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812352|NCT04788810|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Oral route = 6 volunteers Dermal route = 6 volunteers||||
33812353|NCT04712032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Intraoperative imaging is unable to blind the surgeon. Patient is only blinded preoperatively.|National randomized controlled trial.|t|f|f|f
33812354|NCT03784222|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812355|NCT04347148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were randomly allocated to SNAGs (n = 41) or placebo (n = 39) treatment, constituted by a detuned laser. Both groups received their interventions 6 times over 4 weeks.|t|f|f|f
33812356|NCT02644980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812357|NCT02673866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812358|NCT00006203|RANDOMIZED|||TREATMENT||||||||
33812359|NCT05605158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812360|NCT01049854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812361|NCT04830345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812362|NCT05670457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119239|NCT00314821|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34119240|NCT02268643|||COHORT||PROSPECTIVE|||||||
34119241|NCT02649764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119242|NCT06072183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119243|NCT03347630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119244|NCT04593121|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34119245|NCT05672914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119246|NCT06718634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119247|NCT06562842|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34149807|NCT05300113|||CASE_ONLY||PROSPECTIVE|||||||
34149808|NCT03144869|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33731961|NCT04428866|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33731962|NCT00581282|||COHORT||PROSPECTIVE|||||||
33731963|NCT01060267|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33731964|NCT04306510|NA|SINGLE_GROUP||OTHER||NONE||||||
33731965|NCT06132022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Rondomized Controlled Trial|t|f|f|f
33731966|NCT06032624|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33731967|NCT04146480|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731968|NCT01528241|NA|SINGLE_GROUP||OTHER||NONE||||||
33731969|NCT00143611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33731970|NCT01876264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33731971|NCT02385812|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33731972|NCT02847793|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33731973|NCT00004804||||TREATMENT||||||||
33731974|NCT00660062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731975|NCT05886166|NA|SINGLE_GROUP||TREATMENT||NONE||Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.||||
33731976|NCT02699294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33731977|NCT00379470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731978|NCT03736824|||OTHER||PROSPECTIVE|||||||
33731979|NCT05161065|||CASE_ONLY||PROSPECTIVE|||||||
33731980|NCT02836171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731981|NCT05580224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33731982|NCT04223076|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Intra individual cross-over, double intervention|f|f|t|t
33731983|NCT06042790|||COHORT||RETROSPECTIVE|||||||
33731984|NCT04174729|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33731985|NCT00749463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731986|NCT04733157|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This trial will be an open-label, two-centre, randomized control trial with two parallel groups including 1,162 women who undergo elective or emergency caesarean deliveries at term. The study group will receive TXA 1g intravenously at the onset of skin incision. There is normal saline placebo for the control group. The study and control groups will both receive the standard care offered at caesarean section including 5 IU of oxytocin intravenously on delivery of the baby.|t|t|f|f
33731987|NCT05364528|||COHORT||RETROSPECTIVE|||||||
33731988|NCT04310761|||CASE_ONLY||RETROSPECTIVE|||||||
33731989|NCT03410225|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized through a permuted random blocks assignment procedure with block stratification (by age group). Strings of varying length (2, 4, 6, 8, for example), with equal allocations T and C (randomly ordered) within a string, are combined to produce a single, long string of T and C combinations (e.g. TTCCTCTTCCC, etc.). Because the long string is made up of blocks of T and C strings with equal allocations of Ts and Cs, the observed percentage of the sample in the treatment condition will always be very close to 0.5, and the true P(T) for all observations will be 0.5. Randomization will be conducted via an algorithm on the online portal at the time of enrollment in order for the project coordinator to assign the participant to an intervention arm.||||
33731990|NCT06336772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33731991|NCT03970473|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33731992|NCT00397995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33731993|NCT06187103|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, single-arm, single-site feasibility study designed to generate data describing the quality and applicability of on-couch high-performance CBCT imaging technology.||||
33731994|NCT02800148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33731995|NCT03352921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731996|NCT00287768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33731997|NCT05575648|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33731998|NCT06381349|||COHORT||PROSPECTIVE|||||||
33731999|NCT03620110|||CASE_ONLY||PROSPECTIVE|||||||
33732000|NCT03493490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomization of the study patient takes place pre-surgery. Successfully randomized patients will receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours postoperatively. All patients will be provided with a PCA device as postoperative rescue medication. Consequently the possibility of an inadequate postoperative pain treatment in the study patients is very low, also in the placebo group.|t|t|t|f
33732001|NCT06060574|||COHORT||PROSPECTIVE|||||||
33732002|NCT01495481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732003|NCT00020670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732004|NCT05598229|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732005|NCT00131235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33732006|NCT01980784|||COHORT||PROSPECTIVE|||||||
33812363|NCT00605605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812364|NCT00674037|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33812365|NCT02304289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812366|NCT05836844|||COHORT||PROSPECTIVE|||||||
33732007|NCT05702216|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomization in two groups: a Hybrid Tele-pulmonary Rehabilitation group and a classic Rehabilitation group.||||
33732008|NCT02109328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732009|NCT05130190|NA|SINGLE_GROUP||OTHER||NONE||||||
33732010|NCT03538340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33732011|NCT03957434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Baseline evaluation - Randomization to physiotherapy or standard usual care (12 weeks) - Post-treatment evaluation|f|f|t|t
33812367|NCT00000250|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33812368|NCT04447898|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34043819|NCT02504827|NA|SINGLE_GROUP||OTHER||NONE||||||
34043820|NCT06503484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732012|NCT03198910|||OTHER||RETROSPECTIVE|||||||
33732013|NCT02719158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33732014|NCT05680766|NA|SINGLE_GROUP||TREATMENT||NONE||IBS subjects fulfilling the eligibility criteria will follow a structured and personalised cardiovascular endurance training (CET).||||
33732015|NCT01720459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732016|NCT03287856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732017|NCT05065476|||OTHER||PROSPECTIVE|||||||
33732018|NCT01007695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732019|NCT01533246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732020|NCT02674178|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33732021|NCT05039970|RANDOMIZED|PARALLEL||OTHER||NONE||This study will be a 2-arm parallel group cluster randomized, prospective, observational study in a real-world setting of organizations delivering the National DPP LCP. Cohorts will be randomized 1:1 to experimental or control arms. Participants in the experimental arm will download WellQuest™ and be instructed on use of the game. Participants in the control arm will proceed with routine National DPP participation. The study will focus on session attendance during the first 6 months of the 12-month program. Data will be received from 2 main sources. A secondary data analysis will be conducted on individual-level data collected by each participating organization (eg, demographics, sessions attended, body weight, minutes of physical activity). For the experimental arm only, individual-level data collected via the game use will include game downloads and daily time spent playing the game. Data on satisfaction will be collected via surveys disseminated through the game.||||
33732022|NCT00134381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732023|NCT05117944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33732024|NCT06388551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732025|NCT01010282|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33732026|NCT01589432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732027|NCT04710251|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33732028|NCT03217929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732029|NCT02378844|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33732030|NCT01973322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732031|NCT01020019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732032|NCT00497536|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732033|NCT01395940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732034|NCT00754182|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33732035|NCT05796245|||COHORT||RETROSPECTIVE|||||||
33732036|NCT05192837|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Throughout the study patient data is collected in the electronic health record (LUKiS) in an uncoded manner. Allocation will be blinded. At the end of the study the LUKiS reporting team will generate a report, which will include all study data in a de-identified form. The analysis of the report with the pseudonymized data will be performed by the project statistician.|Patients will be randomised in a 1:1 ratio to either the intervention or control group using service of the University of Graz (www.randomizer.at). Before randomisation patients will be pre-stratified for age (≤60, \>60 years) and procedure (intermediate versus high-risk procedures). Both factors have been identified in a previous retrospective cohort study at our institution as risk factors for complications. For that reason, minimization, as an efficient way to control for confounding in small to moderately sized trials, will be used. Also, minimization automatically ensures concealment of random allocation since there is no pre-existing randomization list.|f|f|t|t
33732037|NCT00953329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119248|NCT03704493|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The intervention consists of a video shown to the patient while exercising on the treadmill. It shows 5 amateur runners running across woods and fields. The group is film form behind giving the patient the impression of running within the group.||||
33732038|NCT04902495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732039|NCT02648191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119249|NCT04102007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119250|NCT06717139|||COHORT||PROSPECTIVE|||||||
34119251|NCT01041261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732040|NCT01310322|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732041|NCT05133882|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Arm 1:30 mg Arm 2:40 mg Arm 3:60 mg|f|f|t|f
33732042|NCT04187365|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|No masking.|In Arm 2, women with severe postpartum urinary retention will be randomized to 3 or 7 days of foley catheter.||||
33732043|NCT02178475|||CASE_ONLY||PROSPECTIVE|||||||
33732044|NCT06379490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732045|NCT03660410|||COHORT||RETROSPECTIVE|||||||
33732046|NCT05441735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33812369|NCT04856098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study is a 2-part crossover study where the study subjects participate either in part 1 (18 subjects) or in part 2 (16 subjects). The parts can run in sequence or in parallel. The study subjects in part 1 receive single doses of Ultibro Breezhaler on 3 periods and the study subjects in part 2 receive single doses of Ultibro Breezhaler on 2 periods.||||
33812370|NCT00269815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812371|NCT04917185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812372|NCT02551705|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33812373|NCT01906905|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812374|NCT01428583||||SUPPORTIVE_CARE||NONE||||||
33812375|NCT05033756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812376|NCT00929526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119252|NCT05459298|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34119253|NCT06717958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119254|NCT03407768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119255|NCT00541112|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119256|NCT05456048|||COHORT||RETROSPECTIVE|||||||
34119257|NCT01889992|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119258|NCT06305208|||COHORT||PROSPECTIVE|||||||
34119259|NCT02878395|||COHORT||PROSPECTIVE|||||||
34119260|NCT04676906|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119261|NCT00871078|||CASE_CONTROL||PROSPECTIVE|||||||
34119262|NCT06717607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119263|NCT06519136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The three interviewers responsible for data collection and the patients will be blinded as to which group they are in.~According to the lists created after block randomization in the computer environment, the researcher will obtain written consent from those who agree to participate in the research. Patients in both groups will be blinded by stating that they will receive Reiki treatment remotely. In addition, until the end of the research, the group the patient is in will not be written on the data collection forms, and all three interviewers will be blinded."||t|f|f|t
34119264|NCT06716242|||COHORT||PROSPECTIVE|||||||
34119265|NCT04076332|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34119266|NCT06694012|||COHORT||PROSPECTIVE|||||||
34119267|NCT04412954|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34119268|NCT01897532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119269|NCT04562116|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119270|NCT06268899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Participant: the researcher learned the study and control groups after the pre-test data. The study group was trained with the mobilization protocol. The control group received training on the current mobilization procedure of the clinic. Participants did not know which group they were in.~Outcomes Assessor. Study and control groups data were coded into the SPSS programme as group one and group two. Analysis of data was done by an independent statistician. The statistician has no information about which group the patients belong to."|This study protocol describes the design of a single-center, single-blind, statistician-blind randomized controlled trial to be conducted in the Orthopedics and Traumatology Clinic of a provincial university hospital in Turkey.|t|f|f|t
34119271|NCT01088503|||COHORT||PROSPECTIVE|||||||
34119272|NCT06716541|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119273|NCT01920490|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34119274|NCT02750514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119275|NCT06669455|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34119276|NCT06648486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119277|NCT00051077|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34119278|NCT01926743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119279|NCT00529360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119280|NCT06330116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will use a prospective randomized open-blinded endpoint (PROBE) design with baseline measurements, intervention phase and follow-up measurements, and controls without intervention. The results are then analyzed and blinded to the evaluators.|141 consecutive adult subjects, 71 men and 70 women, referred to hospital, due to symptoms of snoring and mild to moderate sleep apnea will be randomized, included, and examined at three different sights, Umeå(Sweden), Lund(Sweden) and Köge(Denmark) One hundred-five of them, 35 in each treatment group, will receive one of the 3 different forms of training and the final 36 persons serving as controls, age/AHI matched (18 in Köge resp Umeå). Patients in Umeå will be randomized to either training with IQoro or serving as controls. Patients in Köge will be randomized to either training with Exciteosa group training, or controls.|f|f|f|t
34119281|NCT05930561|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|No masking in Dose Confirmation (Part 1). In Dose Expansion (Part 2), participants and outcomes assessors will be masked to treatment arm for the duration of the trial.|In Dose Confirmation (Part 1), subjects (n=12-18) will be sequentially assigned to one of two open-label dose levels of 4D-150 (n=6-9 per dose level). In Dose Expansion (Part 2), subjects (n=54) will be randomized to receive one of two dose levels of 4D-150 (n=18 per dose level) based on results from Dose Confirmation, or aflibercept control (n=18). Subjects will be masked to treatment arm in Dose Expansion (Part 2).|t|f|f|t
34119282|NCT06714305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119283|NCT06148818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119284|NCT06709079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119285|NCT06087133|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34119286|NCT04084041|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34119287|NCT06716840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119288|NCT00210444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119289|NCT02817958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119290|NCT01105663|||COHORT||PROSPECTIVE|||||||
34119291|NCT06718517|||COHORT||PROSPECTIVE|||||||
34119292|NCT04596644|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This study comprises a 16-day inpatient stay. On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.||||
34119293|NCT03690908|||CASE_CONTROL||RETROSPECTIVE|||||||
34119294|NCT03448042|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119295|NCT05589909|||COHORT||PROSPECTIVE|||||||
34119296|NCT06714864|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149119|NCT04055454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"As safety precaution, the study will begin with enrollment of two successive unblinded dose groups of sentinel participants randomized into groups of four in an open-label fashion (group A and B). All site personnel, Sponsor and participants will be unblinded.~Then remaining participants will be randomized in a blinded manner to one of three Treatment Groups (A, B, C). Site personnel responsible for study medication handling, preparation and Administration will be unblinded, only."||t|t|t|t
34149120|NCT00457223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812377|NCT05175794|||COHORT||PROSPECTIVE|||||||
33812378|NCT05856409|||COHORT||PROSPECTIVE|||||||
33812379|NCT06086548|||CASE_CONTROL||RETROSPECTIVE|||||||
33838437|NCT03230604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Intervention: Bulk full composite (3M) bulk fill composite in posterior class one cavities bulk fill composite in posterior class two cavities bulk fill composite in posterior class five cavities~Intervention:Bulk full composite (Ivoclar-Vivadent) bulk fill composite in posterior class one cavities bulk fill composite in posterior class two cavities bulk fill composite in posterior class five cavities Other: bulk fill composite Intervention Control: Nano resin composite (K Z350 xt) Restoration in class one cavities Restoration in class Two cavities Restoration in class five cavities"|t|t|t|t
33838438|NCT06035042|||COHORT||PROSPECTIVE|||||||
33732047|NCT03085329|RANDOMIZED|PARALLEL||TREATMENT||NONE|The nature of this comparative study makes masking device assignment impractical. The objectivity of the outcome assessment will rely upon adherence to formally defined criteria for device support failure.|With written informed consent from the mother or parents, infants born at less than 30 weeks gestation and who are capable of breathing spontaneously within the first 72 hours postnatal, will be supported by bubble nasal continuous positive airway pressure (Bn-CPAP), randomized to the standard device from Fisher \& Paykel or to Seattle-PAP.||||
33732048|NCT04587193|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33732049|NCT02805530|NA|SINGLE_GROUP||TREATMENT||NONE||"First line systemic treatment Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.~Radical treatment to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.~Radiation: radiation therapy Patients will receive dose and fraction regimen according to the metastatic site.~Chemoradiotherapy Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin."||||
33732050|NCT00340262|||COHORT||PROSPECTIVE|||||||
33732051|NCT01045304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732052|NCT02850874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732053|NCT06317493|||CASE_CONTROL||PROSPECTIVE|||||||
33732054|NCT06269172|||OTHER||PROSPECTIVE|||||||
33732055|NCT03307668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732056|NCT04042883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732057|NCT02967367|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732058|NCT02420106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732059|NCT01026870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732060|NCT04702373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732061|NCT00570518|||CASE_CONTROL|||||||||
33732062|NCT02677090|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33732063|NCT02266056|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33732064|NCT05188352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732065|NCT03109678|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33732066|NCT03684447|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Participants randomized to the high dose will exit the study after treatment. Participants randomized to the low dose who have not experienced response are able to crossover to the high dose.|t|t|t|t
33732067|NCT01193907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33732068|NCT00957437|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732069|NCT01454934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732070|NCT05161676|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33732071|NCT01140763|||CASE_ONLY||PROSPECTIVE|||||||
33732072|NCT00754247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33732073|NCT01252290|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732074|NCT04181346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinding|"chemotherapy-naive patients, scheduled to receive moderately and highly emetogenic chemotherapy will be randomized for two arms: pregabalin and placebo.~All patients received will receive IV ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg before chemotherapy on day 1 and oral dexamethasone 4 mg, bd, on days 2 and 3."|t|f|t|f
33732075|NCT05818371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single center, prospective, open diagnostic study, proof-of-concept||||
33732076|NCT04490993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732077|NCT03214003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732078|NCT02639364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732079|NCT01632891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732080|NCT05013931|||COHORT||PROSPECTIVE|||||||
33732081|NCT01703637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732082|NCT05473975|||COHORT||PROSPECTIVE|||||||
33732083|NCT03989193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732084|NCT04450251|||OTHER||PROSPECTIVE|||||||
33732085|NCT04296396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were randomized to either an individualized opioid prescription protocol (IOPP) that includes shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg.|f|f|f|t
33732086|NCT04144166|||COHORT||CROSS_SECTIONAL|||||||
33732087|NCT01626261|||COHORT||PROSPECTIVE|||||||
33732088|NCT01183975|||COHORT||PROSPECTIVE|||||||
33812380|NCT04062578|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"In order to achieve the objectives of the study the investigators have chosen to conduct a controlled clinical trial. For the clinical trial they will define two intervention groups in collaboration with two women's soccer clubs: CD Oliver Urrutia and SD Huesca.~They will carry out the physiotherapy program of lumbopelvic stabilization and strengthening of the musculature of the hip region carried out in the CD Oliver Urrutia (Zaragoza), club where the principal investigator will have a practice contract. The club will agree to implement the physiotherapy program in training with players from the Second National Division. The SD Huesca will be the control group, in which they will only perform the pre and post intervention measurements. The selected team was the first women's team of the club, which plays in group 1 of the Aragonese territorial league.~When selecting football clubs, they will be taken into account the same profile of players and training."||||
33838439|NCT02292472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838440|NCT02205034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732089|NCT05934435|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Biostatistician will be blinded to ER treatment group or Wait-list Control group.|After randomized 1:1 to one of two unblinded study groups: ER and Wait-List Control, participants randomized to the ER group will complete the ER class. A crossover intervention class will be offered to those patient participants randomized to WLC once the ER group has completed their class and follow up assessments, estimated at 2 months post intervention.|f|f|f|t
33732090|NCT05752968|||COHORT||CROSS_SECTIONAL|||||||
33732091|NCT04528810|||COHORT||PROSPECTIVE|||||||
33732092|NCT02353559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732093|NCT01660711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732094|NCT03376243|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33732095|NCT02482350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732096|NCT05832346|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|masking the participants that they do not know which group will be allocated in this pilot study.||t|f|f|f
34043821|NCT04988880|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Pre-post intervention multicenter clinical study to evaluate the territorial implementation of a specific Multiple Sclerosis Expert Patient Program of Catalonia (PPEC-EM) based on peer learning regarding quality of life, knowledge and self-management related to the health process of participants in 6 areas in Catalonia. It will start after the approval of the respective CEICs. The deployment will consist of 12 groups of patients (2 per unit): 6 groups with people with recurrent MS and 6 with people with progressive MS.||||
34043822|NCT06198491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34043823|NCT04398589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119297|NCT05874089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinding is achieved by packaging probiotics and placebo in the same sealed and consecutively numbered containers with sachets similar in packaging, smell, and taste. All study participants and on-site study personnel will remain masked for the treatment allocation (randomized controlled trial phase) until database lock and signature of the statistical analysis plan.|This is a single-center randomized, double-blind, placebo-controlled trial. Patients will be recruited from Long Covid out-patient Clinics at Policlinico di Milano Hospital (Milan, Italy) and randomly assigned (1:1) to receive VSL#3® or placebo at the dosage of 2 sachets/die for 28 days. Fasting blood samples and feces will be collected before (t0) and after treatment (t4). Primary and secondary outcome will be assessed at baseline (t0), end of treatment (t4) and end of follow-up (t8) using validated questionnaires (i.e. CFS- Chalder Fatigue Scale; HAD- Hospital Anxiety and Depression Scale, SF36 - Short Form Health Survey, Structured Assessment of Gastrointestinal Symptoms Scale - SAGIS; Symptoms Check List 12 - SCL-12; Karnofsky Performance Status - KPS; Visual Analogue Scale- VAS). Subject participation in this study will be approximately 10 weeks, which include 2-weeks screening/run in period, 4-weeks treatment period and 4-weeks follow-up period.|t|f|t|f
34119298|NCT06590181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119299|NCT06714721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients included in the study will be randomized using the Random Allocation Software (RAS) on the computer and divided into two groups: the treatment group and the sham group. All patients will receive an outpatient pulmonary rehabilitation program that includes bronchial hygiene techniques, controlled breathing techniques, respiratory muscle training, aerobic exercises, muscle strengthening, flexibility and stretching, and posture exercises. In addition to the PR program, rPMS will be applied to the patients in the treatment group to stimulate and strengthen the diaphragm muscle. rPMS will be applied to the patients in the sham group without switching it on and a recorded sound of the machine will be played in the background.|Prospective, sham-controlled, single-blind, randomized controlled trial|t|f|f|f
34119300|NCT06336213|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119301|NCT06719388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are unaware of their group allocation (experimental or control) to minimize bias in self-reported outcomes and adherence to the intervention. However, investigators and outcome assessors are not masked due to the nature of the intervention.|Participants are randomly assigned to one of two parallel groups: the experimental group, which receives exercise therapy combined with a jaw-mobilizing device, or the control group, which receives exercise therapy only. Both groups are followed concurrently throughout the study period.|t|f|f|f
34119302|NCT02740465|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119303|NCT06423508|||COHORT||PROSPECTIVE|||||||
34119304|NCT06420297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119305|NCT06717906|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34119306|NCT02828384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34119307|NCT06593600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732097|NCT03761251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732098|NCT00848328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732099|NCT04491162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The observer was not allowed to know the treatment allocation. The patients were instructed not to discuss anything regarding his/ her treatment allocation with the examining investigator.||f|f|t|f
33732100|NCT04038489|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will receive aspirin and tamoxifen with standard AC-T chemotherapy||||
33732101|NCT05731401|||OTHER||CROSS_SECTIONAL|||||||
33732102|NCT04871243|||COHORT||PROSPECTIVE|||||||
33732103|NCT01639040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732104|NCT04265573|||OTHER||PROSPECTIVE|||||||
33732105|NCT03492697|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732106|NCT03987958|||COHORT||PROSPECTIVE|||||||
33732107|NCT05873595|||COHORT||OTHER|||||||
33732108|NCT01228929|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33732109|NCT00503386|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33732110|NCT03744377|||COHORT||PROSPECTIVE|||||||
33732111|NCT04334642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The research will have as a convenience sample Athletes from the Paralympic Boccia Brazilian Team, which will be compared with itself in the data analysis.||||
33732112|NCT03083691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The treatment period is subdivided in Treatment Part A and B which differ between the two cohorts:~Cohort 1 (non-squamous NSCLC):~During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At time of disease progression another re-biopsy is mandatory before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.~Cohort 2 (SCLC):~Patients have to undergo a prescreening for high Tumor Mutation Burden. Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, another re-biopsy is mandatory before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity."||||
33732113|NCT01753635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812381|NCT06430086|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Statistician will be masked to study condition. Participants cannot be masked. Other personnel involved in the study cannot be masked.|Randomized crossover design|f|f|t|f
33732114|NCT01020071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812382|NCT05830032|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Healthy adults will be recruited for this single blind randomised controlled cross over study. Participants will be provided with powdered fibres and a non-fibre control (blinded) with detailed instruction on how to dilute these to produce an orange flavoured drinks. They will record any digestive symptoms experienced over four different 7-day intervention arms. The participants will record their bowel habits (stool frequency and form) during these intervention periods and provide stool samples before and after each period from which we will measure pH, water content and short chain fatty acids (SCFA) concentration.|t|f|f|f
34119308|NCT06581575|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Triple-blinded study||t|t|t|t
34119309|NCT01812057|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34119310|NCT03157050|||OTHER||PROSPECTIVE|||||||
34119311|NCT00002322||||TREATMENT||DOUBLE||||||
34119312|NCT02807701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119313|NCT01638507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119314|NCT00551889||||TREATMENT||||||||
34119315|NCT05160701|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||To test our research aims we will use a stepped wedge cluster randomized design (SWD) and matched control group. All enrolled individuals will be grouped into a rollout unit. This unit could be comprised of individuals living in a group home or multiple group homes, a group of clients served by a case manager at an agency or a division of an agency. We anticipate that units will have approximately 10 - 15 clients and that we will have approximately 25 units across participating agencies. This design allows the study team to address problems with the rollout of the machines facilitating a good phase-in of the intervention for each unit. Third, this design addresses issues associated with the diffusion of the intervention within agencies that would occur with individual randomization while maintaining strong internal validity and assessment of the treatment effect.||||
34119316|NCT01843530|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119317|NCT02375100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119318|NCT00329043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119319|NCT01081158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119320|NCT01079312|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119321|NCT02373904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119322|NCT02622035|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34119323|NCT06622005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119324|NCT00102661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119325|NCT03634956|NA|SINGLE_GROUP||PREVENTION||NONE||Group A. Sugammadex sodium-IONM in thyroid surgery Group B.Standart technique-IONM in thyroid surgery||||
34119326|NCT06070662|||CASE_CONTROL||PROSPECTIVE|||||||
34119327|NCT05874726|||CASE_CONTROL||PROSPECTIVE|||||||
34119328|NCT05722015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119329|NCT06678542|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34119330|NCT06716255|||COHORT||PROSPECTIVE|||||||
34119331|NCT06033625|||CASE_CONTROL||OTHER|||||||
34119332|NCT06719245|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33732115|NCT00889343|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732116|NCT01331070|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838441|NCT03376750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||three-arm randomized control trail (RCT) including pre/post intervention and follow-up|f|f|t|t
33838442|NCT00660322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33838443|NCT02616159|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33838444|NCT02710331|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34119333|NCT01191151|||COHORT||PROSPECTIVE|||||||
34119334|NCT04896801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119335|NCT06340763|||COHORT||OTHER|||||||
34119336|NCT04855370|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single center study to evaluate the use of non-invasive measurement of stroke volume and cardiac output to assess risk and response to treatment in patients with acute pulmonary embolism (PE). We anticipate enrolling a total of 40 subjects at Ronald Reagan UCLA Medical Center.||||
34119337|NCT06637462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119338|NCT05261711|NA|SEQUENTIAL||TREATMENT||NONE||This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.||||
34119339|NCT06176248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119340|NCT05024474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The interventions were not possible to mask for participants or health care professionals (physiotherapist leading interventions). The physiotherapists who performed the tests after interventions were blinded to the group allocation. All data were coded and group assignment was blinded for the outcome analyses.|Randomized controlled trial|f|f|f|t
34119341|NCT00473018|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE||||||
34119342|NCT05622578|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34119343|NCT06635551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34119344|NCT04332783|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119345|NCT06715358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119346|NCT03364153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119347|NCT01621178|RANDOMIZED|PARALLEL||TREATMENT||NONE|Dulaglutide dose was blinded to participant, care provider, investigator and outcomes assessor.|||||
34119348|NCT03959085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119349|NCT04461639|||COHORT||PROSPECTIVE|||||||
34119350|NCT05770596|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34119351|NCT02259816|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34119352|NCT05942716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119353|NCT05986929|||CASE_ONLY||PROSPECTIVE|||||||
33732117|NCT01959646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33732118|NCT00763659|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33732119|NCT00577083|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33732120|NCT00006125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732121|NCT02993679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732122|NCT02493634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119354|NCT00900497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119355|NCT03278548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119356|NCT06717698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34119357|NCT00879489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119358|NCT06026865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119359|NCT04708535|||COHORT||PROSPECTIVE|||||||
34119360|NCT04979598|||COHORT||PROSPECTIVE|||||||
34119361|NCT06105866|||COHORT||PROSPECTIVE|||||||
34119362|NCT00034216|||COHORT||PROSPECTIVE|||||||
34119363|NCT06007677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732123|NCT03731533|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will be enrolled in WellStart. The control group will continue with usual care. Study subjects from both groups will be sent commercial home lab kits to test lipid and hemoglobin A1c levels, as well as a digitally connected scale and blood pressure monitoring device.||||
33732124|NCT01764607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812383|NCT05508477|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In this clinical trial, the experimental vaccine and the control vaccine will have different packages. In order to maintain the blinding process, the unblinded team will be appointed to place the vaccine in the syringe. The other team members will later inject the vaccines according to the random group that has been selected. The injection team do not know what kind of vaccine is in the syringe.|There will be 2 groups in the study. One adult group (18 year-old and above) with 5 µg dose, and 1 control group using CoronaVac Bio Farma. The UNAIR vaccine group will consist of 3 sub group based on different lot. Both vaccines will be administered with 2-dose schedule, intramuscularly. All cohorts will be followed for 6 months.|t|f|t|f
33812384|NCT01252537|||COHORT||PROSPECTIVE|||||||
33812385|NCT02123667|||COHORT||PROSPECTIVE|||||||
33812386|NCT03224988|||CASE_CONTROL||PROSPECTIVE|||||||
33812387|NCT04728100|||CASE_ONLY||PROSPECTIVE|||||||
33812388|NCT01456156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812389|NCT03730727|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Although the trial order will be randomized, it is not possible to blind the participant or the investigator to the timing between meals and physical activity. However, the trial allocation and order will be blinded to the outcomes assessor when statistical analyses are performed.|Three independent groups of participants will enter 1 of 3 studies, each of which involves a randomised, crossover, controlled trial containing 4 trials: (i) control, meal ingestion no activity; (ii) activity bout immediately prior to meal; (iii) activity bout immediately after ingestion of meal; (iv) activity bout 30-mins after ingestion of meal.|f|f|f|t
33812390|NCT03741621|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34119364|NCT06138366|||COHORT||PROSPECTIVE|||||||
33812391|NCT02056847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119365|NCT06717464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119366|NCT05154227|||COHORT||PROSPECTIVE|||||||
34119367|NCT06578182|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119368|NCT06093464|RANDOMIZED|CROSSOVER||OTHER||NONE||All participants will do the intervention but at different times and in different orders.||||
34119369|NCT05918445|NA|SEQUENTIAL||TREATMENT||NONE||||||
34119370|NCT03827239|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34119371|NCT06718530|||COHORT||PROSPECTIVE|||||||
34119372|NCT01977222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119373|NCT00403130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119374|NCT06525480|||CASE_ONLY||RETROSPECTIVE|||||||
34119375|NCT02273089|||COHORT||PROSPECTIVE|||||||
34119376|NCT04073056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119377|NCT00281593||||TREATMENT||||||||
34119378|NCT03319641|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||diagnostic study||||
34119379|NCT03787329|||CASE_CONTROL||PROSPECTIVE|||||||
34119380|NCT06589050|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|After the participants have completed the pre-measurements, they will be assigned to their group allocation. The intervention´s nature precludes blinding the participants and the trainer; however, a supervisor will monitor data collection.|This is a parallel-group randomized controlled study. Participants will be randomly assigned to one of three parallel groups (two experimental groups and one control group) with a 1:1:1 ratio. To balance the covariates of age and sex among the three groups, a computer-based program will perform stratified randomization within three blocks.||||
33812392|NCT00164996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33812393|NCT05058157|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each testing cycle design will be either a complete or partial cross-over.||||
33812394|NCT01747538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812395|NCT05950594|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732125|NCT05593796|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In phase 0:~. These patients will undergo toxicological and psychiatric assessment and will be screened using the inclusion and exclusion criteria.~phase 1:~treatment-as-usual (TAU)- Group offered usual treatment include detoxification, medical care. Clinician-delivered CBT-Group offered 12 weekly, individual sessions of manual-guided CBT (15) delivered by trained clinician .~phase2: a follow-up at 3-month post treatment phase without treatment."||||
33812396|NCT05579717|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomized to an intervention group or a waitlist control group. Individuals in the waitlist control group will be offered the opportunity to participate in EAL once they have completed the study.||||
33838445|NCT03414541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838446|NCT02946671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838447|NCT04051086|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838448|NCT02539849|NA|SINGLE_GROUP||OTHER||NONE||||||
33732126|NCT03179826|||CASE_ONLY||CROSS_SECTIONAL|||||||
33732127|NCT00376168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732128|NCT01018459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33732129|NCT03808402|||COHORT||PROSPECTIVE|||||||
33732130|NCT02090452|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732131|NCT05900479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732132|NCT02822508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119381|NCT05962229|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Within-subject, single-blinded crossover study. Participants will be randomized to the order of the 3 conditions using a Latin Square design.|t|f|f|f
34119382|NCT06263595|||COHORT||PROSPECTIVE|||||||
34119383|NCT05804721|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34119384|NCT00812955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119385|NCT05324579|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Human subjects undergoing clinically planned neurosurgical procedures||||
34119386|NCT00216281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119387|NCT06157034|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Phase1 - 200 population size will be divided into 4 treatment groups~Phase2~* The phase will check the impact of selected nutraceuticals on TB patients with dietary counseling and all collected data in Phase1 will be repeated at the end~* 3 selected nutraceuticals Zingiber officinale, Carum carvi, and Mentha spicata will be used against placebo and each placed in a separate group with 50 subjects for 3 months~* Before dispensing treatments, raw material will be processed and encapsulated in prescribed doses in 4 groups after breakfast and dinner T1-Placebo 100mg/d, T2-Zingiber Officinale powder (500mg 2x/d=1000mg/d), T3-Carum powder(1g 2x/d=2g/d), T4-Mentha oil(2% of oil1.5ml 2x/d=30mg/d)~Phase3~- The impact of withholding the intervention will be studied to observe any change in selected parameters"||||
34119388|NCT03885401|RANDOMIZED|PARALLEL||SCREENING||SINGLE|It is not possible to blind clinicians, patients, or patient navigators. Outcomes assessors (e.g. chart abstractors, database managers, and the researchers) will be blinded to condition when abstracting, entering, or assessing data.|This study is a clinician level randomized controlled trial. Sixty clinicians will be randomized to intervention (enhanced care planning for health behaviors, mental health, and social needs) or control condition (usual care). The investigators will randomly survey all patients with MCC from each clinicians' patient panel. Patients with at least one uncontrolled MCC will be randomly selected for inclusion until 10 patients are recruited from each clinician. The investigators will use hybrid implementation-effectiveness design to measure outcomes. Implementation outcomes include enhanced care plan completion; the prevalence of health behavior, mental health, and social needs; goals patients prioritize and how they want to address them; and the type, intensity, and follow-up of care team support provided to address patient goals. Effectiveness outcomes include the number of uncontrolled chronic conditions and patient reported physical, mental, and social health..|f|f|f|t
34119389|NCT04321005|||COHORT||PROSPECTIVE|||||||
34119390|NCT00648284|||||PROSPECTIVE|||||||
34119391|NCT05912621|RANDOMIZED|PARALLEL||TREATMENT||NONE||204 patients with BMI 27-39.9 kg/m2 and fasting plasma glucose \< 126 mg/dL will be screened to enroll 68 (to complete 60) who will be randomized 1:1 (computer generated randomization with blocking by sex and BMI category (27-29.9, 30-34.9, 35-39.9 kg/m2) to tirzepatide or dietary weight loss for 22 wks. Individuals with BMI 27-29.9 kg/m2 must have an additional cardiovascular risk factor or weight-related comorbidity.||||
34119392|NCT03534388|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility comparing to retrospective data.||||
34119393|NCT03111030|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119394|NCT05195489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119395|NCT06715176|||OTHER||PROSPECTIVE|||||||
34119396|NCT04944147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119397|NCT05035238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Each subject will receive triple intramuscular dose of TURKOVAC 3 µg/0.5 mL or 4,5 µg/0.5 mL Vaccine on Day 0, Day 28, and Day 120. 200 healthy subjects in both genders will be dosed in double blinded groups with 1:1 randomization ratio.|t|f|t|t
34119398|NCT06206850|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm||||
34119399|NCT03364647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, outcomes assessors, and the PI will be blinded as to the participant's group assignment.|Parallel assignment|t|f|t|t
34119400|NCT05905536|NA|SINGLE_GROUP||OTHER||NONE||cardiac patient population through the major part of their continuum of care, with monitoring starting at the start of the subjects holding room pre-operative preparation and continuing through surgery to recovery in the Cardiovascular Intensive Care Unit (CVICU), where monitoring will continue until the pulmonary artery catheter (PAC) is removed||||
34119401|NCT04760873|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with GAVE will undergo therapy with a cryotherapy device||||
34119402|NCT05105321|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34119403|NCT05958914|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study involves an enrollment of 45 total patients, referred to the Medically assisted reproduction Center, divided into 3 groups, of 15 patients each: Group 1 (control) women with regular ovarian cycle; Group 2- non-PCOS women undergoing ovarian stimulation and ICSI treatment; Group 3- women with PCOS undergoing ovarian stimulation and ICSI treatment||||
34119404|NCT05444881|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parents will be randomly assigned to either receive treatment immediately after consent is obtained or wait for 6 weeks. Parents and children in the intervention group will be asked to complete a phone assessment at baseline and immediately after the intervention (posttreatment) to assess preliminary clinical outcomes. Hair and saliva samples will be collected from both parents and children at baseline and posttreatment. Parents will also complete a brief semi-structured interview on the feasibility and acceptability of the mHealth mindfulness program at posttreatment. There will be a brief follow-up phone assessment for clinical outcomes in parents at 4-8 weeks posttreatment. Parents and children in the waitlist group will complete the same measures as those in the intervention group at baseline and after their six weeks wait before they complete the mHealth intervention. There will be a brief phone assessment at posttreatment (parent and child) and 4-8 weeks follow-up (parent only).||||
34119405|NCT06530277|RANDOMIZED|CROSSOVER||OTHER||NONE||The intervention will be compared to a 6-week passive control (waitlist with delayed intervention, AB-BA design) in a cross-over study design.||||
34119406|NCT06645886|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149121|NCT02282904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812397|NCT04378036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two different treatment methods were applied to the participants (n=30). Rehabilitation programs based on individual Neurodevelopmental Therapy were applied to the participants included in the study for eight weeks (first group). In the next eight weeks, the Hippotherapy Simulator system was applied to the same participants in addition to individual Neurodevelopmental Therapy-based rehabilitation programs (study group).||||
33812398|NCT06451107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The design will consist of a single-blind, randomized controlled trial, corresponding to an experimental longitudinal analytical study.|f|f|f|t
34119407|NCT05859178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor will not be involved in treatment delivery. Participants in the control group will carry out sham exercise.|Participants assigned to the exercise group will perform strengthening exercise. Those assigned to the control group will carry out stretch exercise that is not known to have any effect on nerve regeneration.|t|f|f|t
34119408|NCT02804061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119409|NCT01136369|||CASE_ONLY||PROSPECTIVE|||||||
34119410|NCT04795531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119411|NCT06717451|||COHORT||PROSPECTIVE|||||||
34119412|NCT00929214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119413|NCT00363584|RANDOMIZED|||TREATMENT||||||||
34119414|NCT05807568|NA|SINGLE_GROUP||OTHER||NONE||||||
34119415|NCT00713687|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119416|NCT06065124|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, prospective, randomized controlled, open-label clinical trial||||
34119417|NCT06090344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34119418|NCT04124627|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119419|NCT03334006|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The control group receives a Standard-of-Care treatment. The intervention group is additionally treated with IgGAM (Pentaglobin®) as an add on treatment to Standard-of-Care.~The preparation to be provided contains (per ml solution) 50 mg human plasma proteins, of which \>95% are immunoglobulins: IgM 6 mg, IgA 6 mg and IgG 38 mg. The IgG subclass distribution is IgG1 \~63%, IgG2 \~26%, IgG3 \~4%, IgG4 \~7%.~Pentaglobin® is administered by continuous intravenous infusion over a period of 5 day of 0.4 ml/kg body weight/hour until the total dose of 7mL/kg body weight/day is reached."||||
34119420|NCT01101451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119421|NCT06554275|||COHORT||PROSPECTIVE|||||||
34119422|NCT04861584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119423|NCT00003929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119424|NCT03573024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119425|NCT02345239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119426|NCT06717009|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The researchers will randomize participants into a 3D trial group and a conventional group for comparison. The 3D trials group will undergo preoperative 3D reconstruction, while the conventional group will only undergo routine CT/MRI.||||
34119427|NCT02530268|||COHORT||PROSPECTIVE|||||||
34119428|NCT06719128|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34119429|NCT06003166|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34119430|NCT02707341|||COHORT||PROSPECTIVE|||||||
34119431|NCT03291340|||COHORT||PROSPECTIVE|||||||
34119432|NCT01925586|||COHORT||PROSPECTIVE|||||||
34119433|NCT06552429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119434|NCT02258802|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119435|NCT06545032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119436|NCT06165991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119437|NCT06131788|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The HAWA study is a community-based participatory research conducted in 22 harm reduction centres in France which will be cluster randomised to determine those who will propose the intervention (standard services + brief education to hand washing + MONO-RUB distribution) and those who will be the control group (standard services). After randomization, each group of HR centres will include 220 PWID within an inclusion period of 12 months and a follow-up period of 6 months.|t|f|f|f
34119438|NCT04641221|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||f|f|t|t
34119439|NCT05421676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119440|NCT05140239|||COHORT||PROSPECTIVE|||||||
34119441|NCT05595746|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are assigned a number by hiding their names. While the measurements are being made, the researcher does not know which group the participant belongs to. All radiographic and clinic measurements are collected in one file.|Controlled, non-randomized, single-blind, parallel|t|f|t|t
34119442|NCT04364555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119443|NCT00508482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119444|NCT03321799|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119445|NCT03561155|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34119446|NCT05194150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119447|NCT03934866|||COHORT||PROSPECTIVE|||||||
34119448|NCT03836040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119449|NCT03663192|||COHORT||PROSPECTIVE|||||||
34119450|NCT05741476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119451|NCT03789981|||COHORT||PROSPECTIVE|||||||
34119452|NCT04175600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812399|NCT02077374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838449|NCT01843725|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838450|NCT00543023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838451|NCT02749110|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34119453|NCT04699344|||COHORT||PROSPECTIVE|||||||
34119454|NCT02622191|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34119455|NCT05566561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group.|There are two models for this study. Parasartorial compartment block (PSCB) group, and control group.|t|f|f|t
34119456|NCT02805140|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34119457|NCT06717477|||COHORT||OTHER|||||||
34119458|NCT06615050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119459|NCT05936424|RANDOMIZED|PARALLEL||OTHER||NONE|As this is a resistance exercise training intervention, participants will be unable to be masked to their treatment condition.|Randomized controlled trial (RCT), within-between subject design. Legs will be randomized to one of four groups: non-exercise control (CON), exercise control (EX), Follicular based training (FOL), Luteal based training (LUT)||||
34119460|NCT04138095|NA|SINGLE_GROUP||TREATMENT||NONE||Within subject design||||
34149122|NCT00624416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812400|NCT03677167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The physiotherapist who examines patients before and after the intervention does not know which group the patient belongs to|The study will include 52 subjects with heel pain for more than 12 weeks. The subjects will be randomly assigned to one of two groups: a barefoot walking group on a treadmill and a walking group in shoes on a treadmill. The subjects will receive treatment twice a week at the Meuhedet Health Fund Institute for 4 weeks. All subjects will be instructed to walk on the treadmill until they reach level 6 on the Short Borg Scale. In addition, all subjects will receive an ultrasound treatment for 5 minutes each session. Before and after the intervention, the subjects will complete the SF-36 questionnaire, and will assess the level of pain they experience on the heel during initial treading down from the bed in the morning. In addition, the minimum pain threshold and pain tolerance will be checked with an algometer at relevant points in the heel and the speed and walking time will be documented.|f|f|f|t
33812401|NCT06237621|||COHORT||PROSPECTIVE|||||||
33812402|NCT04737993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812403|NCT00884676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812404|NCT06404983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33812405|NCT00003599|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33812406|NCT04313985|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Both the participant and the care provider will be masked as to what treatment the participant is receiving during each study visit. Only the study coordinator will know which treatment is being conducted.||t|t|t|f
33812407|NCT04582994|||OTHER||PROSPECTIVE|||||||
33812408|NCT03853889|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33812409|NCT00985088|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33812410|NCT01765855|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812411|NCT03490500|||COHORT||PROSPECTIVE|||||||
33812412|NCT02763657|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812413|NCT01413737|||COHORT||RETROSPECTIVE|||||||
33812414|NCT01049698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812415|NCT00063089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812416|NCT00388856|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33812417|NCT01109277|||COHORT|||||||||
33812418|NCT00489554|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33812419|NCT03105960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This was a double-blind study as the investigator was unaware about the sampling of the groups and study subjects were unaware about the mouthwash they were using|A Randomized Clinical Trial parallel|t|f|t|f
33812420|NCT01662713|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33812421|NCT03890653|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33812422|NCT06390345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812423|NCT02555865|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812424|NCT02009332|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The phase 1 dose-escalation portion used the 3+3 dose escalation rule. Initially 3 patients will be treated. If none develops DLT following the third weekly instillation, the dose can be escalated. If only 1 of the first 3 patients develops DLT, then an additional 3 patients will be treated at that dose. At any dose level, if 2 or more cases develop DLT, the prior dose will be defined as the MDD once 6 patients have been treated at this level with less than 2 patients experiencing a DLT.~In phase 2, up to 29 patients will receive intravesical ABI-009 and gemcitabine using the Simon 2-stage design: initially, there will be only 10 patients enrolled with a rejection rule that only if there are 2 or more positive responses will the study proceed to further enrollment of the next 19 patients."||||
33812425|NCT01607320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812426|NCT02815800|NA|SINGLE_GROUP||OTHER||NONE||||||
33812427|NCT05804357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible patients were divided into two groups using the closed envelope method at a ratio of 1:1. The patients did not know which group they were in. Mobilization applications and other clinical tests were performed by the same physiotherapist in the study.|This study was designed as a double-blind randomized controlled clinical trial. In order to carry out the prospectively designed study, ethics committee approval was obtained from the Non-Interventional Clinical Research Ethics Committee of Muş Alparslan University with the decision numbered 21 taken at the meeting dated 29.12.2020 and numbered 15. Informed consent was obtained from all patients included in the study before the study.|t|f|f|f
33812428|NCT05647642|||COHORT||PROSPECTIVE|||||||
33812429|NCT02428595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812430|NCT01019226|||COHORT||RETROSPECTIVE|||||||
33812431|NCT05298540|NA|SINGLE_GROUP||OTHER||NONE||||||
33838452|NCT04366505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participants will be allocated to one of two NFB groups (real NFB or control group) in a double-blind procedure.~Participants of both groups will be further sub-divided into a mindfulness-based relapse prevention (MBRP) and a TAU group (single-blind)."||t|f|t|f
33838453|NCT02555553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838454|NCT05342805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119461|NCT04764526|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The participant will be their own control and will be randomised to start with control followed by intervention or the opposite order.||||
34119462|NCT06705569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34119463|NCT04345055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119464|NCT05122546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119465|NCT00457392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119466|NCT01580228|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119467|NCT00477984|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34119468|NCT02751944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34119469|NCT04760769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119470|NCT06577337|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34119471|NCT05473507|||COHORT||PROSPECTIVE|||||||
34119472|NCT00339716|||COHORT||PROSPECTIVE|||||||
34119473|NCT04663074|||COHORT||PROSPECTIVE|||||||
34149123|NCT01077089|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34149124|NCT06391853|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34149125|NCT02517671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149126|NCT01638104|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33837027|NCT04851158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The sample of the study consisted of volunteer patients who applied to the adult emergency service, and who were administered antibiotics (amoxicillin / cefuroxime sodium) upon the physician's request, and who met the inclusion criteria of the study.~Criteria for inclusion in the study:~* Being over the age of 18,~* Having no communication problem such as seeing, hearing and understanding problem,~* Having no disease that can cause sensory loss,~* Not having had IM injection in the last week,~* Having no complication related to IM injections such as pain, abscess, infection, tissue necrosis, and hematoma at the injection site."|The sample size was determined as 35 persons for each group at the 0.5 effect size and 0.05 error level with the power analysis performed by taking into account the numerical values of the findings obtained from a previous study on this subject. ShotBlocker group:35; Local vibration group: 35; Control group:35 person|t|f|f|f
34119474|NCT05086393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study will be triple-blind, thus, the patients, clinicians, and study members involved will be unaware of patient allocation during this study. After the patient completes his or her Central Sensitization Inventory, a study coordinator will grade the survey to determine if the patient should be allocated to the groups with central sensitization or without. Each patient will receive a study ID based on his or her group (detailed in Section XIV). A computer randomization system will be used to allocate patients to receive either duloxetine or a placebo based on their study ID. Only members of the Rush pharmacy staff will possess the list matching the study ID to the study group assignment, ensuring that the study remains triple-blinded and that study coordinators are unaware of a patient's assignment when he or she picks up the study medication from the pharmacy.|Patients randomized to the experimental arm of the study will receive 30 mg of duloxetine and will be advised to consume the medication orally daily starting one week prior to surgery and to continue until 6 weeks following surgery. The dose of 30 mg was selected as that has been used as that is the largest starting dose used in other RCTs without requiring a preceding adjustment period at a lower dosage. Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm. Both groups of patients will receive their medications from the pharmacy at Rush Medical Center, which will be responsible for providing patients with the appropriate regimen. All patients will receive the same postoperative multimodal analgesic regimen that is normally administered as part of conventional care to patients undergoing THA and TKA at Rush University Medical Center.|t|t|t|f
34119475|NCT06450886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119476|NCT04565990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119477|NCT00727116|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119478|NCT02761135|||CASE_CONTROL||PROSPECTIVE|||||||
34119479|NCT06676280|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34119480|NCT05231876|||COHORT||PROSPECTIVE|||||||
34119481|NCT05278520|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34119482|NCT06717542|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two arm designed||||
34119483|NCT06206434|||COHORT||PROSPECTIVE|||||||
34119484|NCT00761345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119485|NCT06447545|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34119486|NCT01378117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119487|NCT06718127|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119488|NCT05231278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119489|NCT06713031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119490|NCT01444105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119491|NCT03783871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119492|NCT06644040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119493|NCT06713590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119494|NCT06274983|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119495|NCT05541848|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34119496|NCT04929210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119497|NCT03239457|||CASE_ONLY||PROSPECTIVE|||||||
34119498|NCT05780879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119499|NCT04855357|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A cluster-randomized, wait-list controlled designed trial where PSH sites will be randomized into intervention and wait-list control groups. Those in the wait-list control group will receive usual care first and then cross over to the intervention arm.||||
34119500|NCT00655837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119501|NCT02896309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119502|NCT06141083|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34119503|NCT06716060|||CASE_ONLY||CROSS_SECTIONAL|||||||
34119504|NCT03390504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119505|NCT06715111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119506|NCT05745155|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants, clinicians, and the research team will be blinded to the device output FLARES until the end of the data collection period|This question will be answered by a double-blinded, comparative, device efficacy investigation, comparing the standard of care with a virtual arm simulating care delivered by acting on FLAREs generated by the Senti-AI subsystem.||||
34119507|NCT05414175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119508|NCT06414668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119509|NCT05130294|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized controlled, double-blinded, placebo-controlled|t|t|t|f
34119510|NCT02121093|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34119511|NCT01538121|||CASE_CONTROL||PROSPECTIVE|||||||
34119512|NCT05751759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119513|NCT05653700|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||This study is a prospective randomized controlled longitudinal crossover design with a per protocol analysis integrating one sensor (WHOOP, inc Platform) and one educational intervention (Arena Strive Platform).||||
34119514|NCT06506110|||COHORT||RETROSPECTIVE|||||||
34119515|NCT04258852|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34119516|NCT01037803|||CASE_ONLY||PROSPECTIVE|||||||
34119517|NCT05384912|||OTHER||OTHER|||||||
34119518|NCT06278922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI will be masked to study condition. All outcome data will be collected via online self-report surveys.||f|f|t|t
33837028|NCT02441439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732133|NCT01394926|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732134|NCT04482296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732135|NCT02567513|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732136|NCT03394872|||COHORT||PROSPECTIVE|||||||
33732137|NCT00775281|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732138|NCT05789836|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This research was planned as a single group pretest-posttest quasi-experimental.||||
33732139|NCT01369875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732140|NCT04359368|||CASE_ONLY||RETROSPECTIVE|||||||
33732141|NCT01693328|||COHORT||PROSPECTIVE|||||||
33732142|NCT02240888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812432|NCT04749329|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients were randomized in two groups (Control Group, without mesh; Mesh Group, receiving Bio-A mesh supported colostomy in an ante rectus fashion). Participants were randomly allocated to one of the two groups using computer-generated permuted blocks (www.randomization.com), just before colostomy fashion. For each patient, an identification number was generated. This latter was utilized during all the follow-up period guarantying the blinding process. Patients, care providers, staff collecting data and those assessing the endpoints, in fact, we're all blinded to group allocation. Because the blinding of the operating surgeons was not feasible, they were not involved in the|This study is a Binary outcome superiority trial. The sample size was calculated by Sealed Envelope Ltd. 2012. The calculation was based on the evaluation of PH rate at 3, 6, 12 and 24 months postoperatively in patients undergoing colostomy. In literature same trials reported a decrease in the incidence of PH in the mesh groups versus suture alone (xx). Therefore, we hypothesized a decrease of PH between Control and Mesh group of 25% (from 35 % to 10%). It was estimated that 49 subjects per group would be required to detect an absolute improvement of 25% (35% vs 10%) in the primary outcome between the two groups, with two-tailed α of 0.05 (2-sided 5% significance level) and a power of 80%. Data analysis was conducted according to an intention-to-treat approach. Loss to follow-up was estimated in about 10% of included patients. Therefore, a total of 110 patients (55 for each group) were included in the study.|t|f|t|f
33812433|NCT01841385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812434|NCT04529200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded randomization as assessor and patient both were unaware|Total 40 patients fulfilling the inclusion criteria will be included in this study. Treatment will be given 3 times a week for 24 weeks by researcher with each session lasting for 40 to 45 Minutes. Assessment will then be done at baseline, after 04, 08, 12 and 24 weeks.|t|t|f|f
33812435|NCT03806205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33812436|NCT00053300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812437|NCT02917759|||COHORT||PROSPECTIVE|||||||
33812438|NCT00534677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812439|NCT02627794|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33812440|NCT01990794|||COHORT||PROSPECTIVE|||||||
33812441|NCT04947618|||COHORT||RETROSPECTIVE|||||||
34119519|NCT01281111|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33812442|NCT03096132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812443|NCT02560155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812444|NCT06233149|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33812445|NCT03500276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blinded rater will be used to assess disease activity by DAS28CRP score.|Randomized controlled clinical trial|f|f|f|t
33812446|NCT03380676|||CASE_CONTROL||PROSPECTIVE|||||||
33812447|NCT04301752|||CASE_ONLY||PROSPECTIVE|||||||
33812448|NCT02578004|||CASE_CONTROL||RETROSPECTIVE|||||||
33837029|NCT04550819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34119520|NCT06247735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119521|NCT03156829|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34119522|NCT02485015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119523|NCT05378113|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34119524|NCT06657105|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34119525|NCT04211363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119526|NCT06126120|||OTHER||CROSS_SECTIONAL|||||||
34119527|NCT02495285|||COHORT||PROSPECTIVE|||||||
34119528|NCT00845702|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119529|NCT00939354|||CASE_ONLY||PROSPECTIVE|||||||
34149127|NCT04689152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149128|NCT05527886|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The researchers collecting data will be blinded to the intervention provided||f|f|t|f
33732143|NCT01470846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732144|NCT00342251|||||PROSPECTIVE|||||||
33732145|NCT00614016|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33732146|NCT05867147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732147|NCT01746758|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732148|NCT00730899|||COHORT||PROSPECTIVE|||||||
33732149|NCT01140477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732150|NCT00743912|NA|SINGLE_GROUP||OTHER||NONE||||||
33732151|NCT01641367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732152|NCT06270550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732153|NCT03391973|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-centre, single arm phase 2 study of Pembrolizumab (Keytruda™ or MK-3475) in treatment naïve patients with poor prognosis carcinoma of unknown primary site (CUP).||||
33732154|NCT03222375|||COHORT||PROSPECTIVE|||||||
33732155|NCT01178892|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33732156|NCT06031259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732157|NCT05459064|||OTHER||RETROSPECTIVE|||||||
33732158|NCT02361528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732159|NCT04796233|||COHORT||CROSS_SECTIONAL|||||||
33732160|NCT02897596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732161|NCT00240370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732162|NCT05583188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119530|NCT03637400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double blind trial in which both subjects and study personnel will be masked to the specific treatment arm to which the subject has been assigned and to the results of cultures obtained from the site of infection. The pharmacist will only be unblinded to the liquid formulation, in order to prepare the formulation based upon the subject's weight.||t|t|t|t
34119531|NCT03613064|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34119532|NCT03457077|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
34119533|NCT03586518|||COHORT||PROSPECTIVE|||||||
34119534|NCT00893360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119535|NCT01020188|||CASE_ONLY||PROSPECTIVE|||||||
34119536|NCT06717841|||COHORT||RETROSPECTIVE|||||||
34119537|NCT06712134|||COHORT||RETROSPECTIVE|||||||
34119538|NCT06417671|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|"The randomization of the participants to the supplement or placebo condition will be performed via a random integer set generator (Random.org) available online.~Neither the participants, nor the supplement provider will be aware of whether participants receive the postbiotic supplement or the placebo. Additionally, blood samples will be masked during the biochemical analysis, and during the statistical analysis."||t|t|f|t
34119539|NCT06715527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119540|NCT06173505|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119541|NCT04815564|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes Assessor will be blinded to the participant information.||f|f|f|t
34119542|NCT02476448|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34119543|NCT04020640|||COHORT||PROSPECTIVE|||||||
34119544|NCT06654037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119545|NCT04660760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119546|NCT03023371|||COHORT||PROSPECTIVE|||||||
34119547|NCT06510816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-masked|t|t|t|t
34119548|NCT05162586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119549|NCT02873078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119550|NCT04047446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119551|NCT03551782|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119552|NCT03978845|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All patients will be submitted to the same procedures. There will be no between-group comparisons.||||
34119553|NCT02341066|||COHORT||PROSPECTIVE|||||||
34119554|NCT02013609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119555|NCT00015847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119556|NCT06032390|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Neither the participant nor the radiologic technician performing the mammography examination will know to what study arm the participant was allocated. Radiologists reading the screening examinations will be blinded to the intervention at initial reading but not in the consensus meeting.|Participants will be randomized to an intervention or control arm. Intervention arm will be triaged based on AI result score.|t|t|f|f
34119557|NCT04286178|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||This study will be a double-blinded, placebo-controlled, randomized, multiple baseline design (MBD) where each subject will be randomly allocated a start time for the active supplements|t|t|t|t
34119558|NCT03760172|||COHORT||OTHER|||||||
34119559|NCT06675461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician||f|f|f|t
34119560|NCT02563782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119561|NCT02885142|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34119562|NCT00147576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34119563|NCT06033287|||COHORT||PROSPECTIVE|||||||
34119564|NCT00017914|||COHORT||OTHER|||||||
34119565|NCT06020261|NA|SINGLE_GROUP||TREATMENT||NONE||pre assessment, 12 sessions of manualized Parent Management Training, post assessment||||
34119566|NCT06481670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119567|NCT04971928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119568|NCT06717243|||COHORT||PROSPECTIVE|||||||
34119569|NCT06524375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119570|NCT02138825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119571|NCT05268757|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Computerized randomization only known to the principal investigator, who are not directly involved in data collection or data analysis|Double blinded randomized clinical trial with a test and placebo group|t|t|t|t
34119572|NCT05425017|||COHORT||PROSPECTIVE|||||||
34119573|NCT02576873|||COHORT||RETROSPECTIVE|||||||
34119574|NCT05634408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119575|NCT04832347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34119576|NCT05248490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119577|NCT05791214|||OTHER||PROSPECTIVE|||||||
34119578|NCT01709357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119579|NCT06252376|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34119580|NCT00748631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119581|NCT05351528|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34119582|NCT06629454|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34119583|NCT06717516|||COHORT||PROSPECTIVE|||||||
34119584|NCT02979574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119585|NCT06716775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119586|NCT06311682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For subjects aged 2 to \<12 years at screening, the trial is double-blind to ensure an objective evaluation of efficacy and safety of the Investigational Medicinal Product (IMP). The subject, the subject's caregiver(s), and the investigator involved in the clinical evaluation and monitoring of the subjects will not be aware of the treatment from baseline to Week 16. However, the site staff that responsible for administering tralokinumab will be aware of the treatment allocation as tralokinumab is visibly different from placebo and has a higher viscosity, requiring more pressure to depress the plunger during injections.|The study design is parallel for children and a single group for infants.|t|t|t|f
34119587|NCT00776789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119588|NCT06716567|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Researchers analyzing the immunological outcomes are blinded to the groups of the subjects (pregnant vs non-pregnant).|Pregnant women and non-pregnant women are recruited in parallel.|f|f|f|t
34119589|NCT04512573|||COHORT||PROSPECTIVE|||||||
34043824|NCT06237738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study employs a single-blind design. In this setup, the participants are unaware of their group allocation, meaning they do not know whether they are in the intervention group (receiving the stress balls) or in the control group (receiving standard care without any additional intervention). The researchers and healthcare professionals administering the treatment are aware of each participant's group assignment. This approach ensures that the participants' responses and reported outcomes, such as pain levels measured by the Visual Analog Scale (VAS), are not influenced by their knowledge of the treatment received. The single-blind design is chosen to maintain the objectivity of the participants' responses while allowing the healthcare team to appropriately administer and monitor the intervention.|This single-blind, randomized, controlled clinical trial evaluated the effectiveness of stress balls in alleviating cannulation-related pain in adults undergoing hemodialysis. The study, which targeted a sample size of 64 based on G\*Power analysis for a 95% confidence interval and 80% power with an expected effect size of 0.68, successfully distributed participants into two equal groups of 32: an experimental group and a control group. Participants, aged 18 and above and experiencing a pain level of 1 or more on the Visual Analog Scale (VAS), were randomly assigned to either group. The experimental group utilized stress balls in their non-cannulating hand for three minutes before cannulation during their Monday, Wednesday, and Friday sessions, while the control group, attending on Tuesday, Thursday, and Saturday, received standard care. Data collection encompassed VAS pain level measurements and socio-demographic and medical information gathered via a semi-structured questionnaire.|f|f|t|f
34043825|NCT05646264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119590|NCT03170375|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Phase 1 of study: randomized crossover design, 14 days each of control vs. sodium-restricted DASH diet Phase 2 of study: randomized assignment, 6 months of motivational interviewing vs. motivational interviewing plus mobile application-based promotion of dietary adherence|f|f|t|t
34119591|NCT04042805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119592|NCT02772029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119593|NCT02670902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119594|NCT06098690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"* Participants \[blinding\]: participants will be randomly assigned to treatment and control groups, they will not be made aware of other participant's receipt of treatment or control materials. Participants will be asked not to discuss this project outside of the intervention; delivery of the intervention or other educational materials will be virtual, limiting the ability of participants to interact with one another during the study.~* Outcome assessor \[blinding\]: to reduce bias in the implementation and assessment of the clinical trial, participant information and pre-post survey responses will be maintained separately from the assignment and delivery of the intervention."|A parallel trial design will be used to examine the effectiveness of the Culturally Tailored HPV Psychoeducational Multimedia Community Intervention. Community members who are HPV vaccine naïve or under-vaccinated (given vaccine recommendations) will be randomly assigned to one of two conditions: 1) experimental condition in which they receive the tailored multimedia intervention, and 2) active control condition in which they receive general/standard materials.|t|f|f|t
34119595|NCT06162624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34119596|NCT06719141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119597|NCT04426747|||COHORT||CROSS_SECTIONAL|||||||
34043826|NCT02416830|||COHORT||PROSPECTIVE|||||||
34043827|NCT04846283|||CASE_ONLY||PROSPECTIVE|||||||
34043828|NCT02092545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043829|NCT03315975|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34043830|NCT05136547|||COHORT||RETROSPECTIVE|||||||
34043831|NCT05225610|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34043832|NCT02964520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34043833|NCT00032149||||TREATMENT||||||||
34043834|NCT00004063||||TREATMENT||||||||
34043835|NCT02196441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34043836|NCT04279470|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34043837|NCT02941211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043838|NCT03806933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043839|NCT00980239|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043840|NCT06471205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043841|NCT04090879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind dosing of tobacco cigarette nicotine levels.|Randomized parallel groups research design|t|f|t|t
34043842|NCT03422068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34043843|NCT06326554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm intervention||||
34043844|NCT01417741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34043845|NCT01156961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34043846|NCT01041157|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34043847|NCT06051266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34043848|NCT03948412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34043849|NCT06575023|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043850|NCT03465059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043851|NCT04808323|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043852|NCT01579786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34043853|NCT02054403|||COHORT||CROSS_SECTIONAL|||||||
34043854|NCT04687917|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blind masking|Cluster-randomized trial|f|f|f|t
34043855|NCT05953259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and primary outcome assessors will not know whether the allocated sternotomy closure system is STERN FIX or wires only.||t|f|f|t
34043856|NCT01232413|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34043857|NCT02507141|||COHORT||PROSPECTIVE|||||||
34043858|NCT01212419|||COHORT||PROSPECTIVE|||||||
34043859|NCT00957684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043860|NCT04267679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043861|NCT03249545|||COHORT||PROSPECTIVE|||||||
34043862|NCT03563352|||CASE_ONLY||PROSPECTIVE|||||||
34043863|NCT06578546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043864|NCT03458481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043865|NCT01122758|||COHORT||PROSPECTIVE|||||||
33732163|NCT04545515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732164|NCT02667938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732165|NCT03242681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732166|NCT02254538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732167|NCT00895180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732168|NCT02634138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732169|NCT04029467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732170|NCT05122949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732171|NCT02133729|NA|SINGLE_GROUP||SCREENING||NONE||||||
33732172|NCT04137796|||COHORT||PROSPECTIVE|||||||
33732173|NCT01445392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732174|NCT03863210|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732175|NCT05714579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732176|NCT02720575|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|t|f|f
33732177|NCT00519649|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33732178|NCT02529410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732179|NCT01325610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732180|NCT05899504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A new endoscopic clipping device called the over-the-scope-clip (OTSC) system (Ovesco Endoscopy, Tübingen, Germany) has become available for the closure of perforations, anastomotic leaks, and fistulas. The OTSC system has a stronger closing force than the through-the-scope hemostatic clip. Therefore, some researchers have reported esophageal SEMS fixation with an OTSC to prevent migration|f|f|t|f
33732181|NCT02833285|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812449|NCT04594876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients were randomly allocated by a computer-generated table into one of two study groups. The randomization sequence was concealed in opaque sealed envelopes. The envelopes were opened by the study investigators just after recruitments and admission to the operation room. Only assessors and data collectors were blinded to the group's allocations|Group P will receive cervical epidural Group F will receive cervical facet injection Both under fluroscopic guidance|f|f|t|f
33732182|NCT00974571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732183|NCT00006184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732184|NCT00395239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732185|NCT05433220|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33732186|NCT00355238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732187|NCT01420302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Algorithm-guided versus Nurse directed Blood Glucose Control|f|f|f|t
33732188|NCT04772534|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732189|NCT00976534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732190|NCT05425901|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33732191|NCT00750854|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33732192|NCT03343769|||CASE_CONTROL||PROSPECTIVE|||||||
34119598|NCT01701388|NA|SINGLE_GROUP||OTHER||NONE||||||
34119599|NCT06479239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119600|NCT02169011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732193|NCT02716233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812450|NCT01048385|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33812451|NCT02705729|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812452|NCT03531892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119601|NCT06717100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732194|NCT04522037|||COHORT||RETROSPECTIVE|||||||
34119602|NCT06689553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149809|NCT03511469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All assesment will be conducted with another therapist who is not aware of patient's treatment groups|Randomized Control, Parallel Group Study|f|f|f|t
33732195|NCT06371222|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||RCT||||
33732196|NCT00670800|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732197|NCT02375672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732198|NCT05871073|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33812453|NCT01754389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812454|NCT01875016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812455|NCT01580436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732199|NCT04808479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732200|NCT05470439|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Month 1 and Month 2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation, and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.|f|f|f|t
33732201|NCT03310424|||COHORT||PROSPECTIVE|||||||
33732202|NCT01403090|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732203|NCT01748786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732204|NCT05850156|||CASE_CONTROL||PROSPECTIVE|||||||
33732205|NCT04683991|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS26.0 will be placed in sequentially coded, sealed, opaque envelopes. Only 1 or 0 will be generated, and the number of 1 or 0 generated by SPSS26.0 is 17. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The number 1 represented the treatment group 1 and the number 0 represented the treatment group 2."||||
33732206|NCT05973591|||COHORT||RETROSPECTIVE|||||||
33732207|NCT04976491|||CASE_CONTROL||PROSPECTIVE|||||||
33732208|NCT04126512|||COHORT||RETROSPECTIVE|||||||
33732209|NCT04774159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind and use of similarly active and placebo tablets.||t|t|t|t
34119603|NCT05753215|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will receive an omadacycline-containing regimen versus SOC. Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.||||
34119604|NCT00030147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119605|NCT00239603|||DEFINED_POPULATION||PROSPECTIVE|||||||
34119606|NCT00358111|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34119607|NCT06578247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study has a double-blind design. Neither the participants nor any of the investigators, Sponsor, Independent Review Committee (IRC) or contract research organizations (CROs) will be aware of the treatments received. An independent biostatistician, not otherwise part of the Sponsor trial team, will generate the randomization schedule.||t|t|t|f
34119608|NCT02612493|||CASE_ONLY||RETROSPECTIVE|||||||
34119609|NCT05286710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119610|NCT00577200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119611|NCT03388372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119612|NCT05178186|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119613|NCT06587386|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34119614|NCT04767711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119615|NCT05149820|RANDOMIZED|PARALLEL||OTHER||NONE||Two stage randomisation process with participants first randomised to receive either Nudge or Preference electronic point of care randomisation prompt design, and then randomised to receive Liberal or Restrictive magnesium supplementation strategy.||||
34119616|NCT01952938|||COHORT||PROSPECTIVE|||||||
34119617|NCT04899895|||COHORT||PROSPECTIVE|||||||
34119618|NCT05212428|NA|SINGLE_GROUP||SCREENING||NONE||||||
34119619|NCT05991427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34119620|NCT03824951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119621|NCT04372875|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
34119622|NCT05237583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119623|NCT04167527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119624|NCT02003222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119625|NCT06480201|NON_RANDOMIZED|CROSSOVER||OTHER||NONE|Infusion order of saline to ketamine is single blind.|This trial is designed to study the mechanics of KET induced gamma band potentiation (GBP) as they relate to antidepressant outcome following a KET induction course. Disease (major depressive disorder \[MDD\]) and healthy control groups are included to measure disease and medication specific effects on initial KET induced GBP. The KET-EEG visits (infusion #1 \[all groups\], infusion #4 \[TRD only\]) follow a fixed-order, single-blind placebo-controlled crossover design.||||
34119626|NCT00994864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119627|NCT06716112|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34119628|NCT06141512|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will undergo the same exercise training intervention. Based on the outcome measure of VO2max, participants will be divided into groups with a low response for VO2max, a medium response, and a high response for VO2max. It will be investigated whether the change in plasma myokine levels differs between the 3 groups.||||
34119629|NCT00594789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34119630|NCT05720455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119631|NCT01823289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119632|NCT01841996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119633|NCT05290766|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119634|NCT05227170|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34119635|NCT05114746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119636|NCT06717789|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device||||
34119637|NCT05910047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34119638|NCT06717373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, non-randomized, un-blinded study in patients scheduled for a standard echocardiographic examination.||||
34119639|NCT06098326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119640|NCT02268383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119641|NCT05733689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119642|NCT01286597|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34119643|NCT04302116|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each patient will visit the clinic at Day 8, 14, 43, and 3 months by outcome assessor who is blinded for treatment to determine seizure frequency and adverse events. Those patients will be seen and under taking care of primary neurologists and pharmacists who are not blinded to treatment at the same visit as a standard clinical practice and check with compliance and adjust vigabatrin or prednisolone following each treatment allocated (if needed). Family or caregivers will not be blinded to treatment. EEG will be scored using BASED scores at Day 0 (before treatment), 14, and 43 to assess the resolution of hypsarrhythmia.|A pragmatic parallel group randomised trial comparing vigabatrin with high dose prednisolone to vigabatrin treatment alone in the treatment of infantile spasm.|f|f|t|t
34119644|NCT04027647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119645|NCT06716138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149810|NCT03854539|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33732210|NCT00169650|||COHORT||RETROSPECTIVE|||||||
33732211|NCT05948111|||CASE_CROSSOVER||PROSPECTIVE|||||||
33732212|NCT04568239|||CASE_ONLY||RETROSPECTIVE|||||||
33732213|NCT06482931|||COHORT||PROSPECTIVE|||||||
33732214|NCT03852316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732215|NCT04157062|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label study for participants who have opioid use disorder (OUD) that are eligible to have repetitive transcranial magnetic stimulation (rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC).||||
33732216|NCT01879696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732217|NCT02314715|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732218|NCT05431062|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Prospective Observational Study|t|f|f|t
33732219|NCT03131063|||CASE_ONLY||PROSPECTIVE|||||||
33732220|NCT01987427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732221|NCT02033733|||COHORT||RETROSPECTIVE|||||||
33812456|NCT06084988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812457|NCT01632085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812458|NCT01753674|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33812459|NCT00164021|||CASE_CONTROL||PROSPECTIVE|||||||
33812460|NCT03782285|||COHORT||PROSPECTIVE|||||||
33812461|NCT02102698|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33812462|NCT01979783|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812463|NCT02520336|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33812464|NCT01838603|||OTHER||OTHER|||||||
33812465|NCT00350129|||CASE_CONTROL||PROSPECTIVE|||||||
33812466|NCT00774592|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812467|NCT03620474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812468|NCT03477799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812469|NCT02733484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812470|NCT06366659|||COHORT||RETROSPECTIVE|||||||
33812471|NCT03541369|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33812472|NCT01187888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812473|NCT00297297|||CASE_ONLY||PROSPECTIVE|||||||
33812474|NCT04645849|||OTHER||PROSPECTIVE|||||||
33812475|NCT03798132|||COHORT||RETROSPECTIVE|||||||
33812476|NCT02560961|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33812477|NCT01019135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33812478|NCT05686837|||COHORT||PROSPECTIVE|||||||
33812479|NCT06499116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812480|NCT03560206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||a randomized controlled trial|t|f|f|f
33812481|NCT06372600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812482|NCT04050514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Unblinded with respect to the examiner, blinded to the patient and statisticians in the evaluation.|Multicenter, randomized two-arm study with active control group, stratified by gender.|t|f|f|t
33812483|NCT00487240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812484|NCT06301945|||COHORT||PROSPECTIVE|||||||
33812485|NCT02652845|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812486|NCT06469931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119646|NCT06719310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded in the stage one, open in the stage two||t|f|t|f
34119647|NCT05185947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119648|NCT02989181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34119649|NCT05710952|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119650|NCT01566240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119651|NCT05555446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both participant and investigator will not be aware whether subject is having the colostrum or the placebo|Subjects will subsequently have either the bovine colostrum and then the placebo or vice-versa|t|f|t|f
34119652|NCT06199232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119653|NCT02114177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119654|NCT05348811|NA|SINGLE_GROUP||TREATMENT||NONE||HAIC (GEMOX regimen) combined with donafenib and sintilimab||||
34119655|NCT03759990|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|f|t
34119656|NCT06718543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119657|NCT05738330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The design is a multi-center cluster-randomized trial with randomization performed at the level of the dialysis clinic. Dialysis clinics will be assigned to either the SMaRRT-HD group (15 clinics) or the Usual Care group (15 clinics). SMaRRT-HD is a symptom monitoring system that includes 1) tablet-based symptom reporting using a patient reported outcome measure (PROM) and 2) supported clinician follow-up consisting of symptom alerts, symptom management guidance, and tracking reports to share with patients. Dialysis clinics assigned to Usual Care will not use SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical interactions with participants and by administering a HRQOL survey. The trial uses a hybrid Type 1 effectiveness-implementation approach with effectiveness of the intervention assessed with patient-reported outcomes and biomedical outcomes, and implementation assessed with integrated qualitative and quantitative outcomes.||||
34119658|NCT04893863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119659|NCT06225115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119660|NCT05710887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomly assigned to one of two treatment arms (nitrous vs placebo). Dosing includes a single inhalation session of either 50% Nitrous oxide in oxygen mixture (FiO2 0.5) vs placebo (oxygen-air mixture FiO2 ≈0.3).|t|f|f|t
34119661|NCT06619899|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34119662|NCT06715605|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119663|NCT01302002|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119664|NCT00362492|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119665|NCT05434234|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119666|NCT06717061|||CASE_ONLY||PROSPECTIVE|||||||
34119667|NCT05056896|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blinded||t|f|t|f
34119668|NCT06360419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119669|NCT04442893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data of PANSS were collected by a research assistant.|The participants were divided into experimental and control groups through block randomization|t|f|f|f
34119670|NCT01120405|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34119671|NCT06716164|NA|SEQUENTIAL||TREATMENT||NONE||||||
34119672|NCT02034643|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149811|NCT06473935|||CASE_ONLY||PROSPECTIVE|||||||
33812487|NCT06369532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be allocated into two groups randomly (using a code). The psychotherapist, the study managers and the patients will not be aware of treatment allocation.||t|t|t|f
33812488|NCT00911638|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33812489|NCT02315014|RANDOMIZED|PARALLEL||||NONE||||||
33812490|NCT03799809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812491|NCT03220815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732222|NCT04197635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"After providing informed consent, patients will be randomly assigned, with a remote, web-based computer-generated block randomization procedure in an allocation 1:1 ratio, to either receive dapagliflozin 10 mg per day or placebo (one tablet a day orally). This system will allow the maintenance of the randomization codes and the opening of them if necessary. Investigators and patients will be blinded to treatment allocations.~Knowing that no treatment crossings between both groups are expected, there is no need of planning washing periods."|This study will be a double-blind multicenter randomized study (1:1) to evaluate the effect of dapagliflozin 10 mg per day or placebo on short-term functional capacity evaluated through changes in peak oxygen consumption The patients will be randomized to receive dapagliflozin or placebo. Once the inclusion criteria are fulfilled and the informed consent signed, patients will be randomized, and efficacy endpoints will be evaluated at 3 time points: 1) baseline (before dapagliflozin/placebo administration), 2) 30 days after randomization, and, 3) 90 days after randomization.|t|t|t|t
33732223|NCT05705908|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled trial||||
33732224|NCT04909086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both the outcome assessors and the study statistician will be blinded to group allocation.||f|f|f|t
33732225|NCT06011915|||COHORT||RETROSPECTIVE|||||||
33732226|NCT04186442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732227|NCT02653859|||COHORT||PROSPECTIVE|||||||
33732228|NCT02170610|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732229|NCT00231127|||COHORT||CROSS_SECTIONAL|||||||
33732230|NCT05576116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"The first phase of the study will assign participants (n=10) to undergo Sleeve Gastrectomy (SG) prior to PAK. 3 months post-SG, patients will be activated on the pancreas transplant waitlist.~If outcomes are favourable, the study may move to phase II (single group, n=10), which would investigate a combined surgery (simultaneous SG and pancreas transplantation)."||||
33732231|NCT04264286|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, randomized, double-blind and placebo-controlled trial|t|t|t|t
33732232|NCT02412969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732233|NCT00758511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812492|NCT01115309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812493|NCT01480258|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33812494|NCT05755178|NA|SEQUENTIAL||TREATMENT||NONE||||||
33812495|NCT01357902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812496|NCT05694286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812497|NCT05803044|||COHORT||PROSPECTIVE|||||||
33812498|NCT03542695|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33812499|NCT05210985|||COHORT||PROSPECTIVE|||||||
33812500|NCT05484921|||COHORT||PROSPECTIVE|||||||
33812501|NCT03950609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812502|NCT01072552|||CASE_CONTROL||PROSPECTIVE|||||||
33812503|NCT06505356|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33812504|NCT02196259|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812505|NCT00490906|||COHORT|||||||||
33812506|NCT01299285|NA|SINGLE_GROUP||OTHER||NONE||||||
33812507|NCT05766566|||COHORT||PROSPECTIVE|||||||
33812508|NCT00572715|||OTHER||PROSPECTIVE|||||||
33812509|NCT03903978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812510|NCT03533894|||COHORT||PROSPECTIVE|||||||
34043866|NCT05601453|||CASE_ONLY||PROSPECTIVE|||||||
34043867|NCT01601119|||COHORT||PROSPECTIVE|||||||
34043868|NCT02533245|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34043869|NCT00036972||||TREATMENT||||||||
34043870|NCT05184504|||COHORT||OTHER|||||||
34043871|NCT04628390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The patients participating in the clinical trial, the statistician in charge of the data analysis and the orthodontist will be blinded to the interventions carried out.~The investigator in charge of applying the intervention will not be blinded."|"Sixty patients (60) will be randomized in a 1: 1 ratio, to either of the two arms of this trial.~Measurements of the primary outcome variable will be done remotely through a virtual pain monitoring questionnaire through a visual analog scale (Baseline, 12 hours, 24 hours, 48 hours, 72 hours)"|t|t|t|t
34043872|NCT06501378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043873|NCT03915587|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|As these devices are experimental in this patient population, anesthesiologists will be blinded to hemodynamic data generated by the CardioQ-EDM, bedside ultrasound, and CipherOx CRI. If data is needed in an emergent setting, the subject will be excluded from analysis. Although recorded measurements from the Cardio-Q EDM monitor will be visible to the study team, IVC measurements will be stored and calculated post-hoc by a co-investigator blinded to whether or not the subject is or is not fluid responsive. Additionally, a trained statistician not involved in data collection will be paid for analysis. It should also be noted at Dr. Steven Moulton is a paid officer of CipherOx but will not be involved in the data collection and analysis.|Single arm prospective trial which will define two groups||||
34043874|NCT06448507|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043875|NCT06340113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043876|NCT03020992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043877|NCT05711355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043878|NCT03316014|||COHORT||RETROSPECTIVE|||||||
34043879|NCT05837910|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.|Participants will be stratified based on gender at birth then randomized to one of the study arms|t|f|t|f
34043880|NCT02400554|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34043881|NCT03028688|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34043882|NCT05214443|NA|SINGLE_GROUP||TREATMENT||NONE||Per-oral endoscopic Myotomy with fundoplication (POEM + F)||||
34043883|NCT05450510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded assessor|Randomized|f|f|f|t
34043884|NCT05300711|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043885|NCT04203602|RANDOMIZED|PARALLEL||TREATMENT||NONE||non-inferiority randomized controlled trial||||
34043886|NCT02048176|||CASE_CONTROL||PROSPECTIVE|||||||
34043887|NCT04768413|||COHORT||PROSPECTIVE|||||||
33812511|NCT01134159|||CASE_ONLY||RETROSPECTIVE|||||||
33812512|NCT01779245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33812513|NCT02058992|||COHORT||PROSPECTIVE|||||||
33812514|NCT03730038|RANDOMIZED|CROSSOVER||OTHER||NONE||Patients who assigned to the pitavastatin treatment first group will be given the pitavastatin, followed by wash-out period and life-style modification treatment. Patients who assigned to the life-style modification treatment first group, will be treated with life-style modification treatment first, followed by wash-out period and pitavastatin treatment.||||
33812515|NCT05264714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812516|NCT01619007|||COHORT||PROSPECTIVE|||||||
33812517|NCT03477032|||COHORT||PROSPECTIVE|||||||
33812518|NCT05790759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||One group of patients underwent all experimental conditions once||||
33812519|NCT02066636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812520|NCT02637089|||CASE_CONTROL||PROSPECTIVE|||||||
33812521|NCT05054751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812522|NCT01958346|RANDOMIZED|PARALLEL||||NONE||||||
33812523|NCT00986505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812524|NCT05884567|RANDOMIZED|PARALLEL||OTHER||SINGLE|Just participants will have no idea in which group they are.|A single blind RCT|t|f|f|f
33812525|NCT02790645|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812526|NCT04981431|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33812527|NCT05545800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119673|NCT06718504|RANDOMIZED|PARALLEL||OTHER||SINGLE||"This study is a single-center parallel-group randomized controlled clinical trial. Participants who met the inclusion criteria for the study were divided into two equal groups: the intervention group (n=30) and the control group (n=30).~according to the computer-based randomization table."|f|f|f|t
34119674|NCT01068184|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34119675|NCT04271800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119676|NCT02934451|||COHORT||PROSPECTIVE|||||||
34119677|NCT03051958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119678|NCT05850247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119679|NCT05904028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Visual acuity and imaging technicians will be masked to the participant's treatment group assignment, as will the central Reading Centers. Investigators, coordinators, and participants will be unmasked to treatment group assignment.||f|f|f|t
34119680|NCT01865487|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE||A 2 phase study based on LTBI status. Phase 1 is a dose ranging study of a 2 dose regimen at 3 dosage levels and placebo in LTBI negative participants. The second phase evaluated 2 and 3 dose regimens and included + and - LTBI participants.|t|t|t|t
34119681|NCT05809388|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34119682|NCT01250054|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34119683|NCT01153035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119684|NCT05203380|||COHORT||PROSPECTIVE|||||||
34119685|NCT00089492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119686|NCT00076440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34119687|NCT05382338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119688|NCT03648710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34119689|NCT06719414|||COHORT||PROSPECTIVE|||||||
34119690|NCT05134649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119691|NCT04461353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"This is a randomized, double-blind placebo-controlled Phase 1 single-dose dose-escalation study to assess the safety, tolerability and PK of oral inhalation of AHCQ in healthy participants.~A sentinel dose strategy will be employed and the decision to escalate to the next dose level, or deescalate or stop the study, will be based on review and analysis of all available blinded safety and tolerability data by the Safety Review Committee (SRC), which will make a recommendation to the Sponsor and the Sponsor will inform the PI of the recommendation."|t|t|t|t
34119692|NCT04875520|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34119693|NCT01677260|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34119694|NCT00200200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119695|NCT02606630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119696|NCT00023049|||FAMILY_BASED||PROSPECTIVE|||||||
34119697|NCT00477815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119698|NCT04753489|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34119699|NCT05499026|||COHORT||RETROSPECTIVE|||||||
34119700|NCT00196040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119701|NCT06716437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119702|NCT06718751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119703|NCT01441388|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119704|NCT06712095|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119705|NCT05501548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812528|NCT01578629|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34119706|NCT05729906|||CASE_ONLY||PROSPECTIVE|||||||
34119707|NCT06719206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812529|NCT05928754|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812530|NCT03887611|||CASE_ONLY||PROSPECTIVE|||||||
33812531|NCT03447912|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a matched-pairs community randomized controlled trial. 14 communities will receive the behavioral intervention and 14 will serve as control communities. Enrollment is on the community level rather than individual level.||||
33812532|NCT00237926|RANDOMIZED|PARALLEL||||NONE||||||
33812533|NCT05234489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The Phase 1 trial will enroll 5 subjects into an initial group receiving a low dose of SIG001. Provided that these subjects tolerate this dose well, will proceed to enroll 5 subjects into a group receiving a high dose of SIG001.||||
33812534|NCT04436549|||COHORT||CROSS_SECTIONAL|||||||
34119708|NCT03667105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34119709|NCT05335967|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33732234|NCT04355962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be informed about their group assignments, technicians processing the samples will not have any access to the ICU or the patient chart (= double-blind trial). Due to the procedures involved in volatile versus intravenous sedation, group assignment cannot be entirely concealed for the study staff and ICU doctors/nurses involved with the procedure in the ICU (pragmatic limits of blinding).|a randomized, controlled multi-center trial|t|f|f|t
33732235|NCT01414569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732236|NCT01545921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732237|NCT00072865|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732238|NCT03246867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All of participants must have subacromial impingement syndrome with glenohumeral internal rotation deficit.|There are 3 groups. First group will receive isolytic stretching in modified cross body position. Second group will receive static stretching in modified cross body position. The stretching exercise will be applied five times each for 15 seconds. After each stretching there will be a resting period for 5 seconds. Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Isolytic and static stretching groups will be evaluated before and just after stretching exercise. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.|t|f|f|f
33732239|NCT01038271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732240|NCT01574872|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732241|NCT01897675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732242|NCT01405638|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33732243|NCT01962558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33732244|NCT03081585|||COHORT||CROSS_SECTIONAL|||||||
33732245|NCT00250211|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732246|NCT03056131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732247|NCT03827486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732248|NCT03814954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732249|NCT03268616|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33732250|NCT05857709|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34119710|NCT05230498|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind study: the patient and the investigator don't know the fitting.|"Two arms A and B:~Arm A: patient's fitting with default fitting --\> 6 weeks use --\> tests and patient's fitting with anatomy-based fitting --\> 6 weeks use --\> tests Arm B: patient's fitting with anatomy-based fitting --\> 6 weeks use --\> tests and patient's fitting with default fitting --\> 6 weeks use --\> tests"|t|f|t|f
34119711|NCT04051606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119712|NCT05504707|NA|SEQUENTIAL||TREATMENT||NONE||||||
34119713|NCT01657305|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34119714|NCT06718829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119715|NCT02054169|||||CROSS_SECTIONAL|||||||
34119716|NCT06462313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119717|NCT04240691|||COHORT||PROSPECTIVE|||||||
34119718|NCT04317144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomization is a in-hospital after consent done by the researcher/ICU-nurse. The participant receives group-specific information after randomization.|Longitudinal observational study.|f|f|t|f
34119719|NCT04734860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119720|NCT05345483|||OTHER||PROSPECTIVE|||||||
34119721|NCT05559099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119722|NCT05913401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119723|NCT06590675|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This is a mixed methods study involving both a prospective interventional cohort study following approximately 240 neonates, and qualitative interviews of 10 caregivers and 20 healthcare workers in the neonatal unit (NNU) and intensive care unit (ICU).||||
34119724|NCT06314425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119725|NCT00066872|RANDOMIZED|||TREATMENT||||||||
34119726|NCT00961038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119727|NCT05411497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119728|NCT02325063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119729|NCT06053528|||COHORT||PROSPECTIVE|||||||
34119730|NCT05211323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119731|NCT06717438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119732|NCT01472731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119733|NCT03110887|||COHORT||RETROSPECTIVE|||||||
34119734|NCT05484128|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|nobody knows the randomization code|randomized double bind with placebo|t|t|t|t
34119735|NCT06294821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119736|NCT03305484|||CASE_CONTROL||PROSPECTIVE|||||||
34119737|NCT01555060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119738|NCT05192421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119739|NCT04128709|NA|SINGLE_GROUP||OTHER||NONE||||||
34119740|NCT03937479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119741|NCT04098705|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Pre-post intervention methodology will be used||||
33732251|NCT02496780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732252|NCT04395716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732253|NCT01417403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732254|NCT06394388|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732255|NCT02995252|||COHORT||PROSPECTIVE|||||||
34119742|NCT05027074|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34119743|NCT03392181|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119744|NCT05578976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119745|NCT06718569|||COHORT||PROSPECTIVE|||||||
34119746|NCT05827887|||COHORT||PROSPECTIVE|||||||
34119747|NCT02172729|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34119748|NCT06717360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119749|NCT06718725|||CASE_ONLY||PROSPECTIVE|||||||
34119750|NCT06623019|||OTHER||PROSPECTIVE|||||||
34119751|NCT02412150|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34119752|NCT00781547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119753|NCT04562311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119754|NCT02374229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119755|NCT06714799|||COHORT||OTHER|||||||
34119756|NCT02783274|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort of Total Hips and the protocol also includes a single cohort for Hemi-hips. No comparisons are made to comparator devices, no randomization (open label). gathering data for a Post-market clinical follow-up study.||||
34119757|NCT06122441|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors and data analysts will be blinded to group assignment from baseline to primary endpoint assessment. It is not possible to blind the participants or intervention staff due to the nature of the intervention.|RESTART is designed as a two-arm, single blind, parallel group RCT, with a 1:1 allocation ratio into either intervention or active control group|f|f|f|t
34119758|NCT03200002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119759|NCT05870345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each participant receives the study intervention which is a pocket-sized ultrasound exam.||||
34119760|NCT06293937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119761|NCT04106115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119762|NCT02418520|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Intervention group would use Miswak chewing sticks along with the regular use of tooth brush and paste||||
34119763|NCT02425397|||CASE_CONTROL||RETROSPECTIVE|||||||
34119764|NCT03883139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119765|NCT06716502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119766|NCT06561152|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119767|NCT04255615|NA|SINGLE_GROUP||OTHER||NONE||||||
34119768|NCT06415487|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119769|NCT05383911|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119770|NCT06032884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119771|NCT03505983|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Outcomes assessor and statistician will be blinded to foot type during data processing and analysis||f|f|f|t
34119772|NCT06122779|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34119773|NCT02616731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119774|NCT04670809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119775|NCT05419856|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||A total of 32 participants will be enrolled in 4 cohorts, in each cohort participants will receive either 4P-004 or placebo (6:2).|t|f|t|f
34119776|NCT06510036|||CASE_CONTROL||PROSPECTIVE|||||||
34119777|NCT00984503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119778|NCT04172766|||COHORT||PROSPECTIVE|||||||
34119779|NCT02655887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119780|NCT06719284|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34119781|NCT04640142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119782|NCT01572337|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119783|NCT00641693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34119784|NCT06533813|||CASE_CONTROL||RETROSPECTIVE|||||||
34119785|NCT05374109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant asking participants questions and the statistician are masked (not aware to which group participants were randomized).|Restricted randomization will be used to balance the randomization across both study arms by site, sex, and enrollment HIV RNA (\<400 copies/mL or ≥400 copies/mL). Those randomized to receive the SYV intervention will be assembled into 33 groups of 10-11 participants per group. Those randomized to SOC will continue to receive routine care, which will be clearly defined by each site. The outcomes assessor and statisticians will be masked to participant study arm through the 6-month study visit (primary aim).|f|f|f|t
34119786|NCT05880147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|As blinding is impossible, we will not conceal allocation from any members of the clinical or study teams.|Open Label Randomized Controlled Trial||||
34119787|NCT06520397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119788|NCT02768207|NA|SINGLE_GROUP||SCREENING||NONE||||||
34119789|NCT05639881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research interviewers are blinded to study condition.|The intervention improves health literacy and self-management skills using a framework comprised of the psychoeducational strategies of explanation, evaluation, and engagement. Over the course of 5 structured sessions, instructors impart immune health information using visual aids. They evaluate what participants already know about immune health to assess how to expand participants' understanding of immunity and health self-management. Instructors engage participants in personally-meaningful activities and goals to improve their immune health literacy and behaviors. For 3 months after class ends, monthly booster sessions are held.|f|f|f|t
34119790|NCT04401462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119791|NCT06715735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34119792|NCT00265915||||TREATMENT||||||||
34119793|NCT04047056|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34119794|NCT04868292|NA|SINGLE_GROUP||OTHER||NONE||||||
34119795|NCT06719037|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
34119796|NCT05215002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34119797|NCT00001561||||TREATMENT||||||||
34119798|NCT06605508|||COHORT||PROSPECTIVE|||||||
33732256|NCT03490266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732257|NCT05936255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732258|NCT01550874|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
33732259|NCT05928650|||OTHER||CROSS_SECTIONAL|||||||
33732260|NCT02994342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732261|NCT01015248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732262|NCT02624284|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33732263|NCT04628962|||CASE_CONTROL||PROSPECTIVE|||||||
33732264|NCT05255458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732265|NCT02192944|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732266|NCT01283048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732267|NCT02933138|||COHORT||PROSPECTIVE|||||||
33732268|NCT01280084|||CASE_CONTROL||PROSPECTIVE|||||||
33812535|NCT01303822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812536|NCT05363397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Independent imaging assessors will review and adjudicate blinded study data to ensure the primary endpoint meets consistent pre-determined diagnostic criteria. This will include centralised review of de-identified CT and MRI/MRA images. Members will be qualified physicians who are independent of the study and not involved in study management.|Continual Reassessment Method|f|f|f|t
34119799|NCT06090669|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34119800|NCT06715059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119801|NCT03795493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34119802|NCT04602091|||COHORT||PROSPECTIVE|||||||
34119803|NCT05758324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812537|NCT02964793|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34119804|NCT04476576|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Both programs are equally planned related with time and number of sessions as well as clinical monitoring.|Active group: 3 months , 3 times/week aerobic program Control group: 3 months, 3 times/week flexibility program|t|t|f|t
34119805|NCT01313507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119806|NCT06411301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119807|NCT05536297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119808|NCT05845112|||OTHER||CROSS_SECTIONAL|||||||
34119809|NCT03781674|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|a double-blind randomized controlled trial|a double-blind randomized controlled trial|t|t|t|t
34119810|NCT06716047|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34119811|NCT06718946|NA|SEQUENTIAL||TREATMENT||NONE||||||
34119812|NCT06718582|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34119813|NCT06715982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119814|NCT03324789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will only be done for the outcome assessor for patient satisfaction and the statistician||f|f|f|t
33732269|NCT04949438|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732270|NCT03672903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking will not be publically revealed before the study ends. Subjects may be able to determine if they are in the control/placebo group or intervention group if we publically reveal our masking procedure. However, the masking procedure is pre-determined and approved by the ethic's committee.|We will use a parallel study design in which we compare the placebo group with the intervention group. In order to avoid the risk of carry-over effects, we have decided to not use a crossover design. This could have decreased the variation of the measurement values and increased the power of the study. However, we believe there could be a risk of a carry-over effect with a cross over design. As this is a completely new effect in clinical studies, we have no information about the wash-out time needed to avoid this problem.|t|f|f|f
33732271|NCT01513252|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732272|NCT03181828|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This pilot randomized crossover study will first evaluate the impact of AHA versus non-AHA primarily on intestinal flora cleavage of an infused bolus of 13C-Urea and secondarily on other biomarkers in healthy adults before applying the same crossover design to UCD subjects.||||
33732273|NCT02388997|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732274|NCT01616186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812538|NCT00721734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812539|NCT01120054|||COHORT||CROSS_SECTIONAL|||||||
34119815|NCT06715644|||COHORT||PROSPECTIVE|||||||
34119816|NCT05906160|||CASE_CROSSOVER||PROSPECTIVE|||||||
34119817|NCT00465673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34119818|NCT04008914|||CASE_ONLY||RETROSPECTIVE|||||||
34119819|NCT03130569|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34119820|NCT03082924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119821|NCT04162548|||OTHER||PROSPECTIVE|||||||
34119822|NCT06639386|||COHORT||PROSPECTIVE|||||||
34119823|NCT06032754|||CASE_CONTROL||RETROSPECTIVE|||||||
34119824|NCT02842593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34119825|NCT06614036|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34119826|NCT06376682|NA|SINGLE_GROUP||TREATMENT||NONE||The Epione device is an image-guided robotized device that assists the physician during CT-guided procedures.||||
34119827|NCT06433700|||COHORT||PROSPECTIVE|||||||
34119828|NCT06202469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119829|NCT03672630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119830|NCT02375074|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34119831|NCT01840033|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119832|NCT06434337|||CASE_ONLY||CROSS_SECTIONAL|||||||
34119833|NCT06714786|||COHORT||CROSS_SECTIONAL|||||||
33732275|NCT01818804|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732276|NCT06431828|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33732277|NCT04464642|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label Randomization controlled clinical study||||
33812540|NCT00222898|||DEFINED_POPULATION||OTHER|||||||
34119834|NCT04122378|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Proposed study is a feasibility study of acupuncture therapy in patients with SCD admitted for management of acute pain. The primary goal of proposed study is to determine (1) if acupuncture is acceptable modality for management of pain in patients with SCD. The investigators will also explore (2) if acupuncture improves pain outcomes in SCD and (3) if use of acupuncture is associated with modulation of cytokines.||||
34119835|NCT02913963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119836|NCT06311591|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34119837|NCT02389244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119838|NCT05812339|||COHORT||CROSS_SECTIONAL|||||||
34119839|NCT05810519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119840|NCT02832414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119841|NCT04907071|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119842|NCT06243068|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||We will use a repeated cross-sectional stepped wedge design with randomization at the practice level.||||
34119843|NCT00299364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34119844|NCT06593210|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34119845|NCT06714734|||COHORT||OTHER|||||||
33732278|NCT03524703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732279|NCT00702130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33732280|NCT00025285||||TREATMENT||||||||
33732281|NCT01072851|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33732282|NCT00753207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732283|NCT05310266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33732284|NCT01613339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732285|NCT01469065|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732286|NCT02243150|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33732287|NCT05814120|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33732288|NCT05545670|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732289|NCT00864461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732290|NCT00409292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732291|NCT03584672|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732292|NCT01739530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732293|NCT00649181|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33732294|NCT06104189|||COHORT||PROSPECTIVE|||||||
33732295|NCT04382638|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessor, statistician and investigator blinded|"Patients diagnosed with AIS referred for bracing through the hospital's specialist outpatient clinic are eligible to enrol the study. The Investigator will document whether each patient meets the selection criteria before enrolment into the study. The Investigator or designee will also obtain an IRB/EC approved Informed consent from each patient and/or guardian.~Eligible patients will be randomly assigned to either RCO group (experimental) or TLSO group (control) in a ratio of 1:1. The radiographic evaluation, physical examination and PROM questionnaires will be assessed at baseline, 3 months, 6 months, 12 months and every year until patients reach skeletal maturity or if surgical intervention is required."|f|f|t|t
33732296|NCT04724239|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized in approximately a 1:1 ratio to receive sintilimab and chidamide with or without IBI305.||||
33732297|NCT00347295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732298|NCT01670162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732299|NCT03306888|NA|SINGLE_GROUP||OTHER||NONE||Single arm feasibility study with 14 participants||||
33732300|NCT04515303|||OTHER||CROSS_SECTIONAL|||||||
33732301|NCT02412631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732302|NCT01027169|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33732303|NCT04666090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732304|NCT00139568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732305|NCT05844514|||CASE_CONTROL||PROSPECTIVE|||||||
33732306|NCT01416883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732307|NCT01106300|||COHORT||PROSPECTIVE|||||||
33732308|NCT04722640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732309|NCT00888303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732310|NCT00895739|NON_RANDOMIZED|||TREATMENT||NONE||||||
33732311|NCT02474199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732312|NCT03858387|||OTHER||PROSPECTIVE|||||||
33732313|NCT00678561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812541|NCT04476524|||COHORT||RETROSPECTIVE|||||||
33812542|NCT00329914|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33812543|NCT06418919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812544|NCT06073470|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732314|NCT01321801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33732315|NCT01329510|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732316|NCT04419688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732317|NCT02831270|||COHORT||PROSPECTIVE|||||||
33732318|NCT06196567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is single-blinded, the investigators don't know the group allocation.|Participants will be randomly assigned to one of three intervention groups, which will have treatment for 8 weeks prior to the surgery.|f|f|t|f
33732319|NCT05151718|||COHORT||RETROSPECTIVE|||||||
33732320|NCT03242499|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33732321|NCT02348242|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732322|NCT04441567|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a two-phase pilot study recruiting approximately 1500 subjects in each of the two phases. Phase 1 - No intervention, create recovery curves only. Phase 2 - Adjust clinic follow-up based on patient responses in relation to recovery curves generated from Phase 1.||||
33732323|NCT01768390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33732324|NCT05036993|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized controlled trial with crossover to intervention||||
33732325|NCT02215590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732326|NCT06123884|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732327|NCT00196781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732328|NCT03657472|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732329|NCT06101264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732330|NCT00688766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732331|NCT00610532|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33732332|NCT05960591|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized in either the control group (bore depth measurement with the manual depth gauge) or in the intervention group (bore depth measurements with the ADEPTH sensor).||||
33812545|NCT05719909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812546|NCT01366976|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812547|NCT04235894|||COHORT||PROSPECTIVE|||||||
33812548|NCT02232997|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812549|NCT02486939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812550|NCT04267952|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participation will not know whether they are in the experimental or control group.||t|f|f|f
33812551|NCT01896609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837030|NCT06037837|||COHORT||PROSPECTIVE|||||||
33837031|NCT02712463|||||RETROSPECTIVE|||||||
33837032|NCT02336100|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33837033|NCT00994175|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33812552|NCT03949959|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participant is not made aware of intervention arm - treat as usual or physiotherapy. Radiologist providing PRP tells participant to refrain from treatment for 6-weeks, or to immediately commence physiotherapy.|A Single Case Experimental Design (SCED) will be used to evaluate the intervention. Participants act as their own controls, and thus are exposed to both the treatment and control conditions. The study will be conducted and reported according to the Singe Case Reporting guidelines in BEhavioural Interventions (SCRIBE). A randomised, concurrent, multiple-baseline A1 (baseline control) - B (intervention)-A2 (follow-up withdrawal) design will be used to meet the methodological recommendations for SCEDs. Participants will be randomly allocated to a 5, 8 or 11 day baseline period during which they will undertake their usual activities. The baseline phase will be followed by a 6-week intervention period during which participants will participate in 10, one hour sessions with an experienced post-graduate trained physiotherapist. The intervention phase will be followed by a 12-week follow-up phase where participants will have no contact with the intervention personnel.|t|f|f|f
33812553|NCT06179485|||COHORT||PROSPECTIVE|||||||
33812554|NCT02913300|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33812555|NCT01363128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812556|NCT03811665|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33812557|NCT01775202|||COHORT||RETROSPECTIVE|||||||
33812558|NCT00525616|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812559|NCT01513005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812560|NCT04093115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812561|NCT04327089|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Open-Label Phase 1 Study||||
33812562|NCT06432036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812563|NCT05859659|||COHORT||PROSPECTIVE|||||||
33812564|NCT03037021|||OTHER||PROSPECTIVE|||||||
34119846|NCT06305754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Unblinded Open-label||f|f|f|t
34119847|NCT06163287|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34119848|NCT02178579|||COHORT||PROSPECTIVE|||||||
34119849|NCT03926455|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|Study vaccine will be administered by an unblinded staff member at the clinic|Randomized, Ascending Dose|t|f|t|f
34119850|NCT05269004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119851|NCT05000372|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Single Group Assignment||||
34119852|NCT05906771|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34119853|NCT06674473|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34119854|NCT03070678|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119855|NCT01162551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119856|NCT06252909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119857|NCT06629688|NA|SINGLE_GROUP||TREATMENT||NONE||Patients between the ages of 45 and 65 with poorly controlled T2DM (HbA1c ≥ 7%) who were candidates for treatment intensification and beginning of parenterally administered semaglutide were eligible to participate in the study.||||
34119858|NCT00546481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119859|NCT06717191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119860|NCT00416117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34119861|NCT06718140|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Within-subject crossover between participants; each participant will receive each condition on different days in a counterbalanced order.|t|f|t|f
34119862|NCT05320406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34119863|NCT01818687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119864|NCT03669796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A double-blind crossover trial, including two different study days, with 4-7 days wash-out (WO) period in between. The intervention implemented 20 mg of MPH per kg body weight (test material) or control (casein).|t|f|t|f
34119865|NCT05108857|||CASE_ONLY||CROSS_SECTIONAL|||||||
34119866|NCT04494048|||OTHER||OTHER|||||||
34119867|NCT00760162|||COHORT||PROSPECTIVE|||||||
34119868|NCT06718868|||OTHER||PROSPECTIVE|||||||
34119869|NCT06411990|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single arm clinical trial||||
34119870|NCT05366712|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Cohort Study||||
34119871|NCT06718205|NA|SINGLE_GROUP||TREATMENT||NONE||nimotuzumab||||
34119872|NCT06691126|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The study will be carried out as a single arm, unblinded, PK study. The total duration of the study is about 24 hours, excluding screening and enrolment time (up to 1 hour).||||
34119873|NCT05304585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812565|NCT02706483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812566|NCT00748891|NA|SINGLE_GROUP||||NONE||||||
33812567|NCT03784898|NA|SINGLE_GROUP||OTHER||NONE||||||
33812568|NCT00516399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119874|NCT04280575|||COHORT||PROSPECTIVE|||||||
34119875|NCT04607343|NA|SINGLE_GROUP||OTHER||NONE||Electrostimulation begins with electrodes placed on the skin in the submental and submandibular triangles, making sure not to place electrodes on the carotid sinus. The goal of this stimulation will be topographical closeness of the genioglossus, geniohyoid, mylohyoid, platysma and digastric muscles.||||
34119876|NCT05615402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial over 24-weeks.|t|f|f|f
34119877|NCT06410144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Research coordinators responsible for administering assessments will remain blinded to the patient's randomization status.||f|f|f|t
34119878|NCT00224393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119879|NCT00379678|||||PROSPECTIVE|||||||
34119880|NCT00894387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119881|NCT05289752|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34119882|NCT00402987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119883|NCT04623541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119884|NCT00905229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119885|NCT06604078|||CASE_ONLY||OTHER|||||||
34119886|NCT06712810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732333|NCT03946163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the capsules of similar shape, size, color, and smell will be packed in in 60 capsules pack by the preparing pharmacist and labeled as 1 or 2 on the pack, the team will be informed by the content of each pack only after the conclusion of the study|The patients will be randomized into two groups, the first group will receive sixty capsules, each capsule contains 1gm of cinnamon bark powder and will be instructed to use it twice daily for one month, the second group will receive 60 capsules containing placebo and will be instructed to use it twice daily for one month|t|t|t|t
33732334|NCT01180712|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33732335|NCT00183716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732336|NCT03271736|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732337|NCT01532765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732338|NCT02300324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732339|NCT04963179|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33732340|NCT01112202|||COHORT||RETROSPECTIVE|||||||
33732341|NCT00638885|||COHORT||PROSPECTIVE|||||||
33732342|NCT05726578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732343|NCT02163928|||COHORT||PROSPECTIVE|||||||
33732344|NCT05551806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33732345|NCT05408663|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double (Participant, investigator)|Single ascending dose with up to 6 sequential dose escalation cohorts. Participants will be randomized to either study intervention (EXT608) or placebo|t|f|t|f
33732346|NCT05204381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33732347|NCT04903132|||CASE_ONLY||PROSPECTIVE|||||||
33732348|NCT05572983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732349|NCT03231306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732350|NCT06074107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732351|NCT00298831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732352|NCT00745914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732353|NCT04770376|||COHORT||PROSPECTIVE|||||||
33732354|NCT06484153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732355|NCT05963542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33732356|NCT04905251|||COHORT||PROSPECTIVE|||||||
33732357|NCT01563575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732358|NCT03613896|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33732359|NCT01631474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732360|NCT01340976|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33732361|NCT03341130|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Analysis of primary outcomes will be performed by an examiner blinded to group allocation.||f|f|f|t
33732362|NCT04047082|||CASE_ONLY||PROSPECTIVE|||||||
33732363|NCT00222469|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33732364|NCT06104267|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33732365|NCT00481728|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33732366|NCT05287191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded follow up for key outcomes|Individual patient, pragmatic, comparative effectiveness, randomised, controlled trial|f|f|f|t
33732367|NCT01437553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732368|NCT01723228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732369|NCT04595487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732370|NCT06163066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study will be conducted in a prospective (pretest-posttest-4. Months fallow test), three-arm (1:1:1), randomized controlled experimental design.|t|f|f|f
33732371|NCT04237961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients could be divided into three groups according to the anatomical site of interferences:~* Group 1: Upper third interferences~* Group 2: Mid third interferences~* Group 3: Lower third interferences"|"Patients could be divided into three groups according to the anatomical site of interferences:~* Group 1: Upper third interferences~* Group 2: Mid third interferences~* Group 3: Lower third interferences"|t|f|f|f
33732372|NCT00480636|||COHORT||PROSPECTIVE|||||||
33732373|NCT05441059|||COHORT||RETROSPECTIVE|||||||
33732374|NCT04325529|||CASE_CONTROL||PROSPECTIVE|||||||
33732375|NCT05395819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors will be blinded to group allocation. The surgeons will use a Research Electronic Data Capture (REDCap) software to randomize the participant. REDCap is password protected and only accessibly for research personnel. The outcome assessors will not have access to the randomization information in REDCap which will maintain blinding to participant group allocation. Surgeons will not informe participant about procedure received until the end of last follow-up.||t|f|f|t
33732376|NCT01787305|||CASE_CONTROL||OTHER|||||||
33732377|NCT00463060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732378|NCT03129672|||CASE_ONLY||RETROSPECTIVE|||||||
33732379|NCT02110992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732380|NCT05567640|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33732381|NCT01715506|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33732382|NCT04554511|||COHORT||RETROSPECTIVE|||||||
33732383|NCT03766100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Application of PSG equipment prior to monitoring sleep efficiency and subsequent analysis of results will be conducted by neurophysiology assistants at the Danish Center for Sleep Medicine (DCSM) blinded to participants' allocation. Examination of participants' joints related to the secondary outcome of disease activity will be conducted by a project nurse specialized in rheumatology blinded to participants' allocation. Blood samples related to RA and disease activity will be taken and analysed by a medical laboratory technologist blinded to participants' allocation. Patient Reported Outcome Measures (PROMs) will be collected via questionnaires on tablets handed out by the project manager, who will also conduct the intervention of CBT-I, and therefore not able to be blinded to allocation.||f|f|f|t
33732384|NCT01417832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732385|NCT01921829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732386|NCT04260815|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33732387|NCT01126164|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33732388|NCT03289728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732389|NCT00003724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732390|NCT05242510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812569|NCT02837419|||COHORT||PROSPECTIVE|||||||
33812570|NCT00696241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812571|NCT01629420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812572|NCT01583959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812573|NCT01382706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812574|NCT00228657|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33812575|NCT00391066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812576|NCT04853654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33732391|NCT01825408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812577|NCT00001628||||TREATMENT||||||||
33732392|NCT00884234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732393|NCT00017758||||TREATMENT||||||||
33732394|NCT03400033|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study, in which the subject, investigator, site staff and the sponsor will remain blinded to each subjects study treatment assignment throughout the course of the study, with the exception of a limited number of unblinded site staff who are necessary to maintain the blind, as well as a limited number of sponsor staff.|Subjects will be randomized to receive either daprodustat or epoetin alfa in a parallel manner. .|t|t|t|t
33732395|NCT05581212|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped-Wedge Cluster Randomised Trial design||||
33812578|NCT04725266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812579|NCT04323800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1:1 ratio|t|t|t|f
33812580|NCT01892007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding||t|t|t|t
33812581|NCT03433885|||COHORT||PROSPECTIVE|||||||
33812582|NCT04301999|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812583|NCT03674476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119887|NCT04103476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization randomly determined with key to treatment groups maintained by a single individual in the data coordinating center (DCC); study product masked with matching placebo.|Randomized (1:1), double-blinded, placebo-controlled trial of BZA/CE versus placebo.|t|t|t|t
33812584|NCT06080087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be blinded into which condition they were assigned into||t|f|f|f
33812585|NCT06399939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are assigned to morning or afternoon nap manipulation In each manipulation, participants complete a nap and a wake condition||||
33812586|NCT04261309|||COHORT||PROSPECTIVE|||||||
33812587|NCT01246635|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33812588|NCT03112005|||CASE_ONLY||CROSS_SECTIONAL|||||||
34119888|NCT06718790|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial, there are two groups: menstrual cup users and menstrual pad users||||
34119889|NCT02359565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119890|NCT05567835|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a two arm phase II pilot design, with eligible subjects randomized 1:1 to either Arm A ( Investigational arm) or Arm B ( Standard arm). The chemotherapy dose modification will follow routine clinical care. Both arms will receive chemotherapy and curative surgery.||||
34119891|NCT03092180|||COHORT||PROSPECTIVE|||||||
34119892|NCT04972266|||CASE_ONLY||PROSPECTIVE|||||||
34119893|NCT05791864|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|In order to minimize the effect of potential bias, wherever possible, endpoints will be measured or interpreted by masked evaluators.||f|f|f|t
34119894|NCT05305924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119895|NCT01193101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119896|NCT00265850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119897|NCT05901649|||COHORT||PROSPECTIVE|||||||
34119898|NCT06241300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors of executive function, disruptive behavior, and parenting outcomes will be blind to which condition participants were randomized to.|The Chicago Parent Program (developer Dr. Deborah Gross) is an evidence-based parenting preventive intervention for urban poor parents with children between the ages of 2-8 years old with behavior problems. The study will include 90 children at risk for disruptive behavior disorders based on demonstrating moderate-to-severe impairments in EF established at the initial screen via parent report on the Behavior Rating Inventory of Executive Function-Preschool Version. Half of the dyads (n = 45) will be randomly assigned to receive the Chicago Parent Program and half (n = 45) will receive no intervention.|f|f|f|t
34119899|NCT04062058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119900|NCT01173679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812589|NCT00978159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812590|NCT01731210|NA|SINGLE_GROUP||TREATMENT||NONE||NANO LV lead||||
33812591|NCT00919698|||COHORT||PROSPECTIVE|||||||
33812592|NCT05798598|NON_RANDOMIZED|FACTORIAL||OTHER||NONE|No masking. Each participant knows which group they belong to.|Non-randomized trial type||||
33812593|NCT06356883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812594|NCT01378884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812595|NCT05959902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812596|NCT01244997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812597|NCT05923788|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812598|NCT01636726|||||RETROSPECTIVE|||||||
33812599|NCT04720209|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812600|NCT01446640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812601|NCT05232357|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33812602|NCT01422265|||COHORT||PROSPECTIVE|||||||
33812603|NCT06157684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812604|NCT03266432|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812605|NCT04266821|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study will enroll practicing primary care physicians in the US. Physicians are randomly assigned to either a control or intervention arm upon enrollment.~All eligible and consented participants will complete two rounds of three patient simulations.~The intervention arm only will receive educational material about the Ethos test in between these two rounds, and be provided simulated Ethos test results in the second round of simulated cases."||||
33812606|NCT06425289|||OTHER||PROSPECTIVE|||||||
33837034|NCT00922688|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33838455|NCT03555253|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33732396|NCT04497987|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33732397|NCT03989297|||CASE_ONLY||RETROSPECTIVE|||||||
33732398|NCT05857605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Principal Investigator will be masked to the patient treatment group assignment.||f|f|t|f
33732399|NCT00333606|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33732400|NCT00033384||||TREATMENT||||||||
33732401|NCT06091553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732402|NCT05556122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33732403|NCT05492058|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732404|NCT03992807|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732405|NCT02386111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732406|NCT01531946|||CASE_ONLY||PROSPECTIVE|||||||
33732407|NCT05614245|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33732408|NCT00077168|RANDOMIZED|||TREATMENT||||||||
33732409|NCT01119911|||||PROSPECTIVE|||||||
33732410|NCT03561974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732411|NCT03410979|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33732412|NCT05716035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732413|NCT03897972|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33732414|NCT03632291|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33732415|NCT01831310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33732416|NCT06192225|RANDOMIZED|PARALLEL||PREVENTION||NONE||Single center, two-group, prospective, randomized controlled trial||||
33732417|NCT02092090|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33732418|NCT06341439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732419|NCT01973101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732420|NCT01874834|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33732421|NCT00524979|||CASE_CONTROL||PROSPECTIVE|||||||
33732422|NCT04041869|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732423|NCT01404468|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33732424|NCT05281250|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732425|NCT05233410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will receive ruxolitinib cream (1.5%) or vehicle cream for 16 weeks, after which they will be offered the opportunity to receive ruxilitinib cream (1.5%) in the open-label treatment extension period for another 16 weeks.|t|t|f|t
33732426|NCT01086592|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33732427|NCT06448741|||CASE_ONLY||RETROSPECTIVE|||||||
33732428|NCT05240846|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732429|NCT03553316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732430|NCT02711800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732431|NCT02584309|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732432|NCT02584751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732433|NCT02051972|||COHORT||PROSPECTIVE|||||||
33732434|NCT03199378|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33732435|NCT00699972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732436|NCT05340153|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible children for whom parent/guardian authorization and assent are obtained will be randomized to receive either artemether-lumefantrine (group A) or dihydroartemisinin-piperaquine (group B) in the ratio 1:1||||
33732437|NCT03491150|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Extension (OLE)||||
33732438|NCT06410872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732439|NCT05770037|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732440|NCT02213939|||CASE_CONTROL||PROSPECTIVE|||||||
33812607|NCT03274648|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Behçet's will be assigned to one of the following treatments:~* vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products~* habitual diet supplemented with 2.4g/day of oral butyrate~* habitual diet without supplementation"||||
33812608|NCT03803657|||COHORT||PROSPECTIVE|||||||
33732441|NCT02659332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732442|NCT02411331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732443|NCT04884152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732444|NCT04212806|||COHORT||PROSPECTIVE|||||||
33732445|NCT02308670|||COHORT||PROSPECTIVE|||||||
33732446|NCT01337297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732447|NCT01043796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732448|NCT01567488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732449|NCT03995576|||COHORT||PROSPECTIVE|||||||
33732450|NCT00094653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732451|NCT04140734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732452|NCT00528528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732453|NCT05514067|RANDOMIZED|PARALLEL||TREATMENT||NONE|After obtaining consent, patient's study arm will be revealed via sequentially numbered, opaque, sealed and stapled envelopes.|Patients will then be randomised 1:1 to receive either the EA or standard care protocols.||||
33732454|NCT01172691|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33732455|NCT04694196|NA|SINGLE_GROUP||TREATMENT||NONE||No evidence of infection or trauma in oral Negative history of TMJ disorders||||
33732456|NCT06333795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is blinded throughout the active study period, both the patient and investigator are blinded.|Participants will undergo 2 interventions. For the first intervention participants are randomised 1:1 for either Active FMT or placebo For the second intervention, all participants receive active treatment.|t|t|t|t
33732457|NCT01749891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732458|NCT05800054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732459|NCT00133081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732460|NCT06027749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective Cohort||||
33732461|NCT00085943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732462|NCT05088291|||COHORT||PROSPECTIVE|||||||
33732463|NCT04690127|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel group randomized controlled trial||||
33732464|NCT02498093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33732465|NCT02505633|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33732466|NCT02745964|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33732467|NCT00237588|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33732468|NCT04054037|||COHORT||PROSPECTIVE|||||||
33732469|NCT02059148|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732470|NCT05882227|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33732471|NCT05817396|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-Randomized Controled Trial (cRCT) with 16 schools||||
33732472|NCT04888065|||COHORT||RETROSPECTIVE|||||||
33732473|NCT03111654|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33732474|NCT00826267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732475|NCT05073406|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Interventional, non-pharmacological, randomized, controlled, double-blinded, cross-over|t|f|f|t
33732476|NCT02760134|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33732477|NCT01173302|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33732478|NCT04358497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Phlebography will be performed to both groups. On the experimental group, the treatment of the pelvic congestion will be performed, while the procedure will be stopped on the control group. Neither the patient or the reference gynecologist will be informed if the treatment took place.|Blind randomized clinical trial designed to compare the efficacy and safety of endovascular treatment of Pelvic congestion syndrome.|t|t|f|t
33732479|NCT01740583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732480|NCT04519658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732481|NCT01330758|RANDOMIZED|CROSSOVER||||NONE||||||
33732482|NCT02566915|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33732483|NCT05471362|||CASE_CONTROL||RETROSPECTIVE|||||||
33732484|NCT04361461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732485|NCT00729352|||CASE_CROSSOVER||PROSPECTIVE|||||||
33732486|NCT00646412|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33732487|NCT06075485|||OTHER||PROSPECTIVE|||||||
33732488|NCT01700179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732489|NCT01384058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732490|NCT04348513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Phase II, parallel, prospective, randomized, double-blind, placebo controlled trial|t|t|t|f
33732491|NCT02259933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732492|NCT02351869|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732493|NCT01964911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732494|NCT00487214|||COHORT||PROSPECTIVE|||||||
33732495|NCT00502697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732496|NCT00352612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34119901|NCT06719466|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812609|NCT02542332|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33812610|NCT03275467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812611|NCT00257894|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812612|NCT04089202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33812613|NCT02518399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812614|NCT03788226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812615|NCT02704156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812616|NCT03006718|NA|SINGLE_GROUP||OTHER||NONE||||||
33812617|NCT06236204|NA|SINGLE_GROUP||TREATMENT||NONE||prospective single center - single surgeon||||
33732497|NCT02684227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732498|NCT02531165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732499|NCT00093457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732500|NCT00880945|||CASE_CONTROL||PROSPECTIVE|||||||
33732501|NCT05902208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732502|NCT02187302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732503|NCT01514552|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33732504|NCT05466396|||COHORT||PROSPECTIVE|||||||
33732505|NCT01345279|||OTHER||RETROSPECTIVE|||||||
33732506|NCT00417183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732507|NCT05125198|||OTHER||CROSS_SECTIONAL|||||||
33732508|NCT04272398|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33732509|NCT01723865|||CASE_CONTROL||PROSPECTIVE|||||||
33812618|NCT01020435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812619|NCT05058885|||OTHER||CROSS_SECTIONAL|||||||
33812620|NCT01916109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732510|NCT00983281|||COHORT||RETROSPECTIVE|||||||
33732511|NCT01374308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732512|NCT03341052|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812621|NCT02860949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812622|NCT01670526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812623|NCT03144440|||OTHER||RETROSPECTIVE|||||||
33812624|NCT01383785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812625|NCT03071523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812626|NCT01223573|||COHORT||PROSPECTIVE|||||||
33812627|NCT02007070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812628|NCT01966679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812629|NCT05193526|||COHORT||RETROSPECTIVE|||||||
33732513|NCT05453838|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single blind||t|f|f|f
33732514|NCT05572502|NA|SINGLE_GROUP||TREATMENT||NONE||single group, multiple replications||||
33732515|NCT04433897|||COHORT||PROSPECTIVE|||||||
33732516|NCT05117463|||CASE_CONTROL||PROSPECTIVE|||||||
33732517|NCT01387607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732518|NCT06478004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-center, prospective randomized controlled clinical trial|f|f|f|t
33732519|NCT01917071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732520|NCT00002082||||TREATMENT||DOUBLE||||||
33812630|NCT04933474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33812631|NCT02010684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812632|NCT02779972|||COHORT||RETROSPECTIVE|||||||
34119902|NCT06155357|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33812633|NCT02588521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812634|NCT00027014|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33812635|NCT05334433|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33812636|NCT04584736|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33812637|NCT05347849|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part A only||t|t|t|t
33812638|NCT00046475|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33812639|NCT04012242|||COHORT||CROSS_SECTIONAL|||||||
33812640|NCT00168506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812641|NCT03531242|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects who successfully complete screening will be enrolled in the study to receive either (1) a series of booster(s) or (2) one booster vaccination(s). Each vaccination will be administered as 0.5 mL subcutaneous doses in the upper outer aspect of the arm (triceps areas)||||
33812642|NCT00941447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812643|NCT00374283|||||PROSPECTIVE|||||||
34043888|NCT03955822|||CASE_ONLY||RETROSPECTIVE|||||||
34043889|NCT05702476|||CASE_ONLY||PROSPECTIVE|||||||
34043890|NCT04973267|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators will be blinded to study condition. Staff collecting dried blood spot samples will also be blinded to condition. Participants will be encouraged to complete online surveys using an automated email system, so outcomes assessors will not be present.|Participants will be randomly assigned 1:1 to one of two conditions: (1) Game Plan for PrEP and (2) an attention-matched control consisting of videos encouraging healthy lifestyle habits.|f|f|t|t
34043891|NCT04002115|NA|SEQUENTIAL||TREATMENT||NONE||Dose de-escalation: Enrollment will begin at 30 mg/m2 to analyze any grade 4-5 organ toxicities as defined in Section 12.2. If the trial is stopped due to excessive toxicities, then dose de-escalation to 20 mg/m2 will occur for the next cohort of participants. For each participant, the observation period is from start of treatment through post-transplant day +30. Adverse effects will be continuously monitored as patients are enrolled. The trial will be stopped when the toxicity rate exceeds 20% with a posterior probability of 80% and a margin of no more than 5%. This leads to the following stopping rule: the trial will be stopped if 2 of the first 3 subjects experience grade 4-5 organ toxicity, or 3 out of 6, 4 out 9, 5 out of 12, 6 out of 16, or 7 out 19.||||
34043892|NCT04620447|RANDOMIZED|PARALLEL||TREATMENT||NONE||"To achieve the stated objective, a two-fold approach comprising of qualitative and quantitative analysis was undertaken. A 7-week intervention course was designed for each subject to reduce symptoms and enhance quality of life as well as to establish clinical efficacy. .~The participants were assigned to three groups using circumstantial sampling methodology. Group 1: IVRTS, Group 2: Mindfulness, Group 3: Cognitive Behavior Therapy, Group 4: Control Group.~Further study carried out A-B-A research design (Pre and Post intervention) which mainly involved establishing a baseline condition, introducing an experimental treatment and then returning to the baseline. The subjects completed standardized self-report measures of Hamilton Anxiety Inventory (HAM-A), Subjective Units of Dysfunction (SUDS) and WHO Quality of Life - BREF Questionnaire (QOL-BREF) at baseline, after seven intervention sessions post assessments on the same scales were repeated to assess the efficacy."||||
34043893|NCT06454669|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled, Parallel Groups|t|t|t|t
34043894|NCT03531203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043895|NCT04487015|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Sequential Multiple Assignment Randomized Trial||||
34043896|NCT06383754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are randomised and masked from the treatment||t|f|f|f
34043897|NCT01803750|||COHORT||PROSPECTIVE|||||||
34043898|NCT03085966|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043899|NCT00532389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043900|NCT06211686|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Phase I: Descriptive survey research Phase II: Quasi-experimental research||||
34043901|NCT02316600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043902|NCT02022280|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34043903|NCT04174599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34043904|NCT02300662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043905|NCT04543149|||CASE_CONTROL||PROSPECTIVE|||||||
34043906|NCT03770754|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Certified endodontists trained in the procedures, devices, and systems investigated took part in the research. All experts tracked a pre-established procedure for Rotary instrument systems and Endo vac system.|"All clinical procedures and measurements were conducted by the author. A #0 periapical radiograph was taken for each tooth in buccolingual projection to allow proper selection. The selected teeth included 7 second maxillary molars (three canals each), 9 first maxillary molars (2 canals each), 3 central incisors (one canal each), 18 first mandibular molars (2 canals each), 8 second mandibular molars (three canals each) for a total of 45 teeth with 102 canals (Table 1).~A standard session time recommended by the pedodontists was approximately 20-35 minutes in length to allow for acceptable time for completion of treatment. All treatment was performed by the author. As a novel treatment in Pedodontics, were included electronic apex locator (EAL), EndoVac system and two rotary systems: LightSpeed LSX instruments and ProTaper Next."|t|f|t|f
34043907|NCT01594736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043908|NCT04860648|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34043909|NCT02268292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043910|NCT03298958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded for study staff (investigator) and patient|"When it is determined that you are eligible for the study, you will be assigned by chance (like flipping a coin) to one of 2 study groups.~* Sirolimus 0.5 mg/day for 2 years or until disease recurrence~* Placebo"|t|f|t|f
34043911|NCT03742362|NA|SINGLE_GROUP||OTHER||NONE||3 groups of women: Group 1: Healthy young women Group 2: Postmenopausal women without Osteoporosis Group 3: Postmenopausal women with Osteoporosis All will undergo the same MRI scans||||
34043912|NCT00179660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043913|NCT04863859|||COHORT||CROSS_SECTIONAL|||||||
34043914|NCT03713060|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34043915|NCT05290883|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34043916|NCT01226966|||COHORT||PROSPECTIVE|||||||
34043917|NCT00188773|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043918|NCT05891834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043919|NCT05461001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732521|NCT05676892|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732522|NCT01852292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732523|NCT00864162|RANDOMIZED|CROSSOVER||||NONE||||||
33732524|NCT03582488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732525|NCT06023784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732526|NCT04209361|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33732527|NCT04452266|||CASE_CONTROL||RETROSPECTIVE|||||||
33732528|NCT05049161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732529|NCT01594593|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732530|NCT05738200|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732531|NCT05272930|||CASE_ONLY||PROSPECTIVE|||||||
33732532|NCT02698358|||CASE_ONLY||PROSPECTIVE|||||||
33732533|NCT00004031|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732534|NCT03892980|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects undergo nipple-sparing mastectomy (NSM) procedures using the da Vinci Surgical Systems||||
33732535|NCT04734340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732536|NCT01166308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732537|NCT01844258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812644|NCT01762839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812645|NCT05757674|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812646|NCT00230269|||COHORT||PROSPECTIVE|||||||
33812647|NCT00999388|||COHORT||PROSPECTIVE|||||||
33732538|NCT01782313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732539|NCT03568942|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive 1500 mg gepotidacin tablets BID via oral route for 5 days.||||
33732540|NCT06538623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732541|NCT00443183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732542|NCT00554827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732543|NCT00887900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732544|NCT02064738|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732545|NCT00013858|||||PROSPECTIVE|||||||
33732546|NCT03618797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732547|NCT02431858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732548|NCT05036564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33732549|NCT05515848|||COHORT||RETROSPECTIVE|||||||
33732550|NCT03962335|RANDOMIZED|CROSSOVER||TREATMENT||NONE|In this trial blinding of participants and investigators will not be possible because of obvious differences between the intervention diets|Randomized crossover open dietary intervention study with 3 arms of intervention||||
33732551|NCT01996670|||COHORT||RETROSPECTIVE|||||||
33732552|NCT06273176|||COHORT||PROSPECTIVE|||||||
33732553|NCT05121584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732554|NCT05657028|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33732555|NCT02117037|NA|SINGLE_GROUP||OTHER||NONE||||||
33732556|NCT00849628|||CASE_ONLY||CROSS_SECTIONAL|||||||
33732557|NCT05780242|||COHORT||PROSPECTIVE|||||||
33732558|NCT05065125|||COHORT||PROSPECTIVE|||||||
33732559|NCT04696705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732560|NCT03646721|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33732561|NCT02287896|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732562|NCT03372512|||COHORT||PROSPECTIVE|||||||
33812648|NCT02817360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812649|NCT03132571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Naltrexone versus Placebo assignment will remain double-blinded for the duration of the study; Bupropion dosing will be open-label and not masked to either participant or investigator.||t|t|t|t
33812650|NCT04281355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812651|NCT01537497|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33812652|NCT06128915|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Enrolled participants will be assigned a unique study identification number followed by a visit number (example 1.1 for donor #1-first visit). The code list, linking patient identities (such as names/phone numbers) and samples, will be kept in a separate file locked in a drawer the PI's office. The code list and code-identified data will be stored in separate locations and only authorized individuals will have access to the list. Experiments and data analysis will be performed only on coded samples and researchers will only have access to the visit number as the experiments to be performed on the collected samples pre and post vaccination differ.|Vaccination with Prevnar.||||
33812653|NCT03478072|||CASE_ONLY||PROSPECTIVE|||||||
33812654|NCT01792505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812655|NCT03038490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043920|NCT03894189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043921|NCT05334953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043922|NCT00590213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043923|NCT05082259|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34043924|NCT00952068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043925|NCT02235064|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34043926|NCT04864938|||CASE_CONTROL||PROSPECTIVE|||||||
34043927|NCT00975611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043928|NCT06534489|||COHORT||PROSPECTIVE|||||||
34043929|NCT01894841|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34043930|NCT05071625|||COHORT||RETROSPECTIVE|||||||
33732563|NCT01826175|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33732564|NCT06382987|||COHORT||PROSPECTIVE|||||||
33732565|NCT06126484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043931|NCT05736016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are provided with either active or shame medical devices. Care providers (rehabilitatin team members) and outcome assessors are not acknowledged about patiens' allocation|double-blind sham-controlled single-centre randomized study|t|t|f|t
34043932|NCT05101863|||CASE_CONTROL||PROSPECTIVE|||||||
34043933|NCT02854332|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34043934|NCT04018846|||COHORT||PROSPECTIVE|||||||
34043935|NCT01544387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043936|NCT02782559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812656|NCT02234999|NA|SINGLE_GROUP||OTHER||||||||
33812657|NCT04478409|||CASE_CONTROL||PROSPECTIVE|||||||
33812658|NCT01504984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812659|NCT02128893|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812660|NCT03611985||SEQUENTIAL||TREATMENT||NONE||||||
33812661|NCT05630313|||OTHER||RETROSPECTIVE|||||||
33812662|NCT02717208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812663|NCT06307574|RANDOMIZED|PARALLEL||OTHER||SINGLE|All primary and secondary outcome assessments following the intervention, Week 4, are blinded. One of the supplementary outcome measures following the intervention at Week 12, requires the assessor to know the group assignment. This outcome pertains to their experience in the intervention. The follow-up outcome assessments at Week 12 will be administered by an unblinded assessor.|Participants will be screened and randomly assigned to either the bpMedManage-S or bpMedManage-P group|f|f|f|t
33812664|NCT02138201|||||PROSPECTIVE|||||||
33812665|NCT02813174|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812666|NCT06131957|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The subjects and the clinical team including the dentist and the dental surgery assistant will all be blinded to the subjects' assignment of the intervention.|Participants are randomized assigned to either experimental group or controlled group.|t|f|t|f
33812667|NCT05452356|||COHORT||PROSPECTIVE|||||||
33812668|NCT02225288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812669|NCT00722865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812670|NCT04048226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* The patients will be blind through the use of closed sealed envelops.~* The investigator will be blind through the use of syringe pump containing normal saline in the control group by the aid of anesthesia resident who will not participate in the study.~* The measurement will be collected by anesthesia nurse not participating in the study and blinded to its group."|Prospective randomized controlled study|t|f|t|t
33812671|NCT05636345|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||exploratory, single-site, mixed-methods study||||
33812672|NCT00828178|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812673|NCT03971539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812674|NCT02070276|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812675|NCT02175810|||COHORT||PROSPECTIVE|||||||
33812676|NCT02917148|||CASE_CONTROL||PROSPECTIVE|||||||
33812677|NCT06422598|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812678|NCT03432871|NA|SINGLE_GROUP||TREATMENT||NONE|Experimental medicine study (open label)|Experimental medicine study (open label)||||
33812679|NCT03147586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812680|NCT05576701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||While the patients were randomized; In order to keep the possibility of being affected by each other at a minimum level, the work was continued with the same application group in the same session group. 72 days in universe, hemodialysis days and sessions at time of day, next Wednesday, Friday = 36 patients); Tuesday, Thursday, evening patient control (n=36 patients are guided by the drawing method.||||
33812681|NCT03226600|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial between two treatment modalities for gingival recession with 6 month follow-up|t|f|t|t
33812682|NCT05763823|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812683|NCT04251455|||COHORT||PROSPECTIVE|||||||
33812684|NCT06562881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812685|NCT02450084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812686|NCT02936609|||CASE_CONTROL||PROSPECTIVE|||||||
33812687|NCT01775657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34119903|NCT06252597|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Clients with neuro-progressive disorders (ALS, multiple sclerosis, Parkinson's, muscular dystrophies, and spinal muscular atrophy) who also use complex power wheelchairs.||||
34119904|NCT03571971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34119905|NCT05775510|||COHORT||PROSPECTIVE|||||||
34119906|NCT02403544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119907|NCT03179761|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34119908|NCT06709287|||COHORT||PROSPECTIVE|||||||
34119909|NCT06360575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119910|NCT03274765|||COHORT||PROSPECTIVE|||||||
34119911|NCT05117996|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blind||f|f|t|f
34119912|NCT02878876|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34119913|NCT01461525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119914|NCT01697709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119915|NCT06412107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|This study can achieve a partial blind design for participants in the true and sham acupressure groups. Blind of outcome assessment will be also achieved in the true and sham intervention groups as all the questionnaires are patient-reported and the participants themselves will be the outcome assessors. Data analysis will be conducted by an independent statistician who are blinded to the group allocation.||f|f|f|t
33812688|NCT06225323|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33812689|NCT02039401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812690|NCT05431322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812691|NCT05244967|||COHORT||PROSPECTIVE|||||||
33812692|NCT04534699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812693|NCT06034977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119916|NCT03766984|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Longitudinal, prospective, crossover, open, randomized, single-dose study with 3 periods, 2 sequences (ACB and BCA), and 3 treatments (A, B, and C) in healthy participants and under fasting conditions.||||
33812694|NCT05352555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Every enrolled patients records were randomized, and based on the outcome, subjects were either assigned to control or experimental arm groups. A report detailing the outcome, but omitting the method of treatment, was given to patients and their care provider.|Patients previously diagnosed with BPPV were referred to vestibular laboratory at the Department of Otolaryngology at Haseki Sultangazi Teaching and Research Hospital. Videonystagmography was performed on all subjects to confirm the BPPV diagnosis. Patients were then randomly divided into two groups; experimental and control. The experimental group was treated with RMS, while control group was treated with traditional manual canalith repositioning maneuvers on an examination table.|t|t|f|f
33812695|NCT00454922|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812696|NCT04506047|||COHORT||OTHER|||||||
34119917|NCT05023460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119918|NCT00069641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119919|NCT06715462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119920|NCT04841993|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participant were aware of the cannabis preparation but not of the administered doses|The study was unicentric, open-label, not randomized, not placebo controlled ,single blind. The study included three substudies (one for each formulation administration). The first one for decoction administration, the second one for oil administration, and finally, an experimental session was held for the administration of the standardized vaporized cannabis preparation. Each subject will participate in one experimental session. One treatment condition per subject (of two possible oral formulations and one inhaled / vaporized formulation of vaporized cannabis. Once the experimental session is over, the subjects have the possibility of being able to participate in the same study after a minimum washout period of 3 weeks.|t|f|f|f
34119921|NCT01127919|||COHORT||PROSPECTIVE|||||||
34119922|NCT06505187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34119923|NCT06556485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119924|NCT04991857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It is a single-blind study. A research assistant (RA1) will identify eligible patients (participants) by record review, invite their participation and obtain their informed consent. After recruiting the participants, simple randomization will be conducted using a computer-generated sequence with a 1:1 allocation ratio to allocate the subjects to receive either the T-FAME-HF or HF education program. Single blinding is maintained by using the another research assistant (RA2), who has no information about group assignment, to collect the post-test self-reported data on outcome variables (i.e. self-care, HRQL and family functioning) via telephone interview.||f|f|f|t
34119925|NCT04337242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34119926|NCT06716723|||COHORT||RETROSPECTIVE|||||||
34119927|NCT00757068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119928|NCT02640937|||CASE_ONLY||PROSPECTIVE|||||||
34119929|NCT06719401|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34119930|NCT01932788|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34119931|NCT06711042|||COHORT||PROSPECTIVE|||||||
34119932|NCT06319820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119933|NCT06431425|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Non-inferiority randomised controlled trial with a parallel group design||||
34119934|NCT03820830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119935|NCT06718439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34119936|NCT04683913|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm delayed control design||||
34119937|NCT04845256|||CASE_ONLY||PROSPECTIVE|||||||
34119938|NCT06715826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34119939|NCT01659450|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34119940|NCT03384875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34119941|NCT03895190|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34119942|NCT02150239|||CASE_ONLY||CROSS_SECTIONAL|||||||
34119943|NCT06340230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119944|NCT04910269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119945|NCT02432625|||COHORT||PROSPECTIVE|||||||
34119946|NCT06345768|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119947|NCT06452732|||COHORT||PROSPECTIVE|||||||
34119948|NCT05455580|NA|SINGLE_GROUP||PREVENTION||NONE||This is a non-randomized, non-blinded, quasi-experimental, pre- and post-test phase I feasibility design pilot study.||||
34119949|NCT06613880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119950|NCT04343092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119951|NCT02710539|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34119952|NCT01830985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119953|NCT04103021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119954|NCT00021970|||||RETROSPECTIVE|||||||
34119955|NCT03168802|RANDOMIZED|PARALLEL||TREATMENT||NONE||50 patients in each arm.||||
34119956|NCT03794349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119957|NCT05291650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34119958|NCT00454116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119959|NCT02812914|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119960|NCT03179917|NA|SINGLE_GROUP||TREATMENT||NONE||This phase II study will use an optimal Simon two-stage design.||||
34119961|NCT02530177|||CASE_CONTROL||RETROSPECTIVE|||||||
34119962|NCT02176148|||COHORT||PROSPECTIVE|||||||
34119963|NCT00494182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812697|NCT01466556|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33812698|NCT01681459|||CASE_CONTROL||PROSPECTIVE|||||||
33812699|NCT02176694|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33812700|NCT04425837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812701|NCT02822703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838456|NCT04901923|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33838457|NCT04513093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33838458|NCT03020953|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33838459|NCT03056651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838460|NCT03003377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34119964|NCT03144167|NA|SINGLE_GROUP||OTHER||NONE||||||
34119965|NCT06696417|||OTHER||PROSPECTIVE|||||||
34119966|NCT06396741|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34119967|NCT04615546|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119968|NCT06107530|NA|SINGLE_GROUP||OTHER||NONE||||||
34119969|NCT01370187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34119970|NCT06479174|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119971|NCT06715449|RANDOMIZED|PARALLEL||PREVENTION||NONE||Parallel-group prospective randomised open-label blinded endpoint (PROBE) controlled trial||||
34119972|NCT00665067|||OTHER||OTHER|||||||
34119973|NCT01242514|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34119974|NCT01977365|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34119975|NCT04736472|NA|SINGLE_GROUP||OTHER||NONE||This is a nonrandomized, open-label study to investigate the feasibility of establishing and integrating a pharmacogenetic test into clinical oncology care. A historical control group of patients with gastrointestinal cancers enrolled in a biobank will be used to compare toxicity outcomes of the prospectively-genotyped patients.||||
34119976|NCT00686673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34119977|NCT04972253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119978|NCT06717022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119979|NCT04097990|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||10 healthy participants, 10 participants with hypertriglyceridemia without prior pancreatitis and 10 participants with hypertriglyceridemia and at least one case of severe pancreatitis in the last 5 years.||||
34119980|NCT00928343|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34119981|NCT06585891|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34119982|NCT03097289|NA|SINGLE_GROUP||OTHER||NONE||Apheresis platelets will be collected on the Trima Accel system and stored in 65% InterSol/35% plasma for all subjects||||
34119983|NCT06438991|NA|SINGLE_GROUP||OTHER||NONE||All subjects will receive a spinal cord stimulator. Muscle strength will be assessed with the stimulation turned on and off. Parameters for motor function will be assessed with the stimulation turned on and off.||||
34119984|NCT02382354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34119985|NCT03126916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119986|NCT05302063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119987|NCT06463366|||COHORT||PROSPECTIVE|||||||
34119988|NCT05957042|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluate whether CEUS can predict response on gold standard imaging in the same individuals||||
34119989|NCT06531538|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study is partially blinded as 2 of the 3 groups are blinded and 1 is unblinded.|Parallel assignment|t|f|t|t
34119990|NCT06715956|||COHORT||PROSPECTIVE|||||||
34119991|NCT05625399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34119992|NCT06279312|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34119993|NCT00888147|||CASE_ONLY||PROSPECTIVE|||||||
34119994|NCT00583219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119995|NCT03096886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An experienced clinical evaluator with established reliability will assess patients pre-treatment and biweekly during CCBT treatment (Weeks 1, 2, 4, 6, 8, 9 of CCBT). All evaluations will be conducted without knowledge of treatment assignment. The evaluator will assess symptom severity according to the MADRS and Hamilton Rating Scale for Depression (HAM-D). Evaluators will have offices remote to the day-to-day operations of the treatment study and will not participate in weekly study management meetings in order to help preserve the blind.|This is a 3-arm, parallel study design. Individuals presenting with MDD will be randomized into either Arm 1: 8 weeks of Computer-Augmented Cognitive Behavioral Therapy (CCBT) Immediately or Arm 2: Waitlist up to 4 weeks followed by 8 weeks of CCBT. Arm 3 is a no treatment arm for matched comparison participants (i.e., healthy controls).|f|f|f|t
34119996|NCT05225103|NA|SINGLE_GROUP||TREATMENT||NONE||Open Trial is Single Group.||||
34119997|NCT04679454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34119998|NCT06088329|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34119999|NCT03367884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120000|NCT06068374|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The evaluator of flow-mediated dilation is blinded||f|f|f|t
34120001|NCT06715410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The purpose of this clinical study is to collect parameter raw data for development and to evaluate the operational and functional features as well as ease of use of the system.||||
33732566|NCT00658112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732567|NCT02434770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33732568|NCT02747069|||OTHER||PROSPECTIVE|||||||
33732569|NCT00095758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732570|NCT01507285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732571|NCT00956410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732572|NCT04508569|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732573|NCT00749970|||||PROSPECTIVE|||||||
33732574|NCT03789552|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732575|NCT02034526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732576|NCT02160366|||COHORT||PROSPECTIVE|||||||
33732577|NCT02957890|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33732578|NCT06084195|NA|SINGLE_GROUP||OTHER||NONE||||||
33732579|NCT04043195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732580|NCT02388737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732581|NCT06295718|||OTHER||CROSS_SECTIONAL|||||||
33732582|NCT05639270|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33838461|NCT02302170|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33838462|NCT05843292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838463|NCT00218153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120002|NCT06714136|||COHORT||RETROSPECTIVE|||||||
34120003|NCT06685198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120004|NCT04214067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120005|NCT06539754|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomized in 1:1 stratification to receive music during their procedure or not. Participants will not be aware of the intervention. If a patient is randomized into music, they will be offered headphones to listen to during their procedure.||t|f|f|f
34120006|NCT06278051|||COHORT||RETROSPECTIVE|||||||
34120007|NCT03300206|||COHORT||PROSPECTIVE|||||||
34120008|NCT05543447|||OTHER||PROSPECTIVE|||||||
34120009|NCT05489887|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120010|NCT06715254|||COHORT||RETROSPECTIVE|||||||
34120011|NCT06218823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120012|NCT04375527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120013|NCT00479063|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120014|NCT06289400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120015|NCT06135584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120016|NCT05587491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120017|NCT06112860|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Those listening and scoring recorded tasks will be blinded to which group the participants are in.||f|f|f|t
34149129|NCT03234231|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|data entered by independent clerical staff with no information of the detail of the study outcomes assessor will not be told which group of subjects are examined but there is a chance that the subjects tell him/her|Cluster randomized controlled trial|f|f|t|t
34149130|NCT02881619|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34149131|NCT00343382|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34149132|NCT06422585|||COHORT||RETROSPECTIVE|||||||
34149133|NCT05453695|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149134|NCT00002447||||TREATMENT||||||||
34149135|NCT03960723|||OTHER||CROSS_SECTIONAL|||||||
34149136|NCT01744314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149137|NCT00267150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149138|NCT02855944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149139|NCT03973905|||CASE_CONTROL||RETROSPECTIVE|||||||
34149140|NCT00664326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812702|NCT04749797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|On the morning of the procedure, participants will be assigned sequentially to the lowest unassigned randomization number. The surgeon performing the procedure and operating room staff will not be blinded to the intervention, since they will see whether the patient is receiving liposomal bupivacaine, bupivacaine or saline. However, all providers obtaining post-operative data from the patients will be blinded as to which treatment the patient received, in addition to the patient themselves.|Participants will be randomized to one of three groups: saline, bupivacaine, liposomal bupivacaine|t|t|f|f
33812703|NCT06498232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812704|NCT01142063|||COHORT||PROSPECTIVE|||||||
33812705|NCT01324089|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33812706|NCT04353856|||CASE_ONLY||PROSPECTIVE|||||||
33812707|NCT01120457|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812708|NCT03222232|||COHORT||RETROSPECTIVE|||||||
34043937|NCT05847465|||CASE_CONTROL||PROSPECTIVE|||||||
34043938|NCT03462160|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34043939|NCT03267524|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34043940|NCT03132857|||COHORT||PROSPECTIVE|||||||
34043941|NCT06577402|||COHORT||PROSPECTIVE|||||||
34043942|NCT02778009|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34043943|NCT05898828|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34043944|NCT03942471|RANDOMIZED|FACTORIAL||TREATMENT||NONE||between and within group repeated measures design||||
34043945|NCT05051280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043946|NCT00940823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043947|NCT04144413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In order to assess the response to IKERVIS® for DED patients with severe keratitis, after 12-month IKERVIS® (once daily) treatment, patients who have shown a marked improvement at Month 12 (as defined below) will be randomised to receive IKERVIS® or Vehicle (ration 3:2) in double-masked fashion.|t|f|t|f
34043948|NCT04614935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043949|NCT04875221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned to either the experimental or sham-control arms under double-blind conditions.|Participants will be randomized to either the experimental or sham arms.|t|f|t|f
34043950|NCT05136105|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Two cohorts. The first cohort receiving treatment as usual in Burundi, mostly a waiting control group, the second cohort receiving a three session family focused intervention.||||
34043951|NCT03581058|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34043952|NCT06572046|||OTHER||OTHER|||||||
34043953|NCT05807698|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34043954|NCT03018080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043955|NCT01136057|||COHORT||PROSPECTIVE|||||||
34043956|NCT01781845|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043957|NCT01791673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043958|NCT03915327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34043959|NCT03288545|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||multi-cohort, open-label, multicenter study, global||||
34043960|NCT02705300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043961|NCT04404764|||COHORT||CROSS_SECTIONAL|||||||
34043962|NCT06026735|||CASE_ONLY||PROSPECTIVE|||||||
34043963|NCT00249132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34043964|NCT00454363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043965|NCT06124950|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34043966|NCT00005580|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34043967|NCT01514539|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34043968|NCT05125848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043969|NCT01838564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34043970|NCT00975117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043971|NCT02395848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043972|NCT04221256|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||We propose a double-blinded, placebo-controlled crossover study to test a range of doses of escitalopram and a placebo control in enhancing PAS-induced plasticity in healthy individuals without neurological disease and patients with chronic stroke.|t|f|t|t
34043973|NCT03477539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043974|NCT00992901|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34043975|NCT02046590|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34043976|NCT03520777|NA|SINGLE_GROUP||OTHER||NONE||||||
34043977|NCT00653133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043978|NCT04411810|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043979|NCT06574074|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Data collectors will be blinded to the allocation of the participants to different groups.|The unit of randomization will be study participants who are identified with depression by FCHVs. Each participant will be randomized into one of eight groups using a computer-generated random number.|f|f|f|t
34043980|NCT03495479|||COHORT||PROSPECTIVE|||||||
34043981|NCT06576583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120018|NCT06711484|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Since the training will be provided by the researcher, blinding the researcher will not be possible.~All participants in the intervention and control groups will think that they will receive the entire language training. It will be explained that the trainings will be planned on different dates, notifications will be sent to mobile phones regarding the start and end times of the trainings, and the nurse whose turn it is will be called to the training. In this way, blinding of the participant will be ensured.~After the explanation, the same informed consent form will be signed by the intervention and control group nurses.~The statistician will perform the statistical analyses without knowing which group is the intervention and which group is the control."|This research is a randomized, pretest-posttest control group, parallel group experimental study that will evaluate the effectiveness of the language training program developed for newly graduated nurses. An introductory information form and a pretest evaluation of the scales will be applied to the participants who accept to participate in the research seven days before the application. Then, the groups will be randomized by an expert other than the researcher and assigned to their groups. The language training program will be applied to the experimental group seven days after the pretest evaluations. No intervention will be made to the control group. The final evaluation of the scales will be made to both groups seven days after the experimental group participants complete the training program. The language training program evaluation form will also be applied to the experimental group participants and their opinions about the training program will be obtained.|t|f|f|t
34120019|NCT06692361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120020|NCT00002217||||TREATMENT||NONE||||||
34120021|NCT00419692|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120022|NCT06361134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120023|NCT05013554|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120024|NCT06653101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120025|NCT04411849|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34120026|NCT03204760|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Children with mild to moderate asthma exacerbation will be given the first dose of salbutamol and will be reassessed after 20 min by the emergency department attending. If further salbutamol is needed, subjects automatically will receive the second dose 20 min apart and receive either single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) or prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .~A repeat physical examination will be performed, including oxygen saturation, vital signs, PRAM, PEFR after the 3rd dose of salbutamol and at the end of the third day to evaluate the effect of prednisolone and dexamethasone on the improvement of asthma scores. Patient compliance to prednisolone therapy for three days will be also recorded."||||
34120027|NCT05640479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The research solutions will be formulated by a devoted pharmacist who had no further involvement in the trial. Intraoperative and postoperative parameters will be examined by a second anesthesiologist who was unaware of group assignment.||t|f|f|t
34120028|NCT02335320|||||CROSS_SECTIONAL|||||||
34120029|NCT05973903|NA|SINGLE_GROUP||TREATMENT||NONE||"Forty-seven patients will be included in the study: 10 patients as lead-in (phase I) and 37 patients in phase II."||||
34120030|NCT01147302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120031|NCT04106245|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34120032|NCT03375320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120033|NCT04363164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120034|NCT05176158|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34120035|NCT06452771|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34120036|NCT04505761|NA|SINGLE_GROUP||TREATMENT||NONE||Participants are asked to use Virtual Reality as an add-on to standard physiotherapy for revalidation after COVID-19.||||
34120037|NCT03212976|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34120038|NCT06358495|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to participants' assigned condition.|Participants will be randomly assigned to either CBT for insomnia or TAU waitlist with a psychoeducational pamphlet about sleep hygiene.|f|f|f|t
34120039|NCT03898284|||COHORT||PROSPECTIVE|||||||
34120040|NCT04445662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120041|NCT06491563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120042|NCT00105534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120043|NCT04724330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34120044|NCT03512093|||COHORT||OTHER|||||||
34120045|NCT06139653|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double (Participant, Outcomes Assessor) Participants will not know about other arms. Outcome assessors will not know the arms participant belong.|Sequential Assignment The participants will be randomized into 2 intervention groups as follows: Group 1: Moment 1: IMT Moment 2: CardioBreath®App. Group 2: Moment 1: CardioBreath®App Moment 2: IMT. The intervention will long five weeks. The exercises will be performed at home for five days/week|t|t|f|t
34149141|NCT06256718|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732583|NCT00240071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732584|NCT04060485|||CASE_ONLY||PROSPECTIVE|||||||
33732585|NCT04869735|||COHORT||PROSPECTIVE|||||||
33732586|NCT01454726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732587|NCT03962803|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732588|NCT02410811|||COHORT||PROSPECTIVE|||||||
33732589|NCT02896400|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
33732590|NCT03895320|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33732591|NCT01547884|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732592|NCT00907920|||COHORT||RETROSPECTIVE|||||||
33732593|NCT01610791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732594|NCT04290091|||COHORT||CROSS_SECTIONAL|||||||
33732595|NCT06457022|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Double||t|f|t|f
33732596|NCT00043693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732597|NCT01278459|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33732598|NCT05053672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective analysis in a 3-arm, randomized single-blind and placebo controlled study|t|f|f|f
34120046|NCT03950427|RANDOMIZED|PARALLEL||TREATMENT||NONE||a pilot 2-arm randomized controlled trial (RCT) to examine the feasibility and potential efficacy of an application of a videogame based group physical activity intervention for smoking cessation in adults with SMI.||||
34120047|NCT06627751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120048|NCT06007027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120049|NCT05692999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120050|NCT04459416|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter, two-arm randomized controlled trial. Randomization will be stratified by study site, primary cancer diagnosis (MM versus HD versus NHL) and transplantation setting (inpatient versus outpatient) to ensure these characteristics are comparably distributed between the two study arms.||||
34120051|NCT05699057|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120052|NCT02343302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120053|NCT00530881|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120054|NCT04658862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120055|NCT04908150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120056|NCT05457556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120057|NCT04401774|NA|SINGLE_GROUP||TREATMENT||NONE||The phase II nivolumab maintenance trial is an open-label trial for patients who have completed high-dose methotrexate-based first-line chemotherapy for primary central nervous system lymphoma (PCNSL) but have persistent cfDNA in their CSF after treatment despite imaging response.||||
34120058|NCT05841498|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Single-blinded, randomized, sham-controlled, crossover trial|t|f|f|f
34120059|NCT06356168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120060|NCT00240851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120061|NCT04388163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120062|NCT06690307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120063|NCT01792167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120064|NCT03504228|||CASE_ONLY||PROSPECTIVE|||||||
34120065|NCT06717035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomization: 202 children will be recruited at 6 institutions following the rules of inclusion and exclusion criteria. Based on a randomization process defined from the study coordinator, children will be allocated to 2 groups: DIMS and PDIMS. The study will be single blinded, meaning that the investigators are not aware of which type of treatment will be associated with which subjects. Subjects cannot be blinded due to the darkening of PDIMS that allows recognition on the type of lens.|f|t|t|t
34120066|NCT06467682|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120067|NCT06713278|||OTHER||CROSS_SECTIONAL|||||||
34120068|NCT00741065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120069|NCT05905237|||COHORT||PROSPECTIVE|||||||
34120070|NCT04375800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120071|NCT04640623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120072|NCT06346704|||COHORT||PROSPECTIVE|||||||
34120073|NCT03767257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120074|NCT06718465|||CASE_CONTROL||PROSPECTIVE|||||||
34120075|NCT03247829|||COHORT||PROSPECTIVE|||||||
34120076|NCT04429464|NA|SINGLE_GROUP||TREATMENT||NONE||The patient population will consist of men and women between the ages of 18 - 80 years, presenting for a de novo or repeat left-sided atrial ablation for symptomatic paroxysmal atrial fibrillation (PAF) or persistent atrial fibrillation (PerAF).||||
34120077|NCT06716203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120078|NCT04633447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120079|NCT05544084|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||Conduct an effectiveness-implementation hybrid type 1 stepped-wedge randomized pragmatic trial of the adapted patient navigation program across Kedougou and Dakar, Senegal.||||
34120080|NCT05626426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120081|NCT06102655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120082|NCT06341881|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The study participants would not be informed of what group they are in. Independent outcome assessors would be utilized for the assessment. Further outcomes assessors and data analysts' would be kept unaware of intervention or group allocations to carry out their assessment after inclusion of participants into the study.~This study which includes three research sites will be taken as preliminary strata via the simple random sampling technique. Lottery method as one of the oldest and commonly used approach would then be followed to recruit the sample size. Screening of the participants would be taken place in the first round based on the inclusion and exclusion criteria. The eligible participants would be assigned with a code in the second round before recruiting the participant into the study. Lottery method (law of chance) would then be follow to allocate the participants randomly into treatment or control groups in the study sites."|The most commonly two armed parallel study design would be used to conduct the current study. The study participants in an intervention group would be compared with that of a control group. Equal number of Participants would be allocated with random assignment in the two groups.|f|t|f|t
34120083|NCT00429988|||COHORT||PROSPECTIVE|||||||
34120084|NCT04752722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120085|NCT06357975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120086|NCT04992026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120087|NCT05121025|||CASE_CONTROL||PROSPECTIVE|||||||
34120088|NCT03910621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120089|NCT04684368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120090|NCT05351632|||COHORT||PROSPECTIVE|||||||
34120091|NCT04443088|NA|SEQUENTIAL||TREATMENT||NONE||||||
34120092|NCT02668666|NA|SINGLE_GROUP||TREATMENT||NONE|Open-Label|||||
34120093|NCT06719375|||OTHER||OTHER|||||||
34120094|NCT05989568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34120095|NCT05714007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34120096|NCT04281784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34120097|NCT06717282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120098|NCT04656587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120099|NCT06317636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120100|NCT02610634|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120101|NCT02835586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120102|NCT06405386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812709|NCT00996242|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33812710|NCT04794985|||CASE_ONLY||PROSPECTIVE|||||||
33812711|NCT00087906|||CASE_CONTROL||PROSPECTIVE|||||||
34120103|NCT01400126|||COHORT||PROSPECTIVE|||||||
34120104|NCT06255808|||COHORT||PROSPECTIVE|||||||
34120105|NCT02030132|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34120106|NCT06062017|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|No masking, open label|After a two-week habitual consumption run-in participants will be assigned to two weeks of water and potassium supplementation.||||
34120107|NCT01595087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120108|NCT06719102|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34120109|NCT02150421|||CASE_CONTROL||PROSPECTIVE|||||||
34120110|NCT05063552|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120111|NCT05155423|||COHORT||PROSPECTIVE|||||||
33732599|NCT05851560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33732600|NCT02130050|||CASE_CONTROL||RETROSPECTIVE|||||||
33732601|NCT00235989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812712|NCT04253951|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Both the clinicians who will perform and score LUS, and the patients' family will be blinded to randomization. The care providers (child neurologist and speech and language pathologist (SLP) will be informed of the result of LUS only in the LUS-m group and will include that result to impact on feeding care (postural, thickening fluids or with drugs available for GERD). LUS results in the SC-m group will be available only at the time of data analyses.|Double-blinded randomized parallel-designed controlled trial (Consort checklist, 21), with block randomization (blocks of size 4), in one of 2 groups: 1) LUS-monitored management (LUS-m); 2) Standard care management (SC-m). Both groups will undergo an experimental 6-months follow-up. In the first 3 months, participants will be evaluated a minimum of 1 time per month, in-hospital, for a total of 3 evaluations (T1, T2 and T3), plus baseline (T0).|t|f|t|t
33812713|NCT01509183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120112|NCT06495892|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms with a standard care control group and a peripheral pressure guided intervention group||||
34120113|NCT02234765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120114|NCT06029127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120115|NCT04753775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|22 patients were assigned to Group-A (5-ASA oral 800mg x 3 / day + 1 enema 60ml Aloe Vera gel / day) and 22 patients to Group-B (5-ASA oral 800mg x 3 / day + enema 60ml 1 Placebo / day).|randomized controlled trial|t|f|f|f
34120116|NCT00352300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120117|NCT06173531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120118|NCT06247982|||COHORT||OTHER|||||||
34120119|NCT01541371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120120|NCT01317992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120121|NCT05330182|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|An open label sentinel cohort will be followed by a double-blind placebo-controlled main cohort.||t|t|t|t
34120122|NCT04326790|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient-level randomization scheme||||
34120123|NCT02162186|||COHORT||PROSPECTIVE|||||||
34120124|NCT05061368|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double Blinded: participants, investigators and outcome assessors are blinded to condition until data entry and analysis are completed.|Double Blinded, Placebo Controlled Repeated Measures|t|f|t|t
34120125|NCT03849105|RANDOMIZED|PARALLEL||TREATMENT||NONE||multi-centre, open-label, dose-finding||||
34120126|NCT01336777|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120127|NCT01847755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120128|NCT05690425|NA|SEQUENTIAL||TREATMENT||NONE||||||
33732602|NCT05669443|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33732603|NCT00366392|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732604|NCT01690767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732605|NCT03706807|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732606|NCT06107491|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33732607|NCT02419846|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33732608|NCT04845737|NON_RANDOMIZED|PARALLEL||OTHER||NONE||We have two groups.First group is fibromyalgia patient and second group is healty control.||||
33732609|NCT05449925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732610|NCT05650372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blind to the randomization and the investigator will be blind to the outcomes|Randomized controlled single-blind study|f|f|f|t
33812714|NCT03455140|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812715|NCT01313663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120129|NCT01130792|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34120130|NCT01339507|||CASE_CONTROL||PROSPECTIVE|||||||
34120131|NCT02275507|||CASE_ONLY||PROSPECTIVE|||||||
34120132|NCT04814914|||COHORT||PROSPECTIVE|||||||
34120133|NCT04324281|||OTHER||RETROSPECTIVE|||||||
34120134|NCT06712732|||CASE_ONLY||PROSPECTIVE|||||||
34120135|NCT01411033|||COHORT||PROSPECTIVE|||||||
34120136|NCT03496116|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34120137|NCT06602791|||COHORT||PROSPECTIVE|||||||
33732611|NCT04820816|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33732612|NCT00004066||||TREATMENT||||||||
33732613|NCT00864773|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33732614|NCT04140461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732615|NCT05054530|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|This study will be double-blinded. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of adverse events, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (GMA106 Injection or GMA106 placebo Injection)|"Phase 1 - divided in 2 stages:~The 1st stage: single ascending dose (SAD) The 2nd stage: multiple ascending doses (MAD)"|t|t|t|t
33732616|NCT05124639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33732617|NCT05224492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732618|NCT02515266|||COHORT||RETROSPECTIVE|||||||
33732619|NCT05703893|||CASE_ONLY||PROSPECTIVE|||||||
34120138|NCT06718777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33732620|NCT00167934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732621|NCT04230096|RANDOMIZED|PARALLEL||PREVENTION||NONE||This will be an experimental; case controlled study||||
33732622|NCT05225961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732623|NCT06522308|||CASE_ONLY||PROSPECTIVE|||||||
33732624|NCT06090110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732625|NCT04766749|RANDOMIZED|PARALLEL||OTHER||SINGLE|"Before the operation, the nurse chooses the patient to perform RIPC or not according to a predefined random method, and then the operation is performed by the operator.~The operator did not know if the patient had undergone RIPC. Outcome evaluators also did not know the grouping of patients"||f|f|f|t
33732626|NCT04675424|||CASE_ONLY||PROSPECTIVE|||||||
33732627|NCT04380857|RANDOMIZED|PARALLEL||TREATMENT||NONE||First eye randomized for either topical prednisolone acetate (control eye) or lower eyelid canaliculus Dextenza insertion (study eye) and the contralateral eye receiving opposite treatment in the OR following SMILE||||
33732628|NCT01234220|||COHORT||RETROSPECTIVE|||||||
33732629|NCT03938116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732630|NCT01657110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732631|NCT01398566|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33732632|NCT05878613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732633|NCT01708772|||CASE_CONTROL||PROSPECTIVE|||||||
33732634|NCT04634149|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732635|NCT00907283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732636|NCT01598116|||CASE_CONTROL||PROSPECTIVE|||||||
33732637|NCT02009033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33732638|NCT04316182|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33732639|NCT06093724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732640|NCT03279276|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33732641|NCT04527081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732642|NCT00496301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732643|NCT00203749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732644|NCT03883204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732645|NCT00006219|RANDOMIZED|||PREVENTION||DOUBLE||||||
33732646|NCT01448850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732647|NCT05851352|||COHORT||PROSPECTIVE|||||||
33732648|NCT05414903|||CASE_CONTROL||PROSPECTIVE|||||||
33732649|NCT01285804|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33732650|NCT04587934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732651|NCT01041716|||CASE_ONLY||PROSPECTIVE|||||||
33732652|NCT01719692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732653|NCT04945434|NA|SINGLE_GROUP||TREATMENT||NONE||Single group cohort study||||
33812716|NCT06244563|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812717|NCT02271906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812718|NCT06344481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812719|NCT02748200|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients receive pelvic EBRT to the lymph nodes located along the common, internal, and external iliac artery; obturator fossa; and presacral nodes.||||
33812720|NCT01302106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812721|NCT00670488|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812722|NCT05121285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812723|NCT00952523|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33812724|NCT04410445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized in a 1:1 ratio to one of two treatment arms||||
33812725|NCT01345708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812726|NCT02487680|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33812727|NCT03022825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732654|NCT00001720||||TREATMENT||||||||
33732655|NCT04971564|||CASE_CONTROL||PROSPECTIVE|||||||
33732656|NCT00797953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732657|NCT01336478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732658|NCT02183441|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732659|NCT04495088|RANDOMIZED|PARALLEL||TREATMENT||NONE|open-label|multicenter, randomized, two-armed||||
33732660|NCT03913949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732661|NCT05291299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732662|NCT01622205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732663|NCT00003255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732664|NCT04320940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732665|NCT03571516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732666|NCT00117143|NA|SEQUENTIAL||TREATMENT||NONE||||||
33732667|NCT00700934|||COHORT||PROSPECTIVE|||||||
33732668|NCT05228782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|We will use intention-to-treat analysis for the primary outcome to further protect against selection bias. It is not feasible to blind participants to the intervention. Primary outcomes will be assessed after 12 weeks by a research assistant who has had no previous contact with participants and is blinded to the intervention group.|This multi-centered, three-arm, outcome assessor blinded randomized clinical trial will follow CONSORT reporting guidelines and is part of a program of research that adheres to the ORBIT model for developing complex behavioural interventions. In this model, the previous study by Lowthian and colleagues established the proof of concept, and the current trial Phase IIb is adequately powered to test whether two versions of the HOW R U? intervention are effective compared to a common standard care wait-list arm.|f|f|f|t
33732669|NCT05808452|||OTHER||PROSPECTIVE|||||||
33732670|NCT05678335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812728|NCT02819609|||COHORT||RETROSPECTIVE|||||||
33812729|NCT01817894|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33812730|NCT05645445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33812731|NCT05996900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33812732|NCT03489356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33812733|NCT03390998|||OTHER||CROSS_SECTIONAL|||||||
33812734|NCT03033667|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33812735|NCT02743039|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732671|NCT03653793|NA|SINGLE_GROUP||TREATMENT||NONE||"This was a single arm pilot study to determine the feasibility of conducting an appropriately sized RCT within the same population using the same clinical outcome measures.~Eligible adult patients of the clinic with varicose veins were asked to use the cream as directed on the packaging for 6-weeks and the post-treatment measures were compared to baseline data. This study also provided SDs of the sample for comparison to the study population."||||
33732672|NCT02190240|||CASE_ONLY|||||||||
33732673|NCT02515539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120139|NCT03346525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732674|NCT04099667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732675|NCT05439603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732676|NCT02915614|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33732677|NCT02438228|NA|SINGLE_GROUP||||NONE||||||
33732678|NCT01217918|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732679|NCT05218759|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33732680|NCT06448234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33732681|NCT00499135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732682|NCT05126407|||COHORT||RETROSPECTIVE|||||||
33732683|NCT00213356|||COHORT||PROSPECTIVE|||||||
33732684|NCT02752295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732685|NCT03930459|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732686|NCT03536039|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive NGR-hTNF at dose of 0.8 mcg/sqm 1 hour before standard R-CHOP (cyclophosphamide-doxorubicin-vincristine-prednisone-rituximab) regimen every 3 weeks for six courses (except for course #1 in which only standard R-CHOP regimen will be administered)||||
33812736|NCT00713466|||COHORT||PROSPECTIVE|||||||
34120140|NCT06714942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120141|NCT05196308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120142|NCT01690754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34120143|NCT05160545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120144|NCT06140329|||COHORT||PROSPECTIVE|||||||
34120145|NCT04188951|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
33732687|NCT06249308|||CASE_CONTROL||PROSPECTIVE|||||||
33732688|NCT00675857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732689|NCT02142452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732690|NCT02534792|||COHORT||RETROSPECTIVE|||||||
33732691|NCT04277988|||COHORT||PROSPECTIVE|||||||
33732692|NCT02098161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812737|NCT05922774|||CASE_CONTROL||PROSPECTIVE|||||||
33812738|NCT05341700|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized crossover study design||||
33812739|NCT04466735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators, participants and outcome assessors will be fully blinded.|Randomized controlled trial. First phase :Two parallel groups, one placebo, one active Second phase : All participants will be invited to take part in an open phase on the active product only.|t|f|t|t
33812740|NCT02134782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812741|NCT00120107|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812742|NCT05832970|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812743|NCT05735379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732693|NCT00782210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732694|NCT06129812|||CASE_CONTROL||RETROSPECTIVE|||||||
33732695|NCT00827411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732696|NCT03022617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732697|NCT01221259|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33732698|NCT03074903|||COHORT||PROSPECTIVE|||||||
33732699|NCT05473533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization is assigned by the pharmacist according to predetermined randomization code.|This is a phase 1, dose escalating study to assess safety, tolerability, and PK of single and multiple doses of PRS-220 administered by oral inhalation to healthy male and female subjects. This study will be conducted utilizing a blinded, randomized, dose-escalating design.|t|f|t|f
33732700|NCT03587610|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center, prospective, cluster randomized trial.||||
33732701|NCT00028756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812744|NCT06519448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812745|NCT01845337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33812746|NCT05692245|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomized assignment maintained in a sealed envelop. Study medication provided by a independent party. Investigators remain blinded until completion of analysis.|Randomized, Double-blind|t|t|t|t
33812747|NCT05197179|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812748|NCT03819543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812749|NCT01114685|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812750|NCT04434872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812751|NCT00863902|RANDOMIZED|CROSSOVER||||NONE||||||
33812752|NCT02593552|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812753|NCT05658094|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812754|NCT04263688|||COHORT||PROSPECTIVE|||||||
34120146|NCT02076945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120147|NCT01619917|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34120148|NCT02572531|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34120149|NCT04671823|||OTHER||CROSS_SECTIONAL|||||||
34120150|NCT04813731|||COHORT||PROSPECTIVE|||||||
34120151|NCT03217266|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120152|NCT04903626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120153|NCT01915212|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34120154|NCT06716866|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120155|NCT03394989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A multicenter, randomized, parallel-group, placebo-controlled|f|f|t|t
34120156|NCT04527835|||COHORT||PROSPECTIVE|||||||
34120157|NCT02286726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732702|NCT04429009|RANDOMIZED|PARALLEL||PREVENTION||NONE||All lobectomy and wedge resection patients meeting the inclusion criteria will be recruited (from the start of the study date until recruitment goal it reached) and consenting participants will be randomized to a study arm or a control arm. Each arm will consist of 50 subjects.||||
33732703|NCT05996861|||COHORT||PROSPECTIVE|||||||
33732704|NCT02286908|||OTHER||PROSPECTIVE|||||||
33732705|NCT02376192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732706|NCT05147857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732707|NCT02827058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732708|NCT02669602|||COHORT||PROSPECTIVE|||||||
33732709|NCT00049062||||TREATMENT||NONE||||||
33732710|NCT04811417|||COHORT||PROSPECTIVE|||||||
33732711|NCT05066620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812755|NCT06413459|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812756|NCT01930188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812757|NCT02338999|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34120158|NCT05221645|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study has two treatment arms to which participants will be randomised on a 3:1 basis to the experimental arm. The control arm (Arm A) will be R-ICE for 3 cycles followed by an autologous stem cell transplant (for patients in a CR or PR on the post treatment PET-CT scan). The experimental arm (Arm B) will consist of P+R-ICE for 3 cycles followed by an autologous stem cell transplant (for patients in a CR or PR on the post treatment PET-CT scan) and maintenance Pembrolizumab every 3 weeks for one year.~All patients will be randomised at study entry and will be stratified by relapse within 12 months or \> 12 months of first line therapy."||||
33812758|NCT03091829|||COHORT||PROSPECTIVE|||||||
34120159|NCT04303858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120160|NCT06397911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Biological: FB825 Other: Placebo|t|t|t|t
34120161|NCT04261088|||CASE_ONLY||CROSS_SECTIONAL|||||||
34120162|NCT05588440|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120163|NCT04943237|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120164|NCT04537741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|CCTA will be analysed at a core lab with no information of the results from invasive angiography or whether coronary revascularization was performed or not.|Single arm study where all patients being included will undergo CCTA before invasive coronary angiography||||
34120165|NCT03792516|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120166|NCT02821325|||COHORT||PROSPECTIVE|||||||
34120167|NCT00891150|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34120168|NCT06473701|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|An external party will manage the randomization process, assigning participants equally to either the active treatment or placebo groups in a 1:1 ratio. The randomization will be conducted using www.sealedenvelope.com and will incorporate varying block sizes, such as 4, 6, and 8 participants per block. Consequently, each medication container will be labeled with a unique participant number.|A randomized, controlled, double-blind, crossover trial|t|t|t|t
34120169|NCT04707092|RANDOMIZED|PARALLEL||OTHER||NONE||Randomization in two treatment arms||||
34120170|NCT06589713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120171|NCT05293340|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study will consist of two groups into which participants will be randomly assigned 1:1. One (active) group will receive vouchers for free avocados. The other (control) group will not receive avocado vouchers (to control for the impact of seasonal changes on diet that are outside the influence of the trial).||||
34120172|NCT06715332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120173|NCT05404958|RANDOMIZED|PARALLEL||OTHER||NONE||"This is a cluster randomized trial enrolling family planning clinics. Participants are FP clinics."||||
34120174|NCT02652221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120175|NCT06543485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812759|NCT03783936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812760|NCT02441829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812761|NCT00364975|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120176|NCT03279653|||COHORT||PROSPECTIVE|||||||
34120177|NCT01371058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120178|NCT06389123|NA|SINGLE_GROUP||TREATMENT||NONE||Single treatment||||
34120179|NCT03245918|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34120180|NCT02977078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34120181|NCT06414044|||CASE_ONLY||PROSPECTIVE|||||||
34120182|NCT06345001|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34120183|NCT06714682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34120184|NCT06226051|||COHORT||PROSPECTIVE|||||||
34120185|NCT03533010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120186|NCT06718985|||CASE_ONLY||CROSS_SECTIONAL|||||||
34120187|NCT06671756|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34120188|NCT06691867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33812762|NCT01514773|||CASE_CONTROL||OTHER|||||||
33812763|NCT01054118|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33812764|NCT03865732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The double-blind phase will randomize subjects to adjunctive ganaxolone or placebo at a 1:1 ratio to standard of care.|t|t|t|t
33812765|NCT02267109|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33812766|NCT01220999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812767|NCT01758068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812768|NCT01098292|||COHORT||PROSPECTIVE|||||||
33812769|NCT02881086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812770|NCT04270032|||OTHER||OTHER|||||||
33812771|NCT05578807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812772|NCT06279416|||COHORT||PROSPECTIVE|||||||
33732712|NCT03389646|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Prospective with retrospective matched controls.||||
33732713|NCT03693768|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33732714|NCT00772551|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812773|NCT01555307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812774|NCT05995691|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33732715|NCT06402058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Randomized, Subject and Evaluator blinded, Matched pairs, Pilot Study|t|f|f|t
33732716|NCT01329081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732717|NCT02539875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33732718|NCT03067779|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812775|NCT02142270|||COHORT||PROSPECTIVE|||||||
33732719|NCT02837432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732720|NCT00325234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732721|NCT06198192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732722|NCT04121325|||OTHER||PROSPECTIVE|||||||
33732723|NCT00420550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33732724|NCT06481059|||OTHER||RETROSPECTIVE|||||||
33732725|NCT06409468|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
33732726|NCT02252627|||||PROSPECTIVE|||||||
33732727|NCT05599178|||COHORT||PROSPECTIVE|||||||
33732728|NCT01378572|||CASE_CONTROL||PROSPECTIVE|||||||
33732729|NCT02170246|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33732730|NCT05026463|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33732731|NCT00279565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732732|NCT00501202|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33732733|NCT00202904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732734|NCT05523531|||CASE_ONLY||CROSS_SECTIONAL|||||||
33732735|NCT02577965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33732736|NCT04990986|RANDOMIZED|PARALLEL||OTHER||NONE||This study applies mixed-methods pragmatic paradigm led by Safety 1 and 2 theory, with participatory approach to an exploratory sequential three-phased study-design, embedding a randomized controlled trial (cRCT).||||
33732737|NCT00004436|RANDOMIZED|||TREATMENT||||||||
33732738|NCT02473068|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33732739|NCT01894828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732740|NCT00973791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732741|NCT02920268|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732742|NCT05429450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732743|NCT04647058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732744|NCT04701775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|Double-blind randomized controlled trial|t|f|t|f
33732745|NCT01100008|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732746|NCT00082108|||OTHER||PROSPECTIVE|||||||
33732747|NCT04948138|NA|SINGLE_GROUP||TREATMENT||NONE||Glutamine oral supplementation||||
33732748|NCT06442501|||COHORT||PROSPECTIVE|||||||
33732749|NCT00677495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732750|NCT01430065|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33812776|NCT05914285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812777|NCT01005602|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812778|NCT04417309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812779|NCT04317937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812780|NCT01184027|||COHORT||PROSPECTIVE|||||||
33812781|NCT03511781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732751|NCT02017587|||COHORT||PROSPECTIVE|||||||
33838464|NCT03878329|RANDOMIZED|PARALLEL||PREVENTION||NONE|Non-blinded.|Randomized Controlled Trial||||
34043982|NCT00285740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043983|NCT03217383|NA|SINGLE_GROUP||OTHER||NONE|Though the study only has one study arm, the participant, medical PI, dental PI will be blinded to the test prediction.|||||
33732752|NCT03913143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732753|NCT05254938|||COHORT||RETROSPECTIVE|||||||
33732754|NCT01698229|||CASE_ONLY||CROSS_SECTIONAL|||||||
33732755|NCT00712088|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732756|NCT03818022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33732757|NCT04257682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732758|NCT05897177|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33732759|NCT01255566|||COHORT||PROSPECTIVE|||||||
33732760|NCT04865497|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732761|NCT02403869|||COHORT||PROSPECTIVE|||||||
33732762|NCT05979103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732763|NCT01721590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732764|NCT06357988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732765|NCT00514410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732766|NCT00365248|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732767|NCT03132597|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"This is an intervention protocol using a randomized controlled clinical trial with cross-over, in order to compare if the implementation of mindfulness for first year medical students will improve their mental health and quality of life in the short term (3 months).~The intervention group will be exposed to mindfulness in the beginning of the medical course and will be compared to a control group, not exposed to mindfulness (exposed to theoretical classes) for 3 months. After that, the intervention group will receive theoretical classes and the control group will be exposed to the mindfulness techniques for 3 months (cross-over). Therefore, both groups will be exposed to mindfulness in the first year of undergraduation. Then, all first year medical students exposed to mindfulness will be compared to another class, which didn't have this mindfulness mandatory course in their formation. They will be compared after 6 months and after one-year of intervention (long-term effect)."||||
33732768|NCT06417086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Streitberger placebo needle will be used as sham acupuncture method to mask the paticipants. The outcome assessors will also be blind to the grouping.||t|f|f|t
33732769|NCT05176093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732770|NCT04284696|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34043984|NCT02230020|||CASE_ONLY||PROSPECTIVE|||||||
34043985|NCT02541357|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34043986|NCT02340403|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34043987|NCT03777436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043988|NCT06353685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149142|NCT06316973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled, Single Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CS-1103 Following Single, Ascending Intravenous Dose Administration in Healthy Participants|t|t|t|t
34149143|NCT05613582|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149144|NCT04033874|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The prospective, randomized controlled trial including pre and post tests of four groups||||
34149145|NCT00780273|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34149146|NCT02303860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34043989|NCT01562600|||COHORT||PROSPECTIVE|||||||
34043990|NCT03642964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|placebo||t|f|f|t
34043991|NCT05145374|||COHORT||CROSS_SECTIONAL|||||||
34043992|NCT02347774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34043993|NCT00664508|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Comparative study with a control group||||
34043994|NCT05414331|RANDOMIZED|PARALLEL||PREVENTION||NONE|Blinding will be only on the investigator interpreting CPET and adjudicating major cardiac and cerebrovascular events|"Aim 1: The investigators will enroll patients with preserved EF (EF ≥50%) who underwent isolated elective or non-elective CABG at Yale New Haven Hospital (YNHH). Blocked randomization will be applied to ensure an equal sample size. Patients will be randomized to 1) continuation of the current BB regimen and 2) discontinuation of all BB, and medication changes will be made at the 1-month clinic visit. A cardiopulmonary exercise test (CPET) will be performed 1 month after the randomization (2 months after CABG).~Aim 2: Patients will be randomized at a 1-month postoperative visit, and the outcome will be adjudicated at 12 months since CABG.~The safety endpoint is all-cause death, myocardial infarction, stroke, or repeat revascularization at 12 months. The investigators will measure patient-reported outcome on 1) 10-item activity level (VSAQ), 2) Fatigue Assessment Scale. 3) 15-item Vertigo Symptom Scale at the time of enrollment and 3 months."||||
34043995|NCT04258644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043996|NCT06574542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34043997|NCT04276480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34043998|NCT00004863||||TREATMENT||||||||
34043999|NCT05808426|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were not explicitly informed about their group assignment and there was no contact between study investigators and participants during the study period. The intervention allocation was masked from investigators by anonymized coding, and the individuals who were assigned interventions were not involved in assessing outcomes and analyzing data. The investigators also avoided any potential interactions between participants in either intervention group.|This study is a single-blind, parallel-group randomized controlled trial. Eligible participants were allocated randomly 1:1, without stratification, to either the intervention or the control group, according to a computer-generated random number sequence.|f|f|t|f
34044000|NCT01591057|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044001|NCT02499367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044002|NCT03673644|||COHORT||CROSS_SECTIONAL|||||||
34044003|NCT06470542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044004|NCT04586699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|t|f|t
34044005|NCT02426905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044006|NCT05688839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044007|NCT05799352|NA|SINGLE_GROUP||TREATMENT||NONE||Before and after study||||
34044008|NCT01155440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34044009|NCT03193372|||COHORT||PROSPECTIVE|||||||
34044010|NCT06576713|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044011|NCT02313168|||CASE_ONLY||PROSPECTIVE|||||||
34044012|NCT05454644|RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparison of person-centred prescription model application versus standard pharmaceutical care alone. The intervention is applied randomly during hospital stay in hospitalised older people at the end of life. The primary outcome is the mean change between admission and discharge in the number of regular medications.||||
34044013|NCT01654718|RANDOMIZED|CROSSOVER||||NONE||||||
34044014|NCT06504693|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044015|NCT02780089|||COHORT||OTHER|||||||
34044016|NCT06239493|||CASE_ONLY||PROSPECTIVE|||||||
34044017|NCT00862823|RANDOMIZED|CROSSOVER||||NONE||||||
34044018|NCT05817149|||COHORT||PROSPECTIVE|||||||
34044019|NCT04194463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044020|NCT04676269|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|None of the participants, gynecologists, statistician, nurses nor of the participant' partners are informed about the treatment groups.||t|t|t|t
34044021|NCT06509464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044022|NCT05008276|||COHORT||CROSS_SECTIONAL|||||||
34044023|NCT01294696|||COHORT||PROSPECTIVE|||||||
34044024|NCT01262222|||CASE_ONLY||PROSPECTIVE|||||||
34044025|NCT00018876|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34044026|NCT06023719|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044027|NCT02780713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044028|NCT06578026|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||randomized control trial|f|f|f|t
34044029|NCT05920967|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34044030|NCT04589936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Case-control study design, with 1:1 for COVID-19 case versus pneumonia unrelated to COVID-19.||||
34044031|NCT03596593|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044032|NCT05007028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized double blind trial with comparator|t|f|t|f
34044033|NCT06167837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044034|NCT03721263|NA|SINGLE_GROUP||TREATMENT||NONE||Single Ascending Dose||||
34044035|NCT00086138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044036|NCT02516514|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34044037|NCT01351792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044038|NCT01408316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044039|NCT05211102|||CASE_ONLY||RETROSPECTIVE|||||||
34044040|NCT03636802|||COHORT||PROSPECTIVE|||||||
33732771|NCT02263638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120189|NCT03430349|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|"the study will be conducted with each candidate vaccine sequentially. After randomization of the first participant of Group 1 the next 14 participants will all be enrolled in the same Group and receive the same nOPV2 candidate and the next 15 participants will be enrolled in the other Group and receive the corresponding nOPV2 candidate. Prior to the start of the study the clinical research organization (CRO) will provide the site with 2 randomization envelopes for the first subject. By randomly choosing 1 of the envelopes first subject will be dedicated to a certain nOPV2 candidate and this will determine the allocation of the next 14 subjects to the same Group.~Study staff will be blinded in the same way and will be blinded for individual shedding results of the participants of a Group until end of containment of this Group."||t|t|t|f
34120190|NCT06716086|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120191|NCT05465525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The patients will be divided randomly by a computer-generated randomization table into three equal groups.|f|t|f|t
34120192|NCT06368570|||COHORT||PROSPECTIVE|||||||
34120193|NCT04519931|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120194|NCT06477848|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will conduct a cluster-randomized stepped-wedge trial to compare the effects of SUD IBH on PCP willingness to engage in adolescent SUD treatment.||||
34120195|NCT05673200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120196|NCT05554315|||CASE_ONLY||PROSPECTIVE|||||||
34120197|NCT01142440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120198|NCT02474979|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34120199|NCT06717594|||COHORT||PROSPECTIVE|||||||
34120200|NCT04861714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120201|NCT05221866|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Randomization to the patient facing app will be implemented via REDCap. There will be no randomization in regard to the provider-facing intervention.|The patient-facing app will be trialed prior to and after implementation of a provider-facing prescription intervention using a 2x2 design.|f|f|t|f
34120202|NCT04716894|NA|SEQUENTIAL||TREATMENT||NONE||||||
34120203|NCT01362101|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34120204|NCT06135948|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study is an open-label, two-arm parallel groups, randomized controlled clinical trial that included Emirati patients with hypothyroidism who attended the Family Promotion Centre, Endocrinology Clinic, regularly. Eligible participants (n = 103) were randomly allocated to the treatment group (patients who received an increased dose of L-thyroxine, 25 mcg, n = 50) and the control group (patients who received standard/regular dose of L-thyroxine, n = 46). Both groups attended 5 visits before, during, and after Ramadan. Several tests were conducted including thyroid function, lipid profile, HbA1c, and Vitamin D.||||
34120205|NCT05513859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120206|NCT06110403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120207|NCT00590967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120208|NCT04122001|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This is a crossover design of active High-Definition tDCS (HD-tDCS) + Word List Learning Intervention (WordLLI) that crossovers to sham + WordLLI in Arm 1, and sham +WordLLI that crossovers to active HD-tDCS + WordLLI in Arm 2.|t|t|f|t
34120209|NCT06072196|||COHORT||RETROSPECTIVE|||||||
34120210|NCT04435743|||COHORT||PROSPECTIVE|||||||
34120211|NCT05670912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120212|NCT06576466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"A professional from the pharmacy service, who will not be involved in data collection or participant care, will handle the blinding.~The care staff responsible for patient care will be unaware of each participant's assignment group.~Blinding may be broken if a serious adverse effect related to the supplementation is suspected in one of the participants."||t|t|t|t
34120213|NCT05008705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120214|NCT01276106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120215|NCT06635148|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Long-term safety study of a single intravitreal dose of JNJ-81201887 administered during parent studies (81201887MDG2001: Randomized trial; 81201887MDG1003: Non-randomized trial)|t|f|t|t
34120216|NCT05618444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120217|NCT02151929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120218|NCT04255914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34120219|NCT06653842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120220|NCT00344331|||COHORT||PROSPECTIVE|||||||
34120221|NCT00244192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120222|NCT05027568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120223|NCT01344148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120224|NCT01489904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120225|NCT06718426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120226|NCT06646484|||COHORT||PROSPECTIVE|||||||
34120227|NCT01383005|||COHORT||CROSS_SECTIONAL|||||||
34120228|NCT00644839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732772|NCT05709821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732773|NCT02665975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732774|NCT03621137|||COHORT||PROSPECTIVE|||||||
33732775|NCT02307552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732776|NCT00000107|||CASE_CONTROL|||||||||
33732777|NCT00792610|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33732778|NCT03275558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732779|NCT01008111|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33732780|NCT03128697|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732781|NCT06574308|||CASE_ONLY||CROSS_SECTIONAL|||||||
33732782|NCT04731844|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732783|NCT05770466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732784|NCT02036099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732785|NCT02409862|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732786|NCT04574947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120229|NCT01056367|||||PROSPECTIVE|||||||
34120230|NCT04478942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120231|NCT04207320|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33812782|NCT05842330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be blinded to the 3-month (12 weeks) in-prison treatment. The research team and statistician will be blinded to the participants' group. The psychiatrist will be unblinded when participants are released. At that time of the study, all participants will be offered to have the treatment (OROS-MPH) without being unblinded regarding their initial group.|"This is a phase 3 parallel randomized controlled trial (1:1 ratio) of OROS-MPH vs. a placebo on a clinical outcome.~Participants will undertake three months (12 weeks) of treatment while they are incarcerated. After three months, all participants will be offered treatment in outpatient care, either in prison or in the community. They will have daily monitoring of medical adherence in prison or in electronic monitors after release (without being unblinded on the treatment they received during detention). They will be followed-up for twelve months as outpatient care (total study duration: 15 months)."|t|f|t|t
33812783|NCT01655082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812784|NCT04863365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812785|NCT05141409|||COHORT||PROSPECTIVE|||||||
33812786|NCT01552083|NA|SINGLE_GROUP||SCREENING||NONE||||||
33812787|NCT02296307|||CASE_ONLY||PROSPECTIVE|||||||
34120232|NCT06119854|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will assign undervaccinated cohort participants, with and without symptoms of anxiety or depression, to: 1) an attitudinal inoculation intervention; 2), a CBT-informed intervention; or 3) a conventional public health messaging intervention. Participants will be randomly assigned to one of the three intervention arms at a ratio of 1:1:1. Each arm will also be stratified 1:1 by presence or absence of anxiety or depression symptoms. Masking of participants to study arm assignment is not feasible due to the nature of the interventions. However, data collection analysts, study staff, and investigators will be masked to study arm assignments until analyses are complete.||||
34120233|NCT00066326||||TREATMENT||NONE||||||
34120234|NCT06126497|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label study||||
34120235|NCT00765219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120236|NCT06663319|NA|SEQUENTIAL||TREATMENT||NONE||||||
34120237|NCT06719323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|To ensure assessor blinding, different personnel conducted the interventions and outcome assessments.||f|f|f|t
34120238|NCT03338985|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120239|NCT05004662|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120240|NCT06482775|||CASE_ONLY||PROSPECTIVE|||||||
34120241|NCT06716346|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120242|NCT06718608|NA|SINGLE_GROUP||OTHER||NONE||||||
34120243|NCT06167486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120244|NCT06167577|||CASE_ONLY||PROSPECTIVE|||||||
34120245|NCT03222674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120246|NCT03158701|||COHORT||PROSPECTIVE|||||||
34120247|NCT00087217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120248|NCT01805284|NA|SINGLE_GROUP||OTHER||NONE||||||
34120249|NCT06716307|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120250|NCT00797719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120251|NCT06440252|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34120252|NCT04306328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120253|NCT06255353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34120254|NCT06715800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind, Randomized, Controlled Trial|t|t|f|t
34120255|NCT06560476|||CASE_CONTROL||PROSPECTIVE|||||||
34120256|NCT06033534|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34120257|NCT00001937||||TREATMENT||||||||
34120258|NCT06716320|||COHORT||PROSPECTIVE|||||||
34120259|NCT06719024|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120260|NCT04565509|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"A cluster randomized adaptive trial will be conducted. The first phase will randomize the 6 Special School District schools to either a general message or focus/targeted message. Data analysis will occur and then the schools will be randomized to the best message strategy from phase 1 alone or best message plus and augmented message or implementation strategy.~The same process will take place independently at the Kennedy Krieger Institutes/Sheppard Pratt Schools."||||
34120261|NCT06715306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120262|NCT01391702|||COHORT||PROSPECTIVE|||||||
34120263|NCT00193024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120264|NCT03698019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120265|NCT06717568|||COHORT||CROSS_SECTIONAL|||||||
34120266|NCT04227028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120267|NCT04055753|||COHORT||PROSPECTIVE|||||||
34120268|NCT00405288|||CASE_CONTROL||PROSPECTIVE|||||||
34120269|NCT02478489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120270|NCT02462226|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34120271|NCT06715631|NA|SINGLE_GROUP||OTHER||NONE||||||
34120272|NCT06712680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120273|NCT05589194|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the randomization process, those who meet the criteria for inclusion in the sample and accept to participate in the study do not know that they will be included in the intervention group or the control group, so it will be single-blind.|The research is a randomized controlled single-blind quasi-experimental research design.|t|f|f|f
34120274|NCT02122380|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34120275|NCT06715423|||OTHER||PROSPECTIVE|||||||
33812788|NCT05954247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120276|NCT00437398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120277|NCT02765048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120278|NCT05083078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34120279|NCT00551083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120280|NCT06716554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120281|NCT04340518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective observational study||||
34120282|NCT06716073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120283|NCT00022438|RANDOMIZED|||TREATMENT||NONE||||||
34120284|NCT00399035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120285|NCT02188979|||CASE_ONLY||PROSPECTIVE|||||||
34120286|NCT03516279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120287|NCT01342926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120288|NCT00017043||||TREATMENT||||||||
34120289|NCT03461471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34120290|NCT05486390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34120291|NCT06413732|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120292|NCT06716827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120293|NCT06666699|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34120294|NCT06073704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be masked using a sham laser. Outcomes assessor will be blinded in relation to naming of the experimental groups.||t|f|f|t
34120295|NCT01155557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120296|NCT01804452|||COHORT||PROSPECTIVE|||||||
34120297|NCT00154349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120298|NCT06716151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120299|NCT05407103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34120300|NCT02102243|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34120301|NCT02811848|||OTHER||PROSPECTIVE|||||||
34120302|NCT04607629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Throughout the study, until the end of the comparative treatment study period, neither the investigators nor the patients knew which drug was being administered|Interventional|t|f|t|f
34120303|NCT06719453|||COHORT||OTHER|||||||
34120304|NCT01850953|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34120305|NCT06715072|||CASE_ONLY||PROSPECTIVE|||||||
34120306|NCT01100112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120307|NCT06017492|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Allocation concealment will be blinded and performed in the order of recruitment using a computerized generated allocation method.|Eligible participants will be randomized in a one- to-one intervention allocation to the intervention (n = 86) or usual hospital method (n=86) group at the time of consent.|t|f|f|f
34120308|NCT06715137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34120309|NCT00720993|||CASE_CONTROL||PROSPECTIVE|||||||
34120310|NCT02918526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120311|NCT01493089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120312|NCT06715215|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34120313|NCT04591119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34120314|NCT05823896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a phase II, interventional, randomized, parallel group, double-blind, placebo-controlled, single-center study of nirmatrelvir/ritonavir (300/100 mg) or placebo/ritonavir (100mg), administered orally twice daily for 15 days in non-hospitalized patients with post- COVID conditions.|t|t|t|t
34120315|NCT04681144|||COHORT||PROSPECTIVE|||||||
34120316|NCT04411303|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34120317|NCT03321071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120318|NCT06717893|||COHORT||RETROSPECTIVE|||||||
34120319|NCT05899114|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The outcome assessor, assessing whether a readmission is drug related will be masked.~Masking the patients, care provider or investigator is not possible in this study."|Cluster randomized study|f|f|f|t
34120320|NCT00582478|||CASE_ONLY||PROSPECTIVE|||||||
34120321|NCT06127433|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||basal insulin and oral antidiabetic drugs group insulin intensive therapy group||||
34120322|NCT06718088|||COHORT||OTHER|||||||
34120323|NCT03846661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Register study||||
34120324|NCT03829111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120325|NCT02160015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120326|NCT02221973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120327|NCT05900076|||COHORT||PROSPECTIVE|||||||
34120328|NCT04418895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120329|NCT03793621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120330|NCT01643460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120331|NCT01171677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120332|NCT05691933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
34120333|NCT05545748|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participating parents will not know which group they are. Also, when the data is analyzed by the statistician, she/he will not know which group it is.||t|f|f|t
34120334|NCT05171166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120335|NCT03351946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Sealed envelopes.||t|f|f|t
34120336|NCT03333356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120337|NCT06124157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120338|NCT02392988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120339|NCT05471986|||CASE_ONLY||RETROSPECTIVE|||||||
34120340|NCT06279611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120341|NCT05848778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will investigate AIH's potential to condition and promote enhanced repair in a Phase I randomized control trial (RCT) of carpal tunnel syndrome (CTS) associated with severe median nerve compression/injury. We predict AIH will have better outcomes than current ES strategies and we aim to non-invasively condition/prime the IRP in compressed nerves by AIH treatment prior to nerve decompression and/or post-nerve decompression.|t|f|f|f
34120342|NCT04735458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120343|NCT03523858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120344|NCT04970069|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34120345|NCT05362292|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120346|NCT05753462|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34120347|NCT03130686|||CASE_ONLY||PROSPECTIVE|||||||
34120348|NCT02746302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120349|NCT05023057|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||outcome assessor-blinded, randomized controlled trial|f|f|f|t
34120350|NCT04275076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patients, data collector, and the statistician all were blinded to the type of intervention that was used in each group.||t|f|t|t
34120351|NCT03246607|||COHORT||PROSPECTIVE|||||||
34120352|NCT06717555|||COHORT||OTHER|||||||
34120353|NCT03206372|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34120354|NCT03496168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812789|NCT04209322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicenter, prospective, randomized trial|t|f|t|f
33812790|NCT03840447|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33812791|NCT02090205|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812792|NCT04721600|NA|SINGLE_GROUP||OTHER||NONE||||||
33812793|NCT03312621|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33812794|NCT01910194|RANDOMIZED|PARALLEL||||NONE||||||
33812795|NCT00007306|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33812796|NCT01071317|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812797|NCT04115670|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33812798|NCT02163850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812799|NCT04703114|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812800|NCT01155843|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812801|NCT01381198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812802|NCT02074384|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120355|NCT02665325|||COHORT||PROSPECTIVE|||||||
34120356|NCT03071965|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120357|NCT06719154|||CASE_CONTROL||PROSPECTIVE|||||||
34120358|NCT06183697|||COHORT||PROSPECTIVE|||||||
34120359|NCT06423391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The following stakeholders will be blinded to participants' group allocation in the test intervention and control intervention groups. Allocation to the Usual Care group will not be concealed from staff or participants, except for the trial statistician:~* Trial participants (except in usual care arm)~* Clinical support and administration staff~* Outcome assessors (collecting data at end-of-treatment and follow-up)~* Trial statistician~  * Provider blinding will not be possible as providers will have to actively deliver both the test and the control intervention. However, extensive pre-trial training and supervision during the trial will ensure that providers understand the purpose of the control intervention and are supported to deliver it with high fidelity."|feasibility study of a single-site parallel three-armed participant-blinded controlled randomised trial|t|f|t|t
34120360|NCT06058962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study was double-blind. Suramin and placebo are both clear solutions when prepared.~Suramin was prepared by an unblinded pharmacist by reconstituting 1 g vial of suramin in 10 mL of sterile water for infusion to prepare a 10% (100 mg/mL) solution."|The participants were randomized to one of three double-blind treatment groups, i.e., Arm A (10 mg/kg suramin) or Arm B (20 mg/kg suramin) or Arm C (placebo) in a targeted 1:1:1 ratio, as per the randomization schedule and stratification plan. The stratification plan was to match patients by age (\< 7 vs ≥ 7), ADOS-2 comparison scores (≤ 8.5 vs \> 8.5) and NVIQ (≤ 80 vs \> 80)|t|t|t|t
34120361|NCT00659035|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120362|NCT04940728|RANDOMIZED|PARALLEL||OTHER||DOUBLE|In this study, the sample groups (experimental and control) were determined by an instructor other than the researchers, and the researchers were blinded while the sample was being created. The researchers and participants did not know who was in the experiment and who was in the control group during the assignment process until the study started. This method is a control method in which the participants in the study are blinded. After the assignment process took place, it was ensured that the students included in the research and the statistician evaluating the data did not know the experimental and control groups. In this context, two-way blinding method was used.|This research was designed in the experimental design model with pretest-posttest randomized control group, one of the quantitative research methods, in order to evaluate the effect of the intervention program developed based on creative thinking techniques on the problem solving and communication skills of nursing students.|t|f|f|t
34120363|NCT05788601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure blinding, the placebo arm is split between 4 mg and 6 mg placebo, making the randomisation sequence 2:2:1:1 (e.i. 2x 4 mg dapiglutide, 2x 6 mg dapiglutide, 1x 4 mg placebo and 1x 6 mg placebo|Three arms: 12 weeks of 4 mg and 6 mg dapiglutide and placebo|t|f|t|f
34120364|NCT01909544|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34120365|NCT01135472|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34120366|NCT03833141|||COHORT||PROSPECTIVE|||||||
34120367|NCT06040541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The monotherapy arm of RMC-9805; the combination arm of RMC-9805 plus RMC-6236||||
34120368|NCT00678730|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34120369|NCT05198258|RANDOMIZED|PARALLEL||OTHER||SINGLE||"The study is a prospective cluster-randomized mixed-design study with hybrid II trial design.~Twenty physiotherapy clinics in primary health care will be included."|f|f|f|t
34120370|NCT03581487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120371|NCT00166127|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120372|NCT00886730|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34120373|NCT02850588|||CASE_CONTROL||PROSPECTIVE|||||||
34120374|NCT05722587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||multi site, non-randomised controlled, mixed methods study||||
34120375|NCT06289868|||OTHER||OTHER|||||||
34120376|NCT06692894|||CASE_ONLY||PROSPECTIVE|||||||
34120377|NCT04051177|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120378|NCT04135079|||OTHER||OTHER|||||||
34120379|NCT06718400|NA|SINGLE_GROUP||OTHER||NONE||Willing participants who will be receiving an intestinal transplantation will receive a sentinel skin flap on their forearm from the same donor||||
34120380|NCT06719167|||CASE_ONLY||PROSPECTIVE|||||||
34120381|NCT04185350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120382|NCT02742129|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33812803|NCT02315209|||COHORT||PROSPECTIVE|||||||
33812804|NCT01790542|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33812805|NCT04475406|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33812806|NCT00650169|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33812807|NCT02799537|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33812808|NCT00913055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812809|NCT02033174|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33812810|NCT01434732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812811|NCT03340662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812812|NCT02535585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33732787|NCT00348205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732788|NCT04276350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732789|NCT02088658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33732790|NCT01971138|||||RETROSPECTIVE|||||||
33732791|NCT03012854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732792|NCT06380478|||CASE_ONLY||RETROSPECTIVE|||||||
33732793|NCT04963686|||CASE_ONLY||RETROSPECTIVE|||||||
33812813|NCT02430909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812814|NCT00930397|||COHORT||PROSPECTIVE|||||||
33812815|NCT05964309|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33812816|NCT06123936|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812817|NCT03293043|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"The purpose of this Phase I Early Feasibility Proof of Concept clinical trial will be to evaluate initial performance and safety of the NPV-EVLP device to assess and improve the function of marginal donor lungs. By nature, efficacy measures and outcomes of the device will also become evident from the results of this study.~This is a prospective, non-randomized, interventional trial, taking place solely at the University of Alberta Hospital/Mazankowski Alberta Heart Institute. Lungs deemed marginal, based on standard lung donor criteria that meet the study's eligibility criteria, will be assessed on our NPV-EVLP device to determine suitability for lung transplantation. Objective assessment of quality will be made while the lungs are on the device based on pre-determined functional parameters of lung physiology. Once a total of 12 sets of lungs are transplanted after using the device, safety will be determined by post-operative lung function and recipient survival."||||
33812818|NCT01668394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812819|NCT06554509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR-1819 compared with placebo|t|t|t|t
33812820|NCT03897491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812821|NCT04848740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120383|NCT05736393|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm clinical trials with propensity-matched control group.||||
34120384|NCT03492177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120385|NCT04236271|NA|SINGLE_GROUP||OTHER||NONE||An open, monocentric prospective pilot study evaluating the reliability of post-operative coronary bypass surgery telemonitoring tools and their diagnostic performance for the detection of postoperative complications.||||
34120386|NCT01632033|||COHORT||PROSPECTIVE|||||||
34120387|NCT02175186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120388|NCT05759338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120389|NCT02764411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120390|NCT06718933|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120391|NCT02996396|||COHORT||PROSPECTIVE|||||||
34120392|NCT06557759|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The participants will listen to the brief music demo together after completing the pre-assessment. After the demo is completed, participants will listen to the 30-minutes of music. For those who opt out of listening to the 30-minutes of music, they will be asked to complete the post-assessment as they exit. Following the 30-minute music session, the remaining participants will be asked to complete the post-assessment.||||
34120393|NCT00565565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120394|NCT05291533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120395|NCT00646126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120396|NCT00707473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120397|NCT06201676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants, their primary treatment teams, study investigators, research personnel, and the statistician will be blinded to each participant's group assignment. A central randomization scheme will be created by the statistician and provided to the Clinical Trials Pharmacy at both sites. Clinical Trials Pharmacy will be the only stakeholders in this study who will be unmasked to the participant's group assignment. The statistician will be blinded to each subject's group assignment when provided with the final dataset for analysis.|Parallel, two-arm, placebo-controlled, randomized controlled trial|t|t|t|t
34120398|NCT01911455|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34120399|NCT01459692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120400|NCT06353815|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120401|NCT04940468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120402|NCT06434324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120403|NCT00079313|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120404|NCT03907397|RANDOMIZED|PARALLEL||TREATMENT||NONE|Although a double-blind, placebo controlled oral food challenge test is used in screening to identify participants eligible to continue to randomization in the study, those randomized to peanut ingestion versus avoidance have participants aware and unmasked regarding the study arm to which they were randomized|150-200 children undergoing DBPCFC to peanut to identify 72 with high threshold peanut allergy for randomization in trial.||||
34120405|NCT02549079|||COHORT||PROSPECTIVE|||||||
34120406|NCT00185887|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34120407|NCT02833883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120408|NCT06715007|||COHORT||PROSPECTIVE|||||||
34120409|NCT06309381|||COHORT||PROSPECTIVE|||||||
34120410|NCT04086316|||CASE_CONTROL||PROSPECTIVE|||||||
33732794|NCT01640730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732795|NCT03626116|||CASE_ONLY||RETROSPECTIVE|||||||
33732796|NCT04911725|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732797|NCT02277496|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||During the 2014-2015 school year a 2-arm design was used to compare outcomes between intervention and comparison schools. Subsequent years utilized a single-arm design to analyse trends between and within intervention schools only.||||
33732798|NCT00750828|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33732799|NCT02559388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732800|NCT01144156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732801|NCT02295748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732802|NCT04242056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732803|NCT05980780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Masking will be used when making the statistical evaluation of the results.|Parallel Assignment|f|f|f|t
33732804|NCT02652975|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732805|NCT05151939|||CASE_ONLY||CROSS_SECTIONAL|||||||
33732806|NCT05028374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812822|NCT02142569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120411|NCT00308334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120412|NCT05969886|||COHORT||PROSPECTIVE|||||||
34120413|NCT06714890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120414|NCT04937192|||COHORT||PROSPECTIVE|||||||
34120415|NCT00002766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120416|NCT02964377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120417|NCT03263403|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Since the test and comparator drugs used in this clinical study have different package of vial, a double blind design is not appropriate. Study investigators along with study staffs involved in safety evaluation and laboratory analysis will be blinded regarding the assigned treatment of the participant. The vaccine administration team will be unblinded to the treatment assignment list. The vaccine administrator team members will not be involved in the evaluation of vaccine safety and laboratory analysis.|Eligible participants will be assigned to receive the Ingovax ACWY Vaccine and Quadri Meningo Vaccine, in a 1:1 ratio across the target population according to the randomization schedule. 44 participants will receive locally produced Ingovax ACWY and 44 participants of comparator groups will receive Quadri Meningo which is produced by BiO-MeD Private Limited.|f|f|t|t
34120418|NCT01310010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120419|NCT02054637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120420|NCT03179878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Randomized, Double-blinded, Placebo controlled|t|t|t|t
34120421|NCT06663332|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120422|NCT06715722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking Description||t|t|t|t
34120423|NCT00956293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120424|NCT06391892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Neoadjuvant chemotherapy (physicians choice) vs. upfront surgery||||
34120425|NCT01216462|||COHORT||PROSPECTIVE|||||||
34120426|NCT02790502|NA|SINGLE_GROUP||OTHER||NONE||||||
34120427|NCT06401421|||COHORT||PROSPECTIVE|||||||
34120428|NCT01679483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120429|NCT06718478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120430|NCT03507582|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34120431|NCT04203316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120432|NCT04099277|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120433|NCT06607991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120434|NCT02982330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120435|NCT03493958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120436|NCT06158867|||CASE_CONTROL||PROSPECTIVE|||||||
34120437|NCT04946695|NA|SINGLE_GROUP||TREATMENT||NONE||This research is a quasi-experimental multicentre pre-post intervention pilot study||||
34120438|NCT06715124|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120439|NCT03152123|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34120440|NCT02365597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120441|NCT02999607|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34120442|NCT04002375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120443|NCT01985022|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120444|NCT04382443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120445|NCT06589596|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120446|NCT02539550|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34120447|NCT06716411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34120448|NCT00827957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120449|NCT02115321|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149147|NCT04758520|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single Group Assignment||||
34149148|NCT06516744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149149|NCT04367467|||COHORT||PROSPECTIVE|||||||
33732807|NCT04164147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participant will not be informed which type of prosthesis was used in their particular case.~Outcomes Assessor will not be informed which type of prosthesis was used in particular patient."||t|f|f|t
33732808|NCT05068973|NA|SINGLE_GROUP||OTHER||NONE||||||
33732809|NCT05112393|||OTHER||CROSS_SECTIONAL|||||||
33732810|NCT04707534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732811|NCT00006484|RANDOMIZED|||TREATMENT||||||||
33732812|NCT02733978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732813|NCT05539235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Peng Hui, chief physician of Ophthalmology Department of the First Affiliated Hospital of Chongqing Medical University, randomly divided the enrolled patients into two groups when they only knew the patient number and did not know the specific situation of the patient.||t|t|t|t
33732814|NCT04285788|||OTHER||RETROSPECTIVE|||||||
33732815|NCT00140075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732816|NCT01228968|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812823|NCT02190656|||||CROSS_SECTIONAL|||||||
33812824|NCT05258929|||COHORT||RETROSPECTIVE|||||||
33812825|NCT04768556|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This study is pathophysiological, monocentric, comparative, and controlled with 3 groups compared: ADHD patients, control patients (negative diagnosis of ADHD), and healthy volunteers.~The three groups will complete the same protocol, in the same manner."||||
33812826|NCT05830422|||COHORT||PROSPECTIVE|||||||
33812827|NCT05065840|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will be implemented at the clinic, Provider, and Patient levels. Every level will receive a different intervention or none in the case of the control. Clinic and Provider level will receive training on recommending and administering the vaccine at the clinic. Patient level will accept or decline the recommendation for the HPV vaccine. The Control arm will be collected from EMR and the GRITS database from patients not receiving the vaccine before the intervention period.||||
34149150|NCT02621073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149151|NCT03495271|||CASE_CONTROL||PROSPECTIVE|||||||
33732817|NCT05444309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The patients will be divided randomly by a computer-generated randomization table into three equal groups|t|t|f|t
33732818|NCT01180738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812828|NCT00488605|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812829|NCT04970459|||COHORT||PROSPECTIVE|||||||
33812830|NCT01852175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120450|NCT05158413|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to two groups. During the maintenance phase, the first group will receive low dose of sesame protein, which amounts 300mg, the second will get high dose, which is 1200 mg of sesame protein. Oral immunotherapy with low (300mg) and high (1200mg) dose of sesame protein in children randomly assigned to two groups (1:1). Patients will receive ground sesame mixed with apple mousse (supposing apple tolerance). For the transparency of the study all patients will receive the same commercially prepared apple muss product.||||
34120451|NCT06718699|||COHORT||CROSS_SECTIONAL|||||||
34120452|NCT06548568|||CASE_ONLY||PROSPECTIVE|||||||
34120453|NCT01293812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120454|NCT05161871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120455|NCT06618274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120456|NCT02311725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120457|NCT04882657|||COHORT||PROSPECTIVE|||||||
34120458|NCT03419429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120459|NCT05918978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120460|NCT06712836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120461|NCT06714825|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34120462|NCT00647543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120463|NCT02379052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120464|NCT03483389|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34120465|NCT04565288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120466|NCT02142088|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120467|NCT04278703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120468|NCT03776630|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34120469|NCT02321228|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120470|NCT05584579|||COHORT||RETROSPECTIVE|||||||
34120471|NCT03609424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120472|NCT05964179|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34120473|NCT06715943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120474|NCT06719271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120475|NCT04168931|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-phase prospective unicentric phase II study evaluating HER2 expression in circulating tumor cells and their response to standard treatment with trastuzumab combination chemotherapy in cases of positive expression in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue.||||
34120476|NCT05089370|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm trial.||||
34120477|NCT05921110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120478|NCT05336890|||COHORT||PROSPECTIVE|||||||
33812831|NCT01274156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812832|NCT01681511|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812833|NCT03706872|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Care provider will not know the arm of randomization|Randomized controlled trial with 2 arms of intervention|f|t|f|f
33812834|NCT02319707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812835|NCT00003634|RANDOMIZED|||TREATMENT||||||||
33812836|NCT02207140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34120479|NCT06163326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120480|NCT06108570|NA|SINGLE_GROUP||TREATMENT||NONE|The randomisation will be done on the side of the treatment.|Intra-individual comparison||||
34120481|NCT03271866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Two groups were observed longitudinally for 24 weeks.|t|t|t|t
34120482|NCT06624800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120483|NCT00725088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120484|NCT06717763|||COHORT||OTHER|||||||
34120485|NCT06097403|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120486|NCT04294355|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Prospective randomized design|t|f|f|f
34120487|NCT06446583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34120488|NCT00818493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120489|NCT03697850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120490|NCT01642303|NON_RANDOMIZED|PARALLEL||||NONE||||||
34120491|NCT06650384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study will be a prospective randomized controlled clinical trial Eligible patients will be randomly assigned by a 1:1:1 ratio using a computer-generated sequence to any of the 3 groups Group1 (n=60): colistin Group2 (n=60): colistin and N-Acetylcysteine Group3 (n=60): colistin and Alpha-lipoic acid|t|f|f|f
34120492|NCT05281913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34120493|NCT00741169|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120494|NCT05311033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120495|NCT01965613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120496|NCT03132285|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34120497|NCT06716424|NA|SINGLE_GROUP||OTHER||NONE||||||
34120498|NCT02298959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120499|NCT02337920|||COHORT||PROSPECTIVE|||||||
34120500|NCT01641484|NA|SINGLE_GROUP||OTHER||NONE||||||
34120501|NCT02850978|||COHORT||PROSPECTIVE|||||||
34120502|NCT00503984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120503|NCT06259357|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120504|NCT03703505|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120505|NCT05142306|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in two cohorts will be enrolled and assigned equally to one of three study arms.||||
34120506|NCT05894057|||COHORT||PROSPECTIVE|||||||
34120507|NCT06690775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120508|NCT03058133|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120509|NCT06551350|||COHORT||RETROSPECTIVE|||||||
34120510|NCT02554994|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120511|NCT04904835|||OTHER||OTHER|||||||
34149152|NCT03928626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732819|NCT05956769|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||Parallel Assignment randomized prospective double-blind placebo-controlled multicenter non-inferior|t|t|t|t
33732820|NCT00960700|||COHORT||PROSPECTIVE|||||||
33732821|NCT04476030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732822|NCT02573077|||COHORT||PROSPECTIVE|||||||
33732823|NCT05550012|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732824|NCT02788110|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732825|NCT06408116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732826|NCT05018572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The groups are predetermined based on the tool randomizer.org and blinded to the researcher assigning the participants to groups.||t|t|f|f
33732827|NCT05320029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A test method in which subjects are not told whether they are a trial device or a control device in order to control intentional or unintentional bias in the course of a clinical trial and in the interpretation of results|Patients randomized to the trial group and the control group will not cross use the product|t|t|t|t
33732828|NCT01437228|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732829|NCT01347190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732830|NCT02041130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732831|NCT01234129|||CASE_CONTROL||PROSPECTIVE|||||||
33732832|NCT01670929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732833|NCT03638986|||COHORT||PROSPECTIVE|||||||
33732834|NCT01399359|||COHORT||PROSPECTIVE|||||||
33732835|NCT00700011|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732836|NCT00774098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732837|NCT00200954|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732838|NCT05371535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects included will be randomly assigned into the experimental group and the control group at a ratio of 1:1. Those in the experimental group will receive MatrixOssTM Bone Graft plus Bio-Gide membrane, and those in the control group will receive Bio-Oss Bone Graft plus Bio-Gide membrane.|t|f|f|f
33732839|NCT05689840|||COHORT||OTHER|||||||
33732840|NCT01251133|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732841|NCT06178874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732842|NCT02175069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732843|NCT04055194|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Visually-identical drug and placebo tablets will be assigned to each participant using SNOSE congaing assignment code.|Pregnant women with symptomatic placenta previa with previous bleeding attacks will be recruited and randomized to receive either tranexamic acid tablets (500mg four times daily) or placebo till delivery. Amount of bleeding during antepartum bleeding attacks will be estimated (by hemoglobin change from baseline at admission till delivery).|t|t|t|t
33732844|NCT00000707||||TREATMENT||NONE||||||
33732845|NCT06051058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The design is a randomized trial with patients recruited inpatient from Brigham and Women's Hospital and nested within primary care practices in the MGB healthcare system. The unit of randomization is the patient.||||
33732846|NCT04460664|||COHORT||PROSPECTIVE|||||||
33732847|NCT03595475|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33732848|NCT00224211|||CASE_CONTROL||PROSPECTIVE|||||||
33732849|NCT03304379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732850|NCT02470728|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33732851|NCT00164450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732852|NCT02021591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33732853|NCT01686243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812837|NCT03132909|||COHORT||PROSPECTIVE|||||||
33812838|NCT03800771|NA|SINGLE_GROUP||OTHER||NONE||Patients are inhomogeneous in term of cognitive and physical function. The aim is to test faisability and security thus investigator will include a relatively large amount of patients.||||
33812839|NCT01959009|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812840|NCT02674399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812841|NCT02562521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812842|NCT05868356|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult Subjects||||
33812843|NCT06026462|||CASE_CONTROL||RETROSPECTIVE|||||||
33812844|NCT01558726|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33812845|NCT04874142|RANDOMIZED|PARALLEL||TREATMENT||NONE||two-cohort, single-sequence, parallel, open label, multiple oral dosing study.||||
33812846|NCT02399111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33812847|NCT01584999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812848|NCT00346398|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33812849|NCT06034145|||CASE_ONLY||PROSPECTIVE|||||||
33812850|NCT03860129|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33812851|NCT03770429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812852|NCT06593691|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120512|NCT05964569|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, observer blind two arm (active control), parallel group||||
34120513|NCT04596592|||COHORT||PROSPECTIVE|||||||
33732854|NCT05957068|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomised into 2 groups: exercise (intervention group, N = 1078) and usual care (control group, N = 1078). The exercise intervention group will undergo an aerobic exercise and strength training programme.||||
33732855|NCT03982329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||2/3 nrTMS, 1/3 sham|t|t|t|t
33732856|NCT02753647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732857|NCT06472349|||COHORT||CROSS_SECTIONAL|||||||
33732858|NCT03983096|||CASE_CONTROL||RETROSPECTIVE|||||||
33732859|NCT00676442|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33732860|NCT01306617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732861|NCT03909711|||COHORT||PROSPECTIVE|||||||
33732862|NCT03537118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33732863|NCT01087424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812853|NCT06313268|||CASE_ONLY||PROSPECTIVE|||||||
33732864|NCT01532466|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33732865|NCT00437034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732866|NCT01479803|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33732867|NCT01356433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732868|NCT00969293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732869|NCT01002144|||CASE_ONLY||PROSPECTIVE|||||||
33732870|NCT03256552|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||randomized, double-blind, chronic-dosing (7-day), four-period, four-treatment, placebo-controlled, crossover, multi-center|t|t|t|t
33732871|NCT04973761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732872|NCT01886833|||COHORT||PROSPECTIVE|||||||
33732873|NCT00805116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732874|NCT05597007|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33732875|NCT03797638|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33732876|NCT01833403|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732877|NCT05074433|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|t|t|f
33732878|NCT05447949|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Both the investigator for postoperative pain and the patients will be blinded|Randomized|t|t|t|t
33732879|NCT06364969|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33732880|NCT05107362|||CASE_ONLY||PROSPECTIVE|||||||
33732881|NCT03541694|||OTHER||PROSPECTIVE|||||||
33732882|NCT01389440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732883|NCT00071812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732884|NCT01712984|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732885|NCT05313165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732886|NCT01174251|||COHORT||PROSPECTIVE|||||||
33732887|NCT02553681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732888|NCT05594342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732889|NCT06136221|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a longitudinal intervention study utilizing diverse cohorts of patients with cirrhosis. It is a 2-arm, patient-randomized controlled trial.||||
33732890|NCT04407728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732891|NCT04593901|NA|SINGLE_GROUP||OTHER||NONE||Study is pre-intervention that uses a participatory, iterative approach to develop an app for use in subsequent intervention studies.||||
33732892|NCT00378014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732893|NCT04749290|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33732894|NCT01695083|||CASE_ONLY||PROSPECTIVE|||||||
33732895|NCT01633944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732896|NCT02310191|||CASE_ONLY||PROSPECTIVE|||||||
33732897|NCT05699070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33732898|NCT06276725|RANDOMIZED|PARALLEL||TREATMENT||NONE||After consenting to participate in the study, participants will be randomized in a 1:1 manner into either the Writing Wrongs Intervention or the Assessment Control condition. All participants will complete a total of five online study sessions including a pre-intervention assessment, three intervention or assessment only sessions, and a one-week follow-up assessment .||||
33732899|NCT03638817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732900|NCT00449293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732901|NCT04659070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33732902|NCT00006475||||TREATMENT||||||||
33812854|NCT01029639|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812855|NCT03326037|||COHORT||PROSPECTIVE|||||||
33812856|NCT03511495|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812857|NCT00947895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732903|NCT02165111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732904|NCT03683381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33732905|NCT01440309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732906|NCT03952169|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.|placebo-controlled, randomized clinical trial|t|t|t|t
33732907|NCT05168475|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Double-blind to patient and trial team. Pharmacy and central coordinator unblinded to minimise risk|Modified-crossover; patients are randomised to a sequence of up to 4 interventions (3x active plus 1x placebo); there are a total of 24 possible sequences a patient can be randomised to.|t|f|t|t
33732908|NCT00779766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33732909|NCT01592188|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33732910|NCT04605575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732911|NCT01036516|||||PROSPECTIVE|||||||
33732912|NCT04784936|||CASE_ONLY||PROSPECTIVE|||||||
33732913|NCT00863642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732914|NCT01403207|||COHORT||PROSPECTIVE|||||||
33732915|NCT01744210|||COHORT||PROSPECTIVE|||||||
33732916|NCT06504030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812858|NCT04111991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812859|NCT03864237|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33812860|NCT02742805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732917|NCT00977067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732918|NCT03866759|||COHORT||PROSPECTIVE|||||||
33732919|NCT06232382|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Participants will be blind to the study hypotheses.~* To keep the experimenter blind, the participants will not reveal what they hear in the audios."|"1. Audio hypnosis (HYP)~2. Audio mindfulness (MM)~3. A control condition (a voice reading neutral text)"|f|f|t|t
33732920|NCT00280566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732921|NCT02533921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838465|NCT06105190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is planned as a double-masked study. The subjects will not be informed about the implanted lens before exiting the study. Only the investigator implanting the lens as well as one administrative person will know about the arm, the subject is assigned to. Outcome assessors will not be able to receive information about the implanted lens. Data analyst will get to know about the patient assignment after data evaluation only.||t|f|f|t
33838466|NCT00068432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812861|NCT05052398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Part 1 is a 2-stage, 2-cohort, open-label study where up to 38 pts with G\>2 CIPN secondary to taxanes and other anti-neoplastic drugs will receive PSP NEURO SERUM (PNS) thrice a day for 28 days. Twelve patients will be evaluated in stage 1, expecting a 20% response per cohort to proceed to stage 2. If needed 7 patients will be recruited, expecting 4/19 response in each cohort. If the number of responses is not met, recruitment will be halted. Part 2 consists of 2 randomized groups of 26 patients each, one control and one experimental group. The population will follow an adaptive approach, considering which cohorts benefited the most from the effects of PNS in Part 1. The 52 patients will be allocated in a 1:1 ratio to Arm A (control) or Arm B with the objective of estimating and comparing the responses of tactile sensitivity using the Semmes-Weinstein monofilament test in hands. Arm A will receive placebo 3 times/day for 28 days, and Arm B will receive PNS 3 times/day for 28 days.|t|f|t|f
33812862|NCT00552461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812863|NCT01890278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812864|NCT01986348|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812865|NCT02166723|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812866|NCT01579955|||COHORT||PROSPECTIVE|||||||
34044041|NCT05517148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The study utilized random sampling to recruit participants, and ethical approval was obtained prior to the commencement of the study. The participants were then divided into two groups through randomization, which was conducted by an independent researcher using the random number calculation procedure available at www.random.org. Following randomization, participants in the same department should were encouraged to adopt a unified intervention mode. Nurses working in the same department were assigned to the same group, and participants were not made aware of the existence of the other group existed. This form of masking is commonly used in randomised controlled trials to prevent potential bias from patients in the control group requesting the intervention or otherwise altering their behaviors. However, the investigators were aware of assignment. Before registering for this study, participants agreed to commence receiving the intervention in September 2022.||t|t|t|f
34044042|NCT02498444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044043|NCT00299338|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044044|NCT01742130|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34044045|NCT01840059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044046|NCT04542486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044047|NCT06335407|NA|SEQUENTIAL||OTHER||NONE|no one will be masked|Participants will receive 40µg on days 1-2. On days 3 and 4, participants will receive 40µg twice per day. On days 5 and 6 participants will receive 40µg in the morning and 80µg in the evening. If dosing is tolerated, per clinical judgement, participants will begin to receive 80µg twice per day on days 7-28.||||
34044048|NCT04266834|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The study will enroll practicing cardiologists in the US. All eligible and consented participants will be randomly assigned to either a control or intervention arm. All participants complete two rounds of three patient simulations. The intervention arm only will receive educational material about the Hikari L-FABP test in between these two rounds, and be provided simulated L-FABP test results in the second round of the simulated cases.||||
34044049|NCT04950348|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33812867|NCT00070642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812868|NCT01817491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812869|NCT05534776|||OTHER||CROSS_SECTIONAL|||||||
34044050|NCT04851990|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 Arms with 15 Subjects per group||||
34044051|NCT05225844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044052|NCT01240577|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044053|NCT06207097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044054|NCT01807572|||COHORT||PROSPECTIVE|||||||
34044055|NCT06237569|||CASE_CONTROL||PROSPECTIVE|||||||
34044056|NCT02218437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044057|NCT00204360|||NATURAL_HISTORY||OTHER|||||||
34044058|NCT02337608|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044059|NCT00548587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044060|NCT01255345|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044061|NCT00907491|||CASE_ONLY||RETROSPECTIVE|||||||
34044062|NCT00328211|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34044063|NCT01098279|||COHORT||PROSPECTIVE|||||||
34044064|NCT05401500|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34044065|NCT02402335|||CASE_CONTROL||PROSPECTIVE|||||||
34044066|NCT00610012|||COHORT||PROSPECTIVE|||||||
34044067|NCT05282992|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34044068|NCT00646815|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044069|NCT06237530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The investigators tested two different versions of the body scan (meditation practice), one focused on visceral signals -visceral body scan (VBS)- and the other on somatosensory signals -somatosensory body scan (SBS)- in comparison to an exteroceptive, non-body focused, control condition -external control meditation (ECM)-. To do so, an online approach was conducted, as it has been proved to be an effective strategy, while being more widely accessible and reducing costs and time.|t|f|f|f
34044070|NCT04024345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044071|NCT04747353|NA|SINGLE_GROUP||TREATMENT||NONE||Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets||||
34044072|NCT03546491|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34044073|NCT05517668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34044074|NCT06576622|||COHORT||PROSPECTIVE|||||||
34044075|NCT05560269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044076|NCT04341805|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34044077|NCT01051297|||COHORT||PROSPECTIVE|||||||
34044078|NCT02428309|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044079|NCT06383897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044080|NCT01405482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044081|NCT00114439|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044082|NCT03651154|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34120514|NCT06719050|||COHORT||PROSPECTIVE|||||||
34120515|NCT01474967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120516|NCT05522647|||COHORT||PROSPECTIVE|||||||
34120517|NCT06270407|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Identically shaped ampoules containing traneamic acid (Cyklokapron, Pfizer) and 0.9% Saline (Lavoisier, France) have been identified. The ampoule top part is camouflaged with a tight-fitting black tube which preserves the breaking point on the neck of the ampoule. The ampoules will be re-labeled with study-specific labels (text will be in accordance with Regulation 546/2014, annex VI). Randomized study envelopes will be provided in packages of two, with a 1:1 TXA:Placebo randomization, enabling a within-patient randomization in bilateral procedures.~Randomization, blinding, labelling, shipment of ampoules and keeping of the randomization code will be done by Smerud Medical Research International AS."|Randomized controlled prospective interventional trial|t|t|t|t
34120518|NCT05965336|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||To evaluate biofeedback-induced changes in plantar pressure, propulsion, and biomechanics during gait in individuals with DPN versus age-similar controls. Then, participants with DPN will will complete an additional four experimental sessions to collect data in a randomized crossover pilot clinical trial to examine the acceptability, feasibility, safety, and preliminary effects of gait biofeedback training in individuals with DPN.||||
34120519|NCT03646357|RANDOMIZED|PARALLEL||TREATMENT||NONE||PROBE - prospective, randomized, open blinded end-point||||
34120520|NCT05811351|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120521|NCT04372108|||COHORT||OTHER|||||||
34120522|NCT00227253|||OTHER||OTHER|||||||
34120523|NCT02781441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120524|NCT06184997|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will not be aware that there are other people consuming a different type of drink than theirs. The person analyzing the results will also be unaware. However, the researchers will be aware because they need to control the supply.|Participants will be assigned to group A (water, placebo) or group B (sugar-free isotonic drink), and will be instructed to consume 265 ml of water or 265 ml of sugar-free isotonic drink, respectively, every day for 12 weeks. During the study period, participants will be advised to maintain their usual diet and physical activity.|t|f|f|t
34120525|NCT03960047|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Control Intervention: Virtual Reality training Intervention: Streetside training||||
34120526|NCT06327789|||CASE_ONLY||PROSPECTIVE|||||||
34120527|NCT06621654|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34120528|NCT01299389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120529|NCT03861182|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120530|NCT04372303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120531|NCT00002907||||TREATMENT||||||||
34120532|NCT01740869|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120533|NCT02972710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120534|NCT06717113|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||This study is an interventional clinical trial in which enrolled patients will undergo a comparative analysis using two PET/CT imaging agents: 68Ga-NB381 and 18F-FDG. The two drugs should be given at least one day apart.||||
34120535|NCT04327440|||COHORT||PROSPECTIVE|||||||
34120536|NCT06706167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This research was designed as a randomized controlled trial conducted by a single operator to minimize operator-induced errors. A total sample of 75 primary molars was determined, allowing for potential dropouts, and was evenly distributed into three groups of 25. Each group recieved different crown, groups A for stianless steel crown, group B for zirconia crown and group C for Bioflx crown. At 6 and 12 months follow up, each crown was evaluated clinically such as plaque index , crown retentivity and gingival index.|t|f|f|f
34120537|NCT01529229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120538|NCT06421051|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34120539|NCT00210847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120540|NCT06344637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34120541|NCT01644643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120542|NCT02701764|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34120543|NCT05973006|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34120544|NCT04985084|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34120545|NCT03960684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120546|NCT04513782|||OTHER||PROSPECTIVE|||||||
34120547|NCT06716697|||OTHER||CROSS_SECTIONAL|||||||
34120548|NCT00735150|||COHORT||PROSPECTIVE|||||||
34120549|NCT06006871|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, single-center, randomized, unblinded, PRE-POST intervention study with concealment of the randomization sequence.~A randomization of 2 groups by blocks will be performed: Group 1: The Secret Trail of Moon (MOON): a personalized cognitive training with a face-to-face and online video game (n=76); Group 2: Passive control (TAU): usual treatment (pharmacological) without cognitive training intervention (n=76)."||||
34120550|NCT06062329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120551|NCT04302025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120552|NCT06078475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the outcomes assessor who performs postoperative pain evaluation will not know the group|There are two models for this study. Modified Perichondral Approach Thoracoabdominal Nerve block (M-TAPA block) group, and Control (C) group|t|f|f|t
34120553|NCT05784181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120554|NCT05402839|||COHORT||PROSPECTIVE|||||||
34120555|NCT05801913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120556|NCT06119503|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120557|NCT02280993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120558|NCT06716294|||COHORT||PROSPECTIVE|||||||
34120559|NCT04858399|||COHORT||CROSS_SECTIONAL|||||||
34120560|NCT06433479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120561|NCT01278264|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|t|f
34120562|NCT06131658|RANDOMIZED|PARALLEL||OTHER||SINGLE|assessor who will take reading is blind|Randomized clinical trial|f|f|f|t
34120563|NCT06603558|||COHORT||PROSPECTIVE|||||||
34120564|NCT06715657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120565|NCT00602693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812870|NCT04470089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812871|NCT04557566|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||RCT- EBT Yoga-Based Course and Control group||||
34120566|NCT05778656|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"A computer-generated randomization with a stratified block design will be used, with sex, age, obesity, and fiber intake as stratification variables using randomly permuted blocks of size 2 and 4. The computer program (RedCap) will reveal the group allocation to the researcher, with no option to visualize the groups that will be assigned to future patients.~It will not be possible to blind patients to the intervention group due to the nature of the intervention. However, the effectiveness measure comparing trial arms (primary outcomes) are objectively measured outcomes (blood lipids and metabolites) and not subject to interpretation by researchers, limiting the effect that researcher knowledge of the intervention group could have on outcomes. Where possible, the study team taking all the outcome measurements will remain blind to group allocation throughout the trial."|The CADIMED study is a randomized, controlled nutritional intervention study (two-arm parallel group design with a 1:1 ratio)|f|t|t|t
34120567|NCT02719392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120568|NCT06592911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multicentric randomized non-inferiority study|f|f|t|t
34120569|NCT02116179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120570|NCT00406861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34120571|NCT04849637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120572|NCT05363150|||COHORT||PROSPECTIVE|||||||
34120573|NCT00708409|||||PROSPECTIVE|||||||
34120574|NCT01605357|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120575|NCT06203210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120576|NCT03568812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double blind placebo control study|t|f|t|f
34120577|NCT05145413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120578|NCT02388906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120579|NCT01334918|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34120580|NCT01402869|RANDOMIZED|PARALLEL||||NONE||||||
34120581|NCT02793583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120582|NCT03983447|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"During the academic year 2016/2017, baseline assessments were carried out in two schools (school A, school B): measures of PA, ST, motors skills, attentional capacity and academic achievement. These assessments were performed in November/December 2016 (First Time - T1) and May/June 2017 (Second time - T2).~During the academic school year 2017/2018, a school-based intervention to increase PA and reduce ST was realised in School A (measure in November 2017 and May/June 2018). Finally, during the academic school year 2018/2019, a school-based intervention to increase PA and reduce ST was realised in School B (measure only in May/June 2019)."|f|f|t|f
34120583|NCT05547412|||COHORT||PROSPECTIVE|||||||
34120584|NCT00771836|||COHORT||PROSPECTIVE|||||||
34120585|NCT04884607|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120586|NCT02705092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34120587|NCT02592421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120588|NCT05988736|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34120589|NCT01098747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120590|NCT05887791|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34120591|NCT00615576|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34120592|NCT03997864|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a randomized double-blind placebo-controlled trial. All study team personnel (PI, RAs) and study participants will be blinded to intervention condition \[prazosin (treatment) vs. placebo (control)\] throughout active data collection.|Participants in this study will include 40 adult females who complete consent (20 per arm), ages 18-50 years, who are evaluated and treated at the University of Colorado Hospital after an alleged sexual assault on their person. Randomization will be completed by the pharmacy and study condition (prazosin/treatment vs. placebo/control) masked throughout the data collection portion of the study. Participants will attend weekly visits during the 3-week medication trial and 2-3 week tapering off of medication, followed regular check-in phone calls with study staff between stopping the medication and the follow-up assessments at the final study visit (approx. 3 moths post study enrollment).|t|t|t|t
34120593|NCT06718114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120594|NCT01058252|||COHORT||PROSPECTIVE|||||||
34120595|NCT02422979|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120596|NCT00038844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120597|NCT01215526|||COHORT||PROSPECTIVE|||||||
34120598|NCT06262438|NA|SINGLE_GROUP||TREATMENT||NONE||Given the rarity of pediatric subjects with newly diagnosed Acute Myeloid Leukemia (AML) with FLT3-ITD mutations and the slow enrollment in historical studies, it is not feasible to enroll a sufficient number of subjects for an adequately powered randomized study. Therefore, a standard oncology Phase 2 response-rate design has been chosen. One of the exploratory objectives planned is to compare the outcome of patients treated in this study to the outcome of patients treated in the NOPHO-DBH AML-2012 study as historical control.||||
33812872|NCT04207372|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Allocation of different proteins(or no protein) is blinded from participant.|Intervention study with 6 test days, testing 3 meals each twice|t|f|f|f
33812873|NCT01204879|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812874|NCT00632736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812875|NCT06443099|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33812876|NCT04876430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812877|NCT01214109|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812878|NCT00658632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812879|NCT00511316|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33812880|NCT01078402|||CASE_ONLY||PROSPECTIVE|||||||
33812881|NCT03853772|||CASE_ONLY||PROSPECTIVE|||||||
33812882|NCT01722097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33812883|NCT00545909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812884|NCT04017299|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33812885|NCT02939742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812886|NCT04968886|||COHORT||PROSPECTIVE|||||||
33812887|NCT02318628|||OTHER||PROSPECTIVE|||||||
33812888|NCT01260883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33812889|NCT03606863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812890|NCT03271359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812891|NCT04891978|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33812892|NCT02792738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34120599|NCT03563092|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized clinical trial||||
34120600|NCT04000061|||COHORT||RETROSPECTIVE|||||||
34120601|NCT06121648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|closed envelopes|"2 groups~1. water group~2. land group"|t|f|f|f
34120602|NCT06483854|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34120603|NCT04781816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120604|NCT03015493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34120605|NCT06005987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Cannot mask participant who needs to use the mobile application, or their care provider, or the investigator who will need to teach the patient how to use the application.|Patients will be randomized to two arms. First is traditional logging of blood glucoses with standard paper form in the clinic. The second arm will log their blood glucoses with the OneTouch Reveal smart phone application.|f|f|f|t
34120606|NCT04095052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind study. The participants will be blinded.|Participants will be randomly assigned to a condition that receives a vitamin supplement (methyl folate), or a placebo group. Both the condition and placebo group will receive the same size pill once daily for 15 days and the pills will look the same. The condition group will receive a gel capsule containing the methyl folate supplement and a microcrystalline cellulose fiber. The placebo group will receive the same size gel capsule containing only the microcrystalline cellulose filler. The methyl folate supplement is the upper tolerable limit set by the Institute of Medicine. Taking more that the upper limit of 1000 mcg of methyl folate may be harmful; for this reason, it is important to discontinue vitamin use while enrolled in the study. Participants assigned to both the condition and placebo groups will be directly observed taking the pill during each daily appointment.|t|f|f|f
34120607|NCT06694246|||OTHER||PROSPECTIVE|||||||
34120608|NCT06716268|||OTHER||CROSS_SECTIONAL|||||||
34120609|NCT05914194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, Double-Blind, Placebo-Controlled|t|f|t|f
34120610|NCT03391999|||COHORT||PROSPECTIVE|||||||
34120611|NCT03343561|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As soon as the samples are obtained from the subjects, subjects will be coded straight-away. No samples will be stored with the subjects' name on, only codes will be used. Only the investigating team will be able to break the codes and trace the results back to the subjects. All the questionnaires will be only shown the subjects' code without subjects' name on them. No data file in hard or soft copy format will contain all the information on the subject's name, project code and experiment result.||f|f|f|t
34120612|NCT01413438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120613|NCT04276025|||COHORT||RETROSPECTIVE|||||||
34120614|NCT04163939|RANDOMIZED|PARALLEL||TREATMENT||NONE||To evaluate the effectiveness of treatment with Vista Therapy Collar for indication of cervical radicular pain, defined as pain radiating into one or both upper extremities compared to standard care.||||
34120615|NCT05685784|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Open-label, monocentric diagnostic study||||
34120616|NCT02717650|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34120617|NCT04919434|NA|SINGLE_GROUP||OTHER||NONE||||||
34120618|NCT03041935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34120619|NCT02255019|||CASE_CROSSOVER||PROSPECTIVE|||||||
34120620|NCT05225909|||COHORT||PROSPECTIVE|||||||
34120621|NCT06718855|||COHORT||CROSS_SECTIONAL|||||||
34120622|NCT06219252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|None of the patients will be informed in what group they are assigned||t|f|f|f
34120623|NCT03390725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34120624|NCT04616937|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34120625|NCT05600413|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Double (Participant, Investigator) Randomized, double-blind, placebo-controlled, parallel study design|t|f|t|f
34120626|NCT00467376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120627|NCT06333548|||COHORT||PROSPECTIVE|||||||
34120628|NCT00682149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120629|NCT05522738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120630|NCT01015521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120631|NCT00608062|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34120632|NCT02999009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120633|NCT01069913|RANDOMIZED|CROSSOVER||||NONE||||||
34120634|NCT03539757|||CASE_CONTROL||PROSPECTIVE|||||||
34120635|NCT03507127|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34120636|NCT00693888|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120637|NCT05341310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120638|NCT05272189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants are naive to the purposes of the study but they are not blinded to the conditions.|||||
34120639|NCT02224534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120640|NCT02196753|||CASE_CONTROL||PROSPECTIVE|||||||
34120641|NCT03670108|||OTHER||PROSPECTIVE|||||||
34120642|NCT04235543|||COHORT||CROSS_SECTIONAL|||||||
34120643|NCT02015403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812893|NCT00831571|||CASE_ONLY||PROSPECTIVE|||||||
33812894|NCT01700699|||COHORT||RETROSPECTIVE|||||||
33812895|NCT01612897|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33812896|NCT00990314|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812897|NCT02262988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33838467|NCT06432114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33838468|NCT05065606|||CASE_ONLY||RETROSPECTIVE|||||||
33838469|NCT04465266|RANDOMIZED|CROSSOVER||OTHER||SINGLE||sequence randomized|t|f|f|f
33838470|NCT05164380|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33838471|NCT00263237||||TREATMENT||||||||
33838472|NCT05092074|||COHORT||PROSPECTIVE|||||||
34120644|NCT05390684|||COHORT||PROSPECTIVE|||||||
34120645|NCT06717581|||COHORT||RETROSPECTIVE|||||||
34120646|NCT02965638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120647|NCT05162690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34120648|NCT06716762|||COHORT||RETROSPECTIVE|||||||
34120649|NCT01824290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120650|NCT02562781|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34120651|NCT06141551|||CASE_ONLY||RETROSPECTIVE|||||||
34120652|NCT04592341|NA|SEQUENTIAL||TREATMENT||NONE||||||
34120653|NCT01085526|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34120654|NCT01852643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120655|NCT00067561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120656|NCT02282748|||COHORT||PROSPECTIVE|||||||
34120657|NCT06714773|||COHORT||RETROSPECTIVE|||||||
34120658|NCT01606579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120659|NCT02761642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120660|NCT06715553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A 86 patients adhering to the inclusion and exclusion criteria will be randomized into two groups (43 patients in the intervention group and 43 patients in the control group) and the interventional model type will be in Parallel.|t|f|t|f
34120661|NCT02404714|||CASE_ONLY||CROSS_SECTIONAL|||||||
34120662|NCT05042206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120663|NCT04179110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120664|NCT06717984|||CASE_CONTROL||PROSPECTIVE|||||||
34120665|NCT04384614|||OTHER||CROSS_SECTIONAL|||||||
34120666|NCT05128565|||OTHER||RETROSPECTIVE|||||||
34120667|NCT02447185|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34120668|NCT05434819|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinding to allocation will be maintained for all parties, excluding the operating surgeon and necessary operating room personnel.|Each patient will be assigned in a blinded fashion to one of two groups (atrial fibrillation ablation or no atrial fibrillation ablation) in a 1:1 ratio.|t|t|t|t
34120669|NCT04868916|||COHORT||PROSPECTIVE|||||||
34120670|NCT06718192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120671|NCT05781581|||COHORT||RETROSPECTIVE|||||||
34120672|NCT03266029|||COHORT||PROSPECTIVE|||||||
34120673|NCT06719297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120674|NCT02121509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120675|NCT05110573|||CASE_CONTROL||RETROSPECTIVE|||||||
34120676|NCT01459666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120677|NCT01999933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120678|NCT04661033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120679|NCT00329030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120680|NCT03974269|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|2 arms : hypnosis group and sedation group||||
34120681|NCT05173376|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34120682|NCT00098995||||TREATMENT||||||||
34120683|NCT03662061|||COHORT||PROSPECTIVE|||||||
34120684|NCT01385150|||OTHER||RETROSPECTIVE|||||||
34120685|NCT04133168|NA|SINGLE_GROUP||TREATMENT||NONE||open label, prospective, single arm study||||
34120686|NCT01159093|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120687|NCT01387750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120688|NCT06521216|||OTHER||OTHER|||||||
34120689|NCT01779414|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34120690|NCT02481414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||PepCan or Candin randomized at a 1:1 ratio in a double-blinded design.|t|t|t|t
34120691|NCT03401203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812898|NCT03799588|NA|SINGLE_GROUP||OTHER||NONE||After routine intubation for elective urologic procedures in the OR, the patient will be placed on a biphasic chest cuirass after anesthesia induction. A esophageal manometer will then be placed to measure transpulmonary pressures. The patient will be switched off the anesthesia ventilator and the biphasic chest cuirass will begin negative pressure ventilation. During this time, the patient will continue to receive inhalation anesthetic gas. After 30 minutes, the biphasic chest cuirass will terminate and the patient will again receive positive pressure ventilation via the anesthesia ventilator.||||
33812899|NCT01970527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838473|NCT05863572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and outcome assessors are masked to study arm.|Cluster randomized controlled trial|t|f|f|t
34120692|NCT04186572|||OTHER||PROSPECTIVE|||||||
34120693|NCT01880983|||COHORT||PROSPECTIVE|||||||
34120694|NCT02573636|||CASE_ONLY||PROSPECTIVE|||||||
34120695|NCT04086680|||CASE_ONLY||RETROSPECTIVE|||||||
34120696|NCT01853709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34120697|NCT06143956|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||The CWMM protocol includes screening assessments plus a framework for the subsequent intervention, which is the primary purpose of the protocol.|t|f|t|f
34120698|NCT06191276|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34120699|NCT04591002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120700|NCT02673944|NA|SINGLE_GROUP||||NONE||||||
34120701|NCT06717048|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34120702|NCT06716814|NA|SINGLE_GROUP||TREATMENT||NONE||Roll-over study to provide post-trial access to treatment for patients with severe haemophilia A who have completed a previous trial with efanesoctocog alfa.||||
34120703|NCT00641732|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34120704|NCT06350422|||COHORT||PROSPECTIVE|||||||
34120705|NCT04270422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120706|NCT04552002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120707|NCT02299310|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120708|NCT04787003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120709|NCT06717308|RANDOMIZED|PARALLEL||TREATMENT||NONE||50% of the patients will receive the KCI® drape (control), and 50% of the patients will receive the Comfort Release® drape (intervention). Outcomes assessed will include the effectiveness of the seal, pain during dressing removal, skin damage upon removal, and clinician acceptability.||||
34149153|NCT05742204|||COHORT||PROSPECTIVE|||||||
33812900|NCT04805008|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Participants will receive a generic bag of 57+/-1 grams of either lactation cookies or conventional cookies for 30 days.~Investigators will be blinded to treatment allocation."||t|f|t|f
33812901|NCT00942266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812902|NCT03430518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812903|NCT06343636|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33812904|NCT05752084|||COHORT||PROSPECTIVE|||||||
33812905|NCT00091572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812906|NCT01314482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812907|NCT06275841|NA|CROSSOVER||OTHER||NONE||||||
33812908|NCT04236297|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33812909|NCT04884256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812910|NCT04707599|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|The aim of the study was presented to all participants (to examine dropout/ retention from treatment), but patients were blinded to information about the phase comparison (i.e., that there was a pretreatment telephone Call from therapist in one phase and not in the other).|Quasi-experimental with an OFF-ON design|t|f|f|f
33812911|NCT01450891|||COHORT||PROSPECTIVE|||||||
33812912|NCT02875730|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33812913|NCT02332824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812914|NCT06598891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812915|NCT05977010|||COHORT||PROSPECTIVE|||||||
33812916|NCT01030263|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33812917|NCT06500910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33812918|NCT00512902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812919|NCT03155035|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33812920|NCT05781932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812921|NCT02547506|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33812922|NCT02064335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33812923|NCT04119700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044083|NCT05732337|NA|SINGLE_GROUP||TREATMENT||NONE||To determine the efficacy of PoxClin® CoolMousse in relieving itching associated with chickenpox after 3 days of use (using 5-point scale)||||
34044084|NCT06115720|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Investigators and outcome assessors are blinded to which arm the participants are allocated when analysing the data.|"Recruited participants, randomised to one of two groups. Control group: standard video verbal consent process for GA and RA for orthopaedic surgery. This verbal communication will be pre-recorded and shown to the participant.~Intervention group: Same pre-recorded standard verbal consent, additionally recorded video of the anaesthetic process for both GA and RA."|f|f|t|t
34044085|NCT00126347|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34044086|NCT06577051|||CASE_CONTROL||PROSPECTIVE|||||||
34044087|NCT01684943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All subjects participated in the single arm of the study. Some subjects participated in the continuous insulin monitoring sub-study in addition to the main protocol, or separate from the main protocol.||||
34044088|NCT04836013|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind trial|Double blind placebo controlled prospective trial|t|t|t|t
34044089|NCT02266797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044090|NCT01983696|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044091|NCT06363370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044092|NCT01861899|||CASE_ONLY||PROSPECTIVE|||||||
34044093|NCT03030560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind||f|t|t|f
34044094|NCT05806632|||COHORT||PROSPECTIVE|||||||
34044095|NCT02730403|||OTHER||PROSPECTIVE|||||||
34044096|NCT01480466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34044097|NCT05250570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044098|NCT03971136|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044099|NCT04932369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044100|NCT02199795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044101|NCT06575231|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each subject should draw two tubes of venous blood in the K2-EDTA. One tube should be tested by POC operator as a study participant using the PixoTest POCT System. The other tube takes 1c.c. blood sample from K2-EDTA to analyzed with a comparison method.||||
34044102|NCT02976558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044103|NCT01732458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be conducted as a partially blinded study. PK samples will not be collected from participants in the control group. To maintain a partial blind, approximately 3 participants randomly selected from each age group in each of the aprepitant treatment groups will not have PK sampling. All participants will remain blinded to the study treatment. The investigator and Sponsor will be blinded to the study medication in participants not providing PK samples. The investigator and Sponsor will remain blinded to the aprepitant dose given to participants from whom PK samples will be collected.||t|f|t|f
34044104|NCT01866111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044105|NCT01342770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044106|NCT03107390|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044107|NCT00002202||||TREATMENT||||||||
34044108|NCT04967924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044109|NCT02505750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044110|NCT01475708|||CASE_CONTROL||PROSPECTIVE|||||||
34044111|NCT04056533|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044112|NCT03876743|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34044113|NCT04269057|||COHORT||RETROSPECTIVE|||||||
34044114|NCT00656292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34044115|NCT06035367|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34044116|NCT06423898|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Randomized 1:1 to experimental group (continuous infusion arm) or control group (intermittent infusion arm)||||
34044117|NCT02695550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149154|NCT02900755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149155|NCT03568955|||COHORT||RETROSPECTIVE|||||||
34149156|NCT05223387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149157|NCT05918627|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732922|NCT05055674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be aware of the intervention received, as well as investigators and professionals responsible for monitoring app usage during the study. The Outcome assessor will be blind to randomization status.|Participants will be randomized to one of two groups: a) intervention, which will have access to the Motherly app; or b) active control, which will be given access to COMVC, a smartphone app that delivers only psychoeducational content.|f|f|f|t
33732923|NCT05927233|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33732924|NCT03750734|||COHORT||PROSPECTIVE|||||||
33732925|NCT03392636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Group A will get Mitchell Banks herniotomy done and Group B will get Fergusson Gross Herniotomy done.|t|t|f|t
33732926|NCT00134875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33732927|NCT05196412|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33732928|NCT01114516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732929|NCT04416035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732930|NCT01815281|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33732931|NCT04541017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732932|NCT05294107|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, monocentric cohort aiming at generating 3D organoids from human digestive samples||||
33732933|NCT04313920|NA|SINGLE_GROUP||OTHER||NONE||||||
33732934|NCT00901875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732935|NCT02149433|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33732936|NCT02420496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732937|NCT01207778|||CASE_CONTROL||PROSPECTIVE|||||||
33732938|NCT05790434|||CASE_CONTROL||OTHER|||||||
33732939|NCT03117387|||COHORT||PROSPECTIVE|||||||
33732940|NCT03446586|||COHORT||OTHER|||||||
33732941|NCT02157766|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33732942|NCT05620290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732943|NCT02684006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732944|NCT06386952|||OTHER||PROSPECTIVE|||||||
33732945|NCT00000439|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732946|NCT02388217|||COHORT||PROSPECTIVE|||||||
33732947|NCT06020404|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||2x2 cross-over design||||
33732948|NCT02023671|||||RETROSPECTIVE|||||||
33732949|NCT04922333|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Both participants and study staff will be blinded to treatment allocation.||t|f|t|t
33732950|NCT06097884|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33732951|NCT02244333|||COHORT||PROSPECTIVE|||||||
33732952|NCT04469361|||OTHER||CROSS_SECTIONAL|||||||
33732953|NCT01204866|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732954|NCT04363658|||OTHER||PROSPECTIVE|||||||
33732955|NCT01516879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732956|NCT00466765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732957|NCT05508061|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Allocation by randomization:~* Study period 1 (Humalog or Lyumjev)~* Wash-out period (Humalog: standard therapy)~* Study period 2 (other type of insulin than in Study period 1 (Humalog or Lyumjev))"||||
33732958|NCT04918680|||COHORT||PROSPECTIVE|||||||
33732959|NCT00104533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33732960|NCT00175903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732961|NCT05950568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732962|NCT01868633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33732963|NCT03148197|||COHORT||PROSPECTIVE|||||||
33732964|NCT04070833|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33732965|NCT02595736|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33732966|NCT01558700|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33732967|NCT04518891|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33732968|NCT00589108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33732969|NCT00305617|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33732970|NCT04447092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732971|NCT06097234|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized controlled prospective trial||||
33732972|NCT00722917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732973|NCT02729649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33732974|NCT03229564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732975|NCT03087201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732976|NCT01987323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33732977|NCT01493271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732978|NCT03501446|||OTHER||PROSPECTIVE|||||||
33732979|NCT03388723|||COHORT||PROSPECTIVE|||||||
33732980|NCT02093572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33732981|NCT01396863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33732982|NCT03373175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33732983|NCT04947943|||COHORT||RETROSPECTIVE|||||||
33732984|NCT03901924|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcomes assessor will be masked to randomization and ventilator settings||f|f|t|t
34044118|NCT04386655|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial Approximately 50 survivors with brain injury who meet inclusion/exclusion criteria and their caregivers will be recruited. There will be 3 waves within one year. Each wave will be split into 2 groups. Half of the participants in each wave will attend a regular BICS program (in-person), while the other half will participate in a BICS-T program.||||
34044119|NCT00181285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732985|NCT03509129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732986|NCT04773262|||OTHER||CROSS_SECTIONAL|||||||
33732987|NCT01546116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812924|NCT06241183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research team member assessing verbal pain score will be blinded to the treatment.|Subjects are divided into two groups and randomly assigned to receive either study drug.|f|f|f|t
33812925|NCT04446949|||COHORT||OTHER|||||||
33812926|NCT00769197|||COHORT||CROSS_SECTIONAL|||||||
33812927|NCT05125549|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33732988|NCT03915288|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||1573 cancer patients, who, after the exclusion criteria, 812 patients with stage II cancer finally started the investigation and were organized into 3 groups. The present, was distributed with a basic probabilistic sampling by means of a table of random numbers, whose order was randomized through the program Microsoft Excel 16.0, being the experimental group 1 with 270 participants (MICT + strength training), 275 participants in experimental group 2 (HIIT + strength training) and control group with 267 (verbal recommendations on exercise, diet, follow-up via telephone call and carrying out activities of daily living).|t|t|t|f
33732989|NCT02694224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33732990|NCT01882127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33732991|NCT06084208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A prospective, single-center, dual-arm, interventional study, where data from 131 recruited patients undergoing a Robotic Navigational Bronchoscopy System procedure with CBCT are compared to 91 matched Navigation Bronchoscopy with CBCT controls.||||
33732992|NCT02073422|||COHORT||PROSPECTIVE|||||||
33732993|NCT02141516|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33732994|NCT02035007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33732995|NCT05227924|||CASE_ONLY||PROSPECTIVE|||||||
33732996|NCT02219815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33812928|NCT01000207|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33812929|NCT00537914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812930|NCT03311802|||CASE_ONLY||CROSS_SECTIONAL|||||||
33812931|NCT03374423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812932|NCT05214092|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33812933|NCT05687825|||COHORT||PROSPECTIVE|||||||
33812934|NCT05481008|||COHORT||PROSPECTIVE|||||||
33812935|NCT00139360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812936|NCT03481153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812937|NCT04023266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical outcomes assessor reading the cardiac MRI would be blinded to the study arm allotment.|Investigator-initiated prospective, single-center, double- arm non-blinded randomized controlled trial.|f|f|f|t
33812938|NCT05757934|||COHORT||PROSPECTIVE|||||||
33812939|NCT02313194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812940|NCT01366053|||CASE_ONLY||PROSPECTIVE|||||||
33812941|NCT06360367|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33812942|NCT01780272|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33812943|NCT01865695|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33812944|NCT03052998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|f|f|f|t
33812945|NCT00009191|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33812946|NCT02584426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812947|NCT00325845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812948|NCT02589548|||COHORT||PROSPECTIVE|||||||
33812949|NCT03721159|||OTHER||OTHER|||||||
33812950|NCT02474004|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33812951|NCT00175253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33812952|NCT03814226|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33812953|NCT00239642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812954|NCT00518440|||OTHER||PROSPECTIVE|||||||
33812955|NCT01113697|||COHORT||PROSPECTIVE|||||||
33812956|NCT06332118|NA|SINGLE_GROUP||PREVENTION||NONE||The research is quasi-experimental and relationship-seeking in a pretest-posttest format.||||
33812957|NCT01190124|||COHORT||RETROSPECTIVE|||||||
33812958|NCT04979702|RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking|Randomised controlled trial||||
33812959|NCT04267523|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33812960|NCT02411175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812961|NCT01051648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812962|NCT05228834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812963|NCT00498797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33812964|NCT04019925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812965|NCT01372917|||COHORT||CROSS_SECTIONAL|||||||
33732997|NCT01792973|||COHORT||PROSPECTIVE|||||||
33732998|NCT01504334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33732999|NCT00322335|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733000|NCT01205165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733001|NCT02293785|||COHORT||PROSPECTIVE|||||||
33733002|NCT03306342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733003|NCT05082194|||CASE_CONTROL||PROSPECTIVE|||||||
33733004|NCT05114603|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33733005|NCT05927610|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733006|NCT03025724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733007|NCT02730416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733008|NCT00720876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733009|NCT01910064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733010|NCT06374329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733011|NCT05029141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733012|NCT05593718|||OTHER||RETROSPECTIVE|||||||
33812966|NCT00001895||||TREATMENT||||||||
33812967|NCT01386632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33812968|NCT06509191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study will be a randomized, double-blind, and parallel arm placebo-controlled trial which will take place at Sultan Qaboos University Hospital. All patients aged 65 years and over admitted through emergency department to General Internal Medical Units will be screen for eligibility.|t|t|t|t
33812969|NCT02245620|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33812970|NCT04100317|||COHORT||PROSPECTIVE|||||||
33812971|NCT02032004|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33812972|NCT03166605|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Randomized control|Control, Sham , Experimental|f|t|f|t
33812973|NCT01242163|||CASE_CONTROL||PROSPECTIVE|||||||
33838474|NCT04618367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838475|NCT03889145|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838476|NCT01562223|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733013|NCT03765307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The enrolled patients are blinded until 12 months after procedure. Physicians who perform post-procedure patient management and physicians who perform bronchial ablation/ bronchial thermoplasty procedures are blinded to each other.|Patients with severe asthma are assigned to the experimental or control group at a 1:1 ratio based on a central randomized system.|t|f|f|t
33733014|NCT05186467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33733015|NCT02191189|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733016|NCT01234467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733017|NCT04300296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||PoC study, 32-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of secukinumab 300 mg in two different dosing regimens in 108 patients with biopsy-proven forms of lichen planus.|t|t|t|t
33733018|NCT02961907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733019|NCT05870527|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733020|NCT00514267|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733021|NCT02320890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733022|NCT01099085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733023|NCT05703191|||COHORT||PROSPECTIVE|||||||
33733024|NCT05907304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733025|NCT04782778|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||RANDOMISED DOUBLE BLINDED INTERVENTIONAL|t|f|t|t
33733026|NCT06274554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded study||t|f|t|f
33733027|NCT04567121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733028|NCT04737642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733029|NCT06538688|NA|SINGLE_GROUP||PREVENTION||NONE||Patients with impacted mandibular third molar in close proximity to the inferior alveolar nerve requiring orthodontic extrusion of the impacted teeth before extraction||||
33733030|NCT03075644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733031|NCT03152318|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I, open-label, single center, dose-escalation, triple-arm clinical trial of an oncolytic virus called rQNestin||||
33733032|NCT01054703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733033|NCT03291912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733034|NCT05483244|||CASE_CONTROL||RETROSPECTIVE|||||||
33733035|NCT00000436|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33733036|NCT01705288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733037|NCT06192602|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Outcome assessors, researchers and center staff are blind to the group assignment and intervention undertaken, and concealed to the participant list.|Assessor-blind, repeated measures, parallel-group randomized controlled trial|f|t|t|t
33733038|NCT05217797|RANDOMIZED|PARALLEL||PREVENTION||NONE|No blinding was feasible, except for in the analysis phase. One member of our team (A.H.) provided the chief analyst (I.H.E.) with a data file in which group allocation was blinded. The chief analyst presented the main results to the project team members, who were also blinded to the group allocation (and data on use of glasses). We discussed how we would interpret the findings depending on whether one group or the other was the intervention group, and we prepared a short report that we posted online before unblinding ourselves to the group allocation.|"Sequence generation We will use a simple 1:1 randomization by means of computer-generated random numbers.~The allocation will be concealed as the participant themselves will be directly informed of their allocation as soon as they have agreed to take part in the trial and have completed the online consent form. Generation of allocation sequence, enrolment of participants and assignment of participants will all be handled by the digital recruitment platform."||||
33733039|NCT01558882|||COHORT||PROSPECTIVE|||||||
33733040|NCT06248983|||COHORT||PROSPECTIVE|||||||
33733041|NCT06664411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733042|NCT04608266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733043|NCT02691767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733044|NCT06103942|||COHORT||PROSPECTIVE|||||||
33812974|NCT06398015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients are allocated when in full general anesthesia. Treatment allocation will be blinded in the electronic patient journal, as the surgeon will insert a general description of the surgery. Unblinding at 6 months at the final consultation with the orthopedic surgeon. At the day of the unblinding the patient will be tested in the Department of Physio- and Occupational Therapy before the consultation with the orthopedic surgeon.||t|t|f|f
33812975|NCT05871502|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). Those patients with blood glucose levels \>155 mg/dl will receive insulin at the discretion of the physician responsible for the patient, following the local protocols for the management of hyperglycemia in hospitalized patients and the guidelines for the management of hyperglycemia in patients with acute stroke.||||
33812976|NCT05778253|||COHORT||PROSPECTIVE|||||||
33812977|NCT01554332|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33812978|NCT02764320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812979|NCT01653392|||CASE_CONTROL||PROSPECTIVE|||||||
33812980|NCT02749253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812981|NCT02776124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812982|NCT06506175|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparisons between arms with different dosing conditions, timing and food for oral HRS9531 tablets||||
33812983|NCT02894086|||COHORT||RETROSPECTIVE|||||||
33812984|NCT06500195|||COHORT||PROSPECTIVE|||||||
33812985|NCT05979766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33812986|NCT05126537|||OTHER||PROSPECTIVE|||||||
33812987|NCT00952003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812988|NCT01861041|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33812989|NCT02648841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33812990|NCT00449254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33812991|NCT03734432|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33812992|NCT05437328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812993|NCT02128269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812994|NCT04155814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733045|NCT03567850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733046|NCT03819231|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33733047|NCT01056848|||COHORT||CROSS_SECTIONAL|||||||
33733048|NCT03262948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733049|NCT05900427|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33733050|NCT03364049|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33733051|NCT02492906|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733052|NCT02694081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733053|NCT03279588|||COHORT||PROSPECTIVE|||||||
33733054|NCT00351234|||COHORT||RETROSPECTIVE|||||||
33733055|NCT01394575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733056|NCT05402527|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Participants are instructed not to disclose the supplement they are taking to their trainers, investigators, or outcome assessors.||f|t|t|t
33733057|NCT05549193|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33733058|NCT01306825|||CASE_ONLY||PROSPECTIVE|||||||
33733059|NCT04282356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733060|NCT04723199|||COHORT||PROSPECTIVE|||||||
33733061|NCT05555433|||COHORT||PROSPECTIVE|||||||
33733062|NCT01706250|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33733063|NCT02580370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733064|NCT01173562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733065|NCT00577122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733066|NCT01348399|||COHORT||PROSPECTIVE|||||||
33733067|NCT03264131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733068|NCT05991102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733069|NCT06217770|||CASE_ONLY||RETROSPECTIVE|||||||
33733070|NCT02837887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733071|NCT00494494|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33733072|NCT00458484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733073|NCT02402452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733074|NCT04505020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded/masked to the treatment (if they do or don't receive a 3D printed model of their hip) they receive until the end of the study. Patients will still be aware of the details of their surgical treatment.|Patients that have consented to the study will be randomized into four groups with a 50% chance of being in either group. The two treatment groups are 1) conventional preoperative imaging (X-ray, CT, and MRI) only 2) those that have had a 3D printed model created in addition to conventional imaging. There will be 40 patients in each group. Randomization will be done with a computer random number generator. Both groups will undergo routine pre-operative imaging but one group will also have a 3D print made from the 3D CT reconstruction. Both patient groups will undergo hip arthroscopy for treatment of their FAI.|t|f|f|t
33733075|NCT04516122|||COHORT||PROSPECTIVE|||||||
33733076|NCT05472259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733077|NCT02043015|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33733078|NCT01430585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733079|NCT00268138|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33733080|NCT06019975|||COHORT||RETROSPECTIVE|||||||
33733081|NCT05625477|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33733082|NCT00353366|||COHORT||PROSPECTIVE|||||||
33733083|NCT04099862|||COHORT||PROSPECTIVE|||||||
33812995|NCT04806659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33812996|NCT04376788|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group I:~Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs daily for 3 days according to daily clinical and investigational follow up~Group II Will receive IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up.~Group III Will receive exchange transfusion by venesection of 500cc blood with good replacement of one unit packed washed RBCs and IV methylene blue 1 mg/kg IV over 30 minutes with 200 CC plasma from convalescent matching single patient by plasma extractor machine for 3 days according to daily clinical and investigational follow up."||||
33733084|NCT06110676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733085|NCT02100891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733086|NCT05984134|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33733087|NCT03429491|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33733088|NCT01945515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733089|NCT03996785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants were unaware as to whether they were assigned to an urban or nature walking condition||t|f|f|f
33733090|NCT06153290|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blinded|Randomized, sham-controlled, proof-of-concept trial|t|f|f|f
33733091|NCT00623883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33733092|NCT04454450|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733093|NCT00153491|||DEFINED_POPULATION||PROSPECTIVE|||||||
33733094|NCT05459636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33733095|NCT05728164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33733096|NCT01501981|||COHORT||PROSPECTIVE|||||||
33733097|NCT05491603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733098|NCT03788733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733099|NCT03212703|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733100|NCT03265119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733101|NCT04596540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733102|NCT05869929|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33733103|NCT00607945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733104|NCT00571259|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33733105|NCT06007469|||COHORT||PROSPECTIVE|||||||
33733106|NCT02227524|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33733107|NCT06472804|||CASE_ONLY||CROSS_SECTIONAL|||||||
33733108|NCT05500859|||COHORT||PROSPECTIVE|||||||
34149158|NCT02795312|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33733109|NCT06095843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733110|NCT05996081|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A cluster randomised controlled trial consists of two parallel groups: group 1 gets a usual care (control), and group 2 receives a usual care and an adherence toolkit (intervention). The unit of randomisation is HIV clinic. Each HIV clinic will be randomly allocated to the intervention or control group. People living with HIV who are attending the clinic and receiving ART will be screened for their adherence prior to trial initiation. Those who are suspected to be nonadherent to HIV medications will be recruited to participate in the trial. The intervention period will last for 12 months for each participant in the intervention group, with equivalent follow-up period for participants in the control group. Outcome measures will be collected at 0, 3, 6, and 12 months.||||
33733111|NCT02260427|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33812997|NCT01000935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intevention involved PRP injection|t|f|f|t
33812998|NCT01973361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33812999|NCT06252454|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The subjects and investigators as well as care provider will not know the order of the studied substances given to subjects.|Two arms. Subjects in both arms will get first inhalation of furosemide or placebo in double blinded order. After cross over the subjects will get placebo instead of furosemide and vice versa. Lastly all subjects will get unblinded levodropropizine|t|t|t|f
33813000|NCT05905068|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||This is a randomized, placebo-controlled, single ascending-dose (SAD) study of RN0191 administered SC to adult subjects with elevated low-density lipoprotein-cholesterol. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study. In this SAD study, adult subjects with elevated LDL-C will be enrolled in up to 4 cohorts. Each cohort will comprise 8 subjects randomized in a 3:1 ratio (1:1 ratio for sentinel subjects; 5:1 ratio for non-sentinel subjects) to receive a single dose of RN0191 (n=6) or placebo (n=2), respectively.|t|f|f|f
33813001|NCT05124210|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label study.|||||
33813002|NCT02131454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33813003|NCT06253962|||COHORT||PROSPECTIVE|||||||
33813004|NCT04856384|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33813005|NCT05898789|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813006|NCT03258788|||COHORT||PROSPECTIVE|||||||
33813007|NCT02855762|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33813008|NCT00017355||||TREATMENT||||||||
33813009|NCT02078999|||OTHER||PROSPECTIVE|||||||
33813010|NCT00512265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813011|NCT02418286|||OTHER||PROSPECTIVE|||||||
33813012|NCT01381549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044120|NCT06270602|||COHORT||OTHER|||||||
34044121|NCT01602861|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34044122|NCT03386994|||COHORT||PROSPECTIVE|||||||
34044123|NCT02531477|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044124|NCT04544657|||OTHER||PROSPECTIVE|||||||
34044125|NCT02571101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044126|NCT06171087|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||Double blind, placebo controlled intervention with 20mg of Domperidon|t|f|t|t
34044127|NCT04091789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044128|NCT06576102|||COHORT||OTHER|||||||
34044129|NCT06021431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044130|NCT04372199|||COHORT||PROSPECTIVE|||||||
34044131|NCT04630691|||CASE_CONTROL||PROSPECTIVE|||||||
33733112|NCT00126295|RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
33733113|NCT04122833|||CASE_ONLY||PROSPECTIVE|||||||
33733114|NCT01655836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733115|NCT01954485|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33733116|NCT00215826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733117|NCT06343077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044132|NCT01997788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813013|NCT05344742|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813014|NCT00115167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813015|NCT04850092|||COHORT||PROSPECTIVE|||||||
33813016|NCT01164176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813017|NCT04883515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044133|NCT03759587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044134|NCT03674112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044135|NCT03424057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044136|NCT05616351|||COHORT||RETROSPECTIVE|||||||
34044137|NCT00857090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044138|NCT01778608|||COHORT||PROSPECTIVE|||||||
34044139|NCT03494634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044140|NCT05006430|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34044141|NCT06068985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044142|NCT02008695|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044143|NCT03554967|||OTHER||OTHER|||||||
33733118|NCT01037790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813018|NCT04518865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813019|NCT00749827|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813020|NCT02858206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813021|NCT00423215|||COHORT||PROSPECTIVE|||||||
33813022|NCT06094439|||OTHER||CROSS_SECTIONAL|||||||
33813023|NCT03204773|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33813024|NCT00785031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044144|NCT03620305|||COHORT||RETROSPECTIVE|||||||
34044145|NCT02148796|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34044146|NCT04199169|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Ascending dose study|t|t|t|f
34044147|NCT00570687|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044148|NCT05508698|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patient-participants will not be explicitly told about the different arms, although clinician-participants will see the different arms and may notice these differences.||t|f|f|f
34044149|NCT01609010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044150|NCT00686829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813025|NCT02470312|||COHORT||PROSPECTIVE|||||||
33813026|NCT05815459|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33813027|NCT02923349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120710|NCT05391230|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double|This is a double-blind, randomized controlled trial of permethrin-treated lesus to prevent P. falciparum malaria in children 6-18 months of age. Study enrollment conducted at two sites in rural western Uganda. Participants will be randomized to one of two arms: permethrin-treated (intervention) or untreated (control) lesus. Participating mother-infant pairs will receive a new Long-lasting Insecticidal Net and two permethrin-treated or untreated lesus at enrollment. Total sample size will be 400 mother-infant pairs with 200 pairs in each arm. Participants will be followed longitudinally for six months, instructed and incentivized to present to one of the two study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will attend scheduled clinic visits every two weeks for routine surveillance of adverse effects and tested for asymptomatic infection. Re-treatment and sham re-treatment of lesus will occur monthly.|t|t|f|f
34120711|NCT06715189|||COHORT||CROSS_SECTIONAL|||||||
34120712|NCT02598037|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34120713|NCT03172143|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with Crohns Disease will be randomized in a 1:1 ratio for mesenteric sparing versus high ligation of the ileocolic artery when performing an ileocolic resection for Crohn's disease.||||
34120714|NCT02099825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120715|NCT03264144|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120716|NCT03764969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120717|NCT03166930|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be randomized to receive one of two exercise programs. Participants will not be masked regarding which group they are in, but they will not be told which group is considered standard of care and which is the intervention.|f|f|f|t
34120718|NCT00487981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120719|NCT02636296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120720|NCT03109405|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34120721|NCT05809089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34120722|NCT03816189|||CASE_CONTROL||PROSPECTIVE|||||||
34120723|NCT03237806|RANDOMIZED|CROSSOVER||SCREENING||NONE|No Masking|Self control||||
34120724|NCT03566420|||OTHER||CROSS_SECTIONAL|||||||
34120725|NCT06715839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120726|NCT05526755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120727|NCT00256126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120728|NCT02343315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120729|NCT05538806|||OTHER||PROSPECTIVE|||||||
34120730|NCT04911491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120731|NCT06715475|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34120732|NCT02086695|||COHORT||PROSPECTIVE|||||||
34120733|NCT00022178||||TREATMENT||||||||
34120734|NCT04391712|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will utilize a randomized parallel assignment||||
34120735|NCT02250417|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34120736|NCT06389058|||OTHER||CROSS_SECTIONAL|||||||
34120737|NCT02794571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120738|NCT03894891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120739|NCT02374125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120740|NCT02475421|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34120741|NCT04584047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120742|NCT05249686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a randomized controlled trial with 3 different groups|t|f|f|t
34120743|NCT01758094|||CASE_CONTROL||PROSPECTIVE|||||||
34120744|NCT01027429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733119|NCT00433992|||COHORT||PROSPECTIVE|||||||
33733120|NCT04379167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733121|NCT01701661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733122|NCT05233878|||COHORT||PROSPECTIVE|||||||
33733123|NCT00578565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733124|NCT03252691|||COHORT||PROSPECTIVE|||||||
33733125|NCT05198791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be masked on their assignment to either the control group vs. registry.~Assessors for the primary outcome (laboratory measurement) will be blinded to treatment group assigment."|Prospective, randomised, open-label, blinded, end-point (mechanistic, PROBE design).|t|f|f|t
33733126|NCT01870128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733127|NCT05685797|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733128|NCT01561768|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33733129|NCT01451424|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733130|NCT03811730|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33733131|NCT02090816|||COHORT||RETROSPECTIVE|||||||
33733132|NCT06399328|||COHORT||CROSS_SECTIONAL|||||||
33733133|NCT05923424|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33733134|NCT03837262|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study assessing the use of flash glucose monitoring together with structured education to improve outcomes in Type 2 diabetes.||||
33733135|NCT05961891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733136|NCT00855140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects were unaware of whether they were receiving verum or sham treatment.||t|f|t|t
33733137|NCT01469325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733138|NCT06184334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733139|NCT00460941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813028|NCT01195584|||COHORT||RETROSPECTIVE|||||||
34120745|NCT02315092|||CASE_ONLY||PROSPECTIVE|||||||
34120746|NCT02868853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120747|NCT01336816|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34120748|NCT01526629|||COHORT||PROSPECTIVE|||||||
34120749|NCT01601184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120750|NCT04837430|||CASE_CROSSOVER||PROSPECTIVE|||||||
34120751|NCT05799118|||COHORT||PROSPECTIVE|||||||
34120752|NCT02550015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813029|NCT01843920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813030|NCT04820088|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34120753|NCT02962921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120754|NCT03557125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Following informed consent, all patients will be positioned, prepped and sedated for a quadratus lumborum block in the preoperative holding area to blind the patient, surgeon, intraoperative anesthesia team and data collectors. The patient will be positioned in the lateral decubitus position with the operative side up and pulse oximetry and blood pressure cuff placed for monitoring.|"The patient will be positioned in the lateral decubitus position with the operative side up and pulse oximetry and blood pressure cuff placed for monitoring. The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point. If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance."|t|f|f|f
34120755|NCT04468373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120756|NCT03101800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120757|NCT02213029|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34120758|NCT03794973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Subjects will be randomly assigned to treatment with TOL-3021 or placebo in a 2:1 fashion|t|t|t|f
34120759|NCT03059784|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34120760|NCT03534050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120761|NCT01263327|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34120762|NCT06179979|||COHORT||PROSPECTIVE|||||||
34120763|NCT02512380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120764|NCT01883024|NA|SINGLE_GROUP||OTHER||NONE||||||
34120765|NCT04280003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment and placebo solutions have identical appearance. Protocols will be designed to ensure that the physician evaluating patient safety and efficacy outcome as well as laboratory analysis, will not have access to the randomisation codes.|Two different treatment grupos; intravenous alogenic adipose tissue-derived mesenchymal stem cells or intravenous placebo solution|t|t|t|t
34120766|NCT06559462|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients and providers will either participate in focus groups or complete a survey to provide feedback on developing nudges||||
34120767|NCT02823002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34120768|NCT00093366||||TREATMENT||||||||
34120769|NCT04409834|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized-controlled trial - 1) full-dose anticoagulation (FDAC) versus standard-dose prophylactic anticoagulation (SDPAC) (pooled across antiplatelet regimens) and in a subset of patients 2) antiplatelet (AP) versus no AP therapy (pooled across anticoagulant regimens)||||
34120770|NCT05398016|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm pilot trial||||
34120771|NCT01930474|||CASE_ONLY||PROSPECTIVE|||||||
34120772|NCT01665313|||COHORT||CROSS_SECTIONAL|||||||
34120773|NCT05754957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120774|NCT02311803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120775|NCT01111643|||COHORT||PROSPECTIVE|||||||
34120776|NCT04608877|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34120777|NCT00098800|RANDOMIZED|||PREVENTION||DOUBLE||||||
34120778|NCT06251414|RANDOMIZED|PARALLEL||TREATMENT||NONE||There is no specific relevant model to refer to for use.||||
34120779|NCT03813017|||COHORT||PROSPECTIVE|||||||
34120780|NCT01394380|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120781|NCT00465426|||CASE_CONTROL||PROSPECTIVE|||||||
34120782|NCT04357899|||COHORT||PROSPECTIVE|||||||
34120783|NCT02442050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120784|NCT00692003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120785|NCT06395701|||COHORT||RETROSPECTIVE|||||||
34120786|NCT03180229|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34120787|NCT03603158|||OTHER||CROSS_SECTIONAL|||||||
34120788|NCT00300378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120789|NCT02928861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120790|NCT06715969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Myofascial release will be applied to one group, miofascial induction treatment will be applied to the other group.|t|f|t|t
34120791|NCT05910567|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients meeting enrollment criteria will be randomized to the FAST examination arm or to a standard of care/non-FAST examination arm using computer randomized order of enrollment. Randomization will be stratified by site and age group. Age groups will consist of participants 0 to their 3rd birthday and participants 3 years of age up to their 18th birthday. A minimum of 794 participants will be enrolled in the 0 to younger than 3 years of age group. To ensure concealment, opaque envelopes will be prepared at each study site using the randomization scheme provided by the lead institution. These envelopes will be readily available in the ED, provide the investigator with the randomized assignment, and contain the appropriate data collection form.||||
34120792|NCT04140617|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34120793|NCT01473030|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33813031|NCT01372800|||COHORT||PROSPECTIVE|||||||
33813032|NCT03471793|||COHORT||PROSPECTIVE|||||||
33813033|NCT04750109|||OTHER||PROSPECTIVE|||||||
33813034|NCT02556697|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813035|NCT04401943|NA|SINGLE_GROUP||OTHER||NONE||||||
33813036|NCT02045914|RANDOMIZED|PARALLEL||||NONE||||||
33813037|NCT05962099|||CASE_CONTROL||PROSPECTIVE|||||||
33813038|NCT00644501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813039|NCT06505096|||CASE_ONLY||OTHER|||||||
33813040|NCT00051753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813041|NCT01990183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33813042|NCT00603798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813043|NCT00663429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733140|NCT01263288|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733141|NCT04924777|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33733142|NCT05345210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733143|NCT05287464|||COHORT||OTHER|||||||
33733144|NCT01769885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733145|NCT01697657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733146|NCT06152965|||COHORT||PROSPECTIVE|||||||
33733147|NCT02373358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733148|NCT01638338|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733149|NCT02907359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733150|NCT03091803|||CASE_ONLY||PROSPECTIVE|||||||
33733151|NCT02424240|||||RETROSPECTIVE|||||||
33733152|NCT05162872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733153|NCT01794104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733154|NCT06662825|||COHORT||RETROSPECTIVE|||||||
33733155|NCT04655911|||COHORT||PROSPECTIVE|||||||
33733156|NCT03413332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733157|NCT00462956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733158|NCT03460522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733159|NCT03955042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733160|NCT02177240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33733161|NCT03550924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The monitor measuring the main outcome parameter will be in a separate room|Prospective, single center, randomized, observer blinded, controlled|f|f|t|f
33733162|NCT00145054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733163|NCT02232659|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733164|NCT06038838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733165|NCT01864291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733166|NCT01121211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733167|NCT03523559|||CASE_CONTROL||PROSPECTIVE|||||||
33733168|NCT04751305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The certified exercise physiologists (CEP) instructing the exercise classes were unaware of the intervention each participant was assigned to. The CEP administering the physical functioning assessment was unaware of the participants intervention and was not the participants exercise class instructor.|At the beginning of the remote ACE maintenance program participants are randomized into either the exercise only group or the exercise with additional health coaching group.|f|t|f|t
33733169|NCT00222495|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733170|NCT04992559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733171|NCT06345638|||COHORT||PROSPECTIVE|||||||
33733172|NCT00394797|||COHORT||RETROSPECTIVE|||||||
33733173|NCT02142530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733174|NCT02720913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733175|NCT02553421|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733176|NCT05120167|RANDOMIZED|PARALLEL||PREVENTION||NONE||Study design Clinical, randomized, controlled trial to evaluate the performance of tests for diagnosing precursor and invasive lesions in the endocervical canal.||||
33733177|NCT01093404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733178|NCT02399150|||COHORT||PROSPECTIVE|||||||
33733179|NCT00646204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733180|NCT06042088|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33733181|NCT01018420|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33733182|NCT01093339|||CASE_CONTROL||PROSPECTIVE|||||||
33733183|NCT04171414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813044|NCT01231074|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813045|NCT03137459|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33733184|NCT04788914|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733185|NCT04039061|||COHORT||OTHER|||||||
33733186|NCT01177033|||COHORT||PROSPECTIVE|||||||
33733187|NCT01690039|||CASE_ONLY||PROSPECTIVE|||||||
33813046|NCT01633359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733188|NCT02467725|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33733189|NCT01826500|||CASE_CONTROL||PROSPECTIVE|||||||
33733190|NCT00226616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733191|NCT06663709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733192|NCT04409041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733193|NCT01420081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733194|NCT06072235|||COHORT||PROSPECTIVE|||||||
33733195|NCT05621564|||COHORT||OTHER|||||||
33733196|NCT03619421|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Random number used to label samples||f|f|f|t
33733197|NCT03707288|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33733198|NCT00132340||||TREATMENT||||||||
33733199|NCT03619395|||COHORT||PROSPECTIVE|||||||
33733200|NCT02310672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733201|NCT04582552|||OTHER||PROSPECTIVE|||||||
33733202|NCT03125369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733203|NCT05907135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Investigators and study participants will be blind to treatment allocation, with the beet-based supplement and placebo supplement of the same color and taste.|Randomized treatment, double blinded procedures, crossover|t|f|t|f
33733204|NCT05120193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to treatment assignment||t|f|f|f
33813047|NCT03779945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the person performing the statistical analysis shall be masked|single center, prospective randomized comparative trial|f|f|f|t
33813048|NCT01260259|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33838477|NCT01395069|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33838478|NCT03437889|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838479|NCT06541496|||COHORT||PROSPECTIVE|||||||
33838480|NCT05053880|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1b dose exploration will enroll up to a maximum of 18 patients. Phase 2a, randomized/2-treatment arm part, will enroll up to 30 patients in two treatment arms. Arm A (treatment with Pembrolizumab) will enroll 10 patients. Arm B (treatment with the combination ACT001 plus Pembrolizumab) will enroll 20 patients.||||
33838481|NCT01803581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34120794|NCT03119168|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|t|f
34120795|NCT01605669|||COHORT||PROSPECTIVE|||||||
34120796|NCT05604261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120797|NCT06132178|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||This will be a phase II 2x2 design (device and dose) clinical trial. 100 participants, ages 22-65, with treatment-resistant MDD will be randomized to treatment with either: a) 25mg of COMP360 (N=50); or b) 1mg of COMP360 (low-dose comparator; N=50) with appropriate psychological preparation, support, and integration sessions with trained therapists. This will then be directly followed by one of two subsequent treatment conditions: i) the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold50,51; or ii) sham iTBS delivered in the same fashion.|t|t|t|f
34120798|NCT06717126|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised parallel-arm, open-label||||
34120799|NCT05670327|||COHORT||PROSPECTIVE|||||||
34120800|NCT02169310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34120801|NCT02655107|||COHORT||PROSPECTIVE|||||||
34120802|NCT05677100|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomized 1:1 and will be receiving their treatment in parallel to each other. An additional non-randomized registry is also included||||
34120803|NCT06714877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120804|NCT06714968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The study was single-blind and the participants were blinded.|This study was a randomized, single-blind, parallel group-controlled trial.|t|f|f|f
34120805|NCT02373618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120806|NCT06563310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All staff present during the MRI session, as well as the participant, will be blinded to group assignment. The Study Coordinator will remain unblinded during the duration of the study.||t|t|f|f
34120807|NCT06252714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120808|NCT02747147|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34120809|NCT01101607|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34120810|NCT06718842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120811|NCT03212352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients will be randomized to oral mifepristone (600mg) or oral placebo (identical in appearance).|t|t|f|f
34120812|NCT01507701|NA|SINGLE_GROUP||||NONE||||||
34120813|NCT00981721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120814|NCT00527228|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34120815|NCT05224661|||OTHER||PROSPECTIVE|||||||
34120816|NCT04902391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic, parallel arm cluster randomized trial||||
34120817|NCT06486181|RANDOMIZED|PARALLEL||TREATMENT||NONE||"After enrollment, patients will be randomized with 1:1 ratio by a web-based randomization tool.~Control Arm:~Control arm will be the continuation of current anticoagulation treatment, which is standard of care for 12 months unless crossover between groups is needed.~Intervention Arm:~Patients will undergo either CDT or MT procedures both of which have been cleared by FDA for the treatment of acute DVT. FDA-cleared endovascular devices currently available at our institution will be used for both procedures. The choice of procedure will be based on operator's preference, availability of device and the patient's bleeding risk. The endovascular procedure will be scheduled within 15 days of the initial symptoms.~Patients' post-procedural Villalta scores and Marder Scores of pre/post-procedure venography and duplex ultrasound will be recorded at discharge."||||
34120818|NCT03151031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be informed about the reason for performing the star excursion balance test before and after the application of cryotherapy||t|f|f|f
34120819|NCT04319172|||COHORT||PROSPECTIVE|||||||
34120820|NCT06443892|||CASE_CONTROL||PROSPECTIVE|||||||
34120821|NCT00419055|||CASE_CONTROL||PROSPECTIVE|||||||
34120822|NCT06718153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Diagnostic identification of possible associations between the biomarkers p53 and beta-Catenin and the presence of the genetic mutations TERT, TP53 and CTNNB1 identified by clinical practice, in patients undergoing hepatic resection of HCC||||
34120823|NCT01829568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120824|NCT06358521|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the new model of care and comparison, it is not possible to blind the patient participants or health care providers. Since the primary outcomes are self-reported outcome measures, the assessor is also not blind to the intervention.|This is a cluster randomized controlled trial randomizing 14 sites to the PT-led primary care model for hip/knee pain or to the usual physician/nurse practitioner-led care model||||
34120825|NCT05960357|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34120826|NCT05518461|NA|SINGLE_GROUP||OTHER||NONE||Preliminary outcomes will be measured from 60 participants at baseline (pre-test), followed by a 12-week intervention through the Thrive4Life Connect smartphone application, and re-assessment of outcomes at months 3 and 6.||||
34120827|NCT04622410|||COHORT||OTHER|||||||
34120828|NCT06716905|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34120829|NCT03950635|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34120830|NCT03761056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120831|NCT05465954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120832|NCT04934683|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34120833|NCT04076267|||OTHER||PROSPECTIVE|||||||
34120834|NCT06619821|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34120835|NCT02332928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34120836|NCT03249402|NA|SINGLE_GROUP||OTHER||NONE||||||
34120837|NCT06713265|||COHORT||PROSPECTIVE|||||||
34120838|NCT04390399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120839|NCT06187324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||two groups comparison,symptomatic and asymptomatic||||
34149159|NCT02479776|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33733205|NCT05521204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733206|NCT02040662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733207|NCT01899469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733208|NCT03904459|||CASE_CONTROL||PROSPECTIVE|||||||
33733209|NCT02259491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733210|NCT05475184|NA|SINGLE_GROUP||TREATMENT||NONE||This study will be conducted with subjects with HRD-positive, platinum-resistant, advanced/relapsed ovarian cancer with a history of ARP inhibitor treatment using Simon's optimal two-stage design. When the confirmed response is observed in ≥3 out of 18 subjects who are available for tumor assessment in Stage 1, the subjects will proceed with Stage 2. After additional enrollment of 40 subjects who are available for tumor assessment in Stage 2, the assessment will be conducted to identify that the confirmed response is observed in ≥11 out of the final 58 subjects.||||
33733211|NCT05564520|||COHORT||CROSS_SECTIONAL|||||||
33733212|NCT01860417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33733213|NCT04748510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733214|NCT01277588|||CASE_ONLY||PROSPECTIVE|||||||
33733215|NCT01919424|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733216|NCT04871334|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33733217|NCT04631939|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33733218|NCT02435251|||CASE_ONLY||PROSPECTIVE|||||||
33733219|NCT00780221|||CASE_CONTROL||PROSPECTIVE|||||||
33733220|NCT02292628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733221|NCT02364310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733222|NCT00858390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733223|NCT00101101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733224|NCT00073671|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor were unaware of condition assignment||f|f|f|t
33733225|NCT05369910|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Due to the nature of the interventions, no blinding is possible, but both Flash and Dark interventions are presented as equivalently treatment options.|Participants receive light exposure therapy (Flash) and light deprivation therapy (Dark) for one hour daily on 7 consecutive days, in a crossover design with a wash-out period of 3 months. The sequence of the interventions is randomly allocated.||||
33733226|NCT05543785|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|An anesthetist, not involved in the study, was responsible for randomization list construction, in blocks, opening the sealed envelopes and so, the preparation of the study drugs. The patient and the data collectors (anesthesia resident) does not know the group assignment.||t|f|t|f
33733227|NCT06192004|||COHORT||PROSPECTIVE|||||||
33733228|NCT04640935|||COHORT||RETROSPECTIVE|||||||
33733229|NCT06026904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study will enroll two groups of patients with Major Depressive Disorder (MDD): one group will receive active transcutaneous auricular Vagus Nerve Stimulation (taVNS) treatment, while the other group will receive sham taVNS treatment (the same flow path, but targeting a different stimulation site).|t|f|t|t
33733230|NCT04652128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733231|NCT00964808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733232|NCT00689481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733233|NCT01333488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733234|NCT02306980|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813049|NCT06129188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Of note, given the differences between propofol (premixed suspension, white color, weight-based dosing, often given via infusion, boluses typically vary from 3-10 mL doses) and remimazolam (requires reconstitution, clear color when reconstituted, non-weight-based dosing, only FDA approved for intermittent bolus administration, only FDA approved for boluses of 1-2 mL doses), it would not be possible for providers to be blinded to treatment group. Subjects and observers monitoring the MOAA/S level of sedation, however, will be blinded to treatment group.|After consenting to participate in the study, participants will undergo randomization in to one of two groups: those receiving remimazolam for sedation and those receiving propofol for sedation.|t|f|f|f
33813050|NCT03989609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813051|NCT00992745|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33813052|NCT01328756|NA|SINGLE_GROUP||OTHER||NONE||||||
33813053|NCT05230394|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813054|NCT04221321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733235|NCT00799149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733236|NCT05540366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733237|NCT06208241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733238|NCT02129361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733239|NCT01304485|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733240|NCT01918475|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33733241|NCT03251248|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33733242|NCT04441294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813055|NCT02607956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813056|NCT06160453|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants are assigned to one of two or more groups in parallel for the duration of the study (Parallel Assignment)||||
33813057|NCT04221165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813058|NCT03660527|||OTHER||CROSS_SECTIONAL|||||||
33813059|NCT03151694|||COHORT||CROSS_SECTIONAL|||||||
33813060|NCT03301597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This is an open-label study.|Subjects will be randomized to 1 of 3 Investigational Arms or a Control Arm in a 1:1:1:1 ratio.|f|f|f|t
33813061|NCT06462378|NA|SINGLE_GROUP||TREATMENT||NONE||Proton therapy||||
33813062|NCT04769921|||COHORT||PROSPECTIVE|||||||
34120840|NCT06489366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients and data analysts were blinded to the allocation measures.||t|f|f|f
34120841|NCT01695018|||COHORT||PROSPECTIVE|||||||
34120842|NCT06190834|||COHORT||PROSPECTIVE|||||||
34120843|NCT05963438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120844|NCT00002139||||TREATMENT||NONE||||||
34120845|NCT05524831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2|t|f|f|f
34120846|NCT01302925|RANDOMIZED|PARALLEL||||NONE||||||
34120847|NCT01011114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733243|NCT04073095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are three models for this study. The first group is erector spinae plane block group, the second one is modified-thoracolumbar interfascial plane block, the third group is the no intervention control group|t|f|f|t
33733244|NCT01900470|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33733245|NCT02543931|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733246|NCT04090567|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733247|NCT01289925|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33733248|NCT03417141|NA|SINGLE_GROUP||TREATMENT||NONE||Adults patient with active Lichen Planopilaris or Frontal Fibrosing Alopecia||||
33733249|NCT05312736|||COHORT||PROSPECTIVE|||||||
33733250|NCT03258372|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33733251|NCT04520425|NA|SINGLE_GROUP||TREATMENT||NONE|As a single arm trial, all participants will know they are receiving a treatment. While the investigator and outcomes assessor will not know which particular patients reported individual responses, they will know that all patients received the same treatment.|Consenting chronic migraine patients will receive 3-5 standardized osteopathic manipulative treatments over the course of ten weeks, and will be assessed for acceptance and efficacy of the treatment.||||
33733252|NCT06662812|||COHORT||RETROSPECTIVE|||||||
33733253|NCT04085822|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33733254|NCT02405416|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33733255|NCT00461539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733256|NCT02044536|||CASE_CONTROL||RETROSPECTIVE|||||||
33733257|NCT01367808|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733258|NCT00728377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733259|NCT04604457|RANDOMIZED|CROSSOVER||SCREENING||NONE||Step-wedge design with 7 wedges: the first wedge has all primary care teams in the standard of care arm; every six weeks one or two care teams switch to the intervention arm.||||
33733260|NCT06087172|||COHORT||CROSS_SECTIONAL|||||||
33733261|NCT02868762|||COHORT||CROSS_SECTIONAL|||||||
33733262|NCT04891939|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|At the time of recruitment, all school administrations, parents, and students will be blinded to the group assignments, i.e., whether the school belonged to the intervention or the control group. A survey at the end of the intervention in the 3rd month will be conducted by an external individual who will be blinded to school allocation. The data analysis will be performed by a researcher from the team who will also be blinded to allocation.|A two-arm parallel assignments to either an intervention or control from randomly selected schools|t|f|f|t
33733263|NCT06027281|||CASE_CONTROL||RETROSPECTIVE|||||||
33733264|NCT03097653|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733265|NCT02383446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733266|NCT00003082||||TREATMENT||||||||
33733267|NCT00865722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733268|NCT02827292|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33733269|NCT02240381|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33733270|NCT02993575|||CASE_ONLY||PROSPECTIVE|||||||
33813063|NCT05773872|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33733271|NCT01263574|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33733272|NCT06017661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33733273|NCT06390020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733274|NCT06089720|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|When applications of orthodontic molar tubes to patients mouth through routine orthodontic treatment, the clinicians will explain the procedure to patients without knowing the about which side coated or not .|72 orthodontic molar tubes will be divided in two groups control 36 uncoated OMT, and 36 experimental groups that will receiving the zinc oxide nanoparticle coating.|t|f|f|t
33733275|NCT03611725|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized either distal radial approach or radial approach.||||
34120848|NCT06135688|||COHORT||PROSPECTIVE|||||||
33733276|NCT00832208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733277|NCT03027466|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733278|NCT02974985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733279|NCT00333112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733280|NCT05973838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At 3-month, 6-month and 12-months following the baseline assessment, a trained and randomization-blinded member of the research team will complete assessments with the participant.|Participants will be randomized in parallel to receive either the Peer Activate intervention on the MTU or enhanced treatment as usual (TAU: treatment as usual services on the MTU in addition to referral to other available services in the community through study contact). Assessments will take place for both groups at baseline, at a midpoint (1-month), and follow ups at 3-month, 6-month and 12-months following the baseline assessment. Follow up assessments will be conducted by a blinded assessor.|f|f|f|t
33813064|NCT03958266|||COHORT||PROSPECTIVE|||||||
33813065|NCT06390176|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813066|NCT06134232|RANDOMIZED|PARALLEL||TREATMENT||NONE||AN OPEN-LABEL, MULTICENTER STUDY OF SUBJECTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER TREATED WITH PROVENGE AND BOOSTED WITH A SINGLE INFUSION OF SIPULEUCEL-T TO MEASURE IMMUNE RESPONSE||||
33813067|NCT06317610|||COHORT||OTHER|||||||
33813068|NCT01189045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813069|NCT05244954|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory technicians processing samples will be blinded to participant's study arm.|Students will be randomized to intermittent screening-and-treatment (IST - Arm 1), intermittent preventive treatment (IPT - Arm 2), or control with no preventive treatment (Arm 3). Females less that 10 years of age (pre-menarche) and all males will be treated with DP if they are in Arm 2 or test positive in Arm 1. Females 10 years and older will be treated with chloroquine if they are in Arm 2 or test positive in Arm 1.|f|f|f|t
33733281|NCT05891236|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
33733282|NCT05593224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733283|NCT01109316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813070|NCT04316494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Central trial pharmacist will be unblinded during trial.||t|t|t|t
34120849|NCT05752656|||COHORT||PROSPECTIVE|||||||
33733284|NCT01502644|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the first 2 weeks of treatment participants took short-acting morphine or oxycodone for 1 week and placebo for 1 week in random order. Participants and investigators were blinded during this period. The remainder of the study was conducted in an open-label design.||t|f|t|f
34120850|NCT00003816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120851|NCT02605408|||COHORT||PROSPECTIVE|||||||
34120852|NCT02947191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120853|NCT03026244|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34120854|NCT06670378|||COHORT||PROSPECTIVE|||||||
34120855|NCT06715085|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120856|NCT05883202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120857|NCT03490929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120858|NCT05385211|||CASE_ONLY||CROSS_SECTIONAL|||||||
34120859|NCT06711276|||COHORT||PROSPECTIVE|||||||
34120860|NCT04255784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120861|NCT05641402|NA|SINGLE_GROUP||OTHER||NONE||||||
34120862|NCT03695887|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized to receive either active study article or inactive comparator then crossed over to other treatment arm on next dressing change.|t|f|f|t
34120863|NCT01643681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120864|NCT03851640|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34120865|NCT01894490|||COHORT||PROSPECTIVE|||||||
34120866|NCT05592301|||COHORT||PROSPECTIVE|||||||
34120867|NCT04217018|||COHORT||OTHER|||||||
34120868|NCT04953611|||COHORT||PROSPECTIVE|||||||
34120869|NCT02012218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120870|NCT06495073|||COHORT||PROSPECTIVE|||||||
34120871|NCT05454280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible adult patients with probable or histologically/cytologically confirmed, primary or recurrent, malignant neoplasms (any stage) scheduled to undergo elective major cancer surgery at FCCC who meet eligibility criteria will be stratified by procedure type and randomized to the Intervention Arm or Control Arm.||||
34120872|NCT04534413|||OTHER||PROSPECTIVE|||||||
34120873|NCT06172582|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||This behavioral weight loss intervention will span 12 weeks. Participants will be randomized to one of two groups within ward (intervention and delayed intervention control) wherein all participants will receive the same 12-week program.||||
34120874|NCT06715267|||OTHER||CROSS_SECTIONAL|||||||
34120875|NCT04218812|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Evaluation of automated electrical source imaging(ESI) in epilepsy surgery.|f|f|f|t
34120876|NCT02022709|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34120877|NCT06716931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120878|NCT03809273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120879|NCT04743713|||OTHER||PROSPECTIVE|||||||
34120880|NCT06646952|||CASE_ONLY||PROSPECTIVE|||||||
34120881|NCT06719193|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||A sequential exploratory mixed-method study with a dominant controlled before-after (or quasi-experimental) design will be the main design of this study, followed by qualitative methods. The aim of the qualitative component is to explore whether the ETB intervention package is feasible and helps achieve TB elimination in Ethiopia. In-depth interviews (IDIs) and focus-group discussions (FGDs) with TB program managers and health extensions workers, community leaders, and selected heads of households involved the study will be conducted.||||
34120882|NCT05468502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120883|NCT04494360|||OTHER||CROSS_SECTIONAL|||||||
34120884|NCT04683705|||COHORT||CROSS_SECTIONAL|||||||
34120885|NCT05691192|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcome assessors will be blinded as to the participant's assigned intervention.|The study will use a randomized, controlled crossover design to investigate the impact of cognitive leisure activities on cognitive function in individuals with multiple sclerosis (MS). 60 participants with RRMS or progressive MS (30 RRMS, 30 PPMS/SPMS) will be randomly assigned to either an intervention group (Group A) or a passive control group (Group B) for 12 weeks. Participants will be randomized using a computer-based random number generator in blocks of 6 based on MS subtype (RRMS/progressive MS). After the initial 12 weeks, the groups will be crossed over and followed for an additional 12 weeks. The passive control group will also receive an additional follow-up after 36 weeks. The total time from enrollment to last follow-up will be 24 weeks for Group A and 36 weeks for Group B.|f|f|f|t
34120886|NCT06719115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120887|NCT05993741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34120888|NCT04781140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120889|NCT01800786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34120890|NCT06226961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34120891|NCT05658328|RANDOMIZED|PARALLEL||OTHER||NONE||Triads are randomized into either the intervention group or the waitlist control group. The intervention group walks for 16 weeks. The waitlist control group completes baseline measures for 16 weeks then continues measures while walking 16 weeks. Wearable technology and weekly surveys are optional for PLWD.||||
34120892|NCT06042426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34120893|NCT00577278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733285|NCT05402943|||CASE_CONTROL||PROSPECTIVE|||||||
33733286|NCT04569851|||OTHER||RETROSPECTIVE|||||||
33733287|NCT04935151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733288|NCT01178970|RANDOMIZED|SINGLE_GROUP||||||||||
33733289|NCT02777762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733290|NCT00650039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733291|NCT00896545|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733292|NCT01161758|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33733293|NCT04671459|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, phase II trial enrolling participants with recurrences or progressive tumor, who will be treated with radiosurgery and TTFields. The investigators will attempt to enroll the maximum number of patients and expect to enroll 40 subjects. All subjects will receive TTFields and radiosurgery plus/minus FET PET imaging to define tumor volume.||||
33733294|NCT03629015|NA|SEQUENTIAL||TREATMENT||NONE||||||
33733295|NCT01110629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733296|NCT06662565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733297|NCT04376034|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Prospective intervention||||
33733298|NCT00013117|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33733299|NCT03623516|||COHORT||RETROSPECTIVE|||||||
33733300|NCT00178438|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733301|NCT00080223|NA|SINGLE_GROUP||OTHER||NONE||||||
33733302|NCT03940378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733303|NCT04870892|||COHORT||PROSPECTIVE|||||||
33733304|NCT01829932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733305|NCT01588782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733306|NCT00591448|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33733307|NCT02863978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733308|NCT03394014|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33733309|NCT04032756|||COHORT||PROSPECTIVE|||||||
33733310|NCT04677946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733311|NCT05315271|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33733312|NCT00749931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733313|NCT04913428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733314|NCT02340234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733315|NCT01457872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733316|NCT04152447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733317|NCT01713868|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33733318|NCT01565135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33733319|NCT00653354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733320|NCT02479854|RANDOMIZED|CROSSOVER||||NONE||||||
33733321|NCT03903666|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Down syndrome patients aged from 4 to 16 years||||
33733322|NCT00791791|RANDOMIZED|||DIAGNOSTIC||||||||
33733323|NCT03979443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33733324|NCT02188381|||COHORT||PROSPECTIVE|||||||
33733325|NCT01209624|||COHORT||PROSPECTIVE|||||||
33733326|NCT02177266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733327|NCT03528434|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized, placebo-controlled, double blind clinical trial|t|t|t|f
33733328|NCT04535128|||COHORT||CROSS_SECTIONAL|||||||
33733329|NCT06074575|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33733330|NCT01655667|||COHORT||RETROSPECTIVE|||||||
33733331|NCT00401011|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In the Phase I part, maximum tolerated dose (MTD) is determined in sequential cohorts of patients. All patients will start with perifosine and bortezomib (cf. arms and interventions). In case of progression, dexamethasone 20 mg will be added to treatment. Phase II: open-label single treatment arm.||||
33733332|NCT01639027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733333|NCT02510911|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733334|NCT06287060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733335|NCT04084353|||COHORT||PROSPECTIVE|||||||
33733336|NCT02477475|||COHORT||PROSPECTIVE|||||||
33733337|NCT04634292|||COHORT||PROSPECTIVE|||||||
33813071|NCT03874091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733338|NCT06100991|||COHORT||PROSPECTIVE|||||||
33733339|NCT03211741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733340|NCT02069561|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733341|NCT00909636|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33733342|NCT00183872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733343|NCT03641378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733344|NCT01506531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813072|NCT03757767|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Research subjects are measured in the fed state and in the prolonged fasted state.||||
33733345|NCT02457494|||COHORT||PROSPECTIVE|||||||
33733346|NCT00495716|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733347|NCT05925894|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this retrospective study, we collected pre- and post-operative data from 60 patients who underwent elective cataract extractions.||||
33733348|NCT00354224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733349|NCT06010394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||classical physical therapy, exercise therapy, classical massage|f|f|f|t
33733350|NCT02379585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733351|NCT03040297|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33733352|NCT00270972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733353|NCT06467266|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an observational cohort mechanistic study.||||
33733354|NCT02376166|NA|SINGLE_GROUP||OTHER||NONE||||||
33733355|NCT06354153|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|A quasi-experimental design utilized one group for pre-, post, and follow-up intervention.||t|f|f|f
33733356|NCT03918343|NA|SINGLE_GROUP||OTHER||NONE||||||
33733357|NCT02488785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733358|NCT01950546|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33733359|NCT04564625|||CASE_ONLY||RETROSPECTIVE|||||||
33733360|NCT03192150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733361|NCT06048484|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733362|NCT01589822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733363|NCT01486017|RANDOMIZED|CROSSOVER||||NONE||||||
33733364|NCT04989049|RANDOMIZED|PARALLEL||TREATMENT||NONE||75 patients divided into two groups 35 in each||||
33733365|NCT01211275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733366|NCT01947400|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33813073|NCT01821040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813074|NCT06210555|||COHORT||PROSPECTIVE|||||||
33813075|NCT00873626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813076|NCT01724905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813077|NCT01644604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838482|NCT02381353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33733367|NCT02537418|NA|SINGLE_GROUP||OTHER||NONE||||||
33733368|NCT03218111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733369|NCT01971827|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33733370|NCT06168526|NA|SINGLE_GROUP||SCREENING||NONE|The assignment to the different conditions will be carried out using a random number generation program stratifying by sex (i.e., the randomizer.org tool).|The study will be carried out following a crossover design with comparisons between the subjects, in which the cognition and the affective dimensions will be analysed before and after each experimental condition (acute exercise vs. sedentary control).||||
33733371|NCT03112161|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33733372|NCT02672371|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33733373|NCT06341127|NA|SINGLE_GROUP||TREATMENT||NONE|This quasi experimental design involves masking of transition moments, but the investigator and participant are aware of the order of cross-over.|||||
33733374|NCT03700359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733375|NCT06073977|||COHORT||PROSPECTIVE|||||||
33733376|NCT05476562|||COHORT||RETROSPECTIVE|||||||
33733377|NCT03722329|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33733378|NCT06021886|||COHORT||RETROSPECTIVE|||||||
33733379|NCT01999621|||COHORT||PROSPECTIVE|||||||
33733380|NCT05854693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733381|NCT05702320|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomized controlled experimental research|t|t|t|t
33733382|NCT02932891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733383|NCT03052582|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33733384|NCT00937638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733385|NCT02904811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33733386|NCT02358746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733387|NCT01406821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733388|NCT00004448|RANDOMIZED|||TREATMENT||DOUBLE||||||
33733389|NCT03662100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33733390|NCT03997318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733391|NCT03746522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813078|NCT04501588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who score/code the parent-child interaction are blind to condition|Children will enroll in the study between 18-48 months of age and will be randomly assigned to either receive responsive training with video feedback or responsive training without video feedback.|f|f|f|t
33813079|NCT02154945|||CASE_ONLY||PROSPECTIVE|||||||
33813080|NCT01542502|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33813081|NCT04301713|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33813082|NCT02107976|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813083|NCT04299009|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33733392|NCT01049724|||COHORT||PROSPECTIVE|||||||
33733393|NCT06469008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733394|NCT03893266|||OTHER||PROSPECTIVE|||||||
33733395|NCT06026891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Effectiveness of MG-K10 humanized monoclonal antibody injection in patients with moderate and severe atopic dermatitis Randomized, double-blind, placebo-controlled phase III clinical study with safety|t|t|t|t
33813084|NCT05155878|||COHORT||PROSPECTIVE|||||||
33813085|NCT03841253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 1 will be observational comparing the software predicted refractive change to the observed refractive change.~Phase 2 will use the software predicted refractive change to plan the refractive component of the treatment."||||
33813086|NCT04543188|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33813087|NCT01945086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813088|NCT03746015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813089|NCT03345407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind, sponsor- open study.|Subjects will be randomized to receive either nemiralisib (50-750 µg) or placebo in a parallel group.|t|f|t|f
33813090|NCT00872339|||COHORT||PROSPECTIVE|||||||
33813091|NCT02979678|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33813092|NCT03206398|NA|SINGLE_GROUP||TREATMENT||NONE||anti-gravity treadmill for a total of 40 days in addition to physiotherapy||||
33813093|NCT05303324|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813094|NCT01681563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813095|NCT00461188|||COHORT||PROSPECTIVE|||||||
34120894|NCT06317662|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34120895|NCT02866812|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733396|NCT03200613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Open Label||f|f|f|t
33733397|NCT03917134|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33733398|NCT01067703|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733399|NCT04919967|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733400|NCT00628550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733401|NCT03794843|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33733402|NCT03218722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733403|NCT03356210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants doing follow-up assessment will be blinded to condition assignment||f|f|f|t
33733404|NCT01644318|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733405|NCT01916304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733406|NCT01107470|||COHORT||PROSPECTIVE|||||||
33733407|NCT03801616|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33733408|NCT01800292|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733409|NCT00850200|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733410|NCT05035017|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33733411|NCT00373243|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733412|NCT04035720|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33733413|NCT04528758|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733414|NCT03211195|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813096|NCT05513027|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813097|NCT00827294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813098|NCT00007826||||TREATMENT||NONE||||||
33813099|NCT02194907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33733415|NCT01860261|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733416|NCT01836484|||CASE_ONLY||RETROSPECTIVE|||||||
33733417|NCT03710278|||CASE_ONLY||PROSPECTIVE|||||||
33733418|NCT02748577|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733419|NCT05053984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733420|NCT01983657|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733421|NCT01885481|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33733422|NCT01873482|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33733423|NCT01888497|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33733424|NCT04404959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33733425|NCT04623164|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33733426|NCT02601040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733427|NCT04643106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733428|NCT06019858|NA|SINGLE_GROUP||OTHER||NONE||||||
33733429|NCT04182581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733430|NCT01487005|||||PROSPECTIVE|||||||
33733431|NCT04548882|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm study design||||
33733432|NCT05993728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The assessor completing the diagnostic interview will be blinded to the condition the participant is in (at all assessments)||f|f|t|f
33733433|NCT02873013|||COHORT||PROSPECTIVE|||||||
33733434|NCT01182909|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733435|NCT02156427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||double-blind, prospective, multicenter, randomised, controlled trial patient is his own control|t|f|t|f
33733436|NCT00940303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733437|NCT03604055|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733438|NCT05410652|||OTHER||CROSS_SECTIONAL|||||||
33733439|NCT02214147|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733440|NCT05004259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733441|NCT01345084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733442|NCT02298738|||CASE_CONTROL||PROSPECTIVE|||||||
33733443|NCT01108549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733444|NCT06114862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33733445|NCT00723606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733446|NCT00243516|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733447|NCT03240575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733448|NCT02517905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733449|NCT03337633|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were blinded to treatment allocation.|Parallel arm randomized controlled trial|t|f|f|f
33733450|NCT03281070|||COHORT||RETROSPECTIVE|||||||
33813100|NCT00188812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813101|NCT04515576|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33813102|NCT06012032|||COHORT||OTHER|||||||
33733451|NCT00013130|RANDOMIZED|PARALLEL||||NONE||||||
33733452|NCT02111252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733453|NCT05862025|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Single arm study, no masking needed|A\>ll patients will undergo mandatory transesophageal and transthoracic echocardiography during the first 2 weeks after Staphylococcus aureus bacteremia onset||||
33733454|NCT01856543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733455|NCT02006238|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33733456|NCT03357406|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|treatment method is masked till the surgical procedure, during which, both surgeon and patient are informed|Split mouth design|f|f|t|t
33733457|NCT03641573|NA|SINGLE_GROUP||OTHER||NONE||||||
33733458|NCT04520945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The outcomes assessor will help to screen the participants and send them to the clinical investigators for further medical screening. The participant's personal details will be private and confidential to the outcomes assessor.|100 patients will be selected from 2 different study sites. Each study site comprises 50 patients.|t|f|t|f
33733459|NCT03436368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Using computer \& sealed envelope randomization, patients are assigned to receive either continuous spinal anesthesia \[CSA group: n =30\] or general anesthesia \[GA group: n=30\]|f|f|f|t
33733460|NCT04269603|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733461|NCT05689385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733462|NCT04340882|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2 with initial run-in safety||||
33733463|NCT05496725|RANDOMIZED|CROSSOVER||OTHER||NONE||An open-label, randomized, balanced, two-treatment, two-period, twosequence, single dose, two-way crossover study||||
33733464|NCT06406062|||OTHER||PROSPECTIVE|||||||
33733465|NCT00231608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733466|NCT06641856|||COHORT||PROSPECTIVE|||||||
33733467|NCT04015219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733468|NCT05994729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733469|NCT05178849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, controlled, randomized, single-blind, multicenter study comparing two approaches to analgesia during BOM.||||
33733470|NCT01689896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33733471|NCT05498636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733472|NCT00431457|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33733473|NCT05668767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733474|NCT03865290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733475|NCT04431362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The measures will be completed by the clinical psychologist while the diary and checklist will be done by the patients with assistance from the research student or activity coordinators.|Participants first complete a baseline phase before starting the intervention phase.|f|f|t|t
33813103|NCT01034813|||||PROSPECTIVE|||||||
33813104|NCT05473117|||COHORT||PROSPECTIVE|||||||
33813105|NCT03030651|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33813106|NCT03110783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813107|NCT04674605|||COHORT||PROSPECTIVE|||||||
33813108|NCT02488733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813109|NCT03956927|||COHORT||PROSPECTIVE|||||||
33733476|NCT04955106|NA|SINGLE_GROUP||PREVENTION||NONE||"The SEM Scanner is placed on three skin areas (left heel, right heel and sacrum). It measures the moisture of the subcutaneous tissues. If returns a figure wich induces a classification~* negative = value \<0.6 no risk, the figure is displayed in green~* positive = value ≥0.6 proven risk, the figure is displayed in orange~For each patient 3 measurements will be performed. Two of them will have been trained in the use of the SEM Scanner, whereas the others will be novice"||||
33733477|NCT03126097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733478|NCT01994304|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733479|NCT00179647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733480|NCT02041598|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33733481|NCT06366971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733482|NCT05023694|||COHORT||PROSPECTIVE|||||||
33733483|NCT03059381|||COHORT||PROSPECTIVE|||||||
33733484|NCT06198907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733485|NCT04194775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733486|NCT03932942|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized controlled trial 2:1||||
33733487|NCT05329597|||COHORT||PROSPECTIVE|||||||
33733488|NCT02097212|||COHORT||PROSPECTIVE|||||||
33733489|NCT01579396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733490|NCT04055116|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Designated Investigators will randomize participants and prepare the local anesthetic with or without buffered solution. The anesthetic will then be given to the care provider at time of procedure. The care provider and participant will not know if the buffered solution has been added or not.|This study has been designed as a longitudinal, double blind, crossover study. Specifically, a split mouth design will be implemented to investigate if there is a significant difference in pain perception between administering buffered local anesthesia versus conventional local anesthesia in a pediatric patient.|t|t|t|f
33733491|NCT04542070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733492|NCT04127760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733493|NCT03517267|||CASE_ONLY||PROSPECTIVE|||||||
33733494|NCT04522024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733495|NCT03560323|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Type 2 diabetic subjects with New York Heart Association (NYHA) Class II-III heart failure and ejection fraction \<50% (documented by patient's medical records with an Echocardiogram (ECHO) or any other heart imaging) will be studied.||||
33733496|NCT03384251|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants are not required to write their names on the questionnaires. therefore responses provided are anonymous|A multi-stage sampling method shall be conducted. A random sampling of six (6) out 12 mixed Senior High Schools in Tamale Metropolis-Northern Ghana would be selected. We shall randomly allocate three (3) schools as the intervention and the other three (3) as control groups respectively. In each school, one class shall be selected at random from each grade in both intervention and control groups.||||
33733497|NCT02384824|||COHORT||PROSPECTIVE|||||||
33733498|NCT04181918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733499|NCT05585216|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733500|NCT00773097|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33733501|NCT02188368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733502|NCT03339375|||CASE_CONTROL||PROSPECTIVE|||||||
33733503|NCT00742976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33733504|NCT03962972|||COHORT||PROSPECTIVE|||||||
33733505|NCT05418556|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Eligible subjects will be randomized 1:1 to a) conventional DAPT strategy or b) tailored anti-platelet strategy (short DAPT followed by P2Y12 inhibitor alone) after optimized DES implantation guided by intravascular imaging.~* All subjects will be clinically followed at 1, 6, and 12 months"||||
33733506|NCT02041026|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33733507|NCT04216862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733508|NCT00219375|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733509|NCT03448003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733510|NCT03191539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733511|NCT03613207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733512|NCT02404363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733513|NCT00122941|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733514|NCT05487963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733515|NCT04102475|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733516|NCT01636895|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33733517|NCT02128295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33733518|NCT04482569|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33733519|NCT02107703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813110|NCT02162823|||CASE_CONTROL||PROSPECTIVE|||||||
33733520|NCT03558633|||COHORT||PROSPECTIVE|||||||
33733521|NCT05276804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733522|NCT06141629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813111|NCT03761199|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33813112|NCT05758532|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Phase IV, single-centre, 4-group, open-label, randomised controlled trial with a factorial design (primary outcome analysed as a 2-group trial)||||
33813113|NCT05028257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813114|NCT04562883|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813115|NCT01062165|NA|SINGLE_GROUP||||NONE||||||
33813116|NCT03140709|||COHORT||PROSPECTIVE|||||||
33813117|NCT02214095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813118|NCT06010173|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33813119|NCT05861232|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Parallel Assignment|f|f|t|f
33733523|NCT00284531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733524|NCT04210011|||CASE_ONLY||CROSS_SECTIONAL|||||||
33733525|NCT03568422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733526|NCT01441193|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733527|NCT04389411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Montelukast and placebo tablets will be over encapsulated before distribution to trial participants.||t|t|t|t
33813120|NCT06505863|||COHORT||RETROSPECTIVE|||||||
34120896|NCT02289469|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34120897|NCT00800800|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120898|NCT02903290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120899|NCT06546085|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a between-within clinical trial study design. Groups (lean, obese/normal glucose tolerance, type 2 diabetes) will be matched on age and sex while those with obesity and normal glucose tolerance (NGT) will have matched BMI to type 2 diabetes (T2D) for cross-sectional comparisons. People with obesity and NGT as well as obesity with T2D will undergo exercise training for 16 weeks to determine EV changes in comparison to lean controls.||||
34120900|NCT06719518|||COHORT||PROSPECTIVE|||||||
34120901|NCT03376516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120902|NCT00628381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120903|NCT06495957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34120904|NCT04617080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120905|NCT04265131|NA|SINGLE_GROUP||TREATMENT||NONE||"The participants are consecutively assigned in two conditions: a within-subjects design. Those from the experimental group receive standard treatment (TAU) with AT as an extra variable. AT is an experiential form of therapy in which art techniques and supplies (including drawing, painting, clay, etc.) are used methodically with a therapeutic purpose. TAU means that individual verbal therapy takes place on a regular basis, whereby the frequency varies depending on the severity of the eating disorder and the patient's request for help. Cognitive-behavioral therapy is provided with elements of dialectical behavioral therapy, and there is also the possibility of family or couple counseling by a family-based therapist. The participants in the control group only receive this standard treatment (TAU), without AT. Waves will be used: a control group will also become an experimental group at a later stage.~In this way the investigators can investigate the additional added value of AT."||||
34120906|NCT06714058|||COHORT||CROSS_SECTIONAL|||||||
34120907|NCT06681649|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective||||
34120908|NCT05698394|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel Assignment|t|t|t|t
34120909|NCT00943761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120910|NCT01384318|||COHORT||PROSPECTIVE|||||||
34120911|NCT06718660|NA|SINGLE_GROUP||OTHER||NONE||||||
34120912|NCT03101319|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120913|NCT02977338|||COHORT||RETROSPECTIVE|||||||
34120914|NCT03344341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120915|NCT04025892|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34120916|NCT00548834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120917|NCT03893526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34120918|NCT02184676|NA|SINGLE_GROUP||SCREENING||NONE||||||
34120919|NCT00882024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120920|NCT05443971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120921|NCT02869724|RANDOMIZED|PARALLEL||||NONE||||||
34120922|NCT04619004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120923|NCT01252082|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120924|NCT06159504|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two study groups will be running in tandem/parallel to one another at the same time.||||
34120925|NCT03313414|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34120926|NCT06020521|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This research will take place at the hospital and at the UFR Simone Veil-Santé with single sessions on the same day of approximately 10 minutes and 1 hour respectively. A list of healthy volunteers has already been established at the faculty. A provisional schedule for passing the various examinations provided for in the protocol is also scheduled. The experiments conducted at the UFR Simone Veil - Santé will take place within the Department of Health Biotechnology. This Department already has all the resources necessary for the successful completion of the study, in particular within the mass spectrometry platform which has the instruments (high resolution mass spectrometer Q-Exactive) and human resources (2 analytical science engineers, 1 data science engineer + technical staff and interns) required.||||
34120927|NCT06717074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120928|NCT02296476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120929|NCT01309061|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34120930|NCT05065658|||CASE_CONTROL||RETROSPECTIVE|||||||
34120931|NCT01175343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120932|NCT06324474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120933|NCT03730610|NA|SINGLE_GROUP||PREVENTION||NONE||Exercise Training for six months||||
34120934|NCT05121961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to which injectate they received.|Single-blind randomized controlled trial|t|f|f|f
34120935|NCT02098135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120936|NCT04954534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120937|NCT05796258|||COHORT||PROSPECTIVE|||||||
34120938|NCT06307613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813121|NCT02270502|||COHORT||PROSPECTIVE|||||||
33813122|NCT00091728|||DEFINED_POPULATION||PROSPECTIVE|||||||
33813123|NCT03544047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813124|NCT00869609|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813125|NCT01330953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33813126|NCT04515550|||COHORT||PROSPECTIVE|||||||
34149160|NCT06286826|||COHORT||PROSPECTIVE|||||||
34149161|NCT02510183|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34149162|NCT06507670|||CASE_CONTROL||PROSPECTIVE|||||||
34149163|NCT02880813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34149164|NCT03689712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34149165|NCT00967161|RANDOMIZED|PARALLEL||||NONE||||||
34149166|NCT03947970|NA|SINGLE_GROUP||OTHER||NONE||||||
34149167|NCT01824706|||COHORT||PROSPECTIVE|||||||
33813127|NCT06368388|||COHORT||PROSPECTIVE|||||||
33813128|NCT00936819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813129|NCT06341309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838483|NCT04560374|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled study||||
33813130|NCT06139835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The group of study subjects, selected from the study site's database were randomized by the statistician into three different treatment groups. The personnel performing the measurements were blinded as to which group the study subjects we in.|Comparison of the change in calculus abundance of two treatment groups, using the same dentifrice with two different methods of application with a control group using a popular standard dentifrice.|f|t|f|f
33813131|NCT02374372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838484|NCT03104010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838485|NCT03354936|||COHORT||PROSPECTIVE|||||||
33838486|NCT03853551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838487|NCT01261000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838488|NCT03381677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120939|NCT06717828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All subjects will undergo all the prescribed baseline assessments before being randomized into groups. The personnel conducting the clinical endpoint assessments will be blinded; they will not be aware of the trial group assignments of the subjects during the measurement of clinical endpoints.|The study design utilizes an open, randomized, parallel, controlled approach. A total of 250 middle-aged and elderly subjects with metabolic associated fatty liver disease are recruited. Participants are randomly assigned in a 2:2:1 ratio to the Tai Chi group, conventional exercise group, and control group, with the entire intervention period lasting for 6 months.|f|f|f|t
34120940|NCT04289779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120941|NCT04826237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Neither the participant, the medical professionals, nor those that initially calculate the testing data will know which patient has the placebo or which has the statin. Each patient will be identified by number and sex. Only the clinical coordinator who records the names and treatments and the principal investigator (who does not see patients) will have access to the key. The drugs will be randomized in two groups (for female and male). No one doing data analysis will have any identifiable information other than sex and when the code is broken, the data will be tagged with the identification number of hte patient||t|t|f|t
34120942|NCT00752414|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34120943|NCT02912819|||CASE_ONLY||PROSPECTIVE|||||||
34120944|NCT01298336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120945|NCT05916300|||COHORT||PROSPECTIVE|||||||
34120946|NCT06315192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.||||
34120947|NCT04846387|||COHORT||PROSPECTIVE|||||||
34120948|NCT02522039|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34120949|NCT05155033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120950|NCT04340154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120951|NCT06464133|||COHORT||PROSPECTIVE|||||||
34120952|NCT05993494|||CASE_ONLY||PROSPECTIVE|||||||
34120953|NCT04630821|NA|SINGLE_GROUP||OTHER||NONE||||||
34120954|NCT06630533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34120955|NCT03680807|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34120956|NCT03702179|NA|SEQUENTIAL||TREATMENT||NONE||The study will be conducted using a two-stage sequential design. Using the assumption that the treatment would be considered ineffective if it had a response proportion similar to radiotherapy alone (P0: 0.5) but would be of considerable interest if it had a response proportion of 70% of more (P1: 0.7), the sample size requirement is 12 patients for the first stage and 20 additional patients for the second stage. Six or more responses in the first stage were required for continuation to second stage accrual. The study was planned to have a type I error of 0.10 and a power of 80% in a one sided test.||||
34120957|NCT04122976|||COHORT||PROSPECTIVE|||||||
34120958|NCT02153489|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34120959|NCT06181981|||COHORT||OTHER|||||||
34120960|NCT03888248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120961|NCT06194305|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This study does not involve treatment randomization so participants and all study personnel will be aware that participants are receiving CBIT. An Independent Evaluator will conduct pre-, post-treatment and 3-month follow-up assessments. This IE will be masked to information related to CBIT progress (e.g., visit attendance, specific content of sessions, therapist/supervisor perspectives on patient progress, CBIT session documentation). The IE will complete the primary outcome measure (YGTSS).|||||
34120962|NCT05304442|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized||||
34120963|NCT00659282|||COHORT||PROSPECTIVE|||||||
34120964|NCT03528317|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34120965|NCT05837234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120966|NCT05227976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120967|NCT00459940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34120968|NCT05543499|||COHORT||PROSPECTIVE|||||||
34120969|NCT00120133|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34120970|NCT05490758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34120971|NCT02996812|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34120972|NCT06573008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120973|NCT01010607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34120974|NCT03224039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Assignment of treatment will be based on randomization. Each patient will be assigned a study number that would correspond to a specific treatment. Only the primary investigator (B.Sin) and the pharmacist procuring the study intervention will be unblinded to the treatment. The physician, nurse, research associate responsible for collecting data, and independent biostatistician responsible for interpreting the data will be blinded. Assignment of treatment will be placed in a opaque envelope where it would be opened only by the pharmacist will who be procuring the intervention.||t|t|f|t
34120975|NCT03995875|||OTHER||PROSPECTIVE|||||||
34120976|NCT05761821|||COHORT||PROSPECTIVE|||||||
34149168|NCT02138695|||COHORT||PROSPECTIVE|||||||
34149169|NCT03233295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149170|NCT04315636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34149171|NCT04221191|||CASE_CONTROL||PROSPECTIVE|||||||
34149172|NCT03353103|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
34149173|NCT05277038|||CASE_CROSSOVER||PROSPECTIVE|||||||
33733528|NCT05318638|NA|SINGLE_GROUP||OTHER||NONE||The study is a cross-sectional intervention study with one measurement session, where participants will perform maximum handgrip strength tests and high-demand ADL-tasks with and without the soft-robotic glove (glove condition in randomized order).||||
33733529|NCT00556842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733530|NCT05583370|||COHORT||PROSPECTIVE|||||||
33733531|NCT00841438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733532|NCT02839499|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733533|NCT01158625|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733534|NCT02189187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733535|NCT05580731|||COHORT||RETROSPECTIVE|||||||
33733536|NCT03076138|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733537|NCT02703103|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733538|NCT00179413|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733539|NCT00803127|||CASE_ONLY||PROSPECTIVE|||||||
33733540|NCT03252522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo-controlled; randomization created by statistician, all involved in the study and assessment are blinded||t|t|t|t
33733541|NCT02327429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733542|NCT05571059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each individual bottle is labelled with a unique numeric code that identifies the contents to the unblinded sponsor representative.|Randomized, Double-Blind, Placebo-Controlled|t|t|t|t
33733543|NCT05892627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Triple blinded|A cohort who will be randomised into PoZibio™ (2 x capsules daily) or placebo (2 x capsules daily) supplementation for 6 weeks.|t|t|t|f
33733544|NCT03784950|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733545|NCT04524273|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study in which the IV inebilizumab and the IV placebo are matching in appearance.|A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study with Open-label Period|t|t|t|t
33733546|NCT00450710|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733547|NCT01849705|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733548|NCT02956213|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33733549|NCT01448668|||COHORT||PROSPECTIVE|||||||
33733550|NCT05168007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733551|NCT00228891|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33733552|NCT05012527|||OTHER||RETROSPECTIVE|||||||
33733553|NCT05000645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33733554|NCT01486563|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33733555|NCT02771639|||COHORT||RETROSPECTIVE|||||||
33733556|NCT00110812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733557|NCT06573502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733558|NCT01714310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Initial arm for open-label titration of lisdexamfetamine followed by randomization of participants who retain eligibility to double blind adjunctive fluoxetine or placebo.|t|t|t|t
33733559|NCT01632371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733560|NCT05380375|||OTHER||PROSPECTIVE|||||||
33733561|NCT01942941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733562|NCT01527552|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33733563|NCT03949075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The present study is double-blinded with regard to ACE genotype and study medication and the blinding is kept until completion of the trial||t|f|t|f
33813132|NCT03471117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects will either receive placebo or pioglitazone pills in a randomized order. Placebo pills will be sugar pills of same shape and size as the pioglitazone pills. The randomization for study drugs will be carried out by research personnel. All treatments will be encapsulated so that pills are identical and patients cannot identify the treatment arm.|This will be a randomized, placebo-controlled crossover design study|t|f|f|f
33733564|NCT03966274|||CASE_CONTROL||PROSPECTIVE|||||||
33733565|NCT03743948|NA|SINGLE_GROUP||OTHER||NONE||||||
33733566|NCT02714452|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733567|NCT00431249|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33813133|NCT06534918|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33813134|NCT02815345|NA|SINGLE_GROUP||OTHER||NONE||||||
33813135|NCT03979352|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33813136|NCT06318572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813137|NCT02919059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33813138|NCT02378584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733568|NCT00220025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733569|NCT05567731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733570|NCT00063505|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733571|NCT03407872|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Only PART C will be double-blind.||t|f|t|f
33733572|NCT05208216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733573|NCT06051773|||COHORT||RETROSPECTIVE|||||||
33733574|NCT04960228|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All data collection and group assignment will be conducted by the survey company, Dynata. Participants' intervention group assignments will be unavailable to the investigator.|Participants will be assigned to either the video intervention or informational text control condition using a 1:1 randomization ratio.|f|f|t|f
33733575|NCT02469610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733576|NCT01081808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733577|NCT04990895|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33733578|NCT04894981|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a pilot, prospective, single-centre, controlled, randomised, crossover, open-label, study. (RIPH2)||||
33733579|NCT06034054|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33733580|NCT01956110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733581|NCT01674686|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33813139|NCT01645241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813140|NCT06226116|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813141|NCT00547456|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838489|NCT06379542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733582|NCT00211471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733583|NCT00684359|||||RETROSPECTIVE|||||||
33733584|NCT05157100|NA|SINGLE_GROUP||TREATMENT||NONE||Experimental||||
33733585|NCT04832373|NA|SINGLE_GROUP||OTHER||NONE||||||
33733586|NCT04976192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733587|NCT04001153|||COHORT||PROSPECTIVE|||||||
33733588|NCT06363175|||OTHER||CROSS_SECTIONAL|||||||
33733589|NCT01862172|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733590|NCT05537233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733591|NCT05681429|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blinded RCT|Single-blinded prospective randomised controlled trial|t|f|f|f
33813142|NCT04101188|RANDOMIZED|CROSSOVER||PREVENTION||NONE||All participants will complete each arm. It is a crossover, randomized design.||||
33813143|NCT03162835|||OTHER||CROSS_SECTIONAL|||||||
33733592|NCT05898945|||OTHER||CROSS_SECTIONAL|||||||
33733593|NCT05049148|NA|SINGLE_GROUP||OTHER||NONE||||||
33733594|NCT00726219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733595|NCT05649605|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|All participating research staff will be blinded to the treatment the patient is receiving. The drug and placebo will be labelled by Tamro AB, which will ensure that Nebido and placebo cannot be separated.|Prospective, randomized, placebo controlled, double blind study.|t|t|t|t
33733596|NCT04540432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be split into 4 groups according to their treatment profile:~Profile A = patients on non-steroidal anti-inflammatory drugs.~Profile AM = patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate until the end of the study.~Profile AB = patients on non-steroidal anti-inflammatory drugs, followed by biotherapy until the end of the study.~Profile AMB = patients on non-steroidal anti-inflammatory drugs followed by treatment with methotrexate and then biotherapy until the end of the study.~Profile M : methotrexate alone~Profile B : biothérapy alone"||||
33733597|NCT02562313|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33733598|NCT00391352|||CASE_CONTROL||PROSPECTIVE|||||||
33813144|NCT02203981|||COHORT||PROSPECTIVE|||||||
33813145|NCT00059527|RANDOMIZED|PARALLEL||||NONE||||||
33838490|NCT06052670|||COHORT||PROSPECTIVE|||||||
33838491|NCT05209516|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Three groups of participants: 2 Parkinson patients groups and 1 control group||||
33838492|NCT05590429|||OTHER||RETROSPECTIVE|||||||
33838493|NCT06330935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838494|NCT04035980|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34044151|NCT05053945|||COHORT||PROSPECTIVE|||||||
34044152|NCT04370171|||COHORT||PROSPECTIVE|||||||
34044153|NCT05538364|||CASE_ONLY||PROSPECTIVE|||||||
34044154|NCT01373502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044155|NCT00949559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044156|NCT02508077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044157|NCT06139783|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044158|NCT02948751|NA|SINGLE_GROUP||OTHER||NONE||||||
34044159|NCT03691051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044160|NCT05957952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044161|NCT05126069|||COHORT||RETROSPECTIVE|||||||
34044162|NCT03690843|||CASE_CONTROL||OTHER|||||||
34044163|NCT01359332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044164|NCT02602990|||COHORT||PROSPECTIVE|||||||
34044165|NCT01142817|||COHORT||PROSPECTIVE|||||||
34044166|NCT01057147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044167|NCT06468800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044168|NCT02954133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044169|NCT04740398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044170|NCT05472272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a non-randomized parallel study without a control arm||||
34044171|NCT05362617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044172|NCT05722288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044173|NCT02893033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044174|NCT02492984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044175|NCT00044070|RANDOMIZED|||TREATMENT||DOUBLE||||||
34044176|NCT03692234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||randomized double-blind placebo controlled|t|f|t|f
34044177|NCT00680095||||OTHER||NONE||||||
34044178|NCT00827905|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044179|NCT00794248|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34044180|NCT02748356|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044181|NCT04717622|||COHORT||PROSPECTIVE|||||||
34044182|NCT03258294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044183|NCT06576635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044184|NCT06355895|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34044185|NCT03658161|NA|SINGLE_GROUP||OTHER||NONE||||||
34044186|NCT06564298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044187|NCT01599182|||COHORT||PROSPECTIVE|||||||
34044188|NCT01421680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044189|NCT04481620|||COHORT||RETROSPECTIVE|||||||
34044190|NCT05342623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Difelikefalin and placebo will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance. Difelikefalin tablets will be provided at doses of 1 mg.|Randomized, double-blind, placebo controlled study|t|f|t|f
34044191|NCT05460013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34044192|NCT05258266|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044193|NCT05387369|||COHORT||OTHER|||||||
34044194|NCT04195633|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044195|NCT02497820|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34044196|NCT06575101|||OTHER||PROSPECTIVE|||||||
34044197|NCT06175078|||CASE_ONLY||PROSPECTIVE|||||||
34044198|NCT06575010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34120977|NCT06104137|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Randomisation Method and Blinding Patients who are eligible and consented to participate in the study will be randomised to either the trial group or the control group with use of the sealed envelope method. The randomization will be blocked with use of random permuted blocks in groups of two, four, or six to help ensure that the groups are balanced. A piece of paper that has the phrase MOOC or Control will be placed in- side an envelope. MOOC patients will have the login and password in the envelope for access."|double blinded RCT The study design is a randomised clinical trial with two arms. The trial will be double blinded to the consultant surgeon seeing them in clinic and to the assessor of recall but not blinded to the patient. Power calculations showed that to detect an improvement of 20% in the primary outcome measure of recall in the experiment group, with a two-sided 5% significance level and a power of 80% and a drop out rate of 10%, a sample size of 40 patients per arm is necessary.|t|t|t|f
34120978|NCT06301646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34120979|NCT06482086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120980|NCT00765414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34120981|NCT01469039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34120982|NCT02669498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34120983|NCT04103242|||CASE_CONTROL||PROSPECTIVE|||||||
34120984|NCT06664554|||CASE_CONTROL||PROSPECTIVE|||||||
34120985|NCT06298227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor and participants will be blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic nephrectomy surgery will be included in the study. Patients will be randomly divided into two groups (Group ESPB = ESPB group, Group QLB = QLB group) including 30 patients each, before entering the operating room.|t|f|f|t
34120986|NCT05007548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34120987|NCT06719440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single blinded, randomized, parallel|t|f|f|f
34120988|NCT03383042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120989|NCT06121895|||CASE_CONTROL||PROSPECTIVE|||||||
34120990|NCT05561647|||OTHER||OTHER|||||||
34120991|NCT01667341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34120992|NCT01952509|||COHORT||PROSPECTIVE|||||||
34120993|NCT04710030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)|Parallel Assignment|t|t|t|f
34120994|NCT05301543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34120995|NCT06712589|||COHORT||RETROSPECTIVE|||||||
34120996|NCT06357845|NA|SINGLE_GROUP||SCREENING||NONE||A cross-sectional study design will be implemented.||||
34120997|NCT06719349|||CASE_ONLY||RETROSPECTIVE|||||||
34120998|NCT02406222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34120999|NCT04870151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors are instructed to assess the outcomes before they log in to the patients' journal. Thereby, they will not have information of the treatment allocation at the time of outcomes assessment. Also, they will not ask the patients to undress or in any other way examine the surgical site, as the location of the scar tissue may disclose the treatment allocation.|Randomised controlled trial|f|f|f|t
34121000|NCT01176617|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121001|NCT01249001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121002|NCT06716944|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is not to test the device (acupunture0 but the trial design||||
34121003|NCT04707079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121004|NCT06714994|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34121005|NCT02603757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121006|NCT06524089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel group prospective randomized clinical trial|t|f|t|f
34121007|NCT00669006|||CASE_ONLY||PROSPECTIVE|||||||
34121008|NCT05034328|||COHORT||PROSPECTIVE|||||||
34121009|NCT05905783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121010|NCT05622942|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121011|NCT05724082|NA|SEQUENTIAL||PREVENTION||NONE||The air filtration system will be cycled monthly, with active filtration alternating with no filtration for one month on/one month off.||||
34121012|NCT02063451|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34121013|NCT04488133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121014|NCT00649350|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34121015|NCT02136914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121016|NCT06718816|||COHORT||PROSPECTIVE|||||||
34121017|NCT01047189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34121018|NCT03480984|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigators will not have direct access to settings on the pump||f|f|t|f
34121019|NCT04016857|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The RIPC procedure were performed in the ward before going to operating room, and this is blinded to Investigators and surgical case anesthesiologist|patients were randomly assigned in 1:1 ratio to either control group or RIPC using computerized randomization table|f|t|t|t
34121020|NCT03440073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121021|NCT05016089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomised, controlled (wait-list control), and two-armed trial.|f|f|t|t
34121022|NCT04343560|||COHORT||PROSPECTIVE|||||||
34121023|NCT06715046|||COHORT||PROSPECTIVE|||||||
34121024|NCT00503490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121025|NCT02117778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34121026|NCT02457026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121027|NCT02326727|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34121028|NCT06717646|||COHORT||PROSPECTIVE|||||||
34121029|NCT03362268|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121030|NCT03709966|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The methodology used for this study consists of a pilot randomized controlled trial of 30 Type 2 diabetes patients already followed by health professionals from GMF-U Quatre-Bourgeois|t|f|f|f
34121031|NCT02423486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121032|NCT06716489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121033|NCT02366325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121034|NCT06714760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813146|NCT03949478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The UofC Clinical Research Unit, which has no contact with patients or clinicians, will prepare the concealed randomization schedule and the randomization tool. Our research pharmacy will prepare three identical tablets to be given to each subject. The participant, care provider, investigators, and outcomes assessors will be blinded to treatment|We will study 90 subjects admitted to hospital for epilepsy investigations. We will randomly divide the patients into three treatment groups (30 patients each). They will receive either placebo, ibuprofen, or nifedipine while in hospital. We will then determine the effect of each of these treatments on the severity of hypoperfusion and neurological deficits that follows their seizures.|t|t|t|t
34121035|NCT04275999|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The project will consist of a trial in which thirty subjects with rosacea receive ivermectin therapy and are randomized to receive either no intervention, a weekly digital survey to assess the subject's attitudes towards ivermectin therapy, or a portal hydration measurement device that measures TEWL rates and SC hydration levels. The study team will measure adherence objectively in all groups with electronic monitors attached to the containers of the ivermectin, which all subjects will be told to use daily for maintenance therapy.||||
34121036|NCT00298636|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34121037|NCT05287243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121038|NCT06058052|||COHORT||PROSPECTIVE|||||||
34121039|NCT02670473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34121040|NCT06717529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients with bilateral knee osteoarthritis will receive hyaluronic acid injection in one knee and steroid injection in the other knee.|t|f|t|f
34121041|NCT06718959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121042|NCT02573948|||COHORT||PROSPECTIVE|||||||
34121043|NCT03653182|||CASE_ONLY||CROSS_SECTIONAL|||||||
34121044|NCT06712914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121045|NCT06714838|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive the same therapy||||
34121046|NCT02545439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121047|NCT06713538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121048|NCT00639951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121049|NCT06715293|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Endoscopists will be blinded from the Hemopill capsule examination results.|All patient will swallow Hemopill to observe the presence of active bleeding or potential bleeding source|f|f|f|t
34121050|NCT05935176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121051|NCT04271475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121052|NCT00001486|||CASE_CONTROL||OTHER|||||||
34121053|NCT06622434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121054|NCT06567002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121055|NCT06631768|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34121056|NCT05167812|||COHORT||PROSPECTIVE|||||||
34121057|NCT06519682|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121058|NCT03240510|||CASE_ONLY||PROSPECTIVE|||||||
34121059|NCT06715514|RANDOMIZED|PARALLEL||TREATMENT||NONE||All efficacy outcomes will be compared primarily between the combined GLP-1RA + MHT and the GLP-1RA only regimen. The third arm (MHT only) will allow exploring mechanistic effects of MHT-mediated restoration of E2 levels on glucose and energy homeostasis and to assess benefits of combined GLP-1RA + MHT, compared to MHT alone, on haemostatic biomarkers.||||
34121060|NCT04778150|||COHORT||PROSPECTIVE|||||||
34121061|NCT06049173|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34121062|NCT05715060|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121063|NCT05152511|||COHORT||PROSPECTIVE|||||||
34121064|NCT02831660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121065|NCT06384170|||CASE_ONLY||PROSPECTIVE|||||||
34121066|NCT05973201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients in whom elective BF has been scheduled and who have given consent to the study will be randomised (1:1) to either the control group (BF after local anaesthesia (LA)) or the experimental group (BF after AL and VR immersion). Randomization will be done 30 minutes before BF, after an initial assessment of anxiety (pre-BF VAS) and will be stratified according to whether or not a psychotropic drug and/or a level II analgesic is taken the day before or on the day of BF.~The randomization list will be programmed in advance by the study statistician using SAS software and will be generated and edited by another statistician independent of the study from the HEGP clinical research unit. The randomization list will be kept by the study sponsor (AP-HP). It will be available to users via web-based software (CleanWeb software (Telemedicine Technologies, http: //www.tentelemed.com/la-solution-cleanweb/)\]."||||
34121067|NCT00587041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121068|NCT01070342|||COHORT||PROSPECTIVE|||||||
34121069|NCT06077994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121070|NCT01732536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were blindfolded and earmuffed during the baseline procedure and follow-up endoscopic examinations. Implants were removed at Day 60 to allow blinded assessment of bilateral polyp grade at Day 90 by a centralized videoendoscopy review by a panel of 3 independent sinus surgeons.||t|f|f|t
34121071|NCT03017443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121072|NCT02255929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121073|NCT02812745|||COHORT||PROSPECTIVE|||||||
34121074|NCT01923883|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34121075|NCT01478932|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121076|NCT01732614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121077|NCT04160104|||OTHER||PROSPECTIVE|||||||
34121078|NCT02582879|||COHORT||PROSPECTIVE|||||||
33813147|NCT00425971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33813148|NCT00584675|NA|SINGLE_GROUP||||NONE||||||
34121079|NCT03652714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121080|NCT00598650|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121081|NCT04236999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In all the assessments, research assistants will be blind to the trial arm where the schools/students were allocated.|Cluster randomized controlled trial|f|f|f|t
34121082|NCT00519727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121083|NCT00202579|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34121084|NCT02782442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733599|NCT06172335|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"All participant, the major investigator, study coordinator and the study staff are blinded for the randomizing. The capsules and capsule containers will only be identifiable by the ID (identifying) numbers on the containers.~Allocation of participants to the specific intervention group is carried out by a statistician and one person not involved in conducting the study."|"Randomized double-blinded controlled trial (Randomized 1:1, control:intervention).~Run-in period of 3 weeks where all participants receive the control capsules."|t|t|t|f
33733600|NCT05924035|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study is a prospective, case-controlled pilot study, performed over three weeks with 6 participants in each group.||||
33733601|NCT01646697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733602|NCT01479621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733603|NCT01191710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733604|NCT03294603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733605|NCT00427635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733606|NCT06319599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733607|NCT01097837|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33733608|NCT04879160|||COHORT||PROSPECTIVE|||||||
33733609|NCT02085564|||COHORT||PROSPECTIVE|||||||
33733610|NCT00357370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733611|NCT05883605|NA|SINGLE_GROUP||OTHER||NONE||||||
33733612|NCT06202638|||COHORT||PROSPECTIVE|||||||
33733613|NCT04261270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733614|NCT02204254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733615|NCT05256017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||2 arms (acoziborole and placebo, ratio 3:1); 5 days post drug administration of hospitalization; follow-up visits at Month 1 and Month 4 (End of Study Visit)|t|t|t|t
33733616|NCT03647696|||COHORT||PROSPECTIVE|||||||
33733617|NCT05216367|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33733618|NCT02591628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733619|NCT02880982|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733620|NCT05755828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733621|NCT00470288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33733622|NCT06562140|||COHORT||CROSS_SECTIONAL|||||||
33733623|NCT05000749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be masked to study condition.|Participants will be randomly assigned to one of two study conditions for the duration of the study.|f|f|f|t
33733624|NCT03132948|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33733625|NCT03794284|||CASE_ONLY||PROSPECTIVE|||||||
33733626|NCT03228680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33733627|NCT04142437|||COHORT||PROSPECTIVE|||||||
33733628|NCT00087633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733629|NCT00770120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733630|NCT01825369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733631|NCT04438928|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33733632|NCT00757575|||COHORT||PROSPECTIVE|||||||
33733633|NCT00869648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33733634|NCT02714049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733635|NCT06097507|NA|SINGLE_GROUP||OTHER||NONE||||||
33733636|NCT06316466|||COHORT||RETROSPECTIVE|||||||
33733637|NCT01624727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733638|NCT01357993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733639|NCT03144180|RANDOMIZED|PARALLEL||OTHER||NONE||Although we tested device feasibility and we should have fewer than 10 participants, we did want to run a two-sided, two-sample t-test with 80% power and an alpha of 0.05, and a common standard deviation of 14 seconds. In order to achieve this, we needed to recruit 30 subjects in total, 15 in the control and 15 in the study group.||||
33733640|NCT01288534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733641|NCT02808845|||COHORT||PROSPECTIVE|||||||
33733642|NCT01775696|||COHORT||PROSPECTIVE|||||||
33733643|NCT04155996|||CASE_ONLY||PROSPECTIVE|||||||
33733644|NCT04838366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized in a 1:1 ratio, and assigned into study group and control group randomly through computer generated block randomization.||||
33733645|NCT06187545|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33733646|NCT02074124|||COHORT||PROSPECTIVE|||||||
33813149|NCT01728090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813150|NCT03260452|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|All laboratory analyses will be performed blindly.|"20 male volunteers: 10 overweight/obese subjects with T2D and 10 healthy volunteers, age-matched.~All volunteers will be treated in the same way."||||
33813151|NCT02446015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33813152|NCT02301286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813153|NCT06395207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813154|NCT03153423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813155|NCT06463509|||COHORT||PROSPECTIVE|||||||
33813156|NCT01787409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813157|NCT02097316|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813158|NCT04604717|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813159|NCT03437655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813160|NCT01667159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813161|NCT02073214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33813162|NCT02499809|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33813163|NCT03791190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813164|NCT00704548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813165|NCT03155399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessment was conducted by two physiotherapists not involved in providing the experimental treatment.||f|f|f|t
33813166|NCT06220578|||COHORT||RETROSPECTIVE|||||||
33813167|NCT04405180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple: Participant, Care Provider, Investigator, Outcome Assessor|Parallel assignment|t|t|t|t
33813168|NCT05514678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044199|NCT00101166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044200|NCT02057133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838495|NCT03142854|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Participants are randomly assigned to group A or B. Participants of group A are given normal bowel preparation, while participants of group B are given personalized regimens according to a predictive model we have established.|f|t|f|t
34121085|NCT06718920|||COHORT||PROSPECTIVE|||||||
34121086|NCT02932826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121087|NCT04940130|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blinded|randomized, placebo controlled, with concurrent arms|t|t|t|t
34121088|NCT03766061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121089|NCT04301648|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Quasi-experimental design study, pre-post intervention type.||||
34121090|NCT06716684|RANDOMIZED|PARALLEL||PREVENTION||NONE||Following recruitment, the nursing students were divided into a intervention and a control group by randomization.||||
34121091|NCT04548206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective randomize controlled study|f|f|t|f
34121092|NCT00151450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121093|NCT03376932|RANDOMIZED|PARALLEL||TREATMENT||NONE|This will be an open-label study. Hence, masking will not be provided.|Subjects will be randomized in a 1:1 ratio to receive either FF/UMEC/VI via the ELLIPTA DPI with the CIS or FP/SAL via the DISKUS DPI plus TIO via the RESPIMAT inhaler.||||
34121094|NCT01977378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121095|NCT05891171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34121096|NCT00219089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121097|NCT03995160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34121098|NCT04929964|||CASE_ONLY||OTHER|||||||
34121099|NCT01900886|||||PROSPECTIVE|||||||
34121100|NCT06714903|||COHORT||PROSPECTIVE|||||||
34121101|NCT06718257|||COHORT||RETROSPECTIVE|||||||
34121102|NCT05528575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34121103|NCT04161534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be treated with an arm sling and will be randomized to kinesio tape (KT Tape) or no kinesio tape (control)||||
34121104|NCT05987982|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Oral management group: oral exercises and oral care.~2. Oral care group: oral hygiene.~3. Routine group"||||
34121105|NCT06718595|||COHORT||PROSPECTIVE|||||||
34121106|NCT05157087|||COHORT||RETROSPECTIVE|||||||
34121107|NCT02711501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121108|NCT02347085|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34121109|NCT05321329|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, non-comparative study||||
34121110|NCT04167254|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34121111|NCT06160323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient will be masked on their randomization until (i) 3 month from randomization (study endpoint) or (ii) after 4 weeks if VAS score \>= 7 or VAS score fails to improve by 20% despite optimal oral analgesics, when they will be allowed to opt for EUS-guided CGN/ CPN. The pain assessment will be performed by assessors who are blinded to the randomized group each time.|Patient will be randomly assigned in a 1:1 ratio to either the upfront EUS-guided CGN/CPN approach or to the conventional step-up approach at the time of EUS. Site-specific block randomization will be performed via an online web-based randomization program with a concealed, fixed block size.|t|f|f|t
34121112|NCT04848402|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121113|NCT06550882|||COHORT||OTHER|||||||
34121114|NCT04442568|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients||||
34121115|NCT00827229|NA|SINGLE_GROUP||||NONE||||||
34121116|NCT03055091|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be randomized to the treatment arm or control arm and will receive the study product or placebo.|This will be a pragmatic triple blind (participant and parents, practitioners and analyst will be blinded), two arm, superiority, placebo controlled randomized trial with 1:1 allocation.|t|t|t|t
34121117|NCT05726149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34121118|NCT06708338|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121119|NCT05525910|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121120|NCT03423121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34121121|NCT06715592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121122|NCT03988946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121123|NCT02011269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121124|NCT05562115|NA|SINGLE_GROUP||OTHER||NONE||||||
34121125|NCT02167789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838496|NCT04985786|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34121126|NCT01209819|||COHORT||PROSPECTIVE|||||||
34121127|NCT05973864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121128|NCT03280368|||COHORT||PROSPECTIVE|||||||
34121129|NCT02199756|||COHORT||PROSPECTIVE|||||||
34121130|NCT05993793|NA|SEQUENTIAL||TREATMENT||NONE||||||
34121131|NCT05562505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34121132|NCT01602835|||COHORT||CROSS_SECTIONAL|||||||
34121133|NCT05747274|||COHORT||RETROSPECTIVE|||||||
34121134|NCT06376864|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34121135|NCT03511001|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121136|NCT04496479|NA|SEQUENTIAL||TREATMENT||NONE|This is no masking in the open-label dose escalation phase.|Open-Label Dose Escalation of Three Increasing Dosages||||
34121137|NCT04841954|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121138|NCT05626933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121139|NCT01760070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121140|NCT05233514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||participants were divided into two groups equal in number: the aerobic exercise group (AEM), and the Metformin group (M). The AEM group performed aerobic exercise three times a week for 12 weeks in addition to Metformin treatment. The M group received Metformin only|f|f|t|f
34121141|NCT00820547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121142|NCT03431597|RANDOMIZED|PARALLEL||TREATMENT||NONE||3-arm randomized controlled trial, unblinded, with 125 women per arm.||||
34121143|NCT04273165|RANDOMIZED|PARALLEL||TREATMENT||NONE||dose comparison in open label pilot study||||
34121144|NCT04034264|||COHORT||CROSS_SECTIONAL|||||||
34121145|NCT05171153|||COHORT||PROSPECTIVE|||||||
34121146|NCT01641107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121147|NCT01572974|||CASE_ONLY||PROSPECTIVE|||||||
34121148|NCT02663310|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121149|NCT02171026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121150|NCT01478984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121151|NCT00460824|||||RETROSPECTIVE|||||||
34121152|NCT05148741|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121153|NCT06179680|||CASE_CONTROL||PROSPECTIVE|||||||
34121154|NCT02552576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121155|NCT06489080|||COHORT||PROSPECTIVE|||||||
34121156|NCT01148667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34121157|NCT06715202|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121158|NCT06332586|NA|SINGLE_GROUP||OTHER||NONE||||||
34121159|NCT05549661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121160|NCT03475602|||COHORT||PROSPECTIVE|||||||
34121161|NCT05833711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121162|NCT05795777|||OTHER||CROSS_SECTIONAL|||||||
34121163|NCT05195203|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34121164|NCT00818090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121165|NCT03807583|RANDOMIZED|PARALLEL||PREVENTION||NONE||This clinical study is a monocentric, randomized, open-label, 3 parallel arms, and controlled study.||||
34121166|NCT01783444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121167|NCT00689806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121168|NCT06159257|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34121169|NCT00948688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121170|NCT06717490|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Patients are divided into two groups, with one group receiving magnesium sulfate and the other receiving normal saline.|t|t|t|f
34121171|NCT06012851|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||All participants receive access to a beta version of the mobile behavioral parent training application. Each participant is randomized multiple times per day (about 4-6 times per day) to received either no push notification (50% chance) or a push notification providing parenting feedback or a suggestion to use a parenting strategy (50% chance).|f|f|t|t
34121172|NCT05987124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121173|NCT04927676|||COHORT||PROSPECTIVE|||||||
34121174|NCT00403143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34121175|NCT04025944|||COHORT||PROSPECTIVE|||||||
34121176|NCT02252315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121177|NCT01711528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121178|NCT04446312|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121179|NCT00034021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121180|NCT03407092|||COHORT||PROSPECTIVE|||||||
34121181|NCT01335425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121182|NCT04366856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121183|NCT01583673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34121184|NCT05361265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121185|NCT05951647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blinded, parallel, randomized clinical trial|t|t|f|f
34121186|NCT00050583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121187|NCT03110705|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34121188|NCT06704100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|We have partnered with Froedtert Hospital's Investigative Drug Services (FH IDS) in order to randomize subjects to either treatment or placebo. Only FH IDS will have the key linking subjects to treatment groups, and the power to conduct an emergency un-blinding.|Proof-of-Concept|t|t|t|t
34121189|NCT03730584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121190|NCT02565992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121191|NCT06701565|||OTHER||CROSS_SECTIONAL|||||||
34121192|NCT05534893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The investigator, participant, care provider, outcomes assessor will not be aware of which participant is in which arm|his will be a parallel, free-living, randomized controlled trial, where 52 overweight men and postmenopausal women will be randomized to receive either the freeze dried blueberries or a placebo powder|t|t|t|t
34121193|NCT05636202|||COHORT||RETROSPECTIVE|||||||
34121194|NCT04362306|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34121195|NCT05198401|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121196|NCT01816048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121197|NCT01936233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121198|NCT02194114|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121199|NCT04955184|||COHORT||RETROSPECTIVE|||||||
34044201|NCT02792543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121200|NCT02273921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044202|NCT01905020|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044203|NCT02564900|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044204|NCT05680220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044205|NCT02110758|||COHORT||PROSPECTIVE|||||||
34044206|NCT02744430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044207|NCT01270984|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044208|NCT01820117|||CASE_CONTROL||OTHER|||||||
34044209|NCT03805035|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044210|NCT03306628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044211|NCT00685204|NA|SINGLE_GROUP||TREATMENT||||||||
34121201|NCT00000134|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34121202|NCT00198679|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121203|NCT04161209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Following the screening, eligible participants will be randomised to receive either a single 20mg oral dose of citalopram or a matched lactose placebo tablet using an online randomisation tool. Note that the study is not assessing the safety or efficacy of citalopram, rather it is using citalopram to understand the role of serotonin in stress reactivity.|t|f|t|t
34121204|NCT02579434|NON_RANDOMIZED|PARALLEL||||NONE||||||
34121205|NCT01720030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121206|NCT05895994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121207|NCT03099122|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33813169|NCT05910788|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||"Main goal~* To evaluate the incidence of in-hospital pulmonary complications in 30 days in patients submitted to the use of HFNC in the perioperative period of patients undergoing thoracic surgery,~* To evaluate in-hospital postoperative mortality within 30 days.~intubation)~Secondary objectives~* Assess the incidence of hypoxemia during orotracheal intubation/ extubation~* Assess the incidence of immediate complications after intubation/ extubation(desaturation, failure of intubation/ extubation)"|t|f|f|f
34121208|NCT04769206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813170|NCT02626494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34121209|NCT01144000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121210|NCT00564109|||COHORT||RETROSPECTIVE|||||||
34121211|NCT05535114|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34121212|NCT00133627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121213|NCT02559648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121214|NCT04174859|||COHORT||PROSPECTIVE|||||||
34121215|NCT03547856|||COHORT||PROSPECTIVE|||||||
34121216|NCT01366573|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34121217|NCT04249401|||COHORT||RETROSPECTIVE|||||||
34121218|NCT01669902|||COHORT||PROSPECTIVE|||||||
34121219|NCT01440361|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34121220|NCT02514343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121221|NCT05070130|||CASE_ONLY||PROSPECTIVE|||||||
34121222|NCT01143402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121223|NCT02505425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121224|NCT06718075|||COHORT||PROSPECTIVE|||||||
34121225|NCT02132403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121226|NCT05924139|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34121227|NCT01425476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34121228|NCT02448966|||CASE_CONTROL||PROSPECTIVE|||||||
34121229|NCT03817489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Randomized Controlled Trail||||
34121230|NCT04704024|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|"Pregnant women will be randomized in open label fashion to early or late initiation of TDF.~Infants will be randomized to receive lamivudine or matching placebo."|2x2 factorial|t|t|t|t
34121231|NCT04457986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Postoperative pain will be assessed by an anaesthesiologist unaware of group assignment||f|f|f|t
34121232|NCT05572840|NA|SINGLE_GROUP||OTHER||NONE||||||
34121233|NCT00896012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121234|NCT00497003|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121235|NCT01951053|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34121236|NCT05687227|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34121237|NCT05739292|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34121238|NCT06416228|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Both participating students and assessors will be blinded to the participants' group assignment. Since students and research staff will not know whether their beetroot juice is depleted or not, treatment conditions are double-blinded (juice shots will be pre-labeled by study statistician with a participant number based on the pre-study randomization, so neither the staff nor the participant know the contents). Students will also be assured of full blinding of course instructors, including the PIs and Co-Is, to names of study participants."|Double blinded, placebo controlled study|t|t|t|t
34121239|NCT00251836|||COHORT||PROSPECTIVE|||||||
34121240|NCT06354673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34121241|NCT04631809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121242|NCT06455722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121243|NCT01451411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121244|NCT05850767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121245|NCT02856022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121246|NCT05295628|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"This is a single-blind study. The following individuals will be blinded to the subject's treatment allocation:~* The subject and his or her family members~* Site personnel administering neurological evaluations~* Pathology Core Laboratory personnel performing debris analyses~Un-blinding will occur only after the database has been locked for the analysis of the primary endpoint or to protect subject rights, welfare, or well-being at the request of the DMC. A site investigator may also reveal treatment allocation to an individual subject if deemed necessary due to complication or injury."|"This prospective, multicenter, single-blind, randomized controlled trial will enroll up to a total of 532 subjects undergoing TAVR at up to 30 investigational sites in the United States.~Prior to enrollment of the first randomized subject at each site, each site will enroll 2 Roll-In subjects (up to 60 subjects total), who will not be randomized but will receive the EMBLOK EPS during TAVR.~In the randomized cohort, up to 422 subjects meeting eligibility criteria will be randomized 1:1 (stratified by operative risk and study site) to one of two treatment arms:~1. Intervention - EMBLOK EPS during TAVR~2. Control - SENTINEL CPS during TAVR~In addition, a nested registry will enroll up to 50 subjects who meet clinical eligibility criteria and are anatomically suitable for the EMBLOK EPS, but whose anatomy precludes the use of the SENTINEL CPS."|t|f|f|t
34121247|NCT00057057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149174|NCT05709262|||CASE_ONLY||PROSPECTIVE|||||||
34149175|NCT00324441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149176|NCT02520921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149177|NCT04464525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813171|NCT00624377|||COHORT||PROSPECTIVE|||||||
33813172|NCT02684136|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33813173|NCT01707563|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33813174|NCT02995447|||COHORT||PROSPECTIVE|||||||
33813175|NCT00805441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813176|NCT02868983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33813177|NCT05873296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33813178|NCT03337022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813179|NCT02392507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813180|NCT00606788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813181|NCT02211872|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813182|NCT01596465|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33813183|NCT06419257|NA|SINGLE_GROUP||OTHER||NONE||||||
33813184|NCT04766996|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Matched Prospective Case with Retrospective Control Study and Staff Survey||||
33813185|NCT01711788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121248|NCT05771532|RANDOMIZED|PARALLEL||OTHER||DOUBLE||For this two-group, controlled trial, 63 participants with cervical cancer were recruited from the gynecological wards of a large-scale medical center in northern Taiwan. The control group (n=30) received routine sexual health teaching (a 10-15-minute routine individual sexual health education and a sexual health pamphlet without a gender-sensitive and theoretically based design. The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet).|t|f|t|f
34121249|NCT02927795|||OTHER||PROSPECTIVE|||||||
34121250|NCT03076606|||COHORT||PROSPECTIVE|||||||
34121251|NCT03790644|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective longitudinal, self-controlled, single-case repeated measures alternating treatment, randomized and counterbalanced cross-over experimental trial design, comparing walking endurance without and with a powered exoskeleton.||||
34121252|NCT04945486|RANDOMIZED|PARALLEL||PREVENTION||NONE|Masking is not possible|||||
34121253|NCT02991339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121254|NCT02544854|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34121255|NCT04385069|||COHORT||RETROSPECTIVE|||||||
34121256|NCT04677998|||COHORT||PROSPECTIVE|||||||
34121257|NCT00893841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121258|NCT00392093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121259|NCT02093260|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34121260|NCT02292537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121261|NCT05927116|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised wait-list controlled trial||||
34121262|NCT06005909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121263|NCT02012803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34121264|NCT04149496|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective series||||
34121265|NCT02739958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34121266|NCT01964183|NA|SINGLE_GROUP||||NONE||||||
34121267|NCT01303692|||CASE_ONLY||PROSPECTIVE|||||||
34121268|NCT04827316|||COHORT||PROSPECTIVE|||||||
34121269|NCT01008618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121270|NCT04473001|||COHORT||PROSPECTIVE|||||||
34121271|NCT06154018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||RCT|t|t|t|f
34121272|NCT03214263|||COHORT||PROSPECTIVE|||||||
34121273|NCT04703140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121274|NCT04029207|||CASE_ONLY||PROSPECTIVE|||||||
34121275|NCT01889394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121276|NCT03154021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The identity of the experimental oral rinse and its placebo will be disguised. Test and control kit boxes will contain toothpaste, a toothbrush, dose cups and a timer. The kit boxes will be labeled with a unique kit number representing the test product or placebo known only to the manufacturer. Kit box labels will also contain the study number, emergency phone number, distributor name/address, appropriate caution statements, content statement and other information as required by internal regulations and clinical SOPs. Kit box content statement will be worded to maintain the study blind.|One half of subjects will be given test product other half will be given placebo.|t|f|t|f
34121277|NCT00372957|RANDOMIZED|PARALLEL||TREATMENT||||||||
34121278|NCT04422431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|This study is only pathologist-blinded for the assessments of liver histology samples.|||||
34121279|NCT03882281|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121280|NCT04229888|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assessor blinded to visit schedule. Participants masked to invalidity of sham treatment.|All subjects will receive first treatment and then second treatment. The eye receiving treatment will be randomly selected. The same eye will receive both treatments.||||
34121281|NCT01794910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34121282|NCT06715566|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel group quasi-experimental design|f|f|f|t
34121283|NCT01203033|||OTHER||PROSPECTIVE|||||||
34121284|NCT04116593|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34121285|NCT00207220|||COHORT||PROSPECTIVE|||||||
34121286|NCT01989429|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121287|NCT04414293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121288|NCT04802603|NA|SEQUENTIAL||TREATMENT||NONE||Cohort 1 (De novo) Cohort 2 (Prior radiotherapy)||||
34121289|NCT02806011|||OTHER||PROSPECTIVE|||||||
34121290|NCT00426803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121291|NCT05106348|||COHORT||OTHER|||||||
34121292|NCT03574961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121293|NCT03710421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121294|NCT02800733|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121295|NCT03092310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121296|NCT00066339||||TREATMENT||NONE||||||
34121297|NCT01926132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121298|NCT00947219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121299|NCT03196830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121300|NCT02814058|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34121301|NCT00499525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121302|NCT03532022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121303|NCT01757665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121304|NCT02574793|||OTHER||PROSPECTIVE|||||||
34121305|NCT01012284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813186|NCT04828915|||COHORT||PROSPECTIVE|||||||
33813187|NCT00915915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813188|NCT03688087|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33813189|NCT04249700|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33813190|NCT01196286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813191|NCT02106325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813192|NCT01634295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813193|NCT02382640|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813194|NCT00397098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813195|NCT01420198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813196|NCT00201825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813197|NCT03175406|||COHORT||PROSPECTIVE|||||||
33813198|NCT05629806|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813199|NCT03875729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Phase 3, randomized, double-blind, placebo-controlled, multinational, multicenter study|t|t|t|t
33813200|NCT03072745|NA|SINGLE_GROUP||SCREENING||NONE||||||
33813201|NCT00907959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813202|NCT03983642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813203|NCT04641715|||COHORT||RETROSPECTIVE|||||||
33813204|NCT04012359|||CASE_CONTROL||PROSPECTIVE|||||||
33813205|NCT01043614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813206|NCT00774605|NON_RANDOMIZED|PARALLEL||||NONE||||||
33813207|NCT02160496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121306|NCT02799550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121307|NCT05378412|RANDOMIZED|PARALLEL||OTHER||NONE||This study is based on a mixed-methods experimental design and concurrent triangulation||||
34121308|NCT06350448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121309|NCT00114725|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34121310|NCT02136225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121311|NCT03064932|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34121312|NCT04095065|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34121313|NCT03424395|NA|SINGLE_GROUP||OTHER||NONE||Single arm (open-label) containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only.||||
34121314|NCT04479592|||COHORT||PROSPECTIVE|||||||
34121315|NCT02844985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121316|NCT04446286|||CASE_ONLY||OTHER|||||||
33813208|NCT00919815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813209|NCT02009865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813210|NCT05747872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34044212|NCT01509560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044213|NCT05852275|NA|SINGLE_GROUP||OTHER||NONE||"This project consists of a quasi-experimental clinical study whose target population is healthy, voluntary adults. Participants will be recruited among men and women, aged 18 years or over, healthy, who belong to the community of the University (Portuguese Catholic University - Porto campus) and who do not meet any of the exclusion criteria.~Individuals will be invited to participate voluntarily in this study, receiving detailed information about the investigation, in order to allow an informed, informed and free decision. Individuals who agree to participate sign an informed consent."||||
34044214|NCT00150488|NA|SINGLE_GROUP||TREATMENT||NONE||Uracyst||||
34044215|NCT05281718|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open Label||||
34044216|NCT00276887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044217|NCT01957098|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
34044218|NCT02028260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044219|NCT05545163|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Each novice resident will place ten times I-gel insertion with each insertion technique in randomized cross over manner by dividing the residents in two groups (5 residents in each group), by draw method. The one group will place I-gel with standard insertion technique and other group will place by modified jaw thrust I-gel insertion technique, then after, the groups will switch over with concerned insertion techniques||||
34044220|NCT04782297|||COHORT||RETROSPECTIVE|||||||
34044221|NCT04481269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044222|NCT04650880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044223|NCT02385838|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34044224|NCT02298777|||CASE_CONTROL||PROSPECTIVE|||||||
34044225|NCT02819973|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044226|NCT03556501|||COHORT||PROSPECTIVE|||||||
34044227|NCT06196112|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044228|NCT04890197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044229|NCT04132869|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This research study uses a cluster randomized design who attend the intervention schools. For the control group, we will invite students from comparison schools that do not participate in the intervention.||||
34044230|NCT01998802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044231|NCT04527718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044232|NCT06270381|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34044233|NCT01948440|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34044234|NCT03117660|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective, randomized, parallel group study||||
34044235|NCT00826683|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34044236|NCT00595855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044237|NCT05907226|||COHORT||CROSS_SECTIONAL|||||||
34044238|NCT04145050|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants as well as researchers will not be informed of trial intervention|Randomized, Cross-Over|t|f|t|f
34044239|NCT01992640|||COHORT||PROSPECTIVE|||||||
34044240|NCT01586923|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044241|NCT04894214|||CASE_CROSSOVER||PROSPECTIVE|||||||
34044242|NCT00781040|||CASE_ONLY||PROSPECTIVE|||||||
34044243|NCT03640390|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34044244|NCT00516672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044245|NCT03207048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044246|NCT04487379|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044247|NCT04405635|||COHORT||PROSPECTIVE|||||||
34044248|NCT02099786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34044249|NCT03443362|||COHORT||PROSPECTIVE|||||||
34044250|NCT05650177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044251|NCT02586038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733647|NCT00383838|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33733648|NCT04687956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733649|NCT05857657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733650|NCT04490434|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34121317|NCT01028235|||||PROSPECTIVE|||||||
34121318|NCT00454935|||COHORT||PROSPECTIVE|||||||
34121319|NCT01049373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733651|NCT03030027|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33733652|NCT05410834|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733653|NCT03161275|||OTHER||PROSPECTIVE|||||||
33733654|NCT04163393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733655|NCT05062668|||CASE_ONLY||RETROSPECTIVE|||||||
33733656|NCT04448470|||COHORT||PROSPECTIVE|||||||
33733657|NCT06205927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733658|NCT05498948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733659|NCT04240899|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group intervention study of adults (18-80 years-old) with Parkinson's Disease and anxiety symptoms undergoing a 6-week intervention of 30-minute yoga classes delivered remotely through videoconferencing 2-3 times per week. There will be baseline testing, a 6-week waiting period, timepoint-two testing, a 6-week intervention, post-intervention testing, and 6-week follow-up testing.||||
33733660|NCT04330079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733661|NCT02337244|||COHORT||PROSPECTIVE|||||||
33733662|NCT00901940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733663|NCT02456922|NA|SINGLE_GROUP||OTHER||NONE||||||
33813211|NCT04128956|RANDOMIZED|PARALLEL||TREATMENT||NONE||a multi-center, international, randomized, open label, controlled trial||||
33813212|NCT01985256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813213|NCT03556852|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33813214|NCT00069706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813215|NCT06285656|||COHORT||PROSPECTIVE|||||||
33813216|NCT01527643|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33813217|NCT01205126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813218|NCT05998720|||COHORT||PROSPECTIVE|||||||
33813219|NCT00629447|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33813220|NCT05624814|||CASE_CONTROL||PROSPECTIVE|||||||
33813221|NCT03012490|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33813222|NCT06173167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813223|NCT04335474|||COHORT||PROSPECTIVE|||||||
33813224|NCT04347005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813225|NCT02889900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813226|NCT00005971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813227|NCT01058694|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33813228|NCT03619044|NA|SINGLE_GROUP||OTHER||NONE||||||
33813229|NCT02682394|||COHORT||PROSPECTIVE|||||||
33813230|NCT01600196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813231|NCT04258891|||COHORT||PROSPECTIVE|||||||
33813232|NCT03133299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813233|NCT01742585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813234|NCT01074281|||COHORT||PROSPECTIVE|||||||
33813235|NCT05603949|||CASE_ONLY||RETROSPECTIVE|||||||
33813236|NCT00824057|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33733664|NCT00259857|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33733665|NCT06103513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733666|NCT04162951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"The participants and the investigator will be kept blinded by the aid of closed sealed envelops.~The measurements will be collected by the aid of assistant resident who will not participating into the study and blinded to it."|Prospective study|t|f|t|t
33733667|NCT05566340|||COHORT||PROSPECTIVE|||||||
33733668|NCT01982422|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733669|NCT05825482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733670|NCT03354494|||COHORT||RETROSPECTIVE|||||||
33733671|NCT01859715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733672|NCT01912248|||CASE_ONLY||CROSS_SECTIONAL|||||||
33733673|NCT05716711|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||GROUP 1 GROUP2 CONTROL GROUP||||
33733674|NCT00072345||||TREATMENT||NONE||||||
33733675|NCT02020668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733676|NCT01271543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733677|NCT03395431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to group assignment|A single blind parallel group randomized control trial|f|f|f|t
33733678|NCT00774995|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733679|NCT02804503|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33733680|NCT02707614|||COHORT||PROSPECTIVE|||||||
33733681|NCT02961426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733682|NCT02047110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733683|NCT06357637|||COHORT||PROSPECTIVE|||||||
33733684|NCT01251484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733685|NCT05765968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733686|NCT01800903|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33733687|NCT06664476|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33733688|NCT03362515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733689|NCT03302702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733690|NCT00590304|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33733691|NCT04607408|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33733692|NCT05024565|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733693|NCT02863224|||CASE_CONTROL||PROSPECTIVE|||||||
33733694|NCT02514252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813237|NCT00855296|||CASE_CONTROL||PROSPECTIVE|||||||
33813238|NCT06604754|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33813239|NCT00882856|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33813240|NCT00374998|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121320|NCT01306747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121321|NCT00998010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121322|NCT02965625|||COHORT||PROSPECTIVE|||||||
34121323|NCT06543875|||COHORT||CROSS_SECTIONAL|||||||
34121324|NCT00003645|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121325|NCT03961802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121326|NCT04067232|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733695|NCT03096522|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733696|NCT00961324|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733697|NCT03032003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733698|NCT00203203|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33733699|NCT00317681|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33813241|NCT00038597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813242|NCT01794351|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33813243|NCT01643122|||COHORT||PROSPECTIVE|||||||
33813244|NCT03236480|||CASE_CONTROL||PROSPECTIVE|||||||
34121327|NCT02361671|||COHORT||PROSPECTIVE|||||||
34121328|NCT01025557|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34121329|NCT00107731|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34121330|NCT05860764|||OTHER||PROSPECTIVE|||||||
34121331|NCT02633735|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel cluster-randomized clinical trial at 14 general EDs in two large care system to evaluate the impact of appy-CDS intervention with a pre and post intervention phases||||
34121332|NCT01426061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34121333|NCT06007417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121334|NCT00216333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121335|NCT03830580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121336|NCT00770302|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121337|NCT01443949|||||RETROSPECTIVE|||||||
34121338|NCT00111072||||TREATMENT||||||||
34121339|NCT00985647|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121340|NCT04361500|||CASE_ONLY||PROSPECTIVE|||||||
34121341|NCT04818905|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121342|NCT04601116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A prospective, two-armed, randomized (1:1), multicenter, national, double-blind, placebo-controlled study in early breast cancer patients.|t|t|t|t
34121343|NCT05465070|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121344|NCT04044963|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121345|NCT02367963|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34121346|NCT04435314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Subjects will be randomized to receive either nitazoxanide (n=100) or placebo (n=100)|t|t|t|t
33733700|NCT01898793|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33733701|NCT05553925|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will implement the combined intervention (online weight management program plus coaching and patient navigator support) as part of standard of care for at least 5,000 patients with overweight or obesity. All eligible patients, in each participating Brigham and Women's Hospital practice/site, who wish to enroll will receive the intervention. The investigators will invite a sample of enrolled patients to participate in a single-arm, longitudinal study to assess changes in patient-reported outcomes.||||
33733702|NCT05061160|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813245|NCT00157222|||DEFINED_POPULATION||OTHER|||||||
33813246|NCT05143099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813247|NCT00839085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33813248|NCT00025376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813249|NCT02695953|||CASE_ONLY||PROSPECTIVE|||||||
33813250|NCT01709630|||COHORT||PROSPECTIVE|||||||
33813251|NCT05597215|||CASE_ONLY||PROSPECTIVE|||||||
34121347|NCT02961244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121348|NCT02961036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34121349|NCT00784862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121350|NCT01819272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121351|NCT01301677|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34121352|NCT01822665|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34121353|NCT02507154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121354|NCT02045784|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34121355|NCT02568722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121356|NCT01535287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121357|NCT01336244|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34121358|NCT04330209|||COHORT||RETROSPECTIVE|||||||
34121359|NCT03852784|||COHORT||RETROSPECTIVE|||||||
34121360|NCT01228214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121361|NCT04556344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121362|NCT02527395|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34121363|NCT06452693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121364|NCT01486303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121365|NCT04389073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121366|NCT04022278|||COHORT||PROSPECTIVE|||||||
34121367|NCT03845829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121368|NCT03764111|||COHORT||PROSPECTIVE|||||||
34121369|NCT02023619|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34121370|NCT02734329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121371|NCT01345448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121372|NCT02061475|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121373|NCT03177538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121374|NCT06101303|||CASE_ONLY||PROSPECTIVE|||||||
34121375|NCT00755170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121376|NCT04924621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34121377|NCT03775993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149178|NCT06172400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149179|NCT02383459|||COHORT||PROSPECTIVE|||||||
34121378|NCT03069378|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, phase II study to evaluate the efficacy of the oncolytic herpes virus talimogene laherparepvec, given in combination with pembrolizumab for patients with metastatic and/or locally advanced sarcomas.||||
34121379|NCT02147821|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34121380|NCT03433976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121381|NCT03940560|NA|SINGLE_GROUP||TREATMENT||NONE||Safety and efficacy study||||
34121382|NCT05748821|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121383|NCT00410475|||COHORT||PROSPECTIVE|||||||
34121384|NCT05978336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34121385|NCT03238989|||COHORT||PROSPECTIVE|||||||
34121386|NCT04792385|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34121387|NCT06716593|||COHORT||RETROSPECTIVE|||||||
34121388|NCT03753022|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The study was planned in 3 groups. Group G5 (control group: no changes will be made to the value of PEEP). Group G10 \[after 30 minutes of admission (time 0) the PEEP will be raised to 10 cmH2O (time1) for 30 minutes and then returned to 5 cm H2O (time 2)\]. Group G15 \[after 30 minutes of admission (time 0) the PEEP will be raised to 15 cmH2O (time 1) for 30 minutes and then returned to 5 cm H2O (time 2)\].|t|f|t|t
34121389|NCT01627691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121390|NCT00589511|||CASE_ONLY|||||||||
34121391|NCT03807388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121392|NCT03348124|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The researchers are outcome assessors, independent from the intervention.|Cluster randomized intervention study with waiting list control group.|f|f|f|t
34121393|NCT02030821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121394|NCT06715098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121395|NCT00690326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34121396|NCT02986074|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34121397|NCT06271824|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121398|NCT01730872|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121399|NCT04941690|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121400|NCT06487780|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two groups, with an equal number in each group.||||
34121401|NCT00819429|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34121402|NCT02901886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121403|NCT05221008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR6508 compared with placebo|t|t|t|t
34121404|NCT00606489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121405|NCT01400009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121406|NCT04992468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121407|NCT04398576|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34121408|NCT01624714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121409|NCT01555866|NON_RANDOMIZED|PARALLEL||||NONE||||||
34121410|NCT06718231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The traditional Chinese medicine doctor will administer the intervention based on the randomized grouping to ensure the double-blind nature of the study. Neither anesthesiologists nor outcome assessors will aware of patient randomization. The participants will be blinded with reference to Song et al.'s study. In TAES group, electrode pads will be fixed on the bilateral HT7 (Shenmen), PC6 (Neiguan), LI4 (Hegu), LU5 (Chize) and Extra (Anmian), the current set based on the participants ' maximum tolerance and muscle fibrillation. In the Sham-TAES group, electrodes will be fixed at 4 cm interior to the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints , and the frequency current setting given in the same way as in the TAES group to make the patients think that they received the TAES treatment. Therefore, all participants will be unaware of randomization||t|f|f|t
34121411|NCT00382174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121412|NCT03147183|||COHORT||PROSPECTIVE|||||||
34121413|NCT02405988|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121414|NCT03510273|NA|SINGLE_GROUP||TREATMENT||NONE||Thermal coagulator ablation treatment||||
34121415|NCT04638751|||COHORT||PROSPECTIVE|||||||
34121416|NCT01178840|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34121417|NCT06714747|||COHORT||RETROSPECTIVE|||||||
34121418|NCT05542459|||COHORT||PROSPECTIVE|||||||
34121419|NCT02629926|||CASE_ONLY||PROSPECTIVE|||||||
34121420|NCT01125579|||COHORT||PROSPECTIVE|||||||
34121421|NCT04830046|||COHORT||PROSPECTIVE|||||||
34121422|NCT05595200|||COHORT||PROSPECTIVE|||||||
34121423|NCT02448199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121424|NCT01861847|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34121425|NCT05447689|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention will be delivered across eight weeks (1 session weekly).||||
34121426|NCT06714071|||COHORT||PROSPECTIVE|||||||
34121427|NCT02295462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34121428|NCT02525926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121429|NCT02662998|||COHORT||PROSPECTIVE|||||||
34121430|NCT01667250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34121431|NCT05292001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled trial|t|t|t|t
34121432|NCT03714438|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34121433|NCT00146744|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34121434|NCT00411424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121435|NCT06353503|NA|SINGLE_GROUP||TREATMENT||NONE||single armed study open label||||
34121436|NCT00532844|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121437|NCT02923154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121438|NCT06159907|||COHORT||RETROSPECTIVE|||||||
34121439|NCT03767543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149180|NCT02478450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149181|NCT06503120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiologists who evaluate the magnetic resonance images, physicians performing transient elastography using Fibroscan, and statisticians analysing the final results will be blinded to the treatment assignments.|A 12-week, prospective, two parallel-group, randomized controlled trial. One group is Mediterranean-diet intervention group; Another group is standard care|f|f|f|t
34121440|NCT03567707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|With the exception of the study nurse performing the vaginal seeding procedure, all study participants and study personnel will be masked (blinded) to the infant's randomization status.|This study will enroll pregnant women during the third trimester of pregnancy whose infants have a first-degree relative ( the mother, biological father, or full sibling) with atopic disease or food allergy.The study excludes women with a history of active atopic dermatitis within the past 5 years to avoid the potential transfer of vaginal microbiota to the infant that may predispose to atopic disease.Women undergoing elective, unlabored C-section will be randomized to have their infants undergo vaginal seeding or placebo seeding plus standard of care. Women and infants who undergo placebo seeding will serve as a control population.In addition, women and infants undergoing vaginal delivery will also be included as a second control group, in part to determine if vaginal seeding will decrease allergen sensitization rates to a level similar to vaginally delivered infants, and also to serve as a comparator group for gut microbiome development during the infant's first year of life.|t|t|t|f
34121441|NCT00411489|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34121442|NCT03692403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121443|NCT02053844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34121444|NCT02318017|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34121445|NCT00099021|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34121446|NCT05926063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Comparison of two treatment strategies||||
34121447|NCT05572879|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121448|NCT05828186|||COHORT||PROSPECTIVE|||||||
34121449|NCT00186628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121450|NCT03905915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121451|NCT05431647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121452|NCT02350218|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121453|NCT02062736|||COHORT||PROSPECTIVE|||||||
34121454|NCT06488924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121455|NCT06565468|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Collected data will be stored and managed using REDCap secure web-based database management system. Any personally identifiable information will be coded.|Cohort cross-over design. The study population will be randomized into two cohorts. The first cohort will begin with the control phase and then transition to the intervention phase. The second cohort will begin with the intervention phase and then transition to the control phase.||||
34121456|NCT02097784|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121457|NCT01453166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121458|NCT03693495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121459|NCT04087356|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121460|NCT04321616|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open randomized adaptive controlled trial||||
34121461|NCT03826043|NA|SINGLE_GROUP||SCREENING||NONE||||||
34121462|NCT03965403|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive the same intervention||||
34121463|NCT01356394|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121464|NCT05721768|||COHORT||RETROSPECTIVE|||||||
33733703|NCT03766503|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.||||
33733704|NCT03161561|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Measurement of the capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.||||
33733705|NCT02806479|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733706|NCT01993108|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33733707|NCT02052479|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733708|NCT01797328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33733709|NCT03945877|||OTHER||OTHER|||||||
33733710|NCT01257204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733711|NCT00685932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733712|NCT06413810|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33733713|NCT04543552|||COHORT||PROSPECTIVE|||||||
33733714|NCT02193594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733715|NCT01575327|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33733716|NCT04002765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"All statistical analysis, including power calculation, will be performed in collaboration with the Plate-forme en méthodologie statistique of the UCLouvain. Pre-study estimations revealed that a sample size of 289 patients produces a two-sided 95% confidence interval with a precision (half-width) of 0,04 when the actual proportion is near 0,14."|||||
33733717|NCT05023590|RANDOMIZED|PARALLEL||TREATMENT||NONE||monocentric, 1:1 randomized (cryo ablation vs. radiofrequency ablation), open-label, parallel, registry||||
33733718|NCT06539026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* The care provider intraoperative; both the anesthesiologist and the obstetrician will be blinded regarding the intervention.~* The anesthetic residents who will assess the outcome of hypotension are blind regarding the group allocation"|a prospective, randomized, parallel-group, superior, controlled single-blinded clinical study|f|t|f|t
33733719|NCT02168166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733720|NCT06078046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this trial, neither the staff, participants nor care provider can be masked to allocation. The data analyst will be blinded after study completion by having the intervention group information coded.||f|f|t|f
34121465|NCT04461496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121466|NCT03250143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized prospective study||||
34121467|NCT02234726|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34121468|NCT03226912|||COHORT||OTHER|||||||
34121469|NCT02370472|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34149182|NCT02570880|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121470|NCT01482858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In this study the oral calcium treatments are blinded. The subjects, the investigators and any personnel involved in subjects' assessment, monitoring, analysis and data management will be blinded to the subject formulation assignment except the Sponsor who will be responsible for preparing, dispensing and labeling the investigational product IP. Blinded labels will be affixed to the vials prior to dosing by the un-blinded Sponsor.|This is a prospective randomized double-blind multicenter study evaluating the safety of GASP and its analgesic effect on pain resulting from OCVF following oral administration of GASP vs. placebo.|t|t|t|f
34121471|NCT04034992|||COHORT||OTHER|||||||
34121472|NCT03707886|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34121473|NCT05415488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will only be told that the both diets aim to relieve symptoms of IBS, and that none of the diets are expected to cure the disorder. No specific names of the diets will be given.|Intervention study with 2 parallel arms (1:1)|t|f|f|f
34121474|NCT05981326|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121475|NCT05081362|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121476|NCT04960124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121477|NCT05211180|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants will know which group they have been randomized to. The investigator and statistician will not know which group a participant belongs to. Group identifiers will be removed prior to analysis.|This study uses a type 1 hybrid design with participants randomized in a 1:1 ratio to either Vida Sana y Completa (an obesity intervention with integrated treatment for food insecurity) or Vida Sana alone (the comparator arm). Vida Sana is a cultural-adaption of Group Lifestyle Balance, a 12-month intervention that targets at least 5% weight loss and at least 150 minutes per week of moderate-to-vigorous physical activity.|f|f|t|t
34121478|NCT05253404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant will going general anesthesia||t|f|f|f
34121479|NCT02710188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121480|NCT01060787|||COHORT||PROSPECTIVE|||||||
34121481|NCT00049361||||TREATMENT||NONE||||||
34121482|NCT05742490|||COHORT||PROSPECTIVE|||||||
34121483|NCT04096417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121484|NCT01576783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121485|NCT04709510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Retrospective Cohort||||
34121486|NCT02249403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121487|NCT03586375|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34121488|NCT00163644|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121489|NCT01500317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34121490|NCT06192914|||COHORT||PROSPECTIVE|||||||
34121491|NCT05081921|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A randomization list and envelope based procedure will be used to eliminate selection bias. In order to maximally reduce bias, the trial is double-blind, with all involved subjects and the investigator blinded to the treatment. The randomization list will not be available to any person involved in the conduct. The evaluation of the trial results will not be performed until the trial database is locked.|Randomized|t|t|t|t
34121492|NCT05805137|NA|SINGLE_GROUP||OTHER||NONE||||||
34121493|NCT04097821|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|"This open-label, multi-center, phase Ib/II platform study design consists of 3 parts. Part 1 is a phase Ib dose escalation and safety run-in for the 5 novel agents in combination with ruxolitinib to assess safety, tolerability and to confirm recommended Phase II dose.~Parts 2 and 3 are phase II selection and expansion respectively, to assess preliminary efficacy of the combination treatments from Part 1 that are evaluated as safe and tolerable.~The number of combination treatment arms opening in part 2 will depend on the results of Part 1. In Part 2, interim analysis was planned to determine if combination treatment (s) can be expanded in Part 3"||||
34121494|NCT00203385|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34121495|NCT04032821|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each subject was randomly given Alkotinib capsules on an empty stomach or after a meal, and the cleaning period between the two dosages was set as 14 days. The actual dosing time was subject to the original clinical records. After admission to the ward on day -1 (1 day before drug administration), subjects will eat light dinner A 1:1 ratio was randomly assigned to 2 sequences (1=AB, 2=BA). Each subject was subject to two cycles of trials, and the study drug was taken once on an empty stomach or after meal according to the dosing sequence in the randomization table.||||
34121496|NCT03709901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assignment to treatment (active allograft, or placebo, or conservative care) is open label at Day 0 of the Active Phase to the extent that subjects receiving allograft or placebo will not be aware of what they have received, while those assigned to conservative care will be aware. All site study staff will be aware of the group to which each subject is randomized. Sites will be trained to ensure that subjects receiving the allograft or placebo treatment will remain blinded to their treatment throughout the study duration.|Multi-center, prospective, randomized, parallel-arm study.|t|f|f|f
34121497|NCT04817202|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34121498|NCT04323254|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121499|NCT06086743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121500|NCT04420676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733721|NCT04639648|||COHORT||PROSPECTIVE|||||||
33733722|NCT00279708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733723|NCT06193538|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a single arm, single center IIT clinical study to evaluate the safety and efficacy of NV-A01 in patients with advanced glioblastoma.||||
33733724|NCT04550624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733725|NCT04118010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733726|NCT03169491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The CPAP equipment will be programed by the technician, not knowing the children, the parents or the main researcher whether the pressure is suboptimal or therapeutic.|All recruited children with diagnosis of mild to moderate OSAS will be randomized to suboptimal (CPAP at 4 cmH2O) or therapeutical (CPAP auto from 4 to 15 cmH2O) arms, from a predetermined list in two groups of 50, blocks of 10 patients. All patients with diagnosis of severe OSAS will receive therapeutic pressure, and are considered as part of a third arm not included in the sample size.|t|f|t|f
33733727|NCT02354638|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
33838497|NCT05768165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blinded|Intervention versus care as usual|f|f|t|t
34121501|NCT02283034|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34121502|NCT06255405|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121503|NCT06056180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The person among the researchers who will evaluate the individuals will be blinded to the treatment.~The person who will make the statistical evaluations of the data will be blind to the treatment and evaluations to be made to the individuals."||f|f|t|t
34121504|NCT03004885|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34121505|NCT04804124|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121506|NCT02047448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121507|NCT04123730|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The patient will be blinded for the oxygen supply. An independent person will prepare the oxygen setup with O2matic in manual mode for fixed dose oxygen and in automatic mode for automated oxygen titration. The assessor conducting the walking test is blinded.|randomised crossover trial|t|f|f|t
34121508|NCT01802788|||COHORT||PROSPECTIVE|||||||
34121509|NCT02441842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121510|NCT05386225|||CASE_CONTROL||PROSPECTIVE|||||||
34121511|NCT01149746|RANDOMIZED|CROSSOVER||||NONE||||||
34121512|NCT03999580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The vitamin D will be donated by a pharmaceutical company. It will be dispensed in anonymized bottles with the content similar in color and taste in order to keep patients unaware of their allocation. We will implement a number of study maneuvers aimed at minimizing measurement biases. These include: (1) masking of the data; (2) documenting the use of major co-interventions such as other multivitamin supplements.|"Time zero for each patient will be the day of randomization. Patients will be randomly assigned (1:1 ratio) in one of two study arms:~3,000 or 4,000 IU/day, according to the patient body weight, as induction for 4 weeks then 2,000 IU/day as maintenance for 48 weeks. Control: 600 IU/day of Vitamin D as induction (4 weeks) and maintenance (48 weeks)."|t|t|t|f
34121513|NCT02717325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121514|NCT00498992||||SUPPORTIVE_CARE||||||||
34121515|NCT05920174|NA|SINGLE_GROUP||OTHER||NONE||an implantable neural acquisitor \& stimulator system||||
34121516|NCT05746858|||COHORT||OTHER|||||||
34121517|NCT00746525|NA|SINGLE_GROUP||OTHER||NONE||||||
34121518|NCT00901303|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121519|NCT01043718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121520|NCT01332214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34121521|NCT02015247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121522|NCT01497834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121523|NCT01416961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121524|NCT01282866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121525|NCT01485848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121526|NCT03382912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121527|NCT01530373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34121528|NCT05713461|NON_RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants do not know if they have metabolic syndrom Physical training supervisors do not know if participants have metabolic syndrom|To compare the effects of an interval training program in obese women with metabolic syndrom vs obese women without metabolic syndrom|t|f|t|f
34121529|NCT06467630|||COHORT||PROSPECTIVE|||||||
34121530|NCT02663154|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34121531|NCT06716918|||COHORT||PROSPECTIVE|||||||
34121532|NCT00297869|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34121533|NCT00014729||||TREATMENT||||||||
34121534|NCT00005579||||TREATMENT||NONE||||||
34121535|NCT04757311|||CASE_ONLY||OTHER|||||||
34121536|NCT03744338|||OTHER||CROSS_SECTIONAL|||||||
34121537|NCT02300233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121538|NCT03492047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121539|NCT02756403|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34121540|NCT01900665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121541|NCT06328842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121542|NCT05778695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121543|NCT00185302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121544|NCT02404168|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34121545|NCT00370292|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121546|NCT00274183|||COHORT||PROSPECTIVE|||||||
34121547|NCT06266000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733728|NCT00700791|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33733729|NCT04921358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733730|NCT02208791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733731|NCT01342562|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34121548|NCT01138475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121549|NCT03737552|||CASE_CONTROL||PROSPECTIVE|||||||
34121550|NCT02443701|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33733732|NCT01735292|NA|SINGLE_GROUP||||NONE||||||
33733733|NCT04708327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
33733734|NCT05973747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733735|NCT05941026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Following recruitment, students were divided into a study and a control group by randomization (1:1 randomization)||||
33733736|NCT05268471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733737|NCT03551470|||COHORT||PROSPECTIVE|||||||
33733738|NCT03886064|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733739|NCT02529384|||||PROSPECTIVE|||||||
33838498|NCT01496222|||COHORT||PROSPECTIVE|||||||
33838499|NCT06350253|||COHORT||CROSS_SECTIONAL|||||||
33838500|NCT00790387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121551|NCT00466180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121552|NCT05236036|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34121553|NCT03358030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121554|NCT01302184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733740|NCT06005025|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Firstly, the names of the personnel will be listed alphabetically. A number will be written opposite each personnel and the number of 160 personnel will be determined from the total number of administrative personnel with high risk level by randomisation generated by an independent researcher in the computer environment. The sequence number of the personnel determined by randomisation will be divided into group A (study) and group B (control) in the computer environment and the information showing that they are assigned to group A and B according to the randomisation table will be placed in an opaque envelope. This envelope will be kept by the coordinator researcher and when the staff is approached for training, it will be learnt which group the staff is in. Since all personnel will be trained, the personnel will be blinded. The data will be computerised by the researcher and a biostatistician independent of the research will blind the groups unknowingly|The study was a prospective, parallel, two-arm (1:1), randomised controlled experimental study.|t|f|t|t
33733741|NCT01745029|||CASE_ONLY||PROSPECTIVE|||||||
33733742|NCT04484246|||COHORT||PROSPECTIVE|||||||
33733743|NCT03337724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733744|NCT02487589|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813252|NCT03884478|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The web app is programmed to invite an eligible sub-sample of participants from the larger population to take part in an evaluation study during the competition's 3rd monthly round. Those who consent to participate are automatically randomized by Qualtrics Research Suite to receive 1 of 3 unique sequences of feedback (i.e., Alcohol \& Stigma-Coping, Alcohol \& Control, or Control topics only) during 2 intervention rounds taking place during a 6-month period.|t|f|t|f
33813253|NCT01853904|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34121555|NCT04942431|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33813254|NCT02841020|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34121556|NCT06280248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121557|NCT02239926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121558|NCT00137059|RANDOMIZED|PARALLEL||||DOUBLE||||||
34121559|NCT04037228|||COHORT||PROSPECTIVE|||||||
34121560|NCT00006356|RANDOMIZED|||TREATMENT||||||||
33733745|NCT05498194|||COHORT||PROSPECTIVE|||||||
33733746|NCT01813565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733747|NCT05009251|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Providers who prescribe vaccination and diagnose conditions will not be randomized to study arms or informed of patient assignment. Although patients will not be explicitly informed which arm they have been randomized to, they will be aware of the messages they receive.|"Patients from the high-risk sample will be randomly assigned to one of five arms:~* No-Contact Control Arm~* Reminder Control Arm~* High Risk Only Arm~* High Risk with Explanation Based on Medical Records Arm~* High Risk with Explanation Based on Algorithm Arm"|f|t|f|f
33733748|NCT03057691|||COHORT||PROSPECTIVE|||||||
33733749|NCT02756793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733750|NCT01800916|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33733751|NCT03595371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733752|NCT02223767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813255|NCT06026202|||OTHER||PROSPECTIVE|||||||
33813256|NCT03740386|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|We use a program to randomize three groups. Double blind study No sham or placebo|Three randomized groups|t|f|t|f
33813257|NCT05271045|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813258|NCT03507998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813259|NCT04105907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813260|NCT05776056|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participant, investigator/study clinicians, and clinical assessors (raters) are blinded to study drug until study completion for each participant.|The study compares MPH (intervention) and PBO (control) using an aggregated N-of-1 trial design. N-of-1 clinical trials are multi-cycle, double-blinded, placebo-controlled cross-over trials based on an individual. In aggregated N-of-1 trials, data from a cohort of participants are analyzed together, often to test the efficacy of a treatment whilst controlling for the heterogeneity of response. Our design consists of 2 cycles, with each cycle including 4 weeks of MPH 10mg twice daily and 4 weeks of PBO twice daily, each followed by a 1-week washout. This provides a total of 8 weeks on active drug and 8 weeks on placebo. Order of MPH vs PBO within cycle is randomly assigned and double-blinded.|t|t|t|t
34121561|NCT01639469|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34121562|NCT01205503|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34121563|NCT05856955|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121564|NCT03425916|||CASE_CONTROL||PROSPECTIVE|||||||
34121565|NCT03788655|||COHORT||PROSPECTIVE|||||||
34121566|NCT05814237|||COHORT||PROSPECTIVE|||||||
34121567|NCT00705705|RANDOMIZED|PARALLEL||||NONE||||||
34121568|NCT02028845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121569|NCT02125955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121570|NCT01868828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121571|NCT00700648|||CASE_ONLY||PROSPECTIVE|||||||
34121572|NCT06216158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121573|NCT03929003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told whether they are in the control or experimental group.|Two group randomization|t|f|f|f
34121574|NCT03381118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121575|NCT03310944|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34121576|NCT00586794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121577|NCT04831840|||COHORT||PROSPECTIVE|||||||
34121578|NCT06353477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \>12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.|f|f|f|t
34121579|NCT03484728|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participants were told that the cream has poweful analgetic effect in one session; and that the cream has minmal analgesic effect in another session.|CPM was tested before and after the placebo manipulation (body cream application on forearm); based on the expectation of the cream analgesic response (high or low), two types of placebo manipulations were performed for each participant.|t|f|t|f
34121580|NCT01871389|||||PROSPECTIVE|||||||
34121581|NCT00159926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121582|NCT02785328|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34121583|NCT05439733|||COHORT||PROSPECTIVE|||||||
34121584|NCT00529672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121585|NCT04023942|RANDOMIZED|PARALLEL||TREATMENT||NONE||This clinical study is a single-center 2\*2 factorial randomized trial. For the weight maintenance step, participants will be randomized into one of the four weight maintenance intervention arms.||||
34121586|NCT03431454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34121587|NCT03902964|||COHORT||RETROSPECTIVE|||||||
34121588|NCT02253043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121589|NCT03842735|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"Eligible patients who provided consent were assigned to one of the two groups according to a cluster time selection model. The methodology was discussed and agreed with expert methodologists of the A.O.U. Città della Salute e della Scienza research group and based assignation to the two groups according to the time of hospitalization: EG enrollment May 2016-December 2016, March 2017-May 2017, November 2017-June 2018 and CG enrollment January 2017-February 2017, June 2017-October 2017, July 2018-August 2018."||||
34121590|NCT00008086||||TREATMENT||||||||
34121591|NCT02217618|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121592|NCT06719492|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One group receives additional nutrition education, the other (control) group receives typical clinic care. Both groups have an option to include a supplemental nutritional beverage if they choose.||||
34121593|NCT05341947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121594|NCT02071771|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34121595|NCT04436341|||COHORT||PROSPECTIVE|||||||
34121596|NCT02679378|||COHORT||PROSPECTIVE|||||||
34121597|NCT02575443|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34121598|NCT06174207|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34121599|NCT02319486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121600|NCT03986125|RANDOMIZED|PARALLEL||TREATMENT||NONE|Prior to randomization all parties will be blinded to experimental condition. Post treatment and follow up assessments will be conducted by a blinded research assistant.|||||
34121601|NCT01960881|||COHORT||PROSPECTIVE|||||||
34121602|NCT00441272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121603|NCT06716372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121604|NCT04575519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentre, phase IIB, placebo controlled, randomized, 3-arm trial in DS and MDR TB patient|t|t|t|t
34121605|NCT06718764|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121606|NCT03827811|||COHORT||PROSPECTIVE|||||||
34121607|NCT04364087|||COHORT||CROSS_SECTIONAL|||||||
34121608|NCT06717412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34121609|NCT06218810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121610|NCT05193760|||CASE_ONLY||CROSS_SECTIONAL|||||||
34121611|NCT03434223|||COHORT||PROSPECTIVE|||||||
34121612|NCT04628130|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34121613|NCT01809665|||CASE_ONLY||PROSPECTIVE|||||||
34121614|NCT02024854|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121615|NCT02832570|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34121616|NCT05288023|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants, investigators, and program implementers will not be actively masked from the study arm allocation given that no placebo will be used. Outcome assessors and data analysts will be masked.|Cluster-randomized trial with response adaptive allocation||||
34121617|NCT00611390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121618|NCT04589169|||COHORT||PROSPECTIVE|||||||
34121619|NCT01248793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121620|NCT01728142|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34121621|NCT01497197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121622|NCT06468787|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121623|NCT04283188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121624|NCT02947828|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121625|NCT05477654|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121626|NCT02020590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121627|NCT00788814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121628|NCT05009095|NA|SINGLE_GROUP||TREATMENT||NONE||The study will use a nonconcurrent AB multiple baseline design, with A representing the baseline phase and B representing the intervention phase with a postintervention non-treatment phase.||||
34121629|NCT01497847|||COHORT||PROSPECTIVE|||||||
34121630|NCT00408980|RANDOMIZED|CROSSOVER||SCREENING||SINGLE||||||
34121631|NCT00364169|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34121632|NCT05011253|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33813261|NCT01123200|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121633|NCT00960544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121634|NCT03130829|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, double-blind, multicenter study|t|t|t|t
34121635|NCT00244621|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121636|NCT01897493|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121637|NCT04169464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121638|NCT00046904|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34121639|NCT04333615|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34121640|NCT04444089|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34121641|NCT02795494|||COHORT||PROSPECTIVE|||||||
33733753|NCT00678691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121642|NCT05362994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will be masked about which treatment strategy will be executed. Randomization will be done after diagnostic invasive pelvic angiography. The intervention procedure between both randomization groups is comparable, thus unmasking is difficult.|Randomization will take place before angioplasty. Patients will be randomized to either the plain old balloon (POB) group or the drug-eluting balloon (DEB) group. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group. While in the drug-eluting balloon (DEB) group, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained.|t|f|f|f
33733754|NCT05835453|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|It will be a single-blind study in which only the evaluator will not know the designation of the groups because he has not participated in the study's randomization and implementation process. Due to the tray test and demonstration of the bleaching procedure, the operator and the participant cannot be blinded.|This is a randomized, single blind (evaluators), split mouth and equivalence study.|f|f|t|t
33733755|NCT00584467|||COHORT||PROSPECTIVE|||||||
33733756|NCT00145509|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121643|NCT04486690|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|- Double blind study|"2 groups of patients subjected to open heart surgery : Propofol group: Propofol, dose 0.5-2 mg/kg.~* Ketofol group: Ketofol,( dose 0.25-1 mg/kg propofol plus 0.25-1 mg/kg ketamine diluted in normal saline with maintained 1:1 ratio between propofol and ketamine. )"|t|f|t|f
34121644|NCT01317303|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34121645|NCT02604459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individuals assessing the patients for delirium after surgery will be unaware of the treatment in the operating room.||f|f|f|t
34121646|NCT05908162|||COHORT||PROSPECTIVE|||||||
34121647|NCT03421184|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121648|NCT03439605|||COHORT||CROSS_SECTIONAL|||||||
34121649|NCT03308682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121650|NCT05948189|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|none of the participants did not know the group they are in.|94 (49 female and 45 male) volunteer academicians divided into two groups:intervention group (n=47) and control group (n=47), randomly.|t|f|f|f
34121651|NCT05439980|||OTHER||PROSPECTIVE|||||||
34121652|NCT01482130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121653|NCT03309982|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||A randomized placebo-controlled cross-over design study|t|t|t|f
34121654|NCT03368781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||None randomized, single-arm, open label.||||
34121655|NCT04197284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research will be single-blind. Randomization of patients will be performed immediately prior to physical therapy using web page www.randomization.com, and the results of the randomization will be known to the physician who will not be directly involved in the treatment or examination of patients.||f|f|t|t
34121656|NCT04772209|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Bicarbonate vs Heparin group (femoral vs jugular catheter)||||
34121657|NCT01044030|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121658|NCT06632626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, randomized, controlled trial|t|f|f|f
34121659|NCT01995747|||CASE_ONLY||RETROSPECTIVE|||||||
34121660|NCT02834429|||COHORT||PROSPECTIVE|||||||
34121661|NCT02332473|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121662|NCT00894595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121663|NCT04595786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121664|NCT03768427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121665|NCT00945659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||3 group (Standard Care: Continuous Glucose Monitor; Continuous Glucose Monitor + Behavior Therapy) X 4 time points (0, 3, 6, and 9 months) Repeated measures randomized treatments design.||||
34121666|NCT03912870|||COHORT||PROSPECTIVE|||||||
34121667|NCT01325064|||COHORT||PROSPECTIVE|||||||
34121668|NCT04482725|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34121669|NCT05505461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121670|NCT00054743||||TREATMENT||||||||
33733757|NCT03279016|||OTHER||RETROSPECTIVE|||||||
33733758|NCT04465045|||COHORT||RETROSPECTIVE|||||||
33733759|NCT04046471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733760|NCT04394728|||CASE_ONLY||PROSPECTIVE|||||||
33813262|NCT02735005|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33813263|NCT02860702|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34121671|NCT03087175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121672|NCT05771129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121673|NCT04960007|||CASE_CROSSOVER||PROSPECTIVE|||||||
34121674|NCT06714695|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34121675|NCT03293121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121676|NCT05821660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective, two-arm interventional study|t|f|f|f
34121677|NCT03637491|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34121678|NCT02805543|||CASE_CONTROL||RETROSPECTIVE|||||||
34121679|NCT01306526|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121680|NCT01291108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121681|NCT05556889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121682|NCT03670160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121683|NCT04065204|||CASE_CONTROL||RETROSPECTIVE|||||||
34121684|NCT06461039|NA|SEQUENTIAL||TREATMENT||NONE||||||
34121685|NCT00395473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121686|NCT01299506|||OTHER||PROSPECTIVE|||||||
34121687|NCT04460781|||COHORT||PROSPECTIVE|||||||
34121688|NCT03070990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121689|NCT03520309|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33813264|NCT03400748|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33813265|NCT01270906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733761|NCT04309435|RANDOMIZED|PARALLEL||OTHER||SINGLE|Clinical research data will be gathered at baseline, post-intervention (week 8) and variable follow-up \[week 24; only those randomised in the first 5 (England) to 8 (Scotland) months\] by research assistants (RAs). RAs will be masked to group allocation to demonstrate to future funders this is achievable in an Umbrella trial. Blind-breaks will be recorded, and minimised using previously successful strategies (e.g., separate offices / diaries).|This study is a pilot/feasibility Umbrella trial, comprising of 3 'interventionist-causal' trials (IC-RCTs).|f|f|f|t
33733762|NCT05104372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomised intervention and a control arm, running in parallel|f|t|t|t
34121690|NCT00795028|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34121691|NCT05067868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121692|NCT05804929|||COHORT||CROSS_SECTIONAL|||||||
34121693|NCT01326299|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34121694|NCT02320864|||COHORT||PROSPECTIVE|||||||
34121695|NCT05925348|||COHORT||PROSPECTIVE|||||||
34121696|NCT05412992|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sponsor, the investigator, personnel at the clinical study unit who are directly involved with monitoring and/or performing study procedures and assessments, and the subjects will be blinded to treatment assignment|Subjects will be randomized in 1:1 ratio to receive DMTS or matching placebo|t|t|t|t
34121697|NCT00998257|||COHORT||PROSPECTIVE|||||||
34121698|NCT05795270|||COHORT||PROSPECTIVE|||||||
34121699|NCT03820011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121700|NCT04982991|NA|CROSSOVER||TREATMENT||NONE||||||
34121701|NCT00509327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121702|NCT03366363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Acupuncturist (Electro-acupuncture group and Manual acupuncture group), Participant, Outcome Assessor||f|f|t|t
34121703|NCT02774434|NA|SINGLE_GROUP||SCREENING||NONE||||||
34121704|NCT00692887|||CASE_CONTROL||PROSPECTIVE|||||||
34121705|NCT04270344|||COHORT||PROSPECTIVE|||||||
34121706|NCT03389308|NA|SINGLE_GROUP||TREATMENT||NONE|Each treatment cycle will consist of 8 weeks on treatment, followed by 8 weeks off treatment with a maximum of 2 treatment cycles allowed for up to 1 year. Subjects should be assessed at minimum every 8 weeks for disease activity. Once a subject completes two cycles of treatment or reaches Week 52, the subject will be discharged from the study. Subjects may not start a new treatment cycle past Week 36 from Baseline Visit without prior sponsor approval. The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject.|This is an international, multicenter, open-label, long term extension study evaluating the safety of topical Diacerein 1% Ointment for the treatment of subjects with EBS. At Baseline Visit, EBS subjects who participated the CCP-020-301 double-blind safety and efficacy study or participated in the CCP-020-101 PK study (feeder studies) and who meet all the inclusion/exclusion criteria will be eligible to enroll in this study.||||
34121707|NCT06275230|||COHORT||CROSS_SECTIONAL|||||||
34121708|NCT03842267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121709|NCT04603001|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121710|NCT00638573|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121711|NCT04162106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121712|NCT04596722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121713|NCT05660603|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blinded(participants and outcome assessors)|"The patients will be divided randomly by a computer-generated randomization table into three groups :~Group C :(Control group) patients will receive standard general anesthesia. Group LSP: patients will receive standard general anesthesia followed by combined lumbar and sacral plexus blocks with 40 ml of bupivacaine 0.25%.~Group CP: patients will receive standard general anesthesia followed by circum-psoas block with 40 ml of bupivacaine 0.25%."|t|f|f|t
34121714|NCT01727934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121715|NCT00281970||||TREATMENT||NONE||||||
34121716|NCT01305187|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34121717|NCT05150678|RANDOMIZED|PARALLEL||OTHER||NONE||there are two gruops in the study ;one with removal of the scar 2nd with non removal in repeated cs||||
34121718|NCT03423511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blind trial, such that the patient or patient's family will NOT be told which stent they have received.|MiStent group vs. the Xience/Promus group.|t|f|f|f
34121719|NCT00204529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733763|NCT02052739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733764|NCT00787410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733765|NCT01482780|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33813266|NCT03564184|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Data collectors (for self-reports) and assessors (for observational measures) will be trained in assessment procedures and blinded to participant allocation. This will be ensured by using assessors from a different ward and by asking participants not to reveal their treatment assignments. Success of blinding will be verified.|2x2 factorial, multinational, single-blind trial|f|f|f|t
33813267|NCT02633228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121720|NCT02935192|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34121721|NCT01269684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121722|NCT05174585|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34121723|NCT03368066|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121724|NCT06718023|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121725|NCT06253715|RANDOMIZED|PARALLEL||TREATMENT||NONE||International, multicenter, randomized, controlled, open-label, non-inferiority||||
34121726|NCT01248325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121727|NCT02814188|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34121728|NCT03006588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121729|NCT02107534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121730|NCT06715280|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-labelled, single-arm study||||
34121731|NCT06368817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121732|NCT00181844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121733|NCT06709547|||COHORT||PROSPECTIVE|||||||
34121734|NCT02588157|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34121735|NCT03423407|||COHORT||PROSPECTIVE|||||||
34121736|NCT02266303|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121737|NCT02700672|||||CROSS_SECTIONAL|||||||
34121738|NCT06718283|||CASE_CONTROL||PROSPECTIVE|||||||
34121739|NCT00947128|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121740|NCT00920556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121741|NCT02501993|||COHORT||PROSPECTIVE|||||||
34121742|NCT03868410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be told they will receive brain stimulation, but will be given no indication as to which target will be stimulated. Investigators analyzing functional outcome data, neurophysiology data and MRI data will receive coded data that conceals the identity of the subject.|In a pilot, randomized, assessor-blind clinical trial, an anticipated 24 patients will be assigned to either receive stimulation to a new brain target- contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere- or the conventional brain target- ipsilesional primary motor cortex (iM1) located in the stroke hemisphere. Stimulation will be delivered in conjunction with rehabilitation for 2 days a week for 6 weeks.|f|f|f|t
34121743|NCT01814956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121744|NCT04086355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants did not have knowldge if they in study or in control group ,as the exercises applied the same in both group and electrical stimulation the same ,the device turn on in both groups but their is no real signals reached to control group.|two parallel groups ,study group received oro motor exercise and neuromuscular electrical stimulation on masseter and digastric muscles.control group received the same but placebo electrical stimulation.|t|f|f|f
34121745|NCT01038505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121746|NCT00905190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121747|NCT04118829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121748|NCT06362109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121749|NCT03859076|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study will implement blinding of staff performing participant assessments and data analysts performing statistical analyses. The principal investigator will be blinded to group allocation, except for participants that he is involved with instructing in the MB-BP intervention (there are multiple instructors). The prinicipal investigator has no access to the master data file. Equipoise is emphasized for all staff who interact with participants.||f|t|t|t
34121750|NCT00182143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121751|NCT03240107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121752|NCT00057564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121753|NCT02432430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34121754|NCT02805452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121755|NCT04257019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34121756|NCT03122093|||COHORT||PROSPECTIVE|||||||
34121757|NCT06334809|||COHORT||PROSPECTIVE|||||||
34121758|NCT01760577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121759|NCT01808378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121760|NCT00276432|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
34121761|NCT04217109|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121762|NCT02745873|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121763|NCT01423552|||COHORT||PROSPECTIVE|||||||
34121764|NCT02189798|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The two main arms are conducted in parallel. The third arm is optional for subjects who complete either of the two main arms using the EAS sound processor.||||
34121765|NCT04341103|||CASE_ONLY||PROSPECTIVE|||||||
34121766|NCT01080417|RANDOMIZED|CROSSOVER||||NONE||||||
34121767|NCT03092479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121768|NCT02137070|||CASE_CONTROL||PROSPECTIVE|||||||
34121769|NCT01682356|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34121770|NCT04712747|||CASE_CONTROL||PROSPECTIVE|||||||
34121771|NCT02927444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34121772|NCT02984670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813268|NCT03659942|||COHORT||PROSPECTIVE|||||||
33813269|NCT01721694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813270|NCT00212459|RANDOMIZED|PARALLEL||||NONE||||||
33813271|NCT04148885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813272|NCT00275314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813273|NCT05602272|||COHORT||PROSPECTIVE|||||||
33813274|NCT02981953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813275|NCT04693598|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study from a low dose to a high dose following safety review||||
33813276|NCT02034188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121773|NCT04028648|||CASE_ONLY||CROSS_SECTIONAL|||||||
34121774|NCT01686113|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33813277|NCT01375725|||CASE_ONLY||PROSPECTIVE|||||||
33813278|NCT05198219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121775|NCT00143052|||CASE_CONTROL||PROSPECTIVE|||||||
33813279|NCT04650009|||CASE_ONLY||CROSS_SECTIONAL|||||||
33813280|NCT00632905|||COHORT||PROSPECTIVE|||||||
33813281|NCT01542983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813282|NCT01190436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813283|NCT01653925|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33813284|NCT04794439|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33813285|NCT04577599|NA|SINGLE_GROUP||SCREENING||NONE||||||
33813286|NCT02206906|||COHORT||PROSPECTIVE|||||||
33813287|NCT04008004|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33813288|NCT03776565|||CASE_CONTROL||PROSPECTIVE|||||||
34121776|NCT00707993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121777|NCT03363178|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34121778|NCT01767896|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34121779|NCT05342948|||COHORT||PROSPECTIVE|||||||
34121780|NCT05523284|||OTHER||PROSPECTIVE|||||||
34121781|NCT04034134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121782|NCT03563482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813289|NCT02598388|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33813290|NCT04419571|||COHORT||RETROSPECTIVE|||||||
33813291|NCT01075854|||CASE_ONLY||PROSPECTIVE|||||||
33813292|NCT02684994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813293|NCT01543789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121783|NCT06632782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Masking of participants is not possible in such alternative intervention|Enrolled participants will be randomized to the intervention and control group.|f|f|t|f
34121784|NCT01240863|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121785|NCT01889043|||COHORT||PROSPECTIVE|||||||
34121786|NCT06714981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121787|NCT06341400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121788|NCT04127526|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Participants will be randomized to 3 baseline periods of two, three or four weeks. Both therapist (who is also the main researcher) and participant will be aware of which baseline arm the participant has been randomised to upon beginning the baseline, however not before this.|Single Case Experimental Design. All participants will receive treatment and outcomes during treatment period will be compared to a randomized baseline period of two, three or four weeks (2 participant in each baseline arm).||||
34121789|NCT04831671|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to mask participants or investigators as the surgical interventions in each arm will have different scars, making blinding impossible.|||||
34121790|NCT04909554|||COHORT||PROSPECTIVE|||||||
34121791|NCT02714660|||CASE_ONLY||CROSS_SECTIONAL|||||||
34121792|NCT03569189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121793|NCT00820989|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34121794|NCT05158920|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial comparing an experimental condition (Treatment As Usual + Mindfulness-Based Cognitive Therapy) and a control condition (Treatment As Usual)||||
34121795|NCT04691921|||COHORT||CROSS_SECTIONAL|||||||
34121796|NCT06389214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121797|NCT04419467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121798|NCT02886130|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34121799|NCT02160288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34121800|NCT00294957|||||RETROSPECTIVE|||||||
34121801|NCT04754763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34121802|NCT00636181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121803|NCT06086964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34121804|NCT00029250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34121805|NCT02803203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121806|NCT06487871|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, placebo-controlled trial|t|t|t|t
34121807|NCT05419752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121808|NCT02896257|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34121809|NCT06717737|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121810|NCT01657370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121811|NCT03134326|NA|SINGLE_GROUP||OTHER||||||||
34121812|NCT03374020|||OTHER||PROSPECTIVE|||||||
34121813|NCT02273102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121814|NCT03408990|||COHORT||CROSS_SECTIONAL|||||||
34121815|NCT03596671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121816|NCT01014702|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121817|NCT00512278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121818|NCT04549480|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open Label|||||
34121819|NCT00881894|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34121820|NCT03186768|RANDOMIZED|PARALLEL||OTHER||SINGLE|School group (intervention or control) will be blinded for data analysis.|School-randomized controlled trial|f|f|f|t
34121821|NCT06134817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121822|NCT02731287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121823|NCT03454230|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||To assess efficacy of a positioning schedule whose frequency of positioning is adapted every day to pressure ulcer risk assessed by Braden scale on occurrence of pressure ulcer in adult ICU in comparison with the routine patient management (without positioning schedule adapted on PU risk) at the 28th day, or when leaving ICU wall, or at death if it occurs before.||||
34121824|NCT03985280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34121825|NCT03435068|RANDOMIZED|PARALLEL||TREATMENT||NONE||The trial is parallel-designed, controlled, prospective clinical study.||||
34121826|NCT01654939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33813294|NCT05589831|||CASE_CROSSOVER||PROSPECTIVE|||||||
33813295|NCT03259126|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of operator radiation dose at pelvic level during percutaneous coronary procedures through transradial access with or without an extension of the leaded curtain under table||||
33813296|NCT02697656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813297|NCT03941977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121827|NCT00560300|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34121828|NCT03091361|||COHORT||PROSPECTIVE|||||||
34121829|NCT03139461|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster-randomized trial|f|f|f|t
34121830|NCT04994223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants enrolled in the study and the principal investigator would not be knowing the drug regimens used in group A and Group B participants|patients enrolled in the study would be taken informed consent and divided in two groups, group A receiving rivaroxaban plus aspirin and Group B receiving placebo plus aspirin|t|f|t|f
34121831|NCT01114737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121832|NCT01385592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121833|NCT06715995|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34121834|NCT05570032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121835|NCT04035889|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33733766|NCT05439850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study participant will not have knowledge of which treatment group he/she is randomized into for the duration of the study. Because the care provider/investigator will be required to implant the bioinductive patch, the physician will know into which treatment group each patient falls.|"Patients will be randomized into one of two groups. In the control group, patients will receive the current surgical treatment for rotator cuff tears: debridement and repair. Patients in the experimental group will receive a bio-inductive patch following the same surgical treatment. Both groups of patients will participate in postoperative ultrasound imaging studies."|t|f|f|f
33733767|NCT03721198|RANDOMIZED|PARALLEL||PREVENTION||NONE||split mouth technique||||
33733768|NCT05717595|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|randomisation|randomized double blinded trial|t|f|t|f
33813298|NCT00636597|||COHORT||PROSPECTIVE|||||||
33813299|NCT03888807|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The participant, investigator, and statistician will be blind to the intervention received|Participants will be randomly assigned 1 of 2 topicals, Gel A or Gel B. Upon completion of study procedures they will return for a second testing session and receive the other topical.|t|f|t|t
33813300|NCT02667509|||||CROSS_SECTIONAL|||||||
33813301|NCT01593137|RANDOMIZED|PARALLEL||||NONE||||||
33813302|NCT00807079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813303|NCT04022707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Tests will not be performed by the investigators providing the interventions.|Comparison of High-Speed Resistance training and educational control|f|f|t|t
33813304|NCT03590483|||CASE_ONLY||CROSS_SECTIONAL|||||||
33813305|NCT06359977|||CASE_ONLY||PROSPECTIVE|||||||
33813306|NCT01751295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813307|NCT04409392|||COHORT||RETROSPECTIVE|||||||
33813308|NCT01248533|||||PROSPECTIVE|||||||
33813309|NCT06509321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813310|NCT00002599|RANDOMIZED|||TREATMENT||||||||
33813311|NCT05297097|NA|SINGLE_GROUP||OTHER||NONE||single arm, prospective||||
33813312|NCT03046394|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||TRIPLE|||t|f|t|t
33813313|NCT04017364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813314|NCT03028961|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33813315|NCT03938792|NA|CROSSOVER||TREATMENT||NONE||This is a one way Cross-Over Prevention study with 1 Arm that has No masking.||||
33813316|NCT05582226|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized into one of two groups, the first group receiving stump stem cell infusion and the second group receiving standard of care ACL reconstruction||||
33813317|NCT05980078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33813318|NCT01442766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813319|NCT01452867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121836|NCT05590247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider and investigator are blinded to the arm, but patient has to know which diet to follow and outcomes assessor assigned the groups and has to counsel patients accordingly.|This is a prospective, single-blind parallel group randomized control trial. Participants will be identified through an electronic medical record search for established patients within the Ohio State Dermatology practice with a diagnosis of mild-to-moderate psoriasis. Patients will then be asked to join the study and subsequently given information to consent. Patients in the control group will be offered entry into the intermittent fasting group after the commencement of the study as an incentive to participate.|f|t|t|f
34121837|NCT06191042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813320|NCT03917589|||COHORT||OTHER|||||||
33813321|NCT03305705|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|The patients will be blinded with respect to the treatment sequence. The outcome assessor (PET scan evaluator) will be blinded with respect to the participant identity and the date of the PET scan.||t|f|f|t
33813322|NCT05308888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813323|NCT02037568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33813324|NCT04985994|||CASE_CONTROL||PROSPECTIVE|||||||
34121838|NCT02752347|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34121839|NCT04636307|||COHORT||PROSPECTIVE|||||||
33813325|NCT01458782|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT, Two arms ACI-C and AMIC||||
33813326|NCT03954106|NA|SEQUENTIAL||TREATMENT||NONE||||||
33813327|NCT00599625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813328|NCT04351243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121840|NCT03557866|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||two groups. Individuals with and without pronated foot.||||
34121841|NCT05534984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121842|NCT03594110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121843|NCT04373421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121844|NCT00059631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121845|NCT06716996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34121846|NCT06180525|||OTHER||OTHER|||||||
34121847|NCT02431325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121848|NCT03375333|||COHORT||PROSPECTIVE|||||||
34121849|NCT03174327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34121850|NCT00628524|||COHORT||PROSPECTIVE|||||||
34121851|NCT02799589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121852|NCT01951664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121853|NCT05973162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121854|NCT05365100|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34121855|NCT03488329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813329|NCT01653106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733769|NCT01684384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733770|NCT00065533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733771|NCT00002495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733772|NCT04237077|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome Assessor will be blinded||f|f|f|t
33733773|NCT05988957|||OTHER||PROSPECTIVE|||||||
33733774|NCT01866709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33733775|NCT01409291|||COHORT||PROSPECTIVE|||||||
33733776|NCT06147011|NA|SINGLE_GROUP||OTHER||NONE||||||
33733777|NCT01976845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733778|NCT01479907|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33733779|NCT02962037|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33733780|NCT05844696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733781|NCT05246605|NA|SEQUENTIAL||TREATMENT||NONE||||||
33733782|NCT04721002|||COHORT||PROSPECTIVE|||||||
33733783|NCT05546333|||COHORT||PROSPECTIVE|||||||
33733784|NCT02118428|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733785|NCT01443442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33733786|NCT01643720|||CASE_CONTROL||PROSPECTIVE|||||||
33733787|NCT02796807|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733788|NCT00040040|RANDOMIZED|||DIAGNOSTIC||DOUBLE||||||
33733789|NCT03268967|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Data analysis|Before and after interventional study|f|f|f|t
33813330|NCT00430586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813331|NCT03768271|||COHORT||PROSPECTIVE|||||||
33813332|NCT00033241||||TREATMENT||||||||
33813333|NCT01381445|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33813334|NCT04524676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813335|NCT02644941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813336|NCT03139045|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33813337|NCT00872859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33813338|NCT00408109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33813339|NCT03043339|||OTHER||PROSPECTIVE|||||||
33813340|NCT03662698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to study design, it is not possible to blind either participants or investigators to study condition. However, the biostatistician will be blinded to participant group to minimize bias in analyzing the data.|Participants will be randomized to the guided imagery intervention or to treatment as usual.|f|f|f|t
33813341|NCT02680314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813342|NCT04443985|||COHORT||RETROSPECTIVE|||||||
33813343|NCT03009123|||COHORT||RETROSPECTIVE|||||||
33813344|NCT03054766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33813345|NCT02053506|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33813346|NCT06305910|NA|SEQUENTIAL||TREATMENT||NONE||3+3 design||||
33813347|NCT04284306|||OTHER||OTHER|||||||
33813348|NCT00383812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813349|NCT00484406|||DEFINED_POPULATION||PROSPECTIVE|||||||
33813350|NCT00249366|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813351|NCT06139419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813352|NCT06306222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813353|NCT05203107|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33813354|NCT01523184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813355|NCT00091676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813356|NCT04309578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813357|NCT04931498|||COHORT||CROSS_SECTIONAL|||||||
33813358|NCT03810300|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33813359|NCT02291549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were blindfolded and earmuffed during the baseline procedure and follow-up endoscopic examinations. Implants were removed at Day 60 to allow blinded assessment of bilateral polyp grade at Day 90 by a centralized videoendoscopy review by a panel of 3 independent sinus surgeons.||t|f|f|t
33813360|NCT00353106|||||PROSPECTIVE|||||||
33813361|NCT04361240|||COHORT||PROSPECTIVE|||||||
33813362|NCT06245902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Factorial Design||t|t|t|t
33813363|NCT03662009|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33813364|NCT00728013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813365|NCT06031506|NA|SINGLE_GROUP||TREATMENT||NONE||"All patients will receive conventional maxillary and mandibular complete dentures The implant size will be selected for each area according to the available bone length and width as measured by CBCT radiograph.~All implants will be surgically installed guided by steriolethognathic stents~- Multi-unit abutments will be connected to implants and will be immedietly loaded by fixed full arch screw retained provisional acrylic restoration.~Final prosthesis will be delivered 6-8 months later"||||
33813366|NCT04105699|||COHORT||PROSPECTIVE|||||||
33813367|NCT04660110|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813368|NCT02180906|||COHORT||PROSPECTIVE|||||||
33813369|NCT04028518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813370|NCT03855514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813371|NCT00651599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813372|NCT06152497|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Parallel groups|t|f|t|t
33813373|NCT02345759|||CASE_CONTROL||PROSPECTIVE|||||||
33813374|NCT02395692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838501|NCT04076462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
33838502|NCT01098916|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33733790|NCT02063997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733791|NCT00614796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733792|NCT01356511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733793|NCT03552887|||COHORT||PROSPECTIVE|||||||
33733794|NCT00795691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733795|NCT00856024|||COHORT||RETROSPECTIVE|||||||
33733796|NCT04190186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733797|NCT01150695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33733798|NCT04921930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733799|NCT02007356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813375|NCT03159494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A pilot group of 6 patients with type 2 diabetes tested before and after 6 times of High Intensity Training One group of patients with type 2 diabetes tested before and after 8 times of High Intensity Training.||||
33813376|NCT00255749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813377|NCT06390462|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33813378|NCT06407141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813379|NCT00147394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813380|NCT06133595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants are allocated to either the Mi Bridge intervention or waitlist during the initial phase of the study and those who receive waitlist receive Mi Bridge during the second phase of the study.||||
33813381|NCT04184349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813382|NCT06463314|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|blinded study design involving participants with known and unknown syphilis and HIV status where test providers are blinded to the participant status.|screening for HIV and syphilis infection at point of care settings by untrained non-professional health care providers||||
33813383|NCT03902626|||COHORT||RETROSPECTIVE|||||||
34121856|NCT06084364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants and the occupational therapist who examine the patients are blinded for the content of the intraarticular injections. The rheumatologist who perform the intraarticular injection will not be blinded for the content.||t|f|t|t
34121857|NCT06718062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121858|NCT06714708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121859|NCT04344184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121860|NCT02696603|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34121861|NCT06021808|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34121862|NCT02793661|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121863|NCT00100802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121864|NCT04249661|||COHORT||PROSPECTIVE|||||||
34121865|NCT00480233|||CASE_ONLY||PROSPECTIVE|||||||
34121866|NCT05275673|RANDOMIZED|PARALLEL||TREATMENT||NONE||"2 dosing schedules: 3 mg once per day (3 mg total) OR 2 mg twice per day (4 mg total)~Group A: 30 participants randomized 1:1 to one of two dosing schedules~Group B: approximately 20 participants randomized 1:1 to one of two dosing schedules"||||
34121867|NCT01979614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blind, randomized, parallel group, placebo controlled study|t|t|t|t
34121868|NCT04478903|||COHORT||PROSPECTIVE|||||||
34121869|NCT02003482|||COHORT||PROSPECTIVE|||||||
34121870|NCT03225482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blind to treatment group assignment.|Two group randomized controlled trial.|f|f|f|t
34121871|NCT03157895|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Interviewers should be blind to condition.||f|f|f|t
34121872|NCT04480229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34121873|NCT02668289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121874|NCT06715930|||COHORT||RETROSPECTIVE|||||||
34121875|NCT06717178|||COHORT||PROSPECTIVE|||||||
34121876|NCT03294005|||OTHER||RETROSPECTIVE|||||||
34121877|NCT00501644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121878|NCT05783752|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34121879|NCT04375436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind|Study NTRX-07-C101 will be conducted with a modified parallel design, incorporating sentinel subjects and a staggered-dosing-days approach.|t|t|t|t
34121880|NCT02382588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34121881|NCT00783432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813384|NCT00065611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813385|NCT03925909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813386|NCT02820506|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Endometrial cancer, Diagnostic; Assessing the safety of the SLN mapping algorithm. Inclusion is defined by a power calculation: Assuming the true incidence of metastasis is 20% and the sensitivity of the SLN mapping algorithm is 96%. To obtain the conclusion that NPV is larger than 94% using a 95% two-sided exact Clopper-Pearson confidence interval, then 150 women with sentinel lymph node mapping, a FDG/PET-CT and Pelvic- and paraaortic lymph node dissection are needed.~Cervical cancer: Study is diagnostic and primarily explorative."||||
33813387|NCT05220813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813388|NCT06168045|||COHORT||PROSPECTIVE|||||||
34121882|NCT03242226|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121883|NCT02950103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121884|NCT06717165|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
34121885|NCT04477616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121886|NCT04082130|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||split-mouth design.|f|f|f|t
34121887|NCT01201980|||||PROSPECTIVE|||||||
34121888|NCT05200312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121889|NCT02264600|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34121890|NCT02005744|NON_RANDOMIZED|PARALLEL||||NONE||||||
34121891|NCT00696878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121892|NCT04402710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The research assistant who is in charge of conducting the statistical analyses will not be involved in the randomization process or running the intervention or control groups.~Research assistants who will be conducting in-person eligibility and/or follow-up visits (e.g. handing out accelerometers) will be blinded to participant group assignment.~Participants will also be blinded to which group they are randomized into. The investigators will present the study as examining different education interventions to increase physical activity and will not let the participants know whether they are in the intervention or control condition."|Participants will be randomized to either a control group or the intervention group. Both sessions will run concurrently.|t|f|f|t
34121893|NCT05691387|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34121894|NCT00318929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121895|NCT03030456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121896|NCT01081522|||CASE_ONLY||PROSPECTIVE|||||||
34121897|NCT06710535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121898|NCT05525962|||COHORT||PROSPECTIVE|||||||
34121899|NCT02863237|||COHORT||PROSPECTIVE|||||||
34121900|NCT02434211|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34121901|NCT03662282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121902|NCT04266522|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34121903|NCT01674790|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34121904|NCT00660803|||||RETROSPECTIVE|||||||
34121905|NCT00201279|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34121906|NCT01160809|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121907|NCT00664950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121908|NCT04926116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34121909|NCT02169648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121910|NCT06151626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34121911|NCT05317598|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants in the pre-randomization study, two of the researchers, and the statistician will be blinded.|This study is a randomized controlled trial with a single-blind, pre-test post-test design.|t|f|t|f
34121912|NCT02665533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34121913|NCT03855943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121914|NCT02072954|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34121915|NCT00805584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121916|NCT06716099|||COHORT||PROSPECTIVE|||||||
34121917|NCT03420365|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34121918|NCT06472037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121919|NCT05882396|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixty Patients with colorectal cancer have oxaliplatin-induced peripheral neuropathy. will be indiscriminately assigned to two groups.||||
34121920|NCT04859998|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two groups: one control (adults with autism that continues with their daily living and therapies) and one experimental group (adults with autism that receive the intervention program added to their daily living and therapies).|f|f|t|f
34121921|NCT04681989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Biostatistician generated the randomization list. The research assistant called the PI for group assignment after baseline measures were taken.|Participants were randomized to either the intervention or control group after baseline (within 1 month of completing active, intent-to-cure breast cancer treatment) measurement by research assistants. Follow-up outcome measures at 1 month after baseline.|f|f|t|t
34121922|NCT03783780|NA|SINGLE_GROUP||OTHER||NONE||||||
34121923|NCT01577602|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34121924|NCT02765399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121925|NCT04847440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34121926|NCT04781530|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The trial is unblinded / open-label.|||||
34121927|NCT00389753|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34121928|NCT04635137|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm prospective study of pain and quality of life before and after ablation/cementoplasty procedure||||
34121929|NCT00551096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121930|NCT05125003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121931|NCT06211699|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The primary surgeon is naturally not blinded to the patient groups and the other surgeon who records and evaluates the data is blinded to the patient groups. The patient was blind to the intervention.|Prospective Randomized Controlled Trial|t|t|f|t
34121932|NCT05214937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Due to the nature of the intervention, it is not possible to blind participants to their group allocation. Coordinating RAs will be the primary individuals responsible for scheduling all data collection assessments.~They will attempt to book all 3 assessments with same research assistant outcome assessor who meets the following criteria:~* Are not a movement specialist delivering one-on-one behavioural counselling~* Are not a movement specialist delivering a group webinar~* Are not aware of participant's group allocation~Any cases of unblinding will be noted in a Protocol Deviation Log."|Randomization will be performed using a stratified randomization scheme via REDCap. The sequence will be random permutated blocks of varying sizes, stratified by ADT use (ADT vs. no ADT). PCS will be assigned in a 1:1 ratio to one of two groups. Randomization codes will be kept in a pre-made digital file that is separate from other study records.|f|f|f|t
34121933|NCT02487966|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34121934|NCT06036199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121935|NCT05291754|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non randomised and single arm||||
34121936|NCT03058601|||COHORT||RETROSPECTIVE|||||||
34121937|NCT06718894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121938|NCT01041430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34121939|NCT04645173|||COHORT||RETROSPECTIVE|||||||
34121940|NCT00527618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813389|NCT00022490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121941|NCT02639247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121942|NCT05018494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34121943|NCT02452073|||COHORT||RETROSPECTIVE|||||||
34121944|NCT03395028|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Dose determination for GCSF||||
34121945|NCT00842387|||COHORT||PROSPECTIVE|||||||
34121946|NCT03489486|||COHORT||PROSPECTIVE|||||||
34121947|NCT00327912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121948|NCT03073174|||COHORT||PROSPECTIVE|||||||
34121949|NCT02267434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34121950|NCT03988426|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121951|NCT06438198|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34121952|NCT03745768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized controlled clinical trial testing iTBS versus sham|t|t|t|t
34121953|NCT04403308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121954|NCT00654537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121955|NCT03929666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121956|NCT04473612|||CASE_CONTROL||PROSPECTIVE|||||||
34121957|NCT01987466|||COHORT||PROSPECTIVE|||||||
34121958|NCT01381770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121959|NCT00976716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121960|NCT02784392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813390|NCT01406041|||CASE_ONLY||RETROSPECTIVE|||||||
33813391|NCT06374082|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blinding technique will be used to conceal the allocation. Participants will not know which group they are in as placebo messages will be introduced. Using a central allocation web-based-controlled randomization, outcome assessors and data analysts will be blind to group allocation, only the principal investigator will be aware of who belongs to the control and intervention groups.||t|f|f|t
33813392|NCT01015274|||COHORT||PROSPECTIVE|||||||
33813393|NCT01948557|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34121961|NCT05367869|NA|SINGLE_GROUP||TREATMENT||NONE||Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy||||
34121962|NCT00429754|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121963|NCT04240431|||CASE_ONLY||PROSPECTIVE|||||||
34121964|NCT03387956|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34121965|NCT03345277|||COHORT||RETROSPECTIVE|||||||
34121966|NCT00835458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121967|NCT03914989|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both the participants and the assessors will be blinded to the group assignments.|Participants will be randomly assigned to either an experimental group or an active control group.|t|f|f|t
34121968|NCT05962281|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
34121969|NCT00003614||||TREATMENT||||||||
34121970|NCT05187260|||COHORT||PROSPECTIVE|||||||
34121971|NCT03925363|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants will be randomized 1:1 to the feedback-app or the blind-app|f|t|t|t
34121972|NCT04707105|||COHORT||PROSPECTIVE|||||||
34121973|NCT04324892|||COHORT||PROSPECTIVE|||||||
34121974|NCT04528238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121975|NCT05045716|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34121976|NCT05878717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study where participant and investigator are masked.||t|t|t|t
34121977|NCT02613195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34121978|NCT06718049|||COHORT||PROSPECTIVE|||||||
34121979|NCT04966325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|LC350189 and placebo will be administered in a double blind, double-dummy manner. Moxifloxacin will be administered open-label.|4-way cross over|t|f|t|f
34121980|NCT01749488|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34121981|NCT03816787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34121982|NCT04793516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121983|NCT00641108|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34121984|NCT05285579|||COHORT||PROSPECTIVE|||||||
34121985|NCT01099241|||||PROSPECTIVE|||||||
34121986|NCT02402595|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34121987|NCT02985411|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34121988|NCT01252615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121989|NCT02091076|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34121990|NCT06546475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34121991|NCT03322982|RANDOMIZED|PARALLEL||OTHER||SINGLE|Diet adherence assessments will be conducted by blinded assessors from OHSU bionutrition team.||f|f|f|t
34121992|NCT01370876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34121993|NCT00266916|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34121994|NCT00790049|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34121995|NCT01211561|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34121996|NCT00766116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34121997|NCT01349673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34121998|NCT05746390|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34121999|NCT06100757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122000|NCT06716515|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34122001|NCT00846846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122002|NCT05935956|||COHORT||PROSPECTIVE|||||||
34122003|NCT01803724|||COHORT||PROSPECTIVE|||||||
34122004|NCT00991809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34122005|NCT04441697|||COHORT||PROSPECTIVE|||||||
34122006|NCT03584906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122007|NCT02560220|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122008|NCT01392573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122009|NCT04416243|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34122010|NCT06715345|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single blind( subject - blind, investigator -open, Outcome assessor- blind)|single blind( subject - blind, investigator -open, Outcome assessor- blind)|t|f|f|t
34122011|NCT02947633|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34122012|NCT03155139|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34122013|NCT02128087|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34122014|NCT02197572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122015|NCT00473109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122016|NCT04355650|NA|SINGLE_GROUP||OTHER||NONE||||||
34122017|NCT06716385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122018|NCT00484341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122019|NCT00325143|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34122020|NCT05579730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122021|NCT02579811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122022|NCT03054714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34122023|NCT05480228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization assignment will be blinded from study participants, staff from clinical sites, investigators, asset owner, IND sponsors, and/or designees.|This study is an interventional, prospective, parallel-group, multicenter, randomized, double-blind, placebo-controlled, Phase 2 study.|t|f|t|f
34122024|NCT01049087|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|f|t
34122025|NCT03946969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122026|NCT03122938|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122027|NCT02569346|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34122028|NCT02095756|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34122029|NCT04325269|||COHORT||PROSPECTIVE|||||||
34122030|NCT03157180|||CASE_CONTROL||PROSPECTIVE|||||||
33813394|NCT01626833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813395|NCT00904085|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33813396|NCT00403845|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33813397|NCT00185692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813398|NCT02469324|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33813399|NCT00787371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813400|NCT00103857|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33813401|NCT00572494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813402|NCT03120936|NA|SINGLE_GROUP||OTHER||NONE||||||
33813403|NCT04413188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trail|f|f|t|f
33813404|NCT06130605|||CASE_ONLY||CROSS_SECTIONAL|||||||
33813405|NCT03720028|||COHORT||PROSPECTIVE|||||||
33813406|NCT04878809|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Experimental Group: People attending L'Horitzó School (students, teachers, administrative and service staff) Control Group (No Intervention): Escola John Talabot||||
33813407|NCT06444087|||OTHER||PROSPECTIVE|||||||
34122031|NCT06178367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All moisturizers used in this clinical trial were made in the same preparation and packaging|This is a split study, one participant receive three interventions in three area in the leg. The distribution of treatment groups is carried out randomly using the block randomization method.|t|t|t|t
34122032|NCT05456529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122033|NCT02238743|||CASE_ONLY||PROSPECTIVE|||||||
34122034|NCT00272792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122035|NCT04860115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Intervention will be done under general anesthesia so participant will be blinded and primary outcome which will be laboratory test will be assessed by a person not aware of intervention.|120 patients randomized into two groups of 60 patients. Group B (PECS II+PIFB with dexmetomidine) and Group C (control).|t|f|f|t
34122036|NCT00901225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122037|NCT01663311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122038|NCT04303975|||COHORT||PROSPECTIVE|||||||
34122039|NCT06105346|||COHORT||PROSPECTIVE|||||||
34122040|NCT00371371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122041|NCT00535418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122042|NCT04067492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122043|NCT02213614|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122044|NCT04792190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122045|NCT04656405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122046|NCT01244386|||COHORT||PROSPECTIVE|||||||
34122047|NCT06114719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122048|NCT06405126|||COHORT||PROSPECTIVE|||||||
34122049|NCT02100293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122050|NCT02422329|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122051|NCT00370903|||||RETROSPECTIVE|||||||
34122052|NCT00613184|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34122053|NCT03388892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122054|NCT05021952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122055|NCT06473532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122056|NCT02656667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122057|NCT01152307|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34122058|NCT04507997|||COHORT||PROSPECTIVE|||||||
34122059|NCT06712706|||COHORT||RETROSPECTIVE|||||||
33813408|NCT00444054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122060|NCT00959907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122061|NCT05017064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122062|NCT05095298|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122063|NCT03247634|NA|SINGLE_GROUP||PREVENTION||NONE||Interrupted Time Series - All cohorts will receive the Getting Ahead program||||
34122064|NCT03931187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34122065|NCT04855175|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two treatment groups.||||
34122066|NCT02524249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34149183|NCT03600454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Patients will be randomized using a computer-generated permuted block randomization sequence (variable block-size, 1:1 allocation). The randomization will be determined on the preoperative anesthesia assessment. After the randomisation, the investigator will inform the patient which anesthesia he/she will get during the operation|"Two independent, but complimentary, studies will be performed to evaluate the primary objective and the secondary objectives in this prospective trail.~Group 1: The effect of spinal anesthesia as compared to general anesthesia for total hip arthroplasty~Group 2: The effect of epidural analgesia compared to general anesthesia alone for major abdominal surgery"|f|f|t|f
33813409|NCT05689424|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33813410|NCT04414319|||COHORT||PROSPECTIVE|||||||
33813411|NCT04213963|||COHORT||PROSPECTIVE|||||||
33813412|NCT02383797|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33813413|NCT03064906|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The two-part study schedule consists of a 7±1 day outpatient, open-loop phase, followed by one 54-hour (Option A - Meal Performance and/or Option B - Exercise), hybrid closed-loop phases conducted in a supervised CRC or hotel/rental house setting. Subjects may participate in hybrid closed-loop session Option A and/or Option B.||||
33813414|NCT00636168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813415|NCT01820702|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813416|NCT02072330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813417|NCT06204107|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813418|NCT03507452|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33813419|NCT00098735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813420|NCT03479437|||OTHER||PROSPECTIVE|||||||
33813421|NCT04572165|||COHORT||RETROSPECTIVE|||||||
33813422|NCT05359302|||COHORT||PROSPECTIVE|||||||
33813423|NCT05441176|NA|SINGLE_GROUP||OTHER||NONE||||||
33813424|NCT00059384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733800|NCT01468662|||CASE_ONLY||PROSPECTIVE|||||||
33733801|NCT03318848|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The teacher that evaluated the students, was not informed if the student was of the control or intervention group. The outcomes assessor was not informed if the group 1 and 2 was control or intervention group.|The students were randomized to one of two groups (control or intervention), according to the sequence determined by the Random System|f|f|t|t
33733802|NCT03427918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33733803|NCT02694341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733804|NCT03612622|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33733805|NCT05443997|RANDOMIZED|PARALLEL||PREVENTION||NONE||The implementation research study uses a cluster-randomized design with cross-sectional baseline and endline surveys||||
33733806|NCT03521492|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33733807|NCT05050643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will conduct a mixed-methods type 3 hybrid implementation-effectiveness evaluation using a Concurrent Stepped Wedge design to compare two implementation strategies to increase adoption of the EBPs in primary care in 16 sites: Evidence-Based Quality Improvement (EBQI)-Individual Consultation (EBQI-IC) and EBQI-Learning Collaborative (EBQI-LC). Each VISN will implement a single EBP \[Comprehensive Assessment and Care Planning (CACP) for High-Risk Veterans or Phone-Based Health Coaching for Medication Adherence (HCMA)\]. Implementation strategies will be randomized by site. Time periods without active implementation will serve as the usual care periods for both EBQI conditions.||||
33733808|NCT05769894|||CASE_CONTROL||PROSPECTIVE|||||||
33733809|NCT03058068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will apply to the randomized phase.|"1. Safety run-in phase will have 3 subjects with 2 treatment groups~2. Randomized phase will have 15 subjects with 3 treatment groups"|t|f|t|f
33733810|NCT02199418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733811|NCT02897739|||CASE_CONTROL||PROSPECTIVE|||||||
33733812|NCT00560261|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33733813|NCT05644327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to the participants' group allocation||f|f|t|f
33733814|NCT02521012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733815|NCT01872871|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33733816|NCT06572592|||CASE_ONLY||RETROSPECTIVE|||||||
33733817|NCT02456831|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33733818|NCT06211816|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33733819|NCT03967470|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blind: participants nor outcome assessors, odor panel or care providers do not know which spray they use.|two groups of 30 people, one month of bacterial spray use and the other month placebo.|t|t|f|t
33733820|NCT02922452|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33813425|NCT00267865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813426|NCT00004400|RANDOMIZED|||TREATMENT||DOUBLE||||||
33813427|NCT02056925|NA|SINGLE_GROUP||OTHER||NONE||||||
33813428|NCT05245474|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is not practically possible|||||
33813429|NCT03615404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813430|NCT00265252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33813431|NCT04037072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813432|NCT01052714|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33813433|NCT03775915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are randomly allocated (1:1 ratio) to either the intervention group (Real Neurofeedback) or the control group (Sham Neurofeedback). Randomisation is done after participants undergo baseline measurements using a computer-generated minimisation method that takes into account baseline upper limb function (Action Research Arm test score) and time since stroke.|t|f|f|t
33813434|NCT04927949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813435|NCT05999448|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Care providers will be masked to the status of peer coaching and algorithm assignment. Peer coaches will be masked to the status of algorithm assignment. Data managers and statisticians evaluating study outcomes will be provided de-identified data and will not be involved in treatment-related study operations.|"For Waves I-II, caregivers are randomly assigned to either (1) route to a treatment using their personalized health data (Algorithm 1) OR route to treatment randomly (No Algorithm); for Waves III and IV, caregivers are randomly assigned to Algorithm 1 or an optimized Algorithm 2 (Wave III) or Algorithm 2 or an optimized and final Algorithm 3 (Wave IV).~Across Waves I-IV, caregivers are randomly assigned to receive peer coaching (Peer Coaching) or to receive check-ins by a staff member unfamiliar with the peer coaching protocol (No Peer Coaching).~Across Waves I-III, a subset of caregivers are assigned to a waitlist control that does not include any treatment or peer coaching."|f|t|f|t
33813436|NCT01239641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813437|NCT02772510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813438|NCT05889832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813439|NCT02949297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149184|NCT03322813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733821|NCT05419102|||COHORT||OTHER|||||||
33733822|NCT01621399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733823|NCT06155617|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm clinical trial. T-test employed to compare PRESS to Function scores before and after treatment. Reliability coefficient were computed to access consistency in the measurements of the Quick DASH and the PRESS to Function Scores||||
33733824|NCT04985253|||COHORT||RETROSPECTIVE|||||||
33733825|NCT03685994|||COHORT||PROSPECTIVE|||||||
33733826|NCT01223716|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33733827|NCT00578240|||CASE_ONLY||OTHER|||||||
33733828|NCT02002234|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122067|NCT03674983|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Aim 1: discrete choice experiment (DCE) with n=200. Aim 2: randomly assign 100 HIV-negative MSW in a 1:1 ratio either to: the SoC group, or to the CEI group. MSW in the SoC group (n=50) will receive transport reimbursement at baseline, 3 and 6 months. MSW in the CEI group (n=50) will receive transport reimbursement at baseline, 3 and 6 months, and additional incentives based on sufficiently high PrEP adherence at months 3 and 6. All participants will provide hair samples and have optional brief counseling based on hair sample results. Those in the CEI group, will receive additional incentives if concentrations of TDF/FTC in hair samples corroborate that they have been sufficiently adherent in recent weeks. The final incentives (amounts, format, location, etc.) will be based on Aim 1 results. 1-2 weeks after study visits, participants will receive a grade depending on the drug level detected in their scalp hair. The CEI amounts will be distributed depending on grade.|f|f|t|t
34122068|NCT01642446|RANDOMIZED|PARALLEL||TREATMENT||NONE||transartery embolization chemotherapy, infusion of Chemoembolization was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of mitomycin C (MMC), mixed with 2-5 mL lipiodol. Then up to 20 mL of additional pure lipiodol was injected into the tumor-feeding artery until stasis of blood flow in the target artery was observed||||
34122069|NCT06348303|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single mask of participants. Participants will be prevented from knowing product dose.|Each participant will be enrolled to two (2), single dose, study treatment arms in a crossover design. The treatments will occur consecutively with seven (7) days separating days of dosing.|t|f|f|f
34122070|NCT04402307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122071|NCT05457062|||COHORT||PROSPECTIVE|||||||
34122072|NCT05510518|||CASE_ONLY||PROSPECTIVE|||||||
34122073|NCT06185426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Not required.|t|t|t|t
34122074|NCT01870869|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122075|NCT05922995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122076|NCT02590289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122077|NCT03698279|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Modified double-blind: the participant's parent / legally acceptable representative, the Investigator, and other study personnel remained unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator administered the appropriate vaccine but was not involved in safety data collection.|The study was divided into 13 groups and enrolled participants in 4 stages. The study used a stepwise age de-escalation and dose ascension design for children 6 months to less than (\<) 5 years of age.|t|f|t|t
34122078|NCT06487754|||COHORT||PROSPECTIVE|||||||
34122079|NCT06101368|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34122080|NCT05650593|||OTHER||CROSS_SECTIONAL|||||||
34122081|NCT02759445|||CASE_ONLY||PROSPECTIVE|||||||
34122082|NCT04093232|||OTHER||PROSPECTIVE|||||||
34122083|NCT01471964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122084|NCT05881707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122085|NCT06718621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122086|NCT01631721|||COHORT||PROSPECTIVE|||||||
34122087|NCT05554276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122088|NCT06048211|||OTHER||OTHER|||||||
34122089|NCT06129019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34122090|NCT01079325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122091|NCT06250764|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34122092|NCT01802099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122093|NCT06225362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122094|NCT05909137|||CASE_CONTROL||PROSPECTIVE|||||||
34122095|NCT04773548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122096|NCT03500211|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122097|NCT06459102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122098|NCT01434654|||COHORT||PROSPECTIVE|||||||
34122099|NCT03100266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122100|NCT02636647|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122101|NCT00286650|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34122102|NCT05511402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122103|NCT00087698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122104|NCT03925987|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34122105|NCT00110214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122106|NCT01033929|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34122107|NCT00412581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122108|NCT01543477|||COHORT||PROSPECTIVE|||||||
34122109|NCT02312648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34122110|NCT02722408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122111|NCT04362007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122112|NCT02170844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122113|NCT00175929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122114|NCT04941105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122115|NCT03678350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122116|NCT05705479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122117|NCT03262805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled, parallel group study.|t|f|t|t
34122118|NCT03815747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733829|NCT01482104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733830|NCT03824197|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33733831|NCT01530191|||CASE_CONTROL||PROSPECTIVE|||||||
33733832|NCT00124215|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33733833|NCT03779412|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two active self-help interventions for the duration of the study.||||
33733834|NCT02554110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33733835|NCT00779675|||COHORT||PROSPECTIVE|||||||
33733836|NCT01184469|||COHORT||PROSPECTIVE|||||||
33733837|NCT01988571|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733838|NCT04316624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733839|NCT04341974|||COHORT||RETROSPECTIVE|||||||
33733840|NCT05758740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813440|NCT01569399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813441|NCT00251199|RANDOMIZED|PARALLEL||||DOUBLE||||||
33813442|NCT04936048|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|To ensure blinding, the primary outcome measure will be completed by special educators who are familiar with the child (rather than their parents). Success of blinding (for all outcomes) will be verified at the last follow-up.|M4A is designed as an assessor blinded crossover RCT, comparing music therapy (MT) to a structurally matched play therapy (PT) intervention. Following the baseline assessment, a concealed random allocation to a sequence of interventions (MT-PT or PT-MT) will be implemented by one researcher who does not have contact with participants. Each intervention has a duration of 3 months and includes a 3 month washout period between interventions. Baseline assessments will be conducted before each intervention period.|f|f|f|t
33813443|NCT03249857|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33813444|NCT05160909|||COHORT||PROSPECTIVE|||||||
33813445|NCT05404802|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants, training session moderators and observers of PARO sessions cannot and will not be blinded to the intervention. Assessors of the follow-up outcomes and the research analysts will not be involved in the recruitment and intervention delivery and will be blinded to the group allocation (single blindness).|Participants will be allocated to the experimental group or the control group according to their floor of the residential care homes. The participants in the experimental group will be arranged to join the PARO intervention in Week 1 to 10. The control group will be arranged to attend 2 PARO training sessions after all assessments are completed.|f|f|f|t
33813446|NCT02169609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813447|NCT05873504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122119|NCT04256239|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122120|NCT04902989|||COHORT||PROSPECTIVE|||||||
34122121|NCT06505746|||OTHER||RETROSPECTIVE|||||||
34122122|NCT00506038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34122123|NCT05232656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34122124|NCT01111162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122125|NCT01107639|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34122126|NCT00888914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122127|NCT02647476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122128|NCT01514721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122129|NCT02668341|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122130|NCT00956761|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122131|NCT05886855|||COHORT||PROSPECTIVE|||||||
34122132|NCT01720394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122133|NCT01419119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122134|NCT04118543|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34122135|NCT04651205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34122136|NCT01544348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122137|NCT03478670|||COHORT||OTHER|||||||
34122138|NCT03102983|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34122139|NCT06022094|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will eat a reduced carb menu for 2 months||||
34122140|NCT03941847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||2 groups will be compared. The experimental group will benefit from musical listening during the induction period of the anesthesia. The control group will have a usual care.||||
34122141|NCT02271061|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34122142|NCT01655186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122143|NCT03067792|RANDOMIZED|PARALLEL||TREATMENT||||||||
34122144|NCT02433912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122145|NCT06199024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34122146|NCT03121144|NA|SINGLE_GROUP||OTHER||NONE||||||
34122147|NCT03034707|NA|SINGLE_GROUP||OTHER||NONE||||||
33838503|NCT01305408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840153|NCT03192475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||An initial (non-randomized) translational Group Lifestyle Balance (GLB) in person, lifestyle intervention designed to mitigate cardiometabolic risk in older adults is delivered to all participants between 0 and 4-months. Subsequently, one-half of the enrolled sample is randomized to either (1) 8-group telephone contacts (8-TC) for the remainder of 12-months; the other one-half is randomized to a newsletter control condition (NC) during this time period.|f|f|t|t
33840154|NCT00512655|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33840155|NCT00871286|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34122148|NCT05960838|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Each brace will be worn for either the first or second half (2 weeks) of the investigated immobilizing time of 4 week as determined by randomization.||||
34122149|NCT05578989|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122150|NCT02449941|||CASE_ONLY||PROSPECTIVE|||||||
34122151|NCT04464551|NA|SINGLE_GROUP||OTHER||NONE||||||
34122152|NCT06320704|||OTHER||PROSPECTIVE|||||||
34122153|NCT02246491|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34122154|NCT04016701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122155|NCT02129712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122156|NCT00869167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122157|NCT06199414|||COHORT||RETROSPECTIVE|||||||
34122158|NCT04877327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122159|NCT06170567|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
34122160|NCT00375921|||||PROSPECTIVE|||||||
34122161|NCT02343770|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34122162|NCT01677052|||||PROSPECTIVE|||||||
34122163|NCT04614844|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34122164|NCT00326599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122165|NCT04892186|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative and non-inferiority study of myo-inositol in relation to metformin. They will be divided into two groups of 30 patients: Group I (control) - they will receive metformin, orally, three times a day; Group II (experiment) - they will receive myo-inositol 2g, orally, twice a day.||||
34122166|NCT01950728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122167|NCT01110057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733841|NCT00373516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33733842|NCT03307330|||CASE_CONTROL||PROSPECTIVE|||||||
33733843|NCT01947504|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733844|NCT05660928|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled trial.||||
33733845|NCT04196556|RANDOMIZED|PARALLEL||TREATMENT||NONE|Intervention can't be masked. Statistician conducting the analysis will not know to which study arm a given patient has been assigned.|A multicenter Cluster Randomized Clinical Trial||||
33733846|NCT03459196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733847|NCT04355884|||COHORT||PROSPECTIVE|||||||
33733848|NCT06272747|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33733849|NCT01087385|||COHORT||RETROSPECTIVE|||||||
33733850|NCT05510323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733851|NCT04706624|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two frontline interventions: contingency management (CM) throughout 12 weeks (high intensity CM); and CM in 6 weeks followed by 6 weeks of weekly group educational sessions (low intensity CM); Consecutive urine tests negative with methamphetamine at week 11 and week 12 (two urine tests per week) are considered as responsive to frontline interventions; any positive with one of the urine tests during week 11 and 12 or failure to provide urine are considered non-responsive; Three treatment alternatives: Responders to frontline interventions will receive two daily automatic unidirectional scripted SMS reminder plus one weekly self-monitoring assessment message over 12 weeks (maintenance treatment); non-responders will be randomized to either Matrix group counseling alone or Matrix group counseling with CM over 12 weeks.||||
33733852|NCT00125827|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733853|NCT01000246|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733854|NCT00545831|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733855|NCT00065884|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33733856|NCT01545817||||TREATMENT||NONE||||||
33733857|NCT03135678|||COHORT||PROSPECTIVE|||||||
33733858|NCT04894617|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Unblinded personnel will perform randomization into one of two arms (ratio 1:1). The randomization list will be generated centrally in random blocks. Blinded personnel will not have access to the randomization key. Unblinded staff will deliver sealed envelopes containing treatment allocation to blinded study personnel to use for emergency unblinding.~All investigators, outcome assessors, and study participants will be blinded to the treatment allocation."|Randomized, double-blinded, placebo-controlled study|t|f|t|t
33733859|NCT05329740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733860|NCT02842502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33733861|NCT00895375|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733862|NCT06663605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind|Phase 1 a/b Double-Blind, Placebo-Controlled, Randomized Single Ascending Dose (SAD)/Multiple Ascending Dose (MAD), Food Effects (FE) crossover and Open-Label Ulcerative Colitis patient cohort study|t|t|t|f
33733863|NCT01539382|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33733864|NCT04224766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||2 groups of patients. Randomization into groups SSNP + costoclavicular or ISBPB as per randomization list, for a total of 50 patients.|t|t|t|t
33733865|NCT05137652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733866|NCT03869125|||COHORT||PROSPECTIVE|||||||
33733867|NCT01895751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733868|NCT05723367|||COHORT||CROSS_SECTIONAL|||||||
33733869|NCT04209088|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33733870|NCT05263661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open|A controlled, randomised clinical trial|f|f|f|t
33733871|NCT02024100|||||PROSPECTIVE|||||||
33733872|NCT06027827|||COHORT||PROSPECTIVE|||||||
33733873|NCT04463381|||COHORT||RETROSPECTIVE|||||||
33813448|NCT03249805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This will be a hospital-based study with single blinding of the investigator. Subjects will be randomized in order to prevent systematic differences between the groups to prevent bias. Our groups will be parallel, there will be no crossover. The two parallel groups will use two different versions of FABs; the Steenbeek Foot Abduction Brace (SFAB) and the MiracleFeet Foot Abduction Brace (mFAB). Both types of FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor to avoid increased compliance due to the sensor. Due to practical constraints (the brace being visibly identifiable), the study will not be blind. This study will use number of recurrences in the two groups as the primary outcome of interest. Recurrence will be checked for at each scheduled follow-up visit (see schedule below) and recorded in event of occurrence. A process of rolling recruitment will be used until our groups are complete.|f|f|t|f
33813449|NCT05558748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant (patient) and the outcome assessor will be masked. Whereas the investigator who performs the block will not be masked.|The patients will be randomized using a computer-generated sequence to one of the two intervention groups: USG-guided Caudal block and USG-guided Ilioinguinal/Iliohypogastric block. There will be no crossover.|t|f|f|t
33813450|NCT03741634|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733874|NCT06024876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733875|NCT01573624|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33733876|NCT02607397|||COHORT||RETROSPECTIVE|||||||
33733877|NCT05166213|||COHORT||PROSPECTIVE|||||||
33733878|NCT04595006|RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Assignment||||
33733879|NCT04488705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733880|NCT01776983|||COHORT|||||||||
33733881|NCT02625493|||COHORT||PROSPECTIVE|||||||
33733882|NCT00488501|||CASE_ONLY||PROSPECTIVE|||||||
33733883|NCT00384813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733884|NCT04812379|||COHORT||PROSPECTIVE|||||||
33733885|NCT05525819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733886|NCT00141063|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33733887|NCT01297673|||CASE_ONLY||PROSPECTIVE|||||||
33733888|NCT00808288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733889|NCT06663566|||COHORT||PROSPECTIVE|||||||
33733890|NCT02357576|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733891|NCT01932216|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813451|NCT01977391|||COHORT||PROSPECTIVE|||||||
33813452|NCT05935839|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813453|NCT01558999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813454|NCT03343041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The ultimate goal is to perform a prospective, single-center, double-blinded, parallel group, randomized, controlled trial on the safety and efficacy of low-carbohydrate enteral nutrition in adult patients admitted to the MICU with bacterial septic shock.|t|f|f|f
33813455|NCT05756400|||COHORT||RETROSPECTIVE|||||||
33813456|NCT03014349|||CASE_ONLY||RETROSPECTIVE|||||||
33813457|NCT03232489|||CASE_ONLY||PROSPECTIVE|||||||
33813458|NCT05844306|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33813459|NCT01635049|||COHORT||PROSPECTIVE|||||||
33813460|NCT00072670|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813461|NCT03980236|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33813462|NCT02297464|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33813463|NCT06133569|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants are allocated to either the ReDirection intervention or waitlist during the initial phase of the study and those who receive waitlist receive ReDirection during the second phase of the study.||||
33813464|NCT01247077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33813465|NCT00248898|||COHORT||RETROSPECTIVE|||||||
33813466|NCT04648904|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, single-site, prospective non-inferiority trial of PMRT delivered in the compressed FAST FORWARD schedule.||||
33813467|NCT03402477|||COHORT||PROSPECTIVE|||||||
33813468|NCT05167578|||COHORT||PROSPECTIVE|||||||
33813469|NCT03506802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813470|NCT04728282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be blinded to their group allocation. This is possible because the incision and rehabilitation processes are consistent between groups. It is not possible for the treating surgeon to be blinded to group allocation, therefore a research team member (athletic or physical therapist) will remain blinded to group allocation and conduct all study related assessments as well as administer the patient-reported questionnaires. This will be maintained by the participant not removing their shirt during the study assessment. Patients will not be informed of which procedure they will undergo until the study is complete.|This is a double-blinded randomized clinical trial comparing two groups, RTSA with and RTSA without subscapularis repair. Eighty-four participants will be randomized at a 1:1 ratio in blocks of 12. All participants will be recruited from the patient populations of six fellowship trained upper extremity orthopaedic surgeons at initial consult. Patients will be randomized intraoperatively using a telephone/web-based system.|t|f|t|t
33813471|NCT01525459|||COHORT||PROSPECTIVE|||||||
33813472|NCT06251791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Parallel Assignment Randomized Healthy participants|t|f|t|f
33813473|NCT00519844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813474|NCT03008785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33813475|NCT00623649|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33813476|NCT05843370|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33813477|NCT02037100|||CASE_CONTROL||PROSPECTIVE|||||||
33813478|NCT05939830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813479|NCT01288729|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33813480|NCT03996798|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33813481|NCT01449175|||COHORT||PROSPECTIVE|||||||
33813482|NCT00604396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813483|NCT06051721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813484|NCT02782000|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34122168|NCT00125970|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34122169|NCT02927158|||COHORT||PROSPECTIVE|||||||
33813485|NCT03998956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33813486|NCT06509295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813487|NCT04635748|||OTHER||CROSS_SECTIONAL|||||||
33813488|NCT03518450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813489|NCT03422705|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33813490|NCT02367248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813491|NCT05920538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33813492|NCT01350167|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33813493|NCT02893618|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813494|NCT06115070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813495|NCT03898999|||COHORT||PROSPECTIVE|||||||
34122170|NCT01781884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122171|NCT00539240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122172|NCT02960633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122173|NCT04236089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122174|NCT03904134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary comparison for the interventional study will be between two arms based on biologic assignment, analyzed on an intention-to-treat basis: Arm 1: Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a \>90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued; and Arm 2: Patients who are Very Unlikely to find a MUD, defined as having a \<10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued. Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.||||
34122175|NCT03928041|NA|SEQUENTIAL||TREATMENT||NONE||All subjects will be recruited and receive the EVOS-HA prospectively.||||
33813496|NCT02430259|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813497|NCT05291403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813498|NCT03304535|||COHORT||PROSPECTIVE|||||||
33813499|NCT03323294|||OTHER||PROSPECTIVE|||||||
33813500|NCT03950726|||CASE_CONTROL||PROSPECTIVE|||||||
33813501|NCT01354288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33813502|NCT02935673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813503|NCT02354417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813504|NCT02915003|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34122176|NCT05749640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Each case will be represented by a code and the group name. These will be sealed in a sequentially numbered opaque envelope and the set of envelopes will be given to the senior supervisor. When the investigator wants to enroll a new case, he will notify the supervisor who will take the next inline envelope and will write the name of the participant on it. At the time of intervention implementation, the investigator will open the sealed envelope and retrieve the allocation and apply.|This study will be a randomized control clinical trial in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines|t|f|f|t
34122177|NCT06237634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122178|NCT06375083|NA|SINGLE_GROUP||TREATMENT||NONE||Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) and Cognitive Behavioral Therapy for Depression (cCBT-D)||||
34122179|NCT00140023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122180|NCT04256187|||CASE_CONTROL||PROSPECTIVE|||||||
34122181|NCT02058225|||COHORT||PROSPECTIVE|||||||
34122182|NCT06026150|||COHORT||CROSS_SECTIONAL|||||||
34122183|NCT05962255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1 randomisation to infusion of 0.9% NaCl vs 5% glucose|t|f|f|f
34122184|NCT05231824|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34122185|NCT03679104|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Patients will be allocated to the corresponding group according to a peri-procedural finding, availability of a respective closure method and endoscopist´s decision.|f|f|t|f
34122186|NCT03332121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122187|NCT00544856|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34122188|NCT06117007|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34122189|NCT03479489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122190|NCT00144326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122191|NCT01450644|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122192|NCT04708886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122193|NCT05908838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122194|NCT06307847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122195|NCT05116956|||COHORT||PROSPECTIVE|||||||
34122196|NCT06718881|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized controlled experimental model|t|f|f|f
34122197|NCT03423602|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, multi-centred, non-randomized study||||
34122198|NCT05364710|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants will not be informed on which intervention they receive on any given day.|Placebo-controlled, double-blinded, cross-over study design.|t|t|t|f
34122199|NCT01874392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122200|NCT03966040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122201|NCT02945124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122202|NCT03348293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122203|NCT00131521|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34122204|NCT00942383|||COHORT||PROSPECTIVE|||||||
34122205|NCT01470183|||CASE_CONTROL||PROSPECTIVE|||||||
34122206|NCT04446221|||OTHER||RETROSPECTIVE|||||||
34122207|NCT01837680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122208|NCT05884372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122209|NCT03521271|||CASE_ONLY||PROSPECTIVE|||||||
34122210|NCT03616119|||COHORT||CROSS_SECTIONAL|||||||
34122211|NCT03888014|||COHORT||PROSPECTIVE|||||||
34122212|NCT01291966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122213|NCT00123825|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122214|NCT01642550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122215|NCT01339793|||||PROSPECTIVE|||||||
34122216|NCT06466525|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Placebo controlled, double blind (patient and investigator)|Placebo controlled, double blind, SAD and MAD dose escalation|t|t|t|t
34122217|NCT01941602|||CASE_ONLY||RETROSPECTIVE|||||||
34122218|NCT01944020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||treatment group: individuals with OSA using CPAP control group: individuals with OSA not using CPAP||||
34122219|NCT02070497|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34122220|NCT00511758|||CASE_ONLY||PROSPECTIVE|||||||
34122221|NCT02156024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122222|NCT02533310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122223|NCT03010943|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33813505|NCT02875704|||CASE_CONTROL||PROSPECTIVE|||||||
33813506|NCT02089945|||COHORT||PROSPECTIVE|||||||
34122224|NCT06007586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients, nurses, and investigators were blinded.||t|t|t|f
34122225|NCT02818517|||OTHER||PROSPECTIVE|||||||
34122226|NCT01589224|||COHORT||PROSPECTIVE|||||||
34122227|NCT05935059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122228|NCT05217459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122229|NCT03517670|||OTHER||PROSPECTIVE|||||||
34122230|NCT02735018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34122231|NCT00440817|||||RETROSPECTIVE|||||||
34122232|NCT04741932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Special qualified nurses with an extended nursing role (Dementia Care Manager) record all nursing, medical, drug, psychosocial and social care needs using an IT-based care management system and then implement them over a period of six months.||||
34122233|NCT06151119|||COHORT||PROSPECTIVE|||||||
34122234|NCT01478022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122235|NCT01082614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122236|NCT03376464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122237|NCT04632394|||CASE_ONLY||PROSPECTIVE|||||||
34122238|NCT00295607|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122239|NCT00233532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122240|NCT04396821|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Part A - 2 arms, Q2w and Q3w, 3+3 design dose escalation; Part B - dose expansion, 3 Cohorts||||
34122241|NCT01220492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733892|NCT01818362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33733893|NCT02484105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33733894|NCT03285321|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33733895|NCT06387329|RANDOMIZED|PARALLEL||PREVENTION||NONE||Nonblinded, randomized, noninferiority trial of single dose nitrofurantoin vs 3 day twice daily course of nitrofurantoin for prevention of post-procedure urinary tract infections after intradetrusor onabotulinumtoxinA injections for OAB and IC/BPS.||||
33733896|NCT00808600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733897|NCT01546948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733898|NCT02143843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733899|NCT01529528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733900|NCT05321303|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33733901|NCT00006482||||TREATMENT||||||||
33733902|NCT03461627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind|Drug：Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) Drug：Seretide (50ug/250ug)|t|t|t|t
33733903|NCT04554433|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* (A) group: will receive the new protocol .~* (B) group: Will receive the standard protocol ."||||
33733904|NCT03411525|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge cluster randomized trial||||
33733905|NCT02489227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733906|NCT01464320|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33733907|NCT04026906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813507|NCT03147222|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||All participants will receive the intervention.||||
33813508|NCT00923078|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33813509|NCT01005030|||COHORT||PROSPECTIVE|||||||
33813510|NCT05280509|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1b - Dose Escalation Design Phase 2 - Dose Expansion||||
33813511|NCT00417885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813512|NCT00334438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813513|NCT04053894|||COHORT||PROSPECTIVE|||||||
33813514|NCT02410109|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813515|NCT05887609|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single-arm, study design evaluating the maintenance therapy combination Mirvetuximab soravtansine and Olaparib in recurrent platinum-sensitive ovarian, peritoneal, and fallopian tube cancers. A six-patient safety lead in will occur, in which relevant the pharmaceutical company will be informed and included in safety evaluation process.||||
33813516|NCT06284356|||COHORT||PROSPECTIVE|||||||
33813517|NCT05602961|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33813518|NCT05711433|||COHORT||OTHER|||||||
33813519|NCT02948309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813520|NCT00237809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813521|NCT03187249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813522|NCT01039909|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33813523|NCT02224755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813524|NCT01444690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813525|NCT02294994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813526|NCT00506025|NON_RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33813527|NCT00604461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813528|NCT03607851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813529|NCT01156675|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122242|NCT06091358|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Randomised parallel control group pilot investigation||||
34122243|NCT05461586|||COHORT||PROSPECTIVE|||||||
34122244|NCT04955067|||CASE_CONTROL||RETROSPECTIVE|||||||
34122245|NCT04674267|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34122246|NCT04003298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34122247|NCT05160948|||COHORT||CROSS_SECTIONAL|||||||
34122248|NCT00710944|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122249|NCT02588469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122250|NCT04753619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122251|NCT02267889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122252|NCT00005590|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
34122253|NCT05038696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733908|NCT02710604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733909|NCT02093637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33733910|NCT06078735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized 1:1 to LockeT device or Manual Compression.||||
33733911|NCT02309281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733912|NCT04514991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813530|NCT05436041|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33840156|NCT03021980|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840157|NCT04870008|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34122254|NCT00711659|||COHORT||PROSPECTIVE|||||||
34122255|NCT02727322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122256|NCT01173510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122257|NCT00800982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122258|NCT05819476|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"In part 1 the assessor won't know whether subjects receive the study intervention or not (single-blinded).~Due to organizational reasons, blinding of the assessor will not be possible in Part 2."|"The first part of this study is designed as a confirmatory, randomized, two-arm, assessor-blinded cross-over trial in a monocentric setup at the University Hospital of Basel.~The second part is designed as a proof-of-concept, randomized, controlled, three-arm trial in a monocentric setup at the University Hospital of Basel."|f|f|f|t
34122259|NCT00328718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122260|NCT06390956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122261|NCT00572182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122262|NCT03323138|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, interventional and monocentric study based in a university hospital setting||||
34122263|NCT06185790|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34122264|NCT06547034|||COHORT||PROSPECTIVE|||||||
33733913|NCT00847496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733914|NCT00160316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733915|NCT02999958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33733916|NCT02821884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733917|NCT06218004|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733918|NCT01282216|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Only the study pharmacist was unblinded.||t|t|t|f
34122265|NCT01312480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34122266|NCT03762161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122267|NCT06476288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants will be split into two different groups: one receiving a high-dose RIC intervention with low-intensity exercise and the other receiving a low-dose RIC intervention with low-intensity exercise. The assignment to the two different groups will be done by a computer in a process similar to flipping a coin in a 1:1 ratio. There will be 10 participants in each group.|t|f|f|f
34122268|NCT03606486|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122269|NCT05816824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122270|NCT04407338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will be blinded from the randomizing arm. As the procedure is performed under general anaesthesia, the patient will not be informed whether or not the B-Dyn® device has been implanted as a result of the procedure. The primary endpoint (the ODI being a reported outcome patient) will therefore be assessed blind to the randomizing arm. Other secondary endpoints such as quality of life or pain intensity will also be assessed blindly from the randomizing arm (patient assessment). Blinding of the surgeon is not possible. The device cannot be blinded from the surgeon's view.|"This is a prospective, randomized, multicentric, comparative study of non-inferiority in parallel groups with an allocation ratio of 1:1, single-blind (the patient will be blinded from the arm of randomization), single blind (The patient will be blinded regarding randomization arm).~The secondary objective of this study will be to assess the performance of the B-Dyn device compared to a simple fusion on dynamic parameters and the prevention of adjacent syndrome.~Randomization, with a ratio of 1:1 will be stratified on the center and on the presence of spondylolisthesis (spondylolisthesis grade 1 on the upper instrumented (treated) level VS no spondylolisthesison the upper instrumented ( treated) level )"|t|f|f|f
34122271|NCT04577911|||OTHER||CROSS_SECTIONAL|||||||
34122272|NCT03400241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122273|NCT03053778|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122274|NCT01929200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122275|NCT04298619|||COHORT||RETROSPECTIVE|||||||
34122276|NCT01652781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122277|NCT01778959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122278|NCT04240340|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122279|NCT05329337|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"This is a two-center proof-of-concept study, ancillary to the MetACTIV study, whose objective is to define immune activation profiles from the data of individuals followed by the Gard health insurance fund. The IRACTIV study will include a subset of volunteers from the MetACTIV study for whom a blood sample will be taken as part of the IRACTIV study.~In order to study the evolution of insulin levels in volunteers, we need to be able to ensure a longitudinal analysis, which requires a link with the MetACTIV study data for the volunteers included in the IRACTIV study."||||
34122280|NCT00565409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34122281|NCT00824798|||COHORT||RETROSPECTIVE|||||||
34122282|NCT01664754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122283|NCT01982903|||COHORT||PROSPECTIVE|||||||
34122284|NCT02669589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122285|NCT02006186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122286|NCT03576261|RANDOMIZED|PARALLEL||OTHER||NONE||A consecutive cohort. Signed informed consent is gathered. Non-blinded randomization is conducted to fluid therapy before anesthesia induction. Preoperative diagnostics by echocardiography is conducted to all participants.Two arms, with or without preoperative fluids, are studied regarding hemodynamic stability during anesthesia induction.||||
34122287|NCT00012441|NON_RANDOMIZED|||TREATMENT||||||||
34122288|NCT03924804|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Doppler Ultrasonography Assessed Bladder and Blood Volume|t|f|t|t
34122289|NCT04474639|||COHORT||PROSPECTIVE|||||||
34122290|NCT01646814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34122291|NCT01444430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122292|NCT01459809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122293|NCT01106989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122294|NCT04582006|||COHORT||PROSPECTIVE|||||||
34122295|NCT00156325|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34122296|NCT01675583|||CASE_CONTROL||RETROSPECTIVE|||||||
34122297|NCT05663385|||COHORT||PROSPECTIVE|||||||
34122298|NCT00383071|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122299|NCT01070979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122300|NCT00970476|||CASE_ONLY||PROSPECTIVE|||||||
34122301|NCT02263014|||COHORT||PROSPECTIVE|||||||
34122302|NCT06054568|||COHORT||PROSPECTIVE|||||||
33733919|NCT05177198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733920|NCT06663618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733921|NCT00686491|||CASE_CONTROL||PROSPECTIVE|||||||
33733922|NCT05631496|||OTHER||OTHER|||||||
33733923|NCT03734198|NA|SINGLE_GROUP||TREATMENT||NONE||Open label multicentre phase 2 study||||
33733924|NCT02837536|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33733925|NCT02397356|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33733926|NCT03527212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33733927|NCT03592641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840158|NCT06136104|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33840159|NCT02727855|||COHORT||PROSPECTIVE|||||||
33733928|NCT05264324|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Patients will be exposed to ambient air at 490m vs. hypoxic air at 2500m in a randomized sequence according to a cross-over design||||
33733929|NCT02461420|||COHORT||PROSPECTIVE|||||||
33733930|NCT06451523|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will follow the same procedures.||||
33733931|NCT06513585|||COHORT||PROSPECTIVE|||||||
33733932|NCT04035785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33733933|NCT04686097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733934|NCT00392613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733935|NCT05478174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blinded, 2:1 ratio of HSK3489 and Propofol respectively|Surgical pre-induction analgesia|t|t|t|t
33733936|NCT02624102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33733937|NCT04135716|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||"Randomization results were kept confidential in the general case, and information on the use of EndoAngel was not reflected in the hospital history and documents obtained by other subjects. During the examination and after the examination, researchers should take care to avoid talking to the subjects about random content and avoid unnecessary blindness.~The evaluator was blinded, and neither the data analysis team nor the pathologist could obtain random result information from the medical history data, regardless of whether the subject used EndoAngel or not."|t|f|f|t
33733938|NCT00226603|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33733939|NCT05301335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is designed as a prospective, multicenter, single blind, two-arm randomized sham-controlled clinical study. Subjects will be randomized into a treatment arm and control (sham) arm in a 2:1 ratio.|t|f|f|f
33733940|NCT05902390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733941|NCT02384603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33733942|NCT02988063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733943|NCT01823029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733944|NCT04777890|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33733945|NCT00333229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33733946|NCT06086184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733947|NCT00858585|||OTHER||PROSPECTIVE|||||||
33733948|NCT02321982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33733949|NCT00466960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733950|NCT00648531|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33733951|NCT02966171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733952|NCT05796128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33733953|NCT01285765|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|||||
33733954|NCT06094959|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33733955|NCT05247190|NA|SINGLE_GROUP||TREATMENT||NONE||Single-case experimental design||||
33733956|NCT02100267||||DIAGNOSTIC||||||||
33733957|NCT05808751|||COHORT||PROSPECTIVE|||||||
33733958|NCT05373511|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733959|NCT05913219|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33733960|NCT02136875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733961|NCT02995395|||CASE_ONLY||PROSPECTIVE|||||||
33813531|NCT04255251|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants will not know which type of fluoride they are getting around their crow margins.~Principal investigator will measuring the extend of the decay does not know about the type of fluoride treatment patient got."|Participants will be assigned randomly into treatment and control group using a predetermined randomization protocol.|t|f|t|f
33813532|NCT02930265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813533|NCT01010256|||CASE_CONTROL||PROSPECTIVE|||||||
34122303|NCT05871619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To avoid bias and for proper randomization, the study will be done per patient using tossing a coin to assign the tooth to be either treated with Nano hydroxyapatite with fluoride or Nano hydroxyapatite with xylitol or sodium fluoride.|"* The first group (A1B1):15 teeth with WSL were treated with Remin Pro with laser application.~* The second group (A1B2): The contralateral 15 teeth were treated with Remin Pro without laser application.~The third group (A2B1): 15 teeth with WSL were treated with X Pur Remin with laser application.~* The fourth group (A2B2): The contralateral 15 teeth will be treated with XPur Remin without laser application.~* The fifth group (A3B1): 15 teeth with WSL were treated with 5% sodium fluoride varnish with laser application.~* The sixth group (A3B2): The contralateral 15 teeth were treated with 5% sodium fluoride without laser application"|f|f|t|f
34122304|NCT00997789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122305|NCT02429817|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
34122306|NCT02811822|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122307|NCT06488651|||COHORT||PROSPECTIVE|||||||
34122308|NCT00396617|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122309|NCT03502564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122310|NCT05531500|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel groups of different intervention||||
34122311|NCT00368524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34122312|NCT01685814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122313|NCT05577026|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized control trial|f|f|f|t
34122314|NCT06320600|||COHORT||OTHER|||||||
34122315|NCT04795401|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122316|NCT05156411|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34122317|NCT00165789|RANDOMIZED|PARALLEL||||DOUBLE||||||
34122318|NCT02432573|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34122319|NCT00917319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122320|NCT02710877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122321|NCT00592865|||OTHER||OTHER|||||||
34122322|NCT02268110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122323|NCT04046393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122324|NCT05260749|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33733962|NCT00554749|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33733963|NCT06352944|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33733964|NCT00705575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733965|NCT01322204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813534|NCT03063021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813535|NCT05907070|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
34122325|NCT03470350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122326|NCT01631968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122327|NCT01086696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122328|NCT06709872|||COHORT||PROSPECTIVE|||||||
34122329|NCT04274595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122330|NCT04535089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122331|NCT06459596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122332|NCT02481258|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34122333|NCT03302143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A comparative, randomized, prospective, clinical study|t|f|f|t
34122334|NCT01254448|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34122335|NCT06347913|||COHORT||PROSPECTIVE|||||||
34122336|NCT02519803|||COHORT||PROSPECTIVE|||||||
34122337|NCT03172273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122338|NCT03980392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Independent raters are blinded to the group of participants.|They will be randomly allocated to facility-based multidomain intervention group, home-based intervention group, and a regular health advice group (referred to as control group) at a ratio of 1:1:1.|f|f|f|t
34122339|NCT05879952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122340|NCT03758807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomly assigned to one of two treatment groups|Randomized Control Trial|t|f|f|f
34122341|NCT01597726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34122342|NCT01768949|NA|SINGLE_GROUP||SCREENING||NONE||||||
34122343|NCT02797314|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122344|NCT02661399|||OTHER||OTHER|||||||
34122345|NCT04340492|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122346|NCT05243407|||COHORT||PROSPECTIVE|||||||
34122347|NCT02987582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122348|NCT00403325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122349|NCT03039387|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34122350|NCT00353080|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34122351|NCT03630146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34122352|NCT00613431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122353|NCT02146131|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34122354|NCT04709120|||COHORT||OTHER|||||||
34122355|NCT00517699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122356|NCT03243773|||COHORT||PROSPECTIVE|||||||
34122357|NCT01788943|||COHORT||PROSPECTIVE|||||||
34122358|NCT00827177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122359|NCT03971929|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122360|NCT02777086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122361|NCT04392973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, parallel groups were participants are assigned to either an intervention arm or standard of care.||||
34122362|NCT03793686|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34122363|NCT06717087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122364|NCT00112892||||TREATMENT||||||||
34122365|NCT05609357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122366|NCT04653974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122367|NCT06209489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34122368|NCT03092700|||CASE_ONLY||PROSPECTIVE|||||||
34122369|NCT03445312|||COHORT||PROSPECTIVE|||||||
34122370|NCT03623438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122371|NCT00205764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122372|NCT01776853|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34122373|NCT05112848|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122374|NCT05508828|||CASE_ONLY||RETROSPECTIVE|||||||
34122375|NCT02431546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122376|NCT03952403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122377|NCT05030584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122378|NCT02946398|||COHORT||PROSPECTIVE|||||||
34122379|NCT01055145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122380|NCT02039830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122381|NCT06373211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122382|NCT06544044|NA|SINGLE_GROUP||SCREENING||NONE||||||
34122383|NCT06716177|||COHORT||PROSPECTIVE|||||||
34122384|NCT03387215|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34122385|NCT01927978|||CASE_ONLY||PROSPECTIVE|||||||
34122386|NCT04416113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled study will be conducted on 60 patients of positive COVID 19. The patients will be divided into 3 equal groups. Group I will receive low level laser (diode laser 980nm) from laser watch for 30 minutes, 20 J for 3 to 5 days and laser acupuncture. Group 2 will be treated with photodynamic therapy by injecting the methylene blue as a photosensitizer and irradiated with laser watch (diode laser 670 nm). Group 3 will serve as a control. Evaluation methods will include laboratory investigations and CT chest.|t|f|f|f
34122387|NCT04462601|||CASE_ONLY||PROSPECTIVE|||||||
34122388|NCT03674892|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomized, open-label, single arm pilot trial||||
34122389|NCT03568747|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122390|NCT06002009|||COHORT||PROSPECTIVE|||||||
34122391|NCT03618381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122392|NCT01298843|NA|SINGLE_GROUP||||NONE||||||
34122393|NCT02465931|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34122394|NCT03313830|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34122395|NCT04650295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122396|NCT02112643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33733966|NCT01544972|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33733967|NCT00414661|||COHORT||PROSPECTIVE|||||||
33733968|NCT05626881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733969|NCT05010174|||OTHER||PROSPECTIVE|||||||
33733970|NCT06663787|||COHORT||PROSPECTIVE|||||||
33733971|NCT01043965|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33733972|NCT05430789|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33733973|NCT02158026|||COHORT||PROSPECTIVE|||||||
33733974|NCT00548860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733975|NCT06146387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Two arms of participants will be assigned masked products (investigational formula and control formula) after randomization, while the participants of breastfeeding arm will not be assigned study products.||t|t|t|t
33733976|NCT05074550|NA|SEQUENTIAL||TREATMENT||NONE||||||
33733977|NCT01122511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33733978|NCT03675048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33733979|NCT00797992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733980|NCT02390583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733981|NCT04458714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients who agreed were asked to sign an informed consent. After patient data input was done, randomization was computer generated in the vascular surgery department in Zagazig university hospitals. Computer generated random numbers were created with the use of randomly permuted blocks with two block sizes; after which they were secured in consecutive numbered envelopes and group allocation was independent of time and person delivering the treatment. Single blinding was used to recruit the patients.||t|f|f|t
33733982|NCT06462690|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants were included in the study using the single-blind randomization method. Block randomization was used in the randomization process. Since the research is a thesis study, double blinding cannot be done because the researcher who collects the data and performs the application is the same. However, blinding will be applied wherever possible in the study.|Experimental Group Control Group|t|f|t|t
33733983|NCT03957538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33733984|NCT06348511|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Personnel who interact directly with the study subjects were not aware of the assigned treatments. Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group.|The study tested the impact of contingent and immediate reward (ICR) given by the game in respect to the participant's tic frequency relative to a random and non-contingent delayed reward (DR) provided by the end of the training day. Each participant underwent three training days in each of the the modes during one week. The training days included 3 (first day) or 4 (second and third days) game sessions. The order of the training modes was random.|f|f|t|f
33733985|NCT00222937|RANDOMIZED|PARALLEL||||NONE||||||
33733986|NCT06404177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||prospective, randomised , double blind controlled trial|t|t|t|t
33733987|NCT04689737|NA|SINGLE_GROUP||OTHER||NONE||"This is a multi-centre, single-arm, open-label, pilot study in HIV-infected participants with ESRD undergoing routine hemodialysis.~All participants will receive doravirine 100 mg once daily during the study (5 days)."||||
34149812|NCT05297526|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be masked as to which group they have been randomized into for the study.|After completing the consent and baseline survey, participants will be randomized into either the control group or the intervention group via Jefferson REDCap. Participants will not know which group they are in, and will receive the corresponding materials for their group to use for the duration of the study (3 months). At the end of the 3 month period, participants will take a post-study survey to gauge changes in knowledge, attitudes, and behaviors regarding oral health. At the end of the trial, participants who were in the control group receiving just the informational pamphlet, will receive a copy of the baby book given to the intervention group.|t|f|f|f
33733988|NCT02661438|NA|SINGLE_GROUP||OTHER||NONE||||||
33733989|NCT04961892|||COHORT||PROSPECTIVE|||||||
33733990|NCT00584038|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33733991|NCT02579616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733992|NCT03829735|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33733993|NCT03787316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733994|NCT00548808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33733995|NCT00263523||||TREATMENT||||||||
33733996|NCT02130401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33733997|NCT03808896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Traditional intubation technique direct and video laryngoscope, bougie-assisted intubation, intubation with stylet assisted epiglottis lifting|t|f|t|f
33733998|NCT06182267|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33813536|NCT01403922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33813537|NCT01928732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813538|NCT06594497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813539|NCT03768453|||CASE_ONLY||PROSPECTIVE|||||||
33813540|NCT01474759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813541|NCT01903954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813542|NCT04918888|||COHORT||PROSPECTIVE|||||||
33813543|NCT04143932|||COHORT||PROSPECTIVE|||||||
33813544|NCT00276679|NON_RANDOMIZED|||TREATMENT||NONE||||||
33813545|NCT01117402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813546|NCT04971902|||CASE_CONTROL||PROSPECTIVE|||||||
33733999|NCT06086535|||COHORT||PROSPECTIVE|||||||
33734000|NCT03906669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734001|NCT01178229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734002|NCT05746546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33813547|NCT05871788|||OTHER||PROSPECTIVE|||||||
33813548|NCT00996164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813549|NCT01390753|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813550|NCT01217294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813551|NCT01233245|||COHORT||PROSPECTIVE|||||||
33813552|NCT05173766|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Quasi-experimental study||||
33840160|NCT01055847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122397|NCT05554458|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Methods: 66 families with a parent being treated for any mental health disorder and with a child aged 6-18 are recruited by ChildTalks+ therapists, professionals from health, social and educational facilities. Paired allocation into intervention group IG (N = 33) and control group CG (N = 33) is based on the number of risk factors identified in the family. IG and CG complete questionnaires at the baseline assessment (T0), at the post-test assessment (T1), and at the follow-up assessments after 6 months (T2) and 12 months (T3). IG receive the ChildTalks+ intervention within 2 months after T0 and CG after the T3 assessment. Questionnaires are completed by parents and children aged 12/15. Quantitative data will be supplemented with qualitative data from ChildTalks+ therapists working with patients with eating disorders.|t|t|t|f
34122398|NCT03757429|||COHORT||PROSPECTIVE|||||||
34122399|NCT01342731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122400|NCT01888861|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34122401|NCT05094843|||COHORT||PROSPECTIVE|||||||
34122402|NCT00569933|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34122403|NCT00572598|NA|SINGLE_GROUP||||NONE||||||
34122404|NCT01437202|||COHORT||RETROSPECTIVE|||||||
34122405|NCT01445847|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122406|NCT00293163|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122407|NCT05986773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122408|NCT01836289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122409|NCT03731403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122410|NCT01938261|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122411|NCT03984721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Inclusion of 40 patients identified by the Department of Anatomy and pathological cytology at the University of Toulouse.||||
34122412|NCT02905578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122413|NCT05245539|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122414|NCT01547819|||||PROSPECTIVE|||||||
34122415|NCT03544450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122416|NCT05046392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122417|NCT01027039|||COHORT||PROSPECTIVE|||||||
34122418|NCT00180037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122419|NCT05719207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel design with optional crossover from control to intervention at 6 weeks.|t|f|f|t
34122420|NCT04014426|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Exposed/ Non-exposed||||
34122421|NCT02270775|||||PROSPECTIVE|||||||
34122422|NCT04470297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122423|NCT06342765|||COHORT||OTHER|||||||
34122424|NCT02043990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122425|NCT02435654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122426|NCT06717620|||CASE_CROSSOVER||OTHER|||||||
34122427|NCT04934267|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Comparing the recovery times and length of DOMS in individuals with JHS to individuals with normal ranges of motion in response to exercise||||
34122428|NCT04868344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122429|NCT06263036|||OTHER||OTHER|||||||
34122430|NCT05233124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122431|NCT03215043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122432|NCT01709526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122433|NCT04097652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122434|NCT06513533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Group 1: oral administration of dimethyl fumarate for 36 months Group 2: oral administration of placebo for 24 months, followed by oral dimethyl fumarate for 12 months.|Double-arm, randomized, placebo-controlled, multicentric trial|t|t|t|f
34122435|NCT03835078|NA|SINGLE_GROUP||OTHER||NONE|Study lenses will be transferred, by an assistant, out of their packaging to unmarked new contact lens cases filled with unpreserved sterile saline just prior to dispensing to maintain subject masking of the study lenses|||||
34122436|NCT06414083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathologist is blinded to treatment arm||f|f|f|t
34122437|NCT04919720|NA|SINGLE_GROUP||TREATMENT||NONE||Step-wedge, cluster-randomised trial||||
34122438|NCT01224236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122439|NCT02949011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122440|NCT04708262|NA|SINGLE_GROUP||TREATMENT||NONE||Single group case series design||||
34122441|NCT00089622||||TREATMENT||||||||
34122442|NCT02399787|||CASE_CONTROL||PROSPECTIVE|||||||
34122443|NCT01864265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122444|NCT00499200|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34122445|NCT04815798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122446|NCT02227810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122447|NCT02459561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122448|NCT04933500|||COHORT||PROSPECTIVE|||||||
34122449|NCT00003365|RANDOMIZED|||PREVENTION||||||||
34122450|NCT00143559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122451|NCT01334554|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34122452|NCT03465722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734003|NCT03228134|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind trial|All treatment group received traditional chinese medicine plus a standard anti-asthma treatment on study entry, and the control group received placebo and standard anti-asthma treatment.|t|t|f|t
33734004|NCT06382623|||OTHER||PROSPECTIVE|||||||
33734005|NCT03545607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734006|NCT02840292|||COHORT||PROSPECTIVE|||||||
33734007|NCT06038591|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33734008|NCT00214955|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33734009|NCT00668681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122453|NCT05775302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122454|NCT04550897|NA|SINGLE_GROUP||OTHER||NONE||Phase 1 study in colorectal cancer patients||||
34122455|NCT01273571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122456|NCT03024424|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Masking is applicable to risk of age-related macular degeneration, not to intervention assignment.||t|f|t|t
33813553|NCT05746026|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"* Session 1: introduction and basic information about Climate Change: the researcher was describing the significance of the intended educational program sessions as well as the expected aims to be met.~* Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being. These consequences obviously include biological impacts and hazards to physical health and to human, also direct and indirect psychological and interpersonal impacts of climate change.~* Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~* Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes"|t|f|f|f
33813554|NCT00602732|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33734010|NCT03296163|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813555|NCT02858115|||||RETROSPECTIVE|||||||
33813556|NCT03632785|||CASE_CONTROL||PROSPECTIVE|||||||
33734011|NCT01994512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813557|NCT05565898|||COHORT||PROSPECTIVE|||||||
33813558|NCT06056726|||COHORT||PROSPECTIVE|||||||
33813559|NCT00508144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813560|NCT06013124|||CASE_ONLY||CROSS_SECTIONAL|||||||
33813561|NCT06244394|||COHORT||RETROSPECTIVE|||||||
33813562|NCT01061658|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33813563|NCT03490006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The practitioner must know which block to perform, and the patient will be able to deduce which block was performed because paravertebral requires two injections, and erector spinae requires only one injection. The outcomes assessor will not know which group each patient is in.|Two parallel arms. One group will receive erector spinae plane block, and the other will receive paravertebral block.|f|f|f|t
33813564|NCT00003049|RANDOMIZED|||TREATMENT||||||||
33813565|NCT00407732|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33813566|NCT03471442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33813567|NCT05533788|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||In this study, a single oral dose of the tablet formulation administered under fed conditions will be compared to administration under fasted conditions to assess the effects of high-fat meal on the rate and extent of absorption and exposure.|t|f|t|f
33813568|NCT03846817|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will be blinded to the potential value of the diagnostic findings, such as response to intra-articular hip injection.~Outcome assessor will be blinded to diagnostic findings, such as response to intra-articular hip injection.~Care Provider (Physiotherapist supervising the intervention) will be blinded to diagnostic findings, such as response to intra-articular hip injection."||f|t|f|t
33813569|NCT00749944|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734012|NCT06218043|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||When the first phase of the iodine balance study without intervention is completed. After an interval of 4 days, subjects who eat iodized salt will be included, the iodized salt will be replaced with non-iodized salt, and the second phase of the iodine balance experiment will begin.||||
33813570|NCT05469607|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33813571|NCT05656456|||COHORT||PROSPECTIVE|||||||
33734013|NCT06165068|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Aspirin 81 mg/d or Clopidogrel 75 mg/d~2. Aspirin 81 mg/d or Clopidogrel 75 mg/d with N-acetylcysteine 600 mg/d~3. No medication"||||
33813572|NCT00773344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813573|NCT04624906|NA|SINGLE_GROUP||TREATMENT||NONE||Bendamustine, Rituximab and Acalabrutinib||||
33813574|NCT02529605|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33734014|NCT02290587|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33734015|NCT01585142|NA|SINGLE_GROUP||||NONE||||||
33734016|NCT05690295|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734017|NCT04024475|||COHORT||PROSPECTIVE|||||||
33734018|NCT06444477|||OTHER||RETROSPECTIVE|||||||
33734019|NCT01045226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734020|NCT05451576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33734021|NCT05703919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial will be single blinded. The patients will be blinded to treatment allocation. The EMTs (emergency medical technicians) or paramedics will not be blinded because of practical, ethical and security problems with carrying compressed gas without known content in an ambulance. As part of study informed and training, the EMT's and paramedics will be attentive to keep all AECOPD suspected patients blinded to the treatment allocated.|Interventional, prospective, randomized 1:1, parallel groups, patient blinded, prehospital, single center, acute, superiority trial|t|f|f|f
33734022|NCT03667339|||COHORT||PROSPECTIVE|||||||
33734023|NCT01395472|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734024|NCT01434823|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33734025|NCT06319196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813575|NCT00222209|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
33813576|NCT03536767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813577|NCT06361212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813578|NCT02705456|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813579|NCT01428622|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33813580|NCT03401099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded outcome assessment|Participants will be randomised 1:1 into two groups to receive either of the two treatments.|f|f|f|t
33813581|NCT01984099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33813582|NCT01322386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813583|NCT04728035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813584|NCT04214093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734026|NCT05741918|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33813585|NCT04471298|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33813586|NCT02221011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813587|NCT02222506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813588|NCT04201275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813589|NCT02664870|||COHORT||PROSPECTIVE|||||||
33840161|NCT03794700|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33840162|NCT04609488|||CASE_ONLY||PROSPECTIVE|||||||
33840163|NCT00669877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734027|NCT05586399|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-test 4 weeks before the intervention period (Subjects functioning as their own control), tests at baseline and 4 weeks after the intervention period.||||
33734028|NCT02734017|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734029|NCT01570023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734030|NCT06034366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33734031|NCT01159301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734032|NCT03785639|||COHORT||PROSPECTIVE|||||||
33734033|NCT06663176|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Ascending Dose, Multiple Daily Dosing||||
33734034|NCT00484302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33734035|NCT05768867|||COHORT||PROSPECTIVE|||||||
33734036|NCT04709965|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33734037|NCT03837899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734038|NCT06055426|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33734039|NCT06341465|RANDOMIZED|PARALLEL||TREATMENT||NONE||3 groups. Schroth exercise group (n=19), schroth exercise and kinesiological taping group (n=19), healthy people (n=19).||||
33734040|NCT05172505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734041|NCT00004923||||TREATMENT||||||||
33734042|NCT01267903|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734043|NCT03757182|||COHORT||PROSPECTIVE|||||||
33734044|NCT06130176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study will be double blinded randomized control trail. The patients and investigators who will collect the data will not be informed about the study|The OMS will be treated with Single-step Functional Sinus Endoscopy and Transoral Surgery via department-integrated therapy|t|f|t|f
33734045|NCT05756764|||COHORT||PROSPECTIVE|||||||
33734046|NCT03544983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes will be assessed via electronic survey and review of medical records. In cases where surveys need to be completed by telephone, the outcomes assessor will be blind to the participant's randomization.|Two group parallel design comparing Web-based education + streamlined telephone genetic information session to usual care.|f|f|f|t
33734047|NCT05645627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734048|NCT04054648|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes are drawn from administrative claims data which derive from hospital separations (diagnoses and procedures) and physician billings. The acute care providers submitting the billings which define our outcomes will typically be meeting the patient for the first time, unaware of the patient's participation in BedMed-Frail, and unaware of the facility's administration time for once daily antihypertensives.|Event-driven Prospective Randomized Open Blinded End-Point (PROBE) Randomized Trial.|f|f|f|t
33734049|NCT05724602|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734050|NCT01931267|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33734051|NCT03623737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734052|NCT03833284|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
33734053|NCT06383299|||OTHER||CROSS_SECTIONAL|||||||
33734054|NCT04953767|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734055|NCT02967952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734056|NCT04926558|||OTHER||OTHER|||||||
33734057|NCT01437514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734058|NCT06117267|NA|SINGLE_GROUP||OTHER||NONE||||||
33734059|NCT05242497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734060|NCT03633435|NA|SINGLE_GROUP||TREATMENT||NONE||All incident and prevalent dialysis patients of our unit will get information on that assisted HHD program and will be able to choose this technique||||
33734061|NCT02872922|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33734062|NCT06608069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|To ensure the security of the patients' information, a double-blind randomization technique will be adopted. The computer gives each patient a code number, and the code numbers will then be allocated randomly to the treatment groups. All data will be kept in a database, and backup file with password protectors.|"The goal of this clinical trial is to compare the adherence of co-morbid patients in control and experimental group~The main question\[s\]it aims to answer are:~* How will pharmacist-led interventions improve the medication adherence level of TB and HIV con-infected patients?~* Has there been an increase in the adherence level of co-infected patients following pharmacist-led interventions?~Participants will be interviewed to measure the level of adherence.~If there is a comparison group:~Enrolled patient will be counselled and educated by pharmacist on the therapy and benefits of adherence (Control group).~Enrolled participants will be counselled and educated by pharmacist on the therapy and benefits of adherence. Patients will be reminded to take the medication through SMS every day by the pharmacist (Experimental group)."||||
33734063|NCT03182348|||COHORT||PROSPECTIVE|||||||
33734064|NCT01276899|||CASE_ONLY||PROSPECTIVE|||||||
33734065|NCT00219128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33734066|NCT02206126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734067|NCT00880451|||||RETROSPECTIVE|||||||
33734068|NCT06251713|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734069|NCT01149798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734070|NCT01440946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734071|NCT05075616|||COHORT||RETROSPECTIVE|||||||
33734072|NCT04170218|||COHORT||PROSPECTIVE|||||||
33734073|NCT04577690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The nursing staff in the post anesthesia care unit, patient and outcome assessors will be blinded to the patient allocation.|Using a computer-generated table, patients will be randomized to one of two groups: PECS block or Local infiltration only. Group allocation are concealed in sealed, opaque, sequentially numbered envelopes that are opened on the day of surgery.|t|t|f|t
33813590|NCT03478306|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Melatonin and placebo tablets are identicle in terms of taste, colour, tablet-size etc. The tablets are packed and masked by external manufacturer.|A Double-blind, randomized, placebo-controlled trial|t|t|t|t
33813591|NCT05722925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813592|NCT04570488|||COHORT||PROSPECTIVE|||||||
33813593|NCT04184765|||OTHER||RETROSPECTIVE|||||||
33813594|NCT01032525|||COHORT||RETROSPECTIVE|||||||
33813595|NCT01729793|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33813596|NCT02216994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813597|NCT01474356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122457|NCT05485844|||CASE_CONTROL||PROSPECTIVE|||||||
34122458|NCT06511687|||COHORT||RETROSPECTIVE|||||||
34122459|NCT05847647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122460|NCT03406403|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients will be randomized into three equal groups. 60 slips of papers will be taken and labeled as group L (LMA), group M (Magnesium sulphate) and group C (Control). These slips will be placed in an envelope and one slip will be raised for each patient.|We hypothesize that the LMA is more effective than Magnesium sulphate in attenuating systemic stress response during emergence of patients undergoing supratentorial tumours|t|t|f|f
34122461|NCT05379699|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34122462|NCT01745588|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122463|NCT05261659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122464|NCT05566938|NA|SINGLE_GROUP||OTHER||NONE||||||
34122465|NCT01722929|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Participants had the skin sensor measure temperature both near a surgery site and also near a non-surgery site. There is one intervention (skin sensor) and the participants were assigned to both arms surgery side and non-surgery side in parallel."||||
34122466|NCT00004227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122467|NCT01023828|||||RETROSPECTIVE|||||||
34122468|NCT06715501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122469|NCT04460183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122470|NCT03940079|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34122471|NCT04709003|||COHORT||PROSPECTIVE|||||||
34122472|NCT03510130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122473|NCT05032547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122474|NCT01612676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122475|NCT02155101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122476|NCT00578032|||CASE_ONLY||PROSPECTIVE|||||||
34122477|NCT00495703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122478|NCT06040736|||COHORT||PROSPECTIVE|||||||
34122479|NCT01914250|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34122480|NCT02008994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122481|NCT01622296|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34122482|NCT01166347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122483|NCT05945888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|SRD part: single blinded FE part: open-label|"The SRD part of the trial is designed as blinded to subjects, randomised, and placebo-controlled within parallel dose groups.~In the FE part, subjects participate in a randomised, open-label, two-way crossover trial part with two treatment periods."|t|f|f|f
34122484|NCT02724241|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34122485|NCT04507906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122486|NCT01828840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122487|NCT02448134|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122488|NCT01979679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122489|NCT05018689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122490|NCT01628913|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122491|NCT00305877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122492|NCT04528589|||CASE_ONLY||PROSPECTIVE|||||||
34122493|NCT03668964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel trial|t|t|t|t
34122494|NCT00041028||||DIAGNOSTIC||||||||
34122495|NCT02737501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122496|NCT04445792|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate vs. delayed pharmacogenetic testing and genotype-guided pain or depression therapy||||
34122497|NCT02157428|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34122498|NCT01549184|||COHORT||RETROSPECTIVE|||||||
34122499|NCT02049411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34122500|NCT06118645|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, open, multicenter clinical study to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel (albumin-bound type) as a second-line treatment for advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma The study included a screening period (no more than 28 days after the subject signed the informed consent letter to the first dose) treatment period (receiving the appropriate treatment regimen until the disease progression and toxicity of intolerable withdrawal of the informed consent letter and death or the end of the study, whichever occurred first) and follow-up period (including safety follow-up and survival follow-up).||||
34122501|NCT01742884|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122502|NCT05832892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122503|NCT06043336|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34122504|NCT01328743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122505|NCT04979806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122506|NCT06084351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122507|NCT06283277|||COHORT||CROSS_SECTIONAL|||||||
34122508|NCT04123301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation masking will be done through sequentially numbered cards that will determine which group each patient will belong to. The card determines whether the coil to be used will produce actual or simulated stimulation. A secretary who does not participate directly in the research will be responsible for handling the numbered cards to the patient prior to each session. Participants and staff will not fully know the status of allocation groups.|Double-blind, randomized, parallel-group, 6-week, sham-controlled clinical trial.|t|t|t|f
34122509|NCT00537043|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122510|NCT01899547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122511|NCT03976297|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Pragmatic Stepped Wedge Cluster Randomized Trial||||
34122512|NCT05330871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122513|NCT02824523|||OTHER||PROSPECTIVE|||||||
34122514|NCT00677976|||CASE_CONTROL||PROSPECTIVE|||||||
34122515|NCT05111145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122516|NCT01567033|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122517|NCT00198471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122518|NCT04555174|||OTHER||PROSPECTIVE|||||||
33813598|NCT01964547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813599|NCT03941366|NA|SINGLE_GROUP||TREATMENT||NONE||All patients in the trial receive the intervention and are followed prospectively.||||
33813600|NCT06147115|||CASE_ONLY||RETROSPECTIVE|||||||
33813601|NCT03361202|||COHORT||PROSPECTIVE|||||||
33813602|NCT01223014|||||PROSPECTIVE|||||||
33813603|NCT02081976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33813604|NCT04710576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813605|NCT02822599|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33813606|NCT04325737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813607|NCT02769130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813608|NCT00289952|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813609|NCT04514094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813610|NCT02643368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122519|NCT04794738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34122520|NCT05592821|||CASE_CONTROL||PROSPECTIVE|||||||
34122521|NCT05711927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Participants will be randomized to either the traditional bassinet condition or the SNOO Smart Sleeper. Depending on the group to which they are assigned, participants will spend six hours total (divided between two time points) under either the traditional bassinet conditions or in the SNOO Smart Sleeper while having a sleep assessment performed.~The first sleep assessment will occur at 35-36 weeks postmenstrual age, and the second will occur at term-equivalent age (37 weeks or greater). Each sleep assessment will last three hours and will occur between feeds (2:00 p.m. to 5:00 p.m.)."||||
34122522|NCT00002237||||TREATMENT||||||||
34122523|NCT00409955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34122524|NCT00051714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122525|NCT01093313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122526|NCT00403156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122527|NCT05548764|||CASE_ONLY||PROSPECTIVE|||||||
34122528|NCT05783895|||CASE_CONTROL||RETROSPECTIVE|||||||
34122529|NCT00698828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122530|NCT00286377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122531|NCT01783210|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122532|NCT04410159|RANDOMIZED|PARALLEL||TREATMENT||NONE||"4 arms~1. Gargle with povidone-iodine~2. Gargle with essential oils~3. Gargle with tap water~4. Control"||||
34122533|NCT03980639|||COHORT||RETROSPECTIVE|||||||
34122534|NCT01978483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34122535|NCT01192126|RANDOMIZED|CROSSOVER||||NONE||||||
34122536|NCT06546891|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Case Series||||
34122537|NCT02330614|||CASE_CONTROL||PROSPECTIVE|||||||
34122538|NCT05850143|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34122539|NCT03129542|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The medical provider, nursing staff, study coordinator and patient will be blinded to randomization, only research pharmacist will be aware of randomization.|The Investigators propose a prospective, randomized, double blind, placebo-controlled pilot study on the efficacy and safety of midodrine in the treatment of sepsis.|t|t|t|t
34122540|NCT05576025|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||In a randomised cross-over design participants will be exposed to two different intensities of shivering thermogenesis, namely mild and moderate. There will be a wash-out period of at least 3 weeks between the interventions.|t|f|f|f
34122541|NCT01196195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122542|NCT05932173|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive one of the three doses of 0.5-2\*10\^6/kg, 3-4\*10\^6/kg, 5-6\*10\^6/kg.||||
34122543|NCT05866692|NA|SEQUENTIAL||TREATMENT||NONE||||||
34122544|NCT04587037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122545|NCT04720378|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34122546|NCT01231789|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34122547|NCT04032145|||OTHER||PROSPECTIVE|||||||
34122548|NCT04658927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"All eyes will undergo iLUX MGD Treatment System for the treatment of evaporative DED secondary to MGD. Patients will have their most symptomatic eye selected to receive the dexamethasone intracanalicular insert at the day of the iLUX MGD Treatment System (study eye). There will be 2 groups:~Group 1: fellow eye will receive topical prednisolone acetate 1% on a 4,3,2,1 taper for 30 days (control eye) Group 2: fellow eye will receive punctal sham dilation (control eye).~If there is no obvious symptomatic difference, the right eye will receive the intracanalicular insert.~Screening Visit Treatment Visit 1 week follow up~1 month follow up 3 month follow up"||||
34122549|NCT01234493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122550|NCT03810846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122551|NCT00237237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122552|NCT01244711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122553|NCT03522961|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34122554|NCT04282850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Serum biomarkers, atrial fibrillation burden, anatomical and functional echocardiographic parameters, and exercise capacity will all be measured and analyzed by study personnel blinded to the patient's intervention.|2:1 randomization to catheter ablation (PVI) or to medical management.|f|f|f|t
34122555|NCT05814471|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized trial with condition crossover||||
34122556|NCT02814656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122557|NCT01382771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149813|NCT05577949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813611|NCT03090698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813612|NCT01887002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813613|NCT04459156|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33813614|NCT02400528|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33813615|NCT02256826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813616|NCT00452894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734074|NCT04805307|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A, Dose Escalation: Modified 3+3 dose escalation design: an accelerated dose titration design followed by traditional 3+3 dose escalation design.||||
33734075|NCT02537964|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33734076|NCT05118594|NA|SINGLE_GROUP||TREATMENT||NONE||Therapists will receive patient-specific treatment recommendations (based on a machine-learning based algorithm developed in a previous study) regarding the most suitable interventions to be used to treat each study patient.||||
33734077|NCT05516251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33734078|NCT02130765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734079|NCT06572839|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patient will be randomized to standard of care (SOC) or Amnio-Maxx as an addition to SOC||||
33734080|NCT02178033|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33734081|NCT03184792|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734082|NCT00947583|||COHORT||PROSPECTIVE|||||||
33734083|NCT05592015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734084|NCT02596529|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734085|NCT01715103|NON_RANDOMIZED|PARALLEL||||NONE||||||
33734086|NCT03440879|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33734087|NCT05848388|||OTHER||CROSS_SECTIONAL|||||||
33734088|NCT00613600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813617|NCT02723799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33813618|NCT05871411|||COHORT||PROSPECTIVE|||||||
34122558|NCT04021290|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized study with parallel group assignment where participants will be randomized into one of the two treatment groups. Participants randomized to DTG/3TC FDC will receive DTG/3TC FDC up to Week 52. Participants randomized to CAR will continue to take their current regimen up to Week 52. Randomization will be stratified by Baseline third agent class (protease inhibitor \[PI\], integrase inhibitor \[INI\], or non-nucleoside reverse transcriptase inhibitor \[NNRTI\]).||||
34122559|NCT04794348|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34122560|NCT04948112|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized control||||
34122561|NCT03246087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122562|NCT03627052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122563|NCT00246363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122564|NCT03654274|NA|SINGLE_GROUP||TREATMENT||NONE||Open label extension||||
34122565|NCT00930449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122566|NCT02969070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122567|NCT00775268|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122568|NCT04999475|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122569|NCT05857566|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1b, randomized, open-label, parallel group study||||
34122570|NCT04379674|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34122571|NCT00005446|||CASE_CONTROL||RETROSPECTIVE|||||||
34122572|NCT05450835|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In OGT group,the oesophagojejunostomy was performed with OGT-assisted overlap method.~In overlap group, the oesophagojejunostomy was performed as reported by Inaba et al."||||
34122573|NCT01180283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122574|NCT06269510|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Computer-generated urn randomization will ensure balanced groups based on stage of ALD (advanced ALD and non-advanced ALD) and inpatient versus outpatient status at time of recruitment. Second stage randomization to 3-month intervention conditions will be stratified based on response and non-response status. Urn randomization using stage of ALD and inpatient versus outpatient recruitment will also be used at the second stage randomization. Re-randomization of non-responders will be computerized and stratified by stage of ALD and inpatient vs outpatient status.||||
34122575|NCT03678545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are assigned to either drug or placebo, followed by an open label extension|t|t|t|f
34122576|NCT02908581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122577|NCT04470388|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34122578|NCT02039011|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122579|NCT04726891|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE||sequential multiple assignment randomized trial|t|f|t|t
34122580|NCT02194790|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122581|NCT03381287|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34122582|NCT00848263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122583|NCT00724100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122584|NCT00830050|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34122585|NCT02308293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34122586|NCT01624935|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122587|NCT00670930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813619|NCT02256241|||COHORT|||||||||
34122588|NCT04141319|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34122589|NCT00518050|||COHORT||RETROSPECTIVE|||||||
34122590|NCT04596683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122591|NCT00959426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122592|NCT03553537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122593|NCT01102595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122594|NCT06194539|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33734089|NCT06499701|||COHORT||PROSPECTIVE|||||||
33734090|NCT02869971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734091|NCT02281721|||COHORT||PROSPECTIVE|||||||
33734092|NCT01187082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33734093|NCT03112434|||COHORT||PROSPECTIVE|||||||
33734094|NCT01543594|||COHORT||PROSPECTIVE|||||||
33813620|NCT01400997|||COHORT||OTHER|||||||
33813621|NCT04087239|||COHORT||PROSPECTIVE|||||||
33813622|NCT03397147|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial with 2 conditions (intervention and usual care).||||
33813623|NCT05778799|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122595|NCT03401437|||COHORT||PROSPECTIVE|||||||
34122596|NCT04305977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734095|NCT03740438|||COHORT||PROSPECTIVE|||||||
33734096|NCT03272594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two research assistants (RA1, RA2) who are blinded to the intervention condition will be hired to complete facial coding and calculation of infant PIPP-R scores. Each research assistant will only code data for infants in the breastfeeding condition (RA1) or the sucrose condition (RA2) and will not be aware of whether they are watching infant responses to noxious or non-noxious stimulation. To minimize observer bias, research assistants will not be informed of the study design, will not be permitted to attend data collection sessions, and will not share datasets or communicate with the other research assistant regarding the study. During data collection, up close video recording of only the infants face will be completed to attempt to keep coders blind to the nature of the intervention.||f|f|f|t
33734097|NCT02163291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734098|NCT00691236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734099|NCT04184076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734100|NCT06251076|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734101|NCT00219934|||COHORT||PROSPECTIVE|||||||
33734102|NCT01389297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734103|NCT03603093|||COHORT||CROSS_SECTIONAL|||||||
33734104|NCT06664749|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33734105|NCT04775017|||COHORT||RETROSPECTIVE|||||||
33734106|NCT04095000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|RA-Assessor will be blinded to randomization to reduce bias in collecting questionnaire data and data abstraction from electronic health record.|This pilot will use a randomized control trial (RCT) design with the intent to treat. Randomization will be generated by computer to ensure the same numbers will be recruited to the FACE-TC Sp intervention and Treatment As Usual comparison group without bias, using a 1:1 ratio. We estimate that 32 adolescents ever diagnosed with cancer, aged 14 to 21, and 32 guardians/surrogates (N=64) will be enrolled and receive secondary screening. They will complete a Demographic Data Sheet. The assent/consent process focuses on readiness to participate, potential barriers to participation, as well as enhancing motivation. Adolescents and families will then be screened for eligibility. Eligible dyads, estimated to be 30 dyads, will complete baseline data. Then, the adolescent/family dyad will be randomly assigned to one of two conditions: 15 dyads will be assigned to FACE-TC SP and 15 dyads to Treatment As Usual.|f|f|f|t
33734107|NCT00079274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734108|NCT06236958|||CASE_CONTROL||PROSPECTIVE|||||||
33734109|NCT01743092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122597|NCT04344730|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The masking label is available only for the treatment assignation|In non-mechanically ventilated patients, a 2x2 factorial design will be used to assess the two interventions, separately.|t|t|t|t
33734110|NCT03148548|||COHORT||CROSS_SECTIONAL|||||||
33734111|NCT03567863|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||DOUBLE|the order of use of the 2 needles is not communicated to the cytologist||t|f|t|f
33734112|NCT00624117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734113|NCT05294705|||CASE_CONTROL||PROSPECTIVE|||||||
33734114|NCT04341038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician who will finally carry out the analyses will be blind to the treatment received by the patients||f|f|f|t
33734115|NCT02316717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734116|NCT02310542|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813624|NCT04897347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813625|NCT01942525|||COHORT||RETROSPECTIVE|||||||
33813626|NCT00113529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813627|NCT04686357|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813628|NCT01623011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813629|NCT05390710|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label for phase I|BOIN for Phase I with 1 treatment arm||||
33813630|NCT05120505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813631|NCT00229892|||||RETROSPECTIVE|||||||
33813632|NCT04552457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122598|NCT05361850|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122599|NCT02589288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34122600|NCT01732991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122601|NCT03289533|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122602|NCT02058979|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122603|NCT05579210|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either receive 10 weekly session of online relapse prevention therapy (e-RPT) or 10 weekly sessions of face-to-face relapse prevention therapy (RPT).||||
34122604|NCT00374114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122605|NCT04230967|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122606|NCT04381247|||COHORT||PROSPECTIVE|||||||
34122607|NCT03433547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122608|NCT05983094|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Study of Utidelone based neoadjuvant treatment on early high-risk or locally advanced breast cancer||||
34122609|NCT02332187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122610|NCT01130337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122611|NCT06046248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122612|NCT02665546|||OTHER||CROSS_SECTIONAL|||||||
34122613|NCT06282861|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase IV, open-label, prospective, pragmatic, interventional, randomized (1:1), multicenter, controlled, 12-month follow-up trial.||||
33813633|NCT03979040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813634|NCT01531413|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34122614|NCT03421886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813635|NCT06510400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|t|f
34122615|NCT05065593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34122616|NCT00761488|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122617|NCT02057965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122618|NCT03940807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122619|NCT01245725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734117|NCT04906434|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Dose escalation study: 60mg QD, 12mg QD, 180mg QD, 240mg QD, 32mg QD，400mg QD. Expansion study will recruit 20 subject in RDE dose level.||||
33734118|NCT01470287|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734119|NCT04204460|||CASE_CROSSOVER||PROSPECTIVE|||||||
33734120|NCT04661345|||CASE_CONTROL||PROSPECTIVE|||||||
33734121|NCT01670357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734122|NCT00084695||||TREATMENT||NONE||||||
33734123|NCT03447171|||COHORT||PROSPECTIVE|||||||
33734124|NCT02970838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734125|NCT04912024|||CASE_CONTROL||RETROSPECTIVE|||||||
33734126|NCT05828628|||CASE_ONLY||PROSPECTIVE|||||||
33734127|NCT01218997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734128|NCT05241223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33734129|NCT06117462|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33734130|NCT01229475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734131|NCT04295889|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33734132|NCT00424372|NON_RANDOMIZED|||TREATMENT||NONE||||||
33734133|NCT03912233|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33734134|NCT00261924|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33734135|NCT01973634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734136|NCT00447928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33813636|NCT00603278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044252|NCT05188261|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|The investigator and all other clinical research unit staff, sponsor study personnel, and the participant will remain blinded to individual participant treatment assignments throughout the study. Treatment assignments of individual participants will only be unblinded to a sponsor representative for regulatory reporting purposes or if warranted by emerging safety or tolerability issues.||t|t|t|f
34044253|NCT01625663|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044254|NCT01721096|||COHORT||PROSPECTIVE|||||||
34044255|NCT06524934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044256|NCT00694083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044257|NCT04046887|NA|SEQUENTIAL||TREATMENT||NONE||"Initially 3 patients will be enrolled to the starting cohort. If 1 of 3 patients experience a dose-limiting toxicity (DLT) in the first cycle, then an additional 3 evaluable patients will be accrued to that dose level. Dose reductions are not permitted during cycle 1. If 2 or more patients in a cohort experience a DLT, then the previous dose will be considered the recommended phase 2 dose (PR2D) and dose escalation will terminate. Dose escalation will proceed according to the scheme above only after all patients (3 or 6 evaluable patients, depending on the incidence of DLT) have been followed for at least 1 full cycle.~Once dose escalation has been completed, if only 2 dose levels were used to determine the RP2D and depending on how many patients were replaced, additional patients will be enrolled at the RP2D in order to obtain data for 18 patients total."||||
33734137|NCT02672735|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33734138|NCT02908529|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33734139|NCT02678039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33734140|NCT01201681|||COHORT||PROSPECTIVE|||||||
33734141|NCT00441337|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734142|NCT03074721|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33734143|NCT04925297|||COHORT||PROSPECTIVE|||||||
33734144|NCT02210585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734145|NCT04708197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734146|NCT03779997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734147|NCT01650181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33734148|NCT04929301|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734149|NCT04579913|||COHORT||PROSPECTIVE|||||||
33734150|NCT03306264|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multicenter, randomized, open-label, 2-period, 2-sequence crossover study||||
33734151|NCT02561507|||COHORT||PROSPECTIVE|||||||
33734152|NCT00028028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734153|NCT04546854|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33734154|NCT03457012|||COHORT||PROSPECTIVE|||||||
33734155|NCT00011804||||TREATMENT||||||||
33734156|NCT01797536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734157|NCT06416748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \< 10 mm on LEEP/cone and \< 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration \>2/3.||||
33734158|NCT05839665|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All volunteers will start with pre-oxygenation using a traditional facemask (vital breathing for four minutes vital and eight vital capacity breaths). They will thereafter be randomised to continue with either pre-oxygenation using a standard nasal cannula or humidified high-flow nasal oxygen.||||
33734159|NCT03243968|||OTHER||CROSS_SECTIONAL|||||||
33734160|NCT05022823|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33734161|NCT03033979|||CASE_ONLY||RETROSPECTIVE|||||||
33734162|NCT03128879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813637|NCT01482091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840164|NCT00280215|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33734163|NCT02753894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734164|NCT00622635|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044258|NCT00501410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044259|NCT01112488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34044260|NCT04993053|||COHORT||RETROSPECTIVE|||||||
34044261|NCT03745846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813638|NCT05371002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A parallel individual RCT with two groups: (1) an intervention group receiving online group based NVC training and (2) a waitlist control (WL) group.||||
33813639|NCT04520321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Masked, Vehicle-controlled, Dose-escalation study|t|t|t|t
33813640|NCT01735435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813641|NCT00570622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813642|NCT00853957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734165|NCT00972491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734166|NCT00627679|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33734167|NCT06408285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734168|NCT04410926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Intervention:~Corrective exercises The experimental and control groups performed a designed strengthening exercises included short-foot exercise, toes-spread-out exercise, toes-extension exercise and toe-curls for 60 minutes. Each exercise was performed for 30 repetitions holding each repetition for 5 seconds (about three minutes).~Neuromuscular electrical stimulation The experimental group received NMES aiming to reinforce the planter intrinsic foot muscles. The surface electrodes were placed over the abductor halluces based on the evidence that it has the largest cross-sectional area of the intrinsic foot muscles"|t|t|f|t
33734169|NCT02573610|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33734170|NCT05448664|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Three-arm parallel design cluster randomized controlled trial|t|t|f|t
33734171|NCT04935307|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The aim of this study is to identify specific MRI and paraclinical measures for multiple chemical sensitivity (MCS) and multi-organ bodily distress syndrome (multi-organ BDS) compared to Healthy controls||||
33734172|NCT01509794|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33734173|NCT04341480|||COHORT||PROSPECTIVE|||||||
33734174|NCT01534624|||||PROSPECTIVE|||||||
33734175|NCT04301167|NA|SINGLE_GROUP||PREVENTION||NONE||AB single-case experimental design||||
33734176|NCT02755831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734177|NCT06335771|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33734178|NCT04581499|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random-controlled trial||||
33734179|NCT03857802|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Experimental study, non-masked clinical trial of evaluation of an educational intervention in the field of Primary Care Nursing: Basic Health Area (BHA) of Balaguer. Two groups will be established randomly: experimental group and control group. In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. In the control group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.||||
33734180|NCT02866877|||COHORT||PROSPECTIVE|||||||
33734181|NCT02333578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734182|NCT06073925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33734183|NCT03501797|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33734184|NCT02472756|||COHORT||PROSPECTIVE|||||||
33734185|NCT00192075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734186|NCT04892485|||COHORT||CROSS_SECTIONAL|||||||
33734187|NCT02538926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734188|NCT05942248|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33734189|NCT01777997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734190|NCT05637645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Health care workers including nurses paramedical staff and ward boys may be masked from this study|Participants are assigned to three groups in parallel for the duration of the study Group M for participants are given spinal anesthesia through Midline approach Group P for participants are given spinal anesthesia through Paramedian approach Group T for participants are given spinal anesthesia through Taylors approach|t|t|f|f
33734191|NCT03160924|RANDOMIZED|PARALLEL||OTHER||NONE||This is a randomised controlled study||||
33734192|NCT05989334|||OTHER||PROSPECTIVE|||||||
33734193|NCT01651572|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33734194|NCT06664307|||COHORT||PROSPECTIVE|||||||
33734195|NCT02984397|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734196|NCT04524403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
33813643|NCT00201656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813644|NCT04151030|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813645|NCT01381341|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813646|NCT05848856|||COHORT||PROSPECTIVE|||||||
33813647|NCT02458274|||CASE_CONTROL||PROSPECTIVE|||||||
33813648|NCT02346409|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33813649|NCT03493282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813650|NCT03129009|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33813651|NCT00973414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813652|NCT00317928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33813653|NCT01237977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813654|NCT00006079|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33813655|NCT05702892|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813656|NCT03647449|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33813657|NCT00689416|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33813658|NCT03421132|||COHORT||PROSPECTIVE|||||||
33813659|NCT03989778|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Infertile females with Polycystic Ovarian Syndrome||||
33813660|NCT00816205|NA|SINGLE_GROUP||||||||||
33813661|NCT01662232|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33813662|NCT04345588|RANDOMIZED|PARALLEL||OTHER||NONE||A convenience sample of 60 male and female adult patients will be taken, the patients will be classified into two equal groups , In all patients, we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In one group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously. Duration of analgesia, onset of sensory block, and onset of motor block will be studied.||||
33813663|NCT00272415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044262|NCT05130541|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Non-Blinded||||
34044263|NCT01718678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044264|NCT03543202|RANDOMIZED|PARALLEL||OTHER||DOUBLE|patients and outcome assesors will be blinded for the analgesia method|prospective randomised|t|f|f|t
34044265|NCT05413551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044266|NCT05800561|||COHORT||PROSPECTIVE|||||||
34044267|NCT04164732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and subject will be blinded to treatment allocation during the treatment period||t|f|t|f
34044268|NCT02148978|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34044269|NCT00846248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34044270|NCT02425124|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34044271|NCT04104542|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34044272|NCT03693612|RANDOMIZED|PARALLEL||TREATMENT||NONE||In Part 1, dose escalation will occur using a zone based approach. Part 2 will be randomized, parallel group study wherein the subjects will be randomized in a ratio of 2:1 to either recommended Phase 2 dose combination of GSK3359609 and tremelimumab or SOC (paclitaxel, docetaxel or cetuximab).||||
34044273|NCT06575907|||OTHER||CROSS_SECTIONAL|||||||
34044274|NCT06134427|NA|SINGLE_GROUP||SCREENING||NONE|statistical analyses using ID (not name) data set|Pre-Experimental Model One-Group Pretest-Posttest Design||||
34044275|NCT03318861|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-Escalation and Dose Expansion||||
34044276|NCT00931255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044277|NCT00005616||||TREATMENT||||||||
33734197|NCT03188965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734198|NCT00338195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734199|NCT03795922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734200|NCT06351605|||CASE_ONLY||OTHER|||||||
33734201|NCT00304785|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33734202|NCT02438566|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33734203|NCT03057145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734204|NCT02399085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734205|NCT02049489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734206|NCT03159663|||COHORT||PROSPECTIVE|||||||
33734207|NCT03780179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Randomization to intervention: MMRvaxpro at 6 months of age, or placebo-vaccine (solvent only)|t|t|t|t
33734208|NCT03178058|||COHORT||PROSPECTIVE|||||||
33734209|NCT01031277|||CASE_ONLY||CROSS_SECTIONAL|||||||
33734210|NCT06158737|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33734211|NCT04302467|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Allocations will be blinded to all participants but the anesthesiologists. If serious adverse events occur, the patients will be removed from the trial, the blinding will be removed, the events will be reported to the institutional review board.|Participants will be randomly allocated to one of the two groups: (1) GDFT group and (2) restrictive fluid therapy group. They will be allocated in a 1:1 ratio using random numbers generated by Microsoft Excel.|t|f|t|t
33734212|NCT06387303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||a single blind study|t|f|f|f
33734213|NCT03830294|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33734214|NCT02488629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734215|NCT06580158|||COHORT||PROSPECTIVE|||||||
33734216|NCT06144073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention group (Mandala art therapy group) Control group||||
33734217|NCT05624099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734218|NCT05301205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734219|NCT03360292|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Infants will be randomised to either higher (92-97%) or lower (90-95%) oxygen saturation target range, and then cross-over to the alternative range after 6 hours of monitoring (with 12 hours in total study time). The study is randomised but not blinded.|This is a randomised cross-over study of oxygen target ranges in premature infants, with infants acting as their own controls.||||
33734220|NCT02460224|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734221|NCT05520671|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participants will be subjected to partial blinding, where the type of platform (i.e. conventional quizzing platform or TESLA-G) will not be revealed to them. Instead, participants will be informed that one of the two platforms has been randomly assigned to them. In addition, all researchers involved in statistical analysis will be blinded as far as possible. Until the data has been fully analysed, they will not be able to identify the nature of each of the two groups.~A single, non-blinded researcher will be in charge of conveying information to participants. This is to ensure that important instructions on accessing and using the platforms, which are different for each platform, are sent to the participants. This researcher will also be the point-of-contact for the participants' platform-related queries throughout the study."|This is an online, pilot randomised controlled trial consisting of two parallel active groups - an intervention group and an active control group. Participants will be randomised into each group with a 1:1 allocation ratio, stratified by year of study.|t|f|t|t
33734222|NCT00434096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734223|NCT03065465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33734224|NCT00203450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734225|NCT01455116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734226|NCT03794115|||COHORT||PROSPECTIVE|||||||
33734227|NCT02439775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734228|NCT04465175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044278|NCT06685302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044279|NCT00994630|||||PROSPECTIVE|||||||
34044280|NCT04322734|||COHORT||PROSPECTIVE|||||||
34044281|NCT01912586|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044282|NCT02932488|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34044283|NCT04938661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044284|NCT00983203|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34044285|NCT01308021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34044286|NCT03667885|||COHORT||PROSPECTIVE|||||||
34044287|NCT04042623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813664|NCT06075641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813665|NCT00005540|||COHORT||RETROSPECTIVE|||||||
34044288|NCT00336401|RANDOMIZED|PARALLEL||||SINGLE||||||
34044289|NCT01353677|||COHORT||PROSPECTIVE|||||||
34044290|NCT01415713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044291|NCT04902638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34122620|NCT04120129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|TMS and sham TMS treatment group participants and researchers will be blinded to which treatment the participant receives|TMS, sham-TMS, and no treatment groups|t|f|t|f
33813666|NCT01543204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840165|NCT03808792|||COHORT||PROSPECTIVE|||||||
34044292|NCT03674346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044293|NCT05940168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking at baseline for both participant and care provider.|The main study in this project (Study 2) is a randomized controlled trial in which the participants are randomly assigned either a group intervention (Navigator ACT), or an internet-delivered ACT intervention (I-Navigator ACT). No treatment-as-usual (TAU) or wait-list control groups are included in this model.|t|t|f|f
34044294|NCT03637062|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Multicentre Randomized Controlled Trial, in parallel groups, based on treatment with progesterone comparing the placement of a prophylactic cervical pessary with usual management in singleton pregnancies at high-risk of PTB due to a history of at least one previous preterm delivery and/or a history of late abortion||||
34044295|NCT06416891|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34044296|NCT02071745|||COHORT||RETROSPECTIVE|||||||
34044297|NCT04674813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122621|NCT03584815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
34122622|NCT03654144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122623|NCT06003439|RANDOMIZED|PARALLEL||PREVENTION||NONE||Health classes in each high school will be randomly assigned using a 1:3 threshold probability using a random digit generator.||||
34122624|NCT03710889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122625|NCT05238415|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||This study has three study arms. Specifically, patients will be randomly assigned to an intervention group or an active control group. Furthermore, a comparison group will be recruited. Whereas the CompG will not receive any treatment, the IG and the ACG will have contacts with a personal pilot who will help the patients to navigate through the study as well as through treatment options and help them seek help for further needs. Aditionally, the intervention group will receive a so called 3-day assessment in a clinic and in which patients will be assessed by a multiprofessional team of health care professionals regarding their post-/long-COVID symptoms.||||
34122626|NCT04547465|||COHORT||PROSPECTIVE|||||||
34122627|NCT03061292|RANDOMIZED|PARALLEL||OTHER||||||||
34122628|NCT06487299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122629|NCT02222103|||OTHER||OTHER|||||||
34122630|NCT01508208|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122631|NCT00054522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122632|NCT01060254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122633|NCT00508092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34122634|NCT03012685|||COHORT||PROSPECTIVE|||||||
34122635|NCT06155162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parents will not be masked to the purpose of the intervention, but will be unaware that there are different types of dolls that are being tested.||t|f|f|f
34122636|NCT02843412|||COHORT||PROSPECTIVE|||||||
34122637|NCT02804438|||OTHER||PROSPECTIVE|||||||
34122638|NCT00981903|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34122639|NCT00039013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122640|NCT04572334|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122641|NCT00394264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34122642|NCT02609425|||CASE_ONLY||PROSPECTIVE|||||||
34122643|NCT05261828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122644|NCT05313763|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34122645|NCT02073162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122646|NCT03314935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122647|NCT02953184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122648|NCT03965182|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34122649|NCT04298489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122650|NCT02951637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122651|NCT06718998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122652|NCT00929916|||COHORT||PROSPECTIVE|||||||
34122653|NCT01424943|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122654|NCT04618588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122655|NCT05431439|||COHORT||PROSPECTIVE|||||||
34122656|NCT00268281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122657|NCT05123300|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Included patients will be randomized 1:1 into a control group (A) and an interventional group (B). Block randomization will be stratified by high-/intermediate-/low-risk PCa patients. Bone Scan has been substituted with NaF-PET/CT in clinical routine at participating departments, and will as well in this study.~Primary staging in each group will be performed as follows:~* Group A: CE-CT and NaF-PET/CT (conventional imaging)~* Group B: 18F-PSMA-1007 PET/CT (interventional imaging) In group B, a sufficient number of patients will have conventional imaging performed (an added NaF-PET/CT), which will be blinded and used for diagnostic accuracy measures. A subset of patients with risk of extracapsular extension planned for radical prostatectomy in group B will also have an 18F-PSMA-PET/MRi-scan performed."||||
34122658|NCT03848416|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34122659|NCT01632254|||||CROSS_SECTIONAL|||||||
34122660|NCT03672214|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122661|NCT03440866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122662|NCT03893981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122663|NCT03318432|||COHORT||OTHER|||||||
33840166|NCT03926195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840167|NCT02459457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840168|NCT02523339|||COHORT||PROSPECTIVE|||||||
33734229|NCT01849952|||COHORT||PROSPECTIVE|||||||
33734230|NCT03427385|NA|SINGLE_GROUP||OTHER||NONE||||||
33734231|NCT02942979|||CASE_CONTROL||PROSPECTIVE|||||||
34122664|NCT03856866|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All parties will be masked except for research pharmacy who will do the randomization.|A randomized, blinded, placebo controlled, crossover N of 1 trial.|t|t|t|t
33734232|NCT00197379|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734233|NCT02898194|||COHORT||RETROSPECTIVE|||||||
33734234|NCT02203591|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33734235|NCT00917813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122665|NCT04580914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734236|NCT00325806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734237|NCT06573190|||COHORT||PROSPECTIVE|||||||
34122666|NCT04815187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122667|NCT03249194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122668|NCT01203709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122669|NCT02088125|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34122670|NCT06716801|||COHORT||PROSPECTIVE|||||||
34122671|NCT05246969|||CASE_ONLY||RETROSPECTIVE|||||||
34122672|NCT05180513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122673|NCT03483454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122674|NCT05759208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double mask and placebo-controlled||t|t|t|t
34122675|NCT02314442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122676|NCT04555070|||OTHER||RETROSPECTIVE|||||||
34122677|NCT03467256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122678|NCT03007771|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34122679|NCT01176760|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34122680|NCT05017623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122681|NCT06167226|||COHORT||PROSPECTIVE|||||||
34122682|NCT04406103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122683|NCT01111227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34122684|NCT05556486|||COHORT||OTHER|||||||
34122685|NCT06288425|||COHORT||PROSPECTIVE|||||||
34122686|NCT00245531|||||PROSPECTIVE|||||||
34122687|NCT00939107|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34122688|NCT03942224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122689|NCT02726958|||COHORT||RETROSPECTIVE|||||||
34122690|NCT02558101|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34122691|NCT03586271|||COHORT||PROSPECTIVE|||||||
34122692|NCT02266563|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34122693|NCT00540696|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122694|NCT05812326|NA|SEQUENTIAL||TREATMENT||NONE||||||
34122695|NCT06209944|||CASE_ONLY||RETROSPECTIVE|||||||
34122696|NCT02067507|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122697|NCT05285228|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor enters the room to observe the dental treatment after the allocation to the group when the fluoride varnish is placed ready.||f|f|f|t
34122698|NCT05930080|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122699|NCT05937529|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized, intraindividual controlled trial||||
34122700|NCT03443687|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either Pelvic Floor Physical Therapy (PFPT) or home biofeedback. The therapy allocation will then be carried out with each arm completing 3 months of therapy.||||
34122701|NCT06323070|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34122702|NCT05662046|||COHORT||RETROSPECTIVE|||||||
33734238|NCT01307241|||CASE_ONLY||PROSPECTIVE|||||||
33734239|NCT03754257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734240|NCT04419155|||COHORT||PROSPECTIVE|||||||
33734241|NCT04920851|||COHORT||RETROSPECTIVE|||||||
34122703|NCT06498115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734242|NCT00002335||||TREATMENT||||||||
33734243|NCT01132521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734244|NCT03446703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained raters who were blind to treatment condition assessed participants on the following variables at baseline, post-treatment and 3-month follow-up|A randomized three group pre-post design will be used to investigate effects of the Training of Affect Recognition (TAR), compared to the Social Cognition and Interaction Training (SCIT). Performance in social cognition measures, basic cognitive functioning symptomatology and functional capacity will be assessed before (T0), after (T1) treatment and (T2) 3 months later.|f|f|f|t
33734245|NCT05608785|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734246|NCT06085898|NA|SINGLE_GROUP||OTHER||NONE||||||
33734247|NCT04160260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734248|NCT04688281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33734249|NCT02592473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122704|NCT03911856|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122705|NCT03983330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34122706|NCT06453031|||COHORT||PROSPECTIVE|||||||
34122707|NCT00987714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34122708|NCT01446874|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34122709|NCT03952208|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34122710|NCT03099473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122711|NCT01227785|||COHORT||PROSPECTIVE|||||||
34122712|NCT01739894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122713|NCT04326062|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Uncontrolled feasibility study based in general practices with a sub-set of patients completing a nested study collecting secondary patient reported outcome measures||||
34122714|NCT05458518|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122715|NCT03771339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34122716|NCT00402129|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122717|NCT00710983|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734250|NCT00574405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734251|NCT00674141|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734252|NCT05613439|||COHORT||PROSPECTIVE|||||||
33734253|NCT00937547|||||PROSPECTIVE|||||||
33734254|NCT04646616|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734255|NCT02426281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734256|NCT05836610|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Pharmacokinetic analysis of the standard dose hydrocortisone therapy (0.5 mg/kg/6 hours) during hypothermia treatment, then compare the effects of the modified dose hydrocortisone therapy which will be determined based on the pharmacokinetic results.||||
33734257|NCT05372016|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Investigator)|Parallel Assignment|t|f|t|f
33734258|NCT03100825|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734259|NCT05112497|||COHORT||PROSPECTIVE|||||||
33734260|NCT04613180|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomly divided into 2 groups. I the group (control) included 40 patients who received standard therapy. The second group included 40 patients who received oral montelukast sodium. The therapeutic dosage of the drug was 0.2 mg/kg/day, the daily dose was prescribed once a day for the entire duration of the disease. As a prevention of repeated episodes of bronchial obstructive syndrome, the drug was prescribed at a dose of 0.1 mg/kg/day, the duration of anti-relapse therapy was 30 days.||||
33734261|NCT04065919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be randomized per study coordinator. SOC includes 0.25%bupivacaine with epinephrine at 1cc/kg total dose and the treatment arm will include liposomal bupivacaine 266mg/20ml added to usual dose.|Study comparing current standard of therapy using 0.25% bupivacaine with epinepherine at 1cc/kg total dose and the addition of liposomal bupivacaine 266mg/20ml for pain management in cardiac surgery. Patient and Investigator are blinded.|t|f|t|f
33734262|NCT01703481|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734263|NCT01601834|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33734264|NCT01795924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734265|NCT01678534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734266|NCT04125108|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The patients with inhalation injury, chest and neck burn injury were included. The burn surface area of chest and neck are more than 50% of the anterior or posterior trunk areas.||||
33734267|NCT02886585|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734268|NCT06572657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734269|NCT06461520|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask both groups about treatment.|It will be a Randomized Controlled Trial in which non-convenient probability sampling will be used. Two groups of 5-8 yrs age will be formed in which participants will be randomly divided. Group A will undergo maze balance board training for 60 minutes a day twice a week. Group B will undergo proprioceptive training of 40 minutes thrice a week|t|f|f|f
33734270|NCT05699668|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Premature infants born at a term ≤28 weeks of amenorrhea, without bronchopulmonary dysplasia (BPD), whether or not followed at CHIC Premature infants born at a term ≤28 weeks of amenorrhea, with bronchopulmonary dysplasia (BPD) and followed or not at CHIC Patients in the control group (without prematurity without BPD) selected at a scheduled routine ophthalmology consultation at CHIC, born at a term ≥ 38SA||||
33734271|NCT04257058|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33734272|NCT00401336|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734273|NCT02059928|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734274|NCT02125539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734275|NCT01930058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734276|NCT01639170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734277|NCT01813981|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33734278|NCT04333680|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33734279|NCT04720859|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intervention arm in patients that present postprandial hypoglycemia following gastric by-pass and a control group of healthy subjects without intervention.|f|f|t|f
33734280|NCT04515186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Initial, late responders and final cure assessments done in a blinded manner by the site clinicians at D90, D105 (if required) and D180, respectively.||f|f|f|t
33734281|NCT01514318|||COHORT||PROSPECTIVE|||||||
33734282|NCT01155895|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734283|NCT02751983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734284|NCT05508113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33734285|NCT03652298|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The research assistant blind to group assignments is responsible to conduct the three follows-ups|prospective randomized|f|f|t|f
33734286|NCT00483847|||COHORT||PROSPECTIVE|||||||
33734287|NCT02548988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734288|NCT04777409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33734289|NCT01500148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734290|NCT00002275||||TREATMENT||||||||
33734291|NCT01585766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734292|NCT04942275|NA|SINGLE_GROUP||OTHER||NONE||||||
33734293|NCT04620148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734294|NCT01852890|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734295|NCT06050408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"3 groups, same treatment provided in all groups but initiation of treatment after stroke differs (acute, subacute and chronic phase)."||||
33734296|NCT03892720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734297|NCT05305794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044298|NCT06181084|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Groups 1 and 2 have a randomized, 2-way crossover design and Groups 3 and 4 have a fixed-sequence design.||||
34044299|NCT04625270|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044300|NCT05681962|||COHORT||PROSPECTIVE|||||||
34044301|NCT03935425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044302|NCT06450327|||OTHER||CROSS_SECTIONAL|||||||
33813667|NCT04813965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Health care professionals were blinded to group assignment, but due to the nature of the study, patients were not. However, patients were not informed about the main outcomes and specific hypotheses of the study, or about the study's experimental conditions and the content of the texts that they did not receive until after T2.|A multicenter, randomized, controlled, prospective, online survey study was conducted. Before completing the study's online baseline survey (pre-chemotherapy; T0), participants were randomly assigned by the online survey program to receive either: standard information on side-effects (control condition), or standard information with additional written information about chemotherapy-related cognitive symptoms (information condition), or standard and additional information with a subsequent self-affirmative text (information+SA condition; SA=self-affirmation). The online experimental texts were presented to patients once, directly after randomization at baseline. At six months (T1) and twelve months (T2) follow-up, all groups received identical general introductions and online surveys, without any experimental manipulations. Outside of the trial, all patients received treatment information from their medical oncologist according to local practice as part of their usual care.|f|t|f|f
33813668|NCT00864188|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33813669|NCT03742011|||COHORT||PROSPECTIVE|||||||
33813670|NCT02214914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122718|NCT04944615|RANDOMIZED|PARALLEL||OTHER||NONE|During the study, it is difficult for researchers, operators and patients to blind the method due to objective reasons.|"Patients were enrolled when the guide wire successfully passed through the CTO lesion (defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography).~Once patients have signed the informed consent form and met all clinical and angiographic inclusion criteria and did not meet all clinical and angiographic exclusion criteria, and the guide wire has successfully passed the CTO lesion, they may be considered for participation in the study and randomized.~The random grouping arrangement is computer generated using a quasi-random number generator.~All randomized subjects will be assigned a unique identification number. Randomized replacement blocks will be used to ensure that the distribution of treatment within each layer is approximately balanced.~The study also used the Interactive Voice Response System (IVRS)/Interactive Internet Response System (IWRS) to assign subjects to the study device treatment group."||||
34122719|NCT01830348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122720|NCT02156193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122721|NCT00002593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122722|NCT02481193|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122723|NCT02099396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122724|NCT03521700|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intensive lipid lowering gourp:10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L; Conventional lipid lowering: 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L||||
34122725|NCT03736148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Electromyographic signal and skin conductance were assessed by blinded assessors before and immediately after the intervention. The participants were not aware of their assigned group.|Double blind randomized control placebo trial|t|f|f|t
34122726|NCT00560508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122727|NCT06301503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Numbers were prepared in sealed envelopes prepared by a third party not involved in the study to ensure allocation concealment, and handed over to the anesthetist performing the block before surgery. Both participants and outcome assessors would be blinded to the group allocation.|One hundred participants are to be randomly assigned by a computer-generated random number table into two parallel groups and 1:1 allocation to either receive a combination of LPB-SNB or no block at all.|t|f|f|t
34122728|NCT03739164|||CASE_ONLY||PROSPECTIVE|||||||
34122729|NCT02270229|||||PROSPECTIVE|||||||
34122730|NCT05495438|||OTHER||PROSPECTIVE|||||||
34122731|NCT06246305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized into one of the 2 groups: the control group receiving the conventional physical therapy intervention or to the experimental group receiving virtual reality intervention|t|f|f|t
34122732|NCT02626169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122733|NCT04861272|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34122734|NCT05322278|||COHORT||RETROSPECTIVE|||||||
34122735|NCT06299592|||CASE_CONTROL||PROSPECTIVE|||||||
34122736|NCT04100408|||FAMILY_BASED||PROSPECTIVE|||||||
34122737|NCT04300387|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34122738|NCT04851574|||COHORT||PROSPECTIVE|||||||
34122739|NCT05040646|||OTHER||OTHER|||||||
34122740|NCT04304079|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective case series to be conducted as a pilot study to evaluate the clinical feasibility and safety of the ARssist system during robotic surgery with the da Vinci Xi system.||||
34122741|NCT06154616|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34122742|NCT04904367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122743|NCT00222976|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122744|NCT05073939|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind between-subject design|t|f|t|t
34122745|NCT02234440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122746|NCT04780139|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34122747|NCT02271529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122748|NCT01263457|||COHORT||OTHER|||||||
34122749|NCT02712996|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34122750|NCT02546882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122751|NCT03578250|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial|t|f|f|t
34122752|NCT00177918|||COHORT||PROSPECTIVE|||||||
34122753|NCT03289143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Additional blinded personnel will include study site personnel who will evaluate participant status, contract research organization (CRO) personnel who will review case report forms (CRFs), and other sponsor agents (with the exception of the interactive voice or web-based response system \[IxRS\] vendor).||t|f|t|t
34122754|NCT01871025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34122755|NCT01892371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122756|NCT04476758|||COHORT||CROSS_SECTIONAL|||||||
34122757|NCT05309044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734298|NCT01835249|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122758|NCT05305898|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34122759|NCT05595850|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34122760|NCT05745649|RANDOMIZED|PARALLEL||OTHER||SINGLE|A single blind RCT|A single blind RCT in which two groups were formulated. One as Control and other as an experimental|t|f|f|f
34122761|NCT01226303|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122762|NCT06316726|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The experimental group was randomly assigned by block to receive intervention A (full bed silicone mattress plus other measures), and the control group received intervention B (full bed silicone mattress plus usual care).|t|t|t|t
34122763|NCT04144114|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34122764|NCT02133469|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122765|NCT06718738|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122766|NCT05055076|||COHORT||RETROSPECTIVE|||||||
34122767|NCT00002143||||TREATMENT||||||||
34122768|NCT02172014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34122769|NCT00994903|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122770|NCT00469833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122771|NCT01030822|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34122772|NCT04601129|||COHORT||PROSPECTIVE|||||||
34122773|NCT02032576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122774|NCT04578626|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34122775|NCT06715020|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122776|NCT03601390|||COHORT||PROSPECTIVE|||||||
34122777|NCT06716853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open label, single-centre phase 1/2 therapeutic-exploratory prospective study where Temferon will be administered to up to 12 patients split into two cohorts according to immune checkpoint inhibitor -ICI- therapy received in the six months prior to entry into the study.||||
34122778|NCT05495880|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34122779|NCT00200967|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34122780|NCT03257358|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two-cohort, non-randomized, open-label multicenter||||
34122781|NCT00122889|||CASE_ONLY||PROSPECTIVE|||||||
34122782|NCT04935255|||OTHER||PROSPECTIVE|||||||
34122783|NCT02868424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122784|NCT00263003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122785|NCT05389748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122786|NCT02736864|||OTHER||CROSS_SECTIONAL|||||||
34122787|NCT01213082|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122788|NCT03975153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122789|NCT03226847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122790|NCT03727035|||OTHER||OTHER|||||||
33734299|NCT06572605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734300|NCT03022149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734301|NCT03244228|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33734302|NCT04453124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of healing outcomes through pictures will not know the arm of origen of the pictures .||f|f|f|t
33734303|NCT02652533|||COHORT||PROSPECTIVE|||||||
33734304|NCT05022810|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open-label|This is a 2-arm, single center, single dose, open-label, randomized, two sequence, two-period crossover, bioequivalence study in healthy adult subjects, separated by one wash-out period of at least 72 hours.||||
33734305|NCT00162578|||DEFINED_POPULATION||PROSPECTIVE|||||||
33734306|NCT01280773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734307|NCT01108575|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734308|NCT04037410|||CASE_ONLY||RETROSPECTIVE|||||||
33734309|NCT06100250|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34122791|NCT00172861|||DEFINED_POPULATION||PROSPECTIVE|||||||
34122792|NCT02044679|RANDOMIZED|PARALLEL||||NONE||||||
33734310|NCT00679341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734311|NCT04099524|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33734312|NCT01172548|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734313|NCT06653946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consisted of two distinct groups. The first group comprised 454 patients who did not experience hemorrhagic infarction, while the second group comprised 252 patients who experienced hemorrhagic infarction.||||
33734314|NCT02224872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734315|NCT06018961|||CASE_ONLY||PROSPECTIVE|||||||
33734316|NCT00804882|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122793|NCT03533660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||RCT feedback vs. enhanced usual care|f|f|f|t
34122794|NCT05465148|||CASE_CONTROL||PROSPECTIVE|||||||
34122795|NCT00414570|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122796|NCT01643057|||CASE_ONLY||PROSPECTIVE|||||||
34122797|NCT06270238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants, assessors, and investigators will be blinded, not be aware of the group allocation. Statistical analysis will also be conducted by data analysts without awareness of the group allocation. Only clinicians applying rTMS intervention will not be blinded, as they will apply rTMS over different stimulation sites based on the protocols. Blinding will be continued until the end of the study, including data analysis.|prospective, single-blind with blind observer, parallel-group design, multi-center, randomized controlled clinical trial|t|f|t|t
34122798|NCT05214352|||OTHER||CROSS_SECTIONAL|||||||
34122799|NCT04800393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34122800|NCT01265017|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34122801|NCT01361659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122802|NCT03186105|NA|SINGLE_GROUP||OTHER||NONE||||||
34122803|NCT00052910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122804|NCT00878267|||CASE_ONLY||PROSPECTIVE|||||||
34122805|NCT01723969|||CASE_ONLY||PROSPECTIVE|||||||
34122806|NCT01103856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122807|NCT06569121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122808|NCT05518006|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34122809|NCT01634217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734317|NCT00772096|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33734318|NCT05403554|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734319|NCT06192342|||COHORT||PROSPECTIVE|||||||
33734320|NCT00523185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734321|NCT01872572|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33734322|NCT05955560|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants are blinded to which device is which and will remain blinded to treatment order until study completion. Investigator, Study Personnel and Sponsor will know which device the participant is treated with at any given time.|Each subject acts as his own control, and therefore the difference in treatments is derived from a within-subject comparison.|t|f|f|f
33734323|NCT01424488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33734324|NCT02422433|NA|SINGLE_GROUP||OTHER||NONE||||||
33734325|NCT06662552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734326|NCT06479109|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734327|NCT06573021|||COHORT||PROSPECTIVE|||||||
33734328|NCT06055088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33734329|NCT00599937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734330|NCT03676660|||CASE_ONLY||CROSS_SECTIONAL|||||||
33734331|NCT04841564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734332|NCT04556305|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||f|t|t|t
33734333|NCT00767676|NON_RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33734334|NCT04587622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734335|NCT06188416|||COHORT||CROSS_SECTIONAL|||||||
33734336|NCT03860896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734337|NCT05996250|NA|SINGLE_GROUP||OTHER||NONE||||||
33734338|NCT04119089|||CASE_ONLY||PROSPECTIVE|||||||
33734339|NCT03113682|NA|SINGLE_GROUP||TREATMENT||NONE||There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.||||
33734340|NCT02353481|||COHORT||RETROSPECTIVE|||||||
33734341|NCT06531863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will not know if they are receiving the intervention or placebo.|Intervention Group (supplementation with 1330mg/day curcumin and 350mg/day EGCG) Placebo Group|t|f|f|f
33734342|NCT02468466|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734343|NCT05493995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734344|NCT00170079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734345|NCT03225794|||COHORT||CROSS_SECTIONAL|||||||
33734346|NCT06533189|||OTHER||PROSPECTIVE|||||||
33734347|NCT03374826|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734348|NCT01015846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33734349|NCT04400097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734350|NCT01035879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734351|NCT03522376|||OTHER||CROSS_SECTIONAL|||||||
33734352|NCT04544449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor will also be blinded.||t|f|t|f
33734353|NCT01117727|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33813671|NCT01950689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813672|NCT05691400|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||arms are designated based off of genotype; however, treatment is the same for each arm||||
33813673|NCT04274127|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||estimate the positive predictive value of an early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.||||
33813674|NCT03489811|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33734354|NCT05649163|||COHORT||PROSPECTIVE|||||||
33734355|NCT05869227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734356|NCT00567775|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734357|NCT01164852|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33734358|NCT03240627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomised, double-blind, vehicle-controlled multicentre trial in parallel groups.|t|t|t|t
33734359|NCT02127307|||COHORT||RETROSPECTIVE|||||||
33734360|NCT03191916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and their care provider will be blinded as to which intervention is being used.|Participants will be randomly assigned to an experimental group (receives stimulation) or a sham group (is set up with tDCS, but no stimulation is received)|t|t|f|f
33813675|NCT06504719|||CASE_ONLY||RETROSPECTIVE|||||||
33813676|NCT02718885|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33813677|NCT05547724|NA|SINGLE_GROUP||OTHER||NONE||||||
33813678|NCT06500104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813679|NCT01827748|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33813680|NCT06470152|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813681|NCT01184105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813682|NCT03073902|||COHORT||PROSPECTIVE|||||||
33813683|NCT02899533|||CASE_ONLY||PROSPECTIVE|||||||
33734361|NCT05596526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734362|NCT04991480|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33734363|NCT04053374|||COHORT||PROSPECTIVE|||||||
33734364|NCT02471521|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33734365|NCT01427296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734366|NCT03393611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734367|NCT03430752|||COHORT||CROSS_SECTIONAL|||||||
33734368|NCT05692141|||CASE_CROSSOVER||PROSPECTIVE|||||||
33734369|NCT00799617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734370|NCT00098839|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734371|NCT02326142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813684|NCT04523909|||COHORT||PROSPECTIVE|||||||
33813685|NCT01359163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813686|NCT02626117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813687|NCT03466645|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33813688|NCT05823714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734372|NCT01767792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734373|NCT02321865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734374|NCT02690285|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33734375|NCT00968175|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33734376|NCT05219136|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33734377|NCT00621426|||COHORT||PROSPECTIVE|||||||
33734378|NCT03768739|||COHORT||PROSPECTIVE|||||||
33734379|NCT05731934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734380|NCT05411510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734381|NCT04814069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734382|NCT05197049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734383|NCT02432716|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33734384|NCT05552313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Control group will be given sham kinesio taping.|This study is a randomized controlled trial which will consist of 2 groups. Experimental group will be given kinesio taping along with thoracic manipulation and conventional treatment whereas control group will be given sham kinesio taping along with thoracic manipulation and conventional treatment. Both groups will be recruited concurrently.|t|f|f|f
33734385|NCT05236309|||CASE_CONTROL||RETROSPECTIVE|||||||
33734386|NCT03916627|RANDOMIZED|PARALLEL||TREATMENT||NONE|Cohorts B and C are not randomized|||||
33734387|NCT06409624|||COHORT||PROSPECTIVE|||||||
33734388|NCT02037711|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33734389|NCT04537806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734390|NCT00820924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734391|NCT03748940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33734392|NCT02443376|||COHORT||PROSPECTIVE|||||||
33734393|NCT06277934|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734394|NCT05052229|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Single center, randomized, double-blind, cross-over design|t|f|t|f
33734395|NCT00191893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734396|NCT03466034|||COHORT||PROSPECTIVE|||||||
33734397|NCT02825511|||COHORT||PROSPECTIVE|||||||
33734398|NCT03087279|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734399|NCT01406691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734400|NCT03359733|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33734401|NCT02611167|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33734402|NCT04143412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Three parallel groups of therapy; Ramipril 10 mg monotherapy (25 patients) ,Eplerenone 50 mg monotherapy (25 patients) and combination therapy of Eplernone/Ramipril 50/10 mg (25 patients)|t|f|f|f
33734403|NCT03265093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator, Outcomes Assessor|Blinded, Parallel group, randomized controlled trial|f|f|t|f
33734404|NCT00588913|NON_RANDOMIZED|||TREATMENT||NONE||||||
33734405|NCT03692546|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33734406|NCT06192745|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigators will be blinded to treatment condition in the analysis of outcomes||f|f|t|f
33734407|NCT00002794||||TREATMENT||||||||
33734408|NCT05447442|||OTHER||PROSPECTIVE|||||||
33734409|NCT01291927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734410|NCT02880566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734411|NCT02285985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813689|NCT04884191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813690|NCT01503450|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813691|NCT00088166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813692|NCT04739306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813693|NCT05684809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813694|NCT04245722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33813695|NCT05792176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33734412|NCT00537446|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33813696|NCT03655366|||OTHER||CROSS_SECTIONAL|||||||
33813697|NCT03143036|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase 2 study of the combination of Daratumumab, thalidomide and dexamethasone in 100 Asian patients with relapse or refractory multiple myeloma.||||
33734413|NCT01045291|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33734414|NCT02674022|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734415|NCT03363230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734416|NCT05617846|||OTHER||PROSPECTIVE|||||||
33813698|NCT05159271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044303|NCT01737710|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044304|NCT03804450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734417|NCT02057107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734418|NCT05335590|||COHORT||PROSPECTIVE|||||||
33734419|NCT00808938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734420|NCT05721417|||COHORT||CROSS_SECTIONAL|||||||
34044305|NCT04973423|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044306|NCT00613964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044307|NCT05722678|||CASE_CONTROL||PROSPECTIVE|||||||
33734421|NCT01006902|||COHORT||PROSPECTIVE|||||||
33734422|NCT04452188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734423|NCT04265937|||CASE_ONLY||PROSPECTIVE|||||||
33734424|NCT05611086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both of the medicines were prepared by the Installation of Pharmacy in Cipto Mangunkusumo National Hospital with the same type and same color of capsules.|Subjects were randomized consecutively and distributed into two groups. Randomization was done by a third person to decide the distribution of the subjects based on the serial number of randomization.|t|t|f|f
33734425|NCT01021124|||COHORT||PROSPECTIVE|||||||
33734426|NCT05986552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors and investigator are blind to treatment arm up to and including the last follow-up assessment.|Multicenter Randomized Clinical Trial|f|f|t|t
33734427|NCT03524027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044308|NCT03200769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044309|NCT01375972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813699|NCT01866527|||COHORT||PROSPECTIVE|||||||
33813700|NCT06061588|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is planned to be conducted at two centers. Patients visiting one hospital will receive standard treatment, while patients visiting the other hospital will receive standard treatment plus VR goggles as part of their therapy. The group receiving standard treatment will constitute the case group, while the other group will form the control group.|f|f|t|t
33813701|NCT04836871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813702|NCT02221466|||COHORT||PROSPECTIVE|||||||
34122810|NCT03974074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34122811|NCT00552071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34122812|NCT04176107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34122813|NCT05002348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind random assignment: When subjects are confirmed to have constipation, they will be given random coding groups with envelope bags after seeking their consent, and they will be divided into experimental and control groups, and the patient will not be told whether they belong to the experimental or the control group. During execution, the laser pen of the control group did not turn on the energy, and the laser pen of the experimental group turned on the energy. The acupoint stimulation was performed for about 3-5 minutes, and each acupoint was performed once a day.||t|f|f|f
34122814|NCT05065801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122815|NCT02035514|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34122816|NCT00209937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122817|NCT01912573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122818|NCT02077231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122819|NCT01887405|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34122820|NCT01482195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Ocular Subretinal administration of rAAV2-VMD2-hMERTK .||||
34122821|NCT03789292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122822|NCT01102738|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34122823|NCT01158547|||COHORT||PROSPECTIVE|||||||
34122824|NCT01998061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122825|NCT04199585|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Cohort A: sequential, cohort B parallel|t|f|t|f
34122826|NCT04144777|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34122827|NCT01727388|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34122828|NCT06279390|||CASE_CONTROL||RETROSPECTIVE|||||||
34122829|NCT02894476|||COHORT||PROSPECTIVE|||||||
34122830|NCT05090618|||OTHER||PROSPECTIVE|||||||
34122831|NCT06447766|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122832|NCT01308840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122833|NCT01341743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122834|NCT01464749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122835|NCT00003869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122836|NCT00510757|||COHORT|||||||||
34122837|NCT06054399|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|All the participants will know about the educational interventional as well as their physicians.|before and after quasi experimental||||
34122838|NCT05784818|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34122839|NCT03842046|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122840|NCT05922618|RANDOMIZED|PARALLEL||TREATMENT||NONE||Spontaneous, prospective, randomized study with control group||||
34122841|NCT01684670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122842|NCT04446403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34122843|NCT01297283|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34122844|NCT00805506|||COHORT||PROSPECTIVE|||||||
34122845|NCT04049500|||COHORT||PROSPECTIVE|||||||
34122846|NCT02025374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122847|NCT04115462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34122848|NCT03083782|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Intervention Model: Crossover Assignment||||
34122849|NCT01790373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34122850|NCT03164005|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122851|NCT05390164|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34122852|NCT00105664|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122853|NCT03131908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122854|NCT05120050|||COHORT||RETROSPECTIVE|||||||
34122855|NCT00445094|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122856|NCT03606291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122857|NCT01571622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122858|NCT04473781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122859|NCT04264039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122860|NCT00672594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122861|NCT02338388|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122862|NCT04283656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Three period crossover||||
34122863|NCT01343888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122864|NCT03402100|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122865|NCT00940550|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34122866|NCT03027674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122867|NCT00205439|||COHORT||OTHER|||||||
34122868|NCT06000592|NA|SINGLE_GROUP||TREATMENT||NONE|Participant awareness during TSCS appears to be unavoidable. The FDA recognizes that some trials of non-pharmacological interventions cannot be fully shammed or blinded, yet with careful blinding of data assessors, it is possible to obtain reliable results that meet FDA approval criteria.|||||
34122869|NCT05498584|||COHORT||PROSPECTIVE|||||||
33813703|NCT04947709|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial, utilizing a delayed-intervention control group.||||
33813704|NCT06093451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813705|NCT06012214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813706|NCT01174472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813707|NCT02696109|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multimodal psychosocial intervention||||
33813708|NCT00259363|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813709|NCT03471884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813710|NCT03741985|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813711|NCT04765046|NA|SINGLE_GROUP||OTHER||NONE||||||
33813712|NCT03425175|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Open label|Non-randomised intervenion||||
33813713|NCT02399202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813714|NCT01263522|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813715|NCT02454556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813716|NCT06220123|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 randomized and paralleled 2 arms: Investigational product arm， Positive control arm||||
33813717|NCT06222437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813718|NCT01441336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813719|NCT05097534|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813720|NCT03031353|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813721|NCT03122860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813722|NCT05943054|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33813723|NCT00924833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813724|NCT05076838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813725|NCT00096278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813726|NCT00546884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813727|NCT02049177|||CASE_ONLY|||||||||
33813728|NCT00004731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33813729|NCT00221988|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33813730|NCT05099562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813731|NCT01159314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813732|NCT06455072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813733|NCT00648895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813734|NCT02625025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813735|NCT01036932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813736|NCT02452567|NA|SINGLE_GROUP||OTHER||NONE||||||
33813737|NCT01107509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813738|NCT04522661|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised control trial||||
33813739|NCT03742882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813740|NCT03118609|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"A single focus group.~A single group will be analyzed based on survey results"||||
33813741|NCT03026920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813742|NCT04838509|||CASE_ONLY||RETROSPECTIVE|||||||
33813743|NCT01992276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813744|NCT02416947|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33813745|NCT00368602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813746|NCT04222088|||COHORT||PROSPECTIVE|||||||
33813747|NCT01811459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813748|NCT04266626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813749|NCT04818476|||COHORT||RETROSPECTIVE|||||||
33813750|NCT00889473|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|randomized, double-blind, placebo-controlled, dose ranging, multicenter|t|f|t|f
33813751|NCT03733860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813752|NCT01501721|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33813753|NCT00994851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813754|NCT05763732|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant and outcomes assessor will be masked to the participants' stimulation state (OFF or ON). However, they cannot be masked whether they will receive rhythmic auditory stimulation (RAS) or not (pre-RAS or post-RAS).||t|f|f|t
33813755|NCT00715598|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044310|NCT03875326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Eligible participants will be randomized 1:1:1:1 to receive either sham, 1mA, 2mA, or 3mA HD-tDCS for at least 5 sessions and up to 30 sessions using a blocked randomization design.|t|f|t|t
34044311|NCT01521520|||CASE_CONTROL||PROSPECTIVE|||||||
34044312|NCT05717296|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34044313|NCT05537818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham and active treatments|Multi-center, double-blind, randomized, sham-controlled trial|t|t|t|f
34044314|NCT06574958|NA|SINGLE_GROUP||TREATMENT||NONE||10||||
34044315|NCT02348788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044316|NCT04305444|NA|SINGLE_GROUP||TREATMENT||NONE||All patients, regardless of disease-specific cohort, will receive the same dose of DTRM-555. There are two stages to the study, and there is the potential for 120 patients in total (potentially 24 patients in each of the 5 cohorts) to participate in the study.||||
34044317|NCT05251337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not be informed of assignment to intervention or control; however, the blank aromatherapy patch (control group) will not have a scent and the essential oil infused aromatherapy patch (intervention group) will. Thus, it may be obvious to participants what group they are randomized to.|Prior to randomization, participants will be asked which symptom, nausea/vomiting or anxiety, is most burdensome for them. Participants will be stratified based on their identified symptom of burden (nausea/vomiting or anxiety) and will then be randomized to either the intervention or control group, with a target of 50 participants in the nausea/vomiting symptom group (25 intervention and 25 control) and 50 participants in the anxiety symptom group (25 intervention and 25 control).|t|f|f|f
34044318|NCT02282813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044319|NCT03564340|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044320|NCT03303456|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34044321|NCT04634591|||CASE_CONTROL||PROSPECTIVE|||||||
34044322|NCT06577727|||COHORT||PROSPECTIVE|||||||
34044323|NCT03726138|||COHORT||PROSPECTIVE|||||||
33734428|NCT00806468|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33734429|NCT05317975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734430|NCT01730495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813756|NCT04453488|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813757|NCT01346345|||CASE_ONLY||PROSPECTIVE|||||||
33813758|NCT02035852|||COHORT||PROSPECTIVE|||||||
33813759|NCT01630668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813760|NCT04296734|||CASE_CONTROL||PROSPECTIVE|||||||
33813761|NCT00943371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813762|NCT02629575|||COHORT||PROSPECTIVE|||||||
34122870|NCT05115435|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Participants did not know they were in the experimental or control group.|The population of the study consisted of patients who had kidney transplants in the hospital in question. The sample of the study was determined by power analysis. According to the calculation made using G\*power 3.1 software, the sample size was determined as 74 (each group 37) with an effect size of 0.80, a margin of error of 0co.05, a confidence level of 0.95, and a population representation of 0.95. Simple random sampling method, one of the probability sampling methods, was used to determine the participants. Single-group columns between 1 and 300 were created using the Random Integer Generator method, which located in the Numbers sub-heading of the random.org website for the participants who met the sample selection criteria. Participants were randomly assigned to numbers 1 and 2, considering the numbers 1 and 2 in the column. The number of the experimental or control group was determined by drawing lots at the beginning of the research.|t|f|f|f
34122871|NCT05545943|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The researchers who analyzed the saliva and venous blood samples were blinded to the experimental conditions.|This project consisted of two parts. For the first part was used randomized parallel model, and we aimed to investigate fasting duration effect, whereas for the second part was used randomized crossover model and we aimed to investigate if cold exposure can modify fasting evoked effects on health-related indicators, cognition and motor function.|f|f|t|f
34122872|NCT06337279|||COHORT||RETROSPECTIVE|||||||
34122873|NCT00001034||PARALLEL||TREATMENT||||||||
34122874|NCT00444925|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34122875|NCT05837221|||COHORT||PROSPECTIVE|||||||
34122876|NCT02593058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122877|NCT04892706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122878|NCT00537537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122879|NCT03667404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"participants will be blinded to condition. control condition (maltodextrin) will be used and has identical appearance.~investigator and research staff (except pharmacy) will be blinded to condition"|Double blind placebo (maltodextrin) controlled randomized trial|t|t|t|t
34122880|NCT01585402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122881|NCT02385006|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34122882|NCT02960425|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
34122883|NCT03322163|||COHORT||PROSPECTIVE|||||||
34122884|NCT01100281|||CASE_CONTROL||PROSPECTIVE|||||||
34122885|NCT02582827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122886|NCT06220877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122887|NCT00178971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122888|NCT01428219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122889|NCT03487016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122890|NCT03273907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122891|NCT02178800|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34122892|NCT00346619|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122893|NCT04624100|||COHORT||PROSPECTIVE|||||||
34122894|NCT06000930|||COHORT||CROSS_SECTIONAL|||||||
34122895|NCT03694951|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study advertisements and information provided to participants will focus on non-specific behaviour change, in order to mask participants to the purpose of the study.|Upon obtaining consent, eligible participants will complete a week-long baseline period and then will be randomly assigned to either a 1-week intervention or control group, followed by a 1-week follow-up period.|t|f|f|f
34122896|NCT00950651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122897|NCT03978039|||COHORT||PROSPECTIVE|||||||
34122898|NCT00295646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122899|NCT01884363|RANDOMIZED|PARALLEL||||NONE||||||
34122900|NCT02890277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122901|NCT04747262|NA|SINGLE_GROUP||OTHER||NONE||The program contains 12 weekly 1-hour sessions with the parents. We will examine the impact of the intervention on family accommodation, ASD and anxiety symptomology, as well as parent and child satisfaction from the intervention, using the attached measures.||||
34122902|NCT03649802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study coordinators will be aware of the allocation into the low and high dose vitamin D groups but the patient and the investigators will be blinded from this information.|Subjects will be randomized in a double blind manner. Arterial stiffness and oxidative stress markers will be evaluated in the low dose Vitamin D (800 IU) versus a high dose vitamin D (5000 IU) over a period of a year|t|f|t|f
34122903|NCT02471053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838504|NCT06518447|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Participant Masking:~Patients will not be informed whether they are receiving the conventional stabilization splint or the CAD/CAM splint. The splints will be marked with small, inconspicuous letters (A for Group A and B for Group B) during the fabrication process to minimize the possibility of the patients identifying which type of splint they are using. Additionally, both splints will be polished similarly to ensure no noticeable differences in appearance or texture.~Researcher Masking:~The primary researcher conducting patient evaluations and data analysis will be blinded to the group assignments. This researcher will not be involved in the fabrication or fitting of the splints, thereby maintaining an objective perspective during assessments."||t|f|t|f
33838505|NCT01600560|||COHORT||PROSPECTIVE|||||||
33838506|NCT02344875|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33734431|NCT03676452|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This is a two-arm randomized controlled trial with an intervention group and a usual care waitlist control group. After pre-measurement, participants of the intervention group train for four months with the Active@Home exergame. Participants of the control group are instructed to continue their usual daily business and activities. Then, post-measurement takes place. After post-measurement, participants of the control group get the Active@Home exergame for their personal use at home (for several months, no additional measurement).||||
33734432|NCT06572514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734433|NCT04506151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Sleep optimization intervention will be compared to an attention control group|f|f|t|t
33734434|NCT03935035|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled case series||||
33734435|NCT05355636|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734436|NCT01020916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734437|NCT04958694|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Wait-list control, no masking|||||
33734438|NCT01934634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734439|NCT00775437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734440|NCT01647867|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33734441|NCT01135810|||CASE_CONTROL||PROSPECTIVE|||||||
33734442|NCT01257594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734443|NCT03833076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||a randomised, double-blind, parallel-groups, multicentric, placebo-controlled, prospective clinical study|t|t|t|t
33734444|NCT04088682|||CASE_ONLY||RETROSPECTIVE|||||||
33734445|NCT01665365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734446|NCT04616781|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blind|The study is a randomized, 2-way placebo-controlled crossover trial in 20 non-treatment seeking individuals with AUD.|t|f|t|f
33734447|NCT03101475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734448|NCT06320470|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734449|NCT04072484|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The participant is unaware of the oxygen concentration that he or she is breathing during either arm of the trial.||t|f|f|f
33734450|NCT05234515|||COHORT||PROSPECTIVE|||||||
33734451|NCT03904979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will have identical journals regardless of the intervention or control group status, and providers will be blinded to the writing prompts that participants are given. Women who are randomized to 'no writing' will be provided a blank journal without any instruction. this will be considered a 'gift' for study participation|Randomized Controlled Trial|t|f|t|f
33734452|NCT03031288|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33734453|NCT00215774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734454|NCT03419091|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a prospective, randomized clinical trial. Patients will be randomized 1:1 in randomization blocks of 4 to undergo the procedure with either the LithoVue single use flexible ureteroscope or the digital reusable flexible ureteroscope. Ureteroscopy will be performed using a standardized technique.||||
33734455|NCT04380207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind, placebo controlled ascending single- and multiple-dose|double-blind, placebo controlled ascending single, multiple and combination dose|t|t|t|f
33734456|NCT05641740|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734457|NCT00385970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734458|NCT04102358|||COHORT||RETROSPECTIVE|||||||
33734459|NCT03952793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33734460|NCT02797262|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734461|NCT04772092|||COHORT||PROSPECTIVE|||||||
33734462|NCT01196767|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33734463|NCT00405574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734464|NCT02572050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734465|NCT06430372|NA|SINGLE_GROUP||SCREENING||NONE||||||
33734466|NCT03477500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734467|NCT05588596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33734468|NCT01163604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734469|NCT01362907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734470|NCT00473915|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33734471|NCT05086692|NA|SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation (MDNA11 monotherapy and MDNA11 + pembrolizumab) followed by dose expansion with MDNA11 monotherapy and combination (MDNA11 + pembrolizumab).||||
34149814|NCT04476927|NA|SINGLE_GROUP||OTHER||NONE||"Total of 300 subjects - 200 suspected to COVID-19 and 100 healthy volunteers. all subjects will be undergo the DiaNose test.~For data analysis and algorithm building, subjects will be divided into one of the following study groups:~* Group 1: Covid-19 infected suspected (up to 300 subjects)~  * Sub-Group A: Clinical symptomatic patients with positive Covid-19 test (positive PCR);~ * Sub-Group B: Asymptomatic patients with positive Covid-19 test (positive PCR)~ * Sub-Group C: Clinical symptomatic patients with negative Covid-19 test (negative PCR) Additional sub-groups may be added according to clinical symptoms.~* Group 2: Healthy volunteers (up to 100 subjects)"||||
34149815|NCT03382028|||CASE_ONLY||RETROSPECTIVE|||||||
33734472|NCT05682482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|Parallel Assignment|t|t|t|f
33734473|NCT06000878|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33734474|NCT00128180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734475|NCT01652456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734476|NCT05668793|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734477|NCT00139126|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33734478|NCT03579199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734479|NCT03968458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734480|NCT04719416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734481|NCT06423716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Group 1: Intervention Duloxetine 60mg OD for 2 weeks preoperatively then 60mg OD for 6 weeks post-surgery.~Group 2: Control Placebo OD for 2 weeks preoperatively then OD for 6 weeks post-surgery."|t|t|t|t
33734482|NCT03030833|||COHORT||PROSPECTIVE|||||||
33734483|NCT00251394|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734484|NCT02373124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734485|NCT05787951|||OTHER||PROSPECTIVE|||||||
33734486|NCT02148003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734487|NCT01611571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734488|NCT00273403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734489|NCT01751503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734490|NCT03697811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734491|NCT00835497|RANDOMIZED|CROSSOVER||||NONE||||||
33734492|NCT00359450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734493|NCT00115596|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33734494|NCT01479634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734495|NCT00006279||||PREVENTION||||||||
33734496|NCT04563312|NON_RANDOMIZED|PARALLEL||SCREENING||NONE|All the volunteers participating in the study signed the informed consent form and filled personal data forms.|A total of 35 participants, 17 athletes (14 men and 3 women) engaged in MT and 18 athletes (13 men and 5 women) engaged in BB were included in the study||||
33734497|NCT05352022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33734498|NCT06466954|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734499|NCT03427658|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Intervention allocation will be undertaken by a researcher not in direct contact with any one participant, following randomization by drawing lots.||f|f|t|t
33734500|NCT02087462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734501|NCT02459314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734502|NCT06161792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734503|NCT03913078|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are aware of the two different exercise conditions and accept randomization into either of the two. The investigator and outcomes assessor are masked, but participant is aware of group assignment.|Increases in perceived enjoyment lead to increases in physical activity adherence which lead to increases in physical fitness|f|f|t|t
33734504|NCT04983394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33734505|NCT01375218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734506|NCT04169295|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33734507|NCT00150020|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734508|NCT01031576|||CASE_CONTROL||PROSPECTIVE|||||||
33734509|NCT05894850|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33734510|NCT04135703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33734511|NCT00736203|||COHORT||PROSPECTIVE|||||||
33734512|NCT04545177|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33734513|NCT01854021|RANDOMIZED|PARALLEL||||NONE||||||
33734514|NCT03580096|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33734515|NCT04019912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study uses a single-blinded study design.|The study is a parallel-group randomized clinical trial using a double-blind study design. The enrolled patients will be randomly assigned to the 2 groups using an automated computerized randomization program. Patients will be informed about the research and will be asked to fill in the informed consent form. The patient's basic characteristics (age, sex, duration of the illness, marital status and educational background) will be recorded. Randomization will be performed using a randomization list, so patients will be randomized in a 1:1 ratio in the intervention or control group. The randomization list is blind to anyone involved in informing potential study participants.|f|f|t|t
33734516|NCT02335138|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33734517|NCT01900613|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734518|NCT04048603|||CASE_CONTROL||PROSPECTIVE|||||||
33734519|NCT04147338|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734520|NCT05916157|||COHORT||PROSPECTIVE|||||||
33734521|NCT00293384|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33734522|NCT00619697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734523|NCT05951244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734524|NCT03763994|||CASE_CONTROL||PROSPECTIVE|||||||
33734525|NCT01929668|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34149816|NCT00186277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149817|NCT03324919|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34149818|NCT01566578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734526|NCT05391217|||COHORT||PROSPECTIVE|||||||
33734527|NCT03194048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734528|NCT00475007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734529|NCT02054364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734530|NCT05956418|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a prospective, multi-centric, open-labeled, single-arm and phase-IV study in 400 hypovolemic shock patients with a systolic arterial blood pressure ≤ 90 mmHg. The study duration will be approximately 15 months, including a 12-month enrollment period. All patients in the single group of the study will receive treatment with Centhaquine (Dose: 0.01 mg/kg) + Standard of care. A second dose of centhaquine may be given if the systolic blood pressure remains low. However, the maximum number of doses per day should not exceed 3, and if needed the treatment will continue for the 2nd day of enrollment. Within the first 48 hours post-enrollment, a minimum of 1 dose and a maximum of 6 doses of centhaquine will be administered. Each patient will be closely monitored throughout their hospitalization and followed until discharge or day 7 (whichever comes earlier) from enrollment."||||
33734531|NCT02544893|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33734532|NCT05411406|||COHORT||PROSPECTIVE|||||||
33734533|NCT04474652|||COHORT||PROSPECTIVE|||||||
33734534|NCT04150081|||COHORT||RETROSPECTIVE|||||||
33734535|NCT02130375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734536|NCT02224365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734537|NCT04990726|||COHORT||PROSPECTIVE|||||||
33734538|NCT03704181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838507|NCT03738553|||COHORT||PROSPECTIVE|||||||
34044324|NCT00933621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044325|NCT03113942|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, phase 2 trial, single-arm||||
34044326|NCT02582892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044327|NCT01500382|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34044328|NCT00605631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044329|NCT05783167|||COHORT||CROSS_SECTIONAL|||||||
34044330|NCT00955955|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044331|NCT06463470|NA|SINGLE_GROUP||TREATMENT||NONE||Non-randomised evaluation study||||
34044332|NCT03110406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Intervention group and control group|t|f|t|t
34044333|NCT01014169|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34044334|NCT04173156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Examiners blinded to treatment allocation||f|f|t|t
34044335|NCT06240273|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|None (open-label) Participants Groups|Single group Assignment Case-control Study||||
34044336|NCT04345250|NA|SINGLE_GROUP||PREVENTION||NONE||Single group, pre to post one week intervention||||
34044337|NCT03314792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were not told which medicine they were given, but due to difference in apperance of pills they would be able to find out which medicine they were given if they wanted to. Care providers at the hospital ward administering the medication would know which medicine were given due to apperance.||f|f|t|t
34044338|NCT02417142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044339|NCT00800878|||||CROSS_SECTIONAL|||||||
34044340|NCT00351624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34044341|NCT04797702|NA|SEQUENTIAL||TREATMENT||NONE||||||
34044342|NCT01920958|||COHORT||PROSPECTIVE|||||||
34044343|NCT06548373|||COHORT||PROSPECTIVE|||||||
34044344|NCT04868045|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, single center, pilot study of the hypothalamic-pituitary-thyroid axis in adult patients with thyroid cancer.||||
34044345|NCT01163851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044346|NCT04813068|||COHORT||RETROSPECTIVE|||||||
34044347|NCT05422274|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind. Participants and interventionists will be blinded to the random allocation to either the verum TPS group or the sham TPS group.|This is a randomized, double-blinded, sham-controlled trial.|t|f|t|f
34044348|NCT02637206|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044349|NCT05139771|NA|SINGLE_GROUP||OTHER||NONE||||||
34044350|NCT02764424|||COHORT||PROSPECTIVE|||||||
34044351|NCT02887976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044352|NCT02948660|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34122904|NCT05853354|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Upon enrollment, each participant will receive a unique participant identification number.Participant numbers must not be re-used for any other participants.~Prior to dosing in the Transition Period and to maintain the blind throughout the study, participants will be re-randomized and receive a second randomization number. Participants randomized to receive EU-Prolia in the Main Period will be re-randomized to receive either LY06006 or continue to receive EU-Prolia. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the IRT system to maintain the blind of treatment assignment."|This is a randomized, double-blind, parallel-group, active-controlled, comparative study (Main Period) with a Transition Period to compare the efficacy, PD, safety, PK and immunogenicity of LY06006 and EU-Prolia among female participants with postmenopausal osteoporosis.|t|t|t|t
34122905|NCT03681379|||CASE_ONLY||PROSPECTIVE|||||||
34122906|NCT02329093|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122907|NCT05844228|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122908|NCT03443635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122909|NCT05935943|||OTHER||PROSPECTIVE|||||||
34122910|NCT02246010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734539|NCT04535284|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blinded to treatment group allocation|Single-blind randomized controlled trial design with two parallel groups|f|f|f|t
34044353|NCT01827267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044354|NCT03189693|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34044355|NCT02855372|||COHORT||RETROSPECTIVE|||||||
34044356|NCT04073706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044357|NCT05053620|||CASE_ONLY||PROSPECTIVE|||||||
34044358|NCT00001198|||FAMILY_BASED||PROSPECTIVE|||||||
34044359|NCT01743560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044360|NCT05000671|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34044361|NCT06271785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044362|NCT02566642|||CASE_ONLY||PROSPECTIVE|||||||
34044363|NCT02406001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044364|NCT01599533|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044365|NCT05656248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044366|NCT01848912|||COHORT||PROSPECTIVE|||||||
34044367|NCT04754958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Invervention group / no intervention group (standard of care)|t|t|f|f
34044368|NCT03757728|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34044369|NCT02746978|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044370|NCT01932060|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34044371|NCT02295592|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044372|NCT03333538|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This clinical trial is designed as a double blind randomized placebo-controlled study|Parallel Assignment|t|f|t|f
34044373|NCT02826486|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044374|NCT03421210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34044375|NCT02914704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044376|NCT05182762|||COHORT||RETROSPECTIVE|||||||
34044377|NCT01579084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044378|NCT05312151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044379|NCT03305341|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|Single Usage / Single Dosage||||
34044380|NCT06024798|||CASE_ONLY||PROSPECTIVE|||||||
34044381|NCT06576310|||COHORT||PROSPECTIVE|||||||
33734540|NCT06574230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734541|NCT00478400|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734542|NCT05142358|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All participants will undergo standard of care radiation treatment. One additional CT scan will be performed with the use of a CPAP device to determine effect on dosimetry.||||
33734543|NCT05095688|||COHORT||CROSS_SECTIONAL|||||||
33734544|NCT01799356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33734545|NCT05176652|||OTHER||PROSPECTIVE|||||||
33734546|NCT04931225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734547|NCT05446350|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|masking to the conditions of the experiments||t|f|f|f
33734548|NCT01487616|||CASE_CONTROL||PROSPECTIVE|||||||
33734549|NCT02145039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734550|NCT05588024|||COHORT||PROSPECTIVE|||||||
33734551|NCT04917094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734552|NCT01470469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734553|NCT04252105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734554|NCT06374433|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33734555|NCT03106727|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The roll-out of this study is designed as a stepped wedge cluster randomised controlled trial. The study consists of six clusters: the first cluster will receive the intervention in March 2017, with a new cluster receiving the intervention every three months thereafter.||||
33734556|NCT02530294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734557|NCT04612634|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33734558|NCT00129233|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734559|NCT00512096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734560|NCT03814694|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734561|NCT02594722|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33734562|NCT03464344|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734563|NCT00830193|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33734564|NCT00000735||||TREATMENT||NONE||||||
33734565|NCT02423265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734566|NCT03497559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|iPods with music and no music, same headphones. Patients and parents are blinded to the intervention the same as bedside nurses, data collectors and principal investigators.|Double blind randomized controlled trial|t|t|t|t
33734567|NCT00785486|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33734568|NCT02459691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33734569|NCT00630422|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33734570|NCT06411548|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover: Participants will be randomized to the order that they experience the use of InsuLearn (for 24 hours each, without washout in between): InsuLearn→UC or UC→InsuLearn. UC stands for usual care.||||
33734571|NCT03661515||SEQUENTIAL||TREATMENT||NONE||||||
33734572|NCT06013371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment will be double-blind|Subjects will be randomized 2:1 to either drug or placebo|t|t|t|f
33734573|NCT00596011|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33734574|NCT00326911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813763|NCT03236779|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants who fulfill the inclusion criteria will receive the standardized oral and written information, and, once they consent to participate in the trial, will be randomized in a block system by blocks of 10 patients. Allocation to the groups will be achieved using a computer program (Randomizer, https://www.randomizer.org/) generated a random patient file numbers sequence by a third person not involved in the study from the file section in Kuwait. This person will be responsible for guarding the envelope with the information of the randomization. The envelopes will be closed until the moment of the intervention to maintain the blinding. This professional also will ask the patients for informed consent. The consent form is recruited upon the ethical medical committee at the ministry of health in the state of Kuwait.|This study is a prospective, two parallel-groups (participant) randomized controlled trial with blinded outcome assessment at baseline, and at 4, 8, 12, 26 and 52 weeks. The study flow chart shown in Figure 1 conforms to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines for nonpharmacological studies|t|f|f|t
34044382|NCT03491462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Placebo-controlled, parallel group|t|t|t|t
34044383|NCT00552396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044384|NCT02083432|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044385|NCT01905527|||COHORT||PROSPECTIVE|||||||
34044386|NCT03455101|||COHORT||CROSS_SECTIONAL|||||||
34044387|NCT04952805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122911|NCT02964806|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33734575|NCT00864474|||CASE_ONLY||RETROSPECTIVE|||||||
33734576|NCT03756766|||CASE_CONTROL||PROSPECTIVE|||||||
33734577|NCT01446562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734578|NCT01785602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734579|NCT04582422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blinding|Interventional research|f|f|f|t
33734580|NCT00003589|RANDOMIZED|||TREATMENT||||||||
33734581|NCT02871375|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33734582|NCT02669290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734583|NCT06139913|NA|SINGLE_GROUP||TREATMENT||NONE||prospective study||||
33734584|NCT03370029|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734585|NCT06174441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734586|NCT06662929|||COHORT||PROSPECTIVE|||||||
33734587|NCT06663865|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Treatment will be blinded according to the randomisation schedule by a research who has no other involvement in the study.|Randomised, double-blind, placebo-controlled, parallel groups design.|t|f|t|t
33734588|NCT03326427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734589|NCT03940209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Survey administrators also will be blinded to individual participant's study group assignment.|In a pragmatic randomized trial, eligible participants who complete a baseline assessment will be randomly assigned to either a basic needs navigation intervention or usual care.|f|f|t|f
34122912|NCT01404650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122913|NCT06041022|||CASE_ONLY||RETROSPECTIVE|||||||
34122914|NCT03040128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|random number generator (placebo vs. study drug)||t|t|t|t
34122915|NCT04685213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Devices may be active or sham.|"Participants will be randomized to intervention (IG) or control group (CG) with ratio of 1:1. The entire cohort will receive daily electrical stimulation (EE) in lower extremity (e.g. Gastronemius muscle) for up to 1 hour. The EE device will be functional for IG and non-functional for CG.~Phase I will include patients (n=19) admitted to the hospital due to severe COVID-19 infection. The time frame for therapy will be 2 weeks or until hospital discharge, whichever comes first."|t|t|f|f
33734590|NCT05933434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded (participant and investigator)|"Interventional group~* Single intraarticular knee injection with allogenic adipose derived mesenchymal stem cells Placebo group~* Single intraarticular knee injection with saline"|t|f|t|f
33734591|NCT06028711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||random selection to two groups (study group and control group)|t|f|t|t
34122916|NCT02553187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734592|NCT05463224|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, phase II single-center trial||||
33734593|NCT05943444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33734594|NCT05526872|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participants will be blinded to their study arm.||t|f|f|f
33734595|NCT01731704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734596|NCT01366040|||COHORT||PROSPECTIVE|||||||
33734597|NCT05168540|||COHORT||PROSPECTIVE|||||||
33734598|NCT05856305|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33734599|NCT02867605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34122917|NCT06439121|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34122918|NCT01122979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122919|NCT03534882|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This randomized-controlled trial studies patients with primary open angle glaucoma or ocular hypertension currently treated with topical IOP-lowering prostaglandin analogue (PGA) medications. Patients meeting inclusion criteria and having none of the exclusion criteria are contacted. If interested, patients meet research staff to discuss the study protocol and informed consent is obtained. Participants are randomized to one of two groups (A or B). Allocation to group is concealed to physicians. Participants have their IOP measured at Day 0. Group A patients are asked to discontinue their PGA for 42 days. Group B patients continue their medications as prescribed by their physician. Patients are closely followed, where IOP is measured on day 7, 21, and 42 in all participants. Once the assessment is complete, participants are debriefed on the nature of the study and potential findings. At the end of trial, participants resume standard therapy according to CJO 2009 Glaucoma Guidelines.|f|t|t|t
34122920|NCT05753514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122921|NCT02603679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734600|NCT00000327||CROSSOVER||TREATMENT||DOUBLE||||||
33734601|NCT05314946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734602|NCT06273553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734603|NCT04879745|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33734604|NCT06052774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Nonsurgical periodontal debridement was performed on patients using an ultrasonic scaler and universal curettes (2R - 2L and 4R- 4L). Oral Hygiene measures were instructed following treatment and follow-up after 3 months.||||
33734605|NCT03307148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734606|NCT01733381|||CASE_CONTROL||PROSPECTIVE|||||||
33734607|NCT05181007|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33734608|NCT01429766|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33734609|NCT05889052|||COHORT||PROSPECTIVE|||||||
33734610|NCT02283502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813764|NCT01077440|||CASE_ONLY||PROSPECTIVE|||||||
33813765|NCT03060525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813766|NCT01802333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813767|NCT02147275|||COHORT||PROSPECTIVE|||||||
33813768|NCT02966197|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813769|NCT02951806|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33813770|NCT03161899|||CASE_ONLY||CROSS_SECTIONAL|||||||
33813771|NCT03434106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813772|NCT00942500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813773|NCT01752816|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||f|t|t|t
33813774|NCT00000111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813775|NCT00623714|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33813776|NCT03482999|||CASE_CONTROL||RETROSPECTIVE|||||||
33734611|NCT04774510|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813777|NCT06288685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Group allocation and Randomization:~Patients were enrolled and randomized into two groups, percutaneous A1 pulley release with steroid injection (Group A) and percutaneous A1 pulley release alone (Group B), by utilizing computer generate randomization and the results were put in opaque sealed envelopes. Informed consent was obtained from all participants, and surgeries were performed by the same surgeon (WJ)."|Patients diagnosed with trigger finger, aged 18 years or older, and classified under Quinell's grade 2, 3, or 4, were included in the study \[ \]. Recruitment took place at the Outpatient Orthopedic Department of the Police General Hospital between October 2023 and January 2024. Exclusion criteria encompassed individuals with a history of prior hand surgery, Dupuytren's disease, type 1 diabetes, previous phalangeal fractures, recent steroid injection within the last month, and autoimmune diseases.|t|t|f|f
33813778|NCT05484765|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734612|NCT06207279|||OTHER||PROSPECTIVE|||||||
33734613|NCT00095784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734614|NCT00947297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734615|NCT03653754|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33734616|NCT01245855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734617|NCT02826889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813779|NCT00993278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33813780|NCT02694107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34044388|NCT01220466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044389|NCT03007082|||CASE_ONLY||PROSPECTIVE|||||||
34044390|NCT02308215|||CASE_ONLY||PROSPECTIVE|||||||
34044391|NCT01136278|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34044392|NCT00109655|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044393|NCT02875626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044394|NCT02183558|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34044395|NCT04283149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All enrolled eyes will undergo phakic eye surgery to have one of the available implantable collamer lenses EVO or EVO+ (spherical or toric) ICL implanted in their primary eye. Fellow eye surgery will occur between 7 and 14 days after primary eye surgery.||||
34044396|NCT04350437|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Detailed data from patients undergoing induction of labor. Analysis of the data will predict the outcomes in regards to possible complications.||||
34044397|NCT05354856|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Only patients with resectable gastric cancer are included in the study||||
34044398|NCT04504214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||pilot, prospective, biomedical, randomized, controlled study with intent-to-treat analysis of a stroke subjects cohort|t|f|t|t
33813781|NCT03991052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||manual versus automated management of MAP|t|f|f|f
34044399|NCT05094869|||COHORT||PROSPECTIVE|||||||
34044400|NCT02414243|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34044401|NCT01726270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044402|NCT03741738|||CASE_CONTROL||PROSPECTIVE|||||||
34044403|NCT05189990|||COHORT||CROSS_SECTIONAL|||||||
34122922|NCT06175780|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34122923|NCT02864264|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34122924|NCT01781377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34122925|NCT03583229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients with antibodies receive 4 ECP-treatments if they have CAV. If patients do not want to receive ECP-treatments, they are allocated to the control group, which do not receive ECP-treatments.~All patients receive 7 days treatment with aspirin and blood samples are drawn before and after."||||
33734618|NCT03372148|NA|SINGLE_GROUP||TREATMENT||NONE||Pharyngeal High Resolution Manometry and Impedance (pHRMi) in the Longitudinal Evaluation of Swallow Function in Head and Neck Cancer Patients||||
33734619|NCT04731441|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Subjects will be partially randomized to 1 of 2 treatment arms. Sarcopenia will be measured at baseline but is not a criterion for enrollment. Sarcopenic patients will all be in the intervention arm and receive the prehab exercise program. Non-sarcopenic patients will be randomized to the intervention arm or the control arm. The allocation scheme for non-sarcopenic subjects will be made with a computerized random number generator. This will take place the day of consent and subjects will be notified in person by the research assistant before the end of their visit with the surgeon.~After randomization, subjects will proceed with a baseline assessment to obtain basic demographics, muscle strength, endurance performance, physical functioning, and physical activity. The subject will then proceed with 6 weeks of participating in the control or intervention arm, followed by surgery and a post-operative assessment. After the post-operative assessment, study is complete."||||
33734620|NCT02316197||PARALLEL||TREATMENT||NONE||||||
33734621|NCT01294995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734622|NCT03009097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734623|NCT05942456|||COHORT||PROSPECTIVE|||||||
33734624|NCT03465293|||COHORT||PROSPECTIVE|||||||
33734625|NCT05044234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734626|NCT01148953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734627|NCT01494311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33734628|NCT05928442|||COHORT||PROSPECTIVE|||||||
33734629|NCT01567189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734630|NCT01228240|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33734631|NCT03454438|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33734632|NCT03723694|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33734633|NCT02306967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734634|NCT00917332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734635|NCT02231242|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33734636|NCT02007928|NA|SINGLE_GROUP||OTHER||NONE||||||
33734637|NCT02513589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734638|NCT01166594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734639|NCT04791800|||CASE_ONLY||PROSPECTIVE|||||||
33813782|NCT05187520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813783|NCT04617925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813784|NCT01310686|||COHORT||RETROSPECTIVE|||||||
33813785|NCT00734253|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813786|NCT01416285|||COHORT||PROSPECTIVE|||||||
34044404|NCT00786760|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34044405|NCT05669417|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double blinded RCT|t|t|t|t
34044406|NCT05752149|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|The pathologist will be initially blinded during intraoperative assessment of the fresh surgical specimen.||f|t|f|f
34044407|NCT03433196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind, Double dummy||t|f|t|f
34044408|NCT05646901|||CASE_CONTROL||PROSPECTIVE|||||||
34044409|NCT00360646|||CASE_CONTROL||RETROSPECTIVE|||||||
34044410|NCT05160623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A prospective, controlled, randomized, observer-masked study. One eye will be allocated for the studied treatment, and the fellow (control) eye will receive the standard treatment.|f|t|t|t
34044411|NCT05198063|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044412|NCT02541578|||COHORT||PROSPECTIVE|||||||
34044413|NCT02918565|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34044414|NCT05871047|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34044415|NCT03882983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044416|NCT01307904|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34044417|NCT02951208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122926|NCT02001129|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813787|NCT04718116|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33813788|NCT05664776|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33813789|NCT03837093|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33813790|NCT04510493|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044418|NCT05161052|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||"* Measurement of corneal stiffness parameters { Deformation Amplitude (DAR1), Integrated radius, Stress parameter (SP A1), Stress strain index (SSI) and Corvis biomechanical index (CBI) } in keratoconic corneas before and after 3 and 6 months CXL using Corvis ST.~* Measurement of demarcation line depth using anterior segment OCT and correlate between corneal stiffness following CXL and demarcation line depth."||||
34044419|NCT06130514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044420|NCT02041663|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044421|NCT00126256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122927|NCT06718972|||COHORT||RETROSPECTIVE|||||||
33838508|NCT04299243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33838509|NCT01364753|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33840169|NCT06317324|||COHORT||PROSPECTIVE|||||||
33840170|NCT04948762|||COHORT||RETROSPECTIVE|||||||
34044422|NCT03296644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044423|NCT00034281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044424|NCT03321851|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Vital sign results obtained by the device under study are not displayed on phone screen.|Each participant tests two equivalent vital sign sensors (devices under test) mounted on two different smartphones, one after another to assess accuracy of the device compared to equivalent reference devices.||||
34044425|NCT01921478|||COHORT||RETROSPECTIVE|||||||
34044426|NCT00593684|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044427|NCT04443946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044428|NCT02502682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044429|NCT06053333|||COHORT||PROSPECTIVE|||||||
34044430|NCT03771560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044431|NCT05510193|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34044432|NCT05694481|||CASE_CONTROL||RETROSPECTIVE|||||||
34044433|NCT02246140|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34044434|NCT02698527|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34044435|NCT03114163|||COHORT||PROSPECTIVE|||||||
34044436|NCT02483221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044437|NCT05335980|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase II Prospective, Single-Arm, Open-Label, Multi-Center Study Using the Nu-V3 Cranial Nerve Stimulation Treatment Device in Patients with Chronic Pain, Anxiety, Depression, and/or Sleeplessness||||
34044438|NCT03721861|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34044439|NCT01813292|||COHORT||CROSS_SECTIONAL|||||||
34044440|NCT01193374|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044441|NCT06465381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Using a three-arm parallel cluster RCT the investigators will randomize 7 secondary schools each to enhanced usual care, Safety Planning Intervention, and Transdiagnostic Cognitive Behavioral Therapy for Suicide prevention (21 schools total) to evaluate effects on suicidal behaviors (primary) and suicidal ideation/depressive symptoms (secondary). EUC will involve screening and active referral to government youth friendly mental health service programs.|f|f|f|t
34044442|NCT05959070|||COHORT||PROSPECTIVE|||||||
34044443|NCT02691949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044444|NCT06495476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This trial is a double-blind design using simulants to ensure blinding. In order to ensure the unbiased clinical operation, observation, and evaluation of this trial, a centralized randomization system will be used to achieve the allocation of subject random numbers and therapeutic drugs.~The simulants are consistent with the corresponding subject medications in terms of specifications, appearance, packaging, labeling, and marking, and are labeled for clinical trial use."|This trial was a randomized, multicenter, double-blind, placebo-controlled parallel trial. Participants were randomly assigned according to the ratio of the experimental group: control group =1:1.|t|t|t|t
34044445|NCT05074940|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label phase II single arm trial||||
34044446|NCT02027805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044447|NCT02459912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044448|NCT01099293|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044449|NCT02768727|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34044450|NCT04604171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||sample of 32 patients with stroke, randomly allocated in the experimental group (EG) or in the control group (CG). Sixteen patients were assigned to EG and sixteen to CG.|t|f|f|t
34044451|NCT04298814|||CASE_ONLY||PROSPECTIVE|||||||
34044452|NCT03542942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044453|NCT01408381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044454|NCT03278613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will remain masked to subject treatment assignment throughout the trial. To maintain masking of participants, the duration of treatment sessions for both the PTNS and sham groups will be 30 minutes and will be conducted with subjects in a supine position with the knees comfortably abducted and flexed. The leg and foot involved in treatment will be obscured from the subject's view with a portable anesthesia drape frame to which an exam sheet will be secured.||t|f|f|f
34044455|NCT00256386|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34044456|NCT01057810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044457|NCT05463380|||COHORT||OTHER|||||||
34044458|NCT01427647|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34044459|NCT01436370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34044460|NCT00893412|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044461|NCT02596971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044462|NCT04490512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|f|t|t
34044463|NCT00070720|RANDOMIZED|PARALLEL||||NONE||||||
34044464|NCT06575829|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a self-controlled cohort study.||||
34044465|NCT03957018|||COHORT||PROSPECTIVE|||||||
34044466|NCT02117284|||COHORT||PROSPECTIVE|||||||
34044467|NCT00169611|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34044468|NCT02798380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044469|NCT05511610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044470|NCT00122837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34044471|NCT01685619|||COHORT||PROSPECTIVE|||||||
34044472|NCT06535152|NA|SINGLE_GROUP||OTHER||NONE||Up to eight pairs of reference and Lifelight recordings (starting and ending with reference recordings) were taken sequentially to obtain a minimum of three valid paired reference and Lifelight BP measurements. At least 60 seconds elapsed between each BP determination.||||
34044473|NCT06384183|||CASE_ONLY||OTHER|||||||
34044474|NCT03674320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044475|NCT02888418|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34044476|NCT02104739|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Placebo pills and placebo injections provided||t|t|t|t
34044477|NCT05207657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044478|NCT02733848|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34044479|NCT04618198|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||This is a phase 3, multi-site, open-label, randomized controlled clinical 2x2 factorial superiority trial of a) immediate initiation of anti-TB therapy and b) sepsis-specific dose anti-TB therapy for people living with HIV and presenting with sepsis to our regional study sites in Tanzania and Uganda.|f|f|f|t
34044480|NCT05571475|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34044481|NCT00000427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044482|NCT06576739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, Provider, and Statistician will be blinded|Pilot, Placebo-Controlled, Double Blinded, Randomized Controlled Trial|t|t|f|t
34044483|NCT01921322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects randomly assigned to undergo treatment using either the Paradigm 722 insulin pump or multiple daily insulin injections.||||
34044484|NCT03425084|NA|SINGLE_GROUP||OTHER||NONE||||||
34044485|NCT06574477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34044486|NCT00502112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044487|NCT01109160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044488|NCT00910143|||COHORT||RETROSPECTIVE|||||||
34044489|NCT01944878|||CASE_CONTROL||RETROSPECTIVE|||||||
34044490|NCT02313207|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34044491|NCT01073813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044492|NCT05330819|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044493|NCT02944695|||OTHER||PROSPECTIVE|||||||
34044494|NCT01780090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044495|NCT06187688|||COHORT||PROSPECTIVE|||||||
34044496|NCT01284348|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34044497|NCT06212414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044498|NCT03941054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044499|NCT00180609|||COHORT||PROSPECTIVE|||||||
34044500|NCT04806711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, controlled, parallel, longitudinal||||
34044501|NCT01967966|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044502|NCT04831411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044503|NCT06340841|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomized to one of four incentive conditions and receive rewards based on their completion of such activities. There are two main factors (Recipient x Restoration) that will create four distinct groups.||||
34044504|NCT02511938|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34044505|NCT01430754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044506|NCT01090349|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34044507|NCT00445172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044508|NCT06428123|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34044509|NCT00589615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044510|NCT02852135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34044511|NCT05992142|NA|SINGLE_GROUP||TREATMENT||NONE||transversal study||||
34044512|NCT01427348|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34044513|NCT01262287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044514|NCT06577389|||COHORT||PROSPECTIVE|||||||
34044515|NCT04453449|||CASE_CONTROL||PROSPECTIVE|||||||
34044516|NCT01399775|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044517|NCT00506324|||COHORT||PROSPECTIVE|||||||
34044518|NCT01473433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044519|NCT05633940|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044520|NCT00832572|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044521|NCT05213611|||COHORT||PROSPECTIVE|||||||
34044522|NCT02690818|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34044523|NCT05537584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044524|NCT05071482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044525|NCT04554901|NA|SINGLE_GROUP||TREATMENT||NONE||Blood samples will be collected from participants in 2 separate instances. Initially, a baseline VerifyNow P2Y12 PRU test assay, followed by a subsequent repeat test 2-week after a 2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars).||||
34044526|NCT05912296|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34044527|NCT03143985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044528|NCT04168112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Two cohorts of patients will be studied (10 patients each group). Cohort A: intracanalicular dexamethasone insert is placed on day of crosslinking (CXL); patients will still receive postoperative fluoroquinolone (or another class if allergy) antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye 4 times daily x 10 days).~Cohort B: Patients are placed on standard postoperative regimen of postoperative fluoroquinolone antibiotic eye drops with instructions for use (i.e. 1 drop in operative eye 4 times daily (QID) x 10 days) and Prednisolone acetate 1% ophthalmic solution tapered over 1 month in the following schedule: 4 times daily x1 week, three times daily (TID) x 1 week, twice daily (BID) x 1 week, and once daily (QD) x 1 week)."||||
34044529|NCT06242548|NA|SINGLE_GROUP||PREVENTION||NONE||a group of type 1 diabetes patients and to a group of controls||||
34044530|NCT01797887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044531|NCT02612623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044532|NCT02609971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34044533|NCT05838937|||COHORT||PROSPECTIVE|||||||
34044534|NCT02416609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044535|NCT01972243|||COHORT||PROSPECTIVE|||||||
34044536|NCT02678065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044537|NCT02914782|||COHORT||PROSPECTIVE|||||||
34044538|NCT06499038|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controled trial||||
34044539|NCT02329379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044540|NCT03466463|NA|SEQUENTIAL||OTHER||NONE||||||
34044541|NCT06065917|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044542|NCT03812016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044543|NCT04623099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|This randomized, controlled trial compares pharmacogenetically-guided and standard dosing of escitalopram in adolescents (12-17 years of age) with anxiety disorders. In this study, investigators will examine these two dosing strategies in terms of efficacy (Aim 1) and tolerability (Aim 2). Investigators will also evaluate the relationship between pharmacodynamic variables and treatment response.|t|f|t|f
34044544|NCT03991923|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044545|NCT05204680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044546|NCT04657029|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinded Assessors|In a cross-over design, each participant was pseudo-randomised to complete an intervention condition (Treadmill) or control condition (Rest) first, returning at least one week later (washout period) to complete the alternate condition. A minimum washout period of one week was used to allow for any physiological changes due to exercise to return to resting levels, but to minimise any stroke recovery-associated changes to function. Participants were asked to refrain from exercising in the 24 hours prior to their visit. At each visit, participants completed the sensorimotor adaptation task on two occasions, pre and post intervention, resulting in four assessment timepoints (PreControl, PostControl and PreTreadmill, PostTreadmill). The post intervention assessment aimed to commence within 15 minutes of completing the treadmill or rest condition.|f|f|f|t
34044547|NCT06011525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34044548|NCT01419392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34122928|NCT04137367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122929|NCT02706925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34122930|NCT01312207|||CASE_ONLY||RETROSPECTIVE|||||||
34122931|NCT02691026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122932|NCT02024412|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34122933|NCT06718309|NA|SINGLE_GROUP||TREATMENT||NONE||In this study, patients with surgically resectable locally advanced non-small cell lung cancer (stage II-IIIA and part of stage IIIB) (EGFR/ALK wild-type for adenocarcinoma patients) are enrolled. Eligible patients firstly receive one cycle of chemoimmunotherapy, followed by stereotactic body radiotherapy (SBRT) (8Gy\*3F) to the primary lung lesion and then continued with another two cycles of chemoimmunotherapy. Surgical treatment was performed within 4-6 weeks after the last chemoimmunotherapy. Immunotherapy continues until 1 year after surgery. Minimal residue lesion (MRD) are monitored at 5 timepoints during the treatment period.||||
34122934|NCT03751397|||COHORT||CROSS_SECTIONAL|||||||
34122935|NCT04937725|||CASE_CONTROL||PROSPECTIVE|||||||
34122936|NCT03509818|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||Description of the sample|t|f|f|f
34122937|NCT03733938|||COHORT||PROSPECTIVE|||||||
34122938|NCT05321459|||COHORT||PROSPECTIVE|||||||
34122939|NCT02065934|||||PROSPECTIVE|||||||
34122940|NCT04740580|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Placebo-controlled trial|t|t|t|f
34122941|NCT05698303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122942|NCT02062515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122943|NCT04868383|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122944|NCT00295789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122945|NCT05117814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122946|NCT04904107|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|EMT personnel will be blinded for the randomisation sequence.|It concerns an investigator initiated prospective 1:1 randomised clinical trial in chest pain patients in a pre-hospital setting. Patients will be randomised to (A, intervention group) a direct assessment of the modified HEART score (including POC high sensitive troponin measurement) by EMT personnel and refrainment of transport to the cardiac emergency department (ED) in cases of a low score or (B, control group) regular triage and hospital evaluation, taking place at the cardiac ED in the majority of cases.|f|t|t|f
34122947|NCT00363571|RANDOMIZED|CROSSOVER||ECT||DOUBLE||||||
34122948|NCT03323684|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34122949|NCT03672149|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||"1. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain treatment, pharmacokinetic, and safety data .~2. If cefazolin is not part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic, and safety data .~3. If a patient does not require any anti-microbial therapy, cefazolin will be given via the CRRT solution(s) to solely obtain pharmacokinetic and safety data."||||
34122950|NCT00421148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34122951|NCT01490034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34122952|NCT04824014|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122953|NCT06388252|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||Electrochemotherapy with intratumoural cysplatin is recommended for smaller (less than 3 cm) and fewer tumours (up to 10 lesions), while electrochemotherapy with intravenous bleomycin is preferable for multiple and larger tumours.||||
34122954|NCT03118336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122955|NCT02328521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122956|NCT03111316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122957|NCT06170151|||COHORT||PROSPECTIVE|||||||
34122958|NCT03307538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044549|NCT01337180|||COHORT||PROSPECTIVE|||||||
34044550|NCT06578598|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34044551|NCT01094158|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044552|NCT00313326|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34044553|NCT00154284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044554|NCT00747019|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34122959|NCT01630317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122960|NCT06717945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044555|NCT06346470|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34044556|NCT06574061|||COHORT||PROSPECTIVE|||||||
34044557|NCT05650684|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044558|NCT04519606|||CASE_CONTROL||PROSPECTIVE|||||||
34044559|NCT05131373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044560|NCT02035449|||COHORT||PROSPECTIVE|||||||
34044561|NCT00433589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044562|NCT05003310|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Multicenter study with 4 periods. Period 1 is a randomized, controlled double-blind period where participants are assigned randomly to either active or sham stimulation. During the open-label Periods 2 through 4, participants are assigned treatment based on responses to treatments in the prior period|t|t|t|t
34044563|NCT01202578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044564|NCT04335773|||CASE_CONTROL||PROSPECTIVE|||||||
34044565|NCT00405431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044566|NCT04088175|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, open label, 2-group, 4-period cross-over study in adult closed system ENDS consumers designed to evaluate puff topography parameters with use of JUUL ENDS products .||||
34044567|NCT04793308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34044568|NCT03163498|||COHORT||CROSS_SECTIONAL|||||||
34044569|NCT03779217|||COHORT||PROSPECTIVE|||||||
34044570|NCT02949440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044571|NCT04569435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044572|NCT00917176||CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044573|NCT03821454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044574|NCT05906615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044575|NCT01307592|NON_RANDOMIZED|||TREATMENT||NONE||||||
34044576|NCT03172923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessor is blinded to treatment given|randomised controlled trial|f|f|f|t
34044577|NCT01493674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044578|NCT03318497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The interim 18F FLT-PET/CT will be performed after the 2nd cycle of chemotherapy regimen, but before the commencement of 3rd cycle.~Clinical Follow Up: Standard of care clinical follow-up data will be collected up to 2 years following the end of chemotherapy."||||
34044579|NCT00004789||||TREATMENT||||||||
34044580|NCT04940754|NA|SINGLE_GROUP||TREATMENT||NONE||Use of an approved implant for expanded application||||
34044581|NCT02901834|||OTHER||PROSPECTIVE|||||||
34044582|NCT03564223|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34044583|NCT05378672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044584|NCT05435729|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Periods 1 and 2 in Part B will be conducted in a double-blinded manner. The subjects, all study staff including the investigator, drug concentration-measuring facility, drug residual amount-measuring facility, safety review team, and the Sponsor are kept blinded to the assignment of treatment during the period from the initiation of the study to database lock.||t|t|t|t
34044585|NCT06505707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044586|NCT04455412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||study divided into three interventions; Conventional ICSI (control group) was compared with LAD-ICSI (Study group 1) and LAT- ICSI (study group 2) in sibling oocytes. then Cases randomly selected for embryo transfer from each group|t|t|f|f
34044587|NCT00006351||||TREATMENT||||||||
34044588|NCT05091541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044589|NCT01204684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044590|NCT02147457|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044591|NCT01438892|||COHORT||PROSPECTIVE|||||||
34044592|NCT00447824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34044593|NCT00367731|||DEFINED_POPULATION||OTHER|||||||
34044594|NCT04646343|||OTHER||PROSPECTIVE|||||||
34044595|NCT02983188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044596|NCT04520997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044597|NCT01234870|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044598|NCT04143698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044599|NCT03805568|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34044600|NCT03515811|||OTHER||PROSPECTIVE|||||||
34044601|NCT03831113|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||dose reductions will alternate between 1 or 2 mg weekly (magnitude group) or 2 mg reductions every 1 or 2 weeks (frequency group)||||
34044602|NCT06575114|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044603|NCT04376580|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34044604|NCT01487122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044605|NCT05807919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and investigators will not know what study cohort participants have been randomized into.|Subjects meeting all eligibility criteria will be randomized in a 1:1 ratio to receive either the MD or the LFD for a four-week period.|t|f|t|f
34044606|NCT01558557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044607|NCT00005891||||TREATMENT||||||||
34044608|NCT02420730|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044609|NCT05847868|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34044610|NCT03322761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044611|NCT00229996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34044612|NCT00017082||||TREATMENT||||||||
34044613|NCT03076034|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Observational||||
34044614|NCT02230904|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34044615|NCT03782012|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Provide information about other parties who may be masked in the clinical trial,|This study will randomly select 300 from Storm Lake students in grades 5-8 (i.e., 75 students per grade) (see Table 1). Because of the short duration of the experiment (3 sessions), we estimate 20% attrition (n = 60 students). We will replace all students who exit from the sample within grade to ensure sufficiently power. Students will randomly be assigned within grade to one of two conditions: support versus no support.|t|f|f|t
33734640|NCT04617093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734641|NCT01848990|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33734642|NCT06232733|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|It is not possible to blind the participants or families to the study group allocation. Investigators will support delivery of the intervention.|Immediate or delayed intervention|f|f|f|t
33734643|NCT03266562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734644|NCT00200226|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33734645|NCT02492451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734646|NCT01996969|NA|SINGLE_GROUP||SCREENING||NONE||||||
33734647|NCT05015218|||COHORT||PROSPECTIVE|||||||
33734648|NCT04858672|||COHORT||PROSPECTIVE|||||||
33734649|NCT02919670|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734650|NCT05920941|NA|SINGLE_GROUP||OTHER||NONE||||||
33734651|NCT03069027|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33734652|NCT05459493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734653|NCT06078631|||COHORT||PROSPECTIVE|||||||
33734654|NCT05230251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734655|NCT00527813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734656|NCT02526992|NA|SINGLE_GROUP||||NONE||||||
33734657|NCT05273112|||COHORT||PROSPECTIVE|||||||
33734658|NCT02483234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734659|NCT05041088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734660|NCT01857258|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33734661|NCT03341624|NA|SINGLE_GROUP||SCREENING||NONE||||||
33734662|NCT01202123|||CASE_ONLY||PROSPECTIVE|||||||
33734663|NCT04458064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33734664|NCT00323128|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734665|NCT00896142|||COHORT||PROSPECTIVE|||||||
33734666|NCT00029731|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33734667|NCT04803929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734668|NCT02360618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734669|NCT04140747|||COHORT||PROSPECTIVE|||||||
33734670|NCT00248573|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734671|NCT03126981|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33734672|NCT04047290|NA|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment Initially, a single-subject cohort will be enrolled at the protocol starting dose of AK112 every 2 weeks (Q2W). Dose escalation will proceed to the next main dose level according to the 3+3+3 dose-escalation procedure until the MTD is reached. Dose expansion phase of the study will be initiated at the Sponsor's discretion at the dose level and treatment schedule which was established as the recommended Phase 2 dose (RP2D) in the dose-escalation phase.||||
33734673|NCT03668652|RANDOMIZED|PARALLEL||TREATMENT||NONE|Focal treatment of prostate cancer using HIFU compared to Radical prostatectomy.|Randomized controlled trial.||||
33734674|NCT04239534|NA|SINGLE_GROUP||TREATMENT||NONE||Continued Access Protocol (CAP), prospective, multi-center, single arm study.||||
33734675|NCT02215070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734676|NCT04996303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734677|NCT02433834|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33734678|NCT02948842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734679|NCT00225355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33734680|NCT02679586|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734681|NCT03899610|NA|SINGLE_GROUP||TREATMENT||NONE||This study is single arm phase II study to evaluate efficacy and safety of durvalumab and tremelimumab and chemotherapy in treatment-naïve clinical stage IIIC/IV ovarian cancer.||||
33734682|NCT04971031|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734683|NCT04103294|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34044616|NCT05345613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34044617|NCT05424510|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In all fluid responsive patients an IV line will be placed, regardless of group allocation into FB+ or FB-. In order to maintain masking of the treating anesthesiologist, patients will be advised regarding the importance to not disclose whether they received a fluid bolus or not to their anesthetist.|Based on the IVC PoCUS exam, volume responsive patients will be randomized into two equal groups: half will receive a fluid bolus (FB+) and half will not (FB-). Patients in the FB+ group will receive a single bolus of 500 ml of Ringer's Lactate over 5-10 minutes with an additional IVC scan at the end of the infusion to record the change in IVC-CI.|f|t|f|f
33734684|NCT05404516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734685|NCT04555135|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Random allocation stratified by gastroenterologist 50% randomized to colonoscopy procedure with device and 50% randomized to colonoscopy procedure without device|t|f|f|f
33734686|NCT04420702|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|-Dr. Kim will be blinded to the DBSI results at the time of biopsy, but will have the conventional MRI interpretation available||f|f|t|f
33734687|NCT01800071||||TREATMENT||||||||
33734688|NCT00594256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734689|NCT02089750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33734690|NCT02857127|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734691|NCT04539028|||COHORT||PROSPECTIVE|||||||
33734692|NCT03444142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734693|NCT06310434|||COHORT||PROSPECTIVE|||||||
33734694|NCT05512221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734695|NCT00501540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734696|NCT05440682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734697|NCT00364897|||DEFINED_POPULATION||PROSPECTIVE|||||||
33734698|NCT02986204|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734699|NCT00827372|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33734700|NCT05040763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The primary objective of this study is to determine whether buccal swabs analyzed with the Abbott ID Now perform acceptably compared to standard of care COVID-19 swabs||||
33734701|NCT02167581|||COHORT|||||||||
33734702|NCT00349596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734703|NCT00802217|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044618|NCT00166972|||NATURAL_HISTORY||OTHER|||||||
34044619|NCT02533050|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044620|NCT01266291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044621|NCT05750602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34044622|NCT03605121|||COHORT||RETROSPECTIVE|||||||
34044623|NCT03754868|||COHORT||PROSPECTIVE|||||||
34044624|NCT00604591|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34044625|NCT01934049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044626|NCT01873404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34122961|NCT05346328|NA|SINGLE_GROUP||TREATMENT||NONE||This study adopts an open research design and selects patients with refractory HER2-positive unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug treatment. The patients who met the enrollment conditions were treated with injection of A166.||||
34122962|NCT01474304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34122963|NCT06400628|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|participants and investigator were informed about the expected outcomes. However, care providers and outcome assessor were masked to overcome any associated bias|Participants will be randomly selected to be included in the study. Once included, baseline data will be collected from the participants on the date of inclusion, which will serve as the control group or Arm 1 data. Subsequently, all participants will receive an educational intervention, consisting of one-to-one nurse-led multi-component chronic disease self-management education (CDSME), for four consecutive months. During this time, the indicated variables, including blood pressure, pulse rate, weight, and complete blood count, will be measured during monthly visits. Finally, the same variables of the base line variables will be measured from the participants and serve as the second arm (arm2). The study aims to recruit 166 patients with rheumatic heart disease (RHD) from the Jimma Medical Center cardiac clinic.|f|t|f|t
34122964|NCT01462071|||COHORT||PROSPECTIVE|||||||
34122965|NCT03314610|||COHORT||PROSPECTIVE|||||||
34122966|NCT06106893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122967|NCT06460870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122968|NCT04541082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122969|NCT02619747|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34122970|NCT05124717|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33813791|NCT03848741|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||"Participants will be randomized to 1 of 4, 12-week interventions. In a double-blinded fashion, participants will be randomized to consume either placebo or HMB + VitD supplementation.~Group 1 will serve as a non-exercise control with placebo; Group 2 will serve as a non-exercise control with β-hydroxy β-methylbutyrate + Vitamin D; Group 3 will complete resistance exercise training with placebo; Group 4 will complete resistance exercise training with β-hydroxy β-methylbutyrate + Vitamin D"|t|f|t|t
33813792|NCT05112302|||COHORT||PROSPECTIVE|||||||
33813793|NCT01207154|||COHORT||PROSPECTIVE|||||||
33813794|NCT06157099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813795|NCT01073722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33813796|NCT04922359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34122971|NCT04933292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122972|NCT02768285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122973|NCT02213068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122974|NCT00848419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33813797|NCT03137732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the intervention that they are randomized to intraoperatively.||t|f|f|f
34122975|NCT04838184|||CASE_ONLY||PROSPECTIVE|||||||
33813798|NCT02312258|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813799|NCT06341504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Participants are recruited under the false pretense of evaluating the realism of a gambling session in a laboratory replicating a bar environment. While the participants in the experimental group should notice the novel prevention messages, before debriefing, for all they know, there are no groups to be assigned to. Therefore they would not be aware, that there are two different groups, nor that this study tests the effects of prevention pop-up messages.~Note that masking becomes open label after debriefing. Indeed, after being informed of the true goals of this study, participants will easily be able to determine in which group they were assigned based on what occured during their gambling session. Though, gambling behaviours are recorded before debriefing and won't be affected by unmasking.~There is no functional way to mask group assignment to the members of the research team. However, the randomization procedure assures that allocation is purely random."|"Stratified block randomization assignment. Blocks are size 4 and strata are divided on problem gambling severity using PGSI categories. Two conditions:~* Experimental: Regular gambling session + Prevention pop-up messages~* Active Comparator: Regular gambling session~Three assessment phases:~* Pre-experiment. Telephone interview before the gambling session. Measures baseline characteristics and schedule the gambling session. Usually done within a couple of days following an application to participate.~* Experiment. Gambling session in the laboratory. Behaviour is continuously measured starting with the first time the participant puts money in the EGM to participant choosing to end their gambling session. Duration is limited to 2 hrs (unbeknownst to participant). Session is scheduled days to weeks after the Pre-experiment, depending on participant's availability.~* Post-experiment. Debriefing and post-experiment interview. Done right after the gambling session is ended."|t|f|f|f
33813800|NCT06092307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813801|NCT02386085|||COHORT||PROSPECTIVE|||||||
34044627|NCT01996254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044628|NCT01052194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044629|NCT06283836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34122976|NCT04231071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34122977|NCT03719807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34122978|NCT04145076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and investigators are blinded to the drug condition.|Repeated-measures cross-over study, where each subject receives each of three pharmacological probes once (order of drug administration was pseudorandomised).|t|f|t|f
34122979|NCT04871477|||CASE_ONLY||CROSS_SECTIONAL|||||||
34122980|NCT05031143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122981|NCT03930589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient outcomes and markers blinded to randomization arm|Remote ischemic condition versus standard of care|f|f|f|t
34122982|NCT00988793|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122983|NCT03571932|||OTHER||OTHER|||||||
33734704|NCT03643822|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Patients who give written informed consent will be randomly assigned on the day of surgery to either of the four study groups using a computer-generated block randomization schedule in blocks of varying sizes. Group allocation will not be disclosed to the anesthesiologist performing the ACB. An anesthesia assistant will receive an opaque envelope containing the result of randomization, and will prepare the block study solution in identical syringes. The patient receiving ACB will also be blinded to the study solution injected. Furthermore, outcome assessment will be performed by a blinded research assistant.|There will be prospective,randomized,controlled,parallel group,factorial,1:1:1:1 allocation,operator,patient and assessor blinded clinical trial.|t|f|f|t
34122984|NCT04659590|||COHORT||PROSPECTIVE|||||||
33734705|NCT02200705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734706|NCT02610868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734707|NCT04232163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734708|NCT01236404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734709|NCT06257784|||COHORT||PROSPECTIVE|||||||
33734710|NCT04631497|||COHORT||PROSPECTIVE|||||||
33734711|NCT05268250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734712|NCT01433263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734713|NCT03394703|||COHORT||PROSPECTIVE|||||||
33734714|NCT03560713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734715|NCT01888289|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734716|NCT01295606|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734717|NCT04794543|||CASE_CONTROL||PROSPECTIVE|||||||
33734718|NCT04947397|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734719|NCT06108856|||CASE_ONLY||CROSS_SECTIONAL|||||||
33734720|NCT02778581|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33734721|NCT04877262|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study is a randomized, crossover, controlled feeding study design consisting of two 9-d weight maintenance diet periods separated by at least 3 weeks.||||
33734722|NCT00626262|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734723|NCT00989729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734724|NCT05862857|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734725|NCT02845661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734726|NCT05232448|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assesors are blinded to randomization|Randomized Controlled Trial|f|f|f|t
33734727|NCT06073405|||COHORT||PROSPECTIVE|||||||
33813802|NCT04413175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813803|NCT03121417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813804|NCT02690792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813805|NCT00409903|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33813806|NCT02070640|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813807|NCT00886548|||CASE_ONLY||PROSPECTIVE|||||||
33813808|NCT05504135|||COHORT||PROSPECTIVE|||||||
33813809|NCT00005654|RANDOMIZED|||TREATMENT||DOUBLE||||||
33813810|NCT02495402|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33813811|NCT02876653|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33734728|NCT01491321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734729|NCT05388890|||COHORT||OTHER|||||||
33734730|NCT00281840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734731|NCT03314948|||OTHER||PROSPECTIVE|||||||
33734732|NCT02451566|||COHORT||PROSPECTIVE|||||||
33734733|NCT06250101|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Caregivers are not informed of their child's treatment target until after treatment concludes.~The clinician measuring retention of learning has not treated the children"|Hybrid single subject/group design|f|t|f|t
33734734|NCT02381080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734735|NCT03722017|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participant and providers involved in their care will not be masked to the intervention, as there is participation of both groups in the deprescribing protocol discussions.|"The investigators will ascertain for each medication: (1) Indication; (2) Deprescribing rationale (i.e., stopping or reducing dose) for each medication.~Deprescribing Recommendations will be specified as: (1) Stop prior to hospital discharge, no monitoring; (2) Stop prior to hospital discharge with monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until stopped; (5) Reduce to lower dose without monitoring; (6) Reduce to lower dose with monitoring. Deprescribing will begin prior to hospital discharge.~The investigators will incorporate Veteran preferences, communicate with all providers involved in prescribing, create final deprescribing actions, and do enhanced hospital discharge communication."||||
33734736|NCT05159843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"To achieve a well balance in the randomization procedure block randomization of size 10 (with five experimental and five control) in seal envelops will be used. It will use the computerized randomization programme to generate the randomization programme to generate the randomization list using with block size of 10. A team member who will not be involved in recruitment and data collection will prepare the sealed envelopes according to the generated randomization list. After a patient is registered, a unique patient ID will be assigned to the patient based on the sequence of his/her enrolment. The envelope according to the patient's ID will be opened on site and the patient will be allocated into either one of the two groups based on the randomization list the treatment indicated.~Both patient and nurses offering therapeutic education will be blinded in this study and they will not know the objectives of the investigation."|A two-group randomized controlled trial will be used in this project. Participants in the experimental group will undergo four-session health education program, while the participants in the control group will receive the existing standard care provided by the hospital. Measurements will be conducted at the baseline prior to the intervention and at 1 an 3 months from the intervention.|t|t|f|f
33813812|NCT01577875|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813813|NCT03878407|||OTHER||PROSPECTIVE|||||||
33813814|NCT02500433|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813815|NCT00605137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813816|NCT05661240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122985|NCT02171689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122986|NCT01163396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34122987|NCT04581785|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33734737|NCT01844635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734738|NCT00225706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734739|NCT05931848|RANDOMIZED|PARALLEL||TREATMENT||NONE||clinical research/randomized controlled trial||||
33734740|NCT01296724|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33734741|NCT06176833|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and outcome assessor will have no knowledge of groups, cannot blind participants as they know when they will be receiving the additional training|Participants will be randomized into one of 4 intervention groups, based around if and when additional walking training is given following injury|f|f|t|t
33734742|NCT00343317|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33734743|NCT02490137|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33734744|NCT01985737|||CASE_CONTROL||PROSPECTIVE|||||||
33734745|NCT01907633|||CASE_CONTROL||RETROSPECTIVE|||||||
33734746|NCT01061554|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33734747|NCT03929835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734748|NCT06659224|||COHORT||RETROSPECTIVE|||||||
33734749|NCT03697200|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33734750|NCT03675958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluator does not know the assignment of the participants to the intervention group.|A randomized experimental study with two intervention groups will be performed. Control group (GS): Stretching and experimental group: (GJPS + S): Johnstone´s Pressure Splint plus Stretching.|f|f|t|f
33734751|NCT05651009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blinded study (patient and research nurse)|Randomized controlled trial|t|f|f|f
33734752|NCT02268981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734753|NCT03126799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734754|NCT05353192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734755|NCT00259558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33734756|NCT01322373|||CASE_CONTROL||PROSPECTIVE|||||||
33734757|NCT06046638|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33734758|NCT05815446|||CASE_ONLY||CROSS_SECTIONAL|||||||
33734759|NCT04614766|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who do not meet eligibility criteria for the combined therapy will be asked to participate in the active comparator, which is single agent Lutathera administered as per FDA guidelines.||||
33734760|NCT05440357|||CASE_ONLY||PROSPECTIVE|||||||
33734761|NCT03344185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were not told which diet they were consuming each day.|All participants took part in both diet conditions|t|f|f|f
33813817|NCT03542604|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will not be blinded to the intervention assignment. However, data collection of anthropometric measurements (including height, weight, hip and waist circumference) will be done by a study member blinded to the randomization. Since participants will be aware of their intervention assignment, there are no anticipated circumstances for breaking the blinding or planned procedures for breaking the blinding.|A total of 30 participants will be randomized to either cognitive-behavioral treatment for insomnia with behavioral weight loss (CBT-I+BWL) or a sleep education control condition with behavioral weight loss (EDU+BWL). The EDU group will have study sessions spread out in a similar fashion to the CBT-I group, and clinical outcomes will be compared between groups at baseline, 8 weeks (after the CBT-I or EDU program) and at 3 and 6 months after starting BWL. The primary outcome will be % total weight loss. Additionally, eating behaviors, physical activity, and sleep parameters will be carefully assessed.|f|t|f|t
33813818|NCT01453764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813819|NCT04631874|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33813820|NCT03845088|||COHORT||PROSPECTIVE|||||||
33813821|NCT00297713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813822|NCT06307951|||COHORT||CROSS_SECTIONAL|||||||
33813823|NCT05936463|||COHORT||PROSPECTIVE|||||||
33813824|NCT02727998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813825|NCT05272254|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded study|At baseline, following oral rehabilitation in the operating room {10% (PVPI + Fluoride Varnish (FV)} will be compared to the current standard of care (Placebo + FV). Study participants will be followed for approximately 24 months post-baseline. The study interventions post-baseline will be administered at 3, 6, 9, 12, 15, 18, and 21 months.|t|t|t|t
33813826|NCT00000892||||TREATMENT||||||||
33813827|NCT05790135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813828|NCT05668845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient and the independent investigator assessing and recording the patient's data will be blinded to treatment arm assignments.|randomized clinical trial|t|f|t|f
33813829|NCT00244556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34122988|NCT02379208|||COHORT||PROSPECTIVE|||||||
34122989|NCT00446329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34122990|NCT01103440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122991|NCT01649713|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34122992|NCT00272220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734762|NCT02652624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734763|NCT05288205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33734764|NCT03142503|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33734765|NCT04409028|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33734766|NCT02138851|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33734767|NCT04230642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734768|NCT02248129|||COHORT||PROSPECTIVE|||||||
33734769|NCT04828655|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33734770|NCT04471584|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33813830|NCT01634802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33813831|NCT01867879|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33813832|NCT01595425|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813833|NCT03447288|||COHORT||PROSPECTIVE|||||||
33813834|NCT05553730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||multi-centre, cluster randomized controlled trial|f|f|f|t
33813835|NCT05351788|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34122993|NCT05357833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34122994|NCT05141838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734771|NCT06437405|RANDOMIZED|PARALLEL||OTHER||SINGLE|participants will be randomly assigned to the liquid vinegar group or the vinegar pill group (control)|12-week randomized controlled trial preceded by a 3-week control period|t|f|f|f
33734772|NCT04926675|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional study of adding money advice to psychological treatment compared to usual treatment from routine data collection||||
33734773|NCT05605067|||CASE_ONLY||CROSS_SECTIONAL|||||||
33734774|NCT03863366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants will be randomly allocated to one of two groups (prucalopride or placebo). Participants in the prucalopride group will receive 1mg of the drug. Participants in the placebo group will receive a lactose placebo. Note that the study is not assessing the safety or efficacy of prucalopride, rather it is using prucalopride to assess the behavioural and neural effects of 5-HT4 partial agonists.|t|f|t|t
33734775|NCT03777189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734776|NCT05829603|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are blinded regarding their allocated study condition as well as the order of doses administered. However, participants are informed about the range and the number of different dosages administered.|Each participants will be randomized into one of two sequences. Each sequence consists of six study days with a minimum of 1 day between each study day. The differences between the sequences are a) the order of dosages administered to minimize confounding effects through expectancy and b) a study day containing only one of the two active ingredients, thus covering each combination in a factorial, cross-over design.|t|f|f|f
33734777|NCT02359292|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33734778|NCT03026673|||COHORT||RETROSPECTIVE|||||||
33734779|NCT02309385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734780|NCT00414050|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33734781|NCT02505243|||COHORT||OTHER|||||||
33734782|NCT06203405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734783|NCT04251533|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734784|NCT04214028|||COHORT||PROSPECTIVE|||||||
33734785|NCT05676034|NA|SINGLE_GROUP||TREATMENT||NONE||A 96 week open-label treatment period of AMX0035 administered twice daily||||
33734786|NCT05784701|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33734787|NCT03620851|||COHORT||RETROSPECTIVE|||||||
33734788|NCT04863976|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734789|NCT00983814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734790|NCT03228810|||CASE_ONLY||PROSPECTIVE|||||||
33813836|NCT06222086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.|Parallel|t|f|t|t
33813837|NCT02978040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is open label. Participant and Investigators will be not masked to randomly assigned treatments. An independent blinded committee will assess clinical adverse events.||f|f|f|t
33813838|NCT04062383|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33813839|NCT02590770|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813840|NCT05520411|NA|SINGLE_GROUP||OTHER||NONE||||||
33813841|NCT04929444|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized community trial, by clusters (CG /IG), multicenter and open, taking as unit of allocation the primary care team (PCT). The professionals of the PCT that are in IG would receive the training at the beginning of the study and those of the control group will be offered after the conclusion of the same||||
33813842|NCT04267549|NA|SINGLE_GROUP||TREATMENT||NONE||eligible patients will be given treatment of sintilimab, apatinib and chemotherapy (nab-paclitaxel) every 3 weeks||||
33813843|NCT03909074|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33813844|NCT02978066|||COHORT||PROSPECTIVE|||||||
33813845|NCT01923402|||COHORT||CROSS_SECTIONAL|||||||
33813846|NCT05226728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813847|NCT00870168||||TREATMENT||||||||
33813848|NCT00209885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33813849|NCT04364399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33813850|NCT01393600|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33813851|NCT03406507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813852|NCT04910711|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33813853|NCT05463302|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|participants receive two similar blankets, while one of them is real and one is sham but they are blind to which one is which.|it is two period design with one cross over|t|f|f|f
33813854|NCT02060175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813855|NCT04439591|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33813856|NCT04202263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each subject will simultaneously be tested for responses to placebo (0%), 1%, 2% and 3% minocycline cream responses to induced allergic skin inflammation.|t|f|f|f
33813857|NCT03486756|NA|SINGLE_GROUP||TREATMENT||NONE||This is an uncontrolled feasibility study with one arm.||||
33813858|NCT03867526|||CASE_ONLY||PROSPECTIVE|||||||
33813859|NCT04553809|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34122995|NCT00547963|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33734791|NCT05848635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33734792|NCT04917302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734793|NCT03101709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734794|NCT05244031|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33734795|NCT00667238|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33734796|NCT05493267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734797|NCT01296958|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34122996|NCT03584347|NA|SINGLE_GROUP||OTHER||NONE||||||
34122997|NCT04118725|NA|SINGLE_GROUP||SCREENING||NONE||||||
34122998|NCT02351011|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34122999|NCT01587248|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123000|NCT01484457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123001|NCT02199483|||COHORT||PROSPECTIVE|||||||
34123002|NCT04559061|||CASE_ONLY||RETROSPECTIVE|||||||
33734798|NCT05954234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734799|NCT01324375|||COHORT||PROSPECTIVE|||||||
33734800|NCT04388579|||COHORT||CROSS_SECTIONAL|||||||
33734801|NCT01632800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33734802|NCT06663527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734803|NCT03609294|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33734804|NCT02729922|||COHORT||PROSPECTIVE|||||||
33734805|NCT06663111|||COHORT||PROSPECTIVE|||||||
33734806|NCT02386202|||||PROSPECTIVE|||||||
33734807|NCT05253482|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33734808|NCT05849402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734809|NCT03135756|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734810|NCT04226079|||CASE_CONTROL||PROSPECTIVE|||||||
33734811|NCT04115358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33734812|NCT01512719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734813|NCT01867034|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734814|NCT01511380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734815|NCT03078998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734816|NCT05524402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734817|NCT01830140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734818|NCT03226067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study: the Sponsor, subjects, investigator staff, persons performing the assessments and data reviewers and statisticians will remain blinded to the identity of the study treatments.|This will be a double-blind, randomized, placebo-controlled, multicenter, parallel group phase 2 trial. A total of 102 subjects will be randomized and allocated to placebo or one of the 2 active treatment arms, according to a 1:1:1 randomization ratio, stratified at study entry by disease severity defined as baseline serum gamma glutamyl transferase (GGT) \< 2.5 x ULN or ≥ 2.5 x ULN). Accordingly, approximately 34 subjects will be allocated to each of the 3 treatment arms.|t|t|t|f
33734819|NCT00968110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734820|NCT05403970|||CASE_ONLY||PROSPECTIVE|||||||
33734821|NCT03794765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734822|NCT01993914|||COHORT||CROSS_SECTIONAL|||||||
33734823|NCT00810121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734824|NCT02881814|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734825|NCT05406544|||CASE_ONLY||PROSPECTIVE|||||||
33734826|NCT06067594|||CASE_CONTROL||PROSPECTIVE|||||||
33734827|NCT02582840|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33734828|NCT02164851|||CASE_ONLY||PROSPECTIVE|||||||
33734829|NCT02612207|||OTHER||PROSPECTIVE|||||||
33734830|NCT00427804|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734831|NCT01281488|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33734832|NCT03643523|||COHORT||PROSPECTIVE|||||||
33734833|NCT00651482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734834|NCT04414384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients are randomized to either the investigational group (abdominal binder) or control group (no abdominal binder). Those two groups are then both given step counters and their steps are recorded over a two week period.|f|f|f|t
33734835|NCT05911620|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33734836|NCT04160299|NA|SINGLE_GROUP||OTHER||NONE||Older adults with Mild Cognitive Impairments, MCI.||||
33734837|NCT00749424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734838|NCT02421458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734839|NCT04844229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734840|NCT00117091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734841|NCT02268097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734842|NCT01500824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734843|NCT06286384|||OTHER||PROSPECTIVE|||||||
33734844|NCT01840670|||CASE_ONLY||PROSPECTIVE|||||||
33734845|NCT03168347|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33734846|NCT03259711|||CASE_ONLY||RETROSPECTIVE|||||||
33734847|NCT03081416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo controlled|Two arm-Randomized placebo controlled|t|f|f|f
33813860|NCT04211194|||COHORT||RETROSPECTIVE|||||||
33813861|NCT02806752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33813862|NCT03654482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813863|NCT05894616|||COHORT||PROSPECTIVE|||||||
33813864|NCT03867656|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||The study is a crossover study with the following interventions: GLP-2, GIP, and placebo.|t|f|f|f
33813865|NCT04690309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813866|NCT06067295|||COHORT||PROSPECTIVE|||||||
33813867|NCT05427942|||COHORT||PROSPECTIVE|||||||
33813868|NCT04794465|||COHORT||PROSPECTIVE|||||||
33813869|NCT01521702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813870|NCT01691404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33813871|NCT02676778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813872|NCT05917158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813873|NCT04251845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33813874|NCT01750411|||COHORT||PROSPECTIVE|||||||
33813875|NCT04917315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind||t|f|t|f
33813876|NCT03754166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813877|NCT02124304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813878|NCT00268697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813879|NCT02994498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123003|NCT01736033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33813880|NCT01465399|RANDOMIZED|PARALLEL||TREATMENT||||||||
33813881|NCT05843526|RANDOMIZED|PARALLEL||PREVENTION||NONE|Patient was allocated to a number. The collected samples were assigned to a reference number|The study included 69 implants divided into 3 groups. The 1st control group with titanium abutments, a second test group on dental resin (Optibond ™ FL, Kerr Dental) and a last test group on polyetheretherketone (PEEK).||||
33813882|NCT02713594|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813883|NCT04851197|RANDOMIZED|PARALLEL||SCREENING||NONE||experimental study with pretest posttest control group||||
33813884|NCT01848132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123004|NCT00700622|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123005|NCT00441766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734848|NCT03778970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will be submitted to Pain Neuroscience Education or Self-Management Education plus movement control exercises. They will not be aware of the education approach they will receive. The assessors will also not be aware whether the participant received Pain Neuroscience Education or Self-Management Education.|Randomized controlled clinical trial, superiority trial|t|f|f|t
33734849|NCT05545852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734850|NCT03683134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33734851|NCT02507713|||CASE_CONTROL||RETROSPECTIVE|||||||
33734852|NCT00062426|RANDOMIZED|||TREATMENT||NONE||||||
33734853|NCT01502722|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33734854|NCT01349283|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33734855|NCT00192452|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33734856|NCT00134108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734857|NCT04139785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||The study will follow a two-armed randomised controlled, single-blind, parallel group, wait-list control design. Individuals with mild-moderate symptoms of depression who do not have a diagnosis of depression are invited to participate|f|f|f|t
33734858|NCT06620237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734859|NCT03318614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (2.5 x 109 cfu/g per sachet) (Morinaga Milk Industry Co. Ltd., Japan) to consume daily for three months in addition to advice of good hygiene and sanitation practices. No drug intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.||||
33734860|NCT05793385|||OTHER||RETROSPECTIVE|||||||
33734861|NCT02709395|NA|SINGLE_GROUP||OTHER||NONE||||||
33734862|NCT05638555|||OTHER||OTHER|||||||
33734863|NCT01461096|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33734864|NCT04257578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734865|NCT04298528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734866|NCT04713384|NA|SINGLE_GROUP||TREATMENT||NONE||"20 elderly subjects. Or these 4 healthy age-matched volunteers for usability, and 8 elderly stroke survivors to determine technology acceptance and clinical benefit to motor, cognitive and emotive function, under remote rehabilitation conditions. We will also recruit their 8 caregivers so to have better feedback in changes they observe in the stroke survivors and any technology issues. Among them, one patient dropped, 7 patients (and their caregivers) completed the study. The subjects in this feasibility study will have UE motor impairments, normal cognition or have Mild Cognitive Impairment (MCI).~Pre- and Post-intervention standardized evaluations will be used to determine benefit. Subjective evaluations and adherence to protocol will indicate acceptance of the technology.~Each session of game exercises will store performance data, which will be monitored remotely."||||
33734867|NCT05600569|||COHORT||PROSPECTIVE|||||||
33734868|NCT00343187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33734869|NCT04266457|||COHORT||CROSS_SECTIONAL|||||||
33734870|NCT01992237|||CASE_ONLY||PROSPECTIVE|||||||
33734871|NCT02800304|||COHORT||PROSPECTIVE|||||||
33734872|NCT01403103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734873|NCT03040258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734874|NCT00008346|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33734875|NCT02317159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734876|NCT05877586|NA|SINGLE_GROUP||OTHER||NONE||Each caregiver will receive a unique invitation code to use the CLARE app. The study team will guide the caregiver through the features of the application. CLARE will provide caregiver training and support up to 7 days after hospital discharge.||||
33734877|NCT05190458|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33734878|NCT02645994|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33734879|NCT06654726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734880|NCT01061749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734881|NCT04835402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734882|NCT04390152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patient code will be stored in sealed, opaque envelops with their respective codification. These envelops will be stored in Clinica Somer's Research Unit and the only person with access permission will be the pharmaceutical chemist in charge. Treatment delivery (MSC or placebo) will also be in charge of the chemist, guaranteeing blinding of patient and healthcare professionals. Data analysis will be done by people blind to the treatment received by each patient.||t|t|t|t
33734883|NCT03390907|NA|SINGLE_GROUP||TREATMENT||NONE|Following Standard EMR all patients will undergo adjuvant Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.|This is a pilot study design in which patients with non-pedunculated large polyps ≥ 20mm undergoing EMR will be recruited. Following standard EMR all patients will undergo adjuvant Hybrid Argon Plasma Coagulation (APC) of the base edges of the polypectomy site to fulgurate any potential microscopic residual disease.||||
33734884|NCT01534468|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734885|NCT02212730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734886|NCT03111992|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is comprised of 3 treatment arms:~* Single agent CJM112 (Arm A)~* A fixed dose of PDR001 in combination with CJM112 (Arm B)~* A fixed dose of PDR001 in combination with LCL161 (Arm C)~Patients may switch from treatment on Arm A to the corresponding CJM112 dose level on Arm B at the time of disease progression if that dose level has been declared safe, and if patients do not have any DLTs on single agent CJM112. Otherwise, patients will switch to a lower dose level that has been declared safe. No other cross-over between treatment arms is allowed."||||
33734887|NCT01752140|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123006|NCT00888225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123007|NCT00212836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123008|NCT03597386|||COHORT||PROSPECTIVE|||||||
34123009|NCT05035459|||COHORT||PROSPECTIVE|||||||
34123010|NCT00696033|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33813885|NCT04379310|||COHORT||RETROSPECTIVE|||||||
33813886|NCT03823690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Recruited patients would not be informed of the type of treatment that was received.|The patients would be randomized to either EUS-guided balloon-occluded gastrojejunostomy bypass (EPASS) or uncovered duodenal stent after cannulation of the obstruction site is achieved with the guide-wire.|t|f|f|f
33813887|NCT00213317|||CASE_CONTROL||PROSPECTIVE|||||||
33813888|NCT04127513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|same vehicle base ingredients, colour, smell, and packaging||t|t|t|f
33813889|NCT00863070|||COHORT||PROSPECTIVE|||||||
33813890|NCT03316170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813891|NCT00005635|RANDOMIZED|||TREATMENT||||||||
33813892|NCT01849523|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813893|NCT02035345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33813894|NCT05193175|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33734888|NCT01282424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813895|NCT02825550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813896|NCT00376324|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813897|NCT03214614|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33813898|NCT05792683|RANDOMIZED|PARALLEL||TREATMENT||NONE||ramdomized control trail||||
33813899|NCT04873986|||OTHER||PROSPECTIVE|||||||
33813900|NCT01517282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734889|NCT01280188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734890|NCT02851238|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33734891|NCT01501812|||CASE_CONTROL||PROSPECTIVE|||||||
33734892|NCT05424471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734893|NCT04541758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734894|NCT03734848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33734895|NCT02892981|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33734896|NCT04216732|||COHORT||PROSPECTIVE|||||||
33734897|NCT03643003|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will engage in a music therapy condition of interest, and a non-music, verbal discussion comparison condition. The order is randomly assigned and counterbalanced across nursing homes, and all participants complete both conditions.||||
33734898|NCT02602405|||COHORT||RETROSPECTIVE|||||||
33734899|NCT04368962|||COHORT||PROSPECTIVE|||||||
33734900|NCT03678012|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The study dentist, specimen/sample analysis technicians and the statistician will be blinded to the product allocation of subjects.|This will be a randomized, crossover, single blind in situ study with three test periods utilizing 16 subjects. The subjects in this study are lower partial denture wearers who have already had a study partial denture made for them as a part of a partial denture panel under 14-I-098 (IRB # 1407637739) or who will wear their own lower partial denture which was previously approved as part of the panel. The study partial dentures or personal partial dentures can house the specimen holders in two hollowed out areas of the buccal surface of two posterior denture teeth. The subjects will wear the lower partial dentures with enamel specimens in place for three consecutive 14-day study periods.|f|t|t|t
33734901|NCT04440293|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33734902|NCT02225964|||COHORT||PROSPECTIVE|||||||
33734903|NCT00796965|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|f|t|t
33813901|NCT03645161|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33813902|NCT03603691|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|the outcome assessors will be blinded for the results of other assessors.|Prospective, cross-sectional and test-retest|f|f|f|t
33813903|NCT03713229|||COHORT||PROSPECTIVE|||||||
34123011|NCT06199765|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Control group will be given materials regarding patient safety as masking. Patient safety will have some element on needlestick and injury prevention.|All house officers who were eligible and consented, who participated in cross sectional study were included into intervention group until the required sample size was achieved. The same numbers of officers, eligible and consented were included into control group. For intervention, only educational intervention will be given which consist of lecture, demonstration, and role play. After that, data collection will be given right after the intervention completion and 4 weeks after that using self administered questionnaire. The same will be applied to the control group which data collection will be done right masking and 4 weeks later.|t|f|f|f
33734904|NCT02516124|||COHORT||PROSPECTIVE|||||||
33734905|NCT01814176|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734906|NCT03555526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734907|NCT01945385|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33734908|NCT01878604|||CASE_ONLY||RETROSPECTIVE|||||||
33734909|NCT02094859|||||PROSPECTIVE|||||||
33734910|NCT01611324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734911|NCT04122248|||COHORT||PROSPECTIVE|||||||
33813904|NCT03080337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33813905|NCT03837015|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813906|NCT03584282|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The investigators will randomly assign 10 participants to each arm: 1) standard of care, 2) text messaging only, 3) peer navigation only, and 4) text messaging and peer navigation.||||
33813907|NCT06471153|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33813908|NCT00801606|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33813909|NCT01035177|||CASE_CONTROL||PROSPECTIVE|||||||
33813910|NCT02152384|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33813911|NCT00126620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813912|NCT01870336|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33813913|NCT00660114|||||PROSPECTIVE|||||||
33813914|NCT02089425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813915|NCT04436965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813916|NCT01566383|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33813917|NCT06196294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813918|NCT05005247|NA|SINGLE_GROUP||PREVENTION||NONE||Open label booster vaccine study||||
34123012|NCT04221633|RANDOMIZED|PARALLEL||SCREENING||NONE||The current clinical trial involves three conditions (N=25 each): webinar-training only, webinar training plus consultation, and waitlist control.||||
33734912|NCT02361567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33734913|NCT06309875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A pre-post test Randomized Clinical Trial (RCT) is proposed with a comparison group, with blinding of the participants with blinding of the participants, with application of a pilot test beforehand. pilot test.~The intervention group is established as the group that receives the PLAN CUIDARTE (intervention described later) and as a comparison group the one receiving the conventional discharge plan (described later)"|t|f|f|f
33734914|NCT04268342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A before-after study design will be used to evaluate the proportion of all cases treated with ceftriaxone at return visit within standard care and the new management program respectively. Cure rates within the standard care and the new management program will also be assessed which will help illustrate the impact of the new management program.||||
33734915|NCT03235024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This is a double blind study. Participants will be assigned to study treatment in accordance with the randomization schedule generated for the allocation of vehicle or B244 prior to the initiation of the trial. Randomization will be centrally-based and performed using an appropriate IWRS (an automated randomization system).~Each participant scheduled to receive investigational product (IP) will receive a randomization number at the time of randomization. The randomization number will be used to identify the study medication kit assigned to the participant and indicate the treatment to be administered to that participant."|Randomization will be 1:1 so that equal number of patients will be treated in each Arm of the study.|t|t|t|t
33734916|NCT00451282|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33734917|NCT02658110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33734918|NCT05501197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734919|NCT04114552|||COHORT||PROSPECTIVE|||||||
33734920|NCT05791838|||COHORT||RETROSPECTIVE|||||||
33734921|NCT02978690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734922|NCT01280929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734923|NCT06333938|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734924|NCT02442817|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33734925|NCT03376997|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33734926|NCT03365284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734927|NCT00774488|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33734928|NCT05664035|||CASE_ONLY||PROSPECTIVE|||||||
33734929|NCT04900103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734930|NCT06142812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734931|NCT01200095|||CASE_ONLY||RETROSPECTIVE|||||||
33734932|NCT01222494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734933|NCT02690961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734934|NCT04374474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734935|NCT00000826||||TREATMENT||NONE||||||
33734936|NCT00951054|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33734937|NCT04915859|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will receive four cooling treatment on separate study visits 1)hand cooling at 12-15C 2)hand cooling at 16-20C 3)passive cooling 4)back and hand cooling (at 12-15C or 16-20C depending on results of trials 1-3)||||
33734938|NCT05698095|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||"This study will include separate single- and multiple-dose parts.~Single-dose part:~A double-blind, placebo-controlled, randomized, sequential-group design with 5-MeO-DMT administered by intramuscular injection in 6 cohorts of 6 subjects (randomized as 5 active and 1 placebo subject(s) per group).~Multiple-dose part:~A double-blind, placebo-controlled, randomized, sequential-group design with 5-MeO-DMT administered by intramuscular injection in up to two doses within a single day (3-hour interval) with two different dose levels (6 subjects per group)."|t|t|t|f
33734939|NCT04630522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734940|NCT03330535|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Four groups of participants will be formulated. Each will will receive messages in different time interval starting from none, once a week, three times a week and daily.|f|t|t|t
33734941|NCT06503588|||OTHER||RETROSPECTIVE|||||||
33734942|NCT00191997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734943|NCT01245179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734944|NCT04217551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessors will be blinded to the treatment assignment of the participant.|Bayesian Adaptive Design|f|f|f|t
33734945|NCT02985242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33734946|NCT04612322|||COHORT||PROSPECTIVE|||||||
33734947|NCT01176825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33734948|NCT01252459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123013|NCT00751478|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33734949|NCT05494255|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Randomized controlled trial|t|f|f|t
33734950|NCT03828305|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This clinical trial aims to determine the effectiveness of a network of volunteers trained in CPR maneuvers and using the AED connected through an application (App) for smartwatch, which allows automatic activation in case of out-of-hospital cardiorespiratory arrest (OHCA), on the start time of the CPR maneuvers and use of the AED.||||
34123014|NCT03521154|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123015|NCT04201639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123016|NCT03505892|||COHORT||PROSPECTIVE|||||||
33734951|NCT00967408|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734952|NCT03317990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded as to whether the person has had NeuroSAFE procedure. The surgeon and pathologist cannot be blinded to this.|A single blinded, multi-centre, randomised controlled trial. Parallel group, two-arm, with 1:1 allocation ratio between nerve sparing guided by NeuroSAFE and current UK practice (guided by MRI, biopsy and clinical examination).|t|f|f|f
33734953|NCT00779948|||COHORT||PROSPECTIVE|||||||
33734954|NCT04742595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734955|NCT05215821|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33734956|NCT03208738|RANDOMIZED|PARALLEL||TREATMENT||NONE|NA: All study measures are self-report.|||||
33734957|NCT00436280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123017|NCT05110326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734958|NCT03575832|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734959|NCT02677831|||COHORT||PROSPECTIVE|||||||
33734960|NCT00296556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33734961|NCT01581203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734962|NCT04795414|||COHORT||PROSPECTIVE|||||||
33734963|NCT01948375|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33734964|NCT01038778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734965|NCT01788501|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33734966|NCT05550129|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33734967|NCT06054672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734968|NCT02338947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment assignments will be performed in a blinded manner according to a blocked randomization scheme with a block size of ten, stratified according to the participating center.|Eligible patients will be randomly assigned to off-pump CABG or on-pump CABG procedure.|t|f|f|t
33734969|NCT00042094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33734970|NCT01401491|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33734971|NCT02953834|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33734972|NCT00656253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33734973|NCT00182949|||||PROSPECTIVE|||||||
33734974|NCT04655404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Feasibility and surgical cohorts||||
33734975|NCT04408196|||COHORT||PROSPECTIVE|||||||
33734976|NCT03759093|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33734977|NCT03563768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734978|NCT06114576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double-blind||t|f|f|f
33734979|NCT01200199|||CASE_ONLY||PROSPECTIVE|||||||
33734980|NCT03490084|||COHORT||PROSPECTIVE|||||||
33734981|NCT05740722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randomised placebo-controlled trial. Experimental: Placebo Placebo vs study drug (Nicotinamid riboside 500 mg x 2 po)|t|f|t|t
33734982|NCT02842268|NA|SINGLE_GROUP||OTHER||NONE||||||
33734983|NCT01162187|||COHORT||RETROSPECTIVE|||||||
33734984|NCT01772498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33734985|NCT04296812|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33734986|NCT05226650|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33734987|NCT05932290|||COHORT||RETROSPECTIVE|||||||
33734988|NCT00727194|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33734989|NCT06572826|||COHORT||OTHER|||||||
33734990|NCT02864641|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33734991|NCT06098950|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are not aware of what type of AI model predictions are shown during the clinical vignettes within the survey.|While participating in a survey, participants are randomized to see different hypothetical patient clinical vignettes, AI model predictions, and then ask questions about the patient's likely diagnosis and treatment.|t|f|f|f
33734992|NCT01697436|RANDOMIZED|CROSSOVER||||NONE||||||
33734993|NCT00879671|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33734994|NCT04865835|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This is a randomized, single-blind, two-period crossover study in adults with schizophrenia|t|f|f|f
33734995|NCT00004091|||COHORT||CROSS_SECTIONAL|||||||
33734996|NCT02618330|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33734997|NCT02995915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33734998|NCT04884516|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123018|NCT05515328|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study has two parts:~Part A: open-label, single-arm, single dose trial, Part B: non-randomised, open-label, fixed sequence crossover trial."||||
34123019|NCT05125744|||COHORT||PROSPECTIVE|||||||
33734999|NCT04409782|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33735000|NCT03177759|||COHORT||PROSPECTIVE|||||||
33735001|NCT06313372|||OTHER||OTHER|||||||
33735002|NCT06468644|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735003|NCT06081218|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735004|NCT03552159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735005|NCT00402389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33735006|NCT02111486|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33735007|NCT01584947|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33735008|NCT05267067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735009|NCT02056171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735010|NCT00393939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735011|NCT01101841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735012|NCT02858375|||CASE_ONLY||RETROSPECTIVE|||||||
33735013|NCT06108934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735014|NCT03228238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735015|NCT06304337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34123020|NCT05887037|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123021|NCT00249587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735016|NCT04284189|||COHORT||PROSPECTIVE|||||||
33735017|NCT03902639|||COHORT||PROSPECTIVE|||||||
33735018|NCT01422434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735019|NCT00853658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735020|NCT00794872|||COHORT||PROSPECTIVE|||||||
33735021|NCT04206163|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33735022|NCT02102139|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33735023|NCT04441450|NA|SINGLE_GROUP||OTHER||NONE||||||
33735024|NCT05492084|||COHORT||OTHER|||||||
33735025|NCT02616250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735026|NCT04894045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In control group patients, the treating anesthesiologists are blinded to the data of preoperative automated blood pressure monitoring. Participants and outcomes assessors are blinded to group allocation.||t|f|f|t
33735027|NCT02099721|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735028|NCT06254417|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33735029|NCT01890200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813919|NCT04464148|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33813920|NCT05398484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813921|NCT03236727|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33813922|NCT04312425|||COHORT||RETROSPECTIVE|||||||
33813923|NCT02212626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813924|NCT04780685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is double-blind study||t|t|t|t
33813925|NCT01688388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813926|NCT02516202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813927|NCT05274490|||CASE_CONTROL||PROSPECTIVE|||||||
33813928|NCT06197100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||there are three sections to it, and they will all be finished simultaneously. This is not a study of drugs or devices. The two arms of the study are Supportive care training, and control groups.|t|f|f|t
33813929|NCT01455779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813930|NCT01739972|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33813931|NCT04526132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813932|NCT02264444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813933|NCT05577182|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part 1 will be dose escalation using a statistical hybrid design to identify the RDE(s). Part 2 will be dose expansion portion which will administer the RDE(s) defined in Part 1 to participants in 2 tumor-specific cohorts.||||
33813934|NCT00000284|RANDOMIZED|||TREATMENT||DOUBLE||||||
33813935|NCT04018521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33813936|NCT04024709|||CASE_ONLY||RETROSPECTIVE|||||||
33813937|NCT02173990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813938|NCT04480957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33813939|NCT04887857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813940|NCT04311983|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are unaware of the arms and principal investigators are unaware of participant's randomization to study arm|Two group intervention; standard care vs. standard + additional service|t|f|t|f
33813941|NCT03804866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813942|NCT06091969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Volunteers will be given an identifier number and then randomized into placebo or active groups by an independent third party meaning that all participants, care providers and investigators will be blinded to the treatment allocations until the end of the study.|This is a 3-month placebo-controlled, double-blinded, randomized clinical trial comparing an active supplement designed to enhance sperm function (Fertility Enhancer) to an inactive placebo (PLACEBO) in overweight or obese and subfertile males.|t|t|t|f
33813943|NCT00106405||||TREATMENT||NONE||||||
33813944|NCT05512299|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33813945|NCT05636306|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33813946|NCT03883217|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33813947|NCT05100511|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||The usability of the investigational device is examined first with 10 healthy subjects and afterwards with total of 10 patients suffering either from macular edema or macular degeneration.||||
33813948|NCT03645213|RANDOMIZED|PARALLEL||PREVENTION||NONE||This randomized controlled trial study was conducted on 120 school-age children (7 -12 years of age) with pain and fear of venipuncture. The children were randomized according to their arrival in the biochemistry laboratory; the first, second, and third children were assigned VR distraction group with a headset (n=40), non-VR distraction group on a tablet computer screen (n=40) and no distraction group (n=40), respectively. The data collection was carried out using the children identification form, Wong-Baker FACES Pain Rating Scale evaluating the pain and Childrens' Fear Scale evaluating the fear. The outcomes reported by the children, parent, and observer.||||
33813949|NCT00476151|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813950|NCT00838448|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33813951|NCT01362309|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33813952|NCT06186063|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The investigators apply a randomized, double-blinded, placebo-controlled, crossover design.|t|f|t|f
33813953|NCT00033748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33813954|NCT03875456|||COHORT||RETROSPECTIVE|||||||
33813955|NCT01668355|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||medical home tailored for people with serious mental illness|f|f|f|t
33813956|NCT00235378|||COHORT||PROSPECTIVE|||||||
33813957|NCT03681067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813958|NCT01528605|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33813959|NCT04167852|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33813960|NCT06022198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective cross sectional study at which COVID-19 patients with persistent pulmonary infiltrate one month after discharge from isolation department at Mansoura university hospitals will be enrolled in the study||||
33813961|NCT03662841|NA|SINGLE_GROUP||TREATMENT||NONE||Use of ACE for HCC of size \> 10cm||||
33813962|NCT00568087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33813963|NCT01794689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33813964|NCT01009645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33813965|NCT04640805|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Assignment to study group will be done in a 1:1 ratio. Twins/triplets will be randomized to the same group.|t|t|f|t
33813966|NCT01218048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813967|NCT05739409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813968|NCT05219747|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomize control trial|t|f|t|f
33813969|NCT05847114|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34123022|NCT00834821|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34123023|NCT04388007|||COHORT||PROSPECTIVE|||||||
33813970|NCT03710850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||single groups assignment||||
33813971|NCT01315418|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33813972|NCT03441464|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||Dose escalation||||
33813973|NCT02223078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123024|NCT02886650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123025|NCT01981798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123026|NCT00003312||||TREATMENT||||||||
33813974|NCT03696563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This will be a single centered prehospital multi-period cluster crossover feasibility trial||||
33735030|NCT00177424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33735031|NCT04643834|||COHORT||PROSPECTIVE|||||||
33735032|NCT00394966|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33735033|NCT05630807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This will be a double blinded study in which investigators/site staff and the Sponsor will remain blinded to treatment assignment.|This is a multicenter, randomized, double-blind, placebo-controlled study.|t|t|t|t
33735034|NCT02636972|||COHORT||CROSS_SECTIONAL|||||||
33735035|NCT04502771|||COHORT||RETROSPECTIVE|||||||
33735036|NCT03138668|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33735037|NCT01769157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735038|NCT03033797|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33735039|NCT01337024|||CASE_CONTROL||PROSPECTIVE|||||||
33735040|NCT04176796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33735041|NCT05802693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735042|NCT04744727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Letters of the allocated were concealed in serially numbered opaque envelope that were only released after recruitment.|"Cases were divided into 2 groups:~Group I (paracetamol group): Included 48 pregnant women who received 1000 mg of intravenous paracetamol. The treatment was administered at the begining of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\].~Group 2 (pethidine group): Included 48 pregnant women who received 50 mg of intravenous pethidine HCL diluted in 10 ml normal saline. The treatment was administered at the beginning of the active phase of 1st stage of labor \[roughly defined as a cervical dilatation of 3-4 cm and a cervical effacement ≥ 50%\]. Randomization was done by a computer-generated randomization system. Letters of the allocated were concealed in serially numbered opaque envelope that were only released after recruitment."|t|f|f|f
33735043|NCT04173130|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33735044|NCT03837795|NA|SINGLE_GROUP||TREATMENT||NONE|The researcher that will perform the measurement assessments will differ from the one that will provide the therapy sessions.|it is a serial experimental research design, which includes 10 individuals with sensory over responsivity aged 21-45 years will participate||||
33735045|NCT01400841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735046|NCT02442830|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33735047|NCT04677920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735048|NCT06453993|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735049|NCT01046916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735050|NCT05867394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants do not know which group they are in.|Parallel Assignment Prospective Randomized Controlled Clinical Trial|t|f|f|f
33735051|NCT01040429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735052|NCT00611702|||COHORT||PROSPECTIVE|||||||
33735053|NCT05100875|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735054|NCT00732121|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33735055|NCT05421078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablet made to resemble active product|Placebo-controlled, double-blind, randomized|t|t|t|t
33735056|NCT05168995|||COHORT||PROSPECTIVE|||||||
33735057|NCT06453590|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial, to either of three groups.||||
33735058|NCT05354375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735059|NCT01698463|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33735060|NCT03191903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study subjects and the Outcomes Assessor are blinded to the study treatment.|Subjects are randomized in a 4:4:1 ratio into the Cingal, Monovisc (hyaluronic acid) or TH (triamcinolone hexacetonide) arms.|t|f|f|t
33735061|NCT04507958|||CASE_CROSSOVER||PROSPECTIVE|||||||
33735062|NCT03500757|||CASE_ONLY||PROSPECTIVE|||||||
33735063|NCT03438435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735064|NCT06471933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735065|NCT04201288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735066|NCT05654324|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Outcomes Assessor)|This research is a prospective and controlled study. The data of the study will be collected from pregnant women (Experimental group) and non-pregnant women (Control group).|t|f|f|t
33735067|NCT01820611|||COHORT||OTHER|||||||
33735068|NCT03252821|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735069|NCT06315257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813975|NCT01789593|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33813976|NCT06488027|||COHORT||RETROSPECTIVE|||||||
33813977|NCT03420040|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33813978|NCT05080556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813979|NCT01114412|||OTHER||PROSPECTIVE|||||||
33813980|NCT01063465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813981|NCT05082688|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33813982|NCT01780428|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33813983|NCT05190289|||CASE_CONTROL||RETROSPECTIVE|||||||
33813984|NCT03602573|||COHORT||PROSPECTIVE|||||||
33813985|NCT05049174|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants were randomized 1:1 to an in-hospital nurse-led smoking cessation intervention with systematic referrral to the municipal healthy life-centres or to written information about smoking cessation and the municipal health service program.|f|f|f|t
33813986|NCT02327806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813987|NCT05863585|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33813988|NCT01098409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33813989|NCT06508762|NA|CROSSOVER||TREATMENT||NONE||||||
33813990|NCT04414865|||COHORT||PROSPECTIVE|||||||
33813991|NCT01717625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33813992|NCT04009109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840171|NCT03501953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Participants are randomly assigned to one of two intervention classes that either take place outdoors or indoors. Intervention conditions are identical in protocol and measurements taken, and differ only in location of intervention.|t|t|f|t
33735070|NCT04891224|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This study will use a pre- post- study design to assess the impact of implementing the Pathway Platform in the primary care setting. Clinic performance and select patient outcomes will be compared before and after implementation. Additional patient outcomes will be assessed after implementation among patients using the Pathway Platform.||||
33735071|NCT02575781|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735072|NCT00061048|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735073|NCT04068181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735074|NCT02820194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735075|NCT06655935|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33735076|NCT02111616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33735077|NCT02081495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735078|NCT05674487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735079|NCT01518075|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735080|NCT05666401|||COHORT||PROSPECTIVE|||||||
33735081|NCT06052904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33735082|NCT03154619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735083|NCT06504238|||OTHER||PROSPECTIVE|||||||
33735084|NCT06050590|NA|SINGLE_GROUP||TREATMENT||NONE||NeuroGlove||||
33735085|NCT04939948|||OTHER||RETROSPECTIVE|||||||
33735086|NCT04423042|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735087|NCT06300554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735088|NCT03518320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735089|NCT03779841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735090|NCT05676671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||104 carious deciduous molars (n=92) were randomly allocated to receive one of the self-etching adhesives: Clearfil SE Bond - control (CB - n =53) or Clearfil SE Protect containing MDPB (CP - n=51) after caries removal selective|t|f|t|t
33735091|NCT01663259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735092|NCT01142739|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735093|NCT00894075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735094|NCT03832959|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients referred for catheter ablation of atrial fibrillation (either cryoablation or radiofrequency ablation (1/1)) will be randomized to either receive or not (1/1) an esophageal temperature adjustment EnsoETM device, to evaluate its role for esophageal protection.||||
33735095|NCT03428776|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Single blinded prospective study|f|f|t|t
33735096|NCT03329352|NA|SINGLE_GROUP||TREATMENT||NONE||After a period of baseline, all enrolled participants will be put on the same trial mask.||||
33735097|NCT05346679|||CASE_ONLY||PROSPECTIVE|||||||
33735098|NCT05953077|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parents are masked concerning children's specific language goals and treatment conditions.|quasi-experimental design with two active treatment groups|f|t|f|f
33735099|NCT04311034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813993|NCT05563987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor who is responsible for collecting outcome data and data entry has no idea about the group allocation of participants.|Participants were random allocated (1:1 ratio) to either the intervention group that received a 6-week (5 sessions) group-based ACT-DE programme. While participants in the control group received 1 session of diabetes education.|f|f|f|t
33813994|NCT01105559|||COHORT||PROSPECTIVE|||||||
33813995|NCT06412809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded to the grouping of the participants and the interventions of the study.|Volleyball and basketball players|f|f|f|t
33813996|NCT01441596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33813997|NCT02970578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33813998|NCT04607356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treating therapists and patient will be aware of treatment. Grip strength objective measure will be performed by a clinician blinded to the participant's treatment group. All other outcome measures are patient-reported on outcome forms.|Randomized control trial|f|f|f|t
33813999|NCT02793752|||COHORT||PROSPECTIVE|||||||
33814000|NCT05107453|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient, intensivist, ICU nurses and data manager are blinded for the randomization.||t|t|f|f
33814001|NCT01264874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123027|NCT01459094|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123028|NCT01414959|||COHORT||PROSPECTIVE|||||||
34123029|NCT00149786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735100|NCT04750122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735101|NCT05875038|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735102|NCT06156215|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes will be assessed at 30 days via EHR review or follow up phone call. EHR review and follow up calls will be conducted in a blinded fashion - the research staff person reviewing outcomes will be unaware of participant's study group assignment.|"PROBOOSTVAXED has 3 arms:~Intervention M (Messaging + Vaccine Question)~* Vaccine messaging given~* Vaccine acceptance question asked~Intervention Q (Vaccine Question, No Messaging)~* No vaccine messaging~* Vaccine acceptance question asked~Control (No Messaging, No Vaccine Question)~* No vaccine messaging~* No vaccine acceptance question"|f|f|f|t
33735103|NCT04354259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735104|NCT05714527|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33735105|NCT06383039|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants were not informed which type of current was applied.|All participants received 3 different interventions at different times.|t|f|f|f
33735106|NCT05684679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735107|NCT02502357|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|simple randomization||t|f|f|t
33735108|NCT04295434|||COHORT||CROSS_SECTIONAL|||||||
33735109|NCT04252859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735110|NCT00595582|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735111|NCT01669551|||CASE_ONLY||PROSPECTIVE|||||||
33735112|NCT00277602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735113|NCT01707004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735114|NCT05691426|||CASE_CONTROL||PROSPECTIVE|||||||
33735115|NCT05555381|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735116|NCT00556595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735117|NCT05834140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735118|NCT01332734|||CASE_ONLY||PROSPECTIVE|||||||
33735119|NCT01850004|NA|SINGLE_GROUP||OTHER||NONE||||||
33735120|NCT02213276|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33735121|NCT06331052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735122|NCT02877550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735123|NCT00109564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33735124|NCT00001839||||TREATMENT||||||||
33735125|NCT06664541|||CASE_ONLY||CROSS_SECTIONAL|||||||
33735126|NCT04400513|||OTHER||CROSS_SECTIONAL|||||||
33735127|NCT06292143|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility study||||
33735128|NCT05650879|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 will be a dose escalation monotherapy according to the Bayesian Optimal Interval Design model Phase 1b will be a dose expansion: up to 40 patients randomized between 2 dose levels||||
33735129|NCT00731328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735130|NCT02607488|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33735131|NCT03152786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735132|NCT05721040|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735133|NCT01037478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735134|NCT01701258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||There were four groups of subjects: those with a history of child sexual abuse that are currently experiencing a major depressive episode, those with a history of child sexual abuse without a current or past diagnosis of major depressive disorder, those without a history of child sexual abuse that are currently experiencing a major depressive episode, and those with without a history of child sexual abuse and without a current or past diagnosis of major depressive disorder. Within each group, half of the subjects were assigned to receive the study drug (amisulpride) and half to receive a placebo for the fMRI session (session 2 or 3).|t|t|t|f
33735135|NCT02287597|||COHORT||PROSPECTIVE|||||||
33735136|NCT03436472|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel Assignment|t|t|t|t
33735137|NCT00073905|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735138|NCT06572956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735139|NCT05554861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735140|NCT06661837|||OTHER||CROSS_SECTIONAL|||||||
33735141|NCT04630405|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33735142|NCT01122199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735143|NCT02502786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735144|NCT00393055|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33735145|NCT04865757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735146|NCT05017441|||COHORT||RETROSPECTIVE|||||||
33735147|NCT05495412|NA|SINGLE_GROUP||TREATMENT||NONE||single case study||||
33735148|NCT02746614|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735149|NCT03245021|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33735150|NCT05283096|||CASE_ONLY||CROSS_SECTIONAL|||||||
33735151|NCT04900896|||COHORT||PROSPECTIVE|||||||
33735152|NCT02649972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735153|NCT00813124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735154|NCT04475393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735155|NCT04085523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There are 5 cohorts enrolling approximately 60 subjects who will be randomized to receive either TransCon CNP or Placebo in a 3:1 ratio|t|t|t|t
33735156|NCT05459129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735157|NCT04047017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123030|NCT02848092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34123031|NCT06200519|||COHORT||PROSPECTIVE|||||||
34123032|NCT00266968|||COHORT||RETROSPECTIVE|||||||
34123033|NCT00432393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34123034|NCT02681081|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34123035|NCT04951765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123036|NCT02625181|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123037|NCT05404971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735158|NCT03559842|||COHORT||PROSPECTIVE|||||||
33735159|NCT00428610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735160|NCT00020111||||TREATMENT||||||||
33735161|NCT02100072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735162|NCT04284657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814002|NCT05639556|||COHORT||PROSPECTIVE|||||||
33814003|NCT01085253|||||PROSPECTIVE|||||||
33814004|NCT01613703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735163|NCT04699994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735164|NCT05198492|||COHORT||RETROSPECTIVE|||||||
33735165|NCT03533075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will remain blinded to the treatment condition for all participants.|Participants will be assigned in even numbers to TMBI + follow-up consultation or care as usual.|f|f|f|t
33735166|NCT01891734|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33735167|NCT01634204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735168|NCT06118294|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||300 Participants are assigned to the probiotics and a placebo group, under the double-blind trial.|t|t|t|t
33735169|NCT04328493|RANDOMIZED|PARALLEL||TREATMENT||NONE||The main trial is an open label, randomised, controlled trial that will be conducted in in-patients in Ho Chi Minh City. Viet Nam. Randomization will be 1:1, stratified by study site and severity of illness, to either with or without chloroquine for 10 days. All patients will also receive a supportive care/treatment according to VN MoH's guideline for COVID-19||||
33735170|NCT04089267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735171|NCT00053430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33735172|NCT00000781||||TREATMENT||DOUBLE||||||
33735173|NCT02082717|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34123038|NCT01653444|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123039|NCT01874548|||CASE_CONTROL||PROSPECTIVE|||||||
34123040|NCT02026011|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34123041|NCT03328832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33814005|NCT01365546|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33814006|NCT02133131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814007|NCT00390806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814008|NCT05200286|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814009|NCT00680134|RANDOMIZED|||TREATMENT||NONE||||||
33814010|NCT01624922|||COHORT||PROSPECTIVE|||||||
33735174|NCT01659424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735175|NCT03481959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735176|NCT04953923|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33735177|NCT05033964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind|prospective, multi-center, single blind, randomized clinical study. Randomization is 1:1|t|f|f|f
33735178|NCT02560636|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735179|NCT01902485|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735180|NCT01344109|||CASE_CONTROL||PROSPECTIVE|||||||
33735181|NCT03063827|||CASE_CONTROL||PROSPECTIVE|||||||
33735182|NCT01438541|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33735183|NCT04817241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735184|NCT00714246|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33735185|NCT06663098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735186|NCT00654524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735187|NCT01323569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33735188|NCT00649116|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33735189|NCT02645916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735190|NCT01418781|||COHORT||PROSPECTIVE|||||||
33735191|NCT03362840|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33735192|NCT01294189|||CASE_ONLY||RETROSPECTIVE|||||||
33735193|NCT06390475|||COHORT||PROSPECTIVE|||||||
33735194|NCT04142541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735195|NCT01158924|NA|SINGLE_GROUP||||NONE||||||
33735196|NCT00902356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735197|NCT03380923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|"Outcomes assessors analyzing biospecimen samples are blinded to the arm to which each participant has been randomly assigned when doing analysis.~Investigators are blinded to each participant's randomized assignment."|Randomized to moderate intensity vs. high-intensity exercise training prescription.|f|f|t|t
33735198|NCT04958733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735199|NCT03082794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735200|NCT00947622|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33735201|NCT03358576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735202|NCT04425499|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33735203|NCT05218174|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33735204|NCT02685774|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735205|NCT01006811|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735206|NCT02583256|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33735207|NCT00253565||||TREATMENT||||||||
33735208|NCT02805647|||CASE_CONTROL||PROSPECTIVE|||||||
33735209|NCT03947060|||COHORT||PROSPECTIVE|||||||
33735210|NCT02036034|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33735211|NCT01978431|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33735212|NCT02676544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735213|NCT04483440|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each dose escalation cohort will initially recruit up to 3 patients to receive a single uniocular intravitreal injection of 4D-110 in a standard 3+3 design. The cohort will be expanded in the event of a dose limiting toxicity (DLT). Once the maximum tolerated dose (MTD)/maximum feasible dose (MFD) has been identified, up to 4 additional patients may be enrolled at that dose level to provide additional safety information.||||
33735214|NCT05510297|NA|SINGLE_GROUP||OTHER||NONE||||||
33735215|NCT03992326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735216|NCT01000051|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33735217|NCT03752723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33735218|NCT04090814|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735219|NCT05295173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735220|NCT02751151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735221|NCT04542629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735222|NCT03178656|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33735223|NCT03998124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An experimental parallel group design|f|f|f|t
33735224|NCT04140994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735225|NCT04299711|||COHORT||CROSS_SECTIONAL|||||||
33735226|NCT05035771|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33735227|NCT06467526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735228|NCT01528358|||COHORT||PROSPECTIVE|||||||
33735229|NCT03538639|||CASE_CONTROL||PROSPECTIVE|||||||
33735230|NCT00546715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735231|NCT02432365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735232|NCT00989144|||COHORT||PROSPECTIVE|||||||
33735233|NCT05063396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735234|NCT04510116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735235|NCT05571501|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE|All children recruited underwent the GAITRite assessment|The tool used for this study has been and was used for routine patient care, but was a novel diagnostic assessment for the typically developing (norms) and some of the clinical groups included. The clinical groups were compared to norms, both had the same diagnostic assessment so there was no control group who did not have the assessment||||
33735236|NCT05040711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735237|NCT06358391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735238|NCT00909805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735239|NCT01648309|||COHORT||PROSPECTIVE|||||||
33735240|NCT05731219|NA|SINGLE_GROUP||TREATMENT||NONE||UTAA06 injection||||
33735241|NCT06493513|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants will be randomized (like flipping a coin or drawing from a hat) to either of the two groups, with the probability of a participant being in the experimental and control groups being 1:1. and neither participant, nor care Provider, nor the outcome assessor, nor the investigator will know to which group participant has been assigned (or add 40 Hz transcranial stimulation).|"Experimental group: at the onset of anesthesia, the child received 40Hz transcranial stimulation for 1h.~Control group: at the start of anesthesia, the child did not receive any additional treatment."|t|t|t|t
33735242|NCT00567788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735243|NCT03237234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735244|NCT06482047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study used a within-participant cross-over design with pre-and post-test comparisons. Participants completed the three following experimental conditions in pseudo-counterbalanced (cannot be completely counterbalanced given that an odd number of participants - hence, was pseudo-counterbalanced) order (odd number of participants) with at least a 7-day washout period between conditions: (i) 115-minute uninterrupted sitting \[control\]; (ii) 50-minute sitting + 15-minute moderate-intensity cycling + 50-minute sitting \[experimental condition 1\]; (iii) 50-minute sitting + 15-minute vigorous-intensity cycling + 50-minute sitting \[experimental condition 2\]. A familiarization session was completed about three days before the experiment started, during which participants were familiarized with the cognitive assessment and cycling protocols.||||
33735245|NCT04368702|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735246|NCT03762603|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735247|NCT06414499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735248|NCT06449781|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, two-arm, randomized study.||||
33735249|NCT01262313|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33735250|NCT03273036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735251|NCT01431027|||CASE_ONLY||PROSPECTIVE|||||||
33735252|NCT06572215|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735253|NCT01687166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735254|NCT05211622|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Nobody else|"Patients will be randomly using a table of random numbers (allocation ratio 1:1:1:1).~* Arm I, OZOCLO~  1. alpha acid lipoic - 600 mg/die per os from 7 days before the beginning of chemotherapy and for other 4 die~ 2. ozonated oil - mouthwash (1 minute- three times/die) for 2 weeks~ 3. chlorhexidine 0,2% - mouthwash (1 minute- three times/die) from five days after the beginning and for other 2 weeks~* Arm II, OBC Sodium bicarbonate 5% solution - mouthwash (1 minute- three times/die) for 3 weeks~* Arm III, CHX Chlorhexidine 0,2% - mouthwash (1 minute- three times/die) from five days after the beginning and for other 2 weeks~* Arm IV, AAL-OZ~  1. alpha acid lipoic - 600 mg/die per os from 7 days before the beginning and continue for other 4 die~ 2. ozonated oil - mouthwash (1 minute- three times/die) from the beginning and for 2 weeks Every interventional arm will be conducted by the patient at home according to indications and will monitored at 8th, 15th, and the 21st day"|t|f|t|f
33735255|NCT06122324|||CASE_CONTROL||PROSPECTIVE|||||||
33735256|NCT04522297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735257|NCT04428138|||COHORT||CROSS_SECTIONAL|||||||
33735258|NCT05556876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|two set of files|A single-blinded randomised study|f|f|f|t
33735259|NCT01685112|||COHORT||RETROSPECTIVE|||||||
33735260|NCT03025022|NA|SINGLE_GROUP||OTHER||NONE||||||
33735261|NCT00057746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735262|NCT01560624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735263|NCT03969355|||COHORT||RETROSPECTIVE|||||||
33735264|NCT01285206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735265|NCT01985984|||COHORT||PROSPECTIVE|||||||
33735266|NCT01427205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735267|NCT05192577|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33735268|NCT06329154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|assessor was blinded. The assessor, who not participated in the study, was experienced, and well qualified in the use.||f|f|f|t
33735269|NCT02821585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735270|NCT01588002|RANDOMIZED|CROSSOVER||||NONE||||||
33735271|NCT02510846|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735272|NCT00433693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735273|NCT01636427|||CASE_ONLY||RETROSPECTIVE|||||||
33735274|NCT05346627|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33735275|NCT01736566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33735276|NCT02042976|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33735277|NCT06659575|||COHORT||CROSS_SECTIONAL|||||||
33735278|NCT06489886|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|A randomized double-blind crossover design with neither the subjects nor the investigators knowing who is on which food. The interventions will be coded using a blinded alphabetical letter code (A, B). A delegate researcher (independent party not further involved in the study) will randomize all interventions using a computer-generated randomization list. The delegate will hand in the code-breaker to the principal investigator in a sealed envelope. The envelope will be stored in a locked filing cabinet in the principal investigator's office, which will also be locked when unoccupied. The envelope will be opened by the principal investigator after completing the analysis of blood samples.|Participants will consume a meal of chicken, which type (conventional vs. regenerative ) consumed will be randomized where neither the participant nor investigator will know which meal is being consumed. Each participant will repeat the protocol two times.|t|f|t|t
33735279|NCT05224947|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind|Randomized cross-over trial|t|f|t|f
33814011|NCT04927507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814012|NCT06296875|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All supplements will be matched for taste and look|1:1 parallel group design|t|f|t|t
33814013|NCT00251147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814014|NCT05726097|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33814015|NCT00391651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814016|NCT06416345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814017|NCT05651802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123042|NCT06069609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33735280|NCT05683600|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33735281|NCT01927250|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735282|NCT04768036|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A multicenter clustered randomized study of a universal electronic health record-based IMPROVE VTE risk assessment model implementation as a quality improvement project for the prevention of venous thromboembolism in hospitalized medically ill patients.|f|t|f|f
33735283|NCT03097419|RANDOMIZED|PARALLEL||TREATMENT||NONE||We will perform a prospective, randomized-controlled study of 300 patients presenting to the BIDMC ED with a suspected non-ST segment elevation myocardial infarction. After obtaining consent, the patients will be assigned to either the intervention or standard of care group via a computerized block 1:1 randomization process.||||
33735284|NCT01014507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735285|NCT05951491|NA|SEQUENTIAL||OTHER||NONE||30 participants will enroll in a first assessment phase in a laboratory stetting comparing function with and without assistance from a wearable system. A subset of these (approximately 12) will enroll in a subsequent at-home phase.||||
33735286|NCT01190540|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33735287|NCT06113718|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735288|NCT06656910|RANDOMIZED|PARALLEL||PREVENTION||NONE||The research was planned as a randomly assigned intervention and control group, pre-test, post-test after the intervention and follow-up test three months after the intervention.||||
33735289|NCT05293275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735290|NCT03152812|||COHORT||PROSPECTIVE|||||||
33735291|NCT04055636|||COHORT||PROSPECTIVE|||||||
33735292|NCT06664424|||COHORT||PROSPECTIVE|||||||
33735293|NCT02479919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735294|NCT06094348|||CASE_ONLY||PROSPECTIVE|||||||
33735295|NCT06003855|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups will complete 12 weeks (36 sessions) of supervised exercise therapy. One group will complete the standard of care and the other group will complete the muscle oxygen guided supervised exercise therapy. Subjects will be randomly assigned to one of the two groups.||||
33735296|NCT05679791|||CASE_CONTROL||PROSPECTIVE|||||||
33735297|NCT02371174|||COHORT||PROSPECTIVE|||||||
33735298|NCT03079258|RANDOMIZED|PARALLEL||OTHER||SINGLE|Collected data at each time point will be blinded to the outcome assessor.|This study comprises of two groups; an exercise and a control group.|f|f|f|t
33735299|NCT00001368||||TREATMENT||||||||
33735300|NCT04705545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33735301|NCT03236844|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735302|NCT03735394|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735303|NCT03595111|NA|SINGLE_GROUP||SCREENING||NONE||Myocardial cell edema either focal or diffuse was detected in histopathological examination in pediatric patients undergoing total repair of Tetrology of Fallout||||
33735304|NCT05225181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735305|NCT03018353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735306|NCT03548870|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|sham transcutaneous electrical nerve stimulation||t|f|t|t
33735307|NCT05800288|||CASE_CONTROL||PROSPECTIVE|||||||
33735308|NCT03919045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|No Outcome assessor present in the study.||t|f|f|f
33735309|NCT02821104|||COHORT||PROSPECTIVE|||||||
33735310|NCT05116735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735311|NCT03199703|RANDOMIZED|PARALLEL||TREATMENT||NONE||150 patients will be randomized in a 1:1, single-blinded fashion to 1 of 2 transseptal groups.||||
33735312|NCT00428545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735313|NCT06661993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||60 septic patients will be enrolled from Damanhur National medical institute, and they will be randomized using simple randomization into two groups (30 patients each): control group will receive placebo and ALA group will be given 1800 mg orally or via a nasogastric tube of ALA daily for seven days .|t|f|t|f
33735314|NCT06615570|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33735315|NCT04512274|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33735316|NCT00933491|||COHORT||PROSPECTIVE|||||||
33735317|NCT03862976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735318|NCT01147419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735319|NCT03759223|RANDOMIZED|PARALLEL||TREATMENT||NONE||Up to 12 participants will first complete an open trial of E-PST to test the feasibility, acceptability, and preliminary clinical effect. Subsequently, up to 38 participants will be randomly assigned (1:1) to E-PST or a control condition comprised of supportive contact and symptom monitoring.||||
33814018|NCT04299022|||COHORT||PROSPECTIVE|||||||
33814019|NCT01594606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814020|NCT02533752|||COHORT||PROSPECTIVE|||||||
33735320|NCT04915781|||COHORT||PROSPECTIVE|||||||
33814021|NCT00529529|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814022|NCT05793489|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective double arm randomized trial||||
33814023|NCT00508183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814024|NCT00990132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814025|NCT05052151|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Temperature or bicarbonate settings will not be revealed to participants during the study.|"The study will be a single-blinded, randomized, controlled, crossover study with each participant being his or her own control. Participants will be blinded to the intervention and the order of the interventions will be random.~Participants will be randomized using bloc randomization. We will create two blocs with 8 participants in each. The four dialysis sessions will be conducted on the same weekday each week, which results in a 1-week wash-out period with standard dialysis treatment between interventions."|t|f|f|f
33814026|NCT03369483|||COHORT||PROSPECTIVE|||||||
33814027|NCT03411408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814028|NCT03270098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a single-blind, parallel assignment, multi-site randomized clinical trial designed to examine the impact of exercise on cognition, daily functioning, and biomarkers of cognitive change in people with schizophrenia.|f|f|f|t
33814029|NCT02542202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814030|NCT03218085|||COHORT||PROSPECTIVE|||||||
34123043|NCT01840488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735321|NCT03325413|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"The study has 3 arms with patients allocated to them in a fixed chronological order.~For six months, patients will be recruited for the control arm. In this arm, participants receive usual care without any additional intervention initiated by the study.~After finishing recruitment for the control arm, patients will be recruited for the implementation arm for six months. In this arm, stepwise implementation of the study interventions begins with the possibility of flexibly adapting them to the specific conditions.~After finishing recruitment for the implementation arm, patients will be recruited for the full-scale intervention arm for six months. In this arm, all study interventions will be utilized."||||
33735322|NCT03621267|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33735323|NCT05304858|||OTHER||PROSPECTIVE|||||||
33735324|NCT03494075|||OTHER||PROSPECTIVE|||||||
33735325|NCT05656378|||COHORT||PROSPECTIVE|||||||
33735326|NCT04272190|||COHORT||PROSPECTIVE|||||||
33735327|NCT00931905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735328|NCT05639088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735329|NCT03882359|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The interpreter of echocardiograms in the trial is blinded to the drug which was administered, MVT-100 or Definity.|Ascending dose comparison in healthy volunteers|f|f|f|t
33735330|NCT05195320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Staff administering assessments will be blinded to group assignment (Intervention or control). Participants and group facilitators will be carefully instructed not to reveal group assignment to assessment administrators. Following each assessment, the blinded data collector will note whether unblinding occurred; this information will be entered into the study's web database. As an additional protection, blinded data collectors will have restricted access to the study database as some of the information that is collected would reveal group assignment (e.g., attendance of group members at sessions); this information will be entered into the database by unblinded staff. To track potential unblinding, blinded data collectors will respond to a two-item assessment of unblinding following each outcome assessment administered.|A sample of 48 participants randomly assigned to either the intervention or control group (Intervention, N=24 and Controls, N=24) over four cohorts. Participants in each cohort will be randomized to either the intervention or control group with equal probability so that each group has 6 participants. That is, once 12 subjects have been recruited, they will form a cohort, be randomized into one of the two groups, and begin the study intervention; this process will continue until 48 subjects have been recruited into four cohorts.|f|t|f|t
33735331|NCT05901285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735332|NCT00981279|||||RETROSPECTIVE|||||||
33735333|NCT02476396|||CASE_CONTROL||PROSPECTIVE|||||||
33735334|NCT03581136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735335|NCT01174030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735336|NCT06193434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735337|NCT03175224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735338|NCT00002010||||TREATMENT||NONE||||||
33735339|NCT00804427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33735340|NCT00958880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735341|NCT02262728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735342|NCT02267655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735343|NCT05913063|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Within-subject, measuring the threshold SL-based entoptic phenomenon circular obstruction size of the radial retinal polarizer||||
33735344|NCT03354429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735345|NCT05390502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33735346|NCT03120013|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33735347|NCT05882539|||COHORT||PROSPECTIVE|||||||
33735348|NCT05630937|NA|SEQUENTIAL||TREATMENT||NONE||||||
33735349|NCT05013944|||COHORT||PROSPECTIVE|||||||
33735350|NCT03093805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814031|NCT01190995|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33735351|NCT01873989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735352|NCT00198783|||DEFINED_POPULATION||PROSPECTIVE|||||||
33735353|NCT03724604|||COHORT||PROSPECTIVE|||||||
33735354|NCT00211081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735355|NCT02121340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735356|NCT04640311|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33735357|NCT02407106|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33814032|NCT02541292|||COHORT||PROSPECTIVE|||||||
33814033|NCT01359059|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33814034|NCT00003754||||TREATMENT||||||||
33837112|NCT06520150|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Anesthesiologists administering anesthesia prior to surgery receive an envelope with a randomly indicated method of anesthesia based on simple randomization determines the type of regional blockade used during the procedure). The subject will not know which study group he or she has been classified into. The operator performing the procedure will not be informed of the type of anesthesia performed -\[randomization by double-blinding\]. The operator performing the procedure will not be informed about the type of block performed in order to objectivize the extent and quality of the subject's anesthesia, which he will evaluate after the procedure according to a scale of subjective operator comfort created (EOA scale).|The subjects will be randomly divided into 2 groups - Group I will be patients administered PSP+SSAP anesthesia (consecutively 20+40ml of the mixture indicated above). Group II will be patients given SPIP+SSAP blockade (consecutively 20+40ml of the mixture indicated above). It was tentatively planned to conduct the study on a group of 32 patients (16 in each of the two groups).|t|t|f|f
33837113|NCT00863759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837114|NCT01328353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123044|NCT03001661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123045|NCT04535726|||COHORT||PROSPECTIVE|||||||
33735358|NCT02128841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735359|NCT06419049|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single subject design||||
33735360|NCT05059457|||COHORT||CROSS_SECTIONAL|||||||
33735361|NCT01222585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735362|NCT01302964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814035|NCT06360120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Our study was single-blinded to the investigators; an independent statistician generated a computer-generated randomization chart with a block size of four in a one-to-one ratio, and participants were randomly assigned to receive either atorvastatin or rosuvastatin by a specially trained and qualified nurse. None of the investigators included in the study knew the patients' assignments. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included atorvastatin bills, and Drug B included rosuvastatin bills. The statistical analysis was performed by an independent statistician.|The study will be composed of 2 arms atorvastatin arm, which consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and the rosuvastatin arm consisted of 300 patients who received 20 mg rosuvastatin daily for 3 months, All the patients in the two groups received open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months|f|f|t|t
33837115|NCT01817920|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33837116|NCT00953147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044630|NCT05954195|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|the studies mask the participants and they randomly divided into 2 groups then the care provider is masked too not to choose specific participant for specific intervention then the outcome assessor is masked to document the outcomes with fair then the investigator is masked too to document results honestly without being motivated towards the intervention.|high intensity interval training starting by warm up period of 40 % from the HRmax then the interval exercise period of 85-90 % from HRmax ending by cool down period from 30 % of HRmax|t|t|t|t
34044631|NCT02496078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044632|NCT01413698|||||RETROSPECTIVE|||||||
34044633|NCT02464332|NA|SINGLE_GROUP||||NONE||||||
34123046|NCT03345303|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34123047|NCT02971709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735363|NCT02201797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735364|NCT02317302|NA|SINGLE_GROUP||SCREENING||NONE||||||
33735365|NCT02176733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735366|NCT05887622|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants will be blinded to the diet they are on.|All participants will complete all arms in a randomized, crossover design.|t|f|f|f
33735367|NCT04219163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735368|NCT05686304|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33735369|NCT06176027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735370|NCT06659445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735371|NCT01649856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735372|NCT04139590|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants had to use versions of the scale. They were randomized to using Panda or the original version of the scales first. Scores obtained using the two versions are then compared.||||
33735373|NCT05993546|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33735374|NCT05802381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735375|NCT05667298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The primary/preferred adjuvant therapy will be immunoradiotherapy (ARM1); however, if this combination is felt to be too high-risk for specific patients, the next preferred therapy will be immunotherapy without radiation (ARM1B). Some patients have medical conditions, i.e., severe auto-immune disease that prohibits them from receiving immunotherapy. In such patients, adjuvant therapy will be provided in the form of concurrent chemoradiotherapy (ARM2).||||
33735376|NCT04698161|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735377|NCT01305031|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735378|NCT02090179|||CASE_ONLY||PROSPECTIVE|||||||
33735379|NCT03417661|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33735380|NCT06663735|||CASE_ONLY||CROSS_SECTIONAL|||||||
33735381|NCT02505126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735382|NCT05009797|||COHORT||PROSPECTIVE|||||||
33735383|NCT06144502|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study has a quasi-experimental Extended Selection Cohorts (ESC) design. The ESC design is a cohort-longitudinal design with adjacent cohorts, that are measured at two or more time points.~To separate any effects of the intervention from changes in variables due to other causes, a wait list control group element will be applied, i.e., delayed intervention/stepped wedge design: ½ of the schools will start the intervention in November 2023, while the remaining schools will start the intervention in January 2024."||||
33735384|NCT06368063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735385|NCT00261482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735386|NCT05239676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044634|NCT06575166|||COHORT||PROSPECTIVE|||||||
34044635|NCT02786875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044636|NCT04994691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34044637|NCT02569151|||COHORT||PROSPECTIVE|||||||
34044638|NCT01199835|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735387|NCT01720095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735388|NCT04904510|||COHORT||PROSPECTIVE|||||||
33735389|NCT06167928|||COHORT||OTHER|||||||
33735390|NCT01687504|||COHORT||PROSPECTIVE|||||||
33735391|NCT01418248|||COHORT||PROSPECTIVE|||||||
34044639|NCT04804423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044640|NCT02882360|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34123048|NCT01623934|||COHORT||PROSPECTIVE|||||||
34123049|NCT00224081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123050|NCT02494154|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33735392|NCT04935697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735393|NCT02028299|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735394|NCT06040346|NA|SEQUENTIAL||TREATMENT||NONE||||||
33735395|NCT06262360|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33735396|NCT00647192|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33735397|NCT04939623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be sequentially randomized. Allocation will be concealed through use of a computer-generated algorithm employing simple randomization without stratification. Participants and the research team will be blinded to group assignment. Randomization will utilize a 2:2:1 ratio (500 mg Probenecid:1000mg Probenecid: placebo).|"40 participants will be randomized in a 2:2:1 ratio to one of:~1. Probenecid 500 mg PO BID (16 participants)~2. Probenecid 1000 mg PO BID (16 participants)~3. Placebo PO BID (8 participants)"|t|f|t|t
33735398|NCT00559962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735399|NCT06230367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Control group content is written to affect an experience as if one were in the intervention group.|Participants will be randomized to either the intervention or control group|t|f|f|f
33735400|NCT02343510|||CASE_CONTROL||RETROSPECTIVE|||||||
33735401|NCT06664242|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33735402|NCT01416012|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735403|NCT05375513|RANDOMIZED|PARALLEL||PREVENTION||NONE||The SYNERGIC-2 Trial is a single-blind, two-arm, randomized controlled trial (RCT) evaluating the cognitive effect of personalized multidomain interventions that target physical exercise, cognitive training, sleep, diet, and vascular risk factors. The SYNERGIC-2 Trial will be administered virtually through online video conferencing platform systems (WeBex or Zoom Healthcare©). Figure 1 illustrates the trial design. The trial adheres to the Consolidated Standards of Reporting Trials (CONSORT) guidelines for conducting and reporting clinical trials, as extended to non-pharmacological interventions. A total of 550 participants with MCI aged 60-85 will be enrolled and randomized into one of two arms, with 275 participants in each arm||||
33735404|NCT02752412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735405|NCT03328689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Given that this is an exercise study blinding of participants and those delivering the exercise program will not be possible. Outcome measures will be collected by an investigator not aware of treatment allocation, but most outcome measures will be self-reported and thus, true assessor blinding will no be possible. All statistical analysis will be conducted by a blinded investigator.||f|f|t|t
33735406|NCT01195467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735407|NCT01110915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735408|NCT02550964|||COHORT||PROSPECTIVE|||||||
33735409|NCT04766879|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33735410|NCT02848118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735411|NCT01410149|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33735412|NCT05610111|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735413|NCT03944122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patients and the physician was blind to the study||t|f|t|f
33735414|NCT02150122|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33735415|NCT03574506|||COHORT||RETROSPECTIVE|||||||
33735416|NCT02095184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735417|NCT03976921|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Upon completion of the screening procedure and enrollment, the patients will be randomized 1:1 to the CT-based strategy (Group A) or usual care (Group B).||||
33735418|NCT02782650|||COHORT||CROSS_SECTIONAL|||||||
33735419|NCT01559792|||CASE_ONLY||PROSPECTIVE|||||||
33735420|NCT04962568|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735421|NCT06574243|||OTHER||PROSPECTIVE|||||||
33735422|NCT05488899|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Participants are not informed of which arm they are assigned to.|RCT: Patients assigned to study or control group|t|f|f|f
33735423|NCT00667342|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735424|NCT03844373|NA|SINGLE_GROUP||OTHER||NONE||||||
33735425|NCT01271400|||CASE_ONLY|||||||||
33735426|NCT04904523|||COHORT||PROSPECTIVE|||||||
33735427|NCT00535886|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735428|NCT00796861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735429|NCT00054613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33735430|NCT06572007|||OTHER||PROSPECTIVE|||||||
33735431|NCT01663272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735432|NCT06663514|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735433|NCT04715984|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33814036|NCT03790098|RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization to arm follows the baseline assessment visit.|Group 1 Participants attend Restorative-Flow Yoga classes, two times per week with a certified yoga instructor and have at-home supplemental materials. Group 2 receive the at-home supplemental materials after outcome visit corresponding to after the 24 classes.||||
33814037|NCT00505024|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814038|NCT00966745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814039|NCT04349709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814040|NCT02717780|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33814041|NCT02568059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814042|NCT01166191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814043|NCT01789866|||COHORT||PROSPECTIVE|||||||
33814044|NCT02591082|||COHORT||PROSPECTIVE|||||||
33814045|NCT05202444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814046|NCT03717558|RANDOMIZED|CROSSOVER||OTHER||NONE||Open label, crossover, randomized, 5-period, 20-sequence, partial replicate, single dose design||||
33814047|NCT00549666|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33814048|NCT05867992|||COHORT||PROSPECTIVE|||||||
33814049|NCT02151994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814050|NCT04189172|||COHORT||PROSPECTIVE|||||||
33814051|NCT00547885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814052|NCT03242863|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33814053|NCT01285167|||COHORT||PROSPECTIVE|||||||
34044641|NCT04429100|||COHORT||RETROSPECTIVE|||||||
34044642|NCT03660111|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|subjects will be assigned to their inclusion number|||||
34044643|NCT02275546|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044644|NCT01760174|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044645|NCT05783440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33814054|NCT05196958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814055|NCT06321094|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814056|NCT03305185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessor, statistician and investigator blinded|"Patients diagnosed with AIS referred for bracing through the hospital's specialist outpatient clinic are eligible to enrol the study. The Investigator will document whether each patient meets the selection criteria before enrolment into the study. The Investigator or designee will also obtain an IRB/EC approved Informed consent from each patient and/or guardian.~Recruited patients will be randomly assigned to either SSE group or control group in a ratio of 1:1. The radiographic evaluation, physical examination and PROM questionnaires will be assessed at baseline, post-treatment 3 months, 6 months, 12 months and until skeletal maturity."|f|f|t|t
33814057|NCT04528602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814058|NCT05837689|||CASE_ONLY||RETROSPECTIVE|||||||
33814059|NCT00193102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814060|NCT02808676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33814061|NCT00001998||||TREATMENT||||||||
33814062|NCT05647941|||COHORT||RETROSPECTIVE|||||||
33814063|NCT01423461|||COHORT||PROSPECTIVE|||||||
33814064|NCT00587405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814065|NCT05450757|||COHORT||PROSPECTIVE|||||||
33814066|NCT05062226|NA|SINGLE_GROUP||OTHER||NONE||15 patients per product will be included in the case studies for a total of 45 patients.||||
33814067|NCT03559777|RANDOMIZED|PARALLEL||OTHER||SINGLE|Each patient will be given a code by the researcher and the observers will be blind to which group this case belong.|The patients will be randomly divided into 2 equal groups|f|f|t|f
33814068|NCT00071188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814069|NCT05813522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814070|NCT04550455|NA|SEQUENTIAL||TREATMENT||NONE||Boxes for treatment cycles distributed will be based on weight||||
33814071|NCT05495633|||COHORT||PROSPECTIVE|||||||
33814072|NCT06342128|||COHORT||PROSPECTIVE|||||||
33814073|NCT05924373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|multicenter, randomized, double-blind, parallel, placebo-controlled study|t|f|t|f
33814074|NCT04392648|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33814075|NCT02122042|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33814076|NCT04737889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814077|NCT05224388|||COHORT||RETROSPECTIVE|||||||
33814078|NCT04430153|||COHORT||CROSS_SECTIONAL|||||||
33814079|NCT02805075|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814080|NCT03571906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814081|NCT04053491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814082|NCT04044885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33814083|NCT01399437|||||OTHER|||||||
33814084|NCT05000359|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.||||
33814085|NCT04645303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34044646|NCT05950919|RANDOMIZED|PARALLEL||OTHER||NONE||hybrid effectiveness-implementation stepped wedge trial||||
34044647|NCT00441129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044648|NCT02555150|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33814086|NCT05556200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044649|NCT01910584|||CASE_ONLY||PROSPECTIVE|||||||
34044650|NCT04707469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34044651|NCT00910533|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044652|NCT04606004|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044653|NCT06574490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044654|NCT00034242||||TREATMENT||||||||
34044655|NCT03369886|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"3 subject groups:~1. Normal control:~   Subjects who has normal fundus, normal visual field and normal intraocular pressure.~2. Early glaucoma:~   : Patients who shows glaucomatous visual field abnormality but visual field mean deviation is \> -6 dB~3. Advanced glaucoma : Patients who shows glaucomatous visual field abnormality but visual field mean deviation is \< -6 dB"||||
34044656|NCT06418724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044657|NCT03423550|||COHORT||PROSPECTIVE|||||||
34044658|NCT02760823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044659|NCT04000425|||COHORT||PROSPECTIVE|||||||
34044660|NCT01055691|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34044661|NCT04439448|||COHORT||CROSS_SECTIONAL|||||||
34044662|NCT04549792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044663|NCT06577272|||COHORT||RETROSPECTIVE|||||||
34123051|NCT05446935|NA|SINGLE_GROUP||TREATMENT||NONE||A Prospective single-arm Study||||
33814087|NCT05238337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814088|NCT02744105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
33814089|NCT06092905|||COHORT||RETROSPECTIVE|||||||
33814090|NCT00476957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33814091|NCT06063993|||COHORT||PROSPECTIVE|||||||
33814092|NCT04733417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814093|NCT03860909|||COHORT||PROSPECTIVE|||||||
34044664|NCT01464164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814094|NCT02424305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814095|NCT03093532|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Research Assistants are blinded to study arm assignment of participant when assessing outcomes measures||f|f|f|t
33814096|NCT01576744|||CASE_ONLY||PROSPECTIVE|||||||
33814097|NCT04543669|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044665|NCT05899517|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled double-blind within-subject design|t|f|t|t
34044666|NCT06286527|||OTHER||OTHER|||||||
34044667|NCT01677572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123052|NCT06049550|||COHORT||RETROSPECTIVE|||||||
34123053|NCT00525434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123054|NCT02910141|||COHORT||RETROSPECTIVE|||||||
34123055|NCT02559973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735434|NCT04010968|RANDOMIZED|PARALLEL||TREATMENT||NONE||Direct comparison between immuno-chemotherapy and effective chemo-free arm combining a BTK inhibitor and a Bcl2 inhibitor.||||
33735435|NCT01157481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735436|NCT05422248|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735437|NCT01593618|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735438|NCT02791815|RANDOMIZED|CROSSOVER||||NONE||||||
33735439|NCT02302105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735440|NCT05281731|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735441|NCT00177723|||||PROSPECTIVE|||||||
33735442|NCT06621121|||COHORT||PROSPECTIVE|||||||
33735443|NCT06573840|NON_RANDOMIZED|PARALLEL||OTHER||NONE||3 healthy volunteers and 10 post stroke patients will be enrolled in the study.||||
33735444|NCT05109585|||COHORT||PROSPECTIVE|||||||
33735445|NCT05291390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All capsules contain either pyronaridine or similar-appearing placebo.|The primary objective is the difference in survival lengths in days between the study arm receiving pyronaridine and the study arm receiving placebo as measured from the date of the first diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).|t|t|t|t
33735446|NCT01416194|||COHORT||RETROSPECTIVE|||||||
33735447|NCT06316414|||CASE_ONLY||PROSPECTIVE|||||||
33735448|NCT00691210|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735449|NCT04700514|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33735450|NCT03946761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735451|NCT02803710|||CASE_CONTROL|||||||||
33735452|NCT01027585|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33735453|NCT00748943|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33735454|NCT03135522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735455|NCT00954213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735456|NCT02247349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735457|NCT00199745|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735458|NCT00654628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735459|NCT00321035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735460|NCT06444620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735461|NCT00953797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735462|NCT04612491|||CASE_CONTROL||PROSPECTIVE|||||||
33735463|NCT06285539|NA|SINGLE_GROUP||TREATMENT||NONE||A 26-week multicenter, open-label, uncontrolled, non-randomized, non-blinded proof-of-concept, two-stage phase 2 study||||
33735464|NCT02065102|||CASE_CROSSOVER||PROSPECTIVE|||||||
33735465|NCT06531564|||COHORT||PROSPECTIVE|||||||
33735466|NCT02170753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735467|NCT02164396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735468|NCT00260234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735469|NCT03613246|||OTHER||PROSPECTIVE|||||||
33735470|NCT01374113|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735471|NCT06569069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735472|NCT01395212|||CASE_ONLY||PROSPECTIVE|||||||
33735473|NCT00886093|RANDOMIZED|CROSSOVER||||NONE||||||
33735474|NCT03826420|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants (parolees) will not be notified as to which arm they are enrolled.||t|f|f|f
33735475|NCT06197451|||OTHER||PROSPECTIVE|||||||
33735476|NCT02616575|||CASE_ONLY||PROSPECTIVE|||||||
33735477|NCT03843684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735478|NCT04279834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735479|NCT03194646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735480|NCT06504017|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33735481|NCT05962905|||COHORT||PROSPECTIVE|||||||
33735482|NCT06199986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735483|NCT04458571|||COHORT||PROSPECTIVE|||||||
33735484|NCT03921411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735485|NCT05145920|NA|SINGLE_GROUP||TREATMENT||NONE||Open, single-group trial||||
33735486|NCT05755373|||COHORT||CROSS_SECTIONAL|||||||
33735487|NCT01201252|||CASE_ONLY||PROSPECTIVE|||||||
33735488|NCT05448924|||CASE_ONLY||RETROSPECTIVE|||||||
33735489|NCT06363084|||CASE_CONTROL||RETROSPECTIVE|||||||
33735490|NCT01540370|||COHORT||PROSPECTIVE|||||||
33735491|NCT00807092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735492|NCT00058331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735493|NCT02835365|||COHORT||PROSPECTIVE|||||||
33735494|NCT01969071|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33735495|NCT05116722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735496|NCT06573411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735497|NCT05491707|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this randomised controlled trial, patients will be identified on the arthroplasty lists. Criteria for inclusion will be determined at the pre-operative assessment. After enrolment, participants will be randomised into two groups in a 1:1 ratio, music (intervention group) and no music (control group). Randomisation will be done using a simple randomisation chart.||||
33735498|NCT00910715|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735499|NCT01440322|RANDOMIZED|PARALLEL||||NONE||||||
33735500|NCT04834011|||CASE_ONLY||PROSPECTIVE|||||||
33735501|NCT00436306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735502|NCT01218139|||COHORT||RETROSPECTIVE|||||||
33735503|NCT06531603|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and assessor were unaware of interventions||t|f|f|t
33735504|NCT03428516|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33735505|NCT02616003|NA|SINGLE_GROUP||OTHER||NONE||||||
33735506|NCT05255289|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735507|NCT01285739|||CASE_CONTROL||PROSPECTIVE|||||||
33735508|NCT03613506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735509|NCT05846009|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33735510|NCT04096560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735511|NCT06029959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735512|NCT00360776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735513|NCT02566759|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33735514|NCT05351008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two arms, parallel-design, assessor-blinded randomized controlled trial|t|f|f|t
33735515|NCT05928702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|f|f|f|t
33735516|NCT00184899|RANDOMIZED|CROSSOVER||ECT||SINGLE||||||
33735517|NCT06567652|||COHORT||RETROSPECTIVE|||||||
33735518|NCT06573216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735519|NCT05796544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33735520|NCT00978731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735521|NCT03567759|||COHORT||PROSPECTIVE|||||||
33735522|NCT02548013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123056|NCT05725122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735523|NCT05917873|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33735524|NCT01606085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123057|NCT03761355|||COHORT||PROSPECTIVE|||||||
33735525|NCT01885442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735526|NCT02155595|||COHORT||PROSPECTIVE|||||||
33735527|NCT00448058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735528|NCT05552703|||COHORT||PROSPECTIVE|||||||
33735529|NCT05855863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735530|NCT01270945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735531|NCT03640663|||COHORT||PROSPECTIVE|||||||
33735532|NCT06224829|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735533|NCT05138380|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Assessor blinding: Participants complete their own outcome measures (questionnaires) online and are thus not blind. Accelerometry data will be assessor blinded. All outcome measures will be analysed by an investigator blind to participant group allocation. Participants will be instructed not to divulge any aspect of their intervention to the research assistant conducting follow-up assessments.~Participant blinding: Participants will be advised that they have an equal chance of being allocated to the either shoe insert, and thus are blind to allocation. Participants will also be blind to the study hypothesis, so they are unaware which of the interventions is 'active'.~Physiotherapist blinding: It is not possible to blind the trial physiotherapist to group allocation. Trial Physiotherapists will however not be involved in assessment of outcome measures."|Two-arm, participant blinded, parallel group feasibility RCT|t|f|f|t
33735534|NCT06426797|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with locally advanced resectable esophageal squamous cell carcinoma||||
33735535|NCT03212677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33735536|NCT01804556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735537|NCT04688840|||OTHER||PROSPECTIVE|||||||
33735538|NCT05875441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded. Subjects will be randomized to one of the treatment arm by Interactive Response Technology at 1:1:1:1|Placebo-controlled, double-blind, randomized, dose ranging study. Four cohorts of 50 subjects per cohort are planned. Subjects will be randomized 1:1:1:1 to receive Moxidectin 8mg, Moxidectin 16mg, Moxidectin 32mg or Placebo as a single oral dose.|t|t|t|t
33735539|NCT01441427|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33735540|NCT00471913|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735541|NCT02327208|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33735542|NCT00236938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735543|NCT04777396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33735544|NCT05664997|||COHORT||CROSS_SECTIONAL|||||||
33735545|NCT01485601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735546|NCT00529386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735547|NCT02810834|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735548|NCT02665728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735549|NCT04805983|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study will enroll four cohorts of 6 participants each. Study drug will be administered in sequentially increasing dose groups. For all 6 participants at a dose cohort, a safety assessment review will be completed prior to advancing the next higher dose level.||||
33735550|NCT06358079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to the group type when analyzing data|A prospective study involving patients undergoing off-pump coronary artery bypass surgery. Patients will be randomized to two groups; an isolated cardiotomy circuit for re-infusion of unwashed shed blood will be used in group (a) and the conventional no re-infusion technique will be used in group (b).|f|f|f|t
33735551|NCT05443477|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Both subjects and researchers were blind to the treatment assignment until the statistical analysis was completed. All the subjects were randomly divided into placebo group and two intervention groups (i.e. supplementation with Grape King Hericium erinaceus Mycelium Capsules and Grape King Probiotic Capsules) by using Excel to generate random numbers.|In the intervention phase of this study, 105 eligible participant were randomly divided into intervention (Grape King Hericium erinaceus Mycelium Capsules and Grape King Probiotic Capsules) and placebo groups (n=35/group). Both subjects and researchers were blind to the treatment assignment until the statistical analysis was completed.|t|f|t|f
33735552|NCT04190745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735553|NCT01608477|||CASE_ONLY||CROSS_SECTIONAL|||||||
33735554|NCT03962881|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33814098|NCT01334606|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33814099|NCT05675748|||OTHER||PROSPECTIVE|||||||
33814100|NCT03374722|||COHORT||PROSPECTIVE|||||||
33814101|NCT05731440|||OTHER||PROSPECTIVE|||||||
33814102|NCT01578304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814103|NCT00068809|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814104|NCT02734784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814105|NCT01767025|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33814106|NCT01779089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814107|NCT00789971|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33814108|NCT02869230|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814109|NCT00257556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814110|NCT02813733|||COHORT||PROSPECTIVE|||||||
34123058|NCT00682045|||COHORT||PROSPECTIVE|||||||
34044668|NCT03901820|NON_RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"An electronic medical record, DrApp, will be used, which will include a drug interaction program, SIMDA, which will automatically indicate the medication prescriptions that involve a risk for the patient.~The first indication of each patient admitted to two rooms of the Internal Medicine Department of the Hospital de Clínicas José de San Martín will be registered. The indications will be compared in the 4 months prior to the incorporation of the SIMDA program with the 4 months after the incorporation of the program. Between both stages a period of 2 weeks will be established in which the data will not be recorded. The minimum number of patients that will be included in each stage is 100."|t|t|t|f
34044669|NCT00573274|||CASE_ONLY||PROSPECTIVE|||||||
34044670|NCT00300885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34044671|NCT04565665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044672|NCT06575764|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Group Assignment||||
34044673|NCT00140244|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34044674|NCT02575326|RANDOMIZED|PARALLEL||OTHER||NONE|Physicians are randomized. Eligible youth that present to the participating physician assume the assignment of that physician|||||
34044675|NCT03021083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044676|NCT06144164|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044677|NCT05297370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044678|NCT01676610|||COHORT||PROSPECTIVE|||||||
34044679|NCT06576232|||COHORT||RETROSPECTIVE|||||||
34044680|NCT06459453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding refers to a practice where study participants are prevented from knowing certain information that may somehow influence them thereby tainting the results.|Participants are assigned to one of the treatment arms at the begining of the trial and continue in that arm throughout the length of the trial.|f|f|f|t
34044681|NCT00144521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044682|NCT02445157|||COHORT||PROSPECTIVE|||||||
34044683|NCT02059655|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33735555|NCT06162741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be enrolled in one of the two intervention groups at the end of the baseline. Research staff enrolling and administering assessments to the participants will be blinded to which intervention a participant is randomized to.|Participants in the study are assigned to one of two treatment arms, Primary Care Brief Mindfulness Training (PCBMT) or Moving Forward (MF) transdiagnostic problem-solving therapy, at the beginning of the trial and continue in that arm throughout the length of the trial. Randomization will occur towards the end of the baseline session, at the individual level, at a 1:1 ratio of assignment to PCBMT or MF. Study participants are only exposed to the treatment that is assigned to the particular study arm they are enrolled in.|f|f|f|t
33735556|NCT01703949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735557|NCT00318487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735558|NCT03056690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735559|NCT04298710|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33735560|NCT06662734|||COHORT||RETROSPECTIVE|||||||
33735561|NCT06534216|||COHORT||PROSPECTIVE|||||||
33735562|NCT02621970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735563|NCT00682019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735564|NCT03685331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The phase I component is a dose-escalation study. Dose escalation will follow a 3+3 design. An additional cohort of at least 36 patients (total number of patients in phase I and phase II = 54) will be included on the single-arm, non-randomized phase II portion of this clinical trial.||||
33735565|NCT02017691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735566|NCT01343160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735567|NCT00103792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735568|NCT00218062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735569|NCT02568410|||COHORT||PROSPECTIVE|||||||
33735570|NCT04122443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735571|NCT06360549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The intervention group was percutaneous acupoint electrical stimulation treatment group, and the control group was conventional treatment group.~Inclusion criteria:~1. Voluntarily sign informed consent;~2. Age ≥18 years old;~3. Patients undergoing thoracoscopic pneumonectomy;~4. ASA Grade I-III;"|t|t|t|t
33735572|NCT05518279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participants and treatment team will be blinded to the treatment medication.||t|t|f|f
33735573|NCT04225559|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33735574|NCT06406205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735575|NCT01641588|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33735576|NCT02828839|NA|SINGLE_GROUP||SCREENING||NONE||||||
33735577|NCT04978662|||CASE_ONLY||PROSPECTIVE|||||||
33735578|NCT00585806|||CASE_CONTROL||PROSPECTIVE|||||||
33735579|NCT05834543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735580|NCT05607992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735581|NCT03684200|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33735582|NCT02720926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735583|NCT00004357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735584|NCT04354922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind (Outcome Assessor)|5 groups ×2 times factorial design|f|f|f|t
33735585|NCT03858075|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33735586|NCT02717533|||CASE_ONLY||PROSPECTIVE|||||||
33735587|NCT04083456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled futility design|f|f|t|t
33735588|NCT03086798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735589|NCT05961215|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735590|NCT01632579|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33735591|NCT03792685|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33735592|NCT02618993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735593|NCT00012961|||||PROSPECTIVE|||||||
33735594|NCT02196597|||COHORT||PROSPECTIVE|||||||
33735595|NCT04749849|||COHORT||PROSPECTIVE|||||||
33735596|NCT00024518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814111|NCT02226237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735597|NCT02465528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Depending on the tumor type, subjects were to be enrolled into one of the following parallel arms: ALCL (anaplastic large cell lymphoma); IMT (inflammatory myofibroblastic tumor); glioblastoma (GBM), and any other ALK+ tumor. If there were 5 or more subjects of the same tumor type in the Any other ALK+ tumor arm, then a separate arm was to be opened for that specific tumor type."||||
33735598|NCT06572085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735599|NCT01927770|||COHORT||PROSPECTIVE|||||||
33735600|NCT01992484|||COHORT||PROSPECTIVE|||||||
33735601|NCT00536367|||||PROSPECTIVE|||||||
33735602|NCT05524324|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Double blind randomized cross-over trial. Two cross-over periods of 3 months comparing biventricular pacing (CRT ON) vs. inactive pacing (ventricular back-up pacing or left ventricular pacing alone in patients requiring pacing, CRT OFF), each period in random order.|t|f|t|f
33735603|NCT00434668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735604|NCT00169637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735605|NCT06265220|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33735606|NCT03895853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735607|NCT03496285|NA|PARALLEL||OTHER||NONE||||||
33735608|NCT03970434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735609|NCT00384137|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735610|NCT06259292|||COHORT||PROSPECTIVE|||||||
33735611|NCT02653677|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33735612|NCT04188535|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33735613|NCT01972360|||OTHER||PROSPECTIVE|||||||
33735614|NCT03131232|||COHORT||PROSPECTIVE|||||||
33735615|NCT01688336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735616|NCT00121771|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33735617|NCT03565185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33735618|NCT06664255|||COHORT||RETROSPECTIVE|||||||
33735619|NCT06572410|||OTHER||PROSPECTIVE|||||||
33735620|NCT04793880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study utilizes a stepped wedge cluster-randomized design where study sites are assigned to transition to the intervention as recruitment milestone are met.||||
33735621|NCT00797667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735622|NCT01980849|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735623|NCT05446909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||mindfulness vs. health education|t|t|t|t
33735624|NCT06663397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A single-center parallel-group randomized controlled trial study|t|f|f|f
33735625|NCT00349492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814112|NCT03264222|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective cohort study.||||
33814113|NCT06015659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814114|NCT05497804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814115|NCT02111499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814116|NCT03996577|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Participants are randomly assigned to controll group or lidocaine group. Participants of control group are given placebo while participants of lidocaine group are given lidocaine.|t|t|f|t
33814117|NCT00826982|||CASE_ONLY||PROSPECTIVE|||||||
33814118|NCT00045201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814119|NCT04086342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Placebo controlled|t|f|t|f
33814120|NCT00689195|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814121|NCT02804074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814122|NCT05749562|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33814123|NCT05285189|||COHORT||PROSPECTIVE|||||||
33814124|NCT00413283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33814125|NCT02134626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814126|NCT04180072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814127|NCT00332852|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814128|NCT01394406|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33814129|NCT03001141|||COHORT||PROSPECTIVE|||||||
33814130|NCT01336907|||COHORT||PROSPECTIVE|||||||
33814131|NCT02918045|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participant (patient) does not know which site received the study local hemostatic or the control local hemostatic.It is not possible for the surgeon to be blinded in this case.|Single-blind, Randomized, Split-mouth|t|f|f|f
33814132|NCT05901688|||COHORT||PROSPECTIVE|||||||
33735626|NCT06349616|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Subjects participate in 4 experiments, 2 for each treatment (folic acid supplementation and placebo). The order of treatment is random.|t|f|t|f
33735627|NCT03815422|||COHORT||OTHER|||||||
33735628|NCT05729620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735629|NCT03660046|||COHORT||PROSPECTIVE|||||||
33735630|NCT03917693|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"This process will be carried out by a QIB scientist who is not part of the study team.~Wendy Hollands (QIB Food Innovation and Health \[FIH\] scientist) will be responsible for this process, and therefore ensures the trial remains blinded to the study participants, Chief Investigators and study scientists/advisors."||t|f|t|t
33735631|NCT00295659|||||OTHER|||||||
33735632|NCT01350427|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33735633|NCT05886764|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Patient participants will not be informed of which intervention they are assigned.||t|f|f|f
33735634|NCT02417454|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735635|NCT02640794|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814133|NCT06483698|||COHORT||RETROSPECTIVE|||||||
33814134|NCT05713136|||COHORT||PROSPECTIVE|||||||
33735636|NCT04015661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814135|NCT02239991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814136|NCT05711589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||zero-fluoroscopic and conventional fluoroscopy groups|t|f|f|f
33814137|NCT00083798|||COHORT||PROSPECTIVE|||||||
33814138|NCT01944774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735637|NCT02864771|||COHORT||PROSPECTIVE|||||||
33735638|NCT01050595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123059|NCT04532515|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Seal-G Product Family variants will be used as the study device (Treatment) according to the following scheme:~1. Seal-G Surgical Sealant \[Seal-G\]- will be applied on colonic anastomosis created by extra-corporal approach.~2. Seal-G MIST System \[Seal-G MIST\]- will be applied on colonic anastomosis created by intra-corporal approach.~Intended Use: Seal-G/Seal-G MIST are surgical sealants intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"||||
33735639|NCT01464528|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735640|NCT02545907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814139|NCT06121778|||COHORT||PROSPECTIVE|||||||
33735641|NCT04065724|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33735642|NCT05166434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33735643|NCT04335344|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735644|NCT00145366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33814140|NCT06585124|||COHORT||OTHER|||||||
33814141|NCT05947071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All study staff, and subjects will be blinded to which vaccine the subject will receive, except for an un-blinded vaccinator. This individual will not inform the study team or the subjects which vaccine they administered to the subject. The un-blinded vaccinator will not participate in any other study activities. The pharmacy will be un-blinded and will have a record of which vaccine was given to each subject.|The primary goal of this two-arm, double blind, randomized controlled trial is to compare influenza vaccine immunogenicity and safety between (a) two doses of SD-QIV and (b) two doses of HD-QIV over one influenza season in a population of pediatric SOT recipients who are ≥1 month and \<24 months post-transplant at the time of study immunization.|t|t|t|t
33814142|NCT05902572|||COHORT||PROSPECTIVE|||||||
33814143|NCT06439797|||CASE_CONTROL||PROSPECTIVE|||||||
33814144|NCT04610606|RANDOMIZED|PARALLEL||OTHER||NONE||Open-label, randomized, controlled trial of two parallel arms: multimodal intervention (MM) and standard of care (SOC).||||
33814145|NCT02198105|||COHORT||PROSPECTIVE|||||||
33814146|NCT01916057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814147|NCT04412174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814148|NCT03166215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814149|NCT02991456|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33814150|NCT02249156|||COHORT||RETROSPECTIVE|||||||
33814151|NCT01287832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814152|NCT06315465|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Label Randomized Controlled Trial||||
33814153|NCT00860301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33814154|NCT03326856|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||sequential, dose escalating study|t|t|t|t
34123060|NCT00352859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123061|NCT02261207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123062|NCT02802293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123063|NCT05236322|||CASE_CONTROL||PROSPECTIVE|||||||
33735645|NCT03925792|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33735646|NCT06364124|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735647|NCT04662307|NA|SINGLE_GROUP||TREATMENT||NONE||A small group of healthy subjects with sedentary lifestyle is recruited to validate the ICRS. They receive training with ICRS three sessions a week, for a total of 12 sessions. The outcome assessments are performed before and after the training.||||
33735648|NCT04118322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised controlled trials||||
33735649|NCT02012946|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735650|NCT06664073|||COHORT||PROSPECTIVE|||||||
33735651|NCT05919394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735652|NCT03378336|||COHORT||PROSPECTIVE|||||||
33735653|NCT05371587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants are allocated using sealed envelops, they receive their arm identification A or B without information regarding the intervention or group differences. Data will be analyzed using the identification letter without treatment allocation information."|A parallel two-armed, non-inferiority randomized controlled trial|t|f|f|f
33735654|NCT06572800|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735655|NCT00575744|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735656|NCT00981500|||COHORT||PROSPECTIVE|||||||
33735657|NCT02880371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735658|NCT04488276|||CASE_ONLY||CROSS_SECTIONAL|||||||
33735659|NCT06664463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735660|NCT02066857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735661|NCT01115426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735662|NCT00064441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33735663|NCT06128525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735664|NCT06572475|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33735665|NCT01620606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735666|NCT03626129|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33735667|NCT00000415|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33735668|NCT00773305|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33735669|NCT05004922|||CASE_ONLY||PROSPECTIVE|||||||
33735670|NCT02803697|||COHORT||RETROSPECTIVE|||||||
33735671|NCT01086579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735672|NCT06602596|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735673|NCT03698773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33735674|NCT06459557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735675|NCT01974050|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33735676|NCT05690737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735677|NCT01236196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735678|NCT05757375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33735679|NCT00622427|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33735680|NCT03691220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study pathologists will perform masked reading of for-cause biopsy slides.|Study participants will be randomized to receive the telemetric intervention or standard of care.|f|f|f|t
33735681|NCT02692157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33735682|NCT01728467|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33735683|NCT02968199|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The study was not a randomized controlled trial. Participants and outcome assessors were not blinded.|||||
33814155|NCT03400059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33814156|NCT00582920|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33735684|NCT00763542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735685|NCT05165121|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735686|NCT00797615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735687|NCT00228527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33735688|NCT04719910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33735689|NCT05631080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735690|NCT05483010|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735691|NCT06115876|||COHORT||PROSPECTIVE|||||||
33735692|NCT02512497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735693|NCT04977843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735694|NCT03274479|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33735695|NCT03146650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735696|NCT00218192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735697|NCT05457309|NA|SEQUENTIAL||TREATMENT||NONE||||||
33735698|NCT04467827|||COHORT||PROSPECTIVE|||||||
33735699|NCT06663930|||COHORT||PROSPECTIVE|||||||
33735700|NCT04439240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735701|NCT00724451|||CASE_ONLY||PROSPECTIVE|||||||
33735702|NCT03145727|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The participant will be blind to the TENS allocation.|The selection of the investigated will be characterized as non-probabilistic with a convenience approach, whose patients will be included in the study sequentially until the necessary sizing has been achieved. Patients will be included sequentially for convenience (according to the inclusion and exclusion criteria) and non-probabilistic. The included individuals will be randomly randomized by Random Allocation System software in three groups, 1) placebo group; 2) High Frequency Group; 3) Low Frequency Group.|t|f|f|f
33735703|NCT02909322|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735704|NCT04080765|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33735705|NCT05489874|||OTHER||RETROSPECTIVE|||||||
33735706|NCT02662387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735707|NCT03900533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735708|NCT01557075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33735709|NCT00027430|RANDOMIZED|PARALLEL||TREATMENT||||||||
33735710|NCT00286949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735711|NCT00882011|||CASE_ONLY||PROSPECTIVE|||||||
33735712|NCT04083872|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735713|NCT06469047|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814157|NCT03364803|||COHORT||PROSPECTIVE|||||||
33814158|NCT02953756|||CASE_ONLY||PROSPECTIVE|||||||
33814159|NCT00915629|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33814160|NCT03029156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814161|NCT01163214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814162|NCT02464215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814163|NCT03886207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are age and core body temperature stratified and then randomized to one of the two groups (footbath with warm water with additional ginger powder or warm water only). Assessments are taken before and after the six-week intervention phase as well as at six-month follow-up.|f|f|f|t
33814164|NCT02784145|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814165|NCT06005116|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814166|NCT01355692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814167|NCT05700656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814168|NCT03445585|||OTHER||PROSPECTIVE|||||||
33814169|NCT02283632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735714|NCT03041259|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33735715|NCT01085175|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735716|NCT03730935|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33814170|NCT04617847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814171|NCT02265497|||COHORT||PROSPECTIVE|||||||
33814172|NCT00631202|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814173|NCT01383590|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814174|NCT04464499|||COHORT||PROSPECTIVE|||||||
33814175|NCT05923307|||COHORT||PROSPECTIVE|||||||
33814176|NCT01781923|RANDOMIZED|PARALLEL||||NONE||||||
33814177|NCT03937752|||COHORT||PROSPECTIVE|||||||
33814178|NCT00321555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814179|NCT02199444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814180|NCT04617145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||parallel randomized single blinded study|f|f|f|t
33735717|NCT03215355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735718|NCT03348761|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants receive a 4-week repetitive transcranial magnetic stimulation to the left dorolateral prefrontal cortex with pre-treatment resting state MRI Brain taken, that will be subsequently used to model the clinical outcome prediction taking into account other biomarkers.||||
33735719|NCT05001789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and research staff will be blinded to participant's training condition (active vs. sham)||t|t|t|f
33735720|NCT01275183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735721|NCT00392964|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33814181|NCT01798537|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33814182|NCT00433706|RANDOMIZED|PARALLEL||||NONE||||||
33814183|NCT00720317|||CASE_ONLY||PROSPECTIVE|||||||
33814184|NCT05509881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814185|NCT04288661|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814186|NCT01921985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123064|NCT04666974|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants in Phase 3 will be randomly assigned to either iCBT + Treatment as Usual or just Treatment as Usual. In phase 4, participants will be randomly assigned to either iCBT + Treatment as Usual or in-person CBT + Treatment as Usual.||||
33814187|NCT01169402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814188|NCT03966456|||CASE_CONTROL||RETROSPECTIVE|||||||
33814189|NCT03987815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814190|NCT00977678|||CASE_CONTROL||PROSPECTIVE|||||||
33814191|NCT04006015|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814192|NCT03366571|||COHORT||PROSPECTIVE|||||||
33814193|NCT00179478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open label study: The outcome committee determined the primary outcome event (the development of Clinically definite MS) without knowledge of original treatment assignment and the central MRI reading center was not aware of original treatment assignments||f|f|f|t
33814194|NCT01806402|||COHORT||PROSPECTIVE|||||||
33814195|NCT02649725|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33814196|NCT00483457|||CASE_ONLY||PROSPECTIVE|||||||
33814197|NCT00079222|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33814198|NCT03615547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814199|NCT02216448|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33814200|NCT03616522|||COHORT||PROSPECTIVE|||||||
33814201|NCT06211998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814202|NCT02745509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814203|NCT03306329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814204|NCT03750890|||CASE_ONLY||PROSPECTIVE|||||||
33814205|NCT01607697|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33814206|NCT00670852|||CASE_CONTROL||RETROSPECTIVE|||||||
33814207|NCT01775878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814208|NCT00452647|||COHORT||RETROSPECTIVE|||||||
33814209|NCT03657745|||COHORT||PROSPECTIVE|||||||
33814210|NCT04372732|||COHORT||PROSPECTIVE|||||||
33814211|NCT01236898|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814212|NCT06505382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814213|NCT04996654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome evaluator of the pre- and post-measurements will be blinded to group allocation. For all data assessed throughout the intervention period (i.e. only applicable for the intervention group), blinding of investigators is not possible. Blinding of participants was also not possible since usual care will be used as a control intervention.|Allocation ration = 2 (Exergame Group) : 1 (Usual Care)|f|f|f|t
33814214|NCT04306081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study subjects will be randomized, to receive either evolocumab or placebo. Each participant will have equal chance of receiving evolocumab or placebo. The study participant, the care provider and the investigator will not know to which study arm the participant was assigned.|This is a double-blinded, prospective, randomized, placebo-controlled study.|t|t|t|f
33814215|NCT02990494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814216|NCT01605084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814217|NCT00780078|||CASE_ONLY||PROSPECTIVE|||||||
33814218|NCT01175980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814219|NCT02726139|||CASE_ONLY||CROSS_SECTIONAL|||||||
33814220|NCT03019432|||COHORT||CROSS_SECTIONAL|||||||
34123065|NCT01949129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814221|NCT03833765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||single-centre, superiority, double blind clinical trial, with balanced randomisation and parallel two groups design according to CONSORT statement|t|f|f|t
33814222|NCT00383994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814223|NCT01513902|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33814224|NCT03191097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814225|NCT01757288|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is Phase I/II study. Phase I has 1 arm and Phase II has 2 arms (total 3 arms)||||
33814226|NCT01588522|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33814227|NCT06226623|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This research is a randomized controlled study. The research was single-centered and was carried out with the academic, administrative and other personnel of Muğla Sıtkı Koçman University Faculty of Health Sciences. A list of all faculty members was created by the researchers. Randomization was made to the experimental and control groups in a 1:1 ratio using the sealed envelope selection method.||||
33814228|NCT03675282|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33814229|NCT02955225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814230|NCT00778609|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33814231|NCT02008214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814232|NCT05334225|||OTHER||PROSPECTIVE|||||||
33814233|NCT01128439|||CASE_ONLY||PROSPECTIVE|||||||
33814234|NCT00000178|RANDOMIZED|||TREATMENT||DOUBLE||||||
33814235|NCT02028390|NA|SINGLE_GROUP||||NONE||||||
33814236|NCT01748058|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814237|NCT01147757|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33814238|NCT00195988|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814239|NCT01117285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33814240|NCT00721097|||CASE_ONLY||PROSPECTIVE|||||||
33814241|NCT05401188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123066|NCT02276742|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34123067|NCT00530231|||DEFINED_POPULATION||PROSPECTIVE|||||||
34123068|NCT04734314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814242|NCT05351411|||CASE_CONTROL||PROSPECTIVE|||||||
33814243|NCT00207909|||COHORT||PROSPECTIVE|||||||
33814244|NCT05179772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814245|NCT05320133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814246|NCT00679809|||COHORT||PROSPECTIVE|||||||
33814247|NCT06485947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814248|NCT01435720|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814249|NCT05584306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044684|NCT00616148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044685|NCT02729766|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044686|NCT02527746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044687|NCT03334643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned to either the Non-Diabetes or Prediabetes/Diabetes group based on their diagnosis of type 2 diabetes (if any) and their fasting blood glucose concentrations.||||
34044688|NCT02868489|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34044689|NCT00597636|||CASE_CONTROL||PROSPECTIVE|||||||
34044690|NCT00953654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044691|NCT05088174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044692|NCT00842023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044693|NCT04551131|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044694|NCT05353842|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34044695|NCT01985932|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044696|NCT00235885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044697|NCT01921712|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044698|NCT04552314|||COHORT||PROSPECTIVE|||||||
34044699|NCT03135054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044700|NCT05125796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34044701|NCT04514445|||FAMILY_BASED||RETROSPECTIVE|||||||
34044702|NCT00375973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044703|NCT05377502|||CASE_CONTROL||PROSPECTIVE|||||||
34044704|NCT02934698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044705|NCT05401253|||COHORT||PROSPECTIVE|||||||
34044706|NCT06570941|NA|SINGLE_GROUP||TREATMENT||NONE||therapeutic open label single group||||
34044707|NCT06158984|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masked examiner for all clinical assessments will not involved in the data collection or group allocation procedure for this research. The investigator will not be aware of the two groups.|Prospective, comparative pilot study|f|f|t|t
34044708|NCT04549090|||COHORT||PROSPECTIVE|||||||
34044709|NCT01904526|NA|SINGLE_GROUP||OTHER||NONE||||||
34044710|NCT01868022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044711|NCT06451536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prediction of immunotherapy response with Ga-68 FAPI PET||||
34044712|NCT05831189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044713|NCT04849910|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044714|NCT03656653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044715|NCT05314127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044716|NCT06088615|||CASE_ONLY||PROSPECTIVE|||||||
34044717|NCT05178160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044718|NCT02166060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044719|NCT04577261|||COHORT||PROSPECTIVE|||||||
34044720|NCT02490501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044721|NCT06578507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044722|NCT01975142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044723|NCT02393950|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34044724|NCT01733667|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044725|NCT02225860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044726|NCT06574971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123069|NCT02381964|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34123070|NCT05162638|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34123071|NCT06163976|||COHORT||PROSPECTIVE|||||||
34123072|NCT01201551|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123073|NCT01405183|||CASE_CONTROL||PROSPECTIVE|||||||
34123074|NCT01626573|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34044727|NCT03820349|||CASE_CONTROL||PROSPECTIVE|||||||
34044728|NCT05066399|||CASE_ONLY||PROSPECTIVE|||||||
34044729|NCT02514798|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34044730|NCT04281758|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Beverage types are as similar as possible in terms of taste, aroma and color.||t|t|t|t
34044731|NCT00006068|NON_RANDOMIZED|||TREATMENT||SINGLE||||||
34044732|NCT06252558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044733|NCT05839080|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|It is not possible to mask the participants since they are signed up for the Gardens to Bellis intervention.|"The study has two different participant samples. In Sub-Study 1 the participants are pupils from 4th-5th grade from Danish municipal primary and lower secondary schools attending the 'Gardens to Bellis' intervention (intervention group) and pupils from 4th-5th grade from Danish municipal primary and lower secondary schools not attending the 'Gardens to Bellis' intervention.~In Sub-Study 2 and Sub-Study 3, the participant sample is a subsample of the intervention sample in SS1. The participants are pupil's 4th-5th grade (n=540) from 30 Danish municipal primary and lower secondary schools."||||
34044734|NCT00968643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044735|NCT00477399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044736|NCT03850496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044737|NCT05608226|||COHORT||PROSPECTIVE|||||||
34044738|NCT01113437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044739|NCT01620190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044740|NCT03378674|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34044741|NCT04640636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123075|NCT04624516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator didn't know the groups. The assessor didn't know the groups|The exercise group was trained structured foot exercise and they did the exercise independently until 24 weeks or until the recurrence occurred The control group had usual care|f|f|t|t
34044742|NCT02147158|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34044743|NCT03032042|RANDOMIZED|FACTORIAL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34044744|NCT03656692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044745|NCT00820053|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34044746|NCT06004921|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34044747|NCT05667857|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"We will have three cohorts:~* Cohort 1: advanced cancer survivors treated with immunotherapy~* Cohort 2: cancer survivors treated with cancer therapy of any kind (excluded immunotherapy)~* Cohort 3: cancer survivors of a CNS tumor, who do not have active disease in the CNS~All patients of cohort 1 will receive a psychosocial and neurocognitive assessment at baseline. Patients who do not have cognitive problems or do not have interest in following the integrative neurocognitive remediation therapy program will go into the non-intervention group for follow-up.~Patients of cohort 1, 2 and 3 who have cognitive problems and/or cognitive complaints who want to follow the integrative neurocognitive remediation program will complete a neurocognitive and psychosocial assessment before and immediately after the remediation program. The same assessment will be repeated six months after finishing the therapy program, to investigate the long-term efficacy of the therapy program."||||
34044748|NCT02589132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34044749|NCT01214967|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
34044750|NCT02964208|||COHORT||PROSPECTIVE|||||||
34044751|NCT03813082|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34044752|NCT01666158|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34044753|NCT00035217|||DEFINED_POPULATION||OTHER|||||||
34044754|NCT05524168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044755|NCT02370303|||CASE_ONLY||PROSPECTIVE|||||||
34044756|NCT01808781|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34044757|NCT04073888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044758|NCT05259774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients will be randomly allocated to one of the following treatment groups: Relizema cream and vehicle|multicenter, double blind, controlled versus placebo, pre-market clinical followup investigation|t|f|t|f
34044759|NCT05117502|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|After the participant has been consented and meets all study enrollment criteria, the participant will be randomized to a sham or real iTBS treatment. The participant and treating researcher will be blinded. A unique code for the iTBS (Magstim) will be provided by an unblinded research team member, this will provide the sham or real treatment to the participant.|All iTBS (intermittent Theta Burst Stimulation) sessions will be double-blinded, but the Attention procession sessions will not. This is a within-subject placebo-controlled partially-blinded treatment study.|t|t|t|t
34044760|NCT03681548|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Bioequivalence study||||
33814250|NCT03999294|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33814251|NCT04212299|NA|SINGLE_GROUP||TREATMENT||NONE||Transfemoral amputees who historically have worn an ischial containment prosthetic socket will be assessed at baseline, fit with the intervention (a sub-ischial socket), and then tested at 8 and 42 weeks after intervention. All comparisons will be made back to baseline.||||
33814252|NCT05197088|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|t|f
33814253|NCT05963113|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The PI, outcome assessors, and individuals conducting data analyses will be blinded to randomization. The treating clinicians and participants will be aware of their study group given that they will be provided with either water or protein drinks.||f|f|t|t
33814254|NCT02834559|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33814255|NCT06085859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomly assign participants to the standard nasal catheter oxygenation group and the endoscopy mask oxygen inhalation group|f|f|f|t
33814256|NCT01790100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814257|NCT06186999|||COHORT||PROSPECTIVE|||||||
33814258|NCT02053714|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33814259|NCT03498456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814260|NCT00914056|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814261|NCT00818519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814262|NCT00911391|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814263|NCT01531699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814264|NCT03743688|||COHORT||PROSPECTIVE|||||||
33814265|NCT00595764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814266|NCT03130946|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two arm, prospective, open label study||||
33814267|NCT01086098|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33814268|NCT01118156|||COHORT||PROSPECTIVE|||||||
33814269|NCT00223769|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33814270|NCT05168345|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"Arm 1: IBD patients, patients of other chronic GI diseases' and healthy volunteers~Both groups will be asked to fill in the knowledge questionnaire and the self-assessment of knowledge questionnaire once, during their routine visit to the GI department. Results of the questionnaire will be compared between the groups.~IBD Patient's knowledge will also be subjectively assessed by their treating physician during their routine clinical visit, and knowledge scores will be compared (physician and questionnaire). Patients who will agree, will be asked to fill in the knowledge questionnaire a second time after two weeks for reliability testing."||||
33814271|NCT03602807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814272|NCT06503991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814273|NCT03883984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||1:1 randomized, double-blind, placebo-controlled trial|t|t|t|t
33814274|NCT02125409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814275|NCT00895076|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814276|NCT01034774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814277|NCT02784366|||COHORT||PROSPECTIVE|||||||
33814278|NCT00589628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814279|NCT02491645|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814280|NCT02274116|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33814281|NCT01819857|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33814282|NCT00138814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814283|NCT05789134|||CASE_ONLY||CROSS_SECTIONAL|||||||
33814284|NCT04243772|||COHORT||RETROSPECTIVE|||||||
33814285|NCT01279863|||CASE_CONTROL||PROSPECTIVE|||||||
33735722|NCT05572242|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants: During the socket preservation surgery, the type of intervention will be disclosure to the surgeon. The patient will not have access to this information. Also, during the controls and following interventions (implant placement and rehabilitation), the intervention group will be masked (test or control).~Investigator: The investigators will be always masked to the intervention group. (Only the surgeon will be able to know the treatment sequence, during the surgery) Outcomes assessor: The outcome reviewers will be blinded to the intervention. The measures of initial cbct, 4 months cbct control, and the following measurements will be always blind with respect to the intervention group."|This study is a non-inferiority clinical controlled trial of parallel groups|t|f|t|t
33735723|NCT00196300|||||PROSPECTIVE|||||||
33735724|NCT05799339|||COHORT||PROSPECTIVE|||||||
33735725|NCT03766321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo will be unrecognizable from active treatment because the patients will undergo endoscopic procedure with sedation|randomized double blind multicentre study on FMT in ALS, with a randomization ratio 2:1 (FMT: placebo).|t|t|t|t
33735726|NCT02112097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735727|NCT04856176|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase II open-label, single-center, single arm trial using a Simon two-stage optimal design.||||
33735728|NCT00912405|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735729|NCT03380468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735730|NCT05844878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735731|NCT02841618|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Two Phases:~Phase 1: Single arm, grapeseed oil cookie (N=39 adults) Phase 2: Triple masked, grapeseed or safflower oil cookie (N=84 adults)"|t|f|t|t
33735732|NCT03842176|||COHORT||PROSPECTIVE|||||||
33735733|NCT01122966|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33735734|NCT05318118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The results refering to the operated limb will be compared in both groups between themselves and furthermore with the results of clinical and biomechanical studies on non-operated limbs.|t|f|f|f
33735735|NCT06189092|||COHORT||PROSPECTIVE|||||||
33735736|NCT06363916|||COHORT||PROSPECTIVE|||||||
33735737|NCT03269279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735738|NCT06243497|||COHORT||PROSPECTIVE|||||||
33735739|NCT02651623|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33735740|NCT01915277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735741|NCT01941953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814286|NCT02025712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814287|NCT00505427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814288|NCT01558765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814289|NCT06096727|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814290|NCT05730192|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Histology of the polyps is performed by the pathologist blinded to the study group assignment.|Parallel trial design|f|f|f|t
33814291|NCT03323502|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Behavioral: ACP Specialist Program|f|f|t|t
33814292|NCT03709225|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814293|NCT03955406|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33814294|NCT00150852|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33814295|NCT03000829|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814296|NCT04776122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814297|NCT01942772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814298|NCT04247256|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a multi-center, open label, dose escalation, Phase 2 study of SCO-101 in combination with FOLFIRI in up to 50 mCRC patients.~Cohorts of FOLFIRI-resistant mCRC patients will be treated with SCO-101 in combination with FOLFIRI . Patients to be enrolled should previously have had either complete response (CR), partial response (PR), or stable disease (SD) (\>16 weeks) on FOLFIRI.~The study is separated in two parts. Part 1 is a dose escalation part with a standard 3+3 design, designed to evaluate the safety and toxicity of the combination of SCO-101 and FOLFIRI, and to identify the maximum tolerated dose (MTD). A maximum of 5 cohorts have been planned. Starting dose of SCO-101 is 150 mg (cohort 1) and maximum dose is 350 mg (cohort 5).~Part 2 is the efficacy part, where patients are treated with the MTD dose identified in the first part and evaluated for efficacy and safety of the combination SCO-101 plus FOLFIRI."||||
33814299|NCT03730688|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|No masking will be used in the study.|Compartment pressure will be measured in a single group of patients, using the conventional and the newly developed experimental means of measurement.||||
33814300|NCT04059575|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Thirty-three young tennis players aged between 9 and 12 yrs were recruited in the study. The exclusion criteria included those (a) with soft tissue or bone problems affecting lower extremity, (b) who had acute inflammation affecting lower extremity region, (c) had scoliosis, (d) who had undergone any orthopedic surgery, (e) who had defined any pain or painful area at lower extremities and (f) who were obese (BMI\>30 kg/m2|The part of muscle with more activation (greater heat) was measured by the thermo graphic camera and the heat was recorded in centigrade. Each participant was thermo graphically evaluated in the same room (ambient temperature, 21°C) and participants were left for 10-20 minutes to 'acclimatize' to the thermographic imaging environment FLIR E5 Thermal Camera, with a resolution of 120 x 90 pixels was used for thermal imaging and the Color Palette iron was chosen for displaying the images. It is indicated that IR imaging may be a reliable and valid measure of treatment outcomes with clinical utility and sensitivity|t|f|f|f
33814301|NCT04608240|||CASE_ONLY||PROSPECTIVE|||||||
33814302|NCT00244452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814303|NCT04093050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814304|NCT01323244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814305|NCT03945084|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm, prospective, randomized (2:1 ratio), open-label, multi-centre, phase II study||||
33814306|NCT00401050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814307|NCT02370953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814308|NCT03237026|||COHORT||PROSPECTIVE|||||||
33814309|NCT05176990|||COHORT||RETROSPECTIVE|||||||
33735742|NCT01993407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123076|NCT04143230|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|The Principal Investigator provided close envelops containing the SIAARTI/NCCN screening tool or the Simplified Screening Tool. The screening tool was inserted in the envelop according with a randomization list. The sub-investigator who wold examine the patient had to take the close envelope marked with the corresponding progressive number of patient enrolled, without possibility of choose the tool.|Eligible patients will be evaluated for the need of palliative care, randomly by means of the EST screening tool (ARM A) or by means of the Simplified Screening Tool (SST), (ARM B).|t|t|f|f
33814310|NCT05804734|||CASE_CONTROL||RETROSPECTIVE|||||||
33814311|NCT01373723|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33814312|NCT05188248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814313|NCT01652014|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814314|NCT02632188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814315|NCT06542614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814316|NCT01245699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Chest Compression before and after RealCPRHelp||||
34123077|NCT04383093|||COHORT||PROSPECTIVE|||||||
34123078|NCT02881736|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123079|NCT04796038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123080|NCT04646577|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Double (Participant, Outcomes Assessor)||t|f|f|f
34123081|NCT04144283|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|For experiment 2, participants will be told that sounds may be played during the nap or wake period, without further knowledge on the anticipated effects of these sounds.|Performance on the MSL task (Experiment 1) will be compared between a group that undergoes a 2-hour post-learning NAP and a group that will undergo a 2-hour post-learning WAKE period. Participants will be randomized (1:1) to either the NAP or WAKE group. Performance on the SRT task (Experiment 2) will be compared between the sequence that was replayed during the post-learning nap using auditory TMR (replay) and the sequence that was not replayed (no-replay). The order of sequence blocks during learning and retest as well as the sequence selected for TMR will be randomized across participants. Randomization for both experiments will be done by an independent researcher who is not involved in the measurements of any of the studies using a computerized random number generation technique.|t|f|f|f
34123082|NCT01820546|||CASE_ONLY||PROSPECTIVE|||||||
34123083|NCT04896853|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open, dose escalating Phase IB Clinical Trial||||
34123084|NCT00497900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123085|NCT05384899|||COHORT||PROSPECTIVE|||||||
34123086|NCT04350801|||COHORT||PROSPECTIVE|||||||
34123087|NCT03461939|||COHORT||PROSPECTIVE|||||||
34123088|NCT01357343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123089|NCT01343745|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34123090|NCT01309789|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123091|NCT05610020|||COHORT||PROSPECTIVE|||||||
34123092|NCT01058239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123093|NCT00852410|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34123094|NCT05994768|||OTHER||RETROSPECTIVE|||||||
34123095|NCT01001351|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34123096|NCT02764996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123097|NCT02622477|||COHORT||CROSS_SECTIONAL|||||||
34123098|NCT02849002|||CASE_ONLY||PROSPECTIVE|||||||
34123099|NCT00436436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123100|NCT04251338|||CASE_ONLY||RETROSPECTIVE|||||||
34123101|NCT03173014|||CASE_ONLY||PROSPECTIVE|||||||
34123102|NCT05342454|||CASE_ONLY||OTHER|||||||
34123103|NCT02935244|||COHORT||PROSPECTIVE|||||||
34123104|NCT04046640|||COHORT||PROSPECTIVE|||||||
34123105|NCT01506024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123106|NCT00836771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123107|NCT00222807|||CASE_CONTROL||PROSPECTIVE|||||||
34123108|NCT00962871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123109|NCT04410965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123110|NCT01541865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123111|NCT03957863|||COHORT||PROSPECTIVE|||||||
34123112|NCT01856322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814317|NCT04265872|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33814318|NCT06119256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814319|NCT01280721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814320|NCT03405480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814321|NCT03469089|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double blinded|All subjects will get each treatment according to balanced latin square design for four treatments with 12 days intervals|t|f|t|f
34123113|NCT05874141|NA|SINGLE_GROUP||SCREENING||NONE||||||
34123114|NCT02227303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123115|NCT03265730|||COHORT||PROSPECTIVE|||||||
34123116|NCT01890096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123117|NCT02347592|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34123118|NCT00507585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123119|NCT00139958|||CASE_CONTROL||PROSPECTIVE|||||||
34123120|NCT01603225|||COHORT||PROSPECTIVE|||||||
34123121|NCT01569412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123122|NCT02725333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123123|NCT01141621|||COHORT||PROSPECTIVE|||||||
34123124|NCT02472912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34123125|NCT04527055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Among the H. pylori-infected patients, they are randomized to the 14-day bismuth-based quadruple therapy group and the 10-day bismuth-based quadruple therapy group to receive a 14-day and 10-day course, respectively, of the bismuth-based quadruple therapy. Afterward, the patients stop taking the proton pump inhibitor and antibiotics for 4 to 6 weeks, and then they receive 13C-UBT or an H. pylori stool antigen test to confirm successful eradication or not.~Patients' fecal microbiota profiling is performed before and after H. pylori eradication. If patients have the depletion of gut F. prausnitzii 12 months after H. pylori eradication, they are enrolled to the probiotic supplement trial. They are randomized to the probiotic therapy group ingesting probiotic powder twice daily for 24 weeks and the non-probiotic control group, respectively."|f|f|f|t
33814322|NCT05928494|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled single-blind experimental study|t|f|f|f
33814323|NCT05009888|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33814324|NCT05748808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123126|NCT00936663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123127|NCT02847169|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34123128|NCT05124353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123129|NCT01407939|||COHORT||CROSS_SECTIONAL|||||||
34123130|NCT00381654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123131|NCT03917030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Split-mouth design, all subjects receive both interventions|t|f|t|f
34123132|NCT02207543|NA|SINGLE_GROUP||OTHER||NONE||||||
34123133|NCT04898478|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34123134|NCT01997645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123135|NCT03111212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123136|NCT04068454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34123137|NCT05165095|||COHORT||PROSPECTIVE|||||||
34123138|NCT03657836|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123139|NCT04024826|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The participants will be randomized into either one of the 4 four phases- namely Early Follicular Phase(EFP-Days1 to 7), Late Follicular Phase(LFP-Days 8 to 14), Early Luteal Phase(ELP-Days 15 to 21) or Late Luteal Phase(LLP-Days 22 to 28) of the menstrual phase. Once the participant is assigned to one of the phases. Each participant will undergo 4 intervention days. the first intervention day will take place during the mid-point of the said phase i.e. EFP- Day 4. After one intervention is complete there will be a washout period and the intervention will take place on the 7th day after the first intervention i.e if the first intervention is LFP done on day 11 of the menstrual cycle the next intervention will take place on day 18 of menstrual cycle which will account for ELP. In this manner, the Participant will be tested in all 4 phases.||||
34123140|NCT02184598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123141|NCT05979961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123142|NCT03654222|||COHORT||RETROSPECTIVE|||||||
34123143|NCT01344798|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123144|NCT04902209|||CASE_CONTROL||PROSPECTIVE|||||||
34123145|NCT02898922|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123146|NCT04061109|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123147|NCT02779868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123148|NCT02143349|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34123149|NCT03165786|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
34123150|NCT00000413|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34123151|NCT01419158|||CASE_ONLY||PROSPECTIVE|||||||
34123152|NCT01692288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123153|NCT05190679|||CASE_CONTROL||PROSPECTIVE|||||||
34123154|NCT05074225|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34123155|NCT02938325|||CASE_CONTROL||PROSPECTIVE|||||||
34123156|NCT05570396|||COHORT||PROSPECTIVE|||||||
34123157|NCT03726632|||CASE_ONLY||PROSPECTIVE|||||||
34123158|NCT02917005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123159|NCT04039529|RANDOMIZED|PARALLEL||TREATMENT||NONE|Masking is impossible due to the hardware that is present when using the SCENERGY|testing whether biopsies and ablations performed with the SCENERGY result in less patient radiation dose or reduced procedure time compared to biopsies performed under CT-guidance only.||||
34123160|NCT05663463|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34123161|NCT03646760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123162|NCT03210701|NA|SINGLE_GROUP||SCREENING||NONE||||||
34123163|NCT06538662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837117|NCT03455205|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123164|NCT01061385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123165|NCT05076344|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34123166|NCT01873105|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Before/after implementation of a health team communication intervention. 2 samples.||||
34123167|NCT01492088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123168|NCT03201640|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34123169|NCT00000389||||TREATMENT||DOUBLE||||||
34123170|NCT01586689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123171|NCT02969642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123172|NCT03369366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123173|NCT01288625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123174|NCT02684968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||local anesthetic continuous infusion (QL block + IV PCA group) or normal saline continuous infusion (IV PCA group).|t|t|t|t
34123175|NCT00005852||||TREATMENT||||||||
34123176|NCT05807373|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123177|NCT04763434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123178|NCT05144828|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123179|NCT06090058|||CASE_CONTROL||RETROSPECTIVE|||||||
34123180|NCT05923697|NA|SINGLE_GROUP||TREATMENT||NONE||Study design: a non-concurrent multiple baseline design is used in which participants are allocated at random to a baseline period of 7, 10, or 13 days after which they proceed to an intervention phase of two weeks in which they receive four 90 min. sessions of AF-EMDR and a follow-up interview after one month. During both the baseline and the AF-EMDR intervention phase, participants also receive Treatment As Usual (TAU: Community Reinforcement Approach (CRA)), aimed at SUD.||||
34123181|NCT05157061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study team and DMC are masked|Phase III, randomized, double-blind, placebo-controlled, multi-centre, 8-week intervention study, preceded by a 2-week run-in period, to assess the efficacy of GOS on symptom severity in adult patients with IBS.|t|t|t|t
34123182|NCT05000307|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||(serial) blood samples in patients with proven SARS-CoV2||||
34123183|NCT01465035|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123184|NCT03048435|||COHORT||PROSPECTIVE|||||||
34123185|NCT05007327|||COHORT||PROSPECTIVE|||||||
34123186|NCT00172315|||DEFINED_POPULATION||OTHER|||||||
34123187|NCT05799391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Soothing cream jel or placebo cream jel|t|f|t|t
34123188|NCT02055950|||CASE_CONTROL||PROSPECTIVE|||||||
34123189|NCT02469220|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34123190|NCT05775211|NA|SINGLE_GROUP||TREATMENT||NONE|Data analysis will be performed by investigators blind to the biopsy group.|All participants will undergo the same procedures.||||
34123191|NCT05749471|||COHORT||CROSS_SECTIONAL|||||||
34123192|NCT02184065|||COHORT||PROSPECTIVE|||||||
34123193|NCT03895294|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34123194|NCT00499668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123195|NCT00000226||||TREATMENT||||||||
34123196|NCT00776360|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34123197|NCT04865666|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34123198|NCT01798381|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123199|NCT00339040|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34123200|NCT01123148|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34123201|NCT05370274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The study model is a pre/post intervention pilot study.||||
34123202|NCT01718899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123203|NCT01521598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123204|NCT02793687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123205|NCT00716001|RANDOMIZED|PARALLEL||||NONE||||||
34123206|NCT01294852|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123207|NCT01531998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123208|NCT03902795|||CASE_ONLY||PROSPECTIVE|||||||
34123209|NCT00202696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123210|NCT01983592|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34123211|NCT05573139|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123212|NCT04635202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123213|NCT01808469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123214|NCT00593060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123215|NCT01790607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123216|NCT04828707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized, double-blind, sham-controlled|t|t|t|f
34123217|NCT01471821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123218|NCT02078752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123219|NCT04500119|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34123220|NCT05189210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123221|NCT03335202|||COHORT||RETROSPECTIVE|||||||
34123222|NCT01057537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123223|NCT03644719|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Participants signed up for a time slot for cognitive behavioral skills training (CBST) or a time slot for education as usual (EAU), without being informed which was which.|Two arms were used to examine the relative effect of the cognitive behavioral skills training (CBSR) and a time slot for education as usual (EAU). The CBST consists of six sessions. The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.|t|f|f|f
34123224|NCT02972229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34123225|NCT00577694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123226|NCT04285697|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled study||||
34123227|NCT03855566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123228|NCT01539447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123229|NCT05314296|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34123230|NCT00087087||||TREATMENT||NONE||||||
34123231|NCT02725905|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123232|NCT03273686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123233|NCT02529683|NA|SINGLE_GROUP||||NONE||||||
34123234|NCT06230484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123235|NCT03856736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34123236|NCT04476667|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants selected for the e-psychotherapy group will receive a 9-week program that includes a combination of CBT, mindfulness, and problem-based therapy, in addition to TAU. The control group will receive treatment as usual during the first 9 weeks; if they still present significant symptoms (less than 50% response to treatment from baseline), they will be offered the e-psychotherapy program.||||
34123237|NCT05188638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123238|NCT01705340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123239|NCT04198883|NA|SINGLE_GROUP||TREATMENT||NONE||the design : pilot, single-arm, open-labelled study||||
34123240|NCT00891696|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34123241|NCT02538120|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123242|NCT02504372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123243|NCT04578756|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123244|NCT05004844|||COHORT||PROSPECTIVE|||||||
34123245|NCT00183014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123246|NCT03918382|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"A prospective nation-wide, sequential cohort study.~* First phase control group. 97 participants. No Intervention: Standard of care.This arm will continue standard procedure regarding side effect registration and handling.~* Second phase. PRO group. 194 participants. Intervention: Active use of electronic patient-reported outcomes.This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life."||||
34123247|NCT06286332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34123248|NCT02900833|||OTHER||CROSS_SECTIONAL|||||||
34123249|NCT03396887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomised to intervention or control condition.||||
34123250|NCT05921617|||COHORT||PROSPECTIVE|||||||
34123251|NCT00776529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735743|NCT06456021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||6 sites will be stratified into 3 tiers (high, medium, low) based on 2022 percutaneous coronary intervention volume. Within each tier, one site will be randomized to the enhanced implementation group and the other to the standard implementation group. This will ensure equal allocation between groups with different site characteristics. An allocation table will be generated in R statistical software and uploaded to a password-protected folder. CCL managers' responsibility will be to implement the Playbook interventions, participate in coaching (Enhanced Group), and participate in data collection. Once randomization is complete, the Enhanced and Standard groups will be invited to participate in a site-specific study launch meeting. Both groups will be sent a link to the Playbook SharePoint site. The Enhanced Group will schedule their initial coaching session. Over the subsequent 6 months, both groups will receive nudges to continue Playbook implementation through a Qualtrics survey.||||
33735744|NCT04670016|||COHORT||PROSPECTIVE|||||||
34123252|NCT02294032|||CASE_ONLY||PROSPECTIVE|||||||
34123253|NCT00161889|RANDOMIZED|PARALLEL||||DOUBLE||||||
34123254|NCT02770066|||COHORT||PROSPECTIVE|||||||
33735745|NCT01537341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735746|NCT03536728|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33735747|NCT02387021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735748|NCT00351494|||||PROSPECTIVE|||||||
33735749|NCT05447988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735750|NCT04897542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735751|NCT04003597|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The biochemical outcome measures were assessed by researchers masked to the phase of the cross-over intervention from which the samples were derived.||f|f|f|t
33735752|NCT02992899|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33735753|NCT02114970|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33735754|NCT01824303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735755|NCT02047617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735756|NCT01182077|RANDOMIZED|CROSSOVER||||NONE||||||
33735757|NCT06192771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735758|NCT00003380||||TREATMENT||||||||
33735759|NCT03339518|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33735760|NCT00864500|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33735761|NCT03016195|||COHORT||CROSS_SECTIONAL|||||||
33735762|NCT00602303|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735763|NCT04862091|RANDOMIZED|PARALLEL||TREATMENT||NONE||Abiraterone Acetate Tablets (I) compared with ZYTIGA®||||
33735764|NCT04717128|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Standardized patients leading the workshop will know which baby doll they are using in the workshop. Participants will not know whether or not they are receiving treatment and investigators and data analysts will be blinded to the treatment."|Participants will be cluster randomized to complete the standardized-patient led breastfeeding skills workshop with one of the baby dolls.|t|f|t|t
33735765|NCT01831687|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735766|NCT01284647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735767|NCT02764749|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33735768|NCT02944877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735769|NCT05695157|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm prospective interventional study||||
33735770|NCT06098820|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||"Forty-eight people aged 18-65 years with serum 25(OH)vitamin D levels below 30 μg/L and who meet the study criteria will be selected for the study. Four groups, 12 per group, will be randomly selected by computer-assisted randomization.~Group 1 (UV-C mushroom+normal bread group):~Group 2 (UV-C mushroom + UV-C bread group) Group 3 (normal mushroom + normal bread group) Group 4 (normal mushroom + normal bread + supplement group)"|t|t|f|t
33735771|NCT04432350|||COHORT||RETROSPECTIVE|||||||
33735772|NCT06664580|||COHORT||RETROSPECTIVE|||||||
33735773|NCT05068440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735774|NCT06325774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735775|NCT06295549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735776|NCT03835442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, parallel, double-blind, placebo-controlled, out-patient, single-center study|t|f|t|t
33735777|NCT00088296||||TREATMENT||||||||
33735778|NCT01024400|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33735779|NCT03930004|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735780|NCT05863754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735781|NCT01298297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735782|NCT04357405|||COHORT||PROSPECTIVE|||||||
33735783|NCT04251559|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33735784|NCT06449157|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33735785|NCT06587347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735786|NCT04996992|||CASE_ONLY||PROSPECTIVE|||||||
33735787|NCT01042964|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735788|NCT02872415|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33735789|NCT04492033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735790|NCT01901380|||COHORT||PROSPECTIVE|||||||
33735791|NCT00306592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735792|NCT04314193|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective, randomized, open-label, multi-center (18 hospitals in the Netherlands), single country, non-inferiority trial.~Randomization 1:1 to oral prednisone (start 40 mg daily, to be tapered to 10 mg daily) or oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks. Thereafter continuation of trial for 18 months on regular treatment (investigator decision)."||||
33735793|NCT02084030|||CASE_CONTROL||PROSPECTIVE|||||||
33735794|NCT06435247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This is a randomized clinical trial design with two groups~* One group will have family accompaniment in the recovery area, the other will not~* The QoR-15 scale will be used to measure the quality of anesthetic recovery~* The randomization was done using the OpenEpi software"||||
33735795|NCT02310659|||COHORT||PROSPECTIVE|||||||
33735796|NCT05369221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735797|NCT00555438|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33735798|NCT01338116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044761|NCT00168363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34044762|NCT02225639|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34044763|NCT03266315|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34044764|NCT00339235|||COHORT||PROSPECTIVE|||||||
34044765|NCT00675363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34044766|NCT02299622|||COHORT||PROSPECTIVE|||||||
34044767|NCT03426124|||COHORT||OTHER|||||||
34044768|NCT03422601|||COHORT||RETROSPECTIVE|||||||
34044769|NCT01686126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044770|NCT05019547|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044771|NCT01130376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735799|NCT04025918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735800|NCT05126888|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33735801|NCT06003725|NA|SEQUENTIAL||TREATMENT||NONE|No masking|Individual interviews with Black justice-involved youth (JIY) and focus groups with guardians of Black JIY and community members will be conducted. Data from focus groups and interviews will be used to inform the cultural adaptation of an evidence-based adolescent substance use treatment. The cultural adapted treatment will then be piloted with 30 Black JIY for feasibility and acceptability.||||
33735802|NCT00779454|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33735803|NCT00233025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837118|NCT01358331|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33837119|NCT00269321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837120|NCT01878396|||COHORT||PROSPECTIVE|||||||
33837121|NCT04162002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044772|NCT01288196|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34044773|NCT05800938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044774|NCT03074058|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044775|NCT02763137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044776|NCT02246179|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34044777|NCT02209519|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34044778|NCT00430573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044779|NCT04774367|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044780|NCT03881085|||COHORT||PROSPECTIVE|||||||
34044781|NCT03293979|||COHORT||PROSPECTIVE|||||||
34044782|NCT03483233|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34044783|NCT03992027|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044784|NCT03732937|||CASE_CONTROL||PROSPECTIVE|||||||
34044785|NCT01162291|||CASE_CONTROL||PROSPECTIVE|||||||
34044786|NCT01488136|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34044787|NCT00943540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044788|NCT00894439|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044789|NCT01332760|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34044790|NCT00042159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34044791|NCT04770220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|This is a multi-center Phase 3, randomized, double-blind, placebo-controlled, parallel-group study.|t|t|t|t
34044792|NCT05684861|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34044793|NCT02861586|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34044794|NCT03697512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044795|NCT01102868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044796|NCT03530592|NA|SINGLE_GROUP||TREATMENT||NONE||Seated Ankle Robot Taining||||
34044797|NCT02484274|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044798|NCT04409236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34044799|NCT01599858|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34044800|NCT02201108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044801|NCT05074121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and study team members will be masked to whether a participant is receiving the study drug or placebo|Randomized Double-Blinded Placebo-Controlled|t|t|t|f
34044802|NCT00135512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044803|NCT00713531|||COHORT||PROSPECTIVE|||||||
34044804|NCT04478695|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044805|NCT02168257|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34044806|NCT04929392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044807|NCT02099617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044808|NCT06059014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044809|NCT06447246|||COHORT||CROSS_SECTIONAL|||||||
34044810|NCT01548911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044811|NCT00748462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044812|NCT00245128|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044813|NCT01341171|||OTHER||OTHER|||||||
34044814|NCT03293212|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044815|NCT01762917|||COHORT||PROSPECTIVE|||||||
34044816|NCT05379283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044817|NCT05938660|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34044818|NCT01082705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044819|NCT00729612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044820|NCT06159751|||OTHER||RETROSPECTIVE|||||||
34044821|NCT01888055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044822|NCT00003441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044823|NCT00664573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044824|NCT00003563|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34044825|NCT04429217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|clinical assessments will be assessed by an investigator blinded with respect to the rehabilitation regimen and all outcomes will be analysed by a statistician blinded to the moment when they were registered / administered (baseline or time points after randomization).||f|f|f|t
34044826|NCT01146093|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34044827|NCT04162431|||CASE_ONLY||CROSS_SECTIONAL|||||||
33814325|NCT03612102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Independent evaluators assigned to assess outcomes will be masked to whether or not families participated in IGBT or were at the end of their waitlist period."|Families of children with selective mutism will be randomly assigned to receive either immediate intensive group behavioral treatment (IGBT) or to a waitlist with psychoeducational materials, and then IGBT.|f|f|f|t
33814326|NCT05675189|||CASE_CROSSOVER||PROSPECTIVE|||||||
33814327|NCT06080945|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33814328|NCT03880981|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33814329|NCT05410717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814330|NCT04285645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814331|NCT04507347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, Placebo-controlled||t|t|t|t
34044828|NCT05776238|||COHORT||PROSPECTIVE|||||||
33814332|NCT00001806|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814333|NCT05285592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814334|NCT00457314|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814335|NCT00199537|||COHORT||PROSPECTIVE|||||||
33814336|NCT05223725|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|participant is masked due to delivery during general anesthesia, outcomes assessors and investigators are fully masked to study group.||t|f|t|t
33814337|NCT01428609|NA|SINGLE_GROUP||||TRIPLE|||t|f|t|t
34044829|NCT03158038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind||t|t|t|t
34044830|NCT01657825|NA|SINGLE_GROUP||||NONE||||||
34044831|NCT00000945||||TREATMENT||||||||
34044832|NCT00534781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044833|NCT04548713|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||Multi-center, cluster-randomized, double-blinded, crossover study.|t|t|t|t
34044834|NCT04398108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044835|NCT03466606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34044836|NCT01417247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044837|NCT02623933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044838|NCT04808063|NA|SINGLE_GROUP||PREVENTION||NONE||Patients with emergency surgery using midline laparotomy||||
34044839|NCT04784429|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34044840|NCT03177460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044841|NCT03300349|||CASE_CONTROL||RETROSPECTIVE|||||||
34044842|NCT03552055|||OTHER||OTHER|||||||
34044843|NCT00078767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044844|NCT05368220|||OTHER||OTHER|||||||
34044845|NCT03415971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044846|NCT00865878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044847|NCT01864031|||COHORT||PROSPECTIVE|||||||
34044848|NCT06576947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Subject)||t|f|f|f
34044849|NCT06186973|||COHORT||PROSPECTIVE|||||||
34044850|NCT00695942|||COHORT||PROSPECTIVE|||||||
34044851|NCT04293939|||CASE_CONTROL||PROSPECTIVE|||||||
34044852|NCT05110937|||COHORT||PROSPECTIVE|||||||
34044853|NCT06574113|||COHORT||PROSPECTIVE|||||||
34044854|NCT04293419|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be included following inclusion/exclusion criteria in a prospective, non-randomized, open label, single arm phase II study to receive 6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.||||
34044855|NCT02960711|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34044856|NCT03819972|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participant will not be told which drink they will ingest until the end of the study.~Individuals not collaborating on the study will randomise the drink order and make up the drinks so the investigator is blinded to which drink the particpant will ingest."|There are 4 conditions where participants will ingest differing amounts of calcium in a randomised order|t|f|t|f
34044857|NCT02184338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34044858|NCT01516008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34044859|NCT02581579|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34044860|NCT01200147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044861|NCT06195527|||CASE_ONLY||PROSPECTIVE|||||||
34044862|NCT03320902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34044863|NCT00478816|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34044864|NCT04989478|NA|SINGLE_GROUP||OTHER||NONE||||||
33814338|NCT02521337|||COHORT||PROSPECTIVE|||||||
33814339|NCT06455605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837122|NCT02986308|||CASE_CONTROL||PROSPECTIVE|||||||
33837123|NCT01425177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34044865|NCT03646864|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||2-way crossover study|t|t|t|t
34044866|NCT00741130|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044867|NCT01763060|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044868|NCT04446208|||COHORT||PROSPECTIVE|||||||
34044869|NCT02723396|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34044870|NCT03143179|||COHORT||PROSPECTIVE|||||||
34044871|NCT02212093|||||RETROSPECTIVE|||||||
34044872|NCT05674435|||OTHER||OTHER|||||||
34044873|NCT00568230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044874|NCT02276989|NA|SINGLE_GROUP||OTHER||NONE||||||
34044875|NCT06475755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044876|NCT01070212|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34044877|NCT01614717|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34044878|NCT04488302|||CASE_ONLY||RETROSPECTIVE|||||||
34044879|NCT02123589|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044880|NCT02256124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044881|NCT03447223|||COHORT||RETROSPECTIVE|||||||
34044882|NCT03731819|NA|SINGLE_GROUP||OTHER||NONE||||||
34044883|NCT06574893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044884|NCT05675904|||COHORT||RETROSPECTIVE|||||||
34044885|NCT02496468|||COHORT||PROSPECTIVE|||||||
34123255|NCT05743374|RANDOMIZED|PARALLEL||OTHER||SINGLE|Although the patients know that they will be given dietary advice they will not know what type of intervention the other group will be offered. Since dietary advice must be given by the investigators the study cannot be blinded to them.|Prospective randomized intervention study with elimination of putatively harmful substances in the diet|t|f|f|f
34123256|NCT01251302|||COHORT||PROSPECTIVE|||||||
34123257|NCT03334838|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123258|NCT03141255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123259|NCT03688919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837124|NCT05974670|||COHORT||PROSPECTIVE|||||||
33837125|NCT00171912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837126|NCT03747406|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33837127|NCT03542513|||COHORT||PROSPECTIVE|||||||
33837128|NCT02875197|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044886|NCT00790634|||CASE_CONTROL||PROSPECTIVE|||||||
34044887|NCT02519998|||COHORT||PROSPECTIVE|||||||
34044888|NCT05038774|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34044889|NCT00485732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34044890|NCT05498844|RANDOMIZED|PARALLEL||TREATMENT||NONE||In a single-blind, randomized controlled, single-center study, Individuals will be randomized to intervention or control groups by stratified randomization where the stratification will be by cardiac risk level and sex. All eligible patients fulfilling the eligibility criteria will be randomly sampled from the clinic lists. These patients will be contacted by study personnel after approval from the treating physician and asked to come for a baseline meeting and explanation of study procedures. Those meeting all inclusion criteria and willing to provide informed consent will be enrolled. A log will be kept of refusals and reasons for refusal.||||
34044891|NCT06574945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients were categorized into three groups: propofol (2 mg/kg) + normal saline (group P), propofol (1.5 mg/kg) + ESK (0.5 mg/kg) (group PK1), and propofol (1.5 mg/kg) + ESK (0.25 mg/kg) (group PK2). In group P, patients received an intravenous injection of an equivalent dose of normal saline followed by 2 mg/kg of propofol. Group PK1 received an intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol. Similarly, group PK2 received an intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol.|t|t|t|t
34044892|NCT04235465|||CASE_CONTROL||PROSPECTIVE|||||||
34044893|NCT04685824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34044894|NCT03995173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A unblinded member(s) of the research team will be provided with randomization codes from the study biostatistician. A unblended research team member will then provide the PI and rTMS treatment providers with a specific code for the rTMS device. rTMS providers enter the specific rTMS code into the rTMS device and the device is designed to deliver active or placebo rTMS based on this code. The rTMS device is designed to deliver placebo rTMS that looks, sounds and feels like active rTMS.|Double-blind, randomized controlled trial of two parallel groups: active and placebo rTMS|t|t|t|t
34044895|NCT05510570|||COHORT||PROSPECTIVE|||||||
34044896|NCT06572384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study.||t|t|t|t
34044897|NCT04161404|RANDOMIZED|CROSSOVER||OTHER||NONE||Open label, block-randomized, three-period, crossover, single dose oral administration of investigational products. Subjects will undergo at least 7 days washout period.||||
34044898|NCT04203446|||COHORT||PROSPECTIVE|||||||
34044899|NCT06353984|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Investigators and participants are partly blinded as the control group receives no placebo product|Three-arm randomized controlled trial that includes a double-blinded, two-armed intervention and a non-blinded control arm without any intervention|t|f|t|t
34044900|NCT00134706|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044901|NCT02482480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044902|NCT06096675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Enrollment in supervised cardiac rehabilitation for 3 one-hour sessions a week for a total of 12 weeks (36 sessions)||||
34044903|NCT06128902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized-control|t|f|f|t
34044904|NCT03240289|NA|SINGLE_GROUP||OTHER||NONE||Single arm feasibility and pilot testing study of a curriculum||||
34044905|NCT06328556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044906|NCT00713947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044907|NCT00442988|||DEFINED_POPULATION||PROSPECTIVE|||||||
34044908|NCT05330156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044909|NCT02346838|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34044910|NCT02205658|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044911|NCT03627026|NA|SINGLE_GROUP||OTHER||NONE||||||
34044912|NCT01308827|||COHORT||PROSPECTIVE|||||||
34044913|NCT00687271|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34044914|NCT02735681|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34044915|NCT02741544|||CASE_ONLY||PROSPECTIVE|||||||
34044916|NCT00983060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044917|NCT05424627|||COHORT||PROSPECTIVE|||||||
34044918|NCT00250952|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34044919|NCT03732482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044920|NCT06094725|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34044921|NCT01333046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044922|NCT01313975|||COHORT||PROSPECTIVE|||||||
34044923|NCT05342389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044924|NCT00688662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044925|NCT00389532|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044926|NCT04043533|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial with a prospective pretest-posttest experimental design.|t|f|f|f
34044927|NCT05879250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044928|NCT03622060|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blind|nitroglycerin and nicardipine|f|f|t|t
34044929|NCT02917291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123260|NCT02746406|NA|SINGLE_GROUP||||NONE||||||
34123261|NCT03645538|||OTHER||CROSS_SECTIONAL|||||||
34123262|NCT01322256|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34123263|NCT00413439|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33814340|NCT04007445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The proposed project utilizes a mixed methods approach. An experimental strategy using a randomized control trial (single-blinded) will be used to assess the efficacy of an established transitional, community-based exercise intervention on people with SCI. Qualitative methods will be used to gather information related to optimizing implementation of a community-based exercise intervention. This project will be conducted in conjunction with Paraquad, a local independent living center. Forty participants will be randomized into an Exercise Group (EG) or Control Group (CG) by the statistician who will not be involved in either conducting outcome assessments or implementation of the intervention. This design will assist in reducing variability and maximizing the effect size for powering subsequent larger randomized control trials.|f|f|f|t
33814341|NCT03769090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814342|NCT02039102|||OTHER||CROSS_SECTIONAL|||||||
33814343|NCT03494088|||COHORT||PROSPECTIVE|||||||
33814344|NCT01864590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814345|NCT04992494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814346|NCT03075475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123264|NCT04568603|NA|SINGLE_GROUP||OTHER||NONE||||||
34123265|NCT05880251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* The pre and post clinical assessment will be performed by a blinded evaluator.~* The participant will not be told about group assignment till the end of the last follow-up session and assessment~* Investigators will keep blinded to the baseline clinical measures."|Participants are randomly assigned to 2 groups, one group receiving the operant conditioning feedback with peripheral stimulation (Intervention group) and the other receiving only peripheral stimulation with no operant conditioning feedback (Control group).|t|f|t|t
34123266|NCT01154452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123267|NCT01165034|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34123268|NCT05260320|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator, surgeon, and anesthesiologists will be aware of study arm (in order to properly implement the intervention). The patient and postoperative care teams (who will asses for postoperative pain and necessity of additional interventions) will be blinded.|Patients will be randomized to one of two study arms: intervention (standardized protocol) or control (no standardized protocol)|t|f|f|t
34123269|NCT02863965|||COHORT||PROSPECTIVE|||||||
34123270|NCT01719848|||CASE_ONLY||PROSPECTIVE|||||||
34123271|NCT03763734|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All intervention drugs will be blinded by a nurse who is not a participant in the study or in the treatment of the patient in any way.~The Patient, the administrator of the drug(nurse or doctor), the assessor, the investigator and the care team will all be blinded."|A randomized double blinded controlled trial.|t|t|t|t
34123272|NCT05376722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123273|NCT06123611|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34123274|NCT04314817|||CASE_ONLY||CROSS_SECTIONAL|||||||
34123275|NCT00429182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123276|NCT03632096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The sham group will have a simulation of application of the laser, with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off. In the group that receives the photobiomodulation the device will have its timer turned off, to avoid the perception of sound difference.||t|f|f|f
34123277|NCT00670566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123278|NCT04781348|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group-I: will receive only fat grafting; Group-II: will receive Platelet Rich Plasma and fat grafting||||
34123279|NCT03665259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The anesthetist who in-charge of the induction of anesthesia is aware of the treatment oxygen concentration.~The patient is unaware of oxygen concentration during the induction of anesthesia.~The outcomes assessors is unaware of the concentration of oxygen treatment."|Group 1: pre-oxygenation with 100% oxygen during induction of anesthesia Group 2: pre-oxygenation with 60% oxygen during induction of anesthesia|t|f|f|t
34123280|NCT03613155|||COHORT||PROSPECTIVE|||||||
34123281|NCT05016258|||COHORT||PROSPECTIVE|||||||
34123282|NCT02148588|NA|SINGLE_GROUP||OTHER||NONE||||||
34123283|NCT03495934|NA|SINGLE_GROUP||OTHER||NONE||||||
34123284|NCT06093399|NA|SINGLE_GROUP||TREATMENT||NONE||Each participant will act as their own control. Each individual's stutter will be assessed with DBS system OFF (control) and DBS ON (treatment).||||
34123285|NCT06312189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123286|NCT03984773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The principal study investigator and data analyst will not have knowledge of when the practices are randomized to the intervention.|Practices will be cluster-randomized in 4-week blocks to the intervention over a 16-week period, after which all practices will receive the email intervention.|f|f|t|t
34123287|NCT00004927||||TREATMENT||||||||
34123288|NCT01023152||PARALLEL||PREVENTION||||||||
34123289|NCT05402254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123290|NCT05960487|||COHORT||RETROSPECTIVE|||||||
34123291|NCT05582681|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open label, phase 4 randomized trial to assess test and treat strategy with simplified video-based patient education versus standard of care referral with health care provider delivered patient education.||||
34123292|NCT00639288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123293|NCT03333694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|investigator and patient blinded|A first in human,proof of concept study. The study is investigator-and patient-blinded, randomized, placebo-controlled study in patients with SCCis, to assess safety, tolerability and initial efficacy of CLL442 after up to 84 days twice daily application of CLL442 or placebo on one lesion.|t|f|t|f
34123294|NCT00373607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123295|NCT00287950|NON_RANDOMIZED|||TREATMENT||NONE||||||
34123296|NCT02603276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123297|NCT03819257|||COHORT||PROSPECTIVE|||||||
34123298|NCT06026280|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123299|NCT02131168|||COHORT||PROSPECTIVE|||||||
34123300|NCT03800030|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded. Neither the investigator nor the participants knows which form of stimulation is received.|Healthy participants will receive three waveforms of transcranial alternating current stimulation (tACS). Delta-beta, Theta-gamma, and Sham.|t|f|t|f
33735804|NCT05606068|NA|SINGLE_GROUP||PREVENTION||NONE||"Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, hypothermia will be administered for no longer than four hours.~Each patient will undergo maximum limb cooling. The initial device settings for the first cycle for each patient will be based on the optimal temperature determined to be safe and tolerable in previous studies. The temperature will be adjusted according to the patient's tolerance/intolerance feedback during each cycle of cooling and documented."||||
33735805|NCT02097134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735806|NCT05528991|||COHORT||PROSPECTIVE|||||||
33814347|NCT01377545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814348|NCT06178744|||COHORT||PROSPECTIVE|||||||
33814349|NCT06412432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients enrolled will be handled in the outpatient's clinic of Cardiometabolic Rehabilitation Program of the Federico II University Hospital of Naples for exercise training and cardiac rehabilitation intervention. Patients will be randomized in blocks to two groups. Specifically, the primary intervention (ET-1) and the control group who won't undergo exercise training (No-ET). Following baseline assessments of both groups at baseline, the ET-1 group will be subjected to exercise training program of 2 weekly sessions for 12 weeks. After 12 weeks, both groups will be reassessed and patients belonging to group No-ET will be offered to undergo the same ET program for further 12 weeks. Those who will accept will join the secondary training group (ET-2). Primary endpoint will be the distance obtained at the 6-minute walk test (6MWD) performed at baseline and after 12-weeks of treatment in pooled ET-1 and ET-2 groups compared to No-ET.||||
33814350|NCT01042132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814351|NCT03883178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814352|NCT01115153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814353|NCT04347889|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors will be masked to study assignment|Open label, controlled, RCT|f|f|f|t
33814354|NCT01285882|||||PROSPECTIVE|||||||
33814355|NCT01427816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814356|NCT00060502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814357|NCT02555397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814358|NCT01185340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814359|NCT02961283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814360|NCT01473459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814361|NCT06354725|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33814362|NCT00911716|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814363|NCT01625494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814364|NCT00709605|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814365|NCT02464839|||COHORT||PROSPECTIVE|||||||
33814366|NCT06448000|||OTHER||PROSPECTIVE|||||||
33814367|NCT02173457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814368|NCT01581320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814369|NCT03260270|||CASE_ONLY||PROSPECTIVE|||||||
33814370|NCT00593528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814371|NCT03748056|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33814372|NCT05055804|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Clinical trials with a single arm||||
33814373|NCT01675063|NA|SINGLE_GROUP||OTHER||NONE||||||
33814374|NCT02526433|||CASE_ONLY||CROSS_SECTIONAL|||||||
33814375|NCT01859689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814376|NCT00337246|RANDOMIZED|||TREATMENT||NONE||||||
33814377|NCT03165825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814378|NCT05701176|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814379|NCT02327975|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33814380|NCT06022653|||COHORT||OTHER|||||||
33814381|NCT03363100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814382|NCT02827110|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814383|NCT03576118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33814384|NCT05529485|||COHORT||RETROSPECTIVE|||||||
33814385|NCT02958722|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33814386|NCT01144533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33814387|NCT03379597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814388|NCT02383134|||||PROSPECTIVE|||||||
34044930|NCT06294639|NA|SEQUENTIAL||OTHER||NONE|Esketamine will be prepared by an investigator who is not involved in anesthesia and outcome assessment. For all participants, esketamine will be diluted to the same volume.|The Biased coin method is used||||
34044931|NCT03198312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34044932|NCT01591850||PARALLEL||||NONE||||||
34044933|NCT02189343|NA|SINGLE_GROUP||OTHER||NONE||||||
33735807|NCT00963729|RANDOMIZED|||TREATMENT||NONE||||||
33735808|NCT01412840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735809|NCT01233297|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33735810|NCT01516190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735811|NCT06573164|||COHORT||RETROSPECTIVE|||||||
33735812|NCT05543213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33735813|NCT04988685|||COHORT||PROSPECTIVE|||||||
33814389|NCT04613947|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33735814|NCT05107310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735815|NCT06449339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735816|NCT04685135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735817|NCT03393221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814390|NCT06506279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814391|NCT00680654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814392|NCT01617889|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33814393|NCT02885376|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33814394|NCT06199011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814395|NCT01984216|RANDOMIZED|PARALLEL||||NONE||||||
33814396|NCT05686967|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants, investigators and assessor will be blinded to MitoQ or Placebo. Participants will not be blinded to exercise or no exercise; investigators and assessor will be blinded.||t|f|t|t
33814397|NCT04182074|||COHORT||PROSPECTIVE|||||||
33814398|NCT05526937|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33814399|NCT00436488|||DEFINED_POPULATION||PROSPECTIVE|||||||
33814400|NCT03071172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814401|NCT00786344|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|f|t
33814402|NCT02314000|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814403|NCT06464666|||COHORT||PROSPECTIVE|||||||
33814404|NCT06475326|NA|SEQUENTIAL||TREATMENT||NONE||||||
33814405|NCT02837705|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814406|NCT01821599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814407|NCT04243954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814408|NCT00409747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814409|NCT01524120|||OTHER||PROSPECTIVE|||||||
33814410|NCT01512355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814411|NCT02613767|||COHORT||PROSPECTIVE|||||||
33814412|NCT00946244|||COHORT||PROSPECTIVE|||||||
33814413|NCT03696342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"In addition, the statistical analysis will be carried out in a blinded manner in the case of a partial and final analysis.~The masking will be done using boxes in the primary packaging identical in the two groups and relabelling the bottles of both interventions.~Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the assignment number."|clinical study of non-inferiority, multicenter, double-blind, with comparative group randomized|t|f|t|f
33814414|NCT04636515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814415|NCT06092736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814416|NCT02056379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814417|NCT00742560|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814418|NCT06119802|||CASE_CONTROL||RETROSPECTIVE|||||||
33814419|NCT05037123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Participants, study members, and treating clinicians will be blinded to intervention.||t|t|t|f
33814420|NCT05583331|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomised, double-arms, parallel, open-label study.||||
33814421|NCT04527965|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|f|t|f|t
33814422|NCT01437540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814423|NCT03109210|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33814424|NCT01641848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814425|NCT00670449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814426|NCT00311545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814427|NCT00209053|RANDOMIZED|PARALLEL||||NONE||||||
33814428|NCT06585163|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE||Subjects will be randomized to receive A) hydrocodone and B) hydrocodone + doxapram in one of two possible sequences (ie. A followed by B or B followed by A).|t|t|t|f
33814429|NCT05034588|||CASE_CONTROL||PROSPECTIVE|||||||
33814430|NCT05780957|||COHORT||PROSPECTIVE|||||||
33814431|NCT04499898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044934|NCT00461773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044935|NCT02791542|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34044936|NCT05511701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044937|NCT03379766|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34044938|NCT05021016|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34044939|NCT04593511|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34044940|NCT03064789|||COHORT||PROSPECTIVE|||||||
34044941|NCT03461952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044942|NCT04245748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044943|NCT02383030|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34044944|NCT01931475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044945|NCT04921098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044946|NCT04296643|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators and laboratory assessors were blinded to the group assignment, but it was not possible to conceal the identity of the medical mask or N95 respirator assignment to the study staff or participants.|pragmatic, randomized, open-label, multicentre, noninferiority trial.|f|f|t|t
34044947|NCT03580837|||COHORT||RETROSPECTIVE|||||||
34044948|NCT05618938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044949|NCT02434003|||COHORT||PROSPECTIVE|||||||
34044950|NCT02693470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044951|NCT00976001|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34044952|NCT06248372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044953|NCT01474473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044954|NCT04809103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044955|NCT00280280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34044956|NCT05493397|||COHORT||PROSPECTIVE|||||||
34044957|NCT03205722|||COHORT||RETROSPECTIVE|||||||
34044958|NCT03800108|NA|SINGLE_GROUP||OTHER||NONE||||||
34044959|NCT01536080|||CASE_CONTROL||RETROSPECTIVE|||||||
34044960|NCT06119308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044961|NCT04724083|||COHORT||PROSPECTIVE|||||||
34044962|NCT00156611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34044963|NCT01742988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044964|NCT01754350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044965|NCT03892044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044966|NCT01560234|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34044967|NCT05561270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Single-center, randomized clinical trial|t|f|t|f
34044968|NCT01377350|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34044969|NCT03916549|NA|SINGLE_GROUP||TREATMENT||NONE||One group of intervention - acupuncture for LARS patients||||
34123301|NCT04180111|||CASE_ONLY||PROSPECTIVE|||||||
34123302|NCT03153748|||CASE_ONLY||PROSPECTIVE|||||||
34123303|NCT05741723|||CASE_ONLY||PROSPECTIVE|||||||
33735818|NCT01587326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735819|NCT01449903|||COHORT||PROSPECTIVE|||||||
33735820|NCT04545242|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, randomized, controlled, open-label trial involving mechanically ventilated adult patients with AHRF (including ARDS) caused by confirmed bacterial or viral infections.||||
33735821|NCT00861497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735822|NCT03556631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735823|NCT06002763|||COHORT||PROSPECTIVE|||||||
33735824|NCT04483804|||COHORT||PROSPECTIVE|||||||
33735825|NCT01916668|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735826|NCT00066196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735827|NCT05843877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735828|NCT04491630|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Both participants and the experimenter who will conduct assessments and administer the audio-recorded interventions will be blind to the condition to which subjects will be assigned and to the study hypotheses. During informed consent, prospective participants will be told that they will listen to an audio-recording that previous research found to be helpful to pain management, and that the purpose of the study is to assess this the effects of this audio-recording on discomfort associated with the sensation of coldness. Participants will also be instructed not to disclose details of the content of the audios they receive to the experimenter. The research staff member responsible for participants' randomization will be blind to identifying information and to the code identifying each condition.|"A randomized 4-group, 196-subject experimental mixed-model repeated-measures study to:~1. compare the immediate effects of self-hypnosis (SH), mindfulness meditation (MM), and Christian meditation (CM), relative to a control group (CN), for increasing pain tolerance and reducing pain intensity and pain-related stress, in response to experimental painful stimulation in a sample of healthy volunteers;~2. to identify possible shared and unique predictors of response to the three treatment conditions."|t|f|f|t
33735829|NCT02002897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735830|NCT05102994|||COHORT||RETROSPECTIVE|||||||
33735831|NCT04852094|||OTHER||PROSPECTIVE|||||||
33735832|NCT02565381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735833|NCT02181231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735834|NCT05226962|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33735835|NCT05591677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735836|NCT00229684|RANDOMIZED|PARALLEL||||NONE||||||
33735837|NCT01422070|||COHORT||PROSPECTIVE|||||||
33735838|NCT03091452|||COHORT||PROSPECTIVE|||||||
33735839|NCT05105503|||COHORT||PROSPECTIVE|||||||
33735840|NCT05430516|||COHORT||PROSPECTIVE|||||||
33814432|NCT05453435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123304|NCT05575544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123305|NCT00538057|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34123306|NCT02539186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34123307|NCT02363114|||COHORT||PROSPECTIVE|||||||
34123308|NCT00648037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735841|NCT05822011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33735842|NCT06142916|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33735843|NCT01208233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735844|NCT04613609|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants were not informed if they were to receive nicotine or placebo|Repeated Measures|t|f|f|f
33735845|NCT04496258|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33735846|NCT03844451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735847|NCT03556046|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735848|NCT05696197|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel, randomization in two groups (intervention/control)||||
33735849|NCT05956314|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"In this phase 1b, open label trial, 2 arms will be treated twice daily with 1% topical KM-001 (2 feet):~1. Arm 1: up to 11 eligible patients.~2. Arm 2: up to 7 eligible patients. During active treatment, safety, tolerability, efficacy, and PK assessments will be performed. Four (4) weeks after the end of active treatment, patients will return to the clinic for additional safety, efficacy, and PK assessments.~Safety, tolerability, and efficacy parameters will be assessed during in-clinic visits as follow:~For both cohorts: Screening, Enrolment, Days 7, 28, 42, 63.~Additionally:~For arm 1: Day 84 \[end of treatment\], 112 \[End of Study\] For arm 2: day 84, 112 \[EoT\] and 140 EoS\] post first investigational medicinal product (IMP) administration.~Safety and treatment compliance assessment will be done by phone calls on - Cohort 1: Days 14, 49, 70, and 98 (follow-up); Cohort 2: Days 14, 49, 70, 98, and 126 (follow-up)."||||
33735850|NCT02855463|||COHORT||PROSPECTIVE|||||||
33735851|NCT04875104|RANDOMIZED|PARALLEL||TREATMENT||NONE|Patients recruited into the study who met the inclusion criteria will be assigned to group 1 Invisalign, group 2 Spark, group 3 Quicksmile or group 4 ClearCorrect. To generate the allocation sequence, a block randomization system with block sizes of 4 and a 1:1:1:1 allocation ratio will be applied using GraphPad online software. The allocation will be concealed from the orthodontist, investigator, and patient. When a patient was determined to be eligible, the orthodontist explained the clinical trial to them, and the patient signed the informed consent to participate. After the allocation of the interventions, neither the patient nor the orthodontist will be blinded.|This study will be a 4-arm parallel-group, randomized, prospective superiority clinical trial with an allocation ratio of 1:1:1:1 There will be four groups of aligners of different brands.||||
33735852|NCT02251665|||CASE_ONLY||PROSPECTIVE|||||||
33735853|NCT00403338|||COHORT||PROSPECTIVE|||||||
33735854|NCT02648087|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735855|NCT05819125|||COHORT||RETROSPECTIVE|||||||
33735856|NCT00550836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814433|NCT05485441|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814434|NCT06257563|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"All dyads will use the Isle of TEND videogame platform for 20-30 minutes three-four times a week for four weeks. The Isle of TEND is supported on computers and laptops and is accessible through a link on any modern browser window."||||
33814435|NCT06387940|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34123309|NCT02132572|||COHORT||RETROSPECTIVE|||||||
34123310|NCT03030898|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735857|NCT01494233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735858|NCT00110266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735859|NCT05002946|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects randomized to Treatment A will fast at least 10 hours prior to and for at least 4 hours following dosing and will be treated with a single dose of SP-104. Subjects randomized to Treatment B will be fed a high-fat breakfast 30 minutes prior to dosing, SP-104 will be administered 30 minutes after start of the meal. No food will be allowed for at least 4 hours after the dose. Subjects randomized to Treatment C will fast at least 10 hours prior to and for at least 4 hours following dosing and will be treated with a single dose of Naltrexone Hydrochloride Tablet. Subjects will crossover to each treatment after a wash out period.||||
33735860|NCT00782652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735861|NCT02905305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735862|NCT02105077|||COHORT||PROSPECTIVE|||||||
33735863|NCT04711304|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33735864|NCT06165744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735865|NCT02628275|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33735866|NCT05732285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the data collectors in this study will be blind to the patient's group allocation.|CRT plus CBT plus lifestyle modification or usual care|f|t|f|f
33735867|NCT05154903|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a Prospective Randomized Open label trial with Blinded Evaluators, Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.~The number of patients needed for this proposal is 200 (100 per group): group 1 (citicoline) : receiving citicoline and group 2 (control) not receiving citicoline. A 10% increase will be expected to avoid possible drop-outs."||||
33735868|NCT02118233|||COHORT||PROSPECTIVE|||||||
33735869|NCT05580718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735870|NCT00464724|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735871|NCT04011878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735872|NCT06283420|||COHORT||PROSPECTIVE|||||||
33735873|NCT04391582|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was an open-label, monocentric, randomized phase II clinical trial.||||
33735874|NCT00595569|||COHORT||PROSPECTIVE|||||||
33735875|NCT01651741|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33735876|NCT01728155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735877|NCT02258282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735878|NCT05448690|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735879|NCT00116389|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735880|NCT06662643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735881|NCT01947530|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735882|NCT06442527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735883|NCT05866094|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants: People with dementia, their relatives, and home care workers||||
33735884|NCT04760275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735885|NCT00237952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33735886|NCT02647034|||COHORT||PROSPECTIVE|||||||
33735887|NCT03842787|||COHORT||PROSPECTIVE|||||||
33735888|NCT05631639|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33735889|NCT05972434|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735890|NCT03842475|||COHORT||PROSPECTIVE|||||||
33735891|NCT05210920|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants will have all three nail types assessed: regular polish, gel polish and bare nail||||
33735892|NCT04736459|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33735893|NCT03331874|||COHORT||PROSPECTIVE|||||||
33735894|NCT01127399|||COHORT||CROSS_SECTIONAL|||||||
33735895|NCT01934153|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735896|NCT00666367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33735897|NCT05062811|||COHORT||PROSPECTIVE|||||||
33735898|NCT04981041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735899|NCT04403022|NA|SINGLE_GROUP||OTHER||NONE||||||
33735900|NCT04424121|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Open-label, 3-arm parallel randomized study|Open-label, 3-arm parallel randomized study||||
33735901|NCT00099775||||TREATMENT||||||||
33735902|NCT03495986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735903|NCT06664229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors will be research assistants who do not know the group assignment of participants.|We will conduct a single-blind randomized control trial design for the main study. The pilot study will have the intervention group only without the control group.|f|f|f|t
33735904|NCT04897581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data will be coded such that the Principal Investigator (PI) analyzing the data will be blind to conditions to prevent bias during the data collection and analysis. Also, the PI will remain blind through the study and will not provide either of the interventions. The statistician will be blind. The examiner will collect the data after de-identification of the sensitive and identifiable data.||f|f|t|t
33735905|NCT03409692|||CASE_ONLY||RETROSPECTIVE|||||||
33735906|NCT02580526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735907|NCT02621164|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33735908|NCT01298024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33735909|NCT03844191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The first 2 subjects in each dose cohort receive RUC-4 in a single- blind manner (only the subjects will blinded to treatment assignment), prior to randomizing the remaining 5 subjects to either RUC 4 (n = 4) or placebo (n = 1) in a double-blind manner.||t|t|t|f
33735910|NCT04040972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735911|NCT00079105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735912|NCT00653107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735913|NCT02447991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735914|NCT00762489|NON_RANDOMIZED|SINGLE_GROUP||||||||||
33735915|NCT05949983|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33735916|NCT01234623|||COHORT||PROSPECTIVE|||||||
33735917|NCT02889159|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735918|NCT04455893|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33735919|NCT02560246|||CASE_CONTROL||PROSPECTIVE|||||||
33735920|NCT06573775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|sealed envelopes|randomized controlled trial|t|f|f|f
33735921|NCT03250663|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|adherence data of the randomized subjects|All subjects will receive study medication. Groups will be randomized to receive online treatment response surveys.|t|f|t|f
33735922|NCT05882513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735923|NCT01823393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735924|NCT05905939|||OTHER||RETROSPECTIVE|||||||
33735925|NCT00861419|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735926|NCT03849638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735927|NCT05779566|||COHORT||PROSPECTIVE|||||||
33735928|NCT02483247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735929|NCT02132000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735930|NCT01332149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735931|NCT00149708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735932|NCT03127124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735933|NCT00881075|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33735934|NCT06514092|||CASE_ONLY||RETROSPECTIVE|||||||
33735935|NCT04147013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The control group will use a placebo pill, instead of an active drug. The randomization process will be held by the Site's Pharmacy. Hence, the investigators will only have access to a list of randomized numbers, associated with the available drug/placebo pills, to implement during the study.|A prospective, double-blinded, randomized controlled study.|t|f|t|f
33735936|NCT05484401|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, double dummy study. There will be two placebo tablets designed to be comparable to each of the active products (200mg Ibuprofen Liquid Capsules and 200mg Ibuprofen Tablets) in both shape, size, colour and weight. All subject packs have been designed and labelled to ensure blinding is maintained. Subjects, investigators and site staff will all be blind to the treatments.|The dental pain model used in this study is a robust and well established postsurgical pain model that produces pain that is predictable in its character, duration, and intensity. The model is widely accepted and has a proven record of assay sensitivity (i.e. separating active drugs from each other, as well as from placebo). The model is frequently used to evaluate NSAID type analgesics. Results from dental pain studies are accepted by the US Food and Drug Administration (FDA) and European authorities and have been widely extrapolated to other general pain conditions.|t|t|t|t
33735937|NCT02358694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33735938|NCT02246504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735939|NCT02897141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33735940|NCT04302571|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33735941|NCT04186910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blind to participants' intervention assignment|Two arms interventional single blind pilot study|f|f|f|t
33735942|NCT05949476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33735943|NCT03773757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33735944|NCT05867784|||COHORT||RETROSPECTIVE|||||||
33735945|NCT00087568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735946|NCT05914571|||OTHER||RETROSPECTIVE|||||||
33735947|NCT02871843|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 Dose Escalation||||
33735948|NCT04263818|NA|SINGLE_GROUP||OTHER||NONE||||||
33735949|NCT04902859|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|None of the above will be aware of study drug or placebo.||t|t|t|t
33735950|NCT06464939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735951|NCT06072066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735952|NCT05590702|||COHORT||PROSPECTIVE|||||||
33735953|NCT02206113|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33735954|NCT03205696|||CASE_CONTROL||PROSPECTIVE|||||||
33735955|NCT04902105|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735956|NCT01314924|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33735957|NCT00399334|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33735958|NCT03073616|||CASE_CROSSOVER||PROSPECTIVE|||||||
33735959|NCT06573307|||COHORT||OTHER|||||||
33735960|NCT06664723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33735961|NCT05604664|||OTHER||RETROSPECTIVE|||||||
33735962|NCT04448860|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||optimal Simon two-stage design||||
33735963|NCT04833166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33735964|NCT05054296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33735965|NCT01818505|||CASE_CONTROL||PROSPECTIVE|||||||
33735966|NCT00648297|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33735967|NCT05724498|RANDOMIZED|PARALLEL||TREATMENT||NONE||Veterans randomized to either brief (4 session) or full (6 session) Cognitive-Behavioral Therapy for Insomnia.||||
33735968|NCT06359405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The researchers declare that the data obtained from randomly formed groups will be numbered and entered into the statistical analysis program to hide the identity information and that two researchers will be assigned during the entry.|This study was planned as a randomized controlled study to evaluate the crisis management skills of student nurses in drug safety simulation.|t|f|f|f
33735969|NCT05146128|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were allocated to a group in a random way||t|f|f|f
33735970|NCT05641194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"1. Legacy Alerting System Description: Standard alerting system in place at the fire station.~2. Intervention 2: EaseAlert Standalone Description: EaseAlert will activate and alert the subject of an emergency call without the legacy alerting system. EaseAlert (standalone) replaces the legacy alerting system."||||
33814436|NCT05458544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814437|NCT05423171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814438|NCT05949788|||COHORT||RETROSPECTIVE|||||||
34123311|NCT01310530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735971|NCT00283725|||CASE_CONTROL||PROSPECTIVE|||||||
33735972|NCT05544968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735973|NCT06113315|||COHORT||PROSPECTIVE|||||||
33735974|NCT02157324|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735975|NCT05061446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814439|NCT00211042|||CASE_ONLY||PROSPECTIVE|||||||
34123312|NCT04834726|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34123313|NCT00602524|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123314|NCT03569943|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34123315|NCT00718536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123316|NCT03192137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123317|NCT02929641|||COHORT||PROSPECTIVE|||||||
34123318|NCT02664519|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34123319|NCT03224364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123320|NCT05501639|||COHORT||RETROSPECTIVE|||||||
34123321|NCT02491281|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34123322|NCT06000670|NA|SINGLE_GROUP||OTHER||NONE|investigator is blinded to clinical and radiological assessments .|||||
34123323|NCT01904721|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123324|NCT06351826|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34123325|NCT00439335|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34123326|NCT04063917|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Multi-center, open label randomized 2x2 cross-over sleep study of the ZENS transcutaneous hypoglossal nerve stimulator in the ON (active) versus OFF (passive) setting during a single over-night sleep study."||||
34123327|NCT04495686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123328|NCT00558636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34123329|NCT01718158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123330|NCT02838641|||CASE_ONLY||PROSPECTIVE|||||||
34123331|NCT03272555|NA|SINGLE_GROUP||OTHER||NONE||||||
34123332|NCT03253718|||COHORT||PROSPECTIVE|||||||
34123333|NCT06361771|||COHORT||OTHER|||||||
34123334|NCT00803361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123335|NCT06512532|||CASE_ONLY||CROSS_SECTIONAL|||||||
34123336|NCT05618756|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34123337|NCT02832193|||COHORT||PROSPECTIVE|||||||
34123338|NCT00570713|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123339|NCT04458740|||COHORT||PROSPECTIVE|||||||
34123340|NCT01936883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123341|NCT02315222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123342|NCT02136043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123343|NCT02381704|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34123344|NCT01174628|||COHORT||PROSPECTIVE|||||||
34123345|NCT03406208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123346|NCT01778998|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34123347|NCT04748692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The allocation of the patients to their treatment group will be concealed from the researcher that assesses the outcome measures.|This study is a randomized controlled trial with a follow-up of 6 weeks. Patients with PFPS will be randomly assigned to one of two intervention groups using an online computer-based pseudo-random number generator on which the numbers were generated by use of a complex algorithm (seeded by the computer's clock). The flow diagram of the progress through the phases of the parallel randomised trial of both intervention groups (that is, enrolment, allocation, follow-up, and data analysis) follows the PRISMA statement.|f|f|t|t
34123348|NCT01147393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123349|NCT04450030|||COHORT||PROSPECTIVE|||||||
34123350|NCT05068349|NA|SINGLE_GROUP||TREATMENT||NONE|Intervention measures are closer to the real-world clinical environment to make up for the shortcomings of RCT.|A single-group clinical trial is a study with only one group, and no corresponding control group is designed for the experimental group.||||
34123351|NCT02546583|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123352|NCT02916069|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
34123353|NCT04419545|||CASE_CONTROL||RETROSPECTIVE|||||||
34123354|NCT05278026|||COHORT||PROSPECTIVE|||||||
34123355|NCT04277624|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34123356|NCT01923766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123357|NCT02525640|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123358|NCT02185534|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34123359|NCT03194399|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34123360|NCT00395109|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123361|NCT00696124|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123362|NCT02965066|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34123363|NCT01534481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34123364|NCT05007886|||COHORT||PROSPECTIVE|||||||
34123365|NCT00688857|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123366|NCT00786162|RANDOMIZED|PARALLEL||||NONE||||||
34123367|NCT03757507|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Open label, single group||||
34123368|NCT01953211|||COHORT||PROSPECTIVE|||||||
34123369|NCT00954161|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34123370|NCT05230511|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized, controlled comparative effectiveness clinical trial.||||
34123371|NCT02282228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123372|NCT03912610|||CASE_CONTROL||PROSPECTIVE|||||||
34123373|NCT00733486|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123374|NCT01252589|||CASE_ONLY||CROSS_SECTIONAL|||||||
34123375|NCT05197465|||COHORT||PROSPECTIVE|||||||
34123376|NCT02248896|||CASE_CONTROL||RETROSPECTIVE|||||||
34123377|NCT05980754|||OTHER||CROSS_SECTIONAL|||||||
34123378|NCT05630781|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34123379|NCT05046626|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34123380|NCT06318689|||COHORT||PROSPECTIVE|||||||
34123381|NCT00361465|||||PROSPECTIVE|||||||
34123382|NCT02102958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123383|NCT04805866|||CASE_CONTROL||PROSPECTIVE|||||||
34123384|NCT03725956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123385|NCT03815149|||COHORT||RETROSPECTIVE|||||||
34123386|NCT00894777|||CASE_ONLY||RETROSPECTIVE|||||||
34123387|NCT03679390|RANDOMIZED|PARALLEL||OTHER||SINGLE||Use same medication for different generations, focus on the reactions.|t|f|f|f
34123388|NCT02581891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123389|NCT01293136|||COHORT||RETROSPECTIVE|||||||
34123390|NCT03706365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123391|NCT05970926|||COHORT||PROSPECTIVE|||||||
34123392|NCT00002348||||TREATMENT||||||||
34123393|NCT05983614|||OTHER||PROSPECTIVE|||||||
34123394|NCT01207206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123395|NCT00532701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123396|NCT02255669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123397|NCT00362895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123398|NCT03991910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|study participants do not know whether they become treatment group or control group the investigator does not know which participant in each group|pre post test design with placebo control|t|f|t|f
34123399|NCT04972188|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase I, Prospective, Open Label, Multiple Dose study||||
34123400|NCT00598819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123401|NCT03857009|||COHORT||PROSPECTIVE|||||||
34123402|NCT05039788|||COHORT||PROSPECTIVE|||||||
34123403|NCT01658085|||CASE_CONTROL||PROSPECTIVE|||||||
34123404|NCT05647499|NA|SINGLE_GROUP||TREATMENT||NONE||The evaluation of changes in school attendance (primary outcome) following the B2S program will be conducted using a multiple - baseline across subjects' design comparing the individuals' baseline levels of school absenteeism with the level of absenteeism following participation in the B2S program. The structure of the multiple baseline design with 14 subjects is comprised of two treatment conditions, a baseline (control) and an intervention condition with N equally spaced measurement occasions (Hedges, Pustejovsky, \& Shadish, 2013). Thus, each subject function as their own control. Changes in secondary outcome measures (psychological wellbeing, school related self-efficacy) are assessed through repeated measurement at pre- (T1), and post intervention (T2).||||
34123405|NCT02837718||SEQUENTIAL||PREVENTION||NONE||A total of 55 ASA I-II patients underwent hand surgery operation by administering USG guided-axillary brachial plexus blockage were included in the study. Ulnar, median and radial nerves were seen and the minimum effective LA volume was investigated starting with total 21 ml of %0.5 bupivacain. After accomplishing the blockage, volume was decreased by 0.5 for each nerves. Block administration time, block onset times, anesthesia times and time to first analgesic requirement were recorded.||||
34123406|NCT06512506|||COHORT||PROSPECTIVE|||||||
34123407|NCT03361488|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34123408|NCT02747758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123409|NCT00781638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123410|NCT04240886|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123411|NCT02521974|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123412|NCT01421966|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123413|NCT04315090|||COHORT||RETROSPECTIVE|||||||
34123414|NCT02126163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123415|NCT03265444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123416|NCT04918147|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34123417|NCT05878171|||CASE_ONLY||CROSS_SECTIONAL|||||||
34123418|NCT01866202|||COHORT||PROSPECTIVE|||||||
34123419|NCT06242847|||CASE_ONLY||PROSPECTIVE|||||||
34123420|NCT04877678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation of medication is conducted by an independent physician who is not a co-investigator of the study.|A Randomized, Double-blind, Placebo Controlled Study|t|f|t|t
34123421|NCT00751712|||COHORT||PROSPECTIVE|||||||
34123422|NCT00967681|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34123423|NCT05983341|||COHORT||RETROSPECTIVE|||||||
34123424|NCT03533088|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised control trial||||
34123425|NCT03645044|||COHORT||PROSPECTIVE|||||||
34123426|NCT06364397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123427|NCT01595529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123428|NCT06017882|||CASE_CROSSOVER||PROSPECTIVE|||||||
34123429|NCT00143000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123430|NCT01247064|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123431|NCT00104390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34123432|NCT03323853|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34123433|NCT01802060|||COHORT||PROSPECTIVE|||||||
34123434|NCT01937520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123435|NCT00720577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34123436|NCT04726995|||OTHER||OTHER|||||||
34123437|NCT01355614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123438|NCT03924544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123439|NCT02809885|NA|SINGLE_GROUP||SCREENING||NONE||||||
34123440|NCT04500457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123441|NCT03661840|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomized to the acceptance and commitment therapy intervention or to treatment as usual.||||
34123442|NCT03982277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123443|NCT06287255|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm trial||||
34123444|NCT04819113|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123445|NCT04130412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123446|NCT04256473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123447|NCT05342298|||COHORT||RETROSPECTIVE|||||||
34123448|NCT05480176|||COHORT||PROSPECTIVE|||||||
34123449|NCT01186250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837129|NCT01898377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837130|NCT05614440|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The solutions were prepared prior to the procedure by an anesthetic nurse who was not involved in the study. Investigator was blind to the groups.|The patients were randomly divided into the following two groups using the sealed envelope method.|f|t|t|f
33837131|NCT02723227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33837132|NCT01523600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33735976|NCT03300245|||COHORT||CROSS_SECTIONAL|||||||
33814440|NCT03956771|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|OCD participants will be blindly split into the two groups before the neurofeedback intervention. The psychologist evaluating the psychometric outcomes will be blind to the type of intervention of each participant.|OCD participants will be blindly split into two groups (n = 15): the real neurofeedback group (group 1, experimental group) and the sham neurofeedback group (group 2, sham comparator control group). Group 1 will receive feedback information from real activity from the target brain region, while group 2 will receive false feedback not matching real brain responses to account for placebo effects (from other participant's data).|t|f|f|t
34123450|NCT05704153|RANDOMIZED|PARALLEL||SCREENING||SINGLE||VaNeSA is a multicentre, national, randomized, double-blind, parallel-group, placebo-controlled, outpatient study.|t|f|f|f
34123451|NCT05087498|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Once the enrollment was confirmed, the research physician contacted the research nurse. They were informed with the assignment and prepared the processed cord blood MNC or normal saline. After preparation, infusion bag was covered with shading bag and infused by light-blocking infusion tube, so that the nurses who conducted the infusion and all physicians who treated the baby were not aware of the treatment assignment. We used the code name of ACBMNC number 1 or number 2 to name the infusion fluid in the computerized physician order entry. The staff who collected and analyzed the patients' data and who followed up the patients were also blinded with the assignment. The research nurse and physician that knew the allocation of treatment did not make decisions in baby's clinical care. The parents or guardians were also not aware of the assignment. Therefore, this study was double-blinded.|eight pairs of VPMTs who were admitted to NICU to receive respiratory support right after birth. The infants were assigned (1:1) to receiving at least 2×107 ACB-MNCs/kg or normal saline, intravenously, within 24-h post-enrollment within each pair.|t|t|f|t
33814441|NCT03717233|NA|SINGLE_GROUP||OTHER||NONE||Participants will be evaluated as their own controls.||||
33814442|NCT00899795|||CASE_CONTROL||PROSPECTIVE|||||||
33814443|NCT04702594|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814444|NCT02912338|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34123452|NCT03938831|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized control|f|f|t|f
34123453|NCT04044014|RANDOMIZED|PARALLEL||OTHER||SINGLE|Two assessors will be evaluating the skin for erythema, dryness and oedema. They will be blinded to which arm has received the treatment and control.|Participants will be randomised to receive the treatment dressing (either the Gellan sheet or Gellan fluid gel) on one arm (Left or Right), and the control dressing (Mepitel One) on the other arm. The first phase will be for 1 hour and the 2nd phase will be for 3 days.|f|f|f|t
34123454|NCT05078905|||COHORT||PROSPECTIVE|||||||
34123455|NCT04815200|NA|SINGLE_GROUP||TREATMENT||NONE|i) To participant (subjects): Patients can be blinded as they do not know the type of wire used. ii) To Assessor: The assessor (different than the main operator) will carry out the measurements blindly on the pre and post models.|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire||||
34123456|NCT00446927|||CASE_ONLY||PROSPECTIVE|||||||
34123457|NCT01135225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123458|NCT03919565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123459|NCT01769976|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123460|NCT03567603|||CASE_CONTROL||PROSPECTIVE|||||||
34123461|NCT01052883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123462|NCT01296503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123463|NCT02340884|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34123464|NCT03765047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34123465|NCT01202240|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34123466|NCT03734822|NA|SINGLE_GROUP||OTHER||NONE||||||
34123467|NCT06322667|||COHORT||PROSPECTIVE|||||||
34123468|NCT02666313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123469|NCT05734664|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||Every subject will first undergo 2 scans with the Pulsify sensor. Immediately after acquisition with the Pulsify sensor, an echocardiographist will record a complete 2D and 3D ultrasound data set using a state-of-the-art equipment.||||
34123470|NCT00003873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123471|NCT06332976|||OTHER||PROSPECTIVE|||||||
34123472|NCT04357561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123473|NCT04122846|NA|SINGLE_GROUP||TREATMENT||NONE||Emotional Awareness and Expression Therapy||||
34123474|NCT00569322|||||PROSPECTIVE|||||||
34123475|NCT04412681|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123476|NCT06341361|||COHORT||RETROSPECTIVE|||||||
34123477|NCT01123226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123478|NCT01848093|||COHORT||RETROSPECTIVE|||||||
34123479|NCT04494685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123480|NCT01337778|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123481|NCT01212029|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34123482|NCT01335126|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34123483|NCT01336348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123484|NCT00561522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123485|NCT02477917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123486|NCT00066053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123487|NCT03982914|||OTHER||PROSPECTIVE|||||||
33837133|NCT00414167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33735977|NCT01978184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33735978|NCT02312310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33735979|NCT02711384|||OTHER||PROSPECTIVE|||||||
33735980|NCT05515523|NA|SINGLE_GROUP||TREATMENT||NONE||single injection of autologous Adipose Derived (AD) Stromal Vascular Fraction (SVF) for the treatment of knee Post Traumatic Osteoarthritis (PTOA)||||
33735981|NCT03837496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcomes assessor will be blinded to the participant's study condition||f|f|f|t
33735982|NCT05673720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33735983|NCT04402827|||CASE_CONTROL||PROSPECTIVE|||||||
33735984|NCT01492140|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33735985|NCT00966498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33735986|NCT04774055|||OTHER||PROSPECTIVE|||||||
33735987|NCT04691466|||COHORT||PROSPECTIVE|||||||
33735988|NCT01438190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33735989|NCT05581368|||CASE_CONTROL||PROSPECTIVE|||||||
33735990|NCT03508089|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33735991|NCT03841643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|single-blind||t|t|f|f
33735992|NCT05060419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-Blind,Double-Dummy||t|f|t|f
33735993|NCT04740606|||CASE_ONLY||PROSPECTIVE|||||||
33735994|NCT04286594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33735995|NCT01744444|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33735996|NCT02692833|||COHORT||PROSPECTIVE|||||||
33735997|NCT00362804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735998|NCT06164873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33735999|NCT04313166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736000|NCT05239624|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II trial of enfortumab vedotin in combination with pembrolizumab as first-line therapy for patients with locally-advanced or node positive urothelial carcinoma.||||
33736001|NCT03572491|NA|SINGLE_GROUP||PREVENTION||NONE||"The main group - group 1 = 1000 volunteers will be vaccinated with the vaccine Allan-toxin split inactivated against seasonal influenza vaccine.~In the main group, a subgroup will be singled out - a group of 1a = 200 volunteers who will be examined for safety, immunogenicity and immunity.~The observation group is a group of 2 = 1000 people who, when confirming the diagnosis of influenza, will compare the incidence with the main group."||||
33736002|NCT03237923|||OTHER||PROSPECTIVE|||||||
33736003|NCT00036920||||TREATMENT||||||||
33736004|NCT00365118|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33736005|NCT02538497|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736006|NCT02061241|||CASE_ONLY||PROSPECTIVE|||||||
33736007|NCT01103804|||COHORT||PROSPECTIVE|||||||
33736008|NCT05479175|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group 1: Ibuprofen 600 mg will be given to the patient one hour before starting root canal treatment.~Group 2: Low-level laser therapy will be applied with an 810 nm wavelength diode laser device for 30 seconds in the area of mesial root and 30 seconds in the area of distal root , total of 60 seconds.~Group 3: Placebo, will be explained to the patients that laser treatment will be applied as in group 2, but laser will not be activated.~Group 4: Control, routine root canal treatment will be done. No medication or laser will be applied before the treatment procedure."||||
33736009|NCT00315094|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33736010|NCT02661828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736011|NCT00951210|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33736012|NCT01905982|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736013|NCT04698005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant and the physician in charge of the participant will be blinded to the given treatment (ketone drink vs. placebo)|randomisation 1:1 to active treatment (exogenous ketones) vs. placebo (drinking water of equivalent volume)|t|t|t|f
33736014|NCT02536859|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736015|NCT00507039|||COHORT||CROSS_SECTIONAL|||||||
33736016|NCT03481946|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33736017|NCT05491629|||CASE_ONLY||CROSS_SECTIONAL|||||||
33736018|NCT02198547|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736019|NCT01922310|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
33736020|NCT05785052|||COHORT||PROSPECTIVE|||||||
33736021|NCT05204953|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736022|NCT01260987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736023|NCT05060224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736024|NCT03056703|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736025|NCT06028022|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33736026|NCT04027686|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Controlled, Split-mouth||||
33837134|NCT03344211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123488|NCT00318669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123489|NCT02808429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736027|NCT01595620|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33736028|NCT01408771|||COHORT||PROSPECTIVE|||||||
33736029|NCT05879146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736030|NCT04016324|NA|SINGLE_GROUP||TREATMENT||NONE||To characterize proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim Basic Evaluation Lead.||||
33736031|NCT04376645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinding was not possible|Patients were allocated into one of 2 groups as follows: - Group 1: - Class III patients with increased vertical relationship Group 2: - Class III subjects with normal vertical relationship||||
33736032|NCT04801446|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Traditional 3+3 (rule-based, modified Fibonacci) dose escalation design|t|t|f|t
33736033|NCT05120544|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Randomization will occur following the baseline appointment. We will not blind participants to arm assignment because they will receive information on both arms during consent. In order to assure blinding of staff conducting outcome data collection, randomization will be managed by staff members not involved with outcome assessment.||f|f|f|t
33736034|NCT05004727|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigator staff, persons performing the assessments, and the CTT will remain blind to the identity of the treatment from the time of randomization until database lock.||t|t|t|f
33736035|NCT06333444|NA|SINGLE_GROUP||OTHER||NONE||Four weekly psychological counselling intervention||||
33736036|NCT06513819|NA|SINGLE_GROUP||PREVENTION||NONE||The Veterans Aging Cohort Study (VACS)-HIV database of 30 thousand veterans will be utilized to recruit eligible participants.||||
33736037|NCT00410696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736038|NCT01049919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736039|NCT04530175|||COHORT||CROSS_SECTIONAL|||||||
33736040|NCT01276327|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123490|NCT03074188|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34123491|NCT06257225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736041|NCT06023641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736042|NCT04002674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized by a Biostatistician by an internet based randomization module into two groups. The researchers include : Primary investigator , Sub-Investigators ,Clinical Coordinators, Nurse Practitioners , and Clinical Reseach unit staff.|"Investigators will evaluate the effects of 200 mg of Nilotinib versus matching Placebo taken daily by mouth for 6 Months, followed by 1 Month wash-out period in individuals with DLB.~Sixty (60) participants will be recruited and randomly assigned 1:1 to placebo (arm 1) or 200 mg Nilotinib (arm 2). Participants will be treated for 6 months and monitored every month (4 weeks) in a total of 9 visits that include screening, baseline, 1, 2, 3, 4, 5, 6 months follow up and 7-month washout."|t|t|t|t
33736043|NCT04206111|||COHORT||PROSPECTIVE|||||||
33736044|NCT00563797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736045|NCT03689127|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736046|NCT01313234|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33736047|NCT04141462|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736048|NCT04903691|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention study with organized exercise program in intervention arm, no organized exercise in control arm||||
33736049|NCT01049659|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736050|NCT04245488|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|used three random numbers and covered cups|sensory||||
33736051|NCT05000996|||COHORT||PROSPECTIVE|||||||
33736052|NCT05928221|||COHORT||PROSPECTIVE|||||||
33736053|NCT02344368|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736054|NCT03320239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33736055|NCT02311049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736056|NCT00368940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736057|NCT03861468|RANDOMIZED|PARALLEL||SCREENING||NONE||Open, controlled, randomized clinical trial (cluster randomization)||||
33736058|NCT01532362|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736059|NCT04011059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This assignment will only be known by the tissue bank that will deliver the syringes with the solution to be administered and the epicardium patches to the study participants|"A randomized clinical trial will be conducted as a proof of concept in 40 patients with previous myocardial infarction and a viable myocardial zone with indications for coronary artery bypass grafts. Twenty patients will be included in each treatment arm over 36 months. One group will undergo revascularization surgery, extracellular matrix patch placement and injection of cell culture medium; the other group will undergo revascularization surgery, extracellular matrix patch placement on the epicardial surface with cultured WJ-MSCs and injection of WJ-MSCs around the infarcted zone.~The allocation of treatments will be defined by block sizes of 2, 4 and 6, randomly determined by a random number generator (ralloc, Stata Co. 8,2). This assignment will only be known by the tissue bank that will deliver the syringes with the solution to be administered and the epicardium patches to the study participants."|t|t|t|t
33736060|NCT01138124|||CASE_CONTROL||RETROSPECTIVE|||||||
33736061|NCT01410110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736062|NCT02791334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736063|NCT06663943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736064|NCT04281277|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736065|NCT02888028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736066|NCT02851108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736067|NCT05070624|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33736068|NCT03014752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736069|NCT00898911|||OTHER||RETROSPECTIVE|||||||
33736070|NCT04219085|RANDOMIZED|PARALLEL||SCREENING||SINGLE||randomized controlled trial, not blinded|f|f|f|t
33736071|NCT03766763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736072|NCT03246958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736073|NCT04575402|||COHORT||PROSPECTIVE|||||||
33736074|NCT04453384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736075|NCT03680729|RANDOMIZED|PARALLEL||PREVENTION||NONE||aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.||||
33736076|NCT05369702|||CASE_CONTROL||RETROSPECTIVE|||||||
33736077|NCT03090399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736078|NCT00054561|RANDOMIZED|||TREATMENT||||||||
33736079|NCT04770480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study participants and clinicians cannot be blinded to study treatments. Randomization assignment will not be revealed until after enrollment and completion of baseline assessments. Study statisticians cannot be blinded to participants' study treatment assignments because they must complete Data Safety Monitoring Reports and analyze the study outcomes by treatment group. Study investigators will remain blinded to participants' treatment group assignment. Follow-up assessments will be performed by a research assistant who will be blinded to participants' treatment group assignment.|"Primary Outcome: The primary analysis will be performed by fitting a longitudinal linear model to the PEG scores at baseline, 2 weeks and 26 weeks.~Secondary Outcome: Kaplan Meier curves with 95% pointwise confidence limits will be constructed to summarize the time to opioid discontinuation in each of the EPM and SC treatment groups. Time to opioid discontinuation will be compared between groups using a stratified log-rank test, with stratification for three randomization stratification factors."|f|f|t|t
33736080|NCT05592886|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837135|NCT06240338|||CASE_ONLY||PROSPECTIVE|||||||
33837136|NCT00967083|||COHORT||PROSPECTIVE|||||||
33837137|NCT05141942|||OTHER||PROSPECTIVE|||||||
33837138|NCT03603639|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33840172|NCT03983967|NA|SINGLE_GROUP||TREATMENT||NONE||Liver cancer patients undergoing liver transplantation with hepatocellular carcinoma exceeding the Milan criteria||||
34123492|NCT04382027|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Neither the participant nor the research nurse will know the administration order of the different treatments administered. All plasma samples collected during the research project will be anonymized i.e. it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.|Double-blind controlled-randomized pharmacokinetic (PK) pilot study with crossover design (10 men and 10 women), with a minimum of 6 days between treatments|t|t|t|t
34123493|NCT05985837|||CASE_ONLY||PROSPECTIVE|||||||
34123494|NCT03620994|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34123495|NCT04369456|NA|SINGLE_GROUP||OTHER||NONE||||||
34123496|NCT05091411|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34123497|NCT05576324|||CASE_CONTROL||PROSPECTIVE|||||||
34123498|NCT01493492|||CASE_CONTROL||PROSPECTIVE|||||||
34123499|NCT02336061|||COHORT||PROSPECTIVE|||||||
34123500|NCT06183489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123501|NCT05262413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123502|NCT06131905|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34123503|NCT04610983|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||A randomised, controlled, acute, 3-way cross-over study design will be used|f|f|f|t
34123504|NCT04660175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123505|NCT01979718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123506|NCT01769053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123507|NCT04995484|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Group||||
34123508|NCT01458678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123509|NCT05613907|||COHORT||PROSPECTIVE|||||||
34123510|NCT04624308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123511|NCT03110484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736081|NCT02258152|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814445|NCT05963802|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be informed about the interventions they will be assigned to, ensuring transparency in the study. However, the investigator responsible for the allocation will be blinded to the group assignment of each participant, maintaining the integrity of the study design. To collect the outcomes, an individual external to the research team will be involved. This approach helps minimize potential bias and ensures the data collection process remains independent and unbiased.|We employed a crossover design to ensure equity in the learning experience for all students. This involved assigning students either the ChatGPD (A) or the regular online tools (B) for accessing resources and assisting them with their assignments. During the initial phase of the intervention, participants in group A will utilize ChatGPT to complete their assignments, while participants in Group B will serve as the control group. In the subsequent period, the interventions will switch between the two groups.|f|f|t|f
33814446|NCT06091709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814447|NCT02003885|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814448|NCT02836184|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33814449|NCT00603018|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33814450|NCT04517669|||COHORT||PROSPECTIVE|||||||
33814451|NCT00629564|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814452|NCT02767037|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33814453|NCT00637559|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33814454|NCT02304445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814455|NCT03107156|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814456|NCT03034863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The individual who evaluates the outcomes of interest will not know the assigned condition of the participants.|Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33814457|NCT00523458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736082|NCT05499676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736083|NCT02147808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736084|NCT03231904|||COHORT||PROSPECTIVE|||||||
33736085|NCT06229574|RANDOMIZED|PARALLEL||OTHER||SINGLE|The application was administered to the participants by the researcher, but postpartum breastfeeding success and breastfeeding self-efficacy were evaluated by an interviewer who was unaware of the participants' group.|The research will be conducted as an experimental single-blind study with a randomized control group.|f|f|f|t
33736086|NCT01256775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814458|NCT03332316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814459|NCT05343936|||COHORT||PROSPECTIVE|||||||
33814460|NCT03014726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814461|NCT05825105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814462|NCT05140499|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33814463|NCT04418609|||COHORT||OTHER|||||||
33814464|NCT03136588|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized in a 1:1 ratio to either Information and Communication Technology (ICT) based centralized clinical trial monitoring system or control group||||
34123512|NCT03187509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123513|NCT02838043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123514|NCT00672230|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34123515|NCT05302310|||COHORT||PROSPECTIVE|||||||
34123516|NCT01035502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736087|NCT02700230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736088|NCT03600168|||COHORT||PROSPECTIVE|||||||
33736089|NCT05459870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736090|NCT01809626|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33736091|NCT04341181|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736092|NCT05337059|NA|SINGLE_GROUP||TREATMENT||NONE||feasibility, monocentric, prospective study||||
33736093|NCT04037527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123517|NCT05739825|||COHORT||PROSPECTIVE|||||||
34123518|NCT04301661|||COHORT||PROSPECTIVE|||||||
34123519|NCT03464526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123520|NCT01129492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736094|NCT03666598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736095|NCT01570075|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33736096|NCT01989533|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33814465|NCT00047684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814466|NCT04382053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814467|NCT05107232|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33736097|NCT03417297|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study. There are no statistical testing. Ten (10) adults with refractory, partial-onset epilepsy with secondary generalization and able to provide informed consent will be enrolled. Initially, 3 participants will be enrolled and followed for 3 months to assess the safety of study intervention. Pending review by the Data and Safety Monitoring Committee (DSMC) and the US Food and Drug Administration (FDA), an additional 7 participants will be enrolled.||||
33814468|NCT05180175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814469|NCT05351515|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814470|NCT04558021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||200 patients will receive either 200 mg niclosamide in 10 mL of suspension or 10 mL of placebo three times a day together with an established treatment regimen in 1:1 ratio. The study will be conducted in 2 parts: an interim analysis will be conducted after the first 100 patients.|t|t|t|f
33814471|NCT00274287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814472|NCT04070521|||COHORT||PROSPECTIVE|||||||
33814473|NCT02871726|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814474|NCT02132195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814475|NCT05135806|||CASE_CROSSOVER||PROSPECTIVE|||||||
33814476|NCT05790317|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34044970|NCT05162924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients will be randomly allocated to either one of two groups receiving real or sham spinal manipulation. The outcomes assessors will be unaware of the group allocation. The investigator will be unaware of the outcomes measured in patients.~Healthy participants in the control group will be unaware of any study hypothesis."|Randomized placebo-controlled trial|t|f|t|t
34044971|NCT04397016|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||This is a stepped wedge randomized trial. The intervention condition (the relevant Option Grid decision aid that includes cost information about option) is sequentially assigned to participating surgeons in 4 clusters. By the end of recruitment, all surgeons will have been exposed to the intervention (about 100 surgeon-patient encounters using the Option Grid) and will have provided data for the control (about 100 control cases). Independent eligible patients will be enrolled at each period within a cluster, thus, analyzed as a repeated cross-sectional study. Periods (steps) are set intervals of time. The length of each step is 3 months. Steps 1-3 provide data from both conditions within each cluster (step 0 provides data only from the control while step 4 provides data only from the Option Grid arm) and data is collected from all clusters. Each step will add one clinician to the Option Grid arm.||||
34044972|NCT02087488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34044973|NCT06452719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044974|NCT06524947|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34044975|NCT04080245|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34044976|NCT05170048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34044977|NCT05117632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044978|NCT04939233|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34044979|NCT05408065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34044980|NCT06574919|||OTHER||PROSPECTIVE|||||||
34044981|NCT05348863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34044982|NCT05543161|||COHORT||CROSS_SECTIONAL|||||||
34044983|NCT04149613|||CASE_CONTROL||PROSPECTIVE|||||||
34044984|NCT00725309|||CASE_ONLY||CROSS_SECTIONAL|||||||
34044985|NCT04134767|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Community randomized trial. Six counties will be randomized to start 6 months of enrollment into an intervention condition. Six other communities will be assigned to 6 months of a comparison condition. All participants in both the intervention and comparison conditions will be followed for 6 months for data collection.|f|f|f|t
34044986|NCT04933552|||COHORT||PROSPECTIVE|||||||
34044987|NCT06409598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded from knowing if the participant assigned to the experimental or the control group.||f|f|f|t
34044988|NCT05931172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34044989|NCT04159857|RANDOMIZED|PARALLEL||OTHER||SINGLE||Arm 1: Fetal head is extracted by conventional one-hand (in hysterotomy) technique during the C-section Arm 2: Fetal head is extracted by an innovative two-hand (in hysterotomy) technique during the C-section|t|f|f|f
34044990|NCT02504242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34044991|NCT01221584|||COHORT||PROSPECTIVE|||||||
34044992|NCT06326398|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34044993|NCT01896128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34044994|NCT03314532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Cases will be randomized by computer into the groups|A randomized controlled experimental design method will be adopted.|t|t|t|t
33736098|NCT06662721|NA|SINGLE_GROUP||TREATMENT||NONE||Ten patients with Takayasu arteritis refractory to TNF-α inhibitors were treated with baricitinib.||||
33736099|NCT04947033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736100|NCT00906308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736101|NCT04162847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736102|NCT03174704|||COHORT||PROSPECTIVE|||||||
33736103|NCT02660736|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736104|NCT01132144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736105|NCT02366481|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736106|NCT05729022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736107|NCT04258839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736108|NCT05502796|||COHORT||PROSPECTIVE|||||||
33736109|NCT06663917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736110|NCT01915563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736111|NCT02049372|||COHORT||PROSPECTIVE|||||||
33736112|NCT04213794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736113|NCT01114841|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33736114|NCT02726763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123521|NCT02043145|||COHORT||PROSPECTIVE|||||||
34123522|NCT01074073|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34123523|NCT02101398|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34123524|NCT02869165|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123525|NCT04319250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123526|NCT00456573|NA|PARALLEL||OTHER||NONE||||||
34123527|NCT02257749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123528|NCT01402960|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|||t|f|t|f
34123529|NCT00529269|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34123530|NCT02797756|||CASE_CONTROL||PROSPECTIVE|||||||
34123531|NCT00337831|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123532|NCT04074083|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 30 clinics in one district will be randomly selected to participate, with 15 clinics each randomly allocated to the intervention (eIMCI) and control (pIMCI) groups. One IMCI trained HW will be randomly selected from among all IMCI trained HWs in the clinic to participate in the study.||||
34123533|NCT01508910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123534|NCT05671770|||COHORT||RETROSPECTIVE|||||||
34123535|NCT03484429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123536|NCT03776084|||COHORT||PROSPECTIVE|||||||
34123537|NCT02907658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34123538|NCT00600067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123539|NCT00806260|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34123540|NCT04179955|||COHORT||PROSPECTIVE|||||||
34123541|NCT03071861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123542|NCT03243227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34123543|NCT04895371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will be blinded to the randomization and allocation. The assessor will have not access to patients' medical record. Patients will be also asked to do not explain about their procedure to the assessor.|"The participants will be randomly allocated to Tele-physiotherapy or control groups.~The sample size was calculated to identify clinically relevant effects on the primary outcome, the distance of six-minute walk test. The calculation was performed using STATA 16 software. Presuming a two-sided significance level (α) of 0.05, the power of 80% (β=0.20) and standard deviation based on the results of a relevant study in COVID-19 survivors which assessed the distance of six-minute walk test. Minimal clinically important difference (MCID) of 54m was reported and considered to be clinically significant. Repeated measurement of ANCOVA was used for the calculation with a baseline and two follow-up measurements (correlation of repeated measurement=0.499). After considering 20% possible participants attrition, It was determined that a sample size of 72 participants would be required to detect a significant change, 36 in each group."|f|f|f|t
34123544|NCT05554302|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123545|NCT03320187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123546|NCT04677491|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Pilot study, randomised prospective study, triple blind, placebo controlled.|t|t|t|t
34123547|NCT01184976|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123548|NCT01616277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34123549|NCT04469205|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34123550|NCT05120700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123551|NCT01899430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123552|NCT02840825|||CASE_ONLY||CROSS_SECTIONAL|||||||
34123553|NCT03444324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study 995 was partially blinded; surgeon, surgical staff and subjects were blinded to treatment allocation throughout the entire surgery. The subject was blinded throughout the study. The IMP (BT524 or FFP/Cryo) was administered by an unblinded anaesthesiologist.|Patients were randomly assigned to treatment with BT524 or FFP/Cryo.|t|f|f|f
34123554|NCT04702386|||CASE_ONLY||PROSPECTIVE|||||||
34123555|NCT05265546|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34123556|NCT05461599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123557|NCT05122507|||COHORT||PROSPECTIVE|||||||
34123558|NCT00107276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123559|NCT00766519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123560|NCT01652313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123561|NCT06370039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123562|NCT05802277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123563|NCT01056614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123564|NCT00772278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123565|NCT00704067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123566|NCT04110106|||COHORT||CROSS_SECTIONAL|||||||
34123567|NCT03593174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123568|NCT02471313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123569|NCT03288844|||CASE_ONLY||PROSPECTIVE|||||||
34123570|NCT00577369|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123571|NCT01273038|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34123572|NCT00607802||||TREATMENT||||||||
34123573|NCT02768259|||COHORT||PROSPECTIVE|||||||
34123574|NCT05230576|||COHORT||PROSPECTIVE|||||||
34123575|NCT02859974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123576|NCT02625350|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34123577|NCT06169163|||CASE_CONTROL||PROSPECTIVE|||||||
34123578|NCT01203449|||COHORT||PROSPECTIVE|||||||
34123579|NCT04883255|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34123580|NCT01312519|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123581|NCT04968392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123582|NCT02274220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123583|NCT02954458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123584|NCT00658489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123585|NCT01119287|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34123586|NCT00997984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123587|NCT03824392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||36 participants with pulmonary sarcoidosis will be randomized into one of 3 sequential cohorts, each comprising 12 participants allocated 2:1 to efzofitimod:placebo matched to efzofitimod|t|t|t|t
34123588|NCT01466465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123589|NCT03089060|RANDOMIZED|CROSSOVER||TREATMENT||NONE||monocentric, prospective, randomized, controlled, pseudo-cross-over||||
34123590|NCT03210857|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subject will realize an apnea of 2 minutes or more, depending on his abilities, and some parameters will be measured.||||
34123591|NCT01379807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123592|NCT03371199|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123593|NCT05855018|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34123594|NCT00365339|RANDOMIZED|PARALLEL||||NONE||||||
34123595|NCT02187835|||CASE_CONTROL||RETROSPECTIVE|||||||
34123596|NCT03218774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to group assignment. It is not possible to blind the participants or the care providers.||f|f|f|t
34123597|NCT01020461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123598|NCT03729843|||OTHER||OTHER|||||||
34123599|NCT04021446|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34123600|NCT02329743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123601|NCT04608019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123602|NCT01706640|||||PROSPECTIVE|||||||
34123603|NCT00989976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34123604|NCT06393842|||CASE_ONLY||PROSPECTIVE|||||||
34123605|NCT03186625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123606|NCT04739111|NA|SEQUENTIAL||TREATMENT||NONE||||||
34123607|NCT04836442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123608|NCT05144672|||OTHER||CROSS_SECTIONAL|||||||
34123609|NCT03767439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123610|NCT01770743|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34123611|NCT05526053|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be allocated to one of the two strategies:~* Standard OR~* Preserving Lung volume"||||
34123612|NCT04764721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients with sequential psycho-cognitive disorders following severe COVID-19 and included in the Neurocog-Covid study||||
34123613|NCT06373003|||COHORT||RETROSPECTIVE|||||||
34123614|NCT03489044|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double blind, block randomised,|Placebo controlled|t|t|t|t
34123615|NCT04593550|||COHORT||PROSPECTIVE|||||||
34123616|NCT03795649|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123617|NCT00771212|||COHORT||PROSPECTIVE|||||||
34123618|NCT01010672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123619|NCT04073901|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|only satiation was blinded|||||
34123620|NCT01132352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123621|NCT00844103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34123622|NCT01331681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123623|NCT02957513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123624|NCT03771040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123625|NCT05710250|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34123626|NCT02598141|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123627|NCT02307448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123628|NCT04093960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123629|NCT04150289|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34123630|NCT00394576|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34123631|NCT01466491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123632|NCT05730881|||COHORT||RETROSPECTIVE|||||||
34123633|NCT00088257|||COHORT||PROSPECTIVE|||||||
34123634|NCT02890134|||COHORT||PROSPECTIVE|||||||
34123635|NCT05754476|||COHORT||PROSPECTIVE|||||||
34123636|NCT02830243|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34123637|NCT05511012|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||It is a prospective, monocentric, exploratory study||||
34123638|NCT03271164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123639|NCT04530305|||OTHER||PROSPECTIVE|||||||
34123640|NCT03150537|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|Observer-blind study|"Eighty healthy adults (18-49 years of age) will be randomized 1:1 to receive:~* A single dose of trivalent inactivated influenza vaccine (TIV: Fluviral™: 0.5mL IM)~  * Half will receive the vaccine using a pre-filled syringe~ * Half will receive the vaccine using a multi-dose vial~* Or,the same vaccine delivered IM using the Medical International Technologies Inc. (MIT) compressed air vaccine delivery system (Med-Jet H4)."|f|f|t|t
34123641|NCT03197610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123642|NCT06168383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123643|NCT02830919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34123644|NCT02135068|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123645|NCT01674504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123646|NCT06122103|||COHORT||PROSPECTIVE|||||||
34123647|NCT00533429|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123648|NCT04524260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123649|NCT05567705|||OTHER||CROSS_SECTIONAL|||||||
34123650|NCT01130181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123651|NCT03150381|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Single Blind (Participant)||t|f|f|f
34123652|NCT03569124|||COHORT||PROSPECTIVE|||||||
34123653|NCT00369837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123654|NCT00003109||||TREATMENT||||||||
34123655|NCT04092114|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm, randomized (1:1), controlled study of a behavioral intervention to increase adherence to daily oral PrEP, improve partner relationships (communication and support) and reduce social harms and IPV.||||
34123656|NCT03549741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34123657|NCT04824703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123658|NCT03785184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123659|NCT00290810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123660|NCT04811352|||COHORT||CROSS_SECTIONAL|||||||
34123661|NCT05175274|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34123662|NCT01436110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123663|NCT00484783|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814477|NCT05876286|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814478|NCT05466760|||COHORT||PROSPECTIVE|||||||
33814479|NCT03455725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple-blinded, placebo-controlled study. Patients, investigators, the CRO, core labs and the sponsor will be blinded for individual treatment adjudication.|Prospective, multi-center, 2:1 randomized (Treatment vs Sham Control), blinded trial comparing 2 paralel groups of patients with CMI treated with CardiAMP cell therapy system vs sham treatment.|t|t|t|t
33814480|NCT01248715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814481|NCT03853525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814482|NCT05689684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33814483|NCT05576779|||COHORT||RETROSPECTIVE|||||||
33814484|NCT05064566|||COHORT||PROSPECTIVE|||||||
33814485|NCT05888285|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33814486|NCT02301689|||COHORT||PROSPECTIVE|||||||
33814487|NCT05081778|||CASE_ONLY||PROSPECTIVE|||||||
33814488|NCT06144723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33814489|NCT01897935|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814490|NCT05590026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814491|NCT00505986|NON_RANDOMIZED|PARALLEL||||NONE||||||
33814492|NCT01251289|||COHORT||RETROSPECTIVE|||||||
33814493|NCT01324648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33814494|NCT03187704|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Participants were blinded as to filtration and no filtration. The lab was blinded as to which samples were from filtration or no filtration periods.|Randomized cross-over|t|f|f|t
33814495|NCT00774826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814496|NCT04191863|||CASE_ONLY||RETROSPECTIVE|||||||
33814497|NCT01439399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814498|NCT04280978|||COHORT||PROSPECTIVE|||||||
33814499|NCT05431426|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814500|NCT03575507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814501|NCT02429973|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814502|NCT04948866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Randomization allocation to study arms is concealed from all study personnel until the point of randomization assignment.~In the ADRD-PC Study, the overall PI (Dr. Hanson) and the research staff Clinical Research Coordinators (CRC) collecting data in 30- and 60-day interviews (data source for primary outcome and most secondary outcomes) are masked to study assignment until planned study arm reveal during final analyses. CRCs will conduct 60-day electronic health record (EHR) reviews only after dyads complete study participation, as EHR content has the potential to reveal study arm assignment. As with most behavioral clinical interventions, participants and care providers cannot be masked."||f|f|t|t
33814503|NCT05281588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814504|NCT01698567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814505|NCT00634998|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34044995|NCT00020865||||SUPPORTIVE_CARE||||||||
34044996|NCT01745536|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34044997|NCT00806663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34044998|NCT04001296|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data analysts / statisticians will not know whether the data they are analysing is from children in an Intervention or a Control school|This study is a two-arm, parallel, stratified, cluster randomised trial. Clusters in this study are infant / junior schools in Indonesia and Nigeria. Ten schools in each country will be recruited. Schools will be matched into pairs by location (urban, semi-urban, rural) and then randomised to the 'intervention' and 'control' groups. using a randomisation table.|f|f|f|t
34044999|NCT00728468||||||NONE||||||
34045000|NCT02080702|||COHORT||PROSPECTIVE|||||||
34045001|NCT04997668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045002|NCT01257113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045003|NCT01360242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045004|NCT04283799|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045005|NCT04335500|||OTHER||CROSS_SECTIONAL|||||||
34045006|NCT04633512|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Target enrollment is 80 patients. Feasibility will be studied under two categories of operations: feasibility in patients undergoing intestinal anastomoses for bariatric or colorectal surgery (n=52); and feasibility in patients undergoing cholecystectomy (n=28).||||
34045007|NCT01329874|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34045008|NCT01455597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736115|NCT05627895|||CASE_ONLY||PROSPECTIVE|||||||
33736116|NCT04420026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736117|NCT05906017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736118|NCT06572969|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33736119|NCT00906646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736120|NCT01079234|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736121|NCT03835260|NA|SINGLE_GROUP||OTHER||NONE||||||
33736122|NCT00826085|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736123|NCT03812718|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The attending anaesthesiologist will not be blinded to the technique utilized to administer GA. An independent assessor unaware of the technique utilized for administering GA will analyse the intraoperative data and conduct the postoperative follow up|"160-patients will be randomly divided into one of the two groups:~Group-I (ETT group, n= 80) ETT will be used as the airway device for maintaining ventilation~Group-2 (PLMA group, n= 80) PLMA will be used as the airway device for maintaining ventilation"|t|f|f|t
33736124|NCT00451763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814506|NCT05815563|||COHORT||PROSPECTIVE|||||||
33814507|NCT04321096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo-controlled|There are 2 cohorts: Cohort 1 - hospitalized patients (n=180); Cohort 2 - outpatients (n=400). All participants in the two cohorts are randomized to one of two arms|t|t|t|t
33814508|NCT01277679|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33814509|NCT03111368|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33814510|NCT04862507|||COHORT||PROSPECTIVE|||||||
33840173|NCT00429780|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840174|NCT00569023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840175|NCT00002341||||TREATMENT||NONE||||||
34045009|NCT05268783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045010|NCT01633723|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34045011|NCT01587846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045012|NCT04384575|||COHORT||PROSPECTIVE|||||||
34045013|NCT05589688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045014|NCT02024074|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045015|NCT01134107|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34045016|NCT05453188|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045017|NCT00826397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34045018|NCT00550745|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34045019|NCT04377425|||COHORT||PROSPECTIVE|||||||
34045020|NCT01547442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736125|NCT05702073|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial||||
33736126|NCT05458479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736127|NCT00544596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736128|NCT03665064|||COHORT||RETROSPECTIVE|||||||
34045021|NCT05687396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34045022|NCT01931072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34045023|NCT06208839|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34045024|NCT04893616|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34045025|NCT04205331|||OTHER||CROSS_SECTIONAL|||||||
34045026|NCT00937469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045027|NCT02251457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045028|NCT03173664|||COHORT||PROSPECTIVE|||||||
34045029|NCT06573450|||OTHER||CROSS_SECTIONAL|||||||
33736129|NCT04112433|||COHORT||PROSPECTIVE|||||||
33736130|NCT06534021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736131|NCT02816216|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33736132|NCT00934999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736133|NCT00002453||||TREATMENT||||||||
33736134|NCT00970463|||COHORT||PROSPECTIVE|||||||
33736135|NCT05737641|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||RCT crossover study|f|f|t|t
33736136|NCT03120065|NA|SINGLE_GROUP||OTHER||NONE||||||
33736137|NCT06087939|||COHORT||RETROSPECTIVE|||||||
33736138|NCT06652035|||COHORT||RETROSPECTIVE|||||||
33736139|NCT06662760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736140|NCT00420680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736141|NCT06664671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Experimental|t|t|f|t
33736142|NCT01795508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736143|NCT01312402|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33736144|NCT06186362|||CASE_CONTROL||PROSPECTIVE|||||||
33736145|NCT02707640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736146|NCT06251700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736147|NCT02330198|||CASE_ONLY||PROSPECTIVE|||||||
33736148|NCT04377139|||COHORT||RETROSPECTIVE|||||||
33736149|NCT03697954|||COHORT||PROSPECTIVE|||||||
33736150|NCT01242904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736151|NCT05543746|||CASE_ONLY||PROSPECTIVE|||||||
33736152|NCT00024362||||TREATMENT||||||||
33736153|NCT03062800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736154|NCT01123538|RANDOMIZED|PARALLEL||||NONE||||||
33736155|NCT01379092|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736156|NCT05337878|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33736157|NCT01632501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736158|NCT05725603|NA|SINGLE_GROUP||OTHER||NONE||||||
33736159|NCT05305313|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The patient will be blinded to the type of anaesthesia intervention. The attending anaesthesiologist will however not be blinded to the technique utilized to administer GA and recovery immediately after extubation inside the OR. The postoperative patient recovery profile will be evaluated by an independent assessor blinded to the technique of GA.|"Forty six- patients of either sex, and schedule for laparoscopic and non-laparoscopic surgery of more than 60-minutes duration will be randomly divided into two groups of 23 each patients:~Group-I \[TBW group, n=23\]: Patients in this group will receive maintenance propofol calculated using total body weight (TBW).~Group-II \[ABW group, n=23\]: Patients in this group will receive maintenance propofol calculated using adjusted body weight (ABW)."|t|f|f|t
33736160|NCT02138318|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736161|NCT04856696|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33736162|NCT02409615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736163|NCT06034821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736164|NCT01465802|NON_RANDOMIZED|||TREATMENT||NONE||||||
33736165|NCT01983800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736166|NCT03154710|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomised, open, multicenter prospective trial||||
33736167|NCT01347203|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736168|NCT06664359|||COHORT||PROSPECTIVE|||||||
33736169|NCT03149328|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Process evaluation with two phases (Phase 1: Usability Testing; Phase 2: Evaluation)||||
33736170|NCT00728858|||CASE_CONTROL||PROSPECTIVE|||||||
33736171|NCT03176732|||CASE_CONTROL||PROSPECTIVE|||||||
33736172|NCT01304888|RANDOMIZED|PARALLEL||||NONE||||||
33736173|NCT05035069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736174|NCT04847050|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736175|NCT00320281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736176|NCT06571214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840176|NCT01417624|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34045030|NCT01222520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045031|NCT05607030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to their randomization arm assignment until the completion of Stage 1 surgery.||t|f|f|f
34045032|NCT04090099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34045033|NCT02304861|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34045034|NCT06122636|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33736177|NCT06618599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|Group 1: received ipsilateral Ultrasound guided midtransverse block and ipsilateral Ultrasound guided ESPB block Group 2: paravertebral block(PVB): Patients received ipsilateral Ultrasound guided paravertebral plane block .|t|t|f|f
33736178|NCT05081323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not be aware the study includes two conditions. The conditions of the study are only known by the researchers and the Research Ethics Committee.|The study has two arms, one is the experimental group that receives the treatment and the other is the comparison group that will receive treatment after the 2 months of the experimental group finished. The patients in both groups will be evaluated pre and post/treatment. The participants are assigned randomly to the intervention or comparison group.|t|f|f|f
33736179|NCT05272592|||OTHER||PROSPECTIVE|||||||
33736180|NCT05971108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736181|NCT04844385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736182|NCT01938534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736183|NCT00422565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736184|NCT05506020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736185|NCT03380039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736186|NCT06139952|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A prospective single blinded multi armed randomized controlled clinical trial|f|f|f|t
33736187|NCT02634294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736188|NCT00001621|||COHORT||PROSPECTIVE|||||||
33736189|NCT05874258|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|Masked investigators responsible for all outcome measures and unmasked investigators responsible for group allocation and intervention. A set of random numbers will be generated by computer and the simple random sampling method (which matches according to age and gender) will be used to allocate the eligible participants into 3 groups.|A prospective, double-masked, randomized, placebo-controlled training RCT design|t|f|f|t
33736190|NCT01981434|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736191|NCT03952533|RANDOMIZED|PARALLEL||PREVENTION||NONE||Monocentric open label randomized controlled study||||
33736192|NCT01495962|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33736193|NCT01164046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736194|NCT00573963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736195|NCT01790750|NA|SINGLE_GROUP||||NONE||||||
33736196|NCT06573125|NA|SINGLE_GROUP||TREATMENT||NONE||Single-Arm, Pre-Post Study||||
33736197|NCT01863446|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33736198|NCT02534610|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33736199|NCT01175382|RANDOMIZED|PARALLEL||TREATMENT||NONE||The design of this study is a 3 group randomized trial. Group 1 was randomized to drug only for the first 6 weeks, followed by a step up to drug plus behavior from 6 weeks to 12 weeks. Group 2 was randomized to behavior only for the first 6 weeks, followed by a step up to behavior plus drug from 6 weeks to 12 weeks. Group 3 was randomized to behavior plus drug from baseline to 12 weeks.||||
33736200|NCT02666235|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||f|t|t|t
33736201|NCT04368923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736202|NCT04824534|||COHORT||PROSPECTIVE|||||||
33736203|NCT02300402|||OTHER||PROSPECTIVE|||||||
33736204|NCT01798446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736205|NCT01675713|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736206|NCT03079336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736207|NCT06535906|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|We conducted our study as a randomized controlled study. There will be no masking in our study.||||
33736208|NCT00134368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736209|NCT06572332|||COHORT||PROSPECTIVE|||||||
33736210|NCT03970135|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33736211|NCT03852329|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, non-controlled||||
33736212|NCT05979792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736213|NCT03150342|||CASE_ONLY||RETROSPECTIVE|||||||
33736214|NCT00240422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33736215|NCT03261349|NA|SINGLE_GROUP||TREATMENT||NONE||New Direct-Acting Antiviral Agent, HARVONI® (ledipasvir/sofosbuvir)||||
33736216|NCT02960880|||COHORT||RETROSPECTIVE|||||||
33736217|NCT02304237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736218|NCT04466514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33736219|NCT02466308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736220|NCT02896127|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736221|NCT04283175|||CASE_CONTROL||PROSPECTIVE|||||||
33736222|NCT04928222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigational product will have randomly generated product code on label.||t|f|t|f
33736223|NCT01837316|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736224|NCT04188899|||COHORT||PROSPECTIVE|||||||
33736225|NCT04931654|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a FTIH, multicenter, open-label, dose-escalation and dose-expansion study. The study includes 2 parts: Part A Dose Escalation and Part B Dose Expansion. Initially, participants with Stage IIIB to IV NSCLC will be enrolled in the study; additional tumor types may be explored and added in a future amendment to the CSP.||||
33736226|NCT02828514|||CASE_ONLY||PROSPECTIVE|||||||
33736227|NCT03738904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33736228|NCT02072850|||COHORT||PROSPECTIVE|||||||
33736229|NCT06294509|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Single-blinded, pseudo-randomised, exploratory, single-centre, national, longitudinal study|t|f|f|f
33736230|NCT05707858|||COHORT||CROSS_SECTIONAL|||||||
33736231|NCT03084016|||COHORT||PROSPECTIVE|||||||
33736232|NCT02994030|||COHORT||PROSPECTIVE|||||||
33736233|NCT01162629|||CASE_ONLY||PROSPECTIVE|||||||
33736234|NCT02908997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814511|NCT05095077|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The tadalafil tablets and placebo are over-encapsulated in identical hard-gelatin capsules. The over-encapsulation, packaging and labelling is performed by the hospital pharmacy.|Two-period (AB/BA) crossover study|t|f|t|t
33814512|NCT02091102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814513|NCT01774617|||COHORT||PROSPECTIVE|||||||
34045035|NCT03714074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34045036|NCT00435708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045037|NCT00002251||||TREATMENT||||||||
34045038|NCT00937027|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045039|NCT00704600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045040|NCT05993897|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34045041|NCT05728827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045042|NCT00221871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34045043|NCT01980459|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34045044|NCT04252625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blinded, placebo-controlled|An asymmetric two-sided group sequential design will be used with an interim analysis for efficacy and futility.|t|t|t|t
34045045|NCT04804826|||COHORT||PROSPECTIVE|||||||
34045046|NCT02315404|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34045047|NCT01583309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045048|NCT05159375|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34045049|NCT02965729|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34045050|NCT04863027|||COHORT||PROSPECTIVE|||||||
34045051|NCT02095691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045052|NCT01985529|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34045053|NCT04353609|||COHORT||RETROSPECTIVE|||||||
34045054|NCT02132182|||COHORT||PROSPECTIVE|||||||
34045055|NCT02483039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045056|NCT03857217|||COHORT||RETROSPECTIVE|||||||
34045057|NCT02641626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045058|NCT00669500|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123664|NCT02990650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123665|NCT06243614|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34123666|NCT04786054|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34123667|NCT04592406|||COHORT||RETROSPECTIVE|||||||
34123668|NCT05504759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123669|NCT04618029|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Different hospitals for the treatment and control group~* Two independent assessor will be recruited for data collection and data analysis of outcomes"|A quasi experimental parallel interventional study model in which there will be 2 groups, a treatment group and a controlled group.|t|f|f|t
34123670|NCT02869672|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34123671|NCT05634473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123672|NCT01952743|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34123673|NCT00407719|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045059|NCT03892395|RANDOMIZED|PARALLEL||OTHER||DOUBLE|2 year randomised, placebo controlled, double blinded intervention|"Supplementation for 2 years with one of the following treatments in capsule form:~1. Active: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined.~2. Control/Placebo: Vitamin D, a daily capsule containing 10 µg/day vitamin D"|t|f|t|f
34123674|NCT00833027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123675|NCT03358602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123676|NCT01051037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123677|NCT06024187|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who met the inclusion criteria and received informed consent were randomly assigned to the group of using cold separation or the group of using electrocautery with 1:1 allocation based on a computer-generated randomization schedule. The randomization was conducted by drawing an envelope containing the allocation to one of the two intervention groups.||||
34123678|NCT01039987|||COHORT||PROSPECTIVE|||||||
34123679|NCT04180098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All participants monitor their physical activity for 1 week, and falls for 15 weeks. After the screening, participants are randomized. Gait and balance capacity will be assessed in the movement lab of Radboudumc. Participants in the intervention group receives 5 weeks of C-mill training, which is immediately followed by an assessment in the movement lab, one-week of activity monitoring and fall monitoring during a 15 week follow-up period. After follow-up they will receive a final assessment in our movement lab. Participants in the control (waiting list) intervention, continue usual care for 5 weeks, followed by an assessment in the movement lab and one-week of activity monitoring. Subsequently, they receive 5 weeks of C-mill training, followed by an assessment in the movement lab, one-week of activity monitoring and fall monitoring in a follow-up period of 15 weeks. After follow-up, they receive a final assessment in the movement lab.||||
34123680|NCT00836264|||COHORT||RETROSPECTIVE|||||||
34123681|NCT02054065|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34123682|NCT00429143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123683|NCT00465972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123684|NCT04405440|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34123685|NCT01333410|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34123686|NCT02982629|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34123687|NCT01796288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123688|NCT01399112|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34123689|NCT04878393|||COHORT||PROSPECTIVE|||||||
34123690|NCT01452477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045060|NCT04106804|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The study is a single arm interventional study with a treatment phase of 6 months.||||
34045061|NCT03360825|||COHORT||PROSPECTIVE|||||||
34045062|NCT04514458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34045063|NCT05169099|||COHORT||RETROSPECTIVE|||||||
34045064|NCT02842580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045065|NCT03937895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045066|NCT03273413|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel study design.|t|t|t|t
34045067|NCT00610155|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34045068|NCT00094393|||CASE_ONLY||RETROSPECTIVE|||||||
34045069|NCT00942890|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34045070|NCT01113385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045071|NCT04244955|||OTHER||CROSS_SECTIONAL|||||||
34045072|NCT03784742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34045073|NCT03809780|NA|SINGLE_GROUP||TREATMENT||NONE||Elderly unfit patients with newly diagnosed multiple myeloma||||
34045074|NCT00894608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045075|NCT06152146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045076|NCT02480569|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34045077|NCT04801680|||COHORT||PROSPECTIVE|||||||
34045078|NCT06257823|||COHORT||PROSPECTIVE|||||||
34045079|NCT04580134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and those who interact with them are blinded to study medication. The pharmacy dispensing team and the Safety Officer will remain unblinded for safety reasons.|"Individuals who previously participated in a B-SNIP trial who have already been biotyped will be grouped accordingly.~New incoming individuals will have their Biotype completed. Those with Biotypes 1 and 2 will be recruited into this protocol. Anyone with Biotype 3 will be excluded from this protocol, but their information will be retained for use in a later study.~Biotypes 1 and 2 will be separated into two groups. Each Biotype, B1 and B2, will be randomized between risperidone and clozapine to create parallel comparator groups."|t|t|t|t
34045080|NCT03132844|||COHORT||PROSPECTIVE|||||||
34045081|NCT00887315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045082|NCT03881189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045083|NCT01543035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045084|NCT05276375|RANDOMIZED|PARALLEL||TREATMENT||NONE|open-label|Comparison of Verum (Bronchipret) versus no verum i.d. standard of care||||
34045085|NCT06052202|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34045086|NCT02236962|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34045087|NCT01463332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045088|NCT02569970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045089|NCT04490291|||COHORT||PROSPECTIVE|||||||
34045090|NCT02812069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045091|NCT04358185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045092|NCT01634737|||CASE_CONTROL||PROSPECTIVE|||||||
34045093|NCT03711565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045094|NCT04793490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045095|NCT01481441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045096|NCT03661242|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The design is a quasi-experimental prospective double- cohort study in which a lead-in group will be enrolled and receive standard of care and an intervention group will be enrolled one year after the last lead-in patient is accrued. The intervention group will receive shared care with an oncologist and an exercise physiologist trained in providing activity and exercise guidelines to the cancer patient population.||||
34045097|NCT03991299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045098|NCT05418998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator will be blinded to group assignment.||f|f|t|f
34045099|NCT06530511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045100|NCT02738099|||COHORT||PROSPECTIVE|||||||
34045101|NCT05746728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045102|NCT04514913|||COHORT||CROSS_SECTIONAL|||||||
34045103|NCT04173780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045104|NCT01097590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045105|NCT02821338|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34123691|NCT04965298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, care provider, investigator, outcomes assessor. Statistician. Double-blind|"This study is an interventional clinical trial of an investigational medicinal product: a phase III, randomised, placebo-controlled, two arm parallel group, double-blind, multicentre clinical trial.~Randomisation will be generated by a secure web-based system on a 1:1 basis with minimisation for recruiting site, baseline IPF treatment, reflux and cough.~All study visits may be conducted remotely without the need for participants to attend the participating site."|t|t|t|t
34123692|NCT00710892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123693|NCT04068948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant is unaware of the regimen given. The care provider and investigator(s) are aware of the regimen given.|This is a randomized clinical trial where participants are assigned randomly to receive a sedation regimen of either midazolam+hydroxyzine+meperidine or midazolam+hydroxyzine.|t|f|f|f
34123694|NCT04818957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123695|NCT05634486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Movement disorders specialists will review the severity of symptoms as blinded raters in the 3th-month and 5th-month follow-up.|40 patients with functional movement disorders will be randomized into two arms of treatments: a one-month multidisciplinary treatment (physiotherapy + cognitive-behavioral therapy) versus a one-month psychoeducation sham intervention (control group).|f|f|t|f
34123696|NCT01451749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123697|NCT02597530|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34045106|NCT03299114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045107|NCT00690677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045108|NCT00885664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All participants received truvada and kaletra in this trial||||
34045109|NCT01426932|||COHORT||PROSPECTIVE|||||||
34045110|NCT01684423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045111|NCT01699269|NA|SINGLE_GROUP||SCREENING||SINGLE|||t|f|f|f
34045112|NCT05081128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The primary intervention will be the initiation of the randomized initial shunt valve opening pressure setting to create a delayed treatment group in half of the study patients.~Randomization will be to active or placebo (closed) shunt settings. At the time of the standard three-month evaluation, all subjects will be similarly non-invasively adjusted to bring all subjects in both groups to the active setting while maintaining blinding of the subjects. All settings will be verified by the adjusting neurosurgeon."|t|f|f|t
34045113|NCT01022320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045114|NCT06310447|||COHORT||CROSS_SECTIONAL|||||||
34045115|NCT00457145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045116|NCT02078245|||OTHER||PROSPECTIVE|||||||
34045117|NCT02619864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045118|NCT02775513|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34123698|NCT01738061|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34123699|NCT03541499|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34123700|NCT00000857||||TREATMENT||DOUBLE||||||
34123701|NCT05689879|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Infliximab stop Methotrexate (without exceed 25mg/kg/week) or azathioprine||||
34123702|NCT02930707|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34123703|NCT05999331|||COHORT||PROSPECTIVE|||||||
34123704|NCT01107067|NA|SINGLE_GROUP||SCREENING||NONE||||||
34123705|NCT03564574|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123706|NCT00921050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34123707|NCT02745496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123708|NCT05323890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123709|NCT05257382|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123710|NCT00913510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123711|NCT04451005|||OTHER||PROSPECTIVE|||||||
34123712|NCT01976299|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34123713|NCT04539834|||CASE_ONLY||RETROSPECTIVE|||||||
34123714|NCT03820284|||COHORT||PROSPECTIVE|||||||
34123715|NCT02785692|||COHORT||RETROSPECTIVE|||||||
34123716|NCT04254146|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123717|NCT02272946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123718|NCT00287781|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34123719|NCT04187131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123720|NCT00811720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123721|NCT04795375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123722|NCT04088968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not know if patients were allocated to intervention or control group|Randomised Controlled Trials, Implementation feasibilty trial, Interviews nested|f|f|f|t
34123723|NCT02057926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34123724|NCT01946334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123725|NCT02305004|||COHORT||PROSPECTIVE|||||||
34123726|NCT00643942|||CASE_ONLY||PROSPECTIVE|||||||
34123727|NCT02388880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123728|NCT05713071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This pilot, single-center, randomized, controlled, clinical study aims to assess the safety, tolerability, and short-term efficacy of BEAM, in addition to exploring its impact on gastric physiology compared to lifestyle modification therapy alone. At 6 months control group will crossover to treatment group.||||
34123729|NCT00742625||PARALLEL||TREATMENT||NONE||||||
34123730|NCT00619944|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123731|NCT03739151|NA|SINGLE_GROUP||OTHER||NONE||All participants in this study receive gold-standard behavioral obesity treatment on an individual basis.||||
34123732|NCT05853588|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study in randomized controlled, pretest, posttest and experiment, control group design||||
34123733|NCT04831905|NA|SINGLE_GROUP||TREATMENT||NONE||Ablate and resect study||||
34123734|NCT03116997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123735|NCT04222530|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|All the subjects who met the inclusion criteria were required to sign an informed consent form before joining the group, but they did not know their own grouping. The team of doctors is composed of four experienced endoscopes from the Department of Gastroenterology of Nanfang Hospital. Patients were randomly divided into group A (patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy) and group B (patients underwent magnifying narrowband endoscopy first and then linear endoscopic ultrasonography). Different examination items are examined by randomly selected doctors, and the two doctors do not know the diagnosis of the other test. The examination results, examination time and complications were recorded in both groups. After examination, continue to follow up the patient's operation until the patient's surgical and pathological results are obtained.|This study is a single-center randomized, self-controlled clinical trial. The subjects were selected according to the inclusion and exclusion criteria, and all subjects who met the inclusion criteria were required to sign an informed consent form before joining the group. The team of doctors is composed of four experienced endoscopes from the Department of Gastroenterology of Nanfang Hospital. Patients were randomly divided into group A (patients underwent linear endoscopic ultrasonography followed by magnifying narrowband endoscopy) and group B (patients underwent magnifying narrowband endoscopy first and then linear endoscopic ultrasonography). The examination results, examination time and complications were recorded in both groups. After examination, continue to follow up the patient's operation until the patient's surgical and pathological results are obtained.|t|t|t|t
33736235|NCT01936259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736236|NCT06568939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736237|NCT02912286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736238|NCT04692246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736239|NCT00901329|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736240|NCT00739336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736241|NCT01843959|||COHORT||CROSS_SECTIONAL|||||||
33736242|NCT05294263|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double Blind Placebo Controlled Trial: . Eligible individuals will be randomized to receive varenicline or matching placebo in a 1:1 manner utilizing a stratified random block design with block sizes of 2, 4 and 6.|t|t|t|t
33736243|NCT00612313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736244|NCT05167344|NA|SINGLE_GROUP||PREVENTION||NONE|Due to the nature of the intervention, it is not possible to have blinded conditions.|Youth and facilitators participating in HRP-E program (intervention arm)||||
33736245|NCT06216951|||COHORT||PROSPECTIVE|||||||
33736246|NCT03064126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be blinded to treatment assigned and treatment received until completion of all 12 month follow-up visits (primary endpoint).|The RANGER™ investigational device is coated with the drug paclitaxel.|t|f|f|f
33736247|NCT04388332|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||retrospective/prospective observational, two arm study - 40 patients in retrospective cohort (data collection from previous procedure) compared to 20 patients in Prospective cohort||||
33814514|NCT03213587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736248|NCT03285477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All Central Vendors and the sponsor were masked. The sponsor was unblind at the end of Day 57.|This study tested KX2-391 Ointment 1% against a placebo.|t|t|t|t
33736249|NCT01462903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736250|NCT05389592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736251|NCT01372436|||COHORT||PROSPECTIVE|||||||
33736252|NCT04035772|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33736253|NCT02653196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736254|NCT04895527|||COHORT||PROSPECTIVE|||||||
33736255|NCT05381792|||CASE_ONLY||PROSPECTIVE|||||||
33736256|NCT03063359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736257|NCT03515460|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33736258|NCT01243385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736259|NCT04642703|||COHORT||RETROSPECTIVE|||||||
33736260|NCT04112693|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33736261|NCT01516268|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33736262|NCT02927691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736263|NCT01645475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736264|NCT06662578|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736265|NCT05114356|||COHORT||PROSPECTIVE|||||||
33736266|NCT02432794|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736267|NCT00895219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736268|NCT05970107|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33736269|NCT05968989|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33736270|NCT02962895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group trial which planned to enroll approximately 180 patients with moderate to severe primary Sjögren's syndrome. The study was divided into 4 study periods:~Period 1: 4-week Screening to assess patient eligibility.~Period 2: 24-week Blinded treatment period.~Period 3: An extended blinded treatment period of 28 weeks. After Week 24 assessments, patients in the ianalumab 300 mg arm were re-randomized in a 1:1 ratio to either continue on ianalumab 300 mg s.c. q4w or switch to matching placebo up to Week 52.~Period 4: Post-treatment safety follow-up period. Patients who prematurely discontinued the study treatment at any time point or completed the treatment as planned entered the safety follow-up period."|t|t|t|f
33736271|NCT06149637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Randomized, parallel, multicenter stratified clinical trial with 1:1 allocation.|t|f|f|f
33736272|NCT05505981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736273|NCT05941039|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33736274|NCT01698697|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736275|NCT03772405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736276|NCT01073488|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736277|NCT06211647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736278|NCT05303805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient will separated by a screen from the treated area. Absorbent material with sevoflurane will be held under the distal pole of the wound to produce a typical smell of sevoflurane.|The intervention group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with , with sevoflurane used to soak the absorbent material held under the distal pole of the wound to produce a typical smell of sevoflurane.|t|f|f|f
33736279|NCT03413878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33736280|NCT00661934|||COHORT||CROSS_SECTIONAL|||||||
33736281|NCT00501891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736282|NCT04464226|NA|SINGLE_GROUP||OTHER||NONE||||||
33736283|NCT03049813|RANDOMIZED|PARALLEL||OTHER||SINGLE|Some, but not all, outcomes require masking for the assessor.||f|f|f|t
33736284|NCT06573866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only the investigator is blinded to group allocation.|Participants are assigned to either the PWI (intervention) or the usual care (control) group, in a 1:1 ratio.|f|f|t|f
33814515|NCT00857077|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33814516|NCT00010959|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814517|NCT02605876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33814518|NCT03853941|NON_RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33814519|NCT01371227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814520|NCT02274753|||COHORT||PROSPECTIVE|||||||
33736285|NCT00191061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814521|NCT00323778|NON_RANDOMIZED|PARALLEL||||NONE||||||
33814522|NCT04937309|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|sham|one control arm and one intervention arm|t|t|t|t
33814523|NCT04004754|||COHORT||PROSPECTIVE|||||||
33736286|NCT05266326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736287|NCT05548244|NA|SINGLE_GROUP||OTHER||NONE||||||
33814524|NCT06017557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This study focuses on individuals diagnosed or suspected to have Stage III-IV ovarian cancer They must be fit for cytoreductive surgery These individuals also be selected for interval cytoreductive surgery after NACT||||
33814525|NCT06008665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One of my group is experimental and the other one is controlled||t|f|f|f
33814526|NCT01313988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814527|NCT04330573|||CASE_CONTROL||PROSPECTIVE|||||||
33814528|NCT02845921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814529|NCT05018065|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33814530|NCT02884609|||COHORT||PROSPECTIVE|||||||
33814531|NCT02109172|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33814532|NCT02365402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045119|NCT04455035|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736288|NCT04394416|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm A: Imatinib~Arm B: Placebo"||||
33736289|NCT02753712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814533|NCT03483714|||COHORT||CROSS_SECTIONAL|||||||
33814534|NCT04407442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814535|NCT00833599|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814536|NCT04177849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045120|NCT03123445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736290|NCT04114058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736291|NCT06568146|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|This is an open-label study where no masking will be implemented.|This is a hybrid single-group clinical trial designed to evaluate the effects of a multivitamin on a range of health and wellbeing outcomes over a 12-week period.||||
33736292|NCT05864313|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33736293|NCT00996567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736294|NCT01734226|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33736295|NCT00151359|||DEFINED_POPULATION||PROSPECTIVE|||||||
33736296|NCT06028061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33736297|NCT05280119|NA|SINGLE_GROUP||SCREENING||NONE|Open Label|A single group, comparative, non-randomized, controlled study. Each patient represents her/his own control: the patient is examined consecutively with the echOpen probe, then with the probe used in the department||||
33736298|NCT01271881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736299|NCT04359173|||CASE_CONTROL||RETROSPECTIVE|||||||
33736300|NCT04364633|||COHORT||PROSPECTIVE|||||||
33736301|NCT01431768|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736302|NCT00079352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736303|NCT03351049|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33736304|NCT06080620|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"The plan for Group A (experimental group) is surgery+systematic treatment; The plan for Group B (control group) is neoadjuvant therapy+surgery+systematic treatment."||||
33736305|NCT06047197|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736306|NCT06663033|||COHORT||PROSPECTIVE|||||||
33736307|NCT06531460|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Use of enteral formula enriched with omega-3 or standard not revealed for participants.|Randomized Clinical Trial|t|t|f|t
33736308|NCT05727358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736309|NCT00853476|||COHORT||CROSS_SECTIONAL|||||||
33736310|NCT06632028|RANDOMIZED|PARALLEL||TREATMENT||NONE||In total, two different groups will be treated. One group will receive spinal rehabilitation supported by artificial intelligence, while the other group will receive traditional physiotherapy applications.||||
33736311|NCT06350864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients and anesthesiologists in charge of the case will be unmasked as High-flow nasal cannula HFNC) shape,setting and preparation are completely different from the Conventional nasal oxygen therapy (COT), so masking both of them is impossible.|A prospective, randomized, comparative, controlled clinical trial study|f|f|t|f
33736312|NCT06664528|||COHORT||PROSPECTIVE|||||||
33736313|NCT04296175|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized controlled trial||||
33736314|NCT02675452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736315|NCT04619316|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736316|NCT02358824|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736317|NCT04693364|||CASE_ONLY||PROSPECTIVE|||||||
33736318|NCT01294618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736319|NCT01599650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736320|NCT05003986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736321|NCT04622254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736322|NCT04922801|||COHORT||PROSPECTIVE|||||||
33736323|NCT02984995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736324|NCT01350206|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33736325|NCT04444128|||COHORT||PROSPECTIVE|||||||
33736326|NCT00718172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736327|NCT00451620|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736328|NCT06180538|||COHORT||CROSS_SECTIONAL|||||||
33736329|NCT00643955|||COHORT||CROSS_SECTIONAL|||||||
33736330|NCT02036905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33736331|NCT04432870|||OTHER||CROSS_SECTIONAL|||||||
33736332|NCT03603795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomization between 2 arms|t|t|t|f
33736333|NCT06234371|RANDOMIZED|PARALLEL||TREATMENT||NONE||After participants give consent, they are enrolled in the study. Randomization will be done via the Qualtrics platform. The treatment group will be offered a $500 gift card for completing 6, 12, and 18 counseling sessions; up to $1,500 in total. Because RRC's practice involves prescribing and scheduling counseling in 6-session blocks, the financial awards are revealed to veterans in the treatment group in stages. After intake, treatment group individuals are told that they will receive a $500 gift card for completing the first 6 sessions. If the counselor decides that another 6-session block should be prescribed, then at the completion of the 5th session (i) the next 6 sessions are scheduled and (ii) the counselor reveals that the participant can earn another $500 for completing the 12th session. The same process takes place during session 11. Other than informing individuals in the treatment group of the gift cards, counseling services will not change as a result of this study.||||
33736334|NCT00239057|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33736335|NCT06663410|||COHORT||PROSPECTIVE|||||||
33736336|NCT04199663|||COHORT||PROSPECTIVE|||||||
33736337|NCT02305303|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736338|NCT03468530|||COHORT||PROSPECTIVE|||||||
33736339|NCT03574025|||FAMILY_BASED||PROSPECTIVE|||||||
33736340|NCT05058014|||CASE_ONLY||PROSPECTIVE|||||||
33736341|NCT05249725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814537|NCT05836402|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective, Interventional, Randomized, Controlled Pilot Study (Treatement with dietary intervention and medical food VS. usual therapy)||||
33814538|NCT00617708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814539|NCT05912998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814540|NCT02453269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814541|NCT01279447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814542|NCT05186402|||CASE_ONLY||RETROSPECTIVE|||||||
33814543|NCT04800263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814544|NCT05986630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814545|NCT03103945|||COHORT||PROSPECTIVE|||||||
33814546|NCT01912521|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814547|NCT06386354|||COHORT||PROSPECTIVE|||||||
33736342|NCT04412096|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The overall study design is a prospective, open-label, randomized clinical trial with randomized order of 7-day treatments with timolol followed by a washout period and then with latanoprost or vice versa. Participants will undergo two 7-day treatments, with timolol 0.5% (1 drop two times daily) and latanoprost 0.005% (1 drop daily in the evening). The order of timolol and latanoprost will be randomized. The IOP, AHD parameters and IOP fluctuation will be compared in an individual under three conditions: (i) baseline, and after a randomized order of 7-day treatment of (ii) timolol 0.5% 1 drop two times daily and (iii) latanoprost 0.005% 1 drop in the evening separated by a 6-week washout period. The overall time commitment to complete these procedures is three to four months.||||
33736343|NCT00214994|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736344|NCT01400594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736345|NCT06468488|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non blindend randomized controlled trial||||
33736346|NCT05726656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736347|NCT05049356|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736348|NCT06572345|NA|SINGLE_GROUP||TREATMENT||NONE||"73 participants in total:~* Thirty-three participants to trial the LED intervention~* Ten participants from the LED intervention and their parents/carers for the interviews.~* Ten dyads undertaking interviews only (1 adolescent and 1 parent/carer) who declined the intervention.~* Ten healthcare practitioners (interviews only)."||||
33736349|NCT05215639|||COHORT||PROSPECTIVE|||||||
33736350|NCT04963504|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomised study||||
33736351|NCT04360824|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-center, randomized, open-label study comparing standard prophylactic dose enoxaparin (40 mg SC daily or 30 or 40 mg SC twice daily if BMI ≥30kg/m2; standard of care arm) versus intermediate-dose enoxaparin (1 mg/kg SC daily or 0.5 mg/kg SC twice daily if BMI≥30kg/m2; intervention arm) in hospitalized patients with laboratory-confirmed SARS-CoV-2 infection.||||
33736352|NCT03671681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736353|NCT05845125|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||All participants will begin with a phase of physiotherapy treatment alone, followed by a phase of physiotherapy coupled with a shoulder intra-articular corticosteroid injection with hydraulic distension.||||
33736354|NCT03068299|RANDOMIZED|PARALLEL||PREVENTION||NONE||The dance protocol will be applied to the experimental group (n=29) in the USFs and the control group (n=29) will receive health care, including guidance on health care and practices||||
33736355|NCT00023816||||TREATMENT||||||||
33736356|NCT05932355|||COHORT||PROSPECTIVE|||||||
33736357|NCT04898231|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized trial of 3 treatment arms||||
33736358|NCT04411043|||COHORT||PROSPECTIVE|||||||
33736359|NCT03079804|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Opaque envelopes||t|f|t|f
33736360|NCT05428969|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736361|NCT02829359|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736362|NCT00699881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736363|NCT06573710|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33736364|NCT06449573|||CASE_CONTROL||PROSPECTIVE|||||||
33736365|NCT05357391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"1. pressure injury prediction and education model group~2. control group"|t|t|f|t
33736366|NCT05340686|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial|f|f|f|t
33736367|NCT06207110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736368|NCT03113591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736369|NCT04549740|||CASE_ONLY||PROSPECTIVE|||||||
33736370|NCT04893889|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33736371|NCT04230382|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33736372|NCT00692965|||CASE_ONLY||PROSPECTIVE|||||||
33736373|NCT01985516|RANDOMIZED|PARALLEL||||NONE||||||
33736374|NCT05380661|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Participants blinded to order of catheterization procedures conducted by the urology nurse.||t|f|f|f
33736375|NCT06126549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Evaluation of two interventions to usual care, comparing change over time in three outcome measures: caregiver stress, caregiver depression, caregiver perceived self-efficacy in care management||||
33736376|NCT01251796|NA|SINGLE_GROUP||TREATMENT||||||||
33736377|NCT06333626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33736378|NCT03302858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736379|NCT04437394|||COHORT||CROSS_SECTIONAL|||||||
33736380|NCT00000601|RANDOMIZED|||PREVENTION||DOUBLE||||||
33736381|NCT04502602|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation will proceed within each cohort. Phase 1b is the expansion cohort at the recommended phase 2 dose found in phase 1.||||
33736382|NCT01787513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736383|NCT05271929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736384|NCT02086435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736385|NCT02449356|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33736386|NCT05872035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736387|NCT03377621|NA|SINGLE_GROUP||TREATMENT||NONE||One group will receive intervention and will be evaluated before and after intervention.||||
33736388|NCT01331148|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized placebo controlled double blind|t|t|t|t
33736389|NCT01138748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736390|NCT02275286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045121|NCT00129012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045122|NCT06379646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045123|NCT05757297|||COHORT||PROSPECTIVE|||||||
34045124|NCT00267969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045125|NCT01688232|||COHORT||PROSPECTIVE|||||||
34045126|NCT02035202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045127|NCT00764036||SEQUENTIAL||TREATMENT||NONE||dose escalation||||
34045128|NCT00713258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045129|NCT02405104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736391|NCT00456092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736392|NCT04849975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736393|NCT03511560|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, Envarsus vs Prograf||||
33736394|NCT06573060|||COHORT||PROSPECTIVE|||||||
33736395|NCT06662981|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33736396|NCT05016102|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33736397|NCT03724825|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736398|NCT06039085|||COHORT||PROSPECTIVE|||||||
33736399|NCT04865822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736400|NCT05870176|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge sequential crossover design||||
33736401|NCT01412775|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33736402|NCT02383758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736403|NCT02633475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736404|NCT02592733|||COHORT||PROSPECTIVE|||||||
33736405|NCT06250738|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736406|NCT05896358|||CASE_CONTROL||PROSPECTIVE|||||||
33736407|NCT03292822|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736408|NCT06664736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736409|NCT06382857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736410|NCT05368207|NA|SINGLE_GROUP||TREATMENT||NONE||It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.||||
33736411|NCT03608800|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736412|NCT05647512|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736413|NCT00901134|||COHORT|||||||||
33736414|NCT03614793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736415|NCT04496921|RANDOMIZED|PARALLEL||PREVENTION||NONE||"* Group A: vitamin K supplement of 2 mg, once a day for 6 months~* Group B: vitamin K supplement of 7 mg, twice a week for 6 months"||||
33736416|NCT02154815|||OTHER||PROSPECTIVE|||||||
33736417|NCT03460184|||COHORT||PROSPECTIVE|||||||
33736418|NCT04254354|||COHORT||PROSPECTIVE|||||||
33736419|NCT03892538|||COHORT||PROSPECTIVE|||||||
33736420|NCT04742738|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736421|NCT05242965|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
33736422|NCT00585754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123736|NCT03417583|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33736423|NCT04054167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736424|NCT04292158|||CASE_ONLY||PROSPECTIVE|||||||
33736425|NCT03966235|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33814548|NCT02316977|||COHORT||PROSPECTIVE|||||||
33814549|NCT04703244|||CASE_ONLY||PROSPECTIVE|||||||
33814550|NCT03277456|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33814551|NCT02331966|||CASE_ONLY||PROSPECTIVE|||||||
33814552|NCT00579020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814553|NCT00301054|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33814554|NCT01499251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736426|NCT05575999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736427|NCT03930316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736428|NCT01544712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736429|NCT04285190|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, randomized, blank-controlled treatment clinical study||||
33736430|NCT00529841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736431|NCT06377579|||COHORT||CROSS_SECTIONAL|||||||
33814555|NCT03811743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814556|NCT04919369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814557|NCT02391766|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33814558|NCT02771366|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33814559|NCT03853746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814560|NCT04923685|||COHORT||OTHER|||||||
33814561|NCT03165032|||CASE_CONTROL||PROSPECTIVE|||||||
34123737|NCT00364247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34123738|NCT04165863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123739|NCT06159283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123740|NCT02996422|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123741|NCT04128150|||COHORT||PROSPECTIVE|||||||
34123742|NCT05373212|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Four-period crossover|t|f|t|f
33736432|NCT01343706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33736433|NCT01231763|||COHORT||CROSS_SECTIONAL|||||||
33736434|NCT06664658|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"two groups:~* PEEP 5 cm H2O~* PEEP 10 cm H2O"|f|f|t|f
33736435|NCT06573112|||COHORT||PROSPECTIVE|||||||
33736436|NCT06223672|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33736437|NCT00315276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33736438|NCT02699905|||COHORT||PROSPECTIVE|||||||
33736439|NCT05267171|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33736440|NCT04111497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736441|NCT04383444|||COHORT||PROSPECTIVE|||||||
33736442|NCT03414242|NA|SINGLE_GROUP||SCREENING||NONE||||||
33736443|NCT00005638||||TREATMENT||||||||
33736444|NCT06393192|||COHORT||PROSPECTIVE|||||||
33814562|NCT05751720|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention group will receive GLP-1 analogues (subcutaneous Tirzepatide or oral semaglutide).The dose of oral semaglutide will be 3 mg daily for 30 days (initiation) and if dose then increased to 7 mg daily for 6 months while the dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly. The blood tests will be done at baseline, 3 months of treatment and at 6 months of treatment. Liver imaging (fibroscan and/or MRI fat measurement) will be done at baseline and at 6 months to see if there is any change.||||
33814563|NCT04795999|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||The treatment condition involves participation in a teen pregnancy prevention program, Project With. The comparison condition for the study is treatment as usual.||||
33814564|NCT06602206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814565|NCT06328296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33814566|NCT00300339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814567|NCT00807053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814568|NCT02708498|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||The knowledge-based palliative care intervention was conducted as a non-randomized control trial.||||
33814569|NCT03618888|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel Assignments||||
33814570|NCT00690313|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123743|NCT00225914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814571|NCT00389285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814572|NCT00937807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814573|NCT00925548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814574|NCT01274000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814575|NCT03816878|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814576|NCT01858909|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840177|NCT05528523|NA|SINGLE_GROUP||OTHER||NONE|Researchers were avoided to have all data in order not to prejudge.|||||
33840178|NCT03513705|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Stepped-wedge cluster randomized trial||||
34045130|NCT00220688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045131|NCT03887442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045132|NCT04527289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|All enrolled 50 patients will be divided into two groups; Group I are patients who will receive amantadine as add on therapy. Group II are patients who will be managed with the standard regimen.|t|f|t|f
34045133|NCT05080075|NA|SINGLE_GROUP||TREATMENT||NONE|All patients will get the treatment, and all those providing care and all involved in the study, including the research participants are aware of this|This study involves a single group, all of whom will be receiving the same treatment (platelet rich plasma injection into the knee)||||
34045134|NCT05465473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045135|NCT04339153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a Randomized Controlled Trial (RCT) with single blind rating. The participants will be randomly divided into two groups. One group will receive the Parent Training (PT) and the other will get the Parent Education (PE).|f|f|f|t
34045136|NCT01091662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045137|NCT04941612|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
34045138|NCT02506556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045139|NCT03068832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045140|NCT04139616|||COHORT||PROSPECTIVE|||||||
34045141|NCT05707026|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045142|NCT02236845|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34045143|NCT04867642|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|This is a participant- and investigator-blind study.|The study consists of a crossover design part (Part A) and two parts (Part B and Part C) with a parallel design.|t|t|t|t
34045144|NCT05416021|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Participants will be randomized to one of two treatment sequences (AB or BA). During two consecutive 90-day treatment periods, the participants will receive each of the following treatments according to their assigned treatment sequence. The treatment periods will be separated by a 28-day washout period.||||
34045145|NCT04157296|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A clinician, blind to whether patients are completing CCT or not, will deliver CBT to the patients.||f|t|f|f
34045146|NCT00277238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045147|NCT00905983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045148|NCT03910036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the outcome measures assessors were blinded to subjects who receive injection and those who didn't|The study was done on 30 patients underwent arthroscopic isolated meniscal repairs performed by a single surgeon but unfortunately didn't receive PRP injection during the repair procedure. Pre-injection guidelines were given to all patients (in PRP group) in the form of stopping steroidal and non-steroidal anti-inflammatory drugs for at least one week before the procedure, as well as stopping any anticoagulant drugs 5 days before the procedure, increasing intake of fluids within the 24 hours prior to the procedure and anti-anxiety medication were required for anxious patients. Injection, under complete aseptic techniques, was performed while the patient was in supine position, and the knee was fully extended, using the lateral approach. Patients were instructed after injection to avoid using the injected leg for 24 hours, to use ice packs over the injected joint and not to use NSAIDs for another one week.|f|f|f|t
34045149|NCT00665431|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045150|NCT05743348|||COHORT||CROSS_SECTIONAL|||||||
34045151|NCT06105775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045152|NCT03910205|||CASE_CONTROL||PROSPECTIVE|||||||
34045153|NCT00879476|RANDOMIZED|CROSSOVER||||NONE||||||
34045154|NCT02511145|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34045155|NCT00413946|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045156|NCT04244084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045157|NCT03390972|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34045158|NCT06520020|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, using transcutaneous spinal cord stimulation.~We aim to include 30 total patients, 10 patients in each of 3 groups:~1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention.~2. Early tSCI screened during the hospital admission when cervical/thoracic spinal injury was diagnosed.~3. Delayed tSCI (control) screened 6-24 months after acute cervical/thoracic spinal injury."||||
34045159|NCT00379080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045160|NCT05795855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34045161|NCT06240169|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients and the outcome assessors will be blinded to the allocation groups (double-blinding). But the operator (Principal investigator) will not be blinded due to the nature of the study.||t|f|f|t
34045162|NCT04747886|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045163|NCT05678374|||COHORT||CROSS_SECTIONAL|||||||
34045164|NCT06576414|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double-blinded (participants and statistician)||t|f|t|f
34123744|NCT03068897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Medications provided to patients are encapsulated. Medications vials are labelled with investigational stickers.||t|t|t|t
34123745|NCT04454060|||COHORT||RETROSPECTIVE|||||||
34123746|NCT05895097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123747|NCT02042287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123748|NCT03920501|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123749|NCT05353413|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Two groups: volunteers with neuropathies and healthy volunteers|f|f|f|t
34123750|NCT05680467|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A masked assessor will conduct the measurements|Sixty participants with chronic low back pain will be randomly assigned to three groups of 20 each. The allocation of the sample to the groups will be performed using a randomization program (https://www.randomizer.org/) by an independent researcher. In the first group, a manual protocol will be applied with the simultaneous application of a high-frequency current through TECAR, in the second group, the same manual protocol will be applied without the TECAR device, while the third group will not receive any treatment. Participants of the two intervention groups will follow a total of six treatments over a period of three weeks with a follow-up after one month.|f|f|f|t
34123751|NCT01761513|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123752|NCT04904172|||CASE_ONLY||PROSPECTIVE|||||||
34123753|NCT03840213|||COHORT||PROSPECTIVE|||||||
34123754|NCT05859139|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Allocation of prenatal services to groups and stages will be blinded by an independent, experienced biostatistician who will not be involved in the data analysis.|This study will consist of four groups receiving the intervention in a sequential way. Each group will include several prenatal services corresponding to the study clusters (the randomization unit). Randomization will occur at the site level. Clinics will be randomized in groups to receive the intervention. At the end, every clinic will be in intervention conditions. The study will be conducted over five periods each corresponding to a data collection period. During the first period, all groups will be in control conditions where health professionals will provide the usual prenatal care to pregnant women (no intervention). Then, after a regular interval of 10 weeks, each group will receive the intervention starting with the beginning of the remaining four periods. Once a group has received the intervention, it will remain in intervention conditions until the end of the study.|f|f|f|t
34123755|NCT01131897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123756|NCT02126319|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34123757|NCT01440764|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34123758|NCT03853044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123759|NCT00283946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123760|NCT00754169|||||OTHER|||||||
34123761|NCT02535897|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34123762|NCT00498043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123763|NCT01233024|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34123764|NCT06139601|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34123765|NCT06351839|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||We randomize patients to receive either the Sleep-Well intervention or to the TAU condition (active waiting-list group). After 3 months, the TAU patients cross over and receive the Sleep-Well intervention; hence, the design is semi-crossover.|f|f|f|t
34123766|NCT02098304|NA|SINGLE_GROUP||||NONE||||||
34123767|NCT06082804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||60 patients will be included, these patients will be randomized into two groups.||||
34123768|NCT01267474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34123769|NCT00827814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123770|NCT00853892|RANDOMIZED|CROSSOVER||||NONE||||||
34123771|NCT02207751|||COHORT||PROSPECTIVE|||||||
34123772|NCT01490918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|placebo medication||t|t|t|f
34123773|NCT02592278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34123774|NCT04718350|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34123775|NCT02054975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123776|NCT00313495|||||PROSPECTIVE|||||||
34123777|NCT00664482|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123778|NCT01406600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123779|NCT01862081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123780|NCT00423033|||||PROSPECTIVE|||||||
34123781|NCT02405299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123782|NCT06239038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"In electrocautery group, using an electrocautery in following step~1. Stop bleeding at subcutaneous tissue layer~2. Remove anterior cruciate ligament and posterior cruciate ligament~3. Bony mark for further bone cut~4. Patellar denervation~5. Soft tissue removal~6. Synovial tissue removal~In scalpel group, proceed with following step~1. Using electrocautery for stop bleeding at subcutaneous tissue layer~2. In deep layer still use scalpel for Remove anterior cruciate ligament and posterior cruciate ligament~3. Soft tissue removal and synovial tissue removal~4. No patellar denervation"|t|f|f|t
34123783|NCT01908140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123784|NCT00616642|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123785|NCT05827289|NA|SINGLE_GROUP||SCREENING||NONE||||||
34123786|NCT02748681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34123787|NCT05017870|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123788|NCT05715658|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Control group: 12 healthy adults (18-30 years old); Test group A: 12 elderly healthy people (≥75 years old); Test group B: 12 elderly patients with atrial fibrillation (≥75 years old).||||
34123789|NCT04240106|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label, single-arm, two-cohort, Simon's two- stage phase II clinical trial.||||
34123790|NCT02269696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123791|NCT03801928|||CASE_ONLY||PROSPECTIVE|||||||
34123792|NCT01339936|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34123793|NCT00366210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123794|NCT00983034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123795|NCT04734158|||CASE_CONTROL||PROSPECTIVE|||||||
34123796|NCT03420144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045165|NCT01835873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814577|NCT04223674|RANDOMIZED|PARALLEL||SCREENING||NONE||"This study evaluates an experimental serological diagnostic technique intended to identify people at high risk of having dormant malaria parasites in their liver.~960 children living in western Indonesia will be individually randomised to the experimental serologic test or routine care.~Children in the serological diagnosis arm will be screened for the presence of antibodies to a previously validated panel of malaria antigens optimized for sensitivity to infection during the prior 9 months. Furthermore, they also will be screened by microscopy. If positive by either test, they will be treated for that malaria infection.~Children assigned to routine care will be screened by microscopic examination and treated when they show or have history of symptoms in the last 3 days.~After initial screening and treating according to diagnostic technique, all children will be actively followed for 9 months with PCR detection every 4 weeks."||||
34045166|NCT00561392|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736445|NCT04083300|||COHORT||PROSPECTIVE|||||||
34045167|NCT01575834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045168|NCT03230058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045169|NCT00945035|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045170|NCT05542147|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Single-blinded for treatment (Participant), double-blinded for genetics (Participant and Investigator)||t|f|t|f
34045171|NCT06279546|||COHORT||CROSS_SECTIONAL|||||||
34123797|NCT04348071|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm, open label, single site study. Data from participants in this study with data from other COVID-19 patients not receiving ruxolitinib.||||
33814578|NCT05236218|||COHORT||PROSPECTIVE|||||||
33814579|NCT01697956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840179|NCT01478997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045172|NCT00436462|||COHORT||PROSPECTIVE|||||||
34045173|NCT00582608|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045174|NCT01417091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045175|NCT05142969|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34045176|NCT03232879|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34045177|NCT00204217|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34045178|NCT01045577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045179|NCT04431349|||COHORT||RETROSPECTIVE|||||||
34045180|NCT05870735|||CASE_CROSSOVER||PROSPECTIVE|||||||
34045181|NCT04105296|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34123798|NCT00839566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123799|NCT04389866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123800|NCT04846231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects, investigator staff, persons performing the assessments, and the clinical trial team will be blinded to assigned study group.|Eligible subjects will be randomized 1:1:1:1:1:1:1:1 to the study groups in a blinded fashion. There will be 25 subjects per study group. The total sample size will be 200 patients.|t|t|t|f
34123801|NCT06420193|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34123802|NCT05703217|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled study||||
33736446|NCT02506114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736447|NCT01328002|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736448|NCT05735080|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part A will be a dose escalation guided by BOIN design for treatment assignment and dosing rules.~Part B will be dose expansion, patients will be randomly assigned to receive one of the identified doses of INX-315 in monotherapy~Part C will be dose expansion, patients will receive INX-315 in combination treatment with CDK4/6i and endocrine therapy"||||
33736449|NCT04816006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33736450|NCT05789732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736451|NCT05210036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736452|NCT00000410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736453|NCT02103478|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736454|NCT00572650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736455|NCT00326534|||CASE_CONTROL||PROSPECTIVE|||||||
33736456|NCT04412941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736457|NCT03541746|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33736458|NCT00363987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736459|NCT02944578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736460|NCT04040101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736461|NCT01312766|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33736462|NCT01086553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736463|NCT03887091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33736464|NCT06664346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants were randomised to an active or delayed group||||
33736465|NCT05756647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* Due to the nature of the randomization process, blinding during the data collection phase will not be possible.~* Participants cannot be blinded either as the treatment modalities differ in a way which makes adequate blinding not possible.~* Prior to data analysis, Dr. Kallogjeri will blind groups as A and B so that the team will not know which intervention corresponds to A and B throughout both the data analysis and manuscript writing process."|This study is a randomized control trial with an active control group.|f|f|t|t
33736466|NCT06142279|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Multicenter cross-sectional study comparing short-term mucosal response in individuals recently infected with SARS-CoV-2 versus recently non-infected individuals. The study will consist of two parts:~1. Part A, which focuses on developing the technique, involves prospective data collection and the collection of biological samples (nasal, salivary, and blood samples).~2. Part B, which aims to qualify the analysis method, also includes prospective data collection and the collection of biological samples.~Once the threshold is reached in one of the two groups in Phase A, Phase B will begin concurrently."||||
33736467|NCT03609177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33736468|NCT04600960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736469|NCT06249100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736470|NCT05559619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736471|NCT03586895|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||pre-post design||||
33736472|NCT04329962|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33736473|NCT05438082|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinded|This trial is a single center, parallel, blinded, randomized, placebo-controlled pilot trial in children|t|t|t|t
33736474|NCT04837794|||CASE_ONLY||PROSPECTIVE|||||||
33736475|NCT04857866|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736476|NCT02705950|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736477|NCT04293159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736478|NCT02644967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736479|NCT05298852|||COHORT||PROSPECTIVE|||||||
33736480|NCT05362032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736481|NCT06663904|||COHORT||RETROSPECTIVE|||||||
33736482|NCT06663800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736483|NCT00323739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736484|NCT03127228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736485|NCT04154280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736486|NCT05597527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736487|NCT00079547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736488|NCT02187016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736489|NCT02912481|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33736490|NCT06061770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33736491|NCT01565993|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736492|NCT03879681|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736493|NCT02914964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736494|NCT06154434|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33736495|NCT04034589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736496|NCT04848766|||COHORT||OTHER|||||||
33736497|NCT04327934|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33736498|NCT01592266|||COHORT||PROSPECTIVE|||||||
33736499|NCT01915368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736500|NCT04698824|||COHORT||PROSPECTIVE|||||||
33736501|NCT04865094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736502|NCT02970968|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736503|NCT05332262|||COHORT||PROSPECTIVE|||||||
33736504|NCT05183685|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33736505|NCT06498973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736506|NCT01175824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736507|NCT02468843|||CASE_ONLY||PROSPECTIVE|||||||
33814580|NCT05951335|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|In this study, the coding process and statistical analysis will carry out by third parties (statisticians) to reduce bias in the results and conflicts of interest.|In cross-study, study participants will be transferred to all treatment groups (both test and reference formulations) after the study period is over. Being a collection of the same population, the advantage of the cross-study was that the patients acted as their controls.|f|f|f|t
33814581|NCT06153706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814582|NCT04117386|||OTHER||CROSS_SECTIONAL|||||||
33814583|NCT05172648|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814584|NCT00587756|||COHORT||PROSPECTIVE|||||||
33814585|NCT03376763|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814586|NCT05459584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Interventional pilot randomized controlled trial|f|f|t|f
33814587|NCT06428799|||COHORT||RETROSPECTIVE|||||||
33814588|NCT05141968|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33814589|NCT02947880|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814590|NCT00003240|RANDOMIZED|||TREATMENT||||||||
33814591|NCT01317914|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123803|NCT01182298|||COHORT||PROSPECTIVE|||||||
34123804|NCT01615744|||CASE_CONTROL||PROSPECTIVE|||||||
33736508|NCT01976416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736509|NCT00058240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736510|NCT04877197|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The only members of the research team who will be aware of randomization assignment will be the project therapists, the research coordinator, and the statistical analyst in charge of randomization. The outcomes assessor and investigator will be blinded to subject assignment, and though treating physicians will be informed of their patient's participation in the study, they will be blinded to treatment condition. Patients will be given instructions not to disclose their treatment assignment to their treating physicians.|The investigators will use a 2x4 (treatment by time) repeated measures RCT crossover design (baseline, post-treatment, 3 \& 9-month follow-up; crossover for standard treatment group at 9 months). At the 9 month point, the comparison group will have the option of receiving the intervention.|f|t|t|t
33736511|NCT06247163|||COHORT||PROSPECTIVE|||||||
33736512|NCT00860652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736513|NCT00194220|||COHORT||PROSPECTIVE|||||||
33736514|NCT05257265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736515|NCT02716844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736516|NCT02046434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736517|NCT05932199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736518|NCT02180425|||CASE_CONTROL||PROSPECTIVE|||||||
33736519|NCT00544245|RANDOMIZED|PARALLEL||||NONE||||||
33736520|NCT03587259|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33736521|NCT05661292|||COHORT||PROSPECTIVE|||||||
33736522|NCT05204134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814592|NCT03037827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814593|NCT05537935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814594|NCT02634593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33814595|NCT02536534|||OTHER||PROSPECTIVE|||||||
33814596|NCT00805792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123805|NCT03037866|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123806|NCT00873925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123807|NCT01948479|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045182|NCT06450392|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, multicenter, randomized, double-blinded, controlled trial. On the day of surgery in the preoperative suite, study participants will be randomly allocated to one of three groups via computer-generated random numbers as described in the Arms and Interventions section.|t|t|t|t
34045183|NCT04637711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045184|NCT06683469|||CASE_ONLY||PROSPECTIVE|||||||
34045185|NCT04332081|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||prospective pilot cohort study||||
34045186|NCT06029374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045187|NCT04375605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045188|NCT02169375|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34045189|NCT01566266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34045190|NCT02955316|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34045191|NCT03239860|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045192|NCT03702335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34045193|NCT04234139|||COHORT||OTHER|||||||
34045194|NCT02040051|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34123808|NCT05769686|||COHORT||PROSPECTIVE|||||||
34123809|NCT00374595|||OTHER||PROSPECTIVE|||||||
34123810|NCT04339413|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123811|NCT02176629|RANDOMIZED|CROSSOVER||||NONE||||||
34123812|NCT02193997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123813|NCT02306811|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123814|NCT05822154|||COHORT||PROSPECTIVE|||||||
34123815|NCT02580877|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123816|NCT04750486|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization of patients to either control or study groups.||||
34123817|NCT03506620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthesiologist, surgeon, and patient will all be blinded to the intervention. After patients consent to join the study, a member of the study team who is not involved in patient care will randomly allocate patients to 1 of 2 groups, the intervention or the controls. A statistician not involved with the study will creat a randomization table and coordinate with the Research Pharmacy to keep the study team blinded. Naropin (Ropivacaine) will be dispensed by the research pharmacy. The nurse will prepare the study injection accordingly for the blind anesthesiologist to administer. The QL block will be administered by a trained musculoskeletal regional anesthesia specialist before the standard induction of general anesthesia. The injection will occur under sedation to minimize discomfort for the patient. The QL block group's injection will consist of 20 cc of 0.25% Ropivacaine, whereas the control group will receive 20 cc of saline.|This study is a randomized, controlled, double-blind trial. Patients undergoing hip arthroscopy who agree to participate will be randomly selected to receive an ultrasound-guided QL block with either local anesthetic (QL block group) or normal saline (control group) preoperatively.|t|t|f|f
34123818|NCT01771874|NA|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34123819|NCT05833412|||COHORT||OTHER|||||||
34123820|NCT00328796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123821|NCT03679364|||CASE_CONTROL||PROSPECTIVE|||||||
34123822|NCT00726128|||CASE_ONLY||PROSPECTIVE|||||||
34123823|NCT01102920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123824|NCT03103854|RANDOMIZED|FACTORIAL||PREVENTION||NONE||This is a 2x2 of burst physical activity (BURST) vs moderate intensity continuous training (MICT) and text message reminders vs no text message reminders. Patients will be randomized to either BURST or MICT and then further randomized to either receive text message reminders or not receive text message reminders.||||
34123825|NCT03007030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123826|NCT01397227|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34123827|NCT01369043|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34123828|NCT04173182|||COHORT||PROSPECTIVE|||||||
34123829|NCT04023292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123830|NCT04859101|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34123831|NCT01193452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123832|NCT03951285|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Study with two interventions in healthy monozygotic twin pairs. In the first intervention, both members of BMI-discordant monozygotic twins are treated with Nicotinamide Riboside (NR). With this unique model, the investigators obtain the information on how beneficial NR is in two different BMI classes (obese and leaner) with an identical genomic background. In the second intervention, monozygotic twins concordant for body weight are selected and randomized to treatment. One member of the twin pair is treated with NR while the other co-twin gets placebo. With the twin set-up, the investigators can detect a significant treatment effect, and the heritability of NR treatment can be estimated as well.||||
34123833|NCT00815386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123834|NCT04222192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34123835|NCT01735305|||COHORT||PROSPECTIVE|||||||
34123836|NCT01773928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34123837|NCT04420858|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34123838|NCT01881789|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34123839|NCT03117114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123840|NCT00199615|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123841|NCT06151470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34123842|NCT06154317|||OTHER||CROSS_SECTIONAL|||||||
34123843|NCT01109186|||COHORT||PROSPECTIVE|||||||
34123844|NCT02607410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045195|NCT02342158|NA|SINGLE_GROUP||OTHER||NONE||||||
34045196|NCT02647723|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34045197|NCT00863356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045198|NCT06575049|||COHORT||PROSPECTIVE|||||||
34045199|NCT02935179|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34045200|NCT02602275|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34045201|NCT02075216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045202|NCT00097825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045203|NCT05408208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045204|NCT01905917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123845|NCT01323985|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123846|NCT06393803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123847|NCT01518387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814597|NCT02416102|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33814598|NCT00749840|||COHORT||PROSPECTIVE|||||||
33814599|NCT03527888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814600|NCT04471805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123848|NCT02339805|NA|SINGLE_GROUP||OTHER||NONE||||||
34123849|NCT06307392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123850|NCT01495325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34123851|NCT03680885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|The scoring of the lidocaine test is masked, using the coded identity of the tastes. The tastes will be assessed in random order. Each subject will have 2 tests with lidocaine gel and 2 with a placebo gel, in random order, each on different days. The subjects and other study personnel will be told not to discuss what the subject could or couldn't taste. Scoring will be done only after all testing on the subject is complete. A person not involved in the testing will keep track of which gels the subject has had.|Half the subjects will have a self-reported history of lidocaine working for them (effective) and half will have a history of difficulty getting numb (ineffective).|t|t|t|t
34123852|NCT05160363|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34123853|NCT00192543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123854|NCT06307249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123855|NCT00006261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123856|NCT02240121|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123857|NCT03368196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123858|NCT01731795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123859|NCT00932035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34123860|NCT06426446|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34123861|NCT06159998|||COHORT||PROSPECTIVE|||||||
34123862|NCT01762683|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123863|NCT02540590|||COHORT||PROSPECTIVE|||||||
34123864|NCT06136143|RANDOMIZED|PARALLEL||TREATMENT||NONE||For this, forty (40) participants will be recruited for procedure surgery of maxillary sinus elevation and subsequent installation of dental implants after 06 months of postoperative. And then, the participants will divided into 4 groups, which will have 10 participants each, namely: Group 1: Autogenous bone; Group 2: Plenum® Osshp; Group 3: Plenum® Osshp; + i-PRF and Group 4: Plenum® Osshp; + autogenous bone. To evaluate the primary outcome, volumetric analysis will be performed by obtaining computed tomography scans at 15 days (T1) and 6 months (T2) after graft surgery.||||
34123865|NCT02625220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123866|NCT05249205|RANDOMIZED|PARALLEL||PREVENTION||NONE|The nature of the intervention does not allow for blinding.|Randomised controlled trial||||
34123867|NCT03612089|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34123868|NCT03296332|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34123869|NCT03261895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34123870|NCT03767465|||COHORT||OTHER|||||||
34123871|NCT05452252|||OTHER||PROSPECTIVE|||||||
34123872|NCT05295264|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34123873|NCT06282718|||COHORT||PROSPECTIVE|||||||
34123874|NCT05807412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The left and right-side assignment will be determined based on the treating physician's selection of a sealed envelope using random numbers on the treatment day.|Each subject will be randomized to have either their right forehead or left forehead treated with 4 units or 0.1 cc of prabotulinumtoxinA 2.5 cm above the orbital rim. As a control, the contralateral forehead half will receive 4 units or 0.1 cc of onabotulinumtoxinA at the same dilution at the same time.|t|f|t|f
34123875|NCT02025998|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34123876|NCT00570323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123877|NCT00752492|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34123878|NCT02311881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123879|NCT01154491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123880|NCT02235571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123881|NCT06292377|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34123882|NCT03388541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34123883|NCT00912626|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34123884|NCT01160133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123885|NCT03018158|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123886|NCT06295380|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34123887|NCT02048995|||COHORT||PROSPECTIVE|||||||
34123888|NCT06110559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patients and the outcome assessor are blinded to the type of treatment received.~Each patient, at the end of the study, will be asked to guess whether the treatment received was active or sham."|"Prospective monocentric interventional randomised controlled trial vs placebo (sham tDCS) in 2 parallel groups.~An interim analysis focusing on the primary objective will be performed when at least 50% of the total expected sample has completed the study."|t|f|f|t
34123889|NCT03540420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123890|NCT03631264|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123891|NCT03317743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123892|NCT05409703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study is a randomized controlled experimental study.|t|f|f|f
34123893|NCT02701205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814601|NCT05863676|||CASE_ONLY||PROSPECTIVE|||||||
33814602|NCT01590056|||CASE_ONLY||PROSPECTIVE|||||||
33814603|NCT01318356|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814604|NCT02791308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814605|NCT00451906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814606|NCT00141271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814607|NCT04829188|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33814608|NCT04323514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814609|NCT03677986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736523|NCT03996928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Single blind randomized controlled trial~INDEPENDENT VARIABLES~Age, Sex, Work activity (referred to a superior member): intense -including, among other kind of activities, keyboards users and housewives-light.~Basal pain according to visual analogue scale (VAS) of 100 mm. Baseline disability according to the DASH questionnaire (Disabilities of the Arm, Shoulder and Hand), which is self-administered.~DEPENDENT VARIABLES~Pain according to the aforementioned scale just after treatment (2 weeks) and at 3 months.~Disability according to the aforementioned questionnaire just after the treatment (2 weeks) and at three months.~Satisfaction with the treatment right after it (2 weeks) and at three months. A Likert scale of five points ( very satisfied, satisfied, neither satisfied nor unsatisfied, very unsatisfied) will be used.~Co-interventions (Systemic and/or topical route drugs, physiotherapy modalities received outside the system, use of orthoses)."|f|f|t|f
33736524|NCT02275897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736525|NCT06032286|NA|SINGLE_GROUP||TREATMENT||NONE||Single group, all subjects will receive intervention.||||
33736526|NCT06433414|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized controlled trial||||
33736527|NCT01947803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736528|NCT00283660|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736529|NCT06664008|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33736530|NCT06116253|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736531|NCT01299233|||CASE_CONTROL||PROSPECTIVE|||||||
33736532|NCT06532201|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33736533|NCT06663124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736534|NCT01771133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33736535|NCT02117063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736536|NCT01068327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736537|NCT06540586|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33736538|NCT03145272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736539|NCT06664489|||OTHER||CROSS_SECTIONAL|||||||
33736540|NCT04932200|||COHORT||PROSPECTIVE|||||||
33736541|NCT01914432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736542|NCT01075334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736543|NCT04926753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736544|NCT05850871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33736545|NCT00625599|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33736546|NCT03281811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736547|NCT04875806|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 will utilize a 3 + 3 design to explore escalating dose levels. Phase 2 Dose Expansion will further evaluate the safety, tolerability, preliminary efficacy, and PK/PD activity of NC762 at the RP2D utilizing a Simon 2-stage design.||||
33736548|NCT02884947|||COHORT||PROSPECTIVE|||||||
33736549|NCT06105476|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33736550|NCT06653257|||CASE_ONLY||RETROSPECTIVE|||||||
33736551|NCT04888000|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33736552|NCT02442700|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33736553|NCT04431232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736554|NCT02291627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736555|NCT01578434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736556|NCT06664294|||COHORT||PROSPECTIVE|||||||
33736557|NCT01738152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736558|NCT01751464|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736559|NCT00184340|||CASE_ONLY||RETROSPECTIVE|||||||
33736560|NCT06464588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736561|NCT02571894|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736562|NCT03945500|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"Evaluate the feasibility of using a Standardized Home Spirometry Method and associated investigational Home Spirometry Mobile Medical Software (IT App) and Server Dashboard in a healthy volunteer population before beginning a separate full clinical trial in the lung transplant population. Feasibility of using the Standardized Home Spirometry Method and associated Home Spirometry Mobile Medical Software (IT App and Server Dashboard to develop normal range values, to detect a value outside of the normal range, to evaluate a value outside of the normal range with a symptom survey and to download all data to a Central Monitoring Institute will be evaluated."||||
33736563|NCT03586999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736564|NCT01581593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736565|NCT05801159|||COHORT||PROSPECTIVE|||||||
33736566|NCT02568488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736567|NCT05634616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736568|NCT02766491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736569|NCT03528330|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33736570|NCT06663215|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33736571|NCT02939417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736572|NCT02082522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736573|NCT05382364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736574|NCT02706210|||CASE_CONTROL||PROSPECTIVE|||||||
33736575|NCT04805814|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33736576|NCT00266175|||||PROSPECTIVE|||||||
33736577|NCT03943810|||COHORT||RETROSPECTIVE|||||||
33736578|NCT02420860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736579|NCT02078739|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33736580|NCT06014112|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736581|NCT04683055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736582|NCT02530229|||COHORT||PROSPECTIVE|||||||
33736583|NCT01152723|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33736584|NCT06240897|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33736585|NCT06146569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Throughout the study, participants and researchers involved in assessments and interventions will remain blinded to group allocation.|Two treatment groups have been formed to receive taVNS and sham taVNS.|t|f|t|f
33736586|NCT05114941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736587|NCT00993213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736588|NCT01435668|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33736589|NCT02090907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736590|NCT06664190|||COHORT||PROSPECTIVE|||||||
33736591|NCT03057626|||COHORT||CROSS_SECTIONAL|||||||
33736592|NCT02422381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736593|NCT01507428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736594|NCT04208412|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736595|NCT00880633|||||RETROSPECTIVE|||||||
33736596|NCT00004917|RANDOMIZED|||TREATMENT||||||||
33736597|NCT01336738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814610|NCT05375578|||OTHER||CROSS_SECTIONAL|||||||
33814611|NCT03392844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research team members who are responsible for the assessment of study outcomes will be blinded to group condition. Blinding of the Lead Investigator is not possible due to the need to coordinate intervention with the Beds for Kids program. Blinds of the participants is not possible due to the nature of the intervention (scheduling and provision of beds).|Caregiver-child dyads will be assigned to the intervention group, in which they receive a bed through the Beds for Kids program after a 7-day period, or to the waitlist control group, in which they receive a bed after a 14-day period.|f|f|f|t
33814612|NCT02770274|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814613|NCT02472808|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814614|NCT00263900|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33814615|NCT01826994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814616|NCT03680768|||COHORT||CROSS_SECTIONAL|||||||
33814617|NCT05034237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814618|NCT04596735|||COHORT||PROSPECTIVE|||||||
33814619|NCT00671853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814620|NCT01257724|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33814621|NCT00119782|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814622|NCT03320278|||COHORT||PROSPECTIVE|||||||
33814623|NCT01838356|||CASE_ONLY||PROSPECTIVE|||||||
33814624|NCT01987245|||CASE_ONLY||PROSPECTIVE|||||||
33814625|NCT02301299|||OTHER||PROSPECTIVE|||||||
33814626|NCT00753896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814627|NCT00002405||||TREATMENT||||||||
33814628|NCT00316121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814629|NCT06160375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33814630|NCT00035256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814631|NCT02617459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814632|NCT05305300|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33814633|NCT01160159|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814634|NCT03840993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814635|NCT01962376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814636|NCT00407706|||DEFINED_POPULATION||OTHER|||||||
33814637|NCT04224597|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814638|NCT02575014|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814639|NCT02569294|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814640|NCT05985668|||COHORT||CROSS_SECTIONAL|||||||
33814641|NCT02141152|||||PROSPECTIVE|||||||
33814642|NCT06100406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once randomized, the participants will know they are receiving the intervention. Outcomes assessor will be masked for data analysis.|Intervention versus waitlist control. The control group will have the option to receive the intervention after the study is completed.|f|f|f|t
33814643|NCT03349476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814644|NCT02301507|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814645|NCT00848952|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814646|NCT04518397|NA|SINGLE_GROUP||PREVENTION||NONE||Pre/post cohort||||
33814647|NCT04717687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814648|NCT03738826|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33814649|NCT03240588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814650|NCT05497167|NA|SINGLE_GROUP||OTHER||NONE||Subjects will be patients with intellectual and developmental disability who have not yet had menarche.||||
33814651|NCT01151397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736598|NCT04738708|||COHORT||PROSPECTIVE|||||||
33736599|NCT02683759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736600|NCT05305365|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736601|NCT04400305|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel Assignment|f|f|f|t
33814652|NCT03070301|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a multicenter, non-randomized, open-label phase II clinical trial.||||
33814653|NCT01624883|||CASE_ONLY||RETROSPECTIVE|||||||
33814654|NCT03967457|||COHORT||PROSPECTIVE|||||||
33736602|NCT04704089|||OTHER||PROSPECTIVE|||||||
33736603|NCT05949086|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33736604|NCT00373737|||COHORT||PROSPECTIVE|||||||
33814655|NCT05198557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814656|NCT05396755|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, open-label, controlled, parallel group, multicenter||||
33814657|NCT02676726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814658|NCT05333835|RANDOMIZED|PARALLEL||TREATMENT||NONE||HR17031 injection compared with Ins068 injection and SHR20004 injection||||
33814659|NCT04314206|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33814660|NCT00153374|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33814661|NCT00158847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814662|NCT06295003|||COHORT||RETROSPECTIVE|||||||
33814663|NCT03279094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814664|NCT02751125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814665|NCT04122820|RANDOMIZED|PARALLEL||SCREENING||SINGLE|An adjudication committee to determine the presence or absence of a specific learning disability will be set up, regardless of the presence of a central reference instability.|Comparison of the presence of a specific learning disability, or a Developmental Coordination Disorder, in the case of the presence or absence of referential instability of central origin.|f|f|f|t
33814666|NCT01002586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736605|NCT04358484|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be recruited from three different sites across Spain: HSJD Barcelona, HGUGM Madrid and HMI Málaga. The first site will recruit parents of premature children and the other two sites will recruit parents of children diagnosed with ASD. Participants who meet inclusion criteria and sign the informed consent will complete a pre-intervention assessment. Families will be randomized to the intervention arm or to the treatment as usual (TAU) group, using stratified randomization regarding cognitive level. Those in the intervention arm will attend the IY-ASLD program and those in the TAU group will continue to receive usual care in their healthcare centers. Due to the COVID-19 pandemic the intervention has been postponed and there will be a re-assessment of parental stress and depressive symptoms in both groups just before starting the intervention. After the IY-ASLD is finished, participants in both groups will complete a post-intervention assessment.||||
33736606|NCT04031885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736607|NCT06661109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||There will be 2 groups (intervention and placebo)|t|f|f|f
33736608|NCT03294369|||COHORT||PROSPECTIVE|||||||
33736609|NCT05591417|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736610|NCT00884351|||||PROSPECTIVE|||||||
33736611|NCT04943016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736612|NCT04010110|||COHORT||PROSPECTIVE|||||||
33736613|NCT01548690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736614|NCT00687505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736615|NCT00285935|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33736616|NCT01960231|||OTHER||PROSPECTIVE|||||||
33736617|NCT06662708|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||Inclusion of enrolled patients in an artificial intelligence predictive model that predicts postoperative pathology, precise preoperative diagnosis (including benign and malignant, invasive, grading, and subtypes) or 3D lesion modelling based on the information provided|t|t|f|t
33736618|NCT03592472|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This is a double-blind study. The sponsor, investigators, study coordinators, and the patients will be blinded to the study drug (abexinostat/placebo).||t|f|t|f
33736619|NCT00075868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||||||
33736620|NCT00256659|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33736621|NCT05397379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736622|NCT05691140|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736623|NCT01375296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736624|NCT06361511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736625|NCT00568308|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736626|NCT01997086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736627|NCT00002181||||TREATMENT||NONE||||||
33736628|NCT05951816|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736629|NCT06662656|||COHORT||PROSPECTIVE|||||||
33736630|NCT04901455|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|This is an open label exposure study.|This study is an early Phase 1, single-center, parallel-group unmasked exposure study of nasal immune responses after controlled exposure to LAIV.||||
33736631|NCT06222255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736632|NCT00785226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736633|NCT04136834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736634|NCT00941733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33736635|NCT05832034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Home-care nurse preparing study medication will be unblinded. Home-care nurse is not involved in outcome assessment.||t|t|t|t
33736636|NCT02472665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736637|NCT01792661|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33736638|NCT02053727|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33736639|NCT06515470|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33736640|NCT05811104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, clinical assessors and treatment providers will be blinded to treatment assignments.|This will be a randomized, sham-controlled, double-blind single centre study using a 1:1 ratio parallel design. We aim to recruit 40 participants (active=20; sham =20) for this pilot study|t|f|t|t
34045205|NCT04908774|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to mask a fasting intervention for the participant or the study personel. Therefore only outcome assessors are masked.|This explorative study is conducted in form of a randomized, controlled trial design with a fasting intervention and a waiting list, which continues the usual diet.|f|f|f|t
34045206|NCT02580760|||CASE_ONLY||CROSS_SECTIONAL|||||||
33814667|NCT03210025|RANDOMIZED|CROSSOVER||OTHER||NONE|Open label|Single-dose, two-treatment, two-period, two-sequence crossover||||
33814668|NCT00416858|RANDOMIZED|||TREATMENT||||||||
33814669|NCT03771261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814670|NCT05843149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814671|NCT06012799|||COHORT||PROSPECTIVE|||||||
33814672|NCT06277206|||COHORT||PROSPECTIVE|||||||
33814673|NCT00648466|RANDOMIZED|CROSSOVER||||NONE||||||
33814674|NCT02953249|||CASE_CONTROL||PROSPECTIVE|||||||
33814675|NCT04188353|||COHORT||PROSPECTIVE|||||||
33814676|NCT04750902|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33814677|NCT01344889|||COHORT||PROSPECTIVE|||||||
33814678|NCT01753440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814679|NCT01692652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045207|NCT03413267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Because the food matrices ingested by the volunteers have different aspects, no masking is really possible. However, blood samples will be analyzed by partners without knowledge of the matrix that has been ingested.|"Bioavailability protocol : each volunteer participates in 4 interventions (4 food matrices), during 4 different days (one food matrix per day). At least 3 weeks between each intervention day. An intervention consists in food matrix ingestion (t=0) and blood sampling for 8 h postprandial (10 sampling times).~Mastication protocol : each volunteer participates in 1 session during which 2 solid matrices will be studied. For each matrix, 13 samples are proposed to the volunteer; food bolus are collected just before the volunteer feels the need of swallowing."||||
34045208|NCT01413932|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34045209|NCT05411783|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33814680|NCT05496829|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814681|NCT02914080|||OTHER||PROSPECTIVE|||||||
33814682|NCT04913194|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm waitlist control trial||||
33814683|NCT03471637|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33814684|NCT01728857|NA|SINGLE_GROUP||OTHER||NONE||||||
33814685|NCT05860894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814686|NCT04734795|||COHORT||CROSS_SECTIONAL|||||||
33814687|NCT06378320|RANDOMIZED|PARALLEL||OTHER||NONE||"This will be a prospective randomized two arm study for expectant women and a prospective randomized two arm study for fathers/partners. All participants receive access to the wireframe app. Maternal participants will be randomized to nudge or no nudge via text with those in the app nudge group receiving questions weekly prior to delivery and biweekly (every 2 weeks) after delivery through 3 months postpartum. The purpose of these nudges is to assess whether participants are more likely to access and benefit from the app if they are encouraged to explore it. Father/partner participants will also be randomized to either a nudge or no nudge group with those in the nudge group receiving questions weekly for the first two months and then biweekly (every 2 weeks) for another two months."||||
33814688|NCT00233142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814689|NCT05333276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814690|NCT02354144|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Carrageenan-containing gel|t|t|t|t
33814691|NCT04438278|||OTHER||PROSPECTIVE|||||||
33814692|NCT01818999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814693|NCT02486107|||COHORT||PROSPECTIVE|||||||
33814694|NCT04502459|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||A randomization list was generated prior to recruitment using a computer software (Random Allocation Software Version 1.0.0, Isfahan, Iran). The participants were randomly allocated to either of the 3 groups with different tourniquet strategies: Group 1) tourniquet inflation from skin to cement hardening (skin to cement); Group 2) tourniquet inflation only from cementation (cement only); Group 3) tourniquet inflation from skin incision to skin closure (skin to skin). The surgeon opened a sealed envelope containing the allocation right before the operation in the theatre. The evaluators who examined and collected the data were blinded to the patients' allocation to the study groups.|t|f|f|t
33814695|NCT02833051|||OTHER||CROSS_SECTIONAL|||||||
33814696|NCT03694145|||OTHER||PROSPECTIVE|||||||
33814697|NCT01017159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814698|NCT04620265|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33814699|NCT05150652|NA|SEQUENTIAL||TREATMENT||NONE||||||
33814700|NCT01098214|||COHORT||PROSPECTIVE|||||||
33814701|NCT02721147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814702|NCT01654198|||CASE_ONLY||CROSS_SECTIONAL|||||||
33814703|NCT05470465|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The study will be double-blind, and the blind will be maintained through a randomization schedule held by the dispensing pharmacist. Treatments (escitalopram, paroxetine, or placebo) will be over-encapsulated. The pharmacist (and designated staff member responsible for confirmation of study drug dose) will be unblinded to subject treatment assignment; however, the pharmacist will not perform any study procedures other than study drug preparation and dispensing.|This is a 3-period, double-blind, randomized crossover study. The duration of each treatment period will be 21 days in addition to a three-week washout between periods. The duration of study participation will be 106 days (excluding the screening period).|t|t|t|t
33814704|NCT02733731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814705|NCT06339788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814706|NCT03200509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814707|NCT03717935|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigational drug pharmacy will performed randomization and dispense the EAA or placebo.||t|t|t|t
33814708|NCT01581333|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814709|NCT03810911|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The groups are randomized not the study drug. The groups will be known by both the participant and the investigator.|All subjects will receive darbepoetin during the study. One group, the immediate start group, will receive the drug the day of randomization. The other group, the delayed start group, will receive the drug 12 weeks later.||||
33814710|NCT06298747|||OTHER||RETROSPECTIVE|||||||
33814711|NCT02635399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814712|NCT03823794|||COHORT||RETROSPECTIVE|||||||
33814713|NCT03543982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814714|NCT01434355|||FAMILY_BASED||PROSPECTIVE|||||||
33814715|NCT04967014|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814716|NCT00355784|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814717|NCT01765023|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33814718|NCT00564447|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045210|NCT01972815|||CASE_ONLY||PROSPECTIVE|||||||
34045211|NCT05581784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Simple (result evaluator)|Parallel Assignment Masking: Simple (result evaluator)|f|f|t|t
33814719|NCT05752370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814720|NCT03040453|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33814721|NCT00896740|||CASE_CONTROL||PROSPECTIVE|||||||
33814722|NCT00878904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814723|NCT01336842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814724|NCT01763502|RANDOMIZED|PARALLEL||||NONE||||||
33814725|NCT01029925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814726|NCT02699619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814727|NCT02652455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814728|NCT01640288|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814729|NCT03560154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814730|NCT03589677|||COHORT||PROSPECTIVE|||||||
33814731|NCT02558907|||COHORT||PROSPECTIVE|||||||
33814732|NCT00861354|||CASE_ONLY||PROSPECTIVE|||||||
33814733|NCT03462277|||COHORT||PROSPECTIVE|||||||
33814734|NCT03788707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Volunteers will lay flat with a face mask breathing room air while expired CO2 is measured. After 30 seconds, legs will be passively raised for 3 minutes. Changes in expired CO2 before and after leg raising will be compared.||||
33814735|NCT01468597|||COHORT||PROSPECTIVE|||||||
33814736|NCT06002672|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Two groups that consumed lettuce. No differences in shape, size, colours of lettuce|control vs intervention|t|f|t|f
33814737|NCT04603898|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33814738|NCT04453930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814739|NCT00777309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814740|NCT00412178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33814741|NCT04400045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814742|NCT06416540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814743|NCT06311292|NA|SINGLE_GROUP||OTHER||NONE|No parties will be prevented from having knowledge of the Volara System use.|||||
33814744|NCT00136851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33814745|NCT03094442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814746|NCT03391700|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33814747|NCT00936065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814748|NCT06014671|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814749|NCT03204175|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814750|NCT00121589||||TREATMENT||||||||
33814751|NCT05710627|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814752|NCT03928743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814753|NCT06074354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33814754|NCT02212275|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33814755|NCT03370588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Investigator prepared the drug and participant and outcomes assessor were blind to the group allocation|Double blind randomized controlled trial|t|f|f|t
33814756|NCT02172937|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814757|NCT04809701|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814758|NCT00245505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814759|NCT04812977|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814760|NCT01074034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814761|NCT03773432|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814762|NCT00264576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33814763|NCT05771272|NA|SINGLE_GROUP||SCREENING||NONE||All rower sport player were assessed by CAIT , lower extremity flexibility.||||
33814764|NCT04967092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814765|NCT00611598|||COHORT||PROSPECTIVE|||||||
33814766|NCT02285322|||COHORT||PROSPECTIVE|||||||
33814767|NCT01526486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814768|NCT02268253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814769|NCT03989232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33814770|NCT05941988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814771|NCT01615614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814772|NCT04187378|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled study||||
33814773|NCT05248217|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33814774|NCT00677742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814775|NCT02525497|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814776|NCT00882050|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814777|NCT02892318|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33814778|NCT01583855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814779|NCT01843049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814780|NCT00430911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814781|NCT04320472|||COHORT||PROSPECTIVE|||||||
33814782|NCT05817292|||COHORT||PROSPECTIVE|||||||
33814783|NCT04671251|NA|SEQUENTIAL||TREATMENT||NONE||||||
33814784|NCT01927484|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33814785|NCT00246350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814786|NCT03178253|||CASE_CONTROL||PROSPECTIVE|||||||
33814787|NCT02020902|||||PROSPECTIVE|||||||
33814788|NCT03105024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814789|NCT06165497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814790|NCT00321971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814791|NCT03780634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814792|NCT01128673|||CASE_ONLY||PROSPECTIVE|||||||
33814793|NCT02852928|||CASE_ONLY||PROSPECTIVE|||||||
33814794|NCT03039556|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33814795|NCT05307302|||OTHER||CROSS_SECTIONAL|||||||
33814796|NCT00264654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814797|NCT03878394|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814798|NCT05693428|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33814799|NCT02188745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814800|NCT02418065|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814801|NCT03927118|||CASE_CONTROL||PROSPECTIVE|||||||
33814802|NCT01494467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33814803|NCT03796364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814804|NCT01778894|||CASE_CONTROL||PROSPECTIVE|||||||
33814805|NCT04681209|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Schools (including teachers and students) were not aware of whether they were receiving an experimental or traditional intervention activity. Those collecting the data were also not aware of the experimental condition of the participants.|Schools were randomly assigned to have their fourth-grade and fifth-grade classrooms participate in either a DRT-based intervention activity or a traditional (i.e., empathy-based) intervention activity.|t|f|f|t
33814806|NCT01555892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814807|NCT03689452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814808|NCT02973035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814809|NCT03822897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814810|NCT00448344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840180|NCT05395195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All injections with be administered behind a screen by dedicated personnel. The control arm will have mock (pretend) injections.|Erythropoietin (intravenous or subcutaneous)|t|t|t|t
33814811|NCT06165133|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The primary outcome assessment 90 days after surgery will be performed by a trained member of the research team who will not have access to the patient's hospital records or notes. If additional data needs to be retrospectively retrieved from hospital notes relating to a patient's secondary outcomes, then this may be accessed by any member of the research staff at that hospital (blinded or unblinded).~The operating surgeon and patient are impossible to blind, as the patient will meet the surgeon on the day of surgery and introduce themselves. It is unethical and impractical not to tell a patient who is doing their surgery."|Multicentre, 2-arm, parallel group, assessor blinded, non-inferiority randomised controlled trial with an internal pilot.|f|f|f|t
33814812|NCT04222400|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814813|NCT05886465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814814|NCT02144285|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33814815|NCT05298709|NA|SINGLE_GROUP||OTHER||NONE||||||
33814816|NCT01163929|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814817|NCT01294644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814818|NCT04904354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two distinct, non-randomized cohorts of subjects will be included; a PAF population and a PerAF population||||
33814819|NCT01123005|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33814820|NCT01921166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814821|NCT00866541|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33814822|NCT06187402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814823|NCT02400749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814824|NCT03209492|||COHORT||PROSPECTIVE|||||||
33814825|NCT00116233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33814826|NCT00458510|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814827|NCT00559728|||||PROSPECTIVE|||||||
33814828|NCT00898313|||COHORT||PROSPECTIVE|||||||
33814829|NCT02338505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814830|NCT02540915|||OTHER||OTHER|||||||
33814831|NCT00142532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814832|NCT00028600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814833|NCT05972161|||COHORT||PROSPECTIVE|||||||
33814834|NCT04849091|||COHORT||PROSPECTIVE|||||||
33814835|NCT01795989|||COHORT||PROSPECTIVE|||||||
33814836|NCT03684317|||COHORT||RETROSPECTIVE|||||||
33814837|NCT06506500|||OTHER||RETROSPECTIVE|||||||
33814838|NCT00266305|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33814839|NCT03123224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814840|NCT06584786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In the COPDAE part, the control group received standard treatment including intravenous steroids, inhaled butanyl and ipratropium, and parenteral antibiotics for secondary infections. Placebo mimics of JSHT were administered to the control group. The JSHT group received standard COPDAE treatment plus JSHT (1 pack thrice daily) for one week. For patients with stable COPD, the control group received standard inhaled medications according to the GOLD guidelines. Placebo mimics of JSHT were administered to the control group. The JSHT group additionally received one pack of JSHT daily for three months.|t|f|f|f
33814841|NCT00785499|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||f|t|t|t
33814842|NCT01565031|||COHORT||PROSPECTIVE|||||||
33814843|NCT01599078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814844|NCT01443572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814845|NCT03824743|||COHORT||PROSPECTIVE|||||||
33814846|NCT04527679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814847|NCT02942771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814848|NCT05111340|NA|SINGLE_GROUP||OTHER||NONE||||||
33814849|NCT05957822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized prospective multicenter non-inferior|t|f|f|t
33814850|NCT03227003|||OTHER||CROSS_SECTIONAL|||||||
33814851|NCT04449822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814852|NCT05472883|NA|SINGLE_GROUP||PREVENTION||NONE||This is an exploratory pilot study, comparing for the first time in humans, the remission of type 2 diabetes, one year after bariatric surgery, with regard to circulating concentrations of 9 candidate proteins measured at T0.||||
33814853|NCT05149716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Supplement capsule packages were labeled as Supplement A and Supplement B and the nutrient (taurine or placebo- starch) was revealed after the end of the intervention."|Double-blind placebo controlled study|t|f|t|f
33814854|NCT06201000|||COHORT||PROSPECTIVE|||||||
33814855|NCT01893671|||CASE_ONLY||PROSPECTIVE|||||||
33814856|NCT05588297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814857|NCT00065247|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33814858|NCT05823766|||COHORT||PROSPECTIVE|||||||
34045212|NCT00532753|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33814859|NCT03530735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814860|NCT01714947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814861|NCT01027455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814862|NCT03635242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814863|NCT00021333||||TREATMENT||||||||
33814864|NCT00880724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814865|NCT06261515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814866|NCT06501521|||CASE_CONTROL||PROSPECTIVE|||||||
33814867|NCT00016042||||TREATMENT||||||||
33814868|NCT01289834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814869|NCT04577391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor was masked to group allocation/ participants were blinded to the presence of two different intervention approaches|Randomized controlled trial: Work consisting of a clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table|t|f|f|t
33814870|NCT01745835|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33814871|NCT04168593|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33814872|NCT05177029|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34045213|NCT03839862|||COHORT||PROSPECTIVE|||||||
34123894|NCT05655975|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|The surgeon who will perform the endoscopy after the Roux nY gastric bypass will not know the preoperative body measurements of the patient and the post-operative weight loss, and the patient who has undergone endoscopy will not know the diameter of the gastrojejunostomy anastomosis. Only the person collecting the data of the study will be able to see these results.|All patients undergoing Roux nY gastric bypass will have their anastomotic diameter measured by performing an upper gastrointestinal endoscopy postoperatively. The effect of anastomosis diameter on weight loss will be investigated. All patients will be compared by recording their %EWL, height, weight and BMI values during endoscopy.|t|t|t|f
34123895|NCT01230320|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34123896|NCT05271942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomization into two groups|f|f|t|f
34123897|NCT00626535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34123898|NCT04170088|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participant do not know about the split face study. Their one side was injected by tranexamic acid diluted in normal saline while other side was injected with simple normal saline.|individual patients were selected in study . To control over confounding factors two sides of same patient were used parallel for intradermal injection ( Mesotherapy) of tranexamic acid and with normal saline|t|t|f|f
34123899|NCT03413904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123900|NCT03091088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34123901|NCT02414516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123902|NCT06252844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123903|NCT05609825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34123904|NCT04196725|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||26 participants will be enrolled in the cross over design consisting of two different rehabilitation programme. In addition there will be a parallel control group with 10 participants not participating in any of the rehabilitation programmes.|f|f|t|t
34123905|NCT02563145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123906|NCT04157881|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34123907|NCT02394821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34123908|NCT05911971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34123909|NCT04853914|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, prospective, mono-centric, non-controlled, non-randomized.||||
34123910|NCT05977218|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34123911|NCT02171143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123912|NCT04589897|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34123913|NCT01087593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34123914|NCT02450305|||CASE_CONTROL||PROSPECTIVE|||||||
33814873|NCT04554615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123915|NCT03436901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Non-inferiority study||||
34123916|NCT02746588|||COHORT||PROSPECTIVE|||||||
34123917|NCT04188249|||COHORT||PROSPECTIVE|||||||
34123918|NCT03938051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34123919|NCT02827812|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34123920|NCT03423433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123921|NCT05086861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123922|NCT04179305|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Non-randomized controlled trial|t|f|f|f
34123923|NCT00286897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123924|NCT04357184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123925|NCT04522934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor responsible for the outcome measures was blinded to the subjetc´s treatment assignment. The assessor was not present in the room while the treatment was delivered. He returned once the treatment was completed to perform the measurements.|Participants were randomly assigned to groups by using an online random generator. This procedure was conducted by an external assessor. The allocation concealment strategy included the use of sealed-opaque and consecutively numbered envelopes.|f|f|f|t
34123926|NCT00652275|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34123927|NCT04286152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is a randomized, placebo-controlled, double blinded trial.|t|t|t|t
34123928|NCT00435630|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33814874|NCT02288572|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33814875|NCT01430299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123929|NCT05731271|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Interventional Model: Sequential Assignment Interventional Model Description: Bayesian Optimal Interval (BOIN) design followed by evaluation for efficacy and safety of TST003 as monotherapy at the recommended dose for dose expansion phase or RP2D in subjects with locally advanced or metastatic colorectal cancer (CRCMasking: None (Open Label)||||
34123930|NCT06028828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123931|NCT04949945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123932|NCT00720694|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34123933|NCT02948764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34123934|NCT02835144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123935|NCT04698239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123936|NCT05123014|NA|SINGLE_GROUP||TREATMENT||NONE||LENTICULE IMPLANTATION AND AUTOLOGOUS SERUM NEW APPROACH IN TREATMENT OF ADENOVIRAL KERATITIS DISEASE||||
34123937|NCT02757807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123938|NCT02438033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123939|NCT00658541|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34123940|NCT02870465|||COHORT||PROSPECTIVE|||||||
33814876|NCT01846078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814877|NCT00046488|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33814878|NCT02462278|NA|SINGLE_GROUP||OTHER||NONE||||||
33814879|NCT03655704|NA|SINGLE_GROUP||SCREENING||NONE||Pilot study to assess the feasibility of a Phase 2 clinical trial assessing apabetalone in 10 PAH patients||||
33814880|NCT03355898|||OTHER||RETROSPECTIVE|||||||
33814881|NCT00785798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814882|NCT02779127|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814883|NCT04424745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814884|NCT05667909|||COHORT||PROSPECTIVE|||||||
34045214|NCT01091857|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
34123941|NCT03874767|RANDOMIZED|CROSSOVER||TREATMENT||NONE||single center, pragmatic cluster trial||||
34123942|NCT01082081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123943|NCT00648258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045215|NCT02155621|NA|SINGLE_GROUP||OTHER||NONE||||||
34123944|NCT03920241|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34123945|NCT02490397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123946|NCT02448147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123947|NCT05834049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34123948|NCT05197400|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
34123949|NCT06406530|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Investigator as well as the Patient are blinded.|RCT|t|f|t|f
34123950|NCT00208065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123951|NCT01476410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123952|NCT02132897|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
34123953|NCT02164526|||COHORT||PROSPECTIVE|||||||
34123954|NCT05910515|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34123955|NCT03929432|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Active tDCS versus sham tDCS will be masked to the participants||t|t|t|t
34045216|NCT06080399|||COHORT||PROSPECTIVE|||||||
34123956|NCT02777411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34123957|NCT05246202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123958|NCT01153204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123959|NCT03475342|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Masking was done by an independent clinical trials supply company. It will involve the removal of the original manufacturer's label and replacement with the clinical trial label bearing the randomisation number, which will be used as the pack identification. Apart from the randomisation number, all pack label texts will be identical for tranexamic acid and placebo.|A randomised, double blind, placebo controlled trial among 15,000 women with moderate or severe anaemia having given birth vaginally.|t|t|t|t
34123960|NCT02941614|||OTHER||PROSPECTIVE|||||||
34123961|NCT04865289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123962|NCT01410929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123963|NCT01510873|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34123964|NCT05858177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123965|NCT00020150||||TREATMENT||||||||
34045217|NCT00178672|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045218|NCT02183038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045219|NCT06255496|||COHORT||PROSPECTIVE|||||||
34045220|NCT00976742|NA|SINGLE_GROUP||PREVENTION||||||||
34045221|NCT04946435|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Participants will consist of 60 patients undergoing primary or revision endoscopic skull base surgery. The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation.||||
34045222|NCT03185195|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE|Open-Label|||||
34123966|NCT05125146|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label|Randomized controlled trial||||
34123967|NCT02852798|||COHORT||PROSPECTIVE|||||||
34123968|NCT03046836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34123969|NCT06078527|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34123970|NCT05043948|||COHORT||PROSPECTIVE|||||||
34123971|NCT02394158|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34123972|NCT00146861|RANDOMIZED|PARALLEL||||SINGLE||||||
34123973|NCT03931226|||CASE_CONTROL||RETROSPECTIVE|||||||
34123974|NCT01787383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123975|NCT05865951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123976|NCT02308761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123977|NCT03920995|||CASE_ONLY||RETROSPECTIVE|||||||
34123978|NCT03063606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34123979|NCT01677871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123980|NCT04915638|NA|SINGLE_GROUP||PREVENTION||NONE||The intervention consisted of enriched cookies given to children at school for one month. The intervention included two stages. First stage, schoolchildren received placebo cookies (20g of cookies without formula) each day (Monday to Friday) in the morning for 4 weeks. Then, in the second stage, schoolchildren received enriched cookies (20g with a formula FV-UNAM) each day (Monday to Friday) in the morning for 4 weeks. The formula was added to the cookies in a daily dose of 0.33g of organic mix that contained two vitamins, four minerals and omega-3 fatty acids. The exact composition of the formula is a trade secret held by UNAM. Schoolchildren were their own controls because the study was a paired study. In both stages we collected venous blood and anthropometric, blood pressure, and cognitive measurements before the placebo intervention, after 4 weeks from the beginning of formula intervention and post- intervention.||||
34123981|NCT01152801|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34123982|NCT05517486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123983|NCT02581436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34123984|NCT04937634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123985|NCT01864083|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34123986|NCT01065025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34123987|NCT01861470|||COHORT||PROSPECTIVE|||||||
34123988|NCT05604443|||OTHER||RETROSPECTIVE|||||||
34123989|NCT00756275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34123990|NCT03073525|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a 3 part study. Parts 1 and 3 did not involve randomization. In part 2, eligible participants were randomized to receive two cycles of either Vigil alone or Atezolizumab alone, then followed by combination treatment with the two agents.||||
34123991|NCT00134615|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34123992|NCT04824664|||OTHER||PROSPECTIVE|||||||
34123993|NCT01152788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34123994|NCT03420937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34123995|NCT05637177|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34123996|NCT05269459|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects and study personnel are blinded to treatment assignment. Randomization will occur in blocks based on self-reported marijuana use (yes/no). Randomization schedule will be provided by the statistician to the research pharmacist for study drug dispensing.|Double-Blind Placebo Controlled Study|t|f|t|t
34123997|NCT01760265|||COHORT||PROSPECTIVE|||||||
34123998|NCT04210492|NA|SINGLE_GROUP||TREATMENT||NONE||The intervention group will be compared with historical controls.||||
34123999|NCT05504512|||COHORT||RETROSPECTIVE|||||||
34124000|NCT00443118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124001|NCT04289558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124002|NCT02654496|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124003|NCT06246747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124004|NCT02651116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124005|NCT01055613|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124006|NCT06448975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124007|NCT01842672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124008|NCT02724488|||COHORT||PROSPECTIVE|||||||
34124009|NCT03110029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124010|NCT05889325|||COHORT||RETROSPECTIVE|||||||
34124011|NCT04096105|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124012|NCT06568549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124013|NCT01492478|||COHORT||PROSPECTIVE|||||||
34124014|NCT03541278|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124015|NCT02462031|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34124016|NCT02274961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124017|NCT05242601|||CASE_ONLY||CROSS_SECTIONAL|||||||
34124018|NCT04023760|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124019|NCT04377503|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective randomized controlled phase 2 study||||
34124020|NCT03717623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124021|NCT06319781|||COHORT||PROSPECTIVE|||||||
34124022|NCT04580043|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34124023|NCT01352286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124024|NCT01628068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124025|NCT03084848|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34124026|NCT04042454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124027|NCT00953992|||COHORT||PROSPECTIVE|||||||
34124028|NCT06525038|||COHORT||PROSPECTIVE|||||||
34124029|NCT03417466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124030|NCT05985707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124031|NCT06488274|NA|SINGLE_GROUP||OTHER||NONE||Interventional, open-label, non-comparative multicenter study||||
34124032|NCT00227084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124033|NCT01016132|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34124034|NCT02212665|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34124035|NCT01267786|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34124036|NCT03142919|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34124037|NCT01562886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124038|NCT02611102|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124039|NCT03538093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34124040|NCT05292690|||COHORT||PROSPECTIVE|||||||
34124041|NCT04161690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124042|NCT06059807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124043|NCT05840835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124044|NCT06016322|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pilot study investigating the effect of additional dietary intake 10-20 gram of a dried vegetable fibre. The difference in outcomes before and after the intervention in fecal calprotectin, IBD complaints, QOL, serum inflammatory markers, gut microbiota and SCFA will be determined||||
34124045|NCT00335166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124046|NCT05254756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients who have an indication for a speculum exam and who meet other inclusion criteria will be randomized to either receive their exam with the traditional plastic 2-blade disposable speculum or the 5-petal Bouquet speculum. After the exam, the patient and the physician will each fill out a questionnaire that will ask about patient comfort, ease of use, visibility of the cervix, and perceived time of the exam.|This randomized single-blinded clinical study|t|t|f|f
34124047|NCT02399644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124048|NCT00548457|||CASE_CONTROL||PROSPECTIVE|||||||
34124049|NCT01678300|||COHORT||PROSPECTIVE|||||||
34124050|NCT02852967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124051|NCT04451759|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124052|NCT06487234|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34124053|NCT02112539|||COHORT||PROSPECTIVE|||||||
34124054|NCT03364231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124055|NCT01971684|||COHORT||PROSPECTIVE|||||||
34124056|NCT05807399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study will be open-label, participants and physicians will be aware of treatment allocation. To ensure unbiased assessment of efficacy endpoints, the personnel assessing participants' outcomes, like the microbiology laboratory staff, will remain blinded to treatment assignment throughout the whole study. Every effort will be made to maintain this blinding.|"The study will compare the efficacy, safety of 3 experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.~In stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing experimental regimens in the ratio 1:1:1. In stage 2, the experimental arm 4 containing BTZ-043 will be added. The allocation ratio will be changed to co-enrol the remaining participants in arms 1- 3 simultaneously with arm 4. When arms 1-2 are fully enrolled and arm 4 is not, further participants will be randomized 1:1 to control and experimental arm 4. Not all countries will participate in stage 2."|f|f|f|t
34124057|NCT01537315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124058|NCT04679038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||SHR-1701 plus famitinib||||
34124059|NCT04346511|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This study is a single-blind crossover design. Participants will be blinded in two trials. Practitioners and operators will not be allowed to communicate with the participants concerning the type of acupuncture devices. Outcome assessors and statisticians may not be blinded to treatment allocation.|"Real Acupuncture(RA): In a supine position with a cardboard blocking view of their legs, patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal. After which the needles will be removed.~Placebo (PL): Specially designed Sham acupuncture needles that are not actually penetrate the skin and activate the acupoint will be used in an identical procedure to RA. The patient would be able to feel light pressure at the site."|t|f|f|f
33814885|NCT05614141|||COHORT||PROSPECTIVE|||||||
33814886|NCT02110914|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814887|NCT02183402|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814888|NCT06207448|||CASE_ONLY||RETROSPECTIVE|||||||
34124060|NCT00066690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814889|NCT02691702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33814890|NCT02935478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814891|NCT02282137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124061|NCT06322030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The coordinator will not see group assignment, only a patient number which is entered into a software package.|The investigators will utilize a 2x2 factorial design to assess for changes in our outcomes over time between treatment groups.|f|f|f|t
34124062|NCT01894945|||COHORT||PROSPECTIVE|||||||
34124063|NCT02822053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124064|NCT05175716|||COHORT||RETROSPECTIVE|||||||
34124065|NCT03115918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124066|NCT03048773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participant, Investigator, Outcomes Assessor||t|f|t|t
34124067|NCT01265992|||||PROSPECTIVE|||||||
34124068|NCT06395116|||COHORT||PROSPECTIVE|||||||
34124069|NCT03591731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124070|NCT02520492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124071|NCT01525693|||COHORT||PROSPECTIVE|||||||
34124072|NCT04536051|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34124073|NCT02743767|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124074|NCT03053934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124075|NCT05298943|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34124076|NCT00524121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124077|NCT05834985|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The investigators included all patients who were presented to General Surgery Department with Controlled Colo-cutaneous Fistula As A complication of Acute Diverticulitis at Zagazig University hospital between (December 2020 to April 2023). the calculated sample size equal 66 patients divided into two equal groups. Included patients were randomized at a 1:1 ratio to Endoscopic Group, EG or Surgical Group , SG via the drawing of sealed envelopes containing computer-generated random numbers prepared by a third party before the start of the intervention.(simple random sample). Patients will be divided into 2 groups in accordance type of preoperative~Therapy :~Group 1: Endoscopic Group, EG included 33 patients. Group 2: Surgical Group , SG included 33 patients.~Inclusion criteria:"||||
34124078|NCT00514930|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124079|NCT05085483|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34124080|NCT05075889|NA|SINGLE_GROUP||OTHER||NONE||All participants will receive the same study drug.||||
34124081|NCT02118519|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124082|NCT04156672|||OTHER||CROSS_SECTIONAL|||||||
34124083|NCT03225391|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|At the moment of running the Iowa Gambling Task and the Psychomotor Visual Test the investigator does not know the schedule of the nap.||f|f|t|f
34124084|NCT02218853|||CASE_CONTROL||PROSPECTIVE|||||||
34124085|NCT01119144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124086|NCT04092777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124087|NCT01896687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124088|NCT01673646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124089|NCT04477460|||COHORT||PROSPECTIVE|||||||
34124090|NCT00521677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124091|NCT03245346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124092|NCT05794737|||CASE_ONLY||RETROSPECTIVE|||||||
34124093|NCT04487197|||COHORT||OTHER|||||||
34124094|NCT04590599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124095|NCT00889707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124096|NCT00196209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124097|NCT03577262|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||evaluate the kinetics and test-retest repeatability and reproducibility of the radioligand \[11C\]-UCB-J for imaging synaptic density in up to10 healthy subjects and then mild to moderate Alzheimer's Disease patients||||
34124098|NCT06139809|NA|SINGLE_GROUP||OTHER||NONE||prospective single-center study||||
34124099|NCT02236819|||COHORT||PROSPECTIVE|||||||
34124100|NCT00190736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124101|NCT04652804|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a 3-arm, individual-level randomized clinical trial, in which treatment assignment probabilities vary according to participants' estimated propensity for treatment failure at baseline (precision randomization). Minimal risk individuals have a higher likelihood of being allocated to lower intensity intervention and elevated risk individuals have higher likelihood of being allocated to higher intensity intervention.||||
34124102|NCT04171505|||COHORT||RETROSPECTIVE|||||||
34124103|NCT03059641|||COHORT||PROSPECTIVE|||||||
34124104|NCT02861339|NA|SINGLE_GROUP||||NONE||||||
34124105|NCT03858348|||OTHER||RETROSPECTIVE|||||||
34124106|NCT04312503|||COHORT||PROSPECTIVE|||||||
34124107|NCT00588796|||CASE_CONTROL||PROSPECTIVE|||||||
34124108|NCT06617286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124109|NCT01913847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124110|NCT04040062|NA|SINGLE_GROUP||TREATMENT||NONE||We will identify the participant's individual spectral correlation coefficient (SCC) by stimulation with 68 different stimulation pulse trains of 40 pulses each at frequencies ranging between 3 and 20 Hz in steps of 0.25 Hz, plus intermittent theta burst (iTBS) stimulation, in randomized order. We will then select the frequency with the largest connectivity density (strong and focal connectivity increase within the fronto-parietal control network) in the range of 3 and 20 Hz as the optimal individual stimulation density and treat the participants at this optimal Hz for the duration of the study.||||
34124111|NCT06184191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were evaluated before rehabilitation and at the first month follow-up. The same therapist who was blind to the type of rehabilitation evaluated the patients before treatment and at the first month follow-up.||f|f|f|t
34124112|NCT06259318|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a Hybrid Type 2 Effectiveness-Implementation Trial of a pilot, 2-arm, parallel-group, quasi-randomized trial.||||
34124113|NCT02264743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124114|NCT05357768|||OTHER||CROSS_SECTIONAL|||||||
34124115|NCT00447798|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
34124116|NCT04227327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124117|NCT00833443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124118|NCT01840943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124119|NCT04013776|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, cross-over design||||
34124120|NCT03044275|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124121|NCT00876252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124122|NCT02869321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34124123|NCT03646058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124124|NCT02377414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124125|NCT02230189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single group before and after administration of allergen||||
34124126|NCT01232439|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124127|NCT06507579|||CASE_ONLY||PROSPECTIVE|||||||
34124128|NCT05851885|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34124129|NCT04149171|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a single-center, not-randomized, open-label, controlled pilot clinical trial. This study compares presence of TIC and acute traumatic hemorrhage treatment at pre-hospital phase of care with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC) with the current treatment based on the administration of Crystalloids and TXA.||||
34124130|NCT05809427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124131|NCT03938818|RANDOMIZED|PARALLEL||PREVENTION||NONE||cluster randomized-controlled trial (RCT)||||
34124132|NCT00948077|RANDOMIZED|CROSSOVER||||NONE||||||
34124133|NCT00537472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124134|NCT00292526|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124135|NCT00330369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124136|NCT00563758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124137|NCT03770858|||COHORT||PROSPECTIVE|||||||
34124138|NCT00505115|||||PROSPECTIVE|||||||
34124139|NCT02981056|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34124140|NCT04762082|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Eligible subjects will receive a single oral dose of one of five treatments (Treatments A, B, C, D or E) in five separate periods in a randomly assigned sequence, with each treatment separated by an approximate 5-day washout period. In each study period, dosing will occur in the morning after an overnight fast of at least 10 hours.~All doses will be administered under fasted conditions except for Treatment C, when tadalafil gummy 10 mg will be administered after consumption of a high-calorie, high-fat breakfast.~All doses will be administered with approximately 240 mL of room temperature water except for Treatment D, when tadalafil gummy 10 mg dose will be administered without water.~All doses of tadalafil gummy 10 mg will be chewed before swallowing except for Treatment E, when subjects will be instructed to swallow the dose whole."||||
34124141|NCT03420742|NA|SEQUENTIAL||OTHER||NONE||||||
34124142|NCT02874443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124143|NCT03800277|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124144|NCT05367193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124145|NCT04154605|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All participants will be blinded to treatment assignment from procedure through their 90-day visit.|Participants will be randomized 1:1 to ClariFix or a sham procedure. After the 90-day visit, control participants may crossover to active ClariFix treatment, if they continue to meet enrollment criteria.|t|f|f|f
34124146|NCT01525823|NA|SINGLE_GROUP||||NONE||||||
34124147|NCT04432922|||OTHER||PROSPECTIVE|||||||
34124148|NCT03440801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124149|NCT02321605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124150|NCT03215498|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
34124151|NCT05211089|||CASE_ONLY||PROSPECTIVE|||||||
34124152|NCT01169727|||CASE_ONLY||PROSPECTIVE|||||||
34124153|NCT06003777|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34124154|NCT06633887|||CASE_ONLY||PROSPECTIVE|||||||
34124155|NCT02761850|||COHORT||PROSPECTIVE|||||||
34124156|NCT00894699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124157|NCT05176951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124158|NCT00152204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124159|NCT05177419|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Double-blind, placebo-controlled, cross-over design.|t|t|t|t
33736641|NCT05552040|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Statistical analysis completed by Virginia Tech Department of Statistics faculty and graduate students who were all blinded with respect to group assignment.|START NOW group psychotherapy versus Treatment-as-Usual group psychotherapy in OUD individuals in an OBOT program|f|f|f|t
33736642|NCT01391117|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736643|NCT03387800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33814892|NCT02753075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840181|NCT02888574|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34045223|NCT04003831|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34045224|NCT01095380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045225|NCT04262089|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A window-of-opportunity study of ICB in primary dMMR UC (n=10) and primary POLE-EDM UC (n=10) patients.||||
33736644|NCT06663007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Simon's two-stage design.If the number of valid cases in the first stage is less than or equal to 0, the study will be terminated prematurely. If the number of valid cases in the first stage is greater than 0, participants will continue to be enrolled in the second stage. If the total number of valid cases is greater than 3 after the completion of the second stage, the queue experimental group is considered valid.|f|f|t|f
33736645|NCT05141292|||COHORT||RETROSPECTIVE|||||||
33736646|NCT05870592|||COHORT||PROSPECTIVE|||||||
33736647|NCT05990049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736648|NCT05592210|||CASE_ONLY||OTHER|||||||
33736649|NCT01752933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736650|NCT02351752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736651|NCT03636490|NA|SINGLE_GROUP||OTHER||NONE|All participants will receive the same intervention. All associated groups will be aware of the intervention protocol and the single-arm study model.|All participants will be receive the same intervention.||||
33736652|NCT02550652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736653|NCT06569576|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Comparing online delivery vs in-person delivery||||
33736654|NCT04186962|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736655|NCT05056168|||COHORT||PROSPECTIVE|||||||
33736656|NCT02229877|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33814893|NCT06193915|RANDOMIZED|PARALLEL||TREATMENT||NONE|Because treatment in both groups are different (one group with and one group without ultrasound) it's not possible to mask the treating physician for the intervention.|||||
33837139|NCT03910322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"This trial is a single-site, randomized, double-blind, placebo-controlled, three-armed, parallel-group trial in healthy volunteers aged 40 - 60 years. The trial will investigate the effect of daily intake of the probiotic strain Bif195 in two different doses or placebo when co-administered to daily intake of 300mg of Acetylsalicylic Acid (ASA).~The trial includes a run-in period of two weeks duration followed by a six weeks intervention period where Bif195/placebo and ASA is co-administered."|t|t|t|t
33837140|NCT00790400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837141|NCT02821351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045226|NCT05836350|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Clinical randomized controlled trial (RCT) with a double-blinded, placebo-controlled, cross-over design, including a wash-out period of 12 weeks. The trial will contain 2 treatment arms, with each a duration of 12 weeks.|t|f|t|f
34045227|NCT03576963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045228|NCT01996007|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34045229|NCT04725955|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34045230|NCT01522378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045231|NCT02844543|NA|SINGLE_GROUP||OTHER||NONE||||||
33837142|NCT00161265|||COHORT||PROSPECTIVE|||||||
34045232|NCT03644394|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34045233|NCT02496130|||COHORT||PROSPECTIVE|||||||
34045234|NCT00002924|||CASE_ONLY||PROSPECTIVE|||||||
34045235|NCT05988177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045236|NCT05491824|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34045237|NCT02782117|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, multi-center, open-label pilot study conducted in two phases. Phase 1 enrolled 10 participants at 1 site and phase 2 enrolled 74 participants at 9 sites.||||
34045238|NCT00944086|||CASE_ONLY||PROSPECTIVE|||||||
34045239|NCT01453088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045240|NCT04869774|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|This study will be unblinded so no attempts at concealment of individuals' allocation will be made.|||||
34045241|NCT04062201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045242|NCT00996125|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34045243|NCT02138799|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34045244|NCT01437995|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045245|NCT05778968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34045246|NCT02654977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045247|NCT00687843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045248|NCT01582360|||COHORT||PROSPECTIVE|||||||
34045249|NCT04075682|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||In a 2 X 2 between subject design, smokers will be randomized into one of four cigarette package labeling conditions: 1. no inserts or pictorial HWLs; 2. inserts only; 3. pictorial HWLs only; 4. inserts \& pictorial HWLs|t|f|f|f
34045250|NCT03271190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34045251|NCT01036958|||CASE_ONLY||CROSS_SECTIONAL|||||||
34045252|NCT00001504||||TREATMENT||||||||
34045253|NCT01545037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045254|NCT01037179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045255|NCT01057966|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34045256|NCT03316391|||CASE_ONLY||PROSPECTIVE|||||||
34045257|NCT04290715|||CASE_ONLY||PROSPECTIVE|||||||
34045258|NCT00239369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045259|NCT00607074|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34045260|NCT04120649|||OTHER||CROSS_SECTIONAL|||||||
34045261|NCT04344028|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Researchers and participants will be blind to the conditions assigned to the participant.|The design is a 2 (positive expectations/negative expectations) x 2 (true cognitive training intervention x control cognitive training intervention) randomized controlled trial.|t|f|t|f
34045262|NCT03734289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Caregivers will be randomized in a 1:1 ratio for immediate intervention vs. a 6 week delayed intervention||||
34045263|NCT01805466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045264|NCT03833479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045265|NCT05539287|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045266|NCT00556933|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34045267|NCT04510623|||COHORT||OTHER|||||||
33736657|NCT03384446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not know which intervention was administered. Outcome assessor will be different than care provider and will be masked.||t|f|f|t
33736658|NCT00265811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736659|NCT02402010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736660|NCT03979716|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736661|NCT03660956|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A Quasi-Experimental design is used in this study. Participants are randomly assigned to exercise and back counselling group or back counselling only group.|f|f|f|t
33736662|NCT04662346|NA|SINGLE_GROUP||OTHER||NONE||||||
33736663|NCT06444789|||CASE_CONTROL||PROSPECTIVE|||||||
33736664|NCT02496884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736665|NCT02100592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736666|NCT02287415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736667|NCT03750396|NA|SINGLE_GROUP||TREATMENT||NONE||"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.~Local treatments for metastatic lesions will be added in this group.~All patients will undergo local treatments in addition to endocrine therapies.~Local treatments include modalities described below:~i) Surgical resection: the achievement of tumor-free margin is not obligatory.~ii) Stereotactic body radiotherapy~iii) Radiofrequency ablation"||||
33736668|NCT05015491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736669|NCT01499823|||COHORT||PROSPECTIVE|||||||
33736670|NCT02023034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736671|NCT05451212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736672|NCT05434897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736673|NCT01341184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736674|NCT02422030|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736675|NCT06376461|||COHORT||PROSPECTIVE|||||||
33736676|NCT01531959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736677|NCT04666038|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eligible patients will be randomized in 1:1 into Arm A or Arm B. Patients randomized to Arm B who have disease progression (PD) confirmed by independent review committee (IRC) may be eligible to crossover into Arm A. Patients who discontinue treatment for toxicity may still be evaluated for cross over at the time of IRC-confirmed PD.||||
33736678|NCT01507415|||COHORT||PROSPECTIVE|||||||
33736679|NCT06488976|||COHORT||PROSPECTIVE|||||||
33736680|NCT05813743|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736681|NCT04638608|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33736682|NCT06663644|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The two treatment groups are muscle energy technique group and hamstring and abdominal muscle activation group. Patients in the muscle energy technique group will receive muscle energy technique on iliotibial band along with conventional treatment. In this technique, after positioning the patient was asked to apply 30% force against therapist force and hold that contraction for 7-10seconds and after that relax for 5seconds and when patient exhale. Therapists take muscle to new restriction barrier; hold this position for 10-60 seconds with 3-5 repetition. The other group will receive 90/90 hip lift with balloon. The technique is performed in supine lying position such that lie on back with feet on a wall and knees and hips bent at 90 degrees angle. Place a 4-6 ball between knees. Place right arm above head and a balloon in left hand. Now inhale through nose and slowly blow out into the balloon. Pause 3 seconds with tongue on the roof of mouth to prevent airflow out of the balloon."||||
33736683|NCT01850199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33736684|NCT05087017|||CASE_CONTROL||PROSPECTIVE|||||||
33736685|NCT06035926|||COHORT||RETROSPECTIVE|||||||
33736686|NCT05299541|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33736687|NCT05389124|||CASE_CONTROL||PROSPECTIVE|||||||
33814894|NCT05776329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Assignor to each group: The assignment of the people to the comparison groups will be carried out by the statistician responsible for the project. The statistician will not participate in any other project stage (registration, intervention, or measurements).~Researcher in charge of the database: A person from outside the workgroup will assign codes to the participants enrolled in the study to prevent the person entering the data into the database from identifying the intervention group they belong to.~Investigator in charge of the analysis of serum and stool samples: The same codes will be used to label the biological samples so that the person carrying out the interleukin and intestinal microbiota analyses cannot identify the intervention group to which they belong.~The keys will be revealed at the end of the statistical analyses."|An interventional randomized controlled clinical trial of parallel design with active control.|f|f|f|t
33814895|NCT02912442|||COHORT||PROSPECTIVE|||||||
34045268|NCT04338841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Quasi-experimental before and after multicentre prospective study||||
34045269|NCT03821948|||COHORT||PROSPECTIVE|||||||
34045270|NCT00225524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045271|NCT05762211|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736688|NCT05898399|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736689|NCT04889092|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Some of the variables will be masked by the outcome assessor as they will not be present during data collection. Other variables will not be masked due to nature of data collection.|This is a crossover model in which subjects will be assigned the blood flow restriction exercise or control condition (standard exercise) in random order. Data will be collected pre, during and at the end of each 8-week exercise intervention. The order of conditions will be randomly assigned.|f|f|f|t
33736690|NCT01117818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736691|NCT00355446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33736692|NCT04584567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double|The participants who meeting study entry criteria will be randomized in a 1:1 blinded comparison of daily low dose DOXY versus oral placebo for 6 weeks.|t|f|t|f
33736693|NCT06662500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736694|NCT04684797|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33736695|NCT03909776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736696|NCT06503835|||COHORT||RETROSPECTIVE|||||||
33736697|NCT04546204|||CASE_ONLY||RETROSPECTIVE|||||||
33736698|NCT02337829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045272|NCT03061825|||COHORT||PROSPECTIVE|||||||
34045273|NCT06065462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045274|NCT03512210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045275|NCT04074369|||COHORT||PROSPECTIVE|||||||
34045276|NCT00217373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045277|NCT06566872|||OTHER||PROSPECTIVE|||||||
34045278|NCT04952025|||CASE_CONTROL||RETROSPECTIVE|||||||
34045279|NCT06578858|||CASE_ONLY||RETROSPECTIVE|||||||
34045280|NCT04339101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045281|NCT03947866|||OTHER||PROSPECTIVE|||||||
34045282|NCT03691207|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34045283|NCT03691987|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045284|NCT02760004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34045285|NCT01120015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045286|NCT06577545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045287|NCT04993638|||COHORT||PROSPECTIVE|||||||
34045288|NCT06184204|||COHORT||PROSPECTIVE|||||||
34045289|NCT06258499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045290|NCT03768154||SEQUENTIAL||TREATMENT||NONE||Measurement 1 (Supine + spontaneous effort) , Measurement 2 (Supine + paralysis) , Measurement 3 (Prone + paralysis) , Measurement 4 (Prone + spontaneous breathing)||||
34045291|NCT04574908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The 2 wards will alternate every 4 weeks as to blinded/unblinded allocations. Blinded will be continuous ward monitoring with alarms silenced and screens covered; unblinded will be continuous monitoring accessible to clinicians with pre-specified alerts at MAP \<65 mmHg, heart rate \>110 b/m, and SpO2 \<90%. Of note, to ensure patient safety and no risk in either arm, factory alarm limits (see table under human subjects protection) at extremes of physiological vital signs will stay on in the blinded/silenced arm, and both arms will have every 4 hourly checks by nursing teams.||t|f|f|f
34045292|NCT02186860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045293|NCT02924168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045294|NCT04754386|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34045295|NCT01268618|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045296|NCT02941536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045297|NCT05464966|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34045298|NCT05657561|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients who have had abdominal surgery|Experimental study with pretest posttest control group||||
34045299|NCT06578013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045300|NCT06247605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To maintain study blinding, until the study is completed, it should be Ensure that blinded staff and associated with this trial may not see the random table and treatment group assignments.||t|t|t|t
34045301|NCT06529445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045302|NCT03800810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045303|NCT04601519|||CASE_ONLY||PROSPECTIVE|||||||
34045304|NCT03224000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045305|NCT04428697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome Assessor doesn't know the type of the surgery.||f|f|f|t
34045306|NCT06574841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045307|NCT05863260|||COHORT||PROSPECTIVE|||||||
34045308|NCT05718869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045309|NCT03568370|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34045310|NCT03267134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045311|NCT05140382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045312|NCT00164528|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34045313|NCT06577792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045314|NCT00624936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045315|NCT00423332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045316|NCT03492723|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|both, the participants and the investigators will be blind 2 groups will be assigned randomally|This is a randomized, controlled, examiner-blind, 2-treatment parallel group study.|t|f|t|f
34045317|NCT03525938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736699|NCT05574348|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34045318|NCT06408714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045319|NCT03333668|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Each participant will complete all three experimental conditions (LISDEX, GXR, placebo) in a randomised order.|t|f|t|f
34045320|NCT02084108|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34045321|NCT00831311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045322|NCT04652531|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied. The contralateral ulcer will be treated with a standard dressing and an elastic compression bandage. The patients will be evaluated on an outpatient basis on day 3 and then weekly.|f|f|t|f
34045323|NCT00268177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045324|NCT01071226|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045325|NCT01172925|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34045326|NCT02308540|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045327|NCT00178685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045328|NCT03893188|||COHORT||PROSPECTIVE|||||||
34045329|NCT00406263|||CASE_ONLY||PROSPECTIVE|||||||
34045330|NCT00722774|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34045331|NCT06102746|||COHORT||PROSPECTIVE|||||||
34045332|NCT03079024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045333|NCT03514043|||OTHER||PROSPECTIVE|||||||
34045334|NCT04150510|||COHORT||OTHER|||||||
34045335|NCT06569771|||COHORT||PROSPECTIVE|||||||
34045336|NCT03773406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045337|NCT02547415|||COHORT||PROSPECTIVE|||||||
34045338|NCT00638716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045339|NCT01242670|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34045340|NCT03346772|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34045341|NCT02295969|||COHORT||PROSPECTIVE|||||||
34045342|NCT01703676|||CASE_CONTROL||PROSPECTIVE|||||||
34045343|NCT03058705|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34045344|NCT04520750|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34045345|NCT01496950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045346|NCT02411396|||COHORT||PROSPECTIVE|||||||
34124160|NCT00888537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124161|NCT03841942|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33814896|NCT03189550|||COHORT||OTHER|||||||
34045347|NCT00098436||||TREATMENT||NONE||||||
34045348|NCT00356122|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045349|NCT04754828|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34045350|NCT03285867|||COHORT||PROSPECTIVE|||||||
34045351|NCT05393648|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A sham component will be used over the right DLPFC for unilateral aiTBS treatment. This treatment component will mitigate concerns of expectancy, and will lead to blinding for patients. The Cool B65 A/P coil is unmarked, with one side producing active treatment and the other sham treatment with concurrent electrical stimulation, which accurately mimics active stimulation.|Patients enrolled in the study will be randomized to sham vs. active accelerated iTBS in a 1:1 ratio. Treatments will be over 1 week.|t|f|f|t
34045352|NCT00312273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045353|NCT01191125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045354|NCT00693238|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045355|NCT00820248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045356|NCT03216005|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, non-randomized, multicenter pre-market feasibility study||||
34045357|NCT05069116|||COHORT||OTHER|||||||
34045358|NCT01485016|||CASE_ONLY||PROSPECTIVE|||||||
34045359|NCT06621537|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34045360|NCT01055860|||CASE_ONLY||RETROSPECTIVE|||||||
34045361|NCT04245631|||COHORT||PROSPECTIVE|||||||
34045362|NCT05174299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045363|NCT01543178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045364|NCT04476589|||COHORT||PROSPECTIVE|||||||
34045365|NCT04081610|RANDOMIZED|PARALLEL||TREATMENT||NONE||single-center, controlled, parallel group, open, randomized||||
34045366|NCT05730361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045367|NCT05742282|||COHORT||PROSPECTIVE|||||||
34045368|NCT04471857|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A blinded observer assessed child distress during anorectal manometry||f|f|f|t
34045369|NCT04673006|||CASE_ONLY||PROSPECTIVE|||||||
34045370|NCT02674958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34045371|NCT02852304|||COHORT||PROSPECTIVE|||||||
34045372|NCT05121701|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34045373|NCT04448444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study was designed as parallel group (outpatients) randomized comparison of two kinds of physiotherapeutic interventions referred to healthy controls.|t|f|t|t
34045374|NCT02774330|||OTHER||PROSPECTIVE|||||||
34045375|NCT03086967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045376|NCT03930563|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34045377|NCT00003446||||TREATMENT||||||||
34045378|NCT01552707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045379|NCT04897061|||COHORT||PROSPECTIVE|||||||
34045380|NCT04009278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Each patient is identified in the study by a Subject Number (Subject No.), that is assigned when the patient is registered for mammography and is retained as the primary identifier for the patient throughout his/her entire participation in the trial.~The allocation to experimental or control arm ill be open to patients and the research staff.~The Image quality evaluations of Radiologists and the Radiographers are performed blindly."|"The study will be proposed to women presenting for a clinical mammography . Randomization will be determined by the machine's order entry system. All women will have a mammogram performed on the Pristina. In the control arm, mammography will be performed as normal clinical practice, with compression controlled by the radiographer.~In the experimental arm the radiographer will first explain to the woman how to use the self-compression device, then position the woman's breasts and reach a compression of 5 daN, that this is a minimum but sub-optimal level of compression, and that at that point the woman will have to complete the compression to reach the optimal compression level up to an acceptable pain."|f|f|f|t
34045381|NCT03138837|||COHORT||PROSPECTIVE|||||||
34045382|NCT05724680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045383|NCT06318637|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34045384|NCT05943236|||COHORT||PROSPECTIVE|||||||
34045385|NCT02857257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045386|NCT01029782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045387|NCT02390596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045388|NCT00204464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34045389|NCT02173002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34045390|NCT04504188|NA|SINGLE_GROUP||TREATMENT||NONE||"Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.~Based on this information, clinicians should follow guideline-directed medical therapy (GDMT) to add or titrate medication accordingly. The goal of these changes will be to achieve the average nighttime HR to recommended guidelines (\<70 bpm) by the end of WCD use."||||
34045391|NCT04532931|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045392|NCT03689205|||OTHER||PROSPECTIVE|||||||
34045393|NCT06410677|||COHORT||RETROSPECTIVE|||||||
34045394|NCT05747001|||COHORT||RETROSPECTIVE|||||||
34045395|NCT00521638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045396|NCT03324347|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34045397|NCT03755557|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The visual aspects of the three treatment arms are identical. Identification of the treatment is achieved via a randomization code.|3-way crossover, randomized, prospective, placebo-controlled, double blinded study in a validated allergen exposure chamber setting using grass pollen allergen|t|t|t|t
34124162|NCT01887925|||COHORT||PROSPECTIVE|||||||
34124163|NCT02515344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34124164|NCT05006105|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The participant and care provider are not blinded for which mHealth method is used (smartphone or smartwatch), but are blinded for the mHealth results (i.e., AF detection) during the monitoring period with the mHealth application.|"Group 1 uses PPG-based mHealth with a smartphone; two times a day, a spot-check measurement is taken; and in case of symptoms, additional measurements can be taken.~Group 2 uses PPG-based mHealth with a smartwatch, this results in semi-continuous measurements that are performed automatically."|t|t|f|f
34124165|NCT06292663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The primary investigator will stay blinded in this study and an assistant to the investigator is screening and including the patients and collecting data.|The subjects are being randomized to one of two groups.|f|f|t|f
34124166|NCT00928187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124167|NCT03115372|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124168|NCT03579758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124169|NCT05143333|||COHORT||PROSPECTIVE|||||||
34124170|NCT05047133|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124171|NCT06308601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Statistical evaluation of the research results will be made by an expert other than the researcher.|"Research Population: The population of this research is the visually impaired individuals who received service from the Disabled Department within the Ataturk Provincial Public Library in Konak district of Izmir province between 2023-2024.~Research Sample: In the research, G. Using the Power-3.1.9.7 program, the sample size of the study was calculated at a 95% confidence level before the data collection phase. The standardized effect size was found to be 0.90 when calculated based on the mean and standard deviation values of previous studies. As a result, the minimum number of samples was calculated as 28 for each group with a 95% confidence level, 0.05 alpha value, 0.90 intervention effect size and 95% theoretical power. It is aimed to reach 56 people in total. Considering that there will be a 20% case loss in experimental studies in the literature (Pan, et al., 2019), the number of samples was determined as 60 (30 interventions; 30 controls)."|f|f|f|t
34124172|NCT03186430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study uses a cluster-randomized design where six health provider practices are randomized to the intervention or control arm where all participants in the respective practices will receive the behavioral intervention or the standard information.||||
34124173|NCT01411423|||CASE_ONLY||PROSPECTIVE|||||||
34124174|NCT03961243|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124175|NCT00893854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124176|NCT05278845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Subjects will be randomized in a 1:1 ratio to one of two treatment sequences with 11 subjects per treatment sequence as outlined below. Each subject will receive both treatments (Treatment A and Treatment B) with a washout period of at least 7 days between successive SLC-391 single doses.||||
34124177|NCT01581684|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34124178|NCT00965289|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124179|NCT02503085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34124180|NCT01063790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34124181|NCT02243683|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34124182|NCT04720651|||OTHER||PROSPECTIVE|||||||
34124183|NCT04662931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124184|NCT04421404|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study investigators analyzing the data and participants will be blinded to the randomization. It may not be feasible to blind nursing staff to the treatment assignment to ensure proper ABO checking of the plasma unit at bedside per standard transfusion procedures, but every effort will be made to preserve blinding of the investigators, participant, and primary team providing care. An unblinded research assistant who is not involved in other aspects of the study will randomize the participant once enrolled. Randomization will be provided to an unblinded provider who is not part of the care team who will place the order for the plasma (CCP vs. control plasma) using a paper order that will not be part of the electronic medical record. The safety monitoring committee (SMC) will review study data, including unblinded data, to evaluate the safety, efficacy, study progress, and conduct of the study.|Subjects enrolled in the study will be randomized using a web based randomization procedure to receive convalescent plasma versus non-immune plasma at a 1:1 ratio.|t|t|t|f
34124185|NCT05863403|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34124186|NCT00051207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124187|NCT02694601|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124188|NCT06012630|||COHORT||CROSS_SECTIONAL|||||||
34124189|NCT00028158|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124190|NCT01734824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124191|NCT00506779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124192|NCT00296218|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34124193|NCT03503396|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants will be assigned to either receive feedback from a breathalyzer device or to receive no information.|f|f|f|t
34124194|NCT05778994|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34124195|NCT03794440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124196|NCT01580774|||CASE_CONTROL||PROSPECTIVE|||||||
34124197|NCT04336657|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34124198|NCT02214901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124199|NCT06470516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124200|NCT06551675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124201|NCT04679961|||CASE_CONTROL||PROSPECTIVE|||||||
34124202|NCT02770131|||OTHER||PROSPECTIVE|||||||
34124203|NCT03446898|||COHORT||OTHER|||||||
34124204|NCT02186483|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124205|NCT01249313|||CASE_ONLY||RETROSPECTIVE|||||||
34124206|NCT00484796|||COHORT||PROSPECTIVE|||||||
34124207|NCT04794868|||CASE_CONTROL||PROSPECTIVE|||||||
34124208|NCT01000506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124209|NCT03828760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigators and statisticians performing final data analysis will be blinded to the group allocations||f|f|t|t
34045398|NCT05131685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045399|NCT06575920|NA|SINGLE_GROUP||OTHER||NONE|The principal investigator kept all records and collected data, which was blinded from the care provider, whose role was solely to perform lectures and exercises.,|Pilot and fesability study.||||
34045400|NCT00754234|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34045401|NCT06171308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045402|NCT04150744|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045403|NCT02236871|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045404|NCT05347576|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045405|NCT04568564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
34045406|NCT02582684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045407|NCT05253573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045408|NCT05679102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045409|NCT00606554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045410|NCT01448330|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045411|NCT06129604|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot window of opportunity study proposes to evaluate the safety and biological efficacy of 50mg TPST-1495 in patients with EC or CRC undergoing surgical therapy.||||
34045412|NCT01986933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045413|NCT05526196|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34045414|NCT05509452|||COHORT||PROSPECTIVE|||||||
34045415|NCT01559025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045416|NCT02477332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045417|NCT00831649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045418|NCT04974060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045419|NCT04947228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34045420|NCT05203796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045421|NCT00183404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045422|NCT01732094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045423|NCT04820699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124210|NCT00652171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124211|NCT04980469|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double-blind|Randomized, Double-blind, Placebo controlled, Parallel group|t|t|t|f
34124212|NCT01206517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124213|NCT04554732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124214|NCT03606148|||CASE_CONTROL||PROSPECTIVE|||||||
34124215|NCT01396590|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124216|NCT04271358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Once enrolled, participants will be randomly assigned to the intervention or control group (1:1 ratio)||||
34124217|NCT02015039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124218|NCT06312163|||COHORT||PROSPECTIVE|||||||
34124219|NCT01406132|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34124220|NCT04780529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124221|NCT03901638|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34124222|NCT06349824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045424|NCT00305084|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose-escalating study||||
34045425|NCT00301353|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34045426|NCT05323162|NA|SINGLE_GROUP||TREATMENT||NONE||Encapsulated autologous fecal microbiota transplantation.||||
34045427|NCT05028556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045428|NCT06575244|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Due to the limited resources available, the study team has decided to adopt a volunteer-based approach for the blinded outcome assessor. Individuals with relevant experience working with children with autism spectrum disorder (ASD) will be recruited and trained to perform the data collection for the study.~The researchers recognize the importance of ensuring the reliability and validity of the study's findings. To address this, the volunteer assessors will undergo appropriate training and supervision to equip them with the necessary skills and knowledge to conduct the assessments in a rigorous and unbiased manner.~By leveraging the expertise and commitment of volunteers with prior experience in the ASD population, the study team aims to overcome the challenge of limited resources and implement the blinded assessment protocol as intended. This approach will help maintain the integrity of the study's methodology and the credibility of the final results."|The Synergy Model of Resilience was selected as the theoretical framework to guide the development of the conceptual model, which comprises four components: adversity, operating factors, resistance to adversity, and outcome indicators, to build resilience, driven by the model's exceptional clarity.|f|f|f|t
34045429|NCT04233112|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34045430|NCT04274010|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124223|NCT05886153|NA|SINGLE_GROUP||OTHER||NONE||Single group verification testing of the Vitaliti Continuous Vital Sign Monitor Model CVSM-1A device||||
34124224|NCT00903422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124225|NCT00473889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124226|NCT05658718|||OTHER||OTHER|||||||
34045431|NCT00655941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124227|NCT01530789|||CASE_ONLY||PROSPECTIVE|||||||
34124228|NCT03240562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34124229|NCT01313910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124230|NCT00133341|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||||||
34124231|NCT04867083|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, multicenter, prospective, randomized trial in 2 parallel groups||||
34124232|NCT00000906||||TREATMENT||||||||
34124233|NCT03491033|||COHORT||RETROSPECTIVE|||||||
34124234|NCT00622921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124235|NCT03761420|||CASE_ONLY||RETROSPECTIVE|||||||
34124236|NCT00002286||||TREATMENT||||||||
34124237|NCT04845594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124238|NCT01603043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124239|NCT01280786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124240|NCT03159468|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34124241|NCT01697085|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34045432|NCT01965340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124242|NCT04120740|||COHORT||PROSPECTIVE|||||||
33736700|NCT02057757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736701|NCT01378000|||CASE_CONTROL||PROSPECTIVE|||||||
33736702|NCT06576765|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Up to three cohorts (two hepatic impairment cohorts and controls with normal hepatic function) will be enrolled into this study.~All subjects will receive the study intervention:~* Cohort 1 will enroll 8 participants with moderate hepatic impairment~* Cohort 2 will enroll 8-16 healthy participants matched by sex, age, and BMI~* Cohort 3 (optional) will enroll 8 participants with mild hepatic impairment"||||
34045433|NCT04478721|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1.1 to temocillin: meropenem||||
34045434|NCT02923453|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34045435|NCT04156906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045436|NCT00247221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045437|NCT04088695|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial conducted online to compare the effect of a web intervention which will be developed through a web page containing a motivational video and an informative text for potential voluntary blood donors. The motivational video or the informative text will be offered randomly to each participant to evaluate the effect of each of them. The website will be offered through social networks Facebook and WhatsApp.||||
34045438|NCT00641602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045439|NCT05855954|RANDOMIZED|PARALLEL||PREVENTION||NONE||intervention group and control group||||
34045440|NCT00039871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045441|NCT03961321|||COHORT||PROSPECTIVE|||||||
34045442|NCT05918601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045443|NCT02693028|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34045444|NCT04947774|||COHORT||PROSPECTIVE|||||||
34045445|NCT00697944|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34045446|NCT00936143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045447|NCT01799512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045448|NCT04324970|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34045449|NCT03003494|||COHORT||PROSPECTIVE|||||||
34045450|NCT05389566|||COHORT||CROSS_SECTIONAL|||||||
34045451|NCT05791539|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be accomplished through the use of computer-generated random numbers and closed opaque envelopes. Another anesthesiologist who will not be involved in the other parts of the study will open the envelopes to enroll patients. and both patients and outcome assessors will be blinded to the assignment of groups.||t|f|t|f
34045452|NCT06568822|||OTHER||CROSS_SECTIONAL|||||||
34045453|NCT05515978|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this pragmatic trial, a 2-step electronic consent approach to enroll patients in the metformin + lifestyle modification or lifestyle modification arms will be used. The initial consent will invite patients to join a cohort to study prostate cancer and it will describe the general pragmatic framework under which this protocol will take place with the opportunity for additional trial opportunities. Subsequent consents will be limited to those who consented to the initial project and are found to be eligible for a specific trial (e.g. this metformin/lifestyle intervention trial). Within the framework of this pragmatic trial and electronic self-consent, these subsequent consents will be more focused and limited to the specific involvement in the arm in which they have been randomized. This general approach will follow the trials within cohorts paradigm.||||
34045454|NCT00174564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045455|NCT02249728|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34045456|NCT06461299|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center, prospective, pilot study to evaluate the efficacy, safety, and tolerability of sarecycline (Seysara) for periorificial dermatitis. This will be a four-week open-label study using sarecycline to treat POD.||||
34045457|NCT01175096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045458|NCT00839683|RANDOMIZED|CROSSOVER||||NONE||||||
34045459|NCT04861350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045460|NCT05355584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Individuals aged 18-25 years who volunteer to participate in the study will be included in this study and randomly assigned to 3 groups. After the demographic information of the volunteers is obtained and their dominant upper extremities are determined, the shoulder isometric muscle strength will be measured with a hand dynamometer. The back scratch test will be used to evaluate the shoulder flexibility of the participants, the modified push-up test will be used to evaluate the endurance, and the upper extremity Y balance test will be used to evaluate the shoulder dynamic balance. Then, cryotherapy will be applied on the shoulder for 10 minutes in Group 1, 15 minutes in Group 2 and 20 minutes in Group 3.After the application, the same measurements will be repeated and the values before and after the application will be compared.|t|f|f|f
34045461|NCT02078440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045462|NCT03684239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045463|NCT00419016|||DEFINED_POPULATION||OTHER|||||||
34045464|NCT05910138|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34045465|NCT03537976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045466|NCT00327808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045467|NCT00538525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045468|NCT06143943|||CASE_CONTROL||RETROSPECTIVE|||||||
34045469|NCT03574272|NA|SINGLE_GROUP||OTHER||NONE||||||
34045470|NCT03475862|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Double-blind, double-dummy|4-way single-dose crossover with an exploratory 5th treatment arm|t|t|t|t
34045471|NCT00098137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045472|NCT02587390|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34045473|NCT02139202|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34045474|NCT05827133|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34045475|NCT00464490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045476|NCT04274036|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34045477|NCT01548625|||COHORT||PROSPECTIVE|||||||
34045478|NCT05823064|||OTHER||PROSPECTIVE|||||||
34045479|NCT01037517|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045480|NCT01492374|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124243|NCT05029310|NA|SINGLE_GROUP||TREATMENT||NONE||Patients already taking tacrolimus start treatment with patiromer. After seven days tacrolimus kinetics are studied. Seven days after discontinuation of patiromer, tacrolimus kinetics are repeated.||||
34124244|NCT03330444|||COHORT||PROSPECTIVE|||||||
34124245|NCT01615562|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124246|NCT04991493|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The anesthesia provider will be blinded to the intervention group allocation. All patients will be blinded. The primary investigator will be blinded. The resident researcher who will be the outcome assessor will also be blinded. The care provider will be blinded.||t|t|t|t
34124247|NCT02560727|||COHORT||PROSPECTIVE|||||||
34124248|NCT03446963|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34124249|NCT02640027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124250|NCT00932074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124251|NCT06361004|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with Treatment-refractory Tourette's syndrome (TR-TS)||||
34124252|NCT05088044|NA|SINGLE_GROUP||PREVENTION||NONE||one group pre-test post-test design.||||
34045481|NCT04614181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124253|NCT00977483|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34124254|NCT01361217|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124255|NCT01573650|||CASE_CONTROL||PROSPECTIVE|||||||
34124256|NCT05276414|||CASE_ONLY||CROSS_SECTIONAL|||||||
34124257|NCT00001040||||TREATMENT||||||||
34124258|NCT02982655|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124259|NCT02383862|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34124260|NCT04725019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34124261|NCT04230616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124262|NCT04379154|NA|SINGLE_GROUP||OTHER||NONE||||||
34045482|NCT04284098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124263|NCT03495726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124264|NCT05547386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124265|NCT05177042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124266|NCT01992224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124267|NCT06120686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||random selection to two groups (study group and control group)|t|f|t|t
34124268|NCT00680628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124269|NCT01791517|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34124270|NCT04361292|RANDOMIZED|PARALLEL||OTHER||TRIPLE|From the randomization list, an independent secretary who was blind to patients' identities applied the allocation in consecutive order. Patients allocated into group A, and group B. Care provider and investigator were blind to patient groups. Participants were informed about the timing of abstinence intervals, but they did not know which groups they were allocated to.|One hundred twenty eligible couples were prospectively randomized into two groups on the second day of the cycle just before starting the treatment protocol. Randomization was performed according to a computer-generated random number list at a ratio of 1:1. From the randomization list, an independent secretary who was blind to patients' identities applied the allocation in consecutive order. Patients allocated into group A, had an ejaculatory abstinence period of one day, whereas patients allocated into group B had an ejaculatory abstinence period of three days.|t|t|t|f
34124271|NCT01187654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124272|NCT06184178|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34124273|NCT03415503|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34124274|NCT05140356|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34124275|NCT01637896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34124276|NCT00100737|RANDOMIZED|||TREATMENT||NONE||||||
34124277|NCT05726331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124278|NCT03457610|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, single arm, single center study||||
34124279|NCT03386435|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||study group : remote ischemic preconditioning control group : none|t|f|t|f
34124280|NCT02334618|||COHORT||PROSPECTIVE|||||||
34124281|NCT01846533|||COHORT||CROSS_SECTIONAL|||||||
34045483|NCT04698330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34045484|NCT06499454|||COHORT||PROSPECTIVE|||||||
34045485|NCT02975388|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34045486|NCT05737381|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Intervention for embryos will be masked when performing the morphokinetic and ROS analysis|Sibling study|t|f|f|f
33736703|NCT06014255|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736704|NCT05022355|||COHORT||PROSPECTIVE|||||||
33736705|NCT00004317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736706|NCT02894203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33736707|NCT05314153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736708|NCT05840965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The data will be coded (pseudonymization). The subject's name or other identifiers will be stored separately from their research data and replaced with a unique code to create a new identity for the subject.~The outcomes assessor will be blind for participants' injury status for the following :~* while conducting kinematic and kinetic data processing,~* while performing muscle size measurements on the ultrasound images,~* while performing statistical analysis (for all outcomes)~There will be no blinding while scoring the following outcomes (because these scores are immediately determined in the presence of the participant) :~* Foot muscle strength~* Foot posture index~* Navicular drop"|Prospective monocentric randomised controlled trial with an asymptomatic control group.|f|f|f|t
33736709|NCT02353312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736710|NCT03670589|||CASE_CONTROL||RETROSPECTIVE|||||||
33736711|NCT01810978|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837143|NCT05792098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837144|NCT03862014|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Two materials on two molars in one patient||||
34045487|NCT05366348|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34045488|NCT00410332|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045489|NCT04675554|||COHORT||PROSPECTIVE|||||||
33736712|NCT05555472|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|"Participants are aware of following the Halt-intervention (with a YIM) but they are not aware of the existence of the other condition. Adolescents in the CAU Halt-condition are not aware of participants following the Halt-YIM condition (and possibly not aware of the YIM approach itself) and vice versa.~The care providers, YIM trained and non-trained professionals, can only include participants for either the experimental or control condition respectively. Whether the adolescent is a participant, only becomes known if the professional explicitly asks the adolescent. After their invitation, adolescents are redirected to give their consent. Actual registration of participants is registered by the researchers. Researchers do not actively communicate which adolescents have registered for the study.~Both the investigator and outcomes assessor are aware of which participant is in which condition but are not directly involved with the participants nor the procedure in the conditions."|Youths will be non-randomly allocated to either a YIM trained Halt professional (N = 31), or a Halt professional not trained in the YIM approach (N = 31). These professionals will implement the Halt-plus-YIM-condition (N =150) or the CAU Halt-condition (N = 150), respectively. Random allocation of cases to Halt professionals was not possible because Halt's distribution office considers individuals' workload. Despite non-random allocation, conditions will be comparable in terms of (1) the professionals who deliver the intervention (i.e., same educational level and from the same region), and (2) case type and severity. Allocation of a youths' case to a professional, is independent of type of offense and its severity as well as the evaluation of number of risk factors present in youth. In addition, due to the equal number of professionals per region, similar distributions of youths per region are expected.||||
33736713|NCT06325462|||COHORT||PROSPECTIVE|||||||
33736714|NCT06663228|||CASE_ONLY||PROSPECTIVE|||||||
33736715|NCT05120219|RANDOMIZED|CROSSOVER||TREATMENT||NONE||According to the objective, the trial is constituted by two study groups: one is food effect assessment group, and another is multiple dose pharmacokinetic assessment group. There will be 18 (food effect cohort) and 10 (multiple dose pharmacokinetics) volunteers to receive the treatment, and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic assessments, with safety and tolerability.||||
33736716|NCT00002604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736717|NCT03331744|||CASE_ONLY||PROSPECTIVE|||||||
33736718|NCT03877393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, and placebo-controlled study|t|t|t|t
33736719|NCT00068055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736720|NCT02458404|||COHORT||PROSPECTIVE|||||||
33736721|NCT05910385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized, controlled, single-blind, two-parallel, bicentric therapeutic trial comparing two referenced surgical techniques|t|f|f|f
33736722|NCT06244316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736723|NCT05975541|||CASE_CONTROL||PROSPECTIVE|||||||
33736724|NCT06556368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants will be randomized 1:1:1 into one of three treatment groups: tarcocimab-ted, tabirafusp-ted or aflibercept.|t|t|t|t
33736725|NCT04524962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736726|NCT00587587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736727|NCT06571279|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736728|NCT01831375|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33736729|NCT03968952|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group cluster will use the SMARThealth Pregnancy training package and mHealth platform. The Control group will have enhanced standard antenatal and postnatal care.||||
33736730|NCT06663657|RANDOMIZED|PARALLEL||TREATMENT||NONE||the patients will be randomized by lottery method and allocated into two intervention groups. Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks. Patients in group B will receive task-oriented training for 30 minutes, sessions for 5 days per week for 8 weeks. Intervention will be applied for 8 weeks it include taking reading 1st at baseline, 2nd reading at 4th week and 3rd reading at 8th week and follow up after 12 weeks||||
33736731|NCT04007536|||COHORT||PROSPECTIVE|||||||
33736732|NCT03726112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A Randomized, Double Blind, Placebo-Controlled Study followed by an open label phase|t|f|t|t
33736733|NCT06661980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"All enrolled 60 patients will be mentioned as two groups; Group 1(n=30):~are the patients who will receive dexmedetomidine. Group 2 (n=30): are the patients who represent the control group."|t|f|t|f
33814897|NCT03430362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Group A will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after. Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after|t|t|t|t
33814898|NCT02734394|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33814899|NCT03937089|||COHORT||RETROSPECTIVE|||||||
33814900|NCT03458416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814901|NCT00157105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814902|NCT03219216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814903|NCT06215326|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study intervention, this study was an open trial and was not blinded to the patients and study executives. Only the outcome assessors and statistical analysts of the study will be blinded.||f|f|f|t
33814904|NCT02859636|||COHORT||PROSPECTIVE|||||||
33814905|NCT01490047|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814906|NCT01219400|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33814907|NCT02010086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814908|NCT00641797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33814909|NCT02408978|RANDOMIZED|PARALLEL||||NONE||||||
33814910|NCT00244426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33814911|NCT02260999|||CASE_CONTROL||PROSPECTIVE|||||||
33814912|NCT06250374|NA|SINGLE_GROUP||OTHER||NONE||||||
34045490|NCT03031483|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34045491|NCT01521286|||COHORT||PROSPECTIVE|||||||
34045492|NCT06337877|||COHORT||PROSPECTIVE|||||||
34045493|NCT03040778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34045494|NCT04755855|||COHORT||PROSPECTIVE|||||||
34045495|NCT04836962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34045496|NCT05067179|||CASE_ONLY||PROSPECTIVE|||||||
34124282|NCT00810875|||CASE_CONTROL||PROSPECTIVE|||||||
34124283|NCT04160312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34124284|NCT03758261|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups of patients will be studied simultaneously. One group will have the intervention of the nerve block in the erector spinae approach and the other group will have the nerve block in the traditional paravertebral approach.||||
34124285|NCT03129464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124286|NCT00083980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124287|NCT03723980|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34124288|NCT06397378|RANDOMIZED|CROSSOVER||OTHER||SINGLE||"The interventions (videos and CDC Fact Sheet) and T0-T2 assessments will be administered online. Videos will be sent out after participants complete T0. One video will be sent out every 3 days and the intervention (4 videos in total) will be completed in 2-week via emails. Participants in the intervention group can watch the videos at their leisure.~A resource kit including available resources to obtain vaccines will be provided to all participants after T2 assessment. We will also provide the video-based intervention to the students in the comparison arm after T2 assessment should they be interested."|t|f|f|f
34124289|NCT01059357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124290|NCT01798888|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34124291|NCT03589287|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The treatment protocol consists of two stages: the first stage is a traditional 3+3 dose-escalation open study design with three cohorts. At the second stage, a total of 6 patients with knee OA will be treated by the cell products of the maximum tolerance dose (MTD) as determined by the results of the first stage.||||
34124292|NCT00104988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124293|NCT01559415|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34124294|NCT04224922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124295|NCT04951102|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The subjects will be clustered in 2 groups of patients and physicians based on participating health care provider and clinic location. Group A will be the intervention group and Group B will be the control group.||||
34124296|NCT00784368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124297|NCT02360852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124298|NCT01276548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124299|NCT03037125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124300|NCT00968773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124301|NCT05137691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Feasibility Randomised Controlled Trial||||
34124302|NCT04512118|||CASE_ONLY||RETROSPECTIVE|||||||
34124303|NCT01533441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34124304|NCT03410069|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124305|NCT01730612|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124306|NCT06393777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This research will be a double blinded study, where the patient (participant) and the statistician will be blind to the treatment groups.|This trial is a randomized clinical trial (parallel design 1:1).|t|f|f|t
34124307|NCT01266330|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34124308|NCT03132558|||COHORT||PROSPECTIVE|||||||
34124309|NCT03775317|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124310|NCT02965989|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34124311|NCT02733003|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34124312|NCT01590368|RANDOMIZED|PARALLEL||||NONE||||||
34124313|NCT02159625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124314|NCT00427011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124315|NCT00976157|||CASE_ONLY||PROSPECTIVE|||||||
34124316|NCT04004767|||COHORT||PROSPECTIVE|||||||
34124317|NCT04630925|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34124318|NCT05035043|NA|SINGLE_GROUP||OTHER||NONE||||||
34124319|NCT05745610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124320|NCT05871580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One group will be lasered off and the other group will be lasered on.||t|f|f|t
34124321|NCT03457714|||COHORT||PROSPECTIVE|||||||
34124322|NCT01670422|||CASE_CONTROL||RETROSPECTIVE|||||||
34124323|NCT03306433|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial design is triple-blinded. The manufacturer will deliver the blinded treatments in identical bottles labelled A and B, therefore, neither the patient nor the clinician will know which treatment is rendered to each tooth. However, the no sealant control will not be blinded. Blinding will continue to be present during the histological portion of the experiment as the assessors will not be aware of which sealant was used to treat each tooth. After a blinded assessment, blinds will be lifted when between-group analysis is performed.|prospective, paired randomized control trial for which treatment (no sealant, UDMA control, UDMA-K18 sealant) will be applied clinically and evaluated on extracted teeth in laboratory conditions.|t|t|t|t
34124324|NCT00222144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124325|NCT03248388|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34124326|NCT04321512|||CASE_CONTROL||PROSPECTIVE|||||||
34124327|NCT03175731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124328|NCT04532840|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will be delimited in the following aspects:~1. Subjects:~   Sixty patients suffering from hypertrophic scar will be randomly divided into two equal groups each one has 30 patients.~2. Equipment and tools:~2.1. Measurement equipment: Vancouver scar scale. MAPS (Matching Assessment of Scars and Photographs) (Masters et al., 2006). 2.2. Therapeutic equipment: Gymna Cryoflow ICE-CT. Temperature resistant polymide tape (48 wide)"||||
34124329|NCT05067205|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124330|NCT00825994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124331|NCT05527600|||COHORT||PROSPECTIVE|||||||
34124332|NCT05696847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34124333|NCT02377557|||COHORT||PROSPECTIVE|||||||
34124334|NCT05674812|||COHORT||PROSPECTIVE|||||||
34124335|NCT00856323|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124336|NCT03673540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124337|NCT06462287|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34124338|NCT04138511|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34124339|NCT05707338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045497|NCT04120077|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Bottle sets (three bottles per set) of the two nutritional supplements and identically packaged placebo will be coded by number and randomly assigned by the supplement manufacturer (ZeaVision, LLC, Chesterfield, MO) to enrolled subjects and distributed at co-investigators' offices. All investigators and enrolled subjects will be naïve as to subjects' supplement/placebo status throughout the study period and during all data analysis by an independent bio-statistician. Subjects will be randomly assigned to take either placebo (group 1), EyePromise DVS™ (group 2) or EyePromise DVS™ combined with EyePromise EZTears™ (group 3) in a ratio of 1:1:1.|Parallel intervention to assess changes in metabolic control, diabetic retinopathy status and patient knowledge with diabetes self-management education (DSME) in isolation, DSME combined with DVS supplement, or DSME combined with both DVS supplement and omega-3 based supplement (EZTears)|t|t|t|t
34045498|NCT05711251|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34045499|NCT00471341|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045500|NCT04042714|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with metastatic high-grade extra pulmonary NEC, who failed front line treatment with a platinum containing regimen, who meets the enrollment criteria will receive TAS-102 as a single agent until either progression or unacceptable toxicity.||||
34045501|NCT01265745|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34045502|NCT00903708|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045503|NCT04122703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Patients in both PTNS and Sham groups will come to the clinic once a week for 30 sessions, and will not know their group assignment until the end of the study.~All the interventions will be performed by the sub-investigator. The care providing physician will not know the group assignment of the patients."|We will be recruiting 66 patients, who will be randomized (1:1) to either the PTNS group or the Sham group.|t|t|f|f
34045504|NCT01059422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045505|NCT00452582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045506|NCT03359759|||COHORT||PROSPECTIVE|||||||
34045507|NCT02097238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045508|NCT04027725|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34045509|NCT05704166|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The biostatistician (Chen Jinhua), who is not related to the statistical analysis of the data management performed in this experiment, used statistical software on the computer to generate random number tables by simple randomization according to the ratio of 1:1 between the experimental group and the control group. According to the existing random number table, the drug was coded by personnel unrelated to this study under the supervision of the clinical trial institution of the unit, and the random number and drug number assigned by the researcher according to the order of case enrollment were administered. The random number table and drug code are sealed together in the blind base as confidential data, and the blind base is kept in two sealed copies in the drug clinical research institution of the sponsor and the main investigator||t|f|t|f
34045510|NCT03860272|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose escalation||||
34045511|NCT06255756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34045512|NCT01327170|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045513|NCT01435304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045514|NCT02955355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045515|NCT04065984|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|"Participants will either receive a device providing active treatment levels of stimulation or a placebo device providing sub therapeutic electrical stimulation.~The main outcome is change in muscle mass of CT at 3 to 6 months. These scans will be assessed by a radiologist using automated software, the radiologist is blinded to which trial arm the patient was in."||t|f|f|t
34045516|NCT05485168|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34045517|NCT03312387|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34045518|NCT04740827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34045519|NCT01948193|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34045520|NCT03806855|||CASE_ONLY||RETROSPECTIVE|||||||
34045521|NCT01788527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045522|NCT01466504|||COHORT||PROSPECTIVE|||||||
34045523|NCT00502970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045524|NCT05486091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045525|NCT04346667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045526|NCT01217164|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34045527|NCT00546065|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34045528|NCT05486533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the research, participants and researchers cannot be blinded. Analyzes will be made by a biostatistician independent of the research and the statistician will be blinded.|Prospective, parallel, three-arm randomized controlled clinical trial|f|f|f|t
34045529|NCT04973969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045530|NCT03002558|||COHORT||PROSPECTIVE|||||||
34045531|NCT05468684|||COHORT||PROSPECTIVE|||||||
34045532|NCT05648942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045533|NCT01861652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045534|NCT02962453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34045535|NCT03990883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|subject- and evaluator-blinded|Pivotal study|t|f|f|t
34045536|NCT01609855|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34045537|NCT02017847|||||CROSS_SECTIONAL|||||||
34045538|NCT01454310|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045539|NCT01718535|||||PROSPECTIVE|||||||
34045540|NCT02926157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045541|NCT05641142|NA|SINGLE_GROUP||OTHER||NONE||cohort study||||
34045542|NCT05550454|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is a study conducted by random assignment to two groups of manual ventilation and automatic mechanical ventilation.||||
34045543|NCT05975333|NA|SINGLE_GROUP||OTHER||NONE||||||
34045544|NCT04463420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045545|NCT00248365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045546|NCT02451592|||COHORT||RETROSPECTIVE|||||||
34045547|NCT01859065|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34045548|NCT03231995|NA|SINGLE_GROUP||OTHER||NONE||||||
34045549|NCT03620825|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34124340|NCT02797912|||COHORT||CROSS_SECTIONAL|||||||
34124341|NCT00753948|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124342|NCT02974608|||COHORT||CROSS_SECTIONAL|||||||
34124343|NCT00867646|||CASE_ONLY||PROSPECTIVE|||||||
34124344|NCT00421512|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124345|NCT05067881|||CASE_ONLY||RETROSPECTIVE|||||||
34124346|NCT04336241|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1 - Dose Escalation - Patients will be enrolled into three sequential dose level cohorts.~Part 2 - Dose expansion - Patients will receive a fixed dose of RP2 in combination with Nivolumab.~Part 3 - Patients will receive four doses of RP2 monotherapy"||||
34124347|NCT04663594|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two arm study, 1:1 randomisation (stratified by gender)|f|f|f|t
34124348|NCT06410989|||COHORT||PROSPECTIVE|||||||
34124349|NCT03218839|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The study is a one arm, open label, prospective, cohort field study to assess the safety and acceptability of PrePex device circumcision device when performed by certified PrePex circumcision providers (physicians \& nurses) in a HIV-infected male population.||||
34124350|NCT04467814|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34124351|NCT02264613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124352|NCT04096586|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34124353|NCT04923243|||CASE_CONTROL||PROSPECTIVE|||||||
34124354|NCT05358743|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34124355|NCT00185237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124356|NCT01900067|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124357|NCT01984047|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34124358|NCT00817934|||CASE_ONLY||PROSPECTIVE|||||||
34124359|NCT03573245|||COHORT||PROSPECTIVE|||||||
34124360|NCT05634330|RANDOMIZED|PARALLEL||TREATMENT||NONE||two group. one of group for exercise and the other group is for control||||
34124361|NCT00190073|||CASE_CONTROL||OTHER|||||||
34124362|NCT00375466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814913|NCT04099186|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|inclusion in each arm was made by pulmonary embolism response team not by the investigators . also at level of follow up assessment was done by blinded investigators.|non randomized case control trial|f|f|t|t
34124363|NCT00980148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124364|NCT02616939|||CASE_ONLY||PROSPECTIVE|||||||
34124365|NCT03886493|NA|SINGLE_GROUP||TREATMENT||NONE||Men will be treated with dupilumab 600 mg s.q. on day 1, and then 300 mg s.q. on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. Fourteen days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints. Follow-up evaluation for adverse events will occur 30 days and 60 days after surgery. Patients will then be followed by their urologists according to standard institutional practices, but will require PSA evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.||||
34124366|NCT02255539|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34124367|NCT05410418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124368|NCT05171972|||COHORT||PROSPECTIVE|||||||
34124369|NCT00126152|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
34124370|NCT06235918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124371|NCT06103344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814914|NCT04650919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814915|NCT01680315|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33814916|NCT03572907|||COHORT||PROSPECTIVE|||||||
33814917|NCT04995601|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will have 2 groups, intervention (RF MAC-group 2) and control (usual care for DVT prevention and mobility-group 1) in postoperative total joint replacement patients at two hospitals.||||
33814918|NCT03170778|||CASE_ONLY||PROSPECTIVE|||||||
33814919|NCT01790659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814920|NCT05511389|RANDOMIZED|PARALLEL||TREATMENT||NONE||With a partial factorial randomization to manual pressure versus not (second intervention) if the first randomized attempt is unsuccessful at restoring normal heart rhythm||||
33814921|NCT03923556|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33814922|NCT01648491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814923|NCT04614688|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814924|NCT01155674|||CASE_CONTROL||PROSPECTIVE|||||||
33814925|NCT03798977|||OTHER||CROSS_SECTIONAL|||||||
33814926|NCT03068741|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The study drug and placebo are prepared in identical masked containers.|"This is a 2x2 factorial RCT, with simultaneous randomization of individual patients into 2 randomized controlled trials.~The first RCT compares administration of 1g of intramuscular ceftriaxone versus placebo. In this RCT, participants, care providers, investigators, and outcome assessors will all be masked to the treatment allocation.~The second RCT compares a liberal fluid resuscitation (up to 2litres of intravenous 0.9% saline) versus conventional resuscitation (administration of intravenous 0.9% saline, started only when systolic blood pressure is \<90mmHg and only continued until systolic blood pressure is \>= 100mmHg). In this RCT, only participants and outcome assessors will be masked."|t|t|t|t
33814927|NCT04109651|RANDOMIZED|PARALLEL||OTHER||SINGLE|"The last data were collected nurses from primary health center (not researher) who did not know anything about participants of experiment and control group.~Data recorded on the computer by the assistant investigator without specifying the experiment and control group.~The experimental and control groups codified by the co-investigator. The analysis of the data encoded by the groups was done by a statistical expert. Data collectors, statistical analyzes and report writing were blinded."|Interventional (Clinical Trial)|f|f|f|t
33814928|NCT05971199|NA|SINGLE_GROUP||TREATMENT||NONE||fruquintinib+sintilimab+TACE||||
33814929|NCT03733574|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33814930|NCT03577054|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessor at analysis stage will be masked to allocation of participants|Parallel Assignment|f|f|f|t
33814931|NCT01995253|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124372|NCT06512610|||COHORT||RETROSPECTIVE|||||||
34124373|NCT00142792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33814932|NCT06476496|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736734|NCT06283628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|We will do computer randomization for the sides for each approach for all the subjects. The subjects will be assigned numbers, and the particular procedural approach for each side will be concealed in the numbered envelopes. The numbers on the envelopes will correspond to the numbers assigned to the patients. The envelopes will be opened by a treating physician in the procedure room. The patient and the assessor (who will not be the treating physician) will not know which procedural approach was used for the sides.|The subjects with bilateral low back pain will undergo radiofrequency ablation of the lumbar medial branch nerves using one approach (traditional) on one side and different approach (parasagittal) on the other side. One arm will use the traditional approach on the left and the parasagittal approach on the right. The other arm will use parasagittal approach on the left and the traditional approach on the right,|t|f|f|t
33736735|NCT00244244|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33736736|NCT02120339|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33736737|NCT03970109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|This study is a 3-arm, double-blind, randomized, placebo-controlled, parallel group, 3-site study designed to assess the effects of ANS-6637 as compared with placebo on responses to in vivo alcohol cue exposure in the human laboratory setting.|t|t|t|t
33736738|NCT02501889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736739|NCT03747484|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33736740|NCT02598349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736741|NCT05217368|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736742|NCT03372408|||COHORT||RETROSPECTIVE|||||||
33736743|NCT06664281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33837145|NCT04301570|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34124374|NCT04912544|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
34124375|NCT05508646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124376|NCT02527473|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34124377|NCT01820806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124378|NCT04065698|NA|SINGLE_GROUP||OTHER||NONE||||||
34124379|NCT04910152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124380|NCT01369199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124381|NCT06116981|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: Conservative Treatment Group Grou 2: Conservative Treatment + High Induction Magnetic Field Therapy||||
34124382|NCT02271893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124383|NCT06302465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124384|NCT03159910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessor will be masked with respect to mechanical shoulder exposures. Statistical analyses will be performed blinded to intervention arm.||f|f|f|t
34124385|NCT05624983|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||one group of cases (children with language disorder) one group of control (children without language disorder)||||
34124386|NCT02359006|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34124387|NCT05243628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124388|NCT01082848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124389|NCT00002170||||TREATMENT||||||||
34124390|NCT06375525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124391|NCT00856609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124392|NCT00548197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124393|NCT01669746|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34124394|NCT01778595|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34124395|NCT00614133|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34124396|NCT05996393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124397|NCT02051478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34124398|NCT04268069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124399|NCT00811954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124400|NCT00148863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124401|NCT01327235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045550|NCT05824702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware of the other condition|A pilot randomized clinical trial of behavioral intervention|t|f|f|f
34045551|NCT03356938|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34045552|NCT06089343|||COHORT||RETROSPECTIVE|||||||
34045553|NCT06275789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045554|NCT05899283|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045555|NCT00208169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045556|NCT05043025|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34045557|NCT01401881|||COHORT||PROSPECTIVE|||||||
34045558|NCT00288366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045559|NCT04121130|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045560|NCT03649061|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Insufficient responders to a COBRA-Slim strategy, defined as not reaching low disease activity based on DAS28 CRP from week 8 until week 32 or not reaching remission based on DAS28 CRP at week 32, will be randomly assigned to one of the two arms.~Randomization will be balanced according to time-point of randomization, baseline (BL) disease activity and Anti-Citrullinated Protein Antibody (ACPA) and Rheumatoid Factor (RF) status to ensure comparability of the treatment groups with respect to these prognostic variables."||||
34045561|NCT00877487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045562|NCT05061940|||CASE_ONLY||RETROSPECTIVE|||||||
34045563|NCT04637984|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34045564|NCT06217666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124402|NCT00005903||||TREATMENT||||||||
34124403|NCT02599480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124404|NCT00934583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124405|NCT00000553|RANDOMIZED|FACTORIAL||PREVENTION||||||||
34124406|NCT03019887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124407|NCT00224965|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34124408|NCT04510467|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124409|NCT03565172|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The methodology used is : Single Case Experimental Design (SCED).||||
34124410|NCT04380623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34124411|NCT01024348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124412|NCT03372161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124413|NCT01370304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814933|NCT05910359|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter prospective cross-sectional interventional study without drug nor device||||
33736744|NCT06081166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, two-cohort, fixed sequence, drug-drug interaction study||||
33736745|NCT04487340|||CASE_ONLY||PROSPECTIVE|||||||
33736746|NCT04577092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Randomized controlled study|t|f|f|t
33736747|NCT03509948|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33736748|NCT02356835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736749|NCT05078645|RANDOMIZED|CROSSOVER||OTHER||NONE||Pilot study with a crossover design. Half of the patients will use the Maya on the first, third and fifth day of their admission and will not use the maya on the second fourth and sixth day (group 1). The other half will use the Maya on the second, fourth and sixth day of their admission and will not use the maya on the first, third and fifth day (group 2). Group allocation will be randomised.||||
33736750|NCT01318564|||COHORT||PROSPECTIVE|||||||
33736751|NCT02109588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33736752|NCT00497926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736753|NCT03808610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736754|NCT02809976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736755|NCT03377348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736756|NCT06664268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736757|NCT02489981|||COHORT||PROSPECTIVE|||||||
33736758|NCT02256046|NA|SINGLE_GROUP||SCREENING||NONE||||||
33736759|NCT01639079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736760|NCT03285646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736761|NCT04205279|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled design to compare the effect of three different perturbation based training devices on the reactive balance control among healthy young adults, healthy older adults and person with stroke.||||
33736762|NCT05155969|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736763|NCT04709237|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33736764|NCT05067140|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33736765|NCT01940705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736766|NCT04221295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group allocation will not be indicated in data analyzed by the outcome assessors.||f|f|f|t
33736767|NCT04840758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736768|NCT00309998||||TREATMENT||NONE||||||
33736769|NCT00647855|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33736770|NCT06040749|NA|SINGLE_GROUP||OTHER||NONE||||||
33736771|NCT03520491|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a pilot study designed to evaluate neoadjuvant nivolumab and nivolumab in combination with ipilimumab in patients with muscle-invasive bladder cancer (MIBC) or urothelial cancers of the upper urinary tract (ureter or renal pelvis) \[UTUC\], who are ineligible for treatment with cisplatin-based chemotherapy. The study is designed with three sequential 15-patient cohorts.||||
33736772|NCT05540392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736773|NCT04809129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736774|NCT06653894|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33736775|NCT05770544|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736776|NCT03621943|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Neurodevelopmental providers will be blinded to the randomization of the toddler during the examination.|Randomization assignment was determined at time of enrollment in the primary study (Umbilical Cord Milking in Nonvigorous Infants Study NCT:03631940). The primary study model was a cluster randomized crossover trial.|f|f|f|t
33736777|NCT01181895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736778|NCT06663579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33736779|NCT06461572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be randomized control trial in which non probability convenient sampling will be used. two groups of 7-12 years of age will be perform in which participants will be randomly divided. Group A will receive conventional therapy. Group B will receive Together with conventional treatment, this group will engage in power ball exercises for neck stability and strengthening.|t|f|f|f
33736780|NCT00445614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33736781|NCT04337554|||OTHER||CROSS_SECTIONAL|||||||
33736782|NCT03384667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A randomized, double-blind, placebo-controlled trial|t|t|t|t
33736783|NCT00827892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736784|NCT03276234|||OTHER||PROSPECTIVE|||||||
33736785|NCT04106791|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||SINGLE GROUP ASSIGNMENT||||
33814934|NCT04841655|||COHORT||PROSPECTIVE|||||||
33736786|NCT04173338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736787|NCT01383681|||CASE_ONLY||RETROSPECTIVE|||||||
33736788|NCT06131411|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736789|NCT05966025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736790|NCT05762107|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||The participant will be randomized to receive placebo and one of three dose levels of ZT-01 in a crossover design|t|t|t|t
33736791|NCT03383588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33736792|NCT04917575|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33736793|NCT04952766|NA|SINGLE_GROUP||OTHER||NONE||"All participants wil have at each of the 4 visits (for patients starting at month 1) or 5 visits (for patients starting at month 0):~1. a venipuncture sample of 2 dry tubes of 7 mL (less than 30 mL in total) to make up 3 aliquots and~2. a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute."||||
33736794|NCT05343611|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736795|NCT04886141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814935|NCT06296784|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label cross-over randomized controlled trial (two arms)||||
33736796|NCT06477796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be blinded to the intervention by way of study personnel's description. Subjects will be told that both devices may or may not be active and thus, will be unaware that all light boxes are active and all negative ion generators are inactivated.|Subjects will be randomized to receive MBLT or a sham/no-light control. Subjects randomized to receive MBLT will be given a light box (LightPad, Aurora Light Solutions) to take home. Subjects randomized to receive the sham/no-light control will be given a modified negative ion generator.|t|f|f|f
33736797|NCT00710502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736798|NCT04048460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736799|NCT06165029|||COHORT||PROSPECTIVE|||||||
33736800|NCT03924817|||COHORT||PROSPECTIVE|||||||
33736801|NCT01105247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736802|NCT04512937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736803|NCT00059904||||TREATMENT||NONE||||||
33736804|NCT06663891|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33736805|NCT06369571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736806|NCT00188526|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33736807|NCT04108039|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||44 women undergoing IVF treatments due to infertility, will be asked to participate in a trial in which they will undergo 2 ovarian stimulation protocols with recombinant follicle stimulating hormone (rFSH): the first one using a flexible antagonist protocol to suppress the endogenous LH rise and the second using oral micronized progesterone 200 mg/day from day 1 of stimulation.||||
33736808|NCT04603430|||COHORT||OTHER|||||||
33736809|NCT05967806|||OTHER||PROSPECTIVE|||||||
33736810|NCT00452881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736811|NCT04604522|||COHORT||PROSPECTIVE|||||||
33736812|NCT02359266|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736813|NCT03112317|||COHORT||RETROSPECTIVE|||||||
33736814|NCT02139163|||COHORT||PROSPECTIVE|||||||
33736815|NCT06018636|||COHORT||PROSPECTIVE|||||||
33736816|NCT06662877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736817|NCT02283216|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33736818|NCT04120389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736819|NCT04471181|||CASE_ONLY||PROSPECTIVE|||||||
33736820|NCT03109275|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33736821|NCT00295672|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736822|NCT06528340|||COHORT||PROSPECTIVE|||||||
33736823|NCT03175042|||COHORT||PROSPECTIVE|||||||
34124414|NCT03154476|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Both the treatment arm (sildenafil) and the placebo arm will receive monthly package of similar pills. Equal number of patients will be randomly assigned to each arm.|Randomized Double-blind Placebo-control study|t|t|t|t
33736824|NCT01064921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736825|NCT02744261|||OTHER||OTHER|||||||
33736826|NCT06293417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814936|NCT04693013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814937|NCT02144883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814938|NCT05997420|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||All hospitals begin the study under the usual care condition. The STAR intervention will be introduced to groups of hospitals at two separate time points approximately six months apart. The sequence of intervention introduction will not be randomized. Once STAR has been introduced at a study hospital, eligible patients will receive STAR during their index hospitalization and extending through 90 days from discharge or date of death.||||
33814939|NCT00274196|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814940|NCT04492085|||COHORT||PROSPECTIVE|||||||
33814941|NCT01642225|||CASE_ONLY||RETROSPECTIVE|||||||
33814942|NCT05940805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Sham Group received the four modalities of the intervention, but these modalities were all inactive. For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used. The patients were blinded to their assigned treatment group. Blinded examiners evaluated patients at baseline, one week post-treatment and three months post-treatment.|Thirty-two subjects diagnosed with a stroke at least six months prior to the study were randomized to receive ten sessions of either the treatment protocol or a sham intervention. The treatment protocol consisted of transcranial low-frequency electrical stimulation using subcutaneous needles over the scalp, paraspinous blocks, spastic muscle needling and functional electrical stimulation. Spasticity, range of motion, pain, functionality and quality of life were evaluated.|t|f|f|t
33814943|NCT03056170|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind||t|t|t|t
33814944|NCT06495463|NA|SINGLE_GROUP||TREATMENT||NONE||"trifluridine / tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~Chemotherapy (choose one) :~oxaliplatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."||||
33814945|NCT02122484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814946|NCT04168450|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33814947|NCT05634161|||OTHER||PROSPECTIVE|||||||
33736827|NCT02233049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736828|NCT06341244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736829|NCT05435599|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE||Patients undergoing liver biopsy for chronic hepatitis b|t|t|t|t
33736830|NCT05345795|||COHORT||RETROSPECTIVE|||||||
33736831|NCT03063541|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|observer blinding|controlled open trial, randomized 1:1|f|f|f|t
33736832|NCT06535204|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736833|NCT04856163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33736834|NCT00485108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33736835|NCT00843791|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33736836|NCT03408106|||COHORT||PROSPECTIVE|||||||
33736837|NCT01922596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045565|NCT03425201|NA|SINGLE_GROUP||OTHER||NONE||Open-label, multicenter, phase I/II dose-escalation study||||
34045566|NCT04429568|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34045567|NCT01168778|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34045568|NCT06436911|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"In Phase 1 up to 50 participants are planned to be randomized 1:1 into one of two groups: either 100 μg intramuscular (IM) injection or 250 μg IM injection. Participants are to receive a single 0.5 mL IM injection of VAX-002 100 μg or 250 μg on Day 0. Follow-up visits will occur on Days 7, 14, 17 (phone call visit), 21, 28, 42, and 180. An interim analysis is planned once all participants in Phase 1 have completed their Day 28 visit to evaluate dose-response and safety to support optimal dose selection for Phase 2.~In Phase 2 approximately 250 participants will be enrolled and will receive a single 0.5 mL IM~injection of the optimal VAX-002 dose (determined in the Phase 1 interim analysis) on Day 0. Follow- up visits will occur on Days 7, 14, 17 (phone call visit), 21, 28, 42, and 180."|t|t|t|t
34045569|NCT04416867|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All pre and post study evaluations will be performed by a single physical medicine and rehabilitation specialist blind to the patients' treatment groups. Patients will be randomised into the groups by a second physical medicine and rehabilitation specialist. PT wil be conducted by a single experienced physiotherapist. All data analysis will be conducted by a PMR specialist blind to the treatment provided.|This study aims to compare the efficacy of RESWT to the recommended conventional PT modalities, including therapeutic US, in the treatment of CTS with regards to nociceptive and neuropathic pain, functionality and nerve conduction study outcomes.|f|f|f|t
34045570|NCT00611572|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34045571|NCT00786981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045572|NCT00902395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045573|NCT00799175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045574|NCT06558383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial. True experimental research design study|t|f|f|f
34045575|NCT02171312|||CASE_CONTROL||PROSPECTIVE|||||||
34045576|NCT01962766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045577|NCT05445635|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34045578|NCT02329314|||CASE_ONLY||RETROSPECTIVE|||||||
34045579|NCT00402688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045580|NCT04998617|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34045581|NCT01600027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045582|NCT04681820|||COHORT||PROSPECTIVE|||||||
34045583|NCT02432612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045584|NCT03318978|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|Deidentified samples will be analyzed by AMS at Lawrence Livermore National Laboratory and the pharmacokinetics determine at Pacific Northwest National Laboratory.||f|f|f|t
34045585|NCT02568293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045586|NCT02085629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045587|NCT06578845|||CASE_ONLY||PROSPECTIVE|||||||
34045588|NCT03570411|||COHORT||PROSPECTIVE|||||||
34045589|NCT00194298|||COHORT||PROSPECTIVE|||||||
34045590|NCT02367027|RANDOMIZED|CROSSOVER||||NONE||||||
34045591|NCT02055989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045592|NCT00665262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045593|NCT03656497|||COHORT||OTHER|||||||
34045594|NCT01762436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045595|NCT00627757|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34045596|NCT05986838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045597|NCT04468347|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34045598|NCT04046510|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|pre filled syringues of ocytocin were given to the care provider who didn't know the exact amount of ocytocin bolus and continious infusion||t|t|f|f
34045599|NCT03442686|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||This study uses a wait list control design. One group of participants will be evaluated before receiving the intervention (in Spring 2018) and compared to those who receive the intervention in Spring 2018. The first group will go on to receive the intervention in Fall 2018.||||
34045600|NCT02764814|RANDOMIZED|PARALLEL||||NONE||||||
34045601|NCT00263939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34045602|NCT05669313|||COHORT||PROSPECTIVE|||||||
34045603|NCT05624021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded study|Randomized controlled Trial|t|f|f|t
34045604|NCT00356135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045605|NCT03924726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34045606|NCT03244930|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-labeled, single-arm study||||
34045607|NCT04854512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124415|NCT01983007|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|t|t|f
34124416|NCT02131662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124417|NCT03729986|||OTHER||CROSS_SECTIONAL|||||||
34124418|NCT02656836|||CASE_ONLY||PROSPECTIVE|||||||
34124419|NCT02393820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124420|NCT02356536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124421|NCT03765125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|test and placebo powder contained in coded blister packages of identical shape and colour Handing out of the assigned powder by a study nurse not involved in the clinical examination and data collection|randomized, double-blind, placebo-controlled 2-arm, parallel group|t|f|t|f
34124422|NCT03017105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124423|NCT00488514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124424|NCT00560092|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34045608|NCT03451383|||CASE_CONTROL||PROSPECTIVE|||||||
34124425|NCT01973868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124426|NCT02548689|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124427|NCT03160456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|No masking|Randomised parallel group controlled clinical trial|f|f|f|t
34124428|NCT01306643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124429|NCT01994681|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124430|NCT00746187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045609|NCT01138813|||COHORT||PROSPECTIVE|||||||
33736838|NCT03569644|NA|SINGLE_GROUP||OTHER||NONE||The study is based on interviews that will be recorded in digital audio and then transcribed literally. The consultation for this research is 45 to 90 minutes long. This prolongs their presence in consultation with the doctor. For this reason, the study was classified as Interventional according to French regulations||||
33736839|NCT03480555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736840|NCT01790412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736841|NCT04116229|NON_RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|Neuroimaging data was processed using automated methods blind to group membership. Blood samples were analyzed by laboratory personnel blind to group membership.|This study employed a single group model in which participants with obesity and participants with normal-weight underwent magnetic resonance imaging, blood draws and cognitive assessment.|f|f|t|t
33736842|NCT03099135|NA|SINGLE_GROUP||OTHER||NONE||||||
33736843|NCT03915548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessments will be administered via telephone by a research assistant blind to group assignment.|The investigators will recruit 300 women over the age of 18 reporting participation restrictions after completing curative treatment for Stage 1-3 breast cancer within the past year. Half of the participants will be randomized to the 4-month BA/PS intervention which consists of 6 weekly telephone calls followed by 3 monthly telephone calls. BA/PS is designed to teach problem-solving and action planning to promote functional recovery. The other half of participants will be assigned to an attention control condition providing education about survivorship topics. This control condition will allow us to account for the effect of time and history, and the non-specific effects of attention|f|f|f|t
33736844|NCT02071576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736845|NCT06314698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33736846|NCT00965900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33736847|NCT02126254|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33736848|NCT06423833|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33736849|NCT04155320|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Outcomes assessor is blinded as to treatment allocation during analyses.||f|f|f|t
33736850|NCT01706952|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33736851|NCT06113042|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33736852|NCT00123981|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736853|NCT04419909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736854|NCT05549674|||COHORT||PROSPECTIVE|||||||
33736855|NCT00716560|||CASE_ONLY|||||||||
33736856|NCT03003520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736857|NCT02209324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736858|NCT04776148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736859|NCT06204393|||COHORT||PROSPECTIVE|||||||
33736860|NCT05889559|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33736861|NCT06523270|||COHORT||PROSPECTIVE|||||||
33736862|NCT03499652|||COHORT||OTHER|||||||
33814948|NCT01266837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814949|NCT04081818|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33814950|NCT01113593|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33814951|NCT00933634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33814952|NCT04950010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33814953|NCT05620199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814954|NCT01962402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814955|NCT02203513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814956|NCT05908136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33814957|NCT03140475|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33814958|NCT04748705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814959|NCT05214248|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33814960|NCT04416100|||COHORT||PROSPECTIVE|||||||
33814961|NCT02174315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814962|NCT03914586|||COHORT||RETROSPECTIVE|||||||
33814963|NCT02869308|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33814964|NCT06376006|||COHORT||PROSPECTIVE|||||||
33814965|NCT02788708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814966|NCT01250223|||COHORT||PROSPECTIVE|||||||
33814967|NCT01424345|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33814968|NCT02980432|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33814969|NCT00621842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33814970|NCT02699398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814971|NCT01648049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814972|NCT04371406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814973|NCT01309815|||COHORT||CROSS_SECTIONAL|||||||
33814974|NCT04527926|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33814975|NCT02346786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814976|NCT06404736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814977|NCT05387629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33814978|NCT06560411|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Study subjects will be blinded to the sequence arm that they are randomized to. Investigators and site study staff will be unblinded. The scorer(s) of the polysomnography will be blinded to which therapy is being used for objective determination of the primary endpoint.|The study is a prospective, multicenter, single-blind, randomized, cross-over study design.|t|f|f|t
34045610|NCT05563779|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Observer bias will be minimized by use of objective endpoints collected in duplicate by \[1\] study personnel blinded to group assignment and \[2\] automated data extraction from the electronic health record.|In the MODE trial, the entire study ICU will be assigned to a single mode for continuous mandatory ventilation and the ICU will switch between volume control, pressure control, and adaptive pressure control every month in a randomly generated sequence (cluster-crossover).|f|f|f|t
34045611|NCT05662254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045612|NCT00331669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34045613|NCT00092625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045614|NCT04160039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045615|NCT00853645|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34045616|NCT02112630|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124431|NCT03291106|||COHORT||PROSPECTIVE|||||||
34124432|NCT03359369|||OTHER||OTHER|||||||
34124433|NCT04691037|||COHORT||PROSPECTIVE|||||||
34124434|NCT01397383|||COHORT||PROSPECTIVE|||||||
34124435|NCT01559246|||CASE_CONTROL||PROSPECTIVE|||||||
34124436|NCT05818826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Pharmacist who does not involve in patient enrollment nor treatment will prepared hydrocortisone or placebo in the identical container, before the study drug will be discontinued from patients , according to their treatment arm.|t|t|t|t
33814979|NCT05917756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-arm randomized controlled trial with an equal allocation ratio (1:1) for the experimental and control groups|f|f|f|t
33814980|NCT00484198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33814981|NCT03117218|||CASE_ONLY||PROSPECTIVE|||||||
33814982|NCT05536440|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33814983|NCT05472532|NA|SINGLE_GROUP||OTHER||NONE||||||
33814984|NCT06080802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33814985|NCT00079235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814986|NCT04463485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33814987|NCT03185143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814988|NCT01979211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33814989|NCT00614900|||||CROSS_SECTIONAL|||||||
33814990|NCT05333757|||COHORT||RETROSPECTIVE|||||||
33814991|NCT04687345|||CASE_ONLY||RETROSPECTIVE|||||||
33814992|NCT01249144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33814993|NCT01285856|NON_RANDOMIZED|PARALLEL||||NONE||||||
33814994|NCT06598774|||CASE_CONTROL||PROSPECTIVE|||||||
33814995|NCT03635801|||COHORT||PROSPECTIVE|||||||
33814996|NCT02558543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33814997|NCT02964234|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33814998|NCT00006214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33814999|NCT00494416|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33815000|NCT05223309|||OTHER||PROSPECTIVE|||||||
33815001|NCT04099576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124437|NCT02524561|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33815002|NCT05029089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815003|NCT02507401|||COHORT||PROSPECTIVE|||||||
33815004|NCT05513729|||CASE_ONLY||PROSPECTIVE|||||||
33815005|NCT00853788|||CASE_CONTROL||PROSPECTIVE|||||||
33815006|NCT04315545|||COHORT||PROSPECTIVE|||||||
33815007|NCT05580809|||CASE_ONLY||RETROSPECTIVE|||||||
33815008|NCT04362618|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Outcome assessors will be blinded to the maximal extent possible. With regard to this, patients will be asked not to communicate with the assessors about the intervention received. The researcher who is responsible for the acute measurements, is not blinded for group allocation but the researcher responsible for the basal measurements is. Both researchers are blinded for the outcome analyses. Furthermore, at the end of each assessment, the success of assessor blinding will be examined by asking whether the assessor thought the participant had received the experimental or control intervention, including the percentage of certainty. The physiotherapists providing BGA will not be involved in providing MST, and vice versa. Additionally, the physiotherapists will be blinded for outcome measures. The statistician will be blinded to the allocation of the treatment groups and statistical analyses will be performed in a blinded manner.|"The patients will be randomly allocated to 12 weeks of either muscle strengthening training (MST), behavioural graded activity (BGA) or control. Randomization will be performed by using the method of randomly permuted blocks, utilising a computer-generated random number sequence. To keep both intervention groups balanced, randomization will be stratified for sex (male versus female) baseline inflammation status (hsCRP\<3mg/L versus hsCRP ≥3mg/L) and baseline central sensitization status (central sensitization inventory (CSI) score \<40 versus CSI score ≥ 40).~A list with patient numbers and the group allocation that results from this randomization procedure will be securely stored and only an independent researcher will have direct access to the randomization list. Patients will be scheduled to receive their first assessment within 1 week of randomisation.~Patients will be recruited in primary care and participating hospitals. Announcements will be placed in newspapers, pharmacies etc."|f|t|t|t
33815009|NCT01732757|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815010|NCT05067816|RANDOMIZED|PARALLEL||PREVENTION||NONE||Effectiveness-implementation hybrid Type 3 study design||||
33815011|NCT04432909|||COHORT||PROSPECTIVE|||||||
33815012|NCT01403727|||CASE_CONTROL||PROSPECTIVE|||||||
33815013|NCT03988855|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815014|NCT04945044|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815015|NCT04014686|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||exercise intervention group, control group||||
33815016|NCT03567356|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label Treatment as Usual vs. Intervention||||
33815017|NCT05483556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant, outcome accessor)||t|f|f|t
33815018|NCT02011789|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33815019|NCT06035627|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815020|NCT01554345|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33815021|NCT03800563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815022|NCT05567848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815023|NCT03703947|||COHORT||PROSPECTIVE|||||||
33815024|NCT02382185|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34124438|NCT04062084|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124439|NCT03116425|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33815025|NCT04610125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815026|NCT04791917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815027|NCT02822092|||CASE_ONLY||PROSPECTIVE|||||||
33815028|NCT02731950|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33815029|NCT04760028|NA|SINGLE_GROUP||OTHER||NONE||||||
33815030|NCT04462159|NA|SINGLE_GROUP||OTHER||NONE||||||
33815031|NCT00521625|||||PROSPECTIVE|||||||
33815032|NCT05642702|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Evaluator Blinded||f|f|f|t
33815033|NCT05992584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815034|NCT06105099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815035|NCT02017509|||COHORT||PROSPECTIVE|||||||
33815036|NCT02820909|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34124440|NCT05335252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124441|NCT06011265|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single Blind|Crossover with a washout of at least 10 days|t|f|f|f
33815037|NCT05828654|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33815038|NCT02543307|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124442|NCT05544435|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34124443|NCT05257928|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124444|NCT02911142|NA|SEQUENTIAL||TREATMENT||NONE||||||
34124445|NCT06284239|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Participants will be informed about the research. However, participants will not know which group they belong to. At the same time, the statistical analysis of the research will be carried out by an independent statistician. Thus, blinding of both the participant and the outcome assessor will be ensured.|"It refers to the intervention group in which the Tell Me game will be played."|t|f|f|t
34124446|NCT03886467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Household clusters (separated geographically) will be randomly assigned to receive either nutrition education or to control status (no education).||||
34124447|NCT01122446|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34124448|NCT05417672|||CASE_ONLY||PROSPECTIVE|||||||
34124449|NCT01680926|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34124450|NCT01763333|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34124451|NCT04203589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is masking.|A parallel randomized controlled study|f|f|f|t
34124452|NCT02814422|||CASE_ONLY||PROSPECTIVE|||||||
34124453|NCT06460038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, placebo controlled trial of tenapanor vs. placebo|t|f|t|f
34124454|NCT02132286|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34124455|NCT00256633|||COHORT|||||||||
34124456|NCT01373190|||CASE_CONTROL||PROSPECTIVE|||||||
34124457|NCT01752556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124458|NCT04677543|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34124459|NCT00337038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124460|NCT04186325|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124461|NCT05259202|||OTHER||RETROSPECTIVE|||||||
34124462|NCT01041950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124463|NCT01881282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124464|NCT00609752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124465|NCT04242706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinded, the two devices have the same appearance.|"Controlled study. Two interventions:~1. Endotracheal tube with evacuation lumen without Bactiguard coating.~2. Endotracheal tube with evacuation lumen with Bactiguard coating."|t|t|t|t
34124466|NCT05712980|||COHORT||PROSPECTIVE|||||||
34124467|NCT04152486|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm, open-label, non-randomized interventional trial of the two dose, Ad26.ZEBOV, MVA-BN-Filo Ebola preventative vaccine||||
34124468|NCT00360958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124469|NCT02921295|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34124470|NCT02250976|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34124471|NCT05460897|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124472|NCT06063681|NA|SEQUENTIAL||TREATMENT||NONE||"The study will follow an accelerated titration dose (ATD) escalation scheme. Single-subject cohorts will open sequentially when previous cohort milestones are met, e.g. completion of the Dose-Limiting Toxicity (DLT) period.~If the single evaluable subject within an ATD cohort experiences a grade ≥ 2 toxicity during the DLT period, the ATD scheme will stop and a traditional 3+3 design will be implemented."||||
34124473|NCT01215656|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34124474|NCT05214066|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124475|NCT05986266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124476|NCT01516632|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124477|NCT03234647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124478|NCT04032925|NA|SINGLE_GROUP||OTHER||NONE||||||
34124479|NCT03101189|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34124480|NCT00041340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124481|NCT03436498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124482|NCT05750108|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34124483|NCT02503449|||COHORT||PROSPECTIVE|||||||
34124484|NCT05695170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Nurses who assess health markers and behaviors pre programs will be masked to group assignment.||f|f|f|t
34124485|NCT03256721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Group A: Apatinib 500mg QD PO d1-21 + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d~Group B: Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d"|t|f|t|f
34124486|NCT01882335|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33815039|NCT03640078|NA|SINGLE_GROUP||OTHER||NONE||||||
33815040|NCT00823966|||CASE_ONLY||PROSPECTIVE|||||||
33815041|NCT02074709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33815042|NCT02697136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124487|NCT05207111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124488|NCT01861665|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Patients are acting as their own control receiving Bupivicaine (Marcaine) on both sides. One arm is pre incision the other arm is post incision.|t|f|f|f
34124489|NCT04602143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participantes are not aware of treatment groups||t|f|f|f
34124490|NCT02817178|NA|SINGLE_GROUP||OTHER||NONE||||||
34124491|NCT04749745|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||This is a pilot study, investigating the effects of single dose L-theanine in Healthy subjects, to further assess the validity and feasibility to study this compound in patient population.|t|f|t|f
34124492|NCT01288157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124493|NCT00506467|||CASE_ONLY||PROSPECTIVE|||||||
34124494|NCT04317235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34124495|NCT04812431|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects with damage to C4-C7 cords diagnosed as AIS-A are administered with PSA-NCAM(+) NPC.||||
33815043|NCT03861884|||COHORT||PROSPECTIVE|||||||
33815044|NCT02081820|||CASE_ONLY||PROSPECTIVE|||||||
33815045|NCT04705779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33815046|NCT03233997|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33815047|NCT01404702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815048|NCT00234585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33815049|NCT01863082|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815050|NCT00042939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815051|NCT06461949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815052|NCT00821093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815053|NCT04989023|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Outcome assessment at baseline and at all follow-up sequence will be conducted by physiotherapists blinded to the group allocation and previous evaluation data of the patient. Participants will blinded to the sham-blood flow restriction application. They will informed that two different percentages of complete occlusion will be evaluated in terms of their effect in pain following low load exercise loading with blood flow restriction.||t|f|f|t
33815054|NCT03701022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815055|NCT01768585|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33815056|NCT03624114|||COHORT||PROSPECTIVE|||||||
34124496|NCT00955474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124497|NCT02722213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124498|NCT03037762|||COHORT||PROSPECTIVE|||||||
34124499|NCT04010097|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34124500|NCT05173974|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
34124501|NCT00974155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124502|NCT02370992|||COHORT||PROSPECTIVE|||||||
34124503|NCT00363311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124504|NCT00447967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124505|NCT03523689|||CASE_ONLY||PROSPECTIVE|||||||
34124506|NCT06046066|NA|SEQUENTIAL||TREATMENT||NONE||||||
34124507|NCT05309681|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124508|NCT04343573|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized (2:1) phase II multicenter trial in patients with leptomeningeal metastases from NSCLC and breast cancer.||||
34124509|NCT02587832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124510|NCT05988918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124511|NCT05444738|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Randomized placebo-controlled triple-blind between-subject design|t|f|t|t
34124512|NCT03100318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124513|NCT04831437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124514|NCT02940340|||COHORT||PROSPECTIVE|||||||
34124515|NCT04815369|||COHORT||PROSPECTIVE|||||||
34124516|NCT04310696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124517|NCT01470222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124518|NCT04872569|NA|SINGLE_GROUP||OTHER||NONE||||||
34124519|NCT06113003|NA|SINGLE_GROUP||TREATMENT||NONE||Pre/Post Trial||||
34124520|NCT06405295|||COHORT||PROSPECTIVE|||||||
34124521|NCT04485845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124522|NCT01456130|NA|SINGLE_GROUP||||NONE||||||
34124523|NCT04523584|||COHORT||PROSPECTIVE|||||||
34124524|NCT02060786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124525|NCT00368030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124526|NCT03155763|||COHORT||RETROSPECTIVE|||||||
34124527|NCT04892030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124528|NCT03202212|RANDOMIZED|PARALLEL||PREVENTION||NONE||30 patients treated with a standard 3-time per week bicarbonate high-flux hemodialysis will be randomized 1:1 to continue the treatment or to be switched to mixed on-line hemodiafiltration for 9 months||||
33815057|NCT00470756|||COHORT||PROSPECTIVE|||||||
34124529|NCT03773003|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Blinding will be made at the probiotics manufacturer's establishment. Neither investigators nor care providers nor patients know their status til the end of the study.|"Double blinded, placebo controlled intervention with probiotics~There are three groups in the study:~1. Tumor disease with fatigue~2. Tumor disease without fatigue~3. Healthy control group"|f|f|t|f
34124530|NCT06416592|||COHORT||PROSPECTIVE|||||||
34124531|NCT03581175|||COHORT||CROSS_SECTIONAL|||||||
34124532|NCT03445767|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34124533|NCT02826616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815058|NCT01543945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815059|NCT04504591|||OTHER||PROSPECTIVE|||||||
33815060|NCT03431649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the researchers don't know which drug taken by the patient and don't know the previous PA pressure||t|f|f|t
33815061|NCT05795283|||COHORT||PROSPECTIVE|||||||
33815062|NCT00286832|||CASE_ONLY||PROSPECTIVE|||||||
33815063|NCT02287948|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815064|NCT05652452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837146|NCT02671500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837147|NCT06404853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837148|NCT05629299|NA|SINGLE_GROUP||OTHER||NONE||||||
34124534|NCT00636844|||COHORT||PROSPECTIVE|||||||
34124535|NCT05163301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||one group will receive computer delivered relapse prevention intervention (RPI); one group will receive person delivered relapse prevention intervention; one group will receive usual care|t|t|t|t
34124536|NCT03596788|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34124537|NCT01115348|||COHORT||PROSPECTIVE|||||||
34124538|NCT03291132|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
34124539|NCT02583347|||COHORT||PROSPECTIVE|||||||
34124540|NCT03509961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124541|NCT01716364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124542|NCT04729348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124543|NCT05922605|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Patients allocated to study groups using computer generates random list \& group assignment is sealed in sequentially numbered opaque envelopes that open after induction of anesthesia.|Parallel Assignment|t|f|t|t
34124544|NCT06167967|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34124545|NCT00257569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124546|NCT05663008|||COHORT||PROSPECTIVE|||||||
34124547|NCT01179308|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34124548|NCT02487953|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34124549|NCT03100448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124550|NCT00712517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124551|NCT02439905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34045617|NCT03382626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective, double-blind, randomized, parallel, controlled study|t|f|t|t
34045618|NCT02329171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045619|NCT05703178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045620|NCT00935402|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34045621|NCT02257489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045622|NCT01450215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045623|NCT02126579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045624|NCT05510362|||COHORT||PROSPECTIVE|||||||
34045625|NCT03547011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, outcome assessors and care providers are not informed with the block type done.|Double blinded randomized study.|t|t|f|t
34045626|NCT06352008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045627|NCT06063070|NA|SINGLE_GROUP||TREATMENT||NONE||Drug: fluzoparib plus Bevacizumab||||
34045628|NCT04150796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045629|NCT06149611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045630|NCT04594772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045631|NCT05333601|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group pilot study||||
34045632|NCT00010010||||TREATMENT||||||||
34045633|NCT01902745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045634|NCT04506463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045635|NCT06032195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient and their legal representatives will be blinded to treatment. All other parties are unblinded.||t|f|f|f
34045636|NCT01902641|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34045637|NCT01811641|||COHORT||PROSPECTIVE|||||||
34045638|NCT00510536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045639|NCT03024957|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34045640|NCT00044629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045641|NCT06587399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045642|NCT03130309|||COHORT||RETROSPECTIVE|||||||
34045643|NCT01927315|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Single blind||t|f|f|f
34045644|NCT01152879|||COHORT||PROSPECTIVE|||||||
34045645|NCT06363773|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, exploratory, prospective, monocentric study||||
34045646|NCT02973503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045647|NCT05410275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045648|NCT05068414|||COHORT||PROSPECTIVE|||||||
34045649|NCT01726907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045650|NCT05883657|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34045651|NCT04128046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045652|NCT02854956|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34045653|NCT00004237|RANDOMIZED|||TREATMENT||NONE||||||
34045654|NCT03445637|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34045655|NCT06278415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045656|NCT05849298|RANDOMIZED|PARALLEL||TREATMENT||NONE||No cross-over allowed||||
34045657|NCT04870385|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomised parallel interventional study model in which there will be 2 groups, an intervention group and a waitlist control group.||||
34045658|NCT03109314|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34045659|NCT00680602|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34045660|NCT05755204|||COHORT||PROSPECTIVE|||||||
34045661|NCT02737930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045662|NCT02972684|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34045663|NCT06362083|||COHORT||PROSPECTIVE|||||||
34045664|NCT00596817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045665|NCT00205556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045666|NCT00513045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045667|NCT02522065|||CASE_CONTROL||PROSPECTIVE|||||||
34045668|NCT01901601|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045669|NCT01118741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045670|NCT04111120|||COHORT||PROSPECTIVE|||||||
34045671|NCT05305417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants don´t know wich intervention receive Investigator (outcome evaluator) don´t know wich intervention evaluate Outcomes Assessor (statistics) don´t know wich arm data evaluate||t|f|t|t
34045672|NCT01152749|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34045673|NCT01947543|||OTHER||PROSPECTIVE|||||||
34045674|NCT05210556|||COHORT||RETROSPECTIVE|||||||
34045675|NCT02771847|||COHORT||PROSPECTIVE|||||||
34045676|NCT03366480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045677|NCT05572957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045678|NCT01348620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045679|NCT01139593|||CASE_CONTROL||PROSPECTIVE|||||||
34045680|NCT06373601|RANDOMIZED|PARALLEL||TREATMENT||NONE||A subject is randomized at a 1:1 ratio either to drug-coated balloon (DCB) angioplasty with a sirolimus-eluting Selution balloon (n=60 subjects) or DCB angioplasty with a paclitaxel-eluting Sequent Please Neo balloon (n=60 subjects).||||
34045681|NCT04493515|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design|t|f|t|t
34045682|NCT03059745|||OTHER||RETROSPECTIVE|||||||
34045683|NCT04237064|||COHORT||PROSPECTIVE|||||||
34124552|NCT05587660|RANDOMIZED|FACTORIAL||TREATMENT||NONE|No masking|Randomization to be done through lottery method and then the allocation to be made in both study groups.||||
34124553|NCT05723744|NA|SINGLE_GROUP||OTHER||NONE|Open-label study|The CS6BP includes a wrist-worn device with a clip connected to the band and is placed over the radial artery or a finger. The device includes a PPG sensor and is connected to ECG cables.||||
34124554|NCT01951898|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34124555|NCT06014307|RANDOMIZED|CROSSOVER||OTHER||SINGLE||SWAP-MEAT Athlete is a randomized crossover trial in which 10 recreational runners and 10 recreational resistance trainers are assigned to one of six possible diet orders. Each diet order contains three phases for 4 to 6 weeks each (4 weeks for universities on the quarter system; 6 weeks for universities on the semester system) -Animal, Plant-Based Meat Alternatives (PBMA), and Whole Food Plant-Based (WFPB)-in random order.|f|f|f|t
34124556|NCT01117194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34124557|NCT01169480|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34124558|NCT05767788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34124559|NCT05225519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124560|NCT00429871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124561|NCT00451399|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34124562|NCT00284180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124563|NCT04038294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|the patient/participants, the treating physician and the outcomes assessor (research assistant will be blinded to the arm of the participant. Only the Mani study coordinator will have known information of arm population||t|t|f|t
34124564|NCT05617118|||COHORT||PROSPECTIVE|||||||
34124565|NCT05394610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators and subjects will be blinded to the randomized arm assignment. Subjects will receive the Active Sana treatment OR Sham-controlled treament. The sham controlled device is physically identical to the active treatment, with pattern of lights and sound varying between the two.|Double blind sham contolled|t|f|t|f
34124566|NCT04564235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124567|NCT00769795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124568|NCT01893255|||COHORT||PROSPECTIVE|||||||
34124569|NCT06121726|||COHORT||PROSPECTIVE|||||||
34124570|NCT01027858|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34124571|NCT04944771|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124572|NCT03153501|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Image guided biopsies Thoracoscopy|||||
34124573|NCT00270127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124574|NCT00153413|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Participants are low income uninsured and underinsured so they must be masked.|||||
34124575|NCT06075875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||prospective, randomized, double blind,single-center study|t|f|t|t
34124576|NCT00209144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124577|NCT01658553|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34124578|NCT05781243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124579|NCT05196750|||COHORT||RETROSPECTIVE|||||||
34124580|NCT04595643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124581|NCT01650948|||COHORT||PROSPECTIVE|||||||
34124582|NCT02073812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124583|NCT02153437|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34124584|NCT00174850|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124585|NCT02652910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124586|NCT03051802|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34124587|NCT01979770|||COHORT||PROSPECTIVE|||||||
34124588|NCT00196677|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34124589|NCT02804490|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34124590|NCT01326806|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34124591|NCT01354223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124592|NCT02980107|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34124593|NCT04326218|NA|SINGLE_GROUP||SCREENING||NONE||Descriptive analysis of patient cohort who will be subjected to specific samples related to the study||||
34124594|NCT05468645|NA|SINGLE_GROUP||OTHER||NONE|Open Label|The subjects fast for at least 10 h before dosing, take orally a suspension prepared with 60 mg of \[14C\]Hemay005 (approximately 100 µCi of radioactivity) and 240 mL of water, and then fast for another 4 h after dosing. One hour of water deprivation is required respectively before and after dosing (except water for dosing).||||
34124595|NCT05325762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The blind group included the principal investigator, and any other participants in the recording, evaluation, analysis, or review of efficacy/safety endpoint data, who were primarily responsible for study operations other than drug administration (e.g., subject screening, efficacy and safety indicator recording, statistical analysis, etc.).|Patients were evaluated with MOAA/S by intravenous administration of propofol, dexmedetomidine, or normal saline until successful sleep (MOAA/S≤2)|t|t|t|t
34124596|NCT02516501|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124597|NCT01969539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124598|NCT00952705|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124599|NCT02985177|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124600|NCT04690218|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34124601|NCT03412825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33837149|NCT00236262|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34124602|NCT01623505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124603|NCT00938262|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34124604|NCT03353662|||COHORT||CROSS_SECTIONAL|||||||
34124605|NCT02970071|||CASE_ONLY||PROSPECTIVE|||||||
34124606|NCT01204645|||COHORT||PROSPECTIVE|||||||
34124607|NCT02818465|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124608|NCT04005586|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the same treatment||||
34124609|NCT00098033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124610|NCT01773954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124611|NCT05915611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815065|NCT05148949|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants and investigators will be kept blinded.|Pulmonary tuberculosis patients will be randomized at a 1:1 ratio to receive two doses of standard dosage CoronaVac plus one dose of double dosage CoronaVac or two doses of standard dosage CoronaVac plus one dose of standard dosage CoronaVac at a schedule of 0, 28, 56 days, respectively. Healthy subjects served as an external control group will be vaccinated with two doses of standard dosage CoronaVac at a schedule of 0, 28 days.|t|f|t|t
33815066|NCT01354080|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815067|NCT03802279|||CASE_CONTROL||PROSPECTIVE|||||||
33815068|NCT05025553|NA|SINGLE_GROUP||TREATMENT||NONE||"In this open trial, each child underwent gut mobilization using a standard protocol with oral administration of PEG (6.9 g/d once a day) for 6 months. Children were observed and behaviorally tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.~At the time of recruitment, Intellectual Quotient (IQ) or Developmental Quotient (DQ) were determined using the Leiter International Performance Scale-Third Edition or the Griffith Mental Development Scales, respectively. Autistic behaviors were assessed using the ADOS-2, and the Children Autism Rating Scales (CARS). Adaptive functioning was assessed using the Vineland Adaptive Behavior Scales-Second Edition"||||
33815069|NCT02985086|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815070|NCT01707914|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33815071|NCT03723902|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815072|NCT06189898|||OTHER||PROSPECTIVE|||||||
33815073|NCT01653509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815074|NCT03434015|||COHORT||PROSPECTIVE|||||||
33815075|NCT03656822|||COHORT||PROSPECTIVE|||||||
33815076|NCT01102426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815077|NCT04113187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815078|NCT06335667|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815079|NCT06420752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind placebo controlled.||t|f|t|f
33815080|NCT02411188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815081|NCT06225063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815082|NCT05253066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815083|NCT05090904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815084|NCT01933776|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815085|NCT01529372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815086|NCT02705885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33815087|NCT03331978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33815088|NCT03122314|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33815089|NCT00795639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815090|NCT02269072|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33815091|NCT03563170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815092|NCT01838707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33815093|NCT00513123|||CASE_ONLY||PROSPECTIVE|||||||
33815094|NCT05681390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815095|NCT03528356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815096|NCT00567606|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815097|NCT04531007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815098|NCT02108496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815099|NCT00905255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815100|NCT01351675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815101|NCT00966706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815102|NCT02501876|||CASE_CONTROL||OTHER|||||||
33815103|NCT00438048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815104|NCT04998825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815105|NCT01074996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815106|NCT06245317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind|effects of Pressure Controlled Ventilation - Volume Guarantee (PCV-VG) mode with volume control ventilation (VCV) and pressure control ventilation (PCV) modes on respiratory mechanics (including the dynamic compliance, PIP, mean airway pressure, driving pressure..etc) and oxygenation in paediatrics laparoscopic surgery.|t|f|f|f
34124612|NCT04111705|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II non-randomized, single group assignment, open-label, multicenter||||
34124613|NCT02746328|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124614|NCT02131311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815107|NCT00857909|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33815108|NCT03647800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will be conducted in 2 parts. The first part of this Phase 1B study is an open-label, multiple dose ascending dose escalation phase to determine the recommended dose (RP2D) level of APVO436 for future Phase 2 studies. The goal of the dose expansion phase of the study (Part 2) is to (i) evaluate the safety and tolerability of APVO436 at the RP2D level when it is used as an adjunct to the standard of care and (ii) obtain a preliminary assessment of the anti-leukemia activity of APVO436-containing experimental monotherapy and combination therapy modalities.||||
33815109|NCT02161588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815110|NCT01694147|||CASE_ONLY||PROSPECTIVE|||||||
33815111|NCT01695044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815112|NCT01697982|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33815113|NCT04583293|||COHORT||PROSPECTIVE|||||||
33815114|NCT02687841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815115|NCT03014024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815116|NCT02907489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815117|NCT02033343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815118|NCT02936401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815119|NCT05967793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33815120|NCT05747352|||COHORT||PROSPECTIVE|||||||
33815121|NCT02450786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815122|NCT02233075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815123|NCT04054245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837150|NCT03427697|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34124615|NCT00876707||PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124616|NCT01079364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815124|NCT04203225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and nurse applied intervention and masked the intervention from the care provider. Separate nurse not caring for the patient, blinded to the intervention, brought in to obtain pain score (outcome)|Single-blinded randomized study; patients are randomized to one of two groups|f|t|f|t
33815125|NCT05360771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815126|NCT02028650|||COHORT||RETROSPECTIVE|||||||
33815127|NCT02693665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815128|NCT00796575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045684|NCT04632082|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-group randomized clinical trial including health professionals and health students suffering from low to moderate levels of anxiety, depression and irritability symptoms during the COVID-19 outbreak, randomized randomized 1:1 to the Telepsychoeducation with personalized videos (2 sessions with a psychologist plus 2 videos a week for 4 weeks chosen based on symptom presentation) or Telepsychoeducation without personalized videos (2 sessions with a psychologist focused on reassurane and aspects of the outbreak).||||
34045685|NCT00977080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045686|NCT00746746|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045687|NCT02530125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045688|NCT06063642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants will be blind to the intervention group assignment until they complete the entire study procedure. An outcome assessor who is blind to this assignment will collect the primary outcome measurement data.|Eligible candidates will be randomly assigned to either receive the experimental feedback intervention or sham feedback intervention.|t|f|f|t
34045689|NCT04454983|RANDOMIZED|CROSSOVER||OTHER||NONE||This study is an open-label, single site, crossover trial comparing LipiFlow Thermal Pulsation System to the iLux System based on patient acceptance, comfort, and preference.||||
34045690|NCT02166398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045691|NCT03668418|||COHORT||PROSPECTIVE|||||||
34045692|NCT03269630|||OTHER||PROSPECTIVE|||||||
34045693|NCT03818633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045694|NCT01864551|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045695|NCT03439761|NA|SINGLE_GROUP||TREATMENT||NONE||PT-112 injection alone-chemotherapy||||
34045696|NCT04017507|||OTHER||RETROSPECTIVE|||||||
34045697|NCT00281788||||TREATMENT||NONE||||||
34045698|NCT05010252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045699|NCT03424902|||CASE_ONLY||CROSS_SECTIONAL|||||||
34045700|NCT05767021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045701|NCT01343680|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34045702|NCT06406907|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34045703|NCT02128373|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045704|NCT06095297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The tester will masked to group assignment.||f|f|f|t
34045705|NCT03825029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045706|NCT04418596|||COHORT||PROSPECTIVE|||||||
34045707|NCT02022384|||CASE_ONLY||PROSPECTIVE|||||||
34045708|NCT01063426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045709|NCT02008474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045710|NCT02880878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045711|NCT03887676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045712|NCT06540638|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single Group Assignment In a pre-operative assessment 1-30 days prior to their scheduled surgery, patients will be asked to participate in our web-based educational program. The program will be delivered on a research laptop/iPad at the clinic. The entire program, including pre- and post-education questionnaires and satisfaction survey should take about 20 minutes to complete.||||
34045713|NCT02882217|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34045714|NCT06491875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045715|NCT01839214|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34045716|NCT05497310|NA|SINGLE_GROUP||TREATMENT||NONE|This is an Open label study|A consecutive sample of 15 patients with newly diagnosed or relapsed APL who have not been previously treated with ATO will be prospectively included in this study.||||
34045717|NCT03883230|||COHORT||PROSPECTIVE|||||||
34045718|NCT03474731|RANDOMIZED|PARALLEL||TREATMENT||NONE||Background and justification: Nearly 29 million Americans (9.3% of the population) have type 2 Diabetes Mellitus (T2DM) and another 86 million are considered prediabetic, 20-30% of whom will develop diabetes within five years.4,5 T2DM disproportionately affects those from lower socioeconomic status (SES) and rural backgrounds. Appalachian residents represent an extreme version of this already vulnerable population, with rates of diabetes 46% higher than national averages.6,7 We have developed, pilot tested (N=41) and refined (N=48 in-depth interviews, 4 focus groups with 31 participants, and 2 CAB meetings with 16 members), a culturally appropriate, feasible, and promising intervention that combines diabetes self-management education and tailored patient navigation intervention.||||
34045719|NCT05601115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34045720|NCT03055312|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045721|NCT03106766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045722|NCT03711682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34045723|NCT00691912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045724|NCT04911023|||COHORT||RETROSPECTIVE|||||||
34045725|NCT02165280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045726|NCT05258279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045727|NCT05175560|||CASE_ONLY||PROSPECTIVE|||||||
33815129|NCT03588195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815130|NCT01438879|||CASE_CONTROL||PROSPECTIVE|||||||
33837151|NCT02839005|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34045728|NCT04724538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045729|NCT06047678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Comparing two groups~1. Normotensive group~2. Hypertension Stage 1 group"|t|t|f|f
34045730|NCT03243669|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34045731|NCT00026494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045732|NCT05416580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045733|NCT01704118|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33736863|NCT05304559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A total of 108 patients were enrolled in this trial (the control group was shared by the two schemes). Research drug (esmolamine) test group: control group was designed at 1:1, 36 cases in each group. Research technique (continuous iliac fascia space block) test group: control group was designed at 1:1, 36 cases in each group.|t|f|f|t
33736864|NCT06663488|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33736865|NCT00857181|||COHORT||PROSPECTIVE|||||||
33736866|NCT03251924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736867|NCT01455324|||CASE_ONLY||CROSS_SECTIONAL|||||||
33736868|NCT01164748|||COHORT||PROSPECTIVE|||||||
33736869|NCT01377974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736870|NCT06276478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33736871|NCT03948685|RANDOMIZED|PARALLEL||TREATMENT||NONE||Carvedilol SR vs. Placebo||||
33736872|NCT01790906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736873|NCT05925517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will be blinded.|In this prospective study, two treatment groups were formed to receive GMI and TENS.|f|f|f|t
33736874|NCT04550481|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736875|NCT02744846|||COHORT||RETROSPECTIVE|||||||
33736876|NCT06599632|NA|SINGLE_GROUP||TREATMENT||NONE||A replicated multiple baselines single-case experimental design with three baseline phases. Baseline randomization into three tiers.||||
33736877|NCT03545126|||CASE_CONTROL||PROSPECTIVE|||||||
33736878|NCT02205892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736879|NCT04086472|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33736880|NCT06460727|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment|It will be Randomized control trial in which non probabilty convenient sampling will be used. Two groups of 6-12 age will be formed in which participants will be randomly divided. Group A will only receive task oriented exercise training on dynamic surface and group B will receive task oriented task training on static surface.|t|f|f|f
33736881|NCT00005758||||TREATMENT||DOUBLE||||||
33736882|NCT02602288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33736883|NCT05435573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All the fluids were prepared according to the group by an anesthetist who will not be involved in data collection. All the bottles were wrapped by opaque cover.|Patients will be randomly allocated via sealed opaque envelops into 2 groups of 17 patients each; crystalloid group and group crystalloid-colloid group|t|f|t|f
33736884|NCT04518735|||CASE_CONTROL||RETROSPECTIVE|||||||
33736885|NCT01696630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33736886|NCT04088461|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33736887|NCT05910762|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33736888|NCT04065347|||COHORT||PROSPECTIVE|||||||
33736889|NCT04380584|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736890|NCT06245070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736891|NCT01845155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736892|NCT03756220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multi-center, Double-blinded, Randomized, Controlled Study|t|t|t|t
33736893|NCT00627406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736894|NCT05379959|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33736895|NCT05080582|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33736896|NCT06664125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736897|NCT05838729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736898|NCT02982473|||COHORT||RETROSPECTIVE|||||||
33815131|NCT05809856|NA|SINGLE_GROUP||TREATMENT||NONE||Non-inferiority analysis with standard of current medical care||||
33815132|NCT02736175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815133|NCT03639649|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33815134|NCT01019824|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815135|NCT02485288|||COHORT||PROSPECTIVE|||||||
33815136|NCT04889326|||COHORT||RETROSPECTIVE|||||||
33815137|NCT04402125|RANDOMIZED|CROSSOVER||TREATMENT||NONE||80 participants are assigned to receive TEAM, and 80 participants are assigned to wait list||||
33815138|NCT05640245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815139|NCT00075699|RANDOMIZED|||TREATMENT||||||||
33815140|NCT02492126|||CASE_ONLY||PROSPECTIVE|||||||
33736899|NCT01819337|||COHORT||PROSPECTIVE|||||||
33736900|NCT02161341|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736901|NCT05621239|||OTHER||RETROSPECTIVE|||||||
33736902|NCT01111656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736903|NCT02321579|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33736904|NCT06526884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized encouragement trial||||
33736905|NCT01085110|||CASE_ONLY|||||||||
33736906|NCT02220010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736907|NCT02558608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736908|NCT04527068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736909|NCT04613297|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736910|NCT06344065|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33736911|NCT05933837|||COHORT||PROSPECTIVE|||||||
33736912|NCT04097379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736913|NCT03755024|||COHORT||PROSPECTIVE|||||||
33815141|NCT05082948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815142|NCT06432959|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants will be randomized to treatment as usual (i.e., CBT or DBT) or treatment-as-usual plus positive affect promoting activities (i.e., CBT with PAPA, DBT with PAPA). Randomization will occur within clinic (i.e., one clinic provides CBT, the other provides DBT). In the clinic providing CBT for depression, a total of 50 participants will be randomized (25 each to CBT or CBT with PAPA). In the clinic providing DBT, 40 participants will be randomized (20 each to CBT or CBT with PAPA). Given the treatments under investigation, neither the interventionist nor the participant could be kept unaware of condition.|Randomized Controlled Trial||||
33840182|NCT03408977|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33840183|NCT04364100|||OTHER||PROSPECTIVE|||||||
34045734|NCT00616343|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33815143|NCT05709886|NA|SINGLE_GROUP||TREATMENT||NONE||To evaluate whether the LaserPro Diode Laser System under the guidance of EUS can achieve the safety and effectiveness of local ablation for liver cancer.||||
33815144|NCT03066986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045735|NCT05087316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045736|NCT00603902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045737|NCT02185118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045738|NCT03766867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045739|NCT00238693|||COHORT||PROSPECTIVE|||||||
34045740|NCT04316104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This intervention, CuidaTXT \[Spanish for self-care and texting\], will be available in English and Spanish, incorporate two-way messaging and will tailor text messages to the preferences of Latino caregivers. CuidaTXT will be multicomponent and based on the Stress Process Framework as supported by evidence. The intervention will incorporate social support and coping components including dementia education, problem-solving skills training, social network support, care management and referral to community resources.||||
34045741|NCT04304599|NA|SINGLE_GROUP||OTHER||NONE||||||
34045742|NCT05901935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045743|NCT01766193|||COHORT||RETROSPECTIVE|||||||
34045744|NCT05411445|||CASE_ONLY||PROSPECTIVE|||||||
34045745|NCT03097276|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045746|NCT02122887|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34045747|NCT03091543|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34045748|NCT05326529|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Three way comparison study.~* Traditional Cardiac Rehabilitation~* Traditional Cardiac Rehabilitation combined with Web-based Cardiac Rehabilitation~* Web-based Cardiac Rehabilitation"||||
34045749|NCT04181528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34045750|NCT06510543|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34045751|NCT00022698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045752|NCT00243295|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34045753|NCT00006178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045754|NCT02992236|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34045755|NCT03097341|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045756|NCT00945724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045757|NCT05321238|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were not aware which arm of the study they were enrolled in.||t|f|f|f
34045758|NCT06575855|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Patients|28 participants divided in to two groups, Group A and Group B||||
34045759|NCT06287151|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Only the individuals performing data analysis will be blinded to type of anesthetic technique performed.|Choice of group will be made by attending anesthesiologist based on clinical judgement.|f|f|f|t
34045760|NCT05312762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045761|NCT01340872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045762|NCT06383910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045763|NCT02781116|||COHORT||PROSPECTIVE|||||||
34045764|NCT03327727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Sponsor, safety monitoring board, and data review committee are masked.||f|f|f|t
34045765|NCT00795470|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34045766|NCT04152811|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Outcomes Assessor are blinded|Waitlist Control Design|f|f|f|t
34045767|NCT05247294|||COHORT||PROSPECTIVE|||||||
34045768|NCT03039530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045769|NCT03973879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045770|NCT03279757|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34045771|NCT03997240|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34045772|NCT00001680||||TREATMENT||||||||
34045773|NCT05007379|||COHORT||PROSPECTIVE|||||||
34045774|NCT04824027|NA|SINGLE_GROUP||OTHER||NONE||||||
34045775|NCT04192071|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34045776|NCT00774514|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34045777|NCT03992924|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045778|NCT00491556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045779|NCT00758485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045780|NCT01413126|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045781|NCT05536232|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34045782|NCT06241170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045783|NCT04895657|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045784|NCT05576272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045785|NCT02823210|||COHORT||RETROSPECTIVE|||||||
34045786|NCT05354388|||CASE_ONLY||PROSPECTIVE|||||||
34045787|NCT03938844|||CASE_CONTROL||RETROSPECTIVE|||||||
34045788|NCT01656135|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34045789|NCT01631149|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34045790|NCT01558440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045791|NCT05593081|||OTHER||OTHER|||||||
34045792|NCT00537576|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34045793|NCT00025675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045794|NCT05468476|||CASE_CONTROL||PROSPECTIVE|||||||
34045795|NCT00468481|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34045796|NCT06572306|||COHORT||PROSPECTIVE|||||||
34045797|NCT02291666|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34045798|NCT04789148|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34045799|NCT02451774|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045800|NCT00912977|||CASE_CROSSOVER||PROSPECTIVE|||||||
34045801|NCT00812383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045802|NCT03197038|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled design with a 1:1 allocation||||
34045803|NCT00275743|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045804|NCT01334242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045805|NCT00256269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736914|NCT05392556|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants, study investigators, and study staff will be blinded to the intervention. A staff member not involved in the study will randomize the participants and inform the Principal Investigator of the randomization order upon enrollment of each participant.|Randomized, double blind, placebo controlled|t|f|t|t
33736915|NCT05663398|RANDOMIZED|CROSSOVER||OTHER||NONE||Two-period, two-sequence, two-way crossover single dose study||||
33736916|NCT03722875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736917|NCT03142295|NA|SINGLE_GROUP||OTHER||NONE||prospective, open label pilot clinical trial.||||
33736918|NCT00417560|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736919|NCT05433558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33736920|NCT04349852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736921|NCT04541446|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736922|NCT06662773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736923|NCT00626977|||COHORT||PROSPECTIVE|||||||
33736924|NCT06311994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
33736925|NCT06142201|||OTHER||RETROSPECTIVE|||||||
33736926|NCT02497768|NA|SINGLE_GROUP||||NONE||||||
33736927|NCT01131481|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33736928|NCT03558828|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||A Sequential Multiple Assignment Randomized Trial (SMART) design is used for this study.|f|f|f|t
33736929|NCT05448001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736930|NCT02811198|||COHORT||PROSPECTIVE|||||||
33736931|NCT06663696|||CASE_ONLY||PROSPECTIVE|||||||
33736932|NCT05705102|||OTHER||PROSPECTIVE|||||||
33736933|NCT03732638|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33736934|NCT02381392|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention group using Accuvein, Control group standard care||||
33736935|NCT03444857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736936|NCT06102421|||COHORT||PROSPECTIVE|||||||
33736937|NCT01542112|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33736938|NCT01623219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736939|NCT06481150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33736940|NCT03992690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33736941|NCT06654310|||CASE_ONLY||PROSPECTIVE|||||||
33736942|NCT03844893|||COHORT||PROSPECTIVE|||||||
33736943|NCT00175474|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736944|NCT00503685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736945|NCT03122912|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33736946|NCT00028834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736947|NCT01019681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736948|NCT01714700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736949|NCT01964612|||CASE_ONLY||PROSPECTIVE|||||||
33736950|NCT03197220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736951|NCT01352520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736952|NCT04745416|||COHORT||RETROSPECTIVE|||||||
33815145|NCT03105726|||COHORT||PROSPECTIVE|||||||
33815146|NCT03091842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815147|NCT04518306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||International, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.|t|t|t|t
33736953|NCT00204841|||COHORT||PROSPECTIVE|||||||
33736954|NCT00764075|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736955|NCT01383902|RANDOMIZED|CROSSOVER||||NONE||||||
33736956|NCT06167096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study is a single-blinded randomized control study. Days before surgery, participants meeting inclusion criteria will be contacted and an electronic consent will be completed. The intervention shall not be disclosed to participants. Days in which lavender is used in clinic will alternate; participants will be scheduled as normal. participants will therefore be randomly assigned to one of two groups, lavender or control, depending on their surgery date. On the day of surgery, participants who previously completed the electronic consent will be brought to a room with a diffuser. The diffusers will be turned on 15 minutes before scheduled time of surgery with lavender for the intervention group (4 drops per 100ml water) or just water for the control group.|t|f|f|f
33815148|NCT02525744|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33815149|NCT02420509|||CASE_CONTROL||PROSPECTIVE|||||||
33815150|NCT00065663|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33815151|NCT01508117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815152|NCT00130026|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33815153|NCT01082159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815154|NCT04054856|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815155|NCT02090478|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815156|NCT01064778|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815157|NCT05197504|||COHORT||RETROSPECTIVE|||||||
33815158|NCT01527461|||||PROSPECTIVE|||||||
33736957|NCT04346615|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736958|NCT04783129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All groups will be assessed before (baseline), and after the end of the intervention by a blinded examiner|Stratified, single-blind, parallel-group, randomised controlled trial|f|f|f|t
33736959|NCT05144152|||CASE_ONLY||PROSPECTIVE|||||||
33736960|NCT05676047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor will be blinded to randomization|Participants will be randomized to either the Therapy (n=50) or Education Group (n=50). At the conclusion of therapy (for the Therapy Group) or after three weeks (for the Education Group), participants will be re-administered the outcome measures. The outcome measures using the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) will then be compared during data analysis between the two groups.|f|f|f|t
33736961|NCT01168999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33736962|NCT06015698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33736963|NCT04670562|||COHORT||PROSPECTIVE|||||||
33736964|NCT00784446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33736965|NCT02549144|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33815159|NCT00021996||||SUPPORTIVE_CARE||||||||
33736966|NCT01696435|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33736967|NCT01792999|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33736968|NCT01956175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33736969|NCT03654677|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33736970|NCT06053658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736971|NCT04768647|||COHORT||CROSS_SECTIONAL|||||||
33736972|NCT02787356|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33736973|NCT06663150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33736974|NCT01088516|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736975|NCT01527916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33736976|NCT05827302|NA|SINGLE_GROUP||OTHER||NONE||The study will compare healthy controls to those with respiratory disease. Both groups will be wearing the watch and completing the same questionnaires||||
33736977|NCT01376024|||COHORT||PROSPECTIVE|||||||
33736978|NCT06662838|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33736979|NCT03011814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736980|NCT03873051|RANDOMIZED|PARALLEL||PREVENTION||NONE||The randomized pilot study compares the effects of receiving a matched (Autonomous \& Challenge-Focused; Controlled \& Rewards-Focused) versus an non-matched (Autonomous \& Rewards-Focused; Controlled \& Challenge -Focused) group-based PA intervention program over an 8-week time period. Randomization to the Rewards- or Challenge-focused intervention is stratified by degree of autonomous motivation (low, medium, high). A total of 150 African American women will be randomly assigned to either receive the Rewards- or the Challenge-focused intervention.||||
33736981|NCT04839081|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33736982|NCT04746937|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized Double-Blind Placebo-Controlled study|t|f|t|f
33736983|NCT02738021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736984|NCT04823845|NA|SINGLE_GROUP||TREATMENT||NONE|patient information will be kept secure and no individual identifiers will be used.|apply study treatment to single group of patients.||||
33736985|NCT05669092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736986|NCT00568984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33736987|NCT04079933|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33736988|NCT06620926|||COHORT||RETROSPECTIVE|||||||
33736989|NCT05892458|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33736990|NCT04770805|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm clinical study. All participants will undergo laparotomy with exteriorization of the uterus followed by fetoscopic repair of the fetal MMC/MyeLDM lesion.||||
33736991|NCT05654506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736992|NCT02047604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33736993|NCT06664372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33736994|NCT06571357|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To minimize biased information, we employed a double-blind approach. The data will be collected by the researcher, and the statistician will be unaware of the groups; data will be analysed as variables x1 and x2.|Participants in this clinical trial will be randomly assigned to one of two groups: an experimental group receiving Pranic Healing and a control group receiving standard care. Both groups will be observed in parallel for the duration of the study.|f|f|t|t
33736995|NCT03296696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Bayesian logistic regression model||||
33736996|NCT02950636|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33736997|NCT00459134|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33736998|NCT06317792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be divided into two groups in a randomized controlled study|t|f|f|t
33736999|NCT01130740|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33815160|NCT02762786|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815161|NCT00796835|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815162|NCT03556267|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33815163|NCT01399905|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815164|NCT04500665|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815165|NCT05500261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815166|NCT06022003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815167|NCT05881213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815168|NCT02037009|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33815169|NCT02271841|||COHORT||PROSPECTIVE|||||||
33815170|NCT03850847|||FAMILY_BASED||PROSPECTIVE|||||||
33815171|NCT01307540|RANDOMIZED|||PREVENTION||TRIPLE|||t|t|t|f
33815172|NCT06049719|||OTHER||RETROSPECTIVE|||||||
33815173|NCT05248672|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Open Label Study|t|t|t|t
33815174|NCT02592902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815175|NCT01801202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737000|NCT02520024|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33737001|NCT00374777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737002|NCT04979728|||COHORT||PROSPECTIVE|||||||
33737003|NCT01636141|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33815176|NCT03100851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815177|NCT04301102|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33815178|NCT06509269|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33815179|NCT03272815|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Radiologists are unaware of the intervention or the nature of the study.|A prospective clinical feasibility cohort study.|f|f|f|t
33815180|NCT00391508|||CASE_CONTROL||OTHER|||||||
33815181|NCT02148120|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815182|NCT05723484|||COHORT||PROSPECTIVE|||||||
33815183|NCT04304014|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both probiotic products will be provided in their commercial form. Both products will be individually placed inside opaque bags so that the investigator can not recognize the external case.||f|f|t|t
33815184|NCT00882375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815185|NCT04095897|||COHORT||CROSS_SECTIONAL|||||||
33815186|NCT00307489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815187|NCT01668498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815188|NCT00312949|RANDOMIZED|PARALLEL||||NONE||||||
33737004|NCT03698682|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33737005|NCT02877706|||COHORT||PROSPECTIVE|||||||
34124617|NCT04375956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124618|NCT00583856|||CASE_CONTROL||RETROSPECTIVE|||||||
34124619|NCT05221372|||COHORT||PROSPECTIVE|||||||
34124620|NCT02840305|RANDOMIZED|PARALLEL||||NONE||||||
34124621|NCT00110045||||SUPPORTIVE_CARE||NONE||||||
34124622|NCT05964491|||OTHER||CROSS_SECTIONAL|||||||
34124623|NCT04749147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34124624|NCT05254353|||OTHER||PROSPECTIVE|||||||
34124625|NCT00606645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124626|NCT04546919|||COHORT||PROSPECTIVE|||||||
34124627|NCT01126190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34124628|NCT00066612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124629|NCT05312606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124630|NCT05005221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants will be randomized in a 1:2 allocation ratio to receive one of two text messaging interventions (basic text message reminders or more intensive bidirectional messages).||||
34124631|NCT05842525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124632|NCT04686344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124633|NCT03637283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124634|NCT00463086|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124635|NCT01823380|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124636|NCT01547156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124637|NCT02117011|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124638|NCT01128725|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124639|NCT01775553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124640|NCT00673231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124641|NCT04888988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34124642|NCT03780751|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of three groups parallel for the duration of the study. 40% of participants will be assigned to one of the two immediate treatment conditions, 20% of participants will be assigned to a waitlist and will begin active treatment after a six months waiting period.||||
34124643|NCT00893178|||CASE_CONTROL||PROSPECTIVE|||||||
34124644|NCT00788060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124645|NCT00645840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124646|NCT06112470|||COHORT||PROSPECTIVE|||||||
34124647|NCT00742521|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34124648|NCT00363142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124649|NCT05956847|||COHORT||PROSPECTIVE|||||||
34124650|NCT06012539|||OTHER||PROSPECTIVE|||||||
34124651|NCT04572646|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124652|NCT00244868|RANDOMIZED|||||||||||
34124653|NCT02046018|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33737006|NCT01590914|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33737007|NCT04319315|||OTHER||PROSPECTIVE|||||||
33737008|NCT03865277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737009|NCT00618215|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33737010|NCT06664086|||OTHER||CROSS_SECTIONAL|||||||
33737011|NCT00818441|NON_RANDOMIZED|||TREATMENT||NONE||||||
33737012|NCT05457881|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Subjects will be discretely randomized by the clinical research assistants upon final clearance for their procedure by the anesthesiology service, and their assigned group will be concealed to all subsequent team members (clinicians, research scientists, statistician) until data lock|3:2 randomization to short-term protein calorie restriction diet versus regular meals prior to elective major vascular surgery|f|f|t|t
33737013|NCT00144118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33737014|NCT00838305|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33737015|NCT03806452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737016|NCT06394128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737017|NCT06663683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737018|NCT03588169|||OTHER||PROSPECTIVE|||||||
33815189|NCT05792475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815190|NCT01486745|||CASE_CONTROL||PROSPECTIVE|||||||
33815191|NCT04361617|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Knowledge of intervention arm will not be given to research labs with samples||f|f|f|t
34124654|NCT00465608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124655|NCT02636387|||COHORT||PROSPECTIVE|||||||
34124656|NCT01133665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124657|NCT02671006|||CASE_CONTROL||PROSPECTIVE|||||||
34124658|NCT02559635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124659|NCT01530529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34124660|NCT02337894|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34124661|NCT02564588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124662|NCT00872274|RANDOMIZED|CROSSOVER||||NONE||||||
34124663|NCT01442337|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124664|NCT05312840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124665|NCT00736112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124666|NCT03306823|||COHORT||PROSPECTIVE|||||||
34124667|NCT03069066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124668|NCT00971282|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34124669|NCT00362882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124670|NCT05135598|NA|SINGLE_GROUP||OTHER||NONE||Pre-post evaluation||||
34124671|NCT02398526|||COHORT||PROSPECTIVE|||||||
34124672|NCT02636504|||COHORT||PROSPECTIVE|||||||
34124673|NCT02135744|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34124674|NCT00717847|||CASE_ONLY||CROSS_SECTIONAL|||||||
34124675|NCT00921726|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124676|NCT01214473|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124677|NCT02228161|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34124678|NCT01382914|NA|SINGLE_GROUP||||NONE||||||
33737019|NCT06663553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will remain blinded to their surgical methods in 24 hours following the operation. To achieve this, we will apply wound pads to each patient's abdomen as the wounds typically seen in tradi tional laparoscopy procedures, no matter whether actual wounds exist.||t|f|f|f
33737020|NCT04751916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After obtaining consent, the patient will receive supplement assignment based on computer-generated, block-randomization with stratification by sex. The intervention and control supplements are packaged, sealed and labeled as group A or B by The Amino Co. The packets are sent to Oregon Health \& Science University at study start and stored at room temperature in the investigators' laboratory. The Oregon Health \& Science University investigators are unaware of which supplements are packaged as group A or B. The research coordinator is responsible for completing the randomization process using a table created by the statistician. The stratification/randomization assignments are kept in a password-protected file; the password known only to the research coordinator and statistician. The powdered and reconstituted forms of the supplements are indistinguishable to an observer.|double-blinded randomized clinical trial|t|t|t|t
33737021|NCT04176770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737022|NCT02097992|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33737023|NCT03083288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737024|NCT05390866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and investigators (except for the principal investigator) will also discover on the day of the HIIT intervention to which group they are allocated (HIIT vs. no exercise intervention). This information will be enclosed in a sealed envelope by the principal investigator.|A prospective 2-arm, monocentric randomised controlled trial (a single HIIT session vs. no exercise intervention).|t|f|t|f
33737025|NCT05775198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data analysis will be performed by investigators blind to the patient group.||f|f|t|t
33737026|NCT04603859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737027|NCT02051179|||CASE_CONTROL||PROSPECTIVE|||||||
33737028|NCT03243734|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33737029|NCT00130767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737030|NCT05446311|||COHORT||PROSPECTIVE|||||||
33737031|NCT00005861||||TREATMENT||||||||
33737032|NCT05658302|||CASE_ONLY||PROSPECTIVE|||||||
33737033|NCT04025814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737034|NCT05002322|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||phased-in (stepped wedge) design with random assignment of two districts to each of the three nine-month intervention waves, to reach six districts in Maputo Province by the end of the trial||||
33737035|NCT01866787|||COHORT||PROSPECTIVE|||||||
33737036|NCT06041477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737037|NCT00451425|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737038|NCT02966405|||CASE_ONLY||PROSPECTIVE|||||||
33737039|NCT06345508|||CASE_ONLY||CROSS_SECTIONAL|||||||
33737040|NCT05508633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737041|NCT01600040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737042|NCT05901129|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33737043|NCT02541266|||COHORT||PROSPECTIVE|||||||
33737044|NCT04928352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33737045|NCT06466395|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737046|NCT06662903|RANDOMIZED|PARALLEL||TREATMENT||NONE||Titanium mesh VS Bone cement in Cranioplasty||||
33737047|NCT03891082|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737048|NCT01607034|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737049|NCT00388518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737050|NCT06440707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Adaptive Bayesian Design|t|t|t|t
33737051|NCT00826189|||COHORT||PROSPECTIVE|||||||
33737052|NCT02123407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737053|NCT00704145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737054|NCT02541721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737055|NCT01312467|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815192|NCT03327025|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33815193|NCT01171950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045806|NCT02173925|||CASE_CONTROL||PROSPECTIVE|||||||
34045807|NCT05026112|||COHORT||PROSPECTIVE|||||||
34045808|NCT01136356|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33737056|NCT06349044|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33737057|NCT02451826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737058|NCT01961830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737059|NCT03198273|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33737060|NCT00127790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737061|NCT00907894|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33737062|NCT06216236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815194|NCT02363153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045809|NCT06143241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be informed about the intergroup practice. The person who will carry out the evaluations will not be informed about the application.|Children diagnosed with epilepsy will be divided into two groups as experimental group and control group using block randomisation method.|t|f|f|t
34045810|NCT00823069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34045811|NCT06001788|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045812|NCT06257472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two-armed blinded clinical trial|t|f|f|t
34045813|NCT02384746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045814|NCT01141946|||COHORT||PROSPECTIVE|||||||
34045815|NCT00237458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045816|NCT02657122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34045817|NCT03223415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045818|NCT05533008|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34045819|NCT05513274|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Both patient and research assistant interviewer will be blinded to condition assignment during the baseline, intervention and follow up assessment.|This is a 2 by 2 factorial study|t|f|t|t
34045820|NCT05099185|||COHORT||CROSS_SECTIONAL|||||||
34045821|NCT03373084|||COHORT||PROSPECTIVE|||||||
33737063|NCT01788540|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737064|NCT05480605|||COHORT||PROSPECTIVE|||||||
33737065|NCT01550939|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737066|NCT05713422|||COHORT||PROSPECTIVE|||||||
33737067|NCT04368598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737068|NCT01723891|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737069|NCT02369497|||COHORT||PROSPECTIVE|||||||
33737070|NCT01697384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737071|NCT01963624|||COHORT||CROSS_SECTIONAL|||||||
33737072|NCT03623958|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737073|NCT00999349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737074|NCT06360588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737075|NCT00764348|||||PROSPECTIVE|||||||
33737076|NCT03174340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737077|NCT03475160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Sildenafil Citrate (SC) vaginal suppositories compared to Placebo vaginal suppositories.|t|f|t|f
33737078|NCT06664632|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737079|NCT05660616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737080|NCT05728892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737081|NCT05676697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737082|NCT05632952|||COHORT||PROSPECTIVE|||||||
33737083|NCT06297824|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility, open trial||||
33737084|NCT01532687|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33737085|NCT02960984|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33737086|NCT00851175|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33737087|NCT01237145|||CASE_CONTROL||PROSPECTIVE|||||||
33737088|NCT00824317||CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33737089|NCT04363281|||COHORT||PROSPECTIVE|||||||
33737090|NCT06142955|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||Typically developing (TD) controls and ASD participants with and without depression will receive both active and sham TMS in a randomized crossover assignment involving two study sessions.|t|t|f|f
33737091|NCT01566136|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33737092|NCT06662955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Paticipants are blinded groups allocation.||t|f|f|f
33737093|NCT01733368|||OTHER||PROSPECTIVE|||||||
33737094|NCT00014534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737095|NCT06664216|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33737096|NCT00485875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737097|NCT01297842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737098|NCT03798431|NA|SINGLE_GROUP||TREATMENT||NONE||There will be no randomization for this pilot study.||||
33737099|NCT04651959|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33737100|NCT06337617|||COHORT||RETROSPECTIVE|||||||
33737101|NCT05164705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not know whether they are receiving active or sham hypoxia during individual AIH sessions.|Randomized sham-controlled crossover trial|t|f|f|f
33737102|NCT06531707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737103|NCT06657274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737104|NCT04104139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815195|NCT03785756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind, double dummy-study. There will be two placebo tablets designed to be comparable to each of the active products (PR and Immediate Release \[IR\]) in both shape, size, colour and weight. All subject packs have been designed and labelled to ensure blinding is maintained. Subjects, investigators and site staff will all be blind to the treatments.|The dental pain model used in this study is a robust and well established postsurgical pain model that produces pain that is predictable in its character, duration, and intensity. The model is widely accepted and has a proven record of assay sensitivity (i.e., separating active drugs from each other, as well as from placebo). The model is frequently used to evaluate NSAID type analgesics. Results from dental pain studies are accepted by the US Food and Drug Administration (FDA) and European authorities and have been widely extrapolated to other general pain conditions.|t|t|t|t
33815196|NCT01351896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815197|NCT03779776|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33815198|NCT04753450|||CASE_ONLY||PROSPECTIVE|||||||
33815199|NCT00166075|||COHORT||CROSS_SECTIONAL|||||||
33815200|NCT01074528|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815201|NCT02565225|||OTHER||PROSPECTIVE|||||||
33815202|NCT05054556|||COHORT||PROSPECTIVE|||||||
33815203|NCT03760809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33737105|NCT03767959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737106|NCT01248117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737107|NCT03198611|||COHORT||PROSPECTIVE|||||||
33737108|NCT04382612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737109|NCT02694991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737110|NCT03377335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737111|NCT03894059|||COHORT||PROSPECTIVE|||||||
33737112|NCT05580913|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737113|NCT05750524|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Patients and the investigator doing the suctioning and assessing the patient's pain and vital signs will be masked.|In the AB trial group, reflexology hand massage will be applied on the first day, classical hand massage on the second day, and in the BA group classical hand massage on the first day and reflexology hand massage on the second day will be applied.|t|f|t|f
33737114|NCT00881309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737115|NCT04300400|||COHORT||PROSPECTIVE|||||||
33737116|NCT01396616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737117|NCT05520476|||COHORT||PROSPECTIVE|||||||
33737118|NCT00061490|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33737119|NCT06573437|||COHORT||PROSPECTIVE|||||||
33737120|NCT04375423|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33737121|NCT06005259|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33737122|NCT06209112|||CASE_CONTROL||PROSPECTIVE|||||||
33815204|NCT00553813|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737123|NCT02444650|||COHORT||PROSPECTIVE|||||||
34124679|NCT02992327|||COHORT||PROSPECTIVE|||||||
33737124|NCT03745703|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Participants are randomly assigned to either the MOCHA standard arm or to the enhanced MOCHA+ arm.|The study design uses a wait-list control to test the effectiveness and relative effectiveness of a community-driven MOCHA intervention, including discussions of salient health topics (such as stress and anger management) and an enhanced version MOCHA+, which incorporates narrative communication strategies to strenghten comprehnsion, retention and motivation.|t|f|f|f
33737125|NCT05696015|RANDOMIZED|PARALLEL||OTHER||NONE|Patients will be randomized using the Randomizer software into a group that will receive the telemonitoring intervention and a control group (which will only receive the hospital's standard hospital discharge instructions).|The randomized clinical trial.||||
33737126|NCT03950024|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||prospective, monocentric, interventional, comparative, controlled, non-randomized study||||
33737127|NCT02340559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737128|NCT06078397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737129|NCT02932397|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33737130|NCT05833984|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33737131|NCT01895894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737132|NCT06573671|||COHORT||OTHER|||||||
33737133|NCT01455675|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33737134|NCT00834301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737135|NCT05750693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737136|NCT01524640|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33737137|NCT06663982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737138|NCT00984841|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737139|NCT05228210|||COHORT||CROSS_SECTIONAL|||||||
33737140|NCT05316298|||COHORT||PROSPECTIVE|||||||
33737141|NCT01433224|||CASE_ONLY||RETROSPECTIVE|||||||
33737142|NCT03983590|||COHORT||PROSPECTIVE|||||||
33737143|NCT03176810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737144|NCT06323304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Triple-blind method (Participant, Investigator, Outcome assessor) Participants will be blinded to their randomization assignment, either to the intervention group or the control group. Sham acupressure therapy will be performed at acupoints that have no therapeutic effect on allergic rhinitis, and the procedures will be similar to auricular pressure therapy. Both groups will be treated with fluticasone propionate nasal spray, which is the standard treatment.~The physician who perform auricular acupressure therapy or sham acupressure therapy will be aware of the intervention assignment for each group, but they will not be involved in data analysis or outcome assessment. The data analysts and outcome assessors will be blinded to the treatment assignment."||t|f|t|t
33737145|NCT04364997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737146|NCT01278069|||COHORT||PROSPECTIVE|||||||
33737147|NCT01205724|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737148|NCT04071951|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33737149|NCT00159523|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33737150|NCT04019535|||CASE_CONTROL||RETROSPECTIVE|||||||
33737151|NCT06489301|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will receive fractionated laser resurfacing.||||
33737152|NCT03986944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737153|NCT04973488|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Not masked|Single group, that is divided into two arms|f|t|f|t
33737154|NCT03353428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737155|NCT03261557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737156|NCT02616224|||CASE_ONLY||PROSPECTIVE|||||||
33737157|NCT05010798|||COHORT||CROSS_SECTIONAL|||||||
33737158|NCT00132769|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737159|NCT05528094|NA|SINGLE_GROUP||OTHER||NONE||||||
33737160|NCT01970202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737161|NCT03262272|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective randomized cross-over study||||
33737162|NCT04870840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737163|NCT03116165|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33737164|NCT02738775|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33815205|NCT01237132|||COHORT||RETROSPECTIVE|||||||
33815206|NCT05118867|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815207|NCT00041639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124680|NCT04814953|||CASE_ONLY||PROSPECTIVE|||||||
33815208|NCT05542004|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33815209|NCT02612285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815210|NCT05702190|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33815211|NCT05159037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815212|NCT00038376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124681|NCT02563730|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124682|NCT03683810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737165|NCT03162861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737166|NCT01480934|||CASE_CONTROL||PROSPECTIVE|||||||
33737167|NCT03183791|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33737168|NCT05701800|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33737169|NCT00578773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737170|NCT04512846|||COHORT||PROSPECTIVE|||||||
33737171|NCT02770339|||CASE_ONLY||PROSPECTIVE|||||||
33737172|NCT04951310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737173|NCT06363097|||OTHER||CROSS_SECTIONAL|||||||
33815213|NCT05700279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815214|NCT04314102|||CASE_CROSSOVER||PROSPECTIVE|||||||
33815215|NCT04292795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815216|NCT03077958|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with degenerative knee disease randomely receive one of two types of total knee prostheses||||
33815217|NCT02358278|||COHORT||RETROSPECTIVE|||||||
34124683|NCT02575144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124684|NCT02789462|||CASE_ONLY||OTHER|||||||
33815218|NCT04168437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815219|NCT03633318|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815220|NCT03824340|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized controlled study|t|t|f|f
33815221|NCT04468659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815222|NCT02716272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815223|NCT03455751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33815224|NCT05242874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815225|NCT00731692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815226|NCT05031052|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter prospective randomized controlled trial||||
33815227|NCT03417115|||COHORT||PROSPECTIVE|||||||
33815228|NCT06473194|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||describe techniques of laparoscopic procedures. 2. Discuss complications and assessments of patients who undergo laparoscopic procedures. 3. to assess liver function and hematological effects due to laparoscopic surgery 4. cardiovascular and respiratory squeal due to laparoscopic complication is minor compared to open surgery and can be managed rapidly.||||
33815229|NCT03829566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815230|NCT01355185|||COHORT||PROSPECTIVE|||||||
33815231|NCT01956396|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815232|NCT01628263|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33815233|NCT05310292|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A case-control intervention study.||||
33815234|NCT02771561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815235|NCT00011102|RANDOMIZED|||PREVENTION||||||||
33815236|NCT01199302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815237|NCT02793557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815238|NCT05353062|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized prospective study||||
33815239|NCT03436537|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815240|NCT01846156|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33815241|NCT01072071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815242|NCT05434507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815243|NCT06032156|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||A randomized double-blind placebo-controlled crossover design will be used to test 3 conditions. Participants will consume 60 mL of a supplement containing: 1) a low β-OHB dose (0.3g/kg) body weight of the ketone monoester; \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate); 2) a high β-OHB dose (0.6g/kg body weight); or 3) a taste-matched calorie-free inert placebo drink.|t|f|t|t
33815244|NCT06421376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045822|NCT05017519|||COHORT||PROSPECTIVE|||||||
34045823|NCT03316651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045824|NCT05236439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045825|NCT04768998|||COHORT||PROSPECTIVE|||||||
34045826|NCT03428503|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34045827|NCT01231724|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34045828|NCT00295204|||||OTHER|||||||
34045829|NCT03464331|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Simple individual randomization method by sequentially numbered, opaque sealed envelopes (SNOSE) will be used to ensure the research staff / interventionists and participants will be concealed from the allocation sequence. The statistician will prepare about 150 identical, opaque, sealed, A5-sized envelops, with a unique 3-digit serial number on the cover of each envelope as an identifier. Half of them will each contain a card indicating EXP and the other half, CON. For EXP, the card will further indicate activity tracker or no tracker, in 1:1 ratio. After consent, the RS will open an envelope according to the sequence of the serial number and assign participant to either EXP or CON group. The envelop must be opened according to the serial number. All others will not know the group allocation before the envelope is opened. Frequent checks (at least weekly) of these numbers will be done to ensure no deviation.|t|f|f|f
34045830|NCT06522698|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34045831|NCT00890370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045832|NCT03317730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045833|NCT04219124|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Matching placebo for Dapagliflozin 10 mg. Dosage form and strength: Green, plain, diamond shaped, and film coated tablet|The study is a randomised double blind placebo control cross over trial. with 4-weeks washout period.|t|f|t|f
34045834|NCT01126814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045835|NCT00585936|||COHORT||PROSPECTIVE|||||||
34045836|NCT02580409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045837|NCT03226769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045838|NCT03157271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045839|NCT03945955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34045840|NCT05235893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045841|NCT01852149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045842|NCT05840211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124685|NCT02125344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815245|NCT00623844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045843|NCT04363671|||OTHER||PROSPECTIVE|||||||
34045844|NCT03220204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and treating study staff will be aware of the participant's treatment condition. However, follow-up assessments will be performed by a study staff member that is masked to the participant's treatment condition.|Randomized, single-blinded, controlled trial|f|f|f|t
34045845|NCT01225016|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045846|NCT04664738|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34045847|NCT00056589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045848|NCT00356148|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|f|t
34045849|NCT01392924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045850|NCT06192329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045851|NCT00966524|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34045852|NCT00471081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045853|NCT01023477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737174|NCT02331446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33737175|NCT01175694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815246|NCT06173297|||CASE_ONLY||PROSPECTIVE|||||||
33815247|NCT04054622|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34045854|NCT02754271|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34045855|NCT06389903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045856|NCT04109274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34045857|NCT00001741||||TREATMENT||||||||
34045858|NCT03491046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045859|NCT03092778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045860|NCT03571282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045861|NCT05896033|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34045862|NCT05350371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045863|NCT00842920|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045864|NCT03710863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045865|NCT01237418|||COHORT||PROSPECTIVE|||||||
34045866|NCT05750329|NA|SINGLE_GROUP||TREATMENT||NONE||"All enrolled patients received assisted liver transplantation combined with two-stage hepatectomy Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy"||||
34045867|NCT04042688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045868|NCT05387096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To mimic the intervention for blinding purposes of the participants, both control and intervention arm patients will receive a sham intervention.While the intervention will be known to clinical staff, the trial statistician will remain blinded until the results are finalized.|A randomized controlled clinical trial is proposed in which it is anticipated to randomize 3 x 463 patients to one of 3 groups: (a) standard pharmaceutical care, or (b) trained physician-implemented DI, or (c) clinical pharmacist-implemented DI.|t|f|f|f
34045869|NCT06501391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045870|NCT02965287|||COHORT||PROSPECTIVE|||||||
34045871|NCT03811093|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial will be conducted employing a double blind study methodology; participants will be randomly assigned to each group through a drawing, neither participants nor clinicians will know to which trial group they are assigned.|The trial compared results between two groups of participants; the first group was treated using a fully functional device. The second, a control group, was treated utilizing a nonfunctional device. At the conclusion of nine (9) therapy sessions; the change in body fat percentage, the change in body fat in pounds, and inches lost of the two groups will be statistically analyzed to determine the efficacy of the invisa-RED Technology Elite as a weight loss therapy. Any medical errors will be included in the statistical analysis.|t|t|f|f
34045872|NCT02635425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34045873|NCT00081224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045874|NCT02027987|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045875|NCT05580536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045876|NCT06156072|||CASE_CROSSOVER||PROSPECTIVE|||||||
34045877|NCT00040274|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34045878|NCT01830868|||OTHER||PROSPECTIVE|||||||
34045879|NCT01127451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045880|NCT04081038|||OTHER||PROSPECTIVE|||||||
34045881|NCT03873857|||COHORT||PROSPECTIVE|||||||
34045882|NCT02096874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045883|NCT03763929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|TSC injections will be prepared and injected by unblinded personnel on each ambulance. All other study personnel will be blinded|Multicenter, randomized, placebo-controlled, double-blind, parallel group|t|t|t|t
34045884|NCT02758938|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34045885|NCT00319319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045886|NCT05400109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045887|NCT05928013|NA|SINGLE_GROUP||SCREENING||NONE||||||
34045888|NCT01039727|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045889|NCT06114901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The research staff and Principal Chief Investigator will not be blinded to the study as they will be managing the online study directly which will lend itself to knowing which groups participants are allocated to. All other Investigators including data analysts will be blinded throughout the course of the trial and analysis of primary and secondary outcomes. Participants will not be blinded as they will know what treatment they receive.|Online (digital), two-arm, open-label randomised clinical trial|f|f|t|t
34045890|NCT00800995|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045891|NCT05925088|||OTHER||OTHER|||||||
33737176|NCT05514834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, investigator, and dermatopathologist (outcomes assessor) will all be blinded to which group the participant belongs too. Given the color difference of the injected solutions, the syringes with the injection material (HA with PRP or saline) will be masked to prevent the patient or investigator from knowing which material they are injecting.|Blinded, randomized control trial|t|f|t|t
33737177|NCT06442267|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737178|NCT00000189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737179|NCT04726410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||permuted block design|f|f|f|t
33737180|NCT00341224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737181|NCT05914584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737182|NCT05012592|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815248|NCT01207453|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815249|NCT01248663|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815250|NCT00477425|||||PROSPECTIVE|||||||
33815251|NCT04819204|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815252|NCT00237705|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33815253|NCT03403153|NA|SINGLE_GROUP||OTHER||NONE||This study is examining the feasibility and acceptability of an intervention to improve parent-child functioning. It will also conduct a preliminary test for movement in target outcomes.||||
33815254|NCT05848102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045892|NCT06067555|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"In the first year, a total of 39 participants will be enrolled (5 for most cohorts; 3 for each saline control group).~After preliminary analysis of the first season, we will choose the two most informative skin biopsy time points (2 hour, 6 hour, Day 1, Day 3, or Day 28) and plan for expansion of these cohorts in subsequent influenza seasons for a total of 100 participants per intradermal influenza vaccination cohort. An IM-control group of N=5 will be kept for each flu season; Therefore the total number of participants will be 249 participants. We will not include saline controls in subsequent seasons.~Participants in saline-control cohorts will be restricted from obtaining flu vaccination until after Day 28; after Day 28, they will be allowed to receive influenza vaccination at their discretion. We will ask and record if and when they received vaccination."||||
34045893|NCT02403479|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34124686|NCT04734262|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|None (Open Label)|"Cohort A Subjects will receive 70mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Cohort B Subjects will receive 100mg sitravatinib in combination with 200mg tislelizumab until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Cohort C Subjects will receive sitravatinib in combination with 200mg tislelizumab and 100 mg/m2 nab-paclitaxel until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first."||||
33737183|NCT03675659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124687|NCT06465784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Used closed envelope method|laster lithotripsy for clearance of uretric stones|t|f|f|t
34124688|NCT04764240|||COHORT||RETROSPECTIVE|||||||
34124689|NCT04828135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This will be a single-blinded open-label study enrolling 30 subjects (accrued 23 subjects (13 subjects who continue to have respiratory symptoms and 10 subjects within competitive sports) with a laboratory-confirmed diagnosis of COIVD-19 infection, and after 60 days or longer||||
34124690|NCT01775527|NA|SINGLE_GROUP||||NONE||||||
34124691|NCT01198821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124692|NCT04893512|NA|SEQUENTIAL||PREVENTION||NONE||||||
34124693|NCT04803474|||COHORT||PROSPECTIVE|||||||
33737184|NCT00111644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737185|NCT00793442|||COHORT||PROSPECTIVE|||||||
33737186|NCT02358889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737187|NCT04995640|||COHORT||OTHER|||||||
33737188|NCT02737566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737189|NCT02621983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737190|NCT06004817|||COHORT||RETROSPECTIVE|||||||
33737191|NCT04487977|||OTHER||CROSS_SECTIONAL|||||||
33737192|NCT01464918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737193|NCT04140149|||CASE_ONLY||PROSPECTIVE|||||||
33737194|NCT01590823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737195|NCT05595291|||CASE_ONLY||CROSS_SECTIONAL|||||||
33737196|NCT03285373|||COHORT||CROSS_SECTIONAL|||||||
33737197|NCT05500976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Participants will complete a 16-week randomized cross-over semi-controlled feeding study comparing two isocaloric dietary interventions. The two diets will be a Mediterranean-amplified habitual/Western (mini-MED) diet, containing 500 kcal/day from Mediterranean target foods (such as raspberries, avocado, red bell pepper, basil, walnuts, chickpeas, oats, salmon) and their habitual/Western (Western) diet,~Participants will be randomized (1:1) to start one of the dietary interventions, with subsequent assignment to the other upon completion of the first. A permuted block randomization scheme using block size of 2 and stratification by sex will be utilized to ensure balance between intervention order and number of males and females in each arm."||||
33737198|NCT04840095|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33737199|NCT06664164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Everyone except the person preparing the medication for the patient will be blinded. The person performing the block, the participants, and those monitoring during the postoperative period will be blinded to the study.||t|f|t|t
33737200|NCT04645381|||CASE_ONLY||CROSS_SECTIONAL|||||||
33737201|NCT00377663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737202|NCT03576001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737203|NCT06580821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participants will not know which technique is being used to treat gingival recession.~The investigator will not be informed which cover up treatment was performed in the gingival recession.~The outcomes assessor will not be informed of which procedures were performed on the participants."|Randomized clinical trial will performed in 30 patient with RT1 gingival recessions at mandibular incisors|t|f|t|t
33737204|NCT05085340|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33737205|NCT03830502|||COHORT||PROSPECTIVE|||||||
33737206|NCT06440772|||COHORT||PROSPECTIVE|||||||
33737207|NCT05078736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737208|NCT02370888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737209|NCT04981288|||COHORT||CROSS_SECTIONAL|||||||
33737210|NCT04165291|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737211|NCT04929561|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737212|NCT03802097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737213|NCT00139997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737214|NCT03905057|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737215|NCT05921773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33737216|NCT04560803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737217|NCT05809895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomized to Arms A, B and C in a double-blind manner Participants will be enrolled in Arm D in an open-label manner||t|t|t|f
33737218|NCT04499404|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33737219|NCT05124873|NA|SINGLE_GROUP||OTHER||NONE||||||
33815255|NCT01730820|||||PROSPECTIVE|||||||
33815256|NCT05568277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||intervention and control group|t|f|t|f
33815257|NCT00465114|||COHORT||PROSPECTIVE|||||||
33815258|NCT05049265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737220|NCT01994395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded research physical therapist will test the outcome measure at baseline, Mid Testing after Session 9 , at Post Testing after Session 18 and at 3 month follow up testing after Session 18.|The SMA group (task specific training) will be trained to simulate the demands of overground walking. The impairment based group will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking. The rationale of this study is to assess task specific training with SMA vs. impairment based training. To this end, we will use the Stride Management Assist device by Honda Corporation and compare it to impairment based physical therapy in outpatient sessions.|f|f|f|t
33737221|NCT05229224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737222|NCT05120908|||COHORT||PROSPECTIVE|||||||
33737223|NCT00678600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33737224|NCT04537715|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737225|NCT01542866|NA|SINGLE_GROUP||OTHER||NONE||||||
33737226|NCT01014494|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
33815259|NCT01868555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815260|NCT04894136|||COHORT||RETROSPECTIVE|||||||
33815261|NCT01255267|||COHORT||PROSPECTIVE|||||||
33815262|NCT05415722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34124694|NCT03301337|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Outcome assessor and investigator will be blindet. Participants cannot be blindet, as they will consume three different meat products, that we cannot mask.|Single-blindet randomized cross-over study|f|f|t|t
33815263|NCT03307356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815264|NCT01714479|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33815265|NCT04387773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815266|NCT03410680|RANDOMIZED|PARALLEL||TREATMENT||NONE|The recruiting staff will not have access to the results of randomization prior to recruiting the participant.|||||
34124695|NCT03714607|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815267|NCT05705245|||COHORT||PROSPECTIVE|||||||
33815268|NCT01246609|||COHORT||PROSPECTIVE|||||||
33815269|NCT00630409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815270|NCT03448302|||OTHER||PROSPECTIVE|||||||
33815271|NCT04409132|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815272|NCT01794234|||COHORT||PROSPECTIVE|||||||
34124696|NCT01261364|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34124697|NCT05497661|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34124698|NCT01053533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124699|NCT00711152|RANDOMIZED|PARALLEL||||NONE||||||
34124700|NCT04650438|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Single-blind, randomized, cross-over trial|t|f|f|f
34124701|NCT05771714|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open label, prospective, randomized clinical agreement study to evaluate the sensitivity and specificity of the CareSuperb™ COVID-19 Antigen Home Test when a lay person conducts the test on themselves, or another study participant, as compared to EUA authorized high sensitivity RT-PCR comparator tests.||||
34124702|NCT01537471|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34124703|NCT04858542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124704|NCT01261975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124705|NCT05945498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124706|NCT00700908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124707|NCT05609175|||OTHER||PROSPECTIVE|||||||
34124708|NCT05502003|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124709|NCT06512688|||OTHER||CROSS_SECTIONAL|||||||
34124710|NCT05350540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124711|NCT06133881|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34124712|NCT02982811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124713|NCT02878083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124714|NCT03469167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124715|NCT03128983|||COHORT||PROSPECTIVE|||||||
34124716|NCT05255302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124717|NCT03783598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study population was 76 individuals whose diagnosis of type 2 diabetes. 9 volunteer individual gave up to participation without for various reasons in the process.That intervention grup (n=33) control group (n=34), between the ages of 18 to 65 years and volunteer individuals.|The problem solving therapy is an social cognitive therapy approach. And ıt support to solve meaningfull occupational performance problems realted to diabetes by invdividuals and this way, it helps to improve the self-management of diabetes.We used that with person centered perspective and support to person with education which was perspective of person environment occupation model.|t|f|f|f
34124718|NCT02901600|||CASE_CONTROL||RETROSPECTIVE|||||||
34124719|NCT05404165|||CASE_ONLY||PROSPECTIVE|||||||
33815273|NCT02443532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124720|NCT00376636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124721|NCT00871663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124722|NCT02769429|||COHORT||PROSPECTIVE|||||||
34124723|NCT02718235|||COHORT||PROSPECTIVE|||||||
34124724|NCT02544347|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34124725|NCT00439101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815274|NCT05567029|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815275|NCT05396573|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33815276|NCT04917601|RANDOMIZED|PARALLEL||TREATMENT||NONE||Children aged 4-17 years old with obesity will be randomized to either the intervention group or the control group. The intervention group will through daily weighings at home be able to follow treatment closely in an application on the parents phone. Through a communication function in the application, families will be able to communicate in a fast and easy way with healthcare professionals at the clinic. The control group will receive Standard Lifestyle Care following local routines. The study duration is 12 months.||||
33815277|NCT01410721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815278|NCT01868607|||CASE_ONLY||CROSS_SECTIONAL|||||||
34124726|NCT04884503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33737227|NCT02782897|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737228|NCT06663059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737229|NCT00393172|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737230|NCT01862055|||COHORT||RETROSPECTIVE|||||||
33737231|NCT05349422|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study trial will utilize a practice-level cluster-randomized design, with 1:1 randomization at 10 clinics.||||
34124727|NCT03263065|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Data analysis will be blinded|This will be a three-period, three-treatment crossover trial with blinding of data analysis|f|f|f|t
34124728|NCT05144776|||COHORT||CROSS_SECTIONAL|||||||
34124729|NCT00003935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124730|NCT02494635|||CASE_ONLY||PROSPECTIVE|||||||
34124731|NCT03305952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124732|NCT00600717|||OTHER||PROSPECTIVE|||||||
34124733|NCT00878592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124734|NCT02785081|||CASE_ONLY||RETROSPECTIVE|||||||
34124735|NCT04966234|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, randomized, multi-center study||||
34124736|NCT04548427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124737|NCT03661177|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34124738|NCT03909412|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and G-CSF||||
34124739|NCT01736267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124740|NCT01941771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124741|NCT03089047|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Addition of rejuvesol will be performed by the blood bank and only they will know of group assignment|"Prospective randomized healthy volunteer study"|t|f|t|t
34124742|NCT00573391|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124743|NCT06209294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124744|NCT02737319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124745|NCT05270148|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
34124746|NCT02578446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124747|NCT03280693|||CASE_ONLY||RETROSPECTIVE|||||||
34124748|NCT03084705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124749|NCT06451874|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Sequential Multiple Assignment Randomized Trial (SMART)||||
34124750|NCT04212130|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124751|NCT02002988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124752|NCT04403919|RANDOMIZED|PARALLEL||OTHER||NONE||prospective, randomized, controlled trial, parallel four-arm design, single-center study||||
34124753|NCT05680493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants|randomized control trial which will consist of two groups, control and experimental|t|f|f|f
34124754|NCT01816425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124755|NCT01818843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124756|NCT05843331|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial study conducted on 12 participants with completely edentulous maxillary ridges. Patients were allocated into one of two treatment groups: 1) The control group ; included 6 patients (3 males and 3 females) who will receive 4 vertical implants with straight trans mucosal abutments retaining locator maxillary overdenture 2) The study group; include 6 participants (3 males and 3 females) who will receive 4 inclined implants with angled trans mucosal abutments for retaining locator maxillary overdenture. A new maxillary conventional dentures will be constructed with a bilateral balanced occlusal concept for all patients. Maxillary dentures were duplicated into heat cure acrylic resin dentures to be used as a radiographic template. Four implants were inserted in the maxilla . For both groups, locator abutments were screwed to the abutments .Clinical and radiographic evaluations were done.||||
34124757|NCT06387069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124758|NCT00476320|||DEFINED_POPULATION||OTHER|||||||
34124759|NCT05399966|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Pilot study; randomized, placebo-controlled, double-blind, parallel design, monocentric.|t|t|t|t
34124760|NCT04335968|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, national multicentric (21 centers), phase III, superiority, comparative randomized (1:1) double-blinded clinical trial with two parallel arms|t|t|t|t
33737232|NCT04456699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737233|NCT06040697|||OTHER||OTHER|||||||
33737234|NCT01212068|||COHORT||RETROSPECTIVE|||||||
33737235|NCT06662591|||CASE_CONTROL||PROSPECTIVE|||||||
33737236|NCT05740839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737237|NCT04667819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737238|NCT05976698|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|double-blinded|Randomized, double-blinded, cross-over study|t|f|t|f
33737239|NCT00950638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737240|NCT04801524|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33737241|NCT02077517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737242|NCT03926858|||COHORT||PROSPECTIVE|||||||
33737243|NCT02096055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737244|NCT00485537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33737245|NCT02788175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737246|NCT04412902|||COHORT||RETROSPECTIVE|||||||
33737247|NCT01196728|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33737248|NCT04151810|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149819|NCT04634942|RANDOMIZED|PARALLEL||PREVENTION||NONE||"In the study, the randomization method was used to assign the patients to the groups to prevent manipulations that could be done consciously or unconsciously. A computer-assisted randomization program was used to make assignments to the groups. A random list was created in the computer environment by using random.org, assigning individuals to groups (117). 195 people, who will form the sample of the study, were divided into sets of 39, and sets were created by assigning numbers from 1 to 5 to each set. When the sets were obtained, the numbers from 1 to 5 were written on small papers, and group assignments were made by lot method.~Group 1 = Control Group 2 = Cold Spray Placebo 3rd Group = Cold Spray 4th Group = ShotBlocker Group 5 = ShotBlocker Placebo"||||
34124761|NCT06059677|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Participants are blind to condition assignment, meaning they are not told in advance which version of the procedure they will experience. While those assigned to the true control condition will obviously realize this during the session, remaining participants are not informed whether the cigarette they smoke contains active cannabis or placebo.~Similarly, the experimenters will necessarily become aware of which individuals are in the control conditions, however, they do not know which of the remaining participants are assigned to active cannabis versus placebo conditions (i.e., the active vs. placebo cannabis cigarettes are not labeled as such).~Most importantly, outcome assessors such as the officers and driving evaluators who supply the ratings that comprise the focal dependent variables will be completely blind to experimental condition, so that there is no straightforward means by which experimenter bias could affect data collected for those variables."|This study is a true experiment in a naturalistic setting designed to maximize ecological validity, that is, designed so that the findings can be expected to generalize to their real-world application of detecting impaired driving. The study features a randomized between-subjects design, in which the main independent variable (Substance) has three levels: active cannabis vs. placebo vs. control (i.e., no substance).|t|f|t|t
34124762|NCT01817361|||CASE_ONLY||CROSS_SECTIONAL|||||||
34124763|NCT00038948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124764|NCT01082627|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124765|NCT05022173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124766|NCT01545596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34124767|NCT03847831|NA|SINGLE_GROUP||PREVENTION||NONE|This is a pilot study of schools enrolled into a program. The students and teachers in the schools are the subjects exposed to the study|Non-randomised single-group at school level pilot study.||||
34124768|NCT06287372|||CASE_CONTROL||PROSPECTIVE|||||||
34124769|NCT01085916|||CASE_ONLY||CROSS_SECTIONAL|||||||
34124770|NCT01303276|||COHORT||PROSPECTIVE|||||||
34124771|NCT05228405|||FAMILY_BASED||PROSPECTIVE|||||||
34124772|NCT04098302|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|UConn Health Investigational Pharmacy will randomize to dutasteride vs. placebo for phase 1 at baseline|The study consists of two 12-week phases, the first being a 12-week parallel-groups comparison of dutasteride and placebo to evaluate the safety and efficacy of dutasteride 1 mg/day in reducing the likelihood of drinking and heavy drinking in treatment-seeking men and women with alcohol use disorder. In the second 12-week phase, responders in phase 1 (defined as a ≥60% reduction in SD/wk for weeks 9-12 compared with screening) will continue on their initial medication assignment, while non-responder subjects treated with placebo in phase 1 will be given dutasteride during phase 2, and non-responder subjects treated with dutasteride in phase 1 will receive naltrexone daily in phase 2. This design maintains double blind conditions in both phases 1 and 2.|t|t|t|t
34124773|NCT02961270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124774|NCT01023217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124775|NCT02457247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124776|NCT02803411|||COHORT||PROSPECTIVE|||||||
34124777|NCT02775266|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34124778|NCT03076281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124779|NCT02881775|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34124780|NCT03908203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124781|NCT04244266|||COHORT||PROSPECTIVE|||||||
34124782|NCT01484145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124783|NCT05657535|NA|SINGLE_GROUP||TREATMENT||NONE|No need of blinding|Before and after of treatment in single group||||
34124784|NCT03678051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124785|NCT01485796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124786|NCT03123770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124787|NCT01059006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124788|NCT00895362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124789|NCT04306562|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The allocation sequence will be concealed from the researcher enrolling and assessing participants in sequentially numbered, opaque, sealed and stapled envelopes. Corresponding envelopes will be opened only after the enrolled participants completed all baseline assessments and it was time to allocate the intervention. Whereas patients and physicians allocated to the intervention group are aware of the allocated arm, outcome assessors and data analysts will be kept blinded to the allocation.|Patients who were diagnosed with sarcopenia or severe sarcopenia, will be randomly assigned following stratified randomization procedures (computerized random numbers) to one of two groups.|f|f|t|t
34124790|NCT03826459|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants will be randomized to either locked or non-locked uterine closure at the time of cesarean section.|t|f|t|t
34124791|NCT02701309|||COHORT||PROSPECTIVE|||||||
34124792|NCT04169516|||COHORT||PROSPECTIVE|||||||
34124793|NCT02903823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124794|NCT04165915|||COHORT||RETROSPECTIVE|||||||
34124795|NCT02259257|||CASE_ONLY||PROSPECTIVE|||||||
34124796|NCT01991483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34124797|NCT03516578|||COHORT||PROSPECTIVE|||||||
34124798|NCT02796833|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34124799|NCT02092727|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34124800|NCT04162470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124801|NCT04157699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124802|NCT03108521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124803|NCT00305448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124804|NCT01476540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124805|NCT00638729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34124806|NCT00000792||||TREATMENT||NONE||||||
33737249|NCT03167294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737250|NCT00970086|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33815279|NCT02824978|||COHORT||PROSPECTIVE|||||||
33815280|NCT02784834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815281|NCT05541185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815282|NCT05689177|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34124807|NCT02491177|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34124808|NCT03670849|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34124809|NCT01916486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124810|NCT05740800|||OTHER||CROSS_SECTIONAL|||||||
34124811|NCT01177124|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124812|NCT02572375|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34124813|NCT02059629|||CASE_ONLY||PROSPECTIVE|||||||
34124814|NCT02406521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124815|NCT01467336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124816|NCT00415870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124817|NCT02990975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34124818|NCT00848458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124819|NCT01760395|||COHORT||RETROSPECTIVE|||||||
34124820|NCT03663309|||OTHER||PROSPECTIVE|||||||
34124821|NCT04064476|||COHORT||PROSPECTIVE|||||||
33815283|NCT06106776|||COHORT||PROSPECTIVE|||||||
33815284|NCT06453759|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815285|NCT05174871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815286|NCT03493906|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33815287|NCT01709045|||COHORT||PROSPECTIVE|||||||
33815288|NCT04397185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Pathologist will be blinded to the study assignment (BCL vs. WL)||f|f|f|t
33815289|NCT04930263|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||We conduct a single-blinded, randomized controlled study. Sixty-six participants are randomly assigned to the experimental group and the control group.|f|f|f|t
33815290|NCT01411605|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815291|NCT06470685|||COHORT||PROSPECTIVE|||||||
33815292|NCT03687554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815293|NCT02400645|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33815294|NCT04135183|RANDOMIZED|PARALLEL||TREATMENT||NONE|The present study is a randomized controlled open label trial. Patients and their physicians know the group and the treatment plan, and there are clear criteria for the final outcome (30-day fatality rate, length of stay). The masking is not required.|This study consisting of two parts: the randomized controlled study include three groups, comprehensive evaluation group (traditional treatment group), PSI evaluation group and Expand-CURB evaluation group.The prospective observational study include one group. There are a total of 4 groups in the present study.||||
33815295|NCT04722471|||CASE_CONTROL||RETROSPECTIVE|||||||
33815296|NCT01330745|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815297|NCT00991185|||CASE_ONLY||CROSS_SECTIONAL|||||||
33815298|NCT03095261|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33815299|NCT03067870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815300|NCT03263117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815301|NCT01992497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33815302|NCT02255006|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33815303|NCT01777789|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815304|NCT03449485|||CASE_ONLY||PROSPECTIVE|||||||
33815305|NCT05976672|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||All participants will be initially monitored for three months before being randomized in a 1:1 ratio to receive either their standard of care treatment as usual, or the PRSS intervention (Peer Recovery Support Specialist)||||
33815306|NCT03060356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815307|NCT00674609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33815308|NCT05771402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815309|NCT00780988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815310|NCT01101633|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33815311|NCT01164319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815312|NCT05353725|||COHORT||RETROSPECTIVE|||||||
33815313|NCT02213094|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Phase 1 dose escalation study||||
33815314|NCT03057197|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33815315|NCT06319924|||COHORT||PROSPECTIVE|||||||
33815316|NCT04118998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The two arms or study interventions are indistinguishable by patients and untrained observers. The Care Providers (Study Intervention Therapists) can not be masked due to their knowledge in the delivery of the physical intervention.||t|f|t|t
33815317|NCT02547974|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33815318|NCT04429672|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|For the formation of the groups, a restrictive randomization was performed by fixed proportion considering the sample size required for the groups, in which the participant did not identify which group was assigned (simple blind)|It is a socio-educational intervention and is composed of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Conduct and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has an established opening, development and closing phase structure|t|f|f|f
33815319|NCT05164926|NA|SINGLE_GROUP||TREATMENT||NONE||two groups with St.John's Wort Oil control group||||
33815320|NCT04657718|NA|SINGLE_GROUP||OTHER||NONE||||||
33815321|NCT06467240|||COHORT||PROSPECTIVE|||||||
33840184|NCT02080962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840185|NCT00237536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840186|NCT03473600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840187|NCT04225481|||COHORT||PROSPECTIVE|||||||
33840188|NCT01722370|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34124822|NCT05386342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124823|NCT04916392|||CASE_ONLY||PROSPECTIVE|||||||
34124824|NCT01600404|||COHORT||PROSPECTIVE|||||||
34124825|NCT02281656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124826|NCT04676893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124827|NCT05353686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treatment is blinded for subjects, care provider and investigator.|This is a 4 weeks randomised, double-blind, placebo-controlled, parallel-group, prospective trial. Each subject will be randomised to 1 out of 2 possible treatment arms and treated for four weeks.|t|t|t|f
34124828|NCT06073197|RANDOMIZED|PARALLEL||OTHER||DOUBLE||randomized, controlled|t|f|f|t
34124829|NCT02362334|||||PROSPECTIVE|||||||
34124830|NCT04778748|||CASE_ONLY||PROSPECTIVE|||||||
34124831|NCT05363488|||COHORT||RETROSPECTIVE|||||||
34045894|NCT06507046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient, nurses and physiotherapists are blinded. Surgeon is of course not blinded.|Randomized controlled trial|t|t|f|t
34045895|NCT06196255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045896|NCT05373979|||CASE_CONTROL||PROSPECTIVE|||||||
34045897|NCT01834742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045898|NCT00530127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045899|NCT05000008|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34045900|NCT02550171|||COHORT||PROSPECTIVE|||||||
34045901|NCT03265951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045902|NCT03815877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All recruited women will be distributed into two groups according to a computer- generated randomization table. The researcher consecutively will open sequentially numbered, opaque, sealed envelopes containing cards with letters either letter (C) or letter (N), Cards with letter (C) will represent the group who will receive the caffeinated coffee and cards with letter (N) will represent the group who will receive the decaffeinated coffee|A randomized controlled trial|t|f|f|f
34045903|NCT06064994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research assistant, who was not involved in any other aspects of the study and was blinded to the randomized allocation, measured the study variables at three points of time|An experimental randomized repeated-measures, parallel control design|f|f|f|t
34045904|NCT01262157|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34045905|NCT02619084|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34045906|NCT06526468|||COHORT||PROSPECTIVE|||||||
34045907|NCT06212700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Consenting participants will undergo baseline assessment immediately prior to randomisation to intervention (virtual multimodal hub and usual care) or control group (usual care alone). The randomisation sequence will be prepared a priori using a central secure randomisation service (1:1 allocation ratio in random permuted blocks of sizes 4 or 2 stratified by hospital, to ensure balance intreatment assignment within hospital) to ensure concealment of treatment allocation and blinding of surgeon, all trial personnel and statistician. Due to the nature of the intervention, it is not possible to blind the clinicians delivering the intervention (virtual multimodal hub); however, the investigators will ensure that all patients' interactions are standardised.|Randomised Type I Hybrid Effectiveness-Implementation Trial|f|f|t|t
34045908|NCT01209000|||COHORT||PROSPECTIVE|||||||
34045909|NCT04817696|||COHORT||PROSPECTIVE|||||||
34045910|NCT06673212|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34045911|NCT04679350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045912|NCT05037045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045913|NCT01491347|||COHORT||PROSPECTIVE|||||||
34124832|NCT05064046|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|The research investigators will be blinded from the study arm of the participants.|Arm 1- LuCa + Health Disparity module: Providers enrolled in the LuCa+ arm will complete lesson 1 of the LuCa training and complete the Health Disparity module. Arm 2- LuCa module: Providers enrolled in the LuCa arm will complete session 1 of the LuCa training.|f|f|t|f
34124833|NCT00087984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124834|NCT02250872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34124835|NCT03962959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34124836|NCT00649285|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34124837|NCT02458872|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34124838|NCT03402932|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34124839|NCT05678166|||COHORT||PROSPECTIVE|||||||
34124840|NCT00925002|NA|||TREATMENT||NONE||||||
34124841|NCT00729443|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34124842|NCT02824692|||CASE_ONLY||PROSPECTIVE|||||||
34124843|NCT03460652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124844|NCT03776188|||COHORT||PROSPECTIVE|||||||
34124845|NCT04698070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124846|NCT02606318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34124847|NCT04460469|||OTHER||CROSS_SECTIONAL|||||||
34124848|NCT05411107|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34124849|NCT00002372||||TREATMENT||NONE||||||
34124850|NCT05632237|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|During baseline data collection, participants were not yet assigned to arms, so all parties were masked.|||||
34124851|NCT03954548|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34124852|NCT05345548|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124853|NCT05781152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124854|NCT05439551|||COHORT||PROSPECTIVE|||||||
34124855|NCT04530201|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124856|NCT04231097|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately N=20 patients (2 cohorts of 10 participants/per cohort, accounting for 20% anticipated lost to follow-up). Assignment to each cohort will be based on timing and/or participant scheduling preferences. Intervention cohort groups will be run either concurrently or sequentially, depending on the enrollment frequency of participants.||||
34124857|NCT04821934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34124858|NCT05011149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045914|NCT05584735|||COHORT||PROSPECTIVE|||||||
34045915|NCT05943106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124859|NCT02861287|||CASE_ONLY||RETROSPECTIVE|||||||
34124860|NCT03012334|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34124861|NCT01880190|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34124862|NCT04001439|NA|SINGLE_GROUP||OTHER||NONE||All patients will receive 30 microbiota capsules in take proceded by bowel lavage by 4 liters macrogo solution.||||
34124863|NCT00592631|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737251|NCT03433456|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Caregiver-child dyads will be randomized to either the intervention group (receiving home intervention + HABITS program) or the a control group to receive their standard of care (home intervention without HABITS)|f|f|f|t
34124864|NCT05775484|||COHORT||PROSPECTIVE|||||||
34124865|NCT01310946|||COHORT||PROSPECTIVE|||||||
34149820|NCT00618605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33737252|NCT05130775|||CASE_CONTROL||PROSPECTIVE|||||||
34124866|NCT04301323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"In the interventions group, the participants and the investigators will be masked to the nature of the drop dispensed. Upon receiving the product, the product will be coded and masked by a person other than the clinicians involved in the study. Only coded and masked product will be dispensed to the participant.~Unmasking should only occur in the case of an adverse event if knowledge of the trial treatment would alter the plan of care for the participant. If at all possible (if time permits) the Sponsor / The Independent Pharmacist should be consulted prior to unmasking. Thorough documentation must occur, and exposure to treatment knowledge should be limited only to those who must know."|"In the intervention group, there will be a minimum of 105 participants enrolled with the participants randomised to 3 groups of 35 in each group to receive either BHVI1, BHVI2 , or BHVI3 per group.~In the non-randomized, matched control group, there will be 105 other participants recruited with similar inclusion and exclusion criteria and similar procedures as outlined but without any eye drops."|t|t|t|t
34124867|NCT05407805|||COHORT||PROSPECTIVE|||||||
34124868|NCT02959788|||COHORT||PROSPECTIVE|||||||
34124869|NCT04862559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124870|NCT05086965|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34124871|NCT03346187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34124872|NCT01749527|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124873|NCT04767672|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||multicentre randomized, parallel arms, double-blind, placebo-controlled clinical trial|t|t|t|t
34124874|NCT00535769|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34124875|NCT01405404|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124876|NCT00178334|||COHORT||PROSPECTIVE|||||||
34124877|NCT06555341|RANDOMIZED|CROSSOVER||OTHER||NONE||"This research was designed as a mixed methods study. This type of methodology with the use of strong aspects of both quantitative and qualitative methods was selected to be able to discover different perspectives and determine relationships between complex layers of the research questions (Shorten \& Smith, 2017). The study was conducted as a randomised, controlled study at the quantitative stage and a descriptive phenomenonological design was used at the qualitative stage. The reporting of the study followed the guidelines of the Control List for the Development of Mixed Methods Research Methodology (Fetters \& Molina-Azorin, 2019)."||||
34124878|NCT05976659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124879|NCT05084248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124880|NCT04895930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124881|NCT02270281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124882|NCT01709552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838510|NCT04699942|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Following baseline measurement, either conventional low-flow oxygen delivery or oxygen delivery via the Revoxa Oxygen Rebreather device is initiated for 20 minutes, followed by the other modality for 20 minutes. The order of treatments will be determined quasi-randomly based on whether the patient is enrolled on an odd-numbered day, or an even-numbered day.||||
34124883|NCT04624789|||COHORT||PROSPECTIVE|||||||
34124884|NCT05225883|||CASE_CONTROL||PROSPECTIVE|||||||
33737253|NCT04800185|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Subjects will function as their own internal control with one lesion left untreated||||
33838511|NCT05858099|||COHORT||PROSPECTIVE|||||||
33838512|NCT00577057|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33737254|NCT01897311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737255|NCT05597020|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This is a multi-center, double-blind, randomized, placebo-controlled, 2-way cross-over post-approval study.|t|t|t|t
33737256|NCT06562036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737257|NCT00654849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737258|NCT05349448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737259|NCT06564376|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33737260|NCT06664177|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33737261|NCT02527057|||COHORT||PROSPECTIVE|||||||
33737262|NCT02953704|||COHORT||PROSPECTIVE|||||||
33737263|NCT06302764|||CASE_ONLY||CROSS_SECTIONAL|||||||
33737264|NCT05405673|||CASE_ONLY||CROSS_SECTIONAL|||||||
33737265|NCT03611634|||COHORT||PROSPECTIVE|||||||
33737266|NCT06533605|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737267|NCT04391010|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33737268|NCT06570772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737269|NCT03135223|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||One intervention and one control condition||||
33737270|NCT05621421|||COHORT||PROSPECTIVE|||||||
33737271|NCT03821571|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33737272|NCT04609319|||COHORT||OTHER|||||||
33737273|NCT03992105|NA|SINGLE_GROUP||OTHER||NONE||||||
33737274|NCT05379829|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
33737275|NCT05322603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737276|NCT05589545|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33737277|NCT01722851|||COHORT||PROSPECTIVE|||||||
33737278|NCT05328362|RANDOMIZED|PARALLEL||TREATMENT||NONE||Micro-Randomized Trial (MRT)||||
33737279|NCT03736421|||COHORT||PROSPECTIVE|||||||
33737280|NCT04997642|||COHORT||OTHER|||||||
33737281|NCT06556680|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Randomized control trial. patients will divided into two groups: 1) control group -Only regular bronchoscopy biopsy, and 2) OCT-guided imaging and biopsy.|t|f|t|f
33737282|NCT06155903|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The triple-blind approach (operating room anesthetist, surgeon, and patient) will be implemented as follows: a team will prepare the anesthetic mixtures in a dedicated room, isolated from the operating room and the Post-Anesthesia Care Unit (PACU) where a different team will be then responsible for the intra and postoperative management. The surgery will be conducted by the surgeon and the surgical team without knowledge of the anesthesiology procedure.||t|f|t|t
33737283|NCT04796610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737284|NCT06236035|||COHORT||PROSPECTIVE|||||||
33737285|NCT03047161|||CASE_CONTROL||RETROSPECTIVE|||||||
34124885|NCT00328029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124886|NCT05837871|||FAMILY_BASED||PROSPECTIVE|||||||
34124887|NCT04642521|||CASE_CONTROL||PROSPECTIVE|||||||
34124888|NCT03011749|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34124889|NCT01761708|||COHORT||PROSPECTIVE|||||||
34124890|NCT03816722|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|As blinding of high flow treatment in not possible this is an open label study|Prospective, unblinded cross over study||||
34124891|NCT05399927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34124892|NCT02620475|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34124893|NCT05356273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34124894|NCT06164522|||OTHER||CROSS_SECTIONAL|||||||
34124895|NCT02192567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124896|NCT01087983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124897|NCT03228862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124898|NCT03675113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34124899|NCT01365793|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34124900|NCT04005495|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124901|NCT02485587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124902|NCT01144143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124903|NCT06041009|||CASE_CONTROL||PROSPECTIVE|||||||
34124904|NCT01462929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124905|NCT00132301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Endpoint Committee will adjudicate evidence for progression, metastasis, and cause of death. The committee will be blinded to the treatment assignment.||f|f|f|t
34124906|NCT00987285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34124907|NCT00777595|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34124908|NCT02314676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124909|NCT02479880|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124910|NCT02543853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34124911|NCT04475159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124912|NCT03856359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124913|NCT04211454|||CASE_ONLY||PROSPECTIVE|||||||
34124914|NCT04680624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124915|NCT04875494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Three independant groups including two intervention groups (Physical Exercise vs. Group Therapy) and one control group||||
34124916|NCT01726543|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34124917|NCT01070134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124918|NCT06547762|NA|SEQUENTIAL||TREATMENT||NONE||Control group and Intervention group||||
34124919|NCT04963023|||CASE_ONLY||PROSPECTIVE|||||||
34124920|NCT02566811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737286|NCT03160703|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Single centre, randomised, examiner blind, parallel design study to evaluate the buildup of extrinsic dental stain over a 4 week treatment period|f|f|f|t
33737287|NCT04682600|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737288|NCT00253526||||TREATMENT||||||||
33737289|NCT05053386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737290|NCT03127397|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33737291|NCT03139656|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33737292|NCT06664684|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737293|NCT05458349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||It is a Level 1 study, a prospective double blind, randomized controlled trial.|t|f|f|t
33737294|NCT04713748|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Participants will collect a small blood sample using the Tasso-SST OnDemand device during a serology blood draw visit already scheduled for the MURDOCK C3PI Study (Pro00105703). Participants will be provided a kit that includes written, step-by-step instructions that include pictures. Participants will also have the option to watch a brief video on using the device, available online, prior to collection.||||
33737295|NCT00650533|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33737296|NCT01044979|||COHORT||PROSPECTIVE|||||||
33815322|NCT05077046|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be informed that the effect of the handwriting pen design on different physiological parameters will be investigated within the study. Although participants know that they will execute the test battery twice with two different handwriting pens, they will receive no information on which of the pens will be the intervention of interest (intervention pen). To realize an efficient masking process, control pens will be exclusively created for the study. Control pens will be made of the same material and will contain cartridge. They will only differ in design.||t|f|f|f
33815323|NCT06173622|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815324|NCT05125614|||COHORT||RETROSPECTIVE|||||||
33815325|NCT00901459|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33815326|NCT00674765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815327|NCT06415825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which group they will be in.|Both groups will receive standard advice. The maneuver group will receive additional advice - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.|t|f|f|f
34124921|NCT03605264|||CASE_ONLY||PROSPECTIVE|||||||
34151112|NCT03499327|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The wheat germ oil is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018).|"The randomized, single-blind human intervention study will be conducted in parallel design.~Half of the participants (n = 17) will consume wheat germ oil UV-treated (intervention) and half of the participants (n = 17) will consume wheat germ oil untreated (placebo). The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~The third group (n = 16) do not receive any study products (control)."|t|f|f|f
34151113|NCT02259855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151114|NCT01536483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737297|NCT05795023|NA|SINGLE_GROUP||OTHER||NONE||All patients will be assessed with MDS-UPDRS and oculometric examination over time||||
33737298|NCT06572488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737299|NCT04406805|||COHORT||PROSPECTIVE|||||||
33737300|NCT02923375|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33737301|NCT06100068|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737302|NCT04595838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737303|NCT01376011|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33737304|NCT00934271|||COHORT||RETROSPECTIVE|||||||
33737305|NCT00125554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33737306|NCT00733824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737307|NCT03227380|NA|SINGLE_GROUP||OTHER||NONE||patients undergo anatomic segmentectomy by video-assisted thoracoscopic surgery (VATS)||||
33737308|NCT00722644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33737309|NCT04949672|||COHORT||PROSPECTIVE|||||||
33737310|NCT04068675|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33737311|NCT05911802|||COHORT||OTHER|||||||
33737312|NCT04101526|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33737313|NCT00949780|NA|SINGLE_GROUP||||NONE||||||
33737314|NCT02734485|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33737315|NCT04661176|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33737316|NCT03835858|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, quasi-experimental study||||
33737317|NCT01438632|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33737318|NCT00718718|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33737319|NCT06663436|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33737320|NCT04060121|||COHORT||PROSPECTIVE|||||||
33737321|NCT05075876|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737322|NCT05979805|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"* The examiner calibrated and certified in the International Caries Detection and Assessment System (ICDAS) visual diagnostic criteria for dental caries at T0, T1, T2 and T3 (primary outcome)~* The examiner calibrated in measurement of risk variables (secondary outcomes) like plaque index, habits of oral hygiene and habits in sugar consumption.~* Statistician"|A controlled, randomized, parallel and pragmatic clinical study is proposed for the evaluation of the effect of conventional educational interventions and motivational interviewing in comparison with conventional educational interventions, in the prevention of dental caries lesions in 94 patients aged 13 to 44 years old, who will begin corrective orthodontic treatment with fixed appliances in the postgraduate clinics of Orthodontics and Maxillary Orthopedics of the National University of Colombia.|f|t|t|t
33737323|NCT01103531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737324|NCT05319418|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33737325|NCT04485481|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33737326|NCT06166953|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Those who accepted the study were asked to read the Informed Volunteer Consent Form indicating that they volunteered to participate in the study, and the control and intervention group patients were instructed not to share information about the application with each other in order to prevent them from being influenced by each other in the outpatient clinic environment/institution."|A mobile application will be developed by software engineer including informational needs of breast cancer patients starting prior to surgery lasting to discharge. Expert opinion will be obtained about contents of mobile application. The application will be downloaded smart phones of patients for use when needed. Patients who meet the inclusion criteria will be informed about the research by the researcher according to the randomization list, and their consent will be obtained from those who agree to participate in the research. Due to the study design, patients will not know which intervention is being applied to them, and it will be done single-blinded. The application will be carried out by the researcher knowing the patients in the intervention and control groups. The analysis of the data coded as A and B will be done by a statistician.|t|f|f|t
33737327|NCT05864027|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33737328|NCT02985736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737329|NCT06573593|||COHORT||PROSPECTIVE|||||||
33737330|NCT01150838|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"This is a single study with 6 parallel groups as noted in the description. With Dixon's Up and Down Method for determining a 50th percentile of a dichotomous outcome, the number of patients required is not known prior to starting a study. Data from Paul and Fisher demonstrated that 6 crossovers (change in the dichotomous outcome from one patient to another, indicating change from increasing the dose of the study drug to decreasing it, or visa-versa). When choosing a meaningful starting point near the 50th percentile, the number required is typically 15-20 patients. With 6 study groups, the estimated number of patients required would be 90-120. Please Note: This is not a study where one can perform a power analysis and determine a required N."||||
33737331|NCT06011213|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737332|NCT00672438|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33737333|NCT05433883|RANDOMIZED|PARALLEL||TREATMENT||NONE||The research plan to enroll 15 simple snoring patients (apnea/hypopnea \<5, control group), 30 severe OSA patients (apnea/hypopnea \>30, treatment group), and 15 mild cognitive impairment patients (comparative group). All patients complete Mini-Mental State Examination, peripheral blood sample for plasma Aβ42, Aβ40, Aβ42/Aβ40, Tau, NfL; amyloid deposit in18F-florbetapir PET; and Taiwan smell identification test. Thirty severe OSA patients (AHI\>30, treatment group) receive comprehensive upper airway surgery with/without bariatric surgery and repeat postoperative assessment in polysomnography and aforementioned examinations 1 year later.||||
33815328|NCT00134056|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815329|NCT05019014|||COHORT||PROSPECTIVE|||||||
33815330|NCT05667740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045916|NCT01528982|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045917|NCT03468686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33737334|NCT05856292|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Group 1: Placebo Group 2: Teach-Back||||
33737335|NCT00477919|||OTHER||OTHER|||||||
33737336|NCT05895006|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33737337|NCT02566551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34045918|NCT05751317|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34045919|NCT00065936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34045920|NCT00690001|||COHORT||CROSS_SECTIONAL|||||||
34045921|NCT04840056|||COHORT||RETROSPECTIVE|||||||
34045922|NCT05319821|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34045923|NCT01017133|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34045924|NCT06060951|||COHORT||PROSPECTIVE|||||||
34045925|NCT05502237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045926|NCT01451528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045927|NCT01219426|||||PROSPECTIVE|||||||
34045928|NCT04364438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The total sample will be divided into three groups i.e., Control group and two experimental groups. Control group will be treated with conventional medical treatment including anticholinergics and pelvic floor muscle exercises while 1st experimental group will be treated with conventional treatment and EMS and the 2nd experimental group will be treated with conventional treatment and TENS.~initial results will be measured by Overactive Bladder Scoring System and King's Health Questionnaire. A follow up chart will be maintained after every 03 weeks regarding the symptoms of the patients and Quality of Life. After 12 weeks( completion of treatment) the patient will be re evaluated for their symptoms and graded by using Overactive Bladder Scoring System and King's Health Questionnaire.~A comparison will be made among data obtained from 03 groups to check the effectiveness of intervention by using statistical analysis"|t|f|f|f
34045929|NCT03813901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045930|NCT04614051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045931|NCT02543905|||COHORT||PROSPECTIVE|||||||
34045932|NCT02293135|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045933|NCT02731352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045934|NCT02958735|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34045935|NCT04713631|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|double-blind||t|f|t|f
34045936|NCT04230564|||COHORT||RETROSPECTIVE|||||||
34045937|NCT04866758|||COHORT||CROSS_SECTIONAL|||||||
34045938|NCT01989325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045939|NCT05450081|||COHORT||RETROSPECTIVE|||||||
34045940|NCT05939869|||COHORT||RETROSPECTIVE|||||||
34045941|NCT00001409||||TREATMENT||||||||
34045942|NCT06167460|||COHORT||PROSPECTIVE|||||||
34045943|NCT03860402|||CASE_CONTROL||PROSPECTIVE|||||||
34045944|NCT00861393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045945|NCT03055338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A double-blind/masking technique will be used. MK-8189 and risperidone will be packaged identically relative to their respective matching placebo so that blinding/masking is maintained.|Participants will be randomly assigned to one of three groups in parallel for the duration of the study.|t|t|t|t
34045946|NCT04727060|||COHORT||OTHER|||||||
34045947|NCT05316961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045948|NCT05560308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045949|NCT00003571|||CASE_ONLY||PROSPECTIVE|||||||
34045950|NCT01197703|||CASE_ONLY||PROSPECTIVE|||||||
34045951|NCT06223399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients cannot be blinded for the treatment allocation, because the person who programs the DBS receives either dictated stimulation parameters based on imaging or proceeds with care as usual with the threshold assessment. Blinded assessment of the primary outcome will be done by means of a physical examination blinded for randomization arm.|The study will be a mono center prospective randomized open label blinded endpoint (PROBE) design trial comparing imaging-based DBS programming with DBS programming based on threshold assessment.|f|f|f|t
34045952|NCT00347139|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34045953|NCT05084651|NA|SEQUENTIAL||TREATMENT||NONE||||||
34045954|NCT04559100|||COHORT||PROSPECTIVE|||||||
34045955|NCT05051930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045956|NCT04468308|||COHORT||PROSPECTIVE|||||||
34045957|NCT04095195|||COHORT||PROSPECTIVE|||||||
34045958|NCT06246240|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34045959|NCT02359487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34045960|NCT06576557|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34045961|NCT02405546|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
34045962|NCT06173037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045963|NCT00723762|||CASE_CONTROL|||||||||
34045964|NCT05174832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045965|NCT05938764|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two phases: Phase one: a feasibility (N = 9) non-randomized, one-group design wherein all participants received culturally adapted Motivational Interviewing and Community Reinforcement Approach (MICRA) Phase two: This study used a mixed efficacy/effectiveness (hybrid) randomized controlled trial of two treatment arms (Treatment as usual-TAU and Motivational Interviewing and Community Reinforcement Approach-MICRA) with a parallel design and follow-up assessments at 4-, 8-, and 12-months post baseline||||
34045966|NCT05582408|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34045967|NCT03429933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045968|NCT05386017|||COHORT||PROSPECTIVE|||||||
34045969|NCT04402099|||COHORT||PROSPECTIVE|||||||
34045970|NCT01109953|||COHORT||PROSPECTIVE|||||||
34045971|NCT05345002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study has a Safety Run-In, a Phase 2 Portion with Arm A and Arm B and a Surgical Portion with Arm C and Arm D. .||||
34045972|NCT06517056|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||The study design is with 1:1 treatment arms: 1) KneeKG informed cared or 2) usual care without any information from the KneeKG|t|f|f|f
34045973|NCT04705961|||CASE_ONLY||OTHER|||||||
34045974|NCT02861378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045975|NCT00200876|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||Hypertonic saline is a challenge to activate endogenous opioid systems as assessed with positron emission tomography. There is no treatment involved. Isotonic saline is the control.|t|f|t|t
34045976|NCT04160546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045977|NCT04545567|RANDOMIZED|CROSSOVER||OTHER||NONE||A randomized cross-over trial assessing glycemic responses to two different approaches to insulin dosing for carbohydrate ingestion (announced vs. unannounced), with two different AP systems (RocketAP vs. USS Virginia, aka Control-IQ, in random order)||||
34045978|NCT04830371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34045979|NCT01964144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151115|NCT04387266|||COHORT||RETROSPECTIVE|||||||
34045980|NCT01151527|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737338|NCT06424301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737339|NCT00298896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737340|NCT02864797|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33737341|NCT05108181|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants don't know their muscle typology during the study. All participants do the same training intervention, no drugs are taken.|All participants will receive the same training intervention but the subjects are divided into two groups based on an inherent physiological characteristic: the muscle typology. A slow typology group (people with a lot of slow muscle fibers) and a fast typology group (people with a lot of fast muscle fibers). Each participant will train their legs and arms unilateral and one arm and one leg will train two times per week, while the other arm and leg will train three times per week for 9 weeks. The assignment of the limbs to the 3x/week condition and the 2x/week condition is randomized. The training outcomes of the two groups will be compared as well as the within subject differences between training two times per week or training 3 times per week.|t|f|f|f
33737342|NCT04885517|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33737343|NCT01070810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737344|NCT04745143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737345|NCT03840161|||COHORT||PROSPECTIVE|||||||
33737346|NCT06269328|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33737347|NCT03861000|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737348|NCT01160965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737349|NCT00756158|||FAMILY_BASED||OTHER|||||||
33737350|NCT06074016|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737351|NCT03969342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737352|NCT06028867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed envelopes|The study was designed as a double-blind randomized controlled trial (RCT) with three parallel groups of individuals.|t|t|f|f
33737353|NCT00162136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737354|NCT00213174|RANDOMIZED|PARALLEL||||NONE||||||
33737355|NCT00917059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34045981|NCT05862350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045982|NCT05420350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Subjects randomized to receive lamotrigine and bupropion or matching placebo randomized 1:1|t|t|t|t
33737356|NCT02436512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737357|NCT01339533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737358|NCT04304001|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Participant will complete surveys and receive mailings and not know if they are in control arm or intervention arm.|Participants will be randomly assigned to the TUNE-UP intervention or a control group that will receive educational materials about colorectal cancer screening plus a resource list but no Community Health Advisor counseling support or cellphone / text contact like in the TUNE-UP Community Health Advisor intervention group.|t|f|f|f
33737359|NCT05247918|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter prospective randomized controlled trial.||||
33815331|NCT01739738|||COHORT||PROSPECTIVE|||||||
33815332|NCT02627586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815333|NCT01839032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815334|NCT02788435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815335|NCT00004250||||TREATMENT||NONE||||||
34045983|NCT00802984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045984|NCT06221241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34045985|NCT02921932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34045986|NCT06074224|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34045987|NCT00312832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045988|NCT02621684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34045989|NCT00952159|||COHORT||PROSPECTIVE|||||||
34045990|NCT06572982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34045991|NCT06685029|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fifty two patients were divided into 4 groups at our study: Group A - Direct In-House Aligner, Group B - Invisalign group, Group C - Clear Correct group, Group D - Fixed Orthodontic Treatment group. Digital models will be obtained from the patients included in our study. In addition, QLF records will be collected from patients at the beginning and end of treatment and saliva samples will be taken at different times of treatment. These saliva samples will be analyzed for Bisphenol A content. The groups will also be compared for the development of white spot lesions. The total treatment time of patients receiving clear aligner treatment and fixed orthodontic treatment will be measured. Treatment effectiveness will be evaluated by scoring digital 3D models taken from patients with the PAR (Peer Assessment Rating) index.||||
34045992|NCT01550263|||COHORT||PROSPECTIVE|||||||
34045993|NCT00077142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34045994|NCT02639650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34045995|NCT04096482|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who have had prior ESS and are scheduled for nasal endoscopy as part of a routine post-operative office visit or due to recurrence of symptoms will be evaluated with the standard endoscope followed by the Peregrine Endoscope.||||
34045996|NCT06116071|||CASE_CONTROL||OTHER|||||||
34045997|NCT02277613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34045998|NCT01513720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34045999|NCT00419861|||CASE_ONLY||PROSPECTIVE|||||||
34046000|NCT06110702|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046001|NCT02285166|||COHORT||PROSPECTIVE|||||||
34046002|NCT02894944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046003|NCT05973305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046004|NCT05146518|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||It will be a theory-driven, inclusive service-delivery package which will be developed using the principles of the human-centred design approach. The model will include capacity-building of maternity teams, and the improvement of governance and accountability mechanisms within public health facilities to ensure that all women are treated with compassion and dignity, while also catering for their diverse needs, including disabilities and common mental health conditions. The integration of psychosocial support in routine maternity care will be a unique feature of the intervention package, a principal aim of which is to address the psychological needs of birthing women and their companions.||||
33815336|NCT03639545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34124922|NCT05484466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The study is planned to enroll 90 adult CHB subjects who have received ETV monotherapy for at least 12 months and are still receiving ETV monotherapy (0.5 mg, QD) continuously. Eligible subjects will be randomized in a 1:1:1 ratio into 3 treatment groups. Both HBeAg positive and negative subjects will be included. There will be 20 HBeAg positive subjects and 10 HBeAg negative subjects in each treatment group. The treatment regimens in each group are as follows:~Group A: ZM-H1505R 50 mg QD + Baraclude 0.5 mg QD Group B: ZM-H1505R 100 mg QD + Baraclude 0.5 mg QD Group C: ZM-H1505R placebo QD + Baraclude 0.5 mg QD After 48 weeks of treatment with the corresponding regimen, subjects will continue to take Baraclude 0.5 mg QD, as a monotherapy for a 12-week follow-up period for observation of efficacy and safety of ZM-H1505R."|t|t|t|t
34124923|NCT01545765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124924|NCT02681653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124925|NCT01787877|||COHORT||PROSPECTIVE|||||||
34124926|NCT04735653|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34124927|NCT05949918|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|"The researchers will use two groups (study and control) in which participants will be randomly selected and assigned in each of the study and control groups using simple random sampling.~The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in."||t|f|f|f
34124928|NCT01504100|||COHORT||PROSPECTIVE|||||||
34124929|NCT01789242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124930|NCT02870985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124931|NCT02946346|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34124932|NCT00413660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124933|NCT01526941|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34124934|NCT00119197|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124935|NCT00002186||||TREATMENT||DOUBLE||||||
34124936|NCT00102986|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124937|NCT01592474|||COHORT||PROSPECTIVE|||||||
34124938|NCT03429738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||open-label, single-dose, randomized, two-period, two-treatment, twosequence, crossover, comparative bioavailability study.||||
34124939|NCT04001491|||COHORT||RETROSPECTIVE|||||||
34124940|NCT01381367|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34124941|NCT04590053|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34124942|NCT02278315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124943|NCT03704038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124944|NCT01987791|||CASE_CONTROL||RETROSPECTIVE|||||||
34124945|NCT00374517||||TREATMENT||||||||
34124946|NCT01524393|||||CROSS_SECTIONAL|||||||
34124947|NCT03117959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34124948|NCT06213207|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|As this is a cluster randomized controlled trial, masking is not possible. The intervention participants from intervention cluster receive intervention and control will be receiving usual services. The outcomes assessor will not be known about the name of health facilities. This is done using coding of the health facilities.|The intervention is targeted to provide simulator based training to newborn care service providers. The training is comprised of essential newborn care practices and the providers will be followed up and provided mentoring and coaching for the period of six months.|f|f|f|t
34124949|NCT02209935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34124950|NCT00886418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124951|NCT02607124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124952|NCT03138785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34124953|NCT02631291|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34124954|NCT00006132||||TREATMENT||||||||
34124955|NCT06160141|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessor was blind to the primary outcome|Training groups vs. Control Group|f|f|f|t
34124956|NCT06315452|||COHORT||RETROSPECTIVE|||||||
33815337|NCT00540800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815338|NCT02344706|||COHORT||PROSPECTIVE|||||||
33815339|NCT06432023|||COHORT||PROSPECTIVE|||||||
33815340|NCT00253851|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33815341|NCT06498323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815342|NCT05555199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, single-center, non-randomized, interventional study.||||
33815343|NCT01864980|||COHORT||PROSPECTIVE|||||||
33815344|NCT03526302|||COHORT||PROSPECTIVE|||||||
33815345|NCT04799756|||OTHER||OTHER|||||||
33815346|NCT03858556|||CASE_CONTROL||PROSPECTIVE|||||||
33815347|NCT04206618|||CASE_CONTROL||PROSPECTIVE|||||||
34124957|NCT01465386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124958|NCT03693144|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34124959|NCT02574728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124960|NCT05159258|||CASE_ONLY||RETROSPECTIVE|||||||
34124961|NCT04303910|||CASE_ONLY||RETROSPECTIVE|||||||
34124962|NCT02473471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34124963|NCT05796388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant or their treating provider will not know if they have been assigned to the sham VR or immersive VR program.|There will be two groups. One will receive the sham VR the other will receive immersive VR.|t|t|f|f
34124964|NCT01963988|||COHORT||PROSPECTIVE|||||||
34124965|NCT00135616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124966|NCT03082677|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase 2 study to evaluate a post-transplant proteasome inhibitor, ixazomib, as prophylaxis against recurrent or late acute and chronic GVHD. Ixazomib will be initiated within days 100 to 150 post-transplant in patient's ≥ 18 years-old with either myeloid or lymphoid hematologic malignancy treated with a RI or NMA HSCT and will have received calcineurin inhibitor based drug (tacrolimus or cyclosporin) and methotrexate as part of their initial GVHD prophylaxis.||||
34124967|NCT00989508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34124968|NCT03281629|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34124969|NCT02905279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124970|NCT00124930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34124971|NCT02778984|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124972|NCT02065492|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34124973|NCT00644826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34124974|NCT03727971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All packaging and labeling of the biological drugs and placebo will be done in a way that ensures blinding for the investigator site staff. Glostrup pharmacy, the hospital pharmacy at the Capital region, will manage randomization and blinding.~Participants will be randomized in two equally big groups, one receiving omalizumab and one receiving placebo, by a computer based program, blinded to investigator. It will be randomized to blocks of 10, in total 16 blocks. It will be automated random assignment of subject numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers."|A randomized, double blinded, parallel group, study|t|f|t|t
34124975|NCT02315703|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34124976|NCT03069508|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124977|NCT01123343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124978|NCT01552837|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34124979|NCT06432686|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|All participants receive both active and sham TENS. Subjects will be told they will get two types of stimulation but they are not being told that one is 'sham' and the other 'active', to minimalize a placebo effect. Researchers are not blinded, but also interacting minimally with the participant while they are lying in the scanner.|"* sham stimulation of the tibialis anterior,~* active stimulation of the tibialis anterior,~* active stimulation of the quadriceps,~* continuous movement of the foot (plantar \& dorsiflexion),~* a combination of sham stimulation of the tibialis anterior and movement of the foot,~* a combination of stimulation of the tibialis anterior and movement of the foot.~The order of these conditions is randomized."|t|f|f|f
34124980|NCT04187261|||COHORT||RETROSPECTIVE|||||||
34124981|NCT02214069|||COHORT||PROSPECTIVE|||||||
34124982|NCT02118948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34124983|NCT04544735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124984|NCT06004297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34124985|NCT02175277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34124986|NCT03159208|||COHORT||PROSPECTIVE|||||||
34124987|NCT04799002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124988|NCT02151656|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34124989|NCT02890459|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34124990|NCT05223998|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of concept||||
34124991|NCT02692963|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34124992|NCT01842711|||COHORT||CROSS_SECTIONAL|||||||
34124993|NCT04719221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34124994|NCT04122872|||COHORT||CROSS_SECTIONAL|||||||
34124995|NCT01866748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34124996|NCT01235663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34124997|NCT02512445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||188 enrollment goal for primary study, 75 enrollment goal for 2021 pandemic guilt supplement study|f|f|f|t
34124998|NCT01550601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34124999|NCT01428310|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34125000|NCT05745766|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125001|NCT04718740|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34125002|NCT03618667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125003|NCT05533632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125004|NCT04472169|||COHORT||PROSPECTIVE|||||||
34125005|NCT04199065|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125006|NCT05922345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125007|NCT05687981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125008|NCT00118274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125009|NCT01220102|||COHORT||PROSPECTIVE|||||||
34125010|NCT00399074|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125011|NCT06364917|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125012|NCT01151020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125013|NCT04541485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125014|NCT01206829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125015|NCT05010083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125016|NCT00808392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34125017|NCT02112305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125018|NCT03637322|||COHORT||PROSPECTIVE|||||||
34125019|NCT01955460|NA|SINGLE_GROUP||TREATMENT||||||||
34125020|NCT03698643|||OTHER||RETROSPECTIVE|||||||
34125021|NCT05865301|||COHORT||OTHER|||||||
34125022|NCT01563900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125023|NCT04408677|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34125024|NCT03255889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125025|NCT02479204|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125026|NCT03154671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcome assessor and statistician will be blinded to group allocation||f|f|f|t
34125027|NCT02126046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815348|NCT04644692|||CASE_CONTROL||PROSPECTIVE|||||||
33815349|NCT06443736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815350|NCT01049815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125028|NCT00728156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125029|NCT00127881|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125030|NCT01907607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125031|NCT00983866|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125032|NCT05555342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125033|NCT05860348|||COHORT||PROSPECTIVE|||||||
34125034|NCT02969915|RANDOMIZED|PARALLEL||TREATMENT||NONE||Matched-pair cluster-randomized trial||||
34125035|NCT04105959|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34125036|NCT00539123|RANDOMIZED|FACTORIAL||TREATMENT||NONE||2x2 factorial design||||
34125037|NCT06029062|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34125038|NCT03751826|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The unit of randomisation will be pairs of peer navigators: 21 pairs of peer navigators will be randomised to 3 arms: two intervention arms, and standard of care (7 pairs per arm).|f|f|t|t
34125039|NCT01308255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125040|NCT02308267|||COHORT||PROSPECTIVE|||||||
34125041|NCT03138525|||COHORT||PROSPECTIVE|||||||
34125042|NCT04636567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125043|NCT01211392|||||PROSPECTIVE|||||||
34125044|NCT02141672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125045|NCT02664480|||CASE_CONTROL||PROSPECTIVE|||||||
34125046|NCT00599352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125047|NCT02688192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125048|NCT04791293|||COHORT||PROSPECTIVE|||||||
34125049|NCT02954224|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34125050|NCT00703742|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34125051|NCT01598714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125052|NCT01883700|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34125053|NCT06004154|||COHORT||PROSPECTIVE|||||||
34125054|NCT03775499|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34125055|NCT02343848|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125056|NCT01885650|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34125057|NCT00375674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125058|NCT02393339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34125059|NCT04164810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125060|NCT01722344|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34125061|NCT06193564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125062|NCT04202666|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34125063|NCT01509846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125064|NCT01822769|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125065|NCT06406244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of participants will be maintained throughout the observation period. The sham group will receive electrode attachment but without stimulation. Throughout the study, for adequate blinding, an opaque tape will be applied to the patient's skin above the electrodes, and the patient's target acupoints will be wrapped in a blanket. All patients will be informed that they might or might not feel a tingling sensation around the acupoints when the TEAS device is working. The patients should not be unblinded until the statistical analysis of the study data is completed.|Patients who meet the enrollment criteria will be randomized 1:1 to either the transcutaneous electrical acupoint stimulation (TEAS group) or the sham groups using a computer-generated random number table.|t|f|f|t
34125066|NCT01145963|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34125067|NCT04132414|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34125068|NCT02901691|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125069|NCT04003844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125070|NCT02733744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125071|NCT04414540|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be on one of two arms that will be studied in parallel.||||
34125072|NCT02922946|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125073|NCT02489149|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125074|NCT01774773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125075|NCT05741892|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective case series||||
34125076|NCT01737762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125077|NCT00211289|RANDOMIZED|PARALLEL||||DOUBLE||||||
34125078|NCT00257946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125079|NCT01849315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125080|NCT03751371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125081|NCT02605356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125082|NCT03040089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125083|NCT04781556|||COHORT||RETROSPECTIVE|||||||
34125084|NCT06493175|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34125085|NCT06377384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737360|NCT03905551|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The current study is a randomized clinical trial lasting for 7 months. Hemodialysis patients, which fulfilled the inclusion criteria, randomly divided into two groups: a) typical dialysis with dialysate temperature at 37°C (TD+EX) in combination with aerobic intradialytic exercise training, b) cold dialysis with dialysate temperature at 35°C (CD) in combination with aerobic intradialytic exercise training (CD+ET).~Patients enrolled by a research assistant assigned into the study while the order that the patients assigned to the first scenario was randomly using a computer random number generator."||||
33737361|NCT02710526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737362|NCT01648777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737363|NCT00512733|||||PROSPECTIVE|||||||
33815351|NCT01862224|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125086|NCT00457847|||COHORT||PROSPECTIVE|||||||
34125087|NCT03384186|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125088|NCT00038090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125089|NCT01715428|||CASE_ONLY||PROSPECTIVE|||||||
34125090|NCT02621476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125091|NCT02379195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125092|NCT01466283|||CASE_CONTROL||RETROSPECTIVE|||||||
34125093|NCT05410496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125094|NCT03117647|||CASE_ONLY||PROSPECTIVE|||||||
34125095|NCT06260605|NA|SINGLE_GROUP||OTHER||NONE||||||
34125096|NCT01187095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34125097|NCT01714323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125098|NCT01853891|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34125099|NCT01027650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125100|NCT03033680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815352|NCT00600366|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815353|NCT03612388|||COHORT||PROSPECTIVE|||||||
33815354|NCT02875444|||CASE_ONLY||RETROSPECTIVE|||||||
33815355|NCT06031493|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, multi-institutional, national, randomized clinical trial with two parallel arms.||||
33815356|NCT03943771|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815357|NCT04420351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815358|NCT03964272|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33815359|NCT03882944|||COHORT||PROSPECTIVE|||||||
34046005|NCT03486301|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||BDB001 followed by combination treatment with KEYTRUDA®||||
34046006|NCT06093516|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The ARUTIS study is a double-masked randomised controlled trial (RCT) having a double-masked crossover (AB/BA) design|t|t|t|t
34046007|NCT02692183|||CASE_ONLY||PROSPECTIVE|||||||
34046008|NCT06215573|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Coded, known only to manufacturer / collaborator|Randomised cross over trial counterbalanced for trial order|t|t|t|t
34046009|NCT03752411|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34046010|NCT05454748|||CASE_CONTROL||PROSPECTIVE|||||||
34046011|NCT05294237|RANDOMIZED|PARALLEL||PREVENTION||NONE|The clubs will be randomly assigned to either the control or intervention group at a 1:1 allocation ratio, using a computer-generated randomisation schedule. The randomisation will be performed by a person not else involved in the trial.|||||
34046012|NCT04822688|||CASE_ONLY||PROSPECTIVE|||||||
34046013|NCT03193320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be under general anesthesia during the interventions. Outcome assessors (nurses) will be blinded to the treatment provided in the operating rooms||t|f|f|t
34046014|NCT04600817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046015|NCT00733850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046016|NCT06683950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046017|NCT01476878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046018|NCT04514874|||COHORT||PROSPECTIVE|||||||
34046019|NCT06461936|||COHORT||OTHER|||||||
34046020|NCT05187936|||OTHER||PROSPECTIVE|||||||
34046021|NCT01006876|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046022|NCT02119455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046023|NCT01109667|||COHORT||PROSPECTIVE|||||||
34046024|NCT03133065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046025|NCT01909193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046026|NCT01542489|||COHORT||PROSPECTIVE|||||||
34046027|NCT01786135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046028|NCT01046903|||COHORT||PROSPECTIVE|||||||
34046029|NCT04712448|||OTHER||RETROSPECTIVE|||||||
34046030|NCT06194110|||CASE_CROSSOVER||PROSPECTIVE|||||||
34046031|NCT02924285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046032|NCT01659593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046033|NCT00701467|||COHORT||PROSPECTIVE|||||||
34046034|NCT03050775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients were randomly assigned to either the treatment group or the control group prior to surgery. Group randomization was performed using a randomization schedule prepared by the Division of Clinical Statistics with patients randomized in blocks of four. For consented and enrolled patients on the day of surgery in the admit areas, a participant was assigned the next sequential participant ID number and the appropriate sealed envelope was opened to reveal the participant's randomized intervention. This occurred before the patient was transferred to the operating suite. Individuals who performed data analysis were blinded to treatment group.|randomized, trial (treatment or no treatment)|t|f|f|t
34046035|NCT03468270|||CASE_ONLY||PROSPECTIVE|||||||
34046036|NCT04664036|||CASE_CONTROL||PROSPECTIVE|||||||
34046037|NCT01811810|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046038|NCT04462068|||COHORT||PROSPECTIVE|||||||
34046039|NCT05896904|NA|SINGLE_GROUP||SCREENING||NONE||||||
34046040|NCT03687333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046041|NCT06575816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34046042|NCT00054431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046043|NCT04963322|||COHORT||RETROSPECTIVE|||||||
34046044|NCT03612661|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to either a group or guided self-help condition, of the same intervention, intuitive eating, of the same duration (8 weeks).||||
34046045|NCT04671498|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34046046|NCT06524830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046047|NCT03970889|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Subjects are randomized so that half will use the Klue App in the first 6 weeks of the study, and half will use the Klue App during the second 6 weeks of the study.||||
34046048|NCT06303557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046049|NCT06524414|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Parallel assignment|t|t|t|t
34046050|NCT04571645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046051|NCT03283410|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34046052|NCT02586532|||COHORT||PROSPECTIVE|||||||
34046053|NCT00284492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046054|NCT01094561|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046055|NCT02841670|||COHORT||PROSPECTIVE|||||||
34046056|NCT03046667|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The beverages are provided to the investigator and volunteers with similar color, taste and bottles, only labelled A or B.||t|t|t|t
34046057|NCT03981484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046058|NCT01653678|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34046059|NCT00576420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046060|NCT06315829|||OTHER||PROSPECTIVE|||||||
34046061|NCT02210598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046062|NCT06685406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046063|NCT03493802|||CASE_CONTROL||PROSPECTIVE|||||||
34125101|NCT01471223|||COHORT||OTHER|||||||
34125102|NCT04967066|||COHORT||CROSS_SECTIONAL|||||||
34125103|NCT00198328|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046064|NCT04215679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be evaluated at baseline, 6 weeks later by an another investigator who does not aware of groups.|The first group of the study is immersive virtual reality therapy (IVR), the second group is motor imagery therapy (MI), and the third group is the conventional physiotherapy group (CG).|f|f|f|t
34046065|NCT06684717|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Random permuted blocks design was used to randomly assign each participant into video education intervention and usual care group by a research assistant, without the principal investigator knowing.|Inclusion criteria were adults (older than age 18) who were diagnosed with moderate to severe OSA or mild OSA with an indication for CPAP therapy by standard polysomnography (PSG) from 1 December 2022 and 31 May 2023 at Siriraj sleep center. Diagnosis of obstructive sleep apnea (OSA) was done according to the AASM criteria; mild (AHI 5 to ≤ 15 events/h), moderate (AHI 15 to ≤ 30 events/h) and severe (AHI ≥ 30 events/h). Subjects who were not CPAP naïve had central sleep apnea, had comorbidities that were contraindicated for CPAP therapy, or denied using CPAP were excluded.|f|f|t|f
34046066|NCT01731184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046067|NCT04280744|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm feasibility trial||||
34046068|NCT01958814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046069|NCT00860535|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046070|NCT02375308|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046071|NCT01210846|NA|SINGLE_GROUP||||NONE||||||
34046072|NCT02830308|||COHORT||OTHER|||||||
34046073|NCT05622474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046074|NCT05404477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is an open label, randomized, cross-over study in adult open cardiac surgery patients. All subjects will receive TransLoc electrodes at the time of open sternotomy cardiac procedure. Half of subjects will have TransAeris turned on upon entry to ICU, the other half will receive standard of care with TransAeris turned on if still intubated on mechanical ventilation after 120 hours.||||
34046075|NCT00305825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046076|NCT05157919|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34046077|NCT03753464|||CASE_CONTROL||PROSPECTIVE|||||||
34046078|NCT03469674|RANDOMIZED|PARALLEL||TREATMENT||NONE|Evaluation of outcomes is done without information on randomised arm|2:1 randomisation to adjuvant treatment assignment based on the integrated molecular risk profile or standard adjuvant vaginal brachytherapy||||
34046079|NCT01060644|||||PROSPECTIVE|||||||
34046080|NCT05271149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34046081|NCT02402959|||COHORT||PROSPECTIVE|||||||
34046082|NCT05122247|||COHORT||RETROSPECTIVE|||||||
34125104|NCT03667989|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125105|NCT02840279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125106|NCT04011592|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34125107|NCT05593315|NA|SINGLE_GROUP||OTHER||NONE||A Mindfulness relaxation program and a Buteyko technique respiratory rehabilitation program will be administered individually and weekly, in 10 sessions (5 face-to-face and 5 telematic sessions afterwards).||||
34125108|NCT06231706|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Phase 1: Parallel arm randomised control trial Phase 2: Randomised crossover trial|f|f|f|t
34125109|NCT05529251|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* In case of negative week-3 (after 1 EP cyle) PET-scan: Randomization according to 2 arms~  1. Boost of radiotherapy 20 to 30 Gray (Gy) (ARM A)~ 2. Carboplatin AUC7 chemotherapy (ARM B)~* In case of positive week-3 PET-scan: 3 courses of EP chemotherapy (ARM C)~Parallel observational cohort for patients scheduled to receive standard lumbo-aortic radiotherapy after orchiectomy"||||
34125110|NCT01106157|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737364|NCT04955808|||CASE_ONLY||PROSPECTIVE|||||||
33737365|NCT00813761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046083|NCT01914614|||||PROSPECTIVE|||||||
34046084|NCT04736277|||COHORT||OTHER|||||||
34046085|NCT00067912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34046086|NCT02439814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046087|NCT03861988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking is for double blind phase only.||t|t|t|t
34046088|NCT01692379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046089|NCT05356013|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046090|NCT04112043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046091|NCT05921643|||COHORT||PROSPECTIVE|||||||
34125111|NCT01724216|NA|SINGLE_GROUP||||NONE||||||
34125112|NCT02478112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125113|NCT00443703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125114|NCT06450015|RANDOMIZED|PARALLEL||TREATMENT||NONE||effectiveness of Vacuum Assisted Closure therapy with saline dressing in management of diabetic foot ulcers||||
34125115|NCT01704508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125116|NCT04790747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125117|NCT00382317|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33815360|NCT03539237|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33815361|NCT02228876|||OTHER||OTHER|||||||
33815362|NCT01858649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815363|NCT05082545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815364|NCT05981209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815365|NCT00990184|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33815366|NCT02082639|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815367|NCT04097314|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815368|NCT01485809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125118|NCT03811522|||OTHER||PROSPECTIVE|||||||
34125119|NCT02953561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125120|NCT00705770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125121|NCT03519997|NA|SINGLE_GROUP||TREATMENT||NONE||Locally advanced or metastatic HCC not amenable to locoregional therapy||||
34125122|NCT02353858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838513|NCT05721547|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34046092|NCT02598531|||CASE_CONTROL||PROSPECTIVE|||||||
34046093|NCT01984632|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737366|NCT06664437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Interventional procedures:~Group (A): GH Joint mobilization techniques (Posterior, Inferior glide). Patients were in supine lying position during the whole treatment. The techniques were performed in a rhythmic way, with 2 seconds of glide distraction and then a 2-second break. Each technique was done for 2 minutes \[36\]. Posterior gliding was performed by maintaining lateral humeral distraction with the glenohumeral in abduction range and the scapula stabilized. Then the therapist applied posterior glide in an oscillating manner. For inferior gliding, with the scapula stabilized, the therapist maintained lateral humeral distraction while applying inferior glide in the resting position of the glenohumeral joint. Patients had 3 sessions of joint mobilization per week for 6 weeks.~Group (B): Median nerve mobilization techniques (ULLT-1) in addition to GH joint mobilization~Patients also in this group remained in supine lying position. Median nerve mobilization was performed by placin"|t|f|f|t
33737367|NCT04530682|||CASE_CONTROL||PROSPECTIVE|||||||
33737368|NCT04678414|||COHORT||CROSS_SECTIONAL|||||||
33737369|NCT06663085|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||control group: not received enteral feeding during transfusion intervention group: received enteral feeding||||
33737370|NCT00220818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737371|NCT06526507|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Difference in differences design, also known as a controlled pre-post design||||
33737372|NCT00673452|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737373|NCT02749903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737374|NCT01007461|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33737375|NCT06546800|||COHORT||PROSPECTIVE|||||||
33737376|NCT05339698|||COHORT||RETROSPECTIVE|||||||
33737377|NCT02665481|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33737378|NCT03427372|||COHORT||PROSPECTIVE|||||||
33737379|NCT06222476|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33737380|NCT04959084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737381|NCT04560504|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33737382|NCT01040871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737383|NCT06662682|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcome assessor were unaware of participants status and were not allowed to ask correpondingly||f|f|f|t
33737384|NCT06262087|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33737385|NCT03370328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737386|NCT02791633|||CASE_ONLY||PROSPECTIVE|||||||
33737387|NCT05458193|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE||2-way cross-over|t|t|t|t
33737388|NCT05007483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Assessors and principle investigator masked|Randomized controlled study design|f|f|t|t
33737389|NCT05814562|NA|SINGLE_GROUP||TREATMENT||NONE||Pre-intervention versus post intervention evaluations||||
33737390|NCT04922593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737391|NCT04516161|||COHORT||RETROSPECTIVE|||||||
33737392|NCT02282475|||OTHER||PROSPECTIVE|||||||
33737393|NCT02261116|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33737394|NCT00161928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33737395|NCT01076725|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
33737396|NCT04886921|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33737397|NCT06008925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737398|NCT06205290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737399|NCT02063165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737400|NCT00393549|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737401|NCT03606161|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33737402|NCT03645200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737403|NCT05802797|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|No masking.|24 participants (12 men and 12 women) will be randomized to two intervention groups.||||
34125123|NCT02967679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737404|NCT02030691|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33737405|NCT04285931|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33737406|NCT06289413|||COHORT||OTHER|||||||
33737407|NCT06364566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737408|NCT06018740|NA|SINGLE_GROUP||OTHER||NONE|Open Label|Single group clinical trial.||||
33737409|NCT03837691|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Forty Patient Study||||
33737410|NCT06428097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737411|NCT06532123|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||to characterize fatigue characteristic of various continence muscles and to determine the relative/individual contribution of striated continence muscles, including Puborectalis muscle (PRM) and External anal sphincter (EAS) motor function enhancement in improving fecal incontinence.||||
33737412|NCT01291797|||CASE_CONTROL||PROSPECTIVE|||||||
33737413|NCT00000153|RANDOMIZED|||TREATMENT||||||||
33737414|NCT02556710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737415|NCT02211755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737416|NCT04226716|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multiparous, pregnant women without PPGP at the time of inclusion are followed over a longer period of time, and assessments are performed during the first and third trimester of pregnancy and six weeks and six months postpartum.||||
33737417|NCT03488576|RANDOMIZED|PARALLEL||TREATMENT||NONE||This was a prospective study including ninety-one eyes of 190 phakic patients scheduled to undergo vitrectomy for idiopathic macular pucker or macular hole, from July 2014 to December 2016. Patients were randomized in a 1:1 ratio to complete peeling of the ILM (CP group) or foveal sparing (FS group).||||
33737418|NCT01159067|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33737419|NCT02747316|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33737420|NCT00764140|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33737421|NCT06256497|||COHORT||PROSPECTIVE|||||||
33737422|NCT00358098|||OTHER||PROSPECTIVE|||||||
33737423|NCT04412135|||COHORT||PROSPECTIVE|||||||
33737424|NCT04560712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737425|NCT02488512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125124|NCT02615977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125125|NCT00666081|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125126|NCT05794880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125127|NCT03888378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Care provider is a designated dosing coordinator who will be unblinded for this study. Both participant and investigator will be blinded.||t|f|t|t
34125128|NCT02081313|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125129|NCT00451061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125130|NCT03149146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125131|NCT00006695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125132|NCT03828630|||COHORT||PROSPECTIVE|||||||
34125133|NCT04463940|||CASE_CONTROL||PROSPECTIVE|||||||
34125134|NCT00701025|||COHORT||PROSPECTIVE|||||||
34125135|NCT03030729|||OTHER||PROSPECTIVE|||||||
34125136|NCT05162378|||COHORT||RETROSPECTIVE|||||||
34125137|NCT03599518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125138|NCT04735315|||COHORT||PROSPECTIVE|||||||
34125139|NCT05108103|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125140|NCT05274412|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34125141|NCT05600829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125142|NCT05820048|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34125143|NCT01647698|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34125144|NCT00992056|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125145|NCT04532346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125146|NCT03110224|||COHORT||OTHER|||||||
34125147|NCT00004049||||TREATMENT||||||||
34125148|NCT04078269|NA|SINGLE_GROUP||TREATMENT||NONE||intra-patient dose escalation scheme||||
34125149|NCT06101004|||COHORT||PROSPECTIVE|||||||
34125150|NCT05214430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125151|NCT04963816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125152|NCT02140970|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125153|NCT03284983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125154|NCT05250921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125155|NCT01007175|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34125156|NCT03133494|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Arterial blood gas sample was drawn from both the groups and analysed for any change in the desired parameters|t|f|t|f
34125157|NCT03765580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125158|NCT00392977|||||PROSPECTIVE|||||||
34125159|NCT06513000|||COHORT||PROSPECTIVE|||||||
34125160|NCT03369665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125161|NCT05940506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125162|NCT04292197|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34125163|NCT03549286|||CASE_ONLY||PROSPECTIVE|||||||
34125164|NCT00414076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125165|NCT00132990|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34125166|NCT04035343|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34125167|NCT02477488|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125168|NCT00595296|||CASE_ONLY||PROSPECTIVE|||||||
34125169|NCT03188263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||half will receive active light treatment device, the other half will receive a placebo device|t|f|t|t
34125170|NCT00556803|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737426|NCT00773175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737427|NCT00130962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33737428|NCT03866616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737429|NCT05486949|RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33737430|NCT05351203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33737431|NCT01256905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737432|NCT06663267|||COHORT||RETROSPECTIVE|||||||
33737433|NCT00491790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737434|NCT05540223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737435|NCT01062685|||COHORT||PROSPECTIVE|||||||
33737436|NCT06377839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33737437|NCT04016168|||COHORT||PROSPECTIVE|||||||
34125171|NCT00682279|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125172|NCT02351492|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34125173|NCT02945163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125174|NCT04155528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125175|NCT01222819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125176|NCT05621122|||CASE_CONTROL||RETROSPECTIVE|||||||
34125177|NCT03204877|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34125178|NCT05821452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125179|NCT05605548|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125180|NCT00076089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34125181|NCT00401843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34125182|NCT02242058|||CASE_CONTROL||PROSPECTIVE|||||||
34125183|NCT02177630|||COHORT||PROSPECTIVE|||||||
34125184|NCT02056028|||COHORT||PROSPECTIVE|||||||
34125185|NCT03314038|||OTHER||CROSS_SECTIONAL|||||||
34125186|NCT00060671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125187|NCT02074943|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34125188|NCT03703934|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125189|NCT00589797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125190|NCT03262584|||COHORT||PROSPECTIVE|||||||
34125191|NCT01908543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125192|NCT01715467|||COHORT||PROSPECTIVE|||||||
34125193|NCT05681338|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The measurements were carried out by the first researcher.||f|f|t|f
34151116|NCT03628729|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A total of 40 volunteer patients with at least 2 non-cavitated molar teeth will be assigned in this study. Patients will be randomly divided into two groups according to type of sealant (S) where in group S1, pits and fissures will be sealed with bioactive pits-and-fissure sealant; while group S2, pits and fissures will be sealed with fluoride releasing resin based pits and fissures sealant. Each restoration will be assessed after three, six months.|t|f|t|t
34151117|NCT05549557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125194|NCT04797377|NA|SINGLE_GROUP||TREATMENT||NONE||After the women are recruited for the study, Antral follicle count (AFC), serum anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) levels will be determined at baseline and will be repeated beginning with the first menstrual cycle after treatment. Approximately 22 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries. Ovarian reserve (AFC, FSH, AMH), and ICSI outcome parameters (number of MII oocytes, fertilization rate, oocyte and embryo quality) will be followed up to three months after the intervention.||||
34125195|NCT01718821|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34125196|NCT03269773|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125197|NCT00194467|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34125198|NCT06486766|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcome measure of the trial is based solely on routinely collected data and those reporting/registering this information will not be aware of whether a vaccinated individual has received an SMS nudge. Thus, the trial is blinded to the outcomes assessor. Moreover, treatment allocation is randomized and computer-generated, there is no interaction between the InfluSMS project team and study participants, and the InfluSMS researchers work with de-identified data and do not know the identity of any participant in the dataset. Due to the inherent characteristics of the intervention, treatment allocation cannot be blinded for participants.|The trial is conducted in three populations of elderly (aged 65 years or older) residing in Norway: (i) the general population; (ii) immigrants born in Poland; (iii) immigrants born in Ukraine. In all three populations, the control arm is standard care, i.e., no individual reminder for influenza vaccination. All populations have an intervention arm that will receive an SMS nudge in the Norwegian language. In addition, the Polish and Ukrainian immigrant populations include a second intervention arm that will receive an SMS nudge in Polish or Ukrainian, respectively.|f|f|f|t
34125199|NCT02164344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125200|NCT03859037|RANDOMIZED|PARALLEL||OTHER||SINGLE||Two groups,one will have umbilical cord milking and other will have immediate cord clamping ,two groups will put on warmer after birth and blood pressure,heart rate ,oxygen saturation will be assessed by monitor every 30 seconds up to 10 minutes|f|f|t|f
34125201|NCT00659841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125202|NCT02678754|||OTHER||OTHER|||||||
34125203|NCT02514291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125204|NCT06070818|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The researcher collecting the outcome measures will not know whether the person is in the intervention or control group.|A randomised trial with a wait-list control.|f|f|f|t
34125205|NCT02225652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125206|NCT01165125|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34125207|NCT04316559|NA|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34125208|NCT05763680|||COHORT||PROSPECTIVE|||||||
34125209|NCT04829890|||COHORT||OTHER|||||||
34125210|NCT00495235|||CASE_CONTROL||PROSPECTIVE|||||||
34125211|NCT05575700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study medication will be masked by the pharmacy. The experimental medicine will be packed and labelled by Region Hovedstadens Pharmacy in accordance with the Good Manufacturing Practice regulations. The sponsor has a set of sealed, opaque envelopes with the participants' allocation, and these will only be revealed for the investigators when the data has been analysed and abstracts and conclusions covering the different possibilities for interpreting the trial results, have been agreed upon by the steering committee||t|t|t|t
34125212|NCT02374541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34125213|NCT00777959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815369|NCT03643445|RANDOMIZED|PARALLEL||TREATMENT||NONE||Eating disorder participants will be randomly assigned either the motivation-oriented treatment condition or the psychoeducation-oriented treatment condition. Patients in both groups will receive the same care in terms of their hospital treatment and opportunities for interaction with the staff. The only difference will be that for ½ of participants, their treatment will be infused with motivation-oriented interventions. For the others, their interactions will be infused with psychoeducation-oriented interventions. All patients have interactions with an individual therapist at various time points in their hospital treatment. The points at which a patient meets with his or her individual therapist are as follows: at the orientation to the program, a 6-week check-in, and a 10-12 week check-in. As well, patients typically meet with their individual therapist whenever the treatment team determines that a patient may be struggling in the program and is at risk of premature drop-out.||||
33815370|NCT05448794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815371|NCT06180109|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34046094|NCT03857386|||CASE_CONTROL||PROSPECTIVE|||||||
33815372|NCT00663923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815373|NCT03563989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815374|NCT00925327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815375|NCT00694902|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33815376|NCT01851694|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33815377|NCT02646878|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33815378|NCT05786911|||COHORT||PROSPECTIVE|||||||
33815379|NCT04803253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815380|NCT00739388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815381|NCT05281809|NA|SINGLE_GROUP||TREATMENT||NONE||administration of locally manufactured cd19-targeted CAR T-cells||||
33815382|NCT05201625|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815383|NCT01201278|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046095|NCT05541835|||COHORT||PROSPECTIVE|||||||
34046096|NCT03484663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patient who will do vats procedure|case of small catheter drainage with chest tube versus chest tube alone after uniport vats|t|f|f|f
34046097|NCT02173665|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34046098|NCT00401024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046099|NCT05464056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046100|NCT05393856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross-over study||||
34046101|NCT02528539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34046102|NCT02915900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33815384|NCT00997152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815385|NCT02506322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815386|NCT00976053|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815387|NCT01637194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815388|NCT04126993|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815389|NCT04004832|||FAMILY_BASED||OTHER|||||||
33815390|NCT00255268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815391|NCT01574105|||COHORT||PROSPECTIVE|||||||
33815392|NCT03924362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be managed either with simultaneous bilateral procedures or staged unilateral procedures based on surgeon's routine practice pattern. Additional surgical interventional will be dependent on initial patient stone-free outcomes.||||
33815393|NCT02033915|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33815394|NCT01092325|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33815395|NCT03968276|NA|SINGLE_GROUP||OTHER||NONE||||||
33815396|NCT03276286|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Nativis Voyager combined with standard radiotherapy and temozolomide||||
33815397|NCT06411054|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815398|NCT01472796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815399|NCT04618653|||COHORT||PROSPECTIVE|||||||
33815400|NCT00763919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815401|NCT05728372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815402|NCT06388824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815403|NCT00903214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815404|NCT00410150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815405|NCT03921775|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815406|NCT02092909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815407|NCT03243838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815408|NCT00589745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815409|NCT05034263|||COHORT||PROSPECTIVE|||||||
33815410|NCT03466775|||COHORT||RETROSPECTIVE|||||||
33815411|NCT05990868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patient and provider will be blinded to the intervention.|The primary outcome in this study is the proportion of the prescribed medications used three days after discharge from the surgery. Assuming that only one third or less of the Narcotics prescribed (2 out of 6 tablets) in Group 1 will be utilized as compared to two thirds or more (4 out of 6 tables) in group 2, 35 patients in each group will be required to achieve 80% power and two-sided level of significance of 0.058. Given we expect possible 10% drop out rate after randomization, we plan to recruit 39 patients in each group (78 total sample). We plan to perform our analysis using SPSS.|t|t|f|f
33815412|NCT00539604|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815413|NCT06063915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815414|NCT03936725|||OTHER||RETROSPECTIVE|||||||
33815415|NCT05088122|||OTHER||CROSS_SECTIONAL|||||||
33815416|NCT04535440|||COHORT||CROSS_SECTIONAL|||||||
33815417|NCT00003731||||TREATMENT||||||||
33815418|NCT05059145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815419|NCT05109832|NA|SINGLE_GROUP||OTHER||NONE||||||
33815420|NCT02710669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815421|NCT03933241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815422|NCT02802176|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm 1: intra-vaginal culture using INVOcell device. Arm 2: Traditional In-Vitro Fertilization (IVF) culture in an embryology laboratory||||
33815423|NCT04664179|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815424|NCT06275256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815425|NCT02173756|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815426|NCT00986661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815427|NCT05481255|||COHORT||PROSPECTIVE|||||||
33815428|NCT05773599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815429|NCT04443556|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33815430|NCT03019809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815431|NCT06437158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The investigators aim to compare the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients.|t|f|f|t
33815432|NCT02674867|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815433|NCT02967822|||COHORT||PROSPECTIVE|||||||
33815434|NCT02611193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815435|NCT04155372|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815436|NCT05652556|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33815437|NCT01134497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125214|NCT02879513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815438|NCT01742832|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33815439|NCT03468348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815440|NCT00558441|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815441|NCT03420729|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33815442|NCT05852197|||COHORT||PROSPECTIVE|||||||
33815443|NCT04503629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815444|NCT04034732|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|In this open-label study, blinding of therapists and participants will not be possible. However, all data collection will be performed by a trained research assistant blinded to the allocation status of the participants. The research assistant will receive rigorous training in standardized data collection procedures. Data entry will be prepared so that the person can conduct the statistical analyses without referring to allocation information, thus ensuring blinding during data analysis.|||||
33815445|NCT04251325|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33815446|NCT03627156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcome assessors are not informed about the intervention and the group to which the intervention is assigned to avoid social desirability bias|A two-arm parallel cluster randomized community trial|f|f|f|t
33815447|NCT00835328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a two-period, two-treatment cross-over clinical study with a dose-escalation component. Each subject, in random order, will receive an intravenous (IV) infusion of Exendin (9-39) and normal saline vehicle for up to 9 hours on two separate days.||||
34125215|NCT05539638|||CASE_ONLY||PROSPECTIVE|||||||
34125216|NCT04009239|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34125217|NCT00243139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34125218|NCT03955328|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125219|NCT03961555|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125220|NCT02775630|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34125221|NCT03759600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125222|NCT01616212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125223|NCT06475768|||COHORT||PROSPECTIVE|||||||
34125224|NCT02354261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125225|NCT04436445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||women's with chronic pelvic pain|f|f|t|f
34125226|NCT05845619|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Pilot study participants will be compared to historical controls.||||
34125227|NCT04944576|||COHORT||PROSPECTIVE|||||||
34125228|NCT02970591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34125229|NCT02537730|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125230|NCT00005739|||CASE_CONTROL||PROSPECTIVE|||||||
34125231|NCT00953810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125232|NCT05521126|||CASE_CONTROL||OTHER|||||||
34125233|NCT02877069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125234|NCT02067143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125235|NCT01541488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34125236|NCT02224508|||COHORT||CROSS_SECTIONAL|||||||
34125237|NCT04592471|||CASE_CONTROL||PROSPECTIVE|||||||
34125238|NCT04299386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double-masked parallel-arm randomized clinical trial|t|f|t|t
34125239|NCT06118424|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34125240|NCT05384834|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125241|NCT04444739|||COHORT||RETROSPECTIVE|||||||
34125242|NCT04476381|NA|SINGLE_GROUP||TREATMENT||NONE||One group, one measurement of the viscoelastic properties with the MyotonPro of a single trigger point before the dry needle insertion, one measurement with the MyotonPro right after and 30 minutes later||||
34125243|NCT01296750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125244|NCT01725802|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34125245|NCT04078204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125246|NCT01665911|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
34125247|NCT06085235|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Randomized Control Trial: exercise or video control condition|t|f|f|f
34125248|NCT05756023|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34125249|NCT03449849|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
34125250|NCT02825446|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34125251|NCT04880239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125252|NCT00642707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125253|NCT06522477|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Blinded clinical assessors will perform assessments of clinical outcomes.|Individuals will be randomly assigned to receive up to 15 visits/5 weeks of high- or low-intensity virtual reality gait training. Following a 4 week washout, they will complete the alternative intervention.|f|f|f|t
34125254|NCT00049257|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815448|NCT01872104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815449|NCT02364856|||OTHER||PROSPECTIVE|||||||
33815450|NCT04721483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients distributed in a prospective randomized fashion between two groups. We calculated the sample size based on previous research and used a block randomization model. We took eight blocks of four and two blocks of five patients with a random distribution of two patients from each group. This project was blind.|Two groups. One with T3-T4 sympathicotomy and another with T3-T4 gray ramicotomy|t|t|t|t
33815451|NCT04655300|||OTHER||CROSS_SECTIONAL|||||||
33815452|NCT00576485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815453|NCT05852509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815454|NCT04748926|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34125255|NCT03679676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a prospective Phase 2, single-center, multi-allergen OIT in participants with proven allergies to 2 or 3 different foods in which one must be peanut. Our intent to treat population will be 110 participants, ages 4 to 55 years with a history of multiple food allergies of 2 or 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.|t|t|t|f
34125256|NCT00255905|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34125257|NCT01495039|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34125258|NCT04233528|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34125259|NCT04729933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125260|NCT05598905|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|"Double-blind cross-over trial in which the order of visits is randomized.~Amendment:~In order to get an impression of the effect of 10 mg oxycodone per se, one open label arm of just 10 mg oxycodone as a visit 3 was added."|"Double-blind, randomized cross-over design.~Amendment:~In order to get an impression of the effect of 10 mg oxycodone per se, one open label arm of just 10 mg oxycodone as a visit 3 was added."|t|f|t|f
34125261|NCT01050725|||CASE_ONLY||PROSPECTIVE|||||||
34125262|NCT02918669|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125263|NCT06440603|||CASE_CONTROL||RETROSPECTIVE|||||||
34125264|NCT01096108|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34125265|NCT06095869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34125266|NCT01718522|||COHORT||PROSPECTIVE|||||||
34125267|NCT01135160|||COHORT||PROSPECTIVE|||||||
34125268|NCT01810900|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34125269|NCT05036161|||COHORT||PROSPECTIVE|||||||
34125270|NCT04495946|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||Pragmatic, stepped-wedge cluster randomized controlled trial|f|f|f|t
34125271|NCT05998486|||COHORT||RETROSPECTIVE|||||||
34125272|NCT06319404|||OTHER||PROSPECTIVE|||||||
34125273|NCT02492243|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151118|NCT00563043|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125274|NCT05309967|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"For the double-blind study, the evaluator and the patient will be blinded. The bleaching procedure and the therapies under study will be performed by one operator and will only involve one evaluator not participant in the randomization and without knowledge of the interventions applied in the groups. The evaluator will be responsible for measuring and tabulating information regarding sensitivity, color analysis and the impact on patients' quality of life.~The desensitizer and its placebo will be placed in similar containers so that they cannot be identified by the volunteers."|It is a split mouth study composed of two groups randomized between left and right sides.|t|f|t|f
34125275|NCT04570618|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34125276|NCT02115035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125277|NCT02916511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125278|NCT05252208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel groups: Two groups: Walking exercise and stretching exercise|f|f|t|t
34125279|NCT05229809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125280|NCT01138085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125281|NCT02552472|||COHORT||PROSPECTIVE|||||||
34125282|NCT04834908|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Clinical phase 1 and phase 2 studies have been planned to be conducted. The phase 1 study will be conducted on two dosages to find the safety and tolerability in patients. Each patient will receive either of the dose BSVEQAb - 5 mg/kg or 10 mg/kg body weight and all will receive standard of care~Based on the results of phase 1 study the phase 2 shall be initiated. In phase 2 study one group will receive the tolerable dose of BSVEQAb selected along with standard of care. The second group will receive only standard of care."||||
34125283|NCT03349255|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34125284|NCT04522050|NA|SINGLE_GROUP||TREATMENT||NONE||The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.||||
34125285|NCT03653442|||CASE_ONLY||PROSPECTIVE|||||||
34125286|NCT05844202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125287|NCT02776046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34125288|NCT03133585|||COHORT||PROSPECTIVE|||||||
34125289|NCT03926910|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125290|NCT00104338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125291|NCT01014806|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125292|NCT04342091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125293|NCT02377024|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125294|NCT00432068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125295|NCT02584712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125296|NCT01968538|||OTHER||PROSPECTIVE|||||||
34125297|NCT03251027|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125298|NCT01973010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125299|NCT02484443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125300|NCT01753817|||COHORT||PROSPECTIVE|||||||
34125301|NCT05369923|||COHORT||CROSS_SECTIONAL|||||||
34125302|NCT05003908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125303|NCT00843440|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125304|NCT00318240|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125305|NCT04571060|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind to Sponsor, Investigator and Participant.||t|t|t|f
34125306|NCT00956358|||CASE_CONTROL||PROSPECTIVE|||||||
34125307|NCT02065323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125308|NCT06205446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125309|NCT00002343||PARALLEL||TREATMENT||||||||
34125310|NCT01602263|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125311|NCT03270059|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34125312|NCT05293327|||OTHER||PROSPECTIVE|||||||
34125313|NCT04603469|||COHORT||PROSPECTIVE|||||||
34125314|NCT06286449|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The intervention in this study consists of a spinal tap that all study participants undergo. We are comparing biomarkers in cerebrospinal fluid collected from either participants with Alcohol Use Disorder or from healthy controls.||||
34125315|NCT01277822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125316|NCT03199677|NA|SINGLE_GROUP||TREATMENT||NONE|no parallel,no control|single group,apatinib 500mg po qd,d1-28||||
34125317|NCT06004206|RANDOMIZED|CROSSOVER||TREATMENT||NONE|All the patients will be ventilated in both modes.|Patients will be ventilated in nPSV or PSV (according to randomization) and then, after an initial period of ventilation, they will be ventilated with the other technique. Ventilation then will be optimized by an expert and the two modes of ventilation will be repeated in succession.||||
34125318|NCT01899781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125319|NCT02690766|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34125320|NCT03161210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125321|NCT04858438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be unaware of their study group status and unaware of level of pneumoperitoneum used during their surgical procedure.|Patients will be randomized to receive either standard pneumoperitoneum (15 mmHg) versus a lower level of pneumoperitoneum (12 mmHg).|t|f|f|f
34125322|NCT01116388|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34125323|NCT01664247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125324|NCT04054336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know that there exists more than one condition.|Alcohol patients are randomly assigned to one of three conditions and are tested on three consecutive points in time.|t|f|f|f
34125325|NCT04684615|||COHORT||PROSPECTIVE|||||||
34125326|NCT00972023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125327|NCT02003443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125328|NCT04524221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind|Randomized, double-blind, placebo-controlled|t|f|t|f
34125329|NCT04782349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125330|NCT05934383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815455|NCT04103333|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815456|NCT00753337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815457|NCT06393855|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33737438|NCT06133582|NA|SINGLE_GROUP||TREATMENT||NONE||Update January 2024: This trial has been transformed from a two arm randomised control trial to a single arm trial, due to challenges with recruitment. 51 participants have been successfully recruited and have now been invited to complete baseline measures. All participants will receive the intervention (the online therapy programme) once baseline data collection is complete.||||
33737439|NCT04891679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Women were randomized (1:1) into the treatment groups A) Titrated-dose OMS group B) Static dose OMS group; using computer generated number sequence. Allocation concealment was carried out by using opaque envelopes that were distributed by the obstetrics nurse. Whereas study investigators and attending care teams were aware of the allocated arm, patients were kept blinded to the allocation. Study investigators and outcome assessors could not be blinded as the data collection and analysis included outcome measures like timing of oral misoprostol solution doses.|Single center interventional single-blinded randomised controlled trial|t|f|f|f
33737440|NCT01548456|||COHORT||PROSPECTIVE|||||||
33737441|NCT04839497|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Cross over design|t|f|f|f
33737442|NCT05785091|||OTHER||CROSS_SECTIONAL|||||||
33737443|NCT04754581|NA|SINGLE_GROUP||OTHER||NONE||This is a single-site, pre-post design pilot study with no control group.||||
33737444|NCT00337649|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33737445|NCT05953584|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737446|NCT01786408|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737447|NCT04360200|||COHORT||PROSPECTIVE|||||||
33737448|NCT04453852|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Non-blind Staff administering vaccine do not participate in any other aspects of the study. Remaining trial staff and participant are blinded|Randomised controlled study|t|f|t|t
33737449|NCT01917851|||||PROSPECTIVE|||||||
33737450|NCT04543422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737451|NCT04558476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737452|NCT06136520|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33737453|NCT06573918|NA|SINGLE_GROUP||OTHER||NONE||||||
33737454|NCT02528292|||COHORT||PROSPECTIVE|||||||
33737455|NCT03899116|||CASE_CONTROL||PROSPECTIVE|||||||
33737456|NCT05494125|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33737457|NCT05915026|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737458|NCT05443984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33737459|NCT05728112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737460|NCT02357316|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33737461|NCT00003341|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33737462|NCT03997903|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33737463|NCT04634227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737464|NCT03065881|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33737465|NCT00484952|||DEFINED_POPULATION||PROSPECTIVE|||||||
33737466|NCT01362855|||OTHER||PROSPECTIVE|||||||
33737467|NCT01646034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737468|NCT04846127|||COHORT||PROSPECTIVE|||||||
33737469|NCT02863354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737470|NCT06592313|||COHORT||PROSPECTIVE|||||||
33737471|NCT02629406|||CASE_CONTROL||PROSPECTIVE|||||||
33737472|NCT00273364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815458|NCT03684499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815459|NCT05121376|NA|SEQUENTIAL||TREATMENT||NONE||||||
33815460|NCT02237872|||CASE_ONLY||CROSS_SECTIONAL|||||||
33815461|NCT02704637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815462|NCT01916447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815463|NCT02049684|||OTHER||PROSPECTIVE|||||||
33737473|NCT01903447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33737474|NCT01986829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737475|NCT02879097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737476|NCT02116322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737477|NCT03672734|||CASE_ONLY||OTHER|||||||
33737478|NCT04475445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737479|NCT01668316|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737480|NCT00546143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737481|NCT04899063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737482|NCT02352324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737483|NCT06511804|||COHORT||PROSPECTIVE|||||||
33737484|NCT06339034|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo-controlled|t|t|t|t
33737485|NCT06663761|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737486|NCT01018264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33737487|NCT05259449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The project is a randomized controlled clinical trial with T2DM and obesity|f|f|f|t
33737488|NCT00018109|RANDOMIZED|||TREATMENT||DOUBLE||||||
33815464|NCT00197444|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815465|NCT00657709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815466|NCT00380809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815467|NCT00000497|RANDOMIZED|||TREATMENT||||||||
33737489|NCT04650828|||COHORT||PROSPECTIVE|||||||
33737490|NCT01449916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33737491|NCT03594591|||COHORT||PROSPECTIVE|||||||
33737492|NCT02264834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33737493|NCT05612516|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33737494|NCT04307758|||CASE_ONLY||PROSPECTIVE|||||||
33737495|NCT02784314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737496|NCT02276495|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33737497|NCT01827904|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33737498|NCT02285751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815468|NCT06430606|||CASE_CONTROL||PROSPECTIVE|||||||
33815469|NCT03312972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838514|NCT02723097|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838515|NCT00534495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838516|NCT01703728|||COHORT||PROSPECTIVE|||||||
34125331|NCT02735603|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34125332|NCT06290492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815470|NCT03382535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not told what kind of a therapy they are receiving.|"Participants are randomly divided into three groups. Group 1: Voice therapy. Group 2: Voice therapy with carryover strategies (supplementary tasks and reminders).~Group 3. Controls. No treatment during control period. After the control period participants are having Voice therapy or Voice therapy with carryover strategies."|t|f|f|f
33815471|NCT02670161|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815472|NCT00190177|||||RETROSPECTIVE|||||||
33815473|NCT05873634|||COHORT||PROSPECTIVE|||||||
33815474|NCT06541795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815475|NCT02384122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial was blinded for the outcome adjudication committee but not for patients or attending physicians.|Multicenter, open-label, randomized, parallel-group, superiority study to compare the efficacy of 40 mg octreotide long-acting release intramuscular every 28 days in addition to standard of care versus standard of care alone in patients with refractory anemia due to gastrointestinal bleeding from angiodysplasias.|f|f|f|t
33815476|NCT01736488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815477|NCT03975361|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815478|NCT05487209|||COHORT||PROSPECTIVE|||||||
33815479|NCT03398902|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33815480|NCT01033123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815481|NCT03610984|||CASE_ONLY||PROSPECTIVE|||||||
33815482|NCT03248076|||CASE_ONLY||PROSPECTIVE|||||||
33815483|NCT01212809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815484|NCT04184271|NA|SINGLE_GROUP||TREATMENT||NONE||Open label exposure--response study||||
33815485|NCT03031782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815486|NCT02663297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815487|NCT00798837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815488|NCT01866904|||COHORT||PROSPECTIVE|||||||
33815489|NCT01414192|||COHORT||PROSPECTIVE|||||||
33815490|NCT02169089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815491|NCT06295029|||COHORT||PROSPECTIVE|||||||
33815492|NCT03707756|||OTHER||RETROSPECTIVE|||||||
33815493|NCT05185089|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blind||t|t|t|t
33815494|NCT02707302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815495|NCT06585137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815496|NCT05428215|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Each subject will take their individualized dose of 17B-estradiol tablet orally for 2 weeks and sublingually for 2 weeks. The subject will then take their same dose of 17B-estradiol via the other means of administration for 2 weeks. The order in which this occurs will be randomized.|f|t|t|t
33815497|NCT03555656|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815498|NCT00939211|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815499|NCT02147652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815500|NCT00027209|RANDOMIZED|||TREATMENT||DOUBLE||||||
33815501|NCT03850678|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34125333|NCT06111638|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815502|NCT02379975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815503|NCT03202056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815504|NCT05885334|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33815505|NCT00391794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815506|NCT03933098|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study is observer blind:~1. Vaccine administrator and vaccine safety evaluator at site will be two distinct persons.~2. Laboratory personnel who analyzes immunogenicity at sponsor is also blinded."|Participants age 6 months to 45 years|t|t|t|t
33815507|NCT01491100|||COHORT||PROSPECTIVE|||||||
33815508|NCT04014452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistician will seal the randomisation codes in sequentially numbered opaque envelopes and send them to the research centres. Allocation will be concealed until participants sign the informed consent, at which time the interventionalist will access the allocation code.||f|f|f|t
33815509|NCT03213379|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A unique code is given to each patient enrolled in the study. Neither the name nor the surname of patient are mentioned.||t|f|f|f
33815510|NCT00554814|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33815511|NCT05796271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815512|NCT01355887|||CASE_ONLY||PROSPECTIVE|||||||
33815513|NCT04814719|||COHORT||PROSPECTIVE|||||||
33815514|NCT02718456|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33815515|NCT00169923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33815516|NCT04213768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815517|NCT00582855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815518|NCT01245998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125334|NCT00709150|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125335|NCT02168101|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125336|NCT05550961|||COHORT||OTHER|||||||
34125337|NCT02015481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815519|NCT01745445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815520|NCT05581394|||OTHER||PROSPECTIVE|||||||
33815521|NCT06224244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two test groups. A Simultaneous integrated boost to 40 Gy (SIB 40): 34 Gy to the ipsilateral breast with concomitant boost to 40 Gy to the tumor bed. A Simultaneous integrated boost to 43 Gy (SIB 43): 34 Gy to the ipsilateral breast with concomitant boost to 43 Gy to the tumor bed||||
33815522|NCT03596697|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815523|NCT03161665|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and 20 patients undergoing autologous or allogeneic BMT.||||
33815524|NCT05214521|NA|SINGLE_GROUP||TREATMENT||NONE||an open-label observational trial||||
33815525|NCT05569018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815526|NCT04148794|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33737499|NCT03394391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The investigators, data manager, research assistants, counselors and other project staff will be blinded throughout the study. An independent medical internet technology firm will be contracted to randomize participants and to send the required SMS to the participants. After scientific review has been completed and data collection has been completed, at the point of analysis, a list of participants' unique identifiers in two groups will be sent to the data analysts without specifying which the investigation or control group is. The blinding of the clinical database will finally be removed after final data analysis has been completed.|A single-blind, parallel-design (ratio 1:1), and multi-centre RCT of 230 adolescent living with HIV who are non-adherent to medications will be conducted over a one-year period in Southwest Nigeria.|f|t|t|t
33737500|NCT06404996|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33737501|NCT01805297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737502|NCT02010424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737503|NCT04003727|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33737504|NCT00042328|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33737505|NCT04933435|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737506|NCT05686330|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33737507|NCT04145791|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33737508|NCT03709550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33737509|NCT01618539|||COHORT||PROSPECTIVE|||||||
33737510|NCT00113113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737511|NCT00949013|||||RETROSPECTIVE|||||||
33737512|NCT06392555|||CASE_CONTROL||RETROSPECTIVE|||||||
33737513|NCT00189371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33737514|NCT01221441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815527|NCT01874470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815528|NCT05486988|||COHORT||PROSPECTIVE|||||||
33815529|NCT06012786|||CASE_ONLY||CROSS_SECTIONAL|||||||
33815530|NCT04425252|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized 1:2 to standard of care (SOC) alone or SOC + brequinar||||
33815531|NCT04072809|||COHORT||CROSS_SECTIONAL|||||||
33815532|NCT01779492|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33815533|NCT01092715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815534|NCT02482324|RANDOMIZED|CROSSOVER||||NONE||||||
33815535|NCT03077256|||COHORT||PROSPECTIVE|||||||
33815536|NCT04893759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815537|NCT04738370|||COHORT||PROSPECTIVE|||||||
33815538|NCT00608959|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815539|NCT05507372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Triple blinded|Blinded, placebo controlled parallel assignment randomised study|t|t|t|t
33815540|NCT01502241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815541|NCT01929616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815542|NCT02935894|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815543|NCT00442559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815544|NCT01571440|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33815545|NCT01299324|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815546|NCT06483594|||CASE_CONTROL||RETROSPECTIVE|||||||
34046103|NCT04550689|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participant, surgeon and assessors of the CBCT will be blinded to the treatment arm. The bone graft will be chosen at random from an envelope with a list generated by Sealed Envelope Ltd|Parallel arm with subjects randomly receiving allograft or xenograft for ridge preservation|t|t|f|t
34046104|NCT03824795|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label study with 3 sequential groups of 10 patients with CDAD with a staggered start.||||
34046105|NCT01393028|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34046106|NCT05518240|||CASE_CONTROL||PROSPECTIVE|||||||
34046107|NCT01593267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046108|NCT04555473|||COHORT||PROSPECTIVE|||||||
34046109|NCT03554278|||COHORT||PROSPECTIVE|||||||
33815547|NCT05206916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815548|NCT03581318|||COHORT||PROSPECTIVE|||||||
33815549|NCT05452408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815550|NCT05665348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815551|NCT02954809|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33815552|NCT06510101|||CASE_ONLY||RETROSPECTIVE|||||||
33815553|NCT02868086|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815554|NCT02267200|||COHORT||PROSPECTIVE|||||||
33815555|NCT04478552|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815556|NCT03798795|||COHORT||RETROSPECTIVE|||||||
33815557|NCT06277245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815558|NCT01308099|||||CROSS_SECTIONAL|||||||
33815559|NCT00884806|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33815560|NCT03368105|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33815561|NCT00004080||||TREATMENT||||||||
33815562|NCT04441983|||COHORT||PROSPECTIVE|||||||
33815563|NCT02349802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815564|NCT03230981|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815565|NCT04371445|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only the readers of the anterior segment OCT will be masked.||f|f|t|f
33815566|NCT05811000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815567|NCT00728325|RANDOMIZED|PARALLEL||||NONE||||||
33815568|NCT02449902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815569|NCT04565873|||OTHER||RETROSPECTIVE|||||||
33815570|NCT01923870|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815571|NCT02207777|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815572|NCT02545426|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33815573|NCT05760417|||CASE_ONLY||PROSPECTIVE|||||||
33838517|NCT05521412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838518|NCT04465955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838519|NCT04486625|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838520|NCT00416195|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838521|NCT01470547|||COHORT||PROSPECTIVE|||||||
33815574|NCT04564222|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A total of 324 pregnant women will be recruited from 28 clusters (villages) and will be randomised to either intervention or control using a randomized sequence, stratified by villages with \< 100 and ≥ 100 infants using block sizes of 2 and 4. Selected pregnant women from these villages will receive daily interventions in the form of 75 gram food products, made from chicken liver and chicken eggshells (Micronutrient-enriched Crackers/MEC) or placebo. The MEC and placebo will be given from 8-14 weeks gestation to 5 months' post-partum.|t|f|t|t
33815575|NCT03145909|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815576|NCT05329142|||COHORT||PROSPECTIVE|||||||
33815577|NCT05557838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815578|NCT05123118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research staff who collect and analyze outcome data will be blinded to participants' group assignments.|The 40 eligible participants will be randomized into either the intervention (N=20) or control group (N=20). A sequence of random numbers in blocks of 2 will be used to ensure equal numbers of participants for each group over time.|f|f|f|t
33815579|NCT03857594|||COHORT||OTHER|||||||
33815580|NCT06280599|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The patients were divided into two groups: intervention (n=40) and contrast (n=40). Both groups received post-stroke usual care. The intervention group received an 8-week transitional care model for stroke patients, which included comprehensive discharge planning and home follow-up||||
33815581|NCT01809444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815582|NCT05506319|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomized, parallel, open-case clinical trial.||||
33815583|NCT04964037|||OTHER||CROSS_SECTIONAL|||||||
33815584|NCT05236868|NA|SINGLE_GROUP||OTHER||NONE||||||
33815585|NCT05053035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815586|NCT01069744|||COHORT||PROSPECTIVE|||||||
33815587|NCT01741207|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33815588|NCT00456235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815589|NCT00761241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815590|NCT06095778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815591|NCT01821222|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33815592|NCT03826056|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The patient will not be informed of whether he or she is receiving the current hospital standard or the new personalized patient education intervention. The study team member will known which intervention is being used for patient education. The intervention arm will not be blinded in the data analysis.|"Study team members will randomize patients to receive either the current standard hospital education material or the new personalized education material. Investigators will use a stratified randomization process to allocate the patients from different categories including age range, gender, and discharge diagnosis into each group. Thereby the investigators will achieve equal distribution of diagnoses and other demographics among groups in real time. They will review the two groups when performing statistical analysis near the end of the study to ensure heterogeneity of distribution.~A study team member who has also been a member of the care team will use the either the current hospital standard or the new personalized education materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience."|t|f|f|f
33815593|NCT02349815|||COHORT||RETROSPECTIVE|||||||
33815594|NCT06351800|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33815595|NCT04907344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815596|NCT01223053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815597|NCT02329886|||COHORT||PROSPECTIVE|||||||
33815598|NCT05607147|NA|SINGLE_GROUP||OTHER||NONE||Pilot study to assess feasibility of testing dental healthcare workers for seropositivity and antigen positivity for SARS-CoV-2 (Rapid Antigen point-of-care testing).||||
33815599|NCT03528447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815600|NCT00443820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815601|NCT03500809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815602|NCT02385539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815603|NCT03308500|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Experimental design is applied where HIIG is compared with MIG. The participants of the study will be divided into two groups; HIIG and MIG. Both of them will have two sessions per week during 12 weeks of intervention.~Follow up: children are contacted 3 months after finishing the intervention."||||
33815604|NCT04372706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815605|NCT05897307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815606|NCT01857245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815607|NCT01432223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815608|NCT00361088|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815609|NCT00788541|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33815610|NCT05151016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815611|NCT06440200|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33815612|NCT05926557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All patients are not masked with respect to test and control procedures, with prior written informed consent. So, they will be divided in the two groups of study after a process of randomization|The study will be designed as a double-arm randomized controlled clinical trial. Mucositis will be treated with spermidine gel + non-surgical debridement (NSMD) in Test group and with NSMD alone in Control group. All clinical parameters will be recorded at baseline, 1 and 3 months.|f|f|t|t
33815613|NCT03183856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33815614|NCT03252210|NA|SINGLE_GROUP||OTHER||NONE|Eventhough only one group of participants，different investigators perform two kinds of localization techniques.|Single group self-control study||||
33815615|NCT00930319|||CASE_ONLY||PROSPECTIVE|||||||
33815616|NCT01727076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815617|NCT01964586|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33815618|NCT05726994|||CASE_ONLY||PROSPECTIVE|||||||
33815619|NCT01454297|||COHORT||PROSPECTIVE|||||||
33815620|NCT03596775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34046110|NCT03442608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34046111|NCT00570141|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34046112|NCT00322231|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33815621|NCT02144116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33815622|NCT00924755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815623|NCT05941156|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815624|NCT03385447|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815625|NCT05652114|NA|SINGLE_GROUP||TREATMENT||NONE||As a single arm study all participants' children will receive a game-based biofeedback intervention. They are encouraged to engage with the intervention in an entirely self-directed manner.||||
33815626|NCT03031223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815627|NCT02060071|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33815628|NCT03122444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815629|NCT01919489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815630|NCT00576550|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815631|NCT01686724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815632|NCT04716517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815633|NCT00474292|||||OTHER|||||||
34046113|NCT02667613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33815634|NCT03046888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospectively randomized study in patients with renal pelvic stones who are candidate to standard PCNL procedure. One to one, controlled clinical trial. Patients will be randomly allocated into two groups, 20 patients in each group. Group A will be scheduled to receive routine standard PCNL. Group B will be scheduled to receive RP.|t|f|f|f
33815635|NCT02107235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815636|NCT03665714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815637|NCT05237037|||COHORT||PROSPECTIVE|||||||
33815638|NCT03726502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815639|NCT04085614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815640|NCT01760876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815641|NCT05745259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815642|NCT01597999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815643|NCT05177835|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Follow-up Study||||
33815644|NCT01405508|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815645|NCT00461656|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046114|NCT03061747|||COHORT||RETROSPECTIVE|||||||
34046115|NCT06685250|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34046116|NCT02664129|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046117|NCT06244511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor will not know which participant received which intervention.|There will be an equal number of participants in the two groups randomized by the computer.|f|f|f|t
34046118|NCT05676463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046119|NCT03134573|||COHORT||PROSPECTIVE|||||||
34046120|NCT00627965|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33815646|NCT01379677|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815647|NCT00457834|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33815648|NCT02938286|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33815649|NCT02250547|||OTHER||PROSPECTIVE|||||||
33815650|NCT06307054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815651|NCT04859062|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||2 group control and xylocaine gel 2% group|t|t|t|f
33815652|NCT02263859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815653|NCT02883985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815654|NCT03196518|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a pilot study evaluating the safety, radiation dosimetry and detection capability of 18F-tetrafluoroborate (18F-TFB), a novel tracer for sodium-iodine symporter (NIS) imaging.||||
33815655|NCT04914520|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33815656|NCT03119051|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815657|NCT05602571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815658|NCT05456061|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Participants were classified into four groups: control group (Group 1), 3% diquafosol group (Group 2), punctal plug insertion group (Group 3), and combined treatment group (Group 4).||||
33815659|NCT02181179|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33815660|NCT05051709|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33815661|NCT00006428|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34046121|NCT00000825||||TREATMENT||||||||
34046122|NCT05423496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046123|NCT03777592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046124|NCT03652220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a three-arm, randomized, active-controlled, unblinded, parallel, exploratory study to compare the outcome in depression between standard specific treatment, multimodal specific treatment and standard treatment plus MBLM. After being screened for eligibility and signing the informed consent patients will be randomized 1:1:1 to either one of the groups. After being enrolled, patients in MBLM group receive an introductory education of the MBLM course and then join group sessions weekly for 8 weeks. They also see a consultant psychiatrist as needed for drug continuation therapy. Patients should practice MBLM related content at home for a proposed duration of 30-45 minutes per day. Patients in the control groups receive standard (control group I) or multimodal (control group II) treatment as administered by their consultant psychiatrist.|f|f|f|t
34046125|NCT02937220|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046126|NCT06203041|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33815662|NCT04604899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815663|NCT00950235|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33815664|NCT03395197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide|t|t|t|t
33815665|NCT05974631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be masked to participants' treatment condition|2-arm randomized clinical trial|f|f|f|t
33815666|NCT01330472|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33815667|NCT04391439|||COHORT||PROSPECTIVE|||||||
33815668|NCT01017055|||COHORT||PROSPECTIVE|||||||
33815669|NCT00689637|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33815670|NCT03975309|||COHORT||PROSPECTIVE|||||||
33815671|NCT06502067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815672|NCT00416442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33815673|NCT03918187|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Controlled comparative Double blind randomized study|t|f|f|t
33815674|NCT00187356|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815675|NCT04804371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Histologically proven well diff GEP NET, G2-3, Ki 67 ≥3% (or mitotic index ≥2 mitosis/10HPF).||||
33815676|NCT03665675|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815677|NCT00584909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815678|NCT06037577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815679|NCT00006229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815680|NCT03044756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled study|f|f|t|t
33815681|NCT04943614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815682|NCT00720161|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815683|NCT01952002|||CASE_ONLY||PROSPECTIVE|||||||
33815684|NCT05316649|||COHORT||PROSPECTIVE|||||||
33815685|NCT05944666|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33815686|NCT04063449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815687|NCT06053983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815688|NCT00407485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815689|NCT05386706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815690|NCT01791335|||CASE_ONLY||PROSPECTIVE|||||||
33815691|NCT04421456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815692|NCT03315195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815693|NCT03262389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815694|NCT00024245||||TREATMENT||||||||
33815695|NCT02043652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815696|NCT05546021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815697|NCT06584734|NA|SINGLE_GROUP||TREATMENT||NONE|There is no masking, patient is his own compared subject|||||
33815698|NCT03762174|||COHORT||RETROSPECTIVE|||||||
33815699|NCT00715156|||CASE_ONLY||CROSS_SECTIONAL|||||||
33815700|NCT00055068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815701|NCT04229940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient undergoing surgery and the physician performing the follow-up are masked to the allocation.|Double-blind randomized controlled trial.|t|f|f|t
33815702|NCT05086302|||COHORT||PROSPECTIVE|||||||
33815703|NCT04293718|||CASE_ONLY||RETROSPECTIVE|||||||
33815704|NCT01662804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815705|NCT04123119|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815706|NCT02913898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815707|NCT05024266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815708|NCT05306483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|"The population of our intervention study is divided into two groups of participants receive different interventions.~group (A) Patients undergoing surgical VSD closure (control group) group (B) Patients undergoing transcatheter VSD closure."|t|t|t|t
33815709|NCT01549171|||CASE_CONTROL||PROSPECTIVE|||||||
33815710|NCT03946631|||CASE_CONTROL||PROSPECTIVE|||||||
33815711|NCT02512315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815712|NCT00236470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815713|NCT02074033|||||RETROSPECTIVE|||||||
33815714|NCT01900015|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815715|NCT03517332|||COHORT||PROSPECTIVE|||||||
33815716|NCT02451553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815717|NCT03889951|||COHORT||PROSPECTIVE|||||||
33815718|NCT00545922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815719|NCT04945616|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33815720|NCT00253552||||TREATMENT||||||||
33815721|NCT04756986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815722|NCT01090739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815723|NCT05192902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815724|NCT06454578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815725|NCT00490113|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33815726|NCT03636958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125338|NCT05940064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125339|NCT05496361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815727|NCT04880135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815728|NCT01918943|||COHORT||PROSPECTIVE|||||||
33815729|NCT00913445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815730|NCT01883297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815731|NCT04704557|||COHORT||PROSPECTIVE|||||||
33815732|NCT02802332|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33815733|NCT00002094||||TREATMENT||NONE||||||
33815734|NCT03277391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random attribution by computer||t|f|f|f
33815735|NCT00048477||||TREATMENT||||||||
33815736|NCT04707885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815737|NCT00427544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33815738|NCT06506578|||COHORT||PROSPECTIVE|||||||
33815739|NCT03575494|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815740|NCT04255823|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33815741|NCT00363090||||TREATMENT||NONE||||||
33815742|NCT03398954|||CASE_ONLY||PROSPECTIVE|||||||
33815743|NCT06497179|||COHORT||PROSPECTIVE|||||||
33815744|NCT03451903|||COHORT||RETROSPECTIVE|||||||
33815745|NCT00959634|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33815746|NCT03338491|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815747|NCT00003245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815748|NCT04669119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815749|NCT05931224|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815750|NCT03798756|||COHORT||PROSPECTIVE|||||||
33815751|NCT02290353|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33815752|NCT05866289|||COHORT||OTHER|||||||
34046127|NCT02312089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046128|NCT04511520|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046129|NCT06409338|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046130|NCT05234736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046131|NCT04489160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046132|NCT01644708|||COHORT||PROSPECTIVE|||||||
34046133|NCT06575075|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomized with a 1:1:1 allocation to either 0.25 mg/kg RR-HNK or 0.5 mg/kg IV RR-HNK + IV placebo (sterile saline)|t|t|t|f
34046134|NCT05393869|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34046135|NCT05248373|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34046136|NCT04819516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046137|NCT04612738|RANDOMIZED|PARALLEL||OTHER||SINGLE|The principal investigator and statistical teams will be blinded to the allocation of study participants to the study arms.|This is a 3-armed, cluster randomized controlled trial that will compare the efficacy of two evidenced based interventions, with a nationally-promoted structured workbook, Conversation Project (CP) Starter Kit; and use of a Placebo/Attention control, non-ACP game called Table Topics. The primary outcome is completion of an advance directive 6 months post-intervention.|f|f|t|f
34046138|NCT03836183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046139|NCT02275455|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34046140|NCT05953688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046141|NCT02875132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046142|NCT05991232|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34046143|NCT05763979|||OTHER||CROSS_SECTIONAL|||||||
34046144|NCT02724046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046145|NCT01680861|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046146|NCT01000844|||COHORT||PROSPECTIVE|||||||
34046147|NCT00886197|||CASE_ONLY||PROSPECTIVE|||||||
33815753|NCT02995707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815754|NCT05894551|||COHORT||PROSPECTIVE|||||||
34046148|NCT05137444|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The phase Ⅱ trial adopts a randomized, double-blind, placebo-controlled design. The phase Ⅲ trial for expanded safety adopts an open-label design.||t|f|t|t
34046149|NCT04920201|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single masking (Outcomes Assessor)||f|f|t|f
34046150|NCT01295671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046151|NCT05484089|||COHORT||PROSPECTIVE|||||||
34046152|NCT01483274|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125340|NCT05407207|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The patients and the clinical coordinator who will evaluate and monitor study patients will both be blinded to the type of electrical stimulation unit (active v. sham).|Prospective cohort study with a double-blinded randomized control trial model.|t|t|f|f
34125341|NCT02438631|||COHORT||OTHER|||||||
34125342|NCT02573571|||CASE_ONLY||PROSPECTIVE|||||||
34125343|NCT01237431|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34125344|NCT02448355|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125345|NCT05115370|||OTHER||OTHER|||||||
34125346|NCT05938348|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815755|NCT01557439|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815756|NCT04996186|||COHORT||PROSPECTIVE|||||||
33815757|NCT05658900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815758|NCT06087159|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815759|NCT05383586|NA|SINGLE_GROUP||TREATMENT||NONE|The intervention can not be masked since it is provided with live music to the infants and parents.|One single group will be included with a pre-during-post intervention design.||||
34046153|NCT05329623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046154|NCT04669873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046155|NCT00782795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046156|NCT02860975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046157|NCT04948749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34046158|NCT04421287|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double mind||t|t|t|t
34046159|NCT04463147|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34046160|NCT02235844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046161|NCT02739425|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046162|NCT01030783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046163|NCT03660332|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34046164|NCT02379702|||||PROSPECTIVE|||||||
34046165|NCT04863378|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34046166|NCT03487627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046167|NCT03250858|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046168|NCT02741830|||COHORT||CROSS_SECTIONAL|||||||
34046169|NCT04657198|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an open-label study, as all participants will receive the same RSVPreF3 OA investigational vaccine. No blind is used. Both the investigator and the participant know the identity of the intervention assigned.|||||
34046170|NCT03926364|||COHORT||PROSPECTIVE|||||||
34046171|NCT05628428|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A researcher unrelated to the intervention will be responsible for randomizing the sample between the two groups. The researchers in charge of evaluating and interpreting the data will not know to which group each participant belongs.|Ramdomized clinical trial|f|f|t|t
34046172|NCT04443075|||COHORT||PROSPECTIVE|||||||
34046173|NCT02252393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046174|NCT05042661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125347|NCT03756116|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125348|NCT04915508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125349|NCT01918865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125350|NCT00682175|||CASE_ONLY||PROSPECTIVE|||||||
34125351|NCT01558596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34125352|NCT01730911|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125353|NCT02098525|||COHORT||RETROSPECTIVE|||||||
33838522|NCT00698503|||COHORT||PROSPECTIVE|||||||
33838523|NCT00407862|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34125354|NCT05152251|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125355|NCT04649658|||COHORT||RETROSPECTIVE|||||||
34125356|NCT04877860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants who meet the inclusion criteria will be randomized into each of the groups using a random number generation program (EPIDAT 4.2, junta de Galicia). The sequence will be placed in an opaque envelope closed by a member outside the investigation and will be opened once the baseline assessment is completed, so the assessment staff will be masked for the randomization of the participants, thus reducing the risk of bias during the evaluation. The blinding of evaluators will be guaranteed by the fact that some members of the group are specialized in the treatment of cancer patients and others in their evaluation.|"Experimental design with two intervention groups and a control group. Effectiveness study.~Intervention group 1: multimodal rehabilitation program + PNE Intervention group 2: multimodal rehabilitation program + traditional biomedical information Control group: Patient waiting list."|t|t|f|f
33815760|NCT03556059|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A cohort of all patients who underwent obesity and metabolic surgery in Germany will be analyzed in relation to preoperative complications||||
33815761|NCT00507702|||COHORT||PROSPECTIVE|||||||
33815762|NCT05270096|||OTHER||PROSPECTIVE|||||||
33815763|NCT03677271|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33815764|NCT04775537|||CASE_ONLY||PROSPECTIVE|||||||
33815765|NCT04750772|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33815766|NCT02287571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815767|NCT01451840|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33815768|NCT02660086|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33815769|NCT03686176|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, unblinded, controlled||||
33815770|NCT00955097|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815771|NCT05060874|||COHORT||CROSS_SECTIONAL|||||||
33815772|NCT04324606|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33815773|NCT05316324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815774|NCT01702103|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33815775|NCT01870895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815776|NCT05174026|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815777|NCT03788278|||COHORT||PROSPECTIVE|||||||
33815778|NCT00700557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815779|NCT04552184|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33815780|NCT01150305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815781|NCT04421534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815782|NCT04669184|||COHORT||PROSPECTIVE|||||||
33815783|NCT06207747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This study will prospectively collect data from metastatic or stage III.D unresectable melanoma patients treated with ICIs and followed regularly with 18F-FDG PET/CT scans. Recruitment is expected to last 18 months. Predictive sample size is 100 melanoma patients.~Timing of PET/CT scans:~* Baseline PET/CT less than 4 weeks before first ICI infusion~* Follow-up: 4 weeks (+/- 5 days) after first infusion, 16 weeks (+/- 7 days) after first infusion, then after every 16 weeks (+/- 7 days) or before in case of PD suspicion ."||||
33815784|NCT02635698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815785|NCT00406276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815786|NCT05256836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33815787|NCT03657641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815788|NCT06606769|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815789|NCT02313077|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33815790|NCT05756101|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
33815791|NCT00538499|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815792|NCT00741923|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815793|NCT06501508|||COHORT||RETROSPECTIVE|||||||
33815794|NCT00731913|||CASE_CONTROL||PROSPECTIVE|||||||
33815795|NCT02558803|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33815796|NCT05809466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33815797|NCT05448222|||COHORT||PROSPECTIVE|||||||
33815798|NCT02316171|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815799|NCT04188457|||CASE_CONTROL||PROSPECTIVE|||||||
33815800|NCT04021277|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|The participant and radiologist are blinded to treatment dose|"Part 1 is divided into two stages:~Part 1a: 3+3 open label non-randomized design to evaluate two doses~Part 1b: Single blind, randomized design to evaluate two doses"|t|f|f|t
33815801|NCT00692757|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33815802|NCT01699178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815803|NCT04532814|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study is aimed to determine whether obesity effects muscle glucose utilization during exercise.||||
33815804|NCT01940913|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33815805|NCT00992849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815806|NCT06452914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is double blinded. Neither the Investigator or the subject will know which arm they have been assigned to.|Participants are assigned to one of two groups; one group that will be assigned the treatment socks and the second group that will be assigned the placebo socks.|t|f|t|f
33815807|NCT05329402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815808|NCT04182217|||CASE_ONLY||RETROSPECTIVE|||||||
33815809|NCT00082576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33815810|NCT02301871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815811|NCT02181881|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33815812|NCT06452888|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33815813|NCT02167191|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815814|NCT03650972|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815815|NCT04769219|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|the participant did not know which group he was in.|There are 2 groups as intervention and control|t|f|f|f
33815816|NCT02482896|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33815817|NCT05058547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815818|NCT03204318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815819|NCT02423707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815820|NCT06493448|||COHORT||PROSPECTIVE|||||||
33815821|NCT05742646|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33815822|NCT04151888|||OTHER||OTHER|||||||
33815823|NCT01255709|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33815824|NCT00828139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815825|NCT03622580|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33815826|NCT05890781|NA|SINGLE_GROUP||OTHER||NONE||||||
33815827|NCT04468737|||OTHER||RETROSPECTIVE|||||||
33815828|NCT03900598|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815829|NCT02442102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815830|NCT05130099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33815831|NCT02463292|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815832|NCT04102605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815833|NCT01815294|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815834|NCT00329771|||COHORT||PROSPECTIVE|||||||
33815835|NCT02105688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815836|NCT01969188|||COHORT||PROSPECTIVE|||||||
33815837|NCT05714774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815838|NCT02531997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815839|NCT01803958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815840|NCT03240172|||CASE_CONTROL||RETROSPECTIVE|||||||
33815841|NCT03819647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815842|NCT03274934|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Treatment, Parallel assessment, Randomized, Efficacy study||||
33815843|NCT05851521|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Prospective randomized clinical trial divided in 3 cohorts: HERMES_CRYO (cryotherapy for targeted therapy of localized prostate cancer), HERMES_REZUM \[water vapor energy ablation for the treatment of benign prostatic hyperplasia (BPH)\], and HERMES_LASER \[ELESTA ECHOLASER® for the treatment of benign prostatic hyperplasia (BPH)\].~In each cohort, two arms will be compared: temporary prostatic stent vs indwelling catheter with a 1:1 randomization ratio."||||
33815844|NCT05809635|||COHORT||PROSPECTIVE|||||||
33815845|NCT04964206|||COHORT||PROSPECTIVE|||||||
33815846|NCT03536637|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33815847|NCT05278117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815848|NCT03473665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815849|NCT02531061|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815850|NCT04135872|||COHORT||PROSPECTIVE|||||||
33815851|NCT03957759|||CASE_ONLY||PROSPECTIVE|||||||
33815852|NCT06285578|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33815853|NCT00825513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815854|NCT00149565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815855|NCT01062776|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33815856|NCT00338325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815857|NCT03576625|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33815858|NCT03199456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815859|NCT02994329|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815860|NCT03562702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The assignment of treatment will be concealed from research team members involved in recruiting patients by using sealed, sequentially numbered, opaque envelopes containing the type of rehydration treatment to be used.||t|t|t|f
33815861|NCT00409006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815862|NCT00949234|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815863|NCT00297089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815864|NCT04095338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815865|NCT01658176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815866|NCT05845866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|f|f|f|t
33815867|NCT02854982|||COHORT||OTHER|||||||
33815868|NCT05725447|||CASE_ONLY||PROSPECTIVE|||||||
33815869|NCT05670600|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Experimental research method was used. There is an intervention and control group. While the intervention group was given foot and ankle exercise training, no intervention was given to the control group. The Visual Analog Scale (VAS) of Neuropathic Pain was calculated by another researcher, who applied foot and ankle exercises to both groups before starting the exercise (1st measurement), fourth (2nd measurement) and at the end of the eighth week (3rd measurement). The Impact on Quality of Life Questionnaire (NePIQoL) was administered.||||
33815870|NCT00551954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815871|NCT02838888|||COHORT||PROSPECTIVE|||||||
33815872|NCT02952170|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815873|NCT04327349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815874|NCT00547716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815875|NCT04394585|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815876|NCT00002045||||TREATMENT||DOUBLE||||||
33815877|NCT04580732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33815878|NCT03639194|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33815879|NCT02581826|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33815880|NCT02951949|||COHORT||CROSS_SECTIONAL|||||||
33815881|NCT06549270|||CASE_CONTROL||PROSPECTIVE|||||||
33815882|NCT02822963|||COHORT||PROSPECTIVE|||||||
33815883|NCT05450159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Video recordings of the on-road evaluation wil be scored by an independent (outcomes) assessor blinded to participant identity, group allocation, and whether the drive was from the baseline or after the intervention. Blinding will be enforced by randomly assigning a unique number to each video after a participant has completed their 3 months of driver monitoring. Videos will be forwarded to the rater in batches of 8-10.|2-arm, parallel-group, double-blinded Randomized Controlled trial|t|f|f|t
33815884|NCT02759406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815885|NCT05989386|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33815886|NCT04725552|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Feasibility study of a digital intervention supporting change in alcohol consumption for patients in general practice. The digital intervention is a supplement to usual care.||||
33815887|NCT01099878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046175|NCT05579470|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||THe investigators propose a quasi-experimental, pretest-posttest design to evaluate the effect of the NIATx strategy on OAT scale-up for three CA countries. Specifically interested in assessing how the introduction of a NIATx model affects two primary outcomes: (1) rate of entry onto OAT, and (2) retention on OAT. Though the implementation science field is rapidly evolving, such an approach is limited by its assumption that existing data were collected and recorded in a manner that adheres to the fidelity of the measures - a noted innovation in this proposal. This limitation is addressed prospectively recording OAT entry and attrition over an extended time period (36 months) and, as part of Aim 3, collect inner and outer context and bridging and innovation of EBP factors as repeated measures to examine trajectories and factors that are associated with them.||||
34046176|NCT01158846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046177|NCT03527589|||COHORT||PROSPECTIVE|||||||
34046178|NCT00951145|||CASE_ONLY|||||||||
34046179|NCT05866848|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Three groups were randomly constituted, with 15 young people each: control group without caffeine, group with relatively small amount of caffeine (45 mg) administered and group with greater amount of caffeine (120 mg). Participants were not aware to which group they belong.|"All subjects were submitted to 2 evaluation moments: the first baseline moment and the second moment, 30 minutes after caffeine ingestion, which constitutes the time required for caffeine absorption.~In each of the 2 moments, they performed 30 seconds of continuous breathing (hypoventilation), followed by 30 seconds of continuous rapid breathing (hyperventilation). VMCA measurements were stabilized between these tests. The study started with apnea testing because VMCA requires less time to return to baseline levels after hypoventilation than after hyperventilation.~When VMCA measurements were stable, a 30-second baseline period was followed by three 30-second cognitive tasks, with a 1-minute break between activities: short-term memory test; solve a vocabulary problem; and solving a math problem. Three versions of each cognitive task were used for the three conditions. The procedure was completed with a final rest period of 60 seconds."|t|f|f|f
34046180|NCT06113640|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|t|f
34046181|NCT01225081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046182|NCT04224610|||CASE_ONLY||RETROSPECTIVE|||||||
34046183|NCT06029413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is planned to compare the effects of USG guided intramuscular trigger point injection with the effects of USG guided intramuscular plus fascial trigger point injection. This is a single-center randomized trial with 2 parallel arms.|t|f|t|t
34046184|NCT04215809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The dose escalation study of APG-2575 as monotherapy will use the standard 3+3 design. APG-2575 will be taken orally, once daily starting with a ramp-up treatment and will receive the full dose starting on Day 1 of 28-Day-Cycle 1. The starting target dose of APG-2575 is 200 mg (using ramp-up) and will be increased in subsequent cohorts to 400 mg, 600 mg, 800 mg and 1200 mg accordingly.||||
34046185|NCT06224816|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046186|NCT00996151|NA|SINGLE_GROUP||||NONE||||||
34046187|NCT00813254|||COHORT||RETROSPECTIVE|||||||
34046188|NCT02339532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046189|NCT00005836||||TREATMENT||||||||
34046190|NCT01521390|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34046191|NCT05619354|||OTHER||PROSPECTIVE|||||||
34046192|NCT02880475|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046193|NCT06206239|||COHORT||PROSPECTIVE|||||||
34046194|NCT01962077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046195|NCT05454527|||COHORT||CROSS_SECTIONAL|||||||
34046196|NCT03198065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046197|NCT06666738|||COHORT||PROSPECTIVE|||||||
34046198|NCT04087720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046199|NCT01634048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046200|NCT05989347|NA|SINGLE_GROUP||OTHER||NONE||Women with BMI ≥ 25 kg/m2 and hyperinsulinemia (HOMA-IR ≥ 2.5) and early stage, operable HER2-negative (by FISH or IHC 0, 1+ or 2+) breast cancer for whom systemic neoadjuvant chemotherapy is indicated.||||
34046201|NCT00182611|RANDOMIZED|||TREATMENT||||||||
34046202|NCT04059705|NA|SINGLE_GROUP||TREATMENT||NONE||This study utilizes a one-group design with repeated measures.||||
34046203|NCT06353607|||COHORT||PROSPECTIVE|||||||
34046204|NCT02640677|||OTHER||PROSPECTIVE|||||||
34046205|NCT03271281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046206|NCT03764397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046207|NCT02504905|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34046208|NCT03442179|||COHORT||PROSPECTIVE|||||||
34046209|NCT02246543|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34046210|NCT05931341|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34046211|NCT02467790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046212|NCT05930626|||COHORT||PROSPECTIVE|||||||
34046213|NCT00410735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046214|NCT04664023|||COHORT||PROSPECTIVE|||||||
34046215|NCT05527327|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All prospective participants will receive the intervention for one occurrence. Retrospective participants' results will be observed without any intervention.||||
33815888|NCT06292247|RANDOMIZED|PARALLEL||OTHER||NONE||Group 1 (CBT) Group 2 (APT) Group3 (control TSD)||||
34046216|NCT05458401|||COHORT||RETROSPECTIVE|||||||
34046217|NCT02620163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046218|NCT02497560|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34046219|NCT02112045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125357|NCT05614752|||CASE_ONLY||PROSPECTIVE|||||||
34151119|NCT06087978|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815889|NCT06584877|||FAMILY_BASED||OTHER|||||||
34151120|NCT00194168|||COHORT||PROSPECTIVE|||||||
33815890|NCT03680781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815891|NCT00514670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815892|NCT02222649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815893|NCT02158845|RANDOMIZED|PARALLEL||||NONE||||||
33815894|NCT06102278|||COHORT||RETROSPECTIVE|||||||
33815895|NCT02912104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046220|NCT00641030|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046221|NCT06308692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046222|NCT05733065|NA|SINGLE_GROUP||OTHER||NONE||||||
34046223|NCT03296410|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046224|NCT03877601|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046225|NCT06574984|||OTHER||RETROSPECTIVE|||||||
34046226|NCT05921292|NA|SINGLE_GROUP||OTHER||NONE||||||
34046227|NCT02752061|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34046228|NCT06274073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two parallel groups (two digital block techniques)|f|f|f|t
34046229|NCT05896891|||COHORT||PROSPECTIVE|||||||
34046230|NCT05425576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046231|NCT03061136|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34046232|NCT02466815|RANDOMIZED|CROSSOVER||||NONE||||||
34046233|NCT01582854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046234|NCT01497925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046235|NCT02999269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (participant and outcomes assessor)|Subjects randomized to right unilateral ECT with 600, 700, or 800 mA pulse amplitude.|t|f|f|t
34046236|NCT02154711|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34046237|NCT01371864|||COHORT||PROSPECTIVE|||||||
34046238|NCT01023945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046239|NCT06601296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046240|NCT04109391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046241|NCT05052372|||CASE_ONLY||PROSPECTIVE|||||||
34046242|NCT03741790|||COHORT||RETROSPECTIVE|||||||
34046243|NCT00707681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046244|NCT03387280|||CASE_ONLY||RETROSPECTIVE|||||||
34046245|NCT04616638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046246|NCT04713254|NA|SEQUENTIAL||TREATMENT||NONE||||||
34046247|NCT04240639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046248|NCT06479967|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34046249|NCT05463094|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34046250|NCT02868190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046251|NCT06631937|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A randomized, placebo controlled trial of term infants with a 6 months intervention phase and 6 months short-term follow-up phase.|t|t|t|t
34046252|NCT04562246|||COHORT||PROSPECTIVE|||||||
34046253|NCT00716014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046254|NCT06284057|||COHORT||RETROSPECTIVE|||||||
34046255|NCT05977387|||COHORT||RETROSPECTIVE|||||||
34046256|NCT00675012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046257|NCT01186692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046258|NCT03740087|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Baseline blood samples were obtained after 12 hours overnight fast; the postprandial miRNA state was measured after intake of a meal with beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice. The control diet consisted of the same intervention, without the roast beef. Each intervention day the meals were prepared with fresh food. Participants ate meals under control of the study staff. Postprandial samples were collected at 2, 4 and 6 hours after the diet intervention. The subjects did not eat or drink again until the end of sample collection.||||
34046259|NCT05010564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046260|NCT05829538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In the study, the women were blind to each other in terms of practice and the data evaluator was blinded to the groups in the study in terms of analysis and reporting. Su Jok and massage application and follow-up were carried out by the researcher (FŞB), who could not be blinded to the applications. Randomization was done by another researcher (ZN). In order to avoid bias, the investigator (FSB) did not participate in any step of the pre-test, post-test and statistical evaluation process.|Single Blind Randomized Controled Trials|t|f|f|f
34046261|NCT06093360|||CASE_ONLY||RETROSPECTIVE|||||||
34046262|NCT03558763|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This clinical trial is an open, randomized, controlled cross-over study. Eligible subjects to include will be given the possibility to participate in the study. They will at their first visit be randomized to start either telemonitoring, using the tablet system arm or to normal standard of care period for 26 weeks. After 26 weeks the subject will have a second visit and after that, four weeks (wash out) of standard of care or telemonitoring treatment. After that there will be a third visit and the subject will start the second treatment period with the alternative management. At the end of this period (56 weeks) there will be a fourth (last) visit at the center for the subject.||||
34046263|NCT04366843|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046264|NCT05020665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046265|NCT00004828|RANDOMIZED|||TREATMENT||||||||
34046266|NCT00725361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046267|NCT02539433|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34046268|NCT00252525|||COHORT|||||||||
34046269|NCT00717834|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046270|NCT03350646|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34046271|NCT01568034|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34046272|NCT06199089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046273|NCT05637996|||CASE_ONLY||PROSPECTIVE|||||||
34046274|NCT04282941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"A randomized system with closed envelopes will be designed in which patients will be assigned to one of the 2 treatment groups, stratified by gestational age (\<28 weeks and ≥28 weeks) and by hospital center. In each center and each stratum, they will be randomly assigned in a 1: 1 ratio to each group of study. The assignment will be sequential.~The doctors responsible for the patient will be blind to the intervention but will be responsible for the sealed envelopes, and at the time of patient randomization, will deliver the sealed envelope corresponding to the nurses responsible for the preparation of the medication."|"Administration schedule A: Ibuprofen in continuous iv infusion and EchoG. Each cycle will be 3 doses.~Administration schedule B: slow iv bolus Ibuprofen and EchoG. Each cycle will be 3 doses."|t|f|t|f
34046275|NCT01560598|||CASE_CONTROL||PROSPECTIVE|||||||
34046276|NCT03080064|NA|SINGLE_GROUP||PREVENTION||NONE||One-arm intervention trial.||||
34046277|NCT00669565|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046278|NCT03831464|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A multi-center, practice-oriented, repurposing, double-blinded, placebo-controlled, randomized clinical trial. The RenoMet trial is repurposing an already approved agent (Metformin , Glucophage SR) in a new indication (renoprotection) in a new class of patients (chronic kidney disease patients CKD 2, 3A, 3B and including patients with renal transplant for more than 3 years),|t|t|t|t
34046279|NCT04818840|||COHORT||PROSPECTIVE|||||||
34125358|NCT06186583|NA|SINGLE_GROUP||TREATMENT||NONE||On Day 1, subjects will receive a single oral dose of approximately 50 mg ABSK021 containing approximately 100 μCi of \[14C\] ABSK021 in the fasted state.||||
34125359|NCT05573698|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34046280|NCT05724251|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34046281|NCT04805801|||COHORT||OTHER|||||||
34046282|NCT00100607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34046283|NCT04263441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34046284|NCT03200314|||COHORT||PROSPECTIVE|||||||
34046285|NCT02418156|||CASE_ONLY||PROSPECTIVE|||||||
34046286|NCT03330704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34046287|NCT00957593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046288|NCT01352351|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046289|NCT00245973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34046290|NCT01942486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046291|NCT04061928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046292|NCT03874481|||COHORT||PROSPECTIVE|||||||
34046293|NCT05216861|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046294|NCT01132248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046295|NCT01047969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046296|NCT03106363|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34046297|NCT04606394|NA|SINGLE_GROUP||TREATMENT||NONE||Open label comparative design||||
34046298|NCT02317276|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|||||
34046299|NCT01011751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046300|NCT01677312|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34046301|NCT03107585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046302|NCT04690231|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046303|NCT02954029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046304|NCT00668980|||CASE_CONTROL||PROSPECTIVE|||||||
34046305|NCT06106412|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective ranzomized analysis||||
34046306|NCT00419848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046307|NCT04950270|||COHORT||PROSPECTIVE|||||||
34046308|NCT03556839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046309|NCT04159454|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|This is a feasibility, safety, and tolerability pilot trial that is double-blinded. To the extent that is possible, the outcome variable collection and analysis will be fully blinded. Only the device nurse responsible for programming ICDs and investigators responsible for performing physical examinations will know specifics of patient protocol (ie which patients will have PITA and when) and will be unblinded; all other investigators and patients will be blinded. Subjects meeting inclusion criteria and not any exclusion criteria (see below) will have PITA on for Weeks 0-8 and PITA off for Weeks 8-12. This design provides assessment of feasibility, tolerability and safety of PITA over a 2 month timepoint and the decay effect of PITA for an additional month once turned off.|The investigators will inform all subjects initially that 50% of the subjects will have PITA on for the first 8 weeks, and 50% will have PITA on for the last 4 weeks. However, all patients will follow the same protocol consisting of PITA on for Weeks 0-8, and PITA off for Weeks 8-12. Because this is a feasibility, safety, and tolerability trial, there is no need for a placebo or non-treatment group. Each patient serves as his or own control with a period of PITA on and PITA off. This data will help inform the investigators' next studies which will include control groups.||||
34046310|NCT02642120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046311|NCT02454816|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A cluster randomised controlled trial will be conducted in 12 health facilities (4 hospitals and 8 health centres) in Bogota and Cali, Colombia.||||
34046312|NCT03512444|RANDOMIZED|PARALLEL||OTHER||SINGLE||"2 groups: intervention and control (both are in each arm of the same participant).~Intervention will be applied at one arm (chosen randomly) with using the contralateral arm as a control."|t|f|f|f
34046313|NCT05001542|NA|SINGLE_GROUP||OTHER||NONE||Users will go through a VR experiment before and after a brief interventional informative video describing moral distress. The VR experiment is a simulation that will lead the participant through a stressful experience about moral distress during the COVID-19 pandemic. Before, during, and after the experiment, active and physiological data will be collected from the participant to monitor their level of acute distress and health, respectively. Following the experiment, active and passive data will be collected on each user through the investigators' mobile platform (DiiG) for longitudinal monitoring of moral distress and injury.||||
34046314|NCT02889939|NA|SINGLE_GROUP||TREATMENT||NONE||A within-subject, repeated-measures design with pretest-posttest evaluation was utilised to assess outcomes after ETT. The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control||||
34046315|NCT06578286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046316|NCT04215003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046317|NCT04048213|||COHORT||PROSPECTIVE|||||||
34046318|NCT01861951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046319|NCT03194880|||COHORT||PROSPECTIVE|||||||
34046320|NCT02995174|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34125360|NCT04974463|||CASE_CONTROL||PROSPECTIVE|||||||
34125361|NCT04381299|||COHORT||PROSPECTIVE|||||||
34125362|NCT03935178|||OTHER||PROSPECTIVE|||||||
34125363|NCT04335448|||COHORT||PROSPECTIVE|||||||
34151121|NCT01840098|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34151122|NCT01746173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151123|NCT02103413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151124|NCT00849108|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151125|NCT01105585|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34151126|NCT01391988|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046321|NCT05498441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046322|NCT04844749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Central reader for scans will be blinded|This randomized, open-label, active-control clinical study consists of two treatment arms:VERU-111 (Sabizabulin) treated group, and Control treated group. Subjects will be randomized in a 2:1 fashion.|f|f|f|t
34046323|NCT05577208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046324|NCT02757833|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34046325|NCT05932693|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants will be exposed to e-liquids containing 16 conditions (WS-3 block: 0.05%, 0.1%, 0.5%, 1.0%, 2.0%, WS-23 block: 0.05%, 0.1%, 0.5%, 1.0%, 2.0%, 4.0%, and menthol block: 0.05%, 0.1%, 0.5%, 1.0%, 2.0%) from low concentration to high concentration.|Participants are exposed to all study conditions (16 e-liquid samples).|t|f|t|f
34046326|NCT05690607|||COHORT||PROSPECTIVE|||||||
34046327|NCT05142631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046328|NCT06524869|||COHORT||PROSPECTIVE|||||||
34046329|NCT03073031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046330|NCT00567658|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34046331|NCT01563822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046332|NCT02120833|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34046333|NCT05108636|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046334|NCT03070002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046335|NCT01511029|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34046336|NCT02966886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046337|NCT02807727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046338|NCT02620176|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34046339|NCT03139578|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the investigator and the subjects are masked to the identity of the study lenses. Lenses were over-labelled and coded to mask the lens foil. Over-labelling was carried out by the study sponsor following specific SOPs (see ICH GCP guidelines Section 5.13).|Contra-lateral Assignment|t|f|t|f
34046340|NCT01368705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046341|NCT00889876|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34046342|NCT00942591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046343|NCT05460819|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046344|NCT03243032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will not know which arm they will be in initially. At the 2 week post-operative visit they may be notified of which arm they participated in if they so choose to find out.|Randomized, parallel arms, double-blinded, placebo-controlled trial|t|f|f|f
34046345|NCT04147676|||COHORT||PROSPECTIVE|||||||
34046346|NCT05388643|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Those assessing the outcomes from the medical chart will be blinded to the randomization process and the assigned study arm. Patients, the primary investigator, and their care providers will be aware of their treatment status.|This is a prospective, single-center, randomized study evaluating an early screening protocol for identifying women at high risk for developing GDM to the routine standard of care for GDM screening.|f|f|f|t
34046347|NCT05468528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046348|NCT06156163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046349|NCT01681212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046350|NCT06189781|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be assigned to either treatment/intervention group (injection only) or control (epidural only). All other aspects of care will be identical between the two groups.|f|f|f|t
34046351|NCT00053781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046352|NCT06517784|||COHORT||CROSS_SECTIONAL|||||||
34046353|NCT05970523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||I applied exercise intervention for the intervention group. I will not apply any intervention for the control group.|t|f|f|f
34046354|NCT02557581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34046355|NCT06217237|||COHORT||CROSS_SECTIONAL|||||||
34046356|NCT02608983|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34046357|NCT06506695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046358|NCT05982483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants in both cohorts had pink chlorhexidine skin prep and a dressing applied to the back. Research team members performing the telephone follow-up were blinded to treatment allocation.||f|t|f|t
34046359|NCT03034174|||COHORT||PROSPECTIVE|||||||
34046360|NCT04167098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046361|NCT02458456|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34046362|NCT06364930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046363|NCT01106911|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046364|NCT00821964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046365|NCT05623540|||COHORT||OTHER|||||||
34046366|NCT00435682|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
34046367|NCT06574737|||OTHER||OTHER|||||||
34046368|NCT03979807|||COHORT||RETROSPECTIVE|||||||
34046369|NCT01998932|||COHORT||PROSPECTIVE|||||||
34046370|NCT05422378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind (investigator \& subjects)|Dose-ranging, double-blind, vehicle-controlled|t|f|t|f
34046371|NCT06250920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34046372|NCT03951883|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046373|NCT02531971|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34046374|NCT03600402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34046375|NCT06035770|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Control trial with educational intervention|f|f|f|t
34046376|NCT03255447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046377|NCT02326935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046378|NCT00911469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046379|NCT02527434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046380|NCT02199288|||COHORT||PROSPECTIVE|||||||
34046381|NCT03565159|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants will be randomised 1:1 to receive one single 0.5ml dose of active or placebo Investigational Medicinal Product at baseline.|t|t|t|t
34046382|NCT06574412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046383|NCT03469128|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|This is a three-group, repeated-measure, parallel-group, Randomized Control Trial design. Patients, study psychiatrists, and assessors were blind to treatment condition assignment. Randomization blocks of three were used to maintain equal group size. The 3-month assessment serves as the post-treatment. Outcome assessments were PTSD severity, substance use severity, and depression. The pharmacy of Ain Shams Hospital created sertraline and matching placebo kits with single-identifier numbers based on a random code that was provided to an unblinded statistician who will instruct the psychiatrist how to distribute kits to patients.|Data were obtained by interviewing 587 patients diagnosed with SUD. Patients were interviewed by a clinician and asked to complete: Mini-International Neuropsychiatric Interview (M.I.N.I), and Clinician-Administered PTSD Scale (CAPS). Patients with comorbid SUD and PTSD were asked to complete: The Brief Addiction Monitor (BAM), PTSD Checklist-Civilian (PCL-5), Beck Depression Inventory (BDI-II), and Timeline Follow Back Interview (TLFB). Patients with comorbid SUD and PTSD were randomized to one of the following groups: 1) received CPT. 2) received Sertraline. 3) the Placebo control group.|t|t|f|t
34046384|NCT05688384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046385|NCT02328469|||CASE_CONTROL||PROSPECTIVE|||||||
34046386|NCT01750697|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046387|NCT01448343|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34046388|NCT04850430|NA|SINGLE_GROUP||PREVENTION||NONE||Patients will be assigned to study after intraoperative evaluation of gastric venous drainage after coronary vein resection during TP. During surgery, onsite evaluation by the surgeon, endoscopic examination, indocyanine green, gastric venous drainage flowmetry, and spectral analysis will be performed. After surgery, patients will receive standard post-TP care and treatment. During hospitalization, endoscopic examination with indocyanine green will be performed on the first, third, and seventh postoperative day to evaluate gastric ischemia. Ischemia markers will be evaluated daily after surgery. After discharge, patients will be followed up for 30 days, during which mortality and morbidities will be recorded.||||
34046389|NCT05472129|||CASE_CONTROL||PROSPECTIVE|||||||
34046390|NCT06141174|||CASE_ONLY||PROSPECTIVE|||||||
34046391|NCT06147947|||CASE_ONLY||CROSS_SECTIONAL|||||||
34046392|NCT06684574|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention is a program of nordic walking and strengtheining exercises||||
34046393|NCT00497289|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34046394|NCT05591976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34046395|NCT03942458|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046396|NCT06684249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blinded to treatment allocation to ensure unbiased evaluation of efficacy and safety outcomes.|Two-group parallel design comparing nerve block injections with Botox injections in chronic migraine management.|f|f|f|t
34046397|NCT02900885|||CASE_ONLY||RETROSPECTIVE|||||||
34046398|NCT04981808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046399|NCT06184646|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046400|NCT04795934|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|"Measures will be taken to minimize or avoid bias in the study masking/blinding procedures. Neither treatment groups will be advised as to which procedure (TIF or LNF) they will be receiving. Randomization assignment will be recorded in the EDC and subject tracking, but will not be recorded within the EMR to reduce clinical team exposure to their randomized status for follow-up care. Research teams will not be blinded to the randomization results."||t|f|f|f
34046401|NCT01468194|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34046402|NCT06682091|||COHORT||RETROSPECTIVE|||||||
34046403|NCT03550092|NA|SINGLE_GROUP||OTHER||NONE||||||
34046404|NCT06140017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34046405|NCT04219111|||OTHER||RETROSPECTIVE|||||||
34046406|NCT03488758|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34046407|NCT00886444|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046408|NCT06198829|||OTHER||CROSS_SECTIONAL|||||||
34046409|NCT01146899|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34046410|NCT02410915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046411|NCT01697098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046412|NCT05791136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046413|NCT04615169|NA|SINGLE_GROUP||TREATMENT||NONE||A multi-center one-group pretest, post-test, and 3-month follow up design||||
34046414|NCT03299179|||CASE_CONTROL||PROSPECTIVE|||||||
34046415|NCT02552069|||COHORT||PROSPECTIVE|||||||
34046416|NCT04328129|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34046417|NCT03868982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized into study group or control group, and which is single blind processes to participants.|Fifty participant with ARDS according to the Berlin Definition will enroll to this study. Participants studied twice daily with collection of data and blood tests.|t|f|f|f
34046418|NCT05886140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046419|NCT02118727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046420|NCT00030667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046421|NCT03683927|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34046422|NCT02397499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046423|NCT02088060|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046424|NCT04444206|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||This is a prospective, non-pharmacological, non-profit interventional study on women with single pregnancy without a history of previous preterm spontaneous birth. Cervical lenght (CL) and Consistence Cervical Index (CCI) will be assessed by transvaginal ultrasound. CL and CCI measurements will be performed in the first trimester, between 11 and 13 weeks + 6 days, in the second trimester, between 19 and 22 weeks and in the third trimester between 29 and 32 weeks during routine ultrasound examinations for monitoring of pregnancy, in accordance with current national guidelines.|t|f|f|f
34046425|NCT02367222|||COHORT||RETROSPECTIVE|||||||
34046426|NCT06502158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815896|NCT01346722|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33815897|NCT00783185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815898|NCT04113226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815899|NCT01526850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815900|NCT00504101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815901|NCT03892265|||COHORT||PROSPECTIVE|||||||
33815902|NCT06600490|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33815903|NCT03616314|||COHORT||RETROSPECTIVE|||||||
33815904|NCT06081972|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33815905|NCT01026441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815906|NCT02079402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815907|NCT05237856|||CASE_CONTROL||PROSPECTIVE|||||||
33815908|NCT00842959|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33815909|NCT00564499|||CASE_CROSSOVER||PROSPECTIVE|||||||
33815910|NCT05935306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Thus for the participant does not identify the group to which he belongs, the device activation sound (beep) will be recorded and it will turn on at the time of application.. Immediately after finishing the suture, the investigator in charge of applying the FBM will remove and open 1 envelope (without changing the numerical sequence of the other envelopes) and perform the indicated procedure or its simulation. Only this researcher will know the nature of the treatments.|This randomized, controlled, double-blind superiority clinical trial meets the criteria for designing a clinical trial in accordance with the SPIRIT Statement. It was accepted by Research Ethics Committee (CEP) of the Catholic University of Uruguay|t|f|t|t
33815911|NCT01161953|||FAMILY_BASED||OTHER|||||||
33815912|NCT01769729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815913|NCT02765204|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815914|NCT05209256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815915|NCT02465632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33815916|NCT00595725|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33815917|NCT02131792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815918|NCT06192537|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33815919|NCT00328120|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33815920|NCT05150275|||CASE_CONTROL||RETROSPECTIVE|||||||
33815921|NCT06200909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researchers who engage in pre-post testing assessment will be blinded to participant allocation.|A prospective single-blinded mixed methods randomized controlled superiority trial, with participants randomized in blocks of 8-12 to either MM, PSY, or RC.|f|f|f|t
33815922|NCT00801151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815923|NCT00891709|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33815924|NCT05893693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815925|NCT03149484|||COHORT||PROSPECTIVE|||||||
33815926|NCT01800994|||OTHER||PROSPECTIVE|||||||
33815927|NCT01844063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33815928|NCT00957918|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815929|NCT00447109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33815930|NCT05512598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815931|NCT00847977|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33815932|NCT03800602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815933|NCT04403815|||COHORT||PROSPECTIVE|||||||
33815934|NCT05007600|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33815935|NCT03946345|||COHORT||PROSPECTIVE|||||||
33815936|NCT02754375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815937|NCT00188747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33815938|NCT00327236|||COHORT||PROSPECTIVE|||||||
33815939|NCT00744705|||CASE_ONLY||RETROSPECTIVE|||||||
33815940|NCT00711022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815941|NCT06266676|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33815942|NCT04037592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33815943|NCT04258306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Single blind, the subject, but not the responsible investigator, does not know which of the two possible treatments he receives.|The subjects will be given, on the first day, in the morning on an empty stomach, a solution of content A or B obtained by dissolving the contents of the capsule in water which will then be taken orally. Samples of 2 ml of venous blood in a tube containing EDTA will be taken from a vein in the arm using a cannula at 0 min (fasting before administration), 15 min, 30 min, 60 min, 90 min, 120 min, 180 min. WASH-OUT on the second day. On the third day, the person who had taken the solution A will take the solution B, and vice versa, with the same methods and times described above.|t|f|f|f
33815944|NCT02054000|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046427|NCT01972438|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34046428|NCT01682226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046429|NCT02841280|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815945|NCT05612113|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Third-party raters, not being involved in the project management of the study or participating in the study, will be blinded to the participating therapists, study phases and the order of recorded sessions. These third-party raters will assess therapists' skills, goal attainment and competences in each recorded session. To test for blinding integrity the third-party raters will note their guesses of which condition the session belonged to (baseline or intervention).|Replicated Single Case Experimental Design with Multiple Baselines|f|f|f|t
33815946|NCT05235815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815947|NCT00956527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815948|NCT04834167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815949|NCT00961389|||COHORT||PROSPECTIVE|||||||
33815950|NCT00575081|||CASE_ONLY||CROSS_SECTIONAL|||||||
33815951|NCT01305837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815952|NCT01177644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815953|NCT02799693|||COHORT||PROSPECTIVE|||||||
33815954|NCT06337799|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33815955|NCT02669056|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815956|NCT01092689|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33815957|NCT01924468|NON_RANDOMIZED|CROSSOVER||PREVENTION||||||||
33815958|NCT05063175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33815959|NCT04680559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815960|NCT02529176|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33838524|NCT05688631|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815961|NCT04428619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients who meet study eligibility criteria will be randomly assigned (1:1) in blocks of two and four, using a code generated by a randomization program to 4 weeks of stimulation with an active or inactive (sham) PENFS device. Per manufacturer design, both active stimulation and sham are below a detectable sensation threshold. Allocation will be concealed, and all physicians, statisticians, participants, and research coordinators will be unaware of device codes. One research coordinator who has no patient contact will be unblinded and handle allocation and storage of devices. At the end of 4 weeks, patients will be asked to which device arm they believe they were randomized.||f|f|t|f
33815962|NCT02865083|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33815963|NCT01469442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815964|NCT03039322|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33815965|NCT06309745|||COHORT||PROSPECTIVE|||||||
33815966|NCT01783379|||CASE_ONLY||PROSPECTIVE|||||||
33815967|NCT05721898|||CASE_CONTROL||RETROSPECTIVE|||||||
33815968|NCT03131271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33815969|NCT03935152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815970|NCT00649402|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33815971|NCT01176409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815972|NCT03386344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815973|NCT05627622|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized control trial|f|f|f|t
33815974|NCT05143320|||CASE_CONTROL||PROSPECTIVE|||||||
33815975|NCT04043663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective randomized controlled trial|f|f|f|t
33815976|NCT01802398|||COHORT||PROSPECTIVE|||||||
33815977|NCT04150900|NA|SINGLE_GROUP||TREATMENT||NONE||Pembro and Bavituximab for progressive recurrent/metastatic squamous cell carcinoma of head and neck||||
33815978|NCT04455542|||CASE_ONLY||PROSPECTIVE|||||||
33815979|NCT04062279|||COHORT||PROSPECTIVE|||||||
33815980|NCT04117659|NA|SINGLE_GROUP||OTHER||NONE||withdrawal of a pharmacologic therapy in pre-treated patients without control group||||
33815981|NCT04277273|NA|SINGLE_GROUP||OTHER||NONE||||||
33815982|NCT00883272|||CASE_CONTROL||PROSPECTIVE|||||||
33815983|NCT02619825|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33815984|NCT03522844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to receive one of two treatments over the course of 8-weeks. One group will participate in an 8-week Mindfulness-Based Stress Reduction Course and the other group will receive a daily medication treatment (escitalopram).|f|f|f|t
33815985|NCT06092684|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815986|NCT02493556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815987|NCT02948686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33815988|NCT00080119|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33815989|NCT01655199|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|f|t
33815990|NCT02501616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33815991|NCT00502359|||DEFINED_POPULATION||OTHER|||||||
33815992|NCT04733573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33815993|NCT02896556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815994|NCT06340191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34151127|NCT05678452|RANDOMIZED|PARALLEL||TREATMENT||NONE|double blind|HoLEP will be performed using 100W Versapulse, Luminis Inc., with 2J/25Hz for LP-HoLEP and 2J/50Hz for HP-HoLEP.||||
34151128|NCT01457846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151129|NCT03566121|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151130|NCT00208351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151131|NCT05971836|||COHORT||PROSPECTIVE|||||||
34151132|NCT05876845|NA|SINGLE_GROUP||OTHER||NONE||||||
33815995|NCT01566552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33815996|NCT04927806|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"In this study, we conduct a cluster-randomized crossover, multicenter trial.There are two groups:~1. Control group: standard ventilator circuit in odd number month.~2. Experimental group: Silver Knight in even number month"||||
33815997|NCT00279409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33815998|NCT01400945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33815999|NCT04320433|NA|SINGLE_GROUP||OTHER||NONE||||||
33816000|NCT05967377|RANDOMIZED|CROSSOVER||OTHER||NONE||Single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study.||||
33816001|NCT04932083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816002|NCT06505252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients will be randomly allocated to two groups:~By using an online research randomizer (http://www.randomizer.org), patients will be randomly allocated to two groups Group (A): will do endoscopic myringoplasty using fat graft augmented by hylourinic acid Group (B): will do endoscopic myringoplasty using fat graft with PRP"|t|t|f|f
33816003|NCT03073122|||COHORT||PROSPECTIVE|||||||
33816004|NCT01465789|||COHORT||PROSPECTIVE|||||||
33816005|NCT02407288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816006|NCT05959226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816007|NCT04278690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816008|NCT04449445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816009|NCT00327314|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816010|NCT02084576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33816011|NCT00984334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816012|NCT04127747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816013|NCT05860218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816014|NCT02607176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816015|NCT00988845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816016|NCT03573375|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33816017|NCT03627299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816018|NCT04755907|||COHORT||PROSPECTIVE|||||||
33816019|NCT00002409||||TREATMENT||||||||
33816020|NCT06233422|||CASE_CONTROL||PROSPECTIVE|||||||
33816021|NCT02398539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838525|NCT00598845|||COHORT||PROSPECTIVE|||||||
33816022|NCT05851144|RANDOMIZED|PARALLEL||PREVENTION||NONE||School-based approach is used to complete the randomized assignment to intervention or control conditions.||||
33816023|NCT03022747|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816024|NCT03503188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816025|NCT02577315|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816026|NCT01259219|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816027|NCT03153566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816028|NCT01540019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816029|NCT04634994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816030|NCT00110422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816031|NCT05031065|||CASE_ONLY||PROSPECTIVE|||||||
33816032|NCT00388765|||||PROSPECTIVE|||||||
33816033|NCT01377844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816034|NCT05549713|||COHORT||PROSPECTIVE|||||||
33816035|NCT03242239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816036|NCT03743909|||COHORT||RETROSPECTIVE|||||||
33816037|NCT01406899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816038|NCT02162927|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33816039|NCT02416349|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33816040|NCT06720701|||COHORT||OTHER|||||||
33816041|NCT01331278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816042|NCT02732470|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816043|NCT00681226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816044|NCT03214471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The investigator who will conduct the follow-up assessments at each visit will be blinded to participants' allocation and will not be involved in delivering any of the intervention. The statistician conducting the data analysis will be blind to group allocation.|The trial will be a two-arm, parallel group, single-blinded, single site RCT (embedded within an observational cohort study) conducted in London, United Kingdom (UK). A two-staged randomised consent design will be applied (See 8.2 Randomisation procedures). Recruitment will take place at the Bariatric Centre for Weight Management and Metabolic Surgery, University College London Hospitals (UCLH) and the Bariatric and Obesity Surgery Clinic at the Whittington Hospital. The trial will be carried out by the Centre for Obesity Research, Division of Medicine, University College London (UCL) at UCLH, which will be commenced in August 2017 with the expected total duration of 36 months. The total duration of each participation in the trial is approximately 12-16 months (12 months from the day of surgery). All participants will have to attend 4 research visits; baseline visit (approximately 6 weeks before surgery), then at approximately 3, 6, and 12-month post-surgery.|f|f|f|t
33816045|NCT02374294|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816046|NCT02069379|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33816047|NCT03267797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the person who analyzed the results were blinded in this study. Participants were aware of the study before being randomized and informed consent was obtained from them. It should be noted that the person analyzing the results had no other role in this study.||t|f|f|t
33816048|NCT04255004|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||We would enroll a cohort of 38 consecutive diabetic patients with CLI in charge at the Diabetic Foot Unit of the San Donato Hospital in Arezzo or referred from other Italian hospitals, who have no option for revascularization or are not further eligible for revascularization according to ESVS ESC 2017 criteria to undergo PB-MNC implantation. Furthermore, an historical control group, with a 1:1 case-control ratio, will be collected backwards from our records, when PBMNCs cellular therapy was not available in our center, with same no-option CLI diagnosis.||||
33816049|NCT05293093|NA|SINGLE_GROUP||TREATMENT||NONE||A one-group pretest-posttest design study will be conducted, consisting of three phases (3- or 5-week baseline phase, 4-week training phase, 4-week retention phase) and four wheelchair skill capacity assessment points (T0: baseline; T1: pre-intervention; T2: post-intervention; T3: retention).||||
33816050|NCT02574234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816051|NCT05494346|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816052|NCT05615506|NA|SINGLE_GROUP||TREATMENT||NONE||patients under 15 years old who are scheduled to undergo elective adenoidectomy with or without ventilation tube application. , selected randomly, with symptoms and signs suggestive of adenoid hypertrophy.||||
33816053|NCT05803122|||OTHER||CROSS_SECTIONAL|||||||
33816054|NCT02803866|||FAMILY_BASED||PROSPECTIVE|||||||
33816055|NCT00440037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816056|NCT05770206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Subjects in the test group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects); subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).|t|t|t|t
33816057|NCT02489799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33816058|NCT01478256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816059|NCT00021099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816060|NCT01351597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816061|NCT01267188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816062|NCT06383507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816063|NCT02835196|||COHORT||PROSPECTIVE|||||||
33816064|NCT05619991|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816065|NCT01647802|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33816066|NCT05444374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046430|NCT01798810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046431|NCT00327873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34046432|NCT01544842|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046433|NCT02273882|||CASE_ONLY||PROSPECTIVE|||||||
34151133|NCT03943849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33816067|NCT01304225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816068|NCT05986851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816069|NCT06381388|NA|SINGLE_GROUP||OTHER||NONE||||||
34046434|NCT06152328|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessor will not know which group the patients are in. Participants in control group will experience a virtual reality environment without any interaction|Two groups parallel design randomized controlled prospective rehabilitation study.|t|f|f|t
34046435|NCT00541411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046436|NCT02796248|||COHORT||CROSS_SECTIONAL|||||||
34046437|NCT06098339|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34046438|NCT01385332|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046439|NCT01831739|||COHORT||PROSPECTIVE|||||||
34046440|NCT01551914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046441|NCT02454465|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046442|NCT05502640|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34046443|NCT05499754|||OTHER||PROSPECTIVE|||||||
34046444|NCT01118793|||CASE_ONLY||PROSPECTIVE|||||||
34125364|NCT04069312|RANDOMIZED|PARALLEL||OTHER||NONE|Treatment assignments will be concealed prior to randomization. Once a patient is assigned to receive a treatment, the clinician, Site Coordinator and patient will not be masked. i.e., they will know the treatment assignment|The trial is a parallel, pragmatic non-inferiority trial with two treatment groups, roflumilast and azithromycin. Up to 1,250 participants will be randomized (1:1) to receive a prescription for one of the two treatments. Treatment assignments will be stratified by site and smoking status (former versus current) using a permuted block design with multiple block sizes.||||
34125365|NCT02673983|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125366|NCT05905380|||CASE_ONLY||RETROSPECTIVE|||||||
34125367|NCT05968248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34125368|NCT02407743|||COHORT||PROSPECTIVE|||||||
34125369|NCT01891981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125370|NCT02685826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125371|NCT06337981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125372|NCT00355030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125373|NCT04563767|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125374|NCT05219253|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Data was collected in an observer-blind manner.||t|t|t|t
34125375|NCT03284060|NA|SINGLE_GROUP||TREATMENT||NONE||open Label||||
34125376|NCT00579423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125377|NCT01158443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125378|NCT05134610|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34125379|NCT01809886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125380|NCT02063685|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125381|NCT01478464|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34046445|NCT04824326|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34046446|NCT01532960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046447|NCT04420533|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, multi-center, randomized, open label study in sexually active male OAB patients treated with behavior therapy alone or behavior therapy plus mirabegron 50mg OD in a 1:2 ratio.||||
34046448|NCT03865316|NA|SINGLE_GROUP||OTHER||NONE||||||
34046449|NCT04591366|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants and staff taking the swab will be blinded as to the randomization allocation.||t|t|f|f
34046450|NCT05198037|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Anticipated 100 participants are assigned to the experimental or sham-controlled groups with an allocation rate of 1:1, for the clinical trial. In addition, another group of patients participates in the observational study (no intervention).|t|f|f|t
34046451|NCT00008255||||DIAGNOSTIC||||||||
34046452|NCT01166438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046453|NCT03973528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046454|NCT05691335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34046455|NCT04411394|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34046456|NCT03602664|||COHORT||PROSPECTIVE|||||||
34046457|NCT05883384|||OTHER||PROSPECTIVE|||||||
34046458|NCT02856126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046459|NCT05912426|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34046460|NCT03140696|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"The children will be randomly allocated to one of the three types of food (egg alone or egg + RUSF or egg + breast milk) in a crossover design.~Each of the diets (egg alone or egg + RUSF or egg + breast milk) will be offered for 2 days each. The order of diets will be randomly allocated over a period of 6 days. There would be 6 possible permutations and combinations of the order of the diets over this 6 days sequential period."||||
34046461|NCT06577558|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046462|NCT00419484|||DEFINED_POPULATION||PROSPECTIVE|||||||
34046463|NCT00340743|||OTHER||PROSPECTIVE|||||||
34046464|NCT04249726|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups parallel to each other randomly assigned to a specific intervention.||||
34046465|NCT03448731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046466|NCT06397365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046467|NCT01991509|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34046468|NCT04161339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046469|NCT03448471|||CASE_CONTROL||PROSPECTIVE|||||||
34046470|NCT05953532|NA|SINGLE_GROUP||OTHER||NONE||Single group pilot study to evaluate youth engagement||||
34046471|NCT01691495|||||RETROSPECTIVE|||||||
34046472|NCT03775265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046473|NCT05569460|||CASE_ONLY||RETROSPECTIVE|||||||
34046474|NCT04180514|||CASE_CONTROL||PROSPECTIVE|||||||
34046475|NCT00140465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125382|NCT05370365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data from the demographic data collection and the outcome parameters will be cleaned blindly from the treatment data|Prospective single-blinded randomised clinical trial|f|f|t|t
34125383|NCT04456205|||CASE_CONTROL||PROSPECTIVE|||||||
34125384|NCT01149330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125385|NCT00471874|||||RETROSPECTIVE|||||||
34125386|NCT02162654|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125387|NCT03102294|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33816070|NCT05610878|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816071|NCT06079047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816072|NCT01803945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816073|NCT00383500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816074|NCT03955341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded as Outcome assessors will be blinded. Both, the participants and principal investigator cannot be blinded owing to the use of two obviously different methods, laser and chemical disinfection, or no disinfection.|evaluate the clinical outcome (in terms of maintaining pulp vitality, assessed by cold pulp testing, absence of spontaneous pain, sensitivity to percussion, inspection for sinus or fistula or swelling, and radiographically using cone beam computed tomography) and the antimicrobial effect of Diode laser and chemical disinfection in comparison to conventional selective caries removal without disinfection in management of deep carious lesions in permanent posterior teeth.|f|f|f|t
33816075|NCT01237600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816076|NCT01016275|||COHORT||PROSPECTIVE|||||||
33816077|NCT06470945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analyst and statistician will be blinded and The patient will be blinded||t|f|f|f
33816078|NCT03150004|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816079|NCT04706442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816080|NCT03256305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Care Provider, Investigator, Outcomes Assessor|t|f|f|f
33816081|NCT04235192|||CASE_CONTROL||PROSPECTIVE|||||||
33816082|NCT00614354|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816083|NCT03928821|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816084|NCT01384916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816085|NCT04434222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33816086|NCT00043459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816087|NCT06021002|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33816088|NCT03778307|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33816089|NCT05128799|||CASE_CONTROL||PROSPECTIVE|||||||
33816090|NCT03042156|||COHORT||PROSPECTIVE|||||||
33816091|NCT02392299|||COHORT||PROSPECTIVE|||||||
33816092|NCT00447356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816093|NCT05161247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||After couples are recruited for the study they will be randomly allocated to zona selection group (study group) and normal ICSI (control group). For the study group zonae pellucidae from germinal vesicle (GV) or metaphase I (MI) stage oocytes from the female partners will be collected and acid-solubilised to obtain zona proteins. The acid-solubilised zonae will be coated on petri dishes. On the day of their follicular punction the spermatozoa for ICSI in the study group will be selected according to their ability to adhere to the coated zona pellucida proteins from their partner. On the day of their follicular punction the spermatozoa for ICSI in the control group will be selected with no intervention.|f|f|f|t
33816094|NCT05793580|NA|SINGLE_GROUP||OTHER||NONE||Prospective longitudinal study||||
33816095|NCT06412029|||COHORT||PROSPECTIVE|||||||
33816096|NCT01492127|NA|SINGLE_GROUP||||NONE||||||
33816097|NCT02376062|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33816098|NCT04187456|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33816099|NCT04178876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816100|NCT00629993|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|f|t
33816101|NCT01092585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816102|NCT01768572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816103|NCT05143580|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||"Acceptance conditions: Patients who are expected to undergo traditional thoracotomy or minimally invasive surgery for cardiac surgery, and those who are over 20 years old and have no cognitive impairment before surgery.~Excluded conditions: patients diagnosed with aortic dissection, over 80 years of age, and previously admitted to the intensive care unit."|t|t|t|t
33816104|NCT04683900|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A randomized, double-blind, controlled parallel study in which participants either follow a Mediterranean diet or their habitual diet for an 8-week intervention.||||
33816105|NCT02097056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816106|NCT01131325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125388|NCT02848456|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34125389|NCT00157963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816107|NCT02481934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816108|NCT04727099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816109|NCT01328223|||COHORT||PROSPECTIVE|||||||
33816110|NCT01498354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816111|NCT04374175|||COHORT||PROSPECTIVE|||||||
33816112|NCT01946256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816113|NCT01429168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816114|NCT03591263|||OTHER||RETROSPECTIVE|||||||
33816115|NCT01308879|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816116|NCT04553627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816117|NCT03338829|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33816118|NCT01070199|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33816119|NCT05434559|||COHORT||RETROSPECTIVE|||||||
33816120|NCT03917342|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Three groups of subjects studied: A: Control group: 15 healthy women B: 15 Healthy parturients: elective cesarean delivery C: 15 preeclamptic parturients: cesarean delivery||||
33816121|NCT01430416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125390|NCT03712774|||COHORT||PROSPECTIVE|||||||
34125391|NCT02251496|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125392|NCT03890523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125393|NCT02903693|||||CROSS_SECTIONAL|||||||
34125394|NCT04084535|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Intervention Model: Crossover Assignment|f|f|f|t
34125395|NCT04384068|||COHORT||PROSPECTIVE|||||||
34125396|NCT04830943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816122|NCT00269256|||COHORT||PROSPECTIVE|||||||
34125397|NCT03128489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125398|NCT05074017|||OTHER||OTHER|||||||
34125399|NCT03512574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816123|NCT05822791|||COHORT||RETROSPECTIVE|||||||
33816124|NCT02896673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816125|NCT05390515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33816126|NCT00801905|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33816127|NCT06023771|||COHORT||PROSPECTIVE|||||||
33816128|NCT03015753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816129|NCT02648659|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816130|NCT04543032|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816131|NCT03029585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046476|NCT06620172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the specific nature of the interventions, it may not be possible to blind participants or operators; however, to minimize potential bias, outcome assessors will be blinded to the treatment assignments.||f|f|f|t
34046477|NCT02548728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046478|NCT06280586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34046479|NCT04512196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study participants, healthcare providers who attend to the participants during the trial (surgeon and nurses), outcome evaluators (surgical doctors and nurses) and data collectors will be blinded to the allocation.~The sterile study solution (super-oxidised solution) or placebo (normal saline 0.9%) will be stored in a similar storage container and will have the same clear appearance."|Randomised double-blind placebo-controlled parallel-group study. This is a superiority study assessing the effectiveness of the intervention|t|t|t|t
34046480|NCT06682663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will randomize eligible MASLD pregnant women into two groups: a control group and an intervention group. The control group will receive standard prenatal care, while the intervention group will receive supervised exercise guidance starting from the 14th week of pregnancy and continuing through the 36+6th week. Quality control, data collection, and biological sample collection will be conducted throughout the intervention period.|f|f|t|t
34046481|NCT00248066|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046482|NCT05657522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046483|NCT02860130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046484|NCT00122993|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34046485|NCT05402410|||COHORT||RETROSPECTIVE|||||||
34046486|NCT00979797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34046487|NCT03160768|||COHORT||PROSPECTIVE|||||||
34046488|NCT03748173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046489|NCT06052800|||COHORT||OTHER|||||||
34046490|NCT01298544|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34046491|NCT05342441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded to group allocation. Before each patient visit, tape will be placed on possible scars to hide donor graft site. Given the nature of the intervention, blinding of patients and surgeons is not feasible.|Prospective, assesor blinded randomized controlled study|f|f|f|t
34046492|NCT03058250|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046493|NCT06494085|||CASE_CROSSOVER||PROSPECTIVE|||||||
34046494|NCT06681363|||OTHER||PROSPECTIVE|||||||
34046495|NCT05537779|||COHORT||PROSPECTIVE|||||||
34046496|NCT03052231|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34046497|NCT05556447|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||pilot trial enrolling 26 cancer survivors with chronic chemotherapy-induced peripheral neuropathy (CIPN) who will undergo the painTRAINER intervention||||
34046498|NCT05443763|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study of children receiving intensive therapy and their caregivers||||
34046499|NCT02302638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046500|NCT06253364|||COHORT||RETROSPECTIVE|||||||
34046501|NCT05865574|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34046502|NCT01761253|||OTHER||RETROSPECTIVE|||||||
34046503|NCT04105218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34046504|NCT04406181|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046505|NCT02401659|||COHORT||PROSPECTIVE|||||||
34046506|NCT05603611|||COHORT||PROSPECTIVE|||||||
34046507|NCT05250310|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two group randomization 1:1||||
34046508|NCT00018187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046509|NCT05389930|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Participants are masked. Outcome assessors who have contact with participants are masked.|Mixed factorial design will use a 3 (within-subjects; cannabinoid dose: 9.53% THC/0.06% CBD, 11.27% CBD/0.35% THC, placebo) X 2 (between-subjects; cannabis + an alcohol-priming dose (0.3 g/kg) versus cannabis + alcohol placebo)|t|f|f|t
34046510|NCT05021029|||CASE_CONTROL||OTHER|||||||
34046511|NCT02638584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046512|NCT01569139|||||RETROSPECTIVE|||||||
34046513|NCT02788409|||COHORT||RETROSPECTIVE|||||||
34046514|NCT00932373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046515|NCT03675165|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34046516|NCT05769075|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34046517|NCT02084043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046518|NCT02547389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34125400|NCT03566472|||COHORT||CROSS_SECTIONAL|||||||
34125401|NCT03853967|NA|SINGLE_GROUP||SCREENING||NONE||prospective single arm study||||
34125402|NCT04942132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125403|NCT01389986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34125404|NCT01588119|||COHORT||PROSPECTIVE|||||||
34125405|NCT05338762|||COHORT||PROSPECTIVE|||||||
34125406|NCT00480740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125407|NCT02461199|||CASE_ONLY||PROSPECTIVE|||||||
34125408|NCT03941418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125409|NCT01503814|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125410|NCT02863393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151134|NCT05104671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816132|NCT00233545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816133|NCT00441168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816134|NCT00019344||||TREATMENT||||||||
33816135|NCT02216955|||COHORT||PROSPECTIVE|||||||
33816136|NCT02249429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816137|NCT01840124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816138|NCT02618876|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33816139|NCT05286242|||COHORT||PROSPECTIVE|||||||
33816140|NCT05581108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125411|NCT06183281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects will be randomized into intervention or enhanced usual care conditions|f|f|f|t
33816141|NCT01282918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816142|NCT04392856|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will know if they are assigned to the treatment condition or to the WLC group. Shelter professionals and researchers will know the condition of each participant, however, independent evaluators will not know whether the woman is in UP or Waitlist.|"All women in a homeless situation attending any of the collaborating shelters will be asked to participate in the present study. Once inclusion criteria are met, each participant will be assigned to experimental condition or control condition.~This research is composed by two sequential studies. The first study will deliver the UP in a group format, while the second study will deliver the UP on a one-to-one basis. Since these studies will not be performed concurrently, women will be assigned within each study to intervention or control condition. In the first study, participants will be assigned to one of two conditions: experimental condition (Unified Protocol, UP in group delivery) or waitlist control condition (WLC). In the second study, participants will be assigned to one of two conditions: experimental condition (Unified Protocol, UP in individual delivery) or control condition (WLC)."|f|f|f|t
33816143|NCT06565416|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the single group design, it is not feasible to blind investigators or outcomes assessor. Given that the intervention occurs at the site level among providers, patients/clients can be considered blinded given that they are not the direct target of the intervention.|A provider-level implementation intervention will be administered at each of the three participating sites. The investigators will examine implementation and effectiveness outcomes before, during, and after implementation.|t|f|f|f
33816144|NCT02195180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816145|NCT06128356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816146|NCT06287671|||COHORT||PROSPECTIVE|||||||
33816147|NCT01469884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816148|NCT01156194|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816149|NCT04158323|||COHORT||PROSPECTIVE|||||||
33816150|NCT00668746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816151|NCT05848219|||COHORT||RETROSPECTIVE|||||||
33816152|NCT01966094|||CASE_CONTROL||PROSPECTIVE|||||||
33816153|NCT06281639|||COHORT||PROSPECTIVE|||||||
33816154|NCT01077284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125412|NCT03579693|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized, placebo-controlled, cross-over trial|t|t|t|f
34125413|NCT01384851|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34125414|NCT04288856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|"During the blinded loading period, the following individuals will be masked:~* Investigator~* Study staff~* Participants~After the loading period has been completed, subsequent doses will be open-label."|||||
34125415|NCT03056833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125416|NCT03341637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125417|NCT04032886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125418|NCT05915585|NA|SINGLE_GROUP||TREATMENT||NONE||Single participant case study||||
34125419|NCT06379828|||OTHER||PROSPECTIVE|||||||
34125420|NCT00142337|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34125421|NCT00553631|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125422|NCT05238519|RANDOMIZED|PARALLEL||SCREENING||NONE||"A baseline survey will be sent to eligible participants age 2-75 years. Participants age 18-75 years who complete the survey will be randomly assigned to receive a motivational interview intervention or usual care.~If an eligible patient is under the age of 18 years, they will not be eligible to receive a motivational interview. Therefore, the patient's parent or legal guardian will be the primary target for participation in the survey and will be asked to complete the survey from their own perspective. The patient's parent will be recognized as the participant in this study and will then be eligible for randomization to the MI arm.~A 6 month follow up survey will be sent to all participants."||||
34125423|NCT04609605|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125424|NCT05058729|||COHORT||PROSPECTIVE|||||||
34125425|NCT03814928|NA|SINGLE_GROUP||OTHER||NONE||feasibility study with the general public, older adults, health providers, and family caregivers.||||
34125426|NCT02782845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125427|NCT04584398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is conducted as a randomized, single-blind (for evaluators), controlled, 30 days intervention trial with two parallel groups|Randomized, controlled, single-blind parallel design with 50-60 subjects suffering from obstructive diseases such as asthma or COPD or both.|f|f|t|t
34125428|NCT03530150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator, the person in charge of gathering the data, and the person analyzing the data will be blinded|Burn patients will be divided to receive either 600 mg of pirfenidone or usual care|f|f|t|t
34125429|NCT05461339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, investigators responsible for patient care, vision examiner (including BCVA assessors), research nurses, independent central reading center staff, and the sponsor are blinded. Unmasked pharmacist, unmasked nurse, unmasked treatment administration physician and unmasked research associates will take part in this study.||t|t|t|t
34125430|NCT02770027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125431|NCT02909660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125432|NCT05186935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125433|NCT01408277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125434|NCT06457477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125435|NCT05585073|||COHORT||RETROSPECTIVE|||||||
34125436|NCT05772403|||COHORT||RETROSPECTIVE|||||||
34125437|NCT05580354|NA|SINGLE_GROUP||TREATMENT||NONE||BCG combined with Tislelizumab||||
33816155|NCT03503500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Open label, randomized parallel controlled trial||||
33816156|NCT02450747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816157|NCT03669419|||COHORT||PROSPECTIVE|||||||
33816158|NCT00286013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816159|NCT01237509|||COHORT||PROSPECTIVE|||||||
33816160|NCT01389791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816161|NCT04976517|||COHORT||PROSPECTIVE|||||||
33816162|NCT01759459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33816163|NCT04448613|||CASE_ONLY||PROSPECTIVE|||||||
33816164|NCT06490497|||COHORT||PROSPECTIVE|||||||
33816165|NCT04387149|||COHORT||PROSPECTIVE|||||||
33816166|NCT03384342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816167|NCT05766371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816168|NCT04611893|||CASE_ONLY||PROSPECTIVE|||||||
33816169|NCT04572425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816170|NCT04651426|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective analysis in a 3-arm, randomized double-blind and placebo-controlled stud|t|f|t|t
33816171|NCT05064059|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open-label)|||||
33816172|NCT04518111|||OTHER||OTHER|||||||
33816173|NCT02632630|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33816174|NCT00003376|RANDOMIZED|||TREATMENT||||||||
33816175|NCT03747575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816176|NCT05971615|NA|SINGLE_GROUP||OTHER||NONE||||||
33816177|NCT05817513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double masking|Two groups, one group will be treated by traditional exercises for scoliosis treatment and another group will be treated by Myofascial release and traditional exercises.|t|f|t|t
33816178|NCT06449599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816179|NCT06348160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816180|NCT05983939|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|All roles are masked with the exception of the pharmacist/dose preparer.||t|f|t|t
33816181|NCT06181019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks, whereas patients in the treatment group were treated with acupuncture combined with mirabegron.|t|t|t|t
33816182|NCT02862158|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816183|NCT02634528|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33816184|NCT00090558||||TREATMENT||||||||
33816185|NCT03868202|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33816186|NCT00234299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33816187|NCT05233904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816188|NCT01688271|||CASE_ONLY||PROSPECTIVE|||||||
33816189|NCT04151147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816190|NCT00547300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816191|NCT01271361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816192|NCT04889820|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. The Control group~   * The patients who are assigned into control group take a curative surgery within 2 weeks after successful SEMS placement. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during 6 months (total 12 cycles).~2. The Experimental group~   * The patients who are assigned into the experimental group take a neoadjuvant FOLFOX chemotherapy within 2 weeks after successful SEMS placement. After three cycles of FOLFOX, they will take a curative surgery. And then, after recovery period, adjuvant FOLFOX chemotherapy will be administered into them. Adjuvnat FOLFOX chemotherapy will be administered every 2week during about 4 months (total 9 cycles). The perioperative FOLFOX chemotherapy in the experimetal group will be totally 12 cycles during 6months."||||
33816193|NCT05670678|||CASE_CONTROL||PROSPECTIVE|||||||
33816194|NCT05851170|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33816195|NCT05839743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816196|NCT02462447|||OTHER||PROSPECTIVE|||||||
33816197|NCT04512456|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||HIV+active group will perform exercise training, while HIV+inactive and HIV- groups will not undergo intervention.|f|f|f|t
33816198|NCT03561870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816199|NCT05114811|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistical analysis was carried out by an investigator blinded to experimental groups (unaware of the meaning of codification of the database of the three sample subgroups).|Non-randomized controlled trial|f|f|f|t
33816200|NCT04173000|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Open Label Trial||||
33816201|NCT03754088|||COHORT||PROSPECTIVE|||||||
33816202|NCT03927963|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33816203|NCT00003996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816204|NCT04727463|||COHORT||OTHER|||||||
33816205|NCT00848198|||CASE_CONTROL||PROSPECTIVE|||||||
33816206|NCT01941706|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33816207|NCT06019715|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816208|NCT06153589|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33816209|NCT00257309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046519|NCT02371317|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34046520|NCT03178188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816210|NCT00135200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816211|NCT01599221|||COHORT|||||||||
33816212|NCT06068803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816213|NCT01659385|||OTHER||CROSS_SECTIONAL|||||||
33816214|NCT02066454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816215|NCT02703519|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33816216|NCT00202228|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816217|NCT02217891|||CASE_CROSSOVER||PROSPECTIVE|||||||
33816218|NCT04231175|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||multi center randomized trial||||
33816219|NCT03169855|||OTHER||PROSPECTIVE|||||||
33816220|NCT04132999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||family-informed intervention (INT) vs standard clinical care (CON).|t|t|t|f
33816221|NCT03846635|||COHORT||PROSPECTIVE|||||||
34046521|NCT06280846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|high-intensity laser acupuncture, low-intensity laser acupuncture and exercise therapy program|t|f|f|t
34125438|NCT05415553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125439|NCT06512142|||COHORT||RETROSPECTIVE|||||||
34125440|NCT04878601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125441|NCT04232943|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The study vaccine for Groups 1 and 2 (IPV alone and IPV + dmLT) will be administered IM in a blinded fashion. An unblinded positive control group (Group 3) will be administered bOPV.~The unblinded Research Pharmacist will perform all preparations of the study product for Groups 1 and 2. Preparation of the study product and administration to the subjects will occur in separate locations to preserve the blinding of staff except for Research Pharmacist. The study subjects, the study personnel who perform study assessments after administration of study product, data entry personnel at the site, and laboratory personnel performing immunologic assays will be blinded to the treatment assignment."|Participants will receive a single dose of licensed trivalent IPV, administered intramuscularly (IM), with or without dmLT, or bOPV, administered orally (PO). IPV or IPV + dmLT will be administered to groups of 30 participants each. Both participants and clinical staff will be blinded to group assignment (IPV alone vs IPV + dmLT). A positive unblinded control group will be included, composed of 20 participants receiving bOPV. One month (28 days) after receiving study vaccine, all participants will receive a standard oral dose of bOPV to assess relative impact of study vaccine on shedding of that challenge virus.|t|f|t|t
34125442|NCT04543916|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation will proceed within each cohort. Phase II is the expansion cohort at the recommended phase 2 dose found in phase 1||||
34125443|NCT05434494|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34125444|NCT04579666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125445|NCT03130998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study design is a cluster (cluster = clinical practice) randomized trial of FHTs participating in the STOP program. FHTs in the STOP program will be randomly allocated 1:1 to receive either generalized messages (related to depression and smoking) exclusively via email (Group A) or be assigned an eKB who provides personalized support through phone- and email-based check-ins (Group B). Academic affiliation and cluster size will be treated as balancing factors in a stratified allocation or as covariates in the statistical analyses.|f|f|t|f
34125446|NCT00973336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125447|NCT00526539|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34125448|NCT00761982|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125449|NCT01448538|||COHORT||PROSPECTIVE|||||||
34125450|NCT01022970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125451|NCT00715247|||CASE_CONTROL||PROSPECTIVE|||||||
34125452|NCT00504439|RANDOMIZED|PARALLEL||TREATMENT||||||||
34125453|NCT02389465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125454|NCT03007420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125455|NCT04305626|||COHORT||PROSPECTIVE|||||||
34125456|NCT00042445|||CASE_CONTROL|||||||||
34125457|NCT00283543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125458|NCT06295900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||It will be conducted as a randomized controlled single-blind study||||
34125459|NCT04133025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125460|NCT04906031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125461|NCT01266889|||COHORT||PROSPECTIVE|||||||
34125462|NCT05320484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125463|NCT05213416|||OTHER||CROSS_SECTIONAL|||||||
34125464|NCT01745653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125465|NCT06094309|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125466|NCT00437268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125467|NCT05619120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125468|NCT00835289|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125469|NCT03339310|NA|SINGLE_GROUP||TREATMENT||NONE||Optimizer Smart System||||
34125470|NCT04245709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125471|NCT04945525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Forty-six clinics with chronic, non-cancer pain patients in both pain management and general practice settings will be randomized to the Care Continuity Program (CCP) intervention or control group. Both groups will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. After four months of intervention, the CCP's ability to lower morphine milligram equivalents (MME), improve physical functioning in patients, mitigate the opioid prescriber's legal risk, and increase confidence levels in opioid prescribing among prescribers will be measured by completing medical record audits.||||
34125472|NCT00915889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125473|NCT05500651|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A repetitive measure design with a pretest-posttest control group|t|f|f|f
34125474|NCT03954912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective cohort study||||
34125475|NCT02082964|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34125476|NCT03982017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125477|NCT05675826|||CASE_CONTROL||PROSPECTIVE|||||||
34125478|NCT05812352|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The outcomes assessor only enters the laboratory after the participant has attempted to apply the tourniquet. Therefore, the outcomes assessor is unaware of the instructional intervention that was employed. The outcomes assessor will assess (1) tourniquet placement sufficient distance above the injury defined as at least 2 inches proximal to the amputation, (2) turning on an external diaphragm pump that attempts to force water through tubing in the mannequin extremity bypassing the tourniquet.|Participants are randomized to 1 of 4 educational interventions. Once the initial instructional intervention is completed, participants subsequently present for a 6-month follow-up.|f|f|f|t
34125479|NCT04347343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125480|NCT03977883|||COHORT||PROSPECTIVE|||||||
33816222|NCT00035919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816223|NCT03249272|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The reader of the CMR scan will be blinded to the stress agent used.|Participants undergoing cardiovascular magnetic resonance stress testing will be recruited and randomized to receive either regadenoson or adenosine.|f|f|f|t
33816224|NCT03398889|||COHORT||CROSS_SECTIONAL|||||||
34046522|NCT03250754|||CASE_CONTROL||RETROSPECTIVE|||||||
34046523|NCT01654120|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046524|NCT00003140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046525|NCT00603590|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046526|NCT01842984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046527|NCT04052243|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Exercise is added to the resting right heart catheterization.||||
34046528|NCT05004493|||COHORT||PROSPECTIVE|||||||
34046529|NCT05672147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046530|NCT04761640|||COHORT||RETROSPECTIVE|||||||
34046531|NCT01452542|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046532|NCT06088485|||CASE_CONTROL||PROSPECTIVE|||||||
34046533|NCT03489577|||COHORT||PROSPECTIVE|||||||
34046534|NCT06208202|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants and study staff will be blinded to the study conditions delivered at each visit.|Randomization to condition order will be completed prior to study Visit 1. Each participant will receive a randomized ordering developed using a random sequence generator. Participants and data collection staff will be blinded to the order/conditions administered at each trial. The sequence list and subsequent participant ID numbers will be kept separate from data collection staff and will only be accessible by staff who will not be interacting with participants.|t|f|f|t
34046535|NCT05580627|NON_RANDOMIZED|PARALLEL||OTHER||NONE||In our quasi-experimental design, we allow participants to select whether they want to participate in a live or livestream program modality. The couples curriculum is the same for both, only the mode of delivery is different.||||
34046536|NCT04557241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Although this is, in practice, a double-blind study since participants will be unaware that they are randomized and all study mechanics will be processed by computer, analysts will not be blinded to the meaning of the assignment variable. However, two independent consultant analysts have been retained to verify all results and subsequent interpretation.||t|f|f|t
34046537|NCT04700579|||COHORT||PROSPECTIVE|||||||
34046538|NCT01168466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046539|NCT01560312|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046540|NCT05832853|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34046541|NCT00294372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34046542|NCT05876832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046543|NCT01328977|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33816225|NCT05301842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label||f|f|f|t
34046544|NCT03284814|RANDOMIZED|CROSSOVER||OTHER||NONE||Three-period crossover bioavailability study will include 21 subjects who will test three CoQ10 formulations. Subjects will test 3 formulations of single dose CoQ10 within first 3 weeks to assess bioavailability, which will be followed with 2 weeks of continuous administration of one of study formulations to demonstrate and assesse multiple-dose profile of CoQ10.||||
34046545|NCT04080388|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34046546|NCT02271152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125481|NCT04095702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125482|NCT06515015|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm trial, intending to enroll 10 subjects. All subjects will be assigned to the treatment group to receive the study treatment.||||
34125483|NCT00080574||||TREATMENT||||||||
34125484|NCT06160596|||CASE_CONTROL||RETROSPECTIVE|||||||
34125485|NCT01673659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125486|NCT02014805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125487|NCT00459641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816226|NCT04787692|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816227|NCT05825456|||COHORT||PROSPECTIVE|||||||
34046547|NCT01959464|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||Initial assignment randomized, then crossed over to the other treatment|t|t|t|f
34046548|NCT03447561|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All participants will receive one PETMR scan session with the combination of anticipatory (viewing high-calorie food images) and consummatory reward (drinking sips of chocolate milkshake), and one PETMR scan session with purely consummatory reward, in a randomized and counterbalanced order.||||
34046549|NCT04424420|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Prospective with placebo-controlled|t|t|t|t
34046550|NCT05515211|||OTHER||CROSS_SECTIONAL|||||||
34046551|NCT06030323|||COHORT||PROSPECTIVE|||||||
34046552|NCT02846155|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34046553|NCT04357067|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125488|NCT00259844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125489|NCT06512779|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125490|NCT01330095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125491|NCT01157832|||CASE_CONTROL||PROSPECTIVE|||||||
34125492|NCT02391324|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34125493|NCT02546726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125494|NCT06071598|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125495|NCT04665804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125496|NCT01905189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125497|NCT00661830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125498|NCT03619993|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125499|NCT02980757|RANDOMIZED|CROSSOVER||||NONE||||||
33816228|NCT03684772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816229|NCT01973296|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816230|NCT02256553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816231|NCT03663049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two arms in the study. Patients will be randomized to either continue medication in the statin group or discontinue.||||
34125500|NCT00503425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125501|NCT03456219|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34125502|NCT01212965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125503|NCT00315510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34125504|NCT04731896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125505|NCT03463837|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125506|NCT02358993|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34125507|NCT00355368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125508|NCT01963767|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34125509|NCT01194245|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34125510|NCT00400855|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34125511|NCT06000488|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study sample will consist of clinical-phase PA students enrolled in the Yale Physician Associate Program Class of 2024.||||
34125512|NCT05939752|||COHORT||PROSPECTIVE|||||||
34125513|NCT03448016|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||\[C-11\]NOP-1A||||
34125514|NCT00280852|||||RETROSPECTIVE|||||||
34125515|NCT03667313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125516|NCT04619667|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125517|NCT04961138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125518|NCT06028698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125519|NCT04576910|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125520|NCT01825330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125521|NCT01820650|||COHORT||PROSPECTIVE|||||||
34125522|NCT03768089|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34125523|NCT01219101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125524|NCT00008801|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34125525|NCT00984776||||DIAGNOSTIC||||||||
34125526|NCT02390492|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34125527|NCT04244071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125528|NCT00251693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125529|NCT04074226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|No other parties will be masked|Randomized controlled trial|t|t|f|t
34125530|NCT04276194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125531|NCT01447745|||COHORT||PROSPECTIVE|||||||
34125532|NCT05406128|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34125533|NCT03432494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125534|NCT05644717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125535|NCT05011175|||COHORT||PROSPECTIVE|||||||
34125536|NCT00310375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125537|NCT02661152|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34125538|NCT05563662|||COHORT||PROSPECTIVE|||||||
34125539|NCT02989116|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34125540|NCT02855658|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34125541|NCT03569358|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34125542|NCT02708316|||CASE_CONTROL||PROSPECTIVE|||||||
34125543|NCT00794846|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34125544|NCT00792090|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125545|NCT02819531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125546|NCT02988726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125547|NCT01770405|||COHORT||PROSPECTIVE|||||||
34125548|NCT04758481|NA|SINGLE_GROUP||TREATMENT||NONE|The study is open label, no masking is being used.|This is a non-randomised study with the primary intent to treat patients with NSCLC||||
34125549|NCT01104454|||COHORT||CROSS_SECTIONAL|||||||
34125550|NCT01179269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125551|NCT02348580|RANDOMIZED|PARALLEL||||NONE||||||
34125552|NCT01842373|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34125553|NCT01515579|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34125554|NCT00003846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125555|NCT05607602|||CASE_CONTROL||PROSPECTIVE|||||||
34125556|NCT06418737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are masked|Single masked, randomized trial (experimental and control group)|t|f|f|f
34125557|NCT00364650|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34125558|NCT03542019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All ceramic materials will be assigned randomly by research assistant who has randomised tables generated by a statistician|Three different ceramic types for restoration of endodontically treated teeth|t|t|f|t
34125559|NCT05842486|||COHORT||RETROSPECTIVE|||||||
34125560|NCT02682459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125561|NCT03367169|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|||||
34125562|NCT01853462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125563|NCT02088853|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34125564|NCT01518790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125565|NCT05101655|||CASE_ONLY||PROSPECTIVE|||||||
34125566|NCT00343564|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125567|NCT05679349|RANDOMIZED|FACTORIAL||SCREENING||QUADRUPLE|||t|t|t|t
34125568|NCT01242631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125569|NCT00643890|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34125570|NCT02253082|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34125571|NCT03159975|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"1. Dose level 1 : GX-70 0.26mg~2. Dose level 2 : GX-70 1mg~3. Dose level 3 : GX-70 4mg"||||
34125572|NCT00763256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125573|NCT01352208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125574|NCT05115565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Due to the nature of the study, patients will not be left blind. The assignment to the groups will be carried out by an independent researcher, and the group will be notified via telephone after the practitioner researcher has approved, evaluated the criteria and performed the pre-tests. At the same time, groups will be named A and B and researchers will be blinded during statistical analysis and reporting.The questionnaires to be applied to the patients included in the study will be administered by an independent researcher.||f|f|t|t
34125575|NCT01964378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125576|NCT05123989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34125577|NCT00120627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125578|NCT04754269|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34125579|NCT03036852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816232|NCT05656937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046554|NCT00280397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046555|NCT03215589|||COHORT||PROSPECTIVE|||||||
34046556|NCT04404517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046557|NCT04771598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised Controlled Study||||
34046558|NCT03625466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blinded in Part 1, and Open label in Part 2||t|t|t|t
34046559|NCT02896062|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34046560|NCT06175026|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046561|NCT04391673|||COHORT||PROSPECTIVE|||||||
34046562|NCT06159465|||COHORT||CROSS_SECTIONAL|||||||
34046563|NCT01355575|NA|SINGLE_GROUP||TREATMENT||NONE||An open label pilot study with two phases (rather than 2 arms). All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.||||
34046564|NCT04170738|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||3-week intervention with Adderall as treatment for ADHD among youth with ADHD + Conduct problems. Pre and post fMRI performed as the outcome measures||||
34046565|NCT00239122|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046566|NCT02304731|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34046567|NCT04791189|||CASE_ONLY||RETROSPECTIVE|||||||
34046568|NCT02625532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046569|NCT03128138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046570|NCT01869205|NA|SINGLE_GROUP||TREATMENT||NONE||Bronchoscopioc lung volume reduction by endobronchial valve||||
34046571|NCT00570193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34046572|NCT04517201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046573|NCT04374695|||CASE_CONTROL||RETROSPECTIVE|||||||
34046574|NCT00057343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046575|NCT03164278|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Subjects will be choose to be in one of three groups: one group will receive transfer training immediately with no follow up, one group will receive the transfer training immediate with a 1 month \& 6 month follow up, and one group that will be randomized to either receive the transfer training immediately or to receive the transfer training after a 6 month wait (with follow ups).|This is a randomized single blind study.||||
34046576|NCT03551171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046577|NCT05162703|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046578|NCT02539927|||COHORT||OTHER|||||||
34046579|NCT01387516|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||This clinical trial uses a 2 x 2 between groups factorial design to investigate Motivational Interviewing versus Relaxation Therapy and Cognitive Behavior Therapy versus Self-Help Programming.|t|t|f|f
34046580|NCT04781920|||COHORT||PROSPECTIVE|||||||
34046581|NCT05581849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046582|NCT04889976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The iBT intervention is performed concomitantly to the ptES session, and consists of an app-based interactive protocol (with a chatbot and online videos), synchronized via bluetooth, to the ptES device. For PSYLECT, the chatbot iBT protocol has been translated from English to Portuguese, and all iBT videos are either presented with Portuguese subtitles, or in the case of meditation videos (which allow participants to close their eyes), have been dubbed to Portuguese. Further details about active and sham iBT sessions are not described in this platform to avoid breaking the blinding of future participants enrolled in this study, with means of access to this platform. The complete details will be provided when the study results are published or upon reasonable request.|"This is a multi-arm, randomized, double-blind, sham-controlled clinical trial with digital features, using portable transcranial electrical stimulation (ptES) and internet-based behavioral therapy (iBT) for major depressive disorder (MDD). The aims of this study are to evaluate the efficacy, safety, tolerability and usability of (1) active ptES + active iBT (double-active), (2) active ptES + sham iBT (ptES-only), and (3) sham ptES + sham iBT (double-sham), in adults with MDD, with a Hamilton Depression Rating Scale - 17 item version (HDRS-17) score ≥ 17 at baseline, during 6 weeks."|t|f|t|f
34046583|NCT02516267|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046584|NCT05050617|||COHORT||PROSPECTIVE|||||||
34046585|NCT00667823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046586|NCT02921880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046587|NCT00601939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34046588|NCT05322941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Up to 330 eligible male or female subjects will be randomized into 1 of 4 treatment groups. The number of females to be enrolled will be limited to ensure that a maximum of 80 female subjects are assigned to active treatment (i.e., to 1 of the AEF0117 treatment groups).~Subjects will be randomized to 1 of 4 treatment groups:~* AEF0117 1.0 mg once daily (QD) (90 subjects)~* AEF0117 0.3 mg QD (90 subjects)~* AEF0117 0.1 mg QD (60 subjects)~* Placebo (90 subjects)"|t|t|t|t
34046589|NCT01488383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34046590|NCT03397706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1: dose escalation phase (3+3 design with definitions of dose limiting toxicity) to define a recommended phase 2 dose~Phase 2: dose expansion~PK Cohort"||||
34046591|NCT02649439|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046592|NCT03090529|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046593|NCT00596687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046594|NCT05599022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34046595|NCT04836273|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind (participants and investigator)|4 weeks x 4 weeks with an interposed washout period of 1 week|t|f|t|f
34046596|NCT04500990|||COHORT||PROSPECTIVE|||||||
34046597|NCT04398303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046598|NCT03192306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046599|NCT05167630|||CASE_ONLY||RETROSPECTIVE|||||||
34046600|NCT00984568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046601|NCT01452893|||COHORT||PROSPECTIVE|||||||
34046602|NCT04728841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046603|NCT01469130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046604|NCT01517763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046605|NCT01832792|RANDOMIZED|PARALLEL||TREATMENT||||||||
34125580|NCT01786681|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34125581|NCT05211349|||OTHER||PROSPECTIVE|||||||
34046606|NCT04790461|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|"Participants were assigned to groups using the simple randomization method. Participants were not informed of which group they were in. Automated computer-based randomization resulted in the implementation of the experiment with the scheduling scenario and confidential allocation of participants to one of the four intervention branches. The researcher was blind to all conditions until the participants started the computer program and the intervention began. Participants were also unaware of whether the group they were assigned to was an experimental or a control condition. In addition, researchers coding and analyzing data will be blind to randomization and interventions."|"1. experimental group: face-to-face training + PMR exercise~2. experimental group: mobile health education + PMR exercise~3. experimental group: face-to-face and mobile health training + PMR exercise control group"|t|f|t|t
34046607|NCT00650247|RANDOMIZED|CROSSOVER||||NONE||||||
34046608|NCT03079141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046609|NCT06192381|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A two-armed, single-blind, parallel groups prospective randomized controlled trial (RCT), with a baseline pre-test and immediate post-test was used to carry out this study|t|f|t|f
34046610|NCT03545685|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34046611|NCT00555815|||COHORT||PROSPECTIVE|||||||
34046612|NCT05923619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046613|NCT02618603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046614|NCT01483963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046615|NCT05736640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046616|NCT02349932|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34046617|NCT02013141|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34046618|NCT01221272|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34046619|NCT00481468|||COHORT||PROSPECTIVE|||||||
34046620|NCT04414020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046621|NCT01557374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046622|NCT01570361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816233|NCT06384859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816234|NCT04555200|||OTHER||RETROSPECTIVE|||||||
34046623|NCT04359940|||COHORT||PROSPECTIVE|||||||
34046624|NCT01213784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046625|NCT01800929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046626|NCT05053022|NA|SINGLE_GROUP||TREATMENT||NONE||A proof of concept study to determine the safety and efficacy of Microneedling in patients with stable Vitiligo.||||
34046627|NCT04119375|RANDOMIZED|PARALLEL||TREATMENT||NONE|Clinic staff are not explicitly informed of an individual's assignment, but it is not possible to mask them. It is also not possible to mask the study team members.|We will employ a four-sided stratified RCT with 15,500 patients in total: a) 2,000 patients in the standard-of-care control group; b) 1,500 patients in the SMS intervention group; c) 6,000 patients in the SBCC intervention group (SBCC); 4) 6,000 patients in the Keheala intervention group.||||
34046628|NCT06576388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046629|NCT05284032|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34046630|NCT06486077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Open Label, Single Arm Study||||
34046631|NCT04138472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients do not know about the interventions.|Randomized control trial|t|f|f|f
33816235|NCT04491370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046632|NCT05766059|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"In a first phase \[Phase 1\], the study aims to assess the motor and neurophysiological effects of a cross-modal 'mirror-PAS' protocol in stroke patients with upper-limb hemiparesis, compared to the standard excitatory M1-PAS.~In a second phase of the study \[Phase 2\], we will test the efficacy of the aforementioned cross-modal PAS in a population of amputated patients affected by phantom limb pain (PLP)."||||
34046633|NCT00232739|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046634|NCT04190940|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046635|NCT06234293|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled multicenter trial Ratio 1:1||||
34046636|NCT02830867|||COHORT||RETROSPECTIVE|||||||
34046637|NCT02423330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046638|NCT02009085|||CASE_ONLY||RETROSPECTIVE|||||||
33816236|NCT00472082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816237|NCT05377372|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized control trial||||
33816238|NCT00001876|||COHORT||PROSPECTIVE|||||||
33816239|NCT05458271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Examiners will be blinded throughout all experimental procedures for all measurements.~Operators will be blinded until they will raise the flap and screw the healing abutment."||f|f|t|t
34046639|NCT05991336|||COHORT||PROSPECTIVE|||||||
34046640|NCT03935776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of trial participants and care providers is not possible because of obvious differences between the interventions. However, the investigator, the outcomes assessor and statistician are blinded to treatment received.|This is a randomised, parallel group, active-control trial, with patients randomised in a 1:1 ratio|f|f|t|t
34046641|NCT04115930|||CASE_CONTROL||PROSPECTIVE|||||||
34046642|NCT06577883|||COHORT||CROSS_SECTIONAL|||||||
34046643|NCT04141501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blinded|Phase II, randomized, double blind, placebo controlled, parallel group, single center study|t|t|t|f
34046644|NCT03408301|||COHORT||PROSPECTIVE|||||||
34046645|NCT00520533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816240|NCT04521088|||COHORT||PROSPECTIVE|||||||
33816241|NCT00911014|||||PROSPECTIVE|||||||
33816242|NCT04493125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816243|NCT03930173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816244|NCT02026583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816245|NCT01732406|||COHORT||PROSPECTIVE|||||||
33816246|NCT00002723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816247|NCT04389684|||COHORT||PROSPECTIVE|||||||
33816248|NCT03958305|||COHORT||RETROSPECTIVE|||||||
33816249|NCT01803828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33838526|NCT03953131|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33838527|NCT01355042|||COHORT||PROSPECTIVE|||||||
34046646|NCT00626379|||COHORT||CROSS_SECTIONAL|||||||
34046647|NCT02659007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046648|NCT02097563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046649|NCT05999435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identically appearing active and placebo capsules|Parallel, regimen-finding, adaptive design well-controlled randomized clinical trial|t|t|t|t
34046650|NCT00945711|||CASE_CONTROL||RETROSPECTIVE|||||||
34046651|NCT04554810|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34046652|NCT04037475|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the researcher responsible for performing the treatments (which will open the envelopes of the randomization) will know which treatment was assigned to each patient. The identification of each group will be revealed only after the statistical analysis of the data for all those involved in the study by this researcher. Therefore, the researcher responsible for data collection, the microbiologist and the statistician will be blind regarding the treatments assigned to the groups. The patient will also be blind to the type of treatment performed, since the treatment of the lesion will be identical in both groups and the treatment with PDT will be simulated in the control group. Aciclovir placebo will be used in the experimental group, so the patient will not know which treatment will be effective.|24 individuals will be randomly divided into 2 groups: G1 (control group) - conventional treatment with acyclovir and simulation of treatment with photodynamic therapy; G2 (experimental group) - photodynamic therapy placebo ointment simulating acyclovir cream.|t|f|t|f
34046653|NCT04075071|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34046654|NCT06433778|||COHORT||RETROSPECTIVE|||||||
34046655|NCT03570164|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34046656|NCT00027222||||TREATMENT||||||||
34046657|NCT01876810|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34046658|NCT02251418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046659|NCT00706576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046660|NCT05082272|||OTHER||PROSPECTIVE|||||||
34046661|NCT05126394|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double blind|A prospective, randomized, controlled clinical trial.|t|f|t|f
34046662|NCT06325384|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34046663|NCT03253549|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are randomized to SMArTVIEW or Standard Care.||||
34046664|NCT01259362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046665|NCT03975140|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34046666|NCT01584986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046667|NCT05340127|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34046668|NCT03953495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046669|NCT04683393|||CASE_CONTROL||PROSPECTIVE|||||||
34046670|NCT05175118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046671|NCT01419067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046672|NCT03425396|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046673|NCT05677256|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046674|NCT01916681|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046675|NCT02126189|||CASE_CONTROL|||||||||
34046676|NCT06152237|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33816250|NCT04175938|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A stress test will be performed (the wearing of a contact lens) to induce swelling in two groups: group A where the subjects have a diagnosis of Fuch's Endothelial Corneal Dystrophy, and group B where subjects have healthy eyes. Once the contact lens is removed, the cornea swelling will be measured in each group. The length of time it takes for the cornea to recover after being swollen will also be compared between the two groups.||||
34046677|NCT06576323|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34046678|NCT04453280|||COHORT||CROSS_SECTIONAL|||||||
34046679|NCT01029301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046680|NCT01540487|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046681|NCT00163761|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046682|NCT00002172||||TREATMENT||NONE||||||
34046683|NCT01564446|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34046684|NCT02650258|||COHORT||CROSS_SECTIONAL|||||||
34046685|NCT03521102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34046686|NCT00478803|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046687|NCT05751980|RANDOMIZED|PARALLEL||OTHER||NONE||Wait-list control, a mixed-methods approach incorporating surveys, observational data collection, and interviews||||
34046688|NCT00919373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046689|NCT01814696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046690|NCT05707741|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||prospective randomized trial|f|f|t|f
34046691|NCT03652571|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046692|NCT06437795|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34046693|NCT06129435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046694|NCT03054155|RANDOMIZED|PARALLEL||TREATMENT||NONE||For each patient, one side of the body will serve as the treatment side and the other side as the control||||
33838528|NCT04709653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The control and intervention group will be formed by randomization. The intervention and control group will be defined as group 1 and group 2 for statistical analysis. Data analysis will be evaluated and reported by the statistician. Also the statistician will be blind.|This was pretest-posttest design, randomized controlled trial.||||
34046695|NCT04638764|RANDOMIZED|PARALLEL||TREATMENT||NONE|Baseline and post-training measurement will be performed by experienced research nurse and physiotherapist, which will not participate in intervention.|Cluster randomisation with three parallel intervention groups||||
34046696|NCT02056015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046697|NCT01069510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046698|NCT05203848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34046699|NCT03854825|||COHORT||PROSPECTIVE|||||||
34046700|NCT03620123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046701|NCT02146196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046702|NCT00424996|||COHORT||PROSPECTIVE|||||||
34046703|NCT05883072|||CASE_ONLY||CROSS_SECTIONAL|||||||
34046704|NCT05356520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046705|NCT00185263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046706|NCT01125241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046707|NCT05506566|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34046708|NCT02913274|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046709|NCT05390567|||OTHER||PROSPECTIVE|||||||
34046710|NCT00552370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046711|NCT03041753|||COHORT||PROSPECTIVE|||||||
34046712|NCT02919969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046713|NCT05995821|||OTHER||PROSPECTIVE|||||||
34046714|NCT00005214|||CASE_ONLY||CROSS_SECTIONAL|||||||
34046715|NCT02993146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046716|NCT02988336|||COHORT||PROSPECTIVE|||||||
34046717|NCT03055481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046718|NCT02246101|||CASE_ONLY||CROSS_SECTIONAL|||||||
34046719|NCT05099029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046720|NCT02713256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046721|NCT01740752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046722|NCT02313493|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34046723|NCT02148757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046724|NCT02888262|||COHORT||PROSPECTIVE|||||||
34046725|NCT06683300|||COHORT||PROSPECTIVE|||||||
34046726|NCT03710473|||CASE_CONTROL||PROSPECTIVE|||||||
34046727|NCT05450276|||OTHER||PROSPECTIVE|||||||
34046728|NCT02316275|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046729|NCT06003374|||COHORT||PROSPECTIVE|||||||
34046730|NCT03268681|||CASE_ONLY||CROSS_SECTIONAL|||||||
34046731|NCT02327715|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34046732|NCT04240717|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to the interventional group (decision aid) or the control group (treatment-as-usual).||||
34046733|NCT05243433|NA|SINGLE_GROUP||OTHER||NONE||||||
34046734|NCT01028547|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046735|NCT01603849|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046736|NCT00633815|||CASE_CONTROL||PROSPECTIVE|||||||
34046737|NCT01135329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046738|NCT01720654|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046739|NCT06117293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046740|NCT02616146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046741|NCT04110340|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open label, randomised, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in treatment of bubonic plague. We are using a non-inferiority design since the overall cure rate for bubonic plague without septicaemia with streptomycin is approximately 95%. As a result, demonstrating superiority would be unnecessary and impractical given the sample size that would be required. Our aim is therefore to demonstrate that ciprofloxacin alone is not more than 15% inferior to an aminoglycoside followed by ciprofloxacin.||||
34046742|NCT03829254|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34046743|NCT05566470|||COHORT||CROSS_SECTIONAL|||||||
34046744|NCT03436693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046745|NCT00659477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046746|NCT00285207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046747|NCT01696929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046748|NCT04609163|||COHORT||RETROSPECTIVE|||||||
34046749|NCT05305885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046750|NCT03877029|||COHORT||RETROSPECTIVE|||||||
34046751|NCT02237196|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816251|NCT03444298|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"The randomization schedule will be generated by the biostatistician and provided to the investigational pharmacy. Only the biostatistician and the pharmacist will have access to the randomization schedule.~Participants will consume 1400 mg of γT-enriched supplement or matching placebo once daily for 7 days."|Subjects will be allocated to begin the first period of the crossover study with placebo or gamma tocopherol treatment using permuted block randomization with a block size of 4 (2 placebo, 2 gamma tocopherol for the first treatment period of the protocol).|t|t|t|f
33816252|NCT00535626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816253|NCT00005713|||COHORT||PROSPECTIVE|||||||
33816254|NCT06585644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816255|NCT02480283|||COHORT||RETROSPECTIVE|||||||
34046752|NCT01778868|||COHORT||CROSS_SECTIONAL|||||||
34046753|NCT06526975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046754|NCT04333095|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The surgeon, coordinator and anesthesiologist on the case are blinded to the block drug. A 2nd (unblinded) anesthesiologist performs the block on the patient.||t|t|t|t
33816256|NCT03838159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046755|NCT01357070|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34046756|NCT06067126|||COHORT||PROSPECTIVE|||||||
34046757|NCT01443585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816257|NCT04326400|||COHORT||PROSPECTIVE|||||||
33816258|NCT05576233|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33816259|NCT04521647|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|t|f|f
33816260|NCT03737188|NA|SINGLE_GROUP||OTHER||NONE||||||
34046758|NCT05812235|||COHORT||PROSPECTIVE|||||||
34046759|NCT03280602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Semi-blinded||f|f|f|t
34046760|NCT02439528|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046761|NCT04707677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two study groups, test (titanium implants) and control (ceramic implants)|f|f|t|t
34046762|NCT03562208|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Group 1 (50 patients): Patients treated with total bone marrow, in the protocol as a group treatment will analyze type OPEN: The patient knows the treatment, as the investigator and sponsor. All patients continue to receive the standard treatment with insulin and other medicines prescribed by your doctor.~Group 2 (50 patients): Patient no treated, as a control group. All patients continue to receive the standard treatment with insulin and other medicines prescribed by your doctor."||||
34151135|NCT00976586|||COHORT||PROSPECTIVE|||||||
34151136|NCT00255775||||PREVENTION||NONE||||||
34046763|NCT04059029|||COHORT||PROSPECTIVE|||||||
34046764|NCT04136340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Noninferiority, randomized, controlled trial (RCT) in which all patients will meet with a supportive care specialist in-person for the initial clinic visit, and then receive follow-up supportive care visits either in-person at clinic or via home video telemedicine.||||
34046765|NCT01761409|||CASE_ONLY||RETROSPECTIVE|||||||
34046766|NCT03485742|||COHORT||CROSS_SECTIONAL|||||||
34046767|NCT04116060|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blinded and randomised|Parallel Assignment to intervention vs. control|t|f|t|f
34046768|NCT03567395|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34046769|NCT06525376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046770|NCT02597153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046771|NCT01772888|||COHORT||PROSPECTIVE|||||||
34046772|NCT05704374|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|In order to ensure that the researcher who took the recordings is blind, sympathetic tone measurement will be made at rest and during the sympathetic stimulation maneuver in healthy subjects 1.5 hours later, and H-reflex and T-reflex recordings will be taken.||f|f|t|f
34046773|NCT05925387|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician who performed the data analysis saw the experimental and control groups as group A and group B, without knowing which group was the experimental or control group.|Randomised Controlled Study|f|f|f|t
34046774|NCT02365389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046775|NCT05473949|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34046776|NCT01835795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34046777|NCT01312883|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34046778|NCT04237701|||COHORT||OTHER|||||||
34046779|NCT04666701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046780|NCT04037163|||COHORT||RETROSPECTIVE|||||||
34046781|NCT00125710|||FAMILY_BASED||PROSPECTIVE|||||||
34046782|NCT01730443|||CASE_ONLY||PROSPECTIVE|||||||
34046783|NCT02971358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046784|NCT05357703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046785|NCT00647738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34046786|NCT05397392|||COHORT||OTHER|||||||
34046787|NCT04737135|||COHORT||PROSPECTIVE|||||||
34046788|NCT02877875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34046789|NCT06614920|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34046790|NCT05110729|||COHORT||PROSPECTIVE|||||||
34046791|NCT02728505|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
34046792|NCT04217200|||CASE_ONLY||PROSPECTIVE|||||||
34046793|NCT05749978|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34046794|NCT05348317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046795|NCT02893150|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34046796|NCT04916626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors are masked. The statistical evaluation of the effects of OY versus TAU will be carried out by researchers who will be masked for the treatment allocation.|The randomized clinical trial is a parallel, two-arm, superiority trial comparing OPUS YOUNG with TAU for children and adolescents aged 12 - 17 years with a first episode psychosis|f|f|t|t
34046797|NCT04180449|||OTHER||RETROSPECTIVE|||||||
34046798|NCT04771221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34046799|NCT03409289|||COHORT||PROSPECTIVE|||||||
34046800|NCT05523895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046801|NCT04797780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046802|NCT01419444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34046803|NCT05732194|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Sequential ascending doses. Parallel (active, placebo) within each cohort|t|f|t|f
33816261|NCT03623776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816262|NCT03697018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|f|f|t
34046804|NCT02615431|||COHORT||PROSPECTIVE|||||||
34046805|NCT01981941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046806|NCT02042950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046807|NCT02737943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046808|NCT04238247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This is a single-blinded study where a portion of the study will include blinding of study team members who are assessing outcomes. The blinding will not include the participants.~The portion of the study that includes blinding is the review of the monthly photo submissions. Participants send us via text message over the course of 12 months. Each photograph is reviewed and scored by two team members. The first reviewer is blinded to study condition and saves the photographs with the child's face blurred. The second reviewer scores the photographs after the child's face has been blurred to verify findings of the first reviewer. The second reviewer is then unblinded to send feedback to the caregiver appropriate for their study condition."|"After the baseline survey, all participants will be randomized into one of two groups: 1) basic intervention or 2) control group. Block randomization (block sizes from four to eight) will be applied to assign participants to intervention or control in a 3:1 ratio. Blocks will be stratified by child passenger safety recommendations for age (\<2 years, rear-facing; 2-4 years, forward-facing; 5+ years, booster seat) and reason for study eligibility (not consistently using the recommended restraint for age and size or planning a premature transition in the coming 6 months).~After 6-month follow-up, participants in the intervention group only who continue suboptimal child passenger safety behaviors will be re-randomized in a 1:1 ratio to basic or enhanced intervention."|f|f|f|t
34125582|NCT04684212|RANDOMIZED|PARALLEL||TREATMENT||NONE||This prospective, randomized, multicenter study will enroll 2,931 subjects (2706 randomized subjects, 225 roll-in subjects) at up to 75 investigational sites in the United States.||||
34125583|NCT03019757|||COHORT||CROSS_SECTIONAL|||||||
34125584|NCT04466384|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||The subjects will receive two regimens of anesthesia with different drug combinations, with at least a 1-week washout period between regimens. Subjects will be sequentially assigned to start with either propofol or propofol with remifentanil regiments.||||
34125585|NCT04623437|||COHORT||PROSPECTIVE|||||||
34125586|NCT04163653|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33838529|NCT04351308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838530|NCT06376760|||COHORT||PROSPECTIVE|||||||
33816263|NCT04405089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The study is not a disease treatment study. It involves of an Non-Significant Risk (NSR) device coupled with a set of computerized cognitive tasks in a small group of participants with primary outcome of change in an NIH Examiner domain (Flanker).|t|f|t|t
33816264|NCT04704115|||COHORT||PROSPECTIVE|||||||
33816265|NCT00515879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125587|NCT02138812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125588|NCT02553928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125589|NCT02487160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||SBL-3 multifocal intraocular lens|t|f|f|f
34125590|NCT00238082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34125591|NCT03345446|||COHORT||PROSPECTIVE|||||||
34125592|NCT04982471|||COHORT||PROSPECTIVE|||||||
34125593|NCT05727046|||COHORT||CROSS_SECTIONAL|||||||
34125594|NCT01302327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125595|NCT04867863|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34125596|NCT02948582|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34125597|NCT03571360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125598|NCT03660969|||COHORT||PROSPECTIVE|||||||
34125599|NCT00892008|||COHORT||PROSPECTIVE|||||||
34125600|NCT04475107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125601|NCT01196013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125602|NCT02862977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125603|NCT01018654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125604|NCT02615119|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34125605|NCT02574039|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125606|NCT03004950|||COHORT||RETROSPECTIVE|||||||
34125607|NCT03390621|||COHORT||CROSS_SECTIONAL|||||||
34125608|NCT05531006|||COHORT||RETROSPECTIVE|||||||
34125609|NCT05529407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125610|NCT00881985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125611|NCT02455102|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34125612|NCT02332785|||COHORT||RETROSPECTIVE|||||||
34125613|NCT04143581|NA|SINGLE_GROUP||TREATMENT||NONE||OFF/ON/OFF design||||
34125614|NCT01466205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125615|NCT02523287|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34125616|NCT04215861|||COHORT||PROSPECTIVE|||||||
34125617|NCT02020473|||COHORT||RETROSPECTIVE|||||||
34125618|NCT03762460|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125619|NCT02276430|||COHORT||CROSS_SECTIONAL|||||||
34125620|NCT03336190|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125621|NCT01239771|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34125622|NCT01435174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125623|NCT03441529|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34125624|NCT03392428|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomised, stratified, 2-arm, phase 2 trial||||
34125625|NCT00906412|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125626|NCT06287021|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled, randomized, unblinded, multicenter||||
34125627|NCT04355195|||COHORT||PROSPECTIVE|||||||
34125628|NCT05703724|NA|SINGLE_GROUP||SCREENING||NONE||||||
34125629|NCT03400410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator assigned to follow up will be masked to which group a participant was assigned to.||f|f|t|f
34125630|NCT00129285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125631|NCT00187304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125632|NCT06536543|||COHORT||PROSPECTIVE|||||||
34125633|NCT06163196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Since there are 40 children with a diagnosis of Thalassemia in total, aged between 6-18 years, who applied to Mersin City Training and Research Hospital Pediatric Hematology Polyclinic and Daily Pediatric Service between 7 February and 4 June 2022, agreed to participate in the study, and gave permission from their parents, without sampling. 39 children participated. The acupressure group consisted of 19 children and the placebo group consisted of 20 children. During the procedure, children were taken into the room where blood collection took place, one by one, together with their parents. Thus, children and parents participating in the study were prevented from influencing each other. During the application and analysis processes of the research, the groups represented by the papers written Group A and Group B were blinded and hidden from the child who agreed to participate in the research, the parents, and the statistician who performed the analyses."|prospective, parallel , randomized controlled clinical trial|t|t|f|t
34125634|NCT00937495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125635|NCT05052944|||COHORT||PROSPECTIVE|||||||
34125636|NCT01043744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125637|NCT02644824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816266|NCT02167334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125638|NCT04308018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125639|NCT05369364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125640|NCT03228784|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125641|NCT00581022|||COHORT||PROSPECTIVE|||||||
34125642|NCT04226625|RANDOMIZED|PARALLEL||OTHER||NONE||Patients were randomized to receive propofol or desflurane as the maintenance anesthetic.||||
34125643|NCT04011735|||COHORT||PROSPECTIVE|||||||
34125644|NCT02085421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125645|NCT04188990|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||After hospital admission, a nutritional screening in all patients who fulfill the selection criteria of the selected centers will be performed. The first branch includes an intervention in the groups of patients who, after screening, are identified as having disease-related malnutrition (DRM) or at risk of DRM, and a follow-up of the rest of the patients; a second cohort / branch will include patients in whom the intervention, if given, is performed by demand by the medical staff responsible for each patient. The third branch / cohort where usual hospital practice will be provided without any explicit nutritional intervention, except the screening to be carried out in all branches||||
34151137|NCT05450627|||COHORT||PROSPECTIVE|||||||
34151138|NCT00578630|||CASE_ONLY||PROSPECTIVE|||||||
33816267|NCT01074229|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33816268|NCT03956147|||OTHER||PROSPECTIVE|||||||
33816269|NCT06171126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816270|NCT05935072|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33816271|NCT05612009|||CASE_CONTROL||PROSPECTIVE|||||||
33816272|NCT01291524|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33816273|NCT02259959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816274|NCT05516511|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33816275|NCT05771285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33816276|NCT02602002|RANDOMIZED|CROSSOVER||||DOUBLE|||t|t|f|f
33816277|NCT01195402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816278|NCT01539148|||COHORT||PROSPECTIVE|||||||
33816279|NCT03419754|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The subject will complete one intervention with consumption of 75 g of glucose with fidgeting and one intervention with no glucose consumption with fidgeting.||||
33816280|NCT00318591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816281|NCT01293201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33816282|NCT02776917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816283|NCT05134233|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Multi-visit study, testing various LIFU parameters per session||||
33816284|NCT00814554|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33816285|NCT00782873|||CASE_CONTROL||PROSPECTIVE|||||||
33816286|NCT01911819|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33816287|NCT05888272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomized using computer-generated randomization at one point in time.|Study participants that meet the eligibility criteria are randomly assigned to the intervention and waitlist control groups.|f|f|f|t
33816288|NCT02467673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816289|NCT03733756|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33816290|NCT00842647|||CASE_ONLY||PROSPECTIVE|||||||
33816291|NCT00567645|||CASE_CONTROL||RETROSPECTIVE|||||||
33816292|NCT00104442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816293|NCT00370747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816294|NCT04785794|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE||Three Cohorts will be enrolled sequentially with safety data reviewed between enrollment of successive cohorts.|t|t|t|t
33816295|NCT00903981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816296|NCT03385109|||COHORT||PROSPECTIVE|||||||
33816297|NCT00074932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816298|NCT03988309|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33816299|NCT04078373|||CASE_CONTROL||PROSPECTIVE|||||||
33816300|NCT06222671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816301|NCT04955886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816302|NCT03778788|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|A computer-generated randomizer will be used to decide the random allocation. Each eligible subject will be assigned a number generated by the computer. By using random numbers, subjects will be randomly allocated to different groups. This randomization ensure equal sample size in the study groups.|A multisite randomized controlled trial with three arms : app group, booklet and leaflet|f|t|t|t
33816303|NCT04783389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816304|NCT03209336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816305|NCT01484015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816306|NCT02344602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816307|NCT03851809|NA|SINGLE_GROUP||TREATMENT||NONE|no masking design|randomized clinical trial||||
33816308|NCT05717725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomized to pulsed-field ablation or sham procedure.|t|f|f|t
33816309|NCT01736722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816310|NCT06593275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will not know what protection technique will be used during surgery, but the operator will know at the time prior to surgery with a randomization|The study includes 30 patients who will undergo periodontal or peri-implant surgery with collection of a connective tissue graft from the palate to assess the perceived postoperative pain according to both palatal protection techniques in reference to L. Tavelli et al. 2017. They will be divided into 2 randomized groups, 15 with photocured fluid resin protection and the remaining 15 with a self-adhesive and sutured dressing.|t|f|f|f
33816311|NCT04554199|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants, as well as the investigating dentist are blind to the result obtained from the EEG recording. The statistician is also unaware of the EEG .||t|f|t|f
34125646|NCT04264923|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Patients between 18 and 80 years old who do not have any known health issues and who have not taken antibiotics within the last two months.||||
34125647|NCT01504295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125648|NCT03395496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34125649|NCT04708808|RANDOMIZED|PARALLEL||TREATMENT||NONE|For those who consented to the study, they will be randomly assigned to receive music therapy or no according to a computer generated random number series. Each number will be placed in an opaque envelope labelled serially: (i) intervention group: routine care plus music given via headphone (ii) control group- routine care with no music or headphones.|First trimester miscarriage case undergo the manual vaccum procedure.||||
34125650|NCT02906410|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34125651|NCT00768976|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34125652|NCT02041299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816312|NCT02518802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816313|NCT03699761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816314|NCT04017598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The manufacturers of the tablets (Dr. Simon Wood, Natural Factors) will be responsible for allocation concealment of the three tablet formulations at time of packaging. All tablets will be non-distinguishable in size, colour, and packaging. Trial investigators, research staff, and participants will all be blinded to the assigned interventions|12-week double-blind, three-arm, placebo-controlled randomized controlled trial|t|t|t|t
33816315|NCT02900937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816316|NCT06721624|||COHORT||PROSPECTIVE|||||||
33838531|NCT02649504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816317|NCT05560061|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes assessor will be blinded to arm.|Participants will be randomized into two groups - 1) uneven - flat; 2) flat - uneven. Uneven and flat sessions will occur on separate days, 12-72 hours apart.|f|f|f|t
33816318|NCT02992496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33816319|NCT01733199|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33816320|NCT05188404|||COHORT||PROSPECTIVE|||||||
33816321|NCT04619823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33816322|NCT05256758|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Randomised double-blind placebo controlled study|Randomised double-blind placebo controlled study|t|f|t|t
33816323|NCT03906240|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomized to either an intervention condition or no-treatment condition. The intervention condition is accessed through an online portal and includes the moral elevation intervention with intervention content and session goals to facilitate social engagement. The no-treatment condition includes accessing the same online portal, but without any intervention content and is limited to repeated self-report measures for the duration of the study.||||
33816324|NCT04636931|||OTHER||PROSPECTIVE|||||||
33816325|NCT04508829|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33816326|NCT00282009|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33816327|NCT06720896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816328|NCT00293085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816329|NCT03543540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816330|NCT03063983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816331|NCT00419172|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33816332|NCT02209376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816333|NCT04845542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized waitlist control design||||
33816334|NCT00721045|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33816335|NCT04694859|||COHORT||PROSPECTIVE|||||||
33816336|NCT05360134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816337|NCT03439800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33816338|NCT01167816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816339|NCT01352026|NA|SINGLE_GROUP||||NONE||||||
33816340|NCT01180400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816341|NCT00082667|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816342|NCT03473652|NA|SINGLE_GROUP||OTHER||NONE||||||
33816343|NCT03529006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816344|NCT03840278|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study follows a 2-treatment, 2-period crossover design, 2 and will consist of two 7-day study arms in random order: one bihormonal bionic pancreas arm using insulin lispro or insulin aspart and dasiglucagon, and one insulin-only bionic pancreas arm using insulin lispro or insulin aspart.||||
33816345|NCT06564077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816346|NCT02571959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816347|NCT01721109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816348|NCT02135445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816349|NCT00336375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816350|NCT03763409|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind|Parallel randomised|t|f|t|f
33816351|NCT04276649|||COHORT||RETROSPECTIVE|||||||
33816352|NCT01387984|||CASE_ONLY||CROSS_SECTIONAL|||||||
33816353|NCT00865033|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816354|NCT00015132||PARALLEL||TREATMENT||||||||
33816355|NCT04271813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125653|NCT01582334|||COHORT||OTHER|||||||
33816356|NCT01005563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816357|NCT04167150|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized dose-response pre-test, post-test study design||||
33816358|NCT06367244|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The TWP is a parallel study design with two arms. Participants are assigned to either the kidney or liver arm depending on the organ transplant they are listed or in evaluation for. Each arm will have a pre- or post- transplant group. Participants will be assigned to group depending on length of time between study enrollment and transplant surgery. Those with more than 12-weeks until surgery will complete the TWP pre-transplant and those with less than 12-weeks will complete the TWP post-transplant.||||
33816359|NCT01718223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816360|NCT04623996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816361|NCT02310035|||COHORT||PROSPECTIVE|||||||
33816362|NCT05601167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816363|NCT04585048|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||waiting list vs. treatment phase||||
33816364|NCT02817685|||COHORT||PROSPECTIVE|||||||
33816365|NCT05779254|||COHORT||PROSPECTIVE|||||||
33816366|NCT02821572|||CASE_CONTROL||PROSPECTIVE|||||||
33838532|NCT06289595|||CASE_CONTROL||RETROSPECTIVE|||||||
33838533|NCT02720562|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34046809|NCT00819845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046810|NCT06326307|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Two evaluators, who are blinded to the experimented techniques, watched recorded videos of both groups separately and gave their behavior assessment.|"* Group I : Children who received puppet behavior guidance during their first visit and tell-show-do guidance in their second visit, 2 weeks later. (P-TSD)~* Group II: Children who received the tell-show-do behavior guidance during their first visit and puppet behavioral guidance in their second visit, 2 weeks later.(TSD-P)"|f|f|f|t
34046811|NCT06155812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Vasopressors will be administered successively in the control group. In the experimental group norepinephrine, angiotensin II, and vasopressin will be administered simultaneously.|f|f|t|f
34046812|NCT05856773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046813|NCT04683692|RANDOMIZED|PARALLEL||PREVENTION||NONE|For both the parent study and the sub-study, participants and investigators will be unblinded.|Parent Study Design: Patients undergoing clinically indicated catheter ablation for AF in the parent study will be randomized 2:1 to two arms: (1) cerebral protection with the Sentinel device and (2) control group without cerebral protection||||
34046814|NCT02401048|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34046815|NCT05153902|||COHORT||RETROSPECTIVE|||||||
34125654|NCT05608954|||COHORT||PROSPECTIVE|||||||
34125655|NCT01621555|||COHORT||PROSPECTIVE|||||||
34125656|NCT02949024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125657|NCT02955238|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125658|NCT05257486|||CASE_ONLY||PROSPECTIVE|||||||
34125659|NCT04262479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125660|NCT00002798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125661|NCT00689897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125662|NCT05896943|||COHORT||PROSPECTIVE|||||||
34125663|NCT00410189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125664|NCT05473455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125665|NCT00755807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125666|NCT01440673|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125667|NCT04694118|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomise controlled clinical trial||||
34125668|NCT01565473|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125669|NCT00841061|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125670|NCT01189344||PARALLEL||BASIC_SCIENCE||NONE||||||
34125671|NCT06554249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125672|NCT04413695|||CASE_CONTROL||PROSPECTIVE|||||||
34125673|NCT02336815|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125674|NCT04295837|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34125675|NCT02307240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125676|NCT01107964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125677|NCT03971175|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34125678|NCT00921388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125679|NCT06481345|||CASE_CONTROL||RETROSPECTIVE|||||||
34125680|NCT00533130|||DEFINED_POPULATION||PROSPECTIVE|||||||
34125681|NCT05770843|||OTHER||OTHER|||||||
34125682|NCT00064532|||COHORT||CROSS_SECTIONAL|||||||
34125683|NCT02909088|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125684|NCT00042237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125685|NCT03486782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125686|NCT02922361|||COHORT||RETROSPECTIVE|||||||
34125687|NCT01634607|||COHORT||PROSPECTIVE|||||||
34125688|NCT02133651|||COHORT||PROSPECTIVE|||||||
34125689|NCT04793282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34125690|NCT03235882|||COHORT||PROSPECTIVE|||||||
34125691|NCT04153695|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125692|NCT04832529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental Randomized Control Trial|t|t|f|f
34125693|NCT01872975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125694|NCT05207748|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125695|NCT01446887|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34125696|NCT04176393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125697|NCT00253916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125698|NCT01847092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125699|NCT06292767|||CASE_CONTROL||PROSPECTIVE|||||||
34125700|NCT05878977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125701|NCT04712123|||COHORT||RETROSPECTIVE|||||||
34125702|NCT03286192|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single group feasibility study of a psychosocial intervention||||
34125703|NCT00003262||||TREATMENT||||||||
34125704|NCT05412043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34125705|NCT00710398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125706|NCT03951610|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double (participant and investigator)|This will be a, prospective, double-masked, randomized, bilateral, 1 week cross-over, dispensing study|t|f|t|f
34125707|NCT04728646|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The randomization results will also be communicated to the treating physician, who will administer the Dextenza and control plug in the respective eyes while keeping the patient blinded.|Eyes of enrolled patients will be randomized to treatment arms in a 1:1 ratio (Dextenza insert:control insert). All study participants will receive the Dextenza insert in the lower puncta of one eye (treatment eye) and a standard dissolvable intracanalicular plug in the lower puncta of the fellow eye (control eye).|t|f|f|f
34125708|NCT04313738|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study had a single-blind, randomized controlled experimental design. To avoid bias, participants were not told whether they were in the experimental or the control group|Randomized controlled experimental design|t|f|f|f
34125709|NCT03680534|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125710|NCT03578107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34125711|NCT04861779|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34125712|NCT00737932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125713|NCT05372393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking is double blinded (patient and investigators). The trial patients are blinded to the randomization. They can't see to the operation field. In the local anaesthesia group care provider pinches from the area of median nerve blockade prior to performing local anaesthesia.|Two concurrent study groups|t|f|t|f
34125714|NCT02263872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125715|NCT06100146|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Flours will be indistinguishable in appearance except for the vitamins added to the flours of the intervention group. An independent trained person will be assigned to monitor the fortification process and the two products will be packed immediately and coded.|"In randomized control trial, eligible teenage girls attending one of the schools in AM-HDSS will be randomly assigned to:~1. An intervention group receiving a standard bag of cereal flours fortified with folic acid and Vitamin B12 at local mills every week for six months.~2. A placebo group receiving a standard bag of unfortified cereal flours every week for six months.~Participants in all the treatment groups remain eligible to benefit from the standard health care and nutrition programs provided at school, such as deworming at the beginning of the school year."|t|t|t|t
34125716|NCT02781961|||CASE_ONLY||PROSPECTIVE|||||||
34125717|NCT05063929|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34125718|NCT05228353|||COHORT||PROSPECTIVE|||||||
34125719|NCT06288204|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33816367|NCT03720717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Coded envelopes as described above|Coded envelopes with study drug/placebo had been generated and randomized. Patients were enrolled and given drug in next envelope. After completion of study patients assigned into opioid-naive or daily opioid-tolerant groups based on history given by patient|t|t|f|f
33816368|NCT01368549|||COHORT||PROSPECTIVE|||||||
33816369|NCT05114499|||CASE_CONTROL||PROSPECTIVE|||||||
33816370|NCT00992693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816371|NCT04762446|||COHORT||RETROSPECTIVE|||||||
33816372|NCT03075449|||COHORT||RETROSPECTIVE|||||||
33816373|NCT04967677|||COHORT||PROSPECTIVE|||||||
33816374|NCT03736889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816375|NCT01426217|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33816376|NCT01217645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33816377|NCT01932645|||CASE_CONTROL||PROSPECTIVE|||||||
33816378|NCT04774198|||COHORT||PROSPECTIVE|||||||
33816379|NCT04114279|NA|SINGLE_GROUP||OTHER||NONE||||||
33816380|NCT03062124|||COHORT||RETROSPECTIVE|||||||
33816381|NCT00942188|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816382|NCT01786915|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33816383|NCT02400398|||COHORT||PROSPECTIVE|||||||
33816384|NCT04475874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816385|NCT01624532|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Step 1 (Number of Arms: 4), Step 2 (Number of Arms: 2)|t|f|t|f
33816386|NCT02286245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816387|NCT04990037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046816|NCT00089063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046817|NCT00892151|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046818|NCT04299893|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking of: patients, Medical Oncologists (clinical assessment), investigators obtaining other parameters (quality of life, biochemical and clinical parameters, hyperspectral images), investigators for statistical analysis|Standard treatment + ozone therapy (O3/O2) versus Standard treatment + oxygen (O2) as placebo|t|t|t|t
34125720|NCT04125329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125721|NCT02897115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125722|NCT01170234|||COHORT||PROSPECTIVE|||||||
34125723|NCT06275828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34125724|NCT03355248|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are blinded to the group assignment and are not made aware of what interventions are being assigned, only that pain management and satisfaction are being evaluated||t|f|f|f
34125725|NCT04190680|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The study will consist of one intervention group (several primary school classes that participate in the Kokkerelli Learning Street) and one control group (several primary school classes that don't participate in the Kokkerelli Learning Street and continue with their regular curriculum).||||
33816388|NCT00634348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816389|NCT00087724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816390|NCT05857163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816391|NCT01280656|||COHORT||PROSPECTIVE|||||||
33816392|NCT03873922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded research assistant will carry out the PANSS assessment and do the SCID-interviews. Care provider will order the meals for the participants, according to the randomization of the patients.|After baseline examinations, participants will be randomized to receive either ketogenic meals or conventional hospital meals during the study (maximum of six weeks). Otherwise treatment as usual.|f|f|t|t
33816393|NCT06721689|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33816394|NCT01755598|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33816395|NCT01201109|||CASE_CONTROL||PROSPECTIVE|||||||
33816396|NCT00509314|||NATURAL_HISTORY||OTHER|||||||
33816397|NCT01720407|RANDOMIZED|PARALLEL||TREATMENT||NONE|Surgeon does not know the result of randomization.|||||
33816398|NCT02161432|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816399|NCT04362683|||COHORT||PROSPECTIVE|||||||
33816400|NCT02889172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816401|NCT01936376|||CASE_CONTROL||PROSPECTIVE|||||||
33816402|NCT05546177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|opaque sealed envelop|instruments assisted soft tissue mobilization and traditional therapy|f|f|t|t
33816403|NCT02464072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816404|NCT02185586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816405|NCT01989845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816406|NCT00782353|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816407|NCT04944836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816408|NCT03114592|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33816409|NCT03599440|||OTHER||PROSPECTIVE|||||||
33816410|NCT00051740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816411|NCT02852499|||COHORT||PROSPECTIVE|||||||
33816412|NCT03037736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|patients, physicians and evaluators will be masked as to the assignment arm.||t|t|t|t
33838534|NCT05596162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will not be aware of group allocation.||f|f|f|t
34046819|NCT04450082|||COHORT||RETROSPECTIVE|||||||
34046820|NCT03014895|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34046821|NCT06270264|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, prospective and controlled||||
34046822|NCT03138759|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is an open-label, 2-treatment sequence, 2-period, crossover study with a washout between doses and treatment periods||||
34046823|NCT03131414|||COHORT||PROSPECTIVE|||||||
34125726|NCT03738722||SEQUENTIAL||TREATMENT||NONE||||||
34125727|NCT01999686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125728|NCT02248766|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34125729|NCT03018860|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125730|NCT05412264|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34125731|NCT02887157|||COHORT||PROSPECTIVE|||||||
34046824|NCT05555940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046825|NCT01693588|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34046826|NCT01828814|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34046827|NCT06459414|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34046828|NCT02004574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046829|NCT04941625|||COHORT||PROSPECTIVE|||||||
34046830|NCT04382755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046831|NCT00457002|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34046832|NCT04872894|||COHORT||RETROSPECTIVE|||||||
34046833|NCT06575946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046834|NCT06685588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34046835|NCT03376646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046836|NCT05432791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046837|NCT05274464|||COHORT||RETROSPECTIVE|||||||
34046838|NCT02211482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046839|NCT01816711|||CASE_CONTROL||RETROSPECTIVE|||||||
34046840|NCT04783623|||CASE_CONTROL||RETROSPECTIVE|||||||
34046841|NCT04959981|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34046842|NCT03040804|NA|SINGLE_GROUP||TREATMENT||NONE||Simon two-stage design. In the first stage, 6 patients will be enrolled. If the patients in the study do not meet the termination criteria then the study will extend to a second stage and a maximum of 20 patients will be enrolled.||||
34046843|NCT05429281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blinded to the treatment allocation|A prospective, assessor-blinded, randomized study|f|f|f|t
34046844|NCT06123221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel randomized controlled trial|f|f|t|f
34046845|NCT02915757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125732|NCT01746446|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046846|NCT05055284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double|"Experimental: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training along with patellar taping at 30, 60, and 90-degree angles.~No Intervention: Control: Participants in this group will receive Sham EMG-BF guided strength training without patellar taping at 30, 60, and 90-degree angles."|t|f|f|t
34046847|NCT00505492|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046848|NCT05804422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
34046849|NCT06573606|||COHORT||OTHER|||||||
34046850|NCT06683365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125733|NCT02642211|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34125734|NCT02232971|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34125735|NCT03950258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125736|NCT01118780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125737|NCT00702832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125738|NCT02973997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125739|NCT03822637|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34125740|NCT06106906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125741|NCT02141165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125742|NCT03127696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125743|NCT03190798|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study|t|t|f|f
34125744|NCT05596734|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Substudy A: Open-label unblinded.~Substudy B: Participants are blinded to their assigned study intervention."||t|f|f|f
34125745|NCT02148068|||CASE_CONTROL||PROSPECTIVE|||||||
34125746|NCT04848480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125747|NCT04549558|||COHORT||PROSPECTIVE|||||||
34125748|NCT04414553|NA|SINGLE_GROUP||TREATMENT||NONE||Pre/Post||||
34125749|NCT03558646|||COHORT||RETROSPECTIVE|||||||
34046851|NCT00485147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046852|NCT05025644|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"This is a monocentric Phase IV prospective study that will be conducted on patients undergoing surgical myectomy treatment for HOCM, at Toronto General Hospital, to assess if LVOT gradients may be reproduced with dobutamine provocation test in HOCM patients under general anesthesia.~The participants in the study will require a standard 2D echocardiography within 6 months pre and post-surgery. Intraoperatively, the patients will be divided into two groups, one with preoperative PG under anesthesia \<50mmHg (Group A), and one with preoperative PG under anesthesia ≥ 50mmHg (Group B)."||||
34125750|NCT06285045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125751|NCT00777348|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34125752|NCT00924001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838535|NCT02675257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838536|NCT01375673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838537|NCT04647747|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125753|NCT01462526|||CASE_CONTROL||PROSPECTIVE|||||||
34125754|NCT00845247|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34125755|NCT06176846|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125756|NCT05816746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125757|NCT05989438|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34125758|NCT01980199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125759|NCT01172444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125760|NCT06300177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125761|NCT02163577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125762|NCT01890265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants, Investigators, and study staff were blinded to treatment assignments and did not have access to the randomization codes. The high-resolution computed tomography (HRCT) readers were blinded to treatment assignments.||t|t|t|t
34125763|NCT01042158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125764|NCT05561933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and data analyst will not know condition assignment until after data analyses are complete.|Random parallel assignment|f|f|t|t
34125765|NCT02453893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125766|NCT03135431|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm randomized controlled trial||||
34125767|NCT04455828|||COHORT||PROSPECTIVE|||||||
34125768|NCT00972517|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125769|NCT00997854|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125770|NCT06513611|||COHORT||PROSPECTIVE|||||||
34125771|NCT02789085|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34125772|NCT00234130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125773|NCT04177537|||COHORT||RETROSPECTIVE|||||||
33816413|NCT03622372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the Occupational Therapist performing the majority of the outcome assessments will be masked to the treatment until the 12 week post-operative visit.|Participants will be assigned using a 1:1 randomization scheme to receive either the investigational device or a suture repair for the surgical treatment of their tendon lacerations.|t|f|f|t
33816414|NCT05959837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816415|NCT04447586|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||"The first part of the study was carried out by using a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer.The sample of this part included all the volunteers.The effectiveness of each command (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) was estimated by comparing the average of the developing pressures during exhalation attempts arose by the corresponding command with the therapeutic range of pressure.Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study.For the second part of the study, a number of n=8 volunteers (intervention group) was selected from the total sample and was requested to exhale as indicated by the right command, for 3 sets of 10 repetitions, included short breaks between sets.The remaining volunteers (n=5) consisted the control group."|t|f|f|f
33816416|NCT05982847|||COHORT||PROSPECTIVE|||||||
34125774|NCT02781571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125775|NCT02140021|NA|SINGLE_GROUP||SCREENING||NONE||||||
34125776|NCT05558488|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively. It was calculated for each individual based on the Mifflin-St Jeor Equation (Basal Metabolic Rate).~After that, the levels of physical activity (PAL) were used to assess physical activity patterns and energy expenditure of individuals for placement into one of four PAL categories: sedentary, low active, active, or very active. That helped to calculate EER and made an individual reduction (minus 500 kcal / day). Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8 g x Kg- 1 x body weight- 1 x day-1) with three meals a day. The distribution of macronutrients during the ketogenic diet (KD) was: protein 1.8 g x Kg-1 x body weight- 1 x day-1 (\~ 25-30%), fats (\~ 65-70%, with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\< 30 g x day- 1; \< 10%)."||||
34125777|NCT00941525|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125778|NCT04765566|||COHORT||RETROSPECTIVE|||||||
34125779|NCT00648648|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34125780|NCT02618798|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125781|NCT05465005|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||We will compare outcome measures across three experimental conditions and each upper extremity in participants with stroke and similarly-aged controls.||||
34125782|NCT04188132|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pilot study in patients with fulfilling the eligibility criteria||||
34125783|NCT05545592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125784|NCT01838460|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34125785|NCT03184883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125786|NCT03685981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125787|NCT00361972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125788|NCT03595735|NA|SINGLE_GROUP||TREATMENT||NONE||Multi-center, prospective, single-arm.||||
34125789|NCT04587882|RANDOMIZED|PARALLEL||OTHER||NONE||A prospective, randomized-controlled trial where the primary purpose is secondary prevention.||||
34125790|NCT00763724|||COHORT||RETROSPECTIVE|||||||
34125791|NCT04661605|||OTHER||PROSPECTIVE|||||||
33816417|NCT03370094|||COHORT||PROSPECTIVE|||||||
33816418|NCT01681394|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816419|NCT04156685|RANDOMIZED|PARALLEL||OTHER||NONE||2 part, 2x2 crossover study||||
33816420|NCT02848898|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33816421|NCT06518811|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|Eligible individuals will be randomly allocated to either the exercise group or the control group. Participants will be blinded to their group assignment.||t|f|f|f
33816422|NCT01551121|||OTHER||PROSPECTIVE|||||||
33816423|NCT04006444|||CASE_CROSSOVER||PROSPECTIVE|||||||
33816424|NCT01709071|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33816425|NCT01342718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816426|NCT04254965|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33816427|NCT05978089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816428|NCT01996514|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33816429|NCT02985476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33816430|NCT00472368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816431|NCT03671356|||COHORT||PROSPECTIVE|||||||
33816432|NCT01894620|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33840189|NCT04179916|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||For this study it was assumed to expose healthy volunteers for stimuli in the immersive virtual reality||||
33840190|NCT06282653|||CASE_CONTROL||OTHER|||||||
34125792|NCT00836394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125793|NCT01896830|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34125794|NCT00754689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125795|NCT01127932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33816433|NCT06185699|RANDOMIZED|PARALLEL||SCREENING||NONE||Individuals (ı) who wore N95/FFP2 masks during the whole working hours, and only took off it for less than 1 hour; (ıı) those who wore a 3-ply surgical mask during all working hours, only took it off for less than 1 hour and (ııı) people who wore a 3-ply surgical mask for less than 3 days a week, less than 2 hours a day and spending time mostly at home during the day or plus those who worked alone all day in their rooms and who wear a 3-ply surgical mask for less than 1 hour during the day as required.||||
33816434|NCT06719791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816435|NCT00755794|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816436|NCT04265417|||COHORT||RETROSPECTIVE|||||||
33816437|NCT00794274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816438|NCT05323643|||OTHER||CROSS_SECTIONAL|||||||
33816439|NCT04485975|||COHORT||RETROSPECTIVE|||||||
33816440|NCT03852771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816441|NCT02755909|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33816442|NCT00578929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816443|NCT06076317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816444|NCT04785261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816445|NCT01037699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816446|NCT03671499|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33816447|NCT06201949|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33816448|NCT01567176|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33816449|NCT04249115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816450|NCT04184609|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||2 repeated measures (within factor): Control and Albuterol||||
33816451|NCT02954276|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816452|NCT01942551|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33816453|NCT01301183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816454|NCT05925751|||COHORT||PROSPECTIVE|||||||
33816455|NCT01572896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816456|NCT02299011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816457|NCT02499991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816458|NCT01261793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816459|NCT05928520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816460|NCT05850286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816461|NCT00215943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816462|NCT05060445|||OTHER||CROSS_SECTIONAL|||||||
33816463|NCT04366895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816464|NCT00210145|||||PROSPECTIVE|||||||
33816465|NCT02474745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816466|NCT02320045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816467|NCT04179799|||CASE_ONLY||PROSPECTIVE|||||||
33816468|NCT01234025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816469|NCT04545775|||COHORT||PROSPECTIVE|||||||
33816470|NCT02558816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816471|NCT04471415|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation cohort, followed by Dose Expansion cohort, followed by NSCLC, and in combination with atezolizumab cohorts.||||
33816472|NCT04999722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Mobile app was used for follow-up|f|f|f|t
33816473|NCT04301947|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|All participants enrolled will receive instructions about the protocols by the same investigator. An independent researcher will perform block randomization, with a 1:1 allocation ratio and allocation order (using the random list generator at www.randomization.com). The results will be stored in sequentially numbered opaque sealed envelopes that will be opened before the first intervention in the presence of the participant. An independent investigator will code the data and make it available to the investigator who applied the intervention after a wash-out period for processing. The processed data will be sent to this independent researcher, who will decode it and perform the statistical analysis.|This is a descriptive quantitative study with cross-over design of repeated measures.The study will be conducted in two stages. In the first stage, anthropometric data collection, intervention protocol application and biomechanical data collection will be performed. The intervention application order will be random and counterbalanced which half of the participants will receive the gluteal pre-activation protocol and the other half a standard warm-up protocol at the first visit. In the second stage, the intervention will be applied and biomechanical data will be collected. In this context, the following routine will be performed: (1) Preparation and familiarization (2) intervention protocol application (standard warm-up or gluteal pre-activation) (3) Immediately after the protocol, three (3) repetitions of the single-legged squat will be performed and (4) data collection of maximal voluntary isometric contraction will be extracted.|f|f|t|t
33816474|NCT06299345|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participants were blinded about which group they were allocated (control or intervention)||t|f|f|f
33816475|NCT05146479|||COHORT||RETROSPECTIVE|||||||
33816476|NCT01219751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816477|NCT05530239|||CASE_CONTROL||PROSPECTIVE|||||||
33816478|NCT01613456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33816479|NCT01537263|||CASE_ONLY||PROSPECTIVE|||||||
33816480|NCT00111865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816481|NCT00118937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816482|NCT04870905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816483|NCT04743999|NA|SINGLE_GROUP||OTHER||NONE||||||
33816484|NCT05587907|RANDOMIZED|PARALLEL||OTHER||NONE||Around half of the participants follow a 6-month exercise program with visual stimuli, 5 times a week and lasting 15 minutes each time, which precedes their regular soccer training program. The other half of the participants will continue their regular soccer training program. After the end of the 6 months, the initial measurements will be repeated in both groups.||||
33816485|NCT06426511|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Incorporate ctDNA-MRD to personalize the administration of consolidation toripalimab therapy for completely resected stage IB-IIIA NSCLC||||
33816486|NCT04263571|||COHORT||PROSPECTIVE|||||||
33816487|NCT01296477|||COHORT||PROSPECTIVE|||||||
33816488|NCT06719947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
33816489|NCT00135226|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34125796|NCT00628446|||OTHER||CROSS_SECTIONAL|||||||
34125797|NCT05595343|||COHORT||RETROSPECTIVE|||||||
34125798|NCT02856971|||COHORT||RETROSPECTIVE|||||||
34125799|NCT05462106|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34125800|NCT04833335|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125801|NCT00286299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125802|NCT02854995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125803|NCT03896958|||CASE_ONLY||PROSPECTIVE|||||||
34125804|NCT01494324|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
34125805|NCT06319209|||COHORT||PROSPECTIVE|||||||
34125806|NCT01880151|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34125807|NCT00537160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125808|NCT02994966|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125809|NCT03110718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125810|NCT01740778|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125811|NCT03922464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125812|NCT02638714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125813|NCT00344175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125814|NCT03345355|||CASE_CONTROL||PROSPECTIVE|||||||
34125815|NCT01337193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125816|NCT03167138|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single Group Assignment||||
34125817|NCT04987827|||COHORT||PROSPECTIVE|||||||
34125818|NCT01144325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125819|NCT05827705|||COHORT||PROSPECTIVE|||||||
34125820|NCT02229708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125821|NCT06285552|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The participants will be assigned to the manualized program according to the inclusion criteria. The comparison group will be composed of families in areas where the intervention is not available but with similar sociodemographic characteristics.||||
34125822|NCT02530476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125823|NCT03745638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125824|NCT00719992|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34125825|NCT02826408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34125826|NCT03346083|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125827|NCT00483678|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34125828|NCT04973358|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125829|NCT02538276|||COHORT||PROSPECTIVE|||||||
34125830|NCT03584126|||COHORT||OTHER|||||||
34125831|NCT03920696|||COHORT||RETROSPECTIVE|||||||
34125832|NCT04762836|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34125833|NCT05730946|||OTHER||CROSS_SECTIONAL|||||||
34125834|NCT02100930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125835|NCT06251622|||CASE_CONTROL||PROSPECTIVE|||||||
34125836|NCT02804477|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125837|NCT05771805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125838|NCT00652015|||COHORT||PROSPECTIVE|||||||
34125839|NCT04930315|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125840|NCT05521009|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34125841|NCT04750863|||COHORT||RETROSPECTIVE|||||||
34125842|NCT00174122|||DEFINED_POPULATION||OTHER|||||||
34125843|NCT04892719|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This study uses a case control design and approximately 15 lung transplant recipients will be enrolled (10 CLAD cases/5 CLAD free controls). The study procedures will be performed during a single research visit.||||
34125844|NCT01444911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125845|NCT03384927|||CASE_CROSSOVER||PROSPECTIVE|||||||
34125846|NCT03293303|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants (i.e., older adults will be blinded); it's not possible to blind the healthcare professionals.|A randomised controlled trial with 12 months follow-up will be conducted. In total, five homecare teams from MeanderGroep Zuid-Limburg and the local domestic support workers will be trained in 'Stay Active at Home' (intervention group). Another five homecare teams and domestic support workers will deliver usual care (control group). Both groups of professionals and their clients will be compared at baseline and after 6 and/or 12 months follow-up.|t|f|f|f
34125847|NCT03475069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125848|NCT04207515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125849|NCT00996658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34125850|NCT02709720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125851|NCT03814356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125852|NCT03652389|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34125853|NCT01312727|NA|SINGLE_GROUP||SCREENING||NONE||||||
34125854|NCT02250469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125855|NCT06251102|||CASE_ONLY||PROSPECTIVE|||||||
34125856|NCT06455878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34125857|NCT00500461|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125858|NCT02508545|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125859|NCT03204604|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Visits are listed at Challenge A or Challenge B. This serves as a double blind crossover intervention for participants and clinic staff.|Challenge A - low calorie Ensure® shake Challenge B - low calorie Ensure® shake with ketone esters|t|t|t|f
34125860|NCT00106041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125861|NCT03513913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34125862|NCT00524888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125863|NCT03782064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125864|NCT00790543|||COHORT||PROSPECTIVE|||||||
34125865|NCT02419378|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125866|NCT04190823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125867|NCT02971319|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125868|NCT03269357|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster randomised trial||||
34125869|NCT00756353|||OTHER||CROSS_SECTIONAL|||||||
34125870|NCT01189786|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125871|NCT04891913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046853|NCT03686228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046854|NCT05209464|NA|SINGLE_GROUP||OTHER||NONE||||||
34046855|NCT02169141|||||PROSPECTIVE|||||||
34125872|NCT02523989|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34125873|NCT03729635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125874|NCT03659110|||CASE_ONLY||PROSPECTIVE|||||||
34125875|NCT00130039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125876|NCT05340530|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34125877|NCT01728285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125878|NCT03375931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective Randomized open study||||
34125879|NCT02791347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125880|NCT05068986|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34125881|NCT04704713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125882|NCT04651465|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised control trial, where both intervention and control group participants are assessed at baseline, and then the intervention groups get the intervention, and all group participants are assessed at follow up.||||
34125883|NCT04971967|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||120 newly identified MSM HIV cases will be randomly assigned into two groups in 2:1 ratio (intervention: control) and receive crowdsourced PS and conventional PS, respectively.|f|f|f|t
34125884|NCT02810795|||COHORT||PROSPECTIVE|||||||
34125885|NCT03500289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125886|NCT00356070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125887|NCT05468281|||COHORT||PROSPECTIVE|||||||
34125888|NCT01603173|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125889|NCT06073080|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized, parallel arm study. All volunteers will complete a sleep satiated phase and sleep restriction phase before randomized allocation to either an even protein nutrition intervention or a skewed protein nutrition intervention during a recovery phase.||||
34125890|NCT03400046|||COHORT||RETROSPECTIVE|||||||
34125891|NCT03554018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125892|NCT01063348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125893|NCT04621994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125894|NCT05762042|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34125895|NCT03547908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125896|NCT02986633|||COHORT||PROSPECTIVE|||||||
34125897|NCT04927481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125898|NCT06090123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125899|NCT00243191|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34125900|NCT03819387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125901|NCT02560090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34125902|NCT04169178|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34125903|NCT01862406|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34125904|NCT01611740|||COHORT||PROSPECTIVE|||||||
34125905|NCT00269607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125906|NCT03935919|||COHORT||PROSPECTIVE|||||||
34125907|NCT05110781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125908|NCT03885375|||CASE_ONLY||PROSPECTIVE|||||||
34125909|NCT03381664|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34125910|NCT00348946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125911|NCT02091635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125912|NCT06351982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125913|NCT02877576|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34125914|NCT05325229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125915|NCT03752203|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Since patients are being recruited from the investigators' practices, and there is only one form of treatment, masking will not be utilized.|The primary neurosurgeons who will perform the resections will be investigators on the study and will identify eligible patients from the established practice. At the time surgical intervention is recommended, the doctors will inform patients and parents/guardians of the existence of the study. Only those subjects with a clinical relationship to the study investigators will be recruited.||||
34125916|NCT00953953|||CASE_ONLY||PROSPECTIVE|||||||
34125917|NCT02382991|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34125918|NCT00626899|||CASE_ONLY||PROSPECTIVE|||||||
34125919|NCT05528406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125920|NCT00457561|||DEFINED_POPULATION||PROSPECTIVE|||||||
34125921|NCT04787731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Double blind randomized clinical trial|t|t|t|f
34125922|NCT00297739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34125923|NCT05854537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046856|NCT03749746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34046857|NCT02137421|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34046858|NCT00823147|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34046859|NCT02399436|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046860|NCT00527293|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125924|NCT06370312|||COHORT||PROSPECTIVE|||||||
34125925|NCT05001971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125926|NCT04514731|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34125927|NCT01393899|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34125928|NCT05442567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125929|NCT03347448|||COHORT||CROSS_SECTIONAL|||||||
34125930|NCT06457113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34125931|NCT04717921|||COHORT||PROSPECTIVE|||||||
34125932|NCT05208008|||CASE_CONTROL||PROSPECTIVE|||||||
34125933|NCT00190333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34125934|NCT05409469|||COHORT||OTHER|||||||
34125935|NCT03774797|||OTHER||CROSS_SECTIONAL|||||||
34125936|NCT01033084|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34125937|NCT04899726|NA|SINGLE_GROUP||OTHER||NONE||Pilot Study||||
34125938|NCT05694663|||COHORT||PROSPECTIVE|||||||
34125939|NCT03513315|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34125940|NCT02994745|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125941|NCT05118113|NA|SINGLE_GROUP||OTHER||NONE||||||
34125942|NCT01527422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125943|NCT03396627|||COHORT||PROSPECTIVE|||||||
34125944|NCT04789720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned to Group A (SyMon-SAYS intervention) or B (waitlist-control), stratified by gender, age (8-12 vs 13-17), and type of cancer (brain tumor vs. leukemia vs. others). To achieve allocation concealment, the computer-based data management system will assign participants to one of two groups after the study enrollment procedures. A permuted block sequence will be used. Participants will be informed of their group assignment (Group A or B) after the baseline assessment. Participants will complete a 9-item SyMon-SAYS Weekly Symptom Assessment Scale via Epic MyChart patient portal during the intervention phase (Group A: Wk1-16 or Group B: Wk9-16)||||
34125945|NCT03048201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects will receive a commercially available Physica system total knee replacement in one of 3 different configurations: KR (Kinematic Retaining), CR (Cruciate Retaining) and PS (Posterior Stabilized). The assignment of any patient involved in the study is determined by the aetiology preoperatively evaluated by the Investigator and falls within current practice.||||
34125946|NCT01460069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125947|NCT00933439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125948|NCT03087604|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|As the patient will be sedated during epidural catheter placement, they will be blinded to their treatment arm. The investigator that determines if the epidural was successful placed will also be blinded to the patient's treatment arm.||t|f|f|t
34125949|NCT06425653|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"In the control group the standard protocol was applied. The standard protocol included routine care and treatment practices conducted by the same physician at the same institution. In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"||||
34125950|NCT00958477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125951|NCT06117345|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125952|NCT05814718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34125953|NCT02526303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125954|NCT05673824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125955|NCT04009798|||COHORT||PROSPECTIVE|||||||
34125956|NCT04156334|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Concealed randomisation table where patients will be consecutively assigned. Every patient will be given a number according to the randomisation table and the study group inclusion will not be revealed to the investigator or patients until the end of the study.|The double-blinded prospective randomised study|t|f|t|t
34125957|NCT01050751|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34125958|NCT01345929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125959|NCT00617383|||COHORT||PROSPECTIVE|||||||
34125960|NCT02441101|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34125961|NCT00782886|||CASE_ONLY||PROSPECTIVE|||||||
34125962|NCT04593368|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34125963|NCT01706653|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34125964|NCT04620889|||COHORT||RETROSPECTIVE|||||||
34125965|NCT01143961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34125966|NCT05494268|||OTHER||PROSPECTIVE|||||||
34125967|NCT05934110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double-blind study, and the allocation of treatments will not be disclosed until clean file has been declared and the database has been locked.|This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat in its conventional dosage form and placebo.|t|t|t|t
34125968|NCT00506454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125969|NCT04738175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34125970|NCT05160506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The hydrocortisone and placebo solutions are identical in appearance/volume. Only the research pharmacist, (not a member of either the research or clinical teams) will have access to the treatment allocations to ensure blinding of the investigators and clinical staff.||t|t|t|t
34125971|NCT00442416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125972|NCT02235792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125973|NCT03455894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125974|NCT05204095|||CASE_CONTROL||PROSPECTIVE|||||||
34125975|NCT02590536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34125976|NCT00633763|||CASE_CONTROL||PROSPECTIVE|||||||
34125977|NCT05198076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was done using Sealed envelopes|Double Blind Randomized Control Trial|t|t|f|f
34125978|NCT00731861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34125979|NCT02491047|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Subjects will be randomized into either Study investigational arm or Study control arm, using a 1:1 ratio. Randomization will be stratified by Gustilo classification (I and II; IIIA ; IIIB).~In the study treatment arm patients will receive BonyPid-1000 in addition to the standard of care treatment. in the control arm patients will receive the standard of care treatment alone."|t|f|f|f
34125980|NCT03650868|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34125981|NCT02655718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34125982|NCT04210661|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||interventionnal, prsopective, randomized, multicentric||||
34125983|NCT03567889|RANDOMIZED|PARALLEL||TREATMENT||NONE||Total patients: approximately 186. Daromun plus surgery and adjuvant therapy treatment group (Arm 1): 93 evaluable patients. Surgery and adjuvant therapy (Arm 2): 93 evaluable patients. Patients enrolled will be randomized to the two different arms of the study.||||
34125984|NCT05837039|||CASE_ONLY||CROSS_SECTIONAL|||||||
34125985|NCT04983771|||COHORT||PROSPECTIVE|||||||
34125986|NCT01993134|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34125987|NCT01419600|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34125988|NCT01757301|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34125989|NCT03551613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34125990|NCT00938613|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34125991|NCT01146613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34125992|NCT00838812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34125993|NCT05224466|||OTHER||RETROSPECTIVE|||||||
34125994|NCT06199128|||COHORT||PROSPECTIVE|||||||
34125995|NCT01722994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34125996|NCT00699413|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125997|NCT02613520|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34125998|NCT02172391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34125999|NCT01224327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126000|NCT05066126|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||"Participants are assigned to one of two between-group conditions: either receiving a high mixed presentation of content in the social media feed (where the topic varies from post to post), or a low mix of presentation of content in the social media feed (where the topic does not vary).~Additionally, two further between-subject groups will be created by independently examining effects among current and former smokers."|t|f|f|f
34126001|NCT03943290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126002|NCT00529243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126003|NCT00860626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126004|NCT06261008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|There will no masking|Patient will be randomized into either standard care or telehealth intervention group||||
34126005|NCT01490255|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34126006|NCT02146053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34126007|NCT01469481|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126008|NCT03552107|||CASE_ONLY||RETROSPECTIVE|||||||
34126009|NCT04469985|||OTHER||RETROSPECTIVE|||||||
34126010|NCT00581048|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126011|NCT05658250|||CASE_ONLY||PROSPECTIVE|||||||
34126012|NCT01559545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126013|NCT03137953|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Examination of the distance between the skin and the base of the tumour would be evaluated clinically (skin Pinch Test) and by CT/MRI with contrast. Post resection, histopathological examination of tumour margins would confirm if the base of the tumour is free or not. The proportion of cases where skin is preserved would be compared to the proportion of cases where skin would have been preserved based on clinical examination would be assessed.||||
34126014|NCT00654225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126015|NCT01922882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34126016|NCT03623698|||CASE_ONLY||RETROSPECTIVE|||||||
34126017|NCT04938284|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34126018|NCT02424058|||CASE_CONTROL|||||||||
34126019|NCT05267535|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo|Randomized, delayed start, double blind, parallel group, placebo controlled, multicenter study|t|t|t|t
34126020|NCT04027868|||COHORT||PROSPECTIVE|||||||
34126021|NCT01918241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126022|NCT02410642|||COHORT||PROSPECTIVE|||||||
34126023|NCT01078792|||COHORT||PROSPECTIVE|||||||
34126024|NCT04538131|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34126025|NCT03468777|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34126026|NCT03856463|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||"As part of usual care, patients with cancer are assigned to services by a lay navigator and this will be the control group.~For patients in the intervention, they will be assigned to the usual care lay navigator but will receive services by a lay navigator who is trained to engage patients in advance care planning."|t|t|t|t
34126027|NCT02063984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126028|NCT04671563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126029|NCT03360162|||COHORT||RETROSPECTIVE|||||||
33840191|NCT02153151|||COHORT||PROSPECTIVE|||||||
33840192|NCT01156376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33840193|NCT06240013|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34126030|NCT04868942|RANDOMIZED|PARALLEL||OTHER||NONE||A randomised, monocentric, open-label, non-inferiority study comparing, in two phases, a group of volunteers participating in a concert, protected by established protection measures (protection kit, distancing, flow management, health mediation), to a group with no other constraints than national recommendations and obligations (2 concerts, one control group at each concert).||||
34126031|NCT04393662|||COHORT||PROSPECTIVE|||||||
34126032|NCT05773495|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126033|NCT02748499|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126034|NCT00845481|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34126035|NCT06216912|||CASE_ONLY||PROSPECTIVE|||||||
34126036|NCT05362357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126037|NCT00638911|||COHORT||PROSPECTIVE|||||||
34126038|NCT03497468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126039|NCT04085978|||COHORT||RETROSPECTIVE|||||||
34126040|NCT03749824|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34126041|NCT06432400|NA|SINGLE_GROUP||OTHER||NONE||||||
34126042|NCT04853771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Research, single -centered , stratified randomization (hafif-moderate, severe-very severe ) with a pre-test and post-test control group parallel randomized control with experimental was designed as an operation.|f|f|f|t
34126043|NCT05629455|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is an open label study to evaluate the usability of the CareSuperb COVID-19 Antigen Home Test using information from the Quick Reference Instructions (QRI).||||
34126044|NCT04209374|||COHORT||RETROSPECTIVE|||||||
34126045|NCT04298294|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double blinded|"Group I (study group)8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with i-PRF\& bone graft~Group II (control group) 8 patients undergo flapless single immediate implant placement surgery with filling the gap distance with bone graft"|f|f|t|t
34126046|NCT00453869|||COHORT||PROSPECTIVE|||||||
33816490|NCT05976828|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Determination of the MTD of IBRX-042 vaccine will utilize 3 + 3 dose escalation design. Subjects will be sequentially enrolled to 1 of 3 dosing cohorts (up to 3-6 subjects per arm).~* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"||||
33816491|NCT00375323|NON_RANDOMIZED|FACTORIAL||||NONE||||||
33816492|NCT00850954|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816493|NCT04823156|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Calcium supplements will be provided open-label.|Crossover randomised controlled trial.||||
33816494|NCT01861509|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33816495|NCT04344886|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is being used in the study|The patients are randomized into two parallel study arms.||||
33816496|NCT02637999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816497|NCT03366727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||one arm treated with drug-coated balloon catheter, the other arm treated with plain balloon catheter|f|f|f|t
33816498|NCT04459949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816499|NCT02465866|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33816500|NCT01525888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816501|NCT01555879|||CASE_ONLY||RETROSPECTIVE|||||||
33816502|NCT04655833|||OTHER||RETROSPECTIVE|||||||
33816503|NCT01529853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816504|NCT05956093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"* This study focuses on individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC).~* They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV.~* These individuals must also be considered for primary cytoreductive surgery or neoadjuvant chemotherapy."||||
33816505|NCT03425500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Control Trial|t|f|f|t
33816506|NCT00313963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816507|NCT04153994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816508|NCT04453137|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Open label lead-in phase, followed by blinded 1:1 randomization with open label extension phase.|t|t|t|t
33816509|NCT04745910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816510|NCT05228964|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label||||
33816511|NCT06076525|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a Parallel Assignment interventional study aimed at investigating the role of behavioral flexibility in multidirectional balance control and fall prevention across different age groups and fall histories. The study will recruit 42 participants divided into three groups: 14 Older Adult Fallers, 14 Older Adult Non-Fallers, and 14 Younger Adult Non-Fallers. Participants will undergo treadmill walking sessions where perturbations in different directions and magnitudes will be introduced. Older Adult Non-Fallers and Younger Adult Non-Fallers will partake in two different aims, involving walking sessions and training epochs. Due to concerns over fatigue, Older Adult Fallers will only participate in one of these aims. The study aims to provide insight into the trade-offs between speed and flexibility in reactive balance control, and the potential for improving balance through targeted interventions.||||
33816512|NCT06561412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||At the end of the baseline assessment, participants will be randomized using a permuted block technique with block size of 4 to either usual care (Arm 1) or to the produce prescription intervention (Arm 2).||||
33816513|NCT05606809|||COHORT||PROSPECTIVE|||||||
33816514|NCT03292744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816515|NCT02951702|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816516|NCT02210949|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816517|NCT00819078|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33816518|NCT03324048|NA|SINGLE_GROUP||OTHER||NONE||||||
33816519|NCT06157294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816520|NCT04780906|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816521|NCT00547326|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33816522|NCT02848586|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33816523|NCT04607889|||COHORT||CROSS_SECTIONAL|||||||
33816524|NCT02326194|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33816525|NCT04694053|||OTHER||RETROSPECTIVE|||||||
33816526|NCT04779047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816527|NCT05028322|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816528|NCT01880359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816529|NCT03583034|||COHORT||PROSPECTIVE|||||||
33816530|NCT01075672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816531|NCT00022399|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33816532|NCT00101296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816533|NCT01215253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816534|NCT06266390|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be informed on which target they have been assigned to.|Participants will receive rTMS to one of two targets. Participants will be randomly assigned to receive the TMS treatment intervention in one of two target conditions: half to their positive sgACC correlation target, while the remaining half to their negative sgACC correlation target.|t|f|f|f
33816535|NCT01835847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816536|NCT00975078|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816537|NCT02936258|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33816538|NCT04408495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Multicenter, randomized, comparative, parallel-group trial||||
33816539|NCT01133678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816540|NCT00513292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816541|NCT02413645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816542|NCT06090253|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816543|NCT02297854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816544|NCT06247267|||CASE_CONTROL||PROSPECTIVE|||||||
33816545|NCT02217098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816546|NCT06527833|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33816547|NCT06149559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816548|NCT05313477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126047|NCT03706027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126048|NCT05782985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126049|NCT00995098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816549|NCT05230056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816550|NCT00732498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816551|NCT02419248|||||PROSPECTIVE|||||||
33816552|NCT04513925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816553|NCT06612515|||COHORT||PROSPECTIVE|||||||
33816554|NCT04692441|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each participant undergoes the same intervention||||
33816555|NCT06232005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816556|NCT06341998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816557|NCT00376935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33816558|NCT00965471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33816559|NCT06197035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two intervention groups, a group with COPCA intervention and a group with standard physiotherapy|f|f|t|t
33816560|NCT04161976|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816561|NCT00296686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816562|NCT01878955|||OTHER||PROSPECTIVE|||||||
33816563|NCT03782545|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study.|A type of intervention model describing a clinical trial in which all participants receive the same intervention/treatment.||||
33816564|NCT06244888|NA|SINGLE_GROUP||TREATMENT||NONE||See study description for details. All participants will receive all intervention elements, with allocation varying randomly across time using procedures appropriate for system identification.||||
33816565|NCT03843333|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||24 participants at two intervention sites (n = 12 participants per site) will be compared with 24 participants at an enhanced usual care comparison site. We will also conduct qualitative interviews with 16 clinical staff and community health workers.||||
33816566|NCT01804140|||COHORT||PROSPECTIVE|||||||
33816567|NCT00241475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816568|NCT02206607|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33816569|NCT05438745|||COHORT||PROSPECTIVE|||||||
33816570|NCT06441214|||COHORT||OTHER|||||||
33816571|NCT06585735|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816572|NCT05327270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816573|NCT00238745|RANDOMIZED|PARALLEL||||DOUBLE||||||
33816574|NCT02797899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33816575|NCT03535545|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Healthy control subjects will be enrolled first and then subjects with lung cancer and idiopathic pulmonary fibrosis or other types of interstitial lung disease with a fibrotic component meeting inclusion criteria.||||
33816576|NCT05365230|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816577|NCT05591937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816578|NCT06090760|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||waitlist control|t|f|f|f
33816579|NCT03694210|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, single arm, open label, multi-center, trial to evaluate the safety and effectiveness of the Interscope EndoRotor® Resection System in subjects requiring direct endoscopic necrosectomy with walled off pancreatic necrosis (WOPN).||||
33816580|NCT01672255|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33816581|NCT04745338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816582|NCT01874210|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33816583|NCT00255242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816584|NCT01358201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816585|NCT04440956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816586|NCT00091520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816587|NCT06035601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33816588|NCT05832489|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816589|NCT04876261|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and the laboratory will be blinded. Laboratory staff will be unblinded after samples are being analysed. Participants will be unblinded after study end.|"Three-armed study with a cross-over design. Participants will be randomly assigned to either group A, B or C. The group allocation will define the sequence of product intake:~* Group A: first OliPhenolia® bitter, second OliPhenolia®, third La Vialla Extra Virgin Olive Oil~* Group B: first OliPhenolia®, second La Vialla Extra Virgin Olive Oil, third OliPhenolia® bitter~* Group C: first La Vialla Extra Virgin Olive Oil, second OliPhenolia® bitter, third OliPhenolia®"|t|f|f|t
33816590|NCT03161509|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants will undergo blood tests for pharmacokinetic of paracetamol before and 6 months after sleeve gastrectomy||||
33816591|NCT01630239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816592|NCT05301725|||COHORT||RETROSPECTIVE|||||||
33816593|NCT01906073|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816594|NCT02168153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816595|NCT02001467|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816596|NCT01659697|||FAMILY_BASED||PROSPECTIVE|||||||
33816597|NCT00163748|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816598|NCT04007822|||OTHER||PROSPECTIVE|||||||
33816599|NCT00782743|||COHORT||PROSPECTIVE|||||||
33816600|NCT00234832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151139|NCT04942990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single blind|randomized controlled study|t|f|f|f
33816601|NCT04182451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816602|NCT04031534|NA|SINGLE_GROUP||OTHER||NONE||||||
33816603|NCT00889863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816604|NCT02267122|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33816605|NCT00455104|||OTHER||OTHER|||||||
33816606|NCT00142376|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33816607|NCT06360445|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open label|2-period Crossover Assignment||||
33816608|NCT04186819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Positron Emission Tomography (PET) Imaging study||||
33816609|NCT02637466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151140|NCT02100306|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34046861|NCT03468114|RANDOMIZED|PARALLEL||PREVENTION||NONE|Outcome assessors are not informed of allocation but would likely infer this from the presence of highly visible domestic products that are part of the intervention. Lab technicians and data analysts are masked to allocation status.|||||
34046862|NCT04010747|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Prior to the crossover the study will be open label. After the crossover, the outcome assessor will be blinded to study condition.|"The first 30 participants to enroll in this study will receive a training intervention called Motivational Interviewing for Loved Ones (MILO).~After that, participants will be randomly assigned to the intervention (MILO) or to a control condition involving a 30-minute mental health services consultation and a 6 week waitlist followed by the opportunity to participate in the MILO intervention (Phase 2)"|f|f|f|t
34046863|NCT01289639|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34046864|NCT05236387|||CASE_ONLY||PROSPECTIVE|||||||
34046865|NCT03641326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046866|NCT02270047|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046867|NCT03758417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046868|NCT02179905|||CASE_CONTROL|||||||||
34046869|NCT06682559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statistician||t|f|f|f
33816610|NCT01628822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046870|NCT05322889|NA|SINGLE_GROUP||PREVENTION||NONE|no blinding necessary|monocentric, open label, single-arm trial||||
34046871|NCT03661931|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046872|NCT06683976|||COHORT||PROSPECTIVE|||||||
34046873|NCT01842633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046874|NCT04008381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046875|NCT02811146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046876|NCT03297320|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Healthcare teams in Internal Medicine at London Health Sciences Centre will be asked if they have any patients that need further goals of care discussions or ACP.~A random selection of Internal Medicine patients will also be selected for further indepth conversations related to goals of care discussions or ACP"||||
34126050|NCT03450239|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||All participants undero go an MRI scan, complete some questionnaires and two computer tasks. Participants are in two groups: those who have recovered from anorexia nervosa, and healthy control participants.||||
33816611|NCT00312546|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816612|NCT00157209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816613|NCT03603275|||COHORT||CROSS_SECTIONAL|||||||
33816614|NCT05357599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816615|NCT04127695|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33816616|NCT00444730|||CASE_CONTROL||PROSPECTIVE|||||||
33816617|NCT04688554|||COHORT||PROSPECTIVE|||||||
33816618|NCT06719570|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33816619|NCT04362059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816620|NCT02319304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816621|NCT01773707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33816622|NCT04339582|||COHORT||PROSPECTIVE|||||||
33816623|NCT01533896|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816624|NCT03557307|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label||||
33816625|NCT03152409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study team will be blinded to participant condition. Pharmacy will be responsible for providing study drug versus identical placebo to participants.|Randomized control trial with about half of all participants receiving placebo.|t|f|t|f
33816626|NCT01079117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816627|NCT06255132|NA|SINGLE_GROUP||OTHER||NONE||||||
33816628|NCT05543759|||CASE_ONLY||PROSPECTIVE|||||||
33816629|NCT03995524|||COHORT||PROSPECTIVE|||||||
33816630|NCT03873038|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34046877|NCT02702557|NA|SINGLE_GROUP||||NONE||||||
34046878|NCT01223625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816631|NCT06034444|||COHORT||PROSPECTIVE|||||||
33816632|NCT03664271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816633|NCT05749315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816634|NCT01448993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816635|NCT01291745|||COHORT||PROSPECTIVE|||||||
33816636|NCT01430546|||COHORT||PROSPECTIVE|||||||
33816637|NCT04999800|NA|SINGLE_GROUP||TREATMENT||NONE||Pembrolizumab combined with Anlotinib||||
33816638|NCT01479842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816639|NCT03157414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816640|NCT06000202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant doesn't know if she receives the sham or laser therapy.||t|f|f|f
33816641|NCT06719739|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33816642|NCT00424476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816643|NCT02782273|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33816644|NCT05007002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816645|NCT05473468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single oral dose of \[14c\]-Famitinib||||
33816646|NCT04789616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816647|NCT00958971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816648|NCT00962559|||COHORT||PROSPECTIVE|||||||
33816649|NCT01621087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816650|NCT02152111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816651|NCT04626128|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Four groups of approximately 5 participants are assigned to receive interventions in sequential dose escalation fashion based on prior milestones being reached.||||
33816652|NCT04854096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816653|NCT00003732||||TREATMENT||||||||
33816654|NCT05322447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33816655|NCT01123356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816656|NCT05147207|RANDOMIZED|PARALLEL||TREATMENT||NONE||superpath approach versus posterior approach||||
34126051|NCT06379633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All pre-assessments and post-assessment will be conducted by researchers who will be blind to the participants' allocated condition.|Participants will be randomly assigned to one of the three conditions and will remain in that condition throughout the training sessions.|f|f|f|t
34126052|NCT00216918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126053|NCT03243565|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be done by throwing the coin. Family of patients and doctor (Coordinator / Responsible Investigator Serap Ozmen and Associate Investigator Soner Sahin) will be blind; Researcher Ilknur Bostanci and assistant researcher Gulay Senel will appoint drugs and placebo.|"A randomised, double-blind, placebo-controlled, parallel group, phase IV study. First group will receive OM-85 (first 10 day consecutive 3 months; standard treatment regimen) Second group will receive matching placebo at the same posology (first 10 day consecutive 3 months).~A second cure of treatment will be given 6 months after inclusion. Patients will be recruited from 01 August 2017 to 01 February 2018. The trial will begin in August 2017 and will be completed in February 2019.~By this way every patient will be studied over all seasons (1 year study) ."|t|t|t|t
34126054|NCT05282875|||COHORT||RETROSPECTIVE|||||||
34126055|NCT05041998|NA|SINGLE_GROUP||TREATMENT||NONE|The Research Technician and Engineer will be blinded to the socket modification when processing radiographic data from each trial. The participant will not be told the modification made to each socket, however the nature of the intervention (body worn prosthetic device) makes masking infeasible.|Participants will perform study activities with nine different versions (including the original unmodified) of their prosthetic socket in a randomized sequence.||||
34126056|NCT02288000|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34126057|NCT06360653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126058|NCT01799343|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34126059|NCT03759639|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The primary evaluation of the Clinical Impression of Change in Severity (CI-CS; Primary Endpoint) will be performed by two independent neurologists whose assessments are based on videos of patient's performance on either the 9 Hole Peg Test of the Dominant Hand (9HPT-D) or the 8 Meter Walk Test (8MWT) taken at each visit.|"In both the Parent Study and Extension Phase, patients will be assessed during three study phases: a baseline period (with or without a study run-in), a treatment period, and a washout period.~Patients who complete the Parent Study have the opportunity to, at the discretion of their Principal Investigator (PI), continue treatment with N-Acetyl-L-Leucine (IB1001) in an Extension Study, provided they fulfill the inclusion/exclusion criteria."|f|f|f|t
34126060|NCT01507909|||COHORT||PROSPECTIVE|||||||
34126061|NCT04554459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126062|NCT04998227|||OTHER||PROSPECTIVE|||||||
34126063|NCT05542446|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The primary objective of the clinical trial is to determine the plasma concentrations of colistin and CMS during the one or more monitored dosing interval(s) in critically ill patients with and without ECMO under the real clinical practice conditions; based on these data to calculate and compare the pharmacokinetic parameters (Cmax, Tmax, Ctrough, AUC, Vd, clearance) of CMS and colistin in each group.||||
34126064|NCT02118454|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126065|NCT01692106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126066|NCT03805854|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Neither participants nor the conducting investigator will be informed about the administered tACS protocol (10 Hz tACS, 80 Hz tACS or sham stimulation) (= double-blind study). Blinding of participants will be achieved by using tACS intensities which should not evoke perceivable stimulation side effects like skin or visual sensations. Blinding of participants will be controlled using post-hoc questionnaires. An unblinded research assistant who does not interact with the participants will be responsible for initiating and monitoring the appropriate tACS protocol and, thus, enable the blinding of the conducting investigator.|Each participant will participate in 6 experimental conditions aimed at studying the effect of different tACS protocols on pain processing: (1) 10 Hz tACS of the bilateral somatosensory cortex, (2) 10 Hz tACS of the prefrontal cortex, (3) 80 Hz tACS of the bilateral somatosensory cortex, (4) 80 Hz tACS of the prefrontal cortex, (5) sham stimulation of the bilateral somatosensory cortex, and (6) sham stimulation of the prefrontal cortex. Each condition will be administered in an individual session. Sessions will be conducted in pseudo-randomized order and separated by at least 24 hours to avoid any carry-over effects of the stimulation. During each tACS administration, pain will be induced by means of an established tonic thermal stimulation paradigm lasting for several minutes (TSA-II; Medoc, Ramat Yishai, Israel) while pain ratings and autonomic responses will be recorded (Nickel et al., 2017a; Nickel et al., 2017b).||||
34126067|NCT03170570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126068|NCT01747915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126069|NCT04872010|||COHORT||PROSPECTIVE|||||||
34126070|NCT00693927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126071|NCT06438185|NA|SINGLE_GROUP||TREATMENT||NONE||Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction||||
34126072|NCT01132703|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34126073|NCT03579069|||COHORT||RETROSPECTIVE|||||||
34126074|NCT03180112|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126075|NCT04384471|||CASE_ONLY||CROSS_SECTIONAL|||||||
34126076|NCT02245321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126077|NCT03134859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34126078|NCT02795299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126079|NCT06059612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126080|NCT06198738|||COHORT||PROSPECTIVE|||||||
34126081|NCT05483959|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Mechanically ventilated ARDS patients|BIPAP mode of ventilation applied to 20patients , SIMV PC mode applied to the other group|t|f|f|f
34126082|NCT05243979|||OTHER||PROSPECTIVE|||||||
34126083|NCT04103281|||COHORT||PROSPECTIVE|||||||
34126084|NCT05669040|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34126085|NCT03666988|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This will be an open-label study. Hence, masking will not be performed.|Eligible participants will receive sequential doses of GSK3368715, administered orally once daily in Part 1 of the study and in Part 2, participants will receive RP2D determined in Part 1.||||
34126086|NCT02547103|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046879|NCT02048982|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34046880|NCT06111859|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046881|NCT00813813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046882|NCT04927130|||CASE_CONTROL||RETROSPECTIVE|||||||
34046883|NCT01077154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046884|NCT05127876|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double-blind study at the level of patients, careproviders, and outcome assessors. Anesthesiologists, surgeons, and operating personnel did not know which study treatment was used. Syringes were identical in terms of volume, color, viscosity, and odor.|"According to patients' randomized groups, study medication was given over 1 min, 5 min before spinal anesthesia~Patients were randomly assigned into 1 of 4 groups, using computer generated sequence and opaque envelopes, according to the prophylactic intravenous drug dose used:~* Group E: were administered intravenous ephedrine 10 mg diluted in 10 mL 0.9% saline over 1 minute;~* Group OL: were administered intravenous ondansetron 4 mg diluted in 10 mL 0.9% saline over 1 minute;~* Group OH: were administered intravenous ondansetron 8 mg diluted in 10 mL 0.9% saline over 1 minute;~* Group P: was a control group who received 0.9% saline 10 mL over 1 minute as a placebo."|t|t|t|t
34046885|NCT05569668|||CASE_CONTROL||RETROSPECTIVE|||||||
34046886|NCT04864860|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The identity of the supplement Study randomization will be administered by encoding participants with numbers and supplements (intervention \& placebo) with letters (A, B). Study supplements (intervention and placebo) will be encapsulated in identical capsules and will be labelled with the letter A and B to conceal which supplement is given to participants each testing occasion.will only be known to an investigator who will not be involved in data collection and analysis. Participants and investigators who will conduct recruitment, data collection and data analysis will be blinded to which supplement is consumed each occasion until data analysis completed.|Computer-generating randomization will be used to randomly select participants from eligible subjects. Then, participants will be assigned randomly into one of the two groups (intervention vs placebo).|t|t|t|t
34046887|NCT03084627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|volunteers (single masking)||t|f|f|f
34046888|NCT03577613|||CASE_ONLY||PROSPECTIVE|||||||
34046889|NCT03300635|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Patients and healthy control subjects will attend the same interventions: a) muscle function test (distressing task vs. relaxing) with e.g. psychological questionnaires, b) glucose tolerance test and other blood analyses including metabolomics, and c) bicycle ergometry with physiological measurements and blood analyses including metabolomics.|f|f|f|t
34046890|NCT04044066|||COHORT||PROSPECTIVE|||||||
34046891|NCT01222130|||||CROSS_SECTIONAL|||||||
34046892|NCT03566069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046893|NCT00707525|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34046894|NCT02467062|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34046895|NCT05906888|||COHORT||PROSPECTIVE|||||||
34046896|NCT06258122|||COHORT||CROSS_SECTIONAL|||||||
34046897|NCT00077298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046898|NCT00001344||||TREATMENT||||||||
34046899|NCT02901067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046900|NCT03350789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046901|NCT04001218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants will be randomized to either the painful condition or the control condition first before crossing over to opposite condition.|t|f|f|f
34046902|NCT03534336|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|A participant knows only the information that is specific to his/her arm.|3-arm RCT (Control, Incentive for Weight Loss, Incentive for Education) stratified by Gender.|t|f|f|f
34046903|NCT05411666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046904|NCT03272295|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|A double-blind study in respect of the site (except pharmacy) and subjects.||t|f|t|f
34046905|NCT01378182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046906|NCT00529308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046907|NCT01497912|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34046908|NCT05180825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046909|NCT05923138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34046910|NCT05835063|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 20 physicians will be recruited. 10 will be randomized to participate in the intervention arm and 10 will be randomized to the control arm. Participants and caretakers will account for approximately 60 enrolled participants that will not be randomized.||||
34046911|NCT05894941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All the participants will be randomly organized into 3 different groups by the researcher.|The participants in each group will receive the same treatment throughout the trial|t|f|t|t
34046912|NCT05047705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046913|NCT03300856|||OTHER||RETROSPECTIVE|||||||
34046914|NCT03210974|||COHORT||RETROSPECTIVE|||||||
34046915|NCT04551274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data analysts and Outcomes Assessors will be blinded to the group labels||f|f|f|t
34046916|NCT01820624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046917|NCT06577571|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34046918|NCT06319612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046919|NCT03551002|||COHORT||OTHER|||||||
34046920|NCT04586816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Healthy females ages 30-70 with Fitzpatrick skin type I-IV|t|t|t|t
34046921|NCT06140056|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34046922|NCT01872117|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34046923|NCT06383338|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34046924|NCT06447207|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single group trial of occupational therapy led social prescription program for people with Parkinson disease||||
34046925|NCT04998123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The subject will be blinded to the treatment condition. The study team clinician will be aware of the treatment condition to provide to the clinical team any necessary information for clinical care. Decisions by expert review of EEG on seizure duration will be blinded to treatment condition as well.||t|f|f|t
34046926|NCT03747120|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1 randomization||||
34046927|NCT02528110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126087|NCT02154165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816657|NCT03602053|RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase IIb, single center, randomized, controlled, open label study||||
33816658|NCT06204237|NA|SINGLE_GROUP||OTHER||NONE||||||
33816659|NCT06479499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816660|NCT06188949|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, placebo-controlled, double-blinded study|t|t|t|f
33816661|NCT05836753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Sarecycline drug used in the study is indistinguishable from the Sarecycline placebo (the shape, color, and appearance are identical).~In addition, to ensure the blind method, the drug packaging and batch numbers of the two groups are identical, and the packaging batch numbers are uniformly marked.~During the implementation of the study, except for the authorized personnel of the company's supply chain, research management department, and subject security department, members of each research execution group, research center personnel, and CRO data processing personnel cannot view the randomization scheme.~The blind method was also used to evaluate the outcome. The subjects were randomly divided into groups and blinded to the members of the adjudication committee."|This trial was a prospective, randomized, multicenter, double-blind, placebo-controlled parallel trial. Subjects were randomly assigned according to the ratio of the experimental group: control group =2:1.|t|t|t|t
33816662|NCT02447861|||CASE_CONTROL||PROSPECTIVE|||||||
33816663|NCT01961934|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816664|NCT04363645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816665|NCT06201754|||COHORT||PROSPECTIVE|||||||
33816666|NCT04288440|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33816667|NCT00740402|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33816668|NCT05688774|||COHORT||PROSPECTIVE|||||||
33816669|NCT03044834|||COHORT||RETROSPECTIVE|||||||
33816670|NCT00379210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33816671|NCT04213235|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33816672|NCT02832830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816673|NCT02291861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816674|NCT05995275|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33816675|NCT04520620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816676|NCT04778605|||COHORT||CROSS_SECTIONAL|||||||
33816677|NCT01256814|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33816678|NCT02077114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816679|NCT05159726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816680|NCT03778606|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816681|NCT05644067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This trial will be conducted in a double-blinded manner. Namely, the participants, site staff, sponsor staff, the study monitor(s) and the trial statistician will be blinded to the treatment allocation. The independent statistician and the pharmacist are not blind throughout the study.|A randomised, controlled, double-blind, parallel group, single center Phase Ib trial to assess safety, reactogenicity, immunogenicity of a candidate dual-stage malaria vaccine, SumayaVac-1 (MSP-1 with GLA-SE as adjuvant) in healthy participants aged 18-45 years.|t|t|t|t
33816682|NCT03042572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816683|NCT03235297|||COHORT||PROSPECTIVE|||||||
33816684|NCT03362853|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Stage I: the administration sequences of the 4 groups were CABD, ADCB, BCDA and DBAC respectively. D represents moxifloxacin, the positive control drug, for which an open design was adopted. For the other 3 groups, i.e. 500 mg nemonoxacin, 750 mg nemonoxacin, and placebo, a double-blind design was employed.~Stage II: An open design for 12 subjects who had completed Stage I to receive a single oral dose of 500 mg nemonoxacin after taking a high-fat test meal"||t|t|t|t
33816685|NCT05690178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (participant, researcher, outcome assessor). Participants did not know which study group they belonged to. Each participant drew a number that was characteristic of a given research group (experimental DTM group or control group). The researcher also did not know which group the participant belonged to (he only used the participant number). Outcome assessor did not know which group was experimental and which was control (they were marked with numbers instead of names). The coordinator supervised the proper course of the study.|The first step was recruitment. Based on the qualifying and disqualifying criteria, 40 people were selected. Each participant was randomly assigned to a specific group (Deep Tissue Massage (DTM) experimental group or control group). Initial measurements were collected from all participants. Participants in the DTM group had therapy, while those in the control group had no therapy. The therapist was responsible for performing the DTM therapy. Each participant in the experimental group received 4 treatments (45 minutes each, 3 days between them) over a period of 2 weeks. After the end of the whole therapy, final measurements were made. The researcher was responsible for taking measurements for each participant. The person acting as the coordinator supervised the proper course of the research. The collected data was analyzed by a person evaluating the results.|t|f|t|t
33816686|NCT02741921|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33816687|NCT06416605|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816688|NCT00004806||||TREATMENT||||||||
33816689|NCT02757456|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33816690|NCT06505499|||COHORT||RETROSPECTIVE|||||||
33816691|NCT02568202|||COHORT||PROSPECTIVE|||||||
33816692|NCT00593983|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816693|NCT04389086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816694|NCT05265247|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33816695|NCT00993434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816696|NCT04995497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816697|NCT02226029|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33840194|NCT02360735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046928|NCT05001633|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will not know what group they are allocated to until the intervention is delivered.|2-arm parallel group|t|f|f|f
34046929|NCT02693145|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34046930|NCT06413901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34046931|NCT02175940|||CASE_CONTROL||PROSPECTIVE|||||||
34046932|NCT02502812|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34046933|NCT01309360|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046934|NCT04874077|||CASE_CONTROL||PROSPECTIVE|||||||
34126088|NCT05172635|||OTHER||RETROSPECTIVE|||||||
34126089|NCT04041557|||COHORT||RETROSPECTIVE|||||||
34126090|NCT05895123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial|t|f|f|f
34126091|NCT05975346|||CASE_CONTROL||PROSPECTIVE|||||||
34126092|NCT04202185|||COHORT||OTHER|||||||
34126093|NCT01640015|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816698|NCT04864353|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The assessor do not allocate the participant to the intervention or waitlist group.||t|f|f|f
33816699|NCT04590625|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816700|NCT03249961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33816701|NCT02824809|||CASE_ONLY||CROSS_SECTIONAL|||||||
34126094|NCT02054039|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126095|NCT06371157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126096|NCT02808897|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34126097|NCT03993665|||CASE_CONTROL||PROSPECTIVE|||||||
34126098|NCT02465476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126099|NCT01904929|NA|SINGLE_GROUP||||NONE||||||
34126100|NCT03111004|||COHORT||PROSPECTIVE|||||||
34126101|NCT04774380|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126102|NCT01605422|||||PROSPECTIVE|||||||
34126103|NCT01590745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126104|NCT05040698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126105|NCT00807183|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34126106|NCT03191942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126107|NCT06437847|||OTHER||CROSS_SECTIONAL|||||||
34126108|NCT00939887|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34126109|NCT03168893|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34126110|NCT06388239|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34126111|NCT00417768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34126112|NCT01062698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126113|NCT04509570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126114|NCT03968692|||OTHER||CROSS_SECTIONAL|||||||
34126115|NCT03336086|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34126116|NCT06425510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Social Cognitive Theory|f|f|f|t
34126117|NCT03003754|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126118|NCT00407602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126119|NCT01029912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126120|NCT06453343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126121|NCT04796129|||OTHER||PROSPECTIVE|||||||
34126122|NCT01158755|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34126123|NCT01015755|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34126124|NCT01715389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126125|NCT03409952|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|"Group A: Three blinded physician evaluators will assess an identical set of split side post-treatment photos, comparing the left and right photo for improvement in benign pigmented lesions.~Group B: Three blinded physician evaluators will assess an identical set of pre-treatment and post-treatment photos, comparing the left and right photo for improvement in benign pigmented lesions."|Subjects will be enrolled first into Group A, then Group B will be enrolled. Subjects may not be enrolled in both groups.|f|f|f|t
34126126|NCT01590472|||CASE_ONLY||CROSS_SECTIONAL|||||||
34126127|NCT02840253|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126128|NCT04047199|||CASE_ONLY||PROSPECTIVE|||||||
34126129|NCT02606071|||COHORT||PROSPECTIVE|||||||
34126130|NCT05448729|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34126131|NCT01460810|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34126132|NCT03948893|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34126133|NCT01465438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126134|NCT05672368|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34126135|NCT01742728|||COHORT||CROSS_SECTIONAL|||||||
33816702|NCT01241448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816703|NCT02391259|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33816704|NCT01589211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816705|NCT03945409|||CASE_ONLY||PROSPECTIVE|||||||
33816706|NCT04843956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The samples will be analyzed independently by the pathology service, not knowing the order and the technique in which the samples were obtained. The histopathological result will be immediately available for patient care, however, the score obtained regarding the quality of the sample will correlate with the technique and the number of passes until the n of the study is completed.|||||
33816707|NCT02781233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33816708|NCT03345199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816709|NCT02830893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816710|NCT00708799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816711|NCT05293691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816712|NCT00227422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816713|NCT02694198|||CASE_ONLY||PROSPECTIVE|||||||
33816714|NCT04191642|||COHORT||PROSPECTIVE|||||||
33816715|NCT03481725|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126136|NCT05576298|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34126137|NCT03930381|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Study will eventually compare health outcomes between a group given the ASTHMAXcel intervention and a group given Usual Care||||
34126138|NCT05504681|||COHORT||PROSPECTIVE|||||||
34126139|NCT00331877|RANDOMIZED|SINGLE_GROUP||ECT||DOUBLE||||||
34126140|NCT02202967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126141|NCT01797757|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34126142|NCT01069393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126143|NCT04645992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126144|NCT00514722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126145|NCT03685058|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Because of the nature of the study, the investigator who will apply the treatment will not be blind to the group allocation of the lesion. Yet, the investigators who will evaluate the radiographs, DIAGNOcam images, and perform the visual examination will be blinded to which group the lesion they are evaluating belongs. In addition, the statistician will be blinded.|"The study design will be a split mouth, randomized controlled clinical trial in which the teeth will be randomly assigned to be either in the test group or control group in a 1:1 ratio.~The control group: will be treated with standard-of-care preventive measures which includes application of 5% sodium fluoride (NaF) topical varnish, oral hygiene instruction, and dietary counseling.~The test group: will be treated with light curable resin modified glass ionomer (RMGI) varnish in addition to standard-of-care preventive measures."|t|f|t|t
33816716|NCT01373359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34126146|NCT00724659|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126147|NCT05697653|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||intervention group and control group, randomized controlled trial.||||
34126148|NCT05475977|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126149|NCT03482986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34126150|NCT05280821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and investigators are blinded, double blind study.||t|f|t|f
34126151|NCT02621437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34126152|NCT04481607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126153|NCT04888806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126154|NCT02065349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126155|NCT04643847|NA|SINGLE_GROUP||TREATMENT||NONE||110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by cone beam computed tomography(CBCT) before each treatment). For patients who are assessed as oligometastasis three month after Almonertinib treatment, stereotactic body radiation therapy(SBRT) is recommended for oligometastatic lesions.||||
34126156|NCT03149523|||COHORT||OTHER|||||||
34126157|NCT01738633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34126158|NCT00790582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126159|NCT02378285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126160|NCT04458246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816717|NCT05072795|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34126161|NCT05237362|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33816718|NCT06158620|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase I will consist of a single-arm open label pilot study. Prior to the initiation of a large-scale randomized trial, we propose a single-arm open label pilot study to evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents. We seek to enroll 20 patients for the initial pilot.~Phase II will consist of a randomized trial comparing intranasal ketorolac to Diclofenac, a commonly used oral NSAID. , Diclofenac potassium. Following ureteroscopy and stent placement, patients will receive standard of care medications to mitigate post operative pain and stent discomfort, and will be randomized to receive either as needed intra-nasal ketorolac or oral diclofenac. We seek to enroll and randomize 60 patients in a 1:1 fashion. Analysis will be intention to treat."||||
33816719|NCT04975386|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33816720|NCT00267774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816721|NCT04497818|||OTHER||PROSPECTIVE|||||||
33816722|NCT06046976|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33816723|NCT06010303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816724|NCT04618211|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33816725|NCT01596894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33816726|NCT06660004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33816727|NCT05051488|||COHORT||PROSPECTIVE|||||||
33816728|NCT06315322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816729|NCT04016298|||OTHER||PROSPECTIVE|||||||
33816730|NCT01236144|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816731|NCT05060406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|It is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial|t|f|t|f
33816732|NCT03196622|NA|SINGLE_GROUP||PREVENTION||NONE|Open|||||
33816733|NCT05676372|||CASE_ONLY||PROSPECTIVE|||||||
33816734|NCT03941756|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816735|NCT04271254|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816736|NCT04884282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816737|NCT05022953|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33816738|NCT02303509|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816739|NCT00585910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816740|NCT06585592|||CASE_CONTROL||RETROSPECTIVE|||||||
33816741|NCT04125342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816742|NCT03490188|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A single institution randomized control trial assigning patients getting discharged after a kidney transplant to treatment and control group||||
33816743|NCT00224913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33816744|NCT03770715|||COHORT||PROSPECTIVE|||||||
33816745|NCT03622242|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33816746|NCT03855384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816747|NCT05331235|||CASE_ONLY||CROSS_SECTIONAL|||||||
33816748|NCT06719895|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34126162|NCT00910494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126163|NCT04284501|||COHORT||PROSPECTIVE|||||||
34126164|NCT04453826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126165|NCT02499627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126166|NCT03366025|||COHORT||PROSPECTIVE|||||||
34126167|NCT05830318|||COHORT||PROSPECTIVE|||||||
34126168|NCT05302427|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33840195|NCT01219907|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126169|NCT04300660|||COHORT||PROSPECTIVE|||||||
34126170|NCT01445613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816749|NCT03795792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the patient nor the treating doctor will know the study group the participant was randomized.|"Study groups:~Intervention group: curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.~Control group: hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise."|t|t|f|f
33816750|NCT01894750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816751|NCT04454125|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|40 child will be 1:1 randomization by age groups 8-12 years, 13-17 years.||||
33816752|NCT03522909|||COHORT||RETROSPECTIVE|||||||
33816753|NCT00242086|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816754|NCT02265471|||OTHER||CROSS_SECTIONAL|||||||
33816755|NCT00460434|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33816756|NCT05531149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All bottles will be indistinguishable.|Subjects will be randomized to receive either trimodulin or placebo on a 1:1 basis, stratified by type of oxygen supply before randomization and by region|t|t|t|t
33816757|NCT06234449|||COHORT||PROSPECTIVE|||||||
33816758|NCT00843076|||COHORT||PROSPECTIVE|||||||
33816759|NCT05501340|NA|SINGLE_GROUP||TREATMENT||NONE||Intraperitoneal infusion of PD-1 inhibitor can produce anti-tumor effect, and intraperitoneal infusion of PD-1 inhibitor combined with PRaG（Radiotherapy and GM-CSF）can benefit the survival of patients with peritoneal metastasis of advanced malignant tumors and malignant ascites||||
33816760|NCT01305551|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33816761|NCT03263845|||CASE_ONLY||PROSPECTIVE|||||||
33816762|NCT00108407|RANDOMIZED|PARALLEL||||NONE||||||
33816763|NCT04887597|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is an open label interventional study in 10 patients with enthesitis in psoriasis arthritis (PsA). The study is composed of a single arm receiving secukinumab for the duration of 6 months.||||
33816764|NCT06414213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34126171|NCT04232982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will not be aware of which type of cyclophotocoagulation treatment they will be allocated.|Prospective, randomized, single blinded study with two interventional arms and one historical cohort as controls.|t|f|f|f
33816765|NCT04366648|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||This study is a multicenter, open labled, positive controled, single, -combined, with multiple dose escalation trial.|t|f|t|f
33816766|NCT01706055|||COHORT||PROSPECTIVE|||||||
33816767|NCT02473549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816768|NCT01341106|NA|SINGLE_GROUP||||NONE||||||
33816769|NCT00340158|||||RETROSPECTIVE|||||||
33816770|NCT03834909|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will randomly allocate participants in a 1:1 ratio to two parallel study arms (based on a computer generated randomization scheme).||||
33816771|NCT03761979|NON_RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Subjects' anonymity was maintained on electronic case report forms (eCRFs) and other documents by utilization of initials, number, or code, and not by using a subject's name. The Investigator kept a separate log showing codes, names, and addresses. All documents showing the subjects' identity were kept in strict confidence by the Investigator.|This was an unblinded, sequential, three dose study. The study consisted of one screening visit (Visit 1; day -7) and three test visits (Visits 2, 3, and 4; days 0, 7, and 14) with at least a 6-d washout between test visits.|t|f|f|t
33816772|NCT04566276|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||"Phase 1: Group 1 (healthy adults aged 18 to 55 years) and Group 2 (elderlies aged 56 to 75 years) will be enrolled sequentially in an ascending dose fashion (10 µg, 25 µg, 50 µg). Up to 36 eligible healthy volunteers for each of the 2 age groups will be enrolled into 1 of 3 treatment cohorts (12 participants/ cohort). For each cohort, if only 1 participant withdraws prior to the second vaccination, no replacement is deemed necessary. For each cohort, if more than 1 participant withdraws prior to the second vaccination all withdrawn participants will be replaced.~Phase 2: The Phase 2 adult cohorts will include adults between 18 and 59 years of age (inclusive). Participants in the Phase 2 will be enrolled into at least 1 dose level cohort with a vaccination dose of 50 ug which was determined by DSMB and SRPT review and approval of the applicable Phase 1 data. Phase 2 treatment group will consist of participants randomly assigned to active treatment versus placebo in a ratio of 4:1."|t|f|t|t
33816773|NCT04536779|NA|SINGLE_GROUP||OTHER||NONE||We will use a study design with pre- and post-measurements. The participant will be their own case-control. For optimizing the statistical strength, the individuals with low mobility will undergo two times of baseline measurements. After a minimum of a three-month trial period followup measurements will be conducted.||||
33816774|NCT04677985|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Placebo and analgesic applications were identified by numbers which were only revealed after the statistical analysis.|Random allocation of the application of a menthol based topical analgesic versus a placebo.|t|f|t|f
33816775|NCT02855892|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816776|NCT02939066|||COHORT||PROSPECTIVE|||||||
33816777|NCT02292056|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816778|NCT02190942|||COHORT||CROSS_SECTIONAL|||||||
33816779|NCT03443739|||COHORT||PROSPECTIVE|||||||
33816780|NCT00751088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816781|NCT02548585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816782|NCT04977089|||COHORT||PROSPECTIVE|||||||
33816783|NCT02713776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816784|NCT03805698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients undergoing arthroscopic debridement for triangular fibrocartilage complex (TFCC) tears will be treated with PRP (24 subjects) versus no treatment with Platelet-rich plasma (PRP) (24 subjects).||||
33840196|NCT02311387|||COHORT||PROSPECTIVE|||||||
33840197|NCT00541177|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33840198|NCT01187381|||COHORT||PROSPECTIVE|||||||
34126172|NCT03943576|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126173|NCT01354522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126174|NCT03961191|||CASE_CONTROL||PROSPECTIVE|||||||
34126175|NCT01072721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126176|NCT00712478|||COHORT||PROSPECTIVE|||||||
34046935|NCT00858455|RANDOMIZED|CROSSOVER||||NONE||||||
34046936|NCT02145260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34046937|NCT02430246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046938|NCT05138588|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"All investigators, participants, care providers and outcome assessors will be blinded, with the exception of the investigator programming the stimulation sequences and the nurses administrating the rTMS sequences.~For the investigators, the unblinding and the taking of knowledge of the subjects in each group will take place after the end of any experimental run, during the data processing phase. In the event of serious adverse events, the unblinding will be carried out before the end of the research.~For participants, the unblinding will take place at the end of the last follow-up visit of the study."||t|t|t|t
34046939|NCT05967299|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34046940|NCT06333756|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Parallel Assignment||||
33816785|NCT06673524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"TAP Block: Aseptic conditions are established. With the patient supine, the ultrasound (USG) probe is placed laterally to the xiphoid process at the rib cage's lower border, visualizing the rectus abdominis above the transversus abdominis. The internal oblique aponeurosis is seen between the transversus and external oblique muscles. Pressure is applied to optimize myofascial plane visualization. A 22-25G, 50-100 mm block needle is used in an in-plane technique to inject 20 ml of 0.25% bupivacaine in the fascial plane between the rectus and transversus abdominis, then repeated on the opposite side.~Rectus-Intercostal Fascial Plane Block: With the patient supine under USG, a probe is placed 2-3 cm lateral to the xiphoid process to visualize the rectus abdominis and 6th-7th costal cartilages. A needle is advanced to inject 20 ml of 0.25% bupivacaine into the interfascial plane, repeated on the opposite side."|t|f|f|f
34046941|NCT01263782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816786|NCT05749939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized wait list control trial. Participants are assigned to treatment and wait list groups. Wait list participants receive treatment after 4 weeks of waiting. Treatment participants receive treatment immediately.||||
34046942|NCT06335199|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34046943|NCT06209216|||CASE_ONLY||PROSPECTIVE|||||||
34126177|NCT03440554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prostate cancer patients will have a research whole body MRI scan within 90 days of their standard of care imaging. Patients receiving additional standard of care imaging within 12 months of the research scan will be asked to have an additional research scan within 90 days of their follow-up imaging.||||
34126178|NCT01004536|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126179|NCT06391580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126180|NCT06270446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Data analysis blinded|||||
34126181|NCT04119765|||COHORT||PROSPECTIVE|||||||
34126182|NCT01530646|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126183|NCT01321853|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126184|NCT02843438|NA|SINGLE_GROUP||SCREENING||NONE||||||
34126185|NCT04631315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126186|NCT01823081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126187|NCT01791491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126188|NCT04280016|NA|SINGLE_GROUP||TREATMENT||NONE|The outcome assessor will be unaware of how much the participant participated in the exercise program. Exercise will occur away from the treatment area so that the care provider will be unaware of whether or not a patient is participating in the study.|A pilot study using retrospective chart review and non-randomized controlled trial methodology (single group).||||
34126189|NCT02804633|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34126190|NCT06107543|||COHORT||RETROSPECTIVE|||||||
34126191|NCT06072625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34126192|NCT04952428|||CASE_CONTROL||RETROSPECTIVE|||||||
34126193|NCT03782623|||COHORT||PROSPECTIVE|||||||
33816787|NCT02153697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816788|NCT01589406|||COHORT||PROSPECTIVE|||||||
33816789|NCT04083950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34046944|NCT01919866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046945|NCT06054009|NA|SINGLE_GROUP||OTHER||NONE|This study does not involve blinding. However, to incorporate a degree of impartiality, assessments will be carried out by a research assistant, not the therapist.|Three N=4 randomised multiple baseline design (MBD) single case experimental design studies, with A1B1A2 structure.||||
34046946|NCT06309979|||COHORT||OTHER|||||||
34046947|NCT04246216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33816790|NCT00916318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816791|NCT00882323||PARALLEL||TREATMENT||NONE||||||
33816792|NCT04616300|||COHORT||PROSPECTIVE|||||||
33816793|NCT00887471|||COHORT||PROSPECTIVE|||||||
33816794|NCT06721195|||COHORT||CROSS_SECTIONAL|||||||
33816795|NCT06309641|||COHORT||PROSPECTIVE|||||||
33816796|NCT00084825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816797|NCT05847634|||COHORT||PROSPECTIVE|||||||
33816798|NCT03781934|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Intrapatient dose escalations continuing into interpatient dose escalations to end with dose expansion cohorts.||||
33816799|NCT03236818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816800|NCT04223141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816801|NCT01918852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816802|NCT01922102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816803|NCT06656663|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study utilises a two-group (intervention vs. active control) parallel randomised design, with YP as the unit of randomisation.||||
33816804|NCT04527341|||COHORT||PROSPECTIVE|||||||
33816805|NCT05852379|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (participants, Care provider, Outcomes Assessor)|Randomized, single-blinded, parallel assignment|t|t|f|t
33816806|NCT02275806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816807|NCT00761332|||COHORT||PROSPECTIVE|||||||
33816808|NCT04257500|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33840199|NCT00577070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840200|NCT01796379|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33816809|NCT05142553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Subjects and the clinical study team will remain blinded to treatment allocation. Clinical staff involved in study drug preparation and administration will be aware of which vaccine the subject is receiving. The extension of the fourth dose will be unblinded.|This is a Phase IIb, randomised, double-blind, active-controlled, multicentre, noninferiority clinical study that aims to determine immunogenicity, reactogenicity, safety, and tolerability of a booster vaccination of test vaccine followed by an extension period to study a fourth dose administration of the vaccine.|t|f|t|f
34126194|NCT02297633|||CASE_CONTROL||PROSPECTIVE|||||||
34126195|NCT03301779|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34126196|NCT03216720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33816810|NCT06472778|||CASE_ONLY||RETROSPECTIVE|||||||
33816811|NCT05734885|RANDOMIZED|PARALLEL||PREVENTION||NONE||The sample size of the study was calculated based on the results of a study aiming to determine the effect of birth dance applied with the support of a spouse and midwife during labor on birth pain and satisfaction \[19\]. It was found as 116 participants, including 39 in each group, on the G\*power 3.1.9.2 (Ver. 3.1.9.2) \[20\] software, based on an effect size of 0.71, a power of 0.95, and an alpha level of 0.05. Considering some attrition, an additional 15% was added to the sample size, and the study was planned to be conducted with 141 women (47 in the partner massage group, 47 in the midwife massage group, and 47 in the control group). During monitoring, two participants were lost from each group. Eventually, the study was completed with a total of 135 women, 45 in each group.||||
33816812|NCT06359574|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33816813|NCT04882956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816814|NCT05165524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816815|NCT00859677|||COHORT||CROSS_SECTIONAL|||||||
33816816|NCT01129375|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816817|NCT06601686|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will not know whether they receive sham or real stimulation|||||
33816818|NCT03562117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no masking, as this is an open-label study.|||||
33816819|NCT02502188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816820|NCT03966599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33816821|NCT05308342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816822|NCT06382155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816823|NCT00474409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816824|NCT04910399|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33816825|NCT03829371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816826|NCT06093893|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816827|NCT04516980|||COHORT||CROSS_SECTIONAL|||||||
33816828|NCT06451705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blind randomized trial|t|f|f|f
33816829|NCT02391714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816830|NCT04896229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomly assign 150 participants (student/parent dyads) to a TSF treatment condition and 150 to treatment-as-usual. Conduct a 6-month intervention among the TSF condition participants. At the conclusion of post-intervention testing, deliver the TSF intervention to the treatment-as-usual condition participants.|One intervention and two arms: Intervention and treatment-as-usual|t|f|f|f
33816831|NCT05438043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816832|NCT03467802|||OTHER||PROSPECTIVE|||||||
33816833|NCT04851288|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33816834|NCT00324571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816835|NCT02887716|||COHORT||RETROSPECTIVE|||||||
33816836|NCT05182242|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816837|NCT05172843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33816838|NCT04264156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The first 2 subjects at each site for each cohort will be dosed with open-label active treatment for training purposes. Following the first 2 subjects, preparation and delivery of treatment will be blinded from the study staff. Treatment will be delivered behind a partition and no information about treatment will be given to investigator, parents, or other applicable study staff.|This study is a multinational, multicenter, double-blind (masked), parallel group, randomized, controlled study, in preterm neonates 26 to 32 completed weeks post-menstrual age (PMA).|t|t|t|f
33816839|NCT04004806|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33816840|NCT00230009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33816841|NCT04526171|RANDOMIZED|PARALLEL||OTHER||NONE||The study was a cluster-randomised trial with 47 intervention and 47 control clusters, with a baseline and an endline survey conducted in the district of Bhavnagar, Gujarat, India. Briefly, 94 villages were randomised to intervention or control groups. We carried out a household census and from this we selected 10 households with a functional 'government' toilet for a baseline and 30 for follow up at endline using random sampling from the census list for each village. Outcomes were measured as the proportion of households where all members were reported to use the toilet and the overall usage of toilets by individuals, employing a standard questionnaire.||||
33816842|NCT00203788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816843|NCT04513041|NA|SINGLE_GROUP||TREATMENT||NONE|PI and statistician will be blinded to the type of investigation for|Right and left sides of the mouth will be randomly assigned to test and control group by computer generated randomization table in a split mouth design||||
33816844|NCT03461120|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The only individuals aware of treatment assignment will be the Investigational Drug Service pharmacists who prepare the treatment infusate||t|t|t|t
33816845|NCT01107717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126197|NCT06069830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126198|NCT01284959|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34126199|NCT04256278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|use of placebo, masked randomization list|quadruple-blind study|t|t|t|t
34126200|NCT02409433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126201|NCT00003631|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126202|NCT02786563|||COHORT||PROSPECTIVE|||||||
34126203|NCT05746182|||COHORT||PROSPECTIVE|||||||
34126204|NCT01569815|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126205|NCT02663336|||COHORT||PROSPECTIVE|||||||
33816846|NCT06172777|||CASE_ONLY||PROSPECTIVE|||||||
33816847|NCT01415180|||COHORT||PROSPECTIVE|||||||
33816848|NCT05108428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816849|NCT06721975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patient will be randomized to one of the following two groups:~1. p-Tm:YAG laser system~2. TFL laser system"|t|f|f|f
33816850|NCT03073915|||COHORT||PROSPECTIVE|||||||
33816851|NCT05876221|||COHORT||RETROSPECTIVE|||||||
33816852|NCT03623308|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33816853|NCT03474978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816854|NCT06721364|NA|SINGLE_GROUP||PREVENTION||NONE|Not any|"Intervention I:RAAHI RAAHI is a suicide literacy module that is specially designed to provide individuals with essential knowledge and skills by equipping them with tools to navigate the complexities of mental health and suicide prevention. This module aims to empower people to recognize signs of suicidal ideation, engage in empathetic communication through open discussion, combat stigma, and connect individuals in crisis with appropriate support and resources.~Intervention II: safeTALK The \&amp;amp;amp;#34;safeTalk\&amp;amp;amp;#34; program is a psychoeducational initiative designed for suicide prevention among adolescents, consisting of a 4-hour workshop that incorporates presentations, videos, discussions, and questions."||||
33816855|NCT01082354|||COHORT||PROSPECTIVE|||||||
33816856|NCT06566079|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33816857|NCT04200898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816858|NCT05888103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sponsor Personnel participating in the study conduct will also be blinded.|Multi-center, randomized, double-blind, placebo-controlled, parallel groups|t|t|t|f
33816859|NCT06721286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816860|NCT05185102|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33816861|NCT01181193|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816862|NCT03537534|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33816863|NCT05488314|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34126206|NCT01198782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126207|NCT00456625|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34126208|NCT00585637|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34126209|NCT00943631|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126210|NCT04406402|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34126211|NCT00405249|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34126212|NCT05792163|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34126213|NCT02056444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126214|NCT06172816|||COHORT||CROSS_SECTIONAL|||||||
34126215|NCT04451408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34126216|NCT03666338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126217|NCT01684839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126218|NCT05424835|RANDOMIZED|PARALLEL||TREATMENT||NONE||SHR-A1811 compared with Pyrotinib in combination with Capecitabine||||
34126219|NCT00901251|||CASE_ONLY||PROSPECTIVE|||||||
34126220|NCT00252512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126221|NCT05065073|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Randomized, controlled study. Each patient will be randomized to undergoing OCT image acquisition with iso-osmolar contrast media first, or with low-osmolar contrast media first. Following this will be a second OCT image acquisition of the same coronary vessel with the other contrast media. Thus, each patient will serve as comparator to themselves, and to each other||||
34126222|NCT04301297|||CASE_ONLY||PROSPECTIVE|||||||
34126223|NCT02505373|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126224|NCT04200092|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34126225|NCT01887964|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34126226|NCT01520467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816864|NCT04344236|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled open label trial, parallel design||||
33816865|NCT04422210|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33816866|NCT01732419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816867|NCT00470990||CROSSOVER||||NONE||||||
33816868|NCT04662320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33816869|NCT02574910|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33816870|NCT05203003|||OTHER||PROSPECTIVE|||||||
33816871|NCT04430400|||COHORT||PROSPECTIVE|||||||
34126227|NCT00114127|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34126228|NCT06346938|||COHORT||PROSPECTIVE|||||||
34126229|NCT00002493||||TREATMENT||||||||
34126230|NCT04967872|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126231|NCT06198062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get a separate treatment protocol and possible efforts will be mask the both groups about their treatment|This will be randomized control trail to see effects of Paraffin wax bath therapy with and without muscle energy technique in children with post burn hand contracture|t|f|f|f
33816872|NCT02004834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816873|NCT06107335|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816874|NCT04599855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816875|NCT06668077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The psychologists that conduct the assessments (screening, assessment sessions and follow-ups) will be blinded to the group allocation during the whole project. Further, all participants will be blind to their condition. Also, the people who perform the statistical analyses will be blind to the condition of the groups, through the coding of the interventions. Only the therapist performing the interventions will not be blind to the allocation of the participants.|Parallel group randomized controlled trial|t|f|f|t
33816876|NCT05061823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816877|NCT01991678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816878|NCT03770156|||COHORT||PROSPECTIVE|||||||
33816879|NCT03527758|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33816880|NCT06075576|||COHORT||PROSPECTIVE|||||||
33816881|NCT05121649|||OTHER||PROSPECTIVE|||||||
33816882|NCT04907877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816883|NCT06095115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34046948|NCT03909347|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Our study will use PRECEDE-PROCEED model for planning and evaluation of interventions to address our intervention delivery model using trained community health workers (CHWs) and community-participatory approaches. Predisposing factors of sociodemographic characteristics like caregiver age, gender, level of education, and English proficiency and the KA elder's Clinical Dementia Rating (CDR) score will be considered as covariates. Enabling factors for the study include caregiver's dementia literacy and self-efficacy in dementia care, and the KA elder's access to medical care, and reinforcing factors include social support and primary physician recommendation for cognitive testing.|f|f|f|t
34046949|NCT03670836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046950|NCT01960907|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046951|NCT03710382|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective pilot study with single group assignment||||
34046952|NCT00542399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046953|NCT02547142|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34046954|NCT00864019|RANDOMIZED|CROSSOVER||||NONE||||||
34046955|NCT06490536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046956|NCT05420363|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34046957|NCT06370000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046958|NCT00257335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34046959|NCT02490046|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34046960|NCT06382246|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled crossover design||||
34046961|NCT01161030|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34046962|NCT03265392|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34046963|NCT00481351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046964|NCT05473923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046965|NCT05167383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator only gets the anonymized prospective data from the patients|Prospective interventional Randomized Controlled Trial|f|f|t|f
34046966|NCT02673125|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34046967|NCT04266327|NA|SINGLE_GROUP||TREATMENT||NONE||Patients meeting the inclusion criteria were enrolled successively in the order of admission and treatment. The dose interval in this study was set as 110-130gy. A total of 30 patients were expected to be enrolled, including 15 patients 110-120gy and 15 patients 120-130gy.||||
34046968|NCT06544954|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|"Freeze-dried grape powder or placebo powder packets labeled A and 1."|Participants will limit intake of grapes and other polyphenol-rich foods while following their usual diet during the 3-day run-in period before the start of the intervention. They will be randomized to start with either grape or placebo powder for 4 weeks, consuming 40 grams of freeze-dried grape powder or placebo dissolved in water twice daily. Compliance will be assessed with three 24-hour dietary recalls using ASA24 and follow-up contact. After a 4-week washout period, participants will crossover to the other intervention. Study outcomes and anthropometry will be measured on the first and last days of each intervention arm, with the study lasting approximately 13 weeks for participants.|t|t|t|t
34046969|NCT05334810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046970|NCT01365078|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34046971|NCT06168942|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 1:1 to the Laminar Left Atrial Appendage Closure System or commercially available WATCHMAN and Amulet left atrial appendage closure devices. .||||
34046972|NCT06683352|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34046973|NCT06185179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Metformin and Placebo pills will be encapsulated by the pharmacy in order to protect treatment assignment|2-weeks single leg immobilization followed by 2-weeks of recovery|t|f|t|f
34046974|NCT01949701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046975|NCT01652768|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34046976|NCT03526874|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind greater occipital nerve injection of lidocaine versus saline after open-label lidocaine cream run-in|t|f|t|f
34126232|NCT04280991|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34126233|NCT05238350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The study was conducted as an experimental study with a pre-posttest and a control group.|t|f|f|f
34126234|NCT03864146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized controlled parallel group study design|t|f|t|t
34126235|NCT05901571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126236|NCT04770688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046977|NCT05140967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046978|NCT06142994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators will be provided with coded and identical products. Each individual involved in the study will be blinded to the assignment until study completion. Considering the established safety profile, emergency unblinding of treatment assignment will not be necessary, and no copies of the treatment assignments will be stored at the enrollment sites. If needed, the Investigators may receive information about the assignment of a particular subject only after review and approval by the Medical monitor. No information about the subjects will be shared with the company conducting the randomization.|Prospective, multicenter, double-blind, placebo-controlled, randomized, parallel-arm clinical study|t|t|t|t
34046979|NCT02488343|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34046980|NCT01506102|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
34046981|NCT00127998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046982|NCT01017523|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34046983|NCT05559801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34046984|NCT03687684|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
34046985|NCT03191461|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34046986|NCT04028804|||CASE_CONTROL||PROSPECTIVE|||||||
34046987|NCT05031195|||CASE_CONTROL||RETROSPECTIVE|||||||
34046988|NCT01965886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046989|NCT06299761|NA|SEQUENTIAL||TREATMENT||NONE||BBI-825 single agent dose escalation||||
34046990|NCT04057560|||COHORT||PROSPECTIVE|||||||
34126237|NCT00169702|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126238|NCT03531814|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126239|NCT02544750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126240|NCT00276406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34046991|NCT06685432|NA|SINGLE_GROUP||TREATMENT||NONE|"A total of 352 individuals who wanted to participate in the study were interviewed and informed about the study by phone. After the evaluation of the inclusion and exclusion criteria, preliminary data were collected from 172 individuals. The individuals included in the study were first stratified according to their BMI classes (25.0-29.9 kg/m2 slightly overweight and ≥30 kg/m2 obese). Then, the BMI classes were divided into the intervention and control groups in a balanced manner using the block randomization method. Randomization lists within each stratum were created with the help of the PASS software 11.0 (NCSS LLC, Kaysville, UT) using the Random sorting randomization algorithm (Maximum Permissible Deviation = 10%). In total, equal numbers of participants were randomly assigned to the experimental and control groups."|"The study included a control group and an intervention group. All participants received medical nutrition therapy. Also, participants in one intervention group were exposed to motivational interviewing techniques for weight loss.~The daily energy needs of the participants in the Medical Nutrition Program were calculated using the basal metabolic rate obtained with the Harris Benedict equation and the PAL (Physical activity level) value obtained from the average of three-day physical activity records (Total Energy Expenditure = BMR x PAL). In the study, a program was prepared in such a way that the daily energy intake of the participants in the nutritional treatment would provide a weight loss of 0.5-1 kg per week. Accordingly, it was aimed to reduce the participant's daily energy intake by approximately 500-600 kcal and provide a 10% kcal decrease in their body weight. A diet program containing 45-60% carbohydrate, 10-20% protein and 20-35% fat in the daily energy needs was applied."||||
34046992|NCT05206084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34046993|NCT03313466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34046994|NCT03486080|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded placebo controlled||t|t|t|t
34046995|NCT04894916|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34046996|NCT05875896|||COHORT||RETROSPECTIVE|||||||
34046997|NCT04231188|||OTHER||PROSPECTIVE|||||||
34046998|NCT02814162|||CASE_ONLY||PROSPECTIVE|||||||
34046999|NCT06147661|||CASE_ONLY||PROSPECTIVE|||||||
34047000|NCT06429787|||COHORT||PROSPECTIVE|||||||
34047001|NCT02858297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047002|NCT03878615|||COHORT||PROSPECTIVE|||||||
34047003|NCT06640335|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34047004|NCT05499221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|data will be sent blinded for statistical analysis|"Subjects will be randomly allocated into two groups:~1. Conventional anchorage CMA group (CAG): conventional mandibular anchorage using Essix retainer.~2. Skeletal anchorage CMA group (SAG): anchorage by infra-zygomatic mini-screws. In the CAG, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with Essix retainer in the lower arch as anchorage means. In the SAG, the closing coil spring will be attached from the maxillary canine to the infra zygomatic miniscrews bilaterally. For each patient, two lateral cephalograms will be obtained: one preoperatively and another after completion of distalization. Model measurements will be made using the attached 3Shape computer software."|f|f|f|t
34047005|NCT02764372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047006|NCT01515865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047007|NCT01293890|||COHORT||PROSPECTIVE|||||||
34047008|NCT02692872|||OTHER||OTHER|||||||
34047009|NCT05045079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047010|NCT03952299|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A: Oral Administration Current standard treatment at U.C. Davis Children's Hospital Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. Our current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.~Post-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital.~Group B: Transdermal Administration Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed."||||
34047011|NCT01397825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047012|NCT03064698|||COHORT||PROSPECTIVE|||||||
34047013|NCT03884530|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided into 2 groups. The first group formed of 85 patients will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours). The second group formed of 84 patients will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that. If the patients showed complications of the loading dose of ticagrelor (central or peripheral bleeding the dose will be minimized to 90 mg (1 tablet of 90 mg).||||
34047014|NCT02857946|RANDOMIZED|CROSSOVER||||NONE||||||
34047015|NCT03804229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047016|NCT00125242|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047017|NCT00445588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047018|NCT06051045|||COHORT||PROSPECTIVE|||||||
34047019|NCT01160081|||||PROSPECTIVE|||||||
34047020|NCT05903625|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||This clinical trial utilizes a cross-over design, administering multiple interventions to the same group of participants. The interventions include standard white bread, lysine-fortified bread, phosphorous-fortified bread, and a combination of lysine and phosphorous-fortified bread. Each participant receives these interventions in a specific sequence, with a washout period between each one to eliminate residual effects. This design allows for within-subject comparisons and minimizes individual variability. By examining the effects on glycemic index and postprandial glycemia, the cross-over design provides comprehensive insights. It enhances efficiency, statistical power, and enables the exploration of treatment interactions. Overall, this cross-over design allows for a thorough investigation of the impact of these interventions on glycemic index and postprandial glycemia in the study's participants.||||
34047021|NCT06120088|||COHORT||PROSPECTIVE|||||||
34047022|NCT04012593|||CASE_ONLY||PROSPECTIVE|||||||
34047023|NCT02693002|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34047024|NCT05969015|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes' assessors will be masked to assigned interventions in all measurements they would perform.|This is an effectiveness/pragmatic, parallel-arm, randomized, superiority trial.|f|f|f|t
34047025|NCT05445362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34047026|NCT04068584|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34047027|NCT01129440|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34047028|NCT05197608|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Participants will be randomized into intervention or control group.~The intervention group will be connected to a system navigator who is a trained staff member embedded within the primary health clinic team with a focus to address participant's biological, psychological and social needs. Control group will be provided a tailored list of community resources."||||
34047029|NCT02754427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047030|NCT05519644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Study product will be distributed in a blinded manner by people not involved with testing.|A double-blind, placebo-controlled, two-period cross-over study|t|f|t|f
34047031|NCT02185742|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34047032|NCT05832931|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047033|NCT01859169|||CASE_CONTROL||PROSPECTIVE|||||||
34047034|NCT06681961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a prospective, randomized-controlled trial.|Thirty PFPS participants were randomly assigned to conventional squatting (SQU) (n=15) or squatting with hip adduction (SQU-HA) (n=15) groups. Participants were blinded to the interventions used in the other group.|t|f|f|f
34047035|NCT02016105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047036|NCT01604928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047037|NCT04998604|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo injections will be administered as needed to blind the number of active dupilumab and omalizumab injections||t|f|t|t
34047038|NCT05175911|||COHORT||PROSPECTIVE|||||||
34047039|NCT03256929|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The first stage will be mapping all of the aged population of the research area, who will be interviewed (after receiving their consent) in order to determine those who are depressed. 200 depressed and pre-depression individuals (according to the GDS) will be chosen, and divided randomly into two groups- one will undergo the diet- driven microbiota adjustment personalized-intervention (nutrition advisory), and the other will get general information on nutrition and health .|t|f|f|f
34126241|NCT04149483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126242|NCT03091790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126243|NCT05034809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research assistant will explain to the parents and to the child if capable of understanding the clinical trial. However, the participants, family and the researcher will not know until the end of the study if they were placed in the control group or treatment group. Blinding will be done using a pre-generated number code and QR code which, when scanned by the research assistant at the end of the study, it will reveal to what group the patient was randomized.|Randomized Controlled Trial|f|f|t|f
34126244|NCT01764490|||COHORT||RETROSPECTIVE|||||||
34126245|NCT02871817|||OTHER||PROSPECTIVE|||||||
34126246|NCT02944838|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34126247|NCT04041232|NA|SINGLE_GROUP||TREATMENT||NONE||Two patients will receive PBA as treatment for ATF6-/- Achromatopsia.||||
34126248|NCT00002548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126249|NCT02385903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126250|NCT04020471|||COHORT||PROSPECTIVE|||||||
34126251|NCT05352984|||COHORT||PROSPECTIVE|||||||
34126252|NCT04750343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126253|NCT01433406||PARALLEL||||||||||
34126254|NCT05952297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Devices will appear the same but some devices will be placebo and some will be turned on as active. This is turned on remotely. A staff member who is blinded to the study screening and outcomes will conduct the randomization allocation.|For the first 28 days, participants will be randomized 1:1 to intervention vs. placebo. Following 28 days, all devices will be active from day 28 to 3 months.|t|t|t|t
34126255|NCT00678288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126256|NCT06549465|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34126257|NCT00331032|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126258|NCT01720303|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126259|NCT03526094|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Investigator processing samples and performing statistical analyses|Cross-over dietary intervention study in healthy young adult males|f|f|t|f
34126260|NCT01970228|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Intra-individual comparison of two diagnostic PET imaging tracers|t|f|f|f
34126261|NCT00843336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126262|NCT04078503|||OTHER||PROSPECTIVE|||||||
34126263|NCT06266559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126264|NCT01821326|||||RETROSPECTIVE|||||||
34126265|NCT04973995|||CASE_CONTROL||PROSPECTIVE|||||||
34126266|NCT01464645|||COHORT||PROSPECTIVE|||||||
34126267|NCT02296710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126268|NCT02460068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126269|NCT00837161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126270|NCT05216939|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34126271|NCT04168567|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34126272|NCT01877681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126273|NCT02109289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126274|NCT04099498|RANDOMIZED|PARALLEL||PREVENTION||NONE||A three-armed randomized controlled trial will be conducted and will include: a standard control group, with no intervention; an online-intervention group, with the program for 20-weeks; and an enhanced-online-intervention group, with the program for 20-weeks embedded with gamification strategies throughout.||||
33816884|NCT00716209|||CASE_ONLY||PROSPECTIVE|||||||
33816885|NCT03726528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126275|NCT01490216|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126276|NCT04379453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126277|NCT05850442|||COHORT||CROSS_SECTIONAL|||||||
34126278|NCT03884153|NA|SINGLE_GROUP||TREATMENT||NONE||Comparisons will be drawn from historic controls from previous observational stroke studies||||
34126279|NCT01160562|||||PROSPECTIVE|||||||
34126280|NCT03527511|||OTHER||CROSS_SECTIONAL|||||||
34126281|NCT01295307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816886|NCT02786277|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33816887|NCT05819177|||COHORT||RETROSPECTIVE|||||||
33816888|NCT05609864|||COHORT||PROSPECTIVE|||||||
33816889|NCT06212596|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomised on a 3:1 basis to receive either selinexor + cyclophosphamide + prednisone (SCP) or cyclophosphamide + prednisone (CP). A computer-generated minimisation programme that incorporates a random element will be used to ensure treatment groups are well-balanced for pre-specified factors:~* Age (\<60 vs. 60-69 years vs. ≥70 years )~* Number of prior lines of therapy (≤3 vs. \>3)~A maximum of 60 participants will be recruited (45 participants in the SCP arm, and 15 participants in the CP arm).~Participants who experience disease progression on the CP arm, may receive SCP, once progression has been confirmed by the CTRU and the participant has been deemed eligible to receive SCP. Patients randomised to SCP have no further trial treatment stipulated following SCP therapy. The analysis of the treatment switch phase of the trial is exploratory."||||
33816890|NCT05250362|NA|SINGLE_GROUP||TREATMENT||NONE||intervention: Expanded NK cells||||
33816891|NCT03321175|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomization will be performed by an online software. Randomized cards will be in sealed envelopes and will be open by surgeon at the time of surgery.|t|t|t|f
33816892|NCT03074968|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33816893|NCT03370861|||COHORT||PROSPECTIVE|||||||
33816894|NCT02240810|||COHORT||PROSPECTIVE|||||||
33816895|NCT01145326|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816896|NCT02033668|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816897|NCT04871932|||COHORT||PROSPECTIVE|||||||
33816898|NCT03867123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816899|NCT05651035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33816900|NCT02125799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816901|NCT06523803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816902|NCT02397902|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33816903|NCT06720376|||COHORT||PROSPECTIVE|||||||
33816904|NCT02496663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816905|NCT04973007|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|We have attempted to mitigate any potential conflict of interest through randomization of the order of exams and blinding the image evaluators to contrast agents.|This is a prospective study. The subjects will be randomized into two groups. Both groups will undergo two complete protocol liver MRs for known or suspected CRC metastasis, one exam with gadoxetate disodium and the other exam with gadobenate dimeglumine, within an interval of 3-10 days, but in opposite order, determined randomly. From the complete protocol liver MR with both contrast agents, an image set of abbreviated HBP protocol liver MR for each agent will be obtained (Fig.1).Two week-intervals will be placed between the evaluations of different image sets of a patient, and the images will be presented in a different random order to each evaluating radiologist. The schedule of random order of protocol liver MRs and presentation of images to radiologists will be determined by the project biostatistician.|f|f|f|t
33816906|NCT02183961|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816907|NCT05771545|||COHORT||RETROSPECTIVE|||||||
33816908|NCT02197494|RANDOMIZED|CROSSOVER||||NONE||||||
33816909|NCT01277302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816910|NCT01894321|||CASE_CONTROL||RETROSPECTIVE|||||||
33816911|NCT04024436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816912|NCT05809271|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||3-period, random order, placebo-controlled, double-blind cross-over study|t|t|t|f
33816913|NCT00083148|NA|SINGLE_GROUP||TREATMENT||||||||
33816914|NCT00124644||||TREATMENT||||||||
33816915|NCT05306158|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are three arms, one intervention (CC+ECIG Condition), one active comparator (CC Condition), and one Sham (control) arm which are randomly assigned at the same time (baseline) and are implemented in parallel.||||
33816916|NCT05816928|||COHORT||PROSPECTIVE|||||||
33816917|NCT01363206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816918|NCT02054442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816919|NCT05759143|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33816920|NCT06067958|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The units pharmacologist will be responsible for patient assignment and preparation of the medication / placebo syringes but will remain blinded to the other aspects of the trial. The patient's nurse, attending physician, ophthalmologist, investigator and outcome assessor will remain blinded to the patient allocation|This will be a crossover, prospective randomized controlled trial. Block randomization will be performed before the first eye examination. Every participant will undergo two eye examinations - one following exposure to dexmedetomidine and one following placebo.|t|t|t|t
33816921|NCT05064475|||COHORT||PROSPECTIVE|||||||
33816922|NCT02823886|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33816923|NCT04769947|||COHORT||PROSPECTIVE|||||||
33816924|NCT03574649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816925|NCT03430609|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label randomized clinical trial to be conducted at Lauro Wanderley University Hospital, at Federal University of Paraiba, from September 2017 to August 2020. Eighty-four patients will be randomly allocated to three groups according to the hemostatic technique used during laparoscopic surgery for ovarian endometrioma: bipolar coagulation, laparoscopic suture and hemostatic matrix. Ovarian function will be assessed by measuring serum anti-Mullerian hormone and by ultrasound antral follicle counts before surgery and 1, 3 and 6 months after surgery.||||
33816926|NCT05810285|||COHORT||CROSS_SECTIONAL|||||||
33816927|NCT06359483|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33816928|NCT00368225|||||PROSPECTIVE|||||||
33816929|NCT00237718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33816930|NCT06720441|||COHORT||PROSPECTIVE|||||||
33816931|NCT01072058|NA|SINGLE_GROUP||SCREENING||NONE||||||
34047040|NCT03107884|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|drug and placebo will be encapsulated therefore concealing the participant, investigator and outcome assessor to group assignment.||t|f|t|t
34047041|NCT00990457|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047042|NCT05269446|||COHORT||PROSPECTIVE|||||||
34126282|NCT03506139|NA|SINGLE_GROUP||TREATMENT||NONE||Group treated to 75 Gray of radiation to at-risk target||||
34126283|NCT00165906|||||PROSPECTIVE|||||||
34126284|NCT01834599|||COHORT||PROSPECTIVE|||||||
34126285|NCT00375427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126286|NCT02897687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126287|NCT00572104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126288|NCT03744195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be a single blinded study.Participants will be randomly allocated to Group (I)|Experimental study|f|f|t|f
33816932|NCT06636708|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|||t|f|t|t
34126289|NCT03604497|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34126290|NCT03843151|NA|SEQUENTIAL||TREATMENT||NONE||||||
34126291|NCT02135627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126292|NCT06237036|||COHORT||PROSPECTIVE|||||||
34126293|NCT04106544|NA|SINGLE_GROUP||OTHER||NONE||||||
34126294|NCT00542126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126295|NCT00730756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126296|NCT01356862|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34126297|NCT01367379|||CASE_CROSSOVER||PROSPECTIVE|||||||
34126298|NCT04513769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126299|NCT00994825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126300|NCT04144738|||COHORT||PROSPECTIVE|||||||
34126301|NCT06411613|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Test the feasibility and acceptability of a novel care program||||
34126302|NCT04858113|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34126303|NCT04294225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126304|NCT01285024|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126305|NCT05895305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126306|NCT04968626|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126307|NCT05072054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomized to two arms in ratio 1:1 using computer-generated random list. Patients, investigator and care provider will be blinded to the treatment group.|Randomized, double-blind clinical study|t|t|t|f
34126308|NCT00961272|||COHORT||PROSPECTIVE|||||||
34126309|NCT05163314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126310|NCT00803595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126311|NCT00041470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126312|NCT06209463|||COHORT||CROSS_SECTIONAL|||||||
34126313|NCT03183752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The same researcher blinded regarding location group will access thyroid volume and thyroid nodule volume by ultrasound, in the beginning, six months and one year after randomization|A randomized clinical trial with two groups: to use placebo or Metformine|t|f|f|t
33816933|NCT04246905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and researchers are blind to treatment allocation (double-blind). An independent researcher developed the computer-generated randomization plan.|Patients will be treated with sulforaphane or placebo for 12 weeks after ramdomization.|t|t|t|t
33816934|NCT00681135|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33816935|NCT01184755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816936|NCT05787197|||COHORT||PROSPECTIVE|||||||
33816937|NCT00409500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33816938|NCT06476483|RANDOMIZED|PARALLEL||OTHER||NONE||"Feasibility and acceptability study.~A mixed methods design will be used to meet the aims of this study. The study will consist of two parts, firstly quantitative; quasi-experimental group comparison design and secondly a qualitative design with data collection based on focus groups and additional surveys being distributed to patients who participate.~The independent variable will be membership of the comparison (DIALOG) or treatment (DIALOG+) group. The dependent variable will be scores on the DIALOG measure at the end of the intervention period."||||
33816939|NCT02005484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33816940|NCT02422355|||CASE_ONLY||PROSPECTIVE|||||||
33816941|NCT03839355|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33816942|NCT01461434|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33816943|NCT02594267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816944|NCT04906759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33837152|NCT04894097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patients in control group will be treated by sham radial extracorporeal shock wave therapy in addition to, the same design physical therapy program. Stimulation will not deliver as the transmitter head will be removed.~The patients will receive the same frequency of air pressure and"|"* The selected patients will be randomly assigned to two equal groups (study group (GI), and control group (GII).~* The study group (GI) will be treated by the radial extracorporeal shock wave in addition to design physical therapy program.~* The control group (GII) will be treated by sham radial extracorporeal shock wave in addition to the same design physical therapy program of (GI)."|t|f|f|f
33837153|NCT02251236|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126314|NCT01662739|||COHORT||PROSPECTIVE|||||||
34126315|NCT02780934|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126316|NCT00889850|RANDOMIZED|CROSSOVER||||NONE||||||
34126317|NCT05946161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126318|NCT01396187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126319|NCT04692012|NA|SINGLE_GROUP||TREATMENT||NONE|pseudophakic (Trifocal IOL) group 492 patients-246 eyes residual hyperopic group 34 patients-38 eyes|pseudophakic group hyperopic group myopic group||||
34126320|NCT04454346|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34126321|NCT00781443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34126322|NCT06191692|RANDOMIZED|PARALLEL||TREATMENT||NONE||Households will be randomized in a 1:1 ratio to the two treatment groups (1HP/3HR) using cluster randomization||||
34126323|NCT02626936|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34126324|NCT03972618|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34126325|NCT00347932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126326|NCT02993627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126327|NCT01813695|||CASE_CONTROL||PROSPECTIVE|||||||
34126328|NCT03658928|||COHORT||RETROSPECTIVE|||||||
34126329|NCT02345655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126330|NCT00348998||||TREATMENT||NONE||||||
34126331|NCT00267306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126332|NCT06059456|||OTHER||PROSPECTIVE|||||||
34126333|NCT01416740|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047043|NCT03971513|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Model description:~Randomization in 2 groups~* Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine if necessary Antimicrobial prophylaxis is performed according to recommendations.~* Experimental group: patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopan and morphine if necessary Antimicrobial prophylaxis is performed according to recommendations. In this group, a trans abdominal plane block, using 20 ml of ropivacaine 5 mg/ml is performed at the beginning of surgery, using ultrasound guidance."|t|f|t|f
34047044|NCT05808465|||CASE_CONTROL||PROSPECTIVE|||||||
34047045|NCT00835224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047046|NCT05956470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The people analysing the results/data were masked.||f|f|f|t
34047047|NCT06033976|||COHORT||PROSPECTIVE|||||||
33816945|NCT06605157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and care providers (music therapists, reading group leaders) will not be masked; both will know what is being received (music therapy or reading). Principal investigator Reschke-Hernandez and Co-Is Schmitt and Abner will remain masked to allocation. Care staff who collect behavior data will not be masked; care staff will know if the facility is receiving music therapy or reading. However, for all other outcomes, research assistants who assess participants will be masked to group assignment without knowledge of the intervention assigned to individual participants. Allocation and assignment information will be kept in a separate secure document that is not accessible to the PI or Co-Is.|To prevent cross-contamination, a research team member will randomize facilities as clusters (N=8) 1:1 to either the music or the reading intervention using a random number table. Opting for four clusters per arm will enable the researchers to estimate cluster effects and evaluate delivery across different care structures. The researchers will enroll at least 5 participants from each cluster/facility to provide a buffer against attrition to maintain a group of at least 3 individuals in each cluster. Delivery of both music and reading is in small groups (3-5 people).|f|f|t|f
33816946|NCT06003686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816947|NCT01540474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816948|NCT05718492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816949|NCT02649478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816950|NCT06337045|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Eligible participants were diagnosed with AF at the hospital and had symptomatic AF rated by the modified European Heart Rhythm Association (mEHRA) score ≥2B. If the patient was eligible based on the mEHRA-score, at least one of the following risk factors had to be present: hypertension, diabetes, obesity, smoking, excessive alcohol consumption, physical inactivity, sleep apnoea, anxiety, depression, or mental vulnerability.||||
33816951|NCT05921487|NA|SINGLE_GROUP||OTHER||NONE||"Intervention: This is a single-arm study in a convenience sample of Veterans with paraplegia and obesity.~Research Design: Those with mean eating windows of at least 10 hours per day will be eligible to participate in the TRE intervention. Tests for adherence (food log) will be collected."||||
33816952|NCT03029689|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33816953|NCT02395406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816954|NCT06721897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816955|NCT05942183|||COHORT||PROSPECTIVE|||||||
33816956|NCT04225871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816957|NCT06154837|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||The primary purpose of the study is to evaluate the safety, and tolerability of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disorder (COPD).|t|f|t|f
33816958|NCT04910204|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816959|NCT06721208|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33816960|NCT05719155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33816961|NCT04976322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816962|NCT00014235|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816963|NCT04150419|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33816964|NCT04552444|||CASE_CONTROL||RETROSPECTIVE|||||||
33816965|NCT05841030|||COHORT||PROSPECTIVE|||||||
33816966|NCT00816816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816967|NCT00282854|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33816968|NCT05104684|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fifty patients scheduled for HSCT at the bone marrow transplant will randomly be assigned into two groups; one will receive Chest Physical Therapy in addition to routine medical treatment and the control group will receive routine medical treatment only. Outcomes will be a pulmonary function that will be measured by spirometry and respiratory muscle strength measure by Respiratory Pressure Meter. Measurements will be before three weeks before then at the end of treatment immediately before Hematopoietic Stem Cell Transplantation and the last assessment at three weeks after hematopoietic Stem Cell Transplantation for all measured variables..||||
33816969|NCT02440256|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33816970|NCT02677688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816971|NCT02862288|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816972|NCT01249794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837154|NCT04623762|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33840201|NCT01644084|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047048|NCT06683391|RANDOMIZED|CROSSOVER||TREATMENT||NONE|open-label masking|Randomized controlled trial||||
34047049|NCT02605343|||CASE_CONTROL||PROSPECTIVE|||||||
34047050|NCT01590043|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34047051|NCT03255161|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34047052|NCT03493815|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34047053|NCT00024596|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34126334|NCT06138808|||COHORT||PROSPECTIVE|||||||
34126335|NCT06424821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126336|NCT00088270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126337|NCT02963883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126338|NCT06375239|||COHORT||PROSPECTIVE|||||||
34047054|NCT04696276|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34047055|NCT05908721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047056|NCT05632289|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34047057|NCT00002931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047058|NCT03014544|||COHORT||PROSPECTIVE|||||||
34126339|NCT00225862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34126340|NCT05060692|||CASE_CONTROL||PROSPECTIVE|||||||
33816973|NCT05967273|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"This will be a stepped-wedge cluster randomization of primary treatment teams. We will have 8 clusters consisting of at least one teaching medicine team, one non-teaching medicine team, one intensive care team, and equal numbers of other teams. The clusters will be assigned to the CirrhosisRx CDS intervention versus usual care with clusters crossing over from usual care to CirrhosisRx at 4 month intervals. All clusters will eventually be exposed to both arms of the study."||||
33816974|NCT04993976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816975|NCT04232410|||COHORT||PROSPECTIVE|||||||
33816976|NCT04058847|RANDOMIZED|PARALLEL||PREVENTION||NONE||Cluster-randomised clinical trial with 1 year follow up. The general practitioners are randomised into an intervention group and a control group. Participants automatically follow their general practitioner into the allocated group.||||
33816977|NCT01086514|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33816978|NCT02976363|||COHORT||PROSPECTIVE|||||||
33816979|NCT00559195|NON_RANDOMIZED|||SUPPORTIVE_CARE||||||||
33816980|NCT06327997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33816981|NCT06492226|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33816982|NCT06496867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816983|NCT01292005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33816984|NCT04505215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33816985|NCT05586165|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33816986|NCT04650763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816987|NCT03286998|||COHORT||PROSPECTIVE|||||||
33816988|NCT06181513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33816989|NCT03347084|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Participants and the participants' caregivers will be blinded to arm assignment.|"Participants will be randomly assigned to one of two LIFUP pulsing paradigms: one that excites the activity of hippocampal neurons (Paradigm A), or a second that inhibits them (Paradigm B). The participants will then be administered four successive LIFUP treatments while the participants are in a functional magnetic resonance imaging (MRI)."|t|f|f|f
33816990|NCT06361056|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33816991|NCT05942664|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|Participants and investigators are blinded to power output during the time trial||t|f|t|f
33816992|NCT06566612|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33816993|NCT01912599|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33816994|NCT05660811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816995|NCT03424187|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33816996|NCT06721468|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Objective 1: Two untrained consumer panels will provide sensory evaluation on three different strains of trout (fish-meal diet, CX line, CLX line).~Objective 2: A within subjects, pre/post design will be employed to compare the effect of repeated exposure (RE) and repeated exposure plus child centered nutrition phrases (RE+CCNP) on eating behaviors of children 4-6 years of age.~Objective 3: A 12-week quasi-experimental design will be employed to capture the translational impact of repeated exposure and nutrition education to the home setting on intake of whole CX line trout and the effect on adult and youth cognitive and emotional wellbeing outcomes. A control and three treatment groups will be recruited from a convenience sample of Eat Smart Idaho participants in northern and south central Idaho."||||
33816997|NCT06334718|||CASE_ONLY||CROSS_SECTIONAL|||||||
33816998|NCT00817739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33816999|NCT02816645|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33817000|NCT04165213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33817001|NCT01622023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33817002|NCT06193382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817003|NCT04080778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817004|NCT04133636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817005|NCT05071105|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Time to Event Key-Board, a dose escalation design study.||||
33817006|NCT06290453|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33817007|NCT03713307|||COHORT||PROSPECTIVE|||||||
33817008|NCT05746585|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817009|NCT03529942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817010|NCT06470373|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a multinational, multi-center, randomized, double-masked, parallel, phase 3 clinical study.|t|t|f|f
33817011|NCT02933645|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33817012|NCT04879823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double blind placebo controlled randomized clinical trial|t|t|t|t
33817013|NCT05881161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will not be informed about condition allocation. Both groups will undergo the same internet intervention (Med-Stress Student) but the experimental group will complete additional procedure at the start of the intervention.||t|f|f|f
33817014|NCT06442462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817015|NCT06291935|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817016|NCT06716970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817017|NCT00360035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047059|NCT05404646|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047060|NCT03658538|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34126341|NCT00825695|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126342|NCT04335630|||CASE_CONTROL||RETROSPECTIVE|||||||
34126343|NCT05101811|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel study||||
34126344|NCT03299478|||COHORT||PROSPECTIVE|||||||
34126345|NCT01447823|||COHORT||PROSPECTIVE|||||||
34126346|NCT04836611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126347|NCT04796558|||COHORT||PROSPECTIVE|||||||
34126348|NCT04439864|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34126349|NCT02030106|||COHORT||PROSPECTIVE|||||||
34126350|NCT05401539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the process of assignment of children into groups, randomization is achieved in the computer by stratifying them in terms of sex and age variables (https://www.randomizer.org/).|This randomized controlled and experimental study will be conducted in the pediatric surgery clinic of a university hospital. Randomization of the children will achieve by checking the children at the beginning of each week and on the day of surgery according to the planned surgery lists. The VR tour provided with a 360° video is prepared to make the child be acquainted with the preoperative preparation process.The VR tour video feature actual nurses and physicians working in the surgery clinic and operating theatre. A professional VR company will performe filming in the hospital's operating theatre. The VR video is then will turn into an app for mobile devices. The children will assign into the VR-Documentary Film Group, VR- Operating Theater Tour Group and Control Group. A parallel trial design will use. Cardboard VR glasses, a non-pharmacological approach and a 3D imaging method, will use by the children to watch the movies.|t|f|f|t
34126351|NCT02453698|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34126352|NCT00286091|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126353|NCT03855345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be present during the treatments, so he will not know to which group the participants belong.||f|f|f|t
34126354|NCT01881009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126355|NCT05340673|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126356|NCT04212715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126357|NCT06239883|||CASE_ONLY||PROSPECTIVE|||||||
34126358|NCT04390269|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126359|NCT05290662|||COHORT||PROSPECTIVE|||||||
34126360|NCT00402844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126361|NCT02148263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126362|NCT02867228|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126363|NCT01282385|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34126364|NCT03573388|||COHORT||RETROSPECTIVE|||||||
34126365|NCT00001964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126366|NCT06521814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126367|NCT01227226|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34126368|NCT02895516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126369|NCT03940989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blinded to activities that the participant is working on during camp||f|f|f|t
34126370|NCT01135992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126371|NCT05043181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126372|NCT02147795|||COHORT||PROSPECTIVE|||||||
34126373|NCT04463537|NA|SINGLE_GROUP||OTHER||NONE|A total of 143 patients who fit the inclusion criteria of the study were included in the sample. The research carried out between 1 November - 31 December 2016 in the emergency department. Body temperature measurements were carried out on the patients in the study firstly by not changing the position of the auricle and then repeated after a minute, this time by changing the position of the auricle.|a quasi-experimental design with a pre-test and a post-test.||||
34126374|NCT04616170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistician performing the primary analysis will be blinded to the assignment of the patients|Patients will be assigned to usual care or hip extension at the time of delivery of the fetal vertex|f|f|f|t
34126375|NCT05949580|||COHORT||PROSPECTIVE|||||||
34126376|NCT03949868|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants are not aware of how the conditions differ, nor are they aware of how many conditions there are.||t|f|f|f
34126377|NCT05710003|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|single group pf patients and follow up effect of breathing exercises and upper limb exercises in perceived dyspnea and quality of life(fatigue scores)|This study will include pregnant ladies presented to respiratory outpatient clinic with physiological dyspnea at the third trimester of pregnancy||||
34126378|NCT03847948|||COHORT||PROSPECTIVE|||||||
34126379|NCT06049147|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34126380|NCT04588636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In the first session, operator A explained to the study subjects the alternatives, benefits and possible complications of the treatments, but it was indicated that at the time of delivery of the treatment it would not be explained to them in which group they were assigned in order to protect blinding of treatments. Operator B was in charge of delivering the treatments randomly among the subjects selected by operator A. Finally, the controls were carried out by operator A in order to protect the blinding by not knowing the treatments of the patients at the time controls.|To protect the blinding of the study, it was carried out by two operators: A (examiner) and B (therapist). The treatment of the subjects consisted of 5 sessions: (1) evaluation and diagnosis of recruited subjects, and taking an impression of the upper jaw by operator A; (2) teaching BST and delivery of OS by operator B; (3) first treatment control and BST booster at 2 weeks; (4) second treatment control and BST booster at 6 weeks; (5) third control of treatment and removal of OS if it corresponds to 10 weeks. All controls were performed by operator A in order to use a blind design without the knowledge of the outcome assessor. To protect this, it is explained to the subject that operator A cannot know the treatment that was delivered. Operator B delivered the treatments at random among the subjects selected by operator A after the initial examination, being himself in charge of contacting them and delivering the corresponding treatment.|t|f|f|t
34126381|NCT00705874|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126382|NCT01701908|||COHORT||PROSPECTIVE|||||||
34126383|NCT06032858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126384|NCT02318836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151141|NCT03930992|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Study type: Interventional, with four arms:~1. arm: 4 mg zoledronic acid annually plus colaren ® in HIV-positive;~2. arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-positive;~3. arm: 4 mg zoledronic acid annually plus colaren ® in HIV-negative;~4. arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-negative."||||
34151142|NCT02519569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151143|NCT01424280|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34151144|NCT04502368|||CASE_ONLY||PROSPECTIVE|||||||
34151145|NCT01912534|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047061|NCT06544291|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The study medication will be prepared by the CMHC research pharmacy using over-encapsulation.|This phase 2 study will utilize a double-blind, placebo-controlled, crossover experimental design. We will enroll 147 participants with co-occurring OUD and chronic pain who are receiving methadone maintenance treatment and randomize them into three groups (n=49). Across three test sessions, each group will receive single doses of THC (5 mg, 10 mg, or placebo) and CBD (300 mg, 600 mg, or placebo) in a 3x3 design, with THC dose as a between-subject (parallel-group) factor and CBD dose as within-subject (crossover) factor.|t|f|t|f
34047062|NCT05263089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34047063|NCT00212342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047064|NCT05127213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047065|NCT05695014|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34047066|NCT01372293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047067|NCT06522087|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34047068|NCT02580292|||COHORT||PROSPECTIVE|||||||
34047069|NCT02782923|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047070|NCT00789256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047071|NCT00247611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047072|NCT05593549|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomized to either active or placebo supplementation, acting as their own control.|t|f|f|t
34047073|NCT02142959|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34047074|NCT04887740|||COHORT||RETROSPECTIVE|||||||
34047075|NCT03309384|||COHORT||PROSPECTIVE|||||||
34047076|NCT05813431|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047077|NCT01742676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047078|NCT04182308|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34047079|NCT00060554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34047080|NCT02144298|||COHORT||PROSPECTIVE|||||||
34047081|NCT06288295|||COHORT||RETROSPECTIVE|||||||
34047082|NCT04964739|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047083|NCT06436950|RANDOMIZED|PARALLEL||TREATMENT||NONE||Transcutaneous electrical phrenic nerve stimulation (TEPNS) group: TEPNS+usual care Control group: usual care||||
34047084|NCT03017378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047085|NCT03508726|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047086|NCT02993328|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047087|NCT03887026|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34047088|NCT01862250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047089|NCT00090493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047090|NCT04321174|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34047091|NCT03254303|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|particippant, investigator, outcomes assessor|randomized and crossover assignemnt|t|f|t|t
34149185|NCT05575908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"It is not possible to blind the participants or the care providers. As the investigators also will be care providers in this study, they will also have knowledge of the allocation.~After the intervention, all data will be depersonalized and the name and other identifiers will be replaced by a study number. The outcome will be collected from national registries and the merging of data will be done by a statistician in the labor- and welfare administration who is not involved in the assessment of data. This allows the researchers to be blinded when they analyze the data."|Sick-listed employees with musculoskeletal disorders and/or common mental disorders will receive an invitation to the study from the labor-and welfare administration. Individuals who consent to participate will be allocated to either treatment as usual or personalized advice from an expert-team.|f|f|f|t
34149186|NCT02699190|||COHORT||OTHER|||||||
34149187|NCT01732913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047092|NCT03028909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047093|NCT01137058|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047094|NCT06003179|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be enrolled in two stages: the dose escalation stage to assess the safety and tolerability of a modified LD regimen, and once the maximum tolerated dose (MTD) is determined, a cohort expansion phase to further characterize the toxicity and efficacy profile and determine the recommended phase 2 dose (RP2D). The study will enroll approximately 20-40 patients in the dose escalation stage (Part 1), and approximately 20 further patients at cohort expansion (Part 2).||||
34047095|NCT03090958|NA|SINGLE_GROUP||OTHER||NONE||In order to assess the feasibility and acceptability of the app. 20 participants will be enrolled in a one month pilot trial. After being screened for eligibility, the research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.||||
34047096|NCT00599287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34047097|NCT04788602|||COHORT||RETROSPECTIVE|||||||
34047098|NCT05229159|||COHORT||PROSPECTIVE|||||||
34047099|NCT03211260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047100|NCT05519358|||CASE_ONLY||PROSPECTIVE|||||||
34047101|NCT01266720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047102|NCT02653118|||COHORT||PROSPECTIVE|||||||
34047103|NCT02196571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047104|NCT06682468|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patient randomization will be completed by an honest broker and blinded to the research team.|Participants will be enrolled into two group intervention and standard care. Patients randomized to the intervention arm will not be blinded to the intervention and will receive the NIDA quick screen via MyChart and at clinic appointments. Patients randomized to the usual care group will receive the NIDA quick screen during appointments with their clinicians and, thus, be blinded to trial assignments. HIV clinicians have been informed of the intervention and will not be informed of the randomization assignment. Still, clinicians will receive NIDA quick screen results when the patient completes the screener via MyChart.|f|f|t|f
34047105|NCT00638222|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33817018|NCT06618001|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817019|NCT06315621|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33817020|NCT05498428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817021|NCT06721533|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33817022|NCT05262660|||COHORT||PROSPECTIVE|||||||
33817023|NCT04203368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33817024|NCT05324748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Bi-centre, randomized, double-blind, placebo-controlled retention trial|t|t|t|t
33817025|NCT00947804|||COHORT||CROSS_SECTIONAL|||||||
33817026|NCT03933735|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817027|NCT01972373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817028|NCT00606723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817029|NCT05820451|||OTHER||RETROSPECTIVE|||||||
33817030|NCT01636700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817031|NCT01497678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817032|NCT04004923|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33817033|NCT00856453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817034|NCT03240471|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33817035|NCT03633045|||COHORT||PROSPECTIVE|||||||
33817036|NCT05722821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For the assignment to the groups, a random sampling will be carried out using the Epidat program. This classification will be hidden, therefore, those responsible for admitting the patients to the intervention phase will not know to which group each one has been assigned. Said assignment will be made previously by a researcher who will not intervene in the subsequent phases of evaluation, data recording intervention and database preparation. The assignment will be communicated using fully opaque sealed envelopes. The analysis of the results will be carried out by a researcher unrelated to the group assignment and the intervention.||f|t|t|t
33817037|NCT05374967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817038|NCT01393964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817039|NCT06587360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Fertility Healthcare Provides (FHPs) will be randomised on a 1:1 ratio via computer-generated randomisation to have access to the fertiShare eLearning or a control condition eLearning (basic communication training), via a URL. Only the creative company responsible for the technical development of fertiShare know which URL (URL a or b) provide access to fertiShare and the control eLearnings. No trial participant (FHPs, patients), clinic managers and/or gatekeepers will be informed of the randomisation result. The trial management team (SG, JB) will know if participants were allocated to URL a or b. The data analyst will not know any randomisation result.||t|t|t|t
33817040|NCT02700009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817041|NCT03974308|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Comparison of the level of pain, life satisfaction and level of disability in people with degenerative spine disease which:~1. use the spa treatment~2. use complex physiotherapy in the place of residence~3. don't use physiotherapy, ad hoc pharmacotherapy"||||
33817042|NCT04050722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind||f|f|f|t
33817043|NCT02857686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817044|NCT06574724|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33817045|NCT06720220|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33817046|NCT02237456|||COHORT||PROSPECTIVE|||||||
33817047|NCT02085824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33817048|NCT02861716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817049|NCT04088305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817050|NCT06506630|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33817051|NCT01852851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817052|NCT00748098|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33817053|NCT00674791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817054|NCT05364073|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817055|NCT06211751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817056|NCT05542589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817057|NCT02192645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817058|NCT04800978|NA|SINGLE_GROUP||TREATMENT||NONE||"•Part A: Open-labeled; 3+3 dose-escalation; Multi-center; safety lead-in phase~•Part B: Open-labeled; Non-randomized, Single arm; Multi-center, efficacy evaluation phase"||||
33817059|NCT03284840|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33817060|NCT02364674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817061|NCT05884671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||This is a within-subjects (i.e., crossover), double-blind, randomized placebo-controlled study.|t|f|t|t
33817062|NCT05524935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149188|NCT01731067|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34149189|NCT01009749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817063|NCT06452095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded to intervention in so far as the HBOT experience will be similar between treatment and sham arms.|"RECLAIM is a Canada-wide phase ll/lll, prospective, adaptive randomized controlled platform trial that is intended to study various interventions for patients with long COVID. Interventional arms may be discontinued based on interim analysis results and new interventions may be selected and included as part of the platform as the trial progresses. As such, the protocol and consent documents are a modular design.~The HBOT arm includes:~* Master Protocol and informed consent documents: Contain information applicable to the whole platform.~* HBOT Sub-Protocol: Contain additional information, specific to the HBOT interventional arm."|t|f|t|t
33817064|NCT05457647|NA|SINGLE_GROUP||OTHER||NONE|"Outcome assessor is masked. Statistician is masked. Participant receives stratification to either corneal cross-linking protocol after consent form signature.~All participants wear contact lens after treatment until first postoperative eye examination at 1 week, when the corneal epithelium is completely healed."|One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, Epi-OFF, or transepithelial, Epi-ON, treatment protocol. Only one eye of each participant is designated as the study eye.||||
33817065|NCT02700386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817066|NCT05356065|||COHORT||PROSPECTIVE|||||||
33840202|NCT06381453|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840203|NCT00905320|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33817067|NCT05570344|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because it will not be possible for participants to be blinded, treatment allocation will be made explicit to them as soon as randomization is concluded. Primary outcome assessors will be blinded to treatment group allocation by not involving them in discussions about study participants and not granting them access to the database which contains the randomization code. After data collection is complete, all data will undergo a blind review for the purposes of finalizing the planned analysis.|This is a prospective, Multicenter, two-arm randomized controlled trial. 200 patients diagnosed with resistant depression in psychiatric care clinics in Edmonton, Alberta, and Nova Scotia, Canada will be randomized to one of two conditions: (1) enrolment in rTMS sessions alone (2) enrolment in the rTMS sessions plus Text4Support.|f|f|f|t
33817068|NCT03473275|||CASE_CONTROL||PROSPECTIVE|||||||
33817069|NCT05982756|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Remove masking if necessary||t|t|t|t
34047106|NCT06420466|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized Controlled Trial|t|f|f|f
34047107|NCT02868814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047108|NCT03617614|||COHORT||PROSPECTIVE|||||||
34047109|NCT05673577|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|||||
33817070|NCT04493307|||OTHER||PROSPECTIVE|||||||
33817071|NCT05206552|||COHORT||PROSPECTIVE|||||||
33817072|NCT04304378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817073|NCT06332391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects and outcomes assessors are blinded to study group (intervention vs. sham) but investigator is not. During intervention vs. sham, subjects do not have access to vital sign data and sham procedures follow intervention procedures exactly with the exception that no change in pacing rate is delivered. A blinding questionnaire is given to subjects to assess adequacy of blinding.|Prospective, single blinded, randomized, controlled trial. Randomization to intervention versus sham groups in a 1:1 ratio.|t|t|f|t
33817074|NCT02301117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817075|NCT05999877|||COHORT||OTHER|||||||
33817076|NCT02799745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817077|NCT00907933|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817078|NCT00555620|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817079|NCT03394508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817080|NCT04109209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817081|NCT03460132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817082|NCT05564221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"As the YH35324 group and placebo group will be double-blinded, YH35324 and placebo will have the same appearance and packaging. Therefore, the double-blind will apply to the subjects, investigators, study coordinators, and study personnel including study pharmacists.~The active control omalizumab has a different appearance and packaging from YH35324 and placebo, and will be administered in an open-label manner."||t|t|t|t
33817083|NCT06143293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||For all participants, study interventions will occur primarily at two visits scheduled 12 weeks apart at the applicable study sites (Visit 1 and Visit 2). Within Visit 1, the CSP is a cross-over design to compare the 3 frequency parameters at a set duty cycle; each participant will receive each frequency in a randomized order and this order will be repeated at Visit 2. Visit 1 and Visit 2 together are a cross-over design to compare the 2 duty cycles; each participant will receive one duty cycle at Visit 1 and the other duty cycle at Visit 2 in a randomized order.|t|f|f|f
33817084|NCT02722278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817085|NCT03020914|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817086|NCT06678256|||COHORT||PROSPECTIVE|||||||
33817087|NCT01018992|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33817088|NCT05213585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor is blind to which eye was treated. This is a single arm study in that only 1 treatment protocol is being tested in one eye and the contralateral eye is being used as the control. Masking of the outcomes assessor is being done to eliminate bias from the treating physician.|The untreated eye will be observed in parallel with the contralateral treated eye.|f|f|f|t
33817089|NCT04019301|RANDOMIZED|PARALLEL||OTHER||NONE||Cancer caregivers will be randomized to one of three conditions: (1) a community-based qigong program; (2) an internet-based qigong program; or (3) a self-care control group.||||
33817090|NCT02556606|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||We use a Bayesian, adaptive, randomized design initially allocating subjects to 2 arms in a 1:3 ratio: ARM 1: MID 0.03 mg/kg (active placebo); ARM 2: four conditions KET 0.1 mg/kg, KET 0.25 mg/kg, KET 0.5 mg/kg or MID 0.03 mg/kg. After 1:1:1:1 allocation of the first 20 subjects to ARM 2, Bayesian adaptive randomization may stop for superiority, change randomization ratios and/or prune arms for futility based on the probability of a day 7 treatment response. ARM 1 remains open for allocation to ensure a placebo group sufficiently large for comparison with best dose KET. For analyses, MID of ARM 1 and ARM 2 will be combined so that there are 4 conditions (or arms) for final statistical analyses. We expected to enroll a maximum 72 patients.|t|t|t|t
33817091|NCT03140345|||OTHER||CROSS_SECTIONAL|||||||
33817092|NCT03928665|||CASE_CONTROL||PROSPECTIVE|||||||
33817093|NCT06717503|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817094|NCT03373188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817095|NCT01989156|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817096|NCT06114537|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized into the treatment group or the control group.||||
33840204|NCT00212394|||||PROSPECTIVE|||||||
33840205|NCT03480477|||COHORT||RETROSPECTIVE|||||||
34047110|NCT00911612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047111|NCT04388475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047112|NCT01849081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047113|NCT02610543|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047114|NCT06006533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||kinesio taping and percussive massage techniques|f|f|f|t
34047115|NCT02986542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34047116|NCT01725022|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047117|NCT03150511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047118|NCT04920396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Ocular assessment will be undertaken by a researcher masked to the participants treatment allocation|Randomized allocation between treatments|f|f|t|f
33817097|NCT06570993|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Trial participants will be aware of the intervention to which they have been allocated, and the research fieldworkers will be aware of the intervention allocation. The trial steering committee members and trial statistician will remain blinded until the end of trial period and data collection.||f|f|t|t
33817098|NCT05196256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized by envelopes. A non-blinded anesthesiologists will perform the anesthetics technique and leave the room immediately; a blinded anesthesiologists will do the data collection and act according to protocol if the patient in case of pain non controllable by the patient controlled anesthesia, in case of hypotension or any other possible complications.||t|t|t|t
33817099|NCT06130904|RANDOMIZED|PARALLEL||OTHER||SINGLE|The analysts will be blinded using codes to prevent bias in analysis.||f|f|f|t
33817100|NCT00070161|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE||||||
33817101|NCT02670408|||COHORT||PROSPECTIVE|||||||
33817102|NCT01892982|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33817103|NCT06068257|||CASE_CONTROL||RETROSPECTIVE|||||||
33817104|NCT06062147|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817105|NCT01123044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817106|NCT01998334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817107|NCT01241032|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33817108|NCT02721849|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33817109|NCT05888493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817110|NCT01923935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817111|NCT02189785|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817112|NCT05033158|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817113|NCT03463122|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33817114|NCT01458288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817115|NCT02167230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817116|NCT03586739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817117|NCT03369119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817118|NCT03472118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817119|NCT06060847|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients 18 years old and older, affected by hepatocellular carcinoma (HCC) with metabolic syndrome (MS) as unique risk factor, with compensated liver function (Child A) who are deemed suitable for liver resection and comply with the criteria for bariatric surgery, will undergo liver resection of HCC and simultaneous sleeve gastrectomy for morbid obesity during the same surgical procedure.~Patients affected by HCC related to metabolic syndrome who fall within exclusion criteria, will undergo liver resection for HCC without sleeve gastrectomy."||||
34126385|NCT06199804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The population of the research consisted of mothers with children aged 1-3 and 4-6 who were treated as inpatients in the pediatric clinics of a public hospital in the central Anatolia region of Turkey between January and August 2023.~Inclusion Criteria;~* Mothers with children in the play (1-3) and preschool (4-6) periods~* Those who keep toys (plastic, metal, wooden, technological) with their children~* Mothers who are always with their children as companions~* Mothers whose children receive inpatient treatment for at least 3 days Exclusion Criteria;~* Mother has hearing, vision or mental problems~* The mother has been diagnosed with OCD (Obsessive Compulsive Disorder) or has an obsession with cleaning.~* Not being able to speak Turkish~* Being under 18 years of age~* Do not place the child in isolation (contact isolation, droplet isolation, respiratory isolation)."|In this study, stratified randomization method was used to determine the intervention and control groups. It is emphasized in the literature that the variables that affect children's compliance with hospital rules are affected by the education level of the mother and the age of the child. Therefore, to ensure homogeneity in the groups, they were stratified as the mother's education level (primary school, high school, university) and age group (1-3 and 4-6). In the study, randomizer.org was used to select 6-block A and B block combinations. Eligible participants were randomly assigned to experimental and control groups using the permuted block randomization method on a 1:1 basis.|f|f|t|f
33817120|NCT05835856|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817121|NCT06374407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be blinded to their group assignment and will use a smartphone app for meal planning. However, those in the intervention group may have some awareness of their assignment due to specific food choices. Meanwhile, the control group will have access to a variety of foods and recipes, maintaining blinding between the groups regarding their assigned diets, addressing a common challenge in diet intervention studies.|We plan to randomly assign participants to either the intervention or control group.|t|t|t|t
33817122|NCT03555617|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33817123|NCT06719882|||COHORT||PROSPECTIVE|||||||
33817124|NCT05567185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34126386|NCT01439737|||COHORT||PROSPECTIVE|||||||
33817125|NCT00224198|||CASE_CONTROL||PROSPECTIVE|||||||
33817126|NCT02655900|||COHORT||PROSPECTIVE|||||||
33817127|NCT05179109|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, controlled clinical trial with an allocation ratio of 1:1.||||
33817128|NCT03034772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind||t|f|f|f
33817129|NCT03059056|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33817130|NCT04853394|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||cluster-randomized parallel groups|t|f|f|t
33817131|NCT05722756|||COHORT||RETROSPECTIVE|||||||
34126387|NCT05014373|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126388|NCT06419439|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|Participants in the second phase only will be blinded to the arm (intervention+minimally enhanced usual care vs minimally enhanced usual care alone).|This study will occur in two phases which will occur sequentially and have different designs. The initial phase is a single-arm open-label, nonrandomized, non-blinded pilot study (n=5). The objective is to develop and assess initial feasibility of study procedures and obtain participant feedback through semi-structured exit interviews. The subsequent phase, informed by these findings, will consist of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT.|t|f|f|f
34126389|NCT00634140|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34126390|NCT02628444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126391|NCT05109962|||COHORT||RETROSPECTIVE|||||||
34126392|NCT02374060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126393|NCT00650052|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817132|NCT00719056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817133|NCT05272631|||COHORT||PROSPECTIVE|||||||
34126394|NCT00618735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126395|NCT00551031|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126396|NCT03710356|NA|SINGLE_GROUP||TREATMENT||NONE||phase ½ therapeutic trial stratified on disease (Severe Hematologic or Pulmonary Disease)||||
34126397|NCT05922007|||COHORT||PROSPECTIVE|||||||
34126398|NCT02709577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126399|NCT02002507|||COHORT||PROSPECTIVE|||||||
34126400|NCT01679938|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126401|NCT05346276|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants with various types of cancer undergo 68Ga-DOTA-hLAG-3 PET/CT for comprehensively evaluation of LAG-3 expression.||||
34126402|NCT04345484|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126403|NCT00178997|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126404|NCT00457678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients with~AMD will be randomly assigned to one of 2 treatments:~* Continuation of previous Lucentis monotherapy (50 patients)~* V-L-D triple therapy with half fluence (300 mW/cm2 for 83 seconds) Visudyne followed within 2 hours by intravitreal Lucentis 0.5 mg (first injection) and intravitreal dexamethasone 0.5 mg (second injection) (50 patients)"|t|f|f|f
34126405|NCT01232816|||COHORT||PROSPECTIVE|||||||
34126406|NCT03691298|||CASE_ONLY||PROSPECTIVE|||||||
34126407|NCT03005730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126408|NCT06511947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"This study will include separate single- and multiple-dose parts.~Part 1 (Single-Dose Part):~An open-label, non-randomized, parallel design where subjects will be assigned to receive single doses of GH001 delivered via a proprietary aerosol delivery device on a single day in three consecutive cohorts (Cohorts A, B, and C) with eight subjects per cohort. Up to two additional cohorts (Cohorts D and E) may be added before Part 2 is initiated.~Part 2 (Multiple-Dose Part):~An open-label, non-randomized design where up to three escalating doses of GH001 will be administered to subjects via a proprietary aerosol delivery device on a single day in one cohort of 12 subjects (Cohort F)."||||
34126409|NCT03191162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126410|NCT00255216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34126411|NCT06009250|||CASE_CONTROL||RETROSPECTIVE|||||||
34126412|NCT02331953|||CASE_CONTROL||PROSPECTIVE|||||||
34126413|NCT00148031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126414|NCT05879809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126415|NCT02309658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126416|NCT05709366|||OTHER||CROSS_SECTIONAL|||||||
34126417|NCT00285285|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126418|NCT00876863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126419|NCT04364815|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Randomized allocation concealment~1. Computer-generated random numbers for two groups will be used by a third party to create an allocation list for participants~2. The pharmacist will prepare the test medication in sequentially numbered packages~3. The third party will be contacted upon enrollment of a participant for the assigned group~Blinding~1. Placebo tablets will have the same appearance as the HCQ tablets~2. The pharmacist will prepare the test medications in sequentially numbered packages~3. Blinding of the outcome assessor will be achieved by using numerical codes on the Case Record Form of each patient with no indication of the group assignment on the Case Record Forms~4. Laboratory specimens, ECG strip, and RT-PCR test specimens will be labeled with the numerical code of the participant and test number"|Randomized, assessor- and patient- blinded, placebo controlled, parallel group trial|t|f|f|t
34126420|NCT05749367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In the control group, patients will undergo SIFIB with ropivacaine and to maintain the masking they will also undergo PENG and LFCNB with saline solution (sham block). In the experimental group, patients will receive ropivacaine in the PENG block associated with LFCNB and saline solution in the SIFIB. All the work of randomization, editing of the spreadsheet, manipulation of the envelopes, as well as the confidential tabulation of the data during collection will be done by an assistant who will not participate in the anesthesia or data collection. The opening of the envelopes and the preparation of the material for anesthesia will also be done by an assistant who will not participate in the evaluation of the outcomes. The researcher will perform all the procedures and data collection and will not know which group the participant belongs to. The patient will also not know in which group he or she is allocated.|Prospective, controlled, randomized and double blind|t|t|t|t
34126421|NCT02681367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126422|NCT04114071|RANDOMIZED|PARALLEL||OTHER||SINGLE|All participants will receive text messages during the 12-week intervention but the frequency, the content of the messages will be different for the control and intervention groups, and these differences will not be discussed.|The researchers hypothesize that older overweight or obese Black women who participate in the PA intervention group (TOSS text messages plus Fitbit) will show increases in self-report and objective (assessed by accelerometer and a Fitbit) PA behaviors compared to the control group.|t|f|f|f
34126423|NCT02454530|||COHORT||PROSPECTIVE|||||||
33817134|NCT02962076|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817135|NCT04528368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817136|NCT03554200|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This trial is double-blinded. After randomization neither the patients nor the investigator will be aware of the treatment allocation. Patients assigned to one of the double-blinded treatment will take one tablet Empagliflozin or matching placebo. The tablets will be identical in appearance.|Single center, prospective, placebo-controlled, double blind, randomized, 2-arm parallel, interventional, exploratory pilot study|t|f|t|f
33817137|NCT06584851|||COHORT||PROSPECTIVE|||||||
33817138|NCT04876092|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817139|NCT05308901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817140|NCT03994185|NA|SINGLE_GROUP||TREATMENT||NONE||Approximately 30 subjects will be enrolled and treated with the study device||||
33817141|NCT03553056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33817142|NCT01864200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817143|NCT03638700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33817144|NCT05219708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33817145|NCT00554905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817146|NCT03317522|||COHORT||PROSPECTIVE|||||||
33817147|NCT01701089|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817148|NCT05234476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817149|NCT05534516|||COHORT||PROSPECTIVE|||||||
33817150|NCT01024023|RANDOMIZED|PARALLEL||||NONE||||||
33817151|NCT06721403|||COHORT||CROSS_SECTIONAL|||||||
33817152|NCT06413472|||CASE_CONTROL||PROSPECTIVE|||||||
33817153|NCT03307993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817154|NCT06185101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817155|NCT00378456|RANDOMIZED|PARALLEL||||DOUBLE||||||
33817156|NCT05145634|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33817157|NCT02416297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817158|NCT06190249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817159|NCT06452043|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial design||||
33817160|NCT06720831|||COHORT||RETROSPECTIVE|||||||
33817161|NCT06721065|||COHORT||PROSPECTIVE|||||||
33817162|NCT05664425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator-blinded|Parallell group two-arm randomised study|f|f|t|f
33817163|NCT05085678|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised controlled trial with convenience sampling||||
33817164|NCT06161012|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817165|NCT03932253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817166|NCT05583474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817167|NCT03095378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor did not have access to patient's records|Interventions in different patients|f|f|f|t
33817168|NCT00835445|||CASE_CONTROL||PROSPECTIVE|||||||
33817169|NCT00718744|NA|SINGLE_GROUP||||NONE||||||
33817170|NCT02199171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817171|NCT02645422|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33817172|NCT06584955|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33817173|NCT04782570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817174|NCT03245996|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||||||
33817175|NCT03241121|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Part 1: Prospective longitudinal observational study. Study Part 2/3: Open-label randomized controlled trial.||||
33817176|NCT01928888|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33817177|NCT01000415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817178|NCT06720467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817179|NCT02642640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33817180|NCT04282018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817181|NCT06565195|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Both the SAD and MAD studies are double blinded (sponsor unblinded); that is, both the participants and the site personnel are blinded to the study intervention.||t|f|t|f
33817182|NCT05363839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817183|NCT05652985|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|open-label|open-label, two-arm Randomized Control Trail (RCT)||||
33817184|NCT06480227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817185|NCT05145491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817186|NCT01250717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817187|NCT06607185|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817188|NCT06585761|||CASE_CONTROL||PROSPECTIVE|||||||
33817189|NCT01469819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817190|NCT06721923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33817191|NCT02831088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817192|NCT06005311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Both patients and clinicians were blinded from the group allocation i.e. a double blind study.|Infertile patients attending IVF treatment at the Centre of Assisted Reproduction and Embryology, Queen Mary Hospital and Kwong Wah Hospital will be recruited during ovarian stimulation for IVF. Subsequently, they will be randomly assigned on the day of oocyte retrieval by a laboratory staff into one of the following two groups: (1) the microfluidic chip group and (2) the density gradient group for sperm preparation and subsequent use in fertilization. Other IVF procedures will be the same as our usual practice.|t|t|t|t
33817193|NCT06155123|||CASE_CONTROL||PROSPECTIVE|||||||
33817194|NCT01002209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817195|NCT02854657|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33817196|NCT05945550|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33817197|NCT05164094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33817198|NCT06719557|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817199|NCT03462771|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33817200|NCT06207383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817201|NCT01727193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817202|NCT05208021|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Experimental: Intervention group Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program was applied to the intervention group No Intervention: Control Group Only data collection was carried out. No attempt was made by the researcher during the study"|Intervention and control group|t|f|f|f
33817203|NCT05899868|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Testing of device for success during endotracheal intubation||||
33817204|NCT04474691|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Acoustic measures will be obtained by research assistants blinded to the treatment condition assigned for each session.|Children with /r/ misarticulation will receive 16 sessions/8 weeks of intervention using staRt. Individual sessions will be randomly assigned to include the visual biofeedback display (visual-acoustic biofeedback treatment) or exclude it (traditional treatment). Participants will receive an equal number of sessions (8) of each type.|f|f|f|t
33817205|NCT06720519|||CASE_ONLY||RETROSPECTIVE|||||||
33817206|NCT06702774|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33817207|NCT06716281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047119|NCT02776436|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047120|NCT04412161|||COHORT||RETROSPECTIVE|||||||
34126424|NCT01125410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126425|NCT01699126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126426|NCT01994746|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33817208|NCT03849300|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||aquatic walking exercise intervention group 1 vs. control group; aquatic walking exercise intervention group 2 vs. land-based walking exercise group||||
33817209|NCT03968094|||COHORT||PROSPECTIVE|||||||
33817210|NCT00123500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817211|NCT03527329|||CASE_CONTROL||PROSPECTIVE|||||||
33817212|NCT02747459|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33817213|NCT05401799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817214|NCT00172705|||DEFINED_POPULATION||OTHER|||||||
33817215|NCT00071929||||TREATMENT||NONE||||||
33817216|NCT01039506|||COHORT||PROSPECTIVE|||||||
33817217|NCT04937049|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33817218|NCT01705444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817219|NCT06395987|||CASE_ONLY||PROSPECTIVE|||||||
33817220|NCT04593004|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||1:1 stratified random allocation||||
33817221|NCT05424952|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33817222|NCT00800917|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817223|NCT01913444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817224|NCT03522688|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33817225|NCT02769754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33817226|NCT03344458|NA|SINGLE_GROUP||TREATMENT||NONE||All study participants will receive TransCon hGH||||
33817227|NCT04678297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|We will employ blinding whenever possible. Assessments, evaluations, and data analysis will be conducted without knowledge of participants' assigned group. Study personnel will be blinded to the assigned condition of subjects when conducting data collection by using unique study identification numbers, by following a strict script to refrain from discussing participant activities, and by using different members of the study team to coordinate assigned condition activities and to collect data. De-identified data with codes for assigned condition will facilitate blinded data analysis.||t|f|t|t
33817228|NCT05791552|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33817229|NCT06027216|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Individuals with Acquired Monocular Vision/ Blindness in One Eye||||
33817230|NCT05103033|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33817231|NCT00002761||||TREATMENT||||||||
33817232|NCT01767376|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33817233|NCT06478589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33817234|NCT03676400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Product group / Control(placebo) group|t|f|t|f
33817235|NCT02205476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817236|NCT06095492|RANDOMIZED|PARALLEL||TREATMENT||NONE||A research assistant will randomize the patients into either Empa group or Lina group in a 1:1 ratio using computer-generated numbers.||||
33817237|NCT05725928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33817238|NCT03417375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817239|NCT00324363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817240|NCT01594944|||CASE_ONLY||PROSPECTIVE|||||||
33817241|NCT06653816|||CASE_ONLY||PROSPECTIVE|||||||
33817242|NCT00928265|||CASE_ONLY||PROSPECTIVE|||||||
33817243|NCT05321576|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33817244|NCT06496750|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817245|NCT04362865|||COHORT||PROSPECTIVE|||||||
33817246|NCT05185739|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomised 3-arm phase II clinical trial in patients with resectable HCC. Sixty patients will be randomized 1:1:1 to pembrolizumab, lenvatinib or the combination of pembrolizumab and lenvatinib.||||
34047121|NCT01735578|||CASE_ONLY||PROSPECTIVE|||||||
34047122|NCT05272995|||CASE_CROSSOVER||PROSPECTIVE|||||||
34047123|NCT04594070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817247|NCT06547775|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33817248|NCT06029595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)|Randomised, double-blind, placebo-controlled, 2-arm parallel group study|t|f|t|f
33817249|NCT06721598|||COHORT||PROSPECTIVE|||||||
33817250|NCT01167972|||COHORT||PROSPECTIVE|||||||
33817251|NCT06577025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817252|NCT00001280||||TREATMENT||||||||
33817253|NCT04867499|||COHORT||RETROSPECTIVE|||||||
34047124|NCT04996498|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"The allocation will be concealed in sealed, sequentially numbered, white envelopes which will be prepared by a statistician where the drug will be covered with adhesive tape and handed over to the data collector. each woman will collect the corresponding sealed envelope directly from the data collector and it will be opened just before application of the drug.~the surgeon, the assistant and the nurse performing the procedure and the patient will be blinded to the medication drug which will be used inside the distention medium."|Randomized controlled double blinded clinical trial.|t|t|t|f
34047125|NCT05101746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047126|NCT02907918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047127|NCT00117104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047128|NCT03423758|||COHORT||PROSPECTIVE|||||||
34047129|NCT06603155|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047130|NCT06416436|NA|SEQUENTIAL||TREATMENT||NONE||Traditional 3+3 model||||
34047131|NCT01662817|||COHORT||PROSPECTIVE|||||||
34126427|NCT02103127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126428|NCT05973708|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34126429|NCT03079531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126430|NCT00644943|RANDOMIZED|||TREATMENT||SINGLE|||f|f|t|f
34126431|NCT04452123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126432|NCT02377843|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126433|NCT00418704|||CASE_ONLY||PROSPECTIVE|||||||
33817254|NCT04978584|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817255|NCT05832320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817256|NCT06075433|||CASE_CONTROL||PROSPECTIVE|||||||
33817257|NCT06291298|NA|SINGLE_GROUP||OTHER||NONE||Pilot test COGMUSE-AUT in a small sample of autistic adults with co-occurring insomnia on primary and secondary outcomes.||||
33817258|NCT06721819|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33817259|NCT06092359|||COHORT||PROSPECTIVE|||||||
33817260|NCT00459849|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817261|NCT02975609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817262|NCT06175637|||CASE_ONLY||PROSPECTIVE|||||||
33817263|NCT05528510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817264|NCT04184622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817265|NCT03001830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817266|NCT04312672|||COHORT||PROSPECTIVE|||||||
33817267|NCT00559871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817268|NCT06660563|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817269|NCT05299606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817270|NCT05753358|NA|SINGLE_GROUP||PREVENTION||NONE||This mixed-methods project had three phases. The initial qualitative phase was assessing the needs of wildland firefighters across segments and geographic locations to identify and prioritize program components. During the first phase, we recruited firefighters and collected baseline data in order to assess their needs. The second phase was to build a comprehensive, engaging TWH program for those fighting wildfires. It needed to be accessible on smartphone, tablet or computer, and suitable for individual, group and classroom settings. The final, third phase was to evaluate the program with a prospective proof-of-concept, usability and effectiveness trial among all types of wildland firefighters in different geographic locations.||||
33817271|NCT01391234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817272|NCT02945137|||CASE_ONLY||RETROSPECTIVE|||||||
33817273|NCT02374476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817274|NCT04456296|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817275|NCT06575751|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Participants will be blind to medication assignment, as will all care providers and investigators|Double-blind placebo controlled clinical trial.|t|t|t|t
33817276|NCT06721481|||COHORT||PROSPECTIVE|||||||
33817277|NCT06720493|||COHORT||PROSPECTIVE|||||||
33817278|NCT00062478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817279|NCT04362111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigator, care provider, and participant blinded|Two parallel treatment arms|t|t|t|f
33817280|NCT02691884|||COHORT||PROSPECTIVE|||||||
33817281|NCT01515202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817282|NCT06641908|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817283|NCT04015050|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33817284|NCT05795309|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Staggered randomised control trial||||
33817285|NCT02791685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817286|NCT00860509|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33817287|NCT06721429|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will include 36 patients with type 2 diabetes mellitus. Patients who meet the inclusion criteria will be randomly assigned to one of three groups: the dual-task exercise training group (n=12), the single-task exercise training group (n=12), or the control group (n=12).In the single-task exercise training group, aerobic exercise, resistance training, and balance training will be performed as separate tasks, while in the dual-task training group, these same exercises will be performed simultaneously with cognitive dual-task training. The control group will be instructed to continue with their daily activities and refrain from participating in any exercise training program for eight weeks after the initial assessment. In the exercise training groups, individuals will undergo a combined exercise program consisting of aerobic exercise, resistance training, and balance training, with three sessions per week on non-consecutive days over a period of 8 weeks, totaling 24 sessions.||||
33817288|NCT00472199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817289|NCT02201992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817290|NCT05107921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817291|NCT03406299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817292|NCT04596917|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|PI will be working collaboratively with primary nurse. Both PI and primary nurse will maintain nursing personal protective equipment (PPE) standard of care required for the PreOp and PACU units. Prep and PACU nurses will be blinded to type of intervention|Randomized comparative study comparing two types of music listening interventions of preferred music with Spotify compared to hypnotic music with relaxation and breathing narrative|t|t|t|f
33817293|NCT06088082|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|. All patients, care providers in PACU \& ward (nurses), and outcome assessors (assistant anesthesiologist) will be blinded to the group allocation. Only the assigned anesthesiologist responsible for perioperative care will be aware of the group allocation to treat any unwanted side effects during and after the|"To evaluate the combined efficacy US-guided TAP block and PRS block in patients undergoing laparoscopic appendectomy.~Early mobilization, opioid consumption, Postoperative Nausea \& Vomiting (PONV), length of hospital stay (LOS), patient satisfaction in patients scheduled for laparoscopic appendectomy."|t|t|f|t
33817294|NCT03315468|||COHORT||PROSPECTIVE|||||||
33817295|NCT06721520|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33817296|NCT03796585|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33817297|NCT05449145|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33817298|NCT04025762|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label, multi-centre randomised, two-period crossover study comparing day and night automated closed-loop glucose control with sensor-augmented pump therapy.||||
33817299|NCT06721936|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||f|t|f|t
33817300|NCT06460103|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Treatment blinding will not be possible as both device types, i.e. test and control implants, can be easily visually differentiated during handling and implantation. Test and control groups will be blinded for evaluation and statistical analysis and performed by independent laboratories.||f|f|f|t
34126434|NCT01580410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047132|NCT04432012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The present study will be double blinded: both participants and assessor will be blinded to the assigned treatment. Only the surgeons and the anaesthetists taking part to surgery will be aware of the group to which the patient was assigned but they will not take part to the follow-up visits.||t|f|f|t
33817301|NCT00067808|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047133|NCT00354003|||CASE_ONLY||PROSPECTIVE|||||||
34047134|NCT03237195|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34047135|NCT01777984|||CASE_CONTROL||PROSPECTIVE|||||||
34047136|NCT04721847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047137|NCT06082518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Specialist hyperbaric physicians, blinded to group allocation, will provide treatment and follow patients daily throughout their treatment course.~Outcomes Assessor will also be blinded to group allocation."||f|t|f|t
34047138|NCT02769975|||CASE_ONLY||OTHER|||||||
34047139|NCT06681103|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This design follows a Solomon three-group structure, enabling the independent evaluation of the immediate effects that the pre-test assessment and the intervention may have on the study's dependent variables (intention to change and help-seeking behavior), as well as their maintenance three months after the intervention. The following experimental conditions will be established: (1) control group with pre- and post-test assessment (assessment group), (2) control group with post-test assessment only (delayed assessment group) and (3) intervention group with pre- and post-test assessment, which will also receive personalised online normative feedback on their gambling and trading behaviour after the initial assessment (PONF group). To adapt the PONF to each participant it is necessary to conduct a pre-test assessment, so an adaptation of Solomon's design will be used.|t|f|t|t
34047140|NCT01015131|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047141|NCT01002430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047142|NCT02840981|||COHORT||CROSS_SECTIONAL|||||||
34047143|NCT02436369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047144|NCT05542784|||COHORT||PROSPECTIVE|||||||
34047145|NCT01698892|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34047146|NCT03019601|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34047147|NCT00466388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34047148|NCT00704080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047149|NCT05263050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will start at 40 mg of cabozantinib daily and dose escalate or de-escalate based on pre-specified criteria and at set dosing schedules to allow for smaller median dose changes between adjustments.~Patients in cohorts A and C will be treated with the same cabozantinib alternative dosing schema and schedule, with the exception of Cohort B patients also receiving monthly fix-dosed nivolumab infusions."||||
34047150|NCT03466515|NA|SINGLE_GROUP||TREATMENT||NONE||pilot study with a maximum of 20 patients||||
34047151|NCT06574698|||COHORT||PROSPECTIVE|||||||
34047152|NCT00081757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047153|NCT06267313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047154|NCT02411448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047155|NCT02907892|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34047156|NCT05025176|||CASE_ONLY||PROSPECTIVE|||||||
34047157|NCT05445414|RANDOMIZED|PARALLEL||PREVENTION||NONE||A two-arm randomised controlled trial with the intervention group receiving an educational app and the control group not receiving any app intervention||||
34047158|NCT05177276|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34047159|NCT05563298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a randomized, single-blind trial. The trial will include patients with amnestic MCI who will be randomized in a 1:1 ratio to treatment with an active or sham Neuro RX Gamma device.|This is a randomized, single-blind trial. The trial will include patients with amnestic MCI who will be randomized in a 1:1 ratio to treatment with an active or sham Neuro RX Gamma device.|t|f|f|f
34047160|NCT01069185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047161|NCT03781635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization into group infusion versus boluses of ketamine will be done prior to the entrance in the OR, the day of the surgery|Two groups of patients. Randomization into group infusion versus boluses of ketamine according to a randomization list for a total number of patients of 50.|t|t|t|t
34047162|NCT03815045|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047163|NCT05745194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The researchers responsible for the data collection at the end of the trial and follow up assessments will be hired and trained by the study staff exclusively for that task to mitigate potential bias.~The statistical analysis will be performed by researchers, prior to the unblinding of participants. The unmasking of participants group allocation will only occur after the statistical analysis of the clinical trial results at 12-week is performed."|"The study will follow a randomized open controlled trial design with concealment of participants allocation to the researchers involved in data collection at the end of the trial and follow-up assessments.~Researchers participating in the statistical analysis of the trial´s data will also be concealed to group allocation.~Participants meeting all inclusion criteria will be randomized to (a) the intervention group: six nutritional consultations with a registered nutritionist promoting adherence to the MedDiet and TAU or (b) the control group: only exposed to TAU for MDD."|f|f|t|t
34047164|NCT01094912|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047165|NCT03687905|||COHORT||PROSPECTIVE|||||||
34047166|NCT01799473|||COHORT||PROSPECTIVE|||||||
34047167|NCT04187872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047168|NCT01895374|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047169|NCT03806725|||COHORT||PROSPECTIVE|||||||
34047170|NCT01579422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047171|NCT03208478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34047172|NCT01433926|||CASE_ONLY||CROSS_SECTIONAL|||||||
34047173|NCT02216942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047174|NCT02119767|||COHORT||PROSPECTIVE|||||||
34047175|NCT04342637|||COHORT||PROSPECTIVE|||||||
34047176|NCT06478212|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047177|NCT01729585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047178|NCT00305708||||TREATMENT||NONE||||||
34047179|NCT02533609|||COHORT||PROSPECTIVE|||||||
34047180|NCT00076830|||COHORT||OTHER|||||||
33817302|NCT01420328|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33817303|NCT02412345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817304|NCT04348799|||OTHER||PROSPECTIVE|||||||
33817305|NCT01071720|RANDOMIZED|CROSSOVER||||NONE||||||
33817306|NCT05813145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Group 1 ( Arm A) (n=25: will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week.~Group 2 ( Arm B) (n=25): will receive the same regimen as group1 in addition to 160mg (17 ,18 ) fenofibrate once daily for 3 month."|t|f|t|f
33817307|NCT05669989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817308|NCT06423430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817309|NCT05319756|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33817310|NCT05044286|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817311|NCT01116700|NA|SINGLE_GROUP||||NONE||||||
33817312|NCT04223323|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33817313|NCT01810328|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817314|NCT01295619|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817315|NCT04958265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817316|NCT05625438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817317|NCT05591456|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.||||
33817318|NCT03219788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33817319|NCT04861259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817320|NCT02272608|||CASE_CONTROL||RETROSPECTIVE|||||||
33817321|NCT06720558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817322|NCT02020200||CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33817323|NCT02270411|||COHORT||CROSS_SECTIONAL|||||||
33817324|NCT02406859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33817325|NCT04909099|||COHORT||PROSPECTIVE|||||||
33817326|NCT06275919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817327|NCT02958826|||OTHER||PROSPECTIVE|||||||
33817328|NCT06270199|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Group Assignment||||
33817329|NCT05393570|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33817330|NCT06452355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817331|NCT05225324|||COHORT||PROSPECTIVE|||||||
33817332|NCT06720766|||COHORT||PROSPECTIVE|||||||
33817333|NCT02724423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|open-label|||||
33817334|NCT06720324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817335|NCT01117532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817336|NCT05859529|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|||||
33817337|NCT03889327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|2, 4, and 6 blocked randomization (by gender) was conducted via computer generator. Group assignment was specified and sealed in individual envelopes by a study coordinator who is not involved in the current project. After participants are enrolled and complete the baseline evaluation, the appropriate envelope will be selected, based on gender, containing group assignment, and the subsequent intervention will be administered. Group assignment is not established until after the baseline evaluation has been conducted. Determining randomization will take place at a separate location from the recruitment/baseline site. No study member will have direct contact with participants following the baseline evaluation since the intervention is computerized and replies on emailing the study link to complete the intervention.|Once written consent is obtained, patients will complete baseline self-report questionnaires and neuropsychological tests. Immediately following the baseline assessment, patients will be notified of their eligibility. If inclusion criteria is met, patients will be randomized, based on gender in a 2, 4, or 6 block randomization into either the treatment or control group. Patients and the research investigator will be blind to treatment assignment. Participants will complete the intervention and follow-up questionnaires through the research electronic data capture (REDCap), a secure internet-based computerized system. The REDCap link will be emailed to participants within 24 hours of their enrollment into the study. Participants should initiate the intervention at their earliest convenience. The one-week post-intervention follow-up questionnaires will also be emailed directly to participants, and accessed using a REDCap link.|t|t|t|t
33817338|NCT05569265|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33817339|NCT05955885|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The study will involve one-way blinding. Participants will be made aware prior to consenting that they will receive either flurbiprofen or a control intervention during the initial briefing and screening communications. However, they will not be told if the intervention they receive will contain flurbiprofen, a low dose of flurbiprofen, or no flurbiprofen. Blinding of the researchers to the identity of the treatment is difficult to achieve in practice given the physical characteristics of the interventions. Regardless of this, the researchers don't have any subjective role in quantifying the endpoint measures (patient-reported outcomes and cough sensitivity), minimising the risk of influencing the findings. For these reasons, the pragmatic approach of single blinding of the experiment is appropriate, acknowledging that this experiment is not designed to be a true clinical trial.|"120 participants will be randomised into four study arms, i.e. treatment with:~1. flurbiprofen lozenge~2. placebo lozenge~3. flurbiprofen spray~4. low dose flurbiprofen spray~Regardless of which arm they are assigned to, each participant will undergo cough challenge testing to test cough sensitivity, fill out quality of life questionnaires, and have their nasal fluid, saliva and pharyngeal fluid sampled for inflammatory markers before and after the intervention."|t|f|f|f
33817340|NCT01356121|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33817341|NCT06720532|||COHORT||PROSPECTIVE|||||||
33817342|NCT02604199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817343|NCT05412927|||CASE_ONLY||PROSPECTIVE|||||||
34047181|NCT05985980|||CASE_CROSSOVER||PROSPECTIVE|||||||
34047182|NCT00427102|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047183|NCT04718532|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34047184|NCT05537987|NA|SEQUENTIAL||TREATMENT||NONE||||||
34047185|NCT02551770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047186|NCT04694989|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33817344|NCT06068348|||OTHER||CROSS_SECTIONAL|||||||
33817345|NCT03571100|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participant will be masked to which drug they receive, the investigator performing the analysis will also be masked|Randomized prospective trial|t|f|f|f
33817346|NCT03050931|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817347|NCT03751761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817348|NCT01488240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817349|NCT06694766|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"* women vaccinated during pregnancy~* women vaccinated outside pregnancy"||||
33817350|NCT06468618|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33817351|NCT00604344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817352|NCT03807934|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Repeated-measures crossover design.|t|f|f|f
33817353|NCT03658018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817354|NCT02114502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817355|NCT06386744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817356|NCT05431543|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Multicenter, double-masked, randomized, crossover, active and vehicle-controlled, safety and effectiveness study|f|t|t|t
33817357|NCT06290557|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33817358|NCT03148353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The treatment is double blind to the participants and outcome assessors. Only the physician performs the injection knows which kind of intervention the patients receive.|randomized controlled trial|t|f|f|t
33817359|NCT04904731|||COHORT||PROSPECTIVE|||||||
33817360|NCT06535607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817361|NCT01598454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817362|NCT06720779|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Twenty patients will be randomly assigned to the experimental or control group in a 1:1 ratio.~Opaque envelopes containing the randomization sequence will be prepared to maintain allocation concealment. Patients meeting the inclusion criteria and agreeing to participate will be consecutively recruited.~Experimental Group (EG):~* Participants receive standard face-to-face rehabilitation twice a week, which involves 25 minutes of conventional rehabilitation (cryotherapy, joint mobilization, strength training, and gait re-education) and 20 minutes of gait exercises.~* Additionally, they perform four weekly 30-minute rehabilitation sessions at home using the TRAK platform.~* The TRAK platform incorporates advanced AI for movement tracking, gamification features, and personalized exercise routines.~Control Group (CG): Participants receive only the conventional rehabilitation protocol."||||
33817363|NCT03426709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817364|NCT06608485|||COHORT||PROSPECTIVE|||||||
33817365|NCT01880008|||CASE_ONLY||PROSPECTIVE|||||||
33817366|NCT02851394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817367|NCT00208832|RANDOMIZED|FACTORIAL||||SINGLE||||||
33817368|NCT06602128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The post-test measurements will be collected by a nurse working in the angiography ward who is not connected with the study.||f|f|f|t
33817369|NCT02617186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817370|NCT00267956|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33817371|NCT01309802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817372|NCT03214432|||COHORT||RETROSPECTIVE|||||||
33817373|NCT01026571|||COHORT||PROSPECTIVE|||||||
33817374|NCT03190941|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817375|NCT06544226|||COHORT||PROSPECTIVE|||||||
33817376|NCT06721832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33817377|NCT01796834|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817378|NCT04528680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817379|NCT05703477|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817380|NCT01075815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817381|NCT00917722|||COHORT||PROSPECTIVE|||||||
33817382|NCT06666387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817383|NCT02104375|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34126435|NCT01101672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126436|NCT00017069||||TREATMENT||NONE||||||
34126437|NCT02534883|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126438|NCT05545410|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126439|NCT00383669|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34126440|NCT00587808|||CASE_CONTROL||PROSPECTIVE|||||||
34126441|NCT01481350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126442|NCT05869968|||COHORT||PROSPECTIVE|||||||
34126443|NCT02902445|||CASE_CONTROL||PROSPECTIVE|||||||
34126444|NCT04963283|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 2, single-arm, open-label study of cabozantinib in combination with nivolumab in subjects with metastatic CRC refractory to standard of care options. The primary endpoint is DCR at 16 weeks. A Simon 2-stage optimal design will be used.||||
34126445|NCT03929354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of trial participants and care providers is not possible because of obvious differences between the interventions. However, the investigator, the outcomes assessor and statistician are blinded to treatment received.|This is a randomised, parallel group, active-control trial, with patients randomised in a 1:1 ratio to one of two treatment arms.|f|f|t|t
34126446|NCT03487484|||CASE_CONTROL||PROSPECTIVE|||||||
33817384|NCT02389894|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33817385|NCT03456778|||CASE_CONTROL||PROSPECTIVE|||||||
33817386|NCT06126315|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817387|NCT03011801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817388|NCT01562275|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817389|NCT06721806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817390|NCT06068335|||CASE_CONTROL||PROSPECTIVE|||||||
33817391|NCT03708744|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, open-label four-way crossover||||
33817392|NCT05248425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817393|NCT06580990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the evaluator does not have access to the intervention|This study will be a single-blinded, randomised, controlled clinical trial and multicentric|f|f|f|t
33817394|NCT05555121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre, prospective, open label study||||
34047187|NCT06191952|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34047188|NCT02048280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047189|NCT05182710|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants will not know which of the two interventions (training modules) is being assessed.~Those facilitating simulations will also be blinded. Those assessing over-all effectiveness of resuscitation will be blinded to which arm participants are in"|Randomised Control Trial|t|f|f|t
34047190|NCT03082157|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a community based, cluster randomized, parallel group longitudinal trial. Each faith-based organization that meets inclusion criteria, agrees to participate and sign the memorandum of agreement will be matched on congregation size and randomized to either: 1) the exercise-only comparison group or 2) the Mighty Men weight-loss intervention||||
34047191|NCT02049814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047192|NCT04206891|||COHORT||RETROSPECTIVE|||||||
34047193|NCT02609620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047194|NCT05580094|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Participant, Outcomes Assessor)|Randomized, double-blinded controlled trial.|t|f|f|t
34047195|NCT01878149|||COHORT||RETROSPECTIVE|||||||
34047196|NCT02661269|||COHORT||PROSPECTIVE|||||||
34047197|NCT06567379|||COHORT||RETROSPECTIVE|||||||
34047198|NCT00119717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817395|NCT01328483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047199|NCT00031967|RANDOMIZED|||TREATMENT||||||||
34047200|NCT02792894|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047201|NCT04799730|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34047202|NCT01014988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047203|NCT03383835|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817396|NCT00583349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817397|NCT03595306|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33817398|NCT02241980|||COHORT||PROSPECTIVE|||||||
33817399|NCT04194671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817400|NCT05417685|||COHORT||PROSPECTIVE|||||||
33817401|NCT00543049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817402|NCT04123938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817403|NCT03602547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817404|NCT02609776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817405|NCT03722602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817406|NCT02674971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817407|NCT05045456|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817408|NCT03867396|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants will be randomized into a group where they wear one of the processors and the order of conditions will be assessed, then they will switch to wear the other processor and the order of conditions will be assessed.||||
33817409|NCT04944589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||: This study was a randomized controlled trial conducted at Department of Operative Dentistry, Fatima Memorial Hospital, Lahore, over a period of six months. A total of 302 patients presented with pulp necrosis in mandibular and maxillary first and second molar were included in this study and divided in two groups of 151. RCT of Group A patients was performed in single visit and RCT of group B patients was performed in multiple visits|f|f|t|f
33817410|NCT05459974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded randomized controlled trial||t|t|t|t
33817411|NCT05972109|RANDOMIZED|FACTORIAL||PREVENTION||NONE|The study is a double-randomized, controlled trial of 700 Sutter Health employees working at 16 hospital campuses. The hospital campuses will be randomized to sales ban or control. After screening employees at the 16 campuses for heavy SSB consumption (\> 30 oz/week), the investigators will further randomize study participants to receive the brief counseling intervention or not.|The study is a double-randomized, controlled trial of 700 Sutter Health employees working at 16 hospital campuses. The hospital campuses will be randomized to sales ban or control. After screening employees at the 16 campuses for heavy SSB consumption (\> 30 oz/week), the investigators will further randomize study participants to receive the brief counseling intervention or not. This will result in a balanced design of n=175 participants in each cell of a 2x2 factorial design: 1) sales ban alone; 2) behavioral counseling alone, 3) combined condition of sales ban and behavioral counseling, and 4) no intervention or control condition. This is an efficient design for testing the effects of the sales ban and brief counseling interventions plus their cross-level interaction within a context of full randomization.||||
33817412|NCT04047303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817413|NCT05799040|||CASE_CONTROL||PROSPECTIVE|||||||
33817414|NCT01693393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047204|NCT06659536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047205|NCT01175174|||||PROSPECTIVE|||||||
34047206|NCT06316232|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The count and duration of FoG episodes during the standardize walking protocol is measured on video-assessment by two blind raters.|"In addition to baseline gait assessment performed in a morning session on MED ON/STIM ON condition (after usual levodopa morning dose and usual parameters of stimulation), patients are evaluated in two following morning sessions under different treatment conditions:~1. STIM ON plus: evaluation after the administration of levodopa morning dose and the increase of intensity of stimulation of 0.5 mA bilaterally,~2. MED ON plus: evaluation after the administration of a 2x levodopa morning dose with usual parameters of stimulation."|f|f|f|t
34047207|NCT04128254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047208|NCT03381079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047209|NCT05256927|||COHORT||PROSPECTIVE|||||||
34126447|NCT03805061|RANDOMIZED|PARALLEL||OTHER||DOUBLE||A total of 40 patients enrolled in the study from outpatient clinics were included. Two groups were formed, namely 'aerobic exercise' and 'isokinetic exercise' groups.|t|f|f|t
34126448|NCT00265486|||CASE_ONLY||PROSPECTIVE|||||||
34126449|NCT03218280|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34149190|NCT02334488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817415|NCT05786768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837155|NCT05995496|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Two participant groups (one with and one without bulimia nervosa) will be scanned using MRI after they have fasted and after they have consumed a standardized meal. The order of these two scans will be counterbalanced across groups.|f|f|f|t
34149191|NCT02704689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047210|NCT04691986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The study design participants, care providers, and investigators will be blinded to the group designation of the participants. To accomplish this, the study statistician will coordinate with the VA pharmacy to assign groups to participants and to dispense appropriate treatments to the study coordinator to give to study participants.|The study will be conducted as a double-blind randomized controlled trial. Participants will be randomly assorted to receive either the nicotinamide riboside supplementation or a placebo pill.|t|t|t|f
34047211|NCT00004407||||TREATMENT||||||||
34047212|NCT02354157|||COHORT||CROSS_SECTIONAL|||||||
34047213|NCT05772221|NA|SINGLE_GROUP||SCREENING||NONE||||||
34047214|NCT05500339|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33817416|NCT03185858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes assessors (staffs from a nearby county) are masked with no information on which villages will be assigned to intervention group or control group.|The SINEMA model, cognizant of health system's organization around primary, secondary and tertiary healthcare levels in China, adopts the principles of cascade training with feedback and task-sharing, and relies on existing human resources available at the community level. It also proposes the use of innovative mobile technology as tools (in the form of an Android-based SINEMA APP for village doctors and cellphone voice messages for participants). The overarching aim is to strengthen the capacity of village doctors on delivering services for the secondary prevention of stroke and promoting medication adherence and physical activity among stroke survivors.|f|f|f|t
34047215|NCT05300009|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047216|NCT04971135|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34047217|NCT00618943|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047218|NCT01999699|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047219|NCT06546930|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Intervention group (will receive VPG curriculum) versus comparator group (not enrolled)||||
34047220|NCT06565260|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047221|NCT05429762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149192|NCT03547934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817417|NCT02306005|||CASE_ONLY||PROSPECTIVE|||||||
33817418|NCT04676763|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE|It is an open-label study.|Parts 1 and 2 will run sequentially. Part 1 will include 1 challenge visit; Part 2 will include two challenge visits.||||
33817419|NCT04566120|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33817420|NCT05491837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients 'selection and their allocation of treatments to experimental and control will be done by team of physiotherapists working in paraplegic center Peshawar who will not the part of investigation team. Treatment will be given by trained physiotherapist within paraplegic center Peshawar while data will be analyzed by statistician working in Riphah International University. The investigator, patients and the treatment providers will be anonymous from the group allocation, treatment they receive and data analysis|The participants are randomly divided into 2 groups. Interventional and SHAM|t|t|t|f
33817421|NCT06343662|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817422|NCT05500313|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817423|NCT02458794|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33817424|NCT06436612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817425|NCT06510205|||COHORT||PROSPECTIVE|||||||
33817426|NCT03636295|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, randomized, open-label, blinded end-point (PROBE) clinical trial.||||
33817427|NCT00587171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817428|NCT02122822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817429|NCT02289885|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33817430|NCT03542721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817431|NCT00393185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817432|NCT00729170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817433|NCT05589129|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33817434|NCT04362722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817435|NCT04704986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817436|NCT01848483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817437|NCT05033054|||COHORT||PROSPECTIVE|||||||
33817438|NCT00874393|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33817439|NCT03362294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||The first 20 subjects are allocated to the 40mg arm and the last 10 subjects are allocated to the 25mg.||||
33817440|NCT03457168|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants unaware of their assigned randomized group. Outcomes evaluated by an independent Events Committee.|Prospective, randomized, open-label (for medication treatment), two-arms, blinded-endpoint clinical trial.|t|f|f|t
33817441|NCT03529435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators, who are blind to treatment condition, conduct semi-structured interviews to assess PTSD diagnosis at the posttreatment, three-month, and six-month follow-up assessments.||f|f|f|t
33817442|NCT06121739|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33817443|NCT04317872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|An anesthetist or study nurse not involved in further care of the patient nor in the study will prepare the medication to administered based on the allocated group. The first syringe with either 5 or 25 mg of Aacidexam will be administered during induction. The second syringe will go with the patient to the ward and will be administered 12 hours after the surgery by the (blinded) ward nurse. The patient will not be made aware of what has been administered.|A randomized, single surgeon, placebo controlled, double blind study using two parallel study groups|t|t|f|f
33817444|NCT02123758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817445|NCT04673357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Induction period is an open-label period and maintenance period is a double-blind period.||t|f|t|f
33817446|NCT00005867|RANDOMIZED|||TREATMENT||||||||
33817447|NCT06721299|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three sequential multiple ascending dose cohorts (of n=10 participants)||||
34047222|NCT03274999|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149193|NCT04799691|||CASE_CONTROL||RETROSPECTIVE|||||||
34149194|NCT03399656|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Placebo control||t|t|t|t
34149195|NCT02058719|||COHORT||PROSPECTIVE|||||||
34149196|NCT05106010|||CASE_CONTROL||PROSPECTIVE|||||||
33817448|NCT06720064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33817449|NCT04047355|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33817450|NCT03793088|||COHORT||PROSPECTIVE|||||||
33817451|NCT05116579|||COHORT||PROSPECTIVE|||||||
33817452|NCT02990845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817453|NCT02531516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817454|NCT04947319|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817455|NCT00801528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817456|NCT06719960|||CASE_CONTROL||PROSPECTIVE|||||||
33817457|NCT05757622|||COHORT||PROSPECTIVE|||||||
33817458|NCT06721377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817459|NCT06673069|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33817460|NCT03479502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind Masking|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician. The Vanderbilt Investigational Pharmacy will provide the doxycycline and the steroid solutions and will be in charge of patient randomization.|t|f|t|t
33817461|NCT00985595|||CASE_CONTROL||PROSPECTIVE|||||||
33817462|NCT00422162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817463|NCT01322347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817464|NCT01707277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817465|NCT04057300|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817466|NCT02031445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817467|NCT00231166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817468|NCT06498388|||COHORT||PROSPECTIVE|||||||
33817469|NCT06720818|||COHORT||PROSPECTIVE|||||||
33817470|NCT06721416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817471|NCT06557330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817472|NCT06508801|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This study will utilize block randomization with permuted blocks in a 1:1 ratio. Individuals will be assigned to either Group 1 or Group 2 after baseline assessment. The randomization will be predetermined, and the allocation will be concealed. Only the statistician and research coordinator will be aware of the randomization.|Two group, randomized, repeated measure design|t|f|t|f
33817473|NCT05963854|||CASE_ONLY||PROSPECTIVE|||||||
33817474|NCT00640354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817475|NCT02755948|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||GMP influenza A/California/04/2009-like (H1N1); influenza A/Belgium/4217/2015 (H3N2); or RSV Memphis 37 virus strains will be used for experimental infection of volunteers.||||
33817476|NCT01895868|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33817477|NCT03578744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed envelopes.|Patients will be equally divided into two test groups, Group A and Group B after phase I therapy. The group A patients will be treated with conventional flap surgery and the furcation would be debrided, following which platelet-rich fibrin will be placed as a graft and a membrane. The flap will then be sutured back. The group B patients will also be treated with conventional flap surgery after furcation area is debrided, and hyaluronic acid (gengigel)will be placed as a graft over which amniotic membrane will be placed. The flap would then be sutured.|t|f|f|f
33817478|NCT01596517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817479|NCT03399799|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817480|NCT05618509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33817481|NCT00765791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817482|NCT06388889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817483|NCT04860245|||COHORT||PROSPECTIVE|||||||
33817484|NCT04807452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817485|NCT04581044|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33817486|NCT00002840|RANDOMIZED|||TREATMENT||||||||
33817487|NCT03809169|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33817488|NCT01862679|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33817489|NCT05975593|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||30 cervical cancer patients and 30 pancreatic cancer patients||||
33817490|NCT02845557|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33817491|NCT00275418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33817492|NCT06721793|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The type of drink ingested by the subjects will be labeled with a letter in a generic water bottle. During the trial with water a non-caloric, non-sodium-containing sweetener will be used.|"Counter balanced cross-over design trial with 4 arms differing only on the type of drink consumed during exercise.~Each trial includes 2 hours of cycling in a warm environment (32ºC), followed by strength and cognitive assessments."|t|f|f|f
33817493|NCT04002856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817494|NCT06721494|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33817495|NCT00101387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817496|NCT03293147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants and clinicians will initially be blinded to the result of the baseline (at trial entry) HPLC-MS/MS based urine test to determine the participant adherence to antihypertensive treatment.~Non-adherent patients allocated to Arm A will be un-blinded at the stage of visit 3 where the results of their HPLC-MS/MS urine test will be revealed to them as a part of HPLC-MS/MS-guided intervention. The doctor will also require un-blinding to provide the required intervention. However, during further study visits the research personnel will remain blinded as to the adherence status of these patients, the results of their HPLC-MS/MS-based analysis and the treatment allocation. The doctor who delivers the intervention will not be involved in collecting clinical information necessary to define outcomes during appointments 4 and 5.~Hypertensive patients randomised to Arms B and C will remain blinded to the results of their HPLC-MS/MS-based urine test throughout all stages of the study."|Multi-center randomised controlled trial|t|f|t|f
33817497|NCT02714244|NA|SINGLE_GROUP||OTHER||NONE||||||
33817498|NCT03443245|||CASE_CONTROL||PROSPECTIVE|||||||
33817499|NCT01776749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817500|NCT01320683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817501|NCT03740919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817502|NCT02765984|||CASE_CONTROL||PROSPECTIVE|||||||
33817503|NCT04759378|NA|SINGLE_GROUP||SCREENING||NONE||||||
33817504|NCT02143713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817505|NCT06607315|||OTHER||CROSS_SECTIONAL|||||||
33817506|NCT02962622|NON_RANDOMIZED|PARALLEL||||NONE||||||
33817507|NCT03803488|NA|SINGLE_GROUP||OTHER||NONE||||||
33817508|NCT06720025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817509|NCT04974021|||COHORT||PROSPECTIVE|||||||
33817510|NCT04195334|NA|SINGLE_GROUP||OTHER||NONE||||||
33817511|NCT01028976|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33817512|NCT03621683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective comparative study||||
33817513|NCT05945979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817514|NCT02903602|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33817515|NCT03442309|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigators responsible for analyzing the data for primary outcomes will be masked.|Two-arm, parallel, non-inferiority cluster randomized trial|f|f|f|t
33817516|NCT06242184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33817517|NCT05672862|||COHORT||RETROSPECTIVE|||||||
33817518|NCT00426218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817519|NCT00993590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817520|NCT06375317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149197|NCT01270009|||COHORT||PROSPECTIVE|||||||
33817521|NCT03734172|||COHORT||PROSPECTIVE|||||||
33817522|NCT05328297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817523|NCT00992030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817524|NCT04374435|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|The patients were not randomly assigned, rather each arm has been done sequentially with a retrospective comparison of the results.|The investigators have completed two arms of the study in sequential study design (each arm has done individually with no random assignment). An exploratory third arm was initiated but then suspended.||||
33817525|NCT04540952|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Block randomization of patients without their knowledge of grouping. Surgical providers become aware of randomized drape selection only at the time of hysteroscopy. Principal investigator blinded to selection and results.|Prospective Randomized Early Clinical Trial|t|t|t|t
33817526|NCT05057819|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, crossover trial|t|f|t|f
33817527|NCT06495177|||COHORT||PROSPECTIVE|||||||
33817528|NCT04065685|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomised controlled trial with three parallel arms (with a waiting list for the control group)||||
33817529|NCT04685434|||OTHER||PROSPECTIVE|||||||
33817530|NCT03852485|||COHORT||PROSPECTIVE|||||||
33817531|NCT02254200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817532|NCT00700999|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817533|NCT00666913|||CASE_ONLY||PROSPECTIVE|||||||
33817534|NCT05943509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817535|NCT01182272||||TREATMENT||NONE||||||
33817536|NCT00795392|||CASE_CONTROL||PROSPECTIVE|||||||
33817537|NCT04954833|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817538|NCT04489914|||COHORT||PROSPECTIVE|||||||
33817539|NCT00763087|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817540|NCT00841425|||COHORT||PROSPECTIVE|||||||
33817541|NCT01025921|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817542|NCT01535261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817543|NCT03364556|||OTHER||CROSS_SECTIONAL|||||||
33817544|NCT04608357|||COHORT||PROSPECTIVE|||||||
33817545|NCT05185674|||COHORT||OTHER|||||||
33817546|NCT00560209|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33817547|NCT06177938|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|NA- No other parties masked|The study intervention is a single acute postprandial carbohydrate challenge (lactose or glucose) test. Baseline assessments of fecal microbiota composition and usual diet are made on 3 days, within four weeks of the intervention day. Dietary restrictions apply 3 days before the carbohydrate challenge, and participants fast on the morning of the intervention day. The intervention day begins with the collection of baseline urine and breath. Participants are assigned to one of the two carbohydrate challenges. The intervention begins with the ingestion of the carbohydrate solution (25 g of lactose or 13 g glucose) dissolved in 150 mL water, followed by the ingestion of a commercially available gas-sensing capsule to measure intestinal gases. Postprandial breath sampling is conducted over 6 hours for H2 and metabolome analyses. Lactose intolerance symptoms are assessed, and two pools of urine are collected. Intestinal excretion of the gas-sensing capsule marks the end of the intervention.|t|f|t|t
33817548|NCT05551273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817549|NCT06720142|||COHORT||PROSPECTIVE|||||||
33817550|NCT02426424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817551|NCT04555694|RANDOMIZED|PARALLEL||TREATMENT||NONE||10 subjects will receive Restasis and Dextenza 10 subjects will receive Restasis and Lotemax 10 subjects will receive Restasis||||
33817552|NCT02659059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817553|NCT05585827|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||This study is a online, randomized delayed start trial of the effectiveness of e-CBT for PD patients with depressive symptoms.|f|f|f|t
33817554|NCT05673772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817555|NCT01182506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817556|NCT02311335|||FAMILY_BASED||PROSPECTIVE|||||||
33817557|NCT00538629|||OTHER||PROSPECTIVE|||||||
33817558|NCT00396409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817559|NCT05163678|||COHORT||PROSPECTIVE|||||||
33817560|NCT00009763||||TREATMENT||||||||
33817561|NCT04783272|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33817562|NCT01587703|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817563|NCT02182245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817564|NCT00296504|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817565|NCT06505785|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomize-control trial|t|f|f|f
33817566|NCT02595788|||COHORT||PROSPECTIVE|||||||
33817567|NCT05333133|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-, post- intervention study design||||
33817568|NCT00702871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817569|NCT04597047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Participants are asked to provide Capillary and Venous Blood Samples.||||
33817570|NCT05993247|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Probiotics group vs. Placebo group|t|f|t|t
33817571|NCT06129422|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817572|NCT02351778|||||CROSS_SECTIONAL|||||||
33817573|NCT00160537|RANDOMIZED|PARALLEL||||DOUBLE||||||
33817574|NCT01602900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817575|NCT04162977|NA|SINGLE_GROUP||PREVENTION||NONE||This study examines the feasibility and proof-of-concept of implementing personality-targeted interventions for high-risk adolescents receiving services from Youth Protection Services. For testing the feasibility, this study compares the following outcomes with the same outcomes from previous Preventure trials with community samples: facilitator's score on Intervention/implementation fidelity, number of high-risk youth who agree to participate in intervention sessions, and elements of youth's feedback. For testing the proof-of-concept, this study examines effects of interventions on change in substance use outcomes, depression symptoms, and self-reported anxiety sensitivity and impulsivity at 3- and 6-month post-intervention. Previous trials with the community samples indicated that these primary outcomes largely accounted for the long-term intervention effects on reduction of substance use outcomes.||||
33817576|NCT04064840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817577|NCT05316311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817578|NCT04829357|||COHORT||PROSPECTIVE|||||||
33817579|NCT06126887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33817580|NCT02998658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817581|NCT01107171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33817582|NCT05517122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817583|NCT03771300|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The assignation of the subjects will be carried out after the evaluation by a member of the research group, who has no knowledge about the study, through a random sequence generated by computer. Participants will be assigned to one of these conditions: 1) Mindfulness condition; 2) Mindfulness condition complemented by VR environments; 3) Relaxation condition.|This is a randomized, controlled, pragmatic trial, involving three assessment time points (baseline, post-intervention and six-month follow-up).|t|f|f|t
33817584|NCT05594537|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817585|NCT01141985|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33817586|NCT06162611|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The University of Utah Investigational Pharmacy encapsulated oral levonorgestrel and placebo pills and applied a randomization scheme that will not be broken until end of study or at the request of the data safety monitoring board|Randomized controlled trial of the etonogestrel contraceptive implant randomized to same day oral levonorgestrel or placebo in emergency contraception patients|t|t|t|t
33817587|NCT01873963|||COHORT||PROSPECTIVE|||||||
33817588|NCT04647409|NA|SINGLE_GROUP||SCREENING||NONE||||||
33817589|NCT03276806|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33817590|NCT02512107|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33817591|NCT02088645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817592|NCT05104242|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817593|NCT00753155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817594|NCT02917434|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817595|NCT01795313|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot study to assess tolerability of our vaccine regimen in children with ependymomas initially arising above or below the tentorium||||
33817596|NCT04318366|||COHORT||PROSPECTIVE|||||||
33817597|NCT05408156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"All assessments will be performed by researcher A, who will not be involved with the interventions and will remain blind to the identification of groups. The results of the evaluations will be delivered to researcher C, a researcher with experience in making the insoles, so that they can be made. GPC participants will receive the insoles according to the assessment measurements, five days after the assessment start date.~Each participant will remain identified by numbers and not names. Participants will be informed about the purpose of the study to compare the two interventions using customized insoles. In order not to compromise the blinding of the study, all participants will be submitted to the same evaluation before the production and delivery of the insoles. When the insoles are ready, participants will be scheduled for removal at different times, avoiding possible meetings or exchange of information."|Customized insoles group and Sham Insoles Group|t|f|t|t
33817598|NCT04107766|||CASE_ONLY||OTHER|||||||
33817599|NCT02867527|||COHORT||PROSPECTIVE|||||||
33817600|NCT03427177|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33817601|NCT06683820|||CASE_ONLY||PROSPECTIVE|||||||
33817602|NCT02885610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817603|NCT06183580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Comparing two different targets of treatment: either amygdala or dorsal anterior cingulate cortex neurofeedback|t|f|t|f
33817604|NCT05746468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33817605|NCT02619578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33817606|NCT05671055|||COHORT||PROSPECTIVE|||||||
33817607|NCT02293278|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33817608|NCT05647304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||An interventional, prospective, monocentric, randomized, comparative and simple-blinded pilot clinical investigation|t|f|f|f
33817609|NCT06458296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33817610|NCT02391389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817611|NCT01560962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817612|NCT01807234|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817613|NCT06351917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817614|NCT02255526|||COHORT||PROSPECTIVE|||||||
33817615|NCT00246389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817616|NCT02842645|||COHORT||CROSS_SECTIONAL|||||||
33817617|NCT06200818|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149198|NCT06546488|||CASE_ONLY||PROSPECTIVE|||||||
34149199|NCT02107157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817618|NCT04733950|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33817619|NCT04992884|||COHORT||OTHER|||||||
33817620|NCT04891497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817621|NCT02774876|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33817622|NCT03576378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817623|NCT04859465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817624|NCT06322589|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33817625|NCT06018233|||OTHER||RETROSPECTIVE|||||||
33817626|NCT03961178|||COHORT||RETROSPECTIVE|||||||
33817627|NCT02275351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817628|NCT00842179|||COHORT||RETROSPECTIVE|||||||
33817629|NCT01276080|RANDOMIZED|CROSSOVER||||NONE||||||
33817630|NCT03302494|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|If the subject is suspected of having a stroke since their most recent follow-up, a Neurologist blinded to subject's randomization and implanted device must evaluate the subject or otherwise provide rationale for why an in-person neurology visit and exam are unnecessary. Neurology or blinded trial personnel should also administer mRS \& NIHSS if there is suspicion of stroke A Clinical Events Committee, also blinded to subject's randomization, will adjudicate primary safety and effectiveness.||f|f|f|t
33817631|NCT03218488|||COHORT||PROSPECTIVE|||||||
33817632|NCT06649019|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33817633|NCT06213363|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33817634|NCT05666193|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective, single-arm, single-site feasibility study designed to generate data describing the quality and applicability of on-couch high-performance CBCT imaging technology during external beam radiation therapy for head and neck cancer patients.||||
33817635|NCT00678821|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33817636|NCT06415071|||COHORT||RETROSPECTIVE|||||||
33817637|NCT03025698|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817638|NCT04210219|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817639|NCT06049758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized controlled trial, single-blind, with randomized block randomization|t|f|f|f
33817640|NCT06234709|||COHORT||RETROSPECTIVE|||||||
34126450|NCT04356300|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Part 1: totally 30 patient will be enrolled, and 15 patients will be given Exosomes of MSCs immediately after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD.~Part 2: totally 30 patient will be enrolled, and 15 patients will be given Exosomes of MSC after onset of multiple organ dysfuntion syndrome after ascending aortic replacement combined with open placement of triple-branched stent graft for ATAAD."|f|f|f|t
33817641|NCT05663541|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817642|NCT04464434|RANDOMIZED|PARALLEL||TREATMENT||NONE||This multicentre, randomized, open label trial aims to compare two treatment strategies in early dcSSc: upfront autologous HSCT versus i.v. CYC pulse therapy followed by MMF and HSCT as rescue option.||||
33817643|NCT06721780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817644|NCT00987155|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33817645|NCT04937179|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33817646|NCT03258034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126451|NCT04406207|||COHORT||PROSPECTIVE|||||||
33817647|NCT05687110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817648|NCT03686917|||OTHER||PROSPECTIVE|||||||
33817649|NCT01678755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817650|NCT02435498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33817651|NCT00832650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817652|NCT02558322|||OTHER||CROSS_SECTIONAL|||||||
33817653|NCT03438968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At stress testing, cardiologist will not know group assignment|Randomized controlled trial|f|f|f|t
33817654|NCT05621096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126452|NCT04067791|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33817655|NCT04909593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126453|NCT05651763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126454|NCT05892419|||OTHER||OTHER|||||||
33817656|NCT05693272|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33817657|NCT04217798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817658|NCT04657224|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817659|NCT05413954|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33817660|NCT01411683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817661|NCT03627572|||COHORT||PROSPECTIVE|||||||
33817662|NCT06634199|||CASE_ONLY||RETROSPECTIVE|||||||
33817663|NCT06399718|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33817664|NCT04937920|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
33817665|NCT01855672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817666|NCT05478564|||COHORT||PROSPECTIVE|||||||
33817667|NCT04920578|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33817668|NCT00463957|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33817669|NCT00104845|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33817670|NCT03180788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomisation to either traction assisted ESD or traditional ESD|Prospective randomiced Clinical trial|f|f|t|f
33837156|NCT05444946|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects with CPA-ABPA overlap will be randomized to receive either a combination of systemic steroids and oral itraconazole or oral itraconazole alone||||
33837157|NCT04538846|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Quasi-Experimental Study||||
33837158|NCT04640740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837159|NCT03034850|||COHORT||PROSPECTIVE|||||||
33837160|NCT02672449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837161|NCT02815020|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33837162|NCT02633436|||CASE_ONLY|||||||||
33837163|NCT02697396|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33837164|NCT02847286|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34126455|NCT02691416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34126456|NCT06305585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126457|NCT00327925|||DEFINED_POPULATION||OTHER|||||||
34047223|NCT05787821|||COHORT||PROSPECTIVE|||||||
34047224|NCT04588532|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34047225|NCT03788031|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047226|NCT01327183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047227|NCT04835090|||COHORT||PROSPECTIVE|||||||
34047228|NCT06142565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047229|NCT04124835|RANDOMIZED|PARALLEL||OTHER||NONE||This will be a randomized, open-label study aimed at evaluating the effectiveness of using the Swiss Ball, without comparing it with usual care in maternal and neonatal outcomes. Patients will be randomized to receive standard care, as the ward is already a humanized, position-free approach, and to press or join all of this standard product, receive guidance on the use of the Swiss Ball.||||
34047230|NCT01338402|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
33817671|NCT05345041|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"The proposed study is a 12-month multi-level behavioral cluster randomized trial testing a church-based intervention to improve physical function (PF) in African Americans with PF limitations (short physical performance battery \[SPPB\]\<10). Churches in both arms (12 in each) will receive a virtual church-wide walking program which will be open to all church members, providing support for physical activity (PA) at interpersonal and community-levels. Churches will be randomized to either the church-wide walking program plus Keep it Movin' (KIM) intervention (intervention arm) or the church-wide walking program plus education (control arm). Using an active comparator will allow the assessment of whether the KIM intervention is more effective than a church-wide walking program along with improving PA individuals with PF limitations.~Individuals who meet study inclusion criteria, including limited PF and at least two chronic conditions will be recruited from churches in both arms."|f|f|t|t
34047231|NCT06683001|||OTHER||OTHER|||||||
34047232|NCT06683443|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A total of 106 patients, ages 65 years or older, with dementia who are admitted to the designated medical-surgical units at SMHCS will be enrolled in the study.||||
34047233|NCT01910480|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047234|NCT05680246|||COHORT||PROSPECTIVE|||||||
34047235|NCT00182455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047236|NCT02851589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047237|NCT04292912|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open-label, single arm study.||||
34047238|NCT04764981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants of groups will be evaluated and random inserted in one of the experimental groups. The person responsible for reassessment will be blinded for which group the individual reassessed came from.|Randomized controlled clinical trial study, with 2 experimental groups|t|f|f|t
34047239|NCT02024607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047240|NCT04999163|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34047241|NCT00814333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047242|NCT06577220|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34047243|NCT03195725|||COHORT||RETROSPECTIVE|||||||
33817672|NCT01816165|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817673|NCT03214055|||CASE_ONLY||PROSPECTIVE|||||||
33817674|NCT04970966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intra-patient control|t|f|f|t
33817675|NCT06720415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817676|NCT06450405|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817677|NCT06700395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817678|NCT05867615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817679|NCT05594225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study PI, Co-Is, and the biostatistician will not know group assignments until after the primary analyses are complete.|Participants will enroll and undergo initial testing within three weeks of mTBI, be randomized to an 8-week vNDTT or standard-of-care intervention, return for post-intervention testing, and be monitored for subsequent MSK injuries in the three months after mTBI|f|f|f|t
33817680|NCT04044820|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33817681|NCT05793983|||COHORT||PROSPECTIVE|||||||
33817682|NCT03969251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817683|NCT00368823|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33817684|NCT00005088||||TREATMENT||||||||
33817685|NCT02430597|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33817686|NCT03423992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047244|NCT05076721|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34047245|NCT06028685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This study employs computer-based random allocation, where the assignments are sealed in opaque envelopes. The researchers open the envelopes to distribute participants into the experimental and control groups, ensuring blinding of the study participants. The data analysts responsible for statistical analysis are separate individuals who are unaware of the participants' grouping.|This study adopts an experimental research design.|t|f|f|t
34047246|NCT02056041|||COHORT||RETROSPECTIVE|||||||
34047247|NCT05475288|||COHORT||OTHER|||||||
34047248|NCT05007743|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||A crossover design is used for the investigation of the healthy cohort and a parallel design will be used for the patient group|t|f|t|f
33817687|NCT06378281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33817688|NCT03310372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817689|NCT04172688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817690|NCT06585436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33817691|NCT04944784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817692|NCT05937581|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33817693|NCT00996905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817694|NCT04873544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817695|NCT05815771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817696|NCT03063346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817697|NCT05492721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor does not know which glue was used|Each subject will have both glue types and serve as their own control|f|f|f|t
33817698|NCT03755271|||CASE_ONLY||PROSPECTIVE|||||||
33817699|NCT00522119|||COHORT||RETROSPECTIVE|||||||
33817700|NCT05195034|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34047249|NCT03658512|||COHORT||OTHER|||||||
33817701|NCT00964756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817702|NCT00871494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817703|NCT03317509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33817704|NCT03685578|||CASE_ONLY||PROSPECTIVE|||||||
33817705|NCT04110327|||COHORT||OTHER|||||||
33817706|NCT02350426|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33817707|NCT05781984|||CASE_ONLY||RETROSPECTIVE|||||||
33817708|NCT05326061|||COHORT||PROSPECTIVE|||||||
33817709|NCT06721169|||COHORT||PROSPECTIVE|||||||
33817710|NCT03368300|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Not masking, 2 groups parallel|"The primary aim of this study is to estimate the frequency and to characterize clinically atypical parkinsonism in the French West Indies and Guyana.~This study has been designed as epidemiological, multicentric transversal descriptive and longitudinal prospective study with biological collection and post-mortem neuropathological sub-study of brain tissue."||||
33817711|NCT05785975|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention is an integrated system built on the concept of nudging and made up of a trained family doctor, community outreach (using landline calls, and a single FIT test for occult blood. Together with the information, education, and communication (IEC) texts that were sent to the outreach participants by SMS. four screening healthcare zones that included 34 public primary care facilities in the Hail region.~The total sample size for the two trial arms is 2520 individuals. The calculation was done using the STATA version 15 data analysis software, the sample size command, and the cluster sizes of m1 = (60), m2 = (60), a control-group rate of (0.4), an experimental group rate of (0.6), the intraclass correlation coefficient (rho) of (0.02), a power beta of (0.8), and a sample of N1 = (1260), N2 = (1260)."||||
33817712|NCT03059147|NA|SINGLE_GROUP||TREATMENT||NONE||3 + 3 Designed Phase I study||||
33817713|NCT04099797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817714|NCT06721338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817715|NCT06442969|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817716|NCT04644770|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817717|NCT05120284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||subsequent ordered and alternating patients||||
33817718|NCT00183209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817719|NCT06176131|||COHORT||PROSPECTIVE|||||||
33817720|NCT00507845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817721|NCT04847908|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33817722|NCT06698276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817723|NCT04540796|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817724|NCT00768911|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817725|NCT05807542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817726|NCT06374186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Because this is a behavioral intervention, participant blinding is not possible. Randomization will occur after baseline assessment and participants will be instructed to not tell their provider their assigned condition.|A randomized parallel-group pilot study of a combination intervention using Motivational Interviewing (MI) and Contingency Management (CM) for patients with T2DM.|f|t|f|f
33817727|NCT02699437|||COHORT||CROSS_SECTIONAL|||||||
33817728|NCT00003697||||TREATMENT||||||||
33817729|NCT03736265|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Parallel Assignment|t|f|f|f
33817730|NCT06721156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817731|NCT06557876|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"* Interventional, single center, prospective, comparative, randomized (ratio of 1:1), open-label study.~* With 2 compared groups"||||
33817732|NCT02325752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33817733|NCT00005771|RANDOMIZED|PARALLEL||TREATMENT||||||||
33817734|NCT05440422|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33817735|NCT04426253|||CASE_ONLY||PROSPECTIVE|||||||
33817736|NCT06564142|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817737|NCT04908488|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Subjects will receive treatment based upon the randomized treatment sequence assignment.|t|f|t|f
33817738|NCT00705172|||OTHER||RETROSPECTIVE|||||||
33817739|NCT01153997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817740|NCT01755130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817741|NCT05650437|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817742|NCT05714280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817743|NCT06096506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817744|NCT03335722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"A researcher from another research group who is not involved in any aspect of the trial will perform the randomisation of participants into the sham and tDCS study arms using a minimisation procedure within randPack package in R (Carey and Gentleman, 2016). Allocation concealment will be achieved by assigning a unique 5-digit code per participant (containing no identifying information regarding trial arm). This will be emailed to the researcher. The code is used to deliver stimulation via study mode on the stimulator (http://www.neurocaregroup.com/dc_stimulator_plus.html). The participants and the researchers who will deliver the intervention, assess the outcomes, and analyse the data will be masked to trial arm."|Double-blind, placebo-controlled (sham tDCS), randomised trial, with 20 participants with developmental stuttering recruited for each of the two arms of the trial.|t|t|t|t
33817745|NCT06695988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817746|NCT05563961|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||t|f|f|f
34047250|NCT01667510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34047251|NCT06644118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817747|NCT04445246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817748|NCT02181192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817749|NCT04764695|NA|SINGLE_GROUP||SCREENING||NONE|Masking during data analysis. Technicians and investigators will not be aware of the participants personal data and particularities.|"Clinical trial with a pre-test/post-test design. Intervention group: Children and adolescents between 2 and 14 years old with a diagnosis of HM in any treatment stage who agree to participate in the project with the approval of their legal guardian.~Control group: Being a pre-test/post-test design, the same child will be the control at the end of the intervention. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed."||||
34047252|NCT01669330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34047253|NCT02076724|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047254|NCT03776942|||CASE_ONLY||RETROSPECTIVE|||||||
34047255|NCT04577027|NA|SINGLE_GROUP||TREATMENT||NONE|no masking|||||
34047256|NCT03955913|||COHORT||PROSPECTIVE|||||||
34047257|NCT00582816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047258|NCT05438108|NA|SINGLE_GROUP||TREATMENT||NONE||SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab||||
34047259|NCT06294366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047260|NCT00693745|||COHORT||PROSPECTIVE|||||||
34047261|NCT00141245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047262|NCT02275260|NA|SINGLE_GROUP||SCREENING||NONE||||||
34047263|NCT01911338|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
34047264|NCT04360135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34047265|NCT01011465|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34047266|NCT03875170|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34047267|NCT02537002|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34047268|NCT05209815|||COHORT||PROSPECTIVE|||||||
34047269|NCT00744965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817750|NCT00635752|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33817751|NCT04831398|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded in two trials. Practitioners and operators will not be allowed to communicate with the participants concerning whether they are receiving placebo/melatonin. Outcome assessors and statisticians may not be blinded to experimental allocation. Our placebo should satisfy two conditions of an ideal placebo: a) it should be indistinguishable from the experimental supplement to blinded participants, and b) it should be physiologically inert. In this study, 1 microliter McCormicks Pure Mint Extract will be mixed with 29 ml of filtered water and given to participants as a sublingual spray. This mixture will be non-caloric and will mimic the taste and sensation of the commercially available melatonin spray that will be used in the study (Onnit Labs Inc., Mint Flavor).|This study is a single-blind crossover design.|t|f|f|f
34047270|NCT03842007|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34047271|NCT04553471|NA|SINGLE_GROUP||TREATMENT||NONE||At least 10 participants will be enrolled in each cohort (soft tissue sarcomas, thoracic cancers, abdominal, and pelvic cancers).||||
34047272|NCT05629221|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047273|NCT03593460|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Adaptive Design||||
34047274|NCT06281496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||One site, two arm randomized controlled trial||||
33817752|NCT05759000|||CASE_ONLY||PROSPECTIVE|||||||
34047275|NCT02570867|||CASE_CONTROL||RETROSPECTIVE|||||||
34047276|NCT02632851|||CASE_CROSSOVER||PROSPECTIVE|||||||
34047277|NCT02159157|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047278|NCT00117884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047279|NCT02369003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817753|NCT02368288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837165|NCT03161613|||COHORT||PROSPECTIVE|||||||
33837166|NCT05354713|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837167|NCT00015080||||TREATMENT||||||||
34047280|NCT06533956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047281|NCT05878002|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047282|NCT06414057|||COHORT||PROSPECTIVE|||||||
34047283|NCT06356662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126458|NCT04212078|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126459|NCT03318445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126460|NCT05757180|RANDOMIZED|PARALLEL||PREVENTION||NONE||A cluster randomized-controlled trial design will be used with a two (condition: PET vs. active control) x three (time-point: baseline, post-training and FU) factorial-design.||||
34126461|NCT04803513|||COHORT||PROSPECTIVE|||||||
33837168|NCT04533048|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34047284|NCT05007431|||COHORT||RETROSPECTIVE|||||||
34047285|NCT03728348|||COHORT||PROSPECTIVE|||||||
34047286|NCT03224598|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The first cohort of the study will enroll a total of 12 subjects. In the second part of the study, subjects will be a randomized to additional two-arm cohorts. Subjects will be randomized to one of the following 2 treatment arms:~* A-101 40% without medically abrading the identified DPN prior to treatment~* A-101 40% with the identified DPN lesions medically abraded prior to treatment"||||
34047287|NCT04956250|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Modified Stepped-Wedge Randomized Controlled Trial||||
34047288|NCT04168060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047289|NCT04711187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047290|NCT01267565|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34047291|NCT03132935|||OTHER||RETROSPECTIVE|||||||
34047292|NCT06218537|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|One member of the team will prepare the two solutions, test and control solution, each 50 ml, and will give it to the patient, whithout the patient knowing what solution is. After 10 minutes, the investigator will perform upper GI endoscopy, also without him knowing what solution has been administered to the patient.|"Patients will be randomly allocated in one of the 2 study groups, using a randomization list.~The test group - 10 minutes before upper GI endoscopy, patients will drink a solution of 50ml water + 2 capsules of KREON 25000 UI, opened (with minimicrospheres, pellets) + 1.2g sodium bicarbonate, mixed. Adding sodium bicarbonate is necessary to dissolve the minimicrospheres of KREON.~The control group - 10 minutes before upper GI endoscopy, patients will drink a solution of 50ml water + 1.2g sodium bicarbonate, mixed."|t|f|t|f
34047293|NCT02897219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126462|NCT05493878|||CASE_CONTROL||OTHER|||||||
34126463|NCT05959317|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34126464|NCT02588417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34126465|NCT03773666|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126466|NCT05113654|||COHORT||CROSS_SECTIONAL|||||||
34126467|NCT05329753|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126468|NCT03410719|RANDOMIZED|PARALLEL||OTHER||SINGLE||block randomized, parallel, controlled,|f|f|f|t
33817754|NCT03094143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The result of the cardiac MRI will be blinded to care provider, participant and investigator. Group A will be unblinded, as participants can only enter group A if mid-wall fibrosis is present. Groups B and C will appear identical and the groups combined so the presence of mid-wall fibrosis will be blinded. Group D will be unblinded, as participants can only enter group D if mid-wall fibrosis is not present.~Outcome assessors will be blinded to allocation in all groups where outcome is adjudicated (groups A, B and C)"|\~1000 patients with asymptomatic severe aortic stenosis will be screened across the sites (this is how we have defined enrollment below). Patients at high risk of left ventricular decompensation based on high-sensitivity troponin or ECG will proceed to CMR. Participants are randomised based on the result of the cardiac MRI. Participants who have mid wall fibrosis (heart scarring) are randomised to receive either early surgical intervention (group A) or routine care (group B). Participants who have no mid wall fibrosis are randomised to routine care with study follow up (group C) or without study follow up (group D).|t|t|t|t
33817755|NCT02076802|||COHORT||PROSPECTIVE|||||||
33817756|NCT04417907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817757|NCT06719583|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33817758|NCT01524887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817759|NCT05217758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817760|NCT01786551|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817761|NCT03807947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817762|NCT03079414|||COHORT||PROSPECTIVE|||||||
33817763|NCT05540951|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33817764|NCT06721455|||COHORT||PROSPECTIVE|||||||
33817765|NCT05026177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Randomized treatments will be assigned by subject numbers in a randomly generated numeric sequence. Randomization (1:1:1) will be stratified by low or high Mini-Mental State Exam (MMSE; 16-20 and 21-27).~The randomization code will not be revealed to study subjects, Investigators, clinical staff, study monitors or the Sponsor until all subjects have completed therapy and the database has been finalized and locked."||t|t|t|t
33817766|NCT05957276|||COHORT||PROSPECTIVE|||||||
33817767|NCT04904302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817768|NCT02769390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33817769|NCT02740517|||CASE_ONLY||RETROSPECTIVE|||||||
33817770|NCT03188978|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33817771|NCT06270004|NON_RANDOMIZED|PARALLEL||OTHER||NONE||smoker and non smoker patients with unstable periodontitis||||
33817772|NCT06389071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817773|NCT02854709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33817774|NCT00914732|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33817775|NCT02400372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817776|NCT00346359||||TREATMENT||NONE||||||
33817777|NCT01461967|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33817778|NCT02659176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817779|NCT04471428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817780|NCT00402298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33817781|NCT05433129|NA|SINGLE_GROUP||OTHER||NONE||Device optimization and assessment||||
33817782|NCT06611423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
33817783|NCT05572515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817784|NCT01345253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817785|NCT03809871|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817786|NCT06036485|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 in-wound split design with random allocation||||
33817787|NCT05338775|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817788|NCT01195987|||COHORT||PROSPECTIVE|||||||
33817789|NCT02720783|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33817790|NCT06212180|||CASE_CROSSOVER||PROSPECTIVE|||||||
33817791|NCT06584760|||COHORT||PROSPECTIVE|||||||
33817792|NCT03152474|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (to investigator, subject, hospital care team and study team members except for research pharmacist), Randomized, Placebo Controlled Clinical Trial; Placebos were wrapped in foil and coded to prevent identification of study material.|Double Blind Placebo Controlled|t|t|t|f
33817793|NCT06720883|||COHORT||PROSPECTIVE|||||||
33817794|NCT06533111|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||The non-cardiac adult operating rooms at Memorial Hermann Hospital are split into 2 floors, Sarofim 2 and Sarofim 3. These floors will be the unit of clustering. One floor will be randomized to the intervention arm and the other to the control arm. Every 4 weeks both floors will be re-randomized again to either arm for a total of 18 weeks.|f|f|f|t
33817795|NCT05549102|||CASE_CONTROL||OTHER|||||||
33817796|NCT06528314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817797|NCT06095089|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817798|NCT00011167|||CASE_CONTROL||RETROSPECTIVE|||||||
33817799|NCT02122354|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33817800|NCT03842189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817801|NCT05021185|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33817802|NCT06721130|||CASE_ONLY||PROSPECTIVE|||||||
33817803|NCT06166901|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817804|NCT05554991|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Randomization will be carried out using iMedidata Randomization Trial Supply Management System with the dynamic allocation algorithm.|Randomized, double-blinded, placebo-controlled, parallel-arm, intervention study|t|f|t|f
33817805|NCT06720636|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817806|NCT05534854|||COHORT||PROSPECTIVE|||||||
33817807|NCT00229294|||||RETROSPECTIVE|||||||
33817808|NCT05144243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817809|NCT06720454|||COHORT||RETROSPECTIVE|||||||
33837169|NCT04259827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The cognitive, motor and wearing sensors assessment will be performed by investigators blind to the treatment performed|The study is a 3-arms single-blind parallel study. The patients are not blind to treatment , the investigators who will perform the baseline and follow-up assessment will be blinded to the treatment performed.|f|f|t|f
34126469|NCT02567799|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817810|NCT06022406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Prior to study commencement, a statistician will develop a randomization list and prepare sequentially numbered sealed envelopes containing the randomization group assignment. In this single blind study, participants will not know which arm they have been assigned to.~After screening, upon validation of eligibility, study staff will open the next sequentially numbered envelope to determine which group the study participant has been assigned to. Randomization after screening will allow sufficient time to prepare capsules and have them shipped to the study site before the first treatment visit (Visit 3-Day 0). The randomization group will be recorded on the randomization electronic case report form (eCRF)."|Single-blind, randomized, placebo-controlled, interventional study|t|f|f|f
33817811|NCT05518149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817812|NCT04898634|NA|SEQUENTIAL||TREATMENT||NONE||||||
33817813|NCT02112799|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33817814|NCT04479020|||COHORT||PROSPECTIVE|||||||
33817815|NCT06720155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817816|NCT04726319|RANDOMIZED|PARALLEL||SCREENING||NONE||Matched-paired randomized control trial||||
33817817|NCT06187155|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33817818|NCT06377059|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817819|NCT00083473|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817820|NCT06005675|||COHORT||PROSPECTIVE|||||||
33817821|NCT02877680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817822|NCT06372756|||COHORT||PROSPECTIVE|||||||
33817823|NCT04882878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817824|NCT03386357|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|Open-label, Controlled, randomized trial||||
33817825|NCT05606094|||OTHER||RETROSPECTIVE|||||||
33817826|NCT04397276|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817827|NCT06602362|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The primary investigator will be blinded to the study participants\&#39; study group status, and the statistician will be blinded from group assignment. Additionally, participants will be blinded to their own group status.||t|f|t|t
33817828|NCT06720103|||OTHER||CROSS_SECTIONAL|||||||
33817829|NCT03976102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Clinical Phase III, randomised, multicentre, double-blind study to demonstrate the equivalence of DRL_RI to MabThera® in subjects with previously untreated, LTB-FL.|t|t|t|t
33817830|NCT00508547|||COHORT||PROSPECTIVE|||||||
33817831|NCT03255785|NA|SINGLE_GROUP||TREATMENT||NONE|IOP outcome masked|iStent and iStent Supra||||
33817832|NCT06108050|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817833|NCT00243568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33817834|NCT03458494|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||randomized crossover dietary intervention|f|f|t|f
33817835|NCT05985525|||COHORT||PROSPECTIVE|||||||
33817836|NCT06642103|||OTHER||CROSS_SECTIONAL|||||||
33817837|NCT03188887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817838|NCT06387576|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parallel-arm control trial|t|f|f|f
33817839|NCT06719921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817840|NCT05053555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817841|NCT04344899|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817842|NCT04276740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817843|NCT05476770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817844|NCT06184295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817845|NCT01476137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047294|NCT06339866|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||The population of the research will be all patients who had adenotonsillectomy surgery between the ages of 6-12 in the Ear Nose and Throat Service of Zonguldak Bülent Ecevit University Hospital, and the sample will be all patients who had adenotonsillectomy surgery between the specified dates and who meet the inclusion criteria.|t|f|f|f
34047295|NCT03795961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To make sure that no bias should enter the assessment of the results, neither the patient nor the clinicians will be aware whether active tDCS will be applicated to a particular case. To ensure this result, two symbols (Square and Triangle) will be applicated to the physiotherapy sheet and only the physiotherapist knew the key for each symbol. The triangle may represent the cases of CTS for active tDCS and the square may represent the sham group or vice versa. At the end of the study the two groups will be revealed in order to analyze the results according to proper statistical measures.|the study subject will be allocated into two group ; active and sham group|t|f|f|t
34047296|NCT05893251|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Using the Random Team Generator mobile application."|The present study is an experimental, analytical, longitudinal, and prospective controlled randomized clinical trial.|t|f|t|t
34047297|NCT01609699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126470|NCT02714491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34126471|NCT04345510|||COHORT||PROSPECTIVE|||||||
34126472|NCT00167375|||||PROSPECTIVE|||||||
34126473|NCT00055926||||TREATMENT||NONE||||||
34126474|NCT03139032|NA|SINGLE_GROUP||TREATMENT||NONE||Proof of concept, open label||||
33817846|NCT06090487|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33817847|NCT04639960|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|the pharmacy has prepared the randomization. group membership will be revealed at the end of the study.|double blind placebo design|t|t|t|t
33817848|NCT06720337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomly allocated into one of the two study designed groups using computer-generated random numbers table.||t|t|t|t
33817849|NCT02451982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817850|NCT02691689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817851|NCT01263223|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817852|NCT05713253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817853|NCT03670277|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817854|NCT06616415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817855|NCT04639752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The person administering the outcome measures is blind to participant group.|Two groups: One receives MSM prevention intervention and the other group receives Enhanced Treatment as Usual (referral and monitoring).|f|f|f|t
33817856|NCT05287178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817857|NCT05798520|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33817858|NCT06686888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33817859|NCT05522777|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34126475|NCT03843528|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose-escalation study||||
34126476|NCT00610259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126477|NCT03686878|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126478|NCT00899418|||||RETROSPECTIVE|||||||
34126479|NCT05863390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34126480|NCT03343678||PARALLEL||TREATMENT||NONE||||||
34126481|NCT02524145|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34126482|NCT01701960|||COHORT||PROSPECTIVE|||||||
34149200|NCT02488642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817860|NCT03771573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|THE BLIND INVESTIGATOR, WHO WILL NOT KNOW THE GROUPS AND THE STUDY, WILL RECEIVE THE DATED NAMES WITH CODES TO CARRY OUT DATA ANALYSIS.|BLINDED AND RANDOMIZED CLINICAL TRIAL|f|f|t|f
33817861|NCT05241197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817862|NCT05037968|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment, Intra-patient control. Each patient serves as their own control.||||
33817863|NCT06719817|||COHORT||PROSPECTIVE|||||||
33817864|NCT04530721|||CASE_ONLY||PROSPECTIVE|||||||
33817865|NCT06644235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33817866|NCT01748851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817867|NCT06171919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817868|NCT05708976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study clinicians, who perform clinical interviews and provide cognitive behavioral therapy (CBT) treatments, will be masked to participant condition.|Participants are randomized to one of two study arms|t|t|f|t
33817869|NCT01608919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817870|NCT06423352|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047298|NCT02505685|||CASE_CONTROL||PROSPECTIVE|||||||
34047299|NCT02967328|||CASE_ONLY||PROSPECTIVE|||||||
34047300|NCT03532386|||CASE_CONTROL||PROSPECTIVE|||||||
34047301|NCT03325023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047302|NCT06684470|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047303|NCT05323448|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047304|NCT04050878|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Altough it is a single arm, the obtained STL files will be identified as A and B and the outcomes assessor will not be informed which group corresponds to the patient without or with the dental prostheses.|Determine the modifications caused by the use of different implant-supported dental prostheses in the soft tissues of the face, mainly upper and lower lips, by the use of a facial scanner.||||
34047305|NCT03821259|||CASE_ONLY||CROSS_SECTIONAL|||||||
34047306|NCT05480696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants will be randomly allocated (1:1) to the OF+INU supplementation (intervention) or placebo group in a concealed fashion using REDCap databases, generated by a computer algorithm in permuted blocks of 2 and 4, to avoid imbalances. Study investigators and participants will be blinded to group allocation.|t|t|t|t
34047307|NCT01993901|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34047308|NCT06683755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047309|NCT04296825|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34047310|NCT04722835|||COHORT||PROSPECTIVE|||||||
34047311|NCT06489782|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34047312|NCT01404156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047313|NCT05763485|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patients are randomized equally into an intervention and control group. The patients remain blinded to the procedure until 4 months after the initial procedure.|4 months after the initial procedure (ARMA or sham-procedure) patients are unblinded. Patients who initially received the sham procedure are now allowed to be treated by ARMA.|t|f|f|f
34047314|NCT02783469|||CASE_CONTROL||PROSPECTIVE|||||||
34047315|NCT06177808|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Intervention group : patients who received PCI with Wolverine cutting balloon to modify calcified coronary lesion; Control group : patients who received PCI with Non-compliant balloon to modify calcified coronary lesion||||
34047316|NCT00627445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047317|NCT02811354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047318|NCT00685399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047319|NCT01371110|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34047320|NCT01735721|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34047321|NCT06477263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047322|NCT05169918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047323|NCT01713764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047324|NCT05183165|NA|SINGLE_GROUP||OTHER||NONE||||||
34047325|NCT02847091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047326|NCT00079729|||||PROSPECTIVE|||||||
34047327|NCT04046770|RANDOMIZED|PARALLEL||OTHER||NONE|Patients and clinical staff will not be entirely blind after group allocation due to the nature of the interventions. Despite this, participants will not be directly informed of their group allocation in terms of usual care or intervention, and the nurses in the clinical staff will only be informed about the broad purposes of the research \[41\] - the study of a new double-chamber syringe for intravenous administration and flushing. In contrast, research nurses from the team outside the orthopaedic department will be blinded when rating some of the main outcomes such as phlebitis and infiltration.|A multi-centre, two-arm randomised controlled trial with partially blinded outcome assessment, of 146 adult patients. After eligibility analysis and informed consent, participants will receive usual intravenous administration of drugs with subsequent flushing procedures, with the double-chamber syringe (arm A) or with the classical syringes (arm B). The outcomes assessment will be performed on a daily basis by the unblind research team, with the same procedures in both groups. Some main outcomes, such as phlebitis and infiltration, will also be evaluated by nurses from a blind research team and registered once a day.||||
34126483|NCT03335150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Assessor are blinded to group assignment.||f|f|t|t
34126484|NCT04430608|RANDOMIZED|PARALLEL||OTHER||NONE||Patients are randomized 1:1 to either CGM or Fingerprick group||||
34126485|NCT00412191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817871|NCT03703492|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective, one-arm, observational study which will enroll participants with biopsy-proven DCIS scheduled for diagnostic breast MRI for preoperative staging/extent of disease evaluation as part of standard of care.||||
33837170|NCT05987020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single blinding|randomized controlled trial，RCT|t|f|f|f
33837171|NCT05698251|NA|SINGLE_GROUP||TREATMENT||NONE||Single Case Design||||
33837172|NCT01282528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837173|NCT02989623|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047328|NCT03383731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|In this study, the third party independent evaluation method is used to evaluate the results of the study. The analyzer is in the masking state, and the subjects and the surgeons are in the non-masking state..|"This is a prospective, randomized, controlled study involving multiple visits within 12 months. The patients with macular hole retinal detachment caused by high myopia are randomly divided into 2 treatment groups.~Group 1: standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion Group 2: standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange"|f|f|f|t
34047329|NCT05494814|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047330|NCT00427921|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047331|NCT06685731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047332|NCT02262312|||CASE_ONLY||CROSS_SECTIONAL|||||||
34047333|NCT02058537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047334|NCT02838914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047335|NCT04155216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047336|NCT00901108|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047337|NCT04076553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The investigators, therapists, and graduate student assessors will be blinded to treatment condition. The only staff member who cannot be blinded to condition is the study coordinator; she will be aware of condition because of managing randomization and assisting participants in the downloading of the intervention to participants' computers.|Participants will be randomly assigned to the ICT or ICT sham condition.|t|t|t|t
34047338|NCT04700917|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047339|NCT01529788|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34047340|NCT04915820|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34047341|NCT04195243|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34047342|NCT06349421|||COHORT||CROSS_SECTIONAL|||||||
34047343|NCT01194999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047344|NCT06672601|||COHORT||PROSPECTIVE|||||||
34047345|NCT01577953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047346|NCT00324025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047347|NCT03768297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|f|t
34047348|NCT04599153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Shunt setting at the two months and three months follow up.|Randomized, double blinded crossover design.|t|f|f|t
34047349|NCT06349226|||OTHER||PROSPECTIVE|||||||
34047350|NCT01745224|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||This was a comparative study where the device was used outside of the recommended treatment usage. It was used to assess the Revlite device for feasibility and not health outcomes.||||
34047351|NCT00555464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047352|NCT06621290|||OTHER||CROSS_SECTIONAL|||||||
34047353|NCT05878184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047354|NCT06520592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participnants will be randomly assigned to experimental or control groups by using block randomized method. In the study, we will use independent staff members who are not involved in outcome assessment to handle administrative tasks related to group assignments. In order to mask outcomes assessors, we will ensure that all documents and data sets used by the outcome assessors do not contain any information that could reveal group allocation.|For the interventional group, they will utilize AR-guided CPAP therapy to ensure a proper fit of the CPAP device mask and successful adherence to the CPAP therapy. For the standard of care group, they will receive the standard of care.|t|f|f|t
34047355|NCT01598571|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047356|NCT00930774|RANDOMIZED|FACTORIAL||||NONE||||||
34047357|NCT04044924|||COHORT||PROSPECTIVE|||||||
34047358|NCT06152874|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34047359|NCT05481541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047360|NCT02888912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047361|NCT01398618|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047362|NCT02469935|||||PROSPECTIVE|||||||
34047363|NCT04731012|||CASE_CONTROL||PROSPECTIVE|||||||
34047364|NCT01880684|||COHORT||PROSPECTIVE|||||||
34047365|NCT05870046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind masking with blinded assessor.|Longitudinal prospective, controlled, single-blind study|t|f|f|t
34047366|NCT00459290||||TREATMENT||NONE||||||
34047367|NCT00006160|RANDOMIZED|||TREATMENT||||||||
34047368|NCT03219840|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE||A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial|t|t|t|t
34047369|NCT04538053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047370|NCT04813575|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients with COVID 19 will be followed prospectively, those who has evidence of pulmonary fibrosis after six weeks of illness will be offered cryobiopsy, and the patients who does not have significant fibrosis or do not warrant biopsy will be control arm||||
34047371|NCT04710784|NA|SEQUENTIAL||PREVENTION||NONE||Stepped-wedge cluster randomized controlled trial||||
34047372|NCT04213066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047373|NCT01094470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047374|NCT00101478|||CASE_CONTROL||OTHER|||||||
34047375|NCT00505960|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33817872|NCT06286592|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Details of the specific interventions will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."||||
33817873|NCT04469517|||CASE_CONTROL||PROSPECTIVE|||||||
34126486|NCT03837990|||CASE_ONLY||PROSPECTIVE|||||||
33817874|NCT04878861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817875|NCT06720987|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33817876|NCT05903820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817877|NCT05557253|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33817878|NCT04045587|||COHORT||CROSS_SECTIONAL|||||||
33817879|NCT04702191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33817880|NCT05699603|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817881|NCT06169878|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817882|NCT06608511|||COHORT||PROSPECTIVE|||||||
33817883|NCT04035733|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase IIa open-label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects||||
33817884|NCT06564246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded study|"* Group 1 (control group): 22 patients who will receive Vonoprazan 20mg (Vonseca) and placebo of pantoloc daily for 8 weeks.~* Group 2: 22 patients who will receive Pantoprazole 40 mg (Pantoloc) and placebo of vonseca daily for 8 weeks."|t|f|f|f
33817885|NCT01998971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817886|NCT05457296|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|healthy volunteers|prospective case control and randomized crossover clinical trial|t|t|f|f
33817887|NCT06645691|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"This is a cross-sectional study conducted in healthy volunteers and patients with cardiovascular/cardiometabolic diseases.~Hyperpolarized 13C-pyruvate will be injected intravenously to participants and the metabolized products will be imaged in real time using MRI scanner. The goal is to determine normal values of glucose metabolism in healthy volunteers and study the potential applications of hyperpolarized imaging in patients with cardiovascular/cardiometabolic diseases.~All patients will be invited to participate in a repeat scan with the same imaging protocol."||||
33817888|NCT01871597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817889|NCT01684345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817890|NCT04810351|||COHORT||PROSPECTIVE|||||||
33817891|NCT00682344|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33817892|NCT06720805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047376|NCT05259462|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pre-to-post design trial that will last 1-year and include 2 waves (n=6 per wave)||||
34047377|NCT06574763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047378|NCT03970083|||OTHER||OTHER|||||||
34047379|NCT00036374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34047380|NCT03320382|||COHORT||CROSS_SECTIONAL|||||||
34047381|NCT05495295|NA|SINGLE_GROUP||TREATMENT||NONE||First-in-human clinical trial, including two parts: a dose escalation phase (part I) which will enroll patients with non-selected tumour types, followed by a cohort expansion phase (part II) in selected tumour types.||||
34047382|NCT06377371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047383|NCT01334827|NA|SINGLE_GROUP||OTHER||NONE||Mixed Methods Measurement Development study||||
34047384|NCT03304314|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34047385|NCT06133751|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Youth National Rowing Team of Poland|Participants randomly divided into one of two groups. The supplemented group (n=7) receives chokeberry capsules, while the control group (n=8) receives a placebo product.|t|f|f|f
34047386|NCT03451591|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Patients will be randomised to start one of four treatments; isosorbide mononitrate only; cilostazol only; both isosorbide mononitrate and cilostazol or neither isosorbide mononitrate nor cilostazol.|f|f|f|t
34047387|NCT01034436|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34047388|NCT00048893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047389|NCT03832517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047390|NCT00939315|||COHORT||PROSPECTIVE|||||||
34047391|NCT04415034|||OTHER||CROSS_SECTIONAL|||||||
34126487|NCT03807050|NA|SINGLE_GROUP||OTHER||NONE||||||
34126488|NCT00403013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126489|NCT05833035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126490|NCT03211819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|due to the nature of the trial only the outcome assessror will be masked from the intervention or control group||f|f|f|t
34126491|NCT03151122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34126492|NCT03051295|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817893|NCT06080438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817894|NCT03821285|NA|SINGLE_GROUP||SCREENING||NONE||Prospective, multicentre international||||
33817895|NCT02142478|||CASE_CONTROL||PROSPECTIVE|||||||
33817896|NCT05955768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817897|NCT00841321|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817898|NCT03841227|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817899|NCT00826527|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817900|NCT04430894|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33817901|NCT03593798|||COHORT||RETROSPECTIVE|||||||
33817902|NCT05189418|||COHORT||PROSPECTIVE|||||||
33817903|NCT00585364|||CASE_CONTROL||PROSPECTIVE|||||||
33817904|NCT05243602|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, controlled open-label clinical trial||||
34126493|NCT04303429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126494|NCT02168062|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34126495|NCT04133350|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126496|NCT03974126|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Genotype were blinded for the participants and all research staff except for the principal investigator. Amount of bread was not blinded.|Participants with low and high copy numbers of AMY1 were randomized to either 40 or 80 grams of starch in a crossover design.|t|t|f|t
33817905|NCT00165035|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817906|NCT04765020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33817907|NCT06720974|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33817908|NCT06632483|||COHORT||RETROSPECTIVE|||||||
33817909|NCT06608498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817910|NCT03234049|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126497|NCT06069180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126498|NCT01619761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126499|NCT01759342|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34126500|NCT02449811|||OTHER||PROSPECTIVE|||||||
34126501|NCT00442377|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34126502|NCT04373343|NA|SINGLE_GROUP||OTHER||NONE||Males and females meeting criteria for severe food addiction and interested in completing 16 week pilot treatment||||
34126503|NCT04015011|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126504|NCT02086981|||COHORT||PROSPECTIVE|||||||
34126505|NCT02870062|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34126506|NCT04430361|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126507|NCT02882191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126508|NCT01097603|||CASE_ONLY||CROSS_SECTIONAL|||||||
34126509|NCT03882593|||CASE_ONLY||PROSPECTIVE|||||||
34126510|NCT02574559|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126511|NCT02536144|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34126512|NCT01898286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126513|NCT03610854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126514|NCT05025410|||CASE_ONLY||PROSPECTIVE|||||||
34126515|NCT01738685|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34126516|NCT01484652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126517|NCT05393999|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34126518|NCT00355355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126519|NCT03399942|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34126520|NCT00047502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126521|NCT00335309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126522|NCT02822742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126523|NCT00608049|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34126524|NCT03384459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126525|NCT02069873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126526|NCT05748301|||OTHER||PROSPECTIVE|||||||
34126527|NCT06384846|||CASE_CONTROL||PROSPECTIVE|||||||
34126528|NCT00988156|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126529|NCT02529111|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34126530|NCT03710265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126531|NCT02849834|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34126532|NCT04940377|||COHORT||OTHER|||||||
34126533|NCT03344783|||OTHER||OTHER|||||||
34126534|NCT01843166|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34126535|NCT06375395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126536|NCT01970644|||COHORT||PROSPECTIVE|||||||
34126537|NCT04543877|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34126538|NCT05173012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126539|NCT04204850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126540|NCT05174338|||COHORT||RETROSPECTIVE|||||||
33817911|NCT03476954|NA|SINGLE_GROUP||OTHER||NONE||||||
33817912|NCT06721247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817913|NCT04190550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817914|NCT04474522|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
33817915|NCT06720363|||COHORT||PROSPECTIVE|||||||
33817916|NCT05022849|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33817917|NCT05632419|||COHORT||PROSPECTIVE|||||||
33817918|NCT04843046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817919|NCT05684120|RANDOMIZED|PARALLEL||TREATMENT||NONE||Waitlist control model||||
33817920|NCT00376259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817921|NCT03805685|||COHORT||PROSPECTIVE|||||||
33817922|NCT05480280|NA|SINGLE_GROUP||TREATMENT||NONE||This is an prospective, single-center, single-arm, Simon's two-stage design, phase IIa study.||||
33817923|NCT06641271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33817924|NCT04747496|||COHORT||PROSPECTIVE|||||||
33817925|NCT04430673|NA|SINGLE_GROUP||TREATMENT||NONE||Action Research Proof of Concept study in 2-Phases. Phase 1, 2-hour workshop: Phase 2 2-week within subject trial.||||
34126541|NCT02094118|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126542|NCT02517398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126543|NCT05841719|NA|SINGLE_GROUP||OTHER||NONE||capillary sampling||||
34126544|NCT00614419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34126545|NCT00331916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34126546|NCT02173405|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34126547|NCT00158626|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126548|NCT01741493|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
34126549|NCT03858517|||COHORT||PROSPECTIVE|||||||
34126550|NCT06363695|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126551|NCT03390517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126552|NCT02398201|NA|SINGLE_GROUP||OTHER||NONE||||||
34126553|NCT05020301|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34126554|NCT01651286|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34126555|NCT04114916|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126556|NCT06401499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126557|NCT05408273|||COHORT||CROSS_SECTIONAL|||||||
34126558|NCT04138563|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126559|NCT01022450|||CASE_ONLY||RETROSPECTIVE|||||||
34149201|NCT00480259|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149202|NCT06454149|||COHORT||PROSPECTIVE|||||||
34126560|NCT04483258|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Sevoflurane insufflation and intravenous sedation will be applied to the patients by changing them sequentially during each radiotherapy session.||||
34126561|NCT00668473|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126562|NCT03096639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The ultrasound core lab reviewers will be blinded to study allocation groups|1:1 randomization of treatment and control group|f|f|f|t
34126563|NCT00765401|||CASE_CONTROL||PROSPECTIVE|||||||
34126564|NCT02122146||||TREATMENT||NONE||||||
34126565|NCT04855240|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126566|NCT03672851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126567|NCT01774812|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34126568|NCT00625586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126569|NCT00411385|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126570|NCT02287194|||COHORT||PROSPECTIVE|||||||
34126571|NCT04556526|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126572|NCT00131352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126573|NCT04845672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126574|NCT03008070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126575|NCT01947335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126576|NCT01234181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126577|NCT02522169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126578|NCT03632460|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126579|NCT02578160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126580|NCT01104480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126581|NCT06301308|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34126582|NCT05287776|NA|SEQUENTIAL||TREATMENT||NONE||||||
34126583|NCT05445258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126584|NCT01502514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126585|NCT01565408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126586|NCT03797430|||COHORT||PROSPECTIVE|||||||
34126587|NCT02735421|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34126588|NCT01686971|||CASE_ONLY||PROSPECTIVE|||||||
34126589|NCT04170998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126590|NCT01768416|||CASE_ONLY||PROSPECTIVE|||||||
34126591|NCT05459441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single center prospective clinical study||||
34126592|NCT02695914|||COHORT||RETROSPECTIVE|||||||
34126593|NCT02645032|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Laboratory personnel who analyzes immunogenicity at sponsor is also blinded.||t|t|t|t
34126594|NCT05271747|RANDOMIZED|PARALLEL||OTHER||SINGLE|Both probiotic products will be provided in their commercial form. Both products will be individually placed inside opaque bags so that the investigator can not recognize the external case.|Randomized, multicentric, single-blind trial in infants between 2 and 12 weeks of age diagnosed with infant colic, who will be allocated to receive one of the two comercialized probiotic products B. Longum and P. Pentosaceus (branch one) or L. Reuteri (branch two) for 21 days|f|f|t|f
34126595|NCT01188941|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34126596|NCT00740753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126597|NCT05080439|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126598|NCT00420381|NA|SEQUENTIAL||TREATMENT||NONE||||||
34126599|NCT00750230|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126600|NCT03549338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126601|NCT03150147|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|PGD and ACR assessment will be performed by a blinded access|"Initially the study is a single center, prospective, open, blinded endpoint, non-randomized, controlled clinical trial. Six patients will be transplanted with the NICHCP method. These will be compared with contemporary control patients transplanted with standard ICSS (N=25). An analyze will be performed when these six patients has passed 180-days post-transplant. The result will be reported.~After the the initially study has been completed, the study will become a single center, prospective, open, blinded endpoint, randomized, controlled clinical trial. The continued study will comprise 17 patients in the test group and 17 control patients. The main outcomes will be reported on intention to treat basis. PGD and ACR assessment will be performed by a blinded access. Randomisation will be computer generated."|t|f|f|t
34126602|NCT00808522|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34126603|NCT02175485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126604|NCT05276128|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34126605|NCT01202890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126606|NCT00334568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126607|NCT00088491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33817926|NCT01072149|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34126608|NCT05402007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be a clinical trial previously randomized by electronic randomization system (www.random.org) and the allocation of volunteers in the study arms will be done without the participation of the researchers. The study will be double-blind since neither the volunteers nor the professional who will perform the Cardiopulmonary Rehabilitation protocol is aware of the objectives and clinical valences that will be measured by the study.|Three pre-post assessment groups (control/face-to-face intervention/self-performed home intervention)|f|f|t|f
34126609|NCT05557994|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126610|NCT05875844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126611|NCT04982705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126612|NCT06499103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126613|NCT00725686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126614|NCT06510179|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher performing the clinical examination will not know the group in which the patients are included.|Patients will randomly allocate one of three groups (Conventional toothbrush group, orthodontic toothbrush group, or single-tufted toothbrush group).|f|f|t|f
34126615|NCT05042648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34126616|NCT02808923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126617|NCT03719963|||COHORT||CROSS_SECTIONAL|||||||
34126618|NCT02542059|||CASE_CONTROL||PROSPECTIVE|||||||
34126619|NCT05789459|||COHORT||RETROSPECTIVE|||||||
34126620|NCT00870480|RANDOMIZED|CROSSOVER||||NONE||||||
34126621|NCT02593903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34126622|NCT00912574|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126623|NCT00270751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126624|NCT03417310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126625|NCT02528942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126626|NCT02342769|||OTHER||PROSPECTIVE|||||||
34126627|NCT06192290|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34126628|NCT01783197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126629|NCT05531552|||COHORT||PROSPECTIVE|||||||
34126630|NCT03804242|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants, school staff, researchers, and outcome assessor will all be aware of condition assignment|Randomized controlled pilot trial of intervention versus usual care||||
34126631|NCT04194879|||CASE_CONTROL||PROSPECTIVE|||||||
34126632|NCT00786305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817927|NCT04026555|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|No masking is completed as the information/waiver of consent sheet for the two arms needed to be individualized.|"For each patient, real-time data from clinical and administrative systems will be used by ReSCUE-ME to produce a MEWS++ score predicting the likelihood that the patient will require escalation of care within the next 6 hours. Upon the patient being admitted to the unit, the patient will be evaluated based on any update in the EMR. If the prediction score exceeds a high threshold, the RRT team will be notified directly. If the score is between a low threshold and the high threshold , the nursing team will be notified and increased nursing monitoring will be initiated. If the patient has met criteria for increased nursing monitoring, a refractory 8-hour refractory window will be applied during which no nursing alerts will be sent. However if the score exceeds the high threshold, the RRT team will be notified. Throughout the trial, the performance of the alerts will be monitored via web-based dashboards. If the performance is poor, the high and low thresholds will be adjusted."||||
33817928|NCT04300478|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Individuals will be randomized to either sedentary control/REx or REx/sedentary control in a 1:1 manner using online software (http://www.randomization.com).||||
33817929|NCT04598776|||COHORT||PROSPECTIVE|||||||
33817930|NCT01850888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817931|NCT05203822|NA|SEQUENTIAL||TREATMENT||NONE||This is a single sequence cross-over trial.||||
33817932|NCT06721260|||COHORT||PROSPECTIVE|||||||
33817933|NCT02475707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817934|NCT06721143|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33817935|NCT06720675|||COHORT||RETROSPECTIVE|||||||
33817936|NCT05065099|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will employ a quasi-experimental mixed design occurring in two sequential phases, assigning the first half of the sample to the control (standard care) group, and the second half to the OnTRACK intervention group. The between-subjects variable will be assignment to intervention or control condition and the within-subjects variable being time (beginning of recovery, end of recovery) to address the specific aims of the study.||||
33817937|NCT00029276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33817938|NCT02267746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817939|NCT06086132|||COHORT||CROSS_SECTIONAL|||||||
34126633|NCT04103112|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|An independent researcher at each site will perform leg assessments blind to participant allocation. This researcher will not have been involved in recruitment, stocking provision, adherence monitoring or behavioural interventions. Participants will be encouraged to remove their stockings on the day prior to their clinic visit, they will be asked not to discuss the stockings with the independent assessor. Blinding will be assessed by asking the assessors whether the patient attended study visits wearing a stocking, and whether the patient made it known that they had been wearing a stocking or not.||f|f|f|t
34126634|NCT01016288|||CASE_CONTROL||PROSPECTIVE|||||||
34126635|NCT03020004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817940|NCT06191419|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Odor bags are prepared by one staff member and labeled with a code so that other investigators administering tests cannot identify which treatment is being given and inadvertently influence outcomes. The code is not visible to participants. This prevents participants from anticipating the effect of the treatment.|Each subject experiences and reports on all of the odor blocker and control treatments.||||
34126636|NCT02962245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126637|NCT04751227|||COHORT||RETROSPECTIVE|||||||
34126638|NCT01882387|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126639|NCT00044369|||DEFINED_POPULATION||PROSPECTIVE|||||||
34126640|NCT00060710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126641|NCT04352543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126642|NCT05026151|||COHORT||PROSPECTIVE|||||||
34126643|NCT01034501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126644|NCT01527877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126645|NCT05394506|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"* To collect biological material (muscle and/or skin biopsies) and the phenotype of patients with mutations in the LMNA gene (within large families with variable clinical presentation or within cohorts of patients with recurrent mutations in the LMNA gene.~* To grade the severity of the muscle phenotype of these patients (severe, moderate, mild).~* Perform omics analysis on their biological material."||||
34126646|NCT04716608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomised controlled parallel groups|f|f|f|t
34126647|NCT02199093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126648|NCT04504630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126649|NCT01308359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126650|NCT01201928|||COHORT||PROSPECTIVE|||||||
34149203|NCT00316420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149204|NCT00509171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149205|NCT05630976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149206|NCT03601559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34149207|NCT03031392|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34149208|NCT01699074|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33817941|NCT00274976||||TREATMENT||NONE||||||
33817942|NCT04242498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817943|NCT06119386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817944|NCT04794101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||97 participants randomized in MGT-RPGR-021. 64 participants randomized to Immediate treatment arm. 33 participants randomized to the deferred arm. These participants will be treated in MGT-RPGR-022. All participants to be followed for 60 months.|f|f|f|t
33817945|NCT06334952|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33817946|NCT01731444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817947|NCT06720922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817948|NCT04893824|||CASE_ONLY||OTHER|||||||
33817949|NCT02465606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817950|NCT06719726|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||"This study utilized a Crossover design with a split-body approach, where each participant served as their own control. The intervention involved two pain management techniques:~PECS I block: Administered to the right breast by an anesthesiologist before surgery.~Local anesthetic infiltration: Performed on the left breast by the plastic surgeon during surgery.~This design allowed for direct comparison of the efficacy of the two interventions (PECS I block vs. local anesthetic infiltration) in managing postoperative pain within the same participant.~The crossover and split-body methodology minimized inter-individual variability and provided robust data on the relative effectiveness of each technique, as all other surgical and anesthetic factors were standardized across both sides."||||
33817951|NCT04295499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817952|NCT06720506|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33817953|NCT05347095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33817954|NCT05744505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817955|NCT06410547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817956|NCT05072678|||CASE_CONTROL||PROSPECTIVE|||||||
33817957|NCT03724695|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33817958|NCT05752058|||CASE_CONTROL||RETROSPECTIVE|||||||
33817959|NCT00420498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33817960|NCT04352894|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817961|NCT03981120|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be assigned a computer generated code to be used on data collection forms.||f|t|t|t
33817962|NCT03876678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||probiotic or placebo capsule|t|f|t|f
33817963|NCT05513222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817964|NCT02154516|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817965|NCT04707287|||COHORT||CROSS_SECTIONAL|||||||
33817966|NCT06585358|||COHORT||PROSPECTIVE|||||||
33817967|NCT04994418|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33817968|NCT05676541|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster randomized||||
33817969|NCT05082493|NA|SINGLE_GROUP||TREATMENT||NONE||This is a Phase 1, multicenter, open-label, dose escalation study of intravenous Berubicin in pediatric patients. The purpose of this first-in-pediatrics study is to examine the safety, tolerability, and PK of Berubicin and to estimate its MTD and/or RP2D when administered to pediatric patients with progressive, refractory, or recurrent HGG who have completed at least 1 standard line of therapy. This study will also make a preliminary assessment of the antitumor activity of Berubicin in this patient population. An exploratory evaluation of quality of life will also be performed||||
33817970|NCT05340283|||OTHER||RETROSPECTIVE|||||||
33817971|NCT05008211|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33817972|NCT04237987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817973|NCT06055972|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33817974|NCT04798898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33817975|NCT03227458|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study drug will be masked. 50 mg DHEA or placebo: double-blinded. Exercise will not be masked.|All participants will take 1 study pill (50 mg DHEA or placebo: double-blinded) daily for 36 weeks. The research pharmacist will dispense study drug according to the randomization code and maintain drug dispensation records, which will be monitored by the study biostatistician. Two-thirds of participants will engage in bone-loading exercise 3 days per week for the 36 weeks.|t|t|t|f
33817976|NCT06647121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to condition assignment||t|f|f|f
33817977|NCT04400214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Independent evaluators will assess pre-, post-, and follow-up naturalistic, food allergy assessment outcomes. These evaluators will have no knowledge as to the intervention participants received via their participation in this study.|Participants enrolled via the open-trial portion of this study will all receive a 5-session skills training intervention (n = 5 participants). All participants enrolled in the randomized trial portion of this study (n = 50 participants) will be randomly assigned to either a 5-session skills training or 5-session food allergy education intervention|f|f|f|t
33817978|NCT06720402|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33817979|NCT04916340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33817980|NCT06202105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33817981|NCT04288414|||CASE_ONLY||PROSPECTIVE|||||||
33817982|NCT03402399|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33817983|NCT05316155|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817984|NCT04462302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a parallel group randomized controlled, prospective study that examines the effect of an Internet-based pain coping skills program on pain severity and pain interference among adult cancer survivors experiencing persistent cancer-related pain.||||
33817985|NCT04205045|||CASE_CONTROL||PROSPECTIVE|||||||
33817986|NCT05394324|||COHORT||RETROSPECTIVE|||||||
33817987|NCT05527691|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33817988|NCT06502678|||CASE_ONLY||CROSS_SECTIONAL|||||||
33817989|NCT01483131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817990|NCT06293053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33817991|NCT04451720|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837174|NCT03618004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149209|NCT05153707|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149210|NCT05077098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047392|NCT06684093|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this study, only the Outcomes Assessor is masked to the group assignments. The assessors responsible for measuring muscle strength, jump height, and ground reaction force (GRF) are unaware of which participants belong to the Blood Flow Restriction (BFR) training group or the traditional high-intensity training group. This masking aims to minimize bias during the evaluation and analysis of performance outcomes. The participants, care providers, and investigators are aware of the group assignments, as they are directly involved in the delivery and participation in the specific training protocols.|"The study uses a Parallel Assignment model where participants are randomly assigned to one of two intervention groups.~Group 1: Blood Flow Restriction (BFR) Training Group - Participants engage in low-load resistance training (20-30% of 1-repetition maximum) with blood flow restriction applied to the working muscles using pressure cuffs. The training focuses on strengthening the quadriceps, hamstrings, and calf muscles.~Group 2: Traditional High-Intensity Training Group - Participants perform high-intensity resistance exercises (70-85% of 1-repetition maximum) targeting the same muscle groups as the BFR group.~Both groups undergo the respective training protocols three times a week over 8-12 weeks. Performance outcomes, including muscle strength, jump height, and ground reaction force (GRF), are measured at baseline, mid-intervention, and post-intervention. The parallel assignment allows a direct comparison of the effects of BFR training versus traditional high-intensity training on"|f|f|f|t
34047393|NCT02101736|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort A: Single-arm open label two-stage Simon optimal study design Cohort B: Single-arm open-label study design||||
34126651|NCT06308744|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants were not aware of the experimental condition in which they were randomly allocated. Data collection was performed blind to the experimental conditions, but data analysis was not performed blind. However, given that all analyses were pre-registered, it is unlikely that the lack of blinding in data analysis introduced bias.|The current multi-site project followed the route of a parallel randomized controlled trial. Each participant was randomly allocated to either an experimental condition corresponding to a 15-minute audio listening of one of four different mindfulness exercises (i.e., mindful walking, mindful breathing, body scan and loving kindness meditation) or to a control condition (i.e., listening to a 15-minute audio story excerpt). Participants who were assigned to the control group randomly listened to an excerpt of one of the three stories that the investigators selected for the present study.|t|f|f|f
34126652|NCT02981862|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33817992|NCT05485415|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are unaware whether they are in the intervention or the control group|Randomized Clinical Trial with a control group|t|f|f|f
34126653|NCT05765058|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigator and Assessor do not know to which group the testing product belongs|RCT (Randomized Clinical Study)|f|f|t|t
34126654|NCT03479450|||COHORT||PROSPECTIVE|||||||
34126655|NCT00405730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126656|NCT01244035|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34126657|NCT05598853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126658|NCT01427218|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34126659|NCT04907253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation of randomization numbers by the pharmacist provided as a randomization list prepared by the biostatisticians of the Montreal Heart Institute|Randomized, double-blind, placebo-controlled|t|t|t|t
34126660|NCT04361448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Each participant get study number. Samples will be identified by the study number.|Beside the regular sampling method of 1 nasopharyngeal swab, 2 extra swabs will be taken in each volunteer. Performance of the 3 methods for laboratory diagnosis by PCR of Covid-19 will be compared.||||
34126661|NCT02333812|||COHORT||CROSS_SECTIONAL|||||||
34126662|NCT02881424|||CASE_CONTROL||PROSPECTIVE|||||||
34126663|NCT05100355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126664|NCT02662426|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126665|NCT02341651|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126666|NCT04114175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34126667|NCT01279876|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126668|NCT04545879|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126669|NCT00373048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126670|NCT05721781|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34126671|NCT01791621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126672|NCT02975804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126673|NCT04941469|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a Pilot Randomized Controlled Trial designed to compare the effectiveness of specifically optimized off-the-counter foot orthosis versus plain off-the-counter foot orthosis in managing mechanical foot pains in the Subtle Cavus foot type~* Subjects recruited will be randomly assigned to either the plain off-the-counter foot orthosis group (Control Group) or the specifically optimized off-the-counter foot orthosis group (Intervention Group) based on a pre-specified randomization list during the Screening Visit.~* Randomization was performed using the Randomized Permuted Block Randomization method with blocks of six."||||
34126674|NCT06231407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects were recruited from an existing psychosis clinic and assigned to the participating psychiatry resident. A small group were misaligned and reconnected to use their data as a comparison for someone not receiving the intervention.||||
34126675|NCT06325254|||COHORT||RETROSPECTIVE|||||||
34126676|NCT02538536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126677|NCT04115124|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34126678|NCT02360072|||CASE_CONTROL||PROSPECTIVE|||||||
34126679|NCT02446821|NA|SINGLE_GROUP||TREATMENT||NONE||VeraCept intrauterine contraceptive device||||
34126680|NCT04754971|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Experimental design with pretest-posttest control group and follow-up measurements||||
34126681|NCT02359032|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34126682|NCT02722005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126683|NCT04149665|||CASE_ONLY||PROSPECTIVE|||||||
34126684|NCT05593354|||COHORT||PROSPECTIVE|||||||
33817993|NCT06450288|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33817994|NCT06721390|RANDOMIZED|PARALLEL||OTHER||SINGLE||Parallel Assignment - We will conduct a 2-arm randomized controlled trial.|f|f|t|f
34126685|NCT00883948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817995|NCT04860193|||CASE_CONTROL||PROSPECTIVE|||||||
33817996|NCT03389399|||COHORT||PROSPECTIVE|||||||
34047394|NCT00544323|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34047395|NCT04403633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047396|NCT03435536|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047397|NCT05481450|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A prospective, randomized, double-blind, parallel, placebo-controlled, clinical interventional study|t|t|t|t
34047398|NCT06197438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047399|NCT02300038|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34047400|NCT05960916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Dividing two groups according drill type and parallelly measured during study|t|f|f|f
34047401|NCT04438733|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047402|NCT06412731|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126686|NCT00115193|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34126687|NCT00173017|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||||||
34126688|NCT00442923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||||||
34126689|NCT02226224|||COHORT||PROSPECTIVE|||||||
34126690|NCT04063891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Double-Blinded, Placebo-Controlled Clinical Trial|t|t|t|t
34126691|NCT03345511|NA|SINGLE_GROUP||TREATMENT||NONE||interventional||||
34126692|NCT05135572|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34126693|NCT01191515|||CASE_ONLY||PROSPECTIVE|||||||
34126694|NCT06286111|||COHORT||PROSPECTIVE|||||||
34126695|NCT06169618|||CASE_CONTROL||OTHER|||||||
34126696|NCT04644510|||CASE_ONLY||PROSPECTIVE|||||||
34126697|NCT00358059|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34126698|NCT01350050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126699|NCT06512077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126700|NCT05369598|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34126701|NCT05593705|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34126702|NCT00898170|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34126703|NCT01484496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126704|NCT01382576|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126705|NCT05140135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126706|NCT00650663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126707|NCT01027962|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126708|NCT05296317|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Patients will be randomized :~* Either to a peg-G-CSF arm (with administration of peg-G-CSF on D2)~* Either to a G-CSF arm (with administration from D4 to D7 or D8). Blood samplig will be taken at D1, D4, D8 and D14 for each arm."|t|f|f|f
34126709|NCT03960879|||COHORT||PROSPECTIVE|||||||
34126710|NCT06090955|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126711|NCT01426204|||CASE_ONLY||PROSPECTIVE|||||||
34126712|NCT00291031|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34126713|NCT03877003|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized crossover design||||
34126714|NCT05509062|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment Group 1 Treatment Group 2 Treatment Group 3||||
34126715|NCT03177018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Exploratory, monocentric and prospective study||||
34126716|NCT02859831|||CASE_CONTROL||PROSPECTIVE|||||||
34126717|NCT05317026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126718|NCT01351701|||CASE_ONLY||PROSPECTIVE|||||||
34126719|NCT06009822|||COHORT||CROSS_SECTIONAL|||||||
33817997|NCT04634552|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33817998|NCT05135741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33817999|NCT01541176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818000|NCT04189224|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33818001|NCT02965352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818002|NCT05815693|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818003|NCT02650661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818004|NCT06638060|||COHORT||PROSPECTIVE|||||||
33818005|NCT04276857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818006|NCT06721104|||CASE_CONTROL||PROSPECTIVE|||||||
33818007|NCT04015180|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33818008|NCT02962609|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33818009|NCT04028063|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, non-randomized, single-institution, single arm Phase II study conducted using a Simon two-stage design with an additional safety lead-in.||||
33818010|NCT06134804|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33818011|NCT03414515|||CASE_ONLY||PROSPECTIVE|||||||
33818012|NCT06720207|||COHORT||PROSPECTIVE|||||||
33837175|NCT00292344|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33837176|NCT00902811|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047403|NCT06328387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The research model consists of four arms：~1. arm A: SG.~2. arm B: HCQ+SG.~3. arm C: T-DXd .~4. arm D: HCQ+T-DXd."||||
34047404|NCT00000495|RANDOMIZED|PARALLEL||PREVENTION||||||||
34126720|NCT06105411|||COHORT||PROSPECTIVE|||||||
34126721|NCT06074237|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Non-blinded, single group educational intervention||||
33837177|NCT02214875|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126722|NCT02705612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126723|NCT06224907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126724|NCT00820144|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34126725|NCT02811120|||OTHER||OTHER|||||||
34126726|NCT03525002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind||t|t|t|f
34126727|NCT03183765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126728|NCT05433701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126729|NCT05255692|NA|SINGLE_GROUP||SCREENING||NONE||||||
34126730|NCT04535973|||CASE_CONTROL||PROSPECTIVE|||||||
34149211|NCT01927042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047405|NCT05756816|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE|No masking|A controlled and stepwise reduction in oxygen blood levels, with both the SurePulse VS and SurePulse VSP placed on the volunteer.||||
34047406|NCT05354778|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This will be a multicenter, randomized, open-label clinical trial with two parallel groups: hydrocortisone and placebo. Data will be analyzed as intention-to-treat."||||
34047407|NCT05225870|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Fifty, paired formalin-fixed and paraffin embedded tissue blocks from the colorectal carcinomas and adjacent non neoplastic colonic mucosa will be prepared and sectioned. From each block; one section will be stained by Haematoxaline and Eosine to establish diagnosis of colorectal carcinomas and to determine the degree of differentiation and degree of invasion of the underlying colonic tissues. Corresponding sections from each Formalin-fixed paraffin embedded tissue blocks will be immunohistochemically stained by anti- Human Cortactin antibody, to detect any association between cortactin expression and colorectal carcinoma.||||
34047408|NCT06165835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047409|NCT04229654|||COHORT||CROSS_SECTIONAL|||||||
34047410|NCT04397497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047411|NCT05504538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047412|NCT02276560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047413|NCT00708812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047414|NCT06575933|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047415|NCT05198024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047416|NCT06444256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047417|NCT03678714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is not possible to mask participants or research team to the allocated intervention. Outcome assessors will be blinded to group allocation for anthropometric and fitness measures.|Participants will be randomised into either an exercise group, a lifestyle physical activity group, or a control group, for a duration of 12 weeks.|f|f|f|t
34047418|NCT06390332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047419|NCT05463289|NA|SINGLE_GROUP||SCREENING||NONE|All participants will undergo point-of-care diabetic retinopathy screening. Participants will know that they will undergo point-of-care diabetic retinopathy screening at the time of consenting.|||||
34047420|NCT00474981|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047421|NCT03121001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047422|NCT01135381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34047423|NCT02640911|||CASE_ONLY||PROSPECTIVE|||||||
34047424|NCT05422755|||OTHER||PROSPECTIVE|||||||
34047425|NCT01875757|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34047426|NCT03999164|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047427|NCT00850408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047428|NCT03829826|||COHORT||PROSPECTIVE|||||||
34047429|NCT05277051|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||4 Dose Escalation arms (Arm A: GSK4381562 alone; Arm B: GSK4381562 plus dostarlimab; Arm C: GSK4381562 plus dostarlimab plus belrestotug; Arm I: GSK5764227 plus dostarlimab) and 5 other arms (Arm D: dostarlimab plus belrestotug; Arm E: dostarlimab plus belrestotug plus GSK4381562; Arm F: dostarlimab plus belrestotug plus nelistotug; Arm G: China cohort: dostarlimab; Arm H: China cohort: dostarlimab plus belrestotug).||||
34047430|NCT04410146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Cognitive improvement, as measured by blinded assessment, utilizing the comprehensive neurocognitive battery.~Imaging assessment by blinded core laboratory"||f|f|f|t
34047431|NCT04638283|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participant is randomized by a lottery to participate either in the intervention group receiving the intervention described above or the controlgroup receiving TAU.||||
34047432|NCT04480424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047433|NCT05648201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047434|NCT06682403|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Participants who fill out the survey linked to study posters and brochures will be randomized to either receive a cable lock as the default safety device option or the choice between a cable lock or lock box, shipped to their address. For individuals who take a cable lock at time of receiving a brochure, they are automatically assigned into the cable lock group.|t|f|f|f
34047435|NCT02403661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047436|NCT03412734|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047437|NCT02701530|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047438|NCT03826888|||CASE_ONLY||PROSPECTIVE|||||||
34047439|NCT04437290|||COHORT||PROSPECTIVE|||||||
34126731|NCT05182450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Capsules will disguise potential differences in colour/particle size of powders||t|t|t|t
34126732|NCT02990715|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The colonoscopists will be blinded to the C-Scan system results and FIT results and the reviewers of C-Scan system results will be blinded to Fit and colonoscopy results||f|t|t|f
34126733|NCT05522283|||COHORT||PROSPECTIVE|||||||
34047440|NCT02714595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126734|NCT04970173|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34126735|NCT03215381|NA|SINGLE_GROUP||OTHER||NONE|No Masking|||||
34126736|NCT04244240|||COHORT||PROSPECTIVE|||||||
34126737|NCT05641012|||COHORT||PROSPECTIVE|||||||
34126738|NCT02339844|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047441|NCT04174664|||COHORT||PROSPECTIVE|||||||
34126739|NCT03023306|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126740|NCT04277546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126741|NCT00618007|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126742|NCT03587896|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants, facilitators, and research staff involved in the screening and baseline assessment will not be blind to the interventions provided during the trial. Outcomes assessors will be kept blind to the study conditions.|RE-DEFINE is a prospective, randomized, parallel-group trial that will follow study participants over a period of 12-months. Syrian refugees with psychological distress, but without a mental disorder according to the MINI International Neuropsychiatric Interview (M.I.N.I.) for DSM-V and ICD-10, will be randomly assigned to the Self Help Plus intervention or to enhanced treatment as usual (ETAU).|f|f|f|t
34126743|NCT03123900|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34047442|NCT05230706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Subjects randomized to the experimental group were allocated to alternating light/darkness conditions as follows: from 07:00 to 19:00 hours the subjects were kept under normal room light conditions; from 19:00 to 07:00 of the following day the conditions were modified by placing the patient under an acrylic cephalic helmet which exposed them to light at 25 lux for 12 hours every day. The control group was kept under normal room light conditions (CBL) 24 hours a day.||||
34047443|NCT04363229|||OTHER||CROSS_SECTIONAL|||||||
34047444|NCT03756623|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34047445|NCT05074238|RANDOMIZED|PARALLEL||OTHER||SINGLE||Factorial Assignment At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).|f|f|f|t
34047446|NCT06128928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047447|NCT02933229|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34047448|NCT01533129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047449|NCT02693535|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047450|NCT00994461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047451|NCT04158284|||COHORT||PROSPECTIVE|||||||
34047452|NCT03763825|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047453|NCT05450575|||OTHER||PROSPECTIVE|||||||
34047454|NCT06413628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The randomization and assignment of patients to treatment groups was carried out by dental experts who were not informed about the treatment groups.|group I received threaded tapered screw appliance therapy , patients in group II received low-level laser therapy, and patients in group III received low-level laser therapy in addition to threaded tapered screw appliance therapy.|f|f|t|f
34047455|NCT00680264|||CASE_CONTROL||PROSPECTIVE|||||||
34047456|NCT06575530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34047457|NCT05068531|||COHORT||PROSPECTIVE|||||||
34047458|NCT06683235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047459|NCT05346081|||COHORT||CROSS_SECTIONAL|||||||
34047460|NCT06061003|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the study design, control group will not receive any fractured models for practical lectures therefore only outcome assessor will be blinded to group allocation.|Two groups as intervention and control groups. Assessments will be performed before intervention, and after the theorical/practical lectures.|f|f|f|t
34047461|NCT00792792|||CASE_ONLY||PROSPECTIVE|||||||
34047462|NCT04974138|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, randomized, controlled, double-blind, double-dummy clinical trial|t|t|t|t
34047463|NCT03338101|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34047464|NCT04116970|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047465|NCT06492850|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047466|NCT04396197|||COHORT||PROSPECTIVE|||||||
34047467|NCT06575036|NA|SEQUENTIAL||TREATMENT||NONE||Up-and-down dose finding method using biased coin design||||
34047468|NCT03176342|NA|SINGLE_GROUP||OTHER||NONE||||||
34047469|NCT04625881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Active product and placebo will have the same appearance. All vials will have an unique numerical code|Double blind parallel study comparing a fiber supplement with a fiberless placebo|t|t|t|t
34047470|NCT00151242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047471|NCT05674708|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34047472|NCT04299061|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047473|NCT02484417|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33818013|NCT04546178|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The trained therapist conducting the symptom assessments will not have access to information regarding that participant's treatment, and the person providing the treatment will not have access to the information regarding assessments of that participant's symptoms. Therapists will only conduct a symptom assessment for participants that are working with another therapist; they may not conduct a symptom assessment for participants with whom they are working through the intervention.|A single-case experimental design (SCED), specifically, a multiple-baseline design (MBD; Kratochwill et al., 2010) will be used; the MBD temporally staggers intervention start times across participants, thereby creating a control group composed of each individual's pre-intervention scores. Randomization of each participant's treatment start time will be used to increase internal validity and minimize bias (Kratochwill \& Levin, 2010). Participants will be randomized using a random sampling/assignment generator (randomizer.org). An MBD is an ideal design for a study focused on the optimization of PE+ and this approach will allow a fine-grained assessment (Lobo et al., 2017) of its effectiveness in EPP. This design can also detect significant changes during each phase of the intervention. In order to meet standards of evidence for SCEDs, this study will include a total of five treatment phases, which exceeds the recommended minimum of three phases (Kratochwill et al., 2010).|f|f|f|t
33818014|NCT02570815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818015|NCT01504178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34047474|NCT04496193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047475|NCT00117533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047476|NCT01416493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047477|NCT03119675|NA|SINGLE_GROUP||SCREENING||NONE||||||
34047478|NCT04132804|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-center pilot study. All patients enrolled in the study will participate in the Tai Chi treatment.||||
34126744|NCT04130893|RANDOMIZED|CROSSOVER||OTHER||NONE||"The study will consist of 3 sessions, It is a prospective crossover study. During the first session, the inclusion and non-inclusion criteria will be checked, then the cold water hand immersion test will be carried out to ensure the good tolerance of this test and then determine the basic values.~During the second and third sessions, Two different auricular stimuli will be done to the ear during the hand immersion test."||||
34126745|NCT04847570|NA|SINGLE_GROUP||OTHER||NONE||Non-clinical intervention||||
34126746|NCT01839461|||COHORT||PROSPECTIVE|||||||
34126747|NCT00418093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126748|NCT04844541|||COHORT||PROSPECTIVE|||||||
34126749|NCT01479764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126750|NCT00604552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126751|NCT01396356|||CASE_CONTROL||PROSPECTIVE|||||||
34126752|NCT02477527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126753|NCT04902430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessors will be blind. The patients name will be sealed from pre and post radiographs and study models. Then two assessors will carry out, blindly and independently, the measurements and analysis of the study||f|f|f|t
34149212|NCT03175146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149213|NCT01951313|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|t|f|f
33818016|NCT05270889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818017|NCT06720090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818018|NCT05028283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818019|NCT06167330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818020|NCT04176549|||COHORT||PROSPECTIVE|||||||
33818021|NCT05721053|||COHORT||PROSPECTIVE|||||||
33818022|NCT05689502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818023|NCT06272981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818024|NCT06638892|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818025|NCT05596851|||OTHER||PROSPECTIVE|||||||
33818026|NCT06665464|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|The researchers performing the sample and data analyses will be blinded until all analyses are finalized.|This intervention study has a randomized, cross-over, open label design||||
33818027|NCT05513560|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants are blinded to intervention in so far as the labelling of the study intervention. However, it is possible that the participant may figure out allocation arm, by the mode of administration, dosing frequency (once a day versus 3 times per day), and treatment form (pill, powder, intervention) etc.|"RECLAIM is a Canada-wide phase ll/lll, prospective, adaptive randomized controlled platform trial that is intended to study various interventions for patients with long COVID. Interventional arms may be discontinued based on interim analysis results and new interventions may be selected and included as part of the platform as the trial progresses. As such, the protocol and consent documents are a modular design including;~* Master Protocol and informed consent documents: Contain information applicable to the whole platform.~* Interventional Sub-Protocols: Contain additional information, specific to the interventional arm.~Interventional Sub-Protocols may be modified, discontinued, or added without revisions to the Master Protocol."|t|f|t|t
33818028|NCT05761873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research team will remain blinded to the identity of which practice has been assigned which pseudonym. However, clearly it is impossible for the ICB and the practices themselves to be blinded to the assignment status of each practice due to the nature of the intervention. The ICB will retain the process of sending out reports by email and post, as would be standard practice in such a quality improvement project.|The study design is a cluster Randomised Controlled trial, where primary care practices within the NHS West Yorkshire ICB region would be randomised by Primary Care Network (PCN) to receive either paper copies of A\&F reports and emailed PDF A\&F reports, or emailed PDF A\&F reports alone. The research team will randomise (using a simple computerised Random Number Generator) each cluster of PCN practice pseudonyms to receive their audit and feedback report either by email alone, or by email and a physical copy through the post. To prevent contamination effects and for ease of analysis, cluster randomisation would be utilised on a Primary Care Network (PCN) basis. Once randomised, each practice will receive 7 A\&F reports over the course of a year in their allocated format, informing them of their progress.|f|f|t|f
33818029|NCT00690534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818030|NCT06648707|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33818031|NCT06650410|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Investigators and outcome assessors will be blind to group allocation of participants. Participants will not be blind to group allocation because they will know what group they are assigned to. The randomization sequence will be created and maintained using REDCap and will be conducted by exercise professionals delivering the intervention who are not blind to group allocation.|Participants will be randomized in a 1:1 ratio to one of two arms. The study includes a wait-list control, indicating all participants will receive the intervention but at different time points. One group will receive the intervention immediately, whereas the other group will receive the intervention 10 weeks after being randomized (wait-list control).|f|f|t|t
33818032|NCT06037109|||COHORT||RETROSPECTIVE|||||||
33818033|NCT00004578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818034|NCT04279054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818035|NCT00703365|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818036|NCT06585332|||CASE_ONLY||PROSPECTIVE|||||||
33818037|NCT06559306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818038|NCT01671371|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33818039|NCT05467267|||CASE_ONLY||PROSPECTIVE|||||||
33818040|NCT06450834|||COHORT||PROSPECTIVE|||||||
33818041|NCT06098508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Other members of the study team, such as those who recruit, screen, and coordinate research visits, will be masked. Additionally, the occupational therapist who performs baseline pain ratings and arm function assessments will also be masked.||t|f|f|t
33818042|NCT05472194|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be randomly assigned for the experimental or control group with no information on the nature of the group they will be assigned. Additionally, no information about the training activities will be passed on to the participants.|The protocol includes a randomized controlled trial with a follow-up at six months involving two groups per age range (5,6 and 7Y) -a training group, which will be enrolled in the InSchool program and an active control group that will be participating in the regular kindergarten/elementary school activities. Participants will be randomly assigned to each group to control for inter-individual variability in executive functions' developmental level, which could distinctly impact the study results.|t|f|f|f
33818043|NCT06130566|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818044|NCT03180086|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33818045|NCT00398749|||||PROSPECTIVE|||||||
33818046|NCT03890692|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818047|NCT01304940|||COHORT||CROSS_SECTIONAL|||||||
33818048|NCT06336642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818049|NCT06412081|||COHORT||PROSPECTIVE|||||||
33818050|NCT00525200|RANDOMIZED|PARALLEL||||NONE||||||
33818051|NCT03363009|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33818052|NCT06280391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33818053|NCT03684434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818054|NCT01668992|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818055|NCT00706602|||COHORT||PROSPECTIVE|||||||
33837178|NCT04625686|||COHORT||PROSPECTIVE|||||||
34126754|NCT04887194|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Two Part, Phase 1 study enrolling patients with advanced tumor types into two cohorts: drug-drug interaction (DDI) and QTc. All patients receive the same anticancer treatment.||||
34126755|NCT05045859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, therapists, investigators and outcome assesors are blind to the condition the individual participant was assigned to, by encrypting the names of the individual into a number-letter codes.The therapists led the intervention group was not aware of the participants condition.|The study will be based on an RCT design. The screening process will consist of an initial phone call and two video conference sessions, to assess eligibility. Eligible Couples will be randomized using block randomization for assignment to two conditions: A CBCT and a waitlist (WL) control. The WL group will be assigned to CBCT after the waiting period. The design includes four points of assessment: Pre-treatment/pre-WL (baseline) (T1); during treatment/waiting period (T2 - different measures at various intervals); post-treatment/post-waiting period (T3); and at a 4-month follow-up (T4). Self- report measures will be administered at all time-points. A dyadic communication lab interaction will be conducted at T1 \& T3. At T2, PTSD and marital satisfaction will be measured in every session. physiological monitoring will be conducted at T1 and T3, and at six out of 15 sessions. qualitative interviews with a randomly selected sub-sample (N=12) will take place at T1 and T3.|t|t|t|t
34126756|NCT03725072|NA|SINGLE_GROUP||OTHER||NONE||||||
34126757|NCT04902690|||COHORT||PROSPECTIVE|||||||
34126758|NCT02432937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126759|NCT01941927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126760|NCT00219596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126761|NCT02599311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126762|NCT04672148|||CASE_CONTROL||RETROSPECTIVE|||||||
34126763|NCT05659914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126764|NCT00628498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126765|NCT00288548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34126766|NCT00809926|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34126767|NCT01779752|||COHORT||PROSPECTIVE|||||||
34126768|NCT03174626|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126769|NCT05449041|||CASE_CONTROL||PROSPECTIVE|||||||
34126770|NCT06091046|||OTHER||CROSS_SECTIONAL|||||||
34126771|NCT03202433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blocks swapped.|Allocation of two groups (Study and Control)|f|f|f|t
34126772|NCT02365181|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126773|NCT01760616|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126774|NCT06513039|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|triple blinding|Three group randomized clinical trial study|t|t|t|t
34126775|NCT03971162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126776|NCT02343601|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34126777|NCT00180557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126778|NCT04984096|||CASE_CONTROL||RETROSPECTIVE|||||||
34126779|NCT03130725|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study design will be parallel group, equivalence randomized controlled trial. Aim is to determine the equality of the Amalgam sealants retention compared to resin based sealants retention.||||
34126780|NCT00886327|||COHORT||PROSPECTIVE|||||||
34126781|NCT00964951|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126782|NCT06114940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126783|NCT06302803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34126784|NCT01977898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126785|NCT00855374|||CASE_CONTROL||PROSPECTIVE|||||||
34126786|NCT00802620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126787|NCT02931838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126788|NCT03274947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126789|NCT03634111|RANDOMIZED|PARALLEL||OTHER||NONE|Participants were cesarean section with general anesthesia|Transversus abdominis plane block under the ultrasound guidance||||
34126790|NCT05912491|||COHORT||PROSPECTIVE|||||||
34126791|NCT04067089|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34126792|NCT01962428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126793|NCT03474263|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label Biomarkers-Driven Study Historical controls||||
34126794|NCT02634242|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34126795|NCT02476604|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34126796|NCT01021176|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34126797|NCT02474303|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group Assignment||||
34126798|NCT01424358||PARALLEL||||SINGLE|||t|f|f|f
34126799|NCT02215057|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126800|NCT05842746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126801|NCT02655276|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33837179|NCT04429295|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837180|NCT02867917|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33837181|NCT02043873|||CASE_CONTROL||RETROSPECTIVE|||||||
33837182|NCT05011344|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34126802|NCT00153595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34126803|NCT03841851|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Each patient will be given acode by the researcher and the observers will be blind to which group this case belong|"This study will be conducted on patients with badely decayed teeth in aesthetic zone and need immediate fixed restoration .~This study is to be conducted in Dental Implant Clinic, Faculty of Dentistry, Cairo University, Egypt.~All the patients will be entailed about the study and given their approval to participate on written consent."|t|f|t|f
34126804|NCT00787241|||COHORT||RETROSPECTIVE|||||||
34126805|NCT01673776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126806|NCT00572429|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34126807|NCT01108328|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34126808|NCT01152125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126809|NCT01316458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818056|NCT04912726|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Assignment concealment will be ensured using sealed and sequenced opaque (dark) sealed envelopes containing the assignments. An investigator will carry out the assignment, write down the assignment number in a specific format, seal the opaque envelope and number it consecutively. These envelopes will be stored in the neonatal intensive care unit of the hospital child jesus where the study will be carried out. Once a subject has met the inclusion criteria, the neonatal intensive care unit pharmacy service will be notified, staff not participating in the study who will make a phone call to the investigator so that he can assign the label number to the new subject who I enter the study, the pharmacy shift personnel are in charge of labeling and delivering the product to the nursing staff. The active product intravenous sildenafil and the placebo are packaged in identical burette, the burette content is visible and the coloration is transparent.|Randomized, controlled, double-blind clinical trial|t|t|t|t
33818057|NCT04107844|||COHORT||PROSPECTIVE|||||||
33818058|NCT06645106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818059|NCT01072734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818060|NCT00266136|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33818061|NCT04972318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818062|NCT06719934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818063|NCT05407844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818064|NCT05652335|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818065|NCT06330363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|One let will receive the laser therapy, the other one will get a sham laser. The person analyzing the samples will be blinded to legs.|Within-subject study|t|f|f|t
33818066|NCT05531292|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818067|NCT06394739|||COHORT||PROSPECTIVE|||||||
33818068|NCT05344352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818069|NCT05130359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818070|NCT06721273|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33818071|NCT04950816|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33818072|NCT02397226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818073|NCT04245423|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33818074|NCT05961228|NA|SINGLE_GROUP||SCREENING||NONE|"participants will not be aware of the Schroth method or the difference between the exercises"|"one group - adolescent with scoliosis. The function and asymmetry of back muscles will be examined in different positions and with specific spinal corrections based on scoliosis pattern and according to the Schroth method in the entire sample."||||
33818075|NCT03512041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked to their group assignment (RLIC or Sham conditioning) throughout the study. Participants will intuitively know the dose (number of cycles) of their assignment.|Single blinded, randomized controlled trial|t|f|f|f
33818076|NCT06286319|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33818077|NCT04606381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818078|NCT01452204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818079|NCT04396236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818080|NCT03144076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33818081|NCT01361789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818082|NCT06173063|NA|SINGLE_GROUP||OTHER||NONE||25 adult subjects from a screening population of 200||||
33818083|NCT02804815|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33818084|NCT05038319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33818085|NCT00001154|||CASE_ONLY||PROSPECTIVE|||||||
33818086|NCT05526248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818087|NCT04485013|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818088|NCT04395196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818089|NCT01445379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818090|NCT00538616|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33818091|NCT06448546|||CASE_ONLY||CROSS_SECTIONAL|||||||
33818092|NCT02959866|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33818093|NCT04653987|||COHORT||OTHER|||||||
33818094|NCT04077463|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818095|NCT02988232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818096|NCT05267379|||COHORT||PROSPECTIVE|||||||
33818097|NCT05871489|||COHORT||PROSPECTIVE|||||||
33818098|NCT04005248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cross-sectional study||||
33818099|NCT05793047|||COHORT||PROSPECTIVE|||||||
33818100|NCT03594045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818101|NCT06611241|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818102|NCT03017716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818103|NCT05341713|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33818104|NCT00804765|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818105|NCT04114903|||OTHER||PROSPECTIVE|||||||
33818106|NCT00405899|||COHORT||PROSPECTIVE|||||||
33818107|NCT06719830|||CASE_ONLY||RETROSPECTIVE|||||||
33818108|NCT05149976|||COHORT||PROSPECTIVE|||||||
33818109|NCT06714929|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE||Stepped wedge cluster randomized controlled trial; 4 groups of schools sequentially receive the intervention each year over 3 years. Assessments of all 12 schools occur at all timepoints over the 3 years.|f|f|t|t
33818110|NCT06719986|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818111|NCT06089915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818112|NCT01366469|||COHORT||PROSPECTIVE|||||||
33818113|NCT05450822|||COHORT||PROSPECTIVE|||||||
33818114|NCT05667012|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator analyzing the results will be blinded to the intervention group to which the participants belong.||f|f|f|t
33818115|NCT05569525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33837183|NCT05884892|||COHORT||PROSPECTIVE|||||||
33837184|NCT03597451|||CASE_CONTROL||PROSPECTIVE|||||||
33837185|NCT00735280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837186|NCT05946694|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33837187|NCT01418404|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34047479|NCT02892110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818116|NCT04512352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants are not aware of which arm they are in|"Large-scale survey: Using the stratified sampling method, a randomized list of 60 samples was selected from the official list of 506 kindergartens-cum-child care center provided by the Bureau of Education. Out of the 60 schools, a total of 40 schools from 12 NGOs agreed to join the survey. As of April 2019, we have received 700 responses for the survey.~Intervention Study: There are two phases of intervention in this stage. The total sample size for both phases is 200 parent-child dyads. For both phases, the team applied stratified randomization method for randomization. Participants were assigned to either treatment group or wait-list control group on a school basis."|t|f|f|f
33818117|NCT03523442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818118|NCT06295692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818119|NCT01595724|||COHORT||PROSPECTIVE|||||||
33818120|NCT06313944|||CASE_ONLY||PROSPECTIVE|||||||
33818121|NCT02077556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818122|NCT00330135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818123|NCT02312245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818124|NCT03582917|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818125|NCT01670942|||COHORT||PROSPECTIVE|||||||
33818126|NCT05594888|||OTHER||PROSPECTIVE|||||||
33818127|NCT05937659|||COHORT||PROSPECTIVE|||||||
33818128|NCT00596960|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818129|NCT03799965|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33818130|NCT05544708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Cluster randomized design|f|f|t|t
33818131|NCT01196741|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33818132|NCT03767244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818133|NCT03514667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33818134|NCT05980325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818135|NCT02884999|||COHORT||RETROSPECTIVE|||||||
33818136|NCT06375460|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Subjects will wear a continuous glucose monitor and activity watch for study duration. Subjects will be micro-randomized once daily for 90 days to receive app prompts regarding nutrition or physical activity.||||
33818137|NCT06719752|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33818138|NCT06415695|NA|SINGLE_GROUP||OTHER||NONE||The interventional study model for this research involves implementing a single-group, pre-post design to assess the effectiveness of a three-month weight loss intervention among participants with a body mass index (BMI) over 25 kg/m². Participants will engage in ten weekly online sessions covering topics related to dietary and lifestyle improvements. The intervention will be delivered through educational materials specifically tailored for the Saudi population and accessed via an online platform. Participants will also receive a Wi-Fi-enabled scale for self-monitoring of their weight loss progress throughout the intervention period. Data collection will include surveys, dietary assessments, physical measurements, and lifestyle habit assessments at baseline and three months.||||
33818139|NCT02219529|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33818140|NCT04273854|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All downstream data analysis will be done by investigators blinded to the allocation||f|f|f|t
33818141|NCT05731492|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818142|NCT05977699|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33818143|NCT06638073|||COHORT||PROSPECTIVE|||||||
33818144|NCT04471051|||COHORT||PROSPECTIVE|||||||
33818145|NCT04823078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818146|NCT06253195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818147|NCT01040299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33818148|NCT06277011|NA|SEQUENTIAL||TREATMENT||NONE||||||
33818149|NCT05939050|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818150|NCT01617759|||COHORT||RETROSPECTIVE|||||||
33818151|NCT04110392|NA|SINGLE_GROUP||PREVENTION||NONE||It is quasi-experimental and it was proposed before and after study, the study will be consisting of a pre-visit, 6 subsequent visits and a last visit to deliver results to the participant.||||
33818152|NCT06005441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818153|NCT04810104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study of AZD0328, a selective α7 nicotinic receptor agonist, in PD-MCI.|t|t|t|t
33818154|NCT05655689|||COHORT||PROSPECTIVE|||||||
33818155|NCT06721754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818156|NCT05346484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818157|NCT03030599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818158|NCT05071664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818159|NCT06590961|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1a: Dose escalation study Phase 1b: Dose expansion study||||
33818160|NCT03891433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An investigator of the research project conducted daily monitoring of the patient and will not be involved in clinical decisions. The statistical analyzes performed finally be blind to the treatment received by the patients (carbapenems vs piperacillin/tazobactam).||f|f|f|t
33818161|NCT01762345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818162|NCT06032273|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33818163|NCT04228068|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818164|NCT00004171||||TREATMENT||||||||
33818165|NCT05588843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818166|NCT04975646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||First part: observational study. Second part: parallel groups.||||
34047480|NCT04275635|||CASE_ONLY||PROSPECTIVE|||||||
33818167|NCT02747056|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818168|NCT04999020|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818169|NCT02726698|||COHORT||PROSPECTIVE|||||||
34047481|NCT04549389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34047482|NCT03612609|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047483|NCT02307279|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047484|NCT05985044|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047485|NCT02751931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818170|NCT06179719|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818171|NCT03015428|NA|SINGLE_GROUP||||NONE||||||
33818172|NCT04741646|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818173|NCT01996098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818174|NCT04933188|||COHORT||PROSPECTIVE|||||||
33818175|NCT03530345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded treatment in Treatment Period A, open-label infusion in Treatment Period B.||t|t|t|t
33818176|NCT01378130|||COHORT||PROSPECTIVE|||||||
33818177|NCT04232202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|CBCT will be used to assess bone density and the assessors will be unaware of the patient allocation.|Patients will be randomly assigned to either laser or control group.|f|f|f|t
33818178|NCT06455098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818179|NCT06633588|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33818180|NCT06555796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818181|NCT01317771|||COHORT||RETROSPECTIVE|||||||
33818182|NCT01596777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33818183|NCT06720181|||COHORT||RETROSPECTIVE|||||||
33818184|NCT06361914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33818185|NCT00331799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818186|NCT04617197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33818187|NCT06023745|||CASE_CONTROL||RETROSPECTIVE|||||||
33818188|NCT05395754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818189|NCT02006914|||CASE_CONTROL||PROSPECTIVE|||||||
33818190|NCT01982266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818191|NCT03249129|||COHORT||PROSPECTIVE|||||||
33818192|NCT05823220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33818193|NCT06385080|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818194|NCT05483478|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818195|NCT05339256|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized, active-control, open-label||||
33818196|NCT02276937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818197|NCT05064709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In addition to the subject, the entire site research team, the implanting physician, the Clinical Events Committee (CEC), and the clinical study monitors will all be blinded to the treatment assignment. Site research staff and Impulse Dynamics monitoring personnel will not have viewing rights to the randomization assignment.|Multicenter, multi-national, randomized, quadruple-blind, sham controlled, 2-part, embedded IDE clinical trial|t|t|t|t
33818198|NCT05350709|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|via closed envelopes||f|f|t|f
33818199|NCT04890093|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818200|NCT06718374|||COHORT||PROSPECTIVE|||||||
33818201|NCT05254782|||OTHER||PROSPECTIVE|||||||
33818202|NCT05280522|||COHORT||CROSS_SECTIONAL|||||||
33818203|NCT02853188|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33818204|NCT05701657|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are masked to the 3 different diets (i.e., Diet A, Diet B, Diet C).|Module 1- Response to liquid mixed meal tolerance test (LMMTT) Module 2- Dietary intervention and response to diet-specific meal test Module 3- Dietary intervention and response to diet-specific meal test and LMMTT|t|f|f|f
33818205|NCT06721871|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This is a randomized, double-blind, placebo-controlled, dose-escalating study with a placebo cross-over design within each participant at each dose level in this ultra-rare MVID participant population|Each dose level will include 2 4-week Treatment Periods for a total of 8 weeks. There will be 3 ascending dose levels for a total of 24 weeks of treatment with either crofelemer or placebo, with safety reviews between dose levels. Within the 24 weeks of treatment, each of crofelemer and placebo will have been administered at 3 ascending dose levels for 4 weeks each, totaling 12 weeks.|t|t|t|t
33818206|NCT03904693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||In total, approximately 170 subjects are planned to be randomized into study to receive either FDC macitentan/tadalafil or macitentan 10 mg or tadalafil 40 mg given once daily and will also receive matching placebos for two other study treatments. Treatment allocation will be stratified based on prior PAH therapy (i.e., treatment-naïve or treated by an Endothelin receptor antagonist or a Phosphodiesterase type-5 inhibitor as a monotherapy) at baseline. Sample size will be re-estimated at interim analysis if study is not terminated early for efficacy/futility up to sample size of 150-250. After completion of double-blind treatment period, subjects will continue study in an open-label treatment (OLT) period for 24 months, which may be prolonged beyond 24 months until macitentan and tadalafil are accessible at required doses, through other options according to local regulations. All assessments at end of double-blind treatment must be completed before subject enters OLT period.|t|t|t|t
33818207|NCT06373328|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33818208|NCT04954898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818209|NCT06195553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single|Randomized Controlled Trial with one treatment condition and one control condition.|t|f|f|f
33818210|NCT02981849|||COHORT||CROSS_SECTIONAL|||||||
33818211|NCT03054194|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818212|NCT06455527|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
33818213|NCT05995353|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33818214|NCT06557889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818215|NCT04004520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837188|NCT06240819|RANDOMIZED|PARALLEL||OTHER||SINGLE|the assessor who will take the readings is blind|randomized clinical trail|f|f|f|t
33837189|NCT05436405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837190|NCT03468790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|placebo parallel-controlled|t|t|t|t
34047486|NCT03816501|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34047487|NCT05567809|||COHORT||PROSPECTIVE|||||||
34047488|NCT05072249|||COHORT||PROSPECTIVE|||||||
34047489|NCT06252493|||COHORT||PROSPECTIVE|||||||
34047490|NCT05097690|||CASE_CONTROL||RETROSPECTIVE|||||||
34047491|NCT05905653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047492|NCT06530576|NA|SINGLE_GROUP||TREATMENT||NONE||Thalidomide at a dose of 50-100 mg/QN||||
34126810|NCT00043745|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126811|NCT04657185|||COHORT||PROSPECTIVE|||||||
34126812|NCT00514098|||CASE_CONTROL||PROSPECTIVE|||||||
34126813|NCT01591265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126814|NCT05131412|||COHORT||RETROSPECTIVE|||||||
34126815|NCT05039866|||CASE_ONLY||PROSPECTIVE|||||||
34126816|NCT04059068|||COHORT||PROSPECTIVE|||||||
34126817|NCT00589173|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34126818|NCT02829996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126819|NCT04263766|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||TMS manipulation. Within-subjects design. Each participant will receive TMS to three different sites: DLPFC, aPFC, and a control site.||||
34126820|NCT04256174|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|Double-Blind||t|t|t|f
34126821|NCT04665427|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33818216|NCT06600581|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"The following roles indicated below will not be made aware of the treatment group assignment during the trial:~Participants Investigators Outcomes assessor~The person responsible for drug dispensing (pharmacist) will be unblinded~Sponsor staff or designees may be unblinded to complete ongoing safety oversight and surveillance reporting.~A planned unblinding will take place at the interim analysis for dose selection in the next phase and futility."|"STEM-META is a placebo-controlled, randomized, dose expansion study that begins with 4 parallel dosing groups and one placebo control group (phase IIa). The treatment period and follow up will last 16 weeks, then an interim adaptation will initiate the second phase of the study (IIb).~Treatment Groups~Group 1 - Placebo - 2 mL USP injectable saline, twice a week Group 2 - 0.5 mg total protein in 2 mL final volume, twice a week Group 3 - 1 mg total protein in 2 mL final volume, once a week, alternating with saline Group 4 - 1 mg total protein in 2 mL final volume twice a week Group 5 - 2 mg total protein in 2 mL final volume, once a week, alternating with saline"|t|t|t|t
33818217|NCT03167437|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818218|NCT00300183|||||OTHER|||||||
33818219|NCT06720844|||COHORT||RETROSPECTIVE|||||||
33818220|NCT00171652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33818221|NCT06297200|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Sham trials will be utilized within subject. All subjects will receive sham and ultrasound conditions.|||||
33818222|NCT05893017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized Controlled Trial||||
33818223|NCT05379400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818224|NCT03630432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised, parallel, controlled study of 8 weeks pulmonary rehabilitation versus usual care||||
33837191|NCT04773067|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33837192|NCT03993808|NA|SINGLE_GROUP||OTHER||NONE||This is an implementation study, testing whether provision of the evidence-based DASH diet for to community-living seniors as a portion of their daily intake, in the setting of congregate meals at senior centers, coupled with evidence-based home self-blood pressure monitoring, can lead to effective blood pressure lowering.||||
33837193|NCT03167151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126822|NCT04570306|||COHORT||PROSPECTIVE|||||||
34126823|NCT02790840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126824|NCT06488690|NA|SEQUENTIAL||PREVENTION||NONE||Pregnant woman||||
34126825|NCT04297150|||COHORT||PROSPECTIVE|||||||
34126826|NCT00384215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126827|NCT00742170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126828|NCT02653339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126829|NCT01534286|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126830|NCT03980782|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A randomized control pilot study will be used to test the effect of a music therapist-developed, music listening intervention on delirium. Acutely ill patients will be randomized into a usual care control group or an experimental group receiving the music intervention twice daily for 30 minutes.||||
34126831|NCT02415244|||COHORT||PROSPECTIVE|||||||
34126832|NCT03810014|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||"A factorial design will be used to test two ACT subsidy levels and two RDT subsidy levels. The unit of randomization will be the individual customer. Using scratch cards, participants will be randomized, in a 1:1:1:1 ratio, to one of four study arms:~1) No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=$0) // 2) No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer= $0.10-0.40, dependent upon patient age) // 3) 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0) // 4) 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)"||||
34126833|NCT01042067|||COHORT||PROSPECTIVE|||||||
34126834|NCT02244372|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34126835|NCT00348959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126836|NCT01540786|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34126837|NCT05706207|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects were enrolled from low to high doses. The dose groups were 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg, a total of 8 dose levels.For the first dose group (0.03mg/kg), the dose was increased according to the principle of accelerated titration combined with 3+3 dose acceleration.from 0.3mg/kg dose group,the study will adopt the 3+3 dose acceleration principle.||||
34126838|NCT02342353|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126839|NCT02904369|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34126840|NCT04312477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126841|NCT01575808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126842|NCT05591638|||CASE_CONTROL||PROSPECTIVE|||||||
34126843|NCT05270018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126844|NCT02444507|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34126845|NCT01768910|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34126846|NCT04532125|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
34126847|NCT05334472|||COHORT||PROSPECTIVE|||||||
34126848|NCT01162473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126849|NCT00529438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126850|NCT03102450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126851|NCT06107985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126852|NCT00690794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126853|NCT02569567|||COHORT||PROSPECTIVE|||||||
34126854|NCT02753478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818225|NCT04828668|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Treatment period 1 will utilize masked study product labels with subject ID. Treatment period 1 will utilized unmasked / open-label study product with subject ID.|"A total of 60 (sixty) participants who meet inclusion and exclusion criteria will be randomized and enrolled in a 1:1 ratio of study product (Formula C) vs. placebo.~Group 1: 30 participants will be randomized to masked active study product (Formula C) for 28-days; they will continue to the open label extension phase (with commercially available product for an additional 28-days when they will receive commercially available product.~Group 2: 30 participants will be randomized to placebo for 28-days; they will roll-over to the open label extension phase of study product (Formula C) for an additional 28-days when they will receive commercially available product.~At the completion of the treatment period, the participants will be followed for 14-days."|t|f|f|f
33818226|NCT02097420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818227|NCT06095102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818228|NCT01314534|||COHORT||PROSPECTIVE|||||||
33818229|NCT05230823|NA|SINGLE_GROUP||TREATMENT||NONE||This novel intervention will be tested in a single group study using a pre-post intervention design prior to testing in a large RCT||||
33818230|NCT06720688|||CASE_ONLY||RETROSPECTIVE|||||||
33818231|NCT04101240|||COHORT||RETROSPECTIVE|||||||
33818232|NCT03610802|||COHORT||PROSPECTIVE|||||||
33818233|NCT04642495|||COHORT||CROSS_SECTIONAL|||||||
33818234|NCT04822246|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind, RCT|t|f|f|f
33818235|NCT05958524|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33818236|NCT05181839|||COHORT||PROSPECTIVE|||||||
33818237|NCT04497844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818238|NCT04256421|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33818239|NCT01493388|||COHORT||RETROSPECTIVE|||||||
34047493|NCT03038685|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||A pilot, double-arm, pre/post study design with compirason between historical, monocenter cohort (Sint-Janhospital, 2011) and prospective, multicenter cohort (4 Belgian Stroke centers, 2017)||||
34047494|NCT01639820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047495|NCT02526420|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047496|NCT05621733|||COHORT||PROSPECTIVE|||||||
34047497|NCT01421823|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34047498|NCT01561703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047499|NCT06683989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047500|NCT00926471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047501|NCT04971200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047502|NCT04054063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047503|NCT05165628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047504|NCT01210508|||CASE_ONLY||PROSPECTIVE|||||||
34047505|NCT03749967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants will be randomized to 10 different active doses of accelerated, intermittent theta burst rTMS.|Veterans will be randomized to 10 different doses of accelerated intermittent theta burst rTMS for remediation of transdiagnostic psychosocial impairment. The goal is to determine the optimal dose in terms of efficacy while minimizing burden and side effects.|t|f|f|f
34047506|NCT02794610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047507|NCT05788367|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047508|NCT01470963|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047509|NCT06319170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047510|NCT03995628|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047511|NCT05930587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"The patients in the experimental and control groups in the study will be assigned to the groups by a statistician using a computer program, and the list of patients in the experimental and control groups will be submitted to the head nurse of the cardiovascular surgery clinic.Researchers will not be informed about which group the patients are in.~In the research, the application of cold immersion to the patients in the experimental group will be explained by the nurse in charge, and data collection forms will be applied to both the experimental and control groups by the head nurse.~As the patients will do the application directly themselves, blinding will not be possible.~In addition, codes in the form of x and y will be given to the experimental and control groups and support will be received from another statistical expert."|2 groups (experimental group and control group)|f|f|t|t
34047512|NCT03290261|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomised, single center, pilote study||||
34047513|NCT00000158|RANDOMIZED|||TREATMENT||||||||
34047514|NCT00004787||||TREATMENT||||||||
34047515|NCT01455532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047516|NCT02982603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047517|NCT01661101|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34047518|NCT01344824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047519|NCT04315974|||CASE_ONLY||PROSPECTIVE|||||||
34047520|NCT03593824|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34047521|NCT05383040|RANDOMIZED|PARALLEL||TREATMENT||NONE||A hospital-based randomized clinical trial study will be carried out to compare the effect of percutaneous release of A1 pulley with steroid injection in the treatment for trigger finger.||||
34047522|NCT04715074|NA|SEQUENTIAL||PREVENTION||NONE||Explanatory Mixed Methods Approach||||
34047523|NCT05138770|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34047524|NCT06412185|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34047525|NCT05721742|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047526|NCT05686135|NA|SINGLE_GROUP||OTHER||NONE||||||
34047527|NCT06202092|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fifty patients with bilateral knee OA whose ages range from 40 to 65 years and body mass indexes between 25 to 35 kg/m2, who will meet the eligibility criteria and will be randomized into two treatment groups using computer-generated numbers in sealed envelopes. The patients will be blinded to the group allocation||||
34126855|NCT01297803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126856|NCT01198574|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34126857|NCT05216718|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34126858|NCT02059564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126859|NCT02099084|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33818240|NCT03503643|||COHORT||PROSPECTIVE|||||||
33818241|NCT04728347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818242|NCT04285671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818243|NCT03979144|||OTHER||PROSPECTIVE|||||||
33818244|NCT06536465|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open Label)|Approximately 80 participants (40 participants in the 500 mg q12h arm and 20 participants in the 250 mg q12h arm; 20 participants in the Observation arm) will be randomized.||||
33818245|NCT05415072|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818246|NCT02516371|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818247|NCT04276142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized controlled trial with two arms: (i) online intervention in addition to treatment-as-usual versus (ii) psychoeducational active control intervention in addition to treatment-as-usual|t|f|f|t
33818248|NCT05056207|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33818249|NCT01818453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818250|NCT02031055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818251|NCT01133600|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818252|NCT06470438|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818253|NCT00416585|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818254|NCT04985266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818255|NCT02885714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818256|NCT06721702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818257|NCT05910879|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33818258|NCT06596473|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818259|NCT02221778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818260|NCT06569836|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33818261|NCT00277056|||COHORT||PROSPECTIVE|||||||
33818262|NCT05476601|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818263|NCT00561678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818264|NCT05105100|||COHORT||PROSPECTIVE|||||||
33818265|NCT05307653|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33818266|NCT02327702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818267|NCT04394078|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33818268|NCT05095506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818269|NCT01348763|NA|SINGLE_GROUP||OTHER||NONE||||||
33818270|NCT00754533|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818271|NCT06721507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818272|NCT01154842|||||CROSS_SECTIONAL|||||||
33818273|NCT06552897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind (Participant, Investigator)|"This study uses a Parallel Assignment design in which participants undergoing total knee arthroplasty (TKA) are randomly assigned to one of two intervention groups.~Group A: Receives an Adductor Canal Block (ACB) alone, which targets the nerves supplying the front and inner parts of the knee.~Group AT: Receives a combination of Adductor Canal Block (ACB) and Selective Tibial Nerve Block (STNB), providing additional analgesia to the back of the knee.~Both groups are assessed for postoperative pain relief, opioid consumption, side effects, and overall patient satisfaction. The parallel assignment allows for a direct comparison of the effectiveness and safety of these two pain management strategies."|t|f|t|f
33818274|NCT03997552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818275|NCT04119050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818276|NCT03115619|||COHORT||PROSPECTIVE|||||||
33818277|NCT05653050|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label, multi-centre, randomised, two-period, crossover study comparing fully closed-loop glucose control to standard insulin pump therapy combined with continuous glucose monitoring||||
33818278|NCT03799757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33818279|NCT00291928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818280|NCT06349941|NA|SINGLE_GROUP||OTHER||NONE||Pilot trial||||
33818281|NCT01911988|||COHORT||PROSPECTIVE|||||||
33818282|NCT06337903|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33818283|NCT03358485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818284|NCT00042510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818285|NCT06538870|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups will be recruited, one taking TNF-alpha inhibitors and one not taking these medications but matched via age and sex to the first group. Both will receive dental implant placement to replace missing teeth and both will be followed at the same intervals, using the same outcome measures, and for the same length of time.||||
33818286|NCT00963105|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818287|NCT06628180|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33818288|NCT02834624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33818289|NCT05564052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818290|NCT06092827|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility and acceptability study||||
33818291|NCT06719687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818292|NCT03761849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818293|NCT01477177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818294|NCT06721949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to one of two groups in parallel for the duration of the study.|t|t|t|t
33818295|NCT06484660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818296|NCT05178069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Time by Treatment|t|t|t|f
33818297|NCT06181123|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126860|NCT02798744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818298|NCT04853238|||COHORT||PROSPECTIVE|||||||
33818299|NCT06720623|||COHORT||RETROSPECTIVE|||||||
33818300|NCT06720129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33818301|NCT06719648|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818302|NCT02880293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818303|NCT00511511|||||PROSPECTIVE|||||||
33818304|NCT04824209|||CASE_CONTROL||PROSPECTIVE|||||||
33818305|NCT01804686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126861|NCT02776683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126862|NCT05643781|||COHORT||OTHER|||||||
34047528|NCT04290208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|When the Principal Investigator calls to enroll patient into the study, pharmacy will be responsible for labelling and delivering the drugs to the labor and delivery unit. The label will include the patient enrollment number and the study name. The investigators will be blind to the patient's drug/placebo assignment. In case of emergency, side effects, or allergic reaction, the pharmacy will be contacted to unblind medication.||t|t|t|f
34047529|NCT01551264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047530|NCT06247527|RANDOMIZED|PARALLEL||TREATMENT||NONE|Providers and participants will know the assigned arm|Cluster randomized controlled trial||||
34047531|NCT03750149|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047532|NCT01597414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047533|NCT00160732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047534|NCT04002245|RANDOMIZED|PARALLEL||PREVENTION||NONE||From the paper randomisation list that has been communicated to him, he learns the application technique to be performed on each of the two arms (right or left).||||
34047535|NCT02173522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047536|NCT02766803|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34047537|NCT06682026|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34047538|NCT04289350|||COHORT||PROSPECTIVE|||||||
34047539|NCT06455293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)~This trial is testing various doses of psilocybin. Participants, study staff and clinical assessors will be blinded to individual treatment conditions until study close-out. The clinician administered instruments will be administered by different clinical study staff than the facilitators who provide the preparation, psilocybin therapy, and integration sessions."|"All participants will receive two doses of psilocybin ranging from low (microdose) to high. All participants will receive three psilocybin preparation sessions, two administration sessions of a single dose of psilocybin within a therapeutic environment (6-8 hours), five integration sessions, and two follow up visits. All drugs will be orally administered during the dosing sessions. The study procedures will follow best practices for administering psilocybin in clinical trials."|t|t|t|t
34047540|NCT06683274|||COHORT||PROSPECTIVE|||||||
33818306|NCT05374174|||COHORT||CROSS_SECTIONAL|||||||
34047541|NCT06585982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Drug coding and group assignment are done by the pharmacy, where the investigator only receives data in the form of sample coding but does not know whether the coded sample received an intervention or control.||t|t|t|t
34047542|NCT02624414|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047543|NCT00177242|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047544|NCT04411056|RANDOMIZED|PARALLEL||OTHER||NONE||Participants assigned to barrier box or no barrier box||||
34047545|NCT04486209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047546|NCT00443079|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34047547|NCT03651362|||COHORT||PROSPECTIVE|||||||
34047548|NCT04126447|||CASE_CONTROL||PROSPECTIVE|||||||
34047549|NCT02241083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047550|NCT04666727|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34047551|NCT03599011|||COHORT||RETROSPECTIVE|||||||
34047552|NCT04347564|||CASE_ONLY||CROSS_SECTIONAL|||||||
34047553|NCT06193811|RANDOMIZED|CROSSOVER||TREATMENT||NONE||4-way crossover design within each treatment group||||
34047554|NCT05305105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047555|NCT01909362|||CASE_CONTROL||PROSPECTIVE|||||||
34047556|NCT05950893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047557|NCT05606874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34047558|NCT06684275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the specific nature of the interventions, it may not be possible to blind participants or operators; however, to minimize potential bias, outcome assessors will be blinded to the treatment assignments.|Participants will be randomly assigned to one of the two groups (PRF or PRF + TRF)|f|f|f|t
34047559|NCT01421160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047560|NCT04033822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|allocation group will not be displayed. All personal identifying information will be removed and a computer generated participant ID will be used instead.|Parallel Randomized Controlled Trial, efficacy trial|f|f|f|t
34047561|NCT02863445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047562|NCT02102620|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34047563|NCT01760915|||COHORT||PROSPECTIVE|||||||
34047564|NCT01256164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047565|NCT04610567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This will be a randomized, double-blind, placebo-controlled, multi-center study.|t|t|f|t
34126863|NCT04328896|NA|SINGLE_GROUP||OTHER||NONE||This study is a 14 week, single center, pilot study of 10 subjects 65-75 yrs old with type 1 diabetes.||||
34126864|NCT01176877|NA|SINGLE_GROUP||||NONE||||||
34126865|NCT01308645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126866|NCT02013349|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, multi-center registry||||
34126867|NCT04645511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Throughout the study, both the patients and the examining doctors are blinded regarding the patients' group status. The patients are randomized using a MINIM-program by a person, who doesn't participate in treating or following up the patients. The operating doctor only operates the patients but doesn't participate in the pre- or postoperative evaluation. The information, whether the patient had a placebo procedure or the balloon sinuplasty procedure, is not written in the patient's medical record but only on the Surgery form and the form is sealed in an envelope. The envelope is only opened in the end of the 12-month follow-up period. The patient's eyes are covered with moist gauze dressing pads during the operation and the staff pays extreme attention not to let the patient know his/her group status. Neither do the examining doctors know the patient's group status during the 12 month follow-up period.|A prospective, randomized, placebo-controlled, double-blinded clinical study|t|f|t|f
34126868|NCT03565341|NA|SINGLE_GROUP||TREATMENT||NONE||Face sides will be randomized to receive either 1064nm alone or 1064nm \& 585nm combination treatment||||
34126869|NCT01668160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126870|NCT01431898||||TREATMENT||SINGLE|||t|f|f|f
34126871|NCT00293930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34126872|NCT03886948|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34047566|NCT02002455|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047567|NCT00863343|||COHORT||PROSPECTIVE|||||||
34047568|NCT00885261|||COHORT||PROSPECTIVE|||||||
34047569|NCT06127693|||OTHER||PROSPECTIVE|||||||
34047570|NCT00003118|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047571|NCT05588219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047572|NCT06638606|||COHORT||CROSS_SECTIONAL|||||||
34047573|NCT02595463|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047574|NCT03825003|||CASE_CONTROL||PROSPECTIVE|||||||
34047575|NCT01896999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047576|NCT02953847|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34047577|NCT00869999|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047578|NCT04447391|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
34047579|NCT04519801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The operating surgeon will remain blinded to the post-operative rehabilitation regimen to which subjects are randomized to post-operative rehabilitation regimen (REHAB vs. REHAB + BFR.)|Patients will be randomized to either REHAB or REHAB + BFR (study intervention) using a block randomization scheme.|f|f|t|f
34047580|NCT05027906|NA|SINGLE_GROUP||TREATMENT||NONE|None ( Open Label)|Phase 1b, open label, single-arm study||||
34047581|NCT06683794|||COHORT||PROSPECTIVE|||||||
34047582|NCT00060203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047583|NCT02129777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047584|NCT05655819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047585|NCT04236141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047586|NCT04936802|NA|SINGLE_GROUP||TREATMENT||NONE||Tricuspid valve repair||||
34047587|NCT00972933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047588|NCT06093048|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34047589|NCT00558350|||COHORT||PROSPECTIVE|||||||
34047590|NCT05287126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047591|NCT01676935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047592|NCT05182814|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34047593|NCT06197646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34047594|NCT00214786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047595|NCT06684158|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional Study Model.||||
34047596|NCT06070181|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047597|NCT04050410|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Subject and investigator will be blinded. The randomization will be generated by the pharmacy. A staff member of the Autonomic Dysfunction Center who is not involved in the study will keep secretly the randomization blinding table for emergencies. Blinding will be broken for intermediate data analysis and in case of emergencies if necessary. The blinding will be broken at the end of statistical analysis for interpretation of results.|Randomized, double-blind, placebo-controlled crossover|t|f|t|f
34047598|NCT04607694|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
34047599|NCT04481789|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Cohort 1 is open-label, non-randomized, sequential, and add-on study. Cohort 2 is single-dose, open-label, randomized, and cross-over study.||||
34047600|NCT05019976|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047601|NCT00323570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047602|NCT03389230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047603|NCT02154503|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34126873|NCT00049322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34126874|NCT02069977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126875|NCT02462187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126876|NCT05986474|||COHORT||CROSS_SECTIONAL|||||||
34126877|NCT01163305|||CASE_ONLY||PROSPECTIVE|||||||
34126878|NCT02116842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34126879|NCT00976638|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34126880|NCT03069833|RANDOMIZED|FACTORIAL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34126881|NCT03091387|||OTHER||PROSPECTIVE|||||||
34126882|NCT03507296|||CASE_CONTROL||PROSPECTIVE|||||||
34047604|NCT06433362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047605|NCT00434616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047606|NCT02531776|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34047607|NCT05731856|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a single group study. All participants will receive identical instructions regarding the device and will complete the same survey measures.||||
34047608|NCT06683196|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The researcher who will evaluate the patients after taping will not know which group the patients are in.|On three different days, each participant will receive taping with one of the three tape types (Kinesiotape, Rigid Tape and Placebo Tape ). This approach aims to prevent fatigue and habituation during evaluations. To minimize potential bias in measurements, the sequence of tape types will be changed across the three days.||||
34047609|NCT02700373|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34047610|NCT00619892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047611|NCT05231746|NA|SEQUENTIAL||TREATMENT||NONE||||||
34126883|NCT00083460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126884|NCT04620616|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34126885|NCT04871828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Prospective randomized placebo-controlled double-blinded clinical trial|t|t|t|f
34126886|NCT05793359|||OTHER||PROSPECTIVE|||||||
34126887|NCT04071431|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34126888|NCT03338400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34126889|NCT06493045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Ascending doses|t|f|t|f
34126890|NCT06015360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126891|NCT03813875|||COHORT||PROSPECTIVE|||||||
34126892|NCT02315040|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149214|NCT00262990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149215|NCT05499624|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149216|NCT03022981|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149217|NCT01345565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149218|NCT04151849|||COHORT||PROSPECTIVE|||||||
34047612|NCT05575778|||COHORT||PROSPECTIVE|||||||
34047613|NCT01259622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818307|NCT04730271|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Quantitative analysis of the X-rays will be conducted by a third party who will be blinded to the treatment group.||f|f|f|t
33818308|NCT03121261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818309|NCT03669965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047614|NCT06186700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34047615|NCT01079702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047616|NCT00033852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34047617|NCT05313568|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34047618|NCT06414395|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Randomization will be performed using computer generated numbers with Random Allocation Software in a 1:1:1:1 ratio. The patient's allocation and drug administration instructions will be kept in consequentially numbered opaque envelopes (equal number per each group). A colleague, not participating to the study, will be responsible for study drugs preparation \& labelling.|This study hypothesizes that lower doses of dexmedetomidine (0.25 µg.kg-1 or the 0.5 µg.kg-1) can co-produce adequate propofol sparing sedation that is not inferior to the standard dose of 1µg.kg-1 and without significantly prolonging the propofol recovery time or increasing the total propofol consumption.|t|t|t|f
34047619|NCT05162287|||COHORT||PROSPECTIVE|||||||
34047620|NCT06575335|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|It will be a double-blinded study where the participants and the microbiologist will be unaware of the group allocation.|The participants will be allocated in either of the two treatment arms through Sequentially Numbered, Opaque, Sealed Envelopes (SNOSE) by the principal investigator.|t|f|f|t
34047621|NCT01419262|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34047622|NCT01082263|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34047623|NCT01508130|||COHORT||PROSPECTIVE|||||||
34047624|NCT00921466|||||PROSPECTIVE|||||||
33818310|NCT05314452|||OTHER||CROSS_SECTIONAL|||||||
33818311|NCT00139659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818312|NCT06585228|||COHORT||PROSPECTIVE|||||||
33818313|NCT04175392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both Participants and Researchers will not know which treatment group assigned to.|Prospective, randomized, double-blind study. Participant will be randomized to either the Treatment (Probiotic) Group or the Control (Placebo) Group.|t|f|t|f
33818314|NCT00612521|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33818315|NCT03352570|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33818316|NCT03580629|NA|SINGLE_GROUP||OTHER||NONE||||||
33818317|NCT02812706|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818318|NCT05816122|NA|SINGLE_GROUP||OTHER||NONE||||||
33818319|NCT02240836|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818320|NCT06532032|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818321|NCT06719531|NA|SINGLE_GROUP||OTHER||NONE||||||
33818322|NCT03441152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818323|NCT04641234|||COHORT||RETROSPECTIVE|||||||
33818324|NCT04590404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818325|NCT00292409|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33818326|NCT02246556|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33818327|NCT00610194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818328|NCT05362279|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled study with pretest-posttest experimental and control groups|t|f|f|f
33818329|NCT06293456|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33818330|NCT03508830|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Syringe with Obscuring Over-Wrap||t|t|t|f
33818331|NCT05596318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33818332|NCT03872661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818333|NCT04517604|NA|SINGLE_GROUP||TREATMENT||NONE||Intermittent Theta Burst Stimulation (iTBS) in combination with Love Your Brain Yoga Program. 6 weekly sessions of iTBS given prior to small group yoga.||||
33818334|NCT01381185|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047625|NCT04178174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047626|NCT03023631|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34047627|NCT04029155|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34047628|NCT01894100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047629|NCT06388278|||OTHER||PROSPECTIVE|||||||
34047630|NCT06181734|||CASE_ONLY||PROSPECTIVE|||||||
34047631|NCT04424706|||CASE_CONTROL||PROSPECTIVE|||||||
34047632|NCT02528006|NA|SINGLE_GROUP||SCREENING||NONE||||||
34047633|NCT01864226|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34047634|NCT04713527|||COHORT||PROSPECTIVE|||||||
34047635|NCT00082446|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34047636|NCT05349110|||COHORT||PROSPECTIVE|||||||
34047637|NCT01661088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047638|NCT03852264|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Personnel analyzing hormones will be blinded to the experimental condition samples were collected from.|Within-subjects, 3 conditions, 2 condition orders balanced across participants|f|f|f|t
34047639|NCT06148038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized placebo controlled double blind window of opportunity trial. A maximum of 120 patients will be enrolled. Up to 60 patients with invasive breast cancer will be enrolled into cohort 1, and up to 60 patients with DCIS will be enrolled into cohort 2. Patients in each cohort will be randomized 1:1 to either CBD or placebo control using permuted block randomization with random block sizes of 2 or 4. The time window between CBD or placebo initiation and surgery will be between 5 days and 56 days.|t|f|f|f
34047640|NCT04905472|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047641|NCT00579579|||CASE_ONLY||PROSPECTIVE|||||||
34047642|NCT02446210|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34149219|NCT00351325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149220|NCT03255876|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34149221|NCT00988481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149222|NCT00506194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149223|NCT02717130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047643|NCT05779033|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Patients with shoulder impingement syndrome from both genders will participate in this study after approval of ethical committee of the faculty of physical therapy, Cairo University, and all participants provided written informed consent.~Sample size: estimate 45 patients until we measure power analysis~The subjects will be arranged into three groups:~* Group I (control group) will receive scapular stabilization exercises 3 times per week for 4 weeks.~* Group II will receive scapular stabilization exercises and Kinesiotape 3 times per week for 4 weeks.~* Group III will receive scapular stabilization exercises and Ultrasound 3 times per week for 4 weeks."|t|f|f|f
34047644|NCT04717531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047645|NCT02471378|||CASE_ONLY||CROSS_SECTIONAL|||||||
34047646|NCT05394259|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047647|NCT04131998|||OTHER||PROSPECTIVE|||||||
34126893|NCT03109743|RANDOMIZED|PARALLEL||OTHER||NONE||The investigators pilot test efficacy of Sisters-GPS intervention in improving ARV adherence by randomizing 60 HIV+ women of color with suboptimal ARV adherence and detectable HIV viral loads (VL) to Sisters-GPS, group clinical visits, or to an appointment with an adherence counselor. The investigators will collect data from interviews, pill counts, medical and pharmacy records, and blood samples. The study's primary outcome will be ARV adherence assessed by pill count at 8 weeks; secondary outcome will be change in HIV VL from baseline to 8 weeks.||||
34126894|NCT03149159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818335|NCT03985020|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of three possible groups.||||
33818336|NCT03145181|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818337|NCT05739019|||COHORT||PROSPECTIVE|||||||
34126895|NCT05953298|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818338|NCT06721910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind|Randomized, double-blind, parallel|t|f|t|f
33818339|NCT04389554|||CASE_CONTROL||PROSPECTIVE|||||||
33818340|NCT05700851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818341|NCT04371029|NA|SINGLE_GROUP||OTHER||NONE||||||
33818342|NCT03658395|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818343|NCT00241956|||CASE_CONTROL||RETROSPECTIVE|||||||
33818344|NCT04754594|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33818345|NCT00515060|||CASE_ONLY||PROSPECTIVE|||||||
33818346|NCT05147545|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Physiological pilot study-two groups||||
33818347|NCT06721572|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Subjects will receive sham or active TEA with an identical device and set of electrodes. Outcomes will be assessed via self-reported surveys. The study coordinator will be unblinded to the randomized treatment assignment. The study coordinator will implement the randomization, conduct the active and sham TEA instruction sessions, and answer study-related questions to patients. The study coordinator will not be involved in the data analysis and will not reveal treatment assignment.|Subjects will be randomly assigned in a 1:1 allocation ratio to one of two treatment sequences: i) active-TEA in treatment period 1 (week 1-4), followed by sham-TEA in treatment period 2 (week 7-10), or ii) sham-TEA in treatment period 1 (week 1-4), followed by active-TEA in treatment period 2 (week 7-10).|t|t|t|t
33818348|NCT04806347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818349|NCT02233504|NA|SINGLE_GROUP||TREATMENT||||||||
33818350|NCT06299306|||COHORT||PROSPECTIVE|||||||
33818351|NCT03353649|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818352|NCT00452322|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818353|NCT04556227|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Upon leaving ICU and admission to general hospital room, study staff will go to patients' room to recruit and consent ICU survivor for study start date approximately two weeks after discharge. Randomize study participant using block randomization program. Document data on patients who decline consent and wish to be randomized to usual care or to the intervention group. This is a single masked (participant) study.||t|f|f|f
33818354|NCT04630028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818355|NCT05256355|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33818356|NCT06282575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818357|NCT05327114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818358|NCT03662737|||CASE_CONTROL||PROSPECTIVE|||||||
33818359|NCT03617549|||COHORT||PROSPECTIVE|||||||
33818360|NCT03729999|NA|SINGLE_GROUP||OTHER||NONE||||||
33818361|NCT03728803|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A controlled before-after trial of inspiratory muscle training will be performed in patients with nemaline myopathy with respiratory muscle weakness. The 2 sequentially tested conditions are sham IMT and active IMT. Patients are not blinded to the conditions, instead patients are instructed that two training methods are tested. First the effect of breathing technique with low resistance (sham IMT) and secondly with high resistance (active IMT).||||
33837194|NCT05769946|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837195|NCT03937102|||COHORT||PROSPECTIVE|||||||
33837196|NCT01835405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837197|NCT04499612|||COHORT||PROSPECTIVE|||||||
33837198|NCT04454034|||COHORT||PROSPECTIVE|||||||
34047648|NCT02308423|||COHORT||RETROSPECTIVE|||||||
34047649|NCT04539899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized||||
34047650|NCT00657904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047651|NCT03231202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047652|NCT00458536|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047653|NCT00723008|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34047654|NCT02849145|NA|SINGLE_GROUP||OTHER||NONE||||||
34047655|NCT01533324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047656|NCT04961450|||COHORT||PROSPECTIVE|||||||
34047657|NCT05708157|||CASE_ONLY||PROSPECTIVE|||||||
34126896|NCT03118505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126897|NCT06512870|||COHORT||PROSPECTIVE|||||||
34149224|NCT03150277|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All the participants will be blinded about the knowledge of the outcomes|Randomized crossover design|t|f|f|f
34149225|NCT02839694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149226|NCT00006455|RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34047658|NCT01163968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047659|NCT01016899|||COHORT||PROSPECTIVE|||||||
34047660|NCT04155229|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|The investigators did not mask the changes to the electronic medical record, but note that they also did not announce them.|Each of two sites underwent block randomization of four treatment assignments.||||
34047661|NCT00839813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34047662|NCT02366637|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34047663|NCT06296979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047664|NCT03449329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double blinded randomized two study group|t|t|t|t
34047665|NCT03004573|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047666|NCT04252521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047667|NCT04877925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047668|NCT06062589|||COHORT||PROSPECTIVE|||||||
34047669|NCT00005807|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047670|NCT03960450|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34047671|NCT03681288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047672|NCT05105542|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups will be studied: 1.) patients diagnosed with schizophrenia or schizoaffective disorder, and 2.) age and gender-matched healthy controls. Both groups will undergo neuroimaging, cognitive assessments, etc.||||
34047673|NCT06684041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047674|NCT06406153|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047675|NCT05890989|||COHORT||PROSPECTIVE|||||||
34047676|NCT02391805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047677|NCT00030394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047678|NCT02977572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047679|NCT06683131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047680|NCT04335409|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047681|NCT02931084|||COHORT||PROSPECTIVE|||||||
34047682|NCT00001807|||COHORT||PROSPECTIVE|||||||
34047683|NCT00970541|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34047684|NCT03518762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34047685|NCT03125538|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants sign an informed written consent but are not aware of the expectations of the study. Assessments will be performed by a PhD student who does not know neither to which group each participants belongs, nor the expectations of the study.|To avoid group contamination, a first group of 10 control participants will be completed. Then, an experimental group of 10 patients will be assessed. In order to complete a 40 persons cohort, this will be repeated one time (other 10 control then 10 experimental participants).|t|f|f|t
34047686|NCT03500783|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Trial participants, data analysts, and report writers are blinded.|Single-center prospective, randomized, placebo-controlled study|t|t|f|t
34047687|NCT05863507|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34047688|NCT04611672|||COHORT||PROSPECTIVE|||||||
34047689|NCT05163496|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The investigators, study therapists, and outcomes assessors will all be blinded in the randomized phase of the study. Participants will be unblinded after the primary outcome, and those receiving placebo will be eligible to receive open label psilocybin.|This study tests a hypothesis that a single session of psilocybin (the 'medication dosing' session) in the context of pre- and post-dose psychotherapy will result in improvement of symptoms of depression and burnout measured 4 weeks post-dose. This study hypothesis will be tested in a single site, double-blind, randomized controlled design involving 30 clinician participants that will compare effects of a single 25mg oral dose of psilocybin to a 250 mg of niacin (active placebo). The primary outcome measurements will be collected 4 weeks after the psilocybin dose, after which the participant group assignment will be unblinded, and participants who received niacin will be offered the opportunity to have a second dose session with a 25 mg dose (with pre- and post-dose psychotherapy).|t|f|t|t
34047690|NCT02086149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047691|NCT00264745|RANDOMIZED|PARALLEL||||NONE||||||
34047692|NCT02656004|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34047693|NCT03933618|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34047694|NCT03433469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047695|NCT03983148|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047696|NCT05233748|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The SRopt and noSR conditions will be presented in random order generated by a computer program and the subjects will be blinded to either condition, due to SR stimulation being below the sensory threshold i.e subjects do not perceive the stimulation at all.|Cross sectional study of responses to visual perturbations in two groups, children with CP and age-and sex- matched TD (typical development). Each group will undergo two stimulation conditions, stochastic resonance (SR) stimulation and a control / no stochastic resonance (noSR) condition while walking with and without visual perturbations.|t|f|f|f
34047697|NCT06065020|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|We will try to mask the outcome assessor, but for the nature of the intervention, it will be difficult that outcome assessor remain blind.|||||
34047698|NCT04836325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047699|NCT02001844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047700|NCT00824902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047701|NCT01561326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047702|NCT04609774|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34047703|NCT04049162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047704|NCT02510326|||COHORT||CROSS_SECTIONAL|||||||
34047705|NCT01496378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047706|NCT02754687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047707|NCT03775902|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34047708|NCT05076591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047709|NCT06683859|||CASE_ONLY||RETROSPECTIVE|||||||
34047710|NCT00449137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047711|NCT06489470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047712|NCT00346541|||CASE_CONTROL||OTHER|||||||
34149227|NCT03006224|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34126898|NCT05024253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The PI, primary surgeon, anesthesiologist, patient, all assisting surgeons and anesthesiologist as well operating and circulating nurse will be blinded to the study arm to which patient belongs to. Only clinical trial unit and pharmacist will be unblinded.|"A prospective, randomized, double-blinded clinical trial will be done on all included case. They will be divided into two groups based randomly using Block Stratified Randomized Software program, after obtaining informed consent from eligible patient or his caregiver into two Arms:~Arm A: patient is not receiving TXA but instead receiving a placebo (saline injection) Arm B: patient is receiving TXA which is colorless solution."|t|t|t|f
34126899|NCT02705482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126900|NCT01531582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126901|NCT01072136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126902|NCT00856635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34126903|NCT02845986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126904|NCT02099773|||COHORT||CROSS_SECTIONAL|||||||
34126905|NCT01543919|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126906|NCT03370211|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34126907|NCT01206634|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34126908|NCT06365658|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126909|NCT03072043|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1b Dose Escalation followed by Phase 2 treatment. Participants will be evaluable for inclusion in the Phase 1b and Phase 2 portions of the study if they receive at least one dose of protocol therapy.||||
34126910|NCT05671523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126911|NCT02648009|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34126912|NCT01016067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126913|NCT00540592|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34126914|NCT01261273|||OTHER||PROSPECTIVE|||||||
34126915|NCT01632852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126916|NCT03456700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126917|NCT02938247|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34126918|NCT00912782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126919|NCT03653806|||OTHER||PROSPECTIVE|||||||
34126920|NCT03724279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126921|NCT02027727|||COHORT||PROSPECTIVE|||||||
34126922|NCT01162538|||||PROSPECTIVE|||||||
34126923|NCT06363474|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention model of this study is a parallel model. Patients meeting inclusion criteria are enrolled from the neurosurgery department of Punjab Institute of Neurosciences, Lahore. After obtaining consent, patients undergo detailed assessments and investigations. They're randomly assigned to Group A (decompressive craniectomy) or Group B (cisternostomy). Both procedures are performed by a single surgical team under anesthesia. Postoperatively, patients are monitored for mechanical ventilation duration, ICU and hospital stay lengths, and Glasgow Outcome Scale at discharge. This model enables outcome comparison between intervention groups while controlling confounding variables.||||
34126924|NCT02678962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34126925|NCT05770700|||COHORT||PROSPECTIVE|||||||
34126926|NCT01399229|||CASE_ONLY||CROSS_SECTIONAL|||||||
34126927|NCT04122989|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Prospective randomized controlled trial, with 1:1 randomization|f|t|f|f
34126928|NCT04951375|||CASE_ONLY||RETROSPECTIVE|||||||
34126929|NCT00039039|RANDOMIZED|||TREATMENT||||||||
34126930|NCT05429580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34126931|NCT05196373|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label, Dose Escalation and Dose Expansion||||
34126932|NCT05280665|||COHORT||RETROSPECTIVE|||||||
34126933|NCT03259243|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34126934|NCT03645278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126935|NCT03310359|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||A double-blinded, placebo controlled, Clinical Trial of Insulin-Sensitizing, Anti-Inflammatory and Anti-oxidant activities of Astaxanthin in Insulin-resistant Subjects|t|t|t|t
34126936|NCT03069040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126937|NCT01184677|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34126938|NCT02872870|||CASE_CONTROL||PROSPECTIVE|||||||
34126939|NCT04486547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34126940|NCT05653401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind study|t|t|f|f
34126941|NCT03998800|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator)|t|f|f|t
34126942|NCT04037098|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Neither the patient nor the treating doctor will know the study group the participant was randomized.|"Study groups:~Intervention group. Women 19 to 35 years of age, in the twelfth week of pregnancy, who will receive magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.~Control group. Women 19 to 35 years of age, in the twelfth week of pregnancy, who will receive 2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement."|t|t|f|f
34126943|NCT05582148|NA|SINGLE_GROUP||TREATMENT||NONE||cohort followed up||||
34126944|NCT03263325|||COHORT||PROSPECTIVE|||||||
34126945|NCT00502580|||CASE_ONLY||PROSPECTIVE|||||||
34126946|NCT00000277||||TREATMENT||||||||
34126947|NCT00004891|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126948|NCT02824393|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34126949|NCT06084000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126950|NCT02782585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149228|NCT02435706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837199|NCT02307045|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33837200|NCT02033447|NA|SINGLE_GROUP||OTHER||NONE||||||
33837201|NCT06370845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33837202|NCT03916640|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33837203|NCT01035268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151146|NCT01331967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047713|NCT06601101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After the assignment of interventions, the patient will be masked, and the research team conducting the postoperative examinations will also be masked. The assisting team performing the crosslinking will document in the research log which group the study participant belongs to. The researchers conducting the evaluations of the participants will only have access to this information at the end of the study for data analysis. In the case of suspected complications, an ophthalmologist independent of the cornea service will evaluate the patient and determine the most appropriate course of action.|The participants will be distributed in blocks of four and stratified by gender: four small envelopes, two from each intervention group, will be sealed and placed in a larger envelope, totaling 10 larger envelopes. This ensures that in each block of four participants, two participants from each studied group will be included.|t|t|t|f
34047714|NCT02484781|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34047715|NCT04939935|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study participants, treating physicians and other care providers, outcome assessors, study investigators, and study statisticians will be blinded. An unblinded statistician will regularly review treatment allocations to ensure balance across treatment arms. The unblinded statistician will also prepare unblinded statistical reports for meetings of the Data and Safety Monitoring Board.|Enrolled participants will be randomised to either (1) intervention group receiving metformin extended release (XR) plus standard of care, or (2) placebo plus standard of care.|t|t|t|t
34047716|NCT03922217|NA|SINGLE_GROUP||TREATMENT||NONE|open label|open label||||
34126951|NCT04318054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Immediate intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, in the 2 months following the randomization, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).~Deferred intervention group : fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice, one year after the inclusion, an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week)."||||
34126952|NCT03182283|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Non-randomized before and after design.||||
34126953|NCT02574988|||COHORT||PROSPECTIVE|||||||
34126954|NCT04124094|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Laboratory blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
34126955|NCT05631171|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental intervention arm in parallel to control arm||||
34126956|NCT03654118|||COHORT||PROSPECTIVE|||||||
34126957|NCT02185261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126958|NCT04684940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126959|NCT01360814|||COHORT||PROSPECTIVE|||||||
34126960|NCT05163327|||COHORT||PROSPECTIVE|||||||
34126961|NCT01558115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34126962|NCT05321017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126963|NCT01901484|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34126964|NCT05547087|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126965|NCT05716867|||CASE_CONTROL||RETROSPECTIVE|||||||
34126966|NCT05496985|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Until the end of the protocol, all three assessors were blinded to the scores acquired by the other assessors.|Each patient was assessed by three distinct assessors who were experienced and trained to use the CRS-R. All assessments were completed within two weeks (i.e., five CRS-R to obtain a reliable diagnosis \[17\], and 7 SECONDs performed by 3 different assessors in the 2 weeks) in five different sessions. Session 1 included one evaluation with the CRS-R performed by one assessor (i.e., concurrent validity) and three evaluations with the SECONDs performed by two assessors (i.e., intra-rater reliability and inter-rater reliability). The other sessions (2 to 5) each included one evaluation with the SECONDs and one evaluation with the CRS-R (i.e., concurrent validity) performed by two assessors. Each SECONDs was performed alternatively either before or after the CRS-R assessment. To avoid fatigue effects and reduce the impact of within-day fluctuations of vigilance, a break of 30 to 80 min between each assessment was taken.|f|f|f|t
34047717|NCT04107311|||OTHER||PROSPECTIVE|||||||
34047718|NCT03485807|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34047719|NCT03907488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047720|NCT05502536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and outcome assessor will be blinded to the groups' allocation.||t|f|f|t
34047721|NCT06684886|||COHORT||PROSPECTIVE|||||||
34047722|NCT05231733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047723|NCT06491329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047724|NCT01435018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047725|NCT00943956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047726|NCT02660957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047727|NCT04639102|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34047728|NCT01668173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047729|NCT00454688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047730|NCT03460405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Subject aged 2 - 40 years old:~Randomized, observer-blind, superiority design compared to Vi polysaccharide vaccine.~Subject 6-23 months old:~Randomized, observer-blind, superiority design compared to Inactivated Poliomyelitis Vaccine (IPV)."|"Subject aged 2 - 40 years old:~Randomized, observer-blind, superiority design compared to Vi polysaccharide vaccine.~Subject aged 6-23 months old:~Randomized, observer-blind, superiority design compared to Inactivated Poliomyelitis Vaccine (IPV)."|t|f|t|f
34047731|NCT04242290|||COHORT||CROSS_SECTIONAL|||||||
34047732|NCT05979025|||COHORT||PROSPECTIVE|||||||
34047733|NCT00950339|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047734|NCT06161974|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Olutasidenib +TMZ||||
34047735|NCT05206955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047736|NCT04349345|||COHORT||RETROSPECTIVE|||||||
34047737|NCT05322577|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34126967|NCT00178074|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34126968|NCT00881530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126969|NCT05604144|NA|SINGLE_GROUP||TREATMENT||NONE||Proof-of-Concept||||
34126970|NCT00399607|||CASE_ONLY||PROSPECTIVE|||||||
34047738|NCT05997069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blinded to the type of treatment. It is essential for more subjective outcomes.|In this research two groups of participants will receive different interventions.|f|f|f|t
34047739|NCT03820635|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34047740|NCT06683456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047741|NCT04106219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047742|NCT03304977|NA|SINGLE_GROUP||OTHER||NONE||||||
34047743|NCT01122394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34047744|NCT00887848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34047745|NCT00399646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047746|NCT03055897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047747|NCT06684873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047748|NCT00836381|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047749|NCT01250574|||COHORT||PROSPECTIVE|||||||
34047750|NCT06419842|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33818362|NCT06439524|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participants and providers will know if participants are assigned to the treatment arm to take Rel-CT or not.|The design of this study will be an unblinded randomized controlled trial of medical suppression with once daily Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis performed by high volume minimally invasive gynecologic surgeons. Researchers will use descriptive statistics to compare the demographics and clinical characteristics of the groups with chi-square and two-sample t-tests. The median differences in EHP-30 from baseline to 6 months will be compared between groups with Mann Whitney U test. The 95% confidence interval of the difference between group medians will be used to measure superiority.||||
34047751|NCT06137859|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34047752|NCT04576377|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34047753|NCT05280626|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with P53 mutation with PD-L1 expressing DLBCL were randomized 1:1 into 2 groups: Group A Sindilizumab + R-CHOP and Group B R-CHOP, Sindilizumab was administered on day 10 after chemotherapy to avoid interference from prednisone. after 6 cycles, the treatment effective in Group A was maintained with Sindilizumab for 6 months as usual.||||
34047754|NCT03850912|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047755|NCT05025228|||COHORT||PROSPECTIVE|||||||
33818363|NCT06203756|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047756|NCT05016180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34047757|NCT04141683|||COHORT||PROSPECTIVE|||||||
34047758|NCT06287164|||COHORT||PROSPECTIVE|||||||
34047759|NCT05175391|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Test meal items will be identical except for the addition of culinary spices. Meals will be prepared by Nutrition Core Laboratory staff who have no contact with participants. Meals will be coded and given to study staff to serve to participants. Entree appearance may differ due to presence of culinary herbs (green specks) and may have different aroma. However, the PI will not be present during meal testing and thus will be masked.|To determine the consumption, liking, flavor intensity and subjective appetite ratings of two different lunch meal treatments in two separate participant groups fed different protein rich meals: 1. Meat-derived protein meal, and 2. Plant-derived protein meal using a randomized, two-period, within participants, crossover design. The two test conditions for each protein meal type will be (1) salt and pepper only preparation (No Spice, NS), and (2) herb and spice preparation (Spice, S). Within each protein meal type, the two test meals will be matched for macronutrients and calories. Each participant will consume either the meat meal or the vegetarian meal at both of their two testing days that will be at least one week apart. Each participant will be randomized into a meal type sequence group so that the order of consuming the No Spice or Spice meals will be randomized.|t|f|t|f
34047760|NCT02975986|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047761|NCT01775072|||COHORT||PROSPECTIVE|||||||
33818364|NCT01109394|||COHORT||OTHER|||||||
33818365|NCT06720649|NA|SINGLE_GROUP||OTHER||NONE||||||
33818366|NCT03709264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33818367|NCT04869046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818368|NCT06642376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33818369|NCT04198272|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Data analysts will be blind to intervention/control attribution|3-arm cluster randomized controlled trial, clusters are secondary schools in Rwanda|f|f|f|t
33818370|NCT06386289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818371|NCT05884398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047762|NCT00950443|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34047763|NCT04972058|||CASE_ONLY||CROSS_SECTIONAL|||||||
34047764|NCT04839523|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Wound size and tissue type will be assessed by a single, blinded, third-party clinician. The clinician will use imaging software to measure the size of the wound and identify tissue types, from baseline to last clinical follow-up.||f|f|f|t
34047765|NCT00526812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047766|NCT04517955|||COHORT||PROSPECTIVE|||||||
34047767|NCT03668847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047768|NCT06682754|NA|SINGLE_GROUP||SCREENING||NONE|Although all participants will perform the same intervention, they will not know which intervention the other participants are performing. In addition, the entire experimental session (both baseline and stress situation) is computerized, so the researcher in charge of the experiment will only ensure that all systems are working properly. On the other hand, the outcome evaluator will analyze the baseline and experimental (stress situation) moments without knowing whether the data belong to one or the other moment.|||||
34047769|NCT05839951|||COHORT||RETROSPECTIVE|||||||
34047770|NCT04300309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047771|NCT02895113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34047772|NCT04436562|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047773|NCT04885439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047774|NCT00794040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047775|NCT05485077|||COHORT||PROSPECTIVE|||||||
34047776|NCT05416684|||OTHER||PROSPECTIVE|||||||
34047777|NCT03364374|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34126971|NCT06023121|||COHORT||RETROSPECTIVE|||||||
34126972|NCT00486356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126973|NCT03411018|||COHORT||PROSPECTIVE|||||||
34126974|NCT04194892|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34126975|NCT04420052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The care provider knows the assignment of patient. In order to know if the blinding was effective, at the end of each treatment, patient will have to tell if they were in the placebo or the OMT group||t|f|f|t
34126976|NCT05253742|||CASE_ONLY||CROSS_SECTIONAL|||||||
34126977|NCT00785187|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34126978|NCT03162172|||COHORT||RETROSPECTIVE|||||||
34126979|NCT03761589|RANDOMIZED|PARALLEL||OTHER||SINGLE||Families (i.e., children and parents/primary caregivers dyads) were randomly assigned to participate in either the intervention group or a wait-list control group. The intervention (AFL) consisted of 24 structured, twice-weekly 90-min family-based, nutrition and sport/fitness-oriented sessions, and was delivered in a municipal recreation center. The wait-list control group received the intervention after all follow-up data had been collected. Data from all participants (both intervention group and wait-list group) were collected in four phases: before the intervention group started the program (week 0) and at 6, 12, and 24 weeks, thereafter.|t|f|f|f
34126980|NCT01168843|||CASE_ONLY||RETROSPECTIVE|||||||
34126981|NCT06554600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34126982|NCT03862612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Blocks will be administered after induction of General Anesthesia so participants will be blinded to which intervention they have had.~Study investigators will not be aware as to what group the participant belongs to when assessing the patient post operative period"|randomised control trial one group receives Serratus Anterior Plane Block the other receives Erector Spinae Plane Block|t|t|t|f
34126983|NCT01485276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34126984|NCT03399864|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34126985|NCT00792311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34126986|NCT05071612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126987|NCT03122145|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126988|NCT06448130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34126989|NCT04955769|||OTHER||CROSS_SECTIONAL|||||||
34126990|NCT02284256|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34126991|NCT03686930|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|double-blind, placebo-controlled|Multiple Dose, Dose Escalation study|t|f|t|t
34126992|NCT03889028|||COHORT||RETROSPECTIVE|||||||
34126993|NCT04650997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126994|NCT00815048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34126995|NCT04980586|||COHORT||CROSS_SECTIONAL|||||||
34126996|NCT01789359|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34126997|NCT06011317|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34126998|NCT03298698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34126999|NCT04981964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127000|NCT00095472||||TREATMENT||||||||
34127001|NCT05920811|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34127002|NCT04763889|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127003|NCT03225248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127004|NCT03190499|||OTHER||PROSPECTIVE|||||||
34127005|NCT00343499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34127006|NCT03343340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127007|NCT02012036|||CASE_ONLY||PROSPECTIVE|||||||
34127008|NCT04165551|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34127009|NCT01393210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127010|NCT04929353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127011|NCT00236964|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34127012|NCT04878107|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127013|NCT04531956|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study will use a before-after design. In the before group (BG) GPs will execute care as usual in the decision-making process for a diagnostic trajectory for memory complaints. In the after group (AG), a patient decision aid will be added to the decision-making process provided by the GP. The same GPs will participate in both the BG and the AG, which maximizes the comparability between the BG and the AG.||||
34127014|NCT05789498|||CASE_CONTROL||PROSPECTIVE|||||||
34127015|NCT01456793|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127016|NCT02569463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127017|NCT04202068|NA|SINGLE_GROUP||TREATMENT||NONE||Ceftriaxone sodium and Sulbactam Sodium for injection||||
33818372|NCT00557518|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818373|NCT06721546|RANDOMIZED|PARALLEL||OTHER||SINGLE||This study aims to examine the effects of nursing interventions, including group training, reminder messages, and telephone counseling, based on a health promotion model, on healthy lifestyle behaviors related to the daily use of functional foods and diabetes self-efficacy among individuals aged 30-64 with Type 2 diabetes. The interventions were implemented through a researcher-prepared healthy nutrition and functional foods education booklet. The study employs a randomized pre-test-post-test controlled experimental design.|f|f|f|t
33818374|NCT06526442|||COHORT||PROSPECTIVE|||||||
33818375|NCT05398042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818376|NCT03598790|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818377|NCT02114372|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33818378|NCT02623101|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34127018|NCT03069742|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127019|NCT01487486|||CASE_CONTROL||PROSPECTIVE|||||||
34127020|NCT05605730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127021|NCT04714866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127022|NCT02445014|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34127023|NCT00330304|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34127024|NCT00612976|||COHORT||PROSPECTIVE|||||||
34149229|NCT03664583|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||A cross-jurisdictional, multi-site implementation-effectiveness type II hybrid randomized controlled trial|t|f|t|t
34149230|NCT01878994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34149231|NCT01243489|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047778|NCT04931823|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Modified 3+3 dose escalation design followed by dose expansion at the MTD (maximum tolerated dose)."||||
34047779|NCT03762863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047780|NCT02298062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047781|NCT03205956|NA|SINGLE_GROUP||OTHER||NONE||All participants receive oral carbidopa before, and i.v. levodopa during brain imaging, to measure regional cerebral blood flow responses to levodopa.||||
34047782|NCT02880865|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047783|NCT02055365|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34047784|NCT00049166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047785|NCT00003620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047786|NCT04447742|||COHORT||PROSPECTIVE|||||||
34047787|NCT04449302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded|it is randomized clinical trial|f|f|f|t
34047788|NCT00925938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34047789|NCT06483438|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34047790|NCT04266587|NA|SINGLE_GROUP||OTHER||NONE||||||
34047791|NCT00666822|||CASE_ONLY||PROSPECTIVE|||||||
34047792|NCT02704065|||CASE_CONTROL||RETROSPECTIVE|||||||
34047793|NCT05594836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34047794|NCT04000438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047795|NCT04074681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818379|NCT05727878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Cohort 1: open-label Cohort 2: masked to participant, Investigator, site staff, outcomes assessor, etc||t|t|t|t
34047796|NCT02295046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047797|NCT04362956|||CASE_CONTROL||PROSPECTIVE|||||||
34047798|NCT01387711|NA|SINGLE_GROUP||||NONE||||||
34127025|NCT04021316|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is not possible to mask participants or the research/clinical teams to the treatment strategy as the DCD graft is visible after application for a period of time. However the primary outcome assessments (verification of index ulcer healing visits) will be completed by an independent clinical assessor trained in the assessment of wound healing, who will have no previous involvement with, or knowledge of, the participant's index ulcer treatment and as such will be blind to the randomised treatment strategy (as the DCD is not expected to be visible after 4 weeks).|Participants will undergo 1:1 web based randomisation to either standard care or the intervention via an automated system. A minimization algorithm using centre, index ulcer size and duration will be used, including a random component to lessen predictability. A separate Randomisation System Description document will contain full details of the cut-offs for index ulcer size and duration, and the probability that the allocation will be switched.||||
34127026|NCT02151786|||COHORT||PROSPECTIVE|||||||
34127027|NCT02060929|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127028|NCT02648594|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818380|NCT05555615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818381|NCT05509777|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047799|NCT06683885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047800|NCT05473299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047801|NCT06238908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127029|NCT01056081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127030|NCT03694184|||OTHER||RETROSPECTIVE|||||||
34127031|NCT02688270|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34127032|NCT00386620|||COHORT||PROSPECTIVE|||||||
34127033|NCT06368843|||COHORT||PROSPECTIVE|||||||
34127034|NCT00535171|||CASE_ONLY||PROSPECTIVE|||||||
34127035|NCT01189630|||||PROSPECTIVE|||||||
34127036|NCT04075305|||COHORT||PROSPECTIVE|||||||
34127037|NCT01815424|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127038|NCT05957458|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No mask for all. Open and retrospective study.|Three groups are all treated with PBM therapy with follow-up but they irradiance is different while one group is as the control.||||
34127039|NCT01791660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127040|NCT06197074|||OTHER||PROSPECTIVE|||||||
34127041|NCT03483792|||CASE_CONTROL||PROSPECTIVE|||||||
34127042|NCT04363242|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818382|NCT04707924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||1:1 within-subject random allocation|f|f|f|t
33837204|NCT06100770|||CASE_CONTROL||PROSPECTIVE|||||||
34047802|NCT06530251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047803|NCT05704101|||CASE_CONTROL||PROSPECTIVE|||||||
34047804|NCT01511354|||COHORT||PROSPECTIVE|||||||
34127043|NCT00360178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127044|NCT06046092|NA|SEQUENTIAL||PREVENTION||NONE||Open label, single arm dose escalation phase I trial||||
34127045|NCT01295944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127046|NCT05059093|||OTHER||CROSS_SECTIONAL|||||||
34127047|NCT02594007|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127048|NCT02501681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127049|NCT02110485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34127050|NCT05370027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127051|NCT00858351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127052|NCT00841412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127053|NCT00311025|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
34127054|NCT04792034|NA|SINGLE_GROUP||PREVENTION||NONE||Open label||||
34127055|NCT03973112|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127056|NCT05524636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental and control group|f|f|f|t
34127057|NCT00730353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127058|NCT03986723|||COHORT||PROSPECTIVE|||||||
34127059|NCT04755764|||COHORT||PROSPECTIVE|||||||
34127060|NCT03072472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127061|NCT06473298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127062|NCT04661111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127063|NCT01869634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127064|NCT02725476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127065|NCT02229695|||COHORT||PROSPECTIVE|||||||
33818383|NCT03770338|RANDOMIZED|PARALLEL||OTHER||NONE||To detect any significant difference between control and teriparatide groups in terms of intraoperative insertional torque strength||||
33818384|NCT05670106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818385|NCT01014013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818386|NCT03153449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818387|NCT06721182|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818388|NCT04136249|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818389|NCT05914792|||COHORT||PROSPECTIVE|||||||
33818390|NCT04298502|||COHORT||PROSPECTIVE|||||||
33818391|NCT05619445|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33818392|NCT01745237|||COHORT||PROSPECTIVE|||||||
33818393|NCT03896971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups of patients will be included one group will be treated with thrombopoietin mimetic and immunosuppressive therapy , another matched group treated with immunosuppressive therapy alone and enrolled retrospectively||||
33818394|NCT05499507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818395|NCT03879252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818396|NCT01534052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818397|NCT03991325|||COHORT||PROSPECTIVE|||||||
33818398|NCT06514742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818399|NCT05083182|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818400|NCT02163499|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33818401|NCT06721858|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The research was designed as a single-blind randomized controlled trial (pre-test-post-test, control group, follow-up measurement) in an experimental setting.|t|f|t|t
33818402|NCT05910619|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All parties involved will be blinded to the participant condition with the exception of 1) the interventionist applying the pulsed stimulation to the participant brain, as they will be required to ensure the TPS device is set to sham/active before application of the stimulation, and 2) the biostatistician who will randomize participants with sex-stratification|2x2 sham-controlled design in which 10 typically-aging older adults and 10 patients with mild AD will be randomized to receive either sham TPS or active TPS|t|f|t|t
33818403|NCT00170950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818404|NCT06083558|||COHORT||OTHER|||||||
33818405|NCT04557150|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818406|NCT01242345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818407|NCT04609826|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818408|NCT04604626|||COHORT||PROSPECTIVE|||||||
33818409|NCT05481996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The Intervention group will perform the 8-week treatment with access to 8 pain education messages (1 message/week) and 8 weeks of an exercise program prescribed for people with chronic low back pain, and the control group will receive information on chronic low back pain for one booklet and access to 8 pain education messages (1 message/week). Randomized through software, so that the subject enters his/her login and password and is directed to one of the study groups, with a blind evaluator without access to randomization information throughout the study and follow-up of the outcome measures for 4 months after randomization.|f|f|f|t
33818410|NCT04736602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818411|NCT00039052||||TREATMENT||||||||
33818412|NCT05452005|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818413|NCT05542836|||COHORT||PROSPECTIVE|||||||
33818414|NCT06720792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818415|NCT06237465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818416|NCT06669533|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE|The PIs, nurses who will be providing the drugs, and study participants will be blinded in the study.|||||
33818417|NCT03687918|||COHORT||RETROSPECTIVE|||||||
33818418|NCT05986279|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One group is enrolled into a longitudinal, single group intervention using vestibular rehab. The other group is enrolled as a cross-sectional observational assessment used for developing normative data.||||
33818419|NCT05656651|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818420|NCT04354623|||CASE_CONTROL||PROSPECTIVE|||||||
33818421|NCT04332991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.|Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.|t|t|t|t
33818422|NCT05159076|NA|SINGLE_GROUP||TREATMENT||NONE|Evaluations will be conducted blindly, that is, by an evaluator who will not be directly involved in the intervention.|Longitudinal intervention study||||
33818423|NCT05802498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818424|NCT01489163|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33818425|NCT02987088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818426|NCT05088733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818427|NCT06473571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33818428|NCT05473130|||COHORT||RETROSPECTIVE|||||||
33818429|NCT01879488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818430|NCT01964118|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818431|NCT04415580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818432|NCT00134797|||DEFINED_POPULATION||PROSPECTIVE|||||||
33818433|NCT01581476|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33818434|NCT02920645|||CASE_ONLY||RETROSPECTIVE|||||||
33818435|NCT06423183|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, pre-post study at a single institution||||
33818436|NCT02920216|NA|SINGLE_GROUP||OTHER||NONE||||||
33818437|NCT05465187|||COHORT||PROSPECTIVE|||||||
34127066|NCT03331991|||COHORT||PROSPECTIVE|||||||
33818438|NCT04067115|NA|SEQUENTIAL||TREATMENT||NONE||This phase I study will follow a standard 3+3 design and the Phase II study will be a single-arm, mini-max Simon two-stage design.||||
33837205|NCT06512844|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This clinical trial aims to evaluate the effectiveness of a mindfulness-based intervention (MBI) in managing psychosocial factors associated with emotional intelligence (EI) in adolescents with physical disabilities. It also seeks to assess the safety and overall impact of the intervention.||||
34047805|NCT06622850|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|During the data collection process, patients will be assessed for inclusion in the study by the researcher M.B. when the patients come to the urology outpatient clinic. Block randomization will be applied to eliminate selection bias. Patients will be assigned to acupressure and placebo acupressure groups according to the permutations (ABBAAB, BABABA, etc.) in the randomization list created in the computer environment by the biostatistician who is not involved in the study. After the randomization list is created, the representation of group A and B to the experimental or control group will be determined by lottery. M.B., who will not be involved in the data collection process of the study, will write numbers from 1 to 68 on the envelope as many as the number of the sample and the letter A or B representing the groups will be added inside the envelopes. M.B. will open the numbered envelope and inform GB which group the patient is in. All other researchers other than M.B. will be blinded|The study was planned as a prospective, two-arm (1:1), randomized controlled trial.|f|f|t|t
34047806|NCT05865496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047807|NCT03006978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047808|NCT01490879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047809|NCT05434338|NA|SINGLE_GROUP||OTHER||NONE||||||
34047810|NCT02429778|RANDOMIZED|PARALLEL||TREATMENT||NONE||Behavioral Intervention (relaxation, breathing, activity engagement)||||
34047811|NCT01470625|NA|SINGLE_GROUP||||NONE||||||
33818439|NCT02287428|RANDOMIZED|PARALLEL||TREATMENT||NONE|After Cohort 1 completed accrual, new patients with MGMT-unmethylated tumors are randomized to one of three new cohorts (1a, 1b, \& 1c) and new patients with MGMT-methylated tumors are registered to new cohort 1d.|Patients on Cohort 1 received Neovax after completing standard RT. After Cohort 1 completed accrual, we added three new cohorts (1a, 1b, \& 1c); patients on Cohorts 1a, 1b, \& 1c (run in parallel) receive pembrolizumab (starting at different times) in addition to standard RT + NeoVax.||||
34047812|NCT04126902|||CASE_CONTROL||PROSPECTIVE|||||||
34047813|NCT03980951|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled trial assignment placed in sealed envelopes.|t|f|t|t
34047814|NCT01479855|||CASE_CONTROL||PROSPECTIVE|||||||
34047815|NCT05786469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Active study treatment and placebo will be provided by Vifor Pharma and will be indistinguishable from one another in terms of labelling and instructions.~Allocation to one of the two treatments will be determined by the randomization's number based on a computer-generated randomization list developed by the Mario Negri Biostatistics Laboratory."|DOUBLE-BLIND, RANDOMIZED, SINGLE CENTRE TRIAL|t|t|t|t
34047816|NCT05375994|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047817|NCT06506474|||COHORT||PROSPECTIVE|||||||
34047818|NCT02915120|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33818440|NCT04890249|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33818441|NCT02119611|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818442|NCT01289899|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33818443|NCT06489977|||COHORT||OTHER|||||||
33818444|NCT06720740|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818445|NCT04836559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047819|NCT00005944|RANDOMIZED|||TREATMENT||||||||
34047820|NCT01102257|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818446|NCT06027424|||CASE_ONLY||RETROSPECTIVE|||||||
33818447|NCT05489770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The placebo has comparable appearance and taste to Sambucol® Black Elderberry Original Liquid.~Trial participants, trial statistician and outcome assessors will be blinded to which arm the participant has been randomised. Investigators, the research delivery team, clinical trial pharmacist and study staff not involved in assessing outcomes will not be blinded.~All research delivery team members will be aware that they are not to divulge the randomised arm to participants at any time point.~Participants will remain blind to their allocated trial arm for the duration of the trial."|"This study is a superiority test of Sambucol to placebo in the treatment of COVID 19 positive patients, with a parallel design.~Single Centre, placebo controlled, single blinded, two arm, randomised controlled trial."|t|f|f|t
33818448|NCT04557098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818449|NCT04696809|NA|SINGLE_GROUP||OTHER||NONE||||||
33818450|NCT06260722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818451|NCT05384808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818452|NCT00908193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818453|NCT05570578|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|sham-tDCS||t|f|f|t
33818454|NCT00877500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818455|NCT05913609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818456|NCT04291560|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Masking will not be completed in this trial.|A parallel design will be used, with an equal allocation of 306 obese pregnant women to the two groups: stretching exercise and enhanced usual care.|f|f|f|t
33818457|NCT06462768|||OTHER||PROSPECTIVE|||||||
33818458|NCT00447499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818459|NCT05831995|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Study consists of two parts:~* Part A: ABM-168 Dose Escalation and DLT Dose Confirmation~* Part B: Dose Expansion (ABM-168 Monotherapy)"||||
33818460|NCT00729261|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33818461|NCT05199935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|All participants will view a video twice. At baseline (Time 0) one group will view the intervention video and the other group the control video. Both video are of the same length. Women are seated in such a way that they cannot view each others screens. All women will view the intervention video after the main outcome has been collected at time 1. Care providers will provide standard care and not know which group women in unless they specifically ask at which point the woman viewed a video and if she talked to someone in person after viewing the video. The data-set will be masked so that the statistician analyzing will not know the code for the two different groups.|A two armed randomized controlled trial|t|t|f|t
33818462|NCT03977337|||COHORT||PROSPECTIVE|||||||
33818463|NCT05683639|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34047821|NCT03880682|||CASE_ONLY||RETROSPECTIVE|||||||
34047822|NCT01180751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047823|NCT06178029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047824|NCT04299555|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33818464|NCT01740284|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33818465|NCT01811329|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34047825|NCT05329363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047826|NCT03069261|||CASE_CONTROL||RETROSPECTIVE|||||||
34047827|NCT02892539|||CASE_ONLY||PROSPECTIVE|||||||
34047828|NCT04447027|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047829|NCT06684392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Control Group (CG): The CG will follow the current protocol at HRLBO. This involves a weaning protocol from mechanical ventilation 24 hours after tracheostomy placement. Initial disconnection windows are 2 hours in the morning and 2 hours in the afternoon. If tolerated, the next day's windows extend to 4 hours each, and by the third day, to 6 hours. On the fourth day, a continuous 12-hour disconnection is attempted, progressing to 24 if successful. Additionally, subjects will train at 50% of their MIP in 5 sets of 6 breaths once weaned.~Intervention Group (IG): The IG will follow the CG protocol plus inspiratory muscle training (IMT). If weaning or disconnection is not achieved, subjects will train for inspiratory strength alone. Once weaning or disconnection is successful, the new IMT protocol combining strength and endurance training will begin. If the patient shows clinical signs of respiratory failure, IMT will be paused for the day."|t|f|f|f
34047830|NCT01925066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127067|NCT01218217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127068|NCT01943786|||COHORT||PROSPECTIVE|||||||
34127069|NCT03614598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34127070|NCT01769534|||OTHER||PROSPECTIVE|||||||
34127071|NCT03267784|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Interventional, single arm, multicenter, phase I/IIa clinical trial||||
34127072|NCT04388215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127073|NCT05980065|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127074|NCT01126710|||CASE_ONLY||RETROSPECTIVE|||||||
34127075|NCT00258908|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34127076|NCT06149923|||CASE_CONTROL||PROSPECTIVE|||||||
34127077|NCT02733822|RANDOMIZED|CROSSOVER||||NONE||||||
34127078|NCT04451200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127079|NCT02941328|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34127080|NCT04365426|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34127081|NCT06057805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Blinded continuous glucose monitor will be compared with routine blood testing postpartum||||
34127082|NCT02549989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127083|NCT01618240|||COHORT||PROSPECTIVE|||||||
34127084|NCT02039765|NA|SINGLE_GROUP||SCREENING||NONE||||||
34127085|NCT03976050|NA|SEQUENTIAL||TREATMENT||NONE||||||
34127086|NCT05050292|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Participants will be randomly assigned to one out of two groups (control/experimental).~The activities presented to Group 1 (experimental group) will target executive functions skills and will be automatically adjusted in difficulty and requirement according to each participant's performance so that a maximum cognitive effort is always required.~The activities for Group 2 (active control group) will be of constant difficulty throughout the intervention and will not target the intended cognitive processes (namely, they will target orthogonal unrelated aspects).~Participants and researchers are blind to whether they are in the intervention or the control group. In this way, placebo or waiting-list effects are avoided."|The intervention will be carried out through the CogniFit® online platform so participants will access it from home using a personal computer or smart device. The training will last for a total of 8 weeks (40 training sessions), with five consecutive training days per week (Monday to Friday). Since this process is autonomous, participants will be contacted periodically (a minimum of one phone call per week) to ensure adherence and check that they have not had any incidence. The platform will records participants' performance, providing researchers with real-time feedback on the performance of each participant.|t|f|t|f
34127087|NCT04494828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127088|NCT05732480|||COHORT||PROSPECTIVE|||||||
34127089|NCT02127554|||COHORT||PROSPECTIVE|||||||
34127090|NCT01542463|||COHORT||PROSPECTIVE|||||||
34127091|NCT03110211|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34127092|NCT02075086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127093|NCT05318495|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34127094|NCT03902392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34127095|NCT04089852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34127096|NCT01715363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127097|NCT02137642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047831|NCT04051411|||COHORT||PROSPECTIVE|||||||
34047832|NCT05164484|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047833|NCT02330367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047834|NCT00536159|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047835|NCT05606172|RANDOMIZED|PARALLEL||TREATMENT||NONE||Mixed methods (qualitative and quantitative) randomized pilot feasibility trial (n=10 to treatment and 10 to waitlist control).||||
34047836|NCT06285851|NA|SINGLE_GROUP||OTHER||NONE||||||
34047837|NCT03213314|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Nested cohort study||||
34047838|NCT00846001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047839|NCT00708214|NON_RANDOMIZED|||TREATMENT||NONE||||||
34047840|NCT05624879|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34047841|NCT00004494||||TREATMENT||||||||
34047842|NCT06683040|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047843|NCT06189144|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|f|t|t
34047844|NCT03575221|||COHORT||OTHER|||||||
34047845|NCT02259192|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34047846|NCT03343704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047847|NCT06075901|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34127098|NCT04744220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The cases will be randomly divided into two groups as 24 control groups and 24 yoga training groups||t|f|f|f
34127099|NCT03247582|||COHORT||PROSPECTIVE|||||||
34127100|NCT02948699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127101|NCT01795014|||||PROSPECTIVE|||||||
33818466|NCT06438549|RANDOMIZED|PARALLEL||TREATMENT||NONE||The model compares the integration of CHW Home visits into healthcare provider-directed clinical care and a schedule of CHW home visits to provide behavioral smoking cessation for pregnant people and adult household members before, during, and after a quit date vs Standard of Care.||||
33818467|NCT04117230|||COHORT||PROSPECTIVE|||||||
33818468|NCT06511076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34047848|NCT04314752|||CASE_CONTROL||OTHER|||||||
33818469|NCT04951609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047849|NCT06685172|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 40 patients with plantar fasciitis were randomly assigned to focal-ESWT treatment (n= 20) or radial-ESWT treatment (n= 20).||||
34127102|NCT02855879|||CASE_ONLY||PROSPECTIVE|||||||
34127103|NCT06128850|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34127104|NCT05289089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized trial comparing PP intervention versus wait list control|f|f|f|t
34127105|NCT03492502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127106|NCT01926444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34127107|NCT01583114|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127108|NCT05360251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients are blinded to laser therapy received|adult patients diagnosed with erythematotelangiectatic rosacea|t|f|f|f
34127109|NCT05481983|RANDOMIZED|PARALLEL||OTHER||SINGLE|The Randomization algorithm (Maximum Allowed % Deviation = 10%) was applied using PASS software 11.0 (NCSS LLC, Kaysville, UT) to generate a randomization list that would assign participants to two groups of 52 each.|Randomized control, single-blind|t|f|f|f
34127110|NCT02070328|||CASE_CONTROL||PROSPECTIVE|||||||
34127111|NCT05822037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127112|NCT05881681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127113|NCT02052869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127114|NCT01251562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127115|NCT02288299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127116|NCT06413147|||COHORT||PROSPECTIVE|||||||
34127117|NCT04826783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127118|NCT03833557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34127119|NCT03302403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127120|NCT05324592|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127121|NCT04839653|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||During the first period patients will receive standard care. During the second period SDD protocol will be implemented.||||
34127122|NCT00758940|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127123|NCT02955108|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34127124|NCT03689569|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This will be a double blind study. Neither the participant nor the investigator will know what substance (resistant starch or corn starch) the participants will be consuming.|An Intention-To-Treat design will be used in this study. Effects of treatment on all dependent variables will be assessed by a 2 (prebiotic supplement or control) by 2 (aerobic exercise or control) by 3 (time) mixed factor ANOVA|t|f|t|f
34127125|NCT04263844|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34127126|NCT04175340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34127127|NCT01148901|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818470|NCT02846142|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33818471|NCT05966896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818472|NCT04734236|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33818473|NCT04503434|||COHORT||CROSS_SECTIONAL|||||||
34047850|NCT02582242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047851|NCT01339923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047852|NCT02482948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34047853|NCT02088671|||CASE_ONLY||PROSPECTIVE|||||||
34047854|NCT01599936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047855|NCT06501014|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047856|NCT03604393|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Aims II and III are interventional, using a randomized stepped-wedge design with the practice as the unit of randomization.||||
34047857|NCT03363776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047858|NCT05107492|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34047859|NCT06261125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047860|NCT05047965|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34047861|NCT02449382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047862|NCT06684262|||COHORT||PROSPECTIVE|||||||
34047863|NCT05172817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047864|NCT03586505|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each patient is its own control||||
34047865|NCT00388869|||DEFINED_POPULATION||PROSPECTIVE|||||||
34047866|NCT04685772|||COHORT||PROSPECTIVE|||||||
34047867|NCT02308891|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34047868|NCT05053451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047869|NCT05392114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047870|NCT00664378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047871|NCT01715727|||CASE_CONTROL||PROSPECTIVE|||||||
34047872|NCT03751839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Identical diagnostic procedures will be performed in participants with type 1 diabetes and age- and sex-matched controls.||||
34047873|NCT02772172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047874|NCT01316107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047875|NCT02749526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047876|NCT05100420|||FAMILY_BASED||PROSPECTIVE|||||||
34047877|NCT05620498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047878|NCT01185184|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34047879|NCT04797741|NA|SINGLE_GROUP||OTHER||NONE||||||
34127128|NCT03765216|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Participants are randomly assigned to group A or B. Participants of group A are given normal bowel preparation, while participants of group B are given personalized regimens according to a predictive model we have established.|f|t|t|t
34127129|NCT05892497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34047880|NCT05719142|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Participants will be aware of the study visit assignment during the study visit when exposed to the experimental stimuli, but not beforehand. Investigators will be aware also before the study visit.|All participants will complete all three study visits. The visits differ in the employed experimental stimuli, namely the pictures (sweet food, savoury food, non-food).||||
34047881|NCT00852891|||||PROSPECTIVE|||||||
34047882|NCT01564108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047883|NCT05982236|||CASE_ONLY||PROSPECTIVE|||||||
34047884|NCT03789149|NA|SINGLE_GROUP||TREATMENT||NONE||Single group assignment||||
34047885|NCT02879617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047886|NCT05226871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047887|NCT05172596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047888|NCT03503864|NA|SINGLE_GROUP||TREATMENT||NONE||Combined induction chemotherapy with arsenic trioxide||||
34047889|NCT00056719|||COHORT||PROSPECTIVE|||||||
34047890|NCT06577662|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34047891|NCT02578368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047892|NCT06374394|RANDOMIZED|PARALLEL||PREVENTION||NONE|Click here to enter text.|||||
34047893|NCT04833270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047894|NCT00444938|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34047895|NCT05055960|||OTHER||RETROSPECTIVE|||||||
34047896|NCT00172328|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34047897|NCT05221151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34047898|NCT03013907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34047899|NCT06546020|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Placebo and haskap interventions were designed to be comparable in taste and appearance.||t|f|t|f
34047900|NCT04483960|RANDOMIZED|FACTORIAL||TREATMENT||NONE|This is an open-label study.|Participants enrolled into the study have the option of deciding whether to be randomised in one or more (if available) treatment domains concurrently, if they meet the eligibility criteria.||||
34047901|NCT06125938|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34047902|NCT03617770|RANDOMIZED|PARALLEL||TREATMENT||NONE||Sleep optimization intervention will be compared to a healthy living attention control||||
34047903|NCT02278939|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047904|NCT00334074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047905|NCT02382497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34047906|NCT03838315|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be assigned randomly into two groups: Neural Mobilization with Soft tissue mobilization and Neural mobilization without Soft tissue mobilization.A coin will be flipped at start of data collection for the first patient to be assigned odd number and included in Neural mobilization with Soft tissue mobilization group. Later on odd and even numbered subjects will be included in specific group.||||
34047907|NCT04393480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34047908|NCT04693026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047909|NCT05200182|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818474|NCT05850858|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33818475|NCT05449756|||COHORT||PROSPECTIVE|||||||
33818476|NCT06715163|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33818477|NCT05556512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34047910|NCT00873847|||COHORT||PROSPECTIVE|||||||
34047911|NCT04832607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be stratified with respect to three age groups: Children up to 6 years, children \>6 and up to 18 years, and adults \>18 years. Accordingly, for each stratum, a separate randomization list will be provided. Randomization will be performed by a representative of the Simbec-Orion Group who will be independent in the sense that he / she will otherwise not be involved in the TRACE trial.|2 (verum): 1 (Placebo) randomization|t|t|t|t
34047912|NCT01507883|||CASE_CONTROL||PROSPECTIVE|||||||
34047913|NCT01600456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047914|NCT03570632|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34047915|NCT05304416|||COHORT||PROSPECTIVE|||||||
34047916|NCT05303298|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will remain unaware of which type of stent they have received. Follow-up will be performed telephonically and the Outcomes Assessor will also remain blinded as to what type of stent the participant received|Participants will be randomised to receive either an anti-reflux oesophageal stent or a conventional oesophageal stent.|t|f|f|t
34047917|NCT03867812|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Open label, randomized, crossover, controlled study||||
34047918|NCT06685263|||COHORT||PROSPECTIVE|||||||
34047919|NCT04673474|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34047920|NCT04781608|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants will be randomized to one of two conditions: 1) Intervention group, which will receive access to the digital intervention program, and 2) Control group, who will not receive immediate acess to the digital intervention program.~Intervention group:~Participants will be asked to complete survey measures at baseline (prior to access to the 4-module digital intervention program), 6-weeks, 10 weeks, and 18 weeks.~Control group:~Participants will be asked to complete survey measures at baseline , 6-weeks, and 10 weeks (control group participants gain access to the digital intervention program after completion of the 10-week survey)."||||
34047921|NCT04961762|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34047922|NCT04058093|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127130|NCT05519111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Dronabinol and placebo will be over-encapsulated so that neither participants nor investigators are aware of the subjects assignment.|Participants will be randomized 1:1 to dronabinol or placebo.|t|t|t|t
34127131|NCT00691457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33818478|NCT04181827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818479|NCT00002371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837206|NCT06198751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837207|NCT01371825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837208|NCT04489277|||COHORT||OTHER|||||||
33837209|NCT04731259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33837210|NCT00128297|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33818480|NCT05741866|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Due to the nature of the intervention, blinding of patients/clinicians to the intervention is not possible. However, the statistician will be blinded for analysis; and the microbiologist and laboratory staff will also be blinded to treatment allocation when apportioning infection outcomes.~Additionally, at the completion of Phase 1 (n=300) an independent data safety monitoring committee (DSMC) comprised of a biostatistician, physician and expert trialist, will review pre-defined blinded analyses, conducting a review of feasibility and safety data to determine if the trial should continue to a fully powered RCT."|A multi-centre, two-arm, parallel group adaptive randomised controlled trial|f|f|t|t
33818481|NCT06049199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818482|NCT06206616|||COHORT||PROSPECTIVE|||||||
33818483|NCT06721741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818484|NCT00557154|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818485|NCT03607578|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33818486|NCT06701149|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33818487|NCT06481982|||COHORT||PROSPECTIVE|||||||
33818488|NCT06571019|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Trial participants will be aware of the intervention to which they have been allocated, and the research fieldworkers will be aware of the intervention allocation. The trial steering committee members and trial statistician will remain blinded until the end of trial period and data collection.||f|f|t|t
33818489|NCT06236815|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
33818490|NCT05129592|RANDOMIZED|FACTORIAL||OTHER||SINGLE||Participants will be randomized to view one of four messages. The message conditions are as follows: condition 1 will not contain either component of coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.|t|f|f|f
33818491|NCT06212622|||COHORT||PROSPECTIVE|||||||
33818492|NCT06559072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818493|NCT05601362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818494|NCT02766764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818495|NCT02671071|||CASE_ONLY||PROSPECTIVE|||||||
33818496|NCT04908800|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33818497|NCT01539902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818498|NCT04396717|NA|SEQUENTIAL||TREATMENT||NONE||Open label, non-randomized, 3+3 dose escalation to determine MTD, followed by exoansion to 6-12 patients to determine RP2D. Subjects will continue study treatment until progressive disease or unacceptable toxicity. Follow-up will occur until death or lost to follow-up.||||
33818499|NCT03761706|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33818500|NCT05576012|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Part 1 single dose: Dose escalation in healthy subjects (up to 6 cohorts). Within each cohort, subjects will be randomized in a 3:1 ratio to receive either SOL-116 (n=6) or matching placebo (n=2) in a double-blind manner.~Part 2 single dose in patients with rheumatoid arthritis (1 cohort). The patients will be randomized in a 3:1 ratio to receive either SOL-116 (n=6) or matching placebo (n=2) in a double-blind manner.~Part 3 multiple dose in healthy subjects (1 or 2 cohorts). The subjects will be randomized in a 3:1 ratio to receive either SOL-116 (n=6) or matching placebo (n=2) in a double-blind manner."|t|t|t|t
33818501|NCT06721650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818502|NCT05951556|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will be provided with device; telehealth appts will be utilized to direct setup and usage of the device.||||
33818503|NCT02572986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818504|NCT04818918|||COHORT||PROSPECTIVE|||||||
33818505|NCT06390124|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective case series||||
33818506|NCT02511106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818507|NCT00874172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818508|NCT03677856|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-centre, parallel group, superiority, with an internal pilot, in a 1:1 ratio||||
33818509|NCT01249378|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33818510|NCT05431608|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33818511|NCT04119778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33818512|NCT06079190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Click here to enter text.||t|t|t|t
33818513|NCT02326493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818514|NCT05012462|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818515|NCT02038803|||COHORT||PROSPECTIVE|||||||
33818516|NCT02332525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818517|NCT01217723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818518|NCT05099068|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33818519|NCT06720597|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|The data analysis will be conducted by statisticians blinded to the intervention status to reduce analysis bias. Data coding will be used to ensure that statisticians are unaware of the group assignments during the analysis phase.|"Study groups:~1. Vasculogenic ED confirmed by penile Doppler ultrasound Population: 40 men aged 18 or above years diagnosed with vasculogenic ED Intervention: None. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.~2. PDE5 Inhibitor Therapy in Men with Vasculogenic Erectile Dysfunction (ED) Population: 40 men aged 18 or above years diagnosed with vasculogenic ED. Intervention: Daily low-dose PDE5 inhibitor therapy. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention.~3. Testosterone Therapy in Hypogonadal Men Population: 40 hypogonadal men aged 18 or above Intervention: Testosterone therapy as per clinical guidelines. Assessments: Endothelial function will be assessed using the EndoPAT device at baseline, 3 months, and 6 months post-intervention."||||
33818520|NCT02104921|||CASE_CONTROL||PROSPECTIVE|||||||
33818521|NCT03255174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127132|NCT04196595|||COHORT||PROSPECTIVE|||||||
34127133|NCT02228044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127134|NCT06396702|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127135|NCT03329625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818522|NCT01313156|||COHORT||PROSPECTIVE|||||||
33837211|NCT02229578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047923|NCT05794776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34047924|NCT02989376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047925|NCT05787496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047926|NCT06482190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047927|NCT05957211|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34047928|NCT02962778|||CASE_ONLY||PROSPECTIVE|||||||
34047929|NCT06601322|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective non-randomized controlled pilot study||||
34047930|NCT00931840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047931|NCT06682221|RANDOMIZED|PARALLEL||TREATMENT||NONE||The elderly participants will be between 60 and 85 years old and will be randomly assigned to one of four groups, with n = 40 in each group: Control Group (CG; untrained and unsupplemented; n = 40), Supplemented Group (SG; untrained and supplemented; n = 40), Trained Group (TG; trained and unsupplemented; n = 40), and Trained and Supplemented Group (TSG; trained and supplemented; n = 40).||||
34047932|NCT04704804|||COHORT||PROSPECTIVE|||||||
34047933|NCT00166309|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047934|NCT03158480|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34047935|NCT00400660|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34047936|NCT04734990|NA|SEQUENTIAL||TREATMENT||NONE||||||
34047937|NCT00373672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047938|NCT06389760|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047939|NCT04865263|||CASE_ONLY||PROSPECTIVE|||||||
34047940|NCT04685616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047941|NCT06682286|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover study where the breathing route of each participant will be assessed off- and on NIV. Additionally, the breathing route of each participant on NIV will be investigated during sleep and in awake state.||||
34047942|NCT00507819|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34047943|NCT05066204|RANDOMIZED|PARALLEL||OTHER||SINGLE|Investigator are blinded/masked against the study arm of the particular assessed participant.|Two unbound samples running through a different sequence of teching-/learningmethods|f|f|t|f
34047944|NCT04422912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047945|NCT01976650|||COHORT||PROSPECTIVE|||||||
34047946|NCT05676931|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34047947|NCT05756803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047948|NCT01176149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047949|NCT02037191|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34047950|NCT04583878|||CASE_CONTROL||PROSPECTIVE|||||||
34047951|NCT03971955|||OTHER||CROSS_SECTIONAL|||||||
33818523|NCT06471127|NA|SINGLE_GROUP||OTHER||NONE||Translational. This protocol 1) tests neural mechanisms of connectivity and reorganization that support post-stroke language recovery and 2) determines biomarkers predictive of language impairments to improve prognostics for persons with aphasia.||||
34047952|NCT02171234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34047953|NCT04215211|||COHORT||RETROSPECTIVE|||||||
34047954|NCT01665625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047955|NCT02828501|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34047956|NCT06035640|||OTHER||RETROSPECTIVE|||||||
34047957|NCT03180684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047958|NCT05924425|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|A randomization list will be generated and will remain confidential until the database is locked. Participants, investigators, and site personnel will be unaware of treatment allocation during the two crossover periods (Period A and Period B)|"During Period A, patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period will be followed by a one-week (range 5-12 days) washout period at home. During the second period (Period B), these patients will receive the placebo.~During Period A, patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period will be followed by a one-week (range 5-12 days) washout period at home. During the second period (Period B), these patients will receive the daridorexant 50 mg."|t|t|t|t
34047959|NCT04355611|||COHORT||RETROSPECTIVE|||||||
34047960|NCT00232986|||DEFINED_POPULATION||OTHER|||||||
34047961|NCT06682845|||COHORT||RETROSPECTIVE|||||||
34047962|NCT06666114|||COHORT||RETROSPECTIVE|||||||
34047963|NCT05299554|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm extension study||||
34047964|NCT06684587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel-arm randomized controlled trial|f|f|f|t
34047965|NCT03445546|||CASE_CONTROL||PROSPECTIVE|||||||
34047966|NCT03822663|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34047967|NCT05347004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047968|NCT02777346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34047969|NCT03670446|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34047970|NCT05069831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a single center, blinded, randomized pilot study.|t|f|t|f
34047971|NCT02787824|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34047972|NCT01524484|||||RETROSPECTIVE|||||||
34047973|NCT04288921|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||A performance evaluation study.||||
34047974|NCT01415869|||OTHER||OTHER|||||||
34047975|NCT06531941|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34047976|NCT01366937|||CASE_ONLY|||||||||
34047977|NCT06031415|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34047978|NCT06177652|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Single(Participant)||t|f|f|f
34047979|NCT02694783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047980|NCT05113251|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of three arms in parallel for the duration of the study.||||
34127136|NCT01100333|||COHORT||PROSPECTIVE|||||||
34127137|NCT01816776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127138|NCT02869542|||COHORT||PROSPECTIVE|||||||
34127139|NCT02425787|||COHORT||PROSPECTIVE|||||||
34127140|NCT03268889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127141|NCT05013021|NA|SINGLE_GROUP||OTHER||NONE||Sedentary participants||||
34127142|NCT03715725|||COHORT||RETROSPECTIVE|||||||
34127143|NCT03107728|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34047981|NCT05906511|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Study medication will be prepared by study pharmacy.|This is a double-blind, placebo-controlled, crossover study, randomizing 20 men and women aged 65 years or older to two doses of oral THC and vaporized THC.|t|f|t|f
34047982|NCT01926613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047983|NCT03182543|RANDOMIZED|CROSSOVER||PREVENTION||NONE||The prescription of the treatments (AM1, AM2) and control (water) was randomized. The subject consumed 600mL of AM1, AM2 or water. 2 hours later subject performed the exercise test. Next treatment was evaluated after a week of wash-out.||||
34127144|NCT01743612|NON_RANDOMIZED|PARALLEL||||NONE||||||
33818524|NCT06640426|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||This study will use a randomized controlled trial to evaluate a health system initiative to improve Medicare Annual Wellness Visit (AWV) completion. Investigators will randomly assign Ascension Health patients who are eligible for an AWV to one of three conditions. Patients in Treatment Condition #1 will receive a set of up to five email and text messages over the course of eight days, while also receiving usual care which could include messaging from their practice or the electronic health record. Patients in Treatment Condition #2 will receive a set of two email and text messages on a single day. Patients in the Control Condition will receive no messages as part of this campaign, but will be receiving usual care, which could include messages related to AWV's from their primary care practice or from the electronic health record.|f|f|t|t
33818525|NCT06519955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33818526|NCT05635526|||OTHER||RETROSPECTIVE|||||||
33818527|NCT00014508||||TREATMENT||NONE||||||
33818528|NCT04407247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818529|NCT06719908|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33818530|NCT03656718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818531|NCT01190488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818532|NCT00110279|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33818533|NCT04795518|||OTHER||CROSS_SECTIONAL|||||||
33818534|NCT00111384|||FAMILY_BASED||PROSPECTIVE|||||||
33818535|NCT00329186|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818536|NCT00725127|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818537|NCT04698499|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818538|NCT05379634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818539|NCT06720727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818540|NCT05092269|NA|SINGLE_GROUP||OTHER||NONE||||||
33818541|NCT01140152|||CASE_CONTROL||PROSPECTIVE|||||||
33818542|NCT06720272|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE||Stepped wedge cluster randomized trial|f|f|f|t
33818543|NCT06721676|NA|SINGLE_GROUP||TREATMENT||NONE||Transcatheter aortic valve system 2.5 generation is a new self-expanding valve system developed by Peijia Medical. Through the improvement of the delivery device to achieve A2 flex and commissural alignment technology, it can better manage the whole life cycle of AS patients||||
33818544|NCT01176747|NA|PARALLEL||TREATMENT||NONE||||||
33818545|NCT02522299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818546|NCT06250322|||COHORT||OTHER|||||||
33818547|NCT06142799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818548|NCT06636773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818549|NCT06721845|||CASE_CONTROL||PROSPECTIVE|||||||
33818550|NCT06719999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818551|NCT01125956|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818552|NCT06705842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818553|NCT05762172|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818554|NCT05419921|||OTHER||CROSS_SECTIONAL|||||||
33818555|NCT06202898|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818556|NCT05789667|||COHORT||PROSPECTIVE|||||||
33818557|NCT01107795|||CASE_ONLY||PROSPECTIVE|||||||
33818558|NCT06106308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818559|NCT06721962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818560|NCT00026078||||TREATMENT||||||||
33818561|NCT03331276|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|This study is a randomized, controlled, double-blind, study of healthy term formula fed (FF) infants.|Formula feed infants will be randomized to receive either a new infant formula formulated for healthy term infants (BBN) or a commercially available infant formula for healthy term infants (Brand). Infants will consume the formula for a total of 16-weeks.|t|t|t|t
33818562|NCT01118429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818563|NCT01815255|||COHORT||PROSPECTIVE|||||||
33818564|NCT03337204|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818565|NCT03015415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818566|NCT06600100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33818567|NCT05369832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818568|NCT06523686|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818569|NCT01078571|||COHORT||PROSPECTIVE|||||||
33818570|NCT01648699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818571|NCT06691659|||OTHER||PROSPECTIVE|||||||
33818572|NCT00965393|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33818573|NCT01802606|||COHORT||PROSPECTIVE|||||||
33818574|NCT05262244|NA|SEQUENTIAL||TREATMENT||NONE||First a dose finding study is performed using bevacizumab-800CW within the AMD patient group. Using the optimal dose and if fluorescence is visible, additional inclusion of patients with the optimal dose.||||
33818575|NCT06519981|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE||Healthy participants are planned to be enrolled in a single ascending dose study. For each cohort, participants will randomly receive HRS-9231/Placebo injection by an intravenous (IV) administration|t|t|t|t
33818576|NCT01623180|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818577|NCT05424822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818578|NCT00969995|||CASE_CONTROL||PROSPECTIVE|||||||
33818579|NCT06555744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837212|NCT04387877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837213|NCT02595580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837214|NCT02593799|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127145|NCT01619293|||COHORT||PROSPECTIVE|||||||
33818580|NCT03422328|NA|SINGLE_GROUP||TREATMENT||NONE||"The study is designed as an open-label, single-arm, multicenter trial in which all participants roll over from a parent study in order to continue their dose of macitentan 10 mg once every day as already received in the parent study."||||
33818581|NCT05512988|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818582|NCT06524739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Period 1 (double-blind): Participant, Care Provider, Investigator, Outcomes Assessor~Period 2 (open-label): No masking"||t|t|t|t
33818583|NCT04387201|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover clinical trial||||
33818584|NCT05519215|||COHORT||PROSPECTIVE|||||||
33818585|NCT05487300|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
33818586|NCT05472142|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33818587|NCT01417923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818588|NCT03770884|||COHORT||PROSPECTIVE|||||||
33818589|NCT06719622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818590|NCT02976961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33818591|NCT02661581|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818592|NCT03587272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818593|NCT06475690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818594|NCT06449612|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33818595|NCT06450639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818596|NCT03229083|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33818597|NCT00483171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818598|NCT06473272|||COHORT||PROSPECTIVE|||||||
33818599|NCT06719973|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149232|NCT05428813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Study||||
33818600|NCT03704363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A computer-generated randomised allocation sequence will be imported into an electronic case report form (eCRF) system (Viedoc) and made available exclusively to a study nurse (mixing nurse) authorised by the local principal investigator to prepare infusions. The mixing nurse is otherwise not involved in the treatment of the patient. The infusion bags containing the study medication will be prepared by the mixing nurse in identical infusion bags, and applied labels with patient number and dose such that blinding of the participants is secured. The Investigational Medicinal Products (IMPs) have the same color and will look the same. After preparing the IMP, the mixing nurse will hand over the IMP to another nurse, blinded to allocation, and authorised by the local principal investigator to administer the infusion.||t|t|t|t
33818601|NCT03749538|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind study to transcranial current stimulation|Prospective, randomized, double-blind, placebo-controlled study with application or not of a transcranial current stimulation session in patients with systemic autoimmune myopathies.|t|f|t|f
33818602|NCT02068079|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818603|NCT06361576|||COHORT||RETROSPECTIVE|||||||
33818604|NCT00966641|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33818605|NCT01525875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818606|NCT06457256|RANDOMIZED|PARALLEL||TREATMENT||NONE||School Services as Usual (SAU) waitlist design||||
33818607|NCT05844982|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33818608|NCT05468697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818609|NCT06614582|NA|SINGLE_GROUP||TREATMENT||NONE||Single group intervention for participants who have completed NCT05527652 (Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia)||||
33818610|NCT05908539|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818611|NCT05451641|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818612|NCT04577833|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33818613|NCT02693548|||COHORT||PROSPECTIVE|||||||
33818614|NCT00473031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818615|NCT05121012|||COHORT||PROSPECTIVE|||||||
33818616|NCT06721728|NA|SINGLE_GROUP||OTHER||NONE||||||
33818617|NCT04915625|||COHORT||RETROSPECTIVE|||||||
33818618|NCT05264506|NA|SINGLE_GROUP||PREVENTION||NONE||Single Arm Study||||
33818619|NCT00087516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818620|NCT03586284|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicenter, double-masked, randomized, placebo-controlled clinical trial|t|t|t|t
33818621|NCT02814461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818622|NCT02896153|||||PROSPECTIVE|||||||
33818623|NCT04560049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818624|NCT06720038|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33818625|NCT03774082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818626|NCT02588027|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33818627|NCT00628706|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33818628|NCT05486819|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33818629|NCT05838300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33818630|NCT00104364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818631|NCT04953793|RANDOMIZED|PARALLEL||TREATMENT||NONE||A small feasibility randomized clinical trial with randomization occurring at school site level. Two sites randomized to intervention and two sites randomized to control conditions.||||
33818632|NCT00755248|||CASE_ONLY||PROSPECTIVE|||||||
33818633|NCT06211764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818634|NCT00158236|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33818635|NCT06415552|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33818636|NCT06347211|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33818637|NCT01202344|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33818638|NCT03901963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818639|NCT04636463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818640|NCT00872404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818641|NCT06721117|||COHORT||CROSS_SECTIONAL|||||||
33837215|NCT03629470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837216|NCT04412083|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837217|NCT04917445|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33837218|NCT01100606|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818642|NCT05259592|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a randomised controlled pilot study that follows the guidelines of the Consolidated Standards of Reporting Trials (CONSORT; Boutron et al., 2017) and the SPIRIT guidelines (Chan et al., 2013).~60 Danish veterans with complex PTSD (CPTSD) will be randomised to either modular patient-centred CBT (MPC) or a control treatment, where the order of the treatment modules is determined in advance. A randomisation list was prepared using R software (www.r-project.org). Participants are randomised into the intervention group or the control group with 30 participants in each group, stratified by recruitment/treatment site. A block size of six will be used to ensure an even balance. The randomisation was pre-pared by a data manager affiliated with the project, and only he is able to see the randomisation list."||||
33818643|NCT06516562|||CASE_CONTROL||PROSPECTIVE|||||||
33818644|NCT00719719|||CASE_ONLY||PROSPECTIVE|||||||
33818645|NCT06494033|||COHORT||PROSPECTIVE|||||||
33818646|NCT05791786|||COHORT||PROSPECTIVE|||||||
33818647|NCT05201781|NA|SINGLE_GROUP||OTHER||NONE||||||
33818648|NCT06406361|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||a pretest-posttest control group design|t|f|f|f
33818649|NCT06082687|||OTHER||OTHER|||||||
33818650|NCT02420847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818651|NCT01093976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818652|NCT02338310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818653|NCT06381921|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||randomized controlled ambulatory trial||||
33818654|NCT02011568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818655|NCT05584397|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33818656|NCT01089270|||COHORT||PROSPECTIVE|||||||
33818657|NCT02119598|||COHORT||PROSPECTIVE|||||||
33818658|NCT05083169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818659|NCT05250973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants of Cohort 1 will be randomized to either Arm A or Arm B of Cohort 1 in a 2:1 ratio. For Cohort 2, participants will be enrolled without randomization.||||
33837219|NCT01991327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837220|NCT05256615|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study comprises of two groups; a diabetes and a non-diabetes group.||||
33837221|NCT00656045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837222|NCT00098397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837223|NCT03204162|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33837224|NCT04121897|NA|SINGLE_GROUP||OTHER||NONE||Prospective single group||||
33837225|NCT02472002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047984|NCT06412757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All study team members will be blinded to allocation. Blinding will be maintained by ensuring that the packaging, appearance and color of the Silexan (treatment) and placebo capsules are identical. Placebo capsules will also include a sub-therapeutic amount of lavender oil to match the odour of the Silexan capsules. In addition, blinding will be maintained by identifying participants using anonymous participant identifier numbers; an independent statistician will coordinate randomization and an independent pharmacist will store and provide blinded batches to study team members for dispensing.|The trial is a phase 3, 12-week, parallel-arm, randomized, placebo-controlled, double-blind trial. Participants will be randomly allocated to receive either (a) Silexan 160 mg or (b) an identical appearing inert placebo, daily for 12 weeks in addition to their usual prescribed medications.|t|t|t|t
34047985|NCT06533137|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The participants did not know which of the three groups they were assigned to.||t|f|f|f
34047986|NCT03449654|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Dobbelt-blinded|Randomized, Placebo-controlled, Parallel|t|f|t|f
34047987|NCT00238940|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34047988|NCT02049892|||COHORT||CROSS_SECTIONAL|||||||
34047989|NCT01702285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047990|NCT06651112|||COHORT||PROSPECTIVE|||||||
34047991|NCT06171932|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34047992|NCT06339463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The rater will be blinded to which condition, self-distancing or classic exposure, child participants receive.|Youth (12-17.99 years) with specific phobia of spiders will be randomized to receive exposure therapy with or without self-distancing. Exposure therapy will be delivered in a single session (i.e., One-Session Treatment \[OST\]) consisting of increasingly challenging exposure tasks, adapted from prior work (Ollendick and Davis III, 2013). These conditions will run in parallel.|f|f|f|t
34047993|NCT04845919|NA|SINGLE_GROUP||OTHER||NONE||||||
34047994|NCT06682260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34047995|NCT03697174|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34047996|NCT05940376|||CASE_CONTROL||RETROSPECTIVE|||||||
34047997|NCT06649968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34047998|NCT04042701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1b, open-label, 2-part, multicenter, non-randomized, multiple-dose study||||
34047999|NCT06664099|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study uses a parallel design to compare the outcomes of One Anastomosis Gastric Bypass at three different distances (150 cm, 170 cm, and 200 cm) from the duodenojejunal junction in separate groups to assess weight loss and nutritional deficiency.||||
34048000|NCT05197569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"In the study, patients will be stratified according to their gender (male and female) status and the blocking process will be performed. In this study, block randomization will be done according to age groups in order to assign the participants to the experimental and control groups. Patients will be listed according to the hospitalization list and numbered up to 140. Numbers will be assigned to the experimental and control groups according to the random numbers list. Thus, the probability of each patient in the groups being in either of the intervention or control groups will be equalized.~Group 1: experimental 2. Group: Control"|t|f|f|f
34048001|NCT01741766|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34048002|NCT05933174|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127146|NCT06227533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eighteen papers were numbered from 1 to 18 and individually packed in opaque envelopes. Each patient picked an envelope before the beginning of the second visit. The number in the envelope determined the regenerative protocol which was to be performed for the participant. The patient was not informed of what procedure he/she was subjected to|The current study was designed as randomized controlled clinical trial with an allocation ratio 1:1|t|f|t|t
33818660|NCT05441410|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||"There will be two groups: Group 1 (PfSPZ-CVac) and Group 2 (ME-TRAP). Within Group 1, Arm 1 (N=12) participants will receive PfSPZ Challenge (NF54) via direct venous inoculation (DVI) along with one weight-adjusted oral dose of Pyramax on day 1, day 6, and day 29. The placebo group of Arm 2 (N=3) will receive an oral placebo pill and saline DVI on day 1, day 6, and day 29.~In Group 2, participants of Arm 1 (N=12) will receive MVA ME-TRAP intramuscularly on day 1 and ChAd63 ME-TRAP intravenously by DVI on day 29. The placebo group of Arm 2 (N=3) will receive saline intramuscularly on day 1 and intravenously on day 29."|t|t|t|t
33818661|NCT04993313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818662|NCT04397263|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33818663|NCT06670755|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"This is a phase 1b vaccine efficacy study of ID93/GLA-SE in historically BCG-vaccinated and BCG-naïve healthy adult volunteers using an aerosol BCG challenge model.~There will be four study groups with twelve volunteers in each group. Volunteers will be randomized to eligible groups based upon their BCG vaccine status, and will either be given 2 μg ID93 + 5 μg GLA-SE at Day 0 and Day 56 (Group A and C) prior to BCG aerosol challenge, or proceed directly to BCG aerosol challenge without vaccination."||||
33818664|NCT05000593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818665|NCT06720428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33818666|NCT05172063|||COHORT||PROSPECTIVE|||||||
33818667|NCT06658704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A two arm intervention study with allocation to usual care (Physical activity on Prescription) or usual care (Physical activity on Prescription) + an exercise intervention.|f|f|f|t
33818668|NCT05526001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded||t|f|t|f
33818669|NCT04902040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818670|NCT05125510|||COHORT||PROSPECTIVE|||||||
33818671|NCT06721325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33818672|NCT05698199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818673|NCT01518517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818674|NCT01823458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33818675|NCT06517706|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants will be randomly assigned to the experimental and control group. Both groups will receive cognitive rehabilitation. The experimental group control group will also active tDCS treatment whereas the control will receive inactive or sham tDCS treatment|Random Assignment|t|t|f|f
33818676|NCT03591328|||CASE_CONTROL||OTHER|||||||
33818677|NCT04360928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818678|NCT04750447|||COHORT||PROSPECTIVE|||||||
33818679|NCT05655260|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comprehensive cohort design||||
33818680|NCT02342275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33818681|NCT06394193|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The 20 anticipated coach participants, 10 will be assigned to the intervention and 10 will be assigned to the comparison group; assignment will occur based on availability.||||
33818682|NCT06318169|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818683|NCT06715787|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||One treatment group and one control group|f|f|f|t
33818684|NCT03590847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818685|NCT04429087|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818686|NCT06116786|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818687|NCT06288347|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||"All participants were requested to complete web-based assessment, with questionnaires relating to maladaptive beliefs associated with ON, ortorexia, eating and depressive symptomatology, obsessive belifs and self-esteem at baseline (T1).~The experimental group started using the app for 15 days, and later completed the following assessment (T2). The control group also completed the T2 in the same date but started to use the app after this second assessment.15 days and one month later, both groups completed T3 and T4."|t|f|f|f
33818688|NCT05710614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818689|NCT00635323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818690|NCT06431360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818691|NCT06028438|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818692|NCT06466798|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818693|NCT03672188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818694|NCT06721039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33818695|NCT06574503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818696|NCT03772119|||COHORT||PROSPECTIVE|||||||
33818697|NCT05968326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818698|NCT05686343|||COHORT||PROSPECTIVE|||||||
34127147|NCT03947268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127148|NCT03464513|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127149|NCT02006108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127150|NCT04608292|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||The study will begin with the simplest imaging measurements, and only proceed to longer or more complicated measurements if necessary. Re-breathing apparatus will be used only once the imaging measurement has been decided upon, and blood sampling will be used only on a few subjects to confirm the results. Thus, while there are 9 arms to this trial, it is possible that as few as 3 arms will actually be used.||||
33818699|NCT06635135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818700|NCT06721767|||COHORT||PROSPECTIVE|||||||
33818701|NCT05935982|NA|SINGLE_GROUP||OTHER||NONE||||||
33818702|NCT05444777|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blinded|Randomized control trial|t|t|t|t
33818703|NCT05390697|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33818704|NCT03907046|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33818705|NCT06209411|RANDOMIZED|PARALLEL||SCREENING||NONE||Cluster Randomized Trial||||
33818706|NCT05016453|||COHORT||PROSPECTIVE|||||||
33818707|NCT04874493|||COHORT||PROSPECTIVE|||||||
33818708|NCT05490680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818709|NCT00518596|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33818710|NCT04928196|||CASE_ONLY||PROSPECTIVE|||||||
33818711|NCT00354809|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33818712|NCT04567745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048003|NCT05339711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|"While the patients were randomized; In order to keep the possibility of being affected by each other at a minimum level, the study was continued with the same application group in the same session group. For example; It's like working only with the robot cat group in the 08:00-12:00 session group on Mondays. In order to reduce the possibility of selection bias due to sample selection, single-stage cluster type random sampling, which is a subtype of random sampling, was used. In addition, before the study, patients were informed about the study and their consent was obtained."|Power analysis was performed in the selection of patients to be sampled. The number of samples, the G\*Power program 3.1.9.6 error rate α=0.05, and due to the lack of work he has done on the subject before in different populations (old) (32) pet therapy is a targeted domain 0.475 three groups (robot kedi grubu, Betta balık grubu, kontrol grubu) by reference to the size and power of test work is 0.80 (80%), while for a group of three in total, 48 (16 for each group) patients was calculated. Considering situations such as wanting to leave the study or death during the study, each group was increased by 10% and a total of 54 patients were included in the study, 18 patients for each group.||||
33818713|NCT02432183|||COHORT||PROSPECTIVE|||||||
33818714|NCT04869462|||CASE_ONLY||PROSPECTIVE|||||||
33818715|NCT05596409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818716|NCT04004663|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33818717|NCT02086071|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818718|NCT04196517|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33818719|NCT06071871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Part 1: 42 patients, Part 2: 42-57 patients (some Part 1 patients may also participate in Part 2)||||
33818720|NCT00730925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818721|NCT02008539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048004|NCT06336655|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127151|NCT01596855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127152|NCT06174155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127153|NCT00200707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818722|NCT03536520|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33818723|NCT05822102|||COHORT||PROSPECTIVE|||||||
33818724|NCT01138098|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818725|NCT06454799|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"On the day of the Applied Oral Exam, which will be administered at the end of the semester within the scope of the Principles of Nursing course, each student in the Acupressure group will be taken to the appropriate classroom 15 minutes before taking the exam and will first fill out the Personal Information Form, State Exam Anxiety Scale and Vital Signs Tracking Chart. Then, acupressure will be applied to the student. After the application, the State Test Anxiety Scale and Vital Signs Follow-up Chart will be filled in again and then the student will be sent for the exam.~The researcher who will conduct the research has an acupressure certificate and will perform the application directly to the students.~The application will be carried out on 3 body points. Acupressure will be applied to each of these acupressure points for 1 minute."|f|f|f|t
33818726|NCT01630161|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33818727|NCT00155740|||DEFINED_POPULATION||OTHER|||||||
33818728|NCT01016730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818729|NCT01412398|||CASE_ONLY||PROSPECTIVE|||||||
33818730|NCT00550927|NON_RANDOMIZED|||TREATMENT||NONE||||||
34127154|NCT03683511|||CASE_ONLY||RETROSPECTIVE|||||||
34127155|NCT05075733|||COHORT||CROSS_SECTIONAL|||||||
34127156|NCT06043180|||COHORT||PROSPECTIVE|||||||
34127157|NCT04346147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127158|NCT05631314|||COHORT||PROSPECTIVE|||||||
34127159|NCT00941291|||COHORT||RETROSPECTIVE|||||||
34127160|NCT03073863|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blind|Parallel Assignment|t|f|t|f
34127161|NCT03015155|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34127162|NCT05079347|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||We will pilot the intervention with a small group of traditional healers who will offer HIV testing to their patients||||
34127163|NCT04389905|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This is a prospective randomized case control study following a cohort, of Children - whose mothers received extended oral health education from (before) birth until their 3-year dental examination - until their 6-year examniation, and comparing the results (e.g. caries experience and economical aspects) with a control group of age-matched individuals born during the same period.~The study group of pregnant mothers (and their children) at the local Public Dental Clinic will be compared to a group of other pregnant mothers (and their children) and pregnant mothers (and their children) from the other dental clinics in the city and from another Public Dental Clinic with similar socioeconomic problems and similar caries prevalence as the clinic of the intervention group."||||
34127164|NCT01538576|||COHORT||PROSPECTIVE|||||||
33818731|NCT00109525|||COHORT||PROSPECTIVE|||||||
33818732|NCT04449549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818733|NCT05413811|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33818734|NCT05119166|||COHORT||PROSPECTIVE|||||||
33818735|NCT05417568|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33818736|NCT03992599|||COHORT||PROSPECTIVE|||||||
33818737|NCT02164578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818738|NCT00105339|||COHORT||PROSPECTIVE|||||||
33818739|NCT05776745|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818740|NCT05006859|||COHORT||PROSPECTIVE|||||||
33818741|NCT06170931|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with the same stage of knee osteoarthritis in both knees were selected. Total knee arthroplasty was performed in the same session by making the appropriate design for the appropriate knee simultaneously. Preoperative and postoperative joint range of motion examinations were performed on both knees separately. WOMAC and OXFORD scores were examined separately for both knees.||||
33818742|NCT03894280|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Laboratory blinded|One-center crossover, randomized, 2-period, 2-sequence (RT and TR), single dose, laboratory-blinded study|f|f|f|t
33818743|NCT04130061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818744|NCT00371696|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||||||
33837226|NCT00289575|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818745|NCT05513261|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients who fulfill criteria will be randomly allocated to high definition colonoscopy or Polydeep assisted high definition colonoscopy.||||
33818746|NCT03960437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818747|NCT05955222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients will not know which group they are assigned. Also the clinician who is going to make the examinations before and after the study will not be aware of groups.|The study is designed as a prospective, randomized, double-blind in-vivo study|t|f|f|t
33818748|NCT01280396|||OTHER||RETROSPECTIVE|||||||
33818749|NCT00113334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818750|NCT05590845|||COHORT||PROSPECTIVE|||||||
33818751|NCT03647709|||COHORT||PROSPECTIVE|||||||
33818752|NCT04116671|NA|SINGLE_GROUP||OTHER||NONE||Participants are contributing to the development of a hybrid device combining surface muscle stimulation and a powered knee orthosis to assist walking after stroke. There is a single group of individuals participating in controller development and then pilot testing of the device to determine both the effect of training with the device and the impact of the device on walking ability.||||
33818753|NCT03387592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818754|NCT06505122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818755|NCT00695149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818756|NCT02659488|NA|SINGLE_GROUP||||NONE||||||
33818757|NCT04933110|||CASE_CONTROL||PROSPECTIVE|||||||
33818758|NCT03771209|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818759|NCT01272388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818760|NCT04433247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcomes Assessor at post-test and 6 month follow-up are blind to participant randomization.||f|f|f|t
33818761|NCT02820298|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818762|NCT01021683|||CASE_ONLY||PROSPECTIVE|||||||
33818763|NCT01844362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818764|NCT05611476|NA|SINGLE_GROUP||TREATMENT||NONE||The primary aim is to develop the intervention. We will do this through delivery of the intervention to three waves of patients. After each of the first two waves, the intervention will be adapted based on participant feedback||||
33818765|NCT05293379|||COHORT||RETROSPECTIVE|||||||
33818766|NCT02843698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818767|NCT03785418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data downloaded from the participants' implantable loop recorders will not be available to the investigators nor anyone involved in direct patient interaction in the study. A blinded event committee composed of three physicians with a specialization in cardiology, who are not directly involved in the research study, will have access to this data.|A randomization schedule will be prepared by the data coordinating centre at Queen's University, Kingston, Ontario using a computerized random number-generator. Random allocation will be determined by a patient randomization software application. Participants will be randomized on a 1:1 fashion between active intervention and control.|f|f|f|t
33818768|NCT00491439|||CASE_ONLY||PROSPECTIVE|||||||
33818769|NCT05416970|||COHORT||RETROSPECTIVE|||||||
33818770|NCT01326624|||COHORT||PROSPECTIVE|||||||
33818771|NCT00050167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818772|NCT04182542|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|The assessor will not know, when analyzing the samples, to which group they belong.||f|f|f|t
33818773|NCT02282917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818774|NCT04232488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818775|NCT02586857|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818776|NCT06648889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818777|NCT01746628|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33818778|NCT00966888|RANDOMIZED|||TREATMENT||||||||
33818779|NCT03900286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818780|NCT03479671|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Baseline insulin sensitivity will be measured in healthy volunteers, and then 1-3 weeks later insulin sensitivity will be measured in response to a low-dose fatty acid infusion. If there is no response to this low-dose infusion, then 1-3 weeks later insulin sensitivity will be measured in response to a medium-dose fatty acid infusion.||||
33818781|NCT06585345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818782|NCT02579941|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33818783|NCT06048471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818784|NCT00475436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818785|NCT04662749|||CASE_CONTROL||RETROSPECTIVE|||||||
33818786|NCT06178471|||COHORT||CROSS_SECTIONAL|||||||
33818787|NCT06057701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"intervention:~Group A:~This group was consisted of 20 postmenopausal women suffering from thoracic kyphosis. They received corrective exercises for twice a week for 12 weeks.~corrective exercises: The patient did a daily session of 20-30 min (under the supervision of the therapist or alone at home). It consisted of warm up phase for 5 minutes (breathing exercises), active phase (corrective exercises) and cooling down phase finally for return to the initial state.~strengthening exercises and stretching exercise~Group B:~The study group consisted of 20 postmenopausal women suffering from thoracic kyphosis, who received corrective exercises prescribed above in addition to resisted diaphragmatic breathing exercise."|t|t|f|t
33818788|NCT05965726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|"As part of screening, potential participants will answer symptom questions. Eligible participants will then complete relevant Symptom Cluster assessments at the Screening visit. Participants will subsequently be assigned to one of the three Symptom Clusters based on the assessments.~Participants must meet certain criteria within a specific symptom cluster in order to be included in the cluster. After study enrollment and initial cluster assignment, further assessments will be performed. Participants will undergo assessments for the symptom clusters for which the participants qualify."|t|t|t|f
33818789|NCT01737645|||COHORT||PROSPECTIVE|||||||
33818790|NCT00487253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818791|NCT01795183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818792|NCT05837650|RANDOMIZED|PARALLEL||TREATMENT||NONE||The participants are randomized to a treatment and waitlist control arms, each arm has 5-6 participants. Participants in the treatment arm will experience a group-based EAET intervention via Zoom. The investigators anticipate having 3 cohorts of treatment vs. controls in this study.||||
34048005|NCT04842825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To further investigate its role in improving pregnancy outcomes of IVF-ET in diminished ovarian reserve (DOR) infertility, in this randomized, controlled clinical trial, 200 patients with DOR infertility who intended to undergo IVF-ET will be randomly divided into two groups: a treatment group (Western conventional treatment + kidney-tonifying and blood-regulating herbs) and a control group (Western treatment only). The intervention will be started from the 5th day of menstruation for two menstrual cycles before undergoing IVF-ET until 14 days after transfer.|t|f|f|f
34048006|NCT05719883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048007|NCT06622161|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048008|NCT05077137|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048009|NCT04203641|NA|SEQUENTIAL||TREATMENT||NONE||This is an open-label, single arm study that includes an initial three cohort dose escalation phase with 3, 6 and 9 µg/kg of L-DOS47 in combination with doxorubicin.||||
34048010|NCT02114229|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048011|NCT02398903|||COHORT||PROSPECTIVE|||||||
34048012|NCT03973411|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Prospective, randomized, duble-blind and placebo-controlled trial|t|t|t|t
34048013|NCT04822792|||CASE_CONTROL||PROSPECTIVE|||||||
34048014|NCT04845308|||COHORT||RETROSPECTIVE|||||||
34048015|NCT06685211|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34048016|NCT02807298|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34048017|NCT06619574|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Cohort comparison study||||
34048018|NCT05587582|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34048019|NCT05256459|||COHORT||PROSPECTIVE|||||||
34048020|NCT03346356|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048021|NCT02235077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048022|NCT05781113|||CASE_ONLY||PROSPECTIVE|||||||
34048023|NCT02084732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048024|NCT04858061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048025|NCT05593692|||CASE_ONLY||RETROSPECTIVE|||||||
34048026|NCT01148160|||CASE_ONLY||PROSPECTIVE|||||||
34048027|NCT06575972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study uses a double-blind design, meaning that both the participants and the investigators are unaware of the group assignments.|This is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy of JoyRise Recovery Powder in mitigating the aftereffects of alcohol consumption. The study involves two groups: one receiving the active supplement (JoyRise Recovery Powder) and the other receiving a placebo.|t|f|t|f
34048028|NCT06487000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048029|NCT02452632|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048030|NCT06683638|NA|SINGLE_GROUP||TREATMENT||NONE||This study will enroll one prospective arm of 15 persons. To contextualize the finding, the investigators will separately determine point-estimates of 6-month treatment response to standard of care regimens in the sexual health program using de-identified retrospective cohorts of 60 persons each.||||
34048031|NCT06264102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048032|NCT04484142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048033|NCT02855554|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048034|NCT03268759|||COHORT||PROSPECTIVE|||||||
34048035|NCT02457715|||COHORT||PROSPECTIVE|||||||
34048036|NCT00872027|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048037|NCT02171559|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048038|NCT03403829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048039|NCT02784210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048040|NCT03573700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048041|NCT01844648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34048042|NCT05196399|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34048043|NCT04674280|||COHORT||PROSPECTIVE|||||||
34048044|NCT02663063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34048045|NCT04545151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Trial participants and research teams will be blinded to the treatment group for the duration of the trial. The double blinding will be achieved by providing verapamil SR identical placebo tablets.||t|f|t|f
34048046|NCT06683066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048047|NCT05606302|||OTHER||PROSPECTIVE|||||||
33818793|NCT03898219|||COHORT||RETROSPECTIVE|||||||
33818794|NCT04269811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818795|NCT06264661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried outwith validated instruments for Mexican population and gene expression was evaluated by real-time PCR.||||
33818796|NCT01743807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818797|NCT02297945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048048|NCT02395107|||COHORT||PROSPECTIVE|||||||
34048049|NCT02038855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048050|NCT01944839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048051|NCT04615013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048052|NCT06238687|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048053|NCT04172259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048054|NCT05325190|NA|SINGLE_GROUP||PREVENTION||NONE||Granisetron transdermal patch for the prevention and treatment of CINV||||
34048055|NCT01265576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048056|NCT00495209|||OTHER||PROSPECTIVE|||||||
34048057|NCT00003830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048058|NCT04488211|||COHORT||PROSPECTIVE|||||||
34048059|NCT04662281|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048060|NCT06100016|||COHORT||PROSPECTIVE|||||||
34048061|NCT02090530|||COHORT||PROSPECTIVE|||||||
34048062|NCT04665128|||CASE_CONTROL||PROSPECTIVE|||||||
34127165|NCT06281977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind||t|t|t|f
33818798|NCT05224596|||CASE_CONTROL||PROSPECTIVE|||||||
33818799|NCT03379428|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a Phase I/II, open-label, unblinded, nonrandomized, standard 3+3 dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of ibrutinib (560 or 840 or 420 mg QD) given orally in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg q3w) administered intravenously (IV) in patients with HER2-amplified MBC.~Once the recommended phase II dose of ibrutinib plus trastuzumab has been determined (no more than 1 of 6 patients with dose-limiting toxicity) in the required 6 to 18 patients over the 3 possible dose levels, additional patients will be enrolled on the phase II part of the study at the recommended phase II dose of ibrutinib plus trastuzumab, for a maximum of 51 patients total."||||
33818800|NCT06107205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818801|NCT01562821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818802|NCT01224509|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818803|NCT04998032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This includes a 24-week double-blind treatment period, followed by a 28-week open-label treatment period.|"This clinical trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase III ). During the phase IIb, subjects were randomly assigned to Supaglutide 1mg + metformin, Supaglutide 3mg + metformin and placebo + metformin according to a 1:1:1 ratio.~When 120 subjects complete the 12 weeks of follow-up, Interim analysis will be performed and the results be evaluated by IDMC to confirm the RP3D dose.~And then during the phase III, subjects were randomly assigned to Supaglutide RP3D + metformin, placebo + metformin group according to a 1:1 ratio."|t|f|t|f
33818804|NCT02368977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Open Label|||||
33818805|NCT03932032|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33818806|NCT06049017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818807|NCT02883361|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33818808|NCT03301220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818809|NCT03572998|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Case-control. Patients function as their own control since the treated arm will be compared with the non-treated arm.||||
33818810|NCT01943370|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
33818811|NCT06162221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818812|NCT04478799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The current single-blind randomized controlled study included 102 children with FNRF who were randomly allocated into two groups. Group 1, Bilateral transcutaneous posterior tibial nerve stimulation and group B, Sham TPTNS. Inclusion criteria included those with FI and normal defecation frequency, normal bowel habits and stool consistency. Children younger than 4 years or those who are not cooperative, or those with traumatic sphincter injury, fecal impaction, spinal diseases causing incontinence, anorectal malformation, were excluded from the study.|t|f|f|t
33818813|NCT05734235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818814|NCT06632418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants in the control arm of the study who have not healed by the time they reach the primary endpoint will have the option to crossover to the investigational arm and receive the investigational intervention. Their outcome measures will be tracked and documented, but their results will not be included in the initial analyses of the original randomized participant data. This will be considered extended open-label use of the investigational intervention and their outcome measures will be analyzed and reported separately.|t|t|f|t
33818815|NCT03440580|RANDOMIZED|PARALLEL||PREVENTION||NONE|Schools will be randomized into intervention or control schools. Randomization will be done by an independent researcher. After the randomization, the intervention school receives the BOOSTH intervention. The control school receives BOOSTH after the study is finished.|The study design will be a randomized controlled trial regarding a physical activity intervention. A 1:1 randomization will be applied with intervention schools and matched control schools. The intervention school will recieve the BOOSTH intervention||||
33818816|NCT02121808|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33818817|NCT04873362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818818|NCT04562714|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The study design is open-label in which neither investigator nor study participants will be blinded to study treatment. All study participants will wear a blinded continuous glucose monitoring device for two weeks at baseline and during the final two weeks of Phase 1, during which they will be blinded to the results of the blinded glucose monitoring device.|The IMMEDIATE study is a two-phased, cross-over study. In Phase 1, participants will be randomized at a 1:1 ratio, stratified by use of glucagon-like peptide-1 receptor agonist to receive either a flash glucose monitor (FGM) + diabetes self-management education (DSME) (Intervention arm) or to DSME alone (Control arm). Participants randomized to the Intervention arm will receive a FreeStyle Libre FGM System, 1 training session on its proper use, and 6 DSME sessions. Participants randomized to the Control arm will receive 6 DSME sessions matched to time and location of the Intervention group. DSME sessions for both groups will consist of four individual in-clinic sessions and two telephone sessions. After 16-weeks, participants initially assigned to DSME alone will cross-over to receive the intervention FGM device, while those initially randomized to using a FGM will continue using their device for an additional 16 weeks (Phase 2). No DSME will provided during Phase 2.||||
33818819|NCT06136156|||OTHER||PROSPECTIVE|||||||
33818820|NCT04542551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818821|NCT05850234|NA|SINGLE_GROUP||TREATMENT||NONE||GC012F (AZD0120) will be administrated in one infusion||||
33818822|NCT02152995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818823|NCT03759405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818824|NCT05240729|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33818825|NCT05118308|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|As EUS and TJ procedures are inherently different, patients and health-care workers directly involved in the procedure, including nurses, physicians, and technicians, will not be blinded. Pathologists interpreting liver biopsies will be blinded to the intervention group.||f|f|f|t
33818826|NCT01094600|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818827|NCT05387785|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Multicenter, randomized, double-blind, placebo-controlled, cross-over design|t|f|t|t
33818828|NCT00511888|||||PROSPECTIVE|||||||
33818829|NCT06585579|RANDOMIZED|PARALLEL||OTHER||NONE||prospective, multicenter, randomized, controlled study||||
33818830|NCT00282061|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33818831|NCT01140724|||OTHER||PROSPECTIVE|||||||
33818832|NCT04150250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818833|NCT06276946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33818834|NCT06460961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818835|NCT05001802|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33818836|NCT05609682|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a randomized controlled pilot trial. Randomization will be computer generated, using a 1:1 allocation and variable block sizes of 2 and 4.||||
33818837|NCT04342715|||CASE_CONTROL||PROSPECTIVE|||||||
33818838|NCT06581224|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33818839|NCT02825849|RANDOMIZED|PARALLEL||TREATMENT||NONE||"During Study Period #1: Subjects were randomized to receive either PRP or standard care. A total of 13 subjects were randomized.~The study design was then altered to remove randomization (10/4/2018). All patients in Study Period #2 received PRP. An additional 14 subjects were enrolled in Study Period #2."||||
33818840|NCT02423447|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33818841|NCT03284957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818842|NCT06485830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed opaque envelopes will be used for treatment allocation. The research in charge of collecting the outcome measures will remained unaware of treatment allocation group||f|f|f|t
33818843|NCT04060641|||COHORT||RETROSPECTIVE|||||||
33818844|NCT04389983|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33818845|NCT05746702|||CASE_CONTROL||PROSPECTIVE|||||||
33818846|NCT06293794|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Compare traditional and personalized CDS in a pragmatic randomized controlled trial at one health system.||||
33818847|NCT00158561|RANDOMIZED|PARALLEL||||NONE||||||
33818848|NCT00113009|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33818849|NCT04673032|||COHORT||PROSPECTIVE|||||||
33818850|NCT05461092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patient (participant) and surgeon will be masked||t|f|t|f
33818851|NCT05994326|||COHORT||PROSPECTIVE|||||||
33818852|NCT04291716|NA|SINGLE_GROUP||OTHER||NONE||This is a single cohort of subjects male or female, aged 18 and above who are epilepsy patients who have been admitted to an epilepsy monitoring unit (EMU).||||
33818853|NCT02739841|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33818854|NCT06577493|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized into experimental or control groups||||
33818855|NCT02453971|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818856|NCT00070707|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33818857|NCT03984734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818858|NCT03287947|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase 2 study.||||
33818859|NCT04973176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33818860|NCT02518659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818861|NCT02639234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818862|NCT00369239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818863|NCT00004045||||TREATMENT||||||||
33818864|NCT03970304|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Volunteers who choose to take part in this study will receive the licensed FDA approved Oral Typhoid Vaccine (Vivotif). Volunteers also have the possibility of being a control participant who will not be vaccinated.||||
33818865|NCT04749771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research assistants collecting the data during lab visits will not know the condition of the participant and will therefore not be biased during data collection.|Two groups. Half of the participants will be randomized into the experimental condition (FIND) while the other half will be randomized into the active control condition (HTP)|t|f|f|f
33818866|NCT02108054|NA|PARALLEL||OTHER||NONE||||||
33818867|NCT02825888|||COHORT||PROSPECTIVE|||||||
33818868|NCT01596699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818869|NCT04544514|||COHORT||PROSPECTIVE|||||||
33818870|NCT04296409|||COHORT||PROSPECTIVE|||||||
33818871|NCT05868746|||COHORT||CROSS_SECTIONAL|||||||
33818872|NCT02714998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818873|NCT06101134|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818874|NCT02884622|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818875|NCT01445509|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818876|NCT06570798|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subprotocol A: Parallel study model Subprotocol B: Sequential study model||||
33818877|NCT06563154|||COHORT||PROSPECTIVE|||||||
33818878|NCT06355271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Allocation will take place immediately before the intervention by the means of access to centralized, real-time allocation through a computer program. The identification code will be present on the data collection form (where the patient's name, surname or date of birth will not appear to ensure blinding of the study).~Personnel not directly involved with patient care, present during the randomization process, will sterilely prepare anesthesia solution while maintaining a total volume of 3,1 ml. This will allow blinding of patients, care providers and data collectors. The procedure will take place as a common clinical practice in our center. When performing spinal anesthesia, sterility is of fundamental importance, so it will not be possible to have the syringe used tagged. In the kit all materials will be sterile"|Single center, multiple-blind, prospective, randomized, controlled trial in 3 parallel groups|t|t|t|f
33818879|NCT03110640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818880|NCT02533804|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33818881|NCT04936308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818882|NCT00464932|||||PROSPECTIVE|||||||
33818883|NCT05931367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818884|NCT02468037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818885|NCT04255485|||COHORT||OTHER|||||||
33818886|NCT05817864|||COHORT||PROSPECTIVE|||||||
33818887|NCT01233193|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818888|NCT06719674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818889|NCT02161393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818890|NCT02606617|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818891|NCT03941587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Multi-center randomized, double-masked clinical trial.|f|t|t|t
34127166|NCT00170326|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Video tapes are provided by the central study organization and are labelled by numbers. The tapes are sent to the echocardiography core laboratory (Malaga, Spain) and are read by the Director of the Echo Core Lab (J.J. Gomez-Doblas). The echo examiner is blinded as to the point of time of the recording and assignment of treatment, although the presence of a LV lead may be adumbrated by visible artefacts.||f|f|f|t
34127167|NCT05809323|RANDOMIZED|PARALLEL||TREATMENT||NONE||The interventional study will be conducted as a parallel study model, with 2 groups in total: Exercise Intervention Group (interventional group) and Current Care Group (control group). Baseline and follow up testing will occur in both groups at identical time intervals.||||
34127168|NCT05498740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818892|NCT01878877|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33818893|NCT06004245|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open label study. Participants will be assigned to dose cohorts in the order in which they are enrolled. However, if two or more cohorts in the same part of the study are open for enrollment at the same time, participants will be randomized into these cohorts.||||
33818894|NCT04214808|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127169|NCT06265155|||CASE_CROSSOVER||PROSPECTIVE|||||||
34127170|NCT05536882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127171|NCT01222988|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127172|NCT06045065|||OTHER||PROSPECTIVE|||||||
34127173|NCT03443089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127174|NCT01495533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127175|NCT03633955|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective pilot study, the primary aim of which is to determine whether the abnormalities in 18F FLT imaging signal uptake correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.||||
34127176|NCT00078806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127177|NCT01340664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127178|NCT00945373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127179|NCT01119443|RANDOMIZED|CROSSOVER||||NONE||||||
34127180|NCT05424965|||COHORT||RETROSPECTIVE|||||||
34127181|NCT02420184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127182|NCT01212471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127183|NCT01635998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127184|NCT03159546|||COHORT||PROSPECTIVE|||||||
34127185|NCT06311773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127186|NCT00161616|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34127187|NCT02134301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127188|NCT04326010|||COHORT||PROSPECTIVE|||||||
34127189|NCT04868305|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with an identified unstable trochanteric hip fracture (AO 31A2.2-3.3) who has fulfilled inclusion criteria and given their consent will be randomized into one of two treatments; Intramedullary nail versus hip arthroplasty||||
34127190|NCT05807152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127191|NCT04550871|||CASE_ONLY||PROSPECTIVE|||||||
34127192|NCT04368377|NA|SINGLE_GROUP||TREATMENT||NONE||Compassionate-use, proof of concept, interventional, prospective,||||
34127193|NCT00271908|||COHORT||CROSS_SECTIONAL|||||||
34127194|NCT02988544|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34127195|NCT03627949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127196|NCT01798095|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34127197|NCT02615418|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34127198|NCT01946659|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34127199|NCT05224427|||COHORT||PROSPECTIVE|||||||
34127200|NCT02532582|||COHORT||PROSPECTIVE|||||||
34127201|NCT01053507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33818895|NCT00002099||PARALLEL||TREATMENT||||||||
33818896|NCT04595500|||CASE_CONTROL||RETROSPECTIVE|||||||
33818897|NCT05662852|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33818898|NCT00466856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818899|NCT00310050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818900|NCT06243666|||COHORT||PROSPECTIVE|||||||
33818901|NCT02829099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818902|NCT00814359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818903|NCT05533814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818904|NCT01678456|||COHORT||PROSPECTIVE|||||||
33818905|NCT00111163|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33818906|NCT05075135|RANDOMIZED|PARALLEL||OTHER||NONE|Masking is not feasible in this feasibility study, as the participants are not allowed to take off their splint (3D or plaster cast) during the bone healing time of 6 weeks. Care providers will take care of the patients prior to splint removal. Both the patients and the care providers are outcome assessors in this study.|"Randomization is based on a single allocation ratio of 1:1~In order to generate an unpredictable allocation sequence and concealment of that sequence until assignment occurs, sequentially numbered, sealed, opaque envelopes will be prepared."||||
34127202|NCT00788983|||||PROSPECTIVE|||||||
34127203|NCT04923334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is outcome assessor and investigator blinded. Blinding will only be broken in emergency situations for reasons of participant safety such as a serious adverse event. If blinding is broken, either intentionally or unintentionally, the reason will be fully documented and entered on an electronic case report form. Every effort will be made to discuss the decision to break blinding with the Data Safety Monitoring Board in advance.|The study design is a clinical trial testing adaptive interventions. All participants receive the Brief Pain Teleconsult in Phase I. We will randomly assign participants with 1:1 distribution to also receive 10-week Telehealth Physical Therapy during Phase I. All participants are re-assessed at 12 weeks and responder status is determined. For participants not receiving Telehealth Physical Therapy in Phase I, further treatment is based on responder status. Responders receive no further treatment. Non-responders receive the 10-week Telehealth Physical Therapy in Phase II. Participants randomized to Telehealth PT in Phase I receive no further treatment. Long-term assessments occur 26 and 52 weeks after randomization.|f|f|t|t
33818907|NCT06721078|NA|SINGLE_GROUP||OTHER||NONE||In Stage 1, we will evaluate the peer navigation intervention in a stepped-wedge, cluster-randomised trial.||||
33818908|NCT05652036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33818909|NCT04826744|||COHORT||PROSPECTIVE|||||||
33818910|NCT02351388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33818911|NCT00401791|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818912|NCT03950583|||COHORT||PROSPECTIVE|||||||
33818913|NCT05776875|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm study which will be performed to examine the safety and tolerability of the combination of atezolizumab and bevacizumab with TACE for patients with BCLC B HCC.||||
33818914|NCT05250492|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33818915|NCT05134142|||COHORT||OTHER|||||||
33818916|NCT03151109|||COHORT||CROSS_SECTIONAL|||||||
33818917|NCT00365183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818918|NCT02335242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33818919|NCT04596358|||COHORT||RETROSPECTIVE|||||||
33818920|NCT03670771|||COHORT||PROSPECTIVE|||||||
33818921|NCT06720935|||COHORT||RETROSPECTIVE|||||||
33818922|NCT04160871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, Efficacy Study.|t|f|t|f
33818923|NCT05755698|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will form groups of five participants with migraine who will experience a group-based EAET intervention.||||
33818924|NCT06166095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33818925|NCT01879735|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33818926|NCT01763645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33818927|NCT03889912|NA|SINGLE_GROUP||TREATMENT||NONE||Cohorts A, B, D and H will enroll sequentially (not randomized). Cohort C and I for BCC will enroll in parallel with, and independently of, Cohorts A, B, D and H for CSCC patients||||
33818928|NCT05054361|||CASE_CONTROL||PROSPECTIVE|||||||
33818929|NCT03733899|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33818930|NCT03697837|NA|SINGLE_GROUP||TREATMENT||NONE||Open feasibility trial||||
33818931|NCT02195219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818932|NCT03749616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818933|NCT06597435|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33818934|NCT01517139|||OTHER||CROSS_SECTIONAL|||||||
33818935|NCT06034002|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818936|NCT04248881|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818937|NCT03803423|NA|SINGLE_GROUP||OTHER||NONE||All participants will be invited to use the Donor App.||||
33818938|NCT02361983|||COHORT||PROSPECTIVE|||||||
33818939|NCT05807555|||CASE_CONTROL||PROSPECTIVE|||||||
33818940|NCT03742388|||COHORT||PROSPECTIVE|||||||
33818941|NCT04246892|||COHORT||PROSPECTIVE|||||||
33818942|NCT06646640|||COHORT||PROSPECTIVE|||||||
33818943|NCT01844908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818944|NCT02010021|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||"10 subjects received no presurgical therapy, and then 7 subjects received presurgical letrozole.~This is a sequential model because the results from Arm A determined the sample size for Arm B. Tumors from each of the 10 untreated patients in Arm A showed induction of AKT activation with RAD001 treatment. Based on these results, we determined that a sample size of seven patients from Arm B would be adequate to detect a significant effect (p≤0.05) of presurgical Letrozole on RAD001-induced changes in phospho-AKT levels with 80% power (calculated using uncorrected chi-squared statistic)."||||
33818945|NCT04563026|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a Phase 2b randomized, double-blind, placebo-controlled, multi-arm, multi-center, parallel design trial.|t|t|t|t
33818946|NCT06720909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818947|NCT05167825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818948|NCT05656404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818949|NCT06006039|||COHORT||PROSPECTIVE|||||||
33818950|NCT03322579|NA|SINGLE_GROUP||TREATMENT||NONE||Unilateral or bilateral balloon catheter dilation will be performed on patients with eustachian tube dysfunction||||
33818951|NCT00926978|NA|SINGLE_GROUP||OTHER||NONE||||||
33818952|NCT05888402|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33818953|NCT01945593|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818954|NCT06182527|NA|SINGLE_GROUP||SCREENING||NONE|Every participant receives a Freestyle Libre PRO IQ Sensor, a system which ensures blinding of the glucose levels to the participants.|||||
33818955|NCT02907502|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33818956|NCT04042259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818957|NCT03734588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818958|NCT04773522|NA|SEQUENTIAL||TREATMENT||NONE||||||
33818959|NCT06554366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818960|NCT02430935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33818961|NCT04169906|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33818962|NCT02434484|||OTHER||PROSPECTIVE|||||||
33818963|NCT00365599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818964|NCT03590067|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33818965|NCT04267393|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33818966|NCT02072837|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33818967|NCT04763863|||CASE_ONLY||PROSPECTIVE|||||||
33818968|NCT06067984|NA|SINGLE_GROUP||TREATMENT||NONE||This study evaluates the efficacy of a prescription digital therapeutic (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.||||
33818969|NCT05439720|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33818970|NCT00972686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818971|NCT00011388|||DEFINED_POPULATION||PROSPECTIVE|||||||
33818972|NCT06406049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33818973|NCT05530434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33818974|NCT06104059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Not aware of the study group|Prospective, Randomized clinical trial|t|f|f|f
33818975|NCT05417971|||COHORT||PROSPECTIVE|||||||
33818976|NCT05325008|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048063|NCT03503370|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This is a single center, randomized, double blind (participant, outcome assessor), parallel group clinical trial comparing daily foot care with cloths containing 2% chlorhexidine compared to daily foot care with cloths not containing chlorhexidine.|t|t|t|t
33818977|NCT02630147|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33818978|NCT02662023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only individual aware of the treatment group assignments is the investigational pharmacist who has no interaction with the study subjects. Treatment group assignments were released by the investigational pharmacy only after completion of data collection.|This is a split-body study in which each study subject receives both treatments: one on each side of the body. Which treatment is applied to which side of the body is randomized (and masked).|t|t|t|t
33818979|NCT04890483|NA|SINGLE_GROUP||TREATMENT||NONE||An open-label uncontrolled study of application of tDCS sessions in ARD patients with post-acute COVID-19.||||
33818980|NCT03990376|NA|SINGLE_GROUP||OTHER||NONE||"Participants include 45 adolescent subjects undergoing spinal fusion for correction of idiopathic scoliosis.~After obtaining a baseline sample of 5 mL of blood, 1 mL of I-131-labeled albumin will be injected intravenously over 1 min. At the time the baseline sample is obtained, a hematocrit will be simultaneously acquired. Five milliliter blood samples will then be collected at 12, 18, 24, 30, and 36 min post-injection, and the Plasma volume (PV) will be measured by extrapolating to time zero. This entire process will occur twice per patient: once pre-procedure and once post-procedure."||||
33818981|NCT06198452|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33818982|NCT01807845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33818983|NCT02261675|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
33818984|NCT04557059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818985|NCT03683212|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33818986|NCT01979822|||COHORT||PROSPECTIVE|||||||
33818987|NCT06584591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The mode of HD-tDCS (active/sham) will be masked for the participant and outcomes assessor.||t|f|f|t
33818988|NCT06539468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818989|NCT02418819|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33818990|NCT06193889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818991|NCT06210178|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33818992|NCT06585371|||COHORT||PROSPECTIVE|||||||
33818993|NCT00919061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33818994|NCT00346242|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33818995|NCT03948815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Decreased stress, increased parasympathisuc, increased physiological oxytocin promotes a normal healthy Labour and birth.||||
33818996|NCT06721052|||CASE_ONLY||RETROSPECTIVE|||||||
33818997|NCT01441258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818998|NCT05275023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33818999|NCT05874843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33819000|NCT04502745|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33819001|NCT05607550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819002|NCT00003541||||TREATMENT||||||||
33819003|NCT02148276|||CASE_CROSSOVER||PROSPECTIVE|||||||
33819004|NCT02970721|||COHORT||RETROSPECTIVE|||||||
33819005|NCT03313544|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33819006|NCT04001582|||COHORT||PROSPECTIVE|||||||
33819007|NCT05861323|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33819008|NCT04232085|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Phase II prospective trial||||
33819009|NCT05943379|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819010|NCT04731506|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819011|NCT03847220|||CASE_ONLY||PROSPECTIVE|||||||
33819012|NCT02187120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819013|NCT01545999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819014|NCT06053645|||COHORT||PROSPECTIVE|||||||
33819015|NCT06059963|||OTHER||PROSPECTIVE|||||||
33819016|NCT01265914|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33819017|NCT05309356|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The investigators will conduct a prospective, pragmatic two-year stepped-wedged cluster RCT to evaluate the impact of ACCEPT on the process of care, patient-reported, and clinical outcomes. The trial was designed based on 24 participating physicians, comprising the study clusters. All physicians will be assigned to the comparator arm (usual care) at the beginning of the study. After 6 months, under a sequential rollout, two randomly selected physicians will be reassigned to the intervention arm (ACCEPT) every month.||||
33819018|NCT06720233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819019|NCT04315428|||CASE_CONTROL||PROSPECTIVE|||||||
33819020|NCT06367426|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To maintain double-blindness, DDN-A-0101 tablets and placebo with the same formulation and properties that cannot be distinguished in appearance will be used, and sub-packaging will also be the same.||t|f|t|f
33819021|NCT04547101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819022|NCT06653569|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Placebo-controlled|t|t|t|t
33819023|NCT03934944|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Parallel assignment|f|t|t|f
33819024|NCT03623100|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-subject staggered multiple baseline design will be used in the speech treatment program. Following procedures for this design, the children with SSD will be randomly assigned to one of two treatment conditions. These groups will be evaluated independently and in combination. Every subject will be evaluated in a baseline period in which no treatment is provided. Every subject will first complete a full baseline assessment. Subsequent baselines will consist only of a shorter baseline probe that specifically targets the phonemes each child did not produce during the initial baseline session. Thus, the first subject in each condition will have 2 baselines and then begin treatment. Each subsequent subject within each condition will have 1 additional baseline before beginning treatment.||||
33819025|NCT05658809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819026|NCT00197262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819027|NCT01125345|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34048064|NCT03925038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048065|NCT03579901|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Multicenter Single arm||||
34127204|NCT03880045|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A double-blinded randomized controlled stud|A double-blinded randomized controlled stud|t|t|t|t
34127205|NCT00221546|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34127206|NCT01239173|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34127207|NCT06361966|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127208|NCT05247684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127209|NCT00638300|RANDOMIZED|CROSSOVER||||NONE||||||
34127210|NCT05145699|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34127211|NCT04192266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|t|f|f
34127212|NCT06199908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819028|NCT00669149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819029|NCT00960284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819030|NCT01094665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819031|NCT04595110|||COHORT||PROSPECTIVE|||||||
33819032|NCT05442593|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Participants will be assigned to different groups according to their biological maturation and they will perform the same acute plyometric exercise||||
33819033|NCT02655536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819034|NCT06143891|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819035|NCT01958047|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819036|NCT01268488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33819037|NCT02301104|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819038|NCT04803994|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Clinical trial with two study arms:~Experimental arm A: 50% of the patients will receive a combination therapy (systemic) of the monoclonal antibodies atezolizumab and bevacizumab.~Control arm B: 50% of the patients will receive TACE therapy (locoregional)."||||
33819039|NCT03010007|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33819040|NCT05096741|||CASE_CONTROL||PROSPECTIVE|||||||
33819041|NCT04205500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819042|NCT06076746|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It will not be known by the Outcomes Assessor that the patients are in the experimental or usual treatment group.|Parallel Assignment|f|f|f|t
33819043|NCT04034095|||COHORT||PROSPECTIVE|||||||
33819044|NCT00769834|||COHORT||CROSS_SECTIONAL|||||||
33819045|NCT03319472|||COHORT||PROSPECTIVE|||||||
33819046|NCT06584773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819047|NCT03369314|||CASE_ONLY||PROSPECTIVE|||||||
33819048|NCT00427245|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
33819049|NCT04061772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819050|NCT06451224|||OTHER||CROSS_SECTIONAL|||||||
33819051|NCT00799188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819052|NCT03851159|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33819053|NCT05029921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819054|NCT06540846|||COHORT||RETROSPECTIVE|||||||
33819055|NCT01148017|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819056|NCT05824078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819057|NCT01325519|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33819058|NCT00862225|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33819059|NCT05618717|||CASE_CONTROL||PROSPECTIVE|||||||
33819060|NCT05929222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819061|NCT05556070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819062|NCT04287036|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33819063|NCT03539497|||COHORT||PROSPECTIVE|||||||
33819064|NCT00308113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819065|NCT06030440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819066|NCT03642899|||CASE_CONTROL||PROSPECTIVE|||||||
33819067|NCT04324047|||COHORT||PROSPECTIVE|||||||
33819068|NCT03283449|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33819069|NCT02720705|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33819070|NCT03663699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819071|NCT04872465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819072|NCT05034393|||COHORT||RETROSPECTIVE|||||||
33819073|NCT03927742|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33819074|NCT03035149|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819075|NCT04172974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Comparison of depression/anxiety treatment versus usual care|f|t|t|f
33819076|NCT03753256|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33819077|NCT01615523|||COHORT||PROSPECTIVE|||||||
33819078|NCT06647004|||COHORT||CROSS_SECTIONAL|||||||
33819079|NCT02447380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819080|NCT04435522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819081|NCT04117334|||CASE_ONLY||PROSPECTIVE|||||||
33819082|NCT02637362|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819083|NCT03109899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819084|NCT00155662|NON_RANDOMIZED|PARALLEL||||NONE||||||
33819085|NCT05453903|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819086|NCT00988130||||TREATMENT||NONE||||||
33819087|NCT06219902|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33819088|NCT03985228|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33819089|NCT03809858|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Subjects will be randomized to the sequence of completion in a 1:1 ratio. All subject will collect data throughout the study with half of them using the Klue App during the first 6 weeks and half using the Klue App during the second 6 weeks.||||
33819090|NCT02873442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127213|NCT06386926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34127214|NCT01578005|||COHORT||PROSPECTIVE|||||||
34127215|NCT03942198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127216|NCT01658605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127217|NCT05722366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127218|NCT02872597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127219|NCT00039169||||TREATMENT||||||||
34127220|NCT04120012|||COHORT||PROSPECTIVE|||||||
33819091|NCT02932280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819092|NCT02070289|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33819093|NCT00322764|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819094|NCT03959579|||COHORT||RETROSPECTIVE|||||||
33819095|NCT03272373|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2 single arms being analyzed separately||||
33819096|NCT06001593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819097|NCT05266209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher is not blind since the group of infants will be assigned by the researcher in order. The statistician was also blinded for the data analysis purpose.|Randomized Controlled Trial|t|f|f|f
33819098|NCT06721663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819099|NCT01876823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819100|NCT04299581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819101|NCT06081010|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819102|NCT02158793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819103|NCT00795977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819104|NCT04827147|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33819105|NCT03980171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819106|NCT03003715|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819107|NCT03856294|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double-blind study||t|f|t|f
33819108|NCT06228209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Before each research interview, subjects will be reminded not to tell the research coordinator to which study group they were assigned. In case of inadvertent unblinding of a blinded study team member, this team member will have to report the unblinding event to the PI. The study team member will not be allowed to collect data for the subjects whose group allocation they have inadvertently been unblinded to. A different, fully blinded study team member has to collect data for the respective subjects henceforth.||f|f|f|t
33819109|NCT03656926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819110|NCT03715634|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33819111|NCT06233682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Longitudinal interventional study in which participants are not randomised, as the experimental design alternates sequentially between the control and experimental groups, with no possibility of interaction between the two groups.||||
33819112|NCT02038114|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33819113|NCT04758559|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomised into:~Usual care; myfood24; myfood24 with automated suggestions"||||
33819114|NCT05299099|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819115|NCT06459128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819116|NCT01877720|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819117|NCT00399659|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819118|NCT06431126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819119|NCT03062488|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"all patients will receive a de-identified PO syrup. The syrup will be prepared by the pharmacy and will contain acetaminophen (15 mg/kg) for the PO acetaminophen group and placebo flavored syrup for the other two groups. This approach will maintain blindness of the peri-operative staff, and patients/parents., all children will receive fentanyl 2 mcg/Kg IV. Intra-op anesthesia team will be blinded to the use of non-opioid IV analgesia and will administer a pharmacy prepared de-identified infusion following intubation that will consist of saline placebo for control groups and IV acetaminophen (15 mg/kg) for the IV acetaminophen group. ,~:A blinded PACU nurse will record degree of agitation using the PAED scale on admission to the PACU"|"Study Design:~1. Prospective Randomized Study~2. Study Period: August 2017 - December 2017~3. Potential participants: 375 - 475 based on 20-25% of 4,459 ENT patients in 2016~4. Study Population: 50 pediatric patients in each group between 24 months through 7 years of age undergoing adenoidectomy or tonsillectomy with or without adenoidectomy Total Number of Patients: 150"|t|t|t|f
33819120|NCT00347451|||||PROSPECTIVE|||||||
33819121|NCT00913562|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33819122|NCT04737499|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pre- and post-test design||||
33819123|NCT01771081|||COHORT|||||||||
33819124|NCT03852381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819125|NCT02536729|||COHORT||PROSPECTIVE|||||||
33819126|NCT01538056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819127|NCT05457972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients will be randomized in a 1:1 ratio into two study groups: vaginal estrogen or vaginal moisturizer. Randomization will be performed using blocking with a block size of 10 and a 1:1 allocation ratio. The randomization sequence will be generated using a random number table.|f|t|t|t
33819128|NCT06571292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The principal investigator will not carry out any intervention or outcome evaluation.~Both the principal investigator and the investigators of the interventions will be blinded to the data of the measurements that have been taken, and must leave the room during the assessment period."||f|f|f|t
33819129|NCT04272099|||COHORT||OTHER|||||||
33819130|NCT02074878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819131|NCT06029803|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33819132|NCT04503551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The visual acuity examiner will only conduct refraction and visual acuity assessments and will be masked, as best as possible, to the following items: study eye assignment; study visit type; and treatment assignment.||f|f|f|t
33819133|NCT02246647|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33819134|NCT01817088|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33819135|NCT02334202|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819136|NCT05872984|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Both the patients and the clinicians involved in patient care were not aware of the results of the absolute blood volume measurements.|The intervention consists of the adjustment of the patients' dry weight, based on absolute blood volume measurement. Dry weight will be adjusted at the start of the intervention period in all subjects in the intervention group with a normalized blood volume below 65 ml/kg, regardless the occurrence of intradialytic hypotension associated adverse events during the baseline period. Dry weight will be increased once with 0,5kg.||||
33819137|NCT05616312|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837227|NCT05466123|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837228|NCT05706545|||COHORT||PROSPECTIVE|||||||
34127221|NCT06062381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127222|NCT01900522|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34127223|NCT02623205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127224|NCT05745103|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Randomized Controlled Trial||||
34127225|NCT02217813|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34127226|NCT01986894|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34127227|NCT04363268|||COHORT||PROSPECTIVE|||||||
34127228|NCT01672879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127229|NCT00002124||||TREATMENT||DOUBLE||||||
34127230|NCT00451958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127231|NCT02421848|||COHORT||PROSPECTIVE|||||||
34127232|NCT05246878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127233|NCT03322527|||COHORT||PROSPECTIVE|||||||
34127234|NCT00211172|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34127235|NCT05498532|||COHORT||RETROSPECTIVE|||||||
34127236|NCT00153673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127237|NCT03502915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The Nitronox device will be covered. The person setting up the device with either 100% oxygen or 50% nitrous/50% oxygen, will not be participating in the study. The patient, investigator and labor and delivery personnel (obstetrician and nursing staff) will be blinded as to the medication being administered during the procedure.||t|t|t|t
34127238|NCT04310319|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34127239|NCT04914156|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34127240|NCT03462641|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34127241|NCT00325507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127242|NCT00848887|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34127243|NCT01607125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127244|NCT02113774||||TREATMENT||||||||
34127245|NCT00235183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127246|NCT06184685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127247|NCT03551834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127248|NCT03074201|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective feasibility study to evaluate potential for cholangioscopy to facilitate radiation-free ERCP.||||
34127249|NCT05427123|||COHORT||PROSPECTIVE|||||||
34127250|NCT00737724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127251|NCT05439343|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participants and outcomes assessor will not know which kind of interventions (adductor canal block and local infiltration) is performed on which knee.|This study is a prospective, single-centered, double-blinded, randomized controlled trial. We intend to compare two methods of postoperative analgesia, adductor canal block (ACB) and multimodal local infiltration (LI), simultaneously in patients receiving bilateral total knee arthroplasty. In other words, the patient will receive ACB in one knee and LI in the other knee after TKA surgery. Because this study is designed to apply these two methods respectively on either knee of the same patient, the relative analgesic efficacy can be assessed simultaneously. Like matched-pair designed study, this method can eliminate some confounding factors affecting pain scores.|t|f|f|t
34127252|NCT01010451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127253|NCT04809493|||COHORT||PROSPECTIVE|||||||
34127254|NCT02348957|||OTHER||PROSPECTIVE|||||||
34127255|NCT04422691|||COHORT||CROSS_SECTIONAL|||||||
34127256|NCT03132961|||COHORT||PROSPECTIVE|||||||
34127257|NCT02974829|||COHORT||PROSPECTIVE|||||||
34127258|NCT00358033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127259|NCT06183151|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127260|NCT05252286|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127261|NCT04345692|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, 2 arm, open label hydroxychloroquine plus usual care compared to usual care in hospitalized patients||||
34127262|NCT04951011|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34127263|NCT04088799|||COHORT||PROSPECTIVE|||||||
34127264|NCT04060004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127265|NCT01594840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34127266|NCT00243867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127267|NCT06513390|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34127268|NCT03369015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34127269|NCT01119066|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127270|NCT02621723|||COHORT||PROSPECTIVE|||||||
34127271|NCT06221410|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|The study was administered by two investigators. A traditional classroom teaching method was employed by the first investigator as a lecturer. the lecturer investigator administered both pre- and post-test scales to students. The second investigator was blinded to the group assignments of the students, ensuring unbiased data collection. The investigator was responsible for preparing and entering the data into SPSS for subsequent analysis.|"The participants were divided into three groups based on their preferences. Through this mechanism, they were able to cultivate a sense of responsibility and a sense of ownership in their educational journey.~Specifically, students who engage in funny scenario-based education prefer to collaborate with peers who share similar interests and learning styles, which makes preparing scenarios more enjoyable.~Meanwhile, in the mind-mapping groups, students draw on their creative skills to deconstruct and assimilate unfamiliar terms, utilizing their sense of humor and artistic competencies.~The control group will only receive traditional teaching methods (PowerPoint). After the study, the control group will also experience Funny Scenario-Based Learning and Mind Mapping."|f|f|t|t
34127272|NCT03235193|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34127273|NCT04981847|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors will be blinded to participant group.||f|f|f|t
34127274|NCT02995512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127275|NCT04268680|||COHORT||PROSPECTIVE|||||||
34127276|NCT01624415|||COHORT||PROSPECTIVE|||||||
34127277|NCT00610844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127278|NCT01899131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127279|NCT04227626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127280|NCT01333722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819138|NCT06650137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|"The reference will be the etiological diagnosis based on expert opinion. Two experts (physicians experienced in the management of ARD) will judge, blind to each other and to the judgement criteria, the cause of the ARD on the basis of a medical file review at least one month after the ARD episode.~Ultrasound measurements will be analyzed a posteriori by an investigator blind to the results of the gold standard."|Prospective interventional multicenter diagnostic study||||
33819139|NCT05978947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the laboratory staff in the IVF laboratory performing sperm preparation will be aware of the group assignment. Another laboratory staff who is not involved in performing sperm preparation and is not aware of the group assignment will perform the semen analysis.|This randomized controlled trial aims compare the effect of sperm preparation by a microfluidic chip method versus a density gradient centrifugation method on semen parameters prior to the start of a randomized trial comparing the effects of the two sperm preparation methods on the cumulative live birth rates of in vitro fertilization.|t|t|t|t
33819140|NCT05908734|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819141|NCT04303962|||COHORT||PROSPECTIVE|||||||
33819142|NCT04586426|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819143|NCT05464992|NA|SINGLE_GROUP||OTHER||NONE||||||
33819144|NCT05999994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819145|NCT06291597|||COHORT||PROSPECTIVE|||||||
33819146|NCT02332421|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819147|NCT04564079|||COHORT||PROSPECTIVE|||||||
33819148|NCT05888142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants will not be told there is more than one treatment group, but during the consenting process each participant will be fully informed about the treatment they will personally receive. The statistician will not be told which group received more treatments.|Participants will be randomly assigned to one of two groups (exploratory). One group will receive VR more often than the other group. Primary Hypothesis. As planned apriori, collapsing across groups, using a within subject repeated measures ANOVA (or non-parametric equivalent), we predict that compared to pre-treatment, our sample of CRPS (chronic pain) patients will report a significant improvement in the amount of CRPS pain (e.g., less pain) and improved (increased) physical ability/functionality after four months of home-based VR therapy homeworks (four months after baseline) and that they would continue to report significant improvements on an ad-hoc one year post-treatment followup. Secondary hypothesis. CRPS patients would show reduced CRPS hypersensitivity to brief thermal (e.g., cold) stimuli. and reduced CRPS-related co-morbid psychological symptoms after 4 months of home-based VR therapy, and on long term improvements on ad-hoc followup measures one year post-treatment.|t|f|f|t
33819149|NCT06140823|||COHORT||PROSPECTIVE|||||||
33819150|NCT03759262|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33819151|NCT06721715|||COHORT||RETROSPECTIVE|||||||
33819152|NCT05903781|||COHORT||PROSPECTIVE|||||||
33819153|NCT05588661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819154|NCT04715945|||COHORT||PROSPECTIVE|||||||
33819155|NCT03205345|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study drug will be double-blind with matching placebo. Emricasan at 25 mg or 5 mg or matching placebo will be administered orally twice a day.||t|f|t|t
33819156|NCT04578691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819157|NCT04380688|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study will consist of two arms Arm 1 is acalabrutinib + best supportive care or Arm 2 is best supportive care alone||||
33819158|NCT01211717|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33819159|NCT01210027|||CASE_ONLY||PROSPECTIVE|||||||
33819160|NCT04582864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819161|NCT06516692|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33819162|NCT05837624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819163|NCT03939871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819164|NCT00669292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819165|NCT06232655|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819166|NCT01765699|||||RETROSPECTIVE|||||||
33819167|NCT04136405|||OTHER||CROSS_SECTIONAL|||||||
33819168|NCT01601925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819169|NCT06073665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|overencapsulated levothyroxine doses will be provided by the investigational drug pharmacy|randomized, parallel, double-blind clinical trial of two 6-month dosing strategies of levothyroxine (LT4)|t|t|t|t
33819170|NCT06168994|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33819171|NCT03500796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819172|NCT00321399|||COHORT||PROSPECTIVE|||||||
33819173|NCT01518127|NA|SINGLE_GROUP||TREATMENT||NONE||intravitreal injection of autologous bone marrow stem cells||||
33819174|NCT05076578|NA|SINGLE_GROUP||TREATMENT||NONE||The ARTTM system is an electrically powered handheld device containing disposable sterile needle cartridges. The control elements include a push button that operates the back and forth movement of the needles in the cartridge. The device can harvest over 300 full thickness MicroColumns.||||
33819175|NCT02379078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33819176|NCT00597779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819177|NCT05939349|RANDOMIZED|PARALLEL||PREVENTION||NONE||The eligible participants will be allocated to one of two arms (i.e., the intervention and delayed intervention groups) and assigned a study number using a SAS-generated random table. The participants will be block randomized in blocks of 4, 6, 8, 10, 12 using a permuted block design in a 1:1 ratio to ensure a balance between the intervention and delayed intervention groups.||||
33819178|NCT06720753|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Research assistants performing behavioral coding will be masked to participant condition.|||||
33819179|NCT05989243|||COHORT||CROSS_SECTIONAL|||||||
33819180|NCT01764204|||COHORT||PROSPECTIVE|||||||
33819181|NCT01993342|||COHORT||RETROSPECTIVE|||||||
33819182|NCT03974997|NA|SINGLE_GROUP||OTHER||NONE||This is a single-center interventional study with minimal risks and constraints on a cohort of MS patients. Patients with clinically isolated syndrome suggestive of MS will be included prospectively and consecutively.||||
33819183|NCT02371278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33819184|NCT04896827|||OTHER||PROSPECTIVE|||||||
33819185|NCT06720480|||CASE_ONLY||CROSS_SECTIONAL|||||||
33819186|NCT05902494|||OTHER||RETROSPECTIVE|||||||
34048066|NCT06418191|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048067|NCT02093364|||CASE_ONLY||PROSPECTIVE|||||||
34048068|NCT02014493|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34048069|NCT04634513|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34048070|NCT05410340|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|Invesigator will not know which infants are premature or not||f|f|t|f
34048071|NCT06144216|NA|SINGLE_GROUP||OTHER||NONE||||||
34048072|NCT06218940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048073|NCT03107364|||COHORT||RETROSPECTIVE|||||||
34048074|NCT01163318|||COHORT||PROSPECTIVE|||||||
34048075|NCT03270852|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34048076|NCT06017297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048077|NCT04191369|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||Randomized controlled trial|t|t|f|f
34048078|NCT05901441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34048079|NCT00604097|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34048080|NCT03538964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048081|NCT01725581|||||PROSPECTIVE|||||||
34048082|NCT02389387|||COHORT||RETROSPECTIVE|||||||
34048083|NCT05353855|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048084|NCT03640559|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The present study was planned as double-blind, placebo-controlled study. With the aim of maximum objectification of end point, neither Medical Investigator, nor patients had access to the code of healthcare institution.~The test drug or the placebo were received by the sites as ready for use and blinded vials, 200 mL each. Each vial had individual number and identification of contents (Drug A or Drug B). Conformity of identification of Seroguard or the placebo was not disclosed to the sites.~Before surgery, the Medical Investigator prepared required number of vials according to identification of the drug on the vial and identification of the group in randomization envelope of patient. Individual number of each vial administered to a patient was recorded in documentation of site."|laparoscopic cholecystectomy|t|f|t|f
34048085|NCT04987229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048086|NCT04015635|||COHORT||PROSPECTIVE|||||||
34048087|NCT03209726|||COHORT||CROSS_SECTIONAL|||||||
34048088|NCT04997135|||COHORT||PROSPECTIVE|||||||
34048089|NCT06665412|||CASE_ONLY||PROSPECTIVE|||||||
34048090|NCT03655470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blind; participants will not be told to what condition they are assigned|2 group randomized controlled trial|f|f|f|t
34048091|NCT06683781|||COHORT||RETROSPECTIVE|||||||
34048092|NCT00378508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819187|NCT03873376|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33819188|NCT05556772|NA|SINGLE_GROUP||SCREENING||NONE||||||
33819189|NCT06480500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819190|NCT04221308|||COHORT||RETROSPECTIVE|||||||
33819191|NCT05500872|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The thickness and cross-sectional area of the quadriceps muscle (rectus femoris, vastus medialis obliques, vastus lateralis) will be measured by ultrasonography before and after each participant's training (4th week and 12th week after surgery). The person making these measurements will not know which group the participants belong to.|Our study was planned to be randomized controlled. Individuals will be stratified into 2 groups (Group I, Group II) based on the order of arrival using the Excel program. After the 4th postoperative week, cross-training will be applied to both groups for 8 weeks in addition to the rehabilitation program. In the study group, cross-education will be performed for 8 weeks with blood flow restriction in the unaffected extremity in the isokinetic system. In the control group, cross-education will be performed for 8 weeks without applying blood flow restriction in the isokinetic system. Before and after cross education, individuals; pain (rest, activity), leg circumference measurement, quadriceps and hamstring muscle strength (isokinetic dynamometer), quadriceps muscle thickness, cross-sectional area (ultrasound) and knee function (IKDC questionnaire, KOOS questionnaire, tampa questionnaire) will be evaluated.|f|f|f|t
33819192|NCT06721884|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33819193|NCT05959018|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised Controlled Trial||||
33819194|NCT00512473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||||||
34048093|NCT05534919|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label, single-arm study with active treatment.|This is an open label, single-arm study with active treatment.||||
34048094|NCT05344703|NA|SINGLE_GROUP||PREVENTION||NONE||Single group of 6th to 12th graders||||
34048095|NCT05207410|||CASE_ONLY||OTHER|||||||
34048096|NCT06576960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34048097|NCT04406584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blindfold during injection and during portions of the smell test|Comparison of two randomized groups|t|f|f|f
34048098|NCT02414360|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34048099|NCT03738813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048100|NCT06523075|||COHORT||PROSPECTIVE|||||||
34048101|NCT06685562|||CASE_ONLY||PROSPECTIVE|||||||
34048102|NCT05626673|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will be provided access to the Pray.com app and directed to use it for at least 5 minutes per day for at least 5 times per week.||||
34048103|NCT05675150|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of this trial, neither the staff, participants nor care provider can be masked to allocation. The data analyst will be blinded after study completion by having the intervention group information coded.|Parallel Randomized Controlled Trial|f|f|f|t
34048104|NCT01316094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048105|NCT03715478|NA|SEQUENTIAL||TREATMENT||NONE||||||
34048106|NCT06297291|||CASE_ONLY||PROSPECTIVE|||||||
34048107|NCT03262922|||COHORT||OTHER|||||||
34048108|NCT06308575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048109|NCT01425216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048110|NCT04508049|NA|SINGLE_GROUP||SCREENING||NONE||||||
34048111|NCT02361346|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127281|NCT01320345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127282|NCT01664117|||COHORT||CROSS_SECTIONAL|||||||
34048112|NCT03403335|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34127283|NCT03456258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048113|NCT01134445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048114|NCT04488198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048115|NCT06685497|NA|SINGLE_GROUP||OTHER||NONE||||||
34048116|NCT03406559|NA|SINGLE_GROUP||TREATMENT||NONE||study on 14 male adolescent patients having skeletal class II, Angle's class II division 2 malocclusion.||||
34127284|NCT01672086|||COHORT||RETROSPECTIVE|||||||
34127285|NCT05685420|NA|SINGLE_GROUP||TREATMENT||NONE||open-label Herombopag plus standard of care||||
33819195|NCT05959447|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819196|NCT03419806|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33819197|NCT06714344|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33819198|NCT05959382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"It has 4 groups in total. The treatments were carried out~* with no magnification aid~* with x2 loupe~* with x5 loupe~* with Dental operation microscope"|t|t|t|t
33819199|NCT05776771|||CASE_CONTROL||PROSPECTIVE|||||||
33819200|NCT06184321|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819201|NCT03198481|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33819202|NCT05615753|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819203|NCT02648737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819204|NCT01540877|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33819205|NCT05862779|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33819206|NCT05404178|||COHORT||PROSPECTIVE|||||||
33819207|NCT05878522|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"Sisunatovir and placebo oral capsules will be prepared in the CRU by 2 operators, 1 of whom is an unblinded pharmacist. Sisunatovir and placebo will be administered in blinded fashion to the subject.~Moxifloxacin 400 mg tablets will be packaged in an open-label manner at the CRU in the individual dosing containers by 2 operators, 1 of whom is an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician's assistant, practitioner, or pharmacist)."|Single Group, Crossover study|t|t|t|f
33819208|NCT06599684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819209|NCT05582447|||CASE_CONTROL||OTHER|||||||
33819210|NCT01290471|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819211|NCT05063162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|MOG001 consists of a Double-Blind (Part A) and an Open-Label Extension Study Period (Part B).||t|t|t|t
33819212|NCT01628939|||CASE_CONTROL||PROSPECTIVE|||||||
33819213|NCT02665624|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33819214|NCT03288480|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, open-label study of PT-112 in patients with relapsed or refractory MM.||||
33819215|NCT04655014|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33819216|NCT02178878|||COHORT||PROSPECTIVE|||||||
33819217|NCT02894216|||CASE_ONLY||RETROSPECTIVE|||||||
33819218|NCT03785041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33819219|NCT04911322|||OTHER||PROSPECTIVE|||||||
33819220|NCT04515745|||COHORT||RETROSPECTIVE|||||||
33819221|NCT05664711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819222|NCT04441073|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33819223|NCT03756896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819224|NCT00608387|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33819225|NCT00501111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819226|NCT06147440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33819227|NCT00037934|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33819228|NCT03423537|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048117|NCT06682390|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34048118|NCT04419532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819229|NCT06448845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819230|NCT04891536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819231|NCT03722732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819232|NCT06416969|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33819233|NCT01023022|||COHORT||PROSPECTIVE|||||||
33819234|NCT00574106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819235|NCT02910323|||COHORT||PROSPECTIVE|||||||
33819236|NCT02607293|||COHORT||CROSS_SECTIONAL|||||||
33819237|NCT06289855|||CASE_ONLY||CROSS_SECTIONAL|||||||
33819238|NCT01642888|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33819239|NCT04538482|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33819240|NCT02215447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819241|NCT00004311||||TREATMENT||||||||
33819242|NCT05788536|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||DB-OTO will be administered as a single intracochlear injection into one (Part A) or both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.||||
33819243|NCT04009902|||COHORT||PROSPECTIVE|||||||
33819244|NCT00362258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819245|NCT01863888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819246|NCT02961816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819247|NCT05729152|||COHORT||OTHER|||||||
33819248|NCT03649659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819249|NCT03502525|NA|SINGLE_GROUP||OTHER||NONE||||||
33819250|NCT03036722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819251|NCT05274906|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Randomized cross-over|f|f|t|t
33819252|NCT01384604|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33819253|NCT03741309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819254|NCT02919865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819255|NCT01770509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819256|NCT04228705|||COHORT||PROSPECTIVE|||||||
33819257|NCT04988958|||COHORT||RETROSPECTIVE|||||||
33819258|NCT06286956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048119|NCT01733290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048120|NCT01363245|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34048121|NCT06015074|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34127286|NCT01804049|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34127287|NCT02130674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048122|NCT04437368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant, Care provider, Investigators and Sponsor are dose masked in Part 1. Part 2 is open label study. Primary outcome assessor is fully masked to the treatment status in both Part 1 and Part 2.|This is a Phase 2, outcomes assessor-masked multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with GA secondary to AMD.|f|f|f|t
34048123|NCT05561322|||COHORT||PROSPECTIVE|||||||
34048124|NCT06684548|||CASE_ONLY||CROSS_SECTIONAL|||||||
34048125|NCT06056687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind|60 patients with type II Diabetes Mellitus with Ischemic Cardiomyopathy on optimal standard medical therapy, who will be consecutively randomized into two groups, group on ALA 600 mg once daily and the second group on placebo.|t|f|t|f
34048126|NCT05577455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||After the patients complete the relevant examinations, and those who meet the inclusion criteria sign the informed consent, they are sequentially assigned to two groups according to the randomization table. The intervention begins from the second menstrual cycle prior to IVF-ET in the experimental group and third menstrual cycle prior to IVF-ET in the control group. TCM treatment is initiated on the 5th day of menstruation in both groups, and medical prescriptions before and after ovulation are administered successively. Subjects do not take any medicine on the 1st to 4th day of menstruation and medications are discontinued on the day of HCG. The TCM is decocted by our hospital, and patients are instructed to take one dose of the the decoction warm per day (400 ml per dose) one hour after meals twice (once in the morning and once in the evening). The occurrence of spontaneous pregnancy and adverse reactions are recorded and dealt with promptly throughout the drug application period.|t|t|f|f
34048127|NCT01728818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048128|NCT06488443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blinded to the randomisation. Principal investigator will not be involved in randomization of participants.|The proposed study is a Randomized controlled trial.. It is two arm study, intervention arm and control arm. Intervention arm will be imparted yoga while control arm will be given the WHO 5As model intervention.|f|f|f|t
34048129|NCT03845218|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048130|NCT05030298|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The first four patients will be treated by standard of care and all subsequently enrolled patients will undergo preoperative radiosurgery by dose escalation schedule.||||
34048131|NCT05856383|||COHORT||PROSPECTIVE|||||||
34048132|NCT01431300|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33819259|NCT03750500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048133|NCT05115188|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||It is a population-based, prospective randomized crossover study. Women who fall into the screen positive group of the 50g GCT (1 hour serum glucose of 7.8-11 mmol/L) will be offered participation in the study. 28 Participants will be recruited and will be randomly assigned using a pre-populated allocation table to take either the standard OGTT test (75g of glucose beverage) first or the alternative OGTT test (21 Dex4® tablets) first. The first test will be referred to as OGTT-1 and the second test will be referred to as OGTT-2.|f|f|f|t
34048134|NCT02318355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048135|NCT06270316|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048136|NCT06575088|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients were categorized into four groups based on the method of choice for determining the level of tourniquet cuff pressure and the PPM applied under the cuff. (i) . Standard tourniquet pressure (STP) with cotton pad; (ii) STP with elastic stockinette; (iii) limb occlusion pressure (LOP) with cotton pad; and finally, LOP with elastic stockinette. Power analysis was performed using the PASS software for sample size calculation. 50 patients were included in each group, considering that some patients might discontinue the trial. Block randomization method was used to randomize patients into study groups. The independent variables of the study were skin complications associated with tourniquet application on the skin under the sleeve. Complications were identified by the study team and confirmed by clinic nurses, and there was no disagreement regarding the occurrence of complications.|t|t|f|t
34048137|NCT06407765|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both group will receive separate treatment and effort will be put to mask the both groups about treatment.|It will be a Randomized control trail. Convenient random sampling is used to collect the sample. The population under study is Cerebral palsy children. The study sample group are between the age of 6 to 12. The group is randomly divided into two groups; Control and experimental group. The control group will receive Dual task training. The experimental group will receive both dual task training and backward walking. The patients will be assesed at the start and then after 4 weeks of treatment.|t|f|f|f
34048138|NCT06594133|||CASE_CONTROL||RETROSPECTIVE|||||||
34048139|NCT02591095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048140|NCT03468413|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048141|NCT05532852|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048142|NCT03129945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048143|NCT06288373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048144|NCT05012722|||COHORT||PROSPECTIVE|||||||
34048145|NCT04759924|||COHORT||PROSPECTIVE|||||||
34048146|NCT02501954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048147|NCT05792332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34048148|NCT00161421|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048149|NCT04881656|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048150|NCT06684600|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048151|NCT00544401|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819260|NCT05692232|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819261|NCT02560142|||COHORT||PROSPECTIVE|||||||
33819262|NCT02403414|||COHORT||CROSS_SECTIONAL|||||||
33819263|NCT02893644|||OTHER||PROSPECTIVE|||||||
33819264|NCT01029418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819265|NCT02538055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819266|NCT01501526|||CASE_ONLY||RETROSPECTIVE|||||||
33819267|NCT00465699|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33819268|NCT05621720|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The individual who evaluates the outcome(s) of interest would be blinded from having knowledge of the intervention and control group assignment.||f|f|f|t
34048152|NCT03937219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio.|t|f|t|t
33819269|NCT05361304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048153|NCT01397396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048154|NCT01749709|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33819270|NCT03109600|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33819271|NCT00946010|||CASE_ONLY||CROSS_SECTIONAL|||||||
33819272|NCT06329661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819273|NCT06387797|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Because of the parallel arm differences, it would not be possible to mask the arm assignment for the participant or investigator. However, we will mask the arm assignment for the outcomes assessor, in particular for the HbA1c% assessment.|"Participants will be randomized to one of two parallel study arms.~1. Cooking Matters for Adults (CMA) Curriculum Delivery over 6 weeks~2. CMA + Enhanced cooking classes with added components comprising cooking practices specific to diabetes prevention, online information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. The CMA+ arm will also have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment visit. This will be an optional component and participants will not be excluded if they do not wish to use the CGM. (6 weeks)"|f|f|f|t
33819274|NCT06628167|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819275|NCT06164119|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||"This is an hybrid type I eﬀectiveness-implementation trial, testing the effectiveness of clinical therapeutic interventions, coupled by exploration of the eﬀects of the implementation of the effective intervention(s) in clinical practice (professional practice changes, changes in processes of care, quality of intervention delivery, patient's satisfaction).~The effectiveness study will be a before-and-after randomized trial performed according to a 2 × 2 factorial design.~Two groups are identified:~* Group A: Premenopausal breast cancer patients treated with tamoxifen and/or luteinizing hormone-releasing hormone (LHRH) analogues.~* Group B: Postmenopausal breast cancer patients treated with aromatase inhibitors.~Patients in each group will be randomly assigned to four treatments arms:~Arm 1, manual treatment with osteopathic techniques and nutritional treatment. Arm 2, manual treatment with osteopathic techniques. Arm 3, nutritional treatment. Arm 4, control."|t|f|f|f
33819276|NCT03111849|||OTHER||CROSS_SECTIONAL|||||||
33819277|NCT02674295|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33819278|NCT06190145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819279|NCT05097183|||COHORT||PROSPECTIVE|||||||
33819280|NCT05067556|NA|SINGLE_GROUP||OTHER||NONE||||||
33819281|NCT04549948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient was blinded to the intervention used. However, it was not possible to blind the clinician during treatment.|Leveling of the curve of Spee|t|f|f|t
33819282|NCT02713217|||OTHER||PROSPECTIVE|||||||
33819283|NCT00942799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819284|NCT03391778|NA|SINGLE_GROUP||OTHER||NONE||||||
33819285|NCT01516710|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819286|NCT00755716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819287|NCT00995618|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33819288|NCT00340184|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819289|NCT01110551|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33819290|NCT02419664|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33819291|NCT05789407|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A prospective cohort tertiary-center study among women undergoing elective laparoscopy due to pelvic endometriosis (arm 1) or idiopathic infertility (arm 2).||||
33819292|NCT03903185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819293|NCT06143878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819294|NCT05487131|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33819295|NCT02338778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819296|NCT04893993|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33819297|NCT05075005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, randomized control trial of patients randomly assigned to one of two groups|t|f|f|f
33819298|NCT06289972|||OTHER||PROSPECTIVE|||||||
33819299|NCT05319444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819300|NCT03966027|RANDOMIZED|PARALLEL||TREATMENT||NONE||Diabetic patients with ankle fractures will be manage operatively and then randomized to be prescribed a hindfoot offloading brace 2 weeks after surgery or be randomized to follow a non-immediate weight bearing rehabilitation protocol||||
33819301|NCT05370352|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819302|NCT00672516|||CASE_ONLY||PROSPECTIVE|||||||
33819303|NCT00319878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819304|NCT01324011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819305|NCT03895216|||COHORT||PROSPECTIVE|||||||
33819306|NCT01057888|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33819307|NCT02645578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819308|NCT01975701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819309|NCT06124599|||CASE_CONTROL||RETROSPECTIVE|||||||
33819310|NCT01655498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048155|NCT06327529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Study participants will be masked to the type of bean that they will be receiving.|A four arm multi-tracer non-randomized crossover design|t|f|f|f
34048156|NCT05446454|||OTHER||CROSS_SECTIONAL|||||||
34048157|NCT04560270|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048158|NCT05605145|||COHORT||PROSPECTIVE|||||||
34048159|NCT00449397|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34048160|NCT05629689|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34048161|NCT01528826|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048162|NCT02162641|||COHORT||PROSPECTIVE|||||||
34048163|NCT03774004|||COHORT||PROSPECTIVE|||||||
34048164|NCT02362672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048165|NCT06166745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048166|NCT00396032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048167|NCT06540456|||CASE_ONLY||PROSPECTIVE|||||||
34048168|NCT01653015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048169|NCT03324555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819311|NCT00620230|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33819312|NCT00275678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819313|NCT06384742|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants are asked to refrain from mentioning any information about the treatment they receive when interacting with the investigator or outcomes assessors. Participants are asked not to share details of their treatment with other individuals at their workplace.||f|f|t|t
33819314|NCT05711745|NA|SINGLE_GROUP||TREATMENT||NONE||A pre-post study||||
33819315|NCT05567302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluation and treatment will be carried out by different physiotherapists. In this way, it is aimed to provide an objective evaluation||t|f|f|f
33819316|NCT04018534|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"90 consecutive fixed orthodontic appliance treatment candidates in compliance with the above mentioned criteria were randomly assigned to 3 groups (n = 30 in each); Control group: The patients in control group received a standard printed educational material assisted with verbal information in accordance with BOS educational goals.~Study group 1: The patients in one of the study groups received a video assisted education .~Study group 2: The patients in other study group received a hands-on training."|f|t|t|t
33819317|NCT05991947|||COHORT||PROSPECTIVE|||||||
33819318|NCT06257082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33819319|NCT06412315|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|All members of the study team will be blinded to the condition a participant is allocated to with the exception of the team member responsible for treatment allocation (who will not interact with the participant).|"Participants will be assigned to receive citalopram or placebo. Citalopram is not being administered for treatment purposes, the purpose is to understand the mechanisms underpinning its effects (no clinical outcome measure).~A double-blind randomised placebo-controlled design (25 participants in each group) will be used, with 1 single dose of citalopram (20mg) or placebo."|t|f|t|f
33819320|NCT01544153|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33819321|NCT06550895|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819322|NCT00730496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819323|NCT05272150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819324|NCT06136325|||COHORT||RETROSPECTIVE|||||||
33819325|NCT05653921|||COHORT||PROSPECTIVE|||||||
33819326|NCT00004662|RANDOMIZED|||TREATMENT||DOUBLE||||||
33819327|NCT06157840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819328|NCT01474265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840206|NCT03342274|RANDOMIZED|PARALLEL||TREATMENT||NONE||After the end of year 1 outcomes the control arm crosses over and a year 2 follow-up is conducted on both arms.||||
33840207|NCT00409721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048170|NCT04762979|NA|SINGLE_GROUP||TREATMENT||NONE||Apelisib 300mg PO, Daily AND Aromatices Inhibitor(AI) or Fulvestrant 500mg IM per Standard of Care||||
34048171|NCT03646240|NA|SINGLE_GROUP||TREATMENT||NONE||"Participation includes a 4-week baseline period, a 3-week dosing period and a 12-week follow-up period. After baseline participants will receive ABI-009 given weekly IV for 3 weeks. ABI-009 will be tested in cohorts of 3 participants using the standard 3+3 dose-finding design.~Escalation to the next dose level with a new cohort of 3 participants will occur after no DLT was observed. There will be no intra-participant dose escalation allowed. If DLT occurs in a cohort, an additional 3 participants will be recruited to the cohort. If no further DLTs occur, a new cohort of 3 participants at the next higher dose level can be enrolled. If 2/6 participants at dose level 1 experience a DLT, then that cohort will be closed to further enrollment and 3 participants will be enrolled at the next lower dose level, and so on. The MTD is the highest dose level in which ≤1 participant has a DLT.~Once MTD has been determined, MTD cohort will be opened for up to 6 additional participants."||||
34048172|NCT06665555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048173|NCT02422940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048174|NCT02582060|NA|SINGLE_GROUP||OTHER||NONE||||||
34048175|NCT06646406|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34048176|NCT02696538|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048177|NCT03579017|||COHORT||PROSPECTIVE|||||||
34048178|NCT06204458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048179|NCT06607588|||COHORT||CROSS_SECTIONAL|||||||
34048180|NCT01245517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048181|NCT01770587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048182|NCT05832502|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048183|NCT02844842|||COHORT||PROSPECTIVE|||||||
34048184|NCT01665157|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34048185|NCT01454154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048186|NCT05381103|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34048187|NCT04133064|NA|SINGLE_GROUP||OTHER||NONE||||||
34048188|NCT06675097|||COHORT||PROSPECTIVE|||||||
34048189|NCT04400864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048190|NCT03737643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study consists of 2 independent cohorts: 3 double-blind treatment arms cohort for patients with no tBRCA mutation, and a single open label arm cohort for patients with tBRCA mutation|t|t|t|t
34048191|NCT06483620|||OTHER||CROSS_SECTIONAL|||||||
34048192|NCT05761535|||COHORT||PROSPECTIVE|||||||
34048193|NCT05206877|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34048194|NCT05119322|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention and control groups||||
34048195|NCT04893447|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Individual-level randomization to one of two treatment arms|f|f|f|t
34048196|NCT06604143|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"To keep the study fair and unbiased, the participants, principal investigator, and the people analyzing the data won't know which training method each participant is using. This means they will be blinded to the study groups. If participants knew why the study groups were chosen and which group they were in, it might affect their performance and the study results.~However, the therapist delivering the piano training will know which method is being used. To reduce bias, this therapist won't be involved in analyzing the data or know the research goals."||t|f|t|t
33819329|NCT04630873|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|In a sequential manner, every second patient that will enter the protocol will be treated with one of the two (high or low) diluted drug and will be assigned a number. Neither the investigator nor the outcome assessor (who will read the gait parameters) will be aware of the dilution used in each case.|In a sequential manner, every second patient that will meet our inclusion criteria will be treated with a low concentration of the drug during their first visit at our outpatient clinic. Then, after a safe washout period of 6 months, the same patients will be injected with a high concentration of the drug. The same procedure will be inversely performed in the other half of the patients.|f|t|t|f
34127288|NCT03896477|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34127289|NCT02835703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127290|NCT04462029|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127291|NCT01845246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127292|NCT02970136|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34127293|NCT02186782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127294|NCT01669525|||COHORT||PROSPECTIVE|||||||
34127295|NCT04195490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127296|NCT00094926|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127297|NCT06056206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127298|NCT05836558|||COHORT||CROSS_SECTIONAL|||||||
34127299|NCT05211193|||OTHER||OTHER|||||||
34127300|NCT05912595|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34127301|NCT02257242|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127302|NCT03723798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127303|NCT00959491|||||PROSPECTIVE|||||||
34127304|NCT01247454|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127305|NCT01444001|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127306|NCT01591408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127307|NCT05340998|||CASE_CONTROL||PROSPECTIVE|||||||
34127308|NCT00334737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127309|NCT02440139|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34127310|NCT02076854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127311|NCT03103646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127312|NCT02216916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127313|NCT03439046|NA|SEQUENTIAL||TREATMENT||NONE||||||
34127314|NCT05540626|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127315|NCT04633135|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There were 4 groups, 3 intervention and 1 control, all operating over the same period.||||
34127316|NCT06156852|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127317|NCT00550342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127318|NCT03160326|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127319|NCT02820844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127320|NCT06075134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127321|NCT00323531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127322|NCT03742570|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127323|NCT03516175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127324|NCT01735383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127325|NCT05976152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127326|NCT03374735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127327|NCT01053598|||COHORT||PROSPECTIVE|||||||
34127328|NCT01569737|||OTHER||PROSPECTIVE|||||||
34127329|NCT04921852|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34127330|NCT03497039|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34127331|NCT05231850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127332|NCT01154335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127333|NCT00183144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127334|NCT04312139|||CASE_CONTROL||OTHER|||||||
34127335|NCT00149539|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34127336|NCT01807325|||COHORT||PROSPECTIVE|||||||
34127337|NCT00534768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127338|NCT00625534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819330|NCT06126471|||OTHER||RETROSPECTIVE|||||||
33819331|NCT06430151|NA|SINGLE_GROUP||TREATMENT||NONE||Useability and acceptability study of a vibrotactile stimulation device||||
34127339|NCT02895178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34127340|NCT01694433|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34127341|NCT03744039|||COHORT||PROSPECTIVE|||||||
34127342|NCT05242341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34127343|NCT05568810|||COHORT||PROSPECTIVE|||||||
34127344|NCT05626179|NA|SINGLE_GROUP||OTHER||NONE||||||
34127345|NCT05982912|||COHORT||PROSPECTIVE|||||||
34127346|NCT05490277|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34127347|NCT01656707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127348|NCT04889248|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34127349|NCT02452385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149233|NCT04863196|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open clinical trial to assess the healing time of a lesion present in the gastric stoma mucosa using laser therapy or protective barrier powder.||||
34149234|NCT01793259|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149235|NCT03958708|NA|SINGLE_GROUP||TREATMENT||NONE||People at early stage of Parkinson's disease||||
34149236|NCT03198806|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34149237|NCT05649592|||CASE_CONTROL||RETROSPECTIVE|||||||
34149238|NCT00937989|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34149239|NCT04566146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149240|NCT05583760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|SINGLE BLIND (PARTICIPANT)||t|f|f|f
34149241|NCT06523062|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|adults \> 18 y|cohort|t|f|f|f
34149242|NCT01583816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149243|NCT06256705|NA|SINGLE_GROUP||OTHER||NONE||||||
34149244|NCT05538390|||OTHER||CROSS_SECTIONAL|||||||
34149245|NCT02060032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048197|NCT04426214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048198|NCT06647797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two hospital sites. One randomized to implement the communication intervention, the other continuing with usual care||||
34048199|NCT06434610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048200|NCT04174040|RANDOMIZED|FACTORIAL||PREVENTION||NONE||One experimental and three control groups involved study model.||||
34048201|NCT02460250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048202|NCT02111577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048203|NCT04270071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048204|NCT06580717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers, research coordinators, and subjects are all blinded.||t|f|f|f
34048205|NCT02695160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048206|NCT05163275|||COHORT||PROSPECTIVE|||||||
34048207|NCT02056561|||CASE_CONTROL||PROSPECTIVE|||||||
34048208|NCT03743805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048209|NCT04445974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not be told whether they have been allocated to intervention or control condition until the end of the study. The control condition is a series of creative writing tasks, which are framed as an intervention within the introduction to the first task. This replicates previous RCTs of the same intervention in different populations (Alleva et al., 2015).|This study is an online single-blinded Randonmised Control Trial, which contains acceptability and feasibility components.|t|f|f|f
34048210|NCT02771223|||CASE_ONLY||PROSPECTIVE|||||||
34048211|NCT01322490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048212|NCT00737906|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33819332|NCT03684018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048213|NCT03964337|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048214|NCT04927416|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048215|NCT02099669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048216|NCT04874662|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomized, double-blind, placebo-controlled, parallel group study|t|t|t|t
34048217|NCT06101628|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is a prospective, self-controlled clinical trial||||
34048218|NCT04230109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048219|NCT04507386|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 4-month parallel-group randomised controlled trial will be performed, in which patients with mild cognitive impairment will be assessed at baseline (PRE) and after 4 months (POST). Moreover, a sub-sample of patients will perform a randomised crossover trial at baseline (PRE). Patients will complete three experimental sessions in a random manner, as follows: Prolonged sitting (SIT), in which participants engaged in prolonged sitting throughout an 5-h period and were instructed to minimize excessive movement; Exercise followed by prolonged sitting (EX), in which participants performed a 30-min moderate-to-vigorous exercise bout on a treadmill, subsequently, participants engaged in prolonged sitting as described for SIT; Light-intensity breaks (BR), in which participants completed a 3-min bout of light-intensity walking every 30 min of sitting throughout the experimental period.||||
34048220|NCT00474045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048221|NCT06220981|||COHORT||PROSPECTIVE|||||||
34048222|NCT04460209|||COHORT||PROSPECTIVE|||||||
34048223|NCT02557802|RANDOMIZED|CROSSOVER||||NONE||||||
34048224|NCT05924386|RANDOMIZED|PARALLEL||TREATMENT||NONE||edentulous patients||||
34048225|NCT02234830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048226|NCT03124589|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34048227|NCT02222545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048228|NCT05195138|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34048229|NCT01403688|||CASE_CONTROL||PROSPECTIVE|||||||
34048230|NCT03943069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048231|NCT06685744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048232|NCT01637922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048233|NCT02610374|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048234|NCT00585845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048235|NCT03159871|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34048236|NCT06474988|||OTHER||PROSPECTIVE|||||||
34048237|NCT03789578|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|This is a three-period cross-over trial. The treatments to be used are: Treatment A: insulin 287, Treatment B: semaglutide, and Treatment C: NNC0148-0287sema. The subjects will be randomised to one of the six treatment sequences in the trial: 1) ABC, 2) ACB, 3) BAC, 4) BCA, 5) CAB, and 6) CBA. The trial includes a screening visit followed by three 5 -week periods with pharmacokinetic sampling after single dose administration. The dose periods are separated by a 1-4 week washout period (from last pharmacokinetic sampling to next dosing). The follow-up period is 1-4 weeks after last pharmacokinetic sampling in period 3 (i.e. 6 to 9 weeks after last trial product administration). The total trial duration for the individual subjects participating in the trial will be 19 to 32 weeks (including follow-up), depending on individual visit schedules.|t|t|t|t
34048238|NCT06617195|||COHORT||CROSS_SECTIONAL|||||||
34048239|NCT03481101|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.||||
34048240|NCT02453035|||CASE_ONLY||PROSPECTIVE|||||||
34048241|NCT00039351||||TREATMENT||NONE||||||
34048242|NCT00803790|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149246|NCT01472211|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149247|NCT05787106|NA|SINGLE_GROUP||OTHER||NONE||||||
34149248|NCT02913768|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34149249|NCT00536887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149250|NCT00584129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149251|NCT00918554|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149252|NCT05490108|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34149253|NCT00566254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819333|NCT01325272|||||RETROSPECTIVE|||||||
33819334|NCT01690286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819335|NCT04829318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819336|NCT03436797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819337|NCT04916847|||CASE_CONTROL||PROSPECTIVE|||||||
33819338|NCT06355531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819339|NCT02592317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819340|NCT06016127|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Randomization to treatment groups according to the randomization assignment||||
33819341|NCT06720116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|opaque sealed envelope|mulligan and iASTM groups|f|f|f|t
33819342|NCT06636786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33819343|NCT06106256|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded to the galvanic stimulation (GVS) intervention.||t|f|f|f
33819344|NCT05036070|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33819345|NCT04768491|||COHORT||PROSPECTIVE|||||||
33819346|NCT05843695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who conduct 3- and 6- months follow-up evaluations will be masked to participant treatment assignment.|3 treatment arms: iTCBT Individual; iTCBT Group; TAU|f|f|f|t
33819347|NCT02746783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819348|NCT04241380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819349|NCT06296797|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|f|t
33819350|NCT05032651|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||"Randomization period All eligible subjects will be randomized 1:1 by their age, gender, and HD vintage into control arm and intervention arm. After randomization, the study subject will enter the study after the nearest Hb measurement coming.~Study period"|t|f|t|f
33819351|NCT00802334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819352|NCT02137603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33819353|NCT04586049|||CASE_CONTROL||PROSPECTIVE|||||||
33819354|NCT00892970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819355|NCT02523417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819356|NCT01863368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819357|NCT02223299|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33819358|NCT02249923|||COHORT||PROSPECTIVE|||||||
33819359|NCT02301078|||CASE_CONTROL||PROSPECTIVE|||||||
33819360|NCT05614843|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants who meet the inclusion and exclusion criteria will be randomized to one of the two study groups using a random number generation program (www.randomizer.org). The randomization sequence will be prepared by a member external to the investigation to respect the masking in terms of randomization of the participants, thus reducing the risk of bias during the evaluations. Therefore both patients and evaluator will be masked.|Randomized controlled trial|t|f|f|t
33819361|NCT00720629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819362|NCT01654289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819363|NCT04260100|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33819364|NCT06720571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819365|NCT04560322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819366|NCT04803058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819367|NCT06474234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819368|NCT00664924|||COHORT||PROSPECTIVE|||||||
33819369|NCT05222178|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Escalation||||
33819370|NCT00003778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819371|NCT02699606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819372|NCT01898026|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33819373|NCT05872958|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33819374|NCT01669720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819375|NCT01536795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819376|NCT03322449|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||randomized crossover dietary intervention|f|f|t|f
33819377|NCT06241677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819378|NCT06577376|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In the dose escalation phase, a 3+3 approach is used to explore the safety and tolerability of subjects, and in the randomized controlled phase, the efficacy of different combination doses is explored"||||
33819379|NCT06286618|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33819380|NCT06267326|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|t|f|f
33819381|NCT04641156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819382|NCT03978299|||COHORT||PROSPECTIVE|||||||
33819383|NCT05327725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819384|NCT01732055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819385|NCT03467594|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819386|NCT02450279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819387|NCT02625636|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33819388|NCT01738087|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819389|NCT00676663|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819390|NCT01463397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819391|NCT03251833|||OTHER||CROSS_SECTIONAL|||||||
33819392|NCT05053399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819393|NCT00930644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048243|NCT03229863|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is designed as a combined randomized, crossover interventional and observational trial. At the start of the study, infants will enter a 7-day lead-in period to establish gut microbiome and GI tolerability baselines. After the 7-day lead-in period, infants will be randomized into one of two feeding arms comprised of two commercially available baby foods: sweet potato (SP) (Plum Organics, Just Sweet Potato) and pears (P) (Earth's Best, First Pears). The first food, either sweet potato or pears, will be consumed for 7 days followed by a 4-day washout period of exclusive breast milk before initiating the alternate 7-day feeding arm of pears or sweet potato, respectively. The second feeding arm will be followed by an additional 4-day washout period of exclusive breast milk before the introduction of any other solid foods. Once the first month of the study is complete, infants will enter an observational phase for the remainder of the study.||||
34048244|NCT05669326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048245|NCT04590586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048246|NCT00612495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048247|NCT02177526|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34048248|NCT05154019|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Waiting list control. Control group receive the training 3 months after completing baseline||||
34048249|NCT02843776|||COHORT||PROSPECTIVE|||||||
34048250|NCT05600621|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Participants will be blinded to the experimental condition that the participant was assigned to.|"The factorial experiment is guided by the Multiphase Optimization Strategy (MOST).~The 4 intervention components are:~Component 1. Financial Literacy Training (FLT); Component 2. Incentivized Matched Youth Savings Accounts (YSA) with income-generating activities (IGAs); Component 3. A manualized visual-based intervention for ART adherence and stigma reduction using multiple family group approach (Suubi Cartoon); Component 4. Engagement with HIV treatment-experienced role models who share their lived experiences of HIV.~Clinics will be randomized to provide one of the 16 conditions, with 12 ALHIV (aged 11-17 years) enrolled per clinic, yielding main effects and interaction effects for the 4 components on sustained viral suppression."|t|f|f|f
34048251|NCT06299878|||CASE_ONLY||PROSPECTIVE|||||||
34048252|NCT01075256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048253|NCT00000753||||TREATMENT||NONE||||||
34048254|NCT01483339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149254|NCT01395407|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819394|NCT06093672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149255|NCT03256786|||CASE_CONTROL||PROSPECTIVE|||||||
34149256|NCT02365415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149257|NCT00064402|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149258|NCT00587847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149259|NCT02273713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149260|NCT02737384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149261|NCT05748314|||COHORT||CROSS_SECTIONAL|||||||
34149262|NCT00513955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149263|NCT01896271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149264|NCT00542061|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34149265|NCT04683458|||COHORT||RETROSPECTIVE|||||||
33819395|NCT04154774|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819396|NCT06585059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819397|NCT02001207|||COHORT||PROSPECTIVE|||||||
33819398|NCT00685659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819399|NCT01648075|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33819400|NCT06317259|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects will be unaware of the other conditions and will thus not know if they are in a 'control' group or not. All experimenters will know subject group assignments. Subjects will be told of all groups at the end.|"We have 3 groups running in parallel (one of each group running in the same week). Group 1 will do breathwork that includes music and positive messaging, group 2 will do breathwork alone with only guided breathing instructions, and group 3 will listen to the music and positive messaging but no breathwork which we call the meditation group."|t|f|f|f
33819401|NCT06255665|NA|SEQUENTIAL||TREATMENT||NONE||||||
33819402|NCT05010499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|neither the patients nor the treating doctor know the type of block patient received.|patients undergoing hip arthroscope are divided into 2 groups. patients either receive femoral nerve block or fascia iliaca block.|t|t|t|t
33819403|NCT05552222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819404|NCT01973478|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33819405|NCT05336409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819406|NCT02099656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819407|NCT03881267|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Human Homologous Autologous Skin Construct (SkinTE™) in the Treatment of Venous Leg Ulcers|f|f|f|t
33819408|NCT05045664|RANDOMIZED|PARALLEL||TREATMENT||NONE||Controlled, open, randomised, 2 parallel groups, multi-centre, national, treatment phase III trial||||
33819409|NCT06014788|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33819410|NCT03120949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819411|NCT01130077|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study to assess tolerability of this vaccine regimen in different strata of children with high risk gliomas||||
33819412|NCT06219174|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819413|NCT02526199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819414|NCT03819296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819415|NCT04844294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819416|NCT03456089|NA|SINGLE_GROUP||OTHER||NONE||||||
33819417|NCT00570804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819418|NCT02440698|||COHORT||PROSPECTIVE|||||||
33819419|NCT04056598|||COHORT||OTHER|||||||
33819420|NCT05898802|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants or study staff working with them will not know what supplements they are receiving.||t|f|t|f
33819421|NCT02116582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819422|NCT04674033|||COHORT||PROSPECTIVE|||||||
33819423|NCT05282316|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Same organoleptic features of the two different kind of EVOO (polyphenols enriched and standard).|Double-blind placebo-controlled|t|t|t|t
33819424|NCT01379989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819425|NCT01772381|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149266|NCT05172674|||COHORT||PROSPECTIVE|||||||
34149267|NCT05606991|RANDOMIZED|CROSSOVER||SCREENING||NONE||Randomized controlled crossover trial||||
33837229|NCT04483856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments and evaluations will be performed by a physician in a blind fashion.|This is a post marketing, interventional, randomized, single-center, prospective, controlled study. Assessments and evaluations will be performed by a physician in a blind fashion.|f|f|f|t
33837230|NCT00001197||||TREATMENT||||||||
33837231|NCT04860440|||COHORT||PROSPECTIVE|||||||
33837232|NCT03169400|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33837233|NCT05656755|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator were blinded for group distribution and randomisation. They also were the outcome assessor and were therefore kept blinded.|Randomised control trial (pilot study)|f|f|t|t
33819426|NCT06638710|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"Blinding will be carried out upstream by the pharmacy that will prepare the treatment kits.~For each nursing treatment, the syringe will contain either midazolam or placebo according to randomization."|"This is a \&#34;n of one design\&#34; study~* Patients presenting opposition to at least two nursing care will be selected for the study.~* Patients included in the study will be assigned a kit of 20 unit doses containing an oral gel of midazolam or placebo, according to a predefined sequence. Maximum 20 nursing care will be included in the study.~* For each new opposition to treatment ≥ 3 on the Pittsburgh scale, the nurse will administer the next syringe from the kit in a double-blind manner, following the predefined order. Thirty to forty minutes after administration, the nurse will reassess the level of opposition and then attempt the same care again."|t|t|t|t
33819427|NCT00001848||||TREATMENT||||||||
33819428|NCT03145142|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819429|NCT01292499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819430|NCT04829994|||COHORT||PROSPECTIVE|||||||
33819431|NCT05085015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819432|NCT05658484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819433|NCT04724668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|On the intervention phase 2 (Specific aim 2). Only subjects with BED (n=40) will participate and be randomly assigned to one of two combinations of morning lights and/or melatonin/placebo (20 subjects/each arm). Researchers and participants will be blinded to the intervention.|The specific aims will be completed in a two-phase experimental approach. In the first phase (specific aim 1), obese subjects with BED (n=40) and without BED (n=40) will participate in a 2-week longitudinal study. In the second phase (specific aim 2), only BED subjects that complete phase 1 will rollover for a 4-week intervention study.|t|t|t|t
33819434|NCT04625023|||OTHER||OTHER|||||||
33819435|NCT03792945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819436|NCT06719843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Wait-list trial|f|f|f|t
33819437|NCT04543942|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33819438|NCT06012877|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE||Cluster randomized controlled trial with an intervention group (IG) and a control group (CG) with pre- and post-measurements|t|t|t|f
33819439|NCT04283097|NA|SINGLE_GROUP||TREATMENT||NONE|This is a open label Phase I study|Dose escalation will use a standard 3+3 approach to establish a maximum tolerated dose (MTD), and the initial escalation dose level will be 2mg/day. Subjects may be enrolled at dose levels 2, 3, 4, and 5 mg and/or intermediate dosing or alternative dosing schedule||||
33819440|NCT01007617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33819441|NCT03214198|||COHORT||PROSPECTIVE|||||||
33819442|NCT05981586|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33819443|NCT05734976|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The measure in this study is the change in Visual Analog Scale (VAS), National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), after completing 2 weeks of electroacupuncture. Clinical measurements are made; blood tests to show the results of the treatment|This study is clinical trialrandomized in electroacupuncture: use a control group and treatment group design(included sharm acupuncture) Practice mainly based on medical experience and evidence from clinical cases of CMUH.clinical measurements are made; blood tests to evidence treatment results.|f|f|t|f
33819444|NCT04337502|||COHORT||RETROSPECTIVE|||||||
33819445|NCT03188549|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Comparative research, Cross-Over, with a quasi-experimental component, comparing trial products to the use of Septol over the course of the year before the research.||||
33819446|NCT05014815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819447|NCT06072352|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33819448|NCT04750798|||COHORT||PROSPECTIVE|||||||
33819449|NCT02213458|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33819450|NCT02543294|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819451|NCT03225092|NA|SINGLE_GROUP||TREATMENT||NONE||Observational pilot study||||
33819452|NCT02270125|||CASE_CONTROL||PROSPECTIVE|||||||
33819453|NCT00787345|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33819454|NCT04051645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No masking will be done|In the experiment, the proband will breathe through the D-Lite measuring screen of the Datex-Ohmeda S/5 Patient Monitor patient monitor (GE, USA). Unlike clinical practice, an adjustable flow resistance will be connected to the system. The flow resistance is set by adjustable by a removable diaphragm with different hole diameters according to the intended flow resistance.||||
33819455|NCT04172571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819456|NCT02475733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819457|NCT04067713|||CASE_ONLY||PROSPECTIVE|||||||
33819458|NCT03449979|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is a double-blind study, meaning that neither the participant nor the experimenter knows what kind of stimulation the participant is receiving. An unblinded monitor (separate from the staff that interacts with the participant) is responsible for creating the stimulation codes that run each session and for ensuring that these codes worked correctly.|This study recruits both participants currently experiencing a depressive episode (regardless of diagnosis) and those with no history of neurological or psychiatric illness. Randomization will occur in a 1:1 ratio for both of these groups, with half of each group receiving transcranial alternating current stimulation (tACS) at 10 Hz and the other half receiving placebo (or sham) stimulation.|t|f|t|f
33819459|NCT02638558|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33837234|NCT01114347|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33837235|NCT04848324|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33837236|NCT00002068||||TREATMENT||||||||
33837237|NCT05536375|NA|SINGLE_GROUP||OTHER||NONE|Participant will be assigned a research ID which will be used for sample and data analysis.|"25 healthy adult volunteers who are:-~1. Aged 21-65 years old with no pre-existing medical condition~2. Not on any long term medication~3. Non smoker"||||
34149268|NCT06506877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149269|NCT05102968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149270|NCT01264419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149271|NCT02973568|||COHORT||PROSPECTIVE|||||||
34149272|NCT04619277|||COHORT||OTHER|||||||
34149273|NCT02687516|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819460|NCT06283693|RANDOMIZED|PARALLEL||OTHER||SINGLE|Computer-assisted randomization will be used in the study, and participants will be randomized to an intervention or control list control group in a 1:1 ratio by entering the number of samples to be reached through the program whose URL address is https://www.randomizer.org. Women who apply to the infertility outpatient clinic by the researcher and volunteer for the study who meet the sample selection criteria will be given numbers according to the order of outpatient clinic registration. A randomization sequence will be created according to these numbers and women will be assigned to the intervention and control groups by computer-assisted randomization. Since the study is a thesis, blinding will not be possible due to its nature.|Randomized controlled classical experimental study|t|f|f|f
33819461|NCT02632045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819462|NCT02628613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819463|NCT01645397|||COHORT||PROSPECTIVE|||||||
33819464|NCT00139971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819465|NCT05646602|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Following enrollment men will be randomized based on the severity of their penile curvature. Separate randomization tables will be established for men with penile curvature (i) 30 to \< 60 degrees and (ii) 60-90 degrees. Patients will be randomized in a 1:1 ratio to CCH + LiSWT versus CCH alone within each severity cohort, with the intention to enroll a similar number of patients within each severity group|t|f|f|f
33819466|NCT00349661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819467|NCT04034056|||COHORT||RETROSPECTIVE|||||||
33819468|NCT00627432|RANDOMIZED|||TREATMENT||||||||
33819469|NCT01385683|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33819470|NCT02785822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33819471|NCT06260059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Group 1: Empagliflozin 10 MG daily Group 2: Placebo|t|t|t|t
33819472|NCT02791009|||CASE_CONTROL||PROSPECTIVE|||||||
33819473|NCT01113541|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819474|NCT06408935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819475|NCT06309771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Assessors of pre and posttest measures will be blinded to the group allocation.|Randomized controlled clinical trial. Randomization into two groups: INTERVENTION group and CONTROL group. The INTERVENTION group will have the opportunity to follow a preventive remediation program based on 3 modules: stress management, sleep improvement and fatigue reduction, and sedentary behaviors reduction and physical activity promotion. The order of following the 3 modules will be randomized. The CONTROL group will not receive any intervention.|f|f|f|t
33819476|NCT04601883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819477|NCT01262794|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33819478|NCT02567435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819479|NCT03231579|||COHORT||PROSPECTIVE|||||||
33819480|NCT04239976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33819481|NCT03745651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819482|NCT06266494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819483|NCT03921216|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33819484|NCT06261567|||COHORT||RETROSPECTIVE|||||||
33819485|NCT01695993|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33819486|NCT04745819|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33819487|NCT02072889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33819488|NCT05438511|||COHORT||PROSPECTIVE|||||||
33819489|NCT06553235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|In addition to investigator and outcome assessor masking, we aim to mask the participants as much as possible. Participants will know what treatment they will receive and that there are two groups. However, they will not know what treatment the other group will receive or that one group is the intervention group and the other an active control group.||f|f|t|t
33819490|NCT04479137|||COHORT||RETROSPECTIVE|||||||
33819491|NCT01247922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819492|NCT03316248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819493|NCT05863871|||COHORT||PROSPECTIVE|||||||
33819494|NCT02303613|||COHORT||PROSPECTIVE|||||||
33819495|NCT04049578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819496|NCT05586178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33819497|NCT01614899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819498|NCT03735368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patients, the surgeons and the research team will be blinded to the randomization.||t|t|t|t
33819499|NCT06049433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819500|NCT05663866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819501|NCT02200016|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33819502|NCT04920045|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomization will occur after patients have consented to participate and will be done using permuted block de-sign with random blocks of 2, 4, or 6 patients per block.||||
33819503|NCT04532333|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819504|NCT02619045|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33819505|NCT01849185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819506|NCT03356145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The provider and staff will be aware of arm allocation, but participants will remain blinded.|Participants will be randomized to one of two study arms via computer-generated block randomization using REDCap software.|t|f|f|f
33819507|NCT05313945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819508|NCT03713502|||OTHER||CROSS_SECTIONAL|||||||
33819509|NCT01558245|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33819510|NCT03126474|||OTHER||OTHER|||||||
33819511|NCT03018288|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819512|NCT03787693|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The PI and the subject will not be aware of the group assignment of each subject.|Chronic stroke survivors will be screened and assigned to either a Symmetric or Asymmetric group based on inter-limb step length and/or step time asymmetry at baseline. Each subject will be randomly assigned to perform a split-belt adaptation protocol in either a VR or a Non-VR environment.|t|f|t|f
33837238|NCT02560753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837239|NCT04075630|||COHORT||PROSPECTIVE|||||||
33837240|NCT05780034|NA|SEQUENTIAL||TREATMENT||NONE||||||
34048255|NCT06181266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|All administrations of ZH9 as an IVI will be open-label in Parts 1, 2, and 3. In Part 2 only, patients will be randomized 1:1 to receive either ZH9 or placebo oral prime. The oral priming condition will be conducted in a double-blind, placebo-controlled manner. The randomization list will only be made available to the unblinded pharmacist dispensing the study drug. At each clinical site, an unblinded pharmacist will be assigned to prepare the blinded study drug for administration (ZH9 oral prime or placebo).|"In Part 1, the safety, tolerability, and pharmacology of ZH9 administered as an IVI will be evaluated in a single ascending dose cohort in patients with NMIBC. Part 1 may examine up to 4 dose levels.~In Part 2, the safety, tolerability, and pharmacology of ZH9 oral prime followed by ZH9 IVI will be evaluated in 2 cohorts in patients with NMIBC at the doses and schedule established in Part 1.~In Part 3, the safety, pharmacology, and clinical efficacy of ZH9 (oral prime and IVI) will be further evaluated in 2 expansion cohorts of patients with recurrent intermediate- and high-risk NMIBC."||||
34048256|NCT02417168|||COHORT||PROSPECTIVE|||||||
34048257|NCT05797935|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blind study|Randomised Control Trial|f|f|t|f
34048258|NCT03676075|||OTHER||PROSPECTIVE|||||||
34048259|NCT03774498|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
34048260|NCT04563884|||CASE_CONTROL||PROSPECTIVE|||||||
34048261|NCT03146208|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048262|NCT01089608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048263|NCT01987739|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34048264|NCT01366235|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34048265|NCT00411242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048266|NCT06668519|||COHORT||PROSPECTIVE|||||||
34048267|NCT01881490|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048268|NCT02233764|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34048269|NCT01055275|||COHORT||PROSPECTIVE|||||||
34048270|NCT01081444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048271|NCT01888445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048272|NCT03831932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048273|NCT06682858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048274|NCT01268930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048275|NCT02887248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048276|NCT01188174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048277|NCT06659094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048278|NCT01264081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048279|NCT06138106|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33819513|NCT05219409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||A randomized controlled open label intervention study is proposed. Relatives of patients with type 1 diabetes in stage 2 will be included in the study and divided into two groups by randomization: sitagliptin add-on therapy vs placebo(group of control)|t|f|t|f
33819514|NCT02468882|RANDOMIZED|PARALLEL||||DOUBLE|||f|t|f|t
33819515|NCT04751019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819516|NCT06721585|||COHORT||PROSPECTIVE|||||||
33819517|NCT02227888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819518|NCT01182285|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819519|NCT05707377|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study consists of 2 parts. Part 1 will evaluate the safety and efficacy of Zanubrutinib in participants with primary membranous nephropathy. Part 2 will evaluate the safety and efficacy of zanubrutinib compared with tacrolimus.||||
33819520|NCT06055478|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|An independent nurse uses a random number generator and allocates paticipants into the two group. Participant, investigator, and outcome assessor are blinded of the allocation information.|Study group: Preemptive US guided suprascapular nerve block (SSNB) and axillary nerve block (ANB) using each 0.75% ropivacaine 10mL Control group: Preemptive US guided suprascapular nerve block (SSNB) and axillary nerve block (ANB) using each 0.9% saline 10mL|t|t|t|t
33819521|NCT06537063|||COHORT||PROSPECTIVE|||||||
33819522|NCT05603299|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33819523|NCT06045221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819524|NCT06649981|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Our research is structured as a randomized, placebo-controlled, double-blind clinical trial.|t|f|t|f
33819525|NCT04301518|RANDOMIZED|PARALLEL||PREVENTION||NONE||To determine the efficacy and safety of a PTB prevention strategy, this study will utilize PreTRM® to prospectively stratify pregnant women with a singleton gestation into categories of risk of PTB and adverse neonatal outcomes. Subjects randomized into the PTB Prevention arm who score at or above the predetermined threshold risk will receive protocol-specified care for the prevention of PTB throughout gestation utilizing defined interventions.||||
33819526|NCT05820256|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Study participants will be block randomized by gender into one of two groups for a parallel-arm trial.||||
33819527|NCT04606732|||COHORT||CROSS_SECTIONAL|||||||
33819528|NCT06645743|||CASE_CONTROL||RETROSPECTIVE|||||||
33819529|NCT02592434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819530|NCT01358643|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33837241|NCT00405119|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33837242|NCT04843579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048280|NCT00652626|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048281|NCT03779750|||COHORT||PROSPECTIVE|||||||
34048282|NCT00226785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34048283|NCT01058993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048284|NCT01192061|||CASE_CONTROL||PROSPECTIVE|||||||
34048285|NCT01698138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048286|NCT00581698|||CASE_ONLY||PROSPECTIVE|||||||
34048287|NCT06017102|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048288|NCT02164331|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34048289|NCT05638672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048290|NCT03928587|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34048291|NCT01766661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048292|NCT05566704|||COHORT||RETROSPECTIVE|||||||
34048293|NCT01167738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048294|NCT02968693|||CASE_CONTROL||RETROSPECTIVE|||||||
33819531|NCT05324527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Masking Description According to the randomization table, the information showing the patients included in the research sample is assigned to the A and B groups will be put in an opaque envelope. This envelope will be kept by the coordinator researcher (DL) and when the researcher (FA) goes to the patient for application, after filling out the Informed Voluntary Consent Form, he will open the envelope and learn which group is in which group. Due to the nature of the study, patients and the researcher (FA) will notbe blinded, since abdominal massage will be applied only to the patients included in the study. When the research is completed, the data will be transferred to the computer environment by a statistician who does not know the A and B groups, and the data will be analyzed by a statistician independent of the research and the findings will be reported. Thus, the data analysis and statistics phase will be blind to group assignment"|Prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
33819532|NCT06381219|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33819533|NCT06385418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819534|NCT00606346|||COHORT||PROSPECTIVE|||||||
33819535|NCT01157442|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33819536|NCT05605899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819537|NCT02214017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819538|NCT04343989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is double-blind and therefore neither the Investigator, the subject, the Sponsor and its representatives, nor other designated study site personnel involved in running of the study will be aware of the identification of the investigational drug administered to each subject.|This is a randomized, double-blind, placebo-controlled, adaptive seamless Phase II/III design (ASD). We propose the administration of an investigational drug in patients with high predicted short-term mortality secondary to COVID-19 disease. 80 patients were randomly assigned in a 1:1:1 ratio to three study arms that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo. Interim analyses occurred every 7 days since the enrollment of the first 30 patients. Based on week 4 interim analysis the DSMB has recommendation discontinuing the low-dose 12.5 mg of clazakizumab arm. The DSMB has advised continuing enrollment in the placebo and high-dose 25mg of clazakizumab arms in a 1:1 randomization.|t|f|t|f
33819539|NCT01388309|||COHORT||PROSPECTIVE|||||||
33819540|NCT05352763|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label extension study||||
33819541|NCT04174170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819542|NCT03317288|NA|SINGLE_GROUP||PREVENTION||NONE|Here is no masking of the intervention.|Repeated measures design. Subject serves as his or her own control.||||
33819543|NCT05804552|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819544|NCT03973437|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33819545|NCT06721611|||COHORT||PROSPECTIVE|||||||
33819546|NCT06039566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33819547|NCT06266611|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33819548|NCT06134986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819549|NCT05523388|||COHORT||PROSPECTIVE|||||||
33819550|NCT05775718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819551|NCT04287361|||COHORT||RETROSPECTIVE|||||||
33819552|NCT01422798|||COHORT||PROSPECTIVE|||||||
33819553|NCT03833206|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
33819554|NCT06181435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819555|NCT02160548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819556|NCT04829058|||COHORT||PROSPECTIVE|||||||
33819557|NCT00194961|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819558|NCT03517371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessors will administer standardizes outcome measures across sites (BU \& WU)|This study will take place at Boston University (BU) and Washington University in St. Louis (WU). This is a two-arm, single-blinded, 1-year randomized controlled trial. Persons with mild to moderate PD are randomly assigned to one of two treatment arms. In the mHealth arm, individuals participate in a cognitive-behavioral community-based walking program plus home-based walking enhancing progressive resistance exercises delivered using a mobile health platform. The active control condition receives the same components and dose of walking and exercise but without a cognitive-behavioral approach or the use of mobile health technology.|f|f|f|t
33819559|NCT06133374|||COHORT||PROSPECTIVE|||||||
33819560|NCT04454671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819561|NCT01636258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819562|NCT04830163|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819563|NCT00776386|||COHORT||CROSS_SECTIONAL|||||||
33819564|NCT04117711|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819565|NCT05490368|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants and group moderators cannot and will not be blinded to the intervention. Assessors of the follow-up outcomes and the research analysts will not be involved in the recruitment and intervention delivery, and will be blinded to the group allocation (single blindness).|The care staff of the home will screen all residents for eligible residents with fall history in the past 12 months or with eligible Morse Fall Scale score. If the potential residents were assessed with Morse Fall Scale before 1 May 2022, Morse Fall Scale will be conducted again to update the score. In the experimental group, recruitment priority starts from those with a highest score in Morse Fall Scale until 10 participants are recruited. In recruiting suitable residents of the control group, the potential residents with similar Morse Fall Scale scores and similar profiles including gender, age, and fall history in the past 12 months to those of experimental group will be recruited. They and their family caregivers will be notified about the utilization about their fall records, and that the existing practice in fall prevention for them will not be altered during the trial. If they do not want to participate, they can notify the care staff (Opt-out participation).|f|f|f|t
33819566|NCT04383288|||COHORT||PROSPECTIVE|||||||
33819567|NCT02457078|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819568|NCT05990088|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33819569|NCT05673616|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Inclusion Criteria~1. Patients having Discogenic LBP referred from hospital.~2. Male and female both~3. Ptients hving Modic changes in MRI.~3.Otherwise, healthy patients with age range from 18 to 55 years.~Exclusion criteria:~1. Patients with non-mechanical LBP~2. Patients not meeting age range~3. Patients with any major co-morbidity~4. Any type of systemic illness"||||
33819570|NCT06647147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819571|NCT04731428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Study||||
33819572|NCT05318716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"When the patients check in at the reception desk, they will be assigned a ticket with a 0 or 1 sequentially. This will be placed in their file. Group 0 patients will receive Decantation, and group 1 will receive Revolve.~The nurse will collect this ticket, along with the patient's registration documents to prepare the equipment.~Photography will be done by a research assistant/coordinator. The person will be responsible for imaging patients, as well as conducting the volume analysis following training by the software manufacturer. This person will be blinded to which method is used.~During subsequent follow ups, the patient will have a 0 or 1 in their chart, to accurately collect data while in follow up.~The surgeon, assistants and nurses will not be able to be blinded as they are the person responsible for using the device in the operating room."|Prospective randomized controlled trial, we aim to recruit patients already scheduled to undergo fat grafting to the breast for reconstruction or cosmetic augmentation.|t|f|f|t
33819573|NCT05707585|||COHORT||PROSPECTIVE|||||||
33819574|NCT05912517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The participants will be randomized in a 2:1 to receive nipocalimab and placebo treatment.|t|f|t|t
33819575|NCT06585189|||COHORT||RETROSPECTIVE|||||||
33819576|NCT00108355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819577|NCT01064180|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819578|NCT05092776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819579|NCT02521428|||COHORT||RETROSPECTIVE|||||||
33819580|NCT03126188|||COHORT||PROSPECTIVE|||||||
33819581|NCT04282863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This is a single-blinded RCT evaluating the effect of RM and LM in the management of uterine leiomyomas. Participants will be stratified on hospital performing the procedure and thereafter randomly assigned to the RM or LM group with allocation ratio 1:1.||t|f|f|f
33819582|NCT04652050|||COHORT||PROSPECTIVE|||||||
33819583|NCT00794573|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33819584|NCT02363933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819585|NCT06386510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||multicentered stratified randomized controlled trial|t|f|f|t
33819586|NCT04038723|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819587|NCT01803854|||COHORT||PROSPECTIVE|||||||
33819588|NCT04586010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor will also be blinded.||t|f|t|f
33819589|NCT00658177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819590|NCT01505699|||OTHER||RETROSPECTIVE|||||||
33819591|NCT04388514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization, 1:1 ratio|"The study includes 2 arms:~* Arm A: Blood ozonization plus BAT (n= 45 subjects)~* Arm B: Standard of Care only without Blood ozonization (n= 45 subjects)~To note that the Standard of Care are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days"|f|f|t|f
33819592|NCT05161988|||CASE_CONTROL||PROSPECTIVE|||||||
33819593|NCT01837199|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819594|NCT06720285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819595|NCT05065580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819596|NCT01843699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819597|NCT05150002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819598|NCT05736237|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33819599|NCT06540859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, single-blind, two-arm sham-controlled clinical trial with two arms (tSCS compared to sham-stimulation) and two parts (Part A and Part B). Part A will be conducted while participants are staying in inpatient rehabilitation. Participants will be randomized to either tSCS or sham stimulation. Part B will take place in outpatient rehabilitation medicine and all participants will receive tSCS stimulation for up to 18 sessions.|t|f|f|t
33819600|NCT06149533|RANDOMIZED|PARALLEL||PREVENTION||NONE||A total of 366 patients with cancers who will be assessed as high risk by the thrombosis risk prediction model (refer to Appendix 1) are planned to be enrolled. All patients are planned to undergo anti-tumor chemotherapy and receive CVC or PICC catheterization on the first day of chemotherapy. The patients are randomly divided into the experimental group and the control group at a ratio of 1:1. The experimental group is treated with edoxaban to prevent catheter-related thrombosis, and the control group won't be treated with edoxaban.||||
33819601|NCT01627496|||COHORT||CROSS_SECTIONAL|||||||
33819602|NCT03586440|||OTHER||CROSS_SECTIONAL|||||||
33819603|NCT05791305|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized controlled trial will be used.|t|t|f|t
33819604|NCT05608408|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34048295|NCT03871946|||CASE_CONTROL||PROSPECTIVE|||||||
34048296|NCT05114096|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Multicentre, blinded, pragmatic, 2 arm non-inferiority RCT|t|t|t|t
34048297|NCT05330364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048298|NCT05783297|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The proposed research uses a cluster randomized controlled trial design to evaluate the effectiveness of TXTXT intervention on adherence and viral load suppression at 3- and 6- months post intervention initiation.||||
34149274|NCT03841136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149275|NCT05302362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Prospective, Double Blind, Randomized Controlled Clinical Trial ,||t|t|t|t
34149276|NCT03410342|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33819605|NCT03379909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819606|NCT05347524|||OTHER||PROSPECTIVE|||||||
33819607|NCT03816839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819608|NCT04306445|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819609|NCT05999344|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33819610|NCT04045561|||COHORT||RETROSPECTIVE|||||||
33819611|NCT04618575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819612|NCT04825210|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33819613|NCT06010368|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A double-blind study is one in which neither the participants nor the experimenters know who is receiving a particular treatment. This procedure is utilized to prevent bias in research results. Double-blind studies are particularly useful for preventing bias due to demand characteristics or the placebo effect. In a double-blind study, the investigators who interact with the participants would not know who will receive the actual drug and who will receive a placebo.|patients assigned to the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation. In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.|t|f|f|t
33819614|NCT05963074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819615|NCT06584929|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33819616|NCT03221634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819617|NCT04485793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819618|NCT04968249|||COHORT||PROSPECTIVE|||||||
33819619|NCT05697822|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"This study is open-label as both the participants and study team members will know whether they are in the intervention or control arms. However, the outcomes related to morbidity will be assessed by a masked assessor.~The outcomes such as severe maternal morbidity (SMM), and neonatal adverse outcomes(NAO) will be assessed by a study technical committee member who do not have any knowledge about the arm in which the study participant is allocated. The information about the study arm will be removed from the database when this assessment is being made. Although the criteria for SMM and NAO are generally objective, there might be some need for judgement on the part of the assessors hence masking will avoid biased assessment of outcome."||f|f|f|t
33819620|NCT02294461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819621|NCT00363389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819622|NCT00857311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819623|NCT03751280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819624|NCT05242471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819625|NCT03792841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819626|NCT04370392|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33819627|NCT05254288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Gels concealed|Split-mouth|t|t|t|t
33819628|NCT05478200|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33819629|NCT00672711|||CASE_CONTROL||PROSPECTIVE|||||||
33819630|NCT01448408|||CASE_CONTROL||PROSPECTIVE|||||||
33819631|NCT06437327|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33819632|NCT00553800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819633|NCT06719713|RANDOMIZED|PARALLEL||PREVENTION||NONE||Waitlist control and intervention||||
33819634|NCT06208150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819635|NCT01159756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819636|NCT02020551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819637|NCT02091271|||||OTHER|||||||
33819638|NCT05913999|||COHORT||PROSPECTIVE|||||||
33819639|NCT05186493|NA|SINGLE_GROUP||TREATMENT||NONE||Open label observational study||||
33819640|NCT04453306|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participants, caregivers, researchers and outcome assessors are blinded to the medications participants are receiving. Participants receive pills with identical size, color and taste between the placebo and the active drug.|Double-blind Placebo-controlled Clinical Trial|t|t|t|t
33819641|NCT01642771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819642|NCT06721442|RANDOMIZED|PARALLEL||PREVENTION||NONE|All eligible patients were randomized into two groups using the REDCap software: one group received dapagliflozin combined with optimized medical treatment, while the other group received only the optimized treatment. Each group included 87 patients. To minimize bias in the open-label design, electrocardiograms performed at baseline and at the final visit were evaluated by external independent examiners blinded to group allocation. The Kappa index was used to ensure data consistency and reliability. These measures provided greater rigor and validity to the study results.|Multicenter, randomized, open-label, controlled trial||||
33819643|NCT06047795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819644|NCT03161652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, care providers, and evaluators are blind to treatment allocation. This reduces the risk of bias in the measurement of outcomes, in the decision to modify or discontinue treatment, or to withdraw from trial or from analysis. The monitoring coordinator allocates the treatment.|The study investigates a medication causing hyperprolactinemia (levosulpiride) to treat diabetic retinopathy (DR) and diabetic macular edema (DME). Subjects are from four different populations, those with DME, non-proliferative DR, those undergoing vitrectomy due to proliferative DR, and those with DME plus standard intravitreal antiangiogenic therapy with ranibizumab. Immediately after baseline, each of the four groups are randomly split into two subgroups: one receiving placebo (sugar pill) and the other levosulpiride. Ophthalmologic and health outcomes between groups 1 and 2 (DME: placebo and levosulpiride), 3 and 4 (DR: placebo and levosulpiride), and 7 and 8 (DME plus ranibizumab: placebo and levosulpiride) evaluate the efficacy and safety of the study medication. Comparison of serum and vitreous prolactin levels between the groups undergoing vitrectomy (DR: placebo and levosulpiride) serve as a proof of principle that prolactin enters the eye to counteract disease progression.|t|t|f|t
33819645|NCT03899844|||CASE_CONTROL||PROSPECTIVE|||||||
33819646|NCT06021834|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
33819647|NCT00683371|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33837243|NCT03867162|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33837244|NCT06489106|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837245|NCT04537533|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33837246|NCT00833872|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33837247|NCT06325917|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two arms parallel randomized controlled||||
33837248|NCT05196282|||COHORT||PROSPECTIVE|||||||
33837249|NCT02279940|||COHORT||PROSPECTIVE|||||||
33837250|NCT00903760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840208|NCT00311987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840209|NCT00009659||||TREATMENT||||||||
33819648|NCT05966623|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Single-blinded - The researcher needs to learn before the patient comes to the hospital as VRI needs to be organised. Thus, they will only know if the participants shall be assigned to the intervention or control group after the patient agrees to take part. Double blinding is not feasible as interpreters will not be available 24x7.|"Arm Intervention Experimental VRI sign language interpretation Participants will be welcome from their entry point to the hospital, they will attend a general check-up with a GP or other services and be provided with VRI until they leave Participants will be provided with a Tablet of 14' inches with interrupted VRI in Colombian Sign Language. Professionally accredited Sign language interpreter. At the end of the hospital visit, they will complete a scale measuring Doctor-Patient-Communication~Experimental: primo control Participants get welcome at the entry point of the hospital, they will attend a general check-up with a GP or other services and they are not provided with by the study with VRI Participants get welcome at the entry point of the hospital, they are not provided with VRI. At the end of the hospital visit, they will complete a scale measuring Doctor-Patient-communication"||||
33819649|NCT04206384|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|Single Treatment Group||||
33819650|NCT06299696|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819651|NCT03239353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33819652|NCT01810406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33819653|NCT02440672|||COHORT||PROSPECTIVE|||||||
33819654|NCT06340334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819655|NCT01436045|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33819656|NCT05430347|RANDOMIZED|PARALLEL||TREATMENT||NONE|This study is an open-design, multicenter, randomized controlled prospective clinical study with 80 patients. Subjects will be randomly assigned 1:1.|The treatment regimen of the experimental group was pyrotinib combined with docetaxel, carboplatin and trastuzumab, while the treatment regimen of the control group was pertuzumab combined with docetaxel, carboplatin and trastuzumab (the control group was standard treatment). Surgical treatment was performed after 6 courses of neoadjuvant therapy||||
33819657|NCT03126266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819658|NCT02257853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819659|NCT00701597|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33819660|NCT00927537|||COHORT||PROSPECTIVE|||||||
33819661|NCT06690996|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33819662|NCT03254524|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33819663|NCT02630927|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33819664|NCT01657552|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33819665|NCT02201368|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819666|NCT05740709|||COHORT||PROSPECTIVE|||||||
33819667|NCT01132378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819668|NCT05854160|NA|SINGLE_GROUP||OTHER||NONE||||||
33819669|NCT05959057|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blinded as to order formulations are received in a standard cross-over design with washout phase|double-blinded, randomized cross-over design in a peri-menopausal/menopausal and preferably symptomatic group of women (target population for commercialization) is best suited to demonstrate equivalent tolerability|t|t|t|f
33819670|NCT01264484|||CASE_CONTROL||OTHER|||||||
33819671|NCT04837235|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819672|NCT05582421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"* In this proposed study, both the participant and assessor will be blinded. This is achieved where the outcome assessor will not be informed of the group in which the participant is enrolled for subjective outcomes. The participants will be blinded to the study hypothesis as to which intervention is expected to be better.~* The patients who already do not know their treatment group will assess the level of their post-operative pain.~* The laboratory technician at the microbiological department will not know the treatment group of the patients.~* The treatment groups will remain anonymous at the end of the study during assessment by the statistician."|Trial Design: Randomized Clinical Trial (Parallel Group) Two Arms Allocation Ratio: 1:1 Framework: Superiority|t|f|t|f
33819673|NCT06037057|||COHORT||PROSPECTIVE|||||||
33819674|NCT03982498|||COHORT||PROSPECTIVE|||||||
33819675|NCT04888208|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819676|NCT06077695|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Repeated measurements, control measurements and neuropsychological examinations will be carried out by an examiner blinded to the intervention phase. The rehabilitator will not carry out these assessments. A neuropsychologist from the neuropsychology unit, not involved in the design and conduct of the Meta-SCED study, will carry out these examinations.|Single Case Experimental Design : SCEDs evaluate the effectiveness of an intervention by recruiting a small number of individuals (typically between 1 and 3). They are different from single case studies (or case reports). SCEDs are based on repeated measurements, sequential introduction of the intervention and specific visual and statistical methods of analyzing the results. The strength of SCED lies in the large number of repeated measurements and not in the number of subjects included.|f|f|t|f
33819677|NCT05866471|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33819678|NCT06585553|||COHORT||PROSPECTIVE|||||||
33819679|NCT05157464|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, randomized, controlled, open label, parallel two-arm design, single-center study to compare the use of losartan in the prevention of stiffness following total knee arthroplasty.||||
33819680|NCT01725087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819681|NCT06422559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819682|NCT05923554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||After non-randomization, patients were assigned to a group with un-congruous single-tooth prostheses and a group with congruous single-tooth prostheses. Patients received a one-stage full-mouth scaling without chlorhexidine. Clinical and microbiological examination was performed at baseline, after 1, 2, and 3 months.||||
33819683|NCT03045289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819684|NCT03435510|NA|SINGLE_GROUP||OTHER||NONE||||||
33819685|NCT05954780|||CASE_ONLY||PROSPECTIVE|||||||
33819686|NCT03371849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837251|NCT04516005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The statistical analysis investigator was blinded to the randomization group|a single-center randomized clinical trial|f|f|t|f
33837252|NCT01904942|||COHORT||RETROSPECTIVE|||||||
34048299|NCT03834636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This study is a prospective randomized clinical trial, triple-blind, (patients, investigator and clinical evaluator) with parallel groups. After completing the ICDAS (International Caries Detection and Assessment), clinical occlusal stress examination and questionnaire application on occlusal stress, patients will be randomly divided into two types of dental adhesives and two types of composite resin. Randomization will be stratified according to the risk of caries determined by the ICDAS and the type of cavity to be filled. Operators (Master students and undergraduate students from the last year of the School of Dentistry, Federal University of Pelotas) will place the restorations supervised by highly trained clinicians.|t|f|t|t
34048300|NCT00557011|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34048301|NCT04214561|||COHORT||PROSPECTIVE|||||||
33819687|NCT04457583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Controlled and randomized clinical trial involving 70 patients with OSAHS diagnosed by polysomnography. Measurements of maximal inspiratory pressure (MIP) will be performed. Pittsburgh scale Epworth, Sleepiness Scale, Short Form-36, and Berlin / Stanford questionnaires will be used for assessment of sleep quality, daytime sleepiness, health related quality of life quality of health (QOL), and the evaluation of snoring. Patients of the intervention group will undergo IMT with an initial load of 40% of MIP. The intervention will be performed daily for 12 weeks employing the exercise inspiratory device (POWERbreathe, HaB Ltd, UK). The main end point will be the effect of the training program on the index of apnea / hypopnea (IAH) assessed by polysomnography. Secondary end points will include effects of the training program on: the quality of sleep, inspiratory muscle strength, the health related QOL|t|f|f|t
33819688|NCT05746676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33819689|NCT06379451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819690|NCT05489003|||CASE_CONTROL||PROSPECTIVE|||||||
33819691|NCT04743284|||CASE_ONLY||PROSPECTIVE|||||||
33819692|NCT02599077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33819693|NCT04542109|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Dyads will be randomized (assigned by chance) to one of two groups: 1) READyR A or 2) READyR B (Wait List Control).||||
33819694|NCT02268526|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33819695|NCT06416189|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The two groups will have lingual arches. However, patients without braces will not be informed about their braces before 5 months of trial initiation.|Two groups; one with fixed braces and one without fixed braces.|t|f|f|t
33819696|NCT05074004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the envelope method, 15 envelopes with '1' symbolizing the intervention group and 15 envelopes with '2' symbolizing the control group were found in the box. All individuals pulled envelopes out of the box, and the envelope was not put in the box again. During the psychoeducation process, one patient from the experimental group did not want to continue the training, and one patient from the control group was hospitalized; two patients were excluded from the sample.The pretest evaluation was made in the first interview with the individuals included in the sample. Posttest evaluation was made at the end of the intervention to the individuals in the intervention group. No intervention was applied to the control group in this process. Posttest evaluation was made at the end of the 8th week following the pretest evaluation to the control group. After all evaluations were completed, a single-session informative training was given to the control group.|The research is a single-blind randomized controlled experimental study|t|f|f|f
33819697|NCT02515500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819698|NCT05819580|||CASE_CROSSOVER||PROSPECTIVE|||||||
33819699|NCT00001623|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819700|NCT04335383|||CASE_ONLY||PROSPECTIVE|||||||
33819701|NCT05921929|NA|SINGLE_GROUP||OTHER||NONE||||||
33819702|NCT03142893|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|3 of the 4 conditions are masked by use of identical injections and pills. However one condition (adrenal testis) is not masked. Hence the study is partially masked.|Blood is sampled every 10 minutes from 4PM to 9PM for future mathematical deconvolution in order to determine hormone pulse characteristics in response to the clamp conditions. These values are the primary endpoints.|t|f|t|t
33819703|NCT01579461|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819704|NCT03597997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will not be aware of the type of anaesthesia they will receive. A separate blinded investigator will assess the patients after the operation. The anaesthetist providing general anaesthesia will be aware of the allocation, but s/he will not be involved in data collection.|Patients in one group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. The patients in the second group (P) will be anaesthetized using total intravenous propofol.|t|f|t|f
33819705|NCT02832453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819706|NCT06030999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34048302|NCT01882114|||COHORT||PROSPECTIVE|||||||
34048303|NCT02112357|||COHORT||PROSPECTIVE|||||||
34048304|NCT06685341|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Single dose, four-cycle crossover|t|f|t|f
34048305|NCT01202942|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048306|NCT02418390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048307|NCT02981576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048308|NCT02600468|||COHORT||PROSPECTIVE|||||||
34048309|NCT02130089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048310|NCT06382194|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34048311|NCT01786421|||COHORT||RETROSPECTIVE|||||||
34048312|NCT06683417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048313|NCT01198561|||CASE_ONLY||PROSPECTIVE|||||||
34048314|NCT03742089|||CASE_ONLY||PROSPECTIVE|||||||
34048315|NCT03161743|||COHORT||PROSPECTIVE|||||||
34048316|NCT01738503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048317|NCT05961072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048318|NCT06287476|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048319|NCT06017466|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||This will be a prospective interventional study with the Dutch VVAS questionnaire as interventional product.||||
34048320|NCT02257645|||COHORT||PROSPECTIVE|||||||
34048321|NCT00387855|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34048322|NCT00384839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048323|NCT04251793|||COHORT||CROSS_SECTIONAL|||||||
34048324|NCT02643758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819707|NCT04792541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33819708|NCT01870687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819709|NCT01899183|||CASE_ONLY||PROSPECTIVE|||||||
33819710|NCT03151161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819711|NCT03869541|||COHORT||PROSPECTIVE|||||||
33819712|NCT03252899|||OTHER||PROSPECTIVE|||||||
33819713|NCT01482819|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33819714|NCT01891006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819715|NCT03071900|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33819716|NCT02798861|||COHORT||PROSPECTIVE|||||||
33819717|NCT05212233|||CASE_ONLY||PROSPECTIVE|||||||
33819718|NCT02375607|NA|SINGLE_GROUP||SCREENING||NONE||||||
33819719|NCT01299441|||CASE_ONLY||PROSPECTIVE|||||||
33819720|NCT06313099|||CASE_ONLY||CROSS_SECTIONAL|||||||
33819721|NCT02446912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819722|NCT03153878|||COHORT||PROSPECTIVE|||||||
33819723|NCT02916524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819724|NCT06285058|||COHORT||RETROSPECTIVE|||||||
33819725|NCT05603546|||CASE_CROSSOVER||PROSPECTIVE|||||||
33819726|NCT04240418|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33819727|NCT06545045|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcomes assessors will be blinded to participant study group assignment.||f|f|f|t
33819728|NCT00276016|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33819729|NCT03110432|||COHORT||PROSPECTIVE|||||||
33819730|NCT01332318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819731|NCT05248269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819732|NCT00525915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819733|NCT01078376|NON_RANDOMIZED|PARALLEL||||NONE||||||
33819734|NCT00471549|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819735|NCT01239225|NA|SINGLE_GROUP||DIAGNOSTIC||||||||
33819736|NCT00015171||PARALLEL||TREATMENT||DOUBLE||||||
33819737|NCT06095817|RANDOMIZED|PARALLEL||PREVENTION||NONE||One group will receive an opportunity to engage with a personalized internet-delivered brief intervention (IDBI) and the second group will not be granted access. This IDBI will serve as a second booster intervention for half o those randomized into the treatment condition. For the other half randomized into the treatment condition, this IDBI will serve as an initial intervention coming 12 months after separation from the military.||||
33819738|NCT05362253|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819739|NCT02045745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819740|NCT05401669|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33819741|NCT01244399|||CASE_ONLY||CROSS_SECTIONAL|||||||
33819742|NCT02438410|||COHORT||PROSPECTIVE|||||||
33819743|NCT03953378|||COHORT||PROSPECTIVE|||||||
33819744|NCT03366987|||OTHER||CROSS_SECTIONAL|||||||
33819745|NCT01033097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819746|NCT04624074|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33819747|NCT04620681|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819748|NCT00302588|||NATURAL_HISTORY||RETROSPECTIVE|||||||
33819749|NCT05812547|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be an open label parallel group 1:1 randomized-controlled trial.||||
33819750|NCT00605384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819751|NCT04229706|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819752|NCT02074865|||COHORT||PROSPECTIVE|||||||
33819753|NCT04829175|||COHORT||PROSPECTIVE|||||||
33819754|NCT00979277|||COHORT||PROSPECTIVE|||||||
34048325|NCT03287635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048326|NCT06242392|||COHORT||CROSS_SECTIONAL|||||||
33819755|NCT03998423|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single dose of 30 capsules (22.5g) of oral FMT will be given once (week 0), twice (week 0 and week 8), or three times (week 0, week 8, and week 24). Participants are randomly assigned to 1, 2, or 3 doses of FMT.||||
33819756|NCT00958633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819757|NCT05579444|||OTHER||PROSPECTIVE|||||||
33819758|NCT00788632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33819759|NCT02899676|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33819760|NCT01219153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819761|NCT05294380|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33819762|NCT05434533|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33819763|NCT02595593|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819764|NCT02080143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819765|NCT02416973|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819766|NCT05271799|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an open-label study|This is a two periods, crossover study||||
33819767|NCT00685347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819768|NCT03924232|||COHORT||PROSPECTIVE|||||||
33819769|NCT04252794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819770|NCT00201214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819771|NCT02115542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819772|NCT03023878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819773|NCT04108208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819774|NCT00788671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819775|NCT01854372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819776|NCT03426332|||COHORT||PROSPECTIVE|||||||
33819777|NCT05716971|||CASE_CONTROL||RETROSPECTIVE|||||||
33819778|NCT06156488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819779|NCT02278822|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819780|NCT01562288|||CASE_ONLY||RETROSPECTIVE|||||||
33819781|NCT03581344|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The Patients included in the study will undergo a chemoradiotherapy neoadjuvant treatment.~Patients will undergo a clinical-instrumental restaging at 7-8 weeks and will be randomized in two groups in case of major or complete response:~1. Surgery 9-11 weeks after the end of neoadjuvant treatment~2. Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy."||||
33819782|NCT04771624|||COHORT||PROSPECTIVE|||||||
33819783|NCT00490243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819784|NCT04096261|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33819785|NCT05324384|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819786|NCT03677102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819787|NCT04827602|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33819788|NCT06057532|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study drink powders will be measured and assigned a code by study staff that will not dispense the study drink powders to participants.|The study is a randomized, double-blinded, clinical trial that will provide a starch or standard sports drink at least 2 hours before surgery to evaluate perioperative glycemic variability. Patients will be randomized and have a 50/50 chance of getting one of the two drinks being studied.|t|t|t|t
33819789|NCT02127892|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819790|NCT01469429|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819791|NCT05516836|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized clinical trial will be conducted between March 2023 and November 2024 in 62 male and female patients impacted by post-COVID-19 musculoskeletal symptoms who will undergo a multicomponent rehabilitation program, together with an intervention and a follow-up using programmed telemedicine sessions.||||
33819792|NCT06328322|||CASE_ONLY||PROSPECTIVE|||||||
33819793|NCT05642663|||OTHER||OTHER|||||||
33819794|NCT02032134|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819795|NCT02085590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819796|NCT04264416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants conducting the assessments and/or analyzed the data are unaware if the status of the participants (WB-EMS vs control) and were not allowed to ask correspondingly||f|f|f|t
33819797|NCT04983147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33819798|NCT01358175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819799|NCT02177058|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33819800|NCT02640326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819801|NCT03600506|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
33819802|NCT04282200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819803|NCT01075607|||CASE_ONLY||PROSPECTIVE|||||||
33819804|NCT00003116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819805|NCT04640376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind. Participants, Investigators, and all persons involved in the conduct, data management, and analysis of the study will be fully blind to the participant's treatment.||t|f|t|f
33819806|NCT01812707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819807|NCT01124916|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819808|NCT05199701|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33819809|NCT01685307|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819810|NCT00000940|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819811|NCT02548052|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33819812|NCT02332096|||COHORT||PROSPECTIVE|||||||
33819813|NCT04546360|||COHORT||PROSPECTIVE|||||||
33819814|NCT03441789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33819815|NCT02627534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819816|NCT02014298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819817|NCT06720870|||COHORT||RETROSPECTIVE|||||||
33819818|NCT01330875|||CASE_ONLY||PROSPECTIVE|||||||
33819819|NCT05631379|||COHORT||RETROSPECTIVE|||||||
33819820|NCT01179659|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819821|NCT01193088|||COHORT||PROSPECTIVE|||||||
33819822|NCT02390752|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819823|NCT00711776|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819824|NCT01493947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33819825|NCT00391521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819826|NCT02369705|||CASE_ONLY||PROSPECTIVE|||||||
33819827|NCT04301843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819828|NCT00072826||||TREATMENT||||||||
33819829|NCT05483192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To maintain double-blinding, in addition to the contents mentioned in the production/packaging and labeling of the products used in the human study, the allocation details of unique codes (information on blinding) for each group will be managed in a sealed state by the principal investigator. Except in cases where it is unavoidably necessary to read the code due to the occurrence of a serious adverse drug reaction\*, it will not be disclosed until the end of the human study. In this human study, no unblinding will occur during the study. The investigator will supply the investigational products that match the randomization code assigned to the selected subject, and maintain blinding by using an extra (by unique code) when the investigational product is defective or damaged.|12-week randomized, double-blind, placebo-controlled trial with subjects administered 400 mg per day of Dyglomera|t|t|f|f
33819830|NCT00100945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819831|NCT02316145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819832|NCT03547648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819833|NCT06030258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819834|NCT00278395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819835|NCT01425541|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819836|NCT03701581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized placebo-controlled trial of 4AP vs placebo for nerve injury|t|t|t|t
33819837|NCT05667688|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819838|NCT02388399|||CASE_ONLY||PROSPECTIVE|||||||
33819839|NCT02896218|||COHORT||OTHER|||||||
33819840|NCT06524960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Subjects will be randomized to receive denosumab (Prolia) or normal saline placebo. Study treatment assignment will be blinded to study participants and investigators using a modified double-blind approach described below. The statistician at the primary site and the Research Pharmacist and Study Nurse administering denosumab (Prolia)/placebo at each site will know the treatment assignment and no disclosure of treatment will be allowed.||t|t|t|f
33819841|NCT03612999|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34048327|NCT06683573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33819842|NCT06687616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33819843|NCT02494076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819844|NCT00386802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819845|NCT00916162|||CASE_ONLY||PROSPECTIVE|||||||
33819846|NCT02978235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048328|NCT01782625|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34048329|NCT01672710|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot||||
34048330|NCT06682429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients are randomized to TR + usual care or usual care alone|f|f|f|t
34048331|NCT03033498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048332|NCT06373393|||COHORT||RETROSPECTIVE|||||||
34048333|NCT06685367|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34048334|NCT00543088|||||PROSPECTIVE|||||||
34048335|NCT02173678|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34048336|NCT06496854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127350|NCT06485726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either lacosamide or propranolol from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labelled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included valproate, and Drug B included propranolol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B.|We will assess The number of migraine days after three months of treatment and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. Treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.|f|f|t|t
34127351|NCT01871545|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127352|NCT02432781|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127353|NCT04951219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Select patients will be randomized in 1:1 manner to a double-blind, 12-week lead-in treatment period. Only investigators, patients, and the Sponsor will be blinded to treatment assignment during the double-blind treatment period.||t|t|t|f
34127354|NCT02656394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127355|NCT03722381|||COHORT||PROSPECTIVE|||||||
34127356|NCT01324960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127357|NCT05882760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127358|NCT00697528|||CASE_CONTROL||PROSPECTIVE|||||||
34127359|NCT01480726|||COHORT||PROSPECTIVE|||||||
34127360|NCT05892991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be allocated to groups by a researcher not involved in assessment or treatment (AAI). Permuted blocks generated using http://www.randomization.com/ were used for the allocation to assure equal and random allocation. Randomization codes were kept confidential in sealed opaque envelopes and sequentially numbered to ensure concealed allocation.|4 arms will receive treatment for 4 weeks|t|f|f|t
34127361|NCT05672940|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34127362|NCT00921115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127363|NCT05266846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127364|NCT02649452|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127365|NCT03538886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical outcomes will be assessed by an independent event committee with no knowledge of treatment allocation.|1:1 randomized clinical trial|f|f|f|t
34127366|NCT00657137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127367|NCT02413476|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127368|NCT06119516|NA|SINGLE_GROUP||OTHER||NONE||||||
34127369|NCT00276068|RANDOMIZED|PARALLEL||||DOUBLE||||||
34127370|NCT04650230|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34127371|NCT06524271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Same appearance of the supplements given. Identity of participant was masked during examination.||t|f|t|f
34127372|NCT03700164|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||It is anticipated that 32 participants will enrol in the study. Specifically, 16 participants will be healthy individuals and the other 16 will be individuals with impaired fasting glucose (5.6 mM to 6.9 mM) and/or blood glucose values 7.8-11.0 mM 2h after glucose drink consumption during the OGTT in screening. Initially, the study will investigate the effect of the cold exposure on healthy individuals, and then depending on the results in these individuals, the intervention may be tested on participants with impaired glucose metabolism.||||
34127373|NCT01681667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34127374|NCT03112291|NA|SINGLE_GROUP||TREATMENT||NONE||This investigation is a longitudinal prospective interventional study of a series of cases||||
34127375|NCT06397859|||COHORT||OTHER|||||||
34127376|NCT04342676|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127377|NCT05508178|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34127378|NCT04888416|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Interrupted time series||||
34127379|NCT01698931|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127380|NCT06266026|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|t|f|f
33819847|NCT03204045|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33819848|NCT02952235|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33819849|NCT00574301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048337|NCT03486158|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048338|NCT04024540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819850|NCT05271305|||COHORT||CROSS_SECTIONAL|||||||
33819851|NCT03108222|||OTHER||PROSPECTIVE|||||||
33819852|NCT01825785|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34048339|NCT02089711|||COHORT||PROSPECTIVE|||||||
34048340|NCT01068730|RANDOMIZED|CROSSOVER||||NONE||||||
33819853|NCT05971758|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819854|NCT04729361|||CASE_ONLY||RETROSPECTIVE|||||||
33819855|NCT05958784|NA|SINGLE_GROUP||OTHER||NONE||||||
33819856|NCT02137928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819857|NCT06350799|||CASE_ONLY||PROSPECTIVE|||||||
33819858|NCT03160859|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This will be a multi-VA site, prospective RCT to compare different methods with 2 arms to determine which is less painful: water alone or water plus cap. Randomization will be based on computer generated random numbers placed inside opaque sealed envelopes. The envelope will be opened to reveal the code when the colonoscopist is ready to insert the endoscope to begin the examination. Patients who are willing to participate will sign an informed consent before starting the colonoscopy procedure. Separate parallel randomization will be set up at each site. Control Method: Involves unsedated colonoscopy with water exchange. Residual air will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion. Study method: Involves unsedated colonoscopy with water exchange and the addition of a commercially available accessory fitted onto the colonoscope.|t|f|f|f
33819859|NCT04917068|||CASE_CONTROL||RETROSPECTIVE|||||||
33819860|NCT01156922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819861|NCT01686256|NA|SINGLE_GROUP||OTHER||NONE||||||
33819862|NCT04248049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Split mouth design allowing to evaluate two conditions in the same patients|Randomized clinical trial (RCT) (Interventional)|t|t|t|t
33819863|NCT03999710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819864|NCT05152706|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33819865|NCT04623671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Syringes (60-mL) with amber film-covered barrels||t|f|t|f
33819866|NCT06584747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33819867|NCT01874522|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33819868|NCT03811483|||COHORT||OTHER|||||||
33819869|NCT00768716|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819870|NCT06407973|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled open label||||
33819871|NCT03797417|||CASE_CONTROL||PROSPECTIVE|||||||
33819872|NCT04404699|||COHORT||OTHER|||||||
33819873|NCT01876719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819874|NCT02225340|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33819875|NCT00218075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33819876|NCT05148247|NA|SINGLE_GROUP||TREATMENT||NONE|Participants are randomized to three different baseline-lengths in each tier, that serve as control data in this design. Blinding is not possible for the conducting OT, but an independent PRPP-trained OT assesses 20 % of the PRPP stage 1 and 2 measurements from each phase by videotaping the assessment situations. The tapes will be presented blinded and randomly for this second and blinded assessor.|Single-Case Experimental Designs with Multiple baselines across participants. At least five data collection points within 4 phases (= at least 20 data points) for each participant (= one tier), and a minimum of three participants (= one sample), is recommended to meet design quality standards. The 'Number of Arms' will in this tradition mean one tier. Data for at least 2 samples will be collected, each of 3 tiers.||||
33819877|NCT05855499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819878|NCT03148301|||COHORT||PROSPECTIVE|||||||
33819879|NCT02250911|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33819880|NCT02879669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819881|NCT02025023|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819882|NCT02660047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819883|NCT00767585|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048341|NCT06680687|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"A caregiver control group of 50 participants receiving usual care will be recruited and sequentially, 50 caregivers will be included in the intervention group. Because follow-up adherence is also time-dependent (the risk of non-adherence increases with time), the investigators reasoned that the Educational Program should be delivered before completion of treatment, to prevent survivors getting lost to follow-up before receiving the intervention.~Healthcare provider training will be provided to at least 75 percent of the healthcare providers that match the inclusion criteria and timing of the training will be determined by availability. The Follow-Up Form will be used to document late effects in all survivors that attend the outpatient clinic, regardless enrollment in the Educational Program."||||
34048342|NCT05162625|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048343|NCT00882778|||CASE_ONLY||RETROSPECTIVE|||||||
34048344|NCT06312826|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34048345|NCT00949403|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34048346|NCT02731937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048347|NCT01152346|RANDOMIZED|CROSSOVER||||NONE||||||
34048348|NCT02644863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048349|NCT01496963|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048350|NCT02217410|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34048351|NCT04913688|||CASE_ONLY||PROSPECTIVE|||||||
34048352|NCT00312260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819884|NCT04676672|||COHORT||PROSPECTIVE|||||||
33819885|NCT04761614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819886|NCT00355771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819887|NCT02419040|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33819888|NCT06009770|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Trial intervention will not be blinded for clinicians or patients due to its nature. Conversely, clinical endpoints and data collection from clinical/psychological questionnaires will be blinded to examiners/assessors. The statistician conducting the data analysis will be masked for the group allocation|This study is designed as a single-blinded, randomized, two-treatment arms controlled clinical trial|f|t|t|t
33819889|NCT02261519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819890|NCT05306613|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33819891|NCT04367948|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33819892|NCT01039116|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33819893|NCT00525642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819894|NCT05763121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048353|NCT00765518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048354|NCT05687136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048355|NCT05684575|NA|SINGLE_GROUP||OTHER||NONE||||||
34048356|NCT05405088|NA|SINGLE_GROUP||SCREENING||NONE||This is a collection of data from postoperative questionnaires and simple, non-invasive clinical observations. The oral surgery acts in question are performed in daily practice without any change in patient management. The intraoperative data collected come from routine care. Postoperative data (pain and analgesic intake) are collected by self-questionnaires and no visit on purpose is required.||||
34048357|NCT03033862|||COHORT||PROSPECTIVE|||||||
34048358|NCT01903967|||CASE_CONTROL||RETROSPECTIVE|||||||
34048359|NCT01196156|||COHORT||PROSPECTIVE|||||||
34048360|NCT02609607|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048361|NCT04180852|||COHORT||PROSPECTIVE|||||||
34048362|NCT05401019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34048363|NCT00099684|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34048364|NCT01661829|||COHORT||PROSPECTIVE|||||||
34048365|NCT04670874|||COHORT||PROSPECTIVE|||||||
34048366|NCT00749307|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34127381|NCT04169646|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|"A senior bio-statistician blinded to the identity of individuals will randomise clusters to a sequence within the period of data collection when clusters change from the control to the intervention condition (group 1 to 3).~The outcome assessors of the physical examination will be blinded to group allocation and previous test results of the participants."|This study is a stepped wedge cluster-randomized controlled trial.|f|f|f|t
34127382|NCT06288633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127383|NCT04901663|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Control Trial||||
34127384|NCT03631381|||COHORT||RETROSPECTIVE|||||||
34127385|NCT03288454|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34127386|NCT01303952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127387|NCT01698203|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34127388|NCT03440567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127389|NCT02556281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127390|NCT03699566|||OTHER||OTHER|||||||
34127391|NCT02748876|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34048367|NCT03724747|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127392|NCT03620032|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, non-blinded, randomised two cohorts study||||
34127393|NCT06273566|||COHORT||PROSPECTIVE|||||||
34127394|NCT06377280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127395|NCT02357199|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34127396|NCT06289946|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34127397|NCT05530902|NA|SINGLE_GROUP||TREATMENT||NONE||Cohort study||||
34127398|NCT03644810|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The participants are blind to the study hypothesis and therefore the expected outcome of the tests performed|The study has a cross-sectional design and includes individuals (males and females) with and without chronic low back pain into two, equally large groups|t|f|f|f
34127399|NCT00553410|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127400|NCT00813579|||CASE_ONLY||PROSPECTIVE|||||||
34127401|NCT05120583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127402|NCT03974932|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127403|NCT03187405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To minimize bias, the randomization and the treatment from V0 to the end of treatment will be performed by the local intensivist designed as investigator. The follow-up until day 4 (V1) to 6 months (V4), so the judgement criteria will be collected by the local neurosurgeon designed as investigator, who will be blinded to the treatment received.|We plan to perform a pragmatic randomized controlled trial: compare the standard of care, i.e. the EVD alone, to the experimental treatment, i.e. IVF. As the standard treatment does not include injection within the EVD, the trial will not include injection through the EVD in the control group, so the trial will have an open design.|f|f|f|t
34127404|NCT01206140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127405|NCT05534477|||COHORT||PROSPECTIVE|||||||
34127406|NCT00986791|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127407|NCT01136525|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127408|NCT00572416|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127409|NCT06343272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127410|NCT00752921|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34127411|NCT03632707|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127412|NCT01393795|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34048368|NCT01663090|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048369|NCT03458806|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048370|NCT01092091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048371|NCT04398082|||COHORT||PROSPECTIVE|||||||
34127413|NCT04683406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127414|NCT04014894|NA|SINGLE_GROUP||TREATMENT||NONE||This study was a single-center, open-label, single-arm, non-randomized,3+3 dose escalation clinical trial.18 patients are separated into 9 leukemia and 9 lymphoma. Each disease has 3 groups by infusion dose level. Each dose group has 3 patients.If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.||||
34149277|NCT03288363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|the operator enters in the tDCS apparatus the code number of the kind of stimulation to deliver; This code number has been randomly assigned, and the correspondence list is not accessible by the different research professionals.|sham versus stimulation|t|t|t|t
34048372|NCT05364281|||CASE_ONLY||PROSPECTIVE|||||||
34149278|NCT04043481|||COHORT||PROSPECTIVE|||||||
34149279|NCT03477058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149280|NCT04330781|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149281|NCT04336527|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigators per study site as well as outcome assessor have no insight on group allocation|Multicentric, randomised-controlled trial (block randomisation stratified by study site)|f|f|t|t
33819895|NCT06646068|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||The study evaluated the effectiveness of the Philips 66 brainstorming technique integrated with case-based learning to enhance clinical judgment competence in nursing students. Using a true experimental pre-test/post-test design, 60 students were randomly assigned to intervention and control groups. Both groups were exposed to the same clinical case scenarios, but the intervention group participated in Philips 66 sessions. The process included individual reflection (6 minutes) on clinical judgment and disaster triage protocols, followed by 6-minute group brainstorming sessions to collaboratively refine ideas. Group leaders then presented their nursing care plans within a 6-minute timeframe. The model aimed to foster critical thinking, collaboration, and clinical decision-making skills. The Lasater Clinical Judgment Rubric (LCJR) was used for evaluation.||||
33819896|NCT03534141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33819897|NCT06646146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819898|NCT04816435|||COHORT||PROSPECTIVE|||||||
33819899|NCT00229190|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33819900|NCT02211508|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819901|NCT06247761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single centre, parallel, two group, randomised control trial|t|f|f|f
33819902|NCT02650453|||||RETROSPECTIVE|||||||
33819903|NCT06720194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819904|NCT00977340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819905|NCT00003588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149282|NCT02054884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149283|NCT02698722|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33819906|NCT05774418|||COHORT||RETROSPECTIVE|||||||
33819907|NCT03435939|NA|SINGLE_GROUP||OTHER||NONE||||||
33819908|NCT05704465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819909|NCT02326740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819910|NCT01604499|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819911|NCT03216915|||COHORT||PROSPECTIVE|||||||
33819912|NCT04711018|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33819913|NCT00896389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819914|NCT05966545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819915|NCT06071715|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All individuals will be masked to treatment with the exception of the anesthesiologist administering the procedure who will choose which probe to use: the functional or sham. Of note, this individual could not be masked to treatment since the cryoneurolysis ice ball is visualized on ultrasound; and, the practitioner would see a lack of ice ball formation for the sham probes.|The primary endpoint at 1 month following the initial treatment will utilize a parallel group study design; however, an optional crossover is offered to subjects between 4-6 months following the initial treatment.|t|t|t|t
33819916|NCT03754686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819917|NCT03360227|||OTHER||PROSPECTIVE|||||||
33819918|NCT00672347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819919|NCT05315817|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-comparative, multi-centre, open-label, interventional, post market clinical follow-up (PMCF) study||||
33819920|NCT06647108|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819921|NCT06345924|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819922|NCT03460444|NA|SINGLE_GROUP||OTHER||NONE||All participants complete the supplementation condition.||||
33819923|NCT00586807|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33819924|NCT03643770|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||4 randomized groups: Acute Intermittent Hypoxia (AIH) treatment, AIH in combination with upper extremity training, Sham AIH therapy in combination with upper extremity training and Sham AIH therapy|t|f|f|t
33819925|NCT02596542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819926|NCT05119231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, parallel group, sham-controlled and double-blinded multicenter trial|t|t|t|t
33819927|NCT03613454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819928|NCT06269900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33819929|NCT00337922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819930|NCT04238130|||COHORT||PROSPECTIVE|||||||
33819931|NCT05057767|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33819932|NCT06369987|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33819933|NCT04905771|||COHORT||PROSPECTIVE|||||||
33819934|NCT05376735|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819935|NCT00511147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819936|NCT04671654|||OTHER||PROSPECTIVE|||||||
33819937|NCT00005908|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819938|NCT04173273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819939|NCT03322475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819940|NCT06149338|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33819941|NCT00781209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149284|NCT00491608|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149285|NCT02703688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819942|NCT03865940|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33819943|NCT06108752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33819944|NCT06646900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This will be a randomized controlled trial to evaluate the feasibility and acceptability of delivering a new intervention. Participants who meet the inclusion criteria will be randomly allocated to intervention or control groups in a 1:1 ratio.||||
33819945|NCT04463888|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33819946|NCT05566626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Alle participants, both healthy subjects and patients, receive the same intervention: hyperspectral image with Mantis Photonics camera||||
33819947|NCT00533182|||COHORT||PROSPECTIVE|||||||
33819948|NCT00739024|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33819949|NCT05057078|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33819950|NCT05567224|||OTHER||PROSPECTIVE|||||||
33819951|NCT03470701|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33819952|NCT02633345|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34127415|NCT04081662|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This study uses a design known as a microrandomized trial. Whereas a multi-arm trial randomizes a subject to an intervention group only once at the start of the study, a microrandomized trial repeatedly randomizes a subject to an intervention group throughout the study. In addition to an overall effect of an intervention on proximal outcomes, a microrandomized trial allows one to determine if the effect is modified by momentary factors (e.g., current mood, day of the week, day in the study).~For the present study, every subject has a equal chance of being assigned to one of two intervention groups at each of 84 time points (2 daily x 42 days). At each time point, the two intervention groups are to either receive a prompt based on Acceptance and Commitment Therapy (ACT) or not receive such a prompt. Regardless of the assigned group, subjects are asked to assess their mood, stress, and activity at every time point prior to assignment to intervention group."||||
34127416|NCT04801485|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The random number table is compiled by the investigator who is specially responsible for grouping and saved. The investigator packaged and coded drugs according to random number table, and recorded. The packaged and numbered drugs are stored in the enrollment office.~When the participants meet the inclusion criteria by care providers (doctors), the enrollment office generates a random number for each subject. The participants received the package of drugs according to their random number, and the random number was recorded in the record book.~If there are adverse events or the subjects request to withdraw from the trial, the investigator should uncover the blind."||t|t|f|f
34127417|NCT04565912|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34127418|NCT00858325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127419|NCT02550444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34127420|NCT03053557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants who conduct assessments with participants will be blinded as to whether participants have been assigned to the intervention or control group.|Convergent parallel mixed methods|f|f|f|t
34127421|NCT05302895|||CASE_ONLY||PROSPECTIVE|||||||
34127422|NCT00161915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34127423|NCT04826263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127424|NCT05849350|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34127425|NCT04220580|NA|SINGLE_GROUP||OTHER||NONE||Case-control study||||
34127426|NCT01795976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127427|NCT05113199|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127428|NCT01009905|||CASE_ONLY||PROSPECTIVE|||||||
34127429|NCT02014662|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127430|NCT05272722|||COHORT||PROSPECTIVE|||||||
34127431|NCT04643366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127432|NCT02345616|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127433|NCT04404101|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34127434|NCT05010070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127435|NCT01696773|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34127436|NCT06374888|NA|SINGLE_GROUP||TREATMENT||NONE||Her2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastases||||
34127437|NCT03497273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127438|NCT02103062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127439|NCT02630069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127440|NCT02031003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127441|NCT02727816|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34127442|NCT01440114|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34127443|NCT03731052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127444|NCT01290042|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34127445|NCT01899638|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127446|NCT05096637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34127447|NCT05936957|||COHORT||PROSPECTIVE|||||||
34127448|NCT06554119|||COHORT||RETROSPECTIVE|||||||
34127449|NCT00292045|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127450|NCT00400517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127451|NCT01269554|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34127452|NCT06084533|||OTHER||PROSPECTIVE|||||||
34127453|NCT02044029|||CASE_CONTROL||PROSPECTIVE|||||||
34127454|NCT04746664|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|Masking will not be possible due to the nature of the study.|The study design will be single-group pretest-posttest quasi-experimental (QE) design. The one-group pretest-posttest design is the QE design typically used when testing knowledge acquisition following a teaching project. Quasi-experimental studies use experiments that do not randomly assign interventions to assess the association between interventions and outcomes. The main advantage of QE studies is that they are cheaper and require less resources than randomized controlled trials (RCT). When randomization is considered unethical or unfeasible, QE research is appropriate.||||
34127455|NCT02832102|||COHORT|||||||||
34127456|NCT03005236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127457|NCT00004744|RANDOMIZED|||TREATMENT||DOUBLE||||||
34127458|NCT04998500|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"This study aims to uncover physiological in vivo effects of growth hormone (GH). The intervention with GH and Pegvisomant will therefore be used as tools to activate a well-known physiological response.~Participants are randomized to receive either control intervention first and then GH intervention, or GH intervention first and then control intervention."|t|f|f|f
34127459|NCT00532311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127460|NCT05218941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127461|NCT03268408|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34127462|NCT02589197|||CASE_CONTROL||PROSPECTIVE|||||||
34127463|NCT00703963|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34127464|NCT03266744|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The reporting radiologist of the WB-MRI will be blinded to the results of the CT. The reporting radiologist of the CT will also be blinded to the results of the WB-MRI. Neither treating clinicians nor patients will be blinded at any point.||f|f|f|t
34127465|NCT02295358|||COHORT||PROSPECTIVE|||||||
34127466|NCT05492539|||COHORT||RETROSPECTIVE|||||||
34127467|NCT01960283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149286|NCT03695952|||COHORT||PROSPECTIVE|||||||
34149287|NCT02554708|||COHORT||PROSPECTIVE|||||||
33819953|NCT02648061|||COHORT||PROSPECTIVE|||||||
33819954|NCT01116830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33819955|NCT04861571|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819956|NCT01599455|||COHORT||PROSPECTIVE|||||||
33819957|NCT02078778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819958|NCT02153216|||COHORT||CROSS_SECTIONAL|||||||
33819959|NCT00599599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33819960|NCT06647953|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33819961|NCT02332122|||CASE_CONTROL||PROSPECTIVE|||||||
33819962|NCT06055400|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33819963|NCT06102005|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33819964|NCT01827176|||CASE_ONLY||RETROSPECTIVE|||||||
33819965|NCT01592565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048373|NCT00875108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048374|NCT01381757|||||PROSPECTIVE|||||||
34048375|NCT02424630|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34048376|NCT05922891|||COHORT||PROSPECTIVE|||||||
34048377|NCT02577120|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048378|NCT01514058|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048379|NCT02324387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048380|NCT00187681|NON_RANDOMIZED|PARALLEL||||NONE||||||
34048381|NCT01683266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048382|NCT06574464|||COHORT||RETROSPECTIVE|||||||
34048383|NCT01857583|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048384|NCT01311765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048385|NCT06131424|||COHORT||RETROSPECTIVE|||||||
34048386|NCT05083936|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048387|NCT01539330|NA|SINGLE_GROUP||||NONE||||||
34048388|NCT06436898|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blind to treatment arm||f|f|f|t
34048389|NCT06668259|||COHORT||PROSPECTIVE|||||||
34048390|NCT04223752|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048391|NCT01892410|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34048392|NCT03937921|||CASE_CONTROL||PROSPECTIVE|||||||
34048393|NCT05833165|||COHORT||RETROSPECTIVE|||||||
34048394|NCT06383234|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048395|NCT01645319|||COHORT||PROSPECTIVE|||||||
34048396|NCT05000554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048397|NCT06682104|NA|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34048398|NCT04308889|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Subjects will participate in a total of 6 study visits clustered into two groups of 3 visits (baseline, 24h and 72h after blister induction) for a total of 72 hours duration. The crossover for each group of 3 visits will be separated by at least 1 week.||||
34048399|NCT06683872|||COHORT||PROSPECTIVE|||||||
34048400|NCT06684691|RANDOMIZED|PARALLEL||OTHER||NONE|There is no blinding because of the nature of the simulation method|Randomized controlled parallel group trial||||
34048401|NCT05478460|||COHORT||PROSPECTIVE|||||||
34048402|NCT04113655|||COHORT||CROSS_SECTIONAL|||||||
34048403|NCT06084845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048404|NCT05113342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048405|NCT04996602|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048406|NCT03944746|||COHORT||PROSPECTIVE|||||||
34048407|NCT01780038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048408|NCT00676247|||COHORT||CROSS_SECTIONAL|||||||
34048409|NCT02064270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048410|NCT02375893|||CASE_CONTROL||PROSPECTIVE|||||||
34048411|NCT06500819|NA|SEQUENTIAL||TREATMENT||NONE||||||
34048412|NCT00611910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048413|NCT01239914|||COHORT||RETROSPECTIVE|||||||
34048414|NCT01600365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048415|NCT01832558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048416|NCT01284673|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048417|NCT05941143|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34048418|NCT05578937|||COHORT||CROSS_SECTIONAL|||||||
34048419|NCT04749641|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048420|NCT03850730|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study and thus all personnel and patients will be aware of the assignment.|After at least a 6 week baseline, patients will be placed on very low dose Pazopanib \[25mg-similar\], for 8 weeks.. If the primary bleeding duration endpoint is achieved, than the patient will continue for another 8wks, or a total of 16 weeks on the same dose. Lack of any response will result in a dose advance to 50mg for another 3mths. If a moderate change has occurred, than the 25mg dose will be continued for another 4 weeks, and if primary endpoint achieved, continue for another 12 weeks... Lack of endpoint achievement, will augment dose to 50mg and extend study for 12 weeks, or a total of 24 weeks.||||
34048421|NCT00115492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34048422|NCT06346821|||COHORT||CROSS_SECTIONAL|||||||
34048423|NCT05236738|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048424|NCT05670860|||OTHER||RETROSPECTIVE|||||||
34048425|NCT04752592|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048426|NCT06685354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048427|NCT01214083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048428|NCT02881489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048429|NCT03770039|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34048430|NCT03789617|NA|SEQUENTIAL||TREATMENT||NONE||||||
34048431|NCT03860376|||COHORT||PROSPECTIVE|||||||
34048432|NCT00568061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048433|NCT01416974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048434|NCT04093011|||COHORT||RETROSPECTIVE|||||||
34048435|NCT06204315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127468|NCT03495141|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessor will not know who was randomized to supervised versus unsupervised simulator training.||f|f|f|t
34127469|NCT01166217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127470|NCT00475592|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127471|NCT00343005||||TREATMENT||||||||
34048436|NCT05320705|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be done by computer generated numbers and concealed by serially numbered, opaque and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. Prior to surgery the appropriate numbered envelopes will be opened by the nurse, the card inside will determine the patient group||t|t|t|t
34048437|NCT04459000|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The outcomes assessor/research technician will not intentionally be made aware of the participant's treatment group, although this information may not be entirely possible to prevent the tech from learning.||f|f|f|t
34048438|NCT01135433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048439|NCT00790244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048440|NCT03220282|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participant, PI, enrolling nurse and clinical care team will not be blinded as to treatment assignment. Outcomes will be assessed by blinded investigators.|Randomized controlled trial with 2 arms|f|f|f|t
34048441|NCT05864079|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34048442|NCT04537377|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
34048443|NCT02907528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34048444|NCT06559215|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized after consent is obtained and will not know if they receive Exparel intraoperatively.||t|f|f|f
34048445|NCT05406284|||COHORT||PROSPECTIVE|||||||
34048446|NCT05356949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048447|NCT04470544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048448|NCT04786340|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Each subject will be randomized by an Interactive Web Response System (IWRS). When a subject is randomized, the IWRS will assign a randomization number for each subject, corresponding to a specific treatment code. The randomization number will be automatically input into the electronic Case Report Form (eCRF) by the system. The corresponding treatment code will only be accessible to the unblinded personnel.|2:1 ratio, Active (4% WST-057 topical solution): Placebo (matching placebo solution)|t|t|t|t
34048449|NCT05797961|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 randomization to either HIV testing with online supervision or venue testing as usual||||
34048450|NCT02727075|||COHORT||PROSPECTIVE|||||||
34048451|NCT02249169|||CASE_CONTROL||PROSPECTIVE|||||||
34048452|NCT01676363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048453|NCT02993250|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048454|NCT00638404|||OTHER||PROSPECTIVE|||||||
34048455|NCT06143345|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Staff conducting the outcome assessments will be blinded to the participants' treatment status.||f|f|f|t
34048456|NCT05672680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048457|NCT04728048|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048458|NCT06571422|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048459|NCT04136704|||OTHER||PROSPECTIVE|||||||
34048460|NCT05903105|||COHORT||CROSS_SECTIONAL|||||||
33819966|NCT03800745|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE|Participants are randomized to their arm on the day of surgery. A manila envelope with the arm written on a paper inside the envelope is opened in the post-anesthesia care unit (PACU) following surgery. A computerized random number generator was used to assign arms.|randomized control trial||||
34048461|NCT03124316|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|The randomization schedule will be generated by a statistician on study IDs. The allocation sequence is applied simultaneously to the full set of eligible family physicians so that each is assigned to one of eight experimental conditions. The assignment to study conditions will be concealed from investigators. The data collection system used for the 4 month outcome assessment will be standardized across all study conditions and conducted by personnel at CCO not already involved in the study trial. No un-blinding is planned or permitted.|We will test three components of reminders to family physicians that could be embedded independently, in combinations of two, and all together in a reminder email. Family physicians will be randomly allocated to one of 8 experimental conditions. Each experimental condition comprises a different combination of the behaviour change techniques featured in the redesigned email reminder.|f|f|t|t
34048462|NCT04428658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048463|NCT04531462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048464|NCT01736397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048465|NCT02438826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048466|NCT06035146|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in the study.|The study subjects will be randomized into two parallel groups.||||
34048467|NCT03329703|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048468|NCT05959005|||COHORT||PROSPECTIVE|||||||
34127472|NCT04133662|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34127473|NCT04660695|||CASE_ONLY||PROSPECTIVE|||||||
34127474|NCT04029428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Every patients from groups as follows: Gastro-Entero-Pancreatic Neuroendocrine Tumours - GEP-NET, (G1, G2 and G3), Broncho-pulmonary Carcinoids (BPCs Atypical-AC or Typical-TC), pheochromocytoma/paragangliomas (PPGLs) and neuroendocrine tumours of unknown primary (NET-CUP).||||
33840210|NCT01016262|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127475|NCT05015647|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants were treated for six months with two different dietary prescriptions:~1. LP group (n=17) was prescribed high calories/low proteins diet (30 Kcal/kg and 0.6-0.7gr/kg respectively). In order to assure prescribed calorie intake, this group was supplemented with commercial protein free products (protein content \<2%).~2. NP group (n=18) was prescribed high calories/normal proteins diet (30 kcal/kg and 0.8 gr/kg respectively)."||||
34127476|NCT03350451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127477|NCT04407156|||CASE_CONTROL||RETROSPECTIVE|||||||
34127478|NCT05879731|||CASE_ONLY||PROSPECTIVE|||||||
34127479|NCT05874505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127480|NCT01981265|||CASE_CONTROL||PROSPECTIVE|||||||
34127481|NCT02084498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048469|NCT05862337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048470|NCT04418830|||COHORT||PROSPECTIVE|||||||
34048471|NCT02578381|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34048472|NCT05922761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048473|NCT06598631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048474|NCT06186427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048475|NCT01931943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048476|NCT03439592|||COHORT||PROSPECTIVE|||||||
34048477|NCT06086145|||COHORT||CROSS_SECTIONAL|||||||
34048478|NCT04134429|||OTHER||PROSPECTIVE|||||||
34048479|NCT01237041|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|Masking only during the two arms of the randomized trial portion of the study, not during the dose-finding arms.|First, we conducted dose-establishing studies using 250mg every 2 hours x 3 doses (2 subjects), 500mg every two hours x 3 doses (5 subjects), and 500mg hourly x 4 doses (5 subjects). This dose-establishing study was followed by the randomized crossover trial using 500mg hourly x 4 doses in conjunction with growth hormone stimulation testing. The RCT was terminated early because of inability to obtain necessary study medications.|t|t|t|t
34048480|NCT00626821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048481|NCT06478251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127482|NCT01504893|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34127483|NCT05930847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127484|NCT05823038|||COHORT||CROSS_SECTIONAL|||||||
34127485|NCT05756920|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Single Ascending Dose and Multiple Ascending Dose|t|t|t|t
34127486|NCT04721158|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127487|NCT00309426|||DEFINED_POPULATION||OTHER|||||||
34127488|NCT03466398|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33819967|NCT06145971|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Case Experimental Design (SCED) methodology using multiple baseline across participants.||||
34127489|NCT05568563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127490|NCT04058015|||CASE_CONTROL||RETROSPECTIVE|||||||
34127491|NCT00326001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127492|NCT01993381|||COHORT||PROSPECTIVE|||||||
34127493|NCT03987711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127494|NCT05918016|||CASE_CONTROL||OTHER|||||||
34127495|NCT04471376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127496|NCT02413944|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127497|NCT01489709|||COHORT||PROSPECTIVE|||||||
34127498|NCT00712387|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34127499|NCT00004215|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34127500|NCT06204588|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34127501|NCT00723905|||COHORT||PROSPECTIVE|||||||
34127502|NCT01670669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819968|NCT04201847|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33819969|NCT06585319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were assigned one of the following treatments: pirfenidone (KitosCell tabs, CellPharma S de RL de CV. Mexico City, Mexico) 1,200 mg of oral q12 h or collagen-PVP (Fibroquel, Aspid SA de CV, Mexico City, Mexico) 2 ml intramuscular q24 h, for 7 days; control group was of patients without pirfenidone or collagen-PVP. Body temperature, heart rate, respiratory rate, pSO2%, PCO2, and pO2, hematic biometry, serum concentrations of glucose, uric acid, cholesterol, and triacyl glycerides, IFN-γ, TNF-α, IL-2, -4, -10, -13 and -17 were measured at the beginning and after 7 days of treatment.|f|f|f|t
33819970|NCT01592422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819971|NCT01294358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819972|NCT02709265|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33819973|NCT02232009|NA|SINGLE_GROUP||OTHER||NONE||||||
33819974|NCT02883140|||CASE_ONLY||PROSPECTIVE|||||||
33819975|NCT00183599|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819976|NCT01100372|RANDOMIZED|||TREATMENT||||||||
33819977|NCT02741297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819978|NCT06475092|||COHORT||CROSS_SECTIONAL|||||||
33819979|NCT05979987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Parallel-arm randomized control trial|t|t|f|f
33819980|NCT05401149|||COHORT||RETROSPECTIVE|||||||
33819981|NCT01320514|||CASE_CONTROL||PROSPECTIVE|||||||
33819982|NCT05800704|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33819983|NCT00319670|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33819984|NCT00688337|||COHORT||PROSPECTIVE|||||||
33819985|NCT04547504|RANDOMIZED|PARALLEL||TREATMENT||NONE||A national, multicenter, phase III, prospective, open label, 1:1 randomized, interventional study||||
33819986|NCT05872906|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33819987|NCT00003934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33819988|NCT00521807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127503|NCT05512481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127504|NCT00005097|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Subjects will have actinic keratosis on both arms and apply Polyphenon E topical ointment on one arm and placebo ointment to apply to the other arm. Subjects will serve as their own control by being unaware of which arm will have the active study drug.|t|f|t|f
34127505|NCT03009162|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34127506|NCT03326635|||COHORT||PROSPECTIVE|||||||
34127507|NCT00002811|RANDOMIZED|||PREVENTION||DOUBLE||||||
34127508|NCT02364011|||COHORT||PROSPECTIVE|||||||
34127509|NCT01527045|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34127510|NCT05415969|||COHORT||CROSS_SECTIONAL|||||||
34127511|NCT05466552|||COHORT||PROSPECTIVE|||||||
34127512|NCT03743545|RANDOMIZED|PARALLEL||TREATMENT||NONE||healthy posterior mandible||||
34127513|NCT01716130|||COHORT||PROSPECTIVE|||||||
34127514|NCT02423525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127515|NCT03915444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127516|NCT05524519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127517|NCT03186092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The equipment is the same for both groups. The change is internal, in the placebo group, patients train without a spring that imposes the load for respiratory muscle training.||t|f|t|t
34127518|NCT01170273|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34127519|NCT02176200|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127520|NCT04873440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33819989|NCT01102985|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33819990|NCT06358040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33819991|NCT05630794|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33819992|NCT03521076|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Researcher #1 will break the blind and know which condition the participant is in. Researcher #1 will then be the one to video record the treatment session. Researcher #1 will leave the room immediately following the treatment intervention. Researcher #2 will enter the room and will support the patient, parent/caregiver, and provider in completing outcomes assessments.|Participants who are having botulinum toxin injections will be enrolled in the study. We will use a crossover study design, such that participants will access VR in addition to standard of care in one session and then experience only standard of care in the other condition. Participants will be randomized following the consent process. The participants will experience the opposite condition at their 2nd visit.|f|f|f|t
33819993|NCT00437086||PARALLEL||TREATMENT||NONE||||||
33819994|NCT02018159|||COHORT||PROSPECTIVE|||||||
33819995|NCT05340426|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I clinical trial involving the use of a porcine kidney xenograft for transplant in place of a human kidney allograft to treat chronic renal failure in patients on dialysis||||
33819996|NCT05415644|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||HRX0701 tablets are used alone, or Retagliptin phosphate tablets are used in combination with metformin hydrochloride tablets.|t|t|t|t
33819997|NCT06385288|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
33819998|NCT00000499|RANDOMIZED|||TREATMENT||DOUBLE||||||
33819999|NCT00161954|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33820000|NCT02684942|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33820001|NCT02066389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820002|NCT05812209|||COHORT||RETROSPECTIVE|||||||
33820003|NCT04086576|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33820004|NCT03538834|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33820005|NCT06423625|||COHORT||RETROSPECTIVE|||||||
33820006|NCT05690477|||COHORT||RETROSPECTIVE|||||||
33820007|NCT02305797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820008|NCT00730392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820009|NCT06381297|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Multiple sclerosis patient group and healthy control group.||||
33820010|NCT00784277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820011|NCT03444155|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Masking was organized and supervised by the randomization person in charge. Group assignment was 1:1 (control vs. verum group) with identical packages for both Vitamin supplements with 126 capsules for each subject per phase. Randomization was done with sealed envelopes.|Vitamin B complex (natural vs. synthetic) administered in capsules each day for 6 weeks - 2 weeks wash-out phase I (2 weeks) - cross-over 6 weeks - wash-out phase II (6 weeks)|t|f|t|f
33820012|NCT05492578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820013|NCT01388088|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820014|NCT05681845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study consists of two parts - an open-label pilot part and a double-blind bioequivalence part.||t|t|t|t
33820015|NCT01000584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33820016|NCT00301015|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33820017|NCT03944499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820018|NCT01531478|||COHORT||PROSPECTIVE|||||||
33820019|NCT02411071|||COHORT||RETROSPECTIVE|||||||
33820020|NCT03727334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The psychometrist will be blind to the arm the participant is assigned to.|This is a randomized two-armed study, comprised of a treatment arm and a control arm. Given the small numbers and the potentially slow rate of recruitment, the investigators will employ simple rather than block randomization. To minimize selection bias, allocation to group will be concealed (i.e., with assignment unpredictable and unchangeable) using software that randomizes each patient upon confirmation of eligibility. Patients will not be blind to group assignment, but the psychometrist completing behavioural outcomes will be kept blind to group assignment.|f|f|f|t
33820021|NCT01702688|NA|SINGLE_GROUP||OTHER||NONE||||||
33820022|NCT05639946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820023|NCT05793827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator and postdoctoral fellow are exclusively responsible for assessing outcomes and both are masked to participant group membership. The participants, interventionists, and other key persons are not masked to participant group membership, but they are not involved in any of the outcome assessments.||f|f|f|t
33820024|NCT05145088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants are randomly allocated by coin toss method in two groups and they are unawre of random allocation.||t|f|f|f
33820025|NCT03721900|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||Each subject will receive one of the following: placebo, 20 mg (low dose), or 40 mg (high dose). All subjects will receive doses in the same order during 3 study periods|t|f|f|f
33820026|NCT01446822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820027|NCT06253689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820028|NCT00036309||||TREATMENT||||||||
33820029|NCT03902327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trails|t|f|t|f
33820030|NCT06138522|||COHORT||PROSPECTIVE|||||||
34048482|NCT04257123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Treatment with Gelesis100 or placebo will be double-blinded and randomly assigned.|Following an initial 3-day run-in period (feeding only), participants will be randomly assigned to two 1-week controlled feeding periods with and without Gelesis100. After a one week washout, participants will complete the other pattern. Following another 1-week washout, participants will be randomly assigned again to two 1-week free-feeding periods with and without Gelesis100. After a one week washout, participants will complete the other pattern.|t|f|t|f
34127521|NCT02089932|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34048483|NCT03360916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34048484|NCT06532799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048485|NCT02953444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048486|NCT00970840|NA|SINGLE_GROUP||OTHER||NONE||||||
34048487|NCT01053663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048488|NCT04267289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048489|NCT04080024|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048490|NCT01803217|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34048491|NCT06685393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double (participant, outcomes assessor)||t|f|f|t
34048492|NCT02699931|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34048493|NCT00095238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048494|NCT05507385|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Eligible participants will be randomised to an intervention group or the control group.|t|f|f|t
34048495|NCT03597750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048496|NCT05051553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048497|NCT00107965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048498|NCT02942368|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assessors are blinded and unaware of the specifics of the study (although only a single arm, blinded raters do not know this).|||||
34048499|NCT06584383|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is contemplated that, if the patients from the control arm require unilateral Exablate MRgFUS subthalamotomy, the treatment could be performed after Month 12 visit.||||
34048500|NCT00577980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048501|NCT03625375|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048502|NCT06685159|||COHORT||PROSPECTIVE|||||||
34048503|NCT06197230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This intervention study is designed as single-blind; all the participants will be blinded to the allocation. To prevent participants from developing expectations regarding the intervention, they will be blinded to their group assignment.The investigator will not tell which is intervention and control group member|Randomized control trial with longitudinal design|t|f|t|f
34048504|NCT04672252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34048505|NCT06666569|||CASE_CONTROL||PROSPECTIVE|||||||
34048506|NCT02082574|||CASE_CONTROL||PROSPECTIVE|||||||
34048507|NCT06683430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048508|NCT05660408|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048509|NCT06685653|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048510|NCT00657488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048511|NCT04501640|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This was an open label study.|This was a two-way crossover design with 2 period and 2 dose groups. Participants were randomized to 1 of 4 sequences dependent on dose and period assigned.||||
34048512|NCT00059124|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34048513|NCT00693498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048514|NCT03359330|||COHORT||PROSPECTIVE|||||||
34048515|NCT06242535|NA|SINGLE_GROUP||TREATMENT||NONE||One group, no-placebo comparer, pre post intervention clinical trial||||
34048516|NCT03703583|||COHORT||CROSS_SECTIONAL|||||||
34048517|NCT01020006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048518|NCT01391208|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048519|NCT04713839|||CASE_ONLY||PROSPECTIVE|||||||
34048520|NCT06665867|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34048521|NCT01711372|NON_RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The person having the patient play the came did not know if the patient had ADHD or not.|Patients were those with ADHD and age and gender matched controls who completed a game placed on Sifteo cubes to assess for ADHD. The intervention was a game to screen for ADHD.|f|f|t|t
33820031|NCT05432258|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double blind|In a split-mouth design, 89 patients' 2 mandibular first molars were divided into 2 groups. Per patient, one mandibular first molar had bulk-fill ormocer-based composite resin restoration and 1 mandibular first molar had nanofill composite resin restoration via incremental technic.|t|f|f|t
34048522|NCT04287231|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34048523|NCT00715416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048524|NCT04399109|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34048525|NCT02865499|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33820032|NCT01252199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048526|NCT05249166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048527|NCT00959374|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34048528|NCT00608764|||COHORT||PROSPECTIVE|||||||
34048529|NCT00756561|||CASE_ONLY||RETROSPECTIVE|||||||
34048530|NCT04936074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048531|NCT03914963|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|The patient, doctors who performed the follow-up and initially the surgeon were blinded to the randomization sequence and site of application. That is, the surgeon was only told to which hemipelvis the sealant was to be applied when he considered that the surgical procedure had been completed.|After standard preoperative assessment, patients were randomly assigned to having Tissucol Duo® applied to the surgical bed in only the right or only the left hemipelvis after bilateral pelvic lymphadenectomy. Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis). We decided to treat only one hemipelvis in each patient, thereby allowing patients to serve as their own controls, in order to compare outcomes with and without the sealant in the same body with the same clinical characteristics and reduce the influence of other factors beyond the treatment.|f|f|f|t
34048532|NCT02702388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048533|NCT03572738|||CASE_ONLY||PROSPECTIVE|||||||
33820033|NCT00607789|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048534|NCT04504071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127522|NCT03990532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127523|NCT02122497|||COHORT||PROSPECTIVE|||||||
33820034|NCT03151551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820035|NCT03012321|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820036|NCT00282711|||COHORT||PROSPECTIVE|||||||
33820037|NCT04562571|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33820038|NCT02552706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820039|NCT00215709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840211|NCT04317391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127524|NCT03162133|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33840212|NCT02122575|||COHORT||PROSPECTIVE|||||||
33840213|NCT00333086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048535|NCT05028062|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, placebo-controlled|Double-blind, placebo-controlled, parallel-group clinical trial|t|f|t|t
34048536|NCT00008866||||TREATMENT||DOUBLE||||||
34048537|NCT05038644|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34048538|NCT01968603|||CASE_ONLY||RETROSPECTIVE|||||||
34048539|NCT05545514|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Phase IV, monocentric, randomised, double-blind, parallel-group, placebo-controlled clinical trial|t|t|t|t
34048540|NCT06003998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048541|NCT06502054|||COHORT||CROSS_SECTIONAL|||||||
34048542|NCT05793801|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective two-center randomized open-label controlled pilot study in two parallel groups according to PICCline dressing repair: (i) Control group (every 8 days, see SF2H recommendations), (ii) Experimental group (every 2 days).||||
34048543|NCT00625417|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Optical spectroscopy is applied to evaluate tumor margins in consenting patients who undergo surgery for breast tumors||||
34048544|NCT06682065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||1:1||||
34048545|NCT04850495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048546|NCT00677703|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34048547|NCT01841762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048548|NCT02857244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048549|NCT03083015|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|For the allocation concealment mechanism, each of 66 papers (each paper was eight folded) numbered from 1 to 66 were, individually packed, in opaque envelopes. Each participant picked an envelope at the beginning of the second visit. The number in the envelope determined which procedure was to be performed for the patient. The partner was to decide the procedure for the operator according to that number.|participants are allocated at random to receive one of two interventions according to the research plan. In RCT the outcomes are measured, so it is considered a quantitative study . This trial conforms to the Consolidated Standard of Reporting Trials (CONSORT)statement.|t|f|t|t
34127525|NCT00097929|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127526|NCT06448728|||CASE_ONLY||PROSPECTIVE|||||||
34127527|NCT05130684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127528|NCT00050830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127529|NCT03965104|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|By necessity, pharmacists in the intervention groups cannot be blinded. However, pharmacists will not be told about the cluster randomization, just that they will be contacted about when they will receive the HC-PCP. During the control period, pharmacists will be told that their patients will be enrolled in an observational hypertension registry to prepare for the intervention phase.|Stepped wedge cluster randomized trial with the unit of randomization being the pharmacy|t|f|f|f
34127530|NCT03183063|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Patients will be imaged with SPECT/CT and 4DCT to compare perfusion with the respiratory induced blood mass changed (RIBMC) defect. Each patient will have both imaging studies performed on the same day.~15 subjects will be enrolled into Cohort 1 and will receive SPECT/CT and 4DCT imaging as described. After those are enrolled another 5 subjects will be enrolled into Cohort 2 and will receive SPECT/CT and 4DCT imaging as previously described with the first 4DCT being obtained with normal breathing and the second scan being obtained with positive pressure breathing via BiPAP. Cohort 3 will enroll 124 participants with clinical suspicion of PE, who will be or have had CTA imaging. 4DCT imaging will be performed for these study participants."||||
34127531|NCT00583674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127532|NCT03576014|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34127533|NCT02923531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127534|NCT05421299|||COHORT||RETROSPECTIVE|||||||
34127535|NCT02741986|||OTHER||PROSPECTIVE|||||||
34127536|NCT00390897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127537|NCT05831904|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34127538|NCT05515406|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127539|NCT03313635|||COHORT||PROSPECTIVE|||||||
34127540|NCT01928290|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127541|NCT00888706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34127542|NCT00776542|RANDOMIZED|CROSSOVER||||NONE||||||
34127543|NCT03560583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127544|NCT05139927|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Full factorial experiment testing 4 behavioral intervention components. There are 16 conditions needed to test the effects of the 4 components. Each condition comprises a combination of components. In the sections that follow, we describe the 16 conditions.||||
34127545|NCT00133263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34127546|NCT01552512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127547|NCT05317650|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127548|NCT01223339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127549|NCT00675831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127550|NCT00996957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127551|NCT00235222|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127552|NCT05226403|||CASE_ONLY||PROSPECTIVE|||||||
34127553|NCT02270658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127554|NCT06038292|||COHORT||CROSS_SECTIONAL|||||||
34127555|NCT01687881|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34127556|NCT00496431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127557|NCT02021786|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127558|NCT04349358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127559|NCT02623777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34127560|NCT04306458|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Anonymous cases|Surgical RCT|f|f|f|t
34127561|NCT02325024|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127562|NCT04550780|||COHORT||RETROSPECTIVE|||||||
34127563|NCT01489865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127564|NCT05155124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127565|NCT03536325|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34127566|NCT06196996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127567|NCT01196897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127568|NCT04219449|||OTHER||CROSS_SECTIONAL|||||||
34127569|NCT02955888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820040|NCT03771378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study was a randomized, double-blind trial in which patients were divided into two groups, one receiving rhTPO injection and oral placebo tablet; the other group receiving oral eltrombopag and receiving a injection placebo.|f|f|t|f
33820041|NCT00884793|NA|SINGLE_GROUP||||NONE||||||
33820042|NCT06407193|||COHORT||PROSPECTIVE|||||||
33820043|NCT06646562|NA|SINGLE_GROUP||TREATMENT||NONE||Phase IV study, prospective, open-label, single arm, multicentre, with a follow-up of 24 months||||
33820044|NCT05043298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820045|NCT00425906|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE||||||
33820046|NCT03469258|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820047|NCT06249594|||OTHER||RETROSPECTIVE|||||||
33820048|NCT00248794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820049|NCT04885478|||COHORT||PROSPECTIVE|||||||
33820050|NCT00515112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820051|NCT00582985|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820052|NCT00095251|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33820053|NCT02632747|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820054|NCT06020495|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicentre, prospective, open-label randomized controlled superiority trial with stratification on the presence of neurological symptoms at inclusion and on the presence/absence of risk factors for central pontine myelinolysis (chronic alcohol abuse, malnutrition, serum potassium \< 3.0 mmol/L).||||
33820055|NCT05698888|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Following completion of the dose escalation phase of the study and determination of maximum tolerated dose or recommended phase 2 dose, patients will be enrolled into dose expansion.||||
33820056|NCT02407197|||COHORT||PROSPECTIVE|||||||
33820057|NCT05126199|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33820058|NCT05534451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||According to the kinds of video methods uesd to assist in nasotracheal intubation, patients will be randomly divided into video laryngoscope group, video fiberoptic scope group and video rigid laryngoscope group, 20 participants in each group.||||
33820059|NCT06396494|||CASE_ONLY||PROSPECTIVE|||||||
33820060|NCT01838629|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33820061|NCT02835209|||COHORT||PROSPECTIVE|||||||
33820062|NCT02800512|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820063|NCT06256484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33820064|NCT01585597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820065|NCT01823926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820066|NCT04285151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820067|NCT05361954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820068|NCT03826797|||COHORT||PROSPECTIVE|||||||
34127570|NCT02920307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127571|NCT02049346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820069|NCT05106023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820070|NCT02523443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820071|NCT04741984|NA|SEQUENTIAL||TREATMENT||NONE||||||
33820072|NCT06509477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a randomized, double-masked, active controlled, within-subject, paired, and equivalency clinical trial. Subjects were treated with Lunaphil Ultra in one NLF and Juvederm Ultra 4® in the opposite NLF.|t|f|f|t
33820073|NCT03500835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Blocked randomization will be utilized, to ensure the groups are balanced in terms of number of subjects and the distribution of potential confounding variables. Blocked randomization will be used to ensure the number of eligible subjects assigned to each group is equally distributed. Block size will be blinded from the primary investigator performing the study.|The proposed multi-site randomized control trial (RCT) will test the effectiveness of an addiction-based weight loss intervention, embodied as a smartphone app with telephone coaching compared 1) an addiction-based weight loss intervention alone and 2) an in-clinic weight management intervention based on a traffic-light based approach in a larger sample of economically, racially and ethnically diverse adolescents (ages 14-18).|f|f|f|t
33820074|NCT04605471|||COHORT||RETROSPECTIVE|||||||
33820075|NCT03532568|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33820076|NCT00579475|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820077|NCT04376255|NA|SINGLE_GROUP||OTHER||NONE||||||
33820078|NCT00138333|||||PROSPECTIVE|||||||
33820079|NCT03258905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33820080|NCT02857309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820081|NCT03613571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820082|NCT02585752|NA|SINGLE_GROUP||OTHER||NONE||||||
33820083|NCT04883606|||COHORT||RETROSPECTIVE|||||||
33820084|NCT03594786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820085|NCT04818047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820086|NCT00212290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33820087|NCT01504919|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33820088|NCT02274350|||COHORT||CROSS_SECTIONAL|||||||
33820089|NCT05586308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study employs a pilot, 4-arm randomized clinical trial design.|f|f|t|t
33820090|NCT03528161|||OTHER||PROSPECTIVE|||||||
33820091|NCT05159778|NA|SINGLE_GROUP||TREATMENT||NONE||Open label Simon 2 stage design.||||
33820092|NCT01636778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820093|NCT04275674|||CASE_CONTROL||RETROSPECTIVE|||||||
33820094|NCT02093078|||COHORT||PROSPECTIVE|||||||
33820095|NCT02286427|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33820096|NCT05942833|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized controlled||||
33820097|NCT01919255|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33820098|NCT05903573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820099|NCT01156818|||CASE_ONLY||PROSPECTIVE|||||||
33820100|NCT00524693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820101|NCT05020886|||CASE_CONTROL||PROSPECTIVE|||||||
33820102|NCT06393712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820103|NCT01953406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820104|NCT04143100|||CASE_ONLY||CROSS_SECTIONAL|||||||
33820105|NCT05833737|||COHORT||PROSPECTIVE|||||||
33820106|NCT02713698|||OTHER||PROSPECTIVE|||||||
33820107|NCT00938041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127572|NCT06543459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127573|NCT04012827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127574|NCT00466947|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34127575|NCT01412125|||COHORT||PROSPECTIVE|||||||
34127576|NCT05490316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127577|NCT01846819|||COHORT||PROSPECTIVE|||||||
34127578|NCT05985798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127579|NCT05701553|||COHORT||PROSPECTIVE|||||||
34127580|NCT02095392|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34127581|NCT04858607|||COHORT||PROSPECTIVE|||||||
34127582|NCT05299177|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34127583|NCT02340169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127584|NCT06512571|||COHORT||PROSPECTIVE|||||||
34127585|NCT00590122|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34127586|NCT01558037|||COHORT||PROSPECTIVE|||||||
34127587|NCT06138353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"To ensure blinding, personnel involved in randomisation coding or with potential access to the blind base, doctors or nurses administering the medication, should not be involved in activities such as selection of subjects, evaluation of efficacy, and assessment of safety, so as not to introduce bias.~In addition, to ensure blinding, the packaging and batch numbers of the drugs in both groups will be identical, and the packaging batch numbers will be uniformly labelled. Each box will be labelled with a unique drug ID number. This number will be used to designate the treatment received by the patient, but will not indicate treatment assignment to the investigator or the patient."|Shuxuening injection treatment : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative aSAH, treatment for 1 course of treatment, a total of 10-14 days.|t|t|t|f
34127588|NCT00700193|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127589|NCT01030120|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127590|NCT05897073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34127591|NCT02537327|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127592|NCT05742412|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The emergency caller (patient or bystander) is initially masked to the intervention (video or telephone communication) when initiating the call to the Emergency Medical Dispatch Center (EMDC). Emergency calls are randomly answered by an EMS Dispatcher using either video or telephone (audio-only) communication.|Cluster Randomised Clinical Trials|t|f|f|f
34127593|NCT06184230|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127594|NCT01202201|||COHORT||RETROSPECTIVE|||||||
34127595|NCT04594629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127596|NCT04055350|||COHORT||PROSPECTIVE|||||||
34127597|NCT03870464|||COHORT||PROSPECTIVE|||||||
34127598|NCT01813201|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127599|NCT01930604|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127600|NCT04884763|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34127601|NCT04770558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127602|NCT03394742|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127603|NCT06162273|||COHORT||PROSPECTIVE|||||||
34127604|NCT05640362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34127605|NCT05179278|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34127606|NCT05715138|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34127607|NCT03360240|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34127608|NCT04118075|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34127609|NCT06226597|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127610|NCT02136004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127611|NCT05908981|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34127612|NCT00430989|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treating anaesthetist will be unblinded to the allocation. All other personnel (surgeon, participant and outcome assessor are all blinded to treatment.|international, randomised, assessor-blinded trial in patients aged at least 45 years with known or suspected coronary artery disease having major non-cardiac surgery.|t|t|f|t
34127613|NCT00714662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127614|NCT00841243|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127615|NCT00532129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127616|NCT01492426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127617|NCT04816981|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single-centre, prospective clinical trial, in which patients will be enrolled in a consecutive sample and patient involvement will conclude when the procedure ends. No follow-up will be required after the study.||||
34127618|NCT01661023|||CASE_CONTROL||RETROSPECTIVE|||||||
34127619|NCT05183074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127620|NCT05525039|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Subjects will be randomized to either (1) Control, (2) HMB only, (3) VT only or (4) HMB +VT group. All subjects will be given protein supplement to ensure minimal daily protein intake. Subject assigned to VT group will receive VT (35Hz, 0.3g, 20min/day, at least 3 times/week) for 6 months. Subjects assigned to HMB group will take HMB capsules 3g/day for 6 months.|f|f|f|t
34127621|NCT01724229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127622|NCT03894696|||COHORT||PROSPECTIVE|||||||
34127623|NCT00854789|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127624|NCT00636103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127625|NCT04831476|||OTHER||PROSPECTIVE|||||||
34127626|NCT00745290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33820108|NCT05538156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820109|NCT00304278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820110|NCT05166317|||CASE_ONLY||PROSPECTIVE|||||||
33820111|NCT02014402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820112|NCT05513417|||COHORT||PROSPECTIVE|||||||
33820113|NCT03379688|||COHORT||RETROSPECTIVE|||||||
33820114|NCT05450939|||CASE_CONTROL||RETROSPECTIVE|||||||
33820115|NCT04479176|||CASE_CONTROL||RETROSPECTIVE|||||||
33820116|NCT05798754|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Member of the study group that assesses the epidural's success|Prospective blind, non-inferiority randomized trial|f|f|f|t
33820117|NCT00281983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820118|NCT02559479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820119|NCT06584994|||OTHER||OTHER|||||||
33820120|NCT06537570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|t|f|f|f
33820121|NCT05993832|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33820122|NCT01015794|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33820123|NCT02891018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820124|NCT04967521|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33820125|NCT00002471||||TREATMENT||||||||
33820126|NCT05420701|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820127|NCT04855396|||COHORT||PROSPECTIVE|||||||
33820128|NCT05572697|RANDOMIZED|PARALLEL||TREATMENT||NONE|Outcomes will be measured by registry data and questionnaires. Researchers will not have access to the randomization key before analyses are performed but blinding is not possible due to different number of participants in the two groups (as randomization is 2:1). The randomization procedure will be performed by the Clinical Research Unit (Klinforsk) at The Faculty of Medicine and Health Sciences at the Norwegian University of Science and Technology (NTNU) by use of a computer-generated block randomization. The randomization will be on group level to avoid contamination between participants in the same rehabilitation group.|Cluster randomized clinical trial with two parallel arms||||
33820129|NCT00850993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Clinical personnel at the site (including investigator, study coordinator and central cardiologist) were blinded to treatment group.~The research pharmacy and the health care provider responsible for giving the injection to patients knew what the treatment was (they were not blinded)."|Sequential experimental cohorts are run in parallel with placebo controls.|t|f|t|f
33820130|NCT02535598|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
33820131|NCT03348800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blindfolded during the tooth extractions and the outcome assessors will be unaware of dental procedures|"This study has a split-mouth model so participants will be anesthetized in one half of the maxilla with a conventional syringe and in the other half with the computer controlled delivery system.~The anesthetic techniques will be the same in the two haves."|t|f|f|t
33820132|NCT02831439|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33820133|NCT01746199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820134|NCT05587361|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33820135|NCT06585722|||COHORT||PROSPECTIVE|||||||
33820136|NCT06240403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will take either digoxin or placebo.||t|t|t|t
33820137|NCT06585007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820138|NCT00441571|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820139|NCT00587899|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33820140|NCT06102538|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The structure of the meetings - once a week~1. An hour and a half of physical activity adapted to the ability of teenagers with morbid obesity.~2. An hour and a half of training and education, which will include:~   * 10 group sessions with a dietician 45 minutes each session~  * 10 group meetings with a mental health staff member, 45 minutes per meeting (at least two of the meetings will be designated for a joint cooking workshop with the parents)~  * 6 meetings with IDF personnel, value meetings: the structure of the army, integration into the army, etc.~3. Meetings for parents - will include guidance from a nutritionist, exercise for parents, resilience for parents."||||
33820141|NCT01586494|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820142|NCT02039596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33820143|NCT04246099|||COHORT||RETROSPECTIVE|||||||
33820144|NCT03859622|||OTHER||OTHER|||||||
33820145|NCT03999398|||COHORT||RETROSPECTIVE|||||||
33820146|NCT04538378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820147|NCT04431739|||COHORT||CROSS_SECTIONAL|||||||
33820148|NCT00732316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820149|NCT03093233|||COHORT||RETROSPECTIVE|||||||
33820150|NCT04839289|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Identifying information will be removed from the hearing instruments before fitting the participants. However, participants may be able to research hearing instruments and identify devices based on physical appearance.||t|f|f|f
33820151|NCT05114629|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33820152|NCT05144854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820153|NCT01121497|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33820154|NCT02524951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820155|NCT03612258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820156|NCT03071874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820157|NCT04607837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820158|NCT05283642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820159|NCT01588379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820160|NCT05685212|||CASE_CONTROL||PROSPECTIVE|||||||
33820161|NCT03029611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048550|NCT03916315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are not aware that there is an intervention group and a control group, the participants are not related and do not know each other. The conditions of the study are only known by the researcher, the therapists and the bioethics committee of the Autonomous University of Baja California. The participants are assigned randomly to the intervention or control group.|The study has two arms, one is the intervention group that receive the treatment and the other is the control group that does not receive treatment, just waiting list, however at the end of the assesment the participants in the control group will also receive the treatment. The patients in both groups will be evaluated pre and post treatment. 11 sessions, once per week, therefore 3 months apart.|t|f|f|f
34048551|NCT04532619|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048552|NCT04581603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|single-blind.|Randomized, behavioral placebo-controlled trial.|f|t|t|t
34048553|NCT03312920|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34127627|NCT01799486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048554|NCT06078150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||The experimental group underwent a standardised AVG intervention according to the protocol of this experiment, and the control group did not do the intervention only recording daily life.|t|f|t|t
34048555|NCT03867136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048556|NCT04690595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048557|NCT00623389|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34048558|NCT02157285|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34048559|NCT02953210|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048560|NCT06646822|||OTHER||CROSS_SECTIONAL|||||||
34048561|NCT06341855|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34048562|NCT02789722|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34048563|NCT01585740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048564|NCT06608563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Outcome assessor (independent examiner) and participants will be blind to study groups.~It is not possible to blind the operator due to differences in material capsule colours/consistency at the time of fissure sealant placement."|Double-blind 2-arm parallel controlled randomised clinical trial.|t|f|f|t
34048565|NCT05359419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34048566|NCT06683261|||COHORT||PROSPECTIVE|||||||
34048567|NCT00250627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048568|NCT05808868|||COHORT||PROSPECTIVE|||||||
34048569|NCT02207803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34048570|NCT03424772|||FAMILY_BASED||PROSPECTIVE|||||||
34048571|NCT00886743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048572|NCT05088460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048573|NCT06441487|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Randomized: Participants are assigned to intervention groups by chance.|f|f|f|t
34048574|NCT02425878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048575|NCT06448767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048576|NCT04326946|||COHORT||PROSPECTIVE|||||||
34048577|NCT01983033|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048578|NCT03921788|||COHORT||PROSPECTIVE|||||||
34048579|NCT02340715|||CASE_CONTROL||PROSPECTIVE|||||||
34048580|NCT06372587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34048581|NCT02078973|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34048582|NCT05163457|||CASE_ONLY||CROSS_SECTIONAL|||||||
33820162|NCT00841945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820163|NCT01754545|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33820164|NCT02498418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820165|NCT00591084|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820166|NCT06096142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048583|NCT06681948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048584|NCT06670170|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34048585|NCT00281177||||TREATMENT||||||||
34048586|NCT03706378|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34048587|NCT05908032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048588|NCT04439214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048589|NCT06684782|||COHORT||PROSPECTIVE|||||||
34048590|NCT03310164|||CASE_CONTROL||PROSPECTIVE|||||||
34048591|NCT01198158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048592|NCT03733145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048593|NCT05436327|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34048594|NCT01071811|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34048595|NCT03048292|||COHORT||PROSPECTIVE|||||||
34048596|NCT03320304|||COHORT||PROSPECTIVE|||||||
34048597|NCT01402843|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34048598|NCT03498378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048599|NCT05902299|||CASE_CONTROL||RETROSPECTIVE|||||||
34048600|NCT05054413|||COHORT||PROSPECTIVE|||||||
34048601|NCT05170386|RANDOMIZED|PARALLEL||TREATMENT||NONE||group A (20 patients): that will receive cognitive training combined with instructive conventional treatment for sleeping disorder, and group B (20 patients): that will receive instructive conventional treatment for sleeping disorder||||
34048602|NCT06046781|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 204 patients who underwent surgery for lumbar disc herniation were included and subsequently randomized into five groups. One group served as the control and was advised not to participate in any postoperative exercise. The remaining groups were recommended different exercises, which began at various times after surgery.||||
34048603|NCT01617382|||CASE_ONLY||PROSPECTIVE|||||||
34048604|NCT06389045|||COHORT||PROSPECTIVE|||||||
34048605|NCT05156372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessments and analysis will be done by study staff blinded to the participant allocation||f|f|f|t
34048606|NCT03997565|||OTHER||OTHER|||||||
34048607|NCT03140410|||CASE_CONTROL||OTHER|||||||
34048608|NCT06568679|||COHORT||PROSPECTIVE|||||||
34127628|NCT01080924|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127629|NCT00099502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34127630|NCT02408679|||COHORT||PROSPECTIVE|||||||
34127631|NCT00778167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149288|NCT01781351|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149289|NCT02068560|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149290|NCT06505759|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149291|NCT00513396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820167|NCT03605745|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a prospective, non-randomized clinical trial of subjects with benign prostatic hypertrophy (BPH).||||
33820168|NCT05601141|||OTHER||OTHER|||||||
33820169|NCT01476709|||||PROSPECTIVE|||||||
33837253|NCT05184322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a single centre, double-blind, randomised, multiple-dose, placebo-controlled study, including six cohorts (Cohorts 1A/1B, 2, 3, 4, 5, 6) with a semi-parallel design.|t|f|t|f
34149292|NCT00005048||||TREATMENT||||||||
34149293|NCT05477199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34048609|NCT03079011|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Step 1: 1000 patients screened for circulating blood ESR1 mutation detection at regular intervals will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off (28-day cycle) + AI (letrozole, anastrozole or exemestane) administered once daily in a continuous scheme until tumor progression (assessed by RECIST) or ESR1 mutation detection~Step 2: Up to 200 Patients with a rising circulating ESR1 mutation and without tumor progression will be randomized (1:1):~* ARM A: no change in therapy until tumor progression (RECIST) or possibility of a cross-over (step 3)~* ARM B: palbociclib 125 mg + fulvestrant 500 mg administered intramuscularly on D1,15 and 29 and once monthly thereafter until tumor progression (RECIST)~* Step 3 (cross over): up to 80 patients who have been randomized in arm A will be offered to be treated by fulvestrant + palbociclib, after having progressed under AI + palbociclib until tumor progression (RECIST) under fulvestrant + palbociclib."||||
34048610|NCT05737225|||CASE_CONTROL||PROSPECTIVE|||||||
34048611|NCT05048147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048612|NCT02973724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048613|NCT06078007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048614|NCT01637454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048615|NCT00878202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048616|NCT00695279|||COHORT||PROSPECTIVE|||||||
34048617|NCT04499300|||COHORT||RETROSPECTIVE|||||||
34048618|NCT06682442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048619|NCT01483729|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048620|NCT03944187|||COHORT||PROSPECTIVE|||||||
34048621|NCT00373620|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048622|NCT00325481|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34048623|NCT01377922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048624|NCT06496685|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were recruited from a community Child and Adolescent Mental Health Service and a Primary Health Care Center. And randomized in two groups.||||
34048625|NCT05262907|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048626|NCT03154190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34127632|NCT03976505|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This study is exploratory, cross-sectional, experimental and monocentric. The experimental design is a split-plot 2(Group: parkinsonian patients vs. healthy volunteers) X 2(Condition: tablet vs. touch-screen + eye-tracker) X 2(Medication type: regular vs. irregular) X 2(Prescription format: table vs. textual) split-plot design in which Group and Condition are between-participants variables and Medication type and Prescription format are within-participants variables.||||
33820170|NCT05553353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"* Participants will be blinded to group (active vs. sham) assignments.~* The assessor performing the resting motor threshold (rMT) testing will be blinded to any pre-determined electric-field modeling values or group assignments.~* Staff member applying the rTMS treatment will be blinded, and an unblinded study staff member will set up the appropriate coil (active vs. sham) prior to each treatment session.~* The staff member completing outcome assessments will be blinded to participant group assignments.~* During the immediate post-testing session, the staff members applying the rTMS treatments and those completing the outcome assessments, as well as each participant, will be asked if they think active or sham treatment was received. This will allow for post-hoc assessment on blinding.~* Unblinding will only occur in the case of a medical emergency or after all follow-up testing has been completed."|"Participants will:~1. undergo high-resolution T1- and T2-weighted MRI scanning. These images will be used for image guided TMS assessments and e-field calculations for rTMS intensity.~2. undergo rTMS to the left dorsolateral prefrontal cortex (DLPFC) as a treatment approach for depression. Treatment (active or sham) will be performed five times/week for six weeks (30 sessions). A total of 3,000 pulses/session will be delivered at 10Hz (4 seconds on and 26 seconds off) for a total of 75 stimulation cycles that lasts 37.5 minutes. The intensity will be individualized, as it will be based on reverse-calculation electric-field modeling. Participants receiving sham stimulation will undergo the same procedures as active rTMS except that a coil specifically designed to provide sham stimulation that is double-blinded will be utilized."|t|f|t|t
33820171|NCT02465944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820172|NCT04966247|||COHORT||PROSPECTIVE|||||||
33820173|NCT05005572|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33820174|NCT00198666|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33820175|NCT03588676|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||randomized, placebo controlled, double blind, cross-over trial|t|f|t|t
33820176|NCT01027507|||CASE_ONLY|||||||||
33820177|NCT06721013|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Phase 1-Open label, Phase 2-Double-blind|Phase 1-Open label Sequential, Phase 2-Double-blind Parallel|t|f|t|f
33820178|NCT01442207|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820179|NCT05023304|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33820180|NCT05065008|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820181|NCT02084589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820182|NCT00101062||||TREATMENT||NONE||||||
33820183|NCT05634083|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will take activated charcoal for two months||||
33820184|NCT04713878|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Coronavirus Disease 2019 (COVID-19) patients with pneumonia~1.group: Intubated without comorbidity, 2.group: Intubated with comorbidity, 3.group: No intubated"||||
33820185|NCT05094947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820186|NCT03437902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820187|NCT04822025|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820188|NCT01995149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820189|NCT04560192|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820190|NCT04826393|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820191|NCT03253783||||PREVENTION||NONE||||||
33820192|NCT04782596|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking will be used in the study.|The study subjects will be randomised into two parallel groups.||||
33820193|NCT06050837|||COHORT||PROSPECTIVE|||||||
33820194|NCT04984980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820195|NCT04029727|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33820196|NCT00442026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820197|NCT01257698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127633|NCT04525144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127634|NCT01731847|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34127635|NCT05002933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127636|NCT06497751|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820198|NCT06000371|||CASE_ONLY||PROSPECTIVE|||||||
33820199|NCT03508882|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33820200|NCT00023465|||DEFINED_POPULATION||PROSPECTIVE|||||||
33820201|NCT01543009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34127637|NCT03021603|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34127638|NCT02977910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34127639|NCT02025634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34127640|NCT05921591|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34127641|NCT00202215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127642|NCT02375373|||COHORT||PROSPECTIVE|||||||
34127643|NCT01435694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127644|NCT02890901|||COHORT||PROSPECTIVE|||||||
34127645|NCT02807389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127646|NCT05551156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34127647|NCT06488937|||CASE_CONTROL||PROSPECTIVE|||||||
34127648|NCT05074823|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34127649|NCT00693446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127650|NCT01945996|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34127651|NCT01194219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820202|NCT02305667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33820203|NCT00860522|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820204|NCT01396122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820205|NCT05279417|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820206|NCT04854616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820207|NCT01204775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820208|NCT05261100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33820209|NCT05559164|NA|SINGLE_GROUP||TREATMENT||NONE||"Stage I-III HER2positive breast cancer receiving anti-HER2 therapy. Participants will receive Lipitor 40 mg PO daily.~Anti-HER2 targeted therapy + Lipitor 40mg daily"||||
33820210|NCT06352034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820211|NCT03552939|||COHORT||PROSPECTIVE|||||||
33820212|NCT05655715|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two experimental treatment arms.||||
33820213|NCT00323895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820214|NCT03133455|NA|SINGLE_GROUP||OTHER||NONE||||||
33820215|NCT03640754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820216|NCT04528875|||COHORT||PROSPECTIVE|||||||
33820217|NCT02444884|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820218|NCT01323309|||COHORT||PROSPECTIVE|||||||
33820219|NCT01970072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820220|NCT04277442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820221|NCT01197183|||COHORT||PROSPECTIVE|||||||
33820222|NCT03612453|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation|||||
33820223|NCT01906255|||COHORT||RETROSPECTIVE|||||||
33820224|NCT00895297|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820225|NCT01304953|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33820226|NCT03640793|NA|SINGLE_GROUP||TREATMENT||NONE||Single center, prospective, non-randomized, and non-blinded study||||
33820227|NCT02676739|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33820228|NCT01552642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820229|NCT03877133|NA|SINGLE_GROUP||PREVENTION||NONE|Does not need masking|A prospective, single group, observational study||||
33820230|NCT03094520|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33820231|NCT03325829|||COHORT||PROSPECTIVE|||||||
33820232|NCT06327984|||CASE_ONLY||PROSPECTIVE|||||||
33820233|NCT05908149|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820234|NCT06585280|||OTHER||OTHER|||||||
33820235|NCT01840696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820236|NCT06225050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127652|NCT06024551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127653|NCT05140772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127654|NCT01744067|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127655|NCT05359315|||COHORT||PROSPECTIVE|||||||
34127656|NCT02558062|NA|SINGLE_GROUP||OTHER||NONE||||||
34127657|NCT06498310|||CASE_CONTROL||RETROSPECTIVE|||||||
34127658|NCT01138696|||COHORT||PROSPECTIVE|||||||
33820237|NCT05650580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820238|NCT03258983|||COHORT||PROSPECTIVE|||||||
33820239|NCT01884376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820240|NCT00003755||||TREATMENT||||||||
33820241|NCT06388876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||there are 2 groups; exercise and control|f|f|t|t
33820242|NCT01556087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820243|NCT00120952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820244|NCT03296007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820245|NCT01601821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820246|NCT03711799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820247|NCT02879448|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820248|NCT04457011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820249|NCT04609579|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127659|NCT05532228|||COHORT||PROSPECTIVE|||||||
34127660|NCT02512289|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34127661|NCT05568160|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127662|NCT04760483|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study using intervention performed with Echolaser X4 that will be offered to men between 40 and 85 years of age, with moderate or severe international prostate symptoms scores and concomitant objective decrease in flow studies of at 30% consistent with bladder outlet obstruction||||
33820250|NCT00214162|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820251|NCT00792402|||CASE_CONTROL||PROSPECTIVE|||||||
33820252|NCT06090318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820253|NCT04793555|NA|SINGLE_GROUP||PREVENTION||NONE||Single-center prospective non-inferiority study||||
33820254|NCT01170871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820255|NCT02497547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127663|NCT02628041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127664|NCT06219915|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34127665|NCT05670639|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127666|NCT02327585||PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33820256|NCT03174470|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34127667|NCT01060748|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34127668|NCT05173844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34127669|NCT03199794|||COHORT||PROSPECTIVE|||||||
34127670|NCT01403779|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127671|NCT01123031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127672|NCT01642056|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34127673|NCT01840813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127674|NCT00046189|||COHORT||PROSPECTIVE|||||||
33820257|NCT00473512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820258|NCT00221156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820259|NCT03126721|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33820260|NCT03167476|||COHORT||PROSPECTIVE|||||||
33820261|NCT06645522|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820262|NCT06539390|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33820263|NCT02765347|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820264|NCT04013347|||CASE_CONTROL||RETROSPECTIVE|||||||
33820265|NCT06113822|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33820266|NCT03741283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820267|NCT06719596|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33820268|NCT04213625|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33820269|NCT02092285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820270|NCT05682040|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820271|NCT00647699|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820272|NCT05613647|||COHORT||PROSPECTIVE|||||||
33820273|NCT04303598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The experiment was conducted under a randomized method, each center disputed into the group via competition. Treatment assignment was carried out in accordance with a central randomization schedule generated with SAS (version 9.4). Randomization was done by a computer-generated system (IWRS). The randomization table (1st blind code) and second blind code were sealed and stored in triplicate offices of the sponsor, investigator and the independent statistician.||t|t|f|f
33820274|NCT00609245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820275|NCT00005843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820276|NCT04770571|||COHORT||PROSPECTIVE|||||||
33820277|NCT00155961|||||OTHER|||||||
33820278|NCT03127475|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33820279|NCT06129656|||COHORT||PROSPECTIVE|||||||
33820280|NCT00216788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820281|NCT06355037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820282|NCT04659083|||COHORT||PROSPECTIVE|||||||
33820283|NCT01257386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33820284|NCT04613817|||COHORT||PROSPECTIVE|||||||
33820285|NCT00432445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820286|NCT03768986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820287|NCT03628612|NA|SINGLE_GROUP||OTHER||NONE||||||
33820288|NCT00043368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820289|NCT04301609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820290|NCT01341418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820291|NCT05315076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820292|NCT04533334|||COHORT||PROSPECTIVE|||||||
33820293|NCT00246129|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820294|NCT05455281|||COHORT||RETROSPECTIVE|||||||
33820295|NCT00266162|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820296|NCT00845286|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33820297|NCT03583944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820298|NCT06049888|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33820299|NCT02672345|||CASE_CONTROL||PROSPECTIVE|||||||
33820300|NCT01774929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820301|NCT02362100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820302|NCT05399667|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33820303|NCT05194631|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a prospective cross-sectional study involving category humans, which aims is to assess the pathophysiological mechanisms of a deficit in muscle fiber regeneration||||
33820304|NCT02261922|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33820305|NCT06577103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820306|NCT04966351|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820307|NCT00002540|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33820308|NCT04503889|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and outcome assessor will be unaware regarding the type (real or sham) taVNS intervention||t|f|f|t
33820309|NCT00841165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820310|NCT04940533|||COHORT||PROSPECTIVE|||||||
33820311|NCT04968314|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33820312|NCT01084408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820313|NCT06529068|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33820314|NCT04883619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820315|NCT04027673|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33837254|NCT03613389|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837255|NCT02975063|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34127675|NCT03276728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|Double-blind, placebo-controlled|t|f|t|f
34048627|NCT04447001|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be randomly assigned to immediately begin short 6-week modified tai chi course along with a personal home practice plan to receive greater Tai chi dose(session 1) or complete a 8-week wait (wait-list control). Wait-list group will be receiving Tai-chi prime intervention after 8 weeks wait time (session-2).~In addition to the pre-post tests of TCF sessions to explore TCF effectiveness, pre-test scores for session 2 are compared to post-test scores of session 1 participants since both are collected at nearly the same time."||||
34048628|NCT04852562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34048629|NCT03119350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048630|NCT06666556|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The main investigators will be in charge of randomizing all the patients ellegible for this protocol, and the care providers and endoscopists will be masked when it comes to knowing to which arm of the study each patient belongs to, untill the moment they need to perform the colonoscopy.|multicenter single-blind randomized clinical trial study|f|t|f|f
34048631|NCT04959929|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will be assigned to a single group that will receive focal vibration therapy using Myovolt.||||
34048632|NCT03870308|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34048633|NCT05924191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34048634|NCT05553457|NA|SINGLE_GROUP||OTHER||NONE||||||
34048635|NCT06082063|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study uses a PROBE design (prospective, cluster-randomized, open, blinded endpoint evaluation). The study is a superiority trial.||||
34048636|NCT02177487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048637|NCT00679029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048638|NCT02697526|RANDOMIZED|PARALLEL||||NONE||||||
34048639|NCT02964507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048640|NCT02272231|||COHORT||PROSPECTIVE|||||||
34048641|NCT05457257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048642|NCT06589778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048643|NCT01580579|||COHORT||PROSPECTIVE|||||||
34048644|NCT01017276|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048645|NCT06601946|RANDOMIZED|PARALLEL||OTHER||SINGLE||randomized controlled trial|t|f|f|f
34048646|NCT06574555|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|||t|t|f|t
34048647|NCT06032377|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants with insomnia and subjective cognitive complaint are randomized into 2 groups with a 1:1 allocation ratio, after the pre-treatment assessment. Allocation will be stratified based on a composite mental health score and hypnotic medication intake. Follow-up assessments will occur 10 weeks and 24 weeks after the start of the intervention.~One group will receive the online CBT for sleep and mental health after the baseline assessment and the other group will receive the control intervention. The group receiving the control intervention will access the CBT intervention after completion of the study.~A good sleepers group, matched on age and gender, will also be recruited and assessed at baseline only to provide a normative reference group.~A subgroup of participants from the insomnia group and the good sleepers group will undergo MRI and classical neuropsychological testing at baseline and 24 weeks after the start of the intervention."||||
34048648|NCT00323791|RANDOMIZED|||TREATMENT||||||||
34048649|NCT06667219|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Children will be invited to participate in the after-school physical activity experiment.This experiment will include more than 108 participants randomly assigned to the experimental group (n=54) and the control group (n=54) (randomly selected two kindergartens, one as experimental group and one as control group). All studies will be conducted in Zengcheng Kindergarten, Guangdong, China. Children will participate in this study and participats (parents/guardians) will receive a prescription for childhood exercise.||||
34048650|NCT06685484|RANDOMIZED|PARALLEL||TREATMENT||NONE||A feasibility trial using the ADAPT-ITT framework will randomly assign participants to two groups.||||
34048651|NCT06684756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048652|NCT01063621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048653|NCT03846154|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048654|NCT00065559|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34048655|NCT04967885|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants are randomly assigned to either the Immediate Intervention, or Waitlist conditions. The Immediate Intervention participants receive the Ecological Momentary Intervention plus Implementation Intentions (EMI-II) immediately after randomization for two weeks, followed by two weeks of surveys. The Waitlist participants complete two weeks of surveys, followed by two weeks of receiving the EMAs plus EMI-II.||||
34048656|NCT02621710|||COHORT||PROSPECTIVE|||||||
34048657|NCT03600194|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will wear a PSG both nights, the set-up between devices will not be the same, but similar|randomized, single-blind, sham-controlled pilot cross-over trial comparing|t|f|f|f
34048658|NCT03619863|||COHORT||PROSPECTIVE|||||||
34048659|NCT04691843|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34048660|NCT02407145|||CASE_ONLY||PROSPECTIVE|||||||
34048661|NCT05758402|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34048662|NCT02254967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048663|NCT03643133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048664|NCT05629637|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34048665|NCT05824507|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective cohort tertiary single-center study||||
34048666|NCT06589245|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||An open label dose escalation||||
34048667|NCT02430649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34048668|NCT06226545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masked treatment arms for patients without prior anti-IGF-1R treatment, and open-label treatment arm for patients with prior teprotumumab treatment||t|f|t|f
34048669|NCT00434902|||COHORT||PROSPECTIVE|||||||
34048670|NCT03598257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048671|NCT03371017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048672|NCT04267757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34048673|NCT03222089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149294|NCT00491374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149295|NCT01560299|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34149296|NCT02274259|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048674|NCT05161780|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The surgeon will be blinded to the type of irrigation being used|Participants will consist of 30 patients undergoing skull base surgery for a Pituitary Adenoma. This study will be a prospective double blinded randomized controlled trial examining the efficacy of normal saline versus Lactated Ringer's in achieving clarity of the surgical field during endoscopic skull base surgery.|f|f|t|f
34048675|NCT02064712|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048676|NCT01258998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048677|NCT02429661|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34048678|NCT06675110|||COHORT||PROSPECTIVE|||||||
34127676|NCT04981301|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Ninety patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for lumbar disc herniation surgery will be included in the study. Patients will be randomly divided into two groups (Group Q = QLB group, Group C = Control group) including 30 patients each, before entering the operating room.|t|f|f|t
34127677|NCT01544101|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34127678|NCT03754556|||COHORT||RETROSPECTIVE|||||||
34127679|NCT02229786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34127680|NCT05042401|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||SHR-1703 low dose VS. placebo low dose. SHR-1703 high dose VS. placebo high dose|t|t|t|t
34127681|NCT02785783|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34127682|NCT04954300|||COHORT||PROSPECTIVE|||||||
34127683|NCT04587206|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127684|NCT05474456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127685|NCT04405999|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127686|NCT02178319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127687|NCT00565396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127688|NCT02492308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127689|NCT04498286|||COHORT||PROSPECTIVE|||||||
34127690|NCT02565693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127691|NCT06030973|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127692|NCT05870462|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34127693|NCT06275854|||COHORT||PROSPECTIVE|||||||
34127694|NCT04083703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127695|NCT00758693|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127696|NCT03391986|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Participant: only participants in the pyonex needle and placebo adhesive group will be masked during the study. Equipment is opened behind the participant and the needles and adhesives are placed outside the view of the participant.~Care Provider: A colored hat that covers the participants ears will be placed. Outcomes Assessor: Group assignment will be masked."|Participants will be randomized to either 1 - auricular acupuncture with pyonex needle, 2 - placebo adhesive, or 3 - routine care using a 1:1:1 ratio. The randomization scheme will use randomly permuted blocks with a block size of 6 or 9.|t|t|f|t
34127697|NCT03842891|||COHORT||PROSPECTIVE|||||||
34127698|NCT00298298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127699|NCT01458301|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127700|NCT04758286|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|An anesthetist who was not in charge for application of the protocol is responsible for assessing the intraoperative findings and another anesthetist was responsible for assessing the postoperative findings|All patients presenting with surgical emergency|f|f|f|t
34127701|NCT01663207|||CASE_CROSSOVER||PROSPECTIVE|||||||
34127702|NCT02610972|||CASE_CONTROL||PROSPECTIVE|||||||
34127703|NCT05123339|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34127704|NCT03181971|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127705|NCT06525610|NA|SINGLE_GROUP||OTHER||NONE||"\<1 week post-operation: 1 unloaded scan with the weight-bearing CT will be conducted 6 weeks: 1 unloaded and loaded scan with the weight-bearing CT. Subjects will get a one-time pre-paid, pre-addressed envelope with a DNA-free bag. They will place a stool sample in the bag collected on dry toilet paper and then send it to Dr. Jeremy Burton's lab at St. Joseph's Hospital for processing and analysis. Data will be processed at St. Joseph's Hospital site. Once DNA is extracted, the specimens will be destroyed and disposed. No further stool samples will be collected on follow-up visits.~1 year: 1 unloaded scan and 2 loaded scans with the weight-bearing CT will be conducted. A second loaded exam is performed at the 1-year visit as a double exposure exam to measure for clinically relevant measurement errors"||||
34127706|NCT01290146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127707|NCT03806530|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The study interventions will be blinded.|Participants will be randomly allocated to 1 of 8 treatment sequences. Each sequence is composed of 4 periods and in each period participants will receive 1 of 4 possible combinations of study medications (gabapentin+ropinirole, gabapentin+placebo ropinirole, ropinirole+placebo gabapentin, placebo gabapentin+placebo ropinirole).|t|t|t|t
34127708|NCT02267291|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127709|NCT05836831|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open-label|Multicentric, randomized, open-label, clinical trial|t|f|f|f
34127710|NCT00290719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149297|NCT01381536|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34149298|NCT01143194|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33820316|NCT05332522|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment A single-arm, open label design; All analyses are pre-post, with participants serving as their own controls.||||
34048679|NCT04792801|||COHORT||PROSPECTIVE|||||||
34048680|NCT06097013|||COHORT||PROSPECTIVE|||||||
34048681|NCT06085469|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048682|NCT03567005|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34048683|NCT01826578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048684|NCT01311076|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
34048685|NCT05018923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048686|NCT00832611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048687|NCT03383640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048688|NCT05348291|RANDOMIZED|PARALLEL||PREVENTION||NONE||Unblinded, randomised controlled trial.||||
34048689|NCT00538577|||CASE_CONTROL||PROSPECTIVE|||||||
33820317|NCT05736458|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|This study will use a single-blind design.|"All healthy participants will have TMS administered to both their high and low regional controllability targets, but the order is randomized and counterbalanced.~ADHD participants will have TMS administered to only their high regional controllability target."|t|f|f|f
33820318|NCT02615041|RANDOMIZED|PARALLEL||||NONE||||||
33820319|NCT04927299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33820320|NCT06032702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820321|NCT03520088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The analysis of the results will be blind for the investigator||f|f|f|t
33820322|NCT06415383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820323|NCT04824456|NA|SINGLE_GROUP||SCREENING||NONE||Patient with skeletal malocclusion, class II or class III that is indicated for bilateral sagittal split osteotomy.||||
33820324|NCT01287624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820325|NCT02159456|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33820326|NCT01545271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820327|NCT03598023|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-site, randomized, prospective study||||
33820328|NCT02440919|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33820329|NCT02325258|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33820330|NCT06111183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This phase 2 study is patient and central evaluator (of wound images) blinded.||t|f|f|t
33820331|NCT02690025|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33820332|NCT02146300|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820333|NCT04946097|RANDOMIZED|PARALLEL||TREATMENT||NONE||the control group which received the conventional selected exercise program and the study group received the same exercise training program in addition to gross Myofascial Release||||
33820334|NCT02886949|||COHORT||PROSPECTIVE|||||||
33820335|NCT03973645|||COHORT||RETROSPECTIVE|||||||
33820336|NCT02586961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820337|NCT04855708|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33820338|NCT02239666|||OTHER||PROSPECTIVE|||||||
33820339|NCT05494099|||COHORT||PROSPECTIVE|||||||
33820340|NCT00591188|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820341|NCT02539602|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33820342|NCT04143802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33820343|NCT02080117|||COHORT||RETROSPECTIVE|||||||
33820344|NCT03463291|||CASE_CONTROL||PROSPECTIVE|||||||
33820345|NCT02618200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820346|NCT03045549|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will be assessed for clinical outcomes by an independent rater blinded to the study arm||f|f|f|t
33820347|NCT01306409|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33820348|NCT04557683|||COHORT||PROSPECTIVE|||||||
33820349|NCT02789098|NA|SINGLE_GROUP||OTHER||NONE||||||
33820350|NCT05480202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820351|NCT03452735|||CASE_CONTROL||PROSPECTIVE|||||||
33820352|NCT00647452|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820353|NCT00049751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820354|NCT04156256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820355|NCT03559452|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820356|NCT00762853|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820357|NCT05395078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820358|NCT01662661|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820359|NCT01717755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820360|NCT01550822|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33820361|NCT01699802|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33820362|NCT04728659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820363|NCT06585410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820364|NCT02815709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820365|NCT04520685|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||"For this study, participants will be randomly assigned to one of the following groups:~1. Group A will receive cannabidiol for the first 12 weeks of the study and placebo for the last 15 weeks.~2. Group B will receive placebo for the first 15 weeks of the study and cannabidiol for the last 12 weeks~3. Group C will receive cannabidiol throughout the entire 27 weeks of treatment"|t|t|t|f
33820366|NCT02819271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820367|NCT00464737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820368|NCT02389335|||COHORT||PROSPECTIVE|||||||
33820369|NCT00109161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33820370|NCT02721420|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33820371|NCT04105764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34048690|NCT06685549|||CASE_CONTROL||PROSPECTIVE|||||||
34048691|NCT00969098|||COHORT||RETROSPECTIVE|||||||
33820372|NCT00974402|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820373|NCT06645990|||COHORT||RETROSPECTIVE|||||||
33820374|NCT03303547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820375|NCT01339156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820376|NCT05921383|||CASE_CONTROL||PROSPECTIVE|||||||
33820377|NCT03079284|NA|SINGLE_GROUP||OTHER||NONE||||||
33820378|NCT02718053|||||PROSPECTIVE|||||||
33820379|NCT02916745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820380|NCT01064856|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820381|NCT02188784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820382|NCT02173561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820383|NCT04297423|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A comparative, parallel, randomized, non-inferiority, non-blinded, single-centre and low-intervention clinical trial||||
33820384|NCT06562244|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33820385|NCT03196180|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820386|NCT06471413|||OTHER||PROSPECTIVE|||||||
33820387|NCT00796640|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34048692|NCT00900159|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820388|NCT02232958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820389|NCT01973179|||COHORT||PROSPECTIVE|||||||
33820390|NCT00489697|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820391|NCT05234008|NA|SINGLE_GROUP||TREATMENT||NONE||This pilot cohort study includes one group of 15 participants (i.e. persons with CLBP) and involves a six-week HIT exercise intervention with a total of 12 rehabilitation sessions (two sessions per week).||||
33820392|NCT01107912|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33820393|NCT01545245|||COHORT||PROSPECTIVE|||||||
33820394|NCT06593288|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized clinical trial with 2 arms||||
33820395|NCT00847847|NON_RANDOMIZED|PARALLEL||||NONE||||||
33820396|NCT06326281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients were not told which method would be used The person evaluating the patients did not know which method was applied to which patient.|Evaluation of postoperative pain in 4 groups in laparoscopic cholecystectomy with control group|t|f|f|t
33820397|NCT05911191|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|None of the evaluators or caregivers will know the group assignment of each participant. The person responsible for analyzing the data will only see on the data sheet whether they belong to group 1 or group 0, but they will not know which group each of the values is assigned to.|A prospective, parallel, non-randomised, single-centre, clinical trial|f|t|t|t
33820398|NCT04161872|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820399|NCT04462653|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820400|NCT02473913|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33820401|NCT04299698|||COHORT||PROSPECTIVE|||||||
33820402|NCT01622088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820403|NCT02100189|NA|SINGLE_GROUP||SCREENING||NONE||||||
33820404|NCT01854164|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820405|NCT02984787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820406|NCT03788941|||COHORT||PROSPECTIVE|||||||
33820407|NCT01817127|||COHORT||PROSPECTIVE|||||||
33820408|NCT06338891|||CASE_CONTROL||PROSPECTIVE|||||||
33820409|NCT01398345|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820410|NCT05728619|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33820411|NCT04851444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820412|NCT02023099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820413|NCT04781699|||COHORT||OTHER|||||||
33820414|NCT04416256|||COHORT||PROSPECTIVE|||||||
33820415|NCT05153161|NA|SINGLE_GROUP||TREATMENT||NONE||a proven protocol to test a pharmacological treatment of agitation in AD/ADRD persons using individuals in nursing homes and assisted care settings||||
33820416|NCT06539936|NA|SINGLE_GROUP||OTHER||NONE||Single-Case Experimental Design (SCED)||||
33820417|NCT04945356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820418|NCT00543634|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33820419|NCT06310278|||COHORT||PROSPECTIVE|||||||
33820420|NCT05971186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This quantitative study uses a Single-blind Randomized Controlled Trial (RCT) design. Key roles, including researcher, subjects, data analyst, collector, and assistant, ensure blinding to individual treatments. Blinding subjects is infeasible due to distinct interventions (young coconut water, dark chocolate, Ibuprofen). The research hypothesis remains undisclosed in the Informed Consent. Subjects won't discuss interventions with involved parties. Implementing this robust design aims to generate unbiased results contributing to scientific knowledge.|"The sample comprised 45 female students from Saleha Midwifery Academy who met the inclusion criteria and voluntarily consented after a detailed explanation. Sample size was determined using the Federer formula, yielding a minimum of 9 participants per group. However, 15 samples were included in each of the three treatment groups, resulting in a total of 45 subjects due to the three interventions.~Simple random sampling via Microsoft Excel's random name selection feature was used to select participants from the accessible population. Random allocation to treatment or control groups was done without bias, using a blocking system and designated application.~The samples were divided into three groups: Group 1 received young coconut water, Group 2 received 70% dark chocolate bar, and Group 3 received 1 tablet of Ibuprofen, an NSAID. Allocation to each group was randomized using a designated application and a block system."|f|t|t|t
33820421|NCT02067000|||COHORT||PROSPECTIVE|||||||
33820422|NCT02788305|||COHORT||PROSPECTIVE|||||||
33820423|NCT04928235|||CASE_ONLY||PROSPECTIVE|||||||
33820424|NCT04026022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820425|NCT01034683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820426|NCT02750371|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33820427|NCT03473912|||COHORT||PROSPECTIVE|||||||
33820428|NCT03899285|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Over-encapsulation was performed to maintain blind.~Every participant will have the same step (visits, follow up, questionnaire and interview)."|"Preparation phase (Phase 1) : Every enrolled patients start with citalopram 10 mg daily for 3 days and 20 mg daily for 11 days.~Escalation phase (Phase 2) :This phase is split in two arms which are the responders and the non-responders. Responders will pursue their citalopram 20 mg for 14 days. Non-responders will be assigned randomly 1:1 in 2 groups. Patients in group A will be randomized to receive a pill of citalopram 20 mg and a capsule of citalopram 20 mg for 14 days. The total dose of citalopram will be 40 mg once daily. Patients in group B receive a pill of citalopram 20 mg and a capsule of placebo (a capsule without medication) for 14 days. The total dose of citalopram will be 20 mg once daily.~Follow-up phase (Phase 3) : Every responders will pursue their treatment of citalopram 20 mg daily for 28 days. It's possible that in this group, the treatment approach may vary depending the physician. Every non-responders (group A and B) will receive 40 mg of citalopram for 28 days."|t|t|t|t
33820429|NCT04815707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820430|NCT01634620|||CASE_ONLY||PROSPECTIVE|||||||
33820431|NCT00054730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33820432|NCT03569891|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The reference therapy is prophylactic factor IX replacement therapy used during the lead-in phase prior to treatment with AAV5-hFIXco-Padua (AMT-061).||||
33820433|NCT05820542|||OTHER||PROSPECTIVE|||||||
33820434|NCT01836497|||CASE_ONLY||PROSPECTIVE|||||||
33820435|NCT02115945|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820436|NCT03556345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820437|NCT03195699|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820438|NCT01090232|NON_RANDOMIZED|PARALLEL||||NONE||||||
33820439|NCT01995565|||||PROSPECTIVE|||||||
33820440|NCT06092879|||COHORT||PROSPECTIVE|||||||
33820441|NCT06600815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researchers, outcome assessors and statisticians will be blinded to the group assignments and will not be involved in the trial operations. The patients will also be blinded to the group assignments. Due to the impossibility of blinding the surgeons, they will not be involved in any outcome assessments. Allocation results will be placed in sealed envelopes before the surgery. The envelopes will be opened prior to surgery after the administration of general anaesthesia.|The trial employs a random allocation method. A randomization table will be generated using SPSS 26.0 software. Treatment groups will be selected based on patients' random numbers, ensuring that this clinical institution stratifies the subjects into a PSIA group and a PLIA group at a 1:1 ratio.|t|f|f|t
33820442|NCT03694249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820443|NCT00233207|RANDOMIZED|||TREATMENT||DOUBLE||||||
33820444|NCT01243086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820445|NCT06510946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820446|NCT02889809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820447|NCT05383053|||OTHER||RETROSPECTIVE|||||||
33820448|NCT01112163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820449|NCT04320602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820450|NCT05849220|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820451|NCT06646120|||OTHER||CROSS_SECTIONAL|||||||
33820452|NCT04971889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820453|NCT02893371|||COHORT||RETROSPECTIVE|||||||
33820454|NCT03703999|||CASE_ONLY||PROSPECTIVE|||||||
33820455|NCT03130699|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820456|NCT05281419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820457|NCT02064309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820458|NCT01095237|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820459|NCT03296176|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33820460|NCT06379321|||COHORT||OTHER|||||||
33820461|NCT03563131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820462|NCT02551926|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33820463|NCT06313606|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820464|NCT04619420|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||There will be 3 treatment arms for the Double-Blind treatment period, whereas there will be only 2 treatment arms for the Long-Term extension treatment period.|t|t|t|t
33820465|NCT03404440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Placebo capsules were identical in shape, colour and taste to Gastrus capsules but without L. reuteri|double-blind randomized, parallel-group, placebo-controlled study.|t|f|t|f
33820466|NCT02359552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820467|NCT01532024|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820468|NCT00006747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820469|NCT04842227|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820470|NCT03330197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820471|NCT00495612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820472|NCT00471562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820473|NCT04233411|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33820474|NCT02382913|RANDOMIZED|PARALLEL||||NONE||||||
33820475|NCT01635699|||CASE_ONLY||PROSPECTIVE|||||||
33820476|NCT03965481|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820477|NCT00839306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820478|NCT05906056|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|CT will not reveal the group of patient's origin to the reader|randomized control trial|f|f|f|t
33820479|NCT06633133|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33820480|NCT05658445|||CASE_CONTROL||PROSPECTIVE|||||||
33820481|NCT04632264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be achieved using a computer generated algorithm. Both patient and provider will be unaware of the allocation arm.|Two parallel randomized, placebo-controlled, and double-blinded studies. For this study we will include 52 scheduled cesarean sections and 52 vaginal deliveries as two separate cohorts.|t|t|f|f
33820482|NCT06471842|||CASE_ONLY||PROSPECTIVE|||||||
33820483|NCT00687128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820484|NCT06230692|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820485|NCT05951777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820486|NCT01375777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820487|NCT00639639|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820488|NCT01651650|NA|SINGLE_GROUP||OTHER||NONE||||||
33820489|NCT01495754|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33820490|NCT03456206|||COHORT||PROSPECTIVE|||||||
33820491|NCT01125436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820492|NCT00293332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820493|NCT02591875|||COHORT||PROSPECTIVE|||||||
33820494|NCT05078450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149299|NCT03323190|NA|SINGLE_GROUP||OTHER||NONE||||||
34149300|NCT06061107|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34149301|NCT00963768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149302|NCT03702907|||COHORT||PROSPECTIVE|||||||
34149303|NCT01998191|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33820495|NCT01818245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33820496|NCT06453304|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820497|NCT06342635|||CASE_ONLY||PROSPECTIVE|||||||
33820498|NCT03552471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820499|NCT03323814|||COHORT||PROSPECTIVE|||||||
33820500|NCT06006780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820501|NCT04712500|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820502|NCT01690871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820503|NCT01061775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820504|NCT02570971|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34127711|NCT04819529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"In this study, researchers, recruiters, evaluators, control group team and data analyst will be masked. These teams will not have contact with the interventionists of the experimental group. Evaluators who have contact with the patients of both groups, they will be professionals from other medical units, who do not know the ICU team, and will only be able to maintain their dialog, according to the guideline of each evaluation.~It is not possible to mask the treating occupational therapist and patient receiving OT."|A control group (standard ASDM measures) or an intervention group (early and intensive occupational therapy + ASDM) will be randomized. The intervention group will receive 20 occupational therapy sessions. The interventions will be organized on the basis of i) level of sedation, ii) presence or absence of delirium (according to CAM ICU +/- (Confusion Assessment Method Intensive Care Unit)), iii) movement with or without gravity (cut-off point 3 points in elbow flexion movement in Medical Research Council(MRC)). The areas of intervention implemented by occupational therapist will be: i) Polysensory stimulation, ii) Cognitive stimulation, iii) Basic activities of daily living, iv) Motor function stimulation, v) Education|f|t|t|t
34127712|NCT05761808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127713|NCT01732705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127714|NCT05674227|||COHORT||OTHER|||||||
34127715|NCT04830839|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group design as all eligible participants will be offered the 8 session Recovery after Stress Toolkit (ReSeT) program, including 8 self-guided child modules and 4 parent modules, as well as 8 parallel videoconferencing sessions with a therapist.||||
34127716|NCT06553105|||CASE_ONLY||OTHER|||||||
34127717|NCT03352999|NA|SINGLE_GROUP||OTHER||NONE||Prospective, monocentric, open, routine care assessment study||||
34127718|NCT04779307|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127719|NCT01470131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127720|NCT03981744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127721|NCT02864212|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127722|NCT04739930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The control group will receive a 0.5cm sham incision over the iliac crest, but bone marrow aspiration will not be performed.|Prospective, Randomized, Single Blind Clinical Trial|t|f|f|f
34127723|NCT02413996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A phase III randomized clinical trial was approved by the San Raffaele Hospital's Ethic Committee of Milan (31/03/2014)|f|f|t|t
34127724|NCT05117151|||COHORT||PROSPECTIVE|||||||
34127725|NCT01417221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127726|NCT00008411|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127727|NCT03706768|NA|SINGLE_GROUP||OTHER||NONE||Aneurysmal Subarachnoid Hemorrhage||||
34127728|NCT04903574|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34127729|NCT02904174|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34127730|NCT04863053|||COHORT||PROSPECTIVE|||||||
34127731|NCT04424459|||CASE_CONTROL||PROSPECTIVE|||||||
34127732|NCT05250167|||OTHER||CROSS_SECTIONAL|||||||
34127733|NCT04961281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Investigate if, and to what extent,carapl tunnel hydro-dissection using DEX or triamcinolone (TM) along with saline, under ultrasound guidance, can improve the clinical condition, change in nerve conduction parameters of patients with CTS and delay or avoid the surgical intervention.|t|f|f|t
34127734|NCT00848237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127735|NCT03000556|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34127736|NCT02750046|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34127737|NCT02466477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127738|NCT01669694|||COHORT||PROSPECTIVE|||||||
34127739|NCT06164691|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomization will achieved with block randomization on the following characteristics:~1. Type of cancer: group 1: pancreatic cancer; group 2: rectal cancer.~2. Stage of cancer as defined by Tumor Node Metastasis classification.~b. Age (\<55 years, \>/= 55 years)"||||
34127740|NCT04715841|||COHORT||CROSS_SECTIONAL|||||||
34127741|NCT06404242|||COHORT||PROSPECTIVE|||||||
34127742|NCT00660972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127743|NCT00839280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127744|NCT06487637|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||CardioCare Quest will be the first telehealth game designed to enhance High Blood Pressure (HBP) treatment compliance and education about HBP, featuring a telemetry system that provides physicians and researchers data about sustainable healthy heart lifestyles beyond the clinic. The novelty of CardioCare Quest lies in its ability to compel HBP patients to playfully celebrate the mundane everyday practices that lead to sustainable habits and improved health outcomes using culturally sensitive and community-based design practices.||||
34127745|NCT02837471|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34127746|NCT05770297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"there will be a comparison group that will receive intervention in the same amount, preparation, and form, but only contain a placebo in the form of a 70% caramel alcohol dye solution. Investigator and participant will not know the contain of intervention that has given.~Randomization of participants was carried out based on the arrival of participants to the obstetrics and gynecology clinic at the Cipto Mangunkusumo Hospital by labeling A for the intervention group and B for the treatment group. then data collection is carried out according to research procedures"|Endometriosis patients with menstrual pain who received LNG implant therapy were divided into two groups, each group consisted of 12 samples. The control group only received LNG, the treatment group received LNG with the addition of propolis. Propolis is given 2 times a day, namely in the morning before breakfast and at night before going to bed, with a dose of 1 drop /10 kg body weight (kgBW). Both groups were followed and reassessed after 1 month, 3 months both clinical and laboratory. Prior to receiving therapy, all subjects received education and signed informed consent for their willingness to participate in the study|t|f|t|f
34127747|NCT01195818|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34127748|NCT01271842|||CASE_CONTROL||PROSPECTIVE|||||||
34127749|NCT04904029|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|The investigator will be blinded for group intervention and outcomes data-analysis.|Pilot study to inform a pilot randomised, double-blinded, crossover, non-inferiority trial with two arms (to account for order effects).|f|t|t|t
34127750|NCT04426773|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127751|NCT01141998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820505|NCT04923893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820506|NCT03082638|||CASE_CONTROL||PROSPECTIVE|||||||
33820507|NCT06608459|NA|SINGLE_GROUP||OTHER||NONE||||||
33820508|NCT03639792|||COHORT||PROSPECTIVE|||||||
33820509|NCT05440578|||COHORT||RETROSPECTIVE|||||||
33820510|NCT04453709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820511|NCT01914302|||CASE_ONLY||CROSS_SECTIONAL|||||||
33820512|NCT03652064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820513|NCT02345421|||CASE_ONLY|||||||||
33820514|NCT02191514|||COHORT||RETROSPECTIVE|||||||
33820515|NCT05532319|NA|SINGLE_GROUP||TREATMENT||NONE||The aim of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with unresectable hepatocellular carcinoma (HCC), and to explore the optimal benefit population.||||
33820516|NCT03275480|||COHORT||OTHER|||||||
33820517|NCT05626920|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized Cross-over study|t|t|t|t
33820518|NCT02454647|||COHORT||RETROSPECTIVE|||||||
33820519|NCT06439537|||COHORT||PROSPECTIVE|||||||
33820520|NCT04551469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33820521|NCT02469493|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33820522|NCT04382807|||CASE_ONLY||PROSPECTIVE|||||||
33820523|NCT00062270|RANDOMIZED|||TREATMENT||NONE||||||
33820524|NCT04121949|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Allocation will be hidden from the independent Clinical Events Committee.|This study is designed as a randomized, controlled, multicentre, superiority trial with two parallel groups including patients with symptoms suggestive of stable CAD at a low-to-intermediate likelihood of obstructive CAD (pre-test probability of 0-85%). Subjects will be randomized 1:1 to either (1) standard diagnostic strategy according to current guidelines, i.e. DF-score stratification followed by NIT, if indicated, or (2) DF-score plus CAD-score stratification followed by NIT, if indicated.|f|f|f|t
33820525|NCT03550014|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized to have receive physical therapy targeting the low back only or low back plus hip(s). Neither the participants or investigators can be blinded during this trial.||||
33820526|NCT05360706|||COHORT||PROSPECTIVE|||||||
33820527|NCT02395588|||COHORT||PROSPECTIVE|||||||
33820528|NCT02942134|||CASE_ONLY||PROSPECTIVE|||||||
33820529|NCT03921164|||OTHER||PROSPECTIVE|||||||
33820530|NCT01189136|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820531|NCT01400217|||CASE_CONTROL||RETROSPECTIVE|||||||
33820532|NCT03868930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessments are all self-report, therefore, blinded assessors are not required.|Participants will be randomly assigned to one of the two group interventions: STEP-Home or Present Centered Group Therapy (PCGT). Each cohort will include a minimum of 8 and a maximum of 20 participants who will be randomized to either STEP-Home (n = 4-10 Veterans) or PCGT (n = 4-10 Veterans). After inclusion and exclusion criteria are verified and a cohort of 8 to 20 is available, randomization into STEP-Home or PCGT occurs and participation in the study begins (i.e., Time 1; T1: Pre), during which the investigators will consent, administer the baseline assessments, randomly assign to the STEP-Home or PCGT arm, and schedule the treatment sessions. All participants will be assessed at the following outcome points: Screening, at randomization (T1), during treatment 4-week skills check (T2), during treatment 8-week skills check (T3), post-intervention (T4), and at 3-months follow up (T5).|t|f|f|f
33820533|NCT03856645|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820534|NCT00117650|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820535|NCT04028128|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Cocoa and maltodextrin (placebo) are provided in identical sachets which are identified with the letters A and B respectively.|Placebo controlled study|f|f|t|t
33820536|NCT00714688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820537|NCT01174147|||CASE_ONLY||PROSPECTIVE|||||||
33820538|NCT04011995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820539|NCT03878147|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The subject population for this proposal will consist of 600 children roughly equally divided between males and females and between HIV exposed uninfected and HIV unexposed and uninfected. These are Ugandan and Malawian children 5-12 years of age at study initiation who live in Uganda or Malawi.||||
33820540|NCT00002878|RANDOMIZED|||TREATMENT||||||||
33820541|NCT06647173|||COHORT||PROSPECTIVE|||||||
33820542|NCT00004276|RANDOMIZED|||TREATMENT||DOUBLE||||||
33820543|NCT05707689|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Statisticians will be masked. Gaming facilitators, research assistant who collect the data or staff working in the study sites are not masked.|A controlled clinical trial with a pragmatic, multi-center, two-arms parallel-group design.|f|f|t|f
33820544|NCT05384522|||CASE_ONLY||PROSPECTIVE|||||||
33820545|NCT06611657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820546|NCT00702520|||OTHER||PROSPECTIVE|||||||
33820547|NCT05510102|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Investigators are blinded to subject intervention group (data blinded versus data unblinded)|Subjects will be randomized to a treatment group (full remote monitoring data) versus a control arm (blinded data).|f|f|t|f
33820548|NCT00160329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820549|NCT04120623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820550|NCT05382390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To compensate for the need for an open-label design, the primary outcome data are collected with blinding. The staff responsible for data monitoring and statistician will also be blinded to the treatment groups until the statistical analysis was finalized.||f|f|f|t
33820551|NCT01765439|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820552|NCT02339506|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33820553|NCT01050699|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33837256|NCT00289250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837257|NCT06012981|NA|SINGLE_GROUP||TREATMENT||NONE||Single-case experimental design.||||
33837258|NCT00512616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837259|NCT05492305|||COHORT||PROSPECTIVE|||||||
33837260|NCT00158067|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837261|NCT02893189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127752|NCT00002395||||TREATMENT||NONE||||||
33837262|NCT05594277|||COHORT||PROSPECTIVE|||||||
33837263|NCT02495766|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33837264|NCT01250509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837265|NCT04849299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837266|NCT02597322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048693|NCT03149133|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The investigator and outcome assessor are blinded to groups.|Randomized controlled trial|f|f|t|t
34048694|NCT01741935|||COHORT||PROSPECTIVE|||||||
34048695|NCT01502332|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34048696|NCT06661954|NA|SINGLE_GROUP||OTHER||NONE||||||
34048697|NCT05711485|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34048698|NCT04800887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masked- patient and investigator are masked|each patient in group received monofocal intraocular lens in one eye and extended depth of focus intraocular lens in second eye|t|f|t|f
34048699|NCT00857896|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34048700|NCT05193539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The researcher responsible for randomization was independent from the assessors, assuring blindness to treatment allocation and randomization procedures. The blinded assessor performed the baseline and post-treatment assessments. The patients and the occupational therapists were not blinded due to the nature of treatment modality.|A randomized, single-blinded study. Individuals were randomly assigned to either the experimental group or control group using a computer-generated randomization technique. The randomization list was created on blocks of four and generated at the start of the study using a computerized program.|f|f|t|t
34048701|NCT03269669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048702|NCT03990350|||CASE_CONTROL||PROSPECTIVE|||||||
34048703|NCT04915976|||COHORT||OTHER|||||||
34048704|NCT02580617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048705|NCT03157128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048706|NCT01498211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34048707|NCT02632409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34048708|NCT06682182|||COHORT||PROSPECTIVE|||||||
34048709|NCT00900887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34048710|NCT00977314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34048711|NCT03798899|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34048712|NCT06202508|||CASE_ONLY||OTHER|||||||
34048713|NCT03814967|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34048714|NCT02880280|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048715|NCT01108276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048716|NCT06604689|||COHORT||PROSPECTIVE|||||||
34048717|NCT04102748|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34048718|NCT03386643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both patients and investigators who will assess the outcomes have no knowledge of the interventions assigned to individual participants.|Symptomatic patients presenting OLP will be randomly assigned to either topical Bifidobacterium animalis subsp lactis HN019 or clobetasol propionate 0.05%, and they will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 (experimental group) or 0.05% clobetasol propionate (control group) for mouth washing, twice a day for 4 weeks.|t|f|t|f
34048719|NCT03769103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048720|NCT03054090|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34048721|NCT01757938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34048722|NCT06573983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors and investigators will be blinded to assignment during phase 2. Participants and care providers are unable to be blinded as delivery of treatment outside of standard of care will demonstrate group assignment.|There are two phases to the study. The first phase will include refinement of the intervention by examining quantitative and qualitative data from a small number of participants with no control. The second phase will be a randomized feasibility pilot where the intervention group will be compared to standard of care.|f|f|t|t
34048723|NCT02401490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34048724|NCT02258438|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34048725|NCT04737252|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled pilot trial||||
34048726|NCT05969977|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||The study consists of 5 planned single-dose cohorts (n = 8 per cohort, total randomized 6 active: 2 placebo) with sentinel design followed by 2 multiple-dose cohorts (n = 8 per cohort, total randomized 6 active: 2 placebo).|t|t|t|t
34048727|NCT06303167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127753|NCT04963075|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects will participate in weekly sessions (1.5-2 hours) for three months which contain baseline testing, training, and repeated testing of visual recovery||||
34127754|NCT04464811|||COHORT||PROSPECTIVE|||||||
34127755|NCT03180580|NA|SINGLE_GROUP||OTHER||NONE||||||
34127756|NCT06092112|NA|SINGLE_GROUP||TREATMENT||NONE||The subjects with advanced HCC will be treated by CD-801 through the hepatic artery injection||||
34127757|NCT05312684|||COHORT||RETROSPECTIVE|||||||
34127758|NCT04181229|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment arm - DBS Control arm - Continued VNS (optimization)||||
34127759|NCT03320967|||COHORT||PROSPECTIVE|||||||
34127760|NCT03353987|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The attending anaesthetist and assessors will be blinded|"Home based cognitive training (CogniTrain)~Intervention: Using memory logbook and newspaper cuttings for cognitive improvement"|f|t|f|t
34127761|NCT01633840|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
34127762|NCT04082650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants and most researchers will be unaware of the actual grouping. Only two researchers who are not involved in participant management or data analysis will be aware of the grouping.~Vitamin D and placebo pills with identical package, size, colour and appearance will be used in this trial. In general, there should be no need to unblind the allocation. If urgent unbinding to participants is necessary, the allocation will be disclosed to the treating physician."||t|f|t|t
34127763|NCT01295151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127764|NCT01951196|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33837267|NCT03394677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837268|NCT03647761|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127765|NCT00414323|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34127766|NCT04470882|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127767|NCT01453491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127768|NCT02159209|||COHORT||PROSPECTIVE|||||||
34127769|NCT04379297|||COHORT||PROSPECTIVE|||||||
34127770|NCT05689489|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34127771|NCT01179984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127772|NCT00984594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127773|NCT03168932|||COHORT||CROSS_SECTIONAL|||||||
34127774|NCT00288886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127775|NCT02585115|||COHORT||PROSPECTIVE|||||||
34127776|NCT00260728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127777|NCT00219492|||||PROSPECTIVE|||||||
34127778|NCT05308303|||COHORT||RETROSPECTIVE|||||||
34127779|NCT01751672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127780|NCT03358420|||CASE_ONLY||RETROSPECTIVE|||||||
34127781|NCT03952767|NA|SINGLE_GROUP||OTHER||NONE||||||
34127782|NCT03565822|NA|SINGLE_GROUP||OTHER||NONE||||||
34127783|NCT03644225|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No randomisation|"Primary outcome:~Mechanical characterization of healthy and diseased skin using novel aspiration device and comparing it to the already validated Cutometer® MPA 580. Comparison of mechanical skin properties of healthy to patients' skin tissue (control vs. examined group).~Secondary outcome:~Defining predictors of the skin worsening."||||
34127784|NCT01423695|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127785|NCT01990976|||COHORT||PROSPECTIVE|||||||
34127786|NCT00924794|||CASE_ONLY||RETROSPECTIVE|||||||
34127787|NCT03570242|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127788|NCT02433496|||CASE_CONTROL||PROSPECTIVE|||||||
34127789|NCT03238703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127790|NCT06447155|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Care provider decides the type of feeding according to the randomization list which were prepared via a website (http://www.randomizer.org)|The babies were randomized into three groups; Group 1.The neonates who received bolus feeding,Group 2. The neonates who received continuous feeding Group 3. The control group who were not fed during TH. The control group was composed of historical newborns. Three groups were compared in terms of demographic characteristics and clinical outcomes.|t|f|t|f
34127791|NCT04090957|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There are 3 blinded arms in the Efficacy part and 1 open-labeled arm in the Safety part.|There are 3 blinded arms in the Efficacy part and 1 open-labeled arm in the Safety part.|t|t|t|t
34127792|NCT00714506|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34127793|NCT00709319|||COHORT||PROSPECTIVE|||||||
34127794|NCT01805687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127795|NCT03696550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single Group Assignment||||
34127796|NCT04399200|||COHORT||PROSPECTIVE|||||||
34127797|NCT04900844|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm trial, where the primary endpoint will be compared to a performance goal. The null hypothesis will be rejected (i.e. performance goal is met) if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is \< 11.6% and the p-value is less than 0.025.||||
34127798|NCT01340222|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127799|NCT03743714|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127800|NCT00429715|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34127801|NCT03472495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127802|NCT02644889|||COHORT||RETROSPECTIVE|||||||
34127803|NCT00378638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127804|NCT05740046|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34127805|NCT05646225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127806|NCT04767061|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34127807|NCT03402139|||COHORT||PROSPECTIVE|||||||
34127808|NCT05989139|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34127809|NCT02151903|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127810|NCT02866162|||CASE_CONTROL||PROSPECTIVE|||||||
34127811|NCT05604573|||COHORT||PROSPECTIVE|||||||
34127812|NCT06374927|||OTHER||PROSPECTIVE|||||||
34127813|NCT00690430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127814|NCT03114111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127815|NCT03911999|||COHORT||PROSPECTIVE|||||||
34127816|NCT00930917|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34127817|NCT02019953|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34127818|NCT03056235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127819|NCT05545787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127820|NCT02253095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127821|NCT04140786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127822|NCT02372695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127823|NCT02614339|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127824|NCT01253369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127825|NCT05386147|NA|SINGLE_GROUP||PREVENTION||NONE||A single group of women with recurrent bacterial vaginosis who elect to participate in the study will be assessed before and after using a vaginal care system.||||
34127826|NCT05169203|||COHORT||RETROSPECTIVE|||||||
34127827|NCT05689450|||COHORT||PROSPECTIVE|||||||
34127828|NCT01121055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34127829|NCT05524077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Randomisation will be performed using a secure, password-protected web portal (REDCap) and the allocation sequence will be blinded to investigators and participants until the participants have been deemed eligible and enrolled in the study. It will not be possible to maintain blinding after study enrolment because the intervention is invasive.~Outcome verification will be blinded."||f|f|f|t
34127830|NCT04757571|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149304|NCT04499911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149305|NCT04515524|||COHORT||PROSPECTIVE|||||||
34149306|NCT02364440|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34149307|NCT06246071|NA|SEQUENTIAL||TREATMENT||NONE||||||
33820554|NCT04438369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The randomization was done through a computer-generated block randomization process (randomization.com) to reduce bias. The block sizes were randomly chosen to 2, 4 and 6. The total patients randomized were 60 patients to account for missing data and protocol violations. A study nurse prepared and placed the notes of study allocation covered with aluminum foil into opaque envelopes. The envelopes were numbered from 1- 70.|The study is planned as a randomized controlled trial (RCT) with two study arms. One arm is the intervention arm, who will receive the active treatment. The other arm is the control arm, who will receive a placebo treatment.|t|t|t|t
33820555|NCT03644277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Upon enrollment in the study, participants will be randomly assigned to one of five groups, including: massed practice training with dAIH, massed practice training with Sham dAIH, Rapael glove with dAIH, Rapael glove with Sham dAIH, and no training with dAIH.||t|f|f|t
33820556|NCT04451902|||COHORT||OTHER|||||||
33820557|NCT06121388|||CASE_CONTROL||PROSPECTIVE|||||||
33820558|NCT02040532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820559|NCT03027999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33820560|NCT01726634|NA|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33820561|NCT00358722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820562|NCT01126177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820563|NCT02409888|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33820564|NCT02871453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820565|NCT03658902|||COHORT||RETROSPECTIVE|||||||
33820566|NCT02236299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820567|NCT00417989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820568|NCT06538675|||COHORT||OTHER|||||||
33820569|NCT06645964|||CASE_ONLY||CROSS_SECTIONAL|||||||
33820570|NCT04088500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820571|NCT00454545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820572|NCT00006104||||TREATMENT||||||||
33820573|NCT06240806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients in both groups were assigned using a random number table, and then we placed the participants in 2 groups receiving mouthwashes A (Manuka honey) or B (saline oral rinse) based on the randomized list. The researcher, patients, and the statistical analyst were all unaware of which code belonged to which mouthwash and just one non-beneficiary person was aware of the contents of the bottles who revealed them after completing all the statistical analyses.|"The experimental group will use a 20ml of (Manuka honey) in 100 ml purified water as mouthwash three times a day (preferably after their meals), kept it for one minute, and then poured it out .~the control arm followed the same protocol with normal saline rinses in the same opaque bottles 3 times per day."|t|f|f|t
33820574|NCT04969900|RANDOMIZED|PARALLEL||OTHER||TRIPLE|For purposes of masking, all patients enrolled in the study will be required to wear a cloth face covering over their nose and mouth during their procedure to minimize diffusion of the aromatic scent in the procedure room.|A single-site, double-blinded, placebo-controlled clinical trial of lavender aromatherapy versus inert oil placebo for patient satisfaction in adult women having a first trimester outpatient surgical abortion before 10 weeks and 0 days gestation.|t|t|t|f
33820575|NCT02963922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820576|NCT04389944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820577|NCT06359821|NA|SINGLE_GROUP||OTHER||NONE||||||
33820578|NCT03332589|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||4 subjects were treated in the E6201 Monotherapy Safety Run-in Phase. A total of 6-12 subjects are anticipated in the E6201 plus dabrafenib Combination Safety Run-in Phase. Once an MTD of the combination is determined, a total of 6 subjects will be treated at the combined MTD before the Expansion Phase will begin. In the Expansion Phase, an additional cohort of up to N=18 subjects will be treated at the combined E6201 plus dabrafenib MTD. Subjects treated at the MTD in the Combination Safety Run-in Phase will count towards accrual in the Expansion Phase.||||
33820579|NCT01432678|||COHORT||PROSPECTIVE|||||||
33820580|NCT06584864|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|open-label study|Open-label, randomized interventional study||||
33820581|NCT06503016|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33820582|NCT05903118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820583|NCT03779334|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, single arm||||
33820584|NCT03910491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820585|NCT02626689|||COHORT||PROSPECTIVE|||||||
33820586|NCT00360971|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33820587|NCT03962270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820588|NCT03226509|||OTHER||PROSPECTIVE|||||||
33820589|NCT00556296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820590|NCT04653571|||COHORT||RETROSPECTIVE|||||||
33820591|NCT01547663|||CASE_ONLY||PROSPECTIVE|||||||
33820592|NCT00144937|RANDOMIZED|PARALLEL||ECT||NONE||||||
33820593|NCT03915535|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a two parallel groups study without randomisation.12 subjects will be enrolled in group A. Afterwards, the remaining 12 subjects will be enrolled in group B.||||
33820594|NCT03696147|||COHORT||PROSPECTIVE|||||||
33820595|NCT01642030|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33820596|NCT03296488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820597|NCT05733013|||COHORT||PROSPECTIVE|||||||
33820598|NCT01165944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820599|NCT03780699|||OTHER||CROSS_SECTIONAL|||||||
33820600|NCT02273856|||COHORT||PROSPECTIVE|||||||
33820601|NCT03999697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820602|NCT03278808|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Because placebo for both products is difficult to obtain and because the primary endpoint of symptomatic parasitemia is an objective measure, treatment will be open-label. Microscopists reading the smears will be blinded to the group, but will be aware of whether or not a particular sample is from a symptomatic subject.~Although symptoms are a subjective measure and part of the primary endpoint of symptomatic parasitemia, subjects will not be told if they are parasitemic prior to treatment initiation thus making symptomatic complaints and this endpoint more reliable."|Subjects will be randomized to either the CQ/AZ group (Group 1 of 15 subjects: 2 g AZ (Zithromax) plus 300 mg CQ base weekly for 6 weeks), or the CQ control group (Group 2 of 8 subjects: 300 mg chloroquine base weekly for 6 weeks)||||
33820603|NCT03518047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820604|NCT05073835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinded: both participants and study doctors will be blind to group allocation|Phase 3b, double-blinded, randomised, parallel group trial|t|f|t|t
33820605|NCT03656445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820606|NCT05534269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Neither patient nor sponsor will know which patient gets which dose|Low dose and High dose evaluation|t|f|f|f
33820607|NCT05105425|RANDOMIZED|PARALLEL||OTHER||TRIPLE|A RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED PILOT STUDY||t|f|t|t
33820608|NCT00584545|||CASE_ONLY||RETROSPECTIVE|||||||
33820609|NCT01177228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820610|NCT02637947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820611|NCT05733793|||COHORT||PROSPECTIVE|||||||
34127831|NCT04449107|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A mixed methods study will be conducted in which a smart phone application will be developed based on the findings of qualitative component of the study, which will have features for text, voice, video and pictorial messages for the participant caregivers to improve RI on 10th and 14th week of child age.|t|f|f|f
33820612|NCT02674555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820613|NCT06458309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820614|NCT04397432|||COHORT||RETROSPECTIVE|||||||
33820615|NCT00475969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33820616|NCT01479322|||CASE_CONTROL||PROSPECTIVE|||||||
33820617|NCT02053402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820618|NCT04223661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg, and in frail subjects (frailty score of 2 or higher) will be 5 mg, and escalate to 10 mg.~All subjects will receive 20mg Dexamathasone and 1800mg Daratumumab during the course of the trial."||||
33820619|NCT06585176|||CASE_ONLY||CROSS_SECTIONAL|||||||
33820620|NCT06223568|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820621|NCT00735228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820622|NCT04832724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33820623|NCT03990909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820624|NCT05039047|||COHORT||PROSPECTIVE|||||||
33820625|NCT05624229|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820626|NCT04527380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820627|NCT04004169|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33820628|NCT03866109|NA|SEQUENTIAL||TREATMENT||NONE||8 cohorts: Cohorts 1-4, 6: Thiotepa and BCNU Conditioning; Temferon dose 0.5 - 3 x10\^6 CD34+ cells/kg; Cohort 5: Thiotepa and Busulfan Condtioning; Temferon 2 x 10\^6 CD34+ cells/kg; Cohort 7: Busulfan conditioning; Temferon 3 x 10\^6 CD34+ cells/kg; Cohort 8: Busulfan conditioning; Temferon 4 x 10\^6 CD34+ cells/kg;||||
33820629|NCT01838512|||COHORT||PROSPECTIVE|||||||
33820630|NCT02119572|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||||||||
33820631|NCT00000647||||TREATMENT||NONE||||||
33820632|NCT02771184|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820633|NCT02543697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820634|NCT02449837|||COHORT||PROSPECTIVE|||||||
33820635|NCT05182671|||OTHER||CROSS_SECTIONAL|||||||
33820636|NCT05762978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820637|NCT01573741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820638|NCT03392779|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking for Participant, Investigator and Clinical Research Associate||t|t|t|t
33820639|NCT03238599|NA|SINGLE_GROUP||OTHER||NONE||Non-randomized prospective non-blinded single-arm clinical phase II study||||
33820640|NCT02735278|||COHORT||CROSS_SECTIONAL|||||||
33820641|NCT00850798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820642|NCT00834483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820643|NCT00762554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127832|NCT03287193|||COHORT||PROSPECTIVE|||||||
34127833|NCT00924677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820644|NCT04374253|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820645|NCT01904253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820646|NCT05041439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33820647|NCT05423015|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|The enrolled children were randomized to the three groups in a 1:1:1 ratio stratified by age at the time of study enrolment. The study's investigators and clinical staff were blinded until the final database. Only appointed staff had access to the randomization list to perform labeling of the study products.|Randomised, double blind controlled protocol in children with overweight or obesity aged 6-11 years|t|f|t|f
33820648|NCT03637621|||COHORT||RETROSPECTIVE|||||||
33820649|NCT00003359||||TREATMENT||||||||
33820650|NCT02259296|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820651|NCT02041897|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820652|NCT03536169|||COHORT||RETROSPECTIVE|||||||
33820653|NCT02567786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820654|NCT04673305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820655|NCT00027963|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33820656|NCT04301063|||OTHER||OTHER|||||||
33820657|NCT05043428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A convenience sample of adults living with COPD (N=22) will be recruited to participate in an 8-week online exercise intervention. The objective is to test a two-arm pilot randomized controlled trial (RCT) for individuals living with COPD and to determine whether the intervention can improve individuals' performance in activities of daily and social living.|f|f|f|t
33820658|NCT02973945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820659|NCT00647985|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33820660|NCT02682849|||CASE_CONTROL||OTHER|||||||
33820661|NCT03480737|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33820662|NCT00122707|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820663|NCT00996619|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33820664|NCT01092936|||||PROSPECTIVE|||||||
33837269|NCT06311370|||COHORT||PROSPECTIVE|||||||
34127834|NCT04119752|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double-blind||t|f|t|f
34127835|NCT04023383|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34127836|NCT00273091|||COHORT||PROSPECTIVE|||||||
34127837|NCT05005273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34127838|NCT00603941|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127839|NCT02279550|||COHORT||PROSPECTIVE|||||||
34127840|NCT04091191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34127841|NCT04855630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127842|NCT05272397|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34127843|NCT05069727|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible subjects shall be randomly assigned to Group 1 or Group 2 in a 1:1 ratio using a computer-generated randomization scheme developed by the data manager.|"This study is Randomized Clinical Trial, two arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months.~Participants will be randomized in two groups:~* Group 1, Regular Clinical Protocol, 17 participants~* Group 2, Simplified Clinical Protocol, 17 participants"|f|t|f|f
34127844|NCT01530503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127845|NCT02189148|||COHORT||PROSPECTIVE|||||||
34127846|NCT01584414|||||PROSPECTIVE|||||||
34127847|NCT01296971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127848|NCT01084343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34127849|NCT01553292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127850|NCT02540512|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
34127851|NCT04774068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127852|NCT05934149|||COHORT||PROSPECTIVE|||||||
34127853|NCT04703192|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127854|NCT01889108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127855|NCT03480893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820665|NCT05472233|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Retrospective cohort study||||
33820666|NCT00312247|||COHORT||PROSPECTIVE|||||||
33820667|NCT03875794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820668|NCT01444547|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820669|NCT05750017|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33820670|NCT05095402|||OTHER||PROSPECTIVE|||||||
33820671|NCT04533971|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The participants were randomly assigned to the two groups, WBC and control.||||
33820672|NCT04891809|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned in a 1:1 ratio to one of the two arms. Randomization will be stratified by the simplified frailty scale (Facon et al, Leukemia 2020) result nonfrail or frail.||||
33820673|NCT01827800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820674|NCT04743453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients will be randomized to add either Dapagliflozin 10 mg or Placebo to their treatment. Study drug will be administered by once-daily orallly.|t|f|t|f
33820675|NCT04627259|||CASE_ONLY||PROSPECTIVE|||||||
33820676|NCT04889833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33820677|NCT02366455|||COHORT||RETROSPECTIVE|||||||
33820678|NCT04458012|||COHORT||PROSPECTIVE|||||||
33820679|NCT04502888|NA|SEQUENTIAL||TREATMENT||NONE||||||
33820680|NCT02785302|||COHORT||PROSPECTIVE|||||||
33820681|NCT01827202|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33820682|NCT04695275|||COHORT||PROSPECTIVE|||||||
33820683|NCT01665014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820684|NCT00848640|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820685|NCT00461227|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33820686|NCT00213915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33820687|NCT03321188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820688|NCT05813132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820689|NCT02151318|||CASE_ONLY||OTHER|||||||
33820690|NCT04057937|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820691|NCT03967899|||COHORT||RETROSPECTIVE|||||||
33820692|NCT05840016|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820693|NCT05262504|||CASE_CONTROL||PROSPECTIVE|||||||
33820694|NCT04476849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820695|NCT01857050|||CASE_CONTROL||RETROSPECTIVE|||||||
33820696|NCT03190317|||COHORT||OTHER|||||||
34127856|NCT00000763||||TREATMENT||||||||
34127857|NCT02749201|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127858|NCT06105515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127859|NCT00804050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127860|NCT03211663|||COHORT||PROSPECTIVE|||||||
34127861|NCT02266979|||||PROSPECTIVE|||||||
33820697|NCT04010981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820698|NCT05418335|||OTHER||PROSPECTIVE|||||||
33820699|NCT03925298|||COHORT||PROSPECTIVE|||||||
33820700|NCT00138645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33820701|NCT03660254|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33820702|NCT03138356|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820703|NCT03614923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33820704|NCT00472056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820705|NCT00195416|||CASE_ONLY||PROSPECTIVE|||||||
33820706|NCT05935098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820707|NCT03055819|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Single arm, open label, multi-center||||
33820708|NCT01780584|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837270|NCT06273813|NA|SEQUENTIAL||TREATMENT||NONE||All cohost 1 subjects receive single ketorolac tromethamine injection, followed by escalating doses of ketorolac tromethamine gel Cohort 2 and 3 subjects receive doses of ketorolac tromethamine gel for 5 days||||
33837271|NCT05339789|||COHORT||PROSPECTIVE|||||||
33837272|NCT04855305|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34127862|NCT06372509|||COHORT||PROSPECTIVE|||||||
34127863|NCT00283101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127864|NCT00005987|RANDOMIZED|||TREATMENT||||||||
33820709|NCT06069596|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Randomization was performed using a computer program. Accordingly, the study group patients were administered Obstetric gel. The researcher administering Obstetric gel ensured the blinding of healthcare providers and other researchers.|The participants were divided into two groups based on their parity; nulliparous and primiparous. At the outset, each group had 110 participants. Nulliparous and primiparous groups were randomly assigned to two groups as study and control groups by using a computer generating random number table. Obstetric lubricant gel was applied to patients in the study groups. Perinatal outcomes and durations of the labor were compared between study and control groups.|f|t|t|t
33820710|NCT05055141|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cluster randomized controlled trial||||
33820711|NCT02176317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820712|NCT01828749|||COHORT||PROSPECTIVE|||||||
33820713|NCT02653066|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33820714|NCT04716283|||OTHER||CROSS_SECTIONAL|||||||
33820715|NCT02927288|||COHORT||PROSPECTIVE|||||||
33820716|NCT06266065|NA|SINGLE_GROUP||TREATMENT||NONE||Single-Center Prospective Study||||
33820717|NCT04200547|RANDOMIZED|PARALLEL||OTHER||SINGLE|An endoscopy will be performed on patients of all groups 6 months after the surgery. Endoscopic results will be measured blindly by one assessor.|"This is a multicenter, interregional, open-label, prospective comparative PHASE III, randomized with a ratio (1:1), with 2 parallel groups (experimental group called immunomonitoring and control group called standard strategy based on clinical and biological activity)."|f|f|f|t
33820718|NCT00978289|||COHORT||PROSPECTIVE|||||||
33820719|NCT00563433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820720|NCT05789927|||COHORT||PROSPECTIVE|||||||
33820721|NCT01596634|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820722|NCT03953209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820723|NCT06646315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33820724|NCT04915456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33820725|NCT02971683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820726|NCT05473221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820727|NCT01901302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820728|NCT02843542|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33820729|NCT05308199|RANDOMIZED|PARALLEL||TREATMENT||NONE|participants didn't know in which group they are and what type of treatment they are given|2 groups , geoup A named as control group and group B named as experimental group||||
33820730|NCT04443881|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase 2/3, randomized, open label, parallel group, 2-arm, multicenter study investigating the efficacy and safety of intravenous administrations of the study drug,||||
33820731|NCT06585475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33820732|NCT02286297|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820733|NCT05558241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective paired diagnostic trial||||
33820734|NCT01066897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820735|NCT03924596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33820736|NCT01114217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820737|NCT03435809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820738|NCT01607099|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33820739|NCT05348642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment randomized, double-blind, placebo-controlled, parallel group, single center trial|t|t|t|t
33820740|NCT01532830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820741|NCT04304898|||CASE_ONLY||PROSPECTIVE|||||||
33820742|NCT05288504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820743|NCT01598688|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33820744|NCT01198899|||COHORT||PROSPECTIVE|||||||
33820745|NCT02169245|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33820746|NCT03942861|||COHORT||PROSPECTIVE|||||||
33820747|NCT00042302|RANDOMIZED|||||DOUBLE||||||
33820748|NCT02154893|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820749|NCT05889221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820750|NCT03599934|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33820751|NCT00998387|||COHORT||PROSPECTIVE|||||||
33820752|NCT05813249|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820753|NCT06470347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820754|NCT03925402|||COHORT||PROSPECTIVE|||||||
33820755|NCT03418701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820756|NCT06247878|||OTHER||CROSS_SECTIONAL|||||||
33820757|NCT03360071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820758|NCT02553616|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Data collectors were blinded to who received the pre-test and/or intervention.|This intervention has one (1) intervention arm. Participants were randomly assigned to the intervention with or without the pre-test or to receiving services as usual, with or without the pre-test.||||
33820759|NCT00488761|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820760|NCT00002401||||TREATMENT||||||||
33820761|NCT05099978|||COHORT||PROSPECTIVE|||||||
33820762|NCT05685251|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||A randomized, single-center study|f|f|f|t
33820763|NCT00796497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33820764|NCT06232941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820765|NCT00010322||||TREATMENT||||||||
33820766|NCT00148616|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820767|NCT05879822|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consists of 2 parts. In Part 1, participants with 6 different tumor types will be randomized 1:1:1 to INCB099280 Dose 1, INCB099280 Dose 2, or INCB099280 Dose 3 twice daily (BID). At the end of Part 1, an integrated analysis will be performed to select a dose. Once a dose is selected, Part 2 will proceed to complete enrollment for each of the 6 disease-specific cohorts at the selected dose.||||
33820768|NCT03362684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820769|NCT02868788|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837273|NCT05371106|||COHORT||RETROSPECTIVE|||||||
33837274|NCT01851889|||COHORT||PROSPECTIVE|||||||
33837275|NCT02960503|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33820770|NCT06248021|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The researcher responsible for the study identified the children who were assigned to the intervention and control groups. This person was not involved in the implementation of the study to ensure that measurement bias was controlled. To avoid detection bias, statistical bias, and reporting bias, a third researcher, who did not know which children were in the intervention and control groups, was responsible for coding and analyzing the research data.|This study was conducted using a cluster randomized controlled pretest-posttest experimental design. It was carried out in four kindergartens located in a city center between April and June 2023. Two of the kindergartens were assigned to the intervention group while the other two were assigned to the control group. Data was collected using the Ecological Footprint Awareness Scale for Children (EFAS-C). The training program was conducted with the children in the intervention group for four weeks, with a 40-minute session each week. The program covered one topic each week, which included waste management, water and energy use, food consumption, and transportation.|t|f|t|f
33820771|NCT01942538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33820772|NCT04006652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The first three recipients will be treated in a sequential manner meaning that subjects will be transplanted with ApoGraft only after the engraftment of the previous subject has occurred.||||
33820773|NCT00002388||||TREATMENT||||||||
33820774|NCT03892122|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||it's a randomized controlled single center study||||
33820775|NCT06301529|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33820776|NCT00001436||||TREATMENT||||||||
33820777|NCT00702234|||OTHER||PROSPECTIVE|||||||
33820778|NCT05530928|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33820779|NCT05326802|||COHORT||CROSS_SECTIONAL|||||||
33820780|NCT03971799|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A 3+3 dose escalation design will be used to determine maximum tolerated dose for both autologous and allogeneic recipients in Phase 1 and Simon's two-stage design will be used to evaluate the efficacy of CD33CART in Phase 2.||||
33820781|NCT02686983|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33820782|NCT01248078|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33820783|NCT06375018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820784|NCT03320941|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Parallel Assignment||t|t|t|f
33820785|NCT03684278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Once the delegated research team member performs randomisation and the staff member responsible for preparation of trial medication is provided with the allocation to either Arm A, B or C, that latter staff member will prepare the infusion, which will be covered by an opaque sleeve and labelled for blinding.|RAPID-I is a randomised, placebo-controlled, double-blind, multi-centre, three-arm, phase IIb efficacy trial of infliximab in patients with AP. Patients will be randomised (1:1:1 allocation ratio) to receive an intravenous infusion of either 5 mg/kg or 10 mg/kg infliximab or placebo, initiated within 36 hours of admission to hospital with acute pancreatitis. Treatment allocation will only be revealed to those responsible for trial treatment preparation (Pharmacy or an independent research team not administering the trial medication) to ensure the research team administering the treatment remains blinded.|t|t|t|t
33820786|NCT03308383|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33820787|NCT00003611|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820788|NCT05168826|||COHORT||PROSPECTIVE|||||||
33820789|NCT02840812|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33820790|NCT05285696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820791|NCT06029920|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33820792|NCT01702155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820793|NCT02420938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820794|NCT02924532|||COHORT||RETROSPECTIVE|||||||
33820795|NCT01269190|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820796|NCT03282071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33820797|NCT00647374|||COHORT||PROSPECTIVE|||||||
33820798|NCT01038128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820799|NCT01810640|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33820800|NCT05291962|||OTHER||RETROSPECTIVE|||||||
33820801|NCT02475499|||COHORT||RETROSPECTIVE|||||||
33820802|NCT05899673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820803|NCT00203502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820804|NCT03336749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors are blinded to the participants' group allocation.|Participants are assigned to one of two or more groups in parallel for the duration of the study|f|f|f|t
33820805|NCT05118009|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33820806|NCT06646250|||COHORT||PROSPECTIVE|||||||
33820807|NCT05283200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820808|NCT02509650|||COHORT||PROSPECTIVE|||||||
33820809|NCT03570996|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Randomization into either transversus abdominis plane catheter (TAP) or epidural for patients undergoing esophagectomy||||
33820810|NCT04488809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820811|NCT01129011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820812|NCT03199495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820813|NCT01323335|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33820814|NCT02465775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820815|NCT00764855|||COHORT||PROSPECTIVE|||||||
33820816|NCT02245971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820817|NCT03600922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820818|NCT03734614|||COHORT||PROSPECTIVE|||||||
33820819|NCT05041478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding|Randomised Controlled Trial|f|f|f|t
33837276|NCT05517226|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837277|NCT01694251|||CASE_ONLY||PROSPECTIVE|||||||
33837278|NCT03833791|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33837279|NCT01948674|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33837280|NCT04560751|||COHORT||PROSPECTIVE|||||||
33837281|NCT01156740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837282|NCT02654197|||COHORT||PROSPECTIVE|||||||
33837283|NCT03994731|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837284|NCT00485953|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34127865|NCT03977545|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34127866|NCT05111197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127867|NCT06008262|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127868|NCT02386787|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127869|NCT06110949|||COHORT||PROSPECTIVE|||||||
34127870|NCT06335069|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-group, single-center pilot study||||
34127871|NCT02012855|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34127872|NCT05922228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127873|NCT05320354|||OTHER||PROSPECTIVE|||||||
34127874|NCT01283438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127875|NCT02497222|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34127876|NCT05480735|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34127877|NCT01349205|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34127878|NCT01941654|NA|SINGLE_GROUP||TREATMENT||NONE||RT + Oral TKI||||
34127879|NCT05592990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127880|NCT06257446|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34127881|NCT02663427|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34127882|NCT00161044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127883|NCT04062188|||OTHER||OTHER|||||||
34127884|NCT01976871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127885|NCT04771689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127886|NCT02652117|||OTHER||RETROSPECTIVE|||||||
34127887|NCT00440492|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127888|NCT02575729|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34127889|NCT05165732|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127890|NCT05296746|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127891|NCT03388762|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study products will be delivered to the investigative sites prior to enrollment of subjects. A study code will be provided for every batch of study product shipped to the investigational site prior to the beginning of the study. The placebo utilized in this clinical trial will be formulated to be as similar as possible to the active in appearance, odor, and other key characteristics, and packaging for both intervention and placebo will be the same. The de-identified study product will be packaged and labeled according to the study code and participant identification numbers; the Study Coordinator will oversee a locked master list of these, in addition to batch numbers.|This study is a 12-week, randomized, double-blinded, placebo-controlled clinical trial of GlucoSupreme™ Herbal. Eligible participants will be recruited from within participating clinical practices. All study outcomes will be biomarkers, capturing normal structure and function of the human body, derived from blood draws ordered during two physician visits spaced 12 weeks apart. This is a typical interval between blood assessments of glycemic control in routine clinical practice. An IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events. Serious adverse events, while not anticipated, will be reported by the participant to a study physician as soon as possible.|t|t|f|f
34127892|NCT04918381|NA|SINGLE_GROUP||TREATMENT||NONE||CellFX System||||
34127893|NCT01741298|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34127894|NCT00847899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127895|NCT01445977|||CASE_ONLY||PROSPECTIVE|||||||
34127896|NCT03462758|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34127897|NCT05961683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127898|NCT00445393|||COHORT||PROSPECTIVE|||||||
34127899|NCT06443333|||COHORT||OTHER|||||||
34127900|NCT03313999|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127901|NCT04812535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm A: IFX-1 monotherapy; Arm B: IFX-1 + in combination with approved dosing scheme of pembrolizumab||||
34127902|NCT02474576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127903|NCT00782899|||COHORT||PROSPECTIVE|||||||
34127904|NCT02409641|NA|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34127905|NCT01142076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837285|NCT00263653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837286|NCT05435950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837287|NCT03508401|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837288|NCT03192345|RANDOMIZED|PARALLEL||TREATMENT||NONE||Escalation monotherapy and escalation combination followed by expansion monotherapy and expansion combination. Escalation phases will not be randomized while expansion phases will be randomized.||||
33837289|NCT03222505|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33837290|NCT01005797|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837291|NCT03845270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837292|NCT04440020|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single (participant)|Single Participant|t|f|f|f
34127906|NCT03166852|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||One group performs HIT with techology-based feedback for 5 weeks and the next group do the same||||
34127907|NCT02905838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127908|NCT01568281|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34127909|NCT06309602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127910|NCT04111796|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127911|NCT04068077|||CASE_ONLY||PROSPECTIVE|||||||
34127912|NCT01970241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127913|NCT00890435|||COHORT||PROSPECTIVE|||||||
34127914|NCT03573752|NA|SINGLE_GROUP||OTHER||NONE||||||
34127915|NCT00852579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127916|NCT04497597|||COHORT||PROSPECTIVE|||||||
34127917|NCT02839174|||COHORT||CROSS_SECTIONAL|||||||
34127918|NCT00711282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127919|NCT05582512|||CASE_CONTROL||PROSPECTIVE|||||||
34127920|NCT03674970|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127921|NCT05991583|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127922|NCT01048398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34127923|NCT02216435|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127924|NCT03842774|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34127925|NCT00000325||||TREATMENT||||||||
34127926|NCT03045588|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34127927|NCT04253210|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34127928|NCT01037998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127929|NCT04909840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34127930|NCT01059864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127931|NCT03058198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34127932|NCT03653234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127933|NCT05100771|||COHORT||PROSPECTIVE|||||||
34127934|NCT04798222|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34127935|NCT05354492|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34127936|NCT04797455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127937|NCT05963243|||CASE_ONLY||PROSPECTIVE|||||||
34127938|NCT00844142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127939|NCT01746381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127940|NCT02548910|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34127941|NCT05859646|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessment was performed by a different researcher who was unaware of the group distributions in which patients were included.|2 separate groups, experimental and control, 6 month follow-up period, randomized distribution|f|f|f|t
34127942|NCT01803971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127943|NCT02344121|||CASE_CONTROL||PROSPECTIVE|||||||
34127944|NCT03544593|NA|SINGLE_GROUP||OTHER||NONE||||||
34127945|NCT01032187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127946|NCT01777048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127947|NCT06442904|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34127948|NCT05503706|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34127949|NCT06269692|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34127950|NCT02941770|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127951|NCT04165408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127952|NCT03109470|||OTHER||PROSPECTIVE|||||||
34127953|NCT02873455|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837293|NCT04081064|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837294|NCT03177720|RANDOMIZED|PARALLEL||OTHER||NONE||24 patients and 18 healthy volunteers are included. 12 patients and 9 volunteers are receiving imipenem as study drug, the other 12 patients and 9 volunteers receive ciprofloxacin.||||
33837295|NCT02947100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837296|NCT05147870|||COHORT||RETROSPECTIVE|||||||
34127954|NCT02752490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127955|NCT00481455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127956|NCT03230318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127957|NCT03611218||SEQUENTIAL||TREATMENT||NONE||Prospective, open, controlled, cross-over (with randomized treatment sequences), interventional, multi-center||||
34127958|NCT00377897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127959|NCT03413033|||CASE_ONLY||PROSPECTIVE|||||||
34127960|NCT01627626|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34127961|NCT02659813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127962|NCT05945381|NA|SINGLE_GROUP||TREATMENT||NONE||The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.||||
34127963|NCT04392674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127964|NCT05077839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34127965|NCT04740086|||COHORT||PROSPECTIVE|||||||
34127966|NCT03953677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34127967|NCT02620033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127968|NCT06187779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837297|NCT03674723|NA|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 4 levels of methionine provided as free amino acids, Mung beans, or Mung beans combined with rice or wheat for a total of 10 studies x 3 days per study.||||
33837298|NCT01423110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127969|NCT04859348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|outcomes accessor donot know the type of intervention given to patient not during evaluation or data record|G- A 36 participants received only routine treatment for GDM G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises.|f|f|f|t
34127970|NCT00302354|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34127971|NCT06156878|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34127972|NCT02816515|||CASE_ONLY||PROSPECTIVE|||||||
34127973|NCT04672980|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34127974|NCT01453972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34127975|NCT04058899|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients will be divided into 2 groups ,dexmedetomidine group (DEX)group who will receive 0.5 µg/kg dexmedetomidine diluted in 50 ml of normal saline 0.9% to be given by IV infusion over 10 minutes after induction of anesthesia then 5ml of 0.9% normal saline IV ,nalbuphine group (NAL)group will receive IV infusion of 50 ml of 0,9%normal saline by IV infusion over 10 minutes then 0.1mg/kg nalbuphine diluted in 5ml of 0.9%normal saline IV after induction of anesthesia.|t|t|f|f
34127976|NCT01489501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127977|NCT03374358|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a randomized, open, parallel design study.||||
34127978|NCT06094608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be blinded to study arm. The PI, study coordinator and research assistants will remain unblinded to perform safety assessments and provide feedback on intervention adherence. Blinded staff will wear buttons as an upfront visual cue to remind participants not to talk about their treatment.||f|f|f|t
34127979|NCT00886769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820820|NCT04117256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinding of the assessor: all the assessments will be made by a different researcher who apply all the interventions. Assessor will not have vision of the place where the electrodes are located neither the parameters used.~Blinding of the subjects: Although subjects will be blinded to the hypothesis of the study, the transcranial and suboccipital location of the electrodes cannot be blinded. Direct current and sham stimulation will be blinded. For the sham condition subjects will feel the stimulation sensation for 30 seconds and then the stimulator will turn off. The same equipment, identical electrodes, and cables will be used. In addition, subjects will not have a view of the computer screen.~Blinding of the person who apply the intervention: Although transcranial and suboccipital conditions cannot be blinded. The direct current and sham stimulation will be apply by the blind-mode of the stimulator using locking codes."|Paralled randomized controlled trial with cross-control design. Two groups of subjects will be randomly selected, a Transcranial stimulation group and a suboccipital stimulation group. Each group will perform two intervention sessions in a randomized order, a session with direct current stimulation and a sham stimulation session.|f|f|t|t
33820821|NCT03244202|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33820822|NCT00988429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820823|NCT03651271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820824|NCT02725359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33820825|NCT02357355|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33820826|NCT00889733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820827|NCT00662415|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820828|NCT06275087|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33820829|NCT05302271|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The clinical study design is a dose-escalation study with 4 cohorts of n=25, 5 subjects at each of 3 doses to establish the safety of the investigational drug product, and 1 cohort with n=10 at the maximum tolerated dose. The vector will be delivered intravenously.||||
33820830|NCT04038034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820831|NCT00755924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33820832|NCT05664061|RANDOMIZED|PARALLEL||OTHER||SINGLE|observer-blind||f|f|f|t
33820833|NCT05374408|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility Pilot Study||||
33820834|NCT05803525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor)||t|f|f|t
33820835|NCT00469352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820836|NCT03681171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820837|NCT04135950|||OTHER||PROSPECTIVE|||||||
33820838|NCT00789399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33820839|NCT02650388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820840|NCT01985945|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33820841|NCT04872166|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33820842|NCT05080803|||COHORT||RETROSPECTIVE|||||||
33820843|NCT00555334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820844|NCT02623400|||COHORT||PROSPECTIVE|||||||
33820845|NCT00741689|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33820846|NCT02350127|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33820847|NCT03750175|||COHORT||PROSPECTIVE|||||||
33820848|NCT00679419|||COHORT||PROSPECTIVE|||||||
33820849|NCT02039297|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33820850|NCT00829517|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33820851|NCT06386575|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Suprainguinal fascia iliaca block will be applied to the patients at the end of the surgery.|t|f|t|f
33820852|NCT05188729|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an open-label, multicenter, dose-escalating study. Eligible subjects will be enrolled sequentially.||||
33820853|NCT01309555|||COHORT||OTHER|||||||
33820854|NCT04477954|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33820855|NCT03082196|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All study personnel except for designated personnel in the data center will be blinded to the participant treatment assignment. In order to maintain blinding, the caries scoring examinations will precede the application of test varnishes at baseline. The staff member applying these varnishes will not perform the caries scoring exams in order to eliminate examiner bias and ensure blinding to treatment assignment. Test drug and comparator are packaged identically.|Single-center, double-blind, controlled Phase 2 study with parallel groups of children.|t|t|t|t
33820856|NCT00487799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33820857|NCT06379763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the participants will not know which of exercises that will be giving for them more better in experimental or control group|randomized clinical trial (RCT) Participants will be randomly allocated into two groups using the block randomization method. The following groups will be formed: experimental group A (diaphragmatic breathing plus conservative physiotherapy intervention, cervical neck ROM, neck stretching exercises), and group B,|t|f|f|f
33820858|NCT01580462|||||PROSPECTIVE|||||||
33820859|NCT02135419|RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants are evaluated with high resolution anoscopy and anal cytology every 6 months during study participation. Participants randomized to treatment undergo biopsy of anal HSIL at each 6-month visit, and receive topical or ablative therapies for incident anal HSIL lesions. Active monitoring participants undergo close observation, with biopsy of anal HSIL at annual visits. Participants undergo biopsy of lesions at any time cancer is suspected.||||
33820860|NCT01855997|||COHORT||OTHER|||||||
33820861|NCT02136797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820862|NCT00145496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820863|NCT04271956|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Recruitment in cohort 1 (double combination therapy) has already been completed. Recruitment in new cohort 2 (triple combination therapy) will start in Q3 2024.||||
33820864|NCT00082784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820865|NCT01161706|RANDOMIZED|PARALLEL||||NONE||||||
33820866|NCT03167645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820867|NCT02745184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820868|NCT04422509|RANDOMIZED|PARALLEL||TREATMENT||NONE||controls will get standard of care and historical controls will be matched to the patients included||||
33820869|NCT05692414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820870|NCT05618054|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820871|NCT06289036|||COHORT||PROSPECTIVE|||||||
33820872|NCT03861286|||COHORT||PROSPECTIVE|||||||
33820873|NCT06041334|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33820874|NCT03652792|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33820875|NCT00144378|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33820876|NCT03380143|RANDOMIZED|PARALLEL||PREVENTION||NONE||This design can be described as a staggered-start, stepped-wedge, community randomized trial. The design includes two sequential intervention waves.||||
33820877|NCT03709485|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33820878|NCT03279172|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33820879|NCT05306223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820880|NCT02710578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33820881|NCT01386411|||FAMILY_BASED||PROSPECTIVE|||||||
33820882|NCT05067972|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33820883|NCT04733989|||CASE_ONLY||PROSPECTIVE|||||||
33820884|NCT05428839|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820885|NCT01721759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820886|NCT05104957|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Before commencing the tests, each participant was familiarized with their course, expressed their informed written consent for participation and random assignment to a specified tested group. The author of this paper had no influence on the categorization of the participants into individual treatment groups. During the studies, the physiotherapists performing the categorization were not informed about the results of the used treatment.|The study participants will be randomly qualified (allocated via a computer program) to the two groups: A - dynamic tape, B - sham (paper) tape|t|f|t|t
33820887|NCT04564027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820888|NCT03089502|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820889|NCT00653419|RANDOMIZED|CROSSOVER||||NONE||||||
33820890|NCT05668442|||OTHER||OTHER|||||||
33820891|NCT04393779|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study||||
33820892|NCT06646588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820893|NCT05115721|||COHORT||CROSS_SECTIONAL|||||||
33820894|NCT04208815|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33820895|NCT01860222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820896|NCT00269126|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33820897|NCT06645977|||OTHER||PROSPECTIVE|||||||
33820898|NCT03936309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820899|NCT04946656|NA|SINGLE_GROUP||OTHER||NONE||open label single group||||
33820900|NCT02064361|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33820901|NCT03234842|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820902|NCT00747149|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820903|NCT00928876|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33820904|NCT00719277|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820905|NCT02995278|||OTHER||OTHER|||||||
33820906|NCT02665806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820907|NCT06285383|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33820908|NCT00021021||||TREATMENT||||||||
33820909|NCT04427397|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33820910|NCT05832216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820911|NCT00642499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820912|NCT02103426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33820913|NCT04635241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33820914|NCT05385991|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33820915|NCT01039597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820916|NCT00966056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820917|NCT01464671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820918|NCT05644236|NA|SINGLE_GROUP||SCREENING||NONE|Mouthwah solution was provided by sponsor who packed experimental and control solution in the bottle. Investigator and participants did not know the contents during treatment period.|||||
33820919|NCT02931994|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33820920|NCT05068687|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820921|NCT00456183|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33820922|NCT00372099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820923|NCT00001079||PARALLEL||TREATMENT||||||||
33820924|NCT05954156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820925|NCT05229549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820926|NCT05493605|NA|SINGLE_GROUP||OTHER||NONE||"All patients with confirmed Wilson Disease presenting for consultation or hospitalization for their follow-up or at the time of diagnosis will be offered to participate in the study.~Patients who have already benefited from a cardiac assessment with installation of an implantable Holter ECG as part of the treatment may be included retrospectively"||||
33820927|NCT00615355|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33820928|NCT03886688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820929|NCT02792296|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33820930|NCT01347281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820931|NCT04521933|||COHORT||PROSPECTIVE|||||||
33820932|NCT05892588|||COHORT||CROSS_SECTIONAL|||||||
33820933|NCT00422786|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820934|NCT05990309|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33820935|NCT00447239|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33820936|NCT03606759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837299|NCT00501423|||COHORT||PROSPECTIVE|||||||
33837300|NCT01609777|NA|SINGLE_GROUP||||NONE||||||
33837301|NCT06520891|||CASE_ONLY||OTHER|||||||
33837302|NCT00219479|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34127980|NCT03749928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33837303|NCT00043069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33837304|NCT01075451|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33837305|NCT04411004|||COHORT||PROSPECTIVE|||||||
33820937|NCT05229848|RANDOMIZED|PARALLEL||TREATMENT||NONE||Total 60 patients will be studied. St.Jude View Flex ICE catheter and Siemens AcuNav ICE catheter are used routinely for all left sided ablation procedures which require transeptal puncture. ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise.Imaging is performed at different levels in right atrium, if needed. Imaging targets included right atrium, coronary sinus orifice, fossa ovalis, interatrial septum(IAS), tricuspid valve,left atrium, left atrial appendage, orifice of all pulmonary veins,mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, right ventricular outflow tract(RVOT),pericardial space,esophagus,aorta and adjoining left ventricular and right ventricular myocardium.||||
33820938|NCT04458376|NA|SINGLE_GROUP||TREATMENT||NONE||Consecutively recruited at Department of Neurology at Molde County hospital, outpatient clinic.||||
33820939|NCT05414656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820940|NCT00191984|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820941|NCT05063292|RANDOMIZED|PARALLEL||OTHER||SINGLE||The study covers 2 groups. Group I will be covered with warmed double layered cotton cloth. Group II will be covered with air forced blanket.|f|f|t|f
33820942|NCT01613573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820943|NCT05910502|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"1. Waitlist control~2. Participants in the control group will be offered the opportunity to participate in the intervention group if the child has not received any autism treatments 6 months after enrollment in this study."||||
33820944|NCT01256645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820945|NCT03002233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820946|NCT00185848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33820947|NCT03158493|||COHORT||PROSPECTIVE|||||||
33820948|NCT01084356|||COHORT||PROSPECTIVE|||||||
33820949|NCT02630537|||COHORT||CROSS_SECTIONAL|||||||
33820950|NCT01511744|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33820951|NCT04891263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820952|NCT04050306|||COHORT||PROSPECTIVE|||||||
33820953|NCT04118088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820954|NCT05717647|||CASE_ONLY||PROSPECTIVE|||||||
33820955|NCT02877745|||COHORT||PROSPECTIVE|||||||
33820956|NCT02383121|||COHORT||PROSPECTIVE|||||||
33820957|NCT04783597|||COHORT||PROSPECTIVE|||||||
33820958|NCT03468387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820959|NCT00961597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820960|NCT04990128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participant will undergo a sham bone needling if assigned to Triamcinolone group to keep patient blinded to their intervention. This will simulate the bone marrow aspiration process.~Outcomes assessor will receive de-identified data including the treatment type."|bone marrow aspirate concentrate versus triamcinolone|t|f|f|f
33820961|NCT01106586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33820962|NCT06561256|||COHORT||RETROSPECTIVE|||||||
33820963|NCT00060268|NA|SINGLE_GROUP||TREATMENT||||||||
33820964|NCT01461343|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33820965|NCT02409732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820966|NCT01314014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820967|NCT00912275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820968|NCT06477887|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A Randomized ControlledTrial|f|f|t|t
33820969|NCT04631341|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33820970|NCT04512560|RANDOMIZED|PARALLEL||OTHER||SINGLE|Technical skills and technical errors will be assessed by a trainer rater blinded to the participant's group allocation and level of training.||f|f|f|t
33820971|NCT04508283|||OTHER||CROSS_SECTIONAL|||||||
33820972|NCT04730570|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Blinding is not possible for participants and thus participants will be informed of their group allocation.~To minimize personnel blinding related to data collection, no hospital staff (nurse midwives, physicians, other healthcare providers) are required to be aware of participant's involvement in the study. This is possible as Essential Coaching for Every Mother is sent to the participant's personal cell phone with no intervention occurring in person.~The PI will be aware of participant allocation and will be responsible for collecting data but will not be involved in the randomization procedure which occurs directly in the TextIt platform. Additionally, there is no interaction with the participants from the PI or anyone on the research team as everything occurs remotely via a previously set up process, reducing any risk of influencing participant response and influencing outcome assessment."|The current study is a 2-group parallel arm randomized controlled trial, stratified by parity.|f|t|f|t
33820973|NCT04593641|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33820974|NCT01225705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820975|NCT03096496|||CASE_ONLY||PROSPECTIVE|||||||
33820976|NCT04643496|||COHORT||RETROSPECTIVE|||||||
33820977|NCT01239056|||CASE_ONLY||PROSPECTIVE|||||||
33820978|NCT05938959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will be randomly allocated to receive ultrasound-guided ESP block with 0,2% ropivacaine or ESP block with the sham block by computer software 1:1. A researcher who will not be involved in the study will prepare the randomization list and concealed group assignments in consecutively numbered, sealed, opaque envelopes. A consultant anesthesiologist will follow management to open the envelopes shortly before the nerve block performance to reveal the group allocation and perform the procedure according to the assignment. The surgeon, patients, and anesthesia team will be masked to the study group. Group blinding unmasking will only occur once the statistical analysis is complete.||t|t|f|t
33820979|NCT01459523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34127981|NCT05551351|||COHORT||PROSPECTIVE|||||||
34127982|NCT01973231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820980|NCT01874717|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33820981|NCT04934124|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Sequential ascending doses. Parallel (active, placebo) within each cohort|t|f|t|f
33820982|NCT02146859|||COHORT||PROSPECTIVE|||||||
34127983|NCT00470262|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34127984|NCT05932576|||COHORT||PROSPECTIVE|||||||
34127985|NCT05318300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34127986|NCT05086900|||COHORT||CROSS_SECTIONAL|||||||
33820983|NCT06072599|||COHORT||CROSS_SECTIONAL|||||||
34127987|NCT01906411|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34127988|NCT06526312|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||This phase of the project consists of recruitment, enrollment, and execution of a cluster randomized factorial implementation trial using a hybrid type 3 effectiveness-implementation approach guided by the RE-AIM plan-ning and evaluation framework. In a type 3 hybrid trial, the primary focus is on implementation outcomes with a secondary focus on intervention effectiveness.|f|f|f|t
34127989|NCT01255839|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127990|NCT02298309|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34127991|NCT05188456|||CASE_ONLY||CROSS_SECTIONAL|||||||
34127992|NCT00848276|||COHORT||PROSPECTIVE|||||||
34127993|NCT00550186|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
34127994|NCT06511960|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Placebo-controlled, double-blind and three-group parallel design|t|f|t|f
34127995|NCT04656808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and assessors are blinded to the study research objectives and aims and to the available and obtained treatment condition.|Randomized controlled trial with two treatment conditions|t|f|f|t
34127996|NCT03330678|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy young women will be given VSL#3 for 4 weeks||||
34127997|NCT03925571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34127998|NCT04804696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34127999|NCT00693069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128000|NCT04442633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33820984|NCT02478762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128001|NCT00495430|||COHORT||PROSPECTIVE|||||||
34128002|NCT02919163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34128003|NCT04916977|||COHORT||RETROSPECTIVE|||||||
34128004|NCT01145781|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128005|NCT04916561|||COHORT||PROSPECTIVE|||||||
34128006|NCT00869635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128007|NCT00143624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33820985|NCT06226896|||COHORT||PROSPECTIVE|||||||
34128008|NCT03577834|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All participants will receive 'vinegar' either in liquid form (active) or pill (not active as acetic acid concentration is below threshold of effect). Investigators measuring outcome variables (visceral fat, tooth enamel, and blood indices) are blinded to treatment assignment.|Qualifying participants will be stratified by gender, age, weight, and waist circumference, then randomized into two groups: the intervention group, vinegar drinks (VIN) or the control group, vinegar pills (CON).|t|f|t|f
34128009|NCT05701839|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34128010|NCT02709512|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33820986|NCT00967915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33820987|NCT01073774|RANDOMIZED|CROSSOVER||||NONE||||||
33820988|NCT01098929|||CASE_ONLY||PROSPECTIVE|||||||
33820989|NCT00942513|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33820990|NCT01114334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Cluster Randomized Clinical Trial|t|f|f|t
33820991|NCT04655222|||CASE_ONLY||OTHER|||||||
33820992|NCT04788472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33820993|NCT01448447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33820994|NCT05659745|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|Due to this study being double-blind, participants will not know if they are in the condition with the test product or the placebo. Neither the test products nor the placebo used during the study will be labeled in any way that will indicate whether participants are taking the placebo or the test product. Participants will just know there is a chance they were randomized into a placebo or test product arm of the study. As mentioned above, only the Research Coordinator will know which group the participant is randomized into. The PI will remain blinded throughout the study.||t|t|t|t
33820995|NCT01446042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33820996|NCT03336684|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The investigator will be blinded from randomization and recruitment process.||f|f|t|f
33820997|NCT02109718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33820998|NCT01338051|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128011|NCT05955664|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128012|NCT03557957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to allocated treatment group|Randomized, controlled, parallel-group trial|f|f|f|t
34128013|NCT04980625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128014|NCT05232214|||OTHER||PROSPECTIVE|||||||
34128015|NCT00540930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128016|NCT00003776||||TREATMENT||||||||
34128017|NCT05960045|RANDOMIZED|PARALLEL||OTHER||NONE||2 groups||||
34128018|NCT00562432|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128019|NCT04544644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128020|NCT04116177|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34128021|NCT01596322|||COHORT||PROSPECTIVE|||||||
34128022|NCT03933683|||CASE_CONTROL||PROSPECTIVE|||||||
34128023|NCT02526810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128024|NCT00080834||||TREATMENT||NONE||||||
34149308|NCT06504069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33820999|NCT01498406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821000|NCT01283971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821001|NCT02574949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33821002|NCT04174378|||CASE_CONTROL||RETROSPECTIVE|||||||
33821003|NCT03928171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33837306|NCT00251706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33837307|NCT04879342|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33837308|NCT01647945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837309|NCT04785196|NA|SEQUENTIAL||TREATMENT||NONE||||||
33837310|NCT05752526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837311|NCT02805478|||COHORT||PROSPECTIVE|||||||
33821004|NCT03869411|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||his study is going to recruit subjects with and without type 2 diabetes and age between 30 and 70 years old. This study will be focused on the effects of diabetes on maximum aerobic exercise intensity (VO2max) and muscle quality including microcirculation (by NIRS), mechanical properties (by elastography) and isometric strength in different age groups, and observe whether these results are related to the clinically relevant findings of diabetes. This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into two groups; aerobic exercise or home exercise intervention.||||
33821005|NCT02841176|NA|SINGLE_GROUP||OTHER||NONE||||||
33821006|NCT03490942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind, placebo-controlled|This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks treatment with CSGI or placebo.|t|f|t|f
33821007|NCT02520414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821008|NCT02368145|||||PROSPECTIVE|||||||
33821009|NCT01976156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33821010|NCT05347602|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Phase 1 was double-blinded, neither investigator nor participants know what products each participant was taking.|"Fifty-one (51) subjects were determined eligible for the study after the screenings and then were divided into two groups, AuNP Supplement (n=26) and Placebo (n=25). The study was partially double-blinded, and divided into three phases as follows:~Phase 1: Supplement and Placebo groups ingested Supplement and Placebo as instructed. This phase was double-blinded.~Phase 2: Both groups underwent a month-long wash out period, during which they did not ingest any of the Supplement or Placebo. This phase was not double-blinded as all participants and the researchers were aware of the wash-out procedure.~Phase 3: Both groups took the Supplement as instructed. This phase was open labeled, as all participants and the researchers were aware that all participants were ingesting the Supplement."|t|f|t|f
33821011|NCT06074055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821012|NCT00489151|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821013|NCT00370188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821014|NCT03054883|||CASE_ONLY||PROSPECTIVE|||||||
33821015|NCT04994314|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study proposed to be double blinded (the patients, investigators and the outcome assessors)|The study planned to be split mouth study with equal randomization (1:1 allocation ratio)|t|t|t|t
33821016|NCT02884219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821017|NCT01125735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821018|NCT05577663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment is disclosed to the examiner after all data have been collected; investigator and care provider are different individuals.|Randomised controlled clinical trial having 3 parallel intervention arms for alveolar ridge preservation and prevention of future alveolar bone resorption due to volumetric changes of tissues post-tooth extraction.|f|f|t|t
33821019|NCT05527054|||OTHER||RETROSPECTIVE|||||||
33821020|NCT03858907|||COHORT||PROSPECTIVE|||||||
33821021|NCT06003478|||COHORT||RETROSPECTIVE|||||||
33821022|NCT02599987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821023|NCT01955720|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33821024|NCT03884179|||COHORT||PROSPECTIVE|||||||
33821025|NCT01631825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821026|NCT06450275|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33821027|NCT02095938|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821028|NCT04891159|||OTHER||PROSPECTIVE|||||||
33821029|NCT04293055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821030|NCT06487897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821031|NCT05243498|||COHORT||RETROSPECTIVE|||||||
33821032|NCT02351609|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33821033|NCT00310024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821034|NCT01103271|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33821035|NCT03343509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821036|NCT00840788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821037|NCT06311448|||COHORT||RETROSPECTIVE|||||||
33821038|NCT05135845|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Multicenter single-arm adaptive phase II trial with 2 cohorts according to MET amplification level :~* Cohort 1: tumor without MET amplification (\< 6 copies);~* Cohort 2: tumor with MET amplification (≥6 copies)."||||
33821039|NCT06402916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33821040|NCT05740371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821041|NCT03427645|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33821042|NCT01938209|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821043|NCT01670032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821044|NCT05673421|RANDOMIZED|PARALLEL||OTHER||SINGLE|Visual Feedback Training Group|Exergaming training|t|f|f|f
33821045|NCT02332434|NON_RANDOMIZED|PARALLEL||||NONE||||||
33821046|NCT01394263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821047|NCT05905445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821048|NCT01803789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821049|NCT02596178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821050|NCT04900545|||COHORT||PROSPECTIVE|||||||
33821051|NCT06584617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821052|NCT05712850|||CASE_CONTROL||PROSPECTIVE|||||||
33821053|NCT05740904|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33821054|NCT03427879|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33821055|NCT01330719|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821056|NCT01870999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821057|NCT02732899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821058|NCT00390936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821059|NCT02931240|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821060|NCT00220116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821061|NCT04225234|RANDOMIZED|PARALLEL||PREVENTION||NONE||Our proposed project would be most appropriately be categorized as a partial factorial with choice model, because our study design includes 2 intervention each alone (weight loss and weigh-in), and in combination (weight loss + weigh-in), and choice. No control group is included.||||
34128025|NCT03235921|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"To avoid significant hypotension during nitroglycerin administration, each patient was evaluated for adequate intravascularvolume as evidenced by repeated volume challenges(250 mL of crystalloid over 10 minutes) up to appoint at which central venous pressure raised by more than 2 mmHg.~When the systolic blood pressure reaches 90mmHg or more we can apply the nitroglycerin patch of 2.5 mg alongside with continuous resuscitation the dose can be doubled according to the change in the peripheral perfusion parameters. Time between administration of nitroglycerin patch and peak of its action will be calculated.~Nitroglycerin patch will be removed if the patient developed significant hypotension (mean arterial pressure of less than 50 mm Hg ) however its action may persist up to 45minutes after removal.~During the study, infusion rates of noradrenaline or other vasoactive drugs were not changed and no additional fluids were administered."||||
34128026|NCT01721486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34128027|NCT05553769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.|f|f|t|t
34128028|NCT04560686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821062|NCT01882088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128029|NCT02576548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128030|NCT03226327|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128031|NCT01037335|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34128032|NCT04294381|NA|SINGLE_GROUP||PREVENTION||NONE||evaluation of tablet-based decision tool||||
34128033|NCT06554106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128034|NCT04917367|||COHORT||CROSS_SECTIONAL|||||||
34128035|NCT00566046|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34128036|NCT00556439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821063|NCT03044951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821064|NCT03162523|||CASE_CONTROL||OTHER|||||||
33821065|NCT04719273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821066|NCT02056873|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33821067|NCT03912298|||CASE_ONLY||PROSPECTIVE|||||||
33821068|NCT01975259|||CASE_CONTROL||PROSPECTIVE|||||||
33821069|NCT01951105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821070|NCT03154827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821071|NCT06423976|||COHORT||PROSPECTIVE|||||||
33821072|NCT02330861|NA|SINGLE_GROUP||OTHER||NONE||||||
33821073|NCT06080178|RANDOMIZED|PARALLEL||TREATMENT||NONE||A monocentric, prospective, non-inferiority, randomised controlled trial. Interventional, phase IV trial. Patients will be randomly assigned to either a static intraoperative fluid management (reflecting the current standard of care), with a limitation of 5ml/kg/h crystalloids from induction of anaesthesia to completed skin closure, or a dynamic goal-directed fluid management, where crystalloid fluids are only administered during surgery if PPV is above 12%.||||
33821074|NCT03816202|||OTHER||RETROSPECTIVE|||||||
33821075|NCT06006754|||COHORT||PROSPECTIVE|||||||
33821076|NCT00512941|||COHORT||RETROSPECTIVE|||||||
33821077|NCT05134948|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33821078|NCT00207935|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821079|NCT02811302|NA|SINGLE_GROUP||SCREENING||NONE||||||
33821080|NCT02775175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33821081|NCT03266003|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33821082|NCT00598156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821083|NCT05928689|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study is multi-arm and single-site randomized study that is placebo-controlled and single- and double-blinded depending on the condition assignment. Some groups will experience reminders, or short exposures to misophonia-related cues. Some groups will take the study intervention, propranolol hydrochloride (or matching placebo) oral tablets, and some will undergo counterconditioning, by presenting the misophonia cues with monetary rewards (in a continuous reinforcement schedule with fixed monetary amounts).|"The study team will measure reactivity to misophonia-related cues following either a pharmacological manipulation via a 40 mg propranolol tablet or behavioral manipulation via counterconditioning.~The study team predicts that participants with misophonia who experience a reminder (reactive a misophonia memory) and receive the pharmacological or behavioral manipulation, will show reduced reactivity to misophonia cues.~Other groups that undergo one of these components alone (reminder only, drug only, counterconditioning only) will continue to show heightened reactivity to misophonia cues."|t|t|t|f
33821084|NCT01174862|||COHORT||PROSPECTIVE|||||||
33821085|NCT00860899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821086|NCT00896584|||CASE_ONLY||PROSPECTIVE|||||||
33821087|NCT05456113|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33821088|NCT03630783|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33821089|NCT05268185|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821090|NCT03386799|||COHORT||PROSPECTIVE|||||||
33821091|NCT05887479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821092|NCT00449033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821093|NCT03538665|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33821094|NCT02042625|NA|SINGLE_GROUP||||NONE||||||
33821095|NCT00002347||||TREATMENT||DOUBLE||||||
33837312|NCT01648153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33837313|NCT01545947|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837314|NCT05516043|||COHORT||RETROSPECTIVE|||||||
33837315|NCT00075777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837316|NCT04315805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33837317|NCT03430622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers doing outcome assessment will be kept blind to the group allocations||f|f|f|t
33840214|NCT03774810|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double Blinded||t|t|t|t
33840215|NCT02469142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821096|NCT03392688|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|The algorithm used to calculate the onset of the EMG was identified according to the point at which the signal deviated by more than three times standard deviations, for a minimum of 25 ms from the baseline level (computing started 200 ms prior to the start of walking). MatLab program (R2011 version) was used for design a custom made program for data analysis. Additionally to automatic calculation, all data was visually checked to ensure that there was no signal noise, deteriorating the signal analysis, possibly caused by the movement artefact. A blind assessor visualy checked the onsets of the MH and LH muscles and record the onset time.|Participants which were included in the study were divided into 2 groups as patient group who included the patients diagnosed with Patellofemoral pain and asymptomatic group which was considered as control group.|f|f|f|t
33821097|NCT03661749|RANDOMIZED|PARALLEL||OTHER||NONE||PR/CR urine collected by clean catch or non -clean catch technique will be compared in term pregnancy||||
33821098|NCT05893225|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821099|NCT03911141|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33821100|NCT03367845|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|Care Providers and Assessors represent two different teams of staff. Each is blind to the other status (how families did during assessment and which group families are assigned to). They do not have access to each others' files.|2 X 2 factorial design testing two different interventions|f|t|f|t
33821101|NCT03191526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821102|NCT02784535|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33821103|NCT02547025|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821104|NCT06329544|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|All participants undergo both treatment arms but will be blinded to the order.|The study will be a double-blinded (participants and select study personnel), randomized controlled crossover dietary intervention design.|t|f|t|f
33821105|NCT04925245|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33821106|NCT00866502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821107|NCT05389254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821108|NCT04786431|||COHORT||RETROSPECTIVE|||||||
33821109|NCT02854436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821110|NCT04178096|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The investigators will select twelve 'low-performing' sites to receive a bundle of strategies that have been empirically determined to be associated with evidence based practices for Veterans with cirrhosis. Using a hybrid type III stepped wedge cluster design, in which the investigators provide the bundle of strategies to four sites every six month period, then will evaluate whether applying these data-driven implementation strategies increases the use of evidence based practices and outcomes for cirrhosis compared to VA sites operating as usual.||||
33821111|NCT04260282|||COHORT||PROSPECTIVE|||||||
33821112|NCT05311956|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821113|NCT03748680|RANDOMIZED|PARALLEL||TREATMENT||NONE||A open label 1:1 randomized phase II exploratory study||||
33821114|NCT05550584|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33821115|NCT01825018|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821116|NCT03740932|||OTHER||CROSS_SECTIONAL|||||||
33821117|NCT02232919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821118|NCT03535493|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33821119|NCT03169530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Clinical outcome events will be assessed through medical record review by a masked Medical Safety Officer (MSO).|Balanced-design randomized trial, comparing the effects of one standard serving (\~15 grams) of alcohol intake daily to abstention.|f|f|f|t
33821120|NCT05974371|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821121|NCT06275906|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study evaluates the effects of two different Mediterranean Diet models, based on different percentages of macronutrients, on NAFLD and Metabolic Risk.~The Mediterranean Diet is associated with a program of moderate intensity aerobic physical exercise (walking) carried out 3 times a week for 3 months."||||
33821122|NCT02884921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821123|NCT00073788|||CASE_CONTROL||PROSPECTIVE|||||||
33821124|NCT05852171|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-center, non-controlled, open-label, prospective single-arm trial (Simon's two-stage design). To evaluate the clinical efficacy and safety of baricitinib for idiopathic granulomatous mastitis. 20 patients will be enrolled, and the clinical complete remission rate is the main endpoint.This study will also assess the degree of focus reduction, the recurrence rate within 12 months after drug withdrawal, the degree of inflammation markers decline, and the toxicity and side effects of the drug.||||
33821125|NCT00464217|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821126|NCT05018871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821127|NCT03558750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821128|NCT03826225|||OTHER||PROSPECTIVE|||||||
33821129|NCT00972114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821130|NCT02101554||||TREATMENT||NONE||||||
33821131|NCT04613219|||CASE_CONTROL||PROSPECTIVE|||||||
33821132|NCT03239171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821133|NCT04715711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants received four cooling treatments on separate study visits: 1) passive cooling 2) forearm cooling 3) mist-fan cooling, 4) ice towel coolng||||
33821134|NCT02946788|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821135|NCT02065895|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Study subjects are studied under closed-loop control on three occasions: once with the glucose values used for control equal to blood glucose (NO error), once with values 33% higher than blood glucose (HIGH error), and once with values 20% lower than blood glucose (LOW error). The six different sequences of these three exposures then comprise the six arms of this crossover study.||||
34128037|NCT00521729|RANDOMIZED|CROSSOVER||OTHER||||||||
34128038|NCT06550206|||CASE_ONLY||CROSS_SECTIONAL|||||||
34128039|NCT00156104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128040|NCT02589028|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34128041|NCT05790044|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double blind||t|f|t|t
34128042|NCT04635371|||COHORT||RETROSPECTIVE|||||||
34128043|NCT06187220|||CASE_CONTROL||RETROSPECTIVE|||||||
34128044|NCT01558284|||COHORT||CROSS_SECTIONAL|||||||
33821136|NCT04260984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821137|NCT05194813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821138|NCT01671826|||COHORT||PROSPECTIVE|||||||
33821139|NCT04746690|RANDOMIZED|PARALLEL||TREATMENT||NONE||simple random sampling||||
33821140|NCT00317317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821141|NCT03520790|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821142|NCT05304884|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Interventions were perfored by a physician and study outcomes were assessed by another physician.|Group 1 received a single dose (n:36), group 2 (n:36) received three doses of ozone injection (n :36). Group 3 (n:36) was treated with a corticosteroid injection.|f|f|f|t
33821143|NCT02331771|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33821144|NCT05189288|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821145|NCT06456788|||CASE_ONLY||CROSS_SECTIONAL|||||||
33821146|NCT01719068|||COHORT||PROSPECTIVE|||||||
33821147|NCT00853203|||COHORT||PROSPECTIVE|||||||
33821148|NCT01112371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821149|NCT04117477|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||1:1, randomized, double-blind, placebo-controlled study|t|t|t|t
33821150|NCT05223452|||COHORT||PROSPECTIVE|||||||
33821151|NCT00729508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821152|NCT05651334|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Condition assignment using the URN procedure will be conducted by the research coordinator who is not involved in treatment delivery or outcome assessment.|Participants will be randomly assigned to active or sham transcranial magnetic stimulation. Assignment to condition will be conducted using the Urn randomization procedure to ensure balancing on nicotine dependence, and age.|t|t|t|t
33821153|NCT00092378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821154|NCT01745380|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821155|NCT00739700|||COHORT||PROSPECTIVE|||||||
33821156|NCT04263909|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821157|NCT00843245|||COHORT||PROSPECTIVE|||||||
33821158|NCT05593016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821159|NCT01189994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821160|NCT04310800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization was performed on the day before surgery through sealed opaque envelopes containing the surgical method. The study was approved by the institutional review boards of the 7 hospitals.||t|f|f|f
33821161|NCT02270606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821162|NCT04566744|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821163|NCT05639166|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33821164|NCT03071341|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be assigned to 1.0, 3.0 or 6.0 mg/kg (same dose taken during the previous study, AGT-181-101)||||
33821165|NCT01366144|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821166|NCT03939793|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33821167|NCT02852486|NA|SINGLE_GROUP||OTHER||NONE||||||
33821168|NCT05400525|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33821169|NCT01347099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821170|NCT01838499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821171|NCT06192693|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821172|NCT05183997|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33821173|NCT04107688|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821174|NCT05016674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821175|NCT02823171|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33821176|NCT01202305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33821177|NCT03617016|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821178|NCT03048058|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33821179|NCT00665392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821180|NCT00386997|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33821181|NCT01624012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821182|NCT00984347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821183|NCT02260583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821184|NCT01377688|||CASE_ONLY||RETROSPECTIVE|||||||
33821185|NCT02035488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821186|NCT05499117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821187|NCT05200299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821188|NCT04892004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33821189|NCT06135883|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33821190|NCT02842125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||3 Arms, no cross-over||||
33821191|NCT05289778|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33821192|NCT01425697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821193|NCT03533803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821194|NCT01747616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821195|NCT03052478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821196|NCT02373345|||||PROSPECTIVE|||||||
33821197|NCT06533020|||COHORT||RETROSPECTIVE|||||||
33821198|NCT03078699||SEQUENTIAL||TREATMENT||NONE||||||
33821199|NCT04242342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821200|NCT05788406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821201|NCT06317311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821202|NCT02653001|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821203|NCT01190228|RANDOMIZED|PARALLEL||PREVENTION||NONE||This was an open, controlled, multicenter, Phase III trial. Participants in Group 1 were previously vaccinated at 12 to 18 months of age with a single dose of JE-CV vaccine and were to receive a booster dose of JE-CV vaccine on Day 0. This group was not randomized. JE vaccine naïve control children were randomized to receive one single dose of JE-CV on Day 0 (Group 2) or a varicella vaccination on Day 0 (Group 3).||||
33821204|NCT02794428|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
33821205|NCT06153836|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821206|NCT03171389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821207|NCT00003057|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33821208|NCT05487937|||OTHER||OTHER|||||||
33821209|NCT01767636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821210|NCT03987672|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821211|NCT02775123|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33821212|NCT01357564|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33821213|NCT03985826|||COHORT||RETROSPECTIVE|||||||
33821214|NCT03624023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821215|NCT05649904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821216|NCT06646094|||COHORT||PROSPECTIVE|||||||
33821217|NCT01973959|||||PROSPECTIVE|||||||
33821218|NCT06288750|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|t|f
33821219|NCT05805033|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33821220|NCT04371471|||COHORT||RETROSPECTIVE|||||||
33821221|NCT02980198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821222|NCT02827851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821223|NCT05797220|||COHORT||RETROSPECTIVE|||||||
33821224|NCT05053256|||COHORT||PROSPECTIVE|||||||
33821225|NCT00441493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821226|NCT05750121|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"1. Care providers are not included in the study and will not be informed about the group assignment.~2. An independent administrator will allocate the identifier to the participants and randomise the participants into groups. The administrator will not be involved in the analysis, data collection, outcome assessments, and intervention delivery.~3. All assessments were conducted by a registered nurse blinded to grouping allocation and will not be involved in intervention training."||f|t|t|t
33821227|NCT02709798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821228|NCT01427179|||FAMILY_BASED||OTHER|||||||
33821229|NCT01142154|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33821230|NCT02828592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821231|NCT03997409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33821232|NCT01527500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821233|NCT02821689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821234|NCT05662878|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33821235|NCT03491774|NA|SINGLE_GROUP||OTHER||NONE||It's a single arm study||||
33821236|NCT06646198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821237|NCT00946088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821238|NCT01286376|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821239|NCT01824719|||||PROSPECTIVE|||||||
33821240|NCT01038206|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33821241|NCT01219335|||COHORT||PROSPECTIVE|||||||
33821242|NCT03103178|||CASE_ONLY||PROSPECTIVE|||||||
33821243|NCT04723784|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33821244|NCT02211599|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33821245|NCT01950286|||COHORT||PROSPECTIVE|||||||
33821246|NCT02166788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821247|NCT01503515|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821248|NCT02157688|||CASE_CONTROL||PROSPECTIVE|||||||
33821249|NCT05842278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821250|NCT03614351|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Physical therapy staff will be blinded.||f|t|f|f
33821251|NCT05324605|||CASE_ONLY||PROSPECTIVE|||||||
33821252|NCT03015961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821253|NCT05066230|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To preserve masking, 2 investigators are required for this study. The masked investigator will be responsible for examinations and safety assessments. The unmasked investigator will perform the injections and post-treatment assessments.|Participants will be randomized 1:1 into one of two arms: KSI-301 or sham.|t|t|f|t
33821254|NCT03455153|||COHORT||PROSPECTIVE|||||||
33821255|NCT04545021|||COHORT||PROSPECTIVE|||||||
33821256|NCT02542293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821257|NCT00562926|||||PROSPECTIVE|||||||
33821258|NCT01507961|||COHORT||RETROSPECTIVE|||||||
33821259|NCT05766124|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The research team, clinicians, nursing staff, and patients will be blinded to the treatment arm. A copy of the randomisation code will be held only by a research team member performing randomisation. Access to this code for a patient before the completion of the trial, will only be permitted in exceptional circumstances, such as being necessary to determine the best acute medical care for a patient, and only after discussion with the Principal Investigator (PI) or his deputy. Pharmacy staff will receive unblinded randomisation information in order to prepare the study drug of assigned doses. The labelling of the blinded drugs will be under the supervision of a dedicated pharmacy. Each course of trial treatments will be pre-prepared in a trial numbered pack and dispensed to the ward at randomisation.|Recruited subjects will be randomized in 1:1 ratio to receive a course of maximum of 6 doses intrapleural tPA (Actilyse®, 50mg ampoule, Boehringer Ingelheim) with starting dose at either low dose (2.5mg) or standard dose (10mg) in addition to fixed dose deoxyribonuclease. The first dose of intrapleural tPA will be given at the time of randomization. At or after the third dose of tPA, the attending physician will be allowed to continue with the assigned dose of tPA or escalate to 10mg tPA for the remaining doses based on the clinical response, without knowing the previous doses and not breaking the blinding. This study will follow patients through their hospital stay and at outpatient visits at 30 and 90 days.|t|t|t|t
33821260|NCT03937076|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients will not be informed as to which study group they assigned to. Only the caregivers will have this information.|"patients will be randomly classified into two groups. In the control group, patients will get intercostal block at the end of the surgery and after then will be treated by the customary postoperative pain control regimen.~In the research group, patients with get PECS II block at the end of the surgery and will get a similar postoperative pain control regimen."|t|f|f|f
33821261|NCT04682223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Raters will be blind to study timepoint, assignment of ART or I-CT, and treatment type (semantically- or phonologically-focused).|To conduct a randomized controlled phase II trial aimed at testing whether aphasia therapy delivered by a remote SLP through videoconferencing (aphasia remote therapy; ART) is non-inferior to in-clinic therapy (I-CT).|f|f|f|t
33821262|NCT05544539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33821263|NCT02295293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821264|NCT06154798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821265|NCT04890158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A list of study participants identified only study number, will be provided to a blinded outcomes assessor at 36 weeks post conceptional age. The respiratory support parameters of study participants will determine the primary outcome of moderate (Grade 2) or severe (Grade 3) BPD.||f|f|f|t
33821266|NCT02333747|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821267|NCT05988385|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Approximately 250 total patients (\~63 per site) will be enrolled. In the 3-month wait-list control randomized trial, 200 patients will be randomized to one of two groups: i) a 3-month OSA treatment by any combination of PAP, OAT, and positional therapy that results in an effective AHI3a\<15 (rapid multi-modal treatment RMMT); ii) a waitlist control group to receive treatment at the conclusion of the 3-month intervention period. The remaining 50, plus an additional \~50 (n\~100 total) participants who declined treatment and were not interested in being randomized for the 3-month trial, or who have tried but failed treatment in the past, will serve as the control group for the 24-month follow-up period."||||
33821268|NCT04364035|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|double Blind, Two or more parties are unaware of the interventional assignment|double-blind, placebo-controlled|t|t|t|t
33821269|NCT00648271|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33821270|NCT04919330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcome assessors and researchers (and health care staff of the study hospital) are blind to the group assignment and intervention undertaken and concealed to the participant list.|Parallel Assignment; repeated-measures 2-arm randomized controlled trial|f|f|t|t
33821271|NCT03856424|RANDOMIZED|CROSSOVER||OTHER||NONE||Three different spontaneous breathing trials modalities will be tested in each patient in a randomized order. Washout periods will be performed between the tested modalities.||||
33821272|NCT05335343|||COHORT||CROSS_SECTIONAL|||||||
33821273|NCT04288778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821274|NCT02612116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821275|NCT03787719|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center pilot study||||
33821276|NCT00254722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821277|NCT04521283|||COHORT||PROSPECTIVE|||||||
33821278|NCT03916159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33821279|NCT02625922|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33821280|NCT02468947|||COHORT||PROSPECTIVE|||||||
33821281|NCT02849509|||COHORT||PROSPECTIVE|||||||
33821282|NCT03115879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33821283|NCT03262753|||COHORT||PROSPECTIVE|||||||
33821284|NCT01249599|||||PROSPECTIVE|||||||
33821285|NCT02746497|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33821286|NCT04745455|NA|SINGLE_GROUP||OTHER||NONE||||||
33821287|NCT05962086|||COHORT||RETROSPECTIVE|||||||
33821288|NCT01682447|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33821289|NCT04322864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33821290|NCT06270849|||COHORT||PROSPECTIVE|||||||
33821291|NCT03816332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821292|NCT03050372|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33821293|NCT03172897|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821294|NCT00623818|||||PROSPECTIVE|||||||
33821295|NCT03786783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821296|NCT03347773|RANDOMIZED|PARALLEL||OTHER||NONE||Open label randomized controlled trial||||
33821297|NCT03159065|RANDOMIZED|CROSSOVER||SCREENING||QUADRUPLE|||t|t|t|t
33821298|NCT02829411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821299|NCT03982082|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33821300|NCT00068718|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821301|NCT03490747|NON_RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|Post hoc data analysis will be blinded via an independent coding method for condition and time frame (i.e. pre-post measures).|"3 arm quasi-experimental trial~1. Co-developed scheme 2. Usual care 3. No treatment control"|f|f|f|t
33821302|NCT06646029|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821303|NCT04372186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821304|NCT04539938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821305|NCT02977468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821306|NCT06195150|||CASE_ONLY||PROSPECTIVE|||||||
33821307|NCT04734171|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33821308|NCT03959735|RANDOMIZED|PARALLEL||TREATMENT||NONE||Feasibility Randomized Controlled Trial (RCT)||||
33821309|NCT02567227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821310|NCT04466293|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The data identified by clinic allocation will be blinded to the PI and co-investigators and study statistician until completion of comparative analysis. There will be no other blinding.|"Clinic randomization to study arm will be conducted publically (either in a single location, or if blocking by country, in each country). Randomization will be achieved either through computer randomization or through drawing marked balls from a bag. Randomization will be stratified by country and within each country by clinic ART population and urban / rural location.~The enrolled number reflects clinics participating in the study rather than individual participants because the study did not enroll individual participants in the trial."|f|f|t|f
33821311|NCT02123680|||||PROSPECTIVE|||||||
33821312|NCT01154699|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821313|NCT03059459|||COHORT||PROSPECTIVE|||||||
33821314|NCT00771238|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821315|NCT03823261|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, open-label cohort study without a control, and no blindness.||||
33821316|NCT00689520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821317|NCT06646887|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821318|NCT03130127|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821319|NCT04260776|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33821320|NCT03395873|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821321|NCT04962347|||COHORT||RETROSPECTIVE|||||||
33821322|NCT05709145|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821323|NCT06646783|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33821324|NCT05213559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821325|NCT05623761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The allocation concealment will be performed using sealed containers numbered by a third party (person who will not participate in the study). The toothpastes in white bottles without any titles will be placed in the containers. Each patient will receive a sealed container with a toothpaste on enrolment. Neither patients nor researchers will be aware of the type of the toothpaste used."|double-blind, randomized, two-arm parallel-group study|t|t|t|t
34128045|NCT01766037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128046|NCT04194944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128047|NCT01294137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128048|NCT05275088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128049|NCT00422188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821326|NCT00125619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821327|NCT02176018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821328|NCT00830284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821329|NCT06376344|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33821330|NCT00244751|RANDOMIZED|PARALLEL||TREATMENT||||||||
33821331|NCT06440980|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821332|NCT02826759|||CASE_CONTROL||PROSPECTIVE|||||||
33821333|NCT05609708|||CASE_ONLY||CROSS_SECTIONAL|||||||
33821334|NCT06584669|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All participants and study staff were blinded to treatment allocations until the last patient had completed the last visit. The study capsules were identical in shape and color and packed in blisters tailor-made for each intervention group.|Randomized, placebo-controlled, double-blind, parallel group study|t|f|t|f
33821335|NCT04225247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821336|NCT01799993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821337|NCT00588042|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33821338|NCT00219635|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33821339|NCT03743597|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"A computer generated list will allocate each participant to either one of the stockings, the innovative SOCKNLEG, or the standard Sigvaris COTTON stocking. In each participant the examinations will be conducted with both stockings.~The allocated group defines with which stocking the examinations will be conducted first."||||
33821340|NCT05757063|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821341|NCT06320535|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants who opt to receive the escalating dose regimen will be randomized to either Group 1 or Group 2. Recruitment to Groups 1 and 2 will be staggered, as these groups assess a novel administration regimen for R21/Matrix-M:~* Two participants will be enrolled first, into Group 1 or 2, with a review of safety data collected up to Day 16 by the DSMC.~* If reactogenicity is acceptable, the remaining participants may be enrolled into Groups 1 and Group 2.~Participants may be recruited to Group 3 at any time.~A second DSMC review will take place 16 days after 10 participants have been recruited in Groups 1 and 2 and 5 participants have been recruited in Group 3"||||
33821342|NCT05180526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821343|NCT03794609|||CASE_ONLY||PROSPECTIVE|||||||
33821344|NCT03302559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821345|NCT00303017|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821346|NCT01090856|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33821347|NCT02001649|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33821348|NCT05029271|NA|SINGLE_GROUP||OTHER||NONE||Single Arm exploratory and descriptive study.||||
33821349|NCT02431832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821350|NCT04128514|||COHORT||PROSPECTIVE|||||||
33821351|NCT05476978|||COHORT||PROSPECTIVE|||||||
33821352|NCT02880306|||CASE_CONTROL||RETROSPECTIVE|||||||
33821353|NCT03873714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821354|NCT03949699|NA|SINGLE_GROUP||PREVENTION||NONE||pre-post||||
33821355|NCT01027988|||COHORT||PROSPECTIVE|||||||
33821356|NCT02316821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821357|NCT04175834|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled, pilot study to determine there is evidence that cetirizine is non-inferior to diphenhydramine in limiting the proportion and severity of infusion related reactions to ocrelizumab infusions.||||
33821358|NCT03851822|||COHORT||PROSPECTIVE|||||||
33821359|NCT01136733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821360|NCT01637337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821361|NCT04809545|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Single-blind study where the intervention is delivered outside of the hours of the investigator and outcomes assessor.|Single blind repeated-measures randomized controlled study with two parallel arms, Intervention and Treatment As Usual (TAU) with a 2:4:1 design (two baseline measures, four intervention measures, 1 post-intervention)|f|f|t|t
33821362|NCT01563445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821363|NCT05018455|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Functional and balance tests will be performed by a skilled physiotherapist, blind to the participant's group affiliation|The intervention program will include Otago- based fall prevention training face-to-face or remote. Each subject will receive the two types of interventions in sequence, with a cooling-off period between them. The intervention program in this study will last 6 months, however, the intervention arm will be swapped after 3 months.|f|f|f|t
33821364|NCT05986799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33821365|NCT05711017|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33821366|NCT00399945|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821367|NCT02010749|||COHORT||RETROSPECTIVE|||||||
33821368|NCT00087919|||COHORT||RETROSPECTIVE|||||||
34128050|NCT04684576|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The researcher who will be completing the developmental assessment scoring will be masked as to which device the child has used and when.|A mixed-methods, randomized, counterbalanced 2x2 crossover intervention study. Condition A is 8-weeks of Permobil Explorer Mini Use, and Condition B is 8-weeks of modified ride-on car use.|f|f|f|t
34128051|NCT01875393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128052|NCT05070793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128053|NCT00647244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128054|NCT02468440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34128055|NCT00885183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34128056|NCT00470002|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34128057|NCT00298441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128058|NCT01460706|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34128059|NCT04237181|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128060|NCT05313607|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34128061|NCT01165411|||COHORT||RETROSPECTIVE|||||||
34128062|NCT00091741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128063|NCT05561101|||FAMILY_BASED||PROSPECTIVE|||||||
34128064|NCT00388492|||DEFINED_POPULATION||PROSPECTIVE|||||||
34128065|NCT02261064|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128066|NCT05677477|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single blind||t|f|f|f
34128067|NCT02628405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128068|NCT02508363|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34128069|NCT01840904|||CASE_CROSSOVER||PROSPECTIVE|||||||
34128070|NCT00635141|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34128071|NCT03444545|||CASE_ONLY||PROSPECTIVE|||||||
33821369|NCT03247985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821370|NCT00991133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821371|NCT02033499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators including the bio-statistician were blind to the study assignment.||f|f|t|f
33821372|NCT05465499|||OTHER||CROSS_SECTIONAL|||||||
33821373|NCT06587854|||COHORT||PROSPECTIVE|||||||
33821374|NCT05727553|||COHORT||PROSPECTIVE|||||||
33821375|NCT05984147|NA|SEQUENTIAL||TREATMENT||NONE||"Sequential Assignment Dose Escalation 3+3 Design"||||
33821376|NCT03453489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821377|NCT04611724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821378|NCT01443546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821379|NCT00938288|NA|SINGLE_GROUP||OTHER||NONE||||||
33821380|NCT03915951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821381|NCT06292832|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33821382|NCT06646107|||COHORT||PROSPECTIVE|||||||
33821383|NCT03595826|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The Pi will not be involved in post intervention testing of the children/participants.|3 phase quasi experimental design. Diagnosis and intervention.|f|f|t|f
34128072|NCT01474005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821384|NCT01846988|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33821385|NCT04369547|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33821386|NCT05968911|||OTHER||RETROSPECTIVE|||||||
33821387|NCT00586430|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
33821388|NCT03866434|NA|SINGLE_GROUP||TREATMENT||NONE||Single sequence crossover drug-drug interaction study||||
33821389|NCT03472859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821390|NCT00527371|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821391|NCT03287375|NA|SINGLE_GROUP||TREATMENT||NONE||Cohorte study||||
33821392|NCT02490059|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33821393|NCT05198323|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821394|NCT00149071|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33821395|NCT01535625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821396|NCT03314116|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"All participants will be randomly assigned to two groups:~The video group will be guided by a 7-minute video that explains the importance of using ear plugs and correct installation.~The control group, will be instructed to use earplugs properly, including practical exercises by a medic"|f|f|f|t
33821397|NCT02464306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821398|NCT00205205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128073|NCT03879928|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34128074|NCT03797066|NA|SINGLE_GROUP||TREATMENT||NONE||non-randomised, open label||||
33821399|NCT05082441|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33821400|NCT03878290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821401|NCT06089759|||CASE_ONLY||PROSPECTIVE|||||||
33821402|NCT03340766|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33837318|NCT05427526|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||group 1: patients that had a LARA IOL implanted in combination with vitrectomy group 2: patients that had a LARA IOL implanted in during surgery for cataract secondary to vitrectomy|t|f|f|f
33837319|NCT00621205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33837320|NCT00115518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837321|NCT02607202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837322|NCT02664090|||COHORT||PROSPECTIVE|||||||
34128075|NCT03439644|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34128076|NCT05597358|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators, outcomes assessors and data analysts will be masked to group assignation.|"* Baseline evaluation~* Randomization to active laser or sham laser (12 sessions in 6 consecutive weeks) Post-treatment evaluation (2 weeks post-treatment)~* Follow-up evaluation (6 months post-treatment)"|t|f|t|t
34128077|NCT01802593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128078|NCT06279117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomised controlled clinical trial|t|f|f|f
34128079|NCT02594228|RANDOMIZED|PARALLEL||||NONE||||||
34128080|NCT01892462|||COHORT||PROSPECTIVE|||||||
34128081|NCT05779228|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The interventional study type is correct. The investigative team is giving all subjects a treatment- behavioral training in visual mode switching- and measuring effects of that treatment, by comparing measures made before to measures made after the treatment. Thus, this is a within-subjects, repeated measures experimental design. The experimenters have 6 different measurements they are using this design in different groups of subjects run in parallel, all examining different effects of the same treatment. . This is why parallel study model is appropriate. These parallel groups with different measurements, but same treatment, are the arms of the study.||||
34128082|NCT01266226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128083|NCT06404788|||OTHER||CROSS_SECTIONAL|||||||
34128084|NCT05679596|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, Investigators and Outcome Accessors will be blinded to the intervention and control drinks. The drinks will be flavor and energy matched and provided in an opaque bottle. An individual not involved with the study data collection, analysis and interpretation will be designated as a study blinder and randomizer.|Randomized, double-blind, parallel group study design.|t|f|t|t
34128085|NCT01144624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128086|NCT03869567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128087|NCT01125475|||COHORT||PROSPECTIVE|||||||
34128088|NCT03277001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128089|NCT04257643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128090|NCT06429709|||COHORT||PROSPECTIVE|||||||
34128091|NCT06164964|||COHORT||PROSPECTIVE|||||||
34128092|NCT04573790|||COHORT||PROSPECTIVE|||||||
34128093|NCT02226588|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128094|NCT03799952|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Randomized to a control or intervention group. The intervention group will have pre- and post-testing following 12-weeks of exercise, while the control group will have pre- and post-testing following 12-weeks of normal activity."|t|f|f|f
34128095|NCT04160923|||CASE_ONLY||RETROSPECTIVE|||||||
34128096|NCT06458621|||COHORT||RETROSPECTIVE|||||||
34128097|NCT04615624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After informed consent and upon meeting inclusion criteria, the study personnel will inform pharmacy personnel who will then randomly assigned the patient to groups by opening the next previously prepared sequential and numbered opaque study envelope. The pharmacy staff will send the assigned treatment, which will be administered by the bedside nurse. The vials containing the treatment will be indistinguishable as both furosemide and normal saline placebo are clear, colorless solutions. Thus, the provider, nurse, and patient will be blinded to the treatment.||t|t|t|f
34128098|NCT05242835|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128099|NCT02008942|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34128100|NCT02680340|||COHORT||RETROSPECTIVE|||||||
34128101|NCT02998879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128102|NCT01160393|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128103|NCT03083665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128104|NCT00005844||||TREATMENT||||||||
34128105|NCT06080763|||COHORT||PROSPECTIVE|||||||
34128106|NCT04725045|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Double-blinded design|Randomized, crossover, double-blinded design|t|f|f|t
34128107|NCT05456997|||COHORT||PROSPECTIVE|||||||
34128108|NCT04145726|||COHORT||PROSPECTIVE|||||||
34128109|NCT03075852|||COHORT||PROSPECTIVE|||||||
34128110|NCT00613548|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128111|NCT06472323|||COHORT||PROSPECTIVE|||||||
34128112|NCT03375645|||COHORT||PROSPECTIVE|||||||
34128113|NCT05231759|||CASE_ONLY||PROSPECTIVE|||||||
33821403|NCT05466968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Drug: Suxiao Jiuxin Pills Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).~Drug: The placebo of Suxiao Jiuxin Pills The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste."|Experimental: Suxiao Jiuxin Pills Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days Placebo Comparator: The placebo of Suxiao Jiuxin Pills The placebo of Suxiao Jiuxin Pills prescription (15 pills loading does, maintenance 6 pills each time, three times a day.) for 90 days|t|t|t|t
33821404|NCT06644391|||COHORT||RETROSPECTIVE|||||||
33821405|NCT03344900|||COHORT||PROSPECTIVE|||||||
33821406|NCT01169571|||||PROSPECTIVE|||||||
33821407|NCT06063564|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Clinic randomized trial|t|f|f|f
33821408|NCT03013725|||COHORT||PROSPECTIVE|||||||
33821409|NCT01350102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821410|NCT04232475|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33821411|NCT02198885|||CASE_ONLY||PROSPECTIVE|||||||
33821412|NCT04861974|||COHORT||PROSPECTIVE|||||||
33821413|NCT05079958|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||For the third stage, subjects will be recruited and randomly divided into experimental or control group to identify the effect of a 12-week brisk walking on improving the participants' immediate (short-term), three-month, and six month (long-term) health status.||||
33821414|NCT02623686|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821415|NCT05852496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33821416|NCT04397822|||COHORT||PROSPECTIVE|||||||
33821417|NCT01757171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821418|NCT06291584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|First of all, the randomization of exercise groups will be performed according to the closed envelope procedure. The student who selects one of the envelopes with the names of the three groups will be included in the group written in the envelope he selected.|The study consists of three groups. Groups to be formed: Group 1: face-to-face exercise group; Group 2: Online (Telehealth) Exercise Group; Group 3: Control Group|t|f|f|f
33821419|NCT03261934|||OTHER||PROSPECTIVE|||||||
33821420|NCT05052333|||CASE_ONLY||CROSS_SECTIONAL|||||||
33821421|NCT05024578|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33821422|NCT03553459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821423|NCT02658032|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34128114|NCT02254044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128115|NCT02669394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128116|NCT00579553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821424|NCT03861078|NA|CROSSOVER||BASIC_SCIENCE||NONE||||||
33821425|NCT00494286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821426|NCT02469051|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821427|NCT05474378|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33821428|NCT01502605|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821429|NCT00005914|||FAMILY_BASED||RETROSPECTIVE|||||||
33821430|NCT05547503|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1 and Part 2 studies are double-blind placebo controlled|Part 1: Single escalation dose Part 2: Multiple escalation doses for 14 days|t|t|t|t
33821431|NCT06057870|||CASE_ONLY||CROSS_SECTIONAL|||||||
34128117|NCT02656966|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128118|NCT04338607|||COHORT||PROSPECTIVE|||||||
34128119|NCT03783962|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The Behavioral Weight Loss Program: Investigators have developed and implemented a theory-based group-delivered behavioral weight control program in two previous studies that incorporates the elements of current thinking and empirical data on successful weight loss programs, including restricted calorie intake and increased physical activity. In addition to attending weekly classes, participants will track their food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on progress.~The Cooking Program Active Intervention. Twelve cooking classes will be run every other week after the in-person weight loss meetings.~Demonstrations. The demonstration condition will serve as an attention only control. All participants will have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."||||
34128120|NCT00993863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128121|NCT05365789|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, randomized, parallel group. Study product and standard of care versus standard of care.||||
34128122|NCT00548626|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34128123|NCT02544867|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34128124|NCT05388604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128125|NCT03798639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128126|NCT03838211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128127|NCT01632592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128128|NCT06044233|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128129|NCT06227312|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||The participants engaged in four experimental sessions within 4 weeks. These sessions were conducted in a randomized sequence, with a one-week gap between each session. During each session, every participant performed one of the following tasks: 5 sets of 30 s calf raises on the platform but without vibration (CTRL); 5 sets of 30 s calf raises on the vibration platform with 30 s rest intervals between sets (WBV); 6 drop jump with a 30 s rest interval between sets (DJ); 5 sets of 30 s calf raises on the vibration platform followed by 6 drop jumps with a 30 s rest interval between sets (WBV + DJ).||||
34128130|NCT06003218|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34128131|NCT03179852||SEQUENTIAL||TREATMENT||NONE||||||
34149309|NCT06208566|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33821432|NCT04093583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821433|NCT02429037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821434|NCT05143437|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821435|NCT05414071|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821436|NCT02007421|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33821437|NCT02241642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821438|NCT03918733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821439|NCT06585072|||COHORT||PROSPECTIVE|||||||
33821440|NCT03296423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Patients vaccinated with placebo or BCG|t|t|t|t
33821441|NCT02618109|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33821442|NCT05256914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Gels concealed|Split-mouth design|t|t|t|t
33821443|NCT00079599|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821444|NCT03022734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821445|NCT02635711|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821446|NCT03172338|||COHORT||PROSPECTIVE|||||||
33821447|NCT06086665|||COHORT||RETROSPECTIVE|||||||
33821448|NCT00212888|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33821449|NCT01390987|||COHORT||PROSPECTIVE|||||||
33821450|NCT01481701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821451|NCT05635994|||COHORT||PROSPECTIVE|||||||
33821452|NCT02589678|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
33821453|NCT03555708|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33821454|NCT02577848|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821455|NCT00975130|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821456|NCT01482871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821457|NCT02165696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33821458|NCT04950790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33821459|NCT00463099|||COHORT||PROSPECTIVE|||||||
33821460|NCT02876393|||CASE_CONTROL||PROSPECTIVE|||||||
33821461|NCT06098443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821462|NCT00396721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821463|NCT04673071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||2-arm parallel design, randomized, controlled, assessor-blinded, clinical trial|t|f|f|t
33821464|NCT03790124|||OTHER||RETROSPECTIVE|||||||
33821465|NCT00176761|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821466|NCT06183944|||COHORT||OTHER|||||||
33821467|NCT03548272|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821468|NCT04546971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821469|NCT00597025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821470|NCT02831751|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33821471|NCT04695249|NA|SINGLE_GROUP||TREATMENT||NONE|All assessment pre-post and follow up were realized by an external assessor. The results were blinded to the main psychotherapist (and investigator) until the end of the study.|||||
33821472|NCT04399798|NA|SINGLE_GROUP||TREATMENT||NONE||Proof-of-concept trial with an exploratory single-arm proof of concept Phase IIa study||||
33821473|NCT02061189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821474|NCT03101098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821475|NCT00731276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821476|NCT02752789|||COHORT||PROSPECTIVE|||||||
33821477|NCT01550783|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33821478|NCT04868734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837323|NCT00786552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837324|NCT00121927|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837325|NCT04845399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128132|NCT05719779|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Participant no informed on the oral appliance position, ie.e, degree of advancement Outcome assessor also not informaed of applaince position: control or active-forward.|Active oral appliance in 60-70% advanced position of maximum jaw possible advancement for a given participant over the control position= neutral position one in 10-20% (no fucntional opening of upper airway at that position)|t|f|f|t
34128133|NCT05978674|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||The study was planned to be conducted in a randomized controlled crossover design. Infants meeting the inclusion criteria will be divided into two groups, group A and group B, according to block randomization. Groups were determined by drawing lots. (A= Rocking bed; B= Jeans) Accordingly, babies included in group A will be taken to the rocking bed first. Babies included in group B will be quoted first. Babies will be laid in these beds for an average of 2 hours. In cross-over design, a washout is recommended in order to control the carry over effect that may result from the interference. We assumed that the total time without interference would be sufficient to control the carryover effect, since the oscillation interference was only applied for half an hour in a two-hour sleep cycle, and there was routine maintenance and feeding cycles between measurements (average 20 min).|f|f|f|t
34128134|NCT04279119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128135|NCT02144571|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34128136|NCT05265858|||COHORT||PROSPECTIVE|||||||
34128137|NCT02134561|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34128138|NCT04444271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128139|NCT00720967|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128140|NCT01692743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34128141|NCT01958255|NA|SINGLE_GROUP||OTHER||NONE||||||
34128142|NCT05107063|||COHORT||PROSPECTIVE|||||||
34128143|NCT03292003|||CASE_ONLY||RETROSPECTIVE|||||||
34128144|NCT01413711|NA|SINGLE_GROUP||||NONE||||||
34128145|NCT01448889|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34128146|NCT04780802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128147|NCT03822143|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128148|NCT03019523|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34128149|NCT02742233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34128150|NCT03857932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128151|NCT00147017|||CASE_ONLY||PROSPECTIVE|||||||
34128152|NCT05634824|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128153|NCT00001901||||TREATMENT||||||||
34128154|NCT03804892|RANDOMIZED|CROSSOVER||PREVENTION||NONE||This study involves 2 trials. Each trial will involve walking for 45 minutes on a treadmill, with muscle biopsies obtained from the thigh before (basal), immediately following (post-exercise) and 3 h post-exercise. Each trial will be identical, except that participants will ingest either Acipimox or a placebo in a double-blind design. Muscle biopsies will be used to examine differences in muscle fat between the two trials||||
34128155|NCT06084143|||CASE_ONLY||RETROSPECTIVE|||||||
34128156|NCT03576781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128157|NCT02485509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128158|NCT03660592|||CASE_ONLY||PROSPECTIVE|||||||
34128159|NCT06005558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34128160|NCT02480088|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34128161|NCT03475446|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind design|Participants are allocated to one of 3 groups: real tACS, real tDCS or sham. Each participant belongs also to a subpopulation with or without memory impairment (Healthy elderly, MCI, AD)|t|f|t|f
34128162|NCT01404728|||CASE_ONLY||CROSS_SECTIONAL|||||||
34128163|NCT03700840|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128164|NCT03584048|||COHORT||PROSPECTIVE|||||||
34128165|NCT06006936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research assistant (RA) who is not involved with this study will use the randomization scheme to prepare opaque envelopes with each participant's treatment assignment, to be opened at the end of each enrolment session. While it is not possible to maintain full blinding of either the participant or the researchers given the nature of the intervention, all outcomes will be collected by an RA who is blind to participants' treatment allocation.|"Participants will be randomly assigned to either receive the CWI program or to remain in a treatment-as-usual (TAU) control condition using stratified block randomization. The two arms will be stratified based on whether participants are attempting to conceive naturally or undergoing fertility treatments.~Participants in the intervention condition will receive one 10-minute video module from the CWI program every week for seven weeks. Each video module will include a homework assignment encouraging participants to integrate the module content into everyday life.~Participants in the TAU control condition will not receive video modules or homework; instead, they will continue with everyday life-including their attempts to conceive-until the conclusion of the study. TAU participants will be offered the intervention following the conclusion of the study."|f|f|f|t
34128166|NCT04769817|||COHORT||PROSPECTIVE|||||||
34128167|NCT01292122|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128168|NCT04538599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128169|NCT04930146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128170|NCT01798147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128171|NCT04185077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128172|NCT02954887|NA|SINGLE_GROUP||TREATMENT||NONE|Open-label|||||
34149310|NCT02102399|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34149311|NCT04777266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837326|NCT00390260|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837327|NCT03680339|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837328|NCT05620797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837329|NCT02002962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837330|NCT00867971|||COHORT||CROSS_SECTIONAL|||||||
33837331|NCT01705899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837332|NCT02421549|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33837333|NCT02646020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837334|NCT00720564||||TREATMENT||||||||
33837335|NCT03117491|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33837336|NCT03172039|||COHORT||RETROSPECTIVE|||||||
34128173|NCT04073862|NA|SINGLE_GROUP||TREATMENT||NONE||Upon training in SC-TF-CBT, therapists in Norwegian municiplaities across the country will administer the treatment as deemed appropriate. Data will be collected to determine feasibility.||||
34128174|NCT00383331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128175|NCT05339399|||OTHER||PROSPECTIVE|||||||
34128176|NCT00164658|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34128177|NCT01546233|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34128178|NCT05480982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors were not considered blinded because participants were not blinded and outcomes were self-reported. However, to guarantee that the treatment expectation was evenly balanced between the groups and decrease measurement bias, the participants did not know the study hypothesis, and the assessors did not know the participant's intervention group. The statistician was blinded to the group allocation.|Randomized controlled clinical trial with allocation of two parallel groups|f|f|t|f
34128179|NCT00633087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128180|NCT02812238|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34128181|NCT05415423|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34128182|NCT01693250|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Primary care providers and outcome assessors were blinded to the group assignment.|A randomized control study design with an active control group was used.|f|t|f|t
34128183|NCT05009576|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34128184|NCT06502522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128185|NCT00382265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128186|NCT02596256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128187|NCT02277574|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34128188|NCT00422877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128189|NCT02194946|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128190|NCT04240379|||OTHER||PROSPECTIVE|||||||
34128191|NCT03136653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128192|NCT03542266|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy. The study has a sample size of 20, and follows two-stage minimax design for primary efficacy analysis.||||
33821479|NCT04593771|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|The statistician and the blind operators who do not participate in the trial will perform drug blinding,stick the printed drug label on the designated position of each drug according to the blind bottom. After completing the blind programming, the blind bottom will be sealed and handed over to the sponsor. The blind editors shall not participate in other related work of this clinical trial, and shall not disclose to any personnel participating in the trial.Subjects were randomly injected intracutaneously with BCG-PPD test drugs or BCG-PPD control drugs.All subjects, some investigators and other staff participating in the study were kept blind.The investigators designated in the study to extract drugs are non-blind personnel, and are not allowed to disclose the subject's grouping and skin test information to others, nor are they allowed to participate in any other procedures in the trial.||t|t|t|t
33821480|NCT00752999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821481|NCT03053908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821482|NCT06336707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821483|NCT05961488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821484|NCT02243488|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33821485|NCT01349699|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33821486|NCT01350388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821487|NCT05765409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This will be a single-blinded, randomised, comparative therapeutic interventions, controlled trial.~This is a prospective, randomized, single-blind, two-arm, parallel, multicenter study to evaluate the non-inferiority of an Integrative Therapy for Adolescent Cannabis Misuse (TIMCA) compared to the Treatment As Usual (TAU) control group using an Adaptive Group-Sequential non Inferiority Study Design. Two interim analyses are planned (when 30 and 60 subjects have completed the study).~Both interventions will take place under similar conditions: 10 sessions, once a week, delivered by clinical psychologists who will be supervised."|t|f|f|f
33821488|NCT05723029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821489|NCT01212952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821490|NCT03731572|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|All testing for Aims 1a and 1b will be conducted by individuals who are masked to subject intervention group assignment at baseline-testing, post-intervention testing, and retention-testing|The investigators will compare changes in protective stepping, hip abduction and adduction muscle power and neuromuscular activation, balance and mobility function, and number of prospective falls between power and strength training groups.|f|f|t|t
33821491|NCT01698216|||CASE_ONLY||PROSPECTIVE|||||||
33821492|NCT00728832|RANDOMIZED|PARALLEL||||NONE||||||
33821493|NCT05455554|||COHORT||PROSPECTIVE|||||||
33821494|NCT03441737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821495|NCT01714414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821496|NCT02029027|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821497|NCT05292170|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821498|NCT00295100|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33821499|NCT02951416|||COHORT||CROSS_SECTIONAL|||||||
33821500|NCT00518310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821501|NCT01573897|||COHORT||CROSS_SECTIONAL|||||||
33821502|NCT01753323|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128193|NCT02807220|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128194|NCT00187538|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34128195|NCT01545297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34128196|NCT02821156|||||PROSPECTIVE|||||||
34128197|NCT04614012|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal assessment of COVID-19 patients treated with hyperimmune plasma||||
34128198|NCT03501901|||COHORT||PROSPECTIVE|||||||
34128199|NCT02391311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128200|NCT03353038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128201|NCT04152954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized controlled trial|t|f|t|t
34128202|NCT05353114|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128203|NCT05147753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128204|NCT03773900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34128205|NCT04113356|||COHORT||PROSPECTIVE|||||||
34128206|NCT05657899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessor of all outcome measures except assessment of a postoperative radiograph will be masked. When the radiograph is viewed the operative method will be apparent, but this assessor is not the same as for the other outcome measures.||f|f|f|t
34128207|NCT04538300|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|When efficient wakefullness was gained the participants were asked for nausea and vomiting at recovery room. The outcomes assessor evaluating the participants after the treatment does not know the treatment type made to the patients.|300 patients ASA I-II, aged between18-65 years who scheduled for elective laparoscopic cholecystectomy under general anesthesia were included. The patients randomly divided into 2 groups (Group G n=150, Group C n=150) with the closed envelope method. In group G peppermint-flavored gum was chewed for 15 minutes in patients with sufficient wakefullness. If PONV persists despite gumming twice, ondansetron iv 4 mg, dexamethasone iv 4 mg, propofol iv 10 mg were given respectively. Patients with moderate and severe nausea in the control group(Group C) were given iv 4 mg ondansetron. If PONV continues, it was planned to give dexamethasone iv 4 mg and propofol iv 10 mg, respectively. In group C(control) degree of nausea and Abramowitz Emezis score were evaluated.|f|f|f|t
34128208|NCT05797051|||OTHER||OTHER|||||||
34128209|NCT06374680|||COHORT||PROSPECTIVE|||||||
34128210|NCT02364037|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE|Due to the controlled time-trend design and, therefore, the different time periods for enrollment and follow up for each group, we were unable to mask the research and clinical staff who administered surveys to the study group assignment when collecting data regarding the study outcomes.|We used a prospective, controlled time-trend study design, a non-randomized design where outcomes are compared before and after a change in the healthcare setting.||||
34128211|NCT01364129|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34128212|NCT05551793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128213|NCT00413673|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128214|NCT02381314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128215|NCT02645565|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128216|NCT02140606|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128217|NCT04901806|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Dose Escalation: Single-subject cohorts will be enrolled initially, until a subject has a Grade 2 or greater adverse event (AE), at which time a 3+3 design will be utilized. Dose escalation will continue until the maximum-tolerated dose (MTD) is reached, or the Recommended Phase 2 Dose (RP2D) is established.~Cohort Expansion: Two cohorts will be opened to accrual. Cohort A will enroll subjects with a non-brain primary tumor and Cohort B will enroll subjects with a primary brain tumor."||||
34128218|NCT03121300|||OTHER||CROSS_SECTIONAL|||||||
34128219|NCT02317497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34128220|NCT05965245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128221|NCT06013722|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128222|NCT02302924|||COHORT||PROSPECTIVE|||||||
34128223|NCT04209023|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Selected patients will undergo 1 session of TMS treatment to include a non-TMS baseline task and a TMS testing task. The baseline and the testing task are the self-same task. The baseline test demonstrates patient comprehension of instructions, as well as a baseline of task performance for comparison analysis. The TMS test will include the self-same task that may be randomized in terms of order of stimulus presentation. Each component--the baseline and the TMS task--will have a duration of 10 minutes, for a total intervention time of 20 minutes.||||
34128224|NCT02244307|||COHORT||PROSPECTIVE|||||||
34128225|NCT03925272|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34128226|NCT01461746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128227|NCT02457650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128228|NCT05176340|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance.||||
34128229|NCT01094977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34128230|NCT05195086|||COHORT||PROSPECTIVE|||||||
34128231|NCT04842851|||COHORT||RETROSPECTIVE|||||||
34128232|NCT01683136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128233|NCT01230190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821503|NCT06647160|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33821504|NCT01700634|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33821505|NCT04553029|||COHORT||CROSS_SECTIONAL|||||||
33821506|NCT05858047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821507|NCT04958629|||COHORT||PROSPECTIVE|||||||
33821508|NCT04034914|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821509|NCT06585501|||COHORT||RETROSPECTIVE|||||||
33821510|NCT05313178|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Supplements blinded to participant and investigator by third party|Randomized, double-blind, crossover study design|t|f|t|f
33821511|NCT05936905|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single blind non randomized clinical trial.|Staff members will administer the HADS, PHQ-9 and GAD-7 through a questionnaire. The scale is being administered to a convenience sample of 30 HIV/AIDs patients, divided into 15 samples of acupuncture treatment and 15 samples of chiropractor treatment, duration 3 months. Patients will complete questionnaire before and at the end of the treatments. Data to be collected includes socio-demographic. Symptoms of anxiety and depression are measured using the Hospital Anxiety and Depression Scale (HADS). The items are rated on 0, 1, 2, and 3 giving scores with minimum scores of 0 to 21. Scores on anxiety or depression subscales ranging from 0-7 are considered normal; 8-10 are considered cause for concern, borderline abnormal, and 11-21 are considered abnormal probable cases of anxiety or depression. The Patient Health Questionnaire 9-item(PHQ-9) if (score ≥9) significant mild depressive symptom and Generalized Anxiety Disorder 7-item (GAD-7) scale, if (score 8+) probable anxiety disorder.|f|t|t|f
33821512|NCT06036797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33821513|NCT00672100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128234|NCT05469633|||CASE_ONLY||PROSPECTIVE|||||||
34128235|NCT01232127|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34128236|NCT00191399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821514|NCT01544309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128237|NCT00370266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34128238|NCT03440515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128239|NCT00285038|||CASE_ONLY||PROSPECTIVE|||||||
34128240|NCT01946633|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|f|t|t
34128241|NCT01083069|||CASE_CONTROL||PROSPECTIVE|||||||
34128242|NCT04773288|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34128243|NCT04054921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821515|NCT03378895|NA|SINGLE_GROUP||PREVENTION||NONE|No masking|||||
34128244|NCT00771927|||COHORT||PROSPECTIVE|||||||
34128245|NCT02386462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128246|NCT04224233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|Intervention model|f|f|f|t
34128247|NCT01150786|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128248|NCT00833469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128249|NCT04339790|||COHORT||PROSPECTIVE|||||||
34128250|NCT02402530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128251|NCT00768261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128252|NCT01162252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128253|NCT01763372|||CASE_CONTROL||PROSPECTIVE|||||||
34128254|NCT01657695|||COHORT||PROSPECTIVE|||||||
34128255|NCT02994485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128256|NCT04803864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128257|NCT05128071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind, placebo controlled||t|t|t|f
34128258|NCT00739310|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128259|NCT02368600|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34128260|NCT02008149|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Group assignment will be based on the preference of potential subjects. Subjects can either participate in the FES-rowing group or they can participate in the standard-of-care group. The standard-of-care group will not perform FES-rowing; they will only receive periodic bone density measurements over a 36-week period, with a total time commitment of approximately 10 hours. Subjects in the FES-rowing group will participate in rowing sessions requiring a 2 to 3 hour time commitment per week for the duration of the participation.||||
34128261|NCT05190978|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will blinded to whether they receive ADM products during their reconstruction.|Randomized Controlled Trial|t|f|f|t
34128262|NCT00439595|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128263|NCT03469622|RANDOMIZED|FACTORIAL||DIAGNOSTIC||SINGLE|||t|f|f|f
34128264|NCT02043418|||COHORT||PROSPECTIVE|||||||
34128265|NCT00530634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128266|NCT01621984|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34128267|NCT05918965|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821516|NCT03575572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821517|NCT00781677|||CASE_ONLY||PROSPECTIVE|||||||
33821518|NCT04419961|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821519|NCT02399982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821520|NCT02841085|||FAMILY_BASED||PROSPECTIVE|||||||
33821521|NCT00692523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821522|NCT00412802|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821523|NCT01769352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821524|NCT04266366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Study protocol for a double blinded two-arm randomized controlled trial|f|f|t|t
33821525|NCT06318364|||COHORT||RETROSPECTIVE|||||||
33821526|NCT01631799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821527|NCT00255515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821528|NCT03802513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821529|NCT03722485|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821530|NCT05312190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a national multicenter prospective, randomized, controlled trial. One third of participanta will receive Zhenqi Buxue Oral Liquid, one third of participanta will receive Progesterone Capsules, and the another third will receive Zhenqi Buxue Oral Liquid and Progesterone Capsules in combination.|t|f|t|f
33821531|NCT06194786|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33821532|NCT00909922|||COHORT||CROSS_SECTIONAL|||||||
33821533|NCT06154733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of examiners is impossible to be done during intervention due to different natures of the materials. However, the evaluator at follow-up visits, patients and the statistician will be blinded.|All selected first permanent molars will be randomly equally allocated into three groups. Group 1(n=15): PBM with LLLT, Group 2 (n=15): Resin-based sealant (Fissured Nova Plus) and Group 3 (n=15): Glass ionomer sealant (Ketac).|t|f|f|t
33837337|NCT03544294|||COHORT||PROSPECTIVE|||||||
33837338|NCT04385576|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837339|NCT04227145|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34128268|NCT00240812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128269|NCT06026605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128270|NCT00961740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128271|NCT05257421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128272|NCT03026296|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128273|NCT04522856|||CASE_ONLY||PROSPECTIVE|||||||
34128274|NCT00843258|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34128275|NCT01770951|||OTHER||RETROSPECTIVE|||||||
34128276|NCT04105686|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34128277|NCT06196151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Participant)||t|f|f|f
34128278|NCT01740258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128279|NCT05121298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128280|NCT04776161|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34128281|NCT01559337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128282|NCT01648023|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128283|NCT05156944|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34128284|NCT00816010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821534|NCT04312971|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The placebo and the norepinephrine solutions look identical and their infusions will be continued until 60 min after skin closure. The test solution will be prepared by one anesthesiologist before the induction of anesthesia.|A single center, interventional, parallel, double-blind (patient - and outcome-assessor), prospective, trial in patients scheduled for elective cardiac procedures using CPB. The RCT will be conducted according to Good Clinical Practice (GCP) Guidelines and comply with the principles of the Declaration of Helsinki. The RCT will be registered in a public registry, and the study protocol with its statistical analysis plan will be published before enrolment of the first patient.|t|f|f|t
33821535|NCT05973357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821536|NCT02131155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821537|NCT02375243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821538|NCT02367664|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33821539|NCT03895892|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants and investigators will be blinded as an individual not involved in the project will assemble and distribute the treatment (drinks) according to a coding system that is kept confidential until the study is completed. Participants will complete the protocol three times and the treatment order will be systematically rotated to avoid any order effect. taste and texture of treatments will be matched and will be distribute in opaque bottles to keep participant blinded|This will be a double blind repeated measures cross over study. There will be three treatments involved: Caffeinated ketone supplements, non-caffeinated ketone supplement and water-placebo. Participants will complete the protocol three times and the treatment order will be systematically rotated to avoid any order effect. Design of the study is composed of two performance tests 30 minutes following supplementation. All participants will arrive in a fed state to the laboratory. the corresponding treatment will be provided and 30 minutes later, they will perform a 20 km time trial. 10 minutes after the time trial, participants will perform a 30 second all-out Wingate test.|t|f|t|f
33821540|NCT05422040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821541|NCT05116865|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double blind (Participant, Investigator)||t|f|t|f
33821542|NCT02939859|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821543|NCT00341588|||CASE_CONTROL||RETROSPECTIVE|||||||
33821544|NCT04581356|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm, open-label, pilot study in which each subject compared to him/herself||||
33821545|NCT02758808|||COHORT||PROSPECTIVE|||||||
33821546|NCT03409276|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821547|NCT04757961|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants will be randomly assigned with equal likelihood to receive the online ACT-based intervention (LifeStories) or the waitlist control condition.||||
33821548|NCT02646644|||COHORT||RETROSPECTIVE|||||||
33821549|NCT00600223|||COHORT||PROSPECTIVE|||||||
33821550|NCT05182216|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33821551|NCT05527509|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The RCMP Study necessarily uses a longitudinal prospective sequential experimental cohort design to create a clustered randomized trial that engages individual participants for 5.5 years. The structure of the Cadet Training Program does not allow for randomizing individual participants or individual groups of participants; nevertheless, meta-analytic evidence suggests that results from studies using this design and results from true randomized controlled trials do not typically differ meaningfully or statistically significantly, and both methods produce comparable groups at baseline.||||
33821552|NCT06365177|RANDOMIZED|CROSSOVER||OTHER||NONE||Cross-sectional interventional multicenter study||||
34128285|NCT03619434|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking as the investigators are assessing differences in surgical technique|"This is a prospective cohort study where a maximum of 30 patients attending the cornea firm at the eye unit in University Hospitals Southampton who are indicated for penetrating keratoplasty as a result of corneal disease or pathology will be recruited.~All patients will receive a complete ophthalmological examination preoperatively.~Subjects will then be divided randomly into 2 groups of 15, should we get 30 patients;"||||
33821553|NCT00647387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821554|NCT05128227|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33821555|NCT04074304|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821556|NCT06646835|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The research will be conducted as a two-group, parallel, randomized, controlled experimental study with a pretest-posttest design.|t|f|f|t
33821557|NCT04257786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821558|NCT00212979|||||PROSPECTIVE|||||||
33821559|NCT05358184|NA|SINGLE_GROUP||OTHER||NONE||||||
33821560|NCT01026116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821561|NCT04542083|||OTHER||RETROSPECTIVE|||||||
33821562|NCT03807271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The anesthesia team must know if the anesthesia will be given by standard procedure or guided by the calculating device in addition.||t|f|f|f
33821563|NCT03902145|||COHORT||CROSS_SECTIONAL|||||||
34128286|NCT01794624|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34128287|NCT02652104|||CASE_ONLY|||||||||
34128288|NCT04807166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128289|NCT02440204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34128290|NCT00868829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128291|NCT01094834|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34128292|NCT05227495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128293|NCT03463863|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128294|NCT05407116|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33821564|NCT00901966|||COHORT||PROSPECTIVE|||||||
33821565|NCT04747717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821566|NCT02108483|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33837340|NCT00384605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128295|NCT03609502|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a 2x2 mixed (Group by Time) design||||
34128296|NCT01474785|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128297|NCT01127984|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821567|NCT04870814|RANDOMIZED|CROSSOVER||OTHER||NONE||"All the participants will test the 4 tourniquets (1 tourniquet model = 1 arm) both as a fitter (the person who set up the tourniquet) and as a receiver (the person on whom the tourniquet is applied)."||||
33821568|NCT04568304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821569|NCT02683213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821570|NCT00645320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821571|NCT04929483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821572|NCT00881972|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821573|NCT03813602|NA|SINGLE_GROUP||SCREENING||NONE||||||
33821574|NCT00572299|||CASE_CONTROL||PROSPECTIVE|||||||
33821575|NCT06645587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821576|NCT04342442|||COHORT||PROSPECTIVE|||||||
33821577|NCT03275441|||COHORT||PROSPECTIVE|||||||
33821578|NCT04915157|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|One nurse will perform the randomization and know to which group the patient was randomized. The same nurse will input the correct settings into the spinal cord stimulator. The other investigators, the participant, care provider and outcomes assessor will remain masked during the study period.|"Patients will be randomized in a 1:1 fashion to either Group A (High Density stimulation - No stimulation) or Group B (No stimulation - High Density stimulation).~All patients will receive an implanted spinal cord stimulator."|t|t|t|t
33821579|NCT03713437|||COHORT||CROSS_SECTIONAL|||||||
33821580|NCT03735147|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821581|NCT04661189|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33821582|NCT02884336|||CASE_ONLY||PROSPECTIVE|||||||
33821583|NCT04572321|||COHORT||PROSPECTIVE|||||||
33821584|NCT00582192|||CASE_ONLY||PROSPECTIVE|||||||
33821585|NCT01411176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821586|NCT06091982|||COHORT||OTHER|||||||
33821587|NCT00665106|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821588|NCT04601090|||COHORT||PROSPECTIVE|||||||
33821589|NCT02978846|||CASE_ONLY||PROSPECTIVE|||||||
33821590|NCT03352661|||COHORT||PROSPECTIVE|||||||
33821591|NCT04339543|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821592|NCT03173300|||COHORT||PROSPECTIVE|||||||
33821593|NCT02804347|||COHORT||PROSPECTIVE|||||||
33821594|NCT04342910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821595|NCT05599516|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33821596|NCT06045364|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33821597|NCT00428441|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821598|NCT00927316|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|t|f|f
33821599|NCT01159990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33821600|NCT05560945|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821601|NCT00331851|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821602|NCT00187135|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33821603|NCT03011671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821604|NCT04960436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33821605|NCT00556751|||COHORT||RETROSPECTIVE|||||||
33821606|NCT04497753|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33821607|NCT05125016|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study contains 3 separate modules in parallel: monotherapy with REGN4336 (Module 1) and combination therapies: REGN4336 plus cemiplimab (Module 2) and REGN4336 plus REGN5678 (Module 3). All 3 modules contain independent dose escalation cohorts and up to 2 recommended phase 2 dose regimens during dose expansion.||||
33821608|NCT05959109|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821609|NCT01198067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821610|NCT05497037|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821611|NCT06415747|||OTHER||RETROSPECTIVE|||||||
33821612|NCT06645782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821613|NCT06042270|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821614|NCT04406142|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
33821615|NCT01799785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821616|NCT04573257|||CASE_CONTROL||PROSPECTIVE|||||||
33821617|NCT00705042|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821618|NCT00168805|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33821619|NCT06164041|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33821620|NCT03237741|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128298|NCT04491903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128299|NCT03635632|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128300|NCT04051749|||COHORT||PROSPECTIVE|||||||
34128301|NCT02097628|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34128302|NCT01927263|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128303|NCT02516358|||COHORT||PROSPECTIVE|||||||
34128304|NCT06207552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821621|NCT00214318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33821622|NCT04761341|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821623|NCT04091945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837341|NCT04027413|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|"Participant in both groups will received either the supplement or the placebo/ control products. Both products will be labelled the same way.~Investigator: someone not from the research team will run the randomisation and deliver the products to participants.~Outcome Assessor: will not be involved in the randomisation and will be blinded"|Participants will be randomised using a web-based service called 'sealed envelope' and stratified BMI less and equal or more than 20 kg/m2 to control group or interventional group.|t|t|t|t
33837342|NCT06479928|||COHORT||PROSPECTIVE|||||||
33837343|NCT02083289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837344|NCT05261308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837345|NCT04873882|||COHORT||PROSPECTIVE|||||||
33837346|NCT05708547|||COHORT||PROSPECTIVE|||||||
33837347|NCT00600613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128305|NCT05656222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128306|NCT03203577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821624|NCT06465615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"An orthoptist fwho may also be in charge of rehabilitation, will carry out the initial assessment (near convergence amplitude, punctum proximum of convergence,...).~Another orthoptist will perform the same assessments at S3 and S6, blinded to the treatment arms and initial measurements to avoid bias:~Another orthoptist in the department, different from the blinded orthoptist, will provide conventional rehabilitation and will not be blinded to the treatment groups assigned to his or her patients. This orthoptist designated for rehabilitation may also be in charge of the initial evaluation.~The department's CRA will be vigilant from the outset to define who will be the blinded orthoptist assessor (assessments at S3 and S6) and the orthoptist rehabilitator and/or assessor for the initial visit. Randomization will be carried out by a CRA, who will only reveal the randomization arm to the orthoptist designated for rehabilitation and/or initial assessment."|Prospective, single-center, randomized, controlled, non-inferiority, open-label study with blinded assessment of primary endpoint.|f|t|f|f
33821625|NCT06538818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821626|NCT00819676|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33821627|NCT03178318|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Healthy volunteers||||
33821628|NCT01132222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821629|NCT02392429|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821630|NCT01953471|||CASE_ONLY||PROSPECTIVE|||||||
33821631|NCT02395224|||COHORT||PROSPECTIVE|||||||
33821632|NCT01509937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821633|NCT04881396|||COHORT||PROSPECTIVE|||||||
33821634|NCT03340818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and PA providing follow up care and assessing data from ODI, VAS etc will be blinded. Physician performing procedure will not be blinded.|Randomized, double-blind placebo controlled|t|f|f|t
33821635|NCT05769361|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind study: only the researchers doing the study know which treatment or intervention the participant is receiving until the study is over.||t|f|f|f
33821636|NCT02785900|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821637|NCT05246618|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33821638|NCT04538534|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821639|NCT03825614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||randomized controlled|f|f|t|f
33821640|NCT03829072|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821641|NCT02581371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821642|NCT01594697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821643|NCT05463445|||COHORT||RETROSPECTIVE|||||||
33821644|NCT03600090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821645|NCT05118737|RANDOMIZED|PARALLEL||TREATMENT||NONE||- To evaluate the efficacy of colchicine versus no colchicine in terms of the need of invasive mechanical ventilation among patients with severe COVID-19 pneumonia who received tocilizumab||||
33821646|NCT00908245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821647|NCT06244706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821648|NCT00842699|||COHORT||PROSPECTIVE|||||||
33821649|NCT00953199|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33821650|NCT06023134|||COHORT||RETROSPECTIVE|||||||
34128307|NCT01739608|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34128308|NCT00040742|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34128309|NCT02761473|||FAMILY_BASED||PROSPECTIVE|||||||
34128310|NCT04742777|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Rapamycin 1mg for 8 weeks||||
34128311|NCT01344486|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34128312|NCT01643408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821651|NCT06554288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821652|NCT03697070|RANDOMIZED|PARALLEL||OTHER||NONE||This cluster-randomized trial will assess a novel quality improvement antibiotic stewardship strategy for empiric antibiotic selection.||||
33821653|NCT05829278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821654|NCT06647212|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, open study||||
33821655|NCT03341312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33821656|NCT06480396|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Patients that are willing to be randomised will be allocated in a 1:1 ratio to a high or lower intensity follow-up schedule. The trial design is partially randomised controlled and partly patient choice with patient preference arms (PPAs) for those that decline randomisation. Patients fulfilling the inclusion criteria and willing to be recruited will be stratified by tumour grade and then randomised to either high or lower intensity surveillance. Patients who decline randomisation will subsequently be offered the opportunity to participate within the PPAs. The PPAs will allow participating patients to choose either high or lower intensity surveillance arms. The data generated from the PPAs will not be included in the comparison of randomised arms. However, they will give important insight into patients' motivations in choosing high or lower intensity surveillance.||||
33821657|NCT03682237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821658|NCT00828542|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821659|NCT01145547|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33821660|NCT04872842|||COHORT||PROSPECTIVE|||||||
33821661|NCT05584709|NA|SEQUENTIAL||TREATMENT||NONE||||||
33821662|NCT01920399|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33821663|NCT06412900|||COHORT||PROSPECTIVE|||||||
33821664|NCT00141336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821665|NCT05127122|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33821666|NCT05257434|||COHORT||PROSPECTIVE|||||||
33821667|NCT05797116|||CASE_ONLY||CROSS_SECTIONAL|||||||
33821668|NCT00237900|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821669|NCT05122078|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients don't know which group they belong to.|Single blinded randomized controlled study|t|f|f|f
33821670|NCT06645717|||COHORT||OTHER|||||||
33837348|NCT02097589|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34128313|NCT02655757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128314|NCT06104007|||COHORT||PROSPECTIVE|||||||
34128315|NCT02598869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128316|NCT03067402|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel Assignment||||
34128317|NCT04556357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34128318|NCT05729113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34128319|NCT01102491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34128320|NCT06469190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821671|NCT05307120|NA|SINGLE_GROUP||TREATMENT||NONE|The primary study aim is to assess intervention usage and acceptability (e.g. effort expectancy, pleasure) regarding the Diameter integrated in regular secondary care and how acceptability is associated with intervention usage. Therefore, the study does not make use of a double blind randomized controlled trial as this design does not fit the study's primary purpose. Consequently, there will be no randomization and treatment allocation. To minimize the treatment effect at baseline, baseline measures will be blinded as much as possible, i.e., participants will not be able to get insight in their glucose values and nutrient intake. The physical activity data collected with the Fitbit cannot be blinded, so that the participants do have insight into their physical activity during the baseline measurements|A prospective single-arm longitudinal mixed-methods design||||
33821672|NCT02956876|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821673|NCT00652496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821674|NCT01846637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821675|NCT04481334|NA|SINGLE_GROUP||TREATMENT||NONE||The proposed mixed methods research follows a convergent design. The qualitative line of inquiry is embedded into the quantitative inquiry, using a one group pretest-posttest design. There is no control group, since there are no participants in the Interactive Vaulting group without disabilities.||||
33821676|NCT01598389|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33821677|NCT01007721|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33821678|NCT00210288|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33821679|NCT05417555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the participants' caregivers will be blinded to arm assignment. Additionally, the person administering memory testing will be blinded to assignment.|Subjects are randomly assigned to one of four treatment dosage conditions: 0, 1, 2 or 3 treatments at each MRI-LIFUP session. After 2 weeks, a second dose is administered with the same dosage level for each subject. Memory assessment occurs once at baseline and remotely after each treatment at the onset of the optimal time window (48 hours) for LIFUP-induced change based on prior data. Finally, after 2 weeks, memory is again assessed. Alternate forms are used for the primary outcome measures to avoid practice effects.|t|f|f|t
33821680|NCT03878797|||COHORT||PROSPECTIVE|||||||
33821681|NCT02281214|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821682|NCT03549299|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be treated in up to four ascending dose groups. After the first treated patient of the first dose group (Group A) was followed for 2 weeks, a safety and tolerability assessment of the applied IMP dose will be conducted by an internal committee. The same approach applies to the second subject.~Dose escalation and recruitment of additional patients into the second dose group (Group B) will depend on the safety and tolerability of the IMP in Group A. A safety and tolerability assessment will be conducted after the last treated patient of the first dose group (Group A) was followed for 12 weeks.~The same approach applies to Group C and D."||||
33821683|NCT05834647|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33821684|NCT01270217|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33821685|NCT02030847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821686|NCT02965599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821687|NCT05100407|||COHORT||CROSS_SECTIONAL|||||||
33821688|NCT00016978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821689|NCT03775278|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33821690|NCT00367445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821691|NCT03436433|RANDOMIZED|PARALLEL||TREATMENT||NONE||Upon consent, patients will be randomized in REDCap™ to receive either LCM, LEV, or no AED. Randomization will be stratified by suspected histologic grade (LGG vs HGG vs brain metastasis) based on MRI review by the treating neurosurgeon and/or neuro-oncologist. A stratified permuted block randomization algorithm will be used assign patients to treatment arms.||||
33821692|NCT02756299|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821693|NCT06584721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821694|NCT00626158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821695|NCT00016237||||TREATMENT||||||||
33821696|NCT01374971|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821697|NCT03323983|||COHORT||PROSPECTIVE|||||||
33821698|NCT03514745|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33821699|NCT02209688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821700|NCT06645509|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding applies to Participant / Investigator \& study site personnel||t|f|t|f
33821701|NCT05076955|NA|SINGLE_GROUP||TREATMENT||NONE||All participants receive the same intervention.||||
33821702|NCT05312021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821703|NCT06244745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821704|NCT06388785|||COHORT||PROSPECTIVE|||||||
33821705|NCT03261713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor does not know the participant's intervention group allocation.|A prospective, single-site, single-blinded, parallel-group (1:1 ratio) randomized feasibility trial on the use of VRT for ongoing stroke rehabilitation after discharge from inpatient or outpatient stroke rehabilitation.|f|f|f|t
33821706|NCT05278442|||CASE_ONLY||RETROSPECTIVE|||||||
33821707|NCT05399082|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33821708|NCT00206609|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33821709|NCT00614536|||CASE_ONLY||PROSPECTIVE|||||||
33821710|NCT04134221|||COHORT||PROSPECTIVE|||||||
33821711|NCT02604147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821712|NCT04759599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821713|NCT04061967|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821714|NCT02994264|||CASE_ONLY||RETROSPECTIVE|||||||
33821715|NCT01088347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128321|NCT05551845|||OTHER||PROSPECTIVE|||||||
34128322|NCT05113316|RANDOMIZED|PARALLEL||PREVENTION||NONE||Complete research clinical trial (RCT) with a sample of frontline healthcare workers to examine the Messy Memories app versus treatment as usual (TAU).||||
34128323|NCT01521338|||COHORT||PROSPECTIVE|||||||
34128324|NCT00181818|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128325|NCT05595265|||CASE_ONLY||RETROSPECTIVE|||||||
33821716|NCT04149197|||COHORT||PROSPECTIVE|||||||
33821717|NCT03165344|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821718|NCT03997708|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33821719|NCT00747578|||COHORT||PROSPECTIVE|||||||
33821720|NCT00399321|||COHORT||PROSPECTIVE|||||||
33821721|NCT01114659|||COHORT||PROSPECTIVE|||||||
33821722|NCT04978688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821723|NCT05453292|NA|SINGLE_GROUP||TREATMENT||NONE||A non-blinded, single center, non-randomized prospective feasibility trial.||||
33821724|NCT01109602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821725|NCT02943109|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33821726|NCT02977780|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).~The drugs involved in this study are:~Abemaciclib: start date= 12/9/2017 Temozolomide (temodar): start date= 12/9/2017 Neratinib: start date= 12/9/2017 CC115: start date= 12/9/2017 QBS10072S: start date= 12/13/2022"||||
33821727|NCT06544421|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33821728|NCT02208271|||COHORT||PROSPECTIVE|||||||
33821729|NCT00724750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821730|NCT05865782|NA|SEQUENTIAL||PREVENTION||NONE||Study design The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. Five schools will yearly receive the intervention (schoolyard reconstruction) at 4 different time points (during the summer breaks in 2023, 2024, 2025 and 2026) and the schools not receiving the intervention the specific year will act as control schools. The units where the proposed outcomes will be observed will be 2nd and 5th grade children (individual level) in the participating schools. Each year, a cross-sectional sample of 2nd and 5th grade children will be measured in all participating schools.||||
33821731|NCT04089332|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821732|NCT00701506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821733|NCT02950870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821734|NCT06228417|||CASE_ONLY||PROSPECTIVE|||||||
33821735|NCT03092323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821736|NCT02409823|||COHORT||RETROSPECTIVE|||||||
33821737|NCT01236963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821738|NCT02338206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821739|NCT05562492|RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, multicentre, randomised, two-arm single-period parallel design study contrasting closed-loop insulin therapy and standard insulin therapy with CGM in young people (≥16 years) and adults with CF related diabetes over 26 weeks.||||
33821740|NCT04357522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821741|NCT02648282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821742|NCT02544841|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821743|NCT05264649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821744|NCT02573883|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33821745|NCT02445781|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33821746|NCT02346942|||COHORT||RETROSPECTIVE|||||||
33821747|NCT03300661|NA|SINGLE_GROUP||TREATMENT||NONE||A single cohort of patients with NAFLD, without control group.||||
33821748|NCT01568021|||COHORT||PROSPECTIVE|||||||
33821749|NCT03845517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821750|NCT00957671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821751|NCT00274846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821752|NCT04809298|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, controlled, parallel group study||||
33821753|NCT02125656|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34128326|NCT04304053|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open label|"Primary study: Cluster-randomized clinical trial of Covid-19 contacts~Secondary study: Randomized clinical trial of Covid-19 cases"||||
34128327|NCT01274598|NA|SINGLE_GROUP||||NONE||||||
34128328|NCT03042429|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|no masking|Randomized, multi-center, non-blinded, prospective, controlled trial||||
34128329|NCT04404673|||CASE_CONTROL||PROSPECTIVE|||||||
34128330|NCT03915990|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128331|NCT01101893|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34128332|NCT04884880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||180 subjects will be randomized to two parallel groups (90 subjects per group) to receive Luo-Fu-Shan Plaster 10g once daily. Placebo will be administered to individuals randomized to that treatment group in a form identical to the Luo-Fu-Shan Plaster. The first investigational medicinal product dose will be administered the day after the randomization.|t|f|t|f
34128333|NCT02100423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149312|NCT01631916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34149313|NCT02718014|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149314|NCT05277428|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33821754|NCT05291585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821755|NCT06646055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821756|NCT00421122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821757|NCT00523133|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33821758|NCT04501107|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33821759|NCT00213226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837349|NCT05811468|||CASE_ONLY||PROSPECTIVE|||||||
33837350|NCT03742375|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837351|NCT03148522|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837352|NCT03586011|||COHORT||PROSPECTIVE|||||||
33837353|NCT00187902|||COHORT||CROSS_SECTIONAL|||||||
33837354|NCT04706936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837355|NCT03041792|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34149315|NCT03041363|NA|SINGLE_GROUP||TREATMENT||NONE||The trial will use an open-label, standard 3+3 phase 1 design for determining the MTD of orally administered C7 in G1D.||||
34149316|NCT04279158|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821760|NCT05731414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"This will be a double-blind (participant, assessor) trial. Participants will be informed that they will receive one individual session and one group session of treatment per week but will not be told which group they are assigned to. Participants will be instructed not to talk about their therapy to the assessor but if the assessor becomes aware of group allocation, then a new assessor will be assigned for all follow-up assessments. Due to the nature of the interventions, it is not possible for therapists to be blind to treatment condition, however, therapist fidelity to each intervention will be monitored through ratings on established fidelity measures. To protect against contamination separate therapists will deliver the active and control therapies.~The Principal Investigator also remains blind to randomization, as the trial manager is the only one who has access to this."|Participants will be randomized to receive a) individual CBT + group sham CR, b) group CR + individual Befriending, or c) individual CBT + group CR. Block, cohort randomization will be coordinated by the trial manager at the central site (UTSC), with stratification by treatment site. Cohorts of 5 participants will be randomized to one of the 3 treatment conditions in randomized block sizes of 4, 8, or 12 using a pre-specified randomization list.|t|f|t|t
33821761|NCT06366724|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|The Mass General Brigham Investigational Drug Services (IDS) will be responsible for randomizing the four arms. The rest of the study staff and collaborators will be blinded as well as the participant.|Randomized factorial group double-blinded placebo-controlled trial|t|t|t|t
33821762|NCT05895110|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821763|NCT04938518|||COHORT||PROSPECTIVE|||||||
33821764|NCT02511171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33821765|NCT06159114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821766|NCT04614285|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study has a prospective multi-center, two arms randomized controlled clinical trial design.||||
33821767|NCT02222844|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33821768|NCT02948205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821769|NCT04472442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Blinding of both participant with actual vs sham treatment and blinding of primary outcome assessments|2-arm, randomized, crossover trial|t|f|f|t
33821770|NCT01737034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821771|NCT02618122|||COHORT||PROSPECTIVE|||||||
33821772|NCT05156216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Limited disclosure will be used to blind participants and thereby reduce bias in responses since participants are also the assessors as all outcome measurements are self-reported. Participants will simply be informed that the trial aim is to assess knee OA educational videos. The investigators will not disclose details about how the educational content/presentation of the two videos differ, nor the hypotheses of the study. The biostatistician who performs the data analysis will be blinded.|Participants will be randomised to one of two groups (1:1) using the randomiser function in Qualtrics (set to 'evenly present elements').|t|f|f|t
33821773|NCT04403178|||COHORT||PROSPECTIVE|||||||
33821774|NCT03604653|||COHORT||PROSPECTIVE|||||||
33821775|NCT00223132|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33821776|NCT02113540|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33821777|NCT01309256|||COHORT|||||||||
33821778|NCT05272787|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will receive the same study regimen consisting of 5 products: a facial moisturizer, a facial moisturizer (control), a lip moisturizer, a sunscreen and a facial wash.The facial moisturizers will be applied on the half face. The choice of the half face on which the product will be applied will be defined by a randomization list, prepared by the statistician in charge.||||
33821779|NCT02321371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821780|NCT00183222|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33821781|NCT06001814|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33821782|NCT03175835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821783|NCT06358339|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After recruitment and the baseline survey, participants will be assigned into Group 1 to Group 16 by simple randomization in R program. The allocation ratio in randomization will be 1:1. Participants, LHSs, nurses who perform recruitment and baseline survey, and investigators who perform follow-ups will be blinded to the assignment.|At the optimization phrase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group. At the confirmation phase, participants will be assigned into Group 1 to Group 16 randomly, with 20 participants in each group. At the confirmation phase, participants will be assigned into Group 17 to Group 18 randomly, with 160 participants in each group.|t|f|t|f
33821784|NCT01209936|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33821785|NCT06640075|RANDOMIZED|PARALLEL||SCREENING||NONE||cluster-randomized controlled trial||||
33821786|NCT03635047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821787|NCT05770193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821788|NCT05835037|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Enrolled subjects will be randomized (1:1) to either the zinc or placebo intervention. Clinical staff and participants will be blinded to treatment assignment. Sealed, opaque assignment envelopes will be shuffled prior to study initiation and opened sequentially by a designated member of the research team who will then deliver the correct study drug to the clinical staff.|Two hundred prediabetic individuals will be enrolled. The investigators will prospectively evaluate the impact of zinc supplementation on fasting glucose levels and HbA1c, through the completion of randomized, placebo-controlled study of zinc gluconate (one 30 mg tablet per day for 1 year) and placebo (1 tablet per day for 1 year). Participants will be randomized 1:1 to either zinc or placebo.|t|t|f|f
33821789|NCT03771534|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821790|NCT06315647|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33821791|NCT00006006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821792|NCT05018949|||COHORT||OTHER|||||||
33821793|NCT01379521|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33821794|NCT00199992|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821795|NCT01282983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149317|NCT04469348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149318|NCT00003719||||TREATMENT||||||||
34149319|NCT00238368||||DIAGNOSTIC||||||||
34149320|NCT02142413|||COHORT||PROSPECTIVE|||||||
34149321|NCT00380419|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128334|NCT03785353|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants will arrive at a location TBD on the day of data collection. Consent forms will be dispersed to participants, who will be able to ask any questions they may have before signing. A Spanish-speaking researcher will be available to answer those questions. After consent is received, each participant will draw a random number that will be used to link their responses to pre- and post-lecture surveys. After consent is received, a pre-test on pain knowledge and beliefs will be administered. A 30-minute Pain Neuroscience Education (PNE) lecture will be given to participants in Spanish. A post-test on pain knowledge and beliefs will be administered.||||
34128335|NCT00358319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128336|NCT02075424|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128337|NCT00628459|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34128338|NCT02779777|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34128339|NCT04177589|||COHORT||PROSPECTIVE|||||||
33821796|NCT05165563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Digital and conventional workflows for treatment of implant single crowns, and also the material used.|f|f|f|t
34128340|NCT04994665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128341|NCT02869178|||||CROSS_SECTIONAL|||||||
34128342|NCT03326063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128343|NCT00510445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128344|NCT02373046|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128345|NCT00651014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128346|NCT03046446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128347|NCT04512001|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128348|NCT03748589|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34128349|NCT01233908|||CASE_CONTROL||PROSPECTIVE|||||||
34128350|NCT03075306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34128351|NCT06323850|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||A hybrid type-2 effectiveness-implementation randomized wait-list control design . The experimental group will receive the intervention first, while the waitlist group receives no intervention (Phase 1). After the 2-month intervention period, the waitlist group will receive the intervention, while the experimental group participates in a 2-month follow-up (Phase 2). During phase three, the waitlist group will participate in the 2-month follow up.||||
34128352|NCT00140712|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128353|NCT02554799|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128354|NCT01356498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128355|NCT00094562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128356|NCT01104545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128357|NCT01007188|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34128358|NCT01896778|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128359|NCT02507596|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128360|NCT03194308|NA|SINGLE_GROUP||PREVENTION||NONE||All participants are assigned to the Safer Conception study intervention.||||
34128361|NCT02880111|||CASE_CONTROL||PROSPECTIVE|||||||
34128362|NCT05754411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128363|NCT05238272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128364|NCT05055609|NA|SEQUENTIAL||TREATMENT||NONE||This is an open label, multi-center, nonrandomized, first in human dose escalation trial of TRE-515 to evaluate safety and tolerability and determine the maximum tolerated dose (MTD) and RP2D of TRE-515 as monotherapy in subjects with advanced solid tumors.The dose escalation phase uses a conventional 3+3 dose escalation study design, where in each cohort, 3 subjects will be initially treated and each subject will be followed for full DLT assessment before the next dose cohort may open. The dose expansion phase will begin once the RP2D is determined and additional subjects will receive TRE-515 at the RP2D to gain additional experience with the safety profile and additional evidence of activity of TRE-515.||||
34128365|NCT01005641|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128366|NCT04251832|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34128367|NCT03279159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128368|NCT06491225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128369|NCT01772550|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128370|NCT06511544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128371|NCT00827645|||CASE_ONLY||PROSPECTIVE|||||||
34128372|NCT01350258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128373|NCT03232827|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34128374|NCT06402929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128375|NCT05733637|||OTHER||OTHER|||||||
34128376|NCT02442505|||CASE_ONLY||PROSPECTIVE|||||||
34128377|NCT00314873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128378|NCT01836536|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34128379|NCT04385316|||COHORT||PROSPECTIVE|||||||
34128380|NCT03146663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128381|NCT03835481|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128382|NCT03619577|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128383|NCT04711239|||COHORT||PROSPECTIVE|||||||
34128384|NCT01833858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128385|NCT01971671|||||CROSS_SECTIONAL|||||||
34128386|NCT02572297|||COHORT||PROSPECTIVE|||||||
34128387|NCT04766320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128388|NCT03794427|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34128389|NCT05761288|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Once participants are enrolled, all participant surgery days will be assessed for inclusion based on the inclusion criteria above. Surgery days will be randomized to surgery days with microbreaks and exercises and surgery days without microbreaks and exercises. The surgeon will be informed of the randomization assignment prior to the surgery day.||||
34128390|NCT02946177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128391|NCT02076529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34128392|NCT06090630|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821797|NCT05741294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821798|NCT02490878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33821799|NCT01370161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821800|NCT00924209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821801|NCT01604720|||||PROSPECTIVE|||||||
34128393|NCT04377958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128394|NCT05712577|||COHORT||CROSS_SECTIONAL|||||||
34128395|NCT00290992||PARALLEL||TREATMENT||NONE||||||
34128396|NCT06493643|||COHORT||PROSPECTIVE|||||||
34128397|NCT04649216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128398|NCT00792740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128399|NCT01486355|RANDOMIZED|||PREVENTION||||||||
34128400|NCT03499860|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128401|NCT03276832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128402|NCT05253755|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128403|NCT00437528|||||PROSPECTIVE|||||||
34128404|NCT06014151|||COHORT||PROSPECTIVE|||||||
34128405|NCT04808713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128406|NCT03045614|||COHORT||RETROSPECTIVE|||||||
34128407|NCT06291311|||CASE_CONTROL||PROSPECTIVE|||||||
34128408|NCT04994639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34128409|NCT05455125|||COHORT||PROSPECTIVE|||||||
34128410|NCT01478100|||CASE_ONLY||RETROSPECTIVE|||||||
34128411|NCT04340388|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The study design is a randomized control trial where patients will be randomized to the dolutegravir or non-dolutegravir arms by random number generation using the statistical software R. A unique identification (ID) key from 1 to 2n will be assigned to each patient.~Additionally, the investigators will utilize a parallel mouse model of HIV mimicking PLWH with stable viral load that can provide mechanistic insight and integrate experiments at the tissue level (adipose tissue) as well. Experiments in the parallel mouse model of HIV will also present the advantage to enable the study the direct effects of HIV viral infection on metabolic and cardiovascular function, a study not feasible in PWH who, for easily understandable ethical reasons, cannot remain without treatment for 6 months (duration of the study)."||||
34128412|NCT05257590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128413|NCT00117780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128414|NCT02443337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128415|NCT00125814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128416|NCT00175565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128417|NCT01309204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821802|NCT01935349|||COHORT||PROSPECTIVE|||||||
33821803|NCT00847223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128418|NCT04791657|||COHORT||RETROSPECTIVE|||||||
34128419|NCT06348641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||In the calculation of the sample size, the power level was 80% and the significance level was 5%. When the effect size was determined as 0.8 in the examination of the difference between the experimental and control groups in terms of the premature infant pain profile (PIPP) variable, it was determined by the statistical expert that the number of babies to be included in each group was 26 and 52 babies in total should be included in the study. Based on this, the study sample was determined as 60 preterm infants in 30 experimental and 30 control groups. Block randomization method will be applied in the randomization of the groups.|t|f|t|t
34128420|NCT03154255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128421|NCT06517368|||COHORT||PROSPECTIVE|||||||
34128422|NCT02997865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128423|NCT04096950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128424|NCT02678403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128425|NCT01597648|RANDOMIZED|CROSSOVER||||NONE||||||
34128426|NCT01564823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128427|NCT01589146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128428|NCT03412110|||OTHER||PROSPECTIVE|||||||
34128429|NCT05168254|||COHORT||PROSPECTIVE|||||||
34128430|NCT03741907|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34128431|NCT02439307|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128432|NCT02915627|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128433|NCT06503822|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128434|NCT06007508|RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a two arm, prospective, randomized, open label trial in patients presenting with DKA. Block randomization will be used to ensure equal group sizes.||||
34128435|NCT01849393|||CASE_ONLY||PROSPECTIVE|||||||
34128436|NCT00000696||||TREATMENT||NONE||||||
34128437|NCT05597540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized double blind trial||f|f|f|t
34128438|NCT01343836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128439|NCT05226832|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128440|NCT01778075|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128441|NCT03011112|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34128442|NCT01875081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128443|NCT01819363|||COHORT||PROSPECTIVE|||||||
34128444|NCT05028699|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821804|NCT03966014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821805|NCT01032746|RANDOMIZED|||SCREENING||||||||
33821806|NCT06038578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128445|NCT02366676|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128446|NCT00093262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821807|NCT03344913|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Adults with knee osteoarthritis and healthy controls will both undergo the same walking intervention. The goal is to examine basic mechanism for pain sensitivity after walking.||||
34128447|NCT03484312|||COHORT||OTHER|||||||
34128448|NCT03116906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128449|NCT03939338|||COHORT||PROSPECTIVE|||||||
34128450|NCT03085134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128451|NCT01127633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128452|NCT00508105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128453|NCT01331746|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34128454|NCT00394758|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128455|NCT05533944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128456|NCT05361382|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821808|NCT04514289|||COHORT||PROSPECTIVE|||||||
33821809|NCT04717362|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective non-blinded study||||
33821810|NCT02042170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821811|NCT06057259|||COHORT||PROSPECTIVE|||||||
33821812|NCT03847389|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, maximal use, in 3 successive age cohorts||||
33821813|NCT00659152|||COHORT||PROSPECTIVE|||||||
33821814|NCT06268600|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33821815|NCT06482502|||COHORT||PROSPECTIVE|||||||
33821816|NCT06051097|||CASE_ONLY||CROSS_SECTIONAL|||||||
33821817|NCT02145195|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33821818|NCT01275872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33821819|NCT06138132|NA|SEQUENTIAL||TREATMENT||NONE||||||
33821820|NCT02442232|||CASE_CONTROL||PROSPECTIVE|||||||
33821821|NCT00513461|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33821822|NCT03194789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomized single blinded (evaluator) controlled trial. The outcomes assessor will be masked in the study. Assessor will be independent of randomization, trial coordination and care providers.|Single blinded (evaluator), single-center, randomized controlled trial Interventional and Control group.|f|f|f|t
33821823|NCT03806218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33821824|NCT01378481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821825|NCT02936193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821826|NCT04130373|||CASE_CONTROL||RETROSPECTIVE|||||||
33821827|NCT02942628|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33821828|NCT04798508|NA|SEQUENTIAL||OTHER||NONE||"Open and prospective study.~Evoked related potentials are recorded for each participant while they listen 3 paradigms successively and in a random order:~i) their own name uttered by a smiling voice ii) their own name uttered by a neutral voice iii) their own name uttered by a rough voice"||||
33821829|NCT02552693|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33821830|NCT00083122|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821831|NCT03314389|NA|SINGLE_GROUP||SCREENING||NONE||||||
33821832|NCT01763489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33821833|NCT05194384|||OTHER||CROSS_SECTIONAL|||||||
33821834|NCT01666717|||CASE_CONTROL||RETROSPECTIVE|||||||
33821835|NCT01537120|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||t|f|f|f
33821836|NCT06443541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||This cluster-randomized design assigns six universities to High-intensity implementation strategies (HIS) or Lower-intensity (LIS) implementation strategies to deliver GlobalConsent education.|t|t|t|t
33821837|NCT01564134|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33821838|NCT03200171|||CASE_CONTROL||PROSPECTIVE|||||||
33821839|NCT04351100|||CASE_ONLY||PROSPECTIVE|||||||
33821840|NCT04384692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821841|NCT01792206|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33821842|NCT01435499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821843|NCT04120064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821844|NCT02135588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821845|NCT03403556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128457|NCT00869544|||COHORT||PROSPECTIVE|||||||
33821846|NCT01509040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821847|NCT02985255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821848|NCT02504034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821849|NCT00946998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821850|NCT06474442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821851|NCT01060163|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33821852|NCT03924778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821853|NCT05733000|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821854|NCT05758922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821855|NCT04796948|NA|SINGLE_GROUP||TREATMENT||NONE||A dose-escalation and expansion study||||
33821856|NCT06647381|||COHORT||PROSPECTIVE|||||||
33821857|NCT03265262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821858|NCT03264599|||COHORT||PROSPECTIVE|||||||
33821859|NCT06437249|||OTHER||CROSS_SECTIONAL|||||||
33821860|NCT01885377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821861|NCT03942276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128458|NCT06005012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128459|NCT00964483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128460|NCT04118751|||CASE_CONTROL||PROSPECTIVE|||||||
34128461|NCT00922246|RANDOMIZED|PARALLEL||PREVENTION||||||||
34128462|NCT03810547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33821862|NCT02931916|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33821863|NCT01538901|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821864|NCT00535483|||||PROSPECTIVE|||||||
33821865|NCT00523926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821866|NCT01403805|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821867|NCT02592486|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33821868|NCT02503488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821869|NCT01389609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821870|NCT05199597|NA|SEQUENTIAL||OTHER||NONE|The participant will not know which of the four drops is being administered in random order|Participants will have one drop of low concentration atropine placed in one eye four different times in random order||||
34128463|NCT01433042|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128464|NCT01606904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821871|NCT04083690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients blinded to which study group they randomized and how their CRT device is programmed. Individuals (readers) who perform echocardiographic measurements blinded to patient randomization and CRT settings.|1:1 randomization - active comparator and experimental arm (note: at 6 months the control arm will crossover)|t|f|f|t
34149322|NCT02713867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821872|NCT04357587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128465|NCT03938987|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients will be included in the safety and PK analyses. All patients receiving the dose and schedule selected for expansion will be included in the efficacy and futility analyses including patients who received the selected dose and schedule in the phase 1b dose selection and dose escalation. Analysis of during phase 2 will occur using a Simon 2-stage design.||||
34128466|NCT02236572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128467|NCT02837523|||COHORT||PROSPECTIVE|||||||
34128468|NCT01673854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128469|NCT01508559|||COHORT||PROSPECTIVE|||||||
34128470|NCT05350215|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34128471|NCT01886235|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128472|NCT04744948|RANDOMIZED|PARALLEL||TREATMENT||NONE||control group receive low caloric diet study group receive high intensity interval training||||
34128473|NCT00124969|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128474|NCT00147992|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128475|NCT01135459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128476|NCT00803738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34128477|NCT00749788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128478|NCT02936869|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128479|NCT00329823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128480|NCT04799457|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|One study control person is organizing the whole trial and provides blinding to both sides (participants and care provider).|Double Blinded Randomised Controlled Trial|t|t|t|f
34128481|NCT05850819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128482|NCT00923351|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128483|NCT05709704|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34128484|NCT00301145|RANDOMIZED|||PREVENTION||NONE||||||
34128485|NCT00048945||||TREATMENT||||||||
34128486|NCT01101763|||CASE_ONLY||PROSPECTIVE|||||||
34128487|NCT01599598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128488|NCT05129163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34128489|NCT04037891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomised, double-masked, placebo-controlled parallel group comparison with open-label sentinel group.||t|f|t|f
34128490|NCT00434993|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34128491|NCT01831609|||COHORT||PROSPECTIVE|||||||
34128492|NCT00977639|||COHORT||PROSPECTIVE|||||||
34128493|NCT01109108|||OTHER||PROSPECTIVE|||||||
34128494|NCT04106128|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128495|NCT01143909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34128496|NCT06431191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128497|NCT01370941|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34128498|NCT01582009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128499|NCT00014274|RANDOMIZED|||TREATMENT||||||||
34128500|NCT04281420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||ATG-019 ATG-019+Niacin ER||||
34128501|NCT00325130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128502|NCT00096642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128503|NCT02827760|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34128504|NCT03535311|||COHORT||PROSPECTIVE|||||||
34128505|NCT02942888|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34128506|NCT02478814|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34128507|NCT03269539|||COHORT||PROSPECTIVE|||||||
34128508|NCT02001324|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128509|NCT00003587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128510|NCT02977364|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128511|NCT04062747|RANDOMIZED|PARALLEL||SCREENING||DOUBLE||Mucosal damage and postoperative complications in laryngopharyngeal structures were compared.|t|t|f|f
34128512|NCT03134391|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34128513|NCT04267887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128514|NCT06138938|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34128515|NCT03925103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||One to one parallel assignment to each treatment|t|f|f|f
34128516|NCT04308655|||COHORT||PROSPECTIVE|||||||
34128517|NCT06341595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128518|NCT06513754|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both participants and investigator will be blinded to ozone status using nose clips|The study design to be employed for this study can be characterized as a double-blind cross over. ozone status (room air (\<10 ppb ozone) and 170 ppb ozone), exercise intensity (moderate and heavy), sex, lung size, and time will be independent variables|t|f|t|f
34128519|NCT04531280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128520|NCT02819297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128521|NCT00773643|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128522|NCT04981106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled||||
34128523|NCT04975659|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants are blinded from their randomization. Personnel assessing the pain score is blinded.|We randomised participants into either the nocebo (N) or placebo (P) group using computer generated numbers|t|f|f|t
34128524|NCT01888068|||COHORT||CROSS_SECTIONAL|||||||
34128525|NCT02205268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128526|NCT01608737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128527|NCT02100254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128528|NCT00910910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128529|NCT03730714|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34128530|NCT04373148|||CASE_CONTROL||PROSPECTIVE|||||||
34128531|NCT04148703|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34149323|NCT03688555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149324|NCT04145674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149325|NCT04518163|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blind randomized controlled trial|Double blind randomized controlled trial|t|t|t|t
34149326|NCT03057470|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149327|NCT00121641|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128532|NCT03096392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, investigators, monitors, sponsor and sponsor representatives are blinded to the treatment group and treatment to patients are randomized. The group randomizing the subjects, the pharmacist preparing the drug, the party shipping the drug are unblinded but do not have contact with the blinded parties. An unblinded monitor will monitor any activities performed by unblinded parties.|Double blind, active comparator controlled (insulin lispro) to HDV insulin lispro, multiple dose safety, tolerability and efficacy study|t|t|t|t
34128533|NCT03323216|||COHORT||PROSPECTIVE|||||||
34128534|NCT02613663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128535|NCT01803685|||COHORT||PROSPECTIVE|||||||
34128536|NCT03685318|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34128537|NCT01861561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128538|NCT05940389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will be single-blinded. The outcome assessors will be blinded as the measurements will be done on laser-scanned casts and 3D facial images. The operator and the patient's parent cannot be blinded due to the nature of the intervention.|A randomized clinical trial, parallel arm, superiority framework with 1:1 allocation ratio.|f|f|f|t
34128539|NCT06503627|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|closed envelope||t|t|t|t
34128540|NCT04413981|||COHORT||CROSS_SECTIONAL|||||||
34128541|NCT06144294|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33821873|NCT06401447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821874|NCT04212559|||CASE_CONTROL||RETROSPECTIVE|||||||
33821875|NCT06167915|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33821876|NCT02905877|||OTHER||OTHER|||||||
33821877|NCT04765540|RANDOMIZED|PARALLEL||PREVENTION||NONE|Primary outcomes will be measured using mechanical tally counters attached to the handwashing station foot pedals. The individuals involved in recording these counters will be exposed to the treatment but will not be aware of the alternative treatments occurring at other handwashing stations.|"Handwashing stations will be assigned, at the village level, to one of three conditions (including one control condition) using a covariate-adaptive randomisation procedure. The investigators will measure usage of the handwashing stations for one week before the treatments are installed, and then for another six weeks, and compare usage between the conditions. A linear regression model will be used to estimate the effects of the treatments relative to the control condition.~Note that residents of a village are free to avoid the stations or use stations outside their village, and primary outcome measurement will be at the handwashing station level, rather than at the individual or household level. Hence the investigators have not 'enrolled' participants into the trial. The number of 'participants' reported below refers to the number of handwashing stations across which treatment will be varied."||||
33821878|NCT04513535|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|outcomes assessor blinded to group allocations|modified crossover, each group will experience 2/4 interventions|f|f|f|t
33821879|NCT02764788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821880|NCT05359926|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33821881|NCT04390893|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33821882|NCT02569944|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33821883|NCT01190449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821884|NCT01263275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821885|NCT05066178|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome assessor will be blinded to participant session|Multiple-baseline single-case design||||
33821886|NCT05455489|||COHORT||PROSPECTIVE|||||||
33821887|NCT05845099|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|neither the patients nor the operator know which type of denture will be inserted|double blind single center crossover design|t|t|t|f
33821888|NCT05356195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821889|NCT05965518|RANDOMIZED|PARALLEL||OTHER||NONE||Participants will be randomized to high-intensity interval training or continuous moderate exercise for 12 weeks.||||
33821890|NCT01794650|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821891|NCT02578628|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33821892|NCT02917083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821893|NCT01199445|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33821894|NCT00645099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821895|NCT01461161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33821896|NCT02867332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821897|NCT02794558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821898|NCT00935129|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821899|NCT01764152|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821900|NCT06001905|||CASE_ONLY||CROSS_SECTIONAL|||||||
33821901|NCT02551471|||COHORT||PROSPECTIVE|||||||
33821902|NCT06584682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821903|NCT00717925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821904|NCT00998114|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821905|NCT00093743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821906|NCT05128539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821907|NCT01948882|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821908|NCT03861429|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||"The investigators propose Stage II efficacy testing of Me \& My Wishes using a randomized wait-list control design that allows the investigators to compare the effects between an early intervention group (Group 1) and a wait-list control group (Group 2).Six NHs matched on number of beds and payor mix will be randomly assigned to one of two groups."||||
33821909|NCT02800135|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821910|NCT03941990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blinding, gas bottles are in undistinguishable boxes, and each gas mask will be filled with odorous ink masking the sweet flavour of N2O. Neither the patient nor the person doing the LP and/or the evaluation of pain and anxiety will know the treatment used|1:1 randomization to receive experimental treatment (50% N2O - 50% O2) or placebo (Medical Air: 22% O2 - 78% N2).|t|t|f|t
33821911|NCT04468633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837356|NCT00387244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837357|NCT04614701|||COHORT||PROSPECTIVE|||||||
33837358|NCT01473277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34128542|NCT06353048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149328|NCT04014127|||OTHER||PROSPECTIVE|||||||
33821912|NCT04193397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Intervention group will perform a supervised resistance training program, while non-exercised control group will receive the standard clinical follow-up and shall not change their physical activity behavior (Study 1) and Post-bariatric group or non-bariatric control group (Study 2)|f|f|f|t
33821913|NCT00558220|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33821914|NCT06551064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821915|NCT05980247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||One control group and three intervention groups.|t|f|t|f
33821916|NCT00965302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821917|NCT02822677|||OTHER||CROSS_SECTIONAL|||||||
33821918|NCT01391533|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33821919|NCT06584981|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33821920|NCT01378533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821921|NCT00306735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821922|NCT04388605|||COHORT||PROSPECTIVE|||||||
33821923|NCT00911183|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized non-comparative phase II trial||||
33821924|NCT05464199|NA|SINGLE_GROUP||TREATMENT||NONE||Single cohort||||
33821925|NCT06645574|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821926|NCT03216252|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33821927|NCT03450018|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a traditional Phase I 3+3 study designed to identify the MTD by assessment of DLT of SLC-0111. Sample size estimates are not statistically based, but are based on acquisition of appropriate numbers of subjects to adequately describe the safety, tolerability, PK, and PD of SLC-0111 in combination with gemcitabine.~Up to 18 subjects are anticipated to be enrolled in the dose escalation part; however, the actual number recruited will be dependent upon the number of dose escalations. Dose expansion (Part 2) may enroll up to 12 subjects."||||
33821928|NCT00767286||||TREATMENT||||||||
33821929|NCT06176378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821930|NCT06296888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821931|NCT03612492|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33821932|NCT06472414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcomes will be assessed by the same experts in every time point. They will be blinded to the group assignment.||f|f|f|t
33821933|NCT02228083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33821934|NCT04860206|||COHORT||PROSPECTIVE|||||||
33821935|NCT04905511|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, nonrandomized, single-arm, single-center, open-label||||
33821936|NCT01535196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33821937|NCT06646263|||COHORT||RETROSPECTIVE|||||||
33821938|NCT01309399|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33821939|NCT02218671||CROSSOVER||TREATMENT||NONE||||||
33821940|NCT00355732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33821941|NCT06589453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821942|NCT02459132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821943|NCT06233045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33821944|NCT03043950|||COHORT||PROSPECTIVE|||||||
33821945|NCT02921438|||COHORT||PROSPECTIVE|||||||
33821946|NCT05760885|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will not be informed of which group participants are assigned to, and will not be present during an training sessions. As participants will be aware whether or not they will receive sensory augmentation (in the form of vibration), they can not be masked.|Participants will be randomly assigned to either a Control or an Experimental group. The Experimental group will receive sensory augmentation during balance training, while the Control group will not.|f|f|f|t
33821947|NCT01536535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821948|NCT05823051|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"As a randomization method, simple randomization method will be used to ensure an equal number of samples in the two groups and to prevent bias. In addition, during the data analysis phase, the database will be created by an academician independent of the researcher providing the training."|The study was planned as a randomized controlled, parallel, double centered and double blind study.|t|f|f|t
33821949|NCT06492057|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Subject A to K|In the second phase of their long-duration flight (\>130 days or more), each participant wears a personalized Easymotionskin body suit (muscle stimulation suit) controlled by Easymotion App software on crew iPad for only for about 15-20 minutes while performing routine inflight exercise using standard inflight countermeasure devices (treadmill=T2, Cycle Ergometer on ISS, CEVIS; advanced Resistive Exercise Device, ARED) available onboard the ISS. Total EMS exercise time and duration: 12 times EMS plus T2, CEVIS or ARED within 3 weeks on ISS.||||
33821950|NCT01442623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821951|NCT04836234|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of participants is not possible during allocation, treatment and data collection. However, blinding can be done during data processing, analysing and data collection for secondary outcome on appliances failure rate.|Method of randomization using online randomization software. All 108 participants will be randomly allocated into 2 groups with a 1:1 allocation. Participants will be grouped into either group 1 (Intervention group, chewing gum) or group 2 (Control group, no chewing gum given) by using block randomization with block size of 4. Each group will have 54 participants. Concealment of the allocation sequence will be done by concealing the sequence in opaque envelopes.|f|f|t|t
33821952|NCT05549479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33821953|NCT04265742|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||The composition of the intestinal microbiota will be evaluated by the ratio between the amount of pro-inflammatory bacteria (Prevotellaceae, E. coli, Bacteroides vulgatus, Proteus mirabili) and the amount of anti-inflammatory bacteria (Faecalibacterium, Roseburia) in postmenopausal women with comparable bone mineral density, according to their fracture status.||||
33821954|NCT00317135|RANDOMIZED|PARALLEL||PREVENTION||||||||
33821955|NCT00183235|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33821956|NCT04073849|RANDOMIZED|PARALLEL||OTHER||SINGLE|Online randomization tool|Cohort A to receive active drug Cohort B to receive placebo, (saline)|t|f|f|f
33837359|NCT03982212|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label, preoperative, window of opportunity trial.||||
33837360|NCT02727569|||COHORT||PROSPECTIVE|||||||
33837361|NCT00660738|||CASE_CROSSOVER||PROSPECTIVE|||||||
33821957|NCT04263558|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study will have a stratified, randomized cluster design. The schools are clusters randomized to different experimental conditions. The factors are (1) feedback from a MFS-system, yes/no, (2) Evidence Based Intervention, long/short (EBI), and (3) parental involvement, high/low. The three factors are related components that, together, should form the strongest intervention outcomes. Each of the 40 recruited schools will therefore be randomly assigned to one of eight experimental conditions||||
33821958|NCT00774306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821959|NCT01697592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33821960|NCT02959255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33821961|NCT05561296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This prospective, open-label, single-center, non-randomized, interventional study will include 50 patients who will undergo femtosecond laser-assisted cataract surgery (Catalys) and astigmatism correction by either EyHance toric II IOLs or corneal relaxing incisions and implantation of EyHance IOL. The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient.||||
33821962|NCT00522678|RANDOMIZED|PARALLEL||TREATMENT||||||||
33821963|NCT01516502|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33821964|NCT00871143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821965|NCT01243398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821966|NCT03238326|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33821967|NCT03968744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821968|NCT06084260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33821969|NCT05311774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33821970|NCT06072833|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants who screen positive all move forward to receive the intervention.||||
33821971|NCT03765814|||COHORT||PROSPECTIVE|||||||
33821972|NCT05300217|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants are not aware of the assigned intervention group|Participants are assigned to two intervention groups in parallel for the duration of the study|t|f|f|f
33821973|NCT05999513|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33821974|NCT01393262|||COHORT||OTHER|||||||
33821975|NCT03483597|||COHORT||CROSS_SECTIONAL|||||||
33821976|NCT03792035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33821977|NCT05388864|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The pediatric patients, their caregivers and teachers are blinded to arm type.|Pediatric providers are randomized to training on the intervention or usual well-child care. Three groups of patients are recruited to evaluate the efficacy of the intervention: 1) Usual well-child care for children with no ACEs; 2) Usual well-child care for children with ACEs; and 3) Well-child care by providers trained in the intervention.|t|f|f|f
33821978|NCT01588847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33821979|NCT01979120|||COHORT||PROSPECTIVE|||||||
33821980|NCT05880771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821981|NCT01103141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33821982|NCT02991781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33821983|NCT02127645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33821984|NCT05827809|NA|SINGLE_GROUP||TREATMENT||NONE||"A clinical open trial evaluating feasibility, acceptability, treatment facilitators as well as treatment effects measured before, after and at 6-month follow-up, for a relatively new transdiagnostic psychological treatment, Unified Protocol, for children and youth with anxiety disorders and/or depression and their parents.~The therapists in the project will also be in-depth interviewed about the treatment feasibility, compliance and acceptance of the treatment intervention. The study is conducted at 2 primary care clinics with patients and parents seeking for routine care."||||
33821985|NCT01174875|||COHORT||PROSPECTIVE|||||||
33821986|NCT02181400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33821987|NCT05113212|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Dual-arm, pilot, randomized, prospective, descriptive and comparative clinical study|f|f|t|t
33821988|NCT02089984|NA|SINGLE_GROUP||||NONE||||||
33821989|NCT05024396|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33821990|NCT00119795|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33821991|NCT01381614|||COHORT||RETROSPECTIVE|||||||
33821992|NCT00161434|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33821993|NCT06584604|||COHORT||PROSPECTIVE|||||||
33821994|NCT05469867|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33821995|NCT04299971|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Randomized but open-label.|Mild and moderate TAK patients were divided into two groups, with 38 cases for each group at the randomized ratio 1:1, prescribed with methotrexate (15mg.qw.po) and tofacitinib (5mg.bid.po) respectively, in the presence of prednisone. After the 24 weeks of treatment, the disease remission is evaluated (primary endpoint). If the disease activity is alleviated, the strategy would be maintained for another 24weeks, otherwise, the treatment strategy would be shifted to the opposite for 24weeks. After 48 weeks, the disease remission would be evaluated once again (secondary endpoint)||||
33821996|NCT03653689|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|The study will be double-blinded. Neither the participant nor the care providers or the outcome assessor will know which treatment is which.|The study will be a double-blinded, randomized, placebo-controlled cross-over study.|t|t|f|t
33821997|NCT05599230|||COHORT||PROSPECTIVE|||||||
33821998|NCT02956915|||COHORT||PROSPECTIVE|||||||
33821999|NCT05361083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822000|NCT00765921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822001|NCT00328276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822002|NCT03480945|||COHORT||PROSPECTIVE|||||||
33822003|NCT02511847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822004|NCT03959930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822005|NCT03623399|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822006|NCT01949649|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33822007|NCT02066961|||COHORT||PROSPECTIVE|||||||
33822008|NCT01107249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822009|NCT03433378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Bioequivalence|t|t|t|f
33822010|NCT00840918|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33822011|NCT00443599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837362|NCT00368875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128543|NCT05600361|NA|SINGLE_GROUP||TREATMENT||NONE||Using 13C pyruvate DNP MR spectroscopy to evaluate for early treatment response in patients with lymphoma||||
34128544|NCT00119028|NON_RANDOMIZED|PARALLEL||||NONE||||||
34128545|NCT00175760|||COHORT||PROSPECTIVE|||||||
34128546|NCT04178928|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34128547|NCT00821158|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34128548|NCT05090878|||COHORT||PROSPECTIVE|||||||
34128549|NCT03740399|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34128550|NCT02289365|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34128551|NCT03599778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128552|NCT03844087|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This project will recruit 60 healthy players from Western University's women's soccer and rugby teams. In addition to the team's standard out-of-season baseline testing, participants will have their height, weight, dynamic and static neck strength, neck circumference and 40-yard dash times assessed at baseline. Players will be invited to participate in a 12-week neuromuscular strength training program using the TopSpin360 neuromuscular neck training device. This program will be supervised by a member of the research team 3 days per week in addition to their out-of-season standard training program that does not currently include any exercise specific to the muscles of the neck. Upon completion of the 12 week TopSpin360 training program the study participants will have their weight, neck circumference, dynamic and static neck strength and 40-yard dash times re-assessed.||||
34128553|NCT01623167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128554|NCT04755998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34128555|NCT06556082|RANDOMIZED|PARALLEL||TREATMENT||NONE||Training and Control Group||||
34128556|NCT02675062|||CASE_ONLY||PROSPECTIVE|||||||
34128557|NCT01088295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128558|NCT00255723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128559|NCT04413058|||CASE_CROSSOVER||PROSPECTIVE|||||||
34128560|NCT05933967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128561|NCT05792007|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Open-label, interventional monocentric biological study in two parallel and controlled groups||||
34128562|NCT04695470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128563|NCT05055973|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34128564|NCT06453382|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33822012|NCT04694300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Administration of naproxen or acetaminophen will be masked by over-encapsulation|Double blind, randomized, active-controlled, two arms|t|t|t|t
34128565|NCT00003322|RANDOMIZED|||TREATMENT||||||||
34128566|NCT05547919|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128567|NCT03415425|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34128568|NCT03522415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128569|NCT05396339|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34128570|NCT02968498|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34128571|NCT03705559|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|This is a randomized, double-blind, double-dummy, placebo-controlled design||t|f|t|f
34128572|NCT04783311|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34128573|NCT04085146|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Anesthesia care-provider cannot be blinded. Surgeon and outcome assessor will be blinded to the group assignment.|Randomized controlled superiority trial with two arms of intervention.|t|f|t|t
34128574|NCT05748509|||COHORT||PROSPECTIVE|||||||
34128575|NCT04295811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multi-center, single arm||||
34128576|NCT06451367|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants are randomly assigned to either a control group or an intervention group (N=30, with 15 participants in each group). This study focuses on football players aged 14 to 18 who are part of the elite team of the football society of Fribourg, Switzerland.~In the control group, participants engage exclusively in regular football training, whereas participants in the intervention group also participate in a 12-week neuromuscular development program.~Measurements~Before and after the intervention, various measurements are taken for each participant, including:~Blood steroid profile Heart rate variability Lung function using ergospirometry (VO2 max with lactate) Body composition using the Inbody 770 machine Muscular strength using a Newton measurement"||||
34128577|NCT06482827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128578|NCT05620810|||COHORT||RETROSPECTIVE|||||||
34128579|NCT04378101|||CASE_CONTROL||RETROSPECTIVE|||||||
34128580|NCT02562846|||COHORT||PROSPECTIVE|||||||
34128581|NCT04894539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blinded|3 groups (TENS1, TENS2, and sham)|t|f|t|f
34128582|NCT00925665|||COHORT||PROSPECTIVE|||||||
34128583|NCT03926377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128584|NCT00091663||||TREATMENT||||||||
34128585|NCT06197152|||COHORT||PROSPECTIVE|||||||
34128586|NCT00924014|RANDOMIZED|CROSSOVER||||NONE||||||
34128587|NCT05710133|NA|SINGLE_GROUP||OTHER||NONE||||||
34128588|NCT01503346|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34128589|NCT05340478|||COHORT||PROSPECTIVE|||||||
33822013|NCT00028509|||COHORT||RETROSPECTIVE|||||||
33822014|NCT04293341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822015|NCT05857618|||COHORT||PROSPECTIVE|||||||
33822016|NCT03036124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822017|NCT05915884|||COHORT||RETROSPECTIVE|||||||
34128590|NCT02213497|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34128591|NCT03017339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128592|NCT05483023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128593|NCT00848835|||||PROSPECTIVE|||||||
34128594|NCT05733741|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128595|NCT00591955|||CASE_ONLY||PROSPECTIVE|||||||
34128596|NCT05572736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128597|NCT01844297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128598|NCT00100958|RANDOMIZED|||PREVENTION||DOUBLE||||||
34128599|NCT01321242|||COHORT||PROSPECTIVE|||||||
33822018|NCT04283058|||COHORT||PROSPECTIVE|||||||
33822019|NCT01611532|||COHORT||PROSPECTIVE|||||||
33822020|NCT00688051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822021|NCT04245878|||COHORT||PROSPECTIVE|||||||
33822022|NCT03553641|||COHORT||CROSS_SECTIONAL|||||||
33822023|NCT01580735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822024|NCT05610254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822025|NCT05102760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822026|NCT03856814|||CASE_ONLY||PROSPECTIVE|||||||
33822027|NCT00341016|||CASE_CONTROL||RETROSPECTIVE|||||||
33822028|NCT05552014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822029|NCT06223958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||1:1|t|t|t|t
33822030|NCT04390971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822031|NCT05952583|||COHORT||PROSPECTIVE|||||||
33822032|NCT06402851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study endpoints will be assessed by an independent Clinical Events Committee (CEC), whose members will be unaware of randomized treatment assignment.|Patients will be randomized in 1:1:2 to warfarin, edoxaban or no OAC, stratified by renal replacement status.|f|f|f|t
33822033|NCT06647368|NA|SINGLE_GROUP||OTHER||NONE||||||
33822034|NCT01026883|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822035|NCT06269887|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822036|NCT03366233|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33822037|NCT05756348|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822038|NCT00485914|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822039|NCT02502851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822040|NCT00561275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822041|NCT06255899|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants, care providers, investigators and primary outcomes assessors will not be masked. Standardized procedures and scripts will be used to ensure consistency of conducting biomechanical assessments for primary outcomes in the absence of masking outcomes assessors.|The pilot study model is a single site, 2-arm parallel quasi-experimental intervention study. After completing the baseline testing, enrolled participants will be purposively assigned (non-random) to one of two intervention groups, control (education only) or education with individualized feedback, which will be balanced based on position, playing time, and history of injury.||||
33822042|NCT00316589|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822043|NCT03237598|||OTHER||CROSS_SECTIONAL|||||||
33822044|NCT04044352|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822045|NCT05872620|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822046|NCT05164133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822047|NCT02103816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822048|NCT05394467|||COHORT||CROSS_SECTIONAL|||||||
33822049|NCT05216952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822050|NCT06552910|||COHORT||RETROSPECTIVE|||||||
33822051|NCT06453161|||COHORT||RETROSPECTIVE|||||||
33822052|NCT01022671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822053|NCT06621875|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822054|NCT02625168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822055|NCT00717106|||COHORT||PROSPECTIVE|||||||
33822056|NCT03453177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822057|NCT02433392|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822058|NCT00059735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822059|NCT01289197|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822060|NCT05729347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33822061|NCT05512910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All study staff is not masked to randomization except the following: independent outcome assessor and statistician.||f|f|f|t
33822062|NCT01295775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822063|NCT00659971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822064|NCT06115642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149329|NCT00299247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822065|NCT06434571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822066|NCT01651416|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33822067|NCT05530460|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33822068|NCT01641289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822069|NCT06302010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The research will be conducted as a two-group, parallel, randomized, controlled experimental study with a pretest-posttest design.|t|f|f|t
33822070|NCT05044078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor involved in the clinical trial will be prevented from having knowledge of the interventions assigned to individual participants.|It is a randomized control trial. Total 80 patients will be recruited, 40 in each group that includes 10 patients as a dropout in both groups. There will be one interventional group and one active comparator group. Treatment will be allocated using a random number sheet generated by statistician. Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33822071|NCT01150500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822072|NCT03915002|||COHORT||PROSPECTIVE|||||||
33822073|NCT06344949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822074|NCT05007834|||COHORT||PROSPECTIVE|||||||
33822075|NCT06170983|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33822076|NCT03087851|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822077|NCT06279780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822078|NCT04143737|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Quasi-experimental, pre-post study||||
33822079|NCT04284774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822080|NCT05115136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33822081|NCT03390270|||COHORT||OTHER|||||||
33822082|NCT01372826|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33822083|NCT06646978|||COHORT||RETROSPECTIVE|||||||
33822084|NCT05401201|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|A sealed envelope system shall be used for randomization.|A total of 60 subjects with histologically confirmed diagnosis of OLP with gingival involvement are enrolled to the study. The subjects are randomized to a study group and a control group. Both groups will use topical corticosteroid treatment for two weeks. In addition, the study group will use Lumoral-device initially once a day.||||
33822085|NCT00374673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822086|NCT04016571|||OTHER||PROSPECTIVE|||||||
33822087|NCT03824353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822088|NCT05969119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822089|NCT05607732|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33822090|NCT01621321|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822091|NCT05155553|||OTHER||PROSPECTIVE|||||||
33822092|NCT03074097|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33822093|NCT02415335|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33822094|NCT00204100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822095|NCT06246227|||COHORT||PROSPECTIVE|||||||
33822096|NCT04413149|||CASE_ONLY||RETROSPECTIVE|||||||
33822097|NCT03138616|RANDOMIZED|PARALLEL||TREATMENT||NONE||intervention group and control group||||
33822098|NCT05001815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822099|NCT02862626|||FAMILY_BASED||RETROSPECTIVE|||||||
33822100|NCT04349124|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment Arm vs Active Control Arm||||
33822101|NCT05168696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Prospective randomized controlled clinical trial|f|f|f|t
33822102|NCT02000232|||CASE_ONLY||PROSPECTIVE|||||||
33822103|NCT05555849|||COHORT||PROSPECTIVE|||||||
33822104|NCT06378918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822105|NCT06546566|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822106|NCT00658801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822107|NCT01383616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822108|NCT00737997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822109|NCT00562484|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33822110|NCT05456308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and statistician blinded|Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.|t|f|f|t
33822111|NCT06473142|||OTHER||CROSS_SECTIONAL|||||||
33822112|NCT04127019|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental: Arm 1 6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .~Experimental: Arm 2 3 cycles of FEC (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)~Experimental: Arm 3 4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1+ , 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)."||||
33822113|NCT01568112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33822114|NCT06501885|NA|SINGLE_GROUP||OTHER||NONE||||||
33822115|NCT00443755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33822116|NCT01521221|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33822117|NCT01910740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822118|NCT00276783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822119|NCT02502487|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33822120|NCT01370564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822121|NCT03810638|||COHORT||PROSPECTIVE|||||||
33822122|NCT02150109|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33822123|NCT06472960|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33822124|NCT00147745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33822125|NCT03240458|||OTHER||PROSPECTIVE|||||||
33822126|NCT02519270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822127|NCT01896921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822128|NCT06646354|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822129|NCT04286893|||COHORT||PROSPECTIVE|||||||
33822130|NCT00092456|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822131|NCT03875599|||COHORT||CROSS_SECTIONAL|||||||
33822132|NCT05933083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822133|NCT03029234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822134|NCT04124016|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||single-dose, partially randomized, cross over design with 4 consecutive treatments|t|f|f|t
33822135|NCT00220571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822136|NCT03326193|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open label study|||||
33822137|NCT04407533|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33822138|NCT02701595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822139|NCT06559098|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who have previously received non invasive vibrotactile stimulation meant to reduce symptoms of Parkinson's disease will be enrolled and will be asked to stimulate with the Stanford Coordinated Reset (CR) glove||||
33822140|NCT05939739|NA|PARALLEL||DIAGNOSTIC||NONE||||||
33822141|NCT03785210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822142|NCT00666991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822143|NCT04390451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study compares Whole Health STEPS to a waitlist control.||||
33822144|NCT01961804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822145|NCT05944133|||COHORT||RETROSPECTIVE|||||||
33822146|NCT02368691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822147|NCT01819428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822148|NCT05285878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and the study team will be blinded as to the assignment until the database is locked. Only the investigational pharmacist will know the study assignment.|Phase 2, Randomized, Placebo-Controlled Study|t|t|f|f
33822149|NCT01099813|||COHORT||PROSPECTIVE|||||||
33822150|NCT01856647|||COHORT||PROSPECTIVE|||||||
33822151|NCT02509754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822152|NCT04500379|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822153|NCT01181206|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33822154|NCT04348383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|Phase IIb prospective, multi-center, randomized, parallel, double blind, placebo controlled|t|f|t|f
33822155|NCT01798238|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822156|NCT05432583|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|observer-blinded trial||t|t|t|f
33822157|NCT00699829|||COHORT||PROSPECTIVE|||||||
33822158|NCT03759132|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33822159|NCT04816539|||COHORT||PROSPECTIVE|||||||
33822160|NCT03603223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822161|NCT03609671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Patients will be randomized to two groups.|t|f|f|f
33822162|NCT00002792||||TREATMENT||||||||
33822163|NCT05742256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822164|NCT02394171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822165|NCT01193283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822166|NCT02636751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33822167|NCT02062671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822168|NCT00749671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822169|NCT01001637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822170|NCT02721628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822171|NCT00762502|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822172|NCT05045638|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33822173|NCT01289158|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822174|NCT01678781|||CASE_CONTROL||PROSPECTIVE|||||||
33822175|NCT03788421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33822176|NCT05167734|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822177|NCT01907971|||COHORT||PROSPECTIVE|||||||
33822178|NCT00527696|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33822179|NCT02744898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822180|NCT04783987|||CASE_CONTROL||PROSPECTIVE|||||||
33822181|NCT02259569|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33822182|NCT03184519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All the patients will undergo 3 blood samples for analyses to determine pregnancy.||||
33822183|NCT03199170|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33822184|NCT06416111|RANDOMIZED|CROSSOVER||OTHER||NONE||NIRS probes will be placed on the hypothenar ,antecubital regions of both hands and arms .The preoperative observed values and data of every 5 minutes during the operation will be recorded.||||
33822185|NCT02507297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822186|NCT02720978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822187|NCT03185910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33822188|NCT05174988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822189|NCT01219972|||COHORT||PROSPECTIVE|||||||
33822190|NCT02683317|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Regarding the Study phase, the intervention was a nutraceutical, docosahexaenoic acid, derived from omega 3 fatty acid family.|t|t|f|t
33822191|NCT02787135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822192|NCT03379311|NA|SINGLE_GROUP||OTHER||NONE||||||
33822193|NCT02488070|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822194|NCT00904384|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822195|NCT03579056|||COHORT||RETROSPECTIVE|||||||
33822196|NCT05008315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822197|NCT03494907|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33822198|NCT03223935|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, controlled cross-over acute trial||||
33822199|NCT04919044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor did not know participants belonged to which group.||f|f|f|t
33822200|NCT02413502|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822201|NCT04675086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized with 1:1 ratio to the high dose of Aralast NP infusion therapy plus antiviral and standard of care versus antiviral therapy and standard of care.||||
33822202|NCT05225285|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|For blinding, the vaccine dose will be prepared by a pharmacist, who will be the only one who will know which immunizer will be administered. Vaccinators, participants and evaluators will not know which immunizer will be given.|Participants will be randomized into 2 groups, in a 2:1 ratio, to receive the inactivated Coronavac/Butantan vaccine (VACC) and a group to receive the immunizing BNT162b2 (Pfizer) (BNTC). The VACC group will also be compared to a group of adults aged 18 to 49 who received Coronavac (ADU).|t|t|t|t
33822203|NCT05928858|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|t|f|f|t
33822204|NCT01388621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822205|NCT04475497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822206|NCT05110651|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter parallel-group open-label randomized clinical trial||||
33822207|NCT00449917|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33822208|NCT03304730|||COHORT||PROSPECTIVE|||||||
33822209|NCT02246387|||COHORT||PROSPECTIVE|||||||
33822210|NCT01380964|||COHORT||PROSPECTIVE|||||||
33822211|NCT01498523|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33822212|NCT06330857|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of recurrence with clinical examination and defecography. Evaluation of bowel function with a questionnaire.||||
33822213|NCT04559516|RANDOMIZED|PARALLEL||TREATMENT||NONE|The principal investigator and co-investigator will be unaware of allocation until after the beginning of the exercise program. There will be no blinding after intervention begins, as is typical with studies of exercise intervention.|||||
33822214|NCT00745069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822215|NCT00662883|NA|SINGLE_GROUP||||NONE||||||
33822216|NCT00762723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822217|NCT05664009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822218|NCT04554316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33822219|NCT03398434|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|blinded (with majuscule) endpoint evaluation|This is a randomized, open-label, blinded endpoint evaluation, active controlled, dose-range finding study.|f|f|f|t
33822220|NCT03227432|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822221|NCT02149576|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33822222|NCT05285345|||COHORT||PROSPECTIVE|||||||
33822223|NCT00347425|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822224|NCT01014663|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822225|NCT03937596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822226|NCT00011778||||TREATMENT||||||||
33822227|NCT00347802|RANDOMIZED|PARALLEL||||SINGLE||||||
33822228|NCT04385849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822229|NCT01099150|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
33822230|NCT03038152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822231|NCT04985071|||COHORT||PROSPECTIVE|||||||
33822232|NCT06116942|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"Randomized placebo-controlled cross-over factorial single-blind mono-center trial with 2 arms (active stimulation-placebo stimulation \| placebo stimulation-active stimulation)."|t|f|f|f
33822233|NCT00393198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822234|NCT04171258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822235|NCT00306878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822236|NCT01407302|||CASE_CONTROL||PROSPECTIVE|||||||
33822237|NCT03779126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The assessments will be conducted for a second investigator to ensure the blinding of first investigator. The subjects will be randomised in four groups (low frequency, high frequency, low and high frequency and sham stimulation) to ensure the blinding of participants.|The subjects will be randomised in four groups: 1) low frequency electrical stimulation (LF), 2) high frequency (HF), low and High frequency (LHF), and sham. The subjects will receive electrical stimulation in quadriceps bilaterally for 60 minutes , three times per week, during two months.|t|f|t|f
33822238|NCT05996458|||COHORT||CROSS_SECTIONAL|||||||
33822239|NCT04027491|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Interventional, randomized, controlled, cross-over study||||
33822240|NCT04658537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment arm will be masked to investigators. Participants will not be masked.|Non Comparative Randomised Trial|f|f|t|f
33822241|NCT01513447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822242|NCT01032200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33822243|NCT05202327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are assigned to one of three groups in parallel for the duration of the study|t|t|t|t
33822244|NCT00871455|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822245|NCT00470041|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822246|NCT01100593|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33822247|NCT04528147|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822248|NCT00262769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822249|NCT00748358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822250|NCT03770299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822251|NCT04440579|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|This study will be a double-blind, randomized control trial, with one additional unblinded arm. The two blinded arms will be PTNS and sham PTNS, with the additional unblinded arm being standard of care|||||
33822252|NCT00629161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822253|NCT02820402|||COHORT||PROSPECTIVE|||||||
33822254|NCT05946447|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822255|NCT03206489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||noninvasive high-frequency ventilation (nHFOV) and nasal continuous positive airway pressure (nCPAP) are used as primary mode of ventilation in preterm twins infants with RDS|f|f|t|t
33822256|NCT02556918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33822257|NCT04436484|||COHORT||PROSPECTIVE|||||||
33822258|NCT01486277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822259|NCT00187122|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822260|NCT04927559|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822261|NCT04092699|RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33822262|NCT04523571|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33822263|NCT05640947|NA|SINGLE_GROUP||TREATMENT||NONE||Placement of a 20mm lumen-apposing metal stent (Hot AxiosR, Boston Scientific) between the gastric pouch or the jejunum and the excluded stomach. The procedure will be performed by a physician with sufficient experience in the technique (more than 30 lumen-apposing metal stent placements of which more than 5 gastro-gastrostomies, the latter being the procedure that will be performed for the study). The proximal flange of the LAMS is preferably placed in the blind jejunal loop or, if this is not feasible, at least as far as possible from the gastro-oesophageal junction.||||
33822264|NCT05400226|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects to be dosed at the same dose level. This is open label and no randomization is required.||||
34149330|NCT06398925|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-blind, randomised study|Single ascending dose|t|t|t|t
34149331|NCT04594863|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822265|NCT06645834|RANDOMIZED|PARALLEL||TREATMENT||NONE|Not Applicable, No masking|Eligible subjects must successfully complete the run-in phase by demonstrating tolerance to sensor wear and compliance with study procedures prior to being randomized for the study phase, in which subjects will either be using the InPen™ with InPen™ App and Simplera™ system (Treatment Arm = T) or will continue under their MDI therapy with CGM (Control Arm = C) for another 6 months.||||
33822266|NCT00647283|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822267|NCT00598637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822268|NCT06570434|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33822269|NCT00778141|RANDOMIZED|CROSSOVER||||NONE||||||
34149332|NCT04762524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822270|NCT02194777|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33822271|NCT03715413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822272|NCT02251405|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33822273|NCT02815618|||CASE_ONLY||PROSPECTIVE|||||||
34149333|NCT04495413|||COHORT||PROSPECTIVE|||||||
34149334|NCT01697943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149335|NCT03470363|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34149336|NCT02035722|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34149337|NCT04844086|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 dose escalation||||
34149338|NCT00073281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822274|NCT01502787|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34149339|NCT01563016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149340|NCT01972685|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822275|NCT02243436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822276|NCT05885464|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The maximum number of patients for this study is approximately 102 patients:~* 36 patients in the Phase 1 dose exploration~* approximately 12 patients in the Phase 1 dose-expansion cohorts~* 6 patients in the pediatric cohort~* approximately 48 patients in the Phase 2 cohort."||||
33822277|NCT00472069|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822278|NCT04910061|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A single-arm, non-randomized, non-controlled, monocenter repeated-dose study||||
33822279|NCT06585293|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822280|NCT03711825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822281|NCT03401411|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33822282|NCT00084409|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33822283|NCT03158519|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33822284|NCT01257048|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33822285|NCT05819983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822286|NCT03024593|RANDOMIZED|PARALLEL||BASIC_SCIENCE||||||||
33822287|NCT00355758|||COHORT||PROSPECTIVE|||||||
33822288|NCT05044065|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822289|NCT01074099|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33822290|NCT02746237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822291|NCT02278133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822292|NCT05179096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33822293|NCT00459433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822294|NCT00588991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822295|NCT03087461|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33822296|NCT03388021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822297|NCT03662854|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinding|Placebo-controlled study|t|t|t|t
33822298|NCT02029521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822299|NCT02133066|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822300|NCT03994900|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33822301|NCT05820087|NA|SINGLE_GROUP||TREATMENT||NONE||This trial is a prospective, multi-center, single-arm.||||
33822302|NCT03586752|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33822303|NCT04895202|||COHORT||PROSPECTIVE|||||||
33822304|NCT02711553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822305|NCT00999271|||CASE_CONTROL|||||||||
33822306|NCT02160834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822307|NCT01802476||CROSSOVER||BASIC_SCIENCE||NONE||||||
33822308|NCT04263935|||CASE_ONLY||PROSPECTIVE|||||||
33822309|NCT02156999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822310|NCT04783519|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822311|NCT03143634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcome assessor will be masked, as this is a psychological intervention it is not possible to mask the participant, care provider or investigator.||f|f|f|t
33822312|NCT01578278|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822313|NCT05935683|||COHORT||PROSPECTIVE|||||||
33822314|NCT01984853|||COHORT||PROSPECTIVE|||||||
33822315|NCT02829905|||COHORT||PROSPECTIVE|||||||
33822316|NCT04388917|||COHORT||RETROSPECTIVE|||||||
33822317|NCT05788081|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study Design Open label multicentre umbrella Bayesian Optimal Phase II study||||
33822318|NCT02790047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822319|NCT03168009|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822320|NCT01613183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822321|NCT00734851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822322|NCT04923230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors and investigators will not have knowledge of parent assignment to conditions.|The pilot evaluation of CAP will be conducted with 60 MM parents who will be randomly assigned to CAP (n=30) or to a wait-list (WL) condition (n=30). Parents and their adolescents (n=120) will be assessed at baseline and at 3- and 6 months. WL parents will receive the CAP intervention after a 3-month waiting period and these participants will receive baseline and 3-month follow-up assessments. The study design and assessment schedule will allow both a between-groups test of the efficacy of CAP between intervention and delayed participants, as well as within-person test of pre- and post-intervention differences in the primary and secondary outcomes among all 60 parent/adolescent dyads.|f|f|t|t
33822323|NCT04655521|||CASE_CONTROL||PROSPECTIVE|||||||
33822324|NCT00907699|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822325|NCT05743114|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Conditions are blinded to the participant and during data analysis and sleep scoring||t|f|f|t
33822326|NCT01369706|NA|SINGLE_GROUP||OTHER||NONE||||||
33822327|NCT00167323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822328|NCT06551116|||COHORT||PROSPECTIVE|||||||
33822329|NCT04466917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects, Amgen, designated PAREXEL, and other clinical site staff will be blinded to the investigational product allocation for each subject.|Subjects will be randomized to receive ABP 215 or bevacizumab on a 1:1 basis. All subjects will receive chemotherapy, following administration of investigational product.|t|t|t|t
33822330|NCT05070637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822331|NCT03164759|||OTHER||OTHER|||||||
33822332|NCT03093597|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822333|NCT05394727|RANDOMIZED|CROSSOVER||OTHER||NONE||"Test group: use needle-free syringe for insulin injection and replace it with conventional insulin pen injection after 2 weeks.~Control group: use traditional insulin pen injection and replace it with needle-free syringe after 2 weeks."||||
33822334|NCT04686370|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||one single group will receive both types of dental implants (Split-mouth)|f|f|f|t
33822335|NCT03698721|||OTHER||PROSPECTIVE|||||||
33822336|NCT01026103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822337|NCT03145519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822338|NCT06182800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837363|NCT02870374|||CASE_ONLY||PROSPECTIVE|||||||
33837364|NCT03684876|||COHORT||PROSPECTIVE|||||||
33822339|NCT06539520|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Another researcher via an opaque envelopes involved number defining the 80 post stroke participants, then randomly allocated.|Prospective, pre-posttreatment, randomized controlled trial.|t|t|t|t
33822340|NCT05465278|NA|SINGLE_GROUP||TREATMENT||NONE||Low-intervention, open-label, multicenter, phase IV clinical trial to evaluate the effect 18 months after initiation of alirocumab (Praluent®) on the volume, architecture, and composition of the coronary atheroma plaque in subjects with FH and without clinical cardiovascular disease followed in the SAFEHEART registry in optimized and stable treatment with maximum tolerated doses of statins with or without other lipid-lowering treatments under clinical practice conditions.||||
33822341|NCT04881045|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33822342|NCT02876003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822343|NCT02609035|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33822344|NCT02467231|||COHORT||PROSPECTIVE|||||||
33822345|NCT00482417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822346|NCT02093117|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33822347|NCT05697393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822348|NCT02156479|||COHORT||PROSPECTIVE|||||||
33822349|NCT02113150|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822350|NCT02797795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822351|NCT04053517|||CASE_ONLY||PROSPECTIVE|||||||
33822352|NCT02651961|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822353|NCT03110692|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33822354|NCT00588341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822355|NCT00126555|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822356|NCT05517577|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Allocation concealment will not be done for study participants, as they would certainly know if they are in the intervention group or not. However, data collectors will be blinded to the allocation assignment by not being informed about it, not being part of the trial implementers, and not being inhabitants of any of the kebeles. Moreover, data analysts will be blinded to group allocation.|First, we selected two districts that have similar characteristics and are adjacent to each other. Both districts have a total of 72 kebeles (the smallest administrative unit), 36 in each district. Then, we chose 20, 10 from each district, kebeles on the boundary of the two districts to act as a buffer zone, to prevent information contamination between the intervention and control clusters. Finally, 26 kebeles in the Dedo district will be assigned to the intervention group while 26 kebeles in the Seka Chekorsa district are assigned to control clusters|f|f|f|t
33822357|NCT06003868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Exercises with Hippotherapy Simulator: This exercise will be applied to the group for 8 weeks, 2 days a week, as a single session (15 minutes) a day. The patients will be placed on the simulator and the starting position will be taught. They will be warned to maintain the starting position throughout the movements of the simulator. The hippotherapy simulator will be operated almost in the gait pattern of the horse and in the 1st stage of the 3-stage speed level. If the patients have unusual complaints such as dizziness, blackout, chest pain and risk of falling during the application. they will be advised to request to stop the application|f|f|f|t
33822358|NCT00690950|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822359|NCT00516178|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33822360|NCT06128434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The toothpastes are sourced from international markets, and both the participants and the outcome assessor will remain unaware of the active remineralizing agent in the toothpaste. This ensures that neither the participants nor the outcome assessor will be informed about the assigned intervention, preventing their expectations from influencing the study results.~The examiner was blinded to participants' codes and previous WSL scores during dental assessments. However, blinding to the type of toothpaste used was not possible. Blinding during image analysis was also unfeasible, but this limitation was deemed manageable since the outcome relied on objective computer-based data, minimizing potential bias"|This study is a randomized controlled trial involving 21 participants ages 12 to 18 years. They will be examined and chosen randomly for the study. Participants will be divided equally into three groups: Group 1 will use zinc carbonate nano-hydroxyapatite toothpaste twice daily; Group 2 will apply 8% arginine and calcium carbonate-containing toothpaste twice daily; and Group 3 will apply fluoridated toothpaste twice daily. Assessment of white spot lesions will be carried out using digital photographs before remineralizing agent application (baseline) and at 3, and 6 month intervals.|t|f|f|t
33822361|NCT04583943|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33822362|NCT04374019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822363|NCT02366702|||CASE_CROSSOVER||PROSPECTIVE|||||||
33822364|NCT03121599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822365|NCT00893477|NON_RANDOMIZED|||TREATMENT||NONE||||||
33822366|NCT00019019||||TREATMENT||||||||
33822367|NCT06584578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were strictly separated and think their intervention is the main intervention. The same is true for care providers. Outcome assessors were unaware of participant group status and were not allowed to ask correspondingly||t|t|f|t
33822368|NCT04194541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822369|NCT00867945|||CASE_CONTROL||PROSPECTIVE|||||||
33822370|NCT00243217|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822371|NCT04214548|||CASE_ONLY||PROSPECTIVE|||||||
33822372|NCT04542200|||COHORT||PROSPECTIVE|||||||
33822373|NCT02481349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822374|NCT00833456|||CASE_CONTROL||PROSPECTIVE|||||||
33822375|NCT06121401|NA|SINGLE_GROUP||OTHER||NONE||||||
33822376|NCT00885859|||COHORT||PROSPECTIVE|||||||
33822377|NCT01003379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822378|NCT05406206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822379|NCT02910336|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822380|NCT00308009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822381|NCT06150222|||COHORT||RETROSPECTIVE|||||||
33822382|NCT00675519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822383|NCT06324188|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|blinded endpoint assessment||f|f|f|t
33822384|NCT02898350|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33822385|NCT05680298|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822386|NCT00000922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822387|NCT05335811|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822388|NCT01427231|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33822389|NCT06127485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822390|NCT03571347|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants, facilitators, and research staff involved in the screening and baseline assessment will not be blind to the interventions provided during the trial. Outcomes assessors will be kept blind to the study conditions.|RE-DEFINE is a prospective, multicentre, randomized, parallel-group trial that will follow study participants over a period of 12-months. Asylum seekers and refugees with psychological distress, but without a mental disorder according to the MINI International Neuropsychiatric Interview (M.I.N.I.) for DSM-V and ICD-10, will be randomly assigned to the Self Help Plus intervention or to enhanced treatment as usual (ETAU).|f|f|f|t
33822391|NCT04034602|RANDOMIZED|PARALLEL||TREATMENT||NONE||30 stroke patients will be included in this study. The patients who meet the inclusion criteria will be divided randomly into 2 groups as vibration (n=15) and placebo (n=15).The vibration group, one session in supine position will be applied to both sides of the soles of the feet under the soles of the feet for 5 minutes with a 15-100 Hz frequency CE certified vibration device. In the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.||||
33822392|NCT06040138|||COHORT||PROSPECTIVE|||||||
33822393|NCT00580047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822394|NCT05071378|RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will determine the feasibility, acceptability and a preliminary estimate of effect size of an evidence-based HIV prevention intervention for Black MSM adapted for HIV status-neutral use with families in the HBC (called: OFOV). The eight-step ADAPT-ITT framework will guide the approach to enhance intervention content to incorporate an asset-building framework. Aim 1 will lead to the combined multi-level intervention adapted to improve congruence with the realities of HBC families. Aim 2 will assess the feasibility and acceptability of conducting a cluster randomized controlled trial of OFOV with a standard of care wait-listed control group. Data collected from the CRCT will be used to estimate the effect size of OFOV on HIV testing and PrEP use (primary outcome for HIV-negative participants), HIV care engagement and use of ARV treatment (primary outcome for PLHIV), as well as number of family-based assets and sexual health measures (status-neutral secondary outcomes).||||
33822395|NCT01047306|||COHORT||PROSPECTIVE|||||||
33822396|NCT05530083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822397|NCT01219361|||OTHER||PROSPECTIVE|||||||
33822398|NCT01393314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822399|NCT05301361|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33822400|NCT01243658|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33822401|NCT02592928|||CASE_ONLY||PROSPECTIVE|||||||
33822402|NCT03373500|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre, randomised controlled parallel study.||||
33822403|NCT06089967|||COHORT||PROSPECTIVE|||||||
33822404|NCT03389321|NA|SINGLE_GROUP||OTHER||NONE||All the subjects included in the study will be included in a single group and will receive the drugs according to the same sequence||||
33822405|NCT00536432|||COHORT||PROSPECTIVE|||||||
33822406|NCT06202547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822407|NCT02134249|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33822408|NCT06103721|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients fulfilling the inclusion criteria will be enrolled and divided into two groups through computer generated random numbers. Intervention will be done in the preoperative area under supervision of consultant anesthetist. Afterwards patient will be shifted to operating room, standard ASA monitoring will be attached. General anesthesia will be induced with 1mg of midazolam, 2mg/kg of propofol and 0.5 mg/kg of atracurium. Patient will then be bag mask ventilated for 3 minutes using 100% oxygen at 5 L/min along with Sevoflurane at a MAC (Minimum alveolar concentration) of 1. Vitals will be measured pre-nebulization, pre-induction, and at 1-minute intervals during bag mask ventilation and finally immediately after endotracheal tube placement. Failure to blunt hemodynamic response will be defined as rise in heart rate or blood pressure by more than 20% from pre-induction values immediately after laryngoscopy and endotracheal tube placement which will be managed accordingly.|t|f|f|f
33822409|NCT06181968|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only the treating physician on the ward will know which arm the patient belongs to|Randomized controlled, blinded|t|f|t|t
33822410|NCT05430074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822411|NCT03319719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822412|NCT02081196|NA|SINGLE_GROUP||OTHER||NONE||||||
33822413|NCT02333071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822414|NCT00292305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822415|NCT01863537|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33822416|NCT06537141|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33822417|NCT03427606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822418|NCT05580783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33822419|NCT00357747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822420|NCT03341858|||FAMILY_BASED||PROSPECTIVE|||||||
33822421|NCT01233089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822422|NCT03967119|||COHORT||PROSPECTIVE|||||||
33822423|NCT03049306|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33822424|NCT00228813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822425|NCT05054517|||CASE_ONLY||PROSPECTIVE|||||||
33822426|NCT03357302|||COHORT||CROSS_SECTIONAL|||||||
33822427|NCT03068676|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822428|NCT05526014|||COHORT||PROSPECTIVE|||||||
33822429|NCT06094842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822430|NCT06543407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor blind||f|f|f|t
33822431|NCT06320509|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33822432|NCT03743987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822433|NCT05364047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822434|NCT00040521|RANDOMIZED|||TREATMENT||DOUBLE||||||
33822435|NCT04283396|||COHORT||PROSPECTIVE|||||||
33822436|NCT05141071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128600|NCT05006976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant is masked to which questionnaire he/she fills out. The primary outcome is functional recovery, operationalized in the short term as prevention of sickness absence or return to work, and in the long term as employment or disability benefits. To this end, registry data on employment status or qualification for disability benefits is applied. Clinicians (usually the patient's general practitioner) and case managers involved in decisions on medically certified sickness absence and disability benefits are blinded to randomization.|Patients are randomized in equal proportions to fill out either of two different questionnaires, consisting either of 1) health related questions only or 2) health related questions as well as questions concerning motivation for work, barriers for return to work and work environment. In both treatment arms, clinicians receive a summary of patient survey information on mental health and musculoskeletal pain. In the intervention arm, clinicians are nudged to have particular attention towards motivation for work, barriers for return to work and work environment.|t|f|f|t
34128601|NCT01803880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128602|NCT04784793|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34128603|NCT01780805|||COHORT||PROSPECTIVE|||||||
34128604|NCT03689608|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128605|NCT04005391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Superiority trial to see if home-based postpartum contraceptive delivery, including a long-acting reversible contraceptive, the contraceptive implant, increases uptake of a highly effective method of postpartum contraception (the implant).||||
34128606|NCT03367403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128607|NCT04911647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128608|NCT04465604|NA|SINGLE_GROUP||TREATMENT||NONE||The sample size was based on the following assumptions: Poor response rate to HTS is set at 10% or less; Good response to HTS is set at 30% or more ;One-sided Alph error probability is set to \< 0.05 (i.e. p \< 0.05) and Power to detect rate difference between good response and poor response to HTS is at least 80%. Using the Fleming single-arm group-sequential design (Fleming 1982) Based on these assumptions; a sample size of N=25 patients is expected to achieve a power of 84% of detecting enough activity by HTS (p\<0.05 one-sided) of improving respiratory parameters of COVID19 patients. This will be achieved if the true remission rate difference between a poor and good HTS is 20%. Considering the dropout rate of 25%, a minimum of 50 patients will be enrolled. This will ensure more than 90% power to detect at least 20% positive effect of HTS||||
34128609|NCT03792555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128610|NCT00920361|||OTHER||PROSPECTIVE|||||||
34128611|NCT04236050|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34128612|NCT01384565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34128613|NCT05388227|||COHORT||PROSPECTIVE|||||||
34128614|NCT04048889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized controlled triple-blinded trial|t|t|f|t
34128615|NCT04358146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822437|NCT04297839|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open label randomized clinical trial with cross-over between the groups||||
33822438|NCT04501354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822439|NCT03875612|||COHORT||PROSPECTIVE|||||||
33822440|NCT06647030|NA|SINGLE_GROUP||OTHER||NONE||||||
33822441|NCT02814279|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822442|NCT04260256|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822443|NCT06647355|||CASE_CROSSOVER||OTHER|||||||
33822444|NCT00607737|RANDOMIZED|FACTORIAL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33822445|NCT00329498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822446|NCT01808144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822447|NCT03256760|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Blinded infusion|Endotoxin vs. Placebo|t|t|f|t
33822448|NCT05306730|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33822449|NCT02176512|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822450|NCT03137654|RANDOMIZED|PARALLEL||OTHER||NONE||The primary design is a 3 (Training Condition: Neutral, Affective, Control) by 2 (Time: Baseline, Post-training) repeated measures design.||||
33822451|NCT01039558|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822452|NCT01772121|||COHORT||PROSPECTIVE|||||||
33822453|NCT01090076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33822454|NCT04740437|||COHORT||RETROSPECTIVE|||||||
33822455|NCT01304251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822456|NCT01313299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822457|NCT03924193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822458|NCT06279637|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33822459|NCT01041599|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822460|NCT02599376|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33822461|NCT00470171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822462|NCT00119756|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33822463|NCT04259736|||COHORT||PROSPECTIVE|||||||
33822464|NCT05320861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822465|NCT04589689|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Randomization to either the intervention group (receives program immediately) or a waitlisted control condition (receives the intervention 6 months later).||||
33822466|NCT01309633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822467|NCT00500539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822468|NCT00537758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822469|NCT00972036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822470|NCT04634812|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822471|NCT06647264|||COHORT||PROSPECTIVE|||||||
33822472|NCT03291899|NA|SINGLE_GROUP||TREATMENT||NONE||Simon 2-stage optimum design Model||||
33822473|NCT02065726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822474|NCT00382408|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822475|NCT00982371|||CASE_CONTROL||PROSPECTIVE|||||||
33822476|NCT00349713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822477|NCT05852054|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE||This is a stepped wedge, pragmatic design. Study sites deliver usual care until they are randomized to provide the STEP-UP intervention.|f|f|f|t
34128616|NCT03585725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128617|NCT05491096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128618|NCT04633369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34128619|NCT06398002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of participants and investigators. Dialysis nurses will be aware of treatment assignment.|Randomised, double-blind, parallel-group, controlled clinical trial|t|f|t|f
34128620|NCT06436222|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants are assigned to two groups either HVNI (intervention group) or CPAP (control group)||||
34128621|NCT06137885|||COHORT||PROSPECTIVE|||||||
34128622|NCT05293600|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34128623|NCT05395039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Intervention Group: VCHIPS Control Group: Usual care||||
34128624|NCT02961504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128625|NCT05746091|NA|SINGLE_GROUP||OTHER||NONE||||||
34128626|NCT02365610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128627|NCT01413295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128628|NCT00295282|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128629|NCT02363777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128630|NCT02509936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128631|NCT05623748|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34128632|NCT04396795|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822478|NCT03083600|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind, computer-generated randomisation|56 participants randomised to receive: 5g, 10g, 15g Pea Protein Hydrolysate v placebo 5g, 10g, 15g v Rice Protein Hydrolysate v placebo|t|t|t|t
33822479|NCT01372202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822480|NCT00220441|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33822481|NCT01343147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822482|NCT01083537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822483|NCT05580302|||COHORT||OTHER|||||||
33822484|NCT03149887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, controlled, parallel|t|t|t|t
33822485|NCT00761618|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822486|NCT01693159|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822487|NCT00910871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822488|NCT01523678|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33822489|NCT02775214|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822490|NCT01554371|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822491|NCT05036499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822492|NCT01475370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822493|NCT00346177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822494|NCT02762500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822495|NCT06525753|||CASE_ONLY||PROSPECTIVE|||||||
33822496|NCT06585683|||CASE_CONTROL||PROSPECTIVE|||||||
33822497|NCT03512288|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33822498|NCT01718613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822499|NCT05112172|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822500|NCT05006703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33822501|NCT04026074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822502|NCT05789199|||COHORT||RETROSPECTIVE|||||||
33822503|NCT05381077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Whole body MRI in addition to the classic PET / CT assessment for all participant.||||
33822504|NCT06012942|||COHORT||PROSPECTIVE|||||||
33822505|NCT00119314||||TREATMENT||NONE||||||
33822506|NCT06646523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822507|NCT01751451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822508|NCT00375778|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822509|NCT01329419|||COHORT||PROSPECTIVE|||||||
33822510|NCT00124137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822511|NCT05522764|||COHORT||RETROSPECTIVE|||||||
33822512|NCT02794441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822513|NCT03638401|NON_RANDOMIZED|SINGLE_GROUP||OTHER||||||||
33822514|NCT04906707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822515|NCT01149499|RANDOMIZED|CROSSOVER||||NONE||||||
33822516|NCT00184496|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822517|NCT02214836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822518|NCT01368055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822519|NCT05937971|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled trial||||
33822520|NCT01514864|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128633|NCT04858841|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded study||t|t|t|t
34128634|NCT01833494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128635|NCT01650831|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34128636|NCT01591434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128637|NCT00942370|||||PROSPECTIVE|||||||
34128638|NCT00407836|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822521|NCT01072396|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33822522|NCT05644041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822523|NCT01381042|||||RETROSPECTIVE|||||||
33822524|NCT01601639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822525|NCT03894033|||COHORT||PROSPECTIVE|||||||
33822526|NCT02078297|||COHORT||CROSS_SECTIONAL|||||||
33822527|NCT04620733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822528|NCT06097247|||CASE_ONLY||PROSPECTIVE|||||||
33822529|NCT02198716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822530|NCT01395706|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822531|NCT00312845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822532|NCT00009789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822533|NCT02652299|||CASE_CONTROL||PROSPECTIVE|||||||
33822534|NCT06363409|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822535|NCT03149432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assossor won't know if the participant has received the mirror therapy||f|f|f|t
33822536|NCT04931199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822537|NCT05264311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34128639|NCT03732716|||COHORT||PROSPECTIVE|||||||
34128640|NCT04365686|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34128641|NCT01467466|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34128642|NCT01784679|||OTHER||PROSPECTIVE|||||||
34128643|NCT03896854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128644|NCT02655952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128645|NCT04311112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128646|NCT05625295|||OTHER||CROSS_SECTIONAL|||||||
34128647|NCT02342860|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128648|NCT04887727|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three groups: Fast, Fed, Ex-Fed Two trials per group||||
34128649|NCT01564251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128650|NCT03592771|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34128651|NCT04719481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128652|NCT03034005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128653|NCT01754246|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||Participants are put into two groups (Pigmented Lesions/Skin Toning) to test prototype design and operating specifications. It is not a full clinical trial.||||
34128654|NCT04414813|NA|SINGLE_GROUP||TREATMENT||NONE||The study plans to recruit 3 patients who meet the criteria. 50 millions HAESCs will be transplanted to participants with PD.||||
34128655|NCT05710731|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34128656|NCT06133556|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34128657|NCT00784199|||CASE_ONLY||PROSPECTIVE|||||||
34128658|NCT03303053|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center, open label, randomised, parallel-group||||
34128659|NCT02973139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128660|NCT06090812|||OTHER||PROSPECTIVE|||||||
34128661|NCT00109252||||TREATMENT||NONE||||||
34128662|NCT04742530|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study design is a randomised, controlled, crossover design in which participants undertake three exercise conditions in a randomised order with at least a seven day period in between trials.||||
34128663|NCT04512677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The secret will be kept by the data collecting investigators and will only be revealed at the end of the data analysis.|Randomized controlled study|f|f|f|t
34128664|NCT01253083|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128665|NCT00033046||CROSSOVER||TREATMENT||DOUBLE||||||
34128666|NCT02463396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822538|NCT02261545|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33822539|NCT04330261|||COHORT||PROSPECTIVE|||||||
33822540|NCT06379906|||OTHER||OTHER|||||||
33822541|NCT05430607|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel study arms||||
33822542|NCT06538727|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"To achieve both aims, a two-arm-experimental design with a posttest control-group-only, will be conducted in a convenience sample of 20 adult patients with MPS of the upper back. Participants will be randomly allocated to one of the following three groups with a 1:1 ratio:~* Group 1: receives one session of OMT~* Group 2: control group - does not receive intervention"||||
33822543|NCT04486742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822544|NCT00803335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128667|NCT01084577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128668|NCT04710498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128669|NCT02383186|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34128670|NCT00075764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128671|NCT00974506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128672|NCT01585779|||COHORT||PROSPECTIVE|||||||
34128673|NCT02141230|NA|SINGLE_GROUP||||NONE||||||
34128674|NCT05247450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128675|NCT00725946|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128676|NCT04723498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128677|NCT00002081||||TREATMENT||NONE||||||
34128678|NCT04380909|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128679|NCT02668705|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34128680|NCT03376711|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34128681|NCT03900728|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A separate investigator will apply the intervention after the initial usual care is complete and participants will go home using the intervention; thus the care provider will not be aware of the treatment. The adhesive disks appear similar for the treatments and the placebo arm; thus the participants will be unaware of their treatment assignment. The research assistant collecting the outcomes data will not know which treatment arm the participant belongs to. Finally, treatment assignment will be coded in the study database until analysis is complete, so that the investigator will be unaware of the treatment assignment until analysis is complete and then un-blinding will occur.|This 3-arm randomized trial will assign participants 1:1:1 to receive either of two active treatments (acupuncture or acupressure) or placebo (insert adhesive disks applied to ears).|t|t|t|t
34128682|NCT00022295||||TREATMENT||||||||
34128683|NCT03926949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128684|NCT03931499|||COHORT||PROSPECTIVE|||||||
34128685|NCT00410969|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128686|NCT01650571|||COHORT||PROSPECTIVE|||||||
34128687|NCT02805634|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128688|NCT01078194|||CASE_ONLY||PROSPECTIVE|||||||
34128689|NCT02689206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128690|NCT00661726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128691|NCT05135039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128692|NCT06422624|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34128693|NCT04875468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128694|NCT01107392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128695|NCT00579969|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34128696|NCT01628523|||OTHER||PROSPECTIVE|||||||
34128697|NCT01602601|||CASE_ONLY||CROSS_SECTIONAL|||||||
33822545|NCT01134718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822546|NCT04595175|||COHORT||PROSPECTIVE|||||||
33822547|NCT00098514|NA|SINGLE_GROUP||TREATMENT||NONE||There were 7 potential PT523 single agent dose levels to be evaluated in this phase I study||||
33822548|NCT02423252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33822549|NCT06108596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822550|NCT03090893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33822551|NCT03058237|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The Clinical Trial Authorisation application for this study describes a flexible protocol design using the formulation design space concept to allow decision-making in response to interim PK observations||||
33822552|NCT06477562|||COHORT||RETROSPECTIVE|||||||
33822553|NCT03504371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822554|NCT02061215|||CASE_CONTROL||PROSPECTIVE|||||||
33822555|NCT03965247|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The randomisation schedule was drawn up by an experimenter in the lab who is not involved in the study, and all information was kept in a locked cabinet in the Neurosciences building at the Department of Psychiatry, University of Oxford.|Participants were randomly assigned to the placebo or lithium group. The two groups were matched in terms of age and gender.|t|f|t|f
33822556|NCT01638533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822557|NCT00185783|||COHORT||PROSPECTIVE|||||||
33822558|NCT03274206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822559|NCT03207620|||COHORT||CROSS_SECTIONAL|||||||
33822560|NCT02264717|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33822561|NCT05575596|||COHORT||PROSPECTIVE|||||||
33822562|NCT03868618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822563|NCT02375932|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33822564|NCT02411422|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33822565|NCT02133183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822566|NCT06646705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822567|NCT03037814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822568|NCT04287816|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33822569|NCT06344494|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822570|NCT05804526|NA|SEQUENTIAL||TREATMENT||NONE||||||
33822571|NCT04748445|||COHORT||PROSPECTIVE|||||||
33822572|NCT05046301|||COHORT||PROSPECTIVE|||||||
33822573|NCT05223283|||OTHER||RETROSPECTIVE|||||||
33822574|NCT01093690|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822575|NCT02367742|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822576|NCT06143488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Drug: Best medical management Procedure: Endovascular therapy|f|f|f|t
33822577|NCT01931683|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33822578|NCT03579680|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33822579|NCT01012999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822580|NCT00003924|RANDOMIZED|||TREATMENT||||||||
33822581|NCT04896502|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33822582|NCT00265096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822583|NCT02409121|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33822584|NCT03777553|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group pre/post trial.||||
33822585|NCT03279770|||CASE_ONLY||RETROSPECTIVE|||||||
33822586|NCT04568083|||COHORT||RETROSPECTIVE|||||||
33822587|NCT04739462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822588|NCT05627583|||CASE_ONLY||OTHER|||||||
33822589|NCT04036773|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33822590|NCT04991623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149341|NCT05429073|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blinded, randomized, placebo-controlled study.||t|f|t|f
34149342|NCT01360177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149343|NCT00073463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149344|NCT05035589|||CASE_CONTROL||RETROSPECTIVE|||||||
33822591|NCT00212862|||CASE_ONLY||PROSPECTIVE|||||||
33822592|NCT03792893|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33822593|NCT04778683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Sociodemographic data of the children and their mothers were collected using the participant information form. Then, the children rated their fear and anxiety on the scales using a pen. Similar assessments were performed by their mothers and the investigator. The investigator explained the use of VR glasses to the children in the VR group. After the surgery, the children, their mothers, and the investigator re-evaluated the fear and anxiety in children using the CFS and the CAM-S. The pain levels in children during the postoperative period were evaluated by both their mothers and the nurse. The same evaluations were performed in children in the control group who received routine clinical care.|This randomized controlled study was conducted a pediatric hospital in Turkey for circumcision between June and September 2019. The sample size for the study was calculated using the G-Power 3.0.10 program and t-test for comparison of two independent groups with an effect size of 0.8, an alpha level and margin of error of 0.05, and a power of 95%. The sample size was determined to be 70; each of the experimental and control groups included 35 children. Data were collected from 78 children. A randomized block design method was used to randomize the participants to the groups. The randomization list was prepared by a third person and was given to the investigator only during the application.|t|t|t|f
33822594|NCT01439997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822595|NCT04990973|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Statistician and research technicians involved in data and sample analyses will be blind to intervention.||f|f|t|f
33822596|NCT01996397|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33822597|NCT01234675|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33822598|NCT02659384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822599|NCT01994135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33822600|NCT06244693|||COHORT||PROSPECTIVE|||||||
33822601|NCT00764010|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34149345|NCT03779503|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34149346|NCT04043832|||OTHER||PROSPECTIVE|||||||
33822602|NCT06512181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822603|NCT04054193|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33822604|NCT05609721|||COHORT||RETROSPECTIVE|||||||
33822605|NCT00574171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822606|NCT03451994|||COHORT||RETROSPECTIVE|||||||
33822607|NCT06242171|||CASE_ONLY||PROSPECTIVE|||||||
33822608|NCT04727242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822609|NCT03228654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822610|NCT05313529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822611|NCT03897049|RANDOMIZED|PARALLEL||PREVENTION||NONE|Participants are randomly assigned to their condition without being made aware of their assigned condition. Each condition downloads and uses an app so study activities are similar reducing the likelihood participants will be aware of their assigned condition.|"This is a two arm randomized controlled trial.~Implementation. After randomization, participants will be granted access to download and install their respective Trans Women Connected mobile apps (intervention or attention control)."||||
33822612|NCT02617667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822613|NCT03386305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822614|NCT03353155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patients are randomly assigned to one of two groups. Group 1 is usual care, in which patients are followed up after surgery by the ambulatory clinic assigned to their case. Patients in usual care have access to occupational and physical therapy, and medical social work, if they choose to use them. Group 2 is CareHub, in which patients are followed up by a dedicated care coordinator who proactively calls patients at home and schedules their clinic appointments, and consults with therapists and medical social workers.||||
33822615|NCT02503839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822616|NCT05181891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Phase II randomized trial|f|f|t|f
33822617|NCT04949789|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Arm 1 (Placebo without Exercise) Arm 2 (Placebo with Exercise) Arm 3 (IP I) Arm 4 (IP II) Arm 5 (IP III)|t|t|t|t
33822618|NCT01124656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822619|NCT04999683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822620|NCT05016778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822621|NCT03039088|||COHORT||PROSPECTIVE|||||||
33822622|NCT00801450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33822623|NCT04015128|||COHORT||PROSPECTIVE|||||||
33822624|NCT02876302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822625|NCT06011928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33822626|NCT03052283|||CASE_CONTROL||PROSPECTIVE|||||||
33822627|NCT03425045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and outcomes assessors will be masked, the investigator will know which treatment is being provided for which patient.|The study is designed as interventional, blinded, randomized, controlled trial with three parallel arms|t|f|f|t
33822628|NCT02511808|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33822629|NCT01081236|||COHORT||PROSPECTIVE|||||||
33822630|NCT03051529|||COHORT||PROSPECTIVE|||||||
33822631|NCT03410095|||COHORT||PROSPECTIVE|||||||
33822632|NCT00703599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822633|NCT05043688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822634|NCT02894359|||OTHER||CROSS_SECTIONAL|||||||
33822635|NCT06274892|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33822636|NCT04879875|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, Cohort||||
33822637|NCT05632016|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33822638|NCT04226183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"care provider is a midwifery as a intructure of excercise and measure of each pregnant participans condition.~investigator is controling all reseach procedure."|There were 24 prenatal pregnant women and separated to 3 groups, which were 8 prenatal pregnant women without exercise as a control group, 8 prenatal pregnant women with exercise as a positive control group and 8 prenatal pregnant women with exercise and consume natural antioxidants after exercise as a treatment group. The antioxidant compounds given in this study were guava juice that contains vitamin C.|f|t|t|f
33822639|NCT04318587|NA|SINGLE_GROUP||SCREENING||NONE||"Correlate donor DNA in blood samples to episodes of Acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry~From this correlation we hope to be able to develop a miniMally invasive test ( blood sample) that can predict or correlate acute and or chronic rejection"||||
33822640|NCT00158886|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822641|NCT04685018|||CASE_CONTROL||PROSPECTIVE|||||||
33822642|NCT04163835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"This study was a double-blind clinical trial, with the patients, the treating physicians, the statisticians, the monitors and any other personnel being unaware of group allocation. Efforts to maintain blinding included identical appearance, packaging and labeling of four groups of experimental drugs.~Unblinding should be done by the statisticians when the data collection process was completed or the treating physicians when serious adverse events occurred.~The maximum sample size required is determined to be 150 cases."|The ratio of high, medium and low dose group and placebo groups are 1:1:1:1. A total of 60 cases are included in the first phase.The maximum sample size required is determined to be 150 cases.|t|f|t|f
33822643|NCT04542642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent Outcomes Assessor will conduct data analysis and be blinded to intervention assignments.|Participants will be randomly assigned to receive either the game-based treatment (PEAR-008) or the original, FDA-authorized treatment (reSET-O).|f|f|f|t
33822644|NCT00692250|RANDOMIZED|PARALLEL||||NONE||||||
33822645|NCT06228027|||COHORT||PROSPECTIVE|||||||
33822646|NCT00291863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822647|NCT04098393|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a pilot study in which adult patients with hematologic malignancies undergoing ex-vivo CD34-selected allo-HCT will receive a condensed version of our standard bu/mel/flu regimen, reducing the length of the conditioning regimen from 8 days to 5 days.||||
33822648|NCT04701073|RANDOMIZED|PARALLEL||TREATMENT||NONE||An interventional, prospective, multicenter, randomized, open and controlled study||||
33822649|NCT04323111|||COHORT||PROSPECTIVE|||||||
33822650|NCT04225078|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33822651|NCT06536374|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a Phase II, open label, randomized controlled trial. Subjects will be randomized 1:1 to either Trimethoprim (TMP) + (Standard of Care) SOC or SOC alone||||
33822652|NCT06447298|||OTHER||PROSPECTIVE|||||||
33822653|NCT05662215|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33822654|NCT01963858|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33822655|NCT06026826|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822656|NCT04494243|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822657|NCT06646575|||OTHER||OTHER|||||||
33822658|NCT06549699|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33822659|NCT01497951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33822660|NCT02754310|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33822661|NCT03596099|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A unique randomization ID number will be assigned by ClaimIt to each enrolled subject and associated with the correct study product kit number; this number will be used throughout the study (includes study execution, safety reporting, compliance with the study product, and efficacy). Both the Mizkan rice vinegar active product (acetic acid) and placebo (no acetic acid) will be labeled identically and will be distinguishable only by the individual subject ID printed on the label.|Randomized, two-arm, parallel-group, double-blind, placebo-controlled|t|t|t|t
33822662|NCT05985109|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822663|NCT04639076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33822664|NCT00156975|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822665|NCT04290416|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822666|NCT04475016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822667|NCT01033279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33822668|NCT04450771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822669|NCT05983328|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822670|NCT02273180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822671|NCT04675671|||OTHER||PROSPECTIVE|||||||
33822672|NCT01024829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822673|NCT02669888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822674|NCT05244226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822675|NCT06268431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822676|NCT05675839|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study were conducted between September and December 2022 on 102 volunteer students studying in the Department of Nursing in Turkey. The inclusion criteria were as follows being 18 years old or over, being a firs year student, be in the classroom on training day. The students included in the study were randomly divided into two groups.Experimental group watched a documantary and a movie about nursing profession and Control group had no intervention.||||
33822677|NCT00616486|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822678|NCT06138483|||COHORT||PROSPECTIVE|||||||
33822679|NCT05240482|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Outcomes will be evaluated by anesthesiologists who are blinded to the treatment allocation. Patients, investigators and observers will be blinded to the patient allocation throughout the entire study period.||t|t|t|t
33822680|NCT06370143|||COHORT||PROSPECTIVE|||||||
33822681|NCT00384761|||COHORT||CROSS_SECTIONAL|||||||
33822682|NCT03188809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||double blind, randomised, controlled train|t|f|t|t
33822683|NCT05987839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Intervention group: Total knee arthroplasty assisted by knee navigation and positioning system. Specification Model: OP-RKL22 Control group: Total knee arthroplasty without knee navigation and positioning system The same joint prosthesis was used in both the experimental group and the control group, and was approved by the manufacturer.|f|f|t|t
33822684|NCT06550297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822685|NCT00481156|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants were randomized to computer-based cognitive training or active social-skills groups. Healthy controls (n=9) received no treatment.|Randomized, placebo-controlled, single-blind. An untreated healthy control group was also included to examine simple retest effects.|t|f|f|f
33822686|NCT06034964|||COHORT||RETROSPECTIVE|||||||
33822687|NCT01655992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822688|NCT06227442|||COHORT||PROSPECTIVE|||||||
33822689|NCT04284722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822690|NCT05888558|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33822691|NCT04345783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822692|NCT03460496|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||An advanced practice nurse (APN)-led Intervention which focuses on improving parental mental health and well-being, on infant growth and development and on lowering overall costs.||||
33822693|NCT06295237|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Anonymized evaluation|"Two 2-hour periods: 1) off mode consisting of a control period with optimized ventilator parameters and 2) on mode with an active automated detection and adjustment for asynchronies. The starting first period is randomized."|f|f|f|t
33822694|NCT03769129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822695|NCT03298347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822696|NCT00092209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822697|NCT01723332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822698|NCT02093897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822699|NCT01694199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822700|NCT01626677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149347|NCT00435526|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34149348|NCT06380894|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34149349|NCT02262754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149350|NCT01009190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822701|NCT01314638|||COHORT||PROSPECTIVE|||||||
33822702|NCT01942434|||COHORT||PROSPECTIVE|||||||
33822703|NCT01462383|||COHORT||RETROSPECTIVE|||||||
33822704|NCT00806741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33822705|NCT00226746|NA|SINGLE_GROUP||TREATMENT||NONE||"Radiation Therapy: 63.80 Gy (1.1 Gy BID X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."||||
33822706|NCT04903912|||CASE_ONLY||PROSPECTIVE|||||||
33822707|NCT03786003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822708|NCT05363098|||COHORT||PROSPECTIVE|||||||
34128698|NCT03534505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Once given general anesthesia in the operating room, the patient will be randomly selected into one of the two arms of this report's diagram (1:1 ratio) through the drawing of a sealed, opaque envelope by one of the surgical residents in charge or by the attending surgeon. All patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. and patients who are the control group will receive local infiltration with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.|t|f|f|f
34128699|NCT04695353|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||International, longitudinal, case-control study comparing in-office visits to virtual visits via Telecommunication Platforms.||||
34128700|NCT03815448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128701|NCT04456478|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Multicentric randomized blinded trial|t|f|f|t
34128702|NCT06089031|||CASE_ONLY||PROSPECTIVE|||||||
34128703|NCT05356988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Investigator will not be involved in randomization, but given the obvious differences in treatment vs. control, participants, investigator, and assessors will be aware of assignment.|The intervention group will have access for one year to a website to help increase aerobic and strength training activities. The control group will have access for one year to a website to help improve balance and flexibility. At the end of the one-year study, each group will get access to the opposite website.||||
34128704|NCT06045273|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128705|NCT01326091|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128706|NCT04469088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128707|NCT00938912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128708|NCT00149240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128709|NCT00385385|RANDOMIZED|PARALLEL||||DOUBLE||||||
34128710|NCT06333002|||COHORT||PROSPECTIVE|||||||
34128711|NCT02180204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128712|NCT02786212|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128713|NCT02283892|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128714|NCT03396302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128715|NCT06353152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128716|NCT00620373|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34128717|NCT00922402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128718|NCT03351868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128719|NCT03849664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128720|NCT03598049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128721|NCT05253937|||COHORT||PROSPECTIVE|||||||
34128722|NCT05096143|||COHORT||RETROSPECTIVE|||||||
34128723|NCT03983044|||CASE_ONLY||PROSPECTIVE|||||||
34128724|NCT02078024|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34128725|NCT02487147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128726|NCT05689918|||OTHER||CROSS_SECTIONAL|||||||
34128727|NCT04648917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||1:1 Randomized grouping|t|t|t|t
34128728|NCT03899025|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study will be composed of two subsequent phases, designed to fit within the standard clinical protocol for patients presenting at the emergency department, suspected of having a scaphoid fracture. Briefly, a patient presenting at the emergency department with a clinically suspected scaphoid fracture (by physical examination) will be subjected to standard radiographs followed by cast immobilization. When a fracture is confirmed, a conventional CT is planned within 10 days to assess fracture classification, for which the standard radiographs are insufficient. When no fracture is seen on the initial radiographs, the patient is reevaluated within 10 days after the trauma and physical examination and a conventional CT are performed.~Based on the CT, a treatment strategy is decided with regular follow up visits. This clinical workup is in accordance with national and regional treatment protocols, as well as with current literature discussed in sections 1.1 and 1.2."||||
34128729|NCT01963247|||COHORT||PROSPECTIVE|||||||
34128730|NCT05168046|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128731|NCT03836846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128732|NCT03634098|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34128733|NCT01637532|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128734|NCT00229697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128735|NCT05257304|||COHORT||PROSPECTIVE|||||||
34128736|NCT04961346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128737|NCT03601065|||COHORT||PROSPECTIVE|||||||
34128738|NCT03196596|||COHORT||PROSPECTIVE|||||||
34128739|NCT02661204|||COHORT||PROSPECTIVE|||||||
34128740|NCT03411629|||COHORT||PROSPECTIVE|||||||
34128741|NCT01978145|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34128742|NCT02713334|||COHORT||PROSPECTIVE|||||||
34128743|NCT00945568|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34128744|NCT03775824|||COHORT||PROSPECTIVE|||||||
34128745|NCT01894724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128746|NCT01520155|||CASE_CONTROL||PROSPECTIVE|||||||
34128747|NCT01679678|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128748|NCT03119805|||COHORT||PROSPECTIVE|||||||
34128749|NCT02967549|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128750|NCT04213469|NA|SEQUENTIAL||TREATMENT||NONE||Patients will receive one of the three doses of 2\*10\^6/kg, 4\*10\^6/kg,6\*10\^6/kg.||||
34128751|NCT02424500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128752|NCT03890900|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||This proposal will develop, evaluate, and refine a patient-centered mobile application (DiabetesXcel), which will deliver tailored and algorithm-based diabetes education to improve the process and diabetes-related outcomes. We also test the reliability of eHEALS and NVS questionnaires.||||
34128753|NCT00236288|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34128754|NCT00402324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128755|NCT02453750|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149351|NCT05105815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149352|NCT01107782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149353|NCT04109833|||CASE_CONTROL||PROSPECTIVE|||||||
33822709|NCT01037829|||COHORT||PROSPECTIVE|||||||
33822710|NCT03269149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822711|NCT02367378|||CASE_CONTROL||PROSPECTIVE|||||||
33822712|NCT00466622|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33822713|NCT03835403|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33822714|NCT00333554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822715|NCT02284802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822716|NCT00307671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822717|NCT00984399|NA|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822718|NCT06321900|||COHORT||PROSPECTIVE|||||||
33822719|NCT05204771|||COHORT||RETROSPECTIVE|||||||
33822720|NCT00376207|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE||||||
33822721|NCT04848116|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33822722|NCT02924181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822723|NCT04320810|||COHORT||PROSPECTIVE|||||||
33822724|NCT05723289|||COHORT||PROSPECTIVE|||||||
33822725|NCT01761474|||COHORT||PROSPECTIVE|||||||
33822726|NCT05330325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822727|NCT00139308|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33822728|NCT06646432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822729|NCT01838447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33822730|NCT02025985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822731|NCT01286870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822732|NCT03604289|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33822733|NCT04186117|NA|SINGLE_GROUP||OTHER||NONE||||||
33822734|NCT06329011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822735|NCT06646731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a single-center, randomized, participant- and observer-masked, human-subjects, post-market clinical pilot study|t|f|f|t
33822736|NCT05657613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An open-label, fixed-sequence, 2-part drug-drug interaction study of pacritinib in healthy adult males||||
33822737|NCT05952908|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33822738|NCT06396923|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33822739|NCT02578667|NON_RANDOMIZED|PARALLEL||||NONE||||||
33822740|NCT00489489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822741|NCT01399502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822742|NCT01610622|||||PROSPECTIVE|||||||
33822743|NCT01364545|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33822744|NCT03627351|||CASE_ONLY||PROSPECTIVE|||||||
33822745|NCT04714697|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822746|NCT01979757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33822747|NCT05736523|||COHORT||PROSPECTIVE|||||||
33822748|NCT05876364|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33822749|NCT04416321|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects recruited and will receive the Keos Lumbar Interbody Fusion Device||||
33822750|NCT06123819|||COHORT||CROSS_SECTIONAL|||||||
33822751|NCT03068143|||CASE_ONLY||PROSPECTIVE|||||||
33822752|NCT03440788|||COHORT||PROSPECTIVE|||||||
33822753|NCT04557865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822754|NCT00951574|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33822755|NCT00786721|||COHORT||PROSPECTIVE|||||||
33822756|NCT05095233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is based on single blind randomized controlled trial with the randomization of study participants across two groups (1). Young Adults Culturally Adapted Manual Assisted Psychological Therapy (2). MINPLAN Tool|f|f|f|t
33822757|NCT03195127|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||Up to 75 patients will be screened with a goal of enrolling 40 for participate in the intervention trial (20 in the multimodal treatment arm and 20 in a group receiving usual care).||||
33822758|NCT04160000|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This is a prospective pilot study utilizing a randomized comparative sequential evaluation of two therapeutic approaches in two consecutive phases. Phase 1 will examine an initial catheter ablation strategy versus an initial antiarrhythmic drug (AAD) therapy strategy for safety and efficacy in patients with atrial fibrillation with preserved systolic cardiac function, heart failure hospitalization in the past year or one or more documented HF events.~Phase 2 will examine optimized rhythm control therapy with and without wireless pulmonary artery pressure hemodynamic monitoring for HF therapy optimization in the same patients as in Phase 1 with documented atrial fibrillation with preserved systolic cardiac function, prior HF hospitalization and class III heart failure."||||
33822759|NCT01137123|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33822760|NCT03415893|||COHORT||RETROSPECTIVE|||||||
33822761|NCT01052870|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33822762|NCT00990821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822763|NCT06472011|RANDOMIZED|CROSSOVER||OTHER||NONE||7 crossover arms for each subject||||
33822764|NCT02599870|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33822765|NCT00530049|||COHORT||PROSPECTIVE|||||||
33822766|NCT05340439|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, open-label, non-randomized, single-arm, dose titration, phase II study.||||
33822767|NCT04753281|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|t|f|f
33822768|NCT01732627|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822769|NCT00888394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33822770|NCT05191121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822771|NCT04092959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822772|NCT03899259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33822773|NCT01540071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822774|NCT00655668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822775|NCT06231550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822776|NCT01954758|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33822777|NCT01766323|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33837365|NCT03925610|||COHORT||PROSPECTIVE|||||||
33837366|NCT00280722|RANDOMIZED|||OTHER||||||||
34149354|NCT01130090|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34149355|NCT02322190|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149356|NCT00167661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822778|NCT06205407|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This will be an open-label, randomized, single-dose, 2-treatment, 2-period, 2-sequence, crossover study in adult healthy male and/or female participants. Approximately 40 participants will be enrolled in the study (20 in each treatment sequence).~There will be a minimum 4-day washout period between successive doses (ie, administration of subsequent doses of study medication will not occur until at least 4 days after the previous dose of study medication)."||||
33822779|NCT00825643|||CASE_ONLY||PROSPECTIVE|||||||
33822780|NCT03964545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822781|NCT00019136||||TREATMENT||||||||
33822782|NCT04759118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822783|NCT04627064|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33822784|NCT00221481|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33822785|NCT05990283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822786|NCT03661008|||COHORT||CROSS_SECTIONAL|||||||
33822787|NCT01707498|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33822788|NCT01631318|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822789|NCT04440683|||COHORT||PROSPECTIVE|||||||
33822790|NCT04387916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822791|NCT03463538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|independent clinical reviewer of patients ROM and collection of outcome scores|randomised control trial between interventions|f|f|f|t
33822792|NCT00400257|||COHORT||PROSPECTIVE|||||||
33822793|NCT00637325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822794|NCT02449993|||||RETROSPECTIVE|||||||
33822795|NCT00207298|||COHORT||PROSPECTIVE|||||||
33822796|NCT00940914|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33822797|NCT01709643|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33822798|NCT01291043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822799|NCT01643018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822800|NCT01256372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33822801|NCT05426655|NA|SINGLE_GROUP||TREATMENT||NONE||Analytical, prospective experimental study: uncontrolled clinical trial.||||
33822802|NCT00356213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822803|NCT02173249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822804|NCT01643902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822805|NCT02657018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33822806|NCT02860858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822807|NCT06446531|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be single blind study, given all treatment arms being pills, once subjects are randomized, they will not be told which mediation they are taking, and treatment will be dispensed in unmarked bottles at each timepoint.|Single-blind Randomized, placebo-controlled trial.|t|f|f|f
33822808|NCT04090788|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
33822809|NCT01600261|||||PROSPECTIVE|||||||
33822810|NCT06012305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The person who will make the assessments will not know in which group the individual he/she is assessing is in.|In the study, there were three groups in which three different treatment programs were applied.|f|f|f|t
33822811|NCT02936739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822812|NCT04565392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|study medication is Pepcid AC or matching placebo|Parallel double-blind placebo-controlled interventional trial|t|f|t|t
33822813|NCT05615558|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33822814|NCT06065202|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822815|NCT05436977|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|"The coronary OCT images acquired will be analyzed off-line by an independent imaging core laboratory (Euroimage Research, Rome, Italy), using validated review stations. OCT-defined plaque classification was performed according to an international consensus statement and validated criteria.~PET-CT and CT coronary angiography images will be analyzed off-line in an experienced imaging laboratory by our collaborators at the University of Cambridge."||f|f|f|t
33822816|NCT06645730|||COHORT||PROSPECTIVE|||||||
33822817|NCT00516061|||DEFINED_POPULATION||OTHER|||||||
33822818|NCT02270463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822819|NCT02987283|||COHORT||PROSPECTIVE|||||||
33822820|NCT02312609|RANDOMIZED|CROSSOVER||||NONE||||||
33822821|NCT06255288|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33822822|NCT06339385|||OTHER||PROSPECTIVE|||||||
33822823|NCT00131690|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33822824|NCT00577096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822825|NCT04135911|||COHORT||PROSPECTIVE|||||||
33822826|NCT01447251|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822827|NCT02368366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822828|NCT02640807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822829|NCT06435624|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33822830|NCT05343819|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Quadruple: Participant, Investigator, Outcomes Assessor and Care provider.|Sequential: Two groups of participants will be assigned to receive AON-D21 or placebo in ascending dose order. Dose will be escalated based on safety and pharmacokinetic data.|t|t|t|t
33822831|NCT03819855|||CASE_ONLY||PROSPECTIVE|||||||
33822832|NCT04581772|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822833|NCT03104309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822834|NCT01018576|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33822835|NCT06016764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822836|NCT03635437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822837|NCT05630599|||COHORT||PROSPECTIVE|||||||
33822838|NCT01695525|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822839|NCT04696926|||COHORT||PROSPECTIVE|||||||
33822840|NCT02046057|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822841|NCT03742232|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33822842|NCT02704026|||COHORT||PROSPECTIVE|||||||
33837367|NCT03662269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a randomized, double-blind, placebo-controlled trial|t|f|t|f
34128756|NCT05434793|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||In this study, the effects of sham acupuncture at Tsu San Li (St-36) were examined by analyzing noninvasive 30-sec. recordings of the radial arterial pulses for 3 groups of patients treated with different probes (blunt, sharp, and patch) on the superficial skin of the acupuncture point. The 3 groups were then treated with the sharp probe for 3 different periods (16, 30, and 50 seconds). Then the investigators compared the harmonics of the radial arterial pulse after Fourier transformation before and after the treatment.||||
34128757|NCT04361539|||COHORT||PROSPECTIVE|||||||
34128758|NCT01545128|||CASE_CONTROL||PROSPECTIVE|||||||
34128759|NCT00626886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128760|NCT06202352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Study||||
34128761|NCT03274011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128762|NCT03559517|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128763|NCT02521038|||COHORT||PROSPECTIVE|||||||
34128764|NCT00222755|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822843|NCT05041842|NA|SINGLE_GROUP||TREATMENT||NONE||Patients treated with pertuzumab and trastuzumab for metastatic breast cancer who will develop an isolated brain relapse treated with local treatment will receive tucatinib in addition to pertuzumab and trastuzumab. Tucatinib will be taken orally 300 mg twice a day, pertuzumab (420 mg) and trastuzumab (6 mg/kg) will be taken every 3 weeks.||||
33822844|NCT05182827|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822845|NCT05613504|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822846|NCT06464614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822847|NCT02892006|NA|SINGLE_GROUP||OTHER||NONE||||||
33822848|NCT04024371|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822849|NCT04531852|||COHORT||PROSPECTIVE|||||||
33822850|NCT04950049|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33822851|NCT00006436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822852|NCT04879095|||OTHER||PROSPECTIVE|||||||
33822853|NCT06028399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be allocated to the intervention group by using sealed envelop methods of simple random sampling. They were masked for the treatment allocation group. For assessment of outcome measures, HbA1C will be assessed by lab investigator, ABI and Functioncal capacity will be assessed by the physiotherapist who will be supervised the session.|In this randomized controlled trial, there are 2 parallel groups. Group A for Concurrent training and Group B for Aerobic training.|t|f|f|t
33822854|NCT02382406|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822855|NCT05422859|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33822856|NCT05626478|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In patient who undergo cataract surgery, subjects will be randomized to 2 arms and be followed for a period of 3 months.~Arm 1- control group, 25 subjects will receive Prednisolone Acetate 1% QID x 2 weeks then BID x 2 weeks.~Arm 2 - study group, 25 subjects will receive Dextenza 0.4mg insert"||||
33822857|NCT04685759|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33822858|NCT04258215|NA|SINGLE_GROUP||OTHER||NONE||Pilot study||||
33822859|NCT06646367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822860|NCT01248143|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822861|NCT03928769|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33822862|NCT03852875|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822863|NCT01886391|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33822864|NCT04309006|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The first factor is the use of connective tissue graft which includes two levels and the second factor is the use of healing abutment which includes two levels.|f|f|f|t
33822865|NCT01796210|||COHORT||PROSPECTIVE|||||||
33822866|NCT05651542|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33822867|NCT00403299|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33822868|NCT06132906|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822869|NCT02586389|||CASE_ONLY||PROSPECTIVE|||||||
33822870|NCT04092621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822871|NCT02619279|RANDOMIZED|PARALLEL||||NONE||||||
33822872|NCT02801747|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33822873|NCT01890798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822874|NCT05051696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822875|NCT00000121|RANDOMIZED|||TREATMENT||||||||
33822876|NCT06646419|||COHORT||PROSPECTIVE|||||||
33822877|NCT00166361|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822878|NCT02391545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822879|NCT05598203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Each group will be exposed to only one of the factors, diabetes education operative groups added usual individual counseling; or usual individual counseling.|f|f|f|t
33822880|NCT03455569|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33822881|NCT03472976|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822882|NCT01689285|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33822883|NCT05674578|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33822884|NCT00789932|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822885|NCT06326216|||CASE_CONTROL||PROSPECTIVE|||||||
33822886|NCT00761410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822887|NCT04822337|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33822888|NCT05882344|NA|SINGLE_GROUP||TREATMENT||NONE||This is a feasibility study to investigate the potential of Deep Brain Stimulation to improve cognitive abilities and counteract the effects of Alzheimer's disease. Deep Brain Stimulation electrodes targeting the Nucleus Basalis of Meynert (NB) will be implanted bilaterally in patients. NB is the sole source of acetylcholine to the neocortex. Such stimulation may not only treat the cognitive symptoms but may have disease-modifying effects. Intermittent stimulation will be delivered at 60 pulses per second for 20 seconds of each minute for one hour per day. The study design will test the safety and feasibility of stimulation, potential benefits in cognitive function assessed with a battery of neurocognitive tests, cholinergic neurotransmission evaluated with Positron Emission Tomography, and ability to reverse Alzheimer's biomarkers, including beta amyloid and tau in the cerebrospinal fluid.||||
33822889|NCT05655624|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128765|NCT06414343|||CASE_ONLY||RETROSPECTIVE|||||||
34128766|NCT02956746|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34128767|NCT05340946|RANDOMIZED|PARALLEL||PREVENTION||NONE||The aim of this study is to compare the effect of two anaesthesia methods in preventing perioperative myocardial infarction in patients with cardiac risk undergoing total knee arthroplasty. The primary outcome included perioperative levels of brain natriuretic peptide \& cardiac troponins. Secondary outcomes included postoperative operative pain assessment using visual analogue scale, total amount of analgesic consumption, patient satisfaction \& cardiovascular complications (myocardial infarction, arrhythmias , heart failure, hypotension, hypertension \& the need for inotropic agents ).||||
34128768|NCT00755963|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34128769|NCT03399279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128770|NCT04635150|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Pre-post intervention study with different cohorts before and after the intervention.||||
33822890|NCT04263883|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33822891|NCT05102656|||COHORT||PROSPECTIVE|||||||
33822892|NCT00271466|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822893|NCT00475787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33822894|NCT04758156|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33822895|NCT03160755|||OTHER||OTHER|||||||
33822896|NCT00111839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822897|NCT04266483|||OTHER||PROSPECTIVE|||||||
33822898|NCT04402021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33822899|NCT05005338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822900|NCT03501888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33822901|NCT05153642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||case-control|t|f|f|f
33822902|NCT02156089|RANDOMIZED|PARALLEL||OTHER||||||||
33822903|NCT04700397|||COHORT||PROSPECTIVE|||||||
33822904|NCT00575900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822905|NCT06646796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||In the first phase, the questionnaire will be validated with all patients of the Family Health Unit diagnosed with fibromyalgia who agree to participate. Subsequently, all participants will be asked if they wish to participate in the intervention study, and those who agree will be randomized into either the intervention or control group. The intervention group will engage in Yoga practice with a certified yoga instructor, three times a week for three months. Quality of life scales, a well-being scale, and pain measurement on a numerical scale from 0 to 10 will be applied before and after the intervention, complemented by an open-ended question for qualitative analysis regarding perceived benefits and difficulties.||||
33822906|NCT05768321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822907|NCT04076956|||COHORT||PROSPECTIVE|||||||
33822908|NCT03314233|NA|SINGLE_GROUP||OTHER||NONE||Unblinded single-arm pilot interventional trial. All enrolled infants will receive the DING intervention (Delayed cord clamping for INtubation and Gentle ventilation)||||
33822909|NCT03334799|NA|SINGLE_GROUP||SCREENING||NONE||case control||||
33822910|NCT00890214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822911|NCT02572999|||COHORT||PROSPECTIVE|||||||
33822912|NCT03097458|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized wait-list control design (cross-over).||||
33822913|NCT06641063|||COHORT||PROSPECTIVE|||||||
33822914|NCT02024399|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
33822915|NCT00311532|||DEFINED_POPULATION||OTHER|||||||
33822916|NCT06538831|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE||Parallel group 2x2 factorial randomized controlled trial in fully controlled feeding conditions|t|t|t|t
33822917|NCT00065234|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33822918|NCT04859218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Study Design A randomized crossover design will be performed at Three (3) out-patient treatment centres in Hamilton, London, and Toronto (Juravinski Hospital Cancer Centre; London Health Sciences Centre; and Sunnybrook Health Sciences Centre). Eligible patients who require at least 2 RBCs transfusions will be randomized to receive either ABO identical followed by ABO non-identical transfusion, or ABO non-identical followed by ABO identical transfusion. The outcome will be biomarkers of inflammation. The trial will be registered on ClinicalTrials.gov and approved by the Research Ethics Boards at each site.||||
33822919|NCT01661244|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822920|NCT00312871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822921|NCT05181878|||CASE_ONLY||PROSPECTIVE|||||||
33822922|NCT04785742|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822923|NCT01242033|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33822924|NCT05584761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822925|NCT04148716|||CASE_CONTROL||PROSPECTIVE|||||||
33822926|NCT01959607|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33822927|NCT04841811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822928|NCT04491136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822929|NCT06647290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822930|NCT02391571|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33822931|NCT04238299|||COHORT||PROSPECTIVE|||||||
33822932|NCT01645358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822933|NCT00312364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33822934|NCT05534802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"1. Voluntarily sign the informed consent;~2. Age ≥18 years old and ≤70 years old;~3. Patients receiving cardiopulmonary bypass~4. Patients undergoing heart valve replacement surgery, major vascular surgery, and other cardiac surgery"|t|t|t|t
33822935|NCT00667550|||COHORT||PROSPECTIVE|||||||
33822936|NCT03630458|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33822937|NCT06016179|NA|SINGLE_GROUP||TREATMENT||NONE||Intra-patient dose escalation administration of tocilizumab via pleural and peritoneal catheters||||
33822938|NCT01298219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Care provider and outcomes assessor were also blinded for this double-blind trial.||t|f|t|f
33822939|NCT01730118|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33822940|NCT01196247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822941|NCT04688086|||COHORT||PROSPECTIVE|||||||
33822942|NCT04624555|||COHORT||PROSPECTIVE|||||||
34128771|NCT01784367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128772|NCT01574287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33822943|NCT06472882|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|To ensure a double-blind design, the researcher who administered the tDCS was not present during the physical measurements, and the evaluator responsible for the physical measurements was unaware of the type of tDCS received by the participant. In this way, participants and evaluators remained blinded to the treatment administered.|"The study applied a double-blind, crossover design to examine the viability of tDCS in improving performance during a maximal effort task, particularly the No Jump Burpee exercise."|t|f|t|f
33822944|NCT01095809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822945|NCT01679613|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822946|NCT03331848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33822947|NCT05558761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded||t|t|f|f
33822948|NCT05756361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822949|NCT06158412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822950|NCT02502721|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822951|NCT00829647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822952|NCT06645756|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33822953|NCT03489837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33822954|NCT04715919|||COHORT||PROSPECTIVE|||||||
33822955|NCT03390933|NA|SINGLE_GROUP||TREATMENT||NONE||The cross-sectional study will involve assessments of depressive symptoms (PHQ-9) and quality of life for 1083 patients. These data will be used to address Aim A. The single arm trial will involve 96 patients with DSM5-confirmed depression.||||
33822956|NCT06125639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822957|NCT04494425|RANDOMIZED|PARALLEL||TREATMENT||NONE|"This study is an open-label study that will be conducted Sponsor-blind. To maintain the integrity of the study, Sponsor personnel directly involved in study conduct will not undertake or have access to efficacy data aggregated by treatment group prior to final data readout for the primary endpoint."|The study consists of 2 independent open label treatment arms: trastuzumab deruxtecan and Investigator's choice chemotherapy (paclitaxel, nab-paclitaxel or capecitabine).||||
33822958|NCT05771558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822959|NCT01670747|||COHORT||PROSPECTIVE|||||||
33822960|NCT01600235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822961|NCT03084614|||COHORT||PROSPECTIVE|||||||
33822962|NCT02032420|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33822963|NCT05610319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two-armed, parallel, non-inferiority randomized controlled trial|f|f|f|t
33822964|NCT02612363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33822965|NCT06329531|||COHORT||PROSPECTIVE|||||||
33822966|NCT05051683|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators included all patients who were developed acute perforated peptic ulcer manifestations and were admitted to our hospital between December 2019 to August 2021. the calculated sample size equal 100 patients divided into two equal groups. Group (1) included 50 patients managed by combined endoscopic \& radiologic intervention , group (2) included 50 patients managed by surgery.||||
33822967|NCT01287416|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822968|NCT03410953|NA|SINGLE_GROUP||PREVENTION||NONE||non-responders to conventional treatment of hepatitis B vaccination and consent to participate||||
33822969|NCT01063127|||||PROSPECTIVE|||||||
33822970|NCT03731637|||COHORT||PROSPECTIVE|||||||
33822971|NCT00794911|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33822972|NCT06611800|||COHORT||RETROSPECTIVE|||||||
33822973|NCT06254079|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||designed as a randomized controlled experimental||||
33822974|NCT05450705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33822975|NCT05262920|RANDOMIZED|PARALLEL||TREATMENT||NONE|The investigators will employ blinding whenever possible. The investigators team members involved in data collection or analysis will be blinded to the group assignment of participants. Research team personnel will follow a strict script to refrain from discussing participant activities, and by using the data management graduate assistant (unblinded) to coordinate assigned condition activities and data collection and analysis. All participants will be assigned a study number, which will be used to track the study measures. De-identified data with dummy codes for assigned condition will be entered into the study database to allow blinded data analysis. Blinding was successfully employed during the BSM pilot study.|The proposed RCT will be conducted to test the effect of the BSM intervention vs. an attention control group on BNP, BF exclusivity and duration, BF self-efficacy, and maternal well-being to 24 weeks||||
33822976|NCT06307964|||COHORT||PROSPECTIVE|||||||
33822977|NCT01842399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33822978|NCT00871832|||COHORT||PROSPECTIVE|||||||
33822979|NCT00457171|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33822980|NCT06646302|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33822981|NCT00631098|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822982|NCT05154539|RANDOMIZED|PARALLEL||SCREENING||NONE||1:1:1 three arm randomized, controlled trial.||||
33822983|NCT00705614|||COHORT||PROSPECTIVE|||||||
33822984|NCT04323332|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822985|NCT01679457|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33822986|NCT01367613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822987|NCT02968121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33822988|NCT03601949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is an assessor blinded trial and deliberate action will be needed to ensure the blind remains. This begins with randomization procedures and carries through the follow up visits. It is suggested that all follow up visit documentation not contain the visit number, but instead utilize visit dates to track progress.||f|f|f|t
33822989|NCT05360290|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33822990|NCT01797822|NA|SINGLE_GROUP||TREATMENT||NONE|Vehicle and therapy groups were not masked.|||||
33822991|NCT04727190|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33822992|NCT03465670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The patient, the clinical operators as well as the clinical examiner were kept blinded with respect to treatment allocation until the termination of the study. To ensure blindness, CHX and CHX+HA+ADS mouthrinses were provided in identical, masked containers numbered according to the randomization sequence.|Single-center, parallel-arm, triple-blind, randomized controlled clinical trial|t|f|t|t
34128773|NCT04187248|||COHORT||OTHER|||||||
34128774|NCT02931409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128775|NCT00243945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128776|NCT01525862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128777|NCT01654874|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34128778|NCT04910386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128779|NCT00213343|||CASE_CONTROL||PROSPECTIVE|||||||
34128780|NCT01097096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128781|NCT02018484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128782|NCT01645774|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|t|f|f
34128783|NCT01487538|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34128784|NCT04172350|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The principal investigator will generate the randomisation number and randomisation sequences according to the block randomisation method. The randomly generated sequences would be used for recruitment of the participants, who will be assigned in successive order according to the sequence. Opaque and sealed envelopes containing slips of paper indicate the randomly allocated group. One research assistant will recruit participants and conduct randomisation and another research assistant who is blind from the group allocation will collect post-test data. Through these carefully deliberated processes, randomization and allocation concealment will be ensured.|A two-group pre- and post-test randomized controlled trial will be conducted. A total of 112 eligible women who are diagnosed with breast cancer and are required for breast surgery will be recruited from the Breast Department in a public tertiary hospital in Singapore. Participants will be randomly allocated to either the intervention group (receiving routine care provided by the hospital plus iCareBreast) or the control group (only receiving routine care provided by the hospital) using a block randomisation.|f|f|f|t
34128785|NCT03167788|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34128786|NCT04130438|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128787|NCT05596539|||COHORT||OTHER|||||||
34128788|NCT01279811|NA|SINGLE_GROUP||OTHER||NONE||||||
34128789|NCT01901614|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128790|NCT00003730|RANDOMIZED|||TREATMENT||||||||
34128791|NCT04741412|||COHORT||PROSPECTIVE|||||||
34128792|NCT02522429|NA|SINGLE_GROUP||TREATMENT||NONE||15 acute DOC patients and 15 chronic DOC patients.||||
34128793|NCT04159402|||CASE_CONTROL||PROSPECTIVE|||||||
34128794|NCT04892472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128795|NCT02402803|||COHORT||PROSPECTIVE|||||||
34128796|NCT00787839|||COHORT||CROSS_SECTIONAL|||||||
34128797|NCT03198091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128798|NCT06339086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128799|NCT06513741|NA|SINGLE_GROUP||OTHER||NONE||||||
34128800|NCT00302744|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Within-subject cross-over study. Each participant received active drug and active placebo on separate dates.|t|t|t|t
34128801|NCT03375086|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multi-center, dose escalation.||||
34128802|NCT04792788|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128803|NCT06170190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128804|NCT04499027|||COHORT||PROSPECTIVE|||||||
34128805|NCT04120246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128806|NCT05737446|||COHORT||PROSPECTIVE|||||||
34128807|NCT04808791|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm, interventional study combining Irinotecan, Trifluridine/Tipiracil (TAS-102), and Oxaliplatin (iTTo)||||
34128808|NCT01720875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128809|NCT01008761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128810|NCT01147159|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Skin prick test of extracts of allergens in 4 tenfold dilutions.||||
34128811|NCT06289387|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34128812|NCT00940290|RANDOMIZED|PARALLEL||||NONE||||||
34128813|NCT00395499|||||PROSPECTIVE|||||||
34128814|NCT04716686|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128815|NCT06093269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128816|NCT00480831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128817|NCT02544035|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33822993|NCT02391116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128818|NCT00817323|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34128819|NCT05254236|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34128820|NCT06315972|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128821|NCT04922853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128822|NCT00472654|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128823|NCT01104402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128824|NCT04820062|||OTHER||PROSPECTIVE|||||||
34128825|NCT06525688|||CASE_CONTROL||RETROSPECTIVE|||||||
33822994|NCT04369664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33822995|NCT06434545|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33822996|NCT04131699|||COHORT||PROSPECTIVE|||||||
34128826|NCT06181838|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34128827|NCT00822445|||COHORT||CROSS_SECTIONAL|||||||
34128828|NCT05695794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||experimental group and control group||||
34128829|NCT02777359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128830|NCT01737983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128831|NCT05094063|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||This research was planned as an experimental randomized controlled trial. Randomization will be done using a computer program. With the computer program (www.randomizer.org), the participants will be divided into 2 subgroups (group 1: patient education group; group 2: patient education group not provided). With the randomization program, the order of the experimental and control groups will be provided.||||
34149357|NCT03038893|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Single Blind Masking||f|f|t|f
34149358|NCT02850900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34149359|NCT01554514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149360|NCT00065806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34149361|NCT00464659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33822997|NCT06045871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33822998|NCT01116453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33822999|NCT01189370||SEQUENTIAL||TREATMENT||NONE||||||
33823000|NCT05360199|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|patients are unaware whether they are in the intervention or control group||t|f|f|f
33823001|NCT02580981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823002|NCT04868981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823003|NCT01278511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823004|NCT01021202|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823005|NCT01138137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823006|NCT02266589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823007|NCT01396733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823008|NCT04398355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823009|NCT06013982|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823010|NCT04864236|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33823011|NCT00460577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823012|NCT03267069|||COHORT||PROSPECTIVE|||||||
33823013|NCT05990075|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The primary goal of the study is feasibility and acceptability of methods.|The study employs a single group design given its focus on feasibility and acceptability.||||
33823014|NCT04104724|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823015|NCT06584565|||COHORT||PROSPECTIVE|||||||
33823016|NCT06645626|||COHORT||PROSPECTIVE|||||||
33823017|NCT03377283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823018|NCT03343288|NA|SINGLE_GROUP||PREVENTION||NONE||In this study, hip joint prostheses, intramedullary nails and external fixator implants to be used in 30 patients . CE marked, domestic manufactured standard orthopedic implants will be used in patients after silver doped HA coating . Antimicrobial effectiveness of the coating will be evaluated. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.||||
33823019|NCT00447629|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE||||||
33823020|NCT06175182|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823021|NCT03152500|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823022|NCT05160402|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Cohorts 1-6 will receive IGM-6268 or placebo. Subjects and Investigators will be blinded.|Subjects will be randomized to receive intranasal and intraoral administration of IGM-6268 or placebo at the assigned doses. Cohorts will be enrolled sequentially.|t|f|t|f
33823023|NCT02031029|||COHORT||PROSPECTIVE|||||||
33823024|NCT00556764|NA|SINGLE_GROUP||SCREENING||NONE||||||
33823025|NCT00884884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823026|NCT01924806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823027|NCT02679079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823028|NCT02581137|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33823029|NCT01971424|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823030|NCT00759681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823031|NCT06646185|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A three-period crossover trial will study the effects of short-term use of 3 menstrual products (menstrual pad, tampon, menstrual cup) on the bacterial composition of the vaginal microbiome in three countries (Peru, Cameroon, and Switzerland). Each crossover period consists of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of 6 exposure sequences (different order of products per sequence); in each sequence, participants will adopt each menstrual product for 2 menstrual cycles. Participants will provide vaginal microbiome samples via self-sample swabs at 3 points during each menstrual cycle. Given the crossover design of the study, there is not a dedicated control group. No wash-out period is included because participants can not stop the use of menstrual products to manage their menstruation.||||
33823032|NCT03157687|||CASE_CONTROL||PROSPECTIVE|||||||
33823033|NCT04088136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823034|NCT00023621|RANDOMIZED|||PREVENTION||DOUBLE||||||
33823035|NCT01346826|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823036|NCT00900471|||CASE_ONLY||OTHER|||||||
33823037|NCT02389725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33823038|NCT00722488|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823039|NCT03263104|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double Blind (Participant, Investigator,Outcomes Assessor)|Single-centre, prospective, randomised, placebo-controlled, parallel-group design to determine the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults|t|f|t|t
33823040|NCT05325658|||OTHER||PROSPECTIVE|||||||
33823041|NCT04833842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In the study, the single blinding method, in which the participants are blinded, will be used. A placebo-controlled approach will be used in the control group (website training group) so that the participants in the groups do not know which group they are in. In the research, the statistician who also evaluates the outputs and performs data analysis will be blinded.|This study is a randomized controlled trial.|t|f|f|t
33823042|NCT03364283|||COHORT||PROSPECTIVE|||||||
33823043|NCT01202383|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823044|NCT05521555|||COHORT||RETROSPECTIVE|||||||
33823045|NCT02944526|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823046|NCT01048983|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33823047|NCT06117761|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33823048|NCT01116414|||COHORT||PROSPECTIVE|||||||
33823049|NCT04421118|||COHORT||PROSPECTIVE|||||||
33823050|NCT06182124|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Parallel Assignment|t|f|t|t
33823051|NCT03030053|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33823052|NCT01789541|||CASE_CONTROL||PROSPECTIVE|||||||
33823053|NCT06643884|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33823054|NCT02824029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823055|NCT02380885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33823056|NCT02373605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33823057|NCT00375583||||TREATMENT||||||||
33823058|NCT06127966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823059|NCT03973047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|BMT will be administered in an open-label manner. Administration of Zofran or placebo will be double-blinded using an over-encapsulation (OE) technique . The randomization assignments and code will not be provided to the Sponsor, sites, or subjects until the study database has been locked, except as unblinding is required for non-study personnel in the regulatory reporting of serious adverse events (SAEs) or for other safety-related reasons.||t|t|t|t
33823060|NCT02990299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A 2-arm, parallel, randomized controlled trial. Patients are randomized 1:1 to (1) mHealth diabetes adherence support intervention for one year and monitored with usual care for the second year, or (2) wait-list usual care for one year, then intervention during the second year.||||
33823061|NCT04501978|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823062|NCT04608006|||COHORT||PROSPECTIVE|||||||
33823063|NCT06575998|RANDOMIZED|PARALLEL||TREATMENT||NONE||The cluster randomization trial involves two randomization procedures. Firstly, on primary care practice level, practices will be randomized to intervention practice or control practice. Secondly, patients in the intervention practices will be randomized to pro-active identification or no identification. Pro-actively identified insomnia patients will be reported back to the PCP.||||
33823064|NCT01678898|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823065|NCT03327051|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33823066|NCT03229096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823067|NCT04337034|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants will be randomly assigned to participate in F@ce 2.0 (IG) or a control group (CG) receiving usual rehabilitation at two different sites; both an urban (IG+CG) and rural site (CG+IG) in Uganda|f|f|f|t
33823068|NCT02461719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823069|NCT03538223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33823070|NCT06645652|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823071|NCT05955365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823072|NCT01075100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823073|NCT04332367|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823074|NCT02534129|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33823075|NCT00169585|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33823076|NCT01372735|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823077|NCT04127383|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of healthcare providers and patients is not possible due to the nature of the intervention, but the study team will be blind to treatment arms in the data set during data cleaning, handling of missing data, statistical analyses and drawing of conclusions.|Pragmatic clustered quasi-experimental study|f|f|f|t
33823078|NCT05595369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind|As part of screening, potential participants will answer symptom questions. Eligible participants will then complete relevant Symptom Cluster assessments at the Screening visit. Participants will subsequently be assigned to one of the three Symptom Clusters based on the assessments. Participants must meet certain criteria within a specific symptom cluster in order to be included in the cluster. After study enrollment and initial cluster assignment, further assessments will be performed. Participants will undergo assessments for the symptom clusters for which the participants qualify.|t|t|t|f
33823079|NCT03273283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823080|NCT04656860|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Both the investigator and the participants will be blinded to study conditions|Participants will be randomized to experimental or placebo controlled condition|t|f|t|f
33823081|NCT05411471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823082|NCT04692129|||COHORT||PROSPECTIVE|||||||
33823083|NCT01502202|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33823084|NCT04361916|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||single arm, open label trial on active home monitoring strategy||||
33823085|NCT05201170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All individuals involved in the conduct of the study, and the enrolled patients, will remain masked to the randomized study treatment assignments until the database is unmasked.|Patients will be randomized 1:1 to either the PL9643 treatment group or to the vehicle control group.|t|t|t|t
33823086|NCT02040545|||CASE_ONLY||PROSPECTIVE|||||||
33823087|NCT02238691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823088|NCT03806283|||COHORT||PROSPECTIVE|||||||
33823089|NCT04230993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823090|NCT01789229|||CASE_CONTROL||OTHER|||||||
33823091|NCT03942783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The Investigators will remain blinded to group allocation until the participant has completed and returned their baseline questionnaire, and the data verified at the Lancashire CTU.~Data co-ordination staff at the CTU, who will be responsible for contacting patients to obtain missing data from 6- and 12-month questionnaires will be blinded to group allocation. The Data Manager and Information Systems team will be unblinded.~Due to the nature of the intervention it will not be possible for therapists to be blinded to group allocation. Participants cannot be blinded to the intervention they receive.~The statistician will be blinded to group allocation by using a dummy variable for group allocation until analysis is complete. The health economist will not be blinded as the costs of WORKWELL will need to be included into the analysis."|"The WORKWELL trial is a definitive, pragmatic, patient-blinded, multi-centre superiority randomised parallel group trial of: a) WORKWELL compared to b) written work self-help advice in people with RA, UIA or PsA. Both groups will continue to receive usual care. The primary endpoint is the summed score of the Work Limitations Questionnaire-25 (a measure of work presenteeism) at 12 months after baseline assessment.~2022 update: An extension to the study had been approved to complete a 36 month follow-up."|f|f|t|t
33823092|NCT02660034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823093|NCT00728884|||COHORT||PROSPECTIVE|||||||
33823094|NCT05234645|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33837368|NCT03394131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837369|NCT02865551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837370|NCT06049368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837371|NCT03670251|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837372|NCT00776906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823095|NCT06159933|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Historic cohort enrolled between January 2020 and December 2021; Prospective enrollment from January 2022 to April 2023. According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group). On the contrary, starting from January 2022 our local protocol was updated and all LT recipients developing PGD \>1 were routinely turned prone within 24 hours after the diagnosis ('early PP').Patients were placed in PP for at least 16 hours before being turned back to the supine position when meeting predefined criteria previously published by Guèrin et al.||||
33823096|NCT01992302|||COHORT||PROSPECTIVE|||||||
33823097|NCT05335005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823098|NCT02988245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823099|NCT05558098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823100|NCT05009147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33823101|NCT04106336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823102|NCT06645899|||COHORT||OTHER|||||||
33823103|NCT05698511|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823104|NCT04127578|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33823105|NCT03967093|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Part 1 dose escalation - sequential cohorts of patients will be treated with escalating doses of BXQ-350 until the maximum tolerated dose (MTD) is established, or in the absence of a maximum administered dose, the highest planned dose level.~Part 2 - patients will be enrolled and administered BXQ-350 at the Part 1 MTD or at the highest planned dose level"||||
33823106|NCT00132925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823107|NCT02375438|||COHORT||PROSPECTIVE|||||||
33823108|NCT02005029|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33823109|NCT02982070|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823110|NCT04410003|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Patients and persons involved in the followup and assessment of the participants will be blinded to the randomized assignment.|Randomized controlled trial|t|t|t|t
33823111|NCT01730261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823112|NCT01545622|||OTHER||RETROSPECTIVE|||||||
33823113|NCT04667442|||OTHER||CROSS_SECTIONAL|||||||
33823114|NCT06538142|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical assessments after 48 horas as well as four, eight and twelve months after treatment (follow-up) will be performed by an examiner blinded to allocation (single-blind study).||f|f|f|t
33823115|NCT05375383|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A staff member not part of the study group will be assigned to distribute blinded samples. The participant or the investigators will not be aware of the dose groups.|"Participants will be randomly assigned to one of the 12 groups consuming powder or lozenges containing Streptococcus salivarius K12 or S. salivarius M18 with or without prebiotic:~Probiotic S. salivarius K12 lozenges Probiotic S. salivarius K12 lozenges containing prebiotic A Probiotic S. salivarius K12 lozenges containing prebiotic B Probiotic S. salivarius K12 lozenges containing prebiotic A and B~Probiotic S. salivarius K12 powder Probiotic S. salivarius K12 powder containing prebiotic A Probiotic S. salivarius K12 powder containing prebiotic B Probiotic S. salivarius K12 powder containing prebiotic A and B~Probiotic S. salivarius M18 lozenges Probiotic S. salivarius M18 lozenges containing prebiotic A Probiotic S. salivarius M18 lozenges der containing prebiotic B Probiotic S. salivarius M18 + lozenges containing prebiotic A and B"|t|f|t|f
33823116|NCT02411214|||COHORT||PROSPECTIVE|||||||
33823117|NCT04987034|||COHORT||PROSPECTIVE|||||||
33823118|NCT06445361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823119|NCT05267249|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823120|NCT03467997|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33823121|NCT03135821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Placebo vs Traditional Chinese Medication (TCM) Drug A,B,C,D|t|f|t|t
33823122|NCT06457347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823123|NCT04063878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823124|NCT05744557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823125|NCT02404012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823126|NCT04440514|||COHORT||PROSPECTIVE|||||||
33823127|NCT03939416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33823128|NCT00527514|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823129|NCT06095518|||COHORT||PROSPECTIVE|||||||
33823130|NCT05354726|||CASE_CONTROL||PROSPECTIVE|||||||
33823131|NCT06258447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind including study participants and care provider (investigator) conducting outcomes assessments|Controlled study of study treatment consisting of intramyocardial autologous cell injections compared to sham control, both performed in cardiac catheterization|t|t|t|t
33823132|NCT00006137||||TREATMENT||||||||
33823133|NCT05048407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823134|NCT00702338|||OTHER||PROSPECTIVE|||||||
33823135|NCT00683514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823136|NCT00348283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823137|NCT00468884|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823138|NCT05022927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823139|NCT03551197|NA|SINGLE_GROUP||TREATMENT||NONE||There is only one group.Patients with diagnosis of Chronic Obstructive Pulmonary Disease are recruited.Subjects will be examined at baseline and after 3 months' treatment of budesonide and formoterol.||||
33823140|NCT01316809|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823141|NCT04934878|||OTHER||OTHER|||||||
33823142|NCT06645639|||OTHER||PROSPECTIVE|||||||
33823143|NCT05773209|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33823144|NCT05021965|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|f|t
33823145|NCT06632834|NA|SINGLE_GROUP||TREATMENT||NONE||"1. A retrospective and prospective cohort study will be conducted. Patients diagnosed with DCM below the age of 35 years from 1990 to 2019 will be enrolled. Medical records will be reviewed. A 3-stage genetic testing will be performed after informed consent.~2. An open-labeled, exploratory study of simvastatin on the cardiac function of DCM patients will be conducted."||||
33823146|NCT05680415|RANDOMIZED|PARALLEL||PREVENTION||NONE||The experimental group and the blank control group were randomly assigned in a ratio of 1:1.||||
33823147|NCT01502371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823148|NCT00678899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823149|NCT02894385|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33823150|NCT06363877|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33823151|NCT04457245|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33823152|NCT02269033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823153|NCT06269796|||OTHER||PROSPECTIVE|||||||
33823154|NCT04795076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823155|NCT06645496|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823156|NCT01249768|||COHORT||PROSPECTIVE|||||||
33823157|NCT00067925|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823158|NCT00102271||||TREATMENT||||||||
33823159|NCT02213224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823160|NCT03282877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33823161|NCT04979234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823162|NCT06096376|||COHORT||PROSPECTIVE|||||||
33823163|NCT06222034|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823164|NCT01841645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823165|NCT04883541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|For Randomization, when the experiment and control group were created, support was received from pregnancy school instructors and groups, and pregnant women were determined by using the method of envelope selection. Pregnancy school instructors asked the group volunteering to participate in the study to independently choose one of two blue or red colored envelopes. Those who chose the blue envelope formed the experiment group, and those that chose the red envelope were taken into the control group. The envelope selection process continued until the desired numbers were reached. The researcher was told advised of the groups to which subjects were included by the pregnancy school instructor only after the subjects were chosen.|The present study was conducted as a randomized controlled study.|t|f|t|t
33823166|NCT00411463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823167|NCT01740999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823168|NCT04188119|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Laboratory staff and the unblinded statistician ill remain blinded to trial treatment|"Patients will be randomly assigned to one of two arms:-~* 21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)~* 21 patients into Arm B: Avelumab + Aspirin + PPI"|f|f|f|t
33823169|NCT01509599|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33823170|NCT04658771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823171|NCT04998084|||COHORT||PROSPECTIVE|||||||
33823172|NCT04158453|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33823173|NCT00877188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33823174|NCT06141694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823175|NCT02328209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823176|NCT00866125|||CASE_ONLY||CROSS_SECTIONAL|||||||
33823177|NCT04769895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823178|NCT04183803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823179|NCT01615107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823180|NCT00730210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823181|NCT04787718|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33823182|NCT00948103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823183|NCT02767596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823184|NCT01828476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823185|NCT03666013|||OTHER||CROSS_SECTIONAL|||||||
33823186|NCT02504502|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|participants do not know whether they are in the intervention (enhanced report) or control (routine clinical care with delayed access to the enhanced report) arm|"intervention = routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study.~Control with delayed intervention = routine clinical care for return of results per whole genome sequencing study with crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report"|t|f|f|f
33823187|NCT05115877|||OTHER||RETROSPECTIVE|||||||
33823188|NCT03075111|||COHORT||RETROSPECTIVE|||||||
33823189|NCT04414254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||An open-label, randomized, single-dose, two-period, two-group, crossover study.||||
33823190|NCT00692445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823191|NCT06285227|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33823192|NCT03302871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33823193|NCT06430671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part A is an open label Phase I trial Part B is randomized, dose-blinded Phase II trial|Individual patients will be assigned to three parallel dose groups. In Part A patients will be allocated in the low, medium, high dose group according to the order of recruitment. In Part B patients will be randomized in a ratio 1:1:1 into one of the three dosing groups.|t|t|t|t
33823194|NCT00433498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823195|NCT02470975|||FAMILY_BASED||PROSPECTIVE|||||||
33823196|NCT05433311|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients included in the treatment group had 15 sessions. Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises will be done face-to-face with a physiotherapist. At the end of the 15 sessions of face-to-face training the patients will be perform the same exercises at home for 15 days. The patients will not given any exercises in the control group. Measurements and evaluations of the patients in the both groups will be made three that pre-treatment, post-treatment, 15 days after the end of treatment.||||
33823197|NCT05664126|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33823198|NCT05028153|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823199|NCT01704859|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|Double Blind||t|f|t|t
33823200|NCT01424176|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823201|NCT06584942|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is an open-label, single-group pilot study.||||
34128832|NCT03621072|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is an open-label, randomized, single-dose, 2-way crossover bioequivalence study under fasted and fed conditions in healthy Chinese subjects. Under each condition, subjects will be randomized to one of the 2 treatment sequences. Each treatment sequence will consist of 2 periods, separated by a washout period of at least 14 days between each period. For sequence 1, first localized originator and then originator will be administered. The order for sequence 2 is originator and localized originator.||||
34128833|NCT02782351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128834|NCT05989672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Click here to enter text.||t|t|t|t
34128835|NCT03233139|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34128836|NCT05497739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128837|NCT06237712|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Single-center, placebo-controlled double-blind randomized crossover study.|t|t|t|f
34128838|NCT01496053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128839|NCT00002108||||TREATMENT||NONE||||||
34128840|NCT01680354|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128841|NCT04575545|||COHORT||PROSPECTIVE|||||||
33823202|NCT01812837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128842|NCT00154817|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128843|NCT03840044|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Healthy volunteers will be compared with asthmatic subjects||||
34128844|NCT06006715|||COHORT||PROSPECTIVE|||||||
34128845|NCT04189302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128846|NCT04965792|||COHORT||PROSPECTIVE|||||||
34128847|NCT05400850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128848|NCT05088434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded placebo-controlled study|Double-blinded placebo-controlled study|t|t|t|f
34128849|NCT00742222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128850|NCT04625400|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128851|NCT02337101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128852|NCT01883622|||COHORT||RETROSPECTIVE|||||||
34128853|NCT02812576|||CASE_ONLY||PROSPECTIVE|||||||
34128854|NCT05330390|||CASE_ONLY||RETROSPECTIVE|||||||
34128855|NCT00135330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128856|NCT04777006|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Those who are screening and diagnosing depression will not be made aware of the randomization sequence. Likewise, those assessing outcomes will not be made aware of the randomization sequence.|Stepped wedge cluster randomized trial|f|t|f|t
34128857|NCT03169868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34128858|NCT04346186|||COHORT||PROSPECTIVE|||||||
34128859|NCT05559905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128860|NCT06417827|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128861|NCT00818402|||CASE_ONLY||PROSPECTIVE|||||||
34128862|NCT01302626|||COHORT||PROSPECTIVE|||||||
33823203|NCT01369147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33823204|NCT02728947|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823205|NCT03904888|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33823206|NCT03258099|||COHORT||OTHER|||||||
33823207|NCT04149587|||COHORT||PROSPECTIVE|||||||
33823208|NCT00116584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33823209|NCT02376322|NA|SINGLE_GROUP||TREATMENT||NONE||Radiotherapy||||
33823210|NCT04611048|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Healthy volunteers will be tested in this study, in order to establish normative values for the new procedure (psi method)||||
33823211|NCT02580019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823212|NCT05834972|||CASE_ONLY||PROSPECTIVE|||||||
34128863|NCT00196794|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128864|NCT04077489|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128865|NCT01814865|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128866|NCT04685980|||CASE_CONTROL||RETROSPECTIVE|||||||
33823213|NCT05904288|||COHORT||PROSPECTIVE|||||||
33823214|NCT06641128|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823215|NCT05502861|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE||stepped-wedge cluster (at hospital-level) randomized trial|t|f|t|t
33823216|NCT01847599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823217|NCT00103116|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823218|NCT03086070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double blind, placebo controlled trial|t|t|t|t
33823219|NCT03862105|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33823220|NCT05472636|||CASE_ONLY||RETROSPECTIVE|||||||
33823221|NCT03016364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823222|NCT02341599|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128867|NCT05948904|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128868|NCT00130104|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34128869|NCT03882437|NA|SEQUENTIAL||TREATMENT||NONE||"Evaluation of RP-A501 in pediatric patients (ages 8-14) will commence only pending determination of safety in the older (adult and age 15-17) population.~In Phase 1, RP-A501 will be investigated in three treatment cohorts, as follows with a single cohort currently recruiting:~Cohort 1: Adult and age 15-17: 6.7 × 1013 GC/kg (n=3-4)~Cohort 2: Adult and age 15-17: 1.1 × 1014 GC/kg (n=2 \[patients already treated; closed for current enrollment\])~Cohort 1A: Pediatric age 8-14: 6.7 × 1013 GC/kg (n=2-4)"||||
34128870|NCT05971992|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34128871|NCT00245453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128872|NCT03138551||SEQUENTIAL||TREATMENT||NONE||Single-Case Experimental Design||||
34128873|NCT05648877|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34149362|NCT06435585|||COHORT||PROSPECTIVE|||||||
34149363|NCT00562042|||COHORT||PROSPECTIVE|||||||
34149364|NCT04190524|NA|SINGLE_GROUP||OTHER||NONE||||||
34149365|NCT00418587|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149366|NCT01908439|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149367|NCT01237379|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34149368|NCT01387724|||COHORT||PROSPECTIVE|||||||
34149369|NCT02498990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823223|NCT02908412|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33823224|NCT02706834|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33823225|NCT05653609|||COHORT||RETROSPECTIVE|||||||
33823226|NCT01020487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823227|NCT00776984|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823228|NCT05294328|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Multicenter, double-masked, randomized, crossover, active and vehicle-controlled, safety and effectiveness study|t|t|t|f
33823229|NCT00192166|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33823230|NCT01233492||||TREATMENT||NONE||||||
33823231|NCT04021147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823232|NCT05657275|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Chronological series in alternating periods, that is to say alternations of periods of more or less short duration, with and without intervention corresponding to a repetition of before/after studies will be carried||||
33823233|NCT01605435|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33823234|NCT06146088|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33823235|NCT00004740|RANDOMIZED|||PREVENTION||NONE||||||
33823236|NCT05814679|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33823237|NCT06645769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33823238|NCT05942573|NA|SINGLE_GROUP||TREATMENT||NONE||Serplulimab||||
33823239|NCT04061317|||COHORT||PROSPECTIVE|||||||
33823240|NCT01436604|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33823241|NCT03106337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823242|NCT06395909|||COHORT||RETROSPECTIVE|||||||
33823243|NCT00003402||||TREATMENT||||||||
33823244|NCT03809806|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with vaginal stump prolapse who had undergone hysterectomy in the past||||
33823245|NCT05208593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823246|NCT02801500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823247|NCT02768077|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823248|NCT04764864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823249|NCT01440699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823250|NCT06468462|RANDOMIZED|PARALLEL||OTHER||SINGLE|Aptima Combo 2 testing for NG and CT will be conducted in Mombasa on a Hologic Panther platform by experienced laboratory staff blinded to randomization assignment.|"The proposed study is an open-label randomized controlled trial with a hybrid type 1 implementation-effectiveness component comparing each intervention (i.e., STI PPT, doxyPEP) to a common control in a 2:2:1 ratio.~Approach for objective 1: We will conduct an open-label randomized clinical trial with 2900 participants to evaluate these two interventions versus the standard of care assigned in a 2:2:1 ratio, with 18 months of follow-up and rigorous culture-based and molecular analysis of AMR in NG at three MSM-friendly research clinics in Kenya.~Approach for objective 2: We will use multidisciplinary science to measure the acceptability, feasibility, and safety of these two interventions, using a conceptual model based on Proctor's Implementation Science Framework.~Approach for objective 3: Aim 1 and 2 results will inform parameters to update a stochastic model of STI transmission and cost-effectiveness analysis to project the impact of scaled-up STI PPT and doxyPEP in Kenya."|f|f|f|t
33823251|NCT05065164|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823252|NCT05752383|||CASE_ONLY||PROSPECTIVE|||||||
33823253|NCT01887418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823254|NCT05923359|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33823255|NCT05012280|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823256|NCT04383834|||OTHER||PROSPECTIVE|||||||
33823257|NCT04134455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and investigator are masked|Clinical trial of non-inferiority|t|f|t|f
33823258|NCT05026242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823259|NCT03800264|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|BLINDED|DOUBLE BLINDED RANDOMIZED STUDY|t|f|f|f
33823260|NCT03219476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823261|NCT01516606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823262|NCT01542749|||COHORT||PROSPECTIVE|||||||
33823263|NCT02864342|RANDOMIZED|PARALLEL||||NONE||||||
33823264|NCT05971147|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|All participants will take part in the same intervention, which will be fully disclosed to each participant.|Single-arm 5g per day of omega-3 fatty acid intake (3750 mg EPA and 1250 mg DHA)||||
33823265|NCT02160561|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823266|NCT05800483|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33823267|NCT02028234|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33823268|NCT05144802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823269|NCT06328725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The investigational drug for the clinical trial of the following cohort or group will be administered intravenously (IV) three times at 6-week intervals.~\<Phase 1 Clinical Trial\> Cohort 1: EN001 5.0x10\^5 cells/kg / Cohort 2: EN001 2.5x10\^6 cells/kg~\<Phase 2 Clinical Trial\> Experimental Group: Recommended Phase 2 Dose (RP2D) for EN001 / Control Group: Placebo for EN001"|"\<Phase 1 Clinical Trial\> A total of 6-12 participants (3-6 participants per cohort).~\<Phase 2 Clinical Trial\> A total of 76 participants (a minimum of 30 participants per group, considering a dropout rate of 20%, resulting in 38 participants per group)."|t|f|t|f
33823270|NCT03121729|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive enhanced recovery after surgery programs.||||
33823271|NCT05620654|NA|SINGLE_GROUP||TREATMENT||NONE||Bayesian Optimal Interval Design||||
33823272|NCT05098197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823273|NCT00612716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823274|NCT05854056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33823275|NCT00273351|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823276|NCT05562583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823277|NCT06115239|||CASE_ONLY||PROSPECTIVE|||||||
33823278|NCT03635775|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and families will be masked to intervention group. The research team members performing assessments will be masked to intervention group.||t|f|f|t
33823279|NCT00240097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823280|NCT04774783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837373|NCT00003485|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128874|NCT05156437|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Postoperative patients who have undergone valvar repair or replacement for IVDA endocarditis will be randomized into two arms: Experimental: 2 weeks of postoperative inpatient IV antibiotic therapy followed by 4 weeks of oral therapy with outpatient follow-up; Control: conventional 2 weeks of postoperative inpatient IV antibiotic therapy followed by 4 weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).~Both groups will receive aggressive drug rehabilitation with mandatory participation in a formal psychiatric rehabilitation program for a minimum of 6 weeks (combined inpatient and outpatient), will be followed by Infectious Disease, will undergo monitoring of treatment efficacy with serum antibiotic levels, will undergo surveillance monitoring of treatment efficacy with blood cultures, will participate in a compliance tracking tool for medication administration (e.g. a centrally managed core site mobile Medisafe compliance program."||||
34128875|NCT02641756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128876|NCT04548700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128877|NCT03235453|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||Randomized clinical trial, two arm study (group 1 - Binary Rhythm; group 2 - Quaternary Rhythm|t|f|t|f
34128878|NCT03075280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128879|NCT01624961|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128880|NCT03556670|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be aware that they're part of a study, but will be masked as to whether their worksite is an intervention or control site.|There are two study conditions: intervention and control. Organizations will be randomized to conditions.|t|f|f|f
34128881|NCT05909033|||COHORT||RETROSPECTIVE|||||||
34128882|NCT02924259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128883|NCT02951234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128884|NCT04805476|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34128885|NCT02676648|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34128886|NCT02075294|||COHORT||RETROSPECTIVE|||||||
34128887|NCT00293228|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34128888|NCT05079802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34128889|NCT02748252|||COHORT||PROSPECTIVE|||||||
34128890|NCT03520296|||OTHER||PROSPECTIVE|||||||
34128891|NCT02976649|||COHORT||RETROSPECTIVE|||||||
34128892|NCT02044224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128893|NCT04317339|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128894|NCT05096975|||COHORT||RETROSPECTIVE|||||||
34128895|NCT00272831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128896|NCT05695040|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128897|NCT00778076|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128898|NCT03582046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128899|NCT02231398|||COHORT||PROSPECTIVE|||||||
34128900|NCT02341768|||COHORT||PROSPECTIVE|||||||
34128901|NCT03398941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823281|NCT04958434|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Part A - Q3w 3+3 design dose escalation Part B - Dose expansion of approximately 30 patients||||
34128902|NCT03226249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128903|NCT02882438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128904|NCT00122616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128905|NCT04239261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34128906|NCT03098433|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||double blind, crossover|t|t|t|f
34128907|NCT02649920|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128908|NCT04945473|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34128909|NCT05017389|||COHORT||PROSPECTIVE|||||||
34128910|NCT02788032|NA|SINGLE_GROUP||||NONE||||||
33823282|NCT05879991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823283|NCT04747847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823284|NCT05021757|||COHORT||PROSPECTIVE|||||||
33823285|NCT00176969|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34128911|NCT01390298|||COHORT||PROSPECTIVE|||||||
34128912|NCT04741841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Pre-masked randomized vegan capsules with probiotic GutMagnific in 2 different doses, or corresponding placebo"||t|t|t|f
34128913|NCT04738994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128914|NCT00220155|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128915|NCT01184703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128916|NCT03715140|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128917|NCT03748706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823286|NCT01657071|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34128918|NCT03271216|||COHORT||RETROSPECTIVE|||||||
34128919|NCT02680938|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34128920|NCT05205616|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and providers assessing postoperative nerve functioning are blinded to which side of the mandible received which intervention|A matched-pair (with-in person) RCT design will be used, wherein one mandibular side (right versus left) in each patient will be randomized to be treated with Sonopet ultrasonic device (with the remaining side being treated with reciprocating saw). Neurosensory impairment, as herein described, will be compared at various post-operative times for a total follow-up of 3 months for each patients. Patients and the researchers examining patients post-operatively will be blinded.|t|f|f|t
34128921|NCT03441022|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128922|NCT00566553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128923|NCT04830306|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||All subjects will be asked to complete the three exercise tests||||
34128924|NCT03763695|||CASE_CONTROL||OTHER|||||||
34128925|NCT03587428|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34149370|NCT04872998|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823287|NCT02411253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823288|NCT04712786|||OTHER||RETROSPECTIVE|||||||
33823289|NCT01523028|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33823290|NCT03747159|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multi-center||||
33823291|NCT05004805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Randomization by phone|Single-center, blind, randomized, controlled clinical trial.|f|f|f|t
33823292|NCT06338254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are blinded.||t|f|f|f
33823293|NCT02895854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823294|NCT00001219|||COHORT||PROSPECTIVE|||||||
33823295|NCT03359187|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Experimental design in 3 groups|t|t|f|t
33823296|NCT04362176|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Eligible participants will be randomized 1:1 to convalescent plasma versus lactated Ringer's solution with multivitamins. Randomization will be completed in permuted blocks and stratified by site, gender, and age. Participants, treating clinicians and outcomes assessors will all be blinded to study group assignment. Study personnel will not be blinded to the study group assignment.|t|t|f|t
33823297|NCT06289114|||COHORT||PROSPECTIVE|||||||
33823298|NCT02802579|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
33823299|NCT01868516|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823300|NCT00173342|||DEFINED_POPULATION||OTHER|||||||
33823301|NCT02302625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823302|NCT03235401|||CASE_ONLY||CROSS_SECTIONAL|||||||
33823303|NCT01164371|||COHORT||RETROSPECTIVE|||||||
33823304|NCT02264353|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33823305|NCT04636099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823306|NCT02068300|||CASE_ONLY||CROSS_SECTIONAL|||||||
33823307|NCT04834518|||COHORT||PROSPECTIVE|||||||
33823308|NCT00873678|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33823309|NCT00249847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823310|NCT04693650|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33823311|NCT05641025|||OTHER||RETROSPECTIVE|||||||
33823312|NCT02537236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823313|NCT01910922|||CASE_CROSSOVER||PROSPECTIVE|||||||
33823314|NCT05242913|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33823315|NCT05873816|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33823316|NCT01905371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823317|NCT04271514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823318|NCT05129371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Patients willing to participate in the study are evaluated according to the inclusion and exclusion criteria. Afterwards, they are divided into 3 groups with the stratified sampling method. The intervention group is given face-to-face breathing exercises under the supervision of the trainer, through video calls over the WhatsApp application after discharge. The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group, under the supervision of the trainer. Venous oxygen saturation, heart rate/minute and respiratory rate/minute are monitored by pulse oximetry given to the participants in the intervention and placebo groups before and after each session for 8 weeks. The severity of fatigue of the participants in all groups; It is measured before starting the application, in the middle of the application period (4th week) and after the application is completed (8th week).|t|f|f|t
33823319|NCT03925519|||OTHER||RETROSPECTIVE|||||||
33823320|NCT03207698|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823321|NCT02513979|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823322|NCT01181687|||CASE_ONLY||PROSPECTIVE|||||||
33823323|NCT00640042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823324|NCT04132388|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Subjects will be randomized to either standard-of-care or to an electronic reporting intervention.|This is a prospective single-center open-label randomized 6 month study. There will not be a washout period.|f|t|t|t
33823325|NCT04456049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823326|NCT05107999|RANDOMIZED|PARALLEL||TREATMENT||NONE||Zhizhu Kuanzhong (ZZKZ) group was treated with ZZKZ capsules with omeprazole. Antidepressant group was treated with doxepin with omeprazole.||||
33823327|NCT01083407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33823328|NCT05834361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33823329|NCT02367339|||||PROSPECTIVE|||||||
33823330|NCT00585208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823331|NCT04204317|||COHORT||PROSPECTIVE|||||||
33823332|NCT05364541|NA|SINGLE_GROUP||SCREENING||NONE||||||
33823333|NCT01359514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823334|NCT04545983|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"This is a fundamental research project in which a cohort of previously operated patients will be included. All of these patients were previously operated in the setting of an RCT an underwent ACD or ACDA for CDDD. In the RCT flexion and extension cinematographic recordings of the cervical spine were made before surgery, and at three months and one-year post-operatively.~This study investigates the long-term follow-up of this same study population. The average follow-up duration is 9 years (range 6-13 years). We make similar flexion and extension cinematographic recordings to assess the sequence of segmental contributions of the lower cervical spine years after ACD and ACDA surgery for CDDD. The sROM and level of degeneration will be assessed as a secondary outcome. Moreover, the long-term clinical outcomes will be assessed through questionnaires."||||
33823335|NCT05818137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823336|NCT00797186|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823337|NCT01878253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823338|NCT03887871|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823339|NCT04764877|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients were randomized to either standard of care/teaching at our Hilltop Primary Care Center Asthma clinic OR to standard of care/teaching PLUS one time osteopathic manipulation focusing on improving lung expansion.||||
33823340|NCT06114511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823341|NCT02245464|||COHORT||PROSPECTIVE|||||||
33823342|NCT01384825|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823343|NCT04380038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo group provides a reference for the interpretation of study results, so the net effect of dupilumab could be discerned.|Double-blind, Randomized study design.|t|t|t|t
33823344|NCT05545319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823345|NCT04620122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33823346|NCT06212934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823347|NCT01946529|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128926|NCT05441423|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|Blinding|Dry human skulls and dry human mandibles will be recruited from Anatomy Department, Faculty of Medicine, Cairo University. Human skulls and mandibles will be recruited according to the following eligibility criteria: inclusion criteria will be mandibles with sound condyles and skulls with sound glenoid fossa. Exclusion criteria will be skulls with fractured glenoid fossa, or glenoid fossa with developmental deformities, mandibles with fractured condylar neck or head, presence of pathological lesions, fracture, Shipping, or developmental deformities in the condyle.|f|f|t|t
34128927|NCT00196690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128928|NCT06514274|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128929|NCT06188598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blood tests and assays, DXA scans, body weight, vitals, etc. are performed by assessors blinded to the condition and aims of the study.|Randomized on 1:1 bases to time-restricted eating or unrestricted eating|f|f|f|t
34128930|NCT04217707|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Research participants will participate in the groups as usual, and after each of their first eight attended sessions, will be asked to fill out outcomes of interest again. Due to the possibility that participants may not attend eight group sessions, length of time for them to attend eight sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment||||
34128931|NCT03731104|||COHORT||PROSPECTIVE|||||||
34128932|NCT00369850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34128933|NCT01220401|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128934|NCT06064006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34128935|NCT02370368|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128936|NCT04729153|||CASE_CONTROL||RETROSPECTIVE|||||||
34128937|NCT00370461|||CASE_ONLY||PROSPECTIVE|||||||
34128938|NCT02104531|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34128939|NCT02777450|||COHORT||PROSPECTIVE|||||||
34128940|NCT02382731|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34128941|NCT06554561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128942|NCT04177615|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128943|NCT06287541|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Participants who meet the inclusion criteria are randomized 1:2 into two parallel groups. Group A: Participants assigned to this group will not undergo reTURBT. They will receive standard follow-up care as per institutional guidelines.~Group B: Participants assigned to this group will undergo reTURBT as part of their treatment protocol. Following reTURBT, they will also receive standard follow-up care. Outcome measures of recurrence rate and RFS would be compared between the two groups to determine the effectiveness and safety of the urine genetic test-guided approach compared to standard care with reTURBT.Throughout the study period, both groups are followed up simultaneously, allowing for parallel comparisons of outcomes."||||
34128944|NCT03012191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128945|NCT01925768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128946|NCT05711875|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This study was designed as a randomized controlled trial conducted with experimental and control groups (71 experimental group, 71 control group).|t|f|f|f
34128947|NCT05327998|||COHORT||PROSPECTIVE|||||||
34128948|NCT03757624|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128949|NCT02000024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128950|NCT04490213|||COHORT||PROSPECTIVE|||||||
34128951|NCT06121076|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34128952|NCT03760198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128953|NCT03173989|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128954|NCT04833660|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128955|NCT03936907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Sequence ABBA||||
34128956|NCT05737823|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Random allocation to the intervention and control conditions will be undertaken by an independent third party not involved with the research. Members of the research team will be blind to allocation to reduce selection bias.||f|t|f|t
34128957|NCT03078439|||COHORT||PROSPECTIVE|||||||
34128958|NCT02053922|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34128959|NCT02277249|RANDOMIZED|PARALLEL||||NONE||||||
34128960|NCT02536716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128961|NCT04206631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128962|NCT03577327|||COHORT||PROSPECTIVE|||||||
34128963|NCT00282087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128964|NCT00631124|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34128965|NCT05711706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34128966|NCT05034042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34128967|NCT01055717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34128968|NCT02674464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128969|NCT03027518|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33823348|NCT04382183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823349|NCT01961453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823350|NCT06212765|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823351|NCT03358303|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34128970|NCT03147378|RANDOMIZED|CROSSOVER||TREATMENT||NONE||After randomization eight patients will receive ModraDoc006/r in fasting condition week 1 and in fed condition week 2, and another eight patients will receive ModraDoc006/r in fed condition week 1 and in fasting condition week 2||||
34128971|NCT04248712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34128972|NCT04265248|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Single Blind||f|f|t|f
33823352|NCT05165303|NA|SINGLE_GROUP||TREATMENT||NONE|Mixtures of propofol, lidocaine and saline will be prepared by an anesthetist who is not involved in the study team, participants, investigator and anesthesia care giver will be blinded for the lidocaine concentration used.|clinical trial with a single arm||||
33823353|NCT00025545||||TREATMENT||NONE||||||
33823354|NCT04770246|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128973|NCT04047368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128974|NCT05124028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128975|NCT04644198|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128976|NCT04294940|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128977|NCT02079909|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128978|NCT01281384|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34128979|NCT02113423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34128980|NCT06467071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34128981|NCT01420224|||||PROSPECTIVE|||||||
34128982|NCT02782234|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34128983|NCT06200168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34128984|NCT01225133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128985|NCT04299828|||COHORT||PROSPECTIVE|||||||
34128986|NCT00148486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34128987|NCT01047917|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34128988|NCT03618771|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34128989|NCT00454740|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34128990|NCT01696799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34128991|NCT02446769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34128992|NCT04401150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the pharmacist of the participating site will be unblinded for the preparation of the study drug to be administered.|Randomized controlled trial|t|t|t|t
34128993|NCT03102515|RANDOMIZED|SEQUENTIAL||TREATMENT||||||||
34128994|NCT00394329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34128995|NCT04169204|||COHORT||PROSPECTIVE|||||||
34128996|NCT01315613|||CASE_CONTROL||PROSPECTIVE|||||||
34128997|NCT06123273|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34128998|NCT02689414|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patient, patient's physician, surgeon, anaesthesiologist and everyone else in the surgical team were blinded to study intervention. Blinding was attained with manometer's scale covered. Second arterial stiffness measurement was carried out by a study member who did not know the patient's group affiliation.||t|t|f|f
34128999|NCT03311581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129000|NCT04069949|NA|SINGLE_GROUP||TREATMENT||NONE||one-arm study||||
34129001|NCT02334072|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34129002|NCT01861704|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34129003|NCT02041390|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34129004|NCT01580709|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33823355|NCT01024036|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823356|NCT05765890|||COHORT||CROSS_SECTIONAL|||||||
33823357|NCT04528537|||COHORT||PROSPECTIVE|||||||
33823358|NCT05914155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823359|NCT00598858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823360|NCT03877952|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823361|NCT02860559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129005|NCT03125330|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34129006|NCT04875455|NA|SINGLE_GROUP||TREATMENT||NONE||"Study procedure guidelines~Patients who were previously treated with a premium IOL (Panoptix, POD FGF, POD F) are continuously included:~Retrospective:~Routine data collected up to the first study visit (preoperative, intraoperative and postoperative) are evaluated retrospectively~Prospective:~2-4 months postoperatively: refraction and vision, slit lamp and fundus examination, intraocular"||||
34129007|NCT01570517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129008|NCT00129090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129009|NCT01268540|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129010|NCT06343545|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Cluster crossover randomized trial||||
34129011|NCT06425913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants were unaware of their group assignments. A therapist who was unaware of the intervention protocol and assigned groups performed the assessment procedures||t|f|t|f
33823362|NCT06619210|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33823363|NCT02222532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823364|NCT03474042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823365|NCT02538471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129012|NCT05447390|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study includes 15 patients diagnosed with Pulmonary Hypertension in Gazi Medical School Hospital Department of Pediatric Cardiology and 40 healthy children who applied to Gazi University Medical School Pediatric Cardiology Clinic||||
33823366|NCT01336387|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129013|NCT01095991|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823367|NCT03456830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823368|NCT01940692|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34129014|NCT04661423|NA|SINGLE_GROUP||OTHER||NONE||||||
34129015|NCT00699946|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34129016|NCT03766464|||COHORT||PROSPECTIVE|||||||
34129017|NCT04285554|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study is a prospective, single-arm, multi-center, non-randomized trial||||
34129018|NCT05833308|||COHORT||RETROSPECTIVE|||||||
34129019|NCT04894019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34129020|NCT06027619|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129021|NCT00001033||||TREATMENT||||||||
34129022|NCT01139541|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34129023|NCT01279044|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129024|NCT04362800|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34129025|NCT04612829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129026|NCT00212875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129027|NCT02445729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129028|NCT02523092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129029|NCT05881486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129030|NCT03663569|||OTHER||PROSPECTIVE|||||||
34129031|NCT01639118|||COHORT||PROSPECTIVE|||||||
34129032|NCT01663766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129033|NCT01901289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129034|NCT01415297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129035|NCT06352697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization was done by the study statistician based on a computer-generated list. The groups were homogeneous according to age, sex and diagnostic criteria. The assignment of groups was blind to participants, research staff and outcome assessors moreover, to maintain blind parallel study the statistician was not aware of the allocation of participants to intervention||t|f|t|t
34129036|NCT03032419|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34129037|NCT00891488|||CASE_CONTROL||PROSPECTIVE|||||||
34129038|NCT00288015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129039|NCT01388179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129040|NCT03451487|RANDOMIZED|PARALLEL||OTHER||SINGLE||Single Blindie|t|f|f|f
34129041|NCT04841785|||COHORT||PROSPECTIVE|||||||
34129042|NCT04669860|||CASE_ONLY||PROSPECTIVE|||||||
34129043|NCT02452216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129044|NCT03666611|||OTHER||RETROSPECTIVE|||||||
34129045|NCT03040739|||CASE_CONTROL||PROSPECTIVE|||||||
34129046|NCT04062864|||CASE_ONLY||PROSPECTIVE|||||||
33823369|NCT03740737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129047|NCT05078931|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, single-arm phase II study of lenvatinib plus pembrolizumab in PD-L1 positive patients with TKI-resistant EGFR-mutated advanced non-small cell lung cancer.||||
34129048|NCT02526212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129049|NCT03061877|||COHORT||PROSPECTIVE|||||||
34129050|NCT00175916|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129051|NCT00389376|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34129052|NCT03168165|RANDOMIZED|PARALLEL||TREATMENT||NONE||Cluster randomized trial||||
34129053|NCT00711594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129054|NCT00828958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129055|NCT02740244|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34129056|NCT01405703|||COHORT||PROSPECTIVE|||||||
34129057|NCT00298389|||CASE_CONTROL||PROSPECTIVE|||||||
34129058|NCT04517344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129059|NCT06291337|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||We are testing individual sin a within subject control for their sweet taste ratings of sugars without and with oral rinses of ibuprofen and naproxen.||||
34129060|NCT06367660|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Research method: Quantitative Type of study: Randomized, interventional, comparative study|t|f|t|f
34129061|NCT01098253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129062|NCT03569787|||COHORT||RETROSPECTIVE|||||||
34129063|NCT06099223|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Single-center, prospective, unblinded, randomized controlled clinical trial||||
34129064|NCT03355950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129065|NCT03504891|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will have cardiac MRI prior to CRT.||||
34129066|NCT00705731|||COHORT||PROSPECTIVE|||||||
33823370|NCT06647342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigators analysing bleomycin concentrations using HPLC.|Double-blinded randomized controlled study|t|t|t|t
34129067|NCT02695017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34129068|NCT01328028|||CASE_ONLY||RETROSPECTIVE|||||||
34129069|NCT00750035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823371|NCT06146790|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823372|NCT06181929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||single-arm prospective pilot study||||
33823373|NCT01889771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33823374|NCT01862614|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33823375|NCT00660764|||COHORT||PROSPECTIVE|||||||
33823376|NCT04140422|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The allocation is done randomly by the hospitals pharmacy. By using identical containers for the hyperosmolar eye drops and the lubricating eye drops participants and medical staff are not able to distinguish both substances.|The study uses both eyes of the participant to allow inter- and intraindividual comparisons. One eye will be randomized to be treated with hyperosmolar eye drops, the fellow eye will be treated with lubricating eye drops.|t|t|t|t
33823377|NCT04364750|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33837374|NCT04496323|||COHORT||CROSS_SECTIONAL|||||||
33840216|NCT05278819|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34129070|NCT05365958|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129071|NCT01957293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34129072|NCT05894356|||COHORT||RETROSPECTIVE|||||||
34129073|NCT03293355|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129074|NCT04314245|||COHORT||PROSPECTIVE|||||||
34129075|NCT02783547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129076|NCT03937388|NA|SINGLE_GROUP||OTHER||NONE||Repeated measures, randomised, controlled, single blinded trial||||
34129077|NCT04328545|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|single (participants)||t|f|f|f
34129078|NCT03498131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is blinded to patients and providers.|Subjects will be randomly assigned to receive melatonin at 3 milligrams (mg) once a day or 5mg once a day. The study drug will be taken at 21:00 each day ± 2 hours.|t|t|t|t
34129079|NCT04574180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129080|NCT02466425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129081|NCT00521209|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34129082|NCT02014259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129083|NCT02626156|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129084|NCT02192892|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34129085|NCT03283488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129086|NCT01771991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129087|NCT01161589|||COHORT||CROSS_SECTIONAL|||||||
34129088|NCT00783653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129089|NCT04021485|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129090|NCT04397588|||COHORT||PROSPECTIVE|||||||
34129091|NCT04868097|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129092|NCT02846792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129093|NCT02531139|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34129094|NCT01683630|||COHORT||RETROSPECTIVE|||||||
34129095|NCT00335738|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129096|NCT02036580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129097|NCT04403607|||COHORT||PROSPECTIVE|||||||
34129098|NCT00057759|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34129099|NCT03130907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34129100|NCT04512820|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129101|NCT00535535|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||||||
34129102|NCT02997696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129103|NCT01465880|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129104|NCT01249755|||COHORT||PROSPECTIVE|||||||
34129105|NCT00735553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129106|NCT01934907|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34129107|NCT00593177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129108|NCT05271734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129109|NCT05795673|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Prospective quasi-experimental before-and-after multicenter study||||
34129110|NCT04713410|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129111|NCT02422069|||COHORT||CROSS_SECTIONAL|||||||
34129112|NCT03423303|RANDOMIZED|PARALLEL||SCREENING||NONE||Of the approximately 117,200 men aged 50-63 years resident in Helsinki and Tampere regions, a fourth will be randomised to screening and the rest to control arm (after exclusion of prevalent cases).||||
34129113|NCT05729555|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Test Product (T)：Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets, 400mg/50mg of Overseas Pharmaceuticals, Ltd.~Reference Product (R)：Motrin® IB (ibuprofen tablets USP) 200mg and BENADRYL® (diphenhydramine hydrochloride tablet) 25 mg Distributed by: Johnson \& Johnson Consumer Inc., McNeil Consumer Healthcare Division"||||
34129114|NCT00464997|||DEFINED_POPULATION||PROSPECTIVE|||||||
34129115|NCT01977196|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129116|NCT00101517|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34129117|NCT03376139|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study will be conducted in a double-masked fashion in that both the participants and the site investigators and staff interacting with participants and assessing study outcomes will be masked to treatment assignment. The only individuals at the site with assess to treatment assignment information will be the research pharmacists.||t|t|t|t
34129118|NCT06285565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The assessors will collect clinical outcomes by telephone and will be blinded to the group assignment|A parallel, open-label randomized controlled feasibility study|f|f|f|t
34129119|NCT06331039|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129120|NCT00625391|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34129121|NCT05997810|||CASE_ONLY||PROSPECTIVE|||||||
34129122|NCT00740454|||COHORT||PROSPECTIVE|||||||
34129123|NCT05645796|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients receiving contrast enhanced chest CT examination|Two groups receiving contrast medium based on different approaches are included and compared with each other|t|f|f|f
34129124|NCT04354948|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The researcher responsible for the statistical analyses are blinded to arm allocation.|This study is a 2-arm randomized controlled cross-over trial with 1 week between arms|f|f|t|f
34129125|NCT02510469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129126|NCT00786968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129127|NCT05944588|||COHORT||PROSPECTIVE|||||||
34129128|NCT01135888|||CASE_CONTROL||PROSPECTIVE|||||||
34129129|NCT01457664|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34129130|NCT04413214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129131|NCT04447235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|doubled-blind and placebo-controlled||t|t|f|f
34129132|NCT00631280|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129133|NCT06513923|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34129134|NCT00237666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129135|NCT06383169|||COHORT||RETROSPECTIVE|||||||
34129136|NCT02318368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129137|NCT04779073|||COHORT||OTHER|||||||
34129138|NCT03162796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129139|NCT05879393|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129140|NCT02310737|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34129141|NCT00819156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129142|NCT00287001|NON_RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
34129143|NCT01882712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129144|NCT02220803|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34129145|NCT05373758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129146|NCT06093633|||OTHER||PROSPECTIVE|||||||
34129147|NCT02018523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129148|NCT01491061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129149|NCT06075719|||COHORT||PROSPECTIVE|||||||
34129150|NCT02252640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129151|NCT04413916|||CASE_ONLY||RETROSPECTIVE|||||||
34129152|NCT04803175|||CASE_CONTROL||PROSPECTIVE|||||||
34129153|NCT01118403|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129154|NCT05639309|||CASE_CONTROL||PROSPECTIVE|||||||
34129155|NCT02448992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129156|NCT03885154|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34129157|NCT05802420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129158|NCT02676674|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34129159|NCT04074070|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129160|NCT02229825|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129161|NCT03238274|||COHORT||PROSPECTIVE|||||||
34129162|NCT03880370|||CASE_CONTROL||OTHER|||||||
34129163|NCT03200431|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34129164|NCT03678337|||COHORT||PROSPECTIVE|||||||
34129165|NCT06254092|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129166|NCT00037440|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33823378|NCT05488002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||"This study comprises 3 trials with the same intervention. Pharmacists will be trained how to recruit patients and perform pharmaceutical interventions. Each pharmacy will be required to recruit 45patients (15 hypertension, 15 diabetes, and 15 obese).~These patients will be randomized into two groups : intervention, which will receive pharmaceutical intervention and control group, which will receive standard care~\*The general practitioner of each participant will be informed about the study by a letter."|t|f|f|f
33823379|NCT02186587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823380|NCT01247870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823381|NCT02961777|||OTHER||CROSS_SECTIONAL|||||||
33823382|NCT01119534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823383|NCT03003884|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33823384|NCT01545778|||COHORT||RETROSPECTIVE|||||||
33823385|NCT05582135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823386|NCT05083871|||COHORT||PROSPECTIVE|||||||
33823387|NCT00449202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823388|NCT01655862|||CASE_ONLY||PROSPECTIVE|||||||
33823389|NCT01618227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823390|NCT00420797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823391|NCT04509583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Computerized label randomization|Men from infertile couples with increased sperm DNA fragmentation will be randomized devided into 2 groups: (1) with multi-micronutrient supplements (PROFortilTM) plus Vitamin E and (2) with Vitamin E only.|t|t|t|f
33823392|NCT01766414|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33823393|NCT05904171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823394|NCT00936195|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823395|NCT00128908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823396|NCT00721019|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33823397|NCT03425461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823398|NCT03809650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823399|NCT04773054|||COHORT||CROSS_SECTIONAL|||||||
33823400|NCT05833399|||CASE_CONTROL||RETROSPECTIVE|||||||
33823401|NCT04923100|||COHORT||RETROSPECTIVE|||||||
33823402|NCT01781156|||CASE_CONTROL||PROSPECTIVE|||||||
33823403|NCT01145859|NA|SINGLE_GROUP||||NONE||||||
33823404|NCT05173259|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33823405|NCT01046071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823406|NCT02406040|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823407|NCT01334905|RANDOMIZED|CROSSOVER||||NONE||||||
33823408|NCT05253547|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blinded parallel study|Parallel randomized control trial|t|f|f|f
33823409|NCT00404547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823410|NCT01881100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823411|NCT06399640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823412|NCT04851145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823413|NCT01062854|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33823414|NCT01628783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823415|NCT06195787|||COHORT||RETROSPECTIVE|||||||
33823416|NCT01498445|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823417|NCT00508417|||||PROSPECTIVE|||||||
33823418|NCT03585621|NA|SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation design||||
33823419|NCT03334773|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The health professionals (physicians, dietitians, nursing professionals) who serve the patients will only know the patient is participating in the study through a sticker on the medical records but they will not know the treatment allocation (group). Outcome assessors for biochemical parameters will not know the patient allocation as the assessments for the parameters are done alongside other routine assessments. Furthermore, they do not have the information that there are different patient groups|The intervention (nutrition education programme) will employ a randomised control design with two parallel groups (intervention \& control). Randomisation will be stratified based on age and gender into four strata. Concealed opaque envelopes for each stratum will be used for randomization. The intervention will be implemented over one year. The (intervention) comprises of four components i) 7-monthly group training (curriculum), ii) 2 bi-monthly group follow-up sessions, iii) one individual counseling and goal setting session (10-15 minutes) fitted during the monthly meetings, and iv) participant's workbook for goal setting activity and education materials (fridge/wall poster, pamphlet). The intervention group will receive the intervention while the control group will only receive the education material (fridge/wall poster, pamphlet). Both groups will continue with usual care at the diabetes outpatient clinic of the hospital.|f|t|f|t
33823420|NCT00113880|||COHORT||PROSPECTIVE|||||||
33823421|NCT00377312|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
33823422|NCT03117842|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|Statistical Analysis will be conducted without knowledge of the assignment of the groups.|A 12-month randomized controlled trial (RCT) will be conducted to evaluate the Mobile Link intervention, with two arms of 300 FEWs each. FEWs will be equally randomized into one of two groups: (1) no intervention and (2) SMS or VM theory-based behavioral messages.|f|f|f|t
33823423|NCT04208685|||COHORT||PROSPECTIVE|||||||
33823424|NCT01905293|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33823425|NCT03224689|NA|SINGLE_GROUP||OTHER||NONE||||||
33823426|NCT01706393|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33823427|NCT04057599|||CASE_ONLY||PROSPECTIVE|||||||
33823428|NCT05926037|||COHORT||PROSPECTIVE|||||||
33823429|NCT02200029|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823430|NCT05166785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823431|NCT02521025|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823432|NCT02933996|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823433|NCT02813447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823434|NCT00674258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837375|NCT04240249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized controlled trial with three groups.|f|f|f|t
33837376|NCT01159470|||COHORT||PROSPECTIVE|||||||
33837377|NCT00108745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129167|NCT02595866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129168|NCT03544905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129169|NCT00791050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129170|NCT03372720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34129171|NCT00511628|||COHORT||PROSPECTIVE|||||||
34129172|NCT02227030|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34129173|NCT04087031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129174|NCT01211977|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34129175|NCT02201329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129176|NCT02357537|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34129177|NCT03930771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129178|NCT04348812|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||All participants received active behavioral intervention combined with either active brain stimulation or sham stimulation control|t|f|f|t
33823435|NCT05478720|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Part 1: None (Open Label) Part 2: Blinded (Participants/ Caregivers, Study Staff)|"Part 1: Adult groups Healthy / Uncomplicated Malaria - Groups of 10 adult participants will be enrolled sequentially, with safety assessment and dose escalation for each group if safety criteria are satisfied in the previous group.~Pediatric Arm: Enrollment of pediatric participants will begin if safety criteria are satisfied in adults previously enrolled. The pediatric study will be randomized and placebo-controlled with DON or Placebo doses added to standard of care therapy. Interim assessments are planned to determine dosing for subsequent participants."||||
33823436|NCT01126879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823437|NCT05724719|||CASE_CONTROL||PROSPECTIVE|||||||
33823438|NCT00515281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823439|NCT05144438|||COHORT||PROSPECTIVE|||||||
33823440|NCT05693480|NA|SINGLE_GROUP||PREVENTION||NONE||"Reference group:~A total of 300 older adults who do not have any fall history in the past twelve months will be recruited for participating in three rounds of tests.~Intervention group:~A total of 1000 older adults who have fall history in the past twelve months will be recruited for participating in three rounds of tests."||||
33823441|NCT03524547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33823442|NCT03341754|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Trial subjects will be blinded from their treatment|The study will include 2 vaccine groups and an infectivity control (IC) group consisting of non-immunized subjects.|t|f|f|f
33823443|NCT05065892|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Serum testing technicians will be masked.||f|f|f|t
33823444|NCT05240664|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessors will be blinded to the group assignment and research question.|Dyads of participants recruited from all elderly community centres will be randomized at block size equals to 4 in 1:1 ratio into intervention group and control group.|f|f|f|t
33823445|NCT05109117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823446|NCT05300698|||COHORT||PROSPECTIVE|||||||
33823447|NCT02832219|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33823448|NCT00996450|||FAMILY_BASED||RETROSPECTIVE|||||||
33823449|NCT06207084|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Sequential Multiple Assignment Randomization Model||||
33823450|NCT04402632|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
33823451|NCT04973332|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, randomized controlled, non-infertility study||||
33823452|NCT05485246|||OTHER||PROSPECTIVE|||||||
33823453|NCT05765838|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"The order of the swabs performed will be decided with randomization to either of the eight combination:~1. NPS right - Nasal swab left - OPS~2. NPS left - Nasal swab right - OPS~3. Nasal swab right - NPS left - OPS~4. Nasal swab left - NPS right - OPS~5. NPS right - OPS - Nasal swab left~6. NPS left - OPS - Nasal swab right~7. Nasal swab right - OPS - NPS left~8. Nasal swab left - OPS - NPS right~9. OPS - NPS right - Nasal swab left~10. OPS - NPS left - Nasal swab right~11. OPS - Nasal swab left - NPS right~12. OPS - Nasal swab right - NPS left"||||
33823454|NCT04449133|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Patients who meet the eligibility criteria will be assigned alternatively to the the treatment with a AD128 or matching placebo. After 7 days of treatment and a washout period, the patients will crossover to the other arm for 7 days.|t|t|t|t
33823455|NCT01945255|||COHORT||PROSPECTIVE|||||||
33823456|NCT00793299|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823457|NCT02871063|||COHORT||PROSPECTIVE|||||||
33823458|NCT02503306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823459|NCT02246634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823460|NCT03529084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded independent review committee for primary endpoint of PFS||f|f|f|t
33823461|NCT01567670|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33823462|NCT02924558|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33823463|NCT03198416|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All patients who meet eligiblity will undergo HRM at the same time as the operative DISE procedure.||||
33823464|NCT03443752|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will complete the experimental procedures of the present study during a 12-week training period. All participants will be asked to participate in a Shotokan-karate or Tai Chi training group. The Shotokan-karate training will involve one hour training sessions broken down into 3 components; warm-up exercises, Katas, and cool-down exercises. The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre. All exercises will be administered by trained instructors throughout the 12-week training period. The 30-minute UPDRS assessment will be administered by Dr. Quincy Almeida,a movement disorder specialist.||||
33823465|NCT04744688|||COHORT||PROSPECTIVE|||||||
33823466|NCT06047379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129179|NCT02533544|||COHORT||OTHER|||||||
34129180|NCT05947916|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129181|NCT06018207|NA|SEQUENTIAL||TREATMENT||NONE||||||
34129182|NCT05712265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129183|NCT00266188|||COHORT||PROSPECTIVE|||||||
34129184|NCT04797689|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149371|NCT03223623|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34149372|NCT06497868|||CASE_ONLY||RETROSPECTIVE|||||||
34129185|NCT03770208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All parties involved until the end of trial. Pharmacy will be the only unblinded party as they need to prepare the study drugs.|RCT, single site, double blinded|t|t|t|f
34129186|NCT05531929|||CASE_ONLY||RETROSPECTIVE|||||||
34129187|NCT06354530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129188|NCT05331053|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Only women with endometriosis will complete this study. Once consented and screened, each subject is asked to take Atorvastatin (Lipitor, 10mg/day) for seven days. Participants will undergo experimental testing before and after the seven day intervention.||||
34129189|NCT04983693|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study will recruit 45 dyads of African American family caregivers and African American persons living with dementia.||||
34129190|NCT05365516|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE||The multi-centre QI project will use a stepped wedge cluster randomized design|f|f|f|t
34129191|NCT05799703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34129192|NCT06215365|NA|SINGLE_GROUP||OTHER||NONE||||||
34129193|NCT00321217|||COHORT||PROSPECTIVE|||||||
34129194|NCT05628870|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of HRS-1358||||
34129195|NCT04984343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129196|NCT00116038|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34129197|NCT04105192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129198|NCT05657938|||COHORT||PROSPECTIVE|||||||
34129199|NCT00955643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129200|NCT04709679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129201|NCT01500785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129202|NCT02435459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129203|NCT03144336|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The statistician will clean the data and compile the analysis dataset. Before sending on to the principal investigator for the outcome analysis, any information allowing inferring treatment assignment will be removed, in particular the two intervention arms will receive a non-descriptive label such as group A and group B. This way, the analysis can be performed without knowing which group corresponds to the intervention group, and which to control.||f|f|t|t
34129204|NCT02204423|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129205|NCT02291133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129206|NCT03861416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34129207|NCT05233501|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||a split-mouth randomized controlled clinical study|t|f|t|f
34129208|NCT00137488|||CASE_ONLY||PROSPECTIVE|||||||
34129209|NCT05954208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34129210|NCT04850924|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34129211|NCT03580538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129212|NCT00861692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129213|NCT02011230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129214|NCT03687775|||CASE_ONLY||CROSS_SECTIONAL|||||||
34129215|NCT03995095|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34129216|NCT03142243|||CASE_ONLY||CROSS_SECTIONAL|||||||
34129217|NCT04290247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Ultrasound before X-ray for all included patients.||||
34129218|NCT04501939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129219|NCT02691910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129220|NCT01243008|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34129221|NCT00677183|||FAMILY_BASED||PROSPECTIVE|||||||
34129222|NCT04504539|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|The mOPV and bOPV vaccine vials will be masked by the Clinical Trials Unit to look identical. The assessor will only be provided the enrollment ID and will not be aware of the participant's randomization status.|Different regimens of mOPV and bOPV in combination with either fractional IPV (fIPV) or full dose IPV (FIPV) will be used.|t|f|f|t
34129223|NCT06018077|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129224|NCT03979469|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
34129225|NCT05562557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129226|NCT04244695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129227|NCT04062981|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Open-Label (OL), multi-center study of carisbamate in subjects with LGS, with safety assessments from Baseline (Visit 1) through early termination (ET)/end of study (EOS) visit||||
34129228|NCT03438708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129229|NCT00074139|RANDOMIZED|||TREATMENT||NONE||||||
34129230|NCT03563755|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129231|NCT03978611|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129232|NCT06216327|NA|SINGLE_GROUP||PREVENTION||NONE||This intervention includes a household safety intervention that is delivered by an interventionist with specific training in facilitating lethal means safety discussions, and the provision of no-cost safety devices for medications and firearms.||||
34129233|NCT03641807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129234|NCT02509364|||CASE_CONTROL||RETROSPECTIVE|||||||
34129235|NCT01539070|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129236|NCT00757952|||CASE_CONTROL||PROSPECTIVE|||||||
34129237|NCT04539054|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34129238|NCT03150290|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34129239|NCT00269087|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129240|NCT01488461|||FAMILY_BASED|||||||||
34129241|NCT03948802|||CASE_CONTROL||PROSPECTIVE|||||||
34129242|NCT00042016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129243|NCT05595070|||COHORT||RETROSPECTIVE|||||||
34129244|NCT00765960|||OTHER||RETROSPECTIVE|||||||
34129245|NCT00286624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129246|NCT06422221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single||t|f|f|f
34129247|NCT01047007|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129248|NCT02229981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129249|NCT02511795|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129250|NCT02833129|||COHORT||RETROSPECTIVE|||||||
34149373|NCT04627935|||CASE_CONTROL||PROSPECTIVE|||||||
34149374|NCT05869500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129251|NCT03423238|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|All assessments will take place by study staff blinded to the participant's treatment assignment. To ensure that staff remain blinded, participants will be asked not to discuss their intervention with the assessor||f|f|t|t
34129252|NCT03897465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129253|NCT00887159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129254|NCT02403063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34129255|NCT00851890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129256|NCT05016024|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Run in period: 2 weeks First Period: two months of treatment with Colilen IBS or Placebo, based on the randomization at Baseline visit Wash out period:3 weeks Second Period: two months of treatment with Colilen IBS or Placebo, based on the randomization at Baseline visit|t|t|t|t
34129257|NCT01520649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129258|NCT03818906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129259|NCT04476446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129260|NCT03774771|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33823467|NCT02739490|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34129261|NCT06386055|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34129262|NCT00002509|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129263|NCT03240861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129264|NCT06035952|||COHORT||PROSPECTIVE|||||||
34129265|NCT01541735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129266|NCT00306839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129267|NCT03697161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129268|NCT02165943|||CASE_CONTROL|||||||||
34129269|NCT03047811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129270|NCT03673280|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Clinical, analytical, prospective, randomized trial.|t|f|t|t
34129271|NCT05815433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors who are conducting the microbial analysis and statistical analysis will not be aware of which group is intervention and which is control. These groups will be assigned a number (Group 1; Group 2).|An experimental study design in which each participants will be randomized to one of two groups (intervention \[DHM\] or standard care/control \[formula\])|f|f|f|t
34129272|NCT05844735|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Applicable for Part I||t|f|t|t
34129273|NCT01662830|||CASE_ONLY||RETROSPECTIVE|||||||
34129274|NCT01789086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129275|NCT02018536|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34129276|NCT03047967|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34129277|NCT00092820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129278|NCT03617718|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants will go through the same study procedures.||||
34129279|NCT00703846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129280|NCT02704624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the pharmacist responsible for confection of the tablets will know who will receive vitamin d or placebo, according to a list of randimization generated in the computer by the statistician. The list will be kept with the pharmacist throughout the intervention.|A double-blind, randomized, placebo-controlled study will be performed. After the evaluation of serum vitamin D levels, patients with vitamin D below 30ng/mL will be randomized into two groups. One group will receive supplementation with cholecalciferol (vitamin D3) tablets and the other group will receive placebo. Those will be provided at no cost to the patients. The dosage of 1.500-2.000 IU (International Units) vitamin D/day is recommended in order to meet the need of vitamin D above 30ng/mL in adults. However, a dose at least 2 to 3 times higher is recommended for CD patients due to malabsorption, significant loss of adipose tissue and use of glucocorticoids. Thus, the dose of 50,000IU/week will be administered in a single dose. The patients drawn to the placebo group will receive inert content tablets without therapeutic effect. After the study completion, these control patients will receive complete treatment for hypovitaminosis D.|t|t|t|t
34129281|NCT00408265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129282|NCT03220646|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open-label, non-randomized, phase II trial of single-agent abemaciclib administered at previously defined MTD/RP2D in three cohorts of patients with primary brain tumors.||||
34129283|NCT04700085|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE|Participants and researcher could not be blinded as participants performed a training session with the ReMotion Knee (one of the conditions) and the prosthetic knee type was visible to both.|Randomized crossover trial design||||
34129284|NCT01234038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129285|NCT03320837|||COHORT||PROSPECTIVE|||||||
34129286|NCT01976546|||CASE_ONLY||PROSPECTIVE|||||||
34129287|NCT02334020|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34129288|NCT06552845|||COHORT||PROSPECTIVE|||||||
34129289|NCT00353301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129290|NCT02033681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129291|NCT02131610|||CASE_CONTROL||PROSPECTIVE|||||||
34129292|NCT00496977|RANDOMIZED|PARALLEL||SCREENING||SINGLE||||||
34129293|NCT05506072|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129294|NCT01496287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129295|NCT02956252|||COHORT||RETROSPECTIVE|||||||
34129296|NCT03964168|||CASE_ONLY||RETROSPECTIVE|||||||
34129297|NCT01132053|||CASE_CONTROL||PROSPECTIVE|||||||
34129298|NCT06117033|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129299|NCT03115411|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with benign biliary obstruction who meet all inclusion criteria will be approached to consent for placement of a winged biliary stent for 90 days with appropriate laboratory studies and clinical evaluations.||||
34129300|NCT01457404|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129301|NCT01458548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129302|NCT02198859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823468|NCT03053661|||COHORT||PROSPECTIVE|||||||
33823469|NCT02261285|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Increase the dose sequentially.||||
33823470|NCT06095154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823471|NCT03727984|||COHORT||RETROSPECTIVE|||||||
34129303|NCT03644498|||CASE_CONTROL||RETROSPECTIVE|||||||
34129304|NCT04941430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823472|NCT02825719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33823473|NCT04893785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823474|NCT05970783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823475|NCT04031547|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823476|NCT06135779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823477|NCT05289375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33823478|NCT06645873|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823479|NCT05517265|||COHORT||PROSPECTIVE|||||||
33823480|NCT04365738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33823481|NCT03097302|||COHORT||PROSPECTIVE|||||||
33823482|NCT04203199|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The proposed study will employ a 1-visit cross sectional, double-blind, placebo-controlled design to parametrically evaluate two promising treatment strategies of rTMS using the H1 and H7-coil for dlPFC stimulation (Strategy 1) or mPFC stimulation (Strategy 2), respectively. Participants will be randomized to receive TMS to the dlPFC or mPFC (50% at each site). This will be done in a cohort of healthy control individuals recruited from the local Wake Forest University (WFU) community. Quantitative Sensory Testing (QST) and subjective pain ratings will be measured before and after the rTMS session.|t|t|f|f
33823483|NCT04030988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Masking involves only oral therapy; 100 patients will be randomized into 2 groups; 50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week while the other 50 patients will receive placebo having the same color, form and packaging for 6 months.~The investigators are blinded."|100 patients with non-segmental vitiligo are randomized to either NB-UVB therapy with placebo versus NB-UVB combined with mini-oral pulse steroids therapy. Vitligo activity will be assessed according to the VIDA scoring system. Skin type, extent of vitiligo using VES score, photography of all areas according to the VES areas at a fixed distance of 50 cm from the patient, and using a 1 cm diameter circular white sticker for reference later will be done. All patients will receive NB-UVB phototherapy at starting dose of 0.3 J/cm2, 3 times per week for 6 months (72 sessions) with gradually increasing increments according until faint erythema is attained at which point the dose is fixed. 100 patients will be randomized into 2 groups; 50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week while the other 50 patients will receive placebo having the same color, form and packaging for 6 months.|f|t|f|f
33823484|NCT05056701|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33823485|NCT03306251|||COHORT||PROSPECTIVE|||||||
33823486|NCT02256488|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33823487|NCT05414435|||COHORT||PROSPECTIVE|||||||
33823488|NCT02517476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823489|NCT02878720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33823490|NCT02499835|RANDOMIZED|PARALLEL||TREATMENT||NONE||Once at least 12 subjects per arm are accrued to Arms 1 and 2, and Arm 3 is open to accrual, accrual will occur only to Arm 3 (other arms will be closed). Extended treatment Arm 4 will open only when Arm 3 has met accrual.||||
33823491|NCT06540248|||COHORT||RETROSPECTIVE|||||||
33823492|NCT05648136|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33823493|NCT05980975|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33823494|NCT05069844|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients included in the study will be divided into 3 groups; the gum group2 (group G2), the gum group4 (group G4) and the control group (group C) by a computer-generated random number table before surgery.||||
33823495|NCT02088723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823496|NCT00294879|RANDOMIZED|CROSSOVER||||SINGLE||||||
33823497|NCT01405521|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823498|NCT03581253|NA|SINGLE_GROUP||OTHER||NONE||||||
33823499|NCT02801916|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33823500|NCT06538220|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823501|NCT04250181|||CASE_CONTROL||RETROSPECTIVE|||||||
33823502|NCT05191186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is run in a double-blind design|parallel group, double blind placebo controlled multi site|t|t|t|t
33823503|NCT04748497|NA|SINGLE_GROUP||OTHER||NONE||||||
33823504|NCT05269303|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823505|NCT05550077|||COHORT||PROSPECTIVE|||||||
33823506|NCT05123144|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33823507|NCT04185142|||COHORT||RETROSPECTIVE|||||||
33823508|NCT03716583|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823509|NCT02604342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823510|NCT04159051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823511|NCT06575881|||COHORT||PROSPECTIVE|||||||
33823512|NCT01432288|||COHORT||CROSS_SECTIONAL|||||||
33823513|NCT00260702||||TREATMENT||||||||
33823514|NCT00156377|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823515|NCT00981071|||COHORT||PROSPECTIVE|||||||
33823516|NCT01275417|||CASE_ONLY|||||||||
33823517|NCT06106789|||COHORT||RETROSPECTIVE|||||||
33823518|NCT05204316|NA|SINGLE_GROUP||OTHER||NONE||||||
33823519|NCT06643052|||COHORT||RETROSPECTIVE|||||||
33823520|NCT02745314|||COHORT||PROSPECTIVE|||||||
33823521|NCT04838145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A double-blind, placebo controlled, prospective, randomized trial examining the effect of antiviral treatment given for 6months on residual insulin secretion|t|t|t|t
33823522|NCT05647109|||OTHER||OTHER|||||||
33837378|NCT03548220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837379|NCT00196352|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33837380|NCT05440747|||COHORT||PROSPECTIVE|||||||
33837381|NCT05091957|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||A multi-centred, pragmatic, 1:1 allocation, parallel-group superiority randomized controlled trial|f|t|t|t
34129305|NCT02030769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129306|NCT03825640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129307|NCT02565875|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34129308|NCT02967419|||||CROSS_SECTIONAL|||||||
34129309|NCT00375505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34129310|NCT00800696|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129311|NCT02636660|||COHORT||PROSPECTIVE|||||||
34129312|NCT01811069|||CASE_CONTROL||PROSPECTIVE|||||||
34129313|NCT00256464|RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
34129314|NCT02702609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129315|NCT01062789|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823523|NCT03393065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Results of the lung ultrasounds will not be made publicly available|The patients will be randomized in two groups: in the intervention group pulmonary congestion, as assessed by the BLS will guide the fluid management, with a target of below 15 BLS. In the control group the fluid management will not be LUS guided. In both groups, further complementary fluid assessment methods will be performed blindly from the investigators: body composition assessment by bioimpedance and biochemical panel consisting in cardiac biomarkers (NTproBNP, cTnT) and inflamatory markers (IL-6).|t|f|f|t
33823524|NCT05087797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823525|NCT02467049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823526|NCT04346433|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33823527|NCT03325608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33823528|NCT00402584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823529|NCT05732922|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823530|NCT04389996|||COHORT||CROSS_SECTIONAL|||||||
33823531|NCT04022603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823532|NCT03526471|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33823533|NCT02896439|NA|SINGLE_GROUP||SCREENING||NONE||||||
33823534|NCT05188547|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|t|f|f
33823535|NCT03865862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33823536|NCT02358499|NA|SINGLE_GROUP||OTHER||NONE||||||
33823537|NCT04832815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823538|NCT02429232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823539|NCT05326633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823540|NCT02668796|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823541|NCT05014906|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33823542|NCT02788617|||COHORT||PROSPECTIVE|||||||
33823543|NCT04858568|||COHORT||PROSPECTIVE|||||||
33823544|NCT01592383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823545|NCT05961618|||COHORT||RETROSPECTIVE|||||||
33823546|NCT06645847|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Study products will be allocated a code and labelled by an external team. The coding of the study products will be recorded and sealed in 'unblinding envelopes' that will only be opened in unblinding becomes necessary for subject safety. No one on the study team (including outcome assessor and statisticians) will be aware of the study product identity. The study products are matched for appearance, taste and calories and will not be visibly distinguishable.|Parallel group, randomized, double-blind, placebo controlled|t|t|t|t
33823547|NCT00002216||||TREATMENT||NONE||||||
33823548|NCT02155218|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33823549|NCT06178198|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, prospective, single-arm, single-center trial||||
33823550|NCT05452837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33823551|NCT03053635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823552|NCT01494298|||COHORT||PROSPECTIVE|||||||
33823553|NCT02231814|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823554|NCT04775173|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823555|NCT06646757|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33823556|NCT01138189|||CASE_CONTROL||PROSPECTIVE|||||||
33823557|NCT06646393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The skin-to-skin group received skin-to-skin contact from a midwife working in the clinic. The outcome assessor is not aware of the groups.|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.|f|f|f|t
33823558|NCT03334071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Cardiopulmonary exercise testing assessor, outcome/toxicity assessor|Exercise intervention|f|f|t|t
33823559|NCT06047041|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessors of schoolwide implementation outcomes (i.e., the School-Wide Evaluation Tool \[SET\] and the Individual Student Systems Evaluation Tool \[ISSET\]) will be masked.|School-level randomization to treatment arm.|f|f|f|t
33823560|NCT04980755|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33823561|NCT03246256|||OTHER||PROSPECTIVE|||||||
33823562|NCT03230071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823563|NCT00247702|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823564|NCT04186884|||CASE_CONTROL||PROSPECTIVE|||||||
33823565|NCT04585568|||COHORT||PROSPECTIVE|||||||
33823566|NCT05934461|||COHORT||RETROSPECTIVE|||||||
33823567|NCT06646237|||CASE_CONTROL||PROSPECTIVE|||||||
33823568|NCT04648111|||COHORT||PROSPECTIVE|||||||
33823569|NCT06209905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33823570|NCT02072681|||COHORT||PROSPECTIVE|||||||
33823571|NCT06645561|||CASE_ONLY||RETROSPECTIVE|||||||
33823572|NCT01779427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823573|NCT01200888|||CASE_ONLY||PROSPECTIVE|||||||
33823574|NCT02642159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823575|NCT02299895|||||RETROSPECTIVE|||||||
33823576|NCT02574897|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33823577|NCT00105521|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823578|NCT03198936|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Double Blind||t|f|t|t
33823579|NCT04113902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823580|NCT04072523|||CASE_ONLY||CROSS_SECTIONAL|||||||
33823581|NCT06646471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823582|NCT03979235|||COHORT||PROSPECTIVE|||||||
33823583|NCT05501483|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are recruited to either of three groups where they receive (in addition to metformin) any of the three study drugs.||||
34129316|NCT05870969|||COHORT||PROSPECTIVE|||||||
34129317|NCT04091932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823584|NCT04320199|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823585|NCT01898442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823586|NCT00945763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823587|NCT03802487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823588|NCT02727647|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823589|NCT04163185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823590|NCT03565302|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33823591|NCT02544113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823592|NCT06647459|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823593|NCT03254992|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33823594|NCT04155333|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Subjects and the research team will both be blind to the stimulation condition delivered at each test session. Access will be limited to the study physicians, investigators, and device programmers.|A double-blind, randomized, sham-controlled, within-subjects design|f|f|t|f
33823595|NCT01914458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823596|NCT02946827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823597|NCT00907517|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823598|NCT02473588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823599|NCT04965090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823600|NCT02941432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823601|NCT00487513|||COHORT||PROSPECTIVE|||||||
33823602|NCT00183183|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33823603|NCT01968083|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823604|NCT00572793|||CASE_CONTROL||PROSPECTIVE|||||||
33823605|NCT00744796|||COHORT||PROSPECTIVE|||||||
33823606|NCT00094497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823607|NCT00919009|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33823608|NCT02536885|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823609|NCT04405856|||COHORT||PROSPECTIVE|||||||
33823610|NCT04596241|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823611|NCT05577689|||COHORT||PROSPECTIVE|||||||
33823612|NCT05576727|||COHORT||PROSPECTIVE|||||||
33823613|NCT03524950|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33823614|NCT02245750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823615|NCT01732926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823616|NCT00364221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823617|NCT01485991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823618|NCT05097664|||COHORT||PROSPECTIVE|||||||
33823619|NCT00424177|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823620|NCT03525483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823621|NCT00926952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823622|NCT06297031|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823623|NCT05913583|||COHORT||RETROSPECTIVE|||||||
33823624|NCT03771183|||COHORT||RETROSPECTIVE|||||||
33823625|NCT05915832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129318|NCT02026947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129319|NCT03497338|||COHORT||PROSPECTIVE|||||||
34129320|NCT06122519|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129321|NCT01014767|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129322|NCT02713113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34129323|NCT00367562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129324|NCT00853710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823626|NCT01110161|||COHORT||CROSS_SECTIONAL|||||||
33823627|NCT06639698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823628|NCT00988897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823629|NCT01399684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823630|NCT04461938|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823631|NCT00051883|||||PROSPECTIVE|||||||
33823632|NCT00067119|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823633|NCT05192226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823634|NCT02580214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33823635|NCT00666835|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823636|NCT00010270||||TREATMENT||||||||
33823637|NCT03021031|||COHORT||PROSPECTIVE|||||||
33823638|NCT03818477|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33823639|NCT02949622|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823640|NCT05971017|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two groups that consumed lettuce. No differences in shape, size, colours of lettuce|control group, biostimulated group|t|f|f|f
33823641|NCT00263783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823642|NCT04341233|||COHORT||PROSPECTIVE|||||||
33823643|NCT06140485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823644|NCT05953818|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823645|NCT04697641|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two study groups receiving two different treatment strategies||||
33837382|NCT03422861|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34129325|NCT05978349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129326|NCT05111431|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Dexmedetomidine hydrochloride nasal spray compared with placebo|t|t|t|t
34129327|NCT06282445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129328|NCT03684837|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129329|NCT05402215|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE||stratified randomization method|t|f|f|f
34129330|NCT01453036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129331|NCT00594607|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34129332|NCT03287323|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Prospective before-and after interventional study including 100 patients who receive usual intensive care followed by an interventional part with 100 patients who receive additional palliative care consultations||||
34129333|NCT01941381|||COHORT||PROSPECTIVE|||||||
33823646|NCT03726125|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind in Part A. Open label in Parts B and C.|Parts B and C are crossover design.|t|f|t|f
33823647|NCT01116440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823648|NCT02615834|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33823649|NCT04091919|||COHORT||PROSPECTIVE|||||||
33823650|NCT02878590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823651|NCT05177770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823652|NCT03574493|||COHORT||PROSPECTIVE|||||||
33823653|NCT02571283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33823654|NCT03078751|RANDOMIZED|PARALLEL||TREATMENT||NONE|The trial used to be a placebo-controlled, blinded trial. It was amended to an open-label trial after protocol amendment 2.|||||
33823655|NCT03389997|NA|SINGLE_GROUP||PREVENTION||NONE||Iterative nasal swabs will be performed to screen for virus shedding||||
33823656|NCT05878990|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823657|NCT01748578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823658|NCT04461314|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33823659|NCT05160597|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33206322|NCT05861037|||COHORT||RETROSPECTIVE|||||||
33823660|NCT05240248|||COHORT||PROSPECTIVE|||||||
33823661|NCT01827449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823662|NCT03968536|||CASE_ONLY||PROSPECTIVE|||||||
33823663|NCT06423859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33823664|NCT05000411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823665|NCT02212301|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33823666|NCT04976283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823667|NCT02899481|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33823668|NCT02123277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823669|NCT02062281|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33823670|NCT01965041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823671|NCT02958475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33823672|NCT00579657|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823673|NCT05436145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823674|NCT01031186|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33823675|NCT00482859|||COHORT||PROSPECTIVE|||||||
33823676|NCT05536921|||CASE_ONLY||PROSPECTIVE|||||||
33823677|NCT02364609|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823678|NCT00609323|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33823679|NCT02722122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823680|NCT04741815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33823681|NCT01333137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823682|NCT06244030|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823683|NCT03650244|||CASE_ONLY||PROSPECTIVE|||||||
33823684|NCT01971034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823685|NCT05744791|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Preschool children will not be aware of which intervention they are in.|Two preschools. One will be randomized to the intervention and one to the control group.|t|f|f|f
33823686|NCT04056117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||This phase 1/2 trial is a multicentre, randomized, controlled, double blind, with two steps; a step 1 with a safety cohort and a step 2 with a dose-finding cohort. Safety of the vaccine will be evaluated first in adults and subsequently in children and infants through an age-descending and dose escalation approach (safety cohort, step 1). Following confirmation of vaccine safety, further cohorts of infants (dose-finding cohort) will be enrolled to evaluate immunogenicity of the vaccine at different doses and expand safety data (step 2). Vaccination in Step 1 will be staggered with adults being the first to be vaccinated and infants last. In step 2 infants will be vaccinated concurrently, with each group randomised to receive 1 of 4 different vaccine doses. A control vaccine will be used, and participants will be randomized at a ratio of 3:1 in adults, 2:1 in children, 2:1 in infants in step 1 and 8:1 in infants in step 2, to receive the candidate vaccine versus the control vaccine.|t|f|t|f
33823687|NCT05114902|||OTHER||PROSPECTIVE|||||||
33823688|NCT05135299|||COHORT||RETROSPECTIVE|||||||
33823689|NCT04231266|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823690|NCT00862485|||CASE_ONLY|||||||||
33823691|NCT02865759|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33823692|NCT04029792|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823693|NCT05924048|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33823694|NCT06478056|NA|SINGLE_GROUP||OTHER||NONE||||||
33823695|NCT03964038|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823696|NCT06288256|||COHORT||PROSPECTIVE|||||||
33823697|NCT05470218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Single-group crossover|t|f|t|f
33823698|NCT06162637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823699|NCT01547182|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823700|NCT04364022|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823701|NCT05699369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The research team will mask the statisticians when data is presented and analyzed.||f|f|f|t
33823702|NCT06224335|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823703|NCT04723888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823704|NCT02621502|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33823705|NCT03714711|||COHORT||PROSPECTIVE|||||||
33823706|NCT03597542|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Both the participants and researchers involved with data analysis will be blinded to which condition given.|Double blind randomized cross-over design|t|f|t|f
33823707|NCT05758376|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Open Pilot Trial (n=15) to examine feasibility, fidelity, and acceptability of study intervention (called Recovery Bridge)||||
33823708|NCT01592058|||COHORT||RETROSPECTIVE|||||||
33823709|NCT00915785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823710|NCT06363136|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823711|NCT02513810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823712|NCT00253019|||COHORT||PROSPECTIVE|||||||
33823713|NCT04999956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837383|NCT03065140|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129334|NCT05798546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129335|NCT05567445|||COHORT||PROSPECTIVE|||||||
34129336|NCT02108756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129337|NCT02094209|||CASE_ONLY||PROSPECTIVE|||||||
34129338|NCT06471699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled trial||||
33823714|NCT05931289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be masked to treatment condition.||f|f|f|t
33823715|NCT00215631|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33823716|NCT05117879|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Three groups: Cold snaring polypectomy, Cold EMR and Hot EMR|t|f|f|f
33823717|NCT03045302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823718|NCT06575699|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823719|NCT03081351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823720|NCT01158716|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823721|NCT04471480|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823722|NCT05738070|||OTHER||RETROSPECTIVE|||||||
33823723|NCT00247117|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823724|NCT04090216|||CASE_ONLY||PROSPECTIVE|||||||
33823725|NCT03794128|||CASE_ONLY||PROSPECTIVE|||||||
33823726|NCT06162806|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33823727|NCT00214071|NON_RANDOMIZED|PARALLEL||||NONE||||||
33823728|NCT06035003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823729|NCT02835937|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823730|NCT05114161|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Before-after study||||
33823731|NCT04966936|||OTHER||PROSPECTIVE|||||||
33823732|NCT03512587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823733|NCT02123797|||CASE_CONTROL||PROSPECTIVE|||||||
33823734|NCT05859009|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33823735|NCT05017883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823736|NCT04391218|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823737|NCT05830305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33823738|NCT06149052|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823739|NCT04577586|||COHORT||PROSPECTIVE|||||||
33823740|NCT04722848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823741|NCT03334747|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were randomized to KAE609 and Coartem in parallel treatment arms. Increasing doses of KAE609 (single dose and multiple dose) were evaluated in dose escalated manner in sequential cohorts||||
33823742|NCT02077153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823743|NCT00189683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823744|NCT01930383|||CASE_ONLY||PROSPECTIVE|||||||
33823745|NCT05195905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823746|NCT06645808|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Initially, three subjects will be included in the 89Zr-F8scFv cohort, in parallel by three subjects in the 89Zr-C9scFv cohort (total of 6 patients). Subsequently, an interim analysis will be conducted to determine the optimal radiation dose and optimal scanning day for each radiolabeled antibody fragment.~After the interim analysis, cohorts will be expanded by seven more subjects each, resulting in 20 subjects (2 x 10) total in the initial study across both cohorts. After completion of the initial study, each cohort may be further expanded by six subjects in additional indications, totaling (2 x 16) 32 patients. This basket trial aims to include at least one patient per indication.~For expansion cohort subjects, IMP-administration will occur on day 1, with one PET/CT scan performed on the most optimal day, either day 1, 2, or 4."||||
33823747|NCT03861585|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823748|NCT05442424|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial, 100 parent-child dyads will receive either $60 per month in vouchers to purchase fresh fruits and vegetables from the community farmers market for 6 months (intervention) or $360 gift certificate to the local grocery store.||||
33823749|NCT04282564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823750|NCT06584825|RANDOMIZED|PARALLEL||OTHER||SINGLE||A pilot single-centre randomized controlled study|f|f|f|t
33823751|NCT05094232|||COHORT||CROSS_SECTIONAL|||||||
33823752|NCT02177435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823753|NCT01653171|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33823754|NCT05283525|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|This is a double-blind placebo-controlled study. An independent body will randomize the study subjects and determine the placebo- and treatment group subjects|A Longitudinal Study To Determine The Efficacy of Trimrox Efficacy On Body Recomposition And Weight Management In Human Volunteers|t|t|t|t
33823755|NCT06290141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part A is a double-blind treatment period and Part B is an open-label period.|t|t|t|t
33823756|NCT04517071|||COHORT||RETROSPECTIVE|||||||
33823757|NCT01475019|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823758|NCT04103905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823759|NCT04130958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823760|NCT06646861|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823761|NCT05930002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Using sealed envelopes for either participants or controls|Three arm randomized controlled clinical trial|t|f|f|f
33823762|NCT00104013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823763|NCT01468025|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33823764|NCT04054596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once enrolled, participants will be randomly assigned to the TX or CTL group via a computerized random number generator coordinated by the statistician, who will not be blinded. Group assignment will be concealed. Both the participant and the examiner conducting the baseline and outcome assessments will be blind to group membership.|The purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with a Traumatic Brian Injury (TBI).|t|f|f|t
33823765|NCT01271036|NA|SINGLE_GROUP||||NONE||||||
33823766|NCT05669287|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823767|NCT00502983|||CASE_CONTROL||PROSPECTIVE|||||||
34129339|NCT00005102|||NATURAL_HISTORY|||||||||
34129340|NCT02944708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129341|NCT01689987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129342|NCT04154644|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129343|NCT04434547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823768|NCT06141772|NA|SINGLE_GROUP||OTHER||NONE||||||
34129344|NCT05056558|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129345|NCT02535013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129346|NCT03506412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Entresto™ will be administered to subjects with high and low circulating neprilysin (NEP) levels.||||
34129347|NCT03275090|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34129348|NCT01258556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129349|NCT04839250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129350|NCT03472820|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34129351|NCT01169701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129352|NCT00804895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129353|NCT05542498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129354|NCT00373646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129355|NCT03022864|||CASE_CONTROL||PROSPECTIVE|||||||
34129356|NCT00127491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129357|NCT04879108|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Outcomes Assessor (pain, pulmonary function tests, 6 minute walking test, peak cough flow)|Crossover Assignment Randomized controlled|f|f|f|t
34129358|NCT00460655|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129359|NCT03125499|||OTHER||OTHER|||||||
34129360|NCT00909441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129361|NCT02552095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129362|NCT03545308|||CASE_ONLY||PROSPECTIVE|||||||
34129363|NCT06214676|||COHORT||PROSPECTIVE|||||||
34129364|NCT02303210|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34129365|NCT04293276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129366|NCT02871349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129367|NCT05710796|||COHORT||RETROSPECTIVE|||||||
34129368|NCT02222857|||CASE_ONLY||RETROSPECTIVE|||||||
34129369|NCT01354730|||COHORT||RETROSPECTIVE|||||||
34129370|NCT05449912|||COHORT||RETROSPECTIVE|||||||
34129371|NCT06057597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129372|NCT02998671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129373|NCT03419312|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|"The stimulation periods with sham stimulation and burst are blinded to all included in the study except SCS nurse 1 who program and reset IPG during study phase 2.~Sham stimulation is achieved by switching of the stimulation equipment in connection with programming prior to the start of the current stimulation period. The programming procedure is identical before burst and sham stimulation periods."|"Patients are randomized to 1 of 2 different treatment sequences:~Sequence A: Active burst stimulation followed by sham stimulation. Sequence B: Sham stimulation followed by burst stimulation. Sham and burst stimulation are separated by 7 days washout."|t|f|t|t
34129374|NCT04198766|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|Part 4 NSCLC cohort is randomized 1;1:1, open-label|||||
34129375|NCT04171908|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34129376|NCT00920348|||COHORT||PROSPECTIVE|||||||
34129377|NCT04800575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129378|NCT05730868|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized control trial|t|f|f|f
34129379|NCT03012828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129380|NCT01599247|||COHORT||PROSPECTIVE|||||||
34129381|NCT02317601|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33823769|NCT02229396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823770|NCT05274100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823771|NCT01855178|||||PROSPECTIVE|||||||
33823772|NCT00002432||||TREATMENT||||||||
33823773|NCT00733564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823774|NCT01939821|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33823775|NCT01703988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823776|NCT02661490|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823777|NCT05269147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"To determine the efficacy of lidocaine versus bupivacaine for sphenopalatine ganglion block in patients undergoing endoscopic septoplasty.~Postoperative Pain-free duration (minutes) will be recorded from the time of extubation to the first postoperative analgesic request when VAS ≥ 4 is the primary outcome."|t|t|t|t
33823778|NCT00915460|NON_RANDOMIZED|PARALLEL||||NONE||||||
33823779|NCT00540384|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823780|NCT01491763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823781|NCT04167085|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33823782|NCT04685317|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized study of Sentinel cerebral protection device vs no cerebral protection device in patients undergoing atrial fibrillation ablation.||||
33823783|NCT00224809|RANDOMIZED|FACTORIAL||PREVENTION||||||||
33823784|NCT06283563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823785|NCT06058117|||COHORT||OTHER|||||||
33823786|NCT04385940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823787|NCT02515097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823788|NCT05262439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823789|NCT04177628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Half the doctors at each center will receive training in SDM. These doctors will practice SDM supported by the in-consultation PtDA during every consultation in this study. The other half of the doctors will continue usual practice of informing the patients.||||
34129382|NCT01618058|||CASE_CONTROL||PROSPECTIVE|||||||
33837384|NCT06485206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837385|NCT02909933|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837386|NCT01258621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837387|NCT02214953|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837388|NCT05780086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837389|NCT01603888|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129383|NCT04821414|||COHORT||PROSPECTIVE|||||||
34129384|NCT06102512|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129385|NCT01455922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823790|NCT04284592|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||35 patients receive RIP on upper limb: 5 min of ischemia followed by 5 min of reperfusion (3 cycles) immediately after leaving on-pump. The primary outcome was to know the time course of HIF-1α plasma levels after surgery in both groups and compare the two groups at specific time points: before starting surgery (T0) and after CPB period at 2 h (T1), 8 h (T2), 24 h (T3), 36 h (T4), 48 h (T5). Secondary outcomes included to measure the cardiac markers levels (Troponin T, CK-MB, CPK), arterial oxygenation (PaO2:FiO2) and others.|t|t|f|f
33823791|NCT06196229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823792|NCT03074383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823793|NCT03303521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823794|NCT01086878|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33823795|NCT04985747|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The outcomes assessor will not be aware of which group he/she is interviewing at the assessment session.|"Patients will randomly be allocated to either group P/R/O. Group P: Patients receiving a smooth palatal surface. Group R: Patients receiving a rough surface in the rugae area. Group O: Patients receiving an open surface in the rugae area~After insertion, all participants will be followed up for a minimum of 1 week to correct any issues with the dentures and eliminate patient complaints.~All patients will be recalled at 2 month after insertion to answer questions using the VAS and to fill out the Oral Health Impact Profile-20 EDENT (OHIP-EDENT), and receive the other type of palatal contour.~After the second and third period the same process will be repeated."|f|f|f|t
33823796|NCT04782505|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Part1. Parallel, Part2. Crossover||||
33823797|NCT01906658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823798|NCT02895698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823799|NCT02598934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823800|NCT02772445|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823801|NCT02161185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823802|NCT05648448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823803|NCT02528864|||CASE_CONTROL||PROSPECTIVE|||||||
33823804|NCT05671744|NA|SINGLE_GROUP||SCREENING||NONE||||||
33823805|NCT03198351|||COHORT||PROSPECTIVE|||||||
33823806|NCT01100268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823807|NCT03230110|||CASE_CONTROL||PROSPECTIVE|||||||
33823808|NCT02037750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823809|NCT01214499|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823810|NCT00076063|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
33823811|NCT05591378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823812|NCT05804981|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE||a new questionnaire is integrated into the annual wellness visit. the questionnaire screens patients for cognitive decline||||
33823813|NCT03570606|||CASE_CONTROL||PROSPECTIVE|||||||
33823814|NCT02782598|||COHORT||PROSPECTIVE|||||||
33823815|NCT01365351|||CASE_ONLY||PROSPECTIVE|||||||
33823816|NCT01406171|NA|SINGLE_GROUP||||NONE||||||
33823817|NCT00830102|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33823818|NCT04410354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Pharmacy prepares medications that are coded|Eligible study subjects will be randomized 1:1 to receive oral administration of study drug or placebo. Both treatment arms will also receive remdesivir.|t|t|t|f
33823819|NCT02248753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823820|NCT04604951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823821|NCT00529555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823822|NCT03681002|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33823823|NCT06646211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823824|NCT02809677|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Study followed caregivers and children for up to 12 months. They were given the option of algorithm-based antidepressant therapy using a variety of standard treatments. However, they could also receive medication or psychotherapy outside of the study, or decline all treatment.||||
33823825|NCT01387776|||COHORT||PROSPECTIVE|||||||
33823826|NCT03003832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823827|NCT02592044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823828|NCT03003923|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823829|NCT05358964|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants assigned to the AFFHEP will receive a culturally tailored Family Health History Tool designed specifically for African Americans. The Control group will receive the Genetic Alliance Does it Run in the Family Toolkit||||
33823830|NCT03377179|NA|SINGLE_GROUP||TREATMENT||NONE||"Part 1- single-arm Phase IIA study, all participants receiving ABC294640, continuously administered in 28 day cycles, until disease progression, unacceptable toxicity or voluntary withdrawal Enrollment in a two-stage design: 12 participants will be accrued, if none of those patients respond, registration will halt. If one or more patients respond, additional 27 patients evaluable for efficacy will be enrolled.~Part 2- identical to Part 1 with the exceptions: co-treatment of both ABC294640 and HCQ and study will consist of two phases: Phase I, a hybrid accelerate dose escalation run-in starting at HCQ dose of 200 mg QD. Based on safety results, patient cohorts will be expanded and dosing will escalate up to 600 mg BID. Phase II, treatment with ABC294640 and HCQ at the Phase I determined dose. Up to 15 participants evaluable for safety and tolerability will be accrued in Phase I and 20 participants evaluable for efficacy in Phase II, Part 2."||||
33823831|NCT05393388|||COHORT||PROSPECTIVE|||||||
33823832|NCT04135469|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33823833|NCT01553578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823834|NCT02822040|||||PROSPECTIVE|||||||
33823835|NCT02510404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823836|NCT00410423|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823837|NCT06006832|||COHORT||PROSPECTIVE|||||||
33823838|NCT01189318|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823839|NCT00230971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823840|NCT02539238|RANDOMIZED|PARALLEL||||NONE||||||
33823841|NCT01954771|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33823842|NCT03229525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823843|NCT01641627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823844|NCT04981184|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823845|NCT03293329|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33823846|NCT02791126|||COHORT||PROSPECTIVE|||||||
33823847|NCT03480919|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33823848|NCT00994396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823849|NCT05249309|||OTHER||PROSPECTIVE|||||||
33823850|NCT05563428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, controlled trial|t|t|t|t
33823851|NCT01520285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823852|NCT04572997|NA|SINGLE_GROUP||TREATMENT||NONE||This was an open-label, single-arm, pilot study to evaluate the efficacy and safety of apremilast.||||
33823853|NCT00448786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823854|NCT00412828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823855|NCT04299724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823856|NCT01557699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823857|NCT04368533|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||double-blind randomized control trial|t|t|t|t
33823858|NCT04482270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823859|NCT05331716|||COHORT||RETROSPECTIVE|||||||
33823860|NCT02112578|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823861|NCT01654445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823862|NCT02292641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823863|NCT02206464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33823864|NCT04454489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823865|NCT03657537|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33823866|NCT05980377|||OTHER||OTHER|||||||
33823867|NCT04137978|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823868|NCT05596149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33823869|NCT06338293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823870|NCT04392297|||COHORT||PROSPECTIVE|||||||
33823871|NCT03539133|||COHORT||PROSPECTIVE|||||||
33823872|NCT04675762|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823873|NCT03920761|||COHORT||PROSPECTIVE|||||||
33823874|NCT03738397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823875|NCT04937205|||COHORT||PROSPECTIVE|||||||
33823876|NCT03993028|||COHORT||PROSPECTIVE|||||||
33823877|NCT05295992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823878|NCT05983068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823879|NCT00551187|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33823880|NCT03739333|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33823881|NCT03199261|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823882|NCT00058942|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33823883|NCT00721825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823884|NCT01532102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823885|NCT06646224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823886|NCT02937051|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823887|NCT03705988|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823888|NCT05699967|||COHORT||PROSPECTIVE|||||||
33823889|NCT00452985|||CASE_ONLY||PROSPECTIVE|||||||
33823890|NCT02455284|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33823891|NCT03292198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823892|NCT04672655|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will then be randomized to receive ONBOARD or CGM-only. Those randomized to the ONBOARD condition will schedule 4 60-minute sessions with study interventionist (every 3 weeks).||||
33823893|NCT06474390|||CASE_ONLY||PROSPECTIVE|||||||
33823894|NCT05235776|||COHORT||PROSPECTIVE|||||||
33823895|NCT01770314|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33823896|NCT05787171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33823897|NCT01902381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823898|NCT00349245|RANDOMIZED|PARALLEL||||DOUBLE|||t|t|f|f
33823899|NCT05616832|||OTHER||PROSPECTIVE|||||||
33823900|NCT01401036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823901|NCT05310344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823902|NCT03451526|||CASE_CONTROL||RETROSPECTIVE|||||||
33823903|NCT04067206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|The infants were randomly assigned to four groups: i) white noise , ii) recorded mother's voice, iii) MiniMuffs, and iv) control. Masking could not be performed because the mother's voice was requested from the mothers.Masking could not be done because researchers and observers heard the mother's voice and white noise and saw the mimimuff.|This experimental study is a randomized controlled research. The infants were randomly assigned to four groups. Three interventions, each alone and in combination, are evaluated in parallel against a control group||||
33823904|NCT02625571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823905|NCT00300963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823906|NCT02872662|||COHORT||PROSPECTIVE|||||||
33823907|NCT01951261|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33823908|NCT05383651|||COHORT||PROSPECTIVE|||||||
33823909|NCT05218421|||COHORT||PROSPECTIVE|||||||
33823910|NCT05990270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|None (Open Label)|Parallel Assignment||||
33823911|NCT02840175|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33823912|NCT06645613|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|A random order of sham and real stimulations will be applied to the participants. A sham TMS coil will be used in the sham stimulations to generate the same sound as the real TMS coil. Moreover, a pulsed electric current will be applied to the scalp of the participants, which generates a feeling similar to that of real stimulations. In this way, the participants will be blind to the stimulation status.|This is a sham-controlled cross-over study. The participants will take a random order of sham or real TMS stimulations.|t|f|f|f
33837390|NCT00642525|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33837391|NCT02250053|NA|SINGLE_GROUP||TREATMENT||||exercise||||
33837392|NCT00842244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837393|NCT05399901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837394|NCT04444531|||COHORT||PROSPECTIVE|||||||
33837395|NCT03534895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129386|NCT05070455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129387|NCT00637624|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129388|NCT01177085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129389|NCT03132649|||COHORT||PROSPECTIVE|||||||
34129390|NCT01251718|||COHORT||PROSPECTIVE|||||||
34129391|NCT01288170|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34129392|NCT01166789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34129393|NCT05082766|NA|SINGLE_GROUP||TREATMENT||NONE||will be treated with the enhanced DefenAge 8-in-1 BioSerum to their entire face||||
34129394|NCT05708573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129395|NCT02295228|||CASE_ONLY||PROSPECTIVE|||||||
34129396|NCT03394781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129397|NCT05541822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129398|NCT02998684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129399|NCT00615719|||COHORT||PROSPECTIVE|||||||
34129400|NCT04732923|NA|SINGLE_GROUP||OTHER||NONE||||||
34129401|NCT05744856|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the overt nature of the intervention, it is not possible to blind the participants, healthcare providers nor the investigators.|"The study is parallel 2-arm non-randomized intervention study with a delayed-start for the intervention group. The study population will be recruited in two phases. Over a period of 4 months (phase I) 1000 pregnant women will be screened for GDM among which 200 will be diagnosed with GDM and receive standard GDM care according to national guidelines in Vietnam (control group). During phase I, the self-care + informal support intervention will be co-created with local health care staff and a sub-group of the control group. Four months after the recruitment for phase I has finished, recruitment for phase II will start. Over a period of 4 months, another 1000 pregnant will be screened for GDM among which 200 will be diagnosed with GDM. These 200 women will be invited to receive the self-care + informal support intervention (intervention group). This pilot study is designed to inform a power calculation and logistics of a future full-scale randomized controlled trial."||||
34129402|NCT03525600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129403|NCT05361538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129404|NCT03360682|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129405|NCT05703425|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34129406|NCT01322724|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
34129407|NCT05244655|||COHORT||CROSS_SECTIONAL|||||||
34129408|NCT00582712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837396|NCT00371176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129409|NCT02705105|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129410|NCT01773967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129411|NCT01510990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129412|NCT05370976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129413|NCT05731635|||CASE_ONLY||CROSS_SECTIONAL|||||||
34129414|NCT04635709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129415|NCT05833009|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129416|NCT05372978|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to condition (cash vs control).||||
34129417|NCT00189579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129418|NCT02840435|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129419|NCT03533699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Then Patients will be randomly assigned to two groups using sealed, sequentially distributed envelopes to which the letters A and B will be allocated. The letter A will be assigned to the propranolol group and the letters B to the oxytocin group. The envelopes, will be opened by the investigator, and according to the letters, the group of patients will be determined. The first vaginal examination will be performed by the investigator, and then the induction will be initiated by the same researcher. Continuation of induction and the control of patients will be monitored by a coworker who knew nothing about the method of initiation of induction, neither did the patients (double blind)|"In the first group (Propranolol plus Oxytocin), a capsule consisting of 20 mg Propranolol will be administered and in the second group (Oxytocin plus placebo), a similar capsule as a placebo will be administrated orally by researcher before beginning of induction of labour.~Induction will be initiated at a dose of 2 mIu/min and it will be increased 2 mIu / minute every 15 minutes until good contractions are obtained (3 forceful contractions within 10 minutes) or to a maximum dose of 30 mIu/min; then, it will be continued at this rate for 8 hours. If patients enter the active phase of labour (cervical dilatation = 3-4 cm), induction will be continued until delivery. If no response to induction of labour, a caesarean section will be performed."|t|f|t|f
34129420|NCT06080074|NA|SINGLE_GROUP||TREATMENT||NONE||Participants going on ECMO with the Cardiohelp Device for clinical reasons will managed /treated according to a standardized protocol (anticoagulation, circuit change, weaning guidelines, adverse event identification) to estimate the safety and effectiveness of the device.||||
34129421|NCT06554977|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129422|NCT00193011|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129423|NCT01926951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129424|NCT00958087|||COHORT||PROSPECTIVE|||||||
34129425|NCT00205153|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129426|NCT03190135|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129427|NCT01746355|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34129428|NCT04013269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129429|NCT00880269|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129430|NCT01229683|||CASE_ONLY||PROSPECTIVE|||||||
34129431|NCT00400218|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129432|NCT02204046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129433|NCT02020798|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33837397|NCT00287443|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33837398|NCT03708653|||COHORT||PROSPECTIVE|||||||
33837399|NCT00349414|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837400|NCT03258736|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
33837401|NCT01224834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837402|NCT01684189|||CASE_ONLY||PROSPECTIVE|||||||
33837403|NCT02349997|||CASE_ONLY||PROSPECTIVE|||||||
33823913|NCT04281875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only participants will be masked to the intervention.|"NIRAF detection technology is used as an adjunctive tool for intraoperative parathyroid identification in patients who undergo total thyroidectomy (TTx) with or without lymph node dissection (LND) in the interventional group.~Generic Name of Device: Parathyroid Autofluorescence Detection Device (NIRAF detection technology).~The Parathyroid Autofluorescence Detection Device consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nanometer (nm) laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 Milliwatts (mW). The device has an FDA clearance for clinical use in general surgeries and dermatological use (Class 2 device)."|t|f|f|f
33823914|NCT06141902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823915|NCT05151198|||OTHER||CROSS_SECTIONAL|||||||
33823916|NCT01360294|||||PROSPECTIVE|||||||
33823917|NCT01018797|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33823918|NCT05319002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33823919|NCT01297452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823920|NCT04750213|||COHORT||PROSPECTIVE|||||||
33823921|NCT02705248|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823922|NCT00985621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823923|NCT02749175|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33823924|NCT06111443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33823925|NCT00400959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823926|NCT01238250|||FAMILY_BASED||PROSPECTIVE|||||||
33823927|NCT00069628|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33823928|NCT03941769|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33823929|NCT05761197|||COHORT||PROSPECTIVE|||||||
33823930|NCT00209222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823931|NCT05581589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823932|NCT01151878|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants and researchers conducting the study were blinded. Intervention products were prepared in sachets centrally by the hospital pharmacy by a person not involved in the conduct of the trial. The active product and placebo were packaged in identical sachets and labeled with one of two codes, each allocated to the experimental product or placebo. This procedure was performed by an independent pharmacist, who was the only person aware of the codes' meaning. The appearance and texture of the dry products were identical.||t|t|t|t
33823933|NCT02127814|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823934|NCT02998918|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33823935|NCT00509925|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823936|NCT06194929|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Cohort A will evaluate the hypothesis that avutometinib and defactinib will have clinical benefit in terms of response rate and/or for prolonging organ specific PFS in patients with cutaneous melanoma and at least one untreated brain metastases after at least one line of immunotherapy (Cohort A), compared to historical controls.~Cohort B will evaluate the hypotheses that avutometinib, defactinib, and encorafenib will have clinical benefit in terms of response rate and/or for prolonging organ specific PFS in patients who have received at least one prior line of immunotherapy and also may have received at least one line of prior BRAF/MEK therapy, compared to historical controls. Cohort B will also include a limited dose escalation cohort using a BOIN design"||||
33823937|NCT02581189|||CASE_ONLY||PROSPECTIVE|||||||
33823938|NCT01785797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823939|NCT01069406|||COHORT||PROSPECTIVE|||||||
33823940|NCT00868842|||CASE_ONLY||CROSS_SECTIONAL|||||||
33823941|NCT03255915|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||Randomized order, placebo-controlled, double blind, crossover|t|f|t|t
33823942|NCT05087329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823943|NCT02737670|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823944|NCT03643705|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33823945|NCT04276636|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823946|NCT03761407|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Twelve volunteers (6 males and 6 females) per dose group will be randomly assigned to two treatment sequences (placebo-verum and verum-placebo, within dose-group randomized) in a ratio of 1:1. There will be a washout period of 7 to 11 days between the treatment sequences.|t|t|t|t
33823947|NCT00317603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823948|NCT02399683|||CASE_ONLY|||||||||
33823949|NCT05818995|||OTHER||RETROSPECTIVE|||||||
33823950|NCT03857516|||COHORT||PROSPECTIVE|||||||
33823951|NCT03327688|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Part 1: All referrals to hospital due to a suspected DVT before intervention in year 2014, vs all referrals due to a suspected DVT after intervention in year 2017.~Part 2: POCUS group vs radiologist group"||||
33823952|NCT02394509|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823953|NCT04691336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823954|NCT05614024|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Participants will be assigned to one of two conditions, either the experimental or sham neurofeedback arm.|t|f|f|t
33823955|NCT04344756|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial with 2 parallels arms, 1:1, stratified on disease severity (ventilation or not)||||
33823956|NCT02329223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823957|NCT06646458|NA|SINGLE_GROUP||OTHER||NONE||||||
33823958|NCT06647186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were randomly selected into either study group (NIPSA) or control group (Conventional falp) using the coin toss method. Hence the study groups were classified into two groups as follows, group I (study group): ten patients treated with NIPSA plus FDBA and group II (Control group): ten patients treated with conventional flap design plus FDBA.||t|f|f|f
33823959|NCT01291550|||||PROSPECTIVE|||||||
33823960|NCT06201715|NA|SINGLE_GROUP||TREATMENT||NONE||Tofacitinib, an oral pan-JAK inhibitor, mainly selective against JAK1 and JAK3.||||
33823961|NCT06269393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823962|NCT06537219|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33823963|NCT00396214|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33823964|NCT04051190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823965|NCT02003716|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33823966|NCT00640185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33823967|NCT00424723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33823968|NCT04531371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33823969|NCT05686681|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33823970|NCT02637258|||COHORT||PROSPECTIVE|||||||
33823971|NCT03696732|||COHORT||PROSPECTIVE|||||||
33823972|NCT00790777|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823973|NCT06512116|NA|SINGLE_GROUP||TREATMENT||NONE||This study is an open, dose expanding, and indication expanding study.||||
33823974|NCT00212719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33823975|NCT04728217|NA|SINGLE_GROUP||PREVENTION||NONE||A 12-month prospective open-label, single-arm multicentre study.||||
33823976|NCT00743223|||CASE_CONTROL||PROSPECTIVE|||||||
33823977|NCT01936298|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33823978|NCT01785771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823979|NCT00287183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33823980|NCT01952106|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33823981|NCT05204472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33823982|NCT06025877|||COHORT||PROSPECTIVE|||||||
33823983|NCT03410108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823984|NCT00078858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823985|NCT00639236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33823986|NCT03279536|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group A will receive oral lactoferrin \& group B will receive Total dose infusion|t|f|f|f
33823987|NCT04613622|||COHORT||PROSPECTIVE|||||||
33823988|NCT05752955|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Investigator, Outcomes Assessor) The investigator and outcomes assessor will be blinded to allocation group. Each cluster will be coded and using a random number generator. The sites will only be unlinked after final database lock after endpoint adjudication for analysis.|Cluster randomised trial|f|f|t|t
33823989|NCT00234221|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33823990|NCT05721378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33823991|NCT04047680|||COHORT||PROSPECTIVE|||||||
33823992|NCT06646744|||OTHER||PROSPECTIVE|||||||
33823993|NCT03792789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33823994|NCT01572493|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33823995|NCT01956071|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33823996|NCT00835783|||CASE_ONLY||PROSPECTIVE|||||||
33823997|NCT05683886|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33823998|NCT03594266|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33823999|NCT02384083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824000|NCT00837096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824001|NCT03372655|||COHORT||PROSPECTIVE|||||||
33824002|NCT01561885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33824003|NCT03369652|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33824004|NCT04659278|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|The study will be double-blind; neither the Investigator nor the study participant will know to which study treatment arm the participant is assigned. All 3 study treatments will be packaged in identical bottles and similar labelling. Study treatment dispensing and return will be managed centrally; study treatment will be mailed directly to study participants. The 2 control test articles have been designed and flavored to look and taste like OMD study product.|"This is a 112-day, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of Endourage 1200 mg Complete Spectrum Oral Mucosal Drops (OMD ™). A total of 32 study participants will be enrolled.~Placebo (Hemp seed oil and peppermint flavoring)~Isolate (CBD no terpenes Hemp seed oil \[slightly lower concentration of CBD ratio\])~Endourage OMD (Full flower extract with a 1:1 ratio of cannabis terpenes, Hemp seed oil and peppermint flavoring)"|t|t|t|t
33824005|NCT02584075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824006|NCT05809245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824007|NCT06038383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824008|NCT00082511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824009|NCT02618785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824010|NCT03348969|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Clinical Trial||||
33824011|NCT03022045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824012|NCT05979402|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcome evaluations will be conducted by a researcher blinded to group allocation.|This study is a randomized controlled study with experimental and control groups consisting of pre-test and post-test|f|f|f|t
33824013|NCT04665349|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824014|NCT05283213|||COHORT||PROSPECTIVE|||||||
33824015|NCT04781543|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824016|NCT05964270|RANDOMIZED|PARALLEL||OTHER||SINGLE|pill count|A two-arm open-label parallel-group randomized controlled trial (RCT) will be conducted at a supra regional cancer center (referred to as 'het oncologisch centrum Isala'), which provides hematology services to a population with 0.5 million adherence and a population of 1 million referral, in the Northern-East region of The Netherlands.|f|t|f|f
33824017|NCT03692689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824018|NCT05918289|NA|SINGLE_GROUP||PREVENTION||NONE|"The trainers were unknown of the data collection and results, they are unaware of the research objective, and research hypothesis.~The data collectors are unaware of the purpose of the study and the intention to treat the mechanism, data analyzer is unaware of the outcome of the results and unaware of which coding number for which group."|This model is focusing on active aging through didactic including information on active aging and aging well, positive thinking, mindful eating, reflection on life, physical exercises, practical group activities, video-guided exercises, a booklet for a home for practice||||
33824019|NCT01939483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824020|NCT06453174|||COHORT||CROSS_SECTIONAL|||||||
33824021|NCT05095714|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34129434|NCT04059081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129435|NCT04833946|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34129436|NCT06373900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|SNOS protocol||t|f|f|f
34129437|NCT02886910|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824022|NCT05264298|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33824023|NCT03139383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients did not know the type of intravenous fluid they received during the surgery. The outcome assessors were blineded too.|a prospective randomized double-blind controlled study of the incidence and severity of postoperative nausea and vomiting in female participants receiving different types of intravenous fluid solution|t|f|f|t
33824024|NCT00791102|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33824025|NCT02186015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824026|NCT05450640|||OTHER||CROSS_SECTIONAL|||||||
33824027|NCT04646135|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Arm I:~* Day 1: 6 Boluses at 0.1 mg/kg LZ every 4 hr~* Day 2: 6 Boluses at 0.2 mg/kg LZ every 4 hr~* Day 3: Continuous Infusion at 0.025 mg/kg/hr LZ~Arm II:~* Day 1: 6 Boluses at 0.2 mg/kg LZ every 4 hr~* Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hr~* Day 3: Continuous Infusion at 0.03 mg/kg/hr LZ~Arm III:~* Day 1: 6 Boluses at 0.3 mg/kg LZ every 4 hr~* Day 2: 6 Boluses at 0.1 mg/kg LZ every 4 hr~* Day 3: Continuous Infusion at 0.025 mg/kg/hr LZ~Patients will be monitored for further 3 days of follow-up, after the end of the administration sequence. In case they would still need to undergo analgosedation, other drugs will be administered (e.g. midazolam, dexmedetomidine).~Patients will also be divided into two age groups - 6 patients: age ≥1 year \<5 years (COHORT 1); 3 patients: age ≥5 years - \<12 years (COHORT 2)"||||
33824028|NCT03721978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824029|NCT05307237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824030|NCT03375697|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33824031|NCT06183827|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open-label study|Multicenter, prospective, cross-over cluster randomized study||||
33824032|NCT06015620|||COHORT||PROSPECTIVE|||||||
33824033|NCT06245499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824034|NCT02722759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824035|NCT03380221|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33824036|NCT01143298|RANDOMIZED|CROSSOVER||||NONE||||||
33824037|NCT04145089|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|Randomization|GlideScope intubation Vs Cmac intubation|t|f|f|f
33824038|NCT04112355|||COHORT||PROSPECTIVE|||||||
33824039|NCT04732832|||COHORT||PROSPECTIVE|||||||
33824040|NCT04893902|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||control clinical rial|f|f|f|t
33824041|NCT05317299|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double|Randomized 3 exercise group (RE, PE and HIIT)|t|f|f|t
33824042|NCT06479551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824043|NCT06646380|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824044|NCT02203045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824045|NCT01903928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824046|NCT03746483|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Unblinded|2x2 Crossover||||
33824047|NCT00161902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33824048|NCT04303871|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33824049|NCT01249976|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824050|NCT02867371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824051|NCT04414397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824052|NCT05266157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33824053|NCT03170947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824054|NCT00511459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824055|NCT00550771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824056|NCT06027697|||COHORT||PROSPECTIVE|||||||
33824057|NCT04918966|||COHORT||PROSPECTIVE|||||||
33824058|NCT03986983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33824059|NCT03042858|||COHORT||PROSPECTIVE|||||||
33824060|NCT02486159|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824061|NCT03047278|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824062|NCT00120822|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33824063|NCT04385628|||FAMILY_BASED||PROSPECTIVE|||||||
33824064|NCT05106816|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The research subjects will be blinded regarding stimulation or sham and specific stimulation settings. Walking will be scored by a blinded rater for number of freezing episodes and walking completion time in seconds in the timed up and go task.|All participants will undergo tremor measurements and perform motor control tasks at baseline and during continuous vibratory stimulation and sham stimulation.|t|f|f|t
33824065|NCT05360342|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824066|NCT00002855|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824067|NCT05354557|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824068|NCT06195878|NA|SINGLE_GROUP||TREATMENT||NONE||Device: Continuous positive airway pressure (CPAP) therapy||||
33824069|NCT04486833|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1: 3+3 dose escalation to identify RP2D.~Phase 2: RP2D further evaluated in Phase 2a followed by parallel randomization in a 1:1 ratio to either investigational arm or control arm."||||
33824070|NCT00952016|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824071|NCT01437384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824072|NCT04086719|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824073|NCT01816100|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33824074|NCT00658983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824075|NCT05335668|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33824076|NCT01741636|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824077|NCT02754752|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33824078|NCT00006578||||TREATMENT||||||||
33824079|NCT01599377|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33824080|NCT06584838|||CASE_CONTROL||PROSPECTIVE|||||||
33824081|NCT05811455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824082|NCT04739293|NA|SEQUENTIAL||TREATMENT||NONE||3+3 dose escalation design with expansion cohort at recommended phase 2 dose||||
33824083|NCT02864147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824084|NCT04585737|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, active-controlled study of virologically suppressed participants living with HIV||||
33824085|NCT03736499|||COHORT||PROSPECTIVE|||||||
33824086|NCT05065918|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824087|NCT03408821|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.||||
33824088|NCT04804228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33824089|NCT02927899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33824090|NCT01811823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824091|NCT00130728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824092|NCT06642363|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|In this study, the individual conducting the blood test, the one prescribing the supplements, and the person analyzing the data are unaware of the division of participants into two groups: drug and placebo. Since the astaxanthin supplement and placebo are identical in color and shape, patients are also unaware of this division.|"Masking In this study, the individual conducting the blood test, the one prescribing the supplements, and the person analyzing the data are unaware of the division of participants into two groups: drug and placebo. Since the astaxanthin supplement and placebo are identical in color and shape, patients are also unaware of this division.~Blinding All baseline assessments will be conducted before randomization, and certain assessments will be performed with blinding for group allocation."|t|t|t|f
33824093|NCT00604240|||COHORT||PROSPECTIVE|||||||
33824094|NCT05484713|||COHORT||PROSPECTIVE|||||||
33824095|NCT04133259|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's Two-Stage Optimal design||||
33824096|NCT05571553|RANDOMIZED|PARALLEL||OTHER||SINGLE||"Phase 1~This is an experimental study of the randomized, longitudinal, prospective clinical trial type with a 3-month follow-up, open, in parallel groups (intervention versus control), carried out in people living with an MNCD and their family caregivers.~Number of participants : 120~Phase 2~This is a randomized, longitudinal, prospective, clinical trial with a 6-month follow-up, open, in parallel groups (intervention versus control), carried out in people living with an MNCD.~The total number of participants needed will be re-evaluated following analysis of the results obtained in Phase 1. We estimate at this time that a total of 40 participants per group, for a total of 80 people, is the number of participants needed for this study"|f|f|t|f
33824097|NCT06647277|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824098|NCT00000137|RANDOMIZED|||TREATMENT||DOUBLE||||||
33824099|NCT00415883|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824100|NCT04901819|||COHORT||CROSS_SECTIONAL|||||||
33824101|NCT04902196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"group 1: 2 testmoments, min. 7 days and max. 14 days in between them. Both have exactly the same design and the same content of measurements, with the exception of the intensity of the performed exercise protocol. The correct wattage for the exercise protocols is extracted from a previous maximum exercise test at the Jessa Hospital. By means of a randomized cross-over design, participants from group 1 will undergo both a moderately intensive cardiorespiratory protocol (MIT) and a high-intensity cardiorespiratory protocol (HIT).~group 2: 2 testmoments, min. 7 days and max. 14 days in between them. During the first testmoment, a maximum exercise test is performed (to establish the exercise protocol that will be used during the second testmoment). The design and content of the second test moment is identical to that of group 1 with the exception of 1) only performing a HIT protocol and 2) not completing the questionnaires only applicable for persons with low back pain (i.e. ODI, BPI)."||||
33824102|NCT00935649|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33824103|NCT00733551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824104|NCT02396550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824105|NCT04872634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824106|NCT02250183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824107|NCT03467789|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|"Neither the participant nor the treating physicians will know which patients receive the Vitamin D3 or placebo pills. Using a coin toss approach, the Research Pharmacist will assign each patient to a study group"|Each patient serves as his/her own control. Two PDT sessions are given, constituting Arm 1 and Arm 2. Arm 1 is placebo pill, then PDT. Arm 2 is Vit D pill, then PDT. In any given patient, the order of Arm 1 vs. Arm 2 will be randomized.|t|t|t|f
33824108|NCT03688022|RANDOMIZED|CROSSOVER||OTHER||NONE||Open Label||||
33824109|NCT06247488|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33824110|NCT02811042|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33824111|NCT04912102|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33824112|NCT01963442|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824113|NCT00052325||||TREATMENT||NONE||||||
33824114|NCT02271737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824115|NCT00352391|||CASE_ONLY||PROSPECTIVE|||||||
33824116|NCT03606850|NA|SINGLE_GROUP||TREATMENT||NONE||The patients will assess for markers of cortical excitability (cortical silent period CSP, resting motor threshold RMT, motor evoked potential MEP, intra-cortical inhibition ICI and intra-cortical facilitation ICF) before treatment, at day 3, day 7, day 14, day28 and day 60 with an assessment of depression (HAMD-21).||||
33824117|NCT05923398|NA|SINGLE_GROUP||OTHER||NONE||"Over approximately 3.5 months, each nursing professional will participate in the following:~A) Undergo a virtual reality scenario to understand and reduce stress and moral distress related to difficult decision-making in complex moral situations during the COVID-19 pandemic.~B) Use a web-based platform to measure stress, moral distress, and other mental health symptoms, as well as a commercial wearable device to collect physiological, sleep, and activity data to understand and examine the contribution of active and passive data to stress and moral distress.~During analysis, once all passive and active data is collected we will create a personal digital phenotype profile (pDPP) based on the physiological data collected during a morally challenging situation in a virtual environment as well as the wearable and web-based data to help understand stress and moral distress at the individual level."||||
33824118|NCT04364503|||COHORT||OTHER|||||||
33824119|NCT05153499|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33824120|NCT01792427|||COHORT||PROSPECTIVE|||||||
33824121|NCT00131183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33824122|NCT04075097|RANDOMIZED|CROSSOVER||OTHER||NONE||The proposed study is an acute, single group, crossover pilot study where participants will complete two different experimental conditions: aerobic exercise and yoga.||||
33824123|NCT03220659|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824124|NCT03913299|||COHORT||PROSPECTIVE|||||||
34129438|NCT04717024|||COHORT||PROSPECTIVE|||||||
34129439|NCT04089527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129440|NCT01389674|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34129441|NCT00396786|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34129442|NCT00886860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129443|NCT06243328|RANDOMIZED|PARALLEL||TREATMENT||NONE|Based on determining the main outcome variable, the estimated minimum required sample size is 39 patients (13 patient in each group|||||
34129444|NCT00162214|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129445|NCT04930835|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129446|NCT05671406|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34129447|NCT04910529|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and the researcher who carried out the application Aslıhan Aksu (A.A.) cannot be blinded due to the nature of the study. When the study is completed, the control and experimental groups will be coded as A and B and the data will be transferred to the computer environment by an independent researcher. The data coded as A and B will be analyzed by a statistician and the findings will be reported.|Prospective, parallel, two arm, randomized controlled clinical trial|f|f|f|t
34129448|NCT03578926|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double masked (participant and investigator)|Prospective, randomized, double masked, bilateral, 2-weeks, crossover study.|t|f|t|f
34129449|NCT00678171|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34129450|NCT00631813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129451|NCT05003323|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129452|NCT03903549|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34129453|NCT01229046|NA|SINGLE_GROUP||||NONE||||||
34129454|NCT00500357|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34129455|NCT02092636|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34129456|NCT04545424|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since it will be obvious to observers of the subjects whether they are in the treatment (TH+NMB) or control groups, the study is not masked but all treatments that determine outcome are protocolized.|Randomized (1:1) control (non-blinded) multicenter trial||||
34129457|NCT00769223|||COHORT||OTHER|||||||
34129458|NCT02346903|NA|SINGLE_GROUP||OTHER||NONE||||||
34129459|NCT02659033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129460|NCT03522935|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
34129461|NCT00140153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34129462|NCT05233488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant applicator are blinded to the US dose used.|Four groups; First group receives pulsed US 1 W/cm2 10% duty cycle. Second group receives pulsed US 1 W/cm2 50% duty cycle. Third group receives pulsed US 3 W/cm2 10% duty cycle. Fourth group receives pulsed US 3 W/cm2 50% duty cycle.|t|t|f|f
34129463|NCT06083168|||COHORT||PROSPECTIVE|||||||
34129464|NCT04621266|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34129465|NCT03873727|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129466|NCT05508542|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129467|NCT00770562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129468|NCT03519724|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34129469|NCT04482439|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a single-arm unmasked clinical evaluation study of binocular distance-corrected near (40 cm) visual acuity, when the non-dominant eye is targeted for slight myopia, after successful bilateral cataract surgery.||||
34129470|NCT03458325|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||A prospective treatment arm (i.e., Furoscix administered via the Furoscix Infusor) administered outside the hospital that will be compared to a propensity-matched historical control arm of patients admitted to the hospital for ≤ 72 hours (i.e., Treatment As Usual (TAU)) that will be derived from administrative claims data.||||
34129471|NCT00758069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129472|NCT01890824|||COHORT||PROSPECTIVE|||||||
34129473|NCT05290506|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||open-labelled, single treatment study between Low GLP-1 group and High GLP-1 group of prediabetes/type 2 diabetes||||
34129474|NCT02078050|NA|SINGLE_GROUP||||NONE||||||
34129475|NCT00581399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129476|NCT05535023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129477|NCT00506402|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129478|NCT01817842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129479|NCT02408172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129480|NCT00075855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34129481|NCT05869253|NA|SINGLE_GROUP||TREATMENT||NONE|The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT).|A prospective cohort study with Interrupted Time-Series design will be conducted.||||
34129482|NCT02676895|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129483|NCT06526182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129484|NCT04331912|||COHORT||RETROSPECTIVE|||||||
34129485|NCT02038751|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34129486|NCT01219478|||||RETROSPECTIVE|||||||
34129487|NCT00641355|||CASE_ONLY||PROSPECTIVE|||||||
34129488|NCT04094324|||COHORT||PROSPECTIVE|||||||
34129489|NCT04009018|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34129490|NCT00529776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34129491|NCT03215628|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34129492|NCT01922362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129493|NCT03544801|||CASE_CONTROL||PROSPECTIVE|||||||
34129494|NCT01378650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129495|NCT06368414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129496|NCT02936518|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129497|NCT02776605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129498|NCT05679960|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34129499|NCT00981162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129500|NCT04408391|||CASE_ONLY||PROSPECTIVE|||||||
34129501|NCT00289289|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34129502|NCT04482777|||CASE_CONTROL||RETROSPECTIVE|||||||
34129503|NCT05656183|NA|SINGLE_GROUP||SCREENING||NONE||||||
34129504|NCT03256669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129505|NCT02840942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129506|NCT02881411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129507|NCT00969163|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34129508|NCT01599429|||CASE_ONLY||PROSPECTIVE|||||||
34129509|NCT04019964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129510|NCT03612128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In this type of controlled clinical trials, the same subjects are used as experimental and control groups, ie both the new treatment method and the classical method or the placebo method are applied to the same subjects. The efficacy is applied to the new treatment method and on the other hand the classical method is applied on the same subjects at different times and the results are compared.||||
34129511|NCT06307990|||CASE_ONLY||PROSPECTIVE|||||||
34129512|NCT05053074|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34129513|NCT04579406|||COHORT||PROSPECTIVE|||||||
34129514|NCT00426868|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129515|NCT02947802|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34129516|NCT01821092|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129517|NCT05503979|||COHORT||PROSPECTIVE|||||||
34129518|NCT00393991|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129519|NCT04263116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Block randomization|Randomized controlled trial|t|t|t|t
34129520|NCT03389698|||COHORT||CROSS_SECTIONAL|||||||
34129521|NCT03419546|||COHORT||CROSS_SECTIONAL|||||||
34129522|NCT01274234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34129523|NCT03060915|NA|SINGLE_GROUP||OTHER||NONE||||||
34129524|NCT04779450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129525|NCT02674113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34129526|NCT03178097|||OTHER||PROSPECTIVE|||||||
34129527|NCT01060904|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129528|NCT06495320|RANDOMIZED|PARALLEL||OTHER||SINGLE||A parallel group (experiment-control) randomized controlled design, which is one of the experimental methods|t|f|f|f
34129529|NCT01876680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129530|NCT00244725|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34129531|NCT05525130|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129532|NCT01736423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129533|NCT02831127|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34129534|NCT01780844|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129535|NCT06421480|||OTHER||CROSS_SECTIONAL|||||||
34129536|NCT04809519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34129537|NCT03345030|||COHORT||PROSPECTIVE|||||||
34129538|NCT05760027|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The evaluator performing the measurements will be blinded.||f|f|f|t
34129539|NCT01430143|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129540|NCT00797264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129541|NCT05085041|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This research project will include two groups; the intervention and the control groups. Participants will be randomly assigned via block randomization with selected block sizes of 4. Randomization will be conducted by a researcher not involved in data management. The statistical software R version 3.5.1 will be used to determine to generate randomized arm allocation sequences through a fixed seed. The randomization will be stratified by centers. Those allocation sequences will be printed out and individually stored in serially numbered, opaque, sealed envelopes. Participants will be informed of group allocation via opaque and sealed envelopes after the collection of baseline data. Participants in the intervention group will receive 8 sessions of an online multi-component nutrition intervention. The control group will receive a copy of the booklet that includes dietary recommendations for adults and children, followed by the 2020 U.S. Department of Agriculture Dietary Guidelines.|t|f|f|f
34129542|NCT01268046|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Randomization was performed by the Research Pharmacy and the investigative team was blinded.|Each participant was randomized to placebo or estrogen using a block randomized design by age group|t|t|t|t
34129543|NCT03024112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129544|NCT05828615|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34129545|NCT05415254|RANDOMIZED|PARALLEL||TREATMENT||NONE||treatment group and control group||||
34129546|NCT04022525|||COHORT||CROSS_SECTIONAL|||||||
34129547|NCT03081663|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be told which group they have been assigned to until they have reached the final follow-up visit for the study.|Participants will be randomized to undergo their surgery through either the quadriceps-sparing mid-vastus approach or the medial para-patellar approach and with or without a tourniquet. We will stratify based on which type of analgesia will be used post-surgery, either an adductor canal block or local infiltration.|t|f|f|t
34129548|NCT05115981|||CASE_CONTROL||RETROSPECTIVE|||||||
34129549|NCT05263570|||COHORT||RETROSPECTIVE|||||||
34129550|NCT05813184|||CASE_CONTROL||PROSPECTIVE|||||||
34129551|NCT01652053|||COHORT||PROSPECTIVE|||||||
34129552|NCT01596712|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34129553|NCT01346943|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129554|NCT05116397|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Single-blinded|Randomized, single-blinded crossover design|t|f|f|f
34129555|NCT02569424|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129556|NCT04192045|||OTHER||PROSPECTIVE|||||||
34129557|NCT05401344|||COHORT||PROSPECTIVE|||||||
34129558|NCT03815630|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34129559|NCT04372550|RANDOMIZED|PARALLEL||TREATMENT||NONE|Analysis of the primary outcome is carried out blind.|Randomized Controlled Trial||||
34149375|NCT05671614|||COHORT||PROSPECTIVE|||||||
34149376|NCT03328416|NA|SINGLE_GROUP||OTHER||NONE||||||
34149377|NCT02718040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149378|NCT05458856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149379|NCT00002077||||TREATMENT||NONE||||||
34149380|NCT03758690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129560|NCT05822947|RANDOMIZED|PARALLEL||OTHER||TRIPLE|"Blinding was the primary outcome of interest. That said, except for intervention providers, every role was, by protocol, blinded to intervention assignment.~To maintain blinding of participants, candidate participants were formally invited to participate by email, with a study information form that masked the blinding feasibility objective.~The intervention providers were kept in a separate room and could not be blinded but were asked not to disclose the intervention group or the nature of the control MT component to participants, outcome assessors, data analysts, and other members of the study team."|Single centre, two-parallel group, blinding feasibility randomized controlled trial.|t|f|t|t
34129561|NCT03265145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129562|NCT04505644|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized controlled study|double blind randomized controlled study|t|t|t|t
34129563|NCT01588041|||COHORT||PROSPECTIVE|||||||
34129564|NCT03820336|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129565|NCT01939522|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129566|NCT06260449|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Single group tested by intervention and medical treatment|t|f|f|f
33824125|NCT04093466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824126|NCT04161547|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33824127|NCT05729477|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The miCOR System used during cataract surgery is a lens fragmentation and lens removal device which is an alternative to conventional phacoemulsification. The miCOR system has no cavitation and no thermogenic energy in the eye which can eliminate the generation of heat inside the eye while at the same time maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.||||
33824128|NCT04321915|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824129|NCT05262465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824130|NCT01357447|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33824131|NCT04355052|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824132|NCT04066400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomization|prospective, randomized, controlled, bicentric pilot study|f|f|f|t
33824133|NCT06462612|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824134|NCT00418418|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33824135|NCT01192672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824136|NCT02117856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824137|NCT00953342|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824138|NCT05190224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824139|NCT03750305|RANDOMIZED|PARALLEL||TREATMENT||NONE||Between groups, comparing Imagery-Focussed therapy with psychoeducation/TAU/within group, comparing baseline phase with treatment phase.||||
33824140|NCT06480851|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824141|NCT06647225|NA|SINGLE_GROUP||SCREENING||NONE|As this is a single arm study no-one will be masked from intervention, however sonographers performing the standard ultrasound and participants will be masked from the results of the AI-ultrasound scan|All participants will undergo the artificial intelligence ultrasound measures in addition to standard care.||||
33824142|NCT02606487|||CASE_ONLY||PROSPECTIVE|||||||
33824143|NCT05958147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824144|NCT06431295|NA|SINGLE_GROUP||SCREENING||NONE||||||
33824145|NCT01870414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824146|NCT01857362|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824147|NCT00038961|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33824148|NCT04705883|NA|SINGLE_GROUP||OTHER||NONE||||||
33824149|NCT05350514|||COHORT||CROSS_SECTIONAL|||||||
33824150|NCT05050019|||OTHER||OTHER|||||||
33824151|NCT04627441|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824152|NCT04462497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One group of patients will receive the existing method of head support (control group), the other group will receive the prototype head and neck support device (study group)|There will be 2 groups of a patients randomized to either the existing method of head support (sponge and towel stack) or prototype head and neck support device.|t|f|f|f
33824153|NCT02997397|||CASE_CONTROL||RETROSPECTIVE|||||||
33824154|NCT00955019|||COHORT||PROSPECTIVE|||||||
33824155|NCT05823519|||COHORT||PROSPECTIVE|||||||
33824156|NCT04017637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel 2-arm randomized-controlled pilot trial||||
33824157|NCT02934815|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824158|NCT06585748|||CASE_CONTROL||PROSPECTIVE|||||||
33824159|NCT04087798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Cluster Randomized Design||||
33824160|NCT00661323|||CASE_CONTROL||PROSPECTIVE|||||||
33824161|NCT06483269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824162|NCT04448821|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824163|NCT04595526|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33824164|NCT05880459|RANDOMIZED|SEQUENTIAL||SCREENING||NONE||||||
33824165|NCT02600988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824166|NCT04928482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors will be masked to group assignment. Outcome Assessors will not deliver the intervention and will not be present in the building when the intervention is being delivered. Participants will be instructed to not reveal their group assignment to the outcome assessor.|Participants will be randomized to receive either: 1) 27 sessions of backward walking training or 2) 18 sessions of backward walking training|f|f|f|t
33824167|NCT00243633|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824168|NCT04176926|||CASE_CONTROL||PROSPECTIVE|||||||
33824169|NCT02055053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824170|NCT00420563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824171|NCT03749148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|randomized, double blind, placebo controlled|Phase 2 multicenter, randomized, double blind, placebo controlled, proof of concept, parallel group, two-arm, investigator-initiated trial (IIT)|t|t|t|t
33824172|NCT02519829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837404|NCT04623606|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Historical and Untreated prospective control and Treatment group||||
33824173|NCT05353296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to treatment condition|This is a parallel-group, single-site, 2-arm Hybrid trial Type-1 effectiveness-implementation study|f|f|f|t
33824174|NCT04070183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Arm 1- Attention Control group Arm 2- Intervention group|f|f|f|t
33824175|NCT05746533|||COHORT||PROSPECTIVE|||||||
33824176|NCT04072198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824177|NCT00413634|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824178|NCT02127983|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33824179|NCT04940780|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patient-preference, pragmatic methodology||||
33824180|NCT05261347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824181|NCT05668000|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824182|NCT03795935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824183|NCT01040403|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33824184|NCT05532683|NA|SINGLE_GROUP||PREVENTION||NONE||One group of 12 participants identified as at clinical high-risk for psychosis (CHR-P) will be recruited to participate in a 9-week health behavior promotion/lifestyle intervention.||||
33824185|NCT02773121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824186|NCT04050319|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33824187|NCT05853432|||COHORT||RETROSPECTIVE|||||||
33824188|NCT01880697|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33824189|NCT04800133|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824190|NCT02906852|||COHORT||PROSPECTIVE|||||||
33824191|NCT00484172|||OTHER||PROSPECTIVE|||||||
33824192|NCT00173199|||DEFINED_POPULATION||OTHER|||||||
33824193|NCT06642337|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824194|NCT01000571|||CASE_ONLY||PROSPECTIVE|||||||
33824195|NCT02096809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824196|NCT01588171|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33824197|NCT01845558|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33824198|NCT04963998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824199|NCT01582412|NA|SINGLE_GROUP||||NONE||||||
33824200|NCT03719118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824201|NCT02919397|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33824202|NCT00627523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824203|NCT01742949|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33824204|NCT05994898|||COHORT||PROSPECTIVE|||||||
33824205|NCT02236702|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33824206|NCT05197153|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33824207|NCT04847778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"* Patients will be instructed on the correct installation and use of the Insulclock 360 system for recording insulin bolus information.~* Patients do not receive any other information and will not have access to the Insulclock 360 application from the Internet.~* They will keep administering insulin treatment as before.~* Randomization is blind to the recruiting investigator."|All participants will start the study using Insulclock, device and app on Masked Mode. At the week 4 patients will be randomized (1:1) to the Active Insulclock group or the Masked Insulclock group. Patients randomized in the Insulclock Active Group will receive detailed instructions on using the Insulclock device and Insulclock 360 mobile application and will be instructed and motivated for full use of all system functions (alarms, messages to the caregivers and investigation team). Patients randomized in the Insulclock Masked Group will be instructed on the correct installation and use of the Insulclock system for recording insulin bolus information but they will not receive any other information and will not have access to the Insulclock 360 application from the Internet and will keep administering insulin treatment as before. A healthcare professional will apply a FreeStyle Libre sensor to the upper arm in all the participants who do not use a CGM.|t|f|f|f
33824208|NCT03275402|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive up to two cycles of intracerebroventricular 131I-omburtamab. Safety and efficacy will be investigated with short-term follow-up at 26 weeks after treatment and with long-term follow-up for up to 3 years following treatment.||||
33824209|NCT06407583|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"The design is a single blind parallel RCT with a control group and intervention group. The study duration is 6 months.~Control: no intervention (education only) Intervention: ProMIO2.0 lifestyle program including multicomponent exercise and protein intake counselling."|f|f|t|f
33824210|NCT00088075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33824211|NCT00003926|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824212|NCT04112875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824213|NCT03329547|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This will be an open-label study. Hence, masking will not be provided.|This will be a two-period crossover study. Subjects will receive single oral dose of cefixime 400 mg test capsules and cefixime 400 mg reference capsules in treatment period 1 and 2 under fasting conditions.||||
33824214|NCT06381856|||COHORT||PROSPECTIVE|||||||
33824215|NCT03282799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824216|NCT04290156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Due to the nature of the study, the blinding of the participants and personnel (pediatric and adult gastroenterologists, medical staff) is not possible, however, the blinding of the data managers and statisticians will be secured.|This is a randomized, controlled, two-arm, multicentre trial. The target patient population consists of adolescents with inflammatory bowel diseases (IBD), aged between 16.75 and 17 years. The sample size calculation suggests that 160 subjects (80/ each arm) is required. The allocation ratio is 1:1. Eligible participants in the intervention arm attend a total of four joint transition visits with the adult and the pediatric gastroenterologist. In the control arm, adolescents meet only the pediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologists regarding the patient's treatment plan. Patients in both groups receive the same training and education, the only determinative difference between the two arms is the presence of the adult gastroenterologist at the joint transition visits.||||
33824217|NCT06425094|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Randomized, parallel arm, double-blind, placebo-controlled diet intervention|t|t|t|t
33824218|NCT05582590|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Standard 3+3 study design for the Dose Escalation Stage and a Dose Expansion Stage||||
33824219|NCT05828602|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129567|NCT04717271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A experient physical therapy will be responsible for assessments of all participants without knowing the group allocation of which.|A single-blind, parallel-group and randomized clinical trial|f|f|t|f
34129568|NCT04646252|||COHORT||PROSPECTIVE|||||||
34129569|NCT04211285|||OTHER||CROSS_SECTIONAL|||||||
33824220|NCT03298555|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
33824221|NCT04187963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||case-control|f|f|t|f
33824222|NCT06647433|||CASE_ONLY||PROSPECTIVE|||||||
33824223|NCT05615896|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||A||||
33824224|NCT06363513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824225|NCT00517270|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33824226|NCT04532008|RANDOMIZED|PARALLEL||TREATMENT||NONE||48 women randomized to either intervention or control.||||
33824227|NCT02091297|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33824228|NCT05666063|||CASE_ONLY||PROSPECTIVE|||||||
33824229|NCT00721708||CROSSOVER||||NONE||||||
33824230|NCT03835247|||OTHER||CROSS_SECTIONAL|||||||
33824231|NCT03729544|RANDOMIZED|PARALLEL||SCREENING||SINGLE|The allocation ratio will be 1:1 for an EPIC BPA on-screen alert versus no notification. Investigators will be assessing the impact of the EPIC BPA on echocardiographic screening for CTEPH and the diagnosis of CTEPH in the patients enrolled in this Quality Improvement Initiative. While investigators will randomize patients by Attending Physician of Record to minimize cluster-effect, the observational unit will be the patient. The cluster-effect describes a type of confounding observed in studies of provider behavior that can result in a bias of the outcome toward the null. In such a case, a provider may carry over knowledge gained from the alert for the intervention group patient to the care of the control group patient.|400-patient single-center Quality Improvement Initiative in the form of a randomized controlled trial|t|f|f|f
33824232|NCT03441750|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824233|NCT03096977|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824234|NCT06080490|||COHORT||RETROSPECTIVE|||||||
33824235|NCT04606745|||COHORT||PROSPECTIVE|||||||
33824236|NCT03122405|NA|SINGLE_GROUP||OTHER||NONE||||||
33824237|NCT04584879|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824238|NCT04021927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824239|NCT04935918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824240|NCT00644735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33824241|NCT01529541|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824242|NCT00287157|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33824243|NCT02137239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824244|NCT03448354|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparative effectiveness of HIPEC following interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy: Multicenter, prospective, cohort study||||
33824245|NCT02535962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824246|NCT03327571|||COHORT||RETROSPECTIVE|||||||
33824247|NCT06577649|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The order of interventions (A) active-sham-active-sham or (B) sham-active-sham-active were randomized using a computer-based random sequence generation program. The allocation was conducted by a nurse not involved in the project and consisted of 12 sealed, opaque and numbered envelopes consisting of information about the treatment order.|"n-of-1 single-blinded randomized controlled cross-over design: (A) active-sham-active-sham or (B) sham-active-sham-active."|t|f|f|f
33824248|NCT03642288|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824249|NCT06140576|NA|SINGLE_GROUP||TREATMENT||NONE||Lenvatinib combined with Sindilimab and Nab-paclitaxel in the first-line treatment for recurrent and metastatic triple negative breast cancer.||||
33824250|NCT01988883|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33824251|NCT06262776|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33824252|NCT05607485|NA|SINGLE_GROUP||OTHER||NONE|All videos were blinded to the participants about the surgeon and the surgical skill level of the surgeon|comparative blinded assessment study||||
33824253|NCT00847158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824254|NCT00655369|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824255|NCT00497692|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824256|NCT02847637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824257|NCT06505239|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33824258|NCT01137552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824259|NCT01745718|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824260|NCT01081730|||COHORT||PROSPECTIVE|||||||
33824261|NCT06395961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824262|NCT00295048|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33824263|NCT01585688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824264|NCT04098497|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This study uses a design known as a microrandomized trial. Whereas a multi-arm trial randomizes a subject to an intervention group only once at the start of the study, a microrandomized trial repeatedly randomizes a subject to an intervention group throughout the study. In addition to an overall effect of an intervention on proximal outcomes, a microrandomized trial allows one to determine if the effect is modified by momentary factors (e.g., current mood, day of the week, day in the study).~For the present study, every subject has a equal chance of being assigned to one of two intervention groups at each of 84 time points (2 daily x 42 days). At each time point, the two intervention groups are to either receive a prompt based on Acceptance and Commitment Therapy (ACT) or not receive such a prompt. Regardless of the assigned group, subjects are asked to assess their mood, stress, and activity at every time point prior to assignment to intervention group."||||
33824265|NCT01552668|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33824266|NCT04872101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824267|NCT01589380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824268|NCT00729885|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33824269|NCT03761134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824270|NCT00809783|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824271|NCT06411210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33824272|NCT03130816|NA|SINGLE_GROUP||TREATMENT||NONE||Patients diagnosed with cerebral palsy volunteered for participation in this study.||||
34129570|NCT01963793|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34129571|NCT03443856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129572|NCT05811754|||COHORT||RETROSPECTIVE|||||||
34129573|NCT04822818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129574|NCT03138317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129575|NCT05752097|||CASE_ONLY||PROSPECTIVE|||||||
34129576|NCT03088787|||COHORT||PROSPECTIVE|||||||
34129577|NCT03191643|||COHORT||RETROSPECTIVE|||||||
34129578|NCT02104791|||CASE_CONTROL||RETROSPECTIVE|||||||
34129579|NCT02266199|||COHORT||PROSPECTIVE|||||||
34129580|NCT01480583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129581|NCT03271320|||CASE_CONTROL||PROSPECTIVE|||||||
34129582|NCT05296551|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are block randomized into 3 parallel groups.||||
34129583|NCT00738608|||CASE_CONTROL||PROSPECTIVE|||||||
34129584|NCT01174979|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129585|NCT04231682|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129586|NCT00265837|RANDOMIZED|||TREATMENT||NONE||||||
34129587|NCT03823105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129588|NCT04504344|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34129589|NCT00598923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129590|NCT05777785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129591|NCT00188617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129592|NCT01282255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824273|NCT03501524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824274|NCT05737797|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824275|NCT01507753|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33824276|NCT05367024|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double blind masking|Crossover Assignment|t|f|t|t
33824277|NCT01933659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824278|NCT01290783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824279|NCT05382871|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33824280|NCT05934084|RANDOMIZED|PARALLEL||OTHER||NONE||It's a longitudinal study with two time-points (6 months and 12 months) after baseline (time 0) and the data will be evaluated by means of ANOVA for repeated measures, considering as baseline the global QoL of 75.||||
33824281|NCT01108484|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824282|NCT02392416|||||PROSPECTIVE|||||||
33824283|NCT04043806|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824284|NCT06008288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824285|NCT05138432|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants upon enrollment will be randomized into two groups, either to immediately receive up to $105 per month in vouchers for 12 months (intervention group) or to receive $105 per month in incentives for 12 months after a 6-month delay (delayed-intervention group)||||
33824286|NCT01533181|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33824287|NCT02099149|||CASE_CONTROL||PROSPECTIVE|||||||
33824288|NCT06642922|||OTHER||RETROSPECTIVE|||||||
33824289|NCT06050226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824290|NCT02921152|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824291|NCT05589584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824292|NCT01716923|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33824293|NCT04041024|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33824294|NCT03945851|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Participants, therapists (care providers), investigators, and outcomes assessors do not know which group (VNS or control VNS) the patients are randomized. Only one person at the site - the programmer who programs the device settings - knows which group the subject is randomized into.|Double blind, randomized, parallel study with partial crossover (control subjects crossover to treatment after randomized portion)|t|t|t|t
33824295|NCT05716152|||COHORT||PROSPECTIVE|||||||
33824296|NCT05533645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824297|NCT03972137|NA|SINGLE_GROUP||TREATMENT||NONE|This is an open trial with all participants receiving what will become the 'active intervention' in a subsequent randomized clinical trial.|All participants received individualized smoking cessation therapy (SCT), nicotine replacement therapy patch (NRT) and heart rate variability biofeedback (HRVB).||||
33824298|NCT05012397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824299|NCT00449488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824300|NCT01191450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824301|NCT05947708|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Only Subjects will be blinded to the dialysis device Qd.|Subjects will be randomized to either arm at a 1:1 ratio using excel's RANDBETWEEN function. Subjects will be randomly assigned a 0 or a 1. Subjects that are assigned '0' will go to Group 1, and subjects that are assigned '1' will go to Group 2.|t|f|f|f
33824302|NCT06371430|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33824303|NCT00301730||||TREATMENT||||||||
34129593|NCT05358626|||COHORT||CROSS_SECTIONAL|||||||
34129594|NCT00241176|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129595|NCT03786926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129596|NCT01835301|||COHORT||PROSPECTIVE|||||||
34129597|NCT06032559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34129598|NCT02516397|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129599|NCT04944238|||CASE_CONTROL||PROSPECTIVE|||||||
34129600|NCT05954949|||CASE_ONLY||PROSPECTIVE|||||||
34129601|NCT06555874|||OTHER||RETROSPECTIVE|||||||
34129602|NCT00845416|||COHORT||PROSPECTIVE|||||||
34129603|NCT03249324|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129604|NCT00515528|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129605|NCT02015949|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34129606|NCT00610792|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129607|NCT05976568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129608|NCT04015570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129609|NCT01637584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129610|NCT04262882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33824304|NCT05982028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824305|NCT02336113|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33824306|NCT01093222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824307|NCT01266499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824308|NCT03950596|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824309|NCT01780363|||CASE_CONTROL||PROSPECTIVE|||||||
33824310|NCT04433949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824311|NCT01379261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824312|NCT01878188|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824313|NCT01537406|||CASE_ONLY||RETROSPECTIVE|||||||
33824314|NCT04285476|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824315|NCT04968015|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase II open label controlled study. Subjects will be randomized 1:1 to receive Venetoclax or Idarubicin associated to Cytarabine||||
33824316|NCT04297436|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||To assess if immunisation of individuals at risk for gonococcal infection with 4CMenB (Bexsero) elicits humoral and T cell cross-reactive responses against Neisseria gonorrhoeae (Ng)||||
33824317|NCT00981929|NON_RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33824318|NCT04430712|||CASE_CONTROL||RETROSPECTIVE|||||||
33824319|NCT01937845|||OTHER||PROSPECTIVE|||||||
33824320|NCT05640973|||COHORT||CROSS_SECTIONAL|||||||
33824321|NCT04139239|||COHORT||CROSS_SECTIONAL|||||||
33824322|NCT05422742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824323|NCT02686359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33824324|NCT00557349|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33824325|NCT04222335|NA|SINGLE_GROUP||TREATMENT||NONE|No masking|||||
33824326|NCT05273177|||OTHER||CROSS_SECTIONAL|||||||
33824327|NCT02429752|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824328|NCT02885883|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33824329|NCT06479252|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33824330|NCT06545721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||the sample size for the normal weight group is 45, and the sample size for the overweight/obese group is 380.||||
33824331|NCT04264507|||OTHER||CROSS_SECTIONAL|||||||
33824332|NCT05624697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824333|NCT03448289|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Because we are studying health behaviors, we cannot share the specific aims of the study with control group participants as this could bias behavior. The control group participants will be told that this is a study monitoring women's general health care experiences at UIH.|The control group will be enrolled during phase 1 (first 4 months) prior to the introduction of the intervention. After enrollment of the control group, a 6-week washout period prior to phase 2 (intervention) will ensure women are not enrolled into both arms of the study.|t|f|f|f
33824334|NCT02805036|||CASE_CONTROL||PROSPECTIVE|||||||
33824335|NCT02218775|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33824336|NCT02262364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824337|NCT06405516|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33824338|NCT01462825|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33824339|NCT05656807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33824340|NCT00906659|||CASE_ONLY||PROSPECTIVE|||||||
33824341|NCT05512832|||COHORT||RETROSPECTIVE|||||||
33824342|NCT02915354|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33824343|NCT01960985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824344|NCT00448773|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824345|NCT02150083|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824346|NCT05715502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824347|NCT02396498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824348|NCT03930238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824349|NCT01334996|||CASE_ONLY||PROSPECTIVE|||||||
33824350|NCT05486871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824351|NCT00661466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824352|NCT02359578|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824353|NCT06645548|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Investigators and outcomes assessors will be blinded to the arm. Coded data will be used for masking.|Intervention cohort (3D camera weight estimation) and control cohort (standard care) will be used|f|f|t|t
33824354|NCT05672498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824355|NCT01829685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824356|NCT00748488|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824357|NCT02683356|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33837405|NCT04626349|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Due to the nature of the intervention neither the patient-caregiver dyads nor the intervention nurses (for the face-to-face FOCUS+ intervention) can be blinded to allocation. Data will be collected via a computer-assisted self-interview with a data collector that is present for assistance and additional explanations. Those conducting the data analyses will be unaware as to what trial arm dyads were randomized to until the end of the last data collection point.|||||
34129611|NCT01119196|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129612|NCT04594135|NA|SEQUENTIAL||TREATMENT||NONE||||||
34129613|NCT05474703|||COHORT||PROSPECTIVE|||||||
34129614|NCT02651324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129615|NCT01151384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129616|NCT00544024|||COHORT||PROSPECTIVE|||||||
34129617|NCT04397367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34129618|NCT05722834|NA|SINGLE_GROUP||TREATMENT||NONE||12 participants along with the Primary care physicians will be enrolled (both will sign consents).||||
34129619|NCT01034982|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34129620|NCT02467192|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129621|NCT05521347|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34129622|NCT04420832|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129623|NCT02195700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129624|NCT04566952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129625|NCT04192669|||COHORT||PROSPECTIVE|||||||
33824358|NCT04506359|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Triple (Care Provider, Investigator, Outcomes Assessor) This study was not fully blinded; however, the group allocation was concealed from the patient and primary researcher until after baseline assessments were completed. A primary researcher obtained patient consent, collected selfreported assessments, and if the patients were randomized to intervention group, the intervention trainer explained the exercise program to participants. The study statistician and data managers remained blinded at all times.|"This is a randomized controlled clinical trial which to compare the short term and long-term effects of the COPSCCP vs. the control group as usual group on early stage lung cancer patients.~For both groups, we assessed patients' outcomes (including baseline data) for 6 times (T1=baseline/during hospitalization of receiving surgery \& before their hospital; T2 to T6 = 1, 3, 6, 12, 24 months after discharge from hospital)."|f|t|t|t
33824359|NCT01565239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824360|NCT01811628|||CASE_ONLY||PROSPECTIVE|||||||
33824361|NCT04599387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33824362|NCT03289416|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomly assigned to either a PRP intervention group or the BMC intervention group. Knee pain and function outcomes of enrolled patients in the two groups will be compared to determine which treatment is more effective in treating knee osteoarthritis.||||
33824363|NCT00095017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824364|NCT05615662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824365|NCT04007848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824366|NCT03849521|||COHORT||PROSPECTIVE|||||||
33824367|NCT02345707|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824368|NCT06155487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|A randomized, double-blind, placebo-controlled, single and multiple ascending dose|t|t|t|t
33824369|NCT04979156|||COHORT||PROSPECTIVE|||||||
33824370|NCT01915992|NON_RANDOMIZED|PARALLEL||||NONE||||||
33824371|NCT06123949|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824372|NCT03154684|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33824373|NCT01091844|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33824374|NCT02806817|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33824375|NCT00355602|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824376|NCT02402699|||CASE_ONLY||PROSPECTIVE|||||||
33824377|NCT03845335|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Both patients and clinicians will be unaware of treatment allocation until the randomization sequence is disclosed. Clinician who will perform test and control treatment will know the group allocation.~Clinician who will do the outcome evaluation will be unaware of the treatment allocation.~A blinded researcher will perform data analysis."||t|f|t|t
33824378|NCT02798276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33824379|NCT04700488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824380|NCT02219763|||COHORT||PROSPECTIVE|||||||
33824381|NCT05561751|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration.~Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms:~* GPC-100 in combination with propranolol; or~* GPC-100 in combination with propranolol and G-CSF."||||
33824382|NCT06632925|||CASE_ONLY||PROSPECTIVE|||||||
33824383|NCT01974661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824384|NCT00003478|RANDOMIZED|||TREATMENT||||||||
33824385|NCT04045522|||CASE_ONLY||PROSPECTIVE|||||||
33824386|NCT02274051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824387|NCT06410625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824388|NCT00033462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824389|NCT02189122|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33824390|NCT02584218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33824391|NCT00981578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824392|NCT03129971|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with atrophic nonunion of femoral shaft fractures, who were treated at the Affiliated Hospital of Qinghai University, China.||||
33824393|NCT03658694|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"This is an adaptive sequential trial of FM patients. In stage 1 patients were randomly allocated into two parallel arms (conventional rTMS, sham) using adaptive methodology. In stage 2, after the end of the first trial, patients will be allocated to two arms (conventional rTMS, patterned rTMS). Both stages will be conducted in a sequential methodology where an interim analysis will take place and indicate whether will take place trial is positive and of the scientific board agrees open its start.~Recruitment time will be extended by 12 months due to dropouts related to the Covid-19 pandemic. We have had dropouts due to some patients who developed Covid-19 and also due to patients who were afraid of becoming infected during hospital visits. Those patients who dropped out of the study due to the pandemic will be excluded from the main analysis and will be analyzed as a secondary outcome."|t|f|t|f
33824394|NCT04808297|||CASE_ONLY||PROSPECTIVE|||||||
33824395|NCT00172913|||DEFINED_POPULATION||OTHER|||||||
33824396|NCT01883778|||COHORT||CROSS_SECTIONAL|||||||
33824397|NCT06084455|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824398|NCT00273650|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33824399|NCT03211897|||COHORT||PROSPECTIVE|||||||
33824400|NCT05478681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824401|NCT05825547|NA|SINGLE_GROUP||OTHER||NONE||||||
33824402|NCT01685125|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824403|NCT00411177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824404|NCT06231498|||CASE_CONTROL||PROSPECTIVE|||||||
34129626|NCT03549494|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34129627|NCT03902015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129628|NCT03402191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129629|NCT04508933|||CASE_CONTROL||PROSPECTIVE|||||||
34129630|NCT02410044|||COHORT||PROSPECTIVE|||||||
34129631|NCT05510466|||COHORT||RETROSPECTIVE|||||||
34129632|NCT05561439|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34129633|NCT02819986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129634|NCT04884750|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34129635|NCT01816191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129636|NCT05154097|||COHORT||RETROSPECTIVE|||||||
34129637|NCT05223023|||OTHER||PROSPECTIVE|||||||
34129638|NCT03449563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824405|NCT05310734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A blood draw will be taken from subjects just before a full body spinosad application (t=0) and then at 0.5 and 3.0 hours. The following PK parameters will be calculated for spinosad (spinosyn A and spinosyn D) and benzyl alcohol in each subject: Cmax, Tmax, and Area Under the Curve (AUC) 0-3h. Safety assessments include monitoring of AEs, general skin and eye irritation, laboratory assessments, prior medications, and concomitant medications. Smaller laboratory blood samples will be collected pre-dose and 3-hours post-dose prior to discharge.||||
34129639|NCT03496064|||COHORT||RETROSPECTIVE|||||||
34129640|NCT03137680|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Care Provider i.e., vascular surgeon are blinded to subject randomisation||f|t|f|f
34129641|NCT02303067|||CASE_ONLY||PROSPECTIVE|||||||
34129642|NCT01101958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129643|NCT06228482|NA|SINGLE_GROUP||TREATMENT||NONE||Single treatment||||
33824406|NCT00462202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824407|NCT06646497|NA|SINGLE_GROUP||TREATMENT||NONE||A phase II multicenter, national, prospective, single-arm trial||||
33824408|NCT02067455|NA|SINGLE_GROUP||||NONE||||||
33824409|NCT01296178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824410|NCT02640222|||COHORT||RETROSPECTIVE|||||||
33824411|NCT00086723||||TREATMENT||||||||
33824412|NCT01092988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824413|NCT04168996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824414|NCT02886234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33824415|NCT03229356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824416|NCT05441371|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Split mouth||||
33824417|NCT04239157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824418|NCT01837719|RANDOMIZED|CROSSOVER||||NONE||||||
33824419|NCT01894256|NON_RANDOMIZED|PARALLEL||||NONE||||||
33824420|NCT05004688|NA|SINGLE_GROUP||OTHER||NONE||open-label||||
33824421|NCT03113214|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33824422|NCT02311985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33824423|NCT04725617|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824424|NCT05869149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824425|NCT03421171|||OTHER||OTHER|||||||
33824426|NCT05213117|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The investigators plan to randomize 16-18 Post Graduate Year (PGY)-1 residents in internal medicine at Massachusetts General Hospital from the possible 74 PGY-1 incoming residents who agree to partake in the study to one general medicine clinical floor for the academic year. These co-localized residents will complete 16-20 weeks of scheduled rotation time on White 9. Similarly, the investigators plan to randomize 6-8 PGY-2 residents from a possible group of 64 PGY-2 residents who agree to participate in the study to one general medical clinical floor for the academic year. These participants will complete 4-6 weeks of scheduled rotation time on White 9. Rotations will be completed in the normal 2 or 4 week block rotations, randomly assigned throughout the academic year.||||
33824427|NCT05803902|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824428|NCT00711555|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824429|NCT05372913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824430|NCT02214771|||COHORT||PROSPECTIVE|||||||
33824431|NCT05612555|||CASE_ONLY||RETROSPECTIVE|||||||
33824432|NCT02413554|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33824433|NCT06153901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824434|NCT02720198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824435|NCT04557332|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators and participants were aware of which group participants were randomly assigned to.|Randomized controlled trial in which participants were randomly assigned to intervention group or control group.|f|f|f|t
33824436|NCT01424189|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824437|NCT01679847|||CASE_ONLY|||||||||
33824438|NCT03638583|||OTHER||OTHER|||||||
33824439|NCT00993018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824440|NCT06646445|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicenter open-label randomized phase II trial. Eligible patients will be randomized to receive pembrolizumab with a watch-and-wait approach (experimental arm) or standard strategy (surgical resection ±adjuvant chemotherapy; control arm) in a 1:1 ratio.||||
33824441|NCT05783154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824442|NCT00002519||||TREATMENT||||||||
33824443|NCT04673799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized、double-blind、parallel-group、single-dosed、positive control|t|f|t|t
33824444|NCT01333683|||COHORT||PROSPECTIVE|||||||
33824445|NCT01829828|||COHORT||PROSPECTIVE|||||||
33824446|NCT01451697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824447|NCT03168425|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants were randomized to either a personalized prescribing algorithm based off of inpatient opioid use versus standard discharge opioid prescribing.||||
33824448|NCT04719819|||COHORT||PROSPECTIVE|||||||
33824449|NCT00404508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824450|NCT02996097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824451|NCT04721132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824452|NCT00823004|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824453|NCT05453396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824454|NCT03134976|||COHORT||PROSPECTIVE|||||||
33824455|NCT01608958|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33824456|NCT06413277|||COHORT||PROSPECTIVE|||||||
34129644|NCT03776318|||COHORT||PROSPECTIVE|||||||
34129645|NCT05084079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129646|NCT04633395|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Pregnant women in the third trimester will be randomised to 2 different groups (intervention group, and active control group).|f|t|t|t
34129647|NCT00995436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34129648|NCT02110186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129649|NCT04920084|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single-arm, single-center pilot.||||
34129650|NCT03427593|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129651|NCT02949050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129652|NCT04667676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129653|NCT05223569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129654|NCT02399124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129655|NCT02219061|||||PROSPECTIVE|||||||
34129656|NCT02088099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34129657|NCT04216849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129658|NCT01248572|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34129659|NCT02342847|||COHORT||PROSPECTIVE|||||||
34129660|NCT03200483|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34129661|NCT00601614||||TREATMENT||||||||
34129662|NCT05178836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129663|NCT05848466|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34129664|NCT04283955|||COHORT||RETROSPECTIVE|||||||
34129665|NCT02531360|NA|SINGLE_GROUP||||NONE||||||
34129666|NCT04823728|||CASE_CONTROL||RETROSPECTIVE|||||||
33824457|NCT01129115|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824458|NCT02410317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824459|NCT00000578|RANDOMIZED|||TREATMENT||DOUBLE||||||
33824460|NCT06646939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824461|NCT04836338|||COHORT||PROSPECTIVE|||||||
33824462|NCT04823117|||CASE_CONTROL||PROSPECTIVE|||||||
33824463|NCT05566002|||CASE_ONLY||RETROSPECTIVE|||||||
33824464|NCT02781077|||CASE_ONLY||PROSPECTIVE|||||||
33824465|NCT01797705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824466|NCT01213615|||COHORT||PROSPECTIVE|||||||
33824467|NCT04183777|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33824468|NCT03268850|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Allocation will be concealed from the study investigators; however, research assistants conducting the assessments will not be blinded since the assessment protocol differs based on group assignment. Study participants will know which arm they are in, but not the reimbursement amount of the other arm.|Candidates will be randomized 1:1 to the LW-A or LW-B arm, with stratification for race. The investigators will prepare the randomization schedule using permuted blocks of randomly varying size to limit predictability and imbalances in arm assignment throughout the study. KT candidates will be informed of group assignment immediately after consenting to the study.|f|t|t|f
34129667|NCT06004258|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Quasi-experimental (non-randomized) controlled study||||
34129668|NCT00232323|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34129669|NCT06370624|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||One group will be followed - with both the standard of care continuous EEG monitoring and near infrared spectroscopy (NIRS) \& the MRI-scan performed at the same time.||||
34129670|NCT05594771|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34129671|NCT00879723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129672|NCT04177004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129673|NCT05232279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129674|NCT05003973|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34129675|NCT03990402|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33824469|NCT02675296|||COHORT||RETROSPECTIVE|||||||
33824470|NCT04783883|||CASE_ONLY||RETROSPECTIVE|||||||
33824471|NCT06584643|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33824472|NCT03189641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824473|NCT01363297||||TREATMENT||NONE||||||
33824474|NCT04547166|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824475|NCT00223561|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33824476|NCT03659890|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33824477|NCT04238871|||COHORT||OTHER|||||||
33824478|NCT01414543|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33824479|NCT06647316|NA|SINGLE_GROUP||TREATMENT||NONE||This project employs a quasi-experimental, analytical, longitudinal, prospective, single-group study design.||||
33824480|NCT03445507|RANDOMIZED|PARALLEL||TREATMENT||NONE|Intervention can´t be masked. We will objectify primary outcome by biochemistry validation, and statistician conducting the analysis will not know to which study arm a given patient has been assigned.|N = 460 smokers (230 in each arm), who will be recruited before randomization. Interventions: Intervention group: Use of an evidence-based chat bot for smoking cessation. Control group: Usual care (Madrid Health System Portfolio).||||
33824481|NCT02541799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824482|NCT00126061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33824483|NCT00694564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824484|NCT04664985|RANDOMIZED|PARALLEL||TREATMENT||NONE||80 women with endometrial cancer or Cervical cancer will be recruited over 8 months, 40 being randomized in the Mucogyne® arm, the 40 others in the control arm.||||
34129676|NCT02869581|||COHORT||PROSPECTIVE|||||||
34129677|NCT01320852|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34129678|NCT06282237|||OTHER||PROSPECTIVE|||||||
34129679|NCT04898348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129680|NCT04224441|NA|SINGLE_GROUP||TREATMENT||NONE||Addition of chlorpromazine to the standard GBM treatment during the adjuvant phase of the therapeutic protocol in un-methylated GBM patients||||
34129681|NCT00817453|||COHORT||CROSS_SECTIONAL|||||||
34129682|NCT03093948|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129683|NCT05141175|NA|SINGLE_GROUP||OTHER||NONE||||||
34129684|NCT05200416|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34129685|NCT03910725|||CASE_CONTROL||PROSPECTIVE|||||||
34129686|NCT00452075|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129687|NCT05070312|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34129688|NCT03461562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129689|NCT00070109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129690|NCT06322550|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double blind|Monocenter, randomized, double blind, three-armed clinical trial|t|f|t|f
33824485|NCT01733082|||COHORT||PROSPECTIVE|||||||
33824486|NCT05359705|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824487|NCT05335239|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single - blind|Randomized controlled trial|f|f|f|t
33824488|NCT03043170|||COHORT||PROSPECTIVE|||||||
33824489|NCT03045055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824490|NCT01276509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824491|NCT00945178|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33824492|NCT01960114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824493|NCT01903668|||COHORT||RETROSPECTIVE|||||||
33824494|NCT01184859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824495|NCT02264418|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33824496|NCT06291402|||COHORT||PROSPECTIVE|||||||
33824497|NCT04483791|NA|SINGLE_GROUP||OTHER||NONE||Prospective, non-randomized, multicenter registry||||
33824498|NCT02728375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824499|NCT02646189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824500|NCT01073215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824501|NCT01696006|||CASE_ONLY||PROSPECTIVE|||||||
33824502|NCT02966418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33824503|NCT04499014|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33824504|NCT03834402|||COHORT||PROSPECTIVE|||||||
33824505|NCT01393613|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824506|NCT01774461|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33824507|NCT00983424|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824508|NCT00067548|NON_RANDOMIZED|||TREATMENT||NONE||||||
33824509|NCT01533064|||CASE_ONLY||RETROSPECTIVE|||||||
33824510|NCT05498077|NA|SINGLE_GROUP||TREATMENT||NONE||Case series||||
33824511|NCT03326050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824512|NCT05317377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will be included in the study and randomly divided into two groups using block randomization in Microsoft Excel 'RAND(WS)' function.||t|f|f|f
33824513|NCT05067543|||COHORT||PROSPECTIVE|||||||
33824514|NCT04682340|||CASE_CONTROL||PROSPECTIVE|||||||
33824515|NCT05642247|||COHORT||RETROSPECTIVE|||||||
33824516|NCT03974100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind||t|f|t|t
33824517|NCT05376787|||OTHER||PROSPECTIVE|||||||
33824518|NCT03412513|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824519|NCT04064723|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Control: Corail femoral stem and Pinnacle cup with Marathon XLPE neutral liner (DePuy Orthopaedics).~Study: LCU femoral stem (Waldemar Link GmbH) and Delta TT cup with Neutral XLPE liner (Lima Corporate)."||||
33824520|NCT05590806|RANDOMIZED|SINGLE_GROUP||SCREENING||DOUBLE|||t|f|t|f
33824521|NCT01177137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824522|NCT05180487|RANDOMIZED|PARALLEL||PREVENTION||NONE||Families will be assigned to treatment vs. wait-list control. The investigators will assess families at baseline and at 3-, 6-, and 12-month follow-ups. Families in the treatment condition will receive the intervention between baseline and the 3-month follow-up. The control group will receive the intervention following the 12-month follow-up.||||
33824523|NCT03578419|RANDOMIZED|CROSSOVER||PREVENTION||NONE||A stepped wedge cluster randomized trial in which ICUs (clusters) switch from a strategy of blood collection using standard-draw tubes (control) to soft-draw tubes (intervention). In this design, the timing at which individual ICUs switch to the intervention is randomly assigned.||||
33824524|NCT01930877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824525|NCT02971995|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33824526|NCT01537900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824527|NCT03440697|||COHORT||PROSPECTIVE|||||||
33824528|NCT05833776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33824529|NCT03517059|||COHORT||PROSPECTIVE|||||||
33824530|NCT06194318|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33824531|NCT02099019|||CASE_ONLY||CROSS_SECTIONAL|||||||
33824532|NCT05122052|||COHORT||PROSPECTIVE|||||||
33824533|NCT02186496|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824534|NCT03039647|||COHORT||PROSPECTIVE|||||||
33824535|NCT03528109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824536|NCT03705533|RANDOMIZED|CROSSOVER||OTHER||SINGLE|\*The randomization code will not be available to the personnel of the bioanalytical facility until the bioanalytical tables have been finalized and audited by the Quality Assurance (QA) department. Study participants will be aware they will receive different formulations of the same drug, without being informed which product (Test or Reference) is being administered.|In compliance with full replicate design there are two sequences in the study: ABAB and BABA where A = the test product, B = the reference product (see detailed description of items below).|f|f|f|t
33824537|NCT00141908|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33824538|NCT04012099|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
34129691|NCT02110433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824539|NCT02004132|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824540|NCT04780113|||COHORT||PROSPECTIVE|||||||
33824541|NCT00123435|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824542|NCT01763346|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33824543|NCT02515526|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33824544|NCT02735798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824545|NCT05211453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824546|NCT02452125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824547|NCT01705951|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33824548|NCT04668534|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824549|NCT01259440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33824550|NCT01095601|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33837406|NCT03315013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837407|NCT01606371|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33837408|NCT05772182|||COHORT||PROSPECTIVE|||||||
33837409|NCT03238963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129692|NCT02225704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129693|NCT00483054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129694|NCT05382884|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study phase uses a randomized controlled trial design and will evaluate the effectiveness and usability of postpartumcare.ca. Fifty participants will be randomized to the intervention group, receiving immediate access to postpartumcare.ca for 4 weeks, and 50 will be assigned to a waitlist control group, receiving treatment as usual for the duration of the 4-week intervention period. Following the 4-week intervention period and 2-week follow-up, participants from both groups will be able to access postpartumcare.ca.||||
34129695|NCT04495530|||COHORT||CROSS_SECTIONAL|||||||
34129696|NCT03941964|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129697|NCT01454505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129698|NCT02016716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129699|NCT00003566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129700|NCT02704949|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129701|NCT01475643|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34129702|NCT02322580|||COHORT||PROSPECTIVE|||||||
34129703|NCT01798901|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129704|NCT01936454|||||PROSPECTIVE|||||||
34129705|NCT02575872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34129706|NCT04848467|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34129707|NCT00335283|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129708|NCT06264908|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients will be randomized into early intervention and routine clinical care (control) group. Patients in control group will crossover to receive the intervention at week 26.||||
34129709|NCT06089733|NA|SINGLE_GROUP||TREATMENT||NONE||On Day 1, subjects will receive a single oral dose of approximately 50 mg ABSK021 containing approximately 100 μCi of \[14C\] ABSK021 in the fasted state.||||
34129710|NCT04815772|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34129711|NCT05323604|||COHORT||RETROSPECTIVE|||||||
34129712|NCT05650463|NA|SINGLE_GROUP||SCREENING||NONE||||||
34129713|NCT02434653|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34129714|NCT01063062|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129715|NCT06421064|||COHORT||RETROSPECTIVE|||||||
34129716|NCT01322854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129717|NCT00069875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34129718|NCT04704297|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The two trigger point injection arms will be drawn-up and randomized by a research pharmacist prior to delivery to the Emergency Department. These two army will be Bupivacaine and Normal Saline, which are identical in appearence.|This will be a prospective three-armed randomized controlled trial. There will be no crossover. The first arm will be single blinded as it will be obvious to the investigators that it does not involve trigger point injections. The other two arms will be double blinded trigger point injections with either Bupivacaine or Normal Saline.|t|t|t|t
34129719|NCT03789123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129720|NCT01661751|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129721|NCT05580263|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|PI (data assessor) will be blinded for the grouping.||f|f|t|t
34129722|NCT03192293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129723|NCT04565340|||COHORT||RETROSPECTIVE|||||||
34129724|NCT04014699|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34129725|NCT01407952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129726|NCT05842941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129727|NCT01248728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129728|NCT05802472|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Block randomization. This procedure aims to ensure a periodic balance in the number of subjects assigned to each intervention group (53). The size of each block will be six individuals, and the number of blocks will be 10; the permutation of the groups was defined as Control (C) and Experimental (E). It is important to note that the blocks and permutations were randomly assigned.|Single-blind, placebo-controlled, randomized clinical trial.|t|f|f|f
34129729|NCT05074511|||COHORT||PROSPECTIVE|||||||
34129730|NCT01030952|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129731|NCT00683930|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129732|NCT01056406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129733|NCT01132846|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129734|NCT05439278|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824551|NCT03565640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and research staff will be masked during the study as much as possible, however there will be a description of the type of sacrospinous ligament fixation device used within the body of the operative note for each patient that research staff could gain access to||t|f|f|f
33824552|NCT06276751|||CASE_CONTROL||PROSPECTIVE|||||||
33824553|NCT00546702|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824554|NCT05655234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|A research team member will be masked when performing data analysis|We will conduct randomised controlled trial (RCT) to evaluate the effects of the MB programme|f|f|f|t
33824555|NCT04397614|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33824556|NCT01995318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824557|NCT01260142|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824558|NCT00024102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824559|NCT06280118|RANDOMIZED|PARALLEL||SCREENING||NONE||Randomized controlled trial||||
33824560|NCT02702739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824561|NCT01880944|||COHORT||PROSPECTIVE|||||||
33824562|NCT04168021|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|f|t
34129735|NCT01131806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129736|NCT06285032|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34129737|NCT00194077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129738|NCT02958254|||OTHER||CROSS_SECTIONAL|||||||
34129739|NCT02250131|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34129740|NCT00056173|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129741|NCT02959294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129742|NCT06365255|||OTHER||OTHER|||||||
34129743|NCT04807608|||COHORT||PROSPECTIVE|||||||
34129744|NCT01262560|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129745|NCT04555863|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34129746|NCT03992716|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34129747|NCT03114735|||CASE_ONLY||PROSPECTIVE|||||||
34129748|NCT00110435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129749|NCT04625101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129750|NCT02473094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129751|NCT01013324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129752|NCT00465452|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129753|NCT03442556|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129754|NCT01461499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129755|NCT01266278|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129756|NCT05429320|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34129757|NCT05993988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|parallel assignment|t|f|f|f
34129758|NCT01942824|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
34129759|NCT05487690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129760|NCT05800353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129761|NCT04130776|||CASE_ONLY||PROSPECTIVE|||||||
34129762|NCT01769950|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129763|NCT00000407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129764|NCT05175131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129765|NCT04222894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129766|NCT00652314|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129767|NCT04905706|||COHORT||PROSPECTIVE|||||||
34129768|NCT05204602|||COHORT||PROSPECTIVE|||||||
34129769|NCT03626012|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34129770|NCT00444483|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34129771|NCT03396497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129772|NCT03043755|||COHORT||PROSPECTIVE|||||||
34129773|NCT05948527|NA|SINGLE_GROUP||OTHER||NONE||||||
34129774|NCT05059301|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study is double blind from start to final analysis after which the study is considered single blind.||t|t|t|f
34129775|NCT02869126|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129776|NCT02707965|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34129777|NCT00100568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129778|NCT02715830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The moment of randomization was after the successful accomplish of the recanalizaripn of the first artery. The used 80 sealed papers - 40 for each treatment. The nurse pick up one of the mixed papers and the procedure stops or continuous to the another artery depending on the randomization.|In this study, there is no use of other drugs, biological vaccine or combination product, but it was used two different approaches to the same problem: the renalization of the tibial arteries in patients with tissue loss. The angioplasty, that is the usual method of treatment, is done for one or more than one artery after randomization. It is phase 4 because it is an usual method of treatment (gold standard) for this disease.|t|f|f|f
34129779|NCT00192920|||DEFINED_POPULATION||OTHER|||||||
34129780|NCT04434430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34129781|NCT06293534|||CASE_ONLY||CROSS_SECTIONAL|||||||
34129782|NCT00822159|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129783|NCT05475028|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129784|NCT04428255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129785|NCT03415581|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34129786|NCT03028129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33824563|NCT04679597|||COHORT||RETROSPECTIVE|||||||
33824564|NCT01245803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824565|NCT00553605|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824566|NCT04486079|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837410|NCT02849470|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837411|NCT02015988|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129787|NCT03038971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129788|NCT06245005|||COHORT||PROSPECTIVE|||||||
34129789|NCT04830215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129790|NCT02058004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129791|NCT01888783|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129792|NCT04570878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129793|NCT05248178|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All outcome assessors will be blinded to participant study group assignment. Participants and investigative team will be blinded to participant tDCS condition (i.e. active vs sham.)||t|f|t|t
34129794|NCT06190470|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34129795|NCT02316353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129796|NCT02456753|||CASE_ONLY||CROSS_SECTIONAL|||||||
34129797|NCT04976790|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two arms recruit and evaluate the participants at the same time, and the included participants have the equal opportunity to either the Chinese Tuina or the Flurbiprofen Cataplasms treatment groups.||||
34129798|NCT01593384|||COHORT||PROSPECTIVE|||||||
34129799|NCT00824889|NON_RANDOMIZED|PARALLEL||||NONE||||||
34129800|NCT05044650|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be assigned randomly 7:3 to either KOVIR group or Non-KOVIR group respectively.||||
34129801|NCT04727996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129802|NCT06039215|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a prospective, multicenter, randomized, controlled, open-label, phase III, stepped wedge cluster randomized design. This experimental design involves the sequential implementation of an intervention in the clusters included over several periods. The order in which the clusters received the intervention was determined by drawing lots; at the end of the study, all the clusters received the intervention at some point and were observed during a pre- and post-intervention control period (each cluster is its own control)."||||
34129803|NCT00109213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824567|NCT05130502|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Individuals will perform foam roller and dynamic warm up and kinesiotape and dynamic warm up. there will be one week wash-out between tests.|t|f|f|f
33824568|NCT00266747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824569|NCT02759276|||||CROSS_SECTIONAL|||||||
33824570|NCT04117906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Measures will be completed online without direct involvement from the research team.||f|f|f|t
33824571|NCT05501496|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824572|NCT03965221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824573|NCT05753241|||COHORT||CROSS_SECTIONAL|||||||
33824574|NCT03436030|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Healthy reclining adult volunteers, with Valsalva manoeuver, Muller manoeuver, light continuous positive airway pressure by mask, passive leg raising, and maximal hand-grip. Ultrasound heart images captured before and during.||||
33824575|NCT00383864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824576|NCT02223507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33824577|NCT06645860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824578|NCT04873297|RANDOMIZED|PARALLEL||PREVENTION||NONE||After taking permission from the Hospital Ethical Committee this study will be conducted at the Neurology department of PIMS. After informed written consent, all patients admitted to the Neurology ward with acute stroke on the basis of the clinical and radiologic evidence as defined in the operational definition will undergo detailed history and neurological examination. Patients beings grouped into 2 subgroup via lottery method. One group is given metoclopramide and one group will be given placebo (normal saline). SPSS version 23 will be used for data analysis. Post stratification chi square test will be applied. P value ≤0.05 will be considered significant.||||
33824579|NCT00613132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824580|NCT00961610|||CASE_CONTROL||PROSPECTIVE|||||||
33824581|NCT05221684|||COHORT||RETROSPECTIVE|||||||
33824582|NCT03598803|||COHORT||PROSPECTIVE|||||||
33824583|NCT00168714|||COHORT||PROSPECTIVE|||||||
33824584|NCT05610943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824585|NCT04750577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentre, randomised, double-blind (within dose groups), parallel, placebo-controlled trial. Patients will be randomised equally into one of three parallel dose groups, and in each dose group to treatment either with BI 685509 or matching placebo in a 3:1 ratio.|t|t|t|t
33824586|NCT03415347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomised to one of two groups, intervention 1 (abscess de-roofing and curettage) or intervention 2 (abscess wide local excision), then followed up for 1 year to detect recurrence rate of pilonidal abscess|t|f|f|f
33824587|NCT02930837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824588|NCT04357496|||COHORT||PROSPECTIVE|||||||
33824589|NCT05509283|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Providers who prescribe vaccination and diagnose conditions will not be randomized to study arms or informed of patient assignment. Although patients will not be explicitly informed which arm they have been randomized to, they will be aware of the messages they receive.||f|t|f|f
33824590|NCT03828877|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33824591|NCT06645535|||COHORT||PROSPECTIVE|||||||
33824592|NCT05542914|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824593|NCT02815735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33824594|NCT02920021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824595|NCT02011061|||COHORT||PROSPECTIVE|||||||
33824596|NCT05054283|||COHORT||RETROSPECTIVE|||||||
33824597|NCT03487341|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824598|NCT03470103|||COHORT||PROSPECTIVE|||||||
33824599|NCT03284593|||COHORT||RETROSPECTIVE|||||||
33824600|NCT02542800|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824601|NCT06477757|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|Randomisation will be done in blocks beforehand. As the patients will be enlisted, the group they were assigned to, will be revealed.|Two groups of patients, each undergoing open-heart surgery with a different type of extracorporeal circulation.||||
33824602|NCT05243342|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33824603|NCT03363542|RANDOMIZED|PARALLEL||OTHER||SINGLE||diet rich in fruits, vegetables and/or whole-grain fiber|t|f|f|f
33824604|NCT03581578|||COHORT||PROSPECTIVE|||||||
33824605|NCT05164718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not blinded to group allocation. Researchers will be blinded to group allocation when performing statistical analyses. At study completion, a de-identified copy of the data will be extracted for statistical analyses. Information on group allocation will be kept at the Clinical research Unit in Mid-Norway and provided to the research team once a blinded interpretation of the results is finalized.||f|f|t|f
33824606|NCT00385697|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33824607|NCT05481814|||COHORT||CROSS_SECTIONAL|||||||
33824608|NCT03069014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824609|NCT01480440|||COHORT||PROSPECTIVE|||||||
33824610|NCT02751645|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33824611|NCT00760877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824612|NCT01002911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824613|NCT00825214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824614|NCT00613223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824615|NCT02946450|||CASE_ONLY||PROSPECTIVE|||||||
33824616|NCT06401785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.|t|f|f|f
33824617|NCT03510377|RANDOMIZED|PARALLEL||PREVENTION||NONE||Volunteers that will meet the inclusion criteria will be randomly divided to three intervention groups.||||
33824618|NCT04950387|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|A randomization sequence has been generated using Randomization.org. An independent person not involved in this study made the computer-generated randomization sequence. Investigator did not know members of groups.||f|f|t|t
33824619|NCT05117385|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33824620|NCT04998097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||one experimental and one sham group|t|f|f|f
33824621|NCT01705314|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33824622|NCT00897754|||OTHER||RETROSPECTIVE|||||||
33824623|NCT02475005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824624|NCT00249119|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33824625|NCT03974789|||CASE_ONLY||PROSPECTIVE|||||||
33824626|NCT03868735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824627|NCT02162914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824628|NCT03698305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824629|NCT02168621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824630|NCT01372683|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33824631|NCT02408497|||CASE_ONLY||PROSPECTIVE|||||||
33824632|NCT03922295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824633|NCT05463835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study will take the form of a 3-arm single blind parallel proof-of-concept RCT with two arms acting as active intervention arms and the third acting as a control arm. This study will use non-random convenience sampling. This sample will be obtained from a combination of sources including the WIT arena, the WIT student population as well being advertised on social media by the researcher, participants of local sporting clubs in the Southeast of Ireland who may be eligible may also be approached.|t|f|f|f
33824634|NCT01815034|||CASE_ONLY||PROSPECTIVE|||||||
33824635|NCT02982096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824636|NCT01083446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824637|NCT02168088|||CASE_ONLY||PROSPECTIVE|||||||
33824638|NCT00639964|NON_RANDOMIZED|PARALLEL||||NONE||||||
33824639|NCT01705223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33824640|NCT06353919|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33824641|NCT05122793|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The attending physician who examines the patients is blinded.|The present study is a prospective, monocentric, randomised controlled trial with stratification and blinded assessment of the endpoint (Prospective Randomised Open Blinded Endpoint (PROBE) design).|f|f|t|f
33824642|NCT04768751|||COHORT||PROSPECTIVE|||||||
33824643|NCT04069429|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||dose assessment of orally administration of Tc99m-Heparin in healthy control and Eosinophilic Esophagitis patients||||
33824644|NCT00586742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33824645|NCT06072963|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Eligible participants will be randomized with equal probability to each of the four study groups. Following the baseline assessment, participants will be assigned to one of the four intervention groups, as determined by an automated randomization algorithm|t|t|t|t
33824646|NCT03700463|||OTHER||PROSPECTIVE|||||||
33824647|NCT05624086|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824648|NCT04233333|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824649|NCT04710836|||COHORT||CROSS_SECTIONAL|||||||
33824650|NCT05465486|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Parallel: Participants are assigned to one of two or more groups in parallel for the duration of the study (Parallel Assignement)||||
33824651|NCT01704014|||CASE_CONTROL||PROSPECTIVE|||||||
33824652|NCT02115178|||COHORT||PROSPECTIVE|||||||
33824653|NCT00584376|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33824654|NCT01284634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study was partially-blinded. Due to the varying numbers of capsules administered, participants and investigators were not blinded to the treatment cohort (one, two or four capsules), but were blinded to the treatment allocation within each cohort (GWP42003 or placebo)||t|t|t|t
33824655|NCT05222009|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824656|NCT03814278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824657|NCT02806596|NA|SINGLE_GROUP||||NONE||||||
33824658|NCT01647152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824659|NCT05042713|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be divided into 4 groups according to the file systems to be used in root canal treatment; Group 1: Wave One Gold Group 2: One Flare + Wave One Gold Group 3: One Curve Group 4: One Flare + One Curve.||||
33824660|NCT02686671|||COHORT||PROSPECTIVE|||||||
33824661|NCT02057302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33824662|NCT00021840|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33824663|NCT05135156|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
33824664|NCT05017688|NA|SINGLE_GROUP||OTHER||NONE||Prospective interventional with low risks and constraints study (RIPH2)||||
33824665|NCT05586516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824666|NCT03696602|||OTHER||RETROSPECTIVE|||||||
33824667|NCT03964818|||COHORT||RETROSPECTIVE|||||||
33824668|NCT06088355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will not be aware if their treatment is experimental or control. With behavioral interventions, it is however, challenging to mask what the actual treatment is.|This RCT assigns n=102 (34 per group) older Veterans with PD to 52 weeks of PDAE at HV or moderate volume (MV) or to MV control (MV-WALK). Overall exercise dose will be 112.5 hours over 52 weeks. MV-PDAE and MV-WALK classes will meet twice-weekly for 65-minutes. HV PDAE classes will meet 5 times a week for 90 minutes for three weeks at trial onset followed by one HV week every 4 weeks for a year.|t|t|f|t
33824669|NCT03487302|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33824670|NCT02201147|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33824671|NCT04939324|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824672|NCT04890886|||COHORT||PROSPECTIVE|||||||
33824673|NCT01203956|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33824674|NCT06454071|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE||The entire number of patients was divided into elderly and non-elderly groups based on the age of 70. 29 patients were assigned in elderly group, and 46 patients were assigned in non-elderly group. Preoperative blood sampling including WBC, lymphocyte, neutrophil, albumin, globulin was performed for all patients. In case of participants, investigators added the additional blood tests including immunologic markers including Interleukin-6 and Natural killer cell. These blood tests including immunologic markers were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery)|t|f|f|f
33824675|NCT02324088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824676|NCT02480244|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33824677|NCT05195450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129804|NCT05511506|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34129805|NCT03233828|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Patients will be given either intralesional IL-2 or intralesional saline as a control|t|t|t|f
34129806|NCT06149676|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129807|NCT00626782|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients requiring trabeculectomy were randomly assigned to either MMC or Ranibizumab during surgery.||||
34129808|NCT00428181|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129809|NCT05054491|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped wedge design||||
34129810|NCT00978419|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34129811|NCT01239277|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129812|NCT01607762|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129813|NCT01048242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129814|NCT06534047|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open-label trial, so there will be no blinding.|Hybrid type 1 Implementation effectiveness trial. Open label, randomized, parallel group||||
34129815|NCT03387709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129816|NCT03657784|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Successive cohorts design and single dose administration||||
34129817|NCT01098331|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34129818|NCT05842434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129819|NCT02412189|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129820|NCT02506855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34129821|NCT01916824|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34129822|NCT03782259|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE||Randomized, double-blind and placebo controlled cardiac MRI study|t|t|t|t
34129823|NCT06386978|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34129824|NCT04923633|||OTHER||OTHER|||||||
34129825|NCT05077540|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blinded a randomized controlled trial|double-blinded a randomized controlled trial|t|t|t|t
34129826|NCT02574767|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129827|NCT03391830|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129828|NCT04389710|NA|SINGLE_GROUP||TREATMENT||NONE||Provide access to COVID-19 convalescent plasma for patients infected with SARS-CoV-2 currently hospitalized in acute care facilities||||
34129829|NCT02584062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129830|NCT02620800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129831|NCT02487758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129832|NCT03184662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129833|NCT02366923|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34129834|NCT02325570|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129835|NCT02038946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129836|NCT04452747|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34129837|NCT05626140|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34129838|NCT00801112|||COHORT||PROSPECTIVE|||||||
34129839|NCT04566939|||OTHER||PROSPECTIVE|||||||
34129840|NCT02578134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33824678|NCT02241161|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129841|NCT01518725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34129842|NCT03964987|||CASE_CROSSOVER||PROSPECTIVE|||||||
33824679|NCT04685109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigator Masked, unmasked Pharmacist|PROSPECTIVE, MULTICENTRE, INVESTIGATOR-MASKED, PARALLEL-GROUP, ACTIVE-CONTROLLED, RANDOMISED, NON-INFERIORITY STUDY|t|t|t|t
33824680|NCT02608697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824681|NCT04871698|||CASE_ONLY||PROSPECTIVE|||||||
33824682|NCT01707511|||COHORT||PROSPECTIVE|||||||
33824683|NCT05254834|||CASE_CONTROL||PROSPECTIVE|||||||
33824684|NCT01215032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129843|NCT04496908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129844|NCT04706312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129845|NCT03533959|||COHORT||PROSPECTIVE|||||||
33824685|NCT06197113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824686|NCT04701970|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||occlusal load distribution was measured by T scan system before and after mandibular complete denture relining with soft denture liner||||
33837412|NCT03215147|||COHORT||PROSPECTIVE|||||||
33837413|NCT00548743|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
34129846|NCT00876096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34129847|NCT03050450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129848|NCT00322049|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34129849|NCT03088644|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34129850|NCT04221503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129851|NCT03612063|RANDOMIZED|PARALLEL||OTHER||NONE||"The five heart rate monitors that will be assessed in this study include the Apple Watch Nike III, Fitbit Iconic, Garmin Vivosmart HR, TomTom Spark 3, and Polar H7 heart rate sensor. During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be assigned, by chance to one of six groups:~1. Fitbit Iconic HR and Garmin Vivosmart HR~2. Fitbit Iconic HR and TomTom Spark 3~3. Fitbit Iconic HR and Apple Watch III~4. Apple Watch III and Garmin Vivosmart HR~5. Apple Watch III and TomTom Spark 3~6. Garmin Vivosmart HR and TomTom Spark 3"||||
34129852|NCT03687242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129853|NCT03278795|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study group will be assigned to SIMV-VC for at least 48 hours . Patients will be assessed daily for fulfillment of criteria of readiness to wean according to European Respiratory Society guidelines (ERS guidelines ).~After fulfillment of ERS weaning criteria patients will be consequently divided into two equal groups: 1. 25 patients will be assigned to PSV weaning mode.~2. 25 patients will be assigned to VSV weaning mode. In PSV weaning group , PS will be adjusted 8 cm H2O. In VSV weaning group ,VT will be adjusted 6 ml/ Kg. Extubation will be done after successful spontaneous breathing trial according to ERS guidelines ."||||
34129854|NCT03049579|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34129855|NCT01527591|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34129856|NCT03954886|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34129857|NCT05860907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129858|NCT05561816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129859|NCT00166933|||||OTHER|||||||
34129860|NCT02110849|||CASE_CONTROL||PROSPECTIVE|||||||
34129861|NCT00931125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129862|NCT03694769|||COHORT||CROSS_SECTIONAL|||||||
34129863|NCT03200197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824687|NCT03498885|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Procedure： Low ligation with apical lymph node dissection~Procedure： High ligation with apical lymph node dissection"|t|t|f|f
33824688|NCT02954796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824689|NCT03121040|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33824690|NCT01394783|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33824691|NCT06500013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel model with 1:1 assignment to one of two study arms.||||
33824692|NCT00321529|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33824693|NCT01911936|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824694|NCT03185845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824695|NCT04077775|||CASE_CONTROL||OTHER|||||||
33824696|NCT01670188|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824697|NCT00635011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824698|NCT03695198|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33824699|NCT04151706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824700|NCT00648206|||CASE_CROSSOVER|||||||||
33824701|NCT04373356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824702|NCT02731456|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33824703|NCT04574661|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33824704|NCT01890499|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33824705|NCT01093183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824706|NCT01128140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824707|NCT03306693|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824708|NCT04360642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities: Newton Abbott and Torquay.||||
33824709|NCT00740298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33824710|NCT01676883|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824711|NCT05578898|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33824712|NCT01105442|||COHORT|||||||||
33824713|NCT00510783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824714|NCT04514796|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34129864|NCT04359524|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Computed randomization was used to divide conscripts into two groups; either the intervention group, who received vitamin D3 capsules (1200 IU/30µg) or the control group, who received placebo (oil capsules).|Triple blinded randomized placebo-controlled study|t|t|t|f
34129865|NCT00276055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129866|NCT01183429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824715|NCT04136964|||CASE_ONLY||CROSS_SECTIONAL|||||||
33824716|NCT04899778|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824717|NCT00349648|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33824718|NCT00793377|RANDOMIZED|PARALLEL||||NONE||||||
33824719|NCT03042559|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824720|NCT02612805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824721|NCT01955681|||||RETROSPECTIVE|||||||
33824722|NCT02643953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33824723|NCT00741351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824724|NCT03753750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Blinded sham-controlled trial|t|f|t|f
33824725|NCT04645953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
33824726|NCT00802438|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824727|NCT03193216|NA|SINGLE_GROUP||TREATMENT||NONE||This is a pilot prospective cohort study at a single tertiary center who will be compared to historical controls.||||
33824728|NCT01933529|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824729|NCT01675050|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33824730|NCT04244708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33824731|NCT03073434|||COHORT||RETROSPECTIVE|||||||
33824732|NCT03383029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824733|NCT04047225|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||THE ANALGESIA NOCICEPTIVE INDEX (ANI)|t|f|f|t
33824734|NCT01549249|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33824735|NCT00949221|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824736|NCT00196118|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33824737|NCT01879085|NA|SEQUENTIAL||TREATMENT||NONE||||||
33824738|NCT02672137|RANDOMIZED|PARALLEL||||NONE||||||
33824739|NCT05037721|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33824740|NCT01562483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824741|NCT01554605|||CASE_CROSSOVER||PROSPECTIVE|||||||
33824742|NCT03158818|||COHORT||PROSPECTIVE|||||||
34129867|NCT04930913|||OTHER||PROSPECTIVE|||||||
34129868|NCT05183516|NA|SINGLE_GROUP||TREATMENT||NONE||single group assignment||||
34129869|NCT02342782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129870|NCT00269750|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34129871|NCT03042650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129872|NCT00331656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34129873|NCT01059045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129874|NCT00407615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34129875|NCT02350075|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129876|NCT06216041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking for Participant, Investigator and Clinical Research Associate||t|t|t|t
34129877|NCT04179357|||COHORT||PROSPECTIVE|||||||
34129878|NCT00050557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129879|NCT03703232|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The research design is an A-B-A design, where the A condition is the participant's usual prosthetic foot and the B condition is the investigational foot.||||
34129880|NCT05367349|||COHORT||PROSPECTIVE|||||||
34129881|NCT02082444|RANDOMIZED|CROSSOVER||||NONE||||||
34129882|NCT06407453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129883|NCT06352736|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34129884|NCT00061035|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129885|NCT00003923||||TREATMENT||||||||
34129886|NCT04245449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129887|NCT06159244|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34129888|NCT02827344|||CASE_ONLY||PROSPECTIVE|||||||
34129889|NCT05684692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|(1) Double-Blind period for Siltuximab or Placebo Arm; and (2) Single-Blind period for Erenumab-Aooe or Placebo Arm||t|f|t|f
34129890|NCT03086408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34129891|NCT03284970|||COHORT||RETROSPECTIVE|||||||
34129892|NCT06110364|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients will be randomized to Premature ventricular contraction suppression strategies: 1) Lower level tragus stimulation 2) Heart rate variability biofeedback and 3) conventional medical therapy (usual care)||||
34129893|NCT03299244|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomized by Interactive Voice Response (IVR)/Interactive Web Response (IWR) in a 1:1 ratio to either three times per week (TIW) intravenous (IV) etelcalcetide (and daily oral placebo tablets) or daily oral cinacalcet tablets (and TIW IV placebo) in a double-blind, double-dummy manner. Treatment groups will be blinded to the investigator, participants, and the Amgen study team.||t|t|t|t
34129894|NCT01823198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129895|NCT05744778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129896|NCT05533541|||COHORT||PROSPECTIVE|||||||
34129897|NCT03611881|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34129898|NCT00648921|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34129899|NCT00292071|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129900|NCT02173639|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34129901|NCT02725450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129902|NCT06094244|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129903|NCT02665559|||CASE_ONLY||CROSS_SECTIONAL|||||||
34129904|NCT06262191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129905|NCT01687543|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34129906|NCT00062491|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129907|NCT04437550|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34129908|NCT05274516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HRS-2261 compared with placebo|t|t|t|t
34129909|NCT03714984|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Superiority trial with 1:1 allocation ratio, randomized with two-arm parallel group|f|f|f|t
34129910|NCT02816268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129911|NCT00935506|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34129912|NCT00982046|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34129913|NCT01441947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129914|NCT04818307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129915|NCT03608241|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Open label|||||
34129916|NCT00255918|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34129917|NCT05127408|||COHORT||OTHER|||||||
34129918|NCT00513084|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129919|NCT02434016|||COHORT||PROSPECTIVE|||||||
34129920|NCT06372431|||OTHER||OTHER|||||||
34129921|NCT00803231|||COHORT|||||||||
34129922|NCT00436046|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129923|NCT01061723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34129924|NCT01527240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129925|NCT01705327|||COHORT||CROSS_SECTIONAL|||||||
34129926|NCT00282633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129927|NCT00140179|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34129928|NCT05373095|RANDOMIZED|PARALLEL||OTHER||SINGLE|Laboratory staff analyzing viral load samples will be blind to intervention/control attribution.||f|f|f|t
34129929|NCT04454320|||COHORT||PROSPECTIVE|||||||
34129930|NCT00932438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129931|NCT00000870||||TREATMENT||||||||
34129932|NCT06274996|||COHORT||RETROSPECTIVE|||||||
34129933|NCT03454997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129934|NCT01555970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34129935|NCT04583124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34129936|NCT03641781|RANDOMIZED|PARALLEL||TREATMENT||NONE||Athletes were randomly assigned into two groups: Isometric (ISOM) and Isokinetic (ISOK). A coin was flipped at start of data collection for the first patient to be assigned odd number and included in isometric group. Later on odd and even numbered patients were included in specific group. Additionally, data was collected from healthy athletes doing their training at Pakistan Sports Board, called healthy control group. Due to ethical constraints knee pain athletes were not included as control subjects||||
34129937|NCT05045430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129938|NCT02085044|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34129939|NCT03595150|RANDOMIZED|PARALLEL||PREVENTION||NONE||Open label randomised controlled trial of Diclofenac as prophylaxis versus no prophylaxis for prevention of post-ERCP pancreatitis||||
34129940|NCT01948154|||CASE_CONTROL||PROSPECTIVE|||||||
34129941|NCT05088759|RANDOMIZED|PARALLEL||TREATMENT||NONE||U.S.-based, single-center, randomized controlled trial||||
34129942|NCT00497419|NA|SINGLE_GROUP||||NONE||||||
34129943|NCT05523557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129944|NCT05498935|||CASE_CONTROL||RETROSPECTIVE|||||||
34129945|NCT04888026|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34129946|NCT02010593|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34129947|NCT05952973|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34129948|NCT04005469|NA|SINGLE_GROUP||PREVENTION||NONE||Treprostinil will be administered intravenously by a standard 3 + 3 dose-escalation approach. The first three patients will receive a starting rate of 1.25 ng/kg/min and if all three patients safely tolerate the first dose, the next three patients will receive a dose of 2.5 ng/kg/min. If any patients experience side effects, additional patients will receive the previous lower dose. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation.||||
34129949|NCT00069134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34129950|NCT02193009|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129951|NCT04560816|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"This study will employ a double-blind study design. The ALXN1840 and matching placebo will be identical in appearance and will be administered in a double-blind manner.~Moxifloxacin will not be blinded."|This will be a 3-treatment, 3-period, 6-sequence, crossover study in healthy adults.|t|t|f|f
34129952|NCT06176781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129953|NCT01861691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129954|NCT02565147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary endpoint was evaluated by a core lab totally blinded to clinical information and the treatment groups.||f|f|f|t
34129955|NCT01185951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129956|NCT06390046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study group will be male and female patients, ASA II or III, over 18 years of age and under 75 years of age. Each patient will undergo abdominal (bariatric) surgery.|f|f|t|f
34129957|NCT06129461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129958|NCT05451589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129959|NCT03917875|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824743|NCT04188717|||COHORT||RETROSPECTIVE|||||||
34129960|NCT00935493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34129961|NCT04812782|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Cross-over, interventional, controlled study.||||
34129962|NCT05788666|NA|SINGLE_GROUP||SCREENING||NONE||||||
34129963|NCT00269113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129964|NCT03144128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|All subjects receive exercise and protein supplementation. Participants, Investigators, Care Providers, and outcome assessors will be blinded to vitamin D vs. placebo capsule allocation|Prospective, double-blinded randomized controlled clinical trial|t|t|t|t
34129965|NCT02208206|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34129966|NCT02505022|||OTHER||PROSPECTIVE|||||||
34129967|NCT04234347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129968|NCT00694577|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34129969|NCT02220192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129970|NCT03993444|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants receive one of two active conditions. Outcome assessors are not part of the study.|randomized controlled trial|t|f|f|t
34129971|NCT03035864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|For the whole duration of the trial, treatment was unknown to the patient, the Investigator and the site staff.||t|f|t|f
34129972|NCT04051294|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34129973|NCT01506557|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34129974|NCT05464238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised, controlled, parallel-group with crossover of the control group|f|f|f|t
34129975|NCT05640050|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||We plan a mixed methods design that integrates formative research and evaluative components into iterative improvements cycles. The interventions undertaken will look at feasibility and document the process and challenges of implementing an Audit system at scale.||||
34129976|NCT04706780|||CASE_ONLY||PROSPECTIVE|||||||
34129977|NCT05698615|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"After inclusion in the study, participation in chess training begins after screening. Patients who have volunteered for chess training are then matched with patients for the comparison group. Care is taken to ensure that this group is similar to the chess group in terms of diagnoses and age (pairwise matching)."||||
34129978|NCT01735734|||CASE_ONLY||PROSPECTIVE|||||||
34129979|NCT01564212|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34129980|NCT04501601|NA|SINGLE_GROUP||OTHER||NONE||||||
34129981|NCT03752996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129982|NCT01374321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34129983|NCT02943317|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129984|NCT04359862|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, national, randomized, 1:1 ratio, controlled, parallel, open study||||
34129985|NCT06288308|||OTHER||CROSS_SECTIONAL|||||||
34129986|NCT03046927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Ergocalciferol and placebo will be prepared as identical capsules by Boulevard Pharmaceutical Compounding Center. Randomization will be conducted by the Investigational Drug Services (IDS), UMMS, using a randomization scheme generated by Dr. Barton. Randomization will be 1:1 (ergocalciferol: placebo) and will use a permuted block design with blocking for every 2 or 4 subjects (at random). IDS will maintain blinding information and PI will contact IDS for emergency unblinding.|12-month randomized, double-blind, placebo-controlled, parallel design trial|t|t|t|t
34129987|NCT00138346|||||PROSPECTIVE|||||||
34129988|NCT04492748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129989|NCT00644072|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129990|NCT01178476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34129991|NCT03275246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129992|NCT02125838|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34129993|NCT02290496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33824744|NCT05055999|||COHORT||RETROSPECTIVE|||||||
33824745|NCT04420741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The preparation will be done by an unblinded study nurse at the respective ICU´s, who will be responsible for preparing the investigational drug so that it can be administered in blinded fashion. Iloprost is a colorless fluid that is to be diluted in 0.9% saline. The infusion pump containing diluted active drug and placebo will be identical on how the fluid looks and behaves.|Randomization active/placebo (1:1) parallel arms|t|t|t|t
33824746|NCT02152241|||||CROSS_SECTIONAL|||||||
34129994|NCT06454136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34129995|NCT05808582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34129996|NCT06496308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34129997|NCT02384044|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34129998|NCT03080571|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PROBE design|test group :Stem cell plus standard care control group : standard care|f|f|f|t
34129999|NCT01364480|NA|SINGLE_GROUP||OTHER||NONE||||||
34130000|NCT03388216|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34130001|NCT02429804|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130002|NCT04790669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130003|NCT02298868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130004|NCT01717196|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34130005|NCT05213949|||COHORT||PROSPECTIVE|||||||
34130006|NCT03281369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130007|NCT02350335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130008|NCT04976881|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34130009|NCT03086616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130010|NCT01897727|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130011|NCT04476901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130012|NCT05753254|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|It is not possible to blind the participants to the different scenarios, neither the field staff, but all the samples will be blinded for the subsequent laboratory analysis, namely blood analysis, urine analysis, wipe samples analysis will all be blinded.|Participants will perform firefighting full day exercises under 3 different conditions (without fire, under wood fire and under gas fire), sessions which will occur with weeks in between, and biological markers will be assessed and compared in relation to a baseline session, where the participants are having theoretical classes.|f|f|f|t
34130013|NCT00164840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130014|NCT06389344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130015|NCT05285761|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|"Parents are informed that the aim of the study concerns the effect of the dissemination of information relating to the conduct of complementary feeding on parental feeding behavior during meals as well as on the eating behavior of their child, but they are blinded to the group (intervention vs. control) to which they are allocated.~Parents are randomized into 2 groups (intervention vs. control) via the smartphone application. The investigators conduct the study without information on group allocation. The investigators will analyse the data without information on group allocation."|Intervention run between 3 and 36 months of the children, randomisation of children within a control (n=165) or intervention group (n=165).|t|f|t|t
34130016|NCT00000673||||TREATMENT||NONE||||||
34130017|NCT05620056|||COHORT||RETROSPECTIVE|||||||
34130018|NCT02236273|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34130019|NCT04427605|||COHORT||PROSPECTIVE|||||||
34130020|NCT05833230|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130021|NCT00723151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130022|NCT00568594|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34130023|NCT00708136|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130024|NCT00296049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34130025|NCT03026231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130026|NCT01959178|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34130027|NCT03353363|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-Blind Study|Parallel Assignment|t|t|t|f
34130028|NCT00918606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130029|NCT05371834|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is an open label study, however, there is a blinded site investigator at each site who will not be aware of the treatment group the subject is assigned. The blinded site investigator will assess resolution and reoccurrence of the warts. Photos of the warts will be taken and these will be reviewed by three independent blinded assessors to assess wart resolution and reoccurrence.|||||
34130030|NCT06291493|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Capillary precision analysis will be performed for Potassium K.||||
34130031|NCT01113177|||CASE_ONLY||RETROSPECTIVE|||||||
34130032|NCT00936637|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|t|f|f
34130033|NCT06068946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130034|NCT05586906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130035|NCT03742479|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group, Open Label Study||||
34130036|NCT03983720|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34130037|NCT01380678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130038|NCT00371202|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33824747|NCT00560807|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34130039|NCT02673099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130040|NCT01181804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130041|NCT04856605|||CASE_ONLY||PROSPECTIVE|||||||
34130042|NCT05720052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130043|NCT01018017|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34130044|NCT04347512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130045|NCT00861172|NA|SINGLE_GROUP||||NONE||||||
34130046|NCT02463708|||CASE_ONLY||PROSPECTIVE|||||||
34130047|NCT05068505|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Participant Recruiters||f|f|f|t
34130048|NCT05174546|||OTHER||PROSPECTIVE|||||||
34130049|NCT03873298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants don't know if the cartridge used in the INO device is placebo or NO|RCT, placebo controlled|t|f|f|f
34130050|NCT03504488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130051|NCT06521827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130052|NCT02266147||SEQUENTIAL||TREATMENT||NONE||||||
34130053|NCT04173286|||CASE_CONTROL||RETROSPECTIVE|||||||
34130054|NCT05444907|||CASE_CONTROL||RETROSPECTIVE|||||||
34130055|NCT01911650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130056|NCT04760860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130057|NCT06177262|||OTHER||PROSPECTIVE|||||||
34130058|NCT04099355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130059|NCT02457689|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34130060|NCT02919891|||OTHER||RETROSPECTIVE|||||||
34130061|NCT01229007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130062|NCT04475562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130063|NCT01671553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130064|NCT05160012|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34130065|NCT01555996|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130066|NCT02455804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130067|NCT02081508|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34130068|NCT06553586|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34130069|NCT04014751|||COHORT||PROSPECTIVE|||||||
34130070|NCT02281227|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34130071|NCT06516081|RANDOMIZED|PARALLEL||PREVENTION||NONE||Iron folic acid tablets versus micronutrient powders containing iron and folic acid (Sprinkles)||||
34130072|NCT03340285|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130073|NCT00996879|NA|SINGLE_GROUP||||NONE||||||
34130074|NCT04563403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial with two treatment conditions|t|f|f|f
34130075|NCT02788084|||CASE_ONLY||PROSPECTIVE|||||||
34130076|NCT06005428|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Investigator and Subject Blinded, Sponsor Unblinded; Placebo-controlled|3-period randomized 2-sequence study|t|t|t|t
34130077|NCT02406573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130078|NCT03836872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34130079|NCT05432830|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double blind, both participant and investigator will be blind to e-liquid being administered|Within subject design, all participants will receive all flavors|t|f|t|f
34130080|NCT03198767|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34130081|NCT00389545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130082|NCT06324773|||OTHER||CROSS_SECTIONAL|||||||
34130083|NCT00817765|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130084|NCT04166773|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130085|NCT05774015|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The Mg oxide tablets or placebo tablets (a total of 4 bottles, 90 tablets in each coded bottle) will be provided for each participant during the study period. The 4 bottles for each participant will be per-coded to match the randomization labels to ensure a double-blinded process|A prospective double-blind RCT with a control group and an interventional group|t|t|t|t
34130086|NCT01966354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34130087|NCT05392673|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130088|NCT04148066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130089|NCT01915537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130090|NCT03141125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind randomized placebo controlled trial|Physalis angulata Linn. ethanol extract 3 x 250 mg|t|t|t|t
34130091|NCT04047615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130092|NCT04482972|||COHORT||RETROSPECTIVE|||||||
34130093|NCT03995745|RANDOMIZED|PARALLEL||TREATMENT||NONE||HIV-positive patients in Philadelphia with non-suppressed viral loads will be randomly assigned to receive the intervention (electronic-pill bottle with adherence based daily financial incentives, and incentive for reaching viral suppression) or control. About 40 patients will be enrolled in the study, 20 in each arm.||||
34130094|NCT04670263|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Blinding will take place at the reading center: the patient measurements will be unidentified. Adom's interpreter will not know to which group the examinee belonged to. After the conclusion of the study, the blindness will be removed, and a retrospective statistical analysis will be conducted.||f|f|f|t
34130095|NCT02332993|||COHORT||PROSPECTIVE|||||||
34130096|NCT04055272|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a randomized trial with two groups: 1) Indoor tanning education only; 2) Mobile text messaging intervention||||
34130097|NCT02096952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130098|NCT03975335|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34130099|NCT02644252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130100|NCT01831466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130101|NCT04819958|||COHORT||PROSPECTIVE|||||||
34130102|NCT05777668|||COHORT||PROSPECTIVE|||||||
34130103|NCT00149799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130104|NCT02795624|||COHORT||PROSPECTIVE|||||||
34130105|NCT02798224|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34130106|NCT02425956|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130107|NCT02147197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130108|NCT05738798|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized open trial (no placebo involved)||||
34130109|NCT04224103|||CASE_ONLY||PROSPECTIVE|||||||
34130110|NCT05937386|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130111|NCT05221996|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||f|f|t|t
34130112|NCT02933879|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130113|NCT05919784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130114|NCT02458131|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824748|NCT02574351|||||PROSPECTIVE|||||||
34130115|NCT02791035|NA|SINGLE_GROUP||OTHER||NONE||||||
34130116|NCT03985462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The number of patients enrolled and the number of injected cells were randomly selected by the investigator|Patients with confirmed premature ovarian failure were divided into three groups, each group was injected with different numbers of VSEL cells, and the control group was injected with platelet-rich serum which is the cell solvent|f|f|t|f
34130117|NCT04206397|NA|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34130118|NCT01786382|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130119|NCT02524236|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34130120|NCT04319068|||COHORT||CROSS_SECTIONAL|||||||
34130121|NCT02045888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130122|NCT05033184|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34130123|NCT00574041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130124|NCT06123715|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34130125|NCT06435988|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34130126|NCT01299467|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34130127|NCT04666142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"The principle of loyalty and confidentiality was adhered to by assuring individuals that their identities and personal information obtained from them would not be disclosed to anyone other than the researcher or that the information would not be allowed to be accessed by anyone other than the intended purpose."|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"|t|f|f|f
34130128|NCT00090961|RANDOMIZED|PARALLEL||||NONE||||||
34130129|NCT03823586|||OTHER||CROSS_SECTIONAL|||||||
34130130|NCT02886507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34130131|NCT01142050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130132|NCT03338478|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34130133|NCT03671421|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinical assessments will be done by someone blinded to the arm of the study the patient is in.|Prospective quasi-randomized clinical trial|f|f|f|t
34130134|NCT00753727|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130135|NCT02016794|||CASE_ONLY||PROSPECTIVE|||||||
34130136|NCT02482298|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34130137|NCT03512808|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130138|NCT01949571|NA|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34130139|NCT01359033|||COHORT||RETROSPECTIVE|||||||
34130140|NCT00659386|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34130141|NCT06093958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130142|NCT05143905|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This study is single blind with regard to treatment (AZD7503 or placebo). This means that the participant and the study centre staff will remain blinded during the dosing phase of the study and the randomisation code will only be available at each pre defined decision point before the Safety Review Committee meeting in order to review the data unblinded.||t|t|f|f
34130143|NCT03884387|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34130144|NCT03860831|RANDOMIZED|PARALLEL||OTHER||DOUBLE|surgeon who are providing medical procedure and nurse who records vital data and level of sedation|2 groups of children aged 4-12 years with mental disabilities(autism,down syndrome,cerebral palsy)|f|t|f|t
34130145|NCT05345405|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130146|NCT03719092|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34130147|NCT05616546|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130148|NCT06552832|NA|SINGLE_GROUP||TREATMENT||NONE||Open Trial with Pre- and Post-Measures (Treatment as Usual as parallel contrast without randomization)||||
34130149|NCT03528655|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34130150|NCT05363722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130151|NCT05031117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34130152|NCT04165460|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34130153|NCT01738815|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130154|NCT03926923|||COHORT||PROSPECTIVE|||||||
34130155|NCT05739396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130156|NCT01865318|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130157|NCT01823107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130158|NCT04852549|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The group of the cases meeting the criteria was determined by the numbers determined by the randomizer program in the Research Randomiser web site."||||
34130159|NCT04959227|||OTHER||CROSS_SECTIONAL|||||||
34130160|NCT00023933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130161|NCT04519216|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes are blinded to the assessor when completing the trial data analysis.|This is a prospective cluster randomized controlled trial of a novel educational intervention in pediatric and family medicine residents during the nursery rotation. In this study, we will enroll 1st year pediatric and family medicine residents and 3rd year supervising pediatric residents on their newborn nursery 4-week rotation and randomization will occur clustered by rotation month. The educational intervention will be conducted during the first week of the rotation. Both groups will complete pre-intervention survey that collects demographic information, personal infant feeding experiences, and any breastfeeding medicine experience. All participants will be invited to complete a free online course (Lactation Support in a Telehealth Setting Course) prior to the telemedicine intervention or control group discussion with the clinical pediatrician.|f|f|f|t
34130162|NCT01146184|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34130163|NCT06277856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"In order to eliminate selection bias in the study, block randomisation method, one of the fixed probability randomisation methods, will be used and women who meet the inclusion criteria will be distributed to the intervention and control groups."||f|f|t|f
34130164|NCT00575107|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130165|NCT00404378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130166|NCT01471795|||COHORT||PROSPECTIVE|||||||
34130167|NCT00348478|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34130168|NCT02151916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130169|NCT00248911|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34130170|NCT06231875|||OTHER||CROSS_SECTIONAL|||||||
34130171|NCT01903122|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130172|NCT00434980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130173|NCT04998916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study will utilize a double-blind, sham-controlled clinical trial to evaluate the efficacy of the TBS treatment to the vmPFC||t|t|f|t
34130174|NCT02518165|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34130175|NCT04852055|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34130176|NCT01662557|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130177|NCT01018173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130178|NCT01643642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33824749|NCT04059913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824750|NCT03600519|||COHORT||PROSPECTIVE|||||||
34130179|NCT05667610|RANDOMIZED|PARALLEL||TREATMENT||NONE|The participants are randomly assigned to an intervention group or control group via castor.edc.|"Children in the intervention group will receive written and oral dietary advice by an allergy-specialist dietitian regarding their peanut or nut free diet according to standard care and, in addition, instructions on an individually tailored immune-supportive diet, including sample menus, recipes, shopping guide and product information.~The dietitian will contact the patients every two to four-weeks as needed, either face-to-face, by video consult or using email or what app. Dietary compliance is orally checked by the dietitian, by Likert scale on feasibility and compliance after 6 weeks and 3 months, as well as by the food diary after 3 months. In addition, 22 healthy controls (without allergies),aged 4 to 12 years, will also be included."||||
34130180|NCT00666653|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34130181|NCT04393597|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130182|NCT03349138|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Conventional treatment allocated to patients in all arms. Supplemental dose matched treatment to each of the four arms (9 weeks, 3 treatments a week) as follows:~* conventional treatment (27 treatments)~* functional electrical stimulation (27 treatments)~* robotic glove ( 27 treatments )~* robotic glove and electrical stimulation ( each session uses one device, half of the sessions uses the robotic glove, half the functional electrical stimulation )"||||
34130183|NCT00230776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130184|NCT03120663|||CASE_ONLY||PROSPECTIVE|||||||
34130185|NCT00124072|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34130186|NCT03704844|||COHORT||PROSPECTIVE|||||||
34130187|NCT00183287|||CASE_ONLY||PROSPECTIVE|||||||
34130188|NCT05328869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130189|NCT00332579|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130190|NCT00260832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130191|NCT03901625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34130192|NCT06287242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded research assistants will perform all baseline and follow-up measures. Investigator providing manipulation is blinded to group allocation (matched/unmatched) Participants will not be told if the CTDT indicates that they would benefit from cervical or thoracic manipulation, and the investigator performing the CTDT will only indicate which region is to be manipulated. All investigators are blinded to the work of the others and submit their results to an additional research assistant who will enter the data in a spreadsheet not accessible to the remainder of the research team until the conclusion of the study.||t|t|t|t
34130193|NCT02704975|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34130194|NCT01519141|||COHORT||PROSPECTIVE|||||||
34130195|NCT00578851|||COHORT||PROSPECTIVE|||||||
34130196|NCT04387006|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130197|NCT03665766|||COHORT||PROSPECTIVE|||||||
34130198|NCT03481842|NA|SINGLE_GROUP||PREVENTION||NONE||"Single application in the morning of a vaginal suppository ELTA:~Five days per week (with a treatment-free interval of two days in a row.) e.g. Monday and Tuesday - treatment-free days."||||
34130199|NCT01027559|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34130200|NCT01270932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130201|NCT02929160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130202|NCT00696371|||||PROSPECTIVE|||||||
34130203|NCT01295138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130204|NCT05582356|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130205|NCT05079178|||CASE_ONLY||RETROSPECTIVE|||||||
34130206|NCT06014853|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130207|NCT01009970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130208|NCT04426175|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130209|NCT01498692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130210|NCT00816491|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34130211|NCT02735057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130212|NCT04603313|||OTHER||PROSPECTIVE|||||||
34130213|NCT06046599|||CASE_ONLY||PROSPECTIVE|||||||
34130214|NCT01336712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130215|NCT05093010|||COHORT||PROSPECTIVE|||||||
34130216|NCT04424394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130217|NCT03950544||SEQUENTIAL||TREATMENT||NONE||||||
34130218|NCT05653245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The total of 45 infra-bony defects were randomly divided into 3 equal groups (n=15 each) by simple randomization and all surgeries were done by the same periodontist (Sh.H):~* Group 1: Fifteen intra-bony defect sites were treated with modified minimally invasive surgical technique M-MIST alone.~* Group 2: Fifteen intra-bony defect sites were treated with M-MIST and placebo hydrogel injection.~* Group3: Fifteen intra-bony defect sites were treated with M-MIST and RGD peptide hydrogel injection."|f|f|t|f
34130219|NCT05746013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34130220|NCT04303104|RANDOMIZED|PARALLEL||SCREENING||NONE||Xpert-oriented active case-fining model for TB: portable GXPU/molecular device hosted in a mobile mini-clinic to perform ACF in peri-urban informal settlements. Open-label randomisation to GXPU performed at POC or a central laboratory.||||
34130221|NCT04356846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824751|NCT00945698|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33824752|NCT05166798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130222|NCT00456755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130223|NCT04307368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130224|NCT05131334|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130225|NCT06658171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34130226|NCT05257395|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130227|NCT05507125|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34130228|NCT02835612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34130229|NCT04300504|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34130230|NCT01463163|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130231|NCT00292201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130232|NCT03637257|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Prospective, randomized, single-blinded cross-over study||||
34130233|NCT02821065|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single arm, pre-post study design.||||
34130234|NCT00333411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130235|NCT05745337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130236|NCT04810364|||COHORT||PROSPECTIVE|||||||
34130237|NCT04266392|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130238|NCT01575236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130239|NCT02101996|||COHORT||PROSPECTIVE|||||||
34130240|NCT05145751|||COHORT||RETROSPECTIVE|||||||
34130241|NCT03174652|||COHORT||RETROSPECTIVE|||||||
34130242|NCT01667497|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34130243|NCT05187897|RANDOMIZED|PARALLEL||PREVENTION||NONE||Facilities will be randomized to 1) Interactive two-way SMS dialogue integrated into CHV workflow or 2) Control (standard care), using 1:1 allocation. All participants at each study facility will receive the assigned treatment.||||
34130244|NCT00652743|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130245|NCT03337802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130246|NCT01956747|||CASE_ONLY||PROSPECTIVE|||||||
34130247|NCT02181946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130248|NCT05964348|||COHORT||RETROSPECTIVE|||||||
34130249|NCT03838614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130250|NCT03263988|||COHORT||PROSPECTIVE|||||||
34130251|NCT02029144|||||PROSPECTIVE|||||||
34130252|NCT05891535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130253|NCT03951766|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study: all participants will use the smartphone app for a total of 7 weeks.||||
34130254|NCT02231528|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34130255|NCT03998514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|randomized, double blind, placebo controlled|This is a 3-part, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, PK, and PD of single- and multiple-ascending SC doses of CB4211 in healthy subjects and subjects with NAFLD. Study treatment (CB4211 or placebo) will be administered SC into the abdomen (and if needed, upper and lower thigh) as bolus injections.|t|t|t|f
34130256|NCT04558541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants and care providers will not be told which condition they are participating in. Investigators will know because of familiarity with the stimuli.|"For children, assessments will determine group assignment. Participants will be randomly assigned to a condition, reflecting each of the 3 phonological patterns (Single Feature, OR, Family Resemblance). Randomization will occur within groups and will be generated a priori.~Children will participate in testing and an experimental session, which includes exposure to the rule followed by a generalization test. A sub-group will participate in the Referential Study."|t|t|f|f
34130257|NCT00263432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130258|NCT03747796|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34130259|NCT04249297|||COHORT||PROSPECTIVE|||||||
34130260|NCT03958864|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130261|NCT01858441|NA|SINGLE_GROUP||OTHER||NONE||||||
34130262|NCT05474287|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34130263|NCT02243371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130264|NCT03109782|||CASE_ONLY||PROSPECTIVE|||||||
34130265|NCT04925219|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent assessment of absolute walking distance and QoL.|Pilot 2 arm RCT|f|f|f|t
34130266|NCT00002028|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130267|NCT06129968|||COHORT||PROSPECTIVE|||||||
34130268|NCT05877937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34130269|NCT04743219|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||Randomized clinical trial|t|f|f|t
34130270|NCT06379503|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||QUADRUPLE||randomized controlled trial|t|t|t|t
34130271|NCT05245682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130272|NCT05792982|||COHORT||PROSPECTIVE|||||||
34130273|NCT02175459|||COHORT||CROSS_SECTIONAL|||||||
34130274|NCT00496678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34130275|NCT04142138|NA|SINGLE_GROUP||OTHER||NONE||This study assesses how nutritional changes, namely DASH diet, change the composition of ion channels in the renal tubule, as exemplified by urine electrolyte ratio.||||
34130276|NCT00005289|||COHORT||PROSPECTIVE|||||||
34130277|NCT02142335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130278|NCT03302689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Women after the operation do not know what drug they injected with TAP-block The researcher does not know what type of drug is injected|Two groups of women after cesarean section under spinal anesthesia|t|f|t|f
34130279|NCT03281031|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130280|NCT05435131|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of GCF, saliva and serum were obtained from 90 systemically healthy non-smoker individuals with stage II grade B (P1, n=9), stage III grade B (P2, n=11) , stage III grade C (n=10), gingivitis (G, n=30) and healthy periodontium (S, n=30).||||
34130281|NCT00086983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130282|NCT04736290|||COHORT||OTHER|||||||
34130283|NCT03712176|||COHORT||PROSPECTIVE|||||||
34130284|NCT02353013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34130285|NCT05679661|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
34130286|NCT04520152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130287|NCT01304615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130288|NCT05342324|||COHORT||RETROSPECTIVE|||||||
34130289|NCT01648244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130290|NCT04417283|||COHORT||PROSPECTIVE|||||||
34130291|NCT00082368|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130292|NCT03528876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130293|NCT02483858|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130294|NCT02720523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130295|NCT00009880||||TREATMENT||||||||
34130296|NCT02272036|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34130297|NCT00522028|||COHORT||PROSPECTIVE|||||||
34130298|NCT02342288|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34130299|NCT05878873|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34130300|NCT02991898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824753|NCT04341415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants and the care providers will not know the arm of randomization. Only the principal investigator who will perform the intervention will know the type of intervention.||t|t|f|f
33824754|NCT00880152|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824755|NCT01763034|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33824756|NCT05028647|RANDOMIZED|PARALLEL||TREATMENT||NONE||open randomized control trial||||
33824757|NCT02162771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824758|NCT05215418|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824759|NCT04035863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824760|NCT06139159|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Our team vision is to develop a multi-level community-based model that is more pragmatic, efficient and effective than programs that address only one level of the socioecological model or rely solely on highly trained mental health professionals, who do not always have the necessary cultural or linguistical competency and are not affordable to many Latino-serving organizations. By tackling multiple levels and domains of influence, and leveraging heavily on cultural and context concordant actors, this project can pave the way for a new, scalable, and sustainable model to improve mental health and mental health treatment among Latino communities in the U.S. The comparison of the three phases can help to identify the optimal level of involvement by the LHWs.||||
33824761|NCT04568356|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824762|NCT03735641|||CASE_ONLY||RETROSPECTIVE|||||||
33824763|NCT00581009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824764|NCT06178055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824765|NCT04493983|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824766|NCT00478439|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33824767|NCT00640523|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824768|NCT00223743|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824769|NCT05063981|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33824770|NCT02174159|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824771|NCT00434577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33824772|NCT06263296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only subject will be single blinded to the intervention provided|Pilot Randomized Controlled Trial|t|f|f|f
33824773|NCT03811834|NA|SINGLE_GROUP||OTHER||NONE||||||
33824774|NCT06480006|||OTHER||PROSPECTIVE|||||||
33824775|NCT05892822|||CASE_ONLY||PROSPECTIVE|||||||
33824776|NCT01547689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824777|NCT05753319|||CASE_CONTROL||PROSPECTIVE|||||||
33824778|NCT02654457|||COHORT||RETROSPECTIVE|||||||
33824779|NCT02676440|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824780|NCT06477237|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824781|NCT04975932|||COHORT||RETROSPECTIVE|||||||
33824782|NCT06197685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to the intent of the two exercise conditions. The outcomes assessor will also be blinded to the random assignment of enrolled participants.||t|f|f|t
33824783|NCT01065493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824784|NCT01688895|||COHORT||OTHER|||||||
33824785|NCT02689752|NA|SINGLE_GROUP||OTHER||NONE||||||
33824786|NCT03698617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33824787|NCT01267058|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33824788|NCT06390085|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Evaluating objective imaging biomarkers using imaging for differentiating myofascial pain states.|t|f|f|f
33824789|NCT00902226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824790|NCT04814992|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized clinical trial is proposed to evaluate the efficacy of the novel computer-assisted preoperative CBT with integrating motivational interviewing intervention to affect acute and chronic post-operative pain outcomes. Specifically, 90 adult patients over the age of 21 meeting study inclusion criteria and preparing to undergo TKA at the Department of Orthopedic Surgery at Penn Presbyterian Medical Center, Penn Medicine University City, Penn Medicine Radnor, and Pennsylvania Hospital will be randomized to either receive the computer-assisted preoperative CBT intervention (n=45) or treatment-as-usual (control, n=45).||||
33824791|NCT01042145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824792|NCT04785573|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824793|NCT06344364|||COHORT||RETROSPECTIVE|||||||
33824794|NCT02132598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824795|NCT05046821|||CASE_ONLY||PROSPECTIVE|||||||
33824796|NCT00678132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824797|NCT00733577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824798|NCT02137395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824799|NCT05540418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled experimental study|t|f|f|f
33824800|NCT06350370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824801|NCT06446999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data obtained as a result of the research will be coded as 'A' and 'B' by the researcher and transferred to the computer. In order to prevent bias in the evaluation of the data, the analysis of the coded data will be carried out by an independent statistician, thus ensuring statistician blinding.|"1. Experimental group: A protocol containing yoga-based breathing exercises will be used. The audio recording of this breathing exercise protocol will be uploaded to the video. After verbal information is given about how to do the exercise, the patient will be listened to the audio recording video and will be explained how to do it in practice. Then, the patient will be placed in a comfortable position by wearing headphones and will be allowed to exercise. The patient will be asked to do yoga-based exercise twice a day, the night before the surgery, once in the morning and once in the evening before going to bed for 3 days after the surgery.~2. Control group: Continuity of routine treatment and care of the patients included in the control group will be ensured."|f|f|f|t
33824802|NCT05161143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824803|NCT06407947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824804|NCT04757519|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824805|NCT00046683|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824806|NCT06348498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130301|NCT02968446|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33824807|NCT03180008|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824808|NCT03831230|||COHORT||PROSPECTIVE|||||||
33824809|NCT06647329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824810|NCT01935193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824811|NCT00812825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33824812|NCT05004961|||CASE_CONTROL||PROSPECTIVE|||||||
33824813|NCT03690284|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33824814|NCT06316778|NA|SINGLE_GROUP||TREATMENT||NONE||pre-treatment assessment - intervention (12 weeks) - post-treatment assessment||||
33824815|NCT03540615|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE||Dose escalation with safety assessment following each dose step.|t|t|t|t
33824816|NCT02827799|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33824817|NCT04101019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded||t|f|t|f
33824818|NCT00784771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824819|NCT04957407|||COHORT||PROSPECTIVE|||||||
33824820|NCT02785575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824821|NCT05951439|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized double-blind study|t|f|t|f
33824822|NCT05826405|||CASE_ONLY||RETROSPECTIVE|||||||
33824823|NCT03375840|RANDOMIZED|FACTORIAL||PREVENTION||||||||
33824824|NCT00388232|||||OTHER|||||||
33824825|NCT01961921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824826|NCT04428983|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33824827|NCT00396097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824828|NCT02950714|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33824829|NCT01517490|||||PROSPECTIVE|||||||
33824830|NCT05481398|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two individuals were assigned the role of outcome assessors to examine the wound after removal of the dressing and score the wound for infection using the ASEPSIS score.|Randomization Patients will be randomly allocated into intervention group A (NPWT) or control group (B) by simple randomization.|f|f|f|t
33824831|NCT03627130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|IMP and placebo will be identical||t|t|t|t
33824832|NCT04059497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33824833|NCT06385314|||CASE_ONLY||CROSS_SECTIONAL|||||||
33824834|NCT03698071|NA|SINGLE_GROUP||OTHER||NONE||||||
33824835|NCT06205576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824836|NCT05781841|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33824837|NCT06438705|||COHORT||PROSPECTIVE|||||||
33824838|NCT06052345|||COHORT||PROSPECTIVE|||||||
33824839|NCT06124183|RANDOMIZED|PARALLEL||PREVENTION||NONE||The design was a quasi-experimental study with intervention and control groups and pre-post-intervention measures.||||
33824840|NCT03009877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824841|NCT02526771|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824842|NCT06408922|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33824843|NCT02759887|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33824844|NCT01876771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824845|NCT03439397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824846|NCT04136587|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33824847|NCT06350591|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||parallel, within-subject design||||
33824848|NCT03727997|||COHORT||PROSPECTIVE|||||||
33824849|NCT02847819|||CASE_CONTROL||PROSPECTIVE|||||||
33824850|NCT00895089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824851|NCT00651937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824852|NCT05648318|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33824853|NCT06331533|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Botulinum toxin will be injected into one randomly selected half of the face, and placebo will be injected into the other half of the face. The patient will not know which half of the face was treated. An independent, blinded dermatologist will evaluate the results of the treatment.|Randomized, split face, efficacy study|t|f|f|t
33824854|NCT02698137|||COHORT||CROSS_SECTIONAL|||||||
33824855|NCT04777097|||COHORT||PROSPECTIVE|||||||
33824856|NCT03438097|||COHORT||OTHER|||||||
33824857|NCT02621047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824858|NCT00372255|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824859|NCT00302406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33824860|NCT04665778|||CASE_ONLY||PROSPECTIVE|||||||
33824861|NCT01428700|||CASE_ONLY||RETROSPECTIVE|||||||
33824862|NCT03327077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Randomized|t|f|f|f
33824863|NCT02810483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33824864|NCT00206505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824865|NCT04765813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824866|NCT02303002|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824867|NCT01861795|||CASE_ONLY||PROSPECTIVE|||||||
33824868|NCT01724047|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33824869|NCT02435381|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33824870|NCT03606226|||COHORT||CROSS_SECTIONAL|||||||
33824871|NCT01261455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824872|NCT05235997|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33824873|NCT03787238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824874|NCT03790878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824875|NCT01325818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824876|NCT06566209|||COHORT||PROSPECTIVE|||||||
33824877|NCT06459037|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20) and with 20 systemically healthy smoker individuals with periodontitis (PS, n=20).||||
33824878|NCT05189171|||COHORT||PROSPECTIVE|||||||
33837414|NCT04012619|NA|SEQUENTIAL||TREATMENT||NONE||The initial dose of anlotinib was set as 12 mg/day with a 2-week on/1-week of schedule. The dose was reduced to 10 mg/day and 8 mg/day in sequence depending on observed DLTs in cycle 1.||||
33824879|NCT04884490|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A data sheet (enclosed) will be prepared, for which a short interview of less than 30 minutes will be required. Ethical risks are deemed minimal as standard therapy as well as co-trimoxazole are extensively used treatments and have well-documented efficacy\& safety. Placebo will be used here along with standard therapy in the control group. Informed oral and written consent will be taken from the study subjects. Patient will be given packs containing total number of 27 tablets of Co-trimoxazoles or placebo which will be coded by a personnel not involved in the study. Research assistant and investigators will not be aware of the drug. After data collection and entry during analysis decoding will be done.|"Study design:Single-centre interventional Prospective double-blind placebo controlled randomized trial.~Study duration: Six months. Place of study: Medicine department (Covid Unit) of Bangabandhu Sheikh Mujib Medical University (BSMMU) Period of Study: Six months following approval of the protocol Sampling technique: Random sampling followed by patients will be assigned in a 1:1 ratio to either oral high dose co-trimoxazole in addition to standard therapy or standard therapy along with placebo~Sample Size:~47 in each group"|t|t|t|f
33824880|NCT03466229|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The active compound and placebo are given a number and the list linking this number to the type of preparation (placebo or active compound) is stored by one of the sponsors (Octean)|Double blind randomised placebo controlled study|f|f|t|f
33824881|NCT03321656|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Treatment: Envarsus® 0.07-0.14 mg/kg/day every morning~* Control: Generic tacrolimus 0.1-0.2 mg/kg/day in 2 divided doses given every 12 hours"||||
33824882|NCT04770740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||double blind, randomized, placebo-controlled (phase 2)|t|t|t|t
33824883|NCT00162552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824884|NCT04584359|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||This study randomized 40 women with symptoms of stress uriray incontinence who were divided into four intervention groups of ten women each (G1: only the high velocity, low amplitude manipulation for the sacroiliac joint and T10-L2; G2: global osteopathic protocol with myofascial, visceral, and articular techniques; G3: pelvic floor muscle training; and G4: control).|f|f|f|t
33824885|NCT03650361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double (Participant, Investigator)|t|t|t|t
33824886|NCT04589390|NA|SINGLE_GROUP||TREATMENT||NONE||Evaluation of hemodynamics and surrogate markers (clinical variables, BNP levels, six-minute walking test distance, and heat shock protein 70 levels) before and after the introduction of selexipag for the treatment of schistosomiasis-associated pulmonary arterial hypertension patients, that were already receiving at least one therapy for pulmonary arterial hypertension, excluding other drugs from the prostacyclin pathway.||||
33824887|NCT06336941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824888|NCT04602039|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This was a non-randomised control trial involving individuals split into 3 groups (healthy, prediabetes, type 2 diabetes) that all received colostrum for 28 days.||||
33824889|NCT00514813|NA|SINGLE_GROUP||OTHER||NONE||||||
33824890|NCT05915013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||The investigators employ a counter-balanced cross-over design in which ketamine plus perampanel is given on one day, and approximately 21 days later ketamine plus placebo is given.|t|f|t|f
33824891|NCT03317678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824892|NCT02130271|||CASE_CONTROL||PROSPECTIVE|||||||
33824893|NCT05671133|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33824894|NCT00603057|||CASE_ONLY||PROSPECTIVE|||||||
33824895|NCT02904161|||COHORT||PROSPECTIVE|||||||
33824896|NCT03284125|||COHORT||PROSPECTIVE|||||||
33824897|NCT04653207|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover study||||
33824898|NCT02254681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824899|NCT03952728|||COHORT||RETROSPECTIVE|||||||
33824900|NCT04037306|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33824901|NCT03346382|||COHORT||RETROSPECTIVE|||||||
33824902|NCT02003664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824903|NCT00747721|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824904|NCT04151771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824905|NCT00438230|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824906|NCT01683643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824907|NCT00961298|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33824908|NCT00836914|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33824909|NCT05566119|||COHORT||RETROSPECTIVE|||||||
33824910|NCT01808521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824911|NCT03630965|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33824912|NCT01994538|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33824913|NCT04639661|||COHORT||RETROSPECTIVE|||||||
33824914|NCT00155376|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33824915|NCT02212197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824916|NCT03022383|||COHORT||PROSPECTIVE|||||||
33824917|NCT01713998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824918|NCT04313036|NA|SINGLE_GROUP||TREATMENT||NONE||The goal of this study is to assess the 100-day survival of a 5-day defibrotide treatment for hepatic SOS in allogeneic stem cell transplant patients compared to the standard 21-day treatment. It is hypothesized that the 5-day treatment will have non-inferior 100-day survival rates to the 21-day treatment. Historically, 100-day survival has been 58.9% in moderate and 38.2% in severe SOS. Investigators believe that the null survival for the 21-day defibrotide treatment is 50%. Investigators wish to determine non-inferiority of the 5-day treatment with a 5% margin of error.||||
33824919|NCT00309621|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824920|NCT04289714|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE|Pragmatic randomization based on inhaled medication|Feasibility Pragmatic randomisation||||
33824921|NCT03435614|||COHORT||PROSPECTIVE|||||||
33824922|NCT02156388|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824923|NCT04258488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824924|NCT04632797|RANDOMIZED|PARALLEL||PREVENTION||NONE|It is an observer blinded study.|1 to 1 randomization in either cryocompression or cryotherapy of the hands||||
33824925|NCT04448925|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Repeated measures, cross-over||||
33824926|NCT05345847|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824927|NCT01494740|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33824928|NCT06337786|RANDOMIZED|PARALLEL||OTHER||NONE||"The trial is an open-label matched register controlled clinical trial with two parallel groups (intervention and matched controls from the DANBIO register).~The number of study participants is 40 in the intervention arm and up to 120 in the matched control arm."||||
33824929|NCT00817336|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33824930|NCT02873325|||COHORT||OTHER|||||||
33824931|NCT03141606|||COHORT||PROSPECTIVE|||||||
33824932|NCT02724163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824933|NCT03134937|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Every participant will recieve one HFHHNO session, will get 30 mins of oxygen up to 60-70 L/min.||||
33824934|NCT06478225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824935|NCT05182970|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824936|NCT00618384|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824937|NCT05854771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33824938|NCT00325546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824939|NCT00543166|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33824940|NCT03212755|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33824941|NCT03005483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824942|NCT03840200|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33824943|NCT05625568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824944|NCT05878249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824945|NCT02188277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824946|NCT02298855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824947|NCT00004016||||TREATMENT||||||||
33824948|NCT06080919|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be an investigator-initiated, single-arm, open-label, pilot study.||||
33824949|NCT02656745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824950|NCT03617458|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|The investigators propose a phase II, 2x2 factorial randomized, blinded trial testing metformin versus placebo and a mobile health intervention (mHealth) versus usual care of 12 weeks.|This is a phase II, 2x2 factorial randomized, blinded trial testing metformin versus placebo and a mHealth intervention (mHealth) versus usual care of 12 weeks.|f|t|t|t
33824951|NCT02733835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824952|NCT01990664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824953|NCT00816153|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33824954|NCT06283511|||CASE_ONLY||PROSPECTIVE|||||||
33824955|NCT04147091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824956|NCT00308919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33824957|NCT04291703|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The randomization method will be stratified by TrialNet study site. The participants will not be informed regarding the intervention assignment until the end of the study. The investigator and clinic personnel will also be masked as to study assignment. Laboratories performing assays for this protocol will be masked as to the identity of biological material to be studied.|Eligible study participants will be randomized in a 2:1 allocation to either ATG vs. placebo treatment arms by the TrialNet Coordinating Center at the baseline visit once eligibility has been confirmed. Randomization will be conducted using block randomization with variable block sizes with stratification on TrialNet study site and age group (\< 12 years old vs. 12 years old or older). Subjects will be assigned a study randomization number corresponding to the treatment group assignment.|t|t|t|f
33824958|NCT02874248|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33824959|NCT02207322|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824960|NCT00757978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824961|NCT02223871|NA|SINGLE_GROUP||OTHER||NONE||||||
33824962|NCT01653093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33824963|NCT03315988|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33824964|NCT04778449|||COHORT||PROSPECTIVE|||||||
33824965|NCT02747121|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||The intervention will be rolled out sequentially during 12 months to 24 hospitals, with six clusters of four geographically close hospitals. We collect data before and after the inspections.||||
33824966|NCT01912183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824967|NCT02083679|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824968|NCT01602003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33824969|NCT05682885|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding is implemented in two conditions: the main researcher (Bayu Brahma) will not know the identity and medical history of the patient when assessing the indocyanine green (ICG) lymphography results and the patients will not know the received type of surgical procedure.|This study is a single-blind pragmatic parallel arm randomized clinical trial to analyze the effectiveness of lymphatic bypass supermicrosurgery (LBS).|t|f|f|f
33824970|NCT04313790|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single (Participant)|Randomized Control Trial|t|f|f|f
33824971|NCT02857699|||COHORT||PROSPECTIVE|||||||
33824972|NCT04177732|NON_RANDOMIZED|PARALLEL||SCREENING||NONE|No masking|Group A: Healthy peri-implant status Group B: Presence of peri-implant diseases||||
33824973|NCT06469814|||COHORT||PROSPECTIVE|||||||
33824974|NCT01421797|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33824975|NCT04885764|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824976|NCT01778647|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33824977|NCT00451555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824978|NCT04225637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33824979|NCT04869878|||OTHER||PROSPECTIVE|||||||
33824980|NCT03277586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||16-week Double-blind randomized placebo-controlled dual-phase trial|t|t|t|t
33824981|NCT06401096|||CASE_CONTROL||PROSPECTIVE|||||||
33824982|NCT00804414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33824983|NCT04108975|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33824984|NCT01792583|||COHORT||OTHER|||||||
33824985|NCT03322514|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||double blind, randomised, controlled, paralleled study|t|t|t|t
33824986|NCT05645809|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33824987|NCT04748471|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33824988|NCT01570621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130302|NCT03755219|||COHORT||PROSPECTIVE|||||||
34130303|NCT02149355|||CASE_CONTROL||RETROSPECTIVE|||||||
34130304|NCT02277691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130305|NCT02156206|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34130306|NCT02003976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130307|NCT00751959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130308|NCT04019808|||OTHER||PROSPECTIVE|||||||
34130309|NCT00241072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130310|NCT01360424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130311|NCT03212508|||CASE_CROSSOVER||PROSPECTIVE|||||||
34130312|NCT06070389|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130313|NCT00352469|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130314|NCT03915158|||COHORT||PROSPECTIVE|||||||
34130315|NCT03026816|NA|SINGLE_GROUP||TREATMENT||NONE|Masking is done during formal testing of BMCA|All subjects will receive study intervention. Outcome assessments will be tested while the stimulator unit is on (intervention) and off (sham) during the study.||||
34130316|NCT05092828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Nursing staff and physical therapists will be blinded to intrathecal morphine utilization as to not bias the input of these variables||t|f|f|t
34130317|NCT04741321|||COHORT||PROSPECTIVE|||||||
34130318|NCT05600985|||OTHER||CROSS_SECTIONAL|||||||
34130319|NCT00182078|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34130320|NCT04586452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"There are two (2) groups in the study.~AAA Group: 40 (20 men; 20 women) participants who will have a PET/CT imaging study performed and a subset of 20 participants who will have an additional PET/CT imaging study performed.~Non-AAA Group: 10 without AAA (5 men; 5 women), above the age of 40, with or without active tobacco use"||||
34130321|NCT01706731|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34130322|NCT03391557|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients who underwent EBUS-TBNA examination in department of respiration,Nanjing Hospital Affiliated to Nanjing Medical University during 21June 2016 and 17 April 2017 were included in the study, All patients were evaluated by chest enhanced CT and/or 18-FDG PET-CT,those who had enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max \> 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction.||||
34130323|NCT03529617|||CASE_CONTROL||PROSPECTIVE|||||||
34130324|NCT05529082|||COHORT||PROSPECTIVE|||||||
34130325|NCT05774249|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34130326|NCT00588237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130327|NCT02990390|||COHORT|||||||||
34130328|NCT02289196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130329|NCT01720589|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34130330|NCT01846299|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130331|NCT00392587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130332|NCT03789656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130333|NCT00902850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130334|NCT06017960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Allocation conceal will be performed using a computer-generated randomized table of numbers created before data collection. Both participants, evaluator and data analyzer will be blinded to the type of intervention.~To take the ultrasound images, an artificial arm will be used to hold the probe and to avoid direct contact by the researcher. Another researcher will analyze the images through a program. Both participants, image analyzer and data analyzer will be blinded to the type of intervention"|Randomized controlled trial|t|f|t|t
34130335|NCT06436014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Group 1 ( Pre-Test + Intervention + Post-Test) (Participants undergoing total knee replacement surgery, subjected to pre-test followed by VR intervention) Group 2 (receiving only pre-test) Group 3 (Intervention Only + Post-Test) (Participants undergoing hysterectomy surgery, subjected to pre-test followed by VR intervention) Group 4 (Post-Test Only) (Participants undergoing hysterectomy surgery, receiving only pre-test)|t|f|f|t
34130336|NCT04351607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824989|NCT05183477|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34130337|NCT03260855|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34130338|NCT04920071|||CASE_CONTROL||PROSPECTIVE|||||||
34130339|NCT05527782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130340|NCT00656058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130341|NCT01557101|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130342|NCT05050968|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is an open-label, randomized, single-center trial with two groups: an Adapted Physical Activity group and a control group performing no controlled physical activity within each group women undergoing bypass or sleeve surgery||||
33824990|NCT03644784|||OTHER||PROSPECTIVE|||||||
33824991|NCT01801813|||COHORT||PROSPECTIVE|||||||
33824992|NCT03191214|||CASE_CONTROL||PROSPECTIVE|||||||
33824993|NCT03212183|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33824994|NCT02812628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33824995|NCT04358068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837415|NCT00609947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837416|NCT01183390|RANDOMIZED|CROSSOVER||||NONE||||||
33837417|NCT06456489|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837418|NCT00855855|||COHORT||CROSS_SECTIONAL|||||||
33837419|NCT04253938|NA|SINGLE_GROUP||OTHER||NONE||||||
33837420|NCT04489953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837421|NCT01613144|||COHORT||PROSPECTIVE|||||||
33837422|NCT02227992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837423|NCT00419302|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837424|NCT05332470|||CASE_ONLY||PROSPECTIVE|||||||
33837425|NCT06146764|||COHORT||RETROSPECTIVE|||||||
33840217|NCT05953649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840218|NCT04659824|||COHORT||CROSS_SECTIONAL|||||||
33840219|NCT05359887|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130343|NCT01999244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130344|NCT06093542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is single blind where the study site staff including the investigator will remain blinded during the clinical conduct of a given cohort.||f|f|t|f
34130345|NCT02089009|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34130346|NCT04247893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130347|NCT06293716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Part II is a randomized, double-blind, placebo-controlled study of approximately 30 patients with APDS/PASLI. On day 1, patients were randomly assigned to the trial and placebo groups in a 2:1 ratio to take an oral CVL237 tablet or a placebo CVL237 simulant once daily. Efficacy and safety were evaluated on days 29, 57, and 85. The efficacy of CVL237 tablets in reducing lymphadyopathy will be investigated as measured by changes in the sum of diameter products (SPD) of target lesions selected from MRI or CT imaging according to the Lugano 2014 method, as well as changes in the percentage of naive B cells to total B cells, relative to baseline. The CVL237 tablets will also be evaluated for safety, PK|CVL237 tablets for APDS/PASLI (Activated phosphoinositol 3-kinase delta syndrome /p110 delta-activated Mutation leading to senescent T cells, lymphadenopathy, and immune deficiency)|t|f|t|f
34130348|NCT00682929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130349|NCT04893317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130350|NCT03163134|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34130351|NCT02072252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130352|NCT02051751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130353|NCT03777046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130354|NCT03400358|||COHORT||PROSPECTIVE|||||||
34130355|NCT03282344|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label, multi-center, pilot study to evaluate the efficacy of NKTR- 214 in combination with nivolumab in patients with selected locally advanced/metastatic, high grade sarcoma.||||
34130356|NCT02890264|||COHORT||CROSS_SECTIONAL|||||||
34130357|NCT00851552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130358|NCT00003421|RANDOMIZED|||TREATMENT||||||||
34130359|NCT01848067|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130360|NCT00688467|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34130361|NCT04031898|||CASE_ONLY||RETROSPECTIVE|||||||
34130362|NCT02052115|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34130363|NCT06467786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130364|NCT02964273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130365|NCT00006459||||TREATMENT||||||||
34130366|NCT01607463|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34130367|NCT00191568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130368|NCT03572959|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34130369|NCT01878578|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34130370|NCT00428935|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34130371|NCT02291783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130372|NCT00322413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34130373|NCT01236261|||CASE_ONLY||PROSPECTIVE|||||||
34130374|NCT03388801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130375|NCT04499781|RANDOMIZED|PARALLEL||OTHER||NONE||The ACCESS II RCT uses a two group, parallel, longitudinal study design. Participants will be randomized to the ACCESS synchronous peer intervention or the asynchronous web-based HIV ART adherence control. Block randomization will be used; the randomization scheme will be developed by the biostatistician and implemented in Research Electronic Data Capture (REDCap) to ensure that assignment to treatment condition is evenly distributed within each site.||||
34130376|NCT03583359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130377|NCT05404191|NA|SINGLE_GROUP||TREATMENT||NONE||60 adult of both sexes will participate in this study selected from burn unit of AHMED ORABI hospital, Their ages range from 10 to 50 years, TBSA more than 15%, partial thickness burn depth.||||
34130378|NCT01643265|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34130379|NCT01872585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837426|NCT05911178|NON_RANDOMIZED|SEQUENTIAL||SCREENING||NONE|This is a non-randomized, open label study including three groups; early onset AD, late onset AD, healthy controls.|Early and late onset AD subjects, matched to controls for age and education level, will be followed up for two years, allowing both longitudinal and cross-sectional comparisons.||||
33837427|NCT00463671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837428|NCT05371366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837429|NCT05624671|NA|SINGLE_GROUP||SCREENING||NONE||||||
33837430|NCT01472419|||||RETROSPECTIVE|||||||
33837431|NCT01989169|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33837432|NCT01234415||PARALLEL||TREATMENT||NONE||||||
33837433|NCT03317847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837434|NCT02134938|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33837435|NCT03002298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130380|NCT02349659|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130381|NCT02501148|||COHORT||PROSPECTIVE|||||||
34130382|NCT02534012|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34130383|NCT02016391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130384|NCT04583436|RANDOMIZED|PARALLEL||TREATMENT||NONE||Group 1: Femoropopliteal distal bypass with a synthetic ePTFE graft; Group 2: Recanalization of occlusion of the arteries of the femoropopliteal segment below the knee joint with angioplasty and stenting with a biomimetic intervowen nitinol stent.||||
34130385|NCT00864175|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34130386|NCT01995526|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130387|NCT01740921|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130388|NCT06378333|||COHORT||RETROSPECTIVE|||||||
34130389|NCT00960791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130390|NCT05734911|||COHORT||OTHER|||||||
34130391|NCT05494463|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||First laryngoscopy with randomly choosed blade and then laryngoscopy wiht second choosen blade in the same patient||||
34130392|NCT04648488|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomised Clinical trail|f|f|t|t
34130393|NCT01144416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130394|NCT04734483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment, prospective, single-center|f|f|f|t
34130395|NCT00742131|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130396|NCT02282072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34130397|NCT00344903|||COHORT||PROSPECTIVE|||||||
34130398|NCT05439369|||CASE_CONTROL||OTHER|||||||
34130399|NCT01977729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130400|NCT04474197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130401|NCT01294111|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34130402|NCT04311970|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34130403|NCT04054206|RANDOMIZED|CROSSOVER||TREATMENT||NONE||12 healthy male and female participants (enrollment is 6 female and 6 male participants). Each enrolled/consented participant will be randomly assigned to 1 of 6 treatment sequences which consists of 3 treatments (ER fasted, ER fed, and IR fasted) in a crossover design, administered one week apart.||||
34130404|NCT06085716|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34130405|NCT02890745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130406|NCT00812396|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34130407|NCT05211674|||CASE_CONTROL||PROSPECTIVE|||||||
34130408|NCT01772069|||CASE_CONTROL||PROSPECTIVE|||||||
34130409|NCT06318247|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130410|NCT00714077|||COHORT||PROSPECTIVE|||||||
34130411|NCT04393038|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded treatment bottles|Phase 2/3, randomized, double blind, placebo-controlled study|t|t|t|f
34130412|NCT03685474|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"In the present study, we will use the measure entitled Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM; Glasgow, 2013) as a framework for planning and implementing FYF-SB in the school environment. The translation of research from controlled research settings to natural environments is often an exceptionally slow process, perhaps because of the emphasis on efficacy. A pragmatic framework such as RE-AIM can hasten the portability of evidenced based intervention to real-world practice by focusing on stakeholder feedback and environmental context, in conjunction with intervention development and content.~We plan to conduct a randomized controlled trial of the FYF-SB intervention across 30 schools within 3 districts. The intervention conditions occur for 1 semester within an academic year. Data will be collected in a pre-post design (before and after the condition of either Facing Your Fears - School Based or Usual Care)."||||
34130413|NCT01057693|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34130414|NCT02317198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130415|NCT03962907|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants are not told colonization status or study arm. Outcome Assessor are not informed as well on this informations.|two groups: S. aureus carrier and non-carriers. Both groups have an intervention and control arm|t|f|f|t
34130416|NCT02068677|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34130417|NCT00828802|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130418|NCT06522009|||COHORT||PROSPECTIVE|||||||
34130419|NCT01505478|||COHORT||PROSPECTIVE|||||||
34130420|NCT00408707|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34130421|NCT03231748|||COHORT||PROSPECTIVE|||||||
34130422|NCT03279887|||COHORT||PROSPECTIVE|||||||
34130423|NCT02466035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130424|NCT03231410|||CASE_CONTROL||PROSPECTIVE|||||||
34130425|NCT01779336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130426|NCT02183493|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130427|NCT01017224|||COHORT||PROSPECTIVE|||||||
34130428|NCT06093308|NA|SINGLE_GROUP||OTHER||NONE||||||
34130429|NCT04490525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130430|NCT05013346|||CASE_ONLY||CROSS_SECTIONAL|||||||
34130431|NCT05151159|||COHORT||RETROSPECTIVE|||||||
34130432|NCT05369962|||COHORT||PROSPECTIVE|||||||
34130433|NCT04762992|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the pharmacological intervention and the standard of care group will be identified by randomized code ID.|pharmacological intervention and standard of care arms|f|t|t|t
34130434|NCT01530854|||COHORT||PROSPECTIVE|||||||
34130435|NCT01802580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130436|NCT01732510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130437|NCT05135559|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33824996|NCT02947581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Tablets containing placebo for PZQ and placebo for ABZ will be purchased from the same commercial sources than those containing active drug if possible. As much as possible, they should have the same size, appearance, excipient, smell, and taste as those containing active drug. A preliminary evaluation of the potential for distinction of active drug and placebo by patients will be performed by the investigators before randomization of the drugs and placebos to their individual coded packages. If distinguishable, a new lot will be ordered.|Double-blind, randomized, placebo-controlled study in patients with subarachnoid cysticercosis of the basal cisterns or the Sylvian fissure, comparing in two parallel arms the efficacy of the standard of care anti-parasitic regime (30 days of ABZ at 15 mg/k/d, up to 1200 mg/k/d) with a combined regime using similar doses of ABZ and adding PZQ at 50 mg/k/d for the initial 15 days of anti-parasitic treatment. The study and interim analysis plan are designed to allow direct, concrete efficacy comparison in this deadly type of NCC while minimizing the risks of disease progression in the standard of care arm.|t|f|t|f
33824997|NCT01414725|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33824998|NCT00074178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33824999|NCT02134899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825000|NCT02371161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130438|NCT02793973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130439|NCT01761006|||CASE_ONLY||PROSPECTIVE|||||||
34130440|NCT00190229|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825001|NCT04730076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825002|NCT00333281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825003|NCT00162058|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33825004|NCT02672514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825005|NCT00930683|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825006|NCT02202148|||COHORT||PROSPECTIVE|||||||
34130441|NCT03346421|||OTHER||PROSPECTIVE|||||||
34130442|NCT02200926|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130443|NCT02263326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130444|NCT03813758|||CASE_CONTROL||PROSPECTIVE|||||||
34130445|NCT01447498|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34130446|NCT03949452|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Double blind (participant, investigator) study|t|f|t|f
33825007|NCT00938132|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33825008|NCT03976778|NA|SINGLE_GROUP||OTHER||NONE||A pre-post interventional study||||
33825009|NCT05284006|||COHORT||PROSPECTIVE|||||||
33825010|NCT01636830|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33825011|NCT03377959|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33825012|NCT06222775|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825013|NCT03293472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patient unaware of the local anesthetic used.|Parallel study|t|f|f|f
33825014|NCT01011127|||CASE_CONTROL||PROSPECTIVE|||||||
33825015|NCT00900861|||COHORT||PROSPECTIVE|||||||
33825016|NCT04701528|RANDOMIZED|PARALLEL||TREATMENT||NONE||single-center, proof-of-concept||||
33825017|NCT06079424|||COHORT||PROSPECTIVE|||||||
33825018|NCT03061305|||COHORT||PROSPECTIVE|||||||
33825019|NCT06168513|||CASE_CONTROL||OTHER|||||||
33825020|NCT06398171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825021|NCT00115817|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33825022|NCT01659177|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33825023|NCT02968654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825024|NCT00280709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825025|NCT05264064|||OTHER||CROSS_SECTIONAL|||||||
33825026|NCT00060723|||COHORT||PROSPECTIVE|||||||
33825027|NCT03738254|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825028|NCT06632340|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825029|NCT01381458|||COHORT||RETROSPECTIVE|||||||
33825030|NCT03219255|||COHORT||PROSPECTIVE|||||||
33825031|NCT02854839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825032|NCT06357936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825033|NCT01049984|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825034|NCT06646809|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blinded|3 groups of patients - low inflammatory responder, high inflammatory responder with AKG, high inflammatory responder with placebo|t|t|t|t
33825035|NCT00359385|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825036|NCT06023888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study was designed to determine the efficacy of substrate ablation using waveform periodicity analysis, similarity analysis with OCTARAY™ Mapping Catheter could collected more AF electrogram and facilitate the mapping resolution and driver identification., plus phase mapping in persistent AF patients who required substrate modification.|t|f|f|t
33825037|NCT03998501|RANDOMIZED|PARALLEL||PREVENTION||NONE||20 participants will receive 5-week CBTm intervention. The other 20 participants will be waitlisted, but they will undergo the same assessment at the same time. Assessment including MRI will be done before and after 5-week intervention and 3 months after.||||
33825038|NCT00985530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825039|NCT06625645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825040|NCT05838976|||OTHER||CROSS_SECTIONAL|||||||
33825041|NCT03955952|||COHORT||RETROSPECTIVE|||||||
33825042|NCT04425200|||COHORT||PROSPECTIVE|||||||
33825043|NCT05453877|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33825044|NCT01889277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825045|NCT00549042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825046|NCT02242799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825047|NCT03799354|RANDOMIZED|PARALLEL||OTHER||NONE||Pilot randomized controlled trial||||
33825048|NCT06530498|||COHORT||PROSPECTIVE|||||||
33825049|NCT03022110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825050|NCT01404377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33825051|NCT04469452|||OTHER||CROSS_SECTIONAL|||||||
34130447|NCT04294459|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130448|NCT02471534|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130449|NCT00531440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130450|NCT02236325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130451|NCT00692627|||CASE_ONLY||PROSPECTIVE|||||||
33825052|NCT00371618|||CASE_ONLY||RETROSPECTIVE|||||||
33825053|NCT02926495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825054|NCT01940523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825055|NCT02402465|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33825056|NCT05844033|||COHORT||PROSPECTIVE|||||||
33825057|NCT00731588|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33825058|NCT04236245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825059|NCT06158971|NA|SINGLE_GROUP||OTHER||NONE||||||
33825060|NCT03233087|||COHORT||OTHER|||||||
33825061|NCT05388149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825062|NCT01873573|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825063|NCT04695314|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
33825064|NCT01514630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825065|NCT01424683|||COHORT||PROSPECTIVE|||||||
33825066|NCT00030303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825067|NCT03709316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825068|NCT04615715|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Laboratory personnel will not know the participant's intervention status.||f|f|f|t
33825069|NCT04225039|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The overall study population will be broken down into two cohorts: Cohort A (N=16) and Cohort B (N=16). Subjects for whom surgical resection is not clinically indicated at the time of study screening will be enrolled into Cohort A (non-surgical cohort). Subjects for whom surgical resection is clinically indicated at the time of study screening will be enrolled into Cohort B (surgical cohort).||||
33825070|NCT04610645|||CASE_ONLY||PROSPECTIVE|||||||
34130452|NCT01109615||FACTORIAL||TREATMENT||NONE||||||
34130453|NCT06314854|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130454|NCT04737434|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34130455|NCT00711750|||CASE_ONLY||RETROSPECTIVE|||||||
34130456|NCT05580770|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will be conducted in two sequential parts: Part 1 dose escalation (Phase 1) and Part 2 dose expansion (Phase 2a).||||
34130457|NCT05609071|||COHORT||PROSPECTIVE|||||||
34130458|NCT00034671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130459|NCT05521191|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This study will have two parts. Part A is the double-blind, randomized, placebo-controlled study. Part B is the open-label fixed-dose study.|The study will consist of two parts. Part A will consist of three sequential cohorts of approximately 12 subjects each randomized centrally to receive RGLS8429 or placebo by subcutaneous injection every other week (Q2W) x 7 doses (approximately 36 subjects total). Part B will be an open-label fixed dose cohort of up to 30 subjects. .|t|f|t|f
34130460|NCT02541058|||CASE_CONTROL||PROSPECTIVE|||||||
34130461|NCT02601430|NA|SINGLE_GROUP||OTHER||NONE||||||
34130462|NCT02330354|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34130463|NCT03611816|||COHORT||PROSPECTIVE|||||||
34130464|NCT02758600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34130465|NCT01800331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130466|NCT05400603|NA|SEQUENTIAL||TREATMENT||NONE||||||
34130467|NCT01050023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130468|NCT05286476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130469|NCT06471959|NA|SEQUENTIAL||TREATMENT||NONE|"All participants who pass screening and have been deemed eligible by the Investigator will be randomized during their baseline visit on a 1:1 ratio to either Group 1 (Control) or Group 2 (Intervention). Randomization will follow a randomization schedule which will be maintained by a person on the research team who is not directly involved with any assessments.~This is an open-label study, and unblinding is not applicable (all participants will be aware of their group assignment)."|"One week prior to the dosing session, participants will be given a list of suggested guidelines designed to enhance the psilocybin experience. The suggestions are optional, but compliance will be recorded. Before arriving at the research unit on the morning of the dosing session day, they will be instructed to consume the same amount of caffeine-containing beverage (e.g., coffee, tea) that he/she consumes on a usual morning and to eat a light breakfast.~Participants in Group 2 (intervention) will be instructed to take ten (10) 1mg capsules at Week 10. Participants will be advised that the capsules should not be opened, chewed, or held in the mouth for an extended period without swallowing."||||
34130470|NCT01479751|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34130471|NCT06351423|RANDOMIZED|PARALLEL||PREVENTION||NONE||a 3-arm randomized controlled study in a parallel design. Eligible participants will be randomly assigned into 3 interventions: (1) FB-MIND, (2) FB and (3) routine care-control.||||
34130472|NCT03953248|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130473|NCT02859285|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34130474|NCT04589572|RANDOMIZED|PARALLEL||TREATMENT||NONE||EXTREME LATERAL INTERBODY FUSION (XLIF) VERSUS POSTERIOR LUMBAR INTERBODY FUSION (PLIF)||||
34130475|NCT03352232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||There will be two populations based on when they experienced a stroke. Subacute stroke patients will have suffered an ischemic stroke within 3 months of enrollment and have persistent neurological deficits. The second group will be patients who suffered an ischemic stroke more than 6 months (chronic) from time of enrollment and have persistent neurological deficits compromising activities of daily living.||||
34130476|NCT03337867|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34130477|NCT04169529|||CASE_ONLY||PROSPECTIVE|||||||
34130478|NCT06139614|NA|SINGLE_GROUP||PREVENTION||NONE||There will be one group of Junior Assistant Residents (JAR, N = 10) and one group of Senior Assistant Residents (SAR, N =10), which will be conducted separately. At baseline, all participants will complete questionnaires related personal resilience, including professional fulfillment (professional fulfillment, work exhaustion, interpersonal disengagement), depression symptoms, anxiety, symptoms, self-valuation, flourishing, and psychosocial working conditions. At post-treatment (end of session 8), participants will complete the baseline questionnaires (with the exception of psychosocial working conditions), as well as a questionnaire assessing acceptability of the group experience and content. The post-treatment questionnaires will be repeated as a 3-month follow-up.||||
34130479|NCT04886102|||CASE_ONLY||CROSS_SECTIONAL|||||||
34130480|NCT00133159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130481|NCT00849355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130482|NCT01822899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130483|NCT01769664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130484|NCT03777254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130485|NCT04322409|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||2x3 Factorial; 2 groups by 3 time points|t|f|f|t
34130486|NCT02180685|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34130487|NCT01190579|||COHORT||PROSPECTIVE|||||||
34130488|NCT04242576|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Single blind||f|f|t|f
34130489|NCT03051464|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34130490|NCT03797963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130491|NCT00252031|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130492|NCT05349968|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34130493|NCT03879616|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33825071|NCT05870813|||COHORT||RETROSPECTIVE|||||||
33825072|NCT04792255|RANDOMIZED|PARALLEL||OTHER||NONE||Enrolled participants will undergo carotid artery stenting with different image acquisition protocol of the pre-and postinterventional angiographies from anteroposterior and lateral views, and intraoperative angiographies with C-arm angulations based on the operator's decision. In the active comparator group, a standard contrast media dose and DSA images will be used for diagnosis whereas in the experimental group a reduced contrast media dose will be applied (50% decrease compared to the standard DSA protocol) and the operator will use DVA images for the diagnosis.||||
34130494|NCT05082519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"This is a randomized Phase 2 study in patients with HR B-ALL comparing the efficacy of one-time education + the IDEAL2 intervention (experimental) versus one-time education alone (control) in reducing the rate (probability) of having detectable minimum residual disease at the end of induction therapy (EOI MRD) and in reducing the amount of fat gained during induction.~Eligible patients will be randomized 1:1 to either the experimental or control arms using stratified, blocked randomization within four strata defined by presenting WBC (\< 50K/uL, ≥ 50K/uL) and body mass index (normal weight vs overweight/obese)."||||
34130495|NCT01667133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130496|NCT03536481|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130497|NCT04600726|||COHORT||PROSPECTIVE|||||||
34130498|NCT06354348|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34130499|NCT05441215|NA|SINGLE_GROUP||OTHER||NONE||||||
34130500|NCT02311036|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34130501|NCT05366127|||COHORT||PROSPECTIVE|||||||
34130502|NCT05924581|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130503|NCT03292874|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm, paired imaging||||
34130504|NCT03666520|||COHORT||PROSPECTIVE|||||||
34130505|NCT04092803|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34130506|NCT04136548|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34130507|NCT05023785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34130508|NCT03363191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will receive either fluticasone furoate/vilanterol 100/25 mcg or fluticasone furoate 100 mcg once daily in this parallel group study.|t|f|t|f
34130509|NCT00600275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130510|NCT04986826|||COHORT||PROSPECTIVE|||||||
34130511|NCT06421714|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130512|NCT03571750|RANDOMIZED|PARALLEL||PREVENTION||NONE||Approximately 510 participants will be randomly assigned to one of two conditions (1) BSA or (2) HET Control.||||
34130513|NCT02733549|||CASE_CONTROL||PROSPECTIVE|||||||
34130514|NCT02943070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130515|NCT01422941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130516|NCT03870373|||CASE_ONLY||PROSPECTIVE|||||||
34130517|NCT06133855|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|pulsed electromagnetic fields therapy and traditional physical therapy program|f|f|t|t
34130518|NCT05801848|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34130519|NCT02346227|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34130520|NCT00954564|||COHORT||PROSPECTIVE|||||||
34130521|NCT01413243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130522|NCT02818764|||CASE_CONTROL||PROSPECTIVE|||||||
34130523|NCT02831504|||COHORT||PROSPECTIVE|||||||
34130524|NCT00633178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130525|NCT04031248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34130526|NCT02515968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130527|NCT04492241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130528|NCT06511479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34130529|NCT00584818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130530|NCT01682317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130531|NCT00249652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130532|NCT03577340|||COHORT||RETROSPECTIVE|||||||
34130533|NCT01186887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130534|NCT01670279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130535|NCT02880228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130536|NCT05690347|||COHORT||PROSPECTIVE|||||||
34130537|NCT02039167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130538|NCT01539122|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130539|NCT02177877|||OTHER||PROSPECTIVE|||||||
34130540|NCT01693198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130541|NCT06345261|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34130542|NCT00976287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130543|NCT04416334|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130544|NCT03312790|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34130545|NCT00517010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130546|NCT04129983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34130547|NCT03172299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130548|NCT01633255|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130549|NCT05302973|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130550|NCT00897780|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34130551|NCT01884181|||CASE_CONTROL||PROSPECTIVE|||||||
34130552|NCT02434549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130553|NCT04320212|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34130554|NCT05026840|||COHORT||PROSPECTIVE|||||||
34130555|NCT03414203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"The patients will be randomized into 1 of 3 groups:~group A: active tDCS for 15 minutes, group B: active tDCS for 15 minutes, with an interval of 20 minutes and group C: more 15 minutes os stimulation, sham tDCS for 15 minutes."|t|t|t|t
34130556|NCT02534025|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34130557|NCT03617601|||COHORT||RETROSPECTIVE|||||||
34130558|NCT01821066|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130559|NCT00867958|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130560|NCT02199470|||CASE_CONTROL||PROSPECTIVE|||||||
34130561|NCT04514627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130562|NCT03180333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130563|NCT04778891|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34130564|NCT00705445|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34130565|NCT05962216|||COHORT||PROSPECTIVE|||||||
34130566|NCT05089552|||OTHER||CROSS_SECTIONAL|||||||
34130567|NCT04105088|||COHORT||CROSS_SECTIONAL|||||||
34130568|NCT01995500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a Drug-Device combination Product|t|f|f|f
34130569|NCT03899233|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participate will be assigned to both arms (split face manner). One half of the face will be assigned to Tranexamic acid alone and the other side of the face will be assigned to combined Tranexamic acid and Fractional CO2 laser. Both sides of the face will take the same time of treatment and will be assessed at the same time.||||
34130570|NCT02520388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130571|NCT03565250|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130572|NCT00720356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130573|NCT01864148|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130574|NCT01336855|||COHORT||PROSPECTIVE|||||||
34130575|NCT01458743|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130576|NCT03680833|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective cohort study||||
34130577|NCT05146219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130578|NCT04635254|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34130579|NCT04368013|||COHORT||PROSPECTIVE|||||||
34130580|NCT03699397|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130581|NCT06393270|||COHORT||RETROSPECTIVE|||||||
34130582|NCT02137980|||CASE_ONLY||PROSPECTIVE|||||||
34130583|NCT01373008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130584|NCT06174012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130585|NCT01014936|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130586|NCT03863561|||COHORT||PROSPECTIVE|||||||
34130587|NCT03246516|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34130588|NCT03969225|||OTHER||PROSPECTIVE|||||||
34130589|NCT04307069|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130590|NCT03213184|||COHORT||PROSPECTIVE|||||||
33825073|NCT00657475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33825074|NCT00601471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825075|NCT00068835|RANDOMIZED|FACTORIAL||ECT||SINGLE||||||
33825076|NCT06647251|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomly assigned to one of the following arms: Q-MODE, Q-MODE+, hybride Q-MODE/Q-MODE+.~The number of patients in each arm is the same."||||
33825077|NCT02773407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825078|NCT04491084|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized, open-label phase I/II study. Subjects will be randomized in a 1:1 ratio to receive FLT3 ligand (CDX-301), anti-CD40 antibody (CDX-1140) and SBRT (Arm 1) versus standard care (Arm 2).||||
33825079|NCT02652715|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33825080|NCT01176136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825081|NCT00235014|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825082|NCT03209297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||One study arm will be treated immediately after inclusion. The other study arm will be treated after a delay of 9 weeks. During these 9 weeks patients will be on a waiting list.|t|t|f|t
33825083|NCT05287698|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients who were hospitalized for suspension laryngoscopy and met the sample selection criteria will be included in the experimental and control groups by block randomization method using the random numbers table on the computer.||||
33825084|NCT03324633|||COHORT||PROSPECTIVE|||||||
33825085|NCT01420900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825086|NCT06306677|||COHORT||CROSS_SECTIONAL|||||||
33825087|NCT01271153|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33825088|NCT06646081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825089|NCT06414681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825090|NCT00006099|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33825091|NCT05459142|||CASE_CROSSOVER||PROSPECTIVE|||||||
33825092|NCT02720081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825093|NCT05674383|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33825094|NCT00572351|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33825095|NCT05858398|NA|SINGLE_GROUP||OTHER||NONE||||||
33825096|NCT02115334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33825097|NCT02314169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825098|NCT05600998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825099|NCT05207449|||OTHER||CROSS_SECTIONAL|||||||
33825100|NCT02068352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130591|NCT01415583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825101|NCT02262390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33825102|NCT04189809|||COHORT||RETROSPECTIVE|||||||
33825103|NCT04376242|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825104|NCT04636021|||OTHER||PROSPECTIVE|||||||
33825105|NCT00399997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825106|NCT01183013|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825107|NCT00453934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825108|NCT01872156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825109|NCT02960321|||COHORT||PROSPECTIVE|||||||
33825110|NCT01560585|NA|SINGLE_GROUP||TREATMENT||NONE|"open label study before being prematurely terminated"|||||
33825111|NCT00924599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130592|NCT02701244|||COHORT||PROSPECTIVE|||||||
34130593|NCT00565162|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130594|NCT02160249|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34130595|NCT01760499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130596|NCT02046837|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34130597|NCT00819000|||COHORT||PROSPECTIVE|||||||
34130598|NCT04314700|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34130599|NCT02517255|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130600|NCT01116466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130601|NCT00479570|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34130602|NCT01762774|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34130603|NCT04934696|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34130604|NCT04381052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This study is double-blind and therefore neither the Investigator, the subject, the Sponsor and its representatives, nor other designated study site personnel involved in running of the study will be aware of the identification of the investigational drug administered to each subject.|This is a randomized, double-blind, placebo-controlled, adaptive seamless Phase II/III design (ASD). The investigators propose the administration of an investigational drug in patients with high predicted short-term mortality secondary to COVID-19 disease. Patients will be enrolled and randomly assigned in a 1:1 ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.|t|f|t|f
34130605|NCT04892524|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130606|NCT01734798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130607|NCT02069821|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130608|NCT02455336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130609|NCT02452957|||COHORT||PROSPECTIVE|||||||
34130610|NCT03957668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34130611|NCT06554704|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34130612|NCT00500565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130613|NCT03520686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130614|NCT02029456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130615|NCT02597452|NA|SINGLE_GROUP||SCREENING||NONE||||||
34130616|NCT04860869|||COHORT||CROSS_SECTIONAL|||||||
34130617|NCT06004713|||COHORT||PROSPECTIVE|||||||
34130618|NCT05260138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34130619|NCT00845468|||COHORT||PROSPECTIVE|||||||
34130620|NCT03531164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34130621|NCT03018535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130622|NCT00245388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130623|NCT03335904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34130624|NCT04404790|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34130625|NCT04230265|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|In the expansion cohort 2 different TM123 dose levels shall be compared descriptively.|Phase 1b Dose Expansion: An expansion cohort of up to 20 patients was initiated.||||
34130626|NCT02052661|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34130627|NCT02622295|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130628|NCT03435120|||COHORT||PROSPECTIVE|||||||
34130629|NCT03272386|||OTHER||PROSPECTIVE|||||||
34130630|NCT02259725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825112|NCT05482256|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33825113|NCT03132753|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825114|NCT00672763|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825115|NCT04796389|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33825116|NCT02210611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825117|NCT02830256|||OTHER||PROSPECTIVE|||||||
33825118|NCT00936754|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33825119|NCT00115986|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33825120|NCT05131789|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33825121|NCT03192202|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33825122|NCT04292925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825123|NCT05740969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825124|NCT00660361|||COHORT||PROSPECTIVE|||||||
33825125|NCT06221800|||COHORT||PROSPECTIVE|||||||
33825126|NCT02364505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33825127|NCT03793140|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open-label multicenter, single-arm, phase II trial of CPI-613 monotherapy.||||
33825128|NCT00768209|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825129|NCT05885841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825130|NCT05245084|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825131|NCT03562897|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825132|NCT02969005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825133|NCT01928407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825134|NCT00033189|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825135|NCT05499247|NA|SINGLE_GROUP||OTHER||NONE||Proof-of-Science, Safety and Efficacy||||
33825136|NCT05381181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825137|NCT05056129|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33825138|NCT03652870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind||t|t|t|t
33825139|NCT02176902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825140|NCT05518877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, double-dummy randomized controlled trial|t|t|t|t
33825141|NCT05809726|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||randomized controlled study|t|f|f|f
33825142|NCT00539487|||||PROSPECTIVE|||||||
33825143|NCT00524810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825144|NCT01178281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825145|NCT00084747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825146|NCT05524285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825147|NCT04522583|||COHORT||RETROSPECTIVE|||||||
33825148|NCT02450123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825149|NCT02726321|||COHORT||CROSS_SECTIONAL|||||||
33825150|NCT06204614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837436|NCT03556787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837437|NCT05454345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837438|NCT04480606|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837439|NCT01533753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837440|NCT02514681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837441|NCT01770795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837442|NCT03438682|||COHORT||RETROSPECTIVE|||||||
33837443|NCT02944812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837444|NCT04654559|NA|SINGLE_GROUP||OTHER||NONE||||||
33840220|NCT03018522|||COHORT||PROSPECTIVE|||||||
34130631|NCT04678362|NA|SINGLE_GROUP||TREATMENT||NONE|None (open label=)|Single-arm phase 2 trial||||
33825151|NCT04787900|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The Examiner 3 will be record the result by placing the device to be measured on the lateral projection of the midpoint of the femur. By preserving the participant's position, measurements will be make with the other device immediately and the values will bw record by the Examiner3.|wo experienced physiotherapists will evaluate the elasticity of both the dominant and non-dominant iliotibial bands after 2 minutes of warm-up before the evaluation. Measurements will be made by two physical therapists for each participant in different rooms without seeing each other. The examiners will carry out three measurements for both extremities, using both the bubble inclinometer and the iPhone® measurement app. A 5-minute passive rest will be give between measurements. All evaluations will be first conducted by Examiner 1 and then by Examiner 2. Measurement values will be record by a third physiotherapist. Data obtained from both devices will be compare in terms of validity and reliability using statistical analysis used in previous studies.|f|f|t|t
33825152|NCT02179710|||CASE_ONLY||PROSPECTIVE|||||||
33825153|NCT05664230|||CASE_ONLY||PROSPECTIVE|||||||
33825154|NCT01107353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825155|NCT00788047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33825156|NCT03854214|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This study is a double-blinded randomized trial. Study physicians and research staff who perform study measurements on participants will be blinded from the intervention the study participants receive. Study participants will not be informed of the intervention he/she will receive. However, because of the nature of the interventions, study participant cannot be completely blinded to the treatment they will receive, as some participants may have residual motor and sensory functions and 'feel' which intervention they are receiving.|"The study will be performed as a randomized, parallel group trial to determine if the amount of changes in brain functional connectivity outcome measures (i.e., between network connectivity) is significantly different between the group of patients that perform FES cycling and another group of patients that perform passive (sham) cycling.~Official screening will be performed after participants consent by signing the study's consent form. Participants will be randomized into 2 groups: FES cycling (Group 1; n=24) and passive cycling (Group 2; n=24). The participants will undergo either an FES cycling or a passive cycling sessions for 4 weeks, 3 times a week. MRI will be performed on all participants at the beginning (prior to cycling sessions) and at the end of the 2nd and 4th weeks of the intervention program. ISNCSCI evaluations will be performed to coincide with the dates of MRI acquisitions, to determine the neurological level and the degree of sensory and motor impairments."|t|t|f|f
33825157|NCT02814097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825158|NCT06001827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825159|NCT04868318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33825160|NCT03628456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825161|NCT02512861|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825162|NCT00138918|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825163|NCT06645925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825164|NCT02895750|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825165|NCT02986659|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33825166|NCT02489721|||COHORT||PROSPECTIVE|||||||
33825167|NCT00115284|RANDOMIZED|FACTORIAL||||SINGLE||||||
33825168|NCT05023941|RANDOMIZED|FACTORIAL||PREVENTION||NONE|Due to the nature of the procedure, it was not possible to blind subjects to the intervention of medicine or RIPC.|||||
33825169|NCT04794894|||CASE_CONTROL||PROSPECTIVE|||||||
33825170|NCT05313815|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825171|NCT03320642|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33825172|NCT05163106|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentre, single-arm, open-label, neoadjuvant study model||||
33825173|NCT04013932|RANDOMIZED|PARALLEL||TREATMENT||NONE|Only the main biostatistician will be masked in the study.|||||
33825174|NCT00574626|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825175|NCT01998997|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825176|NCT02962063|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase Ib/II trial of durvalumab (MEDI4736), a monoclonal antibody against programmed death ligand-1 (PD-L1)), and tremelimumab, an anti-CTLA-4 antibody, in combination with chemoradiation for patients with locally advanced (TanyN+M0 or T3-4NanyM0) esophageal or gastroesophageal (GE) junction adenocarcinoma.||||
33825177|NCT04995406|||COHORT||PROSPECTIVE|||||||
33825178|NCT04350983|||COHORT||RETROSPECTIVE|||||||
33825179|NCT03885622|||CASE_ONLY||PROSPECTIVE|||||||
33825180|NCT00785850|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825181|NCT06003738|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33825182|NCT01906645|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33825183|NCT04201717|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825184|NCT05046652|||CASE_ONLY||RETROSPECTIVE|||||||
33825185|NCT00053391|NON_RANDOMIZED|||TREATMENT||NONE||||||
33825186|NCT02865135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130632|NCT05237505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcomes Assessor|"6-month, 2-arm randomized, parallel, interventional mechanistic study of COPD/OSA overlap syndrome to compare bi-level PAP vs. O2 therapy~Qualified participants will be randomized to receive either O2 therapy or bi-level therapy."|f|f|t|t
34130633|NCT05130385|||COHORT||PROSPECTIVE|||||||
34149381|NCT04326816|RANDOMIZED|PARALLEL||TREATMENT||NONE||After written informed consent, patients fulfilling the inclusion criteria were assigned to an experimental group using block randomization with a block size of eight and the trial design had an intended allocation ratio of 1:1. Patients were allocated randomly to one of the two restorative treatment protocols: (1) Direct Composite restorations (DCR): using direct composite restorations on all teeth or (2) Indirect Composite Restorations (ICR): using ICR on all first molars and palatal veneer restorations on maxillary anterior teeth and DCR on remaining teeth.||||
34149382|NCT02690454|||COHORT||PROSPECTIVE|||||||
33825187|NCT01002547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825188|NCT03038945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825189|NCT05501665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825190|NCT05088447|||COHORT||PROSPECTIVE|||||||
33825191|NCT00788879|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130634|NCT04242628|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention consists of the attendance to two training courses. T1 study members attended a three week course (two classes per week) on smartphones and SNS use. T2 study members attended 5 interactive 90-min meetings on lifestyle education and brain functioning in older people. A goodbye tea was offered after T2 meetings. Throughout the duration of the intervention, we put C study members on a waiting list; at the end of the intervention, in June 2019, interested group C study members attended the SNSs course (held on June 2019). One year after the first intervention, i.e. in March 2020, we will carry out a follow up assessment on T1 and T2 participants. Note that, due to the constraints imposed by the ethical committee (i.e. we offered members of the C group the possibility to attend the SNS course during the first intervention), the members of the C group are excluded from the follow up.||||
33825192|NCT03669900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130635|NCT03201575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130636|NCT01389453|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34130637|NCT03067519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomly put in group using sealed envelop.||t|f|f|f
33825193|NCT02497196|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34130638|NCT02202915|NA|SINGLE_GROUP||OTHER||NONE||||||
33825194|NCT02995733|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33825195|NCT02958813|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825196|NCT00549861|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825197|NCT06223100|||COHORT||PROSPECTIVE|||||||
33825198|NCT03416335|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825199|NCT01292317|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825200|NCT03684356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825201|NCT02548754|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825202|NCT00826371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825203|NCT01623206|NA|SINGLE_GROUP||OTHER||NONE||||||
33825204|NCT04491006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel-group study|t|t|t|t
33825205|NCT05347121|||CASE_ONLY||PROSPECTIVE|||||||
33825206|NCT05460429|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825207|NCT01295788|RANDOMIZED|PARALLEL||TREATMENT||NONE||Simultaneous or Delayed initiation of continuous glucose monitoring||||
33825208|NCT02494453|||OTHER||PROSPECTIVE|||||||
33825209|NCT05093023|||COHORT||PROSPECTIVE|||||||
33825210|NCT01304108|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33825211|NCT04050423|||CASE_ONLY||PROSPECTIVE|||||||
33825212|NCT01189617|NA|SINGLE_GROUP||||NONE||||||
33825213|NCT03560414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825214|NCT05540262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825215|NCT04236622|||COHORT||RETROSPECTIVE|||||||
33825216|NCT06330233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825217|NCT06247618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825218|NCT04340726|RANDOMIZED|PARALLEL||TREATMENT||||||||
33825219|NCT03455218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double Blinded, Placebo Controlled|t|t|t|t
33825220|NCT00397202|RANDOMIZED|PARALLEL||||NONE||||||
33825221|NCT00507429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825222|NCT00114543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825223|NCT05047497|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33825224|NCT01990911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825225|NCT04212897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients and the outcomes assessor are blinded in this study|Parallel assignment|t|f|t|t
33825226|NCT00005797|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825227|NCT05842915|||COHORT||OTHER|||||||
33825228|NCT04473768|||COHORT||PROSPECTIVE|||||||
33825229|NCT06283199|||COHORT||PROSPECTIVE|||||||
33825230|NCT06397950|||CASE_ONLY||PROSPECTIVE|||||||
33825231|NCT01712698|||COHORT||PROSPECTIVE|||||||
33825232|NCT00676429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825233|NCT02641106|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825234|NCT06217497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|two groups|This study was conducted in a randomized controlled design.|t|f|f|f
33825235|NCT05583734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Self-controlled, prospective trial||||
33825236|NCT00475735|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33825237|NCT05011617|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"We set a blind code in case patients have adverse effects. The random code and blind code will be conducted using opaque envelopes by a third party independent of the study. The envelopes will be sealed and shuffled, and the assignment records will not be disclosed until the end of the study. Trial participants, cardiothoracic surgeons, anesthesiologists, outcome assessors, and data analysts will be blinded to the treatment allocation to minimize potential sources of bias. Only the nurse of the anesthesiology department (having received specialized acupuncture training) will know the participants' group allocations. However, this nurse will not know any other information about the patients."||t|t|t|t
33825238|NCT04788277|||CASE_CONTROL||PROSPECTIVE|||||||
33825239|NCT02900222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825240|NCT06277024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825241|NCT04473118|||COHORT||PROSPECTIVE|||||||
33825242|NCT03083093|||CASE_CONTROL||OTHER|||||||
33825243|NCT00282828|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825244|NCT04335695|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will enroll in the Vascular Rehab program at Baylor Scott \& White Heart Hospital and be followed for 1 year after the program ends.||||
33825245|NCT03371706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||NIH Stage 2 behavioral clinical trial|t|f|f|t
33837445|NCT01411241|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|An observer-blind design was chosen since the products were visually different. For the second dose of CYD dengue vaccine, the person who administered the injections knew which product was administered while the subject/parent and Investigator were blinded. The first and third doses of CYD dengue vaccine were administered according to an open-label procedure. A placebo dose was administered at Month 7(Group 1) and concomitantly with Pentaxim vaccine at Month 6 (Group 2) to maintain the blind.||t|t|t|t
33825246|NCT06339814|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will be with two parallel branches, thus conforming to a Randomized Group Treatment Trial: Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol (those who will receive Eye Movement Desensitization and Reprocessing treatment plus the standard support) versus Treatment As Usual condition (those who will receive only standard support). The assessment will be performed at the moment of recruitment (T0), after the intervention for the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol group and after 1 month for the Treatment As Usual condition (T1), and for both 2 months after T1 (T2).||||
33825247|NCT05610059|RANDOMIZED|PARALLEL||OTHER||DOUBLE|All primary and secondary outcomes completed at 3-months and 6-months are blinded.|Participants will be screened and assigned to one of two groups using a blood pressure technology system.|t|f|f|t
33825248|NCT04445519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-masked||t|f|t|f
33825249|NCT06646718|RANDOMIZED|PARALLEL||OTHER||NONE||"* The study will include children (age 5-14years) post selective dorsal rhizotomy.~* Children meeting the inclusion criteria will be randomly assigned to one of two groups:~  * Experimental Group: children in this group will receive closed kinetic chain.~ * Control Group: Patients in this group will receive Traditional physical therapy."||||
33825250|NCT01909947|||COHORT||PROSPECTIVE|||||||
33825251|NCT00439348|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33825252|NCT05818436|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33825253|NCT05303090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825254|NCT00535795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825255|NCT01282697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825256|NCT05579587|||CASE_ONLY||PROSPECTIVE|||||||
33825257|NCT00497198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825258|NCT04056741|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
33825259|NCT06539416|||COHORT||PROSPECTIVE|||||||
33825260|NCT02611375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825261|NCT02277587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825262|NCT06210737|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825263|NCT02542085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825264|NCT00000441|RANDOMIZED|||TREATMENT||DOUBLE||||||
33825265|NCT01489462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825266|NCT03305471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking description is for Part B only - Parts A and C are Open Label, so have no masking|"Part A has a 2-period, open-label, randomized, 2-way crossover design with a single dose of Treatments A1 and A2~Part B participants are randomized with a 2:3:3:3 ratio to Treatment B1, B2, B3, and B4, respectively, using a double-blind, repeated dose, parallel design~Part C is an optional, single-arm, open label, repeated dose design"|t|f|t|f
33825267|NCT01171885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825268|NCT01644825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825269|NCT04238559|||COHORT||PROSPECTIVE|||||||
33825270|NCT04814615|NA|SEQUENTIAL||DIAGNOSTIC||NONE||Individual dose of 89Zr-DFO-daratumumab will be requested from Memorial Sloan Kettering Cancer Center and received at the Hoag Family Cancer Institute radiopharmacy for each individual 89Zr-DFO-daratumumab administration.||||
33825271|NCT04457089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825272|NCT05056298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825273|NCT00148499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825274|NCT05512234|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825275|NCT05210374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825276|NCT03568708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825277|NCT04274699|||CASE_ONLY||PROSPECTIVE|||||||
33825278|NCT05451056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825279|NCT06645951|||COHORT||OTHER|||||||
33825280|NCT06399003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study will have an observer-blinded phase for Group 1 and Group 2 followed by an open label phase from Day 43. Group 3 will remain an open label arm throughout the period of the study.|The enrolled children will be randomized to three groups in the ratio of 1:1:1 receiving different vaccines.|f|f|f|t
33825281|NCT03672383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Observer-blind||f|f|t|t
33825282|NCT00727259|||COHORT||PROSPECTIVE|||||||
33825283|NCT02108197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825284|NCT05304221|||CASE_CROSSOVER||PROSPECTIVE|||||||
33825285|NCT05633849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized, multicentre, double-blind, placebo-controlled, parallel-group pilot study|t|t|t|f
33825286|NCT03707418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825287|NCT00495261|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825288|NCT03900715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825289|NCT02613143|||||RETROSPECTIVE|||||||
33825290|NCT01501747|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|f|t
33825291|NCT03826147|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Double-blind||t|f|t|t
33825292|NCT04039555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single blind study||f|t|f|f
33825293|NCT02666170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825294|NCT01630395|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33825295|NCT05221216|||COHORT||RETROSPECTIVE|||||||
33825296|NCT03519477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33825297|NCT04041323|||COHORT||RETROSPECTIVE|||||||
33825298|NCT03011554|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825299|NCT05646589|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33825300|NCT01591668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825301|NCT01685047|||COHORT||PROSPECTIVE|||||||
33825302|NCT03888261|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825303|NCT06588725|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33825304|NCT05335577|||COHORT||PROSPECTIVE|||||||
33825305|NCT06646874|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants were required to attend one experimental session in a random order using Microsoft Excel's (Microsoft Corp., Redmond, WA, USA) random list function.||t|f|f|f
33825306|NCT02902497|||||PROSPECTIVE|||||||
33837446|NCT05316792|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||Case-Control Study|f|f|f|t
33837447|NCT02848768|||COHORT||RETROSPECTIVE|||||||
34130639|NCT02688829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130640|NCT00349349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130641|NCT06180499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130642|NCT04075747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130643|NCT03292640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130644|NCT03377816|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The control group is designed to be similar to the intervention, participants will be engaged in interacting with art materials. Research assistants will be blinded to group allocation when collecting data.||t|f|f|t
34130645|NCT03548896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34130646|NCT05441605|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A double-blind, experimental type of study.|This research is a randomized controlled double-blinded experimental design. First experimental group, 1% chlorhexidine, n=24 patients, second experimental group, 2% chlorhexidine, n=24 patients, third experimental group, 4% chlorhexidine, n=24 patients, control group, 70% iso-propyl alcohol, n=24 patients|t|f|t|f
34130647|NCT04491435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and outcome assessor blinded to allocation of treatment, which was only revealed after completion of data collection||t|f|f|t
34130648|NCT02841579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130649|NCT00861757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130650|NCT01564849|||CASE_CONTROL||PROSPECTIVE|||||||
34130651|NCT04010656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subjects will be taught to perform self-catheterization prior to prolapse repair or incontinence surgery; voiding data will be collected on the participant's first void after surgery. Participants will be discharged home to perform self-catheterization until post-void residual is less than half the volume voided on 2 sequential voids to assess actual voiding function, and this data will be used to calculate the diagnostic accuracy of pre-determined combinations of the TOV parameters.||||
34130652|NCT01551654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130653|NCT03377595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130654|NCT01453452|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34130655|NCT03640507|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34130656|NCT02509468|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34130657|NCT05939245|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34130658|NCT00271141|||||OTHER|||||||
34130659|NCT03993886|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Multi-Arm study with different patient populations evaluating the CorBand.||||
34130660|NCT03489772|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34130661|NCT05754398|NA|SINGLE_GROUP||PREVENTION||NONE|The data will be collected through a face-to-face administered structured survey questionnaire, and anthropometrical physical measurements. To reduce assessor bias, CHWs will not be involved in the data collection process. Hence, two professional nurses from Bahir Dar city will be recruited for data collection. The data collectors will not be involved in providing the intervention.|A single-group pre-, post-, and follow-up single-group quasi-experimental study design will be adopted to examine the effect of a nurse-led intervention on frailty among older persons living in Bahir Dar City, Ethiopia.||||
34130662|NCT01506635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130663|NCT02755662|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130664|NCT03076489|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130665|NCT00690690|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130666|NCT03171584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130667|NCT04796272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34130668|NCT02374788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130669|NCT01439659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130670|NCT02526953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130671|NCT05159687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130672|NCT05818540|RANDOMIZED|PARALLEL||TREATMENT||NONE|Data collected will be deidentified upon collection - surveys and assessment forms will be labelled with a numerical identifier.|||||
34130673|NCT02504398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34130674|NCT00988052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130675|NCT04535102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130676|NCT05046873|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.||t|t|t|t
34130677|NCT03520920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130678|NCT01245686|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130679|NCT01536561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130680|NCT04789954|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34130681|NCT04120844|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34130682|NCT04089670|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups are created through randomization to either the treatment group or the control group. The treatment includes 8 online intervention modules that are administered weekly for 8 weeks. A 7-day sleep diary is administered one week prior to the intervention and one week after the intervention. The control group completes the online sleep diaries and all the same assessments as the treatment group. At the end of the 1 month follow-up they are given the opportunity to receive the intervention.||||
34130683|NCT05421169|||COHORT||PROSPECTIVE|||||||
33837448|NCT02526498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837449|NCT01217437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837450|NCT04841434|NA|SINGLE_GROUP||TREATMENT||NONE||Dose escalation will be performed using three dose levels of MTX.||||
34130684|NCT03356353|NA|SINGLE_GROUP||PREVENTION||NONE||This is an open label single arm trial.||||
34130685|NCT03962894|||COHORT||RETROSPECTIVE|||||||
34130686|NCT03375489|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34130687|NCT06554054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130688|NCT03672812|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34130689|NCT00543270|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130690|NCT04839458|NA|SINGLE_GROUP||SCREENING||NONE||||||
34130691|NCT02036710|||CASE_CONTROL||PROSPECTIVE|||||||
34130692|NCT05953597|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34130693|NCT06264466|NA|SINGLE_GROUP||TREATMENT||NONE||interventional trial||||
34130694|NCT04522882|NA|SINGLE_GROUP||OTHER||NONE||Actimetry is performed in all patients included.||||
34130695|NCT00733733|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130696|NCT06339450|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130697|NCT05965076|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34130698|NCT05691790|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34130699|NCT00855777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130700|NCT04883749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825307|NCT03115229|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"In the RCT, blindness was done in terms of data collectors and statistician. The data were collected by another investigator (assistant investigator) who did not know who was in the experiment and control group, and the data were recorded by the assistant investigator on the computer, without specifying the experiment and control group.~Experimental and control groups were coded by an assistant investigator. Analysis of the data encoded by groups was done by a statistician.~After the statistical analyzes were made and the research report was written, the assistant investigator explained the coding for the experiment and control group.~In this way, data gathering, statistical analysis and reporting have been blinded.~Note: Two assistant researchers received support from the research process. One of the assistant researcher is a coach who is a graduate of the Faculty of Sport Sciences other than Ph.D. Student of the Department of Public Health Nursing"||f|f|f|t
33825308|NCT02053740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825309|NCT02081742|||COHORT||PROSPECTIVE|||||||
33825310|NCT04159805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825311|NCT06052683|RANDOMIZED|PARALLEL||TREATMENT||NONE||For the pilot study, patients will be randomized to receive one of the following treatments to a planned sample size of 48 patients. 24 patients will be randomized in each treatment arms. Once the pilot study will be completed, the investigators will conduct the large-scale research study enrolling 208 patients||||
33825312|NCT00571558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825313|NCT03441919|||CASE_CONTROL||PROSPECTIVE|||||||
33825314|NCT04617262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825315|NCT03732950|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825316|NCT04227171|||COHORT||PROSPECTIVE|||||||
33825317|NCT00427297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825318|NCT04659200|||CASE_ONLY||RETROSPECTIVE|||||||
33825319|NCT05135988|||OTHER||OTHER|||||||
33825320|NCT02879539|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825321|NCT03187041|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||In order to acquire our data, a Microlab PicoPress device will be employed. It has been shown to provide accurate, linear, and reproducible measures of surface pressure between the skin and device. For tourniquets, the investigators will be using a MedSource perforated tourniquet, which is the type of elastic tourniquet the phlebotomists are accustomed to using in their daily practice. For each experiment throughout both phases of the study, the PicoPress pressure sensor will be folded in half and taped over the lateral aspect of the right arm, approximately 2 inches distal to the deltoid muscle along the brachialis muscle. Arm circumferences will be taken prior to experimentation at this same location. For each trial, the phlebotomists will tie the 2.5cm elastic tourniquet around the arm and pressure sensor while ensuring that the tourniquet is not knotted directly on top of the sensor. The study will be divided into two phases of experimentation conducted sequentially.||||
33825322|NCT01089387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825323|NCT04977297|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825324|NCT05645744|||OTHER||PROSPECTIVE|||||||
33825325|NCT04420897|||CASE_CONTROL||RETROSPECTIVE|||||||
33825326|NCT02600897|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825327|NCT02146729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825328|NCT03590938|||COHORT||PROSPECTIVE|||||||
33825329|NCT04608032|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The first group is about cognitive remediation therapy (ECo-Sz). The second group is about recovery oriented therapy (ThOR).|t|f|f|t
34130701|NCT06468891|||CASE_CONTROL||PROSPECTIVE|||||||
34130702|NCT02596568|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34130703|NCT04506593|||COHORT||PROSPECTIVE|||||||
34130704|NCT01918605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34130705|NCT01749280|||||PROSPECTIVE|||||||
34130706|NCT00422448|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130707|NCT04550520|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||"Double-blind randomized-controlled cross-over trial consisting of two parts, including healthy adults (study part 1 - proof of concept) and adults with known diagnosis of cDI or PP (study part 2 - pilot study). Study parts 1 and 2 will be conducted consecutively. If the results of study part 1 suggest that glucagon is a potent stimulator of Copeptin in healthy adults, study part 2 will be conducted.~The half of the study group will start with test day A (injection of glucagon), followed by test day B (injection of placebo) and the other half will start with test day B (injection of placebo), followed by test day A (injection of glucagon). The randomization will be performed by an independent third party."|t|t|t|f
34130708|NCT00002552||||TREATMENT||||||||
34130709|NCT01140594|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130710|NCT01156025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130711|NCT05006989|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34130712|NCT04764097|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blinded clinical trial.|Randomised (1:1) to either Dapaglifozin 10mg or placebo.|t|f|t|f
34130713|NCT05332392|NA|SINGLE_GROUP||OTHER||NONE||||||
34130714|NCT00982683|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34130715|NCT00140296|RANDOMIZED|PARALLEL||ECT||SINGLE||||||
34130716|NCT03626064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130717|NCT00315952|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130718|NCT05764252|||COHORT||PROSPECTIVE|||||||
34130719|NCT01864967|||||CROSS_SECTIONAL|||||||
34130720|NCT00574392|||COHORT||PROSPECTIVE|||||||
34130721|NCT01628484|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130722|NCT03798535|||COHORT||OTHER|||||||
34130723|NCT00824252|||COHORT||PROSPECTIVE|||||||
34130724|NCT06271681|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130725|NCT05202899|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130726|NCT03976024|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130727|NCT03764319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of 2 groups||||
34130728|NCT05088330|NA|SINGLE_GROUP||TREATMENT||NONE||D-VRD||||
34130729|NCT02905539|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130730|NCT02479958|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130731|NCT01720004|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130732|NCT00770627|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130733|NCT01804933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130734|NCT01188902|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130735|NCT03763812|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No masking since patients, doctor and researchers know if patients undergo EVAR or EVAS.|||||
34130736|NCT00811291|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130737|NCT04438759|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is a comparison between the current standard practice of performing a diagnostic hysteroscopy and a relatively recently developed technology that is added to the standard diagnostic hysteroscopy. The aim of the study is to find out whether this newer technology has an advantage for the patient, in the form of anxiety and pain reduction.||||
34130738|NCT03066960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130739|NCT06089863|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130740|NCT00391053|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34130741|NCT05201885|||COHORT||PROSPECTIVE|||||||
34130742|NCT02188940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130743|NCT03001193|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130744|NCT02417610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130745|NCT00330980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130746|NCT02209792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34130747|NCT02064049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130748|NCT03877614|||COHORT||PROSPECTIVE|||||||
34130749|NCT03444103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130750|NCT03073811|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34130751|NCT04107740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130752|NCT05117567|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Stepped-wedge cluster-randomized controlled trial (one-way crossover) with nested mixed methods study||||
34130753|NCT03365687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The manufacturer, Europharm, will provide the active vitamin D3 and placebo preparations, identical in appearance and taste, in coded latex-free bottles. A web-based randomisation system will allow Site pharmacies to obtain allocated treatment number, prepare the 2 mL bolus in coded syringes and the coded bottles containing the daily dose, and dispense study drugs in masked kits.|This is a randomised, triple-blind, placebo-controlled, parallel-group multicentre trial of vitamin D3 supplementation.|t|f|t|t
34130754|NCT03762512|||CASE_ONLY||PROSPECTIVE|||||||
34130755|NCT03316716|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34130756|NCT03687294|||CASE_CONTROL||PROSPECTIVE|||||||
34130757|NCT01501890|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34130758|NCT01671709|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130759|NCT00289172|RANDOMIZED|PARALLEL||PREVENTION||||||||
34130760|NCT04475419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel groups|f|f|t|t
34130761|NCT01713582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130762|NCT06513130|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825330|NCT05310058|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Bioanalytics and biostatistics services will be blinded to treatment identity until after the database has been locked and all analysis is complete.|Randomized, parallel, open label study with assessor masked|f|f|f|t
33825331|NCT01842919|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825332|NCT05278065|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 allocation of experimental to assessment only control||||
34130763|NCT03073083|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34130764|NCT01389726|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34130765|NCT05225077|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130766|NCT03956992|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34130767|NCT00310336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130768|NCT00106119|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34130769|NCT04115774|||COHORT||OTHER|||||||
34130770|NCT01159678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130771|NCT04931797|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Primary outcome will be obtained through natural language processing (NLP) from the EHR, in which the RA conducting the NLP will not know which arm of the study the patient was in.|RCT|f|f|f|t
33825333|NCT00405002|||COHORT||PROSPECTIVE|||||||
33825334|NCT00043407|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825335|NCT01341444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825336|NCT05611489|RANDOMIZED|PARALLEL||TREATMENT||NONE||laparoscopic versus open appendectomy||||
33825337|NCT01170923|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33825338|NCT00926302|RANDOMIZED|CROSSOVER||||NONE||||||
33825339|NCT02453802|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825340|NCT01181583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825341|NCT03709056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825342|NCT06353009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33825343|NCT02510222|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825344|NCT01074437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825345|NCT01405534|||COHORT||PROSPECTIVE|||||||
33825346|NCT05255276|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||This is a Phase 1, single-center, open-label, 2-cohort, 1-sequence crossover study to investigate the effect of coadministration of a P glycoprotein (P-gp) inhibitor, itraconazole, (Cohort 1) and a P-gp inducer, rifampin, (Cohort 2) in healthy subjects.||||
33825347|NCT00694135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825348|NCT05317221|||COHORT||PROSPECTIVE|||||||
33825349|NCT04257942|||CASE_ONLY||OTHER|||||||
33825350|NCT06337240|||COHORT||PROSPECTIVE|||||||
33825351|NCT05469763|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130772|NCT05783128|||COHORT||PROSPECTIVE|||||||
34130773|NCT05971368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"* Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~* Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia."||t|f|f|f
34130774|NCT03654924|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Observational study||||
34130775|NCT04251234|NON_RANDOMIZED|PARALLEL||OTHER||NONE|There is no masking. The dim light (\<1 lux) condition is first, followed by the room light (\~30 lux) condition. Participants are aware of this condition order.|||||
34130776|NCT04984395|||OTHER||PROSPECTIVE|||||||
34130777|NCT00727545|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130778|NCT05206214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34130779|NCT05824663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130780|NCT03863379|||CASE_CONTROL||PROSPECTIVE|||||||
34130781|NCT05147532|NA|SINGLE_GROUP||OTHER||NONE||||||
34130782|NCT05371158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130783|NCT00740441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130784|NCT03383250|NA|SINGLE_GROUP||OTHER||NONE||||||
34130785|NCT03451513|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator will not be told which condition individual participants are in. Outcome assessors at follow-up will not be told which condition the participant was in; any assessments regarding the content of intervention will be done by a separate, unblind assessor. The research assistants who enter the data from the clinician-based assessments administered by the outcome assessors will also be blind to participant condition assignment.|On a phone screen, participants will be orally consented, and assessed briefly for eligibility. Participants who seem eligible will come in for an assessment made up of self- and clinician-report assessments, where they will be consented and assessed for eligibility. Eligible participants will be randomized. All participants completed intervention as determined by randomized assignment (i.e., MA or PBP). Each subject ID is pre-assigned to a study condition, determined by an online randomization program, prior to recruitment. Each eligible participant had a 1/2 chance to be assigned to either of the two study conditions. Participants will take part in two intervention sessions spaced a week apart. 1 to 2 weeks after the last session, participants will complete a follow-up, where they will do self- and clinician-report assessments. Further follow-up assessments, also comprised of both self- and clinician report assessments will be completed 6, 12, 18, and 24 months after treatment.|f|f|t|t
34130786|NCT05031299|RANDOMIZED|PARALLEL||PREVENTION||NONE||The present study is a cluster-randomized lifestyle intervention aimed at primary and secondary prevention of MetS, including three study arms: standard care (control group), standard care plus lifestyle application (intervention group 1) and standard care plus lifestyle application and wearables and devices (intervention group 2). It is conducted with older adults and elderly (aged ≥55 years old) living at home and at risk for MetS, as well as their carers. The total duration of the intervention for each participant will be 3 months.||||
34130787|NCT05066750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants in each condition do not know what other participants are doing, nor that there is another condition.|Participants are randomly assigned to one of two behavioral intervention conditions before performing a word retrieval task|t|f|f|f
34130788|NCT02173483|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34130789|NCT02583633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34130790|NCT02853552|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34130791|NCT02886260|||COHORT||PROSPECTIVE|||||||
34130792|NCT06430242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130793|NCT02684617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130794|NCT02974140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130795|NCT05723692|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Study consists of 2 parts: Part A: a single ascending dose (SAD) and Part B: multiple ascending dose (MAD).|t|f|t|f
34130796|NCT02634775|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130797|NCT00268944|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130798|NCT03520140|||COHORT||PROSPECTIVE|||||||
34130799|NCT05969639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130800|NCT05382741|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130801|NCT00068315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130802|NCT04042597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130803|NCT01812213|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130804|NCT01550406|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34130805|NCT06091124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130806|NCT06380725|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators designed a double-blinded trial in which neither the investigator nor the subjects know whether they will be received the treatment or a placebo.|Investigators designed a randomized double-blinded placebo-controlled trial by randomly dividing subjects into two groups: one is the treatment group and the other is the placebo group.|t|t|t|f
34130807|NCT02697760|||CASE_ONLY||CROSS_SECTIONAL|||||||
34130808|NCT06353633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34130809|NCT00662831|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130810|NCT00000788||PARALLEL||TREATMENT||||||||
34130811|NCT00563082|||CASE_CONTROL||RETROSPECTIVE|||||||
34130812|NCT05101733|||CASE_ONLY||PROSPECTIVE|||||||
34130813|NCT04528550|RANDOMIZED|PARALLEL||TREATMENT||NONE||A 2:1 ratio of randomization (intervention group: control group) was used.||||
34130814|NCT04626284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130815|NCT00681395|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34130816|NCT05628285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130817|NCT01890590|NA|SINGLE_GROUP||TREATMENT||NONE||Cyberknife treatment||||
34130818|NCT02388464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825352|NCT04451031|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825353|NCT00096681|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33825354|NCT05325476|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825355|NCT04760327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130819|NCT04314024|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34130820|NCT06496425|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130821|NCT00750906|||CASE_ONLY||PROSPECTIVE|||||||
34130822|NCT05448248|||COHORT||OTHER|||||||
34130823|NCT04238091|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130824|NCT06404333|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130825|NCT02561481|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130826|NCT00348101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34130827|NCT04186533|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)||t|f|f|f
34130828|NCT05970536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double ( participant, outcome assessor)|Parallel double blinded.|t|f|f|t
34130829|NCT05369377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130830|NCT02855021|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130831|NCT00624624|||COHORT||PROSPECTIVE|||||||
34130832|NCT04380779|||OTHER||RETROSPECTIVE|||||||
34130833|NCT04928885|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm, randomized trial with a treatment group and a waitlist control group.||||
34130834|NCT04345900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130835|NCT00562822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130836|NCT04423679|||CASE_CONTROL||PROSPECTIVE|||||||
34130837|NCT02388165|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34130838|NCT05303506|||COHORT||RETROSPECTIVE|||||||
34130839|NCT04072952|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Subsequent dose level is determined by the Cohort Review Committee after the initial starting dose cohort and each subsequent dose cohort completes the first 28 days of treatment~Dose escalation followed by expansion at a RP2D including a combination cohort with palbociclib (IBRANCE®)"||||
34130840|NCT02944721|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130841|NCT05301621|||OTHER||PROSPECTIVE|||||||
34130842|NCT03567967|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|24-hour dietary recalls are conducted by blinded registered dietitians||f|f|t|t
34130843|NCT05887713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130844|NCT03306472|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a three arm, open-label, multicentre, randomized, window of opportunity, Phase II trial which will evaluate the effects of 15 days (+ 4 days) preoperative therapy with Letrozole, or Letrozole plus low dose Megestrol acetate (40mg), or Letrozole plus high dose Megestrol acetate (160mg) in postmenopausal women with newly diagnosed, ER-positive, HER2-negative, invasive primary breast cancer of at least 1 cm size.||||
34130845|NCT01794507|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130846|NCT01014572|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130847|NCT00003065||||TREATMENT||||||||
34130848|NCT06026072|NA|SINGLE_GROUP||PREVENTION||NONE||The doctor in charge of the patient will have to examine him and take care of him according to the service protocol. He will also completed the CLAD-V score and gives his intuition on the surgical outcome of the patient||||
34130849|NCT03216785|||COHORT||PROSPECTIVE|||||||
34130850|NCT02264379|||CASE_CONTROL||PROSPECTIVE|||||||
34130851|NCT04317443|||COHORT||PROSPECTIVE|||||||
34130852|NCT03271242|||COHORT||PROSPECTIVE|||||||
34130853|NCT04073511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130854|NCT00203918|||COHORT||PROSPECTIVE|||||||
34130855|NCT03440463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The intervention is an online program, not an individual, so masking is not necessary. Similarly, the same online survey is deployed in all follow-up assessments regardless of condition, and data are not collected by individuals, so masking is not necessary.||t|f|f|f
34130856|NCT01841021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130857|NCT05999578|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130858|NCT05007197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Among the individuals who applied to the outpatient clinic and were eligible for inclusion in the study, the odd numbers were assigned to the application group, and the even numbers to the control group. The practice group of 30 people and the control group were divided into 3 groups as auditory (n: 10), visual (n: 10) and physical learners (n: 10).||||
34130859|NCT04789473|||COHORT||RETROSPECTIVE|||||||
34130860|NCT04044196|||COHORT||PROSPECTIVE|||||||
34130861|NCT01264692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130862|NCT04461873|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients of the caregivers who met the study criteria were listed according to the protocol numbers and the participants were assigned to the reiki and sham reiki groups using simple random sampling method by the charge nurse of the chemotherapy unit. Thus, the participants were blinded to the intervention and placebo groups.|The study was conducted using a pre-test and post-test, single-blind randomized controlled trial pattern and semi-structured in-depth interview method of qualitative research.|t|f|f|f
34130863|NCT05711160|||OTHER||CROSS_SECTIONAL|||||||
34130864|NCT05538949|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34130865|NCT04315727|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130866|NCT03459469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130867|NCT00958360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130868|NCT04383028|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130869|NCT04775355|||COHORT||PROSPECTIVE|||||||
34130870|NCT04786821|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|It is not practical to blind the participants to the intervention as the study team are studying two different types of physical activities. The study team will explore whether it is feasible for the outcome assessor to be blind to the treatment allocation.|The eligible participants will be allocated to either arm using an online randomisation site in 1:1 randomisation ratio. All participants will have equal chance of getting allocated to either arm.|f|f|f|t
34130871|NCT01074476|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130872|NCT02679937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130873|NCT05606211|||COHORT||PROSPECTIVE|||||||
34130874|NCT02397915|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34130875|NCT04002583|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130876|NCT03685903|NA|SINGLE_GROUP||SCREENING||NONE||||||
34130877|NCT01811524|||COHORT||RETROSPECTIVE|||||||
34130878|NCT04234009|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34130879|NCT04279691|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34130880|NCT03982108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825356|NCT03925662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825357|NCT05168514|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|Single-blind randomized control method will be used in the study, patients in the experimental and control groups will not know which group they are in. Randomization Method: Experimental and control groups will be determined from patients who meet the sampling selection criteria, using the Random Integer Generator method from the random.org site, Numbersalt.|||||
33825358|NCT01747837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825359|NCT03868098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Intra-individual|t|t|t|t
33825360|NCT02775279|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825361|NCT00414219|||COHORT||PROSPECTIVE|||||||
33825362|NCT01618071|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33825363|NCT04095598|||OTHER||CROSS_SECTIONAL|||||||
33825364|NCT00383955|||||OTHER|||||||
33825365|NCT04315129|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The biosensors will monitor for infections. As this is an unverified, experimental diagnosis, this will not be made available to the patient or care provider. similarly this will not be available to the clinical researchers in order to avoid observation bias. While the participants, providers and investigators will all be aware that the participants have an active biosensor, they will be blinded to the output thereof.|Singlearm blinded study in which biosensor diagnosed infection (experiment) will be compared to clinical diagnosis (control) in a single cohort of surgical patients||||
33825366|NCT05591963|||CASE_ONLY||PROSPECTIVE|||||||
33825367|NCT05531734|NA|SINGLE_GROUP||OTHER||NONE||||||
33825368|NCT04141722|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33825369|NCT02446379|||OTHER||PROSPECTIVE|||||||
33825370|NCT05755217|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The sonographer will be blinded for the study intervention (eg, dark or white chocolate consumption)|This study will be a single-blinded randomized cross-over study, comparing the renal physiological effects of dark chocolate (DC) with white chocolate (WC). Doppler ultrasounds will take place in the Service of Nephrology of the CHUV, between late morning and early afternoon. Healthy participants who meet the inclusion criteria will be divided in small groups of 3-4 persons according to the order of inclusion. CKD participants will be investigated separately. Every participant will sign an informed consent form before the beginning of the study|f|f|t|f
33825371|NCT04850859|||OTHER||OTHER|||||||
33825372|NCT02605772|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825373|NCT03214900|||COHORT||PROSPECTIVE|||||||
33825374|NCT04994158|||CASE_ONLY||OTHER|||||||
33825375|NCT05173506|||COHORT||PROSPECTIVE|||||||
33825376|NCT04707456|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33825377|NCT03991507|||COHORT||PROSPECTIVE|||||||
33825378|NCT04503837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcome assessment - inhaler technique assessment and asthma control questionnaire will be administered by a blinded assessor.||f|f|f|t
33825379|NCT02862652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33825380|NCT02551692|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33825381|NCT05183321|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825382|NCT04156178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825383|NCT05579145|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33825384|NCT06646770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825385|NCT00169962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825386|NCT00770640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825387|NCT03779321|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33825388|NCT00905814|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33825389|NCT01422083|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33825390|NCT03461211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825391|NCT02929706|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33825392|NCT02657954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825393|NCT01530659|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants are considered in screening upon signing of the consent. Enrollment does not occur until participant is deemed eligible, as per screening, and randomized for implant. As such, there were 22 total participants enrolled in the study. There was a participant who died prior to screening procedures being conducted of which was captured in the AE section as the death occurred after consent to enter screening period. However, this participant was not enrolled as they had not completed screening or randomization for implant.|t|f|t|f
33825394|NCT06646913|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33825395|NCT06493669|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33825396|NCT04845087|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825397|NCT06219161|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized, placebo controlled, double blind, crossover study with a two-week washout period.|t|f|t|t
33825398|NCT01730742|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33825399|NCT03036150|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825400|NCT00509821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825401|NCT00136175|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825402|NCT01078584|||COHORT||PROSPECTIVE|||||||
33825403|NCT03595137|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"1. sono with simple needle guide device group~2. sono only group"|t|f|t|t
33825404|NCT02780739|RANDOMIZED|PARALLEL||||DOUBLE|||f|f|t|t
33825405|NCT01585805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825406|NCT05139576|||CASE_ONLY||PROSPECTIVE|||||||
33825407|NCT02453516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825408|NCT00392314|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825409|NCT01593436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33825410|NCT04392479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825411|NCT01107106|||CASE_ONLY||PROSPECTIVE|||||||
34130881|NCT06299865|||CASE_ONLY||RETROSPECTIVE|||||||
33837451|NCT04131816|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837452|NCT03797482|||OTHER||PROSPECTIVE|||||||
33837453|NCT00895895|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130882|NCT04094259|||COHORT||PROSPECTIVE|||||||
34130883|NCT04644588|||CASE_ONLY||CROSS_SECTIONAL|||||||
34130884|NCT01790646|||COHORT||PROSPECTIVE|||||||
34130885|NCT02065843|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130886|NCT03115827|NA|SINGLE_GROUP||TREATMENT||NONE|All patients will receive the same treatment.|This is a single-arm study enrolling 15 patients that will all receive the experimental treatment.||||
34130887|NCT02096250|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34130888|NCT01563705|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130889|NCT01093248|||CASE_ONLY||PROSPECTIVE|||||||
34130890|NCT02212366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34130891|NCT05894135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130892|NCT01350674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34130893|NCT03447405|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.||||
34130894|NCT06340724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130895|NCT05027347|||COHORT||PROSPECTIVE|||||||
34130896|NCT02853396|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130897|NCT01084291|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34130898|NCT03280199|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|f|t
34130899|NCT01341535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130900|NCT02808325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130901|NCT04737356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130902|NCT02284815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130903|NCT00254150|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130904|NCT06268184|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||group 1: 30 children with ESRD receive omega 3 supplementation group 2:15 children with ESRD receive lpacebo|t|f|f|f
34130905|NCT03978741|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130906|NCT00293813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130907|NCT02137447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130908|NCT04469023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34130909|NCT05858476|NA|SINGLE_GROUP||OTHER||NONE||||||
34130910|NCT05965583|NA|CROSSOVER||TREATMENT||NONE||Patients cross over from test treatment (T) to reference treatment (R) (two periods, fixed sequence).||||
34130911|NCT01921556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34130912|NCT00000428|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34130913|NCT03780621|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34130914|NCT05319808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Two groups will receive physiotherapy. Both will receive a hands-on individualized treatment of manual therapy. The hands-off treatment differs between groups and goes as follows:~Group A will receive a novel, remote computer based cervical joint positioning exercise and cervical kinaesthesia exercise program with a 6-month follow-up.~Group B will receive a non-computer based exercise regime at the need of each individual (pragmatic approach). This group will not be followed up on their exercises post intervention but will be encouraged to continue doing their exercises. They will be asked during follow-up measurements if they have been doing their exercises.~The treatment as usual group (group C) will/will not receive treatment at his/her own choice and/or convenience and without any instructions from research staff to reflect general practice. In addition to follow-up assessments, data will be collected which asks about treatment modalities used."|f|f|t|t
34130915|NCT04277481|||CASE_ONLY||PROSPECTIVE|||||||
34130916|NCT05210088|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|The patients, as well as the experimenters performing the assessment sessions, will be blinded to the level of hypoxia. Only operators not involved in the monitoring of patients within the protocol and who will set the hypoxia generator device will not be concerned by the blind procedure.|Phase I (safety and tolerability) clinical trial (impact on intermediate endpoints) evaluating a chronic (one month) hypoxic conditioning strategy for stroke, single-center, dose-escalation accelerated titration design (Liu S., Contemp. Clin. Trials. 2013) with continuous safety reassessment method. Dose escalation protocol. Dose escalation consisting of 4 successive steps, with increasing doses of hypoxia and continuous reassessment of safety criteria (primary endpoint, see below) Phase 2: Randomised, double-blind, controlled study comparing a group exposed to intermittent hypoxic post-conditioning versus a group exposed for the same duration and under the same conditions to a normoxic stimulus.|t|f|f|t
34130917|NCT06158464|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomised controlled trial will be set up (RCT). For this purpose, 10 consulting physicians, 30 occupational therapists, and 200 persons on incapacity will be recruited. Then, persons on sick leave/work disability are randomly divided into two groups: 1) Persons in the control group receive care-as-usual without modifications. 2) Persons in the intervention group receive usual care and a functional capacity evaluation (FCE). Both groups are asked to complete questionnaires at baseline, and after 3,6, and 9 months. Primary outcome is the difference in workability at 6 months follow-up.||||
34130918|NCT00285155|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34130919|NCT04768205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34130920|NCT00832598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130921|NCT01297608|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34130922|NCT00729911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130923|NCT05538104|||OTHER||RETROSPECTIVE|||||||
34130924|NCT01062724|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34130925|NCT03638050|||OTHER||CROSS_SECTIONAL|||||||
34130926|NCT03334981|||COHORT||PROSPECTIVE|||||||
34130927|NCT02396108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130928|NCT02676700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34130929|NCT05291546|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34130930|NCT03831178|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130931|NCT02726464|||CASE_CONTROL||PROSPECTIVE|||||||
34130932|NCT01091038|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||f|t|t|t
33837454|NCT02594449|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33837455|NCT00697398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130933|NCT01958528|||COHORT||PROSPECTIVE|||||||
34130934|NCT02508584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130935|NCT06346509|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34130936|NCT04320056|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34130937|NCT06154148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130938|NCT00924612|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, five-period, randomized, four-sequence (ABCDE, BDCEA,CBEDA, DBAEC), cross-over study to determine the effect of food containing various amounts of dietary fat on the pharmacokinetics of oral TU.||||
34130939|NCT04601207|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized, double-blind, comparator-controlled|t|t|t|t
34130940|NCT04098887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130941|NCT04124237|||COHORT||PROSPECTIVE|||||||
34130942|NCT05151510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Given the trigger point injection is physician performed, and very different from placing a lidocaine patch, we cannot blind investigators nor the patient to the intervention. We will, however, blind our outcome assessors in regards to which intervention the patient had received.|This will be a single-center, prospective, randomized, pragmatic trial carried out with patients that have a primary complaint of myofascial back and/or posterior neck pain. Upon presentation to the emergency department, if the patient is found to have myofascial pain, they will be approached by research personnel to be enrolled in the study. If the patient consents to be in the study, the patient will then be randomly assigned to either receive a trigger point injection or receive lidocaine patch (5%) therapy. The lidocaine patch therapy group cannot receive a trigger point injection. Randomization will occur in blocks of 2, using a Web- based randomization program (http://sealedenvelope.com).|f|f|f|t
34130943|NCT02729116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130944|NCT05544201|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34130945|NCT03981640|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34130946|NCT02483442|||COHORT||PROSPECTIVE|||||||
34130947|NCT05820841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130948|NCT04979026|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130949|NCT02286804|NA|SINGLE_GROUP||TREATMENT||SINGLE|Improvement of leg telangiectasia was determined by a masked, qualitative assessment of 2D photographs compared to baseline.||f|f|f|t
34130950|NCT01111734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130951|NCT01625416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130952|NCT01208324|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34130953|NCT01523743|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34130954|NCT05018195|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Two groups: women receive surgery for benign gynecologic lesions and women receive surgery for endometrial cancer||||
34130955|NCT01645735|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130956|NCT05011136|||COHORT||PROSPECTIVE|||||||
34130957|NCT05197933|NA|SINGLE_GROUP||TREATMENT||NONE|Blinding Method: Open Label|Prospective, multicenter, open-label, single-arm||||
34130958|NCT02122666|||CASE_CONTROL||PROSPECTIVE|||||||
34130959|NCT05587179|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This study is a cross-over Randomized Controlled Trial in which the sequence of the lateral recovery position will be randomized.||||
34130960|NCT01756573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130961|NCT06660758|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34130962|NCT04166370|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cluster-randomized, controlled trial (cRCT)||||
34130963|NCT02585986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130964|NCT00969605|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34130965|NCT00033423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34130966|NCT01279291|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130967|NCT05645237|||COHORT||PROSPECTIVE|||||||
34130968|NCT02620423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130969|NCT04077424|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This is an open label trial, the study nurse and participant know which of 3 FDA approved influenza vaccines are given (Fluzone-HD, FluAd, or Flublok). However the investigator and outcomes assessor are blinded to the actual vaccine given.||f|f|t|t
34130970|NCT02789358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34130971|NCT04784351|||COHORT||RETROSPECTIVE|||||||
34130972|NCT03370419|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two group randomized controll trial||||
34130973|NCT03689049|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Blinding of participants cannot be achieved in pragmatic trials of QI interventions in primary care.|The intervention will first be tested for feasibility using a single-arm, prospective, explanatory mixed approach. What we learn from the feasibility will then be applied to a 2-arm pragmatic cluster RCT where practices enrolled in the intervention group will be compared with those enrolled in the usual care group. Randomization will be at the practice level to avoid potential contamination where physicians practicing at the same location are enrolled in different arms.||||
34130974|NCT04396548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation and administer oral tablet.|Prospective, randomized, double blind study|t|f|f|t
34130975|NCT03493672|||COHORT||PROSPECTIVE|||||||
34130976|NCT06129591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will know which part of the scar receives the silicone patch or silicone patch plus CBD because CBD requires separate oil application before the patch. However, the reviewing physicians will be blinded when assessing post-operative photos and using the SCAR scale.|This is a double arm, open label, single-site pilot trial aims to evaluate the feasibility of using topical CBD oil on paramedian forehead scars to determine if there is an improved outcome in the appearance of the scar.|f|f|f|t
34130977|NCT02429193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130978|NCT04309851|||OTHER||RETROSPECTIVE|||||||
34130979|NCT00383968|||DEFINED_POPULATION||OTHER|||||||
34130980|NCT00612378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130981|NCT04827342|||COHORT||PROSPECTIVE|||||||
34130982|NCT05153603|||COHORT||RETROSPECTIVE|||||||
34149383|NCT06177093|NA|SINGLE_GROUP||TREATMENT||NONE||Single centre phase II non-randomized study||||
34130983|NCT04300205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants wear black-out glasses during LED phototherapy|Participants with chronic foot and leg ulcers less than 8 cm in diameter (longest direction) will randomized into one of 2 groups for this study: 1) to receive a free 10 minute light treatment with the KPTL10 device in addition to standard care, or 2) strictly be a part of the standard care control group (no light treatment). For treatment, the light device is placed at a fixed distance (1 cm) above the wound. All participants will have wound measurements taken with digital software throughout the course of the study to track wound healing. Patients will also record their pain levels by filling out a VAS pain scale throughout the study.|t|f|f|f
34130984|NCT01642901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34130985|NCT02077777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34130986|NCT05454462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The study will be performed double-blind. Double-blind means that neither the patient nor the investigational staff (investigator, study nurse, evaluators, etc.) will know which IMP a patient is receiving.~This is to ensure that the evaluations are carried out without bias. The IMPs will be blinded by the manufacturer via the labelling procedure. IMPs will be identical in appearance and will be packaged identically so that treatment blind is maintained."|Topical application of approximately 1 g cream per defined treatment area (2% body surface area \[BSA\] including target lesion \[minimum 0.5% to maximum 2% BSA\]) twice daily during a 4-week treatment period (on Days 0 to 27 and one additional application in the morning of Day 28, i.e., 57 treatments)|t|t|t|f
34130987|NCT01321255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130988|NCT02653586|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34130989|NCT00989677|||CASE_ONLY||CROSS_SECTIONAL|||||||
34130990|NCT06442566|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Arm 1 open label, double blind procedures for randomization of BUP and TMS|SMART|t|f|t|f
34130991|NCT01628354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130992|NCT05523830|||OTHER||OTHER|||||||
34130993|NCT05142696|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34130994|NCT02221635|||CASE_CONTROL||RETROSPECTIVE|||||||
34130995|NCT03846427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34130996|NCT05801146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34130997|NCT01469936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34130998|NCT00635349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34130999|NCT03380637|||CASE_CONTROL||PROSPECTIVE|||||||
34131000|NCT00576628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131001|NCT02469701|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131002|NCT01268592|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34131003|NCT05454800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131004|NCT03569878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131005|NCT05410925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131006|NCT00796731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131007|NCT05075018|||OTHER||PROSPECTIVE|||||||
34131008|NCT00004573||||DIAGNOSTIC||||||||
34131009|NCT05087368|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"This study will be observer-blind for Stage 1 and Stage 2. The participants will be blinded before receiving the study vaccination. An unblinded dosing team, not involved with study participant's evaluation, will prepare and administer the study vaccines.~The investigational product syringe will be opacified. The administration of the study vaccine will also be performed behind a closed curtain. The investigative study center personnel, as well as the sponsor personnel involved in the monitoring or conduct of the study, will be blinded to the study vaccine code.~The laboratories will also be blinded, so that associating the sample with an assigned treatment or study visit will not be possible."|Controlled, observer-blinded, Phase 2 Study|t|t|t|t
34131010|NCT03802630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A masked evaluating investigator was responsible for all aspects of the study except the injections and the safety assessment following the injections. An unmasked treating investigator performed the injections and assessed patient safety following the injections.||t|f|t|t
34131011|NCT01221753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131012|NCT04418063|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34131013|NCT05262777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131014|NCT01134744|||||CROSS_SECTIONAL|||||||
34131015|NCT03297684|||CASE_ONLY||PROSPECTIVE|||||||
34131016|NCT03158571|||COHORT||PROSPECTIVE|||||||
34131017|NCT00056576|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34131018|NCT02107625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131019|NCT04651764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131020|NCT04154423|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34131021|NCT03604172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131022|NCT01967797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131023|NCT06200597|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34131024|NCT02258568|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34131025|NCT02972346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131026|NCT02141750|||COHORT||PROSPECTIVE|||||||
34131027|NCT02097719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34131028|NCT02210988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131029|NCT03851887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131030|NCT04844723|||COHORT||PROSPECTIVE|||||||
34131031|NCT06405165|RANDOMIZED|PARALLEL||OTHER||NONE||The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.||||
34131032|NCT05937256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||controlled, randomized, assessor blinded clinical trial.|t|t|f|t
33825412|NCT04885426|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participant, investigator, data analyst, endoscopist and pathologist involved in this study are all blinded of which treatment the participants are receiving. The pharmaceutical company provided blinded bottles of study pills with the label 'A' , 'B' or 'C'. Unblinding will be advanced only in case of emergency.||t|t|t|t
33825413|NCT00255944|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131033|NCT06205563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34131034|NCT06316856|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131035|NCT04169503|||CASE_ONLY||CROSS_SECTIONAL|||||||
34131036|NCT05778864|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34131037|NCT03393897|||COHORT||PROSPECTIVE|||||||
34131038|NCT05662540|NA|SINGLE_GROUP||OTHER||NONE||||||
34131039|NCT06351163|||COHORT||RETROSPECTIVE|||||||
34131040|NCT05648617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34131041|NCT00584532|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34131042|NCT01958580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131043|NCT06215820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131044|NCT01454609|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34131045|NCT06417385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131046|NCT03617536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"CR845 will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose.~CR845 tablets will be provided at doses of 0.25, 0.5, and 1 mg."|Randomized, double-blind, placebo controlled study|t|f|t|f
34131047|NCT04749043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"Comparing VR to an active control of nitrous oxide as a current standard of care for non-epidural analgesic in a crossover design"||||
34131048|NCT06149221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131049|NCT05618210|||COHORT||PROSPECTIVE|||||||
34131050|NCT01701362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131051|NCT01692496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131052|NCT01170052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131053|NCT05263180|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment Dose escalation followed by Cohort Expansion Phase at the RP2D.||||
34131054|NCT00241410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131055|NCT03969290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Contralateral|t|f|t|f
34131056|NCT04704687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131057|NCT02243319|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131058|NCT02653443|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34131059|NCT01890044|||COHORT||PROSPECTIVE|||||||
34131060|NCT05002985|NA|SINGLE_GROUP||OTHER||NONE||||||
34131061|NCT00763191|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34131062|NCT01876303|||FAMILY_BASED||RETROSPECTIVE|||||||
34131063|NCT04820114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131064|NCT01058681|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34131065|NCT00025792||||TREATMENT||||||||
34131066|NCT01703871|||COHORT||PROSPECTIVE|||||||
34131067|NCT04505319|NA|SINGLE_GROUP||TREATMENT||NONE||"* prospective,~* non comparative~* single centre,~* on healthy subjects."||||
34131068|NCT06051019|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131069|NCT01681186|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34131070|NCT03030352|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34131071|NCT03593486|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants will be randomly assigned to either the active or sham stimulation group. Because the parameters are programmed into the stimulator by the manufacturer and given generic names (Stim 1 and Stim 2), the investigators and physicians performing the procedure will not know which protocol is active or sham.||t|t|t|t
34131072|NCT02398136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131073|NCT02304341|||COHORT||PROSPECTIVE|||||||
34131074|NCT05962151|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34131075|NCT01732029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131076|NCT00192764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131077|NCT01540526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131078|NCT03560102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131079|NCT04153981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131080|NCT02901249|NA|SEQUENTIAL||TREATMENT||NONE||Patients start treatment according to the algorithm and follow a sequence of steps. There is no comparison between groups. It is a single group. Primary and secondary outcomes are only assessed at the end of the protocol, not at each step.||||
34131081|NCT01808872|||||PROSPECTIVE|||||||
34131082|NCT03316573|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131083|NCT04154293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|A Randomized, Parallel, Double-Blind, Vehicle-Controlled Study|t|t|t|t
34131084|NCT02044952|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34131085|NCT00873821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131086|NCT06520696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligible Hispanic participants in their third trimester will be recruited for the study. The intervention group will receive standard WIC services plus the MILC application. Participants will be asked to participate in the periodic follow-up assessments at 1, 3, and 6 months along with demonstrating breastfeeding via the MILC app. Participants in the control group will receive standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3, and 6 months.||||
34131087|NCT01071499|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131088|NCT04407793|||COHORT||PROSPECTIVE|||||||
34131089|NCT03407469|||COHORT||PROSPECTIVE|||||||
34131090|NCT04472481|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131091|NCT05132179|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The wound irrigation solutions will be filled in identical 5 ml syringes, marked with study number and date of filling. To mask the smell of chlorine a tin without lid with 15 ml 5% chloride will be placed maximally 1 meter from the treating place|Randomized, double-blind, controlled, multi-center, clinical trial with parallel-group design|t|t|t|f
34131092|NCT06658938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131093|NCT01482806|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34131094|NCT02952313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131095|NCT01091714|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131096|NCT04301934|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131097|NCT02644096|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34131098|NCT00371215|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131099|NCT00272155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34131100|NCT00141648|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131101|NCT03790813|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131102|NCT00479102|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34131103|NCT01204905|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm treatment study||||
34131104|NCT02370823|||COHORT||PROSPECTIVE|||||||
34131105|NCT06422325|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131106|NCT03772795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups receiving 2 interventions. In the first group patients received fixed orthodontic appliance and in the second, they received clear aligner orthodontic appliance||||
34131107|NCT05570656|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34131108|NCT01635270|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131109|NCT04628702|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Neurologist and neuropsychologist are not informed about intervention|two groups: interventional group with 1.5 years tablet training and a control group; both groups receive pre-post neurological, neuropsychological examination, MRI and blood sampling at study inclusion and 1.5 years later.|f|f|t|f
34131110|NCT03989349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment||t|t|t|t
34131111|NCT02540733|||COHORT||PROSPECTIVE|||||||
34131112|NCT04333979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131113|NCT03504293|||COHORT||PROSPECTIVE|||||||
34131114|NCT04808726|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The randomization process was created by a neutral researcher who was not involved in the study. The women were not informed about the groups they were in. Single blind was provided in the study by knowing which group they would be in by the researcher.|randomized controlled experimental research design||||
34131115|NCT02628600|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131116|NCT02148536|||CASE_ONLY||PROSPECTIVE|||||||
34131117|NCT03909906|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Triple masking (Participant, investigator, outcomes assessor)|Balanced crossover|t|f|t|t
34131118|NCT03267979|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131119|NCT01065675|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34131120|NCT04701853|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Assessor will not be aware of which group the patients are included in.|A single blind, randomized, controlled, intervention study. Evaluation of the addition of specific muscle training for patients undergoing intestine surgery including a sigmoidostomy compared to standard care|f|f|f|t
34131121|NCT00062855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131122|NCT05007418|NA|SEQUENTIAL||TREATMENT||NONE||To determine DLT and MTD, the design uses a 3+3 rule-based design. Dose escalation is permitted between successive cohorts based upon a specified algorithm, using discrete dosage steps.||||
34131123|NCT03357029|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34131124|NCT02738541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131125|NCT04753346|||OTHER||CROSS_SECTIONAL|||||||
34131126|NCT06369753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131127|NCT06035406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131128|NCT00332085|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34131129|NCT02667041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131130|NCT03483779|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34131131|NCT03107052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131132|NCT03154515|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34131133|NCT06186908|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||According to full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL),bleeding on probing (BOP), gingival index (GI) and plaque index (PI) samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20)||||
34131134|NCT06651775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131135|NCT03621904|||COHORT||PROSPECTIVE|||||||
34131136|NCT01864681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131137|NCT06290531|RANDOMIZED|PARALLEL||OTHER||NONE|The statistician was only blinded for data analysis. But it was not feasible to blind the participant, investigator or the outcome assessor due to the nature of the study.|||||
34131138|NCT03371576|||COHORT||PROSPECTIVE|||||||
34131139|NCT00485563|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131140|NCT03395782|||COHORT||PROSPECTIVE|||||||
34131141|NCT00606411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34131142|NCT00956722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131143|NCT01130909|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34131144|NCT03636672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131145|NCT05358262|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131146|NCT02469987|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34131147|NCT00368680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131148|NCT02297815|||COHORT||PROSPECTIVE|||||||
34131149|NCT01032434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131150|NCT00800527|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131151|NCT05376059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131152|NCT03996681|NA|SINGLE_GROUP||TREATMENT||NONE||TACE plus methylcantharidimide tablets||||
34131153|NCT05570279|||COHORT||PROSPECTIVE|||||||
34131154|NCT00533728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131155|NCT01951989|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131156|NCT00475085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34131157|NCT00021567||||TREATMENT||||||||
34131158|NCT05664503|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Quasi-experimental study with a post-test control group.||||
34131159|NCT05224076|||COHORT||PROSPECTIVE|||||||
34131160|NCT02894957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131161|NCT02342691|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131162|NCT01127672|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131163|NCT01335256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131164|NCT02021890|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131165|NCT03456349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34131166|NCT06547333|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131167|NCT03076060|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34131168|NCT00179062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131169|NCT02934841|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131170|NCT04209634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131171|NCT02388477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131172|NCT02850224|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34131173|NCT01581229|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131174|NCT01412905|||COHORT||PROSPECTIVE|||||||
34131175|NCT01700959|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131176|NCT04643587|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34131177|NCT06155006|||CASE_ONLY||CROSS_SECTIONAL|||||||
34131178|NCT04795115|||OTHER||OTHER|||||||
34131179|NCT03071315|||COHORT||PROSPECTIVE|||||||
34131180|NCT01301053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131181|NCT01234480|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131182|NCT04052750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131183|NCT02297711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131184|NCT00162591|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34131185|NCT01076205|||CASE_ONLY||PROSPECTIVE|||||||
34131186|NCT05815095|||COHORT||PROSPECTIVE|||||||
34131187|NCT06474000|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34131188|NCT03835182|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|The investigator assessing the patient before and post treatment will be blind to the treatment received by the patient.|Three groups of patients, each containing 31 patients, will be included in the study. Patients in each group will receive a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five sessions of physical therapy on consecutive days. The first group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation applied to the lower back (frequency, ultrasound 1MHz frequency (ten minutes), abdominal and lower back muscle strengthening exercises. The second group will be treated with hotpack, TENS and exercises as previously described plus short wave diathermy at 27.12MHz frequency for ten minutes applied to the lower back. The third group will receive hotpack, TENS applied to the lower back and strengthening exercises as previously described.|f|f|t|f
34131189|NCT04415294|||COHORT||PROSPECTIVE|||||||
34131190|NCT04102709|||COHORT||PROSPECTIVE|||||||
34131191|NCT00399568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131192|NCT01541007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131193|NCT04660552|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To minimize the bias, Jelikalight hired an independent pediatric psychiatrist, to act as a PI and supervise the study. The PI is blind (and will remain blind until the end of the study data collection and analysis) to the participants' condition. He will supervise data collection and analysis. The PI will supervise parental interviews. The PI will conduct before and after treatment testing of participants with CARS2. The PI will supervise analysis for raw data. Experimental and control groups will undergo the same experience apart from having the device turned on or turned off during the sessions. The participants (and their parents) will remain blind to their experimental condition, therefore, ensuring double blindness.|This is a Randomized, Placebo-controlled, Double Blind, Mixed Design study|t|t|t|f
34131194|NCT05281237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131195|NCT01919073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131196|NCT05551169|||COHORT||PROSPECTIVE|||||||
34131197|NCT04311268|NA|SINGLE_GROUP||OTHER||NONE||||||
34131198|NCT03780530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131199|NCT01808638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131200|NCT04599491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||INTELLiSTREAM is a single-center randomized clinical noninferiority trial|t|f|f|f
34131201|NCT03645941|RANDOMIZED|PARALLEL||TREATMENT||NONE||Our approach follows the three-stage model of behavioral therapies development and the proposed aims correspond to the two sub-stages characterizing Stage I work. In Stage Ia formative work, we will develop the Facebook intervention. In Stage Ib, we will use rigorous design and methodology to evaluate the intervention's feasibility and potential efficacy. Stage Ib results will inform a future R01, Stage II, randomized efficacy trial||||
34131202|NCT05474833|||COHORT||PROSPECTIVE|||||||
34131203|NCT05849675|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Matched placebo capsule|Participants will be randomly allocated to one of two groups (pitolisant or placebo). This study uses a novel procedure known as variance minimisation (described in Sella, Raz \& Cohen Kadosh, 2021) to randomise participants allocation to the two intervention groups based on equalising baseline cognitive functioning and gender. Participants will receive a single dose of the drug (pitolisant, 36mg) or placebo, and undertake fMRI and cognitive/emotional assessment three hours after dose. The study is assessing the effect antagonising the H3 receptor on functional connectivity/cognitive ability, it is not an efficacy or safety study.|t|f|t|t
34131204|NCT06138600|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Adult (≥18 and ≤ 35 years old) male or female willing to access PrEP at the same pharmacy for up to 2 years||||
34131205|NCT04727450|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|No information will be given to test administrators about intervention or control groups with the exception of project staff.|Cluster RCT. Each elderly center as a cluster will be randomly assigned to be either an intervention group (IG) to receive intervention training modes (A: cognitive training, B: physical training only, C: CCPT) or a control group (CG). IGs will either receive integrated format of ABC or two training modes of AB or BC or CA.|f|f|f|t
34131206|NCT05073484|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149384|NCT03783494|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34149385|NCT02198794|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149386|NCT02401204|||OTHER||PROSPECTIVE|||||||
34149387|NCT00006268||||TREATMENT||||||||
34149388|NCT04608422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825414|NCT02966600|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33825415|NCT03715738|NA|SINGLE_GROUP||OTHER||NONE||||||
33825416|NCT03799289|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825417|NCT02166047|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
33825418|NCT05736302|||CASE_ONLY||CROSS_SECTIONAL|||||||
33825419|NCT00144716|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33825420|NCT02312622|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837456|NCT02690844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131207|NCT04894838|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients who meet the eligibility criteria will be included in this trial at the outpatient clinic of the participating bariatric centres after informed consent is obtained. The participating patients will be randomised into one of the surgical techniques: type I or type II DGB. Randomisation will take place in the operating room through an internet-based randomisation system in REDCap. Only the participants are blinded to the treatment allocation. The randomisation table will be created by an independent epidemiologist in the St. Antonius hospital, ensuring concealment of treatment allocation. Participants will be randomised in equal numbers to both interventions. The randomisation will be stratified by participating hospitals to ensure participants are evenly allocated to each treatment arm at each participation hospital.|In total, 150 morbidly obese patients are eligible for distalisation surgery following RYGB. The participants will be randomised into DGB type I (group a) or DGB type II (group b). The study population consists of morbidly obese patients with insufficient weight loss or weight regain following primary Roux-en-Y gastric bypass, who are eligible for distalisation surgery.|t|f|f|f
34131208|NCT05199636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34131209|NCT02685566|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34131210|NCT05383781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131211|NCT04381416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131212|NCT04189796|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The study will be performed as a randomized Norwegian multicenter study with a semi-cross over design in which the participants randomized to Camembert cheese will be switched to Jarlsberg cheese after 6 weeks.||||
34131213|NCT03130517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||intervention group will recieve intravenous immunoglobulin and phototherapy and control group that will receive phototherapy only||||
34131214|NCT03221465|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Principal Investigators are neither given names of particular participants nor assignment to study arms.||f|f|t|f
33825421|NCT03756064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Experimental: Pyrotinib (400mg orally daily)+Trastuzumab (8mg/kg iv load followed by 6mg/kg iv 3-weekly)+Docetaxel (75mg/m2)+ Carboplatin(AUC=5), for a total of 6 cycles.~Placebo Comparator: Placebo Oral Tablet (400mg orally daily)+Trastuzumab (8mg/kg iv load followed by 6mg/kg iv 3-weekly)+Docetaxel (75mg/m2)+ Carboplatin(AUC=5), for a total of 6 cycles."|t|t|t|f
34131215|NCT01385618|||CASE_CONTROL|||||||||
34131216|NCT02922816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131217|NCT00814580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825422|NCT00778518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825423|NCT03690921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825424|NCT06299956|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33825425|NCT04878575|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825426|NCT01248156|||CASE_CONTROL||PROSPECTIVE|||||||
33825427|NCT00135447|||COHORT||CROSS_SECTIONAL|||||||
33825428|NCT00685425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825429|NCT02217241|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33825430|NCT05721209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825431|NCT06031870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825432|NCT01792778|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33825433|NCT00465907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825434|NCT05959811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33825435|NCT03905213|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized in three groups||||
33825436|NCT02236598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825437|NCT05329649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825438|NCT06048809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33825439|NCT03857737|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825440|NCT03594578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants assigned to both groups will be masked to experimental hypotheses.|Participants will be randomly assigned to either an episodic future thinking group or a control group (episodic recent thinking), stratified by menopausal status and baseline level of delay discounting.|t|f|f|f
33825441|NCT06349317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825442|NCT05643898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"An independent person not involved in the study will generate the allocation sequence. Stratified randomization will be conducted according to depressive symptom severity. Researchers will be blind to the randomization process and will be notified through email regarding participant allocation by an independent researcher.~Outcome interviews will be conducted by clinical psychologists that will be masked for the condition.~It is not possible to mask personnel and participants to the treatment allocation because of the nature of the intervention."|"The present study is a two-armed randomized controlled trial. A guided app-based intervention to reduce depressive symptoms and prevent major depression onset (Mamá, te entiendo) will be compared to waitlist."|f|f|t|t
33825443|NCT05012943|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Observer-blind design:~Investigators, site staff, participants, CRO staff, Sponsor representatives with oversight of study conduct or study-related assessments will remain blinded to vaccine assignments for the study duration."|"Phase 1, 2, 3a, 3b: Participants will be randomly assigned to a study group that will receive up to 2 vaccination series. Each vaccination series comprises two vaccinations at 28-day intervals: an initial vaccination series with vaccinations on Day 1 and Day 29 and an additional vaccination series at around 2 months after the first series on Day 92 and 120. Each participant is planned to receive a two-dose vaccination series of ARCT-154 at a dose of 5 µg or a two-dose vaccination series of placebo (saline) in the first series.~Participants in Phase 2, 3a who received 2 doses of ARCT-154 vaccine in the first vaccine series will be rerandomized to receive either dose 3 of ARCT-154 on Day 92 plus placebo on Day 120 or placebo on Day 92 plus placebo on Day 120.~Phase 3c: Participants will be randomly assigned to a study group to receive two-dose vaccination series of ARCT-154 at a dose of 5 µg or approved COVID-19 vaccine comparator (Astra Zeneca's COVID-19 vaccine)."|t|f|t|t
33825444|NCT05286775|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33825445|NCT01913288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825446|NCT02880969|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33825447|NCT00261625|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825448|NCT05472519|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825449|NCT00854152|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825450|NCT04195607|||COHORT||PROSPECTIVE|||||||
34131218|NCT01723046|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34131219|NCT05453071|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Evaluation parameters will be applied to the participants twice with an interval of 12 weeks. The first evaluation will be made if the individuals who come to the routine doctor's examination agree to participate in the study. According to being included in one of the two groups as those who decided to attend the BETY sessions that have been going on for 18 years and those who did not agree to attend the sessions; The individuals included in the BETY group (Group 1) will be evaluated on the day of the last exercise session after their participation in the 12-week exercise group, the individuals who do not agree to participate in the BETY sessions but agree to participate in the evaluations at 12-week intervals (Group 2) will be evaluated when they come 12 weeks apart for their routine controls. For patients with systemic sclerosis, the recommendations given routinely in our unit will be made.||||
34131220|NCT04087941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
34131221|NCT01111383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131222|NCT05780008|NA|SINGLE_GROUP||PREVENTION||NONE||This will be a one-group quasi-experimental design.||||
34131223|NCT04835220|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Telehealth intervention group and a control group.||||
34131224|NCT04036201|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34131225|NCT04900246|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33825451|NCT02538718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131226|NCT04922372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131227|NCT03545087|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34131228|NCT01547351|||COHORT||PROSPECTIVE|||||||
34131229|NCT01532921|||COHORT||PROSPECTIVE|||||||
34131230|NCT03529838|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||45 women taking different antihypertensives (15 no medications, 15 angiotensin receptor blockers and 15 beta blockers) for at least 6 months will be assessed at baseline and after 12 weeks of combined exercise training.||||
34131231|NCT00276939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131232|NCT05745272|||COHORT||CROSS_SECTIONAL|||||||
34131233|NCT05556083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants of both groups will have no knowlage regarding the added medication they will recieve either sildinafile or placebo.|Single blind placebo randomized controlled trial|t|f|f|f
34131234|NCT03698578|NON_RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34131235|NCT01457963|||COHORT||PROSPECTIVE|||||||
34131236|NCT01715688|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34131237|NCT05062694|||COHORT||CROSS_SECTIONAL|||||||
34131238|NCT02472587|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34131239|NCT02250079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131240|NCT00778336|||CASE_ONLY||PROSPECTIVE|||||||
34131241|NCT03770741|RANDOMIZED|PARALLEL||TREATMENT||NONE|Due to the nature of the experimental intervention, no blinding can be done for the clinical staff and the parents. Outcome assessment of mortality will not be blinded, but the diagnosis and classification of brain injury and the entry of this into the eCRF, will be done by a person that is blinded to group allocation. Principal investigators must develop a local procedure description that describe how this is done. The local procedure description must be approved by the sponsor. Furthermore, mortality will be checked by Good Clinical Practice (GCP) through source data verification in all patients. The data managers, statisticians and those drawing conclusions will be blinded to treatment allocation. Data management will be blinded.|||||
34131242|NCT03711370|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The video coders were masked during video analysis.|All participants were randomly assigned to either the opaque bottle group or the clear bottle group. Mothers were asked to use their assigned bottle type to feed their infant for a full 12-week period. Pre-tests were given before the 12-week period and post-tests occured after the 12-week period. During these tests, we observed each mother using the clear bottle to feed her infant on one visit and the opaque bottle on another visit. The order of these conditions was randomized and counterbalanced.|f|f|f|t
34131243|NCT04072835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131244|NCT05426967|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Bayesian-adaptive trial design|t|t|t|t
34131245|NCT06660589|||CASE_ONLY||OTHER|||||||
34131246|NCT05020834|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34131247|NCT00505973|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34131248|NCT05119374|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects will receive the Investigational device - SenseGuard for daily measurement of respiratory parameters.||||
34131249|NCT03593122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825452|NCT06053047|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33825453|NCT01204593|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825454|NCT02434523|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825455|NCT00478998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825456|NCT04964609|NA|SINGLE_GROUP||OTHER||NONE||||||
33825457|NCT00357318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825458|NCT02694588|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33825459|NCT01156402|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825460|NCT01395914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825461|NCT04248036|NA|SINGLE_GROUP||OTHER||NONE|Group Care providers are masked for outcome assesment|Pilot study||||
33825462|NCT06640998|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825463|NCT05270473|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double blinding is difficult because the observer will see the type of procedure done. However, the measured outcomes are objective and unlikely to be biased by lack of blinding.|randomised controlled trials 2 groups|f|f|f|t
33825464|NCT02753764|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33825465|NCT01111136|NA|SINGLE_GROUP||TREATMENT||||||||
33825466|NCT02056600|RANDOMIZED|CROSSOVER||||NONE||||||
33825467|NCT04857775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825468|NCT02206087|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33825469|NCT04270656|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825470|NCT00683397|||COHORT||PROSPECTIVE|||||||
33825471|NCT01849679|||CASE_ONLY||PROSPECTIVE|||||||
33825472|NCT03664453|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825473|NCT05434715|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825474|NCT01319825|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33825475|NCT03201029|||OTHER||CROSS_SECTIONAL|||||||
33825476|NCT06460181|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will supplement with either AX or a matched placebo. The dosage of AX (12 mg/day) is FDA approved and will be administered orally by one soft gel capsule. The treatments will be blinded to the participants and the investigator. Treatments will be sorted be an independent party not associated with data collection or analysis.|Groups will be randomized and parallel. They will not cross-over with each other.|t|f|t|t
33825477|NCT03338257|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The evaluation follows a pre-test/post-test control group design with children nested within classrooms at center and school-based early care programs located in low-income communities or areas with high SNAP eligibility rates||||
33825478|NCT00984698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825479|NCT01076322|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825480|NCT05619900|||COHORT||OTHER|||||||
33825481|NCT03698630|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Pediatric Respiratory Assessment Measure score will be performed by a clinician blinded to treatment allocation.|Randomized, open-label, non-inferiority trial|f|f|f|t
33825482|NCT03910296|||OTHER||PROSPECTIVE|||||||
33825483|NCT00592735|||COHORT||PROSPECTIVE|||||||
33825484|NCT04577976|||COHORT||PROSPECTIVE|||||||
33825485|NCT00153023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825486|NCT03883698|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a three arm, case control study aimed at studying the pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in people with estimated GFR (eGFR) \<30 ml/min. Two arms will include participants with advanced renal failure with eGFR below 30 ml/min and third arm will include participants with normal eGFR. Participants with eGFR \<30 ml/min will receive sofosbuvir in doses of either 400mg on alternate days or 200mg daily. The participants with normal eGFR will receive the standard of care, i.e, 400mg of sofosbuvir daily||||
33825487|NCT01654835|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33825488|NCT02388932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825489|NCT00317759||||TREATMENT||NONE||||||
33825490|NCT00302497|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825491|NCT01702519|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33825492|NCT02946749|||COHORT||PROSPECTIVE|||||||
33825493|NCT04369300|||OTHER||CROSS_SECTIONAL|||||||
33825494|NCT00377338|||COHORT||PROSPECTIVE|||||||
33825495|NCT03675308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825496|NCT04031118|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||SINGLE|||f|f|f|t
33825497|NCT00035061||||TREATMENT||||||||
33825498|NCT03830515|NA|SINGLE_GROUP||TREATMENT||NONE||A single arm open label study testing the ability of microMend to close lacerations.||||
33825499|NCT03666208|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a phase 2, pilot clinical trial to investigate the effect of SCB on thrombosed AVG. Specifically, we are focusing on AVG as they have a higher thrombosis rate than AVF and the patency rate even after successful thrombolysis is much lower than AVF. As neointimal hyperplasia is the predominant cause for stenosis at the graft vein junction, treatment with Sirolimus will intuitively delay the recurrence of neo-intimal hyperplasia and result in better patency of the AVG after successful thrombolysis.~Patients with ESRD presenting with a thrombosed AVG between June 2018 and December 2018 will be screened for suitability. Eligible patients of at least 21 years of age will be offered participation. The potential benefits and risks of SCB will be explained and informed consent obtained from participants. A total of 20 patients will be recruited for the trial and they will be followed up for 6 months after the interventions."||||
33825500|NCT05113485|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All assessments will be conducted by project personnel blind to the study participants' randomization status. The investigators responsible for helping participants complete the Automated Self-administered 24-hour (ASA 24) dietary recalls and for assessing their body composition via dual x-ray absorptiometry (DXA) will be kept blind to the study participants' randomization status. Investigators will be kept blind to participant assignment to condition by having the two health coaches refer to their patients by an arbitrary, unique study identifier during weekly debriefings when the study progress by individual participants might be discussed.|The two lifestyle change interventions feature a similar exercise prescription and the same sequence of intervention contacts (2 virtual home visits; 2 virtual group education sessions, 7 individual telephone coaching sessions) but differ in dietary approach. The DPP-based diet approach prescribes desired weight loss in overweight breast cancer survivors by restricting daily calorie intake and promoting increased calorie expenditure via physical activity. The HMAFs approach prescribes consuming an optimal six microbiota-accessible foods unaccompanied by pro-inflammatory food components such as saturated fat or added sugar as well as engaging regularly in exercise that elevates the heart rate and reduces inflammation. Only 20 percent of daily calories need to be devoted to HMAFs; the remaining calories can come from daily food choices conforming to the 2020-2025 Dietary Guidelines for Americans.|f|f|t|t
33825501|NCT03015181|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33825502|NCT02960334|||CASE_ONLY||CROSS_SECTIONAL|||||||
33825503|NCT00991029|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825504|NCT03459521|NA|SINGLE_GROUP||OTHER||NONE||||||
34131250|NCT02579421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131251|NCT01948219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131252|NCT05087433|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double (Participant, Outcomes Assessor)|Randomized Controlled Trial|t|f|f|t
34131253|NCT00197418|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34131254|NCT05906485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly allocated into groups.|"Experimental group: receives 8-week functional near-infrared spectroscopy (fNIRS) neurofeedback training (coupled with virtual reality) in Phase 1, twice per week, each lasts 1 hour.~Active control group: receives 8-weeks computerized cognitive training in Phase 1, twice per week, each lasts 35 minutes.~Waitlist control group: either receives 8-weeks fNIRS neurofeedback training (coupled with virtual reality) or computerized cognitive training in Phase 2 (i.e., after the completion of training for intervention group and active control group)."|t|f|f|f
34131255|NCT03970876|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131256|NCT05368389|||OTHER||PROSPECTIVE|||||||
34131257|NCT02454946|||CASE_CONTROL||RETROSPECTIVE|||||||
34131258|NCT01621256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131259|NCT03226886|||OTHER||PROSPECTIVE|||||||
34131260|NCT00915759|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131261|NCT06554535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131262|NCT06363812|||COHORT||PROSPECTIVE|||||||
34131263|NCT00540241|||CASE_ONLY||PROSPECTIVE|||||||
34131264|NCT01498744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131265|NCT00342628|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131266|NCT02293967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131267|NCT05672641|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131268|NCT02552173|||COHORT||PROSPECTIVE|||||||
34131269|NCT02329977|||CASE_CONTROL||PROSPECTIVE|||||||
34131270|NCT02480413|||CASE_ONLY||PROSPECTIVE|||||||
34131271|NCT02594930|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131272|NCT06662175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131273|NCT02345408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131274|NCT02013778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131275|NCT05464940|RANDOMIZED|PARALLEL||OTHER||DOUBLE||The COFFEE-AF (How caffeine Induces Atrial Tachyarrhythmias) trial will be a multi-center, randomized, double-blinded trial of intravenous caffeine versus placebo among patients undergoing pulmonary vein isolation procedures for AF.|t|f|t|f
34131276|NCT02319460|||COHORT||OTHER|||||||
34131277|NCT01325051|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131278|NCT06519240|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34131279|NCT06661252|||CASE_CONTROL||PROSPECTIVE|||||||
34131280|NCT05575856|||COHORT||CROSS_SECTIONAL|||||||
34131281|NCT00703274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131282|NCT03693677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131283|NCT00475553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131284|NCT06173440|||CASE_ONLY||RETROSPECTIVE|||||||
34131285|NCT01731340|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34131286|NCT00459576|||COHORT||PROSPECTIVE|||||||
34131287|NCT01447342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131288|NCT03541889|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34131289|NCT01034644|||||RETROSPECTIVE|||||||
34131290|NCT04368299|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34131291|NCT02038777|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||MTD was determined in monotherapy cohort. Then two combination cohorts (Combination Cohorts 1 and 2) were added to evaluate the safety of glasdegib administered with chemotherapies. Another combination cohort (Combination Cohort 3) was added to evaluate the safety of glasdegib administered with Azacitidine. Then, Continuation Cohort which allows one Japanese patient enrolled from another trial in the same project was added. Afther that, Expansion Cohort of LDAC Combination for efficacy was added.||||
34131292|NCT02794896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131293|NCT00604318|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34131294|NCT02929199|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131295|NCT05827328|||COHORT||PROSPECTIVE|||||||
34131296|NCT06012747|||COHORT||PROSPECTIVE|||||||
34131297|NCT00150215|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34131298|NCT04624867|NA|SINGLE_GROUP||OTHER||NONE||||||
34131299|NCT05083884|||COHORT||CROSS_SECTIONAL|||||||
34131300|NCT03389412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The children and the parents will not know, if there treatment is based on home recordings or not.|Randomized, controlled study|t|f|f|f
34131301|NCT01899508|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34131302|NCT06107374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131303|NCT01419496|||CASE_ONLY||RETROSPECTIVE|||||||
34131304|NCT01032408|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131305|NCT06660082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants will not be aware of the experimental or sham status of the arm they'll be allocated to.~Investigator realising offline analysis will not know the arm of allocation of the subject they are analysing."|Exploratory, single-centre, randomised, sham-controlled, single-blind, superiority study, with comparison of two groups.|t|f|f|t
34131306|NCT00305903|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131307|NCT02191878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131308|NCT03957005|||COHORT||PROSPECTIVE|||||||
34131309|NCT00232999|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34131310|NCT00617058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131311|NCT00003352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131312|NCT01204983|||COHORT||PROSPECTIVE|||||||
34131313|NCT01270880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131314|NCT02525484|RANDOMIZED|CROSSOVER||||NONE||||||
34131315|NCT01471769|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34131316|NCT01334385|||CASE_ONLY||CROSS_SECTIONAL|||||||
34131317|NCT03855046|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A multicenter, prospective, randomized, controlled clinical study. Surgical removal of anal fissure followed by internal sphincter relaxation with Botulinum toxin type A is performed in the study group.~Lateral subcutaneous sphincterotomy to relax sphincter is a method of choice in the control group. Patients are randomized with envelope method"||||
34131318|NCT02658552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131319|NCT00868972|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34131320|NCT03742310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131321|NCT05773807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34131322|NCT01774669|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131323|NCT03932318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131324|NCT03485261|||OTHER||CROSS_SECTIONAL|||||||
34131325|NCT00118248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131326|NCT03017690|||COHORT||CROSS_SECTIONAL|||||||
34131327|NCT05109429|RANDOMIZED|SINGLE_GROUP||OTHER||NONE|It is not possible to blind the participant nor some of the research staff to the study condition. The research staff who will interview the participant will be blinded to what cue condition participant had completed.|Participants will experience all three cue-induced craving tasks (no, low, and high) in a random order (6 possible orders)||||
34131328|NCT01212887||||TREATMENT||NONE||||||
34131329|NCT02831855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131330|NCT02769364|||CASE_ONLY||RETROSPECTIVE|||||||
34131331|NCT02445105|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34131332|NCT06182098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131333|NCT05072860|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|a double-blinded randomized controlled trial|a double-blinded randomized controlled trial|t|t|t|t
34131334|NCT01053104|||COHORT||PROSPECTIVE|||||||
34131335|NCT06263608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131336|NCT05420961|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Cohorts 1 and 2: participants, investigator, sponsor Cohort 3: no blinding||t|f|t|f
34131337|NCT00418600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131338|NCT04043793|||COHORT||PROSPECTIVE|||||||
34131339|NCT06510803|||CASE_CONTROL||PROSPECTIVE|||||||
34131340|NCT05221567|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34131341|NCT05450224|NA|SINGLE_GROUP||OTHER||NONE||||||
34131342|NCT02040922|||COHORT||PROSPECTIVE|||||||
34131343|NCT01997593|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34131344|NCT01095081|||COHORT||PROSPECTIVE|||||||
34131345|NCT01976702|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34131346|NCT06659042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131347|NCT00586716|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131348|NCT00429676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131349|NCT03898271|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34131350|NCT02752919|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34131351|NCT06659146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131352|NCT03139994|||COHORT||PROSPECTIVE|||||||
34131353|NCT06196658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131354|NCT05533294|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131355|NCT00420082|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34131356|NCT05170477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34131357|NCT03920462|NA|SINGLE_GROUP||OTHER||NONE||All volunteers realise a programme of 6 excursions with intelligent electric bike for health and connected vests.||||
34131358|NCT03719001|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131359|NCT03254706|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|A staff member not involved in the research protocol performed the randomization process with computer-generated tables. Details of the allocated groups were recorded on cards contained in sequentially numbered, opaque, sealed envelopes. Opening the envelope only on the day of the restorative procedure guaranteed the concealment of the random sequence. The examiners were not involved with the restoration procedures and therefore blinded to the group assignment, performed the clinical evaluation. Patient were also blinded to group assignment in a double-blind randomized clinical trial design.|This was a double-blind, superiority, split-mouth randomized clinical trial. The study was carried out in the clinics of the School of Dentistry at the local University from August 2015 to August 2017.|t|f|f|t
34131360|NCT05254951|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Interventional Prospective Study||||
34131361|NCT03774043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131362|NCT05959655|||COHORT||PROSPECTIVE|||||||
34131363|NCT03097523|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34131364|NCT06040684|||CASE_ONLY||PROSPECTIVE|||||||
34131365|NCT04098185|||COHORT||PROSPECTIVE|||||||
34131366|NCT01047137|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131367|NCT01266109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131368|NCT04193904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131369|NCT01924039|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34131370|NCT06005532|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34131371|NCT05052463|||COHORT||RETROSPECTIVE|||||||
34131372|NCT03213132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131373|NCT06477003|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34131374|NCT02840318|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34131375|NCT00906178|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131376|NCT04970823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131377|NCT03955783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131378|NCT01626586|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131379|NCT01473199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131380|NCT01927523|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34131381|NCT04033081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131382|NCT05606848|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131383|NCT00780767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131384|NCT03029039|||CASE_CONTROL||PROSPECTIVE|||||||
34131385|NCT00211796|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131386|NCT05466084|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized control trial||||
34131387|NCT01017042|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131388|NCT02057640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837457|NCT02276105|||COHORT||PROSPECTIVE|||||||
33837458|NCT06184035|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131389|NCT04254653|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34131390|NCT05083611|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131391|NCT06339346|||OTHER||RETROSPECTIVE|||||||
34131392|NCT00005699|||COHORT||PROSPECTIVE|||||||
34131393|NCT05415267|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131394|NCT05284500|||COHORT||RETROSPECTIVE|||||||
34131395|NCT02792764|||COHORT||RETROSPECTIVE|||||||
34131396|NCT06643858|||COHORT||OTHER|||||||
34131397|NCT00585988|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131398|NCT00484861|||||PROSPECTIVE|||||||
34131399|NCT06140368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34131400|NCT03572569|||FAMILY_BASED||PROSPECTIVE|||||||
34131401|NCT02805465|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34149389|NCT06137872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149390|NCT03674879|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149391|NCT05623215|||COHORT||PROSPECTIVE|||||||
34131402|NCT03999099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The order or medication/placebo administration will be randomized. The study staff and participant will be blinded to which medication they are receiving.|A single group will undergo three study visits where, on different days, they will receive placebo, 10 mg, or 20 mg lorcaserin.|t|f|t|t
34131403|NCT00002134||||TREATMENT||||||||
34131404|NCT02668354|||COHORT||RETROSPECTIVE|||||||
34131405|NCT02688504|||COHORT||CROSS_SECTIONAL|||||||
34131406|NCT03809078|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34131407|NCT03910790|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This research will be carried out in a non-randomized, prospective trial pattern.||||
34131408|NCT00159679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34131409|NCT05351840|RANDOMIZED|SEQUENTIAL||OTHER||NONE||open label, multiple dose, Fixed sequence, 3 Period design||||
34131410|NCT04094493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131411|NCT02223052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131412|NCT01001767|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34131413|NCT01657968|||CASE_CONTROL||PROSPECTIVE|||||||
34131414|NCT00000333||||TREATMENT||||||||
34131415|NCT00783835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131416|NCT00862368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131417|NCT01646541|||CASE_CONTROL||PROSPECTIVE|||||||
34131418|NCT02672189|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131419|NCT06169787|||CASE_CONTROL||RETROSPECTIVE|||||||
34131420|NCT00111449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34131421|NCT00907322|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34131422|NCT03148379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131423|NCT05294484|RANDOMIZED|PARALLEL||TREATMENT||NONE||A comparative randomized, single-dose, two-treatment (fed vs. fasting), parallel design of indapamide in healthy adult Egyptions||||
34131424|NCT06130475|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34131425|NCT05828589|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34131426|NCT05252494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"In this study, the Urn method, which is a randomization method equivalent to the full randomization method, will be used to determine the groups. In this randomization method, there are two parameters such as α and β. These parameters represent balls of two different colors, red and white. As a result of the lottery drawn in the research, the white ball will represent the Animal assisted treatment group, and the red colored ball will represent the Control Group. When there is a child who meets all the sampling criteria, the balls previously prepared by the researcher will be placed in a black bag and selection will be made by the nurse practitioner with their eyes closed. According to the color of the selected ball, it will be assigned to the child group, so that the children will be randomly distributed to the two groups."|The research consists of 2 groups as experimental and control group. In the experimental group, the children who watched the fish during the bloodletting process comprised the animal-assisted treatment group, and the control group consisted of the children who underwent routine bloodletting.|t|f|f|f
34131427|NCT04196855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded assessment of MR scans||f|f|f|t
34131428|NCT06221761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants do not know which group they will be assigned to.|Participants will be randomly divided into two groups, one using antibiotics and the other not using antibiotics|t|f|f|f
34131429|NCT02441907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131430|NCT05466136|RANDOMIZED|CROSSOVER||SCREENING||NONE||The participants will visit the lab on two counterbalanced order occasions to complete either an incongruent version Stroop task (mental fatigue condition, MF) or a congruent version Stroop task (control condition, CON) for 30 minutes to induce the mental fatigue state.||||
34131431|NCT06519032|||CASE_ONLY||RETROSPECTIVE|||||||
34131432|NCT03727022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131433|NCT06221943|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825505|NCT06646653|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-randomized, feasibility pilot study of 10 women with vaginal or caesarean deliveries in a hospital setting who failed first-line interventions for postpartum hemorrhage||||
33825506|NCT04549142|||CASE_CONTROL||PROSPECTIVE|||||||
33825507|NCT05806164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the interventions, masking of patients will not be possible; however, outcome assessors will be masked. Masked staff will not be able to see certain forms that may result in unmasking. All PROs will be administered prior to any clinical assessments to minimize bias that may occur due to clinical evaluation.|At 3 months, the effect of treatment with beta agonist oral medication or onabotulinumtoxinA will be evaluated within a classic RCT model. The analysis will determine the effect of treatment on the co-primary outcomes: Treatment satisfaction and urinary symptom severity.|f|f|f|t
33825508|NCT04405141|||CASE_ONLY||OTHER|||||||
33825509|NCT00257764|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33825510|NCT06255912|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33825511|NCT05353621|||OTHER||PROSPECTIVE|||||||
33825512|NCT05143879|RANDOMIZED|CROSSOVER||OTHER||SINGLE|This study was a double-blind, placebo-controlled trial where participants (n = 32) were random-ized into 4 different groups: placebo group (PLG; n = 8), CIT group (CITG; 3 g/day of CIT; n = 8), BEET group (BEETG; 2.1 g/day of BEET (300 mg/day of NIT) ; n = 8) and CIT-NIT group (CIT-BEETG; 3 g/day of CIT plus 2.1 g/day of BEET (300 mg/day of NIT); n = 8)|The main purpose of this study was to determine the effect and degree of potentiation of the long-term (9 weeks) mixture of 3 g/day of CM plus 2.1 g/day of BEET (300 mg/day of NIT) supplementation on EIMD markers (urea, creatinine, AST, ALT, GGT, LDH and CK) and anabolic/catabolic hormone status (testosterone (T), cortisol (C), and T/C) in male trained triathletes.|f|f|t|f
33825513|NCT06312995|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825514|NCT02953028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825515|NCT05856318|||COHORT||PROSPECTIVE|||||||
33825516|NCT05334706|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33825517|NCT00932659|||COHORT||PROSPECTIVE|||||||
33825518|NCT01732588|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837459|NCT04053439|||COHORT||PROSPECTIVE|||||||
34131434|NCT06245486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Probiotic Crispact® (20 Bld CFU/Stick of Lactobacillus crispatus M247)|f|f|t|f
34131435|NCT03803735|||COHORT||PROSPECTIVE|||||||
34131436|NCT05308355|||CASE_CONTROL||PROSPECTIVE|||||||
34131437|NCT06385379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131438|NCT05922943|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34131439|NCT03586024|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 parallel cohort||||
34131440|NCT01677416|||||CROSS_SECTIONAL|||||||
34131441|NCT01999842|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34131442|NCT05276336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131443|NCT02761681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131444|NCT02435667|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131445|NCT04381624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomised controlled, two-arm, double-blind|t|f|f|t
34131446|NCT04952662|||CASE_CONTROL||RETROSPECTIVE|||||||
34131447|NCT06400589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131448|NCT05743127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131449|NCT03851627|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34131450|NCT06242990|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131451|NCT04098653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131452|NCT02371785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131453|NCT05139745|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34131454|NCT06175598|||CASE_ONLY||RETROSPECTIVE|||||||
34131455|NCT00810771|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||||||
34131456|NCT04931914|||COHORT||RETROSPECTIVE|||||||
34131457|NCT02265185|||COHORT||CROSS_SECTIONAL|||||||
34131458|NCT00124163|||||PROSPECTIVE|||||||
34131459|NCT04239066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131460|NCT06368284|||COHORT||RETROSPECTIVE|||||||
34131461|NCT01709617|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34131462|NCT01947283|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34131463|NCT02314156|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34131464|NCT03493061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131465|NCT01221623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131466|NCT01375816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825519|NCT03756025|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Each evaluation was performed by a different blind examiner for the type of GIC used in ART Patients did not know what material was being used on their teeth.|The study is characterized by longitudinal follow-up of a randomized, double-blind, split-mouth-type clinical trial performed in babies affected by early childhood caries|t|t|f|t
33825520|NCT05532618|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Medication is prepared by study personell not otherwise involved in the study according to a computer generated randomization plan. This plan will be available for analyses after the study. Primary investigator is able to retreive the allocation prematurely if indicated (emergency).|Patients are randomized to receive an intervention (nerve block) with either an active drug or placebo.|t|t|t|t
33825521|NCT00962221|||CASE_ONLY||CROSS_SECTIONAL|||||||
33825522|NCT03317899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825523|NCT01408875|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825524|NCT06274450|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33825525|NCT05750342|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33825526|NCT04068285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants wil be making exercise. It is not possible to make participants blinded to the study.|The study has 3 arms.|f|f|t|t
33825527|NCT02160678|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825528|NCT02345083|||COHORT||PROSPECTIVE|||||||
33825529|NCT06138834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825530|NCT00668330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825531|NCT02440737|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34131467|NCT03569449|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34131468|NCT02033629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131469|NCT05442723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131470|NCT02924441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34131471|NCT06140251|||COHORT||PROSPECTIVE|||||||
34131472|NCT01480024|||COHORT||PROSPECTIVE|||||||
34131473|NCT03337984|||CASE_ONLY||OTHER|||||||
34131474|NCT04325295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131475|NCT00854724|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34131476|NCT02111915|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34131477|NCT04224831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective, open label study; The cases resistant to all known conventional treatment methods were compared before and after the application. The control group cannot be formed because there are cases resistant to all treatment methods.||||
34131478|NCT04033614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131479|NCT04169984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two arms: active treatment group (myofunctional therapy) and placebo group|t|f|f|f
34131480|NCT05132400|||COHORT||PROSPECTIVE|||||||
34131481|NCT02471118|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34131482|NCT04732442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized 2-arm controlled trial||||
34131483|NCT04747236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131484|NCT03886194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131485|NCT05829005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Multi-centre, two-arm (active TMS, inactive TMS), double-blind (outcome assessor, patient), parallel-group RCT. Patients and researchers rating outcomes will be blind to the treatment arm, but it is not possible to blind the (different) researcher who is administering the treatments.~There will be two treatment sessions, between 4-20 days apart, and two follow-up assessments one and three months after the first treatment session."|t|f|f|t
34131486|NCT00692744|||COHORT||PROSPECTIVE|||||||
34131487|NCT03931850|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34131488|NCT05624502|||OTHER||CROSS_SECTIONAL|||||||
34131489|NCT05584488|||OTHER||PROSPECTIVE|||||||
34131490|NCT03333928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A primary parallel group comparison for a 6-week treatment period (Period 1), followed by a 6-week dose-controlled extension (Period 2), and followed by a 6-week placebo-controlled randomized withdrawal (Period 3).|t|t|t|t
34131491|NCT01891396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and Outcomes Assessor were blinded to treatment||t|f|f|t
34131492|NCT03153891|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34131493|NCT06429046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study was planned to compare the effects of lidocaine gel and cold lidocaine gel application to the rectal area on the pain level in patients who underwent TRUSG-guided prostate biopsy.||||
34131494|NCT03992781|||COHORT||PROSPECTIVE|||||||
34131495|NCT02966288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131496|NCT00830375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131497|NCT03244709||SEQUENTIAL||TREATMENT||NONE||||||
34131498|NCT02467127|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34131499|NCT04259437|NA|SINGLE_GROUP||OTHER||NONE||||||
34131500|NCT05445219|||COHORT||CROSS_SECTIONAL|||||||
34131501|NCT01581528|||CASE_ONLY||RETROSPECTIVE|||||||
34131502|NCT02368093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131503|NCT06403553|||CASE_CONTROL||PROSPECTIVE|||||||
34131504|NCT05201105|||COHORT||RETROSPECTIVE|||||||
34131505|NCT02574078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131506|NCT04188834|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34131507|NCT05256888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131508|NCT00632775|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131509|NCT04119804|||OTHER||RETROSPECTIVE|||||||
33825532|NCT03907254|NA|SINGLE_GROUP||TREATMENT||NONE||Up to 156 participants will be recruited in the National Capital Region (NCR) for a ten-week longitudinal pre-post study, in which each participant will serve as their own control. Additionally, up to 104 participants will be recruited for a three-week longitudinal parallel-randomized study through the National Intrepid Center of Excellence (NICoE) four-week Intensive Outpatient Program (IOP). A three-month post-intervention follow-up will be conducted for both designs (optional for IOP participants).||||
34131510|NCT05594485|||COHORT||RETROSPECTIVE|||||||
34131511|NCT01503684|||COHORT||PROSPECTIVE|||||||
34131512|NCT01301287|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34131513|NCT03726658|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131514|NCT03786224|NA|SINGLE_GROUP||OTHER||NONE||||||
34131515|NCT02789436|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34131516|NCT00070928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34131517|NCT02888184|||COHORT||RETROSPECTIVE|||||||
34131518|NCT00586872|||COHORT||RETROSPECTIVE|||||||
34131519|NCT01003236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131520|NCT05310123|NA|SINGLE_GROUP||PREVENTION||NONE||prospective, non-randomized||||
34131521|NCT05315934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131522|NCT05667883|||COHORT||PROSPECTIVE|||||||
34131523|NCT00164008|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131524|NCT01384552|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33825533|NCT05286086|RANDOMIZED|PARALLEL||OTHER||NONE|due to the characteristics of the study, it is not possible to perform masking|Prospective , unicentric, randomized||||
33825534|NCT00598117|||COHORT||PROSPECTIVE|||||||
33825535|NCT04387422|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33825536|NCT03231761|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33825537|NCT05427019|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33825538|NCT04903847|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled open-label superiority trial||||
33825539|NCT05404126|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33837460|NCT03491670|||COHORT||PROSPECTIVE|||||||
33837461|NCT00639522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131525|NCT02570724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131526|NCT02372513|||COHORT||PROSPECTIVE|||||||
34131527|NCT03107858|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34131528|NCT05234918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131529|NCT04891575|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, intervention providers and assessors are blinded to which arm is the active intervention and which is the active comparator and are blinded to hypotheses regarding group differences.||t|t|f|t
34131530|NCT04963036|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131531|NCT03402594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131532|NCT06119971|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"In this study, the acupuncturist is a registered anaesthetist doctor (=investigator) who also holds the Acupuncture Diploma of the Medicine Faculty of Paris. After opening an opaque and sealed envelope, this acupuncturist is in charge of stimulating the true or sham points for each patient, according to the allocated group. As an anaesthetist, he is also responsible of carrying out the anaesthesia. The other care providers (anaesthetic nurses and surgeons) and the patients are blinded. Notably, the primary outcome consists of a self-administered questionnaire. Moreover, to prevent any difference or modification in care according to the results of the questionnaire, the latter is only recovered when the patient leaves the postoperative recovery room. The randomisation list was created with EXCEL software. Finally, an independent person is in charge of the statistical analysis.~Considering the above, we describe the study as single-blind."||t|t|f|t
34131533|NCT03358355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131534|NCT04535817|NA|SINGLE_GROUP||TREATMENT||NONE||Baseline testing, followed by 24-week treatment period, followed by 24-week follow-up period.||||
34131535|NCT01266252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131536|NCT00100074||||DIAGNOSTIC||||||||
34131537|NCT05236725|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131538|NCT03461549|||COHORT||PROSPECTIVE|||||||
34131539|NCT01399983|||COHORT||PROSPECTIVE|||||||
34131540|NCT03962088|||COHORT||PROSPECTIVE|||||||
34131541|NCT04532294|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34131542|NCT05064501|||CASE_CONTROL||PROSPECTIVE|||||||
34131543|NCT05700058|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34131544|NCT00019968||||TREATMENT||||||||
34131545|NCT00399217|||COHORT||PROSPECTIVE|||||||
34131546|NCT01143155|||COHORT||PROSPECTIVE|||||||
34131547|NCT04966312|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33825540|NCT06105996|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be assessed at the end of the study by members of the research team who have been blinded to whether the participant was randomised to the intervention group of the study, or the treatment as usual group.|Participants in the study will be randomised to the intervention group (interoceptive training) or the treatment as usual group.|f|f|f|t
33825541|NCT01800578|||CASE_ONLY||PROSPECTIVE|||||||
33825542|NCT01165502|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33825543|NCT02611921|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33825544|NCT04672499|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33825545|NCT00927550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825546|NCT06102798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825547|NCT00344539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825548|NCT00629317|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33825549|NCT01458756|||CASE_ONLY||PROSPECTIVE|||||||
33825550|NCT02084355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825551|NCT05906901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825552|NCT02591914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825553|NCT04636879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825554|NCT02178397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825555|NCT01258296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825556|NCT05558813|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825557|NCT01574014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825558|NCT00875615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825559|NCT05992662|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33825560|NCT05425173|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825561|NCT00985634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825562|NCT04007146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825563|NCT05869383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both participant and investigator dont know the intervention that have been given.||t|f|t|f
33825564|NCT05447728|||COHORT||PROSPECTIVE|||||||
33825565|NCT01362283|||||CROSS_SECTIONAL|||||||
33825566|NCT06308731|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|All energy drink supplements are provided in identical, unlabeled cans, using a randomization code.|Double-blind, placebo controlled, crossover design|t|f|t|f
33825567|NCT01750177|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33825568|NCT02108418|RANDOMIZED|CROSSOVER||||NONE||||||
33825569|NCT00316459|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33825570|NCT01772147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825571|NCT03690570|||COHORT||RETROSPECTIVE|||||||
33825572|NCT02716753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825573|NCT06190184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Once enrolled, participants are randomized into one of the 2 study arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.|Randomized, blinded, cohort study divided into two study arms: 1) control group (placebo), 2) precision-supplement|t|f|f|f
33825574|NCT01993576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825575|NCT00515697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825576|NCT02134847|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33825577|NCT06048939|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825578|NCT06006897|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131548|NCT02348034|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131549|NCT06246838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131550|NCT04479059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825579|NCT02534753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825580|NCT02679547|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825581|NCT02301364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825582|NCT06354192|||CASE_ONLY||PROSPECTIVE|||||||
33825583|NCT02508779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825584|NCT04164498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825585|NCT04091464|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825586|NCT02622464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825587|NCT04838964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825588|NCT00445861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825589|NCT01723514|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825590|NCT01456533|||COHORT||PROSPECTIVE|||||||
33825591|NCT04863638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825592|NCT01823640|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33825593|NCT02394925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825594|NCT01201915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825595|NCT00978497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825596|NCT02856841|||COHORT||PROSPECTIVE|||||||
33825597|NCT02723305|||CASE_ONLY||CROSS_SECTIONAL|||||||
33825598|NCT04097691|||COHORT||PROSPECTIVE|||||||
33825599|NCT01828593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33825600|NCT06245161|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"participants are blinded to the group assignment, as their visual field is blocked during needle adminstration in both groups, and the Audible sounds of the QuickSleeper5 will be mimicked in the control group.~The operator will not be blinded to the type of the anesthesia administered due to different devices to be used."|"120 children eligible for the study will be divided into: Group I (restorative group): includes 60 quadrants, each have at least one primary molar indicated for restorative treatment or vital pulp therapy. It will be subdivided into 4 subgroups, each consists of 15 quadrant (upper and lower) allocated to Intra-osseous Anesthesia by QuickSleeper5 for the test groups or to infiltration or IANB in the control group~Group II (extraction group): includes 60 primary molars indicated for extraction. It will be subdivided into 4 subgroups; according either maxillary or mandibular primary molar is indicated for extraction, using Intra-osseous Anesthesia by QuickSleeper5 for the test groups ,or infiltration or IANB in the control group"|t|f|f|f
33837462|NCT03006185|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||f|f|t|t
34131551|NCT00395278|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131552|NCT06596616|||COHORT||PROSPECTIVE|||||||
33825601|NCT06176183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients have been randomly assigned into two groups using computerised randomizer for clinical trial lite. One group of patients has received a standard meniscus suturing technique, whereas another group has experienced the meniscus suturing treatment with an additional fibrin clot approach"|t|t|f|f
33825602|NCT02607345|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33825603|NCT06420141|||COHORT||PROSPECTIVE|||||||
33825604|NCT00053768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825605|NCT06008106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825606|NCT02312362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825607|NCT01364441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825608|NCT04939883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be in the proportion of 1: 1 (carvedilol x placebo). Both randomization and allocation of patients will be chosen in a veiled manner to patients and to assess. Data on randomization and allocation will be under custody of the Data analysis and safety committee.||t|f|t|f
33825609|NCT05171465|||CASE_ONLY||PROSPECTIVE|||||||
33825610|NCT05739799|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825611|NCT04024514|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33825612|NCT01842542|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825613|NCT03285633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825614|NCT00644332|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33825615|NCT00702273|||OTHER||PROSPECTIVE|||||||
33825616|NCT03194854|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants who have completed the full online T1 battery will be randomly assigned in real-time by the computer to either the intervention condition or the UC control condition. Randomization, group assignment, and assessments will be conducted solely by the computer program, so researchers will be blind to participant randomization, group assignment, and participant group identity during assessment times. With regard to group size and power, experience from our prior efficacy study of FFW indicates that for the current study, the computer program will use a 1:1 randomization algorithm.|The intervention group will be compared to a usual care (UC) control group on outcomes of self-efficacy, physical activity, and well-being. The intervention group will participate in online activities for 30 days while UC control group participants will be asked to conduct their lives as usual for the same 30 day period. Both groups will complete assessments during this time period. The UC group will be given access to the intervention for 30 days after all study participants have completed the three survey battery administrations.|f|f|t|t
33825617|NCT03096197|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
33825618|NCT05042362|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825619|NCT05645900|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33825620|NCT05212597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825621|NCT00828529|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825622|NCT00030745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825623|NCT04978012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825624|NCT06400264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825625|NCT05762081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized Controlled Trial||||
33825626|NCT04087070|||COHORT||PROSPECTIVE|||||||
33825627|NCT03944902|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33825628|NCT05236140|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825629|NCT01157377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131553|NCT01653587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825630|NCT06448442|||CASE_CROSSOVER||PROSPECTIVE|||||||
33825631|NCT06294483|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33825632|NCT02109861|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33825633|NCT01379131|||||RETROSPECTIVE|||||||
33825634|NCT00012636|RANDOMIZED|PARALLEL||||SINGLE||||||
33825635|NCT02675998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825636|NCT02110225|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825637|NCT02125097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825638|NCT02209727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825639|NCT04560023|RANDOMIZED|PARALLEL||SCREENING||SINGLE|"Randomization variable encoding will be blinded for researchers, only known by an external collaborator designed by the main researcher.~Statistical analysis will be performed by researchers who will be blinded for the assignation to experimental and control groups."|Randomisation in blocks will be considered. Software will contain and allocation sequence, in each block, 50% of patients will be allocated in control group (standard practice) and the other 50% will be allocated in the experimental group (multimedia exposure).|f|f|f|t
33825640|NCT03582150|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825641|NCT00743496|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825642|NCT05199441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825643|NCT02624505|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33825644|NCT06278753|||COHORT||PROSPECTIVE|||||||
33825645|NCT02990364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34131554|NCT00712686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149392|NCT01420666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825646|NCT06347029|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33825647|NCT02151578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825648|NCT02556541||CROSSOVER||SUPPORTIVE_CARE||||||||
33825649|NCT00578318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825650|NCT02343978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825651|NCT03644706|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825652|NCT05470881|NA|SINGLE_GROUP||TREATMENT||NONE||Phase I, controlled, non-comparative, open, unicentric study.||||
33825653|NCT02201771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149393|NCT03106285|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34149394|NCT04056858|||COHORT||RETROSPECTIVE|||||||
33825654|NCT05554042|||COHORT||PROSPECTIVE|||||||
33825655|NCT01165164|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825656|NCT00747045|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33825657|NCT01124214|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33825658|NCT01341314|||COHORT||PROSPECTIVE|||||||
33825659|NCT04237623|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825660|NCT02617433|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825661|NCT03928678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
33825662|NCT00917631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825663|NCT00051103|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825664|NCT03271177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825665|NCT01059526|||COHORT||PROSPECTIVE|||||||
33825666|NCT05422339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Statistical analyses of all data will be carried out independently of investigators by a biostatistical resource department of an academic health center for validation.|The study will be a randomized controlled clinical trial, in which three conditions will be investigated: a control, experimental, and exploratory condition.|t|f|f|t
33825667|NCT00745121|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825668|NCT00317850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825669|NCT06319547|NA|PARALLEL||TREATMENT||NONE||||||
33825670|NCT05047653|||COHORT||RETROSPECTIVE|||||||
33825671|NCT00520403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825672|NCT00439361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825673|NCT05132088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825674|NCT04573868|||CASE_ONLY||PROSPECTIVE|||||||
33825675|NCT05439525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|permuted block|mulligan and conventional therapy|f|f|f|t
33825676|NCT01997437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825677|NCT05418868|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33825678|NCT04807283|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33825679|NCT00465478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825680|NCT00373308|||COHORT||RETROSPECTIVE|||||||
33825681|NCT01768741|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33825682|NCT03439345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825683|NCT00757432|||COHORT||RETROSPECTIVE|||||||
33825684|NCT03471390|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||non- randomized incomplete stepped-wedge design||||
33825685|NCT02450617|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33825686|NCT04199676|||COHORT||PROSPECTIVE|||||||
33825687|NCT05599646|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33825688|NCT05091554|RANDOMIZED|PARALLEL||TREATMENT||NONE|In this study, double blindness was not possible because of the nature of the ice packs, the patients and the physician were aware of the cryotherapy groups. Therefore, patients were only blinded before the treatment procedures.|||||
33825689|NCT00335374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825690|NCT05592769|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will be enrolled to the one study arm, in which they will all be provided with access to the HealthBeacon Injection Care Management System (ICMS). Participants will be identified and enrolled from the clinical site by the Study Personnel.||||
33825691|NCT05362760|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized phase 4 clinical trial with two arms (cohorts), i.e. abemaciclib plus aromatase inhibitor or abemaciclib plus fulvestrant, with patient assignment to the arms by physician's choice||||
33825692|NCT00245440|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33825693|NCT04115371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33825694|NCT05808062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825695|NCT02606383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825696|NCT00873561|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33825697|NCT05615480|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|In this study, different researchers will be responsible for randomization, anesthesia and visit. A researcher is responsible for assigning random numbers to ensure the randomness of the study groups. Due to the intraoperative monitoring of cerebral oxygen saturation in the experimental group, it is impossible to blind the researchers implementing anesthesia. In order to ensure that the whole study is not affected by subjective factors, the visiting researchers are blinded, who do not know the anesthesia grouping, and are responsible for case enrollment screening, signing informed consent, preoperative and postoperative cognitive function evaluation, postoperative pain evaluation, complications and safety evaluation.|Recruited patients will be randomly divided into control group and experimental group according to whether cerebral oxygen saturation monitoring was used during the operation. The control group maintain the target blood pressure only according to the controlled hypotension guideline, and the experimental group adjust the controlled hypotension level under the guidance of cerebral oxygen saturation monitoring.|t|f|f|t
33825698|NCT04530877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33825699|NCT05261230|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825700|NCT06219681|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33825701|NCT03703141|RANDOMIZED|FACTORIAL||SCREENING||DOUBLE|||t|t|f|f
33825702|NCT02295852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825703|NCT06090019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825704|NCT02867241|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33825705|NCT02547298|||COHORT||PROSPECTIVE|||||||
33825706|NCT01294410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825707|NCT01856010|||CASE_CONTROL||PROSPECTIVE|||||||
33825708|NCT06478732|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149395|NCT02520739|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33825709|NCT03704649|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825710|NCT03891498|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825711|NCT02306213|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825712|NCT03703843|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33825713|NCT03765528|||COHORT||PROSPECTIVE|||||||
33825714|NCT01755052|||COHORT||PROSPECTIVE|||||||
33825715|NCT04389918|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34149396|NCT04182061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial|f|f|t|f
34149397|NCT01722292|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149398|NCT02174653|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34149399|NCT03637712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149400|NCT02831556|||COHORT||PROSPECTIVE|||||||
33825716|NCT02253147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825717|NCT02459236|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825718|NCT03704571|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33825719|NCT04205214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are not aware of their allocation to the intervention group or control group. All||t|f|f|f
33825720|NCT01355471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825721|NCT06059209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants and research nurse/coordinator will be blinded to the formula assignment. The formulas used will be a standard infant formula (Enfamil Infant) and a new infant formula designed to be more similar to breast milk (Enfamil NeuroPro); both formulas are available for purchase by the public and meet FDA requirements for infant formulas. Each formula can (identical size) will be relabeled and coded by the investigators. Participants in the formula group will be provided with a four-month supply of powdered formula at the time of discharge from the hospital, along with stool collection kits.|Subjects will be able to choose between the breast-fed or formula-fed group. Subjects in the formula-fed group will be randomly assigned to one of the two formulas, with a 50% chance of being assigned to each group.|t|f|f|f
33825722|NCT00333502|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825723|NCT04263389|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825724|NCT05424211|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825725|NCT05226988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33825726|NCT05256771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Blinded, independent photo review comparing the pre-treatment and post-treatment Follow-up 2 photographs by a physician board-certified in dermatology to evaluate contour improvement per the Global Aesthetic Improvement Scale (GAIS).~Blinded Investigator review comparing the pre-treatment photographs and post-treatment Follow-up 1 \& 2 live assessment by the Primary Investigator to evaluate contour improvement per the Global Aesthetic Improvement Scale (PI-GAIS)."|3 Arms at a ratio of 2:1:1 (A:B:C): Arm A: Full Treatment Arm (Laser + EMS + RF/PEMF) Arm B: EMS/RF Arm (EMS + RF/PEMF) Arm C: EMS Arm (EMS only)|f|f|t|t
33825727|NCT01314898|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33825728|NCT00583050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825729|NCT06646601|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33825730|NCT05367752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor) Assessor-blind randomized control trial. A masked assessor conducted the measurements.|An assessor-blind randomized control trial with a duration of three weeks and a one-month follow up will be performed in 80 adults with neck pain due to the presence of trigger points on the upper part of trapezius muscle. The participants will be allocated into four groups of 20 persons each (three intervention groups and one control group). In the first group, a combination therapy of myofascial release with conductive TENS gloves will be applied, in the second group the same protocol of myofascial release without conductive gloves, in the third group a high frequency (conventional) TENS, and the fourth group will get placebo TENS with the device closed. All participants will follow a total of six treatments over a period of three weeks.|f|f|f|t
33825731|NCT00352053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825732|NCT04255121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33825733|NCT01667042|||COHORT||CROSS_SECTIONAL|||||||
33825734|NCT03265847|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825735|NCT02777242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825736|NCT02515656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825737|NCT01329185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825738|NCT00647998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825739|NCT04010383|||CASE_CONTROL||PROSPECTIVE|||||||
33825740|NCT06016998|||COHORT||PROSPECTIVE|||||||
33825741|NCT05139498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825742|NCT00729053|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825743|NCT05492123|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized trial, stratified by center, disease stage and type of radiation||||
33825744|NCT03421600|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33825745|NCT02625129|||COHORT||PROSPECTIVE|||||||
33825746|NCT04827186|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The protocol presented a single center, open label, prospective trial in which subjects, highly sensitized recipients with a positive T and B flow or positive B standard crossmatch, will undergo spleen transplant and kidney or simultaneous kidney pancreas transplant at the University of Illinois at Chicago. The expected number of patients is 40. Graft and patient survival will be monitored and compared with an historical cohort of highly sensitized patient which received kidney or simultaneous kidney pancreas transplant alone without spleen.||||
33825747|NCT01150019|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825748|NCT01335321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825749|NCT05903677|||COHORT||PROSPECTIVE|||||||
33825750|NCT03184142|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Students cannot be masked as an arm undergoes a simulation intervention. The researcher evaluating the outcomes through the questionnaires will be blinded.|Single-blind randomised controlled trial with two experimental arms and a control arm|f|f|t|t
33825751|NCT05867550|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized Control Trial in which participants will be divided into 3 treatment groups i.e. Group A, Group B and Group C.~* Participants of Group A will receive drug combination of Rifaximin and Mebeverine~* Participants of Group B will receive drug combination of Rifaximin and Amitriptyline~* Participants of Group C will receive drug combination of Rifaximin and Psyllium Husk~* Each group will be given a combination of drugs for 2 weeks~Stool Frequency, Characteristic of Stool and Abdominal Pain will be assessed at day 0 and day 14 of intervention~At the end of study period , efficacy of different drug combinations and their potential side effects will be compared between the treatment groups"||||
33825752|NCT01932983|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825753|NCT01729091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825754|NCT02016664|NA|SINGLE_GROUP||||NONE||||||
33825755|NCT02914717|||COHORT||RETROSPECTIVE|||||||
33825756|NCT03723915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825757|NCT03982875|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33825758|NCT03936075|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||two randomised groups, one intervention group and one placebo group|t|t|f|f
33825759|NCT01128777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131555|NCT04191304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All eligible patients will be centrally randomly assigned in a 1:1 ratio to receive either benralizumab or placebo. Randomisation will be done using an IWRS/IVRS.~Benralizumab and placebo will not be visually distinct from each other. All packaging and labelling of the IP will be done in such a way as to ensure blinding for all Sponsor and investigational site staff. Neither the patient nor any of the Investigators or Sponsor staff who are involved in the treatment, clinical evaluation, and monitoring of the patients will be aware of the treatment received. Since benralizumab and placebo are not visually distinct, IP will be handled by an appropriately qualified member of the study team (e.g., pharmacist, Investigator, or designee) at the site."||t|t|t|t
34131556|NCT03332199|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34131557|NCT03470194|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34131558|NCT02514811|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34131559|NCT01826539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34131560|NCT00104728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131561|NCT06552975|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131562|NCT02620878|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131563|NCT01521923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131564|NCT05912894|||COHORT||PROSPECTIVE|||||||
34131565|NCT03136224|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|Statistician was masked|Thermocautery group Plastic clamping group Classic (Surgical) circumcision group|f|f|f|t
34131566|NCT01788397|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34131567|NCT03403530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131568|NCT00107900|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131569|NCT01574820|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131570|NCT04321473|||COHORT||PROSPECTIVE|||||||
34131571|NCT02801682|||COHORT||PROSPECTIVE|||||||
34131572|NCT00570778|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34131573|NCT00795444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131574|NCT04342949|||CASE_ONLY||PROSPECTIVE|||||||
34131575|NCT02363972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131576|NCT02283905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131577|NCT01500252|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131578|NCT00799630|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34131579|NCT03201718|||COHORT||PROSPECTIVE|||||||
34131580|NCT03972462|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34131581|NCT01884324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131582|NCT03598062|||OTHER||OTHER|||||||
34131583|NCT05905224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131584|NCT01843673|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131585|NCT00943098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131586|NCT01819207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131587|NCT06349265|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131588|NCT02565758|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131589|NCT00154700|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131590|NCT06280638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825760|NCT03966534|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Prospective partially blinded randomized study|f|f|t|f
34131591|NCT06300749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825761|NCT02036606|||OTHER||OTHER|||||||
34131592|NCT04497103|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||"Task-oriented training TOT group and Xbox training group were conducted with an average of 50-min sessions three times a week for 8 weeks.~The traditional rehabilitation program conducted for 40-min sessions, three times per week for 8 weeks for all children."|t|f|f|t
34131593|NCT03060993|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34131594|NCT05082012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131595|NCT04644146|||CASE_CONTROL||RETROSPECTIVE|||||||
34131596|NCT00301262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34131597|NCT05117684|||COHORT||RETROSPECTIVE|||||||
33825762|NCT00841477|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33825763|NCT02906995|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34131598|NCT04539613|||COHORT||PROSPECTIVE|||||||
34131599|NCT05281627|||COHORT||PROSPECTIVE|||||||
34131600|NCT01586598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34131601|NCT06656923|||CASE_ONLY||RETROSPECTIVE|||||||
34131602|NCT06299618|||COHORT||PROSPECTIVE|||||||
34131603|NCT05541406|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131604|NCT05421130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825764|NCT03824145|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Attention Control||||
33825765|NCT00669266|||CASE_CONTROL||OTHER|||||||
33825766|NCT04897685|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825767|NCT05216029|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33825768|NCT00155883|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825769|NCT06293014|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825770|NCT04184856|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825771|NCT01191697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131605|NCT05339841|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Patients will be randomized in two parallel groups: intervention group and usual care. In the setting of general medicine, the procedure randomises the general practitioners (GPs) assuring that in each recruiting centre the number of GPs assigned to the control group (usual care) is balanced with that assigned to the intervention group. In the setting of community pharmacies, the procedure randomises the pharmacies assuring that in each geographic area the number of pharmacies assigned to the control group and is balanced with that assigned to the intervention group. In the setting of IRCCS the procedure directly randomises the patients."||||
34131606|NCT05712096|||COHORT||RETROSPECTIVE|||||||
34131607|NCT06474468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131608|NCT00879034|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34131609|NCT03066323|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33825772|NCT05529225|||CASE_CONTROL||PROSPECTIVE|||||||
33825773|NCT04335370|||COHORT||PROSPECTIVE|||||||
34131610|NCT04193111|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131611|NCT04211792|||COHORT||PROSPECTIVE|||||||
34131612|NCT04500392|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34131613|NCT05009173|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34131614|NCT04776616|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will choose a piece of folded paper from a container. This piece of paper will indicate whether they are receiving the control or the experimental intervention.|This is a pilot randomized controlled trial with 1:1 control and intervention|t|f|f|f
34131615|NCT05820139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The voiding trial instructions for each specific patient will be given to the Post Anesthesia Care Unit (P(ACU) or floor Registered Nurse (RN) taking care of the patient and will include what volume voided equals a passing voiding trial.|Patients will be recruited at an Urogynecology office either at the pre-operative visit or on the day of surgery|t|f|f|f
34131616|NCT03914430|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participants were blinded and could not distinguish the breakfast cereals made with Greek yogurt or with cultured coconut product. The taste and flavour in both treatments was similar due to added blueberry flavouring.||t|f|f|f
34131617|NCT05965050|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34131618|NCT00318279|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34131619|NCT02295696|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34131620|NCT00213941|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131621|NCT01032603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131622|NCT03309254|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized crossover study||||
34131623|NCT01895400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131624|NCT03784911|||COHORT||PROSPECTIVE|||||||
34131625|NCT03580278|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||An exploratory, clinical study with 2 open-dose cohorts is designed to analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 in the treatment of subjects with active plaque psoriasis.||||
34131626|NCT02501668|||CASE_CONTROL||RETROSPECTIVE|||||||
34131627|NCT01301066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131628|NCT02120781|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131629|NCT03850093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34131630|NCT01672281|RANDOMIZED|PARALLEL||||NONE||||||
34131631|NCT04257968|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131632|NCT05407012|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131633|NCT05430503|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131634|NCT02182778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131635|NCT05336929|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34131636|NCT06479512|||OTHER||PROSPECTIVE|||||||
34131637|NCT03776812|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131638|NCT04299152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective, two-arm, partially masked, single center clinical study to assess the safety, feasibility, and efficacy of SCE therapy for the treatment of patients with SARS-CoV-2.|f|t|f|f
34131639|NCT01003756|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34131640|NCT01188551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131641|NCT02705846|||CASE_CONTROL||PROSPECTIVE|||||||
34131642|NCT06552455|||OTHER||PROSPECTIVE|||||||
34131643|NCT02074670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131644|NCT04691245|RANDOMIZED|PARALLEL||OTHER||TRIPLE||randomized clinical trial with two arms|t|f|t|t
34131645|NCT01277705|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131646|NCT02120768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131647|NCT04217499|||COHORT||RETROSPECTIVE|||||||
34131648|NCT02405247|||COHORT||PROSPECTIVE|||||||
34131649|NCT01434628|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34131650|NCT00442533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131651|NCT01373255|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131652|NCT06659497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The research is being conducted as a randomized controlled experimental study to determine the effects of web-based training on the treatment process of women undergoing Intrauterine Insemination (IUI) treatment on the level of infertility, fertility readiness and pregnancy outcomes. There are 2 groups of subjects in the study as experimental and control. Block randomization was applied in determining the groups. In this direction, the following randomization steps were followed by the statistics expert in order to eliminate bias and increase the reliability of the study. Randomization was done according to the educational status of the women (primary school - secondary school, high school, university and above when grouped) in a way that homogeneity was ensured in each group and it was planned to be statistically re-evaluated at the end of the study.||||
34131653|NCT04646746|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|Color labeling|Randomized, double-blinded, cross-over, acute, dietary intervention study|t|f|t|f
34131654|NCT03532698|||COHORT||PROSPECTIVE|||||||
34131655|NCT05538910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34131656|NCT03818763|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, nonrandomized, single-center phase I cohort study||||
34131657|NCT03403062|||CASE_ONLY||PROSPECTIVE|||||||
34131658|NCT03404063|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The Data and Safety Monitoring Board (DSMB) will be blinded at project start, but may request unblinding if necessary to accommodate effective review of data.~Other than the DSMB (if necessary), the only other un-blinded parties, meaning that they will have knowledge as to the patient's treatment assignment, will be the PBTiK UJ CM employee who participates in randomization utilizing randomization lists and investigational medication preparation."|"The AMI trial will enroll 105 patients with randomization into active vs. sham therapy with 2:1 ratio.~Additional 5-10 subjects meeting inclusion/exclusion criteria will receive, in a non-blinded fashion, labelled CardioCell to determine the early uptake and retention of IMP in the target ischemic tissues."|t|t|t|t
34131659|NCT01963182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131660|NCT02450435|||COHORT||RETROSPECTIVE|||||||
34131661|NCT00482040|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
33825774|NCT04131010|NA|SINGLE_GROUP||TREATMENT||NONE||International prospective multicenter cohort study||||
34131662|NCT03470740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The researcher who collected the data and the researcher who applied the intervention program was never the same.|Participants were randomly assigned to experimental group who received a rheumatoid arthritis self-management intervention based on self-efficacy theory for 6 weeks, and a control group receiving standard rheumatology care only.|f|f|f|t
34131663|NCT02645045|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34131664|NCT05908357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both assessors participating in the study will be masking for the group of the participant.||f|f|f|t
34131665|NCT00453609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131666|NCT04947345|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a open label clinical trial.|||||
34131667|NCT02988947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34131668|NCT05772689|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131669|NCT06329466|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131670|NCT02144688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131671|NCT03423030|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34131672|NCT06302881|||COHORT||RETROSPECTIVE|||||||
34131673|NCT03177512|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131674|NCT05757518|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants will be allocated to intervention (cryostimulation using cryosauna) or a control group (without any intervention) using a randomized list of allocated numbers generated by a computer program. The investigator and Outcomes Assessor will be blinded to the allocation process.|Randomized controlled trial|f|f|t|t
34131675|NCT02415049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131676|NCT05856929|||OTHER||CROSS_SECTIONAL|||||||
34131677|NCT03002324|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131678|NCT02723552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131679|NCT02131090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34131680|NCT00989846|||COHORT||PROSPECTIVE|||||||
34131681|NCT02601638|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34131682|NCT06125171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131683|NCT01545869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131684|NCT05645393|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34131685|NCT03960060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131686|NCT04262466|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34131687|NCT00719498|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131688|NCT00887367|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34131689|NCT01849692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131690|NCT03614741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131691|NCT02798315|||COHORT||PROSPECTIVE|||||||
34131692|NCT06554782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34131693|NCT04963855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131694|NCT02453542|||COHORT||PROSPECTIVE|||||||
34131695|NCT00834600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131696|NCT03628105|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will complete baseline pretreatment outcome measures at the first visit to the lab. All participants will watch the same psychoeducation video explaining the nature of anxiety and rationale for exposure therapy. Participants will then be randomly assigned to either the CR Before condition or the CR After condition. CR Before will complete 15 minutes of CR (Preparation) before engaging in six 5-minute exposure trials in a claustrophobic chamber, and complete the 15-minute filler task after exposure. CR After will complete the 15-minute filler task before exposure, engage in six 5-minute exposure trials in a claustrophobic chamber, and engage in 15 minutes of CR (Consolidation) after exposure. Participants will complete posttreatment outcome measures immediately following the intervention. Participants will return one month later to complete followup outcome measures.||||
34131697|NCT04079231|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131698|NCT01557543|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131699|NCT05273372|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|2 sets of bottles will be delivered to the Bateman Horne Center-- Group 1 and Group A. One of the groups will contain the active, the other the placebo.|Placebo-controlled double blinded 2 arm study. 40 patients in treatment arm, 40 patients in placebo arm.|t|t|t|t
34131700|NCT06179810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Pre/posttest randomized control trial|t|f|f|t
34131701|NCT01127464|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34131702|NCT03419637|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33825775|NCT00404599|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825776|NCT05900401|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825777|NCT03389451|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825778|NCT05524415|||CASE_ONLY||PROSPECTIVE|||||||
34131703|NCT02181491|NA|SINGLE_GROUP||OTHER||NONE||||||
34131704|NCT03572231|||COHORT||PROSPECTIVE|||||||
34131705|NCT05503095|||CASE_CONTROL||PROSPECTIVE|||||||
33825779|NCT00018577|||||PROSPECTIVE|||||||
34131706|NCT05445921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131707|NCT02654821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131708|NCT02520544|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131709|NCT00419211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131710|NCT03745872|NA|SINGLE_GROUP||PREVENTION||NONE|Participant names will be written on pre and post test to enable matching purposes, but once this has been completed, only the study ID will be used.|All students who participate in this study will be given a pre test, instruction regarding sun exposure and a post test to determine their sun exposure behaviors and knowledge of sun exposure risks.||||
34131711|NCT04644276|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34131712|NCT01508377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131713|NCT05237063|NA|SINGLE_GROUP||SCREENING||NONE||||||
34131714|NCT04237233|||OTHER||PROSPECTIVE|||||||
34131715|NCT02973295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131716|NCT04701606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"* Stage 1: Single Group (Experimental drug only)~* Stage 2: Parallel (Placebo control and Experimental drug)"|t|t|t|f
34131717|NCT00952861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131718|NCT03178136|||COHORT||PROSPECTIVE|||||||
33825780|NCT02766010|NA|SINGLE_GROUP||SCREENING||NONE||||||
33825781|NCT02021305|||CASE_CONTROL||PROSPECTIVE|||||||
33825782|NCT06645938|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33825783|NCT05927714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned to either the hemostatic agent or the amnio-chrionic membrane, but will be blinded to which standard of care intervention to which they are assigned.|This is a two-independent arm, parallel-design randomized, prospective trial designed to compare two standard of care techniques.|t|f|f|f
33825784|NCT01874665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825785|NCT00825734|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825786|NCT01463514|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33825787|NCT03140449|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825788|NCT03017313|||COHORT||PROSPECTIVE|||||||
33825789|NCT01580007|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33825790|NCT00220597|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33825791|NCT05207631|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Quasi-experimental study||||
33825792|NCT03795402|||COHORT||PROSPECTIVE|||||||
33825793|NCT04048798|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33825794|NCT03950557|||COHORT||PROSPECTIVE|||||||
33825795|NCT00853021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825796|NCT05965960|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The subject will be blind to stimulation condition (sham/active TUS). The assessor will be blind to stimulation condition (sham/active TUS) while analyzing LFPs. The UPDRS examination will be video-recorded and blindly assessed by a research team member.||t|f|f|t
33825797|NCT05336136|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Within subject crossover||||
33825798|NCT03974451|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825799|NCT02763150|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33825800|NCT02969629|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33825801|NCT04702399|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825802|NCT06392919|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33825803|NCT01001130|||||PROSPECTIVE|||||||
33825804|NCT02007759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825805|NCT00153348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33825806|NCT06047613|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825807|NCT01209286|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825808|NCT01090700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825809|NCT00525018|||DEFINED_POPULATION||OTHER|||||||
33825810|NCT03579433|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825811|NCT00877747|||COHORT||RETROSPECTIVE|||||||
33825812|NCT02263625|||COHORT||PROSPECTIVE|||||||
33825813|NCT05169814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind, controlled study. Participants will be selected and matched based on similar wound profiles, pathology mechanisms, comorbidity profiles, and age. They will randomly be assigned to the experimental (MNB) or control (normal saline) group. The randomization ratio between both groups will be 1:1. Measurements of objective datapoints (e.g. StO2), cytokines, proteases, and pH will be taken by blinded research personnel.|"This is a pilot study that consists of 4 arms:~* Acute wounds: 1 control arm; 1 experimental arm (treated with MNB irrigation)~* Chronic wounds: 1 control arm; 1 experimental arm (treated with Negative pressure wound therapy with MNB instillation)"|t|f|f|t
33825814|NCT01747629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825815|NCT00163800|||DEFINED_POPULATION||PROSPECTIVE|||||||
33825816|NCT05188872|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825817|NCT03330717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825818|NCT00468065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825819|NCT06276634|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Randomized, double-blind, placebo-controlled, cross-over, repeated measures study design|t|f|f|t
33825820|NCT00566059|||COHORT||PROSPECTIVE|||||||
33825821|NCT01032356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825822|NCT06479447|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33825823|NCT03433209|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33825824|NCT05603390|||COHORT||RETROSPECTIVE|||||||
33825825|NCT00397137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825826|NCT00931008|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33825827|NCT01093170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825828|NCT01162564|||COHORT||PROSPECTIVE|||||||
33825829|NCT05291806|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33825830|NCT05428241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants and caregivers were not informed about intervention content and measurements.|Randomized controlled pre-post test design|t|t|f|f
33825831|NCT02274519|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825832|NCT06215625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825833|NCT01527903|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825834|NCT03545178|||COHORT||RETROSPECTIVE|||||||
33825835|NCT05722613|||CASE_CONTROL||PROSPECTIVE|||||||
33825836|NCT02893358|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33825837|NCT00702546|||OTHER||PROSPECTIVE|||||||
33825838|NCT05846048|||COHORT||CROSS_SECTIONAL|||||||
33825839|NCT06050083|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a 2-arm randomized controlled trial in which individuals will be assigned to a treatment group (8 weeks of access to hypnosis recordings) or a waitlist group (4 weeks of no access followed by 4 weeks of access to hypnosis recording access).||||
33825840|NCT02634398|||COHORT||PROSPECTIVE|||||||
33825841|NCT01742234|||CASE_ONLY||CROSS_SECTIONAL|||||||
33825842|NCT01630837|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33825843|NCT00833183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825844|NCT03334695|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33825845|NCT04620031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825846|NCT00218998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33825847|NCT03331432|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants are not told which are placebo or tauroursodeoxycholic acid capsules|Single-blinded randomized crossover study|t|f|f|f
34131719|NCT01562392|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34131720|NCT02590276|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34131721|NCT01039545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131722|NCT03511014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131723|NCT00956137|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131724|NCT06301516|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized clinical trial of psychological intervention. Once all assessments are completed, the treatment group allocation will be disclosed to the administrating researcher, youth, and caregiver. This blinded approach to block randomization prevents any bias from occurring during the assessment phase by the researcher.||||
34131725|NCT00842283|||OTHER||OTHER|||||||
34131726|NCT00118638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131727|NCT06517069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131728|NCT01437111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131729|NCT04811755|||COHORT||OTHER|||||||
34131730|NCT03150550|RANDOMIZED|PARALLEL||TREATMENT||NONE|Simple Blind|||||
34131731|NCT02817594|||COHORT||PROSPECTIVE|||||||
34131732|NCT04593186|NA|SINGLE_GROUP||SCREENING||NONE||Trans-oral magnifying endoscopy with Narrow Band Imaging assessment of nasopharynx||||
34131733|NCT06407128|NA|SINGLE_GROUP||SCREENING||NONE||||||
34131734|NCT05568680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131735|NCT04793204|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131736|NCT06294262|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34131737|NCT00284414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131738|NCT03449940|RANDOMIZED|PARALLEL||TREATMENT||NONE||A block randomization sequence was created and cases were allocated 1:1 to either immediate repair (group 1) or delayed repair (group 2). Allocation sequence numbers were kept concealed in sequentially numbered folders and access was only granted to the principal investigator.||||
34131739|NCT02858440|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34131740|NCT05166356|||OTHER||PROSPECTIVE|||||||
34131741|NCT06658977|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Extension||||
34131742|NCT05945069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131743|NCT05037695|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, unblinded, randomized (1:1), single-center pilot study of 40 patients allocated to one of the treatment arms (OMT + empagliflozin or OMT).||||
34131744|NCT05944068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||EMBODY (Effects of a Mindfulness Based interventiOn on ibD disabilitY) will be a prospective, randomized-controlled, monocentric, superiority trial using a waiting list with treatment as usual as control arm. Half of the patients will immediately start the mindfulness based intervention (early intervention group). In the other half, there will be a waiting time of 6 months before starting the mindfulness based intervention (late intervention or control group).||||
34131745|NCT05934591|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34131746|NCT06497283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34131747|NCT00807586|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131748|NCT00005947|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34131749|NCT00589706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131750|NCT05144893|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34131751|NCT02853708|||COHORT||PROSPECTIVE|||||||
34131752|NCT03818607|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|double-blind||t|t|t|t
34131753|NCT05561283|NA|SINGLE_GROUP||OTHER||NONE||||||
34131754|NCT03994211|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33825848|NCT03087994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825849|NCT02737202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825850|NCT05736445|||COHORT||PROSPECTIVE|||||||
33825851|NCT02880124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33825852|NCT03175198|||COHORT||PROSPECTIVE|||||||
34131755|NCT06134115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131756|NCT02242136|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34131757|NCT05257499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34131758|NCT04384705|||COHORT||PROSPECTIVE|||||||
34131759|NCT03252041|||COHORT||PROSPECTIVE|||||||
34131760|NCT02701959|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34131761|NCT02727595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131762|NCT06024109|||CASE_CONTROL||PROSPECTIVE|||||||
34131763|NCT04905524|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"This is a single group cohort study; the first cohort consists of participants with self reported Irritable Bowel Syndrome (IBS), the second cohort consists of participants with self reported depression and the last cohort consists of participants with self reported anxiety.~All cohorts receive diet and supplement recommendations from Viome based on participants' sample results."||||
34131764|NCT06289894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131765|NCT05302869|||COHORT||CROSS_SECTIONAL|||||||
34131766|NCT02763813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131767|NCT05810909|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A Randomized, Double-Blind Trial|A Placebo-Controlled Parallel-Group Trial|t|t|t|t
34131768|NCT04453358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is a randomized-comparative study investigating the effectiveness of either low-level virtual coaching vs. high-level virtual coaching in improving airway clearance treatment adherence.||||
34131769|NCT04626687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131770|NCT04061824|RANDOMIZED|PARALLEL||OTHER||NONE|No masking|Patients are divided into 2 group, one with fixed-dose combination of 2 drugs, while another with 2 separated drugs.||||
34131771|NCT02911298|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34131772|NCT01811589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131773|NCT05081167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131774|NCT05215470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131775|NCT04296188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34131776|NCT02152475|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131777|NCT05446038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131778|NCT02591537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34131779|NCT01420913|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34131780|NCT01712581|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131781|NCT04946500|||COHORT||RETROSPECTIVE|||||||
34131782|NCT02507661|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131783|NCT00025571||||TREATMENT||||||||
34131784|NCT02681419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131785|NCT05040971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131786|NCT01597765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34131787|NCT04806061|RANDOMIZED|PARALLEL||PREVENTION||NONE||open label randomised controlled trial||||
34131788|NCT05797909|||OTHER||CROSS_SECTIONAL|||||||
33825853|NCT03386214|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34131789|NCT02010242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825854|NCT05420623|||CASE_CONTROL||PROSPECTIVE|||||||
34131790|NCT01634880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131791|NCT06451692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34131792|NCT02091362|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34131793|NCT06253455|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131794|NCT02700620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131795|NCT01631487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131796|NCT00094159|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131797|NCT06532929|||COHORT||OTHER|||||||
34131798|NCT01668446|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34131799|NCT00382421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131800|NCT04452305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131801|NCT06661616|||CASE_CONTROL||PROSPECTIVE|||||||
34131802|NCT01483235|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34131803|NCT04654169|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Allocation information of patients was only given to the physiatrists who would apply the intervention. Another physiatrist who completed the pre and post-treatment assessments and the patients were blinded to the allocation.|A double-blind, randomized controlled trial, to have two groups with a single arm|t|f|f|t
34131804|NCT02765815|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131805|NCT04117373|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34131806|NCT04027595|||CASE_ONLY||PROSPECTIVE|||||||
34131807|NCT06191874|||COHORT||PROSPECTIVE|||||||
34131808|NCT01168830|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131809|NCT03824873|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131810|NCT02810288|||||CROSS_SECTIONAL|||||||
34131811|NCT05683405|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A periodontist that is not involved in the treatment and who is blinded to the treatment received will evaluate the treatment results.|Each participant will be randomized to non-surgical treatment of peri-implantitits with either mechanical debridement or with air-polishing.|f|f|f|t
34131812|NCT06000475|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Blinded to treatment status during feasibility trial||t|f|t|t
34131813|NCT00889603|||CASE_ONLY||PROSPECTIVE|||||||
34131814|NCT02905799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34131815|NCT06290466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131816|NCT06659419|||OTHER||OTHER|||||||
34131817|NCT06305299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131818|NCT05908994|||COHORT||PROSPECTIVE|||||||
34131819|NCT02724579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131820|NCT02031991|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34131821|NCT06208293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825855|NCT03041701|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33825856|NCT05300997|||CASE_CONTROL||PROSPECTIVE|||||||
33825857|NCT05171361|||COHORT||PROSPECTIVE|||||||
33825858|NCT04959825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|Patients will be allocated to the study groups using a computer-generated random list, and the group assignments will be sealed in sequentially numbered opaque envelopes that will be opened before induction of anesthesia. The data collector will be blinded to the group assignment and to the monitoring anesthetist, and the person who will give the drug will not bethe data collector.|randomized controlled trial|t|t|t|t
33825859|NCT03605368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825860|NCT02690415|||CASE_CONTROL||PROSPECTIVE|||||||
33825861|NCT00629551|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131822|NCT03420755|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The investigators will use a stepped wedge design-a form of RCT that involves sequential, but random, rollout of the intervention over multiple time periods. The investigaotrs have created two HV program clusters. Both clusters will initially implement MB 1-on-1 and will recruit MB participants for one quarter (i.e., three months) before crossing over to recruit MB-TXT participants for one quarter. MB-TXT's core curriculum is identical to MB 1-on-1 and adds a series of text messages throughout the curriculum.||||
34131823|NCT05966090|RANDOMIZED|PARALLEL||PREVENTION||NONE|The laboratory in charge of sample testing will be blinded to the study intervention assignment.|||||
34131824|NCT05335304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the investigator who perform muscle thickness and muscle morphology measurements is blinded||f|f|t|f
33825862|NCT04157959|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131825|NCT04568486|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34131826|NCT06574880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825863|NCT00690859|||CASE_CONTROL||PROSPECTIVE|||||||
33825864|NCT01490359|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants were masked to intervention arm at time of recruitment.||t|f|f|f
34131827|NCT01835977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131828|NCT02177331|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131829|NCT04093193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient will know if he/she is getting debridement or not. The PI will comment on all the objective outcome measures and will be the blinded assessor (he will not perform the debridements).|"There will be two possible scenarios resulting from randomization:~1. The patient is randomized to the arm that receives routine post-operative debridement (treatment group).~2. The patient is randomized to the arm that will not receive post-operative debridement (control group)."|f|f|t|f
34131830|NCT00970723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131831|NCT00256360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131832|NCT05631340|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|participants do not know the group they belong, case or control|same follow up time|t|f|f|f
34131833|NCT04733118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131834|NCT05974384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34131835|NCT02697981|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131836|NCT05532722|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34131837|NCT06660966|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34131838|NCT01903772|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34131839|NCT04078958|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34131840|NCT00193791|RANDOMIZED|PARALLEL||TREATMENT||NONE||Concomitant chemo-radiation versus radiation alone||||
34131841|NCT02438683|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34131842|NCT04313777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131843|NCT01479244|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34131844|NCT04365530|||COHORT||OTHER|||||||
34131845|NCT05709223|NA|SINGLE_GROUP||OTHER||NONE|Participants are blinded to the order of fitting method. Some participants will use first the Behavioural program followed by the investigational program while the other group will use each of these conditions in the opposite order.|||||
34131846|NCT00446121|||OTHER||PROSPECTIVE|||||||
34131847|NCT01964495|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131848|NCT01869036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131849|NCT05322291|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The mobile application developed will be installed on the phones of hemodialysis patients.||||
34131850|NCT00879151|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131851|NCT03241277|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non surgical periodontal treatment||||
34131852|NCT00219193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34131853|NCT06523764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131854|NCT03880188|||COHORT||CROSS_SECTIONAL|||||||
34131855|NCT02706418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131856|NCT01505036|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34131857|NCT04182477|||COHORT||PROSPECTIVE|||||||
34131858|NCT06655363|||COHORT||RETROSPECTIVE|||||||
34131859|NCT01713647|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131860|NCT05894304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131861|NCT02253433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131862|NCT05869058|||COHORT||PROSPECTIVE|||||||
34131863|NCT06568003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131864|NCT02456207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131865|NCT03084094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34131866|NCT03544424|||COHORT||RETROSPECTIVE|||||||
34131867|NCT06433687|||COHORT||PROSPECTIVE|||||||
34131868|NCT01267864|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131869|NCT02262026|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34131870|NCT02470585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131871|NCT00353808|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131872|NCT00407368|||DEFINED_POPULATION||PROSPECTIVE|||||||
34131873|NCT04254692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34131874|NCT06565780|NA|SINGLE_GROUP||OTHER||NONE||||||
34131875|NCT02566187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131876|NCT04763252|||COHORT||PROSPECTIVE|||||||
34131877|NCT01697475|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33825865|NCT00202332|RANDOMIZED|PARALLEL||||NONE||||||
33825866|NCT04915079|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33837463|NCT00927173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131878|NCT02660593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131879|NCT05366816|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131880|NCT06321445|||CASE_ONLY||PROSPECTIVE|||||||
34131881|NCT05852938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34131882|NCT02442986|||CASE_CONTROL||PROSPECTIVE|||||||
34131883|NCT02110355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131884|NCT04739319|||COHORT||PROSPECTIVE|||||||
34131885|NCT04966182|||CASE_CONTROL||RETROSPECTIVE|||||||
34131886|NCT02248649|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34131887|NCT06657846|||COHORT||CROSS_SECTIONAL|||||||
34131888|NCT00752739|RANDOMIZED|||TREATMENT||||||||
34131889|NCT00958347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131890|NCT03575663|||CASE_CROSSOVER||PROSPECTIVE|||||||
33837464|NCT00276835|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131891|NCT04343534|||OTHER||RETROSPECTIVE|||||||
34131892|NCT05502926|||COHORT||PROSPECTIVE|||||||
34131893|NCT04075513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131894|NCT06458062|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34131895|NCT04887584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Unblinded|||||
34131896|NCT02358200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131897|NCT00002297||||TREATMENT||DOUBLE||||||
34131898|NCT06661434|||COHORT||RETROSPECTIVE|||||||
34131899|NCT04904419|||CASE_ONLY||PROSPECTIVE|||||||
34131900|NCT04143152|||COHORT||PROSPECTIVE|||||||
34131901|NCT01543282|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34131902|NCT06444854|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study is a single centre, prospective clinical trial evaluating the safety and feasibility.||||
34131903|NCT03500016|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34131904|NCT03254628|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34131905|NCT00856596|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131906|NCT03248167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131907|NCT01644669|NA|SINGLE_GROUP||TREATMENT||NONE||Single 20Gy dose of electronic brachytherapy (IORT)||||
34131908|NCT02200757|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131909|NCT00090779|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825867|NCT05534464|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||Participants will have three test days, each separated by two weeks. The participants will randomly consume one of the three protein sources on each test day respectively.|f|f|t|f
33825868|NCT05060237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825869|NCT01849913|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33825870|NCT00001077|||COHORT||PROSPECTIVE|||||||
33825871|NCT04466397|||CASE_ONLY||RETROSPECTIVE|||||||
33825872|NCT04564859|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33825873|NCT04193709|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Cross-sectional and observational (Arm 1) Prospective, cohort, and interventional (Arm 2).||||
33825874|NCT03379779|||CASE_ONLY||PROSPECTIVE|||||||
33825875|NCT04359264|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33825876|NCT03618719|||CASE_CONTROL||PROSPECTIVE|||||||
33825877|NCT05644535|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33825878|NCT01243021|||COHORT||RETROSPECTIVE|||||||
33825879|NCT00236483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33825880|NCT04063345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825881|NCT02090998|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825882|NCT03354897|NA|SINGLE_GROUP||TREATMENT||NONE|prospective cohort study|This study is a multi-centre prospective cohort study to investigate whether individuals possessing the AA genotype of the single nucleotide polymorphism, rs13333226, are better responders to loop diuretics compared to those possessing the G allele.||||
33825883|NCT00621946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33825884|NCT04561583|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|In this trial, single-blind method will be used, which means that the investigators know about the device used for treatment of the subjects while the subjects know nothing about it.|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."|t|f|f|f
33825885|NCT06389929|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Prospective randomized controlled n = 86 (43 = control, 43 = intervention) students who took the Women's Health and Diseases Nursing course at Bartın University, Faculty of Health Sciences, Department of Nursing and volunteered to participate in the study were randomly assigned to two groups: intervention and control.||||
33825886|NCT01020747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825887|NCT02275845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825888|NCT03503487|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825889|NCT03220776|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Double-Blind||t|t|t|t
33825890|NCT00004403|RANDOMIZED|||TREATMENT||DOUBLE||||||
33825891|NCT02671864|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825892|NCT01098799|||||PROSPECTIVE|||||||
33825893|NCT01218295|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825894|NCT00260676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825895|NCT06435741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825896|NCT05394389|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33825897|NCT02750553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825898|NCT03238456|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825899|NCT00570921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825900|NCT01315197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825901|NCT04279756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The care provider (Cathy Arnot) was not blinded as she knew the groups of the participants. The Investigators and the Outcomes Assessors were blinded as they were not aware of the group each participant was placed in.|A parallel design, also called a parallel group study, compares two or more treatments. Participants are randomly assigned to either group, treatments are administered, and then the results are compared.|f|f|t|t
33825902|NCT00202306|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825903|NCT00092313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825904|NCT05157568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825905|NCT01862185|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33825906|NCT05221983|||CASE_ONLY||RETROSPECTIVE|||||||
33825907|NCT02269917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825908|NCT01801462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33825909|NCT00057044|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825910|NCT02216149|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825911|NCT00931918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825912|NCT06479122|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825913|NCT00555646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825914|NCT02536547|||COHORT||PROSPECTIVE|||||||
33825915|NCT02795715|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33825916|NCT02878460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825917|NCT00078234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825918|NCT04930185|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33825919|NCT06374342|||COHORT||OTHER|||||||
33825920|NCT01079377|||CASE_CONTROL||PROSPECTIVE|||||||
33825921|NCT02469077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825922|NCT04433286|||OTHER||CROSS_SECTIONAL|||||||
33825923|NCT05324813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33825924|NCT04106583|||COHORT||PROSPECTIVE|||||||
33825925|NCT05688098|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33825926|NCT01974934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825927|NCT01011049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825928|NCT00326703|RANDOMIZED|PARALLEL||||SINGLE||||||
33825929|NCT06192017|||COHORT||PROSPECTIVE|||||||
33825930|NCT02186314|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33825931|NCT01474421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825932|NCT01802892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825933|NCT00087997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825934|NCT06073444|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
33825935|NCT06010550|||COHORT||CROSS_SECTIONAL|||||||
33825936|NCT01448382|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825937|NCT02703402|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33825938|NCT03983018|NA|SINGLE_GROUP||TREATMENT||SINGLE|Each patient will be video recorded at base line, week 12, 20 and 40 in order to enable blinded assessment by an independent rater, and for the patient's own evaluation.||f|f|f|t
33825939|NCT01431950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825940|NCT01532583|||CASE_ONLY||RETROSPECTIVE|||||||
33825941|NCT03521206|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|During the data collection the investigators cannot be blinded, due to the nature of the intervention. However, during data analysis the researchers will be blinded for the unit of randomization of each nursing home, making use of encrypted data.|Seven of the 14 nursing homes will be randomized to the intervention group. The other seven nursing homes will be randomized to the control group.|f|f|t|f
33825942|NCT02111720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33825943|NCT03781947|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This Phase I clinical study is an open-label, parallel-design, single-centre study to investigate the PK, safety and PD following subcutaneous and intramuscular administration of single doses of teverelix TFA in healthy male subjects.||||
33825944|NCT05470569|||OTHER||PROSPECTIVE|||||||
33825945|NCT04372537|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825946|NCT03683914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825947|NCT02387281|||CASE_CONTROL||PROSPECTIVE|||||||
33825948|NCT02369588|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33825949|NCT01708005|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825950|NCT02169778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825951|NCT01229527|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33825952|NCT05110833|||CASE_ONLY||PROSPECTIVE|||||||
33825953|NCT01318538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825954|NCT05380388|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blinded placebo|Randomized placebo-controlled trial|t|t|t|f
33825955|NCT05621213|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Patient assigned to the interventional group or to the control group if they do not wish to be followed up by teleconsultation||||
33825956|NCT02795819|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33825957|NCT02094547|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33825958|NCT03280108|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33825959|NCT01495234|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825960|NCT04003961|||CASE_CONTROL||PROSPECTIVE|||||||
33825961|NCT02811393|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825962|NCT01755247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825963|NCT05203224|NA|SINGLE_GROUP||TREATMENT||NONE|No blinding given single arm study but Independent core laboratory adjudication of the primary outcome, mRS (secondary outcome) performed by central assessor.|Bayesian Optimised Phase 2 dose-finding umbrella trial||||
33825964|NCT01263990|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33825965|NCT04897789|||OTHER||CROSS_SECTIONAL|||||||
33825966|NCT00219869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33825967|NCT05085808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only unmasked participant will be the pharmacist (who is not part of the study) who will be preparing and packaging the 3 different study medications. The intensivist, ICU RN, patients, patient's family members/legal representative, and additional study personnel will be masked to the intervention.||t|t|t|t
33825968|NCT00930735|||COHORT||PROSPECTIVE|||||||
33825969|NCT05762471|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind study in which the GSBR-1290 and the matching placebo are matching in appearance||t|t|t|f
33825970|NCT05297253|||OTHER||OTHER|||||||
33825971|NCT02143063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825972|NCT05291897|||CASE_ONLY||PROSPECTIVE|||||||
33825973|NCT04210804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|One month placebo run in prior to randomisation||t|f|t|f
33825974|NCT02303847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33825975|NCT01878136|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33825976|NCT03904875|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33825977|NCT02456675|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33825978|NCT05253911|||COHORT||PROSPECTIVE|||||||
33825979|NCT06008340|||CASE_CONTROL||PROSPECTIVE|||||||
33825980|NCT01319227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825981|NCT06230133|RANDOMIZED|PARALLEL||TREATMENT||NONE||Our study was designed as a controlled trial with a MBSR intervention and an control condition. Psychological data was assessed at baseline, at the end of the intervention, and one month later after the intervention, respectively.||||
33825982|NCT02485223|||COHORT||PROSPECTIVE|||||||
33825983|NCT00563745|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825984|NCT02801409|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33825985|NCT01268696|||CASE_CONTROL||PROSPECTIVE|||||||
33825986|NCT04935762|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-Blind|Two 14-day periods, 2-way crossover design|t|t|t|t
33825987|NCT02934893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33825988|NCT05770908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators involved in the recruitment, and data analysis will be masked of participant's allocation group.||f|f|t|f
33825989|NCT01620307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825990|NCT01613807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825991|NCT01388478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33825992|NCT04809168|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33825993|NCT01797133|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33825994|NCT03028012|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33825995|NCT03462914|||COHORT||PROSPECTIVE|||||||
33825996|NCT00891189|||CASE_CONTROL||PROSPECTIVE|||||||
34131910|NCT04400916|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34131911|NCT00128024|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131912|NCT01601756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34131913|NCT02942836|||COHORT||RETROSPECTIVE|||||||
34149401|NCT04093804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a randomized trial consisting of female patients undergoing reverse shoulder arthroplasty for rotator cuff tear arthropathy or a massive irreparable rotator cuff tear. The experimental group will receive a 36mm glenosphere and the control group will receive the standard 32mm glenosphere. All other conditions of the surgical procedure will be identical as well as the clinical follow-up.|t|f|f|t
34149402|NCT04225819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33825997|NCT00598286|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33825998|NCT04751461|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33825999|NCT02054598|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33826000|NCT04018547|||CASE_ONLY||RETROSPECTIVE|||||||
33826001|NCT00153556|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33826002|NCT04017949|||CASE_CONTROL||PROSPECTIVE|||||||
33826003|NCT05925114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826004|NCT06304597|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826005|NCT02945007|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826006|NCT06043453|||COHORT||PROSPECTIVE|||||||
33826007|NCT04725097|||COHORT||PROSPECTIVE|||||||
33826008|NCT05233761|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33826009|NCT00799747|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
33826010|NCT03835130|||COHORT||OTHER|||||||
33826011|NCT02003378|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33826012|NCT03391583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will be randomized via block randomization. An outcome assessor will have sealed envelopes that will assign the patients to either the intervention group versus the current standard of care. There will be three intervention time points 0, 6 and 12 weeks from the patient's initial presentation at the St. Michael's head injury clinic.|Randomized Control Feasibility trial looking at educational intervention at multiple time points during a patient's recovery from mild traumatic brain injury. The control group will be followed at these time points as well and will continue on with the current standard of care.|f|f|f|t
33826013|NCT00198198|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826014|NCT03670199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826015|NCT05240547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826016|NCT06112522|NA|SINGLE_GROUP||TREATMENT||NONE||Single-Arm, Open-Label, Single Center||||
33826017|NCT04171921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826018|NCT01370018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826019|NCT03163836|||COHORT||RETROSPECTIVE|||||||
33826020|NCT06013306|||CASE_ONLY||PROSPECTIVE|||||||
33826021|NCT01349036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826022|NCT00159341|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33826023|NCT00387907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826024|NCT06117202|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826025|NCT02081118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826026|NCT06045325|||CASE_CONTROL||PROSPECTIVE|||||||
33826027|NCT02251197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33826028|NCT05324007|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33826029|NCT00631397|||CASE_ONLY||PROSPECTIVE|||||||
33826030|NCT06184555|||COHORT||RETROSPECTIVE|||||||
33826031|NCT01520844|NA|SINGLE_GROUP||OTHER||NONE||||||
33826032|NCT05943210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This is a molecular characterization trial (MCT) of 25 consecutively treated rectal cancers with short-course radiotherapy (scRT; 25Gy/5 fractions). Tissue and imaging will be collected at three time-points: 1. Baseline (day -28 to 0) - pelvic MRI and CT, research biopsy, blood (50ml), stool. 2. After 5 RT fractions (day 5-10) - CT, research biopsy, blood (50ml), stool 3. At time of surgery (wk 6) - MRI and CT, surgical tumor and nodal specimens, blood (50ml), stool.||||
33826033|NCT02025361|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33826034|NCT06188858|||COHORT||RETROSPECTIVE|||||||
33826035|NCT06477250|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking will be used since both participants and staff need to be aware which condition the participant belongs to in order to be able to attain and provide the appropriate training and practice prior to starting the actual interventions.|||||
33826036|NCT02671578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826037|NCT02650934|||COHORT||PROSPECTIVE|||||||
33826038|NCT02856061|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826039|NCT05362513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826040|NCT01068223|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33826041|NCT00819013|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33826042|NCT02660112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826043|NCT01176435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826044|NCT05217290|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826045|NCT02122549|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826046|NCT01746108|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826047|NCT03853642|||COHORT||PROSPECTIVE|||||||
33826048|NCT00508534|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826049|NCT03819842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826050|NCT01319578|NON_RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33826051|NCT02262065|||CASE_CONTROL||RETROSPECTIVE|||||||
33826052|NCT01820637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826053|NCT00691847|||COHORT||PROSPECTIVE|||||||
33826054|NCT00248079|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826055|NCT02945371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33826056|NCT01482507|||COHORT||PROSPECTIVE|||||||
33826057|NCT03238443|||COHORT||PROSPECTIVE|||||||
33826058|NCT06413017|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826059|NCT04714788|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826060|NCT02199249|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826061|NCT05230095|||CASE_CONTROL||PROSPECTIVE|||||||
34131914|NCT04772352|RANDOMIZED|PARALLEL||TREATMENT||NONE||A total of 200 subjects are enrolled in this study. After the initial screening, the subjects were randomly divided into the control group and the drug treatment group. The control group was given lifestyle intervention at 0-24 weeks, and the experimental group was given febuxostat oral therapy on the basis of lifestyle intervention. If the results showed that the reduction of liver fat content of subjects in the lifestyle intervention combined with febuxostat treatment group was significantly better than that in the lifestyle intervention group alone, the original intervention was continued in the drug treatment group, and the control group was given febuxostat orally on the basis of the lifestyle intervention at 24-48 weeks.||||
34131915|NCT02279368|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34131916|NCT05911360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131917|NCT02062229|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34131918|NCT01110525|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34131919|NCT02739386|||COHORT||RETROSPECTIVE|||||||
34131920|NCT06097078|||COHORT||PROSPECTIVE|||||||
34131921|NCT01140867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131922|NCT06233162|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34131923|NCT01832493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131924|NCT06566170|||COHORT||PROSPECTIVE|||||||
34131925|NCT00416494|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131926|NCT04554693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34131927|NCT03358875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131928|NCT00442494|RANDOMIZED|PARALLEL||||NONE||||||
34131929|NCT05322811|||OTHER||RETROSPECTIVE|||||||
34131930|NCT01144169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131931|NCT02499913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131932|NCT00046293||||TREATMENT||||||||
34131933|NCT04982341|||COHORT||PROSPECTIVE|||||||
34131934|NCT00617097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131935|NCT06187766|||COHORT||PROSPECTIVE|||||||
34131936|NCT04904406|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized controlled open-label superiority trial||||
34131937|NCT03138460|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34131938|NCT04803292|||COHORT||RETROSPECTIVE|||||||
34131939|NCT04769271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131940|NCT00998452|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131941|NCT05442372|||CASE_ONLY||CROSS_SECTIONAL|||||||
34131942|NCT00431444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131943|NCT01338519|||COHORT||PROSPECTIVE|||||||
34131944|NCT01775163|||COHORT||PROSPECTIVE|||||||
34131945|NCT01766804|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization was computer based in blocks of eight to ensure an equal number of participants in each randomization group. The randomization scheme was generated by using the web site Randomization.com ⟨http://www.randomization.com⟩. The randomization center was located at the same hospital as one of the recruitment sites (OUH). The randomization list was sent directly and exclusively to the research secretariat in charge of treatment allocation. Bovine colostrum or the placebo supplement was provided in identical foil sachets differing only in randomization code. Participants, their treating physicians, and any individual involved in the coordination and implementation of the trial were masked to treatment allocation.||t|t|t|t
34131946|NCT06463743|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131947|NCT02088879|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34131948|NCT00512850|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34131949|NCT03072394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34131950|NCT04589234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Design and Investigational Plan: Open-label, phase II, two arm, interventional, prospective, non-randomized multiple dose study in unresectable, metastatic pancreatic cancer patients 18 years of age or older~Subject Number: 60 (30 per arm)~Study Duration: 24 months per patient or when the patient ceases to be administered chemotherapy; whichever comes first"||||
34131951|NCT01553682|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34131952|NCT06659601|||COHORT||RETROSPECTIVE|||||||
34131953|NCT04683146|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The samples will be sent to the laboratory with numbers|Crossover Assignment Crossover design is used|f|f|f|t
34131954|NCT03400865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131955|NCT03581149|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34131956|NCT05306834|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34131957|NCT02859727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131958|NCT00211354|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131959|NCT00171457|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34131960|NCT01332591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131961|NCT06552936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33826062|NCT03630523|NA|SINGLE_GROUP||OTHER||NONE||||||
33826063|NCT01579110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826064|NCT02852811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131962|NCT04367155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|randomization|tranexamic acid during and after percutanous nephrolithotomy procedure|f|t|f|t
34131963|NCT06388148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131964|NCT02950155|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34131965|NCT00913887|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131966|NCT00284505|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34131967|NCT06661499|||OTHER||PROSPECTIVE|||||||
34131968|NCT06412835|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34131969|NCT01132950|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131970|NCT02026674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131971|NCT05611255|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double blind||t|t|f|f
34131972|NCT06659484|||COHORT||RETROSPECTIVE|||||||
34131973|NCT00837421|||COHORT||PROSPECTIVE|||||||
34131974|NCT00929435|||CASE_ONLY||PROSPECTIVE|||||||
34131975|NCT01918891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131976|NCT00708591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131977|NCT06348251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131978|NCT01067118|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34131979|NCT02333825|RANDOMIZED|PARALLEL||TREATMENT||||||||
34131980|NCT03171519|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34131981|NCT01765036|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131982|NCT06134648|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"Sentinel, Main, and Booster Cohorts: observer-blind; for safety evaluation purposes, the Sponsor will be unblinded~* Investigators, laboratory personnel, and participants will be blinded~* Sponsor study staff and study staff preparing/administering the study interventions will be unblinded"|Dose-escalation (Phase I, sentinel cohort), parallel (Phase IIa, main cohort), multi-center|t|t|t|t
34131983|NCT00203736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34131984|NCT06421519|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|During the study the infant and their parents will not be aware of which pressures they are on. Due to the nature of the study it is not possible to blind the care provider who in this case is the investigator since they need to manipulate the ventilator settings. However, data analysis with be done using anonymous data and the investigator will be blinded to which pressure settings were used.|Infants receive receive three upper pressures of BiPAP: 7, 10 or 13cmH2O for a period of 20 minutes each. Additionally, there will be a control period of 20 minutes between each upper pressure with a baseline pressure constant of 5cmH2O. The order in which they receive the levels of respiratory support will be randomised using an excel random number generator. This allows each infant to be used as their own control, minimising the impact of any underlying confounding factors. The results on each pressure setting will be meaned and compared to each other|t|f|f|t
34131985|NCT04474535|||COHORT||CROSS_SECTIONAL|||||||
34131986|NCT00234715|||COHORT||CROSS_SECTIONAL|||||||
34131987|NCT05913713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34131988|NCT06112080|||COHORT||PROSPECTIVE|||||||
34131989|NCT03332173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131990|NCT04539964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, investigators, joint evaluators and study staff will be blinded. Blinding of subjects, joint evaluators and investigators will be assessed at Weeks 4 and 12.|An operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter study. Subjects will be assigned randomly in a 1:1 ratio into either a treatment or control group. Subjects assigned to the treatment group will receive active stimulation for 1 min once per day, and those assigned to the control group will receive non-active stimulation for 1 min once per day.|t|t|t|t
34131991|NCT04723355|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34131992|NCT03076216|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34131993|NCT06662305|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into an ACTIVE group or CONTROL group.||||
34131994|NCT04870463|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized clinical trial of two parallel arms, that analysed the possible superiority of one treatment compared to the gold standard of reference|t|t|f|t
34131995|NCT01099748|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34131996|NCT04207411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The dentist will prepare the product in another room, so the patient will not know the type of product used.|bupivacaine or lidocaine randomized treatment.|t|f|f|t
34131997|NCT01278238|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34131998|NCT03652766|NA|SINGLE_GROUP||OTHER||NONE||Single group feasibility and acceptability trial||||
34131999|NCT00479128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132000|NCT02249091|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In the initial protocol, 25 patients are included in the clinical trial on the schedule described as cohort 1. After an amendment 15 further patients are included on the schedule described as cohort 2.||||
34132001|NCT04869059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, assessors, and technicians interacting with participants will be blind to assigned conditions.|"Participants will be randomly assigned to 1 of 2 treatment arms: (1) 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to presupplementary motor area for 20 minutes over 15 sessions to (2) sham tDCS following the same schedule.~Additionally, after completing the initial active or sham treatment and 3-month follow-up testing sessions, selected participants will be invited back for newly assigned treatment conditions, 20 minutes over 15 sessions and will be and re-evaluated at 2- and 3-months follow-up testing sessions."|t|t|f|t
34132002|NCT03053440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132003|NCT06395896|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The statistical evaluation will be performed by a person other than the researchers and the experimental and control groups will be anonymized.|There are two groups: experimental group and control group.|f|f|f|t
34132004|NCT05844111|NA|SINGLE_GROUP||OTHER||NONE||||||
34132005|NCT06660095|||CASE_ONLY||PROSPECTIVE|||||||
34132006|NCT02665663|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34132007|NCT01484483|||COHORT||PROSPECTIVE|||||||
34132008|NCT02308163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132009|NCT01504516|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132010|NCT03533816|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This dose escalation study will be conducted in two phases. The first phase will have three cohorts with three recipient/donor pairs at different dose levels for each cohort. The second phase is an expansion cohort at the maximum tolerated dose determined in the first phase.||||
34132011|NCT03465579|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132012|NCT03758131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132013|NCT06547697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132014|NCT06277947|NA|SINGLE_GROUP||TREATMENT||NONE||Patients would receive C-HIPEC in the general ward after interval debulking surgery in 24 hours.||||
34132015|NCT06373354|||CASE_ONLY||PROSPECTIVE|||||||
34132016|NCT00904670|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33826065|NCT02105727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826066|NCT03413540|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826067|NCT00649142|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826068|NCT01680302|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33826069|NCT02315079|||COHORT||PROSPECTIVE|||||||
33826070|NCT04301700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single (Outcomes Assessor)|Parallel Assignment|t|f|f|f
33826071|NCT04145323||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33826072|NCT01625949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826073|NCT00221702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132017|NCT02889497|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34132018|NCT03515122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34132019|NCT02945358|||COHORT||CROSS_SECTIONAL|||||||
34132020|NCT04616313|||COHORT||PROSPECTIVE|||||||
34132021|NCT05785286|||OTHER||PROSPECTIVE|||||||
34132022|NCT01271907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132023|NCT00601692|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132024|NCT06342492|||COHORT||RETROSPECTIVE|||||||
34132025|NCT05040165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132026|NCT01576939|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132027|NCT04878510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To minimize performance and ascertainment biases, and maintain blinding of patients, investigators, clinical staff, and research coordinators; a Research Pharmacist, who is not involved in assessment of patient outcomes or patient care, will prepare infusion bags|The inDEX trial is a pragmatic, international, multi-centered, stratified, randomized, parallel-group, double-blind, placebo-controlled vanguard trial.|t|t|t|t
34132028|NCT05036655|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Non-random stepped wedge||||
34132029|NCT01449396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132030|NCT03969745|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants monitored for a one week baseline period before being allocated to either a caloric deficit group or a time-restricted feeding group for two weeks.||||
34132031|NCT04904744|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34132032|NCT04017780|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Analysis of respiratory tracings will be blinded to the type of respiratory support.||f|f|f|t
34132033|NCT02657694|||COHORT||PROSPECTIVE|||||||
34132034|NCT05287958|||COHORT||PROSPECTIVE|||||||
34132035|NCT02364245|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34132036|NCT05395650|||CASE_CONTROL||RETROSPECTIVE|||||||
34132037|NCT03652363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132038|NCT05069597|NA|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34132039|NCT01582516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132040|NCT00769171|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34132041|NCT00079261|RANDOMIZED|||TREATMENT||NONE||||||
34132042|NCT01202916|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34132043|NCT05267470|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132044|NCT04654221|||COHORT||PROSPECTIVE|||||||
34132045|NCT02485639|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132046|NCT03491813|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34132047|NCT02403934|||COHORT||PROSPECTIVE|||||||
34132048|NCT01016119|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132049|NCT02836717|||COHORT||RETROSPECTIVE|||||||
34132050|NCT05327075|||OTHER||CROSS_SECTIONAL|||||||
34132051|NCT05941208|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132052|NCT01088204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132053|NCT04166591|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34132054|NCT02515799|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34132055|NCT02242214|||COHORT||PROSPECTIVE|||||||
34132056|NCT02764359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132057|NCT01175876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34132058|NCT06404021|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132059|NCT01638013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132060|NCT01404559|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34132061|NCT04248244|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132062|NCT02649959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132063|NCT05582395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132064|NCT02972606|||CASE_ONLY||CROSS_SECTIONAL|||||||
34132065|NCT04193449|||OTHER||RETROSPECTIVE|||||||
34132066|NCT01170832|||COHORT||PROSPECTIVE|||||||
34132067|NCT02792309|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132068|NCT02982772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132069|NCT00001335||||TREATMENT||||||||
34132070|NCT02661386|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132071|NCT01195519|||CASE_ONLY||PROSPECTIVE|||||||
34132072|NCT00412958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132073|NCT01887613|||CASE_ONLY||PROSPECTIVE|||||||
34132074|NCT00869492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132075|NCT01892150|NA|SINGLE_GROUP||||TRIPLE|||t|f|t|t
34132076|NCT05425498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132077|NCT05546658|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open-label, wait-list control, cross-over study||||
34132078|NCT06166342|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34132079|NCT04142580|||COHORT||PROSPECTIVE|||||||
34132080|NCT00000401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132081|NCT01292980|||COHORT||PROSPECTIVE|||||||
33826074|NCT02928809|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33826075|NCT03932422|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826076|NCT02189577|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33826077|NCT00496834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826078|NCT04772313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826079|NCT04529811|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34132082|NCT05360693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132083|NCT02923830|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132084|NCT04379687|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132085|NCT06540703|NA|SINGLE_GROUP||TREATMENT||NONE||therapeutic ketogenic diet for 14 weeks||||
34132086|NCT05724862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132087|NCT06537765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34132088|NCT06365437|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34132089|NCT00232284|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34132090|NCT01703052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132091|NCT04607434|||COHORT||PROSPECTIVE|||||||
34132092|NCT05304975|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34132093|NCT02642393|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34132094|NCT02019615|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34132095|NCT02797301|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34132096|NCT01157572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132097|NCT06657898|||CASE_CONTROL||RETROSPECTIVE|||||||
34132098|NCT02476032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132099|NCT05051670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132100|NCT05502718|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with cervical dystonia who received botulinum toxin type A injection will be divided into study group and control group.The patients in the study group will be given stretching, strengthening, breathing and rhythmic coordination exercises for the muscles involved. (Personalized exercise program) In the control group, only breathing and rhythmic coordination exercises will be given and the two groups will be compared.||||
34132101|NCT02810769|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34132102|NCT04812769|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Two participating nursing homes will be assigned to the intervention. One participating nursing home will serve as a control.||||
34132103|NCT03462927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132104|NCT03796390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132105|NCT02374281|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34132106|NCT01534585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132107|NCT03982784|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34132108|NCT05936619|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34132109|NCT06661460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132110|NCT04748679|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132111|NCT06631469|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single-blinded parallel study|Parallel randomized controlled trial|t|f|f|f
34132112|NCT05029128|NA|SINGLE_GROUP||OTHER||NONE||"All participants will undergo the same exercise intervention for this proof-of-concept project, so there is no randomization. The exercise will be treadmill walking at 70-80% of HRmax for 60 min/d, 4 d/wk, for 4 wk. The mode and intensity of exercise were selected because high-intensity weight-bearing exercise is recommended for bone health, and walking is the most common weight-bearing activity. Although high-intensity exercise for bone health refers to the intensity of bone-loading forces, %HRmax is a good proxy because peak bone-loading forces increase as walking or running speed increases. Exercise sessions will be supervised by the research team.~This exercise prescription was used in the studies of young and older adults that provided the scientific premise for the current study and resulted in robust PTH and CTX responses."||||
34132113|NCT00863044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132114|NCT04797273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132115|NCT06521385|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34132116|NCT05363501|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34132117|NCT04802031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132118|NCT04631198|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||"This is a pilot randomized clinical trial. The randomization technique for proposed proposals will be performed using a computer program (www.random.org) containing the coded distribution. The allocation confidentiality will be guaranteed by a randomization list that will be in a remote place, which will prevent the researcher from identifying which intervention will be specified by each patient. The generation of the sequence of numbers will be performed by a researcher blind to the study, after selection of the patients by the inclusion criteria. The sequence of numbers one used for randomization will be kept confidential until the exact moment of the beginning of the study. The randomization of the subjects in the proposed groups will be done in two blocks, in which the program will randomly distribute each new participant to one of the blocks: conventional physical therapy group and thoracoabdominal rebalancing group."|t|f|f|f
34132119|NCT01312805|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34132120|NCT05469425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132121|NCT01101282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132122|NCT05648344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34132123|NCT06264986|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Double-blind, placebo-controlled, randomised trial|t|f|t|f
34132124|NCT00432328|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34132125|NCT02038972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132126|NCT06661655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Cross sectional investigation||||
34132127|NCT06454279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132128|NCT06238336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132129|NCT00325260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34132130|NCT04662775|RANDOMIZED|PARALLEL||TREATMENT||NONE||Block randomisation with country-level stratification was used using Microsoft Excel to allocate the participants on entry (1:1 ratio to groups)||||
34132131|NCT04491682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132132|NCT06009991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132133|NCT06244407|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34132134|NCT03162744|||CASE_ONLY||CROSS_SECTIONAL|||||||
34132135|NCT05563311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132136|NCT04041544|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|In each dose panel in this study, eight healthy subjects will be randomized in a 6:2 ratio to receive XNW3009 or placebo in SAD and MAD.|In total there are planned to be 2 parts to the study. Part A will look at the effects of a single dose of the study drug and Part B will look at the effects of multiple doses of the study drug.|t|f|t|f
34132137|NCT01707680|||COHORT||RETROSPECTIVE|||||||
34132138|NCT06659250|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34132139|NCT00351767|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132140|NCT01309997|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132141|NCT06280768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132142|NCT03528122|NA|SINGLE_GROUP||TREATMENT||NONE||Individuals with recurrent macular hole associated retinal detachment||||
34132143|NCT04679506|||CASE_ONLY||PROSPECTIVE|||||||
34132144|NCT06291012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The randomization will be carried out by minimization with stratification on the investigating center and age (\< 1 year and ≥ 1 year)|f|t|f|f
34132145|NCT02371577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132146|NCT03984890|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34132147|NCT01905943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132148|NCT01206920|||COHORT||PROSPECTIVE|||||||
34132149|NCT05487677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physician performing the ultrasound evaluation will be blinded to which treatment arm.|Patients undergoing reverse shoulder arthroplasty will be recruited, consented, \& enrolled. Patient will be randomized to standard repair with sutures versus standard repair with BioBrace augmentation of the repair.|t|f|f|t
34132150|NCT05895877|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132151|NCT03800524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132152|NCT05927519|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|the participant and the outcome assessor will not know which device was used in this trail|Airtraq video laryngoscope will be used in morbid obese and non obese patients|t|f|f|t
34132153|NCT00438360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132154|NCT05659043|||COHORT||PROSPECTIVE|||||||
34132155|NCT06660862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132156|NCT02110654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"There are two study groups listed as below.~1. Montelukast 10mg once daily + Mometasone furoate nasal spray 100 µg/per nostril once daily for 6 months.~2. Mometasone furoate nasal spray 100 µg/per nostril once daily for 6 months."|f|f|f|t
34132157|NCT05657080|||CASE_CONTROL||PROSPECTIVE|||||||
34132158|NCT05112770|||COHORT||RETROSPECTIVE|||||||
34132159|NCT00698438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132160|NCT04923737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132161|NCT04293224|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34132162|NCT04973202|||COHORT||RETROSPECTIVE|||||||
34132163|NCT03205358|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132164|NCT01421238|RANDOMIZED|PARALLEL||||NONE||||||
34132165|NCT06657599|||CASE_ONLY||PROSPECTIVE|||||||
34132166|NCT06331156|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132167|NCT02058316|||COHORT||PROSPECTIVE|||||||
34132168|NCT01026090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132169|NCT03245242|||CASE_ONLY||PROSPECTIVE|||||||
34132170|NCT05366088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132171|NCT05483699|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34132172|NCT00003420|RANDOMIZED|||DIAGNOSTIC||||||||
34132173|NCT02115724|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132174|NCT00705497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132175|NCT04110691|||COHORT||PROSPECTIVE|||||||
34132176|NCT00883168|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132177|NCT04432649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132178|NCT04887168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||non-randomised control trial||||
34132179|NCT06489184|||COHORT||RETROSPECTIVE|||||||
34132180|NCT06262048|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||single centre, double blind randomized controlled trial|t|t|t|f
34132181|NCT01230996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132182|NCT03287882|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Some investigators are blinded to the allocation of the intervention, and all study data collectors are blinded.||f|f|t|t
34132183|NCT05308407|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132184|NCT06335537|RANDOMIZED|CROSSOVER||TREATMENT||NONE|This is an unblinded study.|"The following study will be a randomized cross-over trial evaluating the effects of baking soda and Urocit-K on 24-hour urinary parameters in hypocitrituric calcium oxalate and uric acid stone formers. All participants that consent to participate in the study will undergo the same tests.~Participants will begin a 2-week washout period of Urocit-K as their standard of care. After completion of the washout period subjects will be randomized to take either Urocit-K or Baking Soda for 4 weeks. After participants undergo a secondary 2-week washout period, then they are assigned to medication not taken in the first study period for 4 weeks."||||
34132185|NCT03032211|NA|SINGLE_GROUP||TREATMENT||NONE||• Prospective, non-randomized, open label, single-arm study to evaluate the safety and feasibility of the use of the alfapump® system in New York Heart Association (NYHA) Class III and ambulatory NYHA Class IV heart failure patients with a history of at least one hospitalization for fluid management within the previous year.||||
34132186|NCT03085459|||COHORT||RETROSPECTIVE|||||||
34132187|NCT06531187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34132188|NCT04176874|||COHORT||PROSPECTIVE|||||||
34132189|NCT03160248|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132190|NCT05314543|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective multi-center exploratory pilot study of physiology study on athletes, track cyclists or rowers national to international level competitors.||||
34132191|NCT01388049|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34132192|NCT00253513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132193|NCT01258790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132194|NCT04166578|||CASE_CONTROL||PROSPECTIVE|||||||
34132195|NCT06661356|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding will not be possible for participants, peer lay workers, and health providers, but the data management and analysis teams will be blinded to the study arm.||f|f|f|t
33826080|NCT02287883|||COHORT||PROSPECTIVE|||||||
33826081|NCT03134261|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||"Study participants will be allocated to the ongoing project arm at the time of enrollment."||||
33826082|NCT06647199|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826083|NCT06647056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132196|NCT06660160|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132197|NCT03465137|RANDOMIZED|PARALLEL||TREATMENT||NONE||Immediate therapy versus waitlist arms||||
34132198|NCT00346658|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34132199|NCT01939977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132200|NCT04497363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132201|NCT06273735|||COHORT||PROSPECTIVE|||||||
34149403|NCT05369481|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34149404|NCT04797806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149405|NCT00487474|||COHORT||PROSPECTIVE|||||||
34132202|NCT04749888|RANDOMIZED|PARALLEL||PREVENTION||NONE|The research management staff, home visit nurses (intervention teams), and study participants will be aware of the allocation results. However, the research nurses making outcome assessments will be blinded to the randomization, and families will be asked not to disclose their group status during the surveys. The research nurses (outcome assessors) will only be notified of the survey schedules (6 weeks, 6 months, 12 months, and 24 months) of both groups so that the outcome indicators can be measured with blinding maintained. Statistical analysts will not be able to access the randomization variable until all 2 years of data are collected.|||||
34132203|NCT02323126|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132204|NCT05148936|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster Randomized Trial||||
34132205|NCT05891080|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132206|NCT02274935|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34132207|NCT04409561|||COHORT||PROSPECTIVE|||||||
34132208|NCT06147128|||COHORT||PROSPECTIVE|||||||
34132209|NCT01019122|||COHORT||PROSPECTIVE|||||||
34132210|NCT05665335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132211|NCT01894048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132212|NCT06657820|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Subject will undergo a graduated desaturation protocol beginning at 100%, then 99%, then descending in 3% increments to a final target of 66%. Arterial and venous jugular bulb co-oximetry measurements will be taken at each saturation plateau yielding a total of 13 paired samples per subject. The weighted average of the SaO2 and the SvO2 will be compared against the Cyban Cerebral Oximeter.||||
34132213|NCT06660485|||COHORT||PROSPECTIVE|||||||
34132214|NCT02303756|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132215|NCT01324050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132216|NCT02088840|||CASE_ONLY||PROSPECTIVE|||||||
34132217|NCT04929223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132218|NCT00472407|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34132219|NCT02032758|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132220|NCT05657249|NA|SINGLE_GROUP||SCREENING||NONE||||||
34132221|NCT01334216|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34132222|NCT02580032|||COHORT||PROSPECTIVE|||||||
34132223|NCT04873141|||CASE_ONLY||PROSPECTIVE|||||||
34132224|NCT04979793|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34132225|NCT00815568|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132226|NCT03834337|||COHORT||PROSPECTIVE|||||||
34132227|NCT06657885|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132228|NCT05092997|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132229|NCT01604525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132230|NCT01244230|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132231|NCT02263196|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34132232|NCT05182658|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34132233|NCT05273814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132234|NCT05266508|||CASE_CROSSOVER||PROSPECTIVE|||||||
34132235|NCT03216343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132236|NCT00851292|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34132237|NCT04222699|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34132238|NCT00136695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132239|NCT04601532|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group).||||
34132240|NCT02020434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132241|NCT05749991|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants, care providers and the principle supervisor were not blinded since they know which isolation technique was used during the placement of sealant. But the outcome assessor was blinded and he assessed the sealants placement after 6, 12, and 18 months.|All eligible study participants were randomised using simple block random allocation to ensure balanced randomization for each isolation system. Each participant was given an envelope and a printed participant number. Each number identified the isolation technique used for sealant placement and the isolation application sequence to be used.|f|f|f|t
34132242|NCT04726930|||OTHER||PROSPECTIVE|||||||
34132243|NCT06635434|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34132244|NCT05965869|NA|SINGLE_GROUP||OTHER||NONE||||||
34132245|NCT02752633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132246|NCT06659367|||COHORT||PROSPECTIVE|||||||
33826084|NCT04851171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826085|NCT02072278|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33826086|NCT00065819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132247|NCT01260688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132248|NCT00952328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132249|NCT05047302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132250|NCT05126511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132251|NCT04662190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132252|NCT03474913|||CASE_ONLY||PROSPECTIVE|||||||
34132253|NCT01951586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132254|NCT05297786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34132255|NCT05748262|||COHORT||RETROSPECTIVE|||||||
34132256|NCT03832322|||COHORT||PROSPECTIVE|||||||
34132257|NCT06311955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132258|NCT06659185|RANDOMIZED|CROSSOVER||TREATMENT||NONE||a double-blind crossover study||||
34132259|NCT05171374|||COHORT||PROSPECTIVE|||||||
34132260|NCT02024425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132261|NCT06049095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132262|NCT06292195|||COHORT||PROSPECTIVE|||||||
34132263|NCT04960748|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled trial of parallel groups||||
34149406|NCT00471887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149407|NCT04356482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132264|NCT05755932|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|This study is double blinded with regard to treatment (MDI administered with 2 different propellants \[Treatment A or B\]), ie, the sponsor, the investigator, all clinical staff involved in the clinical study, the participants, and the study monitor will remain blinded, unless safety concerns or a regulatory requirement necessitate unblinding.|"A randomized, double-blind, multi-site, two-way crossover study to assess the effect on MCC and safety of HFO propellant compared to HFA propellant in healthy participants. Mucociliary clearance will be determined after 1 week of twice daily (BID) administration of HFO MDI (test) and HFA MDI (reference). Study treatment will be administered via MDI device as 6 inhalations BID Participants will receive treatments in 1 of 2 possible treatment sequences: A followed by B, or B followed by A.~* Treatment A: HFO MDI - test formulation~* Treatment B: HFA MDI - reference formulation The study will comprise~* A Screening Period 7 to 14 days prior to first dosing;~* Two Treatment Periods (TPs) of 7 days each, a 7 to 14 day Washout Period between the 2 TPs; and~* A final safety Follow-up Visit"|t|t|t|t
34132265|NCT04599803|NA|SINGLE_GROUP||OTHER||NONE||||||
34132266|NCT02552745|||COHORT||PROSPECTIVE|||||||
34132267|NCT00113633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132268|NCT05788419|||CASE_ONLY||PROSPECTIVE|||||||
34132269|NCT05033587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132270|NCT04431843|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34132271|NCT01308814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132272|NCT06071793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132273|NCT03248531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132274|NCT00392834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132275|NCT05365997|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Each clinician pod will be randomized in a 1:1 fashion to either intervention or usual care.|f|f|t|f
34132276|NCT02516982|||OTHER||PROSPECTIVE|||||||
34132277|NCT00068263||||TREATMENT||NONE||||||
34132278|NCT02400606|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34132279|NCT05489354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The research assistants who assess outcome data, data entry and analysis will be blinded to avoid the risk of assessor bias. The assistants will not participate in any other stage of implementing the program|Parallel Assignment|f|f|f|t
34132280|NCT01376622|||CASE_ONLY||PROSPECTIVE|||||||
34132281|NCT05596461|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132282|NCT05289492|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132283|NCT06192472|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34132284|NCT03540706|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132285|NCT02661737|||OTHER||PROSPECTIVE|||||||
34132286|NCT00610857|NA|SINGLE_GROUP||OTHER||NONE||||||
34132287|NCT00559104|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132288|NCT06040385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"For group (I):~For each patient, two final impressions will be made a) Final impression will be done by conventional one-step impression technique.For the same patient, another final impression using unmodified scan bodies will be done by direct intraoral scan technique.~For group (II):~For each patient, two final impressions will be made~a) Final impression will be done by conventional one-step impression technique.For the same patient another final impression using subtractive modified scan bodies will be done by direct intraoral scan technique.~Conventional impression for both groups will be poured into stone cast with multiunit abutments analogues, then scanned to be as a reference file for each patient."|t|f|f|f
34132289|NCT03082911|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34132290|NCT04975984|||COHORT||RETROSPECTIVE|||||||
34132291|NCT01393483|||COHORT||PROSPECTIVE|||||||
34132292|NCT05655533|||OTHER||CROSS_SECTIONAL|||||||
34132293|NCT01762384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132294|NCT04469387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132295|NCT01465867|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34132296|NCT01022710|||CASE_ONLY||CROSS_SECTIONAL|||||||
34132297|NCT03092999|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132298|NCT00277810|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34132299|NCT06012084|NA|SINGLE_GROUP||PREVENTION||NONE||Single-case experimental design (SCED), across-participant AB design. Randomized phase-order will be used in that the start point of the intervention phase will be randomized across participants.||||
34132300|NCT05625516|||COHORT||PROSPECTIVE|||||||
34132301|NCT03550443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized double-blinded part followed by open label extension part.|t|f|t|f
34132302|NCT04637776|||COHORT||PROSPECTIVE|||||||
34132303|NCT00758368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132304|NCT03143153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132305|NCT05088915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This study will utilize a hybrid effectiveness-implementation approach to conduct a randomized pilot feasibility trial of the PCIP screening and intervention protocol in adolescent primary care with two treatment arms:~1. PCIP delivered through telehealth (computer or smartphone delivered videocall)~2. Treatment as usual (TAU)"|f|f|f|t
34132306|NCT01282242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132307|NCT02222688|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132308|NCT00789152|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34132309|NCT00405392|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132310|NCT04004338|||COHORT||PROSPECTIVE|||||||
34132311|NCT00933608|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34132312|NCT00600106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132313|NCT00224120|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132314|NCT06419959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo (i.e., sham intervention) controlled parallel proof-of-concept study|t|t|t|t
34132315|NCT06549504|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132316|NCT03753360|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective Parallel non-blinded randomized two arms, intervention group and active control group||||
34132317|NCT00319202|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132318|NCT03577041|||COHORT||PROSPECTIVE|||||||
33826087|NCT01172899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826088|NCT06353802|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826089|NCT03140878|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33826090|NCT01187147|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33826091|NCT01123642|||COHORT||PROSPECTIVE|||||||
33826092|NCT03291873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826093|NCT03065478|||COHORT||PROSPECTIVE|||||||
33826094|NCT02475018|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826095|NCT06406998|||COHORT||RETROSPECTIVE|||||||
33826096|NCT06437054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33826097|NCT00360750|NON_RANDOMIZED|||TREATMENT||NONE||||||
33826098|NCT01623414|||COHORT||PROSPECTIVE|||||||
33826099|NCT03120299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826100|NCT05470361|||CASE_ONLY||PROSPECTIVE|||||||
33826101|NCT06442293|RANDOMIZED|PARALLEL||OTHER||SINGLE||single blind, placebo controlled|t|f|f|f
33826102|NCT02041221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826103|NCT04766047|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33826104|NCT06094335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Study and control groups|f|f|f|t
33826105|NCT05255198|||COHORT||PROSPECTIVE|||||||
33826106|NCT02723383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826107|NCT02555488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826108|NCT00064428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826109|NCT02187926|||COHORT||PROSPECTIVE|||||||
33826110|NCT02371330|||COHORT||PROSPECTIVE|||||||
33826111|NCT04116242|||COHORT||PROSPECTIVE|||||||
33826112|NCT03503162|NA|SINGLE_GROUP||SCREENING||NONE||||||
33826113|NCT01069887|||COHORT||PROSPECTIVE|||||||
33826114|NCT02413099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33826115|NCT04630470|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33826116|NCT03568305|||COHORT||RETROSPECTIVE|||||||
33826117|NCT02943642|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826118|NCT00816621|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826119|NCT00922441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826120|NCT01705145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826121|NCT01643564|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826122|NCT03092245|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33826123|NCT00277342|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33826124|NCT00110955|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826125|NCT03645005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33826126|NCT02546778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826127|NCT05764642|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33826128|NCT05431725|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33826129|NCT02591797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33826130|NCT03067610|NA|SINGLE_GROUP||TREATMENT||NONE||radiation therapy||||
33826131|NCT01502462|||COHORT||PROSPECTIVE|||||||
34132319|NCT06416878|NA|SINGLE_GROUP||TREATMENT||NONE||Consecutive patients presenting to neurosurgical department with acute cauda equina syndrome with autonomic dysfunction.||||
34132320|NCT02289911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132321|NCT06420349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826132|NCT06232317|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826133|NCT00037661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33826134|NCT01115283|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826135|NCT05964556|||CASE_ONLY||CROSS_SECTIONAL|||||||
33826136|NCT06647134|||COHORT||PROSPECTIVE|||||||
33826137|NCT02335398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826138|NCT00751205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33826139|NCT01472471|||||PROSPECTIVE|||||||
33826140|NCT00742898|NON_RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33826141|NCT04316221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This is a randomized controlled trial involving children ages \~6 to 12 months from communities in central Guatemala within Wuqu' Kawoq's catchment area individually randomized to either the intervention or control group.|f|f|t|f
33826142|NCT05127590|NA|SINGLE_GROUP||TREATMENT||NONE||RBN-2397 in combination with pembrolizumab||||
33826143|NCT01521689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826144|NCT05662683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|IT WILL BE APPLIED BY THE SAME HEALTH PERSONNEL WORKING AT THE KETEM CENTER After the women who meet the sample criteria of the study are determined and they accept to participate in the study, it will be determined which group the women are in from the list determined by randomization (determined from the www.randomizer.org site) according to the acceptance sequence number of the women.|Randomized controlled trial|t|t|f|f
33826145|NCT04006236|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33826146|NCT04208542|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both participants and anesthesia provider will not know which intervention applied. Another anesthesia provider who did not perform nerve block will follow and record to the study data.|2 groups of patients will be studied simultaneously. One group will have the intervention of the ESP block and IV PCA. The other group will have only IV PCA.|t|t|f|t
33826147|NCT01228305|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33826148|NCT00087477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826149|NCT04512898|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with IBS and have H. pylori||||
33826150|NCT01978236|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826151|NCT02955836|||CASE_ONLY||CROSS_SECTIONAL|||||||
34132322|NCT01422785|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34132323|NCT01114087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826152|NCT04770142|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||multi-center, open label, single arm, investigator initiated exploratory pilot study||||
33826153|NCT01251887|RANDOMIZED|PARALLEL||TREATMENT||||||||
33826154|NCT00132951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826155|NCT01806532|||CASE_ONLY||PROSPECTIVE|||||||
34132324|NCT01807169|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132325|NCT02833584|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826156|NCT02383927|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132326|NCT05703958|||COHORT||OTHER|||||||
34132327|NCT02764112|||OTHER||PROSPECTIVE|||||||
34132328|NCT06346431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132329|NCT04511143|||OTHER||OTHER|||||||
34132330|NCT02305589|||COHORT||RETROSPECTIVE|||||||
34132331|NCT00437957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132332|NCT04457791|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|participants are not informed about the content and focus of the personalized dietary advice|One group is followed over time (within person design)|t|f|f|f
34132333|NCT01191645|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34132334|NCT01846962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132335|NCT03013387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132336|NCT04667598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132337|NCT01318135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132338|NCT04580836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132339|NCT06661811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132340|NCT02295631|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826157|NCT02657759|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33826158|NCT04441996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826159|NCT05712655|||OTHER||CROSS_SECTIONAL|||||||
33826160|NCT00159549|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826161|NCT00866918|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826162|NCT01431105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826163|NCT04041661|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826164|NCT06089486|RANDOMIZED|PARALLEL||SCREENING||NONE||1:1 randomization to PET or ICA||||
33826165|NCT03821064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826166|NCT00812123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826167|NCT02681445|||COHORT||PROSPECTIVE|||||||
33826168|NCT04927338|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, care providers, investigators, study coordinators, and laboratory technicians will be masked to the participants' treatment group status. Placebo capsules will be identical in size, color, and shape to that of the Bacopa capsules.|This is a double-blinded, two-arm, placebo-controlled, randomized phase II study in 170 participants born between 1946 and 1978 who are Gulf War Veterans and meet the modified Kansas and Centers for Disease Control and Prevention (CDC) case definition for Gulf War Illness.|t|t|t|t
33826169|NCT02024477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826170|NCT01309113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826171|NCT00596258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826172|NCT00308399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33826173|NCT04072666|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Given the clear differences in interventions, participants and those administering the interventions will not be blinded. However, those analysing data and assessing the outcomes will be blinded to group assignment.|Randomisation will occur after recruitment. Participants will be randomised to either SPP, SPP alone + ASSIP or SPP + CBT. An intent-to-treat approach will be used and all participants randomly assigned to treatment groups using the ralloc command of Stata, which will employ block randomisation.|f|f|t|t
33826174|NCT05087667|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded study. The patient will be blinded from the randomization arm. As the procedure is performed under general anaesthesia, the patient will not be informed whether or not the Sterile Self Locking Polymer Cerclage System has been implanted as a result of the procedure.|Cluster's randomization|t|f|f|f
33826175|NCT02230423|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33826176|NCT04270747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is double-masked; therefore, the investigators, study personnel, and the study subjects will remain masked to treatment allocation. Unmasking is only allowed in the case of an emergency, when knowledge of the investigational product is essential for the clinical management of the subject.||t|t|t|f
33826177|NCT04595097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826178|NCT02685007|||COHORT||PROSPECTIVE|||||||
33826179|NCT04125771|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
33826180|NCT03730311|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Double-blind study||t|f|t|f
34132341|NCT01908491|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132342|NCT06503848|||CASE_ONLY||PROSPECTIVE|||||||
34132343|NCT00361231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132344|NCT06653764|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132345|NCT00994019|||COHORT||PROSPECTIVE|||||||
34132346|NCT04333888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132347|NCT01016717|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132348|NCT06625515|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33837465|NCT01062581|||COHORT||PROSPECTIVE|||||||
33837466|NCT01981005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837467|NCT00078377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837468|NCT00980642|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132349|NCT04164433|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34132350|NCT06644833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132351|NCT05336734|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There was no assignment to different groups and as a result, no masking.|The study was designed to examine changes in inter-brain synchrony over the course of standard psychotherapy, and not treatment effectiveness. As such, a single group design was deemed adequate.||||
34132352|NCT04155619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study statistician will be blinded. To the degree possible for each task, other study staff will be blinded during outcome assessments and analysis.||f|f|t|f
34132353|NCT03218449|||COHORT||RETROSPECTIVE|||||||
34132354|NCT06652178|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34132355|NCT03839849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132356|NCT06653140|||COHORT||CROSS_SECTIONAL|||||||
34132357|NCT06315673|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34149408|NCT05118490|RANDOMIZED|PARALLEL||PREVENTION||NONE||A randomization list will be generated prior to starting enrolment using random block sizes that are stratified by HIV status \& country.||||
34149409|NCT00708760|||CASE_CROSSOVER||PROSPECTIVE|||||||
33826181|NCT05493228|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The PI (anesthesiologist), neurosurgeon ,patient, all assisting surgeons and anesthesiologist as well operating and circulating nurse will be blinded to the study arm to which patient belongs to. Only clinical trial unit and pharmacist will be unblinded.|"A prospective, randomized, double-blinded clinical trial will be done on all included cases. They will be divided into two groups after induction of general anathesia using propofolwhich will be started at 100 ug/kg/min) and titrated to maintain the bispectral index at 40-60 and fentanyl will be started at 0.5ug/kg/min) and to be adjusted as needed to control the hemodynamic response to the surgical procedure and maintain the mean arterial pressure (MAP) at 55-65 mmHg. Then will randomly divided using Block Stratified Randomized Software program, after obtaining informed consent from eligible patient or his caregiver into two Arms:~Arm A: will receive dexmedetomidine infusion at the rate of 0.5 μg kg-1 hr-1, started after the induction of general anesthesia without a loading dose which is colorless solution.~Arm B :will receive placebo (saline injection) only after the induction of general anesthesia"|t|t|t|f
33826182|NCT00172497|||DEFINED_POPULATION||OTHER|||||||
33826183|NCT02601105|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE||15 patients were enrolled. All 15 patients had one side of abdomen randomized to placebo and one randomized to Centella Asiatica.|t|f|t|t
33826184|NCT04734847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826185|NCT02973477|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Randomization will be performed by the research Pharmacy. The study coordinator will not be blind to the randomization so that they can adequately discuss the medication with the participant. The study investigator will be blind to the randomization so as to not introduce bias in data qualification.||f|f|t|f
33826186|NCT03788954|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double|Crossover Assignment|t|f|f|t
33826187|NCT01536613|||COHORT||PROSPECTIVE|||||||
33826188|NCT01929577|RANDOMIZED|CROSSOVER||||NONE||||||
33826189|NCT03159325|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33826190|NCT01626729|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826191|NCT03042221|||OTHER||OTHER|||||||
33826192|NCT02960126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826193|NCT01297699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826194|NCT02674048|||OTHER||PROSPECTIVE|||||||
33826195|NCT05896137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826196|NCT01828385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826197|NCT02493881|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33826198|NCT01916642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33826199|NCT01529021|||CASE_CONTROL||PROSPECTIVE|||||||
33826200|NCT01620398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826201|NCT03431480|NA|SINGLE_GROUP||TREATMENT||NONE||Safety||||
33826202|NCT05813535|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33826203|NCT01997749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826204|NCT00857233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826205|NCT06276114|||COHORT||CROSS_SECTIONAL|||||||
33826206|NCT00676897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826207|NCT05290857|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, multicenter, cohort management study and parallel registry||||
33826208|NCT05404698|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Each participant performed 2 experimental conditions (rest, moderate continuous aerobic exercise with our cycle ergometer prototype - EXALT).||||
33826209|NCT00815022|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826210|NCT03646695|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826211|NCT00301041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826212|NCT06404073|RANDOMIZED|PARALLEL||TREATMENT||NONE||This platform protocol is designed to allocate participants into an appropriate intervention appendix based on their symptoms of exercise intolerance or post-exertional malaise (PEM). Once assigned to an appendix, eligible participants are randomized in a 1:1 ratio to either the study intervention group or a control group.||||
33826213|NCT03494985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The examiner and site staff reviewing the efficacy assessments were blinded to the treatment allocation of participants. All other study personnel (study statistician, data management staff and other employees of the Sponsor who may influence study outcomes) were blinded to the study treatments.||f|f|f|t
33826214|NCT06042023|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33826215|NCT01378598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33826216|NCT01281917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826217|NCT00583115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826218|NCT01246232|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826219|NCT04801784|RANDOMIZED|PARALLEL||OTHER||SINGLE|Group allocation masking to staff performing result analyses||f|f|f|t
33826220|NCT02383238|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33826221|NCT05896540|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The assignment of the participants to the groups will be implemented in a two-stage selection of the students; since there are already existing teaching-learning processes in process in the schools, with their time limitations, the investigators will have to choose entire courses (in Chilean secondary schools, a course is a group of about 40 students who have all classes together) rather than choose individual students. The investigators will establish groups among the schools to compensate for their different sizes; some schools in the commune are much larger than the others (four or more courses per grade. Thus the investigators will divide the schools into two blocks; one with the largest schools and one with the medium- and small-sized schools. In the second stage, courses that meet the inclusion criteria to participate in the study will be selected randomly within each of the blocks. Table 1 details the distribution of the samples."||||
33826222|NCT05657132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|blinded|randomized control trial|t|f|f|f
33826223|NCT02136342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826224|NCT02870751|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149410|NCT05170789|NA|SINGLE_GROUP||TREATMENT||NONE||All patients enrolled in this clinical trial will receive the study drugs; elotuzumab, selinexor, and dexamethasone (ESd).||||
34149411|NCT00131651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149412|NCT02624336|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
34149413|NCT00869401|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132358|NCT06249152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study subjects, investigators, study staff, Sponsor and designates involved in the conduct, monitoring and outcome evaluation of the study will be masked to IP assignment identity until final database lock is complete. IP will be provided in in identical packaging. Unmasked statistician will prepare the randomization schedule.|Multi-site, double-masked, vehicle-controlled randomized prospective, parallel study of 14-day QPM dosing followed by 14-day BID dosing of QLS-111 (3 concentrations versus vehicle in combination with latanoprost. Dosing is OU.|t|t|t|t
34132359|NCT05207644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132360|NCT03683420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132361|NCT03828097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Pills are in white bottles with unique ID numbers (1-110). Pills are also flavor-matched (mint).|Double-blinded, parallel|t|f|t|f
34132362|NCT06027814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to treatment group. Group assignment will occur through computerized (REDCap) randomization procedures. The investigators will stratify randomization by whether the patient has buprenorphine treatment in the past year. Randomization lists will be prepared within each stratum using random block sizes of 4 to ensure balanced groups throughout the enrollment period. Participants will be informed of their assignment by research staff after completion of informed consent and the baseline survey.|f|f|t|f
34132363|NCT01904396|NA|SINGLE_GROUP||||NONE||||||
34132364|NCT06659003|||OTHER||RETROSPECTIVE|||||||
34132365|NCT02709460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132366|NCT03206918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132367|NCT04848519|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132368|NCT04876404|||COHORT||CROSS_SECTIONAL|||||||
34132369|NCT05511376|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132370|NCT03781973|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||An intervention with integrated components||||
34132371|NCT04488354|NA|SINGLE_GROUP||OTHER||NONE||||||
34132372|NCT01734785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34132373|NCT05436522|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132374|NCT06137430|||COHORT||PROSPECTIVE|||||||
34132375|NCT05330936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized clinical trial|t|f|f|f
34132376|NCT04817839|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||f|t|t|t
34132377|NCT00191945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132378|NCT05114707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826225|NCT03917537|||COHORT||PROSPECTIVE|||||||
33826226|NCT06079203|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33826227|NCT03756922|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Parts 1, 2, and 3 are Open Label, while Part 4 is randomized and blinded|Parallel for Part 1 and Part 2; Sequential for Part 3 and Part 4|t|t|t|f
33826228|NCT02228135|||COHORT||RETROSPECTIVE|||||||
33826229|NCT03262155|||COHORT||PROSPECTIVE|||||||
33826230|NCT04758546|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
33826231|NCT02552810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826232|NCT03101033|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826233|NCT01074736|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33826234|NCT02357719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826235|NCT01088178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826236|NCT02943200|||||CROSS_SECTIONAL|||||||
33826237|NCT03456635|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE|unblinded|quasi-experimental study Time-series analysis, with a non-equivalent variable prospective Quality Improvement project||||
33826238|NCT04340466|||COHORT||PROSPECTIVE|||||||
33826239|NCT01020942|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33826240|NCT02979613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826241|NCT03277417|||CASE_CONTROL||PROSPECTIVE|||||||
33826242|NCT00468858|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33826243|NCT03383809|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"Acute human bioavailability studies with a cross-over design will be given to subjects in the form of a drink in one of three combinations~1. Strawberry juice alone~2. Inulin alone~3. Mixture of strawberry juice and inulin"||||
33826244|NCT01593865|||CASE_CONTROL||PROSPECTIVE|||||||
33826245|NCT03686241|||COHORT||PROSPECTIVE|||||||
33826246|NCT03122483|||COHORT||PROSPECTIVE|||||||
33826247|NCT00000521|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826248|NCT00141713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826249|NCT00288379|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33826250|NCT03214250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826251|NCT06263530|||CASE_CONTROL||PROSPECTIVE|||||||
33826252|NCT05185492|||COHORT||PROSPECTIVE|||||||
33826253|NCT02570256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826254|NCT01351883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826255|NCT03535077|||COHORT||PROSPECTIVE|||||||
33826256|NCT02456298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33826257|NCT02146092|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34132379|NCT02940899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132380|NCT01472354|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826258|NCT02778334|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826259|NCT04612699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826260|NCT00700518|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33837469|NCT02750449|NA|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
33837470|NCT03308175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837471|NCT00002107||||TREATMENT||||||||
33837472|NCT01240551|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33837473|NCT00883974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837474|NCT06067607|NA|SINGLE_GROUP||TREATMENT||NONE|Masking is not used as this is not a randomized control study and because eye gaze software will objectively document improvements in visual abilities. Scoring on COPM will be conducted by separate investigator from the CVI Range.|Mixed Design, Pre/Post Pre-Experimental Design||||
33837475|NCT05429242|||COHORT||PROSPECTIVE|||||||
33837476|NCT04570098|||OTHER||PROSPECTIVE|||||||
34132381|NCT02159898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132382|NCT00586040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132383|NCT00297960|RANDOMIZED|PARALLEL||||NONE||||||
34132384|NCT02356523|||COHORT||PROSPECTIVE|||||||
34132385|NCT00395070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132386|NCT06661291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A Randomized Clinical Trial to determine the effectiveness of Pip Care in improving clinical and patient reported outcomes when compared to standard perioperative care in 1300 subjects.||||
34132387|NCT06351774|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|The investigator was masked to the initial treatment assignment. The outcome assessor was not masked to treatment assignment and monitored treatment response at the mid-intervention in order to recommend continuation of current treatment or to augment treatment with the Healthy Mind Innovations training program for individuals who did not favorably respond to standalone PT.|A 2 armed sequential, multiple-assignment randomized trial design|f|f|t|f
33826261|NCT03116672|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patient selection.~Fifty-four of sixty-five patients (29 women and 25 men), 18 to 60 years of age with 54 eligible teeth consented to participate in the study. The patients were randomly divided into three groups using a web program. The patient number and group number were recorded. Informed consent was obtained from each patient and the possible discomforts and risks were fully explained.~A total of 54 patients were divided into three groups (n = 18) according to the type of preoperative drug administrated, as follows: Group A: Administration of ketorolac 10mg, Group B: Administration of Diclofenac Na 50mg, and Group C: A placebo (capsule filled with sugar).~After 15 minutes each participant received the treatment."|"Patient selection.~Fifty-four of sixty-five patients (29 women and 25 men), 18 to 60 years of age with 54 eligible teeth consented to participate in the study. The patients were randomly divided into three groups using a web program. The patient number and group number were recorded. Informed consent was obtained from each patient and the possible discomforts and risks were fully explained.~A total of 54 patients were divided into three groups (n = 18) according to the type of preoperative drug administrated."|t|f|f|f
33826262|NCT02445183|||CASE_CONTROL||OTHER|||||||
33826263|NCT04231747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826264|NCT02846597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826265|NCT02897999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826266|NCT02881021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826267|NCT03416621|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33826268|NCT02132078|||||RETROSPECTIVE|||||||
33826269|NCT01130714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826270|NCT04015596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826271|NCT01989923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826272|NCT02118038|||COHORT||PROSPECTIVE|||||||
33826273|NCT04961983|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to two groups (intervention and control groups) in parallel for the duration of the study. The allocation of participants into the intervention and control groups will be carried out using permuted block randomization technique.||||
33826274|NCT02840071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826275|NCT05459025|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33826276|NCT02582034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826277|NCT00591604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826278|NCT00000236||||TREATMENT||||||||
33826279|NCT04679740|||OTHER||PROSPECTIVE|||||||
33826280|NCT03223714|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33826281|NCT03806413|||COHORT||PROSPECTIVE|||||||
33826282|NCT00437619|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826283|NCT03074045|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826284|NCT00726388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826285|NCT02557243|||COHORT||RETROSPECTIVE|||||||
33826286|NCT02760472|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826287|NCT05568199|||CASE_ONLY||PROSPECTIVE|||||||
33826288|NCT02517125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826289|NCT04189341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patient, investigators and the pain nurse who performs postoperative pain evaluation will not know the group.|There are three models for this study. The first group is erector spinae plane block group. The second one is thoracal paravertebral block group. The third one is the no intervention control group.|t|f|t|t
33826290|NCT01503437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826291|NCT05996497|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33826292|NCT02936232|||COHORT||PROSPECTIVE|||||||
33826293|NCT02134613|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826294|NCT01363336|||CASE_ONLY||PROSPECTIVE|||||||
33826295|NCT01827852|||COHORT||PROSPECTIVE|||||||
33826296|NCT00413075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826297|NCT05823805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33826298|NCT05764577|||CASE_ONLY||PROSPECTIVE|||||||
33826299|NCT04009720|||COHORT||PROSPECTIVE|||||||
33826300|NCT05417464|NA|SINGLE_GROUP||OTHER||NONE||This is a non-comparative prospective interventional study, involving the human category, which aims to evaluate the efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR||||
33826301|NCT01179906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826302|NCT04528290|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826303|NCT01386697|||CASE_CONTROL||PROSPECTIVE|||||||
33826304|NCT05848453|RANDOMIZED|SEQUENTIAL||SCREENING||DOUBLE|||t|f|t|f
33826305|NCT05205252|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826306|NCT04067921|||COHORT||PROSPECTIVE|||||||
33826307|NCT02845375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33826308|NCT01136798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132388|NCT03073317|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||stepped-wedge cluster-randomised trial in seven clusters||||
34132389|NCT04839068|||COHORT||CROSS_SECTIONAL|||||||
34132390|NCT05906680|||COHORT||CROSS_SECTIONAL|||||||
34132391|NCT04829786|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||The subjects will be randomized to receive in Period 1 either the low-dose or high-dose first, and in Period 2 they received the alternate dose.|t|t|t|t
33826309|NCT01307917|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826310|NCT03618212|||CASE_ONLY||PROSPECTIVE|||||||
33826311|NCT03962478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826312|NCT03614221|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33826313|NCT05798247|||OTHER||RETROSPECTIVE|||||||
33826314|NCT00298337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33826315|NCT04885634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Investigator-driven, prospective, parallel-group, double-blind, randomized controlled clinical trial|t|t|t|t
33826316|NCT03904277|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826317|NCT01742650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826318|NCT05414201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826319|NCT03653377|||COHORT||CROSS_SECTIONAL|||||||
33826320|NCT04785586|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients are randomized into three groups all of which include the HealthyWeightCoaching (HWC) platform. In addition, group 1 will be offered three individual face-to-face sessions via video and group 2 three group face-to-face sessions via video. Group 3 acts as the control group offering the basic HWC protocol.||||
33826321|NCT02078947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826322|NCT03535480|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33826323|NCT03135613|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||The control group was recruited from healthy subjects. The experimental group was recruited from patients with tumor around knee after microwave ablation with plate internal fixation.|f|f|f|t
33826324|NCT02691637|||CASE_CONTROL||PROSPECTIVE|||||||
34132392|NCT01023685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826325|NCT03975296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33826326|NCT03545321|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge cluster randomized design||||
33826327|NCT05542225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be a another person who will be unaware of the group the particpant belong to.|This study is a randomized controlled trial which will consist of two groups. Once will recieve conventional physcial therapy and the sencond will recieve conventional physcial therapy and slump stretching.Both groups will be recruited concurrently.|f|f|f|t
33826328|NCT05147649|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33826329|NCT00610818|||||PROSPECTIVE|||||||
33826330|NCT00858247|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826331|NCT06170502|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The type of study is a randomized controlled experimental study. In the research, it is aimed to evaluate the effectiveness of the mobile application (Akil Mobil).||||
33826332|NCT03484078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Children with CP will be randomly assigned to a vibration or a placebo group.|t|t|t|f
33826333|NCT04311385|||COHORT||RETROSPECTIVE|||||||
33826334|NCT05111678|||COHORT||PROSPECTIVE|||||||
33826335|NCT02618564|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
33826336|NCT00422305|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826337|NCT01133925|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826338|NCT02277392|NA|SINGLE_GROUP||TREATMENT||||||||
33826339|NCT03442140|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33826340|NCT01006447|RANDOMIZED|PARALLEL||||NONE||||||
33826341|NCT05306522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826342|NCT06238297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826343|NCT01240239|||||PROSPECTIVE|||||||
33826344|NCT02344056|RANDOMIZED|CROSSOVER||||NONE||||||
33826345|NCT06304532|||CASE_ONLY||OTHER|||||||
33826346|NCT03590717|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||Cluster randomized controlled trial clustered at the village level, 2 treatment arms and one control group.|f|f|f|t
33826347|NCT03248713|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|This is a double blind randomized study|The primary analyses will use linear mixed models (LMMs). LMMs can handle continuous and dichotomous outcomes, as well as missing data. Analyses will include baseline (pre-treatment) measures of these variables as covariates and other baseline variables where appropriate.|t|f|t|f
33826348|NCT01330992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826349|NCT02893475|||CASE_ONLY||CROSS_SECTIONAL|||||||
33826350|NCT06309485|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33826351|NCT00569036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826352|NCT00329017|||COHORT||PROSPECTIVE|||||||
33826353|NCT02631616|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826354|NCT05550597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132393|NCT05536414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132394|NCT04370587|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132395|NCT05270941|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE||As a randomized controlled clinical trial, in the patients' bilateral recession sites, while gingival recessions of one group were treated with T-PRF, the gingival recessions of the other group were treated with SCTG using a simple randomization method.|t|f|t|f
33826355|NCT05469906|||CASE_CONTROL||RETROSPECTIVE|||||||
33826356|NCT00961896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826357|NCT04986670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||For the proposed study, we will randomize participants into two groups at a 1:1 ratio to an intervention or an enhanced control group. For participants randomized to the enhanced control group, the NutriTool, the oncology care team will provide participants with a nutrition toolkit involving printed educational materials. For participants randomized to the intervention group, the NutriCare, the oncology care team will additionally provide participants with home-delivery of medically tailored meals and referral to registered dietitians (RDs) for remotely-delivered nutrition counseling.||||
33826358|NCT05598606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants were randomized using a block randomization model (block size 5). Computer-generated, random-number sequences were prepared by an experienced statistician. Consecutive treatment allocations were stored in sealed opaque envelopes and assigned to doctors. Patients and doctors were blinded to the assignments; all researchers and data analysts were blinded as to the allocation during the 12-month follow-up period.||t|f|t|t
33826359|NCT00593970|||COHORT||CROSS_SECTIONAL|||||||
34132396|NCT01049204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149414|NCT01777945|||COHORT||PROSPECTIVE|||||||
34132397|NCT05330494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34132398|NCT04919031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132399|NCT00460460|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132400|NCT06662318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132401|NCT05661864|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants are randomly assigned to one of two groups. Both groups receive intervention, but to different classroom management strategies.||||
34132402|NCT03133819|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132403|NCT05876962|||OTHER||PROSPECTIVE|||||||
34132404|NCT03146559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132405|NCT05175430|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Triple (Participant, Care Provider, Investigator)|2-period cross-over, randomized, double-blind (paroxetine vs. placebo) study|t|t|t|f
34132406|NCT02977429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132407|NCT06235593|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132408|NCT05245110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Eligible participants were invited to data collection including sociodemographic characteristics and outcome measures in a local medical centre at baseline and 12 weeks by a separate research nurse, blinded to the group assignments.|A parallel-group randomized controlled trial|f|f|f|t
34132409|NCT06301776|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132410|NCT03040518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132411|NCT06662045|||COHORT||PROSPECTIVE|||||||
34132412|NCT01703091|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132413|NCT03490292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is a two-part phase 1/2 clinical trial conducted in one center.~Part 1. Run-in phase to assess the safety and tolerability of avelumab in combination with chemoradiation. Will enroll 6 patients, after which accrual will be stopped temporarily while safety data is being obtained.~Part 2. An open-label phase 2 study. Part 2 will obtain further safety data of the proposed drug combination and will evaluate the anti-tumor efficacy of perioperative avelumab and chemoradiation in this patient population. Will enroll 18 additional patients.~Each phase of the study will have a 21-day screening period, treatment procedures (neoadjuvant therapy, resection and adjuvant therapy), and active surveillance for a year after the completion of adjuvant therapy.~After active surveillance visit at 12 months post treatment completion, survival data and disease status will be collected via phone calls or medical record review every 6 months during the following 3 years."||||
34132414|NCT00595881|||||CROSS_SECTIONAL|||||||
34132415|NCT03122899|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Minimally invasive sacroiliac joint fusion surgery with iFuse-3D||||
34132416|NCT06446596|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132417|NCT03989375|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34132418|NCT06053151|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132419|NCT00488020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132420|NCT05645107|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132421|NCT00061854||||TREATMENT||NONE||||||
34132422|NCT01518686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132423|NCT05139719|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132424|NCT05464771|||OTHER||RETROSPECTIVE|||||||
34132425|NCT04642118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34132426|NCT06456008|||COHORT||OTHER|||||||
34132427|NCT05292495|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Compare the pharmacokinetics of HR17031 injection in subjects with mild, moderate, severe renal insufficiency and end-stage renal disease and subjects with normal renal function.||||
34132428|NCT05961111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132429|NCT00577707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132430|NCT05740527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132431|NCT05688202|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||Each patient will undergo three sessions of subcision combined with fractional CO2 laser with a 1-month interval between sessions. The face's left side is treated with simultaneous combination therapy, in which fractional CO2 laser is performed immediately following subcision. The face's right side receives sequential combination therapy with fractional CO2 laser conducted two weeks after subcision.|f|f|f|t
34132432|NCT04610619|||COHORT||CROSS_SECTIONAL|||||||
34132433|NCT00048022||||TREATMENT||||||||
34132434|NCT02220153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132435|NCT05609305|||COHORT||OTHER|||||||
34132436|NCT01042587|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33826360|NCT00562185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826361|NCT03679468|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|In order to prevent bias in our research results, we will employ a double-blind study design in which the examiner nor the research participant will know which group membership they were assigned to.|We propose undertaking a randomized, blinded, sham controlled clinical trial investigating the effectiveness of CR and exercise, either singly or in combination, in treating cognitive dysfunction in people with progressive MS. Subjects will be randomly assigned to one of four groups: CR plus exercise; CR plus passive exercise; passive CR plus exercise and passive CR plus passive exercise. Subjects will receive one of these four treatments for 12 weeks, twice a week. One in three subjects will undergo structural and functional MRI to investigate how the brain responds to the two interventions.|t|f|t|f
34132437|NCT00489320|||DEFINED_POPULATION||PROSPECTIVE|||||||
34132438|NCT01591954|NA|SINGLE_GROUP||||NONE||||||
34132439|NCT03267615|||COHORT||PROSPECTIVE|||||||
34132440|NCT05170958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132441|NCT04114708|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132442|NCT00841776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34132443|NCT05633836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132444|NCT03896061|||OTHER||OTHER|||||||
34132445|NCT04053972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132446|NCT03849053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34132447|NCT03181217|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34132448|NCT03308968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132449|NCT06464731|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132450|NCT06463431|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132451|NCT03530254|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132452|NCT06128889|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132453|NCT02767869|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132454|NCT05689671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132455|NCT03087877|NA|SINGLE_GROUP||OTHER||NONE|The system will be blinded to the user, i.e. no glucose values will be displayed to the subject during the study duration.|||||
34132456|NCT00729495|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34132457|NCT05891015|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132458|NCT02216968|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34132459|NCT04483193|||CASE_ONLY||PROSPECTIVE|||||||
34132460|NCT04974827|NA|SINGLE_GROUP||TREATMENT||NONE||Patients fulfilling Eligibility Criteria will be included in this study.Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 5 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.||||
34132461|NCT04787783|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34132462|NCT04896619|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34132463|NCT06032104|RANDOMIZED|CROSSOVER||OTHER||SINGLE||The randomized clinical trial has a cross-over design. The 20 participants will be randomized to a 14-day bean intervention versus usual care pre- or post-colonoscopy with a cross-over design. The 14-day bean intervention will be preceded by a 3-day ramp-up, acclimation, phase of beans feeding starting at one 1/2 cup of beans for day 1, followed by two 1/2 cups/day for days 2 and 3, then the full dose of three 1/2 cups/day for 14 days afterwards. Participants will be randomized 1:1 using a stratified randomization design. The randomization strata will be sex and presence/absence of metabolic syndrome factors with 1:1 ratio. Investigators anticipate a 20% dropout; therefore, investigators will recruit 25 participants to complete procedures on 20.|f|f|f|t
34132464|NCT01162954|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132465|NCT06607445|||OTHER||PROSPECTIVE|||||||
34132466|NCT05719857|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparative study between diagnostic methods, with a cross-sectional design.||||
34132467|NCT03573206|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the study device for femoral venotomy closure.||||
34132468|NCT03702062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132469|NCT00698750|||COHORT||PROSPECTIVE|||||||
34132470|NCT05351177|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132471|NCT05135585|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34132472|NCT05209620|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132473|NCT04103151|||COHORT||PROSPECTIVE|||||||
34132474|NCT00922376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132475|NCT03548025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132476|NCT04989556|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132477|NCT04817475|||CASE_ONLY||PROSPECTIVE|||||||
34132478|NCT03299205|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132479|NCT04102800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132480|NCT00253773|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34132481|NCT05306665|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34132482|NCT06619392|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HRS-2129 for dose escalation|t|t|t|t
34132483|NCT01201824|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132484|NCT00602225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132485|NCT04834193|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34132486|NCT05530668|||CASE_ONLY||RETROSPECTIVE|||||||
34132487|NCT05331300|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34132488|NCT00763295|||CASE_CONTROL||PROSPECTIVE|||||||
34132489|NCT01766297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132490|NCT01147250|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132491|NCT02951403|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132492|NCT04102904|||COHORT||PROSPECTIVE|||||||
34132493|NCT05619094|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34132494|NCT06402526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligible participants will be randomly allocated in a 1:1 ratio to the intervention group (use of MEEP) or the control group (standard care).||||
34132495|NCT05076773|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34132496|NCT04636840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132497|NCT00700882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132498|NCT02572505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132499|NCT01195376|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132500|NCT06515574|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34132501|NCT02371460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132502|NCT03932773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Cognitive Processing Therapists will be blind to the treatment arm to which the participants are assigned.~Baseline and outcome measure neuropsychological assessments will be conducted by an independent, blinded evaluator who is not part of the treatment team.~Electroencephalography and magnetic resonance imaging data will be collected by technicians who are blinded to the arm to which the participants are assigned.~Technicians administering repetitive transcranial magnetic stimulation (rTMS) will be blind to whether they are using an active or sham coil and to the treatment arm to which the participants are assigned. The coils are identical and will be setup by a different technician.~Participants assigned to the 1 Hz rTMS coupled with Cognitive Processing Therapy or sham rTMS coupled with CPT will be blind as to whether they are receiving active or sham rTMS.~Participants receiving rTMS only will not be blind to their group assignment."|Participants will be randomly assigned to one of three treatment arms: (1) 1 Hz (hertz) repetitive transcranial magnetic stimulation (rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) coupled with Cognitive Processing Therapy (CPT), (2) sham rTMS coupled with CPT, or (3) 1 Hz rTMS to the rDLPFC alone.|t|t|f|t
34132503|NCT06370923|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Analysts blinded to allocation|Cluster randomised trial|f|f|f|t
34132504|NCT05538377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132505|NCT06405438|||CASE_CONTROL||OTHER|||||||
34149415|NCT00527332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149416|NCT00036101||||TREATMENT||||||||
34149417|NCT06129929|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34149418|NCT03890328|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132506|NCT04930861|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label study to evaluate the safety and preliminary efficacy of Codivir in 12 mild or moderate COVID-19 patients and onset of symptoms within 72h prior to their inclusion. Treatment will begin in the hospital, participants will be discharged at Day 4 and continue the treatment up to Day 10 at home.||||
34132507|NCT04317521|||CASE_CONTROL||PROSPECTIVE|||||||
34132508|NCT05592327|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This is a prospective, randomized, triple blind, controlled clinical trial|t|f|t|t
34132509|NCT04120883|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).|f|f|f|t
34132510|NCT05136222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The attending sleep scientist will refer to a database that reveals (statistician-generated) participant's treatment allocation. The sleep scientist will not reveal the treatment allocation to the Clinical team, Research team or the participant.~Centralised allocation concealment will be ensured through the Adept/REDCap trial database."|Randomised controlled trial with 12 month cohort follow-up|t|t|t|t
34132511|NCT02308592|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34132512|NCT02882061|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34132513|NCT00037518|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132514|NCT04603495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This study has a double-blind design in which patients and investigators are blinded to study drug; study drugs will be packaged identically. All patients will be randomly assigned to either treatment group in a 1:1 ratio. The blind should only be broken in the case of emergency.||t|t|t|t
34132515|NCT06288724|||COHORT||PROSPECTIVE|||||||
34132516|NCT02224443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132517|NCT05090163|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Each site will deliver 6 weeks of the intervention / control with a new set of participants before post intervention qualitative measures are used to inform the design of the next wave.|f|f|f|t
34132518|NCT05961241|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||Two groups.||||
34132519|NCT05940857|||OTHER||OTHER|||||||
34132520|NCT03222362|||COHORT||RETROSPECTIVE|||||||
34132521|NCT06660810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132522|NCT04171635|||COHORT||PROSPECTIVE|||||||
34132523|NCT04402905|||COHORT||RETROSPECTIVE|||||||
34132524|NCT01419379|||COHORT|||||||||
34132525|NCT04296305|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Participants and study staff||t|t|t|t
34132526|NCT02904850|||CASE_ONLY||PROSPECTIVE|||||||
34132527|NCT05880849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132528|NCT03981094|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study will be conducted in three periods, so that all the randomized participants receive treatment (participants receive pirfenidone only, or BMS-986278 only, or both together during each treatment period).||||
34132529|NCT00161837|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34132530|NCT04188067|NA|SINGLE_GROUP||OTHER||NONE|Through use of SHAM rTMS stimulation|Within-subject crossover design||||
34132531|NCT06095934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132532|NCT00543933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132533|NCT02812264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not know which arm they have been randomized to. Additionally, the investigators will be blinded to participant assignment. Randomization will be completed by the program manager.||t|f|t|f
34132534|NCT03049358|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34132535|NCT03574376|RANDOMIZED|PARALLEL||TREATMENT||NONE|No participants are blinded to treatment arms. Patients and investigators are aware of which patients are assigned to each treatment group.|"This is a two arm, randomized trial. Patients suffering multiple traumatic rib fractures will be offered CEA or LBINB. As the current standard of care, CEA will serve as the control, and outcomes measured in patients receiving LBINB will be statistically evaluated relative to the CEA control group.~All patients will receive standardized NSAID and opioid analgesia protocol for break through pain, as well as standardized routines for pulmonary hygiene and physiotherapy."||||
34132536|NCT04615234|||CASE_CONTROL||PROSPECTIVE|||||||
34132537|NCT03027440|||COHORT||RETROSPECTIVE|||||||
34132538|NCT02441153|||CASE_ONLY||PROSPECTIVE|||||||
34132539|NCT05388383|||COHORT||PROSPECTIVE|||||||
34132540|NCT01020409|||COHORT||PROSPECTIVE|||||||
34132541|NCT01375127|||||RETROSPECTIVE|||||||
34132542|NCT01091558|||CASE_CONTROL||PROSPECTIVE|||||||
34132543|NCT01153711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132544|NCT00520702|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132545|NCT00624468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132546|NCT05914077|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33826362|NCT01891656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826363|NCT05515913|||CASE_CONTROL||PROSPECTIVE|||||||
33826364|NCT05424094|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826365|NCT05394883|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a pilot investigation (feasibility) of a future larger study of interventional design with randomization. Participants in the pilot phase of the project will be randomized into one of three groups: supervised exercise, home exercise, or usual care.||||
33826366|NCT06161818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826367|NCT02066493|||COHORT||PROSPECTIVE|||||||
34132547|NCT00858728|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34132548|NCT04829526|||COHORT||RETROSPECTIVE|||||||
34132549|NCT06661642|||COHORT||PROSPECTIVE|||||||
34132550|NCT01149005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132551|NCT02931643|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34132552|NCT00684710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132553|NCT02547246|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34132554|NCT02840188|||CASE_CONTROL||RETROSPECTIVE|||||||
34132555|NCT02253290|||COHORT||OTHER|||||||
34132556|NCT02048644|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132557|NCT02830854|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132558|NCT02860208|||COHORT||PROSPECTIVE|||||||
34132559|NCT04157153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132560|NCT02468687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132561|NCT03875105|||COHORT||PROSPECTIVE|||||||
34132562|NCT05504187|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132563|NCT02209558|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132564|NCT00425022|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132565|NCT02370316|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132566|NCT02584452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132567|NCT03718884|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34132568|NCT01207609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132569|NCT01178944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132570|NCT05003180|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial. Subjects are identified through spine services at hospitals throughout Sweden and Norway. The subjects are screened for eligibility. Subjects are randomized in a 1:1 ratio to surgical or non-surgical treatment.||||
34132571|NCT04916353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132572|NCT00641238|||CASE_ONLY||PROSPECTIVE|||||||
34132573|NCT02748044|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132574|NCT04170400|||CASE_ONLY||PROSPECTIVE|||||||
34132575|NCT01770275|||CASE_ONLY||RETROSPECTIVE|||||||
33826368|NCT02017132|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34132576|NCT01210963|||COHORT||PROSPECTIVE|||||||
34132577|NCT04125212|||COHORT||PROSPECTIVE|||||||
34132578|NCT02819258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132579|NCT03574766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132580|NCT01877525|||COHORT||PROSPECTIVE|||||||
34132581|NCT02146872|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34132582|NCT06376162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132583|NCT02820246|||COHORT||CROSS_SECTIONAL|||||||
34132584|NCT03026114|||CASE_ONLY||PROSPECTIVE|||||||
33826369|NCT04148521|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33826370|NCT04356638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33826371|NCT03716947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33826372|NCT00668512|NA|SINGLE_GROUP||||NONE||||||
33826373|NCT01801423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826374|NCT02024750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826375|NCT05590962|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The Principal Investigator (RBP) and primary statistical analyst will be blinded to arm assignment.||f|f|t|f
33826376|NCT05338112|||CASE_ONLY||PROSPECTIVE|||||||
33826377|NCT06329271|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826378|NCT00001941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826379|NCT01100918|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826380|NCT04287634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826381|NCT03988478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826382|NCT00069277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826383|NCT03342170|||COHORT||PROSPECTIVE|||||||
33826384|NCT03226106|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial; Two groups.|f|f|f|t
33826385|NCT02553876|||COHORT||PROSPECTIVE|||||||
33826386|NCT04314570|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826387|NCT04724005|||OTHER||RETROSPECTIVE|||||||
33826388|NCT03044002|||CASE_CONTROL||PROSPECTIVE|||||||
33826389|NCT04355013|||CASE_CROSSOVER||PROSPECTIVE|||||||
34132585|NCT01145001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34132586|NCT00388206|||COHORT||PROSPECTIVE|||||||
33826390|NCT00125853|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34132587|NCT06379035|||COHORT||PROSPECTIVE|||||||
34132588|NCT03079934|||COHORT||PROSPECTIVE|||||||
34132589|NCT03427814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132590|NCT01000298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132591|NCT06653803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34132592|NCT00443053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132593|NCT04303013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34132594|NCT05533307|||CASE_CONTROL||PROSPECTIVE|||||||
34132595|NCT05288361|||COHORT||PROSPECTIVE|||||||
33826391|NCT00806299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33826392|NCT02730676|||COHORT||CROSS_SECTIONAL|||||||
33826393|NCT04165525|RANDOMIZED|PARALLEL||TREATMENT||NONE||Perspective, randomized, concurrently controlled||||
33826394|NCT00131547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826395|NCT03994341|||COHORT||PROSPECTIVE|||||||
33826396|NCT02290197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826397|NCT00020709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826398|NCT05490147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a surgeon blinded randomized controlled study|t|t|f|t
33826399|NCT06309849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|includes 30 participants.|Randomized Control Trail (RCT) will be used in the study. Participants will be dived into experimental group and control group. Each group will includes 30 participants.|t|f|f|f
33826400|NCT00160979|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826401|NCT02815137|NA|SINGLE_GROUP||OTHER||NONE||||||
33826402|NCT05306340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826403|NCT00196378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826404|NCT01689467|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33826405|NCT06620432|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33826406|NCT05940714|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33826407|NCT05193500|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33826408|NCT00409123|||CASE_ONLY||PROSPECTIVE|||||||
33826409|NCT01848262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826410|NCT01730547|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33837477|NCT01487187|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34132596|NCT03800537|NA|SINGLE_GROUP||OTHER||NONE||||||
34132597|NCT05268692|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132598|NCT06328270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132599|NCT04264520|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label Pilot Trial (no control group)||||
34132600|NCT03158740|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The two arms of this intervention study will be the DII-Based Counseling System, including access to our Imagine Healthy Online Portal, and a general health education control. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another. Both arms will be composed of 1 wave of 15 individuals. Participants will be required to invite a partner of their choosing to join them in the intervention activities to improve social support for behavioral change. Investigators have experience conducting studies where participants invite partners to participate.||||
34132601|NCT06440954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132602|NCT03150745|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132603|NCT02731820|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34132604|NCT03814382|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132605|NCT01761799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132606|NCT02933424|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34132607|NCT03688334|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34132608|NCT04106258|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34132609|NCT06659354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34132610|NCT03754127|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132611|NCT04674111|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective, open-label, single-arm feasibility study||||
34132612|NCT03620136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132613|NCT03176862|||COHORT||CROSS_SECTIONAL|||||||
34132614|NCT06659302|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132615|NCT05962619|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33826411|NCT05501847|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective multicenter interventional study.||||
34132616|NCT02023580|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132617|NCT00615693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132618|NCT00551434|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34132619|NCT02488135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132620|NCT03478254|||COHORT||CROSS_SECTIONAL|||||||
34132621|NCT06658314|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132622|NCT04224714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132623|NCT02408718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34132624|NCT05898711|||CASE_ONLY||PROSPECTIVE|||||||
34132625|NCT00135538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132626|NCT01825148|||CASE_CONTROL||PROSPECTIVE|||||||
34132627|NCT06045858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||a Haybittle sequential plan (PROC SEQDESIGN, SAS 9.4) with decision rule for better safety (larger than expected effect)|f|f|f|t
34132628|NCT03637361|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34132629|NCT01764269|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34132630|NCT02704806|||CASE_CONTROL||PROSPECTIVE|||||||
34132631|NCT00316706|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132632|NCT02143856|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132633|NCT04216472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132634|NCT04699032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132635|NCT06024616|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132636|NCT00648427|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34132637|NCT02144402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132638|NCT00596674|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132639|NCT02364804|||CASE_CONTROL||OTHER|||||||
34132640|NCT01560936|||COHORT||PROSPECTIVE|||||||
34132641|NCT03657134|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132642|NCT05398029|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Single ascending dose escalation/adaptive design followed by single dose expansion.||||
33826412|NCT04816708|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single site, pilot randomized waitlist control trial||||
33826413|NCT03505918|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised controlled trial with two parallel groups|f|f|t|f
34132643|NCT02483091|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34132644|NCT00632827|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132645|NCT01895426|||CASE_ONLY||PROSPECTIVE|||||||
33826414|NCT01708421|||COHORT||PROSPECTIVE|||||||
33826415|NCT03133078|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826416|NCT04832581|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are two groups in the study, namely the experiment (33) and the control (34) group. The experimental group was included in the program based on the Orem Self Care Model. The program includes anatomical, physiological and hormonal changes during pregnancy, urinary system infections and preventive measures. In the experimental and control groups, the data were collected byface-to-face interview technique and telephone interviews. Pregnant Information Form, Pregnant Evaluation Form, Genital Hygiene Behavior Inventory (GHBI) and routine laboratory testsof pregnant women were used to collect data.||||
34132646|NCT02406469|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34132647|NCT03213743|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34132648|NCT04168164|NA|SINGLE_GROUP||OTHER||NONE|This study was a randomized, single-blinded controlled trial. The participants were recruited from three brain injury associations and those who fulfilled the inclusion criteria were randomly assigned to three treatment groups.|||||
33826417|NCT03891485|||COHORT||PROSPECTIVE|||||||
33826418|NCT03372577|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33826419|NCT00547183|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34132649|NCT04002050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34132650|NCT00709176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132651|NCT05562206|NA|SINGLE_GROUP||OTHER||NONE||||||
34132652|NCT05558137|||COHORT||PROSPECTIVE|||||||
34132653|NCT02729818|||OTHER||PROSPECTIVE|||||||
34132654|NCT06479291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132655|NCT04150237|||COHORT||PROSPECTIVE|||||||
34132656|NCT04502316|||COHORT||PROSPECTIVE|||||||
34132657|NCT01142869|||COHORT||PROSPECTIVE|||||||
34149419|NCT02703168|||||PROSPECTIVE|||||||
33826420|NCT04226651|RANDOMIZED|CROSSOVER||TREATMENT||NONE||randomized, two-armed, within-subject, cross-over, controlled||||
33826421|NCT03800485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is blinded so neither the patient, neither the psysical therapist nor the investigator knows in which group the patient is|There are two groups, the intervention group and the placebo group.|t|t|t|f
33826422|NCT03412578|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33826423|NCT03691142|||OTHER||PROSPECTIVE|||||||
33826424|NCT03134274|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Assess usability and preference of digital home urine testing with pregnant women. 300 pregnant women will be given a test kit and smartphone application during a clinic visit. Participants are instructed to conduct the test the next day. After conducting the urine test home participants fill out a survey assessing the satisfaction with digital home urine testing.||||
33826425|NCT05458154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826426|NCT03465085|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Investigators prepared and administered the study medication. participants, ICU physician and nurses, and the outcomes assessor were blinded to the two randomized groups|"Group (I): Heparin group (n=20) received nebulized Heparin 10000 IU/4h. Group (II): Streptokinase group (n=20) received nebulized Streptokinase 250,000 IU/4h.~Group (III): Control group (n=20) received conservative management"|t|t|f|t
33826427|NCT02650726|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826428|NCT04255654|NA|SINGLE_GROUP||OTHER||NONE||||||
33826429|NCT04964778|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Each subject will be packaged with SKED© only; SKED©+OSS-II©; SKED©+Vacuum mattress; SKED©+foam padding. Each arm will consist of the same interventions in a specified, but unique order. Each patient packaged within their respective systems as one unit will be subject to a 30 meter controlled drag over terrain chosen to mimic a standard dry backcountry extrication drag.||||
33826430|NCT05790187|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33826431|NCT02222077|||COHORT||CROSS_SECTIONAL|||||||
33826432|NCT05654558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826433|NCT05680285|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826434|NCT04237675|||COHORT||PROSPECTIVE|||||||
33826435|NCT01239537|||CASE_ONLY||PROSPECTIVE|||||||
33826436|NCT02068378|NA|SINGLE_GROUP||OTHER||NONE||||||
33826437|NCT04089839|||COHORT||PROSPECTIVE|||||||
33826438|NCT04565210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33826439|NCT06646133|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33826440|NCT03838419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826441|NCT01553227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826442|NCT00000904||||PREVENTION||DOUBLE||||||
33826443|NCT04974086|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Single arm prospective cohort study||||
33826444|NCT04857047|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826445|NCT03544437|||COHORT||PROSPECTIVE|||||||
33826446|NCT03487653|||OTHER||PROSPECTIVE|||||||
33826447|NCT01274559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826448|NCT05985083|NA|SEQUENTIAL||TREATMENT||NONE||||||
33826449|NCT02380638|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33826450|NCT03549988|||OTHER||PROSPECTIVE|||||||
33826451|NCT02907450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826452|NCT02470611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826453|NCT02001389|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826454|NCT00635570|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826455|NCT01187810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826456|NCT04183244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33826457|NCT04560777|NA|SINGLE_GROUP||OTHER||NONE||"Single case experimental study design with multiple baselines across individuals and behaviors.~Randomization:~1. Which patient starts when the COOP sessions?~2. What are the possible starting points for the 3 goals to be worked on?~3. Which of the 4 goals ABCD is assigned to which goal number? The most important goal (A) will necessarily be worked on first. We will draw lots to determine the order in which the goals will be worked on and which goal will be designated as the control goal."||||
33826458|NCT06076798|||CASE_ONLY||PROSPECTIVE|||||||
33826459|NCT03385798|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized clinical trial||||
33826460|NCT02035098|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33826461|NCT00203723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33826462|NCT06024135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826463|NCT04662736|||COHORT||RETROSPECTIVE|||||||
33826464|NCT00555997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826465|NCT03851614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826466|NCT05056675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Interdisciplinary, prospective, double-blind (participant and investigator), placebo-controlled, parallel-group study (experimental study, level of evidence I).|t|t|t|f
33826467|NCT06414759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, randomized, single-blinded, controlled trial|t|f|f|f
33826468|NCT04033770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826469|NCT04377412|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33826470|NCT03307083|NA|SINGLE_GROUP||OTHER||NONE||||||
33826471|NCT01202669|||CASE_ONLY||PROSPECTIVE|||||||
33826472|NCT01751165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826473|NCT04306913|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33826474|NCT03494621|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826475|NCT02046447|||CASE_CONTROL||PROSPECTIVE|||||||
33826476|NCT00434707|||CASE_CONTROL||OTHER|||||||
33826477|NCT02709447|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826478|NCT03879083|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The outcomes assessor will not be aware of which group he/she is interviewing at the assessment session.|"Patients will randomly be allocated to either group A/B or B/A. Group A: Patients receiving a reproduction of their palatal rugae Group B: Patients receiving a smooth palatal surface.~After insertion, all participants will be followed up for a minimum of 1 week to correct any issues with the dentures and eliminate patient complaints.~All patients will be recalled at 2 month after insertion to answer questions using the VAS and to fill out the Oral Health Impact Profile-20 EDENT (OHIP-EDENT), and receive the other type of palatal contour.~After the second periodthe same process will be repeated."|f|f|f|t
34132658|NCT05634785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132659|NCT06238193|||COHORT||CROSS_SECTIONAL|||||||
34132660|NCT05889793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded trial|Double-blinded randomized controlled clinical trial (RCT) with placebo and intervention group|t|t|t|f
34132661|NCT02147210|||CASE_CONTROL||RETROSPECTIVE|||||||
34132662|NCT04788485|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34132663|NCT04967287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132664|NCT05612893|||COHORT||PROSPECTIVE|||||||
34132665|NCT00006144||||TREATMENT||||||||
34132666|NCT03423446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132667|NCT05740631|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34132668|NCT00066599||||SUPPORTIVE_CARE||NONE||||||
34132669|NCT02501967|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34132670|NCT00294671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132671|NCT03756051|||COHORT||PROSPECTIVE|||||||
34132672|NCT01996696|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132673|NCT00453245|||DEFINED_POPULATION||RETROSPECTIVE|||||||
34132674|NCT05725226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to study where two groups of treatments, Group 1 (6 Fr) and Group 2 (4Fr), are given so that Group 1 will receive 6Fr Double J stent after endourological stone fragmentation and Group 2 will receive 4Fr Double J stent after endourological stone fragmentation.|t|f|f|f
34132675|NCT05849194|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132676|NCT00939289|||COHORT||PROSPECTIVE|||||||
34132677|NCT02860234|||COHORT||PROSPECTIVE|||||||
34132678|NCT06659796|||CASE_ONLY||RETROSPECTIVE|||||||
34132679|NCT05046119|||COHORT||PROSPECTIVE|||||||
34132680|NCT03625869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Analysis of the primary endpoint, infarct size 5-days post MI assessed by CMR, will be analyzed by an independent Corelab, blinded to the allocated treatment arm.|A prospective, multicenter, randomized (1:1), controlled, study|f|f|f|t
34132681|NCT02547038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34132682|NCT05447520|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34132683|NCT05962684|||COHORT||PROSPECTIVE|||||||
34132684|NCT02498054|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34132685|NCT00551343|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132686|NCT00983333|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132687|NCT01534351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132688|NCT00908323|||CASE_ONLY||PROSPECTIVE|||||||
34132689|NCT05207033|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34132690|NCT01058915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34132691|NCT00693537|RANDOMIZED|||||||||||
33826479|NCT02440646|||COHORT||PROSPECTIVE|||||||
33826480|NCT00668785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132692|NCT04452357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132693|NCT03127917|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double-blind research study||t|f|t|f
34132694|NCT05727007|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|There will be no blindness at the level of the patient, the treating physicians (surgeon, oncologist, radiologist) and the researcher who will record the data|The study will employ a prospective design||||
34132695|NCT04809766|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132696|NCT03935867|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34132697|NCT06658158|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34132698|NCT06387927|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34132699|NCT02123771|||CASE_ONLY||PROSPECTIVE|||||||
34132700|NCT06199375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34132701|NCT05883995|||OTHER||CROSS_SECTIONAL|||||||
34132702|NCT03669666|||CASE_CONTROL||PROSPECTIVE|||||||
34132703|NCT06488092|||COHORT||PROSPECTIVE|||||||
34132704|NCT04891718|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"This Master Protocol is designed as an umbrella concept trial for the ongoing evaluation of multiple agents in individual CIVO Phase 0 substudies. Each substudy is considered an Experimental Arm with specified investigational agents and combinations to be evaluated. Comparisons will not be made between experimental arms."||||
34132705|NCT05483231|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132706|NCT05068323|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||case control|t|f|f|f
34132707|NCT04547634|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34132708|NCT05772455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132709|NCT06656052|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||research|t|f|t|t
34132710|NCT03594747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826481|NCT00888407|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33837478|NCT04867447|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34132711|NCT04524715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All participants undergo LLLT treatment; however, the active group receives LED light in the red and IR range while the placebo group is told they are receiving IR light not visible to naked eye. All participants continue receiving standard treatments for COVID19 symptoms.|Blinded before and after comparison of COVID-19 patients treated with a red-light LLLT therapy in addition to standard treatment measures compared to a control group receiving only standard treatment measures.|t|f|f|f
34132712|NCT06270082|NA|SINGLE_GROUP||TREATMENT||NONE||Dose Escalation: BOIN design Dose Expansion: 4 genetically/molecularly defined cohorts using Simon 2-stage adaptive design||||
34132713|NCT04452058|||COHORT||RETROSPECTIVE|||||||
34132714|NCT00453037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132715|NCT02690688|||COHORT||PROSPECTIVE|||||||
34132716|NCT05129657|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34132717|NCT06381076|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will receive a 3-digit coded product that either contains 7 mls of liposomal curcumin or food colorant.|Randomized comparator-controlled trial|t|f|t|f
34132718|NCT03305796|||CASE_ONLY||PROSPECTIVE|||||||
34132719|NCT02482428|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149420|NCT00875173|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149421|NCT02198235|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34132720|NCT03778749|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Twenty mechanically ventilated ICU patients: the investigators will compare the mean TOF% between three different measurement techniques in 20 mechanically ventilated ICU patients: 1/electromyographic neuromuscular transmission monitoring at the hand muscle - 2/acceleromyographic neuromuscular transmission monitoring at the hand muscle - 3/acceleromyographic neuromuscular transmission monitoring at the eyebrow muscle; and the investigators will determine how the three TOF% values vary in each individual patient.||||
34132721|NCT06281652|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132722|NCT05730556|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34132723|NCT01804439|||COHORT||PROSPECTIVE|||||||
34132724|NCT03378544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A cluster randomized controlled trial|f|f|f|t
34132725|NCT02558036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132726|NCT02427139|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132727|NCT05524857|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132728|NCT02562300|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132729|NCT02606123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132730|NCT00969306|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132731|NCT05101265|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective, open-label, parallel, phase Ib, hepatic impairment study in patients with advanced solid tumors who either have HI at varying degrees (mild, moderate or severe) or qualify for the control group (normal hepatic function) according to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) classification criteria of HI.||||
34132732|NCT05107011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132733|NCT05864430|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132734|NCT05151692|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34132735|NCT04097275|||COHORT||CROSS_SECTIONAL|||||||
34132736|NCT04645680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants will be blinded to their assigned diet throughout the intervention as will the investigators and research staff with the exception of the dietitian and the staff performing group assignment and data entry who will not have contact with participant||t|f|t|f
34132737|NCT04538118|||COHORT||PROSPECTIVE|||||||
34132738|NCT05077982|||COHORT||RETROSPECTIVE|||||||
34132739|NCT06485713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34132740|NCT00960401|||OTHER||RETROSPECTIVE|||||||
34132741|NCT06306196|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Single||t|f|f|t
34132742|NCT01391689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132743|NCT01933698|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34132744|NCT01599312|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34132745|NCT02579148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132746|NCT00785590|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132747|NCT04097028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132748|NCT00207623|RANDOMIZED|CROSSOVER||ECT||NONE||||||
34132749|NCT04145544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132750|NCT01877980|||CASE_ONLY||PROSPECTIVE|||||||
34132751|NCT00231686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132752|NCT03125031|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34132753|NCT06659874|||OTHER||CROSS_SECTIONAL|||||||
34132754|NCT01404143|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132755|NCT01120470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132756|NCT02543073|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132757|NCT05860257|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Investigators will allocate 20 high schools to intervention vs. control groups. Investigators will recruit in two cohorts (Fall 2023 and Fall 2024). Students will be in 9th grade in the first year, and will be followed into 10th, 11th, and then 12th grade, so in total the investigators will be working in each school for four years.|f|f|f|t
34132758|NCT03560960|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132759|NCT06660459|||COHORT||PROSPECTIVE|||||||
34132760|NCT00348738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132761|NCT01238991|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132762|NCT03919084|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132763|NCT00718575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132764|NCT02217423|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34132765|NCT06499415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator, who is also a physician and will evaluate treatment effect, is blinded to the allocated treatment||f|f|t|t
34132766|NCT05254990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||male and female patients \>18 years, hospitalised for COVID-19, will be assigned (1:1) to receive either oral reparixin (treatment group) or matched placebo (control group) three times a day (TID) for up to 21 days.|t|t|t|f
34132767|NCT02453152|||COHORT||PROSPECTIVE|||||||
34132768|NCT03450343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132769|NCT06662331|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Double Blind|t|f|t|f
34132770|NCT04757480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132771|NCT02030925|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132772|NCT06284460|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132773|NCT03447210|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study with nested cross-sectional studies||||
34132774|NCT03812341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132775|NCT06269185|||COHORT||RETROSPECTIVE|||||||
34132776|NCT05049564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132777|NCT04587830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132778|NCT04832789|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132779|NCT04528017|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132780|NCT06219967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132781|NCT02870517|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132782|NCT06440122|||COHORT||RETROSPECTIVE|||||||
34132783|NCT00956007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132784|NCT06659133|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This study was conducted as a randomized controlled trial to investigate the effect of music recital on pain and anxiety in women undergoing pipelined endometrial biopsy.|t|f|f|f
33826482|NCT05452421|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Two drinks similar in colour and texture have been provided by a local manufacturer which are coded. The code is held with a third party not involved in the research. Participants and researchers will be asked to guess which drink has been used at the end of each trial to confirm the effectiveness of the masking procedure.||t|f|t|t
33826483|NCT06310226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826484|NCT05463926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two-group parallel-armed randomized controlled trial (RCT) with a pretest and repeated posttest experimental design||||
33826485|NCT02788578|||OTHER||RETROSPECTIVE|||||||
33826486|NCT03650829|||COHORT||PROSPECTIVE|||||||
33826487|NCT05233098|||COHORT||PROSPECTIVE|||||||
33826488|NCT00702650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826489|NCT00056329|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826490|NCT00002597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826491|NCT03743129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826492|NCT01692132|||COHORT||PROSPECTIVE|||||||
33826493|NCT05268822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||An open-label feasibility study with study subject allocated to movement control exercise with specific breathing techniques (experimental group) or movement control exercise without specific breathing techniques (control group)|t|f|f|t
33826494|NCT05341063|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|They did not know if they were in the control and intervention group at the time of randomization.||t|f|f|f
33826495|NCT05175300|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"A single-centre, prospective, randomised, single-blind, comparative, category 2 study of two parallel groups of patients undergoing total hip arthroplasty:~* Group 1: Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.~* Group 2: Prosthesis with ceramic-on-ceramic (CoC) torque."|t|f|f|f
33826496|NCT02010983|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826497|NCT01919177|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33826498|NCT00700947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826499|NCT06266468|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention study model is a 2-arm randomized control trial with a 1:1 allocation of participants to the treatment group (Nutricity) or the control group (usual care without Nutricity). After 12 weeks in the control group, participants will be introduced to Nutricity.||||
33826500|NCT02316392|||CASE_ONLY||PROSPECTIVE|||||||
33826501|NCT06240546|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33826502|NCT02154477|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33826503|NCT03979547|RANDOMIZED|PARALLEL||TREATMENT||NONE||perform an interventional pilot trial and randomize 21 subjects who have had a complete response to TACE to a 3-month exercise intervention (n=14) versus standard of care (n=7) where subjects are instructed to maintain their current activity level.||||
33826504|NCT06009263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group will receive open chain segmental control exercises versus closed chain segmental control exercises|Group will receive ultrasound and TENS as conventional treatment|t|f|f|f
33826505|NCT03955861|||COHORT||PROSPECTIVE|||||||
33826506|NCT00949598|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33826507|NCT02428218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826508|NCT05188898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only patients will be unaware of the type of treatment performed, with prior written informed consent. So, they will be divided in the two groups of study after a process of randomization|The study will be designed as a double-arm randomized controlled clinical trial. The intraosseous defects of subjects allocated in HA group will be treated with MINSD and application of hyaluronic acid, while in No-HA Group only MINSD will be performed. The null hypothesis of no statistically significant differences between the two modalities for the treatment of intraosseous defects will be tested.|t|f|f|f
33826509|NCT03209050|NA|SINGLE_GROUP||TREATMENT||NONE||patients requiring venous access||||
33826510|NCT05449847|||CASE_CONTROL||PROSPECTIVE|||||||
33826511|NCT02694796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33826512|NCT05262218|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826513|NCT06479200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|This is a single-blind study. Participants and outcome assessors are blinded to group allocation.|This study uses a parallel group design with two arms: a VR-guided mindfulness intervention group and a sham VR control group.|t|f|f|t
33826514|NCT06379555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826515|NCT02901483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826516|NCT00000636||PARALLEL||TREATMENT||||||||
33826517|NCT02645773|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33826518|NCT02536456|||OTHER||PROSPECTIVE|||||||
33826519|NCT03128541|||CASE_CROSSOVER||PROSPECTIVE|||||||
33826520|NCT04739488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||quantitative and qualitative methods||||
33826521|NCT05767814|||CASE_CROSSOVER||PROSPECTIVE|||||||
33826522|NCT04531878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826523|NCT00571337||PARALLEL||TREATMENT||NONE||||||
33826524|NCT04854902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826525|NCT02859558|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826526|NCT03951012|||OTHER||PROSPECTIVE|||||||
33826527|NCT00113997||||TREATMENT||||||||
33826528|NCT00439647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826529|NCT00003185||||TREATMENT||||||||
33826530|NCT01397188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33826531|NCT03357471|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826532|NCT05162196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826533|NCT03179059|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33826534|NCT02176356|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33826535|NCT05896696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826536|NCT05436600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcomes assessor will be masked to group assignment.|Patients will undergo 1:1 blocked randomization on sex into either the exercise training group plus standard-of-care or the control group undergoing standard-of-care vascular risk-factor modification with weekly contact by the study team.|f|f|f|t
33826537|NCT04597099|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Randomized, placebo-controlled, double-blinded, crossover study|t|t|t|f
33826538|NCT00003502||||TREATMENT||||||||
34132785|NCT05591859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132786|NCT04982315|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34132787|NCT05155345|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132788|NCT04772625|||COHORT||RETROSPECTIVE|||||||
34132789|NCT00516906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132790|NCT05770635|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132791|NCT00143494|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132792|NCT04245306|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Three groups of children are included to be compared, in order to test the primary and secondary hypothesis of this study :~* A group of 25 children with autism spectrum disorders (ASD)~* A larger group of 190 typically developing children (TD)~* A group of 25 children with developmental language disorders (DLD)~* A group of 25 children with attention-deficit/hyperactivity disorder (ADHD group)"||||
34132793|NCT03654040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132794|NCT00833963|||COHORT||PROSPECTIVE|||||||
34132795|NCT04346173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132796|NCT04523623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132797|NCT04507048|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132798|NCT02841007|NA|SINGLE_GROUP||OTHER||NONE||||||
34132799|NCT03319459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132800|NCT06660017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator and pharmacist will be the only ones who are aware of whom gets which arm of the study.|There will be a control group and an intervention group in this study. The control group will receive an unmedicated syrup solution in addition to standard treatment for oral mucositis. The intervention group will receive ketamine oral rinse in addition to standard treatment for oral mucositis.|t|f|f|f
34132801|NCT00488449|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||||||
34132802|NCT01555073|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34132803|NCT02580123|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34132804|NCT03602157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132805|NCT03978598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132806|NCT04081402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132807|NCT06264089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132808|NCT06660654|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132809|NCT04573439|NA|SINGLE_GROUP||OTHER||NONE||"Dietary Supplement: Dietary supplement: Protein intake Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."||||
34132810|NCT02364115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132811|NCT03861104|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||one group will watch informative video and the control group will not before nasal packing removal||||
34132812|NCT04410848|||CASE_ONLY||PROSPECTIVE|||||||
34132813|NCT06555978|||COHORT||CROSS_SECTIONAL|||||||
34132814|NCT00000487|RANDOMIZED|||PREVENTION||||||||
34132815|NCT00311740|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34132816|NCT03944564|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Participants will receive a general information about the study protocol and received three conditions in a random order.|Randomized, controlled crossover trial||||
33826539|NCT04649333|||COHORT||CROSS_SECTIONAL|||||||
33826540|NCT04958941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132817|NCT01679171|||COHORT||PROSPECTIVE|||||||
34132818|NCT00002050||||TREATMENT||DOUBLE||||||
33826541|NCT01956955|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33826542|NCT03891641|RANDOMIZED|PARALLEL||TREATMENT||NONE|No Masking|Subjects will be randomized into a treadling group (n=15) or a control group (n=15). Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks. The control group will be instructed to continue their normal daily activities.||||
33826543|NCT05142072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33826544|NCT05694533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826545|NCT02935777|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33826546|NCT04218552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826547|NCT01716091|||CASE_CONTROL||PROSPECTIVE|||||||
33826548|NCT05756049|||COHORT||RETROSPECTIVE|||||||
33826549|NCT00632723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826550|NCT06173232|||COHORT||PROSPECTIVE|||||||
33826551|NCT02899819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826552|NCT04532983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the participants and the follow up surgeon don't know which received fixation|; group A; patients underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was fixed in position using absorbable Vicryl tacks (abstack30 medtronic), and group B patient underwent laparoscopic TAPP repair of inguinal hernia and the mesh prosthesis was placed in position without fixation.|t|t|f|f
33826553|NCT02579278|||COHORT||PROSPECTIVE|||||||
33826554|NCT02846935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826555|NCT00548002|||COHORT||PROSPECTIVE|||||||
33826556|NCT04612478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826557|NCT01508832|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33826558|NCT02396758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826559|NCT01929564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33826560|NCT04349657|RANDOMIZED|PARALLEL||TREATMENT||NONE|All parties will know in what arm the study subject is randomized before the study procedure|The subjects will be randomly assigned in a 1:1 manner to treatment with either the Supera stent or endarterectomy.||||
34132819|NCT00982761|||CASE_CONTROL||RETROSPECTIVE|||||||
34132820|NCT04067973|||CASE_CONTROL||PROSPECTIVE|||||||
34132821|NCT06289426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132822|NCT02574884|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132823|NCT05064358|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is an open label study|Belantamab mafodotin will be administered using various dosing regimens.||||
34132824|NCT04227795|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132825|NCT02382874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132826|NCT03367962|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34132827|NCT05332639|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132828|NCT06318273|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132829|NCT06659809|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34132830|NCT02644213|NA|SINGLE_GROUP||||NONE||||||
34132831|NCT00588549|||COHORT||PROSPECTIVE|||||||
34132832|NCT04747054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132833|NCT04956640|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132834|NCT03734016|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132835|NCT05171309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132836|NCT05749666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132837|NCT06176690|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132838|NCT06657911|||OTHER||OTHER|||||||
34132839|NCT05397041|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||SAD, FE, MAD, dose escalating|t|t|t|t
34132840|NCT00778375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132841|NCT05816993|||OTHER||PROSPECTIVE|||||||
34132842|NCT00434447|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34132843|NCT06176430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|laboratory personnel only will be blind||f|f|f|t
34132844|NCT04493541|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132845|NCT06658509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34132846|NCT06655181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132847|NCT00151684|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132848|NCT05968495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132849|NCT02483923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132850|NCT05359276|||COHORT||PROSPECTIVE|||||||
34132851|NCT06426693|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132852|NCT00386217|||COHORT||PROSPECTIVE|||||||
34132853|NCT06125236|||COHORT||PROSPECTIVE|||||||
34132854|NCT01133756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132855|NCT05790018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34132856|NCT06215859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132857|NCT00713778|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132858|NCT04829682|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Everyone except for the biostatistician will be blind to condition until randomization at the end of the pre-treatment assessment session. Outcome assessors will remain blind to condition for the duration of the study.|Participants will be randomized to ACT for Life or Present Centered Therapy. Additionally all participants will continue to receive treatment as usual.|t|t|t|t
34132859|NCT01674049|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34132860|NCT00392158|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826561|NCT00507975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33826562|NCT00925288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826563|NCT02836054|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33826564|NCT00308841|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34132861|NCT06482229|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|t|t|f
34132862|NCT01519687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132863|NCT03650413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132864|NCT05095727|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132865|NCT06464705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132866|NCT03884660|||COHORT||PROSPECTIVE|||||||
34132867|NCT06662344|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33826565|NCT01820221|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826566|NCT00372177|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826567|NCT01951378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826568|NCT02747719|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826569|NCT03681353|NA|SINGLE_GROUP||OTHER||NONE||||||
33826570|NCT02304562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826571|NCT01780545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132868|NCT03394651|||COHORT||PROSPECTIVE|||||||
34132869|NCT03855787|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132870|NCT05501080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132871|NCT06040424|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, Parallel Group, Phase III, Non-inferiority Study||||
34132872|NCT03420495|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The current study has two diagnostic arms (the OCD group and the Non-Psychiatric Control group) all receiving a single interventional protocol.||||
34132873|NCT04749628|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34132874|NCT03647345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34132875|NCT02709551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826572|NCT06171282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826573|NCT04597905|||COHORT||CROSS_SECTIONAL|||||||
33826574|NCT03460093|||CASE_CONTROL||PROSPECTIVE|||||||
33826575|NCT01012596|||COHORT||PROSPECTIVE|||||||
33826576|NCT02740621|||CASE_CONTROL||PROSPECTIVE|||||||
33826577|NCT00151697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826578|NCT03847922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are blinded to their group assignment (they are not aware of whether they are receiving nitrous oxide or room air)|Randomized controlled trial with patients randomized 1:1 into two groups|t|f|f|f
34132876|NCT04630860|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132877|NCT05509647|||COHORT||RETROSPECTIVE|||||||
34132878|NCT04458532|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a single-center randomized controlled trial (RCT) study designed to evaluate the cardiorespiratory fitness (CRF) response rate to different aerobic therapy (AT) doses in patients with post-treatment primary breast cancer.||||
34132879|NCT06025942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132880|NCT05236179|||COHORT||CROSS_SECTIONAL|||||||
34132881|NCT01880294|||COHORT||CROSS_SECTIONAL|||||||
34132882|NCT05614258|NA|SEQUENTIAL||TREATMENT||NONE||||||
34132883|NCT01594554|||COHORT||PROSPECTIVE|||||||
34132884|NCT05327127|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34132885|NCT03028415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132886|NCT00020098||||PREVENTION||||||||
34149422|NCT03987386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132887|NCT04361136|RANDOMIZED|PARALLEL||OTHER||DOUBLE||All subjects will receive all treatments with treatments randomised over test fields.|t|f|f|t
33826579|NCT04151823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132888|NCT04697537|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34132889|NCT05915195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132890|NCT02270528|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34132891|NCT06352060|||COHORT||RETROSPECTIVE|||||||
34132892|NCT00140907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132893|NCT01581021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132894|NCT00741897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132895|NCT01555034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132896|NCT06454890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132897|NCT02771574|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|t|f|f
34132898|NCT06477393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants can guess indirectly, and the main researcher, the laboratory investigator, will be blind to the group assignments. This single-blinded design is chosen to facilitate the implementation and adherence to the rehabilitation programs.|The study employs a parallel-group design, where participants are randomly assigned to one of two groups: an experimental group receiving the enhanced rehabilitation program with natural healing factors and a control group receiving the standard rehabilitation program. The randomisation ensures that each participant has an equal chance of being assigned to either group, minimising selection bias and ensuring comparability between the groups.|f|f|t|f
34132899|NCT03660865|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Select post operative assessments will be performed on both the experimental and control eye by an examiner who will be masked to the eye assignments.|All subjects will receive the same treatment; however, each subject will have their eyes randomized to receive the experimental treatment in either the left/right eye. The control will then be assigned to the other.||||
34132900|NCT01835288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132901|NCT00737217|||CASE_CONTROL||PROSPECTIVE|||||||
34132902|NCT00001244|||COHORT||PROSPECTIVE|||||||
34132903|NCT06637488|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132904|NCT06614855|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132905|NCT04742803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132906|NCT02063867|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34132907|NCT04401800|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132908|NCT02557451|RANDOMIZED|PARALLEL||||NONE||||||
34132909|NCT01925040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34132910|NCT05327660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132911|NCT03730233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization process was initiated after general anesthesia had been induced and the group affiliation was determined by opening of a sealed envelope specifying the group assignment. The subsequent operation report, with information on the specific type of repair performed, was not included in the digital patient-chart. Instead, a hard copy was printed and kept in a sealed envelope, which was filed in a locked archive to maintain the patient, staff and clinical assessors blinded to the study group allocation.|repair by tension-free mesh closure or simple suturing of the diaphragmatic|t|f|f|t
34132912|NCT04964505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132913|NCT02985918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34132914|NCT01400061|||COHORT||PROSPECTIVE|||||||
34132915|NCT04861818|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826580|NCT00170417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826581|NCT02692287|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||If the device is not of the correct size, then the device is changed and the recruitment process is repeated until the correct size is obtained.||||
33826582|NCT02370199|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826583|NCT05927506|||OTHER||OTHER|||||||
33826584|NCT01497340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826585|NCT04488978|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33826586|NCT02596399|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826587|NCT00996359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132916|NCT02603237|RANDOMIZED|CROSSOVER||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34132917|NCT01947621|||COHORT|||||||||
34132918|NCT06542978|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34132919|NCT01429597|||COHORT||PROSPECTIVE|||||||
34132920|NCT03799055|||OTHER||PROSPECTIVE|||||||
34132921|NCT03292549|||COHORT||PROSPECTIVE|||||||
34132922|NCT05219149|||COHORT||PROSPECTIVE|||||||
34132923|NCT04609592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132924|NCT01326884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132925|NCT06306911|NA|SINGLE_GROUP||OTHER||NONE||||||
34132926|NCT06152042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|COVALENT-112 consists of two parts. Part 1 is a single-arm, open-label study; Part 2 is a randomized, double-blind, placebo-controlled study. Both will enroll adults with Stage 3 T1D (HbA1c ≥6.5 and ≤ 10.0%).||t|t|t|f
34132927|NCT03792438|||COHORT||CROSS_SECTIONAL|||||||
34132928|NCT06125184|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The statisticians and researcher responsible to perform the measurement will be blinded to the group allocation. Nonetheless, the research nurse responsible for event assignment will not be blinded to the group allocation.|Prospective, randomized, double-blinded, controlled clinical trial.|t|t|t|f
34132929|NCT06112288|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34132930|NCT03971318|||COHORT||PROSPECTIVE|||||||
34132931|NCT06654856|||CASE_ONLY||PROSPECTIVE|||||||
34132932|NCT04571424|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34132933|NCT03239951|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132934|NCT06084182|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132935|NCT02047773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132936|NCT05617989|||COHORT||PROSPECTIVE|||||||
34132937|NCT06312579|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a single center, randomized, outcome assessor blinded, parallel group clinical trial comparing a 12-week exercise regimen to standard of care.|f|f|f|t
34132938|NCT04611347|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized controlled trial with crossover|t|t|t|t
33826588|NCT01797978|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826589|NCT02657421|||COHORT||PROSPECTIVE|||||||
33826590|NCT04502043|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826591|NCT04835233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33826592|NCT05001425|||COHORT||PROSPECTIVE|||||||
33826593|NCT04083937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826594|NCT00004097||||TREATMENT||||||||
33826595|NCT03313583|||CASE_ONLY||PROSPECTIVE|||||||
33826596|NCT00020969||||TREATMENT||||||||
33826597|NCT06153498|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33826598|NCT01280383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826599|NCT04767802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826600|NCT00332488|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826601|NCT03284489|||COHORT||PROSPECTIVE|||||||
33826602|NCT03856398|||CASE_ONLY||PROSPECTIVE|||||||
33826603|NCT05784649|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33826604|NCT00518583|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826605|NCT01750086|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826606|NCT00977795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826607|NCT02917798|||COHORT||PROSPECTIVE|||||||
33826608|NCT04782700|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826609|NCT05363605|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33826610|NCT00251290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826611|NCT00672672|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826612|NCT04933838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826613|NCT01319864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826614|NCT01885936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826615|NCT00039117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826616|NCT01704547|||OTHER||PROSPECTIVE|||||||
33826617|NCT02654899|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33826618|NCT02450097|NA|SINGLE_GROUP||OTHER||NONE||||||
33826619|NCT02845713|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826620|NCT06347770|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33826621|NCT05537519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826622|NCT01219777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826623|NCT00564252|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33826624|NCT05279534|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|All study staff, including the Principal Investigator and the persons performing the subject assessments, will be blinded during the study. Sealed individual treatment code envelopes will be kept at the clinic to be able to break the code if any emergency occurs, as judged by the Investigator|Randomized controlled trials. Study subjects (6 months to 5 years-old) will be allocated to receive a combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and P. acidilactici CECT7483 (arm one) or placebo (arm two)|t|t|t|t
33826625|NCT02673554|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826626|NCT03447977|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826627|NCT05550714|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826628|NCT04523298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826629|NCT01180790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826630|NCT02509988|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33826631|NCT06144788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|t|t|f
33826632|NCT00554086|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826633|NCT00026013|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33826634|NCT04993807|NA|SINGLE_GROUP||OTHER||NONE||This is a single arm feasibility study.||||
33826635|NCT01193023|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33826636|NCT00286975|RANDOMIZED|PARALLEL||||SINGLE||||||
33826637|NCT00096109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826638|NCT06175221|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Open Label, All Comers, Single Arm Study.||||
33826639|NCT04848103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826640|NCT02043470|||CASE_ONLY||PROSPECTIVE|||||||
33826641|NCT01729923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826642|NCT01580111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33826643|NCT03377725|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826644|NCT06162325|||COHORT||PROSPECTIVE|||||||
34132939|NCT00579618|||COHORT||PROSPECTIVE|||||||
34132940|NCT05803161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132941|NCT00814021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132942|NCT05294497|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34132943|NCT06658223|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal quasi-experimental study. The application of the study protocol will be carried out, in its entirety, at the kinesiology center of the Universidad San Sebastián, Concepción campus.||||
34132944|NCT06156176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessors (physiotherapists) will be blinded to group allocation.|There are two parallel treatment groups: COVIDEx rehabilitation program and standard of care.|f|f|f|t
33826645|NCT06162065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||prospective experimental study|f|f|f|t
33826646|NCT04655183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826647|NCT06399341|||OTHER||PROSPECTIVE|||||||
33826648|NCT00255671|||CASE_ONLY||PROSPECTIVE|||||||
33826649|NCT02587923|||CASE_ONLY||RETROSPECTIVE|||||||
33826650|NCT05908305|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|Dentists providing dental care participating in the study are masked.|Assessing local dental anesthesia success while performing different dental care among Algerian males addicted or not addicted to tramadol.|f|t|f|f
33826651|NCT01939405|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826652|NCT02482935|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33826653|NCT06400797|||COHORT||PROSPECTIVE|||||||
33826654|NCT02604706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826655|NCT01194271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826656|NCT01182181|RANDOMIZED|CROSSOVER||||NONE||||||
33826657|NCT04563247|||COHORT||RETROSPECTIVE|||||||
33826658|NCT00097669|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34132945|NCT03980743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132946|NCT02745678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132947|NCT04463563|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The personnel assessing and collecting the post-operative data were unaware of the patient group in the operating room.|This prospective, single centre, double-blinded controlled study randomized 182 consecutive patients, scheduled for cardiac surgical procedures using cardiopulmonary bypass. Participants were randomized by concealed envelope.|t|f|f|t
34132948|NCT04655807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34132949|NCT01198210|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34132950|NCT06538025|||OTHER||RETROSPECTIVE|||||||
34132951|NCT00799227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132952|NCT03363360|||OTHER||CROSS_SECTIONAL|||||||
34132953|NCT02963363|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132954|NCT01834950|NA|SINGLE_GROUP||OTHER||NONE||||||
34132955|NCT04608383|||CASE_ONLY||PROSPECTIVE|||||||
34132956|NCT00386750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132957|NCT02791516|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34132958|NCT04458935|||COHORT||OTHER|||||||
34132959|NCT03015363|||CASE_ONLY||PROSPECTIVE|||||||
34132960|NCT01222598|||||RETROSPECTIVE|||||||
34132961|NCT01241188|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34132962|NCT05713981|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34132963|NCT03005561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34132964|NCT03482648|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132965|NCT06650228|||CASE_ONLY||CROSS_SECTIONAL|||||||
34132966|NCT05128864|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34132967|NCT06549166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132968|NCT04678986|||COHORT||OTHER|||||||
34132969|NCT02287090|||COHORT||PROSPECTIVE|||||||
34132970|NCT02422693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34132971|NCT01837446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34132972|NCT00263042|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34132973|NCT01027494|||CASE_CONTROL||PROSPECTIVE|||||||
34132974|NCT00100256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34132975|NCT04789629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomize clinical trail|f|f|t|t
34132976|NCT00328887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132977|NCT01339819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132978|NCT01704950|||COHORT||PROSPECTIVE|||||||
34132979|NCT03082443|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34132980|NCT06544785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132981|NCT01320839|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34132982|NCT05406739|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34132983|NCT05734443|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34132984|NCT00394043|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34132985|NCT04638413|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34132986|NCT02066831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34132987|NCT03101488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132988|NCT05541627|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34132989|NCT05611645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132990|NCT02422641|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34132991|NCT02483793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34132992|NCT04556591|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This behavioral trial will use a two-arm randomized controlled design.||||
34132993|NCT04351399|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34132994|NCT03926741|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34132995|NCT01191736|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34132996|NCT02691520|||COHORT||RETROSPECTIVE|||||||
34132997|NCT05081518|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34132998|NCT05271253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients were randomly allocated into 3 equal groups (25 patients each): Group (C): caudal group, where caudal anaesthesia was given using 1 mL/kg dose of 0.25% bupivacaine without epinephrine. Dexmedetomidine (D) group, where Dex. (Precedex, hospira, Egypt) 0.8 μg/kg was given intravenously over 10 min as a loading dose, and then infused at a rate of 0.4 μg/kg/h; and Placebo (P) group, where normal saline instead of Dex was given in volume (ml) and rate (ml/h) calculated related to the patient's body weight.|t|f|f|f
34132999|NCT06661551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133000|NCT06427096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133001|NCT01198704|||COHORT||PROSPECTIVE|||||||
34133002|NCT03702868|||COHORT||PROSPECTIVE|||||||
34133003|NCT00203866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133004|NCT05709561|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Student|randomized controlled trial|t|f|f|f
34133005|NCT06352151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133006|NCT00039780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133007|NCT04787549|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133008|NCT00304616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133009|NCT06057935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133010|NCT01907321|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133011|NCT02749006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133012|NCT06203392|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Assessment of some but not all outcomes will be masked. More specifically, assessment of all outcomes determined by laboratory assay will be masked (e.g., bone turnover markers and 24-hour urine analytes).||f|f|f|t
34133013|NCT04693702|||COHORT||OTHER|||||||
34133014|NCT03851328|||COHORT||PROSPECTIVE|||||||
34133015|NCT03889340|||COHORT||PROSPECTIVE|||||||
34149423|NCT04419441|||CASE_ONLY||RETROSPECTIVE|||||||
34149424|NCT04248335|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34149425|NCT02198690|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34149426|NCT02155530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149427|NCT00819455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133016|NCT05960643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The sample size of the study was calculated in the G\*Power 3.1.9.7 program such that the error amount was α=0.05, the power of the test was 0.80 (80%) and the effect size was 0.60. As a result of the statistical analysis, it was found that a total of 90 students, 45 in the experimental group and 45 in the control group, should be included in the study. Considering that if the sample size increases, the standard error will decrease and the working power will increase, each group was increased by 22% (10 people) and it was planned to include 110 students in the study, 55 students for each group. In the first stage, the sample consisted of 148 students who agreed to participate in the study. In the second phase of the study, the sample was planned to consist of 110 female students selected by simple and stratified randomization method (55 experimental, 55 control).|t|f|f|f
34133017|NCT04837118|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133018|NCT06658418|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34133019|NCT04679623|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133020|NCT04521231|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133021|NCT02569476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133022|NCT06586138|||COHORT||PROSPECTIVE|||||||
34133023|NCT06660147|||COHORT||RETROSPECTIVE|||||||
34133024|NCT03286543|RANDOMIZED|PARALLEL||TREATMENT||NONE||Half of the subjects enrolled will be randomized (like flipping a coin) to the treatment group and half will be randomized to the control group. Both groups will receive the standard of care for pain management following total knee replacement surgery. Subjects in the treatment group will receive SPR's SPRINT Beta Peripheral Nerve Stimulation (PNS) System in addition to standard of care.||||
34133025|NCT06484127|||CASE_CONTROL||RETROSPECTIVE|||||||
34133026|NCT06289361|||COHORT||RETROSPECTIVE|||||||
34133027|NCT01112345|||COHORT||PROSPECTIVE|||||||
34133028|NCT03870451|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34133029|NCT00332384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34133030|NCT05627232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133031|NCT06660693|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, pragmatic, multi-centre, randomized control trial.||||
34133032|NCT05962645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133033|NCT02192151|||CASE_CROSSOVER||PROSPECTIVE|||||||
34133034|NCT03935672|NA|SINGLE_GROUP||TREATMENT||NONE||PEARL is a prospective, interventional, non-randomised, phase II feasibility study for patients with good prognosis Human Papillomavirus (HPV)-associated oropharyngeal squamous cell cancer (OPSCC) who are suitable for treatment with concurrent chemo-radiotherapy (CCRT).||||
34133035|NCT03302884|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34133036|NCT06661577|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34133037|NCT01545934|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133038|NCT05647837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133039|NCT01604577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133040|NCT00150111|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133041|NCT06382870|NA|SINGLE_GROUP||OTHER||NONE||||||
34133042|NCT04473274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Matching cohort||||
33826659|NCT04410315|||CASE_CONTROL||PROSPECTIVE|||||||
34133043|NCT01741233|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826660|NCT03065205|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34133044|NCT06660797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34133045|NCT00540657|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133046|NCT06539338|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133047|NCT06411327|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Masking not possible given the nature of the intervention(s)|"Our factorial study design will assess the individual and synergistic impact of two interventions designed to provide decision support: (a) Augmented reality devices; and (b) LCD Screen.~Intervention A: Augmented Reality Devices Intervention B: LCD Screen Intervention C: InterFACE-AR System Control Group: AHA Pocket Reference Card"||||
34133048|NCT06660719|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133049|NCT00780143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133050|NCT06660303|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34133051|NCT05243121|||COHORT||PROSPECTIVE|||||||
34133052|NCT04233398|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in the test group will be treated with high intensity focused ultrasound (HIFU), while patients in the control group will be actively observed and followed up by ultrasound examination. during the follow-up period, the follow-up visits time and follow-up examination items (clinical examination, ultrasonic examination and laboratory examination etc.) were the same in the both groups||||
34133053|NCT01377909|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133054|NCT04908384|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133055|NCT04299503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|All site staff will be masked with the exception of pharmacy staff|Double-Blind Period: Weeks 0-12; Open-Label Period: Weeks 12-24|t|t|t|t
34133056|NCT04004221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133057|NCT05223179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133058|NCT04000607|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133059|NCT03707990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|In total, 11 cohorts are planned. Five cohorts in Part 1 (cohort 1-5), and 6 cohorts (cohort 6-11) in Part 2. Each cohort will contain 8 participants. The first 2 participants will be randomised so one participant will receive active (Part 1: NNC0165-1875; Part 2: NNC0165-1875 and semaglutide) while the other receive placebo (Part 1: placebo; Part 2: placebo and semaglutide) treatment. The participants will remain in-house for a 5 days safety observation period. The remaining 6 subjects will be dosed at least after 96 hours.|t|t|t|t
34133060|NCT02402205|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34133061|NCT06166459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133062|NCT06504459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133063|NCT04183504|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||One group pretest-posttest design||||
34133064|NCT00744380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133065|NCT02360670|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33826661|NCT05600036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33826662|NCT06355128|||COHORT||CROSS_SECTIONAL|||||||
34133066|NCT02492191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33826663|NCT03226353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826664|NCT06498804|||COHORT||RETROSPECTIVE|||||||
33826665|NCT05950776|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind: two or more parties are unaware of the intervention assignment.|"Male and female individuals in stable health conditions (group I and II, see below) will be stratified for age and included to the following groups with a random allocation to one of the two dose groups or the placebo in a 4:4:1 ratio:~* 1 x 107 ± 0.5 log IU MVA-SARS-2-S~* 1 x 108 ± 0.5 log IU MVA-SARS-2-S~* Placebo~Male and female individuals in stable health conditions will be stratified for age and randomized to low dose, hogh dose of MVA SARS-2-S or the placebo in a 4:4:1 ratio:~* 1 x 107 ± 0.5 log IU MVA-SARS-2-S~* 1 x 108 ± 0.5 log IU MVA-SARS-2-S~* Placebo"|t|f|t|t
33826666|NCT06448936|||COHORT||PROSPECTIVE|||||||
33826667|NCT04609410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826668|NCT03364478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826669|NCT05939089|||COHORT||RETROSPECTIVE|||||||
33826670|NCT04331015|||COHORT||RETROSPECTIVE|||||||
33826671|NCT04704388|||COHORT||RETROSPECTIVE|||||||
33826672|NCT00246610|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826673|NCT03635840|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826674|NCT02936492|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33826675|NCT04912700|||COHORT||RETROSPECTIVE|||||||
33826676|NCT01233414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826677|NCT01859221|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826678|NCT02906696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826679|NCT04081428|||COHORT||PROSPECTIVE|||||||
33826680|NCT06136507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826681|NCT05375617|||COHORT||PROSPECTIVE|||||||
33826682|NCT04440930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826683|NCT03722797|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826684|NCT04615910|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Type 1 Diabetes Mellitus|f|f|t|f
33826685|NCT03858647|||COHORT||PROSPECTIVE|||||||
33826686|NCT02730000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826687|NCT06295315|||COHORT||PROSPECTIVE|||||||
33826688|NCT03675412|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All eyes will undergo imaging to measure blood flow in the back of the eye (retina and optic nerve) using the Avanti AngioVue HD OCTA (optical coherence tomography angiography)||||
33826689|NCT05955755|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826690|NCT00706914|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826691|NCT04052932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826692|NCT04509414|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826693|NCT00262249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826694|NCT01967719|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33826695|NCT00917423|||CASE_CONTROL||PROSPECTIVE|||||||
33826696|NCT01533558|||CASE_ONLY||PROSPECTIVE|||||||
33826697|NCT06478810|NA|SINGLE_GROUP||OTHER||NONE||||||
33826698|NCT01520077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826699|NCT01457833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826700|NCT01039259|||CASE_CONTROL||PROSPECTIVE|||||||
33826701|NCT04384718|||CASE_CONTROL||PROSPECTIVE|||||||
33826702|NCT02347969|NA|SINGLE_GROUP||||NONE||||||
33826703|NCT00688077|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33826704|NCT01701271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826705|NCT04826926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826706|NCT05033899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|single||f|f|f|t
33826707|NCT03688997|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Fifteen attending surgeons and 30 first year surgical residents were recruited to the study held at tertiary medical center during the years 2016-2017. The participants tied eight knots in different settings (Superficial vs. Deep) and techniques (One hand vs. two hands).||||
33826708|NCT01999543|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33826709|NCT05286008|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double (Investigator, Outcomes Assessor)||f|f|t|t
33826710|NCT02181998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826711|NCT01547247|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33826712|NCT01717547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826713|NCT03905421|||COHORT||PROSPECTIVE|||||||
33826714|NCT01935596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826715|NCT06302413|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All study participants are randomly assigned to a group prior to study enrollment. Participants will not be made aware of their group assignment.||t|f|f|f
33826716|NCT02459808|||COHORT||CROSS_SECTIONAL|||||||
33826717|NCT01376050|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33826718|NCT02205723|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826719|NCT00361842|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826720|NCT02251340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826721|NCT03220165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826722|NCT02867111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33826723|NCT06104579|||COHORT||PROSPECTIVE|||||||
33826724|NCT02234635|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826725|NCT03557450|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33826726|NCT02987322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826727|NCT00275145|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33826728|NCT04854278|||COHORT||PROSPECTIVE|||||||
33826729|NCT04435405|||CASE_ONLY||RETROSPECTIVE|||||||
34133067|NCT02680041|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133068|NCT04907305|||COHORT||PROSPECTIVE|||||||
34133069|NCT03702569|||CASE_ONLY||PROSPECTIVE|||||||
34133070|NCT00314899|||||OTHER|||||||
34149428|NCT05258539|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149429|NCT01943552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149430|NCT04546542|||COHORT||PROSPECTIVE|||||||
34149431|NCT00211952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149432|NCT02938273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133071|NCT05292924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||6000 births per year were considered, of which 30% correspond to births by cesarean section. For a non-random and voluntary sampling with a homogeneous population and a sampling error of 5%, at a confidence level of 95%, the sample size is 278. Of this number of participants, 50% will be assigned to the experimental group (birth by cesarean section and EFS within the first 30 minutes of birth) and 50% to the control group (caesarean birth and EFS one hour after birth) by simple randomization.||||
34133072|NCT01794208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133073|NCT06236087|||COHORT||PROSPECTIVE|||||||
34133074|NCT06036355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133075|NCT00568763|RANDOMIZED|||TREATMENT||||||||
34133076|NCT02061072|||OTHER||OTHER|||||||
34133077|NCT06621732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133078|NCT03122808|||CASE_CONTROL||RETROSPECTIVE|||||||
34133079|NCT05517980|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133080|NCT00002032||||TREATMENT||DOUBLE||||||
34133081|NCT05804955|||COHORT||PROSPECTIVE|||||||
34133082|NCT02557776|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133083|NCT06251375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To maintain blinding of patients, investigators, clinical staff, and research coordinators, pre-packaged study medication kits will be used. Upon randomization, the website will assign a unique study number and a unique 'medication kit number' to each participant. The unique medication kit number is matched to blinded study drug according to the patient's treatment allocation, supplied to the site. Each medication kit will contain either: dexmedetomidine 200 µg/2 ml vials or normal saline vials. Blinding of study medications within the medication kit will be achieved by identical labelled 2 ml vials.|The SPICE IV trial is a prospective, double-blind, placebo controlled, randomised trial of early sedation with dexmedetomidine in invasively mechanically ventilated patients who are ≥ 65 years of age and who are expected to remain ventilated more than one calendar day after randomization|t|t|t|t
34133084|NCT06405607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133085|NCT00937742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133086|NCT00097227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133087|NCT03929952|NA|SINGLE_GROUP||OTHER||NONE||||||
34133088|NCT06393920|||COHORT||PROSPECTIVE|||||||
34133089|NCT02621541|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133090|NCT04416152|||CASE_ONLY||OTHER|||||||
34133091|NCT05285215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133092|NCT00750568|||COHORT||PROSPECTIVE|||||||
34133093|NCT04481204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133094|NCT01231334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34133095|NCT01435473|||COHORT||PROSPECTIVE|||||||
34133096|NCT02142400|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34133097|NCT05947461|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants in the interventional group received 100mg rectal dicfenac|t|t|t|t
34133098|NCT06660251|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A randomized, crossover intervention with two active groups (subjects with and without MetS) using two test foods (egg and meat, with high content of TMAO precursors) was carried out.||||
34133099|NCT03940638|||CASE_ONLY||RETROSPECTIVE|||||||
34133100|NCT06078371|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will be conducted using block randomization, with two six-month blocks of patient enrollment. Block selection will be determined based on the date of the surgery.||||
34133101|NCT06659978|||COHORT||CROSS_SECTIONAL|||||||
34133102|NCT06658561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133103|NCT04322474|||COHORT||PROSPECTIVE|||||||
34133104|NCT02896881|||OTHER||CROSS_SECTIONAL|||||||
34133105|NCT04270682|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Two-cohort study. One cohort is for adult patients with a double-blind placebo withdrawal (with CDCA rescue) crossover. Second cohort will dose titrate pediatric patients into a stable, open-label treatment.|t|t|t|t
34133106|NCT00146926|RANDOMIZED|PARALLEL||||DOUBLE||||||
34133107|NCT02836470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133108|NCT06662201|||COHORT||PROSPECTIVE|||||||
34133109|NCT02079116|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34133110|NCT05787899|||COHORT||PROSPECTIVE|||||||
34133111|NCT00081549|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133112|NCT03088930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133113|NCT05274971|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Experimental group versus Control group|f|f|f|t
34133114|NCT00073736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133115|NCT04435639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor was blinded to treatment allocation. They evaluated participant's prior to treatment commencing and after treatment has been completed and compression garment/ compression bandaging has been removed.|Pilot Randomised Controlled Trial|f|f|f|t
34133116|NCT00663806|RANDOMIZED|PARALLEL||||NONE||||||
34133117|NCT06416150|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34133118|NCT01143363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34133119|NCT02638467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133120|NCT06169943|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The outcome assessor will be blinded to the participants' group allocation throughout the study.|Intervention group Control group|f|f|f|t
34133121|NCT02459431|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34133122|NCT03670654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All the measurements will be performed by a blinded professional, who will be masked from randomization and other results. For each test, the same investigator will be maintained before and after the intervention. The participants will know what treatment (exercise) they will receive, but they don't will know what exercise belongs to the control group.||f|f|f|t
34133123|NCT00119769|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133124|NCT01213459|||CASE_ONLY||PROSPECTIVE|||||||
34133125|NCT01536028|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34133126|NCT00463138|||CASE_ONLY||CROSS_SECTIONAL|||||||
34133127|NCT05671718|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|We will mask the investigators, statistician and safety review committee to treatment assignment.|Nurse-led primary care management for patients newly diagnosed with rifampicin-resistant tuberculosis (i.e. intervention) will be compared to physician-led, hospital-based management (i.e. standard of care)|f|f|t|t
34133128|NCT06110936|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34133129|NCT03872895|||OTHER||PROSPECTIVE|||||||
34133130|NCT01912443|||COHORT||PROSPECTIVE|||||||
34133131|NCT05407649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133132|NCT06661070|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A triple-blinded, pilot randomized controlled trial|t|f|t|f
34133133|NCT01781806|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133134|NCT06659471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133135|NCT03869385|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133136|NCT01899950|||CASE_ONLY||PROSPECTIVE|||||||
34133137|NCT04230733|||CASE_ONLY||RETROSPECTIVE|||||||
34133138|NCT04379635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133139|NCT05549232|||COHORT||PROSPECTIVE|||||||
34133140|NCT05910957|||CASE_CONTROL||PROSPECTIVE|||||||
34133141|NCT06431672|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133142|NCT00485758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133143|NCT04054479|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34133144|NCT03392831|RANDOMIZED|PARALLEL||OTHER||NONE||Prospective Randomized Open Blinded End-Point (PROBE) study||||
34133145|NCT02003794|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133146|NCT02231892|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Within-subject design with each subject completing up to 10 rTMS sessions.|t|f|t|f
34133147|NCT05337982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants' primary physical therapist who will also be the outcomes assessor for clinical outcomes will be masked. Two collaborators will be masked when assessing outcomes including myelin plasticity and biomechanical outcomes.||f|t|f|t
34133148|NCT04552041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind placebo-controlled randomized|t|t|t|t
34133149|NCT01679600|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133150|NCT04252313|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The infant's parents signing the participation consent are blinded to the child's randomization allocation. The Surgeon performing the circumcision is wearing noise-cancelling headphones, therefore is unaware of the patient's randomization. The outcomes assessors are evaluating the videos in mute. Both surgeons and assessors are investigators on the study; only the statistician, the study coordinator and the assistant are aware of the randomization allocation.|Participants are assigned to either the control group \[Only EMLA+Sucrose+Ring Block\] or the Intervention \[EMLA+Sucrose+Ring Block+ Music\]|t|t|t|t
34133151|NCT06516146|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Adults 50-75 years of age without a diagnosis of a neurodegenerative condition, will be recruited and screened for eligibility. Sixty participants will be randomly assigned to the waitlist group or the intervention group and will be striated into cohorts blocks. Each cohort block will start the intervention at the same time and will participate in the intervention together. This will allow for social interaction, engagement with their peers, and hopefully encouraging better adherence.||||
34133152|NCT02963168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133153|NCT03718806|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"It is planned to enroll 2 cohorts of 24 subjects each. Single doses of zoliflodacin (3 g and 4 g) will be assessed within each cohort in a two period cross-over design.~Cohort 1~* Regimen A: 3 g zoliflodacin oral suspension; oral administration after an overnight fast~* Regimen B: 3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast~Cohort 2~* Regimen C: 4 g zoliflodacin oral suspension; oral administration after an overnight fast~* Regimen D: 4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast~There will be a minimum washout of 4 days between each period."||||
34133154|NCT01166893|||CASE_ONLY||PROSPECTIVE|||||||
34133155|NCT06180616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133156|NCT00883818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133157|NCT06210594|RANDOMIZED|PARALLEL||PREVENTION||NONE||"This study will be an open-label randomized controlled trial to determine the feasibility, acceptability, and efficacy of a carriage suppression regimen in reducing the prevalence of SA carriage and SA infections among adults at high risk of SA infections who are currently carrying SA in the oropharynx or anterior nares. Participants will be randomized in a ratio of 1:1 to either:~1. education about SA and receipt of household supplies to reduce SA transmission in the home plus use of a nasal antibiotic twice daily for 5 days then maintenance with an antiseptic regimen (N=50; intervention group);~   or~2. education/household supplies alone (N = 50; control group).~All participants will be followed for 4 months."||||
34133158|NCT06658548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133159|NCT06314659|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133160|NCT03090659|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133161|NCT00999635|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34133162|NCT06406582|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants: Single-blind. Participants are unaware of which ceramic laminate veneer material (Zirconia or Lithium Disilicate) they are receiving.|Zirconia Group (Intervention): Participants receive zirconia laminate veneers. Lithium Disilicate Group (Control): Participants receive lithium disilicate laminate veneers. Lithium disilicate is a standard ceramic material for laminate veneers.|t|f|f|f
34133163|NCT05932654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149433|NCT02759991|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||"1. Pilot study completed in 2017 with 100 participants, 50 women and 50 men aged 16-39, randomized to be vaccinated with either 2 doses of Hecolin or Hepa-B. These 100 participants are not included in the main trial.~2. Main clinical trial designed to enroll 20.745 women aged 16-39 years living in Matlab area. All participants randomized to be vaccinated with either Hecolin or Hepa-B three doses."|t|t|t|t
34149434|NCT01704703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149435|NCT00226070|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
34149436|NCT01779505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149437|NCT05484284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149438|NCT06181370|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34149439|NCT01128088|||COHORT||PROSPECTIVE|||||||
34133164|NCT04470050|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Phase 1b: morphine maintenance, blinded to BXCL501 sublingual treatment (placebo).~Phase 2: Randomized, Double-blind, placebo-controlled (4:1, active to placebo ratio, respectively).~Follow-On portion of Phase 2: Double-blind, placebo-controlled (treatment with morphine-placebo capsules and BXCL501-placebo sublingual films as administered during phase 1b)"|"Phase 1b: The blinded opioid maintenance phase (Days 1 to 5). Doses of morphine during Phase 1b varied at the discretion of the investigator, between 120-150 mg per day, depending on patients abuse history and need for a higher dose to stabilize withdrawal symptoms. In addition to morphine maintenance, all subjects received sublingual placebo films, approximately 12 hours apart, at 8 am and 8 pm (30min) during this period to simulate and thus blind treatment to BXCL501 sublingual films during Days 6 to 12 (Phase 2).~Phase 2: The randomized BXCL501/placebo phase (both active and placebo administered as sublingual films) occurred on Days 6 to 12, followed by 2 days of BXCL501-placebo sublingual film and morphine-placebo capsule treatment for all remaining subjects on Days 13 and 14 following the dosing timeline as administered in the Phase 1b portion of the study."|t|t|t|t
34133165|NCT02748421|RANDOMIZED|PARALLEL||||NONE||||||
34133166|NCT03625778|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In Cohort 1 participants are blinded however site staff, investigator, and sponsor are unblinded. In Cohorts 2 and 3 participants, investigators, site staff, and clinical research organization staff are blinded and sponsor is unblinded.||t|t|t|f
34133167|NCT04994028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133168|NCT04027283|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34133169|NCT05636046|||COHORT||OTHER|||||||
34133170|NCT05815810|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133171|NCT01509976|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34133172|NCT00582543|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133173|NCT03783442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133174|NCT04322435|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133175|NCT02778542|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34133176|NCT00309985|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133177|NCT03601039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133178|NCT03459534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133179|NCT02378233|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34133180|NCT00127452|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133181|NCT01530178|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34133182|NCT01814397|||COHORT||PROSPECTIVE|||||||
34133183|NCT00152828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133184|NCT02289053|||CASE_CONTROL||PROSPECTIVE|||||||
34133185|NCT04110756|RANDOMIZED|PARALLEL||PREVENTION||NONE||In Year 4 of the study, we will investigate the effect of the CHANGEGRADIENTS system on behavior related to alcohol use:100 adolescents will be enrolled in the CHANGEGRADIENTS intervention, and 100 will be enrolled in the comparison, non-intervention condition, for a total of 200 participants.||||
34133186|NCT06132724|||COHORT||PROSPECTIVE|||||||
34133187|NCT04699838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133188|NCT02461446|||COHORT||PROSPECTIVE|||||||
34133189|NCT05046717|||COHORT||PROSPECTIVE|||||||
34133190|NCT03629223|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34133191|NCT05070819|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133192|NCT06659835|||COHORT||PROSPECTIVE|||||||
34133193|NCT06401694|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133194|NCT01832324|||CASE_CONTROL||PROSPECTIVE|||||||
34133195|NCT06650748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133196|NCT06478316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34133197|NCT05898620|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133198|NCT02516995|NA|SINGLE_GROUP||||NONE||||||
34133199|NCT01736072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826730|NCT00053352|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826731|NCT01182207|RANDOMIZED|CROSSOVER||||NONE||||||
34133200|NCT06658145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133201|NCT06615661|||COHORT||PROSPECTIVE|||||||
33826732|NCT02276209|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826733|NCT03439098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826734|NCT01174485|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826735|NCT03935932|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open label|Open label, single treatment administration, crossover||||
33826736|NCT06196073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sealed envelope method|Parallel two group which are equal|f|f|f|t
33826737|NCT06197841|||CASE_ONLY||PROSPECTIVE|||||||
33826738|NCT02762721|||CASE_ONLY||CROSS_SECTIONAL|||||||
33826739|NCT06480370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826740|NCT01293799|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826741|NCT01831726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826742|NCT03453424|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33826743|NCT05323188|||OTHER||CROSS_SECTIONAL|||||||
33826744|NCT04054453|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|Magnetic resonance biomarkers will be quantified masked to the interventional group|Interrupted Time Series Evaluation|f|f|f|t
33826745|NCT02299856|||CASE_CONTROL||PROSPECTIVE|||||||
33826746|NCT00005058||||DIAGNOSTIC||||||||
33826747|NCT00002621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826748|NCT01053897|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33826749|NCT01960348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826750|NCT00349388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826751|NCT03672071|RANDOMIZED|PARALLEL||OTHER||SINGLE||A randomized prospective controlled study|t|f|f|f
33826752|NCT03126214|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"Prospective, open-label, randomized, stepped wedge trial design. Participants will be randomized to early (day 0-90) versus delayed pharmacist intervention (starting day 90-180)."||||
33826753|NCT03185585|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33826754|NCT01009762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826755|NCT04584216|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826756|NCT03256370|||CASE_CONTROL||PROSPECTIVE|||||||
34133202|NCT06222346|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133203|NCT05719350|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133204|NCT05810571|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|participant will not know which block applied, and the outcome assessor of the postoperative analgesia will not know||t|f|f|t
34133205|NCT05032677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34133206|NCT02083341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133207|NCT06482099|||COHORT||PROSPECTIVE|||||||
34133208|NCT05019508|||COHORT||PROSPECTIVE|||||||
34133209|NCT00351793|||CASE_CONTROL||PROSPECTIVE|||||||
34133210|NCT05522582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133211|NCT05906472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133212|NCT02994082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34133213|NCT06419556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133214|NCT03193970|||COHORT||PROSPECTIVE|||||||
34133215|NCT03273452|NA|SINGLE_GROUP||TREATMENT||NONE||single arm trial, patients enrolled would be treated in this arm.||||
34133216|NCT05492227|||COHORT||RETROSPECTIVE|||||||
34133217|NCT00499330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133218|NCT03273647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133219|NCT03267433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133220|NCT06310642|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were blinded in this study.|Enrolled a cohort of consenting, healthy subjects aged \>17 years. Thirty subjects enrolled in the study. 15 subjects received prochlorperazine. 15 subjects received placebo.|t|f|f|f
34133221|NCT04270149|NA|SINGLE_GROUP||OTHER||NONE||||||
34133222|NCT04788004|||COHORT||PROSPECTIVE|||||||
34133223|NCT03966209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133224|NCT02145052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133225|NCT05052255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133226|NCT03865433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Study physicians will be blinded to group allocation|Subjects will be randomly assigned to one of two groups: the intervention group or the placebo/control group|f|t|f|f
34133227|NCT01420991|||CASE_ONLY||PROSPECTIVE|||||||
34133228|NCT06651268|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133229|NCT00339651|||CASE_CONTROL||RETROSPECTIVE|||||||
34133230|NCT06251466|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomized in either the control group or the telemonitoring group. The control group receives the standard care of gestational diabetes mellitus, meaning that the participants need to call their blood glucose levels weekly to the endocrinology department. The telemonitoring group receives telemonitoring, meaning that the participants need to register their blood glucose levels weekly in a smartphone application which is coupled to a platform in the hospital.||||
34133231|NCT01610219|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133232|NCT04216563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133233|NCT02844244|NA|SINGLE_GROUP||||NONE||||||
34133234|NCT06661200|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"Device feasability - Exploratory and feasibility study, monocentric, open, comparative, cross-sectional, made up of three groups:~* cardiopathies (150 subjects)~* healthy subjects (30 subjects)~* pulmonary diseases (90 subjects)"||||
34133235|NCT01849575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The cleaned structured data which is generated from the original data and does not contain personal numbers (identity data) and is stored on an encrypted E: drive on a computer that is exclusively used for VIPVIZA by the data manager. Access only by the data manager with password. The password is only known by the data manager. It is also kept in a sealed envelope in the save of the Medical Faculty.~For each sub-project, data on selected variables in the structured data base is exported to a researcher by the data manager after approval from the VIPVIZA steering group. Thus, the participants' identity is masked for the outcome assessors since they have nu access neither to the original or the structured data."||f|f|f|t
33826757|NCT01114269|||COHORT||PROSPECTIVE|||||||
33826758|NCT02618863|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33826759|NCT01086332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826760|NCT01726517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826761|NCT06074445|||OTHER||CROSS_SECTIONAL|||||||
33826762|NCT03047902|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826763|NCT01196143|||COHORT||PROSPECTIVE|||||||
33826764|NCT02414555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826765|NCT00001083||||TREATMENT||||||||
33826766|NCT06123364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.|t|f|f|f
33826767|NCT04322916|||CASE_ONLY||PROSPECTIVE|||||||
33826768|NCT03618927|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826769|NCT03834207|NA|SINGLE_GROUP||OTHER||NONE||A single intervention group that will use and evaluate the C3-Cloud system during the 12 month study. Please note that an anonymous group of patients meeting the same criteria will be identified retrospectively at the end of the study so that healthcare resource utilisation during the same period can be compared.||||
33826770|NCT03844178|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33826771|NCT03592823|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33826772|NCT06308549|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826773|NCT06104384|||COHORT||PROSPECTIVE|||||||
33826774|NCT00231517|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33826775|NCT02168478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826776|NCT01738464|||CASE_CONTROL||PROSPECTIVE|||||||
33826777|NCT01077622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826778|NCT02014415|||COHORT||PROSPECTIVE|||||||
33826779|NCT04143906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826780|NCT00177385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826781|NCT02018471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33826782|NCT00528710|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826783|NCT02778906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826784|NCT03521583|||COHORT||PROSPECTIVE|||||||
33826785|NCT00000725||||TREATMENT||NONE||||||
33826786|NCT01414556|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33826787|NCT05934656|||CASE_ONLY||PROSPECTIVE|||||||
33826788|NCT03336073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826789|NCT02212483|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Substantial modification of the 20th of June, 2016 : Modification of the design : change into a 2 parallel groups evaluation Justification: At its meeting of June 1, 2016, considering the inclusion difficulties, the Scientific Council decided to give up the Control group.~The study design is then : a prospective multicenter randomised, open label, controlled trial with blind evaluation of the primary evaluation criterion on three parallel groups of patients.~The objective is to recruit 50 to 70 patients by arm.~The Control group will still be described."||f|f|f|t
33826790|NCT00978783|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33826791|NCT00256347|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33826792|NCT05258877|||COHORT||PROSPECTIVE|||||||
33826793|NCT01887990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826794|NCT03936764|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33826795|NCT03166397|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826796|NCT04739189|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826797|NCT05051124|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33826798|NCT04584333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33826799|NCT04310176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826800|NCT05510739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33826801|NCT05861778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826802|NCT03128788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826803|NCT06345378|||COHORT||RETROSPECTIVE|||||||
33826804|NCT01029678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826805|NCT02713607|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33826806|NCT05402618|||COHORT||RETROSPECTIVE|||||||
33826807|NCT04760197|||COHORT||RETROSPECTIVE|||||||
33826808|NCT02224352|NA|SINGLE_GROUP||OTHER||NONE||||||
33826809|NCT03939598|||OTHER||PROSPECTIVE|||||||
33826810|NCT02985034|||COHORT||PROSPECTIVE|||||||
33826811|NCT03206476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826812|NCT04684771|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Two parallel-groups either the MYOSTIM® or a PLACEBO in a double blinded manner.|"Double blind, exploratory study, monocentric, with a group of control patient with placebo.~Two parallel-groups receiving during 12 weeks either the MYOSTIM® or a PLACEBO in a double blinded manner."|t|t|t|f
33826813|NCT05431621|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826814|NCT03168698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826815|NCT05213325|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33826816|NCT00989313|||CASE_ONLY||PROSPECTIVE|||||||
33826817|NCT06041178|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33826818|NCT02127489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826819|NCT04130581|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33826820|NCT04146285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826821|NCT00920699|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826822|NCT01225159|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33826823|NCT02183350|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33826824|NCT05694936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826825|NCT04357964|||COHORT||PROSPECTIVE|||||||
33826826|NCT02044341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826827|NCT00004090||||TREATMENT||||||||
33826828|NCT04559451|||COHORT||PROSPECTIVE|||||||
33826829|NCT00086021|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826830|NCT01123512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826831|NCT02476708|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133236|NCT01794663|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34133237|NCT06018311|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133238|NCT03779867|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|All study personnel other than the statisticians and exercise physiologist will be masked to participant study arm||f|f|t|t
33826832|NCT02018705|||COHORT||RETROSPECTIVE|||||||
33826833|NCT02222961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33826834|NCT06061224|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826835|NCT02253745|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33826836|NCT02714699|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33826837|NCT02923817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826838|NCT00997932|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33826839|NCT00296023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826840|NCT03496337|||COHORT||PROSPECTIVE|||||||
33826841|NCT01865578|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33826842|NCT02863913|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826843|NCT01174498|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33826844|NCT04591964|RANDOMIZED|PARALLEL||OTHER||NONE||"Interventional, prospective, open-labled, comparative, randomized clinical trial.~Baseline group: standard medical treatment + using of mobile application for remote monitoring, base of self-controlling, 12 month.~Control group: standard medical treatment + base of self-controlling."||||
33826845|NCT06234813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826846|NCT02654613|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33826847|NCT06118177|||CASE_CONTROL||PROSPECTIVE|||||||
33826848|NCT01916798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826849|NCT03424525|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826850|NCT02929316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826851|NCT01133197|||CASE_CONTROL||PROSPECTIVE|||||||
33826852|NCT05388097|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826853|NCT03168399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826854|NCT01287871|||COHORT||PROSPECTIVE|||||||
33826855|NCT03577925|||OTHER||CROSS_SECTIONAL|||||||
33826856|NCT04983225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826857|NCT04071093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826858|NCT00104975||||TREATMENT||||||||
34133239|NCT01469143|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34133240|NCT05972356|||COHORT||PROSPECTIVE|||||||
33826859|NCT05666271|||COHORT||PROSPECTIVE|||||||
33826860|NCT04933162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33826861|NCT00912054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826862|NCT02991703|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33826863|NCT01919346|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33826864|NCT01281215|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33826865|NCT02435797|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33826866|NCT05194228|RANDOMIZED|FACTORIAL||OTHER||NONE||Participants will be randomized into 1 of 32 conditions in a 2x2x2x2x2 design (i.e., number of questions per EMA survey \[15 vs. 25\] x number of EMAs per day \[2 vs. 4\] x EMA prompting schedule \[random vs. fixed times\]) x payment type \[per EMA vs. based on percentage of EMAs completed\] x order of EMA item question types \[i.e., slider type first 2 weeks vs. Likert-type questions first 2 weeks\]).||||
33826867|NCT00003698||||TREATMENT||||||||
33826868|NCT02358083|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
33826869|NCT06208800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826870|NCT00541840|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826871|NCT00006005||||TREATMENT||||||||
33826872|NCT02411695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826873|NCT04120662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826874|NCT02183077|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826875|NCT02844348|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826876|NCT01145417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826877|NCT03025555|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33826878|NCT04061863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||ER+/HER2- BC cohort: 45 pts ER-/HER2- (Triple negative) BC cohort: 45 pts||||
33826879|NCT01650727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826880|NCT00899379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826881|NCT02606097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826882|NCT02599090|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826883|NCT00600301|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826884|NCT04310683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826885|NCT01327027|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The Maine Medical Pharmacy prepared drug and placebo doses; when subjects were enrolled, the pharmacy randomly assigned the subject to a condition, and gave the unmarked nasal applicator to the subject, who was accompanied by the nurse/technician. Neither the subject nor the nurse/technician collecting data knw whether it was placebo or drug, nor which dose (20IU or 40IU) the subject would be receiving on the drug day.|"In the work at Maine Medical, each subject received one of two doses of vasopressin (20IU or 40IU) on one test day, and placebo (sterile saline) on the other, in counterbalanced order. All subjects reported back for a 3rd day, 2-21 days after the 2nd test day, for a third test when no drug was administered.~Because preliminary data analysis suggested the drug may have longer lasting, generalized effects on behavioral responses than anticipated, the second study done at Emory University with a single dose and in which subjects were also tested in fMRI, was changed to between-subjects design in which each subject either received placebo or 40IU on an initial test day and were then tested on a follow up test, 2-21 days later, when no drug was given."|t|f|t|f
33826886|NCT04299113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826887|NCT02790112|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33826888|NCT03294421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826889|NCT03556540|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Volunteers will not know that there are two groups. Evaluators will not know which groups the volunteers belong to when evaluating the variables.|"Each participant will perform 30 minutes of aerobic on cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis performed three times a week for three months.~The sessions will be divided into heating, conditioning and cooling. In the warm-up phase 5 minutes of exercise will be performed between 60-70% of maximal heart rate, with Borg between 1 and 2. In the conditioning phase, 20 minutes of moderate exercise will be performed, with HR between 70-80% And Borg (modified) between 3 and 4. And the quench phase will be 5 min, with FC between 60-70% of the maximum and Borg (modified) between 1 and 2.~Exercise will be discontinued if the participant has a systolic pressure above 180mmHg, a diastolic pressure above 95mmHg, a 20% change in heart rate, a saturation of less than 88%, physical exhaustion, chest pain, dyspnoea, dizziness and fatigue of the exercised limbs ."|t|f|t|f
33826890|NCT05436106|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33826891|NCT02269683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826892|NCT03184597|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33826893|NCT00506922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826894|NCT04737005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826895|NCT00443677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826896|NCT05498454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The data analysis will be performed blind by one of the researchers - after data has been anonymised and transferred.|waiting list controlled - then waiting list randomly allocated to one or two possible treatments. Effectively, one Arm, then splitting into two ( 1 + 2)|f|f|f|t
33837479|NCT00781495|||COHORT||PROSPECTIVE|||||||
33837480|NCT00540943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837481|NCT04226989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837482|NCT02993406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837483|NCT05372107|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837484|NCT02971566|||CASE_CONTROL||PROSPECTIVE|||||||
33837485|NCT00561106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840221|NCT05167422|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Nested quasi-experimental||||
33840222|NCT01375998|||CASE_ONLY||PROSPECTIVE|||||||
33840223|NCT00438672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33840224|NCT02903563|||||CROSS_SECTIONAL|||||||
34133241|NCT04938310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133242|NCT03891992|||CASE_ONLY||OTHER|||||||
34149440|NCT04113460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149441|NCT00014898|||CASE_CONTROL||RETROSPECTIVE|||||||
34133243|NCT04058561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiographs will be uploaded by each site to the coordinating team and will not have access to the information on exposure arms.|Sites will be randomized into two arms of lengthening intervals: 6 weeks (+/- 2 weeks) or 16 weeks (+/- 2 weeks).|f|f|f|t
33826897|NCT04049240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Anesthesiologist who interviews and examines patients scheduled for PPV under analgo-sedation will enroll eligible participants and offer procedure explanation with possibility to sign uniformed written consent. Unique personal hospital admission number (UPHAN) will be assigned to all eligible participants. Participants will be randomized to control or intervention group by using random numbers generator. Anesthesiologist who implements anesthesia will receive nontransparent envelope with assigned intervention provided by independent investigator and will not decide which participant will receive LFNO or HFNO. However, attending anesthesiologist and participants will unavoidably be aware of type of oxygenation applied. Collected data are objective measures. Investigator who collects data after procedure will be unaware of study protocol and will enter data to formatted database. Participants' data will be noted under UPHAN. Outcome assessors will be unaware of intervention applied.|"Investigators plan to conduct prospective, parallel group, randomized controlled clinical trial.~In total, 126 participants will be included in this trial. These participants are patients scheduled for outpatient analgo-sedation for vitrectomy."|f|f|t|t
33826898|NCT06640491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826899|NCT05729945|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|||||
33826900|NCT02603861|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33826901|NCT00857298|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33826902|NCT04316520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826903|NCT04318314|||COHORT||PROSPECTIVE|||||||
33826904|NCT03426553|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33826905|NCT01692613|||CASE_CONTROL||PROSPECTIVE|||||||
33826906|NCT05959161|||COHORT||RETROSPECTIVE|||||||
33826907|NCT04938934|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33826908|NCT03787277|||CASE_ONLY||RETROSPECTIVE|||||||
33826909|NCT02151071|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33826910|NCT02787759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33826911|NCT02158247|||||PROSPECTIVE|||||||
33826912|NCT03803553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826913|NCT02639078|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33826914|NCT02648113|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826915|NCT00112710|RANDOMIZED|||TREATMENT||||||||
33826916|NCT03228953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
33826917|NCT05077241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826918|NCT02036255|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826919|NCT02046941|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826920|NCT03084198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826921|NCT00887380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826922|NCT00192322|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826923|NCT00088452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826924|NCT00483925|||CASE_CONTROL||PROSPECTIVE|||||||
33826925|NCT02396953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826926|NCT00695136|NA|SINGLE_GROUP||||NONE||||||
33826927|NCT04219917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826928|NCT05511558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826929|NCT00347737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826930|NCT03807700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33826931|NCT00887185|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33826932|NCT00913783|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33826933|NCT01027663|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34133244|NCT06344104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||placebo control|t|t|t|t
34133245|NCT00115271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34133246|NCT01749124|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34133247|NCT04098419|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826934|NCT01486511|||COHORT||PROSPECTIVE|||||||
33826935|NCT00498433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826936|NCT02868619|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33826937|NCT01202409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826938|NCT03290222|||CASE_ONLY||PROSPECTIVE|||||||
33826939|NCT04826497|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826940|NCT05643443|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33826941|NCT03497780|||COHORT||PROSPECTIVE|||||||
33826942|NCT03927222|NA|SINGLE_GROUP||TREATMENT||NONE||Newly-diagnosed WHO Grade IV glioma patients with their tumor resected and found to be MGMT unmethylated will be accrued to this study before the standard of care chemoradiation with the goal of treating with dose-intensified TMZ and pp65 loaded dendritic cell vaccine after completion of the standard of care chemoradiation.||||
33826943|NCT00735462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826944|NCT04228900|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A pragmatic clinical controlled study. Intervention in one municipality. Participants in neighbor municipality will comprise control group.||||
33826945|NCT05243537|||CASE_CONTROL||RETROSPECTIVE|||||||
33826946|NCT00476918|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33826947|NCT04342988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826948|NCT00695370|NON_RANDOMIZED|||TREATMENT||NONE||||||
33826949|NCT05475496|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33826950|NCT06591767|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826951|NCT01355822|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33826952|NCT02949076|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33826953|NCT06210399|NA|SINGLE_GROUP||TREATMENT||NONE||Quasi-Experimental Study||||
33826954|NCT03010345|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33826955|NCT02001077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826956|NCT06382077|||COHORT||PROSPECTIVE|||||||
33826957|NCT04550286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34133248|NCT03853382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133249|NCT00738569|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133250|NCT00998322|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133251|NCT06655298|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE|closed envelop|Patients will be randomized into two groups using a closed envelope technique in sequentially numbered opaque envelopes that will be opened before carrying out the block|t|f|f|f
34133252|NCT03316118|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34133253|NCT02546258|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133254|NCT04619238|||CASE_ONLY||PROSPECTIVE|||||||
34133255|NCT04583215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A unique advantage of Paired Associative Stimulation (PAS) over other TMS-based interventions is that its control condition (PAS-C) is almost impossible to distinguish from active PAS. Thus, the RCT phase of the study will be completed under triple-blind conditions. First, participants will be blind to whether they are randomized to PAS or PAS-C. Second, the investigator team (investigators and interventionists delivering the 10-session course) will be blind to group assignment. Third, the outcomes assessors conducting the clinical, cognitive and PAS-EEG assessments at baseline and follow-ups will be blind to group assignment.|At screening 100 MCI and 50 HC participants will undergo clinical and cognitive assessments and a brain MRI to localize the DLPFC. If eligible, at baseline, all participants will undergo N-back and PAS-EEG to assess baseline DLPFC plasticity. Following baseline procedures, MCI participants will be randomized (1:1) to the study intervention consisting of 10 sessions of either bilateral PAS or PAS-C to the right and left DLPFC, 1 session/day, for 10 days. On the last day of the intervention, participants will repeat the cognitive assessments and on the following day they will repeat N-back and PAS-EEG to assess the effect of daily PAS on executive function and DLPFC plasticity. Finally, on the 7th day following the intervention (Visit 16), MCI participants will repeat N-back and PAS-EEG, and on the 28th and 29th day (Visit 17 and Visit 18) following the intervention, MCI participants will repeat the cognitive assessments, N-back and PAS-EEG to evaluate the sustainability of effects.|t|f|t|t
34133256|NCT02468531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133257|NCT00771706|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34133258|NCT00318318|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34133259|NCT06610838|||COHORT||PROSPECTIVE|||||||
34133260|NCT05921266|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34133261|NCT04057924|||CASE_ONLY||PROSPECTIVE|||||||
34133262|NCT06247345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||5 cohort in Single Ascending Dose (SAD) in healthy participants and 3 cohort in Multiple Ascending Dose (MAD) in participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) and mild AD|t|t|t|t
34133263|NCT05613322|||OTHER||PROSPECTIVE|||||||
34133264|NCT00395824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133265|NCT03018197|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133266|NCT05646784|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|A double-blind randomized probiotic versus placebo clinical trial will be performed on the target population under medical secured environment. A re-evaluation of the gut bacterial profile, inflammatory markers and depression scoring will be performed at the end of the study. Depression score at baseline and at the end using the same scoring test (MADRS) will be assessed||t|t|t|t
34133267|NCT03773237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The randomization list will be generated using http://www.randomization.com and blinded at enrollment using supplement codes. The study coordinator will hold the randomization codes and will be revealed to the investigators only after the statistical analysis is complete.|Prospective Randomized Controlled|t|t|t|f
34133268|NCT05898581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study will be a single-centre, double-blinded non-inferiority randomized controlled trial.|t|f|f|t
34133269|NCT01223651|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34133270|NCT04333524|||CASE_ONLY||RETROSPECTIVE|||||||
34133271|NCT01712997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133272|NCT05068791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a double-blind, placebo- controlled clinical trial.|t|t|t|t
34133273|NCT05931471|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34133274|NCT05663177|||COHORT||PROSPECTIVE|||||||
34133275|NCT01158820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133276|NCT02713984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133277|NCT01248988|||COHORT||PROSPECTIVE|||||||
34133278|NCT01698619|||COHORT||PROSPECTIVE|||||||
34133279|NCT01157338|NON_RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133280|NCT00107432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133281|NCT04707118|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133282|NCT00990431|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34133283|NCT02406924|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133284|NCT00768846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133285|NCT02819843|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133286|NCT03703804|||COHORT||PROSPECTIVE|||||||
34133287|NCT00564733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133288|NCT03530995|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||Two-Part, Non-Randomised||||
34133289|NCT06556875|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133290|NCT00331994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133291|NCT05547399|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34133292|NCT02027311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133293|NCT06660511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133294|NCT05483712|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-site study designed to generate data quantifying the skin dose under brass mesh bolus.||||
34133295|NCT06106581|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133296|NCT06659653|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133297|NCT01234454|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34133298|NCT01228136|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133299|NCT01304992|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34133300|NCT05656469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient- and rater-blinded|A two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT)|t|f|f|t
34133301|NCT01930422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133302|NCT01591837|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133303|NCT01538355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133304|NCT03296748|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||female patients with stress urinary incontinence and asymptomatic grade II anterior vaginal wall prolapse were divided into Group A: treated only with trans-obturator tape (TOT) and group B where' TOT was associated with anterior colporrhaphy .||||
34133305|NCT03960567|||OTHER||PROSPECTIVE|||||||
34133306|NCT03007199|||CASE_CONTROL||PROSPECTIVE|||||||
34133307|NCT00073411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34133308|NCT02551380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133309|NCT04493424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133310|NCT03117868|||COHORT||PROSPECTIVE|||||||
34133311|NCT00604149|||CASE_CONTROL||PROSPECTIVE|||||||
34133312|NCT00757510|||COHORT||PROSPECTIVE|||||||
34133313|NCT05126810|||CASE_ONLY||PROSPECTIVE|||||||
34133314|NCT06090305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34133315|NCT01063335|||||PROSPECTIVE|||||||
34133316|NCT01173107|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34133317|NCT02048137|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133318|NCT02236234|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133319|NCT01006655|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34133320|NCT01468948|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133321|NCT01039324|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34133322|NCT05607173|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133323|NCT04791215|||COHORT||OTHER|||||||
34133324|NCT06658925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133325|NCT01719458|||CASE_CONTROL||PROSPECTIVE|||||||
34133326|NCT04624919|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomized, counterbalanced crossover design||||
34133327|NCT02130349|||COHORT||PROSPECTIVE|||||||
34133328|NCT04774588|RANDOMIZED|PARALLEL||OTHER||NONE||"Methodology:~Single center randomized controlled pilot feasibility study. Firstly, VSI streamer software will be used for real time streaming of input from the fluoroscopy unit to a Head mounted display (Hololens 2) worn by the operator. This will be utilized to perform angiographic procedures on a 3D vascular model. Mock benchtop~angiographic catheterization procedures will be performed in order to ensure practicality, safety and initial usability.~Subsequently, appropriate patients undergoing elective Interventional Radiology procedures will be screened and enrolled. After performing these procedures on the first two patients, procedural parameters will be reviewed and subsequent patients will be enrolled if no safety concerns have arisen in the first two patients. Patients will be enrolled until a total of 60 procedures have been performed."||||
34133329|NCT05694871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133330|NCT01884506|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34133331|NCT05139329|||COHORT||RETROSPECTIVE|||||||
34133332|NCT05862974|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133333|NCT05871424|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34133334|NCT05556291|||COHORT||PROSPECTIVE|||||||
34133335|NCT02250794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133336|NCT03185598|||COHORT||RETROSPECTIVE|||||||
34133337|NCT06101342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133338|NCT03645096|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Adult women with mild to moderate major depressive disorder (MDD) will receive pregnenolone (500 mg/d, 800 mg/d and placebo) in a randomized, double-blind, crossover design.|t|t|t|t
34133339|NCT01179828|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34133340|NCT00869791|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133341|NCT06660108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133342|NCT01150058|||CASE_ONLY||RETROSPECTIVE|||||||
34133343|NCT05751993|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34133344|NCT04935190|||CASE_CONTROL||PROSPECTIVE|||||||
34133345|NCT06091943|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133346|NCT04930120|||COHORT||RETROSPECTIVE|||||||
34133347|NCT01532076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133348|NCT00180193|||COHORT||PROSPECTIVE|||||||
34133349|NCT04746118|RANDOMIZED|PARALLEL||TREATMENT||NONE||Besides the control group (n=60), three other groups with different severity of hypertension will be included in the study. To evaluate strategies adopted as primary prevention 60 pre-hypertensive patients will be recruited. To evaluate blood pressure control and cardiovascular risk reduction, other 60 hypertensives will be also invited to the study. Finally, 60 individuals with resistant hypertension will be recruited to access secondary and tertiary prevention with possible blood pressure control, reduction in the number of drugs in use and subclinical lesions regression.||||
34133350|NCT02237001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133351|NCT04075006|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133352|NCT00911976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133353|NCT04418492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133354|NCT06136689|||COHORT||PROSPECTIVE|||||||
34133355|NCT01827436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133356|NCT00784888|||COHORT||PROSPECTIVE|||||||
34133357|NCT04305509|||COHORT||PROSPECTIVE|||||||
34133358|NCT03694340|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-case research design||||
34133359|NCT05614609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|A study nurse will prepare sealed envelopes with the study-arm specified inside. Patients fullfilling the inclusion criteria will be invited to participate. Patients will be blinded for study arm. Intubation will be performed by trained intubators. However, due to the medications possible risk for rest-curarisation, the anesthesia personnel will possibly be able to detect intervention. However, care personnel collecting data will not know which study arm the patient belongs to.|"Block randomization through randomization.com. Proprotion of hoarseness grade-2-or-3 = 30 % in spray and 10 % in rocuronium.~59 patients in each arm.~sig p \<= ,05, H0 = 0 + 1,96\*√\[30(100-30)n + 10(100-10)/n\] Gitt power \>= ,80 , HAlt = (30-10) - 0,84\*√\[30(100-30/n) + 10(100- 10/n)\]"|t|t|f|f
34133360|NCT06660134|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133361|NCT04405778|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133362|NCT02340858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34133363|NCT02902302|RANDOMIZED|CROSSOVER||||NONE||||||
34133364|NCT04003051|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133365|NCT04949516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133366|NCT02907216|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133367|NCT06604858|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, single arm, non-comparative, phase II clinical trial.||||
34133368|NCT02502292|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133369|NCT03680196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133370|NCT03981757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will have NeurOS pads placed on their foreheads. Continuous monitoring of arterial blood pressure, cerebral oxygenation and brain blood volume index for the whole length of surgery will be recorded and saved in a USB drive for retrieval and analysis. Key point data include: Baseline, Anesthesia Induction, Incision, Carotid Clamping, Clamp Release and Skin Closure. These key points data will be extracted for analysis.||||
34133371|NCT04985500|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|The anesthesiologist assessing the patient will be blinded|Patients will be assigned randomly using a computer-generated table of numbers to one of the three groups: 1) ESP group, 2) PIF group, or 3) no block group.|f|f|t|t
34133372|NCT04208386|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133373|NCT03928418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Research Assistant, who will collect study data including the study questionnaire and biological specimens for testing, will be blinded to the participants' study arm assignment.|Participants will be randomized to 1 of 3 arms. After the trial, participants in the standard of care arm, will be offered the intervention.|f|f|t|f
34133374|NCT01754038|||COHORT||PROSPECTIVE|||||||
34133375|NCT02228694|||COHORT|||||||||
34133376|NCT04042909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34133377|NCT06661135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The investigator and the outcomes assessor who asses the postoperative pain were not aware of which type of surgery the participant have had.~Also the pathologist assessing the accuracy of oncology cal resection doesn't know the type of approach that participant had ( open or laparoscopic )"|The included patients were equally randomized into two groups: the OPD group, which included patients that would undergo the traditional open procedure, and the LPD group, which included patients that would be subjected to the laparoscopic approach.|f|f|t|t
34133378|NCT00809835|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34133379|NCT06131983|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133380|NCT03709069|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||One group receives routine diet while other group receives supplemental albumin along with routine diet|t|t|f|t
34133381|NCT04601259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133382|NCT04941183|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Randomized, placebo-controlled, double-blind, single-ascending-dose and multiple-ascending-dose|t|t|t|f
34133383|NCT04963244|||OTHER||CROSS_SECTIONAL|||||||
34133384|NCT00321243|RANDOMIZED|PARALLEL||||NONE||||||
34133385|NCT00422643|NON_RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34133386|NCT01887730|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34133387|NCT06516991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133388|NCT04678037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133389|NCT04329728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133390|NCT04053855|||COHORT||PROSPECTIVE|||||||
34133391|NCT06662396|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34133392|NCT01434901|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34133393|NCT06548087|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34133394|NCT06658782|||COHORT||PROSPECTIVE|||||||
34133395|NCT01978054|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133396|NCT00428571|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133397|NCT00553436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133398|NCT05546697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133399|NCT06614101|NA|SINGLE_GROUP||OTHER||NONE||||||
34133400|NCT02775591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133401|NCT00027144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133402|NCT03465644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133403|NCT05313269|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133404|NCT02919202|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133405|NCT03870035|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34133406|NCT01636336|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34133407|NCT04249492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind masking; Patient will not be informed which IOL model was implanted until end of the study.||t|f|f|f
34133408|NCT01596140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133409|NCT03245554|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133410|NCT00372619|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133411|NCT04136093|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34133412|NCT05812963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical events will be independently adjudicated by Clinical Event Adjudication Committee (CEAC) who are blinded to clinical information or group allocation.|Prospective, multicenter, randomized controlled non-inferiority trial to compare clinical outcomes between IVUS-guided PCI versus FFR-guided PCI in patients with acute MI and multivessel disease.|f|f|f|t
34133413|NCT05723536|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomized clinical trial in patients with persistent and long-standing persistent AF in two groups: conventional ablation vs partial endo-epicardial isolation.||||
34133414|NCT01742442|||COHORT||PROSPECTIVE|||||||
34133415|NCT03208660|||COHORT||RETROSPECTIVE|||||||
34133416|NCT02686632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34133417|NCT06024239|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133418|NCT01116999|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34133419|NCT04818216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study drug (NR or placebo) packaging and labeling will be designed to maintain the blinding of the investigator's team and the participants.|Prospective, double-blind, placebo-controlled clinical interventional trial|t|f|t|f
34149442|NCT01569386|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34149443|NCT02136056|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34149444|NCT04462939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34133420|NCT05096273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Researchers who conduct baseline and follow-up visits will be blinded to the condition (booster or no booster) to which the patient has been assigned. The statistician and data manger will be blinded to treatment condition when analyzing data. The PI and therapists will be blinded to participant's baseline target scores.|Children with PNES and matched controls will be prospectively enrolled.|f|f|t|t
34133421|NCT03803358|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 26 COPD patients in GOLD Stages IV diagnosed with CHRF, already treated with nocturnal NIV and referred for a comprehensive PR program will be recruited and randomized into two groups: 1) exercise with NIV during exercise (nocturnal NIV will continue) and 2) control group - exercise without NIV during exercise (nocturnal NIV will continue).|f|f|f|t
34133422|NCT05420181|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34133423|NCT05405634|||COHORT||PROSPECTIVE|||||||
34133424|NCT06662136|||CASE_CONTROL||PROSPECTIVE|||||||
34133425|NCT03839225|NA|SINGLE_GROUP||SCREENING||NONE||A mixed study of before and after using quantitative and qualitative research techniques||||
34133426|NCT06421506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This will be a prospective single centre study with a treatment arm and a control group.||||
34133427|NCT01193634|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133428|NCT05731817|||COHORT||PROSPECTIVE|||||||
34133429|NCT03393936|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||Subjects with ROR2 positive biopsy will receive CCT301-59. Subjects with AXL positive biopsy that are ROR2 negative will receive CCT301-38.||||
34133430|NCT02511015|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34133431|NCT00617084|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34133432|NCT05158751|||COHORT||RETROSPECTIVE|||||||
34133433|NCT02783872|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34133434|NCT02876406|||COHORT||PROSPECTIVE|||||||
34133435|NCT05449340|NA|SINGLE_GROUP||OTHER||NONE||||||
34133436|NCT02241733|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34133437|NCT00778297|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34133438|NCT00072046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133439|NCT06025695|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This study will be conducted in an observer-blind manner.||t|t|t|t
34133440|NCT02077829|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34133441|NCT04620772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, investigator, assessor and the statistician will be blinded to the treatment allocation||t|t|t|t
34133442|NCT03116035|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133443|NCT00971581|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133444|NCT06320106|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34133445|NCT00145210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34133446|NCT06598787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133447|NCT06078553|||COHORT||OTHER|||||||
34133448|NCT02443246|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133449|NCT02817776|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133450|NCT03721146|||COHORT||PROSPECTIVE|||||||
34133451|NCT02402504|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34133452|NCT03357796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133453|NCT05046067|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34133454|NCT01685242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133455|NCT00120081|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
34133456|NCT06384313|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34133457|NCT04670068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133458|NCT03668496|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133459|NCT06129474|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Even though this is an open label study, the investigators have measures in place to mask the participants as much as possible. Patients of both groups will receive a description of the trial, which mentions inappropriate prescription of medications but not PPI, which keeps them blinded. However, GPs and patients in the intervention group may not necessarily remain blinded, since they may be questioned about the intervention as part of the integrated process evaluation of the intervention. The control group will remain unaware of the detailed nature of the intervention. In case more than one GP from a group practice takes part in this trial, GPs are instructed to keep trial-related communication and exchanges to a minimum. Team members collecting data will remain blinded to the group allocation of the patients.|In this trial, adult patients with inappropriate PPI prescription will be recruited by GPs in the German speaking part of Switzerland. Based on 1:1 cluster randomization of GPs, patients will be assigned to either the control group or to the group receiving an intervention to guide deprescribing of inappropriate PPIs. The control group will receive usual care.||||
34133460|NCT06302426|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase Ia/Ib, open-label, dose-escalation and dose expansion study. This study will be conducted in two parts: Phase Ia (dose escalation) and Phase Ib (dose expansion).||||
34133461|NCT03628066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133462|NCT06180629|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133463|NCT05422534|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|The randomization will be accomplished through a 2-step procedure. In Step 1, subjects will be randomized to one of the two treatment arms (HIIT and observation) using a permuted-block randomization algorithm. In Step 2, subjects will be randomized to receive either CoQ10 supplement or placebo. Investigators cannot be blinded to HIIT or observation assignments. To avoid bias, study personnel will be blinded to this assignment as much as possible while collecting data at rest during the study visits. Study personnel will be blinded to the study drug assignment that has been determined by the Step 2 randomization schedule.|Randomized, doubled-blinded, 2x2 factorial design, placebo-controlled clinical trial|t|f|t|f
34133464|NCT05340569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133465|NCT06400290|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Participants and outcomes assessors will be briefly blinded during the experimental research procedure, during the placebo-controlled balloon inflations when they are asked to report their symptoms. Once the inflations have been completed, all patients will go on to have stents and the blinded part of the protocol will be over.|All participants will partake in the same research protocol.||||
34133466|NCT01227109|||COHORT||PROSPECTIVE|||||||
34133467|NCT06327373|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133468|NCT05143593|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34133469|NCT03944265|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133470|NCT06343818|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study uses a repeated AB design on two ward sites to assess feasibility, acceptability and usefulness of a novel intervention for empathy-based stress in staff, and to test feasibility of this study design. It is not assessing efficacy. The extended baseline measure is the control, there is no control group||||
34133471|NCT05046990|||COHORT||PROSPECTIVE|||||||
34133472|NCT03518918|||COHORT||PROSPECTIVE|||||||
34133473|NCT06661941|||CASE_CONTROL||RETROSPECTIVE|||||||
34133474|NCT05290402|||COHORT||PROSPECTIVE|||||||
34133475|NCT00584792|||CASE_CONTROL||PROSPECTIVE|||||||
34133476|NCT05700786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study design reflects an external, third-party evaluation. The evaluation team (i.e. the researcers conducting the analysis) will be independent from both the application vendor (i.e. the therapists conducting the intervention) and the recruitment team (i.e. the researchers recruiting and randomly allocating the participants).|Pragmatic waiting-list randomized controlled trial with blinded outcome assessment|f|f|t|t
34133477|NCT03325348|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133478|NCT05302167|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133479|NCT06372652|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34133480|NCT01109121|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33826958|NCT04825834|||CASE_CONTROL||PROSPECTIVE|||||||
33826959|NCT02554552|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33826960|NCT00797511|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33826961|NCT04817033|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||factorial randomised controlled trial|f|f|t|t
33826962|NCT02222337|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33826963|NCT06276101|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33826964|NCT04150341|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33826965|NCT02913170|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33826966|NCT01673100|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33826967|NCT06298968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33826968|NCT01559532|||COHORT||PROSPECTIVE|||||||
33826969|NCT01627210|||COHORT||PROSPECTIVE|||||||
33826970|NCT05687318|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|||f|f|f|t
33826971|NCT01489098|||CASE_CONTROL||PROSPECTIVE|||||||
33826972|NCT03772613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33826973|NCT01473641|||COHORT||PROSPECTIVE|||||||
33826974|NCT06114134|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33826975|NCT01193062|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33826976|NCT05867914|NA|SINGLE_GROUP||TREATMENT||NONE|"eNOfit an Electric Nitric Oxide (NO) Ambulatory Production and Delivery System, Delivering Nitric Oxide for Inhalation~The treatment period with inhaled Nitric Oxide (iNO) will include start of iNO at a device setting of 2 mg/hr iNO for 2 hours (+15 minutes), device setting escalation to 6 mg/hr iNO for 2 hours (+15 minutes) and then weaning of iNO treatment."|eNOfit system delivering iNO||||
33826977|NCT04252170|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||6 will be stroke survivors inpatients at PowerBack, Piscataway NJ, USA.||||
33826978|NCT04578899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The hidden distribution of patients will be made with using sequentially numbered sealed opaque envelopes containing the patient's digital code. The randomization code will be recorded in the participant's notes, the patient report form. Then the sent out code will be provided to the doctor to prepare a stimulation or placebo.Blinding during the study will be achieved by using a specialized placebo function built into the magnetic stimulator Neuro-MS/d Therapeutic. When using this option, the patient will hear the characteristic sound of the device running, but full pulse stimulation will not be performed. Patients will be deprived of information about the treatment received (stimulation/placebo)."|In case of presence/absence of inclusion/exclusion criteria and written informed consent will be obtained, patients will be randomized in a 1:1 ratio according to the list of randomized blocks using a computer generator. Patients will be randomized at the last available moment in order to minimise bias.|t|f|f|f
33826979|NCT03188536|||COHORT||RETROSPECTIVE|||||||
33826980|NCT05611658|||COHORT||PROSPECTIVE|||||||
33826981|NCT02845310|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33826982|NCT00402636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33826983|NCT00001234||||TREATMENT||||||||
33826984|NCT06348745|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33826985|NCT02589418|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33826986|NCT03165578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33826987|NCT00035802|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826988|NCT00814632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133481|NCT01755962|RANDOMIZED|FACTORIAL||TREATMENT||NONE||There are four intervention arms designed to compare two factors, glycemic load and resistance training. Arms consist of high glycemic diet, no exercise, high glycemic diet, resistance training; low glycemic diet, no exercise; low glycemic diet, resistance training.||||
33826989|NCT01512914|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33826990|NCT04358614|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||Baricitinib treated patients compared with controls (previously COVID-19 receving standard therapy)||||
33826991|NCT06170229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33826992|NCT00005968||||TREATMENT||||||||
33826993|NCT06223841|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33826994|NCT01830764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33826995|NCT02038088|||COHORT||PROSPECTIVE|||||||
33826996|NCT05266625|RANDOMIZED|PARALLEL||TREATMENT||NONE|While patients and providers will not be told which arm they are in, it will be obvious when they complete the installation of the mobile application which arm they are in.|Patients will be randomized to an intervention arm or control arm. After 6 months, patients in the control arm will be able to cross over to using the intervention.||||
33840225|NCT00581893|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33840226|NCT00560846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840227|NCT05926778|||COHORT||RETROSPECTIVE|||||||
33840228|NCT03073720|||OTHER||PROSPECTIVE|||||||
34133482|NCT04653090|||CASE_CONTROL||RETROSPECTIVE|||||||
34133483|NCT01283776|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133484|NCT05155761|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34133485|NCT00080080|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133486|NCT06658639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133487|NCT06215105|||COHORT||PROSPECTIVE|||||||
34133488|NCT04050787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33826997|NCT05513950|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The Investigational Medicinal Product is blinded for the participant, the investigators and the Sponsor. At site an unblind pharmacist is foreseen to prepare the Investigational Medicinal Product and an unblinded Clinical Research Associate will check the documents of the Investigational Medicinal Product preparation.|Treatment with single dose escalation: 3 different cohorts receive 3 incremental doses of Investigational Medicinal Product. Each cohort can start when the previous cohort is complete and the data are evaluated by the Safety Committee.|t|t|t|t
33826998|NCT05643313|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33826999|NCT02602795|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827000|NCT05493098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827001|NCT00519714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827002|NCT04304313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827003|NCT05705336|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Patients agreed to receive either placebo or medication, without knowing which they were getting|2 randomized groups|t|f|f|f
33827004|NCT05169177|||COHORT||OTHER|||||||
33827005|NCT06088810|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||The study will consist of 144 participants (72 dyads). Dyads will receive 4 weekly phone calls in addition to the baseline and post-intervention in-person home visits. Those receiving the CoMPoSER intervention will undergo the following components: A) relaxation techniques; B) meaningful and relaxing music playlist, tailored to PLWD preferred genre, and C) nighttime routine guidance. Those undergoing the attention control intervention will receive sleep education. The attention control design includes participants finding their own treatment if assigned to no-treatment group and higher study dropout rates.|f|f|t|t
33827006|NCT02028468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827007|NCT02456259|||CASE_CONTROL||PROSPECTIVE|||||||
33827008|NCT03694119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33827009|NCT01121913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827010|NCT00338988|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827011|NCT05321381|RANDOMIZED|SEQUENTIAL||OTHER||NONE||Complete stepped-wedge cluster randomized design||||
33827012|NCT05866341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients were allocated using a computer-generated randomization list in blocks of six either to the test or the placebo group. Assignment to a participant number was done according to the chronological order of enrolment in the study. All therapeutic and diagnostic interventions were performed at the Department of Periodontology of the University Hospital of Wuerzburg. All examinations were performed by two experienced, inter- and intra-calibrated periodontists not being involved in patient assignment and hand out of the experimental juices respectively.|double blind randomized prospective placebo-controlled|t|t|t|t
33827013|NCT05288777|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants, clinical research staff, and treating clinicians will be aware of arm assignment. The labels on research blood will not include the treatment arm on which the participant is assigned and this information will not be provided to lab investigators and staff.|Non-randomized assignment based on Her2/neu status and lymph node involvement|f|f|f|t
33827014|NCT05006417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827015|NCT02625753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827016|NCT05245305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|56 caregiver family members who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental and control groups by simple randomization by an independent researcher who is not included in the study. After the assignments, the statistician will put the 56 family members in which group in sealed envelopes and hand them over to the researcher. The researcher and participants will not know the intervention and control groups until they open the envelope at this stage (single blinding).|Prospective, parallel, two-arm randomized controlled clinical trial Masking: Single (Participant)|t|f|f|f
33827017|NCT02762539|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827018|NCT05296252|RANDOMIZED|FACTORIAL||TREATMENT||NONE|There is no need, and it is not possible to blind condition|The factors are study condition order (reading, math), proactive and reactive mind-wandering manipulation (yes, no), and lesson target (reading, math, both, neither)||||
33827019|NCT00815347|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33827020|NCT01807936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827021|NCT01922622|||COHORT||PROSPECTIVE|||||||
34133489|NCT03043690|||OTHER||RETROSPECTIVE|||||||
34133490|NCT03287934|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|due to the nature of study only the participants could be blinded||t|f|f|f
34133491|NCT05853705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133492|NCT01618435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133493|NCT04952597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133494|NCT06646172|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133495|NCT03890926|||COHORT||RETROSPECTIVE|||||||
34133496|NCT05626322|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open label/randomized||||
34133497|NCT02693080|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133498|NCT05750056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133499|NCT02302248|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34133500|NCT03089333|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Two-way crossover design|f|f|t|f
34133501|NCT00810277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133502|NCT00368745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133503|NCT05264987|||COHORT||RETROSPECTIVE|||||||
34133504|NCT01252160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133505|NCT00201422|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133506|NCT01961297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133507|NCT02548481|||CASE_ONLY||PROSPECTIVE|||||||
34133508|NCT01262638|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133509|NCT02245269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133510|NCT04310982|||COHORT||PROSPECTIVE|||||||
34133511|NCT04250558|||COHORT||PROSPECTIVE|||||||
34133512|NCT04521946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133513|NCT00158249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133514|NCT00423982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133515|NCT03335072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133516|NCT04496206|||OTHER||RETROSPECTIVE|||||||
34133517|NCT01814046|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133518|NCT01296893|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133519|NCT03206970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133520|NCT04915118|||COHORT||RETROSPECTIVE|||||||
34133521|NCT04873258|||COHORT||PROSPECTIVE|||||||
34133522|NCT02876458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133523|NCT04470804|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133524|NCT04639466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133525|NCT00759876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133526|NCT00801073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133527|NCT06232642|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Supplement arms will be marked with a random number code assigned by a non-participating researcher immediately after supplements are prepared. Supplements will be provided to participants in unmarked sachets.|"The study has three arms to which participants will be randomly assigned to:~Arm 1: A lactoferrin- (200 mg), iron (6 mg) and Vitamin B12 (5.2µg)- enriched whey drink (10 g protein; FerriUpTM).~Arm 2: A protein control (rice protein containing drink matched for protein, iron and B12).~Arm 3: A lactoferrin control (maltodextrin containing drink matched for lactoferrin, iron, and B12).~The parallel design 16 weeks in length with blood draws before and after intervention period to assess iron status, and markers of iron metabolism and inflammation."|t|f|f|t
34133528|NCT01932372|||COHORT||PROSPECTIVE|||||||
34133529|NCT04382586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133530|NCT06409936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133531|NCT06623994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133532|NCT03536780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133533|NCT04985201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133534|NCT00036855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133535|NCT01463696|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133536|NCT03683316|||COHORT||PROSPECTIVE|||||||
34133537|NCT06096090|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133538|NCT05484973|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133539|NCT02995161|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133540|NCT03066700|||CASE_ONLY||RETROSPECTIVE|||||||
34133541|NCT04932434|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34133542|NCT04147429|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133543|NCT04823286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A team of assessors, different to the researchers implementing the exercise, will record all dependent variables. A blind researcher will randomize participants|Participants will be randomized into one of two groups, intradialysis virtual reality platform or usual care|f|f|t|t
34133544|NCT02675751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133545|NCT06643702|||COHORT||PROSPECTIVE|||||||
34133546|NCT03055715|||COHORT||RETROSPECTIVE|||||||
34133547|NCT01691105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34133548|NCT00949923|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133549|NCT03166462|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133550|NCT04266730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133551|NCT01232504|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133552|NCT06660186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133553|NCT01854216|NON_RANDOMIZED|PARALLEL||||NONE||||||
34133554|NCT01833728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133555|NCT00105456|||COHORT||PROSPECTIVE|||||||
34133556|NCT06014229|NA|SINGLE_GROUP||TREATMENT||NONE||pilot study||||
34133557|NCT05357339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34133558|NCT00761384|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133559|NCT06426875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Group 1 Experimental Group 2 Control|t|f|t|f
34133560|NCT05542095|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is an open-label phase 1 trial of topical simvastatin delivered via nasal irrigation using a standard three plus three (3+3) dose-escalation design. Subjects are entered into the study in groups of 3. The study will continue with successive cohorts of 3 subjects until dose-limiting toxicities (DLT) are observed in greater than 33% of the enrolled subjects. DLT is defined as the development of statin intolerance with liver toxicity or muscle toxicity or the development of significant systemic or sinonasal symptoms requiring drug discontinuation. The first cohort will receive the lowest dose of simvastatin (0.1mg) via nasal irrigation for 4 weeks. The next group of 3 subjects will receive the consecutive higher dose of simvastatin. We anticipate that 4 doses will be trialed (0.1 mg, 0.25 mg, 0.5 mg, 1 mg) within the predetermined safety range.||||
34133561|NCT04217811|||COHORT||RETROSPECTIVE|||||||
34133562|NCT03941379|||CASE_ONLY||PROSPECTIVE|||||||
34133563|NCT03333252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34133564|NCT05145322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34133565|NCT05636969|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to the allocation of patients for some outcome measures (complications, neoadjuvant-related outcomes). Researchers conducting analyses will be blinded to patient allocation.||f|f|f|t
34133566|NCT05523609|RANDOMIZED|PARALLEL||TREATMENT||NONE||Forty breast cancer patients were included. They were divided into 2 equal groups: Control group received Letrozole only, and VitD/Ca group received Letrozole in addition to 2000 IU vitamin D3 and 1000 mg of calcium per day for 12 weeks. Baseline serum 25-hydroxy vitamin D concentrations were assayed and standard health assessment questionnaire was completed to assess the disability caused by musculoskeletal symptoms.||||
34149445|NCT03755583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149446|NCT01836081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149447|NCT03199391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827022|NCT00607256|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133567|NCT06662214|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|A randomized double-blind crossover design with neither the subjects nor the investigators knowing who is on which food. The interventions will be coded using a blinded alphabetical letter code (A, B). A delegate researcher (independent party not further involved in the study) will randomize all interventions using a computer-generated randomization list. The delegate will hand in the code-breaker to the principal investigator in a sealed envelope. The envelope will be stored in a locked filing cabinet in the principal investigator's office, which will also be locked when unoccupied. The envelope will be opened by the principal investigator after completing the analysis of blood samples.|Participants will consume a meal corn bread plus mung bean stew, which type (refined vs. whole grain) consumed will be randomized where neither the participant nor investigator will know which meal is being consumed. Each participant will repeat the protocol two times.|t|f|t|t
34133568|NCT00559455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133569|NCT03957421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133570|NCT00077714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34133571|NCT06173544|RANDOMIZED|PARALLEL||TREATMENT||NONE||Three-Arm Individually Randomized Trial||||
34133572|NCT04990505|||COHORT||PROSPECTIVE|||||||
34133573|NCT01374347|||COHORT||PROSPECTIVE|||||||
34133574|NCT00455091|||CASE_CONTROL||PROSPECTIVE|||||||
34133575|NCT05103384|||COHORT||PROSPECTIVE|||||||
34133576|NCT05999630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133577|NCT03300024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study will not be blinded because patient side blinding is expected to have minimal to no effect, while physician side blinding is impractical; and difficult to achieve due to the primary surgeon being the one usually who follows up on any intervention or treatment.|Patients will undergo surgery as per standard of care and receive the randomized graft in compliance to National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines for Arteriovenous graft creation. Surgeries will be elective in nature. The grafts will be placed either in the arm (brachial artery-axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) based on anatomic suitability|f|f|f|t
34133578|NCT03361657|||COHORT||PROSPECTIVE|||||||
34133579|NCT02293252|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34133580|NCT05993533|||COHORT||PROSPECTIVE|||||||
34133581|NCT05809544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|This is a randomized, double-blinded design, with three points of measurement. The subjects will receive either the WELT-IP app or sham app.|t|f|t|f
34133582|NCT03397745|NA|SINGLE_GROUP||OTHER||NONE||||||
34133583|NCT05025397|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34133584|NCT00868088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133585|NCT03203824|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34133586|NCT02780583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133587|NCT03987139|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||"Intervention is performed once in both patients (after the aneurysm is closed and max. 5 days after ictus) and controls. The procedure consists of the following sessions:~1. Induced hypertension; as well~2. (Only in mechanically ventilated patients) either~   1. Mild hyper- and hypocapnia or~  2. Mild hyper- and hypoxia.~In session 2 (hyper- / hypoxia or hyper- / hypocapnia), patients are randomized to order the interventions."||||
34133588|NCT03935789|NA|SINGLE_GROUP||TREATMENT||NONE||Single group feasibility study||||
34133589|NCT04142424|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"Subjects in this study will be categorized as follows:~1. Overweight/mildly obese, but otherwise healthy subjects: There will be 6 cohorts, with 8 subjects in each cohort.~2. Japanese and Chinese subjects: There will be 2 cohorts for Japanese subjects, and one cohort for Chinese subjects, with 8 subjects in each cohort."|t|t|t|f
34133590|NCT06661447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The participants will not know which technique is being used in their edentulous area.~The investigator will not be informed which grafting technique was performed in the edentulous areas.~The outcomes assessor will not be informed of which procedures were performed on the participants."|Split mouth randomized clinical trial will performed in 40 patient with bilateral edentulous atrophic posterior region.|t|f|t|t
34133591|NCT03834610|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133592|NCT03010774|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34133593|NCT01920828|||COHORT||CROSS_SECTIONAL|||||||
34133594|NCT05878678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133595|NCT00582270|||COHORT||PROSPECTIVE|||||||
34133596|NCT06661239|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|The studied patients will be masked for the intervention|"The Benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes."|t|f|f|f
34133597|NCT00666549|||OTHER||OTHER|||||||
34133598|NCT03263910|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34133599|NCT00912834|||CASE_CONTROL||RETROSPECTIVE|||||||
34133600|NCT02519478|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34133601|NCT01825512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133602|NCT01926899|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133603|NCT05097560|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133604|NCT03756155|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized into two different groups (Group 1 and Group 2) in 10 participant blocks, meaning after every 10 participants eligible and completing the study, there will be 5 participants assigned to each group.||||
34133605|NCT03110978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133606|NCT02013557|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34133607|NCT05849272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133608|NCT00752934|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34133609|NCT03624478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133610|NCT05386862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133611|NCT06658691|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34133612|NCT00426595|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133613|NCT06491823|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Healthy right-handed adults with normal hearing will be recruited in equal number from both sexes. All participants will be fluent English speakers.||||
33827023|NCT05188313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827024|NCT01488838|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827025|NCT03106935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827026|NCT03333083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827027|NCT05803291|||OTHER||PROSPECTIVE|||||||
33827028|NCT06037239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827029|NCT00646711|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827030|NCT00449436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827031|NCT05131711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827032|NCT02314585|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33827033|NCT04996537|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Both the experimental group and the control group received the educational intervention.|Quasi-experimental research, with repeated measures research design|t|f|f|f
33827034|NCT01723007|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
33827035|NCT01410526|||CASE_CONTROL||PROSPECTIVE|||||||
33827036|NCT06034028|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827037|NCT03882996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827038|NCT02652377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827039|NCT05912569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827040|NCT04924088|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial comparing an intervention to treatment-as-usual||||
33827041|NCT00334971|NON_RANDOMIZED|PARALLEL||||NONE||||||
33827042|NCT01612221|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33827043|NCT05436652|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Drug and Placebo are masked and assigned via Interactive Response Technology (IRT)||t|f|f|f
33827044|NCT05854121|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827045|NCT05727488|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33827046|NCT03948399|||CASE_CONTROL||RETROSPECTIVE|||||||
33827047|NCT01208870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827048|NCT01040923|||CASE_ONLY||CROSS_SECTIONAL|||||||
33827049|NCT04498988|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33827050|NCT04677933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827051|NCT00815919|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827052|NCT02223013|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827053|NCT05957445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827054|NCT04717713|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827055|NCT01470664|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827056|NCT00982540|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827057|NCT05257252|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized controlled pretest- post test experimental design|t|f|f|t
33827058|NCT02251756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827059|NCT03157492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are randomly assigned to either AR Treatment or Active (Cognitive Training) Control Group. Participants are not told they are in the control group. After the final assessment (two-month post-treatment), control group participants are offered the AR treatment.|t|f|f|f
34133614|NCT05561595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133615|NCT01935323|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133616|NCT05577000|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133617|NCT03669757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The trial will be performed investigator-blind with random assignment of the 4 Investigational Medicinal Products (IMPs), the placebo and the active comparator.|Intra-individual comparison of all treatment|f|f|t|f
34133618|NCT05295121|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133619|NCT06661512|||COHORT||PROSPECTIVE|||||||
34133620|NCT01887561|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133621|NCT02540187|||COHORT||PROSPECTIVE|||||||
34133622|NCT06433154|||COHORT||RETROSPECTIVE|||||||
34133623|NCT04973683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133624|NCT05800925|||CASE_ONLY||PROSPECTIVE|||||||
34133625|NCT01255176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827060|NCT03841006|||CASE_CROSSOVER||PROSPECTIVE|||||||
33827061|NCT03277560|||COHORT||PROSPECTIVE|||||||
33827062|NCT03053115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827063|NCT05193747|||COHORT||PROSPECTIVE|||||||
33827064|NCT03143296|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827065|NCT02403284|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33827066|NCT05820321|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33827067|NCT01359878|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33827068|NCT01212484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827069|NCT03328845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827070|NCT06120114|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective cohort study||||
33827071|NCT04265911|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33827072|NCT01384721|||COHORT||RETROSPECTIVE|||||||
33827073|NCT00742014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827074|NCT00131898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827075|NCT00655083|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827076|NCT04598945|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33837486|NCT05403931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Person assessing the outcomes will have no knowledge that patient received laser therapy on which points of knee area.|Interventional study to compare the effectiveness of low level laser therapy on two groups of points of irradiation in knee OA grade III. One group of points involves 6-7 particular points on tibiofemoral and patellofemoral joints. Other group involves the 6-7 particular acupuncture points which have been previously used in a study. Outcomes will indicate that which group irradiation will produce better therapeutic results.|f|f|f|t
33837487|NCT05736926|||COHORT||CROSS_SECTIONAL|||||||
34133626|NCT05706623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133627|NCT06658587|||COHORT||PROSPECTIVE|||||||
34133628|NCT01183520|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34133629|NCT05479097|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34133630|NCT06391008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133631|NCT00014443|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133632|NCT04012502|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133633|NCT05687773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133634|NCT05816343|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE||A randomized, double-blind, placebo-controlled, parallel, study design will be employed for the first 24 weeks (Phase 1) followed by an open-labeled period of 24 weeks (Phase 2).|t|t|t|f
34133635|NCT05435807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133636|NCT04813835|||CASE_CONTROL||RETROSPECTIVE|||||||
34133637|NCT01885884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133638|NCT01688245|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34133639|NCT01202188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133640|NCT05252013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomised controlled crossover non-blinded design||||
34133641|NCT01426893|||||PROSPECTIVE|||||||
34133642|NCT06517277|||CASE_ONLY||RETROSPECTIVE|||||||
34133643|NCT03690401|||COHORT||PROSPECTIVE|||||||
34133644|NCT03539744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133645|NCT00002389||PARALLEL||TREATMENT||||||||
34133646|NCT04003207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133647|NCT03322046|||CASE_CONTROL||PROSPECTIVE|||||||
34133648|NCT06658964|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133649|NCT06660927|NA|SINGLE_GROUP||OTHER||NONE||||||
34133650|NCT06235359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133651|NCT05243524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133652|NCT05157971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133653|NCT00086528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133654|NCT05677490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133655|NCT03941873|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133656|NCT01377155|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133657|NCT04178525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients, investigators and other personnel involved in the study will be blinded with respect to the study treatment of the patient, until the end of the study.|Randomization will be applied at a 1:1 ratio on study level, and at each individual site. Sixty (60) patients will be included in the study, 30 in each arm.|t|f|t|f
34133658|NCT00964002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133659|NCT02431780|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34133660|NCT03211611|||OTHER||PROSPECTIVE|||||||
34133661|NCT03293849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133662|NCT03922594|||COHORT||PROSPECTIVE|||||||
34133663|NCT05724953|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will attend 8 weeks of blended psychoeducation and digital mHealth (mobile health) intervention using smartphones designed to target poor emotion awareness to reduce suicide risk in veterans with SMI.||||
34133664|NCT01379248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133665|NCT03029182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133666|NCT05181618|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||"The intervention study model is single group because all three cohorts of participants with hemophilia A will be receiving the same intervention: emicizumab."||||
34133667|NCT01650649|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133668|NCT00345566|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34133669|NCT05714449|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133670|NCT03938766||SEQUENTIAL||DIAGNOSTIC||NONE||||||
34133671|NCT06661382|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133672|NCT04646304|RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Phase 1 will recruit 4 groups of participants that vary in surgical experience (junior residents, senior residents, surgical fellows, and staff surgeons). Significant differences in objective measures of surgical performance will be identified. A target interval will be computed for each significant factor based on the staff surgeons' average performance.~Phase 2 will recruit junior residents to complete the same sets of surgical tasks. Half of the participants will receive objective feedback comparing their performance in Set 1 to the staff surgeons' target interval while the other half will receive no feedback. Differences in performance between Sets 1 and 3 will be quantified and compared between groups."||||
34133673|NCT04597216|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||phase 1: patients with Covid-19 or with anotther respiratory infection phase 2 : patients with a supsected Covid-19||||
34133674|NCT04145921|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133675|NCT00093899|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133676|NCT02876237|NA|SINGLE_GROUP||OTHER||NONE||||||
34133677|NCT01437579|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133678|NCT02499900|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133679|NCT03661307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133680|NCT05373784|NA|SINGLE_GROUP||TREATMENT||NONE||This will be a pilot study of 10 patients with a diagnosis of uncomplicated diverticulitis who will undergo FMT.||||
34133681|NCT05366621|||COHORT||RETROSPECTIVE|||||||
34133682|NCT03866408|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||immediate weight loss (placebo) will be compared with deferred weight loss (placebo) to determine the effects of weight loss alone immediate weight loss placebo will be compared with deferred weight loss pioglitazone to determine the effects of weight loss vs. pioglitazone deferred weight loss placebo will be compared with deferred weight loss pioglitazone to determine the effects of pioglitazone alone deferred weight loss placebo will be compared with deferred weight loss pioglitazone to determine the effects of weight loss alone vs. previous exposure to pioglitazone immediate weight loss placebo and deferred weight loss placebo will be pooled to create a larger group to determine the effects of weight loss on outcome variables|t|t|t|f
34133683|NCT06279949|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34133684|NCT01071252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133685|NCT04008303|||COHORT||PROSPECTIVE|||||||
33827077|NCT06180902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||For all patients included in the study, a designated algorithm will be applied. The initial phase of the clinical study, aimed at evaluating responsiveness to infusion therapy, starts with a precise measurement of the inferior vena cava's diameter. After a brief two-minute interval subsequent to the measurement, the focus shifts to the assessment of central venous pressure. A further two-minute pause following the central venous pressure evaluation signals the commencement of the passive leg raise test, an essential element in the protocol. The conclusion of the passive leg raise test is followed by a fifteen-minute waiting period, which precedes the start of the fluid challenge, completing the thorough evaluation sequence.||||
33827078|NCT00175656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827079|NCT01437813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827080|NCT06096818|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Double (Participant, Investigator) Women who meet the inclusion criteria were included in the sample using a simple random method. Before the research numbers were produced from random.org, envelopes of the same size and characteristics were created for each participant by someone other than the researcher (IU-C, Research Assistant B.Y), and numbers between 1 and 100 were written on them. Then, considering the data losses, numbers from 1 to 100 were generated from random.org. Single-column groups were created between 1 and 100 by the help of the Random Integer Generator at the Numbers title of the Random.org website. The numbers (1 or 2) were assigned to the groups (study and control) randomly by tossing a coin. Number 1 was assigned to the control group, and number 2 to the experimental group.~Experimental Group: 35 women Control Group: 35 women"|Parallel Assignment Type of Study: This study is a randomized controlled trial. The pre-test-post-test has be carried out with a pattern.|t|f|t|f
33827081|NCT00988117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827082|NCT03500263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827083|NCT03124550|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Participants will use the exergame for 6 weeks. Physical activity will be recorded. Participants will receive game-related rewards when they are active.||||
33827084|NCT06546514|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33827085|NCT00676195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827086|NCT02748902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827087|NCT01347177|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827088|NCT00937456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827089|NCT06439147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized clinical trial|t|f|f|f
33827090|NCT01211223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33827091|NCT00193596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827092|NCT00900406|||COHORT||PROSPECTIVE|||||||
33827093|NCT00297778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827094|NCT04470570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827095|NCT06039943|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827096|NCT01562587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827097|NCT05404217|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, double-blind, placebo-controlled parallel-group|t|t|t|f
33827098|NCT00318305|||CASE_ONLY||PROSPECTIVE|||||||
33827099|NCT03228277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827100|NCT00281502|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33827101|NCT00979745|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827102|NCT00169949|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827103|NCT01907022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827104|NCT06465992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827105|NCT04020198|||OTHER||OTHER|||||||
33827106|NCT00312234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33827107|NCT01639014|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827108|NCT06123832|||COHORT||RETROSPECTIVE|||||||
33827109|NCT05705232|||OTHER||CROSS_SECTIONAL|||||||
33827110|NCT05573347|||COHORT||PROSPECTIVE|||||||
33827111|NCT01091519|||||PROSPECTIVE|||||||
33827112|NCT02970786|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827113|NCT01871168|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33827114|NCT03511378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827115|NCT03246399|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33827116|NCT03801447|||COHORT||PROSPECTIVE|||||||
33827117|NCT01664897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827118|NCT00334139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827119|NCT01577433|||OTHER||OTHER|||||||
33827120|NCT04107077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827121|NCT03752489|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33827122|NCT04887623|||COHORT||PROSPECTIVE|||||||
33827123|NCT04233502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827124|NCT06235853|||COHORT||PROSPECTIVE|||||||
34133686|NCT02353819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827125|NCT02176837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827126|NCT02679313|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827127|NCT00006145||||PREVENTION||DOUBLE||||||
33827128|NCT00212797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33827129|NCT01860495|||COHORT||PROSPECTIVE|||||||
33827130|NCT01649297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827131|NCT01774019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827132|NCT02650206|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33827133|NCT06088797|||CASE_CONTROL||PROSPECTIVE|||||||
33827134|NCT06086522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose escalation, Dose expansion||||
33827135|NCT01700114|||COHORT||PROSPECTIVE|||||||
33827136|NCT01530477|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33827137|NCT06531811|RANDOMIZED|CROSSOVER||OTHER||NONE||This is an open-label, 2-period cross over study.||||
33827138|NCT00814645|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827139|NCT05641714|||OTHER||CROSS_SECTIONAL|||||||
33827140|NCT06369883|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33827141|NCT00463580|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827142|NCT03147508|||COHORT||CROSS_SECTIONAL|||||||
33827143|NCT02016690|||COHORT||PROSPECTIVE|||||||
34133687|NCT03737448|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34133688|NCT04622501|||CASE_ONLY||CROSS_SECTIONAL|||||||
34133689|NCT02203110|||COHORT||PROSPECTIVE|||||||
34133690|NCT03280849|NA|SINGLE_GROUP||TREATMENT||NONE||Use of a novel bilaminar chitosan scaffold in the repair of the sellar floor after an endoscopic endonasal transsphenoidal surgery for a suspected hipofisary macroadenoma.||||
34133691|NCT01974206|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133692|NCT01132651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133693|NCT05195437|||CASE_ONLY||PROSPECTIVE|||||||
34133694|NCT04551898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133695|NCT03931382|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized, unblinded, controlled||||
34133696|NCT01877850|||CASE_CONTROL||PROSPECTIVE|||||||
34133697|NCT04247412|||CASE_ONLY||PROSPECTIVE|||||||
34133698|NCT05809050|||CASE_CONTROL||PROSPECTIVE|||||||
34133699|NCT03815058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133700|NCT00677846|||CASE_ONLY||PROSPECTIVE|||||||
34133701|NCT05687032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133702|NCT06657638|||CASE_ONLY||PROSPECTIVE|||||||
34133703|NCT05684445|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This study is an experimental one-group pre-test-post-test design.||||
34133704|NCT00163241|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34133705|NCT01059487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133706|NCT06252870|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, phase 2, non-comparative, randomized, open-label, prospective drug trial||||
34133707|NCT01577264|||COHORT||PROSPECTIVE|||||||
34133708|NCT04715828|||COHORT||PROSPECTIVE|||||||
34133709|NCT03985943|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Treatment||t|t|t|t
34133710|NCT02378077|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34133711|NCT00985608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133712|NCT04715854|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||One group will receive oxygen by classical nasal cannula. The second group will receive oxygen by aerosol mask associated with the nasal cannula. Afterward, the sequence will be inverted.|f|f|f|t
34133713|NCT05641584|||OTHER||RETROSPECTIVE|||||||
34133714|NCT05530863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133715|NCT04833686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133716|NCT00356772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34133717|NCT00884962|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133718|NCT03379948|||OTHER||PROSPECTIVE|||||||
34133719|NCT06072144|||OTHER||CROSS_SECTIONAL|||||||
34133720|NCT01803100|||COHORT||PROSPECTIVE|||||||
34133721|NCT04327427|||COHORT||RETROSPECTIVE|||||||
34133722|NCT06020391|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34133723|NCT01108731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133724|NCT01684696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34133725|NCT03415594|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34133726|NCT03890354|||CASE_ONLY||RETROSPECTIVE|||||||
34133727|NCT04428788|NA|SEQUENTIAL||TREATMENT||NONE||||||
34133728|NCT05655650|||COHORT||PROSPECTIVE|||||||
34133729|NCT05507567|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, Double-blind, Placebo-controlled study|t|f|t|f
34133730|NCT01478269|||COHORT||RETROSPECTIVE|||||||
34133731|NCT00494650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133732|NCT02463084|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34133733|NCT06284590|RANDOMIZED|PARALLEL||TREATMENT||NONE||"162 patients. Patients enrolled will be randomized in a 1:1:1 ratio. i) systemic pembrolizumab in combination with intralesional L19IL2 (Arm 1): 54 patients.~ii) systemic pembrolizumab in combination with intralesional L19TNF (Arm 2): 54 patients iii) systemic pembrolizumab in combination with intralesional L19IL2/L19TNF (Arm 3): 54 patients"||||
34133734|NCT02485249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133735|NCT06426563|RANDOMIZED|PARALLEL||TREATMENT||NONE||One group is for radiofrequency ablation treatment (RFA), another group is for microwave ablation treatment (MWA)||||
34133736|NCT00422630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133737|NCT03122678|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133738|NCT04332536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133739|NCT05963282|||COHORT||RETROSPECTIVE|||||||
34133740|NCT01954459|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133741|NCT06255002|||CASE_ONLY||PROSPECTIVE|||||||
34133742|NCT04516070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827144|NCT04811118|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33827145|NCT01086618|RANDOMIZED|||TREATMENT||||||||
33827146|NCT00135785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133743|NCT06660849|||CASE_ONLY||CROSS_SECTIONAL|||||||
34133744|NCT06479954|||COHORT||PROSPECTIVE|||||||
34133745|NCT04860557|||OTHER||CROSS_SECTIONAL|||||||
34133746|NCT05129280|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133747|NCT04234646|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34133748|NCT04538495|||CASE_ONLY||PROSPECTIVE|||||||
34133749|NCT06028152|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133750|NCT00053677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34133751|NCT06477952|NA|SINGLE_GROUP||TREATMENT||NONE||120 Veterans will be screened and enrolled to achieve 45 participants completing the study. All participants will receive oral Dronabinol treatment nightly for two weeks.||||
34133752|NCT04400019|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The HCQ and the placebo will be manufactured by Laboratorios Rubio, blinded in similar containers for HCQ and placebo and will be stored in the pharmacy of the participating reference hospitals and will be distributed to the participating residences by the research technicians hired for the project.~A record of doses delivered and monitoring of doses consumed will be carried out. The containers must be wrapped in a disposable protective cover, which can be removed before entering the residences, in order to minimize the accidental transmission of the virus through this route."|Controlled, randomized, triple-blind cluster study.|t|f|f|t
34133753|NCT02119429|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34133754|NCT06659237|||CASE_CONTROL||PROSPECTIVE|||||||
34133755|NCT05959577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827147|NCT03371485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827148|NCT02107729|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33827149|NCT05458830|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The study is designed as a randomised controlled trial for the anonymous users of an online self-test for suicidal thoughts in which individuals with severe suicidal thoughts and no interest in contacting the helpline will be randomly allocated either to a short barrier reduction intervention (BRI) or receive a general advisory text (care as usual). To minimise the burden on the high-risk and sensitive study population, the investigators aim that it is feasible to complete the intervention within 10 minutes.|t|f|f|f
33827150|NCT02172950|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827151|NCT01265121|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33827152|NCT00225277|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827153|NCT05146661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827154|NCT00531063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827155|NCT00024570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827156|NCT04360434|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827157|NCT00373022|RANDOMIZED|||SUPPORTIVE_CARE||||||||
33827158|NCT00935714|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33827159|NCT03453203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The follow-up physician will be blinded to treatment vs control arm. Patient will be selected randomly depending on the time of recruitment.|Blinded control trial|f|t|f|f
33827160|NCT04527783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827161|NCT01282749|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827162|NCT03744741|||CASE_ONLY||PROSPECTIVE|||||||
33827163|NCT02831998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33827164|NCT01013064|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33827165|NCT00014222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827166|NCT05212311|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33827167|NCT00679549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827168|NCT01793298|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33827169|NCT04435470|||CASE_CONTROL||PROSPECTIVE|||||||
33827170|NCT01904019|||COHORT||PROSPECTIVE|||||||
33827171|NCT01245335|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827172|NCT05566353|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827173|NCT01997489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827174|NCT03935061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The clinical assessments of clinical symptoms and social functions are self-reported and thus clinicians or care providers have no knowledge of the outcomes. The self-reported assessments are then coded by a research assistant with masked group labels and handled to the statistician for analysis.|Patients who agree to join our study are measured at baseline. Randomization is carried out by using a computer program and 2 bottles (600 ml/bottle) of sanitized mulberry juice are delivered to the experimental group 20 days before the next clinic visit, with instruction to consume 50 ml of juice diluted with drinking water at room temperature. For the control group, patients are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and social functions and inflammation status are conducted. A between-group difference at this stage represents changes caused by the intervention. No mulberry juice is given to patients for either group further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.|f|f|t|t
33827175|NCT05087953|||COHORT||CROSS_SECTIONAL|||||||
33827176|NCT04840498|||COHORT||PROSPECTIVE|||||||
33827177|NCT05858801|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33827178|NCT02324309|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33827179|NCT04479514|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827180|NCT03402321|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33827181|NCT02187445|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827182|NCT04237714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827183|NCT01674452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827184|NCT03144778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827185|NCT06186726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827186|NCT02564718|NA|SINGLE_GROUP||OTHER||NONE||||||
33827187|NCT06538519|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|t|t|f
33827188|NCT05414006|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||According to different groups, s-ketamine and placebo were given respectively According to the different PCA methods, different subgroups were included|t|t|f|t
33827189|NCT00932555|||COHORT||PROSPECTIVE|||||||
33827190|NCT03164525|||COHORT||PROSPECTIVE|||||||
33827191|NCT04799418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827192|NCT00506272|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827193|NCT03292497|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Echocardiographic outcome assessment will be blinded.||f|f|f|t
34133756|NCT00560651|||OTHER||PROSPECTIVE|||||||
34133757|NCT04743336|||OTHER||RETROSPECTIVE|||||||
34133758|NCT05171400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a double-blind, parallel, superiority, randomized clinical trial with 3 months of follow-up.|t|f|f|t
34133759|NCT05425394|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133760|NCT01319253|||COHORT||PROSPECTIVE|||||||
33827194|NCT02157129|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33827195|NCT04518761|||CASE_ONLY||PROSPECTIVE|||||||
33827196|NCT02097849|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133761|NCT00050206|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827197|NCT06165536|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827198|NCT00216801|||COHORT||PROSPECTIVE|||||||
33827199|NCT00317447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827200|NCT03767400|||CASE_CONTROL||PROSPECTIVE|||||||
33827201|NCT01920178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827202|NCT05384236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827203|NCT03945097|||CASE_CONTROL||PROSPECTIVE|||||||
33827204|NCT01406808|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34133762|NCT04549571|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|The enhanced content of the ESE version iCanDecide-ESE is available to the patient, but does not populate differently into the CDB, allowing clinicians to remain blinded to the patient-level randomization arm; therefore, both the patient and the practice and clinicians will be blinded as to which arm the patient is assigned to. However, the surgical practices and their clinicians will know when they are using the CDB so the clinician level intervention will not be blinded.||t|t|f|f
34133763|NCT04292431|||CASE_CONTROL||PROSPECTIVE|||||||
34133764|NCT05416372|RANDOMIZED|PARALLEL||TREATMENT||NONE||20 communities will be stratified by population size (\< or ≥ 20,000) and randomly ordered within strata using a computerized random number generator. A statistician will generate a list of all of possible random permutations that allocate equal numbers of communities from each stratum to the intervention and to the control. Investigators will then invite two representatives from each of the 20 communities to a public randomization ceremony. During this ceremony, representatives will blindly choose numbered tennis balls from an opaque bag to identify the permutation of allocations that will be used.||||
34133765|NCT02214888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34133766|NCT03091517|NA|SINGLE_GROUP||OTHER||NONE||||||
34133767|NCT03851406|RANDOMIZED|CROSSOVER||TREATMENT||NONE||To determine the efficacy of nebulized 5% hypertonic saline (HS) (v. no treatment) in mitigating wood smoke particulate (WSP)-induced neutrophilic airway inflammation, assessed via sputum %polymorphonuclear leukocytes (PMNs), in healthy adults 4 hours post WSP exposure.||||
34133768|NCT06421168|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34133769|NCT06570512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133770|NCT01639339|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133771|NCT06659120|||COHORT||PROSPECTIVE|||||||
34133772|NCT01651819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133773|NCT00425698|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34133774|NCT05537064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34133775|NCT02832557|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34133776|NCT02102685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133777|NCT04907825|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, open-label, cluster-randomized controlled trial||||
34133778|NCT03877315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will be blinded to which implant type they are receive. This will be done by not sharing the operation chart files with the patient's online file records; the inserted shoulder prosthesis will be noted by a unique code in operation file, and the radiologist will be asked not to describe the post-operation x-ray controls.~The primary investigator will conduct the blinded statistical analysis supervised by the biostatistician."||t|f|f|f
34133779|NCT02855866|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133780|NCT00479505|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133781|NCT06316934|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Randomization will be performed once the patient agrees to participate and has signed the consent document. A random number generator will be used to designate each arm of the study. Odd numbers will be assigned to the aromatherapy arm while the even numbers will be assigned to the placebo arm. Each assignment will be placed into a sealed opaque numbered enveloped. After the participant has agreed to participate, the clinic nurse will open the envelope to identify the study arm.|The participants will be randomized into two arms - aromatherapy or placebo. The protocol will be the same for the two arms except that the towel held over the mouth will be scented either with lavender essential oil or distilled water. The clinic nurse will prepare the scented towel and hand it to the participant according to the random assignment.|t|t|t|f
34133782|NCT00515606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34133783|NCT04925999|||COHORT||CROSS_SECTIONAL|||||||
34133784|NCT00461149|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133785|NCT05368259|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133786|NCT03990623|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133787|NCT05055011|||COHORT||CROSS_SECTIONAL|||||||
34133788|NCT00472316|||COHORT||PROSPECTIVE|||||||
34133789|NCT03641716|NA|SINGLE_GROUP||PREVENTION||NONE||Repeated Measures||||
34133790|NCT00606034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133791|NCT02903225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133792|NCT06321211|||CASE_ONLY||CROSS_SECTIONAL|||||||
34133793|NCT04246775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133794|NCT06592833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133795|NCT02851797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133796|NCT02029755|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34133797|NCT00101920|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133798|NCT03332017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133799|NCT00711048|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34133800|NCT02143453|RANDOMIZED|PARALLEL||||NONE||||||
34133801|NCT04189965|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34133802|NCT03468751|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133803|NCT00633568|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827205|NCT03614286|||OTHER||OTHER|||||||
34133804|NCT02494518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133805|NCT06659952|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Natural randomization will take place as OPTN organ offers become available and will be assigned to either arm based on whether the subject accepts/ declines the HIV+ donor heart."||||
34133806|NCT06058429|||OTHER||PROSPECTIVE|||||||
33827206|NCT00570557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827207|NCT00049335|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827208|NCT06365125|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33827209|NCT06308497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Products will be concealed.|Double-arm parallel design|t|f|t|t
33827210|NCT01237652|||COHORT||PROSPECTIVE|||||||
34133807|NCT00395486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133808|NCT03441035|||COHORT||PROSPECTIVE|||||||
34133809|NCT03924219|||COHORT||PROSPECTIVE|||||||
34149448|NCT00549770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149449|NCT05442177|||COHORT||PROSPECTIVE|||||||
33827211|NCT05226247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|All echographic measurements will be analyzed offline, blinded to the patients' response to spontaneous breathing trial|Cohort Study||||
33827212|NCT02864199|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827213|NCT04877249|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827214|NCT01435798|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33827215|NCT04082377|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The management was carried out by a member of research team only aware of allocation group. The participants ,outcome assessor, surgeons and nursing staff will be totally blind of randomization schedule. All postoperative clinical staff handling patient care will be also unaware of the aim of the work.||t|f|f|t
33827216|NCT03671798|||CASE_CONTROL||PROSPECTIVE|||||||
33827217|NCT03552237|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827218|NCT01154465|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827219|NCT03553849|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The operative surgeons will be blinded to the randomization. The patient, by nature of the study, will not be blinded.|The patient will be randomized into the treatment or control arm by the research team. If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery.|f|t|f|t
33827220|NCT05993520|||CASE_ONLY||PROSPECTIVE|||||||
33827221|NCT03987659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33827222|NCT00488228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827223|NCT00363649|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Participants were randomly assigned to Arm A or Arm B and received up to twelve months of protocol therapy. If at any point a participant progressed, relapsed, or had unacceptable toxicity, they could cross over to the other arm. Participants could only cross over once.||||
33827224|NCT03667599|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827225|NCT06320847|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33827226|NCT00392886||||TREATMENT||||||||
33827227|NCT06121583|||COHORT||CROSS_SECTIONAL|||||||
33827228|NCT06134583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Trible masking (participant, care provider and outcomes assessor)|Comparison between superior cervical sympathetic block and stellate ganglion block to treat cerebral vasospasm in post-traumatic subarachnoid hemorrhage|t|t|f|t
33827229|NCT02986750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33827230|NCT02950688|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827231|NCT03822195|||COHORT||PROSPECTIVE|||||||
33827232|NCT06416319|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants with an indication for radical cystectomy are included in this study. Recruitment, including eligibility criteria testing and randomized allocation to the intervention or control group, will take place on the day of premedication approximately 7 to 10 days prior to surgery. This period represents the prehabilitation period.||||
33827233|NCT04126122|||COHORT||PROSPECTIVE|||||||
33827234|NCT02973256|||CASE_ONLY||PROSPECTIVE|||||||
33827235|NCT04423536|||COHORT||PROSPECTIVE|||||||
33827236|NCT06240377|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Simple Blind, Evaluator||f|t|t|t
33827237|NCT02299427|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827238|NCT06178575|||CASE_CONTROL||RETROSPECTIVE|||||||
33827239|NCT02651883|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33827240|NCT00548795|||COHORT||PROSPECTIVE|||||||
33827241|NCT03553485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33827242|NCT03497221|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827243|NCT04929054|||COHORT||PROSPECTIVE|||||||
33827244|NCT06479226|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33827245|NCT02053064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827246|NCT04152395|||CASE_CONTROL||PROSPECTIVE|||||||
33827247|NCT00282698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827248|NCT00594178|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827249|NCT05155709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827250|NCT05201521|||COHORT||PROSPECTIVE|||||||
33827251|NCT01584271|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827252|NCT00510263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827253|NCT02358213|NA|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33827254|NCT03987464|NA|SINGLE_GROUP||OTHER||NONE||||||
33827255|NCT06105047|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827256|NCT01721174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827257|NCT02316847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827258|NCT00554944|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827259|NCT04520841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827260|NCT01102387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827261|NCT00003212|RANDOMIZED|||TREATMENT||||||||
33827262|NCT00474383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827263|NCT05772481|||CASE_ONLY||PROSPECTIVE|||||||
33827264|NCT04185987|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||2 a cross-over, in vivo study.|f|f|f|t
33827265|NCT04915547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33827266|NCT05127330|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827267|NCT01648985|||COHORT||PROSPECTIVE|||||||
33827268|NCT02774564|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827269|NCT02586662|||||CROSS_SECTIONAL|||||||
33827270|NCT00115947|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33827271|NCT02664025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827272|NCT01099683|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827273|NCT03471897|||COHORT||RETROSPECTIVE|||||||
33827274|NCT06233474|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Run-in phase followed by randomization phase|t|f|t|f
33827275|NCT04145609|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827276|NCT03023852|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827277|NCT02025647|||COHORT||PROSPECTIVE|||||||
33827278|NCT05910697|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Physicians who were enrolled in the ongoing study will keep their arm assignments. Intervention physicians will have access to educational materials as well as a diagnostic test.||||
33827279|NCT05708313|NA|SINGLE_GROUP||PREVENTION||NONE||Groups will be assigned to the exercise treatment group||||
33827280|NCT04938765|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Study drug or the placebo will be administered after inducing general anesthesia hence patient will be masked. study drug or the placebo will be administered by the anesthesia team and this will not be disclosed to the neuro monitoring team who sits far away from the anesthesia workstation.|Prospective double blind randomized clinical trial|t|f|f|t
33827281|NCT02413593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827282|NCT04947826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827283|NCT00498758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827284|NCT01572298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827285|NCT00574600|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33827286|NCT03427008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a single center, prospective, randomized control trial with two arms. Participants in the intervention arm will use the mHealth app to manage and track their immunosuppression medical regimen post-transplant, and participants in the control arm will receive the current standard of follow-up care post-transplant.||||
33827287|NCT02981537|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827288|NCT00356564|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827289|NCT02999932|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827290|NCT01575483|||CASE_ONLY||PROSPECTIVE|||||||
33827291|NCT00575367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827292|NCT05052749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Female participants in clinical trial will be kept blind about their exercise group allocation.|This will be a single factor, Pretest-Posttest Control Group Design with parallel assignment of patients in to two groups.|t|f|f|f
33827293|NCT02182583|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827294|NCT02010398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33827295|NCT06183619|||COHORT||RETROSPECTIVE|||||||
33827296|NCT02210013|||COHORT||PROSPECTIVE|||||||
33827297|NCT01836016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827298|NCT00664456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827299|NCT00471172|RANDOMIZED|PARALLEL||||NONE||||||
33827300|NCT00337285|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827301|NCT02604797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827302|NCT06266442|||COHORT||PROSPECTIVE|||||||
33827303|NCT00718198|||COHORT||CROSS_SECTIONAL|||||||
33827304|NCT01141829|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33827305|NCT03282578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827306|NCT03903562|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827307|NCT04068909|||COHORT||PROSPECTIVE|||||||
33827308|NCT04458987|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||patients hospitalized for addiction withdrawal in the addiction service of the university hospital Bichat, Paris, France||||
33827309|NCT02189369|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33827310|NCT05923502|||COHORT||PROSPECTIVE|||||||
33827311|NCT03394183|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||All participants will be enrolled in the cardiac rehabilitation program which involves weekly 1.5 hour visits at the Toronto Rehabilitation Institute Rumsey Centre for 6 months. Each visit will consist of an exercise and a risk factor education lecture. Prior to the start of the program, participants will attend two assessment sessions with cardiac rehabilitation staff members to review medical history as well as complete a cardiopulmonary exercise test. During the cardiac rehabilitation program, participants will walk at 60-80% of their VO2peak heart rate based on the results of their exercise test, as per standard care procedures. Adjustments will be made to the patient's exercise prescription under the discretion of the cardiac rehabilitation supervisor, as per standard care procedures. Patients will also be asked to exercise an additional four times during the week on their own time for a total of five times per week, as per standard care procedures.||||
33827312|NCT02872818|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33827313|NCT03294941|NA|SEQUENTIAL||DIAGNOSTIC||NONE||All subjects receive HepQuant SHUNT test and DSI measurement, but must first be enrolled into one of the three Gilead clinical trials listed above before they can be enrolled in the HepQuant study. Since the assigned intervention, the HepQuant SHUNT test, is the same for all participants in all three Gilead clinical trials, there is only one arm and intervention for the HepQuant study itself. Some analyses are conducted by grouping subjects into those who took the placebo in the parallel drug study versus those who were on active study drug in the parallel study.||||
33827314|NCT02142998|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33827315|NCT05259397|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33827316|NCT00438139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827317|NCT05082233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827318|NCT03315234|||COHORT||PROSPECTIVE|||||||
33827319|NCT04306549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827320|NCT02615548|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33827321|NCT03111797|||COHORT||PROSPECTIVE|||||||
33827322|NCT06479330|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|The products will be labelled with a code so study staff and research participants will be blinded as to which test meal is which. After the database will be cleaned and locked, and statistical analysis will be completed, and the codes will be broken.|In a 5-way cross-over, there is a set of 10 balanced sequences to which participants will be randomly assigned. Blocks of 1 or 2 sets of sequences will be randomly ordered to create a balanced sequence for n=60 participants. Orders will be assigned to participants in the order they attended for the first visit after being recruited.|t|f|t|t
33827323|NCT01344499|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33827324|NCT02880332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33827325|NCT02032108|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827326|NCT05593510|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Randomized repeated measures between-subjects design||||
34149450|NCT02576808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149451|NCT04208048|||COHORT||PROSPECTIVE|||||||
34149452|NCT02901652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149453|NCT02440789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149454|NCT04109976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149455|NCT03201315|||COHORT||PROSPECTIVE|||||||
34133810|NCT04192136|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|"The participants and the investigator team will be blinded as to the group assignment: NR vs Placebo. All collected data (e.g., questionnaires) will be coded, so initial analysis will be conducted without knowledge of the participant's group status.~While the assignment of participants to the exercise groups will not be blinded to the participant or majority of the study team, a designated blinded technician will perform the follow-up Cardio Pulmonary Exercise Testing. Follow-Up Cardio Pulmonary Exercise Testing will be performed by a dedicated blinded study team member, an exercise technician, who will not know if the participant was assigned to an arm including the exercise intervention."|Randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise.|t|t|t|t
34133811|NCT03021655|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34133812|NCT04798352|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133813|NCT04164095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133814|NCT04748328|||COHORT||PROSPECTIVE|||||||
34133815|NCT02507466|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||3 arm RCT - high intensity variable, high intensity forward, low intensity variable|f|f|f|t
34133816|NCT04926610|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34133817|NCT05497531|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133818|NCT03315793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133819|NCT00249808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133820|NCT04075890|NON_RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34133821|NCT02835313|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34133822|NCT05923827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133823|NCT02426567|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34133824|NCT00616018|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34133825|NCT02145806|||COHORT||CROSS_SECTIONAL|||||||
34133826|NCT06287840|||OTHER||PROSPECTIVE|||||||
34133827|NCT02461459|||COHORT||PROSPECTIVE|||||||
34133828|NCT06230419|||OTHER||RETROSPECTIVE|||||||
34133829|NCT02920528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133830|NCT06326008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133831|NCT06096688|||COHORT||PROSPECTIVE|||||||
34133832|NCT03658343|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133833|NCT05607511|NA|SINGLE_GROUP||TREATMENT||NONE|Masked laboratory staff about the clinical details and disease-related information of participants.|Single-group, open-label interventional clinical trial||||
34133834|NCT02553551|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34133835|NCT04167059|RANDOMIZED|PARALLEL||TREATMENT||NONE|We note that our primary outcomes of sedentary behaviours and physical activity will be measured objectively by physical activity devices.|We are using a waitlist controlled trial study design. Group membership will be determined using a concealed allocation randomisation after the baseline assessment. The 'immediate treatment' group will receive the 12-week intervention period following the assessment at baseline followed by a 12 week non-intervention period. The 'waitlist control' group receive no intervention in the first 12 week period and will then receive the intervention in the second 12 week period.||||
34133836|NCT00748618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133837|NCT03940846|||COHORT||RETROSPECTIVE|||||||
34133838|NCT05398159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133839|NCT05612061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Wait-list control group|f|f|t|f
34133840|NCT05312749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34133841|NCT04551963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133842|NCT04934839|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Osseointegration for lower limb amputation is a rare procedure. Therefore, a convenience sample of patients will be enrolled. Efforts will be made to match the participants with controls, fitted with conventional socket prosthesis, by age, gender, height and weight without the prosthesis, prosthetic side, and type of prosthesis, but an exact matching is not considered a strict requirement.||||
34133843|NCT04874883|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All individuals directly involved in the research will be masked. The modules used in the study were masked by an individual external to the research, being the only one who knew the composition.|The study will be double-masked and individuals will be randomly divided into two groups: Symbiotic group (S) - will receive the symbiotic (association of fructooligosaccharide, prebiotic, and four probiotic strains: Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus Acidophilus, and Bifidobacterium bifidum) enterally or orally in the amount of a sachet, twice a day. Control Group (C) will receive maltodextrin placebo (carbohydrate easily absorbed and digested, not fermented by colonic bacteria and which does not interfere in the microbial ecology of the gastrointestinal tract or in the metabolism and function of the intestine), either enterally or orally in a sachet. hours until hospital discharge.|t|t|t|t
34133844|NCT06660875|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34133845|NCT05103553|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133846|NCT04472650|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133847|NCT03077438|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34133848|NCT04692649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The enumerator will not know about the interventions used for the side of the body|RCT|f|t|t|t
34133849|NCT03397433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a prospective, pragmatic trial of initial antibiotic prescribing review by Infectious Disease Specialists. The study involves 4 hospitals, 2 of which are intervention and 2 control for 18 months, followed by switching the intervention and control hospitals in a crossover fashion for another 18 months. Medical and economic outcomes will be assessed and reported||||
34133850|NCT02701283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133851|NCT00583752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133852|NCT06659211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149456|NCT04622904|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827327|NCT01085812|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33827328|NCT03628690|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 randomization||||
33827329|NCT02779283|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827330|NCT04459221|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827331|NCT03106298|||OTHER||PROSPECTIVE|||||||
33837488|NCT00822770|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34133853|NCT03350035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind study that will randomize subjects to ganaxolone or placebo in a 1:1 ratio as adjunctive therapy to their standard of care.|t|t|t|t
34133854|NCT02364427|||COHORT||PROSPECTIVE|||||||
34133855|NCT05904496|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133856|NCT06312410|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34133857|NCT00037193|||DEFINED_POPULATION||PROSPECTIVE|||||||
34133858|NCT05142917|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133859|NCT02912494||||||DOUBLE|||t|f|t|f
34133860|NCT02446678|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34133861|NCT06555016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133862|NCT05913050|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be a non-controlled multicenter clinical trial with the main aim of developing a multivariable prediction model of the improvements after a physical therapy treatment based on exercise and education.||||
34133863|NCT04728360|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133864|NCT00189800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34133865|NCT04790435|||CASE_ONLY||PROSPECTIVE|||||||
34133866|NCT04969094|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133867|NCT01659996|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133868|NCT06660940|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133869|NCT03755674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34133870|NCT04475523|NA|SINGLE_GROUP||TREATMENT||NONE||Each patient will be administered a step-dose of CI-8993. If a patient experiences a DLT following the step dose, treatment will be discontinued for that patient. If there are no safety concerns following the step dose, the patient will receive the first full dose of CI-8993 a week later. If none of the 3 patients in each cohort (or 1 in 6 patients) experiences a DLT during the first cycle (28 days following the first full dose), the SRC may clear the next dose level for enrollment.||||
34133871|NCT00504361|||CASE_CONTROL||PROSPECTIVE|||||||
34133872|NCT06659757|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34133873|NCT01092780|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34133874|NCT03269916|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133875|NCT03145064|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133876|NCT03892057|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blind to intervention assignment and will only collect clinical data at baseline, 5-, and 12-weeks.|Randomized control trial|f|f|f|t
34133877|NCT04517695|||COHORT||PROSPECTIVE|||||||
34133878|NCT00626509|RANDOMIZED|||TREATMENT||||||||
34133879|NCT04714827|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133880|NCT04291196|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34133881|NCT06300151|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34133882|NCT03450694|||COHORT||PROSPECTIVE|||||||
34133883|NCT03673085|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34133884|NCT04559022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133885|NCT05977816|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34133886|NCT02712983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133887|NCT05140304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133888|NCT02745704|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133889|NCT04091581|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34133890|NCT03595020|||CASE_CONTROL||PROSPECTIVE|||||||
34133891|NCT05460533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133892|NCT06661083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133893|NCT00000805||||TREATMENT||NONE||||||
34133894|NCT02920736|||COHORT||PROSPECTIVE|||||||
34133895|NCT06657963|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34133896|NCT01777464|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34133897|NCT03501992|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The data analyst will conduct the measurement of the patients eligible and vaccinated and the calculations of the outcomes. The investigators will blind the data analyst to which intervention(s) each practice was assigned to receive. However that only masks the practices' interventions for Step 2 and Step 3 as all practices receive the same interventions in Step 1 (current care) and Step 4 (combined reminder-audit).|A factorial, stepped-wedge cluster randomized trial with process evaluation|f|f|f|t
34133898|NCT02464995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133899|NCT05739006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133900|NCT04060069|||COHORT||PROSPECTIVE|||||||
34133901|NCT04590430|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34133902|NCT01623765|||CASE_ONLY||PROSPECTIVE|||||||
34133903|NCT06625099|||COHORT||PROSPECTIVE|||||||
34133904|NCT04149470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133905|NCT01391169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827332|NCT03411928|NA|SINGLE_GROUP||TREATMENT||NONE|Unblinded|Prospective interventional study||||
33827333|NCT01649037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827334|NCT00723918|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33827335|NCT02684799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133906|NCT04541043|NA|SINGLE_GROUP||TREATMENT||NONE||This is an open label, single-arm study with active treatment||||
34133907|NCT03186508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34133908|NCT06658860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study followed a parallel-group design. Participants were randomly assigned to two groups: one received the modified socket shield technique and the other received conventional extraction without the socket shield. Both groups were monitored after 6 months to compare alveolar ridge preservation outcomes, with delayed implant placement performed in both groups at 6 months after tooth extraction.|t|f|f|f
34133909|NCT01678859|||CASE_CONTROL||PROSPECTIVE|||||||
34149457|NCT04066634|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149458|NCT04406688|||COHORT||PROSPECTIVE|||||||
34149459|NCT02489812|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149460|NCT04161781|||COHORT||PROSPECTIVE|||||||
34149461|NCT02001337|||COHORT||PROSPECTIVE|||||||
34149462|NCT01612455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149463|NCT02506686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133910|NCT06659380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participant, care provider, investigator, and outcomes assessor are blind to treatment status as well as patients and families.|All patients will receive Metronidazole antibiotic treatment then blind-randomly be divided into two groups: the treatment group, receiving Floragyn® probiotic tablets (Lapi, Indonesia), and the placebo group, receiving Cal 95® (Lapi, Indonesia). As a control, postmenopausal women without bacterial vaginosis will also be included and receive Floragyn® probiotic tablets only. Patients are assessed at T0, T1 and T7 week.|t|t|t|t
34133911|NCT04223765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133912|NCT04607174|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34133913|NCT04450706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133914|NCT03763656|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, observational, pharmacokinetic study of oral hydroxyurea solution administered to children from 6 months-17.99 years over a 12-15-month period||||
34133915|NCT03186443|RANDOMIZED|PARALLEL||PREVENTION||NONE||control group is to oral gabapentin 0.4 tid； experiment group is to oral pregabalin 300mg q 12h||||
34133916|NCT02336685|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133917|NCT03601858|||COHORT||RETROSPECTIVE|||||||
34133918|NCT06662071|||COHORT||PROSPECTIVE|||||||
34133919|NCT06586918|||CASE_ONLY||PROSPECTIVE|||||||
34133920|NCT05192616|||COHORT||PROSPECTIVE|||||||
34133921|NCT06002906|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34133922|NCT06029283|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34133923|NCT05957393|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||t|f|f|f
34133924|NCT05241860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133925|NCT05199233|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive and use the Muse S™ Headband system||||
34133926|NCT00123162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34133927|NCT06519513|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34133928|NCT00218634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133929|NCT06659926|NA|SINGLE_GROUP||TREATMENT||NONE|The treating physicians will be blinded to the result of the baseline 68Ga-PSMA-PET/CT scan|The investigators will conduct a prospective clinical study in which patients with mCRPC and bone-only disease according to ceCT and bone scan will receive standard-of-care treatment with Radium-223. In addition to standard-of-care systemic treatment, each patient will undergo an additional 68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis.||||
34133930|NCT03955250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133931|NCT02965794|||OTHER||RETROSPECTIVE|||||||
34133932|NCT06574126|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II Open-Label, Single Arm, Multicenter Study in which all patients with receive Dara-VRD and cilta-cel therapy||||
34133933|NCT06661928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34133934|NCT06661876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133935|NCT04887610|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34133936|NCT06532500|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants have a 50/50 chance of being assigned to the CBT-MyOWL or CBT-as-usual group for 12 sessions of either therapy.||||
34133937|NCT03503097|||CASE_ONLY||CROSS_SECTIONAL|||||||
34133938|NCT00614718|||CASE_CONTROL||RETROSPECTIVE|||||||
34133939|NCT05844943|NA|SINGLE_GROUP||OTHER||NONE||||||
34133940|NCT05210582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133941|NCT03922672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133942|NCT04046016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133943|NCT00340002|||COHORT||PROSPECTIVE|||||||
34133944|NCT00974441|RANDOMIZED|CROSSOVER||||NONE||||||
34133945|NCT06652412|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133946|NCT02603601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133947|NCT01147887|NA|SINGLE_GROUP||||NONE||||||
34133948|NCT02676947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133949|NCT01185314|NA|SINGLE_GROUP||SCREENING||NONE||||||
34133950|NCT06224140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34133951|NCT05707442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34133952|NCT04444986|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34133953|NCT04965259|||COHORT||PROSPECTIVE|||||||
34133954|NCT04463823|||CASE_ONLY||PROSPECTIVE|||||||
34133955|NCT01627808|||CASE_ONLY||CROSS_SECTIONAL|||||||
34133956|NCT06660615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will not know which group they are in, so they will be blind to differences in the interventions.||t|f|f|f
34133957|NCT06659510|RANDOMIZED|PARALLEL||OTHER||NONE||"Transtheoretical Mode Transtheoretical Model in Behavior Change TTM is an integrative behavior change model developed by Prochaska and Diclemente (1982). The model explains how an individual changes an unhealthy behavior or acquires a healthy behavior (Velicer et al., 2000).~The key concept in the model is the stages of change. For this reason, the model is also called the Stages of Change Model (Marcus and Forsyth, 2009).~This model, which allows evaluating the individual's level of readiness for change and level of self-efficacy, provides health professionals with a consultative approach that assumes that individuals have different counseling needs at different stages (Adams Fryatt, 2010)."||||
34133958|NCT04022226|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34133959|NCT01405781|||COHORT||OTHER|||||||
34133960|NCT04387357|||CASE_CONTROL||PROSPECTIVE|||||||
34133961|NCT02014506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133962|NCT04265157|||COHORT||PROSPECTIVE|||||||
34133963|NCT01360749|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34133964|NCT03383913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34133965|NCT05781945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34133966|NCT05592626|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34133967|NCT05085093|||COHORT||PROSPECTIVE|||||||
34133968|NCT06646965|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter, randomized, open-label clinical study.||||
34133969|NCT03866317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133970|NCT01098188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133971|NCT06430463|||COHORT||PROSPECTIVE|||||||
34149464|NCT06387641|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33827336|NCT05088538|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The assignment to the groups will be carried out by an independent researcher, and the group will be notified via telephone after the practitioner researcher has approved, evaluated the criteria and performed the pre-tests. At the same time, groups will be named A and B and researchers will be blinded during statistical analysis and reporting.It will not be disclosed to the participants and their caregivers in which group they belong. Surveys will be filled in by a different independent researcher blinded to the groups||t|t|f|t
34133972|NCT05675722|NA|SINGLE_GROUP||TREATMENT||NONE||Ten women, ages 15-45 years, meeting criteria will undergo vaginal/vulva biopsy and biologic vaginal-construct implantation.||||
34133973|NCT06659081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827337|NCT00564564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827338|NCT06480331|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827339|NCT06140914|||CASE_CONTROL||PROSPECTIVE|||||||
33827340|NCT03397316|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Each patient will be given a code by researcher (A.A) and the observers will be blind to which group this case belong.||t|t|t|t
33827341|NCT03648684|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33827342|NCT02246218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827343|NCT02940210|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33827344|NCT00239681|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827345|NCT04295018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827346|NCT01628341|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33827347|NCT05654298|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33827348|NCT00399503|||||PROSPECTIVE|||||||
33827349|NCT04280679|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric study||||
33827350|NCT04402203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double-blind, placebo-controlled randomized control study. Randomization will be done by computerized randomization table Group A Patient (25) = Favipiravir + Standard Treatment Group B Patient (25) = Only Standard Treatment For better result sample size may be multiply on the basis of availability of COVID-19 patient in the study hospital.|t|t|f|f
33827351|NCT03616236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827352|NCT04633213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827353|NCT04741854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827354|NCT03436550|||COHORT||PROSPECTIVE|||||||
33827355|NCT01661530|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827356|NCT01558778|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827357|NCT05575661|||COHORT||PROSPECTIVE|||||||
33827358|NCT04567797|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827359|NCT03371537|||COHORT||PROSPECTIVE|||||||
33827360|NCT01878383|||COHORT||PROSPECTIVE|||||||
33827361|NCT04635085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33827362|NCT00866827|||OTHER||RETROSPECTIVE|||||||
33827363|NCT00207233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827364|NCT05897528|||COHORT||RETROSPECTIVE|||||||
33827365|NCT04112641|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo capsules and drug capsules look alike|Two independent treatment arms to which patients will be randomized by variable size blocks|t|t|f|t
33827366|NCT02702583|||CASE_CONTROL||PROSPECTIVE|||||||
33827367|NCT05548413|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827368|NCT00516828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827369|NCT01938898|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|f|t
33827370|NCT02325583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827371|NCT04505345|RANDOMIZED|PARALLEL||TREATMENT||NONE||The individuals will be distributed by two groups: experimental and control. The experimental group consists of treatment with virtual reality cognitive training and the control group of treatment-as-usual.||||
33827372|NCT04441827|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33827373|NCT01911923|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34133974|NCT06658821|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34133975|NCT00172250|||CASE_CONTROL||OTHER|||||||
34133976|NCT01353443|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34149465|NCT05025722|||CASE_CONTROL||PROSPECTIVE|||||||
33827374|NCT04019249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827375|NCT05781997|||COHORT||PROSPECTIVE|||||||
33827376|NCT05908578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Participants will undergo the same baseline testing before being pseudo-randomly (block randomization) allocated to one of two groups, each following a different exercise training program for eight weeks.||||
33827377|NCT03177200|||COHORT||PROSPECTIVE|||||||
33827378|NCT04669002|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827379|NCT02412111|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827380|NCT04202016|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|A third party will have the randomization of which side to be chosen for each case. An IT student will be asked to prepare randomized two lists using excel Microsoft program. Each list was defined based on facial divergence type; adult high, and adult average lists in the Excel columns. Underneath each list, the raws, equal number of R(right) and L(left) letters will be generated randomly. The orthodontic department's receptionist will receive the excel file, and based on which, prepare closed envelops that will be numbered. Each of which will contain a piece of paper having a letter, either R or L accordingly. The envelops will be dark and difficult to see through even under light. The periodontist will open the envelope of each patient only prior to their piezocision surgery without the involvement of the orthodontist.|The design will be a split-mouth where the participants should need extraction based treatment in collateral sides of the upper arch with one of the sides serving as the treatment while the other will be the control. Then they will be grouped based on their facial type.|f|t|t|t
33827381|NCT05725044|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827382|NCT03738306|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827383|NCT01501227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827384|NCT05432999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, controlled trial with sham control|t|f|t|t
33827385|NCT06511375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827386|NCT00005845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149466|NCT02893124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133977|NCT03895580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Due to COVID-19, recruitment and all in-person visits had to be temporarily stopped due to safety concerns in March 2020. Due to this stoppage, 20 randomized subjects could not complete their in-person study visits or data collection as per protocol. These 20 subjects will be excluded from all primary analyses, including the primary endpoint. Recruitment and in-person visits resumed in June 2020. To account for the exclusion of these 20 subjects, we randomized 267 subjects by the end of the study in order to have 247 subjects available for the primary analyses (e.g. 267-20= 247). A prespecified COVID impact analysis has been included in the statistical analysis plan.|f|f|t|t
34133978|NCT06660329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133979|NCT04168203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, double-dummy|600-patient U.S.-based, single-center, randomized, double-blinded, placebo-controlled study of apixaban 2.5 mg orally twice daily for extended prevention of recurrence after provoked VTE in patients with at least one persistent provoking factor who have completed at least 3 months of standard therapeutic anticoagulation and who have a low risk of bleeding.|t|t|t|t
34133980|NCT04974905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133981|NCT05130905|NA|SINGLE_GROUP||OTHER||NONE||||||
33827387|NCT01354236|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33827388|NCT02448498|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827389|NCT00582114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827390|NCT02597036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827391|NCT02879799|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827392|NCT02725008|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827393|NCT01858064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827394|NCT04892602|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33827395|NCT02073253|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33827396|NCT05726552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33827397|NCT03065439|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Balance testing will be performed and data saved without the testers knowing the results. Afterwards the testers will ask patients to fill in questionnaires. An assessor (not participating in testing) will be cleaning the data and establishing the models without knowledge of the SBT score. The STarT Back score will be cleaned, saved in another data set and established by another assessor. When agreed upon the model, the two data sets will be merged.|This is a double blinded experimental study comparing sub-groups of patients with low back pain|t|f|t|t
33827398|NCT00088543|RANDOMIZED|PARALLEL||||NONE||||||
33827399|NCT05050435|||COHORT||RETROSPECTIVE|||||||
33827400|NCT00772655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827401|NCT06403098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33827402|NCT02205047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827403|NCT02427958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827404|NCT05526456|||CASE_CONTROL||RETROSPECTIVE|||||||
33827405|NCT05849571|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled experimental design||||
33827406|NCT05173233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827407|NCT06002633|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33827408|NCT00520871|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33827409|NCT00690378|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827410|NCT02955706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827411|NCT05572385|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33827412|NCT01741311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827413|NCT05380102|||COHORT||PROSPECTIVE|||||||
33827414|NCT01210300|||||PROSPECTIVE|||||||
33827415|NCT02786290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827416|NCT05742659|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827417|NCT00806598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827418|NCT00787813|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33827419|NCT04339023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827420|NCT03159078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind, Double dummy|One arm with Polyxyxin B monotherapy and another arm with Polymyxin B plus carbapenem|t|t|t|f
33827421|NCT03769077|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827422|NCT03739697|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33827423|NCT04153422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind trial. The participant and the investigator will be masked to the treatment assignment.|"This is a randomized, double-blind, placebo-controlled study with 10 patients in the treatment arm and 10 in the placebo arm. Patients in the treatment arm will receive 2g/kg IVIG every 4 weeks (over 2 days, 1g/kg dose on Day 1 and 1g/kg dose on Day 2) for 24 weeks (6 doses total). Patients in the placebo arm will receive 0.9% NaCl infusions on the same schedule as the active treatment group (Day 1 and Day 2 every 4 weeks for 24 weeks total, (6 doses)).~All study visits will take place at Henry Ford Health in Detroit, Michigan. Guest housing is available for patients and their families. To make reservations, please call 1-313-916-3299 or visit this link: https://hfhguesthousing.hfhs.org/"|t|f|t|f
33827424|NCT03015597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827425|NCT01585818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827426|NCT01054365|||COHORT||PROSPECTIVE|||||||
33827427|NCT01269255|NA|SINGLE_GROUP||||NONE||||||
33827428|NCT05277818|||COHORT||CROSS_SECTIONAL|||||||
33827429|NCT06479486|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33827430|NCT04973514|||COHORT||RETROSPECTIVE|||||||
33827431|NCT04815785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827432|NCT01759238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827433|NCT04815473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827434|NCT00000701||||TREATMENT||NONE||||||
33827435|NCT06544967|||COHORT||PROSPECTIVE|||||||
33827436|NCT06541340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827437|NCT00435981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827438|NCT00826436|||COHORT||PROSPECTIVE|||||||
33827439|NCT00634426|||COHORT||PROSPECTIVE|||||||
33827440|NCT01484314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827441|NCT01498783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827442|NCT02661503|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133982|NCT04771299|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133983|NCT02993822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133984|NCT05010200|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34133985|NCT01454128|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133986|NCT06486493|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34133987|NCT06593236|||COHORT||PROSPECTIVE|||||||
34133988|NCT03697005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Double blinding (trial participants and outcome assessor)~* Dental colleague assessors who are blinded about the aim of the study and participant's allocation will be responsible for assessing the outcomes of this study.~* The level of intra- and inter-examiner reliability will be determined for each assessor by the performance of a calibration session prior to the start of the trial. A training exercise to the assessors with the main investigator will help to standardize measurement techniques and parameters. An interactive calibration session will enable the investigator to quantitate the measurement variability among and between assessors and enable the optimization of the measurement process. The main supervisor will solve any conflict that may arise between the assessors by repeating the assessing and giving the final opinion."|patients requiring posterior single crowns.|t|f|f|t
34133989|NCT05041907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133990|NCT03844672|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
34133991|NCT03462017|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34133992|NCT06529003|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34133993|NCT00987441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34133994|NCT02340208|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827443|NCT03378778|||CASE_CONTROL||PROSPECTIVE|||||||
34133995|NCT04641728|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34133996|NCT06657118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A randomized control trial, parallel group, allocation ratio 1:1 Framework equivalence|t|f|f|f
34133997|NCT00596557|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34133998|NCT04654624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34133999|NCT01299337|||COHORT||RETROSPECTIVE|||||||
34134000|NCT06410352|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"One of the methods that will be used in project is a new drug combination for weight loss in patients with T2D - Glucagon-like-peptide-1-receptor-agonists with sodium-glucose-co-transporter-2-inhibitors. Guidelines on hyperglycemic management recommend either GLP-1RAs or SGLT-2is as second-line treatments for patients with T2D on metformin monotherapy. The use of both antidiabetic drugs in combination is rare in the literature. During the last decade, the results of large-scale, randomized, clinical trials on newer antidiabetic agents, GLP-1RA and SGLT-2 inhibitor have been shown to modify cardiovascular risk factors, such as insulin resistance, body weight, BP, and lipid profile, additionally to induce weight loss.~The second method is a bariatric operation - minigastric bypass (MGB) that is endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal"||||
34134001|NCT01656005|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134002|NCT00239993|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34134003|NCT04464655|||OTHER||PROSPECTIVE|||||||
34134004|NCT04699695|||COHORT||PROSPECTIVE|||||||
34134005|NCT06661824|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|Patients and nurses do not know which group they are in, or which experimental or control groups they are in. The first tests were taken after patient consent to ensure blinding, but without assignment to groups.|In order to keep the clinic, health worker and other conditions that may affect the development of aggression constant, a sequential design was preferred. A single clinic was determined for the study. The care bundle is a clinical tool. Therefore, the interventions begin when the patient is admitted to the clinic and end with discharge. First, the routine care and routine aggression management interventions adopted in the clinic will be applied to the control group. At this stage, the staff and patients are blinded. After the control group sample size determined according to the sample calculation is completed, the experimental group intervention will begin. Training will be given to the clinic nurses regarding the care bundle to be applied. Then, the experimental group will be recruited and the experimental group application will begin.|t|t|f|f
33827444|NCT06017336|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple-blind study; the patients will not be informed about training group or control group and they will be evaluated and trained at different places and times.|Parallel Assignment|t|f|t|t
33827445|NCT02975297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33827446|NCT03380364|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827447|NCT01977183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827448|NCT04024098|||OTHER||CROSS_SECTIONAL|||||||
33827449|NCT01302301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827450|NCT05413863|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Double-blind|Partially replicated design, crossover trial|t|f|t|f
33827451|NCT00720369|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33827452|NCT00630136|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33827453|NCT04583462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827454|NCT01837797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827455|NCT04546659|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827456|NCT04292821|||COHORT||PROSPECTIVE|||||||
33827457|NCT00944996|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33827458|NCT02738957|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827459|NCT00537329|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827460|NCT04255173|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827461|NCT03300609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827462|NCT06455332|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827463|NCT04452409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827464|NCT02348372|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33827465|NCT02853305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827466|NCT00427778|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827467|NCT00582959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827468|NCT02582697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827469|NCT03228342|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33827470|NCT01220856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134006|NCT06353295|NA|SINGLE_GROUP||PREVENTION||NONE||A single-arm pilot trial to evaluate a community-based, peer-led and delivered intervention to provide biomedical prevention products (e.g. pre-exposure prophylaxis \[PrEP\] and post-exposure prophylaxis \[PEP\]) for women who engage in sex work in southwestern Uganda. This study will test whether the intervention is feasible, acceptable, and increases biomedical prevention uptake.||||
34134007|NCT03721484|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134008|NCT05422495|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34134009|NCT04643873|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34134010|NCT06657924|RANDOMIZED|PARALLEL||PREVENTION||NONE|Pragmatic (non-blinded)|Intervention (TXA) and control (no TXA) cohorts||||
34134011|NCT05667584|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134012|NCT02888691|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134013|NCT06658197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134014|NCT03425435|||COHORT||PROSPECTIVE|||||||
34134015|NCT02461290|||CASE_CONTROL||RETROSPECTIVE|||||||
34134016|NCT02195999|||COHORT||PROSPECTIVE|||||||
34134017|NCT04739553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134018|NCT04653922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134019|NCT06334159|RANDOMIZED|FACTORIAL||TREATMENT||NONE||non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group)||||
33827471|NCT05418686|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827472|NCT04082481|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33827473|NCT04458181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827474|NCT01940289|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||f|f|t|f
33827475|NCT02669134|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33827476|NCT05089604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827477|NCT05231655|||COHORT||PROSPECTIVE|||||||
33827478|NCT02742792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827479|NCT04683328|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||SCTA01+BSC vs Placebo+BSC|t|f|t|t
33827480|NCT03713073|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"The study is a split-mouth design, in which two treatments (test and control) are randomly assigned to either the right or left halves of the dentition/palate."|t|f|f|f
33827481|NCT06077877|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This is an open-label non-blinded study|||||
33827482|NCT01417702|||CASE_ONLY||PROSPECTIVE|||||||
33827483|NCT04510025|||COHORT||PROSPECTIVE|||||||
33827484|NCT03536078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Group allocation blinded to the investigator.||f|f|t|f
33827485|NCT02979171|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33827486|NCT02350855|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827487|NCT05321771|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single arm single center prospective interventional study.||||
33827488|NCT02368899|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33827489|NCT00306956|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33827490|NCT03243500|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33827491|NCT02480751|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827492|NCT02782572|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827493|NCT03478410|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Comparative study between patients with and without atrial fibrillation||||
33827494|NCT00710814|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33827495|NCT06369857|NA|SINGLE_GROUP||TREATMENT||NONE||Case series study||||
33827496|NCT05469412|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827497|NCT01293383|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33827498|NCT03215342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827499|NCT02943707|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827500|NCT01436968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827501|NCT02967809|||CASE_CONTROL||PROSPECTIVE|||||||
33827502|NCT05506215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827503|NCT02025478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134020|NCT05929391|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|The attachments will carry out by main investigator who give each side coded key then the attachments will be rebond by blind specialist. The participants will be blinded to group assignment and interventions (double-blinded trial).|split-mouth, cross-quadrant|t|t|f|f
34134021|NCT06661343|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||This study uses a stepped-wedge cluster randomized trial. Participants from multiple networks are introduced to the intervention in a sequential manner, with each cluster beginning in a control phase and transitioning into one of two intervention phases over time. This design allows for comparison between groups while also ensuring all participants eventually receive the intervention.||||
34134022|NCT04776720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34134023|NCT03172754|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134024|NCT01979172|||||PROSPECTIVE|||||||
34134025|NCT06657950|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134026|NCT06459999|||COHORT||PROSPECTIVE|||||||
34134027|NCT06659965|||COHORT||RETROSPECTIVE|||||||
33827504|NCT04626271|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827505|NCT02869945|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
33827506|NCT04207697|||COHORT||PROSPECTIVE|||||||
33827507|NCT02960256|||COHORT||PROSPECTIVE|||||||
33827508|NCT04785716|||COHORT||RETROSPECTIVE|||||||
33827509|NCT03212950|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827510|NCT04651556|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33827511|NCT00487318|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827512|NCT01650935|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827513|NCT04780971|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827514|NCT00614588|||CASE_ONLY||PROSPECTIVE|||||||
33827515|NCT03765515|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial (RCT)||||
33827516|NCT04366518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Rivastigmine vs Placebo||||
33827517|NCT02553577|||OTHER||PROSPECTIVE|||||||
33827518|NCT03277677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827519|NCT05082623|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33827520|NCT03766373|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33827521|NCT06129045|RANDOMIZED|PARALLEL||PREVENTION||NONE||Three arm study: No intervention, video only, video plus text messaging||||
33827522|NCT01839786|||OTHER||OTHER|||||||
33827523|NCT01337908|||COHORT||RETROSPECTIVE|||||||
33827524|NCT03060213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants who have completed the full online T1 battery will be randomly assigned in real-time by the computer to either the intervention condition or the UC control condition. Randomization, group assignment, and assessments will be conducted solely by the computer program, so researchers will be blind to participant randomization, group assignment, and participant group identity during assessment times. With regard to group size and power, experience from our prior efficacy study of FFW indicates that for the current study, the computer program will use a 2:1 randomization algorithm so that there are twice as many FFW intervention participants as UC control participants.|The intervention group will be compared to a usual care (UC) control group on outcomes of overall subjective well-being, domain-specific well-being, health-related quality of life, and well-being self-efficacy. The intervention group will participate in online activities for 30 days while UC control group participants will be asked to conduct their lives as usual for the same 30 day period. Both groups will complete assessments during this time period. The UC group will be given access to the intervention for 30 days after all study participants have completed the three survey battery administrations.|f|f|t|t
33827525|NCT04241887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Participants were randomly assigned into 2 groups (computerized randomization program).~group PVB - patients under paravertebral block anesthesia, group BB - patients under local anesthesia, without paravertebral block."|"30 patients scheduled for an elective Percutaneus Radiofrequency Ablation (PRFA) of a hepatocellular carcinoma were enrolled in the study. Patients were divided in 2 groups:~* group PVB - 15 patients under paravertebral block anaesthesia~* group BB - 15 patients under local anesthesia, without paravertebral block."|t|f|f|f
33827526|NCT05757778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Within patients, treatment with neurotization to one breast will be randomly assigned intra-operatively. Patients will remain blinded from intraoperative details until the completion of the study. Patients will consent to remain blinded to the operative and postoperative reports until completion of the study.||t|f|f|f
33827527|NCT05280743|||COHORT||PROSPECTIVE|||||||
33827528|NCT02041312|||CASE_CONTROL||PROSPECTIVE|||||||
33827529|NCT04419649|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Ascending dose study||||
33827530|NCT00487526|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827531|NCT02703753|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827532|NCT00853229|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33827533|NCT03371121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827534|NCT03352882|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827535|NCT00238992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827536|NCT04100811|||COHORT||PROSPECTIVE|||||||
33827537|NCT06418399|||OTHER||CROSS_SECTIONAL|||||||
33827538|NCT01230762|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827539|NCT00989898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827540|NCT05438446|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center, prospective, interventional, 1:1 randomized controlled trial||||
33827541|NCT02148653|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827542|NCT06105762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827543|NCT04605822|||COHORT||PROSPECTIVE|||||||
33827544|NCT02798913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827545|NCT02241278|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827546|NCT03793322|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827547|NCT01880437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827548|NCT05946122|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33827549|NCT03618706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827550|NCT01104064|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827551|NCT02915562|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33827552|NCT04233983|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective Randomised Controlled Trial||||
33827553|NCT05808855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827554|NCT02271685|RANDOMIZED|FACTORIAL||SCREENING||SINGLE|||t|f|f|f
33827555|NCT05264272|||CASE_ONLY||CROSS_SECTIONAL|||||||
33827556|NCT04604379|||COHORT||RETROSPECTIVE|||||||
33827557|NCT01209741|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827558|NCT03298633|RANDOMIZED|PARALLEL||TREATMENT||NONE|The blinding method in out study is open-label in general. However, in order to avoid psychological effect for participants and unexpected drop-off, the trial is designed to inform participants their insemination method on the day of fresh embryo transfer or the day of embryo freezing. Prior to this, randomization will be strictly performed and keep secret to participants and clinicians.|Eligible patients that have provided informed consent will be randomized to either ICSI or conventional IVF. Randomization and allocation of patients to study groups will be performed on the day of oocyte retrieval. Stratified permuted block randomization will be centrally controlled by administrative staffs in the trial center, who are not involved in the treatment procedure. When there is an eligible participant to be enrolled into the study, nurses from the specific site will login the trial system to get allocation of patients according to a computer-generated randomization list in a 1:1 ratio, with a variable block size of 2, 4 or 8 and stratified by center.||||
33827559|NCT06227559|||CASE_CONTROL||OTHER|||||||
33827560|NCT04807023|||COHORT||PROSPECTIVE|||||||
33827561|NCT00848068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827562|NCT04676633|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Accelerated titration design followed by expansion to standard 3+3 design||||
33827563|NCT06366997|||COHORT||PROSPECTIVE|||||||
33827564|NCT05655780|||COHORT||PROSPECTIVE|||||||
33827565|NCT01493999|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33827566|NCT01640613|||COHORT||PROSPECTIVE|||||||
33827567|NCT05773027|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33827568|NCT00519285|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827569|NCT02258997|||COHORT||CROSS_SECTIONAL|||||||
33827570|NCT02514577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827571|NCT01722045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134028|NCT03235895|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34134029|NCT05143528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind|Double-Blind Placebo Controlled|t|t|t|t
34134030|NCT03419897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827572|NCT05457322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827573|NCT03644524|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It was not possible to blind the subject or PI to treatment group, but all measures that were collected were analyzed offline by a blinded investigator.|Subjects were matched for age and BMI, then assigned to either a heat therapy intervention or time control (no intervention, just outcomes assessment at matched timepoints).|f|f|f|t
33827574|NCT02468310|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827575|NCT06035185|||CASE_CONTROL||PROSPECTIVE|||||||
33827576|NCT01308047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33827577|NCT00101998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827578|NCT04533828|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827579|NCT00946634|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827580|NCT02591706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827581|NCT02668198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827582|NCT02893488|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827583|NCT06386198|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827584|NCT01660919|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827585|NCT01300078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827586|NCT05241054|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-blind study (patient and data collector)||t|f|f|t
33827587|NCT00269841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827588|NCT02647645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827589|NCT00857740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827590|NCT01659047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827591|NCT02678364|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33827592|NCT00157690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827593|NCT00298077|||OTHER||RETROSPECTIVE|||||||
33827594|NCT06380647|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|parents were blinded to group allocation|Sample size of 64 patients (32 patients in each group) was estimated by using 5% level of significance, 90% power of test with expected percentage of patients given prophylactic acyclovir as 81.3% and patients given placebo as 42.9%.|t|f|f|f
33827595|NCT05080842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827596|NCT01510002|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827597|NCT01250847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827598|NCT04413877|||COHORT||PROSPECTIVE|||||||
33827599|NCT04364685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator responsible for evaluation of patient was blinded to the allocation of the participants.|The study consists of two groups, one control group (Normal Walking) and experimental group (sand walking).|f|f|t|t
33827600|NCT05122741|||COHORT||PROSPECTIVE|||||||
33827601|NCT05090475|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827602|NCT03219307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827603|NCT04972539|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827604|NCT04137861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827605|NCT03961997|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827606|NCT01544504|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827607|NCT03134547|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33827608|NCT04326153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827609|NCT05466188|||COHORT||RETROSPECTIVE|||||||
33827610|NCT02106637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827611|NCT01252511|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827612|NCT04295850|||COHORT||PROSPECTIVE|||||||
33827613|NCT00995319|||COHORT||PROSPECTIVE|||||||
33827614|NCT01721083|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34134031|NCT04406818|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134032|NCT03734926|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134033|NCT02326168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827615|NCT06214598|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo capusuls will be identical as supplement|AID project consists of a 3-arm clinical trial in BRC patients with 4-month nutritional intervention to assess the effects of personalized anti-inflammatory diet enriched with anti-inflammatory PUFA, or PUFA supplemental pills in 90 postmenopausal BRC patients receiving AI, randomly assigned in a ratio of 1:1:1 (diet:supplements:placebo). Since inflammation and oxidative stress are important promoters of cancer development and progression, we have chosen Fish oil and evening primrose oil as the richest sources of anti-inflammatory PUFA (n-3 and n-6). Anti-inflammatory diet enriched with PUFA and polyphenols was beneficial n many chronic diseases, and is named fatigue-reduction diet, especially relevant here as the fatigue is one of the most common side effects of AI. We will test the hypothesis that these interventions improve patients' nutritional status, QoL and clinical outcomes, by decreasing systemic inflammation and oxidative stress and reverting disrupted lipid metabolism.|t|f|t|t
33827616|NCT00000370||||TREATMENT||||||||
33827617|NCT02197143|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33827618|NCT01006083|||COHORT||PROSPECTIVE|||||||
33827619|NCT00107081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827620|NCT00840671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827621|NCT04376112|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
33827622|NCT00948610|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33827623|NCT04719468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded rater||f|f|f|t
34149467|NCT00646997|||CASE_CROSSOVER||PROSPECTIVE|||||||
34149468|NCT01839656|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149469|NCT03066167|||COHORT||PROSPECTIVE|||||||
33827624|NCT02587013|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33827625|NCT03384771|||OTHER||PROSPECTIVE|||||||
33827626|NCT04938622|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827627|NCT04011683|||COHORT||PROSPECTIVE|||||||
33837489|NCT05005962|||OTHER||PROSPECTIVE|||||||
33837490|NCT00564616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134034|NCT03907176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In Part 1, subjects who meet the Screening eligibility criteria (Section 4.1) will be randomized to one of the 2 parallel cohorts. In Part 2, prior to surgery, the Investigator will select for the subject one of the 2 postoperative MMA regimens, based on Investigator and/or subject preference.||||
34134035|NCT01771692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134036|NCT06512675|NA|SINGLE_GROUP||OTHER||NONE||||||
34134037|NCT03709277|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134038|NCT06660602|||COHORT||PROSPECTIVE|||||||
34134039|NCT04868682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participant or staff who conduct the follow-up assessments will be aware of group assignment.||t|f|f|t
34134040|NCT06365216|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with ALS to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c.~Two doses of NX210c (5 mg/kg and 10 mg/Kg) will be investigated, along with a placebo group which will serve as a reference. Patients will be randomized to one of 3 arms in an allocation ratio of 3:3:2.~Patients will participate up to approximately 20 weeks: up to 30 days for screening, 26 days of treatment and 3 months of follow-up. Lumbar punctures will assess cerebrospinal fluid (CSF) NfL and other key CSF biomarkers related to ALS and drug mechanism of action. Blood sampling will be drawn for safety, PK and biomarkers testing. Urine will equally be collected for biomarkers. A comprehensive assessment of the disease, including the ALS Functional Rating Scale (ALSFRS-R) will be performed."|t|f|t|f
34134041|NCT06660901|||COHORT||PROSPECTIVE|||||||
34134042|NCT06099912|||COHORT||PROSPECTIVE|||||||
34134043|NCT06145035|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"As a double-blind study, bias control will be achieved by maintaining the blind on treatment group assignments. The master randomization lists containing the treatment assignments will be protected in secure, controlled access drives/folders and will not be released to any blinded study personnel prior to final database lock. A centralized Core laboratory will be used for MRI analyses to maintain the blind across the study team.~The designated cell processing technicians will prepare the investigational product for infusion. The investigational agent infusions will be prepared in identical infusion bags and labeled with the identical investigational drug labels as to preserve the blind. The designated technicians in the ISCI Cell Processing Laboratory (CPL) or designee will be responsible for maintaining the investigational product records including randomized treatment assignments by subject identification."|randomized, double blind, placebo controlled,|t|f|t|f
34134044|NCT06062667|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34134045|NCT04720755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134046|NCT06331546|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134047|NCT06402955|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134048|NCT03651765|NA|SINGLE_GROUP||TREATMENT||NONE||Open label treatment||||
34134049|NCT06660953|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE||randomised controlled clinical study|t|t|f|t
34134050|NCT06167291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134051|NCT05475743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134052|NCT03275506|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label, multicentric||||
34134053|NCT02304887|||CASE_ONLY||RETROSPECTIVE|||||||
34134054|NCT06660706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134055|NCT02672059|||COHORT||CROSS_SECTIONAL|||||||
34134056|NCT05997914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34134057|NCT01263418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134058|NCT02777203|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134059|NCT06473077|||COHORT||PROSPECTIVE|||||||
34134060|NCT05034627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134061|NCT06662253|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34134062|NCT05733949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134063|NCT05393531|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential||||
34134064|NCT03738631|||COHORT||PROSPECTIVE|||||||
34134065|NCT01152593|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34134066|NCT00630006|RANDOMIZED|FACTORIAL||||NONE||||||
34134067|NCT02160665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34134068|NCT05767398|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134069|NCT03879902|||COHORT||PROSPECTIVE|||||||
34134070|NCT05118165|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34134071|NCT03178825|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134072|NCT01709110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134073|NCT03385915|||COHORT||RETROSPECTIVE|||||||
34134074|NCT01140100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134075|NCT02677207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134076|NCT02331589|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134077|NCT02379988|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827628|NCT00766142|NA|SINGLE_GROUP||TREATMENT||NONE||Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer||||
33827629|NCT02026505|||CASE_ONLY||PROSPECTIVE|||||||
34134078|NCT02910752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134079|NCT01292889|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134080|NCT01986231|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134081|NCT06388746|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34134082|NCT00603096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134083|NCT02330653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149470|NCT03619135|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149471|NCT04037150|||COHORT||PROSPECTIVE|||||||
34149472|NCT06364904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149473|NCT01800656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149474|NCT03055390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34149475|NCT02514005|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34149476|NCT00786539|||CASE_CONTROL||PROSPECTIVE|||||||
33827630|NCT05354310|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827631|NCT02696863|||OTHER||PROSPECTIVE|||||||
33827632|NCT00478322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134084|NCT04452331|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Arm 1 is the intervention, with both provider and patient aware of the recording. It is designed to represent how OAA would be utilized in actual practice. In Arm 2 all parties are also aware of the audio recording, but this time neither gets access to the audio after the visit (although the research team does). Arm 2 is a control for isolating the effect of patient access after the visit to the audio in Arm 1. Both patient and physician are blind to whether they are in Arm 1 or 2 until after the visit. Arm 3 is a second kind of control, as the audio is again not shared with the patient. In this arm, however, the patient conceals the audio recorder, so that the provider is unaware they are being audio recorded until after the visit.|The setting will be primary care and diabetes clinics, at two facilities for generalizability. To achieve aims 1 and 2, the investigators plan a randomized controlled three arm design: (1) the encounter is recorded, with provider and patient aware, and uploaded to a server the Veteran, provider, and research team can access post visit; (2) the encounter is recorded, with both parties aware, and uploaded to a server only the research team can access; and (3) the encounter is recorded, with only the patient aware, and uploaded to a server only the research team can access. Resource utilization and disease measures indicated in aims 1 and 2 will be collected in all arms.|t|t|f|t
34134085|NCT03037476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134086|NCT06657131|||CASE_ONLY||PROSPECTIVE|||||||
34134087|NCT02625480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134088|NCT00564902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34134089|NCT05980416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34134090|NCT05208606|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"A novel model will be used in alignment with community feedback on study design. Patients will be allocated to the intervention arm as dictated by interventionist panel capacity. Patients will be added to a waitlist control arm as dictated by intervention arm capacity."||||
34134091|NCT04510987|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134092|NCT01496326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134093|NCT02108327|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134094|NCT06325657|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This is a double-blinded, placebo-controlled study||t|t|t|t
34134095|NCT02569255|||COHORT||PROSPECTIVE|||||||
34134096|NCT04310436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Experimental Group instructed to modify saccadic origin by looking to naval for the start of the words dysfluencies were predicted~Placebo Group instructed to modify saccadic origin by looking up for the start of the words dysfluencies were predicted~Outcome assessor was blinded to treatment allocation. Participants Stammering behaviour to be assessed using SSI-4 a reliable validated objective measure of stuttering severity. Participants stammering behaviour is to be recorded via video link or in a separate lab and the assessor will be asked asked not to discuss the technique prescribed given to patients. Even if the patient mentioned the trials they would not discuss the intervention"|Pilot Randomised Placebo Controlled Trial|t|f|f|t
34134097|NCT06320678|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34134098|NCT00503412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134099|NCT01943058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134100|NCT03983382|||COHORT||PROSPECTIVE|||||||
34134101|NCT04165382|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|Masking will be applied to the Assessor who is responsible for auditing nurses' compliances to the guideline in the NICU. The Assessor is asked to perform audits regarding the care to infants receiving NIV in the pre-implementation period and post-implementation period without informing him/her for the study period.|Usual care will be provided to the study group of the Pre-implementation period, and interventions in the guideline will be started to provide to the study group in the Post-implementation period.|f|f|f|t
34134102|NCT03007329|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134103|NCT06657872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134104|NCT04017819|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134105|NCT01804426|||COHORT||PROSPECTIVE|||||||
34134106|NCT05010486|||COHORT||PROSPECTIVE|||||||
34134107|NCT06341114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134108|NCT06460493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134109|NCT05634694|||COHORT||PROSPECTIVE|||||||
34134110|NCT04989309|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will receive stimulation at different sites (left and right temporal areas, vertex control), and may be aware of the location of placement of the TMS coil, so in a strict sense participants cannot be fully unaware of the stimulation site.|"Participants will receive blocks of stimulation at the left temporal lobe, right temporal lobe, and vertex, with the order of stimulation counterbalanced across participants (a crossover design). All analysis is within-subject.~Participants in each arm will hear different types of speech stimuli, which allows for the assessment of the effect of stimulation at different stimulation sites on processing that specific aspect of the speech signal."|t|f|f|f
34134111|NCT01863069|RANDOMIZED|||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34134112|NCT01386489|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134113|NCT01246765|||CASE_CONTROL||PROSPECTIVE|||||||
34134114|NCT01575639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134115|NCT03723330|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|f|t|t
34134116|NCT04751604|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34134117|NCT02791932|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34134118|NCT01971944|||COHORT||PROSPECTIVE|||||||
34134119|NCT05016817|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134120|NCT05128786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134121|NCT02193737|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134122|NCT05070845|NA|SINGLE_GROUP||TREATMENT||NONE|open label|||||
34134123|NCT03260374|||CASE_ONLY||CROSS_SECTIONAL|||||||
34134124|NCT05895331|||CASE_CONTROL||PROSPECTIVE|||||||
34134125|NCT00726791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134126|NCT06290076|||CASE_CONTROL||RETROSPECTIVE|||||||
33827633|NCT03892551|||COHORT||PROSPECTIVE|||||||
33827634|NCT02877264|RANDOMIZED|CROSSOVER||||NONE||||||
33827635|NCT05659654|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827636|NCT03831646|||CASE_CONTROL||PROSPECTIVE|||||||
34134127|NCT03776669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134128|NCT06484179|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomized to (1) Usual Care or (2) Usual Care + targeted self-help intervention.||||
34134129|NCT04047706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134130|NCT01786213|||||RETROSPECTIVE|||||||
34134131|NCT06658106|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|In this clinical trial, there will be no masking of participants, care providers, investigators, or outcomes assessors. All parties involved will be aware of the interventions assigned to participants. This decision was made to facilitate adherence to the Thera-Band elastic band-assisted progressive resistance training program and to ensure that the research team can monitor the participants effectively throughout the intervention. While this approach allows for clear communication and immediate feedback regarding the exercise protocol, it may introduce bias in the assessment of outcomes. However, objective measures such as blood glucose levels and physical performance assessments will be used to minimize this potential bias.|This clinical trial will utilize a parallel study design, wherein participants will be randomly assigned to one of two groups: the research group receiving Thera-Band elastic band-assisted progressive resistance training (PRT) and the control group receiving conventional diabetes management. Each group will be treated independently throughout the study duration of 12 weeks. The outcomes of interest will be assessed at baseline and after the intervention period to determine the effectiveness of the exercise program in improving physical health and reducing frailty in older adults with diabetes mellitus. This design allows for a direct comparison between the intervention and control groups, providing robust data on the efficacy of the Thera-Band PRT approach.||||
34134132|NCT04116983|||COHORT||PROSPECTIVE|||||||
34134133|NCT05400057|||CASE_CONTROL||RETROSPECTIVE|||||||
34134134|NCT05074680|||COHORT||PROSPECTIVE|||||||
34134135|NCT02250508||||TREATMENT||||||||
34134136|NCT05346744|NON_RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Care providers and outcomes assessors wouldn't know the materials of the specimen.|Ten individuals with tooth defect of mandibular first molar were selected to participate in the study. 6 crowns made from 6 chairside materials were milled by CEREC MCXL-EF mode for each mandibular first molar.|f|t|f|t
34134137|NCT06450964|||COHORT||PROSPECTIVE|||||||
34134138|NCT01214408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134139|NCT01606176|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134140|NCT05994924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134141|NCT02321917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134142|NCT02119195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134143|NCT06169319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134144|NCT06403982|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34134145|NCT00298623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134146|NCT00995891|||COHORT||PROSPECTIVE|||||||
34134147|NCT01018329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134148|NCT00648388|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34134149|NCT06615817|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134150|NCT06054113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134151|NCT04597645|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134152|NCT05007899|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34134153|NCT06553118|||COHORT||PROSPECTIVE|||||||
34134154|NCT00772915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134155|NCT03905148|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A will consist of dose escalation and dose-finding components to establish the max tolerated dose and/or recommended Phase 2 dose Part B will investigate efficacy and further evaluate the PK, safety, and tolerability of the combination of PD-0325901 and BGB-283 (lifirafenib).||||
34134156|NCT02148887|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134157|NCT05297058|||CASE_ONLY||CROSS_SECTIONAL|||||||
34134158|NCT03722420|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel, 2 arms||||
34134159|NCT02269553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134160|NCT01677598|||CASE_ONLY||PROSPECTIVE|||||||
34134161|NCT03636438|||OTHER||PROSPECTIVE|||||||
34134162|NCT05242068|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study was a prospective randomized controlled clinical study of children treated in a pediatric surgical ward who required PIC. The aim of the research was to evaluate whether the Veinlite would prevent catheter-related complications||||
34134163|NCT00093197|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134164|NCT06662110|||COHORT||PROSPECTIVE|||||||
34134165|NCT04573153|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was planned as a parallel group, randomized and open label study. The subjects will be randomized on a 3:1 basis to the cofactor supplementation combination plus hydroxychloroquine treatment or hydroxychloroquine +placebo treatment.||||
34134166|NCT02497365|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134167|NCT01390974|||COHORT||PROSPECTIVE|||||||
34134168|NCT00001766||||TREATMENT||||||||
34134169|NCT04115878|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34134170|NCT01312493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134171|NCT01311154|||COHORT|||||||||
34134172|NCT04771520|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134173|NCT02619591|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34134174|NCT06355414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-blind trial, and efforts will be made to mask the study drug (psilocybin) and the active control (methylphenidate) from participants, guides, and study staff. Participants will be debriefed about their randomly assigned drug condition after the completion of the final follow-up assessment, or after discontinuation/withdrawal, whichever comes first.|Randomized, double-blind, active control study comparing the effects of psilocybin (25mg fixed dose) and methylphenidate (40mg fixed dose)|t|f|t|t
34134175|NCT00033566||||TREATMENT||||||||
34134176|NCT03193554|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134177|NCT04493970|||OTHER||PROSPECTIVE|||||||
33827637|NCT06259513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33827638|NCT04011397|NA|SINGLE_GROUP||PREVENTION||NONE||Feasibility study||||
33827639|NCT06414005|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134178|NCT05042323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34134179|NCT03871010|||CASE_ONLY||PROSPECTIVE|||||||
34134180|NCT05968053|||COHORT||PROSPECTIVE|||||||
34134181|NCT04044053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134182|NCT03420508|NA|SINGLE_GROUP||TREATMENT||NONE||This single arm, single center, open label Phase 2 trial will utilize a Simon 2 stage design.||||
34134183|NCT06227676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants are randomly assigned either 'Cramp Bites' or our Placebo Snack over the duration of one menstrual cycle.|t|t|t|t
34134184|NCT03370380|||OTHER||PROSPECTIVE|||||||
34134185|NCT04588220|||CASE_CONTROL||PROSPECTIVE|||||||
34134186|NCT03946774|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134187|NCT04877288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134188|NCT04629391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|While the patients and care providers will be aware of the type of prosthesis, the physicians who assessed the outcomes and analyzed the data will be blinded to this information.||f|f|f|t
34134189|NCT05563805|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two group (intervention and control) randomized trial|t|f|f|f
34134190|NCT06661018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participant, care Provider, and investigator will not know either they include in treatment or control group|This research is an experimental clinical study with a double blinded randomized controlled trial design. The study group consisted of patients with acute STEMI underwent primary PCI. The first group was patients who received standard treatment plus coenzyme Q10 100mg / 12 hours orally for up to 8 weeks (group A). Meanwhile, the second group was patients who received standard treatment plus placebo for up to 8 weeks (group B).|t|t|t|f
34134191|NCT06568731|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134192|NCT04435600|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|f|t
34134193|NCT06659588|||CASE_CONTROL||PROSPECTIVE|||||||
34134194|NCT03300141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134195|NCT03714217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134196|NCT04637724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Active tDCS versus Sham tDCS intervention|t|t|t|t
34134197|NCT03102827|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34134198|NCT01905046|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34134199|NCT03702959|||COHORT||OTHER|||||||
34134200|NCT03916536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134201|NCT05265234|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34134202|NCT03008668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134203|NCT00668382|NA|SINGLE_GROUP||||NONE||||||
34134204|NCT00542373|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134205|NCT00722722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134206|NCT01664611|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34134207|NCT01117298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134208|NCT00711230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134209|NCT03558269|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will not be exposed to the participant group||f|f|f|t
34134210|NCT05584163|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34134211|NCT05273255|NA|SINGLE_GROUP||OTHER||NONE||||||
34134212|NCT01055938|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134213|NCT01164891|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134214|NCT05028348|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134215|NCT00526656|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134216|NCT00148993|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34134217|NCT00500799|||||PROSPECTIVE|||||||
34134218|NCT03305588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134219|NCT02381717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134220|NCT04207593|RANDOMIZED|CROSSOVER||TREATMENT||NONE|PAH patients experiencing oxygen desaturations at rest and during physical activity, when O2 partial pressure is repeatedly \<8 kPa (\<60 mmHg; alternatively, 90% of O2 saturation). Patients will be divided in a supplemental-oxygen group (primary intervention group) and no-supplemental-oxygen group (control group). Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). Randomization will be performed in a 1:1 ratio. Randomization to one of the groups will be performed by block randomization. Randomization lists will be created by the data management using a computer to generate random numbers.|||||
34134221|NCT01252186|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134222|NCT02182024|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134223|NCT05230446|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134224|NCT06659731|||CASE_CONTROL||PROSPECTIVE|||||||
34134225|NCT04801459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134226|NCT06509997|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm Phase II clinical trial||||
34134227|NCT02626429|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134228|NCT06661213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134229|NCT04377321|||COHORT||PROSPECTIVE|||||||
34134230|NCT06660680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134231|NCT00623233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134232|NCT06071663|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34134233|NCT06493786|NA|PARALLEL||OTHER||NONE||||||
34134234|NCT06232980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||"Group O: HR, SAB, DAB, OAB, SpO2, and BIS values will be recorded at 2-minute intervals for 14 minutes. A standard initial dose of 1.5 mg/kg of propofol and an infusion rate of 100 mg/min will be applied. An additional 20 mg of propofol will be administered every 30 seconds until the Observer's Assessment of Alertness/Sedation (OAA/S) score reaches 1.~Group B: HR, SAB, DAB, OAB, SpO2, and BIS values will be recorded at 2-minute intervals for 14 minutes. The BIS index will be evaluated every 30 seconds. The initial dose and infusion rate will be applied as in Group O, with the target index in the BIS group being 40-60. An additional dose of 20 mg will be planned every 30 seconds until the target index is reached."|t|f|f|f
33827640|NCT03187353|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33827641|NCT03713697|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33827642|NCT02161198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827643|NCT02453477|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827644|NCT00093132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827645|NCT05598138|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134235|NCT00042952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134236|NCT01813058|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134237|NCT00705250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134238|NCT03294044|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|No masking|Parallel Assignment||||
34134239|NCT06661148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134240|NCT01038479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34134241|NCT06657651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134242|NCT05505396|||COHORT||PROSPECTIVE|||||||
34134243|NCT03245268|||COHORT||PROSPECTIVE|||||||
34134244|NCT00967694|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34134245|NCT05540340|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34134246|NCT05051293|||COHORT||RETROSPECTIVE|||||||
34134247|NCT02319616|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134248|NCT03430843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134249|NCT06655792|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34134250|NCT04724694|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the outcomes assessor will be masked|Two arm parallel design: 1) primary care treatment as usual, or 2) primary care treatment as usual and Brief Cognitive Behavioral Therapy for Chronic Pain|f|f|f|t
34134251|NCT04802512|||CASE_ONLY||CROSS_SECTIONAL|||||||
34134252|NCT01063608|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134253|NCT02377752|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134254|NCT00606541|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134255|NCT06659614|||COHORT||PROSPECTIVE|||||||
34134256|NCT06249698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Experimental randomly assigned unblinded||||
34134257|NCT03249909|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|"Subjects were to be assigned in the following order:~* Eligible Subjects 1 to 50 were to be assigned to the Exufiber Ag+ cohort~* Eligible Subjects 51 to 65 were to be assigned to Exufiber~* Eligible Subjects 66 to 85 were to be assigned to Aquacel Ag Extra~* Eligible Subjects 86 to 105 were to be assigned to Exufiber Ag+ on eligible pressure ulcer subjects~The statistical analysis of the groups treated will be analysed separately with the same statistical methods."||||
34134258|NCT04129268|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134259|NCT01651065|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134260|NCT05757440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134261|NCT05111002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134262|NCT04840485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134263|NCT05394597|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Treatment versus control. 13 with repellent and 2 without, for 15 subjects. Median Complete Protection Time for each repellent product tested against mosquitos for prevention of biting.||||
34134264|NCT06002555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34134265|NCT01851265|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34134266|NCT06104878|||COHORT||RETROSPECTIVE|||||||
34134267|NCT01882556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134268|NCT06660043|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134269|NCT06660472|||OTHER||CROSS_SECTIONAL|||||||
34134270|NCT03934580|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34134271|NCT04287309|||CASE_ONLY||PROSPECTIVE|||||||
34134272|NCT02417662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134273|NCT04926636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34134274|NCT05996965|||COHORT||PROSPECTIVE|||||||
34134275|NCT05255991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134276|NCT06090864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134277|NCT05629065|RANDOMIZED|FACTORIAL||OTHER||SINGLE||4 arm randomized clinical trial|f|f|t|f
34134278|NCT06660394|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134279|NCT03848130|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134280|NCT04668833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134281|NCT01524224||SEQUENTIAL||TREATMENT||NONE||||||
34134282|NCT06658379|||COHORT||PROSPECTIVE|||||||
34134283|NCT06553300|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134284|NCT06209138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134285|NCT04801849|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||multicenter, randomized, double masked, placebo-controlled, parallel treatment groups|t|t|t|f
34134286|NCT01562314|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134287|NCT01716039|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34134288|NCT05457153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34134289|NCT06435416|||COHORT||RETROSPECTIVE|||||||
34134290|NCT01247025|||COHORT||CROSS_SECTIONAL|||||||
34134291|NCT06661187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||group one will use cryoanalgesia group two will use simple psychological instruction control group|t|f|f|f
34134292|NCT05148650|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34134293|NCT00682903|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34134294|NCT00695916|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34134295|NCT03583268|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34134296|NCT01630252|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134297|NCT04751994|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|This will be a two-arm, randomised, placebo-controlled double-blind study. Children will be randomised (1:1) to iron drops or placebo arm.|"Daily iron (7.5mg/day as ferrous sulphate) or placebo drops starting from six to ten weeks of age for 98 days.~Please note that the daily iron supplement is the intervention product/drug"|t|t|t|t
34134298|NCT03724058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134299|NCT01697423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34134300|NCT02512874|NA|SINGLE_GROUP||OTHER||NONE||||||
34134301|NCT06029868|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34134302|NCT00140049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34134303|NCT02482597|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134304|NCT06660823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"This study is a prospective, randomized controlled trial that will study the postoperative clinical outcomes of levothyroxine supplementation in delayed recovery or prolonged ventilation patients post cardiac surgery.~Randomization will be performed using a computer-generated randomization sequence and allocation concealment to be maintained all through the time of procedure, by using opaque, numbered, and sealed envelopes.~Patients will be randomly allocated by computer generated randomization into two groups A and B:~* Group A (Study group): patients receiving oral supplementation of levothyroxine.~* Group B (Control): patients receiving Placebo drug."|t|t|f|f
34134305|NCT06661889|||CASE_ONLY||PROSPECTIVE|||||||
34134306|NCT00916201|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134307|NCT06658392|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134308|NCT00146016|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34134309|NCT01267110|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34134310|NCT04181008|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134311|NCT04917952|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134312|NCT03691337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134313|NCT01263431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134314|NCT04082845|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Parallel Assessment|t|f|f|f
34134315|NCT06552793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A randiomized clinical trial|t|f|t|t
34134316|NCT05558358|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Participants and all study personnel are blinded to subject assignment except the physician completing DBS programming.|All participants undergo surgery. Some receive 6 months of active DBS stimulation of the bilateral nucleus accumbens followed by 6 months of sham stimulation. While some receive the opposite order.|t|f|f|t
34134317|NCT06661473|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134318|NCT00205517|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134319|NCT01066104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34134320|NCT01222117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134321|NCT04015817|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134322|NCT05638412|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134323|NCT05927428|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, Randomized Study||||
34134324|NCT00613327|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134325|NCT01485731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134326|NCT02047422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134327|NCT04651686|NA|SINGLE_GROUP||PREVENTION||NONE||Sixty patients with thoracoscopic lobectomy and systemic lymph node dissection were selected from the same surgical group in the thoracic surgery department of the First Affiliated Hospital of Suzhou University from August 1, 2020 to October 31, 2020. According to the random number grouping method, they were divided into two groups: the bronchial artery protection group (the experimental group) and the conventional surgical treatment group (the control group). In the experimental group, 64 slice spiral CT was used for chest enhanced CT examination before operation, and mimics software was used for 3D reconstruction of bronchial artery. During the operation, the bronchial artery was protected according to the preoperative three-dimensional reconstruction image during lymph node dissection. In the control group, three-dimensional reconstruction of bronchial artery was not performed before operation, and lobectomy and systematic lymph node dissection were performed routinely||||
34134328|NCT02295085|||COHORT||PROSPECTIVE|||||||
34134329|NCT05203211|||COHORT||RETROSPECTIVE|||||||
34134330|NCT06053541|||COHORT||RETROSPECTIVE|||||||
34134331|NCT06164652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||comparing data (gait kinematics) gathered with GAITRite and Ceriter Stride One by walking at comfortable and increased speed||||
34134332|NCT04579536|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple blinding. Because of the nature of the material, the investigator who will apply the material to the occlusal surfaces will not be blinded to the group allocation. However, the investigators who will perform the clinical visual examination and the radiographic examination will be blinded to which group the teeth they are evaluating belongs. In addition, the statistician will be blinded.|The design of the study is a split-mouth, randomized controlled clinical trial in which the teeth are randomly assigned to be either in the test group or the control group in a 1:1 ratio. The control group: will be treated with 5% sodium fluoride (NaF) white varnish, oral hygiene instruction, and dietary counseling. The test group: will be treated with light curable resin modified glass ionomer (RMGI) varnish.|t|f|t|t
34134333|NCT06412978|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Scars will be digitally photographed by study staff and scored by 2 independent judges. The judges will be blinded to the closure method at time of scar evaluation.|trial comparing skin closure with absorbable subcuticular staples with subcuticular suture|f|f|f|t
34134334|NCT01028768|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34134335|NCT06662149|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34134336|NCT02021383|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134337|NCT06368505|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134338|NCT04711369|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham-controlled|Randomized double blinded sham-controlled clinical study|t|f|t|t
34134339|NCT03268954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134340|NCT05704257|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34134341|NCT01919580|||CASE_CONTROL|||||||||
34134342|NCT05213637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134343|NCT05829447|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34134344|NCT02478931|||COHORT||OTHER|||||||
34134345|NCT00464061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134346|NCT06659666|||COHORT||CROSS_SECTIONAL|||||||
34134347|NCT02110680|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34134348|NCT04251897|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34134349|NCT00084708|NA|SINGLE_GROUP||TREATMENT||||||||
34134350|NCT03347526|RANDOMIZED|PARALLEL||TREATMENT||NONE|Blinded outcome measure|||||
34134351|NCT01965769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134352|NCT04960059|||COHORT||RETROSPECTIVE|||||||
34134353|NCT00113672|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33827646|NCT04040283|||CASE_ONLY||RETROSPECTIVE|||||||
33827647|NCT04921748|||CASE_CONTROL||PROSPECTIVE|||||||
34134354|NCT06407869|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask both groups about treatment.|It will be randomized control trial in which random sampling technique will be used. Two groups of 6-12 age will be formed in which participants will randomly be divided. Group A will receive Functional Progressive Resistance Exercises and group B will receive conventional stretching and strengthening exercises|t|f|f|f
34134355|NCT06446375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134356|NCT03716778|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134357|NCT00204594|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134358|NCT06156657|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anasthesiologist who perform postoperative pain will not know the group.||t|f|f|t
34134359|NCT06014606|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|double-blind (randomised) between-subjects design||t|f|t|f
34134360|NCT05704023|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34134361|NCT06204900|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134362|NCT04022629|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134363|NCT06125925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The End Point and Adverse Event Committee is constituted of three experts in the field of heart failure and ablation of atrial fibrillation, but independent of the study. The End Point Adverse Event Committee have received blinded data regarding all serious adverse events, all deaths, all hospitalizations, all outpatient or emergency visits, all cerebrovascular accidents, and all first recurrences of atrial fibrillation, from the Contact Research Organization. The End Point and Adverse Event Committee was responsible for the classification of all received events, for the determination of which events fulfill the end point criteria.||f|f|f|t
34134364|NCT02881931|||OTHER||PROSPECTIVE|||||||
34134365|NCT01781793|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34134366|NCT02806336|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blinded to group, statistical analyses blinded to group|Two group RCT|f|f|f|t
34134367|NCT05178316|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134368|NCT03062280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134369|NCT06651385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134370|NCT03684603|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134371|NCT02565264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134372|NCT00570011|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134373|NCT05200611|||COHORT||PROSPECTIVE|||||||
34134374|NCT03841513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study surgeons will provide clinical care to study participants, and therefore blinding the surgeon to treatment allocation is not feasible. However, we intend that all outcomes assessors and participants will be blinded to treatment allocation until 3-months outcomes are collected.|Enrolled subjects will be assigned to one of two treatment groups with equal probability. A randomly permuted blocked randomization schema will be generated and maintained by a statistician not otherwise involved in the study.|t|f|f|t
34134375|NCT00917683|||CASE_CONTROL||PROSPECTIVE|||||||
34134376|NCT00825942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134377|NCT06447779|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134378|NCT02640001|||COHORT||PROSPECTIVE|||||||
34134379|NCT06492707|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134380|NCT03938103|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34134381|NCT00043355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134382|NCT02684058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134383|NCT06491641|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|randomized|Experimental, randomised controlled, single-blind study|t|f|f|t
34134384|NCT02818023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134385|NCT05556421|||CASE_CONTROL||PROSPECTIVE|||||||
34134386|NCT01555853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134387|NCT06303375|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134388|NCT03773536|NA|SINGLE_GROUP||TREATMENT||NONE||A one-armed prospective antimalarial drug efficacy trial.||||
34134389|NCT03070639|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34134390|NCT05872542|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34134391|NCT03771638|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized, controlled study||||
34134392|NCT06625138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134393|NCT02185573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134394|NCT06524635|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134395|NCT03325868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134396|NCT05866029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134397|NCT05841888|||OTHER||PROSPECTIVE|||||||
34134398|NCT02692768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134399|NCT02621151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134400|NCT05420311|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A randomized cross-over study testing three different dietary weight-loss interventions||||
34134401|NCT06016946|||CASE_ONLY||PROSPECTIVE|||||||
34134402|NCT05023291|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134403|NCT06660524|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized grouping is generated by applying the data entry platform. According to the randomization results, the experimental group is given a sevelamer prescription, and the control group is given a calcium carbonate prescription.||||
34134404|NCT06657092|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients were randomized into two groups, ESPB and control.||||
34134405|NCT00316225|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134406|NCT03668470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Multicentric, investigator-initiated, randomized, double-blinded, therapeutic clinical trial, placebo-controlled, two arm parallel group intervention trial during 24 weeks, phase II.|t|t|t|t
34134407|NCT01096368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134408|NCT03540589|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34134409|NCT06656078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE||Research|t|f|t|t
34134410|NCT06053138|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants are blinded to the drink (intervention) being either ketosis (obtained by ingestion of a ketone monoester drink) or plaacebo (a tate and volume matched drink). Drinks are provided in similar neutral unlabelled bottles|Participants are all exposed to the intervention (ketosis) in part 1 followed by randomization to either active intervention (ketosis) or placebo in part 2 of the study|t|t|t|f
34134411|NCT05780801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134412|NCT03440151|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Because the two interventions used in this trial are clearly different and easly recognized by the participants and investigators, neither investigators nor Participants can be blinded.~The statistician will be blinded."|||||
34134413|NCT00140283|RANDOMIZED|PARALLEL||ECT||NONE||||||
34134414|NCT02904629|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134415|NCT04324541|||COHORT||PROSPECTIVE|||||||
34134416|NCT04190381|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134417|NCT04313400|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part 1 (Phase I) of the study is open-labeled. Part 2 (Phase II) of the study is double-blinded (Masking: Participant, Care Provider, Investigator, and Outcomes Assessor).|"Part 1 (Phase I):~Part 1 of the study is an open-label, dose escalation study to determine the MTD of AMTX-100 CF (1.1% w/w) for the highest treated percentage of the BSA affected with AD. Five (5) cohorts will be sequentially enrolled in the Part 1 of the study. Each cohort will include five (5) patients with eligible, treatable percentages of BSA affected with AD.~Part 2 (Phase II):~Part 2 of the study is a multi-center, double-blind, randomized, vehicle-controlled, dose ranging study of the safety and efficacy of topically applied AMTX-100 CF3 in adult patients with Mild to Moderate AD. Sixty (60) patients will be enrolled in 2 groups of AMTX-100 CF3 along with a placebo (vehicle). The patients will be randomized in a 1:1 ratio with thirty (30) subjects in Group A: 1.1% of AMTX-100 CF3 and thirty (30) subjects will be randomized to Group B placebo (vehicle 0% w/w)."|t|t|t|t
34134418|NCT04732702|||COHORT||PROSPECTIVE|||||||
34134419|NCT02353702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134420|NCT06444867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134421|NCT06329752|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, single-arm, feasibility trial||||
34134422|NCT01925118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134423|NCT03430024|||OTHER||PROSPECTIVE|||||||
34134424|NCT06659549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Reading Centers||t|t|t|t
34134425|NCT01374165|||COHORT||PROSPECTIVE|||||||
34134426|NCT03023579|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134427|NCT02159339|||COHORT||PROSPECTIVE|||||||
34134428|NCT05289141|||COHORT||RETROSPECTIVE|||||||
34134429|NCT03927547|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will undergo sleep study in subjects' randomized sleep posture. Randomization will be recorded separately from sleep study recordings. These recordings will be reviewed by trained sleep study technicians who will be blinded to randomization. Blood samples will also be assayed for markers of glucose control.||f|f|f|t
34134430|NCT03791281|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34134431|NCT01017744|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134432|NCT06268873|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo controlled||t|t|t|t
34134433|NCT06365775|||COHORT||PROSPECTIVE|||||||
34134434|NCT04343170|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34134435|NCT06651151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134436|NCT04458441|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||f|t|t|f
34134437|NCT04374734|||CASE_ONLY||RETROSPECTIVE|||||||
34134438|NCT03094091|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
34134439|NCT06495060|||CASE_ONLY||CROSS_SECTIONAL|||||||
34134440|NCT06439654|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a prospective quantitative study of individuals with FH to examine the benefit of comprehensive supportive care to lower elevated LDL-C and sustain healthy levels through 36 months from baseline enrollment. We propose to demonstrate improvement in lipid parameters and outcomes in patients referred to the study. Specifically, we will target patients with documented hypercholesterolemia, hypertriglyceridemia, prior myocardial infarction, and personal or family history of coronary artery disease, who may be living with undiagnosed/untreated familial hypercholesterolemia FH.||||
34134441|NCT04122911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134442|NCT02419222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134443|NCT06012318|||COHORT||PROSPECTIVE|||||||
34134444|NCT03654404|NA|SINGLE_GROUP||OTHER||NONE||||||
34134445|NCT06658444|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Ultrasound-based therapy has proven to be a viable option for treating abnormal scarring. It has been shown to reduce the growth of keloids or postoperative scars. Phonophoresis's advantages include noninvasiveness, good compliance, low cost, and minimal gastrointestinal side effects. Onion extracts were originally used for treating full and partial-thickness burns; however, more recently these have been trialed for treating hypertrophic and keloid scarring, and healing wounds. onion extract plays the main role in reducing scar through the inhibition of fibroblast proliferation and collagen production.|t|f|f|f
34134446|NCT01983488|||COHORT||PROSPECTIVE|||||||
34134447|NCT04109807|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34134448|NCT00969644|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134449|NCT04030546|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|t|f
34134450|NCT06658626|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134451|NCT05434871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors are blinded to the group allocation.|Randomised controlled trial|f|f|f|t
34134452|NCT02894723|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134453|NCT06194604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Investigator and The outcomes assesor different persons|Randomised controlled|f|f|t|t
34134454|NCT02255058|||COHORT||PROSPECTIVE|||||||
34134455|NCT00779428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134456|NCT03589989|RANDOMIZED|PARALLEL||PREVENTION||NONE|Statisticians and laboratory personnel will be blinded to group allocation.|||||
34134457|NCT06212115|||COHORT||PROSPECTIVE|||||||
34134458|NCT05031091|||CASE_CONTROL||OTHER|||||||
34134459|NCT01139203|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34134460|NCT06538051|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134461|NCT01663116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134462|NCT04176991|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134463|NCT03539211|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34134464|NCT05609370|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134465|NCT02825706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134466|NCT00501722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134467|NCT02407080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134468|NCT04414592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134469|NCT00060801||||TREATMENT||||||||
34134470|NCT02991495|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34134471|NCT00680979|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134472|NCT03219034|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134473|NCT01601106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134474|NCT06094361|RANDOMIZED|PARALLEL||TREATMENT||NONE||There were two separate groups in the study. The first group received iontophoresis and the other group received phonophoresis. The effects on treatment outcomes were compared.||||
34134475|NCT02175719|||COHORT||PROSPECTIVE|||||||
34134476|NCT04569864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The total patient population will be randomized into 2 groups. The first group of the patients during aortic hemiarch replacement, mild hypothermia (30-32°C) will be used during circulatory arrest. (main group). The second group of the patients during aortic hemiarch replacement, moderate hypothermia (26-28°C) will be used during circulatory arrest. (control group).|t|f|f|t
34134477|NCT03878381|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Block randomization will be utilized to determine which side will be the treatment side.|Patients will engage in a split face trial, where each participant uses the vehicle on one side of the face and active ingredient treatment cream on the other side|t|t|t|f
34134478|NCT00992199|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134479|NCT04884217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134480|NCT04053725|||CASE_ONLY||PROSPECTIVE|||||||
34134481|NCT02493478|||CASE_ONLY||PROSPECTIVE|||||||
34134482|NCT02139878|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34134483|NCT06412705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134484|NCT03379259|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134485|NCT00699387|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134486|NCT02137018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34134487|NCT05998850|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||IMPaCT (Individualized Management for Patient-Centered Targets)||||
34134488|NCT04195399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134489|NCT04661371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34134490|NCT03939962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134491|NCT05572606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134492|NCT01773005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34134493|NCT00295009|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134494|NCT05875727|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be assigned into 2 cohorts by age: 18 to 49 years of age and ≥50 years of age.||||
34134495|NCT02300571|||CASE_ONLY||OTHER|||||||
34134496|NCT06660836|NA|CROSSOVER||SCREENING||NONE||||||
34134497|NCT06658483|||OTHER||CROSS_SECTIONAL|||||||
34134498|NCT03807791|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134499|NCT04309890|||COHORT||PROSPECTIVE|||||||
34134500|NCT04645654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134501|NCT05066152|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||prospective, single center, interventional|t|f|f|f
34134502|NCT06086704|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Window of Opportunity||||
34134503|NCT03367923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134504|NCT04818463|||COHORT||RETROSPECTIVE|||||||
34134505|NCT03492060|||COHORT||PROSPECTIVE|||||||
34134506|NCT06046183|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Interventionist is blinded to which group participants are also research participants.|Control group and intervention group who self-selects|f|t|f|f
34134507|NCT03576196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134508|NCT00001106||||TREATMENT||NONE||||||
34134509|NCT03303170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134510|NCT00585442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134511|NCT00425997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34134512|NCT06659029|||COHORT||PROSPECTIVE|||||||
34134513|NCT04645316|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34134514|NCT04062214|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research Assistants collect data from participant interviews at 12 and 36 weeks follow-up. They will be blind to randomization condition.|Participants receive either usual care or study intervention|f|f|f|t
34134515|NCT06537310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134516|NCT04530487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134517|NCT06659900|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34134518|NCT03625947|||COHORT||PROSPECTIVE|||||||
34134519|NCT02222194|||COHORT||PROSPECTIVE|||||||
34134520|NCT02269813|||CASE_CONTROL||PROSPECTIVE|||||||
34134521|NCT06636318|||COHORT||PROSPECTIVE|||||||
34134522|NCT00320905|||||PROSPECTIVE|||||||
34134523|NCT01278121|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34134524|NCT00302172|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134525|NCT06098911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34134526|NCT02094378|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34134527|NCT01322113|||CASE_ONLY||PROSPECTIVE|||||||
34134528|NCT01766063|||COHORT||PROSPECTIVE|||||||
34134529|NCT01000883|||CASE_ONLY||PROSPECTIVE|||||||
34134530|NCT03070223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Participants were randomized as part of REPRIEVE.|t|t|t|t
34134531|NCT04204694|||COHORT||PROSPECTIVE|||||||
34134532|NCT05203757|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134533|NCT04362488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients who undergo surgery for a ankle lateral ligament reconstruction from 4th Febbruary 2019 till to the end of the study on 4th August 2020||||
34134534|NCT01828606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134535|NCT05005403|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34134536|NCT00210353|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134537|NCT00157196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134538|NCT00303654||||TREATMENT||NONE||||||
34134539|NCT03017872|RANDOMIZED|PARALLEL||TREATMENT||NONE||A third arm has been incorporated using a multi-arm, multi-stage (MAMS) design. This design allows for the 2-arm study (DTG+DRV/r vs DRV/r+2NRTI) to continue accrual while preparation of the new arm (DTG+2NRTI) is begun in parallel. Once that arm is ready, accrual to it begins and the study switches to the second stage. All participants accrued to Arm 1 and 2 throughout the trial are contemporaneous and can be compared, while the subjects accrued to Arm 3 are compared only to their contemporaries in Arms 1 and 2. The size of Arm 3 is sufficient to allow adequate power comparisons, and stage effects are minimized while non-contemporaneous control data are not required.||||
34134540|NCT01984307|||COHORT||RETROSPECTIVE|||||||
34134541|NCT00980512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34134542|NCT05315115|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Research|t|f|t|t
34134543|NCT06273722|||COHORT||RETROSPECTIVE|||||||
34134544|NCT01468857|||COHORT||PROSPECTIVE|||||||
34134545|NCT02970630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134546|NCT01054053|||COHORT||PROSPECTIVE|||||||
34134547|NCT06225518|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||This research was planned as an experimental type study. Randomization will be achieved by randomly selecting women from the study population and randomly assigning from the sample group women to the experimental and control groups by two people other than the researcher. Supervision in the research will be provided by creating a control group. Management will be provided by evaluating and comparing the effect of the mobile application on the physical activity level of women in experimental and control groups.|t|f|t|t
34134548|NCT02989584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134549|NCT00346606|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34134550|NCT03631771|NA|SINGLE_GROUP||OTHER||NONE||||||
34134551|NCT05512065|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134552|NCT00962533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134553|NCT00260767|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134554|NCT04424823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134555|NCT00529347|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134556|NCT02684877|||COHORT||PROSPECTIVE|||||||
34134557|NCT03296137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134558|NCT01647243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134559|NCT06658795|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med) (Figure 1-5a). For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI) (Figure 1-5b). In the sham stimulation group, the electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.|t|f|t|t
34134560|NCT02899455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134561|NCT01033006|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34134562|NCT01258933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134563|NCT01545791|||COHORT||PROSPECTIVE|||||||
34134564|NCT03044119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The selected sites would be randomly (coin toss method) assigned into an edentulous area .|The selected sites would be randomly (coin toss method) assigned into an edentulous area allowing for the placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM and (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.|t|f|t|t
34134565|NCT06114914|||COHORT||PROSPECTIVE|||||||
34134566|NCT02814240|NA|SINGLE_GROUP||OTHER||NONE||||||
34134567|NCT06035172|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134568|NCT06203457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134569|NCT02815696|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134570|NCT00678938|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34134571|NCT06659016|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants are blind to treatment arm||t|f|f|f
34134572|NCT03515135|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34134573|NCT04451226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134574|NCT04918290|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||The investigators will perform a prospective, double-blind, randomized controlled trial. The co-investigator will ask the study subject to close his or her eyes and will take a photograph of the eyelids as a baseline assessment. Then, the co-investigator will apply the Transpore® on one eye and the TegadermTM on the other eye according to the randomization schema. The exact time of application will be documented. At the end of the surgery, the co-investigator will remove the Transpore® and TegadermTM. She will then take another photograph of the eyelids and document the time. The Cloud storage folder containing the photographs will be shared with the dermatologists who will evaluate the degree of erythema.|t|t|t|t
34134575|NCT04739670|NA|SINGLE_GROUP||TREATMENT||NONE||This is a multi-center, single arm phase II study designed to evaluate the efficacy and safety of atezolizumab plus bevacizumab plus carboplatin plus gemcitabine in patients with locally recurrent, inoperable or metastatic recurrent PD-L1 positive or stromal TIL positive TNBC.||||
34134576|NCT00654745|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134577|NCT00413894|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134578|NCT04270578|||CASE_CONTROL||PROSPECTIVE|||||||
34134579|NCT04650568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient remains blinded throughout trial. Imaging evaluator will be blinded to which study arm the patient belongs to.|Randomized Control Trial|t|f|f|t
34134580|NCT05955820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134581|NCT00911196|||CASE_ONLY||RETROSPECTIVE|||||||
34134582|NCT06306729|||CASE_ONLY||PROSPECTIVE|||||||
34134583|NCT01179750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134584|NCT00565149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134585|NCT05733234|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134586|NCT01726400|||CASE_ONLY||PROSPECTIVE|||||||
34134587|NCT05793255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134588|NCT00104416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134589|NCT02966145|||COHORT||PROSPECTIVE|||||||
34134590|NCT06651346|||COHORT||PROSPECTIVE|||||||
34134591|NCT00455819|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134592|NCT06314373|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134593|NCT01830283|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134594|NCT02890953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134595|NCT00307281|||COHORT||OTHER|||||||
34134596|NCT05647772|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This study is a randomized control trial. The investigators will use stratified randomization to ensure that the groups are equivalent on key clinical features. Randomization will take place after completion of the initial baseline assessment. Parents of children (ages 5-8) with disruptive behaviors (N = 324 subjects) will be randomly assigned to Group 1 (standalone app; n = 108), Group 2 (coach-assisted app; n = 108), or Group 3 (control app; n = 108).|f|f|t|f
34134597|NCT04339998|||COHORT||PROSPECTIVE|||||||
34134598|NCT00060541|||CASE_ONLY||PROSPECTIVE|||||||
34134599|NCT03142841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The PI and data collectors will be blinded in this study.|A two-arm (8-session intervention vs. standard care), randomized controlled clinical trial with three assessment points will be conducted. Baseline measurements will be conducted with the caregivers prior to the intervention. Post-test assessments will be collected at 1 and 12 weeks post-intervention. In addition, the investigators will obtain pre- and post-test measures of Veteran-related variables via CPRS electronic health records. Qualitative interviews will be conducted to assess caregivers' perceptions of the intervention.|f|f|t|t
34134600|NCT01129765|||CASE_CONTROL||PROSPECTIVE|||||||
34134601|NCT06658353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134602|NCT00901238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134603|NCT02446249|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134604|NCT06661330|||COHORT||RETROSPECTIVE|||||||
34134605|NCT03576404|NA|SINGLE_GROUP||OTHER||NONE||A Quasi-Experimental Interrupted Time Series Study||||
34134606|NCT04635384|||COHORT||PROSPECTIVE|||||||
34134607|NCT06611345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134608|NCT00657293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134609|NCT03493451|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134610|NCT03788642|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"The randomised clinical trial with participants randomised1:1 to either~* Control group : Patients will wear LED shoe (Placebo) 30 minutes once daily~* Laser group : Patients will wear Laser shoe 30 minutes once daily"|t|f|f|t
34134611|NCT00113399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134612|NCT06170463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134613|NCT02723916|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134614|NCT04756999|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blind Randomised Controlled Trial|Randomised Controlled Trial|t|f|f|f
34134615|NCT05056805|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134616|NCT05786937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To avoid bias in evaluating the results, the research volunteer and the team that will perform the application of the vaccine product will be blind in the present study. The team responsible for coordinating the project will not be blind.|Phase I, double-blind, randomized study with three parallel groups as follows: : G1) placebo; G2) aDC1immunization; G3) aDC1 immunization with analytical treatment interruption of ART.|t|t|f|f
34134617|NCT04838054|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Once a subject has been screened and qualified for study participation, that subject will be enrolled and assigned the next available randomization number. The study randomization table will be generated by a third-party statistician. This procedure will be used to keep the Study Statistician blinded to subject treatments prior to database lock.|Subjects will receive an Oral Hygiene Kit at Visit 1. The MGI, BOP and PI, Pocket depth and radiographs will be measured and all oral tissues examined (baseline examination). Subjects will return for Visit 2 in 14 days ± 3 days to: 1) assess and record changes in indices and oral health and any adverse conditions. Visit 3 (45 days ± 7) will be a compliance visit for study drug utilization. Visit 4 (90 days ± 7) will be a repeat of Visit 1.|t|f|t|t
34134618|NCT06274034|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134619|NCT05097651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134620|NCT05851534|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Stepped-wedge cluster randomized superiority trial||||
34134621|NCT00397852|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134622|NCT00705913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134623|NCT02744495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134624|NCT06355596|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE||Participants are randomly allocated to either face-to-face or virtual teaching groups|f|f|f|t
34134625|NCT01253694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134626|NCT02700035|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134627|NCT01924273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134628|NCT00175630|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134629|NCT03706742|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|t|f|t
34134630|NCT03286829|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34134631|NCT05476497|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part A is open label. Part B is double blind, placebo controlled|"Two part clinical trial:~Part A- Open-label with two groups (A1 and A2):~i) A1 (Healthy Subjects): subcutaneous (SC) dosing with ascending concentrations of VLP Peanut.~ii) A2 (peanut allergic subjects): skin prick test (SPT) performed with ascending concentrations of VLP Peanut.~Part B - double-blind, placebo-controlled part that will enroll Peanut Allergic Subjects: subcutaneous (SC) dosing with ascending concentrations of VLP Peanut."|t|t|t|t
34134632|NCT00802997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134633|NCT04616183|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134634|NCT00725192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134635|NCT06445647|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134636|NCT01997606|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
34134637|NCT05282030|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134638|NCT02150551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134639|NCT02774200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134640|NCT06661629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134641|NCT05636124|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134642|NCT02687971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134643|NCT05508984|||CASE_ONLY||PROSPECTIVE|||||||
34134644|NCT06660641|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134645|NCT01436656|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134646|NCT01289275|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34134647|NCT04975412|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134648|NCT01841138|||COHORT||PROSPECTIVE|||||||
34134649|NCT03408418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34134650|NCT00258765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134651|NCT06326359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134652|NCT03473730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134653|NCT04116411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|VIGAS 2 is conducted under a randomised double blinded protocol. The study team and the patients are blinded to the randomisation list. Randomisation is performed by the contracted Clinical Cancer Center Unit at the Karolinska University Hospital by an unblinded person, Claudia Maes who holds responsibility to select out number codes for coded cans of the study drug. Claudia Maes is unrelated to the sponsor and the study team.|A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients. Patients will receive either placebo or valganciclovir according to a randomisation list, blinded to the sponsor and study team. Seven centers are aimed to include patients once approval is received for each respective study center.|t|t|t|t
34134654|NCT00443872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134655|NCT01263678|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34134656|NCT02355652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134657|NCT02728648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134658|NCT01269229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134659|NCT06347068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134660|NCT06658184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34134661|NCT05536557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator) Blocks will be administered after induction of general Anesthesia so participants will be blinded to which intervention they have had.Study investigators will not be aware of what group the participant belongs to when assessing the patient at post-operative period|"There are two group;~1. Experimental Group: Group (EOI) Plane Block ; A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to EOI plane. The same procedure will be repeated on the contralateral side. Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.~2. Sham Comparator Group:The patients will not receive any intervention. Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol."|t|t|t|f
34134662|NCT01824810|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134663|NCT04334135|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The member of the study team performing data analysis will be blinded when performing data analysis and unblinded after final statistical analysis|The intervention is to provide subjects with either a mitochondrial antioxidant, MitoQ (no more than 160 mg) and a placebo (dextrin and silica), in a randomized order.|f|f|f|t
34134664|NCT04588415|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||All participants in the prospective bereavement data collection component of this study will be invited to participate in the virtual support group (VSG) intervention, regardless of the severity of their symptoms. Those with severe symptoms (indicated by an ICG-r score \>25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the VSGs. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were \>6 months post-loss, and those with higher baseline symptom levels. However, no participant in the study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the participants.|t|f|f|f
34134665|NCT00321074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134666|NCT05332743|NA|SINGLE_GROUP||TREATMENT||NONE||6-month, multi-center, single-arm prospective interventional study||||
34134667|NCT03043352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134668|NCT04294901|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||"The investigators will target Veterans at three primary care sites who meet eligibility criteria for one of the PIM cohorts and are prescribed the target medication at the time of their scheduled primary care visit. At each intervention site, individual PCPs will be randomized to the sequence of patient cohorts. The study will begin with a 13-month retrospective baseline period, with one month for baseline subject identification and 12 months for observation of baseline subjects' deprescribing outcomes. Then, each PCP will be randomized to the order of three 4-month periods during which their eligible patients receive medication-specific brochures, one medication cohort at a time. The primary comparisons are between brochure-intervention patients and baseline patients (matched in terms of eligibility) from the same provider."||||
34134669|NCT04507828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134670|NCT06481878|||COHORT||PROSPECTIVE|||||||
34134671|NCT02118181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134672|NCT02591472|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134673|NCT06014541|||COHORT||OTHER|||||||
34134674|NCT02860247|||OTHER||PROSPECTIVE|||||||
34134675|NCT06659991|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|This study does not employ masking.|This is a crossover design wherein participants consume either alcohol-containing beverages (beer or cider) or sparkling water over two laboratory sessions.||||
34134676|NCT01534299|||CASE_ONLY||PROSPECTIVE|||||||
34134677|NCT04247555|||CASE_CONTROL||PROSPECTIVE|||||||
34134678|NCT02177734|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134679|NCT03331601|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34134680|NCT02494973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134681|NCT00665054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134682|NCT03037359|||COHORT||PROSPECTIVE|||||||
34134683|NCT01281254|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134684|NCT05083403|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
34134685|NCT05439174|||COHORT||RETROSPECTIVE|||||||
34134686|NCT00640809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134687|NCT04669262|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34134688|NCT06660914|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34134689|NCT05047939|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients will receive general anesthesia, therefore they cannot know their anesthetic agents.~Physicians involved in this study will investigate the outcomes."|A prospective randomized single-blinded study|t|f|f|f
34134690|NCT05358522|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The feedback intervention will be rolled out across all participating Penn Medicine surgical departments and divisions currently using Penn Medicine's post-operative text-messaging learning health system platform. Timing of intervention roll-out within each department and division will be randomly assigned to permit evaluation of the effect of the intervention.||f|f|f|t
34134691|NCT01551680|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134692|NCT00005643||||TREATMENT||||||||
34134693|NCT00170768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134694|NCT02337998|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134695|NCT06315907|||COHORT||CROSS_SECTIONAL|||||||
34134696|NCT06234579|||COHORT||PROSPECTIVE|||||||
34134697|NCT04629079|||COHORT||PROSPECTIVE|||||||
34134698|NCT02550288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134699|NCT05665101|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized controlled||||
34134700|NCT02255448|NA|SINGLE_GROUP||||SINGLE|||f|f|t|f
34134701|NCT02454439|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34134702|NCT06580249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134703|NCT00788931|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134704|NCT04023799|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34134705|NCT01749657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134706|NCT05993429|||COHORT||PROSPECTIVE|||||||
34134707|NCT00205088|||||PROSPECTIVE|||||||
34134708|NCT02301546|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34134709|NCT06662006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134710|NCT00487942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134711|NCT00435227|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134712|NCT04202406|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34134713|NCT04163861|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134714|NCT02834117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34134715|NCT05834400|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants are randomly assigned to one of two groups in parallel for the duration of the study|f|f|f|t
34134716|NCT04842149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134717|NCT01009944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134718|NCT06601699|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34134719|NCT05113121|||COHORT||PROSPECTIVE|||||||
34134720|NCT05311176|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134721|NCT03709745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134722|NCT01660672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134723|NCT06661863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants will not know wich biomaterial will be grafted|The study includes 28 patients who have a tooth extraction indicated in reference to g. avila-ortiz et al. 2020. They will be divided into 2 randomized groups, 14 sockets with an infectious process will be preserved with autologous bone and the remaining 14 with 58s bioactive glass|t|f|f|f
34134724|NCT04104815|NA|SINGLE_GROUP||OTHER||NONE||||||
34134725|NCT00786175|||CASE_ONLY||RETROSPECTIVE|||||||
34134726|NCT02824770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134727|NCT02910401|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34134728|NCT04115514|RANDOMIZED|PARALLEL||TREATMENT||NONE|None applicable|Randomized, unblinded, intervention versus non-intervention trial. 68 \[50 treatment + 18 controls\]||||
34134729|NCT00703521|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134730|NCT00344318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34134731|NCT06397443|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134732|NCT04015427|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34134733|NCT02078180|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34134734|NCT02713386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134735|NCT03968029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134736|NCT04815512|||CASE_CONTROL||RETROSPECTIVE|||||||
34134737|NCT05643001|NA|SINGLE_GROUP||SCREENING||NONE||||||
34134738|NCT06659692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134739|NCT02719691|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134740|NCT01120860|||COHORT||PROSPECTIVE|||||||
34134741|NCT06553651|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot, single-center, open-label, prospective, single-arm clinical study||||
34134742|NCT01402557|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34134743|NCT00632047|RANDOMIZED|||SCREENING||||||||
34134744|NCT01242839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134745|NCT00822627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34134746|NCT03588806|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34134747|NCT02207049|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34134748|NCT06657859|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is an open-label extension study. Participants will continue to receive the same dose level they received in the prior study.||||
34134749|NCT03635424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134750|NCT06598670|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134751|NCT01877486|||CASE_ONLY||PROSPECTIVE|||||||
34134752|NCT06279598|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The study is a randomized controlled trial (RCT) conducted in two phases. Patients with PTSD will first be randomized to PE or EMDR in the first treatment phase. After this first phase of treatment, non-responders are re-randomized for a second phase of treatment. They receive either the alternative phase 1 trauma-focused psychotherapy or IPT as non-trauma-focused therapy for PTSD. In both phases (phase 1 and 2) the treatment lasts 8 weeks. Patients receive 14 sessions of 1 hour in 8 weeks.|f|f|t|t
34134753|NCT06068478|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134754|NCT02384473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134755|NCT04785534|NA|SINGLE_GROUP||SCREENING||NONE||||||
34134756|NCT00946608|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134757|NCT00733070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134758|NCT06659172|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participant will not know the randomization order before starting the fMRI|The study design is a randomized controlled fMRI study. Subjects will receive two types of stimulation (i.e. taVNS vs sham) during a single scanning visit. The order of stimulation applied during each visit is randomised. Infusion of capsaicin via a nasoduodenal tube will be used as co-intervention.|t|f|f|f
34134759|NCT06659822|||OTHER||CROSS_SECTIONAL|||||||
34134760|NCT05236452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The random allocation process, enrolling participants and participants assigned in the intervention group will be done by statisticians who will not have awareness about the characteristics of the intervention and control groups using the computer random.org website. The study subjects will be unaware of the intervention they received. Laboratory personnel who will be involved in the tuberculosis diagnosis and a person who will assess the outcomes of intervention will be unaware of the group assignment. Intervention outcomes will be assessed by research assistants who are not participating in participant recruitment and they are masked. The study participants, caretakers/attendants, and healthcare providers will be masked at any point.|Participants will be randomly allocated to the intervention and control arms. In the intervention arm training for practitioners, patient education, screening, and referring suspected TB cases from traditional care centers to modern care services and vice versa.|t|f|f|f
34134761|NCT00550810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134762|NCT06531213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single participant will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|"it will be randomized control trail in which nonprobability convenient sampling will be used .two groups 5 to 9 age will be formed in which participants will randomly divided.~Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Control Group: Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones)."|t|f|f|f
34134763|NCT04666558|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34134764|NCT05456542|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The Research Coordinator will randomize eligible patients in a 1:1 allocation using undisclosed variable block sizes through a central computer system on REDCap. Randomization algorithm will stratify patients by recruitment site. This is an unblinded study as group allocation will be known. However, outcome adjudicators and the study statistician will be blinded to the group allocation.|Multicentred, national, parallel-group, pragmatic vanguard pilot trial.|f|f|f|t
34134765|NCT02973347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134766|NCT06661564|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34134767|NCT06212063|NA|SINGLE_GROUP||OTHER||NONE||||||
34134768|NCT01780337|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134769|NCT05570760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134770|NCT05214638|||CASE_ONLY||CROSS_SECTIONAL|||||||
34134771|NCT04200755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Permuted blocks of varying length with allocation ratio (verum:placebo = 2:1); double-blind, i.e. patients and investigators are masked|Randomized, multi-center, double-blind, placebo controlled, parallel group, multiple dose, phase IIa trial|t|f|t|f
34134772|NCT01511614|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34134773|NCT01037725|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34134774|NCT06230549|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34134775|NCT01051531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134776|NCT03990415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary investigator (Dr. Duren) will randomize participants into each of the three study groups. The research team responsible for assessments and analysis will be blinded to each participant's assignment. Dr. Duren will unblind the research team after the intervention period and data collection and analysis has been completed.|Participants will be randomized into three groups of equal size. The experimental group (Stay Strong, Stay Healthy strength training program), the walking exercise group, and the sedentary control group will participate in the trial in parallel for up to ten weeks. After the intervention period, participants from each group will have the opportunity to participate in an interview about their experiences.|f|f|t|t
34134777|NCT03674073|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134778|NCT05403372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134779|NCT01597908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134780|NCT04731298|NA|SEQUENTIAL||PREVENTION||NONE||Sequential dose cohorts. The first cohort of patients will receive a first emapalumab infusion of 6 mg/kg at TD0, followed by a second infusion at 3 mg/kg after 3 days. Subsequent infusions of 3 mg/kg will be every 3 or 4 days from previous dose until dose 15 or until engraftment. A maximum of 2 additional cohorts may be added to allow dosing regimen adaptation based on the PK/PD data observed from the previous cohort(s).||||
34134781|NCT03655054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149477|NCT05805644|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"To prevent subversion of the allocation sequence, study team members who enroll patients to the trial will be distinct and kept separate from the study team member that perform the randomization. We will establish the procedures to maintain separation between study team members that assess the outcomes, and those that perform group assignment. At the start of every assignment, patients will be reminded to not reveal their treatment assignment by referring to elements of the treatment that are unique to their treatment group.~Functional outcome scales are performed by blinded therapists who work in the unit."|Randomized controlled study|f|t|f|t
34149478|NCT06241521|||COHORT||PROSPECTIVE|||||||
34149479|NCT01393938|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149480|NCT02452203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33827648|NCT00118703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827649|NCT06292559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33827650|NCT05661253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33827651|NCT00001383||||TREATMENT||||||||
33827652|NCT03404050|NA|SINGLE_GROUP||TREATMENT||NONE||Assessments taken at three different time periods: week zero, week five and week eleven.||||
33827653|NCT01121185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33827654|NCT02807961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827655|NCT04397146|NA|SINGLE_GROUP||OTHER||NONE||Each study participant evaluates 8 different ONS products on palatability and perceived satiety||||
33827656|NCT04875598|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE||"A total of 60 patients will be included in the study; Group 1: 30 patients will be injected with local anesthetic into the fascia between the transversus abdominis and internal oblique muscles with the help of ultrasound from the designated area (Before the operation starts, TAPBwith 20 ml 0.25 % bupivacaine will be applied to the surgical side under ultrasonography)~Group 2: 30 patients, local anesthetic injection will be made to the same area under laparoscopic direct vision. 50 mg Bupivacaine (0.25 % 20 ml bupivacaine solution) has been determined as the application dose and this amount will be applied in both groups."|t|t|f|t
33827657|NCT00405912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827658|NCT05070234|||COHORT||RETROSPECTIVE|||||||
33827659|NCT03181906|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33827660|NCT02037256|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827661|NCT01019499|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33827662|NCT01543906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827663|NCT05022290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There will be an opaque fabric shade that covered the participant's right upper arm during treatment that does not allow them to see the methods of drug administration.|In a randomized controlled trial, participants will be allocated into 2 groups. Each group receives adenosine with the same dosage but different methods of administration.|t|f|f|f
33827664|NCT01238653|||CASE_ONLY||PROSPECTIVE|||||||
33827665|NCT05294406|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827666|NCT03676478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is single blinded at the level of outcome assessment. As in the postoperative setting it will be clear which subject is in the delayed enteral feeding group, masking cannot be performed for participants, care providers and the investigators. Therefore the study is considered to be open label, but single blinded for the primary outcome analysis.|Single blinded (for outcome), open label, prospective, randomized, controlled, parallel-group designed interventional study|f|f|f|t
33827667|NCT02868333|||COHORT||PROSPECTIVE|||||||
33827668|NCT04052997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827669|NCT05851456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827670|NCT01993745|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33827671|NCT04599907|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33827672|NCT04588519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827673|NCT05527743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827674|NCT05004311|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827675|NCT05063123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827676|NCT04817930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827677|NCT05819047|||COHORT||CROSS_SECTIONAL|||||||
33827678|NCT01272323|||COHORT||PROSPECTIVE|||||||
33827679|NCT00546078|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827680|NCT01042847|||CASE_ONLY||PROSPECTIVE|||||||
33827681|NCT04715503|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827682|NCT03190629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827683|NCT01905852|||||PROSPECTIVE|||||||
33827684|NCT02638233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827685|NCT03823274|||COHORT||PROSPECTIVE|||||||
33827686|NCT02352077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827687|NCT04771962|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33827688|NCT05707715|||COHORT||PROSPECTIVE|||||||
33827689|NCT04254562|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827690|NCT05846308|RANDOMIZED|PARALLEL||TREATMENT||NONE||Each participant will be randomized into one of two groups.||||
33827691|NCT06158828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will enroll both transplant recipients and their haploidentical donors.||||
33827692|NCT06423677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827693|NCT02629419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149481|NCT02744989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827694|NCT04970381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827695|NCT04176783|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33827696|NCT02740205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33827697|NCT04826419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomised-controlled trial|t|f|f|t
33827698|NCT05524506|||COHORT||PROSPECTIVE|||||||
33827699|NCT03794817|||COHORT||PROSPECTIVE|||||||
33827700|NCT05124002|NA|SINGLE_GROUP||TREATMENT||NONE||HAIC (FOLFOX) + H101||||
33827701|NCT05216393|RANDOMIZED|PARALLEL||PREVENTION||NONE||two groups, repeated measures, pre and post intervention measures||||
33827702|NCT06488885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This research was conducted at a foundation university's nursing school. The elderly care training given to students regarding ageism a randomized controlled study was conducted to determine the effect of It was designed as.|f|f|t|f
33827703|NCT01991925|||OTHER||PROSPECTIVE|||||||
33827704|NCT00536081|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827705|NCT00574483|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827706|NCT01748123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827707|NCT04520074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827708|NCT01476124|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827709|NCT05557149|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837491|NCT03435731|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837492|NCT06056778|||OTHER||PROSPECTIVE|||||||
33837493|NCT01546246|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34134782|NCT03388866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Subjects will be randomly divided into blocks of random size 4 or 6 and stratified according to age (less than 12 years and greater / equal 12 years) and severity (SCORAD less than 50 and greater / equal 50)\*\*, performed through the RedCap platform, available at FMRPUSP. This process will be performed by laboratory staff who will provide the extracts and the researchers will not have access to the lists of patients in each group. As for blinding, the bottles with extract and placebo will be provided by the already coded laboratory, and the team will only be responsible for the delivery and storage of the same.~\*\* Initial SCORAD was not part of the stratification because it was part of the primary outcome variable."|"A total of 94 patients, 3 years of age or older, with clinical diagnosis of AD, without distinction of gender, ethnicity or social group, will be selected at HCFMRP-USP Allergy and Dermatology outpatient clinics. These patients will undergo clinical evaluation and laboratory tests, including blood count, total IgE, inhalant panel specific IgE, and / or immediate hypersensitivity skin tests, and mite allergen specific IgG4 (Der p 1 and Der p 2), before of the study.~Patients in the treatment group will undergo sublingual allergen-specific immunotherapy with weekly and weekly doses of extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae mites (60% and 40% respectively), according to the predetermined schedule. Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin)."|t|t|t|f
34134783|NCT01357161|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134784|NCT04607512|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|telaglenastat, placebo|double-blind (with respect to telaglenastat and placebo), placebo- and positive controlled, 3 way crossover|t|t|t|t
34134785|NCT04810741|||COHORT||RETROSPECTIVE|||||||
34134786|NCT00578877|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134787|NCT01440218|||COHORT||PROSPECTIVE|||||||
34134788|NCT01490008|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134789|NCT03631004|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33827710|NCT03834155|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants will be randomized to hospital-based cardiovascular rehabilitation (CR), or choice of hospital-based or home-based CR. All participants will also have access to the the application. Participants will be randomized to either application only or application + NUDGE messaging.||t|f|f|f
34134790|NCT01040091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134791|NCT03660202|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134792|NCT01748708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134793|NCT04867512|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label Prospective Study||||
34134794|NCT00296465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134795|NCT00842153|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134796|NCT02191657|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34134797|NCT06658262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134798|NCT04750226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134799|NCT06660979|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33827711|NCT05192564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||DESIGN: Controlled, randomized, prospective, single-blind (staff of the otorhinolaryngology department) intervention study carried out in a cohort of patients (over 18 yr old) with a diagnosis of bilateral or unilateral vestibular hypofunction divided into two groups: intervention group with exercise + conventional rehabilitation treatment (EX group) and a group without intervention that will receive only conventional rehabilitation treatment (attention control group, AC).|f|f|t|f
33827712|NCT04387903|||CASE_CONTROL||RETROSPECTIVE|||||||
33827713|NCT03019198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33827714|NCT03836742|||CASE_ONLY||PROSPECTIVE|||||||
33827715|NCT03836170|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827716|NCT05514197|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33827717|NCT02762292|NA|SINGLE_GROUP||OTHER||NONE||||||
33827718|NCT06480578|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827719|NCT05964751|||CASE_CONTROL||RETROSPECTIVE|||||||
33827720|NCT05338541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827721|NCT03644615|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33827722|NCT05377645|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33827723|NCT02483598|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33827724|NCT05998226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will conduct a multi-center, two-arm, randomized controlled trial to evaluate a virtual antibiotic stewardship team (VAT) compared to standard care in Dutch NHs. After assessment of eligibility, the participants (clinicians) in the study are randomized (1:1) to the standard of care arm or to the intervention arm (weekly VAT meeting for 9 months). Randomization will be done stratified on the basis of function (group 1. elderly care physicians, group 2. physicians in training to become a specialist/ other physicians, group 3. nurse practitioners/ physician assistants).||||
33827725|NCT05676125|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33827726|NCT04693845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors were blind to treatment condition|Randomized Controlled Trial|f|f|f|t
33827727|NCT05426447|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||A pair-matched group, parallel design within each sex||||
33827728|NCT06277518|||OTHER||RETROSPECTIVE|||||||
33827729|NCT06350708|NA|SINGLE_GROUP||OTHER||NONE||||||
33827730|NCT03583411|||CASE_ONLY||RETROSPECTIVE|||||||
33827731|NCT00878319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827732|NCT00513058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827733|NCT00511797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827734|NCT01412632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827735|NCT04461184|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827736|NCT01065207|NA|SINGLE_GROUP||||NONE||||||
33827737|NCT05314426|||COHORT||OTHER|||||||
33827738|NCT02160470|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33827739|NCT03820570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827740|NCT04621422|||CASE_ONLY||RETROSPECTIVE|||||||
33827741|NCT00740597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837494|NCT03591133|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33837495|NCT01028677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33837496|NCT02292147|||COHORT||PROSPECTIVE|||||||
34134800|NCT03465397|RANDOMIZED|PARALLEL||PREVENTION||NONE||Multicenter open clinical trial, randomized, stratified by age, parallel groups||||
34134801|NCT00416065|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34134802|NCT03811392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34134803|NCT00562263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134804|NCT04442243|||OTHER||PROSPECTIVE|||||||
34134805|NCT05984758|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34134806|NCT04327362|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Customized software involving use of a coding scheme will be used to allow complete blinding to whether active or sham tDCS is administered. The participants, tDCS administrators, therapists, and outcome assessors will remain blind to tDCS condition. The integrity of blinding procedures will be evaluated by self-report questionnaires administered at each treatment visit.|Participants will be randomly assigned following stratification by baseline severity of PTSD symptoms, medication status, and sex to one of five clusters defined by the point of cross-over from sham to active tDCS administered just prior to PE therapy sessions, with the earliest cross-over occurring at session 4, and the latest at session 8.|t|t|t|t
34134807|NCT00234663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134808|NCT00313313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134809|NCT03828903|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134810|NCT02815657|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134811|NCT04294615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134812|NCT03549572|||CASE_ONLY||PROSPECTIVE|||||||
34134813|NCT04644471|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134814|NCT01081704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134815|NCT01794312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134816|NCT06388096|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34134817|NCT05984654|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34134818|NCT06538077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind placebo-controlled multicentric randomized controlled trial|In addition to the BCAA vs Rifaximin, both groups will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day.|t|t|t|t
34134819|NCT04736212|||COHORT||PROSPECTIVE|||||||
34134820|NCT02428751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134821|NCT01780246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134822|NCT04123093|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study has two interventions: (1) Noxsano Bandage (Healthy Volunteers) and (2) Noxsano Bandage (Wound Care). Each intervention is associated with a separate group of participants.||||
34134823|NCT03489655|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34134824|NCT02249390|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34134825|NCT01093378|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134826|NCT04331340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34134827|NCT03220464|NA|SINGLE_GROUP||SCREENING||NONE||||||
34134828|NCT02050347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134829|NCT04676087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134830|NCT06661720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134831|NCT00614445|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34134832|NCT06658769|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blind Randomized Clinical Trial, both participants and outcomes assessors will be blinded to active or sham stimulation.|After patients are recruited according to the eligibility criteria during the medical screening at the first preoperative outpatient clinic visit or through active search on the waiting list, agree to participate in the protocol, fill out the safety questionnaire for the use of TMS and the transcranial electrostimulation application form, they will be randomized and allocated into two intervention groups different from the surgical group, based on a random table generated by the website www.randomization.com . The person responsible for the randomization stage will not have any other participation in the study. The group allocation will be confidential and the information regarding the patient group will be placed in opaque and numbered envelopes. Each envelope will be opened on the first day of the neuropsychological evaluation. Group 3, non-surgical control with cognitive impairment, will be automatically directed to active stimulation.|t|f|f|t
34134833|NCT02414607|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134834|NCT04781855|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134835|NCT02390440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149482|NCT03480009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized Controlled Trial|t|t|t|t
34149483|NCT00647114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149484|NCT01284972|||CASE_ONLY|||||||||
34149485|NCT06507514|NA|SEQUENTIAL||TREATMENT||NONE||||||
34149486|NCT04106102|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149487|NCT05701449|||COHORT||OTHER|||||||
34149488|NCT02644382|||OTHER||OTHER|||||||
33827742|NCT05140707|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|There wasn't a masking in the study.|The study was of a randomized controlled design. There were two groups in the study; intervention and control. For the intervention group, the virtual reality distraction method was administered to the patients during the port catheter implantation in the intervention group while it wasn't administered to the patients in the control group.|t|f|f|f
33827743|NCT00601133|||CASE_ONLY||PROSPECTIVE|||||||
33827744|NCT02145897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827745|NCT02125318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827746|NCT02878421|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33827747|NCT04132193|||COHORT||RETROSPECTIVE|||||||
33827748|NCT03322241|||OTHER||OTHER|||||||
33827749|NCT06176898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827750|NCT06471907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827751|NCT06086119|||COHORT||PROSPECTIVE|||||||
33827752|NCT00449332|||COHORT||PROSPECTIVE|||||||
33827753|NCT00177684|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33827754|NCT01525641|||CASE_ONLY||PROSPECTIVE|||||||
33827755|NCT06504212|||OTHER||CROSS_SECTIONAL|||||||
33837497|NCT04831879|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Randomized sham-controlled cross-over trial|t|f|t|t
33837498|NCT00305838||||DIAGNOSTIC||NONE||||||
33837499|NCT01578213|NA|SINGLE_GROUP||OTHER||NONE||||||
34134836|NCT05149651|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The included teeth were assigned randomly into two groups (Totalfill or MTA) using randomized sequences generated by the computer using Random Integer Generator (RANDOM.ORG, Randomness and Integrity Services Ltd.). The allocation ratio to the groups was set to be equal.~To ensure double blinding at both patients and evaluators level during treatment, the type of material was concealed from the patient, and the patient had no information which material was used. In addition, the type of material was not mentioned in the patient file. Instead, it was replaced by a 4 digit code. The operators were also blinded for the type of material during the whole procedure starting from tooth preparation till the hemostasis was achieved and then were only informed at the time of material placement."|An experimental prospective double-blind, randomized clinical trial (RCT) with parallel design.|t|f|f|t
34134837|NCT04858815|NA|SINGLE_GROUP||TREATMENT||NONE||single arm longitudinal trial||||
34134838|NCT01296711|NA|SINGLE_GROUP||TREATMENT||NONE||RA0057 is a single arm study, however, analyses will also be performed according to the original treatment arms of the parent study RA0056 (NCT01242488).||||
34134839|NCT04876066|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be an open-label study of eligible male and female patients and minorities diagnosed with post stroke depression (PSD) conducted by West Virginia University faculty and research associates.||||
34134840|NCT02856945|||COHORT||PROSPECTIVE|||||||
34134841|NCT02600416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134842|NCT02526563|||COHORT||PROSPECTIVE|||||||
34134843|NCT02305017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134844|NCT05416489|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, controlled.||||
34134845|NCT00823433|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34134846|NCT04031664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Investigator)||t|f|t|f
34134847|NCT02930382||PARALLEL||DIAGNOSTIC||NONE||||||
34134848|NCT03629665|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34134849|NCT00669825|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34134850|NCT04150146|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34134851|NCT06323941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134852|NCT05317143|||OTHER||PROSPECTIVE|||||||
34134853|NCT02604368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34134854|NCT02265536|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827756|NCT03142828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blindness performed for patients and for statistical analysis|After the first week, the healling abutment will be randomly distributed in a test group with application of chlorhexidine gel or a control group without the application of the chlorhexidine gel.|t|f|f|t
34134855|NCT05699551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134856|NCT02234713|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34134857|NCT06260631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|random generator|high-intensity laser acupuncture and exercise therapy program|t|f|f|t
34134858|NCT05301257|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly allocated to either control or intervention group. Participants in the control group will receive the same treatment once the intervention group is finished with the treatment.||||
34134859|NCT05586503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134860|NCT03467893|||COHORT||PROSPECTIVE|||||||
34134861|NCT06520462|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134862|NCT00716482|||CASE_ONLY||CROSS_SECTIONAL|||||||
34134863|NCT04880746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134864|NCT00670618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134865|NCT00153140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134866|NCT06501547|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34134867|NCT05594498|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||"All patients will receive the StrataXRT intervention. StrataXRT will be given to patients in one of five patient populations:~1. Patients with large breasts (minimum of band size of 36 inches or cup size C) treated in the prone position-breast radiation only~2. Patients with large breasts (minimum of band size of 36 inches or cup size C) treated in the supine position---breast radiation only~3. Patients with locoregional breast radiation (any breast size)~4. Patients with local chest wall radiation alone~5. Patients with locoregional chest wall radiation"||||
34134868|NCT04897230|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34134869|NCT04730635|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single-blind (placebo run-in) followed by double-blind||t|t|t|f
34134870|NCT05460052|||COHORT||PROSPECTIVE|||||||
34134871|NCT03831295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134872|NCT06525077|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|For the double-blind, randomized withdrawal portion of the study, the subject and all members of the study team will remain blinded to treatment assignment.||t|t|t|t
34134873|NCT01420692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134874|NCT01731158|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134875|NCT06435403|||COHORT||PROSPECTIVE|||||||
34134876|NCT05033886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134877|NCT00040781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134878|NCT05790798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134879|NCT00707603|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34134880|NCT04098211|||CASE_ONLY||PROSPECTIVE|||||||
34134881|NCT02895672|||COHORT||RETROSPECTIVE|||||||
33827757|NCT03722836|||OTHER||PROSPECTIVE|||||||
33827758|NCT00865813|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837500|NCT05173337|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33837501|NCT01467310|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34134882|NCT04826107|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34134883|NCT02520869|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34134884|NCT03523416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837502|NCT05707247|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34134885|NCT04473157|||CASE_ONLY||PROSPECTIVE|||||||
34134886|NCT04875377|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Masking of pizzas was achieved by the use of pizzas with identical appearance and taste.~Iodine and control supplements were also identical in appearance. Both pizzas and supplements were provided to investigators already masked. Pizzas labelled X and Y. Supplements labelled A and B"|Randomized, double-blind, placebo-controlled trial|t|f|t|f
34134887|NCT03181061|||OTHER||OTHER|||||||
34134888|NCT03081819||SEQUENTIAL||OTHER||NONE||||||
34134889|NCT05126992|||COHORT||RETROSPECTIVE|||||||
34134890|NCT05045482|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Saroglitazar Magnesium at 1 mg and 2 mg single and once a daily multiple dose administration.||||
34134891|NCT06625606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134892|NCT04933045|||COHORT||PROSPECTIVE|||||||
34134893|NCT01669252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134894|NCT02808546|||CASE_CONTROL||RETROSPECTIVE|||||||
34134895|NCT01404403|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134896|NCT02926027|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134897|NCT00192660|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134898|NCT01253148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134899|NCT06462365|NA|SEQUENTIAL||PREVENTION||NONE||||||
34134900|NCT05712785|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134901|NCT05978440|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34134902|NCT03947281|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Both the investigator and the participant will be aware of the group assignment. The persons handling the data and statistics will not be aware of the group assignment.|The study will be a randomized, parallel design that includes an almond snack group and a cereal-based snack group. The intervention will be for 28 days. The almond intervention will be roasted almonds 56 grams/day. The cereal-based snack intervention will be the caloric equivalent.|f|f|f|t
34134903|NCT06416358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134904|NCT06382103|||OTHER||PROSPECTIVE|||||||
34134905|NCT06658327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134906|NCT00491270|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34134907|NCT04104191|NA|SINGLE_GROUP||SCREENING||NONE||||||
34134908|NCT05847660|RANDOMIZED|PARALLEL||TREATMENT||NONE||this is a randomized controlled non-blinded study. it will include 210 pt all of them PCO pt with infertility||||
34134909|NCT02315248|||COHORT||PROSPECTIVE|||||||
34134910|NCT06563466|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators, outcome assessor and statistician will be blinded. Because of the nature of this study, it will not be possible to blind the participant or therapists providing the intervention.|We have planned a single blinded randomized controlled trial (RCT) pilot study. The group of participating patients and their participating relatives will be randomized into treatment as usual (TAU) or to receive the additional PEGASUS intervention, and we will be comparing the two groups. The randomization will be made 1:1 and created in the randomization module in REDCap with a block-size unknown to the assessors. Since we are conducting a pilot study, sample size is small, and we won't be able to create a stratified randomization.|f|f|t|t
34134911|NCT06592014|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134912|NCT03424993|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34134913|NCT06285201|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34134914|NCT06576674|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|participant will be blinded to the session order in which they receive either the dietary supplements (fiber and green tea) or a placebo.|within-subjects placebo-controlled design|t|f|f|f
34134915|NCT05555641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134916|NCT00426400|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134917|NCT01200407|||OTHER||PROSPECTIVE|||||||
34134918|NCT01566149|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134919|NCT03184493|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134920|NCT02542033|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34134921|NCT00024024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134922|NCT05308017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||randomized to one of two different types of scopes.|t|f|f|f
34134923|NCT00524355|||||PROSPECTIVE|||||||
34134924|NCT02720380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34134925|NCT04901949|||COHORT||RETROSPECTIVE|||||||
34134926|NCT00313144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134927|NCT03016624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134928|NCT01331837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134929|NCT01355679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837503|NCT04053062|NA|SEQUENTIAL||TREATMENT||NONE||3 x 10\^6/ KgBW; 6 x 10\^6/ KgBW||||
34134930|NCT03563742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134931|NCT06661005|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The patient will be consented for the study at their office visit when the decision is made to schedule them for a procedure meeting inclusion criteria for our study. After the patient is consented, they will be randomized to either nitrous oxide or IV sedation. Depending on their randomization group, they will be scheduled on a Nitrous Day or an IV Sedation Day."||||
34134932|NCT02978157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134933|NCT06163950|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34134934|NCT04187508|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be randomized and double blinded, ie, subjects, Investigators, and other study site personnel must be kept blinded to avoid bias, although due to the differences between the AZD8154 and placebo treatments unblinded pharmacy/site staff will be required for dose preparation and administration.||t|f|t|f
34134935|NCT02781129|NA|SINGLE_GROUP||OTHER||NONE||||||
34134936|NCT01205932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34134937|NCT00519324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134938|NCT02924246|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34134939|NCT05015855|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134940|NCT06151041|||COHORT||PROSPECTIVE|||||||
34134941|NCT05098574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34134942|NCT00110786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34134943|NCT02815605|||COHORT||RETROSPECTIVE|||||||
34134944|NCT04819893|||CASE_CONTROL||PROSPECTIVE|||||||
34134945|NCT02161094|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34149489|NCT06282601|NA|SINGLE_GROUP||OTHER||NONE||||||
34149490|NCT04947540|||COHORT||PROSPECTIVE|||||||
34134946|NCT06292637|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized stepped wedge design (R-SWD), a type of cluster randomized controlled trial, will be used to randomize a cluster (church groups with a group of 10 participants), not individual subjects.~At the start of a R-SWD, all clusters begin as control groups. At certain time points during the course of the trial, some of the clusters are randomly selected to be switched to the CB-FAITH treatment, with all clusters eventually crossing over to receive the treatment. The sample will be comprised of 12 groups, each with 10 individuals (N=120)."||||
34134947|NCT03172078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34134948|NCT04291690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will be blinded to the allocated group of the patients, and they will not be the same team members that delivered the intervention.|Single-center randomized clinical trial with parallel group design at the Jewish General Hospital (JGH); an academic tertiary care center in Montreal, Quebec, Canada.|f|f|f|t
34134949|NCT04818502|||COHORT||PROSPECTIVE|||||||
34134950|NCT06608524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|In this experiment, the experimental group will use self-regulated learning strategy, and the control group will use standard learning method. Each parallel group has 40 physical education stuednts.|t|f|f|f
34134951|NCT03139643|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34134952|NCT01207076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134953|NCT02719964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34134954|NCT00000293||||TREATMENT||DOUBLE||||||
34134955|NCT06659770|||COHORT||PROSPECTIVE|||||||
34134956|NCT05787587|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential||||
34134957|NCT05666999|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The subjects will be randomized by using a sealed envelope system.||t|f|t|t
34134958|NCT05343689|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134959|NCT01833910|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34134960|NCT03154242|||OTHER||PROSPECTIVE|||||||
34134961|NCT03561389|||COHORT||PROSPECTIVE|||||||
34134962|NCT03309319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134963|NCT04218214|||COHORT||PROSPECTIVE|||||||
34134964|NCT02482662|||COHORT||PROSPECTIVE|||||||
34134965|NCT05625789|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34134966|NCT05934994|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||People with indeterminate solitary bone lesions on conventional imaging, for whom a biopsy or surgery is scheduled||||
34134967|NCT03223922|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will be treated to a total dose of 30 Gy with a once daily fractionation schedule of 3 Gy per fraction, administered five days per week.||||
34134968|NCT02117960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134969|NCT05769855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HR18034 compared with active comparator and placebo|t|t|t|t
34134970|NCT02095873|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34134971|NCT04651439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a single blind patient trial. The outcomes assessor of the primary endpoint outcome, the adjudication committee and the statistician, will also be blinded to the allocated treatment.||t|f|f|t
34134972|NCT06497062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134973|NCT02806219|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34134974|NCT05992844|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RANDOMIZED CONTROLLED|t|f|f|f
34134975|NCT06090539|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34134976|NCT03886870|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Single blind masking|"The study was designed as a randomized controlled study with an exploring prospective design. The intervention lasted 12 months and each patient had three visits (baseline, 6 and 12 month) at Muritunet, each lasting 4-2-2 weeks. The participants was randomized either into a lifestyle and work intervention or into a lifestyle intervention.~Data material gathered at each stay consisting of self-reported forms, test, journal and individual interviews. These were all collected at baseline, and at six and twelve months."|t|f|f|f
34134977|NCT06659055|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34134978|NCT04060888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34134979|NCT05355259|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective monocenter, non-randomized, open clinical investigation to evaluate the safety and technical success of the Basecamp Vascular controllable directional GECKO guidewire when used to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.||||
34134980|NCT02358161|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134981|NCT04005508|||COHORT||PROSPECTIVE|||||||
34134982|NCT05662280|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34134983|NCT04029168|||COHORT||PROSPECTIVE|||||||
34134984|NCT03526393|NA|SINGLE_GROUP||OTHER||NONE||||||
34134985|NCT04999384|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34134986|NCT04657705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134987|NCT01722526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134988|NCT02696057|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34134989|NCT00271856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34134990|NCT01764477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34134991|NCT03982719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134992|NCT02965742|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34134993|NCT04585269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This is a two-arm parallel randomized controlled trial (RCT) of the intervention versus enhanced usual psychosocial care.||||
34134994|NCT06080464|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34134995|NCT00602004|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34134996|NCT05795569|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention Group: Nasogastric tube removal upon extubation with protocolized PED screening Control Group: Conventional nasogastric tube management and PED screening strategy.||||
34134997|NCT02131103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34134998|NCT02688699|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34134999|NCT00868140|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34135000|NCT00651430|||COHORT||PROSPECTIVE|||||||
34135001|NCT02901587|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135002|NCT00876850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135003|NCT01390831|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135004|NCT05826613|||CASE_ONLY||PROSPECTIVE|||||||
34135005|NCT03155087|||CASE_CONTROL||RETROSPECTIVE|||||||
34135006|NCT05172245|NA|SEQUENTIAL||TREATMENT||NONE||||||
34135007|NCT02664311|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34135008|NCT05446766|NA|SINGLE_GROUP||TREATMENT||NONE|Psychological intervention, patient-reported outcomes.|||||
34135009|NCT01889264|||COHORT||PROSPECTIVE|||||||
34135010|NCT04621240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135011|NCT05580367|||COHORT||PROSPECTIVE|||||||
34135012|NCT01397110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135013|NCT04956276|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Cohorts 1 and 2 will be participant and investigator blinded, Cohort 3 will be open label (if initiated).||t|f|t|f
34135014|NCT06626321|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||We will randomize clinics 2:1 to the nudge arm or control arm using covariate-constrained randomization. Within the high-risk patient subgroups, stratifying by intervention clinics, patients will be randomized 1:1 in Way to Health using permuted block randomization using random block sizes of 2, 4, and 6 to receive the additional intensification bidirectional text messaging nudge or standard messaging.|f|f|t|t
34135015|NCT05805696|NA|SINGLE_GROUP||TREATMENT||NONE|The participants will get a code to use for all questionnaires. The questionnaires and the intervention messages will be handled by a person that will not be involved in the answers. The questionnaires will be answered on-line with a code and handled by a person not former involved and thus completely unaware of which patients are attending.|All patients will get the same questionnaires and the same intervention||||
34135016|NCT06557057|||COHORT||PROSPECTIVE|||||||
34135017|NCT00840268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135018|NCT02986672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135019|NCT05329480|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135020|NCT03987802|||COHORT||PROSPECTIVE|||||||
34135021|NCT02339142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34135022|NCT06127381|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135023|NCT05175222|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135024|NCT04564807|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34135025|NCT01608698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135026|NCT01202019|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135027|NCT04153175|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135028|NCT03428477|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135029|NCT02650154|||CASE_CONTROL||PROSPECTIVE|||||||
34135030|NCT02865954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34135031|NCT02975739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135032|NCT02582814|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
34135033|NCT04821102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135034|NCT05588960|||COHORT||PROSPECTIVE|||||||
34135035|NCT02217059|||COHORT||PROSPECTIVE|||||||
34135036|NCT04019288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135037|NCT05359874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135038|NCT06100848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34135039|NCT01905345|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34135040|NCT00857831|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135041|NCT06658093|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Blinding will only occur in Aim 2 (Sub-study 3). Randomization will be done by the research pharmacy providing the investigational drug.|"A single site open label adaptive clinical trial (Aim 1:Sub-study 2) followed by a placebo-controlled blinded clinical trial (Aim 2) to optimize the use of mTOR inhibitors in older persons a functions of drug, dose, dosing schedule and sex. It will be carried out in 2 sub-studies:~Aim 1:~-Sub-study 2: Comparison of 2 mTOR inhibitors in an adaptive open-label dose finding pharmacokinetic/pharmacodynamic study~Aim 2:~Sub-study 3: Assess the safety/tolerability/adverse events of optimized dose of mTOR inhibitors in daily vs intermittent dosing"|t|t|f|f
34135042|NCT02543866|NA|SINGLE_GROUP||OTHER||NONE||||||
34135043|NCT06221358|||CASE_ONLY||PROSPECTIVE|||||||
34135044|NCT04715204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135045|NCT00349011|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34135046|NCT03826654|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135047|NCT00767663|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135048|NCT04187794|||OTHER||PROSPECTIVE|||||||
34135049|NCT05556057|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34135050|NCT01961856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135051|NCT01239628|||COHORT||PROSPECTIVE|||||||
34135052|NCT05558592|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135053|NCT06661538|||OTHER||PROSPECTIVE|||||||
34135054|NCT05910372|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34135055|NCT05504291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135056|NCT05933356|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Experimental group, in addition to scheduled activities, will be provided with the individual brain training exergames (a program for improving cognitive function and eye-hand coordination) three times a week and 30 minutes each time. The control group will be maintained with their scheduled activities in daycare as usual."||||
34135057|NCT03241680|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135058|NCT05872386|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will conduct a 12-week pilot 2-arm randomized controlled trial (RCT) (n=40-60). Research staff will recruit library patrons and randomize them to weekly telehealth at the library or in-person clinic control arms across two participating libraries in San Diego.||||
34135059|NCT02756962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135060|NCT02601235|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135061|NCT05721352|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-group pre-post intervention design||||
34135062|NCT02346643|||COHORT||PROSPECTIVE|||||||
34135063|NCT05105581|||CASE_CONTROL||PROSPECTIVE|||||||
34135064|NCT01928550|||CASE_ONLY||PROSPECTIVE|||||||
34135065|NCT01179217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135066|NCT05970003|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34135067|NCT01532284|RANDOMIZED|SINGLE_GROUP||SCREENING||TRIPLE|||t|t|f|t
34135068|NCT03492957|NA|SINGLE_GROUP||TREATMENT||NONE|Blinding: outcomes are assessed by independent assessors, otherwise not involved in the study.|Participants can select either individual treatment at home, or group treatment in a community setting, but the intervention content and dose are the same.||||
34135069|NCT04113733|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34135070|NCT04981639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135071|NCT02800694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135072|NCT01323088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135073|NCT06658730|||COHORT||PROSPECTIVE|||||||
33827759|NCT04882748|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Oswestry disability index (ODI) will be performed by an independent physician blind to the treatment.|Forty-four patients suffering from NSLBP will be recruited after signing the informed consent and randomly assigned to one of two experimental arms: physical therapy with or without the help of a robot for 10 sessions. Pain evaluation will be performed with the Oswestry disability index (ODI), which will be applied before starting and at the end of the treatment, and the visual analogue scale (VAS) which will be applied after each session. The ODI will be performed by an independent physician blind to the treatment. Statistical analysis will be performed to compare both treatments.|f|f|f|t
34135074|NCT06661902|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34135075|NCT00235235|||||PROSPECTIVE|||||||
34135076|NCT05749510|||COHORT||PROSPECTIVE|||||||
34135077|NCT00566982|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135078|NCT02136758|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135079|NCT04380194|||CASE_CONTROL||RETROSPECTIVE|||||||
34135080|NCT05432596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Randomized, Double-blind, Vehicle-controlled, Parallel-group Study|t|t|t|t
34135081|NCT01964157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135082|NCT03441867|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|The neuroimaging analysis will be masked.|||||
33827760|NCT00721981|||CASE_ONLY||PROSPECTIVE|||||||
33827761|NCT06257641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Experimental, randomised, controlled, open-label, single-blind (outcome assessor) study.|f|f|f|t
33827762|NCT04367363|||COHORT||PROSPECTIVE|||||||
33827763|NCT03772041|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827764|NCT00945451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827765|NCT02428816|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33827766|NCT00304668|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33827767|NCT02060513|||CASE_CONTROL||PROSPECTIVE|||||||
33827768|NCT00429442|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33827769|NCT02207036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827770|NCT05546736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33827771|NCT00392535|RANDOMIZED|PARALLEL||TREATMENT||||||||
33827772|NCT05624489|NA|SINGLE_GROUP||PREVENTION||NONE||Each participant-time point (which will occur twice daily, in the morning and the evening) will be randomized between a prompt containing an engagement strategy vs. no prompt.||||
33827773|NCT01260207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827774|NCT01540812|||CASE_ONLY||PROSPECTIVE|||||||
33827775|NCT04723732|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33827776|NCT00488319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827777|NCT00953212|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33827778|NCT02628964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33827779|NCT01647399|||COHORT||PROSPECTIVE|||||||
33827780|NCT02143310|NA|SINGLE_GROUP||OTHER||NONE||||||
33827781|NCT04700566|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, prospective, interventional clinical trial||||
33827782|NCT05465928|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33827783|NCT00941109|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827784|NCT05904756|||CASE_CROSSOVER||PROSPECTIVE|||||||
33827785|NCT01334762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827786|NCT05566509|||COHORT||CROSS_SECTIONAL|||||||
33827787|NCT01657643|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33827788|NCT00953862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827789|NCT04058236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomized concealed assignment into 2 groups in opaque envelopes will be opened by care provider. Anaesthetic and ICU notes must not be revealed to outcome assessor.|Randomized control trial with Albumin 5% given as the intervention and Gelofusine as active control.|t|f|f|t
33827790|NCT01989949|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827791|NCT00632931|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33837504|NCT01250925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33837505|NCT03453697|NA|SINGLE_GROUP||OTHER||NONE||||||
33837506|NCT02738645|||COHORT||OTHER|||||||
33837507|NCT06355804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837508|NCT04155203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837509|NCT03468062|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34135083|NCT00675623|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135084|NCT06658743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants are randomized to standard of care or shared medical appointments||||
34135085|NCT05030610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135086|NCT04182399|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|the PD will be randomized to 3 arms. Randomization was done by a research randomization, The copy of the randomization table of patients to the 3 groups was kept with 2 different personnel not working on the study.|"Eligible patients will be randomly assigned to one of three groups: placebo group , ZNS group 25 mg and ZNS group 50 mg (30 patients each).In ZNS 50 mg group, ZNS will be started with a dose of 25 mg daily for one week then increased to 50 mg once daily to minimize side effects. Randomization was done by a research randomization program (https://www.randomizer.org), The copy of the randomization table of patients to the 3 groups was kept with 2 different personnel not working on the study.~Amid to COVID19 and less access to patients in an advanced stage, a crossover design will be included SO patients in:~Placebo arm will be randomized to arm 25 mg or 50 mg with at least 1-month washout Arm 25 mg \& arm 50 mg will be shifted to placebo with at least 1 month washout"|t|f|t|t
34135087|NCT05414448|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34135088|NCT00000149|RANDOMIZED|||TREATMENT||||||||
34135089|NCT00002412||||TREATMENT||DOUBLE||||||
34135090|NCT01955369|||COHORT||PROSPECTIVE|||||||
34135091|NCT05995678|RANDOMIZED|PARALLEL||PREVENTION||NONE||Following T1 baseline assessment, participants will be randomized to STEP-Home-SP + Usual Care or Usual Care (UC) using randomly permuted block sizes stratified by presence or absence of SI.||||
34135092|NCT02420288|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34135093|NCT03201965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135094|NCT05980871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135095|NCT02632669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135096|NCT06086158|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The trial was open or unblinded, the nature of the intervention prevented it from being blinded from the participants. The investigator in charge of collecting the data and carrying out the statistical study was the blind evaluator.|Randomized Controlled Trial|f|f|t|f
34135097|NCT02948556|||CASE_CONTROL||PROSPECTIVE|||||||
34135098|NCT06153420|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135099|NCT00044837||||TREATMENT||||||||
34135100|NCT00177294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135101|NCT04418869|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34135102|NCT04343430|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135103|NCT01787396|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135104|NCT05051722|||COHORT||PROSPECTIVE|||||||
34135105|NCT03220932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135106|NCT01649674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135107|NCT06452641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135108|NCT00822419|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135109|NCT02789345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135110|NCT06277414|||CASE_ONLY||PROSPECTIVE|||||||
34135111|NCT00969592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34135112|NCT03667807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135113|NCT02487654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34135114|NCT01584791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135115|NCT03789136|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34135116|NCT06088953|NA|SINGLE_GROUP||SCREENING||NONE||||||
34135117|NCT03118856|||COHORT||PROSPECTIVE|||||||
34135118|NCT00149136|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34135119|NCT02724917|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135120|NCT00915161|||COHORT||PROSPECTIVE|||||||
34135121|NCT04008641|||COHORT||PROSPECTIVE|||||||
34135122|NCT04972682|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center prospective open-label single-arm clinical trial||||
34135123|NCT00167609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135124|NCT00979966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135125|NCT05024916|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34135126|NCT04190407|NA|SINGLE_GROUP||OTHER||NONE||Patients with American Society of Anesthesiologists physical status I or II; age between 2 months to 11 years; and scheduled for day case surgery||||
34135127|NCT00594763|||CASE_ONLY||CROSS_SECTIONAL|||||||
34135128|NCT03363087|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Biatrial automated scar mapping in patients undergoing ablation for atrial fibrillation. Confirmation of scar by pacing in all patients. Collection of impedance data during clinical ablation.||||
34135129|NCT00673348|||CASE_ONLY||PROSPECTIVE|||||||
34135130|NCT04234204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135131|NCT02189044|NA|SINGLE_GROUP||||NONE||||||
34135132|NCT05760131|||CASE_ONLY||PROSPECTIVE|||||||
34135133|NCT04240041|||COHORT||CROSS_SECTIONAL|||||||
34135134|NCT03445377|RANDOMIZED|CROSSOVER||OTHER||NONE|This is an open-label, multi-centre, randomised, crossover design study, involving a 2-week run-in period with blinded CGM, followed by two 8 weeks study periods during which subjects will monitor daily glucose levels either with real-time CGM or SMBG in random order.|This is an open-label, multi-centre, randomised, crossover design study, involving a 2-week run-in period with blinded CGM, followed by two 8 weeks study periods during which subjects will monitor daily glucose levels either with real-time CGM or SMBG in random order.||||
34135135|NCT03859440|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34135136|NCT04345029|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34135137|NCT02841683|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34135138|NCT05222620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135139|NCT02599207|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135140|NCT06662266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135141|NCT03393819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of the participants and care providers after the assignment of the intervention is not possible as the two solutions are distinct, and one creates a unique discolouration of the skin. Those performing the laboratory analysis and reporting the results of the bacterial culture of will be blind to which treatment the participant was assigned (i.e. the label will not identify which group the participant belongs to).||f|f|f|t
34135142|NCT03515733|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Participants will be randomly allocated to one of two groups (PF-04995264 or placebo) and receive their allocated study medication for 7 days.|t|t|t|t
34135143|NCT06607666|||COHORT||RETROSPECTIVE|||||||
34135144|NCT00021957|||||RETROSPECTIVE|||||||
34135145|NCT04308239|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A two-group, pretest-posttest parallel design was employed. Participants were first assigned to either the reactive balance training or control intervention using minimization. During the first week, participants completed a pre-intervention assessment involving exposure to a single laboratory-induced slip or trip based upon random assignment. During the second and third weeks, participants completed a total of four sessions of their assigned intervention (two sessions per week for two weeks). During the fourth week, participants completed a post-intervention assessment involving exposure to the other perturbation (slip or trip) that they did not experience during the pre-intervention assessment. This design was selected to evaluate gait and reactive balance prior to any training intervention, and to avoid any unintended training effects induced by exposing participants to the same perturbation more than once.||||
34135146|NCT03106441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135147|NCT00566410|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135148|NCT05011305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind Masking|180 subjects randomized in a 1:1:1 ratio to Saroglitazar 2 mg, Saroglitazar 4 mg or Placebo.|t|t|t|t
34135149|NCT02879643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135150|NCT03829462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135151|NCT04181593|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135152|NCT06661317|||COHORT||RETROSPECTIVE|||||||
34135153|NCT01175265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135154|NCT02243618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135155|NCT06087237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135156|NCT04096872|||CASE_ONLY||PROSPECTIVE|||||||
34135157|NCT04199975|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34135158|NCT01675297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135159|NCT01453205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135160|NCT02931513|||COHORT||PROSPECTIVE|||||||
34135161|NCT03762889|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||In this cohort study, 100 preoperative patients from Jackson Memorial Hospital would be randomly assigned based on age, gender, and type of anesthesia to three samples: anesthesia with Eyeprotx™ Goggles, anesthesia with eyelid tape, and anesthesia with ointment application. Analysis of samples will be based on length of procedure, length of preventative measure application, position during operation(supine or prone), and postoperative events. Patient discomfort or pain, eye dryness intensity would be rated on numerical rating scale. Qualitative analysis will include additional comments from patients and the anesthesiologist.||||
34135162|NCT05972421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135163|NCT02086487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135164|NCT03822455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomised to receive OligoG or placebo DPI. The investigational medicinal products will have identical appearance|Randomised, double blind, placebo controlled|t|t|t|t
34135165|NCT05031338|||COHORT||PROSPECTIVE|||||||
34135166|NCT02041637|||COHORT||PROSPECTIVE|||||||
34135167|NCT01667276|||||PROSPECTIVE|||||||
34135168|NCT04548934|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135169|NCT04565444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135170|NCT00491946|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135171|NCT01907308|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135172|NCT04723472|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135173|NCT04283214|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34135174|NCT06077955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Two groups: group A, a variant of the surgery with the stapled formation of a GJS, and group B, a variant with a hand-sewn formation of a GJS.|t|f|f|f
34135175|NCT01521871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135176|NCT06659913|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34135177|NCT00950391|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34135178|NCT02897037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135179|NCT04295681|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135180|NCT01631201|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135181|NCT04047108|||COHORT||PROSPECTIVE|||||||
34135182|NCT05686746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|participant and investigator and outcome assessor||t|t|t|t
34135183|NCT06532526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participants as well as the evaluators will be informed about the nature and objectives of the study; however, they will not be informed what desensitizing material they would receive.|The study will be a double blinded (Patient and evaluator) randomized clinical trial with a sample size of 51, 17 participants for each group (n=17).|t|f|f|t
34135184|NCT04566900|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind, randomized.|MCI subjects will be assigned to active intervention or placebo.|t|t|f|t
34135185|NCT03724383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigators involved in analyzing test results or treating patients are blinded to the participant's study group.|This is a parallel-group randomized controlled trial. Consecutive patients meeting eligibility criteria that are seen for routine cardiology follow-up will be invited to participate in this study. Patients who accept the possibility of diet counseling and exercise program will be randomized and stratified to 'control arm' versus 'intervention arm.' The final study results will be reported after completion of one-year follow up. We will also carry out a mid-study data analysis at six-months. Forty patients will be randomized to control arm and 40 patients randomized to the intervention arm. Intervention will include Phase 1, a six month program including three months of diet counseling combined with home exercise, followed by three months (starting at week 13) of an in-hospital, Cardiac rehabilitation exercise program. Phase 2 of the intervention will include six months of home-based maintenance exercise and diet (starting at week 25). The entire intervention period will be one year.|f|f|t|t
34135186|NCT04606706|RANDOMIZED|PARALLEL||OTHER||SINGLE||Quasi-experimental design|t|f|f|f
34135187|NCT01477710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135188|NCT05484934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135189|NCT00323960|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135190|NCT04186416|||COHORT||PROSPECTIVE|||||||
34135191|NCT01240798|||COHORT||RETROSPECTIVE|||||||
34135192|NCT06151613|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A single center prospective cohort intervention study with historical controls.||||
34135193|NCT01934712|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34135194|NCT06430580|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Double-blind|2x2 randomized double-blind within-subject crossover|t|f|t|t
34135195|NCT03650374|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135196|NCT00257582|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135197|NCT04200794|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Longitudinal cluster RCT (randomized controlled trial) with an intervention group and an active control group||||
34135198|NCT00789594|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135199|NCT05735184|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135200|NCT01329276|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34135201|NCT06128707|||OTHER||CROSS_SECTIONAL|||||||
34135202|NCT06661967|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||The participants are randomized into two groups. The first group receives lidocaine oral spray during preoxygenation while the latter will receive NSS spray as placebo.|t|t|t|f
34135203|NCT00338286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135204|NCT05664659|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Eligible patients will be randomised \& allocated into 2 groups (A) \& (B). Randomization will be done using computer generated list.~Allocation \& concealment will be done using sealed envelopes prepared according to computer generated list into ratio 1:1."||t|f|f|t
34135205|NCT02042586|||CASE_CONTROL||PROSPECTIVE|||||||
34135206|NCT06039176|||COHORT||PROSPECTIVE|||||||
34135207|NCT04238481|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135208|NCT01226641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135209|NCT06661785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135210|NCT06162078|||OTHER||PROSPECTIVE|||||||
34135211|NCT03692754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135212|NCT04339933|||COHORT||PROSPECTIVE|||||||
34135213|NCT02412891|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34135214|NCT02839720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135215|NCT04282096|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|double blind||f|f|t|f
34135216|NCT00206128|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135217|NCT01045148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135218|NCT00575276|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34135219|NCT02581046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135220|NCT03215992|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34135221|NCT06438016|RANDOMIZED|PARALLEL||PREVENTION||NONE||Treatment group will obtain stress management whilst the control will not. The control group will obtain stress management one month upon study completion||||
34135222|NCT01832129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135223|NCT06658288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants are blind|Randomized clinical trial|t|f|f|f
34135224|NCT03086291|NA|SINGLE_GROUP||TREATMENT||NONE||Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days||||
34135225|NCT05878886|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|All subjects at treatment group given mangrove sword bean food bar during 15 days to examine their weight and WAZ score at pre-post study.|"Treatment group consumed 50 g mangrove sword bean food bar each day during 15 days.~Control group consumed 50 g sword bean food bar each day during 15 days. Mothers of two groups received balanced nutrition education once at the first week of study.~The compliance of subject consumed food bar undertaken by home visit of field enumerators to subjects' house.~They collected three days food recalls and monitored the distribution and stocks of food bar at the subjects' house."|t|f|f|f
34135226|NCT00515658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135227|NCT00522418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135228|NCT01689025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135229|NCT01357538|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135230|NCT00703443|||FAMILY_BASED||RETROSPECTIVE|||||||
34135231|NCT06162559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135232|NCT04367311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135233|NCT00957944|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34135234|NCT00003434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135235|NCT03016377|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135236|NCT06660628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135237|NCT03116802|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135238|NCT01520701|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135239|NCT06495723|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135240|NCT05468190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135241|NCT06395675|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Each female participant will provide a 20-50 mL first-catch urine (FCU) sample, one (1) self-collected vaginal swab sample (SVS) and three (3) clinician-collected vaginal swabs (CVS). Each male participant will provide a 20-50 mL first-catch urine sample. Standard of care (SOC) samples should be collected first prior to clinical trial specimen collection If sites use urine as SOC, then SOC urine sample can be taken from the untreated sterile urine cup provided to collect first catch urine for this study. Samples will be collected, handled, stored, shipped, and tested according to the applicable package insert(s), as appropriate. The site will record the order of sample collection for each participant. The remaining urine will be aliquoted into applicable transport.~tubes for each comparator method (3 tubes) and one (1) retained urine sample (5mL)"||||
34135242|NCT05103670|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include patients in both arms of the RAMBO study. All participants will undergo a PET/CT scan at inclusion and at 3 months.||||
34135243|NCT02241213|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34135244|NCT00464373|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135245|NCT04624386|||CASE_CONTROL||PROSPECTIVE|||||||
34135246|NCT00594919|||||PROSPECTIVE|||||||
34135247|NCT06239220|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135248|NCT02003638|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34135249|NCT06658535|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Up to six subjects will be enrolled at each dose level||||
34135250|NCT03276026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34135251|NCT01208883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135252|NCT03136497|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135253|NCT00031408|||COHORT||PROSPECTIVE|||||||
34135254|NCT01853579|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135255|NCT03547739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135256|NCT00397761||||TREATMENT||NONE||||||
34135257|NCT01396824|||COHORT||PROSPECTIVE|||||||
34135258|NCT00694837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135259|NCT05892770|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patient will be followed for one botox cycle as is current standard of care, and another botox cycle with the proposed intervention of zinc supplementation. Each patient will serve as their own control group.||||
33827792|NCT05350124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"randomization into four groups, each group will include 40 patients. A. Group 1: Will receive vitamin C (200 mg) tablet and vitamin E (a-tocopherol) (400 mg) capsule every day for 12 weeks. B. Group 2: Will receive vitamin E (400 mg) capsule and placebo every day for 12 weeks.~C. Group 3: Will receive vitamin C (200 mg) tablet and placebo every day for 12 weeks. D. Group 4: Will receive two placebo every day for 12 weeks. Of note, the personal responsible for randomization will not be involved in the trial."|t|t|t|f
33827793|NCT00204516|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827794|NCT00761397|||COHORT||PROSPECTIVE|||||||
33827795|NCT00414583|||COHORT||PROSPECTIVE|||||||
33827796|NCT02825277|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33827797|NCT03632902|||OTHER||RETROSPECTIVE|||||||
33827798|NCT00121446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827799|NCT05155488|||CASE_ONLY||RETROSPECTIVE|||||||
33827800|NCT02151643|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827801|NCT06127940|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm phase I study||||
33827802|NCT04477941|||OTHER||OTHER|||||||
33827803|NCT05432700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||After reading the patient information sheet and accepting the informed consent, they will be registered on the Breastfeeding Study web platform and included in one of the groups (intervention/control) through a randomisation process. Women will be selected during the third trimester of pregnancy at the surgery and during the midwifery routine care in each health department. Women in the intervention group will be provided with information on how to download the free LactApp® app for iOS and Android.|t|t|f|f
33827804|NCT01619722|||COHORT||PROSPECTIVE|||||||
33827805|NCT03018847|||CASE_ONLY||OTHER|||||||
33827806|NCT03398421|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE|This will be an open-label study. Hence, there will be no masking.|Subjects will receive nemiralisib alone on Day 1 in Period 1 and itraconazole from Day 1 to Day 10 followed by nemiralisib on Day 5 in Period 2.||||
33827807|NCT04239950|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827808|NCT04266613|||COHORT||PROSPECTIVE|||||||
33827809|NCT05853692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The principal investigator will be encharged of generating the allocation sequence, of enrolling the participants and of assigning the interventions to the participants.~The coworkers who will evaluate the onset of OM and its severity will be blinded about the selected product."|The study will be conducted as a single-blind randomized clinical trial (RCT). The population will be divided into two groups, receiving respectively the medical device and a solution based on Sodium Bicarbonate (5 g/L)|f|f|f|t
33827810|NCT03972397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827811|NCT04244422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827812|NCT02353455|||COHORT||PROSPECTIVE|||||||
33827813|NCT01818427|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33827814|NCT05678010|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33827815|NCT04904237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827816|NCT02996318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827817|NCT03361618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Semen volume after treatment.||||
33827818|NCT04335747|||COHORT||PROSPECTIVE|||||||
33827819|NCT03796598|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||"Subjects will be divided into 4 groups via randomization~Group 1: Dual oral and rectal FMT, Group 2: Oral FMT and rectal placebo, Group 3: Oral placebo and rectal FMT and Group 4: Oral and rectal placebo"|t|t|t|t
33827820|NCT04675398|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||In a small, double-blinded trial, the investigators will compare the overall efficacy of closed-loop and open-loop paradigms in terms of behavioral performance improvements in validated motor skill learning tasks and measurements from wearable devices. During this chronic aDBS phase, aDBS and open-loop stimulation settings will be randomized for 30-day periods and motor skill and gait related measurements will be obtained from a combination of computerized motor tasks and wearable devices that track movement kinematics. Patients will participate in daily, if possible, motor learning and gait tasks at home with triggered stimulation settings and recordings. Data will be collected and reviewed from the wearable monitors, Summit RC+S, and home motor learning tasks remotely. Researchers will have weekly check-in sessions with patients by video conferencing or in-person meetings. At minimum, researchers will have in-person sessions with patients every 4 weeks during Phase 3.|t|f|f|t
33827821|NCT00496626|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33827822|NCT06236828|||COHORT||RETROSPECTIVE|||||||
33827823|NCT02684955|||COHORT||PROSPECTIVE|||||||
33827824|NCT04514692|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33827825|NCT02957162|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33827826|NCT00269997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827827|NCT03463577|||COHORT||RETROSPECTIVE|||||||
33827828|NCT00238498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33827829|NCT02672397|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33827830|NCT02110511|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33827831|NCT02999347|||COHORT||RETROSPECTIVE|||||||
33827832|NCT04700878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study is a single-blind randomized trial where eligible participants will informed about that they will be assigned to either of two different stress-management courses or to waitlist, but they are unaware of which particular conditions. The waitlist group (ten weeks waitlist and thereafter either compassion- or cognitive behavioural courses) will receive thorough information about the two different courses and thereafter rate how attractive they find each course. Then they get to choose which course they want to attend to.|"The sample size was determined based on an expected between group effect size (between ICOP and ICB) of Cohen's d = 0.4 for the primary outcome at the five-week follow-up for the primary analysis for participants with SCQ scores of 45 and higher. To reach 80% power, the study need 100 participants in each active arm. Expecting 20% attrition, the investigators will include 120 participants. Thirty participants are required in the waitlist group with an expected between-group effect between the ICOP group and the waitlist of d = 0.8. Including the expected attrition, 36 participants will be required. Given the 200 participants and a power of 80%, the non-inferiority analysis will provide a minimal clinically important difference of roughly d = 0.35.~Participants with SCQ scores below 45 will be included for secondary analyses, thus expect to include 480 participants (ICOP and ICB), with an additional 72 participants in the waitlist group, for a total of 552."|f|t|f|f
34135260|NCT02584530|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135261|NCT03735199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135262|NCT02527226|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135263|NCT00332020|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135264|NCT01126437|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135265|NCT01848977|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34135266|NCT03230890|NA|SINGLE_GROUP||TREATMENT||NONE||Single site, non-randomized, single arm, open label design,with collection of outcome measures before, and at intervals after the intervention||||
34135267|NCT06065657|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Three-way, open-labeled, crossover trial in which participants will undergo three alcohol tolerance tests, each following a 3-days dietary intervention: (1) control diet (\~ 50% kcal carbohydrates), (2) ketogenic diet (\~5-10% kcal carbohydrates), and (3) control diet with 3x daily administration of 10 g Ketone Supplement (KS) drink (30 g/day, Kenetik: ketone Drink, VitaNav Inc., Washington D.C.).||||
34135268|NCT02017392|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135269|NCT04666103|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135270|NCT06658834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135271|NCT05796921|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomized double-blind placebo-control|t|t|t|f
34135272|NCT06088394|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|random generator|pelvic floor exercises and acupuncture|t|f|f|f
34135273|NCT01519544|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135274|NCT01112774|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135275|NCT00362271|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34135276|NCT02414945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135277|NCT02321319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135278|NCT06263907|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The anesthesiologist, who will be responsible for opening the envelope and do the block or not according to the group besides, evaluation of its success and covering the skin over the site of ipsilateral stellate gangalion with sterile dressing in both groups, will not be involved in data collection.|Patients will be randomization into two equal groups using computer-generated random numbers prior to surgery of 70 each; Group S: will receive ipsilateral stellate gangalion block and Group C: will receive no block.|t|f|t|f
34135279|NCT01015495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135280|NCT00855933|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135281|NCT01529515|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135282|NCT01258465|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135283|NCT03568448|||COHORT||PROSPECTIVE|||||||
34135284|NCT00327015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135285|NCT00580034|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135286|NCT06271265|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135287|NCT05402163|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34135288|NCT05764005|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135289|NCT03226379|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Cohort study with a before and after design||||
34135290|NCT00745654|||COHORT||RETROSPECTIVE|||||||
34135291|NCT04663906|||OTHER||RETROSPECTIVE|||||||
34135292|NCT00367718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135293|NCT02125916|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34135294|NCT04955223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135295|NCT02503670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135296|NCT06341296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135297|NCT06026540|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135298|NCT04683549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."||||
34135299|NCT04534179|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A specialist physician will be diagnosed chronic nonspecific low back pain|f|f|f|t
34135300|NCT04344977|||CASE_ONLY||PROSPECTIVE|||||||
34135301|NCT06019039|||OTHER||PROSPECTIVE|||||||
34135302|NCT01236066|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34135303|NCT06607497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135304|NCT04135560|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34135305|NCT04300361|||COHORT||PROSPECTIVE|||||||
34135306|NCT06523218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135307|NCT05690399|||CASE_CONTROL||RETROSPECTIVE|||||||
34135308|NCT01940367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135309|NCT05248282|||COHORT||RETROSPECTIVE|||||||
34135310|NCT05528653|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34135311|NCT02483156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135312|NCT00274859||||TREATMENT||NONE||||||
34135313|NCT05436535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135314|NCT06064461|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34135315|NCT05623787|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135316|NCT01378702|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34135317|NCT02056886|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135318|NCT06380322|||COHORT||CROSS_SECTIONAL|||||||
34135319|NCT04403152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients and the researcher who were responsible for the analyzing of the data were blinded to the randomization results.|Parallel Assignment|t|f|f|f
34135320|NCT03471338|RANDOMIZED|FACTORIAL||OTHER||NONE||||||
34135321|NCT04319029|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135322|NCT03453619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135323|NCT00322452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135324|NCT05598944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Investigator: researchers have no information on participants' allocation in the groups; a research assistant from the Cognitive Neuroscience Group of the CIMCYC is designated for this purpose. None of the participants are students of any of the researchers. For the purpose of communicating with the participants over group allocation, another lecturer from the UGR is appointed. Outcome Assessors: all measures are collected online via the UGR LimeSurvey platform and no recording of group assignment is introduced in the system. Care providers: they are not informed about the outcome measures or specific research hypothesis regarding expected effects for each program. Participants: although it is not possible to blind their assignment to the groups in this type of study, they are not informed about the specific hypothesis regarding the expected outcomes of the programs.|Students are randomly assigned to three groups: the MBSR group that receives an adapted version of the MBSR program, the Más Presente group that receives training on transversal competences following the EU framework, LifeComp, and a third group that receives a neuro-muscular stimulation-based program. All participants are asked to fill in an informed consent and a demographic questionnaire to determine eligibility. Eligible participants are randomly assigned to either group. The three programs are given simultaneously.|t|t|t|t
34135325|NCT00467194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135326|NCT02321787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135327|NCT01534936|||COHORT||PROSPECTIVE|||||||
34135328|NCT03394040|||COHORT||CROSS_SECTIONAL|||||||
33827833|NCT03820869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135329|NCT06607211|||COHORT||PROSPECTIVE|||||||
34149491|NCT03510325|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"Real-World Study Based on SMART Design: Subjects were arranged according to patient's wishes and randomized allocation. Next phase of treatment was determined based on the patient's response (efficacy and adverse reactions). We could not achieve double blind designed protocol; however, assessor's blindness could be achieved in the design."|f|f|t|t
34149492|NCT02283307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149493|NCT01401699|NA|SINGLE_GROUP||OTHER||NONE||||||
34149494|NCT06203977|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort||||
34149495|NCT03235219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149496|NCT04903145|||CASE_ONLY||PROSPECTIVE|||||||
34149497|NCT01848847|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33827834|NCT02241447|||COHORT||PROSPECTIVE|||||||
33827835|NCT02044614|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33827836|NCT01732341|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827837|NCT03454659|||CASE_CONTROL||PROSPECTIVE|||||||
33827838|NCT01015378|||COHORT||PROSPECTIVE|||||||
33827839|NCT06454318|||COHORT||CROSS_SECTIONAL|||||||
33827840|NCT04196829|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827841|NCT01214681|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33827842|NCT00566345|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33827843|NCT00953511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827844|NCT00523549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827845|NCT06478576|NA|SINGLE_GROUP||OTHER||NONE||||||
33827846|NCT03822377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Site investigators performing platelet function tests will be blinded regarding patient randomization arm and the blood samples will be fully anonymized.|Comparison of platelet inhibition at different timepoints between 65 patients in the treatment arm (receiving orodispersible formulation of ticagrelor loading dose) versus 65 patients in the control arm (receiving standard coated formulation of ticagrelor loading dose). Randomization will be further stratified according to morphine use.|f|f|t|f
33827847|NCT03719378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827848|NCT02861625|||FAMILY_BASED||PROSPECTIVE|||||||
33827849|NCT02893761|||COHORT||PROSPECTIVE|||||||
33827850|NCT02741258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827851|NCT02356484|||COHORT||PROSPECTIVE|||||||
33827852|NCT03524768|||COHORT||PROSPECTIVE|||||||
33827853|NCT02604485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827854|NCT05951621|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33827855|NCT00352963|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827856|NCT01178177|||COHORT||RETROSPECTIVE|||||||
33827857|NCT04052477|||OTHER||RETROSPECTIVE|||||||
33827858|NCT05101083|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Crossover Assignment - Each participant will experience both test conditions (counterbalanced)|t|f|f|f
33827859|NCT03094624|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33827860|NCT04853407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827861|NCT01052389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827862|NCT02085902|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33827863|NCT02705625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827864|NCT02867098|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33827865|NCT03030105|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827866|NCT04389346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double||t|f|f|t
33827867|NCT06126510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827868|NCT00129506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827869|NCT02956278|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33827870|NCT00503217|RANDOMIZED|PARALLEL||||SINGLE||||||
33827871|NCT03927677||SEQUENTIAL||TREATMENT||NONE||||||
33827872|NCT05198206|||COHORT||RETROSPECTIVE|||||||
33827873|NCT04731142|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||An experimental feasibility study with a pre-test/post-test design using a matched control.||||
33827874|NCT00204828|||CASE_CONTROL||PROSPECTIVE|||||||
33827875|NCT01764698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827876|NCT06545110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|asses level of retinol binding protein 4 before and after barcitinib treatment.||f|f|t|f
33827877|NCT06248112|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33827878|NCT01554293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827879|NCT04620369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34135330|NCT04026009|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|"This is a randomized, observer-blind and partial blind (only for third dose) study.~Given the different appearance of the C.difficile investigational vaccines and placebo, double blinding is not possible, and the study will be conducted in an observer-blind manner. In an observer-blind study, the subject, the Contract Research Organization personnel, and the study center and Sponsor personnel involved in the clinical evaluation of the subjects are blinded while other study personnel may be aware of the treatment assignment.~When all data up to Day 61 are available, a statistical analysis will be performed.This analysis may lead to the unblinding of some subjects.A statistician will be unblinded for the analysis.The study will be considered as partial blind from this point onwards.~The Investigator and the subjects will not have access to the treatment allocation up to Day 390. After Day 390, only the subjects will remain fully blinded, while the Investigator will be partially blinded."|"A 4-step staggered design will be used to ensure maximum safety of the participating subjects:~Step 1: Vaccination of approximately 20 subjects aged 18-45 years. Step 2: Vaccination of approximately 20 subjects aged 50-70 years. Step 3: Vaccination of approximately 30 subjects aged 50-70 years. An iSRC will review all accumulating safety data after Dose 1 and 2 in Steps 1 to 3. If considered appropriate to proceed, the next step will start.~Step 4: Vaccination of approximately 70 subjects aged 50-70 years. An iSRC will review all accumulating safety data 3 weeks after the start of vaccination in Step 4 and then about every 3 weeks until all subjects have received Dose 1. In addition, the iSRC will review all safety data after Dose 2 and after that a subcohort of subjects will receive the third dose. If there are any safety concerns observed during SRT reviews post Dose 3, an ad hoc iSRC meeting will take place to review the unblinded safety data."|t|t|t|t
34135331|NCT02864888|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34135332|NCT02465723|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135333|NCT02529462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135334|NCT04313374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient, the investigator of the study will be blinded|parallel assignment|t|f|t|f
34135335|NCT02374814|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34135336|NCT01399151|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34135337|NCT05091281|RANDOMIZED|PARALLEL||OTHER||SINGLE|Before the study, the computerized randomization will be performed and the allocation results will be placed in individual numbered and sealed envelopes. Patients remained blinded about their intubation technique until post-operative assessment was completed.|Patients randomly assigned into Macintosh group, GlideScope (Verathon Medical, Bothwell, UT, USA) group, or CMAC(D) (Karl Storz GmbHand Co.KG, Tuttlingen, Germany) group. After pre-oxygenation , anesthesia will be induced with intravenous midazolam 0.05 mg. kg- 1 , propofol 1.5 mg. kg- 1 , fentanyl 5 μg. kg- 1 , and rocuronium 0.6 mg. kg- 1 . . The DLT will be inserted with the distal concavity facing anteriorly until the bronchial lumen cuff passed the vocal cords. The stylet will be then removed, and rotation will be performed while tube will be advanced. The left DLT rotated 90° counter-clockwise, and the right DLT will be rotated 90° clockwise to enter the respective mainstem bronchus.|t|f|f|f
34135338|NCT04461691|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open label||||
34135339|NCT01260090|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34135340|NCT01076868|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34135341|NCT06608550|RANDOMIZED|PARALLEL||OTHER||NONE||In the study, 90 children in the sample will be randomly assigned to the control and short film viewing groups. In determining the group of 90 children in the sample, random assignment will be made using a computer program||||
34135342|NCT03092986|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled type, 60 patients randomized with help of randomized number generator in two arms, Arm A and Arm B, each with at least 30 number of patients, research material will be data collection form,Arm A will receive paclitaxel 200 mg/m2 i.v over 3 hrs on D1; carboplatin AUC 6 i.v over 60 minutes on D1 every 3 wks for 2 cycles followed by radiotherapy with 6000 c Gy given in 30 fractions beginning on day 42 , Arm B willl receive - cisplatin (100 mg/m2 BSA i.v over 2 hrs. on days 1 and 29) and vinblastine (5 mg/m2 BSA i.v rapidly push weekly on days 1,8,15,22 and 29) followed by radiotherapy with 6000 cGy given in 30 fractions beginning on day 50 ,data will be analysed and interpreted and result will be drawn on basis of outcome measures which is again based on tumor response RECIST criteria||||
34135343|NCT06302400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135344|NCT02975479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135345|NCT05484505|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135346|NCT05608993|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135347|NCT01986192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135348|NCT05733091|||COHORT||PROSPECTIVE|||||||
34135349|NCT05358418|||CASE_CONTROL||RETROSPECTIVE|||||||
34135350|NCT06440967|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135351|NCT06398132|||COHORT||CROSS_SECTIONAL|||||||
34135352|NCT01883115|||COHORT||PROSPECTIVE|||||||
34135353|NCT02184091|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135354|NCT04948320|||COHORT||CROSS_SECTIONAL|||||||
34135355|NCT00061815|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135356|NCT00664339|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34135357|NCT03524963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135358|NCT01633632|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135359|NCT00303771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135360|NCT06661408|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled experimental research||||
34135361|NCT02070419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135362|NCT06236061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In the Core part, Participant, care provider and Investigator will be masked. In the OLE part, no masking to anyone.|"This study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part.~The Core part is a parallel model, and the OLE is a sequential model."|t|t|t|f
34135363|NCT00057733|RANDOMIZED|||||||||||
34135364|NCT00229047|||COHORT||PROSPECTIVE|||||||
34135365|NCT01216709|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34135366|NCT06279364|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised in a 1:1 ratio to one of two intervention groups.||||
34149498|NCT01562236|||COHORT||PROSPECTIVE|||||||
34149499|NCT06464861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149500|NCT01447121|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149501|NCT00011011|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33827880|NCT01665599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827881|NCT04793581|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm||||
33827882|NCT02019238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827883|NCT03264547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827884|NCT04362098|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33827885|NCT03738098|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The overall design is a Randomized Controlled Trial (RCT), evaluating the use of GUÍA to facilitate the return of WGS genomic results and comparing it to return of results using routine genetic counseling. The RCT will occur in the context of the performing WGS and TGP for diagnostic purposes in 1,130 children in an effort to assess clinical utility. Children and young adults with specific disorders will be recruited from MS and EM. In the Traditional GC group, participants will receive traditional genetic counseling for the Baseline and Return of Results (ROR1) visits. In the GUÍA group, they will receive traditional GC for the Baseline visit, and traditional GC plus GUÍA for the ROR1 visit (see arm descriptions below). Based on the subjects' randomization, they will be scheduled to see a specific genetic counselor, as the genetic counselors will be assigned to a specific arm and will remain in that arm for the duration of the study.||||
33827886|NCT05167513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827887|NCT00951964|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827888|NCT01064505|NA|SINGLE_GROUP||||NONE||||||
33827889|NCT02965053|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33827890|NCT00604513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827891|NCT00849745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827892|NCT05830357|||CASE_ONLY||CROSS_SECTIONAL|||||||
33827893|NCT06199206|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827894|NCT05650047|||COHORT||PROSPECTIVE|||||||
33827895|NCT04713813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All evaluations for outcomes will perform by the same experienced physiotherapists who will be blind to the study groups.|randomized, single-blind, controlled clinical trial|f|f|f|t
33827896|NCT02723513|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827897|NCT01834768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827898|NCT03459612|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33827899|NCT05157737|||COHORT||PROSPECTIVE|||||||
33827900|NCT05028946|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33827901|NCT01109719|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33827902|NCT03230409|NON_RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33827903|NCT04526314|||COHORT||RETROSPECTIVE|||||||
33827904|NCT00040898||||TREATMENT||||||||
33827905|NCT03595423|||COHORT||RETROSPECTIVE|||||||
33827906|NCT01612767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827907|NCT02191527|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Before and after intervention study design||||
33827908|NCT01084239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33827909|NCT01222078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827910|NCT03098797|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||28 weeks, double-blinded crossover followed by a 168-week open label long term safety \& tolerability trial.|t|t|t|t
33827911|NCT05082662|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33827912|NCT03847480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827913|NCT00821119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827914|NCT04545476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827915|NCT05530382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33827916|NCT01658956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33827917|NCT00841607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827918|NCT01087814|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33827919|NCT01980524|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33827920|NCT05771597|RANDOMIZED|PARALLEL||OTHER||SINGLE||This is a new home biofeedback device feasibility study that will be tested in 3 groups of patients; 1. Fecal incontinence (24 subjects); 2. Dyssynergic constipation (24 subjects); 3. Urinary incontinence (24 subjects). The investigators anticipate enrolling 20 in each group and an expected 20% dropout.|f|f|f|t
33827921|NCT00451438|||CASE_CONTROL||OTHER|||||||
33827922|NCT00458354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827923|NCT05229341|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33827924|NCT03391141|||COHORT||PROSPECTIVE|||||||
33827925|NCT01858051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33827926|NCT04278495|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827927|NCT00848393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827928|NCT00161408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827929|NCT02721433|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827930|NCT00993798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827931|NCT04650659|||CASE_ONLY||CROSS_SECTIONAL|||||||
33827932|NCT02274623|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827933|NCT06192719|||CASE_CONTROL||PROSPECTIVE|||||||
33827934|NCT05591170|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33827935|NCT01703845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827936|NCT01565252|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33827937|NCT04570254|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|They will be blinded to the patient's treatment, the patient or participant, the investigator, and the outcome assessor. You will only receive the participant number during the analysis. The care provider will not be blinded; they will know which antioxidant plus pentoxifylline the patient will receive; however, they will not have access to the results until the clinical trial is concluded.|septic shock and without septic shock will be divided into two groups. An antioxidant will be administered orally or by orogastric tube (vitamin C, melatonin, n-acetylcysteine, vitamin E) plus pentoxifylline. Following a decision tree that the treating physician will follow.|t|f|t|t
33827938|NCT06345898|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33827939|NCT02763163|||COHORT|||||||||
33827940|NCT04308642|||COHORT||PROSPECTIVE|||||||
33827941|NCT04251546|||CASE_ONLY||PROSPECTIVE|||||||
33827942|NCT06477991|||CASE_ONLY||PROSPECTIVE|||||||
33827943|NCT02165397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827944|NCT02921139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827945|NCT01016223|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33827946|NCT04846855|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||monocentric, interventional, longitudinal, prospective, non-comparative.||||
33827947|NCT01246219|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33827948|NCT02562144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33827949|NCT00664261|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||NONE||||||
33827950|NCT01246050|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827951|NCT02624375|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33827952|NCT02767518|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33827953|NCT02292485|||COHORT||PROSPECTIVE|||||||
33827954|NCT00175370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33827955|NCT02112513|||CASE_ONLY||PROSPECTIVE|||||||
33827956|NCT03911908|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|On group will have NIRS reading available to adjust CPR interventions, whereas the control group will not be able use NIRS readings (masked by cover)|Does near-infrared spectroscopy (NIRS) technology based advanced cardiac life support improve cardiopulmonary resuscitation (CPR) quality in patients (in-house \[IHCA\] and out-of-hospital cardiac arrest \[OHCA\], randomized enrollment immediately with CPR) and thereby improve return of spontaneous circulation (ROSC) rate (primary outcome) and patient outcome compared to European Resuscitation Council (ERC)-based CPR (concealed NIRS recording).|t|t|f|t
33827957|NCT00634218|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33827958|NCT03919318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827959|NCT00502164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827960|NCT06213064|||CASE_CROSSOVER||PROSPECTIVE|||||||
33827961|NCT05296447|||OTHER||PROSPECTIVE|||||||
33827962|NCT03598725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827963|NCT02971228|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33827964|NCT03989583|||CASE_ONLY||PROSPECTIVE|||||||
33827965|NCT01442077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827966|NCT02206945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33827967|NCT01728688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827968|NCT04280562|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Double blind, randomized, sham-controlled trial parallel arm study that will assess the effectiveness and patient perception of the benefit of the Sana Pain Reliever in individuals with chronic neuropathic pain.|t|f|f|t
33827969|NCT05002530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827970|NCT04228354|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33827971|NCT03068221|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33827972|NCT04317001|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Randomized double-blinded placebo control|t|t|t|t
33827973|NCT04455685|||OTHER||RETROSPECTIVE|||||||
33827974|NCT00008320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827975|NCT00691678|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33827976|NCT03449134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants with refractory or unexplained chronic cough will be randomized to 1 of 3 treatment groups during the Treatment Period: Placebo, gefapixant 15 mg twice daily (BID), or gefapixant 45 mg BID. Participants will remain on their assigned treatment throughout the study. A safety follow-up phone call will be conducted at a minimum of 14 days after last dose of study treatment.|t|f|t|f
33827977|NCT05103098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|a double-blind randomized controlled trial|a double-blind randomized controlled trial|t|t|t|t
33827978|NCT01046422|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33827979|NCT06250478|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Both stroke patients and age and gender matched healthy controls will be included||||
33827980|NCT02068196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827981|NCT05571306|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Patients are blinded to what treatment their are given and the investigator and outcome Assessor is likewise blinded as each patients and general practices are annonymized..|As the study is a cluster randomized trial, General Practitioners are those being allocated for either intervention or control (care as usual), with controls being enrolled as late intervention.|t|f|t|t
33827982|NCT03726983|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study was longitudinal approach and repeated testing using an experimental design to evaluate the follow-up outcomes of the e-heath management platform intervention.||||
33827983|NCT00419419|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33827984|NCT05546424|||OTHER||PROSPECTIVE|||||||
33827985|NCT04208347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33827986|NCT04237519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Assessors are blind to the hypotheses and to participants' assignment as they only have access to the testing sessions. Participants are asked not to mention elements of their training program to assessors . Would such circumstance occur, it will be reported but this should have minimal effect on integrity as the assessors are blind to the hypotheses.~Team members responsible of the statistical analyses are blind to the training assignment as they only have access to anonymized data set and have no access to neither participants' assignment nor the randomization list.~At each study site, study coordinators and trainers responsible for the introductory and refresher courses, and supervision of participants during the home-based training are not blind.~Participants are aware that the trial has two different training conditions that are compared to each other and that they are randomly allocated to one of them. However, they are not informed of the study hypotheses."|"Double-blind, parallel-group (intervention A vs B), multicentric randomized control trial (RCT). A stratification will separate robust from pre-frail healthy older adults in each intervention.~Note that the study is combined with a further 6-month observational study to test adherence, user experience and acceptability in all participants."|t|f|f|t
33827987|NCT02490605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135367|NCT03952468|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Prior to each TMS session, un-blinded study staff will attach the appropriate (i.e., active or sham) coil according to the participants' randomization code (obtained from the urn randomization computer program). This will facilitate triple blind stimulation, where the participant, TMS provider, and outcome rater are blind to group assignation."|130 Veterans admitted to the Providence VAMC psychiatric inpatient unit due to suicide attempt or ideation with intent to make an attempt will be recruited and randomly assigned to receive: a) active TMS+BCBT or b) sham TMS+BCBT. Both interventions will begin within the week following hospital discharge, and Veterans will be followed for 12 months post-discharge.|t|t|f|t
34135368|NCT05155618|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Supportive Care: protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.||||
34135369|NCT03006458|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34135370|NCT02036333|||CASE_CONTROL||PROSPECTIVE|||||||
34135371|NCT02668770|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135372|NCT04890496|||COHORT||RETROSPECTIVE|||||||
34135373|NCT05524623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both groups do not know if the treatment has emission or not while the sessions are carried out.|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius. Both will take place over 3 weeks, with one session per week. The evaluation is carried out through the visual analogue scale (VAS), measurement of force with a dynamometer and mobility with a goniometer. The score will be recorded on a validated neck pain questionnaire (NPQ).|t|f|f|f
34135374|NCT02182063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135375|NCT06259487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135376|NCT06410742|||CASE_CONTROL||PROSPECTIVE|||||||
34135377|NCT00504517|||COHORT||PROSPECTIVE|||||||
34135378|NCT06656650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135379|NCT03218072|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135380|NCT04627675|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135381|NCT01984645|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34135382|NCT02141867|||COHORT||PROSPECTIVE|||||||
34135383|NCT00542490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135384|NCT05548712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|It is doubled blinded, a subject 's specific ID card will be provided for each of the enrolled subject and the investigators don't know whether it is PEMF or Sham treatment for that subject's specific ID card. And the investigator will ask the manufactory about the number of grouping at the end of the study.|Participants will be assigned into either treatment group or sham group.|t|t|t|f
34135385|NCT01335724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135386|NCT01142778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135387|NCT03760887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomly assigned to one of two groups (control or experimental).|Randomized Control Trial|t|f|f|f
34135388|NCT03011970|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34135389|NCT03401944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34135390|NCT04309877|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34135391|NCT04314466|||COHORT||PROSPECTIVE|||||||
34135392|NCT06324942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135393|NCT03867266|||COHORT||PROSPECTIVE|||||||
34135394|NCT01244594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135395|NCT01527305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135396|NCT03155529|||CASE_CONTROL||OTHER|||||||
34135397|NCT06658652|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34135398|NCT02350166|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135399|NCT02793349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135400|NCT06643234|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled study||||
34135401|NCT06616740|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|patients, care providers, investigator and outcome assessors will be blinded.|"There are two groups;~1. Experimental Group: Group P; paratracheal compression will be applied during LMA ProSeal insertion.~2. Sham Comparator: Group C; cricoid compression will be applied during LMA ProSeal insertion."|t|t|t|t
34135402|NCT04880083|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135403|NCT06132477|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients will be continued on currently prescribed GLP-1 agonist after bariatric surgery or medication will be held||||
34135404|NCT04587700|||CASE_CONTROL||PROSPECTIVE|||||||
34135405|NCT05835336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135406|NCT03459001|||COHORT||PROSPECTIVE|||||||
34135407|NCT04354077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135408|NCT06394544|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A longitudinal, prospective clinical trial will be carried out with patients with CKD undergoing conservative treatment. Volunteers will be randomized into groups G1 and G2, and in the first stage, G1 will be in the intervention group and G2 in the control group. In the second stage, everyone will undergo washout and, in the third stage, a crossover between groups will be carried out, passing G2 to intervention and G1 to control.||||
34135409|NCT05754944|||COHORT||PROSPECTIVE|||||||
34135410|NCT06659107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135411|NCT04426149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135412|NCT03653156|||COHORT||PROSPECTIVE|||||||
34135413|NCT01218958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135414|NCT04825964|||CASE_CONTROL||PROSPECTIVE|||||||
34135415|NCT04277663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135416|NCT06238895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135417|NCT00178919|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34135418|NCT02727933|||CASE_ONLY||PROSPECTIVE|||||||
34135419|NCT00624585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135420|NCT06659562|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1: Open-label. Part 2: Double-blind, randomized, placebo-controlled.|"Part 1: Single dose cohort in older and elderly (50-75 years of age) healthy volunteer subjects.~Part 2: Two multiple dose cohorts in patients with mild or moderate PD (45-80 years of age)."|t|t|t|t
33827988|NCT00611728|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33827989|NCT05051475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33827990|NCT01037413|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
33827991|NCT01984749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827992|NCT00275301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827993|NCT06452927|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33827994|NCT03712384|||COHORT||RETROSPECTIVE|||||||
33827995|NCT00003162|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33827996|NCT01601717|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33827997|NCT04257747|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33827998|NCT04593706|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33827999|NCT03354234|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33828000|NCT02649361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828001|NCT06278012|||CASE_ONLY||CROSS_SECTIONAL|||||||
33828002|NCT00675038|||CASE_ONLY||PROSPECTIVE|||||||
33828003|NCT01753596|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33828004|NCT05507398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828005|NCT01114308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828006|NCT01299298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828007|NCT06146413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828008|NCT00001440||||TREATMENT||||||||
33828009|NCT04882189|||OTHER||RETROSPECTIVE|||||||
33828010|NCT01984671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828011|NCT05715736|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|The study will be double-blinded. The participants and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the participant's treatment assignment (APB-R3 or placebo).||t|t|t|t
33828012|NCT04001998|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828013|NCT05187000|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33828014|NCT04028947|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33828015|NCT01328808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828016|NCT04113928|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Double blind|Randomised double blind crossover design.|t|f|t|f
33828017|NCT00619983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828018|NCT01252056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828019|NCT04294524|||COHORT||PROSPECTIVE|||||||
33828020|NCT06475027|||COHORT||RETROSPECTIVE|||||||
33828021|NCT06479525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828022|NCT01120288|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828023|NCT02164136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828024|NCT00352378|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828025|NCT04360083|||COHORT||OTHER|||||||
33828026|NCT04343859|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828027|NCT05971277|||COHORT||PROSPECTIVE|||||||
33828028|NCT02271659|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828029|NCT02169921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828030|NCT00725036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828031|NCT02220777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828032|NCT00448500|||CASE_CONTROL||PROSPECTIVE|||||||
33828033|NCT06271564|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828034|NCT05884983|||COHORT||PROSPECTIVE|||||||
33828035|NCT00787683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828036|NCT00985283|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33828037|NCT03462498|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828038|NCT05029349|NA|SINGLE_GROUP||OTHER||NONE||||||
33828039|NCT06271083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828040|NCT01335633|||COHORT||PROSPECTIVE|||||||
33828041|NCT03626311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Eligible patients will be randomized (1:1) to receive either AKBM-3031 or placebo during the randomized period.The randomized subjects will take (4)1 gram capsules of product or placebo every day, (2) 1 gram capsules in the morning and (2) 1 gram capsules in the evening, for a total of 4 grams per day for the first 24 weeks (randomized period). All subjects may continue to a 24-week extension (Open Label Extension) of open-label AKBM-3031, 4 grams/day. The total study duration per subject is 48 weeks. With about 4 months for site activation and 12 months for enrollment, the entire study is expected to complete in approximately 116 weeks.|t|t|t|t
33828042|NCT00082641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828043|NCT06003023|RANDOMIZED|PARALLEL||PREVENTION||NONE|Group assignment will be generated through the data capture system (REDCap) in which the randomization scheme was developed by the study statistician. Investigator, research assistants, coaches (interventionists), and participants do not know which condition a participant is in until after Phase 2 consent.|Study includes 2 possible conditions to which participants are randomized: (1) Control: Fitbit + tailored exercise prescription + information on living well with CHD (2) Fitbit + tailored exercise prescription + theory-driven health coaching sessions.||||
33828044|NCT00658840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828045|NCT00495872|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828046|NCT05832944|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|double-blinded||t|f|t|t
33828047|NCT03697083|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33828048|NCT02610621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828049|NCT04841070|NA|SINGLE_GROUP||OTHER||NONE||||||
33828050|NCT06478108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828051|NCT02633397|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828052|NCT03004326|||COHORT||PROSPECTIVE|||||||
33828053|NCT05745181|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828054|NCT01673295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828055|NCT01891890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828056|NCT05734742|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33828057|NCT01631786|||CASE_ONLY||PROSPECTIVE|||||||
33828058|NCT03758456|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828059|NCT04213820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34135421|NCT06401668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Eligible participants will include primary and specialty care patients who identify as Hispanic with T2D and low incomes.||||
34135422|NCT01231542|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135423|NCT02112474|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34135424|NCT02752685|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135425|NCT01321944|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135426|NCT06340321|||COHORT||PROSPECTIVE|||||||
34135427|NCT01707654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135428|NCT05764161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135429|NCT05307705|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33828060|NCT04124471|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33828061|NCT02872519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828062|NCT05027880|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828063|NCT01522677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828064|NCT06171503|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A non randomized control trial is conducted to see the effect of letter of invitation on promoting male involvement in PMTCT service. Pregnant women visiting antenatal care clinic with out their partners will be enrolled for the intervention and receive letter of invitation from mother support group to invite their partners on subsequent visit at ANC clinic while pregnant woman visiting ANC clinic with out their partners on comparison group will not receive letter and continue to take the usual care and appointed for their next visit||||
33828065|NCT05065697|||COHORT||PROSPECTIVE|||||||
34135430|NCT04074694|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828066|NCT00703105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828067|NCT00181532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828068|NCT02275299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828069|NCT05692271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828070|NCT00249730|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828071|NCT03762083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828072|NCT04204811|||COHORT||PROSPECTIVE|||||||
33828073|NCT02460536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828074|NCT04839614|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33828075|NCT00374088|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828076|NCT00270647|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33828077|NCT03148483|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|"This is a multi-component intervention. The participants will be blinded for the milk fortification component of the intervention only.~Participants will receive daily sachets with similar appearance either with vitamin D and calcium (intervention) or flour (control)."|2x2 factorial design|t|f|f|f
33828078|NCT00123019|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828079|NCT05124821|||COHORT||PROSPECTIVE|||||||
33828080|NCT02716857|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34135431|NCT06486662|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828081|NCT01586429|||COHORT||PROSPECTIVE|||||||
33828082|NCT00143598|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33828083|NCT01707706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828084|NCT00258362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828085|NCT04520581|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33828086|NCT04100239|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This study is designed as a pilot and feasibility trial, using a stepwedged design. Pilot trials are used in advance of a larger future definitive randomised controlled trial (RCT) to focus on the development and refinement of the intervention, assess potential effectiveness, intervention acceptability and to determine whether a larger RCT is feasible. In step-wedged designs, all participants begin the study as 'control participants' and at regular 'steps' one group is crosses from the control to the intervention condition, until all groups have completed the intervention.||||
33828087|NCT00485706|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828088|NCT03240497|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|We employ a PROBE design (Prospective Randomized Open Blinded End-point) \[41\]. All subjects will receive a code number. Almost all of our end-points, especially the most important ones including the primary endpoint, are laboratory measurements, which will be performed blinded for the treatment of the subjects.|A parallel randomized controlled explorative study in healthy male volunteers during experimental endotoxemia.|f|f|f|t
33828089|NCT00003912|RANDOMIZED|||TREATMENT||||||||
33828090|NCT00487552|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33828091|NCT02760693|||COHORT||PROSPECTIVE|||||||
33828092|NCT01077011|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33828093|NCT02306083|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33828094|NCT00003133||||TREATMENT||||||||
33828095|NCT00460564|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828096|NCT05031468|||COHORT||PROSPECTIVE|||||||
33828097|NCT02257918|RANDOMIZED|PARALLEL||TREATMENT||||||||
33828098|NCT01524419|||||PROSPECTIVE|||||||
33828099|NCT01845649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828100|NCT06509945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828101|NCT03233347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837510|NCT04197375|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33837511|NCT01122875|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135432|NCT04336046|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34135433|NCT00883545|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34135434|NCT01541904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151147|NCT05052593|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||the purpose of this study is to compare the effects of compressive myofascial release on lateral patellar tracking inpatients with knee osteoarthritis. an RCT trial was conducted at Railway general hospital, Ahad medi care clinics and physiotherapy centre rawat and THP Bahria town phase 6.sample size was 52 calculated through open-epi tool. participants divided into control and experimental group.participants diagnosed with grade 2and 3 K\&L classification of knee OA included.|f|f|f|t
34151148|NCT04104880|NA|SINGLE_GROUP||TREATMENT||NONE||Uncontrolled before-and-after study||||
34151149|NCT01551524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151150|NCT05284916|||CASE_ONLY||OTHER|||||||
33828102|NCT03115671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinicians conducting the study assessments and teachers who will be providing feedback will be blinded to the study arm.||f|f|f|t
33828103|NCT06483386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828104|NCT03121612|RANDOMIZED|PARALLEL||TREATMENT||NONE|As the machines are physically distinct, blinding of participants, care providers and investigators is not feasible. The assessment of most outcomes cannot therefore be blinded, with one exception: x-rays for neonates with suspected pneumothorax will be provided to a radiologist for independent verification; the radiologist will not be in the nursery and will therefore be blinded to treatment allocation.|||||
33828105|NCT04967586|||COHORT||CROSS_SECTIONAL|||||||
33828106|NCT00700453|RANDOMIZED|PARALLEL||||NONE||||||
33828107|NCT01410084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828108|NCT06176053|NA|SINGLE_GROUP||TREATMENT||NONE|Participants were blinded to the results of all measurements and naïve to research hypotheses.|Feasibility and acceptability study||||
33828109|NCT05685953|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|Double-blinding: subjects, study personnel and outcome assessors are blinded to treatment.|Randomized, placebo-controlled, double-blinded phase I study including three dose levels of the DNA vaccine OC-007.|t|t|t|t
33828110|NCT00287547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828111|NCT05183243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828112|NCT05725733|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A single- blinded randomized controlled study design will be used, the exercise program will be administrated for four weeks, three times per week, and sixteen minutes per session. Heart rate, ECG, Measurements of respiration, and blood pressure will be measured three times every session: at rest before starting exercises (baseline), directly after finishing exercises, and 15 minutes after finishing exercises.||||
33828113|NCT00618917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828114|NCT03658577|||COHORT||PROSPECTIVE|||||||
33828115|NCT00321490|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828116|NCT02185365|||COHORT||PROSPECTIVE|||||||
33828117|NCT02585141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828118|NCT00264498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828119|NCT01797562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||3 T.R.U.E. Test panels were applied to the paraspinal regional of the back and were to be worn for approximately 48 hours. Post application evaluations were performed at days 3, 4, 7(+1) and 21(+2).||||
33828120|NCT04876768|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Endoscopist will be blinded but the anesthetist will not.||t|t|f|f
33828121|NCT05132530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33828122|NCT05841056|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 ratio to receive amiodarone 200 mg maintenance therapy daily for four weeks or no maintenance therapy||||
33828123|NCT00420147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828124|NCT02470299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33828125|NCT04515628|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828126|NCT05784077|||COHORT||PROSPECTIVE|||||||
33828127|NCT04703257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A monocenter, prospective, double-blind, randomized controlled superiority trial is designed to investigate the superiority of the combination of metamizole and paracetamol compared to paracetamol treatment in patients undergoing arthroscopic shoulder surgery with tendon repair.|t|t|t|t
33828128|NCT01839383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828129|NCT02381652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Cingal 13-02 was an open label follow-up study. The participants, investigators and outcomes assessors were blinded to the specific study injection subjects had previously received in Cingal 13-01.|All subjects enrolled into the Cingal 3-02 follow-on study received an intra-articular injection of Cingal. The three 'arms' of the study were for subjects who received a Cingal, Monovisc, or saline initial injection in the Cingal 13-01 study.||||
33828130|NCT04938739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33828131|NCT02568878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828132|NCT04174222|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33828133|NCT00579748|||CASE_ONLY||PROSPECTIVE|||||||
33828134|NCT05844865|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828135|NCT00791297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828136|NCT03020056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828137|NCT03401723|NON_RANDOMIZED|PARALLEL||OTHER||NONE|This is a vialidation study of a computerized analysis of the colonoscope movements during a simulated procedure.|||||
33828138|NCT05764590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828139|NCT04269434|RANDOMIZED|PARALLEL||SCREENING||NONE|The study statistician will be blinded until the statistical analysis plan (SAP) is approved|||||
33828140|NCT01667172|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|t|f|f
33828141|NCT02622711|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828142|NCT05864885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828143|NCT01249677|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828144|NCT05139823|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"Randomization occurs at the time of discharge, meaning that the treatment and post-discharge treatment recommendations given in the ward will not in any way be affected by whether or not the patient is allocated to intervention or control group. Thus, everyone at the geriatric ward is blinded, including the patient, the doctors, nurses, and the investigator who carries out the randomization.~At discharge the patient is informed about the allocation group. If control, i.e., usual care, nothing further is done. If intervention, the patient, the investigator and the visiting geriatric nurses are made aware of the result of the allocation.~The outcome assessor is also the investigator, however the results are scrambled by a third party and any identifying information is removed, thus allowing blinded data analysis."|Single-centre two-arm parallel group randomised controlled trial using permuted block randomisation|f|t|t|t
33828145|NCT05615246|||COHORT||OTHER|||||||
33828146|NCT03443063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828147|NCT01223963|||COHORT||RETROSPECTIVE|||||||
34151151|NCT06194344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151152|NCT05855343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151153|NCT06352255|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34151154|NCT05399004|||COHORT||PROSPECTIVE|||||||
34151155|NCT00001696||||TREATMENT||||||||
34151156|NCT05091515|||CASE_CONTROL||PROSPECTIVE|||||||
34135435|NCT04537208|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, outcome assessors, Investigators, laboratory personnel, and the majority of Sponsor study staff will be blinded to vaccine group assignment; injection schedule will be unblinded and those preparing/administering the study interventions will be unblinded.|"This was a parallel group prevention study. Participants from 2 age groups (adults 18 through 49 years of age and adults 50 years of age and older) received either 1 injection (Cohort 1) or 2 injections (Cohort 2) of study vaccine or placebo control.~As a precautionary step, a sentinel safety cohort of 6 participants (younger adults only) within each dosing group from Cohort 1 was enrolled. An early safety data review was performed, including evaluation of safety data and laboratory measures to Day 9. Upon acceptable safety demonstrated from unblinded data review by limited members of the Sponsor Study Team, the remaining participants were enrolled simultaneously."|t|t|t|t
34135436|NCT05362773|NA|SEQUENTIAL||TREATMENT||NONE||||||
34135437|NCT04793724|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||"First session - initial medical and physiotherapy assessment~Second session - medical and physiotherapy assessment, respiratory physiotherapy with Simeox/PARI O PEP (according the randomization)~Third session - medical and physiotherapy assessment, respiratory physiotherapy with Simeox/PARI O PEP (according the randomization)"||||
34135438|NCT00964041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135439|NCT06464380|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blinded|randomized clinical trial|t|f|f|f
34135440|NCT04115748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135441|NCT00025207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135442|NCT03134495|||COHORT||RETROSPECTIVE|||||||
34135443|NCT00406874|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135444|NCT06649942|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34135445|NCT06400576|||CASE_ONLY||CROSS_SECTIONAL|||||||
34135446|NCT05096247|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||One site will enroll patients to be treated with the the RF device, and the other site will enroll patients to be treated with the RF device and the Intense Pulsed Light (IPL) laser.||||
34135447|NCT06606327|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34135448|NCT04186988|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135449|NCT01468233|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135450|NCT00735826|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34135451|NCT01932229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135452|NCT00160017|||||PROSPECTIVE|||||||
34135453|NCT05944081|||COHORT||PROSPECTIVE|||||||
34135454|NCT06658990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135455|NCT04550832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135456|NCT03574610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135457|NCT06607744|||COHORT||PROSPECTIVE|||||||
34135458|NCT05315674|||COHORT||PROSPECTIVE|||||||
34135459|NCT05486325|NA|SINGLE_GROUP||TREATMENT||NONE||"The sample size (n) will be 20-30 Bariatric patients. Twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the Endolumik Gastric Calibration Tube instead of the standard bougie calibration tube.~Ten participants will undergo laparoscopic gastric bypass using the Endolumik Gastric Calibration Tube instead of the standard calibration tube.~The current pilot protocol is a qualitative, not quantitative, study design, thus no power calculation is indicated. The goal of the present pilot study is to serve as the First In Human trial and confirm that the Endolumik Gastric Calibration Tube performs similar to predicate devices currently on the market, as well as to get end-user feedback prior to 510(k) application to the FDA. The sample size was chosen because 20 to 30 uses will allow the development team to appropriately evaluate device performance."||||
34135460|NCT00211757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135461|NCT04945278|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Prospective interventional case / control trial||||
34135462|NCT04147377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135463|NCT03632993|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135464|NCT00270088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135465|NCT04961528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135466|NCT06657391|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The researchers and the subjects wil aware of the grouping and the intervention they received. However, this trail will implement a blind method for the outcomes assessors, who objectively evaluated the outcome indicators without knowing the grouping of the subjects.||f|f|f|t
34135467|NCT02777047|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34135468|NCT04799171|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135469|NCT01292356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135470|NCT04171219|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135471|NCT06106061|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135472|NCT01235845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135473|NCT01663571|||CASE_ONLY||PROSPECTIVE|||||||
34135474|NCT06660992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135475|NCT03443479|||COHORT||RETROSPECTIVE|||||||
34135476|NCT03984474|||COHORT||RETROSPECTIVE|||||||
34135477|NCT06659159|||COHORT||PROSPECTIVE|||||||
34135478|NCT01928589|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized trial of Partial Breast Irradiation (PBI) with concurrent or sequential chemotherapy||||
34135479|NCT01476319|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135480|NCT05720689|RANDOMIZED|CROSSOVER||OTHER||NONE||Intra-individual comparison by cross-over||||
34135481|NCT01293344|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135482|NCT00760942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135483|NCT06660576|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135484|NCT06429696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135485|NCT02566785|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135486|NCT04607304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828148|NCT04865783|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Before elective surgery, all patients will have an intravenous line placed before induction of anaesthesia. Patients will be blinded to whether cryospray or placebo is used. Two anaesthesia trained persons (nurse/doctors) will perform the procedure. One person will randomize and apply the randomized spray and the other person will be blinded to the randomized treatment. The anesthesiologist performing the puncture but blinded for randomization will fill out a questionnaire||t|t|f|t
33828149|NCT00874497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828150|NCT04971629|||OTHER||PROSPECTIVE|||||||
33828151|NCT03269513|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33828152|NCT00957996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828153|NCT05588544|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33828154|NCT02896101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828155|NCT01606891|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||f|f|t|t
33828156|NCT06014502|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33828157|NCT05955547|||CASE_ONLY||RETROSPECTIVE|||||||
33828158|NCT04848376|||COHORT||PROSPECTIVE|||||||
33828159|NCT01213992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828160|NCT04389827|||COHORT||PROSPECTIVE|||||||
33828161|NCT01458964|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33828162|NCT02710097|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33828163|NCT00816647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828164|NCT03813732|NA|SINGLE_GROUP||TREATMENT||NONE|"Outcomes:~outcome Method of measurement Measuring unit Primary outcome Assessment of the esthetics. Visual analog scale Numerical Secondary outcome pain Visual analog scale Numerical (1-10)"|"1. Pre-operative phase:~   Patients will be subjected to:~  1. Case history including personal data, medical, surgical and family history.~  2. Clinical examination.~  3. Preoperative anesthesia assessment for fitness for general anesthesia.~  4. Treatment planning.~2. Operative phase:~   All cases will undergo surgery under general anesthesia.~3. Postoperative care:~   Proper postoperative instructions will be given the patient, in addition to the postoperative medications including antibiotics, corticosteroids and analgesics.~4. Postoperative evaluation and follow-up:~12) Outcomes: outcome Method of measurement Measuring unit Primary outcome Assessment of the esthetics. Visual analog scale Numerical Secondary outcome pain Visual analog scale Numerical (1-10)"||||
33828165|NCT02765464|||COHORT||PROSPECTIVE|||||||
33828166|NCT06299553|||COHORT||PROSPECTIVE|||||||
33828167|NCT05621928|||CASE_CONTROL||PROSPECTIVE|||||||
33828168|NCT05285956|RANDOMIZED|PARALLEL||TREATMENT||NONE|Researchers will assign participants to groups based on a randomized allocation list, which will be generated prior to the start study by a team member who is not involved in the group-assignment process. Allocation sequences will be concealed until the time of group assignment.|||||
33828169|NCT03696888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Note: A pilot period with interim 6-week analyses following recruitment of about 10% of the maximum anticipated sample of 1000 is part of the study. This offers an opportunity to assess trial continuation from an ethical perspective. The rationale for this is that individuals with relatively severe levels of alcohol use can be included in the trial and the investigators harbor a concern that the components in the intervention and control conditions might be insufficient to support the participants in remaining stable or reducing their alcohol intake. The pilot period covers a recruitment period from Dec 7, 2019 to February 15, 2019 (n=89) and includes a 6-week follow-up. The interim analysis from May 1, 2019 indicates group declines in alcohol use over the 6-week follow-up period for both conditions, suggesting that continuation of the trial is warranted. Pilot participants will be included in the final study sample.|t|f|f|f
33828170|NCT01656486|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33828171|NCT02205541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828172|NCT03505255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33828173|NCT00960505|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828174|NCT03834818|NA|SINGLE_GROUP||PREVENTION||NONE||Patients undergoing orthopedic surgery at Duke Health will be eligible for enrollment. Additionally, all potential participants must be an adult at least 18 years of age, speak and read English, own a smartphone they are willing to use for the study, and live in the United States of America. All study assessments will take place on the app and other than baseline screening all assessments will take place after surgery until the patient stops taking opioids. Patients will be approached in the orthopedic clinic up to the day of surgery and asked if they are willing to be screened for inclusion. If they accept the screening request a link will be emailed to them or a QR code supplied that permits them to download the study app on their phone. Screening, consent, and all study data collection will occur from the app launch. All data will be collected after enrollment and consent through the Medable Research Application.||||
33828175|NCT01828398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33828176|NCT00384865|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33828177|NCT00876499|||COHORT||PROSPECTIVE|||||||
33828178|NCT05428592|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||A randomized, blinded, parallel-controlled design|t|f|t|t
33828179|NCT00812838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828180|NCT03269695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828181|NCT04891471|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828182|NCT04745377|||CASE_CONTROL||PROSPECTIVE|||||||
33828183|NCT04805047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828184|NCT05052723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828185|NCT01589523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828186|NCT05135923|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33828187|NCT05992636|||CASE_CONTROL||PROSPECTIVE|||||||
33828188|NCT04934241|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Self-Acupressure and control group|This study is an experimental study with pre-test and post-test control groups|t|f|f|f
33828189|NCT06344806|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33828190|NCT00494208|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828191|NCT00792259|||COHORT||PROSPECTIVE|||||||
33828192|NCT06433440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828193|NCT02767102|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33828194|NCT00249171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828195|NCT03258502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828196|NCT00874484|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828197|NCT05074277|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33828198|NCT01222702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828199|NCT01540578|||||RETROSPECTIVE|||||||
33828200|NCT03730662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828201|NCT00730847|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34135487|NCT04360239|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135488|NCT05935657|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34135489|NCT02957747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135490|NCT06517225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All perceptual ratings will be obtained from blinded, naive listeners recruited through online crowdsourcing. Following protocols refined in previous published research, binary rating responses will be aggregated over at least 9 unique listeners per token.|All participants will complete an initial evaluation to determine eligibility and estimate the severity of speech sound disorder. Participants will be categorized into low and high severity groups and will be randomized with stratification by severity to the in-person or telepractice treatment condition. Participants will then complete 10 weeks of visual-acoustic biofeedback treatment in their randomly assigned condition. Treatment will be delivered individually by a speech-language pathologist and will elicit structured practice of /r/ in 20 semiweekly sessions.|f|f|f|t
34135491|NCT04790279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135492|NCT00025064||||TREATMENT||||||||
34135493|NCT00798460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135494|NCT06604767|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|-Investigators, Sponsor and study site staff, laboratory personnel, and participants will be blinded. Study staff preparing/administering the study interventions will be unblinded. Specific Sponsor personnel will be unblinded for the assessment of safety in the sentinel cohorts|Modified double-blind study|t|f|t|t
34135495|NCT00665795|||COHORT||PROSPECTIVE|||||||
34135496|NCT02639169|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135497|NCT04185337|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135498|NCT05193201|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135499|NCT06232603|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135500|NCT02900690|||OTHER||RETROSPECTIVE|||||||
34135501|NCT05189756|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Verum, placebo and block-randomisation will be provided by hospital pharmacy. Therefore, patients, treating team and researcher will be blinded.|This is a prospective, randomised, placebo-controlled, triple-blind, single centre, two-arm parallel groups superiority trial assessing incidence of PONV 48 hours after laparoscopic bariatric surgery.|t|t|t|t
34135502|NCT02710981|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135503|NCT00439543|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135504|NCT04812028|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135505|NCT06130254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135506|NCT05538065|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135507|NCT05131542|||CASE_ONLY||CROSS_SECTIONAL|||||||
34135508|NCT06661096|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135509|NCT05582707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||All subjects enrolled in this trial will be in the Experimental arm and receive intervention of MIPS + Pioglitazone. These patients will be compared to a dataset of subjects who have already undergone MIPS alone in a previous trial.||||
34135510|NCT05867420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135511|NCT02604602|||COHORT||PROSPECTIVE|||||||
34135512|NCT01350752|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135513|NCT00189332|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135514|NCT04217135|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This prospective study will recruit 400 patients aged 18 years or older, and hospitalization to E-Da Hospital for acute decompensated heart failure due to severe left ventricular systolic dysfunction combined with hemodynamically significant mitral regurgitation. Severe systolic dysfunction and hemodynamically significant mitral regurgitation are defined as left ventricular ejection fraction less than 35% and mitral regurgitant volume more than 45 ml (more than moderate degree), respectively. All participants will be randomly divided into two groups according to 1 to 1 fashion. One group will receive conventional evidence-based medication with up-titration to maximal tolerable dose and another group will receive low-dose hydralazine initially with rapid up-titration, if no adverse effect including hypotension with worsening low cardiac output sign, skin rash and joint pain occurred.||||
34135515|NCT02753907|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135516|NCT05497115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34135517|NCT02592720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135518|NCT01152047|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34135519|NCT06084637|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135520|NCT01747343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135521|NCT02402244|||OTHER||OTHER|||||||
34135522|NCT03522324|||COHORT||PROSPECTIVE|||||||
34135523|NCT02168049|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34135524|NCT03750760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135525|NCT03853850|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34135526|NCT00826696|||CASE_CONTROL||RETROSPECTIVE|||||||
34135527|NCT06308341|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated||f|f|f|t
34135528|NCT04627090|||CASE_ONLY||OTHER|||||||
34135529|NCT04433741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participant, outcomes assessor and investigator will be blinded to the randomization order. Research pharmacist will prepare each infusion.|Cross over model: each participant will be randomized to receive oxytocin and placebo in a random order|t|f|t|t
34135530|NCT05451706|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34135531|NCT04673942|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study is an exploratory open label single-arm interventional study using a 3 + 3 dose escalation safety run-in (PART 1) followed by a dose expansion single-agent (PART 2), followed by expansion (PART 3) single agent or single agent plus checkpoint inhibitor, followed by an adaptive designed Phase 2..||||
34135532|NCT05222893|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33828202|NCT04241783|||OTHER||CROSS_SECTIONAL|||||||
33828203|NCT04134598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828204|NCT02533349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828205|NCT01066936|||COHORT||PROSPECTIVE|||||||
33828206|NCT04538222|||COHORT||PROSPECTIVE|||||||
33828207|NCT01028755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828208|NCT03626025|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135533|NCT05761639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135534|NCT03973554|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34135535|NCT03640325|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34135536|NCT00675441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135537|NCT05055518|NA|SINGLE_GROUP||TREATMENT||NONE||"Subjects will be assigned to a dose level of APL-102 in the order of study entry. A total of seven therapeutic dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned. To reduce the number of subjects exposed to potentially ineffective doses and protect the rights and interests of subjects, rapid titration was used in the low-dose group (1 mg, 2 mg, 3 mg); When approaching the expected effective dose of 5 mg, the 3 + 3 study design was used."||||
34135538|NCT06659406|NA|SINGLE_GROUP||OTHER||NONE||||||
34135539|NCT05472909|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135540|NCT04683276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135541|NCT05807256|||COHORT||RETROSPECTIVE|||||||
34135542|NCT06350136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34135543|NCT05960903|||COHORT||RETROSPECTIVE|||||||
34135544|NCT03621176|NA|SINGLE_GROUP||TREATMENT||NONE||All participants will undertake the exercise intervention. We will compare effects of the intervention between different cohorts included (advanced chronic kidney disease, end-stage renal disease hemodialysis o peritoneal dialysis)||||
34135545|NCT02196883|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
34135546|NCT05116319|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34135547|NCT06658210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135548|NCT01745744|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135549|NCT06659848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A total of 160 men with T2DM were recruited from nearby hospitals and clinics to participate in this study and 123 completed the study follow-up. A licensed physician performed the preliminary evaluation for all participants. Participants were instructed to maintain their medications, their usual dietary habits and usual physical activity throughout the study period.~Only men diagnosed with T2DM, aged 40-60 years and inactive (performing less than 150 min/week of moderate-intensity exercise for at least the last six months) were included in this study. Subjects treated with exogenous insulin, and those with cardiovascular or musculoskeletal diseases limiting participation in HIIT were excluded.~Eligible subjects were randomly assigned to one of four groups. The Fasted-group practiced HIIT prebreakfast in the fasted state (8-12 h fasting). The Post-breakfast, Post-lunch and Post-dinner groups practiced HIIT 2h after breakfast, lunch, and dinner respectively. The primary outcome was gly"|t|f|f|f
34135550|NCT06656117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was single blinded,as accessor of the study were kept blind to the intervention group|In this parallel-group randmoized control trial (RCT),post Cabag patients will br assigned to either elliptical training group or to resistance training group .This study aims to evualate the comparative effects of eliptical training vs resistance training on cardiopulmonary parameters|f|f|f|t
34135551|NCT02172573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135552|NCT05658796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135553|NCT02147730|||COHORT||PROSPECTIVE|||||||
34135554|NCT04574258|||OTHER||PROSPECTIVE|||||||
34135555|NCT00970892|||COHORT||PROSPECTIVE|||||||
34135556|NCT01856075|||COHORT|||||||||
34135557|NCT04644237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135558|NCT03278912|||COHORT||PROSPECTIVE|||||||
34135559|NCT04784052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135560|NCT03438279|||COHORT||RETROSPECTIVE|||||||
34135561|NCT02539199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135562|NCT04131322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135563|NCT01760538|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135564|NCT00433966|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34135565|NCT03977025|||CASE_CONTROL||PROSPECTIVE|||||||
34135566|NCT04985409|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Subjects who are randomized to not get feedback about their activity will not be aware that there is another group that is receiving feedback||t|f|f|f
34135567|NCT03207321|||CASE_CONTROL||RETROSPECTIVE|||||||
34135568|NCT06407349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135569|NCT06462040|||COHORT||OTHER|||||||
34135570|NCT01369472|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135571|NCT05425732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34135572|NCT06361394|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."||||
34135573|NCT04410562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blinded, placebo-controlled multicentre clinical trial.|t|t|t|t
34135574|NCT06660056|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3||||
34135575|NCT05366179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135576|NCT05837611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135577|NCT03296826|||COHORT||PROSPECTIVE|||||||
34135578|NCT04023370|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multi-centre, randomised controlled trial design||||
34135579|NCT02882620|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34135580|NCT05807854|RANDOMIZED|PARALLEL||TREATMENT||NONE|The statistician will be blinded to patient allocation groups.|Multicenter, Randomized Comparative Surgical Trial||||
34135581|NCT03086707|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135582|NCT02998411|||COHORT||PROSPECTIVE|||||||
33828209|NCT02764177|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33828210|NCT06434233|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33828211|NCT01591655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135583|NCT05457907|NON_RANDOMIZED|SEQUENTIAL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
34135584|NCT03824678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135585|NCT00320554|||||PROSPECTIVE|||||||
34135586|NCT05139953|||CASE_ONLY||RETROSPECTIVE|||||||
34135587|NCT03227653|||COHORT||CROSS_SECTIONAL|||||||
34151157|NCT00683969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151158|NCT03731806|||CASE_ONLY||CROSS_SECTIONAL|||||||
34135588|NCT05732935|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to either a time restricted eating intervention, in which they will be instructed to fast for a target of 16 hours per day, or a successful aging (SA) comparison group for a 24-week period. This Study will examine the effects of TRE on changes in cognitive function, as assessed by the Repeatable Battery of the Assessment of Neuropsychological Status (RBANS), examine the effects of TRE on cognitive physical function, as assessed by the six-minute walk and short physical performance battery, and examine the effects of TRE on changes in mood, sleep patterns, metabolic function, and self-reported quality of life.||||
34135589|NCT02808052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135590|NCT06121609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34135591|NCT03490591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135592|NCT06428916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34135593|NCT06275776|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|No one in this study can reasonably be blinded for the suturing technique during the duration of the study, since the suturing techniques differ substantially in shape, appearance and size. The only blinding in this study is the blinding of the outcome assessor to data of the test subjects. The assessor will only see the photographs of the wound/plaster, and the moment on which the photograph was taken. Additional information on the test subject, such as age, comorbidities, et cetera, will be withheld from the assessor.|Test subjects are randomised into one of four study arms. Each study arm corresponds with one of the suturing techniques that are going to be used to close the superficial skin after Total Hip Arthroplasty.|f|f|f|t
34135594|NCT01805908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135595|NCT00517348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135596|NCT02613494|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135597|NCT06658717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|A randomized, double-blind, two-arm, placebo-controlled clinical study|t|t|t|t
34135598|NCT04823923|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135599|NCT03871309|||COHORT||PROSPECTIVE|||||||
34135600|NCT05238207|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34135601|NCT02479087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135602|NCT05001152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135603|NCT02274480|||CASE_CONTROL||PROSPECTIVE|||||||
34135604|NCT01487174|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135605|NCT00884091|||COHORT||CROSS_SECTIONAL|||||||
34135606|NCT04037449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135607|NCT03195218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Trial with a single arm||||
34135608|NCT01370577|||CASE_ONLY||PROSPECTIVE|||||||
34135609|NCT00599534|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135610|NCT04622670|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135611|NCT03582553|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|Except for the pharmacist who will prepare and dispense the capsules, all study staff and the investigators will be blinded to the randomization.|The study consists of two cohorts of nine subjects each. In the first cohort subjects will receive the 150 mg dose and proceed to the 300 mg dose only if the 150 mg dose is deemed safe. The study is a double blind randomized controlled crossover trial, therefore, subjects could receive a placebo at the first or second visit. Similarly in the second cohort, 600 mg and 900 mg doses will be evaluated.|t|t|t|t
34135612|NCT02863146|||CASE_ONLY||PROSPECTIVE|||||||
34135613|NCT03597581|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135614|NCT06661174|||COHORT||OTHER|||||||
34135615|NCT03061721|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135616|NCT06657352|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34135617|NCT04958993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135618|NCT03566771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135619|NCT06051318|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study is a N-of-1 randomized series trial with multiple crossovers.||||
34135620|NCT06482203|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135621|NCT06054152|||COHORT||PROSPECTIVE|||||||
34135622|NCT02997436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135623|NCT03267719|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135624|NCT00954629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135625|NCT01364454|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34135626|NCT06425887|||OTHER||PROSPECTIVE|||||||
34135627|NCT06229028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135628|NCT05476887|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34135629|NCT05097677|||COHORT||PROSPECTIVE|||||||
34135630|NCT02443480|||COHORT||PROSPECTIVE|||||||
34135631|NCT02578966|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135632|NCT06452108|||OTHER||CROSS_SECTIONAL|||||||
34135633|NCT00776672|RANDOMIZED|CROSSOVER||||NONE||||||
34135634|NCT04806776|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34135635|NCT06661486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||the participants will be randomly assigned to one of the three arms, uniformed intervention, individualized intervention or the control group.|f|f|t|t
34135636|NCT00066222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135637|NCT04446624|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135638|NCT01922947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135639|NCT03365258|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34151159|NCT03143751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking: Open label , Masked Roles: Subject and Outcomes assessor||t|f|f|f
34151160|NCT01040364|||COHORT||RETROSPECTIVE|||||||
33828212|NCT04167228|||COHORT||RETROSPECTIVE|||||||
33828213|NCT04016350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This is a randomised study with parallel design. Study participants underwent 4 week supervised moderate intensity exercise training combined either with IPE or cellulose as placebo supplementation at doses of 10g/day. Measurements were done before and after intervention||||
33828214|NCT04528953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828215|NCT04747821|RANDOMIZED|PARALLEL||PREVENTION||NONE||Groups of cluster are allocated to offer vaccination in a stepped-wedge mode.||||
33828216|NCT02805985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135640|NCT03228459|RANDOMIZED|PARALLEL||SCREENING||NONE||A randomized interventional study with 2 arms that will include 16,660 individuals with at least one cardiovascular risk factor from the province of Lleida, Spain. Patients will be recruited from January 2015 to December 2018. Patients will be followed for 10 years.||||
34135641|NCT06411769|RANDOMIZED|SEQUENTIAL||OTHER||NONE||This study will draw upon Sequential, Multiple Assignment, Randomized Trials (SMART) design to reduce barriers for both individuals and worksites to improve responsiveness to individual performance. The investigators are using the Consolidated Framework for Implementation Research (CFIR) across all project activities to establish proof-of-concept and improve the quality of behavioral intervention delivery to disparate populations on the U.S.-Mexico border and other similar regions.||||
34135642|NCT01180036|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135643|NCT06510777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary endpoint (i.e., 100% epithelialization) includes a blind assessment to reduce bias. The Blind Assessment Board will assess the primary endpoint using subject-series of wound photos, being unaware of treatment allocation of subjects.||f|f|f|t
34135644|NCT05396222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135645|NCT06608251|||COHORT||PROSPECTIVE|||||||
34135646|NCT05963204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135647|NCT01099098|||CASE_CONTROL||PROSPECTIVE|||||||
34135648|NCT02973204|||COHORT||PROSPECTIVE|||||||
34135649|NCT03031626|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The split-night polysomnograms (Arm A, Arm B) will be scored by a blinded independent sleep technologist. A Sleep Physician will report the sleep study and be blinded as to the gas assignment (ie Arm A or Arm B).|"The screening visit will occur during a regularly scheduled clinic visit. The patients that have consented for the study will all undergo the baseline PSG. Only patients with clinically significant CSA after Visit 1 will undergo randomization and complete Visit 2.~Those who have a CAHI greater or equal to 5 will be randomly assigned to Arm A or Arm B. Randomization will be performed using a computer with random numbers drawn. Arm A will receive Medical Air followed by Oxygen and Arm B will receive Oxygen followed by Medical Air."|f|t|t|t
34135650|NCT01979666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135651|NCT03192280|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135652|NCT06017609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135653|NCT01204047|||COHORT||PROSPECTIVE|||||||
34135654|NCT05859412|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcomes assessor and the person responsible for the statistical analysis will be blinded to the participants' allocation.||f|f|f|t
34135655|NCT03063723|||CASE_CONTROL||PROSPECTIVE|||||||
34135656|NCT00634725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135657|NCT06474520|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135658|NCT00851981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135659|NCT02141399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135660|NCT02603458|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135661|NCT06249048|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135662|NCT03689491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Outcomes Assessor)|Randomized|f|f|f|t
34135663|NCT05988528|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|t|f|f
34135664|NCT04594902|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Independent evaluators and coders assessing response over time are kept unaware of the condition to which each participant is assigned.|Randomized control trial in which participants are randomly assigned to either receive the Infant Behavior Program (IBP) or the Enhanced Pediatric Primary Care (EPPC).|f|f|f|t
34135665|NCT01429857|||COHORT||PROSPECTIVE|||||||
34135666|NCT04600505|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This is a single blind study with regard to BGF MDI treatment, administered with 3 different propellants (Treatment A, B or C), in which the participants will remain blinded.||t|f|f|f
34135667|NCT05799521|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|Providing pharmacy will randomize doses and provide blinded doses|People who test positive for COVID-19|t|f|t|t
34135668|NCT05424978|||COHORT||PROSPECTIVE|||||||
34135669|NCT03470324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34135670|NCT01250184|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135671|NCT06141538|||COHORT||OTHER|||||||
34135672|NCT03392363|||COHORT||PROSPECTIVE|||||||
34135673|NCT02661555|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34135674|NCT05936840|||COHORT||PROSPECTIVE|||||||
34135675|NCT01210248|||CASE_ONLY||CROSS_SECTIONAL|||||||
34135676|NCT04767581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135677|NCT05806515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135678|NCT04227275|NA|SEQUENTIAL||TREATMENT||NONE||Sequential dose escalation||||
34135679|NCT03051880|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135680|NCT06460779|||OTHER||CROSS_SECTIONAL|||||||
34135681|NCT02218697|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135682|NCT03397524|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient participant will be unaware of randomization.|The interventional arm outcomes will be compared to the control.|t|f|f|f
34135683|NCT03090516|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135684|NCT01248039|||COHORT||PROSPECTIVE|||||||
34135685|NCT02309645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135686|NCT01134913|||COHORT||PROSPECTIVE|||||||
34135687|NCT05850663|NA|SINGLE_GROUP||OTHER||NONE||||||
34135688|NCT05348356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135689|NCT05623475|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34135690|NCT02258971|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135691|NCT00222235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135692|NCT02762656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34135693|NCT06154889|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135694|NCT03203811|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135695|NCT05868265|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm phase II trial.||||
33828217|NCT06050018|RANDOMIZED|CROSSOVER||TREATMENT||NONE||In a crossover design the effect of Yes Milk Diet (YesMdiet) and of No Milk Diet (NoMdiet) on Gut Microbiome (GM) and Bone Turnover Markers will be assessed in the participants in random order||||
33828218|NCT04641416|||COHORT||PROSPECTIVE|||||||
33828219|NCT00762645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828220|NCT00709540|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33828221|NCT02822209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828222|NCT00938990|RANDOMIZED|PARALLEL||||DOUBLE||||||
33828223|NCT01781013|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33828224|NCT03376698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828225|NCT02600598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828226|NCT06099288|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Intervention staff (Project coordinator \& Community Health Workers) will know what group each participant has been allocated to. Evaluation teams will be masked. Additionally, participants will know if they have been assigned to the group focused on child feeding or the group focused on child reading readiness, but will not be told that one is the intervention group and one is the comparison group."|After baseline measures are complete, parent-child dyads will be randomly assigned to either the Intervention (I) or Comparison group (C) using random generator software. Because parents will need to complete a second recall over the phone after completing in-person measurements, randomization will happen over the phone. The project manager will let parents know by phone what group they are in and conduct an orientation about upcoming activities for each group.|t|f|f|t
33828227|NCT01965145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828228|NCT01695447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33828229|NCT00010842|RANDOMIZED|||TREATMENT||||||||
33828230|NCT05470959|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33828231|NCT01649505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828232|NCT00185796|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828233|NCT02702336|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828234|NCT06187597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828235|NCT00979329|||CASE_ONLY||PROSPECTIVE|||||||
33828236|NCT03993496|||COHORT||PROSPECTIVE|||||||
33828237|NCT05319132|||COHORT||PROSPECTIVE|||||||
33828238|NCT00654615|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study was a prospective clinical trial comparing two different types of hardware to fix a specific type of distal radius fracture.||||
33828239|NCT01624597|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33828240|NCT03411798||SEQUENTIAL||TREATMENT||NONE||Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.||||
33828241|NCT00197119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828242|NCT01195740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828243|NCT03718819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828244|NCT02388113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828245|NCT00383630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828246|NCT03028259|||COHORT||RETROSPECTIVE|||||||
33828247|NCT03142113|||COHORT||RETROSPECTIVE|||||||
33828248|NCT05899621|||COHORT||PROSPECTIVE|||||||
33828249|NCT05850182|NA|SINGLE_GROUP||OTHER||NONE||Pilot study||||
33828250|NCT05062837|NA|SINGLE_GROUP||TREATMENT||NONE|Tumor response will be assessed with revised Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and mRECIST. All imaging data were independently assessed by one radiologist who is blinded to the clinical data and one hepatologist who is not blinded to the clinical data.|Hepatectomy Combined With Camrelizumab and Apatinib||||
33828251|NCT02624869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828252|NCT03937232|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Outcomes assessor blinded to group allocation|Cross-education OR Mirror visual feedback OR Cross-education + mirror visual feedback OR usual care|f|f|f|t
33828253|NCT01262118|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828254|NCT04768868|NA|SEQUENTIAL||TREATMENT||NONE||"The dose schedules will be explored in this study (described below):~Dose Schedule: IMP7068 administered QD on Days 1-3, Days 8-10 and Days 15-17 on a 21-day cycle.~The other Dose Schedules may be explored according to SMC decision.~The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage. Approximately100 patients each with advanced solid tumor who has exhausted available treatment options with respective biomarker(s) determined by central laboratory will be evaluated. Single dosing will not be performed in the dose-expansion stage of the study."||||
33828255|NCT05730517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828256|NCT03494855|||COHORT||PROSPECTIVE|||||||
33828257|NCT01657565|||||RETROSPECTIVE|||||||
33828258|NCT05172518|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33828259|NCT04604470|||OTHER||OTHER|||||||
33828260|NCT00383747|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33828261|NCT02406495|NA|SINGLE_GROUP||OTHER||NONE||||||
33828262|NCT00935259|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33828263|NCT04795583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Placebo-controlled||t|t|t|f
33828264|NCT00820729|||COHORT||CROSS_SECTIONAL|||||||
33828265|NCT01430078|RANDOMIZED|CROSSOVER||||NONE||||||
33828266|NCT05955963|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828267|NCT00721214|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828268|NCT00711997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828269|NCT00980577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828270|NCT06295042|||COHORT||RETROSPECTIVE|||||||
33828271|NCT01722864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828272|NCT04232878|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A sample size of 9 subjects per cohort has been chosen based on the need to minimize exposure of humans to CVL-936 and PF-06815106 and the requirement to provide adequate safety, tolerability, and PK information at each dose. Each cohort will be conducted as a crossover design with 3 periods and each cohort will have up to 6 subjects receiving CVL-936 and 3 subjects receiving placebo within each period, with a total of approximately 18 subjects if 2 cohorts complete or a total of approximately 27 subjects if 3 cohorts complete.|t|t|t|t
33828273|NCT05082844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828274|NCT01136447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828275|NCT04699123|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828276|NCT03650673|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33828277|NCT01438515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828278|NCT04883021|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm prospective cohort study||||
33828279|NCT04683211|||COHORT||PROSPECTIVE|||||||
33828280|NCT05596578|||COHORT||PROSPECTIVE|||||||
33828281|NCT00171795|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828282|NCT01700023|||COHORT||PROSPECTIVE|||||||
33828283|NCT04205136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|"Both groups will receive treatment as usual for obstructive sleep apnea. Spironolactone and placebo will be prescribed by one of the study physicians (who will not be blinded to treatment condition \[care provider\]) ."|The researchers will do a trial of spironolactone in 30 obstructive sleep apnea (OSA) patients with cardiovascular disease who are non-adherent with Positive Airway Pressure (PAP) therapy.|t|f|t|f
33828284|NCT03714542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828285|NCT04319614|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828286|NCT03511573|||COHORT||PROSPECTIVE|||||||
33828287|NCT00414089|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828288|NCT05479747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33828289|NCT06065306|||COHORT||PROSPECTIVE|||||||
33828290|NCT03181282|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor will be blinded to group assignment.||f|f|f|t
33828291|NCT05191836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828292|NCT03015870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828293|NCT03849768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828294|NCT01583738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828295|NCT02216578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828296|NCT02856490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828297|NCT04591821|||COHORT||PROSPECTIVE|||||||
33828298|NCT05857514|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828299|NCT04778787|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828300|NCT01143883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828301|NCT05371145|NA|SINGLE_GROUP||TREATMENT||NONE||In a single arm open labelled safety trial, we will supplement carnosine for 3 months to subjects with non-claudication and claudication peripheral arterial disease (PAD), and determine if it improves walking ability. In our pilot study, we will enroll 20 male subjects measure the distance covered on the 6-minute walk test and the pain free walking capacity on the treadmill before, at baseline, and three months after carnosine supplementation.||||
33828302|NCT04786483|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33828303|NCT02507687|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33828304|NCT03011905|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828305|NCT03239197|||FAMILY_BASED||PROSPECTIVE|||||||
33828306|NCT00195442|||COHORT||PROSPECTIVE|||||||
33828307|NCT02712307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828308|NCT01712295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828309|NCT05865925|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33828310|NCT03626805|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828311|NCT05871190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33828312|NCT00576823|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828313|NCT03964922|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828314|NCT04787289|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828315|NCT01101464|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33828316|NCT05500898|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828317|NCT00918710|||COHORT||PROSPECTIVE|||||||
33828318|NCT01540903|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33828319|NCT03544229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828320|NCT00384098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828321|NCT02362347|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828322|NCT02565888|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33828323|NCT00002971||||TREATMENT||||||||
33828324|NCT03153098|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33828325|NCT04647318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828326|NCT03962517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded research physical therapist will test the outcome measure at baseline, mid testing after 9th session of training, at post testing after 18th session of training, at 1 month follow up testing after 18th session of training and at 3 months follow up testing after 18th session of training.|Training in the GEMS-H group consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device, whereas training in the control group consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments without device.|f|f|f|t
33828327|NCT01135030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828328|NCT04214613|||COHORT||RETROSPECTIVE|||||||
33828329|NCT00738985|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828330|NCT03508934|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Glucose Telemetry System (Continuous Glucose Monitoring Devices)~Active Comparator: Intervention group (Continuous Glucose Monitroring and POC) Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)~Placebo Comparator: Control group (Point of Care-POC) Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)"||||
33828331|NCT05856578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828332|NCT05229471|||COHORT||PROSPECTIVE|||||||
33828333|NCT03429595|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Subjects will be randomly assigned (stratified by age) by using an Interactive Web Response System (IWRS) to one of five treatment groups|t|f|t|f
33828334|NCT03311269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828335|NCT01171300|NA|SINGLE_GROUP||OTHER||NONE||||||
33828336|NCT03586141|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||measurement of hemoglobin by a noninvasive sensor clip||||
33828337|NCT01530087|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828338|NCT00264823|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135696|NCT00578188|||CASE_CONTROL||PROSPECTIVE|||||||
34135697|NCT01320553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135698|NCT04904276|||COHORT||PROSPECTIVE|||||||
34135699|NCT04160286|||COHORT||PROSPECTIVE|||||||
34135700|NCT04042051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135701|NCT02543281|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135702|NCT06389721|||COHORT||PROSPECTIVE|||||||
34135703|NCT04150666|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135704|NCT05469230|||OTHER||CROSS_SECTIONAL|||||||
34135705|NCT02040350|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||f|t|t|t
34135706|NCT05850910|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135707|NCT05340712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The allocation of the formula to each infant is drawn according to a randomization list developed using a software by the clinical research organization in charge of statistics and known only to him until the blind is lifted, i.e. after the statistical analysis. A 1:1 double-blind randomisation will be computer-generated by block (in each center).|Superiority, double-blind, randomized, placebo-controlled trial of 60 days followed by an optional 60 day, open-label follow-up period with the tested formula only|t|t|t|t
34135708|NCT02351063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135709|NCT00499291||||TREATMENT||NONE||||||
34135710|NCT05143749|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135711|NCT05655559|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
34135712|NCT06659939|||CASE_CONTROL||PROSPECTIVE|||||||
34135713|NCT01618045|||OTHER||OTHER|||||||
34135714|NCT03542656|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135715|NCT03069248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135716|NCT06401889|||COHORT||PROSPECTIVE|||||||
34135717|NCT05666934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135718|NCT05359822|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135719|NCT06533501|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single-day interventions; Repeated Measures Design||||
34135720|NCT00361868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135721|NCT04660851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135722|NCT01985711|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34135723|NCT00129584|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135724|NCT06437288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135725|NCT04999215|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135726|NCT02491242|||COHORT||PROSPECTIVE|||||||
34135727|NCT00663884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135728|NCT04261725|||COHORT||PROSPECTIVE|||||||
34135729|NCT01728558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135730|NCT03729583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34135731|NCT01825486|||COHORT||PROSPECTIVE|||||||
34135732|NCT02766439|||CASE_ONLY||PROSPECTIVE|||||||
34135733|NCT03936634|||COHORT||PROSPECTIVE|||||||
34135734|NCT04685005|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Blinding will be kept by the manufacturer of the beverages (Frutarom USA, Inc). All 5 beverages (placebo, 100mg Caffeine, WakeUp® regular dose, WakeUp® double dose, and WakeUp® triple dose) will be marked by a letter beween A to E, which will be blinded to the participants and the staff of the study. Only after the completion of the study (all 30 participants), and statistical analysis and reporting will the various beverages (letters) will be unblinded. The only occasion of unblinding prior to study completion will be the unexpected occasion of a serious side effect.|Participants will be randomized regarding the order of the various beverages they drink, in a double blind placebo and active control model.|t|t|t|t
34135735|NCT05103579|||COHORT||CROSS_SECTIONAL|||||||
34135736|NCT02227082|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135737|NCT03529188|||COHORT||PROSPECTIVE|||||||
33828339|NCT00926198|||COHORT||CROSS_SECTIONAL|||||||
33828340|NCT02118194|||COHORT||PROSPECTIVE|||||||
33828341|NCT00607139|||COHORT||PROSPECTIVE|||||||
33828342|NCT06235385|||COHORT||PROSPECTIVE|||||||
33828343|NCT02652390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828344|NCT05510622|||COHORT||PROSPECTIVE|||||||
33828345|NCT00173238|||CASE_CONTROL||OTHER|||||||
33828346|NCT04952337|||COHORT||PROSPECTIVE|||||||
33828347|NCT03745378|||CASE_CONTROL||RETROSPECTIVE|||||||
33828348|NCT02600585|||COHORT||RETROSPECTIVE|||||||
34135738|NCT06030466|RANDOMIZED|CROSSOVER||OTHER||NONE||Randomization with crossover design||||
34135739|NCT03913013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Outcomes assessor will be unaware of whether the patient is in FFT-MCC or FFT-Assess.|The investigation is comparing youth who receive family-focused treatment with the MyCoachConnect (FFT-MCC) mobile application (assessments, skill training, psychoeducation) to youth who receive FFT plus only the assessment components of the MCC app (FFT-Assess) on symptomatic outcome and family functioning over 27 weeks.|f|f|f|t
34135740|NCT00374946|||COHORT||PROSPECTIVE|||||||
34135741|NCT04435301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34135742|NCT00479817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135743|NCT02720055|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135744|NCT05327842|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34135745|NCT01558492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135746|NCT00387569|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34135747|NCT05347680|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34135748|NCT03541486|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Radiologic measurements will be completed by a reviewer blinded to treatment assignment|Randomized trial (standard vs. experimental) in a one-to-one ratio.|f|f|f|t
34135749|NCT02453945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135750|NCT02889289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135751|NCT06661161|||COHORT||PROSPECTIVE|||||||
34135752|NCT04521686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135753|NCT04622891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|clarithomycin group Azithromycin group control group|t|f|f|t
34135754|NCT01452061|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34135755|NCT02248441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135756|NCT02679144|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34135757|NCT02748668|||CASE_CONTROL||PROSPECTIVE|||||||
34135758|NCT03455933|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34135759|NCT01411579|||||PROSPECTIVE|||||||
34135760|NCT04065074|NA|SINGLE_GROUP||OTHER||NONE||||||
34135761|NCT05659017|||COHORT||RETROSPECTIVE|||||||
34135762|NCT03278717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135763|NCT04822896|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135764|NCT01533337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135765|NCT01956097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135766|NCT02732795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135767|NCT03252444|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34135768|NCT01615952|||COHORT||PROSPECTIVE|||||||
34135769|NCT04703270|||CASE_CONTROL||PROSPECTIVE|||||||
34135770|NCT06661278|||OTHER||PROSPECTIVE|||||||
34135771|NCT01794078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135772|NCT05896098|||CASE_ONLY||PROSPECTIVE|||||||
34135773|NCT06608238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded (Participant and Investigator)|60 subjects randomized in a 1:1:1 ratio to receive placebo or one of the D-MNA doses weekly for three doses.|t|f|t|t
34135774|NCT00945347|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34135775|NCT00610350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135776|NCT06385795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135777|NCT05804656|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind||t|f|t|f
34135778|NCT00044681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135779|NCT02285023|||CASE_ONLY||PROSPECTIVE|||||||
34135780|NCT01916252|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135781|NCT03362502|NA|SEQUENTIAL||TREATMENT||NONE||||||
34135782|NCT04353375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135783|NCT04017572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135784|NCT06660290|NA|SINGLE_GROUP||TREATMENT||NONE|In this single arm study, the subject is masked as to when they receive the Refresh Classic.|||||
34135785|NCT02589665|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135786|NCT01756690|||COHORT||PROSPECTIVE|||||||
34135787|NCT00298805|||CASE_ONLY||PROSPECTIVE|||||||
34135788|NCT01858142|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34135789|NCT02038140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135790|NCT06527144|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135791|NCT00412347|||||RETROSPECTIVE|||||||
34135792|NCT04130724|||COHORT||PROSPECTIVE|||||||
34135793|NCT04117490|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34135794|NCT05638802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135795|NCT06066021|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34135796|NCT06483191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The Chief Investigator will be blinded to what group patients are randomised to. It will not be possible to blind the patients, research team or physiotherapists involved in the study.|A single centred, parallel group, randomised controlled trial|f|f|t|f
34135797|NCT04470908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135798|NCT02551094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135799|NCT05901675|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Participants will undergo the intervention within one arm alone.|t|f|f|f
34135800|NCT02130687|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34135801|NCT04044599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135802|NCT00895440|||||CROSS_SECTIONAL|||||||
34135803|NCT05431387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135804|NCT03255967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135805|NCT04801225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135806|NCT04652206|NA|SINGLE_GROUP||TREATMENT||NONE||Standard 3+3 dose escalation design to determine the Maximum Tolerated dose (MTD) of SCO-101 when administered in combination with gemcitabine and nab-paclitaxel, in patients with inoperable pancreatic cancer||||
34135807|NCT02890303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135808|NCT00776594|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135809|NCT02617407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34135810|NCT05501210|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be assigned into either vibration or control groups.||||
34135811|NCT04597359|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34135812|NCT03386136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135813|NCT02126553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135814|NCT00046761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135815|NCT02256384|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135816|NCT05613452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135817|NCT02921217|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135818|NCT06658951|NA|SINGLE_GROUP||TREATMENT||NONE||Accelerated titration and 3+3 design dose escalation phase||||
34135819|NCT00434733|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34135820|NCT06239441|||COHORT||RETROSPECTIVE|||||||
34135821|NCT01410175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34135822|NCT00625196|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34135823|NCT00227344|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135824|NCT05830214|||CASE_CONTROL||PROSPECTIVE|||||||
34135825|NCT03172884|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135826|NCT00395187|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135827|NCT00223405|||COHORT||PROSPECTIVE|||||||
34135828|NCT04639232|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34135829|NCT06662240|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Each patient in the experimental and control groups received two subcutaneous injections. Each patient in the experimental group received one injection with vibration and one without vibration. Each patient in the control group received two injections without vibration. The purpose of administering two injections was to obtain control data within the experimental group by controlling individual factors related to the dependent variables of the study.|t|f|f|t
34151161|NCT01224444|||CASE_ONLY||PROSPECTIVE|||||||
34151162|NCT02591368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151163|NCT02273960|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135830|NCT04727632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a companion imaging study to IRB # 131027 FORESEE: Functional precision oncology for metastatic breast cancer: a feasibility trial. This companion imaging study will obtain \[18F\]Fluoroestradiol (FES)-PET/CT imaging of breast cancer patients refractory to all combinatorial hormonal therapies enrolled in the FORESEE trial and correlate the FES-PET/CT results with data from FORESEE including estrogen receptor (ER) status and drug profiling results from patient-derived organoid models.||||
34135831|NCT00391430|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34135832|NCT04647942|||CASE_ONLY||RETROSPECTIVE|||||||
34135833|NCT06107816|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34135834|NCT04579237|||OTHER||RETROSPECTIVE|||||||
34135835|NCT03046095|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE|Investigators and participants will have knowledge or which leg will be undergoing resistance training and which will be immobilized.|The model will be a within-subject intervention. Each subject will have one leg randomized to unilateral resistance exercise (for 10 weeks) and the other to immobilization (for the last 2 weeks of the study).||||
34135836|NCT05718167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135837|NCT01303718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135838|NCT01557257|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34135839|NCT01579058|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135840|NCT04927156|||COHORT||OTHER|||||||
34135841|NCT05463718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135842|NCT03260192|||COHORT||PROSPECTIVE|||||||
34135843|NCT00182715|RANDOMIZED|||TREATMENT||NONE||||||
34135844|NCT00615589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135845|NCT04888689|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||all patients undergo clinical evaluation while wearing Actimyo device to assess their gait.||||
34135846|NCT05898776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135847|NCT06658665|||COHORT||RETROSPECTIVE|||||||
34135848|NCT04563234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|All study team members will be blinded to the subject assignment to either intervention (cognitive flexibility training) or control groups (crossword puzzle training), except one coordinator who will monitor participant adherence with the cognitive flexibility training, and send prompts or contact participants to understand barriers to adherence.||f|t|t|t
34135849|NCT00765037|||COHORT||RETROSPECTIVE|||||||
34135850|NCT04813614|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The subjects randomized in the study will be blinded to the treatment administered by using a blindfold during injection session(s).~All the evaluators and operators who will take part in the investigation will be different than the legally qualified clinical practitioners who will realize injections and will be blinded to the treatment administered:~* Live blinded independent evaluators will oversee the inclusions of subjects, the follow-up of subject's tolerance and the scoring in live of the GAIS (also using the photograph taken at V1 before first injection as a reference). The same blinded independent evaluator will follow-up the same subjects over the study period as far as possible.~* Technicians who will oversee the photographs taking."|Prospective, double blinded, randomized, active controlled, multicenter study (post-market clinical follow-up).|t|f|t|t
34135851|NCT03905031|NA|SINGLE_GROUP||SCREENING||NONE||||||
34135852|NCT04148196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135853|NCT00499512|||CASE_ONLY||PROSPECTIVE|||||||
34135854|NCT03900104|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
34135855|NCT03516773|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized, active comparator, two-part, within-part, partial crossover design.||||
34135856|NCT02179424|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34135857|NCT04088240|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34135858|NCT06607341|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Randomized delayed control group with phased recruitment design||||
34135859|NCT03770325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34135860|NCT02251834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34135861|NCT03811769|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135862|NCT00142168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135863|NCT00005077||||TREATMENT||||||||
34135864|NCT05723562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135865|NCT05069077|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135866|NCT03551405|||CASE_ONLY||RETROSPECTIVE|||||||
34135867|NCT04671212|||OTHER||PROSPECTIVE|||||||
34135868|NCT00118846|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34135869|NCT03316287|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34135870|NCT05538312|NA|CROSSOVER||OTHER||NONE||||||
34135871|NCT00551148|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34135872|NCT04516499|||FAMILY_BASED||PROSPECTIVE|||||||
34135873|NCT03330483|||CASE_CONTROL||PROSPECTIVE|||||||
34135874|NCT04322331|||CASE_CONTROL||RETROSPECTIVE|||||||
34135875|NCT02826824|||COHORT||RETROSPECTIVE|||||||
34135876|NCT02885480|||COHORT||PROSPECTIVE|||||||
34135877|NCT01345513|||COHORT||PROSPECTIVE|||||||
34135878|NCT06428058|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A randomized, controlled, single blinded trial, stratified by health profession, of the intervention vs waitlist control.|Testing of an Afrocentric sexual health curriculum for Midwifery, Nursing and Medical Students.|f|f|f|t
34150250|NCT03584555|RANDOMIZED|PARALLEL||TREATMENT||NONE||Enrollment period : 24 months after IRB approval Methods: The subjects are randomly divided into two groups. One group underwent SMILE surgery using 120 μm cap thickness, and the other group underwent SMILE surgery using 140 μm cap thickness. Before surgery, all patients underwent a detailed ophthalmological examination that included evaluation of logarithm of the minimum angle of resolution (logMAR) uncorrected-distance visual acuity (UDVA) and CDVA, manifest refraction, slit-lamp examination (Haag-Streit, Köniz, Switzerland), keratometry, and Scheimpflug-based corneal topography (Pentacam HR, Oculus). Dynamic corneal response (DCR) parameters were examined using Corvis ST. Corneal wavefront aberrations were measured using Keratron Scout (Optikon 2000, Rome, Italy). All examinations were repeated at 1, 3, and 6 months after surgery.||||
33828349|NCT05469113|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33837512|NCT01871688|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33837513|NCT05444634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34135879|NCT05920681|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|During the research, the name and surname of the subject will be replaced by a special code, according to which it will not be possible to determine the identity of the subject. The subject will be randomly assigned a combination of numbers and/or letters, which will not use the patient's name, surname, initials or other personally identifiable information. This code will be used in all study documents except the consent form. If the law does not provide otherwise, only the doctor conducting the study, the research staff will be able to get acquainted with the confidential data revealing the name and surname.|"Individuals participating in this study will be randomly divided into groups 1 and 2 by randomization. The probability of falling into one or the other group is equal.~* Group 1. This is a group of patients who will be subjected to transanal irrigation (experimental).~* Group B. This is a group of patients who will receive only the best currently in use maintenance treatment (control)."|t|t|f|f
34135880|NCT03786081|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135881|NCT01317576|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135882|NCT02855957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135883|NCT01738607|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34135884|NCT05317715|RANDOMIZED|PARALLEL||OTHER||NONE||Single-centre, prospective, randomised, open-label study comparing a group of patients who had information and demonstration about IUDs prior to completing a questionnaire and a group of patients who did not have information and demonstration about IUDs prior to completing the questionnaire||||
34135885|NCT04943341|NA|SINGLE_GROUP||TREATMENT||NONE||The pilot study will be include a single group of 30 patience affected by the medial plica syndrome. Patients will be treated with an eco-guided injection of Triamcinolone-Acetonide and will be evaluated clinical and radiological outcomes||||
34135886|NCT01237457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135887|NCT00083954|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34135888|NCT05808946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135889|NCT05439993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135890|NCT06661668|||COHORT||PROSPECTIVE|||||||
34135891|NCT00817570|||COHORT||PROSPECTIVE|||||||
34135892|NCT01132534|||CASE_CROSSOVER||PROSPECTIVE|||||||
34135893|NCT05705778|||COHORT||OTHER|||||||
34135894|NCT01106859|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34135895|NCT05628090|||COHORT||RETROSPECTIVE|||||||
34135896|NCT01811485|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135897|NCT04614870|||COHORT||PROSPECTIVE|||||||
34135898|NCT00501592|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135899|NCT00801723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135900|NCT00277927|||||RETROSPECTIVE|||||||
34135901|NCT02662504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135902|NCT06506188|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is an effectiveness-implementation type I hybrid cluster randomized trial which includes prospective data collection (both quantitative and qualitative) as well as use of existing surveillance data to inform pre-defined effectiveness and implementation outcomes of interest. Randomization and implementation of the LINK model occurs at the clinic level, and individuals are considered exposed or unexposed based on their attendance at intervention or control clinics.||||
34135903|NCT06660537|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive (interventional group) balloon-blowing exercises in 90/90 bridge position with a ball and the other group (control group) will receive buteyko breathing exercises.||||
34135904|NCT03172325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135905|NCT04314999|||CASE_ONLY||RETROSPECTIVE|||||||
34135906|NCT02244476|||OTHER||OTHER|||||||
34135907|NCT03091998|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The Research Pharmacists will manage the randomization of the study and release information at the conclusion, once all participants have been recruited and completed study measures.|Injection of CD-NP vs Placebo|t|t|t|f
34135908|NCT03783000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135909|NCT01311115|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135910|NCT01121445|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34135911|NCT04277858|NA|SINGLE_GROUP||TREATMENT||NONE||neoadjuvant Docetaxel and Cisplatin and transoral surgery||||
34135912|NCT02058511|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135913|NCT00146809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34135914|NCT02110537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135915|NCT06115473|RANDOMIZED|PARALLEL||PREVENTION||NONE||: septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) \> 0.9.||||
34135916|NCT00835198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34135917|NCT02437630|||CASE_CONTROL||PROSPECTIVE|||||||
34135918|NCT03384355|||COHORT||PROSPECTIVE|||||||
34135919|NCT02928302|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34135920|NCT03639636||SEQUENTIAL||SCREENING||NONE||interventional prospective study||||
33828350|NCT04431219|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a phase I/II interventional, uncontrolled, single center, open-label study with an adaptive design conducted in two cohorts: Ascending Dose (AD) cohort and Therapeutic Dose (TD) cohort.||||
33828351|NCT02496143|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33828352|NCT01627470|||COHORT||PROSPECTIVE|||||||
33828353|NCT03906604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135921|NCT00556608|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34135922|NCT00152477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135923|NCT03397394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135924|NCT06008561|||CASE_ONLY||PROSPECTIVE|||||||
34135925|NCT02387333|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34135926|NCT01271712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34135927|NCT06362330|||OTHER||RETROSPECTIVE|||||||
34135928|NCT01114971|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
34135929|NCT04850222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers collecting survey data will be blinded to patients' intervention status.||f|f|t|f
34135930|NCT05828394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135931|NCT01075867|||COHORT||PROSPECTIVE|||||||
34135932|NCT06659458|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34135933|NCT05240157|||COHORT||PROSPECTIVE|||||||
34135934|NCT06552546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135935|NCT03374683|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34135936|NCT03237494|||COHORT||PROSPECTIVE|||||||
34135937|NCT06097533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|IMPs are centrally blinded and randomised at the pharmacy.|Multi-center, prospective, interventional, randomized, two-arm, placebo-controlled, parallel, double-blinded clinical trial according to German Drug Law (AMG)/GCP and German Narcotic Drugs Act (BtMG)|t|t|t|t
34135938|NCT03650894|NA|SINGLE_GROUP||TREATMENT||NONE||This is a phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer.||||
34135939|NCT04914481|||COHORT||RETROSPECTIVE|||||||
34135940|NCT04348318|||COHORT||RETROSPECTIVE|||||||
34135941|NCT06019663|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34135942|NCT05935358|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135943|NCT04630132|||COHORT||CROSS_SECTIONAL|||||||
34135944|NCT03077152|||CASE_ONLY||PROSPECTIVE|||||||
34135945|NCT04353999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135946|NCT00483366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135947|NCT04570605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients will be randomized to standard urotherapy or urotherapy + PTENS|randomized controlled trial|t|f|f|f
34135948|NCT02229305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34135949|NCT04818827|||COHORT||RETROSPECTIVE|||||||
34135950|NCT05898672|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34135951|NCT00006447|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34135952|NCT01766739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135953|NCT00721578|||||PROSPECTIVE|||||||
34135954|NCT01424748|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34135955|NCT02891902|||COHORT||PROSPECTIVE|||||||
34135956|NCT05128474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34135957|NCT00777985|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34135958|NCT04378491|||COHORT||PROSPECTIVE|||||||
34135959|NCT04020926|||COHORT||PROSPECTIVE|||||||
34135960|NCT05466955|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|"The trial will be investigator-masked, but not participant-masked, because all participants who are eligible for eye glasses will be given them. The study's outcomes, including Crash and near Crash (CNC) events per 1,000 km, self-reported visual function (Visual Function Questionnaire (VFQ-25), and CI SRQ Crash and Injury Self report Questionnaire for all crashes, Dula Dangerous Driving Index (DDDI) will be masked from assessors.~All care will be taken to ensure that the study team are kept masked and the trial team do not foresee conditions that will require emergency unmasking."|STABLE is a naturalistic driving trial with a Stepped Wedge-Cluster Randomised Trial (SW-CRT) design. The unit of randomisation in STABLE is the cluster: five universities in Ho Chi Minh City, Vietnam. The design involves random, sequential crossover of clusters from control to intervention until all clusters are exposed to the study intervention. The stepped-wedge cohort design with exchangeable correlation structure will comprise six sequences (steps) of an estimated seven myopic participants per cluster, and five clusters per sequence. The duration of each sequence is 12 weeks. Participants will not be masked to whether they are in the control or intervention period but investigators assessing study outcomes will be masked to this.|f|f|t|f
34135961|NCT01948765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34135962|NCT01595971|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34135963|NCT01779856|NA|SINGLE_GROUP||OTHER||NONE||||||
34135964|NCT00528502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135965|NCT00812409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34135966|NCT04832802|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The investigators will use a 4-year, 2-armed, multi-site randomized controlled study design with concurrent mixed methods data collection at two VAMCs (Tampa and Richmond), to compare ACCESS-Vets intervention to treatment-as-usual (TAU), which is IPS.||||
34135967|NCT04494542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135968|NCT02876523|||COHORT||PROSPECTIVE|||||||
34135969|NCT03772834|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34135970|NCT00183781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135971|NCT00579410|||COHORT||PROSPECTIVE|||||||
34135972|NCT04158037|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135973|NCT06358664|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34135974|NCT05998070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Hip strengthening exercises will be performed 3 times a week for 6 weeks in the exercise group. The control group will continue their routine sport training program.|t|t|t|t
34135975|NCT02746887|||CASE_CONTROL||PROSPECTIVE|||||||
34135976|NCT05959538|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will recruit a group of caregivers in which the caregiver meets the current criteria for elevated symptoms of psychological distress as measured by a score of 9 and above on the Patient Health Questionnaire 9-item. Eligible female caregivers (mothers, grandmothers, aunts, guardians) will be randomly assigned to one of three intervention arms, which will occur concurrently over 16-weeks. One arm will incorporate intervention materials from Dialectical Behavior Therapy (DBT) and parent skills training (BRIDGE), another will provide DBT only, while the third will provide community family support services as usual.||||
34135977|NCT02227069|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|f|t
34135978|NCT03409705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34135979|NCT04657835|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34135980|NCT03894982|||FAMILY_BASED||PROSPECTIVE|||||||
34135981|NCT03517839|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34135982|NCT00301392|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34135983|NCT05551923|||COHORT||PROSPECTIVE|||||||
34135984|NCT01696019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34135985|NCT04034719|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34135986|NCT05221632|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34135987|NCT04892550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, parallel-group, randomized clinical trial participants will be randomly assigned to the control group or intervention group.|f|f|f|t
34135988|NCT00453700|||COHORT||PROSPECTIVE|||||||
34135989|NCT04305769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Block randomization will be applied to assign participants to one of the four study groups, either one of the three experimental (AQ) or control (placebo) group in 1:1:1:1 allocation from a list containing the randomized and blinded treatment assignments.|t|t|t|f
34135990|NCT02427386|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34135991|NCT00640380|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|f|t
34135992|NCT06477965|||OTHER||OTHER|||||||
34135993|NCT03951831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135994|NCT01513187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135995|NCT05566691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34135996|NCT04545723|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34135997|NCT02244840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34135998|NCT03883347|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All syringes and solutions will be prepared by an independent researcher who will not be further involved in the study eg data collecting or analyzing them.All syringes will look identical to the anesthetist who will administer them to the patients.Apart from the anesthetist, the surgery staff and the researchers recording the measurements will not know the therapeutic intervention team in which each patient has been randomized.||t|t|t|t
34135999|NCT05610618|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136000|NCT01212679|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34136001|NCT06185907|||COHORT||PROSPECTIVE|||||||
34136002|NCT04685720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136003|NCT04068519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136004|NCT05929612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136005|NCT02976636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The assessors will not know which arm of the study each family is in.||f|f|f|t
34136006|NCT05342012|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double blind randomised control trial. Supplements will be dispensed by a member of the research team.||t|f|t|t
34136007|NCT05529277|||COHORT||PROSPECTIVE|||||||
34136008|NCT04234529|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blinded|Participants will receive each of the 3 interventions over a 3 week period i.e. one acute dose once per week. The 3 interventions include 1) AMATEA, 2) Caffeine, or 3) Placebo|t|f|t|f
34136009|NCT01407835|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136010|NCT06090981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34136011|NCT00607269|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136012|NCT01394692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136013|NCT06653751|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136014|NCT01412450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136015|NCT03494530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136016|NCT01576146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136017|NCT06587334|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study adopts a split-mouth design with each subject serving as their own control. A random number method is used to determine whether the left or right half of the mouth will be assigned to the laser group, with the remaining half assigned to the control group. The laser group will receive SRP combined with Nd laser-assisted therapy, while the control group will receive SRP alone.||||
34136018|NCT04924894|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34136019|NCT01243372|||CASE_ONLY||RETROSPECTIVE|||||||
34136020|NCT00022763|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136021|NCT06034873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34136022|NCT02043106|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136023|NCT02896491|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34136024|NCT05582018|NA|SINGLE_GROUP||OTHER||NONE||||||
34136025|NCT00445367|||CASE_CONTROL||OTHER|||||||
34136026|NCT01413906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136027|NCT00292279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136028|NCT02428998|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34136029|NCT04331184|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136030|NCT03053986|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136031|NCT05534659|||COHORT||RETROSPECTIVE|||||||
34136032|NCT00733837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136033|NCT00145184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136034|NCT01910324|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34136035|NCT03721783|||COHORT||PROSPECTIVE|||||||
34136036|NCT02140008|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34136037|NCT02292082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34136038|NCT05659407|||COHORT||PROSPECTIVE|||||||
34136039|NCT00937729|||COHORT||PROSPECTIVE|||||||
34136040|NCT00306293|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34136041|NCT03758092|||CASE_CONTROL||RETROSPECTIVE|||||||
34136042|NCT02082080|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136043|NCT03004261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136044|NCT03789435|||COHORT||OTHER|||||||
34136045|NCT03865745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136046|NCT01476865|||||CROSS_SECTIONAL|||||||
34136047|NCT01549808|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136048|NCT01944098|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34136049|NCT06104488|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34136050|NCT03469518|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Crossover Assigment|t|f|f|t
34136051|NCT00245050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34136052|NCT03679858|||COHORT||PROSPECTIVE|||||||
34136053|NCT06657989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34136054|NCT05333627|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each client will choose one of the following: Wellbeing Course for Students (Fast-Track), Wellbeing Course for Students (5 weeks), and Wellbeing Course (8 weeks)||||
34136055|NCT06655207|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136056|NCT05459649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136057|NCT00489671|||CASE_CONTROL||PROSPECTIVE|||||||
34136058|NCT02383888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34136059|NCT00221000|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136060|NCT03539822|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Phase II has 4 disease cohorts, the first 3 with 29 patients each, the 4th cohort for advanced HCC patients with 24 patients, preceded by a 6-9 patient safety lead-in.||||
34136061|NCT00144989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136062|NCT00002249||||TREATMENT||DOUBLE||||||
34136063|NCT05086224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136064|NCT02024360|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136065|NCT05894980|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136066|NCT06179134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a randomized controlled single-blinded trial with treatment and wait list control group.|f|f|f|t
34136067|NCT01106651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136068|NCT02018848|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34136069|NCT01891617|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34136070|NCT04183127|||OTHER||PROSPECTIVE|||||||
34136071|NCT03978052|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Randomized, double-blind clinical trial (participant, investigator, outcomes assessor)|Arm I: EGCG and a multimodal intervention (n=50) Arm II: Placebo EGCG and a multimodal intervention (n=50) Arm III: Healthy lifestyle recommendations (n=50)|t|f|t|t
34136072|NCT04147897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136073|NCT06296199|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136074|NCT03277430|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136075|NCT04771923|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34136076|NCT05237791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34136077|NCT05247957|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136078|NCT05275387|||COHORT||CROSS_SECTIONAL|||||||
34136079|NCT02030197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136080|NCT04244981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Allocation will be concealed using an interactive web response system, and nurse anaesthetists will prepare the corresponding products for each patient according to the group assignments in an anaesthesia preparation room. PCC or FFP will be pumped into 50 ml syringes firstly, covered with opaque paper to hide the contents. For group PCC, we first diluted PCC to 50ml with normal saline, and then supplemented subsequent volume using normal saline to make it equal to the corresponding required volume of FFP.|796 patients who meet the criteria will be randomly divided into 2 groups, named prothrombin complex concentrate group (group PCC) and fresh frozen plasma group (control group, group FFP), with 398 cases in each group. Preoperative management, anesthetic and surgical techniques will be standardized for all patients. Prolonged APTT (\> 45 s) will be regarded as a trigger for administration of PCC or FFP, according to the randomized groups. In group PCC, patients will be given 8\~15 IU/kg PCC. In group FFP, patients will be given 6\~10 mL/kg FFP.|t|t|f|t
34136081|NCT04486430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|t|t|f
34136082|NCT02813096|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34136083|NCT05058690|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Personal identifiable data (including the code-break/participant key) collected at the recruitment site will be recorded electronically on a database that is stored on an access-restricted computer and either encrypted and/or located on a secure server and accessed only by authorised staff. Any copies leaving the study site will be completely anonymised/de-identified. Informed consent forms that contain participant names will be stored securely at study sites in locked cupboards and will only be accessible to study staff and authorised personnel.|Multi-centre, prospective cohort, study|t|f|f|f
34136084|NCT04452071|||COHORT||CROSS_SECTIONAL|||||||
34136085|NCT02022761|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136086|NCT04976673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||full contralateral split-mouth|t|f|t|f
34136087|NCT04342494|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34136088|NCT00633633|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136089|NCT01700998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34136090|NCT01299220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136091|NCT04746924|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136092|NCT00116675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34136093|NCT00377845|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE||||||
34136094|NCT06661395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136095|NCT01152918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136096|NCT04607213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136097|NCT02399540|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136098|NCT00939029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136099|NCT02524275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136100|NCT04523818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136101|NCT05779241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136102|NCT05587231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136103|NCT04779567|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|matching placebo. prepared by pharmacist|Prospective, Single center parallel-group, randomized double-blinded controlled study|t|t|t|t
34136104|NCT05962632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|assessors will unaware of the treatment assigned to the patients therefore the assessors will not be included in the pre clinical assessment.||f|f|f|t
34136105|NCT05870150|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double-blinded|A two-arm study where participants will receive one of two strains of Salmonella Typhimurium (ST19 or ST313).|t|t|t|t
34136106|NCT03402204|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828354|NCT06014047|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828355|NCT02866071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136107|NCT03639623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136108|NCT00845039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136109|NCT02810912|||COHORT||PROSPECTIVE|||||||
34136110|NCT01450696|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136111|NCT04251299|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150251|NCT00888641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151164|NCT00149175|||CASE_CONTROL||PROSPECTIVE|||||||
34151165|NCT06504186|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151166|NCT05228561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828356|NCT06105112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828357|NCT02185677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828358|NCT00643435|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33828359|NCT04680637|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828360|NCT00716066|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828361|NCT05917548|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The random assignment was blinded for the dental care provider, outcome assesor and for the co-investigator in charge of the statistical analysis. (Double-blind RCT)|The participants were contacted via phone calls for enrolment in TEGO platform where the pre-test of knowledge, attitudes and oral health self-efficacy was applied. Then, they were scheduled for medical-dental-geriatric diagnosis in a mobile dental clinic where all receive a standardized face-to-face oral health individual education. The investigator in charge of sending the videos performed age-stratified randomization in every city of the study using a random number generator function of the Epidat 4.2 program for the allocation of the participants in comparison or intervention groups. The videos were sent to the participants in the intervention group, this information is masked for the dental care providers and for the outcome assessor. 6 weeks later the face-to-face intervention both groups were assessed in with the post-test via phone call.|f|t|f|t
33828362|NCT03937037|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33828363|NCT04865614|||COHORT||RETROSPECTIVE|||||||
33828364|NCT04758676|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|No masking is used in the study|There are two arms in the study - experimental group (diagnostics with the Multiscan 5000 device, nutritional recommendations, physiotherapy protocol), and control group (standard of care)||||
33828365|NCT03408223|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828366|NCT00616577|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|t|f|f
33828367|NCT02291809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828368|NCT03643497|||COHORT||PROSPECTIVE|||||||
33828369|NCT05840822|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828370|NCT02951169|||COHORT||PROSPECTIVE|||||||
33828371|NCT03272711|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828372|NCT01481519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828373|NCT00999141|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33828374|NCT01226485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828375|NCT02629276|||CASE_ONLY||PROSPECTIVE|||||||
33828376|NCT03161223|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase 1 A minimum of 3 patients will be treated at the entry Dose Level, that is the MTD, in each arm. An estimated 10 patients will be accrued in each Arm, assuming ≤ 1 patients experience DLT. If a DLT is reached early we will treat fewer patients. For each study Arm, we will expand the MTD cohort to a total of 10 patients. We estimate that a total of 40 patients will be needed.~Phase 2 Once the recommended phase 2 dose is identified, a planning meeting with the Sponsor and involved investigators will be convened to discuss which Arm(s) to advance to phase 2. The sample size of the phase 2 portion of the study will be calculated on an optimal 2-stage design. We will first enroll 8 patients. If at least 3 objective responses (PR or CR) are seen, then an additional 16 patients will be enrolled. If 10 or fewer patients respond, the combination will not be considered for further study. We will enroll a total of 24 patients per arm."||||
33828377|NCT04830878|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33828378|NCT01233271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828379|NCT04115956|NA|SINGLE_GROUP||TREATMENT||NONE||Melflufen + Dexamethasone||||
33828380|NCT00483080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828381|NCT00053378|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33828382|NCT02716688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828383|NCT05666817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|2|The study will be conducted with 76 women, 38 controls and 38 interventions.|t|f|f|f
33828384|NCT01789619|||COHORT||PROSPECTIVE|||||||
33828385|NCT04240236|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828386|NCT04687098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828387|NCT04295330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The participants, the anesthesiologist, data collectors, the physicians performing the follow-up, and data analysts will be blinded to the group allocation. Blinding will maintain until the completion of the final analyses.|The experimental group received lidocaine and the control group received the same amount of saline.|t|t|t|t
33828388|NCT03892928|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828389|NCT01379703|||||PROSPECTIVE|||||||
33828390|NCT01837589|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828391|NCT06201871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828392|NCT05364086|||COHORT||PROSPECTIVE|||||||
33828393|NCT05652790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Pragmatic Prospective, multicentre feasibility non-randomised controlled trial||||
34150252|NCT05386316|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Data include Medicaid claims and birth and death records.|Individuals who live in the intervention counties at the time of birth will be assigned to the intervention condition. Individuals who live in control counties at the time of birth are assigned to the control condition.|t|f|f|t
34150253|NCT00847015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151167|NCT03420105|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"50 patients including:~* 25 patients being treated with adjuvant hormone therapy (Group A)~* 25 patients not receiving adjuvant hormone therapy (Group B)~* 25 healthy volunteers"||||
34151168|NCT02414620|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828394|NCT06521294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33828395|NCT02654132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828396|NCT05219929|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33828397|NCT05523219|||COHORT||PROSPECTIVE|||||||
33837514|NCT03053453|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized prospective study looking at the impact sensor guidance has on the outcome of patients and comparing to that of patients with a standard technique.||||
33837515|NCT04589299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837516|NCT05701904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||a control group and 2 intervention groups||||
33837517|NCT02125279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837518|NCT00170183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151169|NCT06507150|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136112|NCT04278768|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 and 1b follow a 3 + 3 design where 3 patients will be enrolled at the starting dose level. If none of the first 3 patients experience a DLT during the 1st cycle, patients may be enrolled into the next higher dose level. If 1 patient out of the first 3 experiences a DLT, the dose level may be expanded with an additional 3 patients. If 2 or 3 patients out of the first six experience a DLT, this will be considered a DLT rate above the max tolerated dose (\> 33%), and additional enrollment will proceed at a lower dose level. The Phase 2a Dose Expansion will be enrolled after the RP2D is determined from Phase 1. It will be in 3 Cohorts of patients: (1) R/R AML with FTLT-3 mutation who have been previously treated with a FLT3 inhibitor; (2) R/R AML with spliceosome mutations of SF3B1 or U2AF1; and (3) R/R hrMDS (IPSS-R \>3.5) with spliceosome mutations of SF3B1 or U2AF1; AND all patients have ≤ 2 lines of prior systemic anti-cancer therapy.||||
34136113|NCT02516098|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34136114|NCT04187144|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136115|NCT00159328|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136116|NCT00408382|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136117|NCT03784131|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136118|NCT03958747|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136119|NCT00734604|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136120|NCT05192928|NA|SINGLE_GROUP||OTHER||NONE||||||
34136121|NCT01027312|||COHORT||PROSPECTIVE|||||||
34136122|NCT01734954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34136123|NCT05618340|NA|SINGLE_GROUP||TREATMENT||NONE|Non-blind method|This trial is a prospective, multicenter, single-group target value method study||||
34136124|NCT01249781|||COHORT||CROSS_SECTIONAL|||||||
34136125|NCT02099877|||OTHER||PROSPECTIVE|||||||
34136126|NCT06662084|||CASE_CONTROL||PROSPECTIVE|||||||
34136127|NCT03415451|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136128|NCT04771416|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, multi-center, dose escalation||||
34136129|NCT00886886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34136130|NCT03178123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136131|NCT03781895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Prospective interventional randomized double blinded study|Two groups of Vitamin D3 deficient stable COPD patients were taken, Group A was given placebo along with standard therapeutic treatment and Group B was given Vitamin D3 along with standard therapeutic treatment|t|t|t|f
34136132|NCT03280823|||OTHER||PROSPECTIVE|||||||
34136133|NCT06375473|||COHORT||PROSPECTIVE|||||||
34136134|NCT03213938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136135|NCT04990063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136136|NCT05984407|||CASE_CONTROL||PROSPECTIVE|||||||
34136137|NCT00867802|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136138|NCT00079391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136139|NCT02213848|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34136140|NCT01668628|||COHORT||PROSPECTIVE|||||||
34136141|NCT02559323|||COHORT||PROSPECTIVE|||||||
34136142|NCT02225847|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34136143|NCT05279924|NA|SINGLE_GROUP||TREATMENT||NONE||outcomes of prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A||||
34136144|NCT06606756|||OTHER||PROSPECTIVE|||||||
34136145|NCT06257667|RANDOMIZED|PARALLEL||TREATMENT||NONE||open label randomized controlled trial||||
34136146|NCT00925106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34136147|NCT00442442|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34136148|NCT05354895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136149|NCT05851079|||COHORT||PROSPECTIVE|||||||
34136150|NCT06600282|RANDOMIZED|CROSSOVER||OTHER||NONE||An open-label, randomized, balanced, two-treatment, two-period, two-sequence, single dose, two-way crossover study under fasting conditions||||
34136151|NCT06637527|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|This is a randomized, double-masked, placebo-controlled trial to investigate the efficacy of OK101 study drug in treating the symptoms of NCP at baseline (Visit 1) through the end of study (16 weeks) in NCP subjects.|Approximately 48 subjects will be randomized in a 1:1:1 ratio to receive treatment with 0.05% OK-101 (Arm A) or 0.1% OK-101 (Arm B) or placebo (Arm C).|t|t|t|f
34136152|NCT05923931|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136153|NCT05286658|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136154|NCT00791453|||CASE_ONLY||PROSPECTIVE|||||||
34136155|NCT00123370|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34136156|NCT02615938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136157|NCT02490995|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34136158|NCT04319341|||COHORT||RETROSPECTIVE|||||||
34136159|NCT06660784|||COHORT||PROSPECTIVE|||||||
34136160|NCT02994472|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136161|NCT06396169|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34136162|NCT03418311|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136163|NCT02241655|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34136164|NCT06362655|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|No apply|Intervention Study||||
34136165|NCT04161092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136166|NCT03322176|||OTHER||PROSPECTIVE|||||||
34136167|NCT04440397|||CASE_CONTROL||PROSPECTIVE|||||||
34136168|NCT00448851|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34136169|NCT06272838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Investigator and Outcomes Assessor will be different persons|Randomised controlled|f|f|t|t
34136170|NCT03225118|||COHORT||PROSPECTIVE|||||||
34136171|NCT06151639|||COHORT||RETROSPECTIVE|||||||
34136172|NCT01377610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136173|NCT04884035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136174|NCT03647150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150827|NCT03772054|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blood samples will be codified by the principal investigator. Laboratory team will receive all samples for biomarkers measures. Results will be analyzed by the principal investigator.||f|f|f|t
34150828|NCT01714258|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136175|NCT05016661|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The investigator, study nurse/other study personnel, and patients will be blinded to the treatment group. An appropriately trained person will reconstitute investigational product, fill masked-labeled syringes and provide them to the investigator, but will not perform any assessments with the patient.|Approximately 666 patients will be randomized in a 1:1 ratio and receive 1 of the following treatments: ABP-450 Low Dose or ABP-450 High Dose via intramuscular injection into pre-specified areas of the head and neck.|t|f|t|t
34136176|NCT06362473|||COHORT||CROSS_SECTIONAL|||||||
34136177|NCT05215808|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|3:1 Randomization ratio of RBN-3143 to Placebo|single dose ascending cohorts followed by multiple dose ascending cohorts|t|t|t|f
34136178|NCT02340247|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34136179|NCT00907530|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34136180|NCT00116701|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136181|NCT03789513|NA|SINGLE_GROUP||SCREENING||NONE||||||
34136182|NCT04445883|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||The investigators will be evaluating patients' nutritional outcomes in units that have the Eating Matters Program available vs. similar units that do not have this program. Therefore, there will be two groups, Study Group A and Control Group B.||||
34136183|NCT04200196|RANDOMIZED|PARALLEL||OTHER||NONE||"This study is an interventional prospective controlled study with 2 arms:~* the fabrique à histoire arm : production and listening a story by the children~* the controlled arm: usual care (to sing, blow up a baloon, etc)"||||
34136184|NCT00984165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136185|NCT04723641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||intervention group received progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.|t|f|f|f
34136186|NCT03967028|||COHORT||PROSPECTIVE|||||||
34136187|NCT03029078|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study of patients colonized by either CRE or GRE will be enrolled in order to evaluate the impact of fecal microbiota transplant on the eradication of XDR bacteria colonization||||
34136188|NCT00946764|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136189|NCT06100965|||COHORT||PROSPECTIVE|||||||
34136190|NCT05056922|RANDOMIZED|PARALLEL||TREATMENT||NONE|Research assistant coders will be blind to treatment condition|||||
34136191|NCT03003182|||COHORT||PROSPECTIVE|||||||
34136192|NCT02643615|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136193|NCT04726592|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136194|NCT02315807|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136195|NCT00815802|||COHORT||PROSPECTIVE|||||||
34136196|NCT03433833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136197|NCT01643252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136198|NCT00368381|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136199|NCT05804487|||COHORT||PROSPECTIVE|||||||
34136200|NCT03939767|||COHORT||PROSPECTIVE|||||||
34136201|NCT05409053|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136202|NCT00132756|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136203|NCT03136146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136204|NCT04807075|||CASE_CONTROL||PROSPECTIVE|||||||
34136205|NCT06292416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and outcome assessors will be kept blind about the intervention which the patients will be receiving.|Assignment|t|f|f|t
34136206|NCT01372943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136207|NCT03271372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136208|NCT00108303|||FAMILY_BASED||PROSPECTIVE|||||||
34136209|NCT06661057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136210|NCT01145287|||COHORT||PROSPECTIVE|||||||
34136211|NCT06415812|NA|SINGLE_GROUP||TREATMENT||NONE|All data will be collected in a blinded manner by an assessor other than the therapists. Subsequently, the data will be anonymized and analyzed by a researcher from an institution different from the one in which the study takes place.|Two individual parallel groups will be recruited: adolescent patients and young adult patients. Both groups will receive a 6-month Evolutionary Systems Therapy treatment. Both groups will access a longitudinal evaluation of the effectiveness of the treatment. All the participants will access a more extensive ecological momentary assessment to evaluate the progress of specific psychopathological mechanisms that are the targets of the treatment. Consistent with the conceptualization model of Evolutionary Systems Therapy and with the scientific literature on dimensional and hierarchical models of psychopathology, this conceptualization will be shared with the patient based on three macro-functionings: externalizing patterns, internalizing patterns, schizotypal patterns.||||
34136212|NCT02664168|RANDOMIZED|PARALLEL||PREVENTION||||||||
34136213|NCT01208961|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136214|NCT05043792|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136215|NCT04491019|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34136216|NCT00117715|||CASE_ONLY||PROSPECTIVE|||||||
34136217|NCT00639041|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34136218|NCT00491036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136219|NCT03065621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136220|NCT06241638|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34136221|NCT01335893|NA|SINGLE_GROUP||OTHER||NONE||||||
34136222|NCT04982328|||CASE_CONTROL||PROSPECTIVE|||||||
34136223|NCT05076409|NA|SEQUENTIAL||TREATMENT||NONE||||||
34136224|NCT05742516|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind||t|f|t|f
34136225|NCT04124562|||OTHER||PROSPECTIVE|||||||
34136226|NCT02305849|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136227|NCT06010758|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34136228|NCT05981001|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"Phase I: Single-arm, dose-escalation and dose-expansion study~Phase II: Two-arm parallel assignment"||||
34136229|NCT03115203|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34136230|NCT03257202|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Healthy volunteers||||
34151170|NCT02998034|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136231|NCT05791565|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|This will be a double-blind study.|This is a 2-way cross-over study.|t|f|t|f
34136232|NCT06067100|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34136233|NCT01539733|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34136234|NCT03174405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136235|NCT03183258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136236|NCT05305118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136237|NCT03686306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The preparation of the 'blinded' treatments will be undertaken by the PPRIGO hospital pharmacist's consortium (Production Pharmaceutique pour la Recherche Institutionnelle du Grand Ouest) under recommended standardised conditions. PPRIGO will provide numbered and labelled boxes each containing 32 capsules of the study drug (sildenafil or placebo according to the randomisation order). All boxes will be identically labelled, with the study number being the only differentiating feature between different drug packs.~The un-blinding will be centralised with eCRF software in agreement with the principal investigator."|Experimental design A Phase III, National, Multicentre, Prospective, Randomised, Double Blind, placebo-controlled clinical trial with two parallel groups.|t|t|t|f
34136238|NCT03055728|||OTHER||OTHER|||||||
34136239|NCT02497144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34136240|NCT06327074|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34136241|NCT04909008|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized control trial||||
34136242|NCT03849820|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136243|NCT05465798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Eligible participants will be randomised to receive either beta-glucan supplements or placebo for up to three days.|t|t|t|t
34136244|NCT03161912|||COHORT||PROSPECTIVE|||||||
34136245|NCT05348993|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|randomized, double-blind, placebo-controlled|Single dose of G03-52-01 100 mg or placebo or a repeat dose of G03-52-01 (50mg or 100mg) or placebo on days 1 and 45|t|t|t|t
34136246|NCT04953819|||OTHER||OTHER|||||||
34136247|NCT04945707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unblinded staff (clinical research nurse and unblinded investigator) prepare and administer study drug to subject and document and follow safety events. The subject is blinded. A tented covering will allow adequate viewing of the IV site, but outside of the view of the subject. All blinded staff will not be present during study drug infusion.|This is a double-blind, prospective, randomized, placebo-controlled study to assess exercise tolerance after iron repletion with a single dose of ferric derisomaltose (Monoferric®) IV compared to placebo in heart failure with preserved ejection fraction and with iron deficiency. Randomization will be stratified by sex and will be performed in permutated blocks of 4 to assure balanced group sizes|t|t|t|t
34136248|NCT05160168|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34136249|NCT03628482|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants were randomly assigned using a computer-generated randomization schedule to receive either continuous or pulsed radiofrequency treatment of genicular nerves. The allocation sequence was concealed from the researcher enrolling and assessing participants in sequentially numbered, opaque, sealed and stapled envelopes. The corresponding envelopes were opened only at the time of intervention.|Participants were randomly assigned using a computer-generated randomization schedule to receive percutaneous radiofrequency treatment of the genicular nerves that was administered in either the continuous or in the pulsed mode.|t|f|f|t
34136250|NCT04448314|||COHORT||OTHER|||||||
34136251|NCT01343186|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34136252|NCT02281110|||COHORT||PROSPECTIVE|||||||
34136253|NCT00003783|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136254|NCT00002873||||TREATMENT||||||||
34136255|NCT03006848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136256|NCT06438471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136257|NCT02503358|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136258|NCT01895439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136259|NCT05570110|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Active and Placebo Capsules of the same shape and size are utilized|Randomized parallel group design, first two subjects open label.|t|t|t|t
34136260|NCT05873153|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34136261|NCT05058196|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136262|NCT02425228|||CASE_CONTROL||PROSPECTIVE|||||||
34136263|NCT05467839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136264|NCT00680355|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136265|NCT06396429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial|t|t|t|t
34136266|NCT04011566|||COHORT||PROSPECTIVE|||||||
34136267|NCT01404793|||COHORT||PROSPECTIVE|||||||
34136268|NCT03112512|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136269|NCT01681069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136270|NCT05677308|||COHORT||PROSPECTIVE|||||||
34136271|NCT03327220|RANDOMIZED|PARALLEL||TREATMENT||NONE||The active group will receive the iovera° treatment prior to a TKA. The control group will receive a TKA and no iovera° treatment.||||
34136272|NCT00289068|||COHORT||PROSPECTIVE|||||||
34136273|NCT06084754|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded||t|f|f|t
34136274|NCT06655558|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudal treatment validation||||
34136275|NCT03020134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136276|NCT04807088|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136277|NCT05489172|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136278|NCT01127607|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34136279|NCT00075725|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136280|NCT01196468|||||CROSS_SECTIONAL|||||||
34136281|NCT02035436|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34136282|NCT06662032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136283|NCT04216784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136284|NCT00979342|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136285|NCT04407923|||COHORT||PROSPECTIVE|||||||
33837519|NCT02871167|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33837520|NCT03749304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837521|NCT04118881|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34136286|NCT03242564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136287|NCT06357091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136288|NCT06076252|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136289|NCT01995994|||CASE_ONLY||PROSPECTIVE|||||||
33828398|NCT05863013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The sample will be divided into two groups: Intervention Group and Control Group. Patients meeting the inclusion criteria will be randomly assigned to one of 2 groups (GI and CG) in a 1:1 ratio using a computer-generated random allocation sequence using the stratified block randomization method of SAS version 9.1. 3 (SAS Institute, Cary, NC, USA). Randomization will be performed by an independent research assistant who will not participate in any other phase of this study. The health professionals who will work in the study (physicians and physiotherapists) will be informed of the assignment of the treatment by telephone confirmation. The evaluators of clinical and statistical results will be blinded to the randomization, since it was not feasible to blind the other professionals involved in the research."|"Patients included in the study will be evaluated:~T0 (baseline): Baseline assessments will be performed immediately prior to randomization and will include lung function \[spirometry, measurement of pulmonary CO2 diffusing capacity (DLCO) and measurement of respiratory muscle strength\], handgrip measurement , measurement of quadriceps strength (HR ), exercise capacity (TGlittre1), level of physical activity in daily life (International Physical Activity Questionnaire - IPAQ) and assessment of QoL (St. George's Respiratory Questionnaire - SGRQ).~T1 (day before surgery): Patients will repeat lung function, HGS measurement, HR measurement, TGlittre2, IPAQ, and SGRQ.~T2 (1 month after surgery): Patients will repeat the tests from the previous phase.~Data on postoperative complications and 30-day complications and mortality will also be recorded.~T3 (4 months after surgery): Patients will have repeat lung function, HGS measurement, HR measurement, TGlittre4, IPAQ, and SGRQ."|f|f|f|t
33828399|NCT06462274|||COHORT||PROSPECTIVE|||||||
33828400|NCT00003693|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828401|NCT03260803|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828402|NCT01744756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828403|NCT02153190|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828404|NCT01222533|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33828405|NCT01101997|NA|SINGLE_GROUP||OTHER||NONE||||||
33828406|NCT05503693|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33828407|NCT02384278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828408|NCT00878293|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33828409|NCT04103502|||CASE_CONTROL||RETROSPECTIVE|||||||
33828410|NCT03630692|||COHORT||PROSPECTIVE|||||||
33828411|NCT05612646|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Use the random number generator of EXCEL to generate the random number assigned by the computer, and put the serial number in the sealed envelope in sequence. After the patients completed the pre-test, the sealed envelopes were opened in sequence, and the patients were randomly assigned to the experimental group and the routine care group. The study used an assessor blinding design, that is, the data collectors were unaware of the patient group assignments until the end of the study|Assignment A two-group controlled, randomized study, the intervention groups: receiving acupressure on 3 acupoints (Tianshu, ST25: Stomach Meridian 25; Zhongwan CV12: Conception Vessel 12; Qihai CV6: Meridian Vessel 6), control groups: receiving routine nursing and fake acupressure.|t|t|t|t
33828412|NCT04107181|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33828413|NCT02900313|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33828414|NCT04652011|||COHORT||RETROSPECTIVE|||||||
33828415|NCT00085878|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828416|NCT01346462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33828417|NCT06546761|||COHORT||PROSPECTIVE|||||||
33828418|NCT01523951|||COHORT||PROSPECTIVE|||||||
33828419|NCT01504009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828420|NCT01603342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828421|NCT05110014|NA|SINGLE_GROUP||OTHER||NONE||||||
33828422|NCT03179774|RANDOMIZED|PARALLEL||TREATMENT||NONE||Part 1: Clinical registry study (Optimal medical therapy group vs. Endovascular revascularization and optimal medical therapy) Part 2: Randomized control trial (Optimal medical therapy group vs. Endovascular revascularization and optimal medical therapy)||||
33828423|NCT04662606|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33828424|NCT03919409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828425|NCT04721405|||COHORT||PROSPECTIVE|||||||
33828426|NCT04363853|NA|SINGLE_GROUP||TREATMENT||NONE||Phase II, single-arm, open-label, prospective, blinded, clinical trial with Tocilizumab as the sole agent.||||
33828427|NCT01064882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828428|NCT02243761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828429|NCT01138761|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
33828430|NCT03561597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||prospective single arm study||||
33828431|NCT02569177|||COHORT||PROSPECTIVE|||||||
33828432|NCT04350112|||COHORT||CROSS_SECTIONAL|||||||
33828433|NCT06157619|||COHORT||PROSPECTIVE|||||||
33828434|NCT06183905|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828435|NCT05426161|NA|SINGLE_GROUP||TREATMENT||NONE||A single-center, prospective, exploratory study||||
33828436|NCT04119206|||CASE_CONTROL||PROSPECTIVE|||||||
33828437|NCT00586118|||CASE_CONTROL||PROSPECTIVE|||||||
33828438|NCT03974698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants attempted masked.||t|f|t|f
33828439|NCT00252018|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33828440|NCT05089981|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double Blind Placebo Controlled|t|t|t|f
34136290|NCT06601517|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136291|NCT06314958|||CASE_CONTROL||RETROSPECTIVE|||||||
34136292|NCT02964559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136293|NCT05711381|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136294|NCT02125851|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34136295|NCT00771043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136296|NCT03926572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients admitted for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary hypertension with samples of blood samples taken at admission, days 3 and 7 in the context of this clinical study||||
34136297|NCT04894344|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups will be formed, the intervention group and the control group. Participants shall be randomly assigned to one of the two groups. Each patient group receives a single treatment simultaneously Urine measured 24 hours before and after the procedure as well as other variables of interest. The duration of the intervention will be 4 weeks.||||
34136298|NCT01184638|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34136299|NCT02863172|||FAMILY_BASED||PROSPECTIVE|||||||
34136300|NCT03289663|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The 2 groups of villages will randomly receive either the bednets treated with conventional insecticide (Pyrethroid) or the synergistic combination of insecticides. None of the groups knows which bednets they receive.|Cluster-randomized trial|t|f|f|f
34136301|NCT01942668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136302|NCT06249555|||COHORT||PROSPECTIVE|||||||
34136303|NCT01194089|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136304|NCT03348774|||COHORT||RETROSPECTIVE|||||||
34136305|NCT00370760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34136306|NCT03321864|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All available patients||||
34136307|NCT06325046|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136308|NCT03150966|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34136309|NCT04786704|||COHORT||PROSPECTIVE|||||||
34136310|NCT06658678|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34136311|NCT05834933|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Participants, Data collectors||t|t|f|f
34136312|NCT04842630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136313|NCT03892668|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34136314|NCT04654611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136315|NCT03804463|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34136316|NCT05295446|||COHORT||PROSPECTIVE|||||||
34136317|NCT03575065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136318|NCT04883125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136319|NCT01557777|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136320|NCT06411912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Patients will be randomly assigned to receive NIDO-361 or placebo at the recommended Phase 2 dose (RP2D) of 100 mg once daily. Patients will receive daily oral doses of NIDO-361 or placebo for 12 months.|t|t|t|t
34136321|NCT01151059|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34136322|NCT04835194|||OTHER||PROSPECTIVE|||||||
34136323|NCT00557310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136324|NCT03181425|||COHORT||PROSPECTIVE|||||||
34136325|NCT03299881|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, adaptive parallel arm study||||
34136326|NCT05627258|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34136327|NCT01642498|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136328|NCT04120753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136329|NCT00274898|RANDOMIZED|||TREATMENT||NONE||||||
34136330|NCT01740466|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34136331|NCT01453751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136332|NCT03951493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136333|NCT05064176|RANDOMIZED|PARALLEL||TREATMENT||NONE|"Given the nature of the trial, blinding of participants, the person who performs the trial assessments (= investigator) and care providers (surgeon/ physical therapist/ compression specialist) is not feasible.~The person who will be performing data analyses (= outcome assessor) will be blinded to the participants' randomization."|||||
34136334|NCT03926533|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34136335|NCT00098046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136336|NCT06107842|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Gerofit intervention vs Health Education Control|randomized controlled study|f|f|f|t
34136337|NCT05594927|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136338|NCT01581034|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34136339|NCT01809509|||COHORT||PROSPECTIVE|||||||
34136340|NCT00916838|||CASE_CONTROL||PROSPECTIVE|||||||
34136341|NCT03241940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136342|NCT02522585|||COHORT||PROSPECTIVE|||||||
34136343|NCT01224340|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136344|NCT03888040|RANDOMIZED|PARALLEL||TREATMENT||NONE||Exercise Training Intervention: The older adult subjects that were recruited for the cross-sectional studies will then be asked to return to perform 8 weeks of resistance exercise training on each leg. The exercise will involve low-load, high-velocity power training of the knee extensor muscles. One of the legs will be counterbalanced based on strength to either exercise with blood flow restriction (BFR), while the other leg will exercise without BFR. Before and after the 8 weeks of training subjects will undergo the same measurements in the cross-sectional studies to assess fatigability, skeletal muscle bioenergetics and vascular function of each leg.||||
34136345|NCT04173260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136346|NCT01321918||||||NONE||||||
34136347|NCT02431910|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34136348|NCT00853242|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136349|NCT01380197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136350|NCT00951080|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136351|NCT06265792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34136352|NCT00006253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136353|NCT01172093|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136354|NCT06207903|||CASE_CROSSOVER||PROSPECTIVE|||||||
34136355|NCT05475483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136356|NCT03570918|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label dose-escalation study||||
34136357|NCT03333096|NA|SINGLE_GROUP||SCREENING||NONE||||||
34136358|NCT04493905|||COHORT||PROSPECTIVE|||||||
34136359|NCT04193865|||COHORT||PROSPECTIVE|||||||
34136360|NCT05577312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136361|NCT00185380|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34136362|NCT01359241|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136363|NCT00015860||||TREATMENT||||||||
34136364|NCT04047875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136365|NCT04810013|||CASE_ONLY||PROSPECTIVE|||||||
34136366|NCT03966963|NA|SINGLE_GROUP||TREATMENT||NONE||Mixed methods study||||
34136367|NCT00115479|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34136368|NCT06414135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136369|NCT03479294|||COHORT||PROSPECTIVE|||||||
34136370|NCT00964665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136371|NCT00559429|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136372|NCT01381276|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34136373|NCT00820859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136374|NCT04553744|||CASE_ONLY||PROSPECTIVE|||||||
34136375|NCT01205061|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136376|NCT01337843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136377|NCT01683747|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136378|NCT01287390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136379|NCT06660771|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|2-arm parallel trial|t|f|f|t
34136380|NCT06394479|||COHORT||RETROSPECTIVE|||||||
34136381|NCT04522336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136382|NCT02643563|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34136383|NCT06435364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34136384|NCT01217879|||COHORT||PROSPECTIVE|||||||
34136385|NCT00152711|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136386|NCT01295840|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136387|NCT01803191|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136388|NCT06485856|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136389|NCT05243745|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34136390|NCT05514756|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be masked to the active vs sham stimulation settings, it is single blinded i.e. study participants are not aware if active or sham stimulation is occurring but the investigator is aware||t|f|f|f
34136391|NCT05866679|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136392|NCT04738760|||COHORT||OTHER|||||||
34136393|NCT01605604|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136394|NCT04009694|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136395|NCT02050802|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34136396|NCT00473668|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34136397|NCT05806541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34136398|NCT05337111|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136399|NCT00000593|RANDOMIZED|||PREVENTION||||||||
34136400|NCT01027234|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34136401|NCT04099719|||OTHER||RETROSPECTIVE|||||||
34136402|NCT00678769|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136403|NCT05379218|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136404|NCT04823455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136405|NCT01162824|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34136406|NCT05250635|||CASE_ONLY||PROSPECTIVE|||||||
34136407|NCT05688215|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136408|NCT05525052|||COHORT||RETROSPECTIVE|||||||
34136409|NCT05158335|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||DOUBLE|Double Blind||t|f|t|f
34136410|NCT02043912|||COHORT||PROSPECTIVE|||||||
34136411|NCT00217997|||COHORT||PROSPECTIVE|||||||
34136412|NCT01904474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34136413|NCT05557851|NA|SINGLE_GROUP||TREATMENT||NONE||Stressing the patient's pancreatic cancer by giving the anti super-enhancer MinnelideTM to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.||||
34136414|NCT00812006|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34136415|NCT01743313|||COHORT||PROSPECTIVE|||||||
34136416|NCT04463186|NA|SINGLE_GROUP||OTHER||NONE||Subjects participated in three experimental trials: Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Strength was measured before (pre), immediately after (post), and at 10- and 20- minutes post stretching.||||
34136417|NCT03922347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136418|NCT01893411|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136419|NCT00460694|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136420|NCT05137197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Double-Blind (Subject and Rater) Controlled Study|t|f|f|t
34136421|NCT04105348|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136422|NCT01031589|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34136423|NCT04535466|||COHORT||PROSPECTIVE|||||||
34136424|NCT01879462|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34136425|NCT04324996|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136426|NCT00676520|||COHORT||PROSPECTIVE|||||||
34136427|NCT02363361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136428|NCT03305081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136429|NCT00005841||||TREATMENT||||||||
34136430|NCT05958953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136431|NCT05352516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel-Controlled|t|t|t|t
34136432|NCT01190761|RANDOMIZED|CROSSOVER||||NONE||||||
34136433|NCT02918461|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136434|NCT03182946|||COHORT||PROSPECTIVE|||||||
34136435|NCT04399863|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136436|NCT01087658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136437|NCT00071682|||||PROSPECTIVE|||||||
34136438|NCT00754949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136439|NCT05723731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136440|NCT00445211|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136441|NCT00196027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136442|NCT02998203|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
34136443|NCT06659276|||COHORT||PROSPECTIVE|||||||
34136444|NCT05846425|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Nose-breathing group, Mouth-breathing group, Control group||||
34136445|NCT04489147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136446|NCT05464641|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|preoperative and 2 year postoperative|preoperative and 2 year postoperative|t|f|f|f
34136447|NCT03126058|NA|SINGLE_GROUP||TREATMENT||NONE||Patients will receive enhanced recovery after surgery programs.||||
34136448|NCT05303168|||COHORT||PROSPECTIVE|||||||
34136449|NCT04659499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136450|NCT01049230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136451|NCT03629340|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34136452|NCT03831191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136453|NCT01897506|||CASE_CONTROL||PROSPECTIVE|||||||
34136454|NCT06629220|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136455|NCT00280618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136456|NCT06560554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants who are randomized to the control group will not be given information on increasing fermented foods|Single center, longitudinal, randomized trial|t|f|f|f
34136457|NCT03495310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136458|NCT01687088|||CASE_CONTROL||PROSPECTIVE|||||||
34136459|NCT05611567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136460|NCT03135808|||COHORT||PROSPECTIVE|||||||
34136461|NCT01538979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136462|NCT03070171|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136463|NCT01293630|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136464|NCT01110330|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136465|NCT03269968|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Study participants will be enrolled in a 1:1 ratio to either Negative Pressure Wound Therapy or standard dressing. Randomization will occur prior to delivery using a computer randomization system.|f|f|f|t
34136466|NCT05153369|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study is targeted toward youth with and/or at familial risk for BD who, at intake, do not want and/or require full DBT. Participants will be enrolled into Level 1 - Enhanced Care or Level 2 - DBT Skills Training; for those whose circumstances change during the course of the study, such that they want and/or require full dose DBT, the intervention also includes potential dose escalation up through Level 3 - DBT Full Intervention. As the levels escalate, frequency of therapy sessions and contact with study therapist will increase. Dosing decisions will be driven by a combination of risk indicators and symptom severity, with an emphasis on emotional dysregulation, suicidality, and functional impairment, along with patient preference. Participants who are initially enrolled into Levels 1 or 2 will be able to escalate to Level 3 up until the end of their first year of enrollment. This is to ensure that they will have time to receive one full year of the DBT intervention.||||
34136467|NCT02010333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136468|NCT05359081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136469|NCT04361409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136470|NCT02312999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136471|NCT05305833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828441|NCT05563636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828442|NCT06289023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828443|NCT05423548|||COHORT||RETROSPECTIVE|||||||
33828444|NCT04522778|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients with central lines ages 0-18 years old who have never worn a wearable central line securement device (vest) will be eligible for the study. Half of the participants will be randomized to the device arm while the other half of participants will be randomized to the non-device arm. They will be block randomized based on age upon enrollment. Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear. The study will follow participants prospectively for approximately one year (2020 - 2021).||||
33828445|NCT05097898|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828446|NCT02315053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828447|NCT00251264|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828448|NCT03895697|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33828449|NCT00027976|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33828450|NCT03000647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828451|NCT00853736|RANDOMIZED|CROSSOVER||||NONE||||||
34136472|NCT05321758|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Partial enteral nutrition,FMT||||
34136473|NCT02793817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136474|NCT02450448|||COHORT||PROSPECTIVE|||||||
34136475|NCT05049707|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34136476|NCT05511727|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34136477|NCT01817699|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34136478|NCT04397939|||COHORT||RETROSPECTIVE|||||||
34136479|NCT01517165|RANDOMIZED|PARALLEL||TREATMENT||||||||
34136480|NCT00962741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136481|NCT03378609|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34136482|NCT05633459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Multiple-ascending doses of QRL-201 or placebo will be administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.|Parallel Assignment|t|f|t|f
34136483|NCT01181999|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149821|NCT03062241|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a Randomized Controlled Trial (RCT), non-blinded, prospective, multicentre performed in up to 4 cardiology centers in Poland. All patients implanted with a dual-chamber implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) with Home Monitoring capabilities and history of paroxysmal, persistent or persistant long-lasting AF will be screened for the study. In patient who fulfill all inclusion and none of the exclusion criteria 1 year after ICD or CRT-D implantation, with exclusion of 1 month directly after implantation, a device check-up and AF burden will be performer and assessed. Randomization will be performed using sealed envelopes and will be conducted in the coordinating center of the study PI in all patients who sign informed consent and met all inclusions and none of the exclusion criteria. The cryoablation of AF will be performed within 1 month from randomization in the invasive treatment group.||||
34136484|NCT05852158|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Surgeons assessing for the presence of surgical site infection will be blinded to the antibiotic regimen that the patient received.|"Our plan is to conduct a prospective, randomized controlled trial evaluating patients undergoing orthognathic surgery including bilateral sagittal split osteotomies with or without concomitant maxillary and/or chin surgery, with or without wisdom teeth extraction. All patients meeting the inclusion criteria will be offered participation, and informed consent will be obtained at the pre-operative appointment following surgical consent. The patients will then be assigned a study number and randomly allocated to one of two groups as follows:~A) Single pre-operative dose of 2g IV Cefazolin B) Single pre-operative dose of 2g IV Cefazolin followed by a 24-hour course of 2g IV Cefazolin every 8 hours All patients will receive the same post-operative instructions and will be discharged with 0.12% chlorhexidine mouth rinse to be used for 2 weeks following discharge. Patients will return for follow-up at 2 weeks, 4 weeks, and 6 weeks following discharge."|f|f|f|t
34136485|NCT00281099|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34136486|NCT03656848|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|This is a blinded clinical trial. Subjects and clinical assessor will be blinded to the assignment results. All the study site personnel will receive training for the blinding measures before the trial initiating. In addition to standard procedural sedation, music-playing headphones will be worn by the patient during the whole procedure, and patients in both groups will be preset a 10 minutes delay for QFR calculation before the PCI procedure, a lesion/device evaluation form is required to fill in during the period in both groups, to reduce the possibility of unblinding. All the study site personnel will be trained not to disclose the treatment assignment to the subject in any unplanned time. Subject blinding should be maintained until the one-year follow-up visit for all registered subjects is completed.||t|f|f|t
34136487|NCT01139411|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136488|NCT04103944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Each patients will be divided into treatment group (osteonecrotic repair device) or control group (core decompression)|t|f|f|t
34136489|NCT00924430|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136490|NCT01314807|||CASE_CONTROL||PROSPECTIVE|||||||
34136491|NCT06354413|||COHORT||RETROSPECTIVE|||||||
34136492|NCT04615572|||COHORT||PROSPECTIVE|||||||
34136493|NCT03325296|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136494|NCT01040988|||OTHER||CROSS_SECTIONAL|||||||
34136495|NCT01694121|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136496|NCT06481371|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34136497|NCT05706155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participants and the care providers will not be blinded. People involved in assessing outcomes and with data analysis will be blinded.|This is a single center and open label randomized controlled trial, in which participants will be assigned to one of the two different dietary interventions|f|f|f|t
34136498|NCT03772028|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled, open-label, multicenter phase III trial||||
34136499|NCT01406938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136500|NCT03389724|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a prospective randomized study where all patients presenting to the CCHE with de novo diagnosis of Bone tumor (ES and OS) and AML will be randomized to receive (Intervention arm) or not to receive (Control arm) prophylactic ACE-I with the start of chemotherapy.||||
34136501|NCT04516538|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136502|NCT00014989|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
34136503|NCT06661707|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136504|NCT00059943||||TREATMENT||NONE||||||
34136505|NCT06102200|RANDOMIZED|PARALLEL||OTHER||NONE||Behavioral intervention||||
34136506|NCT01568450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34136507|NCT04342806|||COHORT||PROSPECTIVE|||||||
34136508|NCT01405352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136509|NCT03149354|NA|SINGLE_GROUP||OTHER||NONE||||||
34136510|NCT03745365|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized into two groups according to the surgical procedure performed as follows:~* Group A: Patients undergoing sleeve gastrectomy.~* Group B: Patients undergoing combined sleeve gastrectomy with loop bipartition."||||
34136511|NCT05151445|||CASE_ONLY||PROSPECTIVE|||||||
34136512|NCT05987605|NA|SEQUENTIAL||OTHER||NONE||||||
34136513|NCT06645457|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34136514|NCT06225375|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||"This will be a single-center, open-label, prospective clinical trial of 30 subjects undergoing pelvic organ prolapse repair using the Restorelle® Flat Mesh in the treatment of uterine (by uterine-sparing hysteropexy) and recurrent or advanced pelvic organ prolapse. They will be followed for a period of 36 months.~Eligible subjects shall undergo a detailed medical history and physical exam including a Pelvic Organ Prolapse Quantification (POP-Q)13 system assessment to determine the degree of prolapse. Validated self-reported questionnaires will be completed at baseline including the PFDI-20, PFIQ-7, MESA, and PISQ-12. Baseline demographic information shall be documented. A pelvic ultrasound assessment will be performed to assess the pelvic prolapse.~Subjects shall undergo transvaginal mesh surgery per the surgeon's specifications."||||
34136515|NCT02174029|||COHORT||PROSPECTIVE|||||||
34136516|NCT01491789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136517|NCT01103544|||COHORT||PROSPECTIVE|||||||
34136518|NCT02502435|||CASE_CONTROL||PROSPECTIVE|||||||
34136519|NCT03571009|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||The patients were supposed to complete three visits (baseline, one month, and three months). Patients in the PAAS group were provided with a wearable device (Painmeter, LST, Seoul, Korea) and smartphone application (DrKooB-PAAS, iKooB Inc. Seoul, South Korea), while the control group was provided conventional treatment without using the system. After screening, patients were randomly assigned to a group with an opaque envelope that contained the written randomization result. After completing the three months of the study, patients in the control group were then allocated to the PAAS group and underwent three additional months of study.||||
34136520|NCT06662097|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The study will begin with a dose-defining stage in each surgical setting. Once dose defining is complete, the study will proceed to a dose expansion phase for each surgical setting.||||
34136521|NCT05904236|NA|SINGLE_GROUP||TREATMENT||NONE||Escalating doses||||
34136522|NCT01285570|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136523|NCT02982434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136524|NCT03900130|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The study is a repeated measures design. It is double blinded in the sense that the participant, brain imager and endocrinologist are masked from the preload condition. One technician is unblinded as to the preload type. The participant is not aware of the possible ways in which the preload can vary, or even that it could vary over testdays.|Repeated measures, fully crossed, factorial design with caloric load and protein to carbohydrate ratio of preload as 2-level factors.||||
34136525|NCT05725005|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||This is a phase 1, open-label, dose escalation, PET study to investigate the brain occupancy of O-GlcNAcase, and the PD response in PBMCs, after repeated doses of ASN51 in healthy subjects. Enrolment of up to 12 healthy subjects is planned, in up to 2 groups (Groups 1 and 2). Each group will consist of up to 6 subjects.||||
34136526|NCT05683938|||COHORT||PROSPECTIVE|||||||
34136527|NCT00054327|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136528|NCT00201357|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136529|NCT01667224|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34136530|NCT06062836|||COHORT||PROSPECTIVE|||||||
34136531|NCT00666588|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136532|NCT02987361|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
34136533|NCT02740062|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136534|NCT01644006|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136535|NCT02021617|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34136536|NCT02612103|||COHORT||PROSPECTIVE|||||||
34136537|NCT06243003|NA|SINGLE_GROUP||TREATMENT||NONE||"For ES-SCLC patients with baseline brain metastasis enrolled in this study, standard chemo-immunotherapy will be delivered every 3 weeks.~Simulation for radiotherapy should be performed at baseline, and WBRT should be completed no later than the start of the third course of systemic treatment. The WBRT dose is 30Gy/10Fx. For patients without brain metastases within 1cm of the hippocampus, hippocampal avoidance technology should be employed. After WBRT, the treating physician will perform another simulation for subsequent SRS treatment to the brain lesions. SRS should be completed no later than the start of the fourth course of drug treatment. Specific SRS dose should be as follows: 16Gy for tumors with a diameter ≤ 2cm; 12Gy for tumors with a diameter of between 2cm and 3cm. WBRT and SRS should be performed during the interval between two systemic drug treatments, concurrent (on the same day) brain radiotherapy with chemo-immunotherapy treatment should be avoided."||||
34136538|NCT02975999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136539|NCT03429985|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34136540|NCT02398422|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34136541|NCT02441491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136542|NCT06661525|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34136543|NCT02533986|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34136544|NCT03883919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136545|NCT03466281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Active Comparator: 1 Structured patients group intervention - IBS School Active Comparator: 2 Structured Patient education via Internet|f|f|f|t
34136546|NCT02739763|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136547|NCT03874741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136548|NCT03206424|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136549|NCT01257568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136550|NCT01748461|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34136551|NCT01054560|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136552|NCT02225483|||CASE_CONTROL||PROSPECTIVE|||||||
34136553|NCT02106949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136554|NCT02302092|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136555|NCT01551576|||OTHER||CROSS_SECTIONAL|||||||
34136556|NCT00346879|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136557|NCT01005316|||COHORT||PROSPECTIVE|||||||
34136558|NCT06660199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136559|NCT01540630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136560|NCT05233969|||COHORT||CROSS_SECTIONAL|||||||
34136561|NCT05806034|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34136562|NCT06318078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Cluster Randomised Control Trial||||
34136563|NCT06523608|||COHORT||PROSPECTIVE|||||||
34136564|NCT00438269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34136565|NCT05798936|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Based on determining the main outcome variable, the estimated minimum required sample size is 30 patients (15 patient in each group).~The sample was calculated using G\*power software 3.1.9.2., based on the following assumptions: Main outcome variable is the difference between mean value of:~Group (A): 15 patients will be treated by Ultrasound-Guided Percutaneous Polidocanol Injection Group (B): 15 patients will be treated by Ultrasound-Guided percutaneous ethanol injection"||||
34136566|NCT05529264|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34136567|NCT05926349|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136568|NCT06654505|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34136569|NCT00336284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136570|NCT00270725|||COHORT||RETROSPECTIVE|||||||
34136571|NCT01942161|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136572|NCT00748397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136573|NCT04783779|NA|SINGLE_GROUP||TREATMENT||NONE||All participants are implanted with the investigational grafts at a single site under consistent conditions. Study follow up examinations are performed at the same site. Routine dialysis procedures over the study period are performed at the participants established clinic.||||
34136574|NCT00964912|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136575|NCT03229772|NA|SINGLE_GROUP||OTHER||NONE||||||
34136576|NCT04330391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomly assigned to the intervention or control group. The Principal Investigator and staff recording outcome measures (e.g. weighing patients) will be blinded to participant assignments.|Two group randomized control trial comparing the intervention and standard care.|f|f|t|t
34136577|NCT00904462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136578|NCT00002858|RANDOMIZED|||TREATMENT||||||||
33828452|NCT01975636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828453|NCT01257152|||CASE_ONLY||PROSPECTIVE|||||||
33828454|NCT04094714|||OTHER||CROSS_SECTIONAL|||||||
33828455|NCT03025997|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33828456|NCT05810441|||OTHER||CROSS_SECTIONAL|||||||
33828457|NCT05938478|||COHORT||PROSPECTIVE|||||||
33828458|NCT00522470|RANDOMIZED|PARALLEL||||NONE||||||
33828459|NCT06172998|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
33828460|NCT03432650|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828461|NCT05226039|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Following the first visit, participants will be randomly counterbalanced to one of the two conditions first (exercise, or control condition). Following completion of the first condition, the third visit will be completion of the other condition.||||
33828462|NCT05167032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33828463|NCT02487251|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33828464|NCT00641836|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828465|NCT02107547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828466|NCT00796614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828467|NCT00747695|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828468|NCT01198847|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828469|NCT05494281|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828470|NCT02109107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828471|NCT00686088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828472|NCT01586533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828473|NCT01231464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828474|NCT05082285|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828475|NCT02959177|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828476|NCT04339140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828477|NCT04342598|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828478|NCT04137302|RANDOMIZED|PARALLEL||OTHER||NONE||"Monocentric, randomized, open-label study~Distribution of patients in groups according to a ratio (1:1)"||||
33828479|NCT04713176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828480|NCT03550183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828481|NCT00903071|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33828482|NCT05583708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828483|NCT02108626|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33828484|NCT03158935|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828485|NCT02998619|||OTHER||RETROSPECTIVE|||||||
33828486|NCT02956083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828487|NCT04728932|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828488|NCT03955354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828489|NCT02592707|NA|SEQUENTIAL||TREATMENT||NONE||||||
33828490|NCT05229770|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Even though complete blinding is regarded as difficult and infeasible, patients will be informed of the follow-up they will receive but not on other follow-up alternatives that are used or the exact hypotheses for the study. Outcomes assessor will be blinded.|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.|f|f|f|t
33828491|NCT00103272|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828492|NCT01860807|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828493|NCT05251857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33828494|NCT04899401|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, multicenter clinical investigation, with two parallel groups of subjects.||||
33828495|NCT01069328|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33828496|NCT02970357|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33828497|NCT01161628|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828498|NCT06130397|||COHORT||RETROSPECTIVE|||||||
33828499|NCT04240600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized clinical trial study|t|f|t|f
33828500|NCT03910777|||COHORT||PROSPECTIVE|||||||
33828501|NCT00816556|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828502|NCT01411449|||CASE_ONLY||PROSPECTIVE|||||||
33828503|NCT00130910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828504|NCT06183411|NA|SINGLE_GROUP||SCREENING||NONE||||||
33828505|NCT02946307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828506|NCT00328380|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33828507|NCT04514172|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Randomized counterbalanced cross-over design||||
33828508|NCT00560313|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33828509|NCT04114812|RANDOMIZED|PARALLEL||OTHER||SINGLE||We will include 152 medical students at the Universities of Bern, Fribourg and Zurich. Stratified by study site, students will be randomized to one of the two interventions. The blended-learning group will receive e-learning and near-peer tutoring over 16 weeks; the other group will receive 21 hours of teaching, from ultrasound experts, in a 2.5-day course.|f|f|f|t
33828510|NCT05828563|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33828511|NCT04811339|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Member of research team not involved in patient care.|Open label trial of Bismuth subsalicylate (10 patients) followed by a second, placebo controlled study (50 patients) for mild to moderate COVID-19+ patients.|f|f|f|t
33828512|NCT01398644|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33828513|NCT05061069|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multicenter non-commercial interventional academic research||||
33828514|NCT02506881|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34136579|NCT06662370|NA|SINGLE_GROUP||OTHER||NONE||Open-label, non-comparative, phase I/II, single-arm, multicenter trial||||
34136580|NCT02518087|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136581|NCT04820010|||CASE_ONLY||RETROSPECTIVE|||||||
34136582|NCT06608654|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136583|NCT01034969|||COHORT||PROSPECTIVE|||||||
34136584|NCT04086693|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled, parallel assignment||||
34136585|NCT05876299|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This study will employ a semi-crossover model whereby participants will complete 2 of 3 conditions, each.||||
34136586|NCT01980836|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136587|NCT02591758|||COHORT||PROSPECTIVE|||||||
34136588|NCT06606522|||OTHER||CROSS_SECTIONAL|||||||
34136589|NCT04689906|||COHORT||RETROSPECTIVE|||||||
34136590|NCT03647410|||COHORT||RETROSPECTIVE|||||||
34136591|NCT00949754|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34136592|NCT04689490|||COHORT||PROSPECTIVE|||||||
34136593|NCT00685269|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34136594|NCT05905835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136595|NCT03514511|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34136596|NCT05190315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136597|NCT04549779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"* The patients will be blinded to their groups.~* An anesthesia resident who will not participate in the study and have no subsequent rule in it will help in the preparation of local anesthetic mixtures under strict aseptic precautions.~* An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in the collection of the data of measurements."||t|f|t|t
34136598|NCT04998994|||CASE_ONLY||PROSPECTIVE|||||||
34136599|NCT03852992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34136600|NCT05698017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Patients will be allocated to one of the following arms:~1. Low dose single intrathecal (IT) administration of hOMSC300~2. High dose single intrathecal (IT) administration of hOMSC300~3. Sham procedure (control)"|t|f|f|t
34136601|NCT02777606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136602|NCT06349460|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||In this micro-randomized trial, participants will have 2 consecutive, independent micro-randomizations at the time of target selection each week for 16 weeks: namely, 1 of 5 treatment targets will be randomly delivered, either as a recommended or assigned target, to each user, of equal probability per randomization.||||
34136603|NCT04177953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136604|NCT05967741|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Experimental and control beverage are formulated to be similar color, taste and volume.|Randomized crossover study with 2-week washout|t|t|f|t
34136605|NCT05980104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136606|NCT05844098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136607|NCT06659328|NA|SINGLE_GROUP||TREATMENT||NONE||This study employs a single-group, quasi-experimental design, where 30 children aged 4 to 6 years with Autism Spectrum Disorder (ASD) participate in a structured walking intervention. The intervention consists of observing the children's gait parameters under varying conditions: walking at normal (120 bpm), slow (100 bpm), and fast (140 bpm) rhythms, while accompanied by either a familiar adult or an unfamiliar adult. Each child will walk a distance of 10 meters, with their gait parameters-such as stride length, step time, cadence, velocity, and joint amplitudes-measured using video analysis software (Kinovea©). This sequential approach enables the assessment of the impact of both speed and social interaction on gait dynamics in a controlled environment. The study aims to elucidate how these factors influence locomotion in children with ASD, providing insights for future therapeutic interventions and rehabilitation strategies.||||
34136608|NCT00803400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136609|NCT02327390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136610|NCT01807559|||CASE_ONLY||PROSPECTIVE|||||||
34136611|NCT06056895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136612|NCT00914446|NA|SINGLE_GROUP||SCREENING||NONE||||||
34136613|NCT04019106|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34136614|NCT06606197|||OTHER||CROSS_SECTIONAL|||||||
34136615|NCT05482529|||COHORT||PROSPECTIVE|||||||
34136616|NCT04851119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136617|NCT05425446|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136618|NCT06540105|||CASE_ONLY||PROSPECTIVE|||||||
34136619|NCT06232018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136620|NCT05456373|RANDOMIZED|PARALLEL||TREATMENT||NONE||multi-center, pivotal prospective, randomized clinical trial of the effect of imaging the excision specimen during surgical treatment of breast cancer||||
34136621|NCT02731677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136622|NCT00145860|||||PROSPECTIVE|||||||
34136623|NCT04547335|||COHORT||PROSPECTIVE|||||||
34136624|NCT06013358|||COHORT||PROSPECTIVE|||||||
34136625|NCT01519791|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136626|NCT04850196|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136627|NCT02767726|NA|SINGLE_GROUP||SCREENING||NONE||||||
34136628|NCT04845009|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33828515|NCT03353142|NA|SINGLE_GROUP||TREATMENT||NONE||Consecutive participants meeting eligibility criteria will be enrolled||||
34136629|NCT02191150|||||RETROSPECTIVE|||||||
34136630|NCT04281225|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|Research Assistants are blind to the conditions of the participants. Participants do not know which condition they have been assigned to either. Only the main investigators (Deb Phillips, Neha Dhawan, Kris Nichols, and Francesco Pagnini) will know which participant is assigned to a particular intervention.||t|f|t|f
34136631|NCT00712036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136632|NCT05555953|||COHORT||CROSS_SECTIONAL|||||||
34136633|NCT02039219|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136634|NCT06543849|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136635|NCT00654836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136636|NCT00223808|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34136637|NCT05635396|NA|SINGLE_GROUP||OTHER||NONE||||||
34136638|NCT02776462|||COHORT||PROSPECTIVE|||||||
34136639|NCT01682655|||COHORT||PROSPECTIVE|||||||
34136640|NCT00072943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34136641|NCT06606249|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The two site investigators will not be made aware of the block size or have any access to the randomization schedule. The software allows for random allocation of participants after the baseline evaluation is performed and inclusion criteria are checked. The study statistician will also be blinded to group allocation.|The study will involve two centers (Padova, Verona). Randomization will be individual and stratified by the two recruiting center, with an allocation rate of 1:1. A centralized system (Redcap) will be used to generate the randomization schedule, using randomly permuted blocks of unequal size,|f|f|t|f
34136642|NCT01748188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136643|NCT04245670|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136644|NCT03503591|||CASE_ONLY||OTHER|||||||
34136645|NCT00283803|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136646|NCT03481166|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34136647|NCT01089413|||COHORT||PROSPECTIVE|||||||
34136648|NCT02202213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136649|NCT01429207|||COHORT||RETROSPECTIVE|||||||
34136650|NCT02977936|||COHORT||PROSPECTIVE|||||||
34136651|NCT03231293|||CASE_ONLY||PROSPECTIVE|||||||
34136652|NCT03082183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136653|NCT02585024|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136654|NCT01686425|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34136655|NCT01801436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136656|NCT05638269|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34136657|NCT05480215|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136658|NCT00426816|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34136659|NCT04743674|||COHORT||PROSPECTIVE|||||||
34136660|NCT04734418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136661|NCT00113204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828516|NCT02101268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828517|NCT03924934|||CASE_CONTROL||PROSPECTIVE|||||||
33828518|NCT05267678|||COHORT||PROSPECTIVE|||||||
33828519|NCT03463434|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This multi-center, randomized, open-label, two treatment, parallel group study is designed to obtain comparative data on the healing rates of type 3 \& 4 pressure injuries.~The randomization schedule will be set up in blocks, and within a block, the randomization numbers will be assigned equally to the two treatment groups (Envella AFT, FIS bed surface types). A separate randomization schedule will be set up for each stage (3, 4 PI). The anticipated number of investigative sites is 3."||||
33828520|NCT02125136|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828521|NCT04261699|||CASE_ONLY||PROSPECTIVE|||||||
33828522|NCT02394964|||CASE_CONTROL||PROSPECTIVE|||||||
33828523|NCT02713737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828524|NCT00788164|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828525|NCT02330562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828526|NCT05930132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828527|NCT04756206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828528|NCT04782518|||OTHER||PROSPECTIVE|||||||
33828529|NCT02206932|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828530|NCT01187407|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828531|NCT04106713|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828532|NCT00002061||||TREATMENT||DOUBLE||||||
33828533|NCT04260399|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|This trial is not blinded|Patients are randomized to lavender aromatherapy or saline placebo aromatherapy using a 1:1 random block allocation||||
33828534|NCT01125566|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828535|NCT01163955|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33828536|NCT01963572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33828537|NCT02179853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828538|NCT02494752|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828539|NCT04254419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828540|NCT00145483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34136662|NCT06429397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136663|NCT00284284|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828541|NCT02925936|RANDOMIZED|PARALLEL||||NONE||||||
33828542|NCT06310798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||In pairs, DHs within public dental care organization in the West of Sweden will be randomized into test and control groups. Due to geographical concerns, NAs within the same municipal as the test control DHs will be asked to participate. As such, the test-group will consist of 12 DHs and 12 NAs. They will form teams in pairs, and each team will collaborate with 15 older adults each in home settings, who participate in the oral assessments and health planning. The control group will consist of 12 DHs which will perform oral assessments according to dental care remuneration programme - business as usual. It is not mandatory but recommended for NAs to participate in the oral assessments, therefore the number of participating NAs within control group is unknown. In total 360 oral assessments and health planning will be performed within the RCT.|t|t|f|f
33828543|NCT01628289|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33828544|NCT03185702|||COHORT||PROSPECTIVE|||||||
33828545|NCT01280747|||COHORT||PROSPECTIVE|||||||
33828546|NCT03142321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828547|NCT04623359|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33828548|NCT01821729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828549|NCT02264964|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33828550|NCT01990313|NA|SINGLE_GROUP||OTHER||NONE||||||
33828551|NCT02813213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Experimental intervention: skin micro grafts Comparative intervention: Meshed Split Thikness Skin Grafts|t|f|t|f
33828552|NCT04106453|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33828553|NCT00382798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828554|NCT00721929|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828555|NCT00934414|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828556|NCT01268098|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136664|NCT01011491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136665|NCT00122876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136666|NCT00535704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136667|NCT05202574|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34136668|NCT02200588|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34136669|NCT05664958|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136670|NCT05758389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136671|NCT03403361|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136672|NCT06205355|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34136673|NCT06606652|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Statistician||t|f|t|f
34136674|NCT04355442|||COHORT||RETROSPECTIVE|||||||
34136675|NCT00794105|||CASE_CONTROL||PROSPECTIVE|||||||
34136676|NCT03028844|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34136677|NCT05130632|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136678|NCT03891537|||CASE_CONTROL||RETROSPECTIVE|||||||
34136679|NCT00098748|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136680|NCT01382355|||COHORT||PROSPECTIVE|||||||
34136681|NCT04236024|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34136682|NCT00441142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136683|NCT06552949|||COHORT||PROSPECTIVE|||||||
34136684|NCT04511871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136685|NCT06291753|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34136686|NCT02172131|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34136687|NCT06582693|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Only adult participants will be blinded during the study. Child participants do not need to be blinded because they will not be engaging in study procedures. Study staff will be aware of the assigned treatment arms. To maintain the blinding of adult participants, study staff will not disclose the treatment assignment to the adult participants at any point during the study. The recruit and consent procedures will describe the study, but not provide the adult participants with details that would reveal their treatment assignment.||t|f|f|f
34136688|NCT00936533|NA|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34136689|NCT05015296|||CASE_ONLY||PROSPECTIVE|||||||
34136690|NCT04628169|||CASE_CONTROL||OTHER|||||||
34136691|NCT05108454|||COHORT||PROSPECTIVE|||||||
34136692|NCT03119181|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34136693|NCT06304584|||COHORT||PROSPECTIVE|||||||
34136694|NCT05401929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136695|NCT00646763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136696|NCT04193345|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34136697|NCT03350958|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|As it necessary in double-blind crossover studies, neither the researchers nor the participants will know which food they are receiving at each visit. All randomisation will be carried out in anonymised fashion by an independent researcher, who will code foods and participants accordingly.|Placebo, controlled double-blind crossover study will recruit participants (males and females, who have previously had ileostomy surgery, but currently have no health issues) from the Newcastle upon Tyne/Gateshead area. Subjects will be randomly allocated to one of two treatment groups. One group will receive a test meal containing the dietary fibre first, then on the second visit, the same meal without dietary fibre. The second group will receive the meal without dietary fibre first, followed by the meal containing dietary fibre on the second visit. For each group, the two visits will be at least 2 weeks apart. As the foods will look exactly the same (the fibres used are colourless and tasteless). As it necessary in double-blind crossover studies, neither the researchers nor the participants will know which food they are receiving at each visit. All randomisation will be carried out in anonymised fashion by an independent researcher, who will code foods and participants accordingly.|t|t|t|t
34136698|NCT05073003|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Observer blind||t|t|t|t
34136699|NCT01829633|||COHORT||RETROSPECTIVE|||||||
34136700|NCT02943330|||CASE_ONLY||PROSPECTIVE|||||||
34136701|NCT02480166|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136702|NCT01709422|RANDOMIZED|PARALLEL||||NONE||||||
34136703|NCT04338139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136704|NCT05968261|||OTHER||PROSPECTIVE|||||||
34136705|NCT05658159|||COHORT||PROSPECTIVE|||||||
34136706|NCT05761106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two researchers will be part of the protocol.One will be responsible for pre and post intervention assessments and will be blind to the type of interventionThe other will be responsible for the treatment phase:Treatment for Temporomandibular Disorder (TMD) and Treatment Oculomotor plus Treatment for TMD. A third-party collaborator will process and statistically analyze the collected data.Individuals will be randomize using the statistical program, two groups.Randomization and concealment of allocation will be made by a fourth external employee,not a research participant, who will organize the allocation in individual opaque envelopes and keep it confidential.There will be 2 blocks of 25 envelopes:Treatment for TMD and Treatment Oculomotor plus Treatment for TMD.With this process, participants will have the same probability of being allocated to one of the two treatment groups.Blinding of the evaluator will be maintained until the end of the research and data tabulation.|f|f|t|t
34136707|NCT00597987|||CASE_CONTROL||PROSPECTIVE|||||||
34136708|NCT02539173|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136709|NCT01882426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136710|NCT06659198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136711|NCT06108193|NA|SINGLE_GROUP||TREATMENT||NONE||PBF Minoxidil Solution 5% PBF Minoxidil Solution 2% Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.||||
34136712|NCT05840952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Parts 1 and 2 are double blinded and randomized. Parts 3, 5, and 6 are open label and non-randomized. Part 4 is partially singled blinded non-randomized. Participants are blinded.|Parts 1 and 2 of the study are parallel assignment, with 2 arms. Parts 3, 5, and 6 are fixed sequence, crossover studies. Part 4 is a partially placebo-controlled, fixed sequence, crossover study.|t|t|t|t
34136713|NCT06608758|||CASE_CONTROL||PROSPECTIVE|||||||
34136714|NCT03103698|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136715|NCT05242224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136716|NCT03726918|||COHORT||PROSPECTIVE|||||||
34136717|NCT00590174|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136718|NCT02305472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136719|NCT06588530|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136720|NCT01835574|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136721|NCT01792375|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136722|NCT04463693|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136723|NCT06112821|||COHORT||PROSPECTIVE|||||||
34136724|NCT01192269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136725|NCT03988699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136726|NCT04117581|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34136727|NCT06329063|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Randomized placebo-controlled double-blind between-subject design||t|f|t|f
34136728|NCT05858853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136729|NCT02534558|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Double-blind||t|f|t|t
34136730|NCT06151886|||COHORT||PROSPECTIVE|||||||
34136731|NCT01060449|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34136732|NCT04429386|||CASE_ONLY||PROSPECTIVE|||||||
34136733|NCT00436423|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136734|NCT05474638|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Controlateral and simultaneous comparison of two different neuromuscular transmission monitorings in a cohort of 20 anesthetised patients.||||
34136735|NCT01630928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136736|NCT04930276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34136737|NCT01543399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136738|NCT05052814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136739|NCT02130830|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34136740|NCT04848220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136741|NCT02816021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136742|NCT04765644|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Healthy male volunteers will be blinded and randomized to 7 days' treatment with celecoxib (200mg bd) or placebo.|t|t|t|t
34136743|NCT02141633|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
34136744|NCT05587062|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136745|NCT01801748|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136746|NCT03018795|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136747|NCT03441997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136748|NCT05093595|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34136749|NCT05444660|||OTHER||RETROSPECTIVE|||||||
34136750|NCT01120236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136751|NCT00801788|RANDOMIZED|CROSSOVER||||NONE||||||
34136752|NCT03744468|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|This is an open-label, multicenter, nonrandomized Phase 1 and Phase 2 clinical trial. Phase 1 will determine the recommended phase 2 dose (RP2D) for the combination of BGB-A425 and Tislelizumab. Phase 2 safety lead-in will determine the RP2D for the combination of BGB-A425, Tislelizumab and/or LBL-007. Phase 2 dose expansion will continue to evaluate the safety but also focus on the efficacy of the double or triplet treatment combination in select tumor types.||||
34136753|NCT00002705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136754|NCT01175486|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136755|NCT06454825|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||randomized double blinded clinical study|t|t|t|t
34136756|NCT01611116|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136757|NCT02342457|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136758|NCT04023591|||CASE_ONLY||PROSPECTIVE|||||||
34136759|NCT00907608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136760|NCT01823159|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34136761|NCT01663818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136762|NCT04595630|||COHORT||PROSPECTIVE|||||||
34136763|NCT04880629|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136764|NCT01900171|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34136765|NCT01329653|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34136766|NCT05289817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Allocation concealment, stratified by sex, will be ensured by the use of sealed envelopes containing the treatment allocation|The study is a prospective, randomized, three-armed, sham-controlled, single-blind, exploratory clinical trial in healthy subjects|t|f|f|f
34136767|NCT02613468|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34136768|NCT05475665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136769|NCT04067297|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The participants and care providers will be masked to what communities are enrolled in the trial, but due to the large scale study promotion that is required for dissemination, they may be aware that the resources they are receiving are part of an ongoing clinical trial. The principal investigator and a statistician will be blinded from which communities are assigned to which arm.|This is a two-arm parallel assignment trial, cluster randomized at a community level. The 14 communities in each arm of the study will receive either the usual standard of care or the intervention in parallel.|f|f|t|t
34136770|NCT04587414|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study is a pragmatic three-arm randomized controlled trial carried out within the primary health care setting. Besides the usual care given to type 2 diabetics, the patients may be assigned either into a 6-month eHealth intervention complemented by face-to-face and telephone counselling contacts on physical activity or into a 6-month eHealth intervention without counselling contacts. After the 6-month intervention, there is a 6-month follow-up period.||||
34136771|NCT04368494|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Random allocation into either a control group or an exercise group (12-weeks of home based exercise).||||
34136772|NCT02511093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136773|NCT02697227|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34136774|NCT01541943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136775|NCT00960011|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34136776|NCT06108726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136777|NCT00978380|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136778|NCT02589652|||COHORT||PROSPECTIVE|||||||
34136779|NCT02429557|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34136780|NCT06094218|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||This study is a two phase, stepped-wedge design. In Phase I, all participants receive TAU. In Phase II, sites are randomized to receive training in BCBT. Prior to the training, participants receive TAU. Following the training, participants may receive BCBT.|t|f|f|f
34136781|NCT04049266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|A masked evaluating investigator will be responsible for subject care except the injections and the safety assessment following the injections. An unmasked treating investigator will perform the injections and assess patient safety following the injections.||t|f|t|t
34136782|NCT02954406|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136783|NCT04956315|||COHORT||PROSPECTIVE|||||||
34136784|NCT03350256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136785|NCT03212482|||COHORT||PROSPECTIVE|||||||
34136786|NCT00926419|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34136787|NCT00930852|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136788|NCT04957992|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34136789|NCT01242696|||CASE_ONLY||PROSPECTIVE|||||||
34136790|NCT06058247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136791|NCT03695614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136792|NCT05495841|||COHORT||PROSPECTIVE|||||||
34136793|NCT05527353|||COHORT||PROSPECTIVE|||||||
34136794|NCT01753869|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34136795|NCT03475706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor representatives Site monitors Data managers Statisticians|This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Eligible female subjects (N=406) with symptoms of overactive bladder for at least 6 months will enter a 14-day single-blind Run-in Period. Subjects (N=375) who meet prespecified criteria based on data entered into an electronic diary over 3 days will be randomized 1:1:1 (125 subjects per arm) to receive solabegron immediate release tablets, low dose or high dose, or matching placebo.|t|f|t|f
34136796|NCT01730365|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136797|NCT04221737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136798|NCT00151710|RANDOMIZED|CROSSOVER||||DOUBLE||||||
34136799|NCT03815695|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|randomized double blind|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption|t|t|t|t
34136800|NCT02946567|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34136801|NCT00730041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34136802|NCT00574730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136803|NCT04969601|NA|SINGLE_GROUP||PREVENTION||NONE||Dose finding, stratified on the age group (≥1-\<2 years, ≥2-\<5 years, ≥5-\<12 years)||||
34136804|NCT02493803|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34136805|NCT03603587|NA|SINGLE_GROUP||OTHER||NONE||This is a prospective mono-centric study of the physiopathology of cutaneous aging.||||
34136806|NCT00006003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136807|NCT01983384|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients are assigned to study arm by random number generator. Anesthesiologists are informed which study arm the patient is assigned before the day of surgery. Patients are not informed of study arm assignment. Research staff assessing for postoperative delirium are not informed of patient study arm assignment.|Patients will be assigned to receive processed EEG-guided anesthesia or standard anesthetic care. Patients in both groups will be monitored with processed EEG, however those in the standard care group will have the anesthesiologist blinded to the machine. Patients in the interventional group receive processed EEG-guided anesthetic maintenance.|t|f|f|t
34136808|NCT05358483|||COHORT||PROSPECTIVE|||||||
34136809|NCT00244933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136810|NCT03195348|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136811|NCT02805751|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136812|NCT02403817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This project develops the intervention and includes a small clinical (behavioral) trial for ASD participants. A small number of ASD participants will be randomly assigned to intervention 'games' played by mouse response--the others to gaze-driven response.||||
34136813|NCT00003191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136814|NCT05455918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136815|NCT01457014|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34136816|NCT05609994|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136817|NCT04703608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind non-identical placebo|"Two cohorts study as follows:~* Cohort 1: intervention with Ivermectin~* Cohort 2: intervention with Aspirin Parallel assignment"|t|f|f|f
34136818|NCT05300568|||CASE_ONLY||CROSS_SECTIONAL|||||||
34136819|NCT05406219|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34136820|NCT03840824|||COHORT||PROSPECTIVE|||||||
34136821|NCT04847752|||COHORT||PROSPECTIVE|||||||
34136822|NCT06349083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34136823|NCT04801433|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149822|NCT00548717|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34149823|NCT04187976|||CASE_CONTROL||PROSPECTIVE|||||||
34149824|NCT05668663|NA|SINGLE_GROUP||OTHER||NONE||||||
33828557|NCT04383847|NA|SINGLE_GROUP||OTHER||NONE|No masking|Feasibility study in 30 groups, pre post, no control||||
33828558|NCT00149617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828559|NCT02238106|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33828560|NCT04842526|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828561|NCT00409591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828562|NCT00466089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828563|NCT05653973|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149825|NCT05117203|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34149826|NCT01263015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149827|NCT00924404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149828|NCT00244491|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34149829|NCT00689793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149830|NCT03273660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136824|NCT04731480|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Inside the operating, the attending anaesthesiologist will not be blinded to the technique utilized to administer general anaesthesia (GA) and the recovery parameters immediately after extubation. However, the postoperative patient recovery profile will be evaluated by an independent assessor blinded to the GA technique and peri-extubation profile.|"One hundred sixty-participants (40/group) aged 18-65 years, ASA physical status I-II, of either sex, and undergoing elective non-cardiac surgery of minimum 60-minutes duration recruitment will be randomly divided into one of the four groups:~Group-1 \[CLADS group, n= 40, study group\], Group-2 \[Marsh model (MM) group, n= 40, study group\], Group-3 \[Schneider Model (SM) Group, n= 40, study group\], and Group-4 \[Manual (M) Group, n= 40, Control group\]."|t|f|f|t
34136825|NCT03736993|NA|SINGLE_GROUP||SCREENING||NONE||||||
34136826|NCT06230510|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to one of two groups in parallel for one year.||||
34136827|NCT04633070|||OTHER||PROSPECTIVE|||||||
34136828|NCT04497857|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34136829|NCT04959617|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34136830|NCT05099705|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Later in the project, a randomized controlled trial will be conducted. 40 participants will be in the intervention group and 15 participants will be in the non-personalized comparison group (i.e., information, training, and referral). Families will complete pre/post measures related to: intervention targets (except the ability to facilitate knowledge), service delivery outcomes, adaptive and maladaptive behavior, and autism symptoms. Information will also be collected via the treatment support system; such information will include the type and frequency of communication between the navigator and the family. Individual interviews will be collected with the navigator supervisor and the 20 navigators to identify barriers to the navigator model for low-resourced families.||||
34149831|NCT03921333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Dose response study|t|f|t|f
34149832|NCT05521633|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34149833|NCT03693547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828564|NCT04858321|NA|SINGLE_GROUP||OTHER||NONE||We plan to run a within-subject, pre-, post-intervention study||||
33828565|NCT00000232||CROSSOVER||TREATMENT||DOUBLE||||||
33828566|NCT03650335|||OTHER||PROSPECTIVE|||||||
33828567|NCT05184621|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Main efficacy indicators. Axial length changes in the left and right eyes (30± 14 days, 90± 14 days, 180± 14 days, 270± 14 days, and 365± 14 days).Secondary efficacy indicator: change in equivalent spherical lens after astigmatism (day 365±14)|f|t|t|t
33828568|NCT02754869|||CASE_ONLY|||||||||
33828569|NCT05330351|||COHORT||CROSS_SECTIONAL|||||||
33828570|NCT02588989|||COHORT||PROSPECTIVE|||||||
33828571|NCT01395511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828572|NCT02349256|||CASE_ONLY||CROSS_SECTIONAL|||||||
33828573|NCT02222883|||COHORT||PROSPECTIVE|||||||
33828574|NCT03776162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment will be determined by intra-operative computer-generated randomization after the diagnostic arthroscopy and participant treatment assignment will not be reported to the participant until termination of the study observation period. Research Assessments by Independent Blinded Assessor for assessments of study endpoints and safety. KT-1000 knee laxity arthrometer testing, International Knee Documentation Committee (IKDC) patient-reported outcome score, Knee Injury and Osteoarthritis Outcome Score (KOOS), Marx knee activity rating scale, Anterior Knee Pain Scale, Quadriceps Strength, Hop testing, and physical examination. The physical therapist implementing the post-surgical rehabilitation will be blinded to the treatment group.|Multi-center, 2-arm, 1:1 permuted block randomized controlled clinical trial, with a blinded patient and outcome assessor.|t|t|f|t
33828575|NCT03602248|RANDOMIZED|CROSSOVER||SCREENING||NONE||||||
33828576|NCT01095913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828577|NCT03530488|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33828578|NCT04675905|||COHORT||PROSPECTIVE|||||||
33828579|NCT04747210|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Two external assessors will measure the fidelity of the implementation of the intervention.|This study is a quasi-experimental pretest-posttest design. Repeated measures on participants in both arms (as in an RCT) enable assessment of both within-person changes over time and between-arm differences.|f|f|f|t
33828580|NCT01340040|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828581|NCT03722693|||CASE_ONLY||PROSPECTIVE|||||||
33828582|NCT05648513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828583|NCT02798692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828584|NCT04661514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828585|NCT03105778|||OTHER||PROSPECTIVE|||||||
33828586|NCT00353093|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33828587|NCT02716077|NA|SINGLE_GROUP||OTHER||||||||
33828588|NCT04012658|||COHORT||PROSPECTIVE|||||||
33828589|NCT05253079|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33828590|NCT03272698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomized to either the HIKER or EAST arms, but due to the different frequencies of treatment, patient and physician blinding will not be possible. Outcome assessor will also not be blinded. As patients were not blinded, they could easily divulge their treatment allocation. The outcome assessor can also deduce treatment allocation from communications with nursing staff or study personnel. However, the follow up assessment at 30 days post-final treatment will be performed by a different study team member who will remain blinded.|Patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule, weekdays only) with ketamine-based general anesthetic (ketamine 0.75 mg/kg, remifentanil 1 mcg/kg, and succinylcholine 0.75 mg/kg for safety. Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, on 8 successive weekdays. Since ketamine without ECT is not the standard of care for TRD, patients in the HIKER arm who do not achieve a 25% reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) after the third treatment will be deemed non-responsive to ketamine and switched to a standard 8 treatment course of ECT with ketamine-based GA as described in the EAST arm - this will be called rescue ECT. The attending psychiatrist may discontinue therapy for either arm if the patient achieves remission or treatment is ineffective based on clinical judgment.|f|f|t|f
33828591|NCT00892944|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828592|NCT05829135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136831|NCT03265002|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Participants will be blind to the fibre product taken on each study visit. Masking will be assisted by adding lemon juice to the vehicle drink.~The staff responsible for preparing this food will be members of the digestive diseases unit at the NIHR Nottingham Biomedical Research Centre and will not be involved in the study otherwise. The investigators responsible for MRI and symptom analysis will be kept blind to the intervention as data will be coded by date of study day, rather than by product received. Additionally MRI data will be assigned a 'scanning number' through the Sir Peter Mansfield Imaging Centre. This will pseudo-anonymise MRI data within the study so that associations between participants and scans will not be immediately obvious."|single-centre, 4 period, 4 treatment, placebo-controlled crossover trial.|t|f|t|f
34136832|NCT02543177|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828593|NCT00329550|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136833|NCT03983265|NA|SINGLE_GROUP||OTHER||NONE||Condylar/Proximal Segments Repositioning Using CAD/CAM Generated Wafer After Bilateral Sagittal Split Osteotomy in Skeletal Mandibular Deformity||||
34151171|NCT05432479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151172|NCT04595162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828594|NCT01677949|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828595|NCT06480253|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Open Label, randomized, controlled with crossover||||
33828596|NCT05710198|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double-blind|Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial|t|t|t|t
33828597|NCT00292981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828598|NCT00996814|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33828599|NCT02418845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828600|NCT03477825|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Double blinded|Thirty (30) subjects meeting the inclusion criteria without any of the exclusion criteria will be enrolled in this study. This study will be a double blinded study. Each subject will be randomized a priori to receive either placebo, Rubia cordifolia, or Triphala tablets.|t|t|t|t
33828601|NCT03245463|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33828602|NCT05592236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828603|NCT01395849|||OTHER||PROSPECTIVE|||||||
33828604|NCT05542121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828605|NCT03561025|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
33828606|NCT00349570|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828607|NCT03440983|NA|SINGLE_GROUP||OTHER||NONE||||||
33828608|NCT02712190|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33828609|NCT00482898|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33828610|NCT01255761|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828611|NCT03436043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blind||t|f|f|f
33828612|NCT02176564|||COHORT||PROSPECTIVE|||||||
33828613|NCT02854397|||OTHER||PROSPECTIVE|||||||
33828614|NCT02230306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828615|NCT04896684|||COHORT||PROSPECTIVE|||||||
33828616|NCT01136681|||COHORT|||||||||
33828617|NCT01674803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828618|NCT02236663|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33828619|NCT00707005|||||PROSPECTIVE|||||||
33828620|NCT04637516|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The investigator does not know the order of versions tested by participants.|Subjects use two versions of the program for a set duration, separated by a washout phase. The order of versions applied is randomised.|f|f|t|f
33828621|NCT01046591|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828622|NCT03812367|||CASE_CONTROL||PROSPECTIVE|||||||
33828623|NCT01721746|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828624|NCT05980819|NA|SINGLE_GROUP||OTHER||NONE||||||
33828625|NCT01432522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828626|NCT02049515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828627|NCT04116281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel assignment|t|f|f|t
33828628|NCT00605566|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33828629|NCT04755023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828630|NCT01869998|||CASE_CONTROL||PROSPECTIVE|||||||
33828631|NCT04353817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828632|NCT02674009|||COHORT||PROSPECTIVE|||||||
33828633|NCT05612451|RANDOMIZED|PARALLEL||TREATMENT||NONE||This randomized clinical trial aimed to assess and compare the clinical and radiographic outcomes of Regenerative Endodontic Procedures (REP) in treating non-vital immature permanent teeth using two intracanal medicaments.||||
33828634|NCT06014970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828635|NCT03184818|||OTHER||PROSPECTIVE|||||||
33828636|NCT04346485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828637|NCT03742817|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33828638|NCT02675803|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828639|NCT02032264|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828640|NCT01744743|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33828641|NCT05159986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were randomly allocated to a Group I (diadynamic currents associated to Exercise; n=30, 60 knees) and Group II (exercises group; n=30, 60 knees) were treated 3 times a week for 8 weeks.|f|f|t|f
33828642|NCT03972865|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828643|NCT04103086|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants, investigators, physicians, and outcomes assessors will be blinded to treatment allocation. The sticks of aromatherapy and placebo are the same, and the smell of them is similar. In order to achieve allocation concealment, a web-based central system will automatically assign a random code for each participant. Each bottle of medicine or placebo will be labeled according to the pre-determined random code by an independent agency that does not involve any persons associated with the trial.|Randomized (two arms), double-blind, placebo-controlled intervention is proposed in this study. 660 participants undergoing PCI are anticipated to be enrolled from the Beijing Anzhen Hospital. Before hospital discharge, participants will be randomly assigned to receive aromatherapy (70% menthol and 30% propanediol) or placebo (10% menthol and 90% propanediol) after PCI for 6 months.|t|t|t|t
34136834|NCT05258578|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will be conducted in two parallel phases. Phase 1 is a multisite randomized controlled trial (RCT) to examine the efficacy of Tele-CBT vs. a control intervention in postoperative bariatric patients experiencing disordered eating and/or psychological distress. Qualitative exit interviews will also be conducted and data used to inform future adaptations of the intervention to meet patients' diverse needs during and post-pandemic. Phase 2 will consist of integrated knowledge translation and the creation of a diverse advisory committee to co-produce knowledge products and inform adaptation of Tele-CBT for diverse populations.||||
34136835|NCT01074463|RANDOMIZED|CROSSOVER||||NONE||||||
33828644|NCT00764270|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Crossover study in which participants are randomly assigned to the sequence of receiving R-Alpha Lipoic Acid and Placebo|t|t|t|t
33828645|NCT00535093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828646|NCT04868253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828647|NCT05606198|||COHORT||RETROSPECTIVE|||||||
33828648|NCT00030537||||TREATMENT||||||||
33828649|NCT05851664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828650|NCT03123419|NA|SINGLE_GROUP||OTHER||NONE||||||
33828651|NCT01013506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828652|NCT02990923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828653|NCT02082418|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33828654|NCT01396200|NON_RANDOMIZED|PARALLEL||TREATMENT||||||||
33828655|NCT04382768|NA|SINGLE_GROUP||TREATMENT||NONE||This is an expanded compassionate use program for patients infected with SARS-CoV-2. All patients or their legally authorized representative must provide written informed consent and the patient will be examined to assess their eligibility. Eligible patients will receive inhalation ibuprofen ate three times a day, plus standard care, until the patient became negative, or their physician considers enough or the patient requested to stop.||||
33828656|NCT03002922|NA|SINGLE_GROUP||OTHER||NONE||||||
33828657|NCT03987490|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|t|f|f
33828658|NCT02531399|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828659|NCT05024409|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828660|NCT04969224|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828661|NCT02005068|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828662|NCT04112277|||CASE_ONLY||PROSPECTIVE|||||||
33828663|NCT02244268|||COHORT||PROSPECTIVE|||||||
33828664|NCT02537145|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828665|NCT05259436|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomly assigned to the caregiver-child intervention using a block allocation scheme. Given the nature of the intervention the participants and their healthcare providers will be unblinded to their assignment.|Wait-list randomized controlled trial.|f|f|t|t
33828666|NCT05238363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828667|NCT04788966|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33828668|NCT00270036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828669|NCT06028217|||COHORT||PROSPECTIVE|||||||
33828670|NCT04410549|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828671|NCT00212277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828672|NCT01143545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828673|NCT04124198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828674|NCT01746277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828675|NCT01588210|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33828676|NCT05887739|||CASE_CONTROL||PROSPECTIVE|||||||
33828677|NCT03204500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a prospective randomized double-blind placebo-controlled trial. The randomization is made in blocks of 4 treatments (2 active and 2 placebo). Only the 4-digit numbers on the bottle label will identify the type of treatment.|Twenty ALS patients under active treatment vs. twenty ALS patients under placebo treatment. 21 months follow-up whith clinimetry and biomarkers|t|f|t|f
33828678|NCT01351337|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33828679|NCT03100864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828680|NCT04209998|||COHORT||OTHER|||||||
33828681|NCT04513275|||CASE_ONLY||CROSS_SECTIONAL|||||||
33828682|NCT02287740|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33828683|NCT03517111|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomization to treatment conditions (FPNG+, FPNG, or comparison \[RAD\]) will occur at the school level. From the 18 participating schools, 6 each will be randomized into one of the three conditions.||||
33828684|NCT02923609|NA|SEQUENTIAL||TREATMENT||NONE|The echocardiographer will be blinded for the timing of echocardiographic recordings.|The study is designed in a prospective crossover fashion. In Phase 1 of the study, all patients are treated with optimization of medical therapy for 6 months. Thereafter, all patients cross over to Phase 2 of the study, where they receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 lasts for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).||||
33828685|NCT06206785|||OTHER||OTHER|||||||
33828686|NCT02605096|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33828687|NCT03068793|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828688|NCT04658654|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828689|NCT01685086|||COHORT||PROSPECTIVE|||||||
33828690|NCT06497712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33828691|NCT06065709|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomised controlled trial|t|t|t|t
33828692|NCT02005393|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828693|NCT03201536|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828694|NCT05999565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828695|NCT06412796|||COHORT||PROSPECTIVE|||||||
33828696|NCT02970305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828697|NCT01487902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828698|NCT05744583|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized, open label design. 3 centers use whole blood while others use packed red cells as pre-hospital transfusion therapy. Only study related intervention is additional blood samples from sub-group of patients for in vivo coagulation studies.||||
33828699|NCT05137405|||COHORT||RETROSPECTIVE|||||||
33828700|NCT01946555|||COHORT||PROSPECTIVE|||||||
33828701|NCT04731675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828702|NCT05010902|||COHORT||PROSPECTIVE|||||||
33828703|NCT00904722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828704|NCT05528822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828705|NCT03758703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Because of the nature of the intervention, it is not possible to perform blinding/masking.|This study will employ a pragmatic parallel randomized-control trial design as a mixed-methods study in which approximately half of the participants will be randomized into a control and the other remaining half in the experimental group.||||
33828706|NCT06254300|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828707|NCT01415258|||CASE_ONLY||PROSPECTIVE|||||||
33828708|NCT00305097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33828709|NCT00104637|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33828710|NCT05797883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828711|NCT01317706|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33828712|NCT01885923|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828713|NCT05098756|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828714|NCT03498352|||COHORT||PROSPECTIVE|||||||
33828715|NCT01653249|NA|SINGLE_GROUP||||NONE||||||
33828716|NCT01436383|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828717|NCT02075398|||CASE_ONLY|||||||||
33828718|NCT03344406|||COHORT||CROSS_SECTIONAL|||||||
33828719|NCT04472988|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|During the study an endocrinologist who will be blinded to randomization groups will evaluate the biological markers of the participants at baseline, post-treatment and follow-up.||f|f|f|t
33828720|NCT00581841|||COHORT||PROSPECTIVE|||||||
33828721|NCT02941848|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828722|NCT05264142|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study will include 3 distinct CYP2C19 genotype groups that will constitute the 3 arms of the study. For each volunteer, the study will consist of 3 sessions. Same drugs will be administered to the 3 arms of the study.||||
33828723|NCT01181219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828724|NCT01742845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33828725|NCT03900026|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Multicenter, double-blind, randomized, placebo-controlled, parallel group study of evolocumab.|t|t|t|t
33828726|NCT06343649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33828727|NCT02821078|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828728|NCT00858507|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33828729|NCT04930003|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Assignment|t|f|f|f
33828730|NCT00591591|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33828731|NCT00318097|||CASE_CONTROL||PROSPECTIVE|||||||
33828732|NCT01238393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828733|NCT00831012|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33828734|NCT04080063|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828735|NCT01319175|RANDOMIZED|||||SINGLE|||f|f|f|t
33828736|NCT01113164|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||TRIPLE|||t|t|t|f
33828737|NCT02331810|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828738|NCT01921114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828739|NCT03146754|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828740|NCT04037943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study is a single-blinded trial where investigators and outcome assessors will be blinded to the groups the participants are randomized to.|This study is a three-group parallel design trial. The paralele groups will be the control group, the low-dose intervention group, and the high-dose intervention group. Eligible participants will be randomly assigned to one of the three groups.|f|f|t|t
33828741|NCT02725528|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828742|NCT05172557|NA|SINGLE_GROUP||OTHER||NONE||||||
33828743|NCT00799136|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828744|NCT02895243|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34136836|NCT02609841|||COHORT||PROSPECTIVE|||||||
33828745|NCT02895334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33828746|NCT04493645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigators collecting the outcomes will be blinded to group allocation. Separate investigators will be used for intervention delivery and outcomes assessment.|The investigators will compare clinical and innovative outcome measures collected at five time points between cohorts of patients with CAI that receive a standard of care (SOC) rehabilitation program compared to an innovative foot intensive rehabilitation (FIRE) program to determine if FIRE can further reduce the rate of re-injury, improve sensorimotor function, and reduce self-reported disability during the 24 months following the intervention.|f|f|f|t
33828747|NCT01175564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828748|NCT02371720|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33828749|NCT01888809|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33828750|NCT01584323|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828751|NCT04921553|||CASE_ONLY||PROSPECTIVE|||||||
33828752|NCT01993628|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33828753|NCT05655039|||CASE_CONTROL||RETROSPECTIVE|||||||
33828754|NCT05654805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|blinding applies to participants, study personnel and statistician|parallel-designed triple-blinded randomised placebo-controlled intervention study|t|t|t|t
33828755|NCT02999737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828756|NCT03663647|||COHORT||RETROSPECTIVE|||||||
33828757|NCT05352971|||COHORT||RETROSPECTIVE|||||||
34136837|NCT06325241|||COHORT||PROSPECTIVE|||||||
34136838|NCT05820568|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot||||
34136839|NCT03825146|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, open label, prospective study||||
34149834|NCT05226585|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and outcomes assessor will not be aware of participant study conditions.|Three treatment arms and a waitlist control|t|f|f|t
34151173|NCT02858921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136840|NCT04526951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective, randomized-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation). At all participating centers, ophthalmologists are involved in the diagnosis and visual outcome measurements using a standardized protocol. The patients will be promptly examined by the ophthalmologist. As soon as the CRAO is diagnosed by the ophthalmologist, the patients will be managed in the stroke unit during treatment, monitoring, and medical investigations. After treatment in the stroke unit, the patients will be re-examined by an ophthalmologist and a neurologist as an out-patient at (30 ±5) and 90 (±15) days.|t|f|f|f
34136841|NCT03267043|NON_RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||f|f|f|t
34136842|NCT03955224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136843|NCT02645877|||COHORT||RETROSPECTIVE|||||||
34136844|NCT03167112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136845|NCT02882867|||COHORT||PROSPECTIVE|||||||
34136846|NCT03911752|||OTHER||OTHER|||||||
34136847|NCT01471028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136848|NCT02975011|||CASE_ONLY||PROSPECTIVE|||||||
34136849|NCT01254149|||OTHER||CROSS_SECTIONAL|||||||
34136850|NCT03927235|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34136851|NCT03764566|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34136852|NCT00330408|RANDOMIZED|PARALLEL||ECT||NONE||||||
34136853|NCT01294306|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136854|NCT04659174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136855|NCT05099354|||CASE_ONLY||PROSPECTIVE|||||||
34136856|NCT03537248|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34136857|NCT06605586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136858|NCT00692614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136859|NCT00918775|||COHORT||PROSPECTIVE|||||||
34136860|NCT02821442|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34136861|NCT06588647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All outcomes assessors will be blinded to participant study group assignment.||f|f|f|t
34136862|NCT05042765|||COHORT||CROSS_SECTIONAL|||||||
34136863|NCT01795495|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34136864|NCT02959853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136865|NCT06117969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136866|NCT03618732|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||stratified, single-blinded, intervention and controlled study|f|f|f|t
34136867|NCT04974346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136868|NCT02694276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136869|NCT06073912|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34136870|NCT04345861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136871|NCT04778631|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34136872|NCT02674919|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34136873|NCT00256035|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34136874|NCT01549886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136875|NCT00721760|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34136876|NCT04301128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136877|NCT05864950|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136878|NCT04500080|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Feasibility pilot study||||
34136879|NCT01140997|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136880|NCT05726981|NA|SINGLE_GROUP||OTHER||NONE||||||
34136881|NCT01713673|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136882|NCT06138015|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34136883|NCT00726037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136884|NCT02514304|||CASE_CONTROL||PROSPECTIVE|||||||
34136885|NCT02627547|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34136886|NCT04717648|||OTHER||RETROSPECTIVE|||||||
34136887|NCT03563677|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Recruitment of 682 patients into control group during first 12 months of the project and, thereafter, recruitment of 682 patients during subsequent 12 months||||
34136888|NCT00733291|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
34136889|NCT01352221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136890|NCT06232850|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34136891|NCT00210457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136892|NCT03231917|RANDOMIZED|CROSSOVER||SCREENING||NONE||In one randomized group, water infusion will be employed as the first method for mucosal inspection while in a second group, CO2 insufflation will be used first. This study will be different than usual care since the participants will receive two successive or tandem colonoscopies versus one||||
34136893|NCT03368053|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Descriptive mono-centric study with one single group.||||
34136894|NCT01031316|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34136895|NCT02164357|||COHORT||PROSPECTIVE|||||||
34136896|NCT06383247|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34136897|NCT05339490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136898|NCT02604654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136899|NCT06146751|||OTHER||PROSPECTIVE|||||||
34136900|NCT00438763|||COHORT||PROSPECTIVE|||||||
34136901|NCT02456090|||COHORT||PROSPECTIVE|||||||
34136902|NCT00194584|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34136903|NCT00070876|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34136904|NCT01500915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136905|NCT04164017|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34136906|NCT02899650|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34136907|NCT05045807|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Given the nature of the interventions, participants, and the investigators responsible for delivering the interventions will be unblinded throughout the trial. However, all researchers performing the laboratory analyses and data analyses will be blinded to the interventions that the participants received until after the data analysis has been performed.|prospective, mono-centre, randomised, controlled, crossover study|f|f|f|t
34136908|NCT01793337|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34136909|NCT00134992|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34136910|NCT04039750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|there is no masking after randomization|"Patients will be randomized into 1 of 2 groups. Group A will be Antibiotic Irrigation with suction and Group B will be Suction Alone."|t|f|f|f
34136911|NCT06157177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136912|NCT03655301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136913|NCT02276352|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136914|NCT01751906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34136915|NCT04809818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Part A: parallel Part B: single group|t|t|t|t
34136916|NCT06157632|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients with thyoid nodules that will do thyriodectomy||||
34136917|NCT05559840|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two treatment strategies will be compared in this pilot study. When PPH will be diagnosed, women will receive standard treatment, 10 units of oxytocin, uterine massage and aortic compression. If bleeding continue, the control group (Group I) will be treated with condom catheter tamponade by inflating the condom with saline according to national protocol. In case of study group (Group II) the condom will be inflated with air.||||
34136918|NCT06324422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled multi-site trial with follow-up|f|f|f|t
34136919|NCT05078515|||COHORT||RETROSPECTIVE|||||||
34136920|NCT04544930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136921|NCT05487040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136922|NCT06046612|NA|SINGLE_GROUP||TREATMENT||NONE||"Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment.~At the start of the study patients will undergo the LASCA measurements. A very small amount of acetylcholine, nitroprusside and insulin will be applied to the skin of the forearm, to stimulate the bloodflow during LASCA. After 3 months of use of Empagliflozin the LASCA measurement will be repeated. Furthermore, at each visit 4 tubes of blood will be drawn for biobanking, and patients will be asked to fill out a quality of life questionnaire. During the trial, patients will be monitored in routine clinical care as indicated by their treating physician."||||
34136923|NCT06662162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||2:1 Randomization of active to sham therapy|t|t|f|t
34136924|NCT03314961|||COHORT||PROSPECTIVE|||||||
34136925|NCT01536665|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34136926|NCT01741025|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34136927|NCT03525301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136928|NCT05073796|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34136929|NCT06606002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136930|NCT05440591|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open Label Parallel Randomised Controlled Trial||||
34136931|NCT01761591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136932|NCT03897153|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136933|NCT00899197|||COHORT||PROSPECTIVE|||||||
34136934|NCT02447250|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136935|NCT04605497|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136936|NCT00920387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136937|NCT01498393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136938|NCT05608395|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||11C-Methionine PET/CT Arm is to be compared to historical cohort A(hist.).||||
34136939|NCT02761187|||CASE_ONLY||PROSPECTIVE|||||||
34136940|NCT02138409|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136941|NCT00431522|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34136942|NCT03074292|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34136943|NCT06220864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136944|NCT06608082|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Study the presence of indocyanine green in the vaginal cuff during the total laparoscopic hysterectomy, in order to assess intraoperative vascularization of the area (fluorescence intensity value different from 0). This is a prospective feasibility study||||
34136945|NCT02258750|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34136946|NCT00148200|||CASE_ONLY||CROSS_SECTIONAL|||||||
33828758|NCT05656963|||COHORT||RETROSPECTIVE|||||||
33828759|NCT01845311|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828760|NCT02930187|||COHORT||PROSPECTIVE|||||||
33828761|NCT01193218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828762|NCT06478901|||COHORT||PROSPECTIVE|||||||
33828763|NCT05442073|||CASE_ONLY||PROSPECTIVE|||||||
33828764|NCT03782610|||COHORT||PROSPECTIVE|||||||
33828765|NCT05411874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828766|NCT05343208|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Randomly selected from an employer list|An empirical and parallel design using raw EFP psychometric data to measure the effectiveness of online therapy to reduce the risk for Burnout between a control group and an online therapy group.||||
33828767|NCT03082612|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33828768|NCT00801086|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828769|NCT02974725|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828770|NCT02406274|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136947|NCT05312632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136948|NCT02220855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136949|NCT06056336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136950|NCT05917496|||CASE_ONLY||PROSPECTIVE|||||||
34136951|NCT05311449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|In the study, a researcher (T.Ç.Y.) will determine the acupressure and placebo points to be applied to women. However, the researcher (A.A.) who will apply acupressure and placebo acupressure be blinded without knowing whether these points are acupressure or placebo points. Participants will not know that they are in the acupressure or placebo group. Thus, the research will be carried out as a double-blind randomized controlled trial. When the research is completed, the data of the control and study groups (A or B) will be transferred to the computer environment by a researcher independent of the research, and the data will be analyzed by a statistician and the findings will be reported.|Prospective, parallel, two-arm, randomized controlled clinical trial, double blind||||
34136952|NCT04945850|||CASE_CONTROL||PROSPECTIVE|||||||
34136953|NCT06290752|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34136954|NCT06662058|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34136955|NCT02531425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136956|NCT02689739|||CASE_CONTROL||PROSPECTIVE|||||||
34136957|NCT01792713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136958|NCT02617394|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34136959|NCT02052726|RANDOMIZED|||PREVENTION||TRIPLE|||t|f|t|t
34136960|NCT06178848|RANDOMIZED|PARALLEL||OTHER||SINGLE|The principal investigator and the anesthesiologist directly involved in anesthetizing the respective patients should be aware of patient allocation due to the nature of research design and anesthesia maintenance. Two research personnel, who are unaware of the type of test drug (blinding), are not involved in anesthesia but are responsible only for data collection and analysis.||f|f|f|t
34136961|NCT02666651|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34136962|NCT03960411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The only party who is not masked is the pharmacist|One arm receives standard care after primary PCI, the other receives doxycycline b.i.d for 7 days as an adjunct to standard care|t|t|t|t
34136963|NCT03584841|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Intervention Model: Three Group Assignment||||
34136964|NCT00585494|||COHORT||PROSPECTIVE|||||||
34136965|NCT05259137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34136966|NCT00948857|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34136967|NCT00448617|||COHORT||PROSPECTIVE|||||||
34136968|NCT03712865|||COHORT||PROSPECTIVE|||||||
34136969|NCT05145764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34136970|NCT01434043|||CASE_ONLY||PROSPECTIVE|||||||
34136971|NCT00142805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136972|NCT02969291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136973|NCT04670458|||CASE_CONTROL||RETROSPECTIVE|||||||
34136974|NCT05707078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136975|NCT01159925|||CASE_ONLY||PROSPECTIVE|||||||
34136976|NCT06196931|||COHORT||RETROSPECTIVE|||||||
34136977|NCT05275608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136978|NCT06010641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136979|NCT06404320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34136980|NCT06287515|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34136981|NCT00176488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136982|NCT01331382|RANDOMIZED|FACTORIAL||||DOUBLE|||t|f|t|f
34136983|NCT01518998|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34136984|NCT03554941|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34136985|NCT06398730|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34136986|NCT05096234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34136987|NCT02156284|NA|SINGLE_GROUP||||SINGLE|||f|f|f|t
34136988|NCT02450461|||CASE_CONTROL||PROSPECTIVE|||||||
34136989|NCT05180799|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136990|NCT03319953|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34136991|NCT03096795|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34136992|NCT03932864|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double Blind||t|t|t|t
34136993|NCT00067964|RANDOMIZED|||PREVENTION||||||||
34136994|NCT01331343|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34136995|NCT01059682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34136996|NCT03319563|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34136997|NCT01858857|||COHORT||PROSPECTIVE|||||||
33828771|NCT03952780|||CASE_ONLY||PROSPECTIVE|||||||
33828772|NCT02918292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828773|NCT02889783|||||RETROSPECTIVE|||||||
33828774|NCT02800421|||COHORT|||||||||
34136998|NCT06051812|||COHORT||PROSPECTIVE|||||||
34136999|NCT06110156|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34137000|NCT05898308|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In both arms, patients will be initially treated according to the French guidelines (PNDS) based on the Ritux-3 regimen: 1000 mg of rituximab on Day1-Day14, and 500 mg at Month 12 and Month 18, plus oral prednisone 1 mg/kg/day initially, with the aim to stop prednisone after 6 months.~standard-of-care arm will be treated as mentioned above. personalized maintenance treatment arm will be treated with the same regimen, adapted according to the evolution of anti-Dsg Abs: During the initial phase of treatment: patients i) whose serum anti-Dsg Abs have not sufficiently decreased ii) and/or those who initially had a severe pemphigus (at the inclusion visit) defined by a PDAI score \> 45) will receive 1 g of rituximab at Month 6 ; the second year from Month 22 (4 months after the Month 18 infusion of 500 mg of rituximab) until the end of the study: patients whose anti-Dsg3 Abs re-increase \>50 UI/ml and/or anti-Dsg1Abs re-increase\>20 UI/ml) will receive 1 g of rituximab."||||
34137001|NCT06053112|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Test group: infant formula with 6 HMOs blend; Control group: infant formula without 6 HMOs blends|t|t|t|t
34137002|NCT03811925|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137003|NCT02345772|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137004|NCT04328753|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|third professional person give the one of opaque coded bottle to the participant|Forty-five adult male patients with generalized gingivitis participated in the double blinded randomized controlled parallel study divided into three groups, two mouth rinses and distilled water( negative control) used during seven days periods as adjunctive to regular mechanical oral hygiene, one group received super oxidized water mouth rinses(microsafe®) three times daily and the second group received Alcohol-free chlorhexidine 0.12% solution(kin gingival®) twice dialy and the third group received distilled water (negative control).|f|f|f|t
34137005|NCT01708265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137006|NCT00412685|||CASE_CONTROL||PROSPECTIVE|||||||
34137007|NCT03971240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137008|NCT03541967|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34137009|NCT04608409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34137010|NCT00883285|||COHORT||PROSPECTIVE|||||||
33828775|NCT05405322|||COHORT||PROSPECTIVE|||||||
33828776|NCT04648852|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33828777|NCT04017897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828778|NCT03199300|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34137011|NCT06283940|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Data collection will be conducted by a physiotherapist not involved in the intervention.|Intervention group and matched controls based on age, gender and exercise capacity in watt.||||
34137012|NCT02007135|||COHORT||CROSS_SECTIONAL|||||||
34137013|NCT00597623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137014|NCT03295383|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137015|NCT01841125|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137016|NCT03713398|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34137017|NCT06608680|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34137018|NCT05434065|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intracerebral hemorrhage||||
34137019|NCT01325454|||CASE_CONTROL||PROSPECTIVE|||||||
34137020|NCT03941457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137021|NCT06507436|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Herombopag compared with placebo|t|t|t|t
34137022|NCT06558422|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participant will be blinded to study group assignment.|All participants will undergo (i.e., cross over between) both pancreatic clamp protocols (MH, RE) separated by 2-8 weeks. The order of the clamp protocols (i.e., MH \> RE, RE \> MH) will be randomized.|t|f|f|f
34137023|NCT05021302|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Physicians that evaluated the perineometer, UDI-6, and 1-hour pad test will be blinded for the group allocation to reduce bias|We recruited consecutively for 40 patients divided into two groups by simple randomization, with 20 participants in each group.|f|f|f|t
34137024|NCT00446823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137025|NCT05092282|||COHORT||PROSPECTIVE|||||||
34137026|NCT03802344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137027|NCT05287841|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The total number of subjects to be accrued locally is 96. We expect 96 patients to be pre-screened, enrolled (consent obtained), randomized, and complete research procedures. Each arm will have 48 patients. 48 patients in two arms for total of 96 patients.|t|f|f|t
34137028|NCT04467658|||CASE_ONLY||RETROSPECTIVE|||||||
34137029|NCT05141708|||COHORT||RETROSPECTIVE|||||||
34137030|NCT05915416|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Researcher and participants could not be blinded due to the nature of the research. Data were coded as 'A' for experiment group and 'B' for control group. Statistical analysis of the coded data was performed by a statistics professional in order to avoid bias in the statistical evaluation of research data.||f|f|f|t
34137031|NCT00615446|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137032|NCT06322745|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A randomized prospective comparative study. Two-arm parallel assignment:~First Arm: involves cases of laparoscopic partial nephrectomy done with suture renorrhaphy only for hemostasis of the tumor bed.~Second Arm: involves cases of laparoscopic partial nephrectomy using thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed."||||
34137033|NCT03199326|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Surveys will be collected without knowledge of intervention assignment||f|f|f|t
34137034|NCT01730326|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137035|NCT06608862|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34137036|NCT02407340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blind, placebo controlled|Oxytocin vs. placebo|t|t|t|t
34137037|NCT05858450|||COHORT||RETROSPECTIVE|||||||
34137038|NCT04505553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137039|NCT03830476|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking at baseline of both participant and care-provider.|Feasibility study and Randomised Controlled Trial|f|t|f|f
34137040|NCT05305222|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34137041|NCT00349921|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34137042|NCT06608160|||COHORT||PROSPECTIVE|||||||
34137043|NCT01892436|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137044|NCT06303089|||OTHER||CROSS_SECTIONAL|||||||
34137045|NCT02382029|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34137046|NCT06606548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137047|NCT02584231|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137048|NCT00001399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137049|NCT00770497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137050|NCT01671293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137051|NCT06229431|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This intervention study has a cluster-randomised design developed in accordance with the CONSORT statement||||
34137052|NCT02592616|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137053|NCT06397651|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||"Treatment Group~* Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of 3 sessions.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements.~Active Comparator (Control) Group~* Participants in this group will receive access to a curated collection of publicly available guidelines for lifestyle modification. These resources, presented through a digital application, will focus on exercise, meditation, diet, and sleep, but without the live coaching or program personalization."|t|f|t|t
34137054|NCT04357730|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is a Phase IIa clinical trial, open label, with a modified stepped-wedge design, testing systemic administration of fibrinolytic therapy with alteplase (tPA) versus standard of care for patients infected with COVID-19 resulting in severe respiratory failure. The design is a rapidly adaptive, pragmatic clinical trial, with 3 interim analyses and 1 final look at the data.||||
34137055|NCT02479685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33828779|NCT04655742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828780|NCT00087555|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828781|NCT05871918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837522|NCT01649154|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34137056|NCT04042142|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137057|NCT01560637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137058|NCT03135158|||COHORT||PROSPECTIVE|||||||
34137059|NCT03802305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Number of Arms: 2 Masking: Simple Blinded, Masked Roles: Subject Allocation: Randomized Study Endpoint Classification: Interventional Research with Minimal Risk and Constraints, Safety/Efficacy Enrollment: subjects (anticipated)|t|f|f|f
34137060|NCT04588857|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137061|NCT05488548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Dose escalation/de-escalation will follow rules by employing the Bayesian optimal interval (BOIN) method for Part 1 and Part 2 and traditional 3+ 3 by modified Fibonacci sequence for Part 3||||
34137062|NCT06453941|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137063|NCT00004112|RANDOMIZED|||TREATMENT||||||||
34137064|NCT04122183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137065|NCT02450383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137066|NCT03501004|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34137067|NCT01431014|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34137068|NCT03240367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137069|NCT03048890|||COHORT||PROSPECTIVE|||||||
34137070|NCT02323685|NA|SINGLE_GROUP||||NONE||||||
34137071|NCT06437613|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
34137072|NCT05441683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137073|NCT01341808|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34137074|NCT05743842|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137075|NCT05695261|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Patients will be randomized on a 1:1 ratio to receive either MTT with antibiotics or placebo/placebo. The unblinding will occur at the end of the study.|t|t|t|t
34137076|NCT00003675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137077|NCT06423495|NA|SEQUENTIAL||TREATMENT||NONE||The sample will consist of 30 individuals who will be allocated to the low-intensity laser treatment group.||||
34137078|NCT04867720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137079|NCT06556095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization will be 1:1 so that 22 subjects are enrolled in each group (test and control). Patients will be blind to the hydrating solution used for their bone graft. Histomorphometric examiners will be blinded when the bone cores are evaluated for % vital bone, % residual graft and % CT/other.|Randomized controlled clinical trial examining wound healing after tooth extraction and ridge preservation.|t|f|f|t
34137080|NCT00538967|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34137081|NCT04726280|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137082|NCT01439971|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||The was an ascending dose trial with one open label treatment, intervention model was sequential dose escalation.||||
34137083|NCT00349323|||||PROSPECTIVE|||||||
34137084|NCT03898466|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34137085|NCT01775579|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137086|NCT03641768|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34137087|NCT02545881|||CASE_ONLY||PROSPECTIVE|||||||
34137088|NCT06145633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137089|NCT03197987|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34137090|NCT04261114|||CASE_ONLY||CROSS_SECTIONAL|||||||
34137091|NCT01542697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137092|NCT00620256|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137093|NCT04110951|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34137094|NCT01367418|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137095|NCT02584543|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137096|NCT05994703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137097|NCT04155086|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34137098|NCT04348149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137099|NCT00951236||PARALLEL||TREATMENT||||||||
34137100|NCT01689012|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34137101|NCT02637414|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137102|NCT04899999|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137103|NCT02375841|||COHORT||PROSPECTIVE|||||||
34137104|NCT06004635|||COHORT||CROSS_SECTIONAL|||||||
34137105|NCT03735628|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34137106|NCT00190021|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34137107|NCT04913168|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137108|NCT05960331|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137109|NCT00918320|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137110|NCT00255138|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34137111|NCT05160974|||CASE_ONLY||PROSPECTIVE|||||||
34137112|NCT05645978|||COHORT||OTHER|||||||
34137113|NCT06214130|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137114|NCT06179277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All participants remained blinded with respect to their group assignment for the duration of the study. Allocation concealment was done by placing randomization codes with group assignment in opaque sealed envelopes that were opened by the operator at the end of the surgical procedure, right before suturing, which means the surgeon was blinded throughout most of the treatment.~Data was collected by a separate examiner who was also blinded to treatment allocation. Data analysis was carried out by an external statistician, minimizing the risk of bias."||t|f|f|t
34137115|NCT00283270|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34137116|NCT02135328|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34137117|NCT05555797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137118|NCT02084706|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34137119|NCT01461265|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34137120|NCT05208515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137121|NCT01847066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137122|NCT01186926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837523|NCT03637647|||COHORT||PROSPECTIVE|||||||
33837524|NCT03321279|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34137123|NCT00144248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137124|NCT04268329|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patient's with head and neck cancer and 1 of their family members will be asked to visit an instructional head and neck cancer website to learn about what they might expect during the process of head and neck cancer treatment.||||
34137125|NCT03215303|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The randomization process will be kept confidential with a single investigator, not involved in data collection or recruitment, so that all other investigators involved will be blinded to the experimental groups throughout the study period.|Patients will be randomized, through a sealed envelope, to initially compose the intervention group or the control group. The sequential order of randomization will be kept confidential with a single investigator, so that the other professionals involved and responsible for data collection will be blinded throughout the study period. Individuals who initially composed the intervention group will then perform, in a second moment, the procedures of the control group.|f|f|t|t
34137126|NCT03116828|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|Arm 1 (ESL as first add-on) Arm 2 (ESL as later add-on)||||
34137127|NCT00790647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137128|NCT00742989|RANDOMIZED|CROSSOVER||||NONE||||||
34137129|NCT06294574|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137130|NCT00686426|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137131|NCT02284529|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34137132|NCT01113008|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34137133|NCT01129713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137134|NCT04971239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137135|NCT02984241|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137136|NCT03720041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation 1 is open label Randomisation 2 is double-blind, placebo-controlled|Phase III, multi-centre, randomised, parallel group trial|t|t|t|t
34137137|NCT04202224|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34137138|NCT00995397|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137139|NCT01097265|RANDOMIZED|||DIAGNOSTIC||NONE||||||
34137140|NCT05396924|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Enrolled patients and investigator of final output data will be blinded to the study protocol. Care providers (surgeons, nurses and OR personnel) will not be blinded.|This is a prospective randomized controlled study with sequential randomization; the first patient will be included in the 1st group, and the second patient will be included into the 2nd group. All patients scheduled for hip arthroscopy during the defined study period are eligible for inclusion. While room temperature irrigation fluids will be used routinely for Group 1, irrigation fluids heated up to 36-38 degrees will be used for the other group. Patients will be operated in the same operating room and at the same room temperature. A probe inserted into the rectal mucosa will measure the patient's body temperature every 15 minutes. In addition, the temperature of the patients will be measured from their temporal regions with a thermometer. Mean body temperatures measured from 2 different locations between the groups will be compared, and the probability of detecting early local and later general hypothermia from the rectal mucosa will be examined.|t|f|t|f
34137141|NCT03509363|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All research study personnel, including those who collect data and assess outcomes will be blinded to the group assignment. The envelopes and the randomization list will not be revealed to any of the study personnel until completion of recruitment and data collection.|randomized, controlled|f|f|f|t
34137142|NCT06061263|||COHORT||RETROSPECTIVE|||||||
34137143|NCT02769338|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge||||
34137144|NCT01579565|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137145|NCT05048836|RANDOMIZED|FACTORIAL||OTHER||NONE||Thus, the investigators propose conducting a 2x2x2 factorial design randomized trial to compare two food insecurity interventions, with or without a lifestyle support intervention that provides culturally tailored Med-style dietary pattern education, disease self-management support, and navigation to community resources for health related social needs, over 2 different time periods.||||
34137146|NCT04424628|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients label|Arm 1: 3 Gy (repeated at 8 weeks if necessary. New ramdomization to 3 Gy or 6 Gy) Arm 2: 6 Gy (repeated at 8 weeks if necessry)|t|f|f|f
34137147|NCT04717336|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34137148|NCT05322512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137149|NCT05678816|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137150|NCT03366558|||CASE_CONTROL||PROSPECTIVE|||||||
34137151|NCT01397773|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34137152|NCT02743507|||CASE_ONLY||RETROSPECTIVE|||||||
34137153|NCT01229254|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137154|NCT06607783|||CASE_ONLY||PROSPECTIVE|||||||
34137155|NCT06626061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137156|NCT05727319|||COHORT||PROSPECTIVE|||||||
34137157|NCT04677608|||COHORT||PROSPECTIVE|||||||
34137158|NCT03170115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||preoperative induction chemotherapy followed by combined radiochemotherapy with capecitabine and aspirin|t|t|t|t
34137159|NCT01611688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137160|NCT04871412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137161|NCT03960086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||The study was a parallel-group, randomized controlled trial with concealed allocation, blinding of investigators and assessors and intention-to-treat analysis.|t|t|t|t
34137162|NCT05951075|NA|SINGLE_GROUP||TREATMENT||NONE||Male patients that used the FDA approved YO Sperm at-home sperm analysis kit, and were identified with low YO Score results (20-40) will be recruited to take a 3 month course of supplements (Power Prenatal for Sperm), and a monthly YO Score at-home sperm test will be performed monthly for 3 consecutive months after starting the supplements.||||
34137163|NCT06655532|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a prospective study, blinded for the evaluator, 2 randomized groups (1:1) to receive standard management alone or combined with a program of training that will be carried out in a single centre.|f|f|t|f
34137164|NCT06493357|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137165|NCT04700345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837525|NCT03554408|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Groups 1A, 1B, 4A, and 4B are double-blinded; All other arms are open label.||t|f|t|f
33840229|NCT02712749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137166|NCT04017923|||CASE_ONLY||PROSPECTIVE|||||||
34137167|NCT01115764|||||PROSPECTIVE|||||||
34137168|NCT05991115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137169|NCT05093673|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137170|NCT01271010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137171|NCT03424967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137172|NCT06606808|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34137173|NCT03130621|||FAMILY_BASED||RETROSPECTIVE|||||||
34137174|NCT01670786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137175|NCT06493305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137176|NCT03300271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|A designated researcher will be responsible for the random allocation and mask the results, so the investigators and the outcomes assessor do know the which group the participants are been allocated in.|Participants will be randomly assigned to either the experimental conditions (mobile application), or the usual condition (education).|f|f|t|t
34137177|NCT02047591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137178|NCT04717297|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137179|NCT05740163|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137180|NCT02545517|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34137181|NCT04085458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137182|NCT06039930|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Standardized assessments will be conducted by trained raters blind to participant assignment.|The investigators will compare the effectiveness of the Tele- PROTECT Intervention against the Depression Education (DepEd) Intervention. To ensure rigor and reproducibility, Tele-PROTECT or DepEd will be offered to randomly assigned depressed elder abuse victims, and standard assessments will be conducted by trained raters blind to participant assignment and our hypotheses.|f|f|f|t
34137183|NCT05009641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34137184|NCT00882583|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137185|NCT01886950|||COHORT||PROSPECTIVE|||||||
34137186|NCT04669938|||CASE_ONLY||PROSPECTIVE|||||||
34137187|NCT00311194|RANDOMIZED|PARALLEL||ECT||NONE||||||
34137188|NCT01824654|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34137189|NCT03306225|||COHORT||RETROSPECTIVE|||||||
34137190|NCT02439151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137191|NCT03487588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137192|NCT00051012|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137193|NCT01024972|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137194|NCT06608134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|With double blinding of the allograft neither participant nor provider will know what is being administered.|randomized, prospective, open label, dose escalation, non-controlled|t|t|f|f
34137195|NCT05834088|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137196|NCT06106724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137197|NCT01814319|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34137198|NCT00811005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34137199|NCT04300517|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34137200|NCT04466631|||CASE_ONLY||PROSPECTIVE|||||||
34137201|NCT05046002|||CASE_CONTROL||PROSPECTIVE|||||||
34137202|NCT00139295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34137203|NCT00451009|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137204|NCT04071262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137205|NCT03263130|||CASE_ONLY||CROSS_SECTIONAL|||||||
34137206|NCT05470179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137207|NCT05099055|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Pilot study for a phase 3 study.|t|t|t|f
34137208|NCT02028117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837526|NCT04380077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The operating surgeons did not participate in the preoperative or postoperative care of the patient, including the data collection.||f|f|t|f
34137209|NCT00177658|||OTHER||RETROSPECTIVE|||||||
34137210|NCT02478697|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137211|NCT00737568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137212|NCT04867187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The (motor) task performed by the patient during the sham control mirror therapy session is identical to that performed in active mirror therapy. The only difference is that in sham mirror therapy there is no optical illusion of movement of the affected hand.|Group 1: patient with 4 sessions of active mirror therapy followed by an rTMS stimulation session of the primary motor cortex (M1), Group 2: patient with 4 sessions of sham mirror therapy followed by rTMS of the primary motor cortex (M1).|t|f|t|f
34137213|NCT04378387|||COHORT||RETROSPECTIVE|||||||
34137214|NCT05598125|||CASE_CROSSOVER||PROSPECTIVE|||||||
34137215|NCT06420856|||OTHER||CROSS_SECTIONAL|||||||
34137216|NCT02314078|||COHORT||RETROSPECTIVE|||||||
34137217|NCT04758884|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137218|NCT00877786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137219|NCT05658627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137220|NCT03928938|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837527|NCT01509001|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137221|NCT04092894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomization in a 1:1 ratio (suvorexant 20 mg versus placebo) will be stratified by duration of perioperative anesthesia and sedation.|t|t|t|t
34137222|NCT06313502|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34137223|NCT01050920|||COHORT||CROSS_SECTIONAL|||||||
34137224|NCT05137288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137225|NCT01734395|||CASE_ONLY||PROSPECTIVE|||||||
34137226|NCT02178852|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34137227|NCT03542903|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|non-blinded treatment and blinded assessment|A multicentric, prospective, random-assignment study incorporating both non-blinded treatment and blinded assessment|f|f|f|t
34137228|NCT05377450|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151174|NCT02072395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151175|NCT05777239|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151176|NCT02012049|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137229|NCT06177197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|neither the patient, the parents nor the investigating physician are aware of the product allocated.|multicenter, prospective, controlled, randomized in two parallel arms, double label blind.|t|t|t|t
34137230|NCT01527344|||CASE_ONLY||PROSPECTIVE|||||||
34137231|NCT06153849|||COHORT||PROSPECTIVE|||||||
34137232|NCT03979456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34137233|NCT05909410|||CASE_CONTROL||PROSPECTIVE|||||||
34137234|NCT01739686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137235|NCT02856243|||COHORT||PROSPECTIVE|||||||
34137236|NCT00350870|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34137237|NCT05743556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34137238|NCT04185402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137239|NCT05839730|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Subjects and assessors of outcomes will be blinded to treatment assignment.|Eligible subjects will have enrollment data collected, including a blood draw. Subjects will then have a pacemaker implanted. After 6 weeks, subjects will have a follow up visit with a blood draw and a cardiac MRI. At this visit, subjects will be randomized 2:1 for pacing therapy or as a control (programmed into either a non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest). After 3, 6 and 9 months after randomization, subjects will return for a follow up visit. At the 9-month visit therapy modifications will be made based on initial pacing randomization assignment: pacing therapy will be terminated in the original therapy group and enabled in the control group. After an additional 3-months of follow-up, subjects will return for their final visit, therapies will be disabled in all subjects and subjects will be exited.|t|f|f|t
34137240|NCT02924207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137241|NCT04966494|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34137242|NCT04730869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137243|NCT01289288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137244|NCT04743752|||COHORT||PROSPECTIVE|||||||
34137245|NCT06659068|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple (Participant, Care Provider, Investigator)|The study was designed as a single-center double-blind randomized controlled clinical trial. Participants were randomized into two groups receiving seluang fish oil and synbiotics supplementation, or placebo.|t|t|t|f
34137246|NCT04413656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137247|NCT02079831|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137248|NCT05134285|||CASE_CONTROL||PROSPECTIVE|||||||
34137249|NCT01345968|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137250|NCT03702348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137251|NCT03887455|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137252|NCT05295784|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each neonate will receive a single dose of caffeine citrate in the first 24 hours of life. The first six neonates will receive low dose (5 mg/kg), the next six neonates will receive a medium dose (15 mg/kg), and the next six neonates will receive high dose or (25 mg/kg).||||
34137253|NCT01177618|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34137254|NCT00459875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137255|NCT03487419|||COHORT||CROSS_SECTIONAL|||||||
34137256|NCT03121235|||COHORT||PROSPECTIVE|||||||
34137257|NCT01510366|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34137258|NCT00052091|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137259|NCT01369641|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34137260|NCT02111876|||COHORT||PROSPECTIVE|||||||
34137261|NCT05605275|||OTHER||RETROSPECTIVE|||||||
34137262|NCT06267469|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137263|NCT05447195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study is double-blinded. Except for the non-blinded team, no other participants associated with this study should attempt to learn the treatment group assignment or which study treatment they are receiving.The unblinding of all subjects must be carried out after the database is locked.||t|t|t|t
34137264|NCT02966964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137265|NCT00271921|||COHORT||PROSPECTIVE|||||||
34137266|NCT02765113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137267|NCT03650803|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137268|NCT03549208|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34137269|NCT01468207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137270|NCT01467050|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34137271|NCT03292887|||OTHER||PROSPECTIVE|||||||
34137272|NCT01418703|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34137273|NCT04916366|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"An investigator will carried out the measurement of the baseline variables. An expertise physiotherapy with experience in kinesio taping application, will performed the intervention with Kinesio taping in neck.~All patients will be told that they are going to undergo a kinesio taping treatment, except for the control group, which will be given the option of being included in the experimental group once the follow-up process is over."|A double-blind controlled clinical trial.|t|t|t|f
34137274|NCT00642434|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34137275|NCT06658054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Spine Surgeon||t|f|f|t
34137276|NCT01414101|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137277|NCT04939181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34137278|NCT06332768|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Randomized assignment||||
34137279|NCT05260073|||COHORT||PROSPECTIVE|||||||
34137280|NCT06607510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluators of the patients and the person analysing the data will be blinded to the patient's group allocation and te corresponding codes.|Prospective single-center randomized clinical trial.|f|f|f|t
34137281|NCT04718766|||COHORT||PROSPECTIVE|||||||
34137282|NCT06404866|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34137283|NCT00996515|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137284|NCT04728477|||COHORT||PROSPECTIVE|||||||
34137285|NCT04567706|||COHORT||PROSPECTIVE|||||||
34137286|NCT02576041|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34137287|NCT00742287|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34137288|NCT04103307|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The participants will receive CRRT in the form of CVVH or CVVHDF using the PrisMaxTM dialysis machine (Baxter Healthcare Corporation) according to local standard operating procedures. Filter anticoagulation will be maintained using either no anticoagulation, regional citrate or heparin. The TherMax™ blood warmer will be used when required to maintain a minimum body temperature.~All participants will undergo CRRT via a temporary double-lumen hemodialysis catheter inserted into a central vein (internal jugular vein, subclavian vein, femoral vein).~The standard of care entails continuous dialysis therapy for as long as deemed clinically necessary by the doctor. An external heater is used to rewarm the blood before delivering it back to the patient. If assigned to the intervention group, cool blood will be received during continuous dialysis. The cool blood will be delivered by having the heater set to 35.5°C."||||
34137289|NCT04210362|RANDOMIZED|PARALLEL||PREVENTION||NONE||A variation of the stepped wedge cluster randomized trial design was specified. Due to ethical and logistical considerations, the intervention in study groups under this design starts sequentially but measurements are performed at the same time period in all groups. The key difference between groups is thus the time of exposure to the intervention. Clusters were randomized into four study groups (30, 24, and 12 months of exposure, and a non-exposed group). The intervention consists of educational workshops for caregivers aimed at promoting healthy nurturing care practices and responsive caregiving. Assessment of intervention effects is performed as in a parallel design.||||
34137290|NCT05249933|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34137291|NCT01186042|||COHORT||CROSS_SECTIONAL|||||||
34137292|NCT03484156|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34137293|NCT04033887|||COHORT||RETROSPECTIVE|||||||
34137294|NCT02183480|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137295|NCT02306863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137296|NCT04925076|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Participants will receive an active oral dose of alcohol or placebo in a counterbalanced manner.|t|f|t|f
34137297|NCT05352061|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137298|NCT00045149||||TREATMENT||NONE||||||
34137299|NCT00952445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137300|NCT01364558|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34137301|NCT04301076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137302|NCT04309305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137303|NCT03677466|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34137304|NCT04011826|NA|SINGLE_GROUP||TREATMENT||NONE||After a period of baseline, all enrolled participants will be put on the same trial mask.||||
34137305|NCT02266251|||CASE_CONTROL||RETROSPECTIVE|||||||
34137306|NCT05349409|NA|SINGLE_GROUP||TREATMENT||NONE||SHR-A1811 for Injection in combination with Fluzoparib Capsule.||||
34137307|NCT04495257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137308|NCT06458530|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The PI will be masked to randomization assignment.||f|f|t|f
34137309|NCT02882906|||COHORT||PROSPECTIVE|||||||
34137310|NCT00633074|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34137311|NCT03532854|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137312|NCT05108272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137313|NCT02060630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137314|NCT06346691|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Crossover randomized controlled trial||||
34137315|NCT00585221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137316|NCT02083848|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137317|NCT01706497|||COHORT||PROSPECTIVE|||||||
34137318|NCT02059941|||COHORT||PROSPECTIVE|||||||
34137319|NCT01865994|||CASE_ONLY||PROSPECTIVE|||||||
34137320|NCT03924063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137321|NCT02247011|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34137322|NCT03934554|||CASE_ONLY||PROSPECTIVE|||||||
34137323|NCT03894410|||COHORT||RETROSPECTIVE|||||||
34137324|NCT05410171|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34137325|NCT04352088|||CASE_CONTROL||PROSPECTIVE|||||||
34137326|NCT02802982|||CASE_ONLY||PROSPECTIVE|||||||
33837528|NCT05656911|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837529|NCT05420545|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837530|NCT00512486|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34137327|NCT03236259|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34137328|NCT02153424|||CASE_ONLY||PROSPECTIVE|||||||
34137329|NCT02899507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137330|NCT01155739|||COHORT||PROSPECTIVE|||||||
34137331|NCT00388388|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137332|NCT04502264|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34137333|NCT04014881|NA|SINGLE_GROUP||TREATMENT||NONE||This study was a single-center, open-label, single-arm, non-randomized,3+3 dose escalation clinical trial.Each dose group has 3 patients.If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level. The maximum dose could be extended.||||
34137334|NCT04611958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137335|NCT00064259|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137336|NCT03426462|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The analysis of the electroencephalogram will be blinded to the age of the participant.|Age groups 1-6 years will be compared with 8-13 years whilst undergoing propofol anesthesia to detect whether there is indeed a difference in the speed of onset of the hypnotic effect of the drug.|f|f|f|t
34137337|NCT06331286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137338|NCT02367001|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34137339|NCT01747408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137340|NCT00500058|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137341|NCT00753103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149835|NCT03645109|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The capsules with vitamin D or placebo have the same organoleptic characteristics. The jars and envelopes that contain them are identical. The envelopes are identified by a code that only knows who will analyze the data|Parallel design, two arms|t|t|f|f
34137342|NCT04545190|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"On each intervention day, participants will receive boluses of supplements in accordance with his or her study ID number. The list that links this ID number to the randomization code will be kept with the person who generated the randomization code (and stored on a safe server) until completion of data sampling and cleaning of data on main outcome measures. The person resonsible for generating the randomization code will not be involved in any aspects of data sampling or handling. None of the project collaborators/participants will have access to this list during the intervention or during data handling.~Half the participants (n=10) will commence the intervention with GLU on Day 1, while the other half will commence with PLAC (randomized). For participants starting with GLU, half will perform training on their dominant leg, while the other half will perform training on their non-dominant leg. The same will be the case for participants starting with PLAC."|The study will be conducted as a 12-day placebo-controlled randomized clinical trial. Each day will consist of concomitant dietary intervention and resistance training. The dietary intervention consists of alternating days of ingesting glucose (GLU, 90 g) or placebo (PLAC) in connection with training. Likewise, training consists of alternating days of resistance training of the two legs (using identical training protocols), with Day 1 involving training of the first leg, Day 2 involving training of the second leg, Day 3 involving training of the first leg, etc. In this way, each of the two dietary interventions will be associated with training of one particular leg, allowing within-subject comparisons of the effects of GLU vs PLAC on muscle biology and recovery.|t|f|t|f
34137343|NCT03593343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34137344|NCT05935878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomised to receive either a cementless or cemented Oxford Unicompartmental Knee Arthroplasty.|t|f|f|f
34137345|NCT02606981|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34137346|NCT02377882|||CASE_CONTROL||PROSPECTIVE|||||||
34137347|NCT00581269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137348|NCT05191888|RANDOMIZED|PARALLEL||TREATMENT||NONE||"1. 14-day vonoprazan high-dose two-in-one therapy~2. 14-day vonoprazan triple therapy~3. 14th Rabeprazole reverse mixed therapy"||||
34137349|NCT04144699|||CASE_ONLY||PROSPECTIVE|||||||
34137350|NCT03556592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137351|NCT04987996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137352|NCT02628431|||COHORT||PROSPECTIVE|||||||
34137353|NCT04186195|||COHORT||CROSS_SECTIONAL|||||||
34137354|NCT04347213|||COHORT||PROSPECTIVE|||||||
34137355|NCT02213185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137356|NCT05472675|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137357|NCT00883870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137358|NCT01116024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137359|NCT04434625|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34137360|NCT00561002|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137361|NCT02652208|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34137362|NCT04161443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinding will be used as the subjects and the assessor both will be blinded for the treatment used.||t|f|f|t
34137363|NCT00917514|||CASE_ONLY||PROSPECTIVE|||||||
34137364|NCT03913026|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137365|NCT00643786|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137366|NCT03200275|||CASE_ONLY||CROSS_SECTIONAL|||||||
34137367|NCT03929653|||OTHER||OTHER|||||||
34137368|NCT00791479|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137369|NCT03761017|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34137370|NCT00365105|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137371|NCT01426152|||COHORT||RETROSPECTIVE|||||||
34137372|NCT01631747|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34137373|NCT02689466|||CASE_CONTROL||PROSPECTIVE|||||||
34137374|NCT01905228|NA|SEQUENTIAL||TREATMENT||NONE||||||
34137375|NCT03558334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137376|NCT03902457|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An author not involved in the surgeries will perform the randomization process. The assignments will be sealed within opaque envelopes that will be opened after the completion of the elevation of the sinus mucosa.|Clinical trial|f|t|t|f
34137377|NCT01703208|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137378|NCT03540537|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34137379|NCT05010122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137380|NCT06572891|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34137381|NCT06197191|||CASE_ONLY||PROSPECTIVE|||||||
34137382|NCT04694352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137383|NCT01595230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137384|NCT02696733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137385|NCT02691624|||COHORT||PROSPECTIVE|||||||
34137386|NCT05552261|||COHORT||PROSPECTIVE|||||||
34137387|NCT04245267|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"The effect of the intervention will be determined on the improvement on metabolic parameters, as well as in self care activities and quality of life using a before and after design. As a secondary analysis, results will be compared with the population in the wait-list receiving routine care in primary care units. Subjects who attend Clinica Especializada en el Manejo de la Diabetes and meet the selection criteria will be included in this study. Once their admission to the study is decided, subjects may participate in the recruitment and intervention stage and then in the annual follow-up visit stage."||||
34137388|NCT06493097|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137389|NCT01302834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137390|NCT04309370|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34137391|NCT01791049|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34137392|NCT06571591|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137393|NCT06606821|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34137394|NCT05384106|NA|SINGLE_GROUP||OTHER||NONE||||||
34137395|NCT01493102|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34137396|NCT04556955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840230|NCT04851353|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33840231|NCT05976139|NA|SEQUENTIAL||TREATMENT||NONE|no masking|||||
34137397|NCT06270836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To preserve masking, 2 investigators are required for this study. The masked investigator will be responsible for examinations and safety assessments. The unmasked investigator will perform the injections and post-treatment assessments.|Participants will be randomized 1:1 into one of two arms: KSI-301 or sham.|t|t|f|t
34137398|NCT00035607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137399|NCT05300230|||CASE_ONLY||PROSPECTIVE|||||||
34137400|NCT00904930|||COHORT||CROSS_SECTIONAL|||||||
34137401|NCT04664972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137402|NCT05427448|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective consecutive enrollment clinical trial to assess the diagnostic performance (sensitivity, specificity) of blood biomarkers for Alzheimer's disease.||||
34137403|NCT04098432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137404|NCT02489708|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34137405|NCT00656149|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34137406|NCT03620578|NA|SINGLE_GROUP||TREATMENT||NONE||The trial is designed as a prospective, multicenter, non-randomized phase II trial. All eligible patients will be registered during or after first R-CHOP, but before start of DA-EPOCH-R treatment and before start of nivolumab treatment.||||
34137407|NCT00706082|||COHORT||PROSPECTIVE|||||||
34137408|NCT06608615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137409|NCT02554149|||COHORT||PROSPECTIVE|||||||
34137410|NCT04714203|||COHORT||PROSPECTIVE|||||||
34137411|NCT03199053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|sponsor|Eligible subjects with HbA1c of 6.5% to 10.5% at screening will be randomized 1:1:1 to receive dapagliflozin 5 mg, saxagliptin 2.5 mg, or placebo. Blinded HbA1c assessment will be performed at Week 12. All subjects with Week 12 HbA1c \< 7% will remain on previously assigned randomized treatment. Subjects taking dapagliflozin with Week 12 HbA1c ≥ 7% will be re-randomized in a 1:1 ratio to continue on the low-dose treatment (dapagliflozin 5 mg) or up titrate to the high-dose treatment (dapagliflozin 10 mg). Subjects taking saxagliptin with Week 12 HbA1c ≥ 7% will be re-randomized in a 1:1 ratio to continue on the low-dose treatment (saxagliptin 2.5 mg) or up-titrate to the high-dose treatment (saxagliptin 5 mg). Subjects taking placebo with Week 12 HbA1c ≥ 7% will continue on placebo treatment. All placebo subjects and all subjects taking saxagliptin or dapagliflozin with HbA1c \< 7% at Week 12 will go through a dummy 2nd randomization process for maintaining the blinding.|t|f|t|f
34137412|NCT00923052|||CASE_CONTROL||PROSPECTIVE|||||||
34137413|NCT04271371|||COHORT||PROSPECTIVE|||||||
34137414|NCT06661772|||CASE_ONLY||PROSPECTIVE|||||||
34137415|NCT05617066|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
34137416|NCT05858632|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34137417|NCT00613002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137418|NCT00338208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137419|NCT01672463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137420|NCT05925452|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137421|NCT03307603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137422|NCT06335030|||CASE_ONLY||PROSPECTIVE|||||||
34137423|NCT00246558|||COHORT||PROSPECTIVE|||||||
34137424|NCT03352557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137425|NCT02585830|||CASE_ONLY||CROSS_SECTIONAL|||||||
34137426|NCT05372731|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137427|NCT05901480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137428|NCT05615675|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34137429|NCT06135896|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Clinical trial phase: Phase 2~* Group allocation: Randomized controlled trial~* Research perspective: Prospective study"||||
34137430|NCT06595823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137431|NCT01614834|||||PROSPECTIVE|||||||
34137432|NCT01372072|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137433|NCT06607380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137434|NCT03723720|||OTHER||RETROSPECTIVE|||||||
34137435|NCT01302223|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34137436|NCT04775862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137437|NCT04149977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind||t|t|f|f
34137438|NCT04348747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137439|NCT06304181|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34137440|NCT00480558|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137441|NCT03221868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137442|NCT02422836|NA|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34137443|NCT01009437|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137444|NCT01190475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137445|NCT01126268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137446|NCT02142322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137447|NCT06163183|||OTHER||PROSPECTIVE|||||||
34137448|NCT03614481|||COHORT||PROSPECTIVE|||||||
34137449|NCT03515226|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized clinical trial||||
34137450|NCT06606496|||COHORT||PROSPECTIVE|||||||
34137451|NCT01424891|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137452|NCT03505788|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137453|NCT06130449|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||Participant-blinded crossover placebo-controlled pilot study|t|f|f|f
34137454|NCT06339242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137455|NCT02222909|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34137456|NCT02136602|||CASE_ONLY||PROSPECTIVE|||||||
34137457|NCT01952548|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34137458|NCT04695600|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|• Participant, investigator, assessor and the statistician will be blinded to the treatment allocation||t|t|t|t
34137459|NCT01069263|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137460|NCT03896724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150829|NCT03576313|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Malaria prevalence will be determined by technicians blinded to the treatment arm|This cluster-randomized trial will involve 32 villages in the Upper River Region of The Gambia that will be randomized to MDA with IVM and DP or to standard of care in a ratio 1:1|f|f|f|t
34137461|NCT06331364|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"stepped-wedge, cluster randomized, two-arm, open label~This design combines elements of a cluster randomized trial (intervention is applied in clusters) and a before-after design (each cluster switches to intervention). All 9 pairs of wards (clusters) will start with an initial period of usual care. At intervals of 3-6 months (steps), a set of 3 pairs of wards (clusters) will switch in a randomized order to use the intervention, until all pairs of wards have crossed over."||||
34137462|NCT05852652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137463|NCT02959541|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137464|NCT06102122|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34137465|NCT05137171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137466|NCT02132923|||CASE_ONLY||PROSPECTIVE|||||||
34137467|NCT06607679|||COHORT||PROSPECTIVE|||||||
34137468|NCT05732506|||CASE_ONLY||PROSPECTIVE|||||||
34137469|NCT04640558|||OTHER||PROSPECTIVE|||||||
34137470|NCT05525091|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34137471|NCT05091697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137472|NCT06355947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137473|NCT04052763|||COHORT||PROSPECTIVE|||||||
34137474|NCT03915574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||140 mother-infant dyads (280 actual participants)|t|t|t|t
34137475|NCT02383654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137476|NCT03907865|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34137477|NCT02481648|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137478|NCT04893239|NA|SINGLE_GROUP||OTHER||NONE||||||
34137479|NCT00251368|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137480|NCT00178165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137481|NCT04950712|||OTHER||PROSPECTIVE|||||||
34137482|NCT00096174|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137483|NCT00022360||||TREATMENT||||||||
34137484|NCT01384448|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34137485|NCT06607536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|sealed envelop|3 arm parallel, split mouth|t|t|f|t
34137486|NCT02392390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137487|NCT00227669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137488|NCT05921682|||COHORT||PROSPECTIVE|||||||
34137489|NCT05148013|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled study|t|f|f|f
34137490|NCT03287024|NA|SINGLE_GROUP||TREATMENT||NONE||"Prospective, multi-centre, explorative single-arm study This open-label, non-randomized multi-centre study uses an umbrella protocol (Part A and Part B) designed to collect data for performance and safety as well as long-term safety data from pulmonary artery stenosis patients who are treated with the BeGrow stent system to treat the stenosis~Part A: Safety and Performance (Implantation and Re-dilatation) Part B: Safety on Long-Term Follow-up"||||
34137491|NCT05553340|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34137492|NCT00305032|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137493|NCT02379221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137494|NCT03800446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort diagnostic study design||||
34137495|NCT00460278|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137496|NCT01683006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34137497|NCT04469920|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137498|NCT04323137|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants (i.e., patients) will not be informed specifically of their assignment to different arms throughout the study. Providers who prescribe vaccination and diagnose conditions will not be randomized to study arms or informed of patient assignment.|"Patients from the high-risk sample will be randomly assigned to one of 4 groups:~1. Control: group that receives no additional pro-vaccination intervention beyond Geisinger's normal efforts.~2. High Risk Only: group that receives messages telling them they have been identified to be at high risk for flu complications without specifying how/why Geisinger believes this to be the case~3. High Risk Based on Medical Records: group that receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records~4. High Risk Based on Algorithm: group that receives messages telling them they have been identified to be at high risk for flu complications via analysis of their medical records by AI/ML~   Two additional groups will be monitored for outcome data:~5. Sub-threshold patients: patients who are in the top 11-20% of risk~6. Household members: patients who share an address with target patients"|t|t|f|f
34137499|NCT06140940|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants and experimenters (including tDCS operator) will not be informed about the nature (active or placebo) of the stimulation they will receive|Single-center prospective randomized, double-blind, sham-controlled, crossover study with two conditions: active tDCS + mental training and sham tDCS + mental training. A control group (participants with typical mental imagery abilities) will also be included for comparison at baseline.|t|f|t|t
34137500|NCT02668900|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34137501|NCT05350228|||OTHER||CROSS_SECTIONAL|||||||
34137502|NCT02087618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137503|NCT00308412|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34137504|NCT06023654|||COHORT||PROSPECTIVE|||||||
34137505|NCT03195244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137506|NCT01950793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137507|NCT03014310|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34137508|NCT05969756|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of examiners is impossible to be done during intervention and follow up due to different natures of the materials. However, participants and outcome assessors could be blinded (double blinding).|This is a 3 arm clinical trial. All selected permanent molars will be randomly equally allocated into three groups according to material used.|t|f|f|t
34137509|NCT00022204||||SUPPORTIVE_CARE||||||||
34137510|NCT03447899|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34137511|NCT00266214|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137512|NCT03625830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137513|NCT02937298|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34137514|NCT00346281|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137515|NCT00395135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137516|NCT00695955|NON_RANDOMIZED|||TREATMENT||NONE||||||
34137517|NCT00567671|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137518|NCT06092216|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label study||||
34137519|NCT00347438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137520|NCT00416936|||||PROSPECTIVE|||||||
34137521|NCT05704621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137522|NCT02569372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137523|NCT02309983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137524|NCT02997553|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137525|NCT06309017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137526|NCT04984265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137527|NCT04451564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34137528|NCT05076279|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137529|NCT04613557|NA|SEQUENTIAL||TREATMENT||NONE||||||
34137530|NCT04638621|||FAMILY_BASED||OTHER|||||||
34137531|NCT04571307|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137532|NCT04246437|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34137533|NCT02704702|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34137534|NCT05053815|||COHORT||RETROSPECTIVE|||||||
34137535|NCT02734771|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137536|NCT03998670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|At the 8-week outcome visit, a Masked Examiner, who is a pediatric ophthalmologist, pediatric optometrist, or certified orthoptist, will assess the control of the exodeviation and perform PACT testing. The Masked Examiner must be someone other than the investigator.||f|f|f|t
34137537|NCT00100997||||TREATMENT||NONE||||||
34137538|NCT03379857|NA|SINGLE_GROUP||PREVENTION||NONE||Cannabis User||||
34137539|NCT02324205|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All participants underwent 2D breast imaging with Full-field digital mammography (FFDM) and by 3D breast imaging with Digital Breast Tomosynthesis (DBT).||||
34137540|NCT06608056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34137541|NCT04736368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study design was a single-blinded randomized, parallel assignment clinical trial of The study design was single blind and the participants did not know what diet intervention is being given to them.|The study design was a single-blinded randomized, parallel assignment clinical trial of CD participants was conducted. Participants were randomized in a 1:1 fashion to either 14-weeks of an EDIP based diet or a normal diet .|t|f|f|f
34137542|NCT06399432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137543|NCT01895543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137544|NCT05557539|NA|SINGLE_GROUP||OTHER||NONE||||||
34137545|NCT05364970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34137546|NCT01115894|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34137547|NCT02429219|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137548|NCT01940250|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137549|NCT03575845|NA|SINGLE_GROUP||TREATMENT||NONE||single arm pretest-posttest design||||
34137550|NCT06232564|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label, Single Arm||||
34137551|NCT03290417|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel groups, one with a control diet, the other with a modified diet||||
34137552|NCT03781180|||CASE_ONLY||RETROSPECTIVE|||||||
34137553|NCT06605547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-mouth, randomized controlled|t|f|t|t
34137554|NCT00262886||||TREATMENT||NONE||||||
34137555|NCT01415479|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34137556|NCT01552551|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34137557|NCT01166373|RANDOMIZED|FACTORIAL||OTHER||QUADRUPLE|||t|t|t|t
34137558|NCT03643341|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34137559|NCT00005605|||COHORT||PROSPECTIVE|||||||
34137560|NCT03017677|||OTHER||PROSPECTIVE|||||||
34137561|NCT03643315|RANDOMIZED|CROSSOVER||OTHER||SINGLE|"Participants are blind to the true aim of the study. In addition, assignment of the experimental sessions are administered at random."|The present study will be of a randomised counterbalanced repeated-measures (crossover) design. Each participant (n = 30) will complete four sessions; one initial screening session (remotely administered), one baseline/familiarisation session (first lab visit) and two subsequent experimental sessions (second and third lab visits). The two experimental sessions will follow a similar protocol, except that one condition will involve an exercise protocol before an ad-libitum meal (Exercise and Meal (EX) condition), and the other, a no-exercise period (rest) before an ad-libitum (NEX) control condition.|t|f|f|f
34137562|NCT04732130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137563|NCT01064102|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137564|NCT03305549|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Pilot 2-arm parallel-comparison randomized clinical trial comparing TIW dialysis (control) to a conservative dialysis strategy."||||
34137565|NCT04378998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137566|NCT03013101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137567|NCT01587261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137568|NCT00006441|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137569|NCT05156099|||COHORT||PROSPECTIVE|||||||
34137570|NCT04261400|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The intervention package was provided to midwives working at two specific antenatal care facilities and the women attending care at these facilities received the health education material.||||
34137571|NCT01895231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137572|NCT02671903|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34137573|NCT03528239|||COHORT||RETROSPECTIVE|||||||
34137574|NCT02862483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137575|NCT05195957|||COHORT||CROSS_SECTIONAL|||||||
34137576|NCT04018976|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34137577|NCT05354609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137578|NCT03055325|||COHORT||PROSPECTIVE|||||||
34137579|NCT02991794|||COHORT||PROSPECTIVE|||||||
34137580|NCT05705375|NA|SINGLE_GROUP||OTHER||NONE||||||
34137581|NCT05120570|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34137582|NCT00994201|||CASE_ONLY||PROSPECTIVE|||||||
34150830|NCT03204292|||OTHER||PROSPECTIVE|||||||
34137583|NCT03905265|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To maintain blinding to treatment allocation, all subjects will receive treatment with the same number of tablets, comprised of moxidectin 2 mg tablets and matched placebo (as required).|Parallel, double blind, multicenter, randomized, pharmacokinetic/pharmacodynamic study. Three cohorts of six subjects per cohort are planned. Subjects will be randomized 1:1:1 to receive 2, 8 or 20 mg moxidectin as a single oral dose. An additional cohort of 36 mg may be initiated with a target sample size of 6 subjects.|t|t|t|t
34137584|NCT03957499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The anesthetists who will prepare the drug and who will collect the data will be blinded to the study protocol||t|t|f|f
34137585|NCT06607757|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluation of treatment outcome||||
34137586|NCT02750345|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34137587|NCT04746235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137588|NCT06608264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In order to prevent assignment bias in the study, blocks will be created by a statistician (in blocks of 6).The letters A, B, C representing the stress ball, hand grip and control arms will be determined by drawing lots.Since the researcher will be with the patient while performing the application, it will not be possible to blind the researcher during the application.However, the consultant will inform the researcher which patient is assigned to which arm once the patient meets the inclusion criteria and gives informed consent.The implementer will be blind to the appointment.The patient will be informed about which intervention (stress ball, hand holding, routine applications) will be performed after this stage. When entering the data into the SPSS database, the researcher will enter the data by coding the branches as A, B, C. Arms will not be reported to the statistician before reporting (blind technique)|Type of research:This study was planned as a randomized controlled experimental design to investigate the effects of stress ball and hand grip on pain and mobility levels during continuous passive movement in patients with TKA.|f|f|f|t
34137589|NCT02665351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137590|NCT06251661|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34137591|NCT05365061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137592|NCT02030717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137593|NCT01684709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137594|NCT00541866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137595|NCT02080481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137596|NCT06606717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137597|NCT04691141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137598|NCT00053976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137599|NCT00372372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34137600|NCT02779088|RANDOMIZED|PARALLEL||OTHER||NONE|Participants and investigator don't know which group the participants are assigned to before randomization.|The investigators invited around 60 persons with sarcopenia by telephone to attend the study and randomly assigned them to group A and B (around 30 persons in each). Group A first accepted exercise and nutrition intervention and then was given the education course. Group B was treated in the reversed order.||||
34137601|NCT00274235|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137602|NCT00890513|||COHORT||PROSPECTIVE|||||||
34137603|NCT03179254|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137604|NCT01945216|||COHORT||PROSPECTIVE|||||||
34137605|NCT04739618|NA|SINGLE_GROUP||TREATMENT||NONE||Male or female subjects greater than 18 years of age with histologically-proven metastatic cancer with at least one imaging- or histologically- proven metastases to lymph nodes, bone, or soft tissue.||||
34137606|NCT00415428|||COHORT||PROSPECTIVE|||||||
34137607|NCT01007435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137608|NCT01022957|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137609|NCT04378465|||COHORT||PROSPECTIVE|||||||
34137610|NCT01714037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137611|NCT02693054|NA|SINGLE_GROUP||OTHER||NONE||||||
34137612|NCT03263728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137613|NCT00096226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137614|NCT01044212|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137615|NCT01972308|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34137616|NCT00061724|||||PROSPECTIVE|||||||
34137617|NCT01185418|||||PROSPECTIVE|||||||
34137618|NCT03315897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137619|NCT04816656|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective, cohort study||||
34137620|NCT03262571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137621|NCT02555813|||COHORT||CROSS_SECTIONAL|||||||
34137622|NCT04751409|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137623|NCT05514938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137624|NCT06606977|||COHORT||PROSPECTIVE|||||||
34137625|NCT00519376|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34137626|NCT05223231|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137627|NCT04885322|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34137628|NCT02649374|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137629|NCT05526664|||CASE_CONTROL||PROSPECTIVE|||||||
34137630|NCT05125718|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|blinding of subject and clinician|split-mouth study|t|t|f|f
34137631|NCT04971538|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study is a matched cluster randomized controlled study, the households in the intervention clusters will be left information on the importance of testing, an HCV self-test and instructions for use while the households in the control clusters will be left information on the importance of testing for HCV and information on how to get tested at the nearest facility.||||
34137632|NCT06608953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Dana analysis personnels are blinded to the reaserch arms. The subjects are not blinded to the treatment (not sham-controlled).|Non sham-controlled, randomized study|f|f|f|t
34137633|NCT05763901|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137634|NCT03590626|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||will randomize the patients into either dulaglutide group or control group in a 1:1 ratio using computer-generated numbers|f|f|f|t
34137635|NCT06604936|||OTHER||PROSPECTIVE|||||||
34137636|NCT02681796|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34137637|NCT02292758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137638|NCT03835754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137639|NCT00215566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34137640|NCT01218750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137641|NCT01522521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137642|NCT01824199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137643|NCT05289271|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137644|NCT01328834|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137645|NCT04314765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34137646|NCT05340621|NA|SEQUENTIAL||TREATMENT||NONE||||||
34137647|NCT01274923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137648|NCT03307161|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34137649|NCT02442310|RANDOMIZED|CROSSOVER||||NONE||||||
34137650|NCT06542601|||COHORT||PROSPECTIVE|||||||
34137651|NCT03549676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137652|NCT00798629|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137653|NCT05386550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137654|NCT06389331|||COHORT||PROSPECTIVE|||||||
34137655|NCT00156988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137656|NCT05893771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, caregivers, investigators, and outcome assessors will be blinded by a pharmacist who will prepare medications in colorless coded sterile syringes.|Patients will be allocated into three equal parallel groups.|t|t|t|t
34137657|NCT03604588|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137658|NCT05593913|||CASE_ONLY||RETROSPECTIVE|||||||
34137659|NCT03232645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137660|NCT01598337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137661|NCT05875753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137662|NCT00737854|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34137663|NCT05251012|||COHORT||RETROSPECTIVE|||||||
34137664|NCT03916185|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34137665|NCT02308527|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34137666|NCT06278506|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34137667|NCT00759265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137668|NCT01165112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137669|NCT05758181|RANDOMIZED|FACTORIAL||OTHER||SINGLE|Two blinded observers will record their scores independently using the POSAS instrument.||f|f|f|t
34137670|NCT06608641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects, investigators and research staff will be blinded to the treatment allocation. Only personnel who are not involved in the interpretation and analysis of the study data will be allowed access to the blinded information||t|t|t|t
34137671|NCT06605300|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34137672|NCT05223348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Participants will be randomly assigned to either the experimental condition, a body scan meditation, or a control condition, a listening task, using a random digit generator. This randomization will be done in a way that is blinded from the participants to ensure that knowledge of the practice to which they are assigned does not impact how they respond to the self-report questionnaires. In addition, the researcher guiding the mood induction will also remain blind to the participant allocation.||t|f|t|f
34137673|NCT03857360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137674|NCT01923363|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34137675|NCT05978011|||COHORT||PROSPECTIVE|||||||
34137676|NCT00569244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137677|NCT04893629|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137678|NCT04376840|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137679|NCT05645406|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34137680|NCT04322305|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Pregabalin will be administered in 75 mg and 100 capsules; placebo capsules will appear identical to the pregabalin capsules. Participants in both study arms will receive the same number of capsules.|Randomized Double blind, placebo controlled trial|t|f|t|t
34137681|NCT03409211|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137682|NCT05088746|||COHORT||PROSPECTIVE|||||||
34137683|NCT02864186|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137684|NCT03165240|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34137685|NCT00798239|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137686|NCT03718572|||COHORT||PROSPECTIVE|||||||
34137687|NCT00885586|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34137688|NCT03911323|||CASE_ONLY||PROSPECTIVE|||||||
34137689|NCT05306561|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137690|NCT03160274|||COHORT||OTHER|||||||
34137691|NCT02813135|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137692|NCT02074345|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34137693|NCT01939002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137694|NCT00793559|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137695|NCT00503581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137696|NCT02360137|||COHORT||PROSPECTIVE|||||||
34137697|NCT00252694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137698|NCT03956277|||COHORT||PROSPECTIVE|||||||
34137699|NCT00788099|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137700|NCT02121106|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34137701|NCT00521391|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137702|NCT00555763|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137703|NCT01607333|||||RETROSPECTIVE|||||||
34137704|NCT00068913|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34137705|NCT04027049|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The clinician assessing outcomes will not have been involved in the care of the patient and will not be aware of the group assignment.|Pilot randomized parallel group design|f|f|f|t
34137706|NCT02974959|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the study coordinator had access to the master list which noted whether the device was active or a sham. This information was not provided to or accessible by the participants, care providers, investigators, or outcome assessors.|Randomized control trial|t|t|t|t
34137707|NCT00948233|||CASE_ONLY||PROSPECTIVE|||||||
34137708|NCT00234871|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137709|NCT03144258|||COHORT||PROSPECTIVE|||||||
34137710|NCT06511700|||COHORT||PROSPECTIVE|||||||
34137711|NCT05783310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The data collection research assistant will be blinded to the participant's allocation group to avoid the risk of assessor bias.|Parallel assignment|f|f|f|t
34137712|NCT05299996|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137713|NCT06132425|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137714|NCT01376063|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137715|NCT05403593|||CASE_ONLY||PROSPECTIVE|||||||
34137716|NCT00017654||||TREATMENT||||||||
34137717|NCT04049253|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34137718|NCT04112797|||COHORT||PROSPECTIVE|||||||
34137719|NCT00396136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137720|NCT06036017|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||During T0 assessment, the TBF (Total Body Function), GCS (Glasgow Coma Scale), GKO (Glasgow-Koma Ölçeği), RCUO (Respiratory Care Unit Observation), RASS (Richmond Agitation-Sedation Scale), and CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) forms will be completed for both groups of patients, and blood samples will be taken. During T1 assessment, the GCS, GKO, RCUO, RASS, and CAM-ICU forms will be completed for both groups of patients, and blood samples will be taken. Additionally, the duration of anesthesia, intubation, and sedation, as well as the amount of sedative drugs used, will be noted. The care package prepared for the study group will be applied by nurses working in the ward.At T2, the GCS, GKO, RCUO, RASS, and CAM-ICU forms will be completed for both groups of patients, and blood samples will be taken. The duration of stay in the intensive care unit will also be recorded.|t|f|f|f
34137721|NCT00712725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137722|NCT01676753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137723|NCT02260778|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137724|NCT05049213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137725|NCT05767346|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137726|NCT00090233|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34137727|NCT06272084|||OTHER||RETROSPECTIVE|||||||
34137728|NCT06067685|||COHORT||PROSPECTIVE|||||||
34137729|NCT04467229|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137730|NCT01628679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137731|NCT03526237|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||f|t|f|t
34137732|NCT05818956|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34137733|NCT00518648|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137734|NCT02250807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137735|NCT03994887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a monocentric and prospective observational study on the physiology of nociception under general anesthesia. The patient will be his own witness.||||
34137736|NCT01643161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137737|NCT03326401|||CASE_CONTROL||RETROSPECTIVE|||||||
34137738|NCT00139542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137739|NCT06161636|||COHORT||PROSPECTIVE|||||||
34137740|NCT04679922|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137741|NCT04703816|RANDOMIZED|PARALLEL||OTHER||SINGLE|In this open label trial, the participating physicians will not be blinded to allocation. Only the physicians who will rate video-recorded consultations and the statistician will be blinded to study arm.|Prospective, randomized (with a 1:1 allocation ratio), controlled, open-label, two parallel arms, superiority interventional trial. The unit of randomization is the physician. Randomization will be performed by minimization, taking into account the status (attending versus non-attending) and specialty (medical versus surgical) of the physician.|f|f|f|t
34137742|NCT06035575|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Follow-up assessments will be conducted by study staff who will be blinded to treatment arm allocation at 1 and 3 months|A total of 225 patients will be assigned to one of two treatment arms using 1:1 randomization, stratified by age (18-40 years; 41+ years) into randomly permuted blocks. Individuals will be recruited from orthopedic urgent care clinics and Emergency Departments.|f|f|f|t
34137743|NCT05211804|||OTHER||PROSPECTIVE|||||||
34137744|NCT01265563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137745|NCT01034566|NA|SINGLE_GROUP||TREATMENT||NONE||Proton radiation for retroperitoneal sarcoma||||
34137746|NCT03354546|||COHORT||RETROSPECTIVE|||||||
34137747|NCT06405737|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34137748|NCT04469933|||CASE_ONLY||RETROSPECTIVE|||||||
34137749|NCT05806905|||COHORT||PROSPECTIVE|||||||
34137750|NCT02513485|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34137751|NCT00769925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137752|NCT00895869|||OTHER||PROSPECTIVE|||||||
34137753|NCT01451931|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34137754|NCT02399280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137755|NCT01327079|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34137756|NCT03628144|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Randomized open-label, medical and radiation oncologist-blinded.||f|f|t|f
34137757|NCT02549625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137758|NCT01743235|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137759|NCT00733161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137760|NCT00162747|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137761|NCT03479268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137762|NCT02823054|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137763|NCT04433689|||COHORT||PROSPECTIVE|||||||
34137764|NCT01480804|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137765|NCT00475202|||DEFINED_POPULATION||PROSPECTIVE|||||||
34137766|NCT02519894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34137767|NCT06072300|RANDOMIZED|CROSSOVER||PREVENTION||NONE|No individuals other than the University facility staff assisting with this study will be aware of the aims of the research. It is not possible to blind the trial statistician to the data.|Stepped-wedge cluster randomised trial||||
34137768|NCT05980091|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137769|NCT05940363|||CASE_ONLY||CROSS_SECTIONAL|||||||
34137770|NCT02553200|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34137771|NCT02784119|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34137772|NCT05413785|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34137773|NCT00230061|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137774|NCT05865340|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137775|NCT02141698|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34137776|NCT02537587|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
34137777|NCT04903873|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34137778|NCT04222634|NA|SINGLE_GROUP||TREATMENT||NONE||single arm study||||
34137779|NCT00194233|||CASE_CONTROL||PROSPECTIVE|||||||
34137780|NCT05486572|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137781|NCT02585063|||COHORT||PROSPECTIVE|||||||
34137782|NCT02752958|NA|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
34137783|NCT01957241|||COHORT||PROSPECTIVE|||||||
34137784|NCT03143907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Five sites in total are participating. Three of the five sites are following a RCT design (randomized group allocation; treatment and control group). Two of the five sites are following a pre-post design (no randomized allocation and no control group).|f|f|f|t
34137785|NCT00423345|||COHORT||PROSPECTIVE|||||||
33828782|NCT04622371|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2-arm cluster randomized controlled trial involved 60 patients aged between 35and 60 years divided randomly into two groups. Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.|t|f|f|f
33828783|NCT03475056|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Dose escalation||||
34137786|NCT01711489|NA|SINGLE_GROUP||||NONE||||||
33828784|NCT02886169|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828785|NCT03500666|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828786|NCT02175745|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828787|NCT02361879|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33828788|NCT04440059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828789|NCT02785731|||COHORT||PROSPECTIVE|||||||
33828790|NCT03418181|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The participants will be randomly allocated to 2 groups:~1. Thrice weekly dialysis (control arm)~2. Incremental dialysis - Twice weekly dialysis to start with and slowly increasing the duration and frequency of dialysis to thrice weekly depending on their native kidney function."||||
33828791|NCT01801839|||CASE_CONTROL||PROSPECTIVE|||||||
33828792|NCT00318981|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33828793|NCT04252300|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33828794|NCT01619462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828795|NCT06018688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828796|NCT03440047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Registry of endoscopic image and pathology correlation of different pathological condition such as: inflammatory bowel disease, colon polyps||||
33828797|NCT02503982|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33828798|NCT03109509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Research team was blinded to participant group assignment until data analysis.|Two-group, randomized controlled trial.|f|f|t|f
33828799|NCT02956356|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33828800|NCT05787145|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||"Comparative study in which two distinct groups of patients will be formed, sequentially. Patients from both groups will be assessed by the same radiation oncologists recruited from each of the three centers. In each center, recruited patients will initially be assigned to Group 1 (Usual Care) until 50 patients will be included in the study (for a total of 150 patients in this group). Recruitment will then pursue and patients will be assigned to Group 2 (Intervention) until 50 patients will be included in the study (for a total of 150 patients in this group).~Patients in Group 1 (Usual Care) will be assessed during regular consultations of the radiation oncology care pathway. Those in Group 2 (Intervention) will be encouraged to prepare each of the four medical encounters targeted in the usual trajectory in radiation oncology using Let's Discuss Health website. For Group 2, the radiation oncologists will have participated in an workshop on the Let's Discuss Health website."||||
33828801|NCT06040047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828802|NCT05635955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33828803|NCT00344253|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33828804|NCT02883179|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828805|NCT02138253|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828806|NCT06064370|||COHORT||RETROSPECTIVE|||||||
33828807|NCT05698862|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828808|NCT06339567|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828809|NCT01734473|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33828810|NCT06074653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828811|NCT01561456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828812|NCT03415399|NA|SEQUENTIAL||TREATMENT||NONE||||||
33837531|NCT05253599|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Due to the design and settings of the study, it was not possible to blind the treating therapist involved in the study. The subject and the therapist who was assessing the outcomes at baseline and after 4 weeks were blinded. Hence, the treating and assessing therapists were different persons and the assessing therapist remains blinded to the subject's treatment group. Subjects were instructed not to disclose their study procedures and treatment protocol with fellow-subjects and the assessing therapist.|The study was a double-blinded randomized control study and the subjects were randomized and allocated equally according to the computer random table method in a 1:1:1 ratio in three groups.|t|f|f|t
33837532|NCT04964856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837533|NCT01255956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837534|NCT03382769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137787|NCT02643888|||COHORT||RETROSPECTIVE|||||||
34137788|NCT03184935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137789|NCT00336570|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34137790|NCT06315231|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137791|NCT01157325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137792|NCT03581695|||COHORT||PROSPECTIVE|||||||
34137793|NCT03159169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137794|NCT02200003|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||RCT of Attention Bias Modification|t|f|t|t
34137795|NCT04127266|||COHORT||CROSS_SECTIONAL|||||||
34137796|NCT06599255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34137797|NCT05680480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137798|NCT06172803|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34137799|NCT00438126|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34137800|NCT03387007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137801|NCT04741958|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The current study is a case series study conducted on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy||||
34137802|NCT01289353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137803|NCT02460354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137804|NCT00937144|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|t|t|f
34137805|NCT05071872|||COHORT||RETROSPECTIVE|||||||
34137806|NCT05497349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind randomized controlled trial with allocation 1:1. Patient blinding will be provided during the injection treatment.|The study is a double-blinded RCT in which one group of patients will be treated with 3 intra-articular injection of Leukocyte Rich-PRP, and one group will be treated with 3 intra-articular injection of Leukocyte Poor- PRP|t|f|f|t
34137807|NCT02513290|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137808|NCT01610557|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34137809|NCT06260436|||COHORT||CROSS_SECTIONAL|||||||
34137810|NCT03969056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137811|NCT00192049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137812|NCT06252961|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"A 3-group, randomized, double-blind, parallel clinical trial:~* Levamisole 2.5 mg for 3 days (followed by 2 days placebo),~* Levamisole 2.5 mg for 5 days,~* Placebo for 5 days."|t|t|t|t
34137813|NCT02019108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137814|NCT05662774|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34137815|NCT06137378|RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no masking|Prospective, randomized, open-label, controlled, two-armed parallel group, phase II multicenter larynx organ-preservation trial with randomization in a 1:1 ratio into standard arm vs. investigational arm with a flexible follow-up of 24-48 months||||
34137816|NCT05867433|RANDOMIZED|PARALLEL||PREVENTION||NONE||School-based cluster randomized controlled trial||||
34137817|NCT00573040|||COHORT||PROSPECTIVE|||||||
34137818|NCT00075114|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137819|NCT05499455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34137820|NCT06428942|RANDOMIZED|PARALLEL||OTHER||NONE|Masking is not allowed in this study|Participants are randomized to intervention group or control group with ratio of 50:25.||||
34137821|NCT03173976|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm open label phase 1b clinical trial assessing the safety and efficacy of neoadjuvant zoledronic acid in patients with resectable any grade chondrosarcoma as measured by pathological characteristics and recurrence free survival.||||
34137822|NCT05478434|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The recruiters, outcomes assessors, physical therapists, participants and their caregivers will be blinded with respect to participants' allocation for the entire period of the study.|Randomised Clinical trial|t|t|f|t
34137823|NCT05868928|||COHORT||PROSPECTIVE|||||||
34137824|NCT01610713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137825|NCT03298984|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137826|NCT04754191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137827|NCT04270942|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm, multicenter, open-label clinical trial||||
34137828|NCT04749758|NA|SINGLE_GROUP||TREATMENT||NONE||One-year prospective observational study of patients treated with stromal vascular fraction treatment for knee osteoarthritis||||
34137829|NCT00086801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137830|NCT03030495|||COHORT||PROSPECTIVE|||||||
34137831|NCT01097317|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34137832|NCT06482697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137833|NCT03702920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137834|NCT03979014|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The patients and clinicians will not be blinded but the laboratory staff performing the HPV assays on vaccinated and non-vaccinated arms will be blinded||f|f|f|t
34137835|NCT05066659|||CASE_ONLY||CROSS_SECTIONAL|||||||
34137836|NCT00043017|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837535|NCT02342990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837536|NCT03776305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137837|NCT05935891|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients will be informed as to which product they are using.|Eligible patients will be randomized to CBD-dominant (Violet) and THC-dominant (Red XS) balms.|f|f|f|t
34137838|NCT03277898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137839|NCT03114579|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137840|NCT05080855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137841|NCT01184313|||CASE_ONLY||PROSPECTIVE|||||||
34137842|NCT06145165|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34137843|NCT00608023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137844|NCT03469986|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34137845|NCT04828577|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34137846|NCT06193408|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|randomized, placebo-controlled, double-blinded||f|f|f|t
34137847|NCT04614207|||COHORT||PROSPECTIVE|||||||
34137848|NCT00385944|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34137849|NCT02649218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137850|NCT05082051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||3-part study Parts A and B are randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single and multiple oral dose administration in healthy adult subjects. Part C is a randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.|t|t|t|t
33837537|NCT05454813|NA|SINGLE_GROUP||OTHER||NONE||||||
34137851|NCT01637636|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137852|NCT00797745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137853|NCT06377696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137854|NCT02839187|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137855|NCT03596047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The Shockwave therapy machine has a device to prevent the patient from receiving the radial wave. This device will be changed for the clinic administrator.~Change device placebo wave therapy, using the respective device t"|Randomized, double-blind clinical trial.|t|f|f|t
34137856|NCT00898300|||COHORT||PROSPECTIVE|||||||
34137857|NCT06277700|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||60 people will participate in the study and the participants will be divided into four groups. The groups will be formed as chiropractic manipulation (CM) group (n=15), dynamic neuromuscular stabilization (DNS) group (n=15), CM + DNS group (n=15) and control group (CG) (n=15). Chiropractic manipulation will be performed once in the side-lying position. An individualized exercise program will be applied to the DNS group under the supervision of a physiotherapist. Kruskal Wallis test for comparisons of quantitative variables between 4 independent groups; Mann Whitney U test with Bonferonni correction will be used in double subgroup comparisons of significant variables. Friedman test was used for comparisons of quantitative variables in 3 dependent groups. Wilcoxon test with Bonferonni correction will be used for two-way subgroup comparisons for significant variables. In all statistical analyzes in the study, results with a p value below 0.05 will be considered statistically significant.|t|f|f|t
34137858|NCT06605768|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137859|NCT01407471|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34137860|NCT00529230|||CASE_CONTROL||PROSPECTIVE|||||||
34137861|NCT04816136|||COHORT||RETROSPECTIVE|||||||
34137862|NCT02180919|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34137863|NCT03666780|||COHORT||PROSPECTIVE|||||||
34137864|NCT06008418|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Once the patients agree to participate and provide written consent, participants will be assigned to a comparison group or treatment group according to the time of their outpatient appointment. Specifically, during the nine-month period of recruitment, the comparison group participants will be recruited during the first half of the period; and the experimental group will be recruited in the next half of the period. The reason of assigning participants according to time rather than randomization is because of the possible contamination. Because the intervention is designed to be interactive, the intervention will affect not only participating patients' communication behavior but also the physician's behavior.||||
34137865|NCT00385281|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34137866|NCT05945602|||CASE_CONTROL||OTHER|||||||
34137867|NCT01241058|||COHORT||PROSPECTIVE|||||||
34137868|NCT06455891|||COHORT||PROSPECTIVE|||||||
34137869|NCT02891148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137870|NCT06372171|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34137871|NCT01588340|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34137872|NCT05771441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34137873|NCT05270330|||COHORT||PROSPECTIVE|||||||
34137874|NCT02901054|NA|SINGLE_GROUP||OTHER||NONE||||||
34137875|NCT04154449|||CASE_CONTROL||PROSPECTIVE|||||||
34137876|NCT01282307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137877|NCT03484507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34137878|NCT03092830|||COHORT||PROSPECTIVE|||||||
34137879|NCT05841004|RANDOMIZED|CROSSOVER||PREVENTION||NONE||controlled crossover study||||
34137880|NCT01352442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137881|NCT03015649|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34137882|NCT04710550|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137883|NCT02178254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137884|NCT05878327|||COHORT||RETROSPECTIVE|||||||
34137885|NCT02831738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34137886|NCT05980273|||COHORT||CROSS_SECTIONAL|||||||
34137887|NCT04817137|NA|SINGLE_GROUP||OTHER||NONE||||||
34137888|NCT04924530|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34137889|NCT06598514|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be blinded to their assigned treatment. All participants will receive a box containing their randomized intervention and identical use instructions. Opaque bottles will contain either a sterile water solution or 2% chlorhexidine. Spray bottles will be identical in external appearance.|Individuals meeting inclusion criteria will be randomized to the treatment (2% chlorhexidine perineal lavage following defecation) or control (sterile water perineal lavage following defecation) and rates of urinary tract infection will be compared. Balanced randomization will be performed via computer-generated assignments in REDCap with random permuted blocks varying in size between 8 and 10.|t|f|f|f
34137890|NCT04587843|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel, randomized, double blind, placebo controlled|t|t|t|t
34137891|NCT05066581|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34137892|NCT01789060|||COHORT||RETROSPECTIVE|||||||
34137893|NCT05556135|||COHORT||PROSPECTIVE|||||||
34137894|NCT03587701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The subject, investigator and study coordinator will all be blinded to the randomization assignment. Only the study pharmacist will be unblinded when dispensing the study medication|This study is a randomized, placebo-controlled design with a 2:1 allocation of anakinra or placebo for the first 42 continuous days. After day 42, a second placebo-controlled period will begin for an additional 42 days.|t|t|t|f
34137895|NCT05507021|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34137896|NCT05723965|||CASE_CONTROL||RETROSPECTIVE|||||||
34137897|NCT03619707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137898|NCT03483272|||COHORT||PROSPECTIVE|||||||
34137899|NCT03127774|NA|SINGLE_GROUP||TREATMENT||NONE||Patients who are successfully debulked will undergo heated intraperitoneal chemotherapy with cisplatin.||||
34137900|NCT00963716|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34137901|NCT05209802|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34137902|NCT03300154|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837538|NCT01511341|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34137903|NCT06447623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137904|NCT00588172|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34137905|NCT01259648|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34137906|NCT02664649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137907|NCT06061276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137908|NCT06106009|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Parts A, B and D are double-blinded and sponsor-open while Part C is open-label.|Part A and B are randomized, double-blinded, sponsor-open, placebo-controlled studies to evaluate safety, tolerability, PK and PD of single and multiple escalating oral doses of PF-07976016 in healthy adult participants, respectively. Part A is a crossover while Part B is a parallel cohort study design. Part A of the study may also evaluate the safety, tolerability and PK in Japanese participants. Part C is an optional open-label, 4-period, fixed-sequence study to evaluate the effect of PF-07976016 on midazolam PK in healthy participants. Part D is an optional sponsor-open, randomized, double-blinded, placebo-controlled multiple dose study of PF-07976016 administered to participants with obesity.|t|f|t|f
34137909|NCT02523157|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34137910|NCT05721326|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Eligible patients will be sent a message through the patient portal to encourage genetic counseling and testing. If the patient does not respond, they will be sent a text message. Should there be no response, the patient\&#39;s clinician will receive a nudge||||
34137911|NCT03351816|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34137912|NCT04005560|NA|SINGLE_GROUP||OTHER||NONE||||||
34137913|NCT00022685||||TREATMENT||NONE||||||
34137914|NCT06301828|NA|SINGLE_GROUP||TREATMENT||NONE||Gastrointestinal neoplasms||||
34137915|NCT04279821|||COHORT||PROSPECTIVE|||||||
34137916|NCT02553980|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|randomly assigned into either treatment 1, treatment 2, or control. All participants were managed in individual basis, hence no interaction between any participants was guaranteed. Participants were informed only their treatment without knowing the existence of other treatment.|From 1,300 recruitment questionnaires, 261 met inclusion criteria, and 119 were randomly assigned into either n=53 in group 1 (VT3 intervention), 38 in group 2 (VT2 intervention), or 28 control (no-VT).|t|f|f|f
34137917|NCT05952765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The two groups will be equally prepared for both surgical procedures. Then the decision of which group will receive (PDDM), and which will receive xenograft will be taken according to the randomized numbers placed in opaque sealed envelopes. The number will be picked by the supervisor.||f|f|t|t
34137918|NCT04158726|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34137919|NCT06267937|||COHORT||RETROSPECTIVE|||||||
34137920|NCT00996827|||CASE_ONLY||PROSPECTIVE|||||||
34137921|NCT01961284|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137922|NCT01103154|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137923|NCT01945411|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34137924|NCT01259778|||COHORT||OTHER|||||||
34137925|NCT05328089|||COHORT||PROSPECTIVE|||||||
34137926|NCT06605612|||COHORT||RETROSPECTIVE|||||||
34137927|NCT03619096|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|The participants and the outcomes Assessor are masked about the surgical technique that was performed. The surgical technique ir randomized in accordance with the arch side of each patient, so the investigator will open a envelope just before starting the incisions to know which technique will be performed.|Split Mouth clinical trial, comparing two different techniques. One side, the tunnel technique will be performed and on the other side, extended flap will be performed. Both surgical techniques will use Porcine Collagen Matrix.|t|f|t|t
34137928|NCT01863173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137929|NCT05475210|NA|SEQUENTIAL||TREATMENT||NONE||||||
34137930|NCT03324334|||CASE_CONTROL||RETROSPECTIVE|||||||
34137931|NCT06003543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34137932|NCT03603899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137933|NCT02894164|||COHORT||PROSPECTIVE|||||||
34137934|NCT03195660|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single-arm, un-blinded, multi-center||||
34137935|NCT05891041|||CASE_ONLY||PROSPECTIVE|||||||
34137936|NCT01971749|||COHORT||PROSPECTIVE|||||||
34137937|NCT00808613|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137938|NCT01578642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137939|NCT04627324|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|A dental hygienist blinded to group assignment determined plaque status. Participants were randomly assigned into two equally sized groups by flipping a coin.||f|f|t|f
34137940|NCT05083013|||COHORT||PROSPECTIVE|||||||
34137941|NCT04599959|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Comparison of SARS-CoV-2-RNA detectability in Swab and Salivette samples.||||
34137942|NCT03831516|||COHORT||PROSPECTIVE|||||||
34137943|NCT02611115|||COHORT||PROSPECTIVE|||||||
34137944|NCT03222973|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137945|NCT05716178|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The intervention will be single-blinded. The outcome assessors will be masked.|The study will have two arms, i.e., intervention and control groups. The intervention group is assigned to receive training from religious leaders on maternal and neonatal health and the control group will be left to continue the routine practices.|f|f|f|t
34137946|NCT04052789|RANDOMIZED|PARALLEL||TREATMENT||NONE|Double(participant, outcome Assessor) Double blind|||||
34137947|NCT05128513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34137948|NCT04686188|||OTHER||PROSPECTIVE|||||||
34137949|NCT04452435|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137950|NCT02961933|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137951|NCT06581731|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34137952|NCT04802135|||COHORT||OTHER|||||||
34137953|NCT03648177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34137954|NCT02607475|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34137955|NCT04286841|||CASE_ONLY||PROSPECTIVE|||||||
33840232|NCT04489810|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||Each participant attended a clinic for one day for an acute assessment of the acute effects of treatment. This was done on the same day over 4 consecutive weeks. At each visit the participant received 1 of 4 different treatments|t|f|t|t
34137956|NCT03401021|||COHORT||CROSS_SECTIONAL|||||||
34137957|NCT00150319|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34137958|NCT01257230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34137959|NCT04883294|||COHORT||PROSPECTIVE|||||||
34137960|NCT01679548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137961|NCT00123279|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34137962|NCT00262236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34137963|NCT00003234||||TREATMENT||||||||
34137964|NCT00433160|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137965|NCT00072293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137966|NCT06605716|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34137967|NCT04964986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137968|NCT04379479|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Exploratory clinical trial, prospective, longitudinal, placebo-controlled, double-blinded, in patients with symptoms of non-severe acute respiratory infection (suspected/confirmed cases of COVID-19).|t|f|t|f
34137969|NCT00563069|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34137970|NCT05807087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137971|NCT02760173|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34137972|NCT00873041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34137973|NCT03259178|||CASE_ONLY||PROSPECTIVE|||||||
34137974|NCT01762735|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34137975|NCT04583787|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patients will receive a 82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care. Subsequently, patients will undergo a stress-rest 99mTc-sestamibi myocardial perfusion SPECT, which will be evaluated both qualitatively and quantitatively||||
34137976|NCT00290771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34137977|NCT01635673|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34137978|NCT04054869|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|participants and the outcomes assessor will be masked (blinded) as to the order in which each participant receives the interventions|each participant receives both treatments in randomized order|t|f|f|t
34137979|NCT02559934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137980|NCT02224287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137981|NCT03729037|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (outcomes assessor)||f|f|f|t
34137982|NCT03217877|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34137983|NCT05382468|NA|SINGLE_GROUP||OTHER||NONE||||||
34137984|NCT06535230|RANDOMIZED|PARALLEL||SCREENING||NONE||"Single-center, prospective, non-blinded, randomized controlled trial. Patients were allocated to 2 groups:~Group 1: Patients who underwent manual anesthesia induction Group 2 : Patients who underwent anesthesia induction with target-controlled infusion,"||||
34137985|NCT05005845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137986|NCT04826848|||COHORT||PROSPECTIVE|||||||
34137987|NCT03537365|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||A multicentre, non-blinded, pilot randomized controlled trial|f|f|f|t
34137988|NCT04776187|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34137989|NCT00729677|||CASE_ONLY||PROSPECTIVE|||||||
34137990|NCT04077346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137991|NCT02974127|||COHORT||PROSPECTIVE|||||||
34137992|NCT06605651|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"All study personnel (Investigator and their team, Sponsor's and CRO's Clinical Study Team will be blinded to subject treatment assignments except for the investigational pharmacist at each study site.~The IWRS system will keep a coding list identifying the randomization number and the nature of the treatment allocated to each randomized patients."|This is an international, multicentric, phase II (proof of concept), randomized, double-blind, parallel group, placebo-controlled study.|t|t|t|t
34137993|NCT02663973|||CASE_ONLY||PROSPECTIVE|||||||
34137994|NCT06660498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants will be randomized 1:1 to pomalidomide 2 mg/d or matching placebo concurrent with aspirin 75 mg.|t|t|t|f
34137995|NCT02115022|||CASE_ONLY||PROSPECTIVE|||||||
34137996|NCT04147390|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34137997|NCT00470093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34137998|NCT01180894|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34137999|NCT01935583|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138000|NCT00211835|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138001|NCT05550870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single-blind clinical trial, in which patients know that fenugreek is being given to them but which form either raw or roasted is unknown to them|There are two groups, Group 1 will be given raw fenugreek and group 2 will be given roasted fenugreek. Results will be compared to baselines.|t|f|f|f
34138002|NCT05311943|NA|SINGLE_GROUP||TREATMENT||NONE||olverembatinib, 40mg, taken orally once every other day of a 28-day cycle||||
34138003|NCT06140498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Parallel Assignment|Random Allocation, 2 Arms allocation to groups blinded, parallel assignment, masking participant, outcome assessor, investigator.|f|f|t|f
34138004|NCT06517394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138005|NCT06006507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Exercise treatments|f|f|f|t
34138006|NCT06018493|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The masking range includes participants, most researchers (including the study leader; subjects screening researchers; follow-up researchers; sonographers; MR scanners, members of the clinical endpoint identification committee,and etc.) except for the study statistical analysts and the therapy operators|This is a randomized, blinded, and sham-control study. The ratio of the intervention group versus sham-control group is 1:1|t|t|t|f
34138007|NCT04266964|||COHORT||PROSPECTIVE|||||||
34138008|NCT00653848|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138009|NCT04573699|||CASE_ONLY||OTHER|||||||
34138010|NCT04694521|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138011|NCT00431886|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34138012|NCT03615872|||COHORT||PROSPECTIVE|||||||
34138013|NCT02853812|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138014|NCT01443364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138015|NCT00883012|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34138016|NCT00132691|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138017|NCT02080897|||CASE_CONTROL||PROSPECTIVE|||||||
34138018|NCT06607874|||COHORT||PROSPECTIVE|||||||
34138019|NCT06606379|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138020|NCT00888524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34138021|NCT02185014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138022|NCT05206188|RANDOMIZED|PARALLEL||TREATMENT||NONE||Study participants randomized to the experimental condition will receive IPS services in combination with the MWW intervention. Study participants randomized to the control condition will receive IPS services as usual.||||
34138023|NCT01888536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138024|NCT04261972|||COHORT||PROSPECTIVE|||||||
34138025|NCT05012631|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138026|NCT03661905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Intervention assessors will not know which participants have been assigned to the different interventions.|A two-arm parallel assignment where one group will receive Cognitive therapy, and the other group will receive ERP.|f|f|f|t
34138027|NCT06315036|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138028|NCT05974618|||COHORT||PROSPECTIVE|||||||
34138029|NCT00445107|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138030|NCT02979509|||COHORT||PROSPECTIVE|||||||
34138031|NCT03775343|||CASE_CONTROL||PROSPECTIVE|||||||
34138032|NCT06441071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34138033|NCT02947178|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34138034|NCT06607640|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34138035|NCT00294645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138036|NCT06037096|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Pre-post intervention study||||
34138037|NCT06518317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Multicenter, open label, blinded endpoint assessment, randomized non-inferiority trial|Multicenter, open label, blinded endpoint assessment, randomized non-inferiority trial|f|f|f|t
34138038|NCT02802423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138039|NCT00467545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138040|NCT04293926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138041|NCT00003406||||TREATMENT||||||||
34138042|NCT01032954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138043|NCT05577598|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||After 8 weeks of open label DBS optimization and treatment, randomization to 12 weeks active or 12 weeks sham DBS treatment followed by a crossover switch at study week 24 to the opposing condition.|t|t|f|t
34138044|NCT06608420|||OTHER||RETROSPECTIVE|||||||
34138045|NCT03466099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138046|NCT05483257|||COHORT||RETROSPECTIVE|||||||
34138047|NCT00415337|||COHORT|||||||||
34138048|NCT00724854|||CASE_CONTROL||PROSPECTIVE|||||||
34138049|NCT04984174|||COHORT||RETROSPECTIVE|||||||
34138050|NCT05072223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138051|NCT06607224|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138052|NCT05426031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34138053|NCT02013206|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138054|NCT05846880|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840233|NCT02923791|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840234|NCT01584960|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33840235|NCT00033618|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138055|NCT05694312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138056|NCT05064020|||CASE_CONTROL||PROSPECTIVE|||||||
34138057|NCT03354312|RANDOMIZED|CROSSOVER||OTHER||NONE||The randomization determines if a subject will be assigned to receive either lidocaine gel or articaine injection anesthesia as the first anesthesia during SRP Treatment of the right upper and lower jaw. The second anesthesia during SRP at visit 2 will be carried out with the remaining anesthetic on the left side of the upper and lower jaw.||||
34138058|NCT02803177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138059|NCT03785249|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34138060|NCT04043585|||CASE_ONLY||PROSPECTIVE|||||||
34138061|NCT01535599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138062|NCT01777217|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34138063|NCT02965183|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138064|NCT03040011|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Three-arm, double-blinded, placebo-controlled, randomized controlled trial|t|t|t|t
34138065|NCT04444778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138066|NCT01700374|||COHORT||PROSPECTIVE|||||||
34138067|NCT00491855|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138068|NCT01239381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138069|NCT01781650|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138070|NCT06605365|||COHORT||OTHER|||||||
34138071|NCT06373926|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34138072|NCT05963412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138073|NCT01220973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138074|NCT03504540|||CASE_CONTROL||PROSPECTIVE|||||||
34138075|NCT06604910|RANDOMIZED|PARALLEL||OTHER||NONE||patient undergoing branched chained amino aicd||||
34138076|NCT05832515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138077|NCT02376725|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138078|NCT06303440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated||f|f|f|t
34138079|NCT00688324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138080|NCT05825430|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34138081|NCT03840772|NA|SINGLE_GROUP||TREATMENT||NONE||Not controlled, single arm study||||
34138082|NCT04978220|||COHORT||PROSPECTIVE|||||||
34138083|NCT01035463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138084|NCT03759886|||CASE_CONTROL||PROSPECTIVE|||||||
34138085|NCT03222154|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||3 groups: Control (n = 20), without intervention; Placebo (n = 20), simulation of the application of shock wave therapy; And shock wave therapy (n = 20).|t|f|t|t
34150831|NCT03431363|||COHORT||PROSPECTIVE|||||||
34150832|NCT02486250|||COHORT||PROSPECTIVE|||||||
34138086|NCT05527587|NA|SINGLE_GROUP||TREATMENT||NONE|Since we have limited evidence on the effects of non-pharmacological treatment for dementia including nature-based activities, we would like to perform an open-label pilot study to understand the effects of nature-based activities in people living with dementia in preparation for a future controlled trial.|||||
34138087|NCT04736004|||CASE_CONTROL||PROSPECTIVE|||||||
34138088|NCT03784599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138089|NCT05296824|||CASE_ONLY||RETROSPECTIVE|||||||
34138090|NCT01304069|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34138091|NCT04225052|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138092|NCT03695627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigator will be blind to condition throughout data accrual.||f|f|t|f
34138093|NCT05055323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138094|NCT01854632|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34138095|NCT06607419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138096|NCT02251561|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34138097|NCT02076308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138098|NCT03019328|||COHORT||PROSPECTIVE|||||||
34138099|NCT05947565|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34138100|NCT05067023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138101|NCT02687685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34138102|NCT01796119|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138103|NCT06243939|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34138104|NCT02349607|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34138105|NCT01732939|||COHORT||PROSPECTIVE|||||||
34138106|NCT05579301|||COHORT||PROSPECTIVE|||||||
34138107|NCT03341364|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Recruitment of participants to the group intervention will start first. When a maximum of 10 participants have been recruited to the group intervention and/or one week before start of group intervention, recruitment to the Active Control group will start. The individual therapies will start at different times, depending on the flow of referrals.||||
34138108|NCT00686985|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138109|NCT05991193|||COHORT||PROSPECTIVE|||||||
34138110|NCT06607029|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138111|NCT01530035|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34138112|NCT04601428|NA|SINGLE_GROUP||TREATMENT||NONE||The dose escalation phase of the study will begin with 3 single cohort subjects and then proceed to a traditional 3 +3 study design until a Maximum Tolerated Dose (MTD) or an active dose (i.e., a dose at which subjects achieve a complete response in the liver or complete elimination of tumor blood flow) is identified. Once an appropriate dose in established, an expansion phase will administer CSR02-Fab-TF to 16 additional subjects to estimate the response proportion in subjects with refractory HCC.||||
34138113|NCT01897350|||||PROSPECTIVE|||||||
34138114|NCT05979220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138115|NCT04036474|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34138116|NCT02582073|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138117|NCT01611363|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34138118|NCT01182805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138119|NCT03520348|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the partial and final analysis.~The masking will be done using boxes in the primary packaging identical in the two groups. Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the allocation number.~Blinding may be opened in the following cases:~1. Presence of a serious adverse event.~2. Safety alarm due to the use of the drugs under study.~3. In case the sponsor determines it for any reason of security or other reason that considers pertinent."|Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory.|t|f|t|t
34138120|NCT03533439|||COHORT||PROSPECTIVE|||||||
34138121|NCT06459089|||COHORT||PROSPECTIVE|||||||
34138122|NCT02373436|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34138123|NCT02513407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138124|NCT00364572|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138125|NCT05223907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138126|NCT02192060|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34138127|NCT00328562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138128|NCT02251704|NA|SINGLE_GROUP||OTHER||NONE||||||
34138129|NCT01097642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138130|NCT05658848|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138131|NCT06485973|||CASE_ONLY||CROSS_SECTIONAL|||||||
34138132|NCT05887544|||COHORT||PROSPECTIVE|||||||
34138133|NCT03736057|||COHORT||PROSPECTIVE|||||||
34138134|NCT01234740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138135|NCT05345574|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34138136|NCT03194568|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34138137|NCT06115486|RANDOMIZED|PARALLEL||OTHER||NONE||The study will include rolling block randomization of two groups of 15 participants in each group. The 6-12-25 arm will be enrolled first, followed by the ACSM arm.||||
34138138|NCT02120300|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138139|NCT06562660|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|A total of 60 male obese patients undergoing elective non-thoracic surgery were divided into two groups (n=30) based on smoking status: smokers(S groups), and never smokers(NS groups). Those in the smoking group were current or past smokers, while those in the nonsmoking group had never smoked.|A total of 60 male obese patients undergoing elective non-thoracic surgery were divided into two groups (n=30) based on smoking status: smokers(S groups), and never smokers(NS groups). Those in the smoking group were current or past smokers, while those in the nonsmoking group had never smoked.|t|t|t|t
34138140|NCT06606678|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138141|NCT00503776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150833|NCT03013049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150834|NCT02742311|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138142|NCT03478475|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Neither the investigator nor the subjects were aware of the group allocation; the pharmacist (in charge of the placebo tablets as well as the packing and coding of the supplements) was the only person to know to which group each participant belonged.|This was a randomized, controlled, double blind study. Participants were randomized into 2 groups; the vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) and the placebo group who also received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving. The treatment was led for a period of 6 months.|t|t|t|t
34138143|NCT03183323|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Group assignment is not masked at performance tests. Group assignment is masked to the echo/MRI technician, and for investigators interpreting the recordings.~Masking is not relevant for laboratory analysis."|RCT, 1:1 into telerehabilitation or standard care. Patients will be stratified by EF \>/\< 40 %, age \>/\< 60 years and by sex.|f|f|f|t
34138144|NCT06607614|||COHORT||PROSPECTIVE|||||||
34138145|NCT01357135|||OTHER||PROSPECTIVE|||||||
34138146|NCT01748812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138147|NCT04715802|||COHORT||RETROSPECTIVE|||||||
34138148|NCT00116064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138149|NCT01478685|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138150|NCT02690428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138151|NCT05720858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138152|NCT06307522|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34138153|NCT05121220|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34138154|NCT00006042||||TREATMENT||||||||
34138155|NCT06162663|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||Randomized double blind placebo controlled trial|t|t|t|t
34138156|NCT03257111|||COHORT||PROSPECTIVE|||||||
34138157|NCT00434083|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138158|NCT06561880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138159|NCT06607120|||COHORT||OTHER|||||||
34138160|NCT02626234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138161|NCT01476189|RANDOMIZED|CROSSOVER||||NONE||||||
34138162|NCT05295901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|participants do not know that they are in the experimental or control group|randomized controlled quasi-experimental study|t|f|f|f
34138163|NCT06536244|||COHORT||RETROSPECTIVE|||||||
34138164|NCT06457776|||COHORT||PROSPECTIVE|||||||
34138165|NCT05149586|||COHORT||PROSPECTIVE|||||||
34138166|NCT05804513|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE||Blinded randomised two group crossover|t|f|f|f
34138167|NCT05055388|||COHORT||RETROSPECTIVE|||||||
34138168|NCT02911740|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34138169|NCT04028765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138170|NCT04823702|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138171|NCT05723081|||COHORT||CROSS_SECTIONAL|||||||
34138172|NCT06397937|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single blinding of outcomes assessor|Phase 3, randomized, blinded outcome|f|f|f|t
34138173|NCT01391780|||||PROSPECTIVE|||||||
34138174|NCT01363921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138175|NCT04220242|||COHORT||OTHER|||||||
33838538|NCT05233475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both groups will recieve enhanced usual care. The care providers providing the enhanced usual care, will be blinded to group assignment. As the outcome assessor are the participants when the outcome is participant-reported outcomes, none of the outcome assessors are blinded, as it is impossible to blind the participants to group assignment.|Feasibility study, randomized controlled trial, implementation study and a prospective cohort study.|f|t|f|f
33838539|NCT01780454|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138176|NCT06236984|||OTHER||RETROSPECTIVE|||||||
34138177|NCT00612417|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34138178|NCT05734001|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34138179|NCT06481228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138180|NCT06607601|||COHORT||RETROSPECTIVE|||||||
34138181|NCT04089241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138182|NCT05696873|||COHORT||PROSPECTIVE|||||||
34138183|NCT03888404|||COHORT||PROSPECTIVE|||||||
34138184|NCT05422365|NA|SINGLE_GROUP||TREATMENT||NONE||Open, multicenter, international, uncontrolled||||
34138185|NCT00628472|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34138186|NCT03336801|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Patients are randomized into one of two treatment groups which during surgery receives one of two different anesthetic agents. The two groups are then compared to each other.|f|f|t|f
34138187|NCT01772524|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34138188|NCT01340625|RANDOMIZED|CROSSOVER||||NONE||||||
34138189|NCT06607653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138190|NCT01693341|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34138191|NCT01537159|||COHORT||PROSPECTIVE|||||||
34138192|NCT00561158|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138193|NCT06458504|||OTHER||PROSPECTIVE|||||||
34138194|NCT00206050|RANDOMIZED|CROSSOVER||||NONE||||||
34138195|NCT05072015|||COHORT||PROSPECTIVE|||||||
34138196|NCT02666495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138197|NCT01448785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138198|NCT02338895|||COHORT||PROSPECTIVE|||||||
34138199|NCT00562497|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34138200|NCT03359785|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34138201|NCT01326156|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138202|NCT05519449|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34138203|NCT02833090|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138204|NCT01057576|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138205|NCT06446856|||CASE_CONTROL||PROSPECTIVE|||||||
34138206|NCT02882789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138207|NCT06346353|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138208|NCT06571708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138209|NCT00621556|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138210|NCT05617924|||CASE_CONTROL||RETROSPECTIVE|||||||
34138211|NCT04849312|||COHORT||RETROSPECTIVE|||||||
34138212|NCT00560534|||CASE_CONTROL||PROSPECTIVE|||||||
34138213|NCT04155918|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138214|NCT05610826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138215|NCT04726137|||COHORT||PROSPECTIVE|||||||
34138216|NCT01441908|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34138217|NCT04850391|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138218|NCT02684812|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|PROBE Design||f|f|f|t
34138219|NCT01368692|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138220|NCT01044745|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138221|NCT00381511|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138222|NCT02782052|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34138223|NCT00875485|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138224|NCT04151927|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34138225|NCT03051412|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138226|NCT01380535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Pilot Study for the 2015 NIH Consensus Criteria to inform the design of subsequent studies|f|f|f|t
34138227|NCT01796990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138228|NCT06356935|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34138229|NCT05131867|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|t|f
34138230|NCT00568373|NA|SINGLE_GROUP||TREATMENT||NONE||All patients who have severe symptoms and have been identified by the PI and Sub I to qualify for the treatment will be under one single group||||
34138231|NCT00342550|||COHORT||PROSPECTIVE|||||||
34138232|NCT05775549|||COHORT||RETROSPECTIVE|||||||
34138233|NCT00199472|||||PROSPECTIVE|||||||
34138234|NCT04487535|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138235|NCT06174454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"1. A sequence of aleatory numbers in blocks of 2 will be generated in each of the study groups using the software randomization.com, done by a person foreign to the research.~2. Using the randomized numbers generated by the software, it will be decided what group each participant belongs to (control or intervention) and what maneuver will be assigned to them.~3. These numbers and their maneuvers will be placed inside dark envelopes.~4. The whole randomization and assignment sequence will be performed by a person foreign to the research and without the knowledge of the researchers. Support will be provided from the coordination for nursing research, who will select the personnel for the process."|The population will consist of children aged from 0 to 8 years old diagnosed with pneumonia with a development time less than 7 days. he sample calculation corresponds to 40 participants per group. The intervention group will be exposed to techniques such as prolonged slow expiration, controlled expiratory flow exercises, tracheal pumping and tracheal reflex. The control group will be subject to postural drainage plus compressions to the muscle belly of the upper limbs. Both groups will go through 10 sessions: One daily session from Monday to Friday with a duration of 10 to 15 minutes each|t|t|f|t
34138236|NCT05335187|NA|SINGLE_GROUP||OTHER||NONE||||||
34138237|NCT02984150|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34138238|NCT05339178|||COHORT||PROSPECTIVE|||||||
34138239|NCT05952011|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34138240|NCT04219319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138241|NCT02593604|||COHORT||RETROSPECTIVE|||||||
34138242|NCT04399473|||COHORT||PROSPECTIVE|||||||
34138243|NCT02352272|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138244|NCT05643196|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34138245|NCT01490736|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34138246|NCT00006313|||||RETROSPECTIVE|||||||
34138247|NCT00704483|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138248|NCT00904098|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138249|NCT04895293|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects receive the study treatment||||
34138250|NCT02715024|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138251|NCT04136327|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34138252|NCT03732495|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with predominant bone metastases from Radioiodine-Refractory Differentiated Thyroid Carcinoma (RR-DTC)||||
34138253|NCT00199251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138254|NCT02239835|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138255|NCT03010137|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138256|NCT00350363|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34138257|NCT02438384|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138258|NCT02511834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138259|NCT04243577|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Experiments will follow a within-subject randomized cross-over design. The purpose is to develop devices that are optimized for their use. To achieve this goal, for each new iteration of the devices, at least ten new participants will be tested using the current prototypes and the commercially available counterpart sensors in counterbalanced order. Results will be analyzed and discussed in regards to design improvements before the next iteration of development. The plan to recruit a large number of total subjects allows for several pre-clinical experiments to be conducted until the final versions of both devices are optimized.|f|f|f|t
34138260|NCT06142513|||CASE_CONTROL||PROSPECTIVE|||||||
34138261|NCT00760435|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138262|NCT05515588|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138263|NCT02985892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34138264|NCT01913028|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34138265|NCT04351464|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|f|t|f
34138266|NCT02354846|||COHORT||PROSPECTIVE|||||||
34138267|NCT06605820|||OTHER||OTHER|||||||
34138268|NCT03771131|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138269|NCT02839447|||COHORT||PROSPECTIVE|||||||
34138270|NCT00318747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138271|NCT01988662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138272|NCT04225676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828813|NCT03384147|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Intake of alcoholic drinks or abstaining cannot be masked to participants or care providers (delivering the alcoholic beverages). The outcomes included biomarkers of alcohol intake so in practice the investigator and outcomes assessor could not be blinded either.|The study was conducted in two predefined groups of volunteers, 1) daily alcohol users of maximally one (females) or two (males) drinks per day, and 2) occasional drinkers (0-2 drinks per week). Group 1 was asked to abstain from alcohol for 3 weeks, then to resume drinking 1-2 drinks daily for the next three weeks. Group 2 was asked to drink 1-2 drinks daily for 3 weeks and then to abstain for the following 3 weeks. During the alcohol intake period both groups were randomized to sequences of 4-5 days with red wine, white wine, lager beer, apple cider, or spirits. The primary endpoint was an effect of alcohol on dihydroepiandrosterone sulphate excretion in urine. Biomarkers of alcohol intake and alcohol-induced metabolic change, physical activity, or well-being were secondary outcomes.||||
33828814|NCT04003025|||COHORT||RETROSPECTIVE|||||||
33828815|NCT00571077|||||PROSPECTIVE|||||||
33828816|NCT04634955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828817|NCT06276517|||COHORT||PROSPECTIVE|||||||
33828818|NCT03044587|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828819|NCT06382571|||COHORT||RETROSPECTIVE|||||||
33828820|NCT01044901|||CASE_CONTROL||PROSPECTIVE|||||||
33828821|NCT05066919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828822|NCT04887701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828823|NCT05277090|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33828824|NCT02844192|||CASE_ONLY||RETROSPECTIVE|||||||
33828825|NCT05185297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blood analysis, maximum oxygen consumption and DEXA scans will have blinded outcome assessors.||f|f|f|t
33828826|NCT02675218|||COHORT||PROSPECTIVE|||||||
33828827|NCT04124783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828828|NCT01489917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828829|NCT04833426|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828830|NCT03231332|RANDOMIZED|PARALLEL||TREATMENT||NONE|Active treatment will be provided unmasked in the treatment groups|Comparison between intervention groups and the group without intervention will be made||||
33828831|NCT03591627|||COHORT||PROSPECTIVE|||||||
33828832|NCT05807269|||COHORT||PROSPECTIVE|||||||
33828833|NCT00733226|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33828834|NCT06409559|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment to two different methods of screw and plate fixation of posterior wall acetabulum fractures.||||
33828835|NCT03880825|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33828836|NCT02547597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828837|NCT00644878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828838|NCT04610632|||OTHER||PROSPECTIVE|||||||
33828839|NCT03347266|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828840|NCT06086405|||COHORT||RETROSPECTIVE|||||||
33828841|NCT00175045|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828842|NCT00951678|||CASE_ONLY||PROSPECTIVE|||||||
33828843|NCT05221437|||CASE_ONLY||PROSPECTIVE|||||||
33828844|NCT06477276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828845|NCT05390996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828846|NCT05268497|NA|SINGLE_GROUP||OTHER||NONE||||||
33828847|NCT00823446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828848|NCT03503383|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33828849|NCT02237625|||FAMILY_BASED||PROSPECTIVE|||||||
33828850|NCT02732002|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33828851|NCT02725398|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
33828852|NCT03271918|RANDOMIZED|PARALLEL||TREATMENT||NONE||A Single Center, Open Label and Randomized Clinical Trial.||||
33828853|NCT05717517|||COHORT||PROSPECTIVE|||||||
33828854|NCT02587897|||CASE_CONTROL||PROSPECTIVE|||||||
33828855|NCT02517528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828856|NCT02520596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828857|NCT05678647|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Drugs:~Oral sucrosomial Iron (SiderAl Forte®) and oral iron sulphate (Duroferon®) to blood donors"||||
33828858|NCT06276205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828859|NCT01172639|RANDOMIZED|PARALLEL||TREATMENT||NONE||Before randomisation patients were stratified to a high-risk or low-risk group according to the presence of risk factors at screening (having erosions, rheumatoid factor and/or anticitrullinated protein antibody and a high disease activity score calculated with C-reactive protein (DAS28-CRP)). Randomisation to treatment arms was performed via a digitally generated sequence. Patients in the high-risk group were randomised into CoBRA Classic, Clim or Avant-Garde arm. Patients in the low-risk group were randomised into CoBRA Slim or Tight Step Up arm.||||
33828860|NCT01413425|||||OTHER|||||||
33828861|NCT03462368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33828862|NCT06045663|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828863|NCT04368871|||COHORT||PROSPECTIVE|||||||
33828864|NCT04271566|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828865|NCT02869906|||COHORT||PROSPECTIVE|||||||
33828866|NCT01624298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828867|NCT01681199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828868|NCT02205099|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828869|NCT00075283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828870|NCT03964181|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33828871|NCT03577756|||CASE_CONTROL||PROSPECTIVE|||||||
33828872|NCT03051997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828873|NCT05495919|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828874|NCT00237861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33828875|NCT00229710|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828876|NCT01046825|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828877|NCT01062971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828878|NCT03776877|||COHORT||OTHER|||||||
33838540|NCT02410005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838541|NCT04113057|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective randomized study||||
34138273|NCT02703012|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138274|NCT02199314|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34138275|NCT00987428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138276|NCT02138305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Controlled prospective observational study||||
34138277|NCT06065059|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Dose Escalation and Phase 2 Dose Expansion||||
34138278|NCT01818739|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138279|NCT05627011|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This is a multi-site, parallel 2-arm cluster randomized controlled trial Hybrid Type 2 effectiveness-implementation study to simultaneously evaluate (1) the effectiveness of iPOP-UP in improving clinical care and child weight outcomes in pediatric primary care setting and (2) the impact of the implementation strategy on the reach, adoption, fidelity, cost, and maintenance of the intervention."||||
34138280|NCT03118427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138281|NCT04271748|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138282|NCT00099944|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138283|NCT04234789|NA|SINGLE_GROUP||OTHER||NONE||Cross-sectional study. All patients underwent to diagnostic tests protocol.||||
34138284|NCT03440736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138285|NCT05540249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The surgeons, anesthesiologists, ICU staff, nurses, outcome assessors, data collectors and data analysts will be blinded to the grouping.||f|t|t|t
34138286|NCT01969396|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34138287|NCT00391469|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138288|NCT01368172|RANDOMIZED|PARALLEL||||NONE||||||
34138289|NCT05964530|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138290|NCT02597218|||COHORT||RETROSPECTIVE|||||||
34138291|NCT03071445|||COHORT||PROSPECTIVE|||||||
34138292|NCT05906758|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138293|NCT06584331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34138294|NCT05978492|NA|SINGLE_GROUP||TREATMENT||NONE||Bayesian optimal interval (BOIN) design will be employed to find the MTD. The target DLT rate for determining the MTD is 30% for this study.||||
34138295|NCT01482169|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138296|NCT06364813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34138297|NCT02934880|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138298|NCT02200328|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34138299|NCT04379245|||COHORT||RETROSPECTIVE|||||||
34138300|NCT03172962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34138301|NCT02872896|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34138302|NCT01858545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138303|NCT05845333|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138304|NCT02110329|NA|SINGLE_GROUP||||NONE||||||
34138305|NCT06163495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138306|NCT01421303|||COHORT||PROSPECTIVE|||||||
33828879|NCT05523479|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||"The METEOR Trial is a batched stepped wedge cluster randomized type 2 hybrid implementation-effectiveness trial. ICUs are randomized rather than individuals, and each ICU will cross over from control to intervention at a randomized timepoint. The trial will employ three variations on the traditional stepped wedge design:~1. A factorial design will be used to estimate the effects of two implementation strategies (IPE and a clinical protocol) separately as well as together.~2. A concurrent design will be used to compare two post-extubation strategies (HFNC for all patients vs. NIV for high-risk patients and HFNC for low-risk patients) with conventional post-extubation oxygen therapy and with each other.~3. A batched design allows for the recruitment of clusters (i.e., ICUs) throughout the duration of the trial rather than requiring that all clusters commence participation in the trial at the same time."||||
33828880|NCT04733599|||COHORT||PROSPECTIVE|||||||
34138307|NCT03587025|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34138308|NCT06386302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138309|NCT04053946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138310|NCT06040008|||COHORT||PROSPECTIVE|||||||
34138311|NCT03241823|||COHORT||PROSPECTIVE|||||||
34138312|NCT00417378|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138313|NCT06606015|||COHORT||CROSS_SECTIONAL|||||||
34138314|NCT00660413|RANDOMIZED|||TREATMENT||SINGLE||||||
34138315|NCT02330666|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138316|NCT04574414|||CASE_CONTROL||RETROSPECTIVE|||||||
34138317|NCT02104596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138318|NCT04804631|||COHORT||PROSPECTIVE|||||||
34138319|NCT06377943|||OTHER||PROSPECTIVE|||||||
34138320|NCT03252249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138321|NCT06605859|||COHORT||PROSPECTIVE|||||||
34138322|NCT03023774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138323|NCT01310543|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34138324|NCT05655325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The PI and the outcome assessors are blinded to group assignment|Randomized controlled trial. Participants are randomized following baseline testing using block randomization of 2 and 4 to either an exercise intervention group or a health education group|f|f|t|t
34138325|NCT04072601|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Allocation and randomisation is blinded. Participants are only identified by randomisation number (no group names) Allocation ratio is 1:1 All personnel and participants are blinded through the study period. All outcome assessors are blinded to treatment, and initial data analysis is performed blinded.|"Part One: Enrolment of 48 participants. Evaluation of safety, resources and recruitment.~If adequate, Part Two: Enrolment up to 162 participants."|t|t|t|t
34138326|NCT04726150|||COHORT||PROSPECTIVE|||||||
34138327|NCT02465788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138328|NCT05800028|||COHORT||PROSPECTIVE|||||||
34138329|NCT01896076|||||CROSS_SECTIONAL|||||||
34138330|NCT03139981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind study||t|t|t|t
34138331|NCT03292055|||COHORT||PROSPECTIVE|||||||
34138332|NCT02030080|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34138333|NCT06385392|||COHORT||PROSPECTIVE|||||||
34138334|NCT04053400|||CASE_CONTROL||RETROSPECTIVE|||||||
34138335|NCT06607471|||CASE_CONTROL||OTHER|||||||
34138336|NCT03197714|NA|SINGLE_GROUP||TREATMENT||NONE||Phase Ib, open-label, dose-escalation clinical trial to evaluate the best-tolerated doses in AML relapsed or refractory to chemotherapy||||
33828881|NCT03380598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138337|NCT00895752|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138338|NCT04308460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138339|NCT01814878|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138340|NCT02717637|||COHORT||PROSPECTIVE|||||||
34138341|NCT01467037|||CASE_CONTROL||PROSPECTIVE|||||||
33828882|NCT00808899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138342|NCT06606093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138343|NCT02706275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138344|NCT04077671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind|SAD - Single Ascending Dose \& MAD - Multiple Ascending Dose|t|t|t|f
34138345|NCT06598228|||COHORT||RETROSPECTIVE|||||||
34138346|NCT02978547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138347|NCT03866603|||COHORT||PROSPECTIVE|||||||
34138348|NCT02350413|||CASE_ONLY||PROSPECTIVE|||||||
34138349|NCT05523128|NA|SINGLE_GROUP||TREATMENT||NONE||Hemophilia A patients||||
34138350|NCT05215223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138351|NCT05927675|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34138352|NCT05594017|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||Patients are randomized to scopolamine or saline solution by the pharmacy upon drug receipt. Both researchers and patients are blinded to which session receives pharmaceutical versus placebo administration. Each of the patients receive scopolamine or placebo on Day 1 and Day 2 before completing tasks at critical time points to parse encoding and retrieval.|t|t|t|t
34138353|NCT04913181|||COHORT||PROSPECTIVE|||||||
34138354|NCT00509860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138355|NCT00584090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138356|NCT02022215|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138357|NCT02725814|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34138358|NCT04557514|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138359|NCT01273116|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34138360|NCT04096820|NA|SINGLE_GROUP||PREVENTION||NONE||Open label||||
34138361|NCT05082454|||COHORT||CROSS_SECTIONAL|||||||
34138362|NCT01644786|||COHORT||PROSPECTIVE|||||||
34138363|NCT05173948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138364|NCT02789943|||COHORT||PROSPECTIVE|||||||
34138365|NCT01444625|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34138366|NCT04083508|NA|SINGLE_GROUP||OTHER||NONE||Mosquito-bite controlled human challenge infection||||
34138367|NCT01980303|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138368|NCT03474900|RANDOMIZED|PARALLEL||TREATMENT||NONE|The patient was informed about the treatment method that he or she was randomised. The operating surgeon knew the group and treatment that the patient belonged to.|The patients were randomised to 2 groups, titanium nailing or biodegradable nailing.||||
34138369|NCT00564863|NA|SINGLE_GROUP||OTHER||NONE||This is a phase 1, open-label, strain and dose-finding study designed to establish a human challenge model for CS19-ETEC that causes a \> 80% attack rate without causing high output diarrhea. This will be a strain and dose-finding study in which CS19-ETEC strain WS0115A will be administered at a starting inoculum of 5 x 108 colony forming units (cfu) to 5 subjects as the initial step to establish a human disease model. If an 80% attack rate (AR) for predefined diarrheal disease is achieved without high output diarrhea, the same inoculum will be given to 5 - 10 more subjects for confirmation of AR. If an 80% AR is not achieved, AR and severity of disease will be evaluated to determine if the dose should be increased. The same sequence may be conducted with DS26-1 as necessary.||||
34138370|NCT02367274|||CASE_ONLY||PROSPECTIVE|||||||
34138371|NCT01222091|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34138372|NCT06289920|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828883|NCT03591432|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33828884|NCT06198413|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33828885|NCT03957408|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138373|NCT06306963|||CASE_CONTROL||PROSPECTIVE|||||||
34138374|NCT02471560|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138375|NCT00121758|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34138376|NCT06601868|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This pilot study will include a total of 200 patients. Participants will be randomly assigned to one of two groups using a randomization algorithm. The study will be non-blinded, meaning both participants and researchers will be aware of group assignments.||||
34138377|NCT06102135|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34138378|NCT02449889|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138379|NCT01827774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138380|NCT05008575|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34138381|NCT00005901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138382|NCT05634746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138383|NCT04224636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138384|NCT03585036|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828886|NCT01042717|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828887|NCT05143138|||CASE_ONLY||OTHER|||||||
33828888|NCT01940406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138385|NCT04312360|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"The same intervention will apply to both arms of this study, the only difference is the patient group which receives the treatment.~In Clinical Trial, Track 1 and Track 2a will be registered as two different arms, but the results from each arm later on is going to be reported in separate publications."||||
34138386|NCT00700544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828889|NCT05706636|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828890|NCT06301971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828891|NCT00281047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828892|NCT01218425|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33828893|NCT05382910|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||About 180 subjects with moderate-to-severe asthma who meet the inclusion criteria will be selected for this study, according to 1:1:1 Randomly assigned to one of the MG-K10 Q2W group, the MG-K10 Q4W group, and the placebo group, with approximately 60 subjects in each group. The Q2W group will receive MG-K10 300mg subcutaneous injection every 2 weeks; Q4W group will receive MG-K10 300mg subcutaneous injection (every 4 weeks) + 2ml placebo subcutaneous injection ; the placebo group will receive 2 ml of placebo subcutaneously administered every 2 weeks. All three groups were followed up for 8 weeks after 24 weeks of treatment.|t|t|t|t
33828894|NCT01648478|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828895|NCT01165359|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828896|NCT05665413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828897|NCT00024323||||TREATMENT||||||||
33828898|NCT03876002|NA|SINGLE_GROUP||OTHER||NONE||||||
33828899|NCT00611299|RANDOMIZED|PARALLEL||||DOUBLE||||||
33828900|NCT01580995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828901|NCT01384383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828902|NCT06252090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828903|NCT01035047|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33828904|NCT01902498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33828905|NCT01792596|RANDOMIZED|CROSSOVER||||NONE||||||
33828906|NCT05041725|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828907|NCT00195884|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33828908|NCT00737269|||||PROSPECTIVE|||||||
33828909|NCT03450148|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33828910|NCT06543550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828911|NCT00486928|||COHORT||RETROSPECTIVE|||||||
33828912|NCT02511340|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828913|NCT00177372|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33828914|NCT02279992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828915|NCT00005064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828916|NCT06158178|||COHORT||RETROSPECTIVE|||||||
33828917|NCT01359722|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33828918|NCT01404533|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33828919|NCT01767662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828920|NCT04649125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators do not know which arm patients have been randomised to|Non Comparative Randomised Trial Randomised between standard dose multifractions (5-10#) and single fraction dose escalated palliative radiation therapy|f|f|t|f
33828921|NCT04842409|||COHORT||PROSPECTIVE|||||||
33828922|NCT06406868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828923|NCT05772195|||COHORT||RETROSPECTIVE|||||||
33828924|NCT05927636|||COHORT||PROSPECTIVE|||||||
33828925|NCT00092365|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828926|NCT02934542|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33828927|NCT03328910|||COHORT||PROSPECTIVE|||||||
33828928|NCT04493697|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|The device uses a bar code reader to import a prescription waveform. The use of the bar code aids blinding during randomization since the QR code is not readable by study members.|All participants will receive a ThermoNeuroModulation device for in-home use. Participants will be randomized to either the active or placebo treatment arm.|t|t|t|f
33828929|NCT04678765|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33828930|NCT02230293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828931|NCT04717947|||COHORT||RETROSPECTIVE|||||||
33828932|NCT06039592|||COHORT||PROSPECTIVE|||||||
33828933|NCT00461123|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828934|NCT04117815|||COHORT||PROSPECTIVE|||||||
33828935|NCT02264236|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828936|NCT01068405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33828937|NCT05549336|||COHORT||PROSPECTIVE|||||||
33828938|NCT05230030|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||Two-part study, starting with observational cohort measuring baseline parameters longitudinally. The second part of the study includes intervention in a single-arm among participants who completed baseline parameters.||||
33828939|NCT00548847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828940|NCT04310527|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33828941|NCT04301115|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33828942|NCT06480279|||CASE_CONTROL||PROSPECTIVE|||||||
33828943|NCT00171418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828944|NCT06336382|||COHORT||PROSPECTIVE|||||||
33828945|NCT00508859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828946|NCT02877732|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33828947|NCT06149143|||CASE_ONLY||PROSPECTIVE|||||||
33828948|NCT03510806|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33828949|NCT06076824|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Phase IV, single-center, randomized, controlled, and open label clinical trial (with blinded outcomes assessor).|f|f|f|t
33828950|NCT02356796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828951|NCT02190552|||COHORT||PROSPECTIVE|||||||
33828952|NCT02051985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33828953|NCT01232569|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33828954|NCT00000398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828955|NCT00151905|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828956|NCT02230709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33828957|NCT02108652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828958|NCT01737970|||CASE_ONLY||RETROSPECTIVE|||||||
33828959|NCT02554422|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33828960|NCT00224978|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33828961|NCT00184197|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33828962|NCT04571086|||COHORT||PROSPECTIVE|||||||
33828963|NCT02048683|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828964|NCT05639478|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Assignment|f|f|t|t
33828965|NCT00698555|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138387|NCT02509052|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The phase I portion will implement a modified rolling six dose escalation design, a more conservative version of the rolling six design of Skolnik, et al., for enrollment with dose escalation, de-escalation, or expansion of a cohort on the basis of the occurrence of dose limiting toxicities (DLTs) during cycle 1. The starting dose of leflunomide is 20mg daily, with the intention to test up to 60mg daily. Escalation will proceed in increments of 20mg/daily; de-escalation will proceed in decrements of 10mg/day. Leglunomide is administered with a loading dose of 100 mg for the 1st three doses.||||
34138388|NCT01416103|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138389|NCT01975519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138390|NCT03589664|||COHORT||CROSS_SECTIONAL|||||||
33828966|NCT05021822|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138391|NCT01661777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138392|NCT04627623|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34138393|NCT04899258|NA|SINGLE_GROUP||PREVENTION||NONE|Patients name and identifiers were masked|prospective, before-after study||||
34138394|NCT02375737|NA|SINGLE_GROUP||||NONE||||||
34138395|NCT01728506|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34138396|NCT03070860|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138397|NCT04540666|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34138398|NCT01741324|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33828967|NCT02316288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138399|NCT02498886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34138400|NCT05513872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34138401|NCT06130774|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138402|NCT05997992|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The research is a single-blind randomized controlled human trial.The participant will divide into control group or experimental group randomly by random number table.|The research is a single-blind randomized controlled human trial.The research is a single-blind randomized controlled human trial. It is planned to select 100 women aged 20-80 years with a diagnosis of OAB in outpatient clinics, and divide them into an experimental group and a control group of 50 each. The experimental group received electroacupuncture at Baihui(GV20), bilateral Sanyinjiao(SP-6) and Fuliu points(KP-7); the control group received placebo acupuncture|t|f|f|f
34138403|NCT03610945|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||2-Part Single Group study||||
34138404|NCT02199951|||COHORT||PROSPECTIVE|||||||
34138405|NCT02936310|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34138406|NCT06605690|NA|SINGLE_GROUP||TREATMENT||NONE||alpiciclib and Letrozole Combined With Anlotinib||||
34138407|NCT02746601|NA|SINGLE_GROUP||SCREENING||NONE||||||
34138408|NCT01124123|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34138409|NCT01168791|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138410|NCT05076916|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|For assigning each patient to a group, the subjects were assigned to the groups according to the randomization list created. Two independent researchers conducted the assignment of the participants on the intervention and control groups and the evaluation of the outcome measurement data. Since the researchers conducted the interventions, they were not be blinded. However, the participants were blinded because they did not know the hypotheses of the study and which group they were in.|"The effect of the web-based education program on patient outcomes was analyzed by dividing the participants into groups through randomization. All patients with cancer who met the sampling criteria were assigned to the intervention and control groups through block randomization (1:1). The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. During the follow-up period, the patients contact the research team by calling or writing messages via the website 24/7.~The control group received routine patient education and routine hospital follow-ups given by Oncology Education Nurses during the three-month follow-up period."|t|f|f|f
34138411|NCT01790282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138412|NCT04477382|||COHORT||PROSPECTIVE|||||||
34138413|NCT03398642|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34138414|NCT05343130|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34138415|NCT03297073|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138416|NCT00461864|||DEFINED_POPULATION||OTHER|||||||
34138417|NCT03831672|||OTHER||RETROSPECTIVE|||||||
34138418|NCT03666897|NA|SINGLE_GROUP||OTHER||NONE||||||
34138419|NCT00874458|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33828968|NCT00217022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828969|NCT02171247|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33828970|NCT00947830|||COHORT||PROSPECTIVE|||||||
33828971|NCT03978078|NA|SINGLE_GROUP||OTHER||NONE||||||
33828972|NCT03100136|NA|SINGLE_GROUP||OTHER||NONE||||||
34138420|NCT00920218|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34138421|NCT06606964|||CASE_CONTROL||PROSPECTIVE|||||||
34138422|NCT00322023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138423|NCT06589583|||OTHER||RETROSPECTIVE|||||||
34138424|NCT04236908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138425|NCT04979767|||COHORT||PROSPECTIVE|||||||
33828973|NCT00884013|||CASE_CONTROL||PROSPECTIVE|||||||
33828974|NCT02736955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828975|NCT02004106|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828976|NCT05584813|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Volunteers|"Five different Groups were analyzed:~* ground control binocular (n=12, Bi/GC)~* ground control monocular (n=11, Mo/GC)~* 10,000 ft, 60 min, monocular (n=10, Mo/60/10,000)~* 15,000 ft, 15 min, binocular (n=11, Bi/15/15,000)~* 15,000 ft, 60 min, monocular (n=10, Mo/60/15,000)"|t|f|f|f
33828977|NCT00887198|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828978|NCT00198302|RANDOMIZED|PARALLEL||||DOUBLE||||||
33828979|NCT00187343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828980|NCT03977571|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138426|NCT05039164|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34138427|NCT00090142|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34138428|NCT04852705|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34138429|NCT05377658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138430|NCT01828619|||CASE_ONLY||PROSPECTIVE|||||||
34138431|NCT03371511|||COHORT||CROSS_SECTIONAL|||||||
34138432|NCT03135769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828981|NCT04651309|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138433|NCT04193761|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
34138434|NCT05762250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138435|NCT03868267|||COHORT||PROSPECTIVE|||||||
34138436|NCT05124652|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All aims will be conducted as randomized control trials and test various developments to the auto adjusting system, with each previous aim informing the next.||||
34138437|NCT00368836|NA|SINGLE_GROUP||OTHER||NONE||||||
34138438|NCT03341078|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Healthy controls will be recruited and have baseline evaluations for neuroinflammation and associated behaviors. Participants with methamphetamine-use disorder will also be recruited and enrolled in a placebo controlled portion of this study. Participants in the placebo controlled portion of this study will be dosed with either the study drug or a placebo twice daily for 6 weeks and will have pre/post evaluations for neuroinflammation and associated behaviors.|t|f|t|f
34138439|NCT06488612|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34138440|NCT02348879|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34138441|NCT06155656|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34138442|NCT01960998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34138443|NCT04482530|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|Same flavor will be used for all matrices. The different matrices will be offered to volunteers in in individual packaged portions.||t|f|f|f
34138444|NCT02193386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34138445|NCT02921555|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138446|NCT00144469|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138447|NCT06215703|RANDOMIZED|CROSSOVER||OTHER||NONE||A 2x2 crossover design will be used such that each participant will complete all music playing conditions, including: (1) with or without improvisation and (2) with or without live accompaniment. Participants will be randomized to one of four condition orders.||||
34138448|NCT03659903|||COHORT||RETROSPECTIVE|||||||
34138449|NCT02657681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138450|NCT01655121|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138451|NCT03448666|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm trial with a single group assignment||||
34138452|NCT02152371|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138453|NCT06604819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|biostatistician||t|f|f|t
34138454|NCT02042053|NA|SINGLE_GROUP||OTHER||NONE||||||
34138455|NCT04132076|||CASE_CONTROL||RETROSPECTIVE|||||||
34138456|NCT04428190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|No other parties will be masked for the study.|One placebo arm and one active treatment arm, participants will be assigned to each arm equally.|t|f|t|f
34138457|NCT03851120|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participant, care provider, investigator, and outcomes assessor do not know which one is the intervention product or placebo.|Combination product: Probiotics and LC-PUFA The product will be given to 314 pregnant women, 157 pregnant women as an intervention group, and 157 pregnant women as a control group|t|t|t|t
34138458|NCT03100240|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138459|NCT05943392|||COHORT||PROSPECTIVE|||||||
34138460|NCT03262766|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|This is a blinded study, which means the participant will not know which treatment they are receiving. They will either receive intermittent periods of low oxygen (hypoxia) or a session composed of only normal room air. They will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither you nor the researcher chooses your assigned group. They will have an equal chance of being in either group. Upon acceptance into the study, subjects will be assigned an identification number. Data pertaining to each subject will only be identified by this number. Any forms/files containing the subject's personal information and their ID number will be housed in a locked office/laboratory space. The outcomes assessor will also be blinded to the intervention the subject received.|"Subjects will then be randomized to one of the four arms. The four arms of interventions are:~1. Acute intermittent hypoxia (AIH) therapy~2. AIH therapy + Upper extremity training~3. Sham AIH therapy + Upper extremity training~4. Sham Hypoxia"|t|f|f|t
34138461|NCT03886337|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective Cohort Study||||
34138462|NCT04915170|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The principal investigator doesn´t know the group of the patients until the study ends|Patients are assigned randomly to the 2 working groups, each patient only receives one of the two protocols.|t|f|t|f
34138463|NCT06116539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34150835|NCT02135978|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34150836|NCT01106274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33828982|NCT01610583|||||PROSPECTIVE|||||||
33828983|NCT03941249|||COHORT||CROSS_SECTIONAL|||||||
33828984|NCT01051102|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33828985|NCT01081119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33828986|NCT02752217|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33828987|NCT02627898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828988|NCT00992121|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33828989|NCT02200978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828990|NCT06191861|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Please note that outcomes are assessed by online survey. No person is in the role of an outcomes assessor.||f|f|t|t
33828991|NCT01309243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828992|NCT00349622|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33828993|NCT00279877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838542|NCT01017718|||COHORT||PROSPECTIVE|||||||
33838543|NCT02864277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838544|NCT04014231|||CASE_ONLY||PROSPECTIVE|||||||
34138464|NCT04660825|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"The study will be a randomised controlled trial of a six-month exercise intervention. Following screening and baseline measurements, participants will be randomly assigned to exercise or control groups, allocated in 2:1 ratio. Randomisation will conducted using computer algorithm. The exercise group will be requested to complete the intervention as detailed below whilst the control group maintain their usual lifestyle.~Participants will complete a six-month programme of muscle-strengthening exercises using resistance bands. Exercises will be introduced through group sessions run three times per week, some of which could be substituted by home exercise supported by an exercise booklet and video."||||
34138465|NCT00724685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138466|NCT02938832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138467|NCT06330103|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||923 samples that were evaluated for LVEF by certified cardiologists, 739 clips were used to train AI, while the remaining 184 clips were used to test if AI could process the results correctly. Artificial intelligence aims to classify cardiac function into three groups: Reduced EF, Mildly Reduced EF, and Preserved LV.|f|f|f|t
34138468|NCT03587831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138469|NCT00634712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138470|NCT06605898|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34138471|NCT02290691|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34138472|NCT00634257|||CASE_CONTROL||PROSPECTIVE|||||||
34138473|NCT00484393|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34138474|NCT02899234|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34138475|NCT02645643|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34138476|NCT03505723|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34138477|NCT06606951|||COHORT||PROSPECTIVE|||||||
34138478|NCT04193085|||COHORT||CROSS_SECTIONAL|||||||
34138479|NCT01885208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138480|NCT02354131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138481|NCT01648296|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34138482|NCT01384669|||CASE_CONTROL||PROSPECTIVE|||||||
34138483|NCT00778258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138484|NCT02421406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33828994|NCT05278013|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"For the GG, the puncture site edges will be approximated between the index and thumb fingers of the practitioner. After ensuring that the puncture edges are approximated, at least two layers of 2-OCA will be applied topically over the skin to cover the puncture site. At least 30 seconds will be allowed for each layer to dry before application of the second layer.~For the NG, the puncture area will be covered using the occlusive dressing supplied in the Safe-T-Centesis kit after catheter withdrawal and cleaning/drying of the skin."||||
33828995|NCT02196168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33828996|NCT02740361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138485|NCT01984463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138486|NCT04616664|||COHORT||PROSPECTIVE|||||||
34138487|NCT00673205|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34138488|NCT04024397|||CASE_CONTROL||PROSPECTIVE|||||||
34138489|NCT02567370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33828997|NCT03237247|||CASE_ONLY||CROSS_SECTIONAL|||||||
33828998|NCT00238719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33828999|NCT02383407|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33829000|NCT04684966|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33829001|NCT05073549|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"Pre- and post-study~* The period from October 1st, 2019 to September 30th, 2021 will be used as the baseline period before the intervention. Clinical data of eligible infants in this period will be retrospectively collected from a previously established database of preterm infants.~* The intervention will be initiated on October 1st, 2021. The period from October 1st, 2021 to September 31st, 2023 will be the intervention period and data will be prospectively collected."||||
33829002|NCT00907946|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829003|NCT04438330|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33829004|NCT01176318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829005|NCT02138656|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33829006|NCT02423785|||COHORT||PROSPECTIVE|||||||
33829007|NCT01917006|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33829008|NCT04804059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138490|NCT04446507|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138491|NCT00306657|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138492|NCT03505294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To ensure blinding, the assessor physiotherapist will not be aware of the arm to which the subjects belong.|Randomized, controlled, single-blind trial|f|f|f|t
34138493|NCT02557100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34138494|NCT01163357|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138495|NCT03836833|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138496|NCT02321189|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34138497|NCT03658200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34138498|NCT02570152|NA|SINGLE_GROUP||OTHER||NONE||||||
34138499|NCT01920568|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138500|NCT04332497|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the anesthesiologist who performs postoperative pain evaluation will not know the group.|There are three models for this study. Patients will be randomly divided into three groups (Group CPB = CPB group, Group ISCB = ISCB group, Group C = Control group), before entering the operating room.|t|f|f|t
34138501|NCT01380470|||COHORT||CROSS_SECTIONAL|||||||
34138502|NCT04056520|||COHORT||PROSPECTIVE|||||||
34138503|NCT05229211|||CASE_ONLY||PROSPECTIVE|||||||
34138504|NCT01958697|||COHORT||RETROSPECTIVE|||||||
34138505|NCT01144975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138506|NCT02352454|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138507|NCT04693273|||OTHER||PROSPECTIVE|||||||
34138508|NCT02335047|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34138509|NCT01414023|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34138510|NCT01941979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138511|NCT05365568|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138512|NCT05875636|||CASE_CONTROL||PROSPECTIVE|||||||
34138513|NCT01314170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138514|NCT03758079|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34138515|NCT03025672|||CASE_CONTROL||RETROSPECTIVE|||||||
34138516|NCT05491070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138517|NCT00125463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138518|NCT04070716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138519|NCT01887015|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34138520|NCT00580580|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138521|NCT04254367|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Investigator blinded of randomization results when informing PCCs about the study and PCCs blinded when selecting patients to the study. The PCCs were instructed to select 20-25 patients following the study's inclusion and exclusion criteria and among these select 12-14 patients to ask first. The other selected patients were to be asked if the first patients did not agree to participate in the study. After selection the PCCs were informed about randomization results.|The study design is a cluster randomized controlled study comparing the intervention in addition to treatment as usual (TAU) with TAU. Follow-up is performed with validated questionnaires after 3, 6 and 12 months. Primary outcome is net inactivity days (net days without employment or rehabilitation) and secondary outcome variables are the number of net and gross days with sick leave during the follow-up period, sense of coherence, health literacy, health-related quality of life, confidence in own problem solving ability, work ability and work satisfaction, social function and health habits, symptoms of depression, anxiety, and exhaustion as well as pain and catastrophization. Randomization will be performed at PCC level. Around 30 PCCs and 400 patients will be included in the study. The intervention consists of patient education with study circles meeting half a day per week for eight following weeks.|f|f|t|f
34138522|NCT05706233|||COHORT||RETROSPECTIVE|||||||
34138523|NCT02797665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138524|NCT02778555|||COHORT||PROSPECTIVE|||||||
34138525|NCT04407026|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138526|NCT02521753|RANDOMIZED|PARALLEL||TREATMENT||NONE|The study is open label. No blindness for participant or investigator is used|||||
34138527|NCT05898425|||COHORT||RETROSPECTIVE|||||||
34138528|NCT00404755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138529|NCT00236990|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138530|NCT05332587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138531|NCT06290167|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|t|f|t
34138532|NCT01663701|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138533|NCT01746511|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138534|NCT00002938|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138535|NCT03201926|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34138536|NCT00759356|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34138537|NCT04774536|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138538|NCT05638334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138539|NCT01054131|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
34138540|NCT06434766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants, investigators and outcomes assessors are all blind to the group assignments.|Sham stimulation is used as a parallel control group for iTBS group.|t|f|t|t
34138541|NCT01425450|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34138542|NCT01644695|||CASE_ONLY|||||||||
34138543|NCT00616811|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138544|NCT00246051|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
34138545|NCT03856476|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138546|NCT05890170|||COHORT||PROSPECTIVE|||||||
34138547|NCT06283823|||COHORT||PROSPECTIVE|||||||
34138548|NCT06537557|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34138549|NCT02538419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138550|NCT00998751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138551|NCT06372522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138552|NCT05122260|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Pharmacy will perform randomization and maintain blinding.||t|f|t|f
34138553|NCT04365361|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34138554|NCT04577300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34138555|NCT05522244|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138556|NCT01174537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138557|NCT01145352|||CASE_ONLY||PROSPECTIVE|||||||
34138558|NCT05751590|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138559|NCT05600816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138560|NCT04182321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138561|NCT02692040|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
33840236|NCT02815579|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33840237|NCT06463782|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138562|NCT00978055|RANDOMIZED|CROSSOVER||||NONE||||||
34138563|NCT02186379|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138564|NCT01872195|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138565|NCT00004495||||TREATMENT||||||||
34138566|NCT03645421|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138567|NCT06608719|||COHORT||RETROSPECTIVE|||||||
34138568|NCT01342354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138569|NCT06605287|||COHORT||PROSPECTIVE|||||||
34138570|NCT00544453|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34138571|NCT03661424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138572|NCT05763381|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single blind masking. The study team will know which group participants has been randomized to. Participants will not know which group they are in until after 6 week follow up visit.|Participants will be randomly assigned to one of two treatment groups: usual care with PBM therapy, or usual care with sham PBM therapy.|t|f|f|f
34138573|NCT04655755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138574|NCT06319469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150837|NCT01110382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138575|NCT05742906|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Data will be collected and reported in the following four (4) groups/cohorts:~* Group A: Adults (≥ 21 years of age) treated with SIS 1.0 study devices~* Group B: Pediatrics (\< 21 years of age) treated with SIS 1.0 study devices~* Group C: Adults Group A: Adults (≥ 21 years of age) treated with SIS 2.0 study devices~* Group D: Pediatrics (\< 21 years of age) treated with SIS 2.0 study devices"||||
34138576|NCT00018330|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34138577|NCT01872039|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138578|NCT03582865|||COHORT||PROSPECTIVE|||||||
34138579|NCT04941807|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment is open-label with respect to patient and investigators but is blinded to an endpoint committee.||f|f|f|t
34138580|NCT02507180|||COHORT||PROSPECTIVE|||||||
34138581|NCT05547633|||COHORT||PROSPECTIVE|||||||
34138582|NCT01261442|||CASE_CONTROL||PROSPECTIVE|||||||
33829009|NCT03897361|NA|SINGLE_GROUP||TREATMENT||NONE||This study will include up to 6 subjects and follows a 3-cohort staggered treatment design with 2 subjects per cohort. The first 2 cohorts will consist of 4 adults (18 years or older), potentially followed by a cohort consisting of 2 adolescents or adults (\>14 years old).||||
34138583|NCT05077995|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34138584|NCT03550170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138585|NCT05470101|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34138586|NCT05476237|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33829010|NCT00000349||||TREATMENT||NONE||||||
34138587|NCT06606184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138588|NCT02767089|RANDOMIZED|CROSSOVER||||SINGLE||||||
34138589|NCT00269269|RANDOMIZED|||TREATMENT||||||||
34138590|NCT05470543|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33829011|NCT04379817|NA|SINGLE_GROUP||SCREENING||NONE||||||
34138591|NCT04503083|||COHORT||PROSPECTIVE|||||||
34138592|NCT00664313|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138593|NCT02958891|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34138594|NCT02101684|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138595|NCT06390696|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829012|NCT01338805|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138596|NCT04829799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34138597|NCT00230802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829013|NCT02273700|||COHORT||PROSPECTIVE|||||||
33829014|NCT00280020|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829015|NCT01311414|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829016|NCT05832619|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829017|NCT02277067|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33829018|NCT04473053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The biomarker analysis team will be masked to the trial treatment.|Randomised clinical trial - currently two treatment arms and one standard of care arm. More assets will be added to the protocol as evidence emerges.|f|f|f|t
33829019|NCT04705402|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829020|NCT06438692|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829021|NCT02852278|||COHORT||PROSPECTIVE|||||||
34138598|NCT01931488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138599|NCT06605248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138600|NCT00530829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829022|NCT00250640|||COHORT||PROSPECTIVE|||||||
33829023|NCT03908398|||OTHER||PROSPECTIVE|||||||
33829024|NCT00090441|||CASE_CONTROL||RETROSPECTIVE|||||||
33829025|NCT01804998|RANDOMIZED|PARALLEL||TREATMENT||NONE||Stomach preserving surgery after laparoscopic sentinel node dissection and evaluation||||
33829026|NCT03980132|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
34138601|NCT05816408|||CASE_CONTROL||PROSPECTIVE|||||||
34138602|NCT06345482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138603|NCT05226780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138604|NCT03994250|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34138605|NCT01539486|||OTHER||RETROSPECTIVE|||||||
34138606|NCT05350930|||COHORT||PROSPECTIVE|||||||
34138607|NCT05316233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138608|NCT06126718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138609|NCT02053207|NA|SINGLE_GROUP||OTHER||NONE||||||
34138610|NCT02850861|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34138611|NCT05132361|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The physician performing the index procedure as well as study site personnel present at the index procedure will not be blinded, however, every effort will be made to maintain blinding for the following:~* Subjects and their families~* Site personnel only involved in conducting study assessments during follow-up."||t|f|f|f
34138612|NCT02235675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138613|NCT03568253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829027|NCT01691547|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33829028|NCT03628183|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829029|NCT01301144|||||PROSPECTIVE|||||||
33829030|NCT03134898|||COHORT||PROSPECTIVE|||||||
33829031|NCT01841112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138614|NCT05220319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138615|NCT00611442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34138616|NCT00701142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138617|NCT04983485|||OTHER||PROSPECTIVE|||||||
34138618|NCT00531557|NA|SINGLE_GROUP||||NONE||||||
34138619|NCT06608823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138620|NCT00146419|||COHORT||PROSPECTIVE|||||||
34138621|NCT06609044|||COHORT||PROSPECTIVE|||||||
34138622|NCT06604533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138623|NCT05849714|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34138624|NCT04095351|||OTHER||PROSPECTIVE|||||||
34138625|NCT06605144|RANDOMIZED|PARALLEL||TREATMENT||NONE||Adaptive Bayesian Platform trial evaluating multiple interventions in multiple domains.||||
34149836|NCT04963907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Devices are programmed by the manufacturer prior to shipping to investigator. Active devices are programmed at 100 uA for 60 minutes, which is subsensory. Sham devices will display 100 uA and count down from 60 minutes, but will not emit a current. Neither the investigators nor the participants will know which devices are active and which are sham.|The study is a multi-centre parallel group, double blind, non-commercial, randomised controlled trial (RCT).|t|f|t|f
33829032|NCT00626613|NA|SINGLE_GROUP||||DOUBLE|||t|t|f|f
33829033|NCT06338436|NA|SINGLE_GROUP||TREATMENT||NONE||a clinical study of prospective, single-arm objective performance criteria||||
33829034|NCT02765308|||CASE_CONTROL||PROSPECTIVE|||||||
34149837|NCT01317511|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33829035|NCT02735356|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829036|NCT01061853|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829037|NCT02146521|||OTHER||PROSPECTIVE|||||||
33829038|NCT00087113||||TREATMENT||NONE||||||
33829039|NCT01087749|NON_RANDOMIZED|PARALLEL||||NONE||||||
33829040|NCT00822666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829041|NCT02224183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33829042|NCT02361177|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33829043|NCT01964339|||OTHER||PROSPECTIVE|||||||
33829044|NCT00143741|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829045|NCT02204319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829046|NCT06209047|RANDOMIZED|PARALLEL||TREATMENT||NONE||a randomized controlled study where we divide the patients in a randomized manner(simple un-restricted randomization) into 2 groups , one group will undergo airway clearance by bronchoscopy followed by local instillation of gentamicin and dexamethasone , the other group will receive only conventional treatment which include antibiotic treatment,suction through the endotracheal tube and physiotherapy but without local instillation of the drugs used in the other arm||||
33829047|NCT05382598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829048|NCT02282059|||OTHER||PROSPECTIVE|||||||
33829049|NCT01137877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829050|NCT04970693|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829051|NCT04219878|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33829052|NCT00557336|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829053|NCT00521443|||DEFINED_POPULATION||PROSPECTIVE|||||||
33829054|NCT02360865|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33829055|NCT05673499|||COHORT||PROSPECTIVE|||||||
33829056|NCT04059887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829057|NCT04673877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829058|NCT02026245|NON_RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33829059|NCT00176475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829060|NCT01501292|||COHORT||PROSPECTIVE|||||||
33829061|NCT01009138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829062|NCT03336697|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33829063|NCT04517877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829064|NCT05019313|||COHORT||PROSPECTIVE|||||||
33829065|NCT03694626|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33829066|NCT03357978|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829067|NCT00677092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829068|NCT00962689|||COHORT||PROSPECTIVE|||||||
33829069|NCT02104505|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33829070|NCT03536702|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Participants will be randomized within strata formed by cancer type in order to assure that these potentially important confounding variables are balanced across groups. Patients will be enrolled on a rolling basis over a three-month period, allowing patients in intervention arm to participate in 3 months workshops (workshops would be held once every 2 weeks). Patients in control arm will be provided a book (Writing Down Bones by Natalie Goldberg) about creative writing and will be asked to do activities for 1.5 hours every 2 weeks. After three months, control group participants can join creative writing workshops at their discretion for the remaining period for writing workshops. Both group members will receive follow up surveys twice a month for two months at the completion of the participant's three-month study period.||||
33829071|NCT02735434|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829072|NCT03703349|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|treatment concealment will be managed by the central pharmacy of the hospital, which will dispense treatment according to the randomization plan.|Patients will be assigned to the 2 groups of treatment by blocks of 8. The randomization list will be computer-generated, with no factors for stratification. To reduce predictability of the random sequence, blocking will be made unavailable to those who assign interventions.|t|t|t|t
33829073|NCT03075098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829074|NCT03046797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829075|NCT00171366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33829076|NCT04158973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829077|NCT03109652|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829078|NCT02836262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829079|NCT00465634|||CASE_ONLY||PROSPECTIVE|||||||
33829080|NCT03433183|NA|SINGLE_GROUP||TREATMENT||NONE||A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNST||||
33829081|NCT01709123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829082|NCT03396211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829083|NCT02413606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33829084|NCT00637247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829085|NCT01853059|||COHORT||PROSPECTIVE|||||||
33829086|NCT03299413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829087|NCT02238964|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33829088|NCT04300322|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomised to either pessary or progesterone in a 1:1 ratio with a variable block size of 2, 4 or 6.||||
33829089|NCT00092521|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33829090|NCT04794166|||OTHER||PROSPECTIVE|||||||
34138626|NCT03420391|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||"Sixty participants will be enrolled in the study. Participants will be randomized in six groups:~Control: Participants will receive no intervention; Placebo: Participants will receive placebo PBMT; 5 minutes: Participants will perform the eccentric exercise protocol 5 minutes after PBMT.~3 hours: Participants will perform the eccentric exercise protocol 3 hours after PBMT.~6 hours: Participants will perform the eccentric exercise protocol 6 hours after PBMT.~24 hours: Participants will perform the eccentric exercise protocol 24 hours after PBMT.~Assessments will be performed at baseline, after 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."|t|t|f|t
34138627|NCT06600243|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34138628|NCT00052611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138629|NCT03345160|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label crossover||||
34138630|NCT00612547|||COHORT||PROSPECTIVE|||||||
34138631|NCT02187276|||CASE_ONLY||PROSPECTIVE|||||||
34138632|NCT03993990|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34138633|NCT00543803|||COHORT||PROSPECTIVE|||||||
33829091|NCT02782208|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34138634|NCT05238142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138635|NCT02451683|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34138636|NCT00243451|||CASE_CONTROL||PROSPECTIVE|||||||
34138637|NCT02739529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138638|NCT03933410|NA|SINGLE_GROUP||TREATMENT||NONE||K020-218 is a single arm, open-label study||||
34138639|NCT03945721|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138640|NCT00336050|||COHORT||PROSPECTIVE|||||||
34138641|NCT03730961|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34138642|NCT00562276|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34138643|NCT03434431|||COHORT||CROSS_SECTIONAL|||||||
34138644|NCT05014464|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138645|NCT00134654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138646|NCT02545660|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138647|NCT01856049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138648|NCT01358812|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138649|NCT01637363|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34138650|NCT01713283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138651|NCT04074018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants are assigned to one of two groups, using computerized randomization, for the duration of the study in each center.|f|f|f|t
34138652|NCT04081753|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Interventional group will be compared with historic group of patients||||
34138653|NCT01457170|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34138654|NCT01461928|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138655|NCT02429492|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34138656|NCT01328535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138657|NCT06527248|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|One group will receive nitrate-rich beetroot juice and the other group will receive nitrate-depleted beetroot juice (as placebo) during the training period, on the background of a low-nitrate diet and an otherwise unaltered lifestyle. All products will be obtained from the same supplier (James White Drinks Ltd., UK). The nitrate-depleted beetroot juice is generated for research purposes only. The two juices will be indistinguishable by taste, color, smell and packaging. The investigators involved in the data acquisition and analysis will be blind to the trial allocation until the study has been completed and all analyses have been performed.|Prospective, mono-center, randomized, double-blind, placebo-controlled, parellel-group study|t|f|t|t
33829092|NCT02941419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829093|NCT01603771|||CASE_CONTROL||PROSPECTIVE|||||||
33829094|NCT03104777|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Parents and pupils will not be informed that their school is taking part in this research or that anonymous photographs will be taken of the contents of the lunch boxes brought into school by children in years 3 - 6.~Written consent was obtained from the Head Teacher in all participating schools.~Providing parents with information about the study is likely to change their behaviour and it will not be possible to assess whether the intervention itself has had an effect."|cluster randomised controlled trial|t|f|f|f
33829095|NCT02906475|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33829096|NCT04735913|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829097|NCT05023200|||COHORT||PROSPECTIVE|||||||
34138658|NCT01170065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138659|NCT01703689|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34138660|NCT04552639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|There is an external statistician who will assess the outcomes.||f|f|f|t
34149838|NCT02880527|||COHORT||PROSPECTIVE|||||||
34149839|NCT06137768|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149840|NCT05257343|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, double-blind, parallel, placebo-controlled, 8-week intervention clinical study.|t|f|f|t
34149841|NCT00565799|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149842|NCT04780789|||COHORT||PROSPECTIVE|||||||
34149843|NCT01530607|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149844|NCT01497613|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33829098|NCT04047771|NA|SEQUENTIAL||TREATMENT||NONE||||||
33829099|NCT02726035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829100|NCT01586975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829101|NCT06511518|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829102|NCT04071509|NA|SINGLE_GROUP||OTHER||NONE||||||
33829103|NCT00003423||||TREATMENT||||||||
33829104|NCT04232800|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Treatment and placebo capsules will be identical, and will be identified with each participants unique randomization number provided by the VA pharmacy. This will ensure blinding until study completion. Neither participants nor any study or treatment team members will know the group allocation.|Participants will be randomized to receive either riboflavin or an identical inert placebo.|t|t|t|t
33829105|NCT02073942|||CASE_ONLY||PROSPECTIVE|||||||
33829106|NCT00233753|NON_RANDOMIZED|||TREATMENT||||||||
33829107|NCT02332083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138661|NCT04092881|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Comparable sides of striae are randomly allocated to one of the treatment modalities in a randomized table technique.|"* Written informed consent is to be obtained from each participant.~* Detailed history taking including onset, course, duration of the disease and received medications.~* Serial digital photography before and after each session and three months after sessions.~* Clinical assessment to determine the severity of SD using modified Davey's visual score.~* Comparable sides of striae are randomly allocated to one of the treatment modalities in a randomized table technique.~* Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® Accelera mode) for one side and 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) on the other. Sessions are separated by one month interval plus three months for clinical follow up.~* Assessment using high frequency skin ultrasound before session, before 4th session and 3 months after last session."|t|t|t|t
34138662|NCT06600633|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Three-period crossover study will include 30 subjects who will test three formulations with diferent melatonin dosages (placebo product without melatonin, and two products with different melatonin levels). Subjects will have 2 week intervention with each of the tested formulations with 2 week wash-out.|t|t|t|t
33829108|NCT01134380|||CASE_CONTROL||PROSPECTIVE|||||||
34138663|NCT06607328|||OTHER||CROSS_SECTIONAL|||||||
34138664|NCT04308434|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138665|NCT05565573|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138666|NCT01746121|||FAMILY_BASED||CROSS_SECTIONAL|||||||
33829109|NCT00000959||PARALLEL||TREATMENT||||||||
34138667|NCT04577716|||COHORT||PROSPECTIVE|||||||
34138668|NCT01809145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138669|NCT04000308|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be performed in a 1:1 ratio using a computer generated randomization sequence. A sealed opaque envelope containing the study number will opened by an anesthetist nurse who will not be involved in the study. This anesthetist nurse will prepare the study medication and label the syringes with a unique study number which will be used to identify the study medication and will be revealed only on completion of data collection at the end of the study. The anesthetists, obstetricians, nurses who will be involved in the study, parturients, and other healthcare providers who will be involved in postoperative care will be blinded to group allocation.|Single-center, randomized, double-blind trial|t|t|t|t
34138670|NCT03730831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138671|NCT01813552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138672|NCT00986401|RANDOMIZED|CROSSOVER||||NONE||||||
34138673|NCT03474848|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138674|NCT02046226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138675|NCT03018418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138676|NCT01177748|||COHORT||PROSPECTIVE|||||||
34138677|NCT05676151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34138678|NCT01415609|||CASE_ONLY||PROSPECTIVE|||||||
34138679|NCT02867813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138680|NCT06606223|||COHORT||PROSPECTIVE|||||||
34138681|NCT03546595|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138682|NCT01516580|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138683|NCT02436707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138684|NCT04480190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138685|NCT01491386|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138686|NCT04478916|||COHORT||PROSPECTIVE|||||||
34138687|NCT00527683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138688|NCT02885740|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34138689|NCT02613117|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138690|NCT04465032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded RCT, randomization by Dutch Donor Feces Bank|Double-blinded randomized controlled trial, randomization 1:1 to allogenic and autologous gut microbiome transplantation|t|t|t|t
34138691|NCT01933438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138692|NCT05319899|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This was single-center, open-label, randomized, 3-period, 3-treatment, 6-sequence crossover study.||||
34138693|NCT01082874|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34138694|NCT06597994|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34138695|NCT03082534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open-label, non-randomized, multi-arm phase II trial of pembrolizumab combined with cetuximab for patients with recurrent/metastatic head and neck squamous cell carcinoma~1. Cohort 1 (PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve): clinical efficacy defined as overall response rate.~2. Cohort 2 (PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve): clinical efficacy defined as overall response rate.~3. Cohort 3 (PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory): clinical efficacy defined as overall response rate.~4. Cohort 4 (cutaneous HNSCC): clinical efficacy defined as overall response rate."||||
34138696|NCT04782050|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients recruited will receive routine care for liver assessment followed by an exam using the device subject of the research.||||
33829110|NCT03809286|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|active vs. sham stimulation|t|t|t|f
34138697|NCT06153277|||CASE_CROSSOVER||PROSPECTIVE|||||||
34138698|NCT05974475|||COHORT||PROSPECTIVE|||||||
34138699|NCT05062304|||COHORT||RETROSPECTIVE|||||||
33829111|NCT01688453|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33829112|NCT02483845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829113|NCT01589549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829114|NCT03565692|||COHORT||RETROSPECTIVE|||||||
34138700|NCT06115382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138701|NCT06604546|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138702|NCT05201430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138703|NCT06188650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138704|NCT06174688|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829115|NCT04866433|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33829116|NCT05549999|||COHORT||PROSPECTIVE|||||||
33829117|NCT03918447|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33829118|NCT01257412|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829119|NCT04633785|||OTHER||CROSS_SECTIONAL|||||||
33829120|NCT03772509|RANDOMIZED|PARALLEL||OTHER||SINGLE||Participants were randomized to one of two introduction and consent modes: 1) computer-assisted telephone interviews, or 2) interactive voice response.|f|f|f|t
33829121|NCT03481556|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829122|NCT01607931|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33829123|NCT04683432|||COHORT||CROSS_SECTIONAL|||||||
33829124|NCT00004758|RANDOMIZED|||TREATMENT||||||||
33829125|NCT02643511|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829126|NCT02741713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829127|NCT04759950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization sequence is concealed (blinded) from research personnel, so that the investigators are not aware of whether a particular subject has been randomized to one of the intervention groups or to the active control group.|141 participants at 3 to 60 months after stroke are randomly allocated to one of three arms: The first group (n=47) receives computer-based cognitive training (CCT) combined with a multicomponent physical exercise program. The second group (n=47) receives CCT combined with mindfulness-based stress reduction therapy. Finally, the third group (n=47), as an active control group, receives only CCT.|f|f|t|t
33829128|NCT00779064|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829129|NCT04162236|||CASE_CONTROL||PROSPECTIVE|||||||
33829130|NCT04249518|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
33829131|NCT04266002|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective Pilot study, open-label, multicenter in the Ile-de-France||||
33829132|NCT04296422|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829133|NCT06002321|||CASE_ONLY||PROSPECTIVE|||||||
33829134|NCT01927822|||CASE_CONTROL||RETROSPECTIVE|||||||
33829135|NCT04964245|NA|SINGLE_GROUP||OTHER||NONE||||||
33829136|NCT00429078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829137|NCT01800539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829138|NCT03199768|||COHORT||PROSPECTIVE|||||||
33829139|NCT02180347|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33829140|NCT03382288|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829141|NCT06442163|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829142|NCT01913626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829143|NCT04678713|RANDOMIZED|PARALLEL||TREATMENT||NONE|As the participants receive a specific diet, and have to buy their gloceries themself, it is not possible to mask what kind of diet they consume. They will be randomised into what kind of diet they receive.|"The participants will be separated into 2 groups by stratified randomization consuming either a Fat rich diet (HiFAT) or a carbohydrate rich diet (HiCHO) (n=40 in total).~When all 40 participants have completed the study, the results will be analysed by separating the two groups into two subgroups based on the median of the MFO"||||
33829144|NCT02824497|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33829145|NCT02765386|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829146|NCT02198261|||CASE_CONTROL||PROSPECTIVE|||||||
33829147|NCT00433797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829148|NCT01347268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829149|NCT02296203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829150|NCT01564953|||||CROSS_SECTIONAL|||||||
33829151|NCT01625676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829152|NCT03245762|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This will be a double-blinded study, as no studies to date have compared this treatment in infants with placebo. Board-certified speech and language pathologist who will be blinded to the treatment arm of each patient.||f|t|f|t
33829153|NCT05896111|RANDOMIZED|PARALLEL||TREATMENT||NONE||pilot testing to get sample.||||
33829154|NCT04959461|RANDOMIZED|PARALLEL||PREVENTION||NONE||Teen participants will be randomized to a single-session, self-guided web-intervention called webCHAT or usual care after completing an online baseline survey. Participants will complete follow-up surveys 3 and 6-months after baseline.||||
33829155|NCT02062112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34138705|NCT05437562|NA|SINGLE_GROUP||OTHER||NONE||Collect feasibility criteria for recruitment, retention, and data collection.||||
34138706|NCT05462444|||COHORT||PROSPECTIVE|||||||
34138707|NCT01321216|||COHORT||PROSPECTIVE|||||||
34138708|NCT03464357|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The study will compare the extent of neuronal activation at the visual cerebral cortex between a group with photophobia related to dry eye syndrome and a group of asymptomatic patients (without dry eye and no photophobia) with an MRIf.||||
34138709|NCT05120765|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138710|NCT04599023|||COHORT||PROSPECTIVE|||||||
33829156|NCT03247361|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829157|NCT00210678|||CASE_CONTROL||PROSPECTIVE|||||||
33829158|NCT02235623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829159|NCT00142038|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829160|NCT05750277|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829161|NCT03016949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829162|NCT05885269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829163|NCT01280422|||CASE_ONLY||RETROSPECTIVE|||||||
33829164|NCT02622256|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829165|NCT00215722|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829166|NCT00210964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33829167|NCT00837395|||COHORT||PROSPECTIVE|||||||
33829168|NCT05554926|NA|SINGLE_GROUP||TREATMENT||NONE||"Up to 8 subjects will be enrolled to ensure that 6 subjects complete the study. Subjects will be admitted into the study site on Day -1.~On the morning of Day 1, all subjects will receive a single oral dose of 2 mg containing approximately 100 μCi of \[4-14C\]AEF0117 approximately 1 hour after completion of a low-fat breakfast.~Subjects will reside at the study site from Day -1 through Day 28 and will be discharged on Day 28"||||
33829169|NCT00833898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33829170|NCT01904136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829171|NCT02720588|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138711|NCT00368615|||CASE_CONTROL||PROSPECTIVE|||||||
34138712|NCT02476084|||CASE_CONTROL||PROSPECTIVE|||||||
34138713|NCT04233307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
34138714|NCT00460759|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138715|NCT02780635|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33829172|NCT04882852|||OTHER||CROSS_SECTIONAL|||||||
33829173|NCT06279299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829174|NCT05329233|||COHORT||PROSPECTIVE|||||||
33829175|NCT02478385|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33829176|NCT00767247|||CASE_CONTROL||PROSPECTIVE|||||||
33829177|NCT06339710|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829178|NCT01921777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829179|NCT01228721|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829180|NCT00315666|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33829181|NCT04531813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829182|NCT04262778|||COHORT||PROSPECTIVE|||||||
33829183|NCT04830761|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||In this study, the MOST methodology (multiphase optimization strategy; Collins et al., 2007) will be applied. First, the most effective intervention components for specific target groups will be determined, which is called the optimisation phase. To this end, the investigators run a parallel randomized trial with nine intervention groups that investigates three interventions modules in different order. After this optimisation phase, the final intervention will be tested against an active control group (basic app content) in a randomized controlled trial, which is called the evaluation phase.|t|t|t|f
33829184|NCT03216941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|care provider were masked with regard to the patient's treatment assignment, and patients were instructed not to reveal their current treatment to the investigators.|double-blind controlled trial to compare the effectiveness of intramuscular olanzapine and ketamine as first medication(s) used to treat patients with agitation caused by psychosis.|f|t|f|f
33829185|NCT01430208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829186|NCT04338230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A Randomized Controlled Trial||||
33829187|NCT03842631|||COHORT||PROSPECTIVE|||||||
33829188|NCT01863797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829189|NCT06471608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829190|NCT06009445|||COHORT||PROSPECTIVE|||||||
33829191|NCT06320327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The research participant's and research personnel conducting the testing will be blinded to who is in the CBD and placebo groups throughout the study. Those in Group 3 (the control group) will be aware that they are in the control group, as they will be skipping the steps involving cream application. The protocols for Group 1 and Group 2 will be identical and the respective cream will be made available to the testers and participants in identical containers.||t|f|f|t
33829192|NCT05665322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829193|NCT05564546|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This is a prospective, longitudinal study, of exposed/non-exposed type, descriptive, comparative and monocentric||||
33829194|NCT06379698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829195|NCT04525456|NA|SINGLE_GROUP||TREATMENT||NONE||single-centre, one-arm, prospective study||||
33829196|NCT05076136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829197|NCT02580968|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829198|NCT03167177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829199|NCT00321321|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829200|NCT03867552|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A total of 4 conditions will be assessed: endometriosis, myoma, hysterectomy and colpopexy. For every group of patients receiving the altered gas, a group of controls which are patients receiving the standardized gas will be assessed to compare the results in a double-blinded fashion|f|f|f|t
33829201|NCT05373225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829202|NCT03783858|NA|SINGLE_GROUP||OTHER||NONE||||||
33829203|NCT06133868|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33829204|NCT03587519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829205|NCT01167192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829206|NCT01292577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829207|NCT04223128|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||Group M and group D are parallel and compared to group C|t|t|f|f
33829208|NCT01304771|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33829209|NCT03460847|||COHORT||PROSPECTIVE|||||||
33829210|NCT05068271|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33829211|NCT03478046|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829212|NCT01108042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829213|NCT05499143|||CASE_ONLY||CROSS_SECTIONAL|||||||
33829214|NCT00637832|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829215|NCT05748678|NA|SINGLE_GROUP||TREATMENT||NONE||Wearing apparell similar to cycling shorts which compresses the target area of the buttocks and thighs||||
33829216|NCT00855322|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829217|NCT04660578|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group||||
34138716|NCT00866034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829218|NCT02073721|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33829219|NCT00233389|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34138717|NCT04761679|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single-blind design||t|f|f|f
33829220|NCT05310747|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||"Eligible individuals will be randomized to one of 4 groups:~1. Artwork present + Social connection prime high~2. Artwork present + Social connection prime low~3. Artwork absent + Social connection prime high~4. Artwork absent + Social connection prime low~5. Hanging control group - no exposure to any independent variables (i.e. artwork: present or absent; social connection prime: high or low)"|t|f|t|t
33829221|NCT06213519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829222|NCT04012723|NA|SINGLE_GROUP||OTHER||NONE||||||
33829223|NCT00282477|||DEFINED_POPULATION||OTHER|||||||
33829224|NCT04785430|||OTHER||PROSPECTIVE|||||||
34138718|NCT06078202|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34138719|NCT02725593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138720|NCT02034682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138721|NCT00737711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829225|NCT00176410|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33829226|NCT01313624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829227|NCT01154270|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829228|NCT00018759|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33829229|NCT02529371|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829230|NCT03033758|||OTHER||PROSPECTIVE|||||||
33829231|NCT02447432|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33829232|NCT01686074|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33829233|NCT03920735|||COHORT||RETROSPECTIVE|||||||
33829234|NCT03618810|||COHORT||PROSPECTIVE|||||||
33829235|NCT05351489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double- blind||t|t|t|f
33829236|NCT05046249|||COHORT||CROSS_SECTIONAL|||||||
33829237|NCT03991598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||This is a step-wedge clinical trial.|f|f|f|t
33829238|NCT06478134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|TriMix tear substitute and 0.15% HA tear substitute are transparent, with no special smell and the bottles were identical in appearance such that patients, investigators and care provider were masked to treatment assignment.|Patients were instructed to instill 1 drop TriMix tear substitute or 0.15% HA tear substitute into each eye 3 times per day for 6 months. HA-based tear substitutes can reduce tear film hyperosmolarity and are effective in treating DED. Therefore, 0.15% HA tear substitute was selected as a suitable comparator.|t|t|t|t
33829239|NCT00263484|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829240|NCT03467698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Participants will be randomly assigned to one of two groups: (1) active tDCS (2) Sham tDCS.|t|f|f|t
33829241|NCT05097209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829242|NCT04156347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829243|NCT03049098|||COHORT||PROSPECTIVE|||||||
33829244|NCT05158283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829245|NCT04303546|||OTHER||CROSS_SECTIONAL|||||||
33829246|NCT01200927|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829247|NCT00420225|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829248|NCT00511277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829249|NCT01004185|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829250|NCT05219578|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33829251|NCT03756168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829252|NCT04469062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829253|NCT06547671|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Not randomized clinical trial in parallel groups||||
33829254|NCT05158023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829255|NCT03921242|||COHORT||RETROSPECTIVE|||||||
33829256|NCT00541671|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33829257|NCT04205955|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33829258|NCT00369603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829259|NCT05235841|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized two arm (intervention and usual care) clinical trial||||
33829260|NCT04234503|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33829261|NCT00223210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829262|NCT04786756|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||RANDOMISED DOUBLE BLINDED INTERVENTIONAL|t|f|t|t
33829263|NCT01919398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829264|NCT02137499|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829265|NCT03112408|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33829266|NCT05851040|||COHORT||OTHER|||||||
33829267|NCT05738447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829268|NCT05001997|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|All yogurt labels will be covered or masked with corrugated sleeves|Single-blinded, randomised crossover study|t|f|f|f
33829269|NCT04307641|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829270|NCT02878759|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective single arm intervention||||
33829271|NCT03689439|||COHORT||PROSPECTIVE|||||||
33829272|NCT05380128|||CASE_CONTROL||PROSPECTIVE|||||||
33829273|NCT00320814|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829274|NCT00718393|||CASE_ONLY||CROSS_SECTIONAL|||||||
33829275|NCT01765452|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829276|NCT00428025|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33829277|NCT02719262|NA|SINGLE_GROUP||PREVENTION||NONE|Blinded by lab. persons who analyzed biomarkers|Install local ventilation or not||||
33829278|NCT05225636|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, prospective clinical trial, under conditions of routine, open-label clinical practice, with the main objective evaluated by an independent investigator who was not blinded to the treatment received. The study will be single-center.||||
33829279|NCT00192426|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34138722|NCT01316757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138723|NCT02858986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829280|NCT02849405|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33829281|NCT00338949|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829282|NCT01817712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829283|NCT04609839|||CASE_ONLY||PROSPECTIVE|||||||
33829284|NCT00155142|||DEFINED_POPULATION||OTHER|||||||
33829285|NCT05869032|||COHORT||CROSS_SECTIONAL|||||||
33829286|NCT05370547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829287|NCT03924947|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33829288|NCT04932226|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Each participant is own control. Each participant will undergo all four interventions in random order.||||
33829289|NCT03739255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829290|NCT01717170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829291|NCT02571998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829292|NCT01585441|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829293|NCT04560478|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||single center, parallel, randomized clinical trial|f|f|f|t
33829294|NCT00174798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829295|NCT02749136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829296|NCT00634920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829297|NCT04011423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blind (Outcomes Assessor)||f|f|f|t
33829298|NCT04882033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829299|NCT00591409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829300|NCT06370117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||It is a randomized controlled experimental study.||||
33829301|NCT04068051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829302|NCT06468267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829303|NCT04991350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829304|NCT04192539|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|f|t
33829305|NCT04302051|||COHORT||PROSPECTIVE|||||||
33829306|NCT04457544|||COHORT||OTHER|||||||
33829307|NCT04225000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Control Trail|t|f|f|f
33829308|NCT00509457|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829309|NCT04141800|||COHORT||PROSPECTIVE|||||||
33829310|NCT03665753|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Dose escalation study.|t|t|t|t
33829311|NCT01536873|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829312|NCT03299127|RANDOMIZED|PARALLEL||TREATMENT||NONE|self-report serves as outcomes, patients are not masked|randomized-controlled trial, wait-list control condition||||
33829313|NCT04605198|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be recruited from two sites. To avoid contamination between subjects living at the sites, using a quasi-randomized method, all participants at each site will receive the same treatment per cohort. Sites will alternate between the assignment of treatment (modified-MBSR) or control (health promotion class) in sequential cohorts to account for between site differences.||||
33829314|NCT01101334|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829315|NCT00543101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829316|NCT03087409|||COHORT||RETROSPECTIVE|||||||
33829317|NCT00694733|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33829318|NCT03239418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants in treatment and sham group undergo all of the same procedures except a sham NMES treatment is provided to the control group. Only the treating clinician is aware of group allocation. The investigator and outcomes assessor are unaware of group allocation.|Active treatment vs. Sham control|t|f|t|t
33829319|NCT05579665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829320|NCT03571451|||COHORT||PROSPECTIVE|||||||
33829321|NCT01077583|||CASE_ONLY||PROSPECTIVE|||||||
33829322|NCT06215417|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients and research assistants collecting data will be unaware of the treatment assigned until the completion of the study.|This study is designed as a parallel group 1:1 randomized controlled trial|t|f|f|t
33829323|NCT00115336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829324|NCT05895968|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829325|NCT04662983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829326|NCT03108638|||COHORT||PROSPECTIVE|||||||
33829327|NCT06342245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This is a multicentre prospective randomized, double-blinded, placebo-controlled superiority trial with two parallel groups and a 1:1 allocation ratio to investigate the effectiveness of radiofrequency coblation micro-tenotomy for patients with Achilles tendinopathy. All participants will be randomized into two groups: the intervention group (n=24; radiofrequency coblation micro-tenotomy + endoscopic Achilles debridement) and the control group (n=24; endoscopic Achilles debridement only).~Investigators will obtain written consent from all participants before the commencement of this study."|t|f|f|f
33829328|NCT04180306|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33829329|NCT00066378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829330|NCT02751801|||CASE_ONLY||RETROSPECTIVE|||||||
33829331|NCT00610025|NON_RANDOMIZED|PARALLEL||||NONE||||||
33829332|NCT05514171|||COHORT||PROSPECTIVE|||||||
33829333|NCT01674673|||CASE_CONTROL||PROSPECTIVE|||||||
33829334|NCT06208878|||COHORT||PROSPECTIVE|||||||
33829335|NCT00271986|||CASE_CONTROL||PROSPECTIVE|||||||
33829336|NCT02841345|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33829337|NCT03023423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829338|NCT02592499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33829339|NCT03167047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33829340|NCT02592681|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33829341|NCT01359683|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829342|NCT03530462|||CASE_CONTROL||RETROSPECTIVE|||||||
33829343|NCT01171183|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829344|NCT03607617|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33829345|NCT01966978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829346|NCT05441098|||OTHER||RETROSPECTIVE|||||||
33829347|NCT05238155|||COHORT||RETROSPECTIVE|||||||
33829348|NCT05870228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829349|NCT05277077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the double blinded study (assessor and statistician)|Randomized|f|f|t|t
33829350|NCT00022815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829351|NCT01168245|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829352|NCT02160964|||COHORT||PROSPECTIVE|||||||
33829353|NCT03520062|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829354|NCT00141362|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829355|NCT03788122|NA|SINGLE_GROUP||OTHER||NONE||||||
33829356|NCT03632005|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829357|NCT03140566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33829358|NCT01560871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829359|NCT03582345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||cohort prospectic, open, non randomized||||
33829360|NCT02895321|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840584|NCT01871051|||OTHER||RETROSPECTIVE|||||||
34138724|NCT02041975|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34138725|NCT03729258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138726|NCT00571870|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33829361|NCT05154240|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||"This is a Phase 1, randomized, 2-part (Part A and B), first-in-human, double-blind, placebo controlled single and multiple ascending dose study designed to assess the safety, tolerability, and PK of INS018_055 when administered as oral doses to healthy subjects. Additionally, this study will investigate the impact of food on the PK of INS018_055.~Part A (Single Ascending Dose \[SAD\]):~Food Effect Assessment (Cohort 4 in Part A only):~Part B (Multiple Ascending Dose \[MAD\]):"|t|f|t|f
33829362|NCT02419209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829363|NCT05817474|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829364|NCT02972242|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33829365|NCT00245245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829366|NCT00579449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829367|NCT06055842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829368|NCT00068978|||DEFINED_POPULATION||OTHER|||||||
33829369|NCT03171532|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829370|NCT04888117|||COHORT||PROSPECTIVE|||||||
33829371|NCT02459405|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829372|NCT01449747|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829373|NCT04312412|||COHORT||RETROSPECTIVE|||||||
33829374|NCT02101983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829375|NCT04263805|RANDOMIZED|PARALLEL||OTHER||NONE|It is not possible to blind participants to the intervention. However, participants will be blinded to the study hypothesis.|||||
33829376|NCT04672798|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be masked to the intervention condition at follow-up assessment time points.|This study will use a parallel study design, where participants are randomized into two groups, BRITEPath or TAU, and will receive interventions in parallel.|f|f|f|t
33829377|NCT04632212|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33829378|NCT00097708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33829379|NCT00489645|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
33829380|NCT04085705|||COHORT||PROSPECTIVE|||||||
33829381|NCT01610830|||COHORT||PROSPECTIVE|||||||
33829382|NCT03889873|RANDOMIZED|FACTORIAL||OTHER||SINGLE|The PI, the project coordinator, and experimenters will not know which participants have been assigned to each condition. Outcomes are assessed via computer/online survey. There is no human outcome assessor in this study.|Participants are randomly assigned to a condition to receive one of eight writing prompt variants in a 2x2x2 study design. There is also a within subjects component as participants complete the same writing prompt 3 times (once per week over a 3-week period).|f|f|t|f
33829383|NCT03779477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33829384|NCT01005368|||CASE_ONLY||RETROSPECTIVE|||||||
33829385|NCT04035330|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829386|NCT04438382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829387|NCT02014883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829388|NCT03700372|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with paroxysmal atrial fibrillation undergoing cardiac surgery and meeting all protocol inclusion/exclusion criteria will be treated with the IOWA Approach Cardiac Ablation System.||||
33829389|NCT04363710|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829390|NCT03845023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829391|NCT04226898|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829392|NCT04573556|||COHORT||PROSPECTIVE|||||||
33829393|NCT02648711|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829394|NCT01316887|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33829395|NCT05010668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829396|NCT02215213|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33829397|NCT04018885|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829398|NCT00713206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829399|NCT03257345|||CASE_ONLY||PROSPECTIVE|||||||
33829400|NCT00510198|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33829401|NCT02932085|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33829402|NCT06546423|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|To ensure the unbiased clinical evaluation of subjects, all participants' parents/guardians and all staff involved in clinical assessment will remain blinded through completion. To assess the magnitude and duration of vaccine virus replication and ensure continued suitability of these vaccines for this population in this Phase 1 trial, a Scientific Investigator who is not involved in clinical assessment of trial participants, will be unblinded once the final participant in each randomization block has completed the assessment phase on Day 28. Should any concerns arise from this review, these will be shared in a blinded fashion with the Medical Monitor and Sponsor Clinical Safety Office for guidance and assistance. Additionally, this information will be reviewed unblinded by the DSMB in collaboration with the Scientific Investigator and any involved non-study-team consultants before any additional dosing or enrollments proceed.|Participants will be randomized to receive B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine or placebo in a 2:2:1 ratio.|t|t|t|t
33829403|NCT03807817|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33829404|NCT04052035|||OTHER||PROSPECTIVE|||||||
33829405|NCT06122454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829406|NCT04865510|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|systemic random sampling (block of four). Group A was the citrate group while group B was heparin- free method.|This study is a prospective,multicenter, open-label randomized trial|f|t|f|f
33829407|NCT02089438|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33829408|NCT03271749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It's impossible to mask the participants, care providers and investigators, because of the apparent differences in both techniques. For this reason the data analysis will be masked to avoid influences by the other participants during the analysis.|Randomized controlled Trial|f|f|f|t
33829409|NCT04458818|NA|SINGLE_GROUP||TREATMENT||NONE|No Masking. Patients in one arm are provided with prolene mesh implant, and is known by the patient, health care provider and the assessor.|The single group will be implanted with Prolene mesh made into Swiss rolls and placed in Laryngeal Window between the cartilage and inner periosteum,||||
33829410|NCT04228406|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829411|NCT03409562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138727|NCT02027818|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138728|NCT03073018|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|t|f
34138729|NCT05928117|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Experimental and control groups|t|f|f|f
34138730|NCT02581956|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138731|NCT06605274|RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking used in this study|Prospective parallel two group unmasked prevention study||||
34138732|NCT04880044|NA|SINGLE_GROUP||SCREENING||NONE||||||
34138733|NCT01100710|||CASE_ONLY||CROSS_SECTIONAL|||||||
34138734|NCT03865108|NON_RANDOMIZED|PARALLEL||OTHER||NONE||The two arms are not randomized under this sub study but carried over from the existing TOPS trial.||||
34138735|NCT05849935|||COHORT||PROSPECTIVE|||||||
34138736|NCT05109858|||COHORT||OTHER|||||||
34138737|NCT06563180|||OTHER||CROSS_SECTIONAL|||||||
34138738|NCT04442126|NA|SEQUENTIAL||TREATMENT||NONE||||||
34138739|NCT05159492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open-label randomised controlled trial, in two parallel groups with a 1:1 allocation ratio|t|f|f|f
34138740|NCT01330628|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138741|NCT00198393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138742|NCT05272137|||COHORT||PROSPECTIVE|||||||
33829412|NCT01832662|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34138743|NCT03038607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138744|NCT06608771|||COHORT||RETROSPECTIVE|||||||
34138745|NCT02200419|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138746|NCT02563535|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138747|NCT05058573|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|it was calculated that 80% power could be achieved at a 95% confidence level when at least 66 people (at least 22 people for each group) were taken into the study. Therefore, our study Decocking TMJ+myofascial release+ a classic medical treatment (N= 25), TMJ Decocking+ classical medical treatment (N= 25), just the usual medical therapy (N=25) Group 3 group to be 75 individuals will be included. Assessments will be made before and after treatment. Treatment will be carried out in the form of 8 sessions in an average of 20-30 minute sessions 2 days a week for 4 weeks.|Randomized controlled study|t|f|f|f
34138748|NCT02281474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138749|NCT01175434|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138750|NCT03117790|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34138751|NCT00346450|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138752|NCT06489158|||COHORT||PROSPECTIVE|||||||
34138753|NCT04886544|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138754|NCT04140695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138755|NCT04206254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138756|NCT05771636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138757|NCT02163967|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Individual calculating heart rate and heart rate variability from ECG recordings was blind to dose of stimulation. Individual collecting side effect information was not blind to dose of stimulation.||t|f|f|t
34138758|NCT01748136|||COHORT||PROSPECTIVE|||||||
34138759|NCT00394251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138760|NCT04485611|NA|SINGLE_GROUP||PREVENTION||NONE||The intervention will consist of a period of supervised multimodal prehabilitation prior to high-risk surgery (aerobic and resistance training sessions 3 times/week plus nutritional support) delivered using telehealth technology, and similar sessions resuming after surgery and for up to 6 weeks (rehabilitation).||||
34138761|NCT06517251|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Assessor-blinded phase III randomized controlled trial with a parallel design|f|f|f|t
34138762|NCT05879770|||COHORT||RETROSPECTIVE|||||||
34138763|NCT00998673|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138764|NCT04127357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138765|NCT05179668|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138766|NCT06604286|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34138767|NCT00831740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138768|NCT00945529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138769|NCT01465217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138770|NCT03761888|||OTHER||PROSPECTIVE|||||||
34138771|NCT06565858|||COHORT||PROSPECTIVE|||||||
34138772|NCT04762043|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34138773|NCT06443177|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138774|NCT03846726|||COHORT||RETROSPECTIVE|||||||
34138775|NCT05401695|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138776|NCT02349191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138777|NCT04138914|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138778|NCT05609877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participant, care provider, investigator and outcomes assessor will initially be blinded to treatment with analgesia or placebo (isotonic saline solution). Need for additional doses of analgesia will be decided according to section Interventions and will not be blinded. To reduce risk of interpretation bias, primary analyses will be performed blinded to the group allocation (Group A compared with Group B) and will be presented to all authors, who will agree on two alternative written interpretations before the randomisation code will be unblinded."|The randomisation will be stratified according to trial site and gestational age (GA) less than 28 or 28+ gestational weeks. Both groups will receive treatment by experienced teams of neonatal nurses and neonatologists. Both groups will receive the non-pharmacological approach as the basic treatment (part of routine).|t|t|t|t
34138779|NCT05087927|||OTHER||PROSPECTIVE|||||||
34138780|NCT02520258|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34138781|NCT02342717|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138782|NCT00005393|||COHORT||PROSPECTIVE|||||||
34138783|NCT05721365|||OTHER||CROSS_SECTIONAL|||||||
34138784|NCT06606938|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The intervention group will receive FMT while the control group will receive 0.9% sodium chloride solution (normal saline) as placebo.|t|f|f|t
34138785|NCT06581614|||CASE_ONLY||PROSPECTIVE|||||||
34138786|NCT06009237|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34138787|NCT02273076|||CASE_CONTROL||PROSPECTIVE|||||||
34138788|NCT03803670|||CASE_ONLY||RETROSPECTIVE|||||||
34138789|NCT06521515|||COHORT||RETROSPECTIVE|||||||
34138790|NCT05755256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This pilot study is a monocentric, randomized, double-blind, placebo-controlled, parallel-arm study. The product allocation will be performed using a dynamic randomization algorithm designed to minimize imbalance between the 2 arms, within the strata defined by 3 factors: age, Global Acne Evaluation (GEA) score and sex.|t|t|t|t
34138791|NCT01646645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138792|NCT03806556|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The investigational pharmacy will be notified when patients enroll on trial. When participants meet criteria for randomization, this will be completed by the Investigational Pharmacy. The pharmacy will prepare and distribute to floor nursing staff all doses of tranexamic acid (available in IV form as a colorless liquid) or placebo (as an equal volume of normal saline). Labels will not carry identifiers of which study arm the enrolled patient is on.|This trial is designed as a prospective, randomized, controlled, blinded (patient, caregiver, physician, assessor) trial with two parallel groups and a primary endpoint of feasibility and safety. Randomization will be performed as block randomization with a 1:1 allocation within blocks of size four.|t|t|t|t
34138793|NCT05120973|||COHORT||PROSPECTIVE|||||||
34138794|NCT04972708|||COHORT||PROSPECTIVE|||||||
34138795|NCT04303078|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34138796|NCT03692377|||COHORT||PROSPECTIVE|||||||
34138797|NCT02052336|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34138798|NCT01774253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138799|NCT02987907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138800|NCT01909180|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138801|NCT03438955|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138802|NCT01310179|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138803|NCT03554057|||CASE_CONTROL||PROSPECTIVE|||||||
34138804|NCT06511674|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Cancer patients and Healthy Volunteers||t|f|f|f
34138805|NCT02105844|||COHORT||PROSPECTIVE|||||||
34138806|NCT04454216|||COHORT||OTHER|||||||
34138807|NCT01685801|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34138808|NCT05971030|NA|SINGLE_GROUP||TREATMENT||NONE||case series||||
34138809|NCT00846417|||CASE_CONTROL||PROSPECTIVE|||||||
34138810|NCT04920630|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34138811|NCT06604923|||OTHER||OTHER|||||||
34138812|NCT04048707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138813|NCT03746600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized waitlist-controlled trial||||
34138814|NCT01891799|||OTHER||PROSPECTIVE|||||||
34138815|NCT03193814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138816|NCT00918164|RANDOMIZED|CROSSOVER||||NONE||||||
34138817|NCT03479177|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34138818|NCT02154100|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34138819|NCT05538832|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator will not know the treatment condition until the trial is completed. Participants will not be notified of which group they are assigned. The study coordinator will be aware of assignment but will not complete any outcomes assessments--these will be self-report.||t|f|t|f
34138820|NCT03468816|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138821|NCT05347225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138822|NCT04907773|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Potassium measurement||||
34138823|NCT03564522|||CASE_CONTROL||PROSPECTIVE|||||||
34138824|NCT01814098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138825|NCT06256666|||CASE_ONLY||PROSPECTIVE|||||||
34138826|NCT02609750|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138827|NCT06219083|||COHORT||PROSPECTIVE|||||||
34138828|NCT05774223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will not be informed of the type of stimulation|Healthy volunteers will receive iTBS two times with active or sham stimulation separated by one week to investigate the effect duration of iTBS on working memory|t|f|f|f
34138829|NCT03267667|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34138830|NCT01529983|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34138831|NCT00362583|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34138832|NCT02655523|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138833|NCT01983605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138834|NCT01880749|NA|SINGLE_GROUP||OTHER||NONE||||||
34138835|NCT03517514|||COHORT||PROSPECTIVE|||||||
34138836|NCT00574782|||||PROSPECTIVE|||||||
34138837|NCT01938508|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34138838|NCT02253563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138839|NCT04981366|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34138840|NCT06352892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138841|NCT06195969|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34138842|NCT05578638|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33829413|NCT02882841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829414|NCT01200485|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138843|NCT04040595|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Anthropometry:~* Baseline data including Height (m), Weight (kg), Waist (cm) and Hip (cm) circumference will be recorded.~* Skin fold measurements (mm) from biceps, triceps, subscapular, and suprailiac regions~* Detailed body fat measures will be obtained from the BodPodTM.~Medical history:~• including current medications and lifestyle information (smoking/alcohol).~Blood sample:~• Up to 20 ml venous blood sample for HbA1c and storage for analysis of biomarkers of adiposity.~Abdominal fat biopsy: for adipocyte measurements and store a sample for future analyses.~A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips."||||
34138844|NCT01322399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138845|NCT06102590|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34138846|NCT03783468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138847|NCT02142517|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829415|NCT01825317|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34138848|NCT04123912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138849|NCT01375803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34138850|NCT04177485|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34149502|NCT04804150|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|"The medical device will be active (plugged) or inactive (unplugged), but the patient nor the investigator won't know if the medical device is active(plugged) or inactive (unplugged).~After one-month accommodation period, patient will be randomly distributed into active or inactive vacuum 7 to 28 days phases with at least three phase change and a maximum of 50 days. The randomization will use a phase length ABAB randomization rather than block randomization commonly used in drug trials. However, because the patient has to come to the rehabilitation center at each phase change which would not allow the patient and the assessors to be blind to the next phase content, phases of a duration \>14, will be further randomized into two half-phases of the same content with a placebo visit between the two half-phases, in order to keep the blinding. All sequences containing 3 true transition of activation/inactivation of the medical device and up to 3 placebo transitions"|Multiple N-of-1 trial. : the principle is to evaluate intensively and prospectively a small group of subjects, each case being its own comparator||||
33829416|NCT00595647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829417|NCT03694262|NA|SINGLE_GROUP||TREATMENT||NONE||Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing||||
33829418|NCT03330171|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Participants receive measles vaccine as part of routine medical care at 6 and 12 months of age. Half of the participants will receive varicella vaccine at 18 months of age and the other half will receive hepatitis-A at 18 months of age. All vaccines are administered according to their approved dosages, formulations and indications.||||
33829419|NCT04759846|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Participants with hepatic impairment will be enrolled sequentially according to their severity.||||
33829420|NCT06383429|||COHORT||RETROSPECTIVE|||||||
33829421|NCT01361958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33829422|NCT04548297|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33829423|NCT04561167|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829424|NCT01628406|||CASE_CONTROL||PROSPECTIVE|||||||
33829425|NCT05544318|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomised controlled trial||||
33829426|NCT03305809|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829427|NCT05393622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829428|NCT00159198|||CASE_CONTROL||RETROSPECTIVE|||||||
33829429|NCT00231764|RANDOMIZED|PARALLEL||||NONE||||||
33829430|NCT04589403|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Pharmacist will be the only unmasked clinical staff as the preparer of the investigational product prior to infusion.|Sentinel dosing of two subjects followed by review of the data by the Data Monitoring Committee (DMC) will be performed prior to enrolling any additional subjects within a cohort. Groups of 3 subjects (2 active:1 placebo) each will be treated at each dose level; for a total of 15 subjects. Additional subjects may be added to any cohort if dose limiting toxicity (DLT) is observed for a maximum of up to 6 subjects per cohort. An additional 6 subjects may also be enrolled in an intermediate dose cohort between the dose level which exceeds the defined MTD and the previous defined dose level.|t|t|t|f
33829431|NCT05102539|||CASE_ONLY||RETROSPECTIVE|||||||
33829432|NCT01024283|||COHORT||PROSPECTIVE|||||||
33829433|NCT00846768||CROSSOVER||TREATMENT||||||||
33829434|NCT00610571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829435|NCT06151847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829436|NCT03696641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participant, outcome assessor double blind||t|f|f|f
33829437|NCT06183671|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double|Double-Blind, Placebo-Controlled, Multi-Part|t|t|t|t
33829438|NCT02542423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829439|NCT04012086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective controlled, parallel-group randomized study||||
33829440|NCT04658550|||COHORT||OTHER|||||||
33829441|NCT01949883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829442|NCT00037115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829443|NCT06454201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829444|NCT02401971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829445|NCT00025662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829446|NCT00727415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829447|NCT01965106|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33829448|NCT01263925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829449|NCT01185171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829450|NCT04255745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Primary investigator will be masked to the outcome data collection|permuted block randomization scheme,|f|f|t|f
33829451|NCT04257422|RANDOMIZED|PARALLEL||OTHER||NONE||Cluster randomized||||
33829452|NCT05937815|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829453|NCT02640170|||COHORT||PROSPECTIVE|||||||
33829454|NCT05286437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149503|NCT03908827|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor will be blinded to treatment group allocation|Randomized Controlled Trial|f|f|f|t
34149504|NCT00560495||||TREATMENT||NONE||||||
33829455|NCT01597583|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829456|NCT02930252|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34149505|NCT04946123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829457|NCT04038749|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33829458|NCT06180863|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm non-randomized pilot study||||
33829459|NCT02724293|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33829460|NCT00910260|||COHORT||PROSPECTIVE|||||||
33829461|NCT05432505|||COHORT||PROSPECTIVE|||||||
33829462|NCT05684666|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829463|NCT03146325|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33829464|NCT00998829|||CASE_ONLY||CROSS_SECTIONAL|||||||
33829465|NCT05688683|||OTHER||PROSPECTIVE|||||||
33829466|NCT05450523|||CASE_CONTROL||PROSPECTIVE|||||||
33829467|NCT01001962|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33829468|NCT02217488|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33829469|NCT00142688|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829470|NCT00129649|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33829471|NCT04414631|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label, parallel-group, controlled, multi-center clinical trial||||
33829472|NCT05612841|||COHORT||PROSPECTIVE|||||||
33829473|NCT01525498|||COHORT||PROSPECTIVE|||||||
33829474|NCT05678686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The physicians who will evaluate imaging methods will not know which arm they are in. In addition patricipants will not know which arm they are in.||t|f|f|t
33829475|NCT00242164|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829476|NCT05260554|||CASE_CONTROL||PROSPECTIVE|||||||
33829477|NCT04035577|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Mobile self-help intervention||||
33829478|NCT01652859|RANDOMIZED|CROSSOVER||||NONE||||||
33829479|NCT03052712|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33829480|NCT01754532|||COHORT||PROSPECTIVE|||||||
33829481|NCT05629247|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829482|NCT05914415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33829483|NCT05466097|||COHORT||PROSPECTIVE|||||||
33829484|NCT03487263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Open-label, dose-escalation, safety and pharmacokinetic||||
33829485|NCT00000133|RANDOMIZED|||||||||||
33829486|NCT05282641|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The subjects will follow one of the two experimental conditions. The decision in which condition they will be placed is based upon a computer-generated table with random numbers. For this, a categorical list in logical order will be created by an independent person before the start of the study. After being found eligible to start the study, the subject gets the following study number that is on the list. Basically, this entire randomization process is blinded and follows the concealed allocation procedures. During this process, it will safeguard that there are equal group sizes and an equal number of men and women in both groups (range 40/60% or 60/40% is accepted).|A 4-weeks randomized, controlled trial with a parallel design. Before the 4-weeks intervention, there is a 2-weeks run period.|t|f|t|f
33829487|NCT01117129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829488|NCT00611715|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829489|NCT04249050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829490|NCT02455999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829491|NCT02813109|||COHORT||PROSPECTIVE|||||||
33829492|NCT04390412|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829493|NCT06325345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829494|NCT04719715|||CASE_CONTROL||PROSPECTIVE|||||||
33829495|NCT02046798|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829496|NCT00062686|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829497|NCT03087331|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33829498|NCT00765154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829499|NCT06437119|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The on-site implementation personnel and those responsible for coordinating the study only received the study number of the subjects, and were unaware of the intervention group allocation of the subjects. The subjects were also unaware of their intervention allocation. A copy of the sealed envelope of the non blinded study number for each subject is provided only to the study supervisor. Before the completion of data collection, the investigators and researchers kept the blind method for treatment allocation. All subjects were monitored in a double-blind way throughout the study period, and the subjects could not distinguish their own grouping by asking questions or from appearance and texture.|Subjects were stratified by gender using SAS 9.3 (SAS Institute Inc. NC, US). Eligible subjects were randomly assigned equally to one of the two survey groups based on a computer-generated randomization list. The generated random list is verified by statisticians and kept confidential during the study period. The random list is kept in a separate envelope.|t|f|t|f
33829500|NCT00089830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33829501|NCT00296010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829502|NCT01458080|||CASE_CONTROL||RETROSPECTIVE|||||||
33829503|NCT04710186|||COHORT||PROSPECTIVE|||||||
33829504|NCT00168493|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829505|NCT06498362|||CASE_CONTROL||RETROSPECTIVE|||||||
33829506|NCT00199160|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829507|NCT05247476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829508|NCT04862676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829509|NCT00630552|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33829510|NCT00291239|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829511|NCT05277506|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829512|NCT05038709|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33829513|NCT05190471|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33829514|NCT05961982|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33829515|NCT04629937|NA|SINGLE_GROUP||OTHER||NONE||All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.||||
33829516|NCT02715427|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829517|NCT00820664|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33829518|NCT00137020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829519|NCT00383409|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33829520|NCT04591262|NA|SINGLE_GROUP||OTHER||NONE||||||
33829521|NCT02288364|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33829522|NCT03937245|||COHORT||PROSPECTIVE|||||||
33829523|NCT03106792|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33829524|NCT01447862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829525|NCT00906217|||COHORT||PROSPECTIVE|||||||
33829526|NCT04959500|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829527|NCT01637285|RANDOMIZED|PARALLEL||||NONE||||||
33829528|NCT01702870|||||PROSPECTIVE|||||||
33829529|NCT01055210|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34138851|NCT04681833|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|This study is double-blinded. Sealed participant-specific code break envelopes will be produced by the unblinded statistician so that the treatment assigned to each participant can be obtained if required, in an emergency only, where knowledge of the randomisation code is required to provide appropriate treatment. The code break envelopes will be retained at the clinical unit in a secure, accessible location. Those blinded to study drug assignment include the sponsor, the PI, clinical study personnel participating in participants' care or clinical evaluations, and the study participants.|"Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of one arm, and one dose of placebo by IM injection to the deltoid region of the other arm, given sequentially (10 μg rRSV G protein/10 μg CsA in total for each vaccination) on Day 1 and 29.~Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.~Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1 and 29.~Placebo: One dose administered by IM injection to both arms, on Day 1 and 29.~Active: One dose of 10 μg rRSV G protein/10 μg CsA administered by IM injection to the deltoid region of each arm, given sequentially (20 μg rRSV G protein/20 μg CsA in total for each vaccination) on Day 1, Day 29 and Day 57.~Placebo: One dose administered by IM injection to both arms, on Day 1, Day 29 and Day 57."|t|f|t|f
34138852|NCT03362060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138853|NCT03472664|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"It is not possible for participants and the dietitian to be blinded to the study diet.~Study personnel involved in performing cognitive testing or other outcome procedures or data analysis will be blinded."|Adults with amnestic mild cognitive impairment will be randomized on a 1:1 schedule to receive either a 4-month Modified Mediterranean Ketogenic Diet or American Heart Association Diet intervention. Diet interventions will be equicaloric with participants' normal diets. Personalized nutritional guidance and menus will be provided, and compliance will be assessed by a registered dietitian. Amyloid positron emission tomography (PET) will be conducted at baseline. Blood collection and cognitive assessment will be conducted at baseline and after 2 and 4 months of diet. Lumbar puncture (LP) and MRI will be conducted at baseline and following the intervention for all participants.|f|f|t|t
33829530|NCT03619798|||COHORT||PROSPECTIVE|||||||
34138854|NCT00651950|||COHORT||CROSS_SECTIONAL|||||||
34138855|NCT05824923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||At the 12-months visit, participants in the control group who still meet the inclusion and exclusion criteria can choose to receive PADN procedure.|f|f|f|t
34138856|NCT00325676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138857|NCT00408655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138858|NCT05592366|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34138859|NCT02279771|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138860|NCT06606132|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm, pre-post-test pilot study was designed||||
34138861|NCT04393363|||COHORT||PROSPECTIVE|||||||
34138862|NCT04901442|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138863|NCT03058185|||CASE_ONLY||PROSPECTIVE|||||||
34138864|NCT06464185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138865|NCT02574650|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138866|NCT03741946|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34138867|NCT01758224|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138868|NCT02098499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138869|NCT06077240|RANDOMIZED|PARALLEL||OTHER||DOUBLE|To avoid randomized non-starters and potential bias due to differential early attrition from prior knowledge of group assignment, randomization will occur at the time of visit 0 when participants first receive tobacco products specific to their assigned condition, and neither the research assistant nor participant will know the assignment in advance. Researchers and participants will be blinded to the nicotine concentration.||t|f|f|t
34138870|NCT06040918|NA|SINGLE_GROUP||OTHER||NONE||Up to 10 healthy subjects||||
34138871|NCT02974855|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34138872|NCT04930549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138873|NCT05585684|||OTHER||PROSPECTIVE|||||||
34138874|NCT00405964|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138875|NCT04025502|||COHORT||CROSS_SECTIONAL|||||||
34138876|NCT03727646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Study biostatistician will be blinded to group (NR vs. untreated controls)|This single-center, open-label study will compare blood and myocardial NAD+ levels and other mitochondrial endpoints in participants with end-stage heart failure receiving open-label nicotinamide riboside prior to LVAD implantation to similar endpoints from patients previously undergoing LVAD implantation.|f|f|f|t
34138877|NCT02124018|||COHORT||PROSPECTIVE|||||||
34138878|NCT06605469|||COHORT||PROSPECTIVE|||||||
34138879|NCT05266872|||COHORT||PROSPECTIVE|||||||
34138880|NCT02839226|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138881|NCT05411588|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34138882|NCT03117374|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34138883|NCT04675658|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|Care provider/study staff will be masked to the arm the participant is assigned.||f|t|f|f
34138884|NCT01534260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829531|NCT01226836|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829532|NCT05199857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829533|NCT04200404|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829534|NCT02444351|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829535|NCT03588819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829536|NCT02637856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829537|NCT06483685|||CASE_ONLY||RETROSPECTIVE|||||||
33829538|NCT05079906|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829539|NCT03671239|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33829540|NCT02711813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829541|NCT01795729|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829542|NCT03749499|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Research Assistants are blinded to study arm assignment of participant when assessing outcomes measures.||f|f|f|t
33829543|NCT00945113|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33829544|NCT04169997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829545|NCT03740204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829546|NCT02447276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829547|NCT03866980|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829548|NCT03381469|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Three groups of patients will be examined parallel to each other||||
33829549|NCT02003690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829550|NCT05120154|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33829551|NCT00827775|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829552|NCT05298293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829553|NCT05153785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized double blinded placebo-controlled study|t|t|t|f
33829554|NCT00721032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829555|NCT05408819|||COHORT||PROSPECTIVE|||||||
33829556|NCT04053569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (participant)|Randomized, single-blind clinical trial|t|f|f|f
33829557|NCT00056810|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33829558|NCT03088189|||CASE_CONTROL||PROSPECTIVE|||||||
33829559|NCT06443424|||COHORT||PROSPECTIVE|||||||
33829560|NCT04982627|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33829561|NCT02742532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33829562|NCT06310083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The surgeons performed the nasal surgery and evaluating postoperative measurable outcomes was blinded about cases who were subjected to Endoscopic submucosal resection Turbinoplasty|"A total of 40 patients were enrolled in the study. The patients were randomly classified into two groups, with 20 in each group.~Group A (study group): who applied for Endoscopic submucosal resection Turbinoplasty.~Group B (control group): Who applied for partial inferior turbinectomy."|t|t|t|t
33829563|NCT03989843|||COHORT||RETROSPECTIVE|||||||
33829564|NCT00001677||||TREATMENT||||||||
33829565|NCT01093599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829566|NCT05187247|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A pregnant women who is designated for induction of labor using an extra-amniotic balloon catheter will complete a STAI questionnaire about the degree of anxiety prior to the procedure. All women then will be randomly assigned to 2 groups according to a randomization table. Women assigned to the VR group will use the virtual reality technology throughout the insertion procedure while the second group will constitute a control group for the intervention group.~During the insertion procedure, a subjective assessment of the degree of pain will be performed using VAS score (Visual Analog Scale), and objective pain assessment which will be performed by measuring a pulse at a predetermined time points.~At the end of the procedure the women will be asked to answer another anxiety questionnaire.~Women in the VR group will also answer a satisfaction questionnaire from the experience"||||
33829567|NCT01947153|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829568|NCT05982080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829569|NCT00443898|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829570|NCT00812721|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33829571|NCT02828163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829572|NCT02550483|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33829573|NCT05955677|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829574|NCT00962806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829575|NCT04214275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33829576|NCT03693040|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33829577|NCT02275013|||COHORT||RETROSPECTIVE|||||||
33829578|NCT01664923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829579|NCT00332826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829580|NCT01830062|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829581|NCT04864717|RANDOMIZED|PARALLEL||TREATMENT||NONE|Unblinded|Two arm study: one arm isotretinoin, one arm doxycycline.||||
33829582|NCT00106665|||COHORT||PROSPECTIVE|||||||
33829583|NCT01058525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829584|NCT01776008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829585|NCT02785276|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33829586|NCT01583049|||COHORT||PROSPECTIVE|||||||
33829587|NCT03901443|||COHORT||CROSS_SECTIONAL|||||||
33829588|NCT01010997|||COHORT||PROSPECTIVE|||||||
33829589|NCT05768737|||CASE_ONLY||PROSPECTIVE|||||||
33829590|NCT03599622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829591|NCT06188312|||OTHER||CROSS_SECTIONAL|||||||
33829592|NCT00209066|||COHORT||PROSPECTIVE|||||||
33829593|NCT02505477|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829594|NCT01792843|||CASE_ONLY||PROSPECTIVE|||||||
33829595|NCT05336981|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829596|NCT05423106|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33829597|NCT00119938|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33829598|NCT01796223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829599|NCT03217461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829600|NCT00715338|||CASE_ONLY||PROSPECTIVE|||||||
33829601|NCT04189510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829602|NCT01749163|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33829603|NCT01284309|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33829604|NCT02168231|||COHORT||CROSS_SECTIONAL|||||||
33838545|NCT05288829|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|This was a partially blinded study. During Cohorts 1a and 1b dosing, participants, study site medical/nursing staff, and other study site staff involved in the safety evaluations were blinded to study drug assignment. The pharmacy staff who prepared the SC injections and the research physician responsible for study drug administration was not blinded. In addition, a data manager responsible for masking some of the PK data was not blinded. Alexion staff were unblinded only on specific occasions (eg, to monitor that the SC injections were being prepared appropriately, to determine reportability of serious adverse events \[AEs\]), and refrained from sharing any information on study drug assignment with the study site staff. During Cohort 2, however, participants and study site staff were made aware of the treatment being administered.||t|t|f|f
34138885|NCT03100916|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34138886|NCT05325749|||COHORT||CROSS_SECTIONAL|||||||
34138887|NCT04606199|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Since the study uses a MRT design (each participant is randomized multiple times), the investigator and outcomes assessor do not know at what time points participants are assigned to an intervention or not over the course of this 30-day study.|A Micro-Randomized Trial (MRT) is a design that randomly assigns an intervention at each notification time point (similar to a crossover design in that each participant is randomized to both conditions at different times, except in the MRT the crossover occurs at multiple times): Participants use the study app for 30 days and receive three notifications per day. At each notification time point, participants complete an Ecological Momentary Assessment (EMA) of their current psychological stress states (pre-EMA). Then, at each notification, each participant is randomized (50 percent probability) to either receive a mindfulness-based intervention or not. Thus, participants are randomized many times over the 30-day study. Approximately thirty minutes post-randomization, an EMA is obtained again to assess psychological stress states (post-EMA). A treatment effect is examined by comparing psychological stress responses after a mindfulness-based intervention compared to no intervention.|f|f|t|t
34138888|NCT05946291|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Students will be assigned to the experiment and control group blind. In addition, double-blind randomization will be provided by appointing a blind researcher who performs the analysis.|The study is planned as a double-blind randomized controlled experimental study.|t|f|f|t
34138889|NCT00162500|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138890|NCT02314065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138891|NCT04285866|||COHORT||RETROSPECTIVE|||||||
34138892|NCT03109093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138893|NCT06495229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138894|NCT04992065|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial will be double-blinded within dose level of oral NNC0385-0434 and size-matched placebo arm. The subcutaneous (s.c.) evolocumab arm will be open label.||t|t|f|f
34138895|NCT03576066|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138896|NCT04015284|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||2 groups of patients. Randomization into groups SSNP + PCB or ISBPB as per randomization list, for a total of 100 patients.|t|t|t|t
34138897|NCT05993312|||COHORT||OTHER|||||||
34138898|NCT05763186|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34138899|NCT03854526|||OTHER||CROSS_SECTIONAL|||||||
34138900|NCT03428581|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138901|NCT01004731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138902|NCT06605404|||COHORT||PROSPECTIVE|||||||
34138903|NCT01023555|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34138904|NCT01384500|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34138905|NCT02227953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138906|NCT04865731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138907|NCT05381441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Nurses and nursing units will not be masked to study arm. Patients cared for on nursing units will be masked to study arm (and will not be consented for participation). Outcome assessors will be blinded to study arm.|Pragmatic randomized controlled trial randomizing blocks of nursing units to either the control or intervention group|t|f|f|t
34138908|NCT06464900|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34138909|NCT01940575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138910|NCT02410473|||COHORT||PROSPECTIVE|||||||
34138911|NCT03036683|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34138912|NCT05383443|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34138913|NCT00515294|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|t|t|f
34138914|NCT02629848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138915|NCT00728247|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138916|NCT05502107|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a multicenter, cluster-randomized, stepped-wedge implementation study of an EMS sepsis screening and early communication protocol. Each study cluster represents one EMS organization and one partnered acute care hospital. Each cluster pair will participate in both a baseline and intervention phase of study varying between 6-18 months each (baseline and intervention), in approximately 6 month blocks, depending on the order of cluster randomization.||||
34138917|NCT04385472|||COHORT||PROSPECTIVE|||||||
34138918|NCT05032690|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||A Phase 1, open-label, randomized, single dose, 3-period, 4 sequence, crossover study in healthy participants||||
34138919|NCT00837265|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34138920|NCT03252886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138921|NCT00592228|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34138922|NCT03233334|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34138923|NCT04018820|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|Most outcomes where not masked, however the outcome assessor was masked for all muscle biopsy analysis: while analysing the muscle biopsy outcomes, the outcome assessor did not know if it was from baseline or from after the training program.|Participants had to complete a 12-week strength training program and return to their normal activities for the following 6 months after the end of the training program||||
34138924|NCT00820794|RANDOMIZED|CROSSOVER||||NONE||||||
34138925|NCT00907803|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34138926|NCT04373408|||CASE_ONLY||PROSPECTIVE|||||||
34138927|NCT04420572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
34138928|NCT06443710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34138929|NCT01576419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138930|NCT06606535|||CASE_CONTROL||PROSPECTIVE|||||||
34138931|NCT00025298|RANDOMIZED|||TREATMENT||||||||
34138932|NCT01370200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138933|NCT04265729|NA|SINGLE_GROUP||OTHER||NONE||||||
34138934|NCT00167141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138935|NCT04545164|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149845|NCT04923217|||CASE_ONLY||CROSS_SECTIONAL|||||||
34149846|NCT06507917|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33838546|NCT03997487|NA|SINGLE_GROUP||OTHER||NONE||||||
34138936|NCT04236180|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Interventional multi-centre study with a hybrid design to determine the clinical effectiveness (comparative effectiveness research) of an existing SPPC programme, while gathering information on its delivery and potential implementation in a real-life situation||||
34138937|NCT06605313|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829605|NCT05333575|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE||Research 28-34 preterm babies with gestational age hospitalized in the 2nd and 3rd level intensive care unit of Selcuk University Medical Faculty Hospital in Konya, Turkey. As a result of the power analysis, it was determined that the inclusion of 45 preterm infants in the study would provide sufficient sample size based on the two-sided hypothesis, 1.392 effect size, 0.05 margin of error and 0.95 power. Since the study period coincided with a period of uncertainties such as the Covid 19 pandemic, it was foreseen that there may be a loss in the number of babies included in the groups, and the sample number was increased by 10%, and the study was completed with a total of 51 premature babies (maternal voice group: 17, control group 17, classical music group 17).Babies of mothers who agreed to participate in the study were randomly assigned to the experimental and control groups. Simple randomization method was used in the study.|t|f|f|f
33829606|NCT01041768|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829607|NCT04001738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829608|NCT02958059|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33829609|NCT02956122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829610|NCT02869815|||COHORT||PROSPECTIVE|||||||
33829611|NCT02319863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829612|NCT02509312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo (normal saline) or ketorolac in syringe prepared by the investigational pharmacy with study kit number and blinding key maintained by investigational pharmacy until time of unblinding.||t|t|t|t
33829613|NCT00505414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829614|NCT06372106|||OTHER||OTHER|||||||
33829615|NCT06315114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829616|NCT05087836|||COHORT||PROSPECTIVE|||||||
33829617|NCT04666376|NA|SINGLE_GROUP||OTHER||NONE||||||
33829618|NCT00715637|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829619|NCT05436015|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Statistician, who is not involved in the study has done block-randomization with variable block-sizes (2,4,6) by StatsDirect program for two groups; an intervention and control group. All study team members and participants will be blind to group allocation with the exception of one research assistant who will not be involved in providing the intervention to the participants or data analysis. Delivery ward staff (midwives) asks informed consent and after receiving it, performs the allocation.|"A randomized controlled trial with a two-arm design will be conducted among women entering deliveryward during first stage of labour. Participants are randomized into two groups, an intervention group (N=30) and a control group (N=30). Intervention group members will receive virtual nature-based intervention; video with nature pictures and nature sounds from a 75 vertical screen monitor. Participants receive standard care during first stage of labour in both groups."||||
33829620|NCT03308747|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33829621|NCT02788526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829622|NCT00307983|||DEFINED_POPULATION||PROSPECTIVE|||||||
33829623|NCT06467214|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-arm, parallel, randomized controlled trial that will enroll 264 Veterans. It will compare the Increasing Veterans' Social Engagement and Connectedness (CONNECTED, intervention arm) to an attention control group (control arm).||||
33829624|NCT04274062|||CASE_CONTROL||PROSPECTIVE|||||||
33829625|NCT01704066|||COHORT||PROSPECTIVE|||||||
33829626|NCT03310671|||CASE_CONTROL||PROSPECTIVE|||||||
33829627|NCT00043186|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829628|NCT00604188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829629|NCT04555005|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33829630|NCT02615678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829631|NCT00678028|||CASE_CONTROL||PROSPECTIVE|||||||
33829632|NCT01940783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829633|NCT04347785|||CASE_CONTROL||PROSPECTIVE|||||||
33829634|NCT01113671|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33829635|NCT01367444|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829636|NCT01176305|||COHORT||RETROSPECTIVE|||||||
33829637|NCT01798862|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829638|NCT04901845|||COHORT||CROSS_SECTIONAL|||||||
33829639|NCT05336513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829640|NCT03864341|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33829641|NCT05674292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829642|NCT05957809|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33829643|NCT01836198|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33829644|NCT05623813|||CASE_CONTROL||PROSPECTIVE|||||||
33829645|NCT01086384|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829646|NCT03361098|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Participants were treated in a double-dummy design. There was no difference in appearance between exenatide and placebo injections, or dapagliflozin and placebo tablets.||t|f|t|f
33829647|NCT00626015|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829648|NCT03862209|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two study groups both consisting of patients with SMI (severe mental illness). One group will be receiving care as usual, which in the actual setting means mostly medical treatment, without home care and assertive treatment through community based outreach teams. Another, intervention group, will be receiving assertive treatment care, with mobile assertive teams, consisting of at least three team members.||||
34138938|NCT01612286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138939|NCT06238843|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149506|NCT05546073|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||632 participants referred to the acute community health care service for in-home assessment due to acute disease will be enrolled and randomized 1:1 to receive usual care or advanced point-of-care technology||||
34149507|NCT03334383|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149508|NCT00094432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138940|NCT03224507|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study has four cycles (28-days each) of drug therapy prior to being evaluated for auto-HCT. After the completion of induction therapy, the patient will be evaluated for a transplant of their own hematopoietic stem cells. If, after the transplant, the patient still has detectable multiple myeloma, the patient will proceed to a series of consolidation blocks, up to three, consisting of four cycles of the KRdD at specified dosages and time frames. After completion of consolidation therapy, maintenance therapy will begin until disease progression or intolerance.||||
34138941|NCT01771848|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34138942|NCT00072930|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138943|NCT06599554|||COHORT||PROSPECTIVE|||||||
34138944|NCT01773551|||CASE_CONTROL||PROSPECTIVE|||||||
33829649|NCT00556647|||COHORT||PROSPECTIVE|||||||
33829650|NCT01308268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829651|NCT06309264|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Factor 1 is single blind: Participants will not know which procedure is used to program their hearing aid, but the investigator/outcomes assessor will. Factor 2 is unblinded: Participants will know whether they are assigned to the daily hearing aid use group.|"This study is a 2x2 randomized trial. Each subject receives a low-gain hearing aid. The randomized factors are:~1. Fitting method. Half of the subjects have their hearing aids programmed using conventional methods based on the pure-tone audiogram. The remainder have their hearing aids programmed using the gain profile selected from speech-based audiometry.~2. Daily hearing aid use. Half of the subjects will be assigned to use their hearing aids routinely in daily life for a six-week acclimatization period. The remaining half will be followed for the same six-week period but will use their hearing aids only to complete pre-post (mQuickSIN, fMRI) and weekly (DIN) laboratory assessments for speech recognition in noise. The daily use group will complete the same assessments.~The factors are fully crossed such that there are four groups in the experiment."|t|f|f|f
33829652|NCT03623477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829653|NCT06101472|||COHORT||PROSPECTIVE|||||||
33829654|NCT03588598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829655|NCT00940654|||CASE_CONTROL||PROSPECTIVE|||||||
33829656|NCT00207961|||DEFINED_POPULATION||PROSPECTIVE|||||||
33829657|NCT02208037|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829658|NCT01584011|||COHORT||PROSPECTIVE|||||||
33829659|NCT05305677|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33829660|NCT02465190|||CASE_CONTROL||PROSPECTIVE|||||||
33829661|NCT02357914|||CASE_ONLY||CROSS_SECTIONAL|||||||
33829662|NCT01471249|||OTHER||PROSPECTIVE|||||||
33829663|NCT03575195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829664|NCT02492698|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33829665|NCT00868764|NA|SINGLE_GROUP||OTHER||NONE||||||
33829666|NCT02949856|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33829667|NCT01321723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829668|NCT00719212|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829669|NCT05383625|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829670|NCT04622475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829671|NCT01125462|||CASE_ONLY||PROSPECTIVE|||||||
33829672|NCT05239598|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33829673|NCT03516045|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829674|NCT00661544|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829675|NCT00781417|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33829676|NCT00236184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829677|NCT02720185|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829678|NCT06225700|||CASE_ONLY||PROSPECTIVE|||||||
33829679|NCT04077814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829680|NCT03754764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829681|NCT02151630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829682|NCT03895502|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829683|NCT01837498|||COHORT||PROSPECTIVE|||||||
33829684|NCT01617798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829685|NCT04699097|||CASE_ONLY||PROSPECTIVE|||||||
33829686|NCT00037895|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829687|NCT04421313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829688|NCT02101658|||COHORT||CROSS_SECTIONAL|||||||
33829689|NCT04764201|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829690|NCT02277197|NA|SINGLE_GROUP||OTHER||NONE||||||
33829691|NCT01127321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829692|NCT04695821|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||A pilot stage, exploratory, First-In-Human and traditional feasibility, interventional study of the Senti V1.0 device (CE marked, Class I device), involving 10 patients attending A\&E with or suspected to have Covid-19, who are being discharged into the community. 5 devices will be used, to cover a range of sizes from extra-small to extra-large.||||
33829693|NCT06086678|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single|random|f|f|f|t
33829694|NCT00148135|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33829695|NCT05560750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One month follow-up time (parents unaware)|"Study patients with parental consent are randomized into 3 study arms:~1. Open study treatment (index therapy) is a frenotomy performed under local anesthesia or general anesthesia, i.e. an operation to release the lingual frenulum immediately after its detection;~2. Conservative treatment is a parental given sensitive movement therapy aiming to tongue-tie stretching for 4 weeks;~3. Follow-up group (no-treatment): appointment for the procedure at one month age with a re-evaluation for the procedure."|f|t|f|f
33829696|NCT00680147|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33829697|NCT02892864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829698|NCT04773730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|pain score assessment will be done by an anesthetist who is not involved in randomization or in the anesthetic technique|patients will be randomly allocated via sealed opaque envelop into 2 groups of 50 patients each; Posterior transversus abdominus block (TAP) group and Quadratus lumborum block type 2 is the second group (QLB)group|t|f|t|f
33829699|NCT01618578|||CASE_CONTROL||PROSPECTIVE|||||||
33829700|NCT05672771|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34138945|NCT04404036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138946|NCT05996055|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34138947|NCT01349322|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138948|NCT06236542|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Because blinding of participants and investigators is not practical, all groups will be aware of their respective treatment protocols, which will be considered in the analysis and interpretation of outcomes.|NextGen Tracheostomy Toolkit||||
34138949|NCT05707351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138950|NCT03315273|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Comparison of 2 groups: one existing of patients with traumatic brain injury and one control group of healthy volunteers matched for age, sex and educational level||||
33829701|NCT01944449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138951|NCT04633811|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34138952|NCT01663324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34138953|NCT00497549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138954|NCT05146713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34138955|NCT04543266|||COHORT||RETROSPECTIVE|||||||
34138956|NCT03373890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Muscle function assessor masked to frequency group, Muscle architecture captured via ultrasound Community walking activity collected by accelerometry, thus non-human data collection|Pre/post intervention design with participants randomized to two different frequency of intervention|f|f|f|t
34138957|NCT03404531|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34138958|NCT05030519|||CASE_ONLY||PROSPECTIVE|||||||
33829702|NCT05365087|||CASE_CONTROL||PROSPECTIVE|||||||
34138959|NCT01131429|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829703|NCT00244907|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
34138960|NCT04902924|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||This study is a randomized controlled trial||||
33829704|NCT00381888|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138961|NCT01975662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34138962|NCT05404347|||COHORT||PROSPECTIVE|||||||
33829705|NCT03909022|||COHORT||RETROSPECTIVE|||||||
33829706|NCT01795521|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829707|NCT00345800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829708|NCT04244149|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829709|NCT00206739|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33829710|NCT00467298|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829711|NCT03628196|||COHORT||PROSPECTIVE|||||||
33829712|NCT03557242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829713|NCT01642043|||COHORT||PROSPECTIVE|||||||
33829714|NCT01151514|||COHORT||RETROSPECTIVE|||||||
33829715|NCT01059188|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829716|NCT02308098|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34138963|NCT00497705|||||PROSPECTIVE|||||||
34138964|NCT00977275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138965|NCT05271032|||CASE_ONLY||PROSPECTIVE|||||||
34138966|NCT05807100|||CASE_ONLY||PROSPECTIVE|||||||
34138967|NCT06607016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138968|NCT02310230|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
34138969|NCT06601647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138970|NCT01833195|||COHORT||PROSPECTIVE|||||||
34138971|NCT01022372|||CASE_CONTROL||PROSPECTIVE|||||||
34138972|NCT00926731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34138973|NCT04388319|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138974|NCT04686851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized Clinical Trial with 2 randomized 1:1 parallel study groups|f|f|f|t
34138975|NCT06477146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138976|NCT03657563|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34138977|NCT05429918|||COHORT||PROSPECTIVE|||||||
34138978|NCT02881112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138979|NCT01432340|||COHORT||PROSPECTIVE|||||||
34138980|NCT06343870|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34138981|NCT05474781|||COHORT||PROSPECTIVE|||||||
34138982|NCT02029807|||CASE_ONLY||PROSPECTIVE|||||||
34138983|NCT00420004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34138984|NCT01255813|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34138985|NCT04929002|||OTHER||PROSPECTIVE|||||||
33829717|NCT03558282|||COHORT||CROSS_SECTIONAL|||||||
33829718|NCT04834063|||CASE_CONTROL||PROSPECTIVE|||||||
33829719|NCT02546505|NON_RANDOMIZED|PARALLEL||||NONE||||||
33829720|NCT03705364|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33829721|NCT06332300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829722|NCT00843115|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33829723|NCT01728207|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829724|NCT02072798|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829725|NCT00002716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829726|NCT05313347|||CASE_ONLY||CROSS_SECTIONAL|||||||
33829727|NCT00071877||||TREATMENT||||||||
33829728|NCT01149876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33829729|NCT05706597|||OTHER||RETROSPECTIVE|||||||
33829730|NCT03127878|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
33829731|NCT02862808|||CASE_ONLY||RETROSPECTIVE|||||||
33829732|NCT00188825|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829733|NCT00241969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33838547|NCT05457751|||CASE_CONTROL||PROSPECTIVE|||||||
33838548|NCT03748862|||CASE_CONTROL||RETROSPECTIVE|||||||
33838549|NCT02175823|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33838550|NCT04001452|||COHORT||PROSPECTIVE|||||||
33838551|NCT00500032|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33838552|NCT01482936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138986|NCT02275715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34138987|NCT05047029|||CASE_ONLY||PROSPECTIVE|||||||
34138988|NCT05433051|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34138989|NCT05757154|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
33829734|NCT03515200|NA|SINGLE_GROUP||TREATMENT||NONE||"Palbociclib will be administered orally on Days 1-5, and 11-15 concurrently with dexamethasone of each 30 day cycle for one cycle (dose escalation) or up to 3 cycles for responders (dose expansion). Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17. If the dose escalation with this schema is tolerated, a final dose level administering additional doses of palbociclib on days 21-30 will be evaluated.~Patients with Ph-like or Ph+ ALL will receive tyrosine kinase inhibitor (TKI) beginning on Day 7.~Triple intrathecal chemotherapy (MHA) will be given on Day 1 of the course. The frequency and total number of IT MHA is based on the patient's level of CNS disease."||||
34138990|NCT02185430|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34138991|NCT01073397|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34138992|NCT01869530|||COHORT||PROSPECTIVE|||||||
34138993|NCT01707433|||COHORT|||||||||
34138994|NCT05838027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||At the end of the baseline assessment, participants will be randomized using a permuted block technique with block size of 4 to either usual care (Arm 1) or to the unconditional cash transfer intervention (Arm 2).||||
34138995|NCT01430962|||||PROSPECTIVE|||||||
34138996|NCT03477851|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained care provider (nurse) prepares the active drug or placebo directly before the procedure according to randomisation list (secured).|Randomized, double blinded two-arm parallel assignment|f|t|f|f
34138997|NCT04002284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34138998|NCT02885454|NA|SINGLE_GROUP||OTHER||NONE||||||
34138999|NCT04251767|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139000|NCT05487651|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase 1 dose escalation||||
34139001|NCT02924194|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34139002|NCT01070693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139003|NCT04812119|||COHORT||CROSS_SECTIONAL|||||||
34139004|NCT00993512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139005|NCT05462834|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||2 intervention periods lasting 14 days, separated by a 7-day washout|t|f|t|f
34139006|NCT01702090|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139007|NCT03897725|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139008|NCT06012500|||CASE_ONLY||PROSPECTIVE|||||||
34139009|NCT03102047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139010|NCT06012019|||CASE_CONTROL||PROSPECTIVE|||||||
34139011|NCT03172806|||COHORT||PROSPECTIVE|||||||
34139012|NCT01028534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139013|NCT04022785|NA|SEQUENTIAL||TREATMENT||NONE||||||
34139014|NCT03478176|||COHORT||PROSPECTIVE|||||||
34139015|NCT00135772|||||PROSPECTIVE|||||||
34139016|NCT03832855|NA|SINGLE_GROUP||OTHER||NONE||||||
34139017|NCT04098367|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139018|NCT03986580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139019|NCT03807297|RANDOMIZED|PARALLEL||OTHER||DOUBLE|participants will be alloted in two groups as per chit system and won't be aware of type of anaesthesia, investigator won't be aware of type of anaesthesia and will record the data.|two groups - one for Total Intravenous Anaesthesia mode and other for Inhalational mode of anaesthesia|t|f|t|f
34139020|NCT01338350|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34139021|NCT01844102|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34139022|NCT04864626|||COHORT||PROSPECTIVE|||||||
34139023|NCT06511557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Masking refers to a practice where study participants are prevented from knowing certain information that may somehow influence them thereby tainting the results.|Clinical study in which two or more groups of participants receive different interventions. Participants are assigned to one of the treatment arms at the beginning of the trial and continue in that arm throughout the length of the trial. Assignment to a group usually is randomized|f|f|f|t
34139024|NCT00129701|NA|SINGLE_GROUP||OTHER||NONE||||||
34139025|NCT06373653|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open-label,|Phase IV non-inferiority, open-label, controlled, comparative, multicenter, clinical study.||||
34139026|NCT04793451|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study was designed as a prospective randomized trial.||||
34139027|NCT02826421|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139028|NCT02816593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34139029|NCT01069159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139030|NCT00858741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139031|NCT01559922|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139032|NCT05733611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139033|NCT00547859|||COHORT||PROSPECTIVE|||||||
34139034|NCT00406705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34139035|NCT02638389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139036|NCT05662761|||COHORT||PROSPECTIVE|||||||
34139037|NCT05002621|||COHORT||PROSPECTIVE|||||||
34139038|NCT01415648|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|f|t
34139039|NCT03638908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139040|NCT01608217|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139041|NCT01714206|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139042|NCT06162546|||COHORT||PROSPECTIVE|||||||
33829735|NCT00067093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829736|NCT03180554|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|All statistical analyses will be performed by a statistician who is blinded by participants' ID and health record.|This study will use a randomized controlled experimental design. A total of N=112 consenting CWP patients will be consecutively recruited from the Department of Pain Management and Research at Oslo University Hospital, Norway, and randomized to one of four intervention groups. Participants will be randomized to either a version 1 tVNS group, a version 2 tVNS group, a version 1 MNRB group, or a version 2 MNRB group. Both version 1 and 2 treatment interventions will be delivered at home, twice a day, for 15 min in the morning and for 15 min in the evening, for a total duration of 2 weeks. The participants' adherence to both interventions will be monitored electronically. An 80 % completion of tVNS stimulation and MNRB training will be regarded as adequate adherence in this project. Participants are invited to the clinic twice for pre- and post-intervention data collection.|t|t|f|t
34139043|NCT00881998|RANDOMIZED|||TREATMENT||||||||
34139044|NCT02288546|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33829737|NCT04191148|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind|2:1 randomized, placebo controlled, blinded study|t|t|t|f
34139045|NCT02023801|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139046|NCT02182440|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139047|NCT04199273|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Each patient, serving as their own control, receives both types of phrenic nerve stimulation : magnetic stimulation and electric stimulation. The order is randomized. For avoid a carry-over effect (diaphragm potentiation), a wash-out period of 15 minutes will be respected between the two type of stimulation.||||
34139048|NCT05055297|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139049|NCT03571802|NA|SINGLE_GROUP||TREATMENT||NONE||Pharmacokinetic parameters of simvastatin before and after laparoscopic sleeve gastrectomy will be compared in 10 patients. Each patient will serve as their own control for comparison.||||
34139050|NCT02214225|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34139051|NCT02867943|||COHORT||PROSPECTIVE|||||||
34139052|NCT00001155||||TREATMENT||||||||
34139053|NCT05576168|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Serum RBP4 level in patients with or without type 2 diabetes||||
34139054|NCT00753805|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34139055|NCT02387905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829738|NCT03389425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139056|NCT03866785|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||This study is composed of 3 dependent steps.||||
34139057|NCT05530408|||COHORT||PROSPECTIVE|||||||
34139058|NCT06126952|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||The study will be a single-center, randomized, placebo-controlled, double-blind trial with three periods and six sequences (cross-over design).|t|f|t|f
34139059|NCT05129904|||COHORT||PROSPECTIVE|||||||
34139060|NCT04381637|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The research does not involve the evaluation or comparison of medical strategies.The order of application of the stimuli will be randomized according to a Latin square of order 3.||||
34139061|NCT02182206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139062|NCT00169234|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34139063|NCT04694755|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|It is jointly completed by the person in charge of the project, the drug preparation personnel and the statistician, and the two-level blind method is adopted. Blinding at the first level: that is to say, blinding is set for experimental Chinese medicine. The test drug and the control drug shall be packed uniformly; the second level shall be provided with blindness, that is, the number of the test drug packaging box shall be provided with blindness.|The experimental group was given TCM syndrome differentiation treatment granules, heart and lung qi deficiency was given invigorating heart and lung formula, lung and kidney qi deficiency was given invigorating kidney and protecting lung formula; the control group was given TCM syndrome differentiation treatment placebo.|t|f|t|f
34139064|NCT05131399|NA|SEQUENTIAL||TREATMENT||NONE||Prospective, multicenter, interventional study, SCED design in ABAB introduction/withdrawal. The timing of the transition from one phase to the next will be randomized. The duration of each of the phases (A1, B1, A2, B2) will therefore be defined randomly, while maintaining a total duration of 12 weeks for each study schema.||||
34139065|NCT04676165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the nature of the intervention, study participants are not blinded to treatment arm allocation, but data analysts are.||f|f|t|t
34139066|NCT03978637|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 Itacitinib administered orally followed by phase 2; Itacitinib administered orally at the recommended dose from Phase 1.||||
34139067|NCT05964465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139068|NCT06399510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139069|NCT05803863|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, comparative, open label||||
34139070|NCT02664051|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34139071|NCT00050531|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139072|NCT01953549|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139073|NCT00682071|||CASE_CONTROL||PROSPECTIVE|||||||
34139074|NCT01048307|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139075|NCT00697866|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34139076|NCT05696353|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139077|NCT01730664|NA|SINGLE_GROUP||OTHER||NONE||||||
34139078|NCT01118520|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139079|NCT05890794|RANDOMIZED|PARALLEL||TREATMENT||NONE|Trial is masked for received dose; type of drug received is open-label|2 doses will be compared||||
34139080|NCT05827549|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Blinatumomab Cycle 1,2 S cycle 1,2 (High risk group) is going to be given for 4 weeks before transplantation||||
33829739|NCT03100955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139081|NCT06315283|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139082|NCT05802082|||OTHER||PROSPECTIVE|||||||
34139083|NCT05581082|||OTHER||PROSPECTIVE|||||||
34139084|NCT00057655|||||RETROSPECTIVE|||||||
34139085|NCT04376684|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study.|Participants will be randomized to receive either a blinded IV infusion of otilimab or placebo, in addition to standard of care.|t|f|t|f
34139086|NCT01588314|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34139087|NCT06416657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Researchers responsible for outcome assessment are unaware of the allocation of anesthesia modalities, but anesthesiologists and neurosurgeons are aware of the allocation of anesthesia modalities because they need to be involved in the safe administration of general or local anesthesia and related medical care.||f|f|f|t
34139088|NCT01783314|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33829740|NCT00551135|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829741|NCT02672579|||OTHER||PROSPECTIVE|||||||
33829742|NCT02072421|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33829743|NCT03035318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829744|NCT04502836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829745|NCT01861639|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34139089|NCT01384630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139090|NCT03262350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139091|NCT06109051|||COHORT||PROSPECTIVE|||||||
34139092|NCT06164496|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The dental investigator who performed the oral health assessment for dentition status and plaque status was blinded during the intervention.|single blinded randomized control trial|f|f|t|f
34139093|NCT05977309|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants were randomly assigned to ozone therapy and placebo groups in a ratio of 1:1 using block randomization with Random Allocation Software (RAS) and block sizes of 4 and 6. By the number of samples, envelopes were prepared, and capsules were deposited within them. 1 to 430 were assigned to each envelope. The envelopes were opened in the order that the participants entered the study, and the type of intervention was determined. A person uninvolved in the sampling process prepared envelopes in the allocation order. In this study, researchers, subjects, and outcome evaluators were all blinded.|In five wound care clinics on Java Island, Indonesia, 430 men and women with diabetic foot ulcer lesions participated in this randomised, triple-blind clinical trial. Inclusion criteria included women and men receiving treatment for diabetic foot ulcers, the Wagner scale, current blood sugar between 120 and 180 mg/dl, Hb1ac between 4.5 and 7%, lesion length greater than 5 cm, and infection. Exclusion criteria in this investigation, such as immunodeficiency disorders, are listed as examples.|t|t|t|t
34139094|NCT05601089|||OTHER||PROSPECTIVE|||||||
34139095|NCT03863470|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34139096|NCT06370962|||COHORT||PROSPECTIVE|||||||
34139097|NCT05678205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34139098|NCT05482620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only investigator making evaluation is blinded||f|f|f|t
34139099|NCT00496483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139100|NCT01636063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139101|NCT05025098|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized open label clinical study phase II||||
34139102|NCT04854525|||CASE_CONTROL||RETROSPECTIVE|||||||
34139103|NCT05118464|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139104|NCT05634733|||COHORT||PROSPECTIVE|||||||
34139105|NCT01611012|||COHORT||PROSPECTIVE|||||||
34139106|NCT01818258|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139107|NCT03384563|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34139108|NCT05449379|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study will be double blind, patients will be unaware of being assigned to a group and investigators assessing functional state in the next stages of the study will not conduct rehabilitation and will not be aware of the allocation of patients to groups.||t|t|t|f
34139109|NCT04299945|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Eligible participants will be randomly assigned using a computer-generated algorithm in a 1:1 ratio to dietary nitrate supplementation (concentrated beetroot juice) or placebo (the same amount of beetroot juice but with naturally occurring nitrate removed).|One or more interventions are evaluated for maximizing comfort, minimizing side effects, or mitigating against a decline in the participant's health or function|t|f|t|t
34139110|NCT04171596|NA|SINGLE_GROUP||OTHER||NONE||||||
34139111|NCT03058315|||COHORT||PROSPECTIVE|||||||
34139112|NCT06298617|||OTHER||PROSPECTIVE|||||||
34139113|NCT05192499|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|DREAM is a case-controlled study in open label|Exploratory multicentric prospective case-controlled study||||
34139114|NCT01858805|||COHORT||PROSPECTIVE|||||||
34139115|NCT06183294|||CASE_ONLY||RETROSPECTIVE|||||||
34139116|NCT03374267|||COHORT||PROSPECTIVE|||||||
34139117|NCT01344681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139118|NCT01240486|||||PROSPECTIVE|||||||
34139119|NCT06608745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139120|NCT05430191|||OTHER||PROSPECTIVE|||||||
34139121|NCT00583414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139122|NCT00782171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139123|NCT03226015|||CASE_ONLY||PROSPECTIVE|||||||
34139124|NCT04834154|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139125|NCT05115240|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34139126|NCT05010369|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34139127|NCT05257460|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34139128|NCT03822312|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139129|NCT05451290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139130|NCT03425006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139131|NCT02762630|||COHORT||CROSS_SECTIONAL|||||||
34139132|NCT05419128|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139133|NCT00396006|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139134|NCT01213147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34139135|NCT04363697|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34139136|NCT05639153|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139137|NCT00155727|||||PROSPECTIVE|||||||
34139138|NCT04333186|||COHORT||PROSPECTIVE|||||||
34139139|NCT00225459|||CASE_CROSSOVER||PROSPECTIVE|||||||
34139140|NCT01713660|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139141|NCT03548753|||COHORT||PROSPECTIVE|||||||
34139142|NCT05375396|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|A staff member not part of the study group will be assigned to distribute blinded samples. The participant or the investigators will not be aware of the dose groups.|Probiotic Streptococcus salivarius M18 lozenges Probiotics dairy free Streptococcus salivarius M18 lozenges|t|f|t|f
34139143|NCT03454399|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33829746|NCT00904683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829747|NCT00204880|||CASE_ONLY||PROSPECTIVE|||||||
33829748|NCT00500981|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34139144|NCT01183052|NA|SINGLE_GROUP||||NONE||||||
34139145|NCT00944814|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34139146|NCT01460914|||CASE_ONLY||PROSPECTIVE|||||||
34139147|NCT00813865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139148|NCT01598558|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829749|NCT00530998|||COHORT||PROSPECTIVE|||||||
34139149|NCT02370485|RANDOMIZED|CROSSOVER||||NONE||||||
34139150|NCT06606054|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34139151|NCT04027803|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139152|NCT04960904|||COHORT||OTHER|||||||
34139153|NCT01575938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139154|NCT04695054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139155|NCT06157996|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139156|NCT06466941|||COHORT||PROSPECTIVE|||||||
34139157|NCT01426919|||COHORT||PROSPECTIVE|||||||
34139158|NCT03012139|||COHORT||CROSS_SECTIONAL|||||||
34139159|NCT06283810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34139160|NCT05659719|||COHORT||RETROSPECTIVE|||||||
34139161|NCT05143307|NA|SINGLE_GROUP||OTHER||NONE||Long term follow up of participants who received EBT-101||||
34139162|NCT04333511|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34139163|NCT00348699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139164|NCT05861960|||COHORT||PROSPECTIVE|||||||
34139165|NCT03972345|||COHORT||PROSPECTIVE|||||||
34139166|NCT04853160|||COHORT||CROSS_SECTIONAL|||||||
34139167|NCT03374800|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|blinded study drug and placebo|A prospective, international, multicentre, parallel group, concealed, blinded, randomized trial in critically ill invasively mechanically ventilated adults|t|t|t|t
34139168|NCT00121524|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139169|NCT00646321|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34139170|NCT06031428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34139171|NCT01425359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139172|NCT03489434|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant and Investigator are blinded to condition||t|f|t|f
34139173|NCT02174367|||COHORT||PROSPECTIVE|||||||
34139174|NCT04964648|||CASE_CONTROL||PROSPECTIVE|||||||
34139175|NCT04956731|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34139176|NCT04712760|||CASE_CONTROL||RETROSPECTIVE|||||||
34139177|NCT05470842|NA|SINGLE_GROUP||OTHER||NONE||Single-centre, single arm study||||
34139178|NCT00559845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139179|NCT00374569|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34139180|NCT04200443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139181|NCT05825534|NA|SINGLE_GROUP||OTHER||NONE||||||
34139182|NCT00441779|||COHORT||RETROSPECTIVE|||||||
34139183|NCT00172887|||||PROSPECTIVE|||||||
34139184|NCT00405509|||COHORT||PROSPECTIVE|||||||
34139185|NCT02453165|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|f|t
34139186|NCT02508272|||COHORT||PROSPECTIVE|||||||
34139187|NCT02472418|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34139188|NCT03968575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139189|NCT04372147|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter open label randomized controlled trial. Eligible patients will be assigned either to the intervention or a control arm||||
34139190|NCT03156686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139191|NCT03395691|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were randomized to the Proximal Approach (PA) or Distal Approach (DA) group in a 1:1 ratio using a computerized system. The allocation process was intensively managed by an allocation group using sequentially numbered containers and the allocation result was concealed until it was implemented. When a patient was eligible, the investigator informed allocation group to get intervention group allocated to the patient: PA or DA group. Because of feasibility issues, operators were not blinded to the assignment.||t|f|f|f
34139192|NCT04845659|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34139193|NCT06060132|||OTHER||CROSS_SECTIONAL|||||||
34139194|NCT00790868|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139195|NCT04549116|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind, double-dummy.||t|t|t|t
34139196|NCT01657344|||OTHER||PROSPECTIVE|||||||
33829750|NCT04696133|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33829751|NCT00480545|||CASE_CONTROL||PROSPECTIVE|||||||
34139197|NCT03215758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139198|NCT02091531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139199|NCT06305715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139200|NCT02017938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139201|NCT05190354|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Subjects with transtibial unilateral or bilateral amputation who have experience using carbon fiber or high temperature thermoplastic prosthetic socket and are at least 6-months post-amputation.||||
34139202|NCT02870075|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34139203|NCT01129089|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34139204|NCT03372434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139205|NCT02660671|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34139206|NCT01215643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139207|NCT02408861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139208|NCT01572363|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139209|NCT02209545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139210|NCT06318806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study is a single site parallel-group randomized-controlled trial with an active run-in treatment. In the first phase of the trial, participants diagnosed with OCD will receive an active run-in treatment consisting of 18 sessions of ERP. In the second phase, non-remitters will be randomly allocated to another 18 sessions of I-CBT or continued treatment with ERP. Non-remission is operationalized in accordance with validated cut-off points established through international consensus and empirical findings (a score of \>12 on the YBOCS and a CGI-S rating of 3 or higher (mild to extremely ill) after the run-in treatment with ERP). I-CBT and continued ERP will be followed by a 6-month and 12-month follow-up conforming to current thinking on relapse and recovery in OCD. Treatments will be administered by trained therapists on a weekly one-on-one basis via videoconferencing for the duration of one hour.|f|f|f|t
34139211|NCT03757650|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34139212|NCT01938924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139213|NCT05413083|||COHORT||PROSPECTIVE|||||||
34139214|NCT00656188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139215|NCT03213782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139216|NCT05007496|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34139217|NCT01402076|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34139218|NCT06280872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139219|NCT00168636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139220|NCT01077999|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139221|NCT06044909|||COHORT||PROSPECTIVE|||||||
34139222|NCT01368783|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34139223|NCT06403306|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139224|NCT05725486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34139225|NCT02780856|NA|SINGLE_GROUP||OTHER||NONE||||||
34139226|NCT05924698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34139227|NCT02743949|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139228|NCT01639573|||COHORT||PROSPECTIVE|||||||
33829752|NCT05700578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants were randomly assigned to complete one of two web based interventions|t|f|f|f
34139229|NCT04503135|||COHORT||PROSPECTIVE|||||||
34139230|NCT03208907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139231|NCT02660450|RANDOMIZED|PARALLEL||||NONE||||||
34139232|NCT01288846|||CASE_ONLY||PROSPECTIVE|||||||
34139233|NCT05098964|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139234|NCT03842345|||COHORT||PROSPECTIVE|||||||
34139235|NCT03232242|||COHORT||PROSPECTIVE|||||||
34139236|NCT05917990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139237|NCT03981887|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34139238|NCT01428037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139239|NCT00532740|||COHORT||PROSPECTIVE|||||||
34139240|NCT05901051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139241|NCT01573221|||COHORT||PROSPECTIVE|||||||
34139242|NCT05734053|||COHORT||PROSPECTIVE|||||||
34139243|NCT05149040|||COHORT||CROSS_SECTIONAL|||||||
34139244|NCT00222430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139245|NCT03120260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139246|NCT01398319|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139247|NCT05291988|NA|SINGLE_GROUP||SCREENING||NONE||||||
34139248|NCT03381365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139249|NCT01865812|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829753|NCT01709955|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34139250|NCT01581749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139251|NCT01915121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829754|NCT06060197|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33829755|NCT01774500|||COHORT||PROSPECTIVE|||||||
33829756|NCT01419977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829757|NCT00037713|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829758|NCT04629443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829759|NCT02338427|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829760|NCT05181397|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are planned to be separated into two groups. 68 participants with severe RP-ILD secondary to systemic diseases will be randomly assigned to receive intravenous 8mg/kg tocilizumab or regular treatment.||||
33829761|NCT05096078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829762|NCT03272529|||COHORT||PROSPECTIVE|||||||
33829763|NCT05771025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139252|NCT06398431|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The subject wears shoes equipped with sensors, and walks for 1 minute, repeating this three times. We plan to machine learn the correlation between walking data and BBS data. Since machine learning becomes more accurate as the number increases, the analysis group was set at 51 people.||||
34139253|NCT01606683|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34139254|NCT04667520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139255|NCT02072460||FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34139256|NCT05882864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study is designed to be a prospective randomized double blind 2 parallel arms controlled clinical trial.|"Group I Will include 14 patients receiving topical ginger extract 1% four times per day (after every meal and before going to bed) for eight weeks (Zakaria et al., 2020).~Group II Will include 14 patients receiving topical steroid (triamcinolone acetonide 0.1%) four times per day for eight weeks (Laeijendecker et al., 2006)"|t|t|f|f
34139257|NCT01025076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139258|NCT00908869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139259|NCT02687555|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139260|NCT01117740|||CASE_ONLY||PROSPECTIVE|||||||
34139261|NCT06438445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34139262|NCT02186652|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139263|NCT06605482|||COHORT||PROSPECTIVE|||||||
34139264|NCT01528891|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34139265|NCT00597311|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139266|NCT06002854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139267|NCT06602388|||COHORT||PROSPECTIVE|||||||
34139268|NCT06218251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139269|NCT04960930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Drug: FMX101 FMX101, 4% minocycline foam~Drug: Vehicle Foam Vehicle Foam"|t|t|t|t
34139270|NCT02685748|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139271|NCT01098604|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139272|NCT01235923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139273|NCT02794844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149847|NCT01518504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34149848|NCT02303106|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34149849|NCT04874090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We have two groups. First group will recieve acupuncture treatment and exercise group, second group will recieve only exercise treatment|f|f|f|t
34149850|NCT06219395|||OTHER||PROSPECTIVE|||||||
34149851|NCT00889200|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139274|NCT06311136|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"During the treatment phase, both the intervention and monitoring-only control groups use a diary called Positive Everyday Affect Knowledge. Participants are informed that the diary entries may include instructions for implementing specific emotion regulation strategies in their daily activities. However, this component of the procedure is not characterized explicitly as an intervention. This methodological consideration ensures that differences observed between the groups can be attributed to the intervention itself, rather than to differences in participants' expectations.~Clinical interviews will be conducted blindly."|Randomized Controlled Trial with an Intervention Group and a Control Group without an intervention.|t|f|f|t
34139275|NCT05752942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||single-level two-arm randomized waitlist-controlled trial|t|t|f|t
34139276|NCT00027365||||PREVENTION||DOUBLE||||||
34139277|NCT00813605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139278|NCT06604988|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|A masking technique will be applied during the evaluation/recording phases of primary and secondary variables, as well as in the statistical analysis phase as described below. During the recording of variables, participants will only be identified by an alphanumeric label and without any reference to the group assigned at the beginning of the investigation. As regards data analysis, this will be carried out using anonymized databases and, automatically, a correspondence will be made between the participant\&amp;amp;amp;amp;#39;s identifier and the group to which he/she has been assigned to carry out the appropriate statistical analyses.|Development of an evidence-based intervention to improve parenting. This evidence is based on a randomized controlled trial with longitudinal data collection. Once the informed consent is signed, all the information that will conform the baseline is collected (Wave 0) in all cases; those families meeting inclusion criteria will be provided with an alphanumeric label which corresponds to their anonymous identifier; families are then randomly assigned to the intervention or control groups according to a computer routine; during the following 6 months, measurements of some of the primary variables are collected up to a total of 3 times; after this time, the post-intervention measurement is collected (Wave 1); and finally a final collection is made after another 6 months (Wave 2).|t|f|t|t
34139279|NCT00537667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139280|NCT04315792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-blind study||t|f|t|f
34139281|NCT05280002|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both clinical and high-frequency-ultrasound-scanning Assessors were blinded about the case and control.||f|f|f|t
34139282|NCT00809991|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139283|NCT02884167|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34139284|NCT00931723|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139285|NCT05230108|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The fourth step is a quasi-experimental study consisting of two phases: the first, a retrospective control phase, and the second, a prospective intervention phase in which advanced triage will be implemented. In phase 1, control, quality of care indicators will be assessed, based on quality indicators in the emergency department, waiting time and satisfaction, and the level of pain. In addition, different epidemiological, socio-cultural and clinical variables will be measured. In phase 2, the intervention phase, advanced triage will be implemented based on advanced practices nurse and the indicators of quality of care and pain will be assessed.||||
34139286|NCT06598072|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking involves several key roles to ensure unbiased results and to maintain the integrity of the study results. The Participant, Care Provider, Investigator, and Outcomes Assessor are all masked in this double-blind study. The participants do not know which group they have been assigned to, the care providers administering the treatments are unaware of the specific products being used by each participant, the investigators conducting the study do not know the group assignments, and the outcomes assessors evaluating the results are blind to the treatment allocations.|This is a Phase III, randomized, controlled, double-blind, parallel-group clinical trial|t|t|t|t
34139287|NCT01408550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139288|NCT01261013|||CASE_ONLY||PROSPECTIVE|||||||
34139289|NCT00191724|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139290|NCT03227952|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|a sham device identical to the active device|Parallel Assignment|t|t|t|t
34139291|NCT06606509|||CASE_ONLY||CROSS_SECTIONAL|||||||
34139292|NCT05986968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139293|NCT05293613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139294|NCT04397159|RANDOMIZED|PARALLEL||TREATMENT||NONE||Flywheel Resistance Plus Aerobic Exercise||||
34139295|NCT06224439|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34139296|NCT02762240|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34139297|NCT01949025|RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|||f|f|f|t
34139298|NCT05894096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be randomly distributed into two arms: Experimental and Control. Ulcers will be treated in all patients of the experimental arm using the PlasmAction Med cold plasma generator. The plasma jet will be programmed to be applied with an intensity of 55% power and with 60 seconds/cm2 of surface, the frequency being twice a week for 10 weeks. This therapeutic regimen is based on previous studies of previously published clinical trials with argon jet cold plasma (14,15). The administration of treatment will be the responsibility of the principal investigator and the collaborator with the help of the nursing staff. After the application of the plasma treatment, the patient will then be cured with alginate (Melgisorb Ag®) of the size 10 X 10 cm and 5x5 (3 units). For patients included in the control arm, alginate (Melgisorb Ag®) will be used as a cure for ulcers, size 10 X 10 cm and 5x5 (3 units), whose replacements will also be carried out twice a week.|"* Prospective, randomized, open-label, controlled clinical trial with conventional treatment.~* Programming and continuous recruitment.~* The ulcers of the experimental group will be treated with 60 seconds/cm2 of the wound surface, carried out twice a week, and with alginate with silver. For their part, the ulcers in the control group will be treated with alginate with silver, which will also be replaced twice a week.~* The total duration of the trial for each patient will be 10 weeks (2 times per week) followed by 8 weeks of follow-up.~* The treatment will be carried out twice a week, maintaining at least 72 hours between treatments.~* The patients included in this trial will be all those who attend consultations or are hospitalized. They must present at least one venous ulcer larger than 1 cm2 that has not healed in the last 8 weeks from its onset and with no surgical indication for ulcer coverage by a skin graft."|t|f|f|f
34139299|NCT04975919|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139300|NCT02446704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139301|NCT02455661|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Radial closure by TR-Band.||||
34139302|NCT02825966|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subject first wears the AUDICOR-AM device for 15 minutes while sitting. Then the AUDICOR device is removed and the subject wears the WCD for 12-16 hours. After the WCD wear period, the WCD device is removed and the subject wears the AUDICOR device again for 15 minutes.||||
34139303|NCT02419196|||COHORT||PROSPECTIVE|||||||
34139304|NCT00842946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139305|NCT02873065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139306|NCT03294174|||CASE_CONTROL||PROSPECTIVE|||||||
34139307|NCT05897190|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34139308|NCT03923621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139309|NCT00797446|||COHORT||PROSPECTIVE|||||||
34139310|NCT00387179|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34139311|NCT02973542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139312|NCT00762138|NA|SINGLE_GROUP||||NONE||||||
34139313|NCT03524690|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized, cross-over controlled trial||||
34139314|NCT05929001|||COHORT||PROSPECTIVE|||||||
34139315|NCT01318278|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139316|NCT01683916|||CASE_CONTROL||PROSPECTIVE|||||||
34139317|NCT02105493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34139318|NCT01280058|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139319|NCT02281786|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33829764|NCT02937896|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139320|NCT02109432|NA|SINGLE_GROUP||OTHER||NONE||||||
34139321|NCT02927704|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34139322|NCT01025349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139323|NCT03584997|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139324|NCT02829736|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization occurs after ended surgery, thus masking allocation to the personnel and participant. After Randomization, there is no masking.||t|t|f|f
34139325|NCT04149158|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34139326|NCT06170346|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34139327|NCT02657655|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139328|NCT03905239|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34139329|NCT00489424|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139330|NCT03828422|||CASE_CONTROL||PROSPECTIVE|||||||
34139331|NCT06020066|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139332|NCT02918396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829765|NCT04199455|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829766|NCT05195892|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829767|NCT02599493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829768|NCT02554383|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139333|NCT00675818|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139334|NCT04419051|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34139335|NCT06439433|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829769|NCT04636957|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829770|NCT02351336|||COHORT||PROSPECTIVE|||||||
33829771|NCT04853134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.|t|t|t|t
34139336|NCT00451126|||NATURAL_HISTORY||OTHER|||||||
34139337|NCT06314477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139338|NCT03600636|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34139339|NCT05166278|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"The hospital staff will be unaware of the aim and the design of the study. All psychiatric hospitals will be informed that de-escalation training will be provided within 2 years.~Data from the SOAS-R forms and documentation for the use of physical restraint will be transferred to electronic databases by an independent collaborator who is not familiar with the design of the study. The randomization will be performed after the baseline period, so the baseline data could not be biased."|During the five months of the baseline period, the management of aggressive behavior in all psychiatric hospitals will be the same as usual. Before the five months of the intervention period, hospitals will be randomly assigned to either an experimental or control group in the 1:1 ratio. The staff in the experimental group will receive training in verbal and nonverbal de-escalation techniques, and in the control group, the staff will manage aggressive behavior as usual. Regular annual training on the use of coercive measures will be conducted as usual in all hospitals during the study.|f|f|f|t
34139340|NCT06367686|||COHORT||PROSPECTIVE|||||||
33829772|NCT04909671|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33829773|NCT02713971|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829774|NCT02163798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829775|NCT04308213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829776|NCT00136682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829777|NCT04060732|||CASE_ONLY||PROSPECTIVE|||||||
33829778|NCT04067271|||COHORT||PROSPECTIVE|||||||
33829779|NCT05064644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139341|NCT05285618|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139342|NCT03457142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139343|NCT01304212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139344|NCT04131387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139345|NCT03526809|||CASE_ONLY||PROSPECTIVE|||||||
34139346|NCT04549805|||COHORT||CROSS_SECTIONAL|||||||
34139347|NCT02727387|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139348|NCT06219772|||COHORT||CROSS_SECTIONAL|||||||
34139349|NCT03752346|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34139350|NCT05921695|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34139351|NCT05392790|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139352|NCT06514664|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Clinical Trial||||
34139353|NCT05480189|||OTHER||PROSPECTIVE|||||||
33829780|NCT03479125|||CASE_ONLY||PROSPECTIVE|||||||
33829781|NCT05887141|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two independent substudies, each with two arms. N=68 per substudy (N=136 total)||||
33829782|NCT01745276|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33829783|NCT00000902||||TREATMENT||||||||
33829784|NCT05609799|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|No treatment intervention, only a blood sample is collected|One group of healthy females. A blood sample is collected in the luteal phase; parts are saved for a biobank for future studies and parts are analyzed immediately for leucocyte subsets. This group will serve as a reference to other studies on (immunological) diseases in women of reproductive age.||||
33829785|NCT04360798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829786|NCT03219671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829787|NCT06480877|||OTHER||CROSS_SECTIONAL|||||||
33829788|NCT02215954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33829789|NCT03043482|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829790|NCT01675310|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829791|NCT05845840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33829792|NCT05938101|||COHORT||PROSPECTIVE|||||||
33829793|NCT02302703|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33829794|NCT05046093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829795|NCT06385613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Individuals assigned to controls and interventions will not know which group they are in.|Groups will be divided into control and intervention. People in the group will be randomly assigned in a simple randomized manner.|t|f|f|f
33829796|NCT00705562|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829797|NCT05348668|NA|SINGLE_GROUP||TREATMENT||NONE||74 patients with metastatic driven-genes negative non-small cell lung cancer to receive the combination of hybrid dose-fraction radiotherapy with ICI||||
33829798|NCT00237354|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829799|NCT02259062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829800|NCT04621968|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
33829801|NCT03827850|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients with NSCLC and FGFR alteration with high evidence on oncogenic transformation according to FIND molecular board will be included to cohort 1 (FGFR translocated NSCLC patients) and cohort 2 (FGFR mutated NSCLC patients). Patients with NSCLC and FGFR alterations without enough evidence (intermediate / low evidence according to FIND molecular tumor board) for recruitment into cohorts 1 or 2, will be treated in cohort 3. Overall response rate under Erdafitinib treatment will be the primary endpoint.||||
33829802|NCT03209245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment with placebo - placebo groub|Treatment of AIT- active group|f|f|t|f
33829803|NCT04703868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829804|NCT05146206|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33829805|NCT00466271|||CASE_ONLY||CROSS_SECTIONAL|||||||
33829806|NCT00146510|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33829807|NCT02785445|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829808|NCT01049386|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33829809|NCT00066846||||TREATMENT||NONE||||||
33829810|NCT03000348|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829811|NCT06216795|||COHORT||RETROSPECTIVE|||||||
33829812|NCT01155076|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33829813|NCT03318783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Investigational pharmacy staff will maintain the randomization list and study/drug placebo assignment. Participants, care providers, the investigators and outcomes assessors will be blinded to the grouping.|"Subjects will be randomized to one of the two treatment arms based on an unrestricted or fair-coin randomization procedure."|t|t|t|t
33829814|NCT04919733|NA|SINGLE_GROUP||TREATMENT||NONE||To ascertain if the use of 3-D mapping systems reduces the need of fluoroscopy during a CIED (pacemaker or defibrillator) implant||||
33829815|NCT01502306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829816|NCT01165398|||COHORT||RETROSPECTIVE|||||||
33829817|NCT00409409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829818|NCT02023905|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829819|NCT01514955|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
33829820|NCT01397500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829821|NCT04532762|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||This is a prospective, placebo-controlled, double-blinded randomized two-way cross-over single site study in adult subjects (18 to 65 years) who demonstrate a grass pollen specific Immunoglobulin E (IgE) reactivity and have a history of grass pollen induced allergic rhinitis/rhinoconjunctivitis with or without controlled asthma. In the cross-over setting Coldamaris akut nasal spray will be evaluated compared to Coldamaris sine 0.5% nasal spray.|t|t|t|t
33829822|NCT00108498|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33829823|NCT01584518|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33829824|NCT00371462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829825|NCT04038671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829826|NCT05376878|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33829827|NCT06386445|||COHORT||PROSPECTIVE|||||||
33829828|NCT00038155|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829829|NCT03616860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829830|NCT04582513|||COHORT||PROSPECTIVE|||||||
33829831|NCT05372471|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized controlled clinical trial, not blinded.||||
33829832|NCT06436495|NA|SINGLE_GROUP||OTHER||NONE||||||
33829833|NCT00522509|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33829834|NCT00222690|||||OTHER|||||||
33829835|NCT03903523|||COHORT||RETROSPECTIVE|||||||
33829836|NCT06497790|||COHORT||PROSPECTIVE|||||||
33829837|NCT04566198|||COHORT||PROSPECTIVE|||||||
33829838|NCT02039544|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829839|NCT04081389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829840|NCT06109168|||COHORT||CROSS_SECTIONAL|||||||
33829841|NCT02650986|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33829842|NCT04427878|NA|SINGLE_GROUP||OTHER||NONE||||||
33829843|NCT03990298|NA|SINGLE_GROUP||OTHER||NONE||||||
33838553|NCT05948969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139354|NCT01593995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139355|NCT04472117|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||There will be three phases in this study. Phase I will comprise 25 evaluable women (15 pre-operatively and a separate 10 post-operatively). The results of the pre-operative interviews will be closely monitored for data saturation and we may stop accrual earlier than the planned 15. Phase II will comprise 100 evaluable women. Phase III will comprise 100 evaluable women. All patients will undergo standard-of-care MIS hysterectomy, with standard follow-up with the addition of the interventions and randomization takes place here. Phase III participants will be deemed evaluable if they complete required surveys and if their charts contain sufficient information to determine their day-surgery status.||||
34139356|NCT00201448|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34139357|NCT03147612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139358|NCT02346331|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139359|NCT05369520|RANDOMIZED|PARALLEL||TREATMENT||NONE||Using a randomized counter-balanced approach, individuals will be allocated in two distinct pathways; the participants in Groups 1 (thoracic stimulation) and Group 2 (lumbosacral stimulation) will receive 8 weeks of TCSCS (3 times/week) at either mid/low thoracic or lumbosacral spinal cord levels respectively.||||
34139360|NCT06410261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34139361|NCT03100981|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Assessors performing introduction calls are masked in the sense that participants will not be randomized until after the introduction call. All questionnaires are completed as online surveys and are hence masked for group allocation.|"After baseline assessment, participants will be randomly assigned to either the intervention or the control group. Both groups will receive online questionnaires at 5 weeks (midway), 10 weeks (post treatment) and 36 weeks (6 months follow-up) after baseline assessment.~The intervention group receives a therapist phone call prior to enrollment in the internet-delivered treatment and then participates in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy. The internet-delivered treatment also comprises weekly distress measures, including suicide risk screening, and assessment of working alliance at week 2, 4, and 7 of the course."|f|f|t|t
34139362|NCT01571050|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34139363|NCT04256668|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Sperm samples will be collected, processed and stained at the hospital site (RME). Slides generated for imaging will be assigned an anonymous code, removing all possible patient identifiable features. Then the slides will be sent to the research laboratory (FMI) for further analysis.|"20 infertile men treated with assisted reproduction with normal embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal fertilization rate \>50% and normal blastocyst development rate \>50%).~20 infertile men treated with assisted reproduction with poor embryo development in vitro, as demonstrated in a previous treatment with assisted reproductive technology (defined by normal or slightly reduced fertilization rate \<50% and low or absent blastocyst development (0 or only 1 blastocyst).~20 previously infertile men, normal history, normal genital status, normal sperm count, DNA fragmentation rate \<20% (as given by TUNEL) and achieving pregnancy naturally (without medical intervention)."|f|f|t|t
34139364|NCT02333682|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139365|NCT02368912|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34139366|NCT06457230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139367|NCT04742348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139368|NCT00709293|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34139369|NCT05333172|RANDOMIZED|PARALLEL||OTHER||NONE||randomized controlled||||
34139370|NCT04894305|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34139371|NCT05826418|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139372|NCT03396367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139373|NCT05210699|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34139374|NCT03418649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Drug or look-alike placebo dispensed according to a randomization schedule.|Double blind placebo controlled. Equal numbers of subjects receive 10 day course of eplerenone or placebo following their clinically indicated epidural steroid injection|t|t|t|f
34139375|NCT04883879|||COHORT||PROSPECTIVE|||||||
34139376|NCT00592163|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139377|NCT01774097|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139378|NCT00570037|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139379|NCT02596958|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34139380|NCT05642234|||CASE_ONLY||PROSPECTIVE|||||||
34139381|NCT05966363|||COHORT||PROSPECTIVE|||||||
34139382|NCT00003603|RANDOMIZED|||TREATMENT||||||||
34139383|NCT05379517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study is planned as simple blind since the person who performs evaluation is external to participant recruitment and intervention.||f|f|f|t
34139384|NCT00932269|||COHORT||CROSS_SECTIONAL|||||||
34139385|NCT05311995|RANDOMIZED|PARALLEL||TREATMENT||NONE||Four trocar tecnıques groups in literature||||
34139386|NCT06454448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139387|NCT03769818|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participating patients, surgeons, anesthesiologists and medical investigators who will be involved in the data collection will be all blinded to the patient's group assignment until the collection of data for all cases will be complete for group 1 and 2.|A prospective Randomized Interventional double-blind study.|t|t|t|t
34139388|NCT03075488|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34139389|NCT01969383|NA|SINGLE_GROUP||||NONE||||||
34139390|NCT02607917|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139391|NCT06608433|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34149852|NCT06530134|RANDOMIZED|PARALLEL||OTHER||NONE||This research is part of a Research Involving the Human Person of the interventional with minimal risks and constraints type (RIPH2).This is a prospective, monocentric, comparative, randomized and controlled study.||||
33829844|NCT06336512|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Newly Pregnant Women with singleton fetus||||
33829845|NCT02565550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829846|NCT00936962|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33829847|NCT03297762|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829848|NCT05000099|||CASE_CONTROL||PROSPECTIVE|||||||
33829849|NCT00251615|||COHORT||CROSS_SECTIONAL|||||||
34139392|NCT05083546|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be computer sequence-randomized to receive either oral daily dosing ofthe MGO cocktail or placebo. Both participants and study team members will be blinded to treatment arm.|Double-Blinded, Randomized Control Trial|t|t|t|f
34139393|NCT02357082|||COHORT||PROSPECTIVE|||||||
34139394|NCT03822598|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Two stages of recruitment: 1) We recruited asylum reception centers and refugee resettlement municipalities located all over Norway 2) Invite asylum-seeking and refugee children in these institutions to participate, and assigning them by intstitution to control and intervention conditions. The intervention groups started implementing TRT between late September and late October. The control groups started implementing TRT between medio November and beginning of February.|f|f|t|t
34139395|NCT06608914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139396|NCT02647541|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139397|NCT03910738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 2 trial|t|t|t|t
34139398|NCT06244082|NA|SINGLE_GROUP||TREATMENT||NONE|Randomization from the parent study, AOC 1044-CS1 will remain blinded.|||||
34139399|NCT03895398|RANDOMIZED|PARALLEL||OTHER||NONE||in the intervention arm: ECE teachesr, community health officers, mother, and children will received treatment in the form of trainings (for ECE teachers and community health officers), parenting class (for mother), and nutrient dense food supplementation (for children) whilst in the control arm will received nothing as comparison to the intervention arm.||||
34139400|NCT05783245|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139401|NCT04809558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will only know exercise instructions for the group he/she is randomized to. Participant will not be provided with information about other groups.||t|f|f|f
34139402|NCT03260894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139403|NCT05504304|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139404|NCT06602050|||COHORT||PROSPECTIVE|||||||
34139405|NCT00835640|RANDOMIZED|CROSSOVER||||NONE||||||
34139406|NCT05700149|||COHORT||RETROSPECTIVE|||||||
34139407|NCT02059889|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139408|NCT02968160|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139409|NCT02654288|||COHORT||PROSPECTIVE|||||||
34139410|NCT04837209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139411|NCT04172415|||OTHER||RETROSPECTIVE|||||||
34139412|NCT03991403|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139413|NCT06607952|RANDOMIZED|PARALLEL||OTHER||NONE|Non|This study is a two-group, pre- and post-test, parallel, non-blind randomized controlled trial. Participants will be randomly assigned to either the experimental group class or the control group class.||||
34139414|NCT01079546|||COHORT||RETROSPECTIVE|||||||
34139415|NCT04404114|||CASE_CONTROL||PROSPECTIVE|||||||
34139416|NCT01815554|||CASE_ONLY||PROSPECTIVE|||||||
34139417|NCT01632475|||CASE_ONLY||PROSPECTIVE|||||||
34139418|NCT00620425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139419|NCT05907954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139420|NCT05731908|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139421|NCT03817463|||COHORT||PROSPECTIVE|||||||
34139422|NCT02906449|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139423|NCT05519436|||OTHER||RETROSPECTIVE|||||||
34139424|NCT05772663|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139425|NCT06596954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139426|NCT00599391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139427|NCT03424954|NA|SINGLE_GROUP||PREVENTION||NONE||All patients undergoing ileostomy surgery will receive the study intervention. We will compare to a historical control.||||
34139428|NCT03620552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139429|NCT02715882|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139430|NCT06599710|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single-arm pilot nutritional study, multicentric||||
34139431|NCT00884039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139432|NCT00378625|RANDOMIZED|PARALLEL||||DOUBLE||||||
34139433|NCT04620382|RANDOMIZED|CROSSOVER||OTHER||SINGLE|placebo pill and sham abdominal compression will be used|Randomized, single-blind, crossover|t|f|f|f
34139434|NCT00516893|NA|SINGLE_GROUP||||NONE||||||
34139435|NCT06489821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139436|NCT02378012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139437|NCT04527237|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34139438|NCT01723293|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34139439|NCT05745987|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants will not know which vaccine they receive until after the study is completed.|Each group will be randomly selected to receive the smallpox vaccine or the typhoid vaccine|t|f|t|t
34139440|NCT01394757|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33829850|NCT03717883|||COHORT||OTHER|||||||
33829851|NCT01084993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838554|NCT00090155|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33838555|NCT04139382|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
34139441|NCT01029990|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|t|f|f
34139442|NCT00340860|||COHORT||PROSPECTIVE|||||||
34139443|NCT02591667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139444|NCT04934709|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|A researcher programmed the device (placebo or PMBT-sMF) and was instructed not to inform the volunteers or other researchers as to the type of treatment (placebo or PBMT-sMF). Therefore, the researcher responsible for the treatment was blinded to the type of treatment administered to the volunteers. The sounds and signals emitted from the device as well as the information displayed on the screen was identical, regardless of the type of treatment (placebo or PBMT).||t|t|t|t
34139445|NCT02203383|||CASE_CONTROL||PROSPECTIVE|||||||
34139446|NCT06542575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34139447|NCT00284557|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139448|NCT05353712|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34139449|NCT02359045|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33829852|NCT03889054|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized and parallel clinical trial of 66 patients (33 with health education associated with respiratory rehabilitation and 33 only with respiratory rehabilitation). There will be a follow-up of 6 months and 4 visits.||||
33829853|NCT02874573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829854|NCT01957592|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33829855|NCT03497143|||CASE_ONLY||PROSPECTIVE|||||||
33829856|NCT00216957|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829857|NCT06009744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Group a) 25-35 kcal/K/d, 1.3-1.5 g/K/d of amino acids and C 100-300 mg/d y zinc 3-5 mg/d Group b) 25-35 kcal/K/d, 1.3-1.5 g/K/d of amino acids and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d.|t|t|f|t
33829858|NCT03550053|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patient will not know which group they are randomized to.|Patients with head and neck cancer, specifically requiring surgery to their mandible.|t|f|f|f
33829859|NCT04250688|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139450|NCT06474507|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829860|NCT01044836|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33829861|NCT04160910|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33829862|NCT02442245|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33829863|NCT00542932|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829864|NCT04913623|||CASE_CONTROL||PROSPECTIVE|||||||
33829865|NCT00345709|||CASE_ONLY|||||||||
33829866|NCT04302649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829867|NCT00643318|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829868|NCT02602353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829869|NCT06194682|||COHORT||OTHER|||||||
33829870|NCT05242822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33829871|NCT00716547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829872|NCT02392663|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33829873|NCT05168137|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double blind, controlled study|t|t|t|f
33829874|NCT03046381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829875|NCT00607997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829876|NCT06308185|||CASE_ONLY||RETROSPECTIVE|||||||
33829877|NCT03022578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829878|NCT00566839|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33829879|NCT01961674|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33829880|NCT04267471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829881|NCT04735198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829882|NCT05221177|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|t|f
33829883|NCT01016418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829884|NCT02283021|||COHORT||PROSPECTIVE|||||||
33829885|NCT05999019|||COHORT||RETROSPECTIVE|||||||
33829886|NCT03032640|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33829887|NCT00730821||||TREATMENT||||||||
33829888|NCT01227928|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829889|NCT05897983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829890|NCT01700322|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33829891|NCT01402063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829892|NCT02726477|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829893|NCT04485754|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829894|NCT01161446|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33829895|NCT00139581|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829896|NCT00970320|RANDOMIZED|PARALLEL||||NONE||||||
33829897|NCT05689281|NA|SINGLE_GROUP||PREVENTION||NONE||Participants will be recruited on a rolling basis for a randomized, unblinded, cross-over stepped wedge study design||||
33829898|NCT00239447|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33829899|NCT04224259|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33829900|NCT02634814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829901|NCT05605561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, study and control groups were determined using the simple randomization method to prevent selection bias. Patients do not know that they are in the experimental and control groups. The data in the study was collected by the researcher. To prevent bias during data collection, the State Anxiety Scale, which could enable patients to self-report, was used. The research was conducted according to the CONSORT 2010 reporting guideline (Schulz et al., 2010). In order to prevent reporting bias, the research data were evaluated by a statistician.||t|f|f|f
33829902|NCT06003699|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
33829903|NCT06410339|||COHORT||PROSPECTIVE|||||||
33829904|NCT01058083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829905|NCT03912974|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Pretreatment condition is double-blinded (escitalopram 10 mg x 7 days, then 20 mg orally x 7 days vs. placebo (mannitol) orally x 14 days) On each of the 2 study days, participants will receive psilocybin 25 mg orally (no placebo control on the study days)|2-period cross-over, randomized, double-blinded (escitalopram vs. placebo)study|t|t|t|f
33829906|NCT04333147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a parallel group treatment study with two arms that are initially participant and investigator blinded. A participant's treatment allocation will remain blinded at least until their qualifying study has been reported.|Participants who received GSK3196165 in their qualifying study will continue in this study on the same dose. Participants who received a comparator (tofacitinib or sarilumab) in their qualifying study will be centrally randomized using interactive response technology (IRT) in a ratio of 1:1 to either GSK3196165 90 mg or 150 mg.|t|f|t|f
33829907|NCT00285441|||DEFINED_POPULATION||PROSPECTIVE|||||||
33829908|NCT01134471|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829909|NCT05671978|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33829910|NCT04111900|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829911|NCT03171116|||COHORT||CROSS_SECTIONAL|||||||
33829912|NCT00569192|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139451|NCT03167970|||OTHER||PROSPECTIVE|||||||
34139452|NCT03123705|||COHORT||PROSPECTIVE|||||||
34139453|NCT00882037|||OTHER||PROSPECTIVE|||||||
33829913|NCT00585975|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139454|NCT04274049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829914|NCT02049112|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829915|NCT00085111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829916|NCT02719925|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829917|NCT01401114|||CASE_ONLY||PROSPECTIVE|||||||
33829918|NCT05220956|RANDOMIZED|PARALLEL||SCREENING||NONE||This is a randomised controlled study with NAFLD-patients. One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks. The control arm is not subject to any time restrictions concerning eating.||||
33829919|NCT02584036|||COHORT||PROSPECTIVE|||||||
33829920|NCT02144168|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33829921|NCT05082207|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33829922|NCT02643745|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33829923|NCT01340014|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33829924|NCT05683912|||COHORT||PROSPECTIVE|||||||
33829925|NCT06264505|||CASE_CROSSOVER||PROSPECTIVE|||||||
33829926|NCT01324700|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
33829927|NCT00220480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829928|NCT01081015|||COHORT||PROSPECTIVE|||||||
33829929|NCT05076188|||CASE_CONTROL||RETROSPECTIVE|||||||
33829930|NCT02584881|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33829931|NCT00239096|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33829932|NCT03470792|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33829933|NCT05484232|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829934|NCT00605995|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829935|NCT02894905|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829936|NCT04012190|||COHORT||PROSPECTIVE|||||||
33829937|NCT05417802|||COHORT||RETROSPECTIVE|||||||
33829938|NCT03584256|||COHORT||CROSS_SECTIONAL|||||||
33829939|NCT04230668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is a two-phased study. Phase 1 of this investigation will consist of an initial case series in which the CPT+SRM manual will be developed along with fidelity measures. The finalized treatment manual will then be tested in Phase 2, a randomized-controlled trial comparing 12 individual sessions/6 weeks of CPT+SRM versus 6 weeks of TAU+SRM.|f|f|f|t
33829940|NCT03428464|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33829941|NCT00644956|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829942|NCT05183256|||COHORT||PROSPECTIVE|||||||
33829943|NCT04150185|||COHORT||PROSPECTIVE|||||||
33829944|NCT04008147|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33829945|NCT03343210|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829946|NCT04668703|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33829947|NCT00865137|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829948|NCT06546150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829949|NCT04136600|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
33829950|NCT05879562|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|Participants are blinded to which test is the one being validated.||t|f|f|f
33829951|NCT00695825|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33829952|NCT00774423|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829953|NCT03884062|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33829954|NCT03146897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829955|NCT04094181|||CASE_ONLY||OTHER|||||||
33829956|NCT03094455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It will be a parallel RCT with a waitlist design|f|f|f|t
33829957|NCT05604508|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33829958|NCT01253447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829959|NCT01816685|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33829960|NCT05399615|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||parallel assignment||||
33829961|NCT01196585|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33829962|NCT00890799|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33829963|NCT00000850||||TREATMENT||||||||
33829964|NCT05413837|||COHORT||PROSPECTIVE|||||||
33829965|NCT02739776|||COHORT||PROSPECTIVE|||||||
33829966|NCT03819751|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients receive both types of biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.||||
33829967|NCT01145820|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33829968|NCT05467345|||COHORT||CROSS_SECTIONAL|||||||
33829969|NCT00127400|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33829970|NCT04212780|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|f|f|t
33829971|NCT02767609|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139455|NCT05210803|||OTHER||PROSPECTIVE|||||||
33829972|NCT01114139|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33829973|NCT06545812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829974|NCT04823364|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE|No masking|Group 1 control healthy people Group 2 ADHD||||
33829975|NCT01650883|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829976|NCT04055415|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33829977|NCT05425225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33829978|NCT00519064|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33829979|NCT04185922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients are randomized to receive RARP and BPLND, with or without Hemopatch, with an allocation ratio of 1:1.|This is a prospective; single-centre phase 3 randomised controlled trial conducted to investigate the efficacy of Hemopatch for preventing lymphatic leak after RARP and BPLND.|t|f|f|f
33829980|NCT02964546|||OTHER||PROSPECTIVE|||||||
33829981|NCT01413022|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829982|NCT02945878|||COHORT||PROSPECTIVE|||||||
33829983|NCT03420261|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33829984|NCT00818870|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33829985|NCT01822145|||COHORT||PROSPECTIVE|||||||
33829986|NCT01531907|||CASE_CONTROL||PROSPECTIVE|||||||
34139456|NCT05133622|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34139457|NCT06414148|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase II open-label, two-arm randomised non-comparative, multicentre study||||
34139458|NCT00713349|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34139459|NCT03317626|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139460|NCT05370963|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139461|NCT05594121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor blinded to intervention code.|"Pragmatic, multi-centre, randomised, controlled, open-label, superiority study with two parallel groups and primary endpoints of opioid positivity and healthcare utilization at 12 months after enrollment. Randomization will be performed with a 1:1 allocation ratio using a stratified, permuted-block group schema according to the following strata (no fixed ratio):~1. RAAM clinic site (Barrie, Orillia, Midland, Wasaga Beach)~2. Severity of OUD according to DSM-V criteria (moderate vs severe)"|f|f|f|t
34139462|NCT05460364|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139463|NCT04686084|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139464|NCT01320319|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34139465|NCT04342026|||CASE_CONTROL||PROSPECTIVE|||||||
34139466|NCT04801238|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The obvious advantages of a one-step procedure compared with a two-step procedure are the fewer surgical procedures required to clear CBDS and to remove the gallbladder. Due to the nature of the surgical interventions, blinding of patients or physicians is not possible for this trial. Most of the outcomes are dependent on the physician's clinical assessment. However, we will engage a blinded adjudication committee of 3 independent experts who will examine medical charts from randomisation to 90-day follow-up for outcome assessment. Photocopies of the medical charts will have intervention blinded. Also photocopies or print outs of medical charts will be changed so that follow up interventions will become blinded for initial intervention in both intervention groups.|The preGallStep is an investigator-initiated, multicentre randomised parallel group, clinical pilot trial, with blinded outcome assessment investigating one-step laparoscopic cholecystectomy with common bile duct exploration and stone extraction versus two-step endoscopic retrograde cholangiography with stone extraction plus laparoscopic cholecystectomy for patients with common bile duct stones.|f|f|f|t
34139467|NCT04484896|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participant did not know the difference between the three message.||t|f|f|f
34139468|NCT01824823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139469|NCT05925413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139470|NCT01345591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139471|NCT04275271|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34139472|NCT01202539|||CASE_ONLY||PROSPECTIVE|||||||
34139473|NCT00241631|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139474|NCT06607133|||COHORT||PROSPECTIVE|||||||
34139475|NCT02624934|||CASE_ONLY||PROSPECTIVE|||||||
34139476|NCT03453762|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34139477|NCT03699059|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No blinding. Purposive sampling of the 15 subjects- 5 HCP, 10 kidney transplant patients.|A small study creating a kidney transplant specific online weight gain prevention tool with qualitative data from 15 participants (5 transplant MDT members and 10 kidney transplant recipients)||||
34139478|NCT02753556|||OTHER||CROSS_SECTIONAL|||||||
34139479|NCT05864365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139480|NCT02347553|||OTHER||PROSPECTIVE|||||||
34139481|NCT05231577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139482|NCT04043234|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|The occupational therapist who graded the AM-ULA functional assessment was masked to participant IDs and intervention|Single-Case Experimental Design (SCED)||||
34139483|NCT05557552|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139484|NCT03103204|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139485|NCT01678573|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139486|NCT06425939|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33829987|NCT06360952|||COHORT||PROSPECTIVE|||||||
33829988|NCT03602222|RANDOMIZED|PARALLEL||OTHER||NONE||120 MHPs will be randomized to receive the training either in-person or mobile on the web, concomitantly.||||
34139487|NCT04734522|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34139488|NCT03416920|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Enroll and onboard 150 patients with the Wellframe application||||
34139489|NCT02534935|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34139490|NCT02495246|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139491|NCT04170504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139492|NCT00619424|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139493|NCT04983875|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|f|t|t
34139494|NCT02808195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139495|NCT05837403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33829989|NCT01799109|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33829990|NCT00392704|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829991|NCT03211585|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33829992|NCT01726049|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33829993|NCT00230945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33829994|NCT04924049|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Two-arm \[1:1\], parallel group, prospective, randomized-controlled clinical trial|f|f|f|t
33829995|NCT01271023|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838556|NCT03011762|NA|SINGLE_GROUP||OTHER||NONE||||||
34139496|NCT04405128|||CASE_CONTROL||PROSPECTIVE|||||||
34139497|NCT00510718||||TREATMENT||NONE||||||
34139498|NCT02154620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139499|NCT00446953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139500|NCT05726565|||COHORT||RETROSPECTIVE|||||||
34139501|NCT00304694|||||OTHER|||||||
34139502|NCT04576039|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139503|NCT06592495|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149853|NCT04312763|||OTHER||CROSS_SECTIONAL|||||||
34149854|NCT01072825|||COHORT||PROSPECTIVE|||||||
34149855|NCT02239146|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149856|NCT02530736|||COHORT||PROSPECTIVE|||||||
34139504|NCT04824768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An introductory massage was performed on the lumbar region and hamstrings of the most affected leg, in conjunction with Tecar therapy in the resistive modality (0W). Functional Massage was then performed on the gastrocnemius, with Tecar in resistive mode (0W), and then in capacitive mode (0VA).|An introductory massage was performed on the lumbar region and hamstrings of the most affected leg, in conjunction with Tecar therapy in the resistive modality (80W). Functional Massage was then performed on the gastrocnemius, with Tecar in resistive mode (100-120W), and then in capacitive mode (180-200VA).|t|f|f|t
34139505|NCT01656993|||COHORT||PROSPECTIVE|||||||
34139506|NCT01792817|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34139507|NCT01460875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139508|NCT00521690|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139509|NCT04282265|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34139510|NCT05482477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34139511|NCT05958394|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34139512|NCT06606873|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34139513|NCT05838053|||COHORT||PROSPECTIVE|||||||
34139514|NCT01419613|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139515|NCT04041466|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34139516|NCT05540561|||CASE_CONTROL||PROSPECTIVE|||||||
34139517|NCT02300558|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34139518|NCT06207812|||COHORT||PROSPECTIVE|||||||
34139519|NCT05810935|||OTHER||CROSS_SECTIONAL|||||||
34139520|NCT04015609|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33829996|NCT05816577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be randomised through Castor (eCRF). Treatment allocation is blinded for investigators and participants. The pharmacist has access to the randomisation list.|Double-blind, randomised, controlled, safety study|t|t|t|f
34139521|NCT06327555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139522|NCT00149695|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34139523|NCT05811520|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139524|NCT02356419|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139525|NCT06350942|||COHORT||RETROSPECTIVE|||||||
34139526|NCT04752566|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139527|NCT06605040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This protocol outlines a randomized, single-blind (assessors), two-arms, parallel-group controlled trial which will evaluate the the impact of an educational program disseminated via social media compared to plain abstracts send via email on the clinical practice, knowledge and perceptions of physiotherapists. The study outcomes will be categorized into three areas, each of which will be addressed in separate articles: i) effectiveness, including feasibility analysis (quantitative outcomes), ii) qualitative outcomes, and iii) technical outcomes.||f|f|f|t
34139528|NCT06605781|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||The participants will be divided into experimental and control groups.|t|f|f|f
34139529|NCT05215860|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigator who provided behavioural counselling to the participants was blinded to their clinical diagnosis of oral lesions|A prospective pilot interventional longitudinal study|f|f|t|f
34139530|NCT02241811|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33829997|NCT00937521|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34139531|NCT04024332|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Single-center, open-label, single-dose study||||
34139532|NCT04290793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139533|NCT01846676|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34139534|NCT06233201|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34139535|NCT05611229|||COHORT||RETROSPECTIVE|||||||
33829998|NCT05694962|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139536|NCT00234481|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139537|NCT02673476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33829999|NCT05588947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective Randomized Controlled Open Blinded Endpoint Feasibility Trial|f|f|f|t
33830000|NCT04959578|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830001|NCT05587452|||COHORT||PROSPECTIVE|||||||
33830002|NCT04005456|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33830003|NCT06551168|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The experimental group will undergo heat acclimation The control group will not undergo heat acclimation. The control group will undergo heart rate matched exercise of the same quantity but in a cool environment||||
34139538|NCT02990182|||COHORT||PROSPECTIVE|||||||
33830004|NCT00791739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830005|NCT00276666||||TREATMENT||NONE||||||
33830006|NCT00946205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830007|NCT01148498|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830008|NCT01814436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139539|NCT03466619|NA|SINGLE_GROUP||TREATMENT||NONE||inflatable penile prosthesis (IPP)||||
34139540|NCT03843385|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"To address concealment of allocation, the randomization will be done centrally and each patient who is randomized and who received one of the compared treatments is part of the full analysis set (ITT analysis set)."|"Patients will be randomized to receive intensive dosing multi-donor FMFT or FMT as therapeutic strategies or saline as a placebo comparator. To achieve balanced distributions for pretreatment factors, we propose to apply stratified (stratum 1: biologicals yes/no; stratum 2: participating centre) block randomization."|t|t|t|t
34139541|NCT06594042|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34139542|NCT01926171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149857|NCT04738591|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33830009|NCT00077597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830010|NCT02822417|||OTHER||PROSPECTIVE|||||||
33830011|NCT05246384|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||open-label, non-randomized, two-part Phase I/Ib study||||
33830012|NCT05910645|||OTHER||CROSS_SECTIONAL|||||||
33830013|NCT04157023|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||Three groups of participants are made. Group 1: Medical Students Group 2: Ophthalmologists Group 3: Neonatologists/Neurologists/Neurosurgeons|t|f|f|f
34139543|NCT04114643|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Patients will be randomized to receive either PCC or FP when the blood bank receives the first order for coagulation factor replacement and deems it to be in accordance with accepted clinical standards.|t|f|t|t
34139544|NCT02480491|||COHORT|||||||||
34139545|NCT00812201|||CASE_ONLY||PROSPECTIVE|||||||
33830014|NCT03908593|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139546|NCT06179628|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139547|NCT00211393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139548|NCT00529126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139549|NCT06052254|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The sponsor, the investigator, personnel at the clinical study unit who are directly involved with monitoring and/or performing study procedures and assessments, and the subjects will be blinded to treatment assignment.|"Subjects in each treatment group will receive a total of 4 patches/systems during the study (2 patches/system each dosing period).~For the second dosing period, subjects will receive the same treatment administered as the first dosing period. An independent data monitoring committee will periodically review safety data to confirm the safety/tolerability of the dose or recommend a dose reduction. Subjects will reside in their care facility for the duration of the trial. The following assessments will be performed according to the Schedule of Events: agitation assessments (frequency and severity); sedation-level assessments; safety assessments (vital signs including oxygen saturation by pulse oximetry pulse oximetry (SpO2)); DMTS/matching placebo adhesion assessments; and skin irritation assessments. In addition, blood samples will be collected for determination of plasma concentrations of dexmedetomidine."|t|t|t|t
34139550|NCT06497777|||CASE_CONTROL||PROSPECTIVE|||||||
34139551|NCT04955483|||COHORT||PROSPECTIVE|||||||
34139552|NCT06264219|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34139553|NCT06116552|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||A within-subjects design is used where participants complete both treatments: listening to more social stories and less social stories.||||
34139554|NCT05254132|||COHORT||PROSPECTIVE|||||||
34139555|NCT00422149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139556|NCT06039436|||COHORT||PROSPECTIVE|||||||
34139557|NCT00000467||PARALLEL||PREVENTION||||||||
34139558|NCT05019742|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||randomized, double-blind, placebo-controlled|t|t|t|t
34139559|NCT01574157|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139560|NCT05460273|NA|SINGLE_GROUP||TREATMENT||NONE|It is a single-arm, multi-cohort study with no blinding.|This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, PK, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours.||||
34139561|NCT03390478|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The randomization process it will be done in https://www.random.org/ by an independent person.|Participants will be assigned in two groups, a control group who will receive institutional usual care and an experimental group who will receive the combined intervention.|f|f|t|t
34139562|NCT02362516|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139563|NCT00004248|NA|SINGLE_GROUP||TREATMENT||||||||
34139564|NCT01182740|||||PROSPECTIVE|||||||
34139565|NCT02952482|||COHORT||PROSPECTIVE|||||||
34139566|NCT01689870|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139567|NCT00027378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139568|NCT01177553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139569|NCT03833986|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34139570|NCT04080219|||COHORT||PROSPECTIVE|||||||
34139571|NCT01932151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139572|NCT01382303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139573|NCT05497102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139574|NCT06292754|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34139575|NCT06432192|||COHORT||PROSPECTIVE|||||||
34139576|NCT00349180|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34139577|NCT03921619|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will be asked to perform two balance assessments (Tinetti Balance Scale, Get Up and Go Test) while: 1) not wearing a sling; and 2) wearing a sling on the dominant arm. Additional data will be collected regarding patient frailty with the Edmonton Frail Scale, as well as data regarding sling use and falls in the form of a questionnaire.||||
34139578|NCT04642560|||CASE_ONLY||OTHER|||||||
34139579|NCT00522314|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139580|NCT04750694|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34139581|NCT05254275|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Gels concealed.|Split-mouth design|t|t|t|t
33838557|NCT05948423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838558|NCT00250744|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33838559|NCT01251770|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139582|NCT00006164|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139583|NCT02482194|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139584|NCT06606145|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139585|NCT04873167|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139586|NCT01271075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34139587|NCT05453760|||COHORT||PROSPECTIVE|||||||
34139588|NCT00473967|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34139589|NCT02320812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139590|NCT00897403|||||PROSPECTIVE|||||||
34139591|NCT01035437|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139592|NCT00394901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34139593|NCT05205538|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34139594|NCT03311139|||COHORT||RETROSPECTIVE|||||||
34139595|NCT01510145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139596|NCT04158141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139597|NCT03027856|NA|SINGLE_GROUP||OTHER||NONE||||||
34139598|NCT01184833|||COHORT||PROSPECTIVE|||||||
34139599|NCT03948009|||COHORT||PROSPECTIVE|||||||
34139600|NCT03098251|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139601|NCT03010891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34139602|NCT06607107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139603|NCT03326414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||40 patients are to be investigated during the project. In phase one 20 patients are ventilated with constant PEEP of 10mbar and the tidal volume is set to 4-5ml/kg IBW or 8-10ml/kg IBW respectively. In phase two further 20 patients are ventilated with a constant tidal volume of 8ml/kg IBW and the PEEP is set to 3mbar or 12mbar respectively.|t|f|f|f
34139604|NCT05304117|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830015|NCT04322760|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were allocated into 2 groups, 20 patients in each received 10 ml 0.5 % bupivacaine and 1µg/kg dexmedetomidine diluted in 10 ml saline injected intra-articularly; group A: no patch, group B: a patch of lidocaine 5% was applied to the skin.||||
34139605|NCT03878030|||COHORT||PROSPECTIVE|||||||
33830016|NCT05630378|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel to the treatment group that visits the outpatient clinic on one day of the week for 11 weeks, the waiting group only fills in a diary and the questionnaires at two timepoints. Diary and questionnaires are the same for both groups.||||
33830017|NCT04383145|||COHORT||PROSPECTIVE|||||||
33830018|NCT02028247|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830019|NCT02673307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33830020|NCT05009381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary hypothesis of this trial will be based on the chin volume change assessed by a central reader blinded to subject treatment|A no-treatment Controlled, Prospective, Randomized, Multimulti-center, Evaluator-Blinded Study|f|f|f|t
33830021|NCT04240028|||COHORT||PROSPECTIVE|||||||
33830022|NCT00237211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830023|NCT05763654|||COHORT||PROSPECTIVE|||||||
33830024|NCT06091137|||COHORT||RETROSPECTIVE|||||||
33830025|NCT05008263|||CASE_ONLY||PROSPECTIVE|||||||
33830026|NCT05974683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830027|NCT00552513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830028|NCT04332432|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830029|NCT03195049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830030|NCT04186052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830031|NCT00623363|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830032|NCT05985902|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830033|NCT01498562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830034|NCT01903369|||CASE_ONLY||CROSS_SECTIONAL|||||||
33830035|NCT04169451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830036|NCT03886597|RANDOMIZED|CROSSOVER||OTHER||NONE||This study involve two stages, the first one corresponding to the pharmacokinetic study of the single administration of table olives in healthy male volunteers and the second one corresponding to the study of a nutritional intervention with 30 table olives during 30 days.||||
33830037|NCT03120598|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Cluster Randomized Trial|f|f|f|t
33830038|NCT05967078|NA|SINGLE_GROUP||OTHER||NONE||||||
33830039|NCT03477409|||COHORT||CROSS_SECTIONAL|||||||
33830040|NCT05663164|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830041|NCT00504413|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830042|NCT01215578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830043|NCT00004178||||TREATMENT||||||||
33830044|NCT02792647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830045|NCT02152254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830046|NCT02561078|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830047|NCT06067022|||CASE_CONTROL||PROSPECTIVE|||||||
33830048|NCT01633138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830049|NCT04131673|||COHORT||PROSPECTIVE|||||||
33830050|NCT04926441|||COHORT||RETROSPECTIVE|||||||
33830051|NCT00869271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830052|NCT06215287|||OTHER||PROSPECTIVE|||||||
33830053|NCT03090971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830054|NCT00040820||||TREATMENT||||||||
33830055|NCT01278615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830056|NCT01340300|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830057|NCT01470729|||OTHER||PROSPECTIVE|||||||
33830058|NCT00740870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830059|NCT00990262|||COHORT||PROSPECTIVE|||||||
33830060|NCT00951171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830061|NCT01264887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139606|NCT02937077|||CASE_ONLY||PROSPECTIVE|||||||
34139607|NCT03842969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830062|NCT00599833||||TREATMENT||NONE||||||
33830063|NCT04486313|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830064|NCT03638258|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Roflumilast drug product will be supplied as a 0.3% and 0.15% cream. The matching vehicle cream will contain only excipients of roflumilast cream.|Parallel group, double blind, vehicle-controlled study|t|f|t|f
33830065|NCT04765553|RANDOMIZED|PARALLEL||OTHER||SINGLE|Double blind||f|t|f|f
33830066|NCT02886598|||CASE_ONLY||PROSPECTIVE|||||||
33830067|NCT00809913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830068|NCT03131349|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830069|NCT01050387|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830070|NCT00944892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830071|NCT04344210|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients will be randomized in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period ; G2: participants will receive the usual care.||||
33830072|NCT03807453|||CASE_CONTROL||PROSPECTIVE|||||||
34139608|NCT00869804|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34139609|NCT02694068|||COHORT||OTHER|||||||
34139610|NCT04804657|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34139611|NCT01839591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149858|NCT03871660|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830073|NCT04262297|||CASE_CONTROL||PROSPECTIVE|||||||
33830074|NCT02925234|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139612|NCT06605092|NON_RANDOMIZED|PARALLEL||OTHER||NONE||2 groups (young adults and older adults), with a 50/50 male/female ratio in each group||||
34139613|NCT01744613|||COHORT||PROSPECTIVE|||||||
34139614|NCT05064293|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||two-group, randomized and pragmatic trial|f|f|t|f
33830075|NCT01325597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139615|NCT02076269|NA|SINGLE_GROUP||||NONE||||||
34139616|NCT00549263|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139617|NCT03549871|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139618|NCT04613934|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34139619|NCT02631174|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139620|NCT00003914||||TREATMENT||||||||
34139621|NCT04086537|||OTHER||CROSS_SECTIONAL|||||||
34139622|NCT03935724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All parties are masked (except for the care provider administering placebo of Neuro-cells). Unmasking will occur after six months when the placebo group receives Neuro-cells.|Patients are randomized into two groups. First groups receives Neuro-cells, second group receives placebo. After six months second group also receives Neuro-cells. This happens in phase 2 and is repeated in phase 3. Therefore there are 4 groups.|t|t|t|t
34139623|NCT04073784|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects receive Apatinib for oral administration, 250mg, once a day, gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) and Apatinib 250mg once a day maintenance for the remainder of the study or until documented PD.||||
34139624|NCT05420714|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34139625|NCT05385887|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patiënt, clinician and investigators are all blinded|double-blind, placebo-controlled, randomized trial|t|t|t|t
34139626|NCT03771118|||COHORT||RETROSPECTIVE|||||||
34139627|NCT04362475|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Hypotheses will be tested in a 2 X 2 design that includes the independent and combined effects of two interventions targeting the individual, family, and community level. Participating neighborhoods will be assigned into one of four cells: FYI alone, ESPI alone, FYI and ESPI combined, and Wait List Control.||||
34139628|NCT01447485|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139629|NCT02848521|||COHORT||PROSPECTIVE|||||||
34139630|NCT03066726|||COHORT||PROSPECTIVE|||||||
34139631|NCT01329796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139632|NCT04796324|NA|SINGLE_GROUP||TREATMENT||NONE||Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle.||||
34139633|NCT00182052|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34139634|NCT03179111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind study. Neither the participant (patient) nor the investigator (surgeon) will know which group the particular participant will be assigned.|There will be two arms in this study. One arm will be the low pressure pneumoperitoneum group (8-10mmHg) where else the other arm will be the standard pressure pneumoperitoneum group (12-15mmHg).|t|f|t|f
34139635|NCT01991080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139636|NCT03171857|||CASE_ONLY||PROSPECTIVE|||||||
34139637|NCT05575492|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|Part 1 of this study will be open-label and blinding is not applicable. Part 2 of the study will be observer-blinded.|Part 1: Dose-escalating, non-randomized Part 2: Randomized|t|t|t|t
34139638|NCT05718752|||COHORT||CROSS_SECTIONAL|||||||
34139639|NCT04740281|||COHORT||CROSS_SECTIONAL|||||||
34139640|NCT01925495|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139641|NCT02363257|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34139642|NCT00004552|RANDOMIZED|||TREATMENT||||||||
34139643|NCT03130660|RANDOMIZED|PARALLEL||PREVENTION||NONE||patient to be randomized to two groups||||
34139644|NCT02082457|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139645|NCT01657890|NON_RANDOMIZED|PARALLEL||||NONE||||||
34139646|NCT02180256|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139647|NCT00770042|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139648|NCT01798173|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139649|NCT05788783|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149859|NCT02024958|||COHORT||PROSPECTIVE|||||||
33830076|NCT03397238|||CASE_CONTROL||PROSPECTIVE|||||||
33830077|NCT04706793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830078|NCT04991688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830079|NCT01310712|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830080|NCT01434537|||COHORT||RETROSPECTIVE|||||||
34149860|NCT02238015|||CASE_CONTROL||PROSPECTIVE|||||||
34149861|NCT02694497|||COHORT||PROSPECTIVE|||||||
34149862|NCT03226977|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149863|NCT02659319|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34149864|NCT00612508|RANDOMIZED|PARALLEL||||NONE||||||
34149865|NCT00667290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33830081|NCT00318786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830082|NCT05367206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830083|NCT00983892|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33830084|NCT00620633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830085|NCT02377011|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830086|NCT03549039|||COHORT||RETROSPECTIVE|||||||
33830087|NCT02860299|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33830088|NCT02780102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830089|NCT03991988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830090|NCT04716218|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33830091|NCT05431998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830092|NCT02802150|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33838560|NCT04956705|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The project estimates the impact of The Model for Improvement on implementing the recommendation of vitamin D and calcium supplementation at nursing homes. Furthermore, the project evaluates which effect an improved implementation can have on vitamin D status and physical functioning in nursing home residents.||||
33830093|NCT04584502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will be blind to the Principal Investigators, the statistician, and to those on the team responsible for participant data collection. The study team will work to try to blind clinicians delivering treatment as usual to participant assignment but there is a chance that patients will reveal their condition to clinicians despite our best efforts. To achieve blindness, treatment assignment will done by the Project Manager, who will not be directly involved in evaluation data collection. Data collection will be conducted by the study Research Assistant who will be blinded to participant treatment assignment.|Intervention as adjunct to usual care.|f|f|t|t
33830094|NCT01773876|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830095|NCT05768269|||COHORT||PROSPECTIVE|||||||
33830096|NCT03014817|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830097|NCT04922645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830098|NCT00047541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830099|NCT00424554|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830100|NCT04680793|NA|SINGLE_GROUP||TREATMENT||NONE||Patients are assessed 9 weeks before the start of the program, at the beginning and at the end of the program, and 6 weeks and 6 months after the end of the program. The 9-week period before the program is used as a control condition. It is of the same duration as the program, which also lasts 9 weeks. Patients are asked not to change their lifestyle during the 9-week period before the rehabilitation program.||||
33830101|NCT02007811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830102|NCT04648098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Interventional (Clinical Trial)|f|f|t|t
33830103|NCT02660268|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830104|NCT02100683|||COHORT||PROSPECTIVE|||||||
33830105|NCT02136771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830106|NCT02929719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830107|NCT06302725|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830108|NCT04134715||SEQUENTIAL||OTHER||NONE||||||
33830109|NCT00134147|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830110|NCT05101915|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single centre, non-randomized, open label study||||
33830111|NCT03183180|||COHORT||RETROSPECTIVE|||||||
33830112|NCT05802914|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Because of the transparency of a back exosuit, it is not feasible to blind participants and study team members. However, an independent blind statistician will perform our primary intention to treat analysis on our primary outcome measures. The statistician will perform analysis consistent with our statistical analysis plan, transforming data prior to knowledge of group assignment.~Additional secondary analysis will be performed on open labeled data."|Participants will be randomized into an exosuit or a control group using a 2:1 stratified ratio. Strata will be developed based on workplace, lifetime back pain history, and job tenure (\>90 days). Participants in each group will complete regular workplace tasks while wearing or not wearing a back exosuit respectively.|f|f|f|t
33830113|NCT03443011|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830114|NCT05479188|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||All eligible patients will be randomized with computer-generated algorithm to receive cardiac surgery with minimal invasive versus conventional extracorporeal circulation.|f|t|f|f
33830115|NCT02477449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830116|NCT04332679|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The surgeon is masked until the envelope is opened at the time of the surgery.||t|t|t|t
33830117|NCT05051215|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830118|NCT03065608|||COHORT||PROSPECTIVE|||||||
33830119|NCT03462537|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830120|NCT02176382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830121|NCT00099203|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830122|NCT03080662|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830123|NCT03599336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830124|NCT04038320|||COHORT||PROSPECTIVE|||||||
33830125|NCT02669407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830126|NCT03211377|||COHORT||PROSPECTIVE|||||||
33830127|NCT03023202|||CASE_ONLY||PROSPECTIVE|||||||
33830128|NCT02050698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830129|NCT04921878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830130|NCT03589300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830131|NCT05043883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830132|NCT06064045|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"A controlled intervention study comparing two groups each consisting of four pediatric departments.~Each group consists of approximately 600 participants"||||
33830133|NCT00345436|||||PROSPECTIVE|||||||
33830134|NCT04540562|NA|SINGLE_GROUP||OTHER||NONE||||||
33830135|NCT00917462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830136|NCT04590950|||COHORT||RETROSPECTIVE|||||||
33830137|NCT04963946|RANDOMIZED|PARALLEL||TREATMENT||NONE||multicenter, non comparative, randomized, stop and restart||||
33830138|NCT02928471|||COHORT||PROSPECTIVE|||||||
33830139|NCT02543788|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830140|NCT00004265||||TREATMENT||||||||
33830141|NCT01543334|||CASE_ONLY||CROSS_SECTIONAL|||||||
33830142|NCT04187430|||CASE_CONTROL||OTHER|||||||
33830143|NCT02942342|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830144|NCT03302442|||COHORT||RETROSPECTIVE|||||||
33830145|NCT03234998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830146|NCT02781298|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33830147|NCT02972814|||COHORT||PROSPECTIVE|||||||
33830148|NCT03410758|||COHORT||RETROSPECTIVE|||||||
33830149|NCT03197077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830150|NCT00389688|RANDOMIZED|||TREATMENT||NONE||||||
33830151|NCT05585671|||COHORT||PROSPECTIVE|||||||
33830152|NCT01510132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830153|NCT01461005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830154|NCT05095662|||COHORT||PROSPECTIVE|||||||
34149866|NCT01401712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149867|NCT06252441|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34139650|NCT04644796|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Liposomal bupivacaine can be differentiated visually from normal saline. In order to blind the surgeons from treatment vs control, the syringes containing the medication or saline will be sheathed by the investigational drug study department.|Patients will be randomly assigned to either the treatment group or the placebo group. Patients in the study group will receive liposomal bupivacaine at the end of the procedure (following fascial closure, but prior to superficial closure), while patients in the placebo group will receive sterile saline. The injectate should be injected slowly and deeply, infusing \~1-2 mL according to manufacture guidelines for infiltration. According to these guidelines, injection should utilize a moving needle technique (inject while withdrawing the needle) at multiple locations surrounding the incision(s) to achieve maximal effect. Care will be taken to aspirate prior to injection to minimize the risk of intravascular injection of medication.|t|t|t|t
34139651|NCT04114604|||COHORT||CROSS_SECTIONAL|||||||
34139652|NCT01174004|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139653|NCT01725230|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34139654|NCT02120092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139655|NCT03350087|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139656|NCT01871259|||CASE_CONTROL||PROSPECTIVE|||||||
34139657|NCT02238431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34139658|NCT06585904|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139659|NCT03790436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139660|NCT03047356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34139661|NCT01845324|||COHORT||PROSPECTIVE|||||||
34139662|NCT01955434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139663|NCT05664347|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Patients diagnosed with asthma or COPD, who were started on any inhaler for a minimum of one month and will continue using them chronically were met in the JUH respiratory clinic and invited to participate.~Patients at high risk for infection, or those presenting with a very severe clinical presentation were excluded.~Taking into account the non-invasive nature of the educational intervention, and the need to reduce the risk of spread of COVID19 virus (sharing pens or papers), a verbal consent was obtained.~Enrolled participants were randomized using simple randomization into two groups; odd numbers for the control group (received a verbal TTG education on their inhaler technique) and even numbers for the intervention group ( received a video based TTG education). The primary and secondary outcomes of the study were inhaler technique mastery, amelioration of disease control, disease related quality of life and medication adherence at follow-up (after 3 months)."||||
34139664|NCT01480713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139665|NCT04080986|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is a cluster randomized trial, with cluster units defined by EMS agency. Each cluster will crossover at six month intervals for each EMS agency during the study.||||
34139666|NCT04692168|||COHORT||PROSPECTIVE|||||||
34139667|NCT02095665|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139668|NCT06604780|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34139669|NCT02334683|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
34139670|NCT01219660|||OTHER||PROSPECTIVE|||||||
34139671|NCT06209593|||OTHER||PROSPECTIVE|||||||
34139672|NCT04591197|||COHORT||PROSPECTIVE|||||||
34139673|NCT03207178||SEQUENTIAL||TREATMENT||NONE||||||
34139674|NCT04218838|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Within the initial phase, referred to as the Randomized Phase, the primary determination of efficacy and safety will be 6-months following the study procedure. The analysis will be based on the randomization assignment. In the second phase of the study, referred to as the Cross-over Phase, patients who fail to respond to the randomized treatment assignment will be permitted to receive the non-randomized treatment.||||
34139675|NCT04253106|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Multicentric, prospective non-randomized study prognostic aim. Control group planned to have standard values.||||
34139676|NCT00001250||||TREATMENT||||||||
34139677|NCT00605098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139678|NCT05292911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139679|NCT03216304|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139680|NCT01500603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139681|NCT05682287|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139682|NCT02313727|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34139683|NCT01894880|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34139684|NCT05802706|||COHORT||PROSPECTIVE|||||||
34139685|NCT02533765|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139686|NCT05950516|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139687|NCT04301479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139688|NCT01083979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139689|NCT06017921|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double-blind||f|t|f|f
34139690|NCT02230761|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139691|NCT02435407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139692|NCT02172833|||CASE_CONTROL||RETROSPECTIVE|||||||
34139693|NCT05379712|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized (multimodal oral nutrition therapy versus standard care), open label, parallel assignment, during cancer treatment (Baseline - Week 7 for Primary endpoint). Starting at Week 8, all patients receive the intervention arm until study ends at Week 14. Patients in the intervention arm continue the intervention, patients on the standard care arm cross over to the intervention (deferred nutrition intervention).||||
34139694|NCT05354466|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34139695|NCT06415981|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139696|NCT06411886|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized placebo control two way crossover study||||
34139697|NCT04082390|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139698|NCT03175601|||COHORT||CROSS_SECTIONAL|||||||
34139699|NCT00803517|||CASE_CONTROL||PROSPECTIVE|||||||
33838561|NCT00921947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33838562|NCT02899351|||COHORT||PROSPECTIVE|||||||
33838563|NCT04446091|NON_RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838564|NCT06335342|||CASE_ONLY||PROSPECTIVE|||||||
34139700|NCT04316611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139701|NCT03739489|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The participant will be received three different sessions of rtms, with wash out 30 days between sessions.||||
34139702|NCT00322296|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139703|NCT04580368|NA|SINGLE_GROUP||TREATMENT||NONE||N of 1 trial using an individual patient as their own control||||
34139704|NCT02916641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139705|NCT05820152|NA|SEQUENTIAL||TREATMENT||NONE||5.0×107 vg, 0.05 mL eye/dose(low dose); 1.5×108 vg, 0.05 mL eye/dose(starting dose); 5.0×108 vg, 0.05 mL eye/dose(intermediate dose); 1.5×109 vg, 0.05 mL eye/dose(high dose)||||
34139706|NCT00003103||||TREATMENT||||||||
34139707|NCT03057041|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139708|NCT05647343|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34139709|NCT00369174|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34139710|NCT06110858|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34139711|NCT03372460|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind tDCS|Participants are assigned to receive either active or sham stimulation during the tDCS+VR sessions in parallel for the duration of the study|t|f|t|t
34139712|NCT03093207|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139713|NCT03586323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34139714|NCT06022965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139715|NCT05263986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139716|NCT06608576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34139717|NCT03965884|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34139718|NCT04720040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139719|NCT01568151|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34139720|NCT04750473|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139721|NCT01388439|||COHORT||PROSPECTIVE|||||||
34139722|NCT05791994|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34139723|NCT04140357|||OTHER||PROSPECTIVE|||||||
34139724|NCT02540330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139725|NCT00301600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139726|NCT00620178|||COHORT||RETROSPECTIVE|||||||
34139727|NCT03371134|||CASE_CONTROL||PROSPECTIVE|||||||
34139728|NCT00218582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139729|NCT05573399|||COHORT||RETROSPECTIVE|||||||
34139730|NCT05978960|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34139731|NCT03162510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139732|NCT05178030|||COHORT||PROSPECTIVE|||||||
34139733|NCT01783574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139734|NCT01892787|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139735|NCT02080039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139736|NCT01753219|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34139737|NCT02802241|RANDOMIZED|PARALLEL||TREATMENT||||||||
34139738|NCT03234855|||OTHER||PROSPECTIVE|||||||
34139739|NCT00130143|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139740|NCT04958044|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34139741|NCT01562522|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139742|NCT03483038|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139743|NCT01133405|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34139744|NCT05852262|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Eligible patients will be randomized (1:1) to high-dose versus standard-dose arms. The randomization sequence will be computer-generated by a statistician|The Investigators will conduct a parallel arm double-blind randomized controlled trial.|t|t|t|f
34139745|NCT01973387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139746|NCT02421731|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139747|NCT04748757|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139748|NCT03200639|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139749|NCT06029673|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34139750|NCT03142399|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34139751|NCT00110630|RANDOMIZED|||TREATMENT||NONE||||||
34139752|NCT02169024|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Expect With Me group prenatal care vs. Individual Care Only prenatal care||||
34139753|NCT06605872|||COHORT||PROSPECTIVE|||||||
34139754|NCT05092763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139755|NCT05118789|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34139756|NCT01671501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139757|NCT06038526|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34139758|NCT04417218|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34139759|NCT04431310|||COHORT||PROSPECTIVE|||||||
34139760|NCT02614170|||COHORT||PROSPECTIVE|||||||
34139761|NCT01088165|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34139762|NCT04397003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139763|NCT02829892|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34139764|NCT04808947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, parallel group, triple blind (patient, assessor, anesthesiologist in the operating room)|t|f|t|t
34139765|NCT02959827|||COHORT||RETROSPECTIVE|||||||
34139766|NCT03474536|||COHORT||RETROSPECTIVE|||||||
34139767|NCT03362099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients are blinded when they use varenicline. The care provider who makes clinical visits of the protocol do not have access to randomizing list, therefore they are blinded for the use of varenicline indicated, but not for bupropion use.|The Patients will be randomized in two arms. 200 will be treated in the pharmacogenetic arm and 200 in the varenicline arm ( control ).|t|t|f|f
33838565|NCT04303507|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34139768|NCT02313870|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139769|NCT01174277|||CASE_ONLY||PROSPECTIVE|||||||
34139770|NCT03069170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139771|NCT01740479|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34139772|NCT06411977|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled clinical trial|t|f|f|f
34139773|NCT01932320|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139774|NCT03321903|||COHORT||PROSPECTIVE|||||||
34139775|NCT05999175|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Study participants would be randomly allocated to one of the following groups: Group 1 (20 subjects) would use the delicate mint toothpaste Dentifricio gel tau-marin® Menta Delicata; Group 2 (12 subjects) mint toothpaste  Dentifricio gel tau-marin® Menta; Group 3 (20 subjects) mint mouthwash Collutorio tau-marin® Menta. Group 4 (20 subjects) would utilize delicate mint toothpaste Dentifricio gel tau-marin® Menta Delicata and mint mouthwash  Collutorio tau-marin® Menta. These products would be applied with tau-marin® scalar toothbrush 33 medium with antibacterial Spazzolino tau-marin® three times a day after the main meals for 28 days. Group 5 (12 subjects) would continue to use routine oral hygiene products for 28 days. Groups 1 to 3 would be provided with a standard toothbrush (without any claims of efficacy) to be used three times a day after the main meals for 28 days."||||
34139776|NCT02833753|NA|SEQUENTIAL||TREATMENT||NONE||"There are three cohorts of patients:~Group #1 is at 25mg/m2 of IP oxaliplatin and has been completed. Group #2 is at 55mg/m2 of IP oxaliplatin is completed. Group #3 is at 85mg/m2 of IP oxaliplatin is currently enrolling. If DLTs found additional 3 subjects will be dosed at the lower dose level cohort.~2 DLTs were found in the 85 mg/m2 cohort therefore 3 additional subjects (Group # 4) will be enrolled to the 55 mg/m2 cohort."||||
34139777|NCT05440006|RANDOMIZED|CROSSOVER||TREATMENT||NONE||There will be 20 volunteers to receive the treatment, and each treatment will be followed by 72 hours of blood sampling for pharmacokinetic and safety.||||
34139778|NCT02509572|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34139779|NCT03871101|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139780|NCT01106339|||COHORT||PROSPECTIVE|||||||
34139781|NCT03263858|NA|SINGLE_GROUP||TREATMENT||NONE||consecutive enrolment of cohort 1 (primary endpoint at 1 month), and cohort 2 (primary endpoint at 9 months)||||
34139782|NCT00346502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139783|NCT00790166|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34139784|NCT06604845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139785|NCT00002211||||TREATMENT||||||||
34139786|NCT03673787|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34139787|NCT03241771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34139788|NCT01566695|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139789|NCT05765461|||COHORT||PROSPECTIVE|||||||
34139790|NCT03717792|||COHORT||PROSPECTIVE|||||||
34139791|NCT03392883|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The investigators will initially pilot test this mental health service delivery model at a single primary care site and then refine the model based on pilot data. The investigators will then expand implementation across 6 Colombia-based healthcare sites in urban and rural communities (including approximately 2000 participants). Consistent with a modified stepped wedge design (multiple baseline design), the investigators will implement the model across sites on a staggered basis and expand the number of sites in which the investigators implement over time. By conducting this multi-site implementation research project, the investigators can assess the extent to which the implementation model and associated outcomes are replicable across sites and/or the extent to which the model needs to be modified for differing contexts.||||
34139792|NCT03121677|NA|SINGLE_GROUP||TREATMENT||NONE||For the first three patients treated on study therapy, treatment of each subsequent patient will not be allowed until the prior patient has completed Cycle 1. If no unexpected adverse events attributed to the combination therapy are observed, after the third patient completes Cycle 1, treatment initiation may occur without restrictions for the remaining patients.||||
34139793|NCT03734653|NA|SINGLE_GROUP||TREATMENT||NONE||This is a longitudinal pilot, single arm, interventional study.||||
34139794|NCT01032291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139795|NCT04151628|NA|SINGLE_GROUP||TREATMENT||NONE||The Coronary IVL System is a proprietary balloon catheter system designed to enhance stent outcomes by enabling delivering of the calcium disrupting capability of lithotripsy prior to balloon dilatation at low pressures. The Coronary IVL System consists of an IVL Balloon Catheter with 2 integrated emitters, a Lithotripsy Generator, and a Connector Cable.||||
34139796|NCT03429673|||COHORT||RETROSPECTIVE|||||||
34139797|NCT05660902|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34139798|NCT00728520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139799|NCT05768438|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139800|NCT04398173|||CASE_CONTROL||RETROSPECTIVE|||||||
34139801|NCT02710123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139802|NCT06608667|||CASE_CONTROL||RETROSPECTIVE|||||||
34139803|NCT04260763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139804|NCT03158012|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34139805|NCT01360398|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139806|NCT00985907|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139807|NCT02280902|||COHORT||PROSPECTIVE|||||||
34139808|NCT04700657|||CASE_CONTROL||PROSPECTIVE|||||||
34139809|NCT04362371|NA|SINGLE_GROUP||TREATMENT||NONE||"Post Marketing Follow Up Study.~Enrolled patients will be 75, divided as follows:~* 25 patients belonging to study DMS/18/AINARA/01 (only Arm A, Ainara®)~* 50 patients belonging to study DMS/18/AINARA/02"||||
34139810|NCT04911907|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139811|NCT06605833|||COHORT||PROSPECTIVE|||||||
34139812|NCT04752137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139813|NCT04330833|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A trained blinded evaluator will meet with participants to complete baseline and subsequent follow-up measures, including end-of-study chart review data. Physician-nurse dyads for each arm are trained differently and naive to alternate study arm.|This is a multi-site, 2-group, cluster-randomized controlled trial, with clusters randomized by pediatric oncology physician-nurse dyads.|t|f|f|t
34139814|NCT00764387|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33830155|NCT06231563|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This is a double-masked, active placebo-controlled, single dose randomized trial of intravenous (IV) ketamine for depression in people with Parkinson's disease (PD).|Veterans with Parkinson's disease (N=80) will be randomized to complete a single IV ketamine infusion or active placebo infusion (remimazolam).|t|f|t|t
33830156|NCT01635543|||COHORT||PROSPECTIVE|||||||
33830157|NCT02121743|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139815|NCT00420615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139816|NCT01581489|||COHORT||PROSPECTIVE|||||||
34139817|NCT05750654|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34139818|NCT04385238|||CASE_ONLY||CROSS_SECTIONAL|||||||
34139819|NCT04384601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139820|NCT03263923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants randomly assigned to groups|Randomized controlled clinical trial|t|f|f|f
34139821|NCT03788018|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34139822|NCT02439450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139823|NCT05582850|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139824|NCT06606470|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||The study design is a prospective stepped wedge group - randomized controlled trial (SWGRT) of interprofessional health care providers (HCPs) who enroll in the ABCs program. In this trial design, half of the participants begin the study in the control condition as randomly assigned, and cross-over to the intervention condition at a pre-determined time points, so that both the intervention and control groups eventually receive the intervention. The primary comparison will be between the trial arms upon completion of a program by the initial intervention group.|f|f|t|t
34139825|NCT05232968|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139826|NCT03651856|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139827|NCT00137137|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139828|NCT05051631|RANDOMIZED|PARALLEL||SCREENING||NONE||Stepped-Wedge Trial. 10 clinics will be assigned to 5 arms to receive the intervention at sequential times. The time at which each arm receives the intervention will be randomized.||||
34139829|NCT00011414|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830158|NCT02351713|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34139830|NCT02402894|||COHORT||PROSPECTIVE|||||||
34139831|NCT04494347|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|This is a prospective multicenter registry of 25 patients who are planned to undergo TMVr with MitraClip and also have an indication for LAAO with the commercially available WATCHMAN device. All patients will undergo TMVr first under general anesthesia and transesophageal echo (TEE) guidance. At the conclusion of the TMVr procedure, the patient will undergo LAAO with the Watchman device using the same transseptal access the was obtained to perform the TMVr. Patients will receive oral anticoagulation with warfarin (or a direct anticoagulant) and subsequent antiplatelet therapy as per standard of care and outlined in protocol for 6 weeks. After 6 weeks, patients will have TEE done as per standard of care in addition to office visit and complete clinical and neurological evaluation. Continuation or discontinuation of oral anticoagulation will depend on the 45-day TEE findings. The anticipated duration of the Clinical Investigation will be 12 months.||||
34139832|NCT02789423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34139833|NCT05997095|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34139834|NCT05989087|||OTHER||RETROSPECTIVE|||||||
34139835|NCT03496233|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139836|NCT05022199|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139837|NCT03155919|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The taurine and placebo powder were offered in capsules identified by Taurine A and Taurine B.|A double-blind, crossover, 2-week washout study will be conducted with 20 male triathletes, aged 30 to 45 years, which will be offered during eight weeks capsules containing three grams of taurine or placebo and 400 ml of chocolate milk ready to drink.|t|f|t|f
34139838|NCT00849615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139839|NCT02324140|||COHORT||PROSPECTIVE|||||||
34139840|NCT03204799|||COHORT||PROSPECTIVE|||||||
34139841|NCT06608810|NA|SINGLE_GROUP||OTHER||NONE||||||
34139842|NCT05770934|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139843|NCT05614908|||COHORT||PROSPECTIVE|||||||
34139844|NCT04552210|||OTHER||PROSPECTIVE|||||||
34139845|NCT02701777|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants will not know if they receive real or sham stimulation||t|f|f|f
34139846|NCT01673815|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34139847|NCT02388035|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139848|NCT03440918|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139849|NCT04051385|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34149509|NCT04391452|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind|"After pre-selection (Day-14 to Day 0), participants will receive one of the two products in random order (Mg or placebo).~Treatment allocation will follow a randomization plan and will be carried out by a Clinical Research Associate totally independent from the protocol. The randomization list and a copy will be edited, placed in a sealed envelope, and submitted to the Pharmacy of the University Hospital of Clermont-Ferrand and the Clinical Pharmacology Centre of Clermont-Ferrand which is the coordinating centre.~For a 5% risk of bilateral species error and a 90% power, it is necessary to include 50 subjects per group to highlight such an effect size. In addition, fMRI examinations will be offered to the first 20 subjects included per group, i.e. 40 subjects, an usual and relatively consensual number for fMRI work."|t|f|f|f
34149510|NCT00076518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830159|NCT01674517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830160|NCT02916706||PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149511|NCT02291926|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830161|NCT04811898|NA|SEQUENTIAL||TREATMENT||NONE|None (Open Label)|monocentric, open label, phase I dose-escalation to determine the safety, the maximum tolerated dose (MTD) and the recommended phase II dose of LNA-i-miR-221 (RP2D) in a minimum/maximum number of 15/36 subjects affected by MM and advanced solid tumors. LNA-i-miR-221 will be administered IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days) with a modified 3+3 Fibonacci dose escalation design, with 5 different dose levels for each cohort (0,5 mg/kg; 1 mg/kg; 2 mg/kg; 3 mg/kg; 5 mg/kg).||||
33830162|NCT06276764|||COHORT||PROSPECTIVE|||||||
33830163|NCT00678977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830164|NCT02960945|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33838566|NCT01661205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838567|NCT02251249|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33838568|NCT04168970|||CASE_ONLY||PROSPECTIVE|||||||
33838569|NCT02314689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838570|NCT05667181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149512|NCT03445221|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34149513|NCT03444454|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149514|NCT05441956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149515|NCT05605171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149516|NCT02451891|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830165|NCT03686618|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"The study is not blinded and does not require any randomization codes. Ten patients each will receive one of three treatments for Days 1, 2, and 3:~1. No secretin - standard of care and observation (Cohort X)~2. 32 mcg (\<50kg) or 40 mcg (≥50kg)IV Bolus every 12 hours (Cohort 1)~3. 32 mcg (\<50kg) or 40 mcg (≥50kg)IV Bolus every 6 hours (Cohort 2)~4. 32 mcg (\<50kg) or 40 mcg (≥50kg)IV Bolus every 4 hours (Cohort 3)"||||
33830166|NCT01181037|||CASE_CONTROL||RETROSPECTIVE|||||||
33830167|NCT03273998|||CASE_ONLY||PROSPECTIVE|||||||
33830168|NCT02194829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830169|NCT04626986|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830170|NCT04311190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830171|NCT05376904|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||HR18034 compared with active comparator|t|t|t|t
33830172|NCT03526497|||COHORT||PROSPECTIVE|||||||
33830173|NCT04673890|||COHORT||PROSPECTIVE|||||||
33830174|NCT02108847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830175|NCT03245619|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33830176|NCT03774212|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830177|NCT04737421|||OTHER||PROSPECTIVE|||||||
33830178|NCT01828359|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830179|NCT05962515|||CASE_ONLY||PROSPECTIVE|||||||
33830180|NCT05925062|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This will be a non-randomized, control-group, year-long study exploring the impact of a mental wellness app on various aspects of mental wellness in first-year medical students and second-year nurse anesthesia (CRNA) students from Wake Forest University School of Medicine (WFUSM) during the 2023 - 2024 academic year (approximately July 2023 - June 2024).||||
33830181|NCT00032747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830182|NCT06260241|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized Control Trial|t|f|f|f
33830183|NCT03615170|||COHORT||PROSPECTIVE|||||||
33830184|NCT00975013|||CASE_ONLY||PROSPECTIVE|||||||
33830185|NCT00001649||||TREATMENT||||||||
33830186|NCT01711346|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
33830187|NCT00806637|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830188|NCT02051569|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33830189|NCT03862261|RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||Cluster-randomized stepped-wedge model, where intervention will be randomly allocated to the different study sites at different time points.||||
33830190|NCT01031849|NA|SINGLE_GROUP||||NONE||||||
33830191|NCT00120575|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830192|NCT01004029|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33830193|NCT00048776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830194|NCT04260464|NON_RANDOMIZED|PARALLEL||OTHER||NONE|No Masking|Single group||||
33830195|NCT00610805|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33830196|NCT01353950|||COHORT||PROSPECTIVE|||||||
33830197|NCT04800783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective interventional study including consecutive patients||||
33830198|NCT03553290|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The investigator and outcome assessor were blinded from the arrangement of the treatment|Split-mouth design in the same individual|f|f|t|t
33830199|NCT01320644|||COHORT||RETROSPECTIVE|||||||
33830200|NCT02114983|||COHORT||PROSPECTIVE|||||||
33830201|NCT05660330|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33830202|NCT02332200|||COHORT||RETROSPECTIVE|||||||
33830203|NCT02415283|||COHORT||PROSPECTIVE|||||||
33830204|NCT03158129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830205|NCT01328210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830206|NCT00117897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830207|NCT00847132|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33830208|NCT04582747|||COHORT||PROSPECTIVE|||||||
33830209|NCT03949712|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||Participants will receive all 3 treatment arms (Right M1 tSMS, Left M1 tSMS, sham tSMS) in a randomized order.|t|f|t|t
33830210|NCT03669198|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830211|NCT04969276|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830212|NCT00867100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830213|NCT05816278|||COHORT||CROSS_SECTIONAL|||||||
33830214|NCT01056263|||||RETROSPECTIVE|||||||
33830215|NCT05716776|||OTHER||CROSS_SECTIONAL|||||||
33830216|NCT04708483|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Morphologic criteria are being compared with analysis of functional (perfusion) CT imaging.||||
33830217|NCT03769545|||CASE_ONLY||RETROSPECTIVE|||||||
33830218|NCT01982786|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830219|NCT02809807|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33830220|NCT03489499|||COHORT||PROSPECTIVE|||||||
33830221|NCT04698798|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830222|NCT01140282|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33830223|NCT02815059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830224|NCT01324739|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33830225|NCT03103113|||COHORT||RETROSPECTIVE|||||||
33830226|NCT01644188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830227|NCT02759926|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33830228|NCT05789550|||OTHER||PROSPECTIVE|||||||
33830229|NCT02690493|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33830230|NCT00462085|||DEFINED_POPULATION||OTHER|||||||
33830231|NCT03128528|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Phase II, randomized (2:1), prospective, double-blind, placebo controlled, parallel-group, single center study.|t|t|t|f
33830232|NCT03866447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149868|NCT04226040|||COHORT||PROSPECTIVE|||||||
34139850|NCT05573750|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In pragmatic terms, masking or trial 'blinding' is not possible nor desirable for this study; instead we will aim to keep assessors and trial statistician in ignorance of participants' allocations, and to monitor success by asking assessors to judge those allocations \& their confidence therein.|"Case-only participant groups comprising of those with dementia and carers. The sessions will be delivered by an experienced leader of singing in dementia, supported by volunteers, and an instrumentalist (guitar or piano). The intervention will be delivered on one day per week to 3 groups of up to 27 couples (not necessarily spouses) in each of which pairs one person has dementia. Singing will last 60 minutes, with 30 minutes for socialising before or after that. The intervention groups will start singing immediately; the control groups will wait 12-13 weeks before starting.~The study will last about two years, with participant involvement expected to last between 12-15 months. The intervention will be delivered in three geographical areas, with a singing intervention group set up in each of these areas. The intervention groups may continue into the second round."|f|f|t|t
34139851|NCT03256903|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IIIb open randomized clinical trial||||
34139852|NCT03394599|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139853|NCT05402176|||COHORT||OTHER|||||||
34139854|NCT01045941|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139855|NCT03511508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Intervention Group and Control group|f|f|f|t
34139856|NCT00091130|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34139857|NCT00792662|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139858|NCT04215939|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34139859|NCT06326619|||CASE_CONTROL||RETROSPECTIVE|||||||
34139860|NCT01559259|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139861|NCT05877027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator administering the treatment and the investigator performing the evaluations will be different. The evaluator will not know about the interventions that the participants received.||f|f|f|t
34139862|NCT04044482|||OTHER||RETROSPECTIVE|||||||
34139863|NCT02662153|||COHORT||RETROSPECTIVE|||||||
34139864|NCT05781061|NA|SINGLE_GROUP||SCREENING||NONE||||||
34139865|NCT02228226|||CASE_ONLY||PROSPECTIVE|||||||
34139866|NCT03284333|NA|SINGLE_GROUP||OTHER||NONE||||||
34139867|NCT00824551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139868|NCT02099344|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Randomized to either~Combination product- device/biologic Artegraft® or Gore® Propaten®."||||
34139869|NCT02512601|NA|SINGLE_GROUP||OTHER||NONE||||||
34139870|NCT06445153|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||Digi-POD is a multicenter, prospective, longitudinal intervention study in a before-and-after design with quantitative process analysis||||
34139871|NCT03785860|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34139872|NCT00923975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139873|NCT00935350|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139874|NCT02493257|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139875|NCT04396769|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139876|NCT06012448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139877|NCT05764304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139878|NCT00724269|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|||f|f|t|f
34139879|NCT03982706|||COHORT||PROSPECTIVE|||||||
34139880|NCT05213104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|only outcomes assessor will be blinded to the study arm (PROBE design)|randomized, controlled, open-label study with a blind evaluation of all the endpoints (PROBE design)|f|f|f|t
34139881|NCT00186212|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139882|NCT01989780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139883|NCT02172495|||COHORT||PROSPECTIVE|||||||
34139884|NCT04671784|||COHORT||PROSPECTIVE|||||||
34139885|NCT01166958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139886|NCT02359357|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34139887|NCT06247111|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139888|NCT06036160|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139889|NCT05024175|||COHORT||PROSPECTIVE|||||||
34139890|NCT01177774|||CASE_CONTROL||PROSPECTIVE|||||||
34139891|NCT03640052|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139892|NCT02099162|||CASE_ONLY||PROSPECTIVE|||||||
34139893|NCT02839577|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34139894|NCT05339750|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34139895|NCT06225739|||COHORT||PROSPECTIVE|||||||
34139896|NCT01636505|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34139897|NCT00355537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139898|NCT00380991|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139899|NCT06606925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a prospective observational study. Subjects will undergo functional and anatomic magnetic resonance imaging a two timepoints during pilot training. Performance in flight simulator will be correlated with fMRI measurements of axonal anatomy and brain activity.||||
33830233|NCT02833623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830234|NCT00545571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830235|NCT01779453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830236|NCT01765790|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830237|NCT00746109|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830238|NCT00749359|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33830239|NCT01755910|||CASE_CONTROL||PROSPECTIVE|||||||
33830240|NCT03818243|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|no masking|the 2 groups (patients with Parkinson disease with and without RLS) received the same intervention||||
33830241|NCT03854019|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33830242|NCT02226497|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34139900|NCT02383745|||COHORT||PROSPECTIVE|||||||
34139901|NCT06305936|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Not possible to blind participants and study staff delivering the intervention to allocation status, whereas all outcome data is planned to be collected by blinded outcome assessors.|Randomised feasibility study of an intervention group, receiving 100% plant-based diet and a control group|f|f|t|t
34139902|NCT03262025|||CASE_ONLY||RETROSPECTIVE|||||||
34139903|NCT02019446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139904|NCT04915989|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34139905|NCT05730543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139906|NCT04352764|||CASE_CONTROL||PROSPECTIVE|||||||
34139907|NCT01978249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139908|NCT05969548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139909|NCT02210221|||COHORT||PROSPECTIVE|||||||
34139910|NCT03380546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139911|NCT00874640|||COHORT||PROSPECTIVE|||||||
34139912|NCT05679544|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34139913|NCT01459653|||CASE_ONLY||PROSPECTIVE|||||||
34139914|NCT00002114||||TREATMENT||DOUBLE||||||
34139915|NCT01497990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139916|NCT01997957|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139917|NCT00256815|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34139918|NCT04821674|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34139919|NCT02237248|||COHORT||PROSPECTIVE|||||||
34139920|NCT05848700|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|double blind, randomized|t|t|t|t
34139921|NCT00123578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139922|NCT05142254|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The primary study statistician will be supported by a local statistician in Nigeria to perform the randomization process. After the random allocation, all study personnel and participants will be blinded to the treatment.|Randomized Controlled Double-Blind Trial|t|t|t|f
34139923|NCT05978388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139924|NCT02242435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139925|NCT03900858|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139926|NCT06604897|||COHORT||RETROSPECTIVE|||||||
34139927|NCT05552794|||COHORT||PROSPECTIVE|||||||
34139928|NCT00147862|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34139929|NCT00570791|||OTHER||PROSPECTIVE|||||||
34139930|NCT06607289|||COHORT||OTHER|||||||
34139931|NCT06034951|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34139932|NCT03938181|||COHORT||PROSPECTIVE|||||||
34139933|NCT02783040|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139934|NCT01851486|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34139935|NCT05818917|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34139936|NCT02182661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139937|NCT04037631|||OTHER||PROSPECTIVE|||||||
34139938|NCT01495130|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139939|NCT04603781|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The PI and all members of the study team will be blind to the drug assignment of the patient. Only the CBD suppliers (John Fornecker- Way West and Anthony Ferrari - SunMed CBD) and a UT LSAD staff member (not connected to the study) will have access to participants' treatment assignment. In the very unlikely event that a participant should have an adverse reaction requiring medical attention, the PI will contact the UT staff person who is keeper of the blind and request the treatment assignment of the subject in question without revealing the treatment condition coding scheme.|4-arm double-blind placebo-controlled trial|t|t|t|t
33830243|NCT03596463|||OTHER||PROSPECTIVE|||||||
33830244|NCT04608136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139940|NCT05210517|RANDOMIZED|CROSSOVER||TREATMENT||NONE||4-arm cross over, open label intervention study||||
34139941|NCT01666535|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139942|NCT03294239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139943|NCT05151432|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34139944|NCT04453085|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139945|NCT02813655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34139946|NCT04395638|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830245|NCT00479843|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33830246|NCT01316965|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830247|NCT04874623|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830248|NCT01690923|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34139947|NCT05894720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139948|NCT00457821|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34139949|NCT01375868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830249|NCT02345915|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34139950|NCT05864521|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34139951|NCT01459640|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139952|NCT02196116|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34139953|NCT03065101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34139954|NCT06605339|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34139955|NCT01665261|||COHORT||PROSPECTIVE|||||||
34139956|NCT02788773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139957|NCT03006029|NA|SINGLE_GROUP||OTHER||NONE||||||
34139958|NCT02763254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139959|NCT04407650|RANDOMIZED|PARALLEL||TREATMENT||NONE||Pilot Phase 4 Randomised Controlled Trial||||
34139960|NCT02630940|||COHORT||CROSS_SECTIONAL|||||||
34139961|NCT00549900|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34139962|NCT00746239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139963|NCT04039711|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"Participants were screenned for genital infections~* performing vaginal and/or cervical classical-sampling (VCS)~* performing vaginal self-sampling (VSS)"||||
34139964|NCT01803178|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34139965|NCT00159731|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149517|NCT05687006|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"Randomization was carried out using an envelope method, during which the patients were randomly assigned in a ratio 1:1 to an active comparator group: CTA+CDU (preoperative examination of vascular anatomy by CTA supplemented with vessel calibre examination of the perforator using CDU) or an experimental group: CDU (preoperative examination of vascular anatomy by colour duplex sonography only)."||||
34149869|NCT01355913|||CASE_ONLY||PROSPECTIVE|||||||
34139966|NCT05106712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and most researchers will be unaware of the actual grouping. Only two investigators who will be not involved in participant management or data analysis will be aware of the grouping. Vitamin D3, Clomiphene citrate, Letrozole and placebo pills with identical package, size, color and appearance will be used in this trial.|the present intervention trial is designed to achieve the following two objectives: 1) measurement of the therapeutic effects of Vitamin D3 supplement alone and in combination with an ovulation-inducing agent (e.g., Clomiphene citrate or Letrozole) on the ovarian functional status and the hormonal and metabolic features of PCOS-Vitamin D-deficient infertile Saudi women; and 2) measurement of the effectiveness of Vitamin D3 supplement versus placebo on the clinical pregnancy rate, fertilization implantation rate, live birth rate, and other outcome parameters following in-vitro fertilization (IVF) application in PCOS-Vitamin D-deficient infertile patients.|t|t|t|t
34139967|NCT00065039|RANDOMIZED|||PREVENTION||||||||
34139968|NCT02264665|||COHORT||OTHER|||||||
34139969|NCT04051710|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34139970|NCT01545882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139971|NCT03804021|||OTHER||PROSPECTIVE|||||||
34139972|NCT01832623|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34139973|NCT03392389|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34139974|NCT05530395|||COHORT||PROSPECTIVE|||||||
34139975|NCT05258214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single Blinding will be performed in this study||t|f|f|f
34139976|NCT05636384|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A cluster, non-randomized controlled trial||||
34139977|NCT05849441|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34139978|NCT00834470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34139979|NCT02124057|||COHORT||PROSPECTIVE|||||||
34139980|NCT00004480||||TREATMENT||||||||
34139981|NCT02518958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139982|NCT04401618|||OTHER||RETROSPECTIVE|||||||
34139983|NCT01438801|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34139984|NCT01740089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34139985|NCT06332664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34139986|NCT06026345|||COHORT||PROSPECTIVE|||||||
34139987|NCT05721937|||COHORT||PROSPECTIVE|||||||
34139988|NCT03447314|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||In Part 1, one dose level of GSK3174998, GSK3359609, or pembrolizumab with up to 5 dose levels of GSK1795091 are planned for evaluation. Sequential cohorts will be enrolled and dose escalation (or de-escalation) will proceed according to Neuenschwander-Continual Reassessment Method (N-CRM design). In Part 2, subjects will be administered GSK1795091 in combination with either 24 mg GSK3174998, 80 mg GSK3359609, or 200 mg pembrolizumab at a dose identified in Part 1.||||
34139989|NCT02916888|||COHORT||PROSPECTIVE|||||||
34139990|NCT02797093|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34139991|NCT05235958|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Randomized controlled training intervention (8-weeks) with assessment of changes in clinical and molecular vascular biomarkers compared to their baseline value before the intervention|f|f|f|t
34139992|NCT00856089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139993|NCT03754582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34139994|NCT02108717|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
34139995|NCT02291757|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||Single-crossover at 4 weeks|t|t|t|t
34139996|NCT04855604|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34139997|NCT06605755|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34139998|NCT03895086|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34139999|NCT00096148|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140000|NCT04272866|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34140001|NCT03832114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open label study|The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).||||
34140002|NCT02578680|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140003|NCT05105750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140004|NCT00307840|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34140005|NCT03962257|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||Randomized controlled trial comparing one group receiving standard care and the other with standard care with the addition of the online learning platform|f|t|t|t
34140006|NCT06534229|||COHORT||RETROSPECTIVE|||||||
34140007|NCT02775487|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34140008|NCT02804698|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140009|NCT02049827|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140010|NCT03703817|||OTHER||CROSS_SECTIONAL|||||||
34140011|NCT06606860|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140012|NCT02502058|||CASE_ONLY||PROSPECTIVE|||||||
34140013|NCT02150057|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Two orthopedic surgeons will blindly grade the osteoarthritis and calculate the mechanical axis and knee angles. The two surgeons' measurements will be averaged. One surgeon's measurements will be repeated to determine intra-observer reliability.|"Subjects who meet the recruitment conditions will be prospectively randomized into one of two treatment groups for 6 month evaluation:~1. Breg Fusion Osteoarthritis Knee Brace~2. No brace group Both groups will be allowed to continue standard conservative treatment of osteoarthritis including anti-inflammatory medications, home exercises and joint supplements."|f|t|f|f
34140014|NCT00664560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140015|NCT05948228|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|double||t|f|f|t
34140016|NCT00000554||||DIAGNOSTIC||||||||
34140017|NCT06606691|||COHORT||CROSS_SECTIONAL|||||||
34149518|NCT03828474|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Visually identical pills|Double blind randomized controlled trial|t|t|t|t
34149519|NCT02686320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34149520|NCT01873248|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149521|NCT05150210|NA|SINGLE_GROUP||OTHER||NONE||||||
34149522|NCT03805516|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830250|NCT04409522|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34140018|NCT04802239|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|"Prospective monocentric trial randomized to cross-over. Each subject is its own witness, in the comparison of the analgesic effect of a hypnotherapy session versus a calm waking state, during standardized stimulation with monitoring of the NOL noxious index. As each of the subjects will be subjected to the two aforementioned states, a minimum time of 48 hours will be observed between the two exposures (hypnotherapy or calm watch) to reduce the memorization and the sensitization generated by the thermal stimulation"|"Prospective monocentric trial randomized to cross-over. Each subject is its own witness, in the comparison of the analgesic effect of a hypnotherapy session versus a calm waking state, during standardized stimulation with monitoring of the NOL noxious index. As each of the subjects will be subjected to the two aforementioned states, a minimum time of 48 hours will be observed between the two exposures (hypnotherapy or calm watch) to reduce the memorization and the sensitization generated by the thermal stimulation"|t|t|f|t
34140019|NCT00856206|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34140020|NCT01057225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140021|NCT03062306|||CASE_CONTROL||PROSPECTIVE|||||||
34140022|NCT00011674|||DEFINED_POPULATION||PROSPECTIVE|||||||
34140023|NCT02583230|NA|SINGLE_GROUP||OTHER||NONE||||||
34140024|NCT01371253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140025|NCT01686763|||COHORT||PROSPECTIVE|||||||
34140026|NCT05714618|||COHORT||PROSPECTIVE|||||||
34140027|NCT01713504|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830251|NCT01743521|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140028|NCT00551915|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34140029|NCT05503771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140030|NCT01838265|||COHORT||PROSPECTIVE|||||||
34140031|NCT04329390|||COHORT||PROSPECTIVE|||||||
34140032|NCT02294838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140033|NCT04137588|||COHORT||PROSPECTIVE|||||||
34140034|NCT01474772|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34140035|NCT05801757|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single blind|Single blind, prospective, randomized controlled study|t|t|f|t
34140036|NCT03201042|||COHORT||PROSPECTIVE|||||||
34140037|NCT00163943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140038|NCT02728544|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140039|NCT03401567|RANDOMIZED|PARALLEL||OTHER||SINGLE|All of the participants must have no neck and upper extremity pain, any fracture and surgical history for the upper extremity, cervical and thoracic area.|There are 2 groups of 30 people each. Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.|t|f|f|f
34140040|NCT04401930|||COHORT||CROSS_SECTIONAL|||||||
34140041|NCT01374867|||CASE_ONLY||PROSPECTIVE|||||||
34140042|NCT05121454|||COHORT||PROSPECTIVE|||||||
34140043|NCT04696367|||COHORT||PROSPECTIVE|||||||
34140044|NCT03360890|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140045|NCT06379958|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140046|NCT02135029|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140047|NCT02106624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34140048|NCT02206451|||CASE_ONLY||PROSPECTIVE|||||||
34140049|NCT04835909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34140050|NCT06355609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140051|NCT04449146|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is mono-center study. Patients in the process of preoperative care of a Reverse Shoulder Arthroplasty (CT Scan already available as part of the extended care course) will be offered the study. A localizer ultrasound will be performed during surgical consultation or the day before the surgical procedure in standing position (duration: 1/2 day).||||
34140052|NCT04159987|NA|SINGLE_GROUP||OTHER||NONE||||||
34140053|NCT01824329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140054|NCT00756795|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34140055|NCT04523454|||COHORT||CROSS_SECTIONAL|||||||
34140056|NCT05058612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140057|NCT03555981|RANDOMIZED|PARALLEL||TREATMENT||NONE||Individually randomised controlled superiority trial||||
33830252|NCT05036525|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830253|NCT00526097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830254|NCT05729204|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized Controlled Trial|f|f|f|t
33830255|NCT03480295|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830256|NCT01895049|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830257|NCT00885326|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830258|NCT04596098|||COHORT||PROSPECTIVE|||||||
34140058|NCT06578416|||CASE_CONTROL||OTHER|||||||
34140059|NCT01313845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140060|NCT04348565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|single-blind|Randomized control trial|f|t|f|f
34140061|NCT05138263|||COHORT||PROSPECTIVE|||||||
34140062|NCT02633254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140063|NCT04288453|NA|SINGLE_GROUP||TREATMENT||NONE|Assessors will be blinded to the time point in which the intervention begins and to the chosen activity|A 22-week interrupted time series design with multiple baselines systematically replicated across 30 youth with physical disabilities will be employed.||||
33830259|NCT00867178|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838571|NCT00448942|||DEFINED_POPULATION||RETROSPECTIVE|||||||
33838572|NCT04744753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838573|NCT00371241|||COHORT||PROSPECTIVE|||||||
34140064|NCT04392141|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140065|NCT00075946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140066|NCT03506451|NA|SINGLE_GROUP||OTHER||NONE||||||
34140067|NCT06479265|||COHORT||CROSS_SECTIONAL|||||||
34140068|NCT04656041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140069|NCT03664791|||COHORT||PROSPECTIVE|||||||
33838574|NCT02604082|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33838575|NCT02900950|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33830260|NCT05559983|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Study investigators, study nurse, and those assessing clinical outcomes, and laboratory analysis will be blinded to investigational product allocation until database lock for the final analysis.|The first fifty participant in the study will be enrolled into cohort A and receive low antigen product with or without adjuvant, or placebo. The Safety Monitoring Committee (SMC) and the independent Data Safety Monitoring Board (DSMB) will review the safety data collected through seven days after the second dose vaccination of the cohort A before the study enrollment can progress to cohort B (middle dose). Dose escalation to cohort C (high dose) will follow the same procedures.|t|t|t|t
33830261|NCT04442347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blinded, Placebo Controlled||t|f|t|f
33830262|NCT00841230|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33830263|NCT02438371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830264|NCT05680324|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830265|NCT04724096|||OTHER||PROSPECTIVE|||||||
33830266|NCT01862588|||COHORT||PROSPECTIVE|||||||
33830267|NCT04482192|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830268|NCT02468908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830269|NCT06360705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830270|NCT03181919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830271|NCT02523495|||COHORT||PROSPECTIVE|||||||
33830272|NCT00103532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830273|NCT05142839|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830274|NCT01947517|||OTHER||PROSPECTIVE|||||||
33830275|NCT03626077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830276|NCT00045097||||TREATMENT||NONE||||||
33830277|NCT01305473|||COHORT||CROSS_SECTIONAL|||||||
33830278|NCT01492621|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830279|NCT01888627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830280|NCT03855176|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830281|NCT02716298|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33830282|NCT05397210|||COHORT||PROSPECTIVE|||||||
33830283|NCT00607061|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33830284|NCT03900429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830285|NCT02575950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830286|NCT06009172|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33830287|NCT02541942|NA|SINGLE_GROUP||OTHER||NONE||||||
33830288|NCT05327101|||COHORT||PROSPECTIVE|||||||
33830289|NCT04137718|||COHORT||PROSPECTIVE|||||||
33830290|NCT01447199|||FAMILY_BASED||PROSPECTIVE|||||||
33830291|NCT05995093|||CASE_CONTROL||RETROSPECTIVE|||||||
33830292|NCT00809679|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830293|NCT00726713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830294|NCT02080377|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830295|NCT00350298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830296|NCT01662037|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830297|NCT01588366|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33830298|NCT02174614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830299|NCT06356623|||COHORT||PROSPECTIVE|||||||
33830300|NCT06478407|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33830301|NCT00119652|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830302|NCT00694798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830303|NCT01216059|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830304|NCT02924350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830305|NCT04119440|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blinded|Randomized, double-blinded with an open-label run-in Phase (Part A) Part A: Open-label Part B: Double-blind|t|f|t|t
33830306|NCT02646722|||CASE_CONTROL||PROSPECTIVE|||||||
33830307|NCT03492710|NA|SINGLE_GROUP||TREATMENT||NONE||Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter||||
33830308|NCT06417944|||CASE_CONTROL||PROSPECTIVE|||||||
33830309|NCT02647788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830310|NCT00865852|RANDOMIZED|CROSSOVER||||NONE||||||
33830311|NCT06402578|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||At the point of consent the participants will be randomised to one of three allocated groups. Control group, Intervention 1 or Intervention 2.|t|f|f|f
33830312|NCT04753944|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Participants and investigators enrolling participants could not foresee assignment because to conceal allocation equentially numbered probiotic containers of identical appearance was used|Intervention, randomized, double-blind, using placebo.|t|t|t|f
33830313|NCT05092477|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The participant, the outcomes assessor, and the Principal Investigator (Jenny J. Lin) are blinded to study randomization and treatment arm for each participant.|Pilot Overview phase and intervention phase|t|f|t|t
33830314|NCT03788564|||CASE_CONTROL||PROSPECTIVE|||||||
33830315|NCT03740477|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830316|NCT03322852|||CASE_CROSSOVER||PROSPECTIVE|||||||
33830317|NCT00302315|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830318|NCT00523198|||COHORT||PROSPECTIVE|||||||
33830319|NCT00080860||||DIAGNOSTIC||||||||
33830320|NCT05379790|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A classic phase I '3+3' dose-escalation study.||||
33830321|NCT04315116|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||single arm, open and fixed sequence||||
33830322|NCT03669328|||OTHER||PROSPECTIVE|||||||
33830323|NCT01884220|||COHORT|||||||||
33830324|NCT04727359|||COHORT||PROSPECTIVE|||||||
33830325|NCT05066295|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33830326|NCT04114097|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||randomised, two-arm, active comparator, double-dummy, double-blinded trial|t|t|t|t
33830327|NCT05026489|||COHORT||PROSPECTIVE|||||||
33830328|NCT01653210|||CASE_ONLY||PROSPECTIVE|||||||
33830329|NCT04340856|||COHORT||RETROSPECTIVE|||||||
33830330|NCT01687868|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830331|NCT02367105|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140070|NCT06602583|||COHORT||OTHER|||||||
34140071|NCT06444555|RANDOMIZED|PARALLEL||OTHER||NONE||200 adolescent girls will be enrolled in Ethiopia and 200 adolescent girls will be enrolled in Burkina Faso.||||
34140072|NCT00118313||||TREATMENT||NONE||||||
34140073|NCT00334997|RANDOMIZED|||TREATMENT||||||||
34140074|NCT05308472|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140075|NCT00973544|||COHORT||PROSPECTIVE|||||||
34140076|NCT00758264|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140077|NCT05814250|||OTHER||CROSS_SECTIONAL|||||||
34140078|NCT06605729|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34140079|NCT06606340|||COHORT||PROSPECTIVE|||||||
34140080|NCT01697163|||||PROSPECTIVE|||||||
34140081|NCT02511483|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140082|NCT04975126|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140083|NCT06587282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140084|NCT04088084|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|examiners were blinded to the assumption or not of PEA in addition to topical therapy|Monocentric, randomized, prospective, single blind, two treatment and two period crossover study.|f|f|t|t
34140085|NCT02370004|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34140086|NCT01364883|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140087|NCT03751358|NA|SINGLE_GROUP||TREATMENT||NONE||Healthy volunteers accepting to have a Unilateral ESP block with an MRI after injection of Low volume of local anesthetic||||
34140088|NCT06238141|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"This study is single-blinded. The intervention trainer will not be blinded because a single researcher conducts the study. In order to minimize experimenter bias, outcome assessments will be conducted through an online questionnaire survey platform (Wenjuanxing), with the trainer distributing the same link to all participants. During data collection, only acronyms of the questionnaires will be used to avoid self-fulfilling expectations.~Participants will be informed during the recruitment phase that the study aims to explore the effect of writing on the internship experience and feelings only. Assignment to the intervention or control group will remain undisclosed to participants until the end of the 3-month follow-up. Participants could unblind themselves by exiting the study and requesting debrief information."||t|f|t|f
34140089|NCT05384418|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140090|NCT02437305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140091|NCT06152835|||COHORT||PROSPECTIVE|||||||
34140092|NCT03523793|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cross-sectional stepped wedge design||||
34140093|NCT06603207|||OTHER||RETROSPECTIVE|||||||
34140094|NCT06424158|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140095|NCT03193086|||COHORT||PROSPECTIVE|||||||
34140096|NCT02045381|||CASE_ONLY||CROSS_SECTIONAL|||||||
34140097|NCT03548506|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34140098|NCT04562402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140099|NCT00693823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140100|NCT06444152|||COHORT||RETROSPECTIVE|||||||
34140101|NCT03569748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140102|NCT03407495|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140103|NCT04506216|NA|SINGLE_GROUP||OTHER||NONE||cohort prospective monocentric||||
34140104|NCT03985410|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The administration of ETX2514 and ETX2514 placebo will be double-blinded. Placebo and moxifloxacin (Treatment Period C) will be administered open-label.||t|f|t|t
34140105|NCT01760330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140106|NCT01730833|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140107|NCT03786302|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The operator will not be blinded to the treatment type. However, the participants, their care givers, the expert assessing the histologic and inflammatory changes and the statistician will be blinded to the treatment groups.|Study group (assigned to TAMP bioglass), and Control group (assigned to Biodentine ™).|t|t|f|t
34140108|NCT04600076|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34140109|NCT05723835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140110|NCT03465462|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Three stages of the study:~* stage 1- diagnosis of primary hypertension~* stage 2 (lasting 3 months) - antihypertensive monotherapy in all subjects~* stage 3 (lasting 30 days) - 3 groups (3 arms): group/arm C (control group), group/arm D (diet group) and group/arm S (supplementation group)."||||
34140111|NCT06608979|NA|SINGLE_GROUP||PREVENTION||NONE||Single arm design with baseline, posttest, and follow-up assessments||||
34140112|NCT03145792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140113|NCT02330302|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140114|NCT05787093|||COHORT||PROSPECTIVE|||||||
34140115|NCT01874275|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34140116|NCT02938078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34140117|NCT06608329|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140118|NCT02090049|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34140119|NCT04092907|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140120|NCT02056548|||CASE_CONTROL||PROSPECTIVE|||||||
34140121|NCT02893865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140122|NCT04363255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140123|NCT00728208|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140124|NCT02524015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140125|NCT05093907|NA|SEQUENTIAL||TREATMENT||NONE||||||
33838576|NCT02480192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors evaluated symptoms at baseline, 12-weeks post-baseline, and 3-month follow-up. Assessors were unaware of participants' assigned condition.|A single-blind, randomized controlled trial was conducted to assess the effectiveness of the CBT-Meno program compared to a waitlist comparison condition.|f|f|f|t
34140126|NCT00839449|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140127|NCT06606795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Individuals will be randomly assigned to control and spinal manipulation groups.||||
34140128|NCT01015235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140129|NCT03280303|||COHORT||PROSPECTIVE|||||||
34149523|NCT01884415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149524|NCT06335355|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140130|NCT05897840|NA|SINGLE_GROUP||PREVENTION||NONE||Assessing the ability of continuously measured SvcO2 to predict the occurrence of IDH in critical patients suffering from an AKI for which RRT is necessary.||||
34140131|NCT03049267|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140132|NCT04188418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140133|NCT00063895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140134|NCT01986309|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34140135|NCT00683917|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34140136|NCT02051153|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34140137|NCT04554966|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34140138|NCT06589791|||COHORT||CROSS_SECTIONAL|||||||
34140139|NCT06445764|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34140140|NCT06089213|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140141|NCT06608199|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34140142|NCT01478802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140143|NCT06609070|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140144|NCT02817113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140145|NCT04899440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects will proceed to an area separated from the examiner/examination area to receive supervised oral hygiene instructions and product usage instructions.||f|f|t|f
34140146|NCT05491941|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hybrid 2 implementation effectiveness trial with a cluster randomized control trial||||
34140147|NCT03579472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140148|NCT05843903|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34140149|NCT06605742|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects.|Randomized Controlled Experimental Design||||
34140150|NCT01693874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140151|NCT05175768|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Sequentially numbered, sealed, opaque envelopes|Randomized, Double-Blind, Placebo-Controlled|t|t|t|f
34140152|NCT04521998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140153|NCT02181361|||COHORT||PROSPECTIVE|||||||
34140154|NCT03764631|||COHORT||PROSPECTIVE|||||||
34140155|NCT02632279|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34140156|NCT04613765|||COHORT||PROSPECTIVE|||||||
34140157|NCT01838330|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34140158|NCT05227560|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This study was carried out in an experimental design with pretest-posttest control group in order to determine the effect of Emotional Freedom Technique (EFT) application on nursing students' anxiety and stress coping styles during the COVID-19 pandemic.|t|t|f|f
34140159|NCT05156840|||COHORT||PROSPECTIVE|||||||
34140160|NCT05791409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140161|NCT05331209|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open, randomized, add-on||||
34140162|NCT01498575|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34140163|NCT06210542|||COHORT||PROSPECTIVE|||||||
33830332|NCT04271046|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The trial will use a parallel, two-arm, randomized trial design. Participants will be randomly assigned to the experimental intervention or control. Participants in the control condition will receive mailed material from the Alzheimer's Association, web links and template secure messages. Everyone will complete assessments at baseline, 8-weeks post-enrollment, and 6 months post-enrollment.||||
33830333|NCT01621789|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34140164|NCT05781334|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140165|NCT06607575|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140166|NCT00082706|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140167|NCT05802576|||COHORT||PROSPECTIVE|||||||
34140168|NCT05135195|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34140169|NCT04527991|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830334|NCT00639314|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830335|NCT03728959|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33830336|NCT03629899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830337|NCT03469492|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830338|NCT01795859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830339|NCT00947141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830340|NCT01951521|RANDOMIZED|PARALLEL||TREATMENT||NONE||cohort multiple randomized controlled trial||||
33830341|NCT06172114|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33830342|NCT04429035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830343|NCT03587779|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830344|NCT04372446|||OTHER||OTHER|||||||
34140170|NCT04640493|NA|SINGLE_GROUP||OTHER||NONE||Study design is prospective, non-randomized, interventional (non-experimental) pre-post study||||
34140171|NCT00534118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140172|NCT01346046|||COHORT||CROSS_SECTIONAL|||||||
34140173|NCT01762956|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140174|NCT04526353|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Phase 2 non comparative randomized multicentre clinical trial with two parallel groups:~* Oxybutynin (0.1 mg/kg twice daily) during 9 months.~* No oxybutynin To determine whether the observed effects of oxybutynin are really due to the treatment we need to perform a randomized clinical trial. There is insufficient evidence in the literature about the natural evolution of the bladder in boys with PUV.~Given the paucity of literature data, our objective is not to formally test the superiority of oxybutynin versus no drug but to detect and quantify the effect of oxybutynin. This is why our clinical is randomized but non-comparative."||||
34140175|NCT02748434|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34140176|NCT04365543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34140177|NCT01159171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140178|NCT00624819|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140179|NCT05687812|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34140180|NCT04807972|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34140181|NCT02526524|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140182|NCT00258232||||TREATMENT||NONE||||||
34140183|NCT01656343|||COHORT||RETROSPECTIVE|||||||
34140184|NCT04132830|||COHORT||CROSS_SECTIONAL|||||||
34140185|NCT00202709|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140186|NCT02123238|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140187|NCT06300125|||COHORT||PROSPECTIVE|||||||
34140188|NCT03326557|RANDOMIZED|PARALLEL||TREATMENT||NONE|This is a non-blinded study in which subjects, medical staffs, and investigators are not blinded to group assignment. This is because both IOL methods are distinctly different procedure. However, both intervention arms are considered receiving equal treatment. In term of safety, both membrane sweeping and transcervical Foley catheter are non-pharmacological in nature and thus the risk of scar rupture does not differ in both methods. In term of efficacy, there is no previous study to compare effectiveness between these two methods. Individual studies revealed that membrane sweeping is likely to reduce the need for formal IOL in post-date pregnancy and transcervical Foley catheter could improve cervical favourability.|"Pregnant women with one previous Caesarean section who are indicated for induction of labour (IOL) and eligible will be recruited in the study.~Eligible subjects will be randomly assigned to one of the treatment groups below.~* Group 1: IOL with membrane sweeping~* Group 2: IOL with transcervical Foley catheter Blocked randomisation, in a block size of 6 and an allocation ratio of 1:1, will be performed using a computer-generated randomisation sequence by Research Randomizer (available online at https://www.randomizer.org/). The allocation assignment indicating membrane sweeping or transcervical Foley catheter will be sealed in sequentially numbered, opaque envelopes by principal investigator. Envelopes will be kept in a locked box in Labour Ward. When study consent is signed, the next sequential envelope will be taken out from the box and opened to determine allocation."||||
34140189|NCT04007237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind randomized clinical trial||t|f|t|f
34140190|NCT06110897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34140191|NCT01748526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140192|NCT03539289|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140193|NCT04239222|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized cross-over controlled trial||||
34140194|NCT04819438|RANDOMIZED|CROSSOVER||TREATMENT||NONE||"The study was designed in agreement with the EMA guideline Guidance on the investigation of bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1 January 2010 (9)."||||
34140195|NCT01426984||CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34140196|NCT02478840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140197|NCT01974557|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140198|NCT04101539|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinding of patient and outcomes assessor to ablation protocol.|Prospective, randomized, controlled|t|f|f|t
34140199|NCT05186103|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34140200|NCT02745782|||||PROSPECTIVE|||||||
34140201|NCT04913987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Consecutive patients placed in to one of two groups.|t|f|t|t
34140202|NCT01225965|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34140203|NCT03608137|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140204|NCT06399185|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34140205|NCT06255418|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34140206|NCT01778335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140207|NCT04146961|||CASE_ONLY||PROSPECTIVE|||||||
34140208|NCT01897753|||CASE_ONLY||RETROSPECTIVE|||||||
34140209|NCT00484380|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140210|NCT05627531|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Quasi-experimental design with untreated comparison group with a dependent pre- and post-test sample developed using non-probability convenience sampling||||
34140211|NCT01813721|||CASE_ONLY||PROSPECTIVE|||||||
34140212|NCT05801393|||COHORT||PROSPECTIVE|||||||
34140213|NCT01626118|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140214|NCT06503328|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34140215|NCT02944357|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140216|NCT05143723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140217|NCT06089460|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140218|NCT06254703|||COHORT||PROSPECTIVE|||||||
34140219|NCT02430948|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
34140220|NCT02093429|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140221|NCT02088619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140222|NCT06607146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140223|NCT06052826|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140224|NCT00004729|RANDOMIZED|||TREATMENT||DOUBLE||||||
34140225|NCT02944864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830345|NCT00177762|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838577|NCT05910970|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838578|NCT04682782|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33838579|NCT03522103|||COHORT||PROSPECTIVE|||||||
33838580|NCT04977570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838581|NCT01947699|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140226|NCT01591421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140227|NCT04989205|||COHORT||PROSPECTIVE|||||||
34140228|NCT03513887|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34140229|NCT02654431|||COHORT||RETROSPECTIVE|||||||
34140230|NCT05853107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140231|NCT05155852|||CASE_ONLY||CROSS_SECTIONAL|||||||
34140232|NCT06384274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34140233|NCT03240315|||COHORT||PROSPECTIVE|||||||
34140234|NCT05043519|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140235|NCT01373684|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140236|NCT05491369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|In an attempt to blind the participants, they will be told there will be two start times for using the app, with randomization to either date. The outcome assessor will not know which group participants are in|Randomized clinical trial (RCT): parallel, two-arm design|t|f|f|t
34140237|NCT06277986|||CASE_ONLY||RETROSPECTIVE|||||||
34140238|NCT03698045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140239|NCT01383382|||COHORT||PROSPECTIVE|||||||
34140240|NCT04773782|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140241|NCT02090803|||COHORT||PROSPECTIVE|||||||
34140242|NCT06037941|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140243|NCT04075968|||COHORT||PROSPECTIVE|||||||
34140244|NCT04644978|||COHORT||CROSS_SECTIONAL|||||||
34140245|NCT00631150|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140246|NCT03271073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140247|NCT04854967|RANDOMIZED|PARALLEL||OTHER||NONE||"Participants will be randomized to receive either usual care or an oxygen de-implementation intervention. The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an unlearning component targeting provider and patient education and 3) a substitution component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing)."||||
34140248|NCT01946672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140249|NCT03732326|||COHORT||PROSPECTIVE|||||||
34140250|NCT06011798|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140251|NCT01691885|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34140252|NCT00932620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140253|NCT03473106|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Surgical side can not be randomized. Only data assessor will be blinded.||f|f|f|t
34140254|NCT04050696|NA|SINGLE_GROUP||TREATMENT||NONE|Treatment-only study|||||
34140255|NCT04359290|NA|SINGLE_GROUP||TREATMENT||NONE||Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function; open design, single arm.If the patient is discharged before day 28, the therapy will be discontinued for discharge.||||
34140256|NCT03659149|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140257|NCT05536492|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140258|NCT05289193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140259|NCT03867786|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140260|NCT06344052|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140261|NCT00233649|||||PROSPECTIVE|||||||
34140262|NCT05170490|||COHORT||PROSPECTIVE|||||||
34140263|NCT06225895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor) double-blinded(participants and outcome assessors)|"computer generating random numbers, the patients will be allocated into three equal groups: Group C: (control group) patients will receive general anesthesia. Group E: patients will receive an Erector spinea plane block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia.~Group R: patients will receive rhomboid intercostal nerve block with 20 ml of bupivacaine 0.25% on each side followed by general anesthesia."|t|f|f|t
34140264|NCT02118766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140265|NCT00092703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140266|NCT01242410|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34140267|NCT01432145|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140268|NCT04965974|RANDOMIZED|PARALLEL||TREATMENT||NONE||The digital blue light blocking filter will be randomly installed in digital devices of the 80 subjects and rest of 80 will be without filter.||||
34140269|NCT00236496|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34140270|NCT01575964|||CASE_CONTROL||PROSPECTIVE|||||||
34140271|NCT01842035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140272|NCT00996294|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140273|NCT02567682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140274|NCT01888133|RANDOMIZED|CROSSOVER||||NONE||||||
34140275|NCT04484649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34140276|NCT06446063|||CASE_CONTROL||PROSPECTIVE|||||||
34140277|NCT02892383|||COHORT||PROSPECTIVE|||||||
34140278|NCT01588262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140279|NCT02479165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140280|NCT06414746|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34140281|NCT04977934|||COHORT||PROSPECTIVE|||||||
34140282|NCT03840304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140283|NCT06605183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140284|NCT03005301|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140285|NCT01741142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140286|NCT03389555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140287|NCT05438602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140288|NCT03504982|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34140289|NCT00909545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140290|NCT05641428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140291|NCT06607094|NA|SINGLE_GROUP||TREATMENT||NONE||Optimized Water Vapor Thermal Therapy (REZUM) in Management of Benign Prostatic Hyperplasia. The optimized methods mainly include ablation optimization and combined imaging techniques.||||
34140292|NCT06121141|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140293|NCT01049165|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34140294|NCT05108025|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140295|NCT04185649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140296|NCT02599649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140297|NCT01317537|RANDOMIZED|FACTORIAL||||SINGLE|||f|f|t|f
33830346|NCT05153330|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The first-in-human (FIH) study is a dose-escalation/dose-expansion study of BMF-219. During the dose-escalation phase of the study, the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D) of BMF-219 will be determined. Subjects in Cohort 1 (acute leukemia) are assigned to one of two parallel arms; ARM A (subjects not receiving CYP3A4 inhibitors) and ARM B (subjects receiving CYP3A4 inhibitors); Subjects in Cohort 2 (DLBCL), Cohort 3 (multiple myeloma), and Cohort 4 (chronic lymphocytic leukemia/ small lymphocytic lymphoma) are assigned to a single arm (ARM A).The dose-expansion phase will obtain further safety, as well as efficacy data for BMF-219 when dosed at the OBD and RP2D.||||
34140298|NCT02001415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140299|NCT05275010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140300|NCT03894631|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140301|NCT04588012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140302|NCT04851210|||CASE_ONLY||PROSPECTIVE|||||||
34140303|NCT01886690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140304|NCT03819556|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open randomized interventional study||||
34140305|NCT06512051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140306|NCT06605105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140307|NCT02845622|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140308|NCT05718271|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140309|NCT04246333|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140310|NCT00395291|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34140311|NCT02663466|||CASE_CONTROL||RETROSPECTIVE|||||||
34140312|NCT03676543|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140313|NCT03738995|||COHORT||RETROSPECTIVE|||||||
34140314|NCT06506032|||CASE_ONLY||PROSPECTIVE|||||||
34140315|NCT03515551|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34140316|NCT02312791|||COHORT||PROSPECTIVE|||||||
34140317|NCT02925078|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140318|NCT06607458|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140319|NCT06605352|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45||||
34140320|NCT01904643|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140321|NCT01161550|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140322|NCT05929118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140323|NCT02103725|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34140324|NCT03062553|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140325|NCT04369118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34140326|NCT04872348|||COHORT||RETROSPECTIVE|||||||
34140327|NCT05219903|||COHORT||OTHER|||||||
34140328|NCT01118169|||COHORT||CROSS_SECTIONAL|||||||
34140329|NCT06490068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140330|NCT00713921|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140331|NCT03334851|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34140332|NCT01456195|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140333|NCT02737553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34140334|NCT05504265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140335|NCT06608628|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Experimental and control group|t|f|f|f
34140336|NCT04919226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140337|NCT04579484|||COHORT||PROSPECTIVE|||||||
34140338|NCT01452230|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140339|NCT00802191|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34140340|NCT06605014|||COHORT||PROSPECTIVE|||||||
34140341|NCT00415064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140342|NCT06142396|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study for combination medication treatment.||||
34140343|NCT06053801|||COHORT||PROSPECTIVE|||||||
34140344|NCT06334081|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140345|NCT05908526|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind, randomized, placebo-controlled, single site clinical trial.|The study employs a two-group (suvorexant, 20mg, qhs, versus placebo) parallel design and involves a baseline assessment, 2-day low-dose run-in, and approximately 14-day active treatment phase with intensive ambulatory monitoring via wrist actigraphy and ecological momentary assessment (EMA). Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and objective cognitive testing administered by computer.|t|f|f|t
34140346|NCT01076062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140347|NCT06140381|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34140348|NCT03042377|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients were unaware as to which study group they had been allocated.|The patients were assigned to four medication groups randomly with an equal allocation rate between groups.The patients in the groups had same characteristics.|t|f|f|f
34140349|NCT02319161|||CASE_CONTROL||RETROSPECTIVE|||||||
34140350|NCT03691818|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140351|NCT01552616|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34140352|NCT03206632|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140353|NCT03130387|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Hysteroscopic examination for patients with AUB||||
34140354|NCT03650101|||COHORT||PROSPECTIVE|||||||
34140355|NCT03228875|||COHORT||PROSPECTIVE|||||||
34140356|NCT01062841|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34140357|NCT05088083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140358|NCT04084548|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Pharmacy-prepared medications.|Double-blind factorial randomization to lidocaine or placebo and ketamine or placebo.|t|t|t|t
34140359|NCT01478230|RANDOMIZED|CROSSOVER||||NONE||||||
34140360|NCT05774054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140361|NCT01789138|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140362|NCT04679857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140363|NCT01926418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140364|NCT03885232|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Data Analysis study team members and parent participants will be masked to study assignment.||t|f|f|t
34140365|NCT05709067|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34140366|NCT04125238|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34140367|NCT02871713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140368|NCT02194647|||CASE_ONLY||OTHER|||||||
34140369|NCT04201366|||COHORT||PROSPECTIVE|||||||
34140370|NCT01906723||||SUPPORTIVE_CARE||||||||
34140371|NCT04986046|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140372|NCT05385081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||prospective, single-center cohorte study||||
34140373|NCT05184101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||investigator-initiated, multi-centre, randomised, open-label trial|f|f|f|t
34140374|NCT04753658|||COHORT||OTHER|||||||
34140375|NCT03085628|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34140376|NCT01988532|||COHORT||CROSS_SECTIONAL|||||||
34140377|NCT05247970|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140378|NCT05467761|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140379|NCT06604793|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140380|NCT04796103|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140381|NCT02388490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140382|NCT04677400|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34140383|NCT03817320|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140384|NCT05027126|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140385|NCT02982317|||COHORT||PROSPECTIVE|||||||
34140386|NCT06230016|||OTHER||PROSPECTIVE|||||||
34140387|NCT03401658|||CASE_ONLY||PROSPECTIVE|||||||
34140388|NCT04446130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140389|NCT04872933|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34140390|NCT04778163|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A treatment arm receives a psychotherapeutic group intervention (based on humor with cognitive behavioural and psychoeducative approaches) over a period 6 weeks.~A control arm is placed on a 6 week waiting list."||||
34140391|NCT05946785|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140392|NCT02545114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140393|NCT02136680|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
34140394|NCT01010568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140395|NCT05566431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessors will not go into the ICU when a study participant is being treated, unmasked study staff will not inform the outcome assessor which protocol was used for a participant. and outcome assessors will remind participant's parents to refrain for telling them which treatment protocol was used for the participant.|In a Phase III multicenter, parallel-group, randomized superiority trial in 428 children with sTBI from 7 Latin American pediatric trauma centers, the objective is to test the efficacy of the treatment protocol from the Guidelines based on ICP monitoring among children with sTBI in improving global outcome measured by Pediatric Quality of Life Inventory (PedsQL) 6 mos after injury compared to treatment based on a non-invasive imaging \& clinical examination (CREVICE) protocol specifically modified for a pediatric population.|f|f|f|t
34140396|NCT04861467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140397|NCT00845260|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140398|NCT00000886||||PREVENTION||DOUBLE||||||
34140399|NCT04510948|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Baseline and follow up interviews will be conducted by a rater blinded to the group assignment.|The aim of this project is to test, using a parallel group design involving 2 matched primary care sites, whether PPC decreases patient treatment burden and unwanted and unnecessary health care as well as assess what the value of this program is for patients.|f|f|f|t
34140400|NCT06035393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a randomized, double blind, double dummy, active-controlled, parallel-group study.|t|t|t|f
34140401|NCT05868005|RANDOMIZED|PARALLEL||SCREENING||NONE||"A pragmatic cluster controlled randomised trial will be conducted in 35 PCCs in Catalonia. The randomization will be performed through a statistical software for each pair of selected health centres, stratified by study area and by density of migrant population in the area (low, medium, and high). For each pair of PCCs, one PCC will be randomly selected to implement the screening programme through the ISMiHealth software, and it will be compared with the other PCC, which will follow the current practices in the routine care. In both cases, health professionals will receive a training session on migrant health; the contents will include, for each condition, epidemiological aspects, diagnosis, treatment, and the screening recommendation.~In Andalusia, a pilot cluster randomized trial will be carried out to evaluate preliminary effectiveness data."||||
34140402|NCT02514694|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34140403|NCT04871893|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, non-comparative, multi-centre, open-label, interventional PMCF study||||
34140404|NCT04155346|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Effectiveness-Implementation hybrid model||||
34140405|NCT03905369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140406|NCT00000273|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140407|NCT00785421|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140408|NCT05275543|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial with Repeated Measures||||
34140409|NCT02068846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140410|NCT06511739|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel assigned|t|t|t|t
34140411|NCT02055261|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34140412|NCT02952963|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140413|NCT04660292|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140414|NCT04767178|||COHORT||PROSPECTIVE|||||||
33830347|NCT03447574|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830348|NCT01454388|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33830349|NCT01551069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830350|NCT00487383|||||PROSPECTIVE|||||||
34140415|NCT04961541|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34140416|NCT02198482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140417|NCT06079060|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Each product will be labeled with a randomly generated code.|A sequential randomised 2-period cross-over trial comparing five uses of a 61 mm width synthetic nitrile male condom with five uses of a 61 mm width standard latex male condom.|t|f|t|t
34140418|NCT04284735|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140419|NCT05371080|RANDOMIZED|FACTORIAL||PREVENTION||NONE||Interventional study model and allocation in the current study follow the same approach as presented in the primary studies.||||
34149525|NCT05592132|RANDOMIZED|PARALLEL||OTHER||NONE||intervention plus standard care versus standard care||||
34149526|NCT02294331|||OTHER||PROSPECTIVE|||||||
34140420|NCT05842954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The Novartis clinical trial team (CTT) will be blinded to the identity of the treatment from the time of randomization until the database lock for the analysis of the Core phase. Prior to unblinding the data of the Core phase (for the Novartis CTT), at least two DMC reviews are planned to minimize risks in this vulnerable patient population:~1. Once the first 200 patients (across both treatment arms) in the Core phase have been dosed and followed up to at least Day 22.~2. Once the first 750 patients (across both treatment arms) in the Core phase have been dosed and followed up to at least Day 22.~3. Additional DMC reviews may be conducted ad-hoc during the study, as deemed necessary.~All safety data from the Core phase as well as from the Extension phase that are available at these 2 scheduled timepoints will be included in the DMC reviews. After the database lock of the Core phase, the CTT will be unblinded."||f|f|f|t
34140421|NCT01389154|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34140422|NCT02913430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140423|NCT02073838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140424|NCT05418283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140425|NCT04407637|||CASE_CONTROL||PROSPECTIVE|||||||
34140426|NCT05103176|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Subjects will be randomly assigned to one of the 3 arms of the study. Subjects will be blind to which arm they are in, however, will be aware of what is involved within each of the arms.|The investigators will use a randomized block design with up to 65 subjects in up to nine sessions. The first session will screen subjects before enrolling subjects into study. Three sessions will collect functional magnetic resonance imaging (fMRI) scans, neurophysiological measures with TMS, and behavioral measures. After a baseline testing session, subsequent sessions over five days will entail rTMS, followed by two assessments to evaluate the effects of stimulation on brain and behavior. rTMS intervention sessions will consist of: (i) Posterior Parietal Cortex (PPC) stimulation alone, (ii) PPC stimulation paired with a grasp task or (iii) vertex stimulation (as a control condition) paired with a grasp task. Duration of study: Approximately 3-4 weeks (depending upon scheduling)|t|f|f|f
34140427|NCT00218816|RANDOMIZED|PARALLEL||||NONE||||||
34140428|NCT01391572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140429|NCT06135636|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140430|NCT06309173|||COHORT||PROSPECTIVE|||||||
34140431|NCT04488159|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140432|NCT01904916|NA|SINGLE_GROUP||OTHER||NONE||||||
34140433|NCT03690492|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34140434|NCT00814697|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140435|NCT02408003|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140436|NCT06607887|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34140437|NCT01790178|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34140438|NCT01118104|NA|SINGLE_GROUP||||NONE||||||
34140439|NCT04257175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140440|NCT03297242|||CASE_ONLY||RETROSPECTIVE|||||||
34140441|NCT01602783|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140442|NCT02795507|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830351|NCT00771095||PARALLEL||TREATMENT||NONE||||||
34140443|NCT03848208|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140444|NCT05606536|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140445|NCT02944227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140446|NCT01505673|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140447|NCT01266356|||CASE_CONTROL|||||||||
34140448|NCT05341895|NON_RANDOMIZED|CROSSOVER||OTHER||NONE|The patient does not know the purpose of the kinesiotape|prospective||||
34140449|NCT05704907|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140450|NCT04105738|||COHORT||PROSPECTIVE|||||||
34140451|NCT04748068|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34140452|NCT02373956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140453|NCT03986879|||OTHER||CROSS_SECTIONAL|||||||
34140454|NCT06608901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140455|NCT03243214|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|"The participant and investigator do not know what treatment is applied (TMS stimulation or Sham-TMS stimulation with a different coil).~The outcomes assessor will also be blinded."|This is a randomized double blind trial.|t|f|t|t
34140456|NCT03424369|||COHORT||PROSPECTIVE|||||||
34140457|NCT02068690|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34140458|NCT04929925|||CASE_CONTROL||PROSPECTIVE|||||||
34140459|NCT03617263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140460|NCT04728152|||COHORT||PROSPECTIVE|||||||
34140461|NCT05550038|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All included patients will have a compression ultrasound performed by the general practitioner followed within 72 hours by a whole leg ultrasound with Doppler performed by the vascular physician.||||
34140462|NCT06303648|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Subjects will be enrolled into one of four cohorts. The study will begin enrolling Cohort 1.||||
34140463|NCT05694338|||COHORT||PROSPECTIVE|||||||
34140464|NCT03305419|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study. Subjects and investigator will be masked.|This study will consist of two parts; Part A and Part B. Part A will be a 3-way crossover design and Part B will be a sequential-group design.|t|f|t|f
34140465|NCT02358031|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140466|NCT03088748|||COHORT||RETROSPECTIVE|||||||
34140467|NCT04319380|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34140468|NCT03259503|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149527|NCT04754230|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34149528|NCT02419170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149870|NCT00265018|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34149871|NCT03166072|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34149872|NCT02404649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149873|NCT00999960|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830352|NCT02892201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149874|NCT02210832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830353|NCT00470405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830354|NCT00444262|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140469|NCT06390540|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"In the PASS 11 program, when the number of groups is calculated as 2, 5% margin of error and 90% power, it has been determined that at least 54 people should be included in the sample, with each group consisting of at least 27 people. Considering that the women taking part in the study may want to leave the study while it is ongoing and may encounter unexpected medical conditions and may be lost; It was decided to include a total of 80 women, 40 in the intervention group and 40 in the control group. In this single-blind randomized controlled study, the group in which women will be included will be determined and randomized via computer. Random Allocation Software Program will be used to randomize women to groups. The randomization process will be generated by the computer into random blocks of permuted length. Women will be assigned to one of the intervention and control groups by the researchers according to the order in the randomization list."|This research will be conducted in accordance with the pre-test-post-test experimental research model in two groups in order to determine the effect of a mobile-based breathing and relaxation exercise program applied to postpartum women on postpartum depression, mother-infant attachment and baby crying behavior.|t|f|f|f
34140470|NCT03349645|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
34140471|NCT00000419|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34140472|NCT00532025|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140473|NCT02463747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140474|NCT05469243|||COHORT||RETROSPECTIVE|||||||
34140475|NCT04979897|||COHORT||PROSPECTIVE|||||||
34140476|NCT01018134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140477|NCT05891886|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34140478|NCT04098237|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34140479|NCT03272828|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140480|NCT04911400|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34140481|NCT05345067|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The women in the experimental and control groups did not know which group they were in. Data were collected online due to the pandemic. Therefore, the researchers and the people who would conduct the analyzes did not know the women in the experimental and control groups. The women used a nickname to fill in the questions on the measurement tools.|randomized controlled trial|t|f|f|t
34140482|NCT02927925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140483|NCT01071200|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140484|NCT05757856|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The pathologist and immunostaining analyst receiving study participant biopsies for analysis, as well as the radiologist scoring the scans will be blinded to EoE diagnosis and other test results.|Open-label single-arm study.||||
34140485|NCT05708638|RANDOMIZED|PARALLEL||SCREENING||NONE||"Single-center, prospective, non-blinded, randomized controlled trial, Patients were allocated to 2 groups:~Group 1 Patients who underwent anesthesia induction with target-controlled infusion, Group 2: Patients who underwent manual anesthesia induction"||||
34140486|NCT01937858|||COHORT||PROSPECTIVE|||||||
34140487|NCT05923294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140488|NCT06607367|NA|SINGLE_GROUP||TREATMENT||NONE||Single group study with historic control||||
34140489|NCT01244633|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140490|NCT01480414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140491|NCT00938821|||CASE_ONLY||RETROSPECTIVE|||||||
34140492|NCT03381482|||COHORT||PROSPECTIVE|||||||
34140493|NCT00711347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140494|NCT00010387|NA|SINGLE_GROUP||TREATMENT||||||||
34140495|NCT02307097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140496|NCT06232148|||COHORT||PROSPECTIVE|||||||
34140497|NCT01110837|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34140498|NCT03626272|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"This is a randomized, non-blind controlled trial that will compare three periodicities of an educational intervention to be performed through in situ simulation. Group A will be submitted to intervention at 8-month intervals, group B every four months and group C every two months; each group will be divided into two subgroups, totaling six subgroups consisting of one nurse and three nursing technicians.~The research was approved by the Research Ethics Committees of the Federal University of Health Sciences of Porto Alegre, under approval certificate no. 56516216.9.0000.5345, and of the Universidade Católica do Rio Grande do Sul/PUCRS, under approval certificate no. 56516216.9.3001.5336."||||
34140499|NCT03568552|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The Patient Decision Aid for Medication Assisted Therapy (PtDA-MAT) will be tested by patients and clinicians during actual visits with OUD patients to assess its acceptability and effectiveness. We will track patients receiving PtDAT-MAT using their clinical and administration data over a 24-month period to assess outcomes associated with PtDAT-MAT. Participating clinics will be randomly selected in sequence to implement the intervention.||||
34140500|NCT04998539|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The participants will be blinded to the expected differences among the test conditions and asked not to discuss their experiences with other potential participants.|This study consists of a randomized crossover trial with within-participant comparisons.|t|f|f|f
34140501|NCT02240823|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140502|NCT05974657|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34140503|NCT06009887|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140504|NCT00961246|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34140505|NCT02877654|NA|SINGLE_GROUP||SCREENING||NONE||||||
34140506|NCT03876015|||COHORT||PROSPECTIVE|||||||
34140507|NCT02444871|||||PROSPECTIVE|||||||
34140508|NCT05497050|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study was completed with the families of 36 children with PKU, 19 in the intervention group and 17 in the control group, who met the inclusion criteria.||||
34140509|NCT01610440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830355|NCT01301703|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830356|NCT00429897|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33830357|NCT04999605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830358|NCT05130346|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33830359|NCT06168162|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830360|NCT04328103|||COHORT||CROSS_SECTIONAL|||||||
33830361|NCT04869813|||COHORT||PROSPECTIVE|||||||
34140510|NCT05413265|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34140511|NCT05482178|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental||||
33830362|NCT04166110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140512|NCT01209455|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34140513|NCT02076399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140514|NCT04909892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140515|NCT00976378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140516|NCT02818348|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140517|NCT02279719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140518|NCT01552785|||CASE_ONLY||PROSPECTIVE|||||||
34140519|NCT04449393|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140520|NCT00777400|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34140521|NCT04432493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded as to TMS condition (active or sham)||t|f|f|f
34140522|NCT00100230|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34140523|NCT02386891|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34140524|NCT01089023|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140525|NCT04397913|||COHORT||PROSPECTIVE|||||||
34140526|NCT04465435|||COHORT||PROSPECTIVE|||||||
34140527|NCT05824039|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34140528|NCT01808391|||COHORT||PROSPECTIVE|||||||
34140529|NCT04071067|||COHORT||PROSPECTIVE|||||||
34140530|NCT02044601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140531|NCT04355897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140532|NCT05451173|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment||||
34140533|NCT01672658|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140534|NCT06194955|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Single-blind, randomized, crossover study|t|f|f|f
34140535|NCT06607393|||COHORT||RETROSPECTIVE|||||||
34140536|NCT01901523|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34140537|NCT00167596|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140538|NCT00102297|NON_RANDOMIZED|||TREATMENT||NONE||||||
34140539|NCT06606457|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140540|NCT03502967|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||TBI patients and healthy control subjects||||
34140541|NCT04070326|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34140542|NCT01613989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140543|NCT05192629|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be assessed in the preoperative anaesthesia consultation. If they meet the criteria for inclusion in our protocol, and have no exclusion criteria, the study will be explained to their parents (and to the child in simple language if they are old enough to understand). On the sedation day, randomisation is carried out by the clinical research unit of the H.U.D.E.R.F. The result of the randomisation is transmitted in opaque and sealed envelopes to the non-blinded members of the team who are responsible for preparing the premedications. Once prepared and anonymously labelled, the premedication is administered to the patient by the blinded nursing staff. The child is monitored for the next 30 minutes. Ten minutes before the examination, the child and his/her parents are taken to the induction room to meet the anesthesiologist who will take charge of the child.||t|t|t|t
34140544|NCT05988294|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34140545|NCT02754141|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140546|NCT01960127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140547|NCT04083261|||COHORT||RETROSPECTIVE|||||||
34140548|NCT00610441|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34140549|NCT03648489|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140550|NCT06216899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140551|NCT03089944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140552|NCT03349424|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830363|NCT02194842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830364|NCT00179257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830365|NCT02239861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830366|NCT04299347|||COHORT||PROSPECTIVE|||||||
33830367|NCT04286854|||COHORT||PROSPECTIVE|||||||
33830368|NCT02804399||CROSSOVER||OTHER||NONE||||||
33830369|NCT05266898|NA|SINGLE_GROUP||PREVENTION||NONE||Single-arm trial of serological response to Gardasil-9 HPV vaccine in immunocompetent adults (age 18-45) with HIV infection. All study participants will receive Gardasil-9 3-dose series.||||
33830370|NCT00661713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33830371|NCT02420405|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830372|NCT00806455|||CASE_ONLY||PROSPECTIVE|||||||
33830373|NCT06486584|NA|SINGLE_GROUP||OTHER||NONE||||||
33830374|NCT00282945|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830375|NCT01285596|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33830376|NCT06428877|||COHORT||RETROSPECTIVE|||||||
34140553|NCT04287569|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140554|NCT02388594|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140555|NCT05577377|NA|SINGLE_GROUP||TREATMENT||NONE||Pre and Post Intervention Study with Orgasmic Meditation - a meditation practice||||
34140556|NCT01865006|||CASE_CONTROL||PROSPECTIVE|||||||
34140557|NCT00379782|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140558|NCT06036615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140559|NCT05186701|RANDOMIZED|PARALLEL||TREATMENT||NONE||68 participants were divided in two groups. Group A got Kinesio taping and conventional treatment while group B got only conventional treatment.||||
34140560|NCT06606912|||OTHER||RETROSPECTIVE|||||||
34140561|NCT03356418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140562|NCT03078790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140563|NCT04583254|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34140564|NCT06105736|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830377|NCT04067908|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830378|NCT01287845|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830379|NCT01752764|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|t|f
34140565|NCT05327634|||COHORT||PROSPECTIVE|||||||
34140566|NCT00799045|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34140567|NCT05401812|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34140568|NCT06464744|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Placebo motor cortex stimulation|Active motor cortex stimulation|t|f|f|f
34140569|NCT04326413|||COHORT||PROSPECTIVE|||||||
34140570|NCT04775927|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The volunteer and the researcher (caregiver) before agreeing to participate in the study will not know which group they will be in. After accepting the research, the participant and the researcher will know who will be in which group.|There will be ywo group. One is interventional group; other is control group.|t|t|t|f
34140571|NCT05102097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Upon completion of baseline assessments, participants will be randomly assigned into two groups A and B in 1:1 ( i.e 20 participants per group) ratio using table of random digit generated from excel.~The study will be single-blind whereby only the outcome assessors will be blinded to participant's group allocation but the type of intervention will not be specified. Because of the nature of the intervention it will be difficult to blind the participants."|Group A (experimental group) participants in this group will walk on treadmill and perform standard of care in form of exercises. Group B (Control Group) participants in this group will receive standard of care alone|f|f|f|t
34140572|NCT04083313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140573|NCT05069714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Single-blinded study. Investigators assessing disease activity will be blinded to the treatment arm.||f|t|f|t
34140574|NCT04463199|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140575|NCT02649023|||COHORT||PROSPECTIVE|||||||
34140576|NCT02502227|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34140577|NCT02842515|||||PROSPECTIVE|||||||
34140578|NCT03133598|||COHORT||PROSPECTIVE|||||||
34140579|NCT02076360|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33830380|NCT00033943|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34140580|NCT03371407|||COHORT||PROSPECTIVE|||||||
34140581|NCT01152905|||CASE_CONTROL||PROSPECTIVE|||||||
34140582|NCT02024269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140583|NCT01543672|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140584|NCT05569057|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140585|NCT00002522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140586|NCT02640625|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140587|NCT01884558|NA|SINGLE_GROUP||||NONE||||||
34140588|NCT05966428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consisted of 2 groups as control and experiment.||||
34140589|NCT05340387|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140590|NCT02175862|||COHORT||PROSPECTIVE|||||||
34140591|NCT01338480|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34140592|NCT01018472|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34140593|NCT00055354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34140594|NCT03659773|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34140595|NCT00024661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140596|NCT03155334|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34140597|NCT01094314|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34140598|NCT00831610|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140599|NCT02210689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140600|NCT02210312|||COHORT||PROSPECTIVE|||||||
33830381|NCT06345326|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective observational||||
33830382|NCT02950181|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830383|NCT04351945|||COHORT||PROSPECTIVE|||||||
33830384|NCT02085473|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830385|NCT01187745|||COHORT||PROSPECTIVE|||||||
33830386|NCT01448369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830387|NCT00854971|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830388|NCT02840916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33830389|NCT02196311|||COHORT||PROSPECTIVE|||||||
33830390|NCT02997683|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830391|NCT05188625|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830392|NCT02128698|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34140601|NCT01296633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140602|NCT02252185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140603|NCT03661788|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34140604|NCT02226562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34140605|NCT02901002|||CASE_CONTROL||PROSPECTIVE|||||||
34140606|NCT00338832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830393|NCT02425241|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33830394|NCT02973802|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830395|NCT00895388|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830396|NCT05708300|||COHORT||PROSPECTIVE|||||||
33830397|NCT03009019|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830398|NCT05162898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830399|NCT04205656|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessor||f|f|f|t
33830400|NCT00514488|RANDOMIZED|PARALLEL||||NONE||||||
34140607|NCT03645694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Individual with memory concerns and their family caregivers were randomly assigned to receive the facial recognition technology or usual care.||||
34140608|NCT05865405|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The statistician will be blinded to what arm participants are a part of.|Both arm 1 and arm 2 groups of participants will receive at least 6 months of MS CATCH tool intervention, with arm 1 receiving 12 months of intervention|f|f|f|t
34140609|NCT06429163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All patients and clinicians involved in the study are unaware of the group assignment and syringe contents.|A single-centre prospective randomized placebo-controlled double-blind pilot study|t|t|f|f
34140610|NCT05636410|||COHORT||PROSPECTIVE|||||||
34140611|NCT05346965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34140612|NCT02994953|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34140613|NCT01430923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140614|NCT03352453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140615|NCT06176872|||COHORT||PROSPECTIVE|||||||
34140616|NCT02282800|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34140617|NCT01990430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140618|NCT06606743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140619|NCT01295008|||COHORT||CROSS_SECTIONAL|||||||
34140620|NCT03752190|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140621|NCT02303080|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34140622|NCT04611425|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Non-controlled||||
34140623|NCT00622089|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140624|NCT05791695|||COHORT||RETROSPECTIVE|||||||
34140625|NCT06537128|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent evaluators will be blind to which group participants are randomized into.|Randomized assignment to one of two conditions|f|f|f|t
34140626|NCT01096537|||COHORT||RETROSPECTIVE|||||||
34140627|NCT01804582|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140628|NCT06027177|||COHORT||PROSPECTIVE|||||||
34140629|NCT05747482|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34140630|NCT05148442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140631|NCT01866423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140632|NCT00762567|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140633|NCT03051984|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34140634|NCT04200768|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140635|NCT05464875|||CASE_ONLY||PROSPECTIVE|||||||
34140636|NCT06321198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140637|NCT06428565|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140638|NCT03618628|NA|SINGLE_GROUP||OTHER||NONE||||||
34140639|NCT02299570|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34140640|NCT06491290|||CASE_CONTROL||RETROSPECTIVE|||||||
34140641|NCT04788797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140642|NCT01571908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140643|NCT03328169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140644|NCT03454269|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140645|NCT03891004|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluators of cosmesis will be blind to the group assignment. The person who will evaluate the scars will be a nurse or medical assistant.|This will be a randomized controlled trial comparing skin closure after robotic urogynecologic surgery with tissue adhesive versus subcuticular suture.|t|f|f|t
34140646|NCT05714072|NA|SEQUENTIAL||OTHER||NONE||This is a multicenter, non-randomized phase 1 clinical trial evaluating the safety and activity of combined ruxolitinib and abemaciclib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Patients will be treated in dose escalation using a 3+3 design.||||
34140647|NCT03764917|||COHORT||PROSPECTIVE|||||||
34140648|NCT00280800|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140649|NCT01539343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140650|NCT01903551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140651|NCT00309712|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34140652|NCT00591968|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140653|NCT05154136|NA|SEQUENTIAL||TREATMENT||NONE||The study consists of 2 periods with participants sequentially receiving Treatment A (etrumadenant) in Period 1, followed by Treatment B (etrumadenant + itraconazole) in Period 2.||||
34140654|NCT00017589||||TREATMENT||||||||
34140655|NCT06266949|||CASE_CONTROL||PROSPECTIVE|||||||
33830401|NCT05623371|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|As the design is a waitlist controlled trial, the participants, the consultans and the some of the involved researchers will know what individuals received the intervention in 2023 (i.e. the treatment group), and 2024 (i.e. the control group).|Cluster, randomized waitlist controlled trial. The treatment group receives the intervention in 2023, and the control group receives it in 2024.|f|f|f|t
33830402|NCT02007395|||CASE_ONLY||PROSPECTIVE|||||||
33830403|NCT02102568|||COHORT||PROSPECTIVE|||||||
33830404|NCT06284434|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Surgeons and patients will be unaware of which cohort the subject will be randomized to be part of. The pharmacist, anesthesiologist, and research coordinator may all be aware of which drug is administered.|The design of this study is a randomized control trial, double-blinded. Patients who meet criteria and consent will be randomized to receive LB or standard bupivacaine.|t|t|t|f
34140656|NCT04239183|||COHORT||PROSPECTIVE|||||||
33830405|NCT05095324|||CASE_CONTROL||PROSPECTIVE|||||||
34140657|NCT00165750|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140658|NCT02430896|||CASE_CONTROL||PROSPECTIVE|||||||
34140659|NCT03488888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140660|NCT03664674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Double-blind, Placebo-controlled, Multicenter|t|f|t|t
34140661|NCT03080545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140662|NCT05888909|||COHORT||PROSPECTIVE|||||||
34140663|NCT00226408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140664|NCT06022081|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-group study where the focus is on evaluating the diagnostic accuracy of both CXR and LUS for PNX detection post-tube removal in cardiac surgery and trauma patients. The study aims to compare the results of both modalities within the same group of participants to assess their performance in detecting PNX.||||
34140665|NCT00822705|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34140666|NCT03604874|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34140667|NCT02956044|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140668|NCT05751889|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups will be assigned to either interventional (serious game intervention) or comparator (traditional health education).||||
34140669|NCT04006990|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140670|NCT05941338|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140671|NCT00278902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140672|NCT00525824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140673|NCT05980364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140674|NCT03651518|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140675|NCT04509518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140676|NCT03521232|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140677|NCT01117506|||COHORT||PROSPECTIVE|||||||
34140678|NCT03354884|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
34140679|NCT03080233|||OTHER||CROSS_SECTIONAL|||||||
34140680|NCT04315688|||COHORT||PROSPECTIVE|||||||
34140681|NCT04660058|||CASE_CONTROL||OTHER|||||||
34140682|NCT03204409|||COHORT||PROSPECTIVE|||||||
34140683|NCT05479344|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34140684|NCT00091338||||TREATMENT||||||||
34140685|NCT05432388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140686|NCT02181101|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140687|NCT06333522|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140688|NCT01823783|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140689|NCT00772369|||COHORT||RETROSPECTIVE|||||||
34140690|NCT00005631||||TREATMENT||||||||
34140691|NCT02694913|||OTHER||PROSPECTIVE|||||||
34140692|NCT04676841|||COHORT||PROSPECTIVE|||||||
34140693|NCT00161577|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140694|NCT06095882|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34140695|NCT05797038|||OTHER||OTHER|||||||
34140696|NCT03003221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140697|NCT02624063|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140698|NCT03937648|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34140699|NCT03440723|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE|Masking is not possible since physicians and participants will know whether they are using the device or not.|Randomized controlled trial in which participants are randomly assigned to one of two arms, control or treatment||||
34140700|NCT02576535|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140701|NCT06281665|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Participants, Investigators and outcomes assessors will be blinded.|This is a pilot randomized, single-center, double-blind placebo-control study of low-dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or similar-appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two additional study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.|t|f|t|t
34140702|NCT00113646|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140703|NCT06289127|||COHORT||CROSS_SECTIONAL|||||||
34140704|NCT02760771|||CASE_CONTROL||PROSPECTIVE|||||||
34140705|NCT01242306|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140706|NCT00801034|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140707|NCT01413620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140708|NCT06597266|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|Prosthetic sockets compared between the two arms are visually identical except for the fine details of their shape (i.e. the design) and participants will not be informed which is which, at the point of assessment.|Study using mixed quantitative/qualitative methodology of quantitative outcome assessment and qualitative semi-structured interviews. A slightly larger than usual number of participants is used based on a power calculation for preliminary assessment of a secondary outcome measure, Socket Comfort Score.|t|f|f|f
34140709|NCT00350272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140710|NCT01534507|||||PROSPECTIVE|||||||
34140711|NCT06487507|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140712|NCT01084980|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140713|NCT00411827|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830406|NCT03269747|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33830407|NCT04014790|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830408|NCT02510053|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830409|NCT06069453|RANDOMIZED|PARALLEL||TREATMENT||NONE||Monocentric, randomized, controlled investigation||||
33830410|NCT04683770|||COHORT||PROSPECTIVE|||||||
33830411|NCT04322812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A researcher will program the device (placebo or PMBT) and will be instructed not to inform the patients or other researchers as to the type of treatment (PMBT or placebo). Therefore, the researcher responsible for the treatment, the investigator and the outcome assessor will be blinded to the type of treatment being administered to the patients. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (placebo or PBMT).||t|t|t|t
33830412|NCT01029236|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830413|NCT02901236|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830414|NCT06315101|||COHORT||RETROSPECTIVE|||||||
33830415|NCT02627768|||COHORT||PROSPECTIVE|||||||
34140714|NCT06453330|RANDOMIZED|PARALLEL||OTHER||NONE|Due to the nature of having to draw blood from participants who will be receiving H-PRF, nobody can be masked/blinded|An intervention group receiving standard placement of single implants with H-PRF and a control group receiving standard placement of single implants without H-PRF||||
34140715|NCT02981407|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140716|NCT06606041|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, Randomized parallel clinical trial comparing Dry Needling, Ischemic Compression, and Cross Tapes||||
34140717|NCT02978963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140718|NCT00962169|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140719|NCT04547907|RANDOMIZED|PARALLEL||TREATMENT||NONE||"An open-label, multicenter, randomized controlled phase III clinical study. Neoadjuvant chemotherapy with 6\*nab-PHP regimen (experimental group): 344 subjects.~Neoadjuvant chemotherapy with 6\*TCbHP regimen (control group): 344 subjects."||||
34149875|NCT00563823||||TREATMENT||NONE||||||
34149876|NCT00898859|||CASE_CONTROL||PROSPECTIVE|||||||
34149877|NCT02286323|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34149878|NCT01411384|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34149879|NCT01945684|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830416|NCT04947436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be blinded to the intervention|A single-blind parallel group design in which 60 patients with probable or definite ALS will be randomized equally into three groups (20 per group) over a period of 12 months|t|f|f|f
33830417|NCT06190288|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Hybrid effectiveness-implementation study (type 1)||||
33830418|NCT04749498|RANDOMIZED|CROSSOVER||SCREENING||DOUBLE|||t|f|t|f
33830419|NCT00277199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830420|NCT04403906|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Evaluation of diagnostic test - point of care||||
33830421|NCT03248141|||COHORT||OTHER|||||||
33830422|NCT02360800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33830423|NCT03289702|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830424|NCT04784455|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, uncontrolled, multi-centre two-part study. Part A: dose algorithm, safety and efficacy Part B: safety and efficacy||||
33830425|NCT04049370|||COHORT||OTHER|||||||
33830426|NCT05234775|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||assignment to initial treatment group with cross over to alternate treatment group||||
33830427|NCT05160311|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who had underestimated STEMI with more than 24 hours up to 28 days referred by the Cross System (Central For Regulation of Health Services Supply) and the Campo Limpo Hospital (Co-participant Center) will be admitted sequentially for coronary angiography in the hemodynamics sector of the Instituto Dante Pazzanese de Cardiologia (IDPC) from August 2021 to February 2023.||||
33830428|NCT06168422|||COHORT||OTHER|||||||
33830429|NCT06258733|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a quasi-experimental study with two arms||||
33830430|NCT00592462|||CASE_ONLY||PROSPECTIVE|||||||
33830431|NCT03980990|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Controlled Trial||||
33830432|NCT01152476|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830433|NCT01808898|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33830434|NCT01579721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830435|NCT04889859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830436|NCT05218746|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33830437|NCT03793062|||COHORT||PROSPECTIVE|||||||
33830438|NCT02854449|||CASE_ONLY||PROSPECTIVE|||||||
33830439|NCT02282306|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830440|NCT05274425|||COHORT||PROSPECTIVE|||||||
33830441|NCT05918393|NA|SINGLE_GROUP||TREATMENT||NONE||Single-case research design including multielement and reversal strategies||||
33830442|NCT00383591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830443|NCT05105568|NA|SINGLE_GROUP||TREATMENT||NONE||Nonconcurrent multiple baseline design with three dyads.||||
33830444|NCT00456417|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830445|NCT03771222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830446|NCT04956614|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830447|NCT00966030|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830448|NCT03008304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830449|NCT02576327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830450|NCT03752242|NA|SINGLE_GROUP||TREATMENT||NONE|In Part A, all subjects will receive study drug and this is Open Label.|||||
33830451|NCT00375765|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830452|NCT03540290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830453|NCT02344173|||CASE_ONLY||PROSPECTIVE|||||||
33830454|NCT05209724|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830455|NCT00746785|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830456|NCT02594410|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830457|NCT04475237|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33830458|NCT02282423|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830459|NCT04957329|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||each subject will be treated with a BAK-preserved eye drop in one eye and PF-eye drops in the other eye for 3 months.|f|f|t|f
33830460|NCT05394090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33830461|NCT01638845|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830462|NCT05154708|||CASE_ONLY||CROSS_SECTIONAL|||||||
33830463|NCT04422977|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830464|NCT02582385|||||RETROSPECTIVE|||||||
33830465|NCT00250978|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830466|NCT04173702|NA|SINGLE_GROUP||SCREENING||NONE||Clinical trials with a single arm||||
33830467|NCT03747614|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||subjects from zhongshan ophthalmic center||||
33830468|NCT00436956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830469|NCT05465759|||COHORT||RETROSPECTIVE|||||||
33830470|NCT00581464|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830471|NCT01852032|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830472|NCT05364034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830473|NCT04560062|||COHORT||OTHER|||||||
33830474|NCT03752255|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33830475|NCT02878369|||CASE_ONLY||PROSPECTIVE|||||||
34149880|NCT01186640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830476|NCT05423431|||OTHER||RETROSPECTIVE|||||||
33830477|NCT01633476|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830478|NCT02884492|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830479|NCT01974453|||COHORT||PROSPECTIVE|||||||
33830480|NCT02210208|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two Parts (part A and B) with one dressing device for the skin graft placed on a surgical burn wound and another dressing device placed on the donor site.||||
33830481|NCT01698853|||||PROSPECTIVE|||||||
33830482|NCT04195932|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Before and after study||||
33830483|NCT05072262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830484|NCT01157351|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830485|NCT01699698|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33830486|NCT05313906|NA|SINGLE_GROUP||TREATMENT||NONE||RC48 plus AK105 and cisplatin||||
33830487|NCT02920255|||COHORT||PROSPECTIVE|||||||
33830488|NCT06142981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140720|NCT06606561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded.||t|t|t|t
34140721|NCT00101764||||TREATMENT||||||||
34140722|NCT00223977|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140723|NCT01212497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140724|NCT04997109|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||Two active treatments will be administered in different sequences, and will be compared with a standard of care study arm.|f|f|f|t
34140725|NCT05056220|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|There will exist two levels of masking in the current trial. Masking of biostratification outcome (high expected effect of human albumin or low expected effect of human albumin): Participant, Investigator and Outcome Assessor Masking of treatment assignment (human albumin 20% or saline 0.9%): Participant and Outcome Assessor||t|f|t|t
34140726|NCT00537732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140727|NCT04194736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140728|NCT02563860|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140729|NCT01360372|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140730|NCT01259076|||CASE_CONTROL||PROSPECTIVE|||||||
34140731|NCT05851872|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140732|NCT00744978|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34140733|NCT02202512|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33830489|NCT05664399|||OTHER||PROSPECTIVE|||||||
33830490|NCT01855477|NA|SINGLE_GROUP||OTHER||NONE||||||
33830491|NCT04869150|||COHORT||PROSPECTIVE|||||||
33830492|NCT01098708|||COHORT||PROSPECTIVE|||||||
33830493|NCT05806606|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|It is a double-blind study. A research nurse will identify potential subjects from the Clinical Management System, and will screen for the patient's cognitive function and NYHA status. Eligible patients and their primary carers will be invited to participate during their hospital stay. After obtaining their written informed consent, the research nurse will collect their baseline demographic data and administer the following outcome measures in a face-to-face interview. The care dyads will be randomized to receive either the De-HF or educational program in an allocation ratio of 1:1. To ensure double blinding, the dyads will not know whether they are participating in the test or control intervention. The assigned intervention will be commenced within 2 weeks of the baseline measure. Post-test outcome evaluation will take place at the 16th week (post-intervention), 24th week, and 32nd week.||t|t|f|f
33830494|NCT01409122|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33830495|NCT05216198|||COHORT||PROSPECTIVE|||||||
33830496|NCT05913869|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||f|t|f|f
33830497|NCT03903835|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||ProBio will use outcome-adaptive randomization, adapting the randomization based on the observed PFS within biomarker signatures. Treatments will initially be assigned to patients based on the biomarker signatures for which that treatment is most likely to be effective. The trial will be analysed within a Bayesian framework, which allows for calculations of the probability for each treatment that is superior to standard of care within a given signature. Each experimental arm will be evaluated for efficacy relative to the control arm with the same biomarker signatures.||||
33830498|NCT03445117|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||two-arm cluster randomised crossover trial||||
33830499|NCT03887247|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830500|NCT04981353|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33830501|NCT02850718|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830502|NCT06055803|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830503|NCT06031961|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830504|NCT05661669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830505|NCT05432921|||COHORT||PROSPECTIVE|||||||
33830506|NCT00238953|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33830507|NCT05177783|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||TRIPLE|"Participants will be condition-blind (i.e., they will not be told whether the health application they use is the treatment or control application). Assignment to treatment arms will be randomized using Qualtrics Experimental Software and treatment assignment group will remain masked to the investigator and those in charge of data analysis until after data analysis is complete."|Parallel|t|f|t|t
34140734|NCT04170530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140735|NCT02943824|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34140736|NCT01502878|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140737|NCT00150358|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140738|NCT05749003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140739|NCT01598883|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34140740|NCT02998905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140741|NCT02183337|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34140742|NCT02645968|||COHORT||PROSPECTIVE|||||||
34140743|NCT01613352|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140744|NCT02630420|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140745|NCT00521430||||TREATMENT||NONE||||||
34140746|NCT03342573|NA|SINGLE_GROUP||TREATMENT||NONE||Cosentyx (Secukinumab) for the treatment of adult onset pityriasis rubra pilaris||||
34140747|NCT04609358|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
34140748|NCT05290454|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140749|NCT02101801|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34140750|NCT04859985|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised controlled trial||||
34140751|NCT02376101|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34140752|NCT00353626|||||PROSPECTIVE|||||||
34140753|NCT02471274|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140754|NCT00805714|||||PROSPECTIVE|||||||
34140755|NCT01846663|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149881|NCT00897390|RANDOMIZED|CROSSOVER||||NONE||||||
34140756|NCT04942340|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The anesthesiologists will be blinded to the medication injected to the subject since the drugs or normal saline are prepared by the pharmacists in the OR pharmacy.|TBA|f|f|t|f
34140757|NCT06086652|||CASE_ONLY||RETROSPECTIVE|||||||
34140758|NCT06552481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140759|NCT06159205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study was designed as a double-blind, randomised controlled trial.|t|f|f|t
34140760|NCT02879591|NON_RANDOMIZED|PARALLEL||||NONE||||||
34140761|NCT04780880|||COHORT||PROSPECTIVE|||||||
34140762|NCT00384319|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140763|NCT05901363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140764|NCT03407053|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33830508|NCT06348264|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830509|NCT01214798|||CASE_ONLY||RETROSPECTIVE|||||||
33830510|NCT04026399|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830511|NCT00002721|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830512|NCT00000447|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33830513|NCT06063447|||OTHER||CROSS_SECTIONAL|||||||
33830514|NCT00256685|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33830515|NCT06210061|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140765|NCT00025428||||TREATMENT||||||||
33830516|NCT05928299|||COHORT||OTHER|||||||
33830517|NCT05380141|||COHORT||PROSPECTIVE|||||||
33830518|NCT01391676|||CASE_CONTROL||PROSPECTIVE|||||||
33830519|NCT00130078|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33830520|NCT02261298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830521|NCT04122482|RANDOMIZED|FACTORIAL||OTHER||NONE||"Factorial Assignment Factor 1: Receive course material immediately Factor 2: Receive course material in 8 weeks~Each client will be randomized to one of two conditions:~Condition 1: They receive access to the course material immediately. Condition 2: They receive access to the course material after 8 weeks."||||
33830522|NCT02419963|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830523|NCT04469790|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized parallel-arm clinical trial||||
33830524|NCT04546022|NA|SINGLE_GROUP||SCREENING||NONE||||||
33830525|NCT05000632|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study personnel, including the PI and Co-Is (with the exception of methodologist) and assessment staff, will be masked to treatment condition until the database is locked. Limited staff will be unmasked to handle randomization codes, delivery support of interventions, and to complete reports.|Participants will be randomized at the provider level. Provider participants will be randomized into either Smoke Free SafeCare or Standard SafeCare. Their arm designation will then determine the group that mother participants will be assigned to.|f|f|t|f
33830526|NCT00358982|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830527|NCT04697368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be blind to the study protocol.|This study is a multicentre, single-blind (evaluator) randomized controlled trial (RCT).|f|f|f|t
33830528|NCT01217619|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830529|NCT05770167|||COHORT||PROSPECTIVE|||||||
33830530|NCT04061070|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830531|NCT05471440|RANDOMIZED|PARALLEL||PREVENTION||NONE||A multicenter, randomized, controlled trial comparing immune responses 7 and 28 days after an additional COVID-19 booster vaccination between Janssen and mRNA primed HCWs to describe the immune response in a cohort representative of the Dutch population, in order to eventually provide data for Dutch policy makers||||
33830532|NCT04226937|||OTHER||PROSPECTIVE|||||||
34140766|NCT04765423|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34140767|NCT05023473|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34140768|NCT03804567|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34140769|NCT00905762|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34140770|NCT05724836|||COHORT||PROSPECTIVE|||||||
34140771|NCT01241344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140772|NCT06430957|||COHORT||PROSPECTIVE|||||||
34140773|NCT03920293|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|All investigative site personnel, sponsor staff, sponsor designees, staff directly associated with the conduct of the study, and all participants will be blinded to treatment assignments.||t|t|t|f
34140774|NCT06358781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34140775|NCT03137797|||COHORT||PROSPECTIVE|||||||
34140776|NCT00712569|||CASE_CROSSOVER||PROSPECTIVE|||||||
34140777|NCT02974335|||OTHER||OTHER|||||||
34140778|NCT00015574|||DEFINED_POPULATION||OTHER|||||||
34140779|NCT00875238|||COHORT||PROSPECTIVE|||||||
34140780|NCT03456791|||CASE_CONTROL||PROSPECTIVE|||||||
34140781|NCT00837824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140782|NCT05363293|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind|Multi-center, placebo-controlled, double-blind, randomized, multiple ascending dose clinical trial to determine the safety and maximum tolerated dose of AL001.|t|f|t|f
33830533|NCT05090605|||COHORT||PROSPECTIVE|||||||
33830534|NCT03677245|NA|SINGLE_GROUP||TREATMENT||NONE||pre- post-test design with each participant serving as his or her own control||||
33830535|NCT00875277|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33830536|NCT00228631|||COHORT|||||||||
33830537|NCT03962764|||OTHER||RETROSPECTIVE|||||||
33830538|NCT00080522|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33830539|NCT01777126|NON_RANDOMIZED|PARALLEL||||NONE||||||
33830540|NCT03785626|||COHORT||PROSPECTIVE|||||||
33830541|NCT01383239|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33830542|NCT02838784|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140783|NCT01470690|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34140784|NCT01039831|||CASE_CONTROL|||||||||
34140785|NCT00292838|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34140786|NCT05797532|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Comparison of three different methods||||
34150838|NCT02387294|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||parallel-group study in two paediatric age groups||||
34150839|NCT06520007|||COHORT||PROSPECTIVE|||||||
34140787|NCT06446752|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind, Placebo-controlled|1:1 randomization to Bexsero vaccine or placebo injection, to be administered as two intramuscular (IM) doses, two months apart (at Enrollment/Visit 1 and Month 2/Visit 3). Assessment for safety events at one month following the IM doses (Visit 2 and Visit 4), followed by 5 in-clinic follow-up visits for safety, clinical, and laboratory assessments.|t|t|t|f
34140788|NCT06608446|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the evaluators do not know the treatment group of the patients.|Non-profit blinded randomized controlled interventional single-center pilot study.|f|f|f|t
34140789|NCT03960580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140790|NCT03096093|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140791|NCT02456636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140792|NCT03571373|||COHORT||PROSPECTIVE|||||||
34140793|NCT03944356|||CASE_ONLY||PROSPECTIVE|||||||
34140794|NCT01275612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140795|NCT04137653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34140796|NCT01007929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140797|NCT01844011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140798|NCT00834990|RANDOMIZED|CROSSOVER||||NONE||||||
34140799|NCT00174681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140800|NCT06605443|||CASE_CONTROL||PROSPECTIVE|||||||
34140801|NCT05839340|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Due to practical limitations, the trial will be open label.|Dual Centre Randomised Cross-Over Trial. Infants that meet inclusion criteria will be randomised to be ventilated with either NIV-NAVA or ACV for four hours, followed by the second mode of ventilation. There will be a 20-minute stabilisation period between ventilatory methods.||||
34140802|NCT02791191|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140803|NCT06287593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140804|NCT06118541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140805|NCT05699993|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140806|NCT05059821|NA|SINGLE_GROUP||TREATMENT||NONE||Personalized peptide based vaccine with autologous heat shock protein 70 and autologous activated monocytes||||
34140807|NCT04376047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Computer generated randomization (www.randomizer.org) was used to randomly assign patients to one of both groups. Information of allocation was available to the principal researcher only. Patients were assigned a sequential number that was placed in an opaque, sealed envelope by the researcher. When the patients were scheduled to be positioning, the envelope was opened by the researcher who then performed the positioning. The nurses could not be blinded to the allocation because of the nature of the intervention. However, the outcome assessment of the patients was blinded.|two-group pre-test and repeated post-test study|f|t|f|f
34140808|NCT03496350|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants get randomly assigned to either treatment or wait-list control.||||
34140809|NCT04418011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140810|NCT05357989|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized|t|t|t|t
34140811|NCT06607068|||OTHER||CROSS_SECTIONAL|||||||
34140812|NCT03402971|||CASE_CONTROL||PROSPECTIVE|||||||
34140813|NCT01122342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140814|NCT02222584|||CASE_ONLY||PROSPECTIVE|||||||
34140815|NCT00760461|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140816|NCT04189653|||COHORT||RETROSPECTIVE|||||||
34140817|NCT01956630|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140818|NCT02645851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140819|NCT03697499|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34140820|NCT03860012|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive 800mcg of supplemental folic acid per week.||||
34140821|NCT01310400|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34140822|NCT03641248|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||Pharmacokinetic|t|f|t|f
34140823|NCT01937793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140824|NCT05061654|NA|SINGLE_GROUP||TREATMENT||NONE||The study will be a prospective, non-comparative, single-arm, single center, open-label interventional study.||||
34140825|NCT02616497|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140826|NCT00166101|||CASE_ONLY||PROSPECTIVE|||||||
34140827|NCT01870531|||COHORT||PROSPECTIVE|||||||
34140828|NCT02904005|NA|SINGLE_GROUP||SCREENING||NONE||||||
34140829|NCT05467332|||OTHER||PROSPECTIVE|||||||
34140830|NCT03627559|||COHORT||PROSPECTIVE|||||||
34140831|NCT05452369|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|- double-blind comparative study.|- Two arms: rhomboid intercostal plane block is the first group Erector spinae plane block is the second group|t|f|f|t
34140832|NCT00958464|||CASE_ONLY||CROSS_SECTIONAL|||||||
34140833|NCT02227173|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34140834|NCT02813668|NA|SINGLE_GROUP||OTHER||NONE||||||
34140835|NCT00945061|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140836|NCT00468676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140837|NCT02298179|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34140838|NCT00923416|||COHORT||PROSPECTIVE|||||||
34140839|NCT06232460|NA|SINGLE_GROUP||OTHER||NONE||An open label, dose escalation, parallel study in two groups||||
34140840|NCT00560248|||CASE_ONLY||RETROSPECTIVE|||||||
34140841|NCT03164317|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140842|NCT05195853|||COHORT||RETROSPECTIVE|||||||
34140843|NCT01151111|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34140844|NCT00002849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140845|NCT02337530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140846|NCT04537299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140847|NCT00000146|RANDOMIZED|||TREATMENT||SINGLE||||||
34140848|NCT04733274|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34140849|NCT01599780|||CASE_CONTROL||PROSPECTIVE|||||||
34140850|NCT02854488|||COHORT||OTHER|||||||
34140851|NCT02062892|RANDOMIZED|CROSSOVER||||NONE||||||
34140852|NCT00524953|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34140853|NCT04195438|NA|SINGLE_GROUP||OTHER||NONE||There is no randomization, every patient gets CO testing and ABG measurements to assess liver regeneration.||||
34140854|NCT03756363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blind||t|f|f|t
34140855|NCT00342173|||COHORT||PROSPECTIVE|||||||
34140856|NCT01688921|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34140857|NCT03913832|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34140858|NCT06345794|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830543|NCT05005325|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34140859|NCT06605937|||COHORT||PROSPECTIVE|||||||
34140860|NCT01367223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830544|NCT06108453|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33830545|NCT05864118|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Adult emergency department patients receiving nasopharyngeal swab for respiratory viral testing meet inclusion criteria and will be asked to provide up to 4 study specimens.||||
33830546|NCT01394549|||COHORT||PROSPECTIVE|||||||
33830547|NCT02876029|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33830548|NCT04805957|NA|SINGLE_GROUP||TREATMENT||NONE||This is a 12 week open label trial.||||
33830549|NCT05584722|||COHORT||PROSPECTIVE|||||||
33830550|NCT03927690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830551|NCT03065998|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33830552|NCT00835510|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830553|NCT04711486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830554|NCT06061380|||CASE_ONLY||OTHER|||||||
33830555|NCT03296566|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33830556|NCT05585177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830557|NCT05980962|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33830558|NCT04578587|NON_RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|t|f
33830559|NCT01454232|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830560|NCT02620956|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33830561|NCT01264445|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33830562|NCT03564834|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830563|NCT04582669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830564|NCT02239081|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33830565|NCT02680197|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33830566|NCT05084599|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830567|NCT03232034|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and Researchers will be blinded to the interventions.||t|f|t|f
33830568|NCT02550912|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830569|NCT03913689|||CASE_ONLY||PROSPECTIVE|||||||
33830570|NCT01337375|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830571|NCT05780216|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Double-blind, randomized, placebo-controlled, between-subjects study design|t|t|t|t
33830572|NCT04300153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830573|NCT01243411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830574|NCT03679897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830575|NCT05875454|||CASE_ONLY||PROSPECTIVE|||||||
33830576|NCT03668171|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization will be blinded to participant, care provider, investigator and outcome assessors.||t|t|t|t
33830577|NCT03344016|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"To provide evidence whether strict follow-up will result in improvement in clinical outcome parameters as compared to standard care follow-up, patients upon inclusion into the study protocol will be randomized into two groups:~* Standard care follow-up group: Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.~* Special care follow-up group: In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.~Stratification will be done for inclusion criteria (newly diagnosed PPGL, previous history of PPGL, gene carrier, presence of malignant PPGL and center)."||||
33830578|NCT05280912|||CASE_CONTROL||PROSPECTIVE|||||||
33830579|NCT03304613|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomized 2:2:1 as follows: e-CBT (n=120), PRISM (n=120) and usual care (n = 60).||||
33830580|NCT03295929|||OTHER||RETROSPECTIVE|||||||
33830581|NCT01355107|||CASE_CONTROL||PROSPECTIVE|||||||
33830582|NCT04317261|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830583|NCT00863798|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830584|NCT04444219|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34140861|NCT02204605|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33830585|NCT04330378|||COHORT||PROSPECTIVE|||||||
33830586|NCT03840109|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830587|NCT04580498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830588|NCT03192969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830589|NCT01875341|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33830590|NCT00310947|||NATURAL_HISTORY||PROSPECTIVE|||||||
33830591|NCT03791606|||COHORT||RETROSPECTIVE|||||||
33830592|NCT05972798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830593|NCT00889837|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33830594|NCT01882478|||COHORT||PROSPECTIVE|||||||
33830595|NCT00156923|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140862|NCT03652857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140863|NCT03593681|||CASE_ONLY||PROSPECTIVE|||||||
34140864|NCT01868620|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140865|NCT01076101|||FAMILY_BASED||PROSPECTIVE|||||||
34150840|NCT06335953|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34150841|NCT04953624|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34150842|NCT02441556|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830596|NCT03102866|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33830597|NCT04587986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830598|NCT02722655|||COHORT||PROSPECTIVE|||||||
33830599|NCT00001123||||TREATMENT||DOUBLE||||||
33830600|NCT03247738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140866|NCT03248193|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||"This study will consist of two parts:~A) Healthy subjects: To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.~B) Cancer patients: Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy."||||
34140867|NCT06056440|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blind method will be carried out on the persons collecting and analysing the data|Parallel Assignment|f|f|f|t
34140868|NCT04171180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140869|NCT00940095|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140870|NCT05105841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140871|NCT01069588|||COHORT||PROSPECTIVE|||||||
34140872|NCT06264817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the same patient, all measurements will be performed as far as possible by the same health professional who doesn't have the knowledge of patient's group.|Prospective, multi-center, interventional, controlled-randomized, single blinded study|f|f|f|t
34140873|NCT02231411|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
34140874|NCT06513650|||COHORT||PROSPECTIVE|||||||
34140875|NCT01727648|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34140876|NCT04561323|||CASE_CONTROL||PROSPECTIVE|||||||
34140877|NCT00492479|RANDOMIZED|PARALLEL||||SINGLE||||||
34140878|NCT03866538|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, open-label withdrawal of budesonide versus continued budesonide therapy in patients with immune-mediated enteropathies that have had symptomatic and histologic improvement||||
34140879|NCT05778084|NA|SINGLE_GROUP||TREATMENT||NONE||Open labelled interventional study||||
34140880|NCT00890994|||CASE_ONLY||CROSS_SECTIONAL|||||||
34140881|NCT04673370|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study was a single-blind controlled trial in which the outcome assessor was blinded to group allocation.|A total of 60 patients were divided into a treatment group and a control group, with 30 cases in each group. The control group received health education，and the treatment group was treated with Ba Duan Jin plus health education program.|f|f|f|t
34140882|NCT01904149|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140883|NCT05098938|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140884|NCT06099418|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||A modified randomized phase 2 selection ('pick-the-winner') design with a margin of practical equivalence will be implemented to monitor efficacy of the two individual arms, and to decide which of the two arms that may be continued further based on the primary endpoint of confirmed ORR.|t|t|t|t
34140885|NCT05280106|NA|SINGLE_GROUP||TREATMENT||NONE||One group interrupted times-series design (ITS)||||
34140886|NCT03106844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140887|NCT00420940|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140888|NCT05788588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||Phase Ⅲ, multi-center, randomized, single-blind, parallel controlled with active drug, confirmatory clinical trial.|t|t|t|t
34140889|NCT00599404|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140890|NCT00051324|||COHORT||PROSPECTIVE|||||||
34140891|NCT03575117|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34140892|NCT04850976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization was done with tables and then presented in a closed envelope when the patient arrived at the operating room to determine the intervention group: (1) the Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group or (2) the McGrath MAC ® videolaryngoscope (McGrath) group. The laryngoscopist is the one who opened the envelope. A research assistant helped to prepare the laryngoscope according to the randomization results.|There were 2 intervention groups: (1) the Self-Assembled Modified Macintosh Videolaryngoscope (SAM-VL) group or (2) the McGrath MAC ® videolaryngoscope (McGrath) group.|t|f|t|f
34140893|NCT05041595|||COHORT||PROSPECTIVE|||||||
34140894|NCT04203069|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|For the same patient, all measurements will be performed as far as possible by the same health professional who doesn't have the knowledge of the patient's group.|Prospective open-label RIPH 2 study multicenter, controlled, randomized, with two parallel groups.|f|f|f|t
34140895|NCT06241001|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140896|NCT01701479|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomised to immunotherapy with isotretinoin (13-cis-RA) and ch14.18/CHO, with or without aldesleukin (IL-2).||||
34140897|NCT00442520|||COHORT||PROSPECTIVE|||||||
34140898|NCT03142555|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|f|t
34140899|NCT04171791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140900|NCT05019612|||COHORT||PROSPECTIVE|||||||
34140901|NCT00237068|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
34140902|NCT02609230|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140903|NCT00969761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140904|NCT04449952|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34140905|NCT04965948|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34140906|NCT01654159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34140907|NCT00273520|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34140908|NCT04284124|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140909|NCT04125056|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34140910|NCT04820257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||starting with a small pilot and will follow with parallell design RCT - starting later||||
34140911|NCT05408507|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140912|NCT06420219|||COHORT||PROSPECTIVE|||||||
34140913|NCT04532593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34140914|NCT01862471|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34140915|NCT05352698|||COHORT||PROSPECTIVE|||||||
34140916|NCT05282576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140917|NCT03537742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34140918|NCT01323270|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34140919|NCT05151640|||COHORT||PROSPECTIVE|||||||
34140920|NCT01819129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140921|NCT03511625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140922|NCT05186831|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34140923|NCT06127264|RANDOMIZED|CROSSOVER||OTHER||SINGLE|Participants will be blinded, to the greatest extent possible, to the different CDO proximal cuff tightness's.|Participants will be asked to fasten the proximal cuff to a self-selected cuff tightness 'SSCT', as well as three different predefined force levels; Loose, Moderate, and Tight. Testing will occur without a CDO (NoCDO) and with each cuff tightness (SSCT, Loose, Moderate, Tight). Forces acting on the leg will be measured using wireless Loadpad sensors and forces acting on the plantar surface of the foot will be measured using wireless Loadsol insoles. Testing will include collection of force data as participants sit quietly, stand quietly, and walk and completion of questionnaires. Testing in the predetermined force levels (Loose, Moderate, Tight) will occur in a randomized order.|t|f|f|f
34140924|NCT01165788|||FAMILY_BASED||RETROSPECTIVE|||||||
34140925|NCT00129870|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34140926|NCT06219837|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|t|f|f
34140927|NCT01253057|||CASE_CONTROL|||||||||
34140928|NCT04108845|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34140929|NCT06357871|||COHORT||RETROSPECTIVE|||||||
34140930|NCT04347473|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
34140931|NCT04009200|||CASE_CONTROL||PROSPECTIVE|||||||
34140932|NCT01238770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140933|NCT06450379|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34140934|NCT02731222|||OTHER||CROSS_SECTIONAL|||||||
34140935|NCT02310854|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140936|NCT03024333|||OTHER||CROSS_SECTIONAL|||||||
34140937|NCT01121627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140938|NCT01207167|||COHORT||PROSPECTIVE|||||||
34140939|NCT03760757|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE||Randomized controlled non-inferiority trial|t|t|t|t
34140940|NCT04332939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140941|NCT02801721|RANDOMIZED|PARALLEL||||NONE||||||
34140942|NCT04538235|||CASE_CONTROL||RETROSPECTIVE|||||||
34140943|NCT03873181|||COHORT||PROSPECTIVE|||||||
34140944|NCT01456208|||COHORT||CROSS_SECTIONAL|||||||
34140945|NCT05637489|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Parallel RCT||||
34140946|NCT03818347|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|the experimental and control machines are of the same appearance and gas generation|the patients will inhale hydrogen and oxygen with oxyhydrogen generator|f|f|t|f
34140947|NCT04269577|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140948|NCT03893240|NA|SINGLE_GROUP||SCREENING||NONE||||||
34140949|NCT01686750|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34140950|NCT00645528|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34140951|NCT04595682|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34140952|NCT03654170|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34140953|NCT03904953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140954|NCT02887040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140955|NCT02323204|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140956|NCT04746482|||COHORT||RETROSPECTIVE|||||||
34140957|NCT06021158|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34140958|NCT04991727|||COHORT||PROSPECTIVE|||||||
34140959|NCT00717522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140960|NCT05867836|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Clinical trial to assess the adherence and acceptability of iron and folic acid (IFA) vs. multiple micronutrient supplementation (MMS) during pregnancy in Cambodian women||||
34140961|NCT03344549|RANDOMIZED|PARALLEL||TREATMENT||NONE||In the experimental group, the nutritional intervention will be done through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic); and in the control group will be offered the nutritional intervention through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution, both arms will be intervened monthly for four months, the duration of the sessions will be 45 minutes and will include evaluation or re-evaluation of dietary data, diagnosis, treatment and educational approach.||||
34140962|NCT05970133|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34140963|NCT00916058|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34140964|NCT06302140|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This clinical trial is divided into 3 parts (Part A, Part B, and Part C).~Patients may begin their study participation in Part A or Part B. Part B (for patients who participate in Part A) and Part C (for patients who participate in Part A and/or Part B) are optional for patients who meet certain conditions for crossover.~In Part A, patients will be given a single dose of radiolabeled nanatinostat by mouth on Day 1. Patients may stay in the hospital up to 8 days.~In Part B, patients will receive both nanatinostat in a salt form and a non-salt form, coadministered with valganciclovir in different order across 2 treatment days. Patients will be randomly assigned to either receive the salt or the non-salt form of nanatinostat first. Patients may stay in the hospital up to 4 days.~Part C will allow patients to continue receiving nanatinostat treatment as long as they are deriving clinical benefit. This part will not require a hospital stay."||||
34140965|NCT05440669|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34140966|NCT02114125|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34140967|NCT02667223|RANDOMIZED|||BASIC_SCIENCE||NONE||||||
34140968|NCT04213703|||CASE_ONLY||PROSPECTIVE|||||||
34140969|NCT01054937|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34140970|NCT05313321|||CASE_ONLY||PROSPECTIVE|||||||
34140971|NCT02165956|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34140972|NCT05292209|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double Blind Double Dummy|A prospective, double-blind, randomized, placebo-controlled, two-arm study design in patients with PAF|t|t|t|f
34150843|NCT03222414|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34150844|NCT04151277|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomised to each of the treatments 1:1||||
34150845|NCT03864913|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized arm (SQ, IM), as well as non-randomized SQ and non-randomized IM.||||
34150846|NCT01792518|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830601|NCT06366503|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Subjects were randomly assigned to use the active post-procedure cream on one side of the face and the comparator anhydrous formulation on the opposite side of the face.~The products were packaged in the same container and labelled post-procedure cream. This was a double blinded study, where the investigator, study subject, and other study personnel involved in the evaluation of the efficacy or safety were blinded to group during the study."|Randomized, Single-Center, Double-Blinded, Split-Face, Controlled|t|f|t|f
33830602|NCT05203809|||COHORT||PROSPECTIVE|||||||
33830603|NCT02983877||SEQUENTIAL||SUPPORTIVE_CARE||NONE||Following a 30 day run-in period, Stage 1 of the iTAB-CV intervention will be introduced. A member of the study team will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month of iTAB-CV, participants will receive alternating daily texts with psychoeducational and motivational content once daily and a daily mood rating request to both monitor their mood and to determine engagement with the iTAB-CV intervention. In the second stage of iTAB-CV, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1.||||
33830604|NCT01494545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830605|NCT06084676|||CASE_ONLY||PROSPECTIVE|||||||
33830606|NCT00458393|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33830607|NCT05932706|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830608|NCT03484299|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects undergoing IRE will receive treatment with either FOLFIRINOX or gemcitabine (based on which regimen was received prior to IRE)||||
33830609|NCT00000104|||DEFINED_POPULATION||OTHER|||||||
33830610|NCT01657877|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
33830611|NCT03758794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33830612|NCT05248698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830613|NCT05412784|||OTHER||CROSS_SECTIONAL|||||||
33830614|NCT01963715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830615|NCT04243642|||COHORT||PROSPECTIVE|||||||
33830616|NCT03420898|||COHORT||PROSPECTIVE|||||||
33830617|NCT04031573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Multi-centre, double-blind, randomised, placebo-controlled, multi-arm multi-stage trial. The trial investigates the efficacy and safety of 2 dosing regimens of ivabradine in order to confirm the efficacy and safety of one dosing regimen for heart rate control in adult patients with septic shock.Two dosing regimens of ivabradine will be investigated in the first part and the best-performing dosing regimen will be selected for the last part of the trial. A multi-arm multi-stage (MAMS) design with 2 stages and 3 arms will be used. The trial incorporates 2 stages: 1. Activity: an interim comparison of activity using the percentage of patients with heart rate control (80-94/min) at hour-48 as primary endpoint. At the end of this stage, an interim analysis will be used in order to select the most promising ivabradine dosing protocol and compare it to placebo in the subsequent stage (pick the winner strategy). 2. Efficacy: final comparison with 28 days mortality as the primary endpoint.|t|f|t|f
33830618|NCT03139305|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33830619|NCT03119688|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33830620|NCT05752045|NA|SINGLE_GROUP||SCREENING||NONE|Ground truth and Results being obtained in the end of recruitment and imaging collection, there are no effects on participant or care provider. Also, experts won't be aware of AI results and vice versa.|Imaging and clinical data will be collected from patients to be reviewed by an expert reader group providing ground truth, and the medical device will be tested against this ground truth||||
33830621|NCT01068106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830622|NCT05821686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830623|NCT03286309|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830624|NCT02390661|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830625|NCT04969809|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment, while half have abandoned the treatment and mostly no longer come for outpatient examinations.|f|f|t|f
33830626|NCT04590872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830627|NCT00855725|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830628|NCT02934945|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830629|NCT04667715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Independent Reviewers (neurosurgeon/neuroradiologist), functioning as an Imaging Review Core Lab, will be blinded to the treatment assignment.||f|f|f|t
33830630|NCT02949232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830631|NCT04100837|||OTHER||PROSPECTIVE|||||||
33830632|NCT04331132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Acute heart failure patients with wet-warm phenotype whose estimated glomerular filtration rates at admission are above 15 and below 60 mL/min/1.73 m2, and cumulative urine output \<300 mL in 2 hours after the first dose of intravenous furosemide will be randomly assigned 1:1 to receive a standard care with uptitrating intravenous furosemide alone or a combination therapy with tolvaptan 15mg once daily for 2 days||||
33830633|NCT01722786|||COHORT||PROSPECTIVE|||||||
33830634|NCT04917263|||COHORT||OTHER|||||||
33830635|NCT01438762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830636|NCT05523856|||COHORT||PROSPECTIVE|||||||
33830637|NCT05997459|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830638|NCT04171934|||COHORT||PROSPECTIVE|||||||
33830639|NCT02794714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830640|NCT02271022|||COHORT||PROSPECTIVE|||||||
33830641|NCT02038998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830642|NCT05197114|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33830643|NCT00165334|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830644|NCT05651113|||COHORT||OTHER|||||||
33830645|NCT06446271|||COHORT||PROSPECTIVE|||||||
33830646|NCT02209610|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34150847|NCT01084681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150848|NCT01442805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150849|NCT02887547|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34140973|NCT04349748|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Because partner notification is a kind of behavioral intervention, participants know what intervention they receive. However, we take efforts to reduce the bias caused by the non-blind design. At the beginning of the research, participants, care providers, and researchers who participate in participants management will not know the randomized scheme. The partner notification will be opened to participants sequentially by the predetermined computer program, and does not need care providers and researchers to implement the intervention manually. The care providers and researchers do not know the implementation of partner notification unless the participants tell them whether they can use the function on their own initiative. Even the care providers know that, the operation and results of the HIV and STDs testing will not be affected. At last, the outcomes assessors do not know the randomized scheme in data analysis.|This study is not a conventional crossover design,we use a pragmatic stepped-wedge cluster-randomised design.The study lasts for 2.5 years, which is divided to five continuous observation periods (every six months).The sixteen districts are assigned to four arms randomly.Four arms began recruiting participants at the same time,and at the first observation period,all groups were given health education and regular HIV and STDs testing prompting service,the two services above are given continuously for five observation periods.At the second observation period,the first group is given permission to query health status (partner notification) through app,but the other three groups do not.At every observation period after that (the third to fifth observation period),the three groups will be given permission to query health status one by one.Once a group is given the permission,it is retained until the end of study.|f|f|f|t
34140974|NCT06157541|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase I of the trial is a 3+3 dose escalation study involving 9-18 participants. Phase II will recruit two cohorts of 20 participants.||||
34140975|NCT04837989|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140976|NCT06289192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140977|NCT05959629|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Participants are assigned to one of two groups in parallel for the duration of the study|t|f|t|t
34140978|NCT00864669|RANDOMIZED|CROSSOVER||||NONE||||||
34140979|NCT04248920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Due to the nature of the intervention, it is not feasible for participants and study personnel to be blinded. However, the letter of information (LOI) indicates that the study aims to evaluate outcomes after an ED visit, and, in addition, evaluate the impact of a community engagement program.|This is a parallel, pilot randomized controlled trial (RCT) comparing the Clinic To Community© program plus treatment-as-usual (TAU) with TAU only (i.e. wait-list control).|f|f|f|t
34140980|NCT04184414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140981|NCT00617071|RANDOMIZED|||HEALTH_SERVICES_RESEARCH||SINGLE||||||
34140982|NCT05037448|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The investigators propose to examine the plausibility of delivering Me \& My Wishes using a telehealth platform. A convenience sample of five residents, their family members and long term care staff will be enrolled.||||
34140983|NCT01956136|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34140984|NCT05287529|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34140985|NCT03885570|||OTHER||CROSS_SECTIONAL|||||||
34140986|NCT02826434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140987|NCT06075329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140988|NCT05950061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34140989|NCT03645525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34140990|NCT03982264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140991|NCT06607042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34140992|NCT02179736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140993|NCT05888961|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34140994|NCT02094742|NA|SINGLE_GROUP||SCREENING||NONE||||||
34140995|NCT05828706|||OTHER||PROSPECTIVE|||||||
34140996|NCT01620502|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34140997|NCT01140568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34140998|NCT06505018|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34140999|NCT04659928|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34141000|NCT02708849|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34141001|NCT00427531||||DIAGNOSTIC||||||||
34141002|NCT02269176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34141003|NCT04446260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141004|NCT00460954|||||PROSPECTIVE|||||||
34141005|NCT06220591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141006|NCT06600763|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830647|NCT03765164|RANDOMIZED|PARALLEL||OTHER||NONE||The study is a pre-post, two-round, randomized controlled study of a nationally representative sample of primary care physicians, including internists and family physicians, randomly assigned to a control or intervention arm. Once eligibility is determined and providers are enrolled in the study, they will be asked to complete a questionnaire describing their practice and professional background. They will then care for a total of 6 CPV® simulated patients over the two rounds (3 per round). The simulated patients are adults aged 18-75 who present with diabetes, different levels of glycemic control and various co-morbidities. The study design consists of two study arms, a control arm and an intervention-arm that receives educational materials and the 1,5-AG results.||||
33830648|NCT04311047|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830649|NCT03723122|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|Randomization allocation is given only at the data manager. Participant, care provider and assessor do not know in which group participants are allocated|Randomized Controlled Trial|t|t|t|t
33830650|NCT02560389|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33830651|NCT02484547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141007|NCT01551290|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141008|NCT01949623|||CASE_CONTROL||PROSPECTIVE|||||||
34141009|NCT00145418|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141010|NCT05993780|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141011|NCT05362591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141012|NCT00377546|RANDOMIZED|PARALLEL||||DOUBLE||||||
34141013|NCT02379026|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141014|NCT05130216|||COHORT||PROSPECTIVE|||||||
34141015|NCT00727142|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34141016|NCT04015037|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The party or parties involved in the clinical trial who are prevented from having knowledge of the interventions assigned to individual participants. Select all that apply.|Randomized double-blind placebo-controlled study with women with age greater than 20, in the menacme, with complaints about sexual activity.|t|f|t|f
34141017|NCT03021967|||COHORT||OTHER|||||||
34141018|NCT02557958|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141019|NCT06484257|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141020|NCT01069302|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34141021|NCT00435162|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141022|NCT06599567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients will not know which group they belong to and the physiotherapist who makes the evaluations will not know which treatment the patients receive. Our study will be conducted in a double-blind manner.|"1. st group traditional therapy~2. nd group : traditional therapy and graded motor imagery~3. rd group traditional therapy and biofeedback training with nintendo wii"|t|t|f|t
34141023|NCT06475209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141024|NCT02899221|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141025|NCT01054040|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141026|NCT01086956|RANDOMIZED|||DIAGNOSTIC||||||||
34141027|NCT01550341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141028|NCT00278369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141029|NCT01968291|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141030|NCT06261736|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141031|NCT04086368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor)||f|f|f|t
34141032|NCT06159881|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141033|NCT01618383|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141034|NCT01713361|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141035|NCT02193035|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141036|NCT00373165|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141037|NCT06110715|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34141038|NCT05783076|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141039|NCT05392855|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial design with 2:1 randomization (2 to symptom driven to 1 in continuous) for this pilot study to determine if intermittent and symptom-driven airway clearance after starting Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy can be determined to be non-inferior to continuing airway clearance therapies.||||
34141040|NCT06608004|||COHORT||PROSPECTIVE|||||||
34141041|NCT03638531|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141042|NCT00246181|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141043|NCT04265508|||COHORT||PROSPECTIVE|||||||
33830652|NCT00027703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830653|NCT00741208|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33830654|NCT04741737|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141044|NCT01689714|NA|SINGLE_GROUP||OTHER||NONE||||||
34141045|NCT06204692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141046|NCT01690559|||CASE_ONLY||PROSPECTIVE|||||||
34141047|NCT05496452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double blinded to supplement (beta-lactoglobulin or carbohydrate)|This study is a double-blind, 2-arm, randomised placebo-controlled trial|t|f|t|f
33830655|NCT03200236|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34141048|NCT03855631|||COHORT||PROSPECTIVE|||||||
34141049|NCT03232814|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141050|NCT02249299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34141051|NCT03826836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized controlled trial|f|f|f|t
34141052|NCT01546025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34141053|NCT04293510|||CASE_CONTROL||PROSPECTIVE|||||||
34141054|NCT06306651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141055|NCT06162195|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, clinical assessors and data analysts will be blinded to the intervention each patient has received for the 24 month post-operative period. The surgeon, operating theatre team, radiographic analysts and CRO cannot be blinded but will not be involved in the care of the patient after the intervention unless the patient requires revision surgery.|Randomisation will be performed using variable block randomisation with block sizes of 4, 6 and 8, with a 1:1 allocation to the 2 groups, with stratification across sites. This will ensure approximately equal numbers across groups and approximately the same number per group at each site (to control for differences in the trial population because of environmental, social and demographic factors), while allowing different total numbers at each site. It will also ensure that at any given time, the numbers in each group will be approximately equal, allowing the interim analyses to take place. The randomisation will be managed by the contract research organisation (CRO) via an electronic data capture (EDC) system, which uses a validated randomisation algorithm. Once a patient has been consented, they will be assigned to a treatment group according to the pre-determined order inside the block. Stratification by site is recommended for multi-centre studies.|t|f|t|t
33830656|NCT03284528|||COHORT||RETROSPECTIVE|||||||
34141056|NCT06437626|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141057|NCT02444546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141058|NCT05410847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141059|NCT04580758|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141060|NCT06041711|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The investigator completing the questionnaires will not be aware of patient group assignment||t|f|t|t
34141061|NCT05545995|||COHORT||PROSPECTIVE|||||||
34141062|NCT00248118|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141063|NCT05683678|||CASE_ONLY||PROSPECTIVE|||||||
34141064|NCT01921374|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|t|f
34141065|NCT00000344|RANDOMIZED|||TREATMENT||DOUBLE||||||
34141066|NCT01524003|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141067|NCT05105282|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141068|NCT06361602|||OTHER||CROSS_SECTIONAL|||||||
34141069|NCT01698450|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141070|NCT01240525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141071|NCT05484531|||COHORT||PROSPECTIVE|||||||
34141072|NCT00596154|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141073|NCT03691844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|3 treatment arms will be double-blind, the 4th (comparator) will be single-blind|placebo-controlled, double-blind, randomized, parallel study|t|f|t|f
34141074|NCT01213186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34141075|NCT05872997|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34141076|NCT05160519|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141077|NCT05124509|||COHORT||PROSPECTIVE|||||||
34141078|NCT02007057|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141079|NCT00801489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141080|NCT01727115|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141081|NCT04812093|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141082|NCT04531358|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Prospective, controlled, double-blinded randomized three-way cross-over single site study In the cross-over setting two treatments, namely Callergin and Vis Alpin® Alpensalz will be evaluated compared to untreated subjects.|t|t|t|t
34141083|NCT06301724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141084|NCT05955924|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Matching placebo|Multicentre, parallel group, placebo-controlled, pragmatic randomized trial with 1:1 allocation and a superiority framework|t|t|t|t
34141085|NCT01398332|||COHORT||PROSPECTIVE|||||||
34141086|NCT01643850|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141087|NCT03038789|||CASE_ONLY||PROSPECTIVE|||||||
34141088|NCT06353256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141089|NCT03387995|||COHORT||PROSPECTIVE|||||||
34141090|NCT04424992|||COHORT||PROSPECTIVE|||||||
34141091|NCT06555302|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141092|NCT00725348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141093|NCT01169415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141094|NCT06605963|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multicenter Study|t|f|t|t
34141095|NCT04393467|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141096|NCT06345950|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Participants are randomly assigned to interventions in a crossover design to assess the pharmacokinetics over 24 hours; subsequently, the safety of one intervention with higher bioavailability is evaluated in an additional single-arm, 30-day trial.|t|f|t|f
34141097|NCT05480436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141098|NCT00635739|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141099|NCT05250076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34141100|NCT05421442|||COHORT||RETROSPECTIVE|||||||
34141101|NCT00616382|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141102|NCT01420874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141103|NCT04610489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|simultaneous acquisition of both test of interest and reference standard without contingency|||||
34141104|NCT01297361|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141105|NCT03193723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Single blinded|A Randomized Controlled study.|t|f|t|t
34141106|NCT06394895|||COHORT||PROSPECTIVE|||||||
34141107|NCT04631289|||COHORT||RETROSPECTIVE|||||||
34141108|NCT00336011|||DEFINED_POPULATION||PROSPECTIVE|||||||
34141109|NCT04590313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To avoid biased interpretation of the trial data, blinded data interpretation will be used in the reporting of the results of this trial (70). Before accessing the primary outcome data, the writing committee will record a 'Background assumptions' document containing our definition of MID of the outcome measures, and a brief summary of the key statistical analysis used in the evaluation of the outcome data. The document will be signed by the members of the writing committee and published as an appendix to the primary publication.|A randomised, controlled trial will be performed by allocating 40 years or older patients with symptomatic hallux rigidus to arthrodesis or watchful waiting group in a ratio of 1:1.|f|f|f|t
34141110|NCT00774839|||COHORT||PROSPECTIVE|||||||
34141111|NCT04038892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141112|NCT02445677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141113|NCT05417269|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|This is a two-step study with a phase I, open-label, dose escalation clinical trial to evaluate the safety of three IMCY-0141 doses followed by a phase II, double-blind, randomized study with an adaptive design to determine if any IMCY-0141 doses offer superior efficacy relative to placebo.|"The study will be conducted under a Bayesian adaptive design approach comprising of two phases:~* Phase I where 3 IMCY-0141 doses will be administered following a dose escalation approach. An IDMC safety assessment will allow the escalation from lower to upper dose.~* Phase IIa leading to a preliminary estimate of the efficacy of each dose and determination of promising doses. The 2 doses that emerge as most promising will be recommended to advance to Phase IIb, where final efficacy will be judged, again relative to placebo. The least promising dose may be dropped, at the discretion of the trial's IDMC.~All told, Phase II will enrol patients who will be randomized to IMCY-0141 or placebo or DMF. At the conclusion of Phase IIb, determined doses will be labelled effective."|t|t|t|t
34141114|NCT01812200|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34141115|NCT06127043|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141116|NCT04795167|||COHORT||PROSPECTIVE|||||||
34141117|NCT00176176|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141118|NCT05918653|||CASE_ONLY||CROSS_SECTIONAL|||||||
34141119|NCT03800342|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||One arm, a single group of healthy individuals, will perform cardiopulmonary exercise testing pre and post an aerobic exercise training program.||||
34141120|NCT01596881|||CASE_CONTROL||PROSPECTIVE|||||||
34141121|NCT06184464|||COHORT||PROSPECTIVE|||||||
34141122|NCT00573560|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141123|NCT01065194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141124|NCT06553716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830657|NCT04338906|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Evaluation of the efficacy and safety of hydroxychloroquine + camostat combination therapy in comparison to hydroxychloroquine + placebo in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial|t|t|t|t
33830658|NCT03414047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830659|NCT00005521|||||RETROSPECTIVE|||||||
34141125|NCT02116647|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33830660|NCT01939951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830661|NCT05161442|||COHORT||RETROSPECTIVE|||||||
33830662|NCT00383903|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33830663|NCT05804682|||COHORT||RETROSPECTIVE|||||||
33830664|NCT01031797|||CASE_CONTROL||PROSPECTIVE|||||||
33830665|NCT03430050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830666|NCT06339749|||COHORT||PROSPECTIVE|||||||
33830667|NCT05913986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Allocation is 1:1 to probiotic and placebo arms|t|f|t|f
33830668|NCT01605656|||COHORT||PROSPECTIVE|||||||
33830669|NCT03260933|||OTHER||CROSS_SECTIONAL|||||||
33830670|NCT01387815|||COHORT||PROSPECTIVE|||||||
33830671|NCT05483114|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|A double-blind study will be carried out, where the patient and the operators who will record the results will be blinded. It is not possible to blind the clinician who performs the indirect bonding process. The processing of the registration of the linear measurements and the statistical advisor will be blinded, this will be done by means of codes for each group.|Split-mouth randomized clinical trial study, with 15 participants.|t|t|f|t
33830672|NCT00809341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830673|NCT00408798|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33830674|NCT05807425|NA|SINGLE_GROUP||TREATMENT||NONE||During the intervention period the participants are observed at 3-week intervals (maximum of 3 sessions). The required number of sessions (maximum of 3) is determined by clinical and anoscopic evaluation (if the participant is non-symptomatic and/or there is no significant hemorrhoidal disease on anoscopy, the patient will not be a candidate for additional instrumental therapy moving directly to the follow-up period). After the intervention period, a one-year follow-up is scheduled with medical appointments performed every 3 months.||||
33830675|NCT00508274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830676|NCT04281693|NA|SINGLE_GROUP||SCREENING||NONE||||||
33830677|NCT00489528|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33830678|NCT04400799|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830679|NCT00070343||||TREATMENT||NONE||||||
33830680|NCT01419938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830681|NCT04815343|NON_RANDOMIZED|PARALLEL||OTHER||NONE||comparision of different conditions with-in subject. (10 bimodal, 10 bilateral CI users)||||
33830682|NCT00163007|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830683|NCT02605278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830684|NCT00314418|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830685|NCT00589836|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830686|NCT00322140||||TREATMENT||||||||
33830687|NCT06023810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830688|NCT06124976|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830689|NCT06250088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830690|NCT05074771|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33830691|NCT03647384|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|"Participants are randomly and evenly assigned to 2 groups using block randomization.Random numbers are generated by the stratified random method using the SAS statistical software and assigned by an independent statistician at the Good Clinical Practice Institute of Xiyuan Hospital. Drugs are numerically labeled and sequenced according to the random numbers. The drug randomization is conducted by drug supplier. The patients are assigned to the intervention according to the sequence.~The clinicians, patients and statistician are blind to the patients' grouping assignment and intervention. Database is locked after all data is inputted. The grouping information will be revealed when statistical analyses are conducted. The researchers reveal the second blinding and write the study report finally. Unblinding is allowed only in emergency situation for the patients"||t|t|t|t
33830692|NCT05330052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830693|NCT01019798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830694|NCT05629143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Evaluation of de-prescription strategies for PPIs||||
33830695|NCT05419310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141126|NCT05923736|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||It's a cross-sectional case-control study. The study will include patients with digital osteoarthritis as case group and patients with lumbago and osteoporosis without a inflammatory arthritis as control group.Imaging exams will be added for research purposes, and are not part of routine care or diagnosis of these conditions: intima-media thickness, arterial compliance and arterial composition; these tests involve minimal risk.||||
34141127|NCT01301521|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33830696|NCT04492137|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||"We will conduct a prospective randomized study. Participants will be randomized by computer into two groups at a 1:1 ratio~1. participants submitted to ultra early NKF~2. participants submitted to standard cannulation techniques (including double-guidewire-assisted cannulation)"|t|f|f|t
33830697|NCT01476813|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33830698|NCT00548756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830699|NCT03789812|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33830700|NCT06112197|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830701|NCT01785147|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830702|NCT06385041|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830703|NCT01592084|||COHORT||PROSPECTIVE|||||||
33830704|NCT00120185|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830705|NCT05719402|||CASE_ONLY||CROSS_SECTIONAL|||||||
34141128|NCT00536874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141129|NCT04131205|||CASE_CONTROL||PROSPECTIVE|||||||
33830706|NCT03277885|||COHORT||RETROSPECTIVE|||||||
33830707|NCT04505475|||COHORT||PROSPECTIVE|||||||
33830708|NCT04266353|NA|SINGLE_GROUP||OTHER||NONE||||||
34141130|NCT04934592|||COHORT||OTHER|||||||
34141131|NCT00867087|NON_RANDOMIZED|||TREATMENT||NONE||||||
34141132|NCT02908646|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141133|NCT01513603|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141134|NCT05176197|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34141135|NCT02818374|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141136|NCT06014931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141137|NCT05507879|||COHORT||PROSPECTIVE|||||||
34141138|NCT00903136||||SCREENING||NONE||||||
34141139|NCT01056003|||COHORT||PROSPECTIVE|||||||
34141140|NCT04942015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141141|NCT00960037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34141142|NCT00107315|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141143|NCT03839485|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both materials will be packed in identical and opaque syringes, identified only with letters (A and B). The codes will be revealed only at the end of the study. Neither the professional who will be performing the treatment, nor the patient or the evaluator, who will perform the exams at follow-up times, will know which of the two materials of choice were selected for each tooth, characterizing the study as triple-blind.||t|t|t|f
34141144|NCT02307292|||COHORT||PROSPECTIVE|||||||
34141145|NCT03660228|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34141146|NCT06602180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double : participant ,investigator||t|f|t|f
34141147|NCT00031655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141148|NCT01314664|||||PROSPECTIVE|||||||
34141149|NCT01472783|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141150|NCT04460924|||CASE_CONTROL||PROSPECTIVE|||||||
34141151|NCT05619835|||COHORT||PROSPECTIVE|||||||
34141152|NCT02723006|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141153|NCT01336530|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141154|NCT00092872|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141155|NCT00539383|NA|SINGLE_GROUP||||NONE||||||
34141156|NCT06059872|NA|SINGLE_GROUP||TREATMENT||NONE||The investigators will enroll 55 Veterans with chronic subcortical stroke in the 12-week HIIT intervention, with the expectation that 48 participants (85%) will complete the entire program. In our experience, 65% of participants will respond to the HIIT intervention, resulting in an estimated 31 responders and 17 resistors. Each chronic subcortical stroke participant will be asked to participate in the overall study protocol with pre-, during-, and post-intervention measurements. The HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.||||
34141157|NCT05423340|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141158|NCT02002936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141159|NCT06344910|||COHORT||PROSPECTIVE|||||||
34141160|NCT03041675|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141161|NCT02928029|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34141162|NCT05081349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-randomized clinical trial||||
34141163|NCT00607113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141164|NCT03985982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141165|NCT06338514|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In the dry needling application, patients will be blinded to the groups they are randomized into. The evaluator will also be unaware of which group the patients belong to. The practitioner will perform the procedures in both groups using ultrasound guidance, targeting the standard trigger points in the painful dorsal trapezius and rhomboid muscles in the study group, and targeting subcutaneous fatty tissue in the same regions in the sham group.|A two-group, sham-controlled, double-blind, prospective, randomized controlled trial|t|f|t|t
34141166|NCT06606431|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Parallel Assignment, Pre-Post Intervention||||
34141167|NCT05894538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.|Double-Blind, Placebo-Controlled, Randomized Trial|t|t|f|f
34141168|NCT05916625|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34141169|NCT01842165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141170|NCT00921414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141171|NCT06056648|||OTHER||PROSPECTIVE|||||||
34141172|NCT00746265|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34141173|NCT02913001|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141174|NCT00803257|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34141175|NCT06605326|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single-arm, retrospective study in which all enrolled patients received subcutaneous treprostinil as a bridge therapy for lung transplantation. The study evaluates the efficacy and safety of the treatment in patients with severe pulmonary hypertension, including both PAH and CLD-PH. No randomization or control group is included in the study.||||
34141176|NCT05056688|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||In the study, 90 individuals, including 1 experimental and 1 control group, were included in the study.|t|f|t|t
34141177|NCT00416663|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141178|NCT06604416|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141179|NCT05785637|||CASE_CONTROL||PROSPECTIVE|||||||
34141180|NCT04677660|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141181|NCT01696344|||COHORT||PROSPECTIVE|||||||
34141182|NCT00037817|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830709|NCT06220812|RANDOMIZED|PARALLEL||TREATMENT||NONE||low level laser and pulsed electromagnetic field will be applied separated to different study groups of children with supracondylar humeral fracture.||||
33830710|NCT02759796|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830711|NCT05655208|||COHORT||RETROSPECTIVE|||||||
33830712|NCT00316498||||TREATMENT||||||||
33830713|NCT03246347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830714|NCT01648595|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141183|NCT02383420|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34141184|NCT00851578|NA|SINGLE_GROUP||||NONE||||||
34141185|NCT05061108|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141186|NCT04857437|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33830715|NCT02783053|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33830716|NCT00636662|||COHORT||PROSPECTIVE|||||||
33830717|NCT02762305|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33830718|NCT04032912|||CASE_ONLY||PROSPECTIVE|||||||
34141187|NCT04016558|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141188|NCT06606236|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The bleaching agent was applied using specific devices, with only the laboratory staff able to identify the corresponding group codes, which consisted of letters and numbers.|"Sample Collection:~Teeth were anesthetized after tooth bleaching using 3% mepivacaine without a vasoconstrictor for maxillary premolars and an inferior alveolar nerve block for mandibular premolars. 10 minutes later, teeth were extracted within 5 minutes. For the control group, extractions also occurred ten minutes post-anesthesia. After extraction, teeth were rinsed with 5.25% sodium hypochlorite to eliminate any remaining periodontal ligament. Teeth were sectioned with a Zekrya bur, and pulp tissue was collected with a sterile excavator, placed in a 1 ml 4% paraformaldehyde Eppendorf tube, and stored at -70°C.~ELISA:~Fifty microliters of each standard, blank, and sample were added to wells in duplicate. A working solution with biotinylated antibody was added, and the plate was incubated at 37°C. After washing, horseradish peroxidase-conjugated solution was added, followed by substrate and stop solution. The optical density of each well was measured at 450 nm."|f|f|t|f
34141189|NCT01761318|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141190|NCT04805203|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141191|NCT00043108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141192|NCT00135928|RANDOMIZED|PARALLEL||||DOUBLE||||||
34141193|NCT03040414|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open label|Randomized crossover trial with two 12-week crossover periods in auto mode preceded by a run-in phase.||||
34141194|NCT02011620|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34141195|NCT03411200|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All physical tests will be conducted by masked health care professionals.|Participants will be randomized 1:1 to the intervention group and control group.|f|f|f|t
34141196|NCT06439888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141197|NCT05513664|||OTHER||RETROSPECTIVE|||||||
34141198|NCT03091985|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34141199|NCT04506060|||CASE_ONLY||PROSPECTIVE|||||||
34141200|NCT03644914|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention will take place in a New York City (NYC) elementary school. 24 first graders, identified by their teachers as reading below grade level, will be randomized to an intervention or control group. The 12 participants randomized to the intervention group will receive the 10-week reading program, twice weekly in 1-hour sessions. The Co-I and child will work together in individual sessions on sight recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Intervention will incorporate word recognition and phonetic decoding within the context of games and play in which the child is able to move about and associate words with color, video, and music. Intervention will also use each child's personal interests as a context around which sight words will be learned. Control group participants will not receive intervention. Both the intervention and control group participants will continue to receive typical classroom reading instruction.||||
34141201|NCT01690546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141202|NCT02933073|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141203|NCT05139381|||CASE_ONLY||OTHER|||||||
34141204|NCT02417116|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141205|NCT01418131|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141206|NCT04889768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141207|NCT02992951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141208|NCT04975737|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141209|NCT05496686|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The continual reassessment method (CRM) will be used for this study. The dose escalation plan is for a doubling of the dose for doses 2 through 6, a 1.67-fold increase for doses 7 and 8, and a 1.33-fold increase for doses 9-12. This plan corresponds roughly to the modified Fibonacci dose escalation plan given by Penel and Kramar.||||
34141210|NCT04503668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141211|NCT05326191|||COHORT||PROSPECTIVE|||||||
34141212|NCT03820453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141213|NCT00873379|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141214|NCT03626636|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34141215|NCT00011362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141216|NCT04757688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141217|NCT00693017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141218|NCT01817673|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34141219|NCT03634566|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34141220|NCT01023087|||COHORT||PROSPECTIVE|||||||
34141221|NCT04350671|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.|t|t|t|f
34141222|NCT03048266|||CASE_CONTROL||RETROSPECTIVE|||||||
34141223|NCT05266183|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34141224|NCT04906720|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141225|NCT00765882|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141226|NCT02759107|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34141227|NCT00297895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141228|NCT03553498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacist working in an area inaccessible to ED staff will ensure blinding by creating identical vials containing either 1000 mg acetaminophen in 100 ml normal saline or 100 ml normal saline placebo and numbering them sequentially for use in this study.|Randomized Clinical Trial|t|t|t|t
34141229|NCT02357693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34141230|NCT06178536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141231|NCT00068224|||COHORT||PROSPECTIVE|||||||
34141232|NCT04682093|||COHORT||RETROSPECTIVE|||||||
33830719|NCT01405677|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830720|NCT02115919|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141233|NCT02840643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34141234|NCT01780714|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141235|NCT05209451|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141236|NCT01223885|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141237|NCT06365567|||COHORT||CROSS_SECTIONAL|||||||
34141238|NCT01309048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141239|NCT02180880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141240|NCT00101816|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141241|NCT05544292|||COHORT||PROSPECTIVE|||||||
34141242|NCT02995083|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141243|NCT05785715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141244|NCT01022931|||COHORT||PROSPECTIVE|||||||
34141245|NCT04361604|||COHORT||OTHER|||||||
34141246|NCT00881764|||OTHER||OTHER|||||||
34141247|NCT05599451|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized, controlled, open-label, 4 parallel arms study||||
34141248|NCT03217370|NA|SINGLE_GROUP||TREATMENT||NONE||observational cross-sectional study with pre and post measurement and in between an interventional phase with education, IT implementations etc.||||
34141249|NCT04134117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141250|NCT03650569|||FAMILY_BASED||OTHER|||||||
34141251|NCT01370837|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34141252|NCT03970096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141253|NCT06608836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34141254|NCT01429428|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34141255|NCT05785533|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141256|NCT04373499|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||We will conduct a single-site randomized clinical trial of V-TTG versus brief intervention (BI) for school-aged children (5-11 years) with severe asthma hospitalized at University of Chicago Comer Children's Hospital. We aim to enroll 70 participants. The project team will identify eligible children who meet inclusion criteria. Block randomization will be utilized, stratified by age (5-8 vs. 9-11 years).|f|f|f|t
34141257|NCT02152059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141258|NCT04774900|||COHORT||PROSPECTIVE|||||||
34141259|NCT03892083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34141260|NCT01381003|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141261|NCT05297279|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|f|t|t
34141262|NCT05709717|||COHORT||PROSPECTIVE|||||||
34141263|NCT03663127|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34141264|NCT04161963|||CASE_CONTROL||PROSPECTIVE|||||||
34141265|NCT02781025|||CASE_ONLY||PROSPECTIVE|||||||
34141266|NCT05654987|||COHORT||CROSS_SECTIONAL|||||||
34141267|NCT06276881|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141268|NCT05628506|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141269|NCT02027467|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34141270|NCT04213781|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141271|NCT06604975|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141272|NCT02858531|||COHORT||PROSPECTIVE|||||||
34141273|NCT03029195|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141274|NCT04344496|||CASE_ONLY||PROSPECTIVE|||||||
34141275|NCT05763615|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141276|NCT03258281|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34141277|NCT03745443|RANDOMIZED|PARALLEL||OTHER||NONE||randomized parallel controlled clinical trial||||
34141278|NCT01430507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141279|NCT06606626|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Statistician||t|f|t|f
34141280|NCT03315104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Staggered enrollment for the first 9 subjects, then parallel low and high dose treatment with a placebo group|t|t|t|t
34141281|NCT02384356|||COHORT||PROSPECTIVE|||||||
34141282|NCT01289340|||COHORT||PROSPECTIVE|||||||
34141283|NCT03666507|||CASE_CONTROL||PROSPECTIVE|||||||
34141284|NCT06566404|||CASE_ONLY||PROSPECTIVE|||||||
34141285|NCT05128084|||CASE_ONLY||RETROSPECTIVE|||||||
34141286|NCT06490653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The study was designed so that patients and researchers in all roles (care provider, outcome assessor, and statistician) were masked to the treatment arms. Following the enrolment, the principal investigator will be contacted to find out which treatment arm the patient will be enrolled in according to the predetermined order. According to the assigned treatment arm, the relevant treatment will be prepared by another researcher in a physically non-distinguishable. A care provider will administer the prepared treatment and assess whether bleeding has stopped approximately 10 minutes after administration.|In this study, there are two parallel treatment arms (tranexamic acid and blood stopper (Ankaferd®) determined by randomization|t|t|t|t
34141287|NCT01820403|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34141288|NCT04963114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141289|NCT00521599|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141290|NCT05456568|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141291|NCT02943356|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141292|NCT06513377|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34141293|NCT04839978|RANDOMIZED|PARALLEL||PREVENTION||NONE||Sixteen to 20 high schools and surrounding towns within the 14 counties that partially or fully fall within the Cherokee Nation reservation in northeast Oklahoma will be randomly assigned to receive the intervention right away or later. A total of 800 to 1200 students are expected to enroll from the randomized sites.||||
34141294|NCT04429659|||CASE_CONTROL||RETROSPECTIVE|||||||
34141295|NCT02627287|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34141296|NCT01791881|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141297|NCT01757561|||CASE_CONTROL||PROSPECTIVE|||||||
34141298|NCT02186054|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
34141299|NCT00286195|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141300|NCT05908071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141301|NCT01546441|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141302|NCT03533907|||COHORT||RETROSPECTIVE|||||||
34141303|NCT03222830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141304|NCT06024850|||COHORT||PROSPECTIVE|||||||
34141305|NCT03036345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141306|NCT02815046|||COHORT||PROSPECTIVE|||||||
34141307|NCT04753554|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
34141308|NCT04139577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141309|NCT02919280|||COHORT||PROSPECTIVE|||||||
34141310|NCT03494517|||CASE_CONTROL||PROSPECTIVE|||||||
34141311|NCT00221806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141312|NCT00012129||||TREATMENT||||||||
34141313|NCT06608706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141314|NCT01299857|NA|SINGLE_GROUP||||NONE||||||
34141315|NCT02924714|NA|SINGLE_GROUP||OTHER||NONE||||||
34141316|NCT02793596|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141317|NCT04960384|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and the subject will be blinded to treatment assignment during the Randomized Treatment phase.||t|f|t|f
34141318|NCT06606080|||OTHER||CROSS_SECTIONAL|||||||
34141319|NCT00230282|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141320|NCT05979636|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34141321|NCT02770755|||CASE_ONLY||PROSPECTIVE|||||||
34141322|NCT02083705|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34141323|NCT04174989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|An unblinded sub-Investigator will prepare the plasma bags to be used for treatment (PDP or FFP). The randomization will be carried out in accordance to the the instructions provided, keeping the Investigator's and Patient's blindness about the content of plasma bags used for transfusion of participants.|Multi-center, international, double-blind, randomized, controlled, prospective, first-in-human clinical investigation, in which Patients presenting with acute upper gastrointestinal hemorrhage (AUGIH) and required plasma transfusion, will be randomized to receive a one-time infusion (up to 8 hours) of up to two 250 mL units of PDP (group A) or FFP (group B). The administration of Plasma needs to be in line with the clinical practice and doctor decision.|t|f|t|f
34141324|NCT00854217|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34141325|NCT03826173|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141326|NCT00112411|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34141327|NCT06225648|NA|SINGLE_GROUP||OTHER||NONE||||||
34141328|NCT03594916|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||active, sham|t|f|t|t
34141329|NCT03304054|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141330|NCT01921218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141331|NCT03798730|RANDOMIZED|CROSSOVER||OTHER||SINGLE|All samples provided to the participant are labelled with 3 digit random codes|This study involves both a crossover design where each participant tastes both the control product (not fortified) and the protein fortified product with an appropriate break between the two sessions. It is also both a within and between groups design as the responses from the older participants will be compared to the younger participants. The study will be conducted single blind as it not feasible to blind the researcher. Each participant will attend 3 study visits and all foods will be presented with random blinding codes.|t|f|f|f
34141332|NCT02878525|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141333|NCT05501431|||COHORT||PROSPECTIVE|||||||
34141334|NCT00314717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141335|NCT01882049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141336|NCT01352741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141337|NCT03362788|||COHORT||PROSPECTIVE|||||||
34141338|NCT01854892|RANDOMIZED|FACTORIAL||OTHER||SINGLE|||f|f|t|f
34141339|NCT03112525|||COHORT||PROSPECTIVE|||||||
34141340|NCT00866047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141341|NCT05526976|||COHORT||PROSPECTIVE|||||||
34141342|NCT05452954|NA|SINGLE_GROUP||TREATMENT||NONE||open label||||
34141343|NCT01571284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141344|NCT02830347|||COHORT||PROSPECTIVE|||||||
34141345|NCT01869361|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141346|NCT04093765|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34141347|NCT02409004|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141348|NCT06366126|||COHORT||RETROSPECTIVE|||||||
34141349|NCT05868863|||COHORT||RETROSPECTIVE|||||||
34141350|NCT05379062|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Experimental group (singing in a group/active) Experimental group (receptive music/auditive) Control group (treatment as usual condition)||||
34141351|NCT03317093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141352|NCT01548313|||COHORT||PROSPECTIVE|||||||
34141353|NCT05617053|||COHORT||RETROSPECTIVE|||||||
34141354|NCT03451565|||COHORT||PROSPECTIVE|||||||
34141355|NCT02413736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141356|NCT04994782|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141357|NCT01900821|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34141358|NCT01409083|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|t|f|f
34141359|NCT03419377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized controlled trial|f|f|t|t
34141360|NCT00820482|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141361|NCT00896363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141362|NCT06605001|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34141363|NCT05122000|||COHORT||CROSS_SECTIONAL|||||||
34141364|NCT01442506|||CASE_CONTROL||PROSPECTIVE|||||||
34141365|NCT05684757|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Investigators, outcomes assessors and analysts will be masked. Masking of participants is not possible.||f|f|t|t
34141366|NCT04862949|||COHORT||RETROSPECTIVE|||||||
34141367|NCT01126658|||CASE_ONLY||PROSPECTIVE|||||||
34141368|NCT00648674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141369|NCT04881929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141370|NCT05034315|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141371|NCT03600766|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151177|NCT04771325|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Educational; training of lay persons on support during labour||||
34151178|NCT01238965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151179|NCT01369186|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33830721|NCT05482490|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33830722|NCT01576913|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|t|f
33830723|NCT04481646|||COHORT||PROSPECTIVE|||||||
33830724|NCT05720377|RANDOMIZED|PARALLEL||TREATMENT||NONE||longitudinal||||
33830725|NCT03371823|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830726|NCT04142411|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830727|NCT04021225|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|||t|f|f|f
33830728|NCT00004445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830729|NCT04610554|||COHORT||CROSS_SECTIONAL|||||||
33830730|NCT04567810|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
33830731|NCT05100810|||COHORT||PROSPECTIVE|||||||
33830732|NCT04668521|||COHORT||RETROSPECTIVE|||||||
33830733|NCT01748045|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33830734|NCT02057575|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830735|NCT04378647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830736|NCT02108392|||OTHER||PROSPECTIVE|||||||
33830737|NCT03409653|||COHORT||PROSPECTIVE|||||||
33830738|NCT03530436|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33830739|NCT04686682|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33830740|NCT06034899|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830741|NCT06545409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized Controlled Trial|t|t|f|t
33830742|NCT02645539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830743|NCT01041989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33830744|NCT02947841|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33830745|NCT01850823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830746|NCT02988349|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830747|NCT04429802|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33830748|NCT03416569|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The study will be double-blind. Only the statistician performing randomization and the dispensing pharmacist will know the sequence of test conditions.|Each participant is tested with each of four test conditions, in counterbalanced sequence.||||
33830749|NCT02569632|NA|SINGLE_GROUP||OTHER||NONE||||||
33830750|NCT00607178|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33830751|NCT04148118|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"The study participants and the study site personnel managing the participants will be blinded to the identity of the test article. The pharmacist and/or the pharmacy technician or non-study nurse at the study site will not be blinded and will be responsible for preparing, labeling, and administering the investigational product. During study drug administration, all the blinded personnel will be excluded from the vaccine administration site. In addition, participants will be asked to close their eyes or be offered the option of wearing a loose-fitting eye mask during the administration of the test article.~Participants in the study arm that receive BioThrax SC and the clinical trial personnel that are managing them will not be blinded for this arm due to the different route of administration that makes blinding impossible. For laboratory and immunological testing, samples from participants receiving BioThrax will be blinded."|"Participants will be randomized to receive BW-1010 in 2 different dose levels (50 µg or 100 µg rPA), using 2 different method of administration (Aptar sprayer or pipette dropper). Negative control participants (Placebo) will receive saline using the 2 different methods as well. The positive control participants will receive BioThrax subcutaneously.~Since this is first in humans, a sentinel group, 4 participants with the smaller dose level (50 µg rPA) and 2 placebos, will be dosed first. The main group of the 50 µg rPA and the higher level rPA sentinels will dosed after day 8 safety clearance of the low dose rPA sentinel participants."|t|t|t|t
33830752|NCT05144685|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|Participants and research assessors will be blinded to treatment assignment.||t|f|f|t
33830753|NCT04795206|||COHORT||RETROSPECTIVE|||||||
33830754|NCT02062645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830755|NCT03736278|||COHORT||RETROSPECTIVE|||||||
33830756|NCT03058380|||COHORT||PROSPECTIVE|||||||
33830757|NCT04206709|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33830758|NCT00151827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830759|NCT05590143|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33830760|NCT00185913|||COHORT||PROSPECTIVE|||||||
33830761|NCT02603705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830762|NCT05256745|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830763|NCT05971628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830764|NCT01516853|||COHORT||PROSPECTIVE|||||||
33830765|NCT04674878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830766|NCT01138371|||CASE_ONLY||PROSPECTIVE|||||||
33830767|NCT03018223|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33830768|NCT04706858|NA|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Participant will be given the unlabeled fiber supplement.|Participants will be randomized to start fiber supplementation with one type of fiber for three weeks. After a washout period, they will supplement with the second type of fiber for an additional 3 weeks.The third cycle will be the same for all participants and they will supplement with a mix of 5 fibers for 3 weeks.|t|f|f|f
33830769|NCT00365547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830770|NCT01445990|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|t|f|f
33830771|NCT03619889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants don´t know to which group are assigned The statistical assessor don´t know the aim of the study|clinical trial, prospective, randomized and experimental with masking of the statistician and the participants|t|f|f|t
33830772|NCT03121495|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33830773|NCT04297072|||COHORT||RETROSPECTIVE|||||||
33830774|NCT03585686|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830775|NCT03618836|||CASE_CONTROL||PROSPECTIVE|||||||
33830776|NCT03717077|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33830777|NCT04262609|||COHORT||PROSPECTIVE|||||||
33830778|NCT00371995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830779|NCT03418493|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33830780|NCT06201637|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33830781|NCT02011217|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34141372|NCT05740605|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The primary aim, the GMFM, will be videotaped and the scoring will be done by a blind evaluator. In secondary outcomes, the BoHA will be blind scored.|The trial will be a single-blind, randomized, monocentric controlled trial. The trial start with a division in two arms HABIT-ILE therapy classic or at home then half of each group will benefit from a HABIT-ILE follow-up while the other will have usual care. That means that participants will be divided into four groups.|t|f|f|t
34141373|NCT00446472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141374|NCT01779869|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141375|NCT02274272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141376|NCT01327053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141377|NCT06080646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141378|NCT02562508|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34141379|NCT06225024|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patients in both groups underwent the following evaluations before treatment, at one month and three months after treatment by a treatment-blinded Physical Medicine and Rehabilitation (PMR) physician:~1. Modified Ashworth Scale (MAS)~2. Brunnstrom Motor Recovery Stage (BMRS)~3. Ankle range of motion (2) measurement~4. Clonus score (CS)~5. Barthel Index (BI)~6. Heckmatt measurements with ultrasonography~7. Visual analog scale (VAS) pain assessment."|Randomized Controlled|f|f|f|t
34141380|NCT02418208|||OTHER||PROSPECTIVE|||||||
34141381|NCT01384331|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141382|NCT06608342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141383|NCT05785741|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34141384|NCT01080768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141385|NCT00534287|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141386|NCT06609018|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Study includes a second phase (Parallel) that has no primary or secondary outcome measures.|t|f|t|f
34141387|NCT04853693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The investigator and person administering the outcome measures are blind to participant group|Two groups: One receives MSM prevention intervention and the other group receives Enhanced Treatment as Usual (referral and monitoring).|f|f|t|t
34141388|NCT00825058|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141389|NCT02345668|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141390|NCT02229214|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141391|NCT00452036|||COHORT||RETROSPECTIVE|||||||
34141392|NCT01080066|||COHORT||PROSPECTIVE|||||||
34141393|NCT04860895|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141394|NCT02509039|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141395|NCT02845479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141396|NCT01806025|||COHORT||RETROSPECTIVE|||||||
34141397|NCT00629746|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34141398|NCT04503161|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34141399|NCT04730778|||COHORT||PROSPECTIVE|||||||
34141400|NCT01434394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141401|NCT06537297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141402|NCT04508751|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Pregnant mothers who's infants were diagnosed with intrauterine growth restriction and mothers with pregnancies complicated by gestational diabetes, and mothers with healthy uncomplicated pregnancies will be recruited to have a fetal MRI in the third trimester.||||
34141403|NCT01284478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141404|NCT05144880|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141405|NCT02240368|||COHORT||PROSPECTIVE|||||||
34141406|NCT03522038|||COHORT||PROSPECTIVE|||||||
34141407|NCT05815836|||CASE_CONTROL||PROSPECTIVE|||||||
34141408|NCT04733170|||CASE_ONLY||PROSPECTIVE|||||||
34141409|NCT05956665|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||All participants will receive a clinical review of their prescribed medications by a research clinician, followed by a resident/surrogate interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the research clinician. The facility's medical providers will also be part of the deprescribing decision process and will initiate any agreed upon deprescribing||||
34141410|NCT05199376|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141411|NCT04618042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141412|NCT02516293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141413|NCT02789670|||COHORT||PROSPECTIVE|||||||
34141414|NCT02029716|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141415|NCT02157441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141416|NCT01563120|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141417|NCT00000429|RANDOMIZED|||TREATMENT||DOUBLE||||||
34141418|NCT04690907|RANDOMIZED|PARALLEL||PREVENTION||NONE||Intervention group and control group.||||
34141419|NCT04338724|NA|SEQUENTIAL||TREATMENT||NONE||||||
34141420|NCT00742365|||COHORT||PROSPECTIVE|||||||
34141421|NCT00198861|||COHORT||PROSPECTIVE|||||||
34141422|NCT01799239|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34141423|NCT00434603|||CASE_CONTROL||PROSPECTIVE|||||||
34141424|NCT03163693|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34141425|NCT02538562|||COHORT||PROSPECTIVE|||||||
34141426|NCT04875507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141427|NCT03054350|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34141428|NCT04801368|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Patient is blind to local anesthetic being administered.|The two anesthetics being used in the study are FDA approved and used in standard practice for the procedure.|t|f|f|f
34141429|NCT01132898|||COHORT||PROSPECTIVE|||||||
34141430|NCT04267731|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Double blinded, placebo controlled, randomised dose response study|t|f|t|t
34141431|NCT05008731|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A placebo is used|"Monocentric, prospective, randomised, double-blind study of two parallel groups of 66 patients with post-reconstruction ACL hamstring contracture treated with an ultrasound-guided injection at two points on the body of the hamstring~* Group 1: botulinum toxin: 100 units (0.5ml) in 1 injection~* Group 2: placebo: 0.5 ml in 1 injection"|t|f|t|f
34141432|NCT01129037|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34141433|NCT03633630|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141434|NCT06040203|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"They will be blinded patients, health professionals who will assess clinical and functional outcomes (outcome assessors), and professionals who will analyze the data."|This is a double-blind randomized controlled clinical trial with 1:1:1 allocation|t|f|f|t
34141435|NCT04124458|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Once eligible, the Redcap will assign the patient to one of the study group. Patients and physician provider will be blinded in the proposed study. Study questionnaires will be completed every three months by patients through RedCap System. Provider physician (here Dr.Rahul Shivaji Pathak) is the person who will perform the procedure.|This is a randomized, double blind, single-center, clinical trial. Participants will be randomly allocated to P-RF or occipital block intervention groups in a 1:1 ratio using a computer-generated algorithm. The study will be conducted over a period of 6 months, during which patients will make 4 visits (screening, baseline visit (Day 0) and 3, 6 months follow up visits, with ±1-week window). The study will be conducted at the Allevio Pain Clinic, Toronto, Canada. Research Ethics approvals will be sought.|t|t|f|f
34141436|NCT06516614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34141437|NCT00975104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141438|NCT04582435|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141439|NCT04962841|||COHORT||PROSPECTIVE|||||||
34141440|NCT00771732|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34141441|NCT01460355|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141442|NCT01527513|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141443|NCT02502669|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141444|NCT03293433|||COHORT||PROSPECTIVE|||||||
34141445|NCT00649766|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33830782|NCT00514475|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830783|NCT00251888|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830784|NCT04081155|||CASE_ONLY||PROSPECTIVE|||||||
33830785|NCT06145789|||CASE_ONLY||CROSS_SECTIONAL|||||||
33830786|NCT03642171|||COHORT||PROSPECTIVE|||||||
33830787|NCT02743988|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830788|NCT00739609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830789|NCT03916822|||CASE_CONTROL||PROSPECTIVE|||||||
33830790|NCT00005569||||TREATMENT||||||||
33830791|NCT04021082|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830792|NCT02525081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830793|NCT03464383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessment phone calls for gathering scaled instrument scores will be carried out by a second study coordinator, blinded to treatment assignment.|Participants will be randomized to one of two groups. Those randomized to the intervention group will receive an epileptologist-driven medication treatment for anxiety and depression, carried out directly in the epilepsy clinic during a regularly scheduled visit and supported by advanced practice provider (APP). Those randomized to the control group will receive an referral order to psychiatry placed by their epileptologist.|f|f|f|t
33830794|NCT01430117|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830795|NCT02137577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830796|NCT02396446|||CASE_ONLY||PROSPECTIVE|||||||
33830797|NCT03634306|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients will be randomized using a paper envelope system, just prior to surgery. Investigator will not be informed of the randomization assignment until after the patient is discharged (end of follow-up period). A simple envelope system is used. Pre-made study arm assignment envelopes will be created. Envelopes will be opened just prior to the procedure. For patients randomized \& withdrawn prior to the procedure or converted to open procedure, replacement envelopes will be added to the envelope pool. To preserve blinding during the procedure, the Ultravision System consumable will be introduced into the patient, generator will appear operational during all procedures. The display will be covered during use so the investigator is not aware the system is on/off. If for any reason un blinding occurs, the reason will be recorded. Study assessments will be collected per protocol, but the data will not be pooled with blinded data for analysis.|"STUDY DESIGN This is a prospective blinded, randomized controlled study. Arms 1 and 2: Patients enrolling in study arms 1 and 2 who are undergoing hysterectomy will be randomized to either the Ultravision™ System (Arm 1) or Standard of Care/no Ultravision (Arm 2) study arms.~Arm 3: Patients enrolling in study arm 3 who are undergoing a myomectomy will have their procedure conducted with the Ultravision™ System. The procedure is purported to generate the greatest smoke and therefore constitutes a worst-case challenge for the system.~All prescribed evaluations will be performed for all study arms.~STUDY SIZE Arms 1 and 2 (randomized) will enroll 15 patients each. Arm 3 will enroll an additional 5 patients.~DURATION The total duration of the study is expected to be approximately 6 months."|f|f|t|f
33830798|NCT00341471||||TREATMENT||||||||
33830799|NCT03600649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two cohorts with single-agent seclidemstat in patients with myxoid liposarcoma and in patients with other sarcomas with similar chromosomal translocations to Ewing sarcoma (FET-family translocations), and one cohort of Ewing sarcoma patients treated with seclidemstat in combination with topotecan and cyclophosphamide||||
33830800|NCT04455607|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33830801|NCT00003597|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33830802|NCT05781009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Randomized Double-blind, placebo-controlled, parallel design|t|t|t|t
33830803|NCT00469859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830804|NCT04875897|NA|SINGLE_GROUP||TREATMENT||NONE||Each subject serves as his/her own control||||
33830805|NCT03984175|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Before and After Comparison||||
33830806|NCT00078728|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33830807|NCT00276900|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33830808|NCT03062345|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||||||
33830809|NCT02089412|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830810|NCT05168709|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||This trial is a non-controlled single-arm post-marketing exploratory trial where the approved COVID-19 vaccine will be used to determine whether COVID-19 vaccination alters heterologous (non-COVID-19-specific) immunity in children.||||
33830811|NCT04761692|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||The VEPMP will consist of recruited churches in 15 cohorts of 2 churches per cohort (total n = 30). Each cohort of church will include an AA and a Latinx church. The 15 church cohorts will be randomized to three arms based on a 1:1:1 ratio, using an online random number generator.||||
33830812|NCT05603065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cohort study|f|f|t|f
33830813|NCT00758823|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33830814|NCT00000319||||TREATMENT||||||||
33830815|NCT05930808|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33830816|NCT03779880|||CASE_ONLY||RETROSPECTIVE|||||||
33830817|NCT00095043|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830818|NCT02582398|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33830819|NCT06319651|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized controlled trial (RCT). Pre \& Post data collection|f|f|f|t
33830820|NCT03954288|||CASE_CONTROL||PROSPECTIVE|||||||
33830821|NCT05865171|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33830822|NCT04265976|||COHORT||PROSPECTIVE|||||||
33830823|NCT03945162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830824|NCT01458847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830825|NCT00968006|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33830826|NCT03523325|NA|SINGLE_GROUP||TREATMENT||NONE||One intervention with comparison between males and females||||
33830827|NCT01743105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830828|NCT00026182|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830829|NCT00320398|RANDOMIZED|PARALLEL||PREVENTION||||||||
33830830|NCT04072445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830831|NCT02168283|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830832|NCT00805285|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830833|NCT00560677|||CASE_ONLY||CROSS_SECTIONAL|||||||
33830834|NCT01043445|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33830835|NCT00567983|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830836|NCT04517942|RANDOMIZED|FACTORIAL||PREVENTION||NONE||After signing up for a specific time slot, participants were randomized in blocks of 10 to the EVERYbody Project or video comparison condition (two blocks of 10 participant slots were available in each time slot).||||
33830837|NCT00715117|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33830838|NCT03331107|||COHORT||PROSPECTIVE|||||||
33830839|NCT00157898|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830840|NCT03373955|||CASE_ONLY||PROSPECTIVE|||||||
33830841|NCT05471804|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind||t|f|t|t
33830842|NCT01545557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830843|NCT03770052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830844|NCT02980705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830845|NCT00983112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33830846|NCT01849445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830847|NCT04787432|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33830848|NCT01162447|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830849|NCT00878553|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33830850|NCT06287086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830851|NCT02135822|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830852|NCT04471649|||CASE_CONTROL||RETROSPECTIVE|||||||
33830853|NCT00523952|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830854|NCT04314388|RANDOMIZED|PARALLEL||OTHER||NONE|Participants or the research team will not be blinded to the allocation.|Participants will be randomly allocated to two groups using blocked randomisation (stratified by site).||||
33830855|NCT04092049|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33830856|NCT03523052|||COHORT||PROSPECTIVE|||||||
33830857|NCT02830009|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830858|NCT04151472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830859|NCT02379793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830860|NCT05632718|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single center 3-parallel-arm open-label randomized clinical trial||||
33830861|NCT05887206|||COHORT||RETROSPECTIVE|||||||
33830862|NCT04733898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The investigator analyzing data will be blind to the group coding and the personal information. Only anonymized data will be available to them.|Three different groups will start simultaneously, with each participant in one and only one condition.|f|f|t|f
33830863|NCT05333822|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33830864|NCT00926380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830865|NCT00002498||||TREATMENT||||||||
33830866|NCT00251056|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830867|NCT04581252|||COHORT||PROSPECTIVE|||||||
33830868|NCT02806505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830869|NCT05328661|||COHORT||PROSPECTIVE|||||||
33830870|NCT03367910|NA|SINGLE_GROUP||PREVENTION||NONE||Participants with eligible MDRO UTIs will receive FMT.||||
33830871|NCT05060497|||OTHER||PROSPECTIVE|||||||
33830872|NCT05559671|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33830873|NCT05060835|||COHORT||RETROSPECTIVE|||||||
33830874|NCT04212975||SEQUENTIAL||TREATMENT||NONE|assessment of improvement|||||
33830875|NCT04757714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830876|NCT04693910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
33830877|NCT02928211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830878|NCT04933981|||CASE_CONTROL||PROSPECTIVE|||||||
33830879|NCT04765410|||COHORT||PROSPECTIVE|||||||
33830880|NCT02192723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33830881|NCT01832454|NA|SINGLE_GROUP||||NONE||||||
33830882|NCT04460729|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 60 participants will be enrolled globally and allocated to one of two cohorts based on whether their metastatic brain disease is symptomatic or asymptomatic and with or without prior brain therapy or if they have been diagnosed with leptomeningeal disease||||
33830883|NCT05005286|||CASE_CONTROL||RETROSPECTIVE|||||||
33830884|NCT03537378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141446|NCT04416529|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Participants were randomized to either the intervention group or the control group. All the participant were assessed at baseline, post-intervention and at 4-weeks follow-up.||||
34141447|NCT06606782|||COHORT||PROSPECTIVE|||||||
34141448|NCT00756184|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141449|NCT01127555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141450|NCT03846882|||COHORT||PROSPECTIVE|||||||
34141451|NCT06457646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141452|NCT04427995|||COHORT||PROSPECTIVE|||||||
34141453|NCT04923646|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34141454|NCT02966093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141455|NCT05045742|||COHORT||RETROSPECTIVE|||||||
34141456|NCT00613925|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34141457|NCT06478797|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a two-armed control study. One of the arms is the control group, so a group of participants, that is being treated with the standard therapy. The other arm is the intervention group, a group of participants that is being treated with adrenaline. It will be random which child is assigned to which group, this insures that the study is not biased.||||
34141458|NCT03796143|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two active self-help interventions, or their choice of intervention, for the duration of the study.||||
34141459|NCT00004206||||TREATMENT||||||||
34141460|NCT04844203|||COHORT||PROSPECTIVE|||||||
34141461|NCT03115853|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34141462|NCT02402361|||COHORT||PROSPECTIVE|||||||
34141463|NCT01108432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141464|NCT00145353|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34141465|NCT02427568|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141466|NCT00190138|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141467|NCT00002955||||TREATMENT||||||||
34141468|NCT03989427|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The outcome assessor will record measurements at baseline and post intervention. The assessor will be blinded from the sequence of intervention allocation.|"Participants will be selected by random sampling and allocated to Two Arms: Arm-I - Brushing first and Flossing later (BF), Arm II- Flossing first and brushing later (FB) after applying inclusion and exclusion criteria.~The participants in BF group will Brush first using Colgate® tooth brush for a 2-week period. and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.~The participants in FB group will floss first with Colgate® dental floss and brush later using Colgate® tooth brush for a 2-week period. This is followed by a one week wash out period. After this cross over is done in which participants will change the sequence to BF wherein they will Brush first and Floss later."|f|f|f|t
34141469|NCT04844658|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141470|NCT01636388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141471|NCT03362931|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141472|NCT06218381|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141473|NCT06489795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Interventional, multicenter, open-label, randomized, controlled non-inferiority trial||||
34141474|NCT02683486|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34141475|NCT05172453|||COHORT||PROSPECTIVE|||||||
34141476|NCT03484832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141477|NCT01294943|||CASE_CONTROL||PROSPECTIVE|||||||
34141478|NCT00442832|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141479|NCT00462735|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141480|NCT04854031|||CASE_ONLY||CROSS_SECTIONAL|||||||
34141481|NCT01339715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34141482|NCT02764723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141483|NCT05268393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34141484|NCT04946409|||COHORT||OTHER|||||||
34141485|NCT01396265|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141486|NCT05813652|||COHORT||RETROSPECTIVE|||||||
34141487|NCT06001437|||COHORT||PROSPECTIVE|||||||
34141488|NCT01819987|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, investigator and outcome assessor were blinded to the group assignment.|A randomized, controlled study was used. The intervention group received tablet based intervention and the control group received printed health information relevant to preschool-aged children in Chinese over the eight weeks.|t|f|t|t
34141489|NCT04120857|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141490|NCT03158623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|computer generated randomization|3 groups with identical surgical closures randomized into 2 groups with wound additives and the third group without wound additives.|t|t|f|f
34141491|NCT06050668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34141492|NCT00348907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34141493|NCT02178813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141494|NCT03442257|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research assistant, the patients' GPs, as well as all researchers except one (MS) will be blinded to group allocation. If the patients have questions regarding the SMS function they will be able to contact MS for help.|Randomized controlled trial|f|t|t|t
34141495|NCT03831880|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34141496|NCT04518852|NA|SINGLE_GROUP||TREATMENT||NONE||This study focuses on the in-operable, BCLC-B/C stage HCC patients. The participants will receive the combined treatment of local therapy (TACE) , anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)||||
34141497|NCT05170750|NA|SEQUENTIAL||OTHER||NONE|"Participants will be exposed to different foams under their feet but neither them, nor the investigator are aware of the expected differences in the effect of the foams.~In the second part, neither the participant, nor the investigator know the result of the first experiment."|"All participants participate to the first experiment. As the outcomes are continuous variables, to be sure to identify a variability between subjects based on their plantar information, we select 3 separated groups (on CoP results) of the initial population.~Based on their results, 3/5 of the initial population can be recruited for the second part of the experiment."||||
34141498|NCT00773786|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34141499|NCT06601959|||COHORT||CROSS_SECTIONAL|||||||
34141500|NCT02256267|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141501|NCT06608108|||OTHER||PROSPECTIVE|||||||
34141502|NCT06608394|||CASE_CONTROL||RETROSPECTIVE|||||||
34141503|NCT00460486|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34141504|NCT01228604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141505|NCT05930522|||COHORT||PROSPECTIVE|||||||
34141506|NCT00687752|||CASE_CONTROL||PROSPECTIVE|||||||
34141507|NCT03122353|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141508|NCT00585546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141509|NCT03032614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141510|NCT00286767|||COHORT||PROSPECTIVE|||||||
34141511|NCT06391281|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141512|NCT04392908|||CASE_ONLY||CROSS_SECTIONAL|||||||
34141513|NCT06605976|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized control trial||||
34141514|NCT02055534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141515|NCT06556238|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34141516|NCT06111066|||COHORT||PROSPECTIVE|||||||
34141517|NCT03789032|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single arm fixed sequence study. Subjects will be administered vadadustat on day 1, rabeprazole on days 2 to 5, and vadadustat and rabeprazole on day 6.||||
34141518|NCT06306664|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|double||t|f|f|f
34141519|NCT00241514|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34141520|NCT04393688|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141521|NCT00747669|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141522|NCT03670329|NA|SINGLE_GROUP||TREATMENT||NONE||Non-comparative study||||
34141523|NCT05256342|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34141524|NCT04419740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141525|NCT01065051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141526|NCT02671539|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141527|NCT05834465|||CASE_ONLY||PROSPECTIVE|||||||
34141528|NCT05568914|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141529|NCT00410319|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34141530|NCT02460783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141531|NCT06463704|||COHORT||PROSPECTIVE|||||||
34141532|NCT05427539|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34141533|NCT01900106|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141534|NCT02666456|||COHORT||PROSPECTIVE|||||||
34141535|NCT00504855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141536|NCT02166775|||||PROSPECTIVE|||||||
34141537|NCT01218100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141538|NCT05596617|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||quasi-experimental||||
34141539|NCT02141490|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141540|NCT02073032|||COHORT||PROSPECTIVE|||||||
34141541|NCT01810068|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141542|NCT02085096|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34141543|NCT02868034|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
34141544|NCT02810301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141545|NCT00937404|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34141546|NCT02098369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141547|NCT00991328|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|t|f
34141548|NCT03908372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141549|NCT03638869|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34141550|NCT04540458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||3D ultrasound and picture of ultrasound or 3D ultrasound and printed model of fetal face||||
34141551|NCT01686659|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34141552|NCT01795326|||||CROSS_SECTIONAL|||||||
34141553|NCT04937335|||CASE_CONTROL||RETROSPECTIVE|||||||
34141554|NCT01641146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141555|NCT01665430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141556|NCT00992381|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34141557|NCT04768959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141558|NCT05153811|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141559|NCT03100539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141560|NCT00787930|||CASE_CONTROL||PROSPECTIVE|||||||
34141561|NCT04794647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||randomized, controlled and double blind clinical trial|t|f|f|t
34141562|NCT04569136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141563|NCT05486000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141564|NCT00408889|||COHORT||PROSPECTIVE|||||||
34141565|NCT06389734|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study population will be randomized and separated in two groups, experimental and control group.||||
34141566|NCT00948558|||CASE_CONTROL||PROSPECTIVE|||||||
34141567|NCT00425581|||||PROSPECTIVE|||||||
34141568|NCT03369041|||COHORT||PROSPECTIVE|||||||
34141569|NCT01449110|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141570|NCT05027490|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141571|NCT00338273|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34141572|NCT02370641|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34141573|NCT01714518|||CASE_ONLY||PROSPECTIVE|||||||
34141574|NCT00888329|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141575|NCT03100812|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150850|NCT06297473|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|"Adverse events (primary outcome) will be established by a blinded adjudication committee.~A committé of external endocrinologist/ophthalmologist will blinded to participant ID/allocation assess all the participants admissions to hospital and assess wether it qualifies as an event"|Patients will be randomized to either intervention or control|f|f|f|t
34150851|NCT05837104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150852|NCT03463954|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141576|NCT04450628|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Surgeons will be blinded to EndoFLIP results for half of the cases, with the first 25 cases blinded and the second 25 cases with the surgeons unblinded. There will be interim analysis between the two groups' surgeries. During blinded cases no adjustment will be made to the surgical procedure based on EndoFLIP results, as the operating surgeon will not be informed of the measured values. After the first 25 cases, the surgeons will be unblinded and be able to determine goal impedance planimetry values based on patient postoperative symptom scores. In the following 25 unblinded cases, the surgeon will be able to augment the surgical intent based on EndoFLIP measurements, such as adding or removing hiatal sutures or repeating the fundoplication . Patients will be blinded to the type of procedure (i.e. surgeon blinded or unblinded).|Surgeons will be blinded to EndoFLIP results for half of the cases, with the first 25 cases blinded and the second 25 cases with the surgeons unblinded. There will be interim analysis between the two groups' surgeries. During blinded cases no adjustment will be made to the surgical procedure based on EndoFLIP results, as the operating surgeon will not be informed of the measured values. After the first 25 cases, the surgeons will be unblinded and be able to determine goal impedance planimetry values based on patient postoperative symptom scores.|t|t|t|f
34141577|NCT01737333|||CASE_ONLY||PROSPECTIVE|||||||
34141578|NCT02082223|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141579|NCT00000224||CROSSOVER||TREATMENT||DOUBLE||||||
34141580|NCT06087263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141581|NCT04862234|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Participants with normoglycemia will be in Aim 1. Participants with lab results indicative of pre-DM or DM will be randomized to Aim 1 or Aim 2, and those in Aim 2 will be further randomized to receive dulaglutide or placebo. Aim 2 was discontinued June 7, 2024.|t|f|f|t
34141582|NCT02671149|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34141583|NCT06607055|||COHORT||PROSPECTIVE|||||||
34141584|NCT03455868|||COHORT||PROSPECTIVE|||||||
34141585|NCT01920997|||CASE_CONTROL|||||||||
34141586|NCT01128348|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|f|t|t
34141587|NCT04270058|||COHORT||PROSPECTIVE|||||||
34141588|NCT00003946||||TREATMENT||||||||
34141589|NCT01466660|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141590|NCT02279849|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34141591|NCT04671758|||COHORT||OTHER|||||||
34141592|NCT04046315|||COHORT||PROSPECTIVE|||||||
34141593|NCT03362125|||CASE_ONLY||PROSPECTIVE|||||||
34141594|NCT04913597|||COHORT||PROSPECTIVE|||||||
34141595|NCT03259048|||COHORT||PROSPECTIVE|||||||
34141596|NCT01389531|NA|SINGLE_GROUP||||NONE||||||
34141597|NCT03602313|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Investigators were blinded to the study intervention. Data collection was performed at a separate location than the primary intervention.|Participants were randomly assigned to 1 of 2 groups for the duration of the study.|f|f|t|f
34141598|NCT00741494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34141599|NCT03745183|NA|SINGLE_GROUP||TREATMENT||NONE||This study is a preliminary open label, single arm, before and after clinical trial, that utilized Akapulko (Senna alata),a medicinal plant, leaf decoction in the treatment of tinea imbricata. Enrolled, who were recruited during the outreach mission were taught how to make a community-prepared akapulko decoction and were asked to apply it as a leave-on body wash once a day for 28+/-3 days.||||
34141600|NCT04911244|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||||||||
34141601|NCT02635139|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34141602|NCT03289832|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34141603|NCT03824275|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective, non-randomized||||
34141604|NCT04755166|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34141605|NCT02032693|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34141606|NCT06487312|||CASE_CROSSOVER||PROSPECTIVE|||||||
34141607|NCT01913665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141608|NCT04573426|||OTHER||CROSS_SECTIONAL|||||||
34141609|NCT00716430|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141610|NCT03897296|NA|SINGLE_GROUP||OTHER||NONE|No masking is possible|"Normative values for the routine procedure of high-resolution anorectal manometry for Russian population has not been studied yet. Some factors allows to suggest that normative values may differ from those obtained in other countries. This pilot study is aimed to either support the null-hypothesis of the presence of the differences or decline it. It is expected to obtain primary data that could be used for further work and planning of the cohort studies. During the study, healthy volunteers are to be examined with a registered diagnostic tool (i.e. high-resolution anorectal manometry with water-perfused catheter). This diagnostic procedure is not intended as one for routine examination, therefore the study type is changed to the interventional, though no pharmacological intervention or surgery is planned. The estimated sample size sufficient to reach the power of 80%, and type 1 error 0.05 was obtained with single-sample t-test of Statistica10 (StatSoft, USA)"||||
34141611|NCT04149223|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||"The experimental design is a stepped roll-out hybrid II effectiveness-implementation trial (Curran et al. 2012), which tests clinical intervention impact and rigorously evaluates implementation strategy in real time. Over three years, the investigators will implement the CCAB intervention across 8 Alberta hospital sites within Alberta Health Services (AHS). The overarching objective of this study is to demonstrate both effectiveness and implementation feasibility for routine patient care within AHS.~Given the pragmatic approach to this study, the commencement and scale-up of the study will coincide with the phases of the planned roll-out of Connect Care (the new Alberta Electronic Medical Record (EMR) platform) across the province. The project allows for an incredibly interesting and unique opportunity to implement and evaluate a comprehensive provincial chronic disease intervention in a real-world context, both in current state and with EMR facilitation"||||
34141612|NCT06284993|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34141613|NCT06086860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141614|NCT02836782|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33830885|NCT02055456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830886|NCT00398723|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830887|NCT02572115|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|t|f|f
34141615|NCT02976480|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141616|NCT01245881|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141617|NCT00336167|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141618|NCT02286934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141619|NCT00497328|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141620|NCT03500172|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This sequential multistage adaptive randomized trial (SMART) assesses two interventions to address treatment barriers: (1) nurse-led mobile decentralized treatment programs (DTP) and (2) peer-led, individualized case management (ICM).||||
34141621|NCT04524559|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34141622|NCT04449939|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after s.c. and i.v. administration, with i.v. KY1005 as a reference treatment.||||
34141623|NCT05108090|NA|SINGLE_GROUP||SCREENING||NONE||||||
34141624|NCT05346146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141625|NCT01710943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141626|NCT05367739|||COHORT||RETROSPECTIVE|||||||
34141627|NCT01467115|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141628|NCT02031081|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34141629|NCT00272948|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141630|NCT06275984|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34141631|NCT02705014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141632|NCT02272751|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141633|NCT01574898|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34141634|NCT03509493|||COHORT||PROSPECTIVE|||||||
34141635|NCT03202355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-arm, parallel, open-label, non-randomized, controlled, private practice study designed to evaluate the intended purposes of the investigation.||||
34141636|NCT03359707|||OTHER||CROSS_SECTIONAL|||||||
34141637|NCT03517930|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34141638|NCT05685563|||COHORT||OTHER|||||||
34141639|NCT05411523|||COHORT||PROSPECTIVE|||||||
34141640|NCT04060381|||COHORT||PROSPECTIVE|||||||
34141641|NCT03833271|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141642|NCT04046354|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141643|NCT05621759|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34141644|NCT00359333|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141645|NCT04796688|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141646|NCT03075722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141647|NCT00408096|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141648|NCT03088631|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Eligible women who gave their informed consent were randomized into two groups: (I) metformin group and (II) placebo group. Randomization was conducted using a computer generated table of random numbers with allocation concealment. Randomization was not changed after it had been done.|t|f|t|f
34141649|NCT03619928|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34141650|NCT02637427|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141651|NCT03062618|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34141652|NCT00731653||PARALLEL||TREATMENT||NONE||||||
34141653|NCT05181774|||CASE_CONTROL||PROSPECTIVE|||||||
34141654|NCT00132795|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141655|NCT01665079|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141656|NCT01567501|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34141657|NCT06607848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141658|NCT01453946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141659|NCT05326581|||COHORT||PROSPECTIVE|||||||
34141660|NCT03926000|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34141661|NCT04527874|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||cluster-randomized||||
34141662|NCT06519123|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34141663|NCT04951271|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Which students were included in the experimental and control groups was determined by simple randomization. Thus, a one-way blinding was made by preventing the adolescent students included in the study from knowing whether they were in the experimental group or the control group.|This research is a single-blind, randomized controlled study with a control group design with pre-test and post-test measurements from experimental research designs.|t|f|f|t
34141664|NCT01028716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141665|NCT03414255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141666|NCT03297489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141667|NCT01719029|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34141668|NCT03995680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141669|NCT04463628|||COHORT||PROSPECTIVE|||||||
34141670|NCT04674501|||COHORT||PROSPECTIVE|||||||
34141671|NCT01567202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141672|NCT06363890|||OTHER||PROSPECTIVE|||||||
34141673|NCT05347927|||COHORT||PROSPECTIVE|||||||
34141674|NCT01216358|||CASE_CONTROL||PROSPECTIVE|||||||
34141675|NCT05472545|RANDOMIZED|PARALLEL||PREVENTION||NONE|Dyads will be randomly assigned to the experimental or control condition. This study cannot have true masking, as participants in the experimental group will know they are receiving neurofeedback. The control group will not be informed of the existence of the neurofeedback condition.|||||
34141676|NCT02233738|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34141677|NCT01211353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34141678|NCT04627181|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE||Participants will be randomized to one of four arms: IV ferric carboxymaltose + placebo, IM hydroxycobalamin + placebo, IV ferric carboxymaltose + IM hydroxycobalamin, placebo + placebo|t|t|t|t
34141679|NCT05652231|||OTHER||CROSS_SECTIONAL|||||||
34141680|NCT02928003|NA|SINGLE_GROUP||OTHER||NONE||||||
34141681|NCT06474091|||COHORT||PROSPECTIVE|||||||
34141682|NCT06083324|||COHORT||PROSPECTIVE|||||||
34141683|NCT02485652|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141684|NCT04538339|||COHORT||PROSPECTIVE|||||||
34141685|NCT00659100|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141686|NCT06086444|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141687|NCT05391425|||COHORT||PROSPECTIVE|||||||
34141688|NCT06296160|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|It is a single-blinded trial as the treatment is blinded by Subjects only, meaning that the type of dry weight modification will not be disclosed to the subject, and they will not know which group he/she will be in at the time of consenting to limit the bias in opinion. The investigator and the research team must know the type of treatment, as the investigator will modify the dry weight according to the treatment group.|"The study will compare two groups according to the dry weight determination method:~(1) Control arm- modification of dry weight according to standardized care only. The standard of care to modify dry weight is what nephrologists use actually to define the best theoretical dry weight, including clinical (blood pressure, edema, shortness of breath, lung auscultation, etc.) and laboratory measures (Protein concentration before and after dialysis sessions ...). (2) Intervention arm- modify patient's dry weight according to standard of care + B lines score on lung ultrasound BLS obtained after the midweek dialysis session, considered as Day one (Day 1)"|t|f|f|f
34141689|NCT05124587|||COHORT||RETROSPECTIVE|||||||
34141690|NCT05648864|NA|SINGLE_GROUP||TREATMENT||NONE|dyads of people living with dementia (n=24) and their informal caregivers (n=24)|||||
34141691|NCT01269359|||COHORT||PROSPECTIVE|||||||
34141692|NCT02084680|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141693|NCT03741023|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34141694|NCT03397888|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141695|NCT01485900|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141696|NCT03770728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141697|NCT01150591|||COHORT||PROSPECTIVE|||||||
34141698|NCT06413420|||COHORT||PROSPECTIVE|||||||
34141699|NCT01888731|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34141700|NCT00232713|||||PROSPECTIVE|||||||
34141701|NCT02209402|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34141702|NCT01204229|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141703|NCT03122821|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|transcranial electrical stimulation|Transcranial magnetic stimulation|t|t|t|t
34141704|NCT05783921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141705|NCT05814198|||CASE_CONTROL||RETROSPECTIVE|||||||
34141706|NCT04940897|NA|SINGLE_GROUP||TREATMENT||NONE||Stepped wedge control trial||||
34141707|NCT05868733|RANDOMIZED|SEQUENTIAL||PREVENTION||TRIPLE|Study staff and participants will be blinded in terms of active product versus placebo.||t|t|t|f
34141708|NCT03310008|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Biological: NKR-2 cells The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).~Other Name: NKG2D CAR-T cells"||||
34141709|NCT06356779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141710|NCT03351686|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34141711|NCT01371149|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141712|NCT02686151|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141713|NCT06026371|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Investigators, treating physicians, staff, and subjects are blinded to study arm assignment (FMT vs. placebo).|The first 12 patients are assigned to the treatment group, remaining patients are randomized to treatment or placebo group.|t|t|t|t
34141714|NCT03419273|||COHORT||PROSPECTIVE|||||||
34141715|NCT03279913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141716|NCT02720601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141717|NCT03430505|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34141718|NCT00994734|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34141719|NCT02267330|||COHORT||PROSPECTIVE|||||||
34141720|NCT06209515|||CASE_CONTROL||RETROSPECTIVE|||||||
34141721|NCT01215617|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34141722|NCT02240849|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34141723|NCT03724981|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34141724|NCT01119833|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141725|NCT01135914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141726|NCT05374577|||COHORT||PROSPECTIVE|||||||
34141727|NCT00780637|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141728|NCT03727087|||COHORT||CROSS_SECTIONAL|||||||
34141729|NCT06099470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141730|NCT04255901|||CASE_ONLY||PROSPECTIVE|||||||
34141731|NCT01537952|||CASE_ONLY||PROSPECTIVE|||||||
34141732|NCT03134365|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||f|f|f|t
34141733|NCT05065086|||COHORT||RETROSPECTIVE|||||||
34141734|NCT00196586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141735|NCT03303859|||COHORT||PROSPECTIVE|||||||
34141736|NCT05132998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141737|NCT05502159|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant were blinded to the study|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic cholesistectomy surgery will be included in the study. Patients will be randomly divided into two groups (Group M = M-TAPA group, Group EOB = EOB group) including 30 patients each, before entering the operating room.|t|f|f|t
34141738|NCT04094142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141739|NCT01567592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830888|NCT01607528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141740|NCT01961960|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34141741|NCT01946464|||||PROSPECTIVE|||||||
34141742|NCT04536922|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141743|NCT00427479|||CASE_CONTROL||OTHER|||||||
34141744|NCT00140829|||FAMILY_BASED||PROSPECTIVE|||||||
33830889|NCT04595942|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830890|NCT04673045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830891|NCT05364645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830892|NCT00640198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141745|NCT00998855|||COHORT||PROSPECTIVE|||||||
34141746|NCT05807776|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141747|NCT04793230|||COHORT||PROSPECTIVE|||||||
34141748|NCT05145361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141749|NCT05366491|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34141750|NCT02949986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141751|NCT04693104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Given the impossibility of obtaining identical presentations of the compared interventions, double-blind conditions will be ensured by appointing at each site one injector investigator in charge only of the administration of the treatments and one clinical assessor investigator as Outcome Assessor, in charge of all safety and efficacy assessments, who will remain always blinded to the treatment. Patient blinding will be ensured by avoiding visual access to the injection field by the use of a screen between the patient and his/her knee."||t|f|f|t
34141752|NCT06420362|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34141753|NCT05415592|||COHORT||PROSPECTIVE|||||||
34141754|NCT03135444|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||Initially, health care providers will give feedback on the tool. The tool will be revised and the second segment of the study will be to give the revised tool to patients with pre- and post-tests which measure changes in prostate cancer screening knowledge.||||
34141755|NCT03482284|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||All participants receive all interventional diets.||||
34141756|NCT00874406|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141757|NCT01082510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141758|NCT01161095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141759|NCT01696617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141760|NCT00712530|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141761|NCT04355533|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34141762|NCT04623268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141763|NCT03411252|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34141764|NCT01480609|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34141765|NCT03581539|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients randomized to four-quadrant Transverses Abdominis Plane (TAP) block, Quadratus Lumborum (QL) block or surgeon infiltration using Exparel for postoperative analgesia after laparoscopic nephrectomy||||
34141766|NCT05067920|||COHORT||PROSPECTIVE|||||||
34141767|NCT02497378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141768|NCT01967017|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141769|NCT00414115|||COHORT||OTHER|||||||
34141770|NCT01842932|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34141771|NCT05190029|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||120 children aged 3 to 8 years from a school in Córdoba (Spain). Subjects of both sexes were included and were divided into two groups according to age ranges: 3 to 6 years and 6 to 8 years.||||
34141772|NCT05363761|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, up to 5 centers, non-randomized open label safety and performance study.||||
34141773|NCT01385111|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34141774|NCT04782245|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141775|NCT03198455|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34141776|NCT06066905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141777|NCT06216782|||COHORT||PROSPECTIVE|||||||
34141778|NCT00657839|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141779|NCT03333122|||COHORT||PROSPECTIVE|||||||
34141780|NCT05587569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141781|NCT05693740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single blinded Prospective, Interventional, randomized, comparative study|f|f|f|t
34141782|NCT03610581|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
34141783|NCT06605573|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|The study staff member who interprets the lay user\&amp;#39;s result will be blinded to the lay user\&#39;s reference test results and medical status. The study staff member who conducts the Panbio™ HCV Self Test for the lay user will also be blinded to the lay user\&#39;s reference test results and medical status as well as the self-test results.|Single group assessment|f|f|f|t
34141784|NCT05967546|||COHORT||OTHER|||||||
34141785|NCT03153644|||COHORT||CROSS_SECTIONAL|||||||
34141786|NCT03858335|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141787|NCT00074529|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34141788|NCT03182023|||CASE_ONLY||RETROSPECTIVE|||||||
34141789|NCT00174863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141790|NCT00062023|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34141791|NCT02031835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141792|NCT05319483|||COHORT||PROSPECTIVE|||||||
34141793|NCT04652375|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34141794|NCT00441649|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34141795|NCT02350387|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141796|NCT02682589|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141797|NCT05293444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34141798|NCT02029183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141799|NCT01101971|NA|SINGLE_GROUP||OTHER||NONE||||||
34141800|NCT04715789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The main investigator will perform the physical therapy program after referral by Blind assessor after assessment.~Main investigator start the treatment based on the randomization made by the software after the referral so he will not know the assessment results before and after he treatment and the assessor will not know the randomization results and the patient group selected for treatment~So this procedures will be done by double blind procedure for the main investigator and research assistance."|Clinical trial controled study with double blind procedures for (main investigator) for treatment interventions and (research assistance) for assessment interventions.|f|t|t|f
34141801|NCT01529580|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34141802|NCT01212211|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141803|NCT06223256|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830893|NCT05585736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141804|NCT04080479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No masking will be used in the study.|The study subjects will be randomized into one of the two study arms.||||
33830894|NCT01382862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830895|NCT01530386|NA|SINGLE_GROUP||||NONE||||||
33830896|NCT00832364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830897|NCT04131686|||COHORT||PROSPECTIVE|||||||
33830898|NCT03123302|||COHORT||RETROSPECTIVE|||||||
33830899|NCT01006889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830900|NCT01391429|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33830901|NCT03592004|||COHORT||PROSPECTIVE|||||||
33830902|NCT03356964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830903|NCT00805597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830904|NCT01003171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830905|NCT00665223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830906|NCT01582503|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830907|NCT04429646|RANDOMIZED|PARALLEL||PREVENTION||NONE||Allocation: Randomized Intervention Model: Parallel Assignment Primary Purpose: Prevention Endpoint Classification: Safety/Efficacy Study Masking: Open Label||||
33830908|NCT01860547|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33830909|NCT04799847|NA|SEQUENTIAL||TREATMENT||NONE||||||
33830910|NCT00571896|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830911|NCT00188721|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830912|NCT01304628|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33830913|NCT03171935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830914|NCT02416713|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830915|NCT04453163|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830916|NCT04358536|||COHORT||RETROSPECTIVE|||||||
33830917|NCT02635386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33830918|NCT04617236|RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE||A randomized controlled trial using a pre-post comparison group design. Eligibility criteria included ages 21 and older for the Pap cohort and 40 and older for the mammography cohort, non-adherence to recommended Pap test screening and/or mammography screening guidelines according to the American Cancer Society, no hysterectomy, no diagnosis of cancer, and not currently pregnant. Trained data collectors administered a baseline survey to eligible women and randomly assigned them to the intervention or to a comparison condition. Lay Health Workers delivered the intervention in women's homes, and administered the follow-up survey by phone 4 to 6 months following baseline.|t|f|f|f
33830919|NCT02147782|||CASE_CONTROL||PROSPECTIVE|||||||
33830920|NCT04744805|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33830921|NCT00051038||||TREATMENT||||||||
33830922|NCT02780895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830923|NCT01803347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33830924|NCT06426147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830925|NCT04178447|NON_RANDOMIZED|PARALLEL||OTHER||NONE||If only Part A will be conducted total subjects of 16 will be enrolled if Part B also will be conducted up to 48 subjects will be enrolled.||||
33830926|NCT06144593|RANDOMIZED|CROSSOVER||OTHER||NONE||Dietary intervention||||
33830927|NCT00498615|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33830928|NCT00069381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830929|NCT04361968|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"As the employed study design necessitates the deception of participants about the true nature of the used intervention, i.e. placebo cream and the true aim of the dog's presence.~After the termination of the study, all the subjects are debriefed regarding the real experimental procedures."|randomized controlled parallel group within-subjects design|t|f|f|f
33830930|NCT02424019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830931|NCT04106570|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830932|NCT03747809|||OTHER||PROSPECTIVE|||||||
33830933|NCT02311777|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33830934|NCT06382389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel assignement|t|f|t|t
33830935|NCT00509405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830936|NCT02481622|||OTHER||RETROSPECTIVE|||||||
34141805|NCT04814368|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Masking only applies to the canakinumab treatment. LNA043 treatment is open label.||t|t|t|t
34141806|NCT05519501|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141807|NCT03387943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141808|NCT00882596|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141809|NCT04217967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141810|NCT06082024|||COHORT||CROSS_SECTIONAL|||||||
34141811|NCT00391677|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33830937|NCT06123806|||COHORT||CROSS_SECTIONAL|||||||
33830938|NCT05964959|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||A cluster-based intervention study in 6 hospitals and 6 nursing homes (n=228), followed by a mixed-methods study and cost-effective analysis.||||
33830939|NCT00207818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830940|NCT00142545|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830941|NCT02185898|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33830942|NCT04198493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Open pilot study with randomized therapeutic intervention of parallel groups and blind evaluation in neuropsychological assessment.|f|f|f|t
33830943|NCT03042299|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33830944|NCT06364176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830945|NCT03796208|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141812|NCT04466267|||COHORT||RETROSPECTIVE|||||||
34141813|NCT06607432|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|The blind will be maintained by the Nathan Kline Institute (NKI) Data management group. Treatment assignment will be transmitted from the NKI Data management group directly to an unblinded research technician who will supervise the stimulation but will not otherwise perform ratings. The research technician will be instructed not to discuss treatment assignment with other members of the research team.||t|f|t|t
34141814|NCT03088436|||CASE_ONLY||RETROSPECTIVE|||||||
34141815|NCT06468527|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34141816|NCT02126228|||CASE_CONTROL||PROSPECTIVE|||||||
34141817|NCT05826691|||COHORT||PROSPECTIVE|||||||
34141818|NCT00006046|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33830946|NCT04036253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830947|NCT04843384|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33830948|NCT00263575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830949|NCT00776659|||CASE_ONLY||PROSPECTIVE|||||||
33830950|NCT03359226|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33830951|NCT04417400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|"Patients and pharmacist were blind to the intervention at the time of enrollment.~Afterwards, pharmacist were notified about the randomization to be able to prepare for the patients that will receive MUR at the visit 1. Patients were blinded until the visit 1 - until after the baseline data collection"|Upon enrollment patients were centrally randomized into two groups -test and control. Patients from the test group received MUR at visit 1. After 12 weeks both groups were reinterviewed. Upon study completion, patients from the control group received MUR due to ethical reasons, however the documentation was not part of the study anymore.||||
33830952|NCT01695408|||COHORT||PROSPECTIVE|||||||
33830953|NCT05327036|||COHORT||PROSPECTIVE|||||||
33830954|NCT01036243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33830955|NCT00784745|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33830956|NCT02759237|||OTHER||PROSPECTIVE|||||||
33830957|NCT04008056|||CASE_ONLY||PROSPECTIVE|||||||
33830958|NCT02835092|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830959|NCT02193659|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33830960|NCT03995225|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830961|NCT03551431|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Open labeled, randomized controlled Non-inferiority study with three parallel arms: video EEG with verbal suggestion only, cotton swab with verbal suggestion and tuning fork along with verbal suggestion||||
33830962|NCT04991636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830963|NCT02373917|||COHORT||PROSPECTIVE|||||||
33830964|NCT03112447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830965|NCT03751553|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33830966|NCT02923193|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830967|NCT01068288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830968|NCT00755898|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33830969|NCT04700475|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The participants are head and neck cancer patients recieving radiotherapy. The care provider are oncologist and nursing stuff. The investigator is phsical therapist (my self)|"In the study, 2 groups of patients will participate First, study group will recieve low level laser on major salivary glands and usual medications.~Second, control group will recieve usual medications. Second, control"|t|t|t|f
33830970|NCT03949465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830971|NCT00456378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830972|NCT02101827|||COHORT||RETROSPECTIVE|||||||
33830973|NCT05459311|||CASE_ONLY||PROSPECTIVE|||||||
33830974|NCT04934605|||CASE_ONLY||RETROSPECTIVE|||||||
33830975|NCT03458728|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830976|NCT03455777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830977|NCT06226298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33830978|NCT02827578|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33830979|NCT01728623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830980|NCT00093288|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33830981|NCT04732247|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|All will remain blinded until completion of human subjects data collection except the research pharmacist providing intranasal oxytocin or placebo.|Double-blind, placebo-controlled, randomized trial leveraging a wash-in design|t|t|t|t
33830982|NCT03004482|||OTHER||CROSS_SECTIONAL|||||||
33830983|NCT04665362|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830984|NCT00693433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830985|NCT04247269|||COHORT||RETROSPECTIVE|||||||
33830986|NCT06488638|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||placebo-controlled, double blind, randomised controlled trial|t|f|t|t
33830987|NCT00477464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33830988|NCT01939210|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33830989|NCT02196077|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double Blind||t|f|t|f
33830990|NCT00905359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830991|NCT00000545||||PREVENTION||||||||
33830992|NCT01907945|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33830993|NCT04051125|||COHORT||PROSPECTIVE|||||||
33830994|NCT02914171|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33830995|NCT04115852|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33830996|NCT03712449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141819|NCT04231058|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34141820|NCT05249881|NA|SEQUENTIAL||TREATMENT||NONE||||||
34141821|NCT00003136|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141822|NCT02362230|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830997|NCT03004586|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33830998|NCT02962414|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33830999|NCT04037345|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831000|NCT06192030|||COHORT||OTHER|||||||
33831001|NCT02621554|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33837539|NCT03435146|NA|SEQUENTIAL||TREATMENT||NONE||Group 1A:12 ppts will take DTG 50mg/TDF/FTC once daily + once weekly HP for 12 weeks. Semi-intensive PK for DTG,RPT,INH will be collected per protocol.An interim PK, safety,and HIV VL assessment will be performed to ensure that DTG 50mg once daily is safe and meets PK targets.Group 1B:18 ppts will receive either DTG 50mg or dose adjusted DTG + once weekly HP. Semi-intensive PK for DTG,RPT,INH will be collected per protocol.Group 2: 30 ppts will receive DTG at the same dose and frequency as Group 1B. Sparse PK for DTG, safety labs and HIV VL will be measured per protocol.Group 3: 25 ppts who are HIV tx naive will start DTG 50mg/TDF/3TC daily as a FDC tablet + standard of care isoniazid preventive therapy. ART and IPT will start together. Sparse PK for DTG will be collected per protocol.Group 4: 50 ppts who are HIV treatment naive will start DTG 50mg/TDF/3TC daily as a FDC tablet + weekly HP for 12 weeks. ART and 3HP will start together. Sparse PK for DTG will be collected per protocol.||||
33837540|NCT02637323|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837541|NCT03457571|||COHORT||PROSPECTIVE|||||||
33831002|NCT05342519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The pharmacy will distribute medications in unlabeled, 60-gram tubes following patient enrollment. Tubes will be marked as Left and Right. The association between tube label and treatment type will only be known to pharmacy staff. The pharmacy staff will allocate 10 patients to receive 0.001% rapamycin and 10 patients to receive 0.1% rapamycin."|During a clinical care visit, if a patient is eligible and agrees to participate, one lesion occupying less than 2% body surface area (BSA) will be identified for treatment with either 0.1% or 0.001% topical rapamycin cream to be applied daily for 6 months. Ten patients will be randomized to each treatment arm, however, if it is clear that one treatment arm is less effective, that treatment arm will be dropped, and study participants will be reallocated to the more effective treatment arm. A second, symmetric lesion about the same size and evolution time occupying less than 2% BSA will be identified for treatment with topical placebo cream to be applied daily for 6 months. The second lesion must be at the corresponding anatomic location on the other half of the body, i.e., if topical rapamycin is applied to the left arm, topical placebo will be applied to the right arm.|t|t|t|t
33831003|NCT01438840|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831004|NCT00359047|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33831005|NCT00470028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831006|NCT04979247|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33831007|NCT00741468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831008|NCT02826798|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33831009|NCT03055923|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831010|NCT03046368|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33831011|NCT01983553|||COHORT||PROSPECTIVE|||||||
33831012|NCT06209203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831013|NCT00376012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831014|NCT01491542|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831015|NCT02902653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831016|NCT06133686|RANDOMIZED|PARALLEL||OTHER||NONE||This is a Phase 3b, open label, hybrid type 2 study with co-primary aims of effective use and implementation. This is a mixed method, multi-setting, multi-country randomized controlled trial, carried out in South Africa and Uganda to compare persistence in care for oral PrEP and CAB-LA in mobile men, which will inform PrEP implementation in men. Mobile men aged 18+ years, will be recruited from outreach settings in in South Africa and Uganda. Those testing HIV negative (target sample size, n=400) will be randomized into 2 groups: Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) and Group B will receive CAB-LA over 9-months. After 9- months participants from both groups will be offered choice of PrEP for a further 9-months, with the ability to change choice as required. Switch PrEP options will be monitored. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.||||
33831017|NCT05692609|||COHORT||PROSPECTIVE|||||||
33831018|NCT01930214|||COHORT||PROSPECTIVE|||||||
33831019|NCT02933307|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831020|NCT01124838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831021|NCT01538225|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33831022|NCT01173783|||CASE_ONLY||PROSPECTIVE|||||||
33831023|NCT01036165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33831024|NCT01865500|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831025|NCT02353871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831026|NCT05940831|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
33831027|NCT05479461|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized open label||||
33831028|NCT01727206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831029|NCT01540162|||COHORT||PROSPECTIVE|||||||
33831030|NCT05477303|||COHORT||PROSPECTIVE|||||||
33831031|NCT03298529|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831032|NCT02854618|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831033|NCT05960890|||COHORT||PROSPECTIVE|||||||
33831034|NCT02321267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831035|NCT03507153|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Only statistician will be blinded as the 2 materials have different colors The patients: they won't be aware of the lab procedures till finishing and delivery of the dentures.~The outcome assessor: the assessor who will assess the muscular activity will be blinded."||t|f|f|t
33831036|NCT01924637|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33831037|NCT05010785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33831038|NCT04211311|NA|SINGLE_GROUP||OTHER||NONE||||||
33831039|NCT00336336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831040|NCT00331708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831041|NCT05603897|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33831042|NCT03774875|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141823|NCT04650412|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial (bundle of comorbidity care vs standard care)||||
34141824|NCT03525184|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Participants will undergo the study during normal sleep, sleep restriction without the multi-nutrient beverage and sleep restriction with the multi-nutrient beverage|t|f|f|f
34141825|NCT00493636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141826|NCT02590822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831043|NCT01427738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831044|NCT05774171|||COHORT||PROSPECTIVE|||||||
33831045|NCT05474898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831046|NCT02682004|||CASE_CONTROL||PROSPECTIVE|||||||
33831047|NCT00932295|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33831048|NCT06029985|||CASE_ONLY||PROSPECTIVE|||||||
33831049|NCT03790904|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33831050|NCT03227978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831051|NCT00397020|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831052|NCT03647202|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Participants will be assigned to 1 of 6 treatment sequences (Sequences ABC, ACB, BAC, BCA, CAB, or CBA), according to a pre-generated randomization scheme.||||
33831053|NCT04070729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831054|NCT03947762|||COHORT||PROSPECTIVE|||||||
33831055|NCT02609152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831056|NCT01684111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831057|NCT05788640|||COHORT||CROSS_SECTIONAL|||||||
33831058|NCT01276613|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831059|NCT01903083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831060|NCT05051423|||COHORT||PROSPECTIVE|||||||
33831061|NCT01357109|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831062|NCT03993561|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A prospective, pilot trial at a single centre with 1 group of 20 adults. The study group will receive a one-hour treatment summary and survivorship care plan (TSSP) intervention specifically tailored to the needs of head and neck cancer patients based on the best available evidence and consultation with patients and a multidisciplinary team of head and neck cancer specialists.||||
33831063|NCT05127018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34141827|NCT05536089|||COHORT||PROSPECTIVE|||||||
33831064|NCT04105062|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||SINGLE|The operating surgeon will remain blinded to the fluorescence images throughout the operation.|A rolling six design will be used to enroll patients in the phase 1 dose escalating portion of the study, during which LS301 will be administered intravenously at one of three doses. After the optimal dose has been determined, an additional 9 patients will be enrolled in the phase I expansion cohort to evaluate for safety. The optimal imaging dose of LS301 determined in phase I will be administered in 88 patients in the phase II portion of the study.|f|t|f|f
33831065|NCT00665132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831066|NCT02836041|||COHORT||PROSPECTIVE|||||||
33831067|NCT04287140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The fluid bag, intravenous pump, serum set will be concealed with opaque coaters, so that patients, doctors, and study investigators will be blinded to the treatment group. Only the nurse who sets the infusion pump will be aware of the treatment group of the patient.|Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Treatment Secondary Purpose: Adverse Event|t|f|t|t
33831068|NCT00870532|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831069|NCT02475876|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33831070|NCT00900783|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831071|NCT04571697|||COHORT||RETROSPECTIVE|||||||
33831072|NCT00237614|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
33831073|NCT03585283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Intervention group will receive myofascial release and control group will receive a sham therapy by using same treatment and handling position without applying myofascial release techniques.~Participant will be evaluated at baseline, 4 weeks later and 12 week later by an another investigator who does not aware of groups."|Patients' information and contact will be obtained from physiatrist and willing participant's gender, age and pain onset data will be processed with a random number generator in order to form groups. Patients will divide randomly into two groups as intervention and control with a normal distribution of gender, age and pain onset.|t|f|f|t
33831074|NCT05988034|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33831075|NCT05698329|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Route of administration is by delivering single injection of AIV007 in the periocular tissue anatomically juxtasclearal where by the drug depot forms and delivers active agent over time.||||
33831076|NCT00963443|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831077|NCT01827098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831078|NCT06254755|RANDOMIZED|PARALLEL||TREATMENT||NONE||Non-inferiority, open-labelled, randomization, case-controlled prospective multicenter trials||||
33831079|NCT05469256|||OTHER||CROSS_SECTIONAL|||||||
33831080|NCT00356993|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831081|NCT03122847|||COHORT||PROSPECTIVE|||||||
33831082|NCT02927652|||COHORT||OTHER|||||||
33831083|NCT01184898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831084|NCT04521270|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33831085|NCT01515722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831086|NCT04833244|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|After qualifying, patients are randomized into intervention or control groups. The investigator and care provider then film the patient, teach the interventional or sham maneuver, and film the patient again. The outcomes assessor then evaluates the patient responses and filmed behaviors, but is not informed about whether the patient received the interventional maneuver or the sham maneuver.|This is a randomized, controlled study in which the patient and investigator are blinded.|t|f|f|t
33831087|NCT01683305|||COHORT|||||||||
33837542|NCT00194324|RANDOMIZED|CROSSOVER||||NONE||||||
33837543|NCT00504777|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837544|NCT00722241|||CASE_ONLY||PROSPECTIVE|||||||
33837545|NCT04470661|||COHORT||PROSPECTIVE|||||||
33837546|NCT01046006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141828|NCT00075387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34141829|NCT05563883|||COHORT||RETROSPECTIVE|||||||
34141830|NCT01498627|||CASE_CONTROL||PROSPECTIVE|||||||
34141831|NCT04597021|||COHORT||PROSPECTIVE|||||||
34141832|NCT04014140|||COHORT||PROSPECTIVE|||||||
34141833|NCT01819558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141834|NCT05870917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141835|NCT05164601|||COHORT||PROSPECTIVE|||||||
34141836|NCT06279104|||CASE_ONLY||RETROSPECTIVE|||||||
33837547|NCT06134336|||COHORT||CROSS_SECTIONAL|||||||
34141837|NCT06606587|RANDOMIZED|PARALLEL||TREATMENT||NONE|When giving data to the statistician, he will not be told which group the data is in. The data will be changed to a and b to try to prevent bias.|The method to be applied to patients who met the inclusion criteria was determined randomly with the help of a computer.||||
34141838|NCT03158272|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel assignment will only in combination therapy arm.||||
34141839|NCT01151735|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34141840|NCT02367391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34141841|NCT06037785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34141842|NCT05752227|||OTHER||PROSPECTIVE|||||||
34141843|NCT05544045|||COHORT||PROSPECTIVE|||||||
34141844|NCT01738932|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141845|NCT03510468|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141846|NCT00792025|NON_RANDOMIZED|||TREATMENT||NONE||||||
33831088|NCT06544252|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||The present study employed a randomised, single-blind, cross-over trial design consisting of two experimental trials separated by a one-week washout period to minimise carryover effects, conducted under hot-humid (32°C, 65% RH) conditions.. The participants were randomised into two groups, each comprising six participants. Six participants were randomised to receive low glycaemic index, and the other six participants received high glycaemic index pre-exercise dietary interventions, followed by a cross-over with the opposing dietary intervention after one week.|t|f|f|f
33831089|NCT04198948|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33831090|NCT01114672|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831091|NCT00286962|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831092|NCT02992444|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831093|NCT04400344|||COHORT||CROSS_SECTIONAL|||||||
33831094|NCT00696553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33831095|NCT04547621|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831096|NCT00468130|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831097|NCT05722405|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831098|NCT05148702|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase III multicentre, open label, two-arm, parallel group, pragmatic, randomised controlled trial with internal pilot.||||
33831099|NCT01159483|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33831100|NCT02832284|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831101|NCT06480435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831102|NCT06544447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Dry Eye Disease With Meibomian Gland Dysfunction|t|t|f|t
33831103|NCT00001107||||PREVENTION||DOUBLE||||||
33831104|NCT03305887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831105|NCT01801982|||OTHER||PROSPECTIVE|||||||
33831106|NCT01692145||PARALLEL||TREATMENT||DOUBLE||||||
33831107|NCT06002646|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|This randomized double blinded clinical trial in which both the participants(patients) and the investigator don't know about which type of treatment groups will be applied.||t|f|t|f
33831108|NCT06397547|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33831109|NCT00532246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831110|NCT03801187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831111|NCT01240252|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33831112|NCT00579709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831113|NCT04134884|NA|SEQUENTIAL||TREATMENT||NONE||"The dose escalation phase will begin by enrolling 3 patients to the cohort 1 dose level. Patients will be observed for 28 days or one cycle of therapy for dose limiting toxicity (DLT).~If 0 of 3 patients experience a DLT, the study will proceed to cohort 2. If 1 patient experiences a DLT, 3 additional patients will be enrolled into cohort 1. If 1 of 6 patients experience a DLT, the study will proceed to the cohort 2 dose level. If \> 2/3 or 2/6 patients in cohort 1 experience DLT, we will de-escalate to cohort -1. Identical DLT evaluation and dose escalation/de-escalation decision rules will be used in subsequent cohorts. A total of 6 patients will be treated at the highest dose level achieved to ensure that 6 patients have been treated at the proposed maximum tolerated dose before proceeding to the expansion cohorts."||||
33831114|NCT04022577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831115|NCT02202109|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33831116|NCT01537445|||CASE_ONLY||PROSPECTIVE|||||||
33831117|NCT02609802|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33831118|NCT02476747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831119|NCT02360813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831120|NCT02880683|NA|SINGLE_GROUP||||NONE||||||
33831121|NCT04128800|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831122|NCT05714423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141847|NCT02636244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141848|NCT05899595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141849|NCT06539858|||CASE_CONTROL||PROSPECTIVE|||||||
34141850|NCT04216368|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141851|NCT04698785|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141852|NCT00182780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33837548|NCT01064700|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837549|NCT01749098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33837550|NCT00777075|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33837551|NCT05354882|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837552|NCT02180750|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33837553|NCT02036138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837554|NCT05094180|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141853|NCT05884112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participant and doctor||t|f|t|f
34141854|NCT03176472|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double-blind|Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study|t|t|t|t
34141855|NCT02704923|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141856|NCT00302276|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34141857|NCT04253899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141858|NCT05859373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141859|NCT05910034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141860|NCT03289221|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.||||
34141861|NCT00902018|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||10 patients on eltrombopag and 3 were then treated with romiplostim 10 healthy controls||||
34141862|NCT03068416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150853|NCT02662179|||OTHER||PROSPECTIVE|||||||
34150854|NCT01848366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141863|NCT06208189|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Data and statistical analysis will be performed by a researcher blinded to groups and participants' identities.|Randomized controlled, crossover, 3-way, clinical trial, following the SPIRIT and the TIDieR guidelines. After being considered eligible and agreeing to participate, participants will undergo anthropometrics assessment, familiarization sessions, and strength assessment before randomly carrying out 3 experimental (2 exercise and one control) periods, each composed of a total of \~48 hours, separated by at least 4 days. During the experimental periods diet will be strictly controlled and provided to the participants. Glycemic control will be assessed by a continuous glucose monitoring system throughout the experimental periods. The exercise sessions will be identical regarding total volume-load and session density, but proximity to failure in each set will be manipulated so effort will be different between the sessions. The control session will be identical in all procedures as the exercise sessions except that participants will remain sedentary.|f|f|f|t
34141864|NCT03054805|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141865|NCT00574665|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
34141866|NCT02337283|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34141867|NCT03174301|||OTHER||PROSPECTIVE|||||||
34141868|NCT00800319|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34141869|NCT00099242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34141870|NCT06605261|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34141871|NCT05192018|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141872|NCT03009708|NA|SINGLE_GROUP||OTHER||NONE||||||
34141873|NCT01598753|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34141874|NCT05517369|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141875|NCT03469830|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subjects and the analyser of the data were blinded.||t|f|f|f
34141876|NCT06608043|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34141877|NCT04486482|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141878|NCT06067048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141879|NCT01173029|||COHORT||PROSPECTIVE|||||||
34141880|NCT00587236|||COHORT||PROSPECTIVE|||||||
34141881|NCT05325216|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141882|NCT04644744|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34141883|NCT04243018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34141884|NCT00453115|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141885|NCT00246025|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34141886|NCT03596073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141887|NCT00164385|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34141888|NCT06606067|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Placebo|Duloxetine Placebo|t|f|t|f
34141889|NCT05976503|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34141890|NCT06606730|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141891|NCT03104972|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||'tDCS-tRNS' arm: a randomized controlled crossover study. 'tRNS-Sham' arm: a randomized controlled trial|t|f|f|f
34141892|NCT04199364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked.||t|f|f|f
34141893|NCT01632228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141894|NCT00966849|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34141895|NCT00324428|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141896|NCT00593853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141897|NCT00858260|||COHORT||PROSPECTIVE|||||||
34141898|NCT03830853|||COHORT||PROSPECTIVE|||||||
34141899|NCT04277117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Research staff responsible for data collection at the sites are blinded to the arm allocation of the participant. At follow-up time points, however, a set of questions is asked that are different for each of the three arms on food intake and preferences, and for arm 2, for the experience of delivery. To minimize influence of unblinding, we will actively cross-assign research staff to different locations for follow-up visits.|Community-based trial randomized on a 2:3:3 ratio|f|f|t|t
34141900|NCT04206475|RANDOMIZED|PARALLEL||TREATMENT||NONE||an intensive program specific to the training and re-adaptation of memory function in children versus standard rehabilitation||||
34141901|NCT06404372|NA|SINGLE_GROUP||TREATMENT||NONE|There will be a panel of the three evaluators who will be blinded. The treating physician, study staff, and office staff do not inform the panel of three blinded evaluators of whom they are viewing or of the chronological timepoint of the photograph.|||||
34141902|NCT06603064|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Participants, study staff, and the principal investigator will be blinded (masked) to participant assignment. The TMS coil to be used for this study is specifically designed to ensure participant and study staff blinding to condition.|This study will use a within-subject crossover design involving an \&#39;active\&#39; TMS arm and a \&#39;sham\&#39; (placebo) TMS arm. Each arm involves one visit (approx 2 hours each). Participants will complete both arms of the design.|t|t|t|f
34141903|NCT06065319|||COHORT||PROSPECTIVE|||||||
34141904|NCT00559468|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141905|NCT00310284|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141906|NCT00531076|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141907|NCT03794206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141908|NCT00387413|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34141909|NCT04666831|RANDOMIZED|PARALLEL||TREATMENT||NONE|Since this study uses a behavioural intervention (psychotherapy), neither the participant nor the care provider can be blinded. Outcomes are assessed using online questionnaires.|Participants will be randomly assigned to an intervention condition (AMI + CBT) or a waitlist control (WLC) group. The WLC group will crossover into the AMI + CBT group following a 3-month waitlist.||||
34141910|NCT00076336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141911|NCT02163720|||COHORT||PROSPECTIVE|||||||
34141912|NCT01238835|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141913|NCT05710211|NA|SINGLE_GROUP||OTHER||NONE||||||
34141914|NCT03396679|||COHORT||PROSPECTIVE|||||||
34141915|NCT03809715|||COHORT||PROSPECTIVE|||||||
33837555|NCT03640247|RANDOMIZED|PARALLEL||TREATMENT||NONE|All party or parties involved have knowledge of the interventions assigned to individual participants|||||
33837556|NCT01731964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141916|NCT04346108|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141917|NCT03233763|||COHORT||PROSPECTIVE|||||||
34141918|NCT01055665|||||RETROSPECTIVE|||||||
34141919|NCT04264312|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34141920|NCT03436875|||COHORT||PROSPECTIVE|||||||
34141921|NCT00097162||||TREATMENT||||||||
34141922|NCT03865667|||COHORT||PROSPECTIVE|||||||
33831123|NCT06547047|RANDOMIZED|PARALLEL||OTHER||SINGLE|In this study, both the participants and the outcomes assessor will be blinded to the group assignments to prevent bias. Participants will not be informed whether they are receiving SAQ training or regular training, and the outcomes assessor will also be unaware of the group assignments to ensure objective evaluation of the results. Care providers and investigators involved in administering the training sessions will know the group assignments due to the nature of the interventions.|This study employs a parallel design in which participants are randomly assigned to two independent groups: the intervention group and the control group. Throughout the study, participants in the intervention group will undergo a 12-week Speed, Agility, and Quickness (SAQ) training program, conducted three times a week, each session lasting 60 minutes, including 15-20 minutes for warm-up and cool-down. Participants in the control group will continue with their regular training regimen. Tests will be conducted before, during, and after the intervention to assess changes in physical, cognitive, and skill performance. This parallel design ensures a clear evaluation of the SAQ training effects and minimizes confounding variables due to differences in training time and content.|f|f|f|t
34141923|NCT05357664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831124|NCT05037253|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assigment||||
34141924|NCT02139735|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34141925|NCT04713904|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34141926|NCT03593928|||COHORT||PROSPECTIVE|||||||
34141927|NCT01229072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34141928|NCT03292419|NA|SINGLE_GROUP||TREATMENT||NONE|N0ne|Topography guided||||
34141929|NCT04709016|||COHORT||PROSPECTIVE|||||||
34141930|NCT03150576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141931|NCT00061074|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34141932|NCT05055258|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34141933|NCT01327274|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141934|NCT06190938|||OTHER||CROSS_SECTIONAL|||||||
34141935|NCT05024929|||COHORT||PROSPECTIVE|||||||
34141936|NCT01389401|||COHORT||PROSPECTIVE|||||||
34141937|NCT03159689|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized Clinical Trial||||
34141938|NCT02129478|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141939|NCT00273325|||COHORT||PROSPECTIVE|||||||
34141940|NCT00387374|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34141941|NCT05618730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Each patient with Dry Eye Disease is tested with EXP-TC tacrolimus releasing punctal plug in one eye. Both eyes will receive standard of care of 0.15% sodium hyaluronate (Hyabak, Théa laboratories).||||
34141942|NCT02390414|||COHORT||PROSPECTIVE|||||||
34141943|NCT04607941|||CASE_CONTROL||PROSPECTIVE|||||||
34141944|NCT00929773|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141945|NCT02502604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141946|NCT06242639|||OTHER||RETROSPECTIVE|||||||
34141947|NCT04214483|||CASE_ONLY||PROSPECTIVE|||||||
33831125|NCT06283498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831126|NCT03893006|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33831127|NCT05744102|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831128|NCT02828150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831129|NCT03324113|NA|SEQUENTIAL||TREATMENT||NONE||||||
33831130|NCT01542398|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831131|NCT02107742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831132|NCT03170843|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Each participant will be under the general anesthesia without knowing which group is assigned to.|The experimental group will be using the plastic wound retractor, while the control group will use a conventional surgical pad for wound protection.|t|f|f|f
33831133|NCT02325830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||With crossover for sham procedure patients who are eligible at time of 12 month follow up.|t|f|f|t
33831134|NCT00107978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831135|NCT01395498|||COHORT||PROSPECTIVE|||||||
33831136|NCT03399838|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||randomised trial comparing 2 drugs (midazolam, dexmedetomidine)|t|f|t|t
33831137|NCT05455372|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831138|NCT02776098|||COHORT||PROSPECTIVE|||||||
33831139|NCT00004478||||TREATMENT||||||||
33831140|NCT00280683|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831141|NCT03211728|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Candidate for arthroscopic ACL reconstruction are divided into two groups of pregabalin and placebo with 48 patients in each group. The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose and a placebo is administered in control group.|t|t|t|t
34141948|NCT04707989|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34141949|NCT03350139|||COHORT||PROSPECTIVE|||||||
34141950|NCT02144506|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34141951|NCT01504633|RANDOMIZED|FACTORIAL||||QUADRUPLE|||t|t|t|t
34141952|NCT00445848|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141953|NCT02608775|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34141954|NCT01867840|||COHORT|||||||||
34141955|NCT04882644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141956|NCT03197428|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34141957|NCT02111135|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141958|NCT06607250|||COHORT||PROSPECTIVE|||||||
34141959|NCT02088073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34141960|NCT04058808|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141961|NCT04538274|RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective, multicentre, randomized controlled trial||||
34141962|NCT03436641|||COHORT||PROSPECTIVE|||||||
33831142|NCT05028036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831143|NCT00494026|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831144|NCT03532399|||CASE_ONLY||PROSPECTIVE|||||||
33831145|NCT01539408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831146|NCT04947462|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33831147|NCT00934700|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831148|NCT00197106|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831149|NCT03497156|||CASE_ONLY||PROSPECTIVE|||||||
33831150|NCT01979263|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831151|NCT00054678|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831152|NCT00889967|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831153|NCT00890890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831154|NCT01615172|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831155|NCT00264563|||COHORT||PROSPECTIVE|||||||
33831156|NCT06224010|||COHORT||PROSPECTIVE|||||||
33831157|NCT04150471|||COHORT||PROSPECTIVE|||||||
33831158|NCT03493568|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Treatments~1. Genvoya 150Mg-150Mg-200Mg-10Mg Tablet ( 1 pill every 24 hours)~2. Dolutegravir 50 mg (1 pill every 24 hours) plus one Reverse Trascriptase Inhibitor (at label dose)"||||
33831159|NCT04038697|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831160|NCT05936918|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Data collector|The study was primarily a randomized controlled study in which patients were randomly assigned to each group.|t|f|f|t
33831161|NCT03598881|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33831162|NCT00704171|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831163|NCT05034536|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831164|NCT05272709|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33831165|NCT01663558|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831166|NCT04657601|||COHORT||PROSPECTIVE|||||||
33831167|NCT01582906|||COHORT||PROSPECTIVE|||||||
33831168|NCT04618380|||COHORT||PROSPECTIVE|||||||
33831169|NCT03567135|||CASE_CONTROL||RETROSPECTIVE|||||||
33831170|NCT00687947|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33831171|NCT01482429|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33831172|NCT03732781|NA|SINGLE_GROUP||PREVENTION||NONE||3+3 Dose escalation with expansion cohort||||
33831173|NCT00277368|||COHORT||CROSS_SECTIONAL|||||||
33831174|NCT05395026|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831175|NCT04374383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33831176|NCT03448705|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study is single-blind (blinded for the participant).|According to the objective, as well as the primary endpoints of the study, this is a Phase I study, open-label to the route of administration, single-blind to the ID doses, randomised, active-controlled that will be conducted in three parallel groups. Three visits will be performed in the study: on Day 0, Day 7-9 and Day 21-28. Pre-vaccination and post-vaccination serum samples are to be taken on Day 0 and Day 21-28. Adverse events will be documented between the enrollment and Day 21-28.|t|f|f|f
33831177|NCT06007105|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a four-country pilot using a before-and-after study design to measure change in quality of life using the 26-item WHOQOL-BREF in participants with lived experience of psychosis who are offered the SUCCEED intervention (including case management, peer support and livelihoods activities) over a four-month follow-up period.||||
33831178|NCT04387045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33831179|NCT04288206|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|'study drug' will be prepared by a participating pharmacist and labeled with a study identification number. The drug will be otherwise not labeled with regard to the arm of the study. This will be delivered to the operating room and administered to the patient. The patient will be entered into a spreadsheet with the study identification number to be used later to evaluate the data. The enrolling/consenting surgeon, and the patient and consenting family member, will be masked to the arm of the study throughout.|intervention arm of intravenous cefazolin at the time of surgery (standard of care) vs placebo arm of intravenous normal saline at the time of surgery|t|t|t|f
33831180|NCT03201900|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831181|NCT03792464|||COHORT||PROSPECTIVE|||||||
33831182|NCT01885468|||CASE_ONLY||PROSPECTIVE|||||||
33831183|NCT03757078|||COHORT||PROSPECTIVE|||||||
33831184|NCT01799655|||COHORT||PROSPECTIVE|||||||
33831185|NCT05749458|||CASE_CONTROL||RETROSPECTIVE|||||||
33831186|NCT04069533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141963|NCT06605235|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34141964|NCT03580642|RANDOMIZED|PARALLEL||PREVENTION||NONE||We will perform a randomised, pilot, prospective, parallel group, open, and unicentric Clinical Trial (RCT) with stroke survivors and their caregivers at Cruces University Hospital.||||
34141965|NCT05925283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34141966|NCT00996281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150855|NCT03672786|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831187|NCT01648036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831188|NCT05174598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831189|NCT02803593|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831190|NCT04040049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831191|NCT03094962|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831192|NCT02757313|RANDOMIZED|SINGLE_GROUP||OTHER||QUADRUPLE|||t|t|t|t
33831193|NCT04147559|||COHORT||CROSS_SECTIONAL|||||||
33831194|NCT03937713|RANDOMIZED|PARALLEL||TREATMENT||NONE||A randomized comparator 1:1 to explore the comparative effectiveness of combination treatment of behavioral and pharmacological interventions with behavioral therapy alone in improving sleep quality of life, Veterans with PTSD and complex insomnia.||||
33831195|NCT00639977|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831196|NCT01582373|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831197|NCT03051893|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831198|NCT01491906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831199|NCT04515056|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34150856|NCT05381285|||COHORT||RETROSPECTIVE|||||||
34141967|NCT05084560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Sequential, ascending dose design, double-blind, placebo controlled.~Part A: single ascending dose design with 6 dosing levels. Part B: multiple ascending dose design with 4 dosing levels."|t|t|t|t
34141968|NCT04657380|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|"Randomisation 1/1 comparing an early intervention program standard and an extended program within a specialized team will be carried out by IWRS (ENNOV Clinical solution) using the swapped block method. A stratification will be carried out on the case-manager. There is no blinding for the patient or the case-manager. Nevertheless, the evaluation of the comparative outcomes between the 2 groups will be carried out by a psychiatrist who is not involved in the patient's follow-up and who will be blinded to the patient's group."|Our hypothesis is that the use of a mobile case-management application for planning and monitoring individualised care objectives, co-designed with patients, their carers, and health professionals, improves the functioning of patients managed for a first psychotic episode, compared to usual case management practices|f|f|f|t
34141969|NCT00612014|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34141970|NCT02046850|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34141971|NCT00478166|||COHORT||CROSS_SECTIONAL|||||||
34141972|NCT04384445|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind: neither subjects nor the investigators who are assessing the patient are award of the treatment assignment until the end of the study.|The trial has two groups, each with 10 subjects (n=20). All eligible study subjects will be randomized, double blinded, to either the treatment group or placebo group.|t|f|t|f
34141973|NCT06299982|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141974|NCT01919047|||COHORT||PROSPECTIVE|||||||
34141975|NCT06607562|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34141976|NCT00929188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34141977|NCT00068250|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34141978|NCT05013918|||CASE_ONLY||PROSPECTIVE|||||||
34141979|NCT04059523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141980|NCT03094650|NA|SINGLE_GROUP||TREATMENT||||||||
34141981|NCT01766492|||COHORT||PROSPECTIVE|||||||
34141982|NCT04288258|NA|SINGLE_GROUP||TREATMENT||NONE||case-control crossover||||
34141983|NCT05643183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34141984|NCT01185964|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141985|NCT01048294|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141986|NCT03431818|||CASE_CROSSOVER||PROSPECTIVE|||||||
34141987|NCT02089464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34141988|NCT04839471|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141989|NCT00342277|||COHORT||PROSPECTIVE|||||||
34141990|NCT06606353|||OTHER||PROSPECTIVE|||||||
34141991|NCT02147223|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34141992|NCT01394224|RANDOMIZED|CROSSOVER||||NONE||||||
34141993|NCT03964246|NON_RANDOMIZED|PARALLEL||OTHER||NONE||This non-randomized feasibility study was designed to collect pilot data to establish feasibility for a future randomized controlled trial (RCT) of manualized compassion meditation (CM) group intervention for older Veterans identified through VA Primary Care clinics as having clinically significant psychological distress. The plan was to enroll 20 to 30 participants in a 10-week CM training group (with 8-10 participants in each group). As part of establishing feasibility for a subsequent large-scale RCT, the investigators also planned to enroll up to 10 additional participants in a 10-session psychoeducational group focused on topics in healthy aging. The intent for the latter was to examine the feasibility and appropriateness of employing this as a control condition in a follow-up RCT.||||
34141994|NCT04686760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34141995|NCT01037049|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34141996|NCT03490422|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141997|NCT06489704|NA|SINGLE_GROUP||OTHER||NONE||Each highlander with HAPH will perform a echocardiography at high altitude (HA, 3200 m) and day 2 and day 7 at low altitude (LA, 760 m) according to a prospective study design||||
34141998|NCT01967823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34141999|NCT04126265|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142000|NCT03257163|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142001|NCT00832130|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142002|NCT05477173|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142003|NCT01860157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142004|NCT01778049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34142005|NCT01981863|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34142006|NCT06378749|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34142007|NCT02366117|RANDOMIZED|PARALLEL||||NONE||||||
34142008|NCT04773561|NON_RANDOMIZED|PARALLEL||OTHER||NONE||"age-stratified sample technique (2 age groups: 24-30 years and 31-37 years)~,twin pregnancy:singleton pregnancy:healthy non-pregnant women = 1: 2 : 2"||||
34142009|NCT04118036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142010|NCT00983515|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142011|NCT04259788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142012|NCT03090386|||CASE_ONLY||PROSPECTIVE|||||||
34142013|NCT03292939|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142014|NCT05949515|||CASE_CONTROL||RETROSPECTIVE|||||||
34142015|NCT06353399|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study involves an investigator (surgeon) and an examiner. The examiner measures the clinical parameters before and after surgery and is blinded to the surgical procedure and if intra-marrow penetrations are utilized.||t|f|t|t
34142016|NCT01203436|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142017|NCT06607198|||COHORT||PROSPECTIVE|||||||
34142018|NCT03385707|||CASE_ONLY||CROSS_SECTIONAL|||||||
33831200|NCT05032846|RANDOMIZED|PARALLEL||TREATMENT||NONE|Non-blinded study|Non-blinded randomised clinical trial||||
34142019|NCT05854576|||COHORT||PROSPECTIVE|||||||
34142020|NCT02779907|||CASE_ONLY||PROSPECTIVE|||||||
34150857|NCT02098811|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
34150858|NCT03204422|||OTHER||CROSS_SECTIONAL|||||||
34150859|NCT00003711||||TREATMENT||||||||
34150860|NCT01515046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150861|NCT00989781|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34142021|NCT06605911|RANDOMIZED|PARALLEL||TREATMENT||NONE||thirty patients with oral lichen planus were divided into three groups, 10 patients each: Group A: ten patients with OLP were received topical triamcinolone acetonide. Group B: ten patients with OLP were received topical curcumin. Group C: ten patients with oral lichen planus were received topical triamcinolone acetonide combiend with topical curcumin. For six weeks. Each patient was examined at baseline, 2, weeks and 1 and 3months of therapy. Pain was scored using the visual analogue scale. Salivary level of interleukin 1 were estimated at baseline, 1 and3 months' evaluation periods.||||
34142022|NCT02003066|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142023|NCT06408675|||OTHER||CROSS_SECTIONAL|||||||
34142024|NCT01069861|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142025|NCT03457506|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All included patients will have two PET scans, one on the conventional PET (Ingenuity TF, Philips Healthcare) and one on the digital PET (Vereos, Philips Healthcare). The order of the two PET scans will differ per patient.||||
34142026|NCT02676336|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34142027|NCT04571268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34142028|NCT01187368|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.||||
34142029|NCT00607711|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142030|NCT03087942|NA|PARALLEL||TREATMENT||NONE||||||
34142031|NCT05664295|||CASE_CONTROL||PROSPECTIVE|||||||
34142032|NCT06462534|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34142033|NCT06139562|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142034|NCT04830904|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34142035|NCT00309699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142036|NCT01041300|NA|SINGLE_GROUP||||NONE||||||
34142037|NCT03037099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142038|NCT06608797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142039|NCT00838825|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142040|NCT01711229|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142041|NCT03989050|||OTHER||PROSPECTIVE|||||||
34142042|NCT04302701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34142043|NCT03354481|NA|SINGLE_GROUP||OTHER||NONE||||||
34142044|NCT02069730|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142045|NCT00686322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142046|NCT06606834|||OTHER||CROSS_SECTIONAL|||||||
34142047|NCT02072135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142048|NCT02593422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34142049|NCT05039671|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34142050|NCT05735366|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34142051|NCT06167005|||COHORT||RETROSPECTIVE|||||||
34142052|NCT00177567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142053|NCT05028517|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This study involves a three arm randomized controlled trial with equal allocation to the following conditions: (1) FMF Connect + coaching, (2) FMF Connect alone, and (3) waitlist control. Quantitative survey data will be collected at three timepoints: baseline (T1), 6-weeks (T2), and 12-weeks (T3).|f|f|f|t
34142054|NCT03217084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142055|NCT01846195|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142056|NCT03692494|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142057|NCT00283426|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142058|NCT02504112|||COHORT||CROSS_SECTIONAL|||||||
34142059|NCT05922072|RANDOMIZED|PARALLEL||PREVENTION||NONE||Total 120 patients will be randomly allocated into two groups using computerized generated numbers (60 in each group). Group A with 6,4 and 2 hours NPO for solids/ formula milk, breast milk and clear fluid respectively. Group B with 6,4 and 1-hour NPO for solids/ formula milk, breast milk and clear fluid respectively||||
34142060|NCT05409859|||COHORT||PROSPECTIVE|||||||
34142061|NCT01445522|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142062|NCT02396771|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142063|NCT04529369|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34142064|NCT02438956|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34142065|NCT00596245|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34142066|NCT05362227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142067|NCT04003480|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142068|NCT00964340|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34142069|NCT03655327|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34142070|NCT00974688|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|t|f|f
34142071|NCT03281330|||COHORT||PROSPECTIVE|||||||
34142072|NCT03120858|||OTHER||PROSPECTIVE|||||||
34142073|NCT06093178|||COHORT||PROSPECTIVE|||||||
34142074|NCT00597363|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142075|NCT02728960|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34142076|NCT04443517|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34142077|NCT03838991|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142078|NCT05473351|||COHORT||PROSPECTIVE|||||||
34142079|NCT04304170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||For each subject enrolled in the trial, the planned length of the trial was 44 days composed of a 14 day period at the beginning of the study without taking the trial product and a 30 day period when it was taken. The trial included three visits to the CEN Experimental Centre at D-14, D0 and D30. The product was taken from D1 onwards, the day after the enrolment visit.|t|t|t|t
34142080|NCT05130606|RANDOMIZED|PARALLEL||PREVENTION||NONE||Hybrid Type 1 research design (efficacy study). Two arm randomized controlled trial and Implementation Focused Process Evaluation||||
34142081|NCT01922063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142082|NCT01749592|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142083|NCT05712304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142084|NCT03668054|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, multicenter study for evaluating the safety and clinical effectiveness of intravitreal bevacizumab||||
34142085|NCT04303143|||OTHER||OTHER|||||||
34142086|NCT04244864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142087|NCT04579302|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34142088|NCT02546440|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142089|NCT02391467|||COHORT||PROSPECTIVE|||||||
34142090|NCT05530044|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|online|RCT|t|f|f|t
34142091|NCT03385265|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142092|NCT00054951|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142093|NCT02115750|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142094|NCT03589391|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|||t|t|f|f
34142095|NCT01463930|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142096|NCT02889679|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142097|NCT03817333|||CASE_CONTROL||PROSPECTIVE|||||||
34142098|NCT03264105|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The primary assessors will not be blind to intervention/control material due to different in material shade. However, the other assessors will be blind from the type of material they will evaluate the retention rate of the restoration; it will not be allowed amongst the assessor to exchange any information throughout the entire study period.||f|f|f|t
34142099|NCT00989521|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34142100|NCT01905488|||||PROSPECTIVE|||||||
34142101|NCT06105216|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34142102|NCT02460913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142103|NCT05763446|||COHORT||OTHER|||||||
34142104|NCT04111016|||COHORT||PROSPECTIVE|||||||
34142105|NCT00481715|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34142106|NCT01704729|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142107|NCT05220280|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label trial|||||
34142108|NCT00328653|RANDOMIZED|PARALLEL||||DOUBLE||||||
34142109|NCT05941520|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34142110|NCT05608525|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and outcome assessor will be blinded to the tDCS stimulation protocol that they will be receiving.|"Participants will be randomized to receive one of the followings:~* Group 1 will receive 1 mA anodal tDCS stimulation to the ipsilesional M1 of cortical representation of the affected upper limb;~* Group 2 to receive 1mA anodal tDCS to the contralesional premotor cortex;~* Group 3 to receive sham tDCS stimulation with anode placed over the scalp area corresponding to ipsilesional M1."|t|f|f|t
34142111|NCT04289077|||COHORT||CROSS_SECTIONAL|||||||
34142112|NCT05889442|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34142113|NCT03114124|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Variable block sizes will be used to improve the blinding of the clinical team. This information will then be used to design a fully-powered randomized study to compare these two arms. Patients will be randomly assigned to study arms. The project biostatistician and team will generate a set of envelopes which contain the random assignments for each patient. Once a patient has consented to participate, the next envelope will be opened for that patient and the catheter assignment will be revealed. This will maintain the blinding of the clinical team.|Standard ablation catheter vs MIFI catheter|f|f|t|f
34142114|NCT04152551|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||"25 adults with type 1 OI and diagnosed hearing loss will be treated with oral risedronate.~25 adults with type 1 OI will be enrolled into the control arm."||||
34142115|NCT02508740|RANDOMIZED|PARALLEL||||NONE||||||
34142116|NCT00871117|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142117|NCT01090388|||COHORT||CROSS_SECTIONAL|||||||
34142118|NCT06245057|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142119|NCT04883710|||COHORT||PROSPECTIVE|||||||
34142120|NCT02477735|||CASE_CONTROL||PROSPECTIVE|||||||
34142121|NCT03249935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142122|NCT05973981|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|f|f|t
34142123|NCT02242981|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142124|NCT04591548|||CASE_CONTROL||PROSPECTIVE|||||||
34142125|NCT03425721|||COHORT||PROSPECTIVE|||||||
34142126|NCT05239455|||CASE_ONLY||PROSPECTIVE|||||||
34142127|NCT03449693|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two groups: Intervention group and control group. The intervention group will receive institutional care protocol plus oral supplementation with magnesium. The control group will receive institutional care protocol only.||||
34142128|NCT03835884|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|No masking|||||
34142129|NCT06608992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|During the trial, patients will not be aware of which hemostatic method corresponds to their assigned group. Except for the operating surgeon, the perioperative assessment of various parameters for the patients will be conducted by a medical team that is also unaware of the intraoperative hemostatic method used for the patient. Thus, the study achieves both patient blinding and assessor blinding, except for the surgeon. Unblinding will occur after the finalization of the statistical analysis plan, data audit report, and database lock, at which point the group assignment corresponding to the treatment group will be revealed. In emergency situations, if the researcher believes that revealing the intraoperative method used would benefit the handling of adverse events, emergency unblinding may occur.|According to the inclusion/exclusion criteria for study participants, patients undergoing unilateral primary total knee arthroplasty will be screened. After obtaining informed consent from the patients, computer-based randomization will be conducted. The patients included in the study will be randomly assigned to either the test group (using SURGICEL® Powder ) or the control group (not using SURGICEL® Powder ).|t|f|t|f
34142130|NCT02970006|NA|SINGLE_GROUP||OTHER||NONE||||||
34142131|NCT05234424|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The participants are aware of the intervention used, but not aware of the order of flow rate tests.|After induction of general anesthesia, confirmation of adequate face mask ventilation, and successful arterial cannulation, participants will be assigned to THRIVE flow rates in a randomized order.|t|f|f|f
34142132|NCT00262093|||CASE_CONTROL||OTHER|||||||
34142133|NCT02241057|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34142134|NCT05540769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142135|NCT01335750|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34142136|NCT00539513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142137|NCT06223789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831201|NCT04431752|||CASE_CONTROL||PROSPECTIVE|||||||
33831202|NCT02066610|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33831203|NCT04587583|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831204|NCT00639769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831205|NCT04574232|NA|SINGLE_GROUP||SCREENING||NONE||||||
33831206|NCT05553223|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The investigator who will analyze the primary outcome data will be blinded to the participant and condition.|The study will be performed using a prospective randomized crossover design with subjects acting as their own control.|f|f|f|t
33831207|NCT02240797|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831208|NCT01076309|||CASE_CONTROL||PROSPECTIVE|||||||
33831209|NCT03104283|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831210|NCT05245591|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831211|NCT00945399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831212|NCT06282640|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142138|NCT03591614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142139|NCT02844335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142140|NCT05670548|||CASE_CONTROL||PROSPECTIVE|||||||
34142141|NCT05291975|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142142|NCT02125903|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142143|NCT02120521|||CASE_ONLY||PROSPECTIVE|||||||
34142144|NCT02521233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142145|NCT04909359|||OTHER||PROSPECTIVE|||||||
34142146|NCT01129882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142147|NCT04982406|||COHORT||PROSPECTIVE|||||||
34142148|NCT02208453|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
34142149|NCT00589056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142150|NCT03099941|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142151|NCT06019247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Our pilot RCT will examine both the implementation and effectiveness of IPS. We will use the Dynamic Adaptation Process model9 to adapt and implement IPS as well as to assess fidelity and identify barriers and facilitators. Then we will enroll 120 PSMI drawn from CAISAME-EP, which covers marginalized and poor communities. The outcomes of this pilot RCT will include employment, financial well-being, and health (i.e., symptoms and functioning). We will also quantify the cost of adapting and delivering IPS in this context. We will follow NIH guidelines on rigor and transparency to ensure strict application of the scientific method. Accordingly, we provide below detailed information regarding adaptation processes, recruitment, inclusion and exclusion criteria, outcomes and measures, and data analysis.||||
34142152|NCT01338610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142153|NCT04904796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142154|NCT01382121|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142155|NCT04095663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142156|NCT00928278|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34142157|NCT00002650|RANDOMIZED|||PREVENTION||||||||
34142158|NCT02753621|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34142159|NCT02280824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142160|NCT04920721|||CASE_CONTROL||RETROSPECTIVE|||||||
34142161|NCT04553653|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Participants will be masked. Investigators and care providers are not masked due to the obvious design and logistics challenges.|This will be a before-after study. Baseline data capturing care and the outcomes of patients presenting with acute severe hypertension will be collected. A checklist will be developed and implemented and a post-implementation data collection will be conducted using the same tool as prior to the intervention.|t|f|f|f
34142162|NCT00067847|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142163|NCT03172091|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142164|NCT02670707|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142165|NCT01245738|||COHORT||PROSPECTIVE|||||||
34142166|NCT05517070|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34142167|NCT04444310|||COHORT||PROSPECTIVE|||||||
33831213|NCT03512197|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831214|NCT02995382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142168|NCT01395121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142169|NCT02838901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142170|NCT04621214|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142171|NCT04732858|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34142172|NCT05945134|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142173|NCT00825890|||COHORT||PROSPECTIVE|||||||
33831215|NCT01936324|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831216|NCT01278706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831217|NCT06413264|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Only patients will be blinded about the allocations.|Single blinded randomised controlled study where only the patient is blinded|t|f|f|f
33831218|NCT02820064|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831219|NCT00228098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831220|NCT00006010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831221|NCT05085561|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831222|NCT01074697|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33831223|NCT03954769|||CASE_ONLY||PROSPECTIVE|||||||
33831224|NCT03587337|||OTHER||PROSPECTIVE|||||||
33831225|NCT02139462|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33831226|NCT00884416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831227|NCT01144962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831228|NCT06156917|||COHORT||PROSPECTIVE|||||||
33831229|NCT05184777|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective unicentric study||||
33831230|NCT03297398|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33837557|NCT01267773|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33837558|NCT03509389|||COHORT||PROSPECTIVE|||||||
33837559|NCT01040169|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837560|NCT02761798|||COHORT||PROSPECTIVE|||||||
34142174|NCT01133275|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142175|NCT01230515|||COHORT||PROSPECTIVE|||||||
33831231|NCT04157218|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized to one of three intervention protocols using Excel 2017 (Microsoft, Redmond, WA, USA):~1. Treatmnet with HIFU and immediately after, the insertion of lifting threads.~2. Treatmnet with HIFU and 6 months later, the insertion of lifting threads.~3. Treatmnet with lifting threads alone ."||||
33831232|NCT06412536|||COHORT||PROSPECTIVE|||||||
33831233|NCT04380883|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831234|NCT02813083|||COHORT||PROSPECTIVE|||||||
33831235|NCT00619268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831236|NCT01284712|||||PROSPECTIVE|||||||
33831237|NCT02281500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831238|NCT06546228|||COHORT||RETROSPECTIVE|||||||
33831239|NCT02163707|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831240|NCT01709396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831241|NCT00445575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831242|NCT00796627|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33831243|NCT06198699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33831244|NCT03089736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|All patients who referred to the Pain and Rehabilitation Centre at the University Hospital, asked about participation in the study. Of those who agreed to participate every second patient were distributed to the control group versus intervention group.|||||
33831245|NCT04016272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831246|NCT04633954|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33831247|NCT00226122|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33831248|NCT01536197|||COHORT||PROSPECTIVE|||||||
33831249|NCT04115267|||COHORT||PROSPECTIVE|||||||
33831250|NCT00047749|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
33831251|NCT02861196|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831252|NCT05815823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831253|NCT05029011|||CASE_ONLY||OTHER|||||||
33831254|NCT03603847|||CASE_ONLY||PROSPECTIVE|||||||
33831255|NCT04378374|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The participants and investigators are blinded and could not distinguish the food formulated with different flours. The taste and flavour in all treatments were similar due to added flavourings.||t|f|t|f
33831256|NCT01507077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831257|NCT01687946|||CASE_CONTROL||PROSPECTIVE|||||||
33831258|NCT03533777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Placement of the IV catheter will occur after the subject is placed under general anesthesia and will be removed immediately upon arrival in the post-anesthesia care unit (PACU). Thus, the study participant will be unaware of which study arm they were in. An anesthesiologist member of the research team will place the IV immediately after randomization in the operating room. They will have a drape obscuring the view from the clinical anesthesia provider and will cover the IV with an opaque towel after insertion. Thus, the care provider will not have knowledge of which treatment arm their patient is randomized to. Intraoperative data will be gathered by the anesthesia care provider and postoperative questionnaire data will be gathered by a research coordinator member of the study team. The anesthesiologist who placed the study IV will not gather or have access to any of the subsequent data gathered on the study subject.|Study participants will be randomized to either antegrade or retrograde IV catheter placement. Although 267 patients were consented/enrolled in the study, only 230 patients were ultimately randomized. 37 patients were withdrawn from the study prior to randomization because they no longer met inclusion/exclusion criteria.|t|t|f|t
33831259|NCT01013740|RANDOMIZED|CROSSOVER||TREATMENT||NONE||After disease progression in the Randomized Phase (in which participants received lapatinib plus vinorelbine), participants were given the option of crossing over to the alternative treatment arm (lapatinib plus capecitabine), and continuing in a post-progression Cross-over Phase.||||
33831260|NCT05530330|||COHORT||PROSPECTIVE|||||||
33831261|NCT02121327|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33831262|NCT00867737|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831263|NCT05445167|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831264|NCT05614323|||COHORT||PROSPECTIVE|||||||
33831265|NCT03837236|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831266|NCT01962311|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831267|NCT02182232|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831268|NCT00984438|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142176|NCT00673023|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33831269|NCT02819219|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33831270|NCT05054465|NA|SINGLE_GROUP||TREATMENT||NONE||A national, multicenter, phase II clinical trial to evaluate the benefit of pre-transplant (alloSCT) consolidation (cons.) and post-alloSCT maintenance with navitoclax (NAV) and venetoclax (VEN) in patients with T-ALL, LBL and MPAL T/M in CR1 designated for alloSCT. Pre-alloSCT cons. with VEN and NAV: Patients will be treated with VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al. (doi: 10.1158/2159-8290.CD-20-1465) for two 28 day cycles. Following 2 cycles re-staging marrow including MRD assessment and imaging will be followed by alloSCT according to local protocol. Post-alloSCT maintenance with VEN and NAV: Within 90 days from alloSCT patients will be started on VEN and NAV maintenance. For post-alloSCT maintenance a dose escalation scheme based on the BOIN design will be applied with a maximal dose of VEN 400 mg QD and NAV 50mg QD according to the RP2D presented by Pullarkat et al.||||
33831271|NCT01183715|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33831272|NCT01811498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831273|NCT00715689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831274|NCT01430936|||||PROSPECTIVE|||||||
33831275|NCT03981497|||COHORT||CROSS_SECTIONAL|||||||
33831276|NCT03526978|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33831277|NCT05650541|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||There is a study group that uses the device \& the data is monitored and sent to the physician. The second group is a control group that will not use the device and will continue with normal standard of care.|f|f|f|t
33831278|NCT02324478|||COHORT||PROSPECTIVE|||||||
33831279|NCT05840562|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142177|NCT03426475|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Blinded study nurses with respect of primary outcome.|||||
34142178|NCT00267605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142179|NCT02128815|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142180|NCT03887260|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142181|NCT06239246|||COHORT||PROSPECTIVE|||||||
34142182|NCT00504504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142183|NCT03023254|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142184|NCT00712621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142185|NCT06605521|||CASE_CONTROL||PROSPECTIVE|||||||
34142186|NCT01666639|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142187|NCT06189703|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The study is double-blind, meaning participants, parents/legal guardians/caregivers, the investigator and all study personnel are blinded. Participants will be randomized in a 1:1 allocation ratio to receive active (Group A) or sham (Group B) tRNS. Randomization will be stratified by age, gender, and baseline ADHD-RS score. Three staff members with no contact with participants will generate balanced random samples throughout the course of the study, using Smith's randomization algorithm based on the variance minimization procedure, and program the respective device to discharge sham/active stimulation according to each participant's allocation.|Randomized, double-blind, sham-controlled between groups|t|t|t|f
34142188|NCT03880448|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The subjects were randomly assigned to the treatment groups in ascending order according to a balanced distribution system through a computer generated random number design table (random block design). Randomization was balanced according to the smoking habit at the initial visit to ensure homogeneity in the treatment groups.~The method of allocation concealment selected were opaque envelopes. The research coordinator was responsible for the randomization and patient allocation."||t|f|t|t
34142189|NCT05285475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will be kept blind from the group allocation of the participants.|There will be two parallel groups in the study.|f|f|f|t
34142190|NCT05318612|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, multicenter, open-label randomized controlled trial||||
34142191|NCT04265040|||OTHER||PROSPECTIVE|||||||
34142192|NCT05579249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831280|NCT04550559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142193|NCT04580706|||COHORT||PROSPECTIVE|||||||
34142194|NCT01778816|||COHORT||RETROSPECTIVE|||||||
34142195|NCT06076096|||COHORT||RETROSPECTIVE|||||||
34142196|NCT05816642|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34142197|NCT00856141|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831281|NCT03379558|||COHORT||PROSPECTIVE|||||||
34142198|NCT05699252|RANDOMIZED|PARALLEL||OTHER||SINGLE||A randomized, 4-group parallel design, 264-subject clinical trial to identify predictive markers that determine who benefits most from two complementary and integrative health (CIH) treatments (Hypnotic Cognitive Therapy \[HYP-CT\] and Mindfulness-Based Cognitive Therapy \[MBCT\]) vs. the current gold standard non-pharmacological treatment (Cognitive Behavioral Therapy, or CBT) vs. usual care (UC). This aim will be addressed in the context of a clinical trial in which participants with chronic pain will be randomized to one of the three active chronic pain treatments or UC.|f|f|f|t
34142199|NCT03336372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142200|NCT02695823|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142201|NCT01403935|||COHORT||PROSPECTIVE|||||||
34142202|NCT04899375|NA|SINGLE_GROUP||TREATMENT||NONE||Randomized Crossover Design||||
34142203|NCT04744389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142204|NCT05533463|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm study of HRS-4642||||
34142205|NCT06204861|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142206|NCT03887520|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a multi-center cross-sectional epidemiological study to estimate the prevalence (%) of patients with elevated Lp(a) in patients with established CVD defined by their medical history. One study visit is planned for data collection. Relevant medical history and laboratory values for LDL-cholesterol (LDL-C) and Lp(a) within a past pre-specified period will be collected retrospectively. In case laboratory data are not available, blood sampling will be performed.||||
33831282|NCT00752245|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142207|NCT01571128|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142208|NCT00416156|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34142209|NCT00579241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142210|NCT02614807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142211|NCT00383734|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34149882|NCT04345718|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multi-site open-label randomized comparative effectiveness trial of a 28-day formulation of XR-BUP versus TAU for hospitalized patients with OUD agreeing to MOUD. Approximately 4-5 sites (hospitals) with existing ACSs experienced in hospital-initiated MOUD will be selected. Identification of patients with OUD will occur as per each site's local practice. Approximately 314 hospitalized patients with OUD who were not receiving prescribed MOUD for at least 14 days prior to hospitalization and are willing to start MOUD including buprenorphine will be randomized 1:1 to two different strategies. After baseline assessments are performed, eligible participants will be randomized in a 1:1 ratio to XR-BUP or TAU||||
34149883|NCT03897530|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33831283|NCT02411617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831284|NCT02142634|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831285|NCT04721899|||CASE_ONLY||PROSPECTIVE|||||||
33831286|NCT05998330|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33831287|NCT00002722|RANDOMIZED|||TREATMENT||||||||
33831288|NCT04224454|||COHORT||CROSS_SECTIONAL|||||||
33831289|NCT04813432|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33831290|NCT00003477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831291|NCT01388062|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33831292|NCT02859064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831293|NCT02462343|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|f|t
33831294|NCT03014908|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831295|NCT00135577|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831296|NCT00723385|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33831297|NCT05473936|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142212|NCT05526144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Study subjects will be blinded whether they will receive Synthroid or placebo. All subjects will be coded serially with no identifiers used. The study coordinator will be the only individual to have access to the key list of Synthroid and placebo groups. Only the study coordinator and safety officer will have access to the thyroid function tests. The safety officer will determine whether a dose needs to be titrated. The study coordinator will coordinate with the Investigational Pharmacy for dispensing the study drug to the subjects. All dosage changes will be done for both study subjects receiving Synthroid and matching control subjects receiving placebo. The investigators will be blinded to the randomization and to dose titration. At interim analysis and final analysis, the statistician will be unblinded and will be provided with the study subjects codes for those in the Synthroid and placebo groups for analysis of the results.|Study subjects who are eligible for the study will be assigned by block randomization to either the study group arm receiving active treatment of a titrated dose of Synthroid (25, 50, or 75 mcg/day) or placebo (25, 50, or 75 mcg/day).|t|t|t|f
34142213|NCT02134665|||CASE_CONTROL||RETROSPECTIVE|||||||
34142214|NCT04943458|||COHORT||PROSPECTIVE|||||||
34142215|NCT01672099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142216|NCT00824083|||COHORT||PROSPECTIVE|||||||
34142217|NCT02059551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142218|NCT02281487|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142219|NCT00321958|||COHORT||PROSPECTIVE|||||||
34142220|NCT05173688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142221|NCT04160247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142222|NCT06606665|||CASE_CONTROL||PROSPECTIVE|||||||
34142223|NCT00953680|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142224|NCT00127283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142225|NCT02177643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34142226|NCT01605227|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142227|NCT01280539|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34142228|NCT02112682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142229|NCT03094078|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
34142230|NCT00951522|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34142231|NCT02707081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142232|NCT05734521|||COHORT||OTHER|||||||
34142233|NCT05384535|NA|SINGLE_GROUP||SCREENING||NONE||||||
34142234|NCT04704427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142235|NCT05270902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective, single-center, single-blinded, randomized, controlled trial|t|f|f|f
34142236|NCT03693963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142237|NCT01400295|||COHORT||PROSPECTIVE|||||||
34142238|NCT02436668|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142239|NCT05137457|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|Following consent, participants will be randomized and allocated to either the intervention or control arm of the trial. Randomization will be centrally controlled, and allocation will be concealed using a secure, web-based randomization on the Research Electronic Data Capture (REDCap) platform. The patients, the clinical care team (pain physicians, sleep physician, occupational therapist, and social worker), outcome adjudicators and the study statisticians will all remain blinded to randomization and group allocation. The personnel teaching the app to the intervention group will be aware of group allocation|"Prospective pilot study with participants randomized to either the intervention Delivering Online ZZZ's with Empirical support- DOZE app with Sleep diary/Cognitive Behavioral Therapy for insomnia- CBTi) or attention control DOZE app with Sleep diary only groups. Participants will input entries into their sleep diary as an attention control over a 10-week period. For the intervention arm, mobile CBTi will be offered using the DOZE app, an integrated smart phone app and web based self-management program. The intervention will be delivered on restricted password-protected applications that will allow adherence to be tracked. Participants will log onto the sleep dairy once a day over 10-weeks to complete sleep diary entries, develop and track their goals, and receive sleep health education tailored sleep health interventions. After 10-weeks, participants will complete questionnaires on sleep health, pain, and Health Related Quality of Life.~Actigraphy use will be optional"|t|t|t|t
34142240|NCT00810485|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142241|NCT02145104|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142242|NCT01287221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142243|NCT00642174|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34142244|NCT00343369|RANDOMIZED|||TREATMENT||||||||
34149884|NCT03594643|||COHORT||PROSPECTIVE|||||||
34149885|NCT04167865|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized controlled trial||||
34149886|NCT00645463|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831298|NCT06294197|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment Randomized Healthy Participants||||
34149887|NCT02219360|||CASE_ONLY||PROSPECTIVE|||||||
34149888|NCT04662372|||COHORT||PROSPECTIVE|||||||
34149889|NCT02537405|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831299|NCT00507806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831300|NCT05849324|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33831301|NCT02187289|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33831302|NCT00004922||||TREATMENT||||||||
33831303|NCT04657562|||COHORT||PROSPECTIVE|||||||
33831304|NCT03041298|||COHORT||PROSPECTIVE|||||||
33831305|NCT05256810|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831306|NCT02628483|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
33831307|NCT03539029|||COHORT||RETROSPECTIVE|||||||
33831308|NCT05318235|||COHORT||PROSPECTIVE|||||||
33831309|NCT02869048|||CASE_CONTROL||PROSPECTIVE|||||||
33831310|NCT00302926|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33831311|NCT00004039||||TREATMENT||||||||
33831312|NCT03194945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831313|NCT02141971|||CASE_CONTROL||PROSPECTIVE|||||||
33831314|NCT00078143||||TREATMENT||||||||
33831315|NCT04639986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142245|NCT05777122|RANDOMIZED|PARALLEL||TREATMENT||NONE||"In our study all the participant were asked to fill the questionnaire.In the topical gel group the patients were directed to apply the gel on the buccal free gingival margin of their first molar at one side when the separators are placed and reapply the gel every 8 hours . T'hey were then requested to mark their level of pain at 2 and 8 hours and at 10 pm of the 2nd,3rd,5th and 7th day after the gel is being applied and mark it on the VAS form.~The patients in the chewing gum group were advised to chew sugar free gum for 5 minutes immediately after separators were placed and at 8 hours interval. The patients were also advised and motivated not to take any additional analgesics.For measuring the perception of pain the most reliable method the Visual Analog Scale (VAS).will be used"||||
34142246|NCT00571246|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34142247|NCT02198599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142248|NCT02825420|||OTHER||PROSPECTIVE|||||||
34142249|NCT00144768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142250|NCT04546373|||CASE_ONLY||RETROSPECTIVE|||||||
34142251|NCT06180681|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142252|NCT03085888|||OTHER||PROSPECTIVE|||||||
34142253|NCT01286987||||TREATMENT||NONE||||||
34142254|NCT03552536|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34142255|NCT03760159|||COHORT||PROSPECTIVE|||||||
34142256|NCT03918226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142257|NCT01925911|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142258|NCT06185842|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34142259|NCT04709484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double(participant, outcomes assesor double)||t|f|f|t
34142260|NCT04852042|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142261|NCT02212509|||COHORT||PROSPECTIVE|||||||
34142262|NCT01555359|||COHORT||PROSPECTIVE|||||||
34142263|NCT05256420|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142264|NCT04052438|||COHORT||PROSPECTIVE|||||||
34142265|NCT04862897|||CASE_ONLY||OTHER|||||||
34142266|NCT02098850|||COHORT||PROSPECTIVE|||||||
34142267|NCT01367704|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34142268|NCT06363578|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34142269|NCT03739645|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Analysis of eye position and skin conductance levels will be examined to identify attentional and anxiety related processes for the fear of pain during the conditioned stage. Correlation of skin conductance levels versus slopes during the conditioning stage with state versus trait anxiety will be taken as confirmatory evidence. Power analysis for a two-way ANOVA was conducted to determine a sufficient sample size using an alpha of 0.05, power 0.80, a high effect size (pilot data indicate η2 values for main effects \> 0.5). Based on these assumptions, we conservatively use a sample size of 40.||||
34142270|NCT02036164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142271|NCT03180437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142272|NCT00858897|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34142273|NCT00612742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142274|NCT03095027|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Alcon Observer and Sponsor personnel were also masked.||t|f|t|f
34142275|NCT03711929|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142276|NCT00842439|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
34142277|NCT03995056|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||The study contains two arms. One arm is the control group without any changes in their lifestyle (sedentary lifestyle) and the other arm is the intervention group with a high-intensity interval training. Both groups have no changes in their diets.||||
34142278|NCT02588703|RANDOMIZED|PARALLEL||TREATMENT||NONE||RCT||||
34142279|NCT00085254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142280|NCT01992614|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34142281|NCT05340634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142282|NCT02100163|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
34142283|NCT00910559|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34142284|NCT05523596|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34142285|NCT02295215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142286|NCT01633203|||COHORT||PROSPECTIVE|||||||
34142287|NCT04860934|RANDOMIZED|PARALLEL||TREATMENT||NONE||Experimental controlled randomization using Block Stratified Randomized Software program, after obtaining informed consent from illegible patient or his caregiver.||||
34142288|NCT00694096|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142289|NCT03224650|||COHORT||PROSPECTIVE|||||||
34142290|NCT01621529|||COHORT||PROSPECTIVE|||||||
34142291|NCT00795548|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142292|NCT04610892|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142293|NCT05082428|||OTHER||RETROSPECTIVE|||||||
34142294|NCT02070393|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34142295|NCT03065842|RANDOMIZED|PARALLEL||PREVENTION||NONE||A quasi-experimental design, which is the Comparison Group Pre-test/Post-test Design, as in the current design. This design is the same as the classic controlled experimental design except that the subjects cannot be randomly assigned to either the experimental or the control group. The design came out because of difficulty of applying the classical natural science method to the social or the researcher cannot control which group will get the treatment, for example interventions targeting school students.||||
34142296|NCT05265884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142297|NCT06254157|||CASE_CROSSOVER||PROSPECTIVE|||||||
34142298|NCT00665756|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831316|NCT00461643|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831317|NCT04458220|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33837561|NCT05648409|||COHORT||CROSS_SECTIONAL|||||||
34142299|NCT00060814|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142300|NCT00183378|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142301|NCT01833260|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34149890|NCT05589883|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The design of this study is a single-arm open trial.||||
34149891|NCT02064608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149892|NCT05173961|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34149893|NCT01236235|||COHORT|||||||||
34142302|NCT03497546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Investigators, study coordinators, outcome assessors, and clinical staff will be blinded to the group allocation.~Participants and providers of the exercise delivery will not be blinded to the group allocation."|"Eligible participants will be randomly assigned (1:1) sequentially, as they will be submitted to bariatric surgery, to one of the two following groups:~CON - Usual care (following international guidelines) after bariatric surgery. EX - Usual care plus supervised exercise program."|f|f|t|t
34142303|NCT04710641|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomised 2:1 to receive either both the experimental drug, MTL-CEBPA, and sorafenib tablets or sorafenib tablets alone||||
34142304|NCT00355342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142305|NCT06607861|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142306|NCT02969590|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34142307|NCT01638052|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34142308|NCT03018470|||COHORT||PROSPECTIVE|||||||
34142309|NCT03159364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142310|NCT00536016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142311|NCT04370990|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled parallel study||||
34142312|NCT03150069|||COHORT||CROSS_SECTIONAL|||||||
34142313|NCT01219036|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142314|NCT04604912|||COHORT||PROSPECTIVE|||||||
34142315|NCT05489627|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group: Clinical trials with a single arm.||||
34142316|NCT02865889|||COHORT||PROSPECTIVE|||||||
34142317|NCT06369207|||CASE_ONLY||PROSPECTIVE|||||||
34142318|NCT04306289|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Crossover Assignment|t|f|f|t
34142319|NCT06606704|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142320|NCT04397809|||COHORT||PROSPECTIVE|||||||
34142321|NCT01497509|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34142322|NCT05773261|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Control: Pinnacle Gription series 100 cup with a Marathon liner combined med with a Corail femoral stem.~Investigational device: MobilLINK TrabecuLINK cup with X-LINKed liner combined with a LCU femoral stem."||||
34142323|NCT06439498|||COHORT||PROSPECTIVE|||||||
33831318|NCT03569605|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||After completing informed consent, 7-day PA assessment, weight measurement, and baseline questionnaires, participants will be randomly assigned with equal probability to 1 of 2 treatment groups: 1) self-help or 2) intervention. Future treatment assignments will be concealed from study staff who are recruiting and enrolling participants.|f|f|t|t
33831319|NCT01018732|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831320|NCT04325009|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment single-dose, 2-sequence, 4-period Bioequivalence Study||||
33831321|NCT06486727|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831322|NCT01382498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33831323|NCT05428111|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831324|NCT00469456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831325|NCT02119533|||OTHER||PROSPECTIVE|||||||
33831326|NCT02872311|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33831327|NCT05761912|||COHORT||PROSPECTIVE|||||||
33831328|NCT04488861|||COHORT||PROSPECTIVE|||||||
33831329|NCT00478647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831330|NCT05731505|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||experimental, randomized controlled, single-blind study||||
33831331|NCT00510146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831332|NCT02635178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831333|NCT04692376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831334|NCT02382523|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831335|NCT06307067|||OTHER||PROSPECTIVE|||||||
33831336|NCT03182296|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Comparison of women with and without a history of gestational diabetes||||
33831337|NCT05758987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessor of secondary outcome CAPS will be masked to participant allocation at post and follow-up assessments.|A randomized controlled non-inferiority trial evaluating if the new blended Tf-CBT is non inferior to the gold standard PTSD treatment Prolonged exposure. The trial is a multicenter study conducted at 3-6 sites. Participants are individually randomized in blocks of 2-4 at each site.|f|f|f|t
33831338|NCT03559829|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142324|NCT04720274|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34142325|NCT03692351|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831339|NCT00344032|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33831340|NCT02676609|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33831341|NCT02875002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831342|NCT02760485|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831343|NCT06148402|NA|SINGLE_GROUP||TREATMENT||NONE||fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w||||
33831344|NCT02471482|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33831345|NCT03852108|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33831346|NCT01518088|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|f|t
33831347|NCT06538298|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Randomized Controlled Pilot Study||||
33831348|NCT02394665|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831349|NCT05147298|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33831350|NCT04654962|||COHORT||OTHER|||||||
33831351|NCT06385106|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34142326|NCT00789581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142327|NCT06599840|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142328|NCT04378829|||CASE_ONLY||RETROSPECTIVE|||||||
34142329|NCT05517213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All patients were randomly assigned 1:1 to CTX 3.0g/m2+ G-CSF 10ug/kg or VP-16 1.2g/m2+G-CSF10ug/kg||||
34142330|NCT04988282|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142331|NCT00681694|||COHORT||PROSPECTIVE|||||||
34142332|NCT03245736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831352|NCT04715685|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|Only than study staff whose role requires unblinding (project manager and the nurse or interventionist providing the treatment) will be made aware of each participant's study assignment by the statistician. Other study personnel (including assessors of key variables) will remain blinded to treatment assignment.||t|f|t|t
33831353|NCT05700604|||CASE_CONTROL||PROSPECTIVE|||||||
33831354|NCT03360110|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Double masked (participant, investigator)||t|f|t|f
33831355|NCT02125071|||CASE_ONLY||PROSPECTIVE|||||||
33831356|NCT01182064|||CASE_CONTROL||PROSPECTIVE|||||||
33831357|NCT03708705|||COHORT||PROSPECTIVE|||||||
33831358|NCT02832349|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33831359|NCT00083330||||TREATMENT||||||||
33831360|NCT02834936|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831361|NCT02394652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831362|NCT01377168|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831363|NCT02976168|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33831364|NCT06262425|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831365|NCT04171245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33831366|NCT04830683|||COHORT||PROSPECTIVE|||||||
33831367|NCT05052710|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831368|NCT01704443|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831369|NCT02165826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831370|NCT00708851|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
33831371|NCT03691545|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33831372|NCT03450447|||COHORT||PROSPECTIVE|||||||
33831373|NCT01067287|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831374|NCT04896788|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33831375|NCT01347606|||||PROSPECTIVE|||||||
33831376|NCT04843982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831377|NCT00510939|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831378|NCT03373851|||COHORT||PROSPECTIVE|||||||
33831379|NCT01287819|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831380|NCT02080390|||COHORT||OTHER|||||||
33831381|NCT06198543|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831382|NCT02149706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831383|NCT05370014|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33831384|NCT05336617|||COHORT||RETROSPECTIVE|||||||
33831385|NCT05092698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33831386|NCT06062199|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33831387|NCT02341586|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831388|NCT00428337|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33831389|NCT04684056|||COHORT||PROSPECTIVE|||||||
33831390|NCT03416413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831391|NCT02854371|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||gadoxetic acid MRI and ICG R15 test||||
33831392|NCT00675792|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831393|NCT01896453|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33831394|NCT06140394|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33831395|NCT01177995|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33831396|NCT00678483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831397|NCT00965120|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33831398|NCT00177021|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831399|NCT03144297|||CASE_CONTROL||PROSPECTIVE|||||||
33831400|NCT01079247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831401|NCT02019641|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33831402|NCT03062085|||OTHER||PROSPECTIVE|||||||
33831403|NCT01980602|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831404|NCT05803642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831405|NCT03277352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831406|NCT00839332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831407|NCT01309477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831408|NCT03201237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831409|NCT00677768|||CASE_CONTROL||PROSPECTIVE|||||||
33831410|NCT02827032|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831411|NCT02330276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831412|NCT04188756|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Patients will randomized for exercice (1:1). After 15 weeks the group without exercise will be offered to take part in an exercise training||||
33831413|NCT05359692|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE|open-label study|||||
33831414|NCT04055259|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831415|NCT06239259|||COHORT||CROSS_SECTIONAL|||||||
33831416|NCT02775071|||CASE_ONLY||PROSPECTIVE|||||||
33831417|NCT04191876|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33831418|NCT01470599|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831419|NCT01965509|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831420|NCT04634370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831421|NCT06541639|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Initial Efficacy of EVM16 Injection as a Single and Combination with Tislelizumab in Subjects with Advanced or Recurrent Solid Tumors.||||
33831422|NCT04302129|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|closed envelope method||t|f|t|f
33831423|NCT00912145|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831424|NCT05780762|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33831425|NCT01711398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831426|NCT03310398|||COHORT||PROSPECTIVE|||||||
33831427|NCT02800447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831428|NCT04366362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will not be aware of the group that they will be part of. Assessors before and after surgery will not be aware of patients groups|Two groups of patients, randomly assigned|t|f|f|t
33831429|NCT05575570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831430|NCT04419363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831431|NCT05281289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33831432|NCT06090175|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33831433|NCT03884712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831434|NCT05595811|||COHORT||RETROSPECTIVE|||||||
33831435|NCT01783509|||COHORT||PROSPECTIVE|||||||
33831436|NCT00663273|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33831437|NCT02267564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33831438|NCT01881152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831439|NCT02838576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831440|NCT00522717|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33831441|NCT06326879|||COHORT||PROSPECTIVE|||||||
33831442|NCT00827736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831443|NCT01867970|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831444|NCT04243122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33831445|NCT03534011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831446|NCT05669976|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Outcome assessors (for primary endpoint: suicide attempts) will be masked for randomized study condition.|Prospective participants will be recruited within Southern California and requested to fill out a brief online survey. A trained member of the study team will contact each potential participant to explain the study, obtain verbal consent for pre-enrollment screening, and conduct the screening process. For those who meet screening criteria, a trained member of the study team will provide more information about the study and engage in an informed consent process during a virtual appointment. Following informed consent, participants will complete self-report questionnaires and clinician-based interviews. When eligible, participants will be randomized to either receive the PN+SPI intervention or SPI alone and offered virtual appointments. At baseline, 3-month, 6-month, and 12-month follow-ups, participants will complete clinical interviews to assess for suicidal ideation and suicidal behaviors and complete measures of suicidal coping and thwarted belongingness.|f|f|f|t
33831447|NCT05316909|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Participants are unaware of their intervention assignment (order of dolls).|Educational intervention with newborn simulators of varying fidelity|t|f|f|t
33831448|NCT05160571|||CASE_ONLY||RETROSPECTIVE|||||||
33831449|NCT06011278|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Assignment to the experimental and control groups will be made by an independent statistician to avoid bias and ensure confidentiality. Thus, selection bias will be controlled by making random assignment and hiding the randomization.~In the study, participant and researcher will not be blinded. Blinding will not be possible because the researcher follows the participants and parents on a daily basis and is aware of the intervention. The data will be coded as 'A' and 'B' by the researcher and transferred to the computer. It is recommended that all stages of randomized controlled trials be conducted according to the Consolidated Standards of Reporting Trials (CONSORT). In this context, the study will be conducted on the basis of the CONSORT 2017 (Updated Guidelines for Reporting Randomized Parallel Group Studies) guideline during the randomization stages of this study."|f|f|f|t
33831450|NCT02803671|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33831451|NCT04466410|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Placebo and active drug are identical in appearance. Randomization will be provided to an unblinded pharmacist. Dosing and clinical assessments will be blinded.|Dose escalation by cohort following safety reviews|t|t|t|t
33831452|NCT03593330|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|All eligible patients will be consented to participate in the study. If they consent, a non-clinician study team member will randomise the patient into the control or intervention arm. Thereafter, all members of the care team will be notified of the patient's allocation in order to deliver the TCP.|Patients will be randomised into two groups: standard of care or Transitional Care Programme (TCP)||||
33831453|NCT03952507|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33831454|NCT00080041|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831455|NCT00600847|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33831456|NCT01380288|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831457|NCT02326259|||COHORT||PROSPECTIVE|||||||
33831458|NCT04373837|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831459|NCT02422225|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33831460|NCT03516097|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33831461|NCT02830048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831462|NCT05254717|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831463|NCT03521518|||COHORT||PROSPECTIVE|||||||
33831464|NCT02530398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831465|NCT01882738|||COHORT||PROSPECTIVE|||||||
33831466|NCT05601128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831467|NCT02124499|||COHORT||PROSPECTIVE|||||||
33831468|NCT01828866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831469|NCT01973062|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831470|NCT06485739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831471|NCT04988399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831472|NCT03501810|||COHORT||PROSPECTIVE|||||||
33831473|NCT02590471|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33831474|NCT01169636|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831475|NCT00175591|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831476|NCT04865055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831477|NCT01718431|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33831478|NCT01876615|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33831479|NCT00578578|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831480|NCT04393792|RANDOMIZED|PARALLEL||TREATMENT||NONE||unblinded parallel group design with 1:1 randomised allocation to treatment or control||||
33831481|NCT03292523|||COHORT||PROSPECTIVE|||||||
33831482|NCT01379456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831483|NCT03765398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831484|NCT00523068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831485|NCT04886817|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study staff collecting data on the primary outcome of beverage consumption at 3 and 6 month follow-up will be blinded to group allocation of participants.||f|f|f|t
33831486|NCT03893110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831487|NCT00450398|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33831488|NCT02514226|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831489|NCT02812875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831490|NCT04276298|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|Double blinded trial, both participant and investigator are blinded.|Parallel with 1:1:1:1 Allocation.|t|t|f|f
33831491|NCT03842436|NA|SINGLE_GROUP||PREVENTION||NONE||Single group pilot demonstration project||||
33831492|NCT05040945|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831493|NCT06542406|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831494|NCT04961632|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33831495|NCT01078922|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831496|NCT05792761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831497|NCT02028286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831498|NCT02335333|||COHORT||PROSPECTIVE|||||||
33831499|NCT03853252|NA|SINGLE_GROUP||OTHER||NONE||||||
33831500|NCT03498105|||COHORT||PROSPECTIVE|||||||
33831501|NCT06128213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831502|NCT00327353|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831503|NCT04641117|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects will power train||||
33831504|NCT02023190|||COHORT||PROSPECTIVE|||||||
33831505|NCT02485314|||FAMILY_BASED||PROSPECTIVE|||||||
33831506|NCT02529943|||COHORT||PROSPECTIVE|||||||
33831507|NCT04076605|||COHORT||PROSPECTIVE|||||||
33831508|NCT00904709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831509|NCT01095133|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33831510|NCT01642147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831511|NCT03434028|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831512|NCT01898715|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831513|NCT05156515|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831514|NCT05486247|||COHORT||RETROSPECTIVE|||||||
33831515|NCT04105075|||CASE_CONTROL||PROSPECTIVE|||||||
33831516|NCT04220268|||COHORT||PROSPECTIVE|||||||
33831517|NCT05604807|RANDOMIZED|PARALLEL||OTHER||SINGLE||two-group randomised controlled trial|f|f|f|t
33831518|NCT04219280|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE||Phase 1 is a Sequential model, Phase 2-3 is a Crossover model, Phase 4 is a Single-Group model.|t|t|f|t
33831519|NCT04216485|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33831520|NCT04745845|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831521|NCT03413215|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831522|NCT04296045|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
33831523|NCT05455086|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33831524|NCT05710289|||COHORT||PROSPECTIVE|||||||
33831525|NCT06168253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will receive one of two matched interventions. They will not be told whether they are receiving the active or control intervention.|Participants will be randomized in to one of two conditions|t|f|f|f
33831526|NCT04674254|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831527|NCT01710800|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
33831528|NCT04920747|||COHORT||RETROSPECTIVE|||||||
33831529|NCT02975791|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33831530|NCT00746356|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831531|NCT04570696|||COHORT||PROSPECTIVE|||||||
33831532|NCT05050526|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The investigators in charge of doing the statistical analysis and assessing the outcome measures (e.g., physical performance tests) will be blinded to group allocation. Due to the characteristics of the study, blinding of the participants (i.e., eldercare workers) and the care provider (i.e., professional conducting the exercise sessions) to the group allocation is not possible.||f|f|t|t
33831533|NCT06189989|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||control grup and intervention grup||||
33831534|NCT05444036|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||comparing caudal block by bupivacaine with and without ketamine in paediatric patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties.|t|f|f|f
33831535|NCT00913068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33831536|NCT05476510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes Assessor and participant will be blinded to the stud|Sixty patients aged 18-65 years old with American Society of Anesthesiologists (ASA) classification I-II and scheduled for laparoscopic inguinal hernia repair surgery will be included in the study. Patients will be randomly divided into two groups (Group M TAPA = M-TAPA group, Group OSTAP = OSTAP group) including 30 patients each, before entering the operating room.|t|f|f|t
33831537|NCT03253068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142333|NCT04685707|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33831538|NCT05243615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831539|NCT03896074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831540|NCT04298099|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Participants will be assigned to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg on an odd/even basis||||
33831541|NCT04797598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to m ask the both groups about their treatment|Its a randomized control trial, used to compare the effects of virtual reality and cyclic training on balance in sub-acute stroke patients. Subjects with sub-acute stroke meeting the predetermined inclusion and exclusion criteria will be divided into two groups using simple random sampling technique|t|f|f|f
33831542|NCT03110263|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831543|NCT04585100|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33831544|NCT02535442|||CASE_CROSSOVER||PROSPECTIVE|||||||
33831545|NCT05047978|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34142334|NCT06069141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142335|NCT06214052|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Data will be collected in a double-blind manner during the monotherapy phase.||t|f|t|f
34149894|NCT04102722|NA|SINGLE_GROUP||SCREENING||NONE||All enrolled subjects will receive breast cancer screening with mammography and MUST||||
34149895|NCT01918449|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831546|NCT00366717|||DEFINED_POPULATION||PROSPECTIVE|||||||
33831547|NCT01398462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831548|NCT00535938|||||PROSPECTIVE|||||||
33831549|NCT02745639|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831550|NCT05400252|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be blind to participant intervention assignment.||f|f|f|t
33831551|NCT05568368|||COHORT||RETROSPECTIVE|||||||
33831552|NCT05091476|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831553|NCT03666195|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The outcome assessor will be blinded as well as the statistician and the participant.~The outcome assessor will count the bacterial colony forming units without knowing the type of the denture material used (Conventional acrylic resin or acrylic resin modified by titanium dioxide nanoparticles)"|Randomized controlled trial|t|f|f|t
33831554|NCT01486381|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831555|NCT00146198|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831556|NCT05799469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831557|NCT05092568|||COHORT||PROSPECTIVE|||||||
33831558|NCT02099136|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33831559|NCT03021278|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33831560|NCT04952701|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33831561|NCT04118283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data will be collected by experienced Research Assistants (Ras) who will receive in-person training on each assessment measure. All RAs involved in the research study will conduct baseline assessments. One RA will remain blind to study condition in order to complete post-treatment and follow-up assessments. A back-up RA supplied by the VISN 5 MIRECC will be trained to conduct assessments in case the blind assessor is unblinded or in need of assistance. If the study condition becomes known, the blind assessor will stop the assessment and either the back-up RA or study PI will finish the assessment(s).|This study involves a pilot randomized controlled trial (RCT) with 45 Veterans with co-occurring SMI and chronic musculoskeletal pain to examine feasibility and acceptability of Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) and preliminarily evaluate participant responses to intervention. The first 45 Veterans who pass screening will be enrolled and randomized to study condition on a rolling basis. Participants will be randomly assigned at a 2:1 ratio to CBT-CP:Health \& Wellness using permuted block randomization with randomly varying block sizes. Veterans will be randomly assigned to either CBT-CP (n = 30) or a manualized Health \& Wellness active control intervention (n = 15). Using an intent-to-treat framework, data will be collected from every participant during the one-week Ecological Momentary Assessment period (prior to RCT baseline assessment) and at baseline, post-treatment, and 3-month follow-up regardless of attendance in their assigned condition.|f|f|f|t
33831562|NCT04491864|||COHORT||PROSPECTIVE|||||||
33831563|NCT01411098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831564|NCT04354246|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33831565|NCT00541151|||COHORT||PROSPECTIVE|||||||
33831566|NCT02150395|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33831567|NCT05111743|||COHORT||RETROSPECTIVE|||||||
33831568|NCT01280604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831569|NCT02500745|||||CROSS_SECTIONAL|||||||
33831570|NCT01189422|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33831571|NCT04950062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33831572|NCT03928392|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups for this study. Both groups will engage in two SCUBA dives. Additionally one group will receive occupational therapy and the other will not. The occupational therapy sessions will occur in conjunction with the SCUBA dive.||||
33831573|NCT04206956|||COHORT||PROSPECTIVE|||||||
33831574|NCT04431245|||CASE_ONLY||PROSPECTIVE|||||||
33831575|NCT00635401|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831576|NCT00060437||||TREATMENT||NONE||||||
33831577|NCT04145388|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33831578|NCT02752607|||COHORT||PROSPECTIVE|||||||
34142336|NCT04006210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded Site Rater, Blinded Clinical Research Associates (CRAs), active drugs and matching placebos are identical in their appearances.|Oral IR-LD/CD Adjustment Period - Run-in 1 (1 arm) followed by ND0612 Conversion Period - Run-in 2 (1 arm) followed by DBDD Parallel Group Maintenance Period (2 arms) followed by optional Open-label Extension Period (1 arm)|t|t|t|t
34142337|NCT03344107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142338|NCT02403635|NA|SINGLE_GROUP||OTHER||NONE||||||
34142339|NCT00002839|RANDOMIZED|||TREATMENT||||||||
34142340|NCT04326244|||CASE_ONLY||PROSPECTIVE|||||||
34142341|NCT06224660|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149896|NCT00003027|RANDOMIZED|||TREATMENT||||||||
33831579|NCT03470545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831580|NCT01806935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831581|NCT02434536|||COHORT||PROSPECTIVE|||||||
33831582|NCT02336256|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831583|NCT00732992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831584|NCT05227664|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831585|NCT00152399|RANDOMIZED|PARALLEL||||DOUBLE||||||
33831586|NCT04246853|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double-blinding is performed by a third-party which is not part of the research group|The current studies have a randomized, parallel, sham-controlled and double-blinded design.|t|f|t|t
33831587|NCT00002430||||TREATMENT||||||||
33831588|NCT00192998|||DEFINED_POPULATION||OTHER|||||||
33831589|NCT06342479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33831590|NCT02482610|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33831591|NCT02801864|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33831592|NCT00391339|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831593|NCT04603833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831594|NCT01303315|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831595|NCT02397343|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33831596|NCT00578162|||||PROSPECTIVE|||||||
33831597|NCT00950196|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149897|NCT05910333|||OTHER||RETROSPECTIVE|||||||
33831598|NCT04805450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831599|NCT01037062||PARALLEL||TREATMENT||NONE||||||
33831600|NCT04902599|RANDOMIZED|PARALLEL||OTHER||SINGLE|A blinded assessor will review the results to determine if there is a significant difference in the two techniques by looking at the photos once the study is over.|Prospective, Randomized, Technique Comparison Trial|f|f|f|t
33831601|NCT02294097|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33831602|NCT02686073|||COHORT||PROSPECTIVE|||||||
33831603|NCT02820545|||COHORT||PROSPECTIVE|||||||
33831604|NCT02486419|||COHORT||CROSS_SECTIONAL|||||||
33831605|NCT05605288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831606|NCT05258955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The mouthwash were distributed in dark color coded bottle and marked with label A and B, as to maintain masking among the the participants of the study.|The participants divided into two groups. one group will received honey based oral rinses and other group received chlorhexidine mouthwash and will evaluate the reduction of dental plaque|t|f|f|f
33831607|NCT03021551|NA|SINGLE_GROUP||OTHER||NONE||||||
33831608|NCT01748305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831609|NCT01646528|||||PROSPECTIVE|||||||
33831610|NCT05337488|||OTHER||RETROSPECTIVE|||||||
33831611|NCT03226301|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles. Patients not achieving MRD negativity after cycle 12 (PB) AND/OR cycle 15 (PB+BM) continue on ibrutinib maintenance (non-randomized group). Patients achieving MRD negativity after cycle 12 (PB) AND cycle 15 (PB+BM) are randomized 1:2 between ibrutinib maintenance (arm A) and stopping treatment (observation, arm B).||||
33831612|NCT00174356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831613|NCT05578508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831614|NCT03993457|RANDOMIZED|PARALLEL||TREATMENT||NONE|Participant, care provider, investigator, and outcomes assessor will only be blinded to the participant's CRP levels and group assignment. However, the study is open label, meaning the participant, care provider, investigator, and outcomes assessor will know what medication the participant is taking.|"Participants will be assigned to one of two groups based on their CRP levels:~* CRP less than 1~* CRP greater than or equal to 1~Participants within both groups will then be randomized to one of 2 groups, which is stratified by a CRP group:~* CRP consistent antidepressant selection (medication will be prescribed based on CRP level)~* CRP inconsistent antidepressant selection (medication will be prescribed in contradiction to CRP level)"||||
33831615|NCT01073319|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33831616|NCT04234945|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The drugs given to participants in Groups A and B are in capsules and have thesame size and packaging but different colors. They will be put in a brown envelop to cover the color. The brown envelops will then be labelled with study number based in the numbers generated by the Random number table (WINPEPI) by a research assistant to ensure the principal investigators do not know the drug inside the brown envelopes. The participants will take the drugs at home. This ensures that the care provider, investigators and outcomes assessors do not know the drug the patient takes. However the patient will know the drug she takes since the drug is labelled.~The"|"Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.~Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding"|f|t|t|t
33831617|NCT04908306|||COHORT||PROSPECTIVE|||||||
33831618|NCT01610960|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33831619|NCT06039722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831620|NCT02814045|||COHORT||PROSPECTIVE|||||||
33831621|NCT05451797|||COHORT||PROSPECTIVE|||||||
33831622|NCT00342537|||FAMILY_BASED||OTHER|||||||
33831623|NCT02674269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831624|NCT01805986|||CASE_CONTROL||PROSPECTIVE|||||||
33831625|NCT00557661|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831626|NCT00302523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831627|NCT01128114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831628|NCT00480155|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33831629|NCT04522206|NA|SINGLE_GROUP||PREVENTION||NONE||A prospective cohort study||||
33831630|NCT00158145|||||PROSPECTIVE|||||||
33831631|NCT03641456|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831632|NCT01505322|||COHORT||RETROSPECTIVE|||||||
33831633|NCT01699464|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831634|NCT05098691|||CASE_CONTROL||PROSPECTIVE|||||||
33831635|NCT04381923|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This will be a randomized study with alternating treatment assignment in which all advanced respiratory units will be assigned to use one of two default interventions (helmet CPAP vs HFNO) as the first-line treatment for refractory hypoxemia (defined as an oxygen saturation (Sp02) of 92% or less on on ≥ 6 LPM (liters per minute) nasal cannula (NC) oxygen). The first-line treatment will be alternated in each unit at 14-day intervals. The initial assignment will be determined by a computer randomization scheme. Patients who are still on their assigned intervention during crossover will remain on that assigned intervention. A design with numerous short periods and frequent crossovers was selected to minimize the risk of changes over time in the patient population and usual care confounding trial results. A 14-day period is also felt to be the minimal time needed to ensure device availability and adherence.|f|f|f|t
33831636|NCT04402983|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled clinical trial||||
33831637|NCT05294718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|concealed in opaque closed envelops|A prospective, randomized comparative study|t|t|t|t
34149898|NCT01378429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149899|NCT05876247|||CASE_CONTROL||PROSPECTIVE|||||||
34149900|NCT03462186|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34149901|NCT02098889|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34149902|NCT03554135|||COHORT||PROSPECTIVE|||||||
34150862|NCT02475187|||CASE_ONLY||PROSPECTIVE|||||||
34150863|NCT01946126|||COHORT||RETROSPECTIVE|||||||
34150864|NCT01452503|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34150865|NCT01641822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150866|NCT06166329|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831638|NCT02411708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831639|NCT04964895|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Prospective observational study||||
33831640|NCT03787420|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33831641|NCT00451828|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33831642|NCT04597190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The survey team members will be masked to which arm the study participant has been randomized.~The PI, Co-PIs, and Co-Is will not have access to the outcomes until the primary data collection phase has been completed. The statistician will present outcomes by arm to the Data Safety Monitoring Board (DSMB) members during closed sessions of DSMB meetings."|Patients will be randomized to treatment sequences, stratified by site and baseline antidepressant use.|f|f|f|t
33831643|NCT00632385|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831644|NCT02316262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831645|NCT06316817|||COHORT||PROSPECTIVE|||||||
33831646|NCT01654068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831647|NCT03465943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33831648|NCT01686490|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831649|NCT03707847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831650|NCT02725567|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831651|NCT05852899|||COHORT||PROSPECTIVE|||||||
33831652|NCT05006222|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33831653|NCT00525278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33831654|NCT05972304|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33831655|NCT04605744|NA|SINGLE_GROUP||OTHER||NONE||||||
33831656|NCT00226993|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831657|NCT03578588|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||A single-center, randomized, open-label, three-period and three-crossover trial design is adopted in the single-dose pharmacokinetic study; A single-center, randomized, open- label, and dose escalation trial design is used in the multiple-dose tolerability and pharmacokinetic studies||||
33831658|NCT05632380|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831659|NCT03020069|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831660|NCT03666806|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The participant and the study team will both be masked to which arm the participant will be assigned. Blinding will be achieved by use of a placebo that has similar characteristics as the influenza vaccine i.e. as the vaccine, the placebo will be formulated and packaged as an injectable placebo. In addition, on enrollment, the participants will be informed by the study team that their assignment to a study arm is completely random and unknown to the study team. The study nurse will pick the study drug from the pharmacist to be used for each participant after the randomization code has been revealed. The randomization code on the study drug will have to be the same as the code in the envelope. Lastly, the envelopes will be kept off site with the statistician who will deliver them every morning before the clinic opens.|Randomized double blinded parallel control study|t|t|t|t
33831661|NCT02629198|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33831662|NCT01184534|||COHORT||PROSPECTIVE|||||||
33831663|NCT00283777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831664|NCT04745936|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33831665|NCT02454049|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33831666|NCT02572635|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33831667|NCT05283356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831668|NCT01017263|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831669|NCT00673127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831670|NCT03871621|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831671|NCT04820647|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831672|NCT01232400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831673|NCT00745771||||TREATMENT||||||||
33831674|NCT05611853|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33831675|NCT00682227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831676|NCT03654768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831677|NCT04293952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831678|NCT03965780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831679|NCT05056727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831680|NCT01186731|NA|SINGLE_GROUP||||NONE||||||
33831681|NCT03029819|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831682|NCT06469567|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
33831683|NCT02421536|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33831684|NCT01918371|||CASE_ONLY||RETROSPECTIVE|||||||
33831685|NCT03980197|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33831686|NCT00512109|||COHORT||PROSPECTIVE|||||||
33831687|NCT01426113|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831688|NCT00321685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831689|NCT01547598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33831690|NCT02765230|||||CROSS_SECTIONAL|||||||
33831691|NCT00088647|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33831692|NCT01135082|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831693|NCT02668627|||COHORT||PROSPECTIVE|||||||
33831694|NCT01985646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831695|NCT00941642|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33831696|NCT06153030|||OTHER||CROSS_SECTIONAL|||||||
33831697|NCT01527162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831698|NCT05293197|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831699|NCT00348868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831700|NCT05683743|||CASE_ONLY||CROSS_SECTIONAL|||||||
33837562|NCT05761340|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Pregnant women meeting the inclusion criteria were assigned to the Helfer skin tap and standard application groups by a computer-based random number generator. The numbers in set 1 were taken to the Helfer skin tap group and the numbers in set 2 to the standard application group by lot method.|randomized clinical trial|t|f|t|f
34142342|NCT05683574|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Comparator Group: etoricoxib 90 mg (Arcoxia®). Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) when postoperative pain intensity reaches moderate to serious intensity (≥ 40 mm at VAS 0-100 mm) and one (01) FDC placebo capsule. The participants will be instructed, from then on, to use this same treatment, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.~Comparator Group: cyclobenzaprine hydrochloride 15 mg (XL - Mitrul®). Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) (which will be masked inside a capsule like the FDC) when postoperative pain intensity reaches moderate to serious intensity (≥ 40 mm at VAS 0-100 mm) and one (01) etoricoxib placebo tablet. The participants will be instructed, from then on, to use this same treatment, respecting a minimum interval of twenty-four (24) hours between doses for 3 days."|"Participants who meet all eligibility criteria will be randomized to one of the following treatment groups:~Investigational group: FDC of etoricoxib 90 mg + cyclobenzaprine 15 mg from Eurofarma Laboratórios SA (investigational drug). Participants randomized to this group will receive one (01) capsule of the investigational drug when postoperative pain intensity reaches moderate to serious intensity (≥ 40 mm at VAS 0-100 mm) and one (01) etoricoxib placebo tablet. The participants will be instructed, from then on, to use this same treatment, respecting a minimum interval of twenty-four (24) hours between doses for 3 days."|t|t|t|f
34142343|NCT04209114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142344|NCT02387801|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831701|NCT04467346|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The study is an open label, randomized, crossover, 2-period study in 30 male/female patients with primary CNS malignancies. Patients will receive, under fasting conditions, 200 mg/m² of Temozolomide Oral Suspension (Ped-TMZ) or Temodal®, as single oral administration in 2 different study periods depending on the randomization, with no wash out period between administrations.||||
34142345|NCT03894969|RANDOMIZED|PARALLEL||PREVENTION||NONE|This is an open-label study. Blinding was not performed on the subjects.|||||
34142346|NCT00922155|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142347|NCT04243902|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||2 groups, 1 group including interim safety review||||
34142348|NCT05553977|||COHORT||PROSPECTIVE|||||||
34142349|NCT01154283|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34142350|NCT05866484|||COHORT||RETROSPECTIVE|||||||
34142351|NCT00003825|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34142352|NCT00315107|RANDOMIZED|PARALLEL||||DOUBLE||||||
34142353|NCT02241876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34142354|NCT03350893|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, Parallel, Open Label Study||||
34142355|NCT03274427|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142356|NCT03707951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind placebo-controlled pharmacotherapy trial|1:1 parallel group allocation randomized placebo controlled trial|t|t|t|t
34142357|NCT01926808|||COHORT||RETROSPECTIVE|||||||
34142358|NCT03365141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142359|NCT04107818|||COHORT||PROSPECTIVE|||||||
34142360|NCT03833089|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142361|NCT04283565|RANDOMIZED|FACTORIAL||PREVENTION||NONE|"The investigators will include the patients before knowing their randomization arm. This procedure is essential to avoid selection bias by having an effect on the level of recruitment and the profile of the people included in the study.~The initial randomization unit is the CRMG. Eight CRMG will be included in the investigator's study. Four CRMGs will be randomly assigned to the group systematic AOMI screening by IPS measurement, four CRMG to the no systematic screening group. Then, each group thus obtained will be randomly divided into two CRMGs with advice and EM and two without CRMG."|"Two strategies are studied in this study:~* Screening for asymptomatic AOMI by measuring IPS~* Management of the FRCV by advices and motivational interviewing~The strategies will be associated according to a factorial plan 2 \* 2 in order to obtain 4 groups:~* Strategy 1: Routine testing for asymptomatic AOMI and management of FRCV.~* Strategy 2: Routine practice of asymptomatic AOMI screening and management of FRCVs by councils and a MA.~* Strategy 3: Systematic Screening of asymptomatic AOMI by measurement of SPI and routine management of FRCV.~* Strategy 4: Systematic screening of asymptomatic AOMI by measuring SPI and taking care of FRCVs by councils and a ME."||||
34142362|NCT02549222|||OTHER||PROSPECTIVE|||||||
34142363|NCT00505037|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142364|NCT03378427|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot study||||
34142365|NCT05460598|RANDOMIZED|PARALLEL||OTHER||SINGLE|single-blinded (only patients blinded)|Single-center, investigator-initiated, single-blinded, interventional, exploratory study.|t|f|f|f
34142366|NCT01952665|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34150867|NCT04383938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150868|NCT02160444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831702|NCT00435955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831703|NCT04966065|||COHORT||PROSPECTIVE|||||||
33831704|NCT00311246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831705|NCT02250768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831706|NCT04721964|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective intervention study||||
33831707|NCT00248534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831708|NCT01503164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831709|NCT02761863|||OTHER||PROSPECTIVE|||||||
33831710|NCT04356586|||COHORT||PROSPECTIVE|||||||
33831711|NCT02171130|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831712|NCT03498586|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33831713|NCT03984877|||COHORT||PROSPECTIVE|||||||
33831714|NCT02418962|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33831715|NCT06546358|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|Pharmacy will randomize and dispense medication. Participants will be started on trazodone 12.5 mg or quetiapine 6.25 mg in identical opaque gelatin capsules at bedtime.|Participants will be randomized in a 1:1 ratio to treatment with trazodone or quetiapine in blocks of 8 with a sequence generated by SPSS.|t|f|f|f
33831716|NCT03962322|NA|SINGLE_GROUP||TREATMENT||NONE||Single Group Assignment||||
33831717|NCT01376297|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33831718|NCT05501782|||CASE_CROSSOVER||PROSPECTIVE|||||||
34142367|NCT03855813|NA|SINGLE_GROUP||OTHER||NONE||Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self-test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.||||
34142368|NCT05268549|||CASE_CONTROL||RETROSPECTIVE|||||||
34142369|NCT04043754|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142370|NCT01480518|||CASE_ONLY||RETROSPECTIVE|||||||
34142371|NCT05068063|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34142372|NCT05533203|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142373|NCT01689623|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142374|NCT00743028|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142375|NCT05179603|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142376|NCT02683070|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
34142377|NCT02275390|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcome assessors are blind to the group assignment and intervention undertaken and concealed to the participant list.|"Repeated measures, two-arm design~\[SPBB: A repeated-measures, two-arm design with 112 outpatients and their family caregivers\]"|f|f|f|t
34142378|NCT06045182|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a randomized controlled trial having two groups. One group will receive maitland mobalizations and the second will receive maitland mobalization along with piriformis stretch. Both groups will be recruited concurrently.||||
33831719|NCT00673556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33831720|NCT00394420|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831721|NCT00927524|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33831722|NCT01640171|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33831723|NCT05347511|||COHORT||RETROSPECTIVE|||||||
33831724|NCT02561806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831725|NCT03927183|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A quasi- experimental study with non-equivalent control group design, pretest-posttest study||||
33831726|NCT05501756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831727|NCT00922922|||CASE_ONLY||CROSS_SECTIONAL|||||||
33831728|NCT00001359||||TREATMENT||||||||
33831729|NCT02625285|||COHORT||PROSPECTIVE|||||||
33831730|NCT02484664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831731|NCT00736125|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33831732|NCT03061604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831733|NCT00702598|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831734|NCT02944396|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831735|NCT02394522|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33831736|NCT04690478|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831737|NCT00433875|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831738|NCT01977027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831739|NCT06060483|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831740|NCT04077697|||CASE_ONLY||RETROSPECTIVE|||||||
33831741|NCT01317823|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|t|f|f
33831742|NCT01700283|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831743|NCT00005946||||TREATMENT||||||||
33831744|NCT06428864|||COHORT||RETROSPECTIVE|||||||
33831745|NCT04933799|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The research Pharmacists are unblinded.||t|t|t|f
33831746|NCT01589705|||COHORT||CROSS_SECTIONAL|||||||
33831747|NCT02842983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831748|NCT02619305|RANDOMIZED|PARALLEL||||NONE||||||
33831749|NCT01472614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831750|NCT05124288|||COHORT||OTHER|||||||
33831751|NCT04394312|NON_RANDOMIZED|PARALLEL||OTHER||NONE|As this was a pragmatic intervention participants, investigators, and outcome assessors were aware of the group allocation based on the workshop they attended and the survey data collected.|Participants are assigned to the intervention group or control group.||||
33831752|NCT02409446|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831753|NCT00330356|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33831754|NCT03981718|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831755|NCT02874105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831756|NCT03712592|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33831757|NCT03055546|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33831758|NCT00995384|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
33831759|NCT04160806|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831760|NCT05258409|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will remain unaware of what group they have been randomized to as both groups will be actively be participating in groups focused on male body image|Participants will briefly be screened for eligibility criteria by phone. Eligible participants will be assessed using two structured clinical interviews (SCID-5 \& EPSI-CRV) and complete a set of self-report measures at baseline. Following assessment participants will be randomized into one of two groups. One group will receive a dissonance-based intervention known as the More than Muscles (MTM), while other participants will engage in a Media Advocacy (MA) active control. Participants will complete the same set of self-report measures from baseline, after their final group, at 1-month follow-up and at 6-month follow-up. During the 6-month follow-up participants will also be reassessed using the same structured clinical interviews at baseline.|f|f|t|t
33831761|NCT01126320|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831762|NCT04363619|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831763|NCT00134771|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
33831764|NCT01192776|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33831765|NCT04513977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831766|NCT04482153|||CASE_ONLY||OTHER|||||||
33831767|NCT05811884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831768|NCT02473822|||||RETROSPECTIVE|||||||
33831769|NCT04555642|||CASE_CONTROL||PROSPECTIVE|||||||
33831770|NCT05269927|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34142379|NCT00064493|||COHORT||RETROSPECTIVE|||||||
34142380|NCT06512896|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142381|NCT00849706|||COHORT||PROSPECTIVE|||||||
34142382|NCT03777917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142383|NCT01952444|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142384|NCT03403231|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||The investigators will use a factorial design to test the main effects and a limited number of interaction effects of 5 messaging strategies.|f|f|t|f
34142385|NCT03885765|||COHORT||PROSPECTIVE|||||||
34142386|NCT04897919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142387|NCT02159222|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142388|NCT00881153|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142389|NCT01537146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142390|NCT02470143|||OTHER||PROSPECTIVE|||||||
34142391|NCT03978962|||COHORT||PROSPECTIVE|||||||
34142392|NCT03220581|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142393|NCT06380439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142394|NCT04368091|||CASE_ONLY||PROSPECTIVE|||||||
34142395|NCT04479475|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Eligible MMT clients identify up to three social support persons to attend intervention sessions. The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks. Social support persons attend up to five sessions over the course of six weeks.||||
34142396|NCT03003078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142397|NCT06456229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142398|NCT03128268|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each participant will receive tradition 2D Cardiac imaging as ordered per standard of care. Then, the participant will receive a 4D image, requiring 6 to 10 additional minutes in the MRI scanner. The 2D and 4D images will be interpreted by readers blinded to the results of the alternate modality. Inter- and intra-reader reliability will be assessed.||||
34142399|NCT04072679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142400|NCT03694392|||COHORT||PROSPECTIVE|||||||
34142401|NCT01338077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142402|NCT01436682|||CASE_CONTROL||PROSPECTIVE|||||||
34142403|NCT05801406|||COHORT||PROSPECTIVE|||||||
34142404|NCT04140955|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33831771|NCT01050361|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142405|NCT05126264|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Split-mouth design|t|t|f|f
34142406|NCT01759563|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142407|NCT01113489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34142408|NCT04165187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142409|NCT02255565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142410|NCT03614416|NA|SINGLE_GROUP||OTHER||NONE||No randomisation. All subjects will test simultaneously the gold standard and the EOXY device||||
34142411|NCT06237920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142412|NCT05746650|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34142413|NCT06320249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study did not implement blinding for the manipulative therapists and participants. However, blinding procedures were employed for the outcome assessors and data analysts, meaning that they remained unaware of the group.||f|f|f|t
34142414|NCT06306690|||COHORT||PROSPECTIVE|||||||
34142415|NCT02185157|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34142416|NCT05011214|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34142417|NCT04763486|RANDOMIZED|PARALLEL||PREVENTION||NONE||parturition||||
34142418|NCT05100940|||CASE_ONLY||OTHER|||||||
34142419|NCT05567419|||CASE_ONLY||PROSPECTIVE|||||||
34142420|NCT05860920|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142421|NCT05423938|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Randomized, crossover, double blind, multicenter, clinical trial|t|t|t|t
33831772|NCT02401100|||COHORT||PROSPECTIVE|||||||
33831773|NCT03371368|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Cohort||||
33831774|NCT00085566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831775|NCT04793750|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142422|NCT05302206|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34142423|NCT01276444|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142424|NCT04183855|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34142425|NCT02169622|||CASE_ONLY||PROSPECTIVE|||||||
34142426|NCT04086797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple||t|t|t|t
34142427|NCT00853125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142428|NCT00671372|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142429|NCT04410666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|It was single blind, since the patient did not wat treatment was receiving. It was used a placebo.|"Experimental group: an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C.~Control group: distilled water, in sterile glass containers. Each application was 10 ml. applied for 1 minute."|t|f|f|f
33831776|NCT04422093|||CASE_CONTROL||PROSPECTIVE|||||||
33831777|NCT00047177||||TREATMENT||NONE||||||
33831778|NCT03300622|||COHORT||PROSPECTIVE|||||||
33831779|NCT02910843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831780|NCT03995342|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33831781|NCT02111408|||COHORT||PROSPECTIVE|||||||
33831782|NCT01805206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142430|NCT05737420|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142431|NCT01878110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142432|NCT03080883|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34142433|NCT00046163|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34142434|NCT00004564|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142435|NCT05842863|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142436|NCT01878669|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34150869|NCT06071156|RANDOMIZED|PARALLEL||PREVENTION||NONE||1:1 randomization||||
34142437|NCT04976218|NA|SINGLE_GROUP||TREATMENT||NONE||TGFβR-KO CAR-EGFR T Cells will be administered to eligible patients in a 3+3 dose escalation manner.||||
34142438|NCT01067482|||||PROSPECTIVE|||||||
34142439|NCT02465749|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142440|NCT06021093|||COHORT||PROSPECTIVE|||||||
34142441|NCT00477269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142442|NCT02337972|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142443|NCT05281536|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|"Data obtained for mechanical ventilation, volumetric capnography, and electric impedance tomography will be download by different investigators when all patients have been recruited.~The results will be analyzed by statisticians, who will not know the participant's identification"|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.||||
34142444|NCT05240768|||COHORT||RETROSPECTIVE|||||||
34142445|NCT02897531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142446|NCT00459693||||TREATMENT||||||||
34142447|NCT01013155|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142448|NCT01850472|||COHORT||CROSS_SECTIONAL|||||||
34142449|NCT06101602|RANDOMIZED|PARALLEL||TREATMENT||NONE||Concurrent Parallel Randomized Controlled Trial||||
34142450|NCT05764668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142451|NCT04077866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142452|NCT03473964|||CASE_ONLY||RETROSPECTIVE|||||||
34142453|NCT02252549|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34142454|NCT02738476|||COHORT||PROSPECTIVE|||||||
34142455|NCT00456066|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142456|NCT02860624|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142457|NCT02430493|||COHORT||PROSPECTIVE|||||||
34142458|NCT04676308|||COHORT||PROSPECTIVE|||||||
34142459|NCT06154941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142460|NCT03795207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142461|NCT05826730|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized-controlled study|t|f|f|f
34142462|NCT02020876|||COHORT||RETROSPECTIVE|||||||
34142463|NCT02261129|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831783|NCT01179412|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831784|NCT02220218|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831785|NCT02324777|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33831786|NCT04164862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831787|NCT04319146|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, monocentric study||||
33831788|NCT05142800|||COHORT||PROSPECTIVE|||||||
33831789|NCT03975842|||OTHER||CROSS_SECTIONAL|||||||
33831790|NCT02626442|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831791|NCT01825005|||COHORT||PROSPECTIVE|||||||
33831792|NCT03354910|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Treatment assignments will be based on a computer-generated randomization scheme, stratified by age (\<60 vs. ≥60 yrs old) and household income (\<250% vs. ≥250% of federal poverty guidelines), since older and low-income patients are known to have lower LDKT rates a priori. Patients will be randomized into one of three treatment arms in a 1:3:3 fashion such that 54 Usual Care, 160 HC and 160 HC+PM patients will be enrolled. The study investigators and research assistants conducting the study assessments of patients will remain blinded to the treatment assignments. KT candidates will be informed of group assignment immediately after completing the Baseline assessment.|f|f|t|t
33831793|NCT04040998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831794|NCT01211444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831795|NCT02518347|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33831796|NCT04696783|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33831797|NCT03631303|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831798|NCT03750526|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831799|NCT00297843|||||OTHER|||||||
33831800|NCT00406900|||DEFINED_POPULATION||PROSPECTIVE|||||||
33831801|NCT05194670|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831802|NCT01587118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831803|NCT00479219|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33831804|NCT02989571|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||A power size calculation was performed using previously published institutional data as well as previously reported literature regarding induction of labor in nulliparous women. Baseline duration of labor induction among nulliparous women range from 21-30 hours. In order to obtain 80% power to detect a 20% decrease in the duration of labor at a statistical significance level of 0.05, 73 participants are needed in each group. In order to account for participant withdrawal and enrollment errors, the sample size is increased to 90 per group for a total of 180 participants.|t|t|t|t
33831805|NCT05088109|||COHORT||PROSPECTIVE|||||||
33831806|NCT00755456|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831807|NCT00503724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831808|NCT06547567|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34142464|NCT00330044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142465|NCT00970814|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142466|NCT03603535|||COHORT||PROSPECTIVE|||||||
34142467|NCT00257595|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142468|NCT04900337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142469|NCT00668018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142470|NCT06535022|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|sealed, opaque envelopes|Prospective, randomized, monocentric, interventional study||||
34142471|NCT00159913|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34142472|NCT03433820|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||A single-arm, observational study||||
34142473|NCT02014480|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34142474|NCT04026269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142475|NCT04832906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142476|NCT02370537|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142477|NCT02811913|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34142478|NCT01058512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142479|NCT03672682|||OTHER||RETROSPECTIVE|||||||
34142480|NCT01437098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142481|NCT02743780|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34142482|NCT00004664|RANDOMIZED|||TREATMENT||||||||
34142483|NCT00644618|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34142484|NCT04509245|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831809|NCT01270698|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831810|NCT03763149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831811|NCT03421639|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will take similar kind medications by an indipendent person|Randomized controlled trial in two arms study (150 each one)|t|t|f|f
33831812|NCT06162481|||OTHER||RETROSPECTIVE|||||||
33831813|NCT00000505|RANDOMIZED|||TREATMENT||||||||
33831814|NCT00554645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831815|NCT03499912|||CASE_ONLY||PROSPECTIVE|||||||
33831816|NCT02450890|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33831817|NCT02719314|||COHORT||PROSPECTIVE|||||||
33831818|NCT02230722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831819|NCT01585545|||CASE_ONLY||PROSPECTIVE|||||||
33831820|NCT03025932|||CASE_ONLY||RETROSPECTIVE|||||||
33831821|NCT02888236|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831822|NCT00778921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831823|NCT01006499|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33831824|NCT02184299|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831825|NCT01672398|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33831826|NCT05783999|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831827|NCT04757077|||CASE_CONTROL||RETROSPECTIVE|||||||
33831828|NCT05696223|||COHORT||RETROSPECTIVE|||||||
33831829|NCT05809102|NA|SINGLE_GROUP||TREATMENT||NONE||Minimal incisions in repair of Zone II flexor tendon of the hand instead of whole exposure of the tendon||||
33831830|NCT03437941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831831|NCT02444728|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831832|NCT02743299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831833|NCT03845075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831834|NCT05642117|||COHORT||PROSPECTIVE|||||||
33831835|NCT02033473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33831836|NCT03542162|NA|SINGLE_GROUP||TREATMENT||NONE||All patients who meet the criteria and agree to paticipate in the clinical study, will be enrolled to this study after signing informed consent.||||
33831837|NCT04718311|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831838|NCT03701633|||COHORT||CROSS_SECTIONAL|||||||
33831839|NCT05377515|||COHORT||PROSPECTIVE|||||||
33831840|NCT03970499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831841|NCT05186896|||OTHER||CROSS_SECTIONAL|||||||
33831842|NCT04654806|||COHORT||PROSPECTIVE|||||||
33831843|NCT05822128|||COHORT||PROSPECTIVE|||||||
33831844|NCT03943836|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33831845|NCT06408363|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33831846|NCT05648396|||COHORT||OTHER|||||||
33831847|NCT01028612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142485|NCT00723866|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142486|NCT01187004|||COHORT||PROSPECTIVE|||||||
34142487|NCT04254159|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34142488|NCT00304018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142489|NCT06078111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34142490|NCT00072891|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34142491|NCT02785458|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142492|NCT00002319||||TREATMENT||NONE||||||
34142493|NCT05397587|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142494|NCT06184412|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34142495|NCT05585229|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831848|NCT04950036|||CASE_CONTROL||RETROSPECTIVE|||||||
33831849|NCT00723125|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831850|NCT00499928|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831851|NCT04324658|||COHORT||PROSPECTIVE|||||||
33831852|NCT01939561|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33831853|NCT05331976|||CASE_ONLY||PROSPECTIVE|||||||
33831854|NCT00968305|||CASE_ONLY||CROSS_SECTIONAL|||||||
33831855|NCT03732976|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831856|NCT03282981|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831857|NCT00413855|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33831858|NCT04089072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831859|NCT04289259|||COHORT||PROSPECTIVE|||||||
33831860|NCT05239715|||COHORT||PROSPECTIVE|||||||
33831861|NCT03764995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831862|NCT05172986|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831863|NCT01674920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831864|NCT01440010|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33831865|NCT02298049|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831866|NCT02081937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831867|NCT02400814|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831868|NCT05765747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831869|NCT03913169|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical DO and PA students. The year two/clinical curriculum will be presented to third year Doctor of Osteopathic Medicine (DO) students and second year Physician Assistant (PA) students once clinic sites are identified.||||
34142496|NCT04706273|||CASE_ONLY||PROSPECTIVE|||||||
34142497|NCT03023826|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34142498|NCT03800589|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized control study with 24-month follow-up.||||
34142499|NCT00824005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142500|NCT04067037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142501|NCT04829474|||COHORT||PROSPECTIVE|||||||
34142502|NCT04283942|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients were randomly divided into intermittent calorie restriction group and control group for 12 weeks of intervention. Both groups will be followed up 4 weeks after intervention.~ICR group: during the 2-day fasting-mimicking period each week, the food based on plant ingredients will be served (4 pieces of nutrition bars / day, 1:2:1 for breakfast, lunch and dinner, 124.4kcal/piece, 497.2kcal / day in total). In the rest 5 days each week, subjects are allowed ad libitum to their usual food.~Control group: continuous calorie restriction (CCR). Under the guidance of nutritionist, subjects have to learn the method of food calories calculation. For each day, the daily calories intake is limited to 25 kcal / kg × standard weight \[kg, estimated by height (cm) - 100\]."||||
34142503|NCT03733028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142504|NCT01086319|||COHORT|||||||||
34142505|NCT00481312|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142506|NCT05131776|NA|SINGLE_GROUP||TREATMENT||NONE||OncoSil™ is comprised of OncoSil Phosphorous-32 Microparticles (hereafter Microparticles) and OncoSil Diluent (hereafter Diluent). OncoSil™ is an active implantable (radiological) medical device intended for use in brachytherapy, where cancer is treated by the insertion of radioactive implants directly into the cancerous tissue. OncoSil™ has been designed to be injected directly into, and to deliver an average absorbed dose of 100 Gy to the target treatment tumour. In therapeutic use 98% of the radiation is delivered within 81 days.||||
34142507|NCT02989051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142508|NCT00902421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142509|NCT02612701|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142510|NCT03282110|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142511|NCT00004446|RANDOMIZED|||TREATMENT||DOUBLE||||||
34142512|NCT05208086|||OTHER||PROSPECTIVE|||||||
34142513|NCT00717587||||TREATMENT||||||||
34142514|NCT06461052|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective study, parallel group||||
34142515|NCT04360512|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34142516|NCT00990899|||OTHER||CROSS_SECTIONAL|||||||
34142517|NCT06309251|||COHORT||PROSPECTIVE|||||||
34142518|NCT01261130|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34142519|NCT06455111|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A randomized block design will be implemented.||||
34142520|NCT06607822|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34142521|NCT03028480|||CASE_ONLY||PROSPECTIVE|||||||
34142522|NCT04220112|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34142523|NCT00150228|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34142524|NCT04522154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142525|NCT04687592|||CASE_ONLY||PROSPECTIVE|||||||
34142526|NCT03399565|||CASE_ONLY||OTHER|||||||
34142527|NCT02763475|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142528|NCT03630198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34142529|NCT06276582|NA|SINGLE_GROUP||SCREENING||NONE||||||
34142530|NCT02238314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142531|NCT00144924|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34142532|NCT03294135|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||All subjects will come to the yearly scheduled blood draw visit for investigation of 11 to 15 year persistence of Neutralization Test (NT) titres. Subjects who have an NT titre below 10 at one of the scheduled visits will receive a second booster dose 6 months after this visit at an unscheduled visit. Subsequent data of these subjects will be analysed separately in a subgroup.||||
34142533|NCT04088435|||COHORT||PROSPECTIVE|||||||
34142534|NCT05176002|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142535|NCT02488213|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142536|NCT03417362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142537|NCT05819021|||OTHER||PROSPECTIVE|||||||
34142538|NCT03404804|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34142539|NCT05857033|RANDOMIZED|PARALLEL||OTHER||SINGLE||The Participants will be randomly and equally allocated into 2 groups with 2 subgroups each|t|f|f|f
34142540|NCT03867565||PARALLEL||SUPPORTIVE_CARE||NONE||Patients found to have nutritional diagnosis will be given tailorized nutritional intervention.||||
34142541|NCT01817101|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34142542|NCT01312389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142543|NCT03109808|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"* Allocation : Randomized (with stratification on center and gender)~* Endpoint Classification : Safety/Efficacy Study~* Intervention Model : Parallel Assignment~* Masking : Double blind (Operator, Outcomes Assessor)~* Primary Purpose : Prevention"|t|t|f|f
34142544|NCT00429117|||CASE_ONLY||PROSPECTIVE|||||||
34142545|NCT02446418|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831870|NCT03336099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831871|NCT03288077|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142546|NCT04533542|||CASE_CONTROL||PROSPECTIVE|||||||
34142547|NCT03546166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142548|NCT06440889|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, Open-Label, Control-group, Proof-Of-Science, Real-life Setting, Clinical Safety and Efficacy Study||||
34142549|NCT02377570|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142550|NCT04165655|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The study will use a between-subject design where by participants will be assigned to either the experimental (10-week programme) or waitlist control group. Participants will be assigned a group based in the area in which they live. As the 10-week programme will be running in Tamworth, those participants living in Tamworth and surrounds will be assigned to the experimental group. The participants living in Cannock and surrounds will be assigned to the waitlist control group and participate in a 10-week programme after this research.||||
34142551|NCT02865798|||COHORT||PROSPECTIVE|||||||
34142552|NCT05535738|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||There are two phases in this study. The first phase involves sensitization to a contact allergen and skin sampling to establish baseline characteristics. In the second phase, the participant will be pre-treated with a one time dose of an immunomodulating medication, re-treated with a contact allergen, followed by skin sampling.||||
34142553|NCT02839902|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142554|NCT06196424|||COHORT||CROSS_SECTIONAL|||||||
34142555|NCT01601080|||COHORT||RETROSPECTIVE|||||||
34142556|NCT06300723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142557|NCT05610631|||COHORT||PROSPECTIVE|||||||
34142558|NCT00034164|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142559|NCT06151951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142560|NCT05571007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142561|NCT01982006|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142562|NCT01283399|||COHORT||PROSPECTIVE|||||||
33831872|NCT01517607|||COHORT||PROSPECTIVE|||||||
33831873|NCT02802358|||COHORT||PROSPECTIVE|||||||
33831874|NCT02594046|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33831875|NCT05604196|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831876|NCT04454788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831877|NCT01642095|||COHORT||RETROSPECTIVE|||||||
33831878|NCT00381797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831879|NCT01542554|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831880|NCT05512078|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||patients with bilateral vertical bone loss in posterior mandible||||
33831881|NCT00105105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831882|NCT04077385|RANDOMIZED|PARALLEL||TREATMENT||NONE|There will not be masking in the current study for participants as they will know if they are observing either high calorie pictorial food cues or non-food-related pictorial cues during the retrieval portion of the R-E/extinction training days. The investigator will also not be masked given that participants will be observed completing the R-E training task during sessions to ensure compliance, which involves observing participants advance through the task via a mirrored image on a second desktop monitor.|This study uses a two-arm parallel assignment in which participants are randomized to either a high calorie food retrieval + high calorie food extinction (R-E training) group or to a non-food retrieval + high calorie food extinction (extinction control) group.||||
33831883|NCT02952859|||COHORT||PROSPECTIVE|||||||
33831884|NCT02274779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831885|NCT03163043|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831886|NCT04470843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831887|NCT02162017|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33831888|NCT05639998|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE||"Group 1 (COVAXIN® + COVAXIN®): In this group, 152 participants will be recruited who will receive COVAXIN® on day 0 and on day 28 via the intramuscular route.~Group 2 (COVAXIN® + BBV154): In this group, 152 participants will be recruited who will receive COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28.~Post 56 days of vaccination, participants with seroconversion rate less than 3 folds will receive another dose of COVAXIN® viaintramuscular route.~Group 3 (BBV154 + COVAXIN®): In this group, 152 participants will be recruited who will receive BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28.~Post 56 days of vaccination, participants with seroconversion rate less than 3 folds will receive another dose of COVAXIN® via intramuscular route.~Group 4 (BBV154 + BBV154): In this group, 152 participants will be recruited who will receive BBV154 on day 0 and on day 28 via the intranasal route"|t|f|f|f
33831889|NCT01719588|||CASE_ONLY||PROSPECTIVE|||||||
33831890|NCT01339624|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831891|NCT02998398|||COHORT||RETROSPECTIVE|||||||
33831892|NCT03772600|RANDOMIZED|PARALLEL||OTHER||NONE||multicenter, randomized, double arm, open label, partial cross-over, parallel group clinical trial||||
33831893|NCT03088098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831894|NCT00832000|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33831895|NCT05200325|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|Participants, who are care providers, do not know what study arm they are included in.||t|t|f|f
33831896|NCT00273208|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33831897|NCT05194475|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33831898|NCT04488042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Physicians who performed manometry were blinded from specimen allocation|the gastric specimen were immediately randomly allocated to the two groups|t|t|f|f
33831899|NCT05969405|||CASE_CONTROL||RETROSPECTIVE|||||||
33831900|NCT02579824|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831901|NCT00521859|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33831902|NCT04843410|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomized Controlled Trial|t|f|f|f
33837563|NCT03359564|||COHORT||PROSPECTIVE|||||||
33837564|NCT01044927|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837565|NCT02429479|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34142563|NCT01461629|||CASE_ONLY||PROSPECTIVE|||||||
34142564|NCT02094027|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142565|NCT04264650|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34142566|NCT05199428|||COHORT||CROSS_SECTIONAL|||||||
34142567|NCT05819307|||COHORT||PROSPECTIVE|||||||
34142568|NCT03503292|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142569|NCT02429713|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34142570|NCT05616819|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|"Participants will not have any knowledge of which of the two condition groups they are apart of during or after the study.~The investigator will not have any knowledge of which of the two condition groups the participant is apart of during or after the study.~Condition groups will be randomly assigned via the web-based portal used for recruitment, data collection, and testing."|All recruitment, data collection, and testing will occur online, through remote interactions. Via a web-based portal, participants will complete a baseline assessment battery to document their sleep habits, mental health, and suicidal ideation. After the baseline assessment, participants will be randomly assigned to one of two treatment orders: Order A) Active Light Condition Therapy (ALT) for 2 weeks, a 2-week washout period, and 2 weeks of Placebo Light therapy, or Order B) PLT for 2 weeks, a 2-week washout period, and 2 weeks of ALT.|t|f|t|f
34142571|NCT02855723|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142572|NCT06127355|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33837566|NCT04856735|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
33837567|NCT00910286||CROSSOVER||||SINGLE|||t|f|f|f
33837568|NCT02952196|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33831903|NCT06226662|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This is a double-blind study (subjects and on-site medical/nursing staff at the study site are blinded to study drug/dose assignment). The pharmacy staff preparing the investigational products will not be blinded to NM8074 study drug assignment, but all other site staff, including the Investigator, will be blinded. Unblinding should only be considered for the safety of the subject.|Eligible subjects will be enrolled and stratified in three strata: (1) granulomatosis with polyangiitis (GPA) (2) microscopic polyangiitis (MPA), and (3) renal-limited vasculitis, and then randomized in a 1:1 ratio of NM8074+SOC to Placebo+SOC (6 subjects in each cohort).|t|f|t|f
33831904|NCT00983905|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831905|NCT04367077|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33831906|NCT04876209|||COHORT||RETROSPECTIVE|||||||
33831907|NCT00839410|||COHORT||PROSPECTIVE|||||||
33831908|NCT02378298|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33831909|NCT04533009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|placebo tablets are used|Randomised, double blinded, placebo controlled study|t|t|t|t
33831910|NCT03259399|||COHORT||OTHER|||||||
33831911|NCT04407598|||COHORT||CROSS_SECTIONAL|||||||
33831912|NCT01006616|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831913|NCT05531890|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33831914|NCT03636373|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple|Subjects will be administered a single dose of etanercept 50 mg subcutaneously (SC), at the onset of an acute gout attack, or a single dose of triamcinolone acetonide 40 mg intramuscularly (IM)|t|t|t|f
33831915|NCT04721782|||CASE_CONTROL||PROSPECTIVE|||||||
33831916|NCT01329471|||||PROSPECTIVE|||||||
33831917|NCT04826276|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants will be instructed to smoke as usual before one fMRI study visit (satiated state) and to abstain from using all tobacco/nicotine for 12 hours before the other fMRI study visit (abstinence and/or withdrawn state). The order of the satiated and abstinence/withdrawn study visits will be randomized and counterbalanced across participants.||||
33831918|NCT01966198|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33831919|NCT02449083|||COHORT||PROSPECTIVE|||||||
33831920|NCT05421767|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|RNS guided RDN|RNS checked RDN||||
33831921|NCT00801411|RANDOMIZED|||TREATMENT||NONE||||||
33831922|NCT00538356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831923|NCT01955759|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33831924|NCT00490945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33831925|NCT04827589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Study consists a placebo controlled period and an open label extension period. Sponsor is also masked for the placebo controlled period.||t|f|t|f
33831926|NCT06146075|||CASE_CROSSOVER||PROSPECTIVE|||||||
33831927|NCT03693209|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The control condition is active and has a similar format to the intervention conditions to avoid participants knowing which condition they have been assigned to. Outcomes are assessed by self-report.|There will be one control group and two intervention groups. Each group will be independently be compared with the others, and not in combination.|t|f|f|t
33831928|NCT00992719|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33831929|NCT06145425|NA|SINGLE_GROUP||TREATMENT||NONE||3 single groups: physicians, resident physicians and nurses||||
33831930|NCT04312542|||COHORT||PROSPECTIVE|||||||
33831931|NCT00646464|||COHORT||PROSPECTIVE|||||||
33831932|NCT01551810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33831933|NCT03801681|||COHORT||PROSPECTIVE|||||||
33831934|NCT01838486|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831935|NCT02670122|||COHORT||PROSPECTIVE|||||||
33831936|NCT01976221|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33831937|NCT01547117|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomization tables will be used to determine whether the 10 mEq sodium/day or 300 mEq sodium/day diet will be consumed first. Both diets will be completed on each subject (randomized crossover study), so all of the study procedures (after screening) will be repeated.||||
33831938|NCT00559377|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33831939|NCT04640818|||COHORT||PROSPECTIVE|||||||
33831940|NCT02754336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831941|NCT04410809|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831942|NCT05569863|||COHORT||PROSPECTIVE|||||||
33831943|NCT06241729|||COHORT||PROSPECTIVE|||||||
33831944|NCT01178307|||COHORT||PROSPECTIVE|||||||
33831945|NCT00751634|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142573|NCT03773133|NA|SINGLE_GROUP||OTHER||NONE||||||
34142574|NCT01034371|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142575|NCT01390779|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142576|NCT02404922|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33831946|NCT03946098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831947|NCT05421156|||CASE_CONTROL||RETROSPECTIVE|||||||
34142577|NCT02435680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142578|NCT04332471|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34142579|NCT00591149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142580|NCT01655043|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE||||||
33831948|NCT00144846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831949|NCT05035797|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33831950|NCT01114763|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831951|NCT03121209|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|single blind by outcomes assessor|Phase 3 prospective blinded outcome randomized clinical trial|f|f|f|t
33831952|NCT00528671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831953|NCT03371745|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837569|NCT00480506|||||RETROSPECTIVE|||||||
33837570|NCT02580747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837571|NCT00419289|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837572|NCT00583297|||COHORT||PROSPECTIVE|||||||
33837573|NCT06530355|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33837574|NCT01932762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837575|NCT03202680|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33837576|NCT02559401|||COHORT||PROSPECTIVE|||||||
33831954|NCT03419676|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"All patient data are anonymous. Each patient who meets the selection criteria and has signed the informed consent will be entered into a database and identified by a number (from 1 to 64). The list of patient identification numbers will be in the hands of the principal investigator. After carrying out the surgery, the patient number is entered into an online computerized randomization tool (Randomizer for clinical trials), https://www.meduniwien.ac.at/randomizer. It is a tool of the University of Vienna in Austria, where it is registered in a study, which allows, once the patient number is entered, the randomization of the same, obtaining one of the two methods to compare (32 patients in each study group):~1. Basic treatment: duct-to-mucosa pancreaticojejunostomy WITHOUT Hemopatch reinforcement.~2. The same, but reinforced WITH Hemopatch.~Once the treatment to be performed is obtained, surgery will be carried out according to the treatment obtained in the randomization."|t|f|f|t
33831955|NCT03330964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33831956|NCT01010087|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33831957|NCT05252728|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33831958|NCT04286763|||OTHER||RETROSPECTIVE|||||||
33831959|NCT04099485|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"For the first aim AF patients in our UC Health primary care network will be randomized into one of two study arms: 1) Atrial Fibrillation Decision-Support Tool (AFDST); 2) AFDST with addition of best practice advisory (BPA) and option to refer to shared decision-making consultation services. Patients will enter the study as their clinicians receive BPAs, or in the case of the first study arm, when BPAs would have been generated as clinicians open medical records of patients for whom current thromboprophylaxis is not optimal.~The second aim is a pre/post study evaluating the impact of shared decision-making tools and services. Patients consenting to participation in this aspect of the study, will have a shared decision-making visit with one of our anticoagulation pharmacists."||||
33831960|NCT03888222|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be randomized by a Biostatistician by an internet based randomization module into two groups. The researchers include : Primary investigator , Sub-Investigators ,Clinical Coordinators, Nurse Practitioners , and Clinical Reseach unit staff.~The investigators will be blinded to the dosage. Medications for any patient will be labeled by the CRU with a package medical identification number (Med. Id). A patient specific patient identification number (Pat. Id.) will be assigned to each patient. The investigator will have to note the Pat.Id on the designated medication package number after randomization."|"We will evaluate the effects of 100 mg Bosutinib versus matching placebo taken daily by mouth for 12 weeks, followed by a 4 week wash-out period in individuals diagnosed with DLB. We will perform physiologically-based population pharmacokinetics (popPK) using a seamless random single dose (RSD) of Bosutinib, where participants (n=30) will be randomized to 3 groups (n=10) and take a single oral dose of 100mg, 200mg, Bosutinib or placebo (1;1;1) open label. Lumbar puncture will be performed between 1-4 hours after dosing. Participants will then be randomized double-blinded into 2 groups 1;1 using placebo(n=15) and 100mg (n=15) for 3 months.~Randomization and Registration will be performed by an internet based randomization module. Randomization of the subjects to the 2 treatment groups will be performed in a stratified manner. The chance for randomization to the groups is 1:1 for placebo: 100 mg Bosutinib."|t|t|t|t
33831961|NCT03672487|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo||t|t|t|t
33831962|NCT02650466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831963|NCT01096576||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831964|NCT03182998|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33831965|NCT05876169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831966|NCT02737111|NA|SINGLE_GROUP||||NONE||||||
33831967|NCT03159351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831968|NCT02670499|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33831969|NCT02164006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831970|NCT00154427|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831971|NCT04615598|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33831972|NCT04718233|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33831973|NCT00503607|RANDOMIZED|PARALLEL||||SINGLE||||||
33831974|NCT00565838|||CASE_ONLY||PROSPECTIVE|||||||
33831975|NCT01045863|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33831976|NCT01850498|||COHORT||PROSPECTIVE|||||||
33831977|NCT05833659|||COHORT||OTHER|||||||
33831978|NCT06110065|||COHORT||PROSPECTIVE|||||||
33831979|NCT00525928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831980|NCT03253432|||COHORT||PROSPECTIVE|||||||
33831981|NCT00002796|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831982|NCT00828893|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33831983|NCT03953456|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|"The Investigator, subject, and study personnel will be blinded to the treatment.~Identification numbers will be assigned to a subject at the Screening Visit. Upon completion of the Screening Visits, eligible subjects will be randomly assigned to Sequence Group A or Group B, defining the order of treatments."|Randomized, double-blind, cross-over (placebo or elafibranor \[GFT505\]) placebo-controlled study|t|t|t|t
33831984|NCT05270369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831985|NCT00621738|||||PROSPECTIVE|||||||
33831986|NCT02482532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831987|NCT00817245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33831988|NCT00133055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142581|NCT03355560|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142582|NCT04662073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142583|NCT00263640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142584|NCT04972227|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Dose escalation study|t|f|t|f
34142585|NCT00517439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149903|NCT05474534|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of two groups: 1) the Treatment group (participants in this group will receive the three-month neurofeedback intervention), or the Wait-list Control Group (participants in this group will not receive the neurofeedback intervention during the data collection period; they will be given the choice to use neurofeedback for after the data collection period has ended).||||
34149904|NCT00498888|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34149905|NCT05569694|NA|SINGLE_GROUP||OTHER||NONE||||||
34149906|NCT05788133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831989|NCT03716388|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33831990|NCT00766402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33831991|NCT02536495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33831992|NCT01356563|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|t|f|t
33831993|NCT03828188|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33831994|NCT02188394|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831995|NCT01057251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33831996|NCT02719756|RANDOMIZED|PARALLEL||||NONE||||||
33831997|NCT03690440|||COHORT||OTHER|||||||
33831998|NCT05889845|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Unblinded site staff will prepare syringes of study drug for administration by blinded study staff|Randomized, Double-Blind, Placebo-Controlled Study|t|t|t|t
33831999|NCT04692545|||CASE_CONTROL||RETROSPECTIVE|||||||
33832000|NCT02851875|||COHORT||PROSPECTIVE|||||||
33832001|NCT03643757|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832002|NCT04866706|||CASE_ONLY||PROSPECTIVE|||||||
33832003|NCT03745586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832004|NCT06266598|NA|SINGLE_GROUP||TREATMENT||NONE||In our study, there are 33 healthy children with normal weight (control group) and 52 obese children who will be treated with metformin. To observe the efficacy of the 3-month treatment before and after metformin treatment, Zn, Zinc α-2 Glycoprotein (ZAG), Peroxisome proliferation activating receptor γ (PPARγ), Leptin (LEP) and Adiponectin (ADIPO) levels were compared, as well as anthropometric measurements and routine biochemistry tests.||||
33832005|NCT00808145|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832006|NCT02420041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832007|NCT03932578|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33832008|NCT01299142|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832009|NCT06545578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832010|NCT05634798|||COHORT||PROSPECTIVE|||||||
33832011|NCT02491710|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33832012|NCT01473745|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832013|NCT05416411|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
33832014|NCT00483353|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832015|NCT05082181|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33832016|NCT02418715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832017|NCT02787811|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832018|NCT04965753|NA|SINGLE_GROUP||TREATMENT||NONE||Open label single arm dose escalation and three-arm expansion study in patients with advanced synovial sarcoma or advanced SMARCB1-loss tumors||||
33832019|NCT03569475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832020|NCT04212754|||COHORT||PROSPECTIVE|||||||
33832021|NCT04502290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832022|NCT05917860|NA|SINGLE_GROUP||TREATMENT||NONE||"Procedure: Magnetic resonance imaging-guided transurethral ultrasound ablation of the prostate (TULSA)~Drug: Degarelix"||||
33832023|NCT05691972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832024|NCT06242704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832025|NCT05810805|||OTHER||PROSPECTIVE|||||||
33832026|NCT02718547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832027|NCT06426095|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33832028|NCT03722498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832029|NCT05425407|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832030|NCT01805245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832031|NCT06202911|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33832032|NCT00719043|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832033|NCT00573651|NA|SINGLE_GROUP||OTHER||NONE|The geometric mean titers are analyzed in a de-identified manner at Merck Contract laboratories.|Open label vaccination study Gardasil vaccine (4 component).||||
33832034|NCT02363998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832035|NCT03245177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832036|NCT05142579|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||The 60 patients who made up the sample were assigned 2 groups using a computer program that produced random numbers. For the purpose of the study, the groups were encoded as groups A and B, and each group was tested with two different endotracheal tube detection methods which was applied to the patients in the groups|t|t|t|t
33832037|NCT00347880|||COHORT||PROSPECTIVE|||||||
33832038|NCT01979289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832039|NCT01441583|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33832040|NCT01182103|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832041|NCT00568698|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33832042|NCT03166046|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Coded devices that are identical in appearance and function. Placebo device does not emit electromagnetic field. Active device electromagnetic field is sub-sensory.|Randomized, double blind, placebo controlled trial using an active pulsed shortwave therapy device or placebo pulsed shortwave therapy device|t|t|t|t
33832043|NCT04476836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832044|NCT03954223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832045|NCT02804451|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832046|NCT01407276|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832047|NCT02701998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832048|NCT00912223|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832049|NCT04354168|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33832050|NCT04433325|||CASE_CONTROL||RETROSPECTIVE|||||||
33832051|NCT04863820|||OTHER||CROSS_SECTIONAL|||||||
33832052|NCT03067363|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE||Part 1: single ascending doses Part 2: parallel group|t|t|t|t
33832053|NCT02958241|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832054|NCT05505370|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||The objective of the present study is to Study the clinical success and clinical safety of the Saneso colonoscope||||
33832055|NCT00103636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837577|NCT00002838|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832056|NCT04962698|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Participants in a single group will receive various types of interventions in random order. The types of interventions are the same across subjects.||||
33832057|NCT01601613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832058|NCT01682746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832059|NCT01477736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832060|NCT01840449|||COHORT||PROSPECTIVE|||||||
33832061|NCT00022607|RANDOMIZED|||TREATMENT||||||||
33832062|NCT02893098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832063|NCT04967183|RANDOMIZED|PARALLEL||SCREENING||TRIPLE||"Patients will be identified in population CRC secreening programs of Galicia, the Basque Country, the Region of Valencia and Murcia. We will considered individuals aged 50 to 65 years with at least one advanced adenoma (tubulovillous or villous histology, high grade dysplasia or ≥ 10mm), and / or at least three non-advanced adenomas detected and resected completely within the population-based CRC screening program.~Patients will be randomly allocated to perform an annual FIT and colonoscopy if fecal hemoglobin concentration is ≥10µg/g, or to perform endoscopic surveillance. Patients will be also stratified into two groups: ≥5 adenomas or an adenoma ≥20mm and the rest of patients.~Patients will be followed for a period of 10 years."|t|t|t|f
33832064|NCT03155217|||COHORT||RETROSPECTIVE|||||||
33832065|NCT05163210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants and their caregivers will be informed about the study aims and procedures, but they will be blinded to group allocation. In the case the patient asks for the presence of the caregiver, she/he will be seated near the participant but out of her/his view, without interfering during the treatment session. The therapist performing the intervention will not be blinded to the group allocation. Outcome assessments will be administered and scored by a member of the staff blinded to group allocation.|This study will consist in a multicentric, randomized, allocation concealed (waitlist-controlled) and evaluator-blinded clinical trial (RCT) with two investigative arms, using an intensive rehabilitation program based on the combined use of AO followed by imitation in VR (AO+VR) (experimental intervention) compared to a control treatment based on observation of control videos followed by action execution in VR (CO+VR) (control intervention).|t|f|f|t
33832066|NCT04266847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832067|NCT04885647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832068|NCT03856047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures.|This is a twelve-armed trial comprising of five (0.3, 0.6, 1.2, 2.4 and 4.5 mg OW) of NNC0174-0833 arms and liraglutide 3.0 mg OD arm as active treatment arms and the corresponding 6 placebo arms as comparators. Participants will be randomised 6:1 between the active treatment arms and the placebo arms. The five different NNC0174-0833 placebo arms and the one liraglutide placebo arm will be pooled into one placebo group for statistical analyses of the results.|t|t|t|t
33832069|NCT06050759|||COHORT||PROSPECTIVE|||||||
33832070|NCT05910892|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33832071|NCT06040632|||COHORT||PROSPECTIVE|||||||
33832072|NCT03989921|||OTHER||RETROSPECTIVE|||||||
33832073|NCT00503503|||||PROSPECTIVE|||||||
33832074|NCT03586349|||OTHER||PROSPECTIVE|||||||
33832075|NCT04461834|||COHORT||CROSS_SECTIONAL|||||||
33832076|NCT05651425|||CASE_CONTROL||RETROSPECTIVE|||||||
33832077|NCT00038298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832078|NCT06547385|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33832079|NCT01246245|||COHORT||PROSPECTIVE|||||||
33832080|NCT02599922|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832081|NCT06418230|||COHORT||RETROSPECTIVE|||||||
33832082|NCT03371277|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33832083|NCT02187731|||OTHER||PROSPECTIVE|||||||
33832084|NCT03268109|||OTHER||CROSS_SECTIONAL|||||||
33832085|NCT02457442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33832086|NCT04698915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832087|NCT00826228|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832088|NCT04886960|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Half of the patients will be in the SOC treatment arm and half of the patients will be in the AF arm. The PI and patients will be blinded as to the arm in which they will be participating. Once the randomization number is obtained, unblinded research staff will prepare the appropriate study drug. The injections will be blinded to the research coordinator in charge of data entry, the treating physician and the patient.||t|t|t|f
33832089|NCT04956562|||COHORT||RETROSPECTIVE|||||||
33832090|NCT01818609|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33832091|NCT03331926|||COHORT||RETROSPECTIVE|||||||
33832092|NCT01452737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832093|NCT03911362|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832094|NCT01743976|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832095|NCT03231098|||CASE_ONLY||PROSPECTIVE|||||||
33832096|NCT03441945|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33832097|NCT03875781|RANDOMIZED|PARALLEL||TREATMENT||NONE||To demonstrate the non inferiority of preoperative modified FOLFIRINOX chemotherapy compared to radiochemotherapy in primary resectable locally advanced rectal cancer||||
33832098|NCT02470923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832099|NCT05109936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832100|NCT00002547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832101|NCT01542346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832102|NCT00438178|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832103|NCT03003598|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
33832104|NCT01893853|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33832105|NCT05317559|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33832106|NCT02658175|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832107|NCT02274077|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832108|NCT03462043|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832109|NCT00301561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832110|NCT01458925|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832111|NCT00372346|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149907|NCT00349830|||COHORT||PROSPECTIVE|||||||
33832112|NCT00616330|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832113|NCT06270589|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33832114|NCT06079268|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33837035|NCT05652803|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"In this study, simple random sampling method was used, in which individuals were selected as samples using probability rules. When using the simple random sampling method, the units in the universe are listed and numbered first. Then, the elements to be included in the sample are determined by using the Draw Method or Random Numbers Table. 39 people who accepted to participate in this study and met the inclusion criteria were assigned to the experimental and control groups by simple randomization method. In order to reduce the selection bias, while determining the experimental and control groups, the assignment of the experimental and control groups by the randomization method from the random numbers table by a statistician who did not have a direct role in the research (https://www.random.org/integers/ random numbers table). group: 13, 2nd experimental group: 13, control group: 13)."|This research is a randomized controlled experimental study to compare the effects of two psychoeducational programs prepared in accordance with the principles of psychoeducation and bibliotherapy on the depression and hopelessness levels of elderly individuals. In this study, there are pre-test, post-test, follow-up test and comparative experimental group. In this model, there are 2 different experimental groups and 1 control group created by randomization. No intervention will be made in the control group. There will be 13 people in each group.|f|f|t|f
33837036|NCT00004251|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837037|NCT05677386|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837038|NCT01218347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837039|NCT01475305|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33837040|NCT04903418|||OTHER||CROSS_SECTIONAL|||||||
33837041|NCT03877861|||CASE_CONTROL||PROSPECTIVE|||||||
33837042|NCT01335347|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837043|NCT01987492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837044|NCT01515943|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33837045|NCT03539068|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||RCT- Screening, Shared-decision making intervention with Veteran and Providers using Agency for Healthcare Research and Quality (AHRQ) model||||
33837046|NCT01529489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837047|NCT04648592|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Trial participants, care providers and study investigators will be blinded to assigned interventions.|Prospective, randomized, double blind clinical trial.|t|t|t|f
33837048|NCT05443113|||COHORT||PROSPECTIVE|||||||
33837049|NCT00389272|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837050|NCT00027391|RANDOMIZED|||TREATMENT||DOUBLE||||||
33837051|NCT02916550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837052|NCT03242512|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837053|NCT01235000|||COHORT||PROSPECTIVE|||||||
33837054|NCT00172939|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837055|NCT04785105|||COHORT||RETROSPECTIVE|||||||
33837056|NCT01391637|||COHORT||PROSPECTIVE|||||||
33837057|NCT04426435|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33837058|NCT02601209|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837059|NCT02344589|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33837060|NCT01186822|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837061|NCT02328079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837062|NCT01001390|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33837063|NCT01976273|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33837064|NCT02497989|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33837065|NCT05620615|||COHORT||PROSPECTIVE|||||||
33837066|NCT03193242|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33837067|NCT05763303|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33837068|NCT01333553|||CASE_ONLY||PROSPECTIVE|||||||
33837069|NCT06230172|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The investigators will compare a retrospective control arm with a prospective intervention arm.||||
33837070|NCT03387761|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, open-label phase 1b clinical trial||||
33837071|NCT03944642|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The allocation was done by outpatient clinic to avoid contamination bias. Participants of the outpatient clinic A will receive the CRIAA Program (intervention group) and participants of the outpatient clinic B will receive the standard care (control group)||t|f|f|f
33837072|NCT02813044|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33837073|NCT03866590|||COHORT||CROSS_SECTIONAL|||||||
33837074|NCT03529227|||COHORT||PROSPECTIVE|||||||
33837075|NCT06026553|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|Allocation group will not be disclosed to the patient or the physician or the nurse or the outcome assessor. The anesthesia provider administering the IV Ketorolac or Placebo will be unblinded.||t|t|f|t
33837076|NCT03721172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837077|NCT02402322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837078|NCT00297804|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837079|NCT01970254|||CASE_ONLY||PROSPECTIVE|||||||
33837080|NCT02372838|||||CROSS_SECTIONAL|||||||
33837081|NCT06220305|||OTHER||RETROSPECTIVE|||||||
33837082|NCT05106205|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837083|NCT01282515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33837084|NCT06422442|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Individuals reviewing and coding data will not be aware of group status or diagnoses for participants.|||||
33837085|NCT05572593|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33837086|NCT00867698|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837087|NCT00220064|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837088|NCT01118559|RANDOMIZED|CROSSOVER||||NONE||||||
33837089|NCT04742231|NON_RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||NONE||||||
33837090|NCT03472989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patients who receive rESWT or sham-rESWT will be blinded.|Participants will be randomly assigned to one of the four intervention groups in parallell for the duration of the study.|f|f|t|t
33832115|NCT03225976|RANDOMIZED|PARALLEL||OTHER||TRIPLE||"Athletes will be randomized allocated the following groups:~* Infrared LED group (G-I; n = 12)~* Red LED group (G-V; n = 12)~* Infrared plus Red LED group (G-IV; n = 12)~* Sham Group (G-S; n = 12)"|f|t|t|t
33832116|NCT04253119|||COHORT||RETROSPECTIVE|||||||
33832117|NCT05184270|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33832118|NCT05700448|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832119|NCT05643547|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33832120|NCT00966979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832121|NCT05080205|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||60 subjects undergoing bariatric surgery (either Roux-en-Y gastric bypass or Sleeve gastrectomy) and 30 healthy controls||||
33832122|NCT00224029|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832123|NCT00072605||||TREATMENT||||||||
33832124|NCT01733589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832125|NCT04709978|||COHORT||PROSPECTIVE|||||||
33832126|NCT03547245|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|t|f|f
33832127|NCT02736279|||COHORT||PROSPECTIVE|||||||
33832128|NCT03581669|||CASE_ONLY||RETROSPECTIVE|||||||
33832129|NCT03634722|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS|t|f|t|f
33832130|NCT00020761|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832131|NCT00581152|||CASE_ONLY||OTHER|||||||
33832132|NCT00107679|||||PROSPECTIVE|||||||
33832133|NCT04752033|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Dose Finding Study Utilizing Sequential Up and Down Method Using Biased Coin Design|t|t|t|f
33832134|NCT01459146|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832135|NCT01159522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832136|NCT06302595|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33832137|NCT05739539|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832138|NCT02585297|||COHORT||PROSPECTIVE|||||||
33832139|NCT01200498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832140|NCT04456712|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE||fifty diabetic patients received intravenous levofloxacin 750 mg/24 hours. fifty diabetic patients received intravenous ciprofloxacin 400mg/12 hours. fifty non-diabetic patients received intravenous levofloxacin 750 mg/24 hours. fifty non-diabetic patients received intravenous ciprofloxacin 400mg/12 hours.|t|t|t|t
33832141|NCT06359496|||COHORT||RETROSPECTIVE|||||||
33832142|NCT05383638|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33832143|NCT06177899|||COHORT||RETROSPECTIVE|||||||
33832144|NCT02639806|||COHORT||OTHER|||||||
33832145|NCT03655665|RANDOMIZED|PARALLEL||OTHER||NONE||Clinical effectiveness model. Each subject will serve as their own control. Subject's ears will be randomized.||||
33832146|NCT06330987|||CASE_CROSSOVER||PROSPECTIVE|||||||
33832147|NCT03990142|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be classified into 2 groups according to the occurrence of intradialytic hypotension which is defined as a decrease in systolic blood pressure greater than 30 mmHg associated with clinical signs (cramps, abdominal pain, unconsciousness, convulsions). Group 1 corresponds to patients with intradialytic hypotension and group 2 corresponds to patients without intradialytic hypotension. This study aims to measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.||||
33832148|NCT03632083|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The first solution, the randomisation determines that the right lens will wear the fanfilcon A lens and the left eye will wear the comfilcon A lens for two hours of wear, with a two-day 'wash-out' period and the laterality of the lenses will be swapped for the second solution for two hours of wear. Lenses will be provided in lens cases which do not detail lens or care system information.|This is a double-masked, randomized, contralateral, crossover study design. Lenses are worn as an unmatched pair.|t|f|t|f
33832149|NCT01190722|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832150|NCT04055610|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33832151|NCT02024659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832152|NCT00979693|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832153|NCT03013140|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33832154|NCT04088929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832155|NCT06317038|NA|SINGLE_GROUP||OTHER||NONE||Open label Observation||||
33832156|NCT05760911|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832157|NCT01537185|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33832158|NCT04418661|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34149908|NCT00552760|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149909|NCT04958746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149910|NCT01458834|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149911|NCT03481426|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34149912|NCT06179316|||CASE_CONTROL||PROSPECTIVE|||||||
34149913|NCT02190890|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149914|NCT05257369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|no masking|Prospective randomized controlled trial|f|f|f|t
34150870|NCT03989323|||OTHER||PROSPECTIVE|||||||
33832159|NCT04531306|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33832160|NCT00996502|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832161|NCT00233662|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832162|NCT01089309|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832163|NCT06102226|||COHORT||PROSPECTIVE|||||||
33832164|NCT02173145|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33832165|NCT01764308|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832166|NCT03156205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832167|NCT05886946|||COHORT||PROSPECTIVE|||||||
33832168|NCT06401837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832169|NCT05596747|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33832170|NCT01488955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150871|NCT06464965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150872|NCT01441700|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142586|NCT05615194|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"The patient, the anesthesiologist in charge, the surgeon, the PACU staff and the research team evaluating the patient in PACU will be blinded to the randomization group.~The syringe containing the dexmedetomidine or the placebo will be prepared by an anesthesiologist or a pharmacist external to the study and identified by a unique number so that the patient's group can be identified if needed. Both solutions are translucent and total volume to be administered on 10 minutes during induction will be of equal volume."|"Patients will be 1:1 randomly assign to one of the two following groups: dexmedetomidine 0.6 mcg.kg-1 (group D) or a saline placebo of equivalent volume (group C) to be administered on 10 minutes during induction.~The patient presenting all the inclusion criteria and no exclusion criteria for this study will be approached by the anesthesia research team. They will provide explanations on the study as well as a consent form to the patient for him to have time to read it before the surgery. The risk of serious and unexpected adverse reactions to dexmedetomidine will also be disclosed to the patient before his agreement to participate to the study. After his approval, the patient will sign the consent and will be randomized."|t|t|t|f
34142587|NCT01102543|||COHORT||PROSPECTIVE|||||||
34142588|NCT04833153|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142589|NCT05492799|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142590|NCT06176495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142591|NCT02226315|||CASE_ONLY||RETROSPECTIVE|||||||
34142592|NCT02100020|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34142593|NCT04947878|RANDOMIZED|PARALLEL||TREATMENT||NONE||All new, adult (18+ years old) patients seeing an orthopedic surgeon for a consultation will be invited to enroll. Randomization will be done through an Excel random number generator. The patients in the intervention group will review a prompt list before their visit. The research assistant will shadow the surgeon to count the amount of questions they ask during their visit. Patients in both groups will fill out a survey entailing demographics, the Decisional Conflict Scale, the JSPPE, the PAM score and a satisfaction scale at the end of the visit.||||
34142594|NCT05665673|||OTHER||PROSPECTIVE|||||||
34142595|NCT03114436|||COHORT||PROSPECTIVE|||||||
34142596|NCT02621177|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34142597|NCT00495521|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142598|NCT06351098|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"Memory will be assessed using the Mnemonic Similarity Task (MST), before and after nap/wake and overnight sleep. The specific variable of interest is the lure discrimination index, which refers to the probability of Similar responses to lure items minus the probability of Similar responses given to foils."||||
34142599|NCT02596373|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142600|NCT03251859|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142601|NCT01389349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142602|NCT02880514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142603|NCT02426190|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34142604|NCT03035773|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142605|NCT06136286|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study will be a prospective randomized control trial consisting of subjects requiring ORIF of the distal radius. Subjects will be divided into two groups based on age, then subsequently be randomly divided into two groups following their inclusion in the study. Group 1) Control group in which subjects receive standard of care rehab. Group 2) BFR group in which BFR is incorporated into the patients' rehab.~Groups will be normalized based on gender. One group will undergo the normal rehabilitation protocol for the hand and wrist as determined by Dr. Liberman. The study group will undergo rehabilitation protocol for distal radius fractures modified by use of a tourniquet for blood flow restriction during selected exercises."||||
34142606|NCT04511117|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||Control group: the patient will receive direct composite resin restorations. Endocrown group: the patient will receive endocrown restorations.|t|f|f|f
34142607|NCT02695368|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34142608|NCT01741532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Placebo solution matched deferiprone oral solution in appearance, taste, and packaging||t|t|t|t
34142609|NCT00826358|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142610|NCT05482815|NA|SINGLE_GROUP||TREATMENT||NONE||prospective, multicenter, single-group test target trial design||||
34142611|NCT05408351|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34142612|NCT00509743|NA|SINGLE_GROUP||||NONE||||||
34142613|NCT05679167|RANDOMIZED|PARALLEL||TREATMENT||NONE|Both patients and physiotherapists know what intervention group they were randomized to.|Three ongoing different treatments at the same time||||
34142614|NCT00549185|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142615|NCT01107600|NA|SINGLE_GROUP||TREATMENT||NONE||Immediate loading||||
34142616|NCT05685732|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study drug will be blinded during the Treatment Period. Neither the subject, the Investigator, nor the Sponsor will know the subject's treatment assignment.|The primary endpoint is defined as the change in a subject's ADHD Rating Scale total score in the Efficacy Population at Visit 6 compared to baseline (ADHD-RS total score at Visit 2). The Visit 2 baseline will be obtained prior to the first administration of study drug. The same analysis will be performed at other post-baseline visits. Visit 6 is the last visit of the Treatment Period (after the last dose of study drug).|t|t|t|t
34142617|NCT05273216|||COHORT||PROSPECTIVE|||||||
34142618|NCT03076086|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142619|NCT00913991|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34142620|NCT01452139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142621|NCT06465303|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142622|NCT00823992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142623|NCT05462990|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|participant, investigator and sponsor-blinded||t|t|t|f
34142624|NCT01650220|||COHORT||CROSS_SECTIONAL|||||||
34142625|NCT06608784|||OTHER||CROSS_SECTIONAL|||||||
34142626|NCT05498233|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34142627|NCT03834506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142628|NCT01166295|||CASE_ONLY||PROSPECTIVE|||||||
34142629|NCT01510184|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832171|NCT04780984|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832172|NCT03781245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33832173|NCT04334278|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832174|NCT00830687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832175|NCT02957695|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832176|NCT02614690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832177|NCT02493465|NA|SINGLE_GROUP||||NONE||||||
33832178|NCT04728139|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33832179|NCT01193998|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33832180|NCT04303442|||CASE_ONLY||PROSPECTIVE|||||||
33832181|NCT06056271|||COHORT||PROSPECTIVE|||||||
33832182|NCT03931993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Single-blind|t|f|f|f
33832183|NCT05549167|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, open-label, non-randomized interventional study with a historical control group and pilot phase||||
33832184|NCT04156399|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|There is no masking. This study is unblinded.|This study is an unblinded, uncontrolled trial.||||
33832185|NCT03449862|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|Electronic web-based simulation study with built-in randomization tool|Multi-center, double-blinded simulation-based randomized controlled trial|t|f|t|t
33832186|NCT04241809|||COHORT||PROSPECTIVE|||||||
33832187|NCT06276400|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will typically be unaware of the conditions presented, though because these involve manipulations of stimuli or task demands, they may be aware of the manipulation. This is not expected to impact the primary outcome measures (e.g., BOLD signal activation patterns).|This is a basic science study in which all participants will participate in all task conditions within each experiment (repeated-measures design).||||
33832188|NCT00692458|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832189|NCT03887169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832190|NCT05492656|||COHORT||PROSPECTIVE|||||||
33832191|NCT00872001|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832192|NCT03176901|RANDOMIZED|PARALLEL||OTHER||SINGLE|This is a blinded, randomized controlled trial. Participants are blinded to condition.|Two armed study with intervention and comparison groups running parallel to one another|t|f|f|f
33832193|NCT06485648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832194|NCT00960609|||COHORT||PROSPECTIVE|||||||
33832195|NCT02414347|||OTHER||PROSPECTIVE|||||||
33832196|NCT04370535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||The pilot-study is a randomized, placebo-controlled and double blinded study. The 4 subject-groups are consisting of group A and B with healthy subjects (A and B are divided into a placebo-group and into a PMA-zeolite- group) and group C and D which are subjects suffering from CD (C and D are divided into a placebo-group and into a PMA-zeolite- group). No washout phase is planned, but if food-supplements are taken this will be protocolled. The diagnostics will be performed through the defined parameters at defined time-points.|t|f|t|f
33832197|NCT03040830|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The randomization|"Double blind Randomized Controlled Trial : the clinicians and the patents were blinded of the allocation group.~A total of 137 embryo transfers (ETs) were randomly allocated into either group A (67 ) starting luteal support as daily intra muscular (IM) injections of 100 mg prontogest on day of egg retrieval, or group B (66) starting the same P4 dose on day of embryo transfer.Transfer technique was blind tactile using Labotect catheter and was considered difficult if the inner ET catheter was blood stained and /or sounding or dilating the cervix was needed. Cervical traction or blood staining of outer sheath did not indicate difficulty"|t|t|f|f
33832198|NCT00894998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33832199|NCT03613636|||COHORT||PROSPECTIVE|||||||
33832200|NCT02772718|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832201|NCT01612247|NA|SINGLE_GROUP||||NONE||||||
33832202|NCT04915131|NA|SINGLE_GROUP||OTHER||NONE||||||
33832203|NCT06049069|||OTHER||CROSS_SECTIONAL|||||||
33832204|NCT05635175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832205|NCT05397366|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33832206|NCT02272361|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832207|NCT01181609|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832208|NCT03202485|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Prospective comparative case series|f|f|f|t
33832209|NCT00890539|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33832210|NCT02264782|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
33832211|NCT03096756|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33832212|NCT02377323|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33832213|NCT04509674|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded investigator review of events in place of centralized adjudication.||t|t|t|t
34142630|NCT03998748|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34142631|NCT03974321|||CASE_CONTROL||PROSPECTIVE|||||||
34142632|NCT05245630|||OTHER||PROSPECTIVE|||||||
34142633|NCT03286946|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
34142634|NCT04422561|RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34142635|NCT04381325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142636|NCT01205802|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832214|NCT03287778|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832215|NCT02452099|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832216|NCT06402214|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33832217|NCT05238649|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832218|NCT03108976|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33832219|NCT03349411|||COHORT||PROSPECTIVE|||||||
33832220|NCT01463228|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832221|NCT02790775|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33832222|NCT01560195|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832223|NCT02051998|||COHORT||PROSPECTIVE|||||||
33832224|NCT01501409|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33832225|NCT04178811|||COHORT||RETROSPECTIVE|||||||
33832226|NCT00019695||||TREATMENT||||||||
33832227|NCT00002647||||TREATMENT||||||||
34142637|NCT02498067|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142638|NCT05331703|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142639|NCT01512680|NA|SINGLE_GROUP||||NONE||||||
33832228|NCT03941899|NA|SINGLE_GROUP||TREATMENT||NONE||Simon's Two-Stage single arm study||||
33832229|NCT03001622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832230|NCT05435326|||CASE_ONLY||CROSS_SECTIONAL|||||||
33832231|NCT02591862|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832232|NCT02735590|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33832233|NCT00483028|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832234|NCT01740154|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832235|NCT05820113|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832236|NCT05410119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832237|NCT04751240|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will participate in an exercise intervention consisting of sprint interval training and resistance training.||||
33832238|NCT01510353|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33832239|NCT04159662|||OTHER||CROSS_SECTIONAL|||||||
33832240|NCT05893914|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Single-case non-concurrent multiple baseline experimental design.||||
33832241|NCT02201901|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832242|NCT00550446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832243|NCT02987998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832244|NCT01440413|NA|SINGLE_GROUP||OTHER||NONE||||||
33832245|NCT04467398|||CASE_CONTROL||PROSPECTIVE|||||||
33832246|NCT04183010|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will not be told if they are assigned to the control arm or the coaching arm of the study.|"Study participants will download the MyHeart Counts 3.0 app from their smartphone app store. They will undergo electronic consent, followed by a week of baseline monitoring, during which the phone will track their step count and acceleration. Participants will additionally complete questionnaires about their lifestyle and any risk factors for cardiovascular disease.~At the end of this initial week of monitoring, participants will be randomized to a control group or an intervention group. Both groups will be followed for three months, with outcome measurements collected monthly.~The intervention arm will also undergo daily coaching with the goal of increasing their daily step count. Members of this arm will receive daily app notifications indicating that they have activities to complete. They will be provided with 5 exercise options."|t|f|f|f
33832247|NCT00549978|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832248|NCT06538467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33832249|NCT05496309|||COHORT||PROSPECTIVE|||||||
33832250|NCT00543153|||CASE_ONLY||PROSPECTIVE|||||||
33832251|NCT03132662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832252|NCT01130311|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33832253|NCT04796675|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832254|NCT02489409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832255|NCT01985997|||||PROSPECTIVE|||||||
33832256|NCT03815383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832257|NCT00315679|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832258|NCT02031536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832259|NCT00908349|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832260|NCT04477356|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The prepared sperms will be proceeded to medical doctor who will carry the IUI and have no information about the semen preparation step.||f|t|f|f
33832261|NCT00265720|RANDOMIZED|FACTORIAL||||NONE||||||
33832262|NCT04287283|||COHORT||RETROSPECTIVE|||||||
33832263|NCT02304081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832264|NCT04346810|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33832265|NCT03664206|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832266|NCT04285047|||CASE_ONLY||OTHER|||||||
34142640|NCT00167102|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34142641|NCT03740542|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34142642|NCT04018560|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34142643|NCT04285307|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142644|NCT03251040|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot study||||
34142645|NCT00580164|||COHORT||PROSPECTIVE|||||||
33832267|NCT03214536|NA|SINGLE_GROUP||OTHER||NONE||observational feasibility trial||||
33832268|NCT00301483|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33832269|NCT01657799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832270|NCT00329563|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832271|NCT05815706|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants were randomized into the experimental and control groups using a block randomization method. Research shows that gestational age and sucking experience affect the sucking behavior of preterm infants (Kaya and Aytekin, 2017; Yildiz and Arikan, 2012). Therefore, gestational age (30-32 and 33-34 weeks), gender (girls and boys), and LATCH scores (0-2, 3-6, and 7-10 points) were used for block randomization. The blocks were repeated three times in each group. Thirty-six participants were assigned to each group. A 2X2X3X3 blocked randomization list was developed using an online randomization tool (Sealed Envelope Ltd, 2018).|f|f|t|f
33832272|NCT03061058|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832273|NCT05115045|||COHORT||RETROSPECTIVE|||||||
34142646|NCT03532932|||COHORT||OTHER|||||||
33832274|NCT01416935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832275|NCT03471377|||CASE_CONTROL||PROSPECTIVE|||||||
33832276|NCT02772562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832277|NCT02580175|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33832278|NCT03817723|||COHORT||RETROSPECTIVE|||||||
33832279|NCT00001509||||TREATMENT||||||||
33832280|NCT00219245|RANDOMIZED|SINGLE_GROUP||||NONE||||||
33832281|NCT05302297|||COHORT||RETROSPECTIVE|||||||
33832282|NCT05480462|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33832283|NCT03038269|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33832284|NCT00598871|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832285|NCT01854736|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33832286|NCT01423708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832287|NCT03840356|||COHORT||PROSPECTIVE|||||||
33837091|NCT01300442|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832288|NCT04752800|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be divided into 02 groups: Active - participants who will receive real current; Sham - participants who will receive simulated stimulation. Participants will be included in the study using the eligibility criteria and will be randomly allocated, in 1: 1 blocks, where a random number generator will be used through an online randomization program (www.random.org). All researchers responsible for the evaluation before and after consultations will be blind to the type of treatment that the patient will receive (active stimulation or sham stimulation). The effectiveness of the masking mechanism will be assessed at the time of the last interview with the patients, when they will be asked about their opinions as to whether the electric current producing system was on or off.|A randomized, double-blind, sham-controlled clinical trial will be carried out involving patients with ischemic stroke in the initial subacute stage, submitted to transcranial direct current stimulation sessions. This study will obey the SPIRIT guidelines, which is considered a guideline composed of minimum contents of a clinical trial protocol|t|f|f|t
33832289|NCT03421405|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded. There will be 5-minute break between each audio sequence. Each experimental session will take approximately 30-45 minutes to complete.||||
33832290|NCT00143026|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832291|NCT05928663|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33832292|NCT04770870|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multicenter, single arm post approval study of 232 subjects up to 10 US study sites||||
33832293|NCT00569010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832294|NCT04054414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"In PMZ group, 3 doses of PMZ-1620, at 0.3 μg/kg body weight will be administered as an intravenous bolus over 1 minute every 3 hours ± 1 hour on day 1, 3, and day 6 (total dose/day: 0.9 µg/kg body weight).~In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, 3 and day 6 post randomization.~In both treatment groups, subjects will be provided the best available standard of care."|t|t|t|t
33832295|NCT02542410|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832296|NCT00943722|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832297|NCT05175469|||COHORT||CROSS_SECTIONAL|||||||
33832298|NCT01812798|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|f|t|t
33832299|NCT02371772|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33832300|NCT01972997|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33832301|NCT02058836|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832302|NCT00458146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832303|NCT01447576|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832304|NCT03660397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832305|NCT00498095|||COHORT||PROSPECTIVE|||||||
33832306|NCT06171022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832307|NCT00155532|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832308|NCT05985447|||COHORT||PROSPECTIVE|||||||
33832309|NCT05276778|||OTHER||CROSS_SECTIONAL|||||||
33832310|NCT04087564|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Each subject serves as their own control||||
33832311|NCT03235362|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832312|NCT04648826|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33832313|NCT02744170|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33832314|NCT05090267|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|This is a 2x2 design in which subjects will be randomly assigned to one of 4 interventions groups: tVNS and probiotic (n=20); tVNS and placebo (n=20), sham stimulator and probiotic (n=20), and sham stimulator and placebo (n=20). We will use a computer-assisted stratified block randomization with block size of 4 to assign participants to the intervention. Study participants, investigators, staff, and physicians administering the probiotics or placebo will be unaware of specific group assignment. The stratified, blocked randomization and assignment of participants to the 4 intervention groups will be guided and monitored by Data Science Core.|This is a 2 x 2 factorial, longitudinal design (tVNS/Sham, Probiotic/Placebo) across three time points (baseline; 30days and 90days).|t|f|t|f
33832315|NCT04425486|||OTHER||CROSS_SECTIONAL|||||||
33832316|NCT03137706|||CASE_ONLY||PROSPECTIVE|||||||
33832317|NCT01085383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832318|NCT03082898|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33832319|NCT06083610|||COHORT||CROSS_SECTIONAL|||||||
33832320|NCT04563598|||COHORT||RETROSPECTIVE|||||||
33832321|NCT03046823|||CASE_ONLY||PROSPECTIVE|||||||
33832322|NCT03939481|||COHORT||PROSPECTIVE|||||||
33832323|NCT00974181|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832324|NCT04306146|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832325|NCT05785065|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|The participant, the physician, the study investigators and the research personnel will be blinded to treatment allocation, whereas the dispensing pharmacy will not.|Patients will be randomized to treatment group or placebo group in a 1:1 ratio and stratified according to the presence of anti-topoisomerase I autoantibody.|t|t|t|t
33832326|NCT06544564|RANDOMIZED|PARALLEL||TREATMENT||NONE||5 parallel groups randomly assigned in a 1:1:1: 1:1 fashion||||
33832327|NCT00387699||||TREATMENT||NONE||||||
33832328|NCT01449786|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832329|NCT04073797|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|Double-blind, placebo controlled.||t|t|t|t
33832330|NCT00000598|RANDOMIZED|FACTORIAL||PREVENTION||||||||
33832331|NCT02549417|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832332|NCT01473992|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832333|NCT02573545|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832334|NCT03139188|||COHORT||OTHER|||||||
33832335|NCT01772823|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832336|NCT02699736|||COHORT||PROSPECTIVE|||||||
33832337|NCT03729713|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE||Placebo controlled|t|t|t|t
33832338|NCT02196805|RANDOMIZED|PARALLEL||||NONE||||||
33832339|NCT01434680|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33832340|NCT03238807|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blinded|Randomized Controlled Trial|t|t|f|f
33832341|NCT01061190|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832342|NCT05140681|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832343|NCT02077725|||COHORT||PROSPECTIVE|||||||
33832344|NCT03780010|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832345|NCT03448536|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33832346|NCT00803777|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832347|NCT04734002|||COHORT||OTHER|||||||
33832348|NCT04231162|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832349|NCT02361398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832350|NCT01517087|||COHORT||PROSPECTIVE|||||||
33832351|NCT00987883|||COHORT||PROSPECTIVE|||||||
33832352|NCT04678908|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33832353|NCT05401383|||OTHER||PROSPECTIVE|||||||
33832354|NCT06183983|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832355|NCT04256369|||COHORT||PROSPECTIVE|||||||
33832356|NCT02788071|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832357|NCT06120647|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832358|NCT01313169|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33832359|NCT00565071|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832360|NCT02247843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832361|NCT05536167|||COHORT||PROSPECTIVE|||||||
33832362|NCT01993849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832363|NCT00220909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33832364|NCT03993275|||CASE_ONLY||PROSPECTIVE|||||||
33832365|NCT01390142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832366|NCT00565266|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33832367|NCT00902902|||CASE_CONTROL||PROSPECTIVE|||||||
33832368|NCT02198976|||COHORT||PROSPECTIVE|||||||
33832369|NCT00336817|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832370|NCT00184379|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832371|NCT00666198|||CASE_ONLY||PROSPECTIVE|||||||
33832372|NCT02276638|||COHORT||PROSPECTIVE|||||||
33832373|NCT02727257|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832374|NCT00501956|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832375|NCT06078098|||COHORT||PROSPECTIVE|||||||
33832376|NCT02619526|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832377|NCT01099579|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832378|NCT04353206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832379|NCT05436210|||COHORT||PROSPECTIVE|||||||
33832380|NCT02780505|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832381|NCT05074199|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33832382|NCT01983462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832383|NCT01101061|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33832384|NCT04086238|RANDOMIZED|CROSSOVER||OTHER||NONE||Open-label, randomized, three-block, four-period study to evaluate the relative pharmacokinetics of three test formulations of decitabine and THU in a modified release THU and decitabine combination capsule (EPI01) in healthy male and female adults||||
33832385|NCT05347862|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind masking|This is a pragmatic trial to assess the effectiveness of a physical activity promotion program on reduction levels of glycated hemoglobin in patients with Type 2 diabetes.|f|f|f|t
33832386|NCT04730128|||COHORT||CROSS_SECTIONAL|||||||
33832387|NCT06194812|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832388|NCT01263054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832389|NCT05271318|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832390|NCT04758052|RANDOMIZED|PARALLEL||TREATMENT||NONE|blinded endpoint|single-center prospective randomized open-label blinded endpoint proof-of-concept study to assess the effect of TSG versus usual care TDG placement on outcomes among neurocritically-ill patients.||||
33832391|NCT00441922|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832392|NCT03497715|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832393|NCT03635086|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832394|NCT02386878|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33832395|NCT02370901|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832396|NCT00296738|||CASE_ONLY||PROSPECTIVE|||||||
33832397|NCT00739076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33832398|NCT00040495||||PREVENTION||||||||
33832399|NCT00130845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832400|NCT05840900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants and clinicians will not be blinded, but the outcomes assessor and analytic teams will be blinded to participant allocation.||f|f|f|t
33832401|NCT05217355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832402|NCT04191408|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832403|NCT02977299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832404|NCT01106365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832405|NCT01408810|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832406|NCT01756144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832407|NCT00463398|||COHORT||PROSPECTIVE|||||||
33832408|NCT05221138|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832409|NCT05367505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832410|NCT04197479|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832411|NCT01927107|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832412|NCT01547624|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33832413|NCT00226915|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832414|NCT00406406|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33832415|NCT02126462|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832416|NCT01555398|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832417|NCT04083924|NA|SINGLE_GROUP||OTHER||NONE||Pre-post education intervention study||||
33832418|NCT02311088|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832419|NCT04797117|NA|SINGLE_GROUP||OTHER||NONE||||||
33832420|NCT00196534|RANDOMIZED|PARALLEL||||DOUBLE||||||
33832421|NCT04952363|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832422|NCT00148252|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832423|NCT00835185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832424|NCT02912754|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832425|NCT05549947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832426|NCT06015906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832427|NCT04839055|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832428|NCT01287728|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832429|NCT05750589|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Treatment assignment will be unknown (or masked) to the study subjects, the evaluating physician, the Sponsor and its agents (with the exception of personnel performing randomization, unmasked drug accountability study monitors, and corporate compliance staff). The treating physician will be unmasked.|Subjects will be randomized to IRX-101 or Providone-Iodine|t|f|t|f
33832430|NCT02531867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832431|NCT01921907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832432|NCT03232710|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33832433|NCT03943017|||OTHER||PROSPECTIVE|||||||
33832434|NCT01275768|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832435|NCT02131727|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832436|NCT04266444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832437|NCT03616795|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33832438|NCT02223442|||COHORT||PROSPECTIVE|||||||
33832439|NCT04157036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33832440|NCT03672942|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|couples are not informed as to what condition they are assigned|random assignment to two active conditions vs. a placebo control|t|f|f|f
33832441|NCT03362541|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Both the MS INFoRm group and the control group will receive a login and password, although participants in the groups will be directed to a different webpages (i.e. a MS INFoRm page or usual care control webpage). This will facilitate blinding of participants to their allocation. The research assistant will complete the scheduling, data collection, and data entry blinded to the group allocation.|This study will use a randomized controlled trial design to test the efficacy and effectiveness of MS INFoRm. Two hundred participants from at least three sites across Canada will be randomly assigned to one of two groups: the experimental (MS INFoRm) group or usual care control group. After completing the study, participants in the usual care control group will be given access to MS INFoRm in order to provide them with any benefits of the website, if any are uncovered. Both groups will be evaluated on primary (fatigue impact) and secondary (self-efficacy, cognitive function, participation and autonomy, depression) outcomes at baseline (week 1), after 3-month use of the MS INFoRm website (week 12), and after 6-month follow-up (week 36).|t|f|f|t
33832442|NCT01741389|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33832443|NCT03188653|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33832444|NCT04510610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832445|NCT02782611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832446|NCT00051623|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832447|NCT02432170|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832448|NCT04311645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832449|NCT01158989|||COHORT||PROSPECTIVE|||||||
33832450|NCT03948464|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization||||
33832451|NCT02250534|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This study was one of three multi-site clinical trials conducted in three different vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder or additional assessments of anxiety and depression for individuals with affective disorders. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by- condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment. Please see Statistical Analysis Plan for more details.|t|f|t|f
33832452|NCT01168336|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33832453|NCT00609401|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832454|NCT03876106|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||3+3 Dose escalation of LUT014||||
33832455|NCT04669379|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients will be randomly distributed to the intervention group (IG/EXPECT) or the control group (CG). The intervention group will receive a psychological preoperative online-intervention to optimize expectations. The control group will receive no intervention at all.||||
33832456|NCT01869140|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33832457|NCT03967912|NA|SINGLE_GROUP||PREVENTION||NONE||Single Group Assignment Implementation research for adapted effective intervention||||
33832458|NCT04185298|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will include two arms: Arm 1: activity monitoring only control (CON), Arm 2: active intervention with mSIM program (mSIM) plus activity monitoring (via Fitbit), to evaluate the efficacy of the mSIM intervention on memory performance and everyday functioning. The 'Activity monitoring only' arm will serve as the control group. Study objectives include measuring treatment related changes in memory performance and everyday functioning along with putative biomarkers of the behavioral changes.||||
33832459|NCT03633864|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832460|NCT01606319|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832461|NCT06311747|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832462|NCT00440388|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832463|NCT02469883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832464|NCT05046106|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832465|NCT01410864|||COHORT||OTHER|||||||
33832466|NCT03796000|||COHORT||PROSPECTIVE|||||||
33832467|NCT00687245|RANDOMIZED|PARALLEL||||NONE||||||
33832468|NCT03234712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832469|NCT04245345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832470|NCT04865692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832471|NCT03446638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832472|NCT02897089|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33832473|NCT05475847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832474|NCT06392893|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Double-blind, randomised, controlled, unicentric trial with two parallel arms depending on the product consumed|t|t|t|t
33832475|NCT05574751|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33832476|NCT02461862|||CASE_ONLY||RETROSPECTIVE|||||||
33832477|NCT01137747|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832478|NCT01522703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832479|NCT03534583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Raters, investigators and physicians will not be aware of participant treatment allocation.||f|t|t|t
33832480|NCT03338647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832481|NCT00699985|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832482|NCT02344017|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832483|NCT03049345|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|no masking|human subjects||||
33832484|NCT01945398|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832485|NCT01477580|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832486|NCT02447718|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832487|NCT02914899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33832488|NCT05143112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832489|NCT04715022|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33832490|NCT02460562|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832491|NCT05208346|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33832492|NCT02968823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832493|NCT00377988|||CASE_CONTROL||RETROSPECTIVE|||||||
33832494|NCT05975632|NA|SINGLE_GROUP||OTHER||NONE||||||
33832495|NCT00985270|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33832496|NCT00907764|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832497|NCT04344665|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33832498|NCT00692549|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832499|NCT00810342|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33832500|NCT03357198|||COHORT||PROSPECTIVE|||||||
33832501|NCT02888223|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832502|NCT06149845|NA|SINGLE_GROUP||TREATMENT||NONE||Longitudinal prospective single-arm cohort study||||
33832503|NCT03848884|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832504|NCT04423419|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|the patient and the assessor will mask about type of block|group A will undergo PENG block group B will undergo fascia iliaca block groupC will receive iv analgesia|t|f|f|t
33832505|NCT04944498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment received by patients was randomized by research team members. The investigator as the oculoplastic surgeon (YI) acknowledged the treatment assigned to each patient based on randomization. Outcomes were measured by other oculoplastic surgeons with equal clinical experiences.||t|t|t|f
33832506|NCT01993277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832507|NCT06456606|||CASE_ONLY||PROSPECTIVE|||||||
33832508|NCT00895726|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832509|NCT02138097|||COHORT||RETROSPECTIVE|||||||
33832510|NCT05311345|||CASE_ONLY||RETROSPECTIVE|||||||
33832511|NCT04374786|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832512|NCT04967352|||CASE_CONTROL||PROSPECTIVE|||||||
33832513|NCT00092326|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832514|NCT03535805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The statistical evaluation of the effects of MMM versus TAU will be carried out by researchers who will be masked for the treatment allocation.~The central research-organization DEFACTUM is responsible for holding separate key files documenting the random allocation to treatment group and linking the ID numbers to the personal civil registration numbers. The analysts will be masked for treatment allocation until they have tested the primary and secondary hypotheses and confirmed or rejected the study hypotheses.~It is not possible to mask the participants and the therapists in this study design."|"The RCT is a parallel, two-arm, superiority trial comparing MMM with TAU for children aged 6-16 years with emotional and behavioural difficulties.~This primary outcome is the parent-reported SDQ-impact of problems (range 0-10). The sample size calculation was based on the parameters from the feasibility RCT. Given an estimated standard variation (SD)=2.7, significance level=0.05, and power=0.90, the sample required to detect (or reject) a difference of at least 1.0 point is N=308. This sample size is also sufficient to detect clinically meaningful group differences in secondary outcome (e.g. 7.5% versus 16% reporting harm).~The expected rate of attrition is 0.25. Hence, the investigators need to include 308/0.75=412 children to be randomly allocated (1:1). The central randomization uses concealed allocation sequences with variable block size, and stratification by region, age (6-10 or 11-16 years) and Top-problem (anxiety, depression, behavioural problems)."|f|f|f|t
33832515|NCT01902186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832516|NCT02602483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832517|NCT06107049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832518|NCT02562898|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832519|NCT01486368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832520|NCT04974177|||OTHER||PROSPECTIVE|||||||
33832521|NCT00504283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832522|NCT01241006|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832523|NCT05573100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832524|NCT02911194|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33837092|NCT00269412|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33837093|NCT06146777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837094|NCT02920112|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837095|NCT03145922|||COHORT||PROSPECTIVE|||||||
33837096|NCT04210999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||RCT|f|f|f|t
33837097|NCT05657418|NA|SEQUENTIAL||TREATMENT||NONE||Sequential||||
33837098|NCT03019419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837099|NCT04829747|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33837100|NCT00845312|||COHORT||RETROSPECTIVE|||||||
33832525|NCT04400968|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The participants in the different intervention groups received real and placebo auricular therapy and kinesio tape treatment.~The kinesio tape placebo group had the application of three elastic bandages that were shorter than the used in the kinesio tape group. In addition, the tape was adhered with no tension and not place in the treatment area. The auricular therapy placebo group had adhesive tapes without seeds displaced from the treatment points.~The outcome assessor was independent to the study and was not aware of the treatments applied or the objective of the therapy."|Double-blind randomized clinical controlled trial. Participants were randomized to a auricular therapy group, an auricular therapy placebo group, a kinesio tape group, a kinesio tape placebo group and a control group for a 11 month study.|t|f|f|t
33832526|NCT01793077|||CASE_ONLY||PROSPECTIVE|||||||
33832527|NCT05611541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Using a computer program, the researchers randomly placed pregnant women who received dietary advice into either the intervention group or the control group.|f|t|f|f
33832528|NCT01859611|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832529|NCT00364390|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832530|NCT00698347|||COHORT||PROSPECTIVE|||||||
33832531|NCT03964051|NA|SINGLE_GROUP||TREATMENT||NONE||10 patients with severe food allergy will receive subcutaneous injections of Omalizumab 300 mg every 2 week for 12 weeks.||||
33832532|NCT03339947|||OTHER||CROSS_SECTIONAL|||||||
33832533|NCT05889962|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"Patients are randomly allocated into pudendal block group or placebo group. Pudendal block group: Patients will receive pudendal nerve block with ropivacaine.~Placebo group: Patients will receive pudendal nerve block with normal saline."|t|t|t|t
33832534|NCT04356625|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single-arm clinical trial to establish diagnostic performance of MEPic||||
33832535|NCT04738643|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832536|NCT04966559|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832537|NCT05086419|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After written informed consent, patients will be randomized to the intervention or control group using computer-generated lists. Block randomization with variable block size that is unknown to the research group will be used. Follow-up tests at T1 and T2 will be performed by a research assistant who is blind to the group distribution and who is not involved in any parts of the intervention. Statisticians will be blinded to group allocation.|Randomized, controlled, single-blind parallel group design.|f|f|f|t
33832538|NCT06228820|NA|SINGLE_GROUP||TREATMENT||NONE||Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.||||
33832539|NCT02132871|||COHORT||PROSPECTIVE|||||||
33832540|NCT05267795|NA|SINGLE_GROUP||TREATMENT||NONE||The experiment used a 2x2 within-subjects design in which participants either listened to music or underwent a silent control period and either performed an active foot tapping task, or a passive control task with no movement resulting in four experimental trial types: (a) Music Active (music with tapping); (b) Music Passive (music without tapping); (c) Silence Active (silence with tapping); and (d) Silence Passive (silence without tapping). The allocation of the music excerpts to the task (active, passive) was random, and the order of the four experimental trial types was counterbalanced. Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.||||
33832541|NCT00169975|||COHORT||PROSPECTIVE|||||||
33832542|NCT00813098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832543|NCT03754790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832544|NCT04419805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor will be blind to allocation|Randomised parallel 2 group clinical trial|f|f|f|t
33832545|NCT03969576|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832546|NCT02077205|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832547|NCT04517383|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832548|NCT03860090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832549|NCT02230462|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832550|NCT06475794|||OTHER||CROSS_SECTIONAL|||||||
33832551|NCT04201899|||COHORT||PROSPECTIVE|||||||
33832552|NCT05379153|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|The provider will not be blinded to the arm the patient is on. PRO measures will be administered by research personnel who are blinded to the arm the patient is enrolled on at each study time point.||t|f|f|t
33832553|NCT01465945|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832554|NCT00299923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832555|NCT02734186|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33832556|NCT01519778|NA|SINGLE_GROUP||OTHER||NONE||||||
33832557|NCT02541045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832558|NCT06021587|||CASE_CONTROL||RETROSPECTIVE|||||||
33832559|NCT05328310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832560|NCT00207402|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832561|NCT05439473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832562|NCT05462782|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blinded to the intervention conditions.|The purpose of this study is to understand how Transcranial Magnetic Stimulation(TMS) synchronized with a memory event can enhance working memory capacity. For this purpose, we will synchronize hippocampal directed stimulation, primary motor cortex stimulation and sham stimulation at Inter Stimulus Interval (ISI) 200 and 0 ms. The effects on memory will be assessed by a working memory task and resting state functional MRI .|t|f|f|f
33832563|NCT03922607|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33832564|NCT05779917|NA|SINGLE_GROUP||TREATMENT||NONE||Use engineered CAR-T cells to kill cancer cells with mesothelin overexpression.||||
33832565|NCT01863628|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33832566|NCT02548676|||COHORT||PROSPECTIVE|||||||
33832567|NCT04248907|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33832568|NCT04974723|||COHORT||RETROSPECTIVE|||||||
33832569|NCT02166476|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind-double dummy||t|f|t|t
33837101|NCT01535027|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837102|NCT01432626|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832570|NCT05115708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Kahook dual blade ab-interno Trabeculotomy versus ab externo viscotrabeculotomy in treatment of primary congenital glaucoma.|t|t|f|f
33832571|NCT01386723|||CASE_ONLY||PROSPECTIVE|||||||
33832572|NCT06102564|||CASE_ONLY||PROSPECTIVE|||||||
33832573|NCT02938897|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832574|NCT00546247|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832575|NCT02864823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832576|NCT03834623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832577|NCT03527498|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||All subjects were divided into two groups: intervention group A (treadmill intervention + routine physical rehabilitation therapy) and positive control group (receiving routine physical rehabilitation therapy only).|f|t|t|t
33832578|NCT05054569|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832579|NCT01574053|||OTHER||PROSPECTIVE|||||||
33832580|NCT00507156|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832581|NCT00232219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832582|NCT04949854|RANDOMIZED|PARALLEL||OTHER||NONE||This is a prospective, parallel, non-blinded, two-arm randomized (like the flip of a coin) controlled trial of catheter failure evaluating the impact of a built-in guide wire. This study plans to enroll 360 participants (two equally sized groups of 180 participants in each arm).||||
33832583|NCT01383447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832584|NCT00370643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832585|NCT01236183|||OTHER||PROSPECTIVE|||||||
33832586|NCT00949793|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832587|NCT03739372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832588|NCT00288275|||CASE_ONLY||PROSPECTIVE|||||||
33832589|NCT00420784|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832590|NCT04155034|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832591|NCT01729715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832592|NCT02119702|||COHORT||PROSPECTIVE|||||||
33832593|NCT00126139|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33832594|NCT00717548|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832595|NCT05554783|||CASE_CONTROL||PROSPECTIVE|||||||
33832596|NCT01739010|||OTHER||PROSPECTIVE|||||||
33832597|NCT03085199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832598|NCT00799955|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832599|NCT01399762|||COHORT|||||||||
33832600|NCT02033811|||COHORT||PROSPECTIVE|||||||
33832601|NCT01755546|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832602|NCT03638921|NA|SINGLE_GROUP||TREATMENT||NONE||MEOPA||||
33832603|NCT00311415|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832604|NCT05768399|||CASE_CONTROL||PROSPECTIVE|||||||
33832605|NCT06054919|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832606|NCT02656849|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832607|NCT00476112|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832608|NCT02431455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832609|NCT01310699|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33832610|NCT05812586|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The participants of this study will be blinded as to the vaccine booster they receive.|Exploratory phase 3, cohort randomized, single-blind, multi-center study|t|f|f|f
33832611|NCT02750644|||CASE_CONTROL||PROSPECTIVE|||||||
33832612|NCT05018897|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled trial with two comparison groups||||
33832613|NCT04238533|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33832614|NCT01266161|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832615|NCT04457258|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832616|NCT00954005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832617|NCT05204186|||CASE_ONLY||RETROSPECTIVE|||||||
33832618|NCT00952848|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832619|NCT02984254|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832620|NCT05241132|NA|SINGLE_GROUP||TREATMENT||NONE|Prior to enrollment in the study, doctors asked and recorded the patient's medical history, and if eligible participants volunteered to participate in the study, they would sign informed consent.If they are not willing to participate in the study, we will do the usual treatment|This is a prospective, single-arm, open phase II clinical study||||
33832621|NCT01682798|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33832622|NCT04398368|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33832623|NCT04472845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832624|NCT05492968|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33832625|NCT03988998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes (recurrence or death) Assessor is blind about the interventions.|Radiofrequency Ablation with or without Radiotherapy|f|f|f|t
33832626|NCT04731974|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This is a prospective single blinded randomized control trial of pediatric patients in the emergency department (ED) diagnosed with an acute concussion.~Group A: melatonin Group B: routine/standard care"|t|f|f|f
33832627|NCT04792398|NA|SINGLE_GROUP||TREATMENT||NONE||Observational study||||
33832628|NCT01906983|||COHORT||PROSPECTIVE|||||||
33832629|NCT03099408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832630|NCT03008109|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832631|NCT01359839|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832632|NCT04221789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysts will not be aware of group allocation||f|f|f|t
33832633|NCT05675319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832634|NCT00907192|||CASE_ONLY||PROSPECTIVE|||||||
33832635|NCT02881047|NA|SINGLE_GROUP||SUPPORTIVE_CARE||||||||
33832636|NCT01783158|||CASE_ONLY||PROSPECTIVE|||||||
33832637|NCT04813497|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Group 1 : participants who did not agree to receive a SARS-CoV-2 vaccine in the first Belgian campaing but who agreed to perform a serological test against COVID-19.~Groups of participants who agree to receive a SARS-CoV-2 vaccine at different specific times determined by the Belgian State for workers at the Grand Hôpital de Charleroi.~Parallel study of immunity to SARS-CoV-2 among staff members."||||
33832638|NCT04647305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832639|NCT05256212|||COHORT||PROSPECTIVE|||||||
33832640|NCT03667937|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832641|NCT04381156|||COHORT||PROSPECTIVE|||||||
33832642|NCT00590226|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832643|NCT00915577||CROSSOVER||||NONE||||||
33832644|NCT00025506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832645|NCT02626247|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832646|NCT03051425|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832647|NCT00884650|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832648|NCT02353416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832649|NCT04427176|||OTHER||PROSPECTIVE|||||||
33832650|NCT00495092|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832651|NCT04847310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes assessors will be blinded during pre- and post-treatment. Participants will be blinded during pretreatment assessment; however, it cannot be guaranteed that they will keep blinded in post-treatment.|Multicenter randomized controlled trial with pre-post measures and follow-ups.|f|f|f|t
33832652|NCT01587443|||||CROSS_SECTIONAL|||||||
33832653|NCT04519593|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients who meet study inclusion criteria will be randomized into one of two treatment arms: 1) laparoscopic myomectomy preceded by temporary uterine blood supply occlusion or 2) laparoscopic myomectomy with a conventional approach.||||
33832654|NCT00494390|||||PROSPECTIVE|||||||
33832655|NCT03391856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832656|NCT02775838|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33832657|NCT01729468|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832658|NCT00585078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832659|NCT02386553|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33832660|NCT00656201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832661|NCT05907642|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832662|NCT02830828|||COHORT||PROSPECTIVE|||||||
33832663|NCT01806389|||COHORT||PROSPECTIVE|||||||
33832664|NCT00394589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832665|NCT02595606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832666|NCT01102192|||CASE_CONTROL||PROSPECTIVE|||||||
33832667|NCT03082755|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The pharmacy, 40 Acres Pharmacy, will maintain records of group assignment. Each participant's assignment will be kept in a separate, unique file uploaded to a UTBox (secure cloud-based file sharing platform) folder created by 40 Acres Pharmacy. Should emergency unmasking be deemed necessary, the Principal Investigator or Co-Investigator will contact the Chief Pharmacist, Forty Acres Pharmacy, who will allow view-only access to the participant's assignment file in UTBox. Participants, their legally authorized representatives and families, participants' physicians, nursing home staff, investigators, and all study personnel will be masked to group assignment. Emergency unmasking of group assignment is expected to be rare. The Data Safety and Monitoring Board will develop guidelines for emergency unmasking.|The investigators plan to conduct a pilot, 8-week, double-blind, placebo-controlled randomized clinical trial of GEn versus placebo, in 136 nursing home residents with nighttime agitation, RLS, and moderate to severe Alzheimer's Disease. A placebo arm will allow for a thorough and systematic assessment of the safety of GEn in this specific patient population. A 2-month post-trial follow-up will assess whether RLS treatment is continued by providers and antipsychotics are reduced.|t|t|t|t
33832668|NCT01605786|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832669|NCT02270307|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33832670|NCT05726266|RANDOMIZED|PARALLEL||TREATMENT||NONE||All included patients must be under regular (maintenance) opioid treatment for at least one month before randomization. Included patients will be randomized (1:1) either to the control (audiobooks) or to the experimental (music) group.||||
33832671|NCT00072683|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832672|NCT04596605|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832673|NCT02632812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832674|NCT03750253|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832675|NCT03626831|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double blind|randomized (1:1), prospective, double-blind, placebo controlled, parallel-group|t|t|t|f
33832676|NCT04003194|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover Assignment Crossover design with 2-12 week intervention and comparator phases separated by a 4-week washout.||||
33832677|NCT05146115|||COHORT||OTHER|||||||
33832678|NCT04213677|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832679|NCT06421987|||CASE_CROSSOVER||PROSPECTIVE|||||||
33832680|NCT03362034|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33832681|NCT01847937|||CASE_CONTROL||PROSPECTIVE|||||||
33832682|NCT00745498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832683|NCT03065933|NA|SINGLE_GROUP||TREATMENT||NONE||Subjects with Bipolar Disorder, mania will receive an extended-release from of clonidine on the second day of this 3-day study. Rating scale, record of sleep, and a questionnaire of adverse effects will be recorded on each of the 3 days.||||
33832684|NCT05784766|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832685|NCT00882076|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33832686|NCT04484389|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Single||t|f|f|f
33832687|NCT04592081|RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will receive: First eye randomized for either lower lid (control eye) or upper lid (study eye) insertion and the contralateral eye receiving the opposite site insertion in the OR following CE/PCIOL||||
33832688|NCT06024915|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832689|NCT02762903|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832690|NCT02239744|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33832691|NCT02526186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832692|NCT00943046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832693|NCT02138344|||CASE_CONTROL||PROSPECTIVE|||||||
33832694|NCT00791193|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832695|NCT02165410|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837103|NCT04540445|||COHORT||PROSPECTIVE|||||||
33837104|NCT03332784|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
33837105|NCT02952521|||COHORT||PROSPECTIVE|||||||
33832696|NCT03825536|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|The order in which participants complete the two treatment phases (i.e., oral methamphetamine and placebo) will be unknown to both the participants and the PI/study team. Both the oral methamphetamine and placebo will be prepared in identical capsules by the UCSF investigational pharmacist, out of sight of the study participant, study coordinator, and study site PI and administered to the participant to maintain double blinding. The investigational pharmacist will randomize each participant according to the methods described above. In the event that participant experiences an adverse event that requires the identity of the study drug be revealed, the PI will be able to contact the investigational pharmacist to break the blind. In the event that a participant blind is broken, the study PIs will determine the impact upon the un-blinded participant's continued participation in the study and if a replacement participant is needed on a case-by-case basis.|This is a phase IV randomized, double-blinded, placebo-controlled crossover study. A placebo treatment arm will be assigned to participants in a randomized crossover design. HIV+ ART-suppressed individuals with no prior history of MA use disorder will be administered 10mg oral methamphetamine hydrochloride, followed by 15 mg methamphetamine hydrochloride two hours later, for a total of 25mg in one 24-hour period (the maximum FDA approved daily dose for the treatment of childhood obesity). Participants will complete the study twice (once on a placebo treatment arm and once with the oral methamphetamine treatment arm). Which treatment arm occurs first will be randomly assigned and will include a 31-day washout period between the two phases.|t|t|t|t
33832697|NCT03772093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832698|NCT05414383|||COHORT||PROSPECTIVE|||||||
33832699|NCT03625453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized, placebo-controlled|t|f|t|f
33832700|NCT03031210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33832701|NCT04759430|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The researcher who will make the measurements will not know the treatment groups of the individuals.|The individuals are randomly allocated into supervised group, telerehabilitation group and control group|f|f|f|t
33832702|NCT01550432|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832703|NCT00480675|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832704|NCT03452813|||COHORT||PROSPECTIVE|||||||
33832705|NCT02508597|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33832706|NCT00628277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832707|NCT04423172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832708|NCT00136110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832709|NCT03238222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832710|NCT05572853|||OTHER||CROSS_SECTIONAL|||||||
33832711|NCT00975676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832712|NCT00000983||||TREATMENT||||||||
33832713|NCT03722511|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832714|NCT03016598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832715|NCT00541905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832716|NCT01233999|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|f|t
33832717|NCT01789840|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832718|NCT05889949|||COHORT||PROSPECTIVE|||||||
33832719|NCT03251612|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832720|NCT02296892|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832721|NCT03532269|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33832722|NCT03411993|||COHORT||CROSS_SECTIONAL|||||||
33832723|NCT05328024|||CASE_ONLY||PROSPECTIVE|||||||
33832724|NCT01083199|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832725|NCT04342312|||COHORT||PROSPECTIVE|||||||
33832726|NCT02023749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832727|NCT05915533|NA|SINGLE_GROUP||OTHER||NONE||||||
33832728|NCT01907113|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832729|NCT02875145|||COHORT||RETROSPECTIVE|||||||
33832730|NCT05760547|||OTHER||PROSPECTIVE|||||||
33832731|NCT00656032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832732|NCT05046925|||OTHER||PROSPECTIVE|||||||
33832733|NCT02037776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832734|NCT00850486|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
33832735|NCT05013515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832736|NCT06334341|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||t|t|f|f
33832737|NCT03040245|||OTHER||OTHER|||||||
33832738|NCT01813305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832739|NCT00259571|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33832740|NCT00673608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832741|NCT02617979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832742|NCT05417347|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|This study will be single-blinded.||f|f|t|f
33832743|NCT04157933|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This study will be conducted in subjects with established Parkinson's disease in 2 parts. Part A will examine the tolerability, safety, and pharmacokinetics of AZ-009 dose escalation ; and Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of AZ-009 compared with placebo in a crossover design|t|t|t|t
33832744|NCT04107597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832745|NCT00927901|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33832746|NCT03457974|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE||cross sectional study was carried out with 42 CHD and 42 healthy children|t|f|f|f
33832747|NCT03596398|||COHORT||CROSS_SECTIONAL|||||||
33832748|NCT04483518|||COHORT||CROSS_SECTIONAL|||||||
33832749|NCT06131775|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Cohort||||
33832750|NCT00672282|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832751|NCT04546802|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832752|NCT02577588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832753|NCT00160797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832754|NCT00910325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832755|NCT00020722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832756|NCT04434118|||CASE_CONTROL||RETROSPECTIVE|||||||
33832757|NCT04632043|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832758|NCT05531071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837106|NCT00532168|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832759|NCT04467645|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE||This study was conducted as a pretest-posttest trial model with a control group in order to determine the effect of reflexology applications on sleep quality and fatigue in postmenopausal women|f|t|f|f
34142647|NCT04412733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832760|NCT01659671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832761|NCT00631345|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832762|NCT05423483|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34142648|NCT02363374|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832763|NCT02113410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33832764|NCT04777825|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832765|NCT01792388|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|f|t|t
33832766|NCT00777634|||COHORT||CROSS_SECTIONAL|||||||
33832767|NCT01636622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832768|NCT01585298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832769|NCT03499262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832770|NCT02466243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832771|NCT05125081|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Liuwei Dihuang Pill Administered by taking orally in Adults With Presbycusis With Shen (Kidney)-Yin Deficiency.|t|t|t|t
33832772|NCT06262178|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blind to treatment arm. Coders blind to treatment arm will also code 10% of dyadic parenting sessions.|PSTAIR combines elements of two existing Evidence-Based Treatments (EBTs): Skills Training in Affective and Interpersonal Regulation (STAIR), targeting maternal trauma and emotion dysregulation, and dyadic Parent-Child Care (PC-CARE), targeting parenting. We will shorten PSTAIR into a 10-15 session modular intervention and individualize treatment using an adaptive decision rule and shared decision making.|f|f|f|t
33832773|NCT00513201|RANDOMIZED|CROSSOVER||||DOUBLE||||||
33832774|NCT00164268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832775|NCT04457596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832776|NCT03378947|||OTHER||RETROSPECTIVE|||||||
33832777|NCT06289647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Investigator, Outcomes Assessor)||f|f|t|t
33832778|NCT06487143|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832779|NCT06416332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The Investigator and outcomes assessor are blinded to patient allocation and data code.|"Parallel Assignment~This a randomized controlled trial with first primary end point at 8 weeks and second primary end point at 3 months. Participants will be allocated randomly into one of two intervention groups. Group1 (Telerehabilitation) Group 2 (in person)"|f|f|t|t
33832780|NCT00674804|||||OTHER|||||||
33832781|NCT05364580|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832782|NCT03548493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||"34 patients are randomly divided by computer designed lists and then concealed in closed envelopes into 2 equal groups:~1. Group A (n=17) will receive magnesium sulphate adjuvant to propofol for sedation.~2. Group B (n=17) will receive fentanyl adjuvant to propofol for sedation"|t|t|t|t
34142649|NCT06247228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832783|NCT00664183|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33832784|NCT01151423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A single-blinded study design was initiated because, in the initial versions of the protocol, the dosing regimen could be adjusted dependent on the results of the Ristocetin Cofactor (RICO) test following the initial dose. Therefore, a double-blind design was not feasible because the results of the RICO test effectively unblinded the Investigator. Single-blind design was maintained due to the objective nature of the primary endpoint.||t|f|f|f
33832785|NCT01932398|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832786|NCT02488083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832787|NCT01466790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832788|NCT04614571|NA|SINGLE_GROUP||OTHER||NONE||||||
33832789|NCT00514800|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33832790|NCT05563649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832791|NCT03037047|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832792|NCT02480478|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832793|NCT04679155|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832794|NCT05891652|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||There were two randomized groups: Group M-TAPA (n=21) and Group Control (no block) (n=21). All patients had standard general anesthesia. Group M-TAPA patients had bilateral M-TAPA block with 0.25% bupivacaine (total volume of 40 ml) at the end of the surgery. Group Control had only tramadol for posteperative pain.|t|t|t|t
33832795|NCT01999777|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832796|NCT02520310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832797|NCT04485299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832798|NCT00542412||PARALLEL||TREATMENT||NONE||||||
33832799|NCT03177681|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832800|NCT02132117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142650|NCT00359944|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142651|NCT00445939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832801|NCT04461769|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Participants were blind to which night was stimulation. Experimenters were blinded until the participant was asleep, when they opened an email that specified delivery of stimulation or sham.|First night adaptation sleep; second and third nights (one week apart) stimulation or placebo control (order randomized).|t|t|f|f
33832802|NCT02813993|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33832803|NCT03596242|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832804|NCT02134366|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33832805|NCT03552562|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33832806|NCT00370110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832807|NCT04011293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142652|NCT01167010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142653|NCT00873535|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142654|NCT00750191|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832808|NCT01003145|RANDOMIZED|||PREVENTION||NONE||||||
33832809|NCT04745520|RANDOMIZED|PARALLEL||TREATMENT||NONE|it is not possible to blind the patients and investigators regarding surgery.|This pragmatic trial is a multi-center, two-arm, parallel-group, superiority randomized-controlled trial.||||
33832810|NCT00997711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832811|NCT05580198|||COHORT||PROSPECTIVE|||||||
33832812|NCT00307164|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33832813|NCT01991145|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832814|NCT02682940|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832815|NCT06514573|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinding will be maintained by making the capsules look identical. Both participants and the research staff who collect the outcome data will be blinded to treatment status. All the data will be recorded anonymously and entered into the study database by each researcher. A blinded statistician will analyze the data.|Double-blind randomized, parallel-group, placebo-controlled study. Groups will receive oral sodium butyrate or placebo (cornstarch) for 16 weeks. The sachets and content of treatments will be indistinguishable (same color, smell, taste) and prepared by the Central Pharmacy Service of the Academic Hospital Federico II of Naples. Parents will receive an anonymous white paper box containing the sachets of placebo or butyrate, instructions for storing at room temperature, preparation (mixing the powder in water, milk, or foods), the daily amount of product, and maintaining the habitual child diet, avoiding probiotics, prebiotics, synbiotics during the entire study.|t|t|t|t
33832816|NCT02171884|||COHORT||PROSPECTIVE|||||||
33832817|NCT01314599|NA|SINGLE_GROUP||||NONE||||||
33832818|NCT04388696|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The 18-24 hour content (divided into 8, 3 hour sessions) are spread over a 3 week to 2 month period. Sessions explored gender, consider harmful messages around femininity and socially acceptable images of women, healthy sexuality, healthy relationships and connections, understanding and identifying sexual abuse and assault, and self care.~Control Program: The control intervention used widely-used curricula focused on job skills development and life skills. Trained prevention educators provided the programs for both intervention and control arms and were trained to implement either the Sisterhood 2.0 program or the job skills curriculum."||||
33832819|NCT03894319|||COHORT||PROSPECTIVE|||||||
33832820|NCT00527150|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832821|NCT03443414|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The nebuliser cup will be obscured to prevent the Investigator or outcomes assessor so the contents are not visible to the Investigator our outcomes assessor. The visual appearance of the study medication will not be discussed with the subject||f|f|t|t
33832822|NCT01547221|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832823|NCT01568385||||TREATMENT||||||||
33832824|NCT05846698|||COHORT||PROSPECTIVE|||||||
33832825|NCT01777490|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|Research Assistant conducting follow-up interviews is blinded as to dyad arm assignment||f|f|f|t
33832826|NCT01993771|||COHORT||PROSPECTIVE|||||||
33832827|NCT01475422|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33832828|NCT04624945|||COHORT||PROSPECTIVE|||||||
33832829|NCT00969969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832830|NCT05223972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33832831|NCT03427983|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized blinded study looking at two different ways of drug administration rather than the drug itself. We will compare ultrasound guided injection with hydrodissection to ultrasound guided injection without hydrodissection. In both groups, the active drug is the same in type and amount.|t|f|t|t
33832832|NCT01947712|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|f|t
33832833|NCT02188537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832834|NCT00002740||||TREATMENT||||||||
33832835|NCT04961242|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33832836|NCT04721288|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33832837|NCT01692093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832838|NCT03471364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33832839|NCT01066715|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832840|NCT04789343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients asked one of three numbers (1-2-3) before treatment.|Conventional root canal treatment was perfomed to 45 patients who had been done unacceptable root canal treatment (such as short root canal filling ) on lower premolar or molar teeth before. The patents were healthy and did not take any antibiotics or any medication .|t|f|f|f
33832841|NCT00412880|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832842|NCT00005219|||COHORT||PROSPECTIVE|||||||
33832843|NCT02354547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832844|NCT05594004|||OTHER||RETROSPECTIVE|||||||
33832845|NCT03514381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832846|NCT06435611|||OTHER||CROSS_SECTIONAL|||||||
33832847|NCT01242371|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832848|NCT01283022|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33832849|NCT04537871|||COHORT||PROSPECTIVE|||||||
33832850|NCT02063464|||COHORT||CROSS_SECTIONAL|||||||
33832851|NCT03613324|||CASE_ONLY||RETROSPECTIVE|||||||
33832852|NCT04643093|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33832853|NCT05161741|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832854|NCT00489788|||COHORT||PROSPECTIVE|||||||
33832855|NCT01380977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33832856|NCT00424788|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832857|NCT04283227|NA|SINGLE_GROUP||TREATMENT||NONE||All eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.||||
33832858|NCT06464952|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Double-blind|RCT in patients with cirrhosis and PTSD focused on feasibility and safety|t|f|f|t
33837107|NCT02570659|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33837108|NCT02980276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837109|NCT02039076|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837110|NCT01762969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837111|NCT03498703|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33837578|NCT01416857|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832859|NCT04334616|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|After approval from Ethical Review Committee potential patients will be screened in the ward. After eligibility, the consent will be administered by the study investigators. If patient agree to participate and signed the consent, he/she will be enrolled in the study. Selected patients will be randomly allocated by a computer-generated number, either into conventional laryngoscopy (CL) group or video laryngoscopy (VDL) group through sealed envelopes.|Randomized Control Trial (Observer Blinded)|t|f|t|f
33832860|NCT00003626||||TREATMENT||||||||
33832861|NCT01937195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832862|NCT03579238|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE|The clinicians, participants, researchers and statistician will not know which stage of interaction (distant, close, touching, pulling) induces entrainment, if at all. Statistician will be blinded to stage allocation of each data set, and stages of interaction will be randomized per encounter.|Intrasubject sequential intervention design|t|t|t|t
33832863|NCT00910819|||COHORT||PROSPECTIVE|||||||
33832864|NCT02900898|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832865|NCT03634839|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Flavor and nicotine concentration is blinded to participant. Research staff and investigators are blinded to flavor order administer to participants.||t|t|t|f
33832866|NCT01765738|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33832867|NCT04451837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832868|NCT04171947|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|blinded from the perspective of the participant, investigator, laboratory analyst and data analyst|vehicle-controlled two-arm|t|f|t|t
33832869|NCT00621192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832870|NCT05923346|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832871|NCT06301347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized into one of the two treatment conditions (LTP Plus or TAU) through computer generated algorithm.|f|f|f|t
33832872|NCT01183442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832873|NCT01257399|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832874|NCT02291822|||CASE_ONLY||RETROSPECTIVE|||||||
33832875|NCT00160550|RANDOMIZED|PARALLEL||||DOUBLE||||||
33832876|NCT04627415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832877|NCT00664105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832878|NCT02985047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832879|NCT05550571|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832880|NCT06499688|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded|Placebo- and active-controlled|t|t|t|t
33832881|NCT05196880|||COHORT||PROSPECTIVE|||||||
33832882|NCT00607464|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832883|NCT00920647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832884|NCT02612506|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832885|NCT04502992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Pre-post (quasi-experimental) design assessing the neural mechanisms underlying and behavioral changes associated with a 4 week Acceptance and Committment Therapy (ACT) intervention among participants with chronic musculoskeletal pain.||||
33832886|NCT05332106|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33832887|NCT05762952|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Pharmacy will manage the randomization of study participants. Assignments will not be unmasked until all outcomes have been assessed.||t|t|t|t
33832888|NCT06456086|||COHORT||PROSPECTIVE|||||||
33832889|NCT05649189|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832890|NCT03886454|||COHORT||PROSPECTIVE|||||||
33832891|NCT03630406|||COHORT||PROSPECTIVE|||||||
33832892|NCT05920863|NA|SINGLE_GROUP||TREATMENT||NONE|Prior to enrollment in the study, doctors asked and recorded the patient's medical history, and if eligible participants volunteered to participate in the study, they would sign informed consent.If they are not willing to participate in the study, we will do the usual treatment|This is a prospective, single-arm, open phase II clinical study||||
33832893|NCT02989090|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832894|NCT05052502|RANDOMIZED|FACTORIAL||SCREENING||NONE||||||
33832895|NCT02561208|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832896|NCT01350232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832897|NCT05070832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832898|NCT01201876|||||CROSS_SECTIONAL|||||||
33832899|NCT04662437|||CASE_CONTROL||RETROSPECTIVE|||||||
33832900|NCT02008071|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832901|NCT00521976|||COHORT||PROSPECTIVE|||||||
33832902|NCT01278147|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832903|NCT05113797|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33832904|NCT00030823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832905|NCT04847245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832906|NCT02835027|||COHORT||PROSPECTIVE|||||||
33832907|NCT00322686|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33832908|NCT02496598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832909|NCT01688310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832910|NCT00761956|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832911|NCT03674762|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The cases were randomly divided into two groups as two-stage/submerged, and one-stage/nonsubmerged. Thus, in each patient, the two implants (submerged and nonsubmerged) were placed randomly in the left and right hemi-mandible or in the left and right hemi-maxilla||||
33832912|NCT02706951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832913|NCT02078414|||COHORT||PROSPECTIVE|||||||
33832914|NCT05353660|||COHORT||PROSPECTIVE|||||||
33832915|NCT04658290|||COHORT||PROSPECTIVE|||||||
33832916|NCT03258671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832917|NCT05434585|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Double-Blind|60 subjects will be randomized in a 2:2:1 ratio to receive ABO1009-DP, ABO-CoV.617.2, or placebo|t|f|t|f
33832918|NCT04142099|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Infant Breastfeeding Assessment Tool Maternal Attachment Inventor Breastfeeding Mothers Social Support Scale Breastfeeding self-efficancy scale-short form||||
33837579|NCT04309461|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33837580|NCT03689842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832919|NCT05834023|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|A research assistant will prepare the solutions before the procedure, utilizing bupivacaine alone or mixing bupivacaine and lidocaine as appropriate. The operator, patient, and investigator assessing the block will be blinded to group allocation.|Randomized Controlled Trial|t|t|t|t
33832920|NCT05586412|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomization will be made by drawing lots. 30 patients will be included in the exercise group, 30 patients in the vagus stimulation group, and 30 patients in the exercise and vagus stimulation group.||||
33832921|NCT03468179|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All subjects will have baseline blood drawn, fed controlled serving of oatmeal, and blood drawn sequentially over subsequent 2 hours.||||
33832922|NCT00936598|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33832923|NCT05438134|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832924|NCT02804321|||COHORT||PROSPECTIVE|||||||
33832925|NCT03045913|||COHORT||PROSPECTIVE|||||||
33832926|NCT04742062|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33832927|NCT00169845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832928|NCT06367634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Blinded-Live evaluator||t|f|f|t
33832929|NCT00724386|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832930|NCT01550523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832931|NCT00750451|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33832932|NCT00594022|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33832933|NCT01299311|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33832934|NCT03897231|||OTHER||CROSS_SECTIONAL|||||||
33832935|NCT05285176|||OTHER||PROSPECTIVE|||||||
33832936|NCT01427049|||COHORT||PROSPECTIVE|||||||
33832937|NCT03177109|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33832938|NCT01434719|||CASE_CONTROL||RETROSPECTIVE|||||||
33832939|NCT01586481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832940|NCT04336345|||COHORT||CROSS_SECTIONAL|||||||
33832941|NCT06333977|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33832942|NCT02871583|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33832943|NCT01103232|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33832944|NCT00299598|||CASE_CONTROL||PROSPECTIVE|||||||
33832945|NCT03447275|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33832946|NCT05168098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33832947|NCT03385577|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33832948|NCT00361036|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33832949|NCT02991586|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33832950|NCT01775293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832951|NCT02306447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832952|NCT02646735|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832953|NCT03263364|||COHORT||PROSPECTIVE|||||||
33832954|NCT02977286|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33832955|NCT02161406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832956|NCT04927962|||COHORT||PROSPECTIVE|||||||
33832957|NCT00249782|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33832958|NCT03630263|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||SINGLE|Participants will be provided with a sample that doesn't contain starch.|Repeated measures ANOVA, within factors.|t|f|f|f
33832959|NCT00511498|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
33832960|NCT02828345|||COHORT||PROSPECTIVE|||||||
33832961|NCT02516865|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33832962|NCT00684203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33832963|NCT04561778|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Subjects will be blinded to treatment arm. Echocardiographic evaluation will be performed by study physician blinded to lead placement||t|f|f|t
33832964|NCT04215315|||OTHER||RETROSPECTIVE|||||||
33832965|NCT05827770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832966|NCT04147195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832967|NCT01630005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832968|NCT01154062|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33832969|NCT00927498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832970|NCT05692219|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832971|NCT04158271|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832972|NCT02671214|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33832973|NCT00160082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33832974|NCT00734045|||||PROSPECTIVE|||||||
33832975|NCT02056002|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33832976|NCT04016805|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832977|NCT06484374|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33832978|NCT04776902|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Survey Study||||
33832979|NCT04962373|||COHORT||CROSS_SECTIONAL|||||||
33832980|NCT01876147|||CASE_CROSSOVER||PROSPECTIVE|||||||
33832981|NCT05747612|NA|SINGLE_GROUP||SCREENING||NONE||||||
33832982|NCT06195462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|In this study, the blinding will be triple blinded because the Investigators, care provider, patients and Outcomes Assessor are unaware of which group the participants were allocated to. To ensure the blinding of the participants, their eyes will be blindfolded with a visor made for the study on a white compress.|Randomized clinical trial, triple blind|t|t|t|t
33832983|NCT01522690|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33832984|NCT01569009|||COHORT||CROSS_SECTIONAL|||||||
33832985|NCT02271230|RANDOMIZED|FACTORIAL||PREVENTION||QUADRUPLE|||t|t|t|t
33832986|NCT00459797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832987|NCT03128671|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study personnel evaluating delirium will use standardized tool (CAM-ICU) and will be blinded to subjects' group assignments.|prospective, randomized, experimental design|f|f|f|t
33832988|NCT04806594|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open label, uncontrolled, single arm, post-market clinical follow-up study.||||
33832989|NCT03616964|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837581|NCT06227221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837582|NCT06180213|||COHORT||RETROSPECTIVE|||||||
33837583|NCT02263807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142655|NCT04139681|NA|SINGLE_GROUP||TREATMENT||NONE||"Eligible patients fulfilling the inclusion criteria will :~1. First suck under supervision in the study centre one lozenge and document every 15 minutes the pain on a 100mmVAS for 90 minutes~2. Receive the rest of the bottle still containing 19 lozenges and have to take them for 4 days (5 lozenges per day). The patients have to fill out a diary in the morning and in the evening filling out the Tonsillopharyngitis Score (TSS), pain on a 100mm VAS and occurrence of adverse events, intake of other medication.~3. After the end of the treatment period patients will return to the study centre for the final visit"||||
34142656|NCT06055465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142657|NCT00444704|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34142658|NCT01267331|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34142659|NCT00005764||||TREATMENT||||||||
34142660|NCT00670891|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142661|NCT02638207|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142662|NCT01298102|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142663|NCT05037487|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||This is a randomized, double-blind, placebo-controlled study. All participants will complete all dose conditions in a randomized order.|t|f|t|f
34142664|NCT02834585|||COHORT||PROSPECTIVE|||||||
34142665|NCT02887053|NA|SINGLE_GROUP||OTHER||NONE||||||
34142666|NCT02818036|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34142667|NCT04429581|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142668|NCT04919460|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34142669|NCT00793572|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142670|NCT04145960|||COHORT||PROSPECTIVE|||||||
34142671|NCT01994772|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34142672|NCT03557346|||CASE_CROSSOVER||PROSPECTIVE|||||||
34142673|NCT04944368|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34142674|NCT02700789|||COHORT||PROSPECTIVE|||||||
34142675|NCT02607241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142676|NCT02978703|||OTHER||PROSPECTIVE|||||||
34142677|NCT00266838|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
34142678|NCT00096499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142679|NCT05756114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142680|NCT04385641|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34142681|NCT00221715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142682|NCT04294316|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest who are eligible for enhanced-contrast brain ultrasound with sulphur hexafluoride microbubbles contrast Sonovue examination||||
34142683|NCT05933642|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Recruited patient randomised into intervention vs control group by non clinical personnel, trial drugs dilution by research assistant, drug administered to patient by staff nurses, data collection by independent group|double blind, randomised, controlled trial|t|t|t|t
34142684|NCT06351319|||OTHER||RETROSPECTIVE|||||||
34142685|NCT04960878|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34142686|NCT02962271|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34142687|NCT05074888|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||double-blind, placebo-controlled, parallel-group, randomized|t|t|t|t
34142688|NCT04599868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142689|NCT03467984|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34142690|NCT04790513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|lipid levels measured and central laboratory will be blinded to participants, investigators, and sponsor, DSMB and CEC (Cardiovascular Events Committee)|randomized, open-label with blinded lipid levels|t|t|t|t
34142691|NCT02138474|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142692|NCT04052087|||OTHER||OTHER|||||||
34142693|NCT00162279|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34142694|NCT01616940|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142695|NCT00642369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142696|NCT02059759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142697|NCT00293709|||COHORT||PROSPECTIVE|||||||
33837584|NCT04654910|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34142698|NCT03934970|||CASE_CONTROL||PROSPECTIVE|||||||
33837585|NCT06282211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33837586|NCT02979106|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33837587|NCT04385758|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34142699|NCT03162484|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34142700|NCT01391598|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142701|NCT01556776|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142702|NCT04720430|||COHORT||OTHER|||||||
34142703|NCT00096525||||TREATMENT||NONE||||||
34142704|NCT00741195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142705|NCT02443194|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34142706|NCT06079073|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization is conducted at the end of the baseline assessment. Participants in the intervention group is handled by an OMT therapist until outcome assessment by the same postdoc student that did the baseline examination. The postdoc student has not been in contact with any participant during the intervention period.|Block randomization to ensure 40% female participants. Intervention: Access to treatment module in application plus access to OMT therapist. Control: Access to application without treatment module. No scheduled appointments with OMT therapist.|f|f|t|t
34142707|NCT01893372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142708|NCT05242666|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Observational study of patients undergoing surgery for degenerative cervical myelopathy, allocated to receive an additional form of imaging assessment before and after surgery.||||
34142709|NCT04551001|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34142710|NCT05179083|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34142711|NCT01330979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142712|NCT01341691|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34142713|NCT05173610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142714|NCT02117895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142715|NCT01620164|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34142716|NCT03647111|||COHORT||RETROSPECTIVE|||||||
34142717|NCT02357862|||COHORT||PROSPECTIVE|||||||
34142718|NCT03225768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142719|NCT03208114|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A total mother-infant pairs enrolled will be randomized to either receive the written information of the name of a breast milk substitute on the infant's discharge documents (group A) or not to receive it (group B).||||
34142720|NCT02344979|||CASE_CONTROL||PROSPECTIVE|||||||
34142721|NCT01975337|NON_RANDOMIZED|PARALLEL||||NONE||||||
34142722|NCT03622112|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"All double-blind medication kits will have similar appearance regardless of the IP (AZD7594 or placebo) contained in a DPI device and will be labelled using a unique medication identification number (Kit ID) that is linked to a treatment arm. IVRS/IWRS will assign the study medication to be dispensed to each subjects at Visit 3.~Supplies of budesonide, FF and SABA (salbutamol/albuterol) will be open-label."||t|t|f|f
34142723|NCT02594800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142724|NCT03029546|||OTHER||PROSPECTIVE|||||||
34142725|NCT05405491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142726|NCT00572611|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142727|NCT01836796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142728|NCT06325293|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||This is a randomized, double-blind, placebo-controlled, multicenter, non-inferiority trial.|t|t|t|t
34142729|NCT01448824|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34142730|NCT03060512|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142731|NCT02908685|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34142732|NCT04604197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142733|NCT03742999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142734|NCT04380103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142735|NCT03738501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142736|NCT04374591|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142737|NCT03770494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142738|NCT04683081|||COHORT||PROSPECTIVE|||||||
34142739|NCT02956759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142740|NCT01258153|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142741|NCT05623254|NA|SINGLE_GROUP||OTHER||NONE|None (Open Label)|A pilot, prospective, interventional, monocenter study||||
34142742|NCT00523705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142743|NCT02241330|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34142744|NCT06605794|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142745|NCT01175200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142746|NCT05238012|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Experimental group: Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.~Control group: Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime; Continuous treatment for 24 weeks."||||
34142747|NCT02125357|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34142748|NCT02131376|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34142749|NCT01007123|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34142750|NCT05159479|||COHORT||PROSPECTIVE|||||||
34142751|NCT03094364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142752|NCT03615287|||OTHER||PROSPECTIVE|||||||
34142753|NCT01340937|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34142754|NCT00644904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142755|NCT04766385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142756|NCT05799989|||COHORT||PROSPECTIVE|||||||
34142757|NCT03210090|||COHORT||PROSPECTIVE|||||||
34142758|NCT05448313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34142759|NCT04113174|||COHORT||PROSPECTIVE|||||||
34142760|NCT01748474|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33837588|NCT02223910|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
33837589|NCT01983423|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837590|NCT04887506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837591|NCT02503319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837592|NCT01791972|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34142761|NCT03872830|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142762|NCT06297850|||CASE_ONLY||PROSPECTIVE|||||||
34142763|NCT00383643|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142764|NCT00369005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142765|NCT05093543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142766|NCT00651495|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34142767|NCT01194843|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34142768|NCT03777709|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142769|NCT06489990|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142770|NCT00502723|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142771|NCT03695380|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837593|NCT00749697|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837594|NCT00966147|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34142772|NCT02904122|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142773|NCT03709836|||COHORT||RETROSPECTIVE|||||||
34142774|NCT01960543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142775|NCT00088283|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34142776|NCT05114122|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinding||t|f|f|t
34142777|NCT01477463|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34142778|NCT05082220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142779|NCT04372654|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Pilot, prospective, multicenter, non-comparative study in 60 patients with a percutaneous cardiovascular intervention indication which requires temporary cardiac stimulation.||||
34142780|NCT01981200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142781|NCT01640418|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142782|NCT01688947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142783|NCT04061954|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142784|NCT02961790|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34142785|NCT02945553|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34142786|NCT01384357|||||RETROSPECTIVE|||||||
34142787|NCT01070563|||CASE_CONTROL||PROSPECTIVE|||||||
34142788|NCT06054516|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142789|NCT01980277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142790|NCT06217523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142791|NCT03286270|||COHORT||RETROSPECTIVE|||||||
34142792|NCT00420810|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34142793|NCT06599983|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The aim of this study, is to evaluate if the novel educational program for dental personnel: Educational Storytelling, an Educational Program Against Child Abuse and Neglect has any effect. A total of 39 public dental health clinics in Vestland county Norway, were randomized into two groups, test and control groups.~The dental clinics in the test group attended the program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect. The control grup did not attend any program.~Both test and control group recieved a total of 3 questionnaires by e-mail in the following timeframe:~* Three weeks before the test group attended the educational program.~* One week after the test group attended the educational program~* Six months after the test group attended the educational program.~A few months after the last questionnaire was closed, the dental clinics allocated in the control group, attended the educational program"||||
34142794|NCT02071420|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34142795|NCT02536066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142796|NCT00869245|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34142797|NCT06346366|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Patients are randomized to a 3-month treatment period with the bihormonal artificial pancreas (BIHAP) (preceded by a training period) or a 3-month treatment with their current diabetes care. Hereafter, all patients will cross over.||||
34142798|NCT01909882|NA|SINGLE_GROUP||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34142799|NCT03610503|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Anonymous data collection to be reviewed|Randomized, intervention-control, trial|t|f|t|t
34142800|NCT04938999|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Eligible participants recruited from the same facility will be allocated to either intervention or control groups accordingly. Group allocation will be concealed from outcome assessors and made according to the random group allocation sequence generated by an independent statistician and the sequence of entry into the study.||f|f|f|t
34142801|NCT02852395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142802|NCT06607159|RANDOMIZED|PARALLEL||PREVENTION||NONE||This is a cluster-randomized, controlled, parallel clinical trial assessing the impact of an educational intervention in the prevalence of obesity in children. The inclusion in both arms of the study was randomized with a 1:1 ratio (even though we performed cluster randomization, the aim was to have a 1:1 participants´ratio, not a 1:1 classroom ratio). To randomize the participant schools, we employed a stratified cluster randomization approach. First, we categorized schools into three types: public, private, and subsidized. Within each category, we assigned a random number to each school a and then ranked them from highest to lowest based on these numbers. Given that we knew the number of children in each class, we started allocating schools with the highest random numbers to either the intervention or control arm, continuing this process until the target number of children in each arm was reached. All children from a given school were assigned to the same study arm||||
34142803|NCT01011803|NA|SINGLE_GROUP||SCREENING||DOUBLE|||f|t|f|t
34142804|NCT00349687|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34142805|NCT02157792|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142806|NCT01158144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142807|NCT05929378|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34142808|NCT06037343|||CASE_ONLY||RETROSPECTIVE|||||||
34142809|NCT04864132|||CASE_CONTROL||PROSPECTIVE|||||||
34142810|NCT02218073|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142811|NCT01730339|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34142812|NCT06327893|||COHORT||RETROSPECTIVE|||||||
34142813|NCT01386541|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34142814|NCT00846040|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142815|NCT01861925|||COHORT||PROSPECTIVE|||||||
34142816|NCT01632813|||COHORT||PROSPECTIVE|||||||
34142817|NCT02699450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142818|NCT01514240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142819|NCT05539560|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142820|NCT05429645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142821|NCT03386786|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142822|NCT05344339|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized control trial||||
34142823|NCT06385093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142824|NCT01825278|||COHORT||PROSPECTIVE|||||||
34150873|NCT06502834|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The pharmacist will provide the study intervention to the investigator in a coded fashion. Both the investigator and the participant are blinded.~In case of emergency, an unblinding protocol is activated."|2x10 participants will be randomly allocated to placebo or d piger suspension once daily.|t|t|t|f
33837595|NCT03834519|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837596|NCT01422473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837597|NCT05967325|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837598|NCT05793203|||COHORT||PROSPECTIVE|||||||
33837599|NCT03032718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding against study arm||f|f|f|t
33837600|NCT03306420|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837601|NCT00186017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837602|NCT03239327|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837603|NCT06507072|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33837604|NCT02108769|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33837605|NCT00077389||||TREATMENT||NONE||||||
33837606|NCT00134355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837607|NCT04511624|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34142825|NCT03373032|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blind ramdomization and blind final evaluation|A computer program will produce a randomization list, which will generate random sequences for the three groups and will be recorded and placed in sealed, opaque, non-translucent and sequentially numbered envelopes. This intervention should be done by someone else and not by the principal investigator. These envelopes will be opened after the consent of the patient to participate in the research and only then will the researcher know as well as the patient the group that she will be allocated. 124 envelopes were available where 31 would contain code that allocates the patients in group A, 31 in group B, 31 in group C or 31 group Follow Up .No Intervention Group - S 'Class wait '. This was done in order to avoid influences such as the therapist's or patient's preferences related to the intervention.|t|f|f|f
34142826|NCT04066686|||COHORT||RETROSPECTIVE|||||||
34142827|NCT04326725|||CASE_CONTROL||PROSPECTIVE|||||||
34142828|NCT00688246|||COHORT||PROSPECTIVE|||||||
34142829|NCT03989973|||COHORT||PROSPECTIVE|||||||
34142830|NCT01556048|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142831|NCT00123097|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||QUADRUPLE|||t|t|t|t
34142832|NCT04270162|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Hospitalized patients who after the exclusion criteria will begin the investigation and organize into 3 groups. The present one will be distributed with a basic probabilistic sampling using a random number table, whose order will be randomized through the Microsoft Excel 16.0 program, being experimental group 1 (New intervention protocol with inspirometer), experimental group 2 (Use of inspirometer in a conventional way) and control group (breathing exercises without the use of inspirometer).|t|f|t|f
34142833|NCT00168103|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142834|NCT04421872|NON_RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34142835|NCT01244581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142836|NCT00402714|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142837|NCT00196859|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142838|NCT01839240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142839|NCT02736266|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142840|NCT04811105|RANDOMIZED|CROSSOVER||TREATMENT||NONE||32 rats have 1 fistula tract 16 rats will treat with steam ablation 16 rats will be control group||||
34142841|NCT04442256|NA|SINGLE_GROUP||TREATMENT||NONE||Only one group||||
34142842|NCT04952974|||CASE_ONLY||OTHER|||||||
34142843|NCT04585711|NA|SINGLE_GROUP||OTHER||NONE||||||
34142844|NCT04966728|||CASE_ONLY||PROSPECTIVE|||||||
34142845|NCT01924442|||COHORT||PROSPECTIVE|||||||
34142846|NCT05082350|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease.||||
34142847|NCT03483805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142848|NCT03704662|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142849|NCT02253823|RANDOMIZED|PARALLEL||||NONE||||||
34142850|NCT03999138|||COHORT||PROSPECTIVE|||||||
34142851|NCT02906215|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34142852|NCT03426358|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All the patients with onco-hematological disease and an indication for transplantation of hematopoietic stem cells will be consecutively studied.||||
34142853|NCT00899717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142854|NCT04185974|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel Assignment||||
34142855|NCT01359761|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34142856|NCT00450671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142857|NCT00199316|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142858|NCT01944566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142859|NCT04636177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142860|NCT03413098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142861|NCT03255213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142862|NCT02425605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142863|NCT06082596|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142864|NCT01263392|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34142865|NCT01215110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142866|NCT06327633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142867|NCT05762861|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34142868|NCT05518773|||COHORT||CROSS_SECTIONAL|||||||
34142869|NCT02360644|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34142870|NCT00110071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142871|NCT01012921|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142872|NCT04867941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142873|NCT03040869|||COHORT||PROSPECTIVE|||||||
34142874|NCT06078319|||COHORT||PROSPECTIVE|||||||
34142875|NCT05476432|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142876|NCT04726579|||CASE_ONLY||PROSPECTIVE|||||||
34142877|NCT00380029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142878|NCT03334279|||OTHER||CROSS_SECTIONAL|||||||
34142879|NCT01187446|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142880|NCT00776464|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142881|NCT04152330|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34142882|NCT01244789|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142883|NCT01533467|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142884|NCT03975127|RANDOMIZED|PARALLEL||SCREENING||NONE||"The study arms are as follow:~1. No intervention: women will routinely be invited to attend for cervical screening via the SCCRS application.~2. Experimental: Women aged under 30 years will be identified to receive an SMS following cervical screening invitation using information from the CHI Broadcast"||||
34142885|NCT00531297|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142886|NCT00003044||||TREATMENT||||||||
34142887|NCT05671575|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142888|NCT05207332|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34142889|NCT06434155|||COHORT||PROSPECTIVE|||||||
33837608|NCT02748551|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837609|NCT06341140|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34142890|NCT05298995|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142891|NCT01767493|NA|SINGLE_GROUP||OTHER||NONE||||||
34142892|NCT02220023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142893|NCT04371822|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|"Patients~This study will performed on 56 participants tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection and 56 participants will divided into 8 equal groups"|"Patients and method :~This study will performed on 56 participants tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection and 56 participants will divided into 8 equal groups"||||
34142894|NCT00827281|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142895|NCT02526823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142896|NCT04726033|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.||||
34142897|NCT03837665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142898|NCT04690803|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|evaluator-blinded|sclerotherapy with forced-air cooling during treatment.|f|f|t|f
34142899|NCT02387125|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34142900|NCT03836430|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two-arm parallel assignment involving two groups of participants. Group A received the intervention of Newborn Behavior Observation (NBO) sessions and Group B did not.|t|f|f|t
34142901|NCT02913209|||COHORT||CROSS_SECTIONAL|||||||
34142902|NCT05389475|||CASE_ONLY||PROSPECTIVE|||||||
34142903|NCT04493814|||COHORT||RETROSPECTIVE|||||||
34142904|NCT06277349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomised controlled trial with intra-patient comparison (bilateral study), patients are either receiving implant of a multifocal toric IOL or implant of a standard multifocal IOL combined with limbal relaxing incisions.|f|f|t|f
34142905|NCT03267173|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142906|NCT00884910|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34142907|NCT05975008|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||This is a pilot randomized controlled trial. Intervention arm participants will participate in the 8-week intervention. Control group participants will receive psychoeducation materials that the intervention group will also receive.|t|f|f|f
34142908|NCT01867957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34142909|NCT02942511|||COHORT||PROSPECTIVE|||||||
34142910|NCT02931604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142911|NCT04714918|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142912|NCT06352593|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142913|NCT01483534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142914|NCT05296460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142915|NCT02980146|||COHORT||PROSPECTIVE|||||||
34142916|NCT04413474|||COHORT||PROSPECTIVE|||||||
34142917|NCT00828399|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34142918|NCT01977443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34142919|NCT04150731|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142920|NCT06495840|||COHORT||PROSPECTIVE|||||||
34142921|NCT02590562|||CASE_ONLY||CROSS_SECTIONAL|||||||
34142922|NCT00308893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142923|NCT01281098|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142924|NCT06148311|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34142925|NCT03446053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142926|NCT04401306|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34142927|NCT05878756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142928|NCT03849690|NA|SINGLE_GROUP||OTHER||NONE||||||
34142929|NCT04424056|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142930|NCT02275117|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34142931|NCT05237011|||COHORT||PROSPECTIVE|||||||
34142932|NCT02218086|RANDOMIZED|CROSSOVER||TREATMENT||NONE||different protocol-arms: crossover for comparing slackline vs. wobble board vs. flamingo balance task parallel for slackline training vs. enhanced standing-on-1-leg training||||
34142933|NCT01991223|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34142934|NCT06339502|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34142935|NCT01239888|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34142936|NCT03938220|||COHORT||PROSPECTIVE|||||||
34142937|NCT05857449|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34142938|NCT01000922|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34142939|NCT02205346|||COHORT||PROSPECTIVE|||||||
34142940|NCT04811443|||CASE_ONLY||PROSPECTIVE|||||||
34142941|NCT04617418|||COHORT||PROSPECTIVE|||||||
34142942|NCT01575093|NA|SINGLE_GROUP||OTHER||NONE||||||
34142943|NCT01900301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142944|NCT03578692|||CASE_CONTROL||PROSPECTIVE|||||||
34142945|NCT04862013|||COHORT||RETROSPECTIVE|||||||
34142946|NCT02323841|NA|SINGLE_GROUP||||NONE||||||
34142947|NCT02479581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34142948|NCT01728077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142949|NCT05304143|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142950|NCT02350049|||CASE_CONTROL||RETROSPECTIVE|||||||
34142951|NCT01971463|NA|SINGLE_GROUP||OTHER||NONE||||||
34142952|NCT03078283|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34142953|NCT00136240|RANDOMIZED|FACTORIAL||||NONE||||||
34142954|NCT02404415|||COHORT||PROSPECTIVE|||||||
34142955|NCT05649267|||OTHER||CROSS_SECTIONAL|||||||
34142956|NCT04216940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34142957|NCT02917213|||COHORT||PROSPECTIVE|||||||
34142958|NCT06396312|||OTHER||PROSPECTIVE|||||||
34142959|NCT04907149|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34142960|NCT04359732|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34142961|NCT02115841|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34142962|NCT04956029|||CASE_ONLY||PROSPECTIVE|||||||
34142963|NCT02046174|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142964|NCT00002454||||TREATMENT||||||||
34142965|NCT01752790|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142966|NCT01933230|NA|SINGLE_GROUP||||NONE||||||
34142967|NCT00954798|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34142968|NCT00511784|||CASE_CONTROL||RETROSPECTIVE|||||||
34142969|NCT05997849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking of the participants will be achieved by assigning them to intervention groups without stating the content or purpose of said group beyond the general guidelines of knowing that the intervention is mental health related. Masking of the outcome assessors will be achieved by providing them an Anonymized participant database after the application period and recollection of data has ended.|The study uses a parallel model for the delivery of the interventions, where the application-based interventions will be carried out simultaneously for all groups.|t|f|f|t
34142970|NCT04405544|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142971|NCT05076760|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142972|NCT01163773|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34142973|NCT01488214|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34142974|NCT04994730|||COHORT||RETROSPECTIVE|||||||
34142975|NCT00309140|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142976|NCT03946982|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34142977|NCT01742910|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34142978|NCT04812990|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34142979|NCT03679078|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34142980|NCT02577770|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34142981|NCT05226364|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34142982|NCT00579046|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34142983|NCT05132257|||COHORT||PROSPECTIVE|||||||
34142984|NCT01996267|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142985|NCT05202665|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34142986|NCT04837729|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34142987|NCT01620515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142988|NCT03592719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142989|NCT01549535|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34142990|NCT00571636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34142991|NCT01079013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34142992|NCT01510015|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34142993|NCT01693380|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34142994|NCT05387980|||COHORT||PROSPECTIVE|||||||
34142995|NCT04852835|||CASE_ONLY||OTHER|||||||
34142996|NCT05010330|||COHORT||RETROSPECTIVE|||||||
34142997|NCT04525924|NA|SINGLE_GROUP||OTHER||NONE||||||
34142998|NCT05728151|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34142999|NCT05223881|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143000|NCT01274780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143001|NCT05006209|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143002|NCT05719506|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34143003|NCT00346489|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143004|NCT06349187|||COHORT||CROSS_SECTIONAL|||||||
34143005|NCT02762955|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143006|NCT03690739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143007|NCT03946124|NA|SINGLE_GROUP||TREATMENT||NONE||prospective cohort design examining effects in adults aged 65 and older with OAB undergoing treatment with medication in a clinical setting. A follow up period of 8 weeks has been selected because this is the period of maximal drop in adherence.||||
34143008|NCT01025362|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34143009|NCT02510365|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143010|NCT02845947|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143011|NCT01257490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143012|NCT03872427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143013|NCT03798054|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143014|NCT01151605|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143015|NCT04736160|||COHORT||RETROSPECTIVE|||||||
34143016|NCT05462002|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143017|NCT01252550|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143018|NCT00374712|||||PROSPECTIVE|||||||
33837610|NCT05692869|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837611|NCT02919553|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33837612|NCT00605488|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837613|NCT04324905|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837614|NCT01808677|||COHORT||PROSPECTIVE|||||||
33837615|NCT03240016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143019|NCT05346991|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143020|NCT01143051|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34143021|NCT03723174|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34143022|NCT03330015|||COHORT||PROSPECTIVE|||||||
34143023|NCT01410669|RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34143024|NCT02615860|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143025|NCT01221025|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143026|NCT00118352|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143027|NCT06333743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143028|NCT05059223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143029|NCT06252896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143030|NCT03415698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143031|NCT04697186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143032|NCT03368716|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143033|NCT02448953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143034|NCT04815122|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143035|NCT02573246|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants were assigned to one of 2 studies (main and supplement) that ran concurrently. 83 participants were enrolled in the main study, and 65 in the supplement.|t|f|f|t
34143036|NCT02947854|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143037|NCT06607237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143038|NCT01007071|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143039|NCT04847895|||COHORT||PROSPECTIVE|||||||
34143040|NCT06269198|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"Participants will not be given information on group allocation. Care-providers will not be blinded, due to having to carry out the intervention.~Investigator will not be blinded to carrie out roles such as safety surveillance, error-solving and quality assurance.~Outcome assessor will be blinded to study allocation."|Randomisation stratified by study site|t|f|f|t
34143041|NCT03488589|||CASE_ONLY||OTHER|||||||
34143042|NCT05607082|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
34143043|NCT05697289|||COHORT||PROSPECTIVE|||||||
34143044|NCT01457950|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143045|NCT04606589|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a simple pre/post interventional study model.||||
34143046|NCT02632201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143047|NCT01201616|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34143048|NCT04412213|||COHORT||CROSS_SECTIONAL|||||||
34143049|NCT04563728|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Comparing two different intervention strategies, participants and research assistants will be masked about the assignment during the 8-week participation. In the camera and mock camera group, participants will not be told which group they are a part of. In either the camera or mock camera group, research assistants (RAs) administering consent will also not be told which group the participant is a part of to avoid accidental reveal of groups. Groups will be revealed at the end of the study participation.|Three groups of people receive different interventions and usual care.|t|t|f|t
34143050|NCT02435290|||CASE_ONLY||CROSS_SECTIONAL|||||||
34143051|NCT03584191|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34143052|NCT02593812|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34143053|NCT00002598||||TREATMENT||NONE||||||
34143054|NCT05358314|||CASE_ONLY||CROSS_SECTIONAL|||||||
34143055|NCT04492709|NA|SINGLE_GROUP||OTHER||NONE||Fixed sequence||||
34143056|NCT02727556|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34143057|NCT05079750|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
34143058|NCT02442791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143059|NCT04927767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143060|NCT03594149|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143061|NCT04371640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143062|NCT01420172|||CASE_ONLY||RETROSPECTIVE|||||||
34143063|NCT05602675|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34143064|NCT01351974|||COHORT||PROSPECTIVE|||||||
34143065|NCT02057094|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34143066|NCT03190265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143067|NCT01976897|||COHORT||CROSS_SECTIONAL|||||||
34143068|NCT05211921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143069|NCT04126720|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143070|NCT05295823|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||DOUBLE|The participant will be blinded to the results of the Urologic healthcare provider's measurements; and the Urologic healthcare provider will be blinded to the results of the patient's measurements.||t|t|f|f
34143071|NCT01480973|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143072|NCT06201793|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143073|NCT00875056|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All participants received the same drug regimen but were allocated to groups based on disease type.||||
34143074|NCT02614040|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143075|NCT01744678|NA|SINGLE_GROUP||OTHER||NONE||||||
34143076|NCT04894643|NA|SINGLE_GROUP||OTHER||NONE||This is a single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer||||
34143077|NCT02583100|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34143078|NCT05086757|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Trained interviewers blinded to condition will administer the 3-, 6-, and 12-month post-baseline assessments||f|f|f|t
34143079|NCT04599270|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143080|NCT04912323|NA|SINGLE_GROUP||TREATMENT||NONE||All subjects will receive the investigational device||||
34143081|NCT02956850|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143082|NCT02034175|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||SINGLE|The two sets of data (PSG and Somnapatch) were scored independently. Therefore it was masked what set of data belonged to what individual.||f|f|f|t
34143083|NCT04926207|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34143084|NCT01773343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143085|NCT01570153|||COHORT||PROSPECTIVE|||||||
34143086|NCT06200974|||COHORT||PROSPECTIVE|||||||
34143087|NCT05772598|||COHORT||PROSPECTIVE|||||||
34143088|NCT04350021|||COHORT||PROSPECTIVE|||||||
34143089|NCT05607498|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143090|NCT02574013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143091|NCT02154048|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143092|NCT03404908|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Participant)|Parallel Assignment|t|f|f|f
34143093|NCT00889889|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143094|NCT01063491|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143095|NCT00701298|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143096|NCT00266929|||COHORT||PROSPECTIVE|||||||
34143097|NCT06031142|||FAMILY_BASED||PROSPECTIVE|||||||
33837616|NCT02209493|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33837617|NCT01436747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837618|NCT06266208|||CASE_CONTROL||PROSPECTIVE|||||||
33837619|NCT00967967|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143098|NCT06044805|NA|SINGLE_GROUP||TREATMENT||NONE||Open label clinical trial study will be conducted in Shecha Health Center from December 2022 to March 2023. Participants will be selected and treated with a 25 mg/kg standard dose of chloroquine over three days and a 0.25 mg/kg standard dose of primaquine over fourteen days. Clinical, parasitologic, and hematologic parameters will be monitored for up to a 42-day follow-up period, which will be used to evaluate therapeutic efficacy of CQ+PQ. Thick and thin blood smears will be prepared and examined to determine parasite clearance, and clinical examination will be performed over 42 follow up periods. Haemoglobin level will be measured on days 0, 14, 28 and 42. WHO double-entry Excel sheet will be used for KaplanMeier survival analysis and SPSS version-26 software will be used to analyse the data. All comparisons will be performed at 95% confidence interval and a significance level of 0.05, Pvalue of \<0.05 will be considered statistically significant||||
34143099|NCT00297102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143100|NCT00494377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143101|NCT01587638|||||RETROSPECTIVE|||||||
34143102|NCT03552211|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143103|NCT02081638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143104|NCT04740840|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143105|NCT04348019|RANDOMIZED|PARALLEL||PREVENTION||NONE||8-week randomized-controlled, 2-arm parallel design trial||||
34143106|NCT04388046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143107|NCT05154617|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143108|NCT05388838|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Prospective Case Control Study||||
34143109|NCT02442453|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143110|NCT00612859|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143111|NCT01493219|||CASE_CONTROL||PROSPECTIVE|||||||
34143112|NCT01943838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143113|NCT05324020|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34143114|NCT01172730|||CASE_ONLY||PROSPECTIVE|||||||
34143115|NCT05145855|||COHORT||RETROSPECTIVE|||||||
34143116|NCT01537081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143117|NCT00525629|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34143118|NCT05315427|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143119|NCT04316078|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Randomized control study (2:1 allocation)||||
34143120|NCT00941369|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143121|NCT01214304|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143122|NCT00004437||||TREATMENT||||||||
34143123|NCT00777530|RANDOMIZED|SINGLE_GROUP||||DOUBLE|||t|f|t|f
34143124|NCT06360081|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33832990|NCT04783103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All subjects will be assigned to one of the treatment arms by use of the top card from a stack of pre-coded cards which were prepared by an independent coder. The card has to be entered in machine in order to operate it and can be an activator of either sham or active treatment (both are integrated in and delivered by the same helmet coil.|In a sham-controlled randomized controlled trial, we will treat 44 geriatric depressed patients with accelerated dTMS (adTMS) (5 sessions/day over 4 days) and evaluate clinical efficacy and safety. One week after the last adTMS or sham treatment, all patients will have access to active treatment in a 3 week open label transcutaneous direct current stimulation (tDCS) with a home-use device. In this manner we can examine clinical effect of tDCS in the adTMS-sham group as well as the possible maintenance effect of tDCS in the adTMS active treatment group. Because newly introduced neuromodulation paradigms should go through profound neurobiological testing before applying them on a regular basis, this research will include multimodal brain imaging techniques to elucidate the working mechanisms of these applications in order to optimize response prediction and treatment|t|t|t|t
33832991|NCT03831854|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The Pharmacy will know the treatment|randomization without stratification|t|t|t|f
33832992|NCT02712164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33832993|NCT02413814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33832994|NCT04291209|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34143125|NCT01912157|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||t|f|f|f
34143126|NCT05877040|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143127|NCT06426368|||COHORT||PROSPECTIVE|||||||
34143128|NCT00066469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143129|NCT02184377|||CASE_ONLY||PROSPECTIVE|||||||
34143130|NCT04092192|RANDOMIZED|PARALLEL||OTHER||NONE|No masking|||||
34143131|NCT00004174||||TREATMENT||||||||
34143132|NCT06162533|||COHORT||RETROSPECTIVE|||||||
34143133|NCT02169128|||COHORT||PROSPECTIVE|||||||
34143134|NCT04408417|RANDOMIZED|CROSSOVER||TREATMENT||NONE|The order of the harnessing periods will be randomly allocated at the start of the study visit and counterbalanced across participants. Participants will be aware that the order of the harnessing periods is randomly assigned. Assignment status will not be concealed from the research assistants enrolling the dyads or the participants, or the rest of the study team.|This study is a 2-treatment, 4-period, 4-sequence crossover design. Each enrolled dyad will experience the prototype seat two times and the control seat two times for a total of four harnessing periods. The order of the harnessing periods will be randomly allocated at the start of the study visit and counterbalanced across participants.||||
34143135|NCT02775110|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34143136|NCT00902993|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34143137|NCT06254872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143138|NCT05671224|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE||Using a web-based randomization sequence on REDCap, patients will be randomized in 1:1 ratio to standard counseling or counseling with a visual aid immediately prior to initiation of their IOL.|t|t|f|f
34143139|NCT05739695|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143140|NCT02648451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143141|NCT04820634|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143142|NCT05978076|||CASE_ONLY||RETROSPECTIVE|||||||
34143143|NCT04274153|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34143144|NCT03177811|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143145|NCT01173549|RANDOMIZED|CROSSOVER||||TRIPLE|||t|t|t|f
34143146|NCT00989638|||CASE_ONLY||PROSPECTIVE|||||||
34143147|NCT03789695|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34143148|NCT05804630|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Split-mouth study design: one dental anesthetic agent at one side (left or right) of mouth and another agent at the other (left or right) side of mouth|t|t|f|f
34143149|NCT04965961|RANDOMIZED|PARALLEL||OTHER||DOUBLE|An algorithm was created using randomizer.org|Explorative|t|f|t|f
34143150|NCT04526145|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34143151|NCT04104685|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143152|NCT02912130|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34143153|NCT01863121|||COHORT||PROSPECTIVE|||||||
34143154|NCT01618617|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34143155|NCT03452826|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143156|NCT01431937|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34143157|NCT02969096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143158|NCT03674099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treating physician not blinded, evaluating physician blinded.|Randomized, single-blinded, controlled.|f|f|f|t
34143159|NCT03209232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143160|NCT00353431|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143161|NCT01703117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143162|NCT04596332|||OTHER||OTHER|||||||
34143163|NCT03564405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143164|NCT05027334|NA|SINGLE_GROUP||PREVENTION||NONE||Single group assignment||||
34143165|NCT01956045|||||CROSS_SECTIONAL|||||||
34143166|NCT05756517|||COHORT||PROSPECTIVE|||||||
34143167|NCT06102356|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143168|NCT04615975|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143169|NCT04881500|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143170|NCT04481802|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143171|NCT04890587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143172|NCT00119912|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143173|NCT00867776|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34143174|NCT00914563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143175|NCT03144193|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blind|Assessment of efficacy of a novel anti-aging topical treatment compared to a placebo control|t|f|t|t
34143176|NCT04688918|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study subjects and the resident assessing the outcomes will be blinded to the study group. A single investigator will assess the patients for eligibility, obtain written informed consent, open the sealed opaque envelopes containing group allocation|Prospective, randomized, double blind study|t|f|f|t
34143177|NCT06046469|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143178|NCT02434354|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143179|NCT02761694|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143180|NCT00463983|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143181|NCT05166382|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Providers and participants in the uninformed arm will not receive CVD-T2D test results until the second research visit in the study.|Providers will be randomized into informed vs uninformed groups. The randomization will occur at each clinic individually to assure equal distribution of informed vs uninformed providers in each clinic. Patients will be assigned a group based on their providers randomization.|t|t|f|f
34143182|NCT02850263|||COHORT||PROSPECTIVE|||||||
34143183|NCT04128397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||first group is traditional stimulation site group ,second group is precise position stimulation group .|f|f|t|f
34143184|NCT03049865|||COHORT||PROSPECTIVE|||||||
34143185|NCT02891681|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143186|NCT02823132|||CASE_CONTROL||PROSPECTIVE|||||||
34143187|NCT02340182|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143188|NCT04736680|||COHORT||RETROSPECTIVE|||||||
34143189|NCT01515475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143190|NCT02630017|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||"There are two parallel arms of this study (ADHD or non-ADHD subjects).~Within each arm, each subject will be exposed to placebo and a drug (each at a different timepoint in the study). Although all subjects will receive both placebo and the drug, the order of presentation of the placebo and drug is counterbalanced across subjects (i.e., approximately half will receive the drug first and approximately half will receive the placebo first).~For both study arms, regardless of whether the placebo is received first or second, the outcome measure will be calculated as the number of high effort selections."|t|f|t|f
34143191|NCT03378089|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143192|NCT05744726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143193|NCT04363593|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143194|NCT00623662|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143195|NCT02217371|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34143196|NCT05466500|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization will be done by computer generated numbers and concealed by serially numbered,opaque and sealed envelopes. The details of the series will be unknown to the investigators and the group assignment will be kept in asset of sealed envelopes each bearing only the case number on the outside. Prior to surgery the appropriate numbered envelopes will be opened by the nurse, the card inside will determine the patient group||t|t|t|t
33832995|NCT00988533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33832996|NCT04622098|||COHORT||PROSPECTIVE|||||||
33832997|NCT04329546|||COHORT||PROSPECTIVE|||||||
33832998|NCT05194163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Subjects will be randomized through a computerized system by a Data/Statistics Group independent from the investigator or Sponsor|double-blind randomized placebo-controlled|t|t|t|t
33832999|NCT05837299|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation of 3 dosage groups||||
33833000|NCT03703726|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34143197|NCT04963140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143198|NCT02436408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143199|NCT02526082|||COHORT||PROSPECTIVE|||||||
34143200|NCT00002427||FACTORIAL||TREATMENT||||||||
34150874|NCT03925688|||CASE_CONTROL||RETROSPECTIVE|||||||
34150875|NCT01818492|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143201|NCT01094353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The participants were randomly allocated to a single-incision mini-sling or a transobturator midurethral tape by a simple randomization procedure using a random number generator computer program. Randomization was performed at the moment of inclusion by a nurse blinded to women's histories. Group assign- ment was concealed in consecutively numbered, sealed, opaque envelopes that were opened in the operating room just before the procedure.|Clinical, prospective, single-center, randomized controlled trial comparing the efficacy and safety of a single-incision mini-sling and a transobturator midurethral sling for female stress urinary incontinence (SUI) treatment.|t|f|t|t
34143202|NCT02822131|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34143203|NCT05774184|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143204|NCT05981079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143205|NCT00642148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143206|NCT04205851|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Randomized, double-blind (Sponsor unblind), multi-cohort, placebo-controlled design.|t|t|t|t
34143207|NCT02209948|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143208|NCT02635347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143209|NCT04536948|RANDOMIZED|PARALLEL||TREATMENT||NONE||Fifty-four volunteers diagnosed with lateral epicondylitis were included in our study and were randomly divided into two groups.||||
34143210|NCT03622671|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The patient will be blinded to LIMA harvesting technique. The laboratory technicians will be blinded to LIMA harvesting technique.|Randomized clinical trial with parallel group design. Equal allocation.|t|f|f|t
34143211|NCT01945645|NA|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
34143212|NCT06108648|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients are randomized to receive standard care with additional lavender essential oil chest wrap during two nights of hospitalization or standard care alone.||||
34143213|NCT05519462|||CASE_ONLY||RETROSPECTIVE|||||||
34143214|NCT02572232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143215|NCT01068951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143216|NCT01511328|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34143217|NCT03641846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34143218|NCT04290468|||COHORT||PROSPECTIVE|||||||
34143219|NCT01317186|||COHORT|||||||||
34143220|NCT01503606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143221|NCT04736953|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143222|NCT00592540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143223|NCT02978105|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143224|NCT00384423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143225|NCT00300482|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143226|NCT02794987|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143227|NCT05516784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143228|NCT00904618|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143229|NCT03332719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143230|NCT02929901|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143231|NCT02119039|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34143232|NCT03694743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double (Participant, Outcomes Assessor)||t|f|f|f
34143233|NCT06103318|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|To implement masking in the outcome assessor, the study will use an external service, the Biostatistical Services of The Bellvitge Biomedical Research Institute (IDIBELL). This external service will collect information through online questionnaires using REDCap, a secure web platform. Using an external service will help maintain the integrity of the study and prevents potential biases. Blinding in this context ensures that the assessment of outcomes is conducted impartially and without any influence from knowledge about the treatment assignments.|The study proposes a superiority RCT with two parallel groups (online psychosocial care vs. online integrated and stepped cognitive intervention) with 1:1 allocation. The study design will contain 2 (treatment conditions) × 3 (follow-up assessments) factors.|f|f|f|t
34143234|NCT04175457|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34143235|NCT01540448|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143236|NCT02501720|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143237|NCT02719119|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143238|NCT06399913|||COHORT||RETROSPECTIVE|||||||
34143239|NCT03168243|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a prospective, single arm, longitudinal, interventional, multi-centre study.||||
34143240|NCT05097508|RANDOMIZED|PARALLEL||SCREENING||NONE||"* Group A: Patients will receive Atracurium.~* Group R: Patients will receive rocuronium."||||
34143241|NCT00908648|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143242|NCT05036382|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143243|NCT04720716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143244|NCT00201591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143245|NCT02653495|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34143246|NCT02963987|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33833001|NCT03713320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833002|NCT01671306|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143247|NCT02851407|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143248|NCT04218357|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34143249|NCT05753566|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143250|NCT02867618|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833003|NCT05282836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833004|NCT04044703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833005|NCT04692298|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34143251|NCT00171925|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143252|NCT06366542|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143253|NCT04072367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143254|NCT05869422|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143255|NCT01255007|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143256|NCT06027333|||COHORT||PROSPECTIVE|||||||
34150876|NCT04452773|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33837620|NCT00150878|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143257|NCT02518594|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Participants and care providers will be blinded to active study drug vs. placebo.|Women will be randomly assigned to study drug (200 mg micronized progesterone daily), placebo study drug appearing identical to progesterone capsule, or Arabin pessary.|t|t|t|t
34143258|NCT00212186|RANDOMIZED|PARALLEL||||DOUBLE||||||
34143259|NCT03589365|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143260|NCT03294096|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34143261|NCT05122923|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143262|NCT01371240|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|f|t
34143263|NCT05761678|||COHORT||PROSPECTIVE|||||||
34143264|NCT00977938|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143265|NCT05908409|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143266|NCT04023357|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143267|NCT04102553|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34143268|NCT05446792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The randomization of the sample will be confidential. A professional in the field who is unaware of the study and the participants will perform the draw through random numbers that will distribute the participants into two groups: Pelvic Floor Muscle Training Group (TMAP) (n= 20) and Pilates Exercise Group (PE) (n= 20). This same professional will deliver the answers in opaque envelopes, which will be sealed and contain the answer. Participants will be duly informed that they can be allocated to either of the two groups at the time of recruitment and selection and, in addition, the participants and the responsible researchers will know in which group each woman will participate at the time of delivery of the envelopes.~The evaluations will be carried out before and after three months of interventions, by the same professionals, experienced in these evaluations, who will be blind to the participants."|"The interventions will last for twelve weeks, three times a week, for one hour, on non days consecutive.~The Pilates exercises group will perform stretching and strengthening exercises in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups.~The Pelvic floor muscle training group will consist of 10 maximal voluntary contractions that must be maintained for at least 6 seconds (participants will be encouraged to sustain the maximal contraction for a longer time each week). The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: 1st lying in lateral decubitus, 2nd sitting, 3rd on all fours and 4th standing."|f|f|t|t
34143269|NCT01605318|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143270|NCT00276094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143271|NCT04931290|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143272|NCT06008769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143273|NCT06350487|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Clinical outcome assessment will be performed under blinded assessment about the allocated treatment group.|A prospective, open label, single center, randomized controlled trial.|f|f|f|t
34143274|NCT01826955|||CASE_CONTROL||PROSPECTIVE|||||||
34143275|NCT00058526|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143276|NCT02703870|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143277|NCT04508465|||COHORT||PROSPECTIVE|||||||
34143278|NCT01443637|||COHORT||PROSPECTIVE|||||||
34143279|NCT00188851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143280|NCT02109523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34143281|NCT05958823|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Results evaluators and surgeons will be unaware of group assignments.|randomized, controlled, prospective|t|t|f|f
34143282|NCT01911312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143283|NCT02980744|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34143284|NCT00070252|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143285|NCT03283098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a multiple dose, double-blind, randomized, placebo-controlled clinical study conducted in Chinese subjects residing in Mainland China with chronic kidney disease receiving hemodialysis. The treatment duration will be approximately 4 weeks with a post treatment followup of 4 weeks. A dose will be given at each scheduled hemodialysis session (Dose administered three times a week for 4 weeks, for a total of 12 doses).|t|t|t|f
34143286|NCT00976885|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143287|NCT02489331|||CASE_ONLY||PROSPECTIVE|||||||
34143288|NCT03783741|||COHORT||PROSPECTIVE|||||||
34143289|NCT03252093|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143290|NCT00374894|||DEFINED_POPULATION||PROSPECTIVE|||||||
34143291|NCT01309906|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
34143292|NCT02228343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143293|NCT01065948|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143294|NCT01095653|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143295|NCT04688541|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34143296|NCT02093988|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833006|NCT04695886|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Stepped-wedge cluster randomized control trial (one-way crossover)||||
34143297|NCT02549352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143298|NCT04022681|||COHORT||RETROSPECTIVE|||||||
34143299|NCT06180330|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143300|NCT04829305|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Three different cohorts can enroll healthy Caucasian participants; males and females in each cohort separately.||||
34143301|NCT05111106|||COHORT||RETROSPECTIVE|||||||
34150877|NCT00003842||||TREATMENT||||||||
34150878|NCT02491424|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150879|NCT03233126|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150880|NCT02785614|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33833007|NCT02335645|||CASE_CONTROL||PROSPECTIVE|||||||
33833008|NCT02931578|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33833009|NCT05376345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833010|NCT01007006|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33833011|NCT00246935|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833012|NCT01179503|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143302|NCT06200922|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The evaluations will be performed by a different researcher.|Participants will be divided into three groups: Synchronous Group: will receive guidance and perform a real-time guided pelvic physiotherapy protocol through online physiotherapy by the physiotherapist, Asynchronous Group: will receive guidance and perform a pelvic physiotherapy protocol after the evaluation, without the real-time monitoring by the physical therapist and face-to-face group: will receive guidelines and will perform a pelvic physiotherapy protocol oriented in person by the physical therapist. All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.|f|f|f|t
34143303|NCT03661736|||COHORT||PROSPECTIVE|||||||
34143304|NCT03958591|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143305|NCT05785260|||OTHER||PROSPECTIVE|||||||
34143306|NCT06052111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143307|NCT04159272|RANDOMIZED|PARALLEL||PREVENTION||NONE||The intervention (MT) group receives a Mindfulness Training (MT) for 8 weeks in school, during regular school hours. The participants in the control group answer the questionnaires and complete the experience sampling assessments at the same timepoints as the intervention group, and follow the regular school curriculum.||||
34143308|NCT04983836|RANDOMIZED|PARALLEL||OTHER||DOUBLE||Prospective, comparative, monocentric, randomized non-inferiority interventional study, in double-blind.|t|f|f|t
34143309|NCT01465750|||CASE_ONLY||RETROSPECTIVE|||||||
34143310|NCT02282371|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143311|NCT00051467|RANDOMIZED|||TREATMENT||NONE||||||
34143312|NCT00168077|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143313|NCT02295007|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34143314|NCT04926090|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833013|NCT05573581|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||randomized controlled trial|f|t|f|t
33833014|NCT05205564|||COHORT||CROSS_SECTIONAL|||||||
33833015|NCT00468507|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33833016|NCT04885348|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33833017|NCT04067349|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||non-randomized cohort study, 2 parallel groups|f|f|f|t
33833018|NCT05663528|||COHORT||RETROSPECTIVE|||||||
33833019|NCT06030960|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33833020|NCT04513743|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833021|NCT02314104|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833022|NCT03124147|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833023|NCT02999243|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33833024|NCT04584892|||COHORT||PROSPECTIVE|||||||
33833025|NCT01774305|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833026|NCT04912713|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|The participant does not know what the other participants are doing, the researcher knows which study and group the subject is in, but only sets up the computerized presentations for each group and assigns folders within the computer that collects the data, thus avoiding a possible information bias, and finally, another researcher blind to the intervention will analyse the data to obtain the results.|As participants complete the State-Trait Anxiety Inventory, and are found to be free of trait anxiety, and state anxiety, they will be randomised in parallel to one of the two intervention groups.|t|f|f|t
33833027|NCT01390350|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833028|NCT03557606|||CASE_ONLY||PROSPECTIVE|||||||
33833029|NCT00830609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833030|NCT01363310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833031|NCT04355936|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to receive standard care or standard care plus Telmisartan 80 mg twice daily upon diagnosis of COVID-19.||||
33833032|NCT05928949|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33833033|NCT02906280|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33833034|NCT01233661|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||f|t|t|f
33833035|NCT00288223|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833036|NCT00034853||PARALLEL||TREATMENT||||||||
33833037|NCT00263497|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33833038|NCT02895360|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33833039|NCT02599688|||COHORT||PROSPECTIVE|||||||
34143315|NCT00645879|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833040|NCT06546059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833041|NCT05557071|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833042|NCT01076998|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33833043|NCT04528823|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833044|NCT02720211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833045|NCT01613963|||COHORT||RETROSPECTIVE|||||||
33833046|NCT02781311|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833047|NCT04199468|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33833048|NCT04310332|||CASE_CONTROL||PROSPECTIVE|||||||
33833049|NCT01509443|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833050|NCT01694888|NA|SINGLE_GROUP||||NONE||||||
34143316|NCT00481325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833051|NCT02778464|||COHORT||PROSPECTIVE|||||||
33833052|NCT00002668|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833053|NCT04911478|||CASE_ONLY||PROSPECTIVE|||||||
33833054|NCT00016445||||TREATMENT||||||||
33833055|NCT03017547|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33833056|NCT04410939|||CASE_CROSSOVER||RETROSPECTIVE|||||||
33833057|NCT00632021|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
33833058|NCT02156310|||||RETROSPECTIVE|||||||
33833059|NCT05383105|||COHORT||PROSPECTIVE|||||||
34143317|NCT02156817|||COHORT||PROSPECTIVE|||||||
34143318|NCT04583202|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34143319|NCT00393302|||COHORT||OTHER|||||||
33833060|NCT04486976|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33833061|NCT04447157|||CASE_ONLY||RETROSPECTIVE|||||||
33833062|NCT01195207|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34143320|NCT05403892|||COHORT||CROSS_SECTIONAL|||||||
34143321|NCT01342965|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143322|NCT03884192|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143323|NCT04316741|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34143324|NCT03504813|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143325|NCT02796872|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34143326|NCT02306304|NA|SINGLE_GROUP||SCREENING||NONE||||||
34143327|NCT05393414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143328|NCT01810848|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34143329|NCT05173428|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In a randomized controlled study, blinding will be done in terms of statistician and reporting. Research data will be encoded and transferred to the computer without specifying the intervention and control group (for example; A group and B group). The analysis of these data coded in terms of groups will be done by a statistician. After the statistical analysis is done and the research report is written, the researcher will explain the coding for the intervention and control group. In this way, detection bias, statistical bias and reporting bias will be controlled.||f|f|f|t
34143330|NCT01945736|||COHORT||PROSPECTIVE|||||||
34143331|NCT01663428|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143332|NCT00006799|RANDOMIZED|||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34143333|NCT01294462|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143334|NCT01697462|||COHORT||PROSPECTIVE|||||||
34143335|NCT01346111|||COHORT||PROSPECTIVE|||||||
34143336|NCT02729610|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34143337|NCT05732584|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34143338|NCT03720665|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|A statistician prepares a randomization list. Only pharmacist knows the medication type (caffeine or placebo) and the type of electrical stimulation. An investigator is blinded to the type of electrical stimulation and medication. In addition, all participants are naive to electrical stimulation and does not know type of medications that they receive|15 participants are assigned to caffeine group and another 15 are assigned to placebo group. Then, the participants who were initially in the caffeine group now be in placebo group and those who were in the placebo group were assigned to caffeine group. Finally, all participants received both placebo and caffeine|t|f|t|f
34143339|NCT05630222|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143340|NCT04615260|NA|SINGLE_GROUP||TREATMENT||NONE||Study is a prospective, non-randomized, single center clinical investigation. Each subject will serve as their own control during this study, as patients will receive the Nanobone graft on the right side of their spine and the local bone graft on their left side.||||
34143341|NCT02744612|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143342|NCT04962607|||CASE_CONTROL||PROSPECTIVE|||||||
34143343|NCT00858598|||COHORT||PROSPECTIVE|||||||
34143344|NCT02265419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143345|NCT06024837|||COHORT||PROSPECTIVE|||||||
34143346|NCT02174523|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34143347|NCT06213142|NA|SINGLE_GROUP||TREATMENT||NONE||Participants in the acceptability test will be assigned to the same set of study tasks, where all participants will engage with the two modules and provide feedback. All participants will complete the RCADS pre and post, in addition to all study-related surveys: demographics, pre- and post-knowledge checks, module component ratings, prototype evaluations, and advocacy ratings. All participants will be invited to the follow-up focus group sessions.||||
34143348|NCT01649544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143349|NCT02654392|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34143350|NCT05023616|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143351|NCT00195520|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143352|NCT04253990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143353|NCT02288962|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143354|NCT02761148|||COHORT||PROSPECTIVE|||||||
34143355|NCT00795041|||CASE_ONLY||PROSPECTIVE|||||||
34143356|NCT04920591|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143357|NCT04202510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143358|NCT01997814|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143359|NCT01716338|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143360|NCT05209308|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This open label study is composed of 2 cohorts:~A safety run-in Cohort A followed by Cohort B.~Both cohorts will follow the same dosing schedule and subjects will receive Zandelisib, however in Cohort A, VEN will be administered at a different dose then Cohort B."||||
34143361|NCT02187523|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143362|NCT05445908|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143363|NCT00000357||||TREATMENT||||||||
34143364|NCT04377802|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34143365|NCT00854165|||CASE_CONTROL||RETROSPECTIVE|||||||
34143366|NCT02110888|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143367|NCT00048815|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143368|NCT06607081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143369|NCT00569309|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143370|NCT05280327|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143371|NCT01778374|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34143372|NCT03302117|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143373|NCT00160199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143374|NCT00872378|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143375|NCT02390674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143376|NCT04507451|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|patients are masked: they will all benefit from respiratory physiotherapy, with placebo or real muscle training investigator and care providers are unmasked, as they set the training parameters||t|f|f|f
34143377|NCT01963013|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143378|NCT01453738|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143379|NCT05462977|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will be invited to participate in a music-based group exercise program for 20 weeks (30 - 40 min/day, up to 6 days/week).||||
34143380|NCT06285747|||COHORT||CROSS_SECTIONAL|||||||
34143381|NCT02510651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143382|NCT03885505|||OTHER||RETROSPECTIVE|||||||
34143383|NCT03197974|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Outcomes Assessors will be blinded as to treatment allocation. To maintain blinding, the Assessor will not be involved in intervention delivery and participants will be instructed not to discuss treatment with their interviewer. When an interview leads to unblinding, the assessor will be replaced.~Participants will be blinded as to the primary hypothesis of which website will have superior benefits for QoL, but will of course be aware of the intervention they receive."|It is a prospective, parallel group, rater-blind, superiority RCT with a 1:1 allocation ratio comparing two websites designed to improve QoL in late stage bipolar disorder. Follow-up time points are immediate post-treatment (primary outcome timepoint), 3-month and 6-month follow-ups. To minimise the risk of bias, we are not publicising which arm is expected to be superior in terms of the primary outcome. Note that we expect that both arms will lead to QoL benefits, and the statistical analysis plan is agnostic about the superiority of the experimental intervention over active control on a number of secondary outcome variables. In both arms, usual management will continue throughout, with medication and psychosocial intervention changes monitored at follow-up interviews. The study setting is online, and participation in both arms will be through a secure server at Swinburne University's National eTherapy Centre (NetC).|t|f|f|t
34143384|NCT04859244|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143385|NCT04091984|||CASE_CONTROL||OTHER|||||||
34143386|NCT02445937|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||Stepped Wedge Design|f|f|f|t
34143387|NCT05264441|NA|SINGLE_GROUP||TREATMENT||NONE||Cross sectional||||
34143388|NCT03153072|NA|SINGLE_GROUP||OTHER||NONE||||||
34143389|NCT03009838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143390|NCT04841759|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Stratification regarding post-COVID-19 fatigue syndrome at baseline yes/no|t|f|f|f
34143391|NCT03780478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|After giving consent to participate in study, patients enrolled in study will be randomly assigned to either the experimental vs. normal standard of care. Patients and members of care team will be unaware as to which group they are assigned.|"rhinoplasty/septoplasty patients will be identified by Dr. Kochhar (PI). Patients' informed consent for participation in this study will be obtained and they will subsequently be enrolled. Participants will be randomized into two arms: experimental vs. placebo.~Study arms:~1. Experimental: SPG block with local anesthetic per normal methods of nerve block.~2. Placebo: Injection of saline"|t|f|f|f
34143392|NCT01247532|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143393|NCT02750384|RANDOMIZED|PARALLEL||||NONE||||||
34143394|NCT05654688|RANDOMIZED|PARALLEL||OTHER||SINGLE||.Design: A randomized controlled experimental pre-post measurement. This study included forty two (30 males and 12 females) patients with NSNP aged between the ages of 40 and 60. Each participant was assigned a unique number, and then those numbers were randomly divided into three groups. Three groups were formed from a random selection of participants: GT Group (A): received 12 sessions of GT and (TPT) over the course of four weeks (three sessions per week). MET Group (B): received 12 sessions of MET treatment and (TPT) over a period of four weeks (three sessions per week). Control Group (C): received 12 sessions of traditional physiotherapy (TPT) over a period of four weeks (three sessions per week).|t|f|f|f
34143395|NCT00682136|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33833063|NCT05317507|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|The experimental portion of the study is double blind.|During the Experimental portion of the study, participants will be randomized to a dosing order of 3 different doses. During the at-home portion of the study all participants will receive the same dose for 4 weeks.|t|t|t|t
34143396|NCT02356094|||CASE_CONTROL||RETROSPECTIVE|||||||
34143397|NCT03103672|||CASE_CONTROL||PROSPECTIVE|||||||
34143398|NCT01889134|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34143399|NCT01766349|||COHORT||PROSPECTIVE|||||||
34143400|NCT04994873|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The baseline assessment will occur prior to randomization and follow-up assessors will be blind to participant condition|2 condition randomized clinical trial|f|f|f|t
34143401|NCT01895933|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143402|NCT02740543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143403|NCT00236418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143404|NCT02193087|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34143405|NCT04015583|RANDOMIZED|PARALLEL||PREVENTION||NONE||exergaming group and treadmill exercise group||||
34143406|NCT02249494|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143407|NCT05569538|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143408|NCT04671082|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833064|NCT04683341|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm, CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm, CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.||||
33833065|NCT01649557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833066|NCT06155110|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833067|NCT01190644|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33833068|NCT04264975|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open label, single-center, non-randomized clinical trial on utilization of microbiome as biomarkers and therapeutics in immuno-oncology.~This research consists of two parts:~part 1: development of microbiome biomarkers for immuno-oncology part 2: proof-of-concept trial on the fecal microbiota transplantation in patients who are being treated with immunotherapy for advanced solid tumor"||||
34143409|NCT02085525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34143410|NCT02418312|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143411|NCT02385916|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34143412|NCT02362126|||COHORT||PROSPECTIVE|||||||
34143413|NCT03032653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143414|NCT05944562|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143415|NCT04382625|RANDOMIZED|PARALLEL||TREATMENT||NONE||Single-center pragmatic randomized open-label trial of hydroxychloroquine + usual care in hospitalized adults with confirmed SARS-CoV-2 infection and acute hypoxia compared to usual care.||||
34143416|NCT01920893|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143417|NCT04819230|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Participants in the control condition will see the same stimuli with a different contingency for correct vs incorrect response on the computerized training task (participant masking)~Outcome assessors will not be involved in administration of the intervention and will not be informed of participant condition (outcomes assessor masking)"||t|f|f|t
34143418|NCT02133664|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143419|NCT04909502|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label design|The study will initially be conducted with 2 treatment arms starting in parallel. Patients will initially receive a 25 mg OD or a 25 mg BID dose. After 28 days, each patient will increase to a 50 mg OD or 50mg BID dose level, respectively, if deemed to be safe by the investigator.||||
34143420|NCT01628614|||CASE_ONLY||PROSPECTIVE|||||||
34143421|NCT02726880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143422|NCT05562362|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143423|NCT01887119|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34143424|NCT03250039|NON_RANDOMIZED|CROSSOVER||OTHER||NONE||This study will be an open label, non randomized, 2 period, fixed sequence, single dose study to characterize the absorption, metabolism and excretion of 14C- PF-04965842 and to evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of PF-04965842 following oral administration of unlabeled PF-04965842 and IV and oral administration of 14C-PF-04965842 to healthy male subjects.||||
34143425|NCT05825924|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants who are eligible and consent to take part will be randomized (1:1 ratio) to receive products accordingly: A total of 258 participants will be enrolled (129 in each arm) and randomized to Study Arm A: 18 mg nicotine e-cigarettes (ad libitum use) for 12 weeks after the nominated quit date; and Study Arm B: 21 mg nicotine patches (one daily) for 12 weeks after the nominated quit date. The duration of counseling will be at least 30 minutes at site. The duration of counseling through telephone will be at least 10 minutes. Participants will be scheduled for a screening visit and a baseline (BL) visit at the trial site. The participants will be scheduled for eight study visits in total, including five treatment sessions and three follow-up visits, using both face to face interaction at trial site as well as follow up on telephone. Eight study visits are planned at weeks 1, 2, 4, 8, 12, 18, 24, and 52.||||
34143426|NCT03854292|||COHORT||PROSPECTIVE|||||||
34143427|NCT01053559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143428|NCT04963530|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"This prospective study will include a sample n of 75 patients. Patients will be treated with single-tooth restorations with partial or complete veneering on the tooth. Depending on the material used to fabricate the restoration, 4 different groups will be differentiated: monolithic zirconia (group 1), metal-ceramic (group 2), lithium disilicate (group 3) and natural tooth (control group).~The sample will be randomised into one of the different groups using the online randomisation software www.alazarinfo.es. All patients will be pseudonymised, assigning each patient a number from 1 to 75 according to the chronology of incorporation into the study."||||
34143429|NCT05801055|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34143430|NCT05433740|RANDOMIZED|PARALLEL||OTHER||SINGLE|undergoing urologic surgery using LMA with ASA Physical Status I-III, Mallampati score I-II, and \>18 years of age|Group I: Adjustable ligament or Group II, adhesive tape|t|f|f|f
34143431|NCT03521713|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only investigators will be blinded||f|f|t|f
34143432|NCT05058105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143433|NCT00167180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143434|NCT02885870|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143435|NCT03455829|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143436|NCT03790774|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143437|NCT06384326|||OTHER||CROSS_SECTIONAL|||||||
34143438|NCT04149860|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34143439|NCT03000491|||OTHER||RETROSPECTIVE|||||||
34143440|NCT00767234|||COHORT||PROSPECTIVE|||||||
34143441|NCT00040807||||TREATMENT||||||||
34143442|NCT02581462|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143443|NCT02739321|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34143444|NCT02441140|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143445|NCT00545220|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143446|NCT04695002|||COHORT||PROSPECTIVE|||||||
34143447|NCT01902888|||COHORT||RETROSPECTIVE|||||||
34143448|NCT05214391|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143449|NCT03285087|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|The primary end point will be the occurrence of at least 1 episode of clinically significant hemodynamic instability during dexmedetomidine therapy defined as systolic blood pressure (SBP) \< 80 mm Hg, diastolic blood pressure (DBP) \<50 mm Hg, or heart rate \<50 beats per minute (bpm) To qualify as an event, the hemodynamic variable had to remain below the specified threshold for at least 2 consecutive readings (≥30 minutes of recorded hemodynamic instability). The cumulative incidence of hemodynamic instability events during dexmedetomidine sedation will be plotted and Cox proportional hazards models will be constructed to determine hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk factors of hemodynamic instability during dexmedetomidine therapy.||||
34143450|NCT03504241|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143451|NCT01869413|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143452|NCT06023628|||COHORT||PROSPECTIVE|||||||
34143453|NCT03035253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143454|NCT00704561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143455|NCT00418275|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143456|NCT02864173|||COHORT||RETROSPECTIVE|||||||
33837621|NCT03812042|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33837622|NCT02613624|||||PROSPECTIVE|||||||
34143457|NCT05516030|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34143458|NCT04969965|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143459|NCT02798770|||COHORT||PROSPECTIVE|||||||
34143460|NCT00074373|||COHORT||PROSPECTIVE|||||||
34143461|NCT01639287|||||RETROSPECTIVE|||||||
34143462|NCT03624426|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The patient and the outcome assessor will be blinded. The physicians and operating room nurses, anesthesiologists could not be blinded due to the nature of the intervention|1:1 parallel, superiority study|t|f|f|t
34143463|NCT04677426|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143464|NCT06068998|||COHORT||RETROSPECTIVE|||||||
34143465|NCT06245239|||OTHER||PROSPECTIVE|||||||
34143466|NCT03861572|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Raters will be blinded to the participants' allocation in each group.||f|f|t|t
34143467|NCT00847665|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143468|NCT01113905|||CASE_CONTROL||PROSPECTIVE|||||||
34143469|NCT03291262|||COHORT||PROSPECTIVE|||||||
34143470|NCT03846531|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|A Reference Key was developed for 3 independent reviewers to use during their review of the full set (196 image pairs) of study photographs. The reference key included 2 representative photographs for each of the 4 possible scores used in the SK study (clear, mostly clear, partially clear, and not clear). The three independent reviewers were not principal investigators at enrolling centers.|Each subject served as their own control. Each subject had 4 lesions with 3 of the lesions serving in the Active Comparative Arm (Lesions treated with Nano-Pulse Stimulation) and 1 lesion serving as control not treated with Nano-Pulse Stimulation and assigned to No Intervention Arm.|f|f|f|t
34143471|NCT01971216|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34143472|NCT01206283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143473|NCT03112967|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34143474|NCT03481712|||COHORT||PROSPECTIVE|||||||
34143475|NCT04942665|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|To mask the investigator randomization will be done with envelopes for this study and the dose given to the patient prior to surgery with the investigator not being aware of the amount given.|Adult patients scheduled to undergo a laparoscopic hepatic or biliary operation will be randomized to two groups 1) low dose (0.05 mg) or 2) standard dose (2.5 mg) of ICG preoperatively on the day of surgery. Patients with a history of adverse reactions or known allergy to ICG, iodine, or iodine dyes will be excluded.|t|f|t|f
34143476|NCT03060395|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34143477|NCT03410797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143478|NCT00496197|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143479|NCT03067493|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143480|NCT04902404|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34143481|NCT06416176|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143482|NCT05250050|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The technicians, who performed culture, antimicrobial susceptibility testing or urea breath test were blinded to treatment allocation.||f|f|f|t
34143483|NCT04716075|NA|SINGLE_GROUP||TREATMENT||NONE||Multicentre, national||||
34143484|NCT04007289|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|double blind|This study will be a prospective, national multicentric, phase III, superiority comparative randomized (1:1) double-blinded clinical trial with two parallel arms: apixaban versus placebo.|t|f|f|f
34143485|NCT02862951|||COHORT||PROSPECTIVE|||||||
34143486|NCT04447599|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143487|NCT05544942|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34143488|NCT06363318|RANDOMIZED|PARALLEL||TREATMENT||NONE||children were randomly divided in two groups. In group A, laparoscopic appendectomy was done. In group B, open appendectomy was done||||
34143489|NCT01488292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143490|NCT04298866|NA|SINGLE_GROUP||OTHER||NONE||||||
34143491|NCT00262678|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34143492|NCT05662904|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143493|NCT00600691|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34143494|NCT03671707|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143495|NCT03186391|||COHORT||PROSPECTIVE|||||||
34143496|NCT02798991|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143497|NCT00823745|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143498|NCT00695799|||COHORT||PROSPECTIVE|||||||
34143499|NCT01603797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143500|NCT01361074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34143501|NCT03351114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143502|NCT01471418|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
34143503|NCT03738059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143504|NCT00361699|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143505|NCT01747200|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||||||||
34143506|NCT02537262|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34143507|NCT03546504|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pre-post-follow-up||||
34143508|NCT00839462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143509|NCT03132103|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34143510|NCT05920044|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143511|NCT00106691|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34150881|NCT06368908|RANDOMIZED|PARALLEL||TREATMENT||NONE||One of legs is randomised to be stimulated by trans-cutaneous functional magnetic stimulation (Arm 1), the other leg is control (Arm 2)||||
34150882|NCT02613169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833069|NCT03639727|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||This study compares citric acid and mannitol bronchial challenges in their ability to separate chronic cough subjects from healthy subjects. There are no therapeutic interventions.||||
33833070|NCT04415645|NA|SINGLE_GROUP||OTHER||NONE||||||
33833071|NCT05846438|RANDOMIZED|PARALLEL||OTHER||NONE|The study is unblinded.|The investigators have two groups of patients. Group one will be allowed to shower 48 hours after surgery. Group two will not be allowed to shower until the drains are removed.||||
33833072|NCT01774136|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34150883|NCT02790021|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34150884|NCT03860467|||COHORT||RETROSPECTIVE|||||||
34150885|NCT03668405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143512|NCT03838016|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Team members who conduct assessments or analyze data do not have access to a child's group assignment.|The investigators created an intervention program, Babble Boot Camp (BBC), designed to support communication skills during the prespeech and early speech and language stages. One cohort with classic galactosemia (CG) enters this treatment at age 2-5 months and is monitored closely using audio and video recordings and questionnaires. A second cohort with CG enters close monitoring at age 2-5 months but starts treatment at age 15 months. A typical cohort enters close monitoring at age 2-5 months. Treatment and close monitoring ends at age 24 months. Follow-up testing of speech and language skills and questionnaire data about child development and parent well-being is collected once a year at ages 2 ½, 3 ½, and 4 ½ years. A cohort with CG, age 6 months to 4 ½ years, too old for any treatment and close monitoring, provides the same data as the other cohorts at ages 2 ½, 3 ½, and 4 ½ years. Results will show whether the BBC is effective and, if yes, which start age is best.|f|f|f|t
34143513|NCT01735708|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143514|NCT00212199|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143515|NCT04364607|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143516|NCT03505489|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34143517|NCT00597831|||COHORT||PROSPECTIVE|||||||
34143518|NCT02419131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143519|NCT06395402|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
34143520|NCT02668861|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34143521|NCT03943550|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
34143522|NCT02615405|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143523|NCT04906967|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143524|NCT05138068|RANDOMIZED|PARALLEL||TREATMENT||NONE|Primary outcome measures will be administered by blinded, independent raters.|This is a randomized, open-label delayed treatment study to assess the safety and effect of MDMA-assisted therapy in treating 20 participants diagnosed with moderate-to-severe social anxiety disorder (SAD) of the generalized subtype.||||
34143525|NCT02466074|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Two phase design: phase 1, patients randomized to ACZ or placebo and followed for 24 weeks; phase 2, patients that received placebo in phase 1 switch to ACZ (delayed-start group) and patients that received ACZ in phase 1 continue on ACZ (ACZ-ACZ group)|t|f|t|t
34143526|NCT01724567|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34143527|NCT05425654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143528|NCT00387738|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34143529|NCT01229943|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143530|NCT05388773|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143531|NCT00763906|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143532|NCT00041171|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143533|NCT00554398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143534|NCT01468610|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143535|NCT05985876|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: text messages, a knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.||||
34143536|NCT00681980|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143537|NCT04079062|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143538|NCT02896036|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34143539|NCT05081063|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Adult male patients brought to the emergency department as Level A trauma activations who are receiving emergency blood transfusion|t|f|f|f
34143540|NCT00197145|RANDOMIZED|PARALLEL||TREATMENT||||||||
34143541|NCT02696499|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143542|NCT05798481|NA|SINGLE_GROUP||PREVENTION||NONE||The optimum levels of 2.5 mg and 5mg mg sodium nitrite and fixed amount of 50 mg N-acetylcysteine are used for this study. Total of 14 subjects are divided to two groups.Group 1 is tested with the low dose of 2.5 mg sodium nitrite. If no adverse effects are noticed in this group, the study is proceed for 2nd group with 5mg sodium nitrite.||||
34143543|NCT02192762|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34143544|NCT00943475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143545|NCT03089879|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143546|NCT05026892|||COHORT||RETROSPECTIVE|||||||
34143547|NCT01986387|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34143548|NCT04928573|||COHORT||RETROSPECTIVE|||||||
34143549|NCT03812926|||COHORT||PROSPECTIVE|||||||
34143550|NCT01620151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143551|NCT03970174|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Care Connector care transition module will be rolled out at 2 of 4 wards (intervention) while the other 2 wards will have usual care||||
34143552|NCT03000543|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143553|NCT03141567|||OTHER||OTHER|||||||
34143554|NCT04477629|NA|SINGLE_GROUP||PREVENTION||NONE||Study population includes first-time Epstein-Barr virus (EBV) seropositive, male and non-pregnant female heart transplant recipients 18 years of age or older, who are able to provide written informed consent for the study.||||
34143555|NCT03148145|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143556|NCT01050374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143557|NCT03058666|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143558|NCT04525261|||CASE_ONLY||RETROSPECTIVE|||||||
34143559|NCT06072716|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||1:1 parallel arms|t|f|t|t
33833073|NCT02250690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143560|NCT00084019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143561|NCT03825250|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Unblinded two phased randomised controlled trial~* Discovery phase: 4 groups (1 control, 3 treatment)~* Efficiency phase: 2 groups (1 control, 1 treatment)"||||
34143562|NCT03024138|||COHORT||PROSPECTIVE|||||||
34143563|NCT03929289|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143564|NCT00953524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143565|NCT03143673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143566|NCT02821377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143567|NCT03213574|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34143568|NCT06081413|||COHORT||RETROSPECTIVE|||||||
34143569|NCT05060380|RANDOMIZED|PARALLEL||OTHER||SINGLE|Outcomes assessor will be blinded to the group assignment.|Individuals will be randomly assigned to exercise or no exercise group.|f|f|f|t
34143570|NCT06606639|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Statistician||t|f|t|f
34143571|NCT00394602|||CASE_CONTROL||PROSPECTIVE|||||||
34143572|NCT00633789|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34143573|NCT04021173|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143574|NCT01449773|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34143575|NCT04835376|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|The cups will be numbered, not identified by manufactured cup or 3D printed.|Randomized crossover intervention|t|f|f|f
34143576|NCT04268433|||COHORT||CROSS_SECTIONAL|||||||
34143577|NCT00898924|||COHORT||PROSPECTIVE|||||||
34143578|NCT01871155|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34143579|NCT05278702|||OTHER||CROSS_SECTIONAL|||||||
34143580|NCT01357824|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143581|NCT00047619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143582|NCT00918268|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34143583|NCT00202813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34143584|NCT02608580|NA|SINGLE_GROUP||OTHER||NONE||||||
34143585|NCT03497091|||COHORT||RETROSPECTIVE|||||||
34143586|NCT00716378|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34143587|NCT04034147|||COHORT||CROSS_SECTIONAL|||||||
34143588|NCT01045603|||COHORT||PROSPECTIVE|||||||
34143589|NCT02181478|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143590|NCT05594069|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143591|NCT01376479|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34143592|NCT05768204|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143593|NCT01545232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143594|NCT01479595|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143595|NCT05675267|||COHORT||PROSPECTIVE|||||||
34143596|NCT04262713|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34143597|NCT05945771|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34143598|NCT05118984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Patients will be randomized to the 2 study groups according to a 2-block randomization list coded I or II at a 1:1 ratio. The randomization list will be prepared using a computer- generated random table by a statistician not otherwise involved in the study. The allocated groups will be masked in serially numbered sealed opaque envelopes that will be opened only after enrollment. Women who will be recruited give consent and open randomization envelopes in early labor, also the women will be recruited before revealing the allocation, the allocation will be blind to both the recruiter and the participant.|"Eligible participant will be allocated to one of two groups :~Group 1 will be offered Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12 hrs on empty stomach for 3 days).~Group 2 will be offered placebo capsules (manufactured in pharmacy department with the same shape, colour and consistency as Azithromycin capsule for 3 days). A single pharmacist will be responsible for manufacturing of placebo capsules and packing all medications into sterile boxes and labelling of them as 1 or 2."|t|f|t|f
34143599|NCT00769717|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There was full allocation concealment through the 3-month recruitment phase of the trial.|1:1 Parallel assignment|t|t|t|t
34143600|NCT06524557|||OTHER||RETROSPECTIVE|||||||
34143601|NCT03781219|NA|SEQUENTIAL||TREATMENT||NONE||If no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.||||
34143602|NCT01658137|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143603|NCT00533065|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34143604|NCT01463111|NA|SINGLE_GROUP||OTHER||NONE||||||
34143605|NCT03344640|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients and investigators were blinded until EOS. Sponsor was blinded until after the analysis of the primary endpoint at week 14.|Parallel Assignment|t|t|t|t
34143606|NCT05566457|RANDOMIZED|PARALLEL||TREATMENT||NONE||This open-label, single-center, prospective, randomized controlled trial was planned to be conducted in the National Cancer Center in China from January 2020 to June 2022.The eligible paticipants were assigned randomly in a 1:1 ratio to a study group (HGWD group) or a control group. PASS software (version 15.0) (Kaysville, Utah, USA) was used to calculate the sample size. Assuming α = 0.05 and 1-β = 0.8, a total of 80 patients were needed for the aim of decreasing the grade 2-3 PN from 60% to 30%. Assuming a lost-to-follow-up rate of 15%, a total of 92 patients were needed.||||
34143607|NCT00549029|||CASE_CONTROL||RETROSPECTIVE|||||||
33833074|NCT00848510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833075|NCT01536171|||CASE_ONLY||PROSPECTIVE|||||||
33833076|NCT03947008|RANDOMIZED|PARALLEL||OTHER||NONE||The proposed pilot study will evaluate the feasibility and acceptability of an intuitive eating program for University of Delaware college women. A randomized controlled design will be used to study the effects of an intuitive eating intervention on body dissatisfaction and dietary restraint in young adult women, thereby reducing risk of eating disorders. There will be 2 arms of this study. The First Intuitive Eating Group (IE1) will act as the intervention group and receive the intervention first. The Second Intuitive Eating Group (IE2) will act as a waitlist group and receive the intervention the week immediately following the end of IE1's course.||||
34143608|NCT00598078|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34143609|NCT03239782|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143610|NCT00545532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833077|NCT02808247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143611|NCT00900146|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143612|NCT01794741|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143613|NCT05615987|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143614|NCT04333953|||CASE_ONLY||PROSPECTIVE|||||||
34143615|NCT03551977|RANDOMIZED|PARALLEL||TREATMENT||NONE||A single-centre, RCT study design with two arms, one control group (N=56) and one intervention group (N=56).||||
34143616|NCT03593135|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blinded trial, Intervention and placebo given|Randomized controlled trial|t|f|f|f
34143617|NCT00360932|||COHORT||PROSPECTIVE|||||||
34143618|NCT01344538|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143619|NCT05254405|NA|SINGLE_GROUP||TREATMENT||NONE||Single-arm open-label study of brexanolone infusion for the treatment of posttraumatic stress disorder (PTSD) in adult women.||||
34143620|NCT05700292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143621|NCT00034229||||TREATMENT||||||||
34143622|NCT04806490|||COHORT||PROSPECTIVE|||||||
34143623|NCT03950687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143624|NCT03263468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143625|NCT03445728|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143626|NCT00301535|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143627|NCT05828875|||OTHER||CROSS_SECTIONAL|||||||
34143628|NCT05764473|RANDOMIZED|CROSSOVER||TREATMENT||NONE||12-week randomised cross-over parallel trial||||
34143629|NCT04027270|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Randomization into treatment and standard of care groups. Treatment group will receive physical therapy in addition to standard of care treatment.||||
34143630|NCT05499338|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The investigators were blinded, so that the initial and final investigators did not know which group everyone belonged to.|Single-blind, randomized, controlled, experimental clinical trial.|f|f|t|f
34143631|NCT03719404|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143632|NCT05477537|RANDOMIZED|PARALLEL||TREATMENT||NONE||"This protocol is to carry out an open, multi-centric, randomized controlled trial assessing a population of adolescents suffering from Anorexia Nervosa according to the DSM-5 criteria.~Randomisation will be centralised and stratified according to the status of treatment at inclusion (ambulatory care or day hospitalisation - the latter possibly entailing a selection bias for reason of severity), and the centre. A randomisation list will be generated on computer with blocks of variable size by a statistician independent from the group recruiting or taking care of patients at INSERM CESP, it will be include in the e-CRF procedure."||||
34143633|NCT01561755|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143634|NCT05300685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Approximately 60 subjects will be randomized in a 1:1:1 ratio to receive 3 different local anesthetic regimens following buccal graft harvest. The care provider administering will not be masked to the type of block, but they will be blinded to the post op outcomes.|This is a blinded, randomized, controlled trial following patients undergoing buccal urethroplasty (see criteria). This study will aim to assess three established anesthetic protocols for oral pain control. Each study arm holds equal weight.|t|f|t|t
34143635|NCT01067599|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143636|NCT04771429|||OTHER||RETROSPECTIVE|||||||
34143637|NCT06605417|||CASE_CONTROL||RETROSPECTIVE|||||||
33833078|NCT06489275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The intervention improves financial literacy by imparting knowledge, increasing self-awareness of spending habits, building on existing money management skills, and setting personally-meaningful financial goals. During the course of the 6-session intervention, participants learn to set and begin working toward attainable financial goals. Learning occurs in a context of acceptance and encouragement aimed at increasing participants' sense of control over their personal finances. For 3 months after class ends, monthly booster sessions are held.||||
33833079|NCT05538247|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33833080|NCT03494465|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33833081|NCT01398696|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833082|NCT01296763|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833083|NCT04182113|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||All patients will receive 1 Hz rTMS, 20 Hz rTMS, and Sham rTMS, in a randomized order.|t|t|t|t
33833084|NCT02638688|||CASE_ONLY||CROSS_SECTIONAL|||||||
33833085|NCT00298688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143638|NCT00162240|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143639|NCT05940545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143640|NCT05640206|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34143641|NCT04357509|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143642|NCT03261856|||CASE_ONLY||RETROSPECTIVE|||||||
34143643|NCT04272008|RANDOMIZED|CROSSOVER||TREATMENT||NONE||This is an open label, randomized, crossover PK study. Participants will be randomized to one of two treatment sequences. Each treatment sequence consists of two cycles of treatment - one with tampon use and one without tampon use. Tampon use will occur on Days 2 to 5 of contraceptive vaginal system (CVS) use and a new CVS will be used for each treatment cycle. Before starting Annovera use, each subject will use a combined oral contraceptive (COC) for one cycle.||||
34143644|NCT06072092|||CASE_CONTROL||PROSPECTIVE|||||||
34143645|NCT04070196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective cohort study||||
34143646|NCT03943680|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143647|NCT03171246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143648|NCT00535158|||OTHER||CROSS_SECTIONAL|||||||
34143649|NCT02854124|||COHORT||RETROSPECTIVE|||||||
34143650|NCT01256281|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143651|NCT02312219|||COHORT||PROSPECTIVE|||||||
34143652|NCT04401956|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33833086|NCT02909309|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833087|NCT04850235|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143653|NCT06606392|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34143654|NCT06606288|||COHORT||RETROSPECTIVE|||||||
34143655|NCT05302856|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143656|NCT00320255|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34143657|NCT00227318|RANDOMIZED|||PREVENTION||DOUBLE||||||
34143658|NCT04237038||SEQUENTIAL||TREATMENT||NONE|Assignment to the treatment or control group was provided with random numbers in sealed envelopes conducted by a physician of the outpatient clinic.|A randomized clinical trial was conducted with patients submitted to laparoscopic Nissen fundoplication between February 2013 to december 2014 according to the guidelines established by the Mexican Consensus for the study of GERD.||||
34143659|NCT02709187|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143660|NCT04875650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143661|NCT03871452|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|I don't understand very well.|The study was conducted on patients with bleeding associated with extremity lacerations. All consecutive patients presented to the emergency department of the high-volume training hospital in Istanbul were recruited within the study period||||
34143662|NCT05180318|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34143663|NCT00990327|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE|||t|f|t|t
34143664|NCT06607926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143665|NCT03732365|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"This study will be observer-blinded. Each investigational site will be required to have a Sponsor-approved plan (a site-specific Blinding Plan) that describes site-specific precautions being taken to ensure that the study is observer-blinded, taking into account the specific subject care procedures, equipment, and information accessibility at that site. At each investigational site, at least 1 blinded investigator (referred to as Blinded Observer) will not know the subject's treatment assignment and will conduct clinical assessments (including efficacy and safety. The Blinded Observer will not ask other members of the study team, the subject, or the subject's parent(s)/legally acceptable representative(s) which study treatment is being given, and will avoid all attempts to uncover treatment assignment. The Blinded Observer will see the subject during times when study treatment is NOT being administered."|Single-center, parallel-group study to compare the efficacy and safety of UDD plus standard of care with standard of care alone for the treatment of skin and soft tissue infections in chronic non-healing wounds.|f|f|f|t
34143666|NCT03856008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34143667|NCT04442321|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143668|NCT02674282|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143669|NCT00058149|RANDOMIZED|||TREATMENT||||||||
34143670|NCT05431920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The masking will be done by a care provider. Each patient will have a randomly assigned envelope with the corresponding vitamin D dose, defining the allocated arm.|"Adolescents with non-allergic asthma, obesity and insufficiency/deficiency of vitamin D will be randomized in block (33 groups with 8 patients), 2 arms of 132 patients each: the experimental group will receive a single dose of 50,000 IU followed by 4,000 IU daily of vitamin D for three months, and the control group will receive 2,000 IU daily of vitamin D for three months.~Each patient will have a monthly follow up (weeks 4, 8 and 12 after the beginning of the intervention) with physical examination, questionnaire to evaluate asthma control, asthma control test and pediatric asthma quality of life questionnaire (PAQLQ), a spirometry with bronchodilator, 10 ml of peripheral blood to measure plasmatic concentration of 25-hydroxyvitamin D with electrochemiluminescence, Th17 inflammatory biomarkers and allergy skin tests (at the beginning and end of the intervention) and each visit will be a capsule count and a registration of adverse effects."|f|t|f|f
34143671|NCT04134130|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized case control study: one arm with FSH treatment for 5 weeks and one arm without FSH.||||
34143672|NCT05615259|||COHORT||OTHER|||||||
34143673|NCT00590824|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143674|NCT00000558|RANDOMIZED|||PREVENTION||DOUBLE||||||
34143675|NCT02276118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143676|NCT05622266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143677|NCT04495556|||COHORT||PROSPECTIVE|||||||
34143678|NCT01985490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143679|NCT01766895|||COHORT||PROSPECTIVE|||||||
34143680|NCT02106247|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34143681|NCT05985213|||COHORT||PROSPECTIVE|||||||
34143682|NCT00628589|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143683|NCT03234556|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143684|NCT05708781|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143685|NCT00934947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143686|NCT05731076|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143687|NCT03085511|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Within subjects comparison will be performed. Subjects will be assigned to either group A (EB first then CB) or group B (CB first then EB) for a week and then reverse to the opposite breakfast the next week||||
34143688|NCT05285124|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34143689|NCT03082573|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Open Label|||||
34143690|NCT00832247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143691|NCT00199225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34143692|NCT04358705|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143693|NCT03002818|||COHORT||PROSPECTIVE|||||||
34143694|NCT03351556|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Participants in the cash transfer arms will be masked to the knowledge that there are two cash value arms.||t|f|f|f
34143695|NCT03160469|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective pilot study of 48 patients underwent Elipse balloon insertion by the same surgeon at Faisal polyclinics in Kuwait city during six months period from July 2016 to January 2017. Ethical approval was obtained from the Ministry of Health in Kuwait \& national ethics committee.||||
34143696|NCT02142283|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143697|NCT00803348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34143698|NCT03117608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143699|NCT02392923|||COHORT||PROSPECTIVE|||||||
34143700|NCT04664530|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150957|NCT00813891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143701|NCT03386747|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|Treatment requires active participation and will be revealed immediately.|||||
34143702|NCT01024582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143703|NCT03340896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143704|NCT04299919|||CASE_CONTROL||RETROSPECTIVE|||||||
34143705|NCT05661305|||CASE_CONTROL||PROSPECTIVE|||||||
34143706|NCT02903758|||||CROSS_SECTIONAL|||||||
34143707|NCT06507501|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143708|NCT05272241|||COHORT||PROSPECTIVE|||||||
34143709|NCT03001700|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143710|NCT04202146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143711|NCT01355263|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34143712|NCT03192033|RANDOMIZED|PARALLEL||OTHER||NONE||A duplex scan guided retrograde femoral puncture is performed followed by the use of a closure arterial device to ensure hemostasis. Patients are randomly assigned to be closed by Proglide® (Abbott) versus Femoseal® (Terumo)||||
34143713|NCT01228994|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143714|NCT01996592|||OTHER||PROSPECTIVE|||||||
34143715|NCT02590601|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143716|NCT03669770|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143717|NCT00000262|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34143718|NCT01022515|||CASE_CONTROL||PROSPECTIVE|||||||
34143719|NCT04790825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143720|NCT01709942|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143721|NCT00000627||||TREATMENT||||||||
34143722|NCT05016167|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143723|NCT03924583|||OTHER||PROSPECTIVE|||||||
34143724|NCT05499793|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|A pharmacist professional was responsible for distributing the treatment (ginger) and placebo and he was in charge to assign the participants to the groups.|Randomized clinical trial|t|f|t|f
34143725|NCT04105439|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143726|NCT02470754|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34143727|NCT05110469|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"Patient allocation was done by randomization by anesthesiologists outside of the research team using randomization software. Patients would be divided into two groups, namely group M which contains MgSO4 30 mg/kg i.v. and group P which contains meperidine 0.5 mg/kg i.v. Anesthesiologists outside of the research team would prepare the study drug according to the randomized group. The formulated drug would be labeled as research drug without mentioning the content or group of the drug.~Prior to spinal anesthesia, another OK team outside of the research team would give the research drug without knowing the contents of the drug, as well as perform spinal anesthesia. Observation of the data would be carried out by the researcher together with the OR team who performed the spinal anesthesia."|Non-pregnant patients between 18-65 years of age, belonging to the American Society of Anesthesiologist physical status I or II who underwent spinal anesthesia.|t|t|t|t
34143728|NCT04920006|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||We will use a randomized waitlist control design. Participants will be randomly assigned to one of two groups. Group A will first participate in the intervention (three meetings offered every 2 weeks at Weeks 2, 4, and 6), followed by 8 weeks of follow-up. T1 will be a pretest gathered at enrollment. Group B will wait 8 weeks and then start the intervention at Weeks 8, 10, and 12, with a posttest at Week 14. Data will be gathered at six time points no less than 2 weeks apart over the course of the control, intervention, and follow-up.||||
34143729|NCT06337474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143730|NCT06519461|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143731|NCT01133626|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143732|NCT05577832|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34143733|NCT06178016|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143734|NCT02829216|||COHORT||PROSPECTIVE|||||||
34143735|NCT01358123|||COHORT||PROSPECTIVE|||||||
34143736|NCT01882010|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143737|NCT03811847|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE||The study uses a double-blinded, multi-crossover, randomized controlled trial design. This type of trial design in AD allow for each subject to serve as their own control as they progress through several randomized blocks of experimental treatment and placebo. Thus, multi-crossover studies carried out with systemically applied outcome measures, pre-specified doses of study drug, and washout periods serve as unbiased estimates of treatment effect for individual subjects. When data from several subjects are analyzed together following such a N-of-1 design, substantial increases in statistical power is afforded with a fraction of the subjects and assessments required for similar levels of power in conventional parallel group trials. There are 6 different block randomization sequences for which subjects were assigned.|t|t|t|t
34143738|NCT04348045|RANDOMIZED|FACTORIAL||TREATMENT||NONE||Patients with a BRCAness somatic profile: olaparib Arm A. Patients with no BRCAness profile and with KRAS mutation randomization between durvalumab plus selumetinib Arm B, versus FOLFIRI Arm C.||||
34143739|NCT06367907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Parallel-group: Both conditions (emotion focussed, ST-EF and active control, ST-AC) are highly standardized and active in terms of their expected clinical effect, which was a precondition for a positive ethics approval.~Randomized: Patients are randomly assigned to the ST-EF or ST-AC condition according to a randomization list established by an independent statistician, and applied to incoming help-seeking patients by an independent admission management (managing nurse, not a member of the research team).~Single-blinded: Researchers are blind as regards group belonging of participants."|randomized, parallel-group, single-blinded|t|f|f|t
34143740|NCT04947631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143741|NCT00100295|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833088|NCT04553445|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized crossover design||||
33833089|NCT01335906|RANDOMIZED|PARALLEL||||NONE||||||
33833090|NCT01688817|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33833091|NCT00000454|RANDOMIZED|||TREATMENT||NONE||||||
33833092|NCT02581059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837623|NCT01385046|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837624|NCT04685746|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143742|NCT06107439|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34143743|NCT05976022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143744|NCT01540409|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143745|NCT00715364|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143746|NCT04612660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34143747|NCT00906139|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143748|NCT04535713|NA|SINGLE_GROUP||TREATMENT||NONE||A total of 260 patients will receive gemcitabine 600 mg/m2 (maximum dose: 1000 mg) on D1 and D8, doxorubicin 18 mg/m2 on D1 and D8 (maximum dose: 32 mg), docetaxel 25 mg/m2 on D1 and D8 (maximum dose: 42 mg), on Days 1 and 8. After the first cycle, nivolumab 240 mg IV will be added on Day 1 of each cycle (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy.||||
34143749|NCT02073357|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143750|NCT02691403|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34143751|NCT03198195|||OTHER||PROSPECTIVE|||||||
34143752|NCT03831945|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34143753|NCT00004142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143754|NCT00274560|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143755|NCT05725460|RANDOMIZED|PARALLEL||TREATMENT||NONE||2 groups comparing the efficacy of dextrose water 5 % in median nerve hydrodissection||||
34143756|NCT00159575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143757|NCT01269385|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143758|NCT04075422|||CASE_CONTROL||PROSPECTIVE|||||||
34143759|NCT02428621|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143760|NCT01524432|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34143761|NCT03008902|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143762|NCT04699812|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34143763|NCT01223898|NA|SINGLE_GROUP||OTHER||NONE||||||
34143764|NCT00686842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143765|NCT03897387|||COHORT||RETROSPECTIVE|||||||
34143766|NCT06160856|||COHORT||PROSPECTIVE|||||||
34143767|NCT05332249|||COHORT||PROSPECTIVE|||||||
34143768|NCT01929720|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143769|NCT05730647|||COHORT||PROSPECTIVE|||||||
34143770|NCT02061397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143771|NCT00681564|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34143772|NCT01778322|||COHORT||PROSPECTIVE|||||||
34143773|NCT02408354|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34143774|NCT03927313|RANDOMIZED|PARALLEL||TREATMENT||NONE||Phase IIA, randomized, active-controlled, open label, parallel-group trial||||
34143775|NCT05281770|||COHORT||PROSPECTIVE|||||||
34143776|NCT03345654|||COHORT||PROSPECTIVE|||||||
34143777|NCT00938977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143778|NCT00413829|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143779|NCT04592172|RANDOMIZED|PARALLEL||TREATMENT||NONE||100 caregiver-infant dyads (infants ages 12.0 to 14.9 months) will be recruited from Temple Pediatric Care Outpatient Pediatric office with follow-up visits at approximately 15 and 24 months of age.||||
34143780|NCT02775331|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143781|NCT02562209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143782|NCT05947279|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||The study will have three groups: (15 people per group) 1) posterior parietal cortex group, which will receive the stimulation to their left posterior parietal cortex, 2) cerebellum group, which will receive stimulation to their right cerebellum, and 3) sham group, which will have the electrode cap placed on their head but receive no stimulation. By comparing motor adaptation reaching performance between these three groups, the investigators can examine how stimulation to each specific area of the brain modulates different aspects of motor adaptation.||||
34143783|NCT02262078|RANDOMIZED|PARALLEL||DIAGNOSTIC||QUADRUPLE|||t|t|t|t
34143784|NCT02937857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143785|NCT01962987|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143786|NCT02529748|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143787|NCT03026478|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143788|NCT00320749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143789|NCT05637697|||COHORT||PROSPECTIVE|||||||
34143790|NCT05361499|NA|SINGLE_GROUP||OTHER||NONE||Single dose open label intervention study||||
34143791|NCT02958202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143792|NCT01579825|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143793|NCT06508307|NA|SEQUENTIAL||TREATMENT||NONE||3+3||||
34143794|NCT04612543|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment|t|f|t|f
34143795|NCT02710435|||OTHER||OTHER|||||||
34143796|NCT06258486|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The investigator and participant will not know which arm the patient is randomized into while undergoing the surgery. It isn't until the surgery is complete that the patient will be randomized into either ICG injection versus not.|Patients will be randomized into ICG versus no ICG injection after pelvic lymphadenectomy is completed.|t|f|t|f
34143797|NCT01666119|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143798|NCT02764528|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34143799|NCT01901965|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143800|NCT03209076|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized trial||||
34143801|NCT03809091|||FAMILY_BASED||PROSPECTIVE|||||||
34143802|NCT02088502|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143803|NCT00903565|||CASE_ONLY||PROSPECTIVE|||||||
34143804|NCT00868530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143805|NCT03649529|NA|SINGLE_GROUP||TREATMENT||NONE||Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells,and then infused back into the patient.||||
34143806|NCT01283880|||COHORT||PROSPECTIVE|||||||
34143807|NCT01887821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143808|NCT03366103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143809|NCT05139199|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34143810|NCT01020162|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143811|NCT05214989|NA|SINGLE_GROUP||PREVENTION||NONE||This is a single group proof of concept study of an intervention involving tailored counseling.||||
34143812|NCT03165123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143813|NCT06352528|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143814|NCT02362945|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143815|NCT05102617|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Randomization is not used for determining which arm subjects will participate in, however, it will be used to determine which side of the treatment area will receive which treatment regimen (if in a group receiving split-face treatments).|||||
34143816|NCT03514680|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"The study expect to enroll 162 patients, 60 clinicians, and 30 healthy controls for a total of 252.~81 patients will be recruited in Period 1 (usual care) and a separate 81 will be recruited in Period 2 (algorithm use). The 60 clinicians will be recruited and will participate in Periods I and II. We will use purposive sampling to recruit 30 health controls to match the age and demographic characteristics of the recruited patients. The healthy controls will receive no intervention."||||
34143817|NCT05244460|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143818|NCT03250078|||COHORT||PROSPECTIVE|||||||
34143819|NCT04420962|||CASE_CONTROL||PROSPECTIVE|||||||
34143820|NCT02017288|||COHORT||CROSS_SECTIONAL|||||||
34143821|NCT03649373|||OTHER||RETROSPECTIVE|||||||
34143822|NCT00511433|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143823|NCT06606418|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34143824|NCT00815191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34143825|NCT04580277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143826|NCT05639101|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Decision support system for professionals and mobile app for self-management in patients based on the analysis of the influence of clinical and environmental characteristics on the population of asthmatic patients in our region.||||
34143827|NCT00182767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143828|NCT06155734|||COHORT||RETROSPECTIVE|||||||
34143829|NCT02273635|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143830|NCT02542891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143831|NCT00438854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143832|NCT05184465|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34143833|NCT02658747|||COHORT||RETROSPECTIVE|||||||
34143834|NCT01898949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143835|NCT05379114|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143836|NCT05374135|||COHORT||PROSPECTIVE|||||||
34143837|NCT06246019|||COHORT||PROSPECTIVE|||||||
34143838|NCT04932330|||CASE_CONTROL||OTHER|||||||
34143839|NCT02238340|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143840|NCT04394273|||COHORT||PROSPECTIVE|||||||
34143841|NCT06198101|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will get separate treatment protocols and possible efforts will be put to mask the both group about the treatment.|It will be Randomized control trial in which non probabilty convenient sampling will be used. Two groups of 6-12 age will be formed in which participants will be randomly divided. Group A will only receive Myofascial release technique and group B will receive Myofascial release technique with segmental massage vibrator|t|f|f|f
34143842|NCT04029389|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143843|NCT05190601|||COHORT||PROSPECTIVE|||||||
34143844|NCT00358332|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34143845|NCT01544413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143846|NCT05630651|NA|SINGLE_GROUP||TREATMENT||NONE||Hemophilia B subjects||||
34143847|NCT00042432|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34143848|NCT04699292|||COHORT||PROSPECTIVE|||||||
34143849|NCT01777555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143850|NCT00672087|||COHORT||PROSPECTIVE|||||||
34143851|NCT04225091|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34143852|NCT01073540|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143853|NCT03211793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143854|NCT04197063|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data was collected during a sham focus group where the purpose of the study was concealed from the participants. The purpose of the study was unmasked to participants when they returned on the following day and completed the study.|This study randomized participants to one of four conditions: 1) Current SSB restaurant portion sizes with the option to purchase beverage refills; 2) Current SSB restaurant portions plus free refills; 3) \</= 16 oz. SSB portions with the option to purchase beverage refills; or 4) \</= 16 oz. SSB portions plus free refills.|t|f|f|f
34143855|NCT05562180|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143856|NCT01234805|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34143857|NCT04711941|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34143858|NCT01296074|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34143859|NCT05820698|RANDOMIZED|PARALLEL||OTHER||SINGLE|Given the nature of dietary interventions, blinding will not always be possible, and this study will be conducted in an unblinded manner. Only the Consultant Dermatologist (Outcome Assessor) undertaking the psoriasis severity examinations will be blinded to the allocated diet interventions of the participants. All statistical data analysis will be carried out blinded using data codes to ensure that the intervention allocation is concealed from the researcher carrying out the statistical analysis.||f|f|f|t
34143860|NCT02868450|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143861|NCT06065605|||CASE_CONTROL||PROSPECTIVE|||||||
34143862|NCT03212417|NA|SINGLE_GROUP||SCREENING||NONE||||||
34143863|NCT00363727|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143864|NCT01660737|||COHORT||PROSPECTIVE|||||||
34143865|NCT01996163|||COHORT||RETROSPECTIVE|||||||
33833093|NCT04120376|NA|SINGLE_GROUP||PREVENTION||NONE||Contraception counseling will occur for all adolescent participants and APPs will be enrolled to conduct counseling. The number of participants enrolled includes the final number of participants including adolescent and APPs.||||
33833094|NCT01473615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833095|NCT06120946|||COHORT||PROSPECTIVE|||||||
34143866|NCT02120170|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34143867|NCT04389112|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143868|NCT03184610|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34143869|NCT01125969|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34143870|NCT01777542|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34143871|NCT05622435|NA|SINGLE_GROUP||OTHER||NONE||||||
34143872|NCT05750810|||COHORT||PROSPECTIVE|||||||
34143873|NCT03726515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143874|NCT02378194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34143875|NCT02594098|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143876|NCT01657136|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143877|NCT01564095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143878|NCT01156389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143879|NCT00023686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143880|NCT05489653|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34143881|NCT00458042|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143882|NCT04617886|RANDOMIZED|PARALLEL||SCREENING||SINGLE||Within subjects design. Each participant will be tested, in a counterbalanced way, through both (sadness vs. joy) conditions|t|f|f|f
34143883|NCT05290987|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Randomized, double-blind, placebo-controlled, parallel-group study.|t|f|t|f
34143884|NCT05401045|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34143885|NCT03784846|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Individually-Randomized Group Treatment|f|f|f|t
34143886|NCT02210481|||COHORT||PROSPECTIVE|||||||
34143887|NCT00170196|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143888|NCT00295230|||CASE_CROSSOVER||PROSPECTIVE|||||||
34143889|NCT00114023|||DEFINED_POPULATION||PROSPECTIVE|||||||
34143890|NCT04526873|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||DOUBLE|Participants (i.e., patients) will not be informed specifically of their assignment to different arms throughout the study. Providers who conduct AWVs will not be randomized to study arms or informed of patient assignment.|Postcard content will follow a factorial design (crossing telehealth vs. non-telehealth with cartoon/salience vs. stock photo). In addition, there will be a no-contact control group and a phone call group.|t|t|f|f
34143891|NCT02699008|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143892|NCT02650128|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143893|NCT06300918|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34143894|NCT01710527|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34143895|NCT01873729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143896|NCT01892761|||||RETROSPECTIVE|||||||
34143897|NCT00869050|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143898|NCT05767580|||CASE_CONTROL||PROSPECTIVE|||||||
34143899|NCT02810938|||CASE_ONLY||PROSPECTIVE|||||||
34143900|NCT00611468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143901|NCT04341545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The identical looking placebo will be given. A computer generated sequence will be created. The sequence will be sealed in consecutively concealed opaque envelopes. Both the participant/ care provider/ investigator and outcomes assessor will blinded to the group assigned.|Participants will be randomized into either receive letrozole or placebo capsules.|t|t|t|t
34143902|NCT05713903|RANDOMIZED|PARALLEL||TREATMENT||NONE|There will be no blindness at the level of the patient, the treating physicians (surgeon, anesthesiologist) and the researcher who will record the data.|The study will employ a prospective, parallel randomized-controlled design||||
34143903|NCT05445206|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The individuals who annotate the capnography waveform are blinded between the reference strip and the test device strip.|Comparison between test device and reference device||||
34143904|NCT00005636|RANDOMIZED|||TREATMENT||||||||
34143905|NCT05835232|||COHORT||PROSPECTIVE|||||||
34143906|NCT02066506|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143907|NCT01046604|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143908|NCT03971604|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group 1: Treated with VA, Group 2: Treated with VE, Group 3: Treated with VA+VE. To evaluate and compare the blood pressure, weight, uterine height, abdominal circumference, fetal b-mode ultrasound, blood results (blood routine, including blood VA/VE level), methods of termination of pregnancy, obstetric complications and neonatal conditions (including body length, weight, Apgar score, umbilical cord blood VA, VE level, etc.) among the three groups.||||
34143909|NCT02954419|||COHORT||PROSPECTIVE|||||||
34143910|NCT05981937|||COHORT||RETROSPECTIVE|||||||
34143911|NCT00146185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34143912|NCT01371643|RANDOMIZED|PARALLEL||||NONE||||||
34143913|NCT03829943|||COHORT||PROSPECTIVE|||||||
34143914|NCT03142724|NA|SINGLE_GROUP||OTHER||NONE||||||
34143915|NCT05544175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143916|NCT01175642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143917|NCT00172731|||DEFINED_POPULATION||OTHER|||||||
34143918|NCT02153346|NA|SINGLE_GROUP||OTHER||NONE||||||
34143919|NCT05063188|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143920|NCT03598205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34143921|NCT00503334|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34143922|NCT00367744|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143923|NCT03359057|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34143924|NCT03164083|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143925|NCT06521775|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143926|NCT04416607|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143927|NCT00546260|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34143928|NCT03221790||SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34150958|NCT01057485|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150959|NCT03778463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150960|NCT03656081|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150961|NCT01600092|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34143929|NCT05385445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|Clinics were randomized to one of three groups. Electronic medical records were extracted for each group. All extracted EMR data is de-identified included the patient, provider and site details. Using a unique site identification number, sites were linked to their randomization group for analysis.|"Cluster Randomized Trial. MaPCReN personnel randomly assigned numbers to clinics for randomization. Number of physicians practicing at each clinic was controlled during randomization. The intervention Group 1 received the standard feedback report with a one-page summary of the CWC recommendations of interest. Group 1 did not receive any data specific to their prescribing. Intervention Group 2 received the standard feedback report, CWC recommendation summary and practice-specific data related to their prescribing rates for the CWC recommendations of interest, compared to rates for other providers at their clinic, in their health region and in the province. The control group received the standard feedback report with no information related to CWC."|t|t|f|f
34143930|NCT05596487|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34143931|NCT02966795|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143932|NCT00600041|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34143933|NCT03630302|||CASE_ONLY||PROSPECTIVE|||||||
34143934|NCT01146652|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143935|NCT00344734|RANDOMIZED|PARALLEL||||SINGLE||||||
34143936|NCT03952117|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34143937|NCT02568098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143938|NCT04104074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143939|NCT04789161|||COHORT||PROSPECTIVE|||||||
34143940|NCT05703620|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143941|NCT01218451|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34143942|NCT03353922|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|subjects are blindfolded to receive oral dose of treatment, matching placebo, or unblinded active control|multiple-dose 3-way cross-over study|t|f|t|t
34143943|NCT02926092|||COHORT||PROSPECTIVE|||||||
34143944|NCT02148432|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34143945|NCT00701636|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34143946|NCT01544452|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34143947|NCT01180816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143948|NCT05606419|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients with active disease will follow either the CDED diet protocol (CDED + PEN), the usual nutritional care plus PEN, or the CDED diet with dairy products included, for 12 weeks. All participants will attend study visits at the beginning, in the middle and at end of the trials, at which points questionnaires will be completed and samples will be collected.||||
34143949|NCT03093974|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34143950|NCT00005303|||NATURAL_HISTORY|||||||||
34143951|NCT00001065||||TREATMENT||||||||
34143952|NCT02488291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34143953|NCT05128162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143954|NCT00413920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143955|NCT03400657|||CASE_CONTROL||PROSPECTIVE|||||||
34143956|NCT04965922|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34143957|NCT04143217|NA|SINGLE_GROUP||TREATMENT||NONE|None (Open Label)|Single Group Assignment||||
34143958|NCT02474537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143959|NCT01691014|||COHORT||PROSPECTIVE|||||||
34143960|NCT00043823|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143961|NCT02362204|||COHORT||PROSPECTIVE|||||||
34143962|NCT03508193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143963|NCT04346979|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34143964|NCT05482581|||COHORT||OTHER|||||||
34143965|NCT00340600|||COHORT||PROSPECTIVE|||||||
34143966|NCT03535662|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143967|NCT02737644|||CASE_CONTROL||PROSPECTIVE|||||||
34143968|NCT06034067|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|- Double-blinded as both the participants and outcome accessors of radiographic outcomes will be blinded to the intervention.|"* Prospective, in which participants will be recruited and then followed up throughout a specified period of time.~* Randomized, parallel designed, concurrent controlled trial with participants randomly allocated to either control or test groups.~* Double-blinded as both the participants and outcome accessors of radiographic outcomes will be blinded to the intervention."|t|f|f|t
34143969|NCT01236092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34143970|NCT04748835|||COHORT||PROSPECTIVE|||||||
34143971|NCT01684644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34143972|NCT01155466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34143973|NCT05004038|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A phase IIA randomized double-blind placebo-controlled single-centre study|t|t|t|t
34143974|NCT02092051|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34143975|NCT06482320|||COHORT||PROSPECTIVE|||||||
34143976|NCT03683654|||COHORT||CROSS_SECTIONAL|||||||
34143977|NCT04140201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143978|NCT04594265|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients are studied in a randomized single-blind cross-over design.|t|f|f|t
34143979|NCT02049190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143980|NCT05133713|||COHORT||PROSPECTIVE|||||||
34143981|NCT02426775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34143982|NCT04297189|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|each participant will receive a coding number and the key will be kept in the primary investigator offices.|||||
34143983|NCT04850079|||CASE_ONLY||PROSPECTIVE|||||||
34143984|NCT05617300|NA|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34143985|NCT01115335|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34143986|NCT01669421|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34143987|NCT01053013|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34143988|NCT02799719|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34143989|NCT04192968|||CASE_ONLY||PROSPECTIVE|||||||
34143990|NCT06536205|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||There is an experimental and a control group in the research.|t|f|t|f
34143991|NCT01084278|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34143992|NCT05879367|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34143993|NCT03663530|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Participants will be masked to the true outcomes of the study.|This is a 2-period crossover study in which sleep is identical in duration and timing but meals/food intake is varied relative to the sleep episode.||||
34143994|NCT05553964|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143995|NCT04451824|NA|SINGLE_GROUP||TREATMENT||NONE||Routine use of device||||
34143996|NCT03797118|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34143997|NCT05961969|||COHORT||PROSPECTIVE|||||||
34143998|NCT00140699|||CASE_CONTROL||PROSPECTIVE|||||||
34143999|NCT05985278|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144000|NCT02124512|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144001|NCT02501317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144002|NCT05873179|||CASE_ONLY||PROSPECTIVE|||||||
34144003|NCT06508268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144004|NCT02580383|||CASE_CONTROL||RETROSPECTIVE|||||||
34144005|NCT04710407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144006|NCT01628367|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144007|NCT01011933|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144008|NCT05693142|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose Evaluation||||
34144009|NCT02352636|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34144010|NCT00989235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144011|NCT02801279|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144012|NCT02291848|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144013|NCT01437527|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144014|NCT02947165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144015|NCT04599517|||COHORT||RETROSPECTIVE|||||||
34144016|NCT01804712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144017|NCT00594542|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34144018|NCT06131944|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34144019|NCT00385398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144020|NCT00723346|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144021|NCT00145691|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144022|NCT00457977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144023|NCT03094286|NA|SINGLE_GROUP||TREATMENT||NONE||Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous(IV) administration||||
34144024|NCT05423574|||CASE_ONLY||PROSPECTIVE|||||||
34144025|NCT00031746|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34144026|NCT01822535|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34144027|NCT00670176|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34144028|NCT04031274|||COHORT||RETROSPECTIVE|||||||
34144029|NCT05347940|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"30 adult of both sexes will participate in this study and selected from outpatient clinic of faculty of physical therapy Cairo university. Their ages range from 20 to 45 years.~Informed consent will be taken from all patients.~All the adult were divided into two groups of equal number (15):~Study group (A): received traditional physical therapy program in addition to motor imagery in form of mirror therapy.~Study group (B): received traditional physical therapy program only."|f|f|f|t
34144030|NCT06276218|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||f|f|t|t
34144031|NCT00005574||||TREATMENT||||||||
34144032|NCT03395301||SEQUENTIAL||TREATMENT||NONE||Platinum coils were inserted into the tubes.||||
34144033|NCT03833570|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144034|NCT00042068|RANDOMIZED|PARALLEL||||DOUBLE||||||
34144035|NCT02496845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144036|NCT02491034|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34144037|NCT04643639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144038|NCT00195000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144039|NCT05853055|RANDOMIZED|PARALLEL||OTHER||NONE||The study population comprises 20 patients suffering from post-COVID-19, since fatigue is a major complaint in this condition. Since abnormal breathing patterns during exertion occur mainly in post-COVID-19 patients, only these will participate in the respiratory training intervention. Half of the post-COVID-19 patients will be the control, and the other half the intervention group.||||
34144040|NCT01165320|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144041|NCT03859518|||COHORT||PROSPECTIVE|||||||
34144042|NCT04224272|NA|SEQUENTIAL||TREATMENT||NONE||||||
34144043|NCT05135858|NA|SEQUENTIAL||TREATMENT||NONE||"The phase I will follow a standard 3+3 dose level escalation design with reduced time interval of HD-MTX injections at fixed dose of HD-MTX to establish the minimum tolerated time interval."||||
34144044|NCT03218358|||CASE_ONLY||PROSPECTIVE|||||||
34144045|NCT04333056|||OTHER||RETROSPECTIVE|||||||
34144046|NCT00541099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144047|NCT05910125|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833096|NCT03318653|||COHORT||CROSS_SECTIONAL|||||||
33833097|NCT00015561|||DEFINED_POPULATION||OTHER|||||||
33833098|NCT05730998|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33833099|NCT00561717|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33833100|NCT05271344|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33833101|NCT04477993|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833102|NCT05657756|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|t|t|f
33833103|NCT01636908|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833104|NCT04695652|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33833105|NCT02787447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833106|NCT02690337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833107|NCT04451811|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34144048|NCT00393406|||||PROSPECTIVE|||||||
34144049|NCT01363180|||OTHER||PROSPECTIVE|||||||
34144050|NCT05999526|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Immediately after successful spontaneous breathing trial, eligible participants will be randomized into 2 groups that will undergo the following interventions:~1. Reconnection to mechanical ventilation for 1 hour: as soon as the success of the spontaneous breathing trial is confirmed, the participants will be reconnected to mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.~   In the experimental group, in case there are signs of respiratory distress or other clinical problems during the resting phase on mechanical ventilation, the intensivist may decide to keep the participant on mechanical ventilation for more than 1 hour until reassessing the appropriate time for extubation.~2. Direct extubation: participants will be extubated immediately after spontaneous breathing trial."||||
34149529|NCT03877653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"A sponsor representative will open the sealed envelopes and assign groups. Investigators and research staff will be blinded to assignment of high frequency or sham. Randomization assignment will be documented post-implant but will be filed separately in a document locker, which will only be available to a sponsor representative until the time of unblinding.~When receiving active stimulation, devices will be programmed to deliver electrical stimulation below perception threshold. Stimulation waveforms delivered above perception threshold have the potential to unblind subjects to their assignments.~When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.~Sites will not have access to the programmer. Study devices can only be programmed by Stimwave representatives."|placebo-controlled double blinded randomized clinical trial|t|f|t|t
34149530|NCT00636051|||||PROSPECTIVE|||||||
34149531|NCT01447303|||CASE_ONLY||PROSPECTIVE|||||||
34149532|NCT04273022|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||SINGLE|Blood and urine samples will be assigned a random code. Testing personnel will be blinded to whether samples are pre- or post-exercise and whether from the SCT or control group.|SCT subjects will be evaluated for activation of five physiological pathways by measuring 15 biomarkers before and after a single bout of moderate exercise. The control group will confirm normal biomarkers at rest and determine the natural response to moderate exercise.|f|f|f|t
34149533|NCT05879575|RANDOMIZED|PARALLEL||TREATMENT||NONE||intervention group: receive weigh training during 16-36 gestational weeks||||
34149534|NCT03412604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149535|NCT00304005||||TREATMENT||||||||
34149536|NCT04547361|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34149537|NCT00068094|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34149538|NCT05920408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149539|NCT02603445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34149540|NCT01423474|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149541|NCT00434356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149542|NCT02925741|RANDOMIZED|PARALLEL||PREVENTION||NONE||Of 5 Medical ICUs at 1 quaternary care medical center, patients were assigned to groups based on bed availability by personnel who were blinded to linens used on those units.||||
34149543|NCT00387647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149544|NCT03832608|||COHORT||CROSS_SECTIONAL|||||||
34149545|NCT03888118|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149546|NCT00864851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149547|NCT04294771|||OTHER||RETROSPECTIVE|||||||
34149548|NCT00230152|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149549|NCT04302064|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149550|NCT04051450|||COHORT||PROSPECTIVE|||||||
34149551|NCT03580928|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149552|NCT02247180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149553|NCT04298424|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34149554|NCT06459882|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34149555|NCT01137019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149556|NCT05660447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34149557|NCT01716104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149558|NCT04867694|RANDOMIZED|PARALLEL||OTHER||NONE||Non-blinded cluster randomized controlled trial||||
34149559|NCT03052140|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34149560|NCT04439994|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||two groups of subjects: one group will receive hypertonic injection (0.1 ml) and the other group will receive isotonic saline injection (0.1 ml)|t|f|f|f
34149561|NCT02495493|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149562|NCT03966131|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34149563|NCT02484924|||COHORT||RETROSPECTIVE|||||||
34149564|NCT04729231|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34149565|NCT01415804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149566|NCT05135962|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34149567|NCT02212678|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149568|NCT06508242|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|double-blind||t|t|t|t
34149569|NCT01875042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34149570|NCT03829956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149571|NCT00554658|NA|SINGLE_GROUP||||NONE||||||
34149572|NCT02408809|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34149573|NCT01462877|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149574|NCT00048113|RANDOMIZED|||TREATMENT||DOUBLE||||||
34149575|NCT00447473|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149576|NCT02896270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149577|NCT02920515|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149578|NCT01435837|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34149579|NCT03281889|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149580|NCT03472690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stage one is Open Label||t|t|t|t
34150962|NCT03855852|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||"Parallel Assignment~* A Randomized clinical trial~* Parallel study group~* A trial will be carried out in outpatient clinic of Periodontology Department ,Faculty of Dentistry , Cairo University .~* Equal randomization with equal probabilities for intervention.~* Positive controlled : Both groups will receive treatment"|f|f|t|t
33833108|NCT01206699|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833109|NCT03968068|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833110|NCT05996978|||COHORT||PROSPECTIVE|||||||
33833111|NCT04063046|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcomes Assessor|A Randomized, outcome assessor-Blinded, Trial|f|f|f|t
33833112|NCT02429986|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833113|NCT02265809|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33833114|NCT04457817|||COHORT||PROSPECTIVE|||||||
33833115|NCT01038453|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833116|NCT04739410|RANDOMIZED|PARALLEL||TREATMENT||NONE||Response of the patients after Ivermectin prescription and response of the patients without Ivermectin prescription was recorded. Response was recorded on the basis of clinical parameters (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue. Any side effects noted after prescription of Ivermectin was recorded.||||
33833117|NCT00404885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833118|NCT00883636|||COHORT||PROSPECTIVE|||||||
33833119|NCT00739115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833120|NCT05513183|||COHORT||PROSPECTIVE|||||||
33833121|NCT02833298|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833122|NCT00763594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833123|NCT04116268|||CASE_CONTROL||PROSPECTIVE|||||||
33833124|NCT05495698|RANDOMIZED|PARALLEL||OTHER||NONE||The first group will receive multi-inhaler triple therapy (control group), the second group single inhaler triple therapy (intervention group 1) and the third group single inhaler triple therapy with extra digital support to increase therapy adherence (intervention group 2).||||
33833125|NCT03039998|||COHORT||PROSPECTIVE|||||||
33833126|NCT05949645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833127|NCT04065828|||COHORT||PROSPECTIVE|||||||
33833128|NCT04543812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833129|NCT02391077|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833130|NCT05575817|NA|SINGLE_GROUP||OTHER||NONE||Study 2 is an open-label (non-randomized) pilot study to determine therapist and patient acceptance, feasibility and whether there is enough of a signal in improving clinical outcomes to warrant a randomized trial of the online patient grief tutorial in conjunction with Prolonged Grief Disorder therapy.||||
33833131|NCT03234361|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33833132|NCT01013545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833133|NCT02543099|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833134|NCT04762303|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33833135|NCT02722811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833136|NCT03229486|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33833137|NCT00415701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833138|NCT01834586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833139|NCT03069144|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833140|NCT00136370|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33833141|NCT04345380|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833142|NCT02719041|||CASE_ONLY||RETROSPECTIVE|||||||
33833143|NCT03685682|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833144|NCT00737828|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833145|NCT02927015|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33833146|NCT02684123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833147|NCT03563313|RANDOMIZED|PARALLEL||OTHER||NONE||A randomized controlled trial of 6 month at home closed loop system vs. sensor-augmented pump.||||
33833148|NCT04290611|||CASE_CONTROL||RETROSPECTIVE|||||||
33833149|NCT00760344|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833150|NCT04181489|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833151|NCT04438122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833152|NCT05553093|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833153|NCT05802771|||COHORT||PROSPECTIVE|||||||
33833154|NCT03219021|||OTHER||CROSS_SECTIONAL|||||||
33833155|NCT06187792|||COHORT||RETROSPECTIVE|||||||
33833156|NCT06499662|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study will employ simple blinding. Participants will be blinded to the intervention group to which they belong. Outcome assessors will also be blinded to group assignment to ensure that heart rate variability (HRV) measurements are not influenced by participants' knowledge of the intervention received. Staff delivering interventions will not be blinded due to the nature of neurodynamic and guided breathing techniques, which require knowledge of the specific protocol applied.|This study is a controlled clinical trial with a parallel design. Participants will be randomised into two groups: one group will receive a combination of vagus nerve neurodynamics, 6 bpm guided breathing and manual therapy, while the other group will receive only 6 bpm guided breathing and manual therapy. Each group will be treated simultaneously and the results will be compared between groups to assess the effect of neurodynamics on heart rate variability in chronically stressed patients.|f|f|t|t
33833157|NCT01210378|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833158|NCT02851849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833159|NCT04735783|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Due to the obvious differences between the three breakfasts meals (viscous, jelly-like placebo breakfast, typical whole-food breakfast, water-only control), participants will be aware that the three trials are different. However, they will not be told that the placebo breakfast contains nearly no energy, and therefore, are blinded to this aspect of the study.|The study design is a randomised, controlled, crossover design in which participants undertake three dietary conditions in a randomised order with at least a four day period in between trials.|t|f|f|f
33833160|NCT00485550|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833161|NCT03834389|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33833162|NCT04731350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled trial|t|f|f|f
33833163|NCT04074447|||CASE_ONLY||PROSPECTIVE|||||||
33833164|NCT06141200|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A Phase III, Randomized, Parallel, Double-Dummy, Active-Controlled Clinical Trial|t|t|t|t
33833165|NCT05574777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833166|NCT04380428|||COHORT||CROSS_SECTIONAL|||||||
34144051|NCT04414124|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144052|NCT01300819|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144053|NCT02421913|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34144054|NCT06348914|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34144055|NCT06061289|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144056|NCT05210868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144057|NCT05226091|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144058|NCT00579995|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144059|NCT04896203|||COHORT||PROSPECTIVE|||||||
34144060|NCT01376570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144061|NCT01763320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144062|NCT05545202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The subject, trial personnel, and Pharmacosmos personnel will be blinded to the CPA. Blinding will be obtained by shielding the blinded trial personnel from seeing the preparation of the CPA and having unblinded personnel not involved in any trial assessments (efficacy or safety) responsible for randomization, preparation, and accountability of the CPA. The CPA will not be labelled in a way that would reveal the content of the CPA for the blinded personnel or the subject. CPA accountability will be monitored by an unblinded CRA.||t|t|t|t
34144063|NCT02130336|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34144064|NCT05863923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144065|NCT03693313|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Wait List Trial||||
34144066|NCT01170598|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144067|NCT01134406|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144068|NCT04128982|||COHORT||PROSPECTIVE|||||||
34144069|NCT04690920|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144070|NCT06455410|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144071|NCT00051220|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34144072|NCT00973882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144073|NCT06105086|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34144074|NCT04465877|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144075|NCT00024310||||TREATMENT||||||||
34144076|NCT05173415|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||A prospective, randomized multi-centre trial||||
34144077|NCT01852825|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34144078|NCT06437886|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144079|NCT00504790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144080|NCT00933244|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144081|NCT04863248|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144082|NCT04580745|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||t|f|t|f
34144083|NCT04808206|||CASE_ONLY||PROSPECTIVE|||||||
34144084|NCT03209648|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144085|NCT02836873|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144086|NCT02649192|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144087|NCT00027105|||COHORT||PROSPECTIVE|||||||
34144088|NCT04598126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144089|NCT04588155|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144090|NCT06120595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144091|NCT03783104|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double-blinded|A total of 720 recruited mothers across India and Nepal will be randomly allocated to 2 equal groups (360 each). Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum. Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.|t|t|t|t
34144092|NCT02845778|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34144093|NCT05528900|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144094|NCT04175925|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34144095|NCT01369082|||COHORT||PROSPECTIVE|||||||
34144096|NCT02118597|||CASE_ONLY||PROSPECTIVE|||||||
34144097|NCT02977845|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In the current study, based on nature of the intervention, blinding was not feasible with researcher, statistician, Qigong master who were responsible for recruitment of subject, randomization, deliver the intervention. However, the investigators who collect the outcome information were blinded to the allocation sequence.|The design of this study was a randomized controlled trial (RCT) with two parallel groups in a 1:1 allocation ratio, allocation concealment, and assessor blinding.|f|f|f|t
33833167|NCT04923945|NA|SINGLE_GROUP||TREATMENT||NONE||locally advanced or metastatic NSCLC patients with MET exon 14 mutations without EGFR, ALK and ROS1 sensitive mutations who had disease progression or intolerable toxicity after previous therapy with platinum-based chemotherapeutic regimen and are treatment-naïve to c-MET therapy OR who did not receive any drug therapy for advanced tumors previously.||||
33833168|NCT01628692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833169|NCT03190512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833170|NCT01971281|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833171|NCT04042818|||COHORT||CROSS_SECTIONAL|||||||
33833172|NCT01043198|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833173|NCT06164015|||CASE_CONTROL||PROSPECTIVE|||||||
34144098|NCT03342040|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participant and assessors are masked|Prospective double blinded balanced allocation, randomized clinical trial|t|f|f|t
34144099|NCT04391595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144100|NCT03423290|||COHORT||PROSPECTIVE|||||||
34144101|NCT00917072|RANDOMIZED|SINGLE_GROUP||OTHER||SINGLE|||f|f|f|t
34144102|NCT04848714|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144103|NCT02921828|||CASE_ONLY||PROSPECTIVE|||||||
34144104|NCT04437719|NA|SINGLE_GROUP||OTHER||NONE||As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.||||
34144105|NCT01169688|RANDOMIZED|PARALLEL||||NONE||||||
34144106|NCT04626089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Parallel assignment experimental and placebo tablets will have same physical appearance and medicine box will be identified by kit number|Experimental group: Metformin glycinate 620 mg bid (PO) plus standard treatment for 14 days. Control Group: Placebo bid (PO) plus standard treatment for 14 days plus|t|t|t|t
34144107|NCT00303446|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144108|NCT02372552|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144109|NCT02047201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144110|NCT03234439|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Double-arm, waitlist control trail with 1:1 randomization|f|f|t|f
34144111|NCT01447004|||CASE_CONTROL||PROSPECTIVE|||||||
34144112|NCT04053751|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||Randomized controlled crossover trial. There are two arms. open and closed suctioning systems (OSS vs CSS). the patients are randomized. They are monitorized for two days. If a patient is suctioned via OSS in the first enrolled day, the same patient is suctioned via CSS in the second enrolled day. For CSS, vice versa.||||
34144113|NCT00354107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144114|NCT00476489|||CASE_CONTROL||OTHER|||||||
34144115|NCT01839019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144116|NCT05837949|NA|SINGLE_GROUP||PREVENTION||NONE||All participants will be given the MS FIT tool intervention||||
34144117|NCT03243578|||COHORT||PROSPECTIVE|||||||
34144118|NCT02750865|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144119|NCT03876691|||CASE_CONTROL||PROSPECTIVE|||||||
34144120|NCT04589351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|To ensure blinding to the trial drug, the tablets containing either ezetimibe or placebo are incapsulated with gelatin and thus identical in appearance (size, color and shape).|"This study consists of a cross-sectional study and an intervention trial. The latter is a single-center, randomized, double-blinded, placebo-controlled and parallel trial in participants with T2D and non-severe diabetic kidney disease.~Trial participants (n=60), by virtue of their baseline examinations (e.g. MR-examinations), also participate in the cross-sectional part of this study where they constitute one of three groups. The other two groups contain controls (n=30) and individuals with T2D and no diabetic kidney disease (n=30)."|t|t|t|t
34144121|NCT03327376|||COHORT||PROSPECTIVE|||||||
34144122|NCT00979368|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34144123|NCT00440856|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34144124|NCT03352583|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34144125|NCT06496438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34144126|NCT00123773|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144127|NCT02523768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833174|NCT06277180|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144128|NCT06594796|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group.||f|f|f|t
34144129|NCT01678352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144130|NCT00966719|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34144131|NCT00739180|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144132|NCT03739957|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34144133|NCT05945056|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144134|NCT04418336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144135|NCT01016314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144136|NCT02116114|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34144137|NCT05295147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34144138|NCT05581095|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Randomized Controlled Trial of mindful eating self-help book (group 1) vs. mindful eating self-help book + companion smartphone app (group 2)|t|f|t|f
34144139|NCT02016937|||CASE_CONTROL||PROSPECTIVE|||||||
34144140|NCT03283969|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The test powders where pre-packaged by the study sponsor and sent to the investigators coded.|Randomized, double-blind, controlled crossover dietary intervention trial|t|t|t|f
34144141|NCT04774471|||OTHER||PROSPECTIVE|||||||
34144142|NCT01958021|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144143|NCT00155623|||DEFINED_POPULATION||PROSPECTIVE|||||||
33833175|NCT01861977|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833176|NCT00944229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833177|NCT00603811|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833178|NCT01403649|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34144144|NCT03843944|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144145|NCT01012466|||COHORT||PROSPECTIVE|||||||
34144146|NCT01410292|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34144147|NCT00987896|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144148|NCT01680692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144149|NCT01813838|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144150|NCT02621398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144151|NCT03749096|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomized double-blind||t|t|t|t
34144152|NCT04656795|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Open Label||||
34144153|NCT06235762|RANDOMIZED|PARALLEL||TREATMENT||NONE||Ranzomized Clinical Trial||||
34144154|NCT04287803|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study to inform the multicentred prehospital prospective observational step wedge design trial||||
34144155|NCT02361424|NON_RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34144156|NCT00830713|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144157|NCT00676624|||COHORT||PROSPECTIVE|||||||
34144158|NCT00047333|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144159|NCT02103374|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34144160|NCT02996799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34144161|NCT01787318|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144162|NCT03691350|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144163|NCT05357963|||COHORT||PROSPECTIVE|||||||
34144164|NCT04584346|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144165|NCT04646161|||CASE_CONTROL||PROSPECTIVE|||||||
34144166|NCT04026360|||COHORT||PROSPECTIVE|||||||
34144167|NCT02024022|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34144168|NCT00453947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144169|NCT05655143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144170|NCT01812356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144171|NCT02088593|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34144172|NCT05123521|||CASE_ONLY||PROSPECTIVE|||||||
34144173|NCT04433559|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144174|NCT05744375|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144175|NCT04634708|||COHORT||PROSPECTIVE|||||||
34144176|NCT04750980|||COHORT||PROSPECTIVE|||||||
34144177|NCT00511056|||COHORT||CROSS_SECTIONAL|||||||
34144178|NCT03705780|NON_RANDOMIZED|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34144179|NCT02448979|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144180|NCT04542460|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Investigator conceived, initiated and driven 1:1 randomized open label clinical trial||||
34144181|NCT01090934|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144182|NCT03875807|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients, assessors, and data analysts will be blinded in regards to treatment status at all times. Surgeons cannot be blinded given the nature of the intervention. We do not anticipate any circumstance in which unmasking of the data management team, or data analysts will be required, or permissible|A Multicentre, Pragmatic, Patient and Assessor Blinded, Stratified, Two-arm Parallel (1:1) Group Superiority Trial|t|f|f|t
34144183|NCT06375642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144184|NCT05185895|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144185|NCT00283972|||DEFINED_POPULATION||PROSPECTIVE|||||||
34144186|NCT04841161|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34144187|NCT00552630|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144188|NCT00871039|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34144189|NCT02582281|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34144190|NCT06196398|||COHORT||PROSPECTIVE|||||||
34144191|NCT01174017|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144192|NCT06472869|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label single-arm pilot clinical trial||||
34144193|NCT01715350|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144194|NCT06037850|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144195|NCT03990207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144196|NCT01424995|||CASE_ONLY||PROSPECTIVE|||||||
34144197|NCT05899231|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144198|NCT05743075|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144199|NCT00174174|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34144200|NCT04103541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34144201|NCT02387164|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144202|NCT03671408|||CASE_ONLY||CROSS_SECTIONAL|||||||
34144203|NCT03383783|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
34144204|NCT03110653|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patients, the anesthesiologist and an external observer will be blinded.||t|f|t|t
34144205|NCT01202604|||CASE_ONLY||PROSPECTIVE|||||||
34144206|NCT05550623|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinding Participants and staff not attendant in the room will be blinded. The use of tourniquet will not be visible in the patient records but recorded directly in the REDCap Database. A standard phrase to describe the surgical procedure will be used in the patient record. Deviations and adverse events will be described. Participants will be able to be informed by the procedure after 6 months.|Randomized, prospective, two-arm, blinded trial. Superiority-design Allocation 1:1 Eligible patients will be randomized to transfemoral surgery with or without the application of a sterile pneumatic tourniquet.|t|f|f|f
34144207|NCT05479435|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE|We will mask only person who will do statistical analysis.|Randomized control trial with statistic analyst blind||||
34144208|NCT00637637|RANDOMIZED|||TREATMENT||||||||
34144209|NCT03481803|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Sequential Assignment Eligible patients will be receiving increased doses from lower, middle to upper range of study medication MS1819-SD||||
34144210|NCT00304824|||CASE_ONLY||PROSPECTIVE|||||||
34144211|NCT04367103|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34144212|NCT02257177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144213|NCT05918900|||OTHER||PROSPECTIVE|||||||
34144214|NCT01633515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144215|NCT00410826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144216|NCT01884493|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34144217|NCT01261169|||COHORT||PROSPECTIVE|||||||
34144218|NCT03001115|||COHORT||PROSPECTIVE|||||||
34144219|NCT01256463|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144220|NCT03223077|||CASE_ONLY||PROSPECTIVE|||||||
34144221|NCT00570934|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34144222|NCT05799001|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34144223|NCT02031224|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144224|NCT02387736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144225|NCT04999865|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34144226|NCT02579694|||COHORT||RETROSPECTIVE|||||||
34144227|NCT04214431|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34144228|NCT03578484|||COHORT||PROSPECTIVE|||||||
34144229|NCT04384380|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study will employ an open-label parallel design, to evaluate the efficacy and safety between hydroxychloroquine sulfate (plaquenil) and controlled standard of care treatment. The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7. All of the enrolled subjects will receive standard of care. The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.||||
34144230|NCT03372551|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Both the participants and study investigators will be masked to the randomization schedule of the contact lenses used.|This will be a, prospective, double-masked, randomized, bilateral, 1 week cross-over, dispensing study|t|f|t|f
34144231|NCT05938920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144232|NCT05787132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This will be single blinded study. The data will be coded and the analyst will also be blinded.||t|f|f|f
34144233|NCT00794365|||COHORT||PROSPECTIVE|||||||
34144234|NCT00919867|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34144235|NCT00852527|||COHORT||PROSPECTIVE|||||||
34144236|NCT02248207|||COHORT||PROSPECTIVE|||||||
34144237|NCT01882517|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144238|NCT04871802|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144239|NCT00662376|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34144240|NCT01738113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34144241|NCT05737277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144242|NCT05026372|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||SINGLE|Participants will not be informed of their group condition, i.e., MC, MG, MV, or AC.|The intervention conditions are divided into Mindfulness + Compassion (MC), Mindfulness + Gratitude (MG), Mindfulness + Value-Based Living (MV), and Attention Control (AC)) on Mindfulness (FFMQ).|t|f|f|f
34144243|NCT06396715|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be assigned to the 30-minute tDCS with mCIMT or 20-minute tDCS with mCIMT group using block randomization. When the informed consent is signed by the patient, the recruiter will notify the person in charge of randomization (the one who has no relationship with the patient or their medical data) to assign the patient to one of the two groups (called group 1) or group 2), without knowing which corresponds to 30 or 20 minutes of stimulation. Once the group is known, the therapy coordinator will be informed, and make a note of the assigned group (1 or 2) on the patient's record sheet. The patient, the therapists and the evaluators will be kept blinded since they will not know the duration of the stimulation of group 1 or 2.|"This methodological design is carried out following the guidelines of the CONSORT 2010 guidelines for clinical trials.~Study type and design: a two-arm, multicenter, double-blind randomized clinical trial (RCT) is proposed.~Population: adults with a diagnosis of subacute unihemispheric stroke with motor and functional deficit of the upper limb who attend the Hospital Clínico de la Universidad de Chile (HCUCH) and the Hospital San José (HSJ)."|t|t|f|f
34144244|NCT05044104|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144245|NCT00342771|||CASE_CONTROL||RETROSPECTIVE|||||||
34144246|NCT04922931|||COHORT||PROSPECTIVE|||||||
34144247|NCT00609791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144248|NCT02787590|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144249|NCT00871546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144250|NCT00088790||||TREATMENT||||||||
34144251|NCT00205842|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34144252|NCT00808457|||||PROSPECTIVE|||||||
34144253|NCT01440517|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144254|NCT03466138|||CASE_ONLY||RETROSPECTIVE|||||||
34144255|NCT03836326|RANDOMIZED|CROSSOVER||PREVENTION||NONE|A prospective randomized block clinical trial will be conducted. Infants will be randomized into experimental (PASI program) and control (standard care program) groups using a block size of four per arm, where the first set of four participants will be in the experimental group and once they have completed the intervention, the subsequent set of four participants will be in the control group. A randomized block design was selected because the treatment assignment cannot be masked. The block randomization procedure will reduce the potential for contamination between groups.|Randomized clinical trail||||
34144256|NCT03237130|||COHORT||PROSPECTIVE|||||||
34144257|NCT06051747|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment group : 1 patient with bioprinted tracheal reconstruction||||
34144258|NCT02393846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144259|NCT00534157|||DEFINED_POPULATION||OTHER|||||||
34144260|NCT05618886|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A research assistant(assessor) will use a Samsung tablet with open data kit software to collect and record baseline questionnaire data containing socio-demographic variables and questions related to knowledge of UI (describe UI, the causes and treatment options and how participant's learnt about it), PFM and experience with PFMT of all the subjects. Assessor will not have any idea about the participant's in the treatment group and the control group. Assessor will be assessing through the patient reported questionnaire tool.|The participants will be randomize into either education only (group A) or education plus PFMT (group B) 1:1 by concealed allocation (sealed envelope with A and B). After allocation, the participants will stay in their assigned intervention group for 1 year|f|f|f|t
34144261|NCT02805400|NA|SINGLE_GROUP||||NONE||||||
34144262|NCT02144545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144263|NCT06608381|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Random group assignment during operation~* Control group : Total omentectomy~* Experimental group : Partial omentectomy Other surgical procedures are the same as usual in both groups."||||
34144264|NCT00220493|RANDOMIZED|PARALLEL||ECT||DOUBLE||||||
34144265|NCT01442064|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144266|NCT01789983|||COHORT||PROSPECTIVE|||||||
34144267|NCT00499382|||CASE_ONLY||PROSPECTIVE|||||||
34144268|NCT04348175|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
34144269|NCT04490980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144270|NCT00020462||||TREATMENT||||||||
34144271|NCT04079543|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized (1:1) into one of the two groups: Strict NPO (NPO after midnight) or liberal NPO (clear liquids up to 2 hours prior to procedure).||||
34144272|NCT02075632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144273|NCT01291693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144274|NCT02677636|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144275|NCT02262819|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144276|NCT02170363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144277|NCT03554772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144278|NCT05187754|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|t|f|t
34144279|NCT05314192|||CASE_ONLY||CROSS_SECTIONAL|||||||
34144280|NCT05995223|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34144281|NCT00200538|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144282|NCT02168972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144283|NCT00143780|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34144284|NCT03524287|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144285|NCT06115694|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144286|NCT03787810|||COHORT||PROSPECTIVE|||||||
34144287|NCT02104271|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144288|NCT03236168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837625|NCT02879383|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34144289|NCT02075047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144290|NCT06053957|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144291|NCT04461574|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||t|f|f|f
34144292|NCT05148416|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144293|NCT05411861|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|Separate blinded and unblinded study teams|Bunion Surgery|t|f|t|t
34144294|NCT03177447|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144295|NCT01093781|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144296|NCT01930552|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144297|NCT02986243|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144298|NCT01325090|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34144299|NCT00081315|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
34144300|NCT03379987|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144301|NCT04612842|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144302|NCT04159363|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34144303|NCT02793830|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144304|NCT00839865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144305|NCT00801476|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144306|NCT02262442|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34144307|NCT02523131|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144308|NCT00089986|RANDOMIZED|PARALLEL||TREATMENT||||||||
34144309|NCT02721121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144310|NCT05242354|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144311|NCT04978870|||COHORT||PROSPECTIVE|||||||
34144312|NCT05093920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144313|NCT01646619|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144314|NCT06607276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144315|NCT02539498|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144316|NCT06000631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144317|NCT04400084|||CASE_ONLY||PROSPECTIVE|||||||
34144318|NCT01811303|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34144319|NCT00099229|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144320|NCT00297973|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144321|NCT03024645|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34144322|NCT04024215|||COHORT||PROSPECTIVE|||||||
34144323|NCT01976858|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144324|NCT04609930|||COHORT||RETROSPECTIVE|||||||
34144325|NCT00906451|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144326|NCT01357876|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144327|NCT03655223|||COHORT||PROSPECTIVE|||||||
34144328|NCT02168738|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34144329|NCT00916812|||OTHER||PROSPECTIVE|||||||
34144330|NCT05203978|||COHORT||PROSPECTIVE|||||||
33837626|NCT04249570|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33837627|NCT01953445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837628|NCT04930497|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144331|NCT05597644|NA|SINGLE_GROUP||TREATMENT||NONE||Angioembolization of uterine artery by PVA particles||||
34144332|NCT01484834|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34144333|NCT03762616|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|Investigator performing the micro-ultrasound biopsy will be blinded to the MRI report, and the investigator performing the MRI targeted biopsy will be blinded to the micro-ultrasound images and targets.||f|f|t|f
34144334|NCT05891028|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144335|NCT03470129|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34144336|NCT05010941|||COHORT||PROSPECTIVE|||||||
34144337|NCT05030064|RANDOMIZED|PARALLEL||TREATMENT||NONE||It is planned to recruit UC patients with depression and voluntarily receive standard enterobacteria capsule or placebo treatment. A total of 54 cases will be completely randomized according to the random number table and randomly divided into 2 groups for intervention.||||
34144338|NCT03279523|||OTHER||PROSPECTIVE|||||||
34144339|NCT05146414|||COHORT||PROSPECTIVE|||||||
33837629|NCT04081077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837630|NCT01853501|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837631|NCT01495351|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144340|NCT05472077|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144341|NCT00183963|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144342|NCT02933567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144343|NCT05694910|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The patients and investigators knew which group they were assigned to. Only that outcome assessor did not know which patient was assigned to which group.||f|f|f|t
34144344|NCT02372708|||COHORT||PROSPECTIVE|||||||
34144345|NCT05625373|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized 1:1 unblinded to either receive vancomycin powder in the operating room or no vancomycin powder (no placebo utilized).||||
34144346|NCT05551676|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144347|NCT01192503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144348|NCT00650520|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34144349|NCT03034512|||COHORT||PROSPECTIVE|||||||
34144350|NCT06256354|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34144351|NCT01920633|||COHORT||PROSPECTIVE|||||||
34144352|NCT05273021|||CASE_ONLY||CROSS_SECTIONAL|||||||
34144353|NCT05765149|||COHORT||PROSPECTIVE|||||||
34144354|NCT03236012|NA|SINGLE_GROUP||TREATMENT||NONE|Open label|"For this study, subjects will be recruited from the amputee clinics held at the Salt Lake Veteran Affairs (VA) Medical Center or the University of Utah. Combined, these clinics serve approximately 500 patients and see approximately 75 new patients each year.~We plan to recruit a total of 25 subjects to this project from the two study sites. It is expected that we will enroll equal numbers from both the University of Utah and VA Medical Center."||||
34144355|NCT00000630|RANDOMIZED|||PREVENTION||||||||
34144356|NCT00420173|||COHORT||PROSPECTIVE|||||||
34144357|NCT05349292|||COHORT||PROSPECTIVE|||||||
34144358|NCT01144260|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144359|NCT05913102|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel assignment split lesion study|t|f|f|t
34144360|NCT03396055|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144361|NCT04881851|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blinded, three-armed RCT|t|t|t|f
34144362|NCT01471912|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144363|NCT04206553|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144364|NCT04151251|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Trained research assistants will introduce the interventions to patients, leaving the outcomes assessor and investigator only able to see results. The care provider is not part of the study decision, as the study does not affect their healthcare.||f|t|t|t
34144365|NCT00099294|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144366|NCT05716412|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34144367|NCT00357656|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144368|NCT03175484|||COHORT||PROSPECTIVE|||||||
34144369|NCT03634371|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34144370|NCT04801888|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144371|NCT02001896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144372|NCT03813004|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144373|NCT04081415|||COHORT||PROSPECTIVE|||||||
34144374|NCT00407004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144375|NCT02194920|||COHORT||PROSPECTIVE|||||||
34144376|NCT04503590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144377|NCT05932121|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144378|NCT00689000|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144379|NCT03061786|||COHORT||RETROSPECTIVE|||||||
34144380|NCT04351360|||OTHER||PROSPECTIVE|||||||
34144381|NCT00619346|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34144382|NCT05027620|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility study||||
34144383|NCT02617940|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34144384|NCT02011490|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144385|NCT00550433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144386|NCT06414421|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This study was conducted as a two-group randomized controlled intervention study to determine the effect of TENS application on pain, complications and comfort in patients undergoing transrectal ultrasound-guided prostate biopsy (TRUSG-PBx).||||
34144387|NCT06378645|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The authorized study nurse will hand the upcoming envelope with the treatment allocation to the anesthesiologist. The patient and the urologists (who is measuring the outcome) will not know which form of general anesthesia will be performed. Herewith, blankets in the operating room will hide installations used by the anesthesiologists to prevent the urologists witnessing the assigned narcosis form. Before the surgical sign-out, while still scrubbed in and with the patient under anesthesia, the anesthesiologists will ask the urologists about the outcome questionnaire. Together, they will fill in the paper case report form (CRF).||t|f|t|t
34144388|NCT02680574|RANDOMIZED|PARALLEL||TREATMENT||NONE|Sponsor was blinded during the study|||||
34144389|NCT00533650|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144390|NCT00000504|RANDOMIZED|||TREATMENT||DOUBLE||||||
34144391|NCT01122537|||COHORT||PROSPECTIVE|||||||
34144392|NCT02226198|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34144393|NCT04851821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34144394|NCT04539522|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144395|NCT02270762|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144396|NCT00808535|||CASE_CONTROL||PROSPECTIVE|||||||
34144397|NCT00912080|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34144398|NCT05507632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144399|NCT03254277|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144400|NCT03159507|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Prospective, single arm trial where each participant receives a personalized dose||||
34144401|NCT00791557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144402|NCT04218162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144403|NCT05302258|||CASE_CONTROL||PROSPECTIVE|||||||
34144404|NCT02010736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144405|NCT04369703|||COHORT||PROSPECTIVE|||||||
34144406|NCT02745847|NA|SINGLE_GROUP||TREATMENT||NONE||Re-irradiation with SBRT||||
34144407|NCT04914754|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144408|NCT04194918|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34144409|NCT03270267|||CASE_ONLY||PROSPECTIVE|||||||
34144410|NCT03371173|NA|SINGLE_GROUP||TREATMENT||NONE||Explorative, open-label, uncontrolled monocenter study||||
34144411|NCT01289223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144412|NCT05529355|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144413|NCT05962034|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33833179|NCT04182347|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||"A ToolKit will be created to support the engagement of people with IDD in the development of research. The toolkit will be the first of its kind to provide an accessible, structured process with the necessary training for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."||||
33833180|NCT00513747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833181|NCT00974389||||TREATMENT||NONE||||||
33833182|NCT03324971|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective cohort study .The aim of this study to recruit a cohort of diabetic patients,eliminate unnecessary medications,aiming at improving adherence to anti-diabetic medications.||||
33833183|NCT03659331|NA|SINGLE_GROUP||TREATMENT||NONE||A model based on the assumption that at least 50 subjects will be recruited, and assuming that 50% of the patients will have a significant reduction of liver enzymes||||
33833184|NCT01684618|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33833185|NCT05456347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144414|NCT03920267|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Participants who successfully complete the protocol-required treatment period of the Phase 2 SLE study (NCT03252587) will be offered the opportunity to continue this study.|t|t|t|t
34144415|NCT01473095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144416|NCT05448404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging completed within one week in the same patients.||||
34144417|NCT03614559|||COHORT||RETROSPECTIVE|||||||
34144418|NCT02262104|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144419|NCT03538184|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34144420|NCT06326749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144421|NCT05378932|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144422|NCT02251717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144423|NCT05669586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144424|NCT00922818|||COHORT||PROSPECTIVE|||||||
34144425|NCT01617135|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34144426|NCT05718193|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34144427|NCT05551975|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34144428|NCT04178993|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34144429|NCT01827813|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144430|NCT03110445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144431|NCT04504890|||COHORT||PROSPECTIVE|||||||
34144432|NCT05786339|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34144433|NCT00775112|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144434|NCT00137696|RANDOMIZED|SINGLE_GROUP||OTHER||DOUBLE|||t|f|t|f
34144435|NCT05255042|||OTHER||PROSPECTIVE|||||||
34144436|NCT02719145|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144437|NCT00321997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144438|NCT05705752|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34144439|NCT01243034|||CASE_ONLY||PROSPECTIVE|||||||
34144440|NCT04840563|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34144441|NCT02252601|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
34144442|NCT02982018|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144443|NCT06183372|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Double-blind|Between- and within-groups (mixed) model|t|f|t|t
34144444|NCT02146677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34144445|NCT06465264|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Double-blind treatment (Week 4\~Week 16):~Open-label period(Week 16\~ Week 56):"||t|t|t|t
34144446|NCT01519050|||COHORT||PROSPECTIVE|||||||
34144447|NCT05206071|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144448|NCT01650714|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144449|NCT03515941|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144450|NCT01428336|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Every participant underwent the four interventional tests in random sequence||||
34144451|NCT05736289|||COHORT||PROSPECTIVE|||||||
34144452|NCT00085982|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144453|NCT02585648|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34144454|NCT03223467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients in this study underwent either gastric bypass, gastric sleeve or biliopancreatic diversion. Some patient choose not to undergo bariatric surgery and function as a control arm.||||
34144455|NCT02557113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144456|NCT02453126|||CASE_CONTROL||PROSPECTIVE|||||||
34144457|NCT00431951|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34144458|NCT00911092|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34144459|NCT01342744|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34144460|NCT01711281|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144461|NCT00716898|||CASE_CONTROL||PROSPECTIVE|||||||
34144462|NCT02312765|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144463|NCT04304183|||COHORT||PROSPECTIVE|||||||
34144464|NCT06010381|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients were subdivided into two groups, fifteen patients in each group. Group A received the muscle energy technique and group B received Maitland's mobilization.||||
34144465|NCT01739933|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34144466|NCT04014543|NA|SINGLE_GROUP||OTHER||NONE||caregivers and children||||
34144467|NCT01243684|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144468|NCT00737594|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144469|NCT02757443|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144470|NCT04831528|||COHORT||PROSPECTIVE|||||||
34144471|NCT04656106|||COHORT||RETROSPECTIVE|||||||
34144472|NCT03954847|||COHORT||RETROSPECTIVE|||||||
34144473|NCT03417596|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144474|NCT04469231|NA|SINGLE_GROUP||TREATMENT||NONE||A multicenter, prospective, non-randomized, historically controlled study.||||
34144475|NCT01047800|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34144476|NCT06023992|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144477|NCT01041443|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144478|NCT01767077|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34144479|NCT04024904|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Patients were coached by a separate practitioner aside from the regional anaesthesiologist performing the regional block. The anesthetists in charge of the patient were not blinded, but data collection and statistical analysis were blinded.|"The Virtual Hypnosis Reality Distraction (VHRD) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes.~In the group VHRD 1 and 2 we use the program throughout the regional block. The time choose for the VHRD program is 15 or 30 min depending of the time required for the regional procedure.~In the group VHRD 2, we use the program of 5 min and we applied the device before the regional procedure."|f|f|f|t
34144480|NCT00221624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144481|NCT02351349|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||allocated intervention to those who were willing to complete the exercise program due to the difficulty for recruitment, this study was changed to a feasibility study||||
34144482|NCT00098722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144483|NCT04344353|||COHORT||PROSPECTIVE|||||||
34144484|NCT04734821|NA|SINGLE_GROUP||OTHER||NONE||||||
34144485|NCT03958760|||OTHER||RETROSPECTIVE|||||||
34144486|NCT00711490|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144487|NCT03263312|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144488|NCT02333149|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144489|NCT01707589|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144490|NCT06422858|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34144491|NCT00293904|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144492|NCT06008496|||COHORT||PROSPECTIVE|||||||
34144493|NCT04373447|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144494|NCT01397682|||CASE_ONLY||OTHER|||||||
34144495|NCT05819073|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34144496|NCT00661024|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34144497|NCT00016367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144498|NCT05942378|NA|SEQUENTIAL||TREATMENT||NONE||||||
34144499|NCT00706329|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144500|NCT02120495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144501|NCT04517786|NA|SINGLE_GROUP||TREATMENT||NONE||MINIject SO627||||
34144502|NCT05105893|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144503|NCT04276688|RANDOMIZED|PARALLEL||TREATMENT||NONE||open-label randomised controlled trial||||
34144504|NCT01829282|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144505|NCT02849782|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144506|NCT01637389|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34144507|NCT03816280|||CASE_CONTROL||PROSPECTIVE|||||||
34144508|NCT02161276|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34144509|NCT05256784|||FAMILY_BASED||RETROSPECTIVE|||||||
34144510|NCT01414764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144511|NCT05228977|||OTHER||CROSS_SECTIONAL|||||||
34144512|NCT04133896|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144513|NCT00376805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144514|NCT00868218|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
34144515|NCT06511297|||COHORT||PROSPECTIVE|||||||
34144516|NCT04668235|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144517|NCT02916407|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34144518|NCT04883840|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
34144519|NCT03889236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The placebo and food supplement groups are double blinded.|Patients are randomized into the diet group, food supplement group or placebo group. The placebo and foodsupplement groups are double blinded.|t|f|t|f
34144520|NCT04883528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144521|NCT03703310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|As a double-blinded study, the Investigators, the site staff, Sponsor, and the Clinical Monitor(s) will be blinded to the treatment assigned to individual participants.|Participants will be randomized 1:1 to receive Patidegib Topical Gel, 2%, or Vehicle (IP)|t|t|t|t
34144522|NCT02244177|||COHORT||PROSPECTIVE|||||||
34144523|NCT04720768|NA|SEQUENTIAL||TREATMENT||NONE||This is an open-label, phase IB, non-randomised study consisting of a dose escalation phase and expansion phase||||
34144524|NCT05396729|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The stimulator is put in an opaque box||f|f|t|t
34144525|NCT00219882|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144526|NCT04698135|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144527|NCT00334906|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144528|NCT03447093|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144529|NCT04441164|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"* Step 1: 40 patients (20 in the Virtual Reality group and 20 in the Relaxation group)~* Step 2: Estimated response rate of approximately 300 caregivers and 50 patients~* Step 3: 40 patients (20 in the Virtual Reality group and 20 in the Relaxation group)~* Step 4: 40 patients (20 in the group Performing Virtual Actions and 20 in the group Observing Virtual Actions)~* Step 5: 40 patients (20 in the group with Haptic stimulation, 20 in the group without Haptic stimulation"||||
34144530|NCT00203112|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144531|NCT05267132|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be told that the investigators are studying the daily lives of teens. They will not be informed of the other arms of the experiment.|120 participants will randomly be assigned to one of three conditions. Participants will complete a 4-week intervention. All outcomes will be measured before and after the intervention, and some psychological measures will be collected weekly throughout the intervention.|t|f|f|f
34144532|NCT03483870|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The trial will be planned that neither the doctors (investigator) nor the parturients will be aware of the group allocation. The study drugs will be prepared by an anesthesiologist not involved in performing the intrathecal anesthesia, patient care or in data collection.|comparison of the effect of intravenous granisetron with the effect of using placebo on morphine induced pruritus in parturients undergoing elective cesarean section under spinal anesthesia.|t|t|t|t
34144533|NCT06185634|RANDOMIZED|CROSSOVER||TREATMENT||NONE|In this study it will not be possible to blind the experimenters and participants. Blinding will be impossible for the experimenters, as they will provide the food plan with the dietary intervention. Blinding will also not be possible for the participants, who will have to eat pasta only at dinner for 3 months and only at lunch for the same period of time.|The experimental study will be a randomised controlled trial and will involve 2 phases of nutritional intervention.||||
34144534|NCT03282773|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144535|NCT04333940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34144536|NCT04000334|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144537|NCT01046227|||COHORT||PROSPECTIVE|||||||
34144538|NCT01768104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144539|NCT01341301|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144540|NCT01098877|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34144541|NCT00463463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144542|NCT00490139|RANDOMIZED|||TREATMENT||NONE||||||
34144543|NCT03529097|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144544|NCT00580125|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144545|NCT00821249|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144546|NCT04054492|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34144547|NCT01130857|||CASE_ONLY|||||||||
34144548|NCT01485380|NA|SINGLE_GROUP||OTHER||NONE||||||
34144549|NCT00835809|||COHORT||PROSPECTIVE|||||||
34144550|NCT06138444|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Male or female received a single oral dose of functional beverages from submerged fermentation of Cordyceps militaris (FCM) or placebo.|t|t|t|t
34144551|NCT02358044|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144552|NCT03224403|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Post-operative dental pain following third molar extraction.|t|t|t|t
34144553|NCT01661998|||CASE_CONTROL||PROSPECTIVE|||||||
34144554|NCT00050973|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144555|NCT05993273|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144556|NCT03963089|NA|SINGLE_GROUP||SCREENING||NONE||||||
34144557|NCT03286777|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34144558|NCT01933126|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144559|NCT01548976|||CASE_ONLY||CROSS_SECTIONAL|||||||
34144560|NCT01768156|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144561|NCT02670798|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34144562|NCT03887065|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34144563|NCT02102542|||||PROSPECTIVE|||||||
34144564|NCT02332772|||COHORT||RETROSPECTIVE|||||||
34144565|NCT04575818|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||QUADRUPLE||Part 1 (SAD) is randomized, double-blind, placebo-controlled; Part 2 (FE and rBA) is randomized, open-label.|t|t|t|t
34144566|NCT01416441|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144567|NCT00837876|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144568|NCT03776773|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Prospective, open study comparing sleep quality in 2 different groups: AR patients and patients without AR during the pollen season and outside the pollen season.||||
34144569|NCT06456125|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144570|NCT02128243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144571|NCT03023696|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144572|NCT04562597|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||"PHASE I. First 20 subjects (4 arms): We will initially randomize 5 patients to each dose group (placebo, 50, 100, and 150 mg/kg) to estimate the dose response curve and to identify the optimal dose. After enrollment of the first 20 patients, the study will undergo review by the study team and statistician.~PHASE II: (2 arms) If the dose response curve is adequate and the optimal dose identified, 15 additional participants will be randomized to placebo and 15 to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.~Primary and secondary outcomes will be evaluated only for the placebo and optimal NAC groups."|t|t|t|f
34144573|NCT01994863|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34144574|NCT04039607|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144575|NCT00413374|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144576|NCT06521073|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144577|NCT02441348|||OTHER||PROSPECTIVE|||||||
34144578|NCT01444586|||CASE_CONTROL||PROSPECTIVE|||||||
34144579|NCT01667146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144580|NCT04859257|||COHORT||PROSPECTIVE|||||||
34144581|NCT04542096|||COHORT||PROSPECTIVE|||||||
34144582|NCT03523273|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34144583|NCT05564884|||OTHER||PROSPECTIVE|||||||
34144584|NCT02196415|||CASE_ONLY||PROSPECTIVE|||||||
34144585|NCT01611051|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144586|NCT03990103|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144587|NCT05258084|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34144588|NCT02650271|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34144589|NCT02635334|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34144590|NCT01503996|||COHORT||PROSPECTIVE|||||||
34144591|NCT02956304|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|f|t
34144592|NCT01188148|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144593|NCT03467490|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144594|NCT04161378|||COHORT||PROSPECTIVE|||||||
34144595|NCT00751283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144596|NCT03582813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research interviewers were blinded to study condition|Self-directed care is a model of service delivery in which service recipients are allocated a individual budget from which they purchase mental health and other services and material goods needed to help them recover from their mental illness and remain outside of restrictive settings such as hospitals..|f|f|f|t
34144597|NCT00685646|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144598|NCT02189499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144599|NCT06287619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a blinded study, with patients randomized to receive ferric derisomaltose (Monoferric) or placebo. Given that the products have different physical appearances, an unblinded research pharmacist will prepare the IMP then blind the appearance of the IMP for both the intervention group and control group by covering the IV bag and tubing with opaque plastic. All other clinicians, research coordinators, outcome assessors, and patients will remain blinded by using a generic product label in the patient chart and/or the electronic product name (i.e., POAM study drug dose 1 and dose 2, rather than specifying type of product used).|POAM is a multicenter, randomized, controlled, internal pilot trial, using a conventional, parallel group, two-armed design at 3 cardiac surgery centres in Canada.|t|t|t|t
34144600|NCT02885857|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144601|NCT02523625|||COHORT||PROSPECTIVE|||||||
34144602|NCT06225947|||COHORT||PROSPECTIVE|||||||
34144603|NCT00123266|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144604|NCT01497821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144605|NCT04773873|RANDOMIZED|PARALLEL||TREATMENT||NONE||90 RCT crowns will be allocated in three groups of ceramic materials (3 materials) and at two tooth locations (premolar and molar)||||
34144606|NCT03819608|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34144607|NCT02606435|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144608|NCT04952038|||COHORT||PROSPECTIVE|||||||
34144609|NCT01592617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144610|NCT02764554|||OTHER||PROSPECTIVE|||||||
34144611|NCT02536300|RANDOMIZED|PARALLEL||TREATMENT||NONE|Double-blind: Prior to protocol amendment 5; Open-label: Participants enrolled as of protocol amendment 5|As of protocol amendment 5, the Idelalisib 100 mg arm is closed to enrollment.||||
34144612|NCT03698175|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34144613|NCT02253056|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144614|NCT02905617|||COHORT||PROSPECTIVE|||||||
34144615|NCT00755469|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144616|NCT05892367|RANDOMIZED|PARALLEL||PREVENTION||NONE||Control group: compression bandage Study group: compression bandage and positioning splint||||
34144617|NCT01404013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144618|NCT05516849|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|All participants, clinicians, and staff will be blinded to the intervention groups. All patients with an adverse event will be reviewed by an onsite internal medicine affiliated with the study but not directly in recruitment or assessment of outcomes. Emergency unblinding will be allowed if participants present with an adverse event that in the opinion of consulting physicians is not explained by other causes AND knowing the treatment allocation will aid in the patient's management. The blind may be broken only with the permission of the Principal Investigator.|Participants will be randomly assigned in a 1:1 fashion to one of the two treatment arms using a minimal sufficient randomization technique in REDCAP.|t|f|t|f
34144619|NCT00165945|||CASE_ONLY||PROSPECTIVE|||||||
34144620|NCT03301064|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study is a phase 2 randomized controlled trial to determine the efficacy of a 3-session intervention that combines Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) to reduce unhealthy alcohol use. Participants (n=234) will be block randomized to either the MET/SBCM intervention or to a control condition that receives an educational brochure about alcohol and its associated risks. Both the MET/SBCM intervention and the control condition (i.e., the educational brochure) will be provided by promotores who work for the Providence Center for Community Improvement in Los Angeles, California. Participants will be Latinos served by Providence's outreach programs who exceed low-risk drinking guidelines.||||
34144621|NCT06508645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144622|NCT04579172|RANDOMIZED|PARALLEL||TREATMENT||NONE||- Randomized controlled trial (RCT) of pregnant women recruited from Department of Obstetrics and Gynecology Mansoura University Hospitals for elective termination of pregnancy||||
34144623|NCT01066780|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144624|NCT03007186|||COHORT||PROSPECTIVE|||||||
34144625|NCT02948907|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144626|NCT00970450|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34144627|NCT00273754|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144628|NCT04358744|||COHORT||PROSPECTIVE|||||||
34144629|NCT03622034|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34144630|NCT04907435|||COHORT||RETROSPECTIVE|||||||
34144631|NCT05785507|||CASE_CONTROL||PROSPECTIVE|||||||
34144632|NCT03765151|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33833186|NCT05742048|||CASE_ONLY||PROSPECTIVE|||||||
34144633|NCT04495868|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34144634|NCT03390894|||COHORT||OTHER|||||||
34144635|NCT00378937|RANDOMIZED|||SUPPORTIVE_CARE||NONE||||||
34144636|NCT01708447|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33833187|NCT01333111|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833188|NCT01582698|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833189|NCT01144390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833190|NCT06395623|||CASE_CONTROL||RETROSPECTIVE|||||||
33833191|NCT03545412|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837632|NCT05953168|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837633|NCT01146392|||||RETROSPECTIVE|||||||
33837634|NCT04513639|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144637|NCT00836459|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34144638|NCT04234087|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144639|NCT01305603|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34144640|NCT05008484|RANDOMIZED|PARALLEL||TREATMENT||NONE||There are two groups||||
34144641|NCT04783649|||COHORT||CROSS_SECTIONAL|||||||
34144642|NCT02953236|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34144643|NCT01530841|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144644|NCT05536622|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144645|NCT00740714|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144646|NCT04970160|||CASE_CROSSOVER||PROSPECTIVE|||||||
34144647|NCT02819960|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34144648|NCT02495064|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34144649|NCT05492760|||COHORT||RETROSPECTIVE|||||||
34144650|NCT01162174|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34144651|NCT03983772|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single-blind (subject)||t|f|f|f
34144652|NCT05873036|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34144653|NCT00162461|NA|SINGLE_GROUP||OTHER||NONE||||||
34144654|NCT00487643|||COHORT||PROSPECTIVE|||||||
34150963|NCT03134339|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participant and Investigator will not know nicotine dose or rate of infusion.|The effects of different IV nicotine delivery rates of (saline), 0.24, 0.048 and 0.024 mcg/kg/s), as a within-subject factor, on peak change in the intensity of subjective effects as measured by the DEQ, will be used as a measured of a reinforcing threshold.|t|f|t|f
34150964|NCT04023682|NA|SINGLE_GROUP||PREVENTION||NONE||Anesthesia providers will serve as their own controls||||
34144655|NCT05231200|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||A stepped-wedge cluster randomized trial (SW-CRT) design. Each of the 12 participating NICUs (10 Level II and 2 Level III) are considered clusters and will be randomized to transition to the intervention arm at one of three-time points over a period of four years. The first year will be a baseline period where no clusters are exposed to the intervention. Based on the randomization, four NICUs will transition to the intervention arm at the end of each year. All clusters will have transitioned to the intervention arm by the start of year four.||||
34144656|NCT01451229|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144657|NCT03728491|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|||f|f|t|t
34144658|NCT00319657|NA|SINGLE_GROUP||TREATMENT||NONE||Combined hematopoietic stem cell and kidney transplantation||||
34144659|NCT04214886|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells administration will follow a Phase I dose escalation design. Each Cohort will start will with the goal of accruing three participants to determine the dose limiting toxicities. Once the maximum tolerated dose is established, an expansion cohort will be treated to include a total of 6 participants.||||
34144660|NCT03597178|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34144661|NCT02607540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144662|NCT04217161|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144663|NCT00768404|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144664|NCT00003671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144665|NCT01945775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144666|NCT04266509|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34144667|NCT01237262|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144668|NCT02080572|||CASE_ONLY||CROSS_SECTIONAL|||||||
34144669|NCT04147299|||CASE_CONTROL||PROSPECTIVE|||||||
34144670|NCT06122883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144671|NCT01801176|NA|SINGLE_GROUP||||NONE||||||
34144672|NCT02576665|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144673|NCT00747344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144674|NCT01731353|||CASE_ONLY||PROSPECTIVE|||||||
34144675|NCT02716701|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34144676|NCT04174300|NA|SINGLE_GROUP||TREATMENT||NONE|Outcome measures will be randomized and anonymized|||||
34144677|NCT05221112|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||total 30 subjects will be randomly assigned to the experiment group (diagonal pattern training) and the control group (single plane training).Diagonal pattern training will be modified with proprioceptive neuromuscular facilitation technique's chopping and lifting pattern to create 10 movements.|f|f|f|t
34144678|NCT00732355|||CASE_CONTROL||PROSPECTIVE|||||||
34144679|NCT01083459|||FAMILY_BASED||CROSS_SECTIONAL|||||||
34144680|NCT02815436|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34144681|NCT02838615|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144682|NCT04423458|||COHORT||PROSPECTIVE|||||||
34144683|NCT05863234|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144684|NCT03900923|NA|SEQUENTIAL||TREATMENT||NONE||||||
34144685|NCT02852941|||COHORT||CROSS_SECTIONAL|||||||
34144686|NCT02175108|||COHORT||CROSS_SECTIONAL|||||||
34144687|NCT01430325|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|f|t|t
34144688|NCT04225442|NA|SINGLE_GROUP||OTHER||NONE||||||
34144689|NCT05443282|||CASE_CONTROL||PROSPECTIVE|||||||
34144690|NCT06305195|||COHORT||CROSS_SECTIONAL|||||||
34144691|NCT05556629|||OTHER||OTHER|||||||
34144692|NCT00252226|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34144693|NCT01609335|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144694|NCT00738764|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144695|NCT04693572|||COHORT||PROSPECTIVE|||||||
34144696|NCT01081301|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144697|NCT03184363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144698|NCT06284616|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|All patient receiving a JIA diagnose was offered to participate in JASP-1. The controls had received diagnose before the start of the study.|The study is a non-randomized intervention study with 2 groups receiving either a Support program (JASP-1) or standard care||||
34144699|NCT06450860|NA|SINGLE_GROUP||OTHER||NONE||||||
34144700|NCT04841525|||CASE_CONTROL||PROSPECTIVE|||||||
34144701|NCT00937118|||COHORT||RETROSPECTIVE|||||||
34144702|NCT01209663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144703|NCT04741191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144704|NCT04945265|||COHORT||PROSPECTIVE|||||||
34144705|NCT00659217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144706|NCT03116542|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144707|NCT05947630|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144708|NCT06323798|||CASE_CONTROL||RETROSPECTIVE|||||||
34144709|NCT06453603|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34144710|NCT03233022|RANDOMIZED|PARALLEL||OTHER||NONE||Users are randomly assigned between arms after completing baseline assessment and stay in that arm for the duration of the study.||||
34144711|NCT04902651|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144712|NCT00520013|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144713|NCT05991765|||OTHER||PROSPECTIVE|||||||
34144714|NCT04129905|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144715|NCT02741570|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144716|NCT01776671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144717|NCT04082910|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144718|NCT02725112|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34144719|NCT01811576|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144720|NCT00493519|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34144721|NCT02004145|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144722|NCT04911712|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||a Preliminary Study|f|t|t|t
34144723|NCT01382004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144724|NCT00033540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144725|NCT05639322|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34144726|NCT00227513|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144727|NCT06289088|RANDOMIZED|CROSSOVER||OTHER||SINGLE||Single group, crossover study|t|f|f|f
34144728|NCT03313284|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144729|NCT03950713|RANDOMIZED|PARALLEL||TREATMENT||NONE||A cluster randomized controlled trial was used to examine the effectiveness of the MBSR-T. The outcomes included HbA1c levels progression as the primary endpoint, and relocation stress, depression as secondary end points. Participants in the intervention group received the MBSR-T in addition to routine care. The control group received the routine care provided in facilities, including routine check-ups at diabetes clinics as necessary.||||
34144730|NCT00143533|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144731|NCT01390207|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144732|NCT05484817|||CASE_CONTROL||PROSPECTIVE|||||||
34144733|NCT00151034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144734|NCT02689076|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34144735|NCT01303146|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144736|NCT00819377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144737|NCT05289583|||CASE_ONLY||RETROSPECTIVE|||||||
34144738|NCT03251586|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34144739|NCT05729698|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144740|NCT00902148|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34144741|NCT00252460|||||PROSPECTIVE|||||||
34144742|NCT03346265|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||Subjects participated in a baseline assessment session (T0, before rehabilitative treatment), followed by random allocation to 8 weeks of rehabilitative treatments (A or B) (T1), followed by 1 month of inactivity wash out period. Following this wash-out period, patients who received treatment A switched to the treatment B and viceversa. A computerized randomization schedule was generated on the computer and held by an investigator not involved in subject recruitment or assessment.|t|t|t|f
34144743|NCT05257148|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"Open Label, two period study. Patients eligible from screening will enter the run-in period on the same day. Patients previously receiving Zofenopril or any other ACE-inhibitor will enter into the run-in period with Zofenopril monotherapy while patients receiving Nebivolol or any other Beta Blockers will enter into the Run-in period with Nebivolol monotherapy in a 1:1 ratio.~Only patients with uncontrolled BP (sitting Systolic Blood Pressure/Diastolic Blood Pressure\>130/80 mmHg) and whose adherence to the treatment ranges from 80% to 120%, will enter the assessment period to receive the extemporaneous combination of NEB and ZOF; while the patients with controlled sitting BP (Systolic Blood Pressure/Diastolic Blood Pressure ≤130/80 mmHg) and/or the patients who do not tolerate the treatment and patients with uncontrolled BP whose adherence to the therapy do not range from 80% to 120%, will be withdrawn from the study."||||
34144744|NCT03378583|||COHORT||PROSPECTIVE|||||||
34144745|NCT00378911|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144746|NCT00970983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144747|NCT03100721|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34144748|NCT03627312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144749|NCT04902521|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34144750|NCT01068782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144751|NCT01044316|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144752|NCT02480400|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34144753|NCT02408081|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34144754|NCT06520631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144755|NCT02609048|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144756|NCT02494843|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34144757|NCT03356977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144758|NCT04326036|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144759|NCT03368014|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144760|NCT04167215|NON_RANDOMIZED|PARALLEL||OTHER||NONE||assessment the role of autologous augmentation in management of different buttock deformity by using either perforator flaps or fat injection||||
34144761|NCT00575432|||COHORT||PROSPECTIVE|||||||
34144762|NCT03897946|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|The participants and care providers will not be masked, but the investigators and data analysts will be masked to group allocation.||f|f|t|t
34144763|NCT03000504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144764|NCT03871348|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144765|NCT00751309|||COHORT||PROSPECTIVE|||||||
34144766|NCT04545437|||COHORT||RETROSPECTIVE|||||||
34144767|NCT03790358|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|f|t
34144768|NCT03984149|||OTHER||RETROSPECTIVE|||||||
34144769|NCT03226756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144770|NCT01920763|||COHORT||PROSPECTIVE|||||||
34144771|NCT03221608|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34144772|NCT02688868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144773|NCT02608450|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144774|NCT00682591|||COHORT||PROSPECTIVE|||||||
34144775|NCT05471102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144776|NCT02060994|||COHORT||RETROSPECTIVE|||||||
34144777|NCT04373889|||COHORT||PROSPECTIVE|||||||
34144778|NCT05104619|||CASE_ONLY||PROSPECTIVE|||||||
34144779|NCT06313840|||OTHER||PROSPECTIVE|||||||
34144780|NCT02366767|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144781|NCT06128980|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized, non-inferiority study||||
34144782|NCT03723538|||COHORT||PROSPECTIVE|||||||
34144783|NCT03481920|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144784|NCT00033709||||TREATMENT||||||||
34144785|NCT03378648|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|"Part 1 double-blind~Part 2 double-blind~Part 3 placebo-controlled (double-blind), active-controlled (open labelled)"|"Part 1 alternating cross-over design~Part 2 parallel group design~Part 3 3-way cross-over design"|t|t|t|t
34144786|NCT05628051|||COHORT||PROSPECTIVE|||||||
34144787|NCT00353873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144788|NCT02182908|NA|SINGLE_GROUP||SCREENING||NONE||||||
34144789|NCT05088187|||COHORT||PROSPECTIVE|||||||
33833192|NCT04909138|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will not know to which treatment they are randomized|Patients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude set just below perception. Group 2 will have their frequency set at 5 Hz with amplitude set just below perception. This study will be performed in a crossover fashion with a washout period, meaning patients will receive one of the stimulation parameters at baseline, return to their pre-study stimulation settings at the 12-week time period and receive the alternate stimulation dosing regimen at the 13-week time period.|t|f|f|f
34144790|NCT00787137|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833193|NCT03667664|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833194|NCT06454305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833195|NCT05132855|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33833196|NCT04692805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833197|NCT02309671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833198|NCT01602094|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144791|NCT00279097|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833199|NCT05155943|NA|SINGLE_GROUP||OTHER||NONE||||||
33833200|NCT04903899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144792|NCT02146703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144793|NCT00758121|||COHORT||PROSPECTIVE|||||||
34144794|NCT05827562|||CASE_CONTROL||RETROSPECTIVE|||||||
34144795|NCT06096974|NA|SEQUENTIAL||TREATMENT||NONE||||||
34144796|NCT05259891|||COHORT||PROSPECTIVE|||||||
34144797|NCT00666497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144798|NCT03908190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The interviewer evaluating progress towards goals will be blinded to condition.|Randomized Controlled Trial|f|f|f|t
34144799|NCT00005647|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144800|NCT03590132|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|Neither the interventionists or the assessors were given information on participants' treatment group; however there is only partial masking for providers given that attendance in the program suggests some information on experimental group.|A 4 arm trial, participants receive either a preadolescent intervention only, a mid-adolescent intervention only, both preadolescent and mid-adolescent intervention, or no intervention|f|t|f|t
34144801|NCT06149117|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144802|NCT01126931|||||PROSPECTIVE|||||||
34144803|NCT00334581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144804|NCT03928288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144805|NCT02834923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833201|NCT02140736|||COHORT||PROSPECTIVE|||||||
33833202|NCT02548078|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34144806|NCT02033590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833203|NCT02779348|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144807|NCT00990145|RANDOMIZED|||||TRIPLE|||t|f|t|t
34144808|NCT02078102|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144809|NCT05680155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144810|NCT04793997|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Double blind, randomized, placebo controlled|t|f|t|t
33833204|NCT03482947|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33833205|NCT05290012|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833206|NCT05739136|||COHORT||RETROSPECTIVE|||||||
34144811|NCT02423499|||COHORT||PROSPECTIVE|||||||
33833207|NCT05580497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833208|NCT01580683|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144812|NCT00002342||||TREATMENT||||||||
34144813|NCT00695656|||COHORT||PROSPECTIVE|||||||
34144814|NCT03778320|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33833209|NCT02019680|||CASE_CROSSOVER||PROSPECTIVE|||||||
33833210|NCT04729842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients were blind to the study of drugs. Blinding was achieved by the examiner of the study. The allocation concealment was done using sealed sequentially numbered containers opaque envelope technique and the identical-looking container was used.|a prospective randomized single-blind study. Patients were blind to the study of drugs. Blinding was achieved by the examiner of the study. Participants were randomly allocated into two groups (Group - B i.e. Bupivacaine Group and Group - R i.e. Ropivacaine group) using computer-generated randomization and allocation concealment was done using sealed sequentially numbered containers opaque envelope technique (SNOSE)|t|f|f|f
33833211|NCT01026129|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33833212|NCT03936959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833213|NCT00243022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833214|NCT05170269|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833215|NCT00227123|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833216|NCT00460668|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34144815|NCT03454815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144816|NCT05828420|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34144817|NCT00944736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144818|NCT00003787|||CASE_CONTROL||PROSPECTIVE|||||||
34144819|NCT02446873|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144820|NCT01804569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144821|NCT06174389|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144822|NCT03781791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144823|NCT01999218|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144824|NCT01735669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144825|NCT03700450|NA|SINGLE_GROUP||TREATMENT||NONE||All patients will receive on day 3 and 4 after allogeneic stem cell transplan-tation 50 mg/kg BW cyclophosphamide||||
34144826|NCT01452295|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34144827|NCT00289198|RANDOMIZED|PARALLEL||TREATMENT||||||||
34144828|NCT00094718|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34144829|NCT01563289|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833217|NCT02851342|||COHORT||PROSPECTIVE|||||||
33833218|NCT02504749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833219|NCT05805839|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33833220|NCT03118167|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33833221|NCT03320395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833222|NCT05286463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833223|NCT01651533|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33833224|NCT01969045|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33833225|NCT03839810|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833226|NCT04009629|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Single visit, case-control study identified as an intervention due to the use of a single bout of aerobic exercise under NIH rules (grants.nih.gov/policy/clinical-trials/definition.htm)||||
33833227|NCT05716529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33833228|NCT04042077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only the blinded observer will be unaware of the treatment assigned to patient.|The study will compare delafloxacin against best available therapy selected by the investigator for the cardiothoracic/leg related or abdominal site infection|f|f|f|t
33833229|NCT06123247|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33833230|NCT00706771|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833231|NCT01667549|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33833232|NCT03017937|NA|SINGLE_GROUP||OTHER||NONE||||||
33833233|NCT02689947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833234|NCT02542098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833235|NCT03236610|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833236|NCT05881239|||COHORT||CROSS_SECTIONAL|||||||
33833237|NCT05953831|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|IMP to be masked after preparation by unblinded staff.||t|t|t|t
33833238|NCT06166212|||CASE_CONTROL||PROSPECTIVE|||||||
33833239|NCT04402697|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||"Volunteers are assigned to three groups for the duration of the study:~1. Normal-weight~2. Overweight-Obese~3. Metabolically obese normal-weight"||||
33833240|NCT02267265|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33833241|NCT02369861|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833242|NCT04268537|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833243|NCT02118298|||CASE_CONTROL||PROSPECTIVE|||||||
33833244|NCT01928693|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33833245|NCT01939301|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833246|NCT02306590|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833247|NCT01856517|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33833248|NCT05474547|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833249|NCT00372736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833250|NCT01150045|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833251|NCT00173381|||NATURAL_HISTORY||OTHER|||||||
33833252|NCT02398045|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833253|NCT00013611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833254|NCT04631588|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833255|NCT06269159|||COHORT||OTHER|||||||
33833256|NCT03200652|NA|SINGLE_GROUP||OTHER||NONE||Each subject will randomly receive 3 levels of lysine provided as free amino acids, wheat, or wheat combined with lentils for a total of 8 studies x 3 days per study.||||
33833257|NCT02119949|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833258|NCT04444843|NA|SINGLE_GROUP||TREATMENT||NONE||To estimate the incidence of DSA formation during 12-months post-transplantation||||
33833259|NCT00552864|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33833260|NCT03783689|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833261|NCT03659383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833262|NCT00652483|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833263|NCT01636583|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33833264|NCT03091322|||COHORT||PROSPECTIVE|||||||
33833265|NCT03959800|||OTHER||OTHER|||||||
33833266|NCT02652195|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33833267|NCT05838690|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33833268|NCT06395922|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833269|NCT00676845|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833270|NCT06080360|||CASE_ONLY||CROSS_SECTIONAL|||||||
33833271|NCT00594698|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833272|NCT02858128|||CASE_ONLY||PROSPECTIVE|||||||
33833273|NCT02673411|||CASE_ONLY||CROSS_SECTIONAL|||||||
33833274|NCT04588675|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33833275|NCT01267240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833276|NCT03716765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33833277|NCT02246881||||TREATMENT||||||||
33833278|NCT01010204|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833279|NCT00044746||||TREATMENT||NONE||||||
33833280|NCT03784781|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33833281|NCT05079594|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833282|NCT05801445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833283|NCT00636480|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33833284|NCT00003495|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833285|NCT05980169|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833286|NCT06129032|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833287|NCT05489562|NA|SINGLE_GROUP||OTHER||NONE||||||
33833288|NCT01095159|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833289|NCT01719341|||COHORT||PROSPECTIVE|||||||
33833290|NCT02781649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833291|NCT02903797|||CASE_CONTROL||RETROSPECTIVE|||||||
33833292|NCT03569215|||COHORT||CROSS_SECTIONAL|||||||
33833293|NCT05114369|||COHORT||RETROSPECTIVE|||||||
33833294|NCT00002463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833295|NCT03453723|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833296|NCT04065126|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150965|NCT00004274||||TREATMENT||||||||
33833297|NCT03062449|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833298|NCT01025505|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833299|NCT05703152|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, longitudinal, quasi-experimental study of repeated measures (pretest-posttest)||||
33833300|NCT01375751|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833301|NCT00080990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833302|NCT03904940|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833303|NCT02953509|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33833304|NCT05739110|||COHORT||RETROSPECTIVE|||||||
33833305|NCT03253120|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will drink 5dl of water. Healthy volunteers will drink 5dl of water.||||
33833306|NCT05890937|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33833307|NCT01335945|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33833308|NCT00079339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833309|NCT06008223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833310|NCT00002406||||TREATMENT||NONE||||||
33833311|NCT00005997||PARALLEL||TREATMENT||NONE||||||
33833312|NCT02751749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833313|NCT05570305|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The first and second treatment period are double-blind, whereas the final and third treatment period (dapagliflozin and zibotentan) is open-label.||t|t|t|t
33833314|NCT01377792|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833315|NCT02866396|||COHORT||PROSPECTIVE|||||||
33833316|NCT06137612|||COHORT||PROSPECTIVE|||||||
33833317|NCT03124654|||OTHER||PROSPECTIVE|||||||
33833318|NCT00639899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833319|NCT00347399|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833320|NCT04658563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833321|NCT04264351|||COHORT||PROSPECTIVE|||||||
33833322|NCT02281162|||COHORT||CROSS_SECTIONAL|||||||
33833323|NCT01803334|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833324|NCT03039881|||COHORT||PROSPECTIVE|||||||
33833325|NCT02830542|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833326|NCT05450536|NA|SINGLE_GROUP||OTHER||NONE||||||
33833327|NCT03118245|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833328|NCT00353886|||DEFINED_POPULATION||OTHER|||||||
33833329|NCT05656612|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a single-center, randomized clinical trial.||||
33833330|NCT06171269|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33833331|NCT04730674|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833332|NCT03570151|||COHORT||RETROSPECTIVE|||||||
33833333|NCT04421339|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|t|f|f
33833334|NCT01515852|RANDOMIZED|PARALLEL||||NONE||||||
33833335|NCT06153992|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33833336|NCT01495910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144830|NCT00405379|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144831|NCT01012206|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144832|NCT01411358|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34144833|NCT00495924|||COHORT||PROSPECTIVE|||||||
34150966|NCT04997525|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34150967|NCT02476474|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34150968|NCT06530719|NA|SINGLE_GROUP||TREATMENT||NONE||Osimertinib treatment for patients with EGFR-sensitive mutated non-small cell lung cancer who have progressed after receiving adjuvant targeted therapy following radical surgery||||
34150969|NCT02237482|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150970|NCT05833724|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833337|NCT04785768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833338|NCT06212089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833339|NCT05015725|||CASE_ONLY||CROSS_SECTIONAL|||||||
33833340|NCT00728000|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833341|NCT03562429|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||180 subjects are divided into treatment group and control group (placebo).|t|t|t|t
33833342|NCT05260593|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833343|NCT03990636|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833344|NCT03297476|||COHORT||PROSPECTIVE|||||||
33833345|NCT00959010|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833346|NCT00755417|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833347|NCT03648528|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Bottles filled with cholecalciferol or placebo pills by the drug company (Celsius) and named after randomization by the pharmacist and delivered to the dialysis unit to be administrated by the nurses|Randomized, double blind clinical trial in two arms|t|t|t|t
33833348|NCT06486142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833349|NCT03956693|NA|SINGLE_GROUP||OTHER||NONE||Pilot study||||
33833350|NCT00196391|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833351|NCT04711083|||CASE_ONLY||PROSPECTIVE|||||||
33833352|NCT03299777|||COHORT||PROSPECTIVE|||||||
33833353|NCT04443959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833354|NCT02731911|||COHORT||PROSPECTIVE|||||||
33833355|NCT02926924|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833356|NCT03546816|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833357|NCT00368641|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833358|NCT01089296|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833359|NCT05995652|||COHORT||PROSPECTIVE|||||||
33833360|NCT06546345|||COHORT||PROSPECTIVE|||||||
33833361|NCT04606147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Performer of nerve blocks will know type of block but investigator for postoperative pain will be blinded||f|f|t|f
33833362|NCT03330613|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
33833363|NCT03835962|NA|SINGLE_GROUP||OTHER||NONE||||||
33833364|NCT01013688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833365|NCT01514851|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833366|NCT04074343|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833367|NCT00004146|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833368|NCT00947232|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833369|NCT01192789|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833370|NCT00919945|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||f|t|t|t
33833371|NCT01425944|||OTHER||CROSS_SECTIONAL|||||||
33833372|NCT02432963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833373|NCT01013142|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33833374|NCT03506347|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833375|NCT00462111|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
33833376|NCT00074295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833377|NCT01012245|||COHORT||PROSPECTIVE|||||||
33833378|NCT06319157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833379|NCT04962451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833380|NCT01055236|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833381|NCT01727869|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833382|NCT03527706|||COHORT||PROSPECTIVE|||||||
33833383|NCT02574962|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833384|NCT02375451|||COHORT||CROSS_SECTIONAL|||||||
33833385|NCT01268124|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833386|NCT00176059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833387|NCT01435707|NON_RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33833388|NCT02665585|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833389|NCT04045847|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833390|NCT03562390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833391|NCT05730114|||COHORT||PROSPECTIVE|||||||
33833392|NCT04176289|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|double blinded study design (participants, evaluator)||t|f|t|f
33833393|NCT02071680|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833394|NCT01018108|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833395|NCT03376035|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Determine skin temperature after breast reconstruction||||
33833396|NCT03163706|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Open|||||
33833397|NCT03672175|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833398|NCT05809336|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833399|NCT03807609|RANDOMIZED|CROSSOVER||OTHER||NONE|No masking|||||
34150971|NCT00909740|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150972|NCT06256991|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Participants, care providers and investigators will be blinded regarding the use of patiromer vs. placebo during the two study periods. Irbesartan will be open label.||t|t|t|f
33833400|NCT02994771|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833401|NCT01214421|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833402|NCT03180944|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33833403|NCT01126697|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33833404|NCT04434248|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This is an adaptive, multicenter, open-label, randomized clinical study of Favipiravir versus standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.||||
33833405|NCT02689453|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33833406|NCT00522743|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833407|NCT01198106|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33833408|NCT01670071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833409|NCT03667118|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Parents received packets of the powder to be fed from their infant directly from the manufacturer.||t|f|f|f
33833410|NCT03792347|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 1 and 22. Surgery will be performed within 6 weeks after completion of preoperative therapy described above||||
33833411|NCT00175747|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33833412|NCT01198483|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833413|NCT03157908|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Prospective cohort study||||
33833414|NCT02885792|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833415|NCT02039245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833416|NCT02607098|||COHORT||PROSPECTIVE|||||||
33833417|NCT00640744|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833418|NCT00512642|||CASE_CONTROL||PROSPECTIVE|||||||
33833419|NCT02284009|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833420|NCT00627354|RANDOMIZED|||TREATMENT||||||||
33833421|NCT05323630|NA|SINGLE_GROUP||TREATMENT||NONE||"This is a prospective, single-center, single arm, evaluator-blinded study of the subjects undergoing a procedure with the Renuvion APR System in the labia. Follow-up visits will occur 1D Contact, 14D, 30D, 90D, and 180D post-procedure. Images will be captured at baseline and all follow-up visits.~Three experienced, independent blinded photographic reviewers will perform a qualitative analysis/review of pre-treatment and post-treatment sets of images for each subject. Images will be provided in a blinded and randomized order. Each blinded reviewer will choose which is the before image and which is the after. Success will be correct identification of before and after by at least 2 of the 3 reviewers."||||
33833422|NCT00938405|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833423|NCT02656550|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833424|NCT02846896|||OTHER||CROSS_SECTIONAL|||||||
33833425|NCT03230045|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33833426|NCT05717218|NA|SINGLE_GROUP||OTHER||NONE||||||
33833427|NCT05052671|||CASE_ONLY||PROSPECTIVE|||||||
33833428|NCT03040947|||COHORT||PROSPECTIVE|||||||
33833429|NCT01667406|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|participants and IVF physicians were blinded.|Different dose for each volunteer|t|t|f|f
33833430|NCT06032507|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||100 patients undergoing primary TKA|t|f|t|f
33833431|NCT00620269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833432|NCT04073342|||COHORT||PROSPECTIVE|||||||
33833433|NCT01855347|||COHORT||PROSPECTIVE|||||||
33833434|NCT05834920|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833435|NCT01674322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833436|NCT01769430|||CASE_ONLY||CROSS_SECTIONAL|||||||
33833437|NCT00190099|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833438|NCT02874599|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33833439|NCT04786418|RANDOMIZED|PARALLEL||PREVENTION||NONE||There are two study groups: Control groups and low-calorie diet intervention group running alongside.||||
33833440|NCT05707884|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33833441|NCT05571826|||COHORT||CROSS_SECTIONAL|||||||
33833442|NCT02578888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833443|NCT01124097|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833444|NCT01183247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833445|NCT01562106|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833446|NCT00347698|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833447|NCT06189209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833448|NCT00087945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833449|NCT04952480|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833450|NCT00348387|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833451|NCT04281888|||COHORT||PROSPECTIVE|||||||
33833452|NCT00612352|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
33833453|NCT06097962|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Dose escalation study||||
33833454|NCT00151398|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833455|NCT06511492|||COHORT||PROSPECTIVE|||||||
33833456|NCT01936467|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33833457|NCT03735953|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|f|t
33833458|NCT04786613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33833459|NCT00754598|NON_RANDOMIZED|||DIAGNOSTIC||||||||
33833460|NCT01853189|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33833461|NCT01042249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33833462|NCT01434745|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33833463|NCT02089139|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833464|NCT02025855|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833465|NCT01425138|||OTHER||RETROSPECTIVE|||||||
33833466|NCT00119561|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833467|NCT02695147|||COHORT||RETROSPECTIVE|||||||
33833468|NCT04732871|RANDOMIZED|PARALLEL||PREVENTION||NONE|Open-label study. Both investigator and participant know the identity of the intervention assigned.|||||
33833469|NCT02993536|||COHORT||PROSPECTIVE|||||||
33833470|NCT03554031|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833471|NCT03783676|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833472|NCT01913899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833473|NCT02233036|||COHORT||RETROSPECTIVE|||||||
33833474|NCT06546540|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833475|NCT00916305|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|f|t
33833476|NCT02528851|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33833477|NCT04036045|||CASE_ONLY||PROSPECTIVE|||||||
33833478|NCT02484378|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833479|NCT01512550|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833480|NCT05298397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833481|NCT01928667|||CASE_CONTROL||RETROSPECTIVE|||||||
33833482|NCT02244138|||CASE_CONTROL||PROSPECTIVE|||||||
33833483|NCT05116332|||COHORT||PROSPECTIVE|||||||
33833484|NCT03409731|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833485|NCT00899977|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33833486|NCT06490601|RANDOMIZED|PARALLEL||TREATMENT||NONE||study participants were divided into 2 groups. one was treated with combination therapy that includes thalidomide and hydroxyurea whereas another group was treated with thalidomide alone.||||
33833487|NCT00406614|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833488|NCT05478382|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833489|NCT03569592|NA|SINGLE_GROUP||PREVENTION||NONE||Incarcerated people living with HIV/AIDS will be given a brief training on overdose prevention and be given naloxone at discharge from jail.||||
33833490|NCT01097499|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833491|NCT01339299|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33833492|NCT02087215|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833493|NCT05205070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded design|Double-blinded, Placebo controlled, 2:1 ratio of Investigational Product vs Placebo|t|t|t|t
33833494|NCT05498922|||CASE_CONTROL||PROSPECTIVE|||||||
33833495|NCT02772237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833496|NCT02950051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833497|NCT01306123|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33833498|NCT05025709|||CASE_CONTROL||RETROSPECTIVE|||||||
33833499|NCT01592812|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833500|NCT02698306|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833501|NCT00449345|||DEFINED_POPULATION||PROSPECTIVE|||||||
33833502|NCT04581928|||COHORT||OTHER|||||||
33833503|NCT04140266|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833504|NCT03778710|||COHORT||RETROSPECTIVE|||||||
33833505|NCT03345147|||COHORT||PROSPECTIVE|||||||
33833506|NCT05197296|||COHORT||CROSS_SECTIONAL|||||||
33833507|NCT01261247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833508|NCT05566392|||CASE_CROSSOVER||PROSPECTIVE|||||||
33833509|NCT00603083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833510|NCT01558323||PARALLEL||OTHER||NONE||||||
33833511|NCT04201587|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33833512|NCT01841697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833513|NCT04943471|||COHORT||PROSPECTIVE|||||||
33833514|NCT03688490|||COHORT||PROSPECTIVE|||||||
33833515|NCT01954433|||OTHER||PROSPECTIVE|||||||
33833516|NCT05311722|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||3 drugs were given to patients|t|f|f|f
33833517|NCT01076790|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33833518|NCT01912989|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833519|NCT03702387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be informed that if they participate in the study, there is a chance they might not receive the modified treatment (and instead receive standard treatment) if they are randomized into the control group. Patients will not be told if they are having the modified IVRA procedure to avoid bias.|Male and female patients aged 18-100 who need short upper extremity or hand surgery (cases lasting less than 45 minutes) in the outpatient setting will be considered for the study. Exclusion criteria: patients requesting to withdraw from the study and patients with a history of drug abuse or illicitly used controlled drugs or substances within the last year. The study population will be divided into two groups: one group receiving the standard IVRA procedure and one group receiving the modified IVRA procedure (which simply includes the reapplication of the Esmarch bandage after the local anesthetic is administered intravenously). Due to limited information from other intravenous regional anesthesia studies, at least 40 subjects in each group will be needed (at least 80 patients total). Any patient who would like to participate will be included regardless of comorbidities. Any patient who refuses participation will be excluded, and patients may withdraw from the study at any time.|t|f|f|f
33833520|NCT00680888|||CASE_ONLY||RETROSPECTIVE|||||||
33833521|NCT01006525|||COHORT||PROSPECTIVE|||||||
33833522|NCT03496376|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|An assessor who was blinded to treatment groups assessed clinical outcomes before the treatment process. The same assessor was also repeated assessments at 6th week (at the end of treatment process)||f|f|f|t
33833523|NCT02191904|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33833524|NCT00930956|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33833525|NCT03119883|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33833526|NCT02185547|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833527|NCT04128462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833528|NCT01270828|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833529|NCT05666362|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833530|NCT00423072|||COHORT||PROSPECTIVE|||||||
33833531|NCT05713162|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833532|NCT04666363|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33833533|NCT01180881|||COHORT||PROSPECTIVE|||||||
33833534|NCT04678778|NA|SINGLE_GROUP||OTHER||NONE||||||
33833535|NCT00770198|||CASE_CONTROL||PROSPECTIVE|||||||
33833536|NCT01338376|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833537|NCT06019065|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33833538|NCT04947514|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|The patient and the surgical team will be blinded to which breast has received the study drug|Each patient undergoing routine bilateral breast reduction randomized to receive the study drug in either the right or left breast|t|t|f|f
33833539|NCT01376154|||OTHER||OTHER|||||||
33833540|NCT03174782|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|To randomize patients, consent forms will be pre-labeled with a random subject identification number. This number will serve as the participants' study ID for all data collection in order to maintain privacy and confidentiality. Additionally, this number will be linked to a sealed envelope containing the random treatment group. The study coordinator will create the labels and assemble the envelopes to ensure all investigators remain blind to the treatment groups. This sealed envelope will be given to the anesthesia providers for the amputation. The anesthesia team will then administer the assigned treatment prior to induction of general anesthesia. Half of the patients will be randomized into the treatment group, and half of the patients will be randomized into the control group.||t|t|t|f
33833541|NCT00464945|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833542|NCT01907932|NA|SINGLE_GROUP||OTHER||NONE||||||
33833543|NCT03095170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833544|NCT01237847|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33833545|NCT00085397|RANDOMIZED|||TREATMENT||||||||
33833546|NCT01430637|||CASE_CONTROL||RETROSPECTIVE|||||||
33833547|NCT05069298|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33833548|NCT00926575|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833549|NCT06087471|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833550|NCT00332969|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833551|NCT00884897|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833552|NCT05979623|||COHORT||RETROSPECTIVE|||||||
33833553|NCT02398032|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33833554|NCT06157528|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833555|NCT03777852|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE||A group of women will be evaluated twice, being one before the intervention and the second after the breast cancer reconstruction surgery|t|f|f|f
33833556|NCT01958242|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833557|NCT01008163|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833558|NCT02755701|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833559|NCT04889027|||COHORT||PROSPECTIVE|||||||
33833560|NCT00940862|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33833561|NCT01601912|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33833562|NCT04636645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833563|NCT06255925|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||Kessler Foundation Strength Identification and Expression (KF-STRIDE® Into Work!)|f|f|f|t
33833564|NCT01120847|||CASE_CONTROL||PROSPECTIVE|||||||
33833565|NCT00178451|RANDOMIZED|SINGLE_GROUP||||DOUBLE||||||
33833566|NCT01705405|NA|SINGLE_GROUP||||NONE||||||
33833567|NCT02169557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833568|NCT03231969|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833569|NCT01991847|NA|SINGLE_GROUP||OTHER||NONE||||||
33833570|NCT04883060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833571|NCT02868372|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33833572|NCT00480142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833573|NCT03003806|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833574|NCT01810276|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833575|NCT00423566|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33833576|NCT03635736|||CASE_CONTROL||PROSPECTIVE|||||||
33833577|NCT02706847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833578|NCT06183242|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|On stage 1, there will be no blinding (because REMAXOL is a solution for infusions). On stage 2, blinding will be ensured by placebo masking and drug assignment via IWRS.|Multicenter prospective two-stage comparative randomized parallel group study with placebo control|t|t|f|f
33833579|NCT02149524|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833580|NCT05702541|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33833581|NCT01114490|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833582|NCT04064294|||CASE_CONTROL||RETROSPECTIVE|||||||
33833583|NCT05574868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833584|NCT00887029|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33833585|NCT03920098|||COHORT||PROSPECTIVE|||||||
33833586|NCT05435911|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833587|NCT02760563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833588|NCT03715868|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833589|NCT06076408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833590|NCT00814411|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833591|NCT04088045||SEQUENTIAL||TREATMENT||NONE||Patients are divided into three groups. Group 1 will receive knee IA PRP injections only. Group 2 will receive simultaneous knee IA PRP injections and PRP injections to the pes anserine complex. Group 3 will receive simultaneous knee IA PRP injections and PRP injections to the pes anserine complex, as well as to the genicular nerve blocks using 5% dextrose solution.||||
33833592|NCT00516139|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833593|NCT01845805|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833594|NCT04544865|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833595|NCT05061199|||COHORT||RETROSPECTIVE|||||||
33833596|NCT03381950|||COHORT||PROSPECTIVE|||||||
33833597|NCT00006328|||NATURAL_HISTORY||RETROSPECTIVE|||||||
33833598|NCT00114296|RANDOMIZED|||PREVENTION||||||||
33833599|NCT02573649|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33833600|NCT05749861|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33833601|NCT04120142|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33833602|NCT04416932|||COHORT||PROSPECTIVE|||||||
33833603|NCT01408745|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833604|NCT04601597|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33833605|NCT02485899|NA|SINGLE_GROUP||TREATMENT||NONE||Because of practical (limited number of available patients) and ethical (neurosurgery in children with fatal neurologic disease) concerns, this study design could not involve contemporaneous, matched, randomized, blinded, or untreated control subjects. As such, data from the DEM-CHILD Multi-Center Clinical NCL Database at the University Medical Center in Hamburg, Germany (NCT04613089) was used as a control group (i.e., Natural History \[NH\] comparator) to determine the primary efficacy outcome measures for this study. The NH comparator was comprised of subjects from the DEM-CHILD database who satisfied the 190-201 inclusion criterion: Age ≥ 3, and at least one ML score ≥ 3 at age ≥ 3 years and further, who had at least two CLN2 assessments with values within the range 1 - 5 and at least 6 months apart.||||
33833606|NCT05282251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833607|NCT02474849|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33833608|NCT04682132|||COHORT||PROSPECTIVE|||||||
33833609|NCT04470869|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||In this study we aimed to investigated the impact of this intervention to prevent the PTSD in the relatives by comparing the PTSD prevalence in a group of relatives that loved ones were hospitalized after the confinement measure but before the OLAF intervention and a group of relatives that loved ones were hospitalized during the OLAF intervention.||||
33833610|NCT04811326|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33833611|NCT02538315|||CASE_CONTROL||PROSPECTIVE|||||||
33833612|NCT05068921|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833613|NCT04553588|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Care provider did not receive communication regarding group assignment; patients allocated to the intervention group received a disposal pouch prior to discharge and after physician discharge orders were finalized.|Two group design; patients randomized to receive usual postoperative care after discharge or usual postoperative care plus a disposal pouch to safely eliminate opioid medication no longer needed|f|t|f|f
33833614|NCT02435576|||COHORT||PROSPECTIVE|||||||
33833615|NCT05005299|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1 study, 3+3 design with dose expansion phase.||||
33833616|NCT05952947|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833617|NCT01003262|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33833618|NCT00798304|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833619|NCT06090162|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a multicenter prospective diagnostic study to compare the performance of experimental diagnostic test (ctDNA) versus conventional cytology (CC) and flow cytometry (FC).||||
33833620|NCT04246398|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33833621|NCT03653247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833622|NCT05203705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||SHR2285 tablets compared with Enoxaparin|t|t|t|t
33833623|NCT00372853|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833624|NCT01846403|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33833625|NCT04456647|||CASE_ONLY||RETROSPECTIVE|||||||
33833626|NCT05081427|||COHORT||CROSS_SECTIONAL|||||||
33833627|NCT01347372|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||||||||
33833628|NCT05879003|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833629|NCT00796393|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33833630|NCT06028490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833631|NCT01355978|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33833632|NCT04564521|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Prior to the procedure, each patient will be randomized into either the saline-first arm or nitroglycerin-first arm.~At the first intra-arterial chemotherapy after enrollment, saline or nitroglycerin is used according to the group allocation.~At the second intra-arterial chemotherapy after enrollment, nitroglycerin is used for the saline-first arm, and saline is used for the nitroglycerin-first arm."|t|t|f|f
33833633|NCT01383330|RANDOMIZED|PARALLEL||||NONE||||||
33833634|NCT06119347|||COHORT||RETROSPECTIVE|||||||
33833635|NCT01026298|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33833636|NCT00174447|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833637|NCT04594733|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||• A simple randomization method will be used to assign the initial treatment and then the opposite treatment will ensure for the second treatment period. Patients will be randomized to (i) 8 weeks of placebo, minimum 2 week washout period, and then 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily) followed by a final 2 week washout or (ii) 8 weeks of a combination minocycline (200 mg daily) and NAC (1200 mg daily), minimum 2 week washout period, and then 8 weeks of placebo followed by a final 2 week washout.|t|f|f|t
33833638|NCT00375531|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833639|NCT01150435|||CASE_CONTROL||PROSPECTIVE|||||||
33833640|NCT00741832|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33833641|NCT02529189|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833642|NCT02297685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833643|NCT00846508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833644|NCT03155854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833645|NCT04749407|||CASE_ONLY||PROSPECTIVE|||||||
33833646|NCT05500781|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33833647|NCT01398098|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33833648|NCT04751136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833649|NCT05332678|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833650|NCT06231537|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||cluster randomized clinical trial||||
33833651|NCT05172492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833652|NCT05225207|||COHORT||PROSPECTIVE|||||||
33833653|NCT00333190|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33833654|NCT02378636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833655|NCT05247697|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Prospective double blind placebo controlled trial|t|f|t|f
33833656|NCT02905409|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833657|NCT00873327|NA|SINGLE_GROUP||OTHER||NONE||||||
33833658|NCT06118242|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33833659|NCT00293345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833660|NCT02677077|||COHORT||RETROSPECTIVE|||||||
33833661|NCT01884103|||COHORT||PROSPECTIVE|||||||
33833662|NCT00187499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833663|NCT03107507|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833664|NCT03533205|||COHORT||PROSPECTIVE|||||||
33833665|NCT06547268|||OTHER||PROSPECTIVE|||||||
33833666|NCT04849377|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||CRT (Cisplatin with IMRT/IMPT): Group I 50 Gy/200 mg/m2, Group II 54 Gy/200 mg/m2, Group III 60 Gy/240 mg/m2 Sequential Therapy: Group IV TPF Induction followed by 60 Gy and Carboplatin AUC 1.5||||
33833667|NCT03662646|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33833668|NCT01289210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833669|NCT05295394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833670|NCT02416245|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33833671|NCT02339545|||COHORT||PROSPECTIVE|||||||
33833672|NCT01656213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833673|NCT01266018|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833674|NCT04833478|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33833675|NCT02868671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833676|NCT05284955|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833677|NCT00443209|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833678|NCT01598103|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33833679|NCT01354249|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33833680|NCT06028165|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33833681|NCT06371586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833682|NCT01718951|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833683|NCT03045809|||OTHER||CROSS_SECTIONAL|||||||
33833684|NCT05141396|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33833685|NCT01965171|||COHORT||PROSPECTIVE|||||||
33833686|NCT02716363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833687|NCT01335412|||COHORT||RETROSPECTIVE|||||||
33833688|NCT03372590|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833689|NCT00371059|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33833690|NCT05479474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833691|NCT06487689|||CASE_CONTROL||RETROSPECTIVE|||||||
33833692|NCT04066517|NA|SINGLE_GROUP||TREATMENT||NONE|No masking in this study.|||||
33833693|NCT03866369|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||Multiple ascending dose study with 3 sequential cohorts of 12 subjects treated by Lanifibranor versus Placebo during 14 days|t|t|t|t
33833694|NCT04404309|||COHORT||PROSPECTIVE|||||||
33833695|NCT02121912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33833696|NCT06121804|||COHORT||RETROSPECTIVE|||||||
33833697|NCT04367207|||COHORT||PROSPECTIVE|||||||
33833698|NCT03927898|NA|SINGLE_GROUP||TREATMENT||NONE||All enrolled patients will receive Toripalimab following stereotactic body radiotherapy||||
33833699|NCT02559310|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833700|NCT01306006|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833701|NCT03282136|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833702|NCT01557465|||COHORT||PROSPECTIVE|||||||
33833703|NCT00791375|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833704|NCT06191081|||OTHER||RETROSPECTIVE|||||||
33833705|NCT00459914|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833706|NCT04292080|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking is used. All involved know the identity of the intervention assignment.|"Participants receive an intervention throughout the protocol. There are 2 groups :~Group 1 : Group TECFIDERA~Group 2 : No active (No treatment)"||||
33833707|NCT04912310|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833708|NCT03189147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833709|NCT06074692|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833710|NCT05167084|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Placebo-controlled|Double-blind, randomized, placebo-controlled cross-over study|t|f|t|f
33833711|NCT05193136|||CASE_ONLY||PROSPECTIVE|||||||
33833712|NCT04454099|||OTHER||PROSPECTIVE|||||||
33833713|NCT03622255|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A software (www.randomizer.org) will be used by one of the investigators who will not participate in the clinical and radiographic measurements nor the therapeutic intervention, to generate a block randomization. Thus, participants will be randomized in one of the two groups in a way that there is no difference between the two groups regarding the initial depth of the intrabony defect. In patients with more than one intrabony defects meeting the inclusion criteria, a second randomization scheme with the same software will take place, to determine which will be included. The randomization results will be placed in sealed envelopes accessible only to the principal investigator and opened for each patient after the end of MINST to determine if EMD will be applied or not.|t|f|f|t
33833714|NCT04652661|RANDOMIZED|PARALLEL||OTHER||DOUBLE||"Sixty children will be randomly allocated into two equal groups by computer generated sequence through sealed opaque envelopes:~Group D: 30 children will be sedated with 2 μg/kg intranasal DEX. Group M: 30 children will be sedated with 0.3 mg/kg intranasal midazolam."|t|f|t|f
33833715|NCT05363332|||COHORT||PROSPECTIVE|||||||
33833716|NCT05213442|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Monocentric, non randomized, non comparative cross-sectional study||||
33833717|NCT01550055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833718|NCT06371469|NON_RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Mothers participating in the research will not know that they are in the intervention or control group. The data of the research will be collected by an independent investigator. In addition telephone support during the research process will be provided by the independent investigator, too||t|f|f|t
33833719|NCT05994469|NA|SINGLE_GROUP||PREVENTION||NONE||Natural experiment||||
33833720|NCT06394609|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with recurrent anterior glenohumeral subluxation or dislocation after an initial episode of traumatic anterior shoulder dislocation, a Bankart lesion confirmed by Magnetic resonance imaging (MRI) and arthroscopic examination. We would like to report the 12 months clinical outcomes of double loaded grand knot technique and knotted double loaded anchor used in traumatic anterior dislocations of the shoulder||||
34144834|NCT04094649|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||DOUBLE|"Randomization will be assigned by the clinical research facility. One of the two experimenters will be blinded. The unblinded experimenter is needed to aim the stimulation to the vagus nerve or sham location. The blinded experimenter will acquire, process, and analyze all data.~Participants will be told that they may or may not feel the stimulation. The uVNS probe will be placed on their neck for each stimulation burst with the unblinded experimenter control-ling whether active or sham uVNS is delivered as determined by the crossover assignment."|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether uVNS inhibits postprandial hyperglycemia in humans. Adults with DMT2 will be recruited and randomized to active uVNS or sham uVNS across two sessions according to a 2x2 crossover design.|t|f|t|f
33833721|NCT03232606|||CASE_ONLY||PROSPECTIVE|||||||
33833722|NCT00949676|||COHORT||PROSPECTIVE|||||||
33833723|NCT05592977|NA|SINGLE_GROUP||TREATMENT||NONE|Due to the nature of the study, the operator and patients can't be blinded. Blinding of the outcome assessors can be done by sealing the name of the patient in the pre and post treatment radiographs used for analysis|||||
33833724|NCT05901155|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Masking is not possible.|The study involves two arms: intervention and control. Health facilities will serve as clusters, with half of the facilities (20) receiving the intervention and the other half serving as controls (20). Health facilities will be randomized to their respective study arm. A parallel design (all health facilities start at the same time) will be used.||||
33833725|NCT04707950|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."||||
33833726|NCT00280865|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833727|NCT04692090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33833728|NCT02686099|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|participants are blinded to treatment choice until completion of the study.|Comparison of intervention using sternal closure with 360 plating system, to closure of the sternum using wire cerclage|t|f|f|f
33833729|NCT04810897|||COHORT||CROSS_SECTIONAL|||||||
33833730|NCT01296009|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33833731|NCT02803099|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833732|NCT00164710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833733|NCT04334447|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33833734|NCT03837483|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837635|NCT01178008|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33837636|NCT00006462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833735|NCT00610727|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Stage 2 was a double-blind, placebo-controlled, 4 step dose-escalation trial|Stage 1: open-label, single-dose stage with 3 treatment periods divided into 2 phases Stage 2: double-blind, placebo-controlled, dose-escalation treatment period|t|t|t|t
33833736|NCT04211389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833737|NCT01258647|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833738|NCT00004254||||TREATMENT||||||||
33833739|NCT04236232|||OTHER||CROSS_SECTIONAL|||||||
33833740|NCT01639742|NA|SINGLE_GROUP||OTHER||NONE||||||
33833741|NCT03598699|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833742|NCT01338974|||||RETROSPECTIVE|||||||
33833743|NCT00671710|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833744|NCT00709501|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833745|NCT03682198|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33833746|NCT06095531|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833747|NCT01238536|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833748|NCT01710059|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33833749|NCT06401278|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833750|NCT00420875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833751|NCT05382039|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Prospective randomized controlled trial||||
33833752|NCT01298882||PARALLEL||TREATMENT||||||||
33833753|NCT02627378|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33833754|NCT03747887|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Random assignment to intervention group or business as usual group.|f|f|f|t
33833755|NCT01196819|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833756|NCT05759286|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||f|f|t|t
33833757|NCT00299806|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833758|NCT05395923|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33833759|NCT02508610|||CASE_ONLY||PROSPECTIVE|||||||
33833760|NCT04665609|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833761|NCT02080546|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833762|NCT02414009|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833763|NCT01783340|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
33833764|NCT03387813|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833765|NCT00283283|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33833766|NCT01227616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833767|NCT03234946|RANDOMIZED|PARALLEL||PREVENTION||NONE||"Relatives of CAIPaDi patients that present on their initial evaluation either overweight, obesity, hypertension, glucose intolerance and/or secondary dyslipidemia will be invited to participate.~Those who accept will require to attend the center twice. On the first visit, an anthropometric evaluation and laboratory studies will be performed; an oral glucose tolerance (OGTT) test will be carried out if the glucose value is over 100 mg/dl. If the OGTT results are abnormal, the individual will be included in the study sample.~Those who have an abnormal OGTT and are included in the study sample will be randomized into two groups.~The change of the main variables (weight, waist circumference, serum glucose, glycated hemoglobin, blood pressure, triglycerides and non-HDL cholesterol) will be assessed 3 months later, along with the effect on patients with diabetes parameters."||||
33833768|NCT00531726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833769|NCT03833362|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833770|NCT04967898|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33833771|NCT04492813|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Each obese patient is matched with a non-obese patient by considering a pairing according to age (more or less 5 years), gender and renal function (more or less 10ml / min / 1.73m² creatinine clearance).|f|f|f|t
33833772|NCT05859438|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33833773|NCT00531622|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833774|NCT04340765|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The patients will receive both 18F-fluorocholine PET and NaF PET||||
33833775|NCT04228198|||COHORT||PROSPECTIVE|||||||
33833776|NCT01389414|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833777|NCT01362647|||COHORT||PROSPECTIVE|||||||
34144835|NCT01568372|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34144836|NCT02610491|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34144837|NCT04931537|||OTHER||PROSPECTIVE|||||||
34144838|NCT01690624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144839|NCT01143922|||COHORT||PROSPECTIVE|||||||
34144840|NCT02096666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833778|NCT01509989|||||PROSPECTIVE|||||||
33833779|NCT02476942|||COHORT||CROSS_SECTIONAL|||||||
33833780|NCT05790525|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833781|NCT00014287||||TREATMENT||||||||
33833782|NCT00728299|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144841|NCT03182595|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144842|NCT01229748|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34144843|NCT02606760|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144844|NCT02072187|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144845|NCT05110560|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||"Stay at Home Take a Step Program (SHTSP) will be performed with the intervention group.~For the control group, only the number of steps will be followed."|t|f|f|t
34144846|NCT02386215|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33833783|NCT04703400|||COHORT||RETROSPECTIVE|||||||
33833784|NCT05672732|||CASE_CROSSOVER||PROSPECTIVE|||||||
34144847|NCT02516826|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144848|NCT01235364|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144849|NCT00491660|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||||||
34144850|NCT01605942|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144851|NCT02813642|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144852|NCT05610306|||OTHER||PROSPECTIVE|||||||
34144853|NCT00526110|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144854|NCT01630551|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Omega 3 fatty acid|t|f|t|f
33833785|NCT06486675|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833786|NCT02447653|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833787|NCT06421805|||COHORT||PROSPECTIVE|||||||
33833788|NCT05515783|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33833789|NCT06001866|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Within-participant design in which each child learns words under two conditions.||||
33833790|NCT03423368|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833791|NCT02717741|NA|SINGLE_GROUP||||NONE||||||
33833792|NCT01809899|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33833793|NCT02022111|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33833794|NCT02675049|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833795|NCT06385847|RANDOMIZED|CROSSOVER||OTHER||NONE||Prospective, randomized, open-label, cross-over phase II trial||||
33833796|NCT02766205|||COHORT||OTHER|||||||
33833797|NCT04502797|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833798|NCT00034554|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833799|NCT00244647|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33833800|NCT00166881|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833801|NCT02211820|||COHORT||PROSPECTIVE|||||||
33833802|NCT01347671|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833803|NCT03432390|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33833804|NCT05140083|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833805|NCT00848848|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||t|f|f|f
33833806|NCT00943787|NA|SINGLE_GROUP||||NONE||||||
33833807|NCT02922205|||COHORT||PROSPECTIVE|||||||
33833808|NCT01485107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833809|NCT05359055|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833810|NCT01309698|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33833811|NCT00776022|RANDOMIZED|CROSSOVER||||NONE||||||
33833812|NCT01919515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833813|NCT02333266|||CASE_ONLY||PROSPECTIVE|||||||
33833814|NCT02887274|||COHORT||PROSPECTIVE|||||||
33833815|NCT02276534|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33833816|NCT06485336|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Triple blind (blinded to patients, study personnel, and statistician)|Parallel group study with two arms, comparing Atorvastatin 40mg against placebo. Each participant will receive 84 encapsulated tablets. The participants will take one capsule orally each day, preferably at the same time of the day.|t|t|f|t
33833817|NCT01320878|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833818|NCT05780905|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE||Randomized, double-blind and placebo controlled MRI study|t|t|t|t
33833819|NCT04092452|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||The treatment period is a parallel design|t|f|t|t
33833820|NCT00583271|||COHORT||PROSPECTIVE|||||||
33833821|NCT00723749|||COHORT||PROSPECTIVE|||||||
33833822|NCT00302159|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833823|NCT06407609|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833824|NCT03070704|||COHORT||PROSPECTIVE|||||||
33833825|NCT03790306|||COHORT||PROSPECTIVE|||||||
33833826|NCT04568863|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||phase II, single-center, double-blind, randomized placebo-controlled trial|t|t|t|t
33833827|NCT03624387|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Parallel Assignment||||
33833828|NCT05891145|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"1. The random numbers will be generated by the Power Analysis and Sample Site Software 9.0 (PASS 9.0), sealed with envelopes, and assigned in the order of enrollment by researchers. The randomized envelopes shall only be opened before anesthesia and resealed right after the operation.~2. Unblinding of results: the monitoring committee did the data unblinding after all enrollment, follow-up, and data entry. Unblinded data was limited to the data monitoring committee and statistical analysts.~3. Patients can have emergency unblinding under the following conditions: 1) serious adverse events; 2) The result of the unblinding was needed for the following treatment. 3) other emergency situations that investigators thought necessary for unblinding, the detailed reasons need to be recorded."|A first open-phase trial in which 50 patients (randomized 1:1 to Remimazolam and control groups) will be enrolled as a pilot study to obtain parameters for sample size calculation. A double-blind randomized controlled trial will be conducted to explore remimazolam's effect on POAF and inflammatory factors' blood levels in patients that receive selective CABG.|t|t|f|t
33833829|NCT00590525|||COHORT||PROSPECTIVE|||||||
33833830|NCT01150461|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833831|NCT02515006|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833832|NCT04487353|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||The sample will consist of 105 midwifery students, 35 control, 35 experiment I and 35 experiment II, as a result of the G-power analysis calculated from 0.95 power, among the midwifery students who took the birth mechanism 4 hours theoretically in their curriculum within the scope of normal birth lesson.|f|f|t|f
33833833|NCT01071837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833834|NCT02460055|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33833835|NCT00518856|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144855|NCT01816906|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34144856|NCT04069247|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34144857|NCT00700102|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144858|NCT05045222|||COHORT||PROSPECTIVE|||||||
33833836|NCT05869695|||COHORT||PROSPECTIVE|||||||
33833837|NCT00216047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833838|NCT01787253|||CASE_CONTROL||PROSPECTIVE|||||||
33833839|NCT03903497|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Endoscopists did not know histology of diminutive colorectal polyps|Colonoscopy with NBI using the WASP classification||||
33833840|NCT03552640|||OTHER||PROSPECTIVE|||||||
33833841|NCT01642953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833842|NCT04911998|||COHORT||PROSPECTIVE|||||||
33833843|NCT02643628|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833844|NCT01021709|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833845|NCT01952847|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
33833846|NCT00751660|NA|SINGLE_GROUP||SCREENING||NONE||||||
33833847|NCT05194033|RANDOMIZED|PARALLEL||OTHER||TRIPLE|This study is double-blinded, which neither participants nor investigators know the results of intervention. In addition, laboratory test of blood samples will also be conducted without knowing the randomization results of participants to ensure the evaluation of outcome measure is objective.|A prospective, randomized, double-blind, placebo parallel controlled clinical trial.|t|f|t|t
33833848|NCT01793636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833849|NCT05563090|||OTHER||PROSPECTIVE|||||||
33833850|NCT00992992|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833851|NCT04517968|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833852|NCT03136536|||COHORT||PROSPECTIVE|||||||
33833853|NCT04104425|||OTHER||CROSS_SECTIONAL|||||||
33833854|NCT00229762|RANDOMIZED|SINGLE_GROUP||ECT||SINGLE||||||
33833855|NCT01629212||||TREATMENT||||||||
33833856|NCT02880839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833857|NCT01530893|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33833858|NCT02643147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833859|NCT02437357|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833860|NCT02719743|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833861|NCT00466713|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33833862|NCT01392703|RANDOMIZED|CROSSOVER||||NONE||||||
33833863|NCT04919070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833864|NCT01424462|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33833865|NCT02187367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833866|NCT05205109|NA|SEQUENTIAL||TREATMENT||NONE||||||
33833867|NCT06242938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833868|NCT00113269|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833869|NCT02888379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833870|NCT04539067|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833871|NCT03617068|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|blinding had to be done by Clinical Research Supporting Unit Faculty of Medicine, Universitas Indonesia|Batik traditional workers with occupational hand dermatitis using emolient for prevention|t|f|t|f
33833872|NCT02967276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833873|NCT01786304|||COHORT||PROSPECTIVE|||||||
33833874|NCT00568841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833875|NCT00784147|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833876|NCT03153813|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
33833877|NCT03763045|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded|"Sildenafil 25: Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.~Sildenafil 50: Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.~Placebo: Twenty hemodialysis patients will receive a placebo tablet daily for 3 months."|t|t|t|t
33833878|NCT00480064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833879|NCT06314139|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833880|NCT01224522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833881|NCT01266746|||COHORT||PROSPECTIVE|||||||
33833882|NCT06296004|||CASE_CONTROL||PROSPECTIVE|||||||
33833883|NCT06495593|NA|SINGLE_GROUP||OTHER||NONE||||||
33833884|NCT04545528|||COHORT||PROSPECTIVE|||||||
33833885|NCT00097838|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833886|NCT05289219|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|"Randomization is performed using a random selection method from the waiting list and the data will be coded and transferred to the database, depending on the intervention group and control group. Data analysis will be done statistically.~Each participant will be randomly assigned to each group after signing the informed consent and conducting the initial assessments. All laboratory samples and data collected will be identified with identification ID, safeguarding the confidentiality of the collected data.~At the end of this study, all participants of the control group will be offered the same intervention as the exercise group."|randomized controlled study|t|f|f|f
33833887|NCT06125899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33833888|NCT02636608|||COHORT||PROSPECTIVE|||||||
33833889|NCT01229774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833890|NCT01972945|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33833891|NCT05525247|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33833892|NCT05472584|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33833893|NCT05549349|||COHORT||PROSPECTIVE|||||||
33833894|NCT05026268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833895|NCT05874778|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833896|NCT00250432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833897|NCT00511836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833898|NCT00430742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144859|NCT00966290|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144860|NCT01669018|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34144861|NCT01898104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144862|NCT03354832|||OTHER||PROSPECTIVE|||||||
34144863|NCT03412097|||OTHER||PROSPECTIVE|||||||
34144864|NCT04685629|||COHORT||PROSPECTIVE|||||||
34144865|NCT00461994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144866|NCT01251198|||COHORT||PROSPECTIVE|||||||
34144867|NCT02830607|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34144868|NCT01741831|||CASE_ONLY||PROSPECTIVE|||||||
34144869|NCT01482897|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34144870|NCT01918969|||COHORT||PROSPECTIVE|||||||
34144871|NCT03275688|||CASE_CONTROL||PROSPECTIVE|||||||
33833899|NCT04189055|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833900|NCT04536285|||CASE_ONLY||CROSS_SECTIONAL|||||||
33833901|NCT04626804|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||single dyadic group focused on determining acceptance and feasibility of the in home computer monitor individually programmed for each dyadic needs||||
33833902|NCT06227728|||COHORT||PROSPECTIVE|||||||
33833903|NCT01752010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144872|NCT00152568|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33833904|NCT01130168|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33833905|NCT01982175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833906|NCT00510900|||COHORT||PROSPECTIVE|||||||
33833907|NCT02204098|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833908|NCT04052945|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33833909|NCT00004072|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833910|NCT02020746|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33833911|NCT05144698|NA|SINGLE_GROUP||TREATMENT||NONE||Simon 2-stage, non-randomized, open label, multi-site, phase I/II trial||||
33833912|NCT01937026|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33833913|NCT05006326|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833914|NCT01988298|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33833915|NCT06050447|||COHORT||PROSPECTIVE|||||||
33833916|NCT02280512|||COHORT||PROSPECTIVE|||||||
33833917|NCT02109666|||COHORT||PROSPECTIVE|||||||
33833918|NCT06351462|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833919|NCT02164019|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833920|NCT01240889|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833921|NCT02206139|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33833922|NCT02830529|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33833923|NCT03965676|NA|SINGLE_GROUP||OTHER||NONE||||||
33833924|NCT02219698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833925|NCT02744339|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833926|NCT05987098|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single dose of BBPA will be intravenously injected and PET examination will carry out 30 minutes later.||||
33833927|NCT02328586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833928|NCT04592497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833929|NCT00691600|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33833930|NCT05874310|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||X-linked retinitis pigmentosa patients||||
33833931|NCT01390441|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833932|NCT01804010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33833933|NCT04058002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833934|NCT01599442|||COHORT||PROSPECTIVE|||||||
33833935|NCT03220997|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Research midwives will attend consent, randomise, collect baseline data and provide the accompanying information and carbohydrate sachets to subjects. The research fellows will be blinded but will collect the data for participants. The research midwives will complete study compliance. To achieve this, participants will bring to ward a completed compliance form ( given at randomisation) in a sealed envelope this will ensure the research investigators remain blinded during their pre op assessments and data collection.||f|f|t|t
33833936|NCT00543062|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|This was a double-blind, double dummy, placebo controlled, randomized 4-period crossover study to assess the effects of single doses of 5 and 10 mg of Staccato Prochlorperazine on QT intervals.|Female and male subjects in approximately equal numbers were randomly assigned (1:1:1:1) to receive the 4 treatment sequences|t|t|t|t
33833937|NCT00205647|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33833938|NCT03304756|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833939|NCT01052363|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833940|NCT01512498|||COHORT||CROSS_SECTIONAL|||||||
33833941|NCT00198003|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34144873|NCT01332188|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144874|NCT01845584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144875|NCT05586672|||COHORT||PROSPECTIVE|||||||
34144876|NCT05753930|NA|SINGLE_GROUP||TREATMENT||NONE||"This is an open-label, non-randomised trial in highly sensitized paediatric kidney transplant patients with positive XM against an available DD or LD.~The rationale for a non-randomised trial in DD kidney transplantation is that there are no other effective or approved desensitisation protocols that would provide a suitable or ethical control.~The rationale for a non-randomised trial in LD kidney transplantation is that potential control treatments have already been tried unsuccessfully in the patients or such treatments are judged as highly unlikely to succeed based on the breadth and depth of the patients' sensitisation. Treatment with little anticipation of success would expose the patients to unnecessary immunosuppression."||||
34144877|NCT06035744|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144878|NCT03459300|||COHORT||PROSPECTIVE|||||||
33833942|NCT04906265|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized controlled clinical trial|f|f|t|f
33833943|NCT04135508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833944|NCT02676843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833945|NCT03922022|NA|SINGLE_GROUP||TREATMENT||NONE||patients will go to different classes: (i) Hypertension basic exercise class (ii) Hypertension advanced exercise class (iii) diabetes basic exercise class (iv) diabetes advanced exercise class; if the patient has normal BMI AND reported some regular exercise, they will be prescribed the advanced level class. There is no control group for this pilot study||||
33833946|NCT02922283|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33833947|NCT03306004|||OTHER||PROSPECTIVE|||||||
33833948|NCT05264701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833949|NCT01699737|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833950|NCT04207645|||COHORT||PROSPECTIVE|||||||
33833951|NCT04853498|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833952|NCT06258954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833953|NCT03845712|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833954|NCT04375267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833955|NCT02706249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833956|NCT03518242|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833957|NCT03253263|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33833958|NCT04749355|NA|SINGLE_GROUP||TREATMENT||NONE||Open-label, multi-center, single arm, single agent study||||
33833959|NCT01339962|||COHORT||RETROSPECTIVE|||||||
33833960|NCT00637468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144879|NCT01120314|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34144880|NCT04579094|||COHORT||PROSPECTIVE|||||||
33833961|NCT03218566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833962|NCT01236352|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833963|NCT01690468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833964|NCT01322009|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833965|NCT03191071|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized clustered pragmatic trial||||
33833966|NCT02219399|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33833967|NCT06205654|||CASE_CONTROL||PROSPECTIVE|||||||
33833968|NCT02960971|||COHORT||PROSPECTIVE|||||||
33833969|NCT05638737|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33833970|NCT03893747|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33833971|NCT03178045|||COHORT||PROSPECTIVE|||||||
33833972|NCT00021047||||TREATMENT||||||||
33833973|NCT00547053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33833974|NCT03543605|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The study will be masked in the first year (pre-intervention) and open in the year of intervention||f|f|t|f
33833975|NCT05673733|RANDOMIZED|PARALLEL||OTHER||SINGLE||Exergaming Training|t|f|f|f
33833976|NCT03113383|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33833977|NCT00909532|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33833978|NCT06120868|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE||a randomized controlled split-mouth study.|t|f|f|f
33833979|NCT01898780|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833980|NCT00585871|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833981|NCT00487032|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33833982|NCT05932147|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Group A:( Pilates exercise) This group includes 34 patients who have axillary web syndrome received Pilates exercise with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients received 3 sessions per week for 8 weeks; time of session is 30 minutes.~) Group B: (Manual Lymphatic Drainage) This group includes 34 patients who axillary web syndrome received Manual lymphatic drainage massage with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients received 3 sessions per week for 8 weeks; time of session is 30 minutes."||||
33833983|NCT04417569|||CASE_ONLY||PROSPECTIVE|||||||
33833984|NCT00827554|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33833985|NCT05196971|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33833986|NCT00390078|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33833987|NCT02399397|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833988|NCT00611169|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33833989|NCT03672799|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|"The outcomes assessor, study investigators, and statistician will remain blinded to group allocation.~Participants and the treating therapist (Rehabilitation Consultant) will remain unblinded."|Randomized controlled trial with two arms, the experimental arm (Rehabilitation Planning Consult; RPC) and a wait list control (WLC) arm.|f|f|t|t
33833990|NCT01650077|||COHORT||RETROSPECTIVE|||||||
33833991|NCT03135106|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33833992|NCT03437135|||COHORT||CROSS_SECTIONAL|||||||
33833993|NCT01228877|NA|SINGLE_GROUP||OTHER||NONE||||||
33833994|NCT02075853|||COHORT||PROSPECTIVE|||||||
33833995|NCT04049981|RANDOMIZED|PARALLEL||OTHER||NONE||1:1 Randomization||||
33833996|NCT04197167|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group Assignment||||
33833997|NCT04127903|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|f|t
33833998|NCT02503826|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
33833999|NCT02630706|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sponsor was masked.||t|f|t|f
33834000|NCT01758744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834001|NCT01852188|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33834002|NCT04101513|||COHORT||PROSPECTIVE|||||||
33834003|NCT03874936|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834004|NCT01747863|||COHORT||PROSPECTIVE|||||||
33834005|NCT06278272|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834006|NCT05092438|||OTHER||RETROSPECTIVE|||||||
33834007|NCT04775147|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Open intervention; outcome assessments undertaken by trained research staff who are kept blind to treatment allocation||f|f|f|t
33834008|NCT02412449|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33834009|NCT01262092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834010|NCT05161793|||COHORT||PROSPECTIVE|||||||
33834011|NCT01531101|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834012|NCT00727506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834013|NCT06545318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants did not know if their sperm would be selected by density gradient centrifugation ir the novel device (CA0 chamber)||t|f|f|f
33834014|NCT05995847|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33834015|NCT06029608|||CASE_CONTROL||PROSPECTIVE|||||||
33834016|NCT06300983|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834017|NCT00557531|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834018|NCT03024996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834019|NCT04864366|||COHORT||PROSPECTIVE|||||||
33834020|NCT01011699|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33834021|NCT01174264|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834022|NCT00298675|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837637|NCT01808131|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837638|NCT03656250|||CASE_ONLY||PROSPECTIVE|||||||
33837639|NCT06085053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837640|NCT04486599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837641|NCT03648424|||COHORT||RETROSPECTIVE|||||||
33837642|NCT05246579|||COHORT||PROSPECTIVE|||||||
33837643|NCT04990232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||multicentre and multinational, double-blind, double-dummy randomized clinical trial|t|t|t|t
33837644|NCT05595577|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|All images will be processed offline by an image analyst blinded to study group||f|f|f|t
33837645|NCT05423899|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144881|NCT04932213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The drops are instilled into the patients' eye by a nurse. Study participants are unaware of the type of medication used. The outcome assessor (ophthalmologist) does not know the type of medication used for each patient. The data is analyzed by an biostatistician. He or she also does not know the type of drug used for each patient.|Intervention group 1: This group receives tropicamide 0.5% drops; Intervention group 2: This group receives tropicamide 1% drops.|t|t|t|t
34144882|NCT06464094|NA|SINGLE_GROUP||OTHER||NONE||||||
34144883|NCT02535260|||COHORT||PROSPECTIVE|||||||
34144884|NCT02012088|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144885|NCT01565941|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144886|NCT05018806|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144887|NCT03112746|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144888|NCT03369899|||COHORT||PROSPECTIVE|||||||
34144889|NCT00049777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34144890|NCT02435017|||COHORT||CROSS_SECTIONAL|||||||
34144891|NCT03141463|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144892|NCT00523835|||NATURAL_HISTORY||OTHER|||||||
34144893|NCT00951249|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34144894|NCT03244319|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144895|NCT02980094|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34144896|NCT03606447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144897|NCT01024491|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144898|NCT00993109|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144899|NCT04312607|||COHORT||PROSPECTIVE|||||||
34144900|NCT00189943|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34144901|NCT00714766|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34144902|NCT02740413|||COHORT||RETROSPECTIVE|||||||
34144903|NCT01059253|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144904|NCT03859739|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34144905|NCT05754060|||COHORT||PROSPECTIVE|||||||
34144906|NCT03278431|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-blind||t|f|f|f
34144907|NCT00866346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144908|NCT02770976|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144909|NCT00235391|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144910|NCT03090074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144911|NCT01928823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144912|NCT01107561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144913|NCT02463032|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144914|NCT05615857|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||We are to count the number of adenomas and polyps identified per patient while using the Endocuff. These numbers will be compared to the number of identified adenomas and polyps found without the use of the Endocuff retrospectively. In addition, the number of adenomas and polyps found in the rectum while using the Endocuff will be compared to the numbers of adenomas and polyps found with retroflexion without the use of Endocuff. Once the colonoscopy is complete, the patient's level of comfort during the procedure will be documented.||||
34144915|NCT06153433|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34144916|NCT01304810|||COHORT||PROSPECTIVE|||||||
34144917|NCT00002824||||TREATMENT||||||||
34144918|NCT01688843|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144919|NCT00346840|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144920|NCT02221518|NA|SINGLE_GROUP||OTHER||NONE||||||
34144921|NCT03173911|RANDOMIZED|PARALLEL||OTHER||SINGLE||Randomized clinical trial where participants will be allocated into four intervention groups: G1 (n = 12) will receive therapeutic elastic bandage by the Therapy Taping® method (BET) in the ankles; G2 (n = 12) will receive the application of the BET in the lumbar region and G4 (n = 12) will receive the application for all the strategies. The individuals' balance will be evaluated in four moments: pre-intervention (Pre), immediately (Ime), 24 and 48 hours after intervention (24h and 48h). The main equilibrium parameters analyzed will be: ellipse area (95%) of COP in square centimeters (A-COP in cm2), average speed in centimeters per second (VM in cm / s) and average frequency in Hertz (FM in Hz) Of COP oscillations in the anterior-posterior (A / P) and mid-lateral (M / L) directions, during three postural control tasks: open-eye semitandem (STOA) and right and left unipodal support (UNPD And UNPE).|t|f|f|f
34144922|NCT03377738|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144923|NCT00839267|||CASE_CONTROL||PROSPECTIVE|||||||
34144924|NCT00385723|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144925|NCT00129610|RANDOMIZED|PARALLEL||ECT||NONE||||||
34144926|NCT04868487|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34144927|NCT02688582|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144928|NCT01969617|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34144929|NCT05778773|||COHORT||PROSPECTIVE|||||||
34144930|NCT05945459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144931|NCT03745352|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144932|NCT02120963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34144933|NCT01509677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34144934|NCT04519047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34144935|NCT01487941|||CASE_ONLY||PROSPECTIVE|||||||
34144936|NCT00301548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837646|NCT00108251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837647|NCT01895790|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34144937|NCT01476280|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34144938|NCT06036381|||CASE_ONLY||RETROSPECTIVE|||||||
34144939|NCT03283436|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients will be blinded to the treatment arm; however, the surgeon will know if a patient has been randomized to receive the block during the hysterectomy.||t|f|f|f
34144940|NCT01478841|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34144941|NCT02675192|||COHORT||PROSPECTIVE|||||||
34144942|NCT05066646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144943|NCT03854890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144944|NCT03815994|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34144945|NCT06430190|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144946|NCT04177420|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34144947|NCT05088993|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34144948|NCT05433038|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34144949|NCT03710239|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know what type of dilator they have been assigned, however the medical care team (including investigators) will be aware.|Participants will be randomly assigned to receive one of two existing dilator times, with the remainder of care and study procedures being identical.|t|f|f|f
34144950|NCT05162001|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144951|NCT05554978|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|study drug preparation by a person not involved in patient recruitment and treatment|randomized, double-blind, placebo-controlled pilot trial|t|t|t|t
34144952|NCT06099106|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144953|NCT04415879|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
34144954|NCT03216486|NA|SINGLE_GROUP||TREATMENT||NONE||Single arm, open-label||||
34144955|NCT04421859|NA|SINGLE_GROUP||OTHER||NONE||||||
34144956|NCT03236870|||COHORT||PROSPECTIVE|||||||
34144957|NCT00733772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34144958|NCT01461070|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34144959|NCT03701997|||COHORT||PROSPECTIVE|||||||
34144960|NCT04888143|NA|SINGLE_GROUP||OTHER||NONE||||||
34144961|NCT04790812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patient regimen randomization will be achieved by use of a random number generator. The care provider or clinic faculty/nurse will blindly administer the regimen to the patient prior to procedure. A placebo capsule will be used to mimic the acetaminophen capsule to maintain blinding of care provider and patient. Preemptive medications will be dispensed in disposable containers prior to the start of daily operations. The research member tasked with dispensing will not be involved with the administration of medications to patients on the day of surgery. The PI and other members of the research team will not be blinded.|A randomized, double-blind, placebo-controlled, prospective clinical trial. Subjects will be given a single oral dose of celecoxib 200 mg with placebo (Group 1), or celecoxib 200 mg in combination with acetaminophen 1000 mg (Group 2) 30 to 60 minutes prior to the dental procedure.|t|t|f|f
34144962|NCT04006301|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34144963|NCT05766904|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Block randomisation would be used to generate the list of treatment groups with a block size of 4 in a centralised computer by a staff in the Research Centre unrelated to data analysis. Group assignment would be concealed and performed by another staff unrelated to data analysis who will pick the group number from the random allocation sequence in sequential order. The subjects and investigators would therefore be blinded.|Participants in the vaccination group would receive two doses of 4CMenB vaccine 1 month apart (at Month 0 and Month 1) while subjects in the control group would receive two doses of normal saline of a similar volume.|t|t|t|t
34144964|NCT04962230|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||This is a Phase 1, fixed sequence, 2-period study to estimate the effect of a strong CYP3A4 inducer, carbamazepine, on the PK of PF-07321332 and ritonavir in healthy participants. A total of approximately 12 healthy male and/or female participants will be enrolled into the study.||||
34144965|NCT04175522|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144966|NCT04492371|||COHORT||OTHER|||||||
34144967|NCT02609685|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34144968|NCT00722189|||OTHER||PROSPECTIVE|||||||
34144969|NCT05236985|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Randomized, double-blinded, 2-arm, parallel study.|t|t|t|f
34144970|NCT04542668|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study period will be 4 weeks. In each week, the subjects will undergo a different physical activity intervention. The order of the interventions will be randomized. The interventions will be separated by a minimum of 4 days. Inteventions: Cycling, Running, exercise-simulation with inotropy and resting.||||
34144971|NCT04304794|||COHORT||RETROSPECTIVE|||||||
34144972|NCT01018095|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34144973|NCT02156557|NA|SINGLE_GROUP||SCREENING||NONE||||||
34144974|NCT06012279|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144975|NCT01318070|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34144976|NCT00103519|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34144977|NCT01158027|||||CROSS_SECTIONAL|||||||
34144978|NCT01891344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34144979|NCT00576030|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34144980|NCT00029458||||TREATMENT||||||||
34144981|NCT04879849|NA|SEQUENTIAL||TREATMENT||NONE||||||
34144982|NCT00802789|||COHORT||PROSPECTIVE|||||||
34144983|NCT00534378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34144984|NCT00570583|||CASE_CONTROL||PROSPECTIVE|||||||
34144985|NCT04642924|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospectively inclusion treatment arm. Compared to historical cohort.||||
34144986|NCT04623515|||COHORT||RETROSPECTIVE|||||||
34144987|NCT01304368|RANDOMIZED|PARALLEL||TREATMENT||||||||
34144988|NCT00785551|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34144989|NCT02494089|||CASE_ONLY||PROSPECTIVE|||||||
34144990|NCT02962596|||COHORT||PROSPECTIVE|||||||
34144991|NCT04557475|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two Group Assignment||||
34144992|NCT03172065|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34144993|NCT03538444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Neither participants nor investigators will know whether the participant is assigned to the active or sham condition.|40 individuals (20 per group) will be randomly assigned to either active or sham rTMS.|t|t|t|t
34144994|NCT04510883|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||SINGLE||An unblinded randomized controlled trial. Participants in the first cohort directly receive the intervention for 8 weeks. Participants in the second cohort receive the intervention after a waiting list condition of 4 weeks, serving as a control group.|f|f|f|t
34144995|NCT06293638|||CASE_CONTROL||PROSPECTIVE|||||||
34144996|NCT04918953|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34144997|NCT00868257|||COHORT||PROSPECTIVE|||||||
34144998|NCT02278614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34144999|NCT02416986|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145000|NCT03628638|||COHORT||PROSPECTIVE|||||||
34145001|NCT04526717|NA|SINGLE_GROUP||TREATMENT||NONE||Classical 3+3 design to determine MTD.||||
34145002|NCT05736705|RANDOMIZED|PARALLEL||OTHER||SINGLE|The patient will not know which electrocautery tool will be used in their procedure.|Two groups with patients randomized into receiving either the standard of care monopolar electrocautery tool or bipolar electrocautery tool.|t|f|f|f
34145003|NCT04341987|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145004|NCT05960305|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34145005|NCT03204552|||COHORT||PROSPECTIVE|||||||
34145006|NCT05767502|||CASE_ONLY||PROSPECTIVE|||||||
34145007|NCT00002368||PARALLEL||TREATMENT||||||||
34145008|NCT05675761|||COHORT||RETROSPECTIVE|||||||
34145009|NCT01083498|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145010|NCT05908708|||CASE_ONLY||PROSPECTIVE|||||||
34145011|NCT02395055|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34145012|NCT03694873|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145013|NCT03207945|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145014|NCT04243395|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||f|f|t|t
34145015|NCT02526862|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145016|NCT01811602|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145017|NCT06357273|||CASE_CONTROL||PROSPECTIVE|||||||
34145018|NCT02311569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145019|NCT03973463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145020|NCT01993316|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145021|NCT04804735|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145022|NCT02649855|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145023|NCT03515174|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34145024|NCT04399954|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE|No masking, product will be given open label.|Single group - all patients to receive Ketoflo.||||
34145025|NCT05126160|||COHORT||PROSPECTIVE|||||||
34145026|NCT02823184|||COHORT||RETROSPECTIVE|||||||
34145027|NCT02333981|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145028|NCT05122117|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34145029|NCT00885768|||CASE_ONLY||PROSPECTIVE|||||||
34145030|NCT00584571|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34145031|NCT00533858|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145032|NCT03423108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34145033|NCT05215015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145034|NCT02679625|||OTHER||CROSS_SECTIONAL|||||||
34145035|NCT05270291|||COHORT||PROSPECTIVE|||||||
34145036|NCT05782192|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blind|Parallel Assignment|t|t|t|t
34145037|NCT01731834|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34145038|NCT02117323|||COHORT||PROSPECTIVE|||||||
34145039|NCT00627536|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
34145040|NCT01336751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145041|NCT01670565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145042|NCT03453866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Sealed Opaque Envelope|Prospective Randomized Controlled Trial|t|f|f|t
34145043|NCT04094233|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
33837648|NCT06292442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837649|NCT05146089|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Subjects will be asked to complete 1 1-hour screening visit, 1 overnight at-home monitoring, and 1 (women) or 2 (men) 5-hour study visits. Subjects will not be blinded to study condition and all subjects will serve as their own controls. All study visits will be separated by a minimum of 1 week and will occur at the same time of day.||||
33837650|NCT00681668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837651|NCT03197168|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|||t|t|t|f
34145044|NCT01376375|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||||||||
34145045|NCT02211118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145046|NCT03468972|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145047|NCT01145274|||COHORT||PROSPECTIVE|||||||
33837652|NCT00482157|NA|PARALLEL||TREATMENT||DOUBLE||||||
33837653|NCT02051374|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145048|NCT04181580|NA|SINGLE_GROUP||OTHER||NONE||Healthy subjects will test made-to-measure compression garments. No comparator group due to exploartive design||||
34145049|NCT00984607|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145050|NCT02111655|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145051|NCT05013268|NA|SEQUENTIAL||TREATMENT||NONE||||||
34145052|NCT02922842|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
34145053|NCT00001812||||TREATMENT||||||||
34145054|NCT03622021|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34145055|NCT02688088|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145056|NCT04434027|||COHORT||PROSPECTIVE|||||||
34145057|NCT03720600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145058|NCT05140265|||CASE_CONTROL||RETROSPECTIVE|||||||
34145059|NCT03303898|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34145060|NCT05140837|||COHORT||PROSPECTIVE|||||||
34145061|NCT04900610|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Multi-centre, placebo-controlled, randomized, open-label intervention clinical trial|t|f|f|f
34145062|NCT06260137|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34145063|NCT06073639|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34145064|NCT03079401|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145065|NCT03224871|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||All patients will go through the same process except that some patients will be on nivolumab as checkpoint blockade and some patients will be on pembrolizumab as checkpoint blockade.||||
34145066|NCT03383757|NA|SINGLE_GROUP||OTHER||NONE||||||
34145067|NCT06373770|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34145068|NCT01603381|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145069|NCT04076345|||COHORT||PROSPECTIVE|||||||
34145070|NCT00022724|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||||||||
34145071|NCT00327574|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34145072|NCT05049330|||COHORT||PROSPECTIVE|||||||
34145073|NCT00003963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145074|NCT03397134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145075|NCT02863523|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145076|NCT04272710|||COHORT||RETROSPECTIVE|||||||
34145077|NCT03981666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145078|NCT05904522|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||Biopsies will be taken from lesional and non-lesional skin of the patients in the dermatology clinic and sent to laboratory for histopathologic examination. Lesional skin of the patient will be compared with the non-lesional skin of the same patient.||||
34145079|NCT05942118|||COHORT||PROSPECTIVE|||||||
34145080|NCT00532571|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34145081|NCT02576860|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145082|NCT04836390|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145083|NCT04488744|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|Participant will not know nicotine dose or rate of infusion.|placebo-controlled, mixed-design with nicotine dose as a between-subject and nicotine delivery rate as a within-subject factor.|t|f|t|f
34145084|NCT05182580|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|The retina specialists are masked both to patient group assignment (that is, whether autonomous AI results were used or not on the particular clinic day) and also masked to the results of the autonomous AI on Intervention days. Patients are also masked to group assignment and autonomous AI screening results.|Cluster-randomized (by clinic day) controlled trial.|t|t|f|f
34145085|NCT04233658|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145086|NCT04493684|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double-blind study with participants and the site-staff blinded and sponsor unblended. Part 3 of the study will be open-label.|Part 1 is a single ascending dose study, Part 2 is multiple ascending dose study while Part 3 is a 3-period crossover design.|t|f|t|f
34145087|NCT00474864|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34145088|NCT02898961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145089|NCT05104632|||COHORT||PROSPECTIVE|||||||
34145090|NCT01329614|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34145091|NCT00279838|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34145092|NCT02532751|||COHORT||PROSPECTIVE|||||||
34145093|NCT04401345|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Glycopyrrolate and normal saline will be administered as 1 ml clear fluid, and therefore, both patient and investigator will be blinded to the randomization and intervention.|"Experimental Group (GP): In the experimental group patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated.~Placebo Group (NS): In the placebo group patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated."|t|t|t|t
34145094|NCT00136968|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34145095|NCT03763344|NON_RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34145096|NCT05911438|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145097|NCT04333602|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Both the patient, the primary doctor and the laboratory worker do not know the result of the culture. Only the doctors in charge of this process know the result and contact the patient directly if they are in the treatment group.|Group 1: Asymptomatic Bacteriuria screening and treatment and Group 2: Asymptomatic Bacteriuria screening and No treatment for AB.|t|t|f|t
34145098|NCT01989702|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145099|NCT02847221|||COHORT||PROSPECTIVE|||||||
34145100|NCT05239221|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Part C is open label||t|t|t|t
34145101|NCT05133869|NA|SINGLE_GROUP||TREATMENT||NONE|All participants receive the same intervention, therefore there is no masking.|This is a randomized multiple baseline single case experimental design (SCED) intervention study.||||
34145102|NCT01414205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145103|NCT00990912|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145104|NCT00000729|RANDOMIZED|||TREATMENT||||||||
34145105|NCT01522144|NA|SINGLE_GROUP||||NONE||||||
34145106|NCT02252809|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34145107|NCT01633346|||COHORT||PROSPECTIVE|||||||
34145108|NCT02634021|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34145109|NCT00682513|||FAMILY_BASED||PROSPECTIVE|||||||
34145110|NCT03527628|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145111|NCT00750529|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34145112|NCT05890378|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34145113|NCT04081961|||COHORT||PROSPECTIVE|||||||
34145114|NCT06055816|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145115|NCT03458858|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||f|f|t|t
34145116|NCT06480175|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837654|NCT00833378|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837655|NCT06405763|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145117|NCT06087900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145118|NCT03920059|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150973|NCT04183088|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Masking is None (open label) and the allocation is N/A for part 1.|This trial consists of 2 parts. Part 1 is a single-arm study. Part 2 of this trial is a randomized study. Subjects will be 1:1 randomized to 2 treatment groups: (1) regorafenib + tislelizumab combination regimen as used in Part 1, versus (2) regorafenib therapy. For subjects in the group 2, when imaging evaluation of tumor response indicates stable disease or progressive disease, according to RECIST v1.1, study treatment will be shifted to regorafenib + tislelizumab combination regimen.|t|t|t|f
33837656|NCT02112890|||CASE_ONLY||CROSS_SECTIONAL|||||||
33837657|NCT03095469|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|all of the participants, operators, investigators and outcomes assessors don't know the grouping situation before the study finished.|coronary artery disease patients with anxiety who receive selective PCI|t|t|t|f
33837658|NCT05681273|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33837659|NCT02397551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837660|NCT04190576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two groups were made one test and control. The control group were treated with MINIMALLY INVASIVE RIDGE AUGMENTATION technique alone and the test group were treated with adjunctive low-level laser therapy for bone regeneration.|t|f|f|t
34145119|NCT04175574|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To ensure non-bias during the randomization, both the researcher and the patient will be masked and this procedure will be carried out by a trained research assistant.|The design of this study is a randomised controlled trial based on the CONSORT 2010 flow diagram. Patients warded at the orthopaedics wards in two government hospitals, who have been hospitalized following a closed midshaft femur fracture and planned for surgery. Patients who fulfill the inclusion criteria will be invited to participate in this study. Recruitment to participate is based on voluntary and they will be given the patient information sheet, written informed consent and briefed on the protocol of the study. The patients will be randomised either in the intervention or control group by selecting an opaque envelope.|t|f|t|f
34145120|NCT03242772|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145121|NCT05481424|RANDOMIZED|CROSSOVER||OTHER||DOUBLE||Investigators will examine a series of participants (N=25), each of whom will participate in a five-week experiment. Each participant will have a screening visit at their home. The study will be conducted over five successive one-week periods with two cohorts of participants experiencing the same series of lighting interventions. All data collection will be performed during the working days (Monday - Friday) when participants are exposed to the lighting in their home offices.|t|f|f|t
34145122|NCT00003772|||CASE_ONLY||PROSPECTIVE|||||||
34145123|NCT02914548|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145124|NCT04119622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145125|NCT06605196|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145126|NCT00005013|RANDOMIZED|||TREATMENT||DOUBLE||||||
34145127|NCT02822378|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145128|NCT03444766|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145129|NCT00563095|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145130|NCT05936502|||COHORT||RETROSPECTIVE|||||||
34145131|NCT03333395|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145132|NCT01596335|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145133|NCT04035564|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34145134|NCT05561465|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145135|NCT01742572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145136|NCT01328041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145137|NCT01718249|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34145138|NCT01054157|||CASE_ONLY||PROSPECTIVE|||||||
34145139|NCT03968159|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145140|NCT02907853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145141|NCT02266277|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145142|NCT03844113|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||parallel assignment|t|t|t|t
34145143|NCT02437409|||COHORT||PROSPECTIVE|||||||
34145144|NCT06467669|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145145|NCT03452436|||CASE_CONTROL||PROSPECTIVE|||||||
34145146|NCT03512431|||COHORT||PROSPECTIVE|||||||
34145147|NCT00148785|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145148|NCT04247191|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||The first group receives the PBI parent intervention; the second group receives the P-Chat intervention; the third group receive the P-Chat+ intervention; and the fourth group is an assessment-only control.|f|f|t|t
34145149|NCT02410824|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34145150|NCT02502513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145151|NCT01683513|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145152|NCT05297487|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145153|NCT01903395|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34145154|NCT03640637|||COHORT||PROSPECTIVE|||||||
34145155|NCT00906724|||CASE_ONLY||PROSPECTIVE|||||||
34145156|NCT04690192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145157|NCT03180398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145158|NCT06516263|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a parallel arm, randomised control clinical Trial (RCT) on a cohort of Dublin Dental University Hospital patients who are having dental implants placed.||||
34145159|NCT01236872|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
34145160|NCT05003661|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34145161|NCT03994315|RANDOMIZED|PARALLEL||OTHER||NONE||This study is a single-center, prospective, randomized, open-label study of an infant probiotic (B. infantis EVC001) and a prebiotic supplement (LNT) in exclusively formula-fed infants. Nine subjects will be randomized (1:1:1) using sealed envelopes into three treatment arms.||||
34145162|NCT00044187|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34145163|NCT00499408|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837661|NCT00544232|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837662|NCT04510480|||OTHER||PROSPECTIVE|||||||
33837663|NCT03488680|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33837664|NCT01777334|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145164|NCT01731730|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145165|NCT05100823|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145166|NCT04619446|||COHORT||PROSPECTIVE|||||||
34145167|NCT00434759|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145168|NCT02606227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145169|NCT00566865|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34145170|NCT03343080|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34145171|NCT05818761|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Randomised|f|f|t|f
34145172|NCT03453255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145173|NCT03579446|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34145174|NCT02648022|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145175|NCT00149994|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34145176|NCT06343038|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||"In Phase Ia:~Radiation dosimetry driven, head-to-head in cross-over design comparison of tumour and critical organ absorbed doses after sequential non-therapeutic injections of 161Tb-SibuDAB and 177Lu-PSMA-I\&T in the same mCRPC patients undergoing standard 177Lu-PSMA-I\&T RLT.~In Phase Ib:~Clinical and radiation dosimetry-based dose escalation study, with a classical 3+3 design, to identify the optimal biologic dose (injected activity) of 161Tb-SibuDAB for safe and effective RLT."|t|f|f|f
33834023|NCT05907317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Step one: The primary outcome will be assessed by a blinded investigator. The principal investigator from each centre must develop a local blinding procedure, describing how blinding is achieved. To support the principal investigators in this work, a Standard Operation Procedure with suggestions for blinding procedures will be developed. Data managers, statisticians, and conclusion drawers will be blinded.~Step two: Due to the nature of the experimental intervention, clinical staff and the parents will not be blinded to group allocation. Thus, the primary outcome will not be blinded in cases when it relies on parental reporting. If there is no contact with the parents, or if they do not return the questionnaire, data will be collected from health care records. Investigators reviewing the health care records will, if possible, be blinded to the allocated intervention. Data managers, statisticians, and conclusion drawers will be blinded."|The trial will recruit 1610 babies in step one. Randomisation will continue until 3000 babies are recruited in step two.|f|f|t|f
33834024|NCT00003072||||SUPPORTIVE_CARE||||||||
33834025|NCT05608031|||COHORT||PROSPECTIVE|||||||
33834026|NCT04333732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|For the MR or MMR vaccine, there will be a placebo vaccine. Attempts will be made to maintain masking for other interventions (e.g. oral tablets) added to the platform by including suitable placebo options.|An international, multi-site, randomized, placebo-controlled, Bayesian platform clinical trial. Initially there will be 2 arms, but we anticipate adding intervention arms to the platform. Combining interventions, allowing assessment of potential interactions, will be considered when arms are added.|t|f|t|f
33834027|NCT00358644|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834028|NCT05597423|RANDOMIZED|PARALLEL||OTHER||SINGLE||All interventions will take place 10 minutes after the end of resistance training focused on the lower limbs (twice a week for four weeks). The intervention group will receive the massage for 16 minutes in 4 muscle groups bilaterally: i) quadriceps ii) calf iii) hamstrings iv) lower back. The techniques used will be the superficial effleurage followed by the deep effleurage, petrissage and tapotement. In the placebo group, the same cream used to perform the massage will be spread over the quadriceps, calf, hamstrings and lower back with three superficial slides on each musculature to spread the cream. This process will be carried out bilaterally and the participant will be asked to remain in the supine position for 16 minutes. In the control group, participants will be asked to rest for 16 minutes and the participants can be seated, standing or walking through the space during this period.|f|f|f|t
33834029|NCT05301998|NA|SINGLE_GROUP||OTHER||NONE||||||
33834030|NCT05500079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834031|NCT02119338|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834032|NCT05442346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834033|NCT02712970|||CASE_ONLY||RETROSPECTIVE|||||||
33834034|NCT03843398|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834035|NCT01632189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834036|NCT04211025|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||"Intervention~Our intervention consists of two parts:~1. Routine screening for sociodemographics and social needs such as poverty~2. Intervening when poverty is identified through linkage to a trained staff member who uses a Benefits Screening Tool to identify benefits that the patient is entitled to, and then provides support"||||
33834037|NCT03617289|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834038|NCT01816347|||COHORT||RETROSPECTIVE|||||||
33834039|NCT00447590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834040|NCT03700905|RANDOMIZED|PARALLEL||TREATMENT||NONE||Arm Ia and Arm Ib are summarized in one Arm, due to central ethics committee, as they both include neoadjuvant and adjuvant treatment compared to Arm II||||
33834041|NCT01188356|||COHORT||PROSPECTIVE|||||||
33834042|NCT01929876|NA|SINGLE_GROUP||||NONE||||||
33834043|NCT03060382|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33834044|NCT02132715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834045|NCT03830762|RANDOMIZED|PARALLEL||OTHER||SINGLE|Study treatment is only blinded for the trial subject.|A Dose Escalation Committee will review the results from Cohort 1 (20 mg active vs. placebo arms) and provide a recommendation to proceed with Cohort 2 (30 mg active vs. placebo arms) randomisation which involves a dose escalation.|t|f|f|f
33834046|NCT01428752|||COHORT||PROSPECTIVE|||||||
33834047|NCT05326698|||CASE_ONLY||PROSPECTIVE|||||||
33834048|NCT01321892|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834049|NCT01562262|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834050|NCT02561247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834051|NCT06377956|||COHORT||PROSPECTIVE|||||||
33834052|NCT03024398|||COHORT||PROSPECTIVE|||||||
33834053|NCT04650399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33834054|NCT02844530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834055|NCT04879264|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834056|NCT01176461|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834057|NCT04670770|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834058|NCT02978677|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834059|NCT02757820|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33834060|NCT01910103|||COHORT||PROSPECTIVE|||||||
33834061|NCT00426634|||||PROSPECTIVE|||||||
33834062|NCT05831436|||OTHER||CROSS_SECTIONAL|||||||
33834063|NCT03888599|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33834064|NCT00431613|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834065|NCT04810468|NA|SINGLE_GROUP||SCREENING||NONE||The study asses the prevelance malnutrition in primary school children by using anthropometric measurment and asses the sociodemographic data and hygiene information and dietary habits affecting it||||
33834066|NCT01209598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834067|NCT00202046|||CASE_CONTROL||PROSPECTIVE|||||||
33834068|NCT01821937|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834069|NCT00440245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834070|NCT03436303|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomly assigned to three groups: CEE 0.3 mg/micronized progesterone (MP) 100 mg group, CEE 0.625 mg/MP 100 mg group,CEE 0.625 mg/dydrogesterone 10 mg group.||||
33834071|NCT04921579|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single ( Outcomes Assessor) Only the outcome assessors will be blind. The patients name will be sealed from pre and post radiographs and study models. Then two assessors will carry out, blindly and independently, the measurements and analysis of the study||f|f|f|t
33834072|NCT00129142|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
33834073|NCT00583947|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33834074|NCT02209181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834075|NCT00373919|RANDOMIZED|PARALLEL||||DOUBLE||||||
33834076|NCT04788342|||COHORT||PROSPECTIVE|||||||
33834077|NCT03144544|||COHORT||RETROSPECTIVE|||||||
33834078|NCT03692156|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834079|NCT04468230|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834080|NCT05129332|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834081|NCT03958006|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834082|NCT04513353|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834083|NCT04834492|||CASE_CONTROL||RETROSPECTIVE|||||||
33834084|NCT00462605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834085|NCT00467415|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834086|NCT02181907|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834087|NCT01177761|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834088|NCT01715207|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open Label|||||
33834089|NCT02530788|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834090|NCT01646385|||COHORT||RETROSPECTIVE|||||||
33834091|NCT02968706|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834092|NCT02422732|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33834093|NCT00167232|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33834094|NCT02412579|||COHORT||PROSPECTIVE|||||||
33834095|NCT03043430|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Medication (ketamine versus midazolam) will be drawn up in unmarked syringe and applied to the patient by mucosal atomization device by a nurse not directly involved in the investigation or the patient's care.|Subjects will be randomized to one of two treatment arms.|t|t|t|t
33834096|NCT05815537|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||There are two arms in the exposure of reverberation for participants. For children (n1=45) and adults (n1=15) assigned to Arm 1, they receive a non-reverberant environment (control) and a low-reverberant environment (intervention A). For children (n2 = 45) and adults (n2 = 15) assigned to Arm 2, they receive the same non-reverberant environment (control) and a high-reverberant environment (intervention B). Both arms of children and adults enrolled perform the same psychoacoustic tasks for outcome assessments.||||
33834097|NCT02414126|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
33834098|NCT00721812|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33834099|NCT00061399|||||PROSPECTIVE|||||||
33834100|NCT04196543|NA|SINGLE_GROUP||OTHER||NONE||||||
33834101|NCT01780298|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834102|NCT04237285|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33834103|NCT04532632|||OTHER||PROSPECTIVE|||||||
33834104|NCT05421468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834105|NCT00003428|RANDOMIZED|||TREATMENT||||||||
33834106|NCT02961478|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834107|NCT04003532|||COHORT||PROSPECTIVE|||||||
33834108|NCT05679999|||CASE_CONTROL||RETROSPECTIVE|||||||
33834109|NCT00511186|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834110|NCT05784610|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|"Masking only for the anesthesist in arms Time 1"|"Time 1: Non-automated neuromuscular blockade monitoring (TOF/PTC). As the NMB monitoring is depending on anesthesiologist usual practice and so only TOF measure is systematic, it is necessary to include a blind anesthesiologist measurement with the ATP mode in order to compare with data obtained during Time 2.~Time 2: Automated neuromuscular blockade monitoring (ATP). TOF and PTC stimulations are regularly performed, and PTC is systematically performed if TOF = 0/4"|f|t|t|f
33834111|NCT05230719|||CASE_CONTROL||RETROSPECTIVE|||||||
33834112|NCT02365103|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33834113|NCT05308277|NA|SINGLE_GROUP||OTHER||NONE||Engineering validation of a lung function monitoring device||||
33834114|NCT04174209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834115|NCT01712269|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834116|NCT00583466|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834117|NCT04131764|||CASE_CONTROL||OTHER|||||||
33834118|NCT02607787|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834119|NCT05021445|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"each participant will be requested to draw either number one or number two from a box. number one will be allocated to group A . and number two will be allocated o group B. The group A consists of 12 elderly participants who received intervention protocol of Pilates- based exercises program in which total 12-sessions were given for thrice a week for four weeks for 50-minutes.~Group B The group B consists of 12 elderly participants who received intervention protocol of Conventional balance training exercises in which total 12-sessions were given for thrice a week for four weeks for 50-minutes."|f|f|f|t
33834120|NCT00490698|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834121|NCT04127071|RANDOMIZED|PARALLEL||TREATMENT||NONE||A prospective, nonblinded, randomized controlled trial comparing ultrasound-guided needle aspiration to incision and drainage of uncomplicated skin abscesses.||||
33834122|NCT02145169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834123|NCT02287233|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33834124|NCT00370370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834125|NCT05470270|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834126|NCT04714398|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
33834127|NCT03157245|||CASE_ONLY||PROSPECTIVE|||||||
34145177|NCT05976451|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34145178|NCT01189058|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|f|t
34145179|NCT06157320|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145180|NCT04149574|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145181|NCT00035360|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834128|NCT03097406|||COHORT||PROSPECTIVE|||||||
33834129|NCT02754193|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834130|NCT06171035|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834131|NCT05921097|||COHORT||CROSS_SECTIONAL|||||||
33834132|NCT03602586|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834133|NCT00976690|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834134|NCT04576845|||CASE_CONTROL||PROSPECTIVE|||||||
33834135|NCT05407077|||CASE_CONTROL||RETROSPECTIVE|||||||
33834136|NCT00333905|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33834137|NCT00121121|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834138|NCT06378697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834139|NCT03302390|||OTHER||PROSPECTIVE|||||||
33834140|NCT00534053|RANDOMIZED|SINGLE_GROUP||SCREENING||TRIPLE|||t|f|t|t
33834141|NCT00718471|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834142|NCT04692467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834143|NCT01199978|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834144|NCT00853372|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834145|NCT04430166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834146|NCT03469726|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||International multicenter prospective cohort study||||
33834147|NCT06066151|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834148|NCT00025909||||TREATMENT||||||||
33834149|NCT01161342|||COHORT||PROSPECTIVE|||||||
33834150|NCT00478283||||HEALTH_SERVICES_RESEARCH||||||||
33834151|NCT05499325|||COHORT||RETROSPECTIVE|||||||
33834152|NCT06292390|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|A pollster who did not know the people in the control and intervention group was selected and collected the data. The SPSS data were entered by someone selected other than the surveyor and the researcher. Thus, the study was conducted as a double-blind.|Randomized controlled trial (Two groups with intervention and control group)|f|f|t|t
33834153|NCT01263249|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33834154|NCT02980523|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834155|NCT02992847|||COHORT||RETROSPECTIVE|||||||
33834156|NCT03645148|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834157|NCT05950100|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The first researcher who will follow the draw will be blinded to the patients' assessments and to the intervention. The second researcher who will evaluate the two groups will be blind to sampling and intervention. And the immersive virtual reality therapy will be conducted by a third researcher (blinded to sampling and assessments).|Participants who meet the inclusion criteria will be randomized into 2 groups - virtual reality group (GRV) and control group (GC). Both groups will undergo the same assessments and tests.|f|t|t|t
33834158|NCT05432180|||COHORT||PROSPECTIVE|||||||
33834159|NCT02872389|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33834160|NCT05668299|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, prospective, single arm study||||
33834161|NCT02660515|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834162|NCT01275742|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834163|NCT02520700|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33834164|NCT03480113|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834165|NCT02692508|||CASE_CONTROL||PROSPECTIVE|||||||
33834166|NCT01087515|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834167|NCT03184506|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834168|NCT02111863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834169|NCT05019170|RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators are proposing a two-condition, parallel groups, randomized controlled pilot study of a smartphone-based financial incentives intervention for AN pregnant smokers. The experimental group will receive financial incentives (money loaded onto a debit card) contingent on the remote submission of breath carbon monoxide and saliva cotinine tests indicating smoking abstinence in addition to best practices for promoting smoking cessation (Best Practices + Incentives). The control group will receive best practices alone (Best Practices). The use of a best practices group reflects a real-world comparison condition in that all women will receive the treatment that practitioners in the community are instructed to provide (the 5As + quitline referral) thereby enhancing the ecological validity of the study. Additionally, the investigators will minimize between-subject variability in the participant's exposure to these practices by implementing these treatment components themselves.||||
33834170|NCT03316807|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33834171|NCT02102412|NA|SINGLE_GROUP||SCREENING||NONE||||||
33834172|NCT02846493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834173|NCT02466347|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834174|NCT00856245|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834175|NCT01772563|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834176|NCT05247008|NA|SINGLE_GROUP||TREATMENT||NONE||"Treatment protocol:~* Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse."||||
33834177|NCT01979419|||CASE_CONTROL||PROSPECTIVE|||||||
33834178|NCT00364364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834179|NCT04075786|||OTHER||PROSPECTIVE|||||||
33834180|NCT01249508|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33834181|NCT02519946|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33834182|NCT01758705|||COHORT||PROSPECTIVE|||||||
33834183|NCT03197025|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33834184|NCT01708434|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834185|NCT04543383|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834186|NCT04767724|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834187|NCT00607581|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834188|NCT04361812|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834189|NCT01062269|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33834190|NCT02833961|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834191|NCT04225741|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33834192|NCT01796054|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33837665|NCT05090527|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE|None, open provocation test with amoxicillin for eligible patients after risk stratification with a questionnaire.|Entry criteria: Penicillin allergy noted in patients journal or patient reported.||||
33837666|NCT00607672|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837667|NCT02574143|||CASE_ONLY||PROSPECTIVE|||||||
33834193|NCT04250779|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"Research will initially involve collection of data describing the participants' current use of their medication following standard education. Subsequent phases will add audio / haptic coaching to the process of administering medication by MDI, and follow the same participants to determine whether or not there is improvement in technique and adherence to therapy.~The device will be used with a placebo inhaler (given AFTER the participant's regular medication is taken by standard techniques), to determine how participants use the device, and to identify the most effective coaching interventions for this age group. This is to ensure that the device does not interfere with delivery of routine asthma controller medications. The data will be used to develop a subsequent, longer term study in which we will evaluate the effect of the coaching device on asthma control, when it is used with the subject's controller medication."|t|f|f|f
33834194|NCT02314351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33834195|NCT00698282|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33834196|NCT01788475|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834197|NCT06379945|||OTHER||PROSPECTIVE|||||||
33834198|NCT05426993|||COHORT||PROSPECTIVE|||||||
33834199|NCT04510298|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834200|NCT00616824|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834201|NCT05728190|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834202|NCT00207753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834203|NCT02719288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834204|NCT05526365|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|"Students will be blinded to allocation; performed using sequentially generated random numbers. The control and intervention exams will be identical in all but the idea density of the questions.~The students are the unit of randomisation and intervention. As the randomisation will be 1:1, the block size multiplier will be 2, 4, 6 and the block size 4, 8, and 12. This approach will reduce bias and balance allocating participants to the treatment arm. Furthermore, the process will adopt block permutation, meaning that treatment assignments within blocks are determined to be random in order but that the desired allocation proportions are achieved exactly within each block.~A computerised random number generator will generate the sequence"|Participants randomised to two arms, control and intervention|t|f|f|f
33834205|NCT04278586|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The principal investigator will be masked to arm assignment.|Two arms, live-online M-ROCC and live-online control, which are randomly assigned in a 1:1 ratio at the same time and are implemented in parallel.|f|f|t|f
33834206|NCT01493037|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834207|NCT00561899|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834208|NCT02315768|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834209|NCT04449237|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33834210|NCT00484692|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834211|NCT03508947|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|t|f
33834212|NCT00517842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834213|NCT00385307|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834214|NCT05638347|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Part 1: HRS-7085 Single Ascending Dose (SAD) Both males and females are planned to be enrolled in five cohorts (optional and determined by Safety Review Committee (SRC) in this SAD study Part 2: Food Effect: Participants in cohort 3 who have finished the follow-up visit will be involved in the food effect study after safety evaluation by the investigator.|t|f|t|f
33834215|NCT01941238|||COHORT||PROSPECTIVE|||||||
33834216|NCT04849689|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33834217|NCT01114451|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834218|NCT05121389|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834219|NCT04565262|RANDOMIZED|PARALLEL||TREATMENT||NONE||These subjects will be randomized (1:1) to group A(treated with NAs + IFN for 96 weeks) and group B(treated with NAs for 48 weeks, then NAs combined with IFN for 96 weeks).Meanwhile, 1-6 years and 7-16 years patients should be distributed by 1:1 ratio by random method in both groups.||||
33834220|NCT01457274|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33834221|NCT01337362|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834222|NCT05057247|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834223|NCT01576198|||CASE_ONLY||RETROSPECTIVE|||||||
33834224|NCT02214680|NA|SINGLE_GROUP||||NONE||||||
33834225|NCT01831037|||COHORT||PROSPECTIVE|||||||
33834226|NCT00575042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834227|NCT00755729|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
33834228|NCT02405897|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
33834229|NCT00652509|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834230|NCT06056089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33834231|NCT04350099|||COHORT||PROSPECTIVE|||||||
33834232|NCT06398990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The subjects randomly assigned to the groups will not be told which group they are in.||t|f|f|f
33834233|NCT04727983|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This study was planned single blinded randomized control.|Patients will be divided into 2 groups randomly.|t|f|f|f
33834234|NCT04686292|||COHORT||PROSPECTIVE|||||||
33834235|NCT00632502|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834236|NCT01191554|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834237|NCT03264690|||COHORT||PROSPECTIVE|||||||
33834238|NCT01782521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834239|NCT02786004|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33834240|NCT05253768|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834241|NCT06402942|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomised control trial||||
33834242|NCT02036437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834243|NCT06019364|||COHORT||PROSPECTIVE|||||||
33834244|NCT01807429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834245|NCT00661843|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834246|NCT01322737|NA|SINGLE_GROUP||||NONE||||||
33834247|NCT02367430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834248|NCT06130072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate with or without Ethiodized oil (Lipidol) in patients with hydrosalpinx prior to IVF|t|f|f|f
33834249|NCT00146445|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834250|NCT03091582|RANDOMIZED|PARALLEL||TREATMENT||NONE||After being clearly told that participation in the study will not impact subsequent care at CSMC, the patient agrees to participate, the patient will review and sign the informed consent form. Next, the patient will be randomized to either receive CBT or BA therapy, and scheduled for CBT or BA therapy sessions.||||
33834251|NCT06034795|||CASE_CONTROL||PROSPECTIVE|||||||
33834252|NCT01498315|||CASE_ONLY||PROSPECTIVE|||||||
33834253|NCT02063581|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834254|NCT01565317|NON_RANDOMIZED|PARALLEL||||NONE||||||
33834255|NCT00157235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834256|NCT01762332|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
33834257|NCT00012662|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33834258|NCT05678283|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834259|NCT05311553|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
33834260|NCT01336205|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834261|NCT00120809|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE||||||
33834262|NCT00132197|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834263|NCT02788266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834264|NCT02977247|||OTHER||PROSPECTIVE|||||||
33834265|NCT04410276|||COHORT||PROSPECTIVE|||||||
33834266|NCT00043953|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834267|NCT02106364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834268|NCT04226092|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834269|NCT04072705|||COHORT||PROSPECTIVE|||||||
33834270|NCT06278337|||OTHER||RETROSPECTIVE|||||||
33834271|NCT03225898|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33834272|NCT00064142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834273|NCT00909129|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834274|NCT04676113|||CASE_CONTROL||PROSPECTIVE|||||||
33834275|NCT04476940|NA|SINGLE_GROUP||PREVENTION||NONE||Pre-Test Post-test||||
33834276|NCT04560647|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834277|NCT05260099|||OTHER||OTHER|||||||
33834278|NCT06114992|||COHORT||PROSPECTIVE|||||||
33834279|NCT01838954|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834280|NCT00861822|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834281|NCT05759533|||CASE_ONLY||PROSPECTIVE|||||||
33834282|NCT05457166|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33834283|NCT00807703|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834284|NCT05969678|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The experimental group will receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete. The control group is only taught the breathing training of abdominal diaphragmatic breathing.||||
33834285|NCT00624013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834286|NCT04147858|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization algorithm, randomization allocation, allocation to study drug or placebo.||t|f|t|t
33834287|NCT02503098|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834288|NCT02566564|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834289|NCT04548505|||COHORT||PROSPECTIVE|||||||
33834290|NCT00891046|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834291|NCT01057745|||COHORT||PROSPECTIVE|||||||
33834292|NCT01377298|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834293|NCT01828086|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834294|NCT02442193|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33834295|NCT02001909|NON_RANDOMIZED|PARALLEL||||NONE||||||
33834296|NCT04524767|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33834297|NCT01042210|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834298|NCT02453984|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834299|NCT03215953|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834300|NCT01453023|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33834301|NCT05803148|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834302|NCT00675584|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834303|NCT02683499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33834304|NCT00823836|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834305|NCT06492772|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33834306|NCT01500993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834307|NCT00774215|||COHORT||RETROSPECTIVE|||||||
33834308|NCT06446232|||OTHER||OTHER|||||||
33834309|NCT01746147|||CASE_ONLY||PROSPECTIVE|||||||
33834310|NCT02024295|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834311|NCT05258591|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834312|NCT05617963|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will be randomized (1:1) to either:~• Experimental arm (A): the patients will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death, patient's decision, or for a maximum of 24 months (26 doses/cycles).~Or~• Control arm (B) or surveillance arm"||||
33834313|NCT03866096|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834314|NCT03451409|||CASE_CONTROL||PROSPECTIVE|||||||
33834315|NCT00344136|||||PROSPECTIVE|||||||
33834316|NCT01854606|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834317|NCT02148510|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834318|NCT01984437|||COHORT||PROSPECTIVE|||||||
33834319|NCT02578498|RANDOMIZED|CROSSOVER||||NONE||||||
33834320|NCT02646709|RANDOMIZED|PARALLEL||||TRIPLE|||f|t|t|t
33834321|NCT05841589|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"the participant didn't know what he rinsed with the prescribed group of mouth rinse.~the outcome assessor didn't know what group of mouth rinse belong to the bacterial count that was evaluated."|the four groups of the mouth rinses were done in parallel with each other|t|f|f|t
33834322|NCT00550212|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834323|NCT06096584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Double blinded randomized controlled study|t|f|f|t
33834324|NCT05572749|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34145182|NCT03069287|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34145183|NCT00915668|RANDOMIZED|CROSSOVER||||NONE||||||
34145184|NCT03208530|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34145185|NCT01921413|||CASE_CONTROL||PROSPECTIVE|||||||
34145186|NCT00006078||||PREVENTION||||||||
34145187|NCT00313768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145188|NCT03922256||SEQUENTIAL||TREATMENT||NONE||This single-cohort, consecutive series clinical study.||||
34145189|NCT00997425|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34145190|NCT04268875|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145191|NCT03398265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145192|NCT02998047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145193|NCT06358560|||CASE_ONLY||PROSPECTIVE|||||||
34145194|NCT00543296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145195|NCT02109874|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34145196|NCT01826266|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34145197|NCT00894478|||COHORT||CROSS_SECTIONAL|||||||
34145198|NCT01459991|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145199|NCT00693654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145200|NCT00219037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34145201|NCT02753127|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145202|NCT06197464|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
34145203|NCT03897894|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34145204|NCT04108715|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor is not aware of the study type||f|f|f|t
34145205|NCT00269503|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
34145206|NCT02443493|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34145207|NCT03801746|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||This is a 2 part study. Part 1 Arm 1 is a cross over design to assess the drug-drug interactions of cyclosporine with vadadustat. Part 1 Arm 2 is a fixed sequence design to assess the drug-drug interactions of probenecid with vadadustat. Part 2 is a crossover design to assess the drug-drug interaction of rifampin with vadadustat||||
34145208|NCT01124227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145209|NCT02221843|||COHORT||PROSPECTIVE|||||||
34145210|NCT01745523|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34145211|NCT03194191|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind (patient blinded to intervention)|"Randomized controlled trial with regular acupuncture needles vs. sham needles. In addition, the sham needles will be placed in areas that do not correspond to any known acupuncture point.~5 bilateral acupoints or placebo acupoints,"|t|f|f|f
34145212|NCT01705158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145213|NCT04728997|||CASE_CONTROL||PROSPECTIVE|||||||
34145214|NCT03879044|NA|SINGLE_GROUP||TREATMENT||NONE||This is a preliminary single-arm study. The study will last up to 6 weeks including the screening period. Subjects will receive active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.||||
34145215|NCT03663374|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||All eligible patients were randomized into two groups to receive investigational drug or placebo at ratio 1:1|t|f|t|f
34145216|NCT01443598|||COHORT||PROSPECTIVE|||||||
34145217|NCT03627065|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145218|NCT05883332|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|The participant and operating urodynamic study practitioner will be blinded to whether SANO or oxygen is given during the study fills. UDS measurements will be assessed by a blinded urologist.|Each participant will undergo urodynamic study (UDS) with two fills. The participant will receive SANO during one fill, and oxygen during the other fill. Participants will be randomized to the order in which they receive SANO or oxygen.|t|t|f|t
34145219|NCT04949568|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Both conditions will receive standard care. We will use sequentially numbered opaque sealed envelopes to conceal the allocation determination|Behavioral: Diabetes Self-management behaviors|t|f|f|f
34145220|NCT03758313|||COHORT||PROSPECTIVE|||||||
34145221|NCT05324423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834325|NCT02016378|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33834326|NCT06222242|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33834327|NCT03478137|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834328|NCT05906797|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834329|NCT05036954|||COHORT||PROSPECTIVE|||||||
33834330|NCT06463236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33834331|NCT04642547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834332|NCT03845062|||COHORT||RETROSPECTIVE|||||||
33834333|NCT06133634|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized, double-blind, placebo-controlled, parallel group design clinical trial.|t|f|t|t
33834334|NCT00738439|||CASE_CONTROL||PROSPECTIVE|||||||
33834335|NCT05442450|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145222|NCT02251132|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145223|NCT01283906|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34145224|NCT05788705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145225|NCT05304429|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Clinical trial with intervention group and control group||||
34145226|NCT04261959|||COHORT||PROSPECTIVE|||||||
34145227|NCT00975819|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145228|NCT03208920|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834336|NCT02671110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834337|NCT03840265|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834338|NCT02838537|||||RETROSPECTIVE|||||||
33834339|NCT02161042|||CASE_CROSSOVER||PROSPECTIVE|||||||
33834340|NCT01776242|||COHORT||PROSPECTIVE|||||||
33834341|NCT00375622|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33834342|NCT04368845|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Block Randomisation, Initial and final outcome assessors blinded to treatment arm|Two arm single blinded randomized control trial|f|f|f|t
34145229|NCT05518370|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145230|NCT01638208|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145231|NCT02840786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834343|NCT03450668|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|Choice of incubator used is randomized and blinded until the subject has been recruited and incubator arm assigned. After which it will be known to all concerned.|a randomized two-arm crossover study|t|t|t|f
33834344|NCT00484601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834345|NCT02432833|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834346|NCT05931445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834347|NCT01114776|||CASE_CONTROL||PROSPECTIVE|||||||
33834348|NCT05064579|||CASE_ONLY||PROSPECTIVE|||||||
33834349|NCT04430803|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33834350|NCT02806843|NA|SINGLE_GROUP||OTHER||NONE||||||
33834351|NCT00356811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834352|NCT06258213|RANDOMIZED|SEQUENTIAL||OTHER||TRIPLE|||t|f|t|t
33834353|NCT02605746|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834354|NCT05777109|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33834355|NCT02155049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834356|NCT02577003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834357|NCT01445795|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33834358|NCT01727661|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834359|NCT05784922|||COHORT||PROSPECTIVE|||||||
33834360|NCT02818998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834361|NCT01210651|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834362|NCT03237169|||COHORT||PROSPECTIVE|||||||
33834363|NCT01984567|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33834364|NCT05078177|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834365|NCT04099654|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834366|NCT00254969|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33834367|NCT05578430|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834368|NCT04767334|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834369|NCT00223275|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33834370|NCT01059305|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834371|NCT05429593|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834372|NCT03652350|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834373|NCT02498262|NA|SINGLE_GROUP||OTHER||NONE||||||
33834374|NCT01677299|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33834375|NCT02320994|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834376|NCT06017908|NON_RANDOMIZED|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||Intervention of the Virtual Reality goggles will be evaluated in a small clinical trial to determine the feasibility of the product.||||
33834377|NCT01181791|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Administration of placebo|Administration of probiotic Lactobacillus Reuteri|t|t|t|f
33834378|NCT04602195|||OTHER||PROSPECTIVE|||||||
33834379|NCT03203837|||COHORT||PROSPECTIVE|||||||
33834380|NCT05997342|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834381|NCT01090011|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834382|NCT01607541|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834383|NCT02478645|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33834384|NCT04413370|||CASE_CONTROL||PROSPECTIVE|||||||
33834385|NCT04112706|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized controlled split-mouth||||
33834386|NCT04109053|||COHORT||RETROSPECTIVE|||||||
34145232|NCT01652352|||CASE_CONTROL|||||||||
33834387|NCT02718261|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33834388|NCT03236532|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|The substances were packed in sachets containing GDP (glutamine) or maltodextrin (placebo). The packages were identical and the substances used had a similar color and texture. An external subject organized group division and substances delivery.|In the first stage, the participants were initially randomly separated in a double-blind way in order to ingest either the GDP (Condition 1) or maltodextrin as a placebo (Condition 2) for seven days. On the seventh and last day of supplementation, they were submitted to the resistance training session. Before and immediately after the exercise session, the cognitive tests were applied. After these procedures there was a one-week rest period (step 2). Then the procedures performed in the first step were repeated (step 3). However, the group that had received GDP started to receive maltodextrin, and the group who had received maltodextrin started to receive GDP, adopting, thus, a randomized double-blind crossover design.|t|f|t|f
33834389|NCT00787072|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
33834390|NCT04258657|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834391|NCT04718636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834392|NCT06140342|||OTHER||PROSPECTIVE|||||||
33834393|NCT02903303|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145233|NCT00640640|NA|SINGLE_GROUP||||NONE||||||
34145234|NCT02568449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145235|NCT01322217|||COHORT||CROSS_SECTIONAL|||||||
34145236|NCT02330523|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145237|NCT01765426|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33834394|NCT04787237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|AE and IR were responsible for measuring the outcomes and they were blinded to the treatments, since they were not involved in the treatment The statistician was also blinded to the treatment.|randomized clinical trial, blinded|f|f|f|t
33834395|NCT02099448|||CASE_ONLY||PROSPECTIVE|||||||
33834396|NCT00496210|||||OTHER|||||||
33834397|NCT02885662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834398|NCT03883464|RANDOMIZED|PARALLEL||OTHER||NONE||Randomly assigned low fat versus balanced diet following cholecystectomy.||||
33834399|NCT06146192|||CASE_CONTROL||PROSPECTIVE|||||||
33834400|NCT05396937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834401|NCT06406036|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33834402|NCT03575676|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33834403|NCT01476605|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33834404|NCT01932268|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834405|NCT04097847|||COHORT||RETROSPECTIVE|||||||
33834406|NCT00601432|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834407|NCT00004060||||TREATMENT||||||||
34145238|NCT00795912|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145239|NCT01969877|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145240|NCT04785625|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Matching placebo||t|t|t|t
34145241|NCT04932603|||COHORT||PROSPECTIVE|||||||
34145242|NCT05867290|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single Case Experimental Design (SCED) methodology using multiple baseline across participants.||||
34145243|NCT03147313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The participant will be wearing an acoustic and visual masking. The outcome assessor won't know if the participant was treated or if he was assigned to the sham group.|Participants will be randomized into three groups: Two treatment groups with different treatment settings and one sham group.|t|f|f|t
34145244|NCT03698786|||COHORT||CROSS_SECTIONAL|||||||
34145245|NCT03008135|||COHORT||PROSPECTIVE|||||||
34145246|NCT02856399|||COHORT||PROSPECTIVE|||||||
34145247|NCT02827500|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145248|NCT02751034|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145249|NCT00554619|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145250|NCT00736775|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145251|NCT02578433|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145252|NCT04702906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145253|NCT06394752|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145254|NCT06370234|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145255|NCT05420220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145256|NCT05129514|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145257|NCT04436471|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||An open, prospective, two-stage, non-randomized, first-phase study involving healthy volunteers||||
34145258|NCT04546295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34145259|NCT00657371|NA|SINGLE_GROUP||SCREENING||NONE||||||
34145260|NCT00025168||||TREATMENT||||||||
34145261|NCT01248754|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145262|NCT01437644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145263|NCT02792491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145264|NCT01332838|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34145265|NCT03905317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145266|NCT03697993|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145267|NCT05229263|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups of subjects (healthy volunteers and CKD patients) are involved in the study and will follow separate workflows.||||
34145268|NCT00064766|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34145269|NCT02571660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145270|NCT04638842|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patients are not aware that there is an experimental group and a control group, the participants are not related and do not know each other. The conditions of the study are only known by the researcher, the therapists, and the Research Ethics Committee of the Universidad Autónoma de Ciudad Juárez.|The study has two arms, one is the experimental group that receives the treatment and the other is the comparison group that will receive treatment after the 12 sessions of the experimental group finished. The patients in both groups will be evaluated pre and post/treatment. The participants are assigned randomly to the intervention or comparison group.|t|f|f|f
34145271|NCT05677503|||CASE_ONLY||PROSPECTIVE|||||||
34145272|NCT06229665|NA|SINGLE_GROUP||TREATMENT||NONE||Valeda Light Delivery System||||
34145273|NCT04401670|NA|SINGLE_GROUP||SCREENING||NONE|The US pathologist was masked to the original cytologic interpretation but unmasked to being hrHPV positive to reduce influence of how the slides were read.|||||
34145274|NCT06309511|||COHORT||PROSPECTIVE|||||||
34145275|NCT01287377|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145276|NCT00622947|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145277|NCT02605811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145278|NCT05639283|||CASE_ONLY||RETROSPECTIVE|||||||
34145279|NCT00002440||||TREATMENT||||||||
34145280|NCT00961792|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|f|t|f
34145281|NCT01004016|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34145282|NCT01074333|||COHORT||PROSPECTIVE|||||||
34145283|NCT05223062|||COHORT||PROSPECTIVE|||||||
34145284|NCT03342352|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145285|NCT01149486|RANDOMIZED|CROSSOVER||||NONE||||||
34145286|NCT03490149|||CASE_CONTROL||PROSPECTIVE|||||||
34145287|NCT04333342|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34145288|NCT02370095|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34145289|NCT03084913|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34145290|NCT01262170|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34145291|NCT03653468|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Behavioral|f|f|t|f
34145292|NCT04104022|RANDOMIZED|PARALLEL||TREATMENT||NONE||The present study is a three condition, parallel group, randomized trial to investigate the contribution of prolonged exposure therapy (PET) above and beyond opioid agonist treatment (OAT) alone for reducing PTSD symptoms among adults with concurrent PTSD and opioid use disorder. Participants will be randomized to one of three conditions: (a) OAT as usual, (b) OAT+PET, or (c) OAT+Enhanced PET (OAT+PET+). Those randomized to OAT as usual will continue to receive standard buprenorphine or methadone treatment from their current treatment provider and complete assessments of PTSD symptom severity, psychosocial functioning and drug use at intake and Study Weeks 4, 8, and 12. In addition to receiving OAT and completing monthly assessments, OAT+PET participants will receive 12 weekly PET sessions with a trained therapist. Finally, OAT+PET+ participants will receive the procedures for the OAT+PET group plus monetary incentives contingent upon completion of PET sessions.||||
34145293|NCT06149039|||COHORT||PROSPECTIVE|||||||
34145294|NCT00992498|||COHORT||PROSPECTIVE|||||||
34145295|NCT02762747|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34145296|NCT05458089|||CASE_ONLY||RETROSPECTIVE|||||||
34145297|NCT00016744|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34145298|NCT02975414|||COHORT||PROSPECTIVE|||||||
34145299|NCT05720364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145300|NCT03653572|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34145301|NCT01034618||CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34145302|NCT03824405|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145303|NCT00322946|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34145304|NCT01560052|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145305|NCT05109221|||CASE_CONTROL||PROSPECTIVE|||||||
34145306|NCT01757223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145307|NCT05650138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145308|NCT04126564|RANDOMIZED|CROSSOVER||OTHER||NONE||A cross over model ensures that both experimental and control group participants get to experience the effects of a proposed intervention. For our study, we are providing Inner Engineering Online as an intervention and both experimental and control group participants get to experience the benefits of meditation.||||
34145309|NCT05364736|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.|placebo-controlled, randomized clinical trial|t|t|t|t
34145310|NCT05922410|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145311|NCT03812185|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Since this is a single group study, participant, care provider, and investigator will NOT be masked. However, outcome assessor (who assess image quality and perform measurement using stored TEE images) will be masked|For intraoperative TEE used cardiac or transplant cases, investigators will compare TEE image quality before and after suctioning using orogastric tube attached TEE probe cover||||
34145312|NCT05081947|NA|SINGLE_GROUP||OTHER||NONE||||||
34145313|NCT06268327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145314|NCT01390324|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145315|NCT05571891|||COHORT||PROSPECTIVE|||||||
34145316|NCT03165214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145317|NCT01659281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145318|NCT03476616|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145319|NCT00247442|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
34145320|NCT04143165|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34145321|NCT05796115|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34145322|NCT00205543|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145323|NCT01636713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145324|NCT05351723|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Before the intervention, the research team will record the video for each group:~  * Intervention group: each session comprises (1) 50 min of physical exercise, (2) 20 min of break time or education on dementia and lifestyle habits, and (3) 50 min of cognitive training.~ * Control group: education on dementia and lifestyle habits.~* Prior to intervening, patients who agree to participate will be screened and evaluated cognitive function, physical function, assessment of Activities of Daily Living, quality of life, depression, anxiety, stress, and sleep quality.~* We will randomly divide the patients into the intervention-control group at each commune. Each group will attend an intervention program once a week within six months.~* We will evaluate the participants in two groups twice after 3 months and after 6 months of intervention."||||
34145325|NCT04275609|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34145326|NCT03461406|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145327|NCT04114799|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145328|NCT01460407|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145329|NCT02534662|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145330|NCT02657564|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34145331|NCT03625232|||CASE_ONLY||PROSPECTIVE|||||||
34145332|NCT03914248|||COHORT||PROSPECTIVE|||||||
34145333|NCT03724656|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34145334|NCT04827797|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34145335|NCT01762267|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145336|NCT03430271|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study assessor will be blinded to the treatment assignment. The study investigators and interventionists will not be blinded.|The ENGAGE Somerville Study is designed as a single blind, randomized-controlled, parallel-group pilot study. This study plans to enroll up to 50 participants to be randomized into the PA or health aging intervention.|f|f|f|t
34145337|NCT03974672|||COHORT||RETROSPECTIVE|||||||
34145338|NCT02437786|NA|SINGLE_GROUP||OTHER||NONE||||||
34145339|NCT03580824|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145340|NCT02833792|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34145341|NCT01359462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145342|NCT01509469|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34145343|NCT06400732|||COHORT||PROSPECTIVE|||||||
34145344|NCT04472325|||CASE_CONTROL||PROSPECTIVE|||||||
34145345|NCT01224821|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145346|NCT05749653|NA|SINGLE_GROUP||PREVENTION||NONE||population based study||||
34145347|NCT03452904|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145348|NCT05942794|NA|SINGLE_GROUP||SCREENING||NONE||The screening will start after a first oral examination, in order to rule out noticeable mucosal lesions.||||
34145349|NCT05531721|||COHORT||RETROSPECTIVE|||||||
34145350|NCT01077180|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145351|NCT05593614|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145352|NCT02525094|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145353|NCT05764031|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|f|t
34145354|NCT03002454|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145355|NCT01628861|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34145356|NCT03164850|||CASE_CONTROL||PROSPECTIVE|||||||
34145357|NCT06330155|||CASE_CONTROL||PROSPECTIVE|||||||
34145358|NCT05577364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145359|NCT03419390|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Proof of concept study, medical device investigation||||
34145360|NCT03738007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145361|NCT01303302|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34145362|NCT01100528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145363|NCT00868673|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34145364|NCT04534907|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|f|f|f|t
34145365|NCT05407961|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34145366|NCT04139278|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34145367|NCT00605553|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34145368|NCT03734068|||COHORT||PROSPECTIVE|||||||
34145369|NCT04353219|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|participant and investigators are not blinded for research groups participants.|research group and control group|t|f|t|f
34145370|NCT01760473|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||In this study's design, all participants received each of the 9 intranasal test drugs under investigation. This study employed a Latin-square randomization procedure, therefore, the sequence of testing for the 9 intranasal drugs was unique for each participant.|t|f|f|t
34145371|NCT06344572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145372|NCT02696408|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145373|NCT01550393|||CASE_ONLY||RETROSPECTIVE|||||||
34145374|NCT04047420|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34145375|NCT01867398|||||PROSPECTIVE|||||||
34145376|NCT03306641|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The contact lenses coding will be masked to both the investigator and subject. If standard labeling does not sufficiently mask the study material then over-labeling will be performed.|This will be a double-masked, bilateral, 1-week crossover, dispensing study, comparing the test daily wear lens against nelfilcon A control lens, such that each lens type will be worn for 1 week each. Each subject will be randomized to wear either the test lenses or the control lenses as a matched pair.|t|f|t|f
34145377|NCT01157208|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34145378|NCT02061046|||CASE_ONLY||PROSPECTIVE|||||||
34145379|NCT00839475|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145380|NCT02369666|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34145381|NCT04133441|||COHORT||RETROSPECTIVE|||||||
34145382|NCT02944565|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145383|NCT02337699|||COHORT||PROSPECTIVE|||||||
34145384|NCT03190694|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||A Randomized Double Blind 6-Weeks Cross-over|t|f|t|f
34145385|NCT04672525|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145386|NCT03299231|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomization carried by a third party not involved in the study.|Prospective, Parallel group (1:1), Randomized, double blind, sham controlled, single center.|t|t|t|f
34145387|NCT01008969|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145388|NCT03081676|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34145389|NCT00390117|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145390|NCT02156544|RANDOMIZED|||TREATMENT||DOUBLE|||t|f|t|f
34145391|NCT01840358|NA|SINGLE_GROUP||||NONE||||||
34145392|NCT04412122|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|The data of the research were collected with personal information, postoperative follow-up and discharge risk assessment forms and Visual Analog Scale by the researcher. Pain levels of women were evaluated with Visual Analog Scale (VAS) before and after administration of the analgesic or interventions by the researcher. Data were collected on the postoperative days 0, 1, 2 and 3 during the hospital stay.|"After abdominal surgery, kinesio taping and breathing exercise were applied.~Intervention Protocol of the Study Kinesio Taping (KT) Group In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique. In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension. No tension was applied to the starting and ending points of the tape. Kinesio tape remained on women for 72 hours.~Breathing Exercises (BE) Group Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing."|f|f|t|f
34145393|NCT03002623|NA|SINGLE_GROUP||TREATMENT||NONE||This is a single group assignment. All patients regardless of subtype of thyroid cancer received one single treatment and follow up plan with option to continue the treatment when scan was negative.||||
34145394|NCT04866875|RANDOMIZED|PARALLEL||TREATMENT||NONE||clinical trial||||
34145395|NCT02317952|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34145396|NCT03697278|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145397|NCT00437450|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145398|NCT00693004||||TREATMENT||||||||
34145399|NCT04015869|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||Randomized, double blind, placebo controlled|t|t|t|t
34145400|NCT01669408|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145401|NCT05845944|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||The research was a randomized controlled, experimental study.|f|f|t|f
34145402|NCT04413903|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||ASA I-II 60 patients aged 18-65 years undergoing laparoscopic cholecystectomy surgery according to mechanical ventilator mode; Group P (n: 30) Pressure controlled ventilation was randomly divided into Group V (n: 30) volume controlled 50% air, PEEP 5 to 8ml / kg tidal volume.||||
34145403|NCT01910870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145404|NCT03340194|||CASE_ONLY||PROSPECTIVE|||||||
34145405|NCT02302183|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145406|NCT00270660|||||OTHER|||||||
34145407|NCT03691779|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34145408|NCT00488124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145409|NCT03757130|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Double-blind study||t|f|t|f
34145410|NCT03452631|||COHORT||RETROSPECTIVE|||||||
34145411|NCT06036329|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145412|NCT02761577|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34145413|NCT00702455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145414|NCT01388751|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145415|NCT06083532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group conducted the post-activation potentiation combined with complex training content intervention designed in this study. In contrast, the control group will perform a training program that combines warm-up routine methods with complex training.|t|f|t|t
34150974|NCT01688908|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||f|f|f|t
33837668|NCT05055947|||COHORT||RETROSPECTIVE|||||||
34145416|NCT05453162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Therapists will be unaware of study hypotheses. therapy supervisor and assessors will be unaware of hypothesis and participants' treatment arms|Participants (52 total) will be randomized, 26 to each of 2 arms one of which has 8 weekly PE sessions in early morning (between 07:00-10:00) and the other 8 sessions PE at 16:00 or later. Homework exposures will occur at the same time of day as PE. Primary outcomes measured at beginning, middle and end of treatment will be psychophysiological reactivity to trauma recall (mechanistic outcome) and CAPS-5 (clinical outcome). Secondary mechanistic outcome is peak SUDS during PE and clinical is PCL-5 measured at each PE session. Endogenous salivary cortisol levels will be tested as a mechanism of circadian effect. Data will be analyzed using multilevel, mixed-effects models.|f|t|f|t
34145417|NCT02581930|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145418|NCT01615055|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34145419|NCT04547114|||CASE_CONTROL||PROSPECTIVE|||||||
34145420|NCT02018874|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145421|NCT01400243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34145422|NCT02307799|||COHORT||PROSPECTIVE|||||||
34145423|NCT04570683|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34145424|NCT02406352|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145425|NCT06027411|||COHORT||PROSPECTIVE|||||||
34145426|NCT02654600|||COHORT||PROSPECTIVE|||||||
34145427|NCT02246192|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34145428|NCT02305628|||COHORT||PROSPECTIVE|||||||
34145429|NCT03535285|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Split-mouth|f|f|f|t
34145430|NCT01688739|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34145431|NCT00901511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145432|NCT01279005|||||PROSPECTIVE|||||||
34145433|NCT05828472|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34145434|NCT06239090|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145435|NCT02055599|||COHORT||PROSPECTIVE|||||||
34145436|NCT00023751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145437|NCT01557881|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145438|NCT05109481|||COHORT||PROSPECTIVE|||||||
34145439|NCT04533399|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34145440|NCT04761744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145441|NCT05976464|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145442|NCT01001546|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145443|NCT00238784|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145444|NCT06031545|RANDOMIZED|PARALLEL||OTHER||SINGLE|Not possible because of the material and characteristics of the catheter||f|f|f|t
34145445|NCT05909774|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||NONE||Prospective, multicentric, comparative, randomized cross-over study||||
34145446|NCT00690287|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34145447|NCT04654871|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145448|NCT01519739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145449|NCT02212171|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145450|NCT03421743|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Open-label, non-controlled, multicenter, pilot clinical trial||||
34145451|NCT03452033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double-masked containers|Double-masked, parallel|t|f|t|f
34145452|NCT06270251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145453|NCT05735522|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145454|NCT01155921|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34145455|NCT03048838|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to either risk-reduction group (Conectado Latinos en Parejas, CLP) or wellness-promotion (WP) control condition||||
34145456|NCT01618279|||CASE_ONLY||PROSPECTIVE|||||||
34145457|NCT02486991|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145458|NCT01726673|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145459|NCT04021524|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34145460|NCT00810901|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34145461|NCT03847857|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A(Surgery+PFS) Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during Mckeown surgery . Biological/Vaccine: Porcine Fibrin Sealant (PFS) 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.~B(Surgery)Arm B for conventional anastomosis"||||
34145462|NCT04159532|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Double blinded. Only the sponsor will have access to the randomisation list. No one at the sites will have access to the list.|Double-blind, 3-arms parallel randomized study.|t|t|t|t
34145463|NCT06294938|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||acute, open-labeled, randomized design||||
34145464|NCT01231815|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34145465|NCT04911764|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Prospective non-randomized interventional study, with low risks and constraints.||||
34145466|NCT02989844|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145467|NCT06515314|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145468|NCT04862728|||OTHER||PROSPECTIVE|||||||
34145469|NCT00979355|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145470|NCT02462408|RANDOMIZED|PARALLEL||||NONE||||||
34145471|NCT02152514|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34145472|NCT05394480|NON_RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|"4 dentist treated 27 patients in 3 different treatment groups, and the study resulted in a total of 108 patients.~Children were grouped after being evaluated by a single pediatric dentist. The patients were randomly distributed to the physicians, and their treatment was carried out. The study did not include children with general health problems or whose parents refused to be treated with general anaesthesia/sedation."|"In the present study, it was aimed to evaluate the stress which was experienced by dentists working with children while treating children in all three treatment protocols by using objective (salivary cortisol, pulse, blood pressure, O2 saturation) and subjective (Dentists' Stress Questionnaire) findings 27. The H0 hypothesis of the study is that the stress levels of dentists change according to the different treatment protocols.~each dentist treated 27 patients in 3 different treatment approaches, and the study resulted in a total of 108 patients."|t|t|f|f
34150975|NCT06149377|||COHORT||RETROSPECTIVE|||||||
34145473|NCT06183879|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1 randomization to two different cryoballoon devices||||
34145474|NCT02159118|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34145475|NCT02008513|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145476|NCT01653899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145477|NCT01730963|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145478|NCT05000268|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Participants will be divided into two groups as those with pain after COVID-19 infection and those with pain not related to COVID-19 infection. Both groups will be applied telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. Progressive myofascial relaxation exercises will be asked to do morning and evening while lying in bed. Posture exercises will be required to perform while standing, at least 2 or 3 sets during work.||||
34145479|NCT01689350|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145480|NCT02673567|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34145481|NCT03541187|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145482|NCT00661388|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145483|NCT04258995|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||There are two arms in the study however based on the prior formulation received participants can only be enrolled into one predetermined arm in the study. Participants are assigned by an interactive response technology (IRT) based on prior formulation received.||||
34145484|NCT05713786|||COHORT||PROSPECTIVE|||||||
34145485|NCT01049802|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145486|NCT03964753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145487|NCT05789186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34145488|NCT01842594|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145489|NCT01890395|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145490|NCT00746733|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34145491|NCT01195688|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34145492|NCT05154760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145493|NCT05389501|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34145494|NCT03927287|||COHORT||RETROSPECTIVE|||||||
34145495|NCT04938375|||COHORT||RETROSPECTIVE|||||||
34145496|NCT01133015|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145497|NCT04347980|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145498|NCT04135859|RANDOMIZED|PARALLEL||PREVENTION||NONE|Investigator, research assistants, coaches (interventionists), and participants do not know which condition a participant is in until the condition is revealed (opening an envelope with the condition listed) after the participant consents to Phase 2. Envelopes with the conditions were prepared by the study statistician.|Study includes 2 possible conditions to which participants are randomized: (1) Fitbit only and (2) Fitbit + coaching sessions.||||
34145499|NCT01643876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145500|NCT05734274|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145501|NCT01663545|||COHORT||PROSPECTIVE|||||||
34145502|NCT06357468|||COHORT||RETROSPECTIVE|||||||
34145503|NCT04676867|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a double blind study.|This is a randomized, double blind, multicenter, Phase 2a proof-of-concept study in outpatients with confirmed, mild to moderate, symptomatic COVID-19.|t|t|t|t
34145504|NCT01333670|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145505|NCT03577392|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Patients were randomly assigned to receive either three treatment cycles of intravenous pump of recombinant human endostatin before chemotherapy.|t|t|t|f
34145506|NCT04528615|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145507|NCT06254664|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145508|NCT02036736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145509|NCT00031980|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34145510|NCT02159677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145511|NCT00164398|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34145512|NCT05052060|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34145513|NCT01960088|||OTHER||CROSS_SECTIONAL|||||||
34145514|NCT02960646|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145515|NCT00115999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34145516|NCT00290875|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145517|NCT04101617|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34145518|NCT06108843|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A participant in a single-blind study does not know which study group they are in, but the study doctor does.|A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions.|t|f|f|f
34145519|NCT05434013|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Participants will be randomly assigned to one of 3 conditions. In each of these conditions participants will see one of the following warning label formats on the cigarillos when they are shopping for tobacco products: a pictorial warning, a text-based warning, or a surgeon general warning. Participants don't know which condition they're assigned to.|The study will conduct a three-group, between-subjects experiment to compare varying cigarillo warning formats: Surgeon General text-only, FDA-proposed text-only, and study developed pictorial cigarillo warning labels.|t|f|f|f
34145520|NCT00320138|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34145521|NCT06224361|||COHORT||PROSPECTIVE|||||||
34145522|NCT00746915|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145523|NCT06421402|||COHORT||PROSPECTIVE|||||||
34145524|NCT02351687|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145525|NCT01790555|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145526|NCT04266470|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34145527|NCT03602885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145528|NCT04806360|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145529|NCT00349258|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834408|NCT03292445|NA|SINGLE_GROUP||TREATMENT||NONE||Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T Cell Transfusion in HLA Haplotype Matched Related and 3 Ag HLA Matched Unrelated Living Donor Kidney Transplantation||||
33834409|NCT05142930|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel groups will be received different treatment modalities||||
34145530|NCT03406416|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145531|NCT01301105|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34145532|NCT03889210|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|||t|f|t|f
34145533|NCT00539929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145534|NCT02768025|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145535|NCT04022018|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Total 122 cases of IB2-IVA cervical cancer will be randomly enrolled. Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients.~Concurrent adaptive external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of experimental group patients. CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy."||||
34145536|NCT01052961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145537|NCT05181202|||COHORT||PROSPECTIVE|||||||
34145538|NCT01998893|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145539|NCT05853315|||COHORT||RETROSPECTIVE|||||||
34145540|NCT03679637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145541|NCT03620357|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, multicenter, two-arm pilot study.||||
34145542|NCT05309213|NA|SEQUENTIAL||TREATMENT||NONE||||||
34145543|NCT06103227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145544|NCT03554980|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (participant, Outcomes Assessor)|patient will receive either Silver Diamine Fluoride or Sodium Fluoride varnish according to the allocation ratio|t|f|f|t
34145545|NCT06216314|RANDOMIZED|PARALLEL||OTHER||NONE||"A 4-week pre-intervention plus 6-week intervention program was set up. Participants were randomly assigned to one of the three groups before the intervention phase using a web-based computer program (www.randomizer.org).~A randomized controlled trial with three-armed parallel group was set."||||
34145546|NCT04832139|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34145547|NCT06286891|||COHORT||PROSPECTIVE|||||||
34145548|NCT04254016|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145549|NCT01582737|||CASE_ONLY||PROSPECTIVE|||||||
34145550|NCT05642143|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145551|NCT02327936|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34145552|NCT03071991|||COHORT||PROSPECTIVE|||||||
34145553|NCT02564861|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34145554|NCT01905722|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34145555|NCT05510882|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145556|NCT01983280|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145557|NCT06136572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145558|NCT06338878|||COHORT||PROSPECTIVE|||||||
34145559|NCT02291393|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145560|NCT05532267|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||A randomized, single-dose, two-way crossover, open-label, laboratory blind, bioequivalence study||||
34145561|NCT05097300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145562|NCT02485925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145563|NCT00057434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34145564|NCT03084354|||OTHER||CROSS_SECTIONAL|||||||
34145565|NCT04251975|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||This is an open-label, parallel, prospective, randomized and controlled trial.|f|f|t|f
34145566|NCT01974752|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145567|NCT05840692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients, doctors, alle people involved in analyses||t|t|t|t
34145568|NCT00229580|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145569|NCT03129594|||COHORT||OTHER|||||||
34145570|NCT02514668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145571|NCT02878668|||CASE_ONLY||PROSPECTIVE|||||||
34145572|NCT00012090||||TREATMENT||||||||
34145573|NCT00722202|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34145574|NCT02126566|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145575|NCT03464422|NA|SINGLE_GROUP||PREVENTION||NONE||Adaptation of the Effective Skills to Empower Effect Men (ESTEEM; Pachankis, 2014; Pachankis et al, 2015) intervention that addresses young gay and bisexual men's occurring maladaptive behavioral patterns, including HIV-transmission risk behavior and mental health concerns, to address multiple stigma-related stressors for young gay and bisexual men of color in a group therapy format. All participants were part of the same intervention (no randomization) to assess the feasibility and acceptability of this adapted intervention (protocol update 4.24.2019; please see attached protocol). Two cohorts were formed to retain ideal group size for group therapy (10-15 participants per group).||||
34145576|NCT05027932|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34145577|NCT04090034|||COHORT||PROSPECTIVE|||||||
34145578|NCT05713084|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145579|NCT06375785|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34145580|NCT04395560|||COHORT||PROSPECTIVE|||||||
34145581|NCT01349062|NA|SINGLE_GROUP||TREATMENT||NONE||Open Label||||
34145582|NCT00364533|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145583|NCT03230812|NA|SINGLE_GROUP||PREVENTION||NONE||One group with type 2 diabetic patients who will undergo oral L-carnitine supplementation for 96 days||||
34145584|NCT04163159|||COHORT||PROSPECTIVE|||||||
34145585|NCT01203501|||COHORT||PROSPECTIVE|||||||
34145586|NCT04423601|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145587|NCT04701580|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||Longitudinal study design (2 years follow up) where results of SV2A PET/CT, FDG PET/MR and clinical rating scales are compared between HD patients and healthy controls.||||
34150976|NCT05512013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||4 trial, block randomized crossover design. Three NSAIDs and one placebo trial.|t|f|t|t
33834410|NCT04910633|||CASE_ONLY||RETROSPECTIVE|||||||
33834411|NCT02415647|||CASE_CONTROL||PROSPECTIVE|||||||
33834412|NCT06488352|||CASE_ONLY||RETROSPECTIVE|||||||
34145588|NCT04412694|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||Patients will be randomly assigned (coin toss) to the supplementation group (preoperative oral supplementation of dexamethasone (8mg in one dose) taken one hour before surgery) and to the placebo group (preoperative oral supplementation of sweetener taken one hour before surgery).|t|t|f|f
34145589|NCT02263456||||TREATMENT||||||||
34145590|NCT01198457|||COHORT||PROSPECTIVE|||||||
34145591|NCT00825396|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145592|NCT00128713|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145593|NCT06184841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145594|NCT05008757|||COHORT||PROSPECTIVE|||||||
34145595|NCT06244836|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||The study compare three phases: a baseline period before bundle implementation (Baseline Group), from January 2011 to June 2016; a Bundle-1 period after the implementation of a six-measure bundle (Bundle-1 Group), from July 2016 to June 2018; and a Bundle-2 period after the implementation of a ten-measure bundle (Bundle-2 Group), from July 2018 to December 2022||||
34145596|NCT05327283|||COHORT||PROSPECTIVE|||||||
34145597|NCT04973462|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|To ensure blindness one placebo capsule will be added to group B.|Simple Randomization Parallel Double Blinded.|t|t|f|f
34145598|NCT05315375|||COHORT||RETROSPECTIVE|||||||
34145599|NCT00138112|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145600|NCT03635034|RANDOMIZED|PARALLEL||OTHER||NONE||We will compare the two groups for complications related to catheter or not having a catheter placed.||||
34145601|NCT00975065|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145602|NCT05001841|||COHORT||RETROSPECTIVE|||||||
34145603|NCT04878744|RANDOMIZED|PARALLEL||TREATMENT||NONE||The app will be delivered as a 'green prescription' which means that health professionals will tell their patients about the intervention. If patients choose to take part, they will be allocated at random to either noticing the good things about green spaces or the good things about built spaces. This is to control for whether noticing green space or noticing other aspects of city life affects health and wellbeing. Patients will complete questionnaires about health, mental wellbeing and their feelings about nature, before, after and 3 months after using the app for one month.||||
34145604|NCT01241760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145605|NCT04284813|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145606|NCT01900977|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145607|NCT01196494|RANDOMIZED|PARALLEL||||NONE||||||
34145608|NCT03752268|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145609|NCT06508931|NA|SINGLE_GROUP||TREATMENT||NONE||A multi-center, international, open-label study||||
34145610|NCT03455439|||COHORT||PROSPECTIVE|||||||
34145611|NCT00801060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145612|NCT05529979|||COHORT||PROSPECTIVE|||||||
34145613|NCT00099060|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145614|NCT01846559|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145615|NCT02869412|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145616|NCT05363865|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|The outcomes assessor will be unaware of the experimental condition.|Clusters will be randomized to either the intervention or the standard of care.|f|f|f|t
34145617|NCT05094479|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145618|NCT06398964|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34145619|NCT02279836|NA|SINGLE_GROUP||SCREENING||NONE||||||
34145620|NCT00493428|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145621|NCT04787068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Experimental study||||
34145622|NCT04141813|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34145623|NCT04798742|NON_RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34145624|NCT04577079|||CASE_ONLY||PROSPECTIVE|||||||
34145625|NCT02513758|||COHORT||PROSPECTIVE|||||||
34145626|NCT04173195|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Patients and outcome assessors will be blinded to treatment allocation. Complete blinding of care providers will not possible as the nurses in charge of chemotherapy admnistration will also be responsible to provide the CT intervention.|This pilot trials will be conducted simultaneously in two outpatient oncology clinics located in the Montreal area: 1) Hôpital du Sacré-Coeur de Montréal, and 2) Hôpital de Saint-Eustache. These sites have been selected has they share the same hemato-oncologists, ensuring some consistency in treatment protocols. Site 1 will serve as the experimental site (combining CT with current care) and site 2 will serve as the control site (current care only).|t|f|f|t
34145627|NCT04527523|||OTHER||PROSPECTIVE|||||||
34145628|NCT06508138|RANDOMIZED|PARALLEL||OTHER||NONE||"Randomized to one of two groups:~Arm A: Donors on this arm of the study will donate cells and bone marrow to the paired recipient (who will receive a standard allogeneic stem cell transplant, Cytoxan, and may receive HPV-specific donor lymphocyte cell infusion (DLI) at Day 90, depending on the donor's response).~Arm B: Donors on this arm of the study will donate cells to the donor's paired recipient (who will receive Cytoxan followed by HPV-specific DLI)."||||
34145629|NCT05058001|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34145630|NCT02583971|||CASE_CONTROL||PROSPECTIVE|||||||
34145631|NCT00121394|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34145632|NCT02165462|||COHORT||PROSPECTIVE|||||||
34145633|NCT05014503|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participating children, their parents/caretakers as well as their guiding therapist will be blinded for allocation to the treatment condition Assessors will be blind to the treatment condition|Double blind, randomized controlled trial|t|t|f|t
34145634|NCT02223611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145635|NCT02032641|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145636|NCT01182974|RANDOMIZED|PARALLEL||||NONE||||||
34145637|NCT02087202|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34145638|NCT01561547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34145639|NCT02511600|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145640|NCT00791401|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145641|NCT02772796|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145642|NCT01136070|||COHORT||PROSPECTIVE|||||||
34145643|NCT00139763|RANDOMIZED|PARALLEL||ECT||NONE||||||
34145644|NCT05260333|NA|SEQUENTIAL||DIAGNOSTIC||NONE|The investigator will not know the digital cervical exam value.|Patients will have a transperineal ultrasound followed by a traditional digital cervical exam.||||
34145645|NCT01504230|||COHORT||CROSS_SECTIONAL|||||||
34145646|NCT05473013|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||MOST: multiphase optimization strategy|t|f|f|f
34145647|NCT03958656|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34145648|NCT03759041|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34145649|NCT03622437|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Participants are randomized (1:1) into either intervention or control group. This is done by block randomization, stratifying by center, sex and treatment type (± postoperative oncological treatment and ± temporary ileal stoma).|f|f|f|t
34145650|NCT02322294|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34145651|NCT03560817|||COHORT||PROSPECTIVE|||||||
34145652|NCT06113224|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145653|NCT02983591|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145654|NCT05352269|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|f|t|t
34145655|NCT01982500|||COHORT||OTHER|||||||
34145656|NCT03788447|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34145657|NCT06427070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145658|NCT04229212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|One independent observer who was not involved with the treatment performed the clinical assessments and laboratory data collection during the preoperative and intraoperative periods and on postoperative days 1, 2, and 4 (during admission) and on postoperative day 10 for suture removal.|This single center study was performed between May 2018 and April 2019. All the 60 patients who were treated with a PFNA system (Depuy Synthes®, Proximal Femoral Nail Antirotation (II), Solothurn, Switzerland) were consecutively included. The investigators established a table of random numbers, which was readily generated by computer 15, and divided participants into the drained and undrained groups based on their arrival time to our hospital.|f|f|f|t
34145659|NCT04739397|||COHORT||PROSPECTIVE|||||||
34145660|NCT00983736|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34145661|NCT00030771|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34145662|NCT03276052|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single and Multiple Dose (Twice-Daily)||||
34145663|NCT03984630|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145664|NCT03980821|NA|SINGLE_GROUP||OTHER||NONE||||||
34145665|NCT01555554|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34145666|NCT00283816|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145667|NCT01634529|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145668|NCT02452853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145669|NCT03236194|||COHORT||PROSPECTIVE|||||||
34145670|NCT03747900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145671|NCT05969717|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145672|NCT04337736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145673|NCT00180167|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145674|NCT02321891|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145675|NCT05598723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||A randomized, double blind, prospective, parallel-group study (non-inferiority trial)|t|t|f|f
34145676|NCT00390481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145677|NCT02897752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145678|NCT02728414|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145679|NCT04402294|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||"Task and resting fMRI will be used to determine an individualized brain target for each participant. In a subsequent session, participants will complete a task fMRI with repetitive TMS neuromodulation; during this session, various stimulation protocols will be interleaved with working memory task blocks to result in online brain readouts of the degree in which modulation affected the brain state in regards to working memory performance.~Based on this testing, an optimal and sub-optimal TMS stimulation frequency will be determined for each individual participant. Each frequency will be administered separately across three stimulation days using a crossover design, with the order of frequencies being randomized and counterbalanced. Therefore, each subject will receive six days of TMS stimulation: three using the optimal frequency, and three using the sub-optimal frequency. The initial TMS/ task fMRI testing session will be completed at the midpoint and end of the study."|t|f|f|f
34145680|NCT05568030|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145681|NCT00048750|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34145682|NCT03242018|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145683|NCT05341999|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145684|NCT00882908|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145685|NCT01987219|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34145686|NCT00886249|||CASE_ONLY||RETROSPECTIVE|||||||
34145687|NCT02182609|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145688|NCT05186441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34145689|NCT03285958|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145690|NCT03403985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|patients are not aware about type of capping material used|Randomized Controlled Retrospective clinical trial|t|f|f|f
34145691|NCT06263049|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145692|NCT05418153|||COHORT||CROSS_SECTIONAL|||||||
34145693|NCT01344629|RANDOMIZED|CROSSOVER||||NONE||||||
34145694|NCT01943019|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145695|NCT03696082|RANDOMIZED|SEQUENTIAL||OTHER||SINGLE|The outcome assessors will be masked to intervention assignment.||f|f|f|t
34145696|NCT03287570|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145697|NCT04927104|NA|SINGLE_GROUP||TREATMENT||NONE||In this study, 10 subjects will be underwent total knee arthroplasty with PEEK knee prosthesis and be followed up 3, 6, and 12 months after surgery. The safety of the knee prosthesis for total knee arthroplasty will be investigated based on X-ray, magnetic resonance imaging, thin-section CT, hematological indexes, knee function, complications and the occurrence of serious adverse events at the 12-month follow-up.||||
33834413|NCT05198726|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sham tACS and cognitive training|double-blinded, parallel randomized trial|t|t|f|t
33834414|NCT02472054|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145698|NCT05794711|||COHORT||PROSPECTIVE|||||||
34145699|NCT00379977|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34145700|NCT01228292|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145701|NCT03901911|||COHORT||CROSS_SECTIONAL|||||||
34145702|NCT00914550|||CASE_CONTROL||PROSPECTIVE|||||||
34145703|NCT05162742|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34145704|NCT00874263|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145705|NCT00603070|||COHORT||PROSPECTIVE|||||||
34145706|NCT05132517|||COHORT||PROSPECTIVE|||||||
34145707|NCT00359567|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34145708|NCT01420627|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145709|NCT03050515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145710|NCT03036462|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34145711|NCT02111291|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145712|NCT01113034|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34145713|NCT00494559|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145714|NCT02002572|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145715|NCT05268744|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145716|NCT05834491|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145717|NCT05823844|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Raters and subjects will be blinded to treatment. At the study's completion (the last subject completes) the blind will be broken, and data will be turned over for analysis. A study physician will be available on call 24 hours to monitor patient safety issues that may arise during the hospitalization and they will have access to the blind. Furthermore, the Research Pharmacy will maintain the blind.|This study is a parallel-group, double-blind, randomized trial where 92 subjects will to randomized 1:1 to either receive 20 mg Suvorexant or placebo (two tablets) and treatment as usual.|t|f|t|t
34145718|NCT03077698|NA|SINGLE_GROUP||TREATMENT||NONE||Phase 2, Single Arm, Two Period Study||||
34145719|NCT03302455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent researcher from the IT department who carries out the randomisation and allocation procedure will be blinded to the study protocol. Participants could not be blinded to treatment allocation as participants in the control group did not receive any intervention from this trial. The research team will have limited contact with both IT staff and study participants, therefore, will not be able to bias the allocation or the assessments. Statistical analyses will be carried out by an independent researcher from the Southern Medical University who is not involved with the randomisation and assessment procedures.|One group receives brief e-aid cognitive behavior therapy, and the other group does not receive any interventions during a clinical study.|f|f|f|t
34145720|NCT01270204|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145721|NCT05769166|||OTHER||CROSS_SECTIONAL|||||||
34145722|NCT05579873|||COHORT||PROSPECTIVE|||||||
34145723|NCT05497258|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Experimental: doctor with AI-assisted system;Control：without AI-assisted system||||
34145724|NCT02425800|||COHORT||PROSPECTIVE|||||||
34145725|NCT00265070|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145726|NCT04956055|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients|Single blind randomized controlled trial|t|f|f|f
34145727|NCT05928832|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145728|NCT03985007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145729|NCT01247363|NA|SINGLE_GROUP||OTHER||NONE||||||
34145730|NCT01605487|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34145731|NCT00654004|||CASE_CONTROL||PROSPECTIVE|||||||
34145732|NCT05069207|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145733|NCT02976025|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34145734|NCT03740789|||COHORT||RETROSPECTIVE|||||||
34145735|NCT01183819|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34145736|NCT03211208|||CASE_CONTROL||PROSPECTIVE|||||||
34145737|NCT05092165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145738|NCT00288457|||||PROSPECTIVE|||||||
34145739|NCT03423836|||COHORT||PROSPECTIVE|||||||
34145740|NCT01312649|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34145741|NCT04117763|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Patient data will be compared before and after treatment||||
34145742|NCT06434129|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145743|NCT04912895|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34145744|NCT00733135|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145745|NCT03923582|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|A randomized, controlled, single blinded trial, stratified by health profession, of the intervention vs waitlist control.|Development and testing of a sexual health curriculum for Midwifery, Nursing and Medical Students.|f|f|f|t
34145746|NCT01333995|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145747|NCT00755534|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145748|NCT02857192|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145749|NCT02961192|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
34145750|NCT03167489|NA|SINGLE_GROUP||PREVENTION||NONE||This pilot study includes a within subjects, delayed intervention design.||||
34145751|NCT00225589|RANDOMIZED|PARALLEL||||DOUBLE||||||
33834415|NCT01360385|||CASE_ONLY||PROSPECTIVE|||||||
34145752|NCT03597607|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Participants will be informed of their group allocation. Health care providers of the intervention will be aware of which program to deliver, therefore knowing group allocation. The investigator will be aware of group allocation. Outcomes will be assessed by a blind data analyst.|Participants randomly assigned to one of three groups: intensive smoking cessation program or an abbreviated smoking cessation program.|f|f|f|t
34145753|NCT06002984|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34145754|NCT01276366|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145755|NCT00044889|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145756|NCT01254968|||CASE_CONTROL||PROSPECTIVE|||||||
34145757|NCT02744807|||COHORT||PROSPECTIVE|||||||
34145758|NCT06339138|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145759|NCT05547529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145760|NCT04211987|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145761|NCT03730766|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145762|NCT00468936|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145763|NCT02033213|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34145764|NCT03895177|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145765|NCT03002688|||OTHER||PROSPECTIVE|||||||
34145766|NCT03906656|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Prospective international multi-center, open-labeled randomized, controlled cross-over trial||||
34145767|NCT06508684|||COHORT||RETROSPECTIVE|||||||
34145768|NCT04095689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145769|NCT04718012|||COHORT||RETROSPECTIVE|||||||
34145770|NCT00000916|RANDOMIZED|||TREATMENT||||||||
34145771|NCT01632241|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145772|NCT05832112|NA|SINGLE_GROUP||OTHER||NONE||||||
34145773|NCT04459806|||COHORT||PROSPECTIVE|||||||
34145774|NCT02525991|NA|SINGLE_GROUP||TREATMENT||NONE||Intervention: treatment with Loxapine staccato- just one treatment arm - outside the hospital setting.||||
34145775|NCT01386242|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145776|NCT05961176|||COHORT||PROSPECTIVE|||||||
34145777|NCT06146868|||COHORT||PROSPECTIVE|||||||
34145778|NCT02749942|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145779|NCT02084238|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145780|NCT00866671|||COHORT||PROSPECTIVE|||||||
34145781|NCT05607329|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145782|NCT02682615|||OTHER||PROSPECTIVE|||||||
34145783|NCT04427735|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34145784|NCT01900119|||COHORT||PROSPECTIVE|||||||
34145785|NCT05336825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145786|NCT00973102|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145787|NCT03411109|||COHORT||RETROSPECTIVE|||||||
34145788|NCT00885638|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34145789|NCT05079633|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34145790|NCT00206284|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34145791|NCT01288612|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34145792|NCT03288194|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145793|NCT00028431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145794|NCT01741714|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145795|NCT04836416|||CASE_CONTROL||PROSPECTIVE|||||||
34145796|NCT05090514|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The primary outcome, reading achievement, is measured by school personnel who are not aware of the child's study group status|Demonstration project in an underserved, urban school with children randomized to intervention group or wait-list control group.|f|f|f|t
34145797|NCT04588506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145798|NCT03631212|RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking was carried out|Comparison between flexiquit and a wait-list control group||||
34145799|NCT00769028|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145800|NCT01632644|||COHORT||CROSS_SECTIONAL|||||||
34145801|NCT04836676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145802|NCT02827383|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34145803|NCT03315169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Note that only the clinician assessing healing and fistulae are masked.||f|f|f|t
34145804|NCT05881720|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind randomized controlled trial|Group 1 (N = 40) received sacubitril/valsartan (target dose, 100 mg twice daily) or group 2 received valsartan (target dose, 80 mg twice daily) in addition to recommended therapy according to physician's judgment.|t|f|t|f
34145805|NCT06105294|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will take part in a baseline assessment, then all will be assigned to time-restricted eating.||||
34145806|NCT02043197|||COHORT||PROSPECTIVE|||||||
34145807|NCT02630368|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145808|NCT00837668|||COHORT||PROSPECTIVE|||||||
34145809|NCT00859339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145810|NCT02818439|NA|SINGLE_GROUP||OTHER||NONE||||||
34145811|NCT04239794|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34145812|NCT03582904|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34145813|NCT03780959|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145814|NCT04453813|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145815|NCT04077294|||COHORT||PROSPECTIVE|||||||
34145816|NCT01243567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34145817|NCT01439074|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145818|NCT02428920|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145819|NCT03454516|RANDOMIZED|PARALLEL||OTHER||SINGLE|the Data analysis will be performed by an independent team with masking the patients groups|two randomized parallel groups. one group with standard care and one group with telemonitoring of blood pressure and hypertension.|f|f|f|t
34145820|NCT04279145|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||patients with primary pulmonary hypertension will submitted to : swanganz cath. detailed echocadiography blood samples for bio markers||||
34145821|NCT05709522|||COHORT||PROSPECTIVE|||||||
34145822|NCT04798469|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145823|NCT01421316|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145824|NCT01576328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145825|NCT03817294|RANDOMIZED|PARALLEL||TREATMENT||NONE||This a pilot/feasibility study, aiming to characterise exercise limitation at baseline and then conducting an abridged RCT with 4 training arms. The main outcomes are related to training progression and perception||||
34145826|NCT00247832|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34145827|NCT05672355|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|"This trial is observer-blinded because the physical appearance of GEO-CM04S1 and mRNA vaccine may vary. The investigators, treating clinicians, participants, and other study staff, including the nurses involved in soliciting or recording of AEs, will be blinded through the day 112 visit.~The study statisticians, pharmacists, and nurses who administer the vaccine injections will be unblinded. To avoid inadvertent unblinding of the participants at the time of injection, the syringe will be obscured from view by the nurse during injection."||t|f|t|t
34145828|NCT03489967|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34145829|NCT04741347|||COHORT||RETROSPECTIVE|||||||
34145830|NCT05781958|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145831|NCT03855202|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34145832|NCT00712218|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145833|NCT06100094|||COHORT||PROSPECTIVE|||||||
34145834|NCT00378599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145835|NCT02885623|||CASE_ONLY||PROSPECTIVE|||||||
34145836|NCT03883334|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145837|NCT01342549|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145838|NCT04857645|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145839|NCT06258057|||COHORT||OTHER|||||||
34145840|NCT04336371|||COHORT||PROSPECTIVE|||||||
34145841|NCT02900638|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145842|NCT05708131|||CASE_CONTROL||PROSPECTIVE|||||||
34145843|NCT05278364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145844|NCT04132492|||COHORT||PROSPECTIVE|||||||
34145845|NCT04813172|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34145846|NCT01295736|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145847|NCT02893826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145848|NCT05079399|||COHORT||PROSPECTIVE|||||||
34145849|NCT06458231|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145850|NCT00136006|||COHORT||RETROSPECTIVE|||||||
34145851|NCT02000011|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145852|NCT05305547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145853|NCT04866355|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145854|NCT00005313|||FAMILY_BASED|||||||||
34145855|NCT02968381|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145856|NCT03808753|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||"The study protocol was started during a period of intraoperative hemodynamic stability, as previously defined (i.e. change in mean arterial pressure of less than 10% during 5 minutes). The study protocol is was the following: 1) a set of measurements was recorded (T0) at a baseline ventilation of 7 ml/Kg and then the EEOT is performed by using the software function, expiratory hold, to interrupt mechanical ventilation; 2) after one minute a set of measurements was recorded (T1); 3) the mFC is then performed; 4) a FC of overall 4 mL/Kg of crystalloid solution is infused over 9 minutes (T2). The attending anesthetist is allowed to interrupt the protocol at any stage for either hemodynamic instability or any other adverse effects requiring urgent treatment."||||
34145857|NCT01246479|NA|SINGLE_GROUP||OTHER||NONE||||||
34145858|NCT05077462|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34145859|NCT02067325|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145860|NCT05927545|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34145861|NCT01797848|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145862|NCT01741337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145863|NCT02667782|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
34145864|NCT00542737|RANDOMIZED|PARALLEL||||NONE||||||
34145865|NCT00371969|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145866|NCT03149952|NA|SINGLE_GROUP||OTHER||NONE||||||
34145867|NCT04332614|||CASE_CONTROL||PROSPECTIVE|||||||
34145868|NCT04184128|||CASE_ONLY||RETROSPECTIVE|||||||
34145869|NCT03454867|RANDOMIZED|PARALLEL||TREATMENT||NONE||Hemofiltration protocol. Hemofiltration was started after all enrollment criteria (informed consent, inclusion/exclusion criteria checklists, registration and assignment to treatment arm) had been met . Vascular access was secured by inserting an 11F double lumen catheter (GamCath, Gambro, Germany) into the jugular, femoral or subclavian vein. CVVH (continuous veno-venous hemofiltration) was carried out using a hemofiltration machine (Fresenius Multifiltrate, Germany). In all patients a 1.9 m2 highly permeable cellulose triacetate hemofilter was used (NIPRO UF205, Nissho corporation, Japan). All patients were treated by CVVH with the predilution mode; the blood flow was set at 180 ml/min.||||
34145870|NCT03132519|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145871|NCT05118815|RANDOMIZED|PARALLEL||OTHER||SINGLE||A total of 60 dental implants Hexagonal Internal Connection Implants (Model IPX), Galimplant® will be used in this study, for the replacement of bilateral maxillary posterior missing teeth in 30 patients (split-mouth study). For the designation of the type of transepithelial abutment to be placed in each hemimaxillary, we will use an online randomization service (www.randomization.com). After surgery, 30 patients will have a conventional straight esthetic abutment 3 mm in height (control group), and the other 30 will have a Slim (New Slim) transepithelial abutment of the same height (test group); in no case will we place the transepithelial closure abutment to achieve contact of the peri-implant mucosa with the surface of the transepithelial abutments. The implant will be placed whenever bone and gingival availability allows it juxta-osseous to avoid collateral damage in the exeresis of the peri-implant perimetral soft tissue (hereinafter donut)|t|f|f|f
34145872|NCT03825692|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, multi-center|t|t|t|t
34145873|NCT01679015|||CASE_ONLY||PROSPECTIVE|||||||
34145874|NCT00784732|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145875|NCT05997667|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145876|NCT02754583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145877|NCT01023386|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145878|NCT00996801|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145879|NCT00497237|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145880|NCT01406496|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145881|NCT04220437|||OTHER||RETROSPECTIVE|||||||
34145882|NCT00892359|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145883|NCT04657640|RANDOMIZED|PARALLEL||PREVENTION||NONE||Schools will be randomly assigned to weekly iron and folic acid (IFA) supplementation; daily multiple micronutrient supplements (MMS); or control.||||
33834416|NCT04088864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834417|NCT04212910|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834418|NCT03012243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33834419|NCT05360628|RANDOMIZED|PARALLEL||OTHER||NONE||D0120 Allopurinol||||
34145884|NCT01952990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145885|NCT04884542|||COHORT||PROSPECTIVE|||||||
34145886|NCT06521437|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34145887|NCT02017145|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34145888|NCT05107973|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomization will be done by the person responsible for the project in the company. Nobody from the research team will know in which arm are enroled the participants.|Parallel Randomized Controlled Trail|f|f|t|f
34145889|NCT02466113|RANDOMIZED|PARALLEL||||NONE||||||
34145890|NCT02446470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145891|NCT05595018|||COHORT||PROSPECTIVE|||||||
34145892|NCT05748704|NA|SINGLE_GROUP||OTHER||NONE||STMF is a 5-day low-calorie and low-protein (totally plant-based) diet that involves a short-term modified fast.||||
34145893|NCT00430001|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34145894|NCT04757948|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Masking of the participant:~The subject is randomized to one of three groups: 1: acupuncture, 2: TENS, and 3: sham-TENS. While those assigned to the acupuncture group are aware of their group assignment, groups 2 and 3 receive an identical TENS pad placement. A sham-TENS unit is used with disconnected wires to provide a blinking light without an electrical signal. Participants are advised that that the sensation of electrical tingling is not necessary.~Masking of the examiner:~The acupuncture or TENS/sham/TENS is performed by one examiner. A second examiner will enter the room to perform the gag reflex measurement, both before and after the treatment"||t|t|f|f
34145895|NCT00287937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145896|NCT00287794|||CASE_ONLY||PROSPECTIVE|||||||
34145897|NCT01356342|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34145898|NCT00857948|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145899|NCT03399357|||COHORT||PROSPECTIVE|||||||
34145900|NCT00524589|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145901|NCT03627169|||COHORT||PROSPECTIVE|||||||
34145902|NCT00002055||||TREATMENT||DOUBLE||||||
34145903|NCT02397135|||CASE_ONLY||RETROSPECTIVE|||||||
34145904|NCT01773525|||COHORT||PROSPECTIVE|||||||
34145905|NCT00366028|NON_RANDOMIZED|FACTORIAL||||NONE||||||
34145906|NCT05709925|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be unaware of the type of the intervention they would be receiving.|Parallel Group Randomized Control Trial|t|f|f|f
34145907|NCT05528367|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34145908|NCT03919513|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34145909|NCT04299763|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||Two groups were used: experimental (n 17): they received oat beta-glucan supplement to be added to breakfast (5 g). Control group: they received a placebo supplement (microcrystalline cellulose). Both groups received a container with the product and a dosing measure (5 g). The intervention was developed for 12 weeks. Blood samples and stools were taken at the beginning and end of the intervention.|t|t|f|f
34145910|NCT06299722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145911|NCT03972319|NA|SINGLE_GROUP||OTHER||NONE||||||
34145912|NCT06385535|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The Principal Investigator and Outcomes Assessors will be blinded to the fractal properties of participants' tics until all study procedures have been completed.|Clinical trial with a single arm (i.e., participants are not assigned to groups).||||
34145913|NCT06298981|||COHORT||CROSS_SECTIONAL|||||||
34145914|NCT04058704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145915|NCT00837018|RANDOMIZED|FACTORIAL||||SINGLE|||t|f|f|f
34145916|NCT05586958|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145917|NCT00630227|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145918|NCT01328262|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145919|NCT04349241|RANDOMIZED|PARALLEL||TREATMENT||NONE||"A block-randomization scheme will be generated by computer software. 100 patients with confirmed COVID-19 will be randomized between favipiravir and the standard of care therapy (treated according to the national protocol) in a 1:1 ratio.~Group 1: 50 patients will receive the investigational drug favipiravir. Group 2: 50 patients will receive oseltamivir and hydroxychloroquine as the national standard of care therapy."||||
34145920|NCT01403545|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145921|NCT03708523|||CASE_CROSSOVER||RETROSPECTIVE|||||||
34145922|NCT02955680|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34145923|NCT02725879|||OTHER||CROSS_SECTIONAL|||||||
34145924|NCT04484623|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145925|NCT02788201|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145926|NCT06484010|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Both the students (participants) and the preceptors (Outcome Assessors) in each group were unaware of the other group participants, Outcome Assessors, and the method used for case presentations.~We ensured that by asking the participants in both groups not to discuss any information regarding the study with anyone."|"Thirty Family Medicine board residents and six preceptors from the department of Community and Family Medicine/ College of Medicine/ Hawler Medical University, were chosen by the convenience method and randomly distributed into two groups; the intervention group with the SNAPPS technique (first-arm) and the control group with the traditional case presentation method (2nd-arm) using a simple random number table by Microsoft Excel program, All residents was asked to prepare and present two different cases (per resident) according to their preferences during their daily training at health centers with a total of 60 case presentations (30 presentations for each group).~data and feedback were gathered after each presentation using validated data recording sheets."|t|f|f|t
34145927|NCT02225912||CROSSOVER||||TRIPLE|||t|f|t|t
34145928|NCT01862341|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145929|NCT02558400|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145930|NCT01189357|||COHORT||RETROSPECTIVE|||||||
34145931|NCT01527383|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34145932|NCT02995226|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34145933|NCT00926133|||COHORT||PROSPECTIVE|||||||
34145934|NCT04665115|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145935|NCT00272116|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33834420|NCT04698746|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834421|NCT00624910|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834422|NCT02758743|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33834423|NCT05693909|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34145936|NCT02654418|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34145937|NCT05045170|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants were not aware of the drug used for sedation||t|f|f|f
34145938|NCT01533090|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34145939|NCT04624334|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34145940|NCT00906269|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34145941|NCT06138925|NA|PARALLEL||OTHER||NONE||||||
34145942|NCT01036529|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145943|NCT02853383|||COHORT||CROSS_SECTIONAL|||||||
34145944|NCT05208736|||COHORT||RETROSPECTIVE|||||||
34145945|NCT00795834|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
34145946|NCT04406636|||COHORT||PROSPECTIVE|||||||
34145947|NCT01071356|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145948|NCT03361904|||COHORT||PROSPECTIVE|||||||
34145949|NCT03442517|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145950|NCT04234958|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||randomized controlled trial|t|f|f|f
34145951|NCT03785587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145952|NCT00350623|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34145953|NCT06441292|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34145954|NCT02448888|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34145955|NCT05210634|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|Phase 1 will follow a single-ascending dose design in 3 participants. This portion of the study will be unblinded. Phase 2 will follow a within-participant crossover design in 15 participants. Participants will be randomized to a dosing order. Phase 2 is double-blind.|The is a two-phase, within participant crossover study.|t|t|t|f
34145956|NCT03395730|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Randomization will be based on the sequence generation created by computer and the randomization tables will be kept with the study supervisor. Consenting patients fulfilling inclusion criteria will be randomized into one of the following 3 groups. Randomized allocation will be kept in opaque sealed envelopes, with enrollment numbers written on the envelopes. The envelopes will contain a card on with the designated study group will be written. After enrollment of the patients in the study, the envelopes marked with study number will be unsealed and the patients allocated to either groups|"The present study will be conducted on 150 women recruited from the delivery ward of our hospital after they had received information on the purpose and course of the study from the medical investigator and had provided the written consent during routine prenatal visits , they will be randomly divided into:~* Group (A) Study Group 1: (n = 50)~* Group (B) Study Group 2: (n = 50)~* Group (C) Control Group: (n = 50)"|t|t|f|f
34145957|NCT00246506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145958|NCT02876497|NA|SINGLE_GROUP||||NONE||||||
34145959|NCT04364061|RANDOMIZED|CROSSOVER||PREVENTION||NONE|Data collected on the volunteers will be made anonymous|||||
34145960|NCT02737995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145961|NCT00231231|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145962|NCT02726191|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34145963|NCT02020772|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34145964|NCT01470833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34145965|NCT00601913|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145966|NCT00284713|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34145967|NCT04462991|||CASE_CONTROL||PROSPECTIVE|||||||
34145968|NCT05300841|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145969|NCT03362697|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomization list will by assembled by independient organization not related with participant, care provider, investigators or sponsors. eCRF will include randomization selection|Randomized controlled trial, double blind allocation concealment, parallel Assignment|t|t|t|t
34145970|NCT05326360|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34145971|NCT02482857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145972|NCT05502666|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34145973|NCT04465318|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34145974|NCT03675425|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34145975|NCT01752400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145976|NCT05036200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145977|NCT04534101|||COHORT||PROSPECTIVE|||||||
34145978|NCT02544256|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34145979|NCT04779086|||COHORT||OTHER|||||||
34145980|NCT01283490|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34145981|NCT05256797|||COHORT||RETROSPECTIVE|||||||
34145982|NCT00392808|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34145983|NCT01100567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34145984|NCT00283868|||COHORT||PROSPECTIVE|||||||
34145985|NCT05375006|||CASE_ONLY||PROSPECTIVE|||||||
34145986|NCT00896415|||ECOLOGIC_OR_COMMUNITY|||||||||
34145987|NCT04600336|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34145988|NCT01216943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34145989|NCT03109262|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34145990|NCT04367714|||COHORT||PROSPECTIVE|||||||
34145991|NCT06126367|||COHORT||RETROSPECTIVE|||||||
34145992|NCT02275728|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34145993|NCT02899923|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145994|NCT06349603|||CASE_ONLY||CROSS_SECTIONAL|||||||
34145995|NCT06477471|NA|SINGLE_GROUP||TREATMENT||NONE||An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study||||
34145996|NCT05359133|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34145997|NCT03839992|||COHORT||RETROSPECTIVE|||||||
34145998|NCT04138719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34145999|NCT02552251|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34146000|NCT06230315|||COHORT||PROSPECTIVE|||||||
34146001|NCT05021692|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, single-blind, randomized-controlled type experimental study||||
34146002|NCT04764734|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Single Group will undergo both gold standard polysomnography (PSG) and NightOwl Sleep Apnea Test||||
34146003|NCT05667805|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|interventional radiologists||f|f|f|t
34146004|NCT00841750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34146005|NCT02714270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34146006|NCT05563116|||COHORT||CROSS_SECTIONAL|||||||
34146007|NCT06506994|RANDOMIZED|PARALLEL||TREATMENT||NONE||HRS-9057 injection was compared with Tolvaptan tablets||||
34146008|NCT00534508|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146009|NCT00001464|||CASE_ONLY||PROSPECTIVE|||||||
34146010|NCT04103463|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146011|NCT00276627|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146012|NCT00554099|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146013|NCT03066362|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146014|NCT01359605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34146015|NCT03227068|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||All subjects in both groups will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge including a list of home medications, and information regarding whom to call for emergencies. The PEDSS - symptom management and PEDSS - support for the caregiver are additional tools designed to reinforce care after the initial hospital discharge.||||
34146016|NCT01335841|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34146017|NCT01798641|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34146018|NCT01150201|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146019|NCT00539422|||CASE_CONTROL||OTHER|||||||
34146020|NCT00040508||||TREATMENT||||||||
34146021|NCT00650455||PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146022|NCT04828291|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146023|NCT02772978|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE||This study is a single-group study in which subjects received both placebo and tolcapone in a randomized, double-blind, counterbalanced, within-subject design.|t|f|t|t
34146024|NCT00002460||||TREATMENT||||||||
34146025|NCT04175067|||CASE_CONTROL||PROSPECTIVE|||||||
34146026|NCT05270226|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"Participants were randomly assigned to Intervention Group A or B. Randomization sequence was created using permuted block design manually, with a 1:2 allocation, using block size of 6. The result of the randomization was blinded for participants and occupational therapists (OTs) who preformatted the intervention processes.~Participants had not contact with other participants during all study phases. To address potential bias, all study assessments completed online, without involvement of the OTs who preformatted the intervention processes. The OTs and the participants were not exposed to baseline assessment scores or post-intervention scores of any study measure."|"The study was designed as a randomized controlled and crossover trial to evaluate the evaluate the effect of the Work-MATE program on occupational performance at work of adults with ADHD.~The first Intervention Group (A) received the Work-MATE intervention. After a crossover switching trial, the second Intervention Group (B) received the Work-MATE intervention in order. All evaluations were online, in similar environmental conditions.~The Ethics Committee of the University of Haifa approved the study."|t|t|f|f
34146027|NCT00319475|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146028|NCT06076928|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors (occupational therapist performing measurements/outcome) not involved in participant training will be blinded to assignments of participants.|The study design is a prospective, single-centre, single blinded 3-arm randomised controlled trial to compare upper extremity motor and functional outcomes and health related quality of life (HR-QOL) of 3 treatment modalities which are fully clinic-based and supervised by trained occupational therapists (OT). Participants will undergo dose matched training interventions with 1:1 allocation using single-blinded RCT.|f|f|f|t
34146029|NCT05900570|NA|SINGLE_GROUP||OTHER||NONE||Participants who meet all eligibility criteria will be enrolled in the study and undergo urodynamic testing and LPP with and without neurostimulation||||
34146030|NCT03619226|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34146031|NCT00803413|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34146032|NCT03385278|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||This study was designed and performed as a randomized, controlled cross-over trial. All patients were randomly received active 20-Hz rTMS and sham stimulation for 5 consecutive days, in separate sessions spaced one week.|t|t|f|t
34146033|NCT04945967|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Premature infants at 28 to 34 weeks of gestational age and has achieved oral feeding readiness but unable to achieve safe and efficient oral feeding will be divided into 2 groups for intervention: New method and conventional method interventions.|t|t|t|f
34146034|NCT04816383|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The participant cannot be blinded as they will be using the application. The investigator cannot be blinded as they have to provide the application to the patient, teach them how to use it, and perform their surveys about the application use.~The outcomes assessor and care provider will be blinded."|Control group will usual breastfeeding care (counseling by provider, access to lactation consultant, etc) Interventional group will receive usual care plus the breastfeeding application introduced between 32 to 36 weeks estimated gestational age.|f|t|f|t
34146035|NCT00314301|RANDOMIZED|CROSSOVER||ECT||NONE||||||
34146036|NCT00300677|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34146037|NCT02320851|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146038|NCT02002468|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146039|NCT03118999|RANDOMIZED|CROSSOVER||OTHER||NONE||Single center, open design, randomized, controlled, cross-over trial with 3 test periods and 3 food supplements containing omega3 (one test period per product).||||
34146040|NCT06390787|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146041|NCT04154319|RANDOMIZED|PARALLEL||PREVENTION||NONE||Group randomized trial||||
34146042|NCT04278937|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146043|NCT00606398|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146044|NCT01789528|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34146045|NCT04104919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834424|NCT04928807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834425|NCT03214445|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The evaluated restorations will be coded, and the data will be delivered in sealed envelopes without any identification of the patient, the data will be processed without identification of the groups. The sealant and the resin will be the same color so the evaluator will not be able to differentiate the treatments|prospective, double blind randomized clinical trial under the recommendations of CONSORT. The statistical unit was considered the patient (n=60), with at least 3 composite resins with marginal defects , randomized into 3 groups A=Sealed with flow composite reinforced with nanofiller , B= Sealed with resin sealant , and C=Control, without intervention.|t|t|t|t
33834426|NCT06547307|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33834427|NCT00227045|||DEFINED_POPULATION||OTHER|||||||
33834428|NCT02465151|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33834429|NCT04119843|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Multicenter, open-label, pivotal phase III study||||
33834430|NCT06324045|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"CKD patients will be screened using medical records. Eligible patients will be approached during their routine visits to FBJ Kidney Center and other ambulatory kidney centers. Due to feasibility and practicality issues, selecting the patients will be consecutive case series as per their availability during the time of the recruitment (nonprobabilistic).~After obtaining informed consent, patients will be randomized into one of the two study arms. Randomization will be stratified by dialysis dependency (dialysis vs. pre-dialysis); randomly permuted balanced block sizes of 4 for dialysis patients and 1 for pre-dialysis will be used. Neither the practitioners nor the patients will be blinded to the patients' allocated groups due to the nature of the intervention. Due to feasibility and practicalities, selecting the patients will be consecutive as per their availability during the time of the recruitment (non-probabilistic)."||||
33834431|NCT05111405|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Multicenter, randomized, prospective trial.||||
33834432|NCT00197795|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33834433|NCT06509360|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Single Case Experimental Design||||
33834434|NCT00048503|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834435|NCT02498236|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|f|t
33834436|NCT00580489|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834437|NCT02825251|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834438|NCT05716022|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834439|NCT00333749|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834440|NCT02994784|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834441|NCT01874509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834442|NCT00002492||||TREATMENT||||||||
33834443|NCT03329729|||OTHER||PROSPECTIVE|||||||
33834444|NCT00269932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834445|NCT02417649|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834446|NCT03210649|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834447|NCT01592396|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834448|NCT00520845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834449|NCT00272350||||TREATMENT||||||||
33834450|NCT04292470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834451|NCT03042364|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Randomized clinical trial||||
33834452|NCT05395364|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33834453|NCT02906722|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834454|NCT06263439|||COHORT||PROSPECTIVE|||||||
33834455|NCT06355323|NA|SINGLE_GROUP||SCREENING||NONE||||||
33834456|NCT03451708|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Patient blinded||t|f|f|f
33834457|NCT01426347|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834458|NCT05075512|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834459|NCT05623956|||CASE_CONTROL||PROSPECTIVE|||||||
33834460|NCT01472029|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834461|NCT03439618|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834462|NCT01146977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834463|NCT02383992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834464|NCT00118612|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834465|NCT00707499|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834466|NCT02906020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834467|NCT01814072|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33834468|NCT03720223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Patient blinded for the intraoperative intervention given (With Liposomal Bupivacaine injection to the buccal mucosal graft harvest site or not)||t|f|t|t
33834469|NCT04252404|||OTHER||PROSPECTIVE|||||||
33834470|NCT02840864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834471|NCT05895708|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834472|NCT03564197|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834473|NCT02453061|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834474|NCT03563625|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded to procedure done|"The patients will be classified randomly into two groups using closed envelope technique, 25 patients each:~Group L: 25 patients will receive 1mg/kg bupivacaine 0.25% (diluted as 1ml bupivacaine + 1ml normal saline) by local infiltration in the wound before closure of the skin and subcutaneous.~Group C: 25 patients will receive caudal block with 1mg/kg bupivacaine 0.25%."|t|t|f|t
33834475|NCT00807105|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834476|NCT04360785|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834477|NCT04530604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834478|NCT02165995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834479|NCT02407210|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834480|NCT03473210|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834481|NCT00825305|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834482|NCT02242643|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33834483|NCT04231045|||COHORT||PROSPECTIVE|||||||
33834484|NCT06420050|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834485|NCT01390155|||||PROSPECTIVE|||||||
33834486|NCT05760521|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Patients will not know to which Randomized group that they have been assigned (intervention or control).||t|f|f|f
33834487|NCT04025268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded|2 cohort double blinded randomized control trial|t|t|f|f
33834488|NCT05806151|||COHORT||PROSPECTIVE|||||||
33834489|NCT05563389|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834490|NCT06413719|||COHORT||PROSPECTIVE|||||||
33834491|NCT02609542|||CASE_CONTROL||PROSPECTIVE|||||||
33834492|NCT02637102|||COHORT||PROSPECTIVE|||||||
33834493|NCT02335905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834494|NCT05038540|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834495|NCT01776164|||COHORT||CROSS_SECTIONAL|||||||
33834496|NCT00832468|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33834497|NCT04715555|||CASE_CONTROL||PROSPECTIVE|||||||
33834498|NCT00847353|||||PROSPECTIVE|||||||
33834499|NCT04945447|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|The medical clinics and polypharmacy patients are blinded from the randomisation process.|RCT of The intervention and control groups will both have access to their physician as usual. At the medical clinic level the intervention group will receive the pharmacist intervention and other medical clinics will act as control groups. At patient level the intervention group will receive the pharmacist intervention and the control group are asked to evaluate the current treatment option.|t|t|f|f
33834500|NCT00902798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834501|NCT00205595|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834502|NCT00476528|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834503|NCT04699045|||COHORT||PROSPECTIVE|||||||
33834504|NCT01022411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834505|NCT03164369|||OTHER||PROSPECTIVE|||||||
33834506|NCT04699968|RANDOMIZED|PARALLEL||TREATMENT||NONE||SHR-1701 with or without Famitinib||||
33834507|NCT00356759|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834508|NCT02557126|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834509|NCT02106195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834510|NCT06108310|||COHORT||OTHER|||||||
33834511|NCT01206400|||CASE_ONLY||PROSPECTIVE|||||||
33834512|NCT04860856|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|The patients and the nursing staff who assess postoperative pain will be blinded to the treatment allocation.|Blinded, randomized control trial|t|t|f|f
33834513|NCT05126771|||OTHER||RETROSPECTIVE|||||||
33834514|NCT03054337|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834515|NCT01341847|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33834516|NCT03537235|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834517|NCT05592184|||OTHER||CROSS_SECTIONAL|||||||
33834518|NCT06099119|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834519|NCT05129410|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm open-label pilot observational study||||
33834520|NCT02760901|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834521|NCT01046045|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834522|NCT01276769|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834523|NCT00167154|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834524|NCT02368938|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33834525|NCT02704013|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834526|NCT03257098|NA|SINGLE_GROUP||TREATMENT||NONE||Interventional, single arm, multicenter, phase I/IIa clinical trial||||
33834527|NCT05132881|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Subjects will be assigned by randomization to place individuals into the TaVNS or wait-list groups using a permuted block design with a 1:1 ratio to the group assignments. Subjects will be assigned a study number that will be used on the research files. Each subject will be informed of their group assignment.||||
33834528|NCT05177692|RANDOMIZED|PARALLEL||TREATMENT||NONE||Intervention group will be compared to a control group||||
33834529|NCT00953316|||CASE_ONLY||PROSPECTIVE|||||||
33834530|NCT00999739|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834531|NCT02080403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834532|NCT02509455|||COHORT||PROSPECTIVE|||||||
33834533|NCT00107523||||TREATMENT||NONE||||||
33834534|NCT04517240|||COHORT||PROSPECTIVE|||||||
33834535|NCT02928731|||COHORT||CROSS_SECTIONAL|||||||
33834536|NCT04980079|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834537|NCT01450293|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834538|NCT03196323|||COHORT||PROSPECTIVE|||||||
33834539|NCT04460833|NA|SINGLE_GROUP||SCREENING||NONE|Feedback modalities are given through an augmented reality headset by random|||||
33834540|NCT00005637||||TREATMENT||||||||
33834541|NCT06471712|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834542|NCT02265666|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834543|NCT03510767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834544|NCT02001142|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834545|NCT03543553|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834546|NCT04268056|||COHORT||CROSS_SECTIONAL|||||||
33834547|NCT02547441|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834548|NCT02547272|||COHORT||PROSPECTIVE|||||||
33834549|NCT02342145|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834550|NCT02697838|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834551|NCT05097937|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
33834552|NCT02872012|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834553|NCT00000897||||TREATMENT||||||||
33834554|NCT03945643|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Utilization of placebo to mask drug administration.|Breath hold divers will be administered sildenafil and placebo. Age-matched controls will be administered sildenafil and placebo.|t|f|f|t
33834555|NCT05834868|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834556|NCT05781165|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33834557|NCT05675462|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837669|NCT03267446|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837670|NCT05518071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837671|NCT06503081|||COHORT||PROSPECTIVE|||||||
33837672|NCT00208455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834558|NCT03815253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects of both groups will be randomly assigned to receive either electro-acupuncture or control (sham) treatment. For randomization, simple, complete non-sequential random numbers will be generated in advance by a computer program in a block of four, and kept by the principal investigator. After a patient's eligibility is confirmed, a randomization number which corresponds to the group allocation will be provided to the acupuncturist by the PI. This arrangement will ensure that the clinical assessor and participants are blinded to the allocation.|single-blinded, randomized, sham-controlled clinical trial|t|f|f|f
33834559|NCT04217772|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33834560|NCT01672138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834561|NCT04500028|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind randomized controlled trial|double blind randomized controlled trial|t|t|t|t
33834562|NCT01115608|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33834563|NCT02797990|||COHORT||CROSS_SECTIONAL|||||||
33834564|NCT01854307|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33834565|NCT00104767|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834566|NCT04331483|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834567|NCT00491621|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834568|NCT04803747|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Over the duration of the study, participating centres will be centrally and randomly allocated to receive either TXA or matching placebo at 1-month intervals for a total of 8 months. Intervention assignment will only be known to the research pharmacy staff who will prepare the study drug specific to the interval assignment. To minimize sources of selection and ascertainment biases, anesthesiologists, surgeons, investigators, research staff, and members of the Data Safety and Monitoring Board will all be blinded to randomization schemes and treatments administered; only the trial statistician will have access to randomization schemes for all sites. The research site's Pharmacy staff will not have contact with the study team or the patient and will be expressly forbidden to discuss individual treatment allocation with the study team, the patient, the operating room and clinical care team unless emergency un-blinding is warranted.|TRACTION is a pragmatic, multicenter, randomized, registry-based cluster-crossover trial.|t|t|t|f
33834569|NCT01907698|||CASE_CONTROL||PROSPECTIVE|||||||
33834570|NCT05210075|NA|SINGLE_GROUP||PREVENTION||NONE||A wait-list controlled pilot trial||||
33834571|NCT04251039|||OTHER||PROSPECTIVE|||||||
33834572|NCT04443478|||COHORT||PROSPECTIVE|||||||
33834573|NCT02069197|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33834574|NCT00141999|||||PROSPECTIVE|||||||
33834575|NCT04816123|NA|SINGLE_GROUP||OTHER||NONE|Nonrandomized and open labeled study|single arm with single dose of 300mg Donafenib, containing about 120μCi \[14C\]Donafenib||||
33834576|NCT05891951|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|In this study, researchers and subjects were not blind. Anesthesiologists and data collectors were blind. Researchers conducted carotid ultrasound guided fluid therapy for experimental groups according to the groups, anesthesiologists performed routine induction for patients in the two groups, data collectors collected data, and anesthesiologists and data collectors did not know the groups of subjects.|This is a randomized controlled clinical study to investigate whether carotid ultrasound-guided fluid therapy reduces the incidence of induced hypotension in elderly patients undergoing gastrointestinal surgery.|f|f|f|t
33834577|NCT02761447|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834578|NCT01973140|NA|SINGLE_GROUP||||NONE||||||
33834579|NCT03313141|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||To compare diaphragm elastrography provided by ultrasound to diaphragm function indices provided by magnetic/electrical phrenic nerves stimulation||||
33834580|NCT00777998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834581|NCT03004404|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834582|NCT05105048|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834583|NCT05616377|||CASE_CONTROL||RETROSPECTIVE|||||||
33834584|NCT01337206|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834585|NCT05776290|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Split mouth design|f|f|f|t
33834586|NCT02029768|||CASE_ONLY||PROSPECTIVE|||||||
33834587|NCT01343251|||COHORT||PROSPECTIVE|||||||
33834588|NCT04855942|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Our study design is mainly to compare the therapeutic effect to trigger finger between extracorporeal shock wave (PiezoWave2 ECO, produced by Richard Wolf) and traditional physiotherapy.|f|f|t|t
33834589|NCT01020214|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33834590|NCT02730754|||COHORT||RETROSPECTIVE|||||||
33834591|NCT05280197|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|The surgeon performing the TAP block will be unblinded. The participant, investigators, and outcomes assessor will be blinded.||t|f|t|t
33834592|NCT06164808|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All subjects will wear the Holter monitor and the HeartWatch.||||
33834593|NCT01301599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834594|NCT03828890|NA|SINGLE_GROUP||SCREENING||NONE||||||
33834595|NCT06161337|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33834596|NCT00182988|||||PROSPECTIVE|||||||
33834597|NCT06515704|||COHORT||PROSPECTIVE|||||||
33834598|NCT04384354|||COHORT||RETROSPECTIVE|||||||
33834599|NCT04990778|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834600|NCT03865953|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||"This is the first study with LAT8881 in subjects with neuropathic pain. As such, it has been designed to evaluate, in a well-defined patient group, the concept that LAT8881 is safe and effective in this indication.~Subjects enrolled into this study have been diagnosed with Post Herpetic Neuralgia (PHN) or Diabetic Peripheral Neuropathy (DPN), both conditions being well accepted examples of neuropathic pain. Because the pain is chronic, without a period effect, and treatment is symptomatic rather than curative, a crossover study is considered appropriate. Studies with other agents have successfully demonstrated analgesic effects in PHN and DPN with a crossover study design"|t|t|t|t
33834601|NCT02386839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834602|NCT05861765|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834603|NCT03186586|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834604|NCT00206856|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
33834605|NCT03219762|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Open label, multicentre, study||||
33834606|NCT02605369|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834607|NCT02419768|RANDOMIZED|CROSSOVER||||SINGLE|||f|f|f|t
33834608|NCT04058834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures|Four (4) cohorts are planned. In 3 cohorts, healthy subjects will be randomised in a 3:1 manner to receive either: 1) NNC0385-0434 or 2) Placebo (NNC0385-0434). Each cohort will last 10 weeks and there will be 3 weeks between cohorts. Following safety observation, a fourth cohort will be initiated with patients with hypercholesterolaemia. Patients will be randomised in a 2:1 manner to receive either: 1) NNC0385-0434 or 2) Placebo (NNC0385-0434).|t|t|t|t
33834609|NCT03294824|||CASE_CONTROL||PROSPECTIVE|||||||
33834610|NCT00738283|||COHORT||PROSPECTIVE|||||||
33834611|NCT01641679|||COHORT||PROSPECTIVE|||||||
33834612|NCT05297344|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834613|NCT04001335|||COHORT||CROSS_SECTIONAL|||||||
33834614|NCT04214327|RANDOMIZED|PARALLEL||PREVENTION||NONE||The study design involves a three-condition parallel randomized control trial contrasting: (1) SFP Online Game, (2) SFP Home-use DVD/video series, and (3) Wait-Listed Controls. (4) We will use a non-inferiority trial (NIT) to empirically examine the efficacy of SFP Online when compared to the SFP Group Norms data. The Group Norms data is a representative, demographically matched sample of n=1400 families drawn from a database of over 6,000 families that have attended the full 14-session traditional group class format of SFP.||||
33834615|NCT02161471|||COHORT||PROSPECTIVE|||||||
33834616|NCT00003564|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834617|NCT04396847|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33834618|NCT06234553|||COHORT||RETROSPECTIVE|||||||
33834619|NCT02493842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834620|NCT03959852|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834621|NCT05588583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The model is a prospective, open, multi-center, interventional, non-comparative investigation with the aim to follow exuding chronic wound progression for 6 weeks according to local standard of care.||||
33834622|NCT01893047|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
33834623|NCT04041973|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834624|NCT00360477|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834625|NCT00393653|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33834626|NCT05811299|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834627|NCT02325362|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33834628|NCT05750836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834629|NCT03559790|||COHORT||PROSPECTIVE|||||||
33834630|NCT03334877|||CASE_CONTROL||PROSPECTIVE|||||||
33834631|NCT03833895|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33834632|NCT04565002|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The study has a double blind characteristic. Neither the researcher nor the research subject is aware of his group.|randomized controlled clinical trial|t|f|t|f
33834633|NCT05385237|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|Statistician blinded for analysis|prospective, national, multi-center study|f|f|f|t
33834634|NCT01246089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834635|NCT01759147|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834636|NCT02379962|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33834637|NCT00696488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834638|NCT02931305|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834639|NCT02518815|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834640|NCT01844726|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834641|NCT05625932|RANDOMIZED|PARALLEL||PREVENTION||NONE||Two-arm, randomized, non-placebo controlled, open-label||||
33834642|NCT00610909|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834643|NCT01256671|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834644|NCT05869045|||COHORT||PROSPECTIVE|||||||
33834645|NCT03167853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834646|NCT06319183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834647|NCT02923505|||COHORT||RETROSPECTIVE|||||||
33834648|NCT05951023|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel trial|t|t|t|t
33834649|NCT03206268|||COHORT||PROSPECTIVE|||||||
33834650|NCT02970097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834651|NCT01843777|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146046|NCT02714361|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33834652|NCT01468077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834653|NCT01292304|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834654|NCT04428008|RANDOMIZED|PARALLEL||PREVENTION||NONE||Subjects will be centrally randomized to receive either study treatment drug (Ta1) or no Ta1. Randomization will be stratified by site.||||
33834655|NCT04970719|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834656|NCT00844597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834657|NCT03678623|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33834658|NCT00000677||||TREATMENT||NONE||||||
33834659|NCT02780297|||COHORT||PROSPECTIVE|||||||
33834660|NCT00455897|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834661|NCT06546722|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33834662|NCT05963009|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Randomized Crossover between 1) oral solution, 2) tablet in the fasted state, and 3) tablet in the fed state||||
33834663|NCT04817423|||OTHER||RETROSPECTIVE|||||||
33834664|NCT02777645|||CASE_CONTROL||PROSPECTIVE|||||||
33834665|NCT06370442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
33834666|NCT01421212|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33834667|NCT05888610|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834668|NCT00131963|||COHORT||PROSPECTIVE|||||||
33834669|NCT05350488|||COHORT||OTHER|||||||
33834670|NCT00519545|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33834671|NCT03850275|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|Double-blinded placebo controlled|Crosover Assignment|t|f|t|t
34146047|NCT00215098|||||RETROSPECTIVE|||||||
33834672|NCT03607409|||CASE_ONLY||PROSPECTIVE|||||||
34146048|NCT04581343|NA|SINGLE_GROUP||TREATMENT||NONE||A Phase 1B study enrolling 10 patients to find 6 evaluable patients starting at a maximum dose and dose reducing if needed.||||
34146049|NCT05128006|||CASE_CONTROL||RETROSPECTIVE|||||||
34146050|NCT00773240|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146051|NCT01071005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146052|NCT00369226|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146053|NCT04879394|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
34146054|NCT03047018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146055|NCT03414112|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The study will be double blind; participants and study staff will not know if the participant is receiving intranasal oxytocin or placebo.|Participants with anorexia nervosa and age-matched control participants will complete two separate fMRI and test meal assessments: one following administration of intranasal oxytocin and one following placebo. The study will be double blind.|t|f|t|t
34146056|NCT00272688|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146057|NCT00693641|RANDOMIZED|SINGLE_GROUP||PREVENTION||QUADRUPLE|||t|t|t|t
34146058|NCT03612323|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34146059|NCT03692481|NA|SINGLE_GROUP||OTHER||NONE||||||
34146060|NCT04353843|||CASE_CONTROL||PROSPECTIVE|||||||
34146061|NCT04100434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34146062|NCT04969848|||OTHER||PROSPECTIVE|||||||
34146063|NCT00000765||PARALLEL||TREATMENT||||||||
34146064|NCT00680368|||CASE_ONLY||PROSPECTIVE|||||||
34146065|NCT00522496|||COHORT||PROSPECTIVE|||||||
34146066|NCT01573637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146067|NCT00612625|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
34146068|NCT05400902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146069|NCT02775942|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34146070|NCT00456976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34146071|NCT05203367|RANDOMIZED|SEQUENTIAL||OTHER||DOUBLE|Double-blind|"A maximum of 4 BAR 502 dose levels are preplanned to be investigated in separate sequential cohorts. Each of these cohorts will consist of 8 healthy male and female subjects (3 subjects of either sex on active treatment, 1 of either sex on placebo).~Each subject will participate in only one cohort."|t|f|t|f
34146072|NCT00428220|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146073|NCT03519334|||OTHER||CROSS_SECTIONAL|||||||
34146074|NCT02365285|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34146075|NCT06013956|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The sequence order for the conditions will be randomized for each study participant.|Each participant is assigned to four different conditions. Kinematic, behavioral, and neurophysiological variables are compared across the conditions.|t|t|f|t
34146076|NCT06356012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146077|NCT02914288|||COHORT||PROSPECTIVE|||||||
34146078|NCT05825144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34146079|NCT02127034|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34146080|NCT01500369|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34146081|NCT00137826|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146082|NCT04616209|NA|SEQUENTIAL||TREATMENT||NONE||||||
34146083|NCT00901797|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146084|NCT00631787|||||PROSPECTIVE|||||||
34146085|NCT06383741|||COHORT||PROSPECTIVE|||||||
34146086|NCT02922166|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34146087|NCT05864131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146088|NCT03978780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Blinded for patient, assessor, anesthesiologist in the operating room|This will be a prospective, double-blinded, randomised controlled trial conducted at Women's College Hospital. The study will enroll patients undergoing unilateral breast cancer surgery involving sentinel lymph node biopsy, axillary lymph node dissection and total axillary lymph node clearance. After obtaining written informed consent from eligible patients, study participants will be randomly assigned to one of two groups, the Erector spinae block group and the Control group.|t|f|t|t
34146089|NCT00442091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834673|NCT05226676|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Randomized double blinded sham controlled study|t|f|t|t
33834674|NCT04539483|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind|t|t|t|t
33834675|NCT01803815|||COHORT||PROSPECTIVE|||||||
33834676|NCT01957540|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33834677|NCT00288951|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834678|NCT02000128|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834679|NCT05147337|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34146090|NCT01322165|||COHORT||PROSPECTIVE|||||||
33834680|NCT05736419|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146091|NCT01706042|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34146092|NCT02492074|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34146093|NCT03000777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834681|NCT04171349|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146094|NCT01668641|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146095|NCT03078738|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|SAD, MAD and Gender parts: double blind randomized. Food Effect part: open label, crossover design||t|t|t|f
34146096|NCT02492360|||CASE_CONTROL||PROSPECTIVE|||||||
34146097|NCT04684732|||OTHER||CROSS_SECTIONAL|||||||
34146098|NCT00623545|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146099|NCT05158985|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146100|NCT00739466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146101|NCT01442792|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834682|NCT01021371|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33834683|NCT04030689|||OTHER||OTHER|||||||
33834684|NCT02775305|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834685|NCT02346929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834686|NCT02312206|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834687|NCT04467892|RANDOMIZED|PARALLEL||TREATMENT||NONE|patients with COPD respiratory failure, patients with congestive heart failure|Patients who had severe chest trauma with massive lung contusion and admitted to King Abdelaziz specialist hospital between January 2018 and February 2020 in the intensive care unit those who showed the following inclusion criteria of ARDS, respiratory failure due to severe lung contusion complicated by VAP enrolled in our study||||
33834688|NCT00886353|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33834689|NCT05336175|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will not know which treatment they're receiving. Research staff and patients care providers will have access to which treatment patients are receiving.|Following baseline assessments of cognitive function, MRI and plasma Nfl levels, 40 subjects who have consented to participate in the Ang-(1-7) sub-study and will be randomly assigned to be given either Ang-(1-7) (100 micrograms/kg/day via subcutaneous injection) for 90 days (n=30) or saline placebo (n=10).|t|f|f|f
33834690|NCT05733416|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33834691|NCT01921361|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834692|NCT01240915|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834693|NCT04535245|||COHORT||PROSPECTIVE|||||||
33834694|NCT03541681|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33834695|NCT01729845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834696|NCT04394884|||COHORT||PROSPECTIVE|||||||
33834697|NCT05979428|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33834698|NCT03766945|||CASE_ONLY||OTHER|||||||
33834699|NCT00005871|RANDOMIZED|||TREATMENT||||||||
33834700|NCT04554745|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33834701|NCT01160237|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834702|NCT02392754|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
33834703|NCT05009199|NA|SINGLE_GROUP||OTHER||NONE||||||
33834704|NCT04771377|RANDOMIZED|PARALLEL||TREATMENT||NONE||2:2:1.||||
33834705|NCT04695704|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (Participant, Care Provider, Investigator and Outcomes Assessor)|Double-blind randomized placebo-controlled clinical trial,.|t|t|t|t
33834706|NCT05736172|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834707|NCT04412525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834708|NCT02389322|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33834709|NCT01356771|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834710|NCT04296747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834711|NCT01915797|||COHORT||OTHER|||||||
33834712|NCT02097186|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33834713|NCT01807182|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834714|NCT05837988|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834715|NCT00966264|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33834716|NCT05345730|||COHORT||PROSPECTIVE|||||||
33834717|NCT05562661|||COHORT||PROSPECTIVE|||||||
33834718|NCT01883284|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33834719|NCT04195347|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834720|NCT00688220|||CASE_CONTROL||PROSPECTIVE|||||||
33834721|NCT06216652|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834722|NCT00786643|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834723|NCT00304772|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834724|NCT03379545|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834725|NCT00797888|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834726|NCT04871347|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33834727|NCT04923308|||COHORT||PROSPECTIVE|||||||
33834728|NCT00398281|RANDOMIZED|||DIAGNOSTIC||DOUBLE||||||
33834729|NCT05227781|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Double-blind, randomized, parallel, placebo-controlled|Double-blind (subject, investigator), randomized, parallel, placebo-controlled|t|f|t|f
33834730|NCT04996940|RANDOMIZED|CROSSOVER||OTHER||NONE||Participants will then be randomized 1:1 to e-cigarette flavor order (tobacco e-cigarette, menthol e-cigarette). They will complete a 30-minute ad libitum session with the first product, based on randomization, followed by a 1.5 hour standard washout period, followed by a 30-minute ad libitum vaping session with the second product.||||
33834731|NCT02019862|||COHORT||RETROSPECTIVE|||||||
33834732|NCT02751047|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33834733|NCT01318876|||COHORT||PROSPECTIVE|||||||
33834734|NCT03789747|||COHORT||PROSPECTIVE|||||||
33834735|NCT04582305|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||A single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design.|t|t|t|t
33834736|NCT01511497|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33834737|NCT05113706|||COHORT||RETROSPECTIVE|||||||
33834738|NCT03787888|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834739|NCT00455741|NON_RANDOMIZED|PARALLEL||OTHER||NONE||Estradiol and progesterone infusion to assess negative and positive feedback on the hypothalamus and pituitary in young and older postmenopausal women.||||
33834740|NCT02522988|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33837673|NCT02565433|NA|SINGLE_GROUP||OTHER||NONE||||||
33837674|NCT05037643|NA|SINGLE_GROUP||PREVENTION||NONE||Prospective single-arm study||||
33837675|NCT04091698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Double-blinded trial, outcome assessors and statistician|two parallel group one take Q10 mucoadhesive tablets and other take topical corticosteroid for 3 months follow up measuring pain ,clinical size of lesion and salivary level of Malondialdehyde as oxidative biomarker|f|f|f|t
33834741|NCT04943354|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||"Women diagnosed with premature ovarian failure were selected from different medical institutions in Ryazan and the Ryazan region, all information was communicated to them in a clear and understandable way and they also signed an informed voluntary consent. Premature ovarian failure - defined as the occurrence of secondary amenorrhoea ≥4 months at the age of under 45 years together with FSH levels above 40 IU/L.~Inclusion criteria were: female gender, age at menopause \< 45 years, onset of secondary amenorrhoea ≥ 4 months, FSH levels higher than 40 IU/l, or a previous diagnosis of premature ovarian failure.~The control group was formed based on comparability criteria of gender, age and BMI to minimise the influence of phenotype on the results. The control group consisted of women without signs of PEN, so we aimed to compare the health status of these two different groups of women."|f|f|t|t
33834742|NCT05090189|RANDOMIZED|PARALLEL||TREATMENT||NONE|Given that this is an exercise trial, blinding of study participants or investigators is not possible. Whenever possible, outcome assessors (e.g., lab technicians) will be blinded to the participants allocation.|This study comprises a 6-month parallel-group, randomized, controlled trial, in which individuals with Systemic Lupus Erythematosus who have undergone glucocorticoid pulse therapy (500-1000mg/d methylprednisolone i.v., 1-3 days), will be randomized into one of two conditions: control, consisting of no intervention and standard medical care; and exercise training, consisting of standard medical care supplemented by a twice-weekly, home-based, remotely monitored exercise training program. Patients will be assessed at three timepoints, namely 1-3 weeks after pulse therapy (according to patient's health state and willingness, PRE); three months after baseline (MID); and six months after baseline (POST).||||
33834743|NCT02168322|NA|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33834744|NCT02869256|||COHORT||PROSPECTIVE|||||||
33834745|NCT00272454|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834746|NCT06016699|||COHORT||PROSPECTIVE|||||||
33834747|NCT04569019|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33834748|NCT01015677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834749|NCT01798342|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|t|f
33834750|NCT03235206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834751|NCT03810651|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834752|NCT05639452|||COHORT||RETROSPECTIVE|||||||
33834753|NCT04646369|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|Outcomes assessors will be masked to the intervention condition at follow-up assessment time points.|"This study will use a parallel study design, where participants are randomized into three intervention groups (screening as usual, Screening Wizard 2.0, Screening Wizard 2.0 + SOVA) and will receive interventions in parallel."|f|f|f|t
33834754|NCT01368237|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834755|NCT05261412|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33834756|NCT05038553|||COHORT||PROSPECTIVE|||||||
33834757|NCT04751682|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The vaccine and placebo are identical in appearance and colour.|A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers.|t|t|t|t
33834758|NCT02153905|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33834759|NCT03720977|||CASE_CONTROL||RETROSPECTIVE|||||||
33834760|NCT03050190|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834761|NCT03745547|||COHORT||PROSPECTIVE|||||||
33834762|NCT04737837|||COHORT||PROSPECTIVE|||||||
33834763|NCT00813982|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33834764|NCT00564148|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834765|NCT04596176|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834766|NCT02600078|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33834767|NCT05956067|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834768|NCT00220623|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33834769|NCT03634397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor will assess all participants and be unaware of the participants' group assignment.|Participants are randomly assigned to one of two groups. One group (treatment group) receives remediation therapy of the less impaired arm while the control group receives paretic arm therapy.|f|f|f|t
33834770|NCT04292964|||COHORT||RETROSPECTIVE|||||||
33834771|NCT02755129|NA|SINGLE_GROUP||OTHER||NONE||||||
33834772|NCT00508495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834773|NCT02714712|||CASE_CONTROL||RETROSPECTIVE|||||||
33834774|NCT02920840|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33834775|NCT02904785|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834776|NCT04661943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834777|NCT06510062|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834778|NCT03758495|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834779|NCT03212768|||CASE_ONLY||PROSPECTIVE|||||||
33834780|NCT02367352|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33834781|NCT05794243|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33834782|NCT00648687|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
33834783|NCT06486337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834784|NCT04755777|||OTHER||CROSS_SECTIONAL|||||||
33834785|NCT04330690|RANDOMIZED|PARALLEL||TREATMENT||NONE|Endpoint assessment|||||
33834786|NCT00662922|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33834787|NCT00160277|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834788|NCT05302245|||OTHER||PROSPECTIVE|||||||
33834789|NCT02968238|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33834790|NCT02250599|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834791|NCT06311643|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|the assessor and statistician remained blinded throughout the assessment period, unaware of the group assignments.|Puerperal woman aged from 25 to 30 years within 4 hours of normal delivery|t|t|t|t
33834792|NCT06008847|||OTHER||PROSPECTIVE|||||||
33834793|NCT00848796|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33834794|NCT02053883|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834795|NCT01013961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834796|NCT00496249|||COHORT||PROSPECTIVE|||||||
33834797|NCT04816864|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834798|NCT03527641|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants are assigned to one of two or more group conditions in parallel for the duration of the study - (1) Salud sin Barreras or (2) La Vida Saludable. Both of these programs meet for 6 weeks, twice per week for 12 total 2-hour sessions. Youth are assessed at baseline, post-treatment, and 6-month follow-up.||||
33834799|NCT02586415|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834800|NCT03060018|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834801|NCT01508637|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33834802|NCT03005990|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834803|NCT01777698|||COHORT||PROSPECTIVE|||||||
33834804|NCT02043834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834805|NCT02347995|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834806|NCT02891642|||CASE_CONTROL||PROSPECTIVE|||||||
33834807|NCT00475644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834808|NCT01536587|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33834809|NCT01288209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834810|NCT01265043|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834811|NCT04031196|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|the participants were masked for the type of regional anesthesia given the care provider was blind to the type of the regional block given to the patient and he was asked to assess the visual analogue scale score, first time of rescue analgesia, the total dose of rescue analgesia given and postoperative side effects.|"34 patients randomly allocated into two equal groups 17 patients in each group: Quadratus Lumborum Block QLB group: ultrasound-guided QLB type 2 with 0.5ml/kg of 0.25% levobupivacaine local anesthetic was done to patients.~and Transversus Abdominis Plane Block group (TAP block): ultrasound-guided TAP block with 0.5ml/kg of 0.25% levobupivacaine local anesthetic was done to patients."|t|t|f|f
33834812|NCT04901832|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834813|NCT05994976|||COHORT||CROSS_SECTIONAL|||||||
33834814|NCT02471456|||CASE_CONTROL||PROSPECTIVE|||||||
33834815|NCT00768495|||COHORT||PROSPECTIVE|||||||
33834816|NCT04417205|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Where applicable (i.e. the two breakfast feeding interventions) participants will be blinded to the breakfast that they receive for 28-days.|Participants will be randomised to one of 3 intervention arms.|t|f|f|f
33834817|NCT05783713|||COHORT||OTHER|||||||
33834818|NCT02562820|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33834819|NCT01130649|||OTHER||OTHER|||||||
33834820|NCT05068947|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE||3:1 GV101 (study drug) to placebo. (1:1 for sentinel 2 subjects and 5:1 thereafter)|t|t|t|t
33834821|NCT01620970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834822|NCT00424567|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834823|NCT00827398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834824|NCT04748536|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834825|NCT02419417|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834826|NCT04382235|||COHORT||PROSPECTIVE|||||||
33834827|NCT05632822|||COHORT||PROSPECTIVE|||||||
33834828|NCT01660256|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834829|NCT02505893|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834830|NCT06442696|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33834831|NCT05252936|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish language, 2) K'iche' language, and 3) Kaqchikel language. We will measure effects of the three treatment arms across Spanish speakers (including K'iche' and Kaqchikel speakers who also speak Spanish). We will also measure the effectiveness of K'iche vs. Spanish content among K'iche speakers and Kaqchikel vs. Spanish content for Kaqchikel speakers.|f|f|f|t
33834832|NCT06415097|||CASE_CONTROL||RETROSPECTIVE|||||||
33834833|NCT01163539|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33834834|NCT04817605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834835|NCT05191147|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834836|NCT04200222|||CASE_CONTROL||PROSPECTIVE|||||||
33834837|NCT06229249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33834838|NCT02395419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834839|NCT01495676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834840|NCT00573456|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834841|NCT01587482|||COHORT||PROSPECTIVE|||||||
33834842|NCT04797390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834843|NCT06544369|||COHORT||PROSPECTIVE|||||||
33834844|NCT01784523|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33834845|NCT00373451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834846|NCT01081275|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834847|NCT03228147|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33834848|NCT00778245|RANDOMIZED|CROSSOVER||||NONE||||||
33834849|NCT05729308|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834850|NCT04363632|||COHORT||OTHER|||||||
33834851|NCT04312932|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834852|NCT03498469|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Randomized assignment will be done by the individuals who are evaluating the study outcomes, but will be blind to participant assignment|Participants are assigned to either of the two arms in parallel for the duration of the study|f|f|f|t
33834853|NCT05763199|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33834854|NCT02075619|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834855|NCT02850042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33834856|NCT06152679|||OTHER||RETROSPECTIVE|||||||
33834857|NCT03422445|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838655|NCT05304234|RANDOMIZED|PARALLEL||SCREENING||NONE||we are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.||||
33834858|NCT05550753|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Data will be de-identified prior to analysis|"This is a randomized controlled trial. All enrolled participants will complete the pretest baseline survey. After baseline data collection is completed, the participants will be randomized into either a control or intervention group. This randomized controlled trial study design will offer the BT coaching to the intervention group for the during of 4-months (February 1st 2023- May 31st 2023) and to the control group for the duration of 4-months (September 1st 2023 - December 31st 2023).~At two different timepoints, all participants will be offered surveys containing the following validated indices: burnout, imposter syndrome, self-compassion, moral injury, discrimination, and flourishing. All participants will be offered the survey at baseline- January 2023 (T0), post intervention- May 2023 (T1)."|f|f|f|t
33834859|NCT01521247|RANDOMIZED|PARALLEL||||NONE||||||
33834860|NCT04629456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33834861|NCT05352945|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Blinding is not possible with the self-hypnosis mask as it emits sounds and lights for its effect.|"Patients newly eligible for treatment of idiopathic overactive bladder with botulinum toxin injection will be randomised into two groups before injection:~* Group 1: conventional anaesthesia~* Group 2: conventional anaesthesia and use of self-hypnosis mask"||||
33834862|NCT00947323|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33834863|NCT04386070|RANDOMIZED|PARALLEL||PREVENTION||NONE||The trial uses a Bayesian adaptive platform design, allowing for termination of arms if their superiority to standard care is established, and addition of new treatment arms. Patients will be randomised 1:1 to (A) Control (normal practice), (B) RESP301||||
33834864|NCT00760747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834865|NCT03055169|||COHORT||PROSPECTIVE|||||||
33838656|NCT03058393|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33838657|NCT03082937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838658|NCT01758679|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146102|NCT03476876|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Both of acellular dermal matrices are considered as a standard of care for non-healing diabetic foot ulcers. The subject will be unaware of type of matrices.|The investigators will randomize using 1-1 ratio and based on diabetic foot ulcer cases. In the case that a subject had two eligible wound cases, the randomization will be done to have similar probably for the wound location (e.g. forefoot, mid-foot, hind-foot, etc). If an eligible subject had more than two wounds, only one of them will be considered as an intervention and only one of them as a control case.|t|f|f|f
34146103|NCT04403594|||CASE_CONTROL||PROSPECTIVE|||||||
34146104|NCT02767479|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146105|NCT02513823|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146106|NCT01873053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146107|NCT01283308|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146108|NCT05697666|||COHORT||PROSPECTIVE|||||||
34146109|NCT03019978|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34146110|NCT00315770|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146111|NCT04810936|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146112|NCT02256410|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34146113|NCT06213337|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34146114|NCT03205904|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146115|NCT05840107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146116|NCT01591863|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146117|NCT03926962|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34146118|NCT06138405|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146119|NCT03861130|||COHORT||OTHER|||||||
34146120|NCT02177409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146121|NCT02165293|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34146122|NCT06255509|||OTHER||PROSPECTIVE|||||||
34146123|NCT05348746|||COHORT||PROSPECTIVE|||||||
34146124|NCT01430676|||COHORT||PROSPECTIVE|||||||
34146125|NCT01615601|||COHORT||PROSPECTIVE|||||||
34146126|NCT00046150|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146127|NCT04214912|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|This study was not fully blinded; however, the group allocation was concealed from the patient and primary researcher until after baseline assessments were completed. A primary researcher obtained patient consent, collected self-reported assessments, and if the patients were randomized to intervention group, the intervention trainer explained the exercise program to participants. The study statistician and data managers remained blinded at all times.|There are various models of SCP, in general, the primary care physician model or nurse-led model are generally being recognized for effective detecting patients' distress and recurrences, effective coordination and communication, and taking SCP as standard cancer care. In Taiwan, we take a large number of advanced OC patients, it is important to integrate the SCP but also need to concern about the limited time in busy OPD clinics and patients' differences because of various physical or psychological conditions and needs. PSCP-OC will include two major modules: General \& Personalized Modules.|f|t|t|t
34146128|NCT03322423|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34146129|NCT01604655|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34146130|NCT04286672|||CASE_CONTROL||RETROSPECTIVE|||||||
34146131|NCT03234348|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participant ot the outcomes assessor will be aware of the treatment received. The patient will be blinded until the primary endpoint is reached (1 year follow-up).|"Patients will be randomised to one of two groups:~MAGMARIS stent arm or ORSIRO stent arm in the ratio of 1:1"|t|f|f|t
34146132|NCT05838014|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Each participant will complete two exercise trials in a hot, dry environment (40°C, 15% relative humidity) where they will perform three 30 min bouts of exercise at incrementally increasing metabolic heat loads (each separated by a 15-min rest) following a period of either (i) normal sleep or (ii) 24 h of sleep deprivation.||||
34146133|NCT05618782|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double- Blind|This is a randomized, double-blind, placebo-controlled trial of multiple doses and multiple administrations of LEVI-04 for the treatment of pain due to osteoarthritis of the knee. The study consists of a Screening Period (including a Diary Run- In/analgesic wash-out Period), Randomization, Post-Randomization Period, and a Follow-up Period. Up to 624 participants will be enrolled and randomized to one of four Treatment Arms at the ratio 1:1:1:1.|t|t|t|t
34146134|NCT05164939|||COHORT||PROSPECTIVE|||||||
34146135|NCT05501613|||COHORT||RETROSPECTIVE|||||||
34146136|NCT00860015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146137|NCT02080325|RANDOMIZED|CROSSOVER||||NONE||||||
34146138|NCT04792333|NA|SEQUENTIAL||TREATMENT||NONE||||||
34146139|NCT02315508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146140|NCT01243528|||COHORT||PROSPECTIVE|||||||
34146141|NCT00003358||||TREATMENT||||||||
34146142|NCT05609344|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34146143|NCT03146780|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146144|NCT02601092|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34146145|NCT01344044|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34146146|NCT03320213|||CASE_CONTROL||PROSPECTIVE|||||||
34146147|NCT03471715|||OTHER||RETROSPECTIVE|||||||
34146148|NCT04319744|||OTHER||OTHER|||||||
34146149|NCT02986100|NA|SINGLE_GROUP||OTHER||NONE|Open Label|||||
34146150|NCT03794869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single-Blind||f|f|f|t
34146151|NCT03322501|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146152|NCT01667562|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146153|NCT04091113|||COHORT||PROSPECTIVE|||||||
34146154|NCT02242175|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34146155|NCT00329927|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34146156|NCT05021549|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. Morbid obesity parturient defined as a body mass index (BMI) above 40 kg/m2.~2. ASA physical status I-II~3. Age above 18 years.~4. Scheduled for elective caesarean section under general anesthesia."||||
34146157|NCT06179420|||CASE_CONTROL||PROSPECTIVE|||||||
34146158|NCT01307202|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146159|NCT04291794|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participant and outcomes Assessor will not know group allocation.||t|f|f|t
34146160|NCT01863134|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34146161|NCT04075409|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34146162|NCT00244348|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146163|NCT03930550|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34146164|NCT03450304|||CASE_CROSSOVER||PROSPECTIVE|||||||
34146165|NCT04342689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146166|NCT05157347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146167|NCT05793606|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146168|NCT04251780|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Imaging Assessment before and after treatment||||
34146169|NCT04304911|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Patients (participants) will know the treatment they have been assigned to, but they will not know whether that treatment is considered TAU or experimental (UP-APP). Healthcare professionals and researchers will know the condition each patient has been assigned to (mandatory to provide a given type of intervention).|All consecutive patients with emotional disorders attending any of the collaborating centers will be asked to participate in the present study. Once inclusion criteria are met, each patient will be randomly assigned to one of the two experimental groups: Treatment as Usual (TAU) or UP-APP. Randomization will be performed by a researcher unrelated to the study using a computer-generated sequence (Randomizer). Randomization will be stratified according to the severity of the primary measures of depression and anxiety, using the recommended cutoff in the manuals. Stratification will be made to ensure a comparable proportion of severely depressed and anxious individuals in each group. For each subgroup (i.e., severe or less severe depression and/or anxiety), participants will be randomly assigned to the UP-APP or to TAU.|t|f|f|f
34146170|NCT03054597|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146171|NCT03093636|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146172|NCT06302894|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34146173|NCT03508323|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146174|NCT03051737|||OTHER||RETROSPECTIVE|||||||
34146175|NCT02183129|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146176|NCT01107119|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146177|NCT03256747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|GCMS record will be coded and analyzed by a blinded investigator||f|f|f|t
34146178|NCT03927352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146179|NCT02927275|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
34146180|NCT04202198|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146181|NCT00494715|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146182|NCT03796754|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34146183|NCT05683873|NA|SINGLE_GROUP||OTHER||NONE||||||
34146184|NCT00350428|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146185|NCT02982499|||CASE_CONTROL||PROSPECTIVE|||||||
34146186|NCT04639817|||COHORT||RETROSPECTIVE|||||||
34146187|NCT04744012|||OTHER||RETROSPECTIVE|||||||
33838659|NCT04154852|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838660|NCT02334280|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34146188|NCT02847858|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34146189|NCT05866120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146190|NCT04392921|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Prospective, single-centre, double arm pragmatic randomized controlled feasibility trial|t|t|t|f
34146191|NCT03246490|NA|SINGLE_GROUP||OTHER||NONE||||||
34146192|NCT00724412|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146193|NCT04900948|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146194|NCT05053841|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34146195|NCT04240093|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two-arm RTC, randomized 1:1 to two arms: (1) the CoMBAT intervention (behavioral activation and substance abuse/health navigation) counseling, which lasts ten sessions; and (2) the standard of care comparison condition, including two equivalent substance abuse/ health navigation counseling sessions.||||
34146196|NCT02254785|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146197|NCT05259644|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||In total 75 patients will be randomized into 3 groups.|f|f|t|f
34146198|NCT02431390|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146199|NCT03205852|||CASE_CROSSOVER||PROSPECTIVE|||||||
34146200|NCT05436587|||COHORT||PROSPECTIVE|||||||
34146201|NCT02818114|NA|SINGLE_GROUP||TREATMENT||NONE||Peer specialist led individual education and support for veterans receiving Prolonged Exposure Therapy||||
34146202|NCT02288013|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34146203|NCT05479929|||COHORT||OTHER|||||||
34146204|NCT01448655|||COHORT||PROSPECTIVE|||||||
34146205|NCT04849442|||COHORT||CROSS_SECTIONAL|||||||
34146206|NCT04594460|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"This study is conducted in a double-blind design with a primary unblinding, and a terminal unblinding is performed after data review, database lock, and finalization of the statistical analysis plan.~Both the investigational device (AMS-H-03 Hydrogen-Oxygen Generator with Nebulizer) and the control device (OLO-1 Medical Molecular Sieve Oxygen Generator) were placed in the shell with the same appearance, with the same operating interface and only ventilation function. During the treatment, neither the investigator nor the subject would be aware of the treatment allocation The study devices will be masked by independent non-blinded personnel of the statistical company according to the corresponding operating procedures, and no specific personnel participating in the clinical operation shall be present during the process."|Subjects in the experimental arm and the control arm will receive hydrogen-oxygen mixed gas inhalation (Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03, output: 3 L/min (hydrogen concentration: 66.7%, oxygen concentration: 33.3%)) and oxygen inhalation (OLO-1 Medical Molecular Sieve Oxygen Generator, output: 3 L/min (oxygen concentration: 33.3%), Shanghai Ouliang Medical Devices Co., Ltd.), respectively; the targeted treatment duration will be 8 hours per day, for 12 weeks.|t|t|t|t
34146207|NCT06397508|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34146208|NCT03618914|||CASE_ONLY||PROSPECTIVE|||||||
34146209|NCT04723225|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34146210|NCT01272518|||COHORT||PROSPECTIVE|||||||
34146211|NCT05506488|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Double-blind randomized controlled proof-of-principle study|t|f|f|f
34146212|NCT02132780|||OTHER||CROSS_SECTIONAL|||||||
34146213|NCT01417117|||COHORT||PROSPECTIVE|||||||
34146214|NCT04393272|||COHORT||PROSPECTIVE|||||||
34146215|NCT03289169|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146216|NCT03895632|||CASE_ONLY||CROSS_SECTIONAL|||||||
34146217|NCT00138047|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34146218|NCT04104659|||OTHER||PROSPECTIVE|||||||
34146219|NCT03395561|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146220|NCT05566262|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146221|NCT00946725|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146222|NCT03908645|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34146223|NCT05896852|NA|SINGLE_GROUP||TREATMENT||NONE|N/A all study participants will be included in the intervention arm.|||||
34146224|NCT01377948|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146225|NCT04301180|RANDOMIZED|PARALLEL||TREATMENT||NONE||"The experimental group conducted 10 weekly sessions, with an approximate duration of 45 minutes per session, which consisted of the presentation of food education content while conducting an orchard with seasonal vegetables. Simple recipes were also described in which these vegetables were included to be made at home, along with information from children's books that dealt with the topic of food and were available in the public library.~The control group received the usual training corresponding to the contents of the human body module that is currently taught in each center.~All children in the experimental groups were given written instructions so that they could perform at their home, together with their parents, the manipulative activities suggested each week. All these contents were common for all the participants in the study."||||
34146226|NCT05525754|||CASE_CONTROL||PROSPECTIVE|||||||
34146227|NCT06162091|||COHORT||PROSPECTIVE|||||||
34146228|NCT05648149|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34146229|NCT02654236|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34146230|NCT06279793|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Researchers and clinical staff will be blinded to study intervention allocation. Unblinded delegates at each site will be able to prepare and dispense the investigational drug or placebo.|Randomization will be stratified by site, employing a web-based system using a 1:1 ratio to either intravenous FO- based lipid emulsion (Omegaven®), or placebo.|t|t|t|t
34146231|NCT03109028|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146232|NCT04066569|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34146233|NCT04355858|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146234|NCT04213144|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146235|NCT04231214|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Staff at study site and data analysts are blinded for the primary endpoint (acute effects of Spiolto® Respimat® on cardiac function)|Spiolto® Respimat® or nebulized 0.9 % saline on Day 1 and Day 9, followed by two weeks open label self-administration of Spiolto® Respimat®|f|f|t|t
34146236|NCT02990195|NA|SINGLE_GROUP||OTHER||NONE||||||
34146237|NCT00316888|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146238|NCT04861246|NA|SINGLE_GROUP||OTHER||NONE||||||
34146239|NCT01569061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146240|NCT03405935|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146241|NCT01786460|||COHORT||PROSPECTIVE|||||||
34146242|NCT05755555|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||t|t|f|f
34146243|NCT05841199|||COHORT||PROSPECTIVE|||||||
34146244|NCT04051554|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146245|NCT04564248|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34146246|NCT02483130|||CASE_ONLY||PROSPECTIVE|||||||
34146247|NCT01335529|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146248|NCT05183269|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Control arm: diclofenac 100 mg suppository + local lidocain/prilocain cream (EMLA 5g, Aspen) Intervention arm: diclofenac 100 mg suppository + local lidocain/prilocain cream (EMLA 5g, Aspen) + Oncomfort virtual reality monitor||||
34146249|NCT02699151|||COHORT||PROSPECTIVE|||||||
34146250|NCT04602767|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146251|NCT02335632|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34146252|NCT04172467|||OTHER||RETROSPECTIVE|||||||
34146253|NCT06232278|||COHORT||RETROSPECTIVE|||||||
34146254|NCT01863251|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34146255|NCT03823872|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146256|NCT04941937|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146257|NCT03753100|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|t|f
34146258|NCT02130986|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146259|NCT05301738|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|This was a single-blind protocol. The researcher who collected the data was blind to the allocation of treatment.|A prospective pre-test post-test randomized controlled trial|f|f|f|t
34146260|NCT01437176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146261|NCT02120365|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34146262|NCT00449449|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146263|NCT01847105|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34146264|NCT04053595|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34146265|NCT05857904|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34146266|NCT02804308|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|t|f
34146267|NCT01145053|||CASE_ONLY||PROSPECTIVE|||||||
34146268|NCT03514498|||CASE_CONTROL||PROSPECTIVE|||||||
34146269|NCT00018382|RANDOMIZED|||TREATMENT||DOUBLE||||||
34146270|NCT00955604|||COHORT||RETROSPECTIVE|||||||
34146271|NCT01754298|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146272|NCT05759468|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The study is double-blind in that the study participants and the study staff involved in outcomes assessments will be unaware of the intervention assignment. The randomization schedule will be masked from all study personnel except those specifically designated below.~1. The unblinded study biostatistician~2. The staff of the Investigational Drug Pharmacy Services.~3. The DSMB, if requested"|This will be two center, randomized, double-blind, placebo-controlled, parallel group trial to determine whether βNMN, after its daily oral administration, is associated with a greater reduction in the UACR compared to placebo.|t|t|t|t
34146273|NCT01730404|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34146274|NCT00240110|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146275|NCT03084042|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34146276|NCT01756859|||COHORT||CROSS_SECTIONAL|||||||
34146277|NCT03417817|NA|SINGLE_GROUP||OTHER||NONE||healthy subjects and subjects referred for gastroscopy in context of other conditions||||
34146278|NCT05692310|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34146279|NCT00391391|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146280|NCT00539617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146281|NCT03738319|||CASE_CONTROL||PROSPECTIVE|||||||
34146282|NCT01457677|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146283|NCT00969436|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146284|NCT02606266|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146285|NCT03849430|||COHORT||PROSPECTIVE|||||||
34146286|NCT03507959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|With regard to the four treatment groups, the investigator is not aware which experimental condition participants were allocated to. Regarding the control group, masking is not feasible.|Participants are assigned to one of five experimental groups in parallel for the duration of the study|f|f|t|f
34146287|NCT05013658|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34146288|NCT02267954|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34146289|NCT03220607|||COHORT||PROSPECTIVE|||||||
34146290|NCT02501564|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146291|NCT05740917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146292|NCT00573807|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146293|NCT05512702|||COHORT||OTHER|||||||
34146294|NCT03308045|NA|SINGLE_GROUP||TREATMENT||NONE||Clinical trial with a single arm||||
34146295|NCT03422692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146296|NCT04127799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34146297|NCT03791853|||COHORT||PROSPECTIVE|||||||
34146298|NCT02382848|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34146299|NCT00136825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34146300|NCT02535299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146301|NCT05394532|NA|SEQUENTIAL||PREVENTION||NONE||||||
34146302|NCT00581867|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34146303|NCT00613080|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146304|NCT00744666|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34146305|NCT04041206|||COHORT||PROSPECTIVE|||||||
34146306|NCT00228046|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34146307|NCT05050396|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34146308|NCT01521910|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146309|NCT01479946|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146310|NCT00377559|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146311|NCT03202108|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146312|NCT04705415|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Randomized, Double-Blind Study||t|t|t|f
34146313|NCT03888677|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146314|NCT02636075|||COHORT||PROSPECTIVE|||||||
34146315|NCT01253265|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34146316|NCT00755547|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146317|NCT04194723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146318|NCT02144987|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146319|NCT01812369|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146320|NCT00946322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146321|NCT05424263|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|This study is double-blind. The study drug and placebo will be compounded into visually-identical oral liquid solutions and packaged in identical opaque brown medicine bottles. Only the pharmacy and biostatistician conducting the randomization will know which group subjects are assigned to.||t|f|t|t
34146322|NCT02707211|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146323|NCT00596141|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146324|NCT00711113|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146325|NCT02338934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146326|NCT01180608|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34146327|NCT06508606|NA|SINGLE_GROUP||TREATMENT||NONE||A single-arm Phase II clinical trial||||
34146328|NCT01724424|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34146329|NCT05490589|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146330|NCT01399632|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34146331|NCT05466695|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Patients will use daily tadalafil 5 mg or daily sildenafil 25 mg 4. Assessment of the grade of erectile dysfunction using international index of erectile function-5.The patients whose international Index of Erectile Function-5 (IIEF-5) scores varied between 5-7 are considered to have severe and 8-16 are considered to have moderate and 17-21 are considered to have mild erectile dysfunction.~2. Blood sample will be obtained before and after 2 months of medical treatment to measure neutrophil-lymphocyte and platelet-lymphocyte ratios."||||
34146332|NCT04581382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146333|NCT05656833|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Photographic assessment by two blinded dermatologists will measure changes will assess improvement in melasma by mMASI score. In addition, an investigator quartile improvement score from baseline to week 12 (0 - 0%, no improvement; 76%-100% - very significant improvement) will be assessed.|Single Center, Prospective, With Before-After Analysis|f|f|f|t
34146334|NCT02574741|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146335|NCT00886119|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34146336|NCT01632098|||COHORT||PROSPECTIVE|||||||
34146337|NCT01744717|||COHORT||PROSPECTIVE|||||||
34146338|NCT02916225|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146339|NCT01813123|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146340|NCT02702531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146341|NCT01434329|||||RETROSPECTIVE|||||||
34146342|NCT03797092|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"The patients will be randomized to either IMP or control in a 2:1 randomization.~The outcome ECHO investigations will be analyzed blinded by an independent core lab."|Open randomized treatment group and control group clinical trial|f|f|f|t
34146343|NCT05758285|||COHORT||RETROSPECTIVE|||||||
34146344|NCT00769249|||COHORT||CROSS_SECTIONAL|||||||
34146345|NCT02258555|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146346|NCT05368584|||COHORT||PROSPECTIVE|||||||
34146347|NCT00418431|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146348|NCT02909855|||COHORT||PROSPECTIVE|||||||
34146349|NCT04479683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146350|NCT00320372|||||PROSPECTIVE|||||||
34146351|NCT03615391|||COHORT||RETROSPECTIVE|||||||
34146352|NCT03397992|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE|Patients, primary providers, ICU nurses and primary nephrology team are blinded. The PI and the dialysis nurses are not.||t|t|f|f
34146353|NCT00974285|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146354|NCT02216396|||COHORT||PROSPECTIVE|||||||
34146355|NCT00766246|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146356|NCT05009602|||OTHER||PROSPECTIVE|||||||
34146357|NCT05052437|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34146358|NCT06008483|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|This clinical trial is unblinded, non-randomized, and there is no placebo group. All participants receive active drug product.|||||
34146359|NCT03845972|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146360|NCT03542851|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34146361|NCT05365737|RANDOMIZED|CROSSOVER||PREVENTION||NONE||randomized, double-blind, crossover study of the in situ antibacterial efficacy of o-Cymen-5-ol plus CPC, o-Cymen-5-ol and CPC on salivary microbiota.||||
34146362|NCT00711802|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146363|NCT03560466|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146364|NCT04660227|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34146365|NCT00391001|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34146366|NCT03741803|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146367|NCT05007977|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The participant, the investigator and site staff conducting all study procedures are masked to treatment administered at each clamp.|Subjects will be randomized to the order in which they receive three treatments during consecutive clamps|t|f|t|f
34146368|NCT02704611|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146369|NCT02316210|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34146370|NCT00003252||||SUPPORTIVE_CARE||||||||
34146371|NCT02745717|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146372|NCT05805748|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Each patient was assigned to a group who received 2 rehabilitations for 3 weeks, 1) both serious game training and a conventional rehabilitation first and then conventional rehabilitation alone (group 1, G1), or 2) a conventional rehabilitation first and then both serious game training and a conventional rehabilitation (group 2, G2).|t|f|f|t
34146373|NCT00473603|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146374|NCT01968577|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834866|NCT03242668|NA|SINGLE_GROUP||TREATMENT||NONE||30 patients, with American Society of Anesthesiologists class I to III risk undergoing elective VATS, aged 32-72 years, scheduled for lung resection surgery , were enrolled in this randomised observer blinded prospective clinical study. Patients who refused to participate, less than 18 years of age, ASA physical status 3 or more, allergy to any of the study drugs, patients having any contraindication for paravertebral block, kyphoscoliosis, presence of acute herpes zoster, chronic pain syndrome, chronic analgesic use and psychiatric disease were excluded from this study.||||
33834867|NCT01030432|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146375|NCT04174651|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Crossover randomization within the arms.||||
34146376|NCT00393341|||CASE_CONTROL||PROSPECTIVE|||||||
34146377|NCT03095586|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be blinded to the study hypothesis.|Two arms, parallel group, randomized controlled trial|t|f|f|f
34146378|NCT01268917|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146379|NCT00432744|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34146380|NCT01546714|||COHORT||PROSPECTIVE|||||||
34146381|NCT03564821|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146382|NCT04276155|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective trial of therapeutic strategy, interventional, randomized and open-label, national and multicenter||||
34146383|NCT02267304|RANDOMIZED|SINGLE_GROUP||OTHER||TRIPLE|||t|t|t|f
34146384|NCT03216759|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||f|t|t|t
34146385|NCT02035956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146386|NCT03571165|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146387|NCT01032317|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146388|NCT00002652||||TREATMENT||||||||
34146389|NCT05792592|||COHORT||PROSPECTIVE|||||||
34146390|NCT03700814|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146391|NCT02644356|NA|SINGLE_GROUP||OTHER||NONE||||||
34146392|NCT02032342|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146393|NCT02713529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146394|NCT03132025|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146395|NCT05453994|||COHORT||PROSPECTIVE|||||||
34146396|NCT00246493|||CASE_CONTROL||PROSPECTIVE|||||||
34146397|NCT05792267|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34146398|NCT01735071|RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a multicentre, randomized, non-comparative phase II study aimed at assessing efficacy and safety of two regimens according to a Bryant and Day two-stage design||||
34146399|NCT00153829|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34146400|NCT04625868|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146401|NCT02166645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34146402|NCT00913393|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146403|NCT05788315|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|One half of the participants will be assessed using the Cultural Formulation Interview The other half will be assessed using the standard practice intake|This study will be set up as a cluster RCT among CMBs who are admitted to outpatient care at the four participating mental healthcare centers.|t|f|f|f
34146404|NCT03894384|||CASE_CONTROL||RETROSPECTIVE|||||||
34146405|NCT05691023|||COHORT||PROSPECTIVE|||||||
34146406|NCT06446908|NA|SINGLE_GROUP||OTHER||NONE||||||
34146407|NCT05586698|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE||A single-blinded pilot study|t|f|f|f
34146408|NCT00084175||||TREATMENT||||||||
34146409|NCT02662114|||COHORT||RETROSPECTIVE|||||||
34146410|NCT03493789|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146411|NCT01529736|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34146412|NCT01403376|NON_RANDOMIZED|PARALLEL||||NONE||||||
34146413|NCT00690807|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146414|NCT06105658|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146415|NCT05017129|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Cognitive interviews and small-scale usability will be conducted prior to conducting the full-scale testing. The full-scale learning system (6 learning modules for inmates; 1 learning module for staff) will be tested in 12 state prison settings. We plan to use a pragmatic approach. Targeted participants to test the inmate-focused modules will include both current Inmate Peer Caregivers and inmates who are naïve to the caregiving role in prison. Staff participants to test the staff-focused module include, but are not limited to security, chaplaincy, medical services, psychology/counseling, and administrative leaders. The number of user-participants is dependent on the institution's size, but our target is to recruit 12 sites (three of which will be women's prisons) and an average of 20 inmates per site (n=240 inmates) to test the six modules that are developed for inmates and an average of four prison staff per site (n=48) to test the one module for staff.||||
34146416|NCT00099281|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146417|NCT04695028|||COHORT||PROSPECTIVE|||||||
34146418|NCT03381313|NA|SINGLE_GROUP||TREATMENT||NONE||12 patients suffering from pure anomia in the chronic stage of the disease underwent a word repetition training with a computerized telemedicine protocol. Each patient trained two word sets, one in a conditioned and the other in a non-conditioned training modality; a third non trained set served as control.||||
34146419|NCT01838785|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146420|NCT06001528|||COHORT||OTHER|||||||
34146421|NCT06054854|||COHORT||PROSPECTIVE|||||||
34146422|NCT01340781|||COHORT||PROSPECTIVE|||||||
34146423|NCT02241187|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146424|NCT01881022|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146425|NCT05207969|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146426|NCT03558074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146427|NCT00111904||||TREATMENT||NONE||||||
34146428|NCT00568477|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146429|NCT05957029|NA|SINGLE_GROUP||OTHER||NONE||||||
34146430|NCT04172961|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|study medication will be provided in an unmarked box with tape externally covering any identifying language||t|f|t|f
34146431|NCT02534116|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146432|NCT02374658|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146433|NCT01151761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146434|NCT06233864|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146435|NCT00186537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146436|NCT04448015|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34146437|NCT03097575|NA|SINGLE_GROUP||OTHER||NONE||||||
34146438|NCT00403533|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146439|NCT04593459|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Only the probiotic and placebo are blinded, metformin is an open intervention arm|Probiotic vs placebo (double-blinded) vs metformin (open-label)|t|t|t|t
34146440|NCT00621829|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34146441|NCT02177513|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33834868|NCT01949636|||COHORT||PROSPECTIVE|||||||
33834869|NCT00617929|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834870|NCT02422680|||CASE_ONLY||PROSPECTIVE|||||||
33838963|NCT01744470|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838964|NCT05875649|||CASE_ONLY||PROSPECTIVE|||||||
33838965|NCT03747627|||COHORT||PROSPECTIVE|||||||
34146442|NCT05479123|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146443|NCT00507104|||OTHER||PROSPECTIVE|||||||
34146444|NCT06486272|NA|SINGLE_GROUP||TREATMENT||NONE||Feasibility Pilot Study||||
34146445|NCT05154604|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146446|NCT03777124|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146447|NCT05666895|||OTHER||CROSS_SECTIONAL|||||||
34146448|NCT03432416|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34146449|NCT02495688|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146450|NCT03494218|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||The order of the administration was randomly selected. All patients' total scores assessed by rater A were recorded to test the internal consistency of NCS-R (A1). Meanwhile, to assess the concurrent validity, the scores of the FLACC were recorded together with NCS-R by rater A on day 1. In order to analyze the test-retest reliability, rater A complete the second evaluation of NCS-R on day 2 (A2)|t|f|t|f
34146451|NCT02809053|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146452|NCT00450294|||||PROSPECTIVE|||||||
34146453|NCT02593708|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146454|NCT03559894|||COHORT||PROSPECTIVE|||||||
34146455|NCT05729139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146456|NCT01740544|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34146457|NCT05714943|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34146458|NCT04082013|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34146459|NCT05455008|NA|SINGLE_GROUP||PREVENTION||NONE||Single-arm remotely-delivered health coaching pilot intervention study||||
34146460|NCT04192175|||COHORT||RETROSPECTIVE|||||||
34146461|NCT04794660|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|Care providers and participants are masked to the intervention ahead of the intervention. However, the strategy delivery is not blinded.||t|t|f|f
34146462|NCT03772418|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146463|NCT03654287|||CASE_CONTROL||PROSPECTIVE|||||||
34146464|NCT04329078|||COHORT||RETROSPECTIVE|||||||
34146465|NCT04239300|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146466|NCT01441375|||COHORT||RETROSPECTIVE|||||||
34146467|NCT05736939|||COHORT||RETROSPECTIVE|||||||
34146468|NCT00993733|RANDOMIZED|PARALLEL||||NONE||||||
34146469|NCT05681260|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146470|NCT06365138|||CASE_ONLY||OTHER|||||||
34146471|NCT01522404|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34146472|NCT02570243|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146473|NCT02303899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146474|NCT03770247|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34146475|NCT02230683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146476|NCT03761394|RANDOMIZED|CROSSOVER||DIAGNOSTIC||SINGLE|||f|f|t|f
34146477|NCT04552548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34146478|NCT03036436|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146479|NCT02616393|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146480|NCT03198364|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34146481|NCT02144155|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34146482|NCT06463353|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34146483|NCT02584387|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146484|NCT03802539|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34146485|NCT04628949|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, Non-Randomized, Single-Arm, Post-Market Observational Study||||
34146486|NCT01492413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146487|NCT02921009|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146488|NCT05012007|RANDOMIZED|PARALLEL||SCREENING||TRIPLE|||t|t|t|f
34146489|NCT03677479|RANDOMIZED|PARALLEL||OTHER||DOUBLE|single blinded|pilot randomized clinical trial|t|f|f|t
34146490|NCT04032080|NA|SINGLE_GROUP||TREATMENT||NONE||Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression.||||
34146491|NCT03099148|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34146492|NCT01557959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146493|NCT06030492|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146494|NCT03571672|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834871|NCT04067843|NA|SINGLE_GROUP||OTHER||NONE||The investigator will collect scrapings from the skin surface and quantitatively evaluate bacterial species and density before and after photodynamic treatment in combination with skin antisepsis of povidone-iodine/alcohol, in aim 1 immediately after skin antisepsis, and in aim 2, 21 days after photodynamic treatment. For aim 2, the investigators will additionally evaluate changes of sebaceous and sweat glands after photodynamic treatment using histopathology.||||
34146495|NCT04362878|||COHORT||CROSS_SECTIONAL|||||||
34146496|NCT03361189|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||"Patient Enrollment: The treating physician will identify potential subjects with a previously implanted pacemaker and present a brief overview of the study. Informed consent will be obtained by the investigator after discussing the study, including the voluntary nature of participation and notification the subject can withdraw at any time. The investigator will give the subject and his/her legal guardian the opportunity to take the consent home to think about it more, with the option to call or meet with the investigator to ask additional questions. If the subject and/or his/her parent/legal guardian agree to participate, the investigator will ask them to sign a written, informed consent and assent.~Randomization Procedure: This will be a single-blind placebo-controlled randomized crossover study with 2 treatments: CLS-on versus CLS-off (accelerometer only). Each enrolled patient will receive both treatments for 3 months. The order of treatments will be randomized 1:1."|t|f|f|t
34146497|NCT05162053|RANDOMIZED|CROSSOVER||TREATMENT||NONE||Multiple-center, open-label, randomized, multiple-dose, crossover design||||
34146498|NCT00687609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146499|NCT01757483|||||CROSS_SECTIONAL|||||||
34146500|NCT02025595|||OTHER||CROSS_SECTIONAL|||||||
34146501|NCT00823277|||CASE_ONLY||PROSPECTIVE|||||||
34146502|NCT04787380|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|"Participants in both arms of the study will have the Heartfelt device installed. The Heartfelt device will be able to operate in two modes: technical checks only mode and full data analysis mode. Only participants in Arm A (Heartfelt device + weight + symptom reporting) will have the device in full data analysis mode. Participants in Arm B (weight + symptom reporting) will have the device in technical checks only mode where the data analysis pipeline will be blocked and therefore will not be detecting changes in foot volume.~Only members of staff at Heartfelt Technologies not otherwise involved in the study will pre-set the devices in the relevant mode. The mode of the device will not be known by anyone in contact with the participants or the participants themselves. The switch between the two modes can be done remotely, to maintain blinding. The team will also receive alerts at random in the technical checks only mode to maintain blinding."||t|t|t|t
34146503|NCT04731207|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146504|NCT06025799|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34146505|NCT02771626|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34146506|NCT00504140|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146507|NCT03885050|||COHORT||PROSPECTIVE|||||||
34146508|NCT02302235|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146509|NCT05894525|||COHORT||RETROSPECTIVE|||||||
34146510|NCT01495520|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34146511|NCT04327635|NA|SEQUENTIAL||TREATMENT||NONE||||||
34146512|NCT06228638|||CASE_CONTROL||PROSPECTIVE|||||||
34146513|NCT03177096|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146514|NCT00334282|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146515|NCT05960084|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34146516|NCT05261581|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34146517|NCT03266913|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146518|NCT01853072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146519|NCT00620152|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146520|NCT01948232|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146521|NCT02933840|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146522|NCT02753686|||COHORT||PROSPECTIVE|||||||
34146523|NCT00581828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146524|NCT03688698|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34146525|NCT05189249|||CASE_CONTROL||RETROSPECTIVE|||||||
34146526|NCT00721721|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146527|NCT04126889|||OTHER||CROSS_SECTIONAL|||||||
34146528|NCT03946865|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146529|NCT05287048|||COHORT||PROSPECTIVE|||||||
34146530|NCT00248430||||TREATMENT||||||||
34146531|NCT02736513|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146532|NCT01920152|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34146533|NCT04403243|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized 3:1:1:3 into four groups: colchicine, ruxolitinib, secukinumab, and control group||||
34146534|NCT04959812|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34146535|NCT04316806|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146536|NCT01134926|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146537|NCT05593276|RANDOMIZED|PARALLEL||TREATMENT||NONE||The purpose of this research project is to assess the effectiveness of a novel internet-based cognitive behavioral therapy (iCBT) program called Empower@Home. The program is intended to decrease depression in participants by encouraging them to participate in meaningful and enjoyable activities while challenging problematic thinking patterns.||||
34146538|NCT05367141|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||multicenter, cluster-randomized, single-blind, controlled study with blinded outcome assessment.|f|f|f|t
34146539|NCT04556032|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34146540|NCT02541136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34146541|NCT02675335|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146542|NCT02713516|NA|SINGLE_GROUP||OTHER||NONE||||||
34146543|NCT03008382|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34146544|NCT05543018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146545|NCT00489736|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146546|NCT03562234|||COHORT||PROSPECTIVE|||||||
34146547|NCT05393453|||COHORT||PROSPECTIVE|||||||
34146548|NCT06161285|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34146549|NCT00004864||||TREATMENT||||||||
34146550|NCT02659553|||COHORT||RETROSPECTIVE|||||||
34146551|NCT02707393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146552|NCT00221975|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34146553|NCT06177470|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146554|NCT02017561|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146555|NCT02757794|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146556|NCT03412149|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34146557|NCT03945019|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146558|NCT03043495|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The patient and the attending anesthetist who will manage the patient intra-operatively and perform the block, will be blinded to the patient group allocation All recorded values will be obtained by personnel blinded to the group allocation of the patient.|"The patients will be randomized to 4 groups:~* Group A: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.~* Group B: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.~* Group C: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.~* Group Control: N-12 will receive a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline."|t|t|t|t
34146559|NCT01201512|||COHORT||CROSS_SECTIONAL|||||||
34146560|NCT02614482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146561|NCT05665699|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized , Open Label, Multiple Dose||||
34146562|NCT00532792|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146563|NCT00241098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834872|NCT01689363|RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
34146564|NCT03262207|||OTHER||OTHER|||||||
34146565|NCT04376957|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to standard of care counselling done for oral myeloma medications or will be counselled using the novel teaching tool MASCC Oral agent Teaching Tool (MOATT). Standard of care consists of standard counselling and written materials provided by the oncologist or pharmacy (e.g. instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered).||||
34146566|NCT03474081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This will be a double blind study. Subjects and investigator will be masked.|Subjects will be randomized 1:1 to receive either FF/UMEC/VI via ELLIPTA DPI along with placebo to match tiotropium or tiotropium via HANDIHALER along with placebo to match FF/UMEC/VI in the morning for 84 days.|t|f|t|f
34146567|NCT02958306|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|t|f|t
34146568|NCT03480789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146569|NCT05569876|NA|SINGLE_GROUP||OTHER||NONE|Participants are aware that hypoglycemia will be induced during the study but they are blinded to their blood glucose levels throughout the hypoglycemia procedure.|||||
34146570|NCT05491421|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146571|NCT01852383|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146572|NCT00260065|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146573|NCT03379142|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34146574|NCT06119438|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE||The study was designed as a placebo-controlled prospective double-blind study|t|f|t|t
34146575|NCT01099657|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34146576|NCT04094961|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146577|NCT06296641|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Participants who screen positive all move forward to receive the intervention||||
34146578|NCT05343234|NA|SINGLE_GROUP||SCREENING||NONE||||||
34146579|NCT03094858|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146580|NCT01555515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146581|NCT01304329|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146582|NCT05610956|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded study|parallel randomized controlled|t|f|t|f
34146583|NCT02236416|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34146584|NCT01123733|||COHORT||PROSPECTIVE|||||||
34146585|NCT06545266|||COHORT||PROSPECTIVE|||||||
34146586|NCT00823212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146587|NCT04557787|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
34146588|NCT03576105|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Endpoint Classification: Bio-equivalence Study Enrollment: 34 \[Anticipated\]|t|f|t|f
34146589|NCT04378400|||COHORT||OTHER|||||||
34146590|NCT03897218|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34146591|NCT04808271|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146592|NCT02182674|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34146593|NCT02087813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146594|NCT01444027|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146595|NCT03839836|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||DOUBLE|"The study was a double-blind, five-arm experimental study. This biomechanical study was designed to examine the effect of weight in the gait of the children with the backpack, no follow-up was undertaken.~A convenience sample of children was approached The potential recruits are asked to attend a screening appointment Children were asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly with 5 different weights inside the backpack."|Clinical trial experimental|t|f|t|f
34146596|NCT04590690|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146597|NCT05956808|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Participants will be blinded as to which hearing device they are wearing during lab testing.|This investigation model is a cross-over design, randomized, and is single-blinded.|t|f|f|f
34146598|NCT04226976|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The sponsor will be randomly assigning the Otoband or placebo device to participants. The investigator will not know which device is assigned.|Participants with Acute Unilateral Vestibulopathy (AUV) will be asked to participate in the study. Subjects that give consent will be entered into the study and randomized to one of two groups (96dB or 98dB bone conduction level re:1dyne) by the study coordinator. Neither the subject nor the investigators in the study will know to which arm the subject was placed; rather the study coordinator will be given two sets of two OtoBands. When turned on, both the effective devices and placebo will be felt to vibrate, making it difficult for the typical subject or investigator to guess which device is effective and which is the placebo. After randomization, all subjects will undergo the vestibular battery. The subjects will complete a Participant Questionnaire following the testing.|t|f|t|f
34146599|NCT00979849|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34146600|NCT03610139|RANDOMIZED|PARALLEL||OTHER||SINGLE|"One of the co-investigators who will perform the MRI segmentation and analysis will be blind to the participants' treatment allocation.~Research assistants who will administer the cognitive tests to all participants will be blind to the participants' treatment allocation."||f|f|f|t
34146601|NCT02498574|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
34151239|NCT03704610|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Only the two first infusions will be blinded. Treatment will be prepared by local pharmacies. The pharmacist will receive a fax with the treatment to prepare (infliximab or placebo). The placebo will be an injectable solution of 0.9% sodium chloride equivalent to the one used for infliximab reconstitution. Both treatments will be presented in an infusion bag. After reconstitution and dilution, infliximab solution is clear and limpid, similar to 0.9% sodium chloride solution.~At week 6, after evaluation of ePOST score, unblinding process will be done. All the patients will receive infliximab treatment."||t|t|t|f
34151240|NCT03492931|NA|SINGLE_GROUP||OTHER||NONE|Study has an Open-Label design.|||||
34151241|NCT05903859|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33834873|NCT04407936|||COHORT||RETROSPECTIVE|||||||
33834874|NCT03509246|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834875|NCT05585918|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||School-level randomization of teachers to arm.|f|f|f|t
34146602|NCT04869033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||Sixteen patients with COPD (GOLD I) with mild and moderate (GOLD II) severity aged 51 - 80 years old who visited at the outpatient examination room, Phramongkutklao Hospital divided into 2 groups; diaphragmatic breathing group (DB; n=8) and Farinelli's breathing group (FB; n=8). Participants in each group were administered to complete breathing exercise 5 times per week for 8 weeks. Physiological data and pulmonary function (FVC, FEV1, PEF, FEV1/FVC, FEF25-75%, MVV, VC, TV, IRV, ERV and IC), respiratory muscle strength (MIP and MEP), aerobic capacity (6-MWD and VO2max), impact of COPD questionnaire (mMRC and CAT), cytokine (TNF-α and IL-6), and oxidative stress (MDA) were analyzed during Pre- and Post-test. The dependent variables between pre-test and post-test were analyzed by a paired t-test. Independent t-test was used to compare the variables between groups. Differences were significant at p \< .05.|f|f|f|t
34146603|NCT00106600|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146604|NCT05372861|||CASE_ONLY||PROSPECTIVE|||||||
34146605|NCT02994368|||COHORT||PROSPECTIVE|||||||
34146606|NCT05113667|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146607|NCT05562349|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, double-blind, placebo-controlled, parallel group study|t|t|t|t
34146608|NCT05291936|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34146609|NCT04326764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146610|NCT01124877|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146611|NCT03502304|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Behavioral|f|f|t|f
34146612|NCT02989129|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146613|NCT00330928|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146614|NCT00699218|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34146615|NCT01310959|||COHORT||RETROSPECTIVE|||||||
34146616|NCT05259761|||COHORT||PROSPECTIVE|||||||
34146617|NCT00652899|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146618|NCT05953116|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|"The trial participants and researchers will be blinded during the conduct of the 12-week intervention. An independent third party will handle randomization and allocation of participants to either intervention group (DOST-FNRI protein drink + physical activity) or placebo group (placebo product + physical activity), while trying to ensure a balanced sex distribution between the groups.~The intervention group will receive a protein-containing product which shall meet the target of 30g of protein per day of supplementation. Meanwhile, the placebo group will receive an isocaloric product (similar caloric value but with minimal to no protein content). Both products will have similar packaging, appearance, taste, and flavoring. A unique serial number only known by the independent third party will be used to differentiate between the two products. Unblinding of trial participants will be done after data analysis of a locked dataset."||t|f|t|f
34146619|NCT01671215|||COHORT||PROSPECTIVE|||||||
34146620|NCT00806442|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34146621|NCT05878587|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146622|NCT02009293|||COHORT||PROSPECTIVE|||||||
34146623|NCT00417131|||COHORT||PROSPECTIVE|||||||
34146624|NCT01727011|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146625|NCT00025116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146626|NCT01971268|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34146627|NCT04754685|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||A prospective study was performed on 90 patients were included and categorized into mild (30 cases, moderate (30 cases) and severe (30 cases) knee OA. Three intra-articular (I.A) injections of PRP, 2 weeks a part, were received. Pain score and MRI Osteoarthritis Knee Score (MOAKS) were assessed. Serial synovial fluid cytokines assays in the form of Tumor necrosis factor-α (TNF-α) and Macrophage migration inhibitory factor (MIF), were performed using commercially available ELISA assay kits. The assays were performed pre-injection (S1), two weeks from the 1st I.A injection and two weeks from the 2nd I.A injection (S3) for all included patients.|t|f|t|t
34146628|NCT03211026|||COHORT||PROSPECTIVE|||||||
34146629|NCT02724735|||COHORT||PROSPECTIVE|||||||
34146630|NCT05323123|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be assigned to a one-arm trial with a baseline and 3-month follow-up.||||
34146631|NCT03729193|||COHORT||PROSPECTIVE|||||||
34146632|NCT02092259|||CASE_ONLY||PROSPECTIVE|||||||
34146633|NCT00376701|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34146634|NCT02680210|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146635|NCT00111540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146636|NCT03294070|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146637|NCT00892203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146638|NCT01788579|RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34146639|NCT04401839|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34146640|NCT02179255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146641|NCT00272324|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE||||||
34146642|NCT01838577|||COHORT||PROSPECTIVE|||||||
34146643|NCT01167868|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34146644|NCT01184573|||CASE_CONTROL||RETROSPECTIVE|||||||
34146645|NCT05786365|||OTHER||PROSPECTIVE|||||||
34146646|NCT05246826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146647|NCT06282965|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Investigators, study site staff, participants, and caregivers will be unaware of the participant treatment assignments for the duration of the study. The pharmacist will prepare the study treatment and will be unmasked.||t|t|t|f
34146648|NCT04017689|||OTHER||PROSPECTIVE|||||||
34146649|NCT01278784|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34146650|NCT03371953|RANDOMIZED|PARALLEL||OTHER||TRIPLE|The patient, the attending anaesthesiologist, and the personnel recording the assessment parameters will be blinded to the randomisation sequence and the drug inside the 5-ml solution is supplied in a 5-ml syringe. The study drug for the three group allocation will be contained in a similar 5-ml solution (drug+0.9% saline solution).|"Patients will be randomly divided into three groups in a 1:1:1 distribution undertaken by a computer-generated random number system.~Vecuronium group - 0.08mg/kg vecuronium alone~Atracurium group- 0.6mg/kg atracurium alone~Vecuronium-atracurium group- 0.04mg/kg vecuronium and 0.3 mg/kg atracurium combination"|t|f|t|t
34146651|NCT00512018|RANDOMIZED|SINGLE_GROUP||||SINGLE|||f|f|t|f
34146652|NCT02257723|||COHORT||PROSPECTIVE|||||||
34146653|NCT03913845|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34146654|NCT01547312|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34146655|NCT01680627|||COHORT||PROSPECTIVE|||||||
34146656|NCT01842581|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146657|NCT05070910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146658|NCT03657147|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34146659|NCT00651963|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146660|NCT00412399|||NATURAL_HISTORY||PROSPECTIVE|||||||
34146661|NCT01460719|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34146662|NCT03188835|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34146663|NCT04842474|NA|SINGLE_GROUP||TREATMENT||NONE||"Gaze stability exercises are included in five phases: eyeball movement, saccadic eye movement, pursuit eye movement, vengeance eye movement, and vestibular-ocular reflex exercise. Gaze stability exercises will be performed while patients are seated, and each exercise lasts for 30 seconds.~Balance exercises, both static and dynamic with or without closing eyes, are recommended to improve postural stability. In the first two weeks, patients will perform balance exercises with opening eyes, and then in the next couple of weeks, participants will do the same exercises with closing eyes. It involves standing on a firm surface with feet apart, heel stand, toe stand, marching on a firm surface, semi tandem stand, walking forward and backward with a normal support base.~It will be applied twice each alternative day with ten repetitions for a total treatment period of four weeks."||||
34146664|NCT03821272|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||PepCan or placebo randomized at a 3:1 ratio in a double-blinded design.|t|f|t|f
34146665|NCT01247935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146666|NCT02359214|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34146667|NCT03225261|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34146668|NCT01519674|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146669|NCT03033953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34146670|NCT05766033|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Allocation concealment is achieved with sequentially numbered, opaque sealed envelopes containing the side allocation of the etchant, prepared before the trial. An independent person is responsible for opening the next envelope in sequence and implementing the randomization process. Blinding of the operator at bracket bonding is not possible because of the nature of the intervention. Blinding of the patient is not considered relevant.|This is a multi-center, single-operator, split-mouth randomized controlled trial with a 1:1 allocation ratio.|f|f|t|f
34146671|NCT03112304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146672|NCT03734029|RANDOMIZED|PARALLEL||TREATMENT||NONE||Parallel model, randomized at a 2:1 ratio||||
34146673|NCT04721522|||COHORT||PROSPECTIVE|||||||
34146674|NCT03449433|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34146675|NCT01005212|||CASE_ONLY||PROSPECTIVE|||||||
34146676|NCT00003847|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146677|NCT01592019|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34146678|NCT03587753|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomised cross-over|t|f|t|f
34146679|NCT03935555|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||The study will employ a standard 3+3 dose escalation design to determine maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), with additional subjects treated in a dose expansion cohort. The time period for collecting dose limiting toxicities (DLTs) is 1 cycle (21 days).||||
34146680|NCT00030277||||TREATMENT||||||||
34146681|NCT02973191|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146682|NCT00724906|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146683|NCT03426631|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34146684|NCT05302141|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146685|NCT02418988|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146686|NCT05612360|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|As treated participants will receive text messages, there is no scope for blinding. Care providers will not be made aware of subjects' participation in the study, or assigned treatment arms. The study team will only receive data on subjects' assigned arms and outcomes at the end of the study.|Participants will be randomly assigned to the different arms.|f|t|f|t
34146687|NCT04825990|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146688|NCT00641342|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34146689|NCT05281094|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34146690|NCT03910166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146691|NCT05736276|||OTHER||CROSS_SECTIONAL|||||||
34146692|NCT02844972|||COHORT||PROSPECTIVE|||||||
34146693|NCT05505188|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||The main objective is to calculate the percentage of patients with neuropathic pain 6 months after the end of the treatments and to analyze the link between this pain and addictions, asthenia, depression, and in a more global way on the quality of life of patients. This evaluation will be done using validated questionnaires and self-questionnaires.||||
34146694|NCT02988999|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146695|NCT01394614|||COHORT||RETROSPECTIVE|||||||
33834876|NCT06545279|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE||Split mouth randomized clinical trial.|t|f|f|t
33834877|NCT01497106|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33834878|NCT01760798|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834879|NCT00590564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146696|NCT04743960|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146697|NCT05886530|||COHORT||PROSPECTIVE|||||||
34146698|NCT06504927|||COHORT||CROSS_SECTIONAL|||||||
34146699|NCT00731965|RANDOMIZED|PARALLEL||||NONE||||||
34146700|NCT04147975|||CASE_ONLY||PROSPECTIVE|||||||
34146701|NCT03460548|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34146702|NCT00239954|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34146703|NCT04384107|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34146704|NCT03418558|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146705|NCT00500227|||COHORT||PROSPECTIVE|||||||
34146706|NCT04500340|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146707|NCT05536856|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151242|NCT00199823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34146708|NCT05117619|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are assigned to an Arm (HOME treatment or Attention-control condition) after the first (T1) interview. The interviewers are blinded to the group assignment.|The design is a two group, randomized controlled trial. The study uses a stratified permuted block randomization, with blocks varying in size of 4 to 6, to conceal treatment allocation and control for possible changes over time in the subject mix. To ensure proper group balance, stratification on sex and civilian/veteran status will be conducted. The study statistician will develop the blocking number and provide a computer-generated randomization list. An intention to treat (ITT) model will be followed. Participants who do not wish to continue after the Time 1 baseline interview will not be randomized and will not count toward the accrual goals.|f|f|f|t
34146709|NCT06346249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146710|NCT01556061|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146711|NCT00453596|||CASE_CONTROL||PROSPECTIVE|||||||
34146712|NCT03382067|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34146713|NCT03921398|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34146714|NCT02192229|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146715|NCT02190305|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146716|NCT01007422|||COHORT||PROSPECTIVE|||||||
34146717|NCT03287674|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146718|NCT00331227|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34146719|NCT05895903|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|A randomized allocation sequence created using GraphPad Prism 9 software divided the patients in two groups.|Nineteen patients (12 females and 7 males) with narrow alveolar ridges participated in this research. Forty-six osteotomy sites were prepared, and 41 DIs were installed. A randomized allocation sequence created using GraphPad Prism 9 software divided the patients in two groups. The SE technique group consisted of 21 DIs after alveolar bone expansion with threaded screw expander drills, and the OD group consisted of 20 DIs after alveolar ridge expansion with Densah® burs.|t|t|t|f
34146720|NCT04524650|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34146721|NCT03542916|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34146722|NCT02794389|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34146723|NCT00913614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146724|NCT04338633|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double||t|f|f|t
34146725|NCT04478032|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this research,we combine a cross-sectional case control study and a randomized controlled study.|t|f|f|t
34146726|NCT02741037|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34146727|NCT02547493|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146728|NCT05378295|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34146729|NCT03510871|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146730|NCT01702740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146731|NCT04460586|NA|SINGLE_GROUP||OTHER||NONE||A single group of patients with CF will receive a single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of 300 mg PO.||||
34146732|NCT03140982|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|after patient constent, and previos the patient arriving the OR, the care provider (designed anesthestist) using a coin decide the arm (GR or GL). The neurologist and investigator was blind to the arm.|comparison of the neurologic behavior between two group, a fast and a slow anesthesia induction|t|f|t|t
34146733|NCT03927079|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146734|NCT05493189|RANDOMIZED|PARALLEL||OTHER||NONE||Experimental case-control study, aligned in two phases.||||
34146735|NCT02471768|||COHORT||PROSPECTIVE|||||||
34146736|NCT01219933|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146737|NCT03411564|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Longitudinal quasi-experimental educational intervention study. The evaluation will be carried out using an on-line questionnaire distributed to an intervention and a control groups at two time periods: before starting the program (Baseline, time 0 or T0), after finishing the study - including the dissemination phase - (time 1 or T1). In addition, a process evaluation will be carried out with the intervention group.||||
34146738|NCT06275750|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146739|NCT01760811|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146740|NCT01545050|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146741|NCT03070197|||CASE_CONTROL||PROSPECTIVE|||||||
34146742|NCT03051815|||CASE_ONLY||PROSPECTIVE|||||||
34146743|NCT03305380|||OTHER||OTHER|||||||
34146744|NCT05517902|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146745|NCT00680758|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146746|NCT03926312|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146747|NCT04014621|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146748|NCT02598128|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34146749|NCT02973776|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|t|f
34146750|NCT04042272|||COHORT||PROSPECTIVE|||||||
34146751|NCT02403895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146752|NCT01013779|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146753|NCT05451680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||controlled study|f|f|t|t
34146754|NCT02476110|||COHORT||PROSPECTIVE|||||||
34146755|NCT01299571|||COHORT||PROSPECTIVE|||||||
34146756|NCT01201200|||COHORT||PROSPECTIVE|||||||
34146757|NCT03311984|||CASE_ONLY||PROSPECTIVE|||||||
34146758|NCT01171586|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834880|NCT03024463|||CASE_ONLY||PROSPECTIVE|||||||
33834881|NCT04802304|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Half of the eligible clinics in each country (233 in total) are randomly assigned to receive the intervention, while the remaining half serves as control.||||
33834882|NCT02358447|||COHORT||PROSPECTIVE|||||||
33834883|NCT05584605|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146759|NCT01595581|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34146760|NCT05358431|NA|SINGLE_GROUP||OTHER||NONE||||||
34146761|NCT05977348|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Study team members who will conduct individual research assessments with each child will be blinded to study condition.|The project is a cluster-randomized trial, with a 1:1 ratio of classroom random assignment to intervention or control.|f|f|f|t
34146762|NCT04504942|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146763|NCT03349866|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146764|NCT04738253|||CASE_ONLY||PROSPECTIVE|||||||
34146765|NCT05229796|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|t|f|f
34146766|NCT06355115|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146767|NCT04284566|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Parallel Assignment Single-blind, parallel-group, randomized controlled trial|f|f|t|t
34146768|NCT02023021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146769|NCT03356509|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146770|NCT04609800|||COHORT||PROSPECTIVE|||||||
34146771|NCT04528459|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Patients will be blinded to treatment group allocation, as will outcomes assessors. Clinicians performing the procedures will not be blinded.|Patients will be divided into two treatment arms: cohort 1 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using traditional fluoroscopy for insertion of the lag screw. Cohort 2 will consist of patients with closed peritrochanteric femur fractures who undergo open reduction internal fixation with a Stryker© Gamma™ cephalomedullary nail using the Stryker© ADAPT™platform to assist with insertion of the lag screw.|t|f|f|t
34146772|NCT03790800|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome assessor is independent of the treatment team|central randomization with stratification|f|f|f|t
34146773|NCT02360293|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146774|NCT03173352|||COHORT||PROSPECTIVE|||||||
34146775|NCT01341626|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34146776|NCT03889548|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||Within-subjects design with mental imagery and control conditions performed in random order|f|f|f|t
34146777|NCT00657150|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34146778|NCT02776033|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146779|NCT05393739|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34146780|NCT04545047|||OTHER||PROSPECTIVE|||||||
34146781|NCT05254561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double masking|Parallel assignment|t|f|t|f
34146782|NCT04320511|||COHORT||PROSPECTIVE|||||||
34146783|NCT04858685|||CASE_ONLY||CROSS_SECTIONAL|||||||
34146784|NCT02188498|||COHORT||CROSS_SECTIONAL|||||||
34146785|NCT02124772|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146786|NCT01828138|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34146787|NCT02611141|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34146788|NCT05045677|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
34146789|NCT01314560|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34146790|NCT05482659|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|f|t
34146791|NCT04317157|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants and the investigator that will be in touch with participants, will be blinded regarding the interventions.|There are five experimental conditions in a crossover design. Participants will receive placebos in four of these trials and caffeine in the other one.|t|f|t|f
34146792|NCT02706561|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146793|NCT05901805|||CASE_ONLY||CROSS_SECTIONAL|||||||
34146794|NCT01193166|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146795|NCT00214474|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146796|NCT00069524|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146797|NCT04841603|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized control trial||||
34146798|NCT01361932|RANDOMIZED|SINGLE_GROUP||||NONE||||||
34146799|NCT06147921|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blind, Placebo-Controlled|Single Ascending Dose (SAD), Single Dose Active Components PK Crossover, Multiple Ascending Dose (MAD)|t|t|t|t
34146800|NCT02433873|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34146801|NCT00831701|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146802|NCT04713618|||COHORT||PROSPECTIVE|||||||
34146803|NCT05153824|||COHORT||PROSPECTIVE|||||||
34146804|NCT04637919|RANDOMIZED|SEQUENTIAL||PREVENTION||QUADRUPLE|||t|t|t|t
34146805|NCT03345719|||COHORT||PROSPECTIVE|||||||
34146806|NCT00436254|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146807|NCT00460590|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146808|NCT04382521|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146809|NCT04109846|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients desiring frozen embryo transfer or aneuploid or mosaic embryo. Patients will be counseled regarding risks and obstetric and pediatric outcomes will be collected.||||
34146810|NCT00093886|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146811|NCT05478291|NA|SINGLE_GROUP||PREVENTION||NONE|Both participants and their clinical care team will be aware of the allocation.|A randomized open labelled placebo-controlled trial.||||
34146812|NCT01656369|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146813|NCT01535794|||COHORT||CROSS_SECTIONAL|||||||
34146814|NCT04008992|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|t|f
34146815|NCT01025570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146816|NCT01102894|NA|SINGLE_GROUP||||SINGLE|||t|f|f|f
34146817|NCT01739803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146818|NCT04515953|RANDOMIZED|PARALLEL||TREATMENT||NONE||The first two arms of the placebo control and the 1st dose level ND-340 were randomly paralleled and then subsequently arms for ND-340 dose escalations.||||
34146819|NCT02025816|||OTHER||OTHER|||||||
34146820|NCT03369431|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||3-month randomised controlled cross-over design with 4-week washout. Outcomes measured at baseline and last week of each treatment phase.|t|t|t|t
34146821|NCT02345356|||CASE_CONTROL||PROSPECTIVE|||||||
33834884|NCT01722747|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33834885|NCT03293836|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146822|NCT02048215|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34146823|NCT04376827|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146824|NCT00404170|NA|SINGLE_GROUP||OTHER||NONE||||||
34146825|NCT05549739|||CASE_CONTROL||PROSPECTIVE|||||||
34146826|NCT06506006|||COHORT||PROSPECTIVE|||||||
34146827|NCT00607854|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146828|NCT02079935|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The one transferring results from lab's and questionaires to SPSS are blinded for group affiliation.|Comparing treatment of cognitive behavioural therapy, with treatment of physical exercise and dietary therapy. All participants randomized to either of the two treatment offers. Waitlist serves as control group.|f|f|f|t
34146829|NCT02178046|||CASE_ONLY||PROSPECTIVE|||||||
34146830|NCT00469963|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146831|NCT01116427|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34146832|NCT04326660|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|To decrease cross-contamination of treatment effect, the six study sites will be the units of randomization. A Statistical Package for Social Sciences (SPSS) program will be used to statistically match the groups and to randomly assign each study group.|This pilot study will utilize a randomized control trail design with a control group.|t|f|f|f
34146833|NCT03899064|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The tests sites (M2-01 Cream, MC2-01 vehicle, control) will not be blinded to the site staff involved in the preparation/application and removal of treatments. The subjects and the trained assessor will be blinded to the IPs and treatment allocation|The study consist of an Induction phase, where treatments (MC2-01 Cream, MC2-01 vehicle) were applied to 2 test sites each (n=4), followed by irradiation/non-irradiation and evaluation 24, 48 or 72 hours post-irradiation. This was repeated in total 6 times over an 3 weeks period. The induction phase was followed by a challenge phase, where treatments (MC2-01 Cream, MC2-01 vehicle) were applied to each two naive test sites and another naive test site was untreated. 24 hours of product application, one of each test sites (MC2-01 Cream, MC2-01 vehicle) + the untreated test site were irradiated. Possible changes in dermal reaction (erythema and edema) was evaluated at all 5 test sites, 24, 48 and 72 hours post-irradiation.|t|f|f|t
34146834|NCT03067285|RANDOMIZED|PARALLEL||TREATMENT||NONE||A phase IV, open-label, randomised, pilot clinical trial||||
34146835|NCT05759130|||COHORT||PROSPECTIVE|||||||
34146836|NCT02389205|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34146837|NCT01665989|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146838|NCT04615325|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34146839|NCT03721133|||COHORT||PROSPECTIVE|||||||
34146840|NCT00892606|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34146841|NCT03987932|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146842|NCT00266344|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146843|NCT01549795|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146844|NCT05666232|||COHORT||PROSPECTIVE|||||||
34146845|NCT03954470|||COHORT||RETROSPECTIVE|||||||
34146846|NCT00869830|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146847|NCT02119156|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146848|NCT01964599|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34146849|NCT04498377|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Patients will be randomized in a 1:1 ratio in a double-blind manner to receive F-652 or placebo.~An independent statistician from Medpace will generate the randomization schedule. Patients meeting eligibility criteria will be randomized on Day 1 in a 1:1 ratio to F-652 or placebo, respectively. Patients will be assigned a randomization number and treatment assignment according to the randomization schedule. This randomization schedule will be maintained by the investigative site pharmacist until it is appropriate to break the blind. The Investigator, investigative site personnel (except site-designated pharmacist and dedicated assistant), study monitors, vendors, Sponsor, and Medpace will remain blinded to treatment assignment."||t|t|t|t
34146850|NCT02892721|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34146851|NCT01565564|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34146852|NCT02202460|||CASE_CONTROL||PROSPECTIVE|||||||
34146853|NCT02303782|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146854|NCT04596865|||COHORT||RETROSPECTIVE|||||||
34146855|NCT02532920|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34146856|NCT06157944|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The grading of responses will be performed by assessors blinded to participant identity and treatment assignment.|The trial will be designed as a randomized, two-arm, single-blind parallel group study.|f|f|f|t
34146857|NCT05583149|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146858|NCT02358655|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34146859|NCT00633230|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146860|NCT04485689|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE||This is a within-between subjects comparisons study.|t|f|f|f
34146861|NCT01367392|NA|SINGLE_GROUP||||NONE||||||
34146862|NCT03384823|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34146863|NCT04065594|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34146864|NCT03059771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146865|NCT02631733|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146866|NCT04591249|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Two-group, single-center randomized, controlled study in 30 patients undergoing spine surgery for a lumbar degenerative condition to examine the feasibility and acceptability of an 8-week remote physical activity intervention.|f|t|f|t
34146867|NCT02279498|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146868|NCT05529342|||CASE_CONTROL||PROSPECTIVE|||||||
34146869|NCT03217032|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146870|NCT06408896|||COHORT||RETROSPECTIVE|||||||
34146871|NCT03490604|||COHORT||PROSPECTIVE|||||||
34146872|NCT05066945|||COHORT||PROSPECTIVE|||||||
34146873|NCT01020708|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146874|NCT03130426|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146875|NCT04973345|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE||A Prospective, Blinded, Cross-over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults with Asthma (TBS02)|t|t|t|f
34146876|NCT02782325|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146877|NCT03808363|NA|SINGLE_GROUP||PREVENTION||NONE||6 week exercise intervention testing the efficacy of high intensity interval training as compared to current research supporting moderate intensity continuous exercise as a means to mitigate cardiometabolic decline following spinal cord injury||||
34146878|NCT05275946|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146879|NCT05732636|||OTHER||PROSPECTIVE|||||||
34151243|NCT00229502|||COHORT||PROSPECTIVE|||||||
34151244|NCT04035746|||COHORT||PROSPECTIVE|||||||
34146880|NCT05610046|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|In this trial, neither the participants, nor the researchers who perform the trial days will be blinded to the intervention allocation. However, the researchers performing the blood analysis are blinded to the treatment allocation and are not involved in the research study during the trial days.|Crossover, randomized, controlled trial|f|f|f|t
34146881|NCT03803813|||COHORT||PROSPECTIVE|||||||
34146882|NCT01634672|||COHORT||PROSPECTIVE|||||||
34146883|NCT02287753|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34146884|NCT05117021|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34146885|NCT04139720|RANDOMIZED|PARALLEL||OTHER||NONE||The repeated measurements randomization control trial will be used for the experimental design. We design a 45-minute course and 15 minutes of Q\&A. Based on the gender in recruitment, the study used block randomization, and randomly assign participants who meet the selection criteria to the experimental group and the control group (1:1 ratio) by Random Allocation Software random assignment table.||||
34146886|NCT01502150|||COHORT||PROSPECTIVE|||||||
34146887|NCT01988545|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34146888|NCT00086502|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146889|NCT00461305|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146890|NCT02953665|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146891|NCT05252221|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34146892|NCT01866033|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146893|NCT04789694|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146894|NCT01152515|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146895|NCT01551277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34146896|NCT04346030|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146897|NCT02008422|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146898|NCT01038726|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34146899|NCT02458547|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34146900|NCT03358641|||COHORT||PROSPECTIVE|||||||
34146901|NCT06508372|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE||Intrapatient randomized controlled study: Topical Thymoquinone ointment will be applied to one psoriatic plaque on one side of the body, while the placebo ointment will be applied to a similar psoriatic plaque on the other side of the body twice daily for 3 months. each patient is randomizied to receive topical thymoquinone ointment on either the left or the right side.|t|t|t|f
34146902|NCT02795013|||CASE_CONTROL||PROSPECTIVE|||||||
34146903|NCT05995977|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|In this study, random selection and assignment will be made by a person other than the researcher and blind technique will be applied by hiding who is in the control and intervention groups from the researcher. In this study, the researcher will not be blinded during the intervention. Patients will not be blinded as consent will be obtained for the application to be made to them. In order to prevent bias in the evaluation of data; Statistical analyzes of the data encoded in the prepared database will be carried out by a statistics expert independently of the researcher. The coding for the control and intervention groups will be explained after the statistical analyzes of the study and the tables suitable for the results are made and the research report is written. Thus, blinding can be made in terms of statistics specialist and reporting. Intention to treat analysis (ITT) will be applied to prevent reduction bias due to lack of data.|"APPLICATION The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on CMT. The second component is the sending of regularly delivered KMT-based SMS messages aimed at reminding, encouraging and motivating patients to maintain medication adherence and healthy lifestyle changes.~Applications made to the intervention group:~NURSING INITIATIVES (HYPERNI)~1. Hypertension Education:~2. Sending an SMS Message:~Applications to the control group: No intervention will be applied to the control group by the researcher during the study. Upon the collection of the follow-up test data of the control group, information notes and brochures created within the scope of the research will be given to the patients who request it from this group."|f|f|f|t
34146904|NCT03504566|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146905|NCT00595933|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34146906|NCT04207918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146907|NCT00000120|RANDOMIZED|||TREATMENT||DOUBLE||||||
34146908|NCT01516567|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146909|NCT00386477|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34146910|NCT01765075|||CASE_ONLY||CROSS_SECTIONAL|||||||
34146911|NCT01433341|||||PROSPECTIVE|||||||
34146912|NCT01638559|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146913|NCT00031018|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34146914|NCT06147687|||COHORT||PROSPECTIVE|||||||
34146915|NCT05953948|NON_RANDOMIZED|PARALLEL||OTHER||SINGLE|The study participants will be aware they are in the experimental or control group; however, the data collector did not know which group the participants are in.|In the feasibility evaluation stage, 200 patients will be recruited for the study. In the quasi-experiment stage, 133 patients will be involved in this experiment: 44 in the experimental group and 89 in the control group. The intervention or usual care will conduct parallel.|f|f|f|t
34146916|NCT01903889|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34146917|NCT01562405|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146918|NCT05308498|||CASE_CONTROL||RETROSPECTIVE|||||||
34146919|NCT02227823|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34146920|NCT04921085|||COHORT||CROSS_SECTIONAL|||||||
34146921|NCT00419315|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146922|NCT03445910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|one hundred opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table. Then all envelopes will be closed and put in one box. When the first patient arrives, the first envelope will be opened and the patient will be allocated according to the letter inside.||f|f|t|f
34146923|NCT00692068|||CASE_CONTROL||PROSPECTIVE|||||||
34146924|NCT01274611|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146925|NCT05275322|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34146926|NCT03816683|||COHORT||PROSPECTIVE|||||||
34146927|NCT02920957|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34146928|NCT02273570|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146929|NCT03858504|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146930|NCT05184790|||COHORT||PROSPECTIVE|||||||
34146931|NCT06090032|||OTHER||CROSS_SECTIONAL|||||||
34146932|NCT05996614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146933|NCT04673916|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||2 groups of patients|t|f|f|f
34146934|NCT02994693|||COHORT||PROSPECTIVE|||||||
34146935|NCT01969500|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146936|NCT00591669|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34146937|NCT06013280|RANDOMIZED|PARALLEL||TREATMENT||NONE||Two groups with a control group||||
34146938|NCT06406803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146939|NCT05693051|||COHORT||RETROSPECTIVE|||||||
34146940|NCT03329963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146941|NCT00589810|||CASE_CONTROL||RETROSPECTIVE|||||||
34146942|NCT00849875|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146943|NCT01617447|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146944|NCT02421601|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146945|NCT01164332|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34146946|NCT01711866|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146947|NCT05929339|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Two 30 minute infusion of oxytocin, 17 micrograms with will be administered. The second infusion will be given 30 minutes after the completion of the first infusion.||||
34146948|NCT01586104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146949|NCT05749354|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34146950|NCT02427724|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34146951|NCT00450736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146952|NCT05205369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146953|NCT06226168|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34146954|NCT04129710|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34146955|NCT04942223|NA|SINGLE_GROUP||TREATMENT||||prospective pilot cohort study||||
34146956|NCT04361890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||ultrasonographic measurements before and after pelvic floor muscle training||||
34146957|NCT02459275|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34146958|NCT01656226|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34146959|NCT01883752|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34146960|NCT06105359|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|To control for performance bias, patients will be blinded to the study hypothesis and will not be informed which group they are in. There will be no blinding for the researcher. However, blind technique will be used in the research. This blind technique will be applied by the researcher with the patients blinded until the application begins. In the research, in order to meet the blind technical conditions, the process steps were carried out by an independent statistician from the first stage. The sample will be sorted by a combination order and number. In this way selection bias will be controlled. The study will also be controlled for attrition bias and Statistics and reporting bias.|Research, experimental control group and pretest-posttest study will be carried out.|t|f|f|t
34146961|NCT00964847|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146962|NCT04589013|||COHORT||PROSPECTIVE|||||||
34146963|NCT02270723|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34146964|NCT00908115|||COHORT||RETROSPECTIVE|||||||
34146965|NCT06110455|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34146966|NCT05665400|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34146967|NCT01689545|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
34146968|NCT06518707|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|During the study period, the investigator will set the intensity of the phrenic nerve stimulation, so the investigator will not be masked. However, patients who are enrolled in this study and assessors who assess the clinical outcomes will be masked.|The intervention groups include two groups: each group will receive phrenic nerve stimulation under different degrees of neuromuscular blockade, i.e., the TOF 0 group and the TOF 1-2 group.|t|f|f|t
34146969|NCT06103929|||OTHER||CROSS_SECTIONAL|||||||
34146970|NCT04411537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146971|NCT00281190|||CASE_CONTROL||PROSPECTIVE|||||||
34146972|NCT00369694|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146973|NCT04668924|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146974|NCT03693339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146975|NCT01203358|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34146976|NCT03381417|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34146977|NCT00343915|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146978|NCT03700619|||OTHER||PROSPECTIVE|||||||
34146979|NCT06308250|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study would be single blinded as assessor of the study would be kept blind of the treatment groups to which patient will be allocated.||f|f|f|t
34146980|NCT03234296|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double-blinded RCT, no care providers, patients or researchers are aware of the randomised treatment. Separate safety monitoring committee and preplanned interim analysis.|Anticipated enrollment delays \> three alternate scenarios for sample size calculations, please see prtocol for details.|t|t|t|f
34146981|NCT02679820|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34146982|NCT06027346|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34146983|NCT05053412|||COHORT||PROSPECTIVE|||||||
34146984|NCT02993042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146985|NCT01651832|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34146986|NCT00225342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34146987|NCT04904809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34146988|NCT01366612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834886|NCT04867109|||COHORT||PROSPECTIVE|||||||
33834887|NCT01111240|||CASE_ONLY||PROSPECTIVE|||||||
33834888|NCT05765201|||COHORT||PROSPECTIVE|||||||
33834889|NCT06417034|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33834890|NCT03343093|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34146989|NCT00971529|||CASE_CONTROL|||||||||
34146990|NCT03299543|||COHORT||PROSPECTIVE|||||||
34146991|NCT04855071|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"The women will be assigned to each of the study groups in an individualized random way, based on the table of random numbers generated prior to the start of the study through the EPIDAT v.4 software (Galicia, Spain). The randomization sequence will be kept hidden, through the use of sealed and opaque envelopes previously prepared by the main investigator of the project (JCFD) and which will be placed in a box available to the physiotherapists who perform each of the interventions.~The allocation of women to the treatment groups will be blinded and also the blinding will be maintained in the analysis (evaluation of results), in such a way that in the data analysis only the groups will be identified.~It is not possible to blind the physiotherapist professionals who perform the intervention (neither in the IG nor in the CG)."|"IG receives the usual intervention, which consists of performing exercises to balance the pelvis and their muscles and activation of the transverse abdominis and pelvic floor muscles and life habit advices plus the application of RF sessions.~CG receives only the usual intervention. Sham RF sessions will be applied, using the same protocol as for the IG."|t|f|t|t
34146992|NCT01206686|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34146993|NCT04463862|||COHORT||OTHER|||||||
34146994|NCT02677844|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
34146995|NCT00697437|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34146996|NCT05139134|||OTHER||PROSPECTIVE|||||||
34146997|NCT00134732|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
34146998|NCT01152060|||COHORT||PROSPECTIVE|||||||
34146999|NCT06349135|||COHORT||PROSPECTIVE|||||||
34147000|NCT03157583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147001|NCT03993223|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Data were collected by the attending surgeon who was blinded to the group assignment.|The treatment allocation and procedures involved in this randomized study were explained to all participants when they met inclusion criteria of VAS score of 4 or greater on the postoperative first day.|f|t|t|t
34147002|NCT05588037|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147003|NCT05919641|||COHORT||PROSPECTIVE|||||||
34147004|NCT02639338|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147005|NCT03826680|NON_RANDOMIZED|CROSSOVER||SCREENING||TRIPLE|||t|t|t|f
34147006|NCT02331979|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147007|NCT01610596|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147008|NCT00598182|||CASE_ONLY|||||||||
34147009|NCT03618940|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147010|NCT01064687|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147011|NCT01655381|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147012|NCT03324425|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147013|NCT00475865|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147014|NCT01883011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147015|NCT01056120|||COHORT||PROSPECTIVE|||||||
34147016|NCT03023163|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147017|NCT03037541|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147018|NCT02163551|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147019|NCT00569088|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147020|NCT05510661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded in-hospital outcomes assessment will be insured by separating patients recruitment and follow-up team and follow-up team will be kept blinded of randomization. All the patients will be assigned a unique identity code and collected data will be stored against the assigned code.|Manual thrombus aspiration (use of export catheter) followed by primary PCI|f|f|f|t
34147021|NCT03605069|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||intra-subject, placebo-controlled|t|t|t|t
34147022|NCT01231321|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147023|NCT00506597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147024|NCT01386268|||||PROSPECTIVE|||||||
34147025|NCT05060094|||COHORT||PROSPECTIVE|||||||
34147026|NCT03873961|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants were informed that they will receive treatment with laser. Participants were not informed which laser (HILT or LLLT) was administered.||t|f|f|f
34147027|NCT00764907|RANDOMIZED|||TREATMENT||||||||
34147028|NCT03624088|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147029|NCT04238039|||COHORT||PROSPECTIVE|||||||
34147030|NCT00487123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147031|NCT05251532|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomised Controlled Trial||||
34147032|NCT02624193|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34147033|NCT00647660|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34147034|NCT04180787|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
34147035|NCT01922375|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147036|NCT03071484|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147037|NCT01356732|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147038|NCT01579487|NA|SINGLE_GROUP||OTHER||NONE||||||
34147039|NCT01189292|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34147040|NCT01187459|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34147041|NCT02068118|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147042|NCT04438876|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
34147043|NCT04928209|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147044|NCT02317809|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147045|NCT03303118|NA|SINGLE_GROUP||OTHER||NONE||Single-Blind study.||||
34147046|NCT00797238|||CASE_CONTROL||PROSPECTIVE|||||||
34147047|NCT01483209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147048|NCT06158230|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34147049|NCT02644902|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147050|NCT00029757|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147051|NCT02467920|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147052|NCT05682300|||COHORT||PROSPECTIVE|||||||
34147053|NCT00952874|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147054|NCT05665049|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147055|NCT03785951|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|Coded protein products will be used.|Double-blind, randomised, controlled, 3-way, cross-over study|t|f|t|t
34147056|NCT01821456|||COHORT||PROSPECTIVE|||||||
34147057|NCT04893083|||COHORT||PROSPECTIVE|||||||
34147058|NCT04041427|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34147059|NCT01166061|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147060|NCT00871923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147061|NCT00170989|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34147062|NCT01831440|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147063|NCT03242252|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34147064|NCT05135611|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34147065|NCT02783378|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147066|NCT00527020|RANDOMIZED|CROSSOVER||TREATMENT||||||||
34147067|NCT03056963|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147068|NCT02071186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147069|NCT03075995|NA|SINGLE_GROUP||TREATMENT||NONE||It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.||||
34147070|NCT00276614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147071|NCT03761212|||COHORT||PROSPECTIVE|||||||
34147072|NCT02532712|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147073|NCT04591743|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147074|NCT05782114|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Extracorporeal Shockwave therapy \&Traditional physical therapy program|f|f|t|t
34147075|NCT04625556|||COHORT||PROSPECTIVE|||||||
34147076|NCT03855800|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34147077|NCT01316952|||CASE_CONTROL||RETROSPECTIVE|||||||
34147078|NCT02496169|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147079|NCT04566653|||OTHER||CROSS_SECTIONAL|||||||
34147080|NCT03597477|||COHORT||PROSPECTIVE|||||||
34147081|NCT01313819|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
34147082|NCT00780481|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147083|NCT06020846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147084|NCT06112652|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple||t|t|t|t
34147085|NCT00265213|||||PROSPECTIVE|||||||
34147086|NCT00424190|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147087|NCT02044666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147088|NCT00334360|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34147089|NCT00841399|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147090|NCT00817648|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147091|NCT05722041|||COHORT||PROSPECTIVE|||||||
34147092|NCT00907296|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147093|NCT01352637|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The two primary co-aims of this study are~1. to examine the effects of DCS versus placebo (PLA) augmentation of exposure therapy on PTSD symptoms and~2. to examine the relative efficacy of virtual reality enhanced exposure therapy (VRE) and exposure therapy (PE) on PTSD symptoms."|t|f|t|t
34147094|NCT02177019|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147095|NCT01672866|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147096|NCT05020964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147097|NCT04512638|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147098|NCT04527419|RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment groups will be open to both patients and surgeons.|Random tables have been respectively developed according to tumor locaiton, which includes right-upper lobe, right-middle lobe, right-lower lobe, left-upper lobe and left-lower lobe. Prior to surgery, patients enrolled in the study will be assigned to treatment groups according to the order of the random tables.||||
34147099|NCT00467675|||||PROSPECTIVE|||||||
34147100|NCT04034940|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147101|NCT00174538|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147102|NCT02089152|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
34147103|NCT02773771|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147104|NCT02634606|RANDOMIZED|SINGLE_GROUP||PREVENTION||DOUBLE|||t|f|t|f
34147105|NCT02646839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147106|NCT06169800|NA|SINGLE_GROUP||TREATMENT||NONE||This investigator-initiated pilot trial will assess patients with a first-time lateral patellofemoral dislocation following surgical MPFL repair augmented with a Biobrace®. Patients will be evaluated for two years post-operative, using patient-reported outcome measures and objective clinical and functional testing.||||
34147107|NCT02102126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147108|NCT00137189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147109|NCT02170766|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147110|NCT05590000|NA|SINGLE_GROUP||OTHER||NONE||||||
34147111|NCT00748709|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147112|NCT01272791|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147113|NCT04778332|||COHORT||PROSPECTIVE|||||||
34147114|NCT06320548|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147115|NCT00027586|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147116|NCT00933920|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34147117|NCT06453564|||COHORT||CROSS_SECTIONAL|||||||
34147118|NCT05096754|||CASE_ONLY||PROSPECTIVE|||||||
34147119|NCT04913701|||COHORT||PROSPECTIVE|||||||
34147120|NCT04292990|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147121|NCT04235218|||COHORT||PROSPECTIVE|||||||
34147122|NCT03275948|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34147123|NCT01399892|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147124|NCT05014113|||CASE_ONLY||RETROSPECTIVE|||||||
34147125|NCT00787202|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147126|NCT00316693|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34147127|NCT06358586|NA|SINGLE_GROUP||OTHER||NONE||Single centre, single dose, single-arm, open-label, palatability study||||
34147128|NCT04933760|||COHORT||PROSPECTIVE|||||||
34147129|NCT01048866|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147130|NCT01048450|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34147131|NCT02259140|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34147132|NCT05308524|||COHORT||PROSPECTIVE|||||||
34147133|NCT00003231||||TREATMENT||||||||
34147134|NCT00299780|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147135|NCT02871687|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34147136|NCT02623075|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147137|NCT04147598|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34147138|NCT05616884|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective randomized trial, unblinded||||
34147139|NCT01357954|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147140|NCT01541917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147141|NCT03452410|||COHORT||RETROSPECTIVE|||||||
34147142|NCT02673320|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147143|NCT01275092|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147144|NCT00182897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147145|NCT01538940|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34147146|NCT01897545|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147147|NCT04944732|||CASE_ONLY||RETROSPECTIVE|||||||
34147148|NCT01837667|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147149|NCT00142623|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34147150|NCT01958892|||COHORT||RETROSPECTIVE|||||||
34147151|NCT00012363|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147152|NCT01407523|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147153|NCT06328452|||COHORT||PROSPECTIVE|||||||
34147154|NCT03755232|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34147155|NCT00989391|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34147156|NCT05901324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147157|NCT05792644|NA|SINGLE_GROUP||TREATMENT||NONE||Some patients with histologically or cytologically confirmed stage IIIB or IV ALK-negative non-small-cell lung cancer (NSCLC) participated in this study following the failure of initial treatments. The ALK phosphorylation expression was detected in histologic samples of patients.||||
34147158|NCT05577546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147159|NCT03107923|||COHORT||PROSPECTIVE|||||||
34147160|NCT01009346|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147161|NCT05015790|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147162|NCT00408590|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147163|NCT04124614|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147164|NCT00586443|NA|SINGLE_GROUP||||NONE||||||
34147165|NCT00005632|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147166|NCT02784015|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147167|NCT01574846|||CASE_ONLY||PROSPECTIVE|||||||
34147168|NCT06140797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834891|NCT03329300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834892|NCT00499278|||NATURAL_HISTORY||RETROSPECTIVE|||||||
33834893|NCT00414258|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834894|NCT01857726|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834895|NCT06547788|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147169|NCT04523259|||COHORT||RETROSPECTIVE|||||||
34147170|NCT04247126|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147171|NCT01127841|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147172|NCT03346551|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34147173|NCT03622177|||CASE_CONTROL||PROSPECTIVE|||||||
34147174|NCT04728594|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will not know what group they are in. The relevant care provider (either their primary care provider or provider administering the vaccine) will not know about this study or assignment into groups.|1 x 3 design|t|t|f|f
34147175|NCT00625612|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147176|NCT00226863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147177|NCT03840525|RANDOMIZED|PARALLEL||OTHER||SINGLE|There will be a sham qigong arm of the study to mask qigong participation for the participants|The study will implement a 3 arm study including the qigong intervention, sham qigong intervention, and a treatment as usual condition. The qigong and sham qigong groups will be delivered virtually due to the coronavirus pandemic.|t|f|f|f
34147178|NCT04500236|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34147179|NCT03302286|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34147180|NCT02789410|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147181|NCT03783611|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147182|NCT06461728|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients will be recruited at the postgraduate Endodontics Clinic of the faculty of dentistry at Saint Joseph University. They will be given a patient health survey form and the ones who meet the inclusion criteria will take part of the study after a written informed consent form is obtained. All patients will be informed about the objectives, methods and follow-up by the same operator|Thirty-two single rooted teeth (N=32) with pulp necrosis and asymptomatic apical periodontitis|t|f|f|f
34147183|NCT00707746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147184|NCT04782947|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147185|NCT05162261|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinded Evaluator|A Randomized, Masked (Evaluator), Controlled, Prospective, open label study.|f|f|f|t
34147186|NCT00382915|||CASE_CONTROL||PROSPECTIVE|||||||
34147187|NCT04095130|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147188|NCT01495468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147189|NCT00844805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147190|NCT05933629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147191|NCT05042960|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147192|NCT05835921|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|All study participants are randomly assigned to a group prior to study enrollment. Participants will not be made aware of their group assignment.|"Two groups:~Experimental Group Control Group"|t|f|f|f
34147193|NCT04700956|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34147194|NCT05120947|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||This study will use a time-to-event continual reassessment method (TITE-CRM) for assigning subjects to the radiation therapy dosages.||||
34151245|NCT05656781|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147195|NCT03345524|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Will be blinded to subjects group assignment|Randomized Controlled Trial|f|f|t|t
34147196|NCT00332865|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147197|NCT04596085|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Randomized, Double - Blind|Double Blind, Randomized, Placebo Controlled|t|f|t|f
34147198|NCT03201692|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147199|NCT02082106|||COHORT||CROSS_SECTIONAL|||||||
34147200|NCT03156959|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147201|NCT04141189|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34147202|NCT06450613|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147203|NCT05538351|||COHORT||PROSPECTIVE|||||||
34147204|NCT02189408|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147205|NCT04595877|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Outcome assessors and data analysts will be kept blinded to the allocation.||f|f|f|t
34147206|NCT01608503|NA|SINGLE_GROUP||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34147207|NCT06519383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147208|NCT03078933|RANDOMIZED|FACTORIAL||DEVICE_FEASIBILITY||SINGLE|Investigator will be blinded to photgraphs and punch biopsy results|Two or more interventions, each alone and in combination, are evaluated in parallel against a control group|f|f|t|f
34147209|NCT06000306|||COHORT||RETROSPECTIVE|||||||
34147210|NCT02091284|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Sham-controlled double-blind randomized trial|t|t|f|t
34147211|NCT05414955|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147212|NCT02221154|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147213|NCT00678535|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147214|NCT00964301|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147215|NCT01710735|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34147216|NCT02778139|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147217|NCT05644795|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, randomized, placebo-controlled, cross-over, single center clinical trials.||||
34147218|NCT03990805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147219|NCT04947306|||COHORT||PROSPECTIVE|||||||
34147220|NCT02117635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147221|NCT00158912|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE||||||
34147222|NCT04152434|||COHORT||PROSPECTIVE|||||||
34147223|NCT01801852|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147224|NCT01950585|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147225|NCT02227836|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147226|NCT03823950|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147227|NCT02421263|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147228|NCT01694277|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147229|NCT04346121|||COHORT||PROSPECTIVE|||||||
34147230|NCT01635764|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147231|NCT04644913|||COHORT||PROSPECTIVE|||||||
34147232|NCT02290938|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147233|NCT02426151|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147234|NCT05867537|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147235|NCT05042609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147236|NCT04552327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147237|NCT02332733|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147238|NCT01711593|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147239|NCT01075971|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147240|NCT05280249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Evaluations will be made by an impartial researcher who was not involved in the study.|Parallel Assignment Parallel Assignment Randomized|f|f|f|t
34147241|NCT04018313|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34147242|NCT00553007|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147243|NCT04035096|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Clinical trial ( Pilot study)||||
34147244|NCT03605290|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|The operative technique (Kinematic Vs. Mechanically aligned) is not revealed to the patient, investigator and outcomes assessor.||t|f|t|t
34147245|NCT00046930|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147246|NCT01109771|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147247|NCT02300597|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147248|NCT02706028|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147249|NCT02416700|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147250|NCT04533074|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147251|NCT05988320|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The caregivers of the patients hospitalized in the medical oncology clinic of the Research Center Mehmet Kemal Dedeman Hematology - Oncology Hospital will be formed. Cancer patient caregivers who meet the inclusion criteria of the study and volunteer to participate in the study will constitute the sample of the study.It is planned to take 30 people per group and 60 people in total.||||
34147252|NCT04406662|||OTHER||PROSPECTIVE|||||||
34147253|NCT03556098|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|The peptides/placebo is prepared, in a randomized fashion, by a laboratory assistant..|Double blinded, randomized, cross-over study|t|f|t|f
34147254|NCT03633669|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147255|NCT02131519|||CASE_ONLY||RETROSPECTIVE|||||||
34147256|NCT01532544|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147257|NCT01815632|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34147258|NCT04701203|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blind, placebo controlled, parallel group with subjects randomized into two treatment groups (3:1): TransCon PTH at a starting dose of 18 mcg/day, and placebo for TransCon PTH|t|t|t|t
34147259|NCT03166579|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147260|NCT05361642|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147261|NCT00663299|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147262|NCT01451190|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34147263|NCT04524455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147264|NCT00052312|RANDOMIZED|||TREATMENT||NONE||||||
34147265|NCT05827107|||OTHER||PROSPECTIVE|||||||
34147266|NCT05004974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147267|NCT06026995|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147268|NCT06040580|||COHORT||PROSPECTIVE|||||||
34147269|NCT03518268|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147270|NCT03817073|NA|SINGLE_GROUP||SCREENING||NONE||||||
34147271|NCT00725244|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147272|NCT03632603|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147273|NCT04186247|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147274|NCT01930760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147275|NCT02804750|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147276|NCT06182605|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34147277|NCT03041142|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147278|NCT03123614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Examiners are masked to the treatment arm when obtaining measurements of intraocular pressure (IOP) and grading corneal haze.||f|f|f|t
34147279|NCT04404270|||COHORT||PROSPECTIVE|||||||
34147280|NCT00364052|||DEFINED_POPULATION||OTHER|||||||
34147281|NCT06373783|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147282|NCT04907968|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147283|NCT00469287|||||PROSPECTIVE|||||||
34147284|NCT03814434|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Surgeon will not be aware of group being treated. Analyses of the data and statistics will not show explain what group has originated the data. Groups will be identified as A, B, C or D.|This is not a randomized study. All patients will entered the study after being diagnosed with periimplantitis. Patients will be allocated to different groups according to their condition: Heavy Smokers, Type 2 Diabetes Mellitus, Chronic periodontitis and systemically healthy patients (control group).|f|f|t|t
34147285|NCT05832736|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147286|NCT00491920|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34147287|NCT04340440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Randomization by opaque sealed envelopes||t|t|f|f
34147288|NCT00762996|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34147289|NCT06077370|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147290|NCT05351268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147291|NCT04294550|||CASE_ONLY||PROSPECTIVE|||||||
34147292|NCT02800590|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147293|NCT03443232|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147294|NCT01196845|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
34147295|NCT06323031|||COHORT||PROSPECTIVE|||||||
34147296|NCT02159378|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147297|NCT05750433|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants, study personnel, and outcomes assessor are all blinded to treatment group. Blinding was completed by an independent individual that was not associated with the study or the sponsors.||t|f|t|t
34147298|NCT00788580||||TREATMENT||||||||
34147299|NCT02595697|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
34147300|NCT03801330|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147301|NCT05809804|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147302|NCT02674425|||CASE_ONLY||OTHER|||||||
34147303|NCT04643119|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Patients are randomised to 2 different treatment groups by a study team member who will not participate in final data analysis; only their surgeon and the clinical team will be aware of the treatment the patient undergoes. Treatment codes will be used to indicate the patient's treatment assignment in study-related documents, and clinical documents will reference their treatment code as well.~Radiological, functional and strength assessments will be conducted by non-study clinical staff who will not be aware of the patient's treatment group.~Analysis will be conducted by a statistician who is uninvolved in the recruitment and data collection process, and only upon completion will the treatment arms will be unblinded."||t|t|f|t
34147304|NCT05173935|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Participants are randomized to receive either RIG or PEG. Investigator and Outcomes Assessors are masked.||f|f|t|t
34147305|NCT06280534|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|||t|f|f|t
34147306|NCT03329716|RANDOMIZED|PARALLEL||TREATMENT||NONE||A non-blinded, randomized controlled trial for testing two brace weaning protocols, being immediate removal of brace or gradual weaning of brace, over a course of 6 months.||||
34147307|NCT03384732|||CASE_ONLY||CROSS_SECTIONAL|||||||
34147308|NCT00311116|RANDOMIZED|CROSSOVER||PREVENTION||DOUBLE||||||
34147309|NCT04432805|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147310|NCT00496132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147311|NCT03364972|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147312|NCT00004751|RANDOMIZED|||TREATMENT||||||||
34147313|NCT02230371|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147314|NCT00487370|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34147315|NCT02333890|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34147316|NCT03333148|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147317|NCT02544334|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147318|NCT01024699|||COHORT||PROSPECTIVE|||||||
34147319|NCT00000652||PARALLEL||TREATMENT||||||||
34147320|NCT01690351|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147321|NCT01188616||||TREATMENT||||||||
34147322|NCT00044824|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34147323|NCT01528748|||COHORT||PROSPECTIVE|||||||
34147324|NCT02817347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147325|NCT01259453|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147326|NCT01355796|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147327|NCT03689075|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147328|NCT02122809|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147329|NCT02723890|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147330|NCT05690620|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34147331|NCT04118907|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34147332|NCT05398536|||CASE_ONLY||PROSPECTIVE|||||||
34147333|NCT03823846|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
34147334|NCT00895960|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151246|NCT00257660|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147335|NCT04170387|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Two cohorts of 20 patients each. The first group includes patients affected by fibromyalgia and the other is the control group.||||
34147336|NCT06318611|||CASE_CONTROL||PROSPECTIVE|||||||
34147337|NCT02984059|||CASE_CONTROL||PROSPECTIVE|||||||
34147338|NCT06476158|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||A retrospective quantitative approach will be used to develop and validate new technology and methods since there is a need to control and check the outcomes, before we use an ambi-directional cohort study design to see how the new technology and methods perform in clinical practice on real world data.||||
34147339|NCT00475215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147340|NCT05227599|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34147341|NCT00382369|||FAMILY_BASED||PROSPECTIVE|||||||
34147342|NCT03481491|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Participants will be blinded to the TMS procedure (SHAM or real stimulation).||t|f|f|f
34147343|NCT00712582|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147344|NCT05529966|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34147345|NCT00848341|||||PROSPECTIVE|||||||
34147346|NCT02008409|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147347|NCT05197582|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE||A Clinical trial with experimental and control groups with|t|f|f|t
34147348|NCT01169584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147349|NCT01531972|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147350|NCT04188652|||COHORT||PROSPECTIVE|||||||
34147351|NCT00002762|||CASE_ONLY||PROSPECTIVE|||||||
34147352|NCT03510351|||CASE_ONLY||RETROSPECTIVE|||||||
34147353|NCT00457444|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147354|NCT04784312|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147355|NCT00204867|||CASE_CONTROL||PROSPECTIVE|||||||
34147356|NCT03947528|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147357|NCT03496636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147358|NCT02714881|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147359|NCT02154685|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147360|NCT04292457|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147361|NCT04254874|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147362|NCT03939078|||CASE_ONLY||PROSPECTIVE|||||||
34147363|NCT03143998|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147364|NCT01986972|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34147365|NCT00495755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147366|NCT02723175|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147367|NCT03721809|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147368|NCT06508736|RANDOMIZED|PARALLEL||PREVENTION||NONE||randomized trial with experimental and control groups||||
34147369|NCT04086446|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Parallel Assignment|t|f|t|t
34147370|NCT01762254|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147371|NCT05135481|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147372|NCT02024880|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147373|NCT04943692|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147374|NCT04243928|RANDOMIZED|PARALLEL||TREATMENT||NONE||children rranged from 4 years uo to 10 years with Spastic diplegia||||
34147375|NCT03088553|||COHORT||PROSPECTIVE|||||||
34147376|NCT00403780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147377|NCT02089113|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147378|NCT02525913|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147379|NCT04569812|RANDOMIZED|PARALLEL||TREATMENT||NONE||prospective, randomized controlled study||||
34147380|NCT02402686|||COHORT||PROSPECTIVE|||||||
34147381|NCT00778492|||COHORT||PROSPECTIVE|||||||
34147382|NCT06334757|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147383|NCT02610933|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147384|NCT03300297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be blinded to group allocation. Blind assessors will be utilized to measure objective change in range of motion and pain pressure threshold.|Participants will be randomly assigned to one of two intervention groups. Both will receive intervention and one group will receive cervical spine thrust joint manipulation while the other receives sham manipulation.|t|f|f|t
34147385|NCT04352257|||COHORT||PROSPECTIVE|||||||
34147386|NCT00378248|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147387|NCT01051206||||PREVENTION||||||||
34147388|NCT05849818|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A prospective Randomized controlled trial of pre-post study design with a two months follow up evaluation will be used|f|f|f|t
34147389|NCT06213285|||COHORT||RETROSPECTIVE|||||||
34147390|NCT04860622|||COHORT||PROSPECTIVE|||||||
34147391|NCT05585515|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34147392|NCT00120055|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34147393|NCT02363231|||COHORT||PROSPECTIVE|||||||
34147394|NCT01995552|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147395|NCT05545865|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Low and High flavanol cocoa will be provided in coded packaging.|Acute crossover design|t|f|t|f
34147396|NCT01167907|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147397|NCT02046694|NA|SINGLE_GROUP||TREATMENT||NONE||Pilot Study||||
34147398|NCT03938675|||COHORT||PROSPECTIVE|||||||
34147399|NCT05292937|||COHORT||PROSPECTIVE|||||||
34147400|NCT02447094|||COHORT||PROSPECTIVE|||||||
34147401|NCT02132273|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE|||t|t|t|t
34147402|NCT03924999|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|single blinded||f|f|t|f
34147403|NCT03144622|||COHORT||PROSPECTIVE|||||||
34147404|NCT02212158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147405|NCT00849602|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147406|NCT05105113|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147407|NCT02195804|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151247|NCT00327990|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151248|NCT05933590|||OTHER||CROSS_SECTIONAL|||||||
34147408|NCT04187742|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The team at Health Quality Ontario will be aware of the physicians' assignment to the different email interventions so that they can send the correct audit-and-feedback report email announcements. However, the analytic team at ICES will be masked, and outcome data will be extracted by the analysis team from routinely collected administrative databases and report opening metrics that cannot be linked back to the original intervention assignments.|Assess three interventional parallel study models consisting of two intervention arms each|t|f|t|t
34147409|NCT02362971|||COHORT||PROSPECTIVE|||||||
34147410|NCT06386341|||COHORT||PROSPECTIVE|||||||
34147411|NCT00927615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147412|NCT03730077|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34147413|NCT05478668|||COHORT||OTHER|||||||
34147414|NCT06197087|||CASE_ONLY||CROSS_SECTIONAL|||||||
34147415|NCT02261233|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||f|t|t|t
34147416|NCT05123404|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147417|NCT01328340|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|f|t|t
34147418|NCT02006563|||COHORT||PROSPECTIVE|||||||
34147419|NCT05497856|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147420|NCT06508879|RANDOMIZED|PARALLEL||PREVENTION||NONE|The patients were blinded until the time of the intervention (application of the bandage after surgery). Due to the nature of this study, it was not possible to conceal the treatment after the procedure, as patients could see their bandages and find out their allocation. Using methods to conceal the dressings (covering with neutral dressing) would have changed the nature of the dressings and affected the treatment. The study team could also see the bandages and was therefore not blinded.|This study was designed as a single-center randomized controlled trial. Primary endpoint was overall rate of incidence of any kind of SSI. Secondary endpoints were number of dressing changes, severity of SSI and need for treatment. Wounds were monitored daily until the 7th and on the 30th postoperative day.||||
34147421|NCT02469714|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147422|NCT00601861|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147423|NCT03435562||CROSSOVER||OTHER||NONE||||||
34147424|NCT03819452|||COHORT||CROSS_SECTIONAL|||||||
34147425|NCT06270368|||COHORT||PROSPECTIVE|||||||
34147426|NCT02051023|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147427|NCT00053807|RANDOMIZED|||TREATMENT||||||||
34147428|NCT03829345|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147429|NCT05410262|||COHORT||PROSPECTIVE|||||||
34147430|NCT06008899|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147431|NCT04069377|||COHORT||RETROSPECTIVE|||||||
34147432|NCT05549310|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects are divided into 2 groups:HFNC group and CPAP group||||
34147433|NCT06187025|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147434|NCT01363583|RANDOMIZED|||TREATMENT||QUADRUPLE|||t|t|t|t
34147435|NCT03047291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The patients, the clinical examiner, the laboratory technician and the statistician did not know the content of the containers (probiotic or placebo).|A randomized controlled, parallel design, triple-blind prospective clinical study with a follow-up of 3 months.|t|f|t|t
34147436|NCT04073160|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147437|NCT04966000|NA|SINGLE_GROUP||TREATMENT||NONE||a single group pre-post pilot study||||
34147438|NCT04506515|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34147439|NCT00599456|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147440|NCT05990023|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147441|NCT01768936|||COHORT||PROSPECTIVE|||||||
34147442|NCT05915624|RANDOMIZED|PARALLEL||OTHER||SINGLE|The participant does not know which group he/she is in|The patients in the experimental group will be given a Preoperative Patient Information Brochure prepared by the researcher when they come to the hospital for the surgery date after the voluntary informed consent form is signed. Data were collected using the Introductory Information Form and the Surgery-Specific Anxiety Scale, and counseling was provided by tele-nursing information about the surgery process one day before the surgery. Patient's Perception of Nursing Care Scale was applied before leaving the hospital after day surgery.The patients in the control group were given a Preoperative Patient Information Brochure, which was prepared by the researcher on the day of the surgery, when they came to the hospital for the surgery date after signing the voluntary informed consent form. Data were collected using the Introductory Information Form and the Surgery-Specific Anxiety Scale. Patient's Perception of Nursing Care Scale was applied before leaving the hospital after day surgery.|t|f|f|f
34147443|NCT00002239||||TREATMENT||||||||
34147444|NCT01237782|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34147445|NCT03550404|||CASE_ONLY||PROSPECTIVE|||||||
34147446|NCT04543240|||CASE_ONLY||PROSPECTIVE|||||||
34147447|NCT05479149|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This will be a randomized controlled trial with 2 different groups|t|f|f|t
34147448|NCT02813395|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
34147449|NCT02127294|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147450|NCT02391376|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34147451|NCT03300076|||OTHER||PROSPECTIVE|||||||
34147452|NCT00298493|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147453|NCT04943562|||COHORT||CROSS_SECTIONAL|||||||
34147454|NCT03186014|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147455|NCT00005079||||TREATMENT||||||||
34147456|NCT03052530|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147457|NCT02410577|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147458|NCT02522442|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
34147459|NCT02575118|||COHORT||PROSPECTIVE|||||||
34147460|NCT02666794|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147461|NCT01519999|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34147462|NCT01616979|||CASE_ONLY||PROSPECTIVE|||||||
34147463|NCT03276949|||OTHER||OTHER|||||||
34147464|NCT05147103|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Multi-visit study, testing various LIFU durations||||
34147465|NCT04916834|||CASE_CONTROL||PROSPECTIVE|||||||
34147466|NCT03899792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147467|NCT03296631|||COHORT||PROSPECTIVE|||||||
34147468|NCT05042180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||single-blinded, randomized, controlled|f|f|f|t
34147469|NCT04846530|||CASE_CROSSOVER||PROSPECTIVE|||||||
34147470|NCT02449018|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147471|NCT01143896|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147472|NCT03096873|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147473|NCT01612650|NON_RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34147474|NCT03075605|||COHORT||PROSPECTIVE|||||||
34147475|NCT01999075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147476|NCT03664804|NA|SINGLE_GROUP||OTHER||NONE||||||
34147477|NCT00003447|RANDOMIZED|||TREATMENT||||||||
34147478|NCT05995197|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147479|NCT02811783|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34147480|NCT03912701|||CASE_CONTROL||RETROSPECTIVE|||||||
34147481|NCT06046690|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147482|NCT01708395|||||PROSPECTIVE|||||||
34147483|NCT00117793|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34147484|NCT01973608|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147485|NCT05641987|RANDOMIZED|CROSSOVER||TREATMENT||NONE||A stepped wedge design (prospective cohort with concurrent controls) among six paired, elementary schools, implement and evaluate the Total Teacher Health Toolkit||||
34147486|NCT02805595|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147487|NCT04373473|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147488|NCT03101007|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Parallel Assignment|t|f|f|f
34147489|NCT03997643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147490|NCT04467476|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34147491|NCT00416715|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34147492|NCT03590925|||OTHER||OTHER|||||||
34147493|NCT02917720|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147494|NCT05570890|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The stimulation intensity is set under the sensory threshold, therefore participants will be masked in the study.||t|f|f|f
34147495|NCT05019391|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE||A cohort study will be performed on at least 100 patients presented with vertebrobasilar insufficiency including vertebrobasilar stroke or vertebrobasilar TIA who will be admitted in department of neurology in assiut university hospital.|t|f|t|f
34147496|NCT00034879|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147497|NCT02887755|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147498|NCT05390541|RANDOMIZED|PARALLEL||PREVENTION||NONE||Participants will be randomly assigned to the intervention or educational control conditions. Participants in both conditions will receive HIV/STI self-testing kits. The intervention condition will have 5 tailored sessions over 4 weeks. The education control condition will have 5 generic sessions equally dispersed over 4 weeks.||||
34147499|NCT01319721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147500|NCT00002177||||TREATMENT||NONE||||||
34147501|NCT02190110|||COHORT||PROSPECTIVE|||||||
34147502|NCT04415996|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"Each participant will pull from a bag within equally number of folded papers with letter A (Intervention Group) and letter B (Control Group) and it will be handled to the investigator.~The outcome assessors won´t also have any contact with the investigator and participant whilst intervention."||t|f|f|t
34147503|NCT01932775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147504|NCT06172920|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blind|3 groups of patients are received different type of analgesics|t|t|f|f
34147505|NCT01030185|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147506|NCT04040842|||COHORT||CROSS_SECTIONAL|||||||
34147507|NCT01965223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147508|NCT04713033|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34147509|NCT04687423|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147510|NCT04485260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147511|NCT00797680|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147512|NCT00068510|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147513|NCT01441011|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147514|NCT00617955|||COHORT||RETROSPECTIVE|||||||
34147515|NCT00955149|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34147516|NCT01902459|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147517|NCT05190861|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34147518|NCT00509093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147519|NCT01213823|||CASE_CONTROL||RETROSPECTIVE|||||||
34147520|NCT06036953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34147521|NCT06416293|||OTHER||RETROSPECTIVE|||||||
33834896|NCT04484584|||COHORT||PROSPECTIVE|||||||
34147522|NCT00583791|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147523|NCT05036850|||COHORT||PROSPECTIVE|||||||
34147524|NCT00181610|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147525|NCT02983422|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147526|NCT01293643|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147527|NCT06385717|||COHORT||PROSPECTIVE|||||||
34147528|NCT04316156|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Range of motion||f|f|f|t
34147529|NCT00535821|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147530|NCT01176955|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147531|NCT00194246|||COHORT||PROSPECTIVE|||||||
34147532|NCT01164553|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147533|NCT02972541|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147534|NCT04148612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147535|NCT02698904|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147536|NCT06075992|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34147537|NCT00663286|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147538|NCT04405271|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The treatment will be the same in both arms: 1 tablet per day will be administered for a total of 12 weeks. Placebo and the active principle will be indistinguishable.|Randomized (1:1), double-blind, placebo-controlled clinical trial|t|t|t|t
34147539|NCT05858957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34147540|NCT01989611|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147541|NCT04523090|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|double-blind|A single-stage, double-blinded, randomised, placebo-controlled trial.|t|t|t|f
34147542|NCT05216276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|patient and assessor blinded study|Patients with indication for inguinal hernia repair are randomized to get a robotic TAPP (rTAPP) or a conventional TEP. Results will be compared primarily pain after 24h hours.|t|f|f|t
34147543|NCT05970094|NA|SINGLE_GROUP||TREATMENT||NONE||Crossover design: 1 arm consisting of three consecutive periods of two weeks (control, intervention and follow up).||||
34147544|NCT04273750|||COHORT||PROSPECTIVE|||||||
34147545|NCT00160654|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147546|NCT00343863|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34147547|NCT00078065|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147548|NCT01022359|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147549|NCT03980717|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The investigators will perform 40 FETO procedures on fetuses diagnosed prenatally with severe right- or left-sided CDH and outcome data will be compared with that of a control group of severe right- or left-sided CDH who will not undergo the FETO procedure because of medical or social issues. Because the prevalence of left-sided CDH is higher than right-side CDH, the investigators will perform 25 FETO procedures in left sided CDH and 15 in right-sided CDH, whose outcomes will be compared to a cohort of 40 non FETO cases. The control group will consist of patients who fit the same fetal inclusion/exclusion criteria as our FETO subjects, and will be matched by variables including maternal age, body mass index, gestational age, severity of CDH and site of CDH (left- or right-sided).||||
34147550|NCT00841048|RANDOMIZED|SINGLE_GROUP||||SINGLE|||t|f|f|f
34147551|NCT00862472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147552|NCT03597282|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147553|NCT04807803|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34147554|NCT00166491|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34147555|NCT02577185|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|t|f
34147556|NCT03690180|||CASE_CONTROL||RETROSPECTIVE|||||||
34147557|NCT06222489|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147558|NCT01676519|||COHORT||PROSPECTIVE|||||||
34147559|NCT04852510|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147560|NCT06486688|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147561|NCT04235569|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147562|NCT00381875||||TREATMENT||||||||
34147563|NCT00806923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147564|NCT02301481|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147565|NCT05988190|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147566|NCT03659058|RANDOMIZED|PARALLEL||TREATMENT||NONE||200 patients will receive silymarin 420 mg + antioxidants + colchicine||||
34147567|NCT00499655|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147568|NCT05825625|NA|SINGLE_GROUP||TREATMENT||NONE||single-arm phase II trial combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC||||
34147569|NCT02559414|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34147570|NCT05571956|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147571|NCT00993499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147572|NCT05530889|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147573|NCT04215432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34147574|NCT04689971|RANDOMIZED|PARALLEL||TREATMENT||NONE|Open label|Eligible subjects were randomly allocated to receive any of the following regiments: standard therapy consists of pregabalin, gabapentine, or amitriptyline (control group) or standard therapy and vitamin B combination (vitamin B1 100 mg, B6 200 mg and B12 200 mcg) tablet once daily (experimental group).||||
34147575|NCT00862914|||CASE_CONTROL||PROSPECTIVE|||||||
34147576|NCT05644093|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147577|NCT01981889|NA|SINGLE_GROUP||||NONE||||||
34147578|NCT05244668|||COHORT||PROSPECTIVE|||||||
34147579|NCT05140551|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34147580|NCT02046070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147581|NCT01747252|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
34147582|NCT06103487|||OTHER||PROSPECTIVE|||||||
34147583|NCT04108728|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34147584|NCT02340390|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147585|NCT01260025|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147586|NCT05491772|||CASE_ONLY||RETROSPECTIVE|||||||
34147587|NCT04897607|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will be randomized to the precision or standard care arms in a 1:1 ratio||||
34147588|NCT04507165|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147589|NCT04311827|||COHORT||PROSPECTIVE|||||||
34147590|NCT04810611|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147591|NCT00469326|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147592|NCT03351907|||COHORT||PROSPECTIVE|||||||
34147593|NCT03517995|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34147594|NCT05335902|||COHORT||PROSPECTIVE|||||||
34147595|NCT03323606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34147596|NCT03074266|||COHORT||PROSPECTIVE|||||||
34147597|NCT05826223|||COHORT||PROSPECTIVE|||||||
34147598|NCT03009643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147599|NCT00313547|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147600|NCT03567018|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Two populations are being investigated in this trial; a healthy volunteer population and a patient population. Each population will receive an MRI scan.||||
34147601|NCT05179499|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, two arm, multicentre, pragmatic parallel group sequential randomised trial with an internal pilot||||
34147602|NCT06252818|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||ReHub is a medical device designed to assist rehabilitation professionals by providing information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation. Patients use the platform to follow the exercise program designed by their therapist from the location that suits them best.||||
34147603|NCT05961449|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Participants will be blinded to the study hypotheses.|A within-subject, cross-over design, will be used: participants will complete two conditions (exercise vs. control) in counter-balanced randomized order.|t|f|f|f
34147604|NCT01864161|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147605|NCT04838704|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147606|NCT04313491|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147607|NCT03684304|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147608|NCT06243120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Preparation of the used infusion volume will performed by anesthesia specialist in our center not sharing in the study, he is the one who know it is placebo or lidocaine. The infusion performed blindly by the researcher and VAS will be assessed by the circulating nurse inside the theater or the nurse in the PACU.~The regression of VAS in comparison to initial pruritus scale will be recorded in both groups. The percentage of incidence of pruritus, body distribution of pruritus, duration of spinal anesthesia and local anesthetic toxicity symptoms will be recorded."|Randomized, prospective trial on 2 equal groups|f|t|f|f
34147609|NCT03715192|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34147610|NCT00322894|||COHORT||OTHER|||||||
34147611|NCT06176508|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147612|NCT01897649|RANDOMIZED|PARALLEL||||TRIPLE|||t|t|t|f
34147613|NCT00944463|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147614|NCT01565395|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34147615|NCT04576078|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Nefopam has a distinct bitter taste. A taste masking compound non interfering with chemical properties of the drug is used in both arms. Orally given mixture (nefopam or placebo) is prepared by an independent nurse in a separate location and given to a patient in patient's ward.||t|t|t|f
34147616|NCT02062983|||COHORT||PROSPECTIVE|||||||
34147617|NCT01255930|||CASE_ONLY||RETROSPECTIVE|||||||
34147618|NCT04905355|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Assessor of the main outcome will be not aware of arm attribution|Use of VR or not during the ambulatory orthopedic surgery will be attributed to patient randomly.|f|f|f|t
34147619|NCT00552448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147620|NCT04402541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147621|NCT03986047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Outcomes assessor is blinded to participant's intervention allocation. Participants are blinded to the nature of interventions given in the other arms' groups.|"Randomized control trial, as following :~* Baseline evaluation~* Randomized assignment to one of 3 intervention groups (Thermal + Exercises, Thermal alone, and Control)~* Post-intervention assessment (current pain)~* 1-week home-based intervention~* Reassessment at 1 week, 1 month, 3 months, 6 months"|f|f|t|t
34147622|NCT04208087|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34147623|NCT04264143|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147624|NCT03283150|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147625|NCT06233994|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147626|NCT03189654|||COHORT||PROSPECTIVE|||||||
34147627|NCT00000572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147628|NCT00004705||||TREATMENT||||||||
34147629|NCT06414330|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147630|NCT01564524|||CASE_CONTROL||PROSPECTIVE|||||||
34147631|NCT00110487|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34147632|NCT03913195|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147633|NCT02723370|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147634|NCT02601547|NA|SINGLE_GROUP||||NONE||||||
34147635|NCT03299569|||CASE_CONTROL||OTHER|||||||
34147636|NCT04371341|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|the care provider and investigator will be masked from the volume injected|4 groups with 20 patients for each group where group C will not receive erector spinae block and so will be the control group while groups which will receive erector spinae block will be E1,E2,E3 and will receive 0.25% bupivacaine with volumes of 2.5,3.4,6.6 ml/segment respectively.|f|t|t|f
34147637|NCT03609476|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
34147638|NCT02185989|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34147639|NCT02604758|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147640|NCT01611220|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147641|NCT03751514|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||Human challenge study||||
34147642|NCT06076811|||COHORT||PROSPECTIVE|||||||
34147643|NCT04467970|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147644|NCT01295684|RANDOMIZED|PARALLEL||||DOUBLE||||||
34147645|NCT04290923|||COHORT||PROSPECTIVE|||||||
34147646|NCT03530332|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147647|NCT02535416|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147648|NCT02830204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147649|NCT00659724|||OTHER||PROSPECTIVE|||||||
34147650|NCT05221775|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147651|NCT04641949|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Both drug interventions (intravenous fentanyl and inhaled methoxyflurane) will have NaCl placebo comparators. As the methoxyflurane has a characteristic smell, some drops of methoxyflurane will be placed on the exterior of the placebo methoxyflurane inhalation devices. Further, the subjects will rinse the mouth with a mouthwash shortly before inhalation to cover the taste of methoxyflurane.|Randomized, placebo controlled, crossover study.|t|t|t|f
34147652|NCT06255067|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34147653|NCT02356887|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147654|NCT02288117|||COHORT||PROSPECTIVE|||||||
34147655|NCT00424268|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147656|NCT06256146|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147657|NCT06133296|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34147658|NCT03323671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834897|NCT06051071|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33834898|NCT00683059|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834899|NCT04649671|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834900|NCT06082570|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834901|NCT03278743|||COHORT||PROSPECTIVE|||||||
34147659|NCT05462808|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147660|NCT04097496|RANDOMIZED|PARALLEL||OTHER||SINGLE|Because of the nature of the ACT OUT! trial, blinding of the trial participants, school officials, and members of Claude McNeal Productions is not possible. Further, since data management will occur via the primary research team, group identity cannot realistically be masked. However, we have included two statistical consultants - one internal to the university and one external to the university - who will be asked to verify all analyses using masked group assignment.|The ACT OUT! Trial is designed as a proof-of-concept, cluster, randomized, superiority trial with two parallel groups. Randomization will be performed within clusters with a 1:1 allocation.|f|f|f|t
34147661|NCT01754194|||COHORT||PROSPECTIVE|||||||
34147662|NCT06243055|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
34147663|NCT01900535|||COHORT||PROSPECTIVE|||||||
34147664|NCT04646993|||COHORT||PROSPECTIVE|||||||
34147665|NCT01805544|||COHORT||PROSPECTIVE|||||||
34147666|NCT00700583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147667|NCT02162212|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147668|NCT03344198|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147669|NCT06505538|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34147670|NCT00997399|NA|SINGLE_GROUP||OTHER||NONE||||||
34147671|NCT04990518|||COHORT||PROSPECTIVE|||||||
34147672|NCT00840580|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147673|NCT04213170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147674|NCT01995955|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147675|NCT00702494|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147676|NCT06422364|NA|SINGLE_GROUP||OTHER||NONE||||||
34147677|NCT01582048|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147678|NCT04363047|||COHORT||RETROSPECTIVE|||||||
34147679|NCT06507033|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
34147680|NCT03794453|||COHORT||PROSPECTIVE|||||||
34147681|NCT05226611|NA|SINGLE_GROUP||TREATMENT||NONE|The participant felt which side was being treated however, the investigator measuring the physiologic parameters of the muscle with the MyotonPRO was blinded in terms of what side was being treated.|||||
34147682|NCT00307567|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147683|NCT06190327|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study follows a randomized controlled experimental design (RCT), parallel type with three groups and being assessed in a pretest, posttest, and after three months of the completion of the intervention. The participants will be randomly allocated to two experimental group, and one non-exercise control group. The non-exercise control group continue to maintain their daily routine and keep diaries to record . To monitor the control condition, participants will need to keep diaries to record their daily physical exercise, medicines used, illness and participation in other health-related activities. The research assistant will give telephone calls to the participants biweekly to check their diaries and identify if they change their lifestyles or experience adverse events. Two exercise groups, one group will perform multicomponent structured exercise in blended indoor and outdoor setting, the other group will conduct the same exercise only in indoor setting.|t|f|f|t
34147684|NCT00001724||||TREATMENT||||||||
34147685|NCT06353074|||CASE_ONLY||RETROSPECTIVE|||||||
34147686|NCT04791059|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34147687|NCT06232551|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||Cluster-randomized, Type II hybrid implementation effectiveness study with step-wedge implementation||||
34147688|NCT00117689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147689|NCT00468845|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147690|NCT06175351|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147691|NCT02805231|||CASE_CONTROL||RETROSPECTIVE|||||||
34147692|NCT04592900|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group 1 (control group) and Group 2 (virtual reality group), group 3 (Biodex Balance Training)|G 1 (control) received traditional physical therapy program for 60 min. G 2(study) received traditional physical therapy program for 30 min. and virtual reality for 30 min. G 3 (study) received traditional physical therapy program for 30 min. and Biodex Balance Training all groups treated for four successive months.|t|f|f|f
34147693|NCT00355498|||COHORT||PROSPECTIVE|||||||
34147694|NCT05513313|||COHORT||PROSPECTIVE|||||||
34147695|NCT05824936|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||15 participants will be enrolled in single-group pilot study to measure acceptability, feasibility, and accessibility of mobile spirometry for asthma||||
34147696|NCT02876328|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147697|NCT03545711|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147698|NCT02400944|||COHORT||PROSPECTIVE|||||||
34147699|NCT04409717|||COHORT||RETROSPECTIVE|||||||
34147700|NCT01292083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147701|NCT05149131|||COHORT||RETROSPECTIVE|||||||
34147702|NCT02525939|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147703|NCT01350115|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147704|NCT03484364|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147705|NCT03484559|||COHORT||RETROSPECTIVE|||||||
34147706|NCT01226004|||COHORT||PROSPECTIVE|||||||
34147707|NCT00994591|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147708|NCT00876590|||CASE_ONLY||CROSS_SECTIONAL|||||||
34147709|NCT01271257|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147710|NCT03271047|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||In phase 1 it is sequential and then in phase 2 it is parallel.||||
34147711|NCT05458453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147712|NCT03689244|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34147713|NCT01522430|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147714|NCT01459913|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151249|NCT06297005|||CASE_CONTROL||PROSPECTIVE|||||||
34151250|NCT01623388|||CASE_CONTROL||PROSPECTIVE|||||||
33834902|NCT03693053|||COHORT||PROSPECTIVE|||||||
33838966|NCT04662060|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147715|NCT03762967|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||The study consist 40 patients in 4 groups. Two working groups and two control groups. Each group consist 10 Males.||||
34147716|NCT05544630|||CASE_CONTROL||PROSPECTIVE|||||||
34147717|NCT01011972|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147718|NCT01694719|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147719|NCT05525949|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147720|NCT05025007|||CASE_ONLY||CROSS_SECTIONAL|||||||
34147721|NCT01536548|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147722|NCT04366557|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Subjects covered by the assigned number|Participants divided into two groups (the study and the control)|t|f|f|f
34147723|NCT03458702|RANDOMIZED|CROSSOVER||TREATMENT||NONE|No masking|Methods: A randomized repeated-measures crossover clinical trial was performed. Forty healthy, female college students completed a 30 min session of YogaFit and a time-matched seated rest condition on separate days. After each condition, participants viewed 30 min of emotional picture stimuli. State anxiety, heart rate and time-domain and frequency-domain measures of HRV were assessed baseline, post- condition, and post-exposure to emotional stimuli.||||
34147724|NCT04515329|RANDOMIZED|PARALLEL||TREATMENT||NONE||"* Study arm: Treatment will be commenced with cyclosporine eye drops twice daily with preservative-free artificial tear drops 4 times a day (Treatment).~* Control arm: Preservative-free artificial tear drops 4 times a day (Control)."||||
34147725|NCT02329483|||COHORT||PROSPECTIVE|||||||
34147726|NCT02383433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147727|NCT06304506|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||Cross sectional study with three groups||||
34147728|NCT02012686|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147729|NCT00259298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147730|NCT03630744|||OTHER||PROSPECTIVE|||||||
34147731|NCT05990699|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34147732|NCT03027232|||OTHER||OTHER|||||||
34147733|NCT01651390|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147734|NCT01504581|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147735|NCT00113750|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
34147736|NCT01028066|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147737|NCT02609945|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147738|NCT06443346|||COHORT||PROSPECTIVE|||||||
34147739|NCT00311142|||COHORT||PROSPECTIVE|||||||
34147740|NCT00668590|RANDOMIZED|PARALLEL||||SINGLE|||f|t|f|f
34147741|NCT03043677|||CASE_CONTROL||PROSPECTIVE|||||||
34147742|NCT04886947|NA|SINGLE_GROUP||TREATMENT||NONE|The radiologist interpreting bone formation of the alveolar will be blinded on which group the participants belongs. whether no or intervention done|case control study with control being those receiving convectional treatment and cases those will have added intervention of autologues stem cell||||
34147743|NCT04839848|||COHORT||PROSPECTIVE|||||||
34147744|NCT00567918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147745|NCT00930436|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147746|NCT02423122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147747|NCT04610918|||COHORT||PROSPECTIVE|||||||
34147748|NCT05928611|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147749|NCT03187834|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|double blind|Households will be randomized to one of four treatment arms (azithromycin, cotrimoxazole, amoxicillin, or placebo), and each child age 6-59 months in the household will receive 5 days of treatment. One child within each of the antibiotic households will be randomly selected to receive placebo instead of the antibiotc, to allow for study of indirect effects of antibiotic use|t|t|t|t
34147750|NCT04325451|||COHORT||PROSPECTIVE|||||||
34147751|NCT01289106|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147752|NCT04932616|||CASE_ONLY||PROSPECTIVE|||||||
34147753|NCT05559125|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34147754|NCT04447014|||COHORT||PROSPECTIVE|||||||
33834903|NCT05511337|RANDOMIZED|PARALLEL||OTHER||DOUBLE|"The person performing the measurements will be blinded to the group to which each participant belongs.~The statistical analysis will be performed by a person who is blinded to the group to which the participants belong."|"Participants are randomized into three groups for 28 days:~Control: caloric restriction or intervention A: Control oxalate and citrate foods or intervention B: Real-life intervention, control of oxalates and citrates without restriction of kilocalories.~Randomization was performed by balanced blocks of three cells, with the research randomizer randomization program, 60 sites were randomized, which 20 participants were divided into three groups. Randomization was carried out by a person outside the study. Treatment will be given only through dietary counseling. Treatment adherence will be assessed in all groups through three food diaries (two on weekdays and one on weekends). Adherence will be considered if the participant complies with 80% of the treatment."|f|t|f|t
33834904|NCT00466336|||CASE_ONLY||CROSS_SECTIONAL|||||||
33834905|NCT02825186|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33834906|NCT01520337|||CASE_ONLY||PROSPECTIVE|||||||
33834907|NCT04413422|||COHORT||PROSPECTIVE|||||||
34147755|NCT01944579|RANDOMIZED|CROSSOVER||||DOUBLE|||f|f|t|t
34147756|NCT06018051|||OTHER||PROSPECTIVE|||||||
34147757|NCT01498185|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34147758|NCT03381027|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Neurodevelopmental assessors are blinded to interventional arm.|single centre, unblinded, randomised, controlled study to evaluate whether a multi-sensory enrichment programme in the first 4 months of life will improve sleep architecture and neurodevelopment in healthy infants.|f|f|f|t
34147759|NCT03675542|NA|SINGLE_GROUP||TREATMENT||NONE||open-label, singlecenter, single-arm, dose-selection, proof of-concept study||||
34147760|NCT05108597|RANDOMIZED|PARALLEL||OTHER||SINGLE|There will be a single trained person who calculated the intra-operative blood loss and was blinded to the randomization of the patients and the use of medication.||f|f|f|t
34147761|NCT00490022|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147762|NCT01310023|||COHORT||PROSPECTIVE|||||||
34147763|NCT01374659|||||PROSPECTIVE|||||||
34151251|NCT01412385|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151252|NCT03127423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147764|NCT06218706|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|Randomization will occur after all inclusion criteria have been met at which time participants will be randomized 1:1 to either the Active or the Sham arm.This study will be performed in a double-blind manner, with participants as well as investigators and study staff involved with assessments unaware of treatment assignment.|"Randomization will occur after all inclusion criteria have been met at which time participants will be randomized 1:1 to either the Active or the Sham arm.~After a participant completes the Week 12 post-LIFU study visit, that participant's treatment assignment is unblinded. Participants randomized to the Sham arm will be crossed over and receive Active LIFU after specified baseline procedures/assessments"|t|f|f|t
34147765|NCT05302622|RANDOMIZED|PARALLEL||OTHER||NONE||There is three group based on the surgical skills and ob/gyn residency years.||||
34147766|NCT03331783|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147767|NCT00741702|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147768|NCT00531583|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147769|NCT01073124|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34147770|NCT03283397|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|A blinded examining neurologist/assessor will conduct neurological examinations, relapse and EDSS evaluations at each site. Treating investigators will not be blinded to the study treatment. Additionally, blinded evaluation of MRI scans will be performed at a central reading facility in which, anonymized and standardized images of patient with RRMS will be read by a treatment blinded assessor and data will be implemented in a post-hoc analysis for selected time-points.|Patients will be randomized to one of the two treatment arms and will be observed during the treatment period of 144 weeks|f|f|f|t
34147771|NCT01972698|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
34147772|NCT05077358|RANDOMIZED|PARALLEL||TREATMENT||NONE||This study is a prospective, randomized, multi-center study comparing intracorporeal versus extracorporeal anastomosis in performing laparoscopic right colectomy. The study subjects will be randomly assigned to: 1. Intracorporeal anastomosis 2. Extracorporeal anastomosis||||
34147773|NCT04976933|||COHORT||PROSPECTIVE|||||||
34147774|NCT05063266|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147775|NCT04485572|||OTHER||PROSPECTIVE|||||||
34147776|NCT05556213|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34147777|NCT03109691|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147778|NCT05920473|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147779|NCT03690271|||COHORT||PROSPECTIVE|||||||
34147780|NCT03867019|||CASE_CONTROL||PROSPECTIVE|||||||
34147781|NCT01373320|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34147782|NCT05473286|||COHORT||PROSPECTIVE|||||||
34147783|NCT02884375|||COHORT||PROSPECTIVE|||||||
34147784|NCT02519868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147785|NCT02231762|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147786|NCT02430324|||CASE_CONTROL||PROSPECTIVE|||||||
34147787|NCT02437604|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147788|NCT04867213|||COHORT||PROSPECTIVE|||||||
34147789|NCT00456599|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147790|NCT04825431|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147791|NCT02326766|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34147792|NCT06522685|RANDOMIZED|PARALLEL||DEVICE_FEASIBILITY||TRIPLE|A numerical code will be put into the device by the participant which will determine whether the device is in real or sham mode. The principal investigator, evaluator and al study staff excepting the device company and study statistician will be blinded to this code.|Double-Blind Sham-controlled Parallel comparing feasibility in non-Hispanic black participants to non-Hispanic white participants (2 arms, 2 groups each arm; total 4 groups with 20 participants in a group.|t|f|t|t
34147793|NCT06491810|||OTHER||CROSS_SECTIONAL|||||||
34147794|NCT02636946|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34147795|NCT03050762|||CASE_ONLY||PROSPECTIVE|||||||
34147796|NCT04526470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147797|NCT01660100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147798|NCT04350060|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147799|NCT06182241|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147800|NCT02342379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147801|NCT02608307|||COHORT||PROSPECTIVE|||||||
34147802|NCT05860491|||CASE_CONTROL||RETROSPECTIVE|||||||
34147803|NCT05004506|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group A will be for single shot adductor canal block. Group B will receive the intra-articular injection.|t|f|f|f
34147804|NCT04946617|||COHORT||PROSPECTIVE|||||||
34147805|NCT06386861|NON_RANDOMIZED|PARALLEL||OTHER||NONE||500 English-speaking individuals identifying as Hispanic, Latino, or Latina 500 Spanish-speaking individuals identifying as Hispanic, Latino, or Latina||||
34147806|NCT01719393|||CASE_CONTROL||PROSPECTIVE|||||||
34147807|NCT02952105|||CASE_ONLY||PROSPECTIVE|||||||
34147808|NCT02492256|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147809|NCT04515368|NON_RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
34147810|NCT05524610|NON_RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34147811|NCT03840343|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147812|NCT03722654|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147813|NCT01066351|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34147814|NCT03308149|||COHORT||RETROSPECTIVE|||||||
34147815|NCT06427694|||COHORT||PROSPECTIVE|||||||
34147816|NCT06507839|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34147817|NCT06187168|||COHORT||PROSPECTIVE|||||||
34147818|NCT00411190|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151253|NCT00590577|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151254|NCT06386705|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34151255|NCT01281085|||||PROSPECTIVE|||||||
34151256|NCT02880150|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34151257|NCT03298399|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34151258|NCT01496911|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34151259|NCT00175448|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151260|NCT00118430|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151261|NCT03764982|||COHORT||PROSPECTIVE|||||||
34147819|NCT02250664|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||This study was one of three multi-site clinical trials conducted in three different vulnerable populations under a similar protocol, with differences between protocols consisting of data collection specific to that vulnerable population. This included information such as use and timing of opioid maintenance therapy for individuals with opioid-use disorder or additional assessments of anxiety and depression for individuals with affective disorders. In order to explore potential differences across individuals with different vulnerabilities, data from all three studies were combined for analysis. A vulnerable population-by-condition or population-by- condition-by-time interaction term was included in all analyses. In the event that these interaction terms were statistically significant, all pairwise comparisons were conducted using a Bonferroni multiple comparison adjustment. Please see Statistical Analysis Plan for more details.|t|f|t|f
34147820|NCT01703065|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|Treatment is open label and non-randomized. Split in to two patient populations - metastatic CRPC and non-metastatic CRPC.|Two separate patient population arms (metastatic CRPC and non-metastatic CRPC) but both populations are given the same interventional treatment and the same safety assessments.||||
34147821|NCT03255538|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34147822|NCT03033342|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
34147823|NCT04603222|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"All SPEED scores and digital images would then be de-identified to avoid any bias by the principal investigator and his research staff.~These scores and images would be uploaded and sent electronically via encrypted password protected file to Giles Duffield, PhD. for interpretation and statistical analysis."|"This multi-site study will involve 60 subjects. Each site will have 20 participants. Each site will divide participants into two groups of 10. The control group will receive the standard of care. The standard of care would be Ocusoft Lid Scrub Original Foaming Eyelid Cleanser to be used once per day. The treatment group would receive the same treatment as the control group with the addition of the experimental disposable ocular brush. The foam will be applied to the brush and the subjects will gently provide a scrubbing action to the eyelids while keeping the eyelids closed. They will also be instructed to perform treatment once per day and to dispose of the brush after two weeks and replace it with a new brush.~Each participant will be asked to return to their respective site for two follow up visits. The first visit will take place at two weeks commencing treatment and the final visit will take place two weeks later for a total treatment duration of one month."|f|f|f|t
34147824|NCT01399203|||COHORT||PROSPECTIVE|||||||
34147825|NCT03705910|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome measures will be performed by an experienced physiotherapist who will be blinded to the group allocation.||f|f|f|t
34147826|NCT02971241|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Quasi-experimental wait-listed control||||
34147827|NCT00161525|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147828|NCT04517838|||CASE_ONLY||PROSPECTIVE|||||||
34147829|NCT03238339|||CASE_CONTROL||PROSPECTIVE|||||||
34147830|NCT04112979|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147831|NCT03773107|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147832|NCT01908036|||COHORT||PROSPECTIVE|||||||
34147833|NCT00779961|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147834|NCT04993729|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147835|NCT03135925|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147836|NCT02916147|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34147837|NCT01986959|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34147838|NCT02124954|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34147839|NCT03833713|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Prospective, randomized, 2-arm (intervention vs. control)|f|t|t|t
34147840|NCT01859845|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34147841|NCT02226549|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147842|NCT03075124|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34147843|NCT02003937|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147844|NCT02038660|||COHORT||PROSPECTIVE|||||||
34147845|NCT05682989|||COHORT||RETROSPECTIVE|||||||
34147846|NCT00624780|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147847|NCT00846989|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147848|NCT04407065|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147849|NCT06507397|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34147850|NCT05271825|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34147851|NCT01101698|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34147852|NCT05883046|NON_RANDOMIZED|PARALLEL||OTHER||DOUBLE|Supplement preparation, as well as the provision and management of blind conditions for both participants and investigators, were performed by a researcher (Celil KAÇOĞLU) who did not participate in the strength measurements.|subjects participated under 5 crossover conditions: control (without supplement) (Con), placebo (maltodextrin) (Pla), caffeine (Caf), sodium bicarbonate (NaHCO3) and caffeine+sodium bicarbonate (Caf+NaHCO3). The control measurement was made as a baseline measurement without supplementation.|t|f|t|f
34147853|NCT04985539|||COHORT||PROSPECTIVE|||||||
34147854|NCT00600769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147855|NCT04941404|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147856|NCT01092598|||||CROSS_SECTIONAL|||||||
34147857|NCT05231447|||CASE_ONLY||PROSPECTIVE|||||||
34147858|NCT05953012|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147859|NCT03645304|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147860|NCT03705975|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34147861|NCT05136898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147862|NCT01186107|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147863|NCT04170829|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE|Open-labelled, non-randomised, dose escalation, extension for a first-in-human, single centre, phase Ib clinical trial|Open-labelled, non-randomised, dose escalation, extension for a first-in-human, single centre, phase Ib clinical trial||||
33834908|NCT00136279|RANDOMIZED|PARALLEL||||NONE||||||
33834909|NCT01348152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834910|NCT02266342|||COHORT||PROSPECTIVE|||||||
33834911|NCT05224843|NA|SINGLE_GROUP||PREVENTION||NONE||VOICES Elder Abuse Intervention||||
34147864|NCT04835168|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34147865|NCT06195995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147866|NCT02874859|||CASE_ONLY||RETROSPECTIVE|||||||
34147867|NCT00342706||||TREATMENT||||||||
34147868|NCT04297969|||COHORT||PROSPECTIVE|||||||
34147869|NCT02080260|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147870|NCT00625638|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34147871|NCT05703451|||CASE_CROSSOVER||PROSPECTIVE|||||||
34147872|NCT04093336|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||placebo controlled, randomized, double blinded|t|t|t|t
34147873|NCT02398695|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34147874|NCT02846246|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147875|NCT05538546|||COHORT||PROSPECTIVE|||||||
34147876|NCT00005976|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147877|NCT05002842|RANDOMIZED|SEQUENTIAL||SUPPORTIVE_CARE||NONE||||||
34147878|NCT01362452|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147879|NCT03474211|||COHORT||PROSPECTIVE|||||||
34147880|NCT00769691|||COHORT||PROSPECTIVE|||||||
34147881|NCT00115895|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147882|NCT02914444|||COHORT||PROSPECTIVE|||||||
34147883|NCT04652674|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147884|NCT04001972|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147885|NCT02686476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147886|NCT00202033|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147887|NCT04833959|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147888|NCT04400604|||COHORT||PROSPECTIVE|||||||
34147889|NCT00180180|||COHORT||PROSPECTIVE|||||||
34147890|NCT03475329|||CASE_ONLY||PROSPECTIVE|||||||
34147891|NCT00832494|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147892|NCT02138240|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147893|NCT01561963|NA|SINGLE_GROUP||OTHER||NONE||||||
34147894|NCT02120703|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34147895|NCT03131596|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Both surgeons conducting the hysteroscopic surgery and follow-up hysteroscopy were blinded to the patient group allocation.||f|f|t|f
34147896|NCT06225271|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147897|NCT04272333|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34147898|NCT03559699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147899|NCT00097890||||TREATMENT||||||||
34147900|NCT03362229|RANDOMIZED|PARALLEL||TREATMENT||NONE|There is no blinding possible in this trial as the presence or absence of medial sided surgery is obvious to both the surgeon and the patient due to the presence or absence of a skin incision.|Randomised controlled trial with 50:50 randomisation into one of 2 groups. Randomisation will also be stratified be age of patient (\>= 65 and \<65 years).||||
34147901|NCT00180297|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34147902|NCT00478790|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147903|NCT03503981|||COHORT||PROSPECTIVE|||||||
34147904|NCT06506799|NA|SINGLE_GROUP||OTHER||NONE||||||
34147905|NCT06547892|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Randomization list will be generated with appropriate software, in blocks of 4, by a statistician not involved in patient care. There will be stratification by center. Randomization confidentiality will be guaranteed by central randomization via REDCap.|Clinical, multicenter, placebo-controlled, double-blind, randomized and feasibility trial with a proposal to include 60 patients in 3 to 4 research centers.|t|t|t|t
34147906|NCT02117349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34147907|NCT00273845|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147908|NCT05837858|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||Randomized Crossover Assignment||||
34147909|NCT06263218|||COHORT||OTHER|||||||
34147910|NCT02981524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147911|NCT03542435|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147912|NCT04386499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||parallel, single blind, grouped randomised, interventional clinical study|f|t|t|f
34147913|NCT00077844|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34147914|NCT03859921|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147915|NCT04560894|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147916|NCT05545644|RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients randomly assigned, prospectively, to one of two study arms.||||
34147917|NCT02099201|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34147918|NCT03463668|||COHORT||RETROSPECTIVE|||||||
33834912|NCT06201546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Due to the double-blind nature of the study, the outcome of the effectiveness of plane blocks will not be known by the anesthesiologist and the patient until the end of the study. Only the effectiveness of blocks will be followed by an another researcher|Clinical trial in which two groups of participants who are applied two type plane blocks. Group A; TAP block and group B; m-TAPA block. Effectiveness of blocks will be followed by appliying Pain Controlled Analgesia(PCA) and with pain scales as Visual Analog Scale(VAS) and Numerating Rate Scale.|t|f|t|f
33834913|NCT05803083|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834914|NCT02778672|||COHORT||PROSPECTIVE|||||||
33834915|NCT04771364|||COHORT||RETROSPECTIVE|||||||
34147919|NCT05097742|||COHORT||CROSS_SECTIONAL|||||||
34147920|NCT04218071|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Patients will receive either single agent 9-ING-41 or 9-ING-41 plus Ruxolitinib||||
34147921|NCT04172168|||COHORT||PROSPECTIVE|||||||
34147922|NCT01556321|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34151262|NCT01120990|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151263|NCT01506661|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||Pilot study||||
34151264|NCT00669201|||COHORT||CROSS_SECTIONAL|||||||
34151265|NCT01029041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151266|NCT06198686|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34151267|NCT01966445|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151268|NCT04758091|||COHORT||PROSPECTIVE|||||||
34151269|NCT01990456|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34147923|NCT04496661|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Participants will be randomly allocated via an online generator (www.random.org) in one of three groups (1:1:1): anodal tDCS of M1 + PES; anodal tDCS of DLPFC + PES; Sham of M1 + PES. This sequence will be performed blindly, independently, and remotely by a blind investigator who will have no contact with other research procedures, and randomization will be hidden until the group is allocated.~The hidden allocation process will be performed using sequential, numbered, opaque and sealed envelopes. The outcome assessors, trialists (care provider and investigator) and participants will be blinded to the performed procedures."|Participants will be randomly allocated via an online generator (www.random.org) in one of three groups (1:1:1): anodal tDCS of M1 + PES; anodal tDCS of DLPFC + PES; Sham of M1 + PES.|t|t|t|t
34147924|NCT00236392|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34147925|NCT02318290|||COHORT||PROSPECTIVE|||||||
34147926|NCT05116605|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||"All participants will complete the following design. Women who experience menstrual flow will be scheduled to ensure that flow occurs on weeks 4 \& 8 for consistency.~Baseline block (weeks 1-4): At intake, participants will complete up to 13 surveys, which includes 2 baseline questionnaires, \& the first rendition of weekly \& monthly surveys, as well as complete a physical performance task \& 4 cognitive tasks. Participants will complete daily surveys each morning \& night, \& wear wearable devices to monitor physiology during sleep. A laboratory visit will occur once per week for completion of weekly surveys, as well as cognitive \& physical performance assessments; monthly surveys will also be completed during the fourth week.~Intervention block (weeks 5-8): Daily, weekly, \& monthly activities described for the baseline block will continue; participants will additionally complete three 20-minute PBM sessions per week. The final week of this block will also involve an exit survey."||||
34147927|NCT03168100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147928|NCT04063787|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34147929|NCT03161860|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Due to the type of intervention, coordinators, volunteers and participants will not be blinded to the interventions. However, they will not be informed about the study hypotheses. Research assistants and the statistician responsible for the analysis will be blinded to the intervention until completion of the study.||f|f|f|t
34147930|NCT04630717|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Prospective randomized double-blind, single-center trial. The patient does not know whether or not he is in the hypnotic conversation group; nor does the anesthesiologist managing the patient intraoperatively knows whether or not the patient had a hypnotic conversation prior to general anesthesia induction."|"Prospective randomized double-blind, single-center trial. The patient does not know whether or not he is in the hypnotic conversation group; nor does the anesthesiologist managing the patient intraoperatively knows whether or not the patient had a hypnotic conversation prior to general anesthesia induction."|t|t|f|f
34147931|NCT03864393|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147932|NCT06013436|||CASE_CONTROL||PROSPECTIVE|||||||
34147933|NCT02583321|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|t|f|f
34147934|NCT01939132|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147935|NCT02137187|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147936|NCT04287686|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-arm pilot study||||
34147937|NCT02916459|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34147938|NCT05291559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34147939|NCT03966677|||COHORT||PROSPECTIVE|||||||
34147940|NCT02683668|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Each volunteer get all treatment in a same sequence||||
34147941|NCT05854953|RANDOMIZED|CROSSOVER||SCREENING||SINGLE|Investigator will be masked with the randomization sequance \& allocation.|"Baseline characteristics - newly constructed Hawley and vacuum-formed retainers will be tested for microbial analysis, phyiscal and mechanical properties as comparisons with other groups~Group 1 - Participants with Hawley retainers will begin storing their retainers in dry condition, 3 months later, they will change the storage to wet condition.~Group 2 - Participants with Hawley retainers will begin storing their retainers in wet condition, 3 months later, they will change the storage to dry condition.~Group 3 - Participants with vacuum-formed retainers will begin storing their retainers in dry condition, 3 months later, they will change the storage to wet condition.~Group 4 - Participants with vacuum-formed retainers will begin storing their retainers in wet condition, 3 months later, they will change the storage to dry condition."|f|f|t|f
34147942|NCT03281551|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147943|NCT04798040|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled study||||
34147944|NCT05826977|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"In the R21 trial, in one high-volume health facility, researchers will randomize PLWH (N=154) to either the CASI-Plus or standard care (SC) APS workflow, and measure the use of the tool and contact index using routinely-collected data.~In the R33 trial, researchers will expand the RCT to three high-volume health facilities and test its effectiveness in improving the HIV testing index (number of partners with unknown HIV status tested per index client; primary outcome, N=888). Secondary outcomes include the percentage of index clients disclosing MSM or PWID partners, HIV case-finding index, and APS-associated adverse events."||||
34147945|NCT06230978|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
34147946|NCT03393507|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147947|NCT00194207|||COHORT||PROSPECTIVE|||||||
34147948|NCT01397760|||CASE_ONLY||RETROSPECTIVE|||||||
34147949|NCT04142151|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34147950|NCT01217320|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147951|NCT05902481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"In the study, Block Randomization method, which is one of the fixed probability randomization methods, will be used in order to ensure homogeneity between the groups and to eliminate selection bias. Pregnant women who meet the criteria for inclusion in the study according to block randomization will be homogeneously distributed to each training group according to their gestational week."||||
34147952|NCT03375372|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147953|NCT06224634|||COHORT||PROSPECTIVE|||||||
34147954|NCT00131456|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151270|NCT04921332|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||This is a non-randomized, single group, pre- and post-intervention project.||||
34151271|NCT02945644|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147955|NCT04123223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Cognitive remediation (CR) is a type of behavioral intervention that addresses cognitive deficits in schizophrenia by restoring lost cognitive skills or providing strategies for bypassing deficits through task practice. The present project seeks to identify cognitive training mechanisms that are most effective at improving cognitive function in schizophrenia by comparing two different systematic programs of CR with different foci: drill-and-practice exercises vs. compensatory strategies.|f|f|f|t
34147956|NCT01362088|||COHORT||PROSPECTIVE|||||||
34147957|NCT02844283|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147958|NCT05110313|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"We will enroll 30 subjects aged 35 years or older.~Arm 1 (psoriasis treatment): 20 subjects with moderate-to-severe psoriasis (including 10 men and 10 women).~Arm 2 (non-psoriasis, non-treatment): 10 age and sex matched controls without psoriasis (including 5 men and 5 women).~The blood leukocytes will be collected to evaluate DNA methylation at baseline (week 0) for both arms. The psoriasis treatment arm will undergo blood leukocytes collection during treatment (at week 28) and post-treatment (week 52)."||||
34147959|NCT02749383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147960|NCT00025623||||TREATMENT||||||||
34147961|NCT01340508|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147962|NCT03100214|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34147963|NCT04304885|||COHORT||PROSPECTIVE|||||||
34147964|NCT03917069|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34147965|NCT06507124|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE|The identify of the participant will not be known to the analysis team|Doctors of various grades will be Invited to take part in the study. Thematic analysis will be used to assess the recordings.||||
34147966|NCT06403878|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147967|NCT02715726|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147968|NCT05833451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34147969|NCT03658070|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34147970|NCT05896787|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147971|NCT05978102|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147972|NCT01580267|||CASE_ONLY||PROSPECTIVE|||||||
34147973|NCT01895244|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147974|NCT04502121|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The psychologist will inform the patient about the group s/he is randomly assigned to. The medical staff will not receive any information about the group a patient is allocated to and therefore be masked regarding group assignments.|Patients will be randomly allocated to the intervention group (IG) or the control group (SOC). The intervention group will receive a psychological preoperative intervention to optimize expectations (in addition to standard medical care). The control group will receive the standard of care only.|f|t|f|f
34147975|NCT03974412|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34147976|NCT04313322|NA|SINGLE_GROUP||TREATMENT||NONE|None. This is a direct study for the potential effects of WJ-MSCs on COVID-19 outcome.|Patients positively diagnosed with COVID-19||||
34147977|NCT00724113|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34147978|NCT05433077|||COHORT||PROSPECTIVE|||||||
34147979|NCT04326686|NA|SINGLE_GROUP||PREVENTION||NONE||This is a series of N-of-1 studies where data from each participant will be analysed separately. Each study follows an A1-B-A2 design consisting of an initial observation phase, an intervention phase and a follow-up phase, each of 8 weeks duration.||||
34147980|NCT06129110|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34147981|NCT02559661|||OTHER||PROSPECTIVE|||||||
34147982|NCT04494724|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Blinded to all except investigational pharmacy. Only the optional second infusion, if determined necessary to administer, will be open-label. The patient and study team will remain blinded until data lock at the end of the study.|This single-site, phase 2 randomized, double-blind, placebo-controlled trial is designed to administer a single dose of clazakizumab or placebo on day 0. If, after 24 hours or up to 14 days from the first infusion, the participant's condition worsens or does not improve, the investigator may elect to provide a single, open-label dose of clazakizumab regardless of the initial group assignment. All except the investigational pharmacist will remain blinded as to the initial group assignment until data lock.|t|t|t|t
34147983|NCT03634267|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34147984|NCT01057056||||SUPPORTIVE_CARE||||||||
34147985|NCT01300351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147986|NCT00340379|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34147987|NCT00969072|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34147988|NCT02194322|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34147989|NCT01737294|||COHORT||PROSPECTIVE|||||||
34147990|NCT01158209|||COHORT||PROSPECTIVE|||||||
34147991|NCT04366375|||CASE_CONTROL||PROSPECTIVE|||||||
34147992|NCT02022241|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34147993|NCT04679909|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34147994|NCT02053662|||COHORT||PROSPECTIVE|||||||
34147995|NCT03606772|||COHORT||CROSS_SECTIONAL|||||||
34147996|NCT06279702|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||serious game and comics|t|f|f|t
34147997|NCT03562793|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Assessors will be blinded to treatment assignment when administering baseline outcome assessments.|Randomized controlled trial with behavioral intervention.|f|f|f|t
34147998|NCT02411786|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34147999|NCT04831099|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|The participant and investigator are blinded. The investigator is also the care provider and investigator.|N-of-1 study: cross-over study in 1 patient with 2 cycles that each consists of 2 periods (one period of placebo and one period of active treatment).|t|t|t|t
34148000|NCT04039867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148001|NCT00697294||PARALLEL||DIAGNOSTIC||NONE||||||
34148002|NCT02986932|NA|SINGLE_GROUP||TREATMENT||NONE||Transcranial ExAblate||||
34148003|NCT04988997|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Double-Blind, Double-Dummy, Placebo-Controlled.|Double-Blind, Double-Dummy, Placebo-Controlled.|t|t|t|t
34148004|NCT03851419|||COHORT||CROSS_SECTIONAL|||||||
33834916|NCT00460902|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834917|NCT00859976|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148005|NCT01199276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148006|NCT00581451|RANDOMIZED|SINGLE_GROUP||||TRIPLE|||t|t|t|f
34148007|NCT03876600|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148008|NCT03667846|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148009|NCT02964832|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34148010|NCT04790487|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double-blinded|Two groups placebo control|t|t|f|f
34148011|NCT01646203||SEQUENTIAL||TREATMENT||NONE||||||
34148012|NCT01571869|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34148013|NCT03792152|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|After receiving the informed consent form patient, The heads of the centers randomly extracted the envelopes and patients are included in the study based on random envelope grouping results.|two groups, group one is for Rivaroxaban 20mg qd (15mg qd If creatinine clearance is between 30-49ml/min), group two is for warfarin, keep the INR between 2-3.|t|t|t|t
34148014|NCT01331096|||||PROSPECTIVE|||||||
34148015|NCT02914561|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148016|NCT04621500|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Single, open-label group||||
34148017|NCT05504668|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Double blind with a placebo control. The study funder organised the formulation of both the active and placebo capsules originally in 2019 so that they were aesthetically identical. Approximately half-way through the trial, the treatments expired due to Covid-19-induced delays and the remainder of the products required to complete the trial were reconstituted by staff at Northumbria University who had no further involvement in the trial. Capsules were again matched to be aesthetically identical between active and placebo but these treatments looked different to those in the first portion of the trial.||t|f|t|t
34148018|NCT01046240|NON_RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
34148019|NCT01510171|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148020|NCT02042534|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148021|NCT06125691|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Open Label (Part 4 only)||t|t|t|t
34148022|NCT02044289|||CASE_ONLY||PROSPECTIVE|||||||
34148023|NCT03897036|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148024|NCT05371041|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34148025|NCT04670393|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34148026|NCT01929538|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148027|NCT02043119|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148028|NCT02968914|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148029|NCT03522597|||COHORT||PROSPECTIVE|||||||
34148030|NCT02699268|||COHORT||PROSPECTIVE|||||||
34148031|NCT00841464|||COHORT||PROSPECTIVE|||||||
34148032|NCT03159104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148033|NCT00357383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148034|NCT03579212|||COHORT||PROSPECTIVE|||||||
34148035|NCT05458661|NA|SINGLE_GROUP||OTHER||NONE||all suitable/eligible subjects will undergo a series of biometry measurements||||
34148036|NCT06004375|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148037|NCT04410744|||COHORT||PROSPECTIVE|||||||
34148038|NCT01490294|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|f|t|t
34148039|NCT05202821|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34148040|NCT04317326|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, open label, randomized controlled trial with two sequential phases||||
34148041|NCT06289816|||COHORT||RETROSPECTIVE|||||||
34148042|NCT02839239|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148043|NCT03224091|||COHORT||PROSPECTIVE|||||||
34148044|NCT05403697|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial, open Phase 3 without experimental product, but experimental strategy||||
34148045|NCT03708601|||COHORT||OTHER|||||||
34148046|NCT01071616|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148047|NCT00780286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148048|NCT03476161|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|t|t|f
34148049|NCT05141656|||CASE_ONLY||RETROSPECTIVE|||||||
34148050|NCT00230360|||DEFINED_POPULATION||PROSPECTIVE|||||||
34148051|NCT00815828|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148052|NCT03551665|NA|SINGLE_GROUP||TREATMENT||NONE|Primary outcomes are objective (i.e. assessed via computer algorithms), thus reducing the need for masking.|Multiple-baseline, within-subject design||||
34148053|NCT00556179|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148054|NCT04498351|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|Prospective randomized double blinded clinical study on humans|"Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction the spermatic cord in short axis and directed towards the deferent duct, contralateral to the testicular artery. The needle tip was advanced to become contact with the deferent. Correct location of the needle tip was confirmed by injecting 0.5-1 ml to see the local anesthetic spreading around the deferent duct. A total of 18ml levobupivacaine 0.5% are then injected into the spermatic cord block .~The procedure is repeated on the contralateral side."|t|t|f|t
34148055|NCT02652416|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148056|NCT05065567|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148057|NCT01256762|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148058|NCT04334213|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34148059|NCT02413801|||CASE_CONTROL||PROSPECTIVE|||||||
34148060|NCT03743220|||COHORT||RETROSPECTIVE|||||||
34148061|NCT06237803|||COHORT||PROSPECTIVE|||||||
34148062|NCT02976103|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148063|NCT00329615|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148064|NCT00581360|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148065|NCT04170270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||comparison between oral and intravenous omeprazole in management of bleeding peptic ulcer|f|f|t|f
34148066|NCT05262686|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151390|NCT02706379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151391|NCT06273748|||COHORT||PROSPECTIVE|||||||
34151392|NCT01942070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148067|NCT05334420|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Staff involved in assessment will be masked to participant allocation.|Randomized controlled trial with family unit (minimum of father-child, maximum of father, 3 siblings, and mother/partner) randomized to intervention or standard of care control.|f|f|f|t
34148068|NCT00278330|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148069|NCT04878536|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34148070|NCT05086055|||CASE_CONTROL||PROSPECTIVE|||||||
34148071|NCT06529848|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial in which 100 angina patients with reduced flow reserve (INOCA patients) are randomized 1:1 to either exercise training or control (no exer-cise training).||||
34148072|NCT05811117|||COHORT||RETROSPECTIVE|||||||
34148073|NCT04098978|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||Before-after comparison of intervention to traditional care||||
34148074|NCT00473525|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148075|NCT01167166|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148076|NCT06419816|||CASE_ONLY||PROSPECTIVE|||||||
34148077|NCT04072107|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148078|NCT04794764|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148079|NCT05874349|||COHORT||PROSPECTIVE|||||||
34148080|NCT02506660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148081|NCT06135363|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34148082|NCT02126072|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34148083|NCT04979403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||It is a feasibility and pilot randomized clinical trial. Participants will be assigned to either the psychologically-informed physiotherapy intervention or to the usual care in physiotherapy.|f|f|f|t
34148084|NCT03974204|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148085|NCT06158776|||CASE_CONTROL||RETROSPECTIVE|||||||
34148086|NCT03951909|RANDOMIZED|PARALLEL||TREATMENT||NONE|Neither the participant or th researcher knew the intervention assignment before enrollment, but there were no masking afterwards (when they had been assigned to either physiotherapy or TRT)|"Participants identified with pain disorders or post-traumatic mental health symptoms according to previously defined objective selection criteria will be invited to the appropriate treatment group conducted by physiotherapists (for those with pain disorders) or health professionals trained in TRT techniques (for those with post-traumatic symptoms). Participants presenting both pain and post-traumatic symptoms will be invited to the intervention treatment for the symptom in which they score highest.~For each group a waiting-list group receiving the same treatment some weeks later was the control group."||||
34148087|NCT00968123|||CASE_ONLY||RETROSPECTIVE|||||||
34148088|NCT04425785|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||"Randomised controlled study. Takotsubo patients will be randomised into one of the following groups:~Exercise Arm Cognitive Behavioural Arm Standard Clinical Care"||||
34148089|NCT06022991|||FAMILY_BASED||PROSPECTIVE|||||||
34148090|NCT03821623|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148091|NCT02720640|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148092|NCT01484379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148093|NCT01063842|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148094|NCT03931915|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148095|NCT05440448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148096|NCT02142036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148097|NCT05700253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148098|NCT06497335|||COHORT||PROSPECTIVE|||||||
34148099|NCT00690170|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34148100|NCT06329882|RANDOMIZED|PARALLEL||TREATMENT||NONE|open label|open label||||
34148101|NCT02867774|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148102|NCT00215215|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148103|NCT02801760|||COHORT||RETROSPECTIVE|||||||
34148104|NCT00139256|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148105|NCT02642146|||COHORT||PROSPECTIVE|||||||
34148106|NCT03873506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148107|NCT02066415|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34148108|NCT04149678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148109|NCT01685983|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148110|NCT05997576|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148111|NCT05996042|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34148112|NCT05810714|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34148113|NCT01534949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148114|NCT03894735|||CASE_CONTROL||RETROSPECTIVE|||||||
34148115|NCT05705661|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"A. Subject selection:~After calculating sample size, sixty hospitalized Covid-19 Patients will be assigned into two equal matched groups randomly:~Group I (Control): will consist of 30 hospitalized covid-19 patients with (nasal cannula/face mask) who will receive traditional respiratory techniques (breathing ex.) plus their traditional medications.~Group II (Study): will consist of 30 hospitalized covid-19 patients with (nasal cannula/ face mask) who will receive high frequency chest wall oscillation in addition to breathing exercise techniques plus their traditional medications."|t|f|f|f
33834918|NCT02484989|||||PROSPECTIVE|||||||
33834919|NCT04853615|||CASE_CONTROL||PROSPECTIVE|||||||
33834920|NCT06136026|||COHORT||PROSPECTIVE|||||||
33834921|NCT02802397|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834922|NCT04719299|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838967|NCT01344551|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33838968|NCT04836169|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized parallel-group||||
33838969|NCT04195802|||COHORT||CROSS_SECTIONAL|||||||
34148116|NCT05207163|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148117|NCT03552588|||COHORT||PROSPECTIVE|||||||
34148118|NCT04788771|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|laryngeal mask airway|Tracheal intubation|f|f|t|f
34148119|NCT04783857|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148120|NCT03353766|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148121|NCT05332808|||CASE_ONLY||RETROSPECTIVE|||||||
34148122|NCT05558462|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34148123|NCT05996809|||COHORT||RETROSPECTIVE|||||||
34148124|NCT05733728|||COHORT||OTHER|||||||
34148125|NCT06466993|RANDOMIZED|PARALLEL||OTHER||DOUBLE|Evaluators of performance are blind to randomisation such as outcome assessor|Prospective randomized controlle monocentric|f|f|t|t
34148126|NCT04682990|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||Positive TB patients (Arm 1) and Negative TB patients (Arm 2 ). All the patients can be HIV positive or not .||||
34148127|NCT04767165|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34148128|NCT02424292|||CASE_ONLY||PROSPECTIVE|||||||
34148129|NCT05463068|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34148130|NCT00459537|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148131|NCT04400578|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148132|NCT00801047|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148133|NCT02816203|NA|SINGLE_GROUP||OTHER||NONE||||||
34148134|NCT06217419|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"Trial 1 15 months Enrollment: month 6 to 9 Fup: 1 year 40 patients: 20 control group:standard fup each 3 months 20:standard on-site fup visit every 6 months + electronic questionnaires to report PROMs + FEV1 and/or PNIF to be performed by turning on the spirometer and connecting it to the app.~Trial 2 1 year Enrollment: month 6 to 12 Fup: 6 months 80 patients: 40+asthma+CRSwNP 20+CRSwNP- asthma 20+asthma-CRSwNP PROM answered remotely weekly+monthly at hospital first by themselves with the aid of one of the 3 channels on the electronic forms and then under supervision of the clinicians. Pts in the standard channel will just fill the forms every month.~Trial 3 6 months Enrollment: month 12 to 15 Fup:3 months Performed at home+periodic visits in the hospital 16 patients asthma+CRSwNP Randomized trial 2 arms, 8 pts per arm: airflow monitoring recorded remotely with Spirometer every 2 weeks or RFID daily + every 2 months at hospital (baseline, month 2) for both arms."||||
34148135|NCT06351709|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148136|NCT05640609|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148137|NCT03263780|NA|SINGLE_GROUP||OTHER||NONE||||||
34148138|NCT00810940|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148139|NCT04539860|||COHORT||PROSPECTIVE|||||||
34148140|NCT02410265|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148141|NCT01278589|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34148142|NCT01756118|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148143|NCT04459975|||COHORT||RETROSPECTIVE|||||||
34148144|NCT02042313|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148145|NCT01242566|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148146|NCT01426308|||CASE_ONLY||RETROSPECTIVE|||||||
34148147|NCT03919227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148148|NCT01330654|RANDOMIZED|PARALLEL||||SINGLE|||f|f|t|f
34148149|NCT06376071|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34148150|NCT03645317|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148151|NCT01354704|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34148152|NCT02747212|||CASE_ONLY||CROSS_SECTIONAL|||||||
34148153|NCT00002363||||TREATMENT||||||||
34148154|NCT05490966|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148155|NCT01305655|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148156|NCT00487448|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148157|NCT00402493|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
34148158|NCT05147714|||COHORT||PROSPECTIVE|||||||
34148159|NCT02528357|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34148160|NCT01883648|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34148161|NCT03546218|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148162|NCT00280345|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148163|NCT05924087|||COHORT||OTHER|||||||
34148164|NCT03759964|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||FCAACS will be a parallel group randomized trial, with a 2-group design and no crossover. Allocation ratio will be 1/1, in an equivalence framework.|t|t|f|t
34148165|NCT00151788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148166|NCT05661266|||COHORT||PROSPECTIVE|||||||
34148167|NCT02641522|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148168|NCT00936078|||COHORT||PROSPECTIVE|||||||
34148169|NCT00348114|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148170|NCT04667416|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148171|NCT01035346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148172|NCT04660721|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148173|NCT04323293|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Participants are unaware of the hypothesis. Outcomes assessors in subprojects are blind to the type of the water bath.|Participants (pain-free controls or patients with low back pain) will undergo either only one intervention (cold water bath) or two interventions in randomized order (cold water bath, water bath of neutral temperature as SHAM condition).|t|f|f|t
34148174|NCT01058135|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34148175|NCT01573481|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148176|NCT02578342|||CASE_CONTROL||PROSPECTIVE|||||||
34148177|NCT02546960|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148178|NCT02295241|||CASE_ONLY||PROSPECTIVE|||||||
34148179|NCT04932291|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148180|NCT04179513|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34148181|NCT02858752|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148182|NCT03149003|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148183|NCT05956509|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34148184|NCT00412074|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148185|NCT05455177|||COHORT||RETROSPECTIVE|||||||
34148186|NCT04708132|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148187|NCT00002514|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148188|NCT04710914|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148189|NCT04832945|||COHORT||RETROSPECTIVE|||||||
34148190|NCT00876785|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34148191|NCT04465565|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized, 2 arms, controlled study||||
34148192|NCT01697150|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148193|NCT03022500|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148194|NCT00771797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148195|NCT02907749|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148196|NCT00002465||||TREATMENT||||||||
34148197|NCT05804149|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||Each woman in both groups (control and study) will receive thyroxine tablets (levothyroxine) (1tablet per day) describe by the physician. Levothyroxine is usually taken 30-60 minutes before breakfast, or four hours after food, as certain substance such as food and calcium can inhabit the absorption of levothyroxine Acupuncture will be applied with a total duration of 35-45 minutes, 2 sessions per week for 4 months.|t|f|f|f
34148198|NCT03675516|||COHORT||RETROSPECTIVE|||||||
34148199|NCT04023123|||CASE_CONTROL||PROSPECTIVE|||||||
34148200|NCT02792998|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148201|NCT04602026|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148202|NCT05027685|||CASE_ONLY||OTHER|||||||
34148203|NCT00286221|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
34148204|NCT03916016|RANDOMIZED|PARALLEL||TREATMENT||NONE||Treatment group participants were randomized to receive enhanced integrated behavioral health care. Control group participants received care as usual.||||
34148205|NCT04142190|||COHORT||RETROSPECTIVE|||||||
34148206|NCT04036994|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148207|NCT05742165|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148208|NCT01584635|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148209|NCT03930875|||OTHER||CROSS_SECTIONAL|||||||
34148210|NCT04796740|||COHORT||RETROSPECTIVE|||||||
34148211|NCT02383602|||COHORT||PROSPECTIVE|||||||
34148212|NCT06234436|NA|SINGLE_GROUP||TREATMENT||NONE||This is a safety and feasibility study.||||
34148213|NCT03121170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148214|NCT04101006|||COHORT||PROSPECTIVE|||||||
34148215|NCT03191877|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34148216|NCT04118569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Assigned group is not masked. All roles will know which group (narrative or usual care) the patient has been assigned to.|50% of patient participants will complete the narrative intervention and outcome measures. 50% will complete outcome measures only.||||
34148217|NCT01656629|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34148218|NCT02610244|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148219|NCT05674253|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34148220|NCT02857101|||COHORT||PROSPECTIVE|||||||
34148221|NCT06414161|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
34148222|NCT04349033|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34148223|NCT06394453|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||"All eligible newborns will be randomized to one of the two groups :~1. unfed during 72 hours of TH (control group);~2. fed group, which will start receiving enteral feeding with mother milk or human donor breast milk at 10 ml/kg/day during first day of TH, 20 ml/kg/day during second day and 30 ml/kg/day during third day (experimental group)."|f|f|f|t
34148224|NCT04069923|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148225|NCT01180517|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148226|NCT02196428|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34148227|NCT02712424|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148228|NCT03698565|NA|SINGLE_GROUP||OTHER||NONE||||||
34148229|NCT01875718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148230|NCT05501314|NA|SINGLE_GROUP||OTHER||NONE||Feasibility study||||
34148231|NCT03613467|||CASE_CONTROL||RETROSPECTIVE|||||||
34148232|NCT00187187|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148233|NCT02008357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148234|NCT02693249|||CASE_ONLY||PROSPECTIVE|||||||
34148235|NCT03891628|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34148236|NCT04408768|||COHORT||PROSPECTIVE|||||||
34148237|NCT05741047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34148238|NCT02779504|||COHORT||RETROSPECTIVE|||||||
34148239|NCT03167320|||COHORT||PROSPECTIVE|||||||
34148240|NCT06358404|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34148241|NCT02220114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148242|NCT00637572|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148243|NCT03766269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148244|NCT04626960|||COHORT||CROSS_SECTIONAL|||||||
34148245|NCT02989805|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148246|NCT00316524|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148247|NCT05107583|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|Due to the obvious differences between fasting and consuming food, participants will be aware of when they have been assigned to the fasted condition. However, the low- and high-carbohydrate content lunch meals will be closely matched for taste, with carbohydrate content being manipulated within a drink. Participants will not be informed that the carbohydrate content of the lunch meals is being manipulated, and will therefore, be blinded to this element of the study.|The study design is a randomised, controlled, crossover design in which participants undertake three exercise conditions in a randomised order with at least a seven day period in between trials.|t|f|f|f
34148248|NCT00275977|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34148249|NCT02580513|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34148250|NCT01475162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148251|NCT02392403|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148252|NCT00206882|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34148253|NCT00220207|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148254|NCT03094559|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148255|NCT04240314|NA|SINGLE_GROUP||TREATMENT||NONE||This trial will deliver the minimal efficacious dose as determined by preclinical studies and approved by the FDA to determine safety and target engagement.||||
34148256|NCT02619721|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151393|NCT03156439|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151394|NCT02760810|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838970|NCT05407831|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33838971|NCT01561677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|t|f|f
34148257|NCT05235919|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and outcomes assessor will be blind to rTMS or sham condition.|Randomized sham-controlled rTMS trial|t|f|t|t
34148258|NCT00214929|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148259|NCT01462890|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized Phase III study||||
34148260|NCT02391532|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34148261|NCT01238978|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148262|NCT05686096|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148263|NCT04489121|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148264|NCT03952715|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|||t|f|t|f
34148265|NCT02645435|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148266|NCT00149019|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148267|NCT04761484|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomly assigned in blocks of 4 in a 1:1 ratio, stratified by GA (23 - 25+6, 26 - 28+6) and by admission temperature (normal temperature \[36.5oC- 37.5oC\] , abnormal temperature \[\<36.5oC or \>37.5oC\]).||||
34148268|NCT00439452|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34148269|NCT02092402|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148270|NCT00636012|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
34148271|NCT00563862|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34148272|NCT01307293|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148273|NCT00001136||||PREVENTION||||||||
34148274|NCT01787656|||OTHER||OTHER|||||||
34148275|NCT06412952|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148276|NCT00215865|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148277|NCT00277394|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148278|NCT02036762|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148279|NCT01467388|||CASE_CONTROL||RETROSPECTIVE|||||||
34148280|NCT06141837|||COHORT||RETROSPECTIVE|||||||
34148281|NCT04433013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
34148282|NCT03166111|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148283|NCT01797380|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148284|NCT01389323|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148285|NCT04214639|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148286|NCT00635089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148287|NCT01013415|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148288|NCT02059954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148289|NCT03625583|||CASE_ONLY||CROSS_SECTIONAL|||||||
34148290|NCT05937594|||COHORT||PROSPECTIVE|||||||
34148291|NCT04367597|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, sham-controlled, double-blind, multi-center|t|t|t|t
34148292|NCT03561701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148293|NCT02668029|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34148294|NCT01073878|NA|SINGLE_GROUP||||NONE||||||
34148295|NCT05736003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148296|NCT04082780|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Patients will be randomized 1:1 into receiving rifamycin or placebo by a random number generator created by Cosmo.||t|t|t|t
34148297|NCT05716243|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|The anesthetist who is blind to study groups will make all postoperative assessments of pain by FLACC (Face, Legs, Activity, Cry, Consolability) behavioral pain assessment score at the postoperative care unit, 6th 12th, and 24th hour postoperatively.|After standard monitorization, general anesthesia will be applied. Once the randomization is concluded to decide the group of the patient, Group A will receive 15 mg/kg (IV) paracetamol and 0,05 mg/kg morphine (IV). For once, NOL monitorization will be applied 30 minutes before waking up the patient to assess standard pain management and if the NOL value is higher than 25; 0,025 mg/kg morphine (IV) bolus doses (the maximum total intraoperative dose is concluded to be 0,5 mg/kg (IV)) will be added to ensure adequate analgesia for all patients within the study. On the contrary, patients within Group B will receive NOL monitorization from the beginning, all along the surgery.|f|f|f|t
34148298|NCT01806649|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148299|NCT01468636|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
34148300|NCT03324698|||COHORT||RETROSPECTIVE|||||||
34148301|NCT01606787|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148302|NCT04176120|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the test article, the trial is open label, with no blinding of the site staff. The determination of wound closure will be made by the Investigator based on visual and tactile assessment of the wound. To reduce bias in the ascertainment of closure, one independent blinded reviewer will review the image obtained from a wound measurement device in each case where the Investigator makes a determination of closure. Discordant opinions will be adjudicated by a second independent blinded reviewer who will examine multiple additional images taken at various angles to the wound surface.||f|f|f|t
34148303|NCT05190055|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34148304|NCT00005053|RANDOMIZED|||TREATMENT||||||||
34148305|NCT00319241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148306|NCT01394887|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34148307|NCT00037674|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148308|NCT04809974|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Double-blinded, randomized, parallel group, placebo-controlled design|t|t|t|t
34148309|NCT01743404|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34148310|NCT06230250|||COHORT||RETROSPECTIVE|||||||
34148311|NCT03211013|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|Blinding of oxytocin drug container + randomization of oxytocin/placebo ordering over sessions|Randomized double-blind crossover design, in which all participants will undergo 2 sessions, receiving either oxytocin nasal spray or placebo nasal spray in random order.|t|f|t|t
34148312|NCT01453517|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148313|NCT04474041|NA|SEQUENTIAL||DIAGNOSTIC||NONE||||||
34148314|NCT01926769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148315|NCT02191839|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148316|NCT03230292|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148317|NCT02108691|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34148318|NCT03364413|||COHORT||OTHER|||||||
34148319|NCT04356794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148320|NCT05932602|||CASE_CONTROL||PROSPECTIVE|||||||
34148321|NCT01808885|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148322|NCT00895687|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148323|NCT05094817|||COHORT||PROSPECTIVE|||||||
34148324|NCT00721175|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148325|NCT03189121|||COHORT||CROSS_SECTIONAL|||||||
34148326|NCT00265265|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34148327|NCT05793034|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148328|NCT03033563|||CASE_ONLY||RETROSPECTIVE|||||||
34148329|NCT05156268|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective, single arm, open-label, single-institution phase II trial.||||
34148330|NCT03274804|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148331|NCT05164588|||COHORT||PROSPECTIVE|||||||
34148332|NCT02076906|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148333|NCT00254683|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||f|f|t|t
34148334|NCT00454649|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148335|NCT05619640|||CASE_CONTROL||PROSPECTIVE|||||||
34148336|NCT05485142|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148337|NCT06384664|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148338|NCT03423524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148339|NCT04487561|RANDOMIZED|PARALLEL||OTHER||SINGLE||Prospective multicentric randomized controlled clinical trial|f|f|f|t
34148340|NCT02049619|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148341|NCT01020903|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34148342|NCT01014455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148343|NCT00905203|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148344|NCT02142881|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148345|NCT00693472|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148346|NCT03266172|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Part A of the study will be a non-randomized 6 period, sequential, 6-way fixed sequence design. Part B of the study will be a repeat dose study. Part C of the study will be a non-randomized 6 period, sequential, fixed sequence crossover design.||||
34148347|NCT05440136|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34148348|NCT03082014|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|Cerebrovascular reactivity measures will be assessed centrally by a blinded rater.|TREAT-SVDs is a multi-centre, multinational phase III b clinical trial with a three sequence crossover design. It will be carried out as a rater blinded trial which is also known as PROBE-design (prospective, randomised, open-label trial with blinded endpoint assessment).|f|f|f|t
34148349|NCT03374202|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148350|NCT01698411|||COHORT||OTHER|||||||
34148351|NCT01181024|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34148352|NCT06470750|||COHORT||PROSPECTIVE|||||||
34148353|NCT01256021|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148354|NCT04821323|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148355|NCT06301139|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized controlled pilot study||||
34148356|NCT02564328|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148357|NCT00840060|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148358|NCT06354374|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34148359|NCT05558215|NA|SINGLE_GROUP||OTHER||NONE||Single group clinical trial with single arm to assess feasibility of remote administration of balance training||||
34148360|NCT01600053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148361|NCT04454645|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
34148362|NCT01576185|||CASE_ONLY||PROSPECTIVE|||||||
34148363|NCT01287195|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148364|NCT02220751|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34148365|NCT02751528|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148366|NCT06053736|NA|SINGLE_GROUP||OTHER||NONE||||||
34148367|NCT01709201|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148368|NCT02776592|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
34148369|NCT02420548|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34148370|NCT00667654|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148371|NCT02323152|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34148372|NCT03687307|||CASE_ONLY||PROSPECTIVE|||||||
34148373|NCT00143377|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148374|NCT02533726|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148375|NCT04464824|||CASE_ONLY||RETROSPECTIVE|||||||
34148376|NCT00330668|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148377|NCT01888419|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148378|NCT00800410|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148379|NCT02876874|||||PROSPECTIVE|||||||
34148380|NCT04966923|||CASE_CONTROL||OTHER|||||||
34148381|NCT02699372|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148382|NCT05856097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148383|NCT04311398|||COHORT||RETROSPECTIVE|||||||
34148384|NCT02371200|||COHORT||PROSPECTIVE|||||||
34148385|NCT05707481|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
34148386|NCT02584361|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148387|NCT01499394|||COHORT||PROSPECTIVE|||||||
34148388|NCT03323736|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Pivotal cohort is single arm. Physician initial subjects evaluated in separate cohorts but not included in primary and secondary analyses.||||
34148389|NCT02461316|||CASE_ONLY||PROSPECTIVE|||||||
34148390|NCT05480449|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34148391|NCT01700465|||CASE_ONLY||PROSPECTIVE|||||||
34148392|NCT01827332|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148393|NCT00007644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148394|NCT02201836|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|t|f
34148395|NCT00127335|RANDOMIZED|CROSSOVER||DIAGNOSTIC||DOUBLE|||t|f|t|f
34151395|NCT02737150|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
34151396|NCT04458415|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|No Masking|||||
34148396|NCT05551624|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, single group, exploratory (proof of concept) clinical trial to evaluate the effect in serum platelet count of Atorvastatin plus N-acetylcysteine in patients with primary immune thrombocytopenia resistent to steroid therapy or in relapse||||
34148397|NCT05614284|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||2:1 Enrollment: Virtuous vs. Autograft||||
34148398|NCT04293367|NON_RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Potential subjects will be from an African American descent which will be defined as having all four grandparents reported as African Americans. The subjects will be healthy (blood work, Hx and PE), non-diabetic (OGTT) pre-menopausal, age range 20-40 years, BMI range of 25-40, with regular menstrual periods, sedentary (exercise no more than 2 times/week, for one hour or spend no more than 1000 - 1500 Kcal/wk in physical activity as determined by a Paffenbarger questionnaire). Subjects will be excluded if there is any indication what so ever that they have any cardiac or pulmonary illnesses which may interfere with their capacity to exercise, if they are smokers, consume more than 2 oz. of ethanol/day, have had a weight change greater than + 2 kg in the past 3 months, are currently taking medications or have any physical conditions which may affect insulin action and/or lipid metabolism or have hyperlipidemia.|The study team will conduct a randomized clinical trial in 48 healthy pre-menopausal sedentary overweight and obese African American women. The women will be randomized to two groups: a) half of the women in each diet group will be training (EX) and b) half of the women in each diet group will be sedentary (C). Each woman will participate over a 5 months period, through 4 menstrual cycles so that baseline and post-intervention measurements are done during the follicular phase of the menstrual cycle. The baseline and post-intervention measurements will be done after a 10-day period of controlled eucaloric High-Fat feeding. On Days 9-11 of the 10 -day period they will be in-patients in the CRR and they will all be sedentary. On Day 9 they will be admitted to the Metabolic Chamber and have 24-hour energy expenditure measurements as previously described which will be used for the diet on subsequent days in the CRR. On Day 10 they will be fed the same amount of calories they bu|t|f|t|f
34148399|NCT01150643|||OTHER||RETROSPECTIVE|||||||
34148400|NCT02358915|NA|SINGLE_GROUP||OTHER||NONE||||||
34148401|NCT02338375|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148402|NCT03551756|||OTHER||CROSS_SECTIONAL|||||||
34148403|NCT04588090|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148404|NCT03696095|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148405|NCT05435066|||COHORT||PROSPECTIVE|||||||
34148406|NCT03668158|||COHORT||RETROSPECTIVE|||||||
34148407|NCT06506539|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148408|NCT06337578|||CASE_CONTROL||PROSPECTIVE|||||||
34148409|NCT02626975|||COHORT||PROSPECTIVE|||||||
34148410|NCT04663334|||OTHER||PROSPECTIVE|||||||
34148411|NCT03684694|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34148412|NCT04453176|||COHORT||PROSPECTIVE|||||||
34148413|NCT01855152|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
34148414|NCT00582738|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148415|NCT01850043|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34148416|NCT00049595|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148417|NCT04721340|||CASE_ONLY||CROSS_SECTIONAL|||||||
34148418|NCT01965899|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148419|NCT05998135|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148420|NCT04110470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148421|NCT00599690|NA|SINGLE_GROUP||SCREENING||NONE||||||
34148422|NCT03541460|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34148423|NCT03563508|||OTHER||CROSS_SECTIONAL|||||||
34148424|NCT00002039||||TREATMENT||||||||
34148425|NCT00024375||||TREATMENT||||||||
34148426|NCT01395277|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34148427|NCT01713556|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148428|NCT01504347|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34148429|NCT02439567|NA|SINGLE_GROUP||OTHER||NONE||||||
34148430|NCT00709878|||COHORT||RETROSPECTIVE|||||||
34148431|NCT01114360|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34148432|NCT04008511|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148433|NCT00262847|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148434|NCT00518674|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148435|NCT06051552|||CASE_ONLY||PROSPECTIVE|||||||
34148436|NCT05236712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34148437|NCT02204852|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34148438|NCT00803972|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34148439|NCT05059964|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148440|NCT05620953|||CASE_ONLY||RETROSPECTIVE|||||||
34148441|NCT02915185|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148442|NCT04438460|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148443|NCT02539511|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148444|NCT02074813|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148445|NCT00247455|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34148446|NCT06198855|||OTHER||OTHER|||||||
33834923|NCT03088774|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The allocation sequence will be delivered by the statistician group at Aalborg University Hospital and delivered to a IT consultant at ProData (Viby, J, Denmark) and integrated in the web-application. The researchers conducting the analysis will be blinded. During the project, data will be stored on a server placed at Aalborg University. Another member of the author Group will prepare a data set with a dummy variable for allocation without free text information from patients and make this data set available for the assessors to analyse. Patients will be aware of their allocation. General practitioners will only be aware of the allocation if the patient chooses to tell it to the general practitioner.|Allocation of patients 1:1 to the new web-application or to Patient's Handbook|f|t|t|t
34148447|NCT00832052|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34148448|NCT02067494|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34148449|NCT00882739|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148450|NCT05160818|RANDOMIZED|PARALLEL||TREATMENT||NONE|The affiliation to the treatment arm will not be blinded to anyone except the study neuroradiologist.|1:1 Parallel Assignment||||
33834924|NCT04897204|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834925|NCT02449057|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834926|NCT06297044|||COHORT||PROSPECTIVE|||||||
33834927|NCT00884559|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|f|t
33834928|NCT01371071|||COHORT||PROSPECTIVE|||||||
33834929|NCT05641779|||COHORT||PROSPECTIVE|||||||
33834930|NCT01496365|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834931|NCT04799769|NA|SINGLE_GROUP||TREATMENT||NONE||Prospective, multi-centred, non-randomized study to investigate the safety and performance of the PerQseal® +||||
33834932|NCT01289132|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834933|NCT00061425|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834934|NCT00641277|||CASE_ONLY||PROSPECTIVE|||||||
33834935|NCT01951768|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834936|NCT02813902|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
33834937|NCT03540745|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|All participants and investigators are blind to condition|Randomized Controlled Trial with block randomization|t|t|t|t
33834938|NCT01755676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834939|NCT00047723|RANDOMIZED|||TREATMENT||DOUBLE||||||
33834940|NCT02209844|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33834941|NCT06391437|||CASE_CONTROL||PROSPECTIVE|||||||
33834942|NCT06544603|||CASE_CONTROL||RETROSPECTIVE|||||||
33834943|NCT03105063|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33834944|NCT01076764|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834945|NCT01642433|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33834946|NCT05428527|||COHORT||RETROSPECTIVE|||||||
33834947|NCT05521711|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834948|NCT01717079|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834949|NCT01132469|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834950|NCT02925845|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33834951|NCT01938313|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834952|NCT00801333|||OTHER||PROSPECTIVE|||||||
33834953|NCT01149122|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834954|NCT01458522|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33834955|NCT00260247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834956|NCT03796078|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834957|NCT02781805|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33834958|NCT02394249|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33834959|NCT04201145|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33834960|NCT02799355|||||RETROSPECTIVE|||||||
33834961|NCT03194867|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834962|NCT05021471|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834963|NCT05625347|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33834964|NCT00346853|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33834965|NCT00448006|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834966|NCT00369096|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834967|NCT03515447|||CASE_ONLY||RETROSPECTIVE|||||||
33834968|NCT00403910|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33834969|NCT00178854|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834970|NCT02582268|RANDOMIZED|PARALLEL||||SINGLE|||t|f|f|f
33834971|NCT05732805|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834972|NCT01844713|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33834973|NCT04685447|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834974|NCT03344068|RANDOMIZED|PARALLEL||TREATMENT||NONE||The patients eligible are divided randomly. All the patients will receive radical radiotherapy with or without chemotherapy. The cases in the Experimental Group will receive Nutren® Optimum of 7 scoops tid at begin of radiotherapy.||||
33834975|NCT03265015|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33834976|NCT03080142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834977|NCT04349007|RANDOMIZED|PARALLEL||OTHER||SINGLE|Single (Investigator)||f|f|t|f
33834978|NCT04940364|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834979|NCT02907437|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33834980|NCT05176691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33834981|NCT05428280|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33834982|NCT02971852|||COHORT||PROSPECTIVE|||||||
33834983|NCT00980590|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33834984|NCT01443923|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33834985|NCT02546947|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33834986|NCT02376647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834987|NCT02453243|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33834988|NCT00665093|||COHORT||PROSPECTIVE|||||||
33834989|NCT03785106|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is a multicenter, randomized, open-label, phase III clinical trial comparing a 4-week daily INH/RPT regimen (1HP) to a 12-weekly INH/RPT (3HP) for the treatment of LTBI in HIV-infected participants without evidence of active TB.||||
33834990|NCT04669145|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33834991|NCT01372007|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33834992|NCT04597346|||COHORT||PROSPECTIVE|||||||
33834993|NCT00343993|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33834994|NCT03364777|||COHORT||PROSPECTIVE|||||||
33834995|NCT05917132|NA|SEQUENTIAL||BASIC_SCIENCE||NONE||||||
33834996|NCT05196451|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33834997|NCT04489108|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33834998|NCT05032404|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33834999|NCT02990468|NA|SEQUENTIAL||TREATMENT||NONE||Dose escalation||||
33835000|NCT04181112|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835001|NCT05244369|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835002|NCT03293069|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835003|NCT01699841|||COHORT||PROSPECTIVE|||||||
33838972|NCT00000683||||PREVENTION||DOUBLE||||||
33835004|NCT05988242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Regarding the nature of the intervention it will be double blind as the women will not know which intervention will take and the randomization of the groups will be done by person other than the researchers.|Parallel randomized controlled trial will be used to fulfill the aim of proposed study. The randomized control trial (RCT) is a trial in which subjects are randomly assigned to one of two or more groups: the intervention (group A) who will receive evening primrose oil, the intervention (group B) who will receive lavender oil, the third group ( C) who will receive placebo (Spieth et al, 2016).|t|f|t|f
33835005|NCT05175196|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835006|NCT02595372|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835007|NCT01696786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835008|NCT02454504|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33835009|NCT02339870|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835010|NCT06292923|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The treating physician, study staff, and patients will be blinded to treatment. The research pharmacy at each site will have the treatment code assignments.||t|t|t|f
33835011|NCT03326362|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835012|NCT01782768|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33835013|NCT05355168|NA|SINGLE_GROUP||TREATMENT||NONE||To enroll 57 patients with resectable \& potentially resectable locally advanced esophageal squamous cell carcinoma to receive neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery.||||
33835014|NCT04214353|NA|SINGLE_GROUP||OTHER||NONE||||||
33835015|NCT01791413|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835016|NCT01103921|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|t|f|f
33835017|NCT04912154|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835018|NCT05399368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double blind||t|f|t|t
33835019|NCT00047255|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835020|NCT06411509|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835021|NCT03566979|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Post-operative dental pain following third molar extraction.|t|t|t|t
33835022|NCT03969498|||COHORT||RETROSPECTIVE|||||||
33835023|NCT01602510|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835024|NCT06134947|||CASE_CONTROL||RETROSPECTIVE|||||||
33835025|NCT06109610|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33835026|NCT01657747|NA|SINGLE_GROUP||DIAGNOSTIC||SINGLE|||f|f|t|f
33835027|NCT04056793|NA|SINGLE_GROUP||OTHER||NONE||||||
33835028|NCT00915083|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835029|NCT01776359|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33835030|NCT02446613|NA|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33835031|NCT04773925|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Women with chronic pelvic pain will be recruited during outpatient visits to Mayo Clinic Florida. Baseline patient-reported outcomes will be obtained using the PROMIS-CAT questionnaire. Questionnaires will be assigned in the electronic medical record. All subjects will receive standard care for their chronic pelvic pain, including a consultation with a gynecologist. Patients will then be referred for three 60-minute mindfulness counseling sessions conducted via telemedicine with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The initial consultation will consist of a 60-minute individual session. The subsequent sessions will be group visits (anticipate 5 subjects per group) lasting 60 minutes. PROMIS-CAT questionnaires will be repeated at 3 months and 6 months, and a satisfaction survey will be distributed at the completion of the program.||||
33835032|NCT02630407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||injection of saline VS injection of Hyaluronic acid|t|f|f|t
33835033|NCT05864677|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||Adult patients undergoing CABG under general anesthesia will be included in this study. After signing informed consent patients will be randomized using a double-blinded envelope method into two groups: C - control and CER - patients receiving Cerebrolysin at the dose of 50 mL before surgery followed by 50 mL on the morning of days 1,2,3 and 4.|f|f|t|f
33835034|NCT04547023|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33835035|NCT06022445|||COHORT||PROSPECTIVE|||||||
33835036|NCT06252012|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33835037|NCT02192593|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33835038|NCT05099289|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835039|NCT02926911|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835040|NCT03513744|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33835041|NCT03708237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33835042|NCT00345475|||||PROSPECTIVE|||||||
33835043|NCT03452683|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835044|NCT02166970|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33835045|NCT02039648|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835046|NCT01928238|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33835047|NCT00009906|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835048|NCT00290901|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33835049|NCT03026647|||COHORT||RETROSPECTIVE|||||||
33835050|NCT06485583|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835051|NCT04218474|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835052|NCT00166946|RANDOMIZED|SINGLE_GROUP||ECT||NONE||||||
33835053|NCT02900235|NA|SINGLE_GROUP||OTHER||NONE||||||
33835054|NCT03990740|||CASE_CONTROL||PROSPECTIVE|||||||
33835055|NCT00003058|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835056|NCT03697694|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33835057|NCT03531554|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double (Participant, Outcomes Assessor)|randomized, blinded, placebo controlled, 2-way cross-over trial|t|f|f|t
33835058|NCT05546944|||COHORT||OTHER|||||||
33835059|NCT02596698|||CASE_CONTROL||PROSPECTIVE|||||||
33835060|NCT02552459|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835061|NCT03691103|||COHORT||PROSPECTIVE|||||||
33835062|NCT05616598|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||DAA oral therapy for HCV.||||
33835063|NCT00903825|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835064|NCT00127842|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835065|NCT02305745|||COHORT||PROSPECTIVE|||||||
33835066|NCT04324190|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|Care providers (providing guidance) are not informed about wether participants have been assigned to the online support program condition or the comparator condition, consisting of a waiting period followed by the online support program.|Randomized controlled trial with a waiting comparator condition (provision of WHO recommendations, comparable to treatment as usual, TAU), consisting of a two weeks waiting period during which general WHO recommendations how to handle stress in the context of the COVID-19 pandemic will be provided. All subjects in the waiting condition will undergo the intervention following the waiting period. Main assessments will be conducted before the waiting period, before beginning of the intervention, two weeks after beginning of the intervention (+2 weeks), +4 weeks, +12 weeks, and follow ups at +6 months and +12 months.|f|t|f|f
33835067|NCT01692509|||COHORT||PROSPECTIVE|||||||
33835068|NCT00785954|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835069|NCT03756376|||COHORT||PROSPECTIVE|||||||
33835070|NCT01111253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835071|NCT03838523|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the study, patients and clinicians are aware of group assignment. Assessors are blinded to group assignment of participants. To prevent the breaking of blinding, participants are requested to not communicate their group affiliation when they have questions about the assessments.|Women with ≥5 daily moderate to severe hot flushes of at least moderate bother are assigned 1:1 to a 4-week OLP treatment or no treatment. To explore the duration and maintenance of placebo effects, participants in the OLP group are randomized a second time and divided into two subgroups who either discontinue (OLP 4wk) or continue the OLP treatment (OLP 8wk) for another 4 weeks.|f|f|f|t
33835072|NCT05337423|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the participants involved in the study, nor the outcomes assessor will be aware of the groups formed, as well as the treatments received.|A Group of participants will receive skin moisturizer and photobiomodulation sham while another group will receive the skin moisturizer and the active photobiomodulation treatment.|t|f|f|t
33835073|NCT04699760|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835074|NCT00362375|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835075|NCT03450499|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835076|NCT01240538|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835077|NCT02339597|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835078|NCT00004449|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835079|NCT01003535|||COHORT||PROSPECTIVE|||||||
33835080|NCT05488288|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835081|NCT02653209|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33835082|NCT01780597|||CASE_CONTROL||PROSPECTIVE|||||||
33835083|NCT02375347|NA|SINGLE_GROUP||||NONE||||||
33835084|NCT05764551|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835085|NCT00574418|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835086|NCT05323045|NA|SEQUENTIAL||TREATMENT||NONE||||||
33835087|NCT04908345|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Methadone x Fentanyl|t|t|t|t
33835088|NCT06385925|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33835089|NCT01790295|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835090|NCT06265324|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835091|NCT00759122|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835092|NCT04135612|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||randomized control trial||||
33835093|NCT02997332|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835094|NCT02209103|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33835095|NCT03002142|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33835096|NCT02957955|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33835097|NCT06499389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835098|NCT01120483|||COHORT||PROSPECTIVE|||||||
33835099|NCT04578288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835100|NCT01177956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835101|NCT00746629|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835102|NCT00922415|||CASE_ONLY||PROSPECTIVE|||||||
33835103|NCT06542939|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835104|NCT04058470|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835105|NCT06447649|||CASE_ONLY||RETROSPECTIVE|||||||
33835106|NCT06009042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835107|NCT01667809|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835108|NCT06456476|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835109|NCT03339271|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835110|NCT02403518|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835111|NCT02313389|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835112|NCT02077582|||COHORT||PROSPECTIVE|||||||
33835113|NCT01275599|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835114|NCT05921669|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|"The lottery method and blocking will be used in assigning individuals to groups. Participants will be laided according to the way of birth and then the draw will be divided into groups. For the first person to be included in the study in the lottery method; In a bag of the same size and the same quality, three separate paper on which Control Group, Mother Training Group, Mother and Father Education Group will be placed. The first participant will be determined in this way. For the second participant; 2 paper containing groups not including the first participant will be thrown into the bag and draw the draw. In the third participant, the draw will not be drawn, and the person will be appointed to the remaining group."|"Before starting the research, parents will be informed about the study and written consent will be obtained from those who agree to participate in the research. There are 3 groups in the study. These; Experimental Group 1: The group in which breastfeeding training was given to mothers and fathers Experimental Group 2: The group in which breastfeeding training was given only to the mother Control Group: The group that did not receive any intervention and received routine hospital care.~Within the first 24 hours after birth, everyone participating in the research will be contacted and the relevant forms will be filled in and breastfeeding training will be given to experimental group 1 and experimental group 2 by the researcher. Then, families will be called in the 1st week, 1st month and 3rd month by phone and the relevant forms will be filled. Families' questions about breastfeeding will be answered."|t|f|f|t
33835115|NCT00905034|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835116|NCT06065137|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835117|NCT03544645|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33835118|NCT04467047|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835119|NCT06270277|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Adolescents with Inflammatory bowel diseases and healthy control group in same age will be administered Pediatric Quality of Life Inventory (PedsQL) and Strengths and Difficulties Questionnaire (SDQ).||||
33835120|NCT06202768|||COHORT||RETROSPECTIVE|||||||
33835121|NCT04434001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835122|NCT05233709|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33835123|NCT00883298|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835124|NCT04907279|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33835125|NCT05472103|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835126|NCT05563701|||OTHER||PROSPECTIVE|||||||
33835127|NCT00011934||||TREATMENT||||||||
33835128|NCT03708796|||COHORT||PROSPECTIVE|||||||
33835129|NCT03404544|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Only the clinical nurse won't be blinded|"Prevention of hemodynamic carbetocin-induced side effects when the study drug carbetocin 100 mcg intravenous is given as an infusion over 10 minutes versus a single shot rapid bolus (same dose). Two syringes per subject will be prepared by the research nurse :~1. one 3 ml syringe containing 1 ml of either carbetocin 100 mcg or normal saline (according to the patient's study group);~2. one 10 ml syringe containing carbetocin 100 mcg (1 ml) diluted with 9 ml of normal saline for a total volume of 10 ml, or 10 ml of normal saline (according to the patient's study group).~The volume in the 3 ml syringe will be injected as an IV push bolus after cord clamping and the volume in the 10 ml syringe will be infused over 10 minutes at cord clamping. The study subject, the attending anesthesiologist and the anesthesiologist collecting intraoperative data will be blinded to patient group allocation. The research nurse will not be blinded to patient group allocation."|t|t|t|f
33835130|NCT04264546|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33835131|NCT03243435|||CASE_ONLY||PROSPECTIVE|||||||
33835132|NCT03267810|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33835133|NCT02400008|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835134|NCT02882997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835135|NCT02264262|NA|SINGLE_GROUP||OTHER||NONE||||||
33835136|NCT02466698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835137|NCT00913523|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33835138|NCT06030869|||COHORT||PROSPECTIVE|||||||
33835139|NCT05646147|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835140|NCT02497846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835141|NCT05559632|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|f|t
33835142|NCT02227797|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835143|NCT03723577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835144|NCT00815113|||COHORT||PROSPECTIVE|||||||
33835145|NCT00042133|||||PROSPECTIVE|||||||
33835146|NCT00333255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33835147|NCT00312585|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835148|NCT03795168|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|"Arm 1: their will be no masking as the participants will either wear the transcranial vibrating system (TCVS) or not.~Arm 2: the investigators will be provided 2 TCVS by the sponsor, labeled A or B, which will be randomly assigned to participants by the sponsor. One TCVS will be set at the optimal vibration frequency and the other TCVS will be set at an irrelevant vibration frequency (sham). The investigators and the participants will not know which TCVS is optimal or sham, thus the arm 2 will be double blinded."|"Arm 1: Participants undergoing vestibular physical therapy (PT) will perform PT exercises with or without wearing the transcranial vibrating system (TCVS). Following the end of their PT exercises (30 minutes or less if the participant was too dizzy to finish), participants will evaluate dizziness using a dizziness symptom scale (DSS) and PT exercise duration will be recorded. A force plate system assessment will also be performed with or without wearing the TCVS during the first and last PT visit to evaluate participant's balance.~Arm 2: Participants will undergo the identical protocol as arm 1 with the exception that participants will wear the TCVS at optimal vibration frequency or the TCVS at irrelevant vibration frequency (sham).~To determine TCVD's effect on dizziness and balance, the outcomes measured in both arms (1. DSS, 2. duration of PT exercise, 3. balance) will be compared statistically between:~* TCVD versus no device~* TCVD optimal frequency versus TCVD sham"|t|f|t|f
33835149|NCT03432468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835150|NCT04042753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835151|NCT03922152|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835152|NCT02232399|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33835153|NCT00281268||FACTORIAL||TREATMENT||||||||
33835154|NCT01781832|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835155|NCT05405699|RANDOMIZED|FACTORIAL||PREVENTION||NONE||The study is a single-blind, randomized, factorial experimental type follow-up study with a control group.||||
33835156|NCT01820884|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835157|NCT01939353|NA|SINGLE_GROUP||TREATMENT||SINGLE|This was a single-blind trial in which participants were blinded to investigational product throughout the trial. Participants were not informed of the exact timing of CTN SR versus placebo treatment, in order to maintain the blinded nature of the placebo treatment and reduce potential placebo effects.||t|f|f|f
33835158|NCT03230825|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Data analysis will be performed according to group code .|"Once informed consent forms are signed, the patient will be randomized (using a randomization table handled by a 3rd party) into one of 2 groups:~1. Expectant management of 3 weeks and a follow up visit a week after.~2. Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal."|f|f|f|t
33835159|NCT01445119||||TREATMENT||||||||
33835160|NCT03223051|NA|SINGLE_GROUP||OTHER||NONE||||||
33835161|NCT04845490|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|the choice of HIPEC drugs is unknown to patients with advanced colorectal cancer, but known to doctors, investigators and outcomes assessors.|We divide patients into 3 groups randomly. drug group 1: Radical Surgery + HIPEC (mitomycin) + mFOLFOX6/XELOX regimen; drug group 2: Radical Surgery + HIPEC (lobaplatin) + mFOLFOX6/XELOX regimen; control group: Radical Surgery + HIPEC (no drug) + mFOLFOX6/XELOX regimen|t|f|f|f
33835162|NCT04312256|NA|SINGLE_GROUP||OTHER||NONE||||||
33835163|NCT03113747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835164|NCT06445088|||COHORT||PROSPECTIVE|||||||
33835165|NCT00799019|||COHORT||PROSPECTIVE|||||||
33835166|NCT03502577|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835167|NCT00064649|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835168|NCT05802927|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33835169|NCT06062524|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835170|NCT01163474|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33835171|NCT03753243|NA|SINGLE_GROUP||TREATMENT||NONE||single arm, single-stage open label Phase II of neoadjuvant immune-hormonal therapy in high-risk Localized prostate cancer.||||
33835172|NCT04194047|||COHORT||PROSPECTIVE|||||||
33835173|NCT03576417|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835174|NCT05741190|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835175|NCT04107753|RANDOMIZED|PARALLEL||OTHER||SINGLE|Patients do not know in which group they were randomized|Patients in whom the inclusion criteria are met are asked by the triage nurses if they are smokers. Those patients are then asked by the triage nurses if they want to participate in the study; those who consent are randomized in the control or intervention group. The triage window of the software currently used for clinical care management in the ED (PsNet, Hi. Tech Spa) has been equiped in such a way that, for patients who agree to participate in the study, is casually print one of the two symbols on the informative consent paper given to patient in the end of the triage procedure.|t|f|f|f
33835176|NCT05558436|||COHORT||PROSPECTIVE|||||||
33835177|NCT03124693|NA|SINGLE_GROUP||OTHER||NONE||||||
33835178|NCT02738528|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835179|NCT04561947|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835180|NCT02083601|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835181|NCT05985720|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33835182|NCT00854204|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835183|NCT00005964|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835184|NCT01108315|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33835185|NCT00307268|||COHORT||PROSPECTIVE|||||||
33835186|NCT05445063|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835187|NCT00593021|||CASE_ONLY||PROSPECTIVE|||||||
33835188|NCT00147277|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835189|NCT05438836|||COHORT||PROSPECTIVE|||||||
33835190|NCT03774290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835191|NCT05333874|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||A pilot study to evaluating the role of ctDNA in patients with Stage II-III triple negative breast cancer and HER2 positive breast cancer. Participants who have ctDNA post neoadjuvant therapy and surgery will be initiated on adjuvant systemic therapy per treating physician's choice. ctDNA will be monitored up to 24 months to study ctDNA kinetics. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.||||
33835192|NCT00866489|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835193|NCT00781937|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835194|NCT01502592|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835195|NCT00127361|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835196|NCT03513068|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835197|NCT00633945|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835198|NCT04157322|||COHORT||PROSPECTIVE|||||||
33835199|NCT02812992|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835200|NCT04160377|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835201|NCT01296555|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835202|NCT00814008|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33835203|NCT03805477|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835204|NCT04821817|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|"* The patients will be blinded to their groups.~* An anesthesia resident who will not participate in the study and have no subsequent rule in it will help in the preparation of local anesthetic mixtures under strict aseptic precautions.~* The anesthetist who will perform the peribulbar block will be blinded to the local anesthetic mixtures he will inject.~* An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in a collection of the data of measurements"||t|t|t|t
33835205|NCT02547376|||CASE_ONLY||PROSPECTIVE|||||||
33835206|NCT00166062|RANDOMIZED|SINGLE_GROUP||||SINGLE||||||
33835207|NCT04689880|||COHORT||PROSPECTIVE|||||||
33835208|NCT05306249|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835209|NCT05276271|||CASE_CONTROL||RETROSPECTIVE|||||||
33835210|NCT05664789|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|The placebo compound will match the active N-acetylcysteine in appearance, odor, taste, and packaging.|Double-blind, randomized, placebo-controlled trial 2 arms, N-acetylcysteine and placebo|t|t|t|t
33835211|NCT03363347|||CASE_CONTROL||RETROSPECTIVE|||||||
33835212|NCT02337621|||COHORT||PROSPECTIVE|||||||
33835213|NCT04415827|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835214|NCT00172432|||CASE_CONTROL||PROSPECTIVE|||||||
33835215|NCT06031636|||CASE_ONLY||PROSPECTIVE|||||||
33835216|NCT01155414|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835217|NCT00092053|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835218|NCT06543563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835219|NCT03944590|||COHORT||PROSPECTIVE|||||||
33835220|NCT00566813|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835221|NCT01791777|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33835222|NCT02681770|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835223|NCT03181659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835224|NCT01726569|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835225|NCT00922168|||COHORT||PROSPECTIVE|||||||
33838973|NCT00763451|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838974|NCT01860599|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||f|f|f|t
33838975|NCT01348334|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33838976|NCT00672685|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33835226|NCT04034849|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|All patients were masked during all the trial. They wore protective glasses and were also advised to close their eyes during treatment. In addition, the laser was programmed not to emit any type of sound alarm. One clinician collected the Visual Analogue Scale and the questionnaires fulfilled by the patients and another clinician applied the laser treatment. All patients were warned of not speaking with the laser clinician.|Randomized single blind placebo controlled study|t|f|f|f
33835227|NCT02229227|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835228|NCT01931982|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|t|f
33835229|NCT04340934|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835230|NCT00000367||||PREVENTION||||||||
33835231|NCT01906619|||CASE_CONTROL||PROSPECTIVE|||||||
33835232|NCT01164111|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33835233|NCT05250427|||COHORT||CROSS_SECTIONAL|||||||
33835234|NCT01452165|||COHORT||PROSPECTIVE|||||||
33835235|NCT05920993|||COHORT||CROSS_SECTIONAL|||||||
33835236|NCT01889069|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835237|NCT03790709|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|There will be blinding procedures for this study. Capsules will be indistinguishable from active ingridient containing capsules.|Randomized 1:1:1 to two different ANAVEX2-73 doses or placebo|t|t|t|t
33835238|NCT05021744|||OTHER||PROSPECTIVE|||||||
33835239|NCT05631743|RANDOMIZED|PARALLEL||TREATMENT||NONE||The study design is a proof-of-concept, two-arm RCT with a VR-assisted therapist -guided psychotherapy and self-management.||||
33835240|NCT04700683|RANDOMIZED|CROSSOVER||DEVICE_FEASIBILITY||SINGLE|||t|f|f|f
33835241|NCT03034590|||COHORT||PROSPECTIVE|||||||
33835242|NCT00001046||PARALLEL||PREVENTION||||||||
33835243|NCT01357642|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835244|NCT02147847|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835245|NCT05072652|RANDOMIZED|PARALLEL||PREVENTION||NONE||Repeated measures design||||
33835246|NCT03836573|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member.||||
33835247|NCT05933785|||COHORT||RETROSPECTIVE|||||||
33835248|NCT01632410|||COHORT||PROSPECTIVE|||||||
33835249|NCT00824330|NA|SINGLE_GROUP||OTHER||NONE||||||
33835250|NCT02846064|NA|SINGLE_GROUP||OTHER||NONE||||||
33835251|NCT00008281||||TREATMENT||||||||
33835252|NCT04614090|||COHORT||RETROSPECTIVE|||||||
33835253|NCT00268372|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835254|NCT02842437|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835255|NCT03553381|||COHORT||PROSPECTIVE|||||||
33835256|NCT04669743|NA|SINGLE_GROUP||OTHER||NONE||Controlled inhalational challenge to ozone||||
33835257|NCT01077128|||||PROSPECTIVE|||||||
33835258|NCT01672593|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835259|NCT03035669|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
33835260|NCT01416675|||COHORT||PROSPECTIVE|||||||
33835261|NCT05030051|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835262|NCT04848831|||COHORT||PROSPECTIVE|||||||
33835263|NCT00726271|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835264|NCT05735665|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835265|NCT04831047|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33835266|NCT04796311|||CASE_CONTROL||PROSPECTIVE|||||||
33835267|NCT01142167|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33835268|NCT05236647|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835269|NCT04102046|||COHORT||CROSS_SECTIONAL|||||||
33835270|NCT00729638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835271|NCT04539223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Twenty-six week treatment with or without evolocumab in addition to current medical management.|f|f|f|t
33835272|NCT00727740|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835273|NCT00625300|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33835274|NCT03921307|||COHORT||RETROSPECTIVE|||||||
33835275|NCT01593930|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835276|NCT04199286|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835277|NCT04613245|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835278|NCT02901847|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33835279|NCT02568670|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835280|NCT04016012|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will receive a diabetic controlled diet using local Zambian foods for 8 weeks and standard health care for 8 weeks while the control group will eat their usual food in their home and receive standard health care for eight (8) weeks.||||
33835281|NCT06155097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blinded (patient and outcomes assessor)|The patients will be divided into 3 groups by a computer-generated randomization table|t|f|f|t
33835282|NCT05000047|||COHORT||CROSS_SECTIONAL|||||||
33835283|NCT03193463|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||"There will be 3 arms to this study, and they will accrue independently of each other as they reflect distinctly separable populations of patients with rHGG.~Arm 1: Predominantly enhancing mass with volume of 8 cc or less. Arm 2: Predominantly enhancing mass with volume of \> 8 cc Arm 3: Predominantly non-enhancing mass"||||
33835284|NCT02046512|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835285|NCT03453047|||OTHER||PROSPECTIVE|||||||
33835286|NCT04558164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835287|NCT02659098|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835288|NCT01341249|RANDOMIZED|CROSSOVER||||NONE||||||
33835289|NCT04403542|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||In this contralateral study, subjects will be randomized to wear the investigational lens in 1 eye and the control lens in the other eye.|t|f|t|f
33835290|NCT04429282|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835291|NCT02211547|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33835292|NCT02441868|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835293|NCT04420429|||COHORT||PROSPECTIVE|||||||
33835294|NCT04769375|||OTHER||CROSS_SECTIONAL|||||||
33835295|NCT05418413|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835296|NCT05790005|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||two groups, the Intervention group and the control group.||||
33835297|NCT02689570|||COHORT||CROSS_SECTIONAL|||||||
33835298|NCT00981539|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|t|f|f
33835299|NCT03181490|||COHORT||CROSS_SECTIONAL|||||||
33835300|NCT03122470|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835301|NCT01982409|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33835302|NCT04069585|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||Split-face design|t|t|t|f
33835303|NCT01175759|NON_RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33835304|NCT05182307|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33835305|NCT03998722|NA|SINGLE_GROUP||TREATMENT||NONE||An open single-armed study||||
33835306|NCT01913977|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835307|NCT00494468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835308|NCT04812743|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33835309|NCT00820261|||COHORT||PROSPECTIVE|||||||
33835310|NCT02634424|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33835311|NCT01850030|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835312|NCT04790864|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants are not aware that there are two different post-treatment exercises and are not informed that the aim of the EV condition is to promote expectancy violation.||t|f|f|f
33835313|NCT01910883|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33835314|NCT01137669|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33835315|NCT01082237|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835316|NCT04988776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33835317|NCT04321122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835318|NCT04955899|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33835319|NCT05655923|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||ozonized olive oil|t|t|t|t
33835320|NCT01896726|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835321|NCT00131105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33835322|NCT06229847|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835323|NCT01461889|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33835324|NCT05614518|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
33835325|NCT00316368|NON_RANDOMIZED|CROSSOVER||||NONE||||||
33835326|NCT06040229|||COHORT||RETROSPECTIVE|||||||
33835327|NCT02968615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835328|NCT01121705|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33835329|NCT01035853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835330|NCT04829123|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33835331|NCT02204020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835332|NCT05393089|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835333|NCT05688163|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835334|NCT01934751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835335|NCT03757871|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835336|NCT04832295|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835337|NCT04361383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double (Participant, Outcomes Assessor)|The patients will be divided randomly by a computer-generated randomization table into three equal groups|t|f|f|t
33835338|NCT01749254|||OTHER||PROSPECTIVE|||||||
33835339|NCT00794170|RANDOMIZED|PARALLEL||||NONE||||||
33835340|NCT02704039|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
33835341|NCT02934204|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835342|NCT06001151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835343|NCT04700059|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33835344|NCT06283342|||COHORT||PROSPECTIVE|||||||
33835345|NCT00798434|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835346|NCT03102489|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835347|NCT00466609|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835348|NCT05344677|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33835349|NCT06029777|||COHORT||RETROSPECTIVE|||||||
33835350|NCT02932553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835351|NCT01019239|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835352|NCT04554641|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835353|NCT05339347|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|We have two identical devices (a and b), that are equal in all aspects, but one of them is sham (does not product infrared (IR) light). As IR light is invisible for human eyes, neither the applicant of the procedure neither the participant will know if it is active or sham. All the participants had a code after randomization that does the allocation to sham or active. The machine (a or b) was chosen for an external researcher that has no contact with the team of the research.|"For the sham, the tip has LED light similar to the real one, but without generating the light field. The treatments will be administered in two sessions (active/sham) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LEDs, wavelength of 850 nm). The irradiation parameters created will be based on the skin phototype according to the Fitzpatrick Scale.~The tip will be positioned in the prefrontal cortex (corresponding to F3 and F4 according to the 10-20 EEG system). This arrangement is commonly known as 'Bifrontal'. In each application, power densities between 45-50 mW/cm², frequency of 10 Hz, and total time of 10 to 15 minutes per session will be used. The tip used has a size equivalent to 70cm² each side."|t|t|t|t
33835354|NCT01004523|||CASE_ONLY||RETROSPECTIVE|||||||
33835355|NCT01295203|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33835356|NCT01629043|||CASE_ONLY||PROSPECTIVE|||||||
33835357|NCT02807974|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835358|NCT04992754|||CASE_ONLY||PROSPECTIVE|||||||
33835359|NCT03815864|||COHORT||RETROSPECTIVE|||||||
33835360|NCT04814498|NA|SEQUENTIAL||TREATMENT||NONE||||||
33835361|NCT04367480|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33835362|NCT00002145||||TREATMENT||||||||
33835363|NCT04702516|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835364|NCT00380315|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835365|NCT04324216|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838977|NCT04578353|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838978|NCT00175539|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835366|NCT05261477|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|All families enrolled in the trial will receive follow-up telephone assessments at 3-, 6-, and 12-months after discharge from the hospital. Follow-up interviews will be conducted by research assistants from the Social Development Research Group, who will be blinded to participant's study group.|Intervention group will receive one in-person education session, bi-weekly video reviews tailored to the child's injury and therapies; and, 3 months of bilingual outpatient navigation, using three way calls to model and coach problem solving skills, with parents as active participants. Attention control group will receive one in person-education session, monthly non-TBI (Well-child) texts and usual institutional follow up care. Participants in the control group do not receive video education or patient navigation.|f|f|f|t
33835367|NCT02661633|||COHORT||PROSPECTIVE|||||||
33835368|NCT02094898|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835369|NCT02844777|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835370|NCT00351377|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835371|NCT05698732|||COHORT||PROSPECTIVE|||||||
33835372|NCT02162498|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33835373|NCT00925392|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33835374|NCT02286453|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835375|NCT06305442|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double blind|Double blind, randomized, parallel group, clinical trial|t|t|t|t
33835376|NCT05828758|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Enrolled children will be equally randomized into study and control group using computer generated numbers, which will be sealed into sequentially numbered opaque envelopes by a person not belonging to the research team. For each enrolled participant, the envelope in order will be opened, and the assigned study drug will be used. A pharmacist will fill the active and placebo preparations in similar containers with sealed code for identification. Participants' families, treating clinicians, and investigators will be unaware of group assignment and drug/placebo therapy.|"Two groups of children with enteral feeding intolerance:~Study group: will receive amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days. The nasogastric tube will be flushed by 5 ml distilled water after each dose.~Control group: will receive equal volume of distilled water (0.2 ml/kg + 5 ml) as a placebo."|t|t|t|t
33835377|NCT01080300|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835378|NCT00869947|NON_RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33835379|NCT01558817|RANDOMIZED|PARALLEL||||NONE||||||
33835380|NCT04325633|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835381|NCT02098447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835382|NCT00672451|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835383|NCT01446146|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33835384|NCT04670445|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33835385|NCT03463551|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835386|NCT02397447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835387|NCT04382846|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835388|NCT02127125|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835389|NCT01339767|||||PROSPECTIVE|||||||
33835390|NCT05907798|RANDOMIZED|PARALLEL||SCREENING||SINGLE|Patients will be randomly divided into 3 groups using the closed envelope method.|Randomized, single-blind, method comparison study|t|f|f|f
33835391|NCT02562157|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835392|NCT03960853|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33835393|NCT02221999|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835394|NCT01937975|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835395|NCT01115686|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835396|NCT04840342|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835397|NCT04394195|||COHORT||PROSPECTIVE|||||||
33835398|NCT01943682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835399|NCT02790879|||COHORT||PROSPECTIVE|||||||
33835400|NCT02383251|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835401|NCT05058053|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33835402|NCT03484494|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|The device is operated using subject-specific links on a laptop. The active or sham identity of the links is prepared automatically and not known to study staff or participants.|This is a sham controlled, randomized, double blinded crossover design study of immediate change to brain activity caused by Low Field Magnetic Stimulation.|t|t|t|f
33835403|NCT00980746|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835404|NCT01821105|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835405|NCT04665752|||COHORT||PROSPECTIVE|||||||
33835406|NCT05519553|RANDOMIZED|PARALLEL||OTHER||NONE|non applicable|a mixed methods randomized controlled trial||||
33835407|NCT01225497|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835408|NCT03614806|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||open label study prospective||||
33835409|NCT04374747|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Key laboratory analyses will conducted by laboratories blinded to intervention arm.||f|f|f|t
33835410|NCT00891033|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835411|NCT00380965|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835412|NCT01880242|||OTHER||PROSPECTIVE|||||||
33835413|NCT05918276|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835414|NCT05044923|NA|SINGLE_GROUP||TREATMENT||NONE||Single-site, single-are, non-blinded, non-randomized, interventional||||
33835415|NCT04218747|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835416|NCT01834612|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33835417|NCT04975503|||COHORT||CROSS_SECTIONAL|||||||
33835418|NCT06202053|||CASE_ONLY||PROSPECTIVE|||||||
33835419|NCT00730613|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835420|NCT01176630|||CASE_CONTROL||PROSPECTIVE|||||||
33835421|NCT00178347|||||RETROSPECTIVE|||||||
33835422|NCT01189110|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835423|NCT03035110|NA|SINGLE_GROUP||OTHER||NONE||||||
33835424|NCT00450918|||COHORT||PROSPECTIVE|||||||
33835425|NCT03673995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835426|NCT02816359|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835427|NCT03151746|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Blinded by using placebo or active drug supplied by Investigational Drug Pharmacy.|Double Blind, Randomized, Placebo Controlled Trial|t|t|t|t
33835428|NCT02592915|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33835429|NCT02137005|||COHORT||PROSPECTIVE|||||||
33835430|NCT05104255|||COHORT||RETROSPECTIVE|||||||
33835431|NCT02444468|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835432|NCT00703183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835433|NCT04527185|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33835434|NCT03751670|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are assigned to one of two groups in parallel for the duration of the study.||||
33835435|NCT02701062|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33835436|NCT02939846|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835437|NCT06016218|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33835438|NCT04978090|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33835439|NCT00460395|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835440|NCT02552017|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33835441|NCT03908892|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835442|NCT02294851|RANDOMIZED|SINGLE_GROUP||TREATMENT||TRIPLE|||t|f|t|t
33835443|NCT00220545|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835444|NCT04253847|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The participant will not know which group they are assigned to, but the surgeons know which group they were randomly assigned to.||t|f|f|f
33835445|NCT05331469|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835446|NCT00098527|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835447|NCT05688553|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835448|NCT01580904|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33835449|NCT00405938|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835450|NCT01263509|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835451|NCT04375553|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835452|NCT03132506|||OTHER||PROSPECTIVE|||||||
33835453|NCT03585088|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835454|NCT02039895|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835455|NCT02838134|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835456|NCT02301338|||COHORT||PROSPECTIVE|||||||
33835457|NCT01587690|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33835458|NCT02420249|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835459|NCT02016209|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835460|NCT06125158|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835461|NCT00989547|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835462|NCT04351269|||COHORT||RETROSPECTIVE|||||||
33835463|NCT01851707|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835464|NCT02619214|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835465|NCT02738905|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835466|NCT06544850|||CASE_CONTROL||PROSPECTIVE|||||||
33835467|NCT03600415|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Including a baseline assessment and assessments at Low altitude and High altitude||||
33835468|NCT01938053|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33835469|NCT06240429|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||QUADRUPLE||This is a single-center, randomized, double-blind, placebo-controlled, 12-week clinical trial involving adults over 55 years of age. Randomization of the participants will be performed by blocks of 4 participants, which will be randomized with the help of a specific software (www.random.org/sequences/), in a ratio of 1:1.|t|t|t|t
33835470|NCT05271968|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835471|NCT02130245|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835472|NCT02784743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835473|NCT00502502|||CASE_ONLY||PROSPECTIVE|||||||
33835474|NCT04601636|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835475|NCT00612118|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835476|NCT01840462|||CASE_CONTROL||PROSPECTIVE|||||||
33835477|NCT05631041|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835478|NCT05440604|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33835479|NCT01508338|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33835480|NCT03682185|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33835481|NCT00935532|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835482|NCT01044992|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||f|f|t|t
33835483|NCT04448145|||COHORT||PROSPECTIVE|||||||
33835484|NCT01613690|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33835485|NCT04597944|||COHORT||PROSPECTIVE|||||||
33835486|NCT05772143|||COHORT||PROSPECTIVE|||||||
33835487|NCT05490212|||COHORT||PROSPECTIVE|||||||
33835488|NCT04192864|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|This study was a single blinded trial, where the participants did not know the technique used in each side.|this study involved 20 patient with bilaterally mesially angulated impacted third molar (class II position B). One side was surgically removed using the lingually based triangular flap and the other side was surgically removed using the bucally based triangular flap|t|f|f|f
33835489|NCT05404555|||COHORT||PROSPECTIVE|||||||
33835490|NCT06360211|NA|SEQUENTIAL||OTHER||NONE||||||
33835491|NCT01546506|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835492|NCT04169191|NA|SINGLE_GROUP||TREATMENT||NONE||3+3 design to escalate the sildenafil dose up to 6 mg/kg/day (3mg/kg/dose q12h)||||
33835493|NCT02623660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835494|NCT02640105|||COHORT||PROSPECTIVE|||||||
33835495|NCT06544681|||COHORT||RETROSPECTIVE|||||||
33835496|NCT06474065|||CASE_CONTROL||PROSPECTIVE|||||||
33835497|NCT05321849|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33835498|NCT06182345|||COHORT||PROSPECTIVE|||||||
33835499|NCT05570812|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|This is a randomized, double-blind, placebo-controlled trial. All roles will be masked except the research pharmacist and statistician.|Participants will be randomized to receive oral pregnenolone or placebo.|t|t|t|t
33835500|NCT05338697|||COHORT||PROSPECTIVE|||||||
33838979|NCT04456387|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835501|NCT04003766|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|The pathologist will be blinded to the procedure received by the patient.|This is a randomized trial comparing two methods for procuring liver biopsy: 1) EUS-guided and 2) percutaneous.|f|t|f|f
33835502|NCT01963169|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835503|NCT03244969|||COHORT||PROSPECTIVE|||||||
33835504|NCT03176004|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|Research assistants assign participants to condition; the investigator is unaware of the assignment. Participants are unaware of the distinction between ABM and CC, though they would know if they were in the wait list group.|Adolescents are randomized to either a game that trains attention away from threat (attention bias modification), a game that trains attention but unrelated to threat (control condition), or a wait list group.|t|f|t|f
33835505|NCT01937169|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835506|NCT04455022|||OTHER||PROSPECTIVE|||||||
33835507|NCT01617499|||COHORT||PROSPECTIVE|||||||
33835508|NCT05144945|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Modified double-blind: A designated unblinded administrator administered the appropriate vaccine but was not involved in the immunogenicity and safety assessments.|In each age group (18-49 and \>= 50 years of age), participants were randomized in a 1:1 ratio to each of the vaccines.|t|t|t|t
33835509|NCT03314831|||COHORT||PROSPECTIVE|||||||
33835510|NCT03000790|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835511|NCT05671497|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835512|NCT04258683|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835513|NCT05390177|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||SINGLE|Participants are unaware which study condition they are in.|Participants from two age groups (young vs. older adults) will be compared for two experimental conditions. Although age group cannot be randomly assigned, the comparison between groups makes the design factorial.|t|f|f|f
33835514|NCT02295176|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835515|NCT04650698|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Neither the anesthesiologist or surgeon will be blinded to the patient's group assignment, as they will be the one performing the treatment. All other stakeholders (patient, other caregivers, and research staff collecting the data) will be blinded to the patient's group assignment.||t|t|f|f
33835516|NCT02747888|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||||||
33835517|NCT05291377|||OTHER||CROSS_SECTIONAL|||||||
33835518|NCT05825222|RANDOMIZED|PARALLEL||OTHER||TRIPLE|Stratified block randomization, Sequentially numbered, sealed, opaque envelopes|Randomized, Parallel Group, Placebo Controlled Trial|t|t|t|f
33835519|NCT05314270|||CASE_ONLY||RETROSPECTIVE|||||||
33835520|NCT02764099|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33835521|NCT01485120|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835522|NCT06171555|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"Group 1 Control Group: standard corticosteroid injection: 1cc of celestone (6mg) diluted with 1 cc of 1% lidocaine and inject at the ECRB origin at area of maximal pain when palpated.~Group 2 Test Group: CTM injection: 1cc of CTM Boost will be diluted with 1 cc of 1% lidocaine and injected at the ECRB origin at area of maximal pain when palpated. CTM Boost is a connective tissue matrix suspended in saline. (injection will need to be with a 23 gauge needle and 3 cc syringe)~Randomization will be through a computerized random allocation assigned by the Research Coordinator on the day of consent."|t|f|f|f
33835523|NCT01474629|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33835524|NCT04785001|||COHORT||PROSPECTIVE|||||||
33835525|NCT02641587|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33835526|NCT06533488|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33835527|NCT00531089|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835528|NCT04247698|||COHORT||RETROSPECTIVE|||||||
33835529|NCT00759642|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835530|NCT05317442|NA|SINGLE_GROUP||TREATMENT||NONE||"1. Uncontrolled~2. Open-label~3. Randomized: N/A~4. Single Arm~5. Duration of treatment: up to 16 weeks~6. Titration: no~7. Multi-center(Taiwan)"||||
33835531|NCT02949245|||CASE_ONLY||PROSPECTIVE|||||||
33835532|NCT05654233|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||A total of 120 patients with varicose veins who received radiofrequency ablation combined with sclerotherapy were randomly divided into two groups。 Each group included 60 people, one group added sulodexide based on the conventional treatment process, and the other group was a control group. The recovery of adverse reactions after surgery in both groups was observed.|t|f|f|f
33835533|NCT05730491|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants are not informed of their condition assignment and both receive online programs focused on healthy child behaviors. Investigators are blinded \& masked to study condition, and all outcomes are assessed via self-reported REDCap surveys. Care providers are not involved in the study (N/A).|Participants will be randomized to either an attention educational control website or social learning cognitive behavioral therapy (SLCBT) prevention intervention. A control arm is necessary in order to evaluate the efficacy of the SLCBT intervention.|t|f|t|t
33835534|NCT00987662|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33835535|NCT05251675|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
33835536|NCT01693835|||CASE_CONTROL||PROSPECTIVE|||||||
33835537|NCT00000685||||TREATMENT||NONE||||||
33835538|NCT03795857|||OTHER||PROSPECTIVE|||||||
33835539|NCT04584671|||COHORT||PROSPECTIVE|||||||
33835540|NCT00979290|||CASE_CONTROL||PROSPECTIVE|||||||
33835541|NCT00778232|RANDOMIZED|CROSSOVER||||NONE||||||
33835542|NCT04830189|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients were assigned to two groups, shoulder supported slings (group 1, n = 20) and forearm supported slings (group 2, n = 20), by an investigator who was blinded to the study via randomization created by a computer software. Evaluation of the detailed physical examination results, evaluation of demographic features such as age, gender, and etiology as well as evaluation of treatment results were performed by the physiatrist who was blind to randomization.|f|f|t|f
33835543|NCT02762188|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835544|NCT02694042|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33835545|NCT06417762|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|De-identified information to data analysis.The list that links the study code to each participant's personal information will be kept completely separate from the de-identified database.|Step wedge|f|f|f|t
33835546|NCT01079910|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835547|NCT05692583|||COHORT||PROSPECTIVE|||||||
33835548|NCT05518695|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|Double-Blind||t|t|t|t
33835549|NCT00122486|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33835550|NCT00497666|||CASE_CONTROL||OTHER|||||||
33835551|NCT01673789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835552|NCT02484586|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33835553|NCT00172692|||||OTHER|||||||
33835554|NCT04411186|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835555|NCT00000770||||TREATMENT||DOUBLE||||||
33835556|NCT05174533|||CASE_ONLY||PROSPECTIVE|||||||
33835557|NCT00891553|||||PROSPECTIVE|||||||
33835558|NCT04250753|||COHORT||PROSPECTIVE|||||||
33835559|NCT01509261|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835560|NCT01611961|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835561|NCT03674775|RANDOMIZED|PARALLEL||TREATMENT||NONE||cluster randomized control trial||||
33835562|NCT03135990|NA|SINGLE_GROUP||TREATMENT||NONE||Cognitive Behavioral Therapy||||
33835563|NCT01197612|NA|SINGLE_GROUP||TREATMENT||TRIPLE|||t|t|t|f
33835564|NCT02430753|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33835565|NCT01139359|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835566|NCT00121667|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835567|NCT04432792|||COHORT||PROSPECTIVE|||||||
33835568|NCT05506423|||COHORT||PROSPECTIVE|||||||
33835569|NCT02623998|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835570|NCT03174665|||COHORT||RETROSPECTIVE|||||||
33835571|NCT01437423|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33835572|NCT00005593|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835573|NCT00629005|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835574|NCT03567044|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835575|NCT06497803|RANDOMIZED|PARALLEL||PREVENTION||NONE||This study is parallel group randomized controlled study.||||
33835576|NCT05878912|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835577|NCT03854357|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835578|NCT00150618|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33835579|NCT05250765|RANDOMIZED|PARALLEL||TREATMENT||NONE||4 study groups are possible (2 types of retainers and 2 types of bonding protocol)||||
33835580|NCT03353597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835581|NCT04470947|||COHORT||PROSPECTIVE|||||||
33835582|NCT00958711|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835583|NCT05262010|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835584|NCT02263040|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835585|NCT02924597|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33835586|NCT04949802|NA|SINGLE_GROUP||TREATMENT||NONE|observer-masked|||||
33835587|NCT00307047|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835588|NCT00279188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33835589|NCT06430333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33835590|NCT00234897|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33835591|NCT05730309|NA|SINGLE_GROUP||PREVENTION||NONE||From the prospective cohort enrolled in Aim 1, after performing the POCUS study, we will offer subjects with LVH on POCUS the three-element intervention (disclosure regarding presence of LVH, pre-specified discharge instruction and referral). Subjects without LVH on POCUS will receive usual ED care and pre-specified discharge instructions about high blood pressure.||||
33835592|NCT04205747|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33835593|NCT01193010|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835594|NCT01782729|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835595|NCT00890292|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835596|NCT04216888|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835597|NCT03197766|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835598|NCT00960362|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33835599|NCT02313337|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835600|NCT05096039|||COHORT||RETROSPECTIVE|||||||
33835601|NCT01964846|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|f|t|t
33835602|NCT04197076|||COHORT||PROSPECTIVE|||||||
33835603|NCT02884037|||COHORT||PROSPECTIVE|||||||
33835604|NCT04547777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835605|NCT02432651|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
33835606|NCT03948906|||COHORT||PROSPECTIVE|||||||
33835607|NCT02272829|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835608|NCT02312557|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835609|NCT03804606|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|t|f|f
33835610|NCT03772769|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835611|NCT01949181|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835612|NCT00770588|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835613|NCT01906697|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835614|NCT00851565|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835615|NCT04969705|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835616|NCT05201053|||COHORT||PROSPECTIVE|||||||
33835617|NCT03570762|||COHORT||RETROSPECTIVE|||||||
33835618|NCT01202799|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33835619|NCT01191008|||CASE_ONLY||PROSPECTIVE|||||||
33835620|NCT02514551|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835621|NCT01173978|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||SINGLE|||t|f|f|f
33835622|NCT01895036|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835623|NCT03827447|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|After enrollment, patients will be randomized to treatment with vancomycin 125 mg capsules by mouth every 6 hours for 14 days or to placebo with identical looking capsules for the same length of treatment. Block randomization will be used to assign patients to the treatment or placebo arms. Randomized assignments will be placed in sealed envelopes which will only be handled by the research pharmacist. Clinical providers, research team, and patients will remain blinded to allocation|Patients will be divided into 2 groups, one receiving oral vancomycin and the other placebo.|t|t|t|f
33835624|NCT04168281|NA|SINGLE_GROUP||OTHER||NONE||deescalation of treatment - watchful observation instead of Whole Brain Irradiation||||
33835625|NCT03338439|||COHORT||RETROSPECTIVE|||||||
33835626|NCT05005702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835627|NCT00932971|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835628|NCT03585777|||CASE_CONTROL||PROSPECTIVE|||||||
33835629|NCT02045290|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835630|NCT02768883|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE|||f|f|f|t
33835631|NCT02464605|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835632|NCT00517049|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835633|NCT02134509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835634|NCT02480699|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835635|NCT03378037|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835636|NCT00000177|RANDOMIZED|||TREATMENT||DOUBLE||||||
33835637|NCT01749852|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33835638|NCT06064747|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|In order to ensure the blind method, the sham stimulation coil was used, which had the same parameters (including location, stimulation frequency, time, etc.) as the LF-rTMS group, and had the same stimulation sound to ensure no effective stimulation, to ensure the blind state is maintained during the test. Investigators and patients who participated in the study treatment or involved in the clinical evaluation of patients were blinded to treatment grouping.||t|f|t|t
33835639|NCT02531854|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835640|NCT00880022|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835641|NCT00589537|RANDOMIZED|||DIAGNOSTIC||||||||
33835642|NCT04016116|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835643|NCT03452865|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835644|NCT03784820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Participants will be randomized to either couple therapy (UNITE) or individual therapy (CBT-E) for binge-eating disorder and will receive 16 1-hour sessions of the respective treatment. All study hypotheses will be tested using recommended Intent-To-Treat (ITT) methods. Differential treatment effects in individual functioning variables will be tested using 2 (time) x 2 (treatment) mixed-effect ANOVAs for binge-purge frequency and eating disorder outcomes and 2 (partner) x 3 (time) x 2 (treatment) mixed-effect ANOVAs for psychological outcomes. (Some variables will have 4 time points). Differential treatment effects in target relationship variables will be tested using 2 (partner) x 2 (time) x 2 (treatment) mixed-effect ANOVAs for all outcomes except vocally encoded emotional arousal. Differential treatment effects of vocally encoded emotional arousal will be tested using repeated-measures Actor Partner Interdependence Models (RM-APIMS).|f|f|f|t
33835645|NCT03126110|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835646|NCT05683145|RANDOMIZED|PARALLEL||TREATMENT||NONE||parallel, two-arm, randomized control trial||||
33835647|NCT01896180|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835648|NCT02901769|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33835649|NCT02296749|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835650|NCT00950482|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835651|NCT02803281|||COHORT||PROSPECTIVE|||||||
33835652|NCT02184403|||COHORT||PROSPECTIVE|||||||
33835653|NCT01921647|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33835654|NCT03455244|||COHORT||PROSPECTIVE|||||||
33835655|NCT00731133|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835656|NCT02669615|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835657|NCT01479270|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33835658|NCT03573869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835659|NCT00926081|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835660|NCT04476212|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|There will be masking for the patient, for the surgeon responsible for the case, for the investigator responsible for each study, for the coordinator of the center and for the main investigator. After the closure of the abdominal fascia, the patients will be randomized to one of the study groups. The circulating nurse will open the randomization envelope and prepare the solution indicated on the outside of the operating room. He/she will record the case on the database and will be the only person with knowledge of the group allocation of the case.|It is a randomized, controlled, multicenter, blind study by observer and patient, with two parallel study groups, phase IV. The irrigation of the wound with 0.9% physiological serum will be compared with the irrigation with a solution of amoxicillin-clavulanate, administered topically and dissolved in saline.|t|t|t|f
33835661|NCT05334043|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Subjects will be given test preparation (A) or control preparation (B) on the first day of the first cycle. After a 7-day washout period, on the 8th day of the second cycle, subjects will be cross-administered with the control preparation (B) or test preparation (A)||||
33835662|NCT06423651|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This will be a randomized clinical trial in which one group will receive combined REHACOP + MCT therapy and another group will receive therapy with MCT alone. The metacognitive treatment will have the same characteristics in the two treatment conditions. Randomisation of the patients for receiving one of the two treatments will be carried out using a random number list based on the order of access to their reference centre. The evaluator will be blinded to the treatment group to which the patient assessed belongs.|t|f|t|t
33835663|NCT00303927||||TREATMENT||NONE||||||
33835664|NCT06239233|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835665|NCT05696132|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835666|NCT03374293|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835667|NCT00388804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835668|NCT02735304|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33835669|NCT05347017|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835670|NCT00967005|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835671|NCT00848822|||COHORT||PROSPECTIVE|||||||
33835672|NCT00208325|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835673|NCT00826332|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835674|NCT06531304|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Clinical/Functional evaluation of patients will be performed by expert physiotherapists blinded to group allocation.~Data analysis (EEG, EMG, Kinematic, Kientic) will be performed by neuroscientists blinded to group allocation."||f|f|f|t
33835675|NCT00197223|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835676|NCT00986596|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835677|NCT02793310|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835678|NCT06050564|||COHORT||CROSS_SECTIONAL|||||||
33835679|NCT00303706|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835680|NCT05879237|RANDOMIZED|PARALLEL||TREATMENT||NONE||To study the efficacy of vitamin D in conjunction with Helicobacter pylori treatment in children in eradication of helicobacter pylori.||||
33835681|NCT05987254|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33835682|NCT02331199|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835683|NCT02593123|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835684|NCT00422734|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835685|NCT02839785|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33835686|NCT00872053|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835687|NCT00003664||||TREATMENT||||||||
33835688|NCT02820597|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835689|NCT01766713|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835690|NCT00206297|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835691|NCT03044977|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||dose-escalation design||||
33835692|NCT00302094|||COHORT||PROSPECTIVE|||||||
33835693|NCT01850537|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835694|NCT04554537|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835695|NCT04925869|||OTHER||PROSPECTIVE|||||||
33835696|NCT01216072|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835697|NCT01719510|NA|SINGLE_GROUP||SCREENING||NONE||||||
33835698|NCT04490785|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835699|NCT02320526|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835700|NCT01301365|||COHORT||PROSPECTIVE|||||||
33835701|NCT00005599||||TREATMENT||NONE||||||
33835702|NCT03298269|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835703|NCT00676104|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33835704|NCT03023722|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835705|NCT04232267|||COHORT||PROSPECTIVE|||||||
33835706|NCT04029805|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835707|NCT02281123|||COHORT||PROSPECTIVE|||||||
33835708|NCT06243237|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33835709|NCT01267669|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835710|NCT05469724|||COHORT||PROSPECTIVE|||||||
33835711|NCT04883112|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33835712|NCT02339623|||CASE_ONLY||PROSPECTIVE|||||||
33835713|NCT05976776|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomized-controlled trial with pretest-posttest control group||||
33835714|NCT04370015|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Double blinding|parallel assignment|t|t|t|t
33835715|NCT03482752|NA|SINGLE_GROUP||TREATMENT||NONE||Open label, non-controlled.||||
33835716|NCT04415853|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835717|NCT05575297|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33835718|NCT00597142|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835719|NCT05203341|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835720|NCT05000905|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Forty participants will be randomized to the Engage intervention (30-session) or low-dose (2-session). Individuals in each active arm will be matched on age and gender.~An additional thirty participants will be enrolled separately (not randomized) into the no-contact group."||t|f|t|t
33835721|NCT05671354|NA|SINGLE_GROUP||PREVENTION||NONE||The participants will be trained by the care staff to use the auto-wrapping commode chair. They will use the auto-wrapping commode chair for 7 days. The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the previous 7 days before the trial, will dispose of the excretions from the auto-wrapping commode chairs during the trial.||||
33835722|NCT06234176|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||"Experimental Group: Personalised psychomotor therapy: 1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale.~The sessions will be based on static and dynamic body exercises involving muscle relaxation, breathing, sensations and moving the body.~Control Group: Usual care for 12 weeks with a weekly telephone interview + Duke's Health Scale."||||
33835723|NCT01809015|||COHORT||PROSPECTIVE|||||||
33835724|NCT04800939|RANDOMIZED|PARALLEL||OTHER||SINGLE|"According to the randomization table, the information showing the nurses included in the research sample is assigned to the A and B groups will be put in an opaque envelope. This envelope will be kept by the coordinator researcher (GAU) when the researcher (TÇY), who has an acupressure application certificate, goes to the nurse's application. After filling out the Informed Consent Form, he will open the envelope and learn which group the nurse is in. Since all nurses included in the study will be applied to the compression point, the participants will be blinded because they do not know that they are a study or control group. The researcher (TÇY), on the other hand, cannot be blinded due to the nature of the research. A statistician will analyze the data, and the findings will be reported."|Prospective, parallel, two-arm, randomized controlled clinical trial|t|f|f|f
33835725|NCT00073398|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835726|NCT05416567|NA|SINGLE_GROUP||TREATMENT||NONE||Historical controls from a regional brain tumor registry||||
33835727|NCT05144399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835728|NCT03024892|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835729|NCT06361862|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33835730|NCT04600986|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33835731|NCT06344468|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|t|f|t
33835732|NCT00582322|||CASE_ONLY||PROSPECTIVE|||||||
33837676|NCT04648137|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE||Randomized, double-blind, placebo-controlled, cross-over (MDMA versus placebo, within subject comparison) study in patients with central diabetes insipidus versus healthy controls (between-subject comparison). Participants will be randomized to receive either first placebo or first MDMA, respectively.|t|f|t|f
33837677|NCT00126698|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33837678|NCT00251342|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33835733|NCT03767972|NA|SINGLE_GROUP||TREATMENT||NONE||This is a prospective clinical trial to compare various energy-based devices for the rejuvenation of the face, neck/décolletage, hands, upper and lower extremities and vagina. Adults seeking rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will be treated with appropriate energy-based device(s) based on investigators' discretion. If patients' require rejuvenation of multiple areas, per investigator assessment, they will be allowed to get treatment in multiple areas. Patients will be followed for 3 months post-treatment to determine if the procedure was efficacious for rejuvenation of the area(s) treated.||||
33835734|NCT02349945|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33835735|NCT01165619|||COHORT||CROSS_SECTIONAL|||||||
33835736|NCT00455845|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33835737|NCT02392104|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835738|NCT00004068||||TREATMENT||||||||
33835739|NCT03694977|NA|SINGLE_GROUP||TREATMENT||NONE||MCS110/PDR001 combination||||
33835740|NCT06445400|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835741|NCT00157027|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835742|NCT01397279|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33835743|NCT04154800|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Parts A,B,(Participant, Care Provider, Investigator) Part C is open-labeled and a cross- over design||t|t|t|t
33835744|NCT00979953|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835745|NCT00855413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835746|NCT01389089|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835747|NCT02034162|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835748|NCT03158909|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33835749|NCT03688776|RANDOMIZED|CROSSOVER||OTHER||SINGLE|||t|f|f|f
33835750|NCT04746885|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|t|f|f
33835751|NCT02012023|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33835752|NCT05176366|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835753|NCT00894504|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835754|NCT01543997|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835755|NCT01603433|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835756|NCT05347472|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33835757|NCT00560144|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835758|NCT02715141|||COHORT||PROSPECTIVE|||||||
33835759|NCT04766190|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||"The research tests the effectiveness of an application-based (app) communication intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions during clinical interactions, and associated measures."||||
33835760|NCT00284193|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835761|NCT00322569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835762|NCT02595320|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835763|NCT00316433|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835764|NCT00092183|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835765|NCT00349466|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835766|NCT04463680|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835767|NCT02523547|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835768|NCT00711308|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835769|NCT01224470|RANDOMIZED|PARALLEL||||QUADRUPLE|||t|t|t|t
33835770|NCT02245646|||CASE_CONTROL||PROSPECTIVE|||||||
33835771|NCT06154928|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||This single-center randomized controlled study, conducted between January 15 and May 15, 2022, comprised 100 patients equally divided into the Water Group (WG) and Control Group (CG). Patients in the WG were allowed to take warm water orally during the 2nd postoperative hour without waiting for the onset of bowel sounds or flatus while those in the CG were not. GI functions were evaluated at 2, 4, 8, and 12 postoperative hours and the findings were recorded.||||
33835772|NCT04082351|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835773|NCT06035081|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33835774|NCT04834713|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33835775|NCT00452231|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
33835776|NCT02834299|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33835777|NCT04729205|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||There will be up to two cohorts, with six subjects per cohort. Eligible subjects will be consecutively assigned, in order of accrual, to receive three cycles of PROMITIL-FOLFOX treatment. Dosing regimens will begin with cohort 1 (PROMITIL dose of 1.6 mg/kg).Dose limiting toxicity (DLT) for the combination treatment will be considered cleared if fewer than two patients per cohort experience DLT events during the first two cycles of treatment. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued.||||
33835778|NCT00955890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835779|NCT00133575|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33835780|NCT03091816|||CASE_ONLY||PROSPECTIVE|||||||
33835781|NCT01862497|||COHORT||CROSS_SECTIONAL|||||||
33835782|NCT05693077|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|The trial is double-blind, placebo-controlled.|The trial consists of two or, if necessary, three consecutive intervention phases with each three parallel intervention arms. The first phase consists 24 volunteers, the second phase of 23 or 26 volunteers, and the optional third phase of another 23 volunteers. The volunteers will be divided over three intervention arms.|t|t|t|t
33835783|NCT06454045|||CASE_CONTROL||PROSPECTIVE|||||||
33835784|NCT00383123|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33835785|NCT05225987|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33835786|NCT00260377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835787|NCT01526837|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835788|NCT05317676|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33835789|NCT03821467|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835790|NCT00065624|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33835791|NCT01913262|||COHORT||PROSPECTIVE|||||||
33835792|NCT01551797|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835793|NCT03814304|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Study personnel administering tDCS and the participants will not be aware of tDCS intervention arm assignment. The investigators will ensure such double-blinding by programming the tDCS software with intervention-specific stimulation codes, as supplied by personnel uninvolved in data collection, prior to study initiation.|The investigators will conduct a single site, sham-controlled, double-blinded, randomized trial of tDCS. Participants will perform baseline functional assessments, as well as a structural MRI of the brain. They will then be assigned to a four-week, 20-session intervention of either personalized tDCS or sham (i.e., control) stimulation, via permuted block randomization stratified by sex to ensure that equal numbers of women, and equal numbers of men, are randomized to each arm.|t|f|t|t
33835794|NCT06012708|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33835795|NCT05012540|||COHORT||RETROSPECTIVE|||||||
33835796|NCT01131104|||CASE_CROSSOVER||PROSPECTIVE|||||||
33835797|NCT02811718|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835798|NCT05965882|||COHORT||RETROSPECTIVE|||||||
33835799|NCT01151215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835800|NCT01436305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835801|NCT03444740|||COHORT||CROSS_SECTIONAL|||||||
33835802|NCT03375736|NA|SINGLE_GROUP||TREATMENT||NONE||The study participants would receive 4 weeks of whole body vibration therapy, 4 sessions per week for 18 minutes per session.||||
33835803|NCT02264119|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835804|NCT01508663|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835805|NCT00305344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835806|NCT05603364|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33835807|NCT02165553|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
33835808|NCT01551368|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835809|NCT02332902|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835810|NCT00502268|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33835811|NCT01882764|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835812|NCT05396508|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835813|NCT04515407|NA|SINGLE_GROUP||OTHER||DOUBLE|Participants will be informed only that three conditions are being delivered and tested. The outcomes assessor will be provided only session (e.g., 1, 2, 3) information without knowledge of the condition experienced in that session.|All participants will receive PAS in all three experimental conditions. Each condition will be delivered in a separate session. Sessions will be separated by one week. The order of conditions will be counterbalanced across subjects.|t|f|f|t
33835814|NCT06450236|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33835815|NCT00547534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835816|NCT03792490|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835817|NCT04249011|||OTHER||PROSPECTIVE|||||||
33835818|NCT01065467|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835819|NCT04588766|||CASE_CONTROL||PROSPECTIVE|||||||
33835820|NCT04337671|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33835821|NCT05389605|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835822|NCT02043743|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835823|NCT05585645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835824|NCT03815370|RANDOMIZED|PARALLEL||TREATMENT||NONE|It is impossible for the participant or anyone within the patients circle of care to be blinded in this study, as it is clear if the abdominal binder is on the participant or not. There is no way to blind in this interventional study.|The purpose of this study is to compare usual care (vacuum or non-vacuum methods for temporary coverage of the OA) versus usual care plus the new abdominal binder device called ABRO™.||||
33835825|NCT01731262|||CASE_CONTROL|||||||||
33835826|NCT00509132|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33835827|NCT02688530|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33835828|NCT05775783|||COHORT||PROSPECTIVE|||||||
33835829|NCT05502822|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835830|NCT03985436|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33835831|NCT03242902|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835832|NCT00947947|RANDOMIZED|SINGLE_GROUP||PREVENTION||SINGLE|||f|f|t|f
33835833|NCT00385099|RANDOMIZED|CROSSOVER||TREATMENT||||||||
33835834|NCT04187859|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835835|NCT02876042|||COHORT||PROSPECTIVE|||||||
33835836|NCT02593383|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835837|NCT03755973|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||All consenting subjects will first undergo an endometrial biopsy seven days after the luteinizing hormone (LH) peak in an unmedicated natural cycle. This biopsy will serve as the baseline endometrial biopsy (natural cycle biopsy) for the gene expression signature analysis. Following this baseline biopsy, the subjects will be randomly allocated to a specific type of ovarian stimulation regimen in order to later perform some second endometrial biopsy, five days after oocyte retrieval (stimulated cycle biopsy).||||
33835838|NCT04936685|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835839|NCT01744704|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33835840|NCT00651898|||COHORT|||||||||
33835841|NCT03774147|||CASE_ONLY||PROSPECTIVE|||||||
33835842|NCT05835076|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835843|NCT03851081|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835844|NCT03078335|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|The final adjudication of events will be completed by two of the investigators blinded to study arm, based on a summary report of each event after completion of the pilot.|This pilot study is a single centre NICU based cluster-randomized crossover trial, with 2 crossover periods each lasting 6 months, and a 2-week washout period in between.|f|f|f|t
33835845|NCT00325598|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835846|NCT05020145|||COHORT||RETROSPECTIVE|||||||
33835847|NCT05536206|||COHORT||PROSPECTIVE|||||||
33835848|NCT04936867|||COHORT||PROSPECTIVE|||||||
33835849|NCT05219838|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835850|NCT05864404|RANDOMIZED|PARALLEL||OTHER||QUADRUPLE|||t|t|t|t
33835851|NCT04036851|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||f|f|t|t
33835852|NCT02740738|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835853|NCT05037747|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||It was non-randomized trial study design, two parallel groups were assigned to time-restricted feeding(TRF) and control group and to do the intervention for 12 weeks.||||
33835854|NCT05859490|NA|SINGLE_GROUP||PREVENTION||NONE||All subjects receive the same intervention.||||
33835855|NCT00592189|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835856|NCT05257447|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||The study will have a randomized, single-dose, 3-way crossover design, with at least one week elapsing between the 3 trials of the study. The sequence of administration is based on a randomization code.||||
33835857|NCT03209869|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835858|NCT02615509|NA|SINGLE_GROUP||SCREENING||NONE||||||
33835859|NCT01573949|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835860|NCT01864460|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33835861|NCT01675349|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33835862|NCT02737813|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835863|NCT01948076|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33835864|NCT06337487|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients, nurses and health professionals and professionals assimilated to the health are recruited in 3 different groups but no comparison will be made between them. Recruitment of patients will be stopped once 79 analyzable patients will be enrolled.||||
33835865|NCT06251999|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835866|NCT03752086|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||f|t|t|t
33835867|NCT05202756|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835868|NCT06315920|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The masking process involves the following steps:~Preparation of Medication: A nurse, who is not involved in the direct care or assessment of the patients, will prepare the medications. This nurse is the only individual aware of the specific treatment being administered to each patient. The medications are prepared in a manner that makes them indistinguishable from each other in appearance, labeling, and administration method.~Administration of Medication: The medications are then administered to the patients by healthcare providers who are blinded to the nature of the medication. This ensures that their assessment of the patient's response is not influenced by knowledge of the treatment being given.~Assessment and Data Collection: The assessment of pain relief, side effects, and other relevant clinical outcomes is conducted by healthcare providers who are blinded to the treatment allocation. This minimizes bias in the evaluation of the treatment's efficacy and safety."||t|t|t|t
33835869|NCT00203034|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835870|NCT00709397|||COHORT||PROSPECTIVE|||||||
33835871|NCT01122563|||CASE_ONLY||PROSPECTIVE|||||||
33835872|NCT06232447|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||All participants will be asked to switch to smoking non-menthol cigarettes for four weeks.||||
33835873|NCT01765062|||COHORT||PROSPECTIVE|||||||
33835874|NCT00040417|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835875|NCT01517204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33835876|NCT04419727|||COHORT||PROSPECTIVE|||||||
33835877|NCT02078492|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835878|NCT00667459|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835879|NCT02536742|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835880|NCT00839956|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835881|NCT03542110|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835882|NCT02987647|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835883|NCT06273618|RANDOMIZED|PARALLEL||OTHER||NONE||Early Childhood Professionals (ECPs) will be randomized to 1 of 4 groups, which will differ in terms of when they receive access to Micro-Learning. Non-ECPs will constitute a separate group, which will receive access to Micro-Learning immediately upon completing the Core Training.||||
33835884|NCT02322086|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835885|NCT03482362|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a two-stage, single-arm, multi-center, open-label, two-cohort, clinical, phase II, proof of principal study.||||
33835886|NCT04625010|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Prospective, randomized controlled trial||||
33835887|NCT04224168|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
33835888|NCT03345745|||CASE_CONTROL||PROSPECTIVE|||||||
33835889|NCT04456244|||OTHER||CROSS_SECTIONAL|||||||
33835890|NCT00334542|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33835891|NCT05508269|||COHORT||PROSPECTIVE|||||||
33835892|NCT03322553|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double blinded|Randomized, Double blinded, sham controlled trial|t|f|t|f
33835893|NCT05828836|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835894|NCT01107899|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835895|NCT00736411|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835896|NCT00616317|||COHORT||RETROSPECTIVE|||||||
33835897|NCT06141720|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33835898|NCT05025462|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|double blind||t|t|t|t
33835899|NCT04669769|||COHORT||RETROSPECTIVE|||||||
33835900|NCT00900263|||COHORT||PROSPECTIVE|||||||
33835901|NCT04710199|RANDOMIZED|PARALLEL||TREATMENT||NONE||In this clinical trial, standard treatment together with Maraviroc (MVC) is evaluated compared to treatment alone.||||
33835902|NCT02450695|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33835903|NCT04721769|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants and guardians of participants will not know which arm the participant is randomized to. Regarding care providers, only care providers performing the surgery will be privy to information regarding which arm the patient is randomized to.|We have two patient groups. Group 1: Endoscopic strip craniectomy with the use of lateral osteotomies. Group 2: Endoscopic strip craniectomy without the use of lateral osteotomies.|t|t|f|t
33835904|NCT02638597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835905|NCT01833689|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33835906|NCT00929253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835907|NCT00905047|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835908|NCT00537121|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835909|NCT00645580|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835910|NCT02718222|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||NONE||||||
33835911|NCT02768597|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835912|NCT02727153|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835913|NCT06237777|NA|SEQUENTIAL||TREATMENT||NONE||||||
33835914|NCT03334253|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Cycloplegic autorefraction, axial length, and additional biometry will be measured by a masked examiner at all follow-up visits using the same instrumentation on the participant throughout the study. Masking will be accomplished by having site personnel administer cyclopentolate to both eyes of each participant and wait 30 minutes before he/she sees the masked examiner. The masked examiner may be a technician or an investigator and must be certified to complete these measurements. Parents, patients, and investigators are also masked to treatment.|The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.|t|f|t|t
33835915|NCT02645123|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835916|NCT01342432|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33835917|NCT06381167|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33835918|NCT03663907|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33835919|NCT03499561|||COHORT||PROSPECTIVE|||||||
33835920|NCT04115189|||OTHER||RETROSPECTIVE|||||||
33835921|NCT00458276|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835922|NCT02876848|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33835923|NCT05729776|||CASE_CONTROL||PROSPECTIVE|||||||
33835924|NCT04820998|||CASE_ONLY||PROSPECTIVE|||||||
33835925|NCT02429908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835926|NCT06427733|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33835927|NCT00416598|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835928|NCT00263211|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835929|NCT03709108|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33835930|NCT03352154|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|Not Apply|Verify the alteration of the latency and amplitude of the P300 as markers of the cognitive response after Cochlear Implant Assist in prognosis after implantation cochlear implant.||||
33835931|NCT04857567|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33835932|NCT02691988|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835933|NCT03067545|NA|SINGLE_GROUP||TREATMENT||NONE||single subject repeated measures design||||
33835934|NCT01806012|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835935|NCT01986114|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835936|NCT04262206|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE||Randomized 1:1 atorvastatin 40mg vs. placebo|t|t|t|f
33835937|NCT04596995|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835938|NCT00577135|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
33835939|NCT01237210|||OTHER||PROSPECTIVE|||||||
33835940|NCT04865042|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33835941|NCT02145845|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835942|NCT03126890|||OTHER||PROSPECTIVE|||||||
33835943|NCT03080493|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized placebo controlled trial, stratified block randomization based on prior vaginal parity (vaginal parity - yes or no). Goal of even distribution of prior vaginal parity between gabapentin and placebo groups as may impact osmotic dilator pain experience|t|t|t|t
33835944|NCT01124071|RANDOMIZED|PARALLEL||||NONE||||||
33835945|NCT02926287|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33835946|NCT04583644|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835947|NCT03832972|||COHORT||CROSS_SECTIONAL|||||||
33835948|NCT05269862|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835949|NCT00478205|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33835950|NCT02570997|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33835951|NCT03550079|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835952|NCT00563407|||COHORT||PROSPECTIVE|||||||
33835953|NCT00924222|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835954|NCT03194997|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE||A randomized clinical trial, three-arm study (group 1 - Dance; group 2 - Pilates and group 3 - Control), single-blinded.|f|f|f|t
33835955|NCT04028817|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33835956|NCT03441100|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835957|NCT03890198|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835958|NCT06087575|NA|SINGLE_GROUP||TREATMENT||NONE||The study is a prospective, non-randomized, single-arm, multicenter, feasibility study||||
33835959|NCT01732549|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835960|NCT01561482|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835961|NCT00513786|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835962|NCT04563299|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The patient and the survey administrator are masked to the treatment assignment in each eye.|This is an investigator initiated prospective open-label, within-patient, masked, randomized study in patients with neovascular AMD, DME, or RVO undergoing bilateral anti-VEGF injections. Within the respective cohorts, one eye per patient will be randomized to receive either an intracanalicular dexamethasone insert or the control treatment at each injection visit.|t|f|f|t
34148451|NCT02380898|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33835963|NCT03127670|NA|SINGLE_GROUP||TREATMENT||NONE||Solanum melongena peel extract||||
33835964|NCT02984553|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835965|NCT04597970|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835966|NCT00475228|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835967|NCT03481257|||COHORT||PROSPECTIVE|||||||
33835968|NCT05958134|||COHORT||RETROSPECTIVE|||||||
33835969|NCT05954572|||CASE_CONTROL||PROSPECTIVE|||||||
33837679|NCT05365399|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33837680|NCT01635023|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33837681|NCT00749229|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148452|NCT00351182|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33835970|NCT04996368|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Participants will be randomized into two groups by sealed envelop methods. The primary investigator and participants will be blinded|The doses of tranexamic acid used during cardiac surgery varies with the institutions that ranges from 10mg/kg to 100mg/kg. This study aims to compare two doses of tranexamic acid, one dose is a conventional dose ( 30mg/kg) and the other is low dose 10mg/kg. Effects of tranexamic acid regarding its effectiveness and side effects profile will be observed. Participants will be randomly selected into two groups ( low dose group and high dose group)|t|f|t|f
33835971|NCT04005716|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33835972|NCT00831077|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835973|NCT05141227|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open reduction and internal fixation versus external fixation||||
33835974|NCT03062696|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835975|NCT00882115|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33835976|NCT01947322|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835977|NCT04386603|||CASE_ONLY||CROSS_SECTIONAL|||||||
33835978|NCT05995509|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835979|NCT04556409|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835980|NCT01862068|||COHORT||PROSPECTIVE|||||||
33835981|NCT02927912|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835982|NCT06444490|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33835983|NCT04264715|RANDOMIZED|SEQUENTIAL||PREVENTION||DOUBLE|||t|f|f|t
33835984|NCT02038712|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33835985|NCT02373540|||COHORT||PROSPECTIVE|||||||
33835986|NCT04079205|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33835987|NCT02356627|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33835988|NCT01806844|||CASE_ONLY||PROSPECTIVE|||||||
33835989|NCT03538782|||COHORT||RETROSPECTIVE|||||||
33835990|NCT01653600|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835991|NCT05701241|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33835992|NCT01663038|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33835993|NCT05306886|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33835994|NCT02876952|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33835995|NCT00193479|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33835996|NCT03723226|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33835997|NCT06398509|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33835998|NCT04210843|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|"Participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated in a double-blind manner for the first 12 weeks of treatment. Thereafter, they were treated in an open-label manner.~No blinding was required for participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278)"||t|t|t|f
33835999|NCT05155566|||COHORT||RETROSPECTIVE|||||||
33836000|NCT02603692|||COHORT||PROSPECTIVE|||||||
33836001|NCT03506659|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Parallel group open label Monocentric||||
33836002|NCT00673907|RANDOMIZED|CROSSOVER||||DOUBLE|||t|f|t|f
33836003|NCT03600025|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||Apparently healthy volunteers will receive typhoid vaccine one time point.||||
33836004|NCT04501393|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836005|NCT03251092|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33836006|NCT02007200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836007|NCT02029963|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836008|NCT04781270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836009|NCT02545829|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836010|NCT03550469|RANDOMIZED|PARALLEL||TREATMENT||NONE||The intervention group will have oxygen therapy adjustment by computer-assistance. The control group will have adjustments by staff.||||
33836011|NCT05826145|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The control group will receive supportive care through vocal expression sessions. The treatment group will receive supportive care through cognitive-behavioral techniques.||||
33836012|NCT05214547|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836013|NCT02366143|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836014|NCT00780455|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836015|NCT01258127|||||PROSPECTIVE|||||||
33836016|NCT01894997|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33836017|NCT01908751|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33836018|NCT00512447|||CASE_ONLY||PROSPECTIVE|||||||
33836019|NCT01530737|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836020|NCT05329168|NA|SINGLE_GROUP||TREATMENT||NONE||Sequential ascending-dose||||
33836021|NCT06322147|||COHORT||OTHER|||||||
33836022|NCT06323967|NON_RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Participants will be blind to condition at the baseline assessment but will be unmasked immediately afterwards (they will receive debit cards and learn whether they are eligible for peer support). At baseline, interviewers will likely be aware of study conditions because they will interview respondents at shelters and shelter is associated with condition. At subsequent assessments interviewers will remain blind to study condition to the extent possible, but may well learn the condition from respondents, especially those who complete qualitative interviews. Win staff who provide usual care to both groups will be blind to the study condition. Participants in the passive comparison group will be unaware of the study.|Parallel assignment to 1) active treatment and 2) active comparison. A third, passive comparison group will be constructed and followed anonymously via administrative records.|t|t|f|t
33836023|NCT03671577|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomized into active treatment or waitlist control, so they will be aware of the condition they are in.|Participants will be randomized into active treatment or waitlist control.|f|f|f|t
33836024|NCT03188367|RANDOMIZED|CROSSOVER||DIAGNOSTIC||TRIPLE||Randomized, dose-finding, double-blind, placebo-controlled, crossover gluten challenge trial|t|t|t|f
33836025|NCT00038480|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836026|NCT00706654|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836027|NCT01594827|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836028|NCT04652388|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836029|NCT03444402|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836030|NCT00135681||||TREATMENT||||||||
33836031|NCT04155970|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|The outcome assessor is blinded as to which intervention each participant received.|Participants are assigned to one of two groups in parallel for the duration of the study.|f|f|f|t
33836032|NCT01774045|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|t|f
33836033|NCT00356005|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836034|NCT01035541|||||PROSPECTIVE|||||||
33836035|NCT01583504|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836036|NCT00535379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836037|NCT05017077|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33836038|NCT02883036|||COHORT||PROSPECTIVE|||||||
33836039|NCT02302677|||COHORT||PROSPECTIVE|||||||
33836040|NCT00979186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836041|NCT01441219|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836042|NCT01376492|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836043|NCT06482411|||COHORT||PROSPECTIVE|||||||
33836044|NCT00919204|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33836045|NCT04902183|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The administrated dose will be unknown to the patients|This is a two arms study; one arm will receive 10\^9 dose and the second arm will receive 10\^10 dose of exosomes overexpressing CD24|t|f|f|f
33836046|NCT01512797|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836047|NCT00504075|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836048|NCT04160988|||CASE_ONLY||RETROSPECTIVE|||||||
33836049|NCT03099252|||COHORT||PROSPECTIVE|||||||
33836050|NCT06177951|NON_RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836051|NCT04970290|NA|SINGLE_GROUP||TREATMENT||NONE||Monocentric, prospective, open label, uncontrolled, post-market clinical investigation||||
33836052|NCT03396068|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Participants and Care Providers will be masked with regard to medication administered. Outcomes Assessors will not be present during IV infusion of medication.|2:1 randomization under FDA Special Protocol Agreement and Breakthrough Therapy Designation|t|t|t|t
33836053|NCT03577847|||CASE_CONTROL||PROSPECTIVE|||||||
33836054|NCT03149705|||COHORT||PROSPECTIVE|||||||
33836055|NCT05167136|||COHORT||PROSPECTIVE|||||||
33836056|NCT06212752|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836057|NCT04603742|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This study is a phase II double-blind, placebo-controlled, multicentered trial. Patients in the intervention arm will receive anakinra IV (N=85) 4 times a day for 7 days. The placebo arm will receive normal saline IV (N=85) 4 times a day for 7 days. The investigators will follow up with patients for up to 60 days.|t|f|t|f
33836058|NCT06546917|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Patients are told that either arm is hypothesized to have effects on their cognition and are therefore blinded to whether they are in the 'active' treatment group.~Assessors for outcomes that are not self-reported or self-administered will also be blinded as to group allocation."||t|f|f|f
33836059|NCT01372839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836060|NCT00513162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836061|NCT05707897|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836062|NCT04935216|||COHORT||RETROSPECTIVE|||||||
33836063|NCT00132678|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836064|NCT05102058|||COHORT||RETROSPECTIVE|||||||
33836065|NCT01872481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836066|NCT00786084|||CASE_CONTROL||RETROSPECTIVE|||||||
33836067|NCT00751322|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
33836068|NCT01262547|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33836069|NCT06077903|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836070|NCT02534727|||COHORT||PROSPECTIVE|||||||
33836071|NCT06042972|||OTHER||PROSPECTIVE|||||||
33836072|NCT03405077|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836073|NCT02238249|||COHORT||PROSPECTIVE|||||||
33836074|NCT03903718|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Subjects will be assigned to Part 1 of the study (Cohort 1) in an unblinded manner.~Part 2 is a partial double-blind study of MEDI8852 and placebo. Because MEDI8852 and placebo are not completely indistinguishable in appearance, an unblinded investigational product manager will prepare the investigational product using a coloured sleeve to cover the infusion bag containing investigational product. An unblinded investigational product monitor will perform investigational product accountability. The unblinded personnel will not reveal the treatment allocation to the sponsor or site staff. Neither the subject/legal representative nor any of the investigator or sponsor staff who are involved in the treatment or clinical evaluation of the subjects will be aware of the treatment received. In the event that the treatment allocation for a subject becomes known to the investigator or other study staff involved in the management of study subjects, the sponsor must be notified immediately."||t|t|t|t
33836075|NCT02323568|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836076|NCT00942747|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836077|NCT03084276|RANDOMIZED|CROSSOVER||OTHER||TRIPLE|||t|f|t|t
33836078|NCT03573193|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Blinded participants|"Randomized clinical trial.~• Unicenter, single blinded, with equal randomization, active controlled, parallel group study"|t|f|f|f
33836079|NCT01807689|||CASE_ONLY||PROSPECTIVE|||||||
33836080|NCT05143164|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomized controlled trial||||
33836081|NCT03022955|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33836082|NCT01067846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836083|NCT00530582|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33836084|NCT05849623|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants will be randomly assigned to one of three study arms.||||
33836085|NCT02361086|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836086|NCT04236687|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836087|NCT02164669|||COHORT||PROSPECTIVE|||||||
33836088|NCT05253859|||OTHER||RETROSPECTIVE|||||||
33836089|NCT02431052|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836090|NCT00168142|||CASE_ONLY||PROSPECTIVE|||||||
33836091|NCT03653000|NA|SINGLE_GROUP||TREATMENT||NONE||Descriptive study||||
33836092|NCT04606940|||COHORT||PROSPECTIVE|||||||
33836093|NCT04610411|RANDOMIZED|SEQUENTIAL||TREATMENT||SINGLE|||t|f|f|f
33836094|NCT01244165|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836095|NCT05613049|||COHORT||PROSPECTIVE|||||||
33836096|NCT02480647|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836097|NCT01998204|||CASE_CONTROL||PROSPECTIVE|||||||
33836098|NCT05594329|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33836099|NCT03042403|||OTHER||PROSPECTIVE|||||||
33836100|NCT02567305|||COHORT||PROSPECTIVE|||||||
33836101|NCT03874923|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836102|NCT01552759|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836103|NCT00847626|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
33836104|NCT00505310|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836105|NCT01266304|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33836106|NCT05860621|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A 3-arm randomized controlled trial, involving a 4-month intervention period and a 12-month follow-up, will be implemented to compare: 1) a brief PA counseling intervention; 2) a structured exercise program; and 3) a waiting-list control group.||||
33836107|NCT05656794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836108|NCT02563548||PARALLEL||TREATMENT||NONE||||||
33836109|NCT01867047|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836110|NCT05335200|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836111|NCT04657042|||CASE_CONTROL||PROSPECTIVE|||||||
33836112|NCT05475275|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Enclosed envelope|The patients were randomly divided into the experimental group and the control group.|t|t|f|t
33836113|NCT01053481|NA|SINGLE_GROUP||PREVENTION||SINGLE|||t|f|f|f
33836114|NCT06507423|||COHORT||PROSPECTIVE|||||||
33836115|NCT01606423|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33836116|NCT03325777|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836117|NCT02344342|RANDOMIZED|FACTORIAL||PREVENTION||NONE||||||
33836118|NCT00798252|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836119|NCT00279253|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33836120|NCT03178344|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|This study will follow a double-blind experimental design, so neither the participant nor the experimenter will know what kind of stimulation the participant is receiving at what session. A separate unblinded monitor, who will not interact with the participants, will be responsible for creating the stimulation codes for each session.|Each participant will receive sham stimulation or 10 Hz tACS stimulation at two separate sessions. The order will be randomized (ie, half the participants will receive sham stimulation at the first session and 10 Hz tACS stimulation at the second session, and the other half will receive 10 Hz tACS stimulation at the first session and sham stimulation at the second session).|t|f|t|f
33836121|NCT01907269|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33836122|NCT05355675|||COHORT||PROSPECTIVE|||||||
33836123|NCT02296216|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836124|NCT00914745|RANDOMIZED|SINGLE_GROUP||PREVENTION||TRIPLE|||t|t|t|f
33836125|NCT06211777|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33836126|NCT01315470|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836127|NCT00663637|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836128|NCT04338789|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding of either patient or clinician was not possible during treatment. However, partial blinding was possible. Orthodontic molar protraction was carried out by the clinician without knowing the GCF levels and the lab was blinded to the clinical findings. Also, periapical radiographs and study casts were masks during data collection.|"Split mouth design where piezocision will be performed at the time of molar protraction on the right or left side of the bilateral first molar extraction subjects and 3 months of molar protraction on the other side. A third group of subjects will act as a control where molar protraction will be done with no piezocision.~- Comparison between the 3 groups of subjects; Early piezocision, late piezocision and no piezocision molar protraction groups."|f|f|f|t
33836129|NCT00506805|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836130|NCT06199310|||COHORT||PROSPECTIVE|||||||
33836131|NCT05312281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|t|f|f
33836132|NCT02493946|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836133|NCT05961540|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33836134|NCT04636762|NA|SINGLE_GROUP||TREATMENT||NONE||To assess safety and tolerability of Atezolizumab Combined with Concurrent Chemoradiotherapy and maintenance therapy with Atezolizumab in untreated participants with extensive-disease small cell lung cancer.||||
33836135|NCT04515498|||CASE_CROSSOVER||PROSPECTIVE|||||||
33836136|NCT06254170|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
33836137|NCT04871399|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836138|NCT00990951|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836139|NCT06146478|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE|No masking|Patients will be grouped into thalidomide and non-thalidomide groups on the basis of their willingness to receive thalidomide therapy. Thalidomide will be given at an average dose of 1.5mg/kg/day (range 1-2mg/kg/day). Patients will be followed up for 12 months and data will be collected at different visits.||||
33836140|NCT00335101|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||||||
33836141|NCT03299348|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|Study participants, group leaders, and outcomes assessors will not know the study objectives or hypotheses.|The study has an active treatment group and an active control group|t|t|f|t
33836142|NCT01836172|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836143|NCT05989594|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836144|NCT04080713|NA|SINGLE_GROUP||OTHER||NONE||||||
33836145|NCT00092092|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33836146|NCT02469155|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836147|NCT05132894|||COHORT||CROSS_SECTIONAL|||||||
33836148|NCT05302440|||CASE_ONLY||PROSPECTIVE|||||||
33836149|NCT02765789|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836150|NCT00566540|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836151|NCT06102447|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836152|NCT00572533|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
33836153|NCT01615549|RANDOMIZED|PARALLEL||||NONE||||||
33836154|NCT01078636|||CASE_CONTROL||PROSPECTIVE|||||||
33836155|NCT04607707|||OTHER||CROSS_SECTIONAL|||||||
33836156|NCT01070576|||||PROSPECTIVE|||||||
33836157|NCT00374751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836158|NCT02867683|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836159|NCT00327509|||CASE_CONTROL||PROSPECTIVE|||||||
33836160|NCT01327612|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836161|NCT01658111|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33836162|NCT01199068|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836163|NCT06201078|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836164|NCT00664963|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836165|NCT06186947|||COHORT||OTHER|||||||
33836166|NCT05658653|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||"The study will enroll physicians and care providers practicing in the VillageMD health system. Participants are randomly assigned to either control or intervention 1 arms upon enrollment. All eligible and consented participants will complete two rounds of three patient simulations.~The intervention arm only will receive educational material about the CDMT test in between these two rounds. Intervention arm participants only will receive the CDMT test results whether they select it or not."||||
33836167|NCT01641653|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836168|NCT00978562|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836169|NCT00533364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836170|NCT00684905||||TREATMENT||||||||
33836171|NCT02522728|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836172|NCT03965338|NA|SINGLE_GROUP||SCREENING||NONE||||||
33836173|NCT00725712|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836174|NCT01985815|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33836175|NCT05547698|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836176|NCT02664597|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33836177|NCT03414528|||FAMILY_BASED||PROSPECTIVE|||||||
33836178|NCT03766958|||COHORT||PROSPECTIVE|||||||
33836179|NCT00323206|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836180|NCT01409005|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836181|NCT05011877|||COHORT||PROSPECTIVE|||||||
33836182|NCT03821233|NA|PARALLEL||TREATMENT||NONE||||||
33836183|NCT02812056|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836184|NCT03721705|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Participants will be randomized to either the treatment group or the sham group.|t|f|f|t
33836185|NCT05262452|NA|SINGLE_GROUP||TREATMENT||NONE||Patients diagnosed with locally advanced/borderline resectable pancreatic cancer through biopsy and CT/MRI imaging and planned to undergo anti-cancer treatment using FOLFIRINOX||||
33836186|NCT00254605|||CASE_CONTROL||PROSPECTIVE|||||||
33836187|NCT00517036|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836188|NCT06474923|||CASE_CONTROL||PROSPECTIVE|||||||
33836189|NCT04438720|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33836190|NCT04727138|RANDOMIZED|SEQUENTIAL||TREATMENT||QUADRUPLE|Part 1 and Part 2 are double blind. Part 3 is open label.||t|t|t|t
33836191|NCT05353777|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836192|NCT01566097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836193|NCT00001039||||TREATMENT||NONE||||||
33836194|NCT04921449|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33836195|NCT01239784|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836196|NCT01702857|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836197|NCT01055977|||||RETROSPECTIVE|||||||
33836198|NCT04154969|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33836199|NCT00272259|RANDOMIZED|PARALLEL||||SINGLE||||||
33836200|NCT06026930|RANDOMIZED|FACTORIAL||BASIC_SCIENCE||NONE||||||
33836201|NCT01572740|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836202|NCT06331104|||COHORT||RETROSPECTIVE|||||||
33836203|NCT04338412|RANDOMIZED|FACTORIAL||OTHER||DOUBLE|||t|f|t|f
33836204|NCT02622399|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836205|NCT06198270|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single blind||f|f|f|t
33836206|NCT03674437|||CASE_CONTROL||PROSPECTIVE|||||||
33836207|NCT04905368|NA|SINGLE_GROUP||OTHER||NONE||||||
33836208|NCT03549091|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836209|NCT01539577|||COHORT||PROSPECTIVE|||||||
33836210|NCT04122547|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33836211|NCT00267098|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836212|NCT01599026|||||CROSS_SECTIONAL|||||||
33836213|NCT03038035|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836214|NCT02160730|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836215|NCT06319794|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836216|NCT03169998|||CASE_CONTROL||OTHER|||||||
33836217|NCT05434325|||COHORT||PROSPECTIVE|||||||
33836218|NCT01798979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836219|NCT05208359|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836220|NCT00203268|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836221|NCT04121780|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|3-D printing used to design matching cases (covers) for both the drug and placebo autoinjector pens|A randomized, double-blind, placebo-controlled trial with an open-label extension|t|f|t|t
33836222|NCT01568125|||COHORT||PROSPECTIVE|||||||
33836223|NCT06044506|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836224|NCT06264193|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||The hypoxic group included rowers participating in sports training and the LH-TL method, hypoxic rooms (FiO2=14.5%, corresponds to an altitude of 3000 meters). And the control group participating only in sports training and living in normoxic rooms, at the same sports camp.||||
33836225|NCT05648487|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836226|NCT05317897|||COHORT||PROSPECTIVE|||||||
33836227|NCT00900692|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836228|NCT04051918|RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||Older adults with mild cognitive impairment||||
33836229|NCT05923645|NA|SINGLE_GROUP||TREATMENT||NONE|Primary Outcome measures (GLAD, CTOPP2, WRAT-5) will be assessed by a clinical psychologist not involved in the study|Ambispective Quasi-experimental study design||||
33836230|NCT06418009|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Pain assessment will be made by a nurse independent of the study||f|f|f|t
33836231|NCT03049670|||COHORT||PROSPECTIVE|||||||
33836232|NCT04529005|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836233|NCT05614310|||CASE_CONTROL||PROSPECTIVE|||||||
33836234|NCT04594837|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836235|NCT02397382|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836236|NCT00065923|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
33836237|NCT05422183|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836238|NCT03287453|NA|SINGLE_GROUP||SCREENING||NONE||||||
33836239|NCT01513330|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33836240|NCT03892005|||COHORT||CROSS_SECTIONAL|||||||
33836241|NCT05281497|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||intervention group and control group||||
33836242|NCT01304498|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836243|NCT04318106|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|The researcher will perform colorimetry testing to measure the chromaticity of the 'experimental' and 'control' coloured lenses.The 'experimental' and 'control' colour will be as similar in chromaticity as possible. The details of the 'experimental' and 'control' colour will be given to an external person who will randomly assign the order in which the spectacles will be collected by the participant. There is a significant time lapse between the colorimetry assessment where the 'experimental' and 'control' colours are measured and the collection of the first pair of spectacles.|The participant will be given either the 'experimental' coloured spectacle lenses or the 'control' coloured spectacle lenses to wear for a minimum of ten weeks, the spectacles will be returned. A 'washout' period will occur and then the participant will be given the alternative pair of coloured spectacles to wear.|t|f|t|f
33836244|NCT00981708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836245|NCT00915824|RANDOMIZED|PARALLEL||||NONE||||||
33836246|NCT06062004|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Hospital-based, comparative, prospective, interventional contralateral eye study||||
33836247|NCT03728751|NA|SINGLE_GROUP||TREATMENT||NONE||Single group pre-test post test study design||||
33836248|NCT00021138||||PREVENTION||||||||
33836249|NCT03768336|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836250|NCT03818126|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836251|NCT03306173|RANDOMIZED|PARALLEL||OTHER||SINGLE|Participants will be randomly assigned to either ventilated or unventilated cigarettes and will not be informed of their group assignment.|Participants will be assigned to either use a ventilated or unventilated cigarette.|t|f|f|f
33836252|NCT00830323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836253|NCT00277095|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836254|NCT01544634|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33836255|NCT03827226|||COHORT||PROSPECTIVE|||||||
33836256|NCT02638103|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836257|NCT05834192|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836258|NCT05733676|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Double, Participant and Outcomes Assessor|"The selected samples will be randomly allocated to two groups according to treatment received.~Group I- Resin infiltration -Icon + etch, DMG, Germany.~Group II- MI paste plus +etch , GC corporation, Germany, Europe,"|t|f|f|t
33836259|NCT04575181|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor staff involved in the clinical trial is masked according to company standard procedures||t|t|t|t
33836260|NCT05823753|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Identical taste, smell, color and viscosity of liquid provided in identical bottles. Each participant will receive two bottles, with instructions of how many ml to take BID from each of Bottle #1 and Bottle #2. The research pharmacy will label the bottles for each randomized participant so they take the dose to which they were randomized.|A phase II, 3-arm, sub-acute (4-day) steady state dosing clinical trial.|t|t|t|t
33836261|NCT00228644|||COHORT||PROSPECTIVE|||||||
33836262|NCT03384303|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||t|f|f|f
33836263|NCT05062512|||COHORT||PROSPECTIVE|||||||
33836264|NCT02465736|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836265|NCT01476683|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
33836266|NCT02828397|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33836267|NCT02177253|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33836268|NCT00600470|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836269|NCT03923686|RANDOMIZED|PARALLEL||TREATMENT||NONE||a prospective randomized cohort study||||
33836270|NCT00689130|||COHORT||PROSPECTIVE|||||||
33836271|NCT00844337|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33836272|NCT00961506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836273|NCT02294747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33836274|NCT01070446|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836275|NCT04205357|NA|SEQUENTIAL||TREATMENT||NONE||3 + 3 dose escalation design: Cohort 1 (3-6 patients): 1.5 gr Sulfasalazine x 1 for 3 days Cohort 2 (3-6 patients): 3.0 gr Sulfasalazine x 1 for 3 days Cohort 3 (3-6 patients): 4.5 gr SSulfasalazine x 1 for 3 days Cohort 4 (3-6 patients): 6.0 gr Sulfasalazine x 1 for 3 days||||
33836276|NCT02379143|||||CROSS_SECTIONAL|||||||
33836277|NCT04283708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836278|NCT04507633|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||TRIPLE|independent researchers will perform intervention and data collection.||t|t|f|t
33836279|NCT02763215|||COHORT||PROSPECTIVE|||||||
33836280|NCT00079755|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836281|NCT03819634|NA|SINGLE_GROUP||TREATMENT||NONE||To determine length of infusion set wear for up to a maximum of 10 days||||
33836282|NCT03928223|||COHORT||PROSPECTIVE|||||||
33836283|NCT04621461|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|Patients will be randomized via a randomization block. Only the research coordinator will know which group the patients belong to. Placebo pills given to the patient will be similar in size and shape to zinc.|This is a randomized, double-blind, placebo-controlled trial to assess the efficacy of zinc in a higher risk COVID-19 positive outpatient population. Patients will randomized to zinc or placebo.|t|f|t|f
33836284|NCT04211077|||OTHER||RETROSPECTIVE|||||||
33836285|NCT06173011|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836286|NCT06081777|||COHORT||PROSPECTIVE|||||||
33836287|NCT04471545|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Randomisation will be performed by an independent pharmacist from the hospital pharmacy before the start of the trial. This pharmacist has no other task then creating this list and overseeing the preparation of the syringes used in this trial. Syringes will be prepared with ropivacaine or placebo based on this randomisation list. This syringe will be delivered to the preoperative holding with a label that clearly states BLOCKTOS medication, patient name, date of birth and patient number. This procedure makes sure that the patients, surgeons, anaesthesiologist and any other medical personnel are blinded for the randomisation.|"Randomization will be done through Research manager©. This research program has the possibility to create randomisation logs before the start of the trial.~A random list of numbers will be generated through Research manager© between 0 and 70. If the number is even, the patient will be allocated to the interventional treatment arm (PECS II block). If the number is uneven, the patient will be allocated to the placebo arm. This list will not be changed during the course of this investigation. Randomisation will be performed by an independent pharmacist from the hospital pharmacy before the start of the trial."|t|t|t|t
33836288|NCT04157192|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"The patient is unaware of the study (and whether he/she is receiving the placebo or not).~The imager is also unaware of whether the patient has had sham or real acupuncture."|40 patients will be randomly assigned to one of two groups (1) The Interventional Group: 20 Patients will receive 5 real acupuncture sessions each spaced 15 days apart. At the first and last sessions of acupuncture, an MRI scan will be performed before and after the acupuncture session and (2) The Placebo Group : 20 patients will receive 5 sham sessions of acupuncture (i.e. using a simulated acupuncture technique) each spaced 15 days apart. At the first and last sham sessions, an MRI scan will be performed before and after the sham acupuncture session.|t|f|f|t
33836289|NCT00307476|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836290|NCT00000469|RANDOMIZED|||PREVENTION||DOUBLE||||||
33836291|NCT02964702|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836292|NCT04608747|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33836293|NCT02382562|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836294|NCT00425607|NA|SINGLE_GROUP||TREATMENT||NONE|Open Label|||||
33836295|NCT02127138|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836296|NCT01377389|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836297|NCT03612076|||COHORT||RETROSPECTIVE|||||||
33836298|NCT01077518|RANDOMIZED|PARALLEL||TREATMENT||NONE||randomized open label bendamustine monotherapy vs. ofatumumab||||
33836299|NCT02385383|||COHORT||PROSPECTIVE|||||||
33836300|NCT01721954|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836301|NCT02356705|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836302|NCT04183998|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836303|NCT00571441|||CASE_CONTROL||PROSPECTIVE|||||||
33836304|NCT03731923|NA|SINGLE_GROUP||OTHER||NONE||||||
33836305|NCT05186311|NA|SINGLE_GROUP||OTHER||NONE||||||
33836306|NCT00012064|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836307|NCT06003205|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33836308|NCT01658020|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33836309|NCT01634269|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836310|NCT03131947|||OTHER||PROSPECTIVE|||||||
33836311|NCT00984191|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33836312|NCT02387151|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836313|NCT03799419|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33836314|NCT01417104|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836315|NCT04779437|RANDOMIZED|CROSSOVER||TREATMENT||NONE|Two active interventions are used, and both participants and researchers are aware of which intervention participants are completing.|The study is an exploratory single-case series using a within-subject ABC design, with a baseline phase (A) followed by two intervention phases (B) and (C). Participants are randomly assigned to the order in which they complete the two different interventions.||||
33836316|NCT06415604|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
33836317|NCT01651169|NON_RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33836318|NCT05941117|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836319|NCT00379769|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836320|NCT00421629|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836321|NCT02301377|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836322|NCT03368976|||COHORT||PROSPECTIVE|||||||
33836323|NCT00953732|||||PROSPECTIVE|||||||
33836324|NCT05262751|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836325|NCT01594645|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836326|NCT02023359|||COHORT||PROSPECTIVE|||||||
33836327|NCT03930329|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33836328|NCT03333161|RANDOMIZED|CROSSOVER||TREATMENT||NONE||The investigators will use the data from the 96 hours of intensive multiparametric physiologic monitoring at 2 weeks postnatal age. The first 24 hours of the data collection will be the baseline data, followed by evaluation of 3 interventions in a cross-over manner, with the initial intervention randomly assigned (computer-generated): Intervention 1 (24-48h of data), Intervention 2 (48-72h), and Intervention 3 (72-96h). The interventions will be to adjust transcutaneous carbondioxide measurements (TcCO2) up or down by 5 mm Hg, while maintaining TcCO2 within usual safe thresholds.||||
33836329|NCT04811144|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836330|NCT05375097|||CASE_CONTROL||RETROSPECTIVE|||||||
33836331|NCT00393497|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836332|NCT06390384|RANDOMIZED|PARALLEL||PREVENTION||NONE||"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 1) digital and mental literacy training for children, parents and teachers in the school; 2) weekly counselling over 6 weeks via videoconference for adolescents and their parents; 3) blinded-care use of the mobile treatment system STEPS®.~Control condition (Treatment as Usual) includes the implementation of the digital and mental literacy training, however, no weekly counselling by the team of the clinic and no blinded-care use of the mobile treatment system STEPS®."||||
33836333|NCT04591379|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836334|NCT03608059|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||ATG+PTCy|t|f|f|f
33836335|NCT03653767|RANDOMIZED|PARALLEL||PREVENTION||NONE||Randomised Control Trial||||
33836336|NCT00412607|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836337|NCT02409095|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33836338|NCT03460054|||COHORT||PROSPECTIVE|||||||
33836339|NCT01893489|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||f|f|t|t
33836340|NCT03321110|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE||placebo-control|t|t|f|f
33836341|NCT02168413|||COHORT||PROSPECTIVE|||||||
33836342|NCT03552523|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836343|NCT00785837||PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33836344|NCT01735175|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33836345|NCT02061878|RANDOMIZED|PARALLEL||||TRIPLE|||t|f|t|t
33836346|NCT01003119|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836347|NCT02833077|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836348|NCT00940875|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836349|NCT01451255|||||PROSPECTIVE|||||||
33836350|NCT05361564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836351|NCT04009031|NA|SINGLE_GROUP||TREATMENT||NONE||Participants will undergo a clinical assessment at 3-time points: baseline, post-intervention, and one-month follow-up. Clinical assessments will take approximately 2 hours and will be carried out at the Holland Bloorview Kids Rehabilitation Hospital by an occupational therapist. A research assistant will visit the child's home 3 times throughout the duration of the intervention (weeks 1, 6 and 12). During the last home visit, semi-structured interviews will be conducted individually with the parent and child.||||
33836352|NCT01896622|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836353|NCT01154140|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836354|NCT03863262|||OTHER||CROSS_SECTIONAL|||||||
33836355|NCT05442268|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836356|NCT02954705|||CASE_CONTROL||PROSPECTIVE|||||||
33836357|NCT01798875|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836358|NCT01049438|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33836359|NCT06059599|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836360|NCT00113815|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836361|NCT01896557|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836362|NCT04309695|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836363|NCT04347057|RANDOMIZED|CROSSOVER||PREVENTION||NONE||Arm 1 (39 patients) included first the control period, followed by one-day wash-out, and then the intervention period. Arm 2 (39 patients) included first the intervention period, followed by one-day wash-out, and then the control period. The first patient was assigned to the second arm after the draw, and the patients continued to take the first arm and second arm respectively. Each period lasted three consecutive days with a total of 7 days for each patient. During the period of the study, 8 patients from Arm1 and 9 patients from Arm 2 could not complete the study due to several reasons. Thus, the final sample consisted of 31 patients in Arm 1 and 30 patients in Arm 2.||||
33836364|NCT02704650|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
33836365|NCT02388347|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836366|NCT05383339|||CASE_ONLY||PROSPECTIVE|||||||
33836367|NCT05833841|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836368|NCT00712647|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836369|NCT05999890|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Single (Outcomes Assessor) The assessor of the outcome would measure hemodynamic parameters and severity of the pain at the mentioned time intervals. The assessor was not involved in the randomization / administration of the intervention|It is a single blind randomized controlled trial comparing the intranasal tapentadol with intravenous paracetamol for post operative analgesia|f|f|f|t
33836370|NCT00450138|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836371|NCT02975076|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||f|f|t|t
33836372|NCT06328218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836373|NCT00663585|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836374|NCT05568186|||COHORT||PROSPECTIVE|||||||
33836375|NCT00004077||||TREATMENT||||||||
33836376|NCT03643549|NA|SEQUENTIAL||TREATMENT||NONE||Botezomib 1.3mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3 until disease progression and/or unacceptable toxicity. Study group will be compared to historical controls on conventional management||||
33836377|NCT04905576|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Patients are randomized to relaxation, healing touch, or standard care arms of the study||||
33836378|NCT02261077|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33836379|NCT01736189|||COHORT||PROSPECTIVE|||||||
33836380|NCT01133223|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836381|NCT03489876|RANDOMIZED|PARALLEL||TREATMENT||NONE|The computer-based randomization sequence will be concealed from investigators using REDCap.|Upon eligibility verification and informed consent, computer-based randomization will allot patients into one of the two treatment groups, either synthetic cartilage implant or osteochondral autograft transfer.||||
33836382|NCT02358668|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836383|NCT06126588|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836384|NCT00435747|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33836385|NCT05893589|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836386|NCT05933889|||COHORT||RETROSPECTIVE|||||||
33836387|NCT03007797|||COHORT||PROSPECTIVE|||||||
33836388|NCT04537598|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836389|NCT02357264|||COHORT||PROSPECTIVE|||||||
33836390|NCT01579643|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836391|NCT05553197|RANDOMIZED|PARALLEL||TREATMENT||NONE|As is common in psychotherapy research, participants and care providers cannot be blinded to the intervention. Only subjective outcomes (i.e., participant-rated) are assessed.|4/7 of participants will be randomised to CBT + EMA and 3/7 to TAU. This randomisation ratio is chosen to foster longitudinal analyses in the CBT + EMA group. Randomisation is stratified by pre-treatment severity of depressive symptoms. Participants with PHQ-9 scores 5-9 will be randomised separately from participants with PHQ-9 scores 10-20.||||
33836392|NCT00174837|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836393|NCT03195361|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836394|NCT05287347|||COHORT||OTHER|||||||
33836395|NCT05889689|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836396|NCT01027052|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33836397|NCT04797234|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The research is carried out to evaluate the effects of the education given to individuals who receive hemodialysis treatment based on Roper, Logan - Tierney's Nursing Model on the independence level and self-care power of the sick individuals in their daily living activities. The research is planned to be conducted as a randomized controlled study determined by simple random method, two groups, pretest - posttest, and experimental research design.||||
33836398|NCT02423603|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836399|NCT00243074|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836400|NCT00401258|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836401|NCT02627339|||COHORT||PROSPECTIVE|||||||
33836402|NCT02914756|||COHORT||PROSPECTIVE|||||||
33836403|NCT01217788|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836404|NCT03040609|||COHORT||PROSPECTIVE|||||||
33836405|NCT04536389|||COHORT||PROSPECTIVE|||||||
33836406|NCT04566913|NA|SINGLE_GROUP||TREATMENT||NONE||Case Series study||||
33836407|NCT02711319|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836408|NCT03940690|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836409|NCT02729467|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836410|NCT03651557|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind (Subject, Caregiver, Investigator)||t|t|t|f
33836411|NCT01730378|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836412|NCT02885415|||COHORT||PROSPECTIVE|||||||
33836413|NCT01279837|RANDOMIZED|FACTORIAL||PREVENTION||DOUBLE|||f|f|t|t
33836414|NCT05431777|||COHORT||RETROSPECTIVE|||||||
33836415|NCT00294411|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836416|NCT00240214|||COHORT||PROSPECTIVE|||||||
33836417|NCT03209947|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836418|NCT05084339|||COHORT||PROSPECTIVE|||||||
33836419|NCT02880943|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836420|NCT03699189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||A randomised, controlled, parallel trial.||||
33836421|NCT00281320|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836422|NCT02567708|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33836423|NCT02853487|||CASE_CONTROL||PROSPECTIVE|||||||
33836424|NCT03681743|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836425|NCT06384105|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836426|NCT00618579|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
33836427|NCT00751543|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836428|NCT03329677|NA|SINGLE_GROUP||TREATMENT||NONE|Not applicable. Treatment is transference-focused psychotherapy for borderline personality disorder and each participant understands that she will receive it for 18 months.|Our study is a longitudinal (i.e., 18-month) treatment outcome study using a within-subjects design with repeated measures. We do not include a control group or a TAU group in our study design.||||
33836429|NCT06432673|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33836430|NCT00351572|||COHORT||PROSPECTIVE|||||||
33836431|NCT06086041|||COHORT||PROSPECTIVE|||||||
33836432|NCT02539732|||COHORT||PROSPECTIVE|||||||
33836433|NCT01666093|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836434|NCT01053767|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33836435|NCT05408195|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836436|NCT01754415|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33836437|NCT03575949|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836438|NCT01407055|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836439|NCT00398190|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33836440|NCT02275208|||CASE_ONLY||PROSPECTIVE|||||||
33836441|NCT03798873|RANDOMIZED|PARALLEL||TREATMENT||NONE||Test group treated with the FeelWell™ Compression garment and control group without compression garment. All subjects will receive the same intervention working with exercise physiologist and physical therapist in order to improve mobility.||||
33836442|NCT02909465|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836443|NCT02809560|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33836444|NCT02370251|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836445|NCT03999632|RANDOMIZED|PARALLEL||OTHER||NONE||Randomized controlled trial||||
33836446|NCT00388440|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33836447|NCT00458588|||OTHER||PROSPECTIVE|||||||
33836448|NCT02338063|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836449|NCT05389995|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836450|NCT05665569|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836451|NCT03656276|||COHORT||PROSPECTIVE|||||||
33836452|NCT04592094|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836453|NCT04972669|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33836454|NCT01712061|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836455|NCT01053247|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836456|NCT05928468|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836457|NCT03617835|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836458|NCT06117228|||CASE_ONLY||CROSS_SECTIONAL|||||||
33836459|NCT00701909|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|t|f
33836460|NCT03933462|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836461|NCT03038204|||COHORT||PROSPECTIVE|||||||
33836462|NCT03162445|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836463|NCT02977390|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836464|NCT03017742|NA|SINGLE_GROUP||OTHER||NONE||||||
33836465|NCT00848484|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33836466|NCT04369690|||COHORT||PROSPECTIVE|||||||
33836467|NCT00002154||||TREATMENT||DOUBLE||||||
33836468|NCT00181142|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836469|NCT05102240|||OTHER||RETROSPECTIVE|||||||
33836470|NCT01071603|||||PROSPECTIVE|||||||
33836471|NCT03758547||SEQUENTIAL||TREATMENT||NONE|patients deeply sedated and therefore not conscious|baseline (time0) application of 10 cycles of positive inspiratory and negative expiratory pressures (time1) application of percussion (time2)||||
33836472|NCT05682534|||OTHER||OTHER|||||||
33836473|NCT01435148|RANDOMIZED|CROSSOVER||||QUADRUPLE|||t|t|t|t
33836474|NCT01783132|RANDOMIZED|PARALLEL||PREVENTION||NONE||SOC||||
33836475|NCT02520583|RANDOMIZED|CROSSOVER||||TRIPLE|||t|f|t|t
33836476|NCT05758805|NA|SINGLE_GROUP||PREVENTION||NONE||Pilot, about the safety, prospective, monocentric||||
33836477|NCT04856683|||COHORT||OTHER|||||||
33836478|NCT00983749|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836479|NCT00965497|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836480|NCT03683550|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836481|NCT01681615|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
33836482|NCT04283890|RANDOMIZED|FACTORIAL||TREATMENT||NONE|Open label, single center, phase Ib/randomized phase II trial, evaluating the safety and efficacy (as measured by RECIST 1.1) of the combination of PHP and ipilimumab/nivolumab in patients with unresectable hepatic and extrahepatic metastases of uveal melanoma.|In the phase 1b part, safety and feasibility of combining percutaneous hepatic perfusion with 4 courses of ipilimumab and nivolumab will be investigated. In the randomized phase 2 part, efficacy as measured by progression-free survival at one year comparing PHP only versus PHP plus ipilimumab/nivolumab will be evaluated.||||
33836483|NCT01075477|||COHORT||PROSPECTIVE|||||||
33836484|NCT02608736|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
33836485|NCT01439386|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836486|NCT04633850|||COHORT||PROSPECTIVE|||||||
33836487|NCT01721733|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33836488|NCT05429047|||COHORT||PROSPECTIVE|||||||
33836489|NCT01901822|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836490|NCT02592213|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836491|NCT06061237|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836492|NCT02213731|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836493|NCT06017739|RANDOMIZED|CROSSOVER||PREVENTION||NONE||"the two arms of the study are:~1. EFA / EFA + High Flow~2. EFA + High Flow / EFA patients are randomly assigned to one of two groups"||||
33836494|NCT00179738|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836495|NCT03514615|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836496|NCT00639327|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836497|NCT06072976|RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836498|NCT03313947|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33836499|NCT04202445|||COHORT||PROSPECTIVE|||||||
33836500|NCT01280851|NA|SINGLE_GROUP||SCREENING||NONE||||||
33836501|NCT05508204|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Open-label, single ascending dose study in Japanese healthy subjects||||
33836502|NCT05131802|||COHORT||RETROSPECTIVE|||||||
33836503|NCT03360578|||CASE_ONLY||PROSPECTIVE|||||||
33836504|NCT05034068|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836505|NCT06413953|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836506|NCT03367598|||CASE_CONTROL||PROSPECTIVE|||||||
33836507|NCT02634047|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33836508|NCT03120429|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836509|NCT02574325|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836510|NCT01932476|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33836511|NCT03276390|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||Two group comparison (intervention vs. control) and pre-post comparison (within each site).||||
33836512|NCT02717182|||OTHER||CROSS_SECTIONAL|||||||
33836513|NCT02408094|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836514|NCT01673022|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836515|NCT05048056|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double Blinded||t|t|t|t
33836516|NCT03481361|||COHORT||CROSS_SECTIONAL|||||||
33836517|NCT05663905|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836518|NCT03080818|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33836519|NCT05306743|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||A total of 126 primary care teams (PCT) will be enrolled in the trial; 63 PCTs will be randomized to the intervention arm and receive the CONQUEST QIP, and 63 to the control arm where they will receive care as usual.|f|f|f|t
33836520|NCT05482191|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836521|NCT03243097|NA|SEQUENTIAL||DEVICE_FEASIBILITY||NONE||||||
33836522|NCT04376502|NA|SINGLE_GROUP||TREATMENT||NONE||Radiation therapy for all subjects will consist of treating one tumor of the treating physician's preference (40 Gray (GY) in 5 fractions), and after a 1-week interval during which Immune checkpoint inhibitor is continued alone, radiation therapy will be given to a second and separate tumor (30 Gy in 5 fractions).||||
33836523|NCT02059356|||COHORT||PROSPECTIVE|||||||
33836524|NCT00209664|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836525|NCT02044068|||COHORT||RETROSPECTIVE|||||||
33836526|NCT04541368|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836527|NCT00636935|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836528|NCT04383951|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|While this is an open label study, the principal investigator will be blinded to the results of efficacy outcomes such as MRI-PDFF, Body composition data, VCTE by FibroScan® and study questionnaires.|Block randomization will be utilized to ensure balancing of treatment groups throughout enrollment. 30 participants will be assigned to the ketogenic diet arm and 10 will be assigned to standard of care.|f|f|t|f
33836529|NCT02614612|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836530|NCT02847442|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836531|NCT05926869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836532|NCT00658294|||COHORT||PROSPECTIVE|||||||
33836533|NCT06186869|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836534|NCT05897047|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective, two-armed randomized controlled trial (RCT)||||
33836535|NCT00181506|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836536|NCT03952442|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33836537|NCT04540237|||CASE_CONTROL||PROSPECTIVE|||||||
33836538|NCT03995797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836539|NCT04198571|||CASE_ONLY||RETROSPECTIVE|||||||
33836540|NCT05914064|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836541|NCT00200070|RANDOMIZED|PARALLEL||||SINGLE||||||
33836542|NCT05109572|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836543|NCT06147492|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836544|NCT06156059|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Indistinguishable oral suspension or capsule|double blind randomized|t|t|t|t
33836545|NCT01454739|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836546|NCT02937649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836547|NCT06225440|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Participants (and supplements) will be coded and randomly allocated (applied randomly by software) to treatment arms to eliminate order effects and maintain research staff blinding.||t|t|t|t
33836548|NCT03599947|||OTHER||PROSPECTIVE|||||||
33836549|NCT01589926|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33836550|NCT05577325|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836551|NCT05707910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836552|NCT00972322|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836553|NCT04923490|||OTHER||PROSPECTIVE|||||||
33836554|NCT04330651|||COHORT||PROSPECTIVE|||||||
33836555|NCT02551211|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836556|NCT02332304|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836557|NCT06265519|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|0|||||
33836558|NCT00402051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836559|NCT03443336|||OTHER||PROSPECTIVE|||||||
33836560|NCT04455503|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836561|NCT00627289|||COHORT||PROSPECTIVE|||||||
33836562|NCT04817358|||CASE_ONLY||CROSS_SECTIONAL|||||||
33836563|NCT05316974|||COHORT||PROSPECTIVE|||||||
33836564|NCT02737423|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836565|NCT01686867|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33836566|NCT02552147|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33836567|NCT02387697|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836568|NCT02523690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836569|NCT02406248|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836570|NCT02034019|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836571|NCT02866669|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|f|f|t
33836572|NCT03439358|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836573|NCT05204069|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33836574|NCT05716568|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33836575|NCT03354468|||COHORT||CROSS_SECTIONAL|||||||
33836576|NCT03266718|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836577|NCT01336998|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836578|NCT02353468|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836579|NCT02389634|||COHORT||PROSPECTIVE|||||||
33836580|NCT00002264||||TREATMENT||||||||
33836581|NCT00061594|RANDOMIZED|||TREATMENT||DOUBLE||||||
33836582|NCT00460018|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33836583|NCT06241781|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836584|NCT00762476|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33836585|NCT04038242|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
33836586|NCT01516749|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836587|NCT00634842|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836588|NCT00003337||||DIAGNOSTIC||||||||
33836589|NCT01972932|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33836590|NCT00025077||||TREATMENT||||||||
33836591|NCT03272503|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836592|NCT05087251|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836593|NCT02270671|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836594|NCT06151210|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836595|NCT02769442|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836596|NCT06146556|||COHORT||PROSPECTIVE|||||||
33836597|NCT00035386||||TREATMENT||||||||
33836598|NCT00775411|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836599|NCT02398253|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836600|NCT01179776|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836601|NCT00273286|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33836602|NCT00155805|||DEFINED_POPULATION||OTHER|||||||
33836603|NCT04193423|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|It is a single-blind study: only the investigator performing the measurements will be blinded.|It is a randomized controlled clinical trial with parallel groups.|t|f|f|f
33836604|NCT06068140|||COHORT||PROSPECTIVE|||||||
33836605|NCT06215209|||OTHER||PROSPECTIVE|||||||
33836606|NCT02373631|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836607|NCT03809039|RANDOMIZED|SEQUENTIAL||OTHER||QUADRUPLE|||t|t|t|t
33836608|NCT01857037|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836609|NCT03740243|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836610|NCT06487663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836611|NCT02180451|||CASE_ONLY||PROSPECTIVE|||||||
33836612|NCT05688618|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
33836613|NCT02888197|||COHORT||PROSPECTIVE|||||||
33836614|NCT00162617|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33836615|NCT02768350|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836616|NCT00730015|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836617|NCT05355129|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE|||t|t|t|f
33836618|NCT02529423|RANDOMIZED|FACTORIAL||PREVENTION||TRIPLE|||t|f|t|t
33836619|NCT00808002|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836620|NCT06385184|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836621|NCT04149704|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836622|NCT00016224||||TREATMENT||||||||
33836623|NCT01535001|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836624|NCT05711277|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33836625|NCT06508892|||COHORT||PROSPECTIVE|||||||
33836626|NCT00524186|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836627|NCT05633498|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836628|NCT04872023|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33836629|NCT04395170|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836630|NCT01893476|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836631|NCT03698799|||COHORT||PROSPECTIVE|||||||
33836632|NCT01353547|||COHORT||PROSPECTIVE|||||||
33836633|NCT05071313|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33836634|NCT03358238|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33836635|NCT03219177|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
33836636|NCT02614183|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836637|NCT04537988|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||Testing a prototype of an eHealt self-management intervention of long-term weight loss maintenance to evaluate usability and preliminary efficacy.||||
33836638|NCT01857336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836639|NCT02693951|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836640|NCT02855736|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836641|NCT01403870|||COHORT||PROSPECTIVE|||||||
33836642|NCT04879212|RANDOMIZED|PARALLEL||PREVENTION||NONE||"1. PCIA +Acupuncture group~2. PCIA +2 Hz Electroacupuncture group~3. PCIA +20/100 Hz Electroacupuncture group"||||
33836643|NCT06442124|||COHORT||PROSPECTIVE|||||||
33836644|NCT01663506|||COHORT||PROSPECTIVE|||||||
33836645|NCT01882153|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836646|NCT04548986|NA|SINGLE_GROUP||SCREENING||NONE||||||
33836647|NCT01999972|NON_RANDOMIZED|||TREATMENT||NONE||||||
33836648|NCT00551746|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
33836649|NCT04696393|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836650|NCT00515788|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836651|NCT05794477|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||"Dose-exploration：Six patients will be enrolled for tolerability observation. If ≥2 subjects in the previous dose level experienced DLTS, an additional 6 subjects in the other dose level were enrolled.~Efficacy-expansion: After determination of the recommended dose for Phase II (RP2D), selected cohorts with different tumor types will be expanded."||||
33836652|NCT01084226||PARALLEL||||TRIPLE|||t|t|t|f
33836653|NCT04923347|NA|SINGLE_GROUP||TREATMENT||NONE|This will be an open-label study.|Participants will receive FF/UMEC/VI via ELLIPTA inhaler.||||
33836654|NCT00292097|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836655|NCT04129047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836656|NCT02081053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836657|NCT00971997|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836658|NCT01371422|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
33836659|NCT02646787|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||f|t|f|f
33836660|NCT06376877|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Nonresponders may have the option for open label active treatment.|t|t|t|t
33836661|NCT02444780|||COHORT||PROSPECTIVE|||||||
33836662|NCT01501851|||COHORT||PROSPECTIVE|||||||
33836663|NCT04229810|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33836664|NCT02129868|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836665|NCT04144647|NA|SINGLE_GROUP||SCREENING||NONE|This is a simple case-controlled study of physiotherapy assessments. It doe snot include masking procedures.|"100 healthy participants aged between 18-80 years old are recruited for this study.~All individuals that express interest in this study, will be provided with a Participant Information Sheet (PIS) either by email or hard copy by post.~All prospective subjects will be screened for matching of inclusion criteria. After a potential participant contacts the PhD student, Ms Viktoria Azoidou, regarding his/her interest in participating in the study, the person will be asked to complete the screening questionnaire via telephone or email as per each individual's preference regarding eligibility criteria. If after screening, a potential participant meets the eligibility criteria, an appointment will be arranged to discuss any concerns or answer any questions participants may have regarding the PIS, then sign the written consent form and be assessed attend the research laboratory for the single testing session."||||
33836666|NCT05238831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836667|NCT00570908|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836668|NCT04030429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836669|NCT05815615|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||t|f|f|f
33836670|NCT04128410|||CASE_ONLY||PROSPECTIVE|||||||
33836671|NCT05213546|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33836672|NCT03570268|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836673|NCT05835271|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective longitudinal, self-controlled, single-case repeated measures alternating treatment, randomized and counterbalanced cross-over experimental trial design, comparing walking endurance without and with a powered exoskeleton.||||
33836674|NCT04852913|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836675|NCT03272906|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33836676|NCT06119152|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836677|NCT00013247|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
33836678|NCT00081575|RANDOMIZED|||TREATMENT||DOUBLE||||||
33836679|NCT06509620|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836680|NCT04627454|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836681|NCT04659122|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Phase 1b portion is a dose escalation study to establish the safest \& most tolerable AT-100 dose.||||
33836682|NCT03786744|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is prospective, non-randomized (open label) with control group study. The total 20 patient will be enrolled in this study. In 10 patient with ASD will be infused with umbilical corb blood. Other 10 patient with ASD will be treated with standard therapy (control group).||||
33836683|NCT01089803|||COHORT||PROSPECTIVE|||||||
33836684|NCT03836859|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Quadruple (subject, Investigator, site staff and Sponsor's clinical research personnel)|Parallel assignment|t|t|t|t
33836685|NCT03725111|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836686|NCT00599274|||CASE_ONLY|||||||||
33836687|NCT02336425|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836688|NCT05323019|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The independent trained individual will not be aware of which treatment arm the participant has been randomized to. The MADRS assessor will have no other contact with the participants apart from remotely assessing the MADRS|Participants will be randomized by a pre-specified block design method after confirming eligibility.|f|f|f|t
33836689|NCT05640492|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33836690|NCT03859817|||COHORT||PROSPECTIVE|||||||
33836691|NCT00537342|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836692|NCT02475304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836693|NCT00955708|||COHORT||PROSPECTIVE|||||||
33836694|NCT01425905|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836695|NCT05518474|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label, pragmatic, randomized controlled internal pilot trial (vanguard phase)||||
33836696|NCT06460792|||COHORT||PROSPECTIVE|||||||
33836697|NCT06113588|||COHORT||OTHER|||||||
33836698|NCT06432244|||COHORT||RETROSPECTIVE|||||||
33836699|NCT00847522|NA|SINGLE_GROUP||PREVENTION||NONE||10 patients were enrolled in the Phase 1 portion of the trial. 80 patients were enrolled in the Phase 2 portion of the trial. 90 patients were enrolled total for the Phase 1 and 2 portions. Results are reported for the 80 patients on the Phase 2 portion.||||
33836700|NCT04266015|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants: patients will receive general anesthesia before intervention Care providers: surgeons will be masked of the treatment group during operation|Randomized double-blind controlled trial|t|t|f|f
33836701|NCT01511263|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836702|NCT01349452|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836703|NCT05893992|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Investigator knows condition assignments; participant knows when they are wearing hearing aids and when they are not|||||
33836704|NCT02981927|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33836705|NCT04041830|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836706|NCT05261841|||COHORT||PROSPECTIVE|||||||
33836707|NCT00399841|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836708|NCT03030313|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33836709|NCT03504345|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836710|NCT05215691|||COHORT||PROSPECTIVE|||||||
33836711|NCT03297502|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836712|NCT04855045|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||The study consists of two parts: an open-label dose escalation part, followed by a double-masked randomized part.|t|t|t|f
33836713|NCT00837590|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836714|NCT01499563|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836715|NCT01383811|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836716|NCT04586166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be masked during the five-year follow-up period. Precautions will be taken to minimize unmasking the study groups. Since RP (retropubic) slings require two suprapubic stab incisions, identical sham incision will also be performed in the SIS (Single-Incision Sling) group.||t|f|f|f
33836717|NCT06205147|RANDOMIZED|PARALLEL||OTHER||SINGLE||Random control trial|f|f|f|t
33836718|NCT04129476|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33836719|NCT02836288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836720|NCT02092532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836721|NCT01560845|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836722|NCT00000331||||TREATMENT||DOUBLE||||||
33836723|NCT04687709|||COHORT||PROSPECTIVE|||||||
33836724|NCT03463499|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836725|NCT05772169|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Double Blind||t|f|t|t
33836726|NCT06106542|||CASE_ONLY||CROSS_SECTIONAL|||||||
33836727|NCT03708497|RANDOMIZED|PARALLEL||PREVENTION||NONE|open label study|women were allocated to one of the three study groups: group I (carbetocin group) received 100 mc carbetocin IV after delivery of the baby, group II (misoprostol group) received 600 mg buccal misoprostol after delivery of the baby, and group III (TA plus misoprostol group) received 1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed||||
33836728|NCT02887820|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836729|NCT02932098|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836730|NCT06291649|||COHORT||PROSPECTIVE|||||||
33836731|NCT04288349|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|"Randomization of the patients included in the study was performed before surgery. Patients were being randomly divided into two groups. All patients getting subarachnoid anesthesia. Perineal block using solution of ropivocaine and epinephrine for the first group was performed and placebo with epinephrine - for the second group. A researcher who does not participate in the surgery and does not contact with patients at all perioperative stages performs randomization and prepares a solution block. Neither the patient nor the operating surgeon and the doctors who register the results of the treatment are not informed about the anesthesia used in each case.~The probability of introduction to each group is 50%. The number of patients in both groups equally and is 50 people."||t|f|t|f
33836732|NCT02902159|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|t|f
33837682|NCT06160661|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
33837683|NCT03510455|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837684|NCT02806492|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33837685|NCT03249870|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837686|NCT00029224|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837687|NCT04237389|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837688|NCT01736540|NA|SINGLE_GROUP||OTHER||NONE||||||
33837689|NCT00661297|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33837690|NCT00480051|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33837691|NCT00358020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33837692|NCT00795223|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33837693|NCT02567851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836733|NCT03924115|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Being treatment supportive care, patients and researchers know who are the participants of the different levels of intervention. The health professionals who attend both CESFAM do not have access to the information of the patients under study, as well as the evaluation of results, to avoid biases both in the care of patients and in the analysis of results. The results evaluator will receive the instrument data and validated questionnaires in previously typed code forms.|Clinical trial with a 3 parallel groups of hypertensive elderly people in 2 primary health center (CESFAM). Group A was chosen at random in CESFAM Hualpencillo, Groups B and C were selected by pairing with group A, in CESFAM Hualpencillo and Talcahuano Sur, respectively. The match was made based on 5 criteria: sex, age (± 5 years), educational level, co-morbidities (diabetes mellitus 2, chronic kidney disease and heart failure) and adherence (adherent or non-adherent). Persons who agreed to participate signed an informed consent before, to be recruited. In Group A, patients were given a smartphone with a data plan for 1 year. In each evaluations, group activities were carried out in CESFAM and home visits to those who did not attend. In each evaluation the instrument developed by the same research team was applied. For updating drugs prescription, in mobile application and collection of clinical data such as tests and controls, weekly visits were made to CESFAM.|f|f|f|t
33836734|NCT05808296|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33836735|NCT03530137|NA|SINGLE_GROUP||OTHER||NONE||||||
33836736|NCT03873454|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836737|NCT01808183|||COHORT||PROSPECTIVE|||||||
33836738|NCT00910897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836739|NCT02760147|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33836740|NCT06544356|||OTHER||CROSS_SECTIONAL|||||||
33836741|NCT01165177|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|f|t|t
33836742|NCT03400683|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836743|NCT00463853|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836744|NCT03380195|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33836745|NCT03614676|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Single Group Assignment is selected because this is a low-interventional, epidemiological study. As such, the study does not have multiple groups/treatment arms that will be compared against one another statistically in the way two study arms would be compared against each other in a clinical trial. Instead, the study will longitudinally follow pregnant women through a 42-day post-delivery period and will also follow the infants born to these women. It should be noted that these are the two populations listed in the protocol, but these are not two groups that will compared against one another. Statistical analyses will be conducted within each group and some analyses will be done across the two groups. However, these two groups should not be considered equivalent to two study arms. This explains why a single group assignment is appropriate while two study groups (mothers and infants) will be examined.||||
33836746|NCT02579772|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33836747|NCT03540277|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836748|NCT02838979|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
33836749|NCT06197659|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|patients, care providers, and outcome assessors will be blinded.|"There are two group;~1. Experimental Group: Group L; Liberal Fluid Group; Peroperative 20 mL/kg/h intravenous ringer lactate will be administered.~2. Sham Comparator: Group R; Restrictive Fluid Group; Peroperative 5 mL/kg/h intravenous ringer lactate will be administered."|t|t|f|t
33836750|NCT05411172|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836751|NCT02054676|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836752|NCT00641680|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33836753|NCT03089996|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33836754|NCT01896765|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836755|NCT03690427|RANDOMIZED|CROSSOVER||OTHER||NONE||Charcoal-heated hookah smoking vs. electronic hookah vaping||||
33836756|NCT04206085|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836757|NCT00855790|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836758|NCT04118413|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|f|t
33836759|NCT05852145|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|colors will be assigned for each sweetener|A Randomized Crossover Clinical Trial|t|t|t|f
33836760|NCT04608838|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Some care providers who involved in the preparation or administration of dosing solutions are unblinded.||t|t|t|t
33836761|NCT01592045|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836762|NCT03936842|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836763|NCT04232904|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|t|f
33836764|NCT02502747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836765|NCT02743897|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836766|NCT06545461|RANDOMIZED|PARALLEL||TREATMENT||NONE|None (Open label)|prospective, randomized parallel three-arm design||||
33836767|NCT03138642|NA|SINGLE_GROUP||TREATMENT||NONE||All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)||||
33836768|NCT00850122|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836769|NCT03157453|||COHORT||PROSPECTIVE|||||||
33836770|NCT00203047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836771|NCT04893525|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Patients will be randomized to receive either a microdosing package or standard dosing package, using permuted blocks of variable sizes (2 and 4). We will stratify randomization by study site.|f|f|f|t
33836772|NCT00560157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836773|NCT00497874|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836774|NCT04420039|||COHORT||RETROSPECTIVE|||||||
33836775|NCT02136368|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
33836776|NCT04437498|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|code for active and sham devices kept by non study personnel.|Veterans are randomized to double blind treatment with active non-invasive Vagal Nerve Stimulation (nVNS) or a sham control.|t|t|t|t
33836777|NCT05728697|||COHORT||CROSS_SECTIONAL|||||||
33836778|NCT00438841||||TREATMENT||NONE||||||
33836779|NCT00658606|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836780|NCT00616083|||COHORT||PROSPECTIVE|||||||
33836781|NCT06297720|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836782|NCT03040934|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836783|NCT00749242|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836784|NCT05713695|RANDOMIZED|PARALLEL||TREATMENT||NONE||MISSION is a time-limited, cross disciplinary, team-based wraparound approach that provides 6 months of psychosocial treatment combined with assertive outreach, empowering clients to access and engage in care and community services to promote recovery. The MISSION treatment curriculum integrates 3 evidence-based practices along with MOUD: 1) Critical Time Intervention (CTI), a time-limited form of assertive community treatment; 2) Dual Recovery Therapy (DRT), which is integrated mental health and substance use group therapy; and 3) Peer Support (PS), offering support for people in recovery by people in recovery.||||
33836785|NCT00760513|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33836786|NCT03142347|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836787|NCT00536276|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836788|NCT01251406|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836789|NCT03435042|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836790|NCT03117764|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836791|NCT02977767|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33836792|NCT03976154|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836793|NCT01617122|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836794|NCT00486252|||CASE_ONLY||PROSPECTIVE|||||||
33836795|NCT01210326|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836796|NCT05398549|RANDOMIZED|PARALLEL||OTHER||SINGLE||Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise|f|f|f|t
33836797|NCT00919451|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836798|NCT04627051|NA|SINGLE_GROUP||TREATMENT||NONE||Treatment of Jetstream™ atherectomy device and Ranger ™ drug coated balloons||||
33836799|NCT03609268|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836800|NCT01181453|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||||||
33836801|NCT00653731|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836802|NCT02847481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836803|NCT02022722|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836804|NCT05055401|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
33836805|NCT05163223|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836806|NCT05773911|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This efficacy study will be a prospective multicenter parallel arm, examiner blinded, randomized clinical trial of 12 months' duration.|t|f|t|f
33836807|NCT02667106|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33836808|NCT03414970|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836809|NCT02828956|||CASE_ONLY||PROSPECTIVE|||||||
33836810|NCT01012947|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33836811|NCT06103643|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE||parallel|t|f|f|f
33836812|NCT02155270|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836813|NCT06266897|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33836814|NCT01621243|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836815|NCT01580553|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
33836816|NCT01243788|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836817|NCT03006640|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836818|NCT05950451|||OTHER||OTHER|||||||
33836819|NCT02931370|||COHORT||PROSPECTIVE|||||||
33836820|NCT02425540|||COHORT||PROSPECTIVE|||||||
33836821|NCT03653923|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE|Psychotherapeutic Investigation - No masking possible|Waiting-List RCT with crossover after Treatment (Waiting-List will be treated, treated subjects will rest)||||
33836822|NCT03090750|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836823|NCT04207580|||COHORT||PROSPECTIVE|||||||
33836824|NCT00002489||||TREATMENT||||||||
33836825|NCT02388152|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836826|NCT05474053|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|The volunteers were randomly allocated to 2 groups, one receiving the brand drug and the other receiving the generic, each receiving a code indicating his/her group and the key of the codes could only be revealed by the principal investigator.||t|t|f|t
33836827|NCT02833805|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836828|NCT04577131|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836829|NCT01377246|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836830|NCT05828004|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33836831|NCT00813722|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836832|NCT06342336|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836833|NCT03520218|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836834|NCT01059162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836835|NCT03272737|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Group 1: Blood flow restriction + low intensity strength exercise Group 2: Low intensity strength exercise|t|f|f|f
33836836|NCT06026475|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant will be masked about allotment of interventional group either CVP or SVV .|"Patients in Conventional Group will be given intraoperative fluids guided by CVP Values .~Patients in GDFT Group will be given fluids guided by SVV values."|t|f|f|f
33836837|NCT02417441|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33836838|NCT02539316|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836839|NCT03181347|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836840|NCT01327846|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836841|NCT04833348|NA|SINGLE_GROUP||OTHER||NONE||||||
33836842|NCT04950946|||COHORT||OTHER|||||||
33836843|NCT04011007|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836844|NCT04591171|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837694|NCT03162107|||COHORT||PROSPECTIVE|||||||
33837695|NCT04392024|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33837696|NCT05529888|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE||group of patients and group of control|f|f|t|t
33837697|NCT04870268|||COHORT||OTHER|||||||
33837698|NCT02903017|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|t|f|f
33837699|NCT01543022|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836845|NCT03620097|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The nutritional supplement used will be a product marketed according to the European Union regulation. This supplement (EUPOLY-3® DHA Infant) will be provided by Biosearch SA (Granada, Spain), as well as the placebo, in identical containers labeled with a numeric code. Product code: EUP007. The composition of both will differ only in that the formula with DHA will be fish oil refined and stabilized by the addition of soy lecithin, tocopherols of natural origin and ascorbic palmitate. In addition, its level of toxic in the raw material is controlled. This product, and the placebo, will keep the rest of the fatty acid profile similar (eg content of linoleic and linolenic fatty acids). It will be designed in a formulation suitable for preschool children with ASD; in liquid form and in a concentrated dose to ingest orally in the least amount possible (approximately 1.5cc in each dose).|The nutritional supplement used will be a product marketed according to the European Union regulation. This supplement (EUPOLY-3® DHA Infant) will be provided by Biosearch SA (Granada, Spain), as well as the placebo, in identical containers labeled with a numeric code. Product code: EUP007. The composition of both will differ only in that the formula with DHA will be fish oil refined and stabilized by the addition of soy lecithin, tocopherols of natural origin and ascorbic palmitate. In addition, its level of toxic in the raw material is controlled. This product, and the placebo, will keep the rest of the fatty acid profile similar (eg content of linoleic and linolenic fatty acids). It will be designed in a formulation suitable for preschool children with ASD; in liquid form and in a concentrated dose to ingest orally in the least amount possible (approximately 1.5cc in each dose).|t|f|t|f
33836846|NCT06064955|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A model to explain factors impacting advance care planning among African Americans||||
33836847|NCT02330770|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836848|NCT03981939|||CASE_CONTROL||RETROSPECTIVE|||||||
33836849|NCT03809598|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|Given the use of a psychotherapeutic intervention involving participation in group sessions, participants and interventionists cannot be blinded to group assignment. The study is designed to minimize the extent to which study staff, aside from interventionists and the primary Study Coordinator(s), are aware of group assignment. The Study Coordinator(s) needs to know group assignment because they will inform participants of their group assignment and will communicate with participants regarding group attendance. The Study Coordinator(s) will be the main point of contact for participants throughout the study to reduce risk of participants revealing their group assignment to other study staff. Participants will be informed that only the Study Coordinator(s) and interventionists, if applicable, are aware of their group assignment. Therefore, in order to ensure the integrity of the research study, they should refrain from discussing their group assignment with other staff members.|The study is a randomized, control trial with an intervention arm, Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnant women (Dimidjian, Goodman, et al., 2016), and treatment as usual (TAU) arm. The study will be blinded to staff (except for the study coordinator(s) and interventionists), but participant blinding is not possible due to the nature of the intervention. Participants will be randomized using a stratified block design after initial eligibility determination.|f|f|t|t
33836850|NCT00654797|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836851|NCT03326024|||CASE_CONTROL||RETROSPECTIVE|||||||
33836852|NCT03288337|||COHORT||CROSS_SECTIONAL|||||||
33836853|NCT02200744|||COHORT||PROSPECTIVE|||||||
33836854|NCT04740723|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||The study is a prospective, single-arm, multi-center, non-randomized feasibility trial||||
33836855|NCT05422989|||CASE_ONLY||PROSPECTIVE|||||||
33836856|NCT02465918|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33836857|NCT04411134|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33836858|NCT00573547|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836859|NCT03210519|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33836860|NCT02082470|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836861|NCT03773913|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
33836862|NCT04200469|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836863|NCT02103114|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836864|NCT00843427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836865|NCT05256862|||COHORT||PROSPECTIVE|||||||
33836866|NCT00983853|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836867|NCT05137743|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The study statistician who will analyze outcome data will be blinded to group assignment.|Randomized controlled trial with participants assigned to one of two treatment groups in parallel for the duration of the study|f|f|f|t
33836868|NCT06109597|||OTHER||RETROSPECTIVE|||||||
33836869|NCT01992367|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33836870|NCT05109767|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33836871|NCT03327831|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836872|NCT00966563|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33836873|NCT04351698|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836874|NCT04040218|NA|SINGLE_GROUP||TREATMENT||DOUBLE||The target population for this study was a representative sample of PT providers that administer and patients that receive dry needling as a treatment modality in the state of Colorado. 440 PT's licensed in Colorado and 2167 patients were recruited for this study. Purposive sampling was implemented through convenience sampling methods; by which PT respondents were included through their association to APTA CO or Kinetacore@ (an education provider in DN) and patients through their PT provider. The PT survey was sent out to APTA CO members and via a Kinetacore email list; which included approximately 900 individuals trained by Kinetacore in CO. All respondents to the PT survey were requested to provide patients with a direct link to the patient survey. Invitation was promoted by APTA CO outside of their member portal to non-members and word of mouth was encouraged.|f|f|t|t
33836875|NCT00725543|||COHORT||PROSPECTIVE|||||||
33836876|NCT02274090|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836877|NCT06307002|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||This is a 2 arm randomized controlled trial comparing standard of care (SOC) counseling alone to What's My Method? (WMM) gameplay in addition to SOC.||||
33836878|NCT06086288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836879|NCT01371708|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836880|NCT03358368|||COHORT||PROSPECTIVE|||||||
33836881|NCT00002198||||TREATMENT||NONE||||||
33836882|NCT00912210|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
33836883|NCT01554722|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33836884|NCT01607151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836885|NCT04518904|||COHORT||RETROSPECTIVE|||||||
33836886|NCT06514976|||CASE_CONTROL||PROSPECTIVE|||||||
33836887|NCT04467723|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836888|NCT02091115|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
33836889|NCT05435053|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836890|NCT02772328|RANDOMIZED|PARALLEL||SCREENING||DOUBLE|||f|f|t|t
33836891|NCT01031498|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33836892|NCT03689777|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33836893|NCT01980004|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836894|NCT04814602|NON_RANDOMIZED|PARALLEL||OTHER||NONE||open labeled||||
33836895|NCT04556812|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836896|NCT02843451|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33836897|NCT00787306|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836898|NCT05464407|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|t|t|f
33836899|NCT00202189|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
33836900|NCT03637413|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836901|NCT00337753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33836902|NCT00102024|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836903|NCT03962140|||COHORT||RETROSPECTIVE|||||||
33836904|NCT00794924|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836905|NCT02928705|||CASE_CONTROL||RETROSPECTIVE|||||||
33836906|NCT03937141|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836907|NCT01174446|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33836908|NCT00219011|RANDOMIZED|PARALLEL||OTHER||DOUBLE||||||
33836909|NCT02000778|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33836910|NCT05406336|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33836911|NCT01758575|||COHORT||PROSPECTIVE|||||||
33836912|NCT03560570|||CASE_CONTROL||RETROSPECTIVE|||||||
33836913|NCT04296968|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|Participants will not be informed about the objective intensities of the painful stimuli as being binary.|Each participant will participate in one experimental session with a duration of 40 minutes. The experimental paradigm consists of 160 painful stimuli of two intensities (low and high), which will be applied using a laser stimulation device (DEKA Stimul 1340, Calenzano, Italy). Preceding to each painful stimulus, visual cues will be presented indicating the intensity of the subsequent stimulus with an accuracy of 75%. After each painful stimulus, participants will be prompted to verbally rate the pain intensity on a scale ranging from 0 ('no pain') to 100 ('maximum tolerable pain'). Brain activity and autonomic activity will be recorded simultaneously using EEG and skin conductance responses (SCRs), respectively.||||
33836914|NCT05115292|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33836915|NCT04377854|||COHORT||PROSPECTIVE|||||||
33836916|NCT03780647|||COHORT||CROSS_SECTIONAL|||||||
33836917|NCT00252083|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33836918|NCT05436925|||COHORT||PROSPECTIVE|||||||
33836919|NCT03477357|||OTHER||CROSS_SECTIONAL|||||||
33836920|NCT00557778|||COHORT||PROSPECTIVE|||||||
33836921|NCT06239415|||COHORT||PROSPECTIVE|||||||
33836922|NCT01445327|||CASE_ONLY||PROSPECTIVE|||||||
33836923|NCT05808803|||COHORT||RETROSPECTIVE|||||||
33836924|NCT03867539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
33836925|NCT02154906|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836926|NCT01160627|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
33836927|NCT03959761|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836928|NCT00387959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836929|NCT01986296|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33836930|NCT01181245|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836931|NCT01951404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836932|NCT00940745|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33836933|NCT00998842|||COHORT||PROSPECTIVE|||||||
33836934|NCT04134624|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||This is a stepwise study with two phases. In phase 1, all eligible patients have a blood culture collected. In phase 2, eligible patients have a blood culture collected and antibiotics started in the prehospital setting.||||
33836935|NCT03898700|NA|SINGLE_GROUP||OTHER||NONE||Pre-post coaching intervention||||
33836936|NCT05439330|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||Each person has a MRI scan done following the requested radiograph. MRI and radiographs are compared for diagnostic purposes.||||
33836937|NCT02986945|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836938|NCT03063684|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33836939|NCT02214511|||COHORT||PROSPECTIVE|||||||
33836940|NCT01355640|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33836941|NCT01159951|||OTHER||RETROSPECTIVE|||||||
33836942|NCT01483144|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33836943|NCT03289559|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33836944|NCT04116801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33836945|NCT05884814|RANDOMIZED|PARALLEL||TREATMENT||NONE||1:1:1 parallel group design||||
33836946|NCT03995927|||COHORT||PROSPECTIVE|||||||
33836947|NCT03350399|||CASE_CONTROL||PROSPECTIVE|||||||
33836948|NCT00171236|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33836949|NCT00460070|||COHORT||CROSS_SECTIONAL|||||||
33836950|NCT04399343|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33836951|NCT02497495|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33836952|NCT00873262|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|||t|f|f|f
33836953|NCT04946578|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||The study conforms to a randomized, single-blinded, placebo-controlled parallel study design.|t|f|f|f
33836954|NCT02119247|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33836955|NCT02170545|||CASE_CONTROL||PROSPECTIVE|||||||
33836956|NCT01667926|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33836957|NCT05761613|NON_RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|All pneumonia outcomes will be adjudicated by a panel blinded to allocation||f|f|f|t
34148453|NCT05996029|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
34148454|NCT01479582|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148455|NCT01950091|RANDOMIZED|FACTORIAL||SUPPORTIVE_CARE||NONE||||||
34148456|NCT01885910|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148457|NCT01905969|||COHORT||RETROSPECTIVE|||||||
34148458|NCT01399008|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148459|NCT03400631|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|Masking only of above.|The first two weeks of this study involve two groups with a crossover at 1 week. From two weeks on, there is a single arm.|t|t|t|t
34148460|NCT03147794|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34148461|NCT04753021|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148462|NCT04795700|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Potential eligible participants were identified by researchers according to medical records at the oncology departments in each hospital. They were recruited with informed consent, and researchers explained the study purposes, procedures, benefits, and risks involved orally. The participants were then randomly allocated to the intervention or the control group according to a computer-generated block randomization list. The generated random numbers were put into consecutively numbered and opaque sealed envelopes. When enrolling and randomising a new participant, the enrolling investigators opened the sealed envelope after participant's name was written on next available envelopes. A sequentially numbered and opaque , sealed envelope system was used by a non-investigator. Additionally, all data collection was conducted by another research assistant who was blind to the study design and allocation of participants.|"Patients in the intervention group had access to conventional care, in addition to receiving the follow-up MSC intervention sessions. The intervention was provided by trained nurses, including one researcher and one MSC therapist. The researcher was regarded as primary leader of the intervention sessions. The leader informed patients of the schedule for each session using the educational manual 'Caring for ourselves, we are together' (developed by psychologists, nursing managers, experienced oncology nurses, and researchers).~No interventions were performed for the control group participants during the study. However, these patients received conventional care in the oncology departments according to the two hospitals' similar nursing guidelines."|t|f|f|t
34148463|NCT05330858|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34148464|NCT01719003|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148465|NCT00384982|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148466|NCT01739543|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34148467|NCT03155308|||CASE_CROSSOVER||CROSS_SECTIONAL|||||||
34148468|NCT04294914|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|The participants are blind to the study hypothesis and therefore the expected outcome of the tests performed|Half the participants will start with intervention 1 after which they will crossover to intervention 2. The other half will start start with intervention 2 before crossing over to intervention 1.|t|f|f|f
34148469|NCT03527719|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Outcome Assessment Committee members will be blinded to outcome assignment.||f|f|f|t
34148470|NCT02499692|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148471|NCT05485883|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148472|NCT02258529|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148473|NCT01146288|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34148474|NCT04845139|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148475|NCT06081192|NA|SINGLE_GROUP||TREATMENT||NONE|Not applied|Single-center, single-group, prospective clinical trial||||
34148476|NCT06194071|||COHORT||PROSPECTIVE|||||||
34148477|NCT04608162|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|f|t
34148478|NCT04983797|NA|SINGLE_GROUP||OTHER||NONE||||||
34148479|NCT02917915|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148480|NCT02105545|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148481|NCT05616585|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||f|f|t|f
34148482|NCT00401505|||COHORT||RETROSPECTIVE|||||||
34148483|NCT02871089|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148484|NCT02990507|NA|SINGLE_GROUP||OTHER||NONE||||||
34148485|NCT04732104|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148486|NCT05514249|NA|SINGLE_GROUP||TREATMENT||NONE|Single patient clinical trial|||||
34148487|NCT03661086|RANDOMIZED|PARALLEL||TREATMENT||NONE||Open label randomized controlled parallel study||||
34148488|NCT00552019|||COHORT||PROSPECTIVE|||||||
34148489|NCT06060860|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148490|NCT01012752|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148491|NCT02881528|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148492|NCT00106574|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148493|NCT00215514|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34148494|NCT01915823|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148495|NCT00164957|RANDOMIZED|PARALLEL||PREVENTION||SINGLE||||||
34148496|NCT02678884|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148497|NCT01029444|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148498|NCT02313883|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148499|NCT05951712|RANDOMIZED|PARALLEL||DIAGNOSTIC||TRIPLE|||t|t|t|f
34148500|NCT00414882|||||PROSPECTIVE|||||||
34148501|NCT02476123|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148502|NCT02179541|||CASE_CONTROL||PROSPECTIVE|||||||
34148503|NCT04274803|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148504|NCT05661045|||COHORT||PROSPECTIVE|||||||
34148505|NCT03529110|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148506|NCT02877498|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148507|NCT01122108|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34148508|NCT02530996|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|Drug was dispensed by the investigational drug services. A controlled, counter-balanced, double-blind, crossover experimental design with two conditions, BH4 and placebo, was employed. There was a washout period of at least 5 days before crossing over into the alternate condition. On|Twelve systemic sclerosis SSc patients were studied 5 hours after oral BH4 administration (10 mg/kg body weight) or placebo on separate days using controlled, counterbalanced, double-blind, crossover experimental design.|t|t|t|t
34148509|NCT05746936|||COHORT||RETROSPECTIVE|||||||
34148510|NCT03623178|||CASE_CONTROL||PROSPECTIVE|||||||
34148511|NCT00002742|RANDOMIZED|||SUPPORTIVE_CARE||||||||
34148512|NCT05618093|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||This is a single center study to evaluate the use of non-invasive measurement of cardiac output and stroke volume to assess risk and response to treatment in patients with pulmonary arterial hypertension (PAH) and non- operable chronic thromboembolic pulmonary hypertension (CTEPH). We anticipate to enroll a total of 100 subjects at Ronald Reagan UCLA Medical Center.||||
34148513|NCT04031872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148514|NCT06164288|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148515|NCT04688463|||COHORT||RETROSPECTIVE|||||||
34148516|NCT04845191|RANDOMIZED|SEQUENTIAL||TREATMENT||TRIPLE||Open label 2 Cohort Phase 1 Study leading to Randomized Phase 2 Study|t|t|t|f
34148517|NCT05204056|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Recruited patients were divided into three groups with different recipes. Group A: twenty patients who were given intraoperative joint cavity infusion therapy using 20ml tranexamic and 40ml iced normal saline; Group B twenty patients who were given 20ml of iced normal saline, 20ml of iced cocktail and 20ml of tranexamic; the left twenty patients were given joint cavity infusion therapy with 20ml tranexamic only as the control group. Intravertebral anaesthesia was selected for the surgery and the operations were performed by the same surgical team. The average operation time was about 1.5 hours, which lasted from the compression of the tourniquet to completed wound dressing.|t|f|f|t
34148518|NCT04463849|NON_RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||||||
34148519|NCT00721539|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34148520|NCT04185415|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34148521|NCT05620784|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the clinical investigator and anesthesiologist/nurse anesthetist will be aware of treatment allocation. The care providers (surgeon, fellow, resident, and nursing team) and patient will be blinded to the treatment allocation. The outcomes assessor will be unblinded at the time of statistical analysis.|Patients will be randomized 1:1|t|t|f|f
34148522|NCT00870194|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148523|NCT01771614|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34148524|NCT05296980|RANDOMIZED|CROSSOVER||PREVENTION||TRIPLE|||t|t|f|t
34148525|NCT00558532|||CASE_CONTROL||PROSPECTIVE|||||||
34148526|NCT02086201|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148527|NCT01862835|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||TRIPLE|||t|t|t|f
34148528|NCT01264614|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148529|NCT04454736|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34148530|NCT01702168|||COHORT||PROSPECTIVE|||||||
34148531|NCT01189305|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148532|NCT04871594|NA|SINGLE_GROUP||TREATMENT||NONE||Multicenter, open-label phase 1b clinical trial||||
34148533|NCT01513681|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34148534|NCT01292564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148535|NCT02845531|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148536|NCT01443130|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148537|NCT00568113|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148538|NCT03636607|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|t|f
34148539|NCT03294629|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34148540|NCT02413411|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||t|f|t|f
34148541|NCT05080634|||COHORT||PROSPECTIVE|||||||
34148542|NCT01095354|||COHORT||PROSPECTIVE|||||||
34148543|NCT05768243|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148544|NCT05986903|||COHORT||PROSPECTIVE|||||||
34148545|NCT00083486||||TREATMENT||||||||
34148546|NCT02320344|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34148547|NCT05895539|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148548|NCT05491746|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34148549|NCT02538133|NA|SINGLE_GROUP||DIAGNOSTIC||DOUBLE|||t|f|t|f
34148550|NCT01521299|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148551|NCT05250791|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148552|NCT02880995|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148553|NCT01459367|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148554|NCT04485195|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148555|NCT01278316|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148556|NCT05500300|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE||"30 male subjects will receive 4 types of electrical stimulation (Aussie, Neo-Russian, Rectangular biphasic symmetric waveform, Rectangular biphasic symmetric waveform with intra-pulse interval) and High Intensity Focused Electromagnetic Field (HIFEM) in a randomized order.~Maximal voluntary isometric contraction (MVIC) and maximal elicited induced contraction (MEIC) will be measured with an isometric dynamometer. The best rep will be used. Whenever the third one is the best, additional measurements will be taken until a decrease in torque is obtained to determine the maximum. MVIC will be used for data normalization.~The Visual Analogue Scale (VAS) will be used to assess tolerance to treatment. One week later, subjects will receive, randomly, a fatigue protocol with the 4 types of electrical stimulation and the HIFEM, which consists in 21 reps. A fatigue index (FI) will be calculated."|t|t|t|t
34148557|NCT04077372|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148558|NCT04475484|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34148559|NCT00066547||||TREATMENT||NONE||||||
34148560|NCT01156168|||OTHER||RETROSPECTIVE|||||||
34148561|NCT01983124|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148562|NCT05592496|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34148563|NCT06120101|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|t|f
34148564|NCT00175409|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148565|NCT00853840|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
34148566|NCT03364140|||CASE_ONLY||RETROSPECTIVE|||||||
34148567|NCT01860898|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148568|NCT01389999|||COHORT||PROSPECTIVE|||||||
34148569|NCT03386734|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34148570|NCT04911179|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148571|NCT02822300|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148572|NCT00499746|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34148573|NCT05245214|||CASE_CONTROL||RETROSPECTIVE|||||||
34148574|NCT04118790|||CASE_CONTROL||PROSPECTIVE|||||||
34148575|NCT04295863|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148576|NCT04527627|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148577|NCT00350467|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148578|NCT02406443|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|f|t|t
34148579|NCT05829863|NA|SINGLE_GROUP||TREATMENT||NONE|The participants will be prevented from knowing the different message appeals to which they are exposed.|During the baseline fMRI scan, participants will be exposed to anti-vaping public service announcements (PSAs) utilizing cognitive, emotional and social appeals to address the negative consequences of vaping.||||
34148580|NCT03839758|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The evaluator who will perform the follow-up clinical examination will also be blind||t|f|f|t
34148581|NCT03128190|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148582|NCT02643823|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148583|NCT01852279|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148584|NCT01249456|||CASE_ONLY||RETROSPECTIVE|||||||
34148585|NCT04808193|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34148586|NCT01893359|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148587|NCT05932264|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148588|NCT06116695|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148589|NCT03463395|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||Sixty patients ≥ 18 years of age presenting to the investigator's laryngology outpatient clinic with LPR, with an RFS ≥ 7 and an RSI ≥ 13, not on anticoagulants, able to tolerate an endoscopy and consent to participate in this research study will be included. One cohort (Group A) will receive standard care (n =30), the other (Group B) will receive standard care plus the Reza band (to be worn as recommended by the manufacturer; n = 30).||||
34148590|NCT03118830|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148591|NCT04419480|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148592|NCT04064346|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Sponsor - identical appearing active and placebo capsules in Part 1; all active capsules in Part 2|"Part 1: 1-week, single-blind, Placebo Run-in Period, followed by a 5- to 6-week single-blind Lixivaptan Titration Period, followed by a 52-week Double-blind, Randomized Treatment Period, with 2/3 participants randomized to receive lixivaptan, and 1/3 participants randomized to receive placebo (the parallel assignment part of the study). There will be a 28-day off-treatment period during which final assessments will be obtained over 3 visits starting on the 8th day after the last dose of double-blind study drug through the 28th day after the last dose of double-blind study drug.~Part 2: 2- to 4-week Lixivaptan Re-titration Period, followed by a 52-week Maintenance Treatment Period. There will be a 28-day off-treatment period during which final assessments will be obtained over 3 visits starting on the 8th day after the last dose of study drug through the 28th day after the last dose of study drug."|t|t|t|t
34148593|NCT02285530|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148594|NCT02222090|||COHORT||PROSPECTIVE|||||||
34148595|NCT06507527|||CASE_ONLY||PROSPECTIVE|||||||
34148596|NCT04591925|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34148597|NCT01840254|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
34148598|NCT03063190|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148599|NCT01767272|RANDOMIZED|CROSSOVER||||NONE||||||
34148600|NCT05192161|||COHORT||RETROSPECTIVE|||||||
34148601|NCT00446186|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148602|NCT01425671|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34148603|NCT03924921|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34148604|NCT00500760|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148605|NCT03562416|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148606|NCT02587546|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148607|NCT00858663|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148608|NCT03333317|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148609|NCT01439126|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148610|NCT03048591|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
34148611|NCT03218579|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148612|NCT02151331|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|||f|f|f|t
34148613|NCT04480034|||COHORT||PROSPECTIVE|||||||
34148614|NCT02297165|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148615|NCT00952614|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148616|NCT00591656|||CASE_ONLY||PROSPECTIVE|||||||
34148617|NCT02308488|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148618|NCT04649047|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148619|NCT03315377|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148620|NCT00554762|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34148621|NCT00422994|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34148622|NCT01188057|RANDOMIZED|CROSSOVER||||NONE||||||
34148623|NCT00846716|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148624|NCT05546255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148625|NCT01940393|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148626|NCT03123042|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148627|NCT00242333|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148628|NCT00214084|RANDOMIZED|PARALLEL||||DOUBLE||||||
34148629|NCT05238259|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148630|NCT05041569|||COHORT||PROSPECTIVE|||||||
34148631|NCT03254355|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148632|NCT01030549|||COHORT||CROSS_SECTIONAL|||||||
34148633|NCT04353882|||CASE_CONTROL||RETROSPECTIVE|||||||
34148634|NCT00190047|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148635|NCT03372005|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34148636|NCT00386555|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148637|NCT05069324|||COHORT||PROSPECTIVE|||||||
34148638|NCT00139217|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148639|NCT02203955|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34148640|NCT05556538|||CASE_CONTROL||PROSPECTIVE|||||||
34148641|NCT02240316|||COHORT||PROSPECTIVE|||||||
34148642|NCT02791412|||COHORT||RETROSPECTIVE|||||||
34148643|NCT02918708|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148644|NCT04052776|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|Double-blinded and undistinguishable pills will be made by a pharmacy laboratory in order to conceal their nature from the clinicians and the participants.|"This study will be monocentric, randomized, double-blind, placebo-controlled with a four-sequence crossover design.~All participants will undergo the 4 treatment arms. and each of them will be their own control."|t|t|t|t
34148645|NCT03090347|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148646|NCT04454541|RANDOMIZED|PARALLEL||TREATMENT||NONE||"Arm A-Greater occipital nerve block The ultrasound-guided GONB was performed to more accurately locate the nerve. The patient was asked to lie prone on the table. To locate the nerve, we searched for the occipital artery in the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process.~Arm B- Multifidus cervicus plan block group (MCPB) Patients will receive continuing low-flow non humidified nasal cannula oxygen (2 L/min) and continued intravenous infusion of Ringer's solution while respiratory signs were closely monitored during the procedure."||||
34148647|NCT04597671|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148648|NCT00188903|||||PROSPECTIVE|||||||
34148649|NCT04287088|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34148650|NCT03131089|||COHORT||PROSPECTIVE|||||||
34148651|NCT02144831|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34148652|NCT00734006|||CASE_CONTROL||PROSPECTIVE|||||||
34148653|NCT01621867|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|f|t|f
34148654|NCT05208775|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148655|NCT05832125|||COHORT||OTHER|||||||
34148656|NCT00777699|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148657|NCT04152213|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Research assistants who have no knowledge about group allocation and study's objectives, will collected the post-intervention data.|prospective, two-arm randomized-controlled trial|f|f|f|t
34148658|NCT03204890|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148659|NCT00783913|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE||||||
34148660|NCT02952560|||OTHER||PROSPECTIVE|||||||
34148661|NCT01214213|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34148662|NCT05116696|||COHORT||RETROSPECTIVE|||||||
34148663|NCT05052619|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34148664|NCT04836988|||CASE_ONLY||OTHER|||||||
34148665|NCT05539209|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148666|NCT01027260|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148667|NCT06040281|RANDOMIZED|PARALLEL||TREATMENT||NONE||Random assignment in 1:1 ratio to either the intervention group (app-assisted, individual support in nutrition and exercise, three-week comprehensive rehabilitation) or control group (Usual care and app-assisted)||||
34148668|NCT06034756|||CASE_ONLY||CROSS_SECTIONAL|||||||
34148669|NCT04590209|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148670|NCT00096018|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148671|NCT01039298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148672|NCT01268215|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148673|NCT04772144|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE||patients were randomized to an in-hospital nurse-led smoking cessation intervention with prescription of free cessation aids and systematic referrral to healthy life-centeres or usual care|f|f|f|t
34148674|NCT00524329|||||PROSPECTIVE|||||||
34148675|NCT00514020|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148676|NCT05389215|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148677|NCT00582881|||COHORT||PROSPECTIVE|||||||
34148678|NCT01650415|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148679|NCT03672955|||COHORT||PROSPECTIVE|||||||
34148680|NCT04248894|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148681|NCT00002807|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148682|NCT04921059|||COHORT||CROSS_SECTIONAL|||||||
34148683|NCT03028636|||COHORT||PROSPECTIVE|||||||
34148684|NCT00775333|||CASE_CONTROL||PROSPECTIVE|||||||
34148685|NCT05330793|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE||This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of an oral probiotic intervention with or without a novel toothpaste and compared with placebo toothpaste and placebo lozenges.|t|t|t|t
34148686|NCT02554214|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148687|NCT04986280|||COHORT||PROSPECTIVE|||||||
34148688|NCT05386212|||CASE_CONTROL||PROSPECTIVE|||||||
34148689|NCT00317408|NON_RANDOMIZED|||TREATMENT||||||||
34148690|NCT02412709|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34148691|NCT01904656|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148692|NCT06242223|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148693|NCT00054691|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148694|NCT03757754|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE|open|Multiple Ascending Dose, Multiple groups, Multiple centers||||
34148695|NCT05407415|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148696|NCT00773890|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148697|NCT05570071|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148698|NCT00388284|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34148699|NCT04496375|||COHORT||PROSPECTIVE|||||||
34148700|NCT00754091|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148701|NCT01763294|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148702|NCT06038994|||CASE_ONLY||PROSPECTIVE|||||||
34148703|NCT03434314|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148704|NCT03963102|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The outcome assessor is blinded to whether the patient is in the control or trial group when assessing the primary outcome at 3 months. There will be an additional member of staff present to ensure blinding is not revealed.|Randomised control study, prospective, assessor blinded.|f|f|f|t
34148705|NCT03052556|NA|SINGLE_GROUP||SCREENING||NONE||||||
34148706|NCT01348555|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34148707|NCT02246608|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148708|NCT00413010|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148709|NCT04764344|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Treatment allocations will be revealed only after study completion, unless there is concern for a serious adverse event in which case treatment team and patient will be unblinded. Interim analysis will be performed at 150 participants to evaluate for effectiveness and power|This is a single-center prospective randomized double-blinded non-inferiority trial with potential assessment of superiority comparing haloperidol to ondansetron for the treatment of nausea and vomiting.|t|t|t|f
34148710|NCT00062608|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE||||||
34148711|NCT03445390|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||Patients selected for this study were being treated for Moyamoya disease and required two operations, scheduled 1-2 weeks apart. With random assignment, patients were administered 1 gram of intravenous acetaminophen at the beginning and end of surgery, and placebo during the other operation.|t|t|f|f
34148712|NCT02274545|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34148713|NCT00409344|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE|||t|t|f|f
34148714|NCT00199888|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148715|NCT00710385|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|f|t
34148716|NCT04024423|||OTHER||RETROSPECTIVE|||||||
34148717|NCT00671450|||CASE_CONTROL||PROSPECTIVE|||||||
34148718|NCT03518346|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34148719|NCT04004403|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34148720|NCT06130982|RANDOMIZED|SEQUENTIAL||BASIC_SCIENCE||TRIPLE||In this experiment, the experimental group intervened in the content of different Health Qigong routines designed in this study. In contrast, the control group intentionally intervened in walking exercise.|t|f|t|t
34148721|NCT02861911|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||f|t|t|t
34148722|NCT00947414|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148723|NCT05301036|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|t|f|t
34148724|NCT06508359|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34148725|NCT03516786|||COHORT||PROSPECTIVE|||||||
34148726|NCT04132635|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148727|NCT03103035|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148728|NCT00508612|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34148729|NCT02054793|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148730|NCT05751148|RANDOMIZED|PARALLEL||DIAGNOSTIC||DOUBLE|||t|f|f|t
34148731|NCT00140959|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148732|NCT02090790|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148733|NCT00154362|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34148734|NCT06508476|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||two groups Group 1 contains 16 patients and will be treated by CAF and SCTG. Group 2 also contains 16 patients and will be treated by CAF and ACM (bioxclude, snoasis medical, Denver, Co.USA).|t|t|t|t
34148735|NCT05165446|||CASE_CONTROL||PROSPECTIVE|||||||
34148736|NCT04542720|||COHORT||PROSPECTIVE|||||||
34148737|NCT00596583|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34148738|NCT04955418|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE||case-control study|f|f|t|f
34148739|NCT02488746|||CASE_ONLY||PROSPECTIVE|||||||
34148740|NCT05977452|||COHORT||PROSPECTIVE|||||||
34148741|NCT05342337|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148742|NCT06102772|||COHORT||PROSPECTIVE|||||||
34148743|NCT01282294|||COHORT||PROSPECTIVE|||||||
34148744|NCT02472496|||COHORT||RETROSPECTIVE|||||||
34148745|NCT05055882|||COHORT||PROSPECTIVE|||||||
34148746|NCT02210091|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148747|NCT02834286|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148748|NCT01477944|||||RETROSPECTIVE|||||||
34148749|NCT00842101|||COHORT||PROSPECTIVE|||||||
34148750|NCT01433302|||CASE_CONTROL||PROSPECTIVE|||||||
34148751|NCT00432939|||COHORT||PROSPECTIVE|||||||
34148752|NCT03505736|||CASE_ONLY||PROSPECTIVE|||||||
34148753|NCT00085332||||TREATMENT||NONE||||||
34148754|NCT00031564|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148755|NCT06295705|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148756|NCT00774020|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148757|NCT03968783|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148758|NCT03612843|||COHORT||PROSPECTIVE|||||||
34148759|NCT00766974|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148760|NCT04314219|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148761|NCT04589143|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Parallel Assignment|t|t|t|t
34148762|NCT01968057|NON_RANDOMIZED|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148763|NCT04050267|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE||All participants go through all study arms, in random order.|t|f|f|f
34148764|NCT05471180|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Only the researcher with a degree in Nursing, who will be responsible for carrying out the treatments (opening the envelopes of randomization), will know which treatment will be assigned to each participant (with photobiomodulation or its simulation). The researcher will not be involved in the assessment of injuries.|participants who developed lesions that present erythema with intact skin and erythema with loss of continuity, resulting from IAD, will be included in the study. Participants will be randomly divided into 2 groups: Control group (n=39) - use of liquid protective film in spray + FBM simulation (placebo), Experimental group (n=39) - use of liquid protective film in spray + FBM. FBM will be performed with a 660 nm 100mW diode laser, 2 J per point, in 8 points and radiant exposure of 707 J/cm2. FBM will be applied once a day every 24 hours for 3 days in a row.|t|f|f|t
34148765|NCT03462953|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|||f|f|f|t
34148766|NCT05898230|||COHORT||RETROSPECTIVE|||||||
34148767|NCT00937755|||CASE_ONLY||PROSPECTIVE|||||||
34148768|NCT04246814|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Masking will be double-blind, the volunteer and outcome assessor will not be aware of the individual allocation of participants in the intervention groups.||t|f|f|t
34148769|NCT01751776|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148770|NCT04212013|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||This is a Phase III randomized, double-blind, placebo controlled, multicenter.|t|f|t|t
34148771|NCT03208439|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34148772|NCT01958853|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148773|NCT01290900|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34148774|NCT05400629|NA|SEQUENTIAL||SUPPORTIVE_CARE||NONE|Most outcomes will not be mask, however the outcome assessor will be mask for all muscle biopsy analysis: while analysing the muscle biopsy outcomes, the outcome assessor will not know if it was from baseline or from after the training program.|Participants will complete a 12-week strength training program and return to their normal activities for the following 6 months after the end of the training program.||||
34148775|NCT05325294|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148776|NCT04222855|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34148777|NCT04927793|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34148778|NCT01060436|||COHORT||PROSPECTIVE|||||||
34148779|NCT06507852|||COHORT||RETROSPECTIVE|||||||
34148780|NCT02546089|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148781|NCT05332093|||CASE_CONTROL||PROSPECTIVE|||||||
34148782|NCT03974737|||COHORT||PROSPECTIVE|||||||
34148783|NCT04064645|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34148784|NCT04847557|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34148785|NCT01806064|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148786|NCT01448005|||COHORT||PROSPECTIVE|||||||
34148787|NCT04334564|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34148788|NCT03715296|||COHORT||PROSPECTIVE|||||||
34148789|NCT05489900|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|Patients were randomly divided into two groups using the sequential distribution procedure of Pocock and Simon to balance the amount of sex and age group of patients between the groups. Participants' registration data were replaced by codes for the preservation of personal information.|Patients with Physical Health Status Classification 1 and 2, submitted to elective videolaparoscopic cholecystectomy surgery and previously signed the Free and Informed Consent Form. Continuous infusions of dexmedetomidine or 0.9% saline (placebo) were used in 52 patients. Dexmedetomidine was infused in the intervention group (26 patients) as follows: beginning of anesthetic induction after obtaining venous access at 1mcg/kg/h for 20 minutes, followed by 0.2 - 0.5 mcg/kg/h until the closure of the surgery. The placebo group (26 patients) received 0.9% saline infusion at the same rates as the intervention group.|t|f|f|f
34148790|NCT03957941|RANDOMIZED|CROSSOVER||HEALTH_SERVICES_RESEARCH||DOUBLE|The investigator and outcomes assessor will be blinded to the order the mothers were randomized to.|Participants will be randomized to the order of Intervention and Control pumping session. Excluding the first pumping session of the day, as the volume is highest at that time and more consistent throughout the rest of the day. All 30 mothers will be asked to A (Control): Pump three times while they are away from their infant without using FamilyLink for video observation of their baby during pumping and B (Intervention): Pump three times while they are away from their infant, while watching their baby via FamilyLink.|f|f|t|t
34148791|NCT01147900|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148792|NCT01978626|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34148793|NCT01105455|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148794|NCT03678831|||CASE_CONTROL||PROSPECTIVE|||||||
34148795|NCT03328923|RANDOMIZED|PARALLEL||OTHER||TRIPLE||Participants will receive either 500mg brown seaweed powder (InSea2) or placebo|t|f|t|t
34148796|NCT02966015|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34148797|NCT02223481|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148798|NCT03444012|||OTHER||CROSS_SECTIONAL|||||||
34148799|NCT05449275|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148800|NCT01076621|||COHORT||PROSPECTIVE|||||||
34148801|NCT00279812|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|t|f|f
34148802|NCT01399268|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34148803|NCT06007625|||COHORT||RETROSPECTIVE|||||||
34148804|NCT01872299|||COHORT||PROSPECTIVE|||||||
34148805|NCT01694745|||COHORT||PROSPECTIVE|||||||
34148806|NCT02355951||||SCREENING||||||||
34148807|NCT00025155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148808|NCT02314364|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148809|NCT06064773|||COHORT||PROSPECTIVE|||||||
34148810|NCT02248740|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148811|NCT05212844|||CASE_ONLY||PROSPECTIVE|||||||
34148812|NCT01487993|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34148813|NCT01207245|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148814|NCT02753634|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148815|NCT00820404|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34148816|NCT01143987|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34148817|NCT04736615|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||Stepped-wedge design, steps: 1 month||||
34148818|NCT02469415|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148819|NCT02072525|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34148820|NCT04059107|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148821|NCT03622320|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34148822|NCT05995041|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148823|NCT04534348|||CASE_CONTROL||PROSPECTIVE|||||||
34148824|NCT03241004|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34148825|NCT03867682|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34148826|NCT00148447|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34148827|NCT05952401|RANDOMIZED|PARALLEL||PREVENTION||NONE||Patients will be randomized on a 1:1 basis to usual care or intervention 'nudges to quit'.||||
34148828|NCT03795090|NON_RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|Study is complete blind as only principal investigator knows the coding on curtains and he can differentiate between two physically similar looking patient privacy curtains.|Phase 1, even numbers in coding are treatment and odd coded curtains are control (Blind) Phase 2, odd numbers in coding are treatment and even coded curtains are control (Blind) Phase 3, even numbers in coding are treatment and odd coded curtains are control (Blind)|t|t|t|t
34148829|NCT03394690|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33836958|NCT04601324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34148830|NCT05043545|||COHORT||RETROSPECTIVE|||||||
34148831|NCT01297400|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34148832|NCT05832840|||COHORT||CROSS_SECTIONAL|||||||
33838362|NCT05555147|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|The patients were randomly assigned to one of two groups by a single nurse, who was not involved in the anesthetic management of the patient, while using a computer-generated randomization sequence with random block sizes of two and four. The same nurse prepared syringes containing the nerve block solution. Syringes for the block group (Block group) were filled with 6 mL of 0.5% ropivacaine. The patient, surgeon,and investigator were all blinded to the study and the adequacy of the block.|Thirty minutes prior to surgery the patients received bilateral infraorbital and infratrochlear nerve block. The patient's head was positioned on a central line in the supine position. A 25 gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger . 2 mL of the study solution was slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed Infratrochlear nerve block. After negative aspiration of blood, 1 mL of the study solution was injected. Contralateral nerve block was performed in the same manner.|t|f|t|t
33838363|NCT01294436|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838364|NCT02965105|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33838365|NCT04716751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838366|NCT03527797|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838367|NCT02089555|||CASE_CONTROL||PROSPECTIVE|||||||
33838368|NCT04833413|||COHORT||PROSPECTIVE|||||||
33838369|NCT03615053|NA|SINGLE_GROUP||OTHER||NONE||The PMCH study is a Canadian multicentre, open-label, historically-controlled clinical trial to evaluate the effects of implementing WAPPS-Hemo PopPK-based tailoring of hemophilia prophylaxis regimens using the tailoring dosing function of the WAPPS-Hemo system (WAPPS-Hemo clinical calculator). The study has a non-inferiority design for the primary efficacy and safety outcomes.||||
33838370|NCT04089397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||Randomized open-label trial||||
33838371|NCT04905953|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838372|NCT06517264|RANDOMIZED|PARALLEL||TREATMENT||NONE||Multicenter, controlled, randomized, and open-label study (without blinding) with two treatment arms.||||
33838373|NCT05609604|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33838374|NCT01976572|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838375|NCT03519204|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33838376|NCT01124968|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33838377|NCT02223104|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838378|NCT01987895|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838379|NCT06508957|||OTHER||CROSS_SECTIONAL|||||||
33838380|NCT06436105|||CASE_CONTROL||PROSPECTIVE|||||||
33838381|NCT01294397|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838382|NCT02467439|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838383|NCT00031070|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838384|NCT04948723|||COHORT||CROSS_SECTIONAL|||||||
33838385|NCT04481568|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE||Nonrandom preliminary efficacy trial comparing 2 groups, intervention and control|f|f|t|t
33838386|NCT03424070|RANDOMIZED|CROSSOVER||OTHER||SINGLE|The evaluator who measures the height between the lateral canthus of the eye of the anesthesiologist to the table top will be blinded to the presence of a shoulder roll. The evaluator who will review the final photos of the laryngeal inlet will be blinded to the order of the positioning.|All children will undergo laryngoscopy with and without a shoulder roll (randomly assigned) during which photos will be taken of the larynx. The views will be compared using the POGO scale. Contemporaneously, the anesthesiologist's height from the table top to the lateral canthus of left eye.|f|f|f|t
33838387|NCT02786472|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33838388|NCT05942846|||COHORT||CROSS_SECTIONAL|||||||
33838389|NCT00382447|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33838390|NCT05089045|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33838391|NCT00867295|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838392|NCT02860897|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838393|NCT01914081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838394|NCT00214253|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838395|NCT01782690|||COHORT||PROSPECTIVE|||||||
33838396|NCT03863132|RANDOMIZED|PARALLEL||TREATMENT||NONE||Prospective, controlled, randomized (2:1), parallel group, open-label, multi-centre, international||||
33838397|NCT04631731|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838398|NCT00532870||PARALLEL||TREATMENT||NONE||||||
33838399|NCT02117986|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838400|NCT01590511|||COHORT||PROSPECTIVE|||||||
33838401|NCT00725270|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838402|NCT05620277|NA|SINGLE_GROUP||OTHER||NONE||30 patients will be examined for changes in tooth color after dehydration and rehydration stages.||||
33838403|NCT05015582|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
33838404|NCT03189342|RANDOMIZED|PARALLEL||PREVENTION||NONE||Exercise training The volunteers were assigned to one of three interventions for 4 weeks. Group 1 performed balance and gait exercises. Group 2 performed cognitive activity simultaneously with balance and gait exercises. Group 3 performed cognitive, balance and gait activity training asynchronously at different times during the same day.||||
33838405|NCT05758103|RANDOMIZED|PARALLEL||TREATMENT||NONE||two-group parallel design||||
33838406|NCT05368155|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33838407|NCT05302180|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||SINGLE|The outcomes' evaluators will be blind about the allocation of participants in the study groups and they will be questioned at the end of the study on which group they believe that each participant was allocated in order to evaluate the success/failure of blinding. Due to the nature of the interventions it will not be possible to blind the participants and researchers responsible for the interventions.|hybrid type III effectiveness-implementation randomized controlled trial|f|f|t|f
33838408|NCT00448201|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838409|NCT03377296|NA|SINGLE_GROUP||OTHER||NONE||||||
33838410|NCT05567042|||COHORT||PROSPECTIVE|||||||
33838618|NCT06149325|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|"Experimenter 2 will be in charge of the randomization. He will establish a randomization list through Excel and assign to each patient one of the two possible order (Day 1 RSS / Day 2 Sham OR Day 1 Sham / Day 2 RSS). This Excel will be protected through a password and kept in the CRNL server. He will then fill the envelopes with the order assigned by the randomization list and seal them. Each envelope is assigned an inclusion number.~On the inclusion visit (J0), once the consent form is signed, the sealed envelope will be kept in the medical file of the patient. On the first visit (J1). Experimenter 1 will assess the performance of the patient through the tactile and motor tests, while the Exp2 will be in charge of applying the stimulation.~Once Exp1 finished doing the tactile and motor tasks, she will leave the room and Exp2 will enter in the room, open the sealed envelope and apply the stimulation. He will stay in the room with the patient during the stimulation duration."|The study is a comparative study, to show that the administration of RSS stimulation leads to a better performance compared to the administration of Sham stimulation (control). The participant's performance after receiving Sham stimulation will be unchanged compared to the baseline performance measured before the stimulation. On the contrary, participant's performance after receiving RSS stimulation will show a considerable improvement compared to the baseline performance, proving the superiority of RSS stimulation over the control. The study has a cross-over design, where each participant receives both stimulations, on different days. The two stimulations will be administered in a randomized order across participants, and in double-blind.|t|f|t|f
33838619|NCT05451667|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Double-blinded with regard to the study treatment that subjects receive, without the Investigator, the Sponsor, or the subjects being aware of whether YJ001 or the placebo is administered. All decisions concerning dose escalation will be made in a blinded manner by the safety review committee (SRC).||t|t|t|t
33838620|NCT04505839|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838621|NCT00340704|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838622|NCT00332462|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838623|NCT04027959|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33838624|NCT04243265|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838625|NCT00501683|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838626|NCT05029453|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838627|NCT03059277|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838628|NCT03999983|||CASE_ONLY||PROSPECTIVE|||||||
33838629|NCT03618199|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||SINGLE|"Subject in both phases will immediately know whether the transcranial vibrating system is on.~Analysis of outcomes (1-dizziness, 2-nausea, 3-clinical measures from vestibular nystagmography resulting from the caloric testing) will be blinded."|"First phase: test 20 subjects. They will undergo the caloric testing part of the standard vestibular testing, with and without our transcranial vibration system (10 with device on then off, 10 with device off then on) and will describe their state on a visual analog scale (both dizziness and nausea) at the end.~Success is 1) substantially reduced dizziness ad nausea, 2) statistically unchanged clinical measures.~If (and only if) the first phase is successful, we proceed to the second phase. Second phase: identical to first phase, but is conducted with patients coming in the clinic for vestibular testing.~The order (device on first, or second) will be randomly assigned."|f|f|f|t
33838630|NCT05809505|NA|SINGLE_GROUP||DIAGNOSTIC||NONE|The researchers who evaluate the results and make statistics will be blinded.|The 360-degree turn test will be applied to patients first in the hospital environment and then by teleconference method, and the results will be recorded.||||
33838631|NCT03133832|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838632|NCT03843099|RANDOMIZED|PARALLEL||OTHER||SINGLE|||f|f|f|t
33838633|NCT01426230|||||PROSPECTIVE|||||||
33838634|NCT00263367|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838635|NCT03674216|||CASE_ONLY||PROSPECTIVE|||||||
33838636|NCT03884322|NON_RANDOMIZED|PARALLEL||OTHER||NONE|Masking not possible as obvious which child in pod. Infants were instead matched by age and weight to guarantee uniformity of sample|"Hypothesis: Premature infants placed in elastic fabric pods with opportunity to self initiate exercise pushing against fabric would maintain bone density as well as premature infants receiving traditional joint compression exercises by trained therapists"||||
33838637|NCT01299051|RANDOMIZED|PARALLEL||||NONE||||||
33838638|NCT03099902|||CASE_CONTROL||RETROSPECTIVE|||||||
33838639|NCT04531020|||COHORT||PROSPECTIVE|||||||
33838640|NCT03847649|RANDOMIZED|FACTORIAL||TREATMENT||NONE||"Cohort 1: High Risk - Receives Durvalumab plus Prednisone~Cohort 2: Standard Risk - Randomize 1:1~* Arm A: Durvalumab plus prednisone~* Arm B: Durvalumab (+/- tremelimumab)~For BR34 pts only: Durvalumab (+/- Tremelimumab)"||||
33838641|NCT03180567|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33838642|NCT00167206|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838643|NCT02323958|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|f|t
33838644|NCT04678739|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838645|NCT03995316|RANDOMIZED|PARALLEL||TREATMENT||NONE||2-Arm random control trial||||
33838646|NCT00246090|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838647|NCT02961257|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838648|NCT00643617|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838649|NCT05872477|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||There will be 2 arms with intra individual comparison. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.|t|f|t|f
33838650|NCT04918004|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33838651|NCT05627869|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838652|NCT05631704|RANDOMIZED|SEQUENTIAL||TREATMENT||DOUBLE|This will be a double blind study.|Participants will receive escalating doses of VH4524184 or placebo in Part 1 and Part 2 of the study. In Part 3, participants will receive VH4524184 under fasted and fed conditions.|t|f|t|f
33838653|NCT03750864|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
33838654|NCT01871337|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838980|NCT02086305|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33838981|NCT00357227|||DEFINED_POPULATION||PROSPECTIVE|||||||
33838982|NCT00421655|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838901|NCT04408352|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|"The device shall be assembled and maintained in a sterile environment outside the view of the subject during procedure preparation and treatment. The treating investigator, applicable nursing and site staff, and any representatives supporting the procedure should refrain from discussing the device or treatment assignment during the procedure and applicable follow-up visits. The sham procedure will mimic the Hologic trigone RF ablation device procedure to maintain subject blinding and provide the most accurate assessment of control data while minimizing risk to the subject. Energy will not be delivered to the tissue when each sham ablation is started.To be comparable to the Hologic trigone RF ablation device procedure, the simulated ablation procedure will need to be repeated as many times as necessary to cover the area of the trigone as is done in the treatment arm."|Subjects will be randomized to either the treatment with the Hologic trigone RF ablation device or a sham procedure. Randomization will occur in a 2:1 fashion (treatment: sham) meaning approximately 150 subjects will be treated with the Hologic trigone RF ablation device and 75 control subjects treated with the sham procedure. Randomization will be stratified by site.|t|f|f|t
33838902|NCT02855580|||COHORT||PROSPECTIVE|||||||
33838903|NCT04709458|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838904|NCT06233305|||COHORT||PROSPECTIVE|||||||
33838905|NCT03337438|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838906|NCT04256863|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
33838907|NCT00012753|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838908|NCT03487198|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33838909|NCT05163340|||OTHER||CROSS_SECTIONAL|||||||
33838910|NCT00755105|||OTHER||PROSPECTIVE|||||||
33838911|NCT03837951|||OTHER||PROSPECTIVE|||||||
33838912|NCT02413281|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
33838913|NCT01202149|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33838914|NCT01804868|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33838915|NCT03362983|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838916|NCT01099917|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838917|NCT04962529|||COHORT||PROSPECTIVE|||||||
33838918|NCT02509949|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|f|t
33838919|NCT04262167|RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33838920|NCT02079025|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33838921|NCT05838963|||COHORT||PROSPECTIVE|||||||
33838922|NCT02207686|||COHORT||RETROSPECTIVE|||||||
33838923|NCT06294067|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|For randomization we will use the Research Electronic Data Capture (REDCap) program. Following successful completion of informed consent, the questionnaire and anthropometric assessment participants will be randomized into groups, of a possible six, using a blocked (Latin squares) randomization. These groups will represent DHA0 (0mg/d), DHA1 (100mg/d), DHA2 (200mg/d), DHA3 (400mg/d), DHA4 (800mg/d), and DHA5 (1000mg/d) groups. The Latin square sequences will be randomly allocated to participants with a similar number of participants allocated to each treatment sequence. The participants will only be randomized once all information is collected, informed consent has been obtained and questionnaires have been filled out following the first study call/zoom meeting. Then following their first study in person visit and post blood sample extraction they will be given their DHA capsules, which have been organized by a lab member not directly involved in the study.|Double blinded, randomized, control, dose-response supplementation trial|t|f|t|f
33838924|NCT04964349|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||there are 2 patches of alopecia areata in the same patient one treated with intralesional injection of corticosteroid and the other one will be treated by jessenersolution|t|f|f|f
33838925|NCT06382402|||CASE_CONTROL||PROSPECTIVE|||||||
33838926|NCT02159040|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838927|NCT02218723|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33838928|NCT01815853|RANDOMIZED|PARALLEL||TREATMENT||NONE||Neoadjuvant Chemoradiotherapy versus Neoadjuvant Chemotherapy||||
33838929|NCT06045052|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838930|NCT06106867|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|||t|f|f|t
33838931|NCT03237442|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838932|NCT04436770|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33838933|NCT01138618|||CASE_CROSSOVER||PROSPECTIVE|||||||
33838934|NCT01135654|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
33838935|NCT04113070|||COHORT||PROSPECTIVE|||||||
33838936|NCT00003622|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838937|NCT04215445|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838938|NCT02630875|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33838939|NCT02933086|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838940|NCT00963144|||COHORT||PROSPECTIVE|||||||
33838941|NCT03274973|||COHORT||PROSPECTIVE|||||||
33838942|NCT02257476|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838943|NCT00682253|||COHORT||PROSPECTIVE|||||||
33838944|NCT03435302|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838945|NCT00328575|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838946|NCT04792203|||COHORT||PROSPECTIVE|||||||
33838947|NCT00276198|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33838948|NCT03247868||SEQUENTIAL||TREATMENT||NONE||||||
33838949|NCT04342143|||COHORT||CROSS_SECTIONAL|||||||
33838950|NCT04997772|||COHORT||CROSS_SECTIONAL|||||||
33838951|NCT00801463|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838952|NCT01126645|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33838953|NCT01481688|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||f|f|f|t
33838954|NCT01646177|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33838955|NCT03470636|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33838956|NCT00804505|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838957|NCT04802889|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
33838958|NCT00958295|||CASE_ONLY||PROSPECTIVE|||||||
33838959|NCT00855504|||COHORT||PROSPECTIVE|||||||
33838960|NCT02784964|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33838961|NCT05829798|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33838962|NCT05715749|NA|SINGLE_GROUP||TREATMENT||NONE|Outcomes assessors are masked to previous participant performance.|||||
33839120|NCT03109236|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding will be maintained by investigators performing analysis of the results. Given the invasive procedure of percutaneous transhepatic cannulation, the investigators felt that it will be unethical to perform sham procedure on control arm patients. Both managing doctors and patient will know which arm they are on but where not inevitable, data collection such as quality of life and results interpretation such as histology and laboratory analysis of results will be performed anonymously.|"This is a 2 arm randomised study patients with decompensated liver cirrhosis involving 33 patients in each arm. Randomisation will be done by statistician to determine which arm patients will be in (control / treatment).~Treatment arm:~Patient will undergo CD133+ cells transplantation at stable compensated state. 5 dose Granulocyte Colony Stimulating Factor (GCSF) will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins.~Control Arm:~Patients will receive 5 doses of GCSF"|f|f|f|t
33839121|NCT03921853|NON_RANDOMIZED|PARALLEL||PREVENTION||SINGLE|According with the availability and the feasibility of the enrolment's requirements, patients will be allocated to a control group with obesity, and another with morbid obesity.|We will compare a control group with obesity with another experimental group with morbid obesity in the metabolic syndrome parameters.|f|f|t|f
33839122|NCT06131151|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33839123|NCT00517023|RANDOMIZED|FACTORIAL||DIAGNOSTIC||NONE||||||
33839124|NCT06031831|||COHORT||OTHER|||||||
33839125|NCT05986500|RANDOMIZED|CROSSOVER||PREVENTION||NONE||||||
33839126|NCT02817061|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
33839127|NCT05567367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839128|NCT03768622|||COHORT||RETROSPECTIVE|||||||
33839129|NCT03404895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Subjects are randomized in the OR to one of two study arms: conventional therapy vs. conventional therapy + venous stent(s).|t|f|f|f
33839130|NCT01849640|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839131|NCT01689857|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839132|NCT03408587|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839133|NCT00426127|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839134|NCT05724238|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33839135|NCT03616483|||COHORT||PROSPECTIVE|||||||
33839136|NCT04277884|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839137|NCT01396850|||CASE_CONTROL||PROSPECTIVE|||||||
33839138|NCT02422576|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839139|NCT01068665|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839140|NCT03434067|||COHORT||PROSPECTIVE|||||||
33839141|NCT06047574|||OTHER||CROSS_SECTIONAL|||||||
33839142|NCT03628547|||COHORT||PROSPECTIVE|||||||
33839143|NCT00368342|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839144|NCT00930670|RANDOMIZED|FACTORIAL||TREATMENT||NONE||||||
33839145|NCT03026439|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839146|NCT01238081|||||PROSPECTIVE|||||||
33839147|NCT02786095|||COHORT||PROSPECTIVE|||||||
33839148|NCT02285296|RANDOMIZED|PARALLEL||OTHER||NONE||||||
33839149|NCT06103604|||COHORT||CROSS_SECTIONAL|||||||
33839150|NCT00734136|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33839151|NCT04791098|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839152|NCT01139853|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839153|NCT04005118|||COHORT||PROSPECTIVE|||||||
33839154|NCT04091061|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33839155|NCT04198155|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839156|NCT00398372|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
33839157|NCT00818727|||CASE_CONTROL||PROSPECTIVE|||||||
33839158|NCT04617470|||COHORT||OTHER|||||||
33839159|NCT01690377|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839160|NCT05383508|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
33839161|NCT02391142|RANDOMIZED|PARALLEL||TREATMENT||NONE||Randomized controlled trial||||
33839162|NCT01685177|||COHORT||PROSPECTIVE|||||||
33839163|NCT05039294|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|using code number and randomly assigned to intervention and control group||t|f|f|f
33839164|NCT04875442|RANDOMIZED|CROSSOVER||OTHER||TRIPLE||"The device studied is worn during the 2 polysomnogaphy nights. The device emits sounds during only one night in order to observe the difference of EEG signals.~The night during which the device emits sounds is determined by randomization. The nature of the second night with the device, will be the reverse of the first, in a crossover fashion."|t|f|t|t
33839165|NCT06517407|||OTHER||PROSPECTIVE|||||||
33839166|NCT02777437|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839167|NCT03023553|NON_RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
33839168|NCT03568643|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839169|NCT03693976|||OTHER||PROSPECTIVE|||||||
33839170|NCT04419233|||CASE_ONLY||PROSPECTIVE|||||||
33839171|NCT05719740|||OTHER||PROSPECTIVE|||||||
33839172|NCT01738126|||COHORT|||||||||
33839173|NCT02343289|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839174|NCT02805712|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
33839175|NCT03780738|||CASE_CONTROL||PROSPECTIVE|||||||
33839176|NCT03042832|RANDOMIZED|FACTORIAL||HEALTH_SERVICES_RESEARCH||NONE||Intention To Treat (ITT) model with clinics randomized to LOCI vs Webinar control||||
33839177|NCT06239051|||ECOLOGIC_OR_COMMUNITY||RETROSPECTIVE|||||||
33839178|NCT02702778|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839179|NCT00990444|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839180|NCT01755377|||COHORT||PROSPECTIVE|||||||
33839181|NCT02251769|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839182|NCT05240066|||COHORT||PROSPECTIVE|||||||
33839183|NCT00426959|NON_RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
33839184|NCT01080326|NA|SINGLE_GROUP||||NONE||||||
33839185|NCT05962190|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33839698|NCT04332159|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||QUADRUPLE|The placebo in this study is a 0,9% saline solution that comes in an identical inhaler as the Methoxyflurane. The inhaler for both group will be prepared by the research pharmacist right before the procedure. The characteristic smell of the Methoxyflurane solution will be reproduced by pouring a few drops of Methoxyflurane just above the tip of the inhaler a couple of minutes before the administration of the Methoxyflurane or placebo (will be done for both groups by a pharmacy technician experienced in double-blind research - CIUSSS de l'Estrie-CHUS site Hôtel-Dieu) to make sure that the double-blind design is respected. The pharmacy is located inside the hospital near the outpatient clinic so packages will be easily available within minutes when patients are recruited. In addition, to lower the risk of group identification, a N-95 mask will be worn during each procedure by the investigators and the research nurse.|"To reach their objectives, the investigators propose a randomized, double-blind, placebo-controlled study on a sample of patients randomized in two different groups:~* Group A (intervention) : Closed nasal fracture reduction under local anesthesia and inhaled Methoxyflurane.~* Group B (control) : Closed nasal fracture reduction under local anesthesia and placebo."|t|t|t|t
33839699|NCT00558844|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839700|NCT00703339|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839701|NCT00558077|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839702|NCT02866513|NA|SINGLE_GROUP||OTHER||NONE||||||
33839703|NCT02237677|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839704|NCT00896597|RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839705|NCT05515354|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839706|NCT01076244|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839707|NCT02506751|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839708|NCT05063695|||COHORT||RETROSPECTIVE|||||||
33839709|NCT03901716|RANDOMIZED|PARALLEL||OTHER||TRIPLE|||t|t|f|t
33839710|NCT04866953|||COHORT||RETROSPECTIVE|||||||
33839711|NCT03128281|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839712|NCT03445793|||COHORT||PROSPECTIVE|||||||
33839713|NCT05511064|NA|SINGLE_GROUP||PREVENTION||NONE||||||
33839714|NCT05152303|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||This is a Multicenter, Randomized, Single Blind, Dose Finding, Phase II Clinical Trial to explore the optimal dose regimen of Remimazolam Tosilate for Injection for sedation in the ICU, as well as preliminarily evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in the ICU|t|f|f|t
33839715|NCT03471858|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839716|NCT06065982|||COHORT||PROSPECTIVE|||||||
33839717|NCT01428427|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839718|NCT01462006|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
33839719|NCT05216822|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33839720|NCT03613025|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
33839721|NCT05909553|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839722|NCT03063151|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||Two groups of participants: Study and control. Each participant will carry out a single one-hour session of EMG test.||||
33839723|NCT02789644|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839724|NCT00555243|RANDOMIZED|PARALLEL||||SINGLE|||f|f|f|t
33839725|NCT02856516|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
33839726|NCT01399918|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839727|NCT04441047|NA|SINGLE_GROUP||PREVENTION||NONE||Subjects over 65yo in two cohorts: ages 65-74 and age 75+||||
33839728|NCT00820170|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839729|NCT05249608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839730|NCT04703998|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33839731|NCT00633269|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839732|NCT04175314|||CASE_CONTROL||CROSS_SECTIONAL|||||||
33839733|NCT03957369|||CASE_ONLY||CROSS_SECTIONAL|||||||
33839734|NCT02922504|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
33839735|NCT01093443|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33839736|NCT00600327|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839737|NCT01622894|||CASE_ONLY||PROSPECTIVE|||||||
33839738|NCT02110004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33839739|NCT04372862|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|double-blinded|prospective comparative randomized clinical trial|t|t|t|f
33839740|NCT03799744|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||"This is a phase I trial, multicenter, open label, and dose escalation study. Patients will be entered at each dose level, according to a planned dose escalation schedule. Absence of unacceptable toxicity at the previous dose is required for entering a patient in the subsequent level.~The investigational treatment will be a single i.v. VCN-01 dose combined with concomitant i.v. durvalumab (MEDI4736) 1500 mg Q4W (Arm I) or durvalumab starting two weeks after VCN-01 administration, sequential schedule (Arm II). Patient recruitment in Arm I and Arm II will be performed in parallel based on slot availability. Only one single dose of VCN-01 will be administered to each patient during the trial. Durvalumab will be administered Q4W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion."||||
33839741|NCT04317378|||COHORT||PROSPECTIVE|||||||
33839742|NCT03553511|RANDOMIZED|PARALLEL||PREVENTION||NONE||Prospective Randomized Clinical trial||||
33839743|NCT06117423|NON_RANDOMIZED|SEQUENTIAL||OTHER||NONE||||||
33839744|NCT05299255|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839745|NCT04806438|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839746|NCT06263075|||COHORT||PROSPECTIVE|||||||
33839747|NCT03808701|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33839748|NCT03366532|||COHORT||PROSPECTIVE|||||||
33839749|NCT00566891|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33839750|NCT04014647|||CASE_CONTROL||PROSPECTIVE|||||||
33839751|NCT04389034|||COHORT||RETROSPECTIVE|||||||
33839752|NCT00858689|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33839753|NCT06307717|||COHORT||PROSPECTIVE|||||||
33839754|NCT02199158|NA|SINGLE_GROUP||TREATMENT||SINGLE|||f|f|f|t
33839755|NCT01038427|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33839756|NCT03923517|NA|SINGLE_GROUP||OTHER||NONE||This pilot study is a single-site study. One intervention group (no control group) Not randomised Open label||||
33840097|NCT05097391|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Upon completion of all the baseline assessments, consenting participants will be stratified by MRS scores (i.e., 1, 2, and 3) and randomized into two groups: over-ground walking with lower limb loading or over-ground walking with lower limb non-loading in a 1:1 ratio by a third party not involved in other aspects of the study.~The allocation of participants will be concealed using consecutively numbered, sealed, and opaque envelopes which will be prepared using a web-based randomization tool (available at https://www.sealedenvelope.com) with permuted block sizes of 6.~All outcome assessors will be blinded to participants' group allocation. However, it will be impossible to blind the therapists and participants considering the nature of the interventions."|"Participants will be randomized into either group A (experimental: over-ground walking with lower limb loading) or group B (control: over-ground walking without lower limb loading).~Both groups will receive a warm-up consisting of passive stretching to hamstrings and calf muscles, and a range of motion exercise to the lower limbs for 5 min. Participants allocated to group A will receive conventional exercises (15 min) and then rest for 2 min, then proceeded with overground walking training with lower limb loading (15-25 min), and rest for 2 min. Those assigned to group B will receive the same conventional exercises (15 min) and overground walking but without lower limb loading.~Treatment in both groups will be delivered thrice weekly for 8 weeks."|f|f|f|t
33840098|NCT02740725|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840099|NCT00368927|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
33840100|NCT03202017|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|f|t
33840101|NCT01008800|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840102|NCT02461004|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
33840103|NCT00672737|||COHORT||CROSS_SECTIONAL|||||||
33840104|NCT06112353|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Triple||t|t|t|f
33840105|NCT05631938|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840106|NCT02144103|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840107|NCT02702323|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840108|NCT04164550|||COHORT||PROSPECTIVE|||||||
33840109|NCT00747227|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840110|NCT04906681|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840111|NCT02775370|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840112|NCT01885169|||COHORT||PROSPECTIVE|||||||
33840113|NCT00500344|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840114|NCT04652505|||COHORT||CROSS_SECTIONAL|||||||
33840115|NCT03452852|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840116|NCT05899062|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
33840117|NCT02799394|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840118|NCT03301155|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33840119|NCT05145959|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840120|NCT00476164|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840121|NCT05626153|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||||||
33840122|NCT03466047|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
33840123|NCT02212652|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
33840124|NCT04596839|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840125|NCT01912404|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840126|NCT05044507|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"This is a double-blind study, subjects and Investigators will be blinded to the device setting (Active/Sham). The study site team members receiving, storing, dispensing, preparing, and administering the study interventions will be blinded. Subjects' caregivers will also be blinded. There are no differences in the active and sham device appearance. Due to the non-invasive nature of the treatment, as well as the physical characteristic of the EMF, there is no noticeable difference between sessions conducted using an active or a sham device, facilitating full blinding of both subjects and Investigators.~An independent unblinded statistician (not the study statistician) will perform the assessments described. Only the unblinded statistician and members of the DSMB will be exposed to the interim report."|subjects will be assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0|t|t|t|f
33840127|NCT03055962|RANDOMIZED|PARALLEL||BASIC_SCIENCE||TRIPLE|||t|f|t|t
33840128|NCT03566004|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840129|NCT04061369|RANDOMIZED|PARALLEL||BASIC_SCIENCE||SINGLE|Both the investigator and the participant will be aware of the group assignment. The persons handling the data and statistics will not be aware of the group assignment.|The study will be a randomized design that includes a volunteer receiving one of four test meals.|f|f|f|t
33840130|NCT02299947|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840131|NCT04958577|||CASE_ONLY||PROSPECTIVE|||||||
33840132|NCT03214211|||COHORT||PROSPECTIVE|||||||
33840133|NCT03416660|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|masked to the parameters of laser treatment in each lesion|"The study included 25 Egyptian patients with burn scars recruited from the Out Patient Clinic, Dermatology Department, Cairo University. Each has three post burn scars, assigned to monthly fractional carbon dioxide laser sessions with a total of 3 sessions. parameters are :~Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).~Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).~Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).~3 mm punch biopsy is taken before and one month after last session for assessment of collagen via (Masson's trichrome strain). In addition clinical evaluation is done via Vancouver \& Patient and Observer Scar Assessment Scale"|f|f|f|t
33840134|NCT00613899|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840135|NCT05788627|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
33840136|NCT01261117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840137|NCT05238753|NON_RANDOMIZED|SEQUENTIAL||PREVENTION||NONE||15 patients in control group, 15 patients in interventional group with sequential design in term of daily frequency of non-invasive electromagnetic phrenic nerve stimulation, i.e. starting with 5 patients with 2 stimulation per day, followed by 5 patients with 3 stimulations and 5 patients with 5 stimulations per day||||
33840138|NCT01381575|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840139|NCT05353075|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840140|NCT04554719|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840141|NCT06269094|NA|SINGLE_GROUP||OTHER||NONE||||||
33840525|NCT03232931|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Except for parent reports, all measures will be administered by masked examiners.|A randomized controlled trial design with intent-to-treat analysis in hospitalized preterm infants between 32 and 36 weeks post-menstrual age. Both the control and intervention groups will receive routine neonatal intensive care protocols (including skin-to-skin care by parent when available and daily sessions of exposure to recorded parent's voice). In addition to routine care, the parent-supported multisensory intervention consists of 10 sessions of standardized, therapist-administered, auditory-tactile stimulation that combines contingent recorded mother's voice delivered using a pacifier-activated system, during holding with supportive tactile containment against the therapist's chest, covered by cloth imprinted with mother's scent. Possible covariates, multi- and uni- sensory processing, will be measured at entry into the study and immediately after the treatment phase. Sensory reactivity will be measured at 1 year and language and motor outcomes will be assessed at 2 years.|f|f|f|t
33840526|NCT06431100|||CASE_ONLY||PROSPECTIVE|||||||
33840527|NCT06387108|NA|SINGLE_GROUP||OTHER||NONE||||||
33840528|NCT04835792|||COHORT||PROSPECTIVE|||||||
33840529|NCT01384162|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840530|NCT00780559|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|double blind|parallel treatments|t|f|t|f
33840531|NCT01981226|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840532|NCT05028114|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||"This is a three-part study.~Part 1 (Formulation Optimisation): Participants will be assigned to all 4 different formulations of tricaprilin, with randomization to one of 4 sequences with a 2-day washout in between different formulations. There are 2 series in this part.~Part 1 (Food Effect): Participants will be administered to 1 formulation of tricaprilin. There are 2 series in this part.~Part 2 (Placebo Assessment): Participants will be randomised to 1 of 2 sequences (tricaprilin formulation - matching placebo; matching placebo - tricaprilin formulation) with a 2-day washout between periods.~Part 3 (Titration Tolerability): Participants will be administered to either tricaprilin or a matching placebo."||||
33840533|NCT02436291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840534|NCT00728910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840535|NCT06066411|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Since the application will be performed by the researcher, patients will be blinded in this study. The statistician will be blinded in the evaluation of the data.|Two groups with a massage ball group and control group|t|f|f|t
33840536|NCT00315991|RANDOMIZED|FACTORIAL||||NONE||||||
33840537|NCT05473611|||CASE_CONTROL||RETROSPECTIVE|||||||
33840538|NCT04549649|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
33840539|NCT06106139|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840540|NCT00095277|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
33840541|NCT04210427|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840542|NCT02157064|||COHORT||PROSPECTIVE|||||||
33840543|NCT00116597|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
33840544|NCT03854747|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
33840545|NCT00925678|RANDOMIZED|||||DOUBLE||||||
33840546|NCT03525262|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840547|NCT04024995|||CASE_ONLY||PROSPECTIVE|||||||
33840548|NCT01736943|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840549|NCT05693298|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
33840550|NCT05563350|||COHORT||PROSPECTIVE|||||||
33840551|NCT01655953|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
33840552|NCT02239874|RANDOMIZED|FACTORIAL||OTHER||TRIPLE|||t|f|t|t
33840553|NCT04038164|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Rater-blinded|The design was a randomized, rater-blinded, controlled pilot trial. Participants were randomly assigned either to DAT group (n=17) or Treatment as Usual (TAU control group) (n=16).|f|f|f|t
33840554|NCT02071290|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|||t|f|t|t
33840555|NCT05857592|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||A mixed-method repeated-measures design will be used: data are collected using both qualitative and quantitative methods at two points in time (before and after adaptation) from the same participants.||||
33840556|NCT01792791|||COHORT||PROSPECTIVE|||||||
33840557|NCT00223223|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE||||||
33840558|NCT00536653|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
33840559|NCT01616004|NON_RANDOMIZED|CROSSOVER||BASIC_SCIENCE||SINGLE|||t|f|f|f
33840560|NCT00527956|||||PROSPECTIVE|||||||
33840561|NCT01601379|||CASE_ONLY||PROSPECTIVE|||||||
33840562|NCT04747197|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
33840563|NCT01603966|||CASE_CROSSOVER||PROSPECTIVE|||||||
33840564|NCT00452907|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840565|NCT00441259|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
33840566|NCT02470676|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840567|NCT01681992|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
33840568|NCT01532804|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840569|NCT06177392|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
33840570|NCT02194504|RANDOMIZED|PARALLEL||||NONE||||||
33840571|NCT02830477|||OTHER||PROSPECTIVE|||||||
33840572|NCT06013631|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The accessor will be unaware of treatment group.||f|f|f|t
33840573|NCT05127980|||COHORT||PROSPECTIVE|||||||
33840574|NCT02100345|||COHORT||PROSPECTIVE|||||||
33840575|NCT00677534|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840576|NCT01824589|RANDOMIZED|CROSSOVER||TREATMENT||SINGLE|||t|f|f|f
33840577|NCT00799981|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|"The subjects were handed out numbered boxes with the catheter randomised to be used and then cathererisized by herself.~The investigator was blinded to which catheter was used."|"The study was designed as a randomised, single blind, cross-over study to eliminate bias.~Every subject was catheterisized with both 7 cm and 10 cm long catheters."|f|f|t|t
33840578|NCT03762200|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840579|NCT01431820|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
33840580|NCT05341739|NA|SINGLE_GROUP||TREATMENT||NONE||||||
33840581|NCT00310557|NON_RANDOMIZED|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
33840582|NCT03274895|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
33840583|NCT00196157|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149961|NCT05115747|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|"Double: (Participants and outcome assessors).~* Participants' random allocation was conducted by an independent person. The participants were unaware of the percentage of weight off-loading during the treadmill aerobic exercise training.~* Outcomes Assessor kept blind about the group's allocation and the applied exercise training protocols."|"This interventional study aims to explore the effectiveness of the lower body positive pressure aerobic exercise training program on the glycemic control and the health-related quality of life in patients with diabetic polyneuropathy. Eighty eligible participants were randomly allocated to either group-A (0-percentage weight off-loading; 16-participants), group-B (25-percentage weight off-loading; 15-participants), group-C (50-percentage weight off-loading; 16-participants), group-D (75-percentage weight off-loading; 15-participants), and group-E (control group; 18-participants).~Participants in the study groups received twelve-weeks mild to moderate intensity aerobic training program on the Alter-G anti-gravity treadmill.~The Glycemic control (Fasting blood glucose in mg/dl, glycated hemoglobin, and health-related quality of life were evaluated at three time points: at the beginning of the study, after three months aerobic exercise training and three months post-training cessation."|t|f|f|t
34149962|NCT03880214|||ECOLOGIC_OR_COMMUNITY||CROSS_SECTIONAL|||||||
34149963|NCT01439178|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149964|NCT05037084|||COHORT||CROSS_SECTIONAL|||||||
34149965|NCT02986802|||COHORT||PROSPECTIVE|||||||
34149966|NCT01071629|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149967|NCT00896649|NA|SINGLE_GROUP||SCREENING||NONE||PEM||||
34149968|NCT03039894|||CASE_CONTROL||PROSPECTIVE|||||||
34149969|NCT00203021|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149970|NCT05377736|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149971|NCT00860834|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34149972|NCT00578409|||COHORT||RETROSPECTIVE|||||||
34149973|NCT06269419|||COHORT||PROSPECTIVE|||||||
34149974|NCT04232215|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE||After approximately 8 weeks of monitoring, patients will complete an ease of use survey, then crossover to the alternate study product.||||
34149975|NCT06481085|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34149976|NCT00753974|||CASE_ONLY||PROSPECTIVE|||||||
34149977|NCT01187342|||CASE_CONTROL||PROSPECTIVE|||||||
34149978|NCT01803867|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34149979|NCT05893472|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149980|NCT00859742|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34149981|NCT05632276|NA|SINGLE_GROUP||TREATMENT||NONE||A 4-week device intervention to demonstrate the efficacy, performance and safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of surgical and traumatic wounds||||
34149982|NCT00801021|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34149983|NCT00269204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149984|NCT01754792|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34149985|NCT00521664|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149986|NCT02797158|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149987|NCT04400929|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|This is a double-blind study to investigate immediate versus delayed treatment of iv Leukine® in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. The study will be unblinded at Day 5, or at any time within the first 5 days of study should the patient deteriorate clinically with need for supplemental oxygen FiO2 requirement ≥ 0.5.|This is a randomized, double-blind, placebo-controlled clinical trial of iv Leukine® in 30 patients with confirmed COVID-19 and acute hypoxic respiratory failure.|t|f|t|f
34149988|NCT02851823|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||split-mouth|f|t|f|t
34149989|NCT04621487|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34149990|NCT05385484|RANDOMIZED|PARALLEL||PREVENTION||NONE||In Kenyan communities with high HIV/STI prevalence, men will be randomized to two groups: a control group that receives basic health and financial education or a savings intervention group that receives a mobile banking account with incentives to save.||||
34149991|NCT04709198|||COHORT||PROSPECTIVE|||||||
34149992|NCT02073851|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149993|NCT03953872|||COHORT||PROSPECTIVE|||||||
34149994|NCT03199521|||COHORT||PROSPECTIVE|||||||
34149995|NCT01095120|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34149996|NCT03848767|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34149997|NCT01665352|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34149998|NCT06362122|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34149999|NCT05772078|||COHORT||RETROSPECTIVE|||||||
34150000|NCT03970616|NA|SEQUENTIAL||TREATMENT||NONE||Phase 1 followed by expansion cohort||||
34150001|NCT00997620|RANDOMIZED|PARALLEL||OTHER||DOUBLE|||t|f|t|f
34150002|NCT01909375|||OTHER||PROSPECTIVE|||||||
34150003|NCT04964323|||COHORT||PROSPECTIVE|||||||
34150004|NCT02975752|||COHORT||RETROSPECTIVE|||||||
34150005|NCT00640367|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150006|NCT04250597|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34150007|NCT05340803|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||DOUBLE|Each group will contain 36 patients by double-blind manner using numbered sealed envelopes and the main investigator responsible for measurement ONSD will not be informed about the drug or drugs used for each patient|To compare use of midazolam alone versus combination of midazolam with dexmedetomidine or magnesium sulfate in patients with sever TBI ( Glasgow Coma Scale \< 8 and in need for mechanical ventilation) as regards effect on ICP monitored by US-ONSD as the primary outcome and anti-inflammatory effect (neuroprotective effect) by measurement of serum IL-6 as a secondary outcome.|t|f|f|t
34150008|NCT01058941|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150009|NCT03886155|||COHORT||PROSPECTIVE|||||||
34150010|NCT00651625|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150011|NCT04878692|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150012|NCT05517798|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150013|NCT04087161|||COHORT||PROSPECTIVE|||||||
34150014|NCT01511809|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150015|NCT01172574|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150016|NCT01306474|||FAMILY_BASED||PROSPECTIVE|||||||
34150091|NCT06429189|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||TRIPLE|"Participants will be told they are part of an exercise intervention without any mention of a control group.~Healthcare professionals responsible for the chemotherapy prescription and administration and registering all clinical information will be blinded to the participants' groups.~None of the research team members will know the number of participants, so data analysis will be performed in a blinded setting.~If, at any given moment, a participant reveals her number to a research team member, all posterior data from that participant will be disregarded.~If a participant decides to leave the study or must abandon it due to health complications, the team member with the number information will be informed, and data will be disregarded from the analysis."|"2-arm pragmatic and superiority randomized controlled trial with an intervention and an active control group, with a 1:1 allocation ratio.~Participants in this group will perform a home-based combined exercise program throughout their chemotherapy treatments, starting within 1-2 weeks of its start and ending within 3-4 weeks post-treatment completion.~Women randomized to the control group will receive weekly 30-minute supervised sessions with breathing, stretching, relaxation exercises, and meditation during the intervention period."|t|f|t|t
34150092|NCT02955459|RANDOMIZED|PARALLEL||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34150093|NCT05454826|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150094|NCT03298841|||COHORT||RETROSPECTIVE|||||||
34150095|NCT00675896|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150096|NCT03622632|||COHORT||PROSPECTIVE|||||||
34150097|NCT03181295|RANDOMIZED|SEQUENTIAL||HEALTH_SERVICES_RESEARCH||SINGLE||Single-centre, pilot step wedge trial, with graduated, random intervention roll-out across the clinical setting in four steps|f|f|f|t
34150098|NCT06448819|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150099|NCT02981966|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150100|NCT05726890|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150101|NCT06337591|||CASE_ONLY||PROSPECTIVE|||||||
34150102|NCT06543927|||COHORT||PROSPECTIVE|||||||
34150103|NCT03168360|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150104|NCT05058846|||COHORT||PROSPECTIVE|||||||
34150105|NCT02365571|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||t|f|t|f
34150106|NCT02499042|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150107|NCT00440310|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150108|NCT02033837|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150109|NCT04533230|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Karolinska Trial Alliance (KTA) will conduct the randomization. The administrator at KTA who conducts the randomization will be blinded to the intervention.|Randomized controlled trial|f|f|f|t
34150110|NCT03082352|RANDOMIZED|CROSSOVER||OTHER||NONE|Open Label|||||
34150111|NCT03530670|RANDOMIZED|CROSSOVER||OTHER||SINGLE|single (participant)|Crossover assignment Effect of pharmacological and nonpharmacological premedication on anxiety|t|f|f|f
34150112|NCT05119140|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE|The gastroenterologist who will review pre- and post-intervention endoscopy and pathology reports will be masked to any and all information about the study participants including disease severity and medication.|This is an Open Label study with blinded scorer for endoscopy and pathology reports.||||
34150113|NCT05192213|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150114|NCT02744417|NA|SINGLE_GROUP||TREATMENT||NONE|The outcome assessor was blind to smoking status. Before each follow-up periodontal examination (3, 6 and 12 months), the following procedures were performed by a periodontist: (1) removal of all tobacco stains from subject's teeth and/or dental polishing, with a standardized duration of up to 30 min., (2) 0.12% chlorohexidine rinse (1min.) aimed to hide any possible cigarette odour exhaled from the oral cavity. After these procedures, the examiner entered the examination room fully equipped (including a mask), in order to avoid noticing the smoking status by odour|||||
34150115|NCT00619489|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150116|NCT02904590|||COHORT||PROSPECTIVE|||||||
34150117|NCT06077097|||COHORT||CROSS_SECTIONAL|||||||
34150118|NCT02782767|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34150119|NCT01300455|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34150120|NCT00843544|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150121|NCT02062203|RANDOMIZED|CROSSOVER||OTHER||QUADRUPLE|||t|t|t|t
34150122|NCT02878044|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34150123|NCT04602923|NON_RANDOMIZED|FACTORIAL||TREATMENT||NONE||"3 groups will be compared:~* Group 1: 30 participants suffering from glaucoma who are candidates for XEN Gel Stent implantation~* Group 2: 30 participants suffering from glaucoma who are candidates for trabeculectomy~* Group 3: 30 participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)"||||
34150124|NCT00042666|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150125|NCT05164146|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150126|NCT04080323|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150127|NCT02566733|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150128|NCT00165542|||CASE_ONLY||PROSPECTIVE|||||||
34150129|NCT00915655|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150130|NCT01088854|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||t|f|f|f
34150131|NCT01755650|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34150132|NCT04566406|||CASE_CONTROL||RETROSPECTIVE|||||||
34150133|NCT05781646|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||All patients older than 15 years old with subacute lymphocytic meningitis presenting to the internal medicine clinics of Maharaj Nakorn Chiang Mai hospital between January 2015 and March 2016 were recruited for the study.||||
34150134|NCT03028987|RANDOMIZED|PARALLEL||BASIC_SCIENCE||NONE||||||
34151111|NCT05597618|RANDOMIZED|PARALLEL||OTHER||DOUBLE|The masking technique was used in the randomization process in the research, and care was taken not to know who was in the intervention and who was in the control group during the assignment process until the study started. In the process of hiding random assignment, the closed envelope method was used.|Sixty-eight participants were randomly selected from the list of newly graduated nurses from the hospital using a simple random numbers table. After obtaining consent from the participants and evaluating the inclusion criteria, 68 participants were randomly assigned to the experimental and control groups. Using the block randomization method (randomizer.org), these nurses were assigned to the experimental and control groups by a research assistant in the institution where the researchers were not involved in the study work.|t|f|f|t
34150766|NCT03845595|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The enrolled patients where masked (single blind study), Patients were randomly assigned into two groups without being informed whether they are in the control or the study(experimental) group.|"Randomized controlled study design were the recruited patients were randomly allocated into two groups (control group(GA) and study group(GB)) by random generator using permuted blocks of different sizes. The treatment for all patients in both groups was conducted daily ﬁve days per week for 2 consecutive weeks.The control group (GA) received their conventional physical therapy upper limb physical therapy interventions.~The study group (GB) received contralesional low frequency repetitive transcranial magnetic stimulation (LF-rTMS) in addition to the conventional upper limb physical therapy interventions. All the selected patients were with mild to moderate motor impairments (according to National Institutes of Health Stroke Scale \*NIHSS\* and with mild upper limb spasticity ( according to modified ashworths scale \*MAS\* 1 or 1+) from both sexes who met all the inclusion criteria after signing an institutionally approved informed consent form prior to data collection."|t|f|f|f
34150767|NCT02163785|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150768|NCT05977166|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150769|NCT01339117|RANDOMIZED|CROSSOVER||TREATMENT||TRIPLE|||t|f|t|t
34150770|NCT03678233|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150771|NCT05156255|||OTHER||CROSS_SECTIONAL|||||||
34150772|NCT02661672|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150773|NCT06120894|||COHORT||PROSPECTIVE|||||||
34150774|NCT01404455|NON_RANDOMIZED|PARALLEL||SCREENING||SINGLE|||t|f|f|f
34150775|NCT04023617|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150776|NCT01175395|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150777|NCT06307236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|Single Blinded|Randomized Controlled Study|t|f|f|f
34150778|NCT03343119|||ECOLOGIC_OR_COMMUNITY||OTHER|||||||
34150779|NCT03652467|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150780|NCT04316000|||COHORT||PROSPECTIVE|||||||
34150781|NCT00295932|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150782|NCT00795288|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150783|NCT03893877|RANDOMIZED|CROSSOVER||PREVENTION||SINGLE|||t|f|f|f
34150784|NCT00075556||||TREATMENT||NONE||||||
34150785|NCT00243984|RANDOMIZED|SINGLE_GROUP||TREATMENT||DOUBLE||||||
34150786|NCT02153060|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150787|NCT03343600|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150788|NCT01024192|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150789|NCT05683015|NA|SINGLE_GROUP||TREATMENT||NONE||A prospective, open label, non-randomized study||||
34150790|NCT05383534|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150791|NCT00537407|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150792|NCT00252772|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150793|NCT01791101|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150794|NCT02647346|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150795|NCT04070066|RANDOMIZED|PARALLEL||OTHER||SINGLE|Due to the nature of the interventions, masking cannot be applied to the researcher or the student. However, blinding will be applied to the research team responsible for data analysis and to the expert neonatologist who will perform the evaluations of the video recorded procedures using the checklist. The database will be coded, and the identification code will not be available to the analyst.|For the assignment of the students to the study groups, a randomization sequence will be generated through a computer-generated process. This process will be centralized in the paediatric office of the Universidad de La Sabana (University of La Sabana). The sequence will be generated through the Research Randomizer page (www.randomizer.org), and a permuted blocks strategy with block size of eight (8) will be used. The permuted blocks strategy and the size of the blocks will not be known by the researcher. To ensure the concealment of the random sequence, it will be placed in opaque envelopes at the time of assignment.|f|f|f|t
34150796|NCT03006133|||OTHER||CROSS_SECTIONAL|||||||
34150797|NCT02184832|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34150798|NCT04446741|||CASE_ONLY||PROSPECTIVE|||||||
34150799|NCT00317590|RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34150800|NCT01063088|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34150801|NCT03809910|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34150802|NCT01026272|||COHORT||PROSPECTIVE|||||||
34150803|NCT01410188|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150804|NCT02555202|||COHORT||PROSPECTIVE|||||||
34150805|NCT01794442|||||PROSPECTIVE|||||||
34150806|NCT00790478|RANDOMIZED|FACTORIAL||TREATMENT||TRIPLE|||t|t|t|f
34150807|NCT02264080|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150808|NCT06206811|RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|||t|f|f|f
34150809|NCT05948046|||OTHER||PROSPECTIVE|||||||
34150810|NCT02623504|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150811|NCT03879421|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150812|NCT05570409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Investigator-initiated, multicenter, randomized, double-blind, placebocontrolled clinical trial|t|t|t|t
34150813|NCT01096511|||COHORT||PROSPECTIVE|||||||
34150814|NCT06301295|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150815|NCT00351962|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150816|NCT05716204|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150817|NCT04330027|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150818|NCT02078648|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150819|NCT01545973|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34150820|NCT04115982|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150821|NCT01331928|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150822|NCT05492981|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34150823|NCT03147638|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||Single arm with retrospective arm The retrospective arm is he comparator and they are historic control||||
34150824|NCT05210426|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34150825|NCT04216355|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150826|NCT04764110|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|Double-blind|Double-blind, randomized, control|t|f|t|f
34150886|NCT01176565|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|The trial intervention is conducted open-label to avoid concealing clinically necessary patient blood pressure and intravenous drug administration information. Clinical data including SBP values are primarily taken from entries recorded in to the patient's official medical record by hospital staff and are independently monitor-verified. Assessors for the primary outcome (mRS) at 90 days are are unaware of the treatment assignment or in-hospital clinical course of the subjects assessed. De-identified imaging studies are coded independently of subject number so the central imaging reader is unaware of the treatment assignment, clinical findings, or time points of image acquisition for data recorded from imaging. The study (lead) principal investigator and leadership committee members are unable to associate the treatment assignment of subjects to their outcomes or adverse events for purposes of trial decision-making. Adverse events are adjudicated by an independent oversight committee.|Eligible patients are randomized 1:1 via computer-generated treatment assignment within 4.5 hours of neurological symptom onset to either standard or intensive SBP management using intravenous nicardipine hydrochloride as the primary BP control agent through 24 hours from randomization. Enrolled patients from both treatment arms are otherwise treated similarly after 24 hours, according to their medical needs. Standards of care management for spontaneous intracerebral hemorrhage published in the 2010 American Heart Association guidelines are incorporated in to the study protocol. All enrolled patients are followed through 90 days (± 14 days per protocol window; up to ± 30 days data is used) unless death or withdrawal occurs sooner. Primary analysis based on intent-to-treat (ITT) principles.|f|f|t|t
34150887|NCT00437255|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150888|NCT06298201|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the nature of the intervention, it is not feasible to blind participants or physiotherapists delivering the program. Nonetheless, to preserve the integrity of the trial, outcome assessors (researchers) will remain blinded to the allocation of treatments.|Randomized controlled trial (RCT) with prospective longitudinal follow up|t|f|f|f
34150889|NCT01427634|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|t|f|f
34150890|NCT01650740|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150891|NCT05843318|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150892|NCT02228096|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150893|NCT02478580|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34150894|NCT03818425|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34150895|NCT04420260|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|Once the participant has given its informed consent, and the research team has verified the fulfillment of the inclusion criteria, the prospect receives a text message, to be directed to the pharmaceutical service. The numbered scheme will be dispensed with the code of the intervention, following the order from the allocation listing, provided by the CTCC. The head of the pharmaceutical service will register the date and time of the first dose. He will provide indications for the use, handling, and conservation of the products. Warning signs and symptoms and instructions for communication with the research team to address any concerns the subject may have will be reviewed. He will remind the subject to avoid its damage or loss. He will give the participant instructions to return the container and surpluses of the products at the end of the trial (day 30), he will point out that they are for personal use only and that they cannot be shared.|"Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in workers in Medellín-Antioquia. The randomized clinical trial, parallel design, triple-blind, phase II.~Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in workers in Medellín-Antioquia. The randomized clinical trial, parallel design, triple-blind, phase II.~A two-arm is stipulated, in the following manner:~Group A: Active principle spray + Active principle emulsion. Group B: Placebo spray + Placebo emulsion."|t|t|t|t
34150896|NCT04190004|RANDOMIZED|CROSSOVER||OTHER||DOUBLE|Double|After completion of clinical assessments all subjects will receive either 40 IU of vasopressin or saline in counterbalanced order on two separate days and perform the behavioral tasks|t|f|t|f
34150897|NCT01896583|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34150898|NCT04054466|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE||"The experimentation period will be carried out with a randomized trial type design with concurrent control. The experimental group will receive the counseling and the control group will be constituted by a group of patients randomly selected from the population of patients who started HAART in the last three months in the Strategy who will receive the usual counseling.~Patients will have a baseline measurement of alcohol consumption, adherence to HAART; then monthly evaluations until six months of intervention."|t|f|t|t
34150899|NCT04166760|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE||Double blinded, randomized, crossover design|t|t|t|t
34150900|NCT06106919|||COHORT||PROSPECTIVE|||||||
34150901|NCT02283203|RANDOMIZED|PARALLEL||||DOUBLE|||t|f|t|f
34150902|NCT04129385|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150903|NCT03629912|RANDOMIZED|PARALLEL||PREVENTION||NONE|Staff collecting pre- and post-intervention data are masked to participant condition.|In each wave of the study (14 weeks per wave), participant groups are randomly assigned to one of four conditions (A,B,C,D). Condition A receives exercise + health education. Condition B receives exercise only. Condition C receives health education only. Condition D receives nothing.||||
34150904|NCT05735756|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150905|NCT05308927|||COHORT||OTHER|||||||
34150906|NCT04379999|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||One group receives atorvastatin 20 mg, and the other group receives atorvastatin 20 mg+ aspirin 325mg||||
34150977|NCT06380010|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.|Recruitment involved adolescents with polycystic ovary syndrome. Participants, who expressed their willingness to take part, attended personal meetings with the appointed dieticians who provided comprehensive explanations on the objectives, methods, and the potential benefits/risks of the study. A leaflet with related information was provided to all patients. Every eligible volunteer, and their guardian, signed a written informed consent and then kept a hard copy of the signed document. All eligible females were recruited in 12/2019 and were randomly allocated in groups of one to either the Control group (CG) or the Intervention group (IG). The IG received a personalized Mediterranean dietary plan, delivered through a clinical decision support system, while the CG received general dietary advice. Every participant had two individual sessions with the assigned dietician, at the beginning and at the trial endpoint, which involved anthropometry, dietary assessment, and blood withdrawal.|f|f|f|t
34150907|NCT05121324|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|"Neurologists will assess the primary outcome of seizing on emergency department arrival using a rapid response electroencephalogram (RR-EEG) that is applied to the patient's scalp upon arrival. Site-specific identifiers will not be available to the neurologist when reading the RR-EEG, so they will be masked to whether the patient was treated under the conventional or standardized protocol.~Since the participants' parents will likely see how the paramedics select the midazolam dose and may share that with the participant, they will not be masked to the intervention. The paramedics are the care providers, and they will not be masked to the intervention since their medical director must inform them when their seizure treatment protocol switches from the conventional to the standardized protocol. The investigators will not be masked because they will conduct the training of the paramedic trainers at each site between randomization and implementation of the intervention."|This is a stepped-wedge, cluster-randomized trial. Every 2 months, 1 of the 20 sites will transition, in a staggered manner, from the control (conventional protocol with calculation-based dosing) to the intervention (standardized protocol with age-based dosing), such that all 20 sites will ultimately implement the intervention during the 4-year enrollment period.|f|f|f|t
34150908|NCT01554995|RANDOMIZED|SINGLE_GROUP||TREATMENT||QUADRUPLE|||t|t|t|t
34150909|NCT03563365|RANDOMIZED|FACTORIAL||TREATMENT||SINGLE|Subject is instructed not to discuss or disclose treatment arm with PI.||f|f|t|f
34150910|NCT05839704|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|The patient, care provider and primary investigator will not be blinded to the intervention. The outcomes assessor who collects the post operative data will be blinded to the intervention.||f|f|f|t
34150911|NCT03443427|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|"By observer-blind, it is meant that during the course of the study, the vaccine recipient and those responsible for the evaluation of any study endpoint (e.g. safety, reactogenicity) will all be unaware of whether vaccine or placebo was administered. Each study site is responsible for having a blinding plan. To work in an observer-blind manner, vaccine preparation and administration will be done by authorised medical personnel (e.g. study nurse) who will not participate in any of the study clinical evaluation assays. Two teams of study personnel will hence be set up:~* A team of unblinded personnel (responsible for the preparation and the administration of the vaccines)~* A team of blinded personnel (responsible for the clinical evaluation of the subjects).~The laboratory in charge of the laboratory testing will be blinded to the treatment, and codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample."||t|t|t|t
34150912|NCT03433534|||COHORT||PROSPECTIVE|||||||
34150913|NCT01272869|RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||||||
34150914|NCT02134288|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150915|NCT02263261|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150916|NCT02087722|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150917|NCT01707927|||COHORT||PROSPECTIVE|||||||
34150918|NCT01762813|||COHORT||PROSPECTIVE|||||||
34150919|NCT00389675|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34150920|NCT05400421|||CASE_ONLY||CROSS_SECTIONAL|||||||
34150921|NCT02541786|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34150922|NCT00442325|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150923|NCT03233035|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Ketamine versus placebo as a double blind study|Double Blind Study|t|t|t|f
34150924|NCT03703323|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34150925|NCT02334397|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||f|f|t|f
34150926|NCT01581008|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34150927|NCT05004129|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150928|NCT00607399|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150929|NCT04123184|||OTHER||OTHER|||||||
34150930|NCT04578561|||COHORT||RETROSPECTIVE|||||||
34150931|NCT03908970|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34150932|NCT00782912|||CASE_CONTROL||PROSPECTIVE|||||||
34150933|NCT02831790|RANDOMIZED|PARALLEL||OTHER||SINGLE|||t|f|f|f
34150934|NCT05528133|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150935|NCT00718341|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34150936|NCT03957876|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34150937|NCT04773236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||SINGLE|||t|f|f|f
34150938|NCT00448331|||COHORT||PROSPECTIVE|||||||
34150939|NCT04356040|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||This is a prospective non-randomized parallel-assignment multi-center clinical investigation. The study design includes two subject cohorts: 1) Paroxysmal Atrial Fibrillation Main Study, and 2) Paroxysmal Atrial Fibrillation High Standard Power Substudy. Subjects in the main study cohorts are to be treated using the full range of ablation power settings in the Instructions For Use. Subjects in the Substudy are to be treated in the upper end of the recommended ablation power settings (40-50 Watts).||||
34150940|NCT04982484|||COHORT||RETROSPECTIVE|||||||
34150941|NCT05037513|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150942|NCT01972789|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34150943|NCT06140459|NON_RANDOMIZED|CROSSOVER||SUPPORTIVE_CARE||NONE||Each subject can be evaluated as its own control; the number of samples is generally less than in studies designed as comparative parallel groups. Crossover design studies ensure that each patient can use each type of toothbrush. In this study, for the results to be reliable, a crossover design was used to ensure that all participants used each brush.||||
34150944|NCT04778800|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34150945|NCT04370379|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34150946|NCT05017662|NA|SINGLE_GROUP||OTHER||NONE||||||
34150947|NCT00785343|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34150948|NCT00418054|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150949|NCT00120601|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34150950|NCT05276895|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34150951|NCT03681613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34150952|NCT03640117|||COHORT||PROSPECTIVE|||||||
34150953|NCT02483949|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34150954|NCT05379309|||COHORT||RETROSPECTIVE|||||||
34150955|NCT02093910|NON_RANDOMIZED|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34150956|NCT03083223|||CASE_ONLY||CROSS_SECTIONAL|||||||
34151027|NCT06107660|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"The patient, orthopedic surgeon (investigator or care provider), and outcome assessor performing data analysis will be blinded to this study. The regional anesthesia block is performed prior to surgical incision without the surgeon present, and thus the surgeon will be blinded to which formulation was provided. The patient will be informed that they are receiving a block but will not be informed until data collection is complete at the 3 month mark as to which group they were part of.~Non-blinded Parties: Due to differences in the physical appearance it is impossible to blind the anesthesia team (attending and fellow) performing the block, as the standard block is clear while the Exparel formulation is milky. However, after the regional block has been performed the regional team will have no further contact with the patient as per standard practice, and thus maintaining a separation between those blinded and not."|Enrolled participants will be randomized to receive either a mixture of liposomal bupivacaine/ bupivacaine or standard bupivacaine with adjuncts for their ESPB.|t|t|t|t
34151028|NCT01375608|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151029|NCT00895661|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151030|NCT05418491|||COHORT||CROSS_SECTIONAL|||||||
34151031|NCT00958217|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151032|NCT06316440|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||Patients were randomly divided into intervention group（noise blocking） and control group（No noise blocking）|t|f|f|t
34151033|NCT04435990|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"During the trial, both the investigator and the included subjects will be unaware of the treatment each subject is receiving.~The person in charge of data analysis will also not know the treatment assigned to each subject until the database has been closed.~So that neither the subject nor the investigator knows what treatment each subject is receiving, all the trial medication is identical in terms of outer packaging and appearance."|Randomized, double-blind, placebo-controlled, multi centre, parallel-group study|t|t|t|t
34151034|NCT02325297|RANDOMIZED|PARALLEL||||NONE||||||
34151035|NCT03212456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151036|NCT00273156|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151037|NCT00576472||CROSSOVER||SUPPORTIVE_CARE||QUADRUPLE|||t|t|t|t
34151038|NCT06334614|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participant masking because the clinical trial involves infants||t|f|f|f
34151039|NCT01192828|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151040|NCT03059953|||COHORT||PROSPECTIVE|||||||
34151041|NCT03553082|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34151042|NCT04934085|||CASE_CONTROL||PROSPECTIVE|||||||
34151043|NCT05141461|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|Study investigators will not be aware of what group the participant belongs to when assessing the patient at post-operative period||t|t|t|t
34151044|NCT05275530|RANDOMIZED|PARALLEL||PREVENTION||NONE||"* Parallel-arm randomized controlled trial~* Patient-level randomization~* Four arms~  * Arm 0: Standard of care control~ * Arm 1: Active FIT choice~ * Arm 2: Active colonoscopy choice~ * Arm 3: Active FIT v. colonoscopy choice"||||
34151045|NCT02544997|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151046|NCT03403023|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||A single group of patients with DES is imaged before and after treatment with Restasis, a medication which is already FDA approved for this indication.||||
34151047|NCT05622214|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34151048|NCT00904072|||CASE_CONTROL||RETROSPECTIVE|||||||
34151049|NCT03737877|NA|SINGLE_GROUP||OTHER||NONE||||||
34151050|NCT06264297|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151051|NCT00251251|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151052|NCT05764915|NA|SEQUENTIAL||TREATMENT||NONE||There will be one arm in the study. Enrolled subjects will be treated with RGT-264 phosphate tablets alone.||||
34151053|NCT01075984|RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34151054|NCT06430515|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151055|NCT00185874|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151056|NCT05105867|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151057|NCT02747511|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151058|NCT02272218|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151059|NCT06546176|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151060|NCT06221748|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151061|NCT01364701|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151062|NCT00548236|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151063|NCT06303856|NA|SINGLE_GROUP||PREVENTION||NONE||||||
34151064|NCT06522399|||CASE_ONLY||RETROSPECTIVE|||||||
34151065|NCT00760838|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151066|NCT04607122|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151067|NCT03843801|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151068|NCT05922241|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151069|NCT00086411|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151070|NCT06507384|||COHORT||PROSPECTIVE|||||||
34151071|NCT00454584|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||f|f|t|t
34151072|NCT00946673|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151073|NCT02949388|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|t|t|f
34151074|NCT00326248|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|f|t|f
34151075|NCT00351273|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151076|NCT03396510|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151077|NCT03959982|RANDOMIZED|PARALLEL||TREATMENT||NONE||Subjects will be randomized into two groups: One will receive the device and one will not. Study procedures will be the same for both groups.||||
34151078|NCT03837288|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151079|NCT00354666|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE||||||
34151080|NCT01274429|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151081|NCT01267175|NON_RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34151082|NCT02025439|RANDOMIZED|FACTORIAL||TREATMENT||QUADRUPLE|||t|t|t|t
34151083|NCT03532217|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151084|NCT00443781|NA|SINGLE_GROUP||DIAGNOSTIC||NONE||||||
34151085|NCT02700165|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151086|NCT00071448|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151087|NCT00445276|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151180|NCT06124456|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Random allocation will be performed after subjects have completed the baseline assessments. Subjects and the research personnel delivering the walking program and health education cannot be blinded to group allocation, but the latter will not be involved in the outcome assessments. All personnel involved in the outcome assessments will be blinded to the group allocation, and subjects will be instructed not to disclose their allocation during the assessments. The research personnel conducting the statistical analysis cannot be fully blinded to the treatment allocation for the between-group comparisons but will be blinded to subjects' identity.|Subjects will be randomly allocated to the usual care control or moderate- or vigorous-intensity walking groups on a 1:1:1 basis using block randomization with a block size between 6 and 12. Randomization will be implemented by the biostatistician Co-I or his delegate, who will not interact with the subjects or research personnel during recruitment to avoid allocation bias. The research personnel will then obtain the sequence for each subject to ensure allocation concealment.|f|f|f|t
34151181|NCT00516035|NON_RANDOMIZED|SINGLE_GROUP||PREVENTION||NONE||||||
34151182|NCT00676910|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151183|NCT00474461|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151184|NCT00089947|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151185|NCT02708355|RANDOMIZED|PARALLEL||BASIC_SCIENCE||QUADRUPLE|||t|t|t|t
34151186|NCT01973556|RANDOMIZED|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34151187|NCT02474251|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE|Mechanistic or physiologic study in humans.|||||
34151188|NCT01154543|||COHORT||PROSPECTIVE|||||||
34151189|NCT01759823|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151190|NCT01742689|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151191|NCT01914653|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151192|NCT05152810|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151193|NCT00779207|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151194|NCT01609413|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||DOUBLE|||f|f|t|t
34151195|NCT04014387|RANDOMIZED|CROSSOVER||TREATMENT||QUADRUPLE|||t|t|t|t
34151196|NCT04819295|||COHORT||PROSPECTIVE|||||||
34151197|NCT00763945|||||PROSPECTIVE|||||||
34151198|NCT03470753|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151199|NCT01587092|RANDOMIZED|SINGLE_GROUP||OTHER||NONE||||||
34151200|NCT01033318|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34151201|NCT03407885|RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||NONE||||||
34151202|NCT04445376|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151203|NCT05188495|||COHORT||PROSPECTIVE|||||||
34151204|NCT03993834|||CASE_CONTROL||PROSPECTIVE|||||||
34151205|NCT05807984|NA|SINGLE_GROUP||TREATMENT||NONE||carbon ion therapy||||
34151206|NCT05553418|RANDOMIZED|CROSSOVER||OTHER||NONE||All participants will participate in three (3) study arms, whereby each participant will wear six (6) OBI prototype devices in total: three (3) on the arm and three (3) on the abdomen. A randomization scheme will be provided with the order of study arm + body location (arm/abdomen) + body side (left/right) randomized.||||
34151207|NCT02497690|NON_RANDOMIZED|PARALLEL||HEALTH_SERVICES_RESEARCH||DOUBLE|||f|f|t|t
34151208|NCT02872532|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151209|NCT01756443|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|||t|f|t|t
34151210|NCT01878331|||OTHER||PROSPECTIVE|||||||
34151211|NCT04094584|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151212|NCT04607876|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34151213|NCT04841369|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151214|NCT04598269|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE||Randomized, Double-blind, Vehicle-controlled, Parallel-group Study|t|t|t|t
34151215|NCT00337584|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34151216|NCT01365624|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151217|NCT04827303|||OTHER||PROSPECTIVE|||||||
34151218|NCT04527939|NON_RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Only investigator|Extraperitoneal rectal cancer stage 1|f|f|t|f
34151219|NCT02789891|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151220|NCT02618668|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE|||t|t|t|t
34151221|NCT01283685|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151222|NCT03755908|||COHORT||PROSPECTIVE|||||||
34151223|NCT01628003|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151224|NCT04828005|RANDOMIZED|CROSSOVER||BASIC_SCIENCE||NONE||||||
34151225|NCT03964792|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151226|NCT03392623|RANDOMIZED|PARALLEL||OTHER||DOUBLE|double bind||t|f|t|f
34151227|NCT03465553|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151228|NCT03281304|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151229|NCT03239002|||COHORT||PROSPECTIVE|||||||
34151230|NCT02472613|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151231|NCT06079151|RANDOMIZED|CROSSOVER||TREATMENT||NONE||All patients will be randomly allocated into two groups using the block randomization technique (4 or 8 according to an equiprobable distribution) in a 1:1 ratio. The randomisation will be performed at the begining of the catheterization procedure. In the first arm, the patient will successively receive 30 L/min then 50 L/min of room air. In the second arm, the patient will successively receive 50 L/min then 30 L/min of room air.||||
34151232|NCT06019806|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151233|NCT06135610|||COHORT||RETROSPECTIVE|||||||
34151234|NCT04231916||SEQUENTIAL||DIAGNOSTIC||NONE||||||
34151235|NCT01954563|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151236|NCT00558272|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151237|NCT05771961|RANDOMIZED|PARALLEL||TREATMENT||NONE||Participants are randomly assigned to receive either the rotational atherectomy or conventional stenting alone.||||
34151238|NCT03101085|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|t|f
34151397|NCT05503056|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||||||
34151398|NCT06147583|NA|SINGLE_GROUP||SUPPORTIVE_CARE||NONE||||||
34151399|NCT05906355|NON_RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34151400|NCT05954299|||COHORT||PROSPECTIVE|||||||
34151401|NCT04041245|||COHORT||PROSPECTIVE|||||||
34151338|NCT03737331|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Participants will be randomly assigned with a block randomization design for one of the four groups: no stimulus (i.e. control), invariant, random and variable stimuli. Subjects will be assigned to unique ID code such as 'S00NC', where S means subject, 00N refers to participant number (i.e., 001 or 100), and C the group condition (N - No stimulus; P - Periodic stimulus; V - Variant stimulus; R - Random stimulus).|Older adults at risk of a fall will participate in an 8-week training program. There will be four groups: no stimulus (i.e., control), invariant, random and variable stimuli. The training program will consist in an 8-week program, 3 sessions per week. For each training session, participants will come to the Biomechanics Research Building for a 30-minute training session (2 x 10-minute walking trials with a 10-minute resting period in between), 3 times per week. During the training session, the subjects will be instructed to walk while viewing and synchronizing the steps with the visual stimulus. In the first session of weeks 3, 5 and 7, the subjects will undergo a reassessment of the preferred stride time, wearing the footswitches. This reassessment will be needed to recalculate the preferred stride time and incorporate it in the stimulus in use, in case it has been changed as an effect of the training.|t|f|f|f
34151339|NCT04259684|RANDOMIZED|PARALLEL||PREVENTION||QUADRUPLE||Each of the 40 participants will be stratified based on type of lesion (single ventricle vs. biventricular lesions) and block randomized into 1 of 2 study arms: treatment arm (receiving intraoperative administration of 20 ppm of gNO to the oxygenator of the CPB circuit) and control arm (standard CPB conduct).|t|t|t|t
34151340|NCT06533930|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34151341|NCT00261573|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34151342|NCT03214731|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151343|NCT00727558|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151344|NCT01416623|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151345|NCT00794066|||COHORT||PROSPECTIVE|||||||
34151346|NCT05333380|||COHORT||RETROSPECTIVE|||||||
34151347|NCT03664765|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|Participants will be randomized and blinded to the intervention arm (upper airway and respiratory muscle training arm) versus sham arm|Randomized controlled pilot trial to assess the feasibility of using combined oropharyngeal and respiratory muscle training versus sham training on OSA in patients with chronic SCI/D|t|f|f|t
34151348|NCT01862367|||COHORT||PROSPECTIVE|||||||
34151349|NCT04877769|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34151350|NCT05650853|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34151351|NCT04755452|RANDOMIZED|PARALLEL||PREVENTION||DOUBLE|||t|t|f|f
34151352|NCT06174909|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|t|f
34151353|NCT01577342|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151354|NCT03679455|NA|SINGLE_GROUP||TREATMENT||NONE||multi-center, single-arm, open label, non-randomized||||
34151355|NCT03975569|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151356|NCT04097977|NON_RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||The project is designed as a non-randomized intervention study with a control group.||||
34151357|NCT04809155|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34151358|NCT04891185|NON_RANDOMIZED|PARALLEL||DIAGNOSTIC||NONE||||||
34151359|NCT00649831|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151360|NCT01269502|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34151361|NCT00224341|RANDOMIZED|FACTORIAL||PREVENTION||SINGLE||||||
34151362|NCT05508893|NON_RANDOMIZED|SINGLE_GROUP||SCREENING||NONE||Every participant will perform an exercise test and receive a CTA afterwards||||
34151363|NCT03852979|NA|SINGLE_GROUP||TREATMENT||NONE||One arm two-stage Simon's design with response to neo-adjuvant chemotherapy as the primary endpoint||||
34151364|NCT05318820|RANDOMIZED|CROSSOVER||OTHER||NONE||This is a monocentric, randomized, open-label, single-dose, three-cycle, partial replicate clinical study designed to evaluate the pharmacokinetic profile and bioequivalence of HMPL-523 Tablets produced by two different manufacturers in healthy subjects. This study plans to enroll 39 healthy Chinese subjects who will be randomized (1:1:1) into one of three sequence groups (Test \[T\]/Reference\[R\]/R group, RTR group and RRT group) to receive a single dose in each cycle with a washout period of at least 7 days, where T is the test product \[i.e., HMPL-523 Tablets manufactured by Hutchison MediPharma (Suzhou) Limited.\], and R is the reference product (i.e., HMPL-523 Tablets manufactured by WuXi STA).||||
34151365|NCT06001619|NON_RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151366|NCT05216627|||COHORT||PROSPECTIVE|||||||
34151367|NCT05845463|RANDOMIZED|CROSSOVER||DIAGNOSTIC||NONE|Not possible as endoscopists randomised into 2 groups one with AI assistance and one without assistance|The research team propose to carry out a randomised crossover trial to assess the impact of AI on the quality of upper GI endoscopy||||
34151368|NCT06227936|||COHORT||RETROSPECTIVE|||||||
34151369|NCT00768482||CROSSOVER||TREATMENT||NONE||||||
34151370|NCT00940784|RANDOMIZED|FACTORIAL||TREATMENT||DOUBLE|||t|f|t|f
34151371|NCT02859896|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151372|NCT04216407|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|f|t
34151373|NCT04738630|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151374|NCT02186704|||CASE_CONTROL||PROSPECTIVE|||||||
34151375|NCT04861428|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34151376|NCT02027753|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151377|NCT05539079|||COHORT||PROSPECTIVE|||||||
34151378|NCT01853956|RANDOMIZED|CROSSOVER||OTHER||NONE||||||
34151379|NCT00552409|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151380|NCT01416480|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151381|NCT03873623|||COHORT||PROSPECTIVE|||||||
34151382|NCT04607460|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151383|NCT06382935|RANDOMIZED|PARALLEL||TREATMENT||TRIPLE|Sealed envelopes|Non-surgical periodontal treatment Subgingival biofilm ultrasonic debridement with MINST or Q-SI|t|f|t|t
34151384|NCT00455208|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151385|NCT01676623|RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151386|NCT06172946|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34151387|NCT06124820|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Sham|Monalisa Touch (SmartXide2 V2LR, DEKA, Florence, Italy)|t|f|f|f
34151388|NCT00708734|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151389|NCT01220180|||ECOLOGIC_OR_COMMUNITY||PROSPECTIVE|||||||
34151861|NCT06175169|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|All image data were anonymized with the deletion of Dicom header information such as sex, age, and CT protocol. Participants were given CT slices that were identical to the range of the VOI for appendicitis generated automatically through the extraction pipeline of the IA model. A total of 20 axial CT slice images of a 5-mm cut were masked with blinded truth labeling and a blackened background on the outside of the body surface.|"A deep learning model, Information of Appendix (IA), based on a fully automated 3D convolutional neural network using transfer learning, has been developed to diagnose appendicitis in an abdominopelvic CT scan. The IA model was trained, validated, and tested on 3D-DenseNet, 3D-EfficientNet, and 3D-ResNet. External validation was completed through the data exfiltration of external institutions. The IA model yielded the probability of three classifications: non-appendicitis, simple appendicitis, and complicated appendicitis for patients who presented to the emergency room with abdominal pain and underwent abdominopelvic CT for suspected acute appendicitis.~In this study, we confirmed that the intervention did not affect the included patients. Considering the minimal risk to human subjects and the ethical and legal aspects of artificial intelligence, we excluded the involvement of the IA model in all treatment processes."|t|f|f|f
34151862|NCT00569868|NON_RANDOMIZED|SINGLE_GROUP||||NONE||||||
34151863|NCT05556577|||COHORT||PROSPECTIVE|||||||
34151864|NCT02903043|||COHORT||PROSPECTIVE|||||||
34151865|NCT06110000|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Blinding,refers to a practice where study participants are prevented from knowing certain information that may somehow influence them-thereby tainting the results.|Participants are divided into two groups. Group A assigned to pragmatic group of interventions and group B assigned with scapular strengthening exercises at the beginning of the trial and continue that throughout the length of the trial.|t|f|f|f
34151866|NCT00819117|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151867|NCT01993563|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|f|t
34151868|NCT02266576|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|f|t
34151869|NCT05760404|||OTHER||PROSPECTIVE|||||||
34151870|NCT06280885|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE|Not indicated for this feasibility study.|Feasibility randomised controlled trial using a 2:1 randomisation||||
34151871|NCT02419820|RANDOMIZED|PARALLEL||SCREENING||QUADRUPLE|||t|t|t|t
34151872|NCT01949519|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151873|NCT06102109|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151874|NCT04365452|NA|SINGLE_GROUP||PREVENTION||NONE||Medela Invia pump||||
34151875|NCT03688100|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151876|NCT03586115|||OTHER||CROSS_SECTIONAL|||||||
34151877|NCT01067469|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151878|NCT05463263|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||Patients will be assigned to a dose level of STP938 (Phase 1) or an expansion cohort (Phase 2) at the time of their enrollment.||||
34151879|NCT03044808|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|"Pharmacy provides the research medicine, it is not possible to see a difference. The envelopes are encrypted. The randomization will only be broken in the end."|2 randomized groups, one getting lidocaine and the other getting saline|t|t|t|t
34151880|NCT04679324|||COHORT||PROSPECTIVE|||||||
34151881|NCT00328250|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151882|NCT05296031|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries|t|f|f|f
34151883|NCT01820312|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34151884|NCT02477553|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34151885|NCT01191346|||CASE_ONLY||PROSPECTIVE|||||||
34151886|NCT02334852|||COHORT||PROSPECTIVE|||||||
34151887|NCT05611814|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|Participants received treatment in private room. Study team and participants were blind to group (treatment received). Only the treatment administrator knew which treatment each participant received and was excluded from the remainder of the protocol.|Between subjects design with two groups: sham and experimental (osteopathic manipulative treatment \[OMT\])|t|f|t|t
34151888|NCT05728281|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34151889|NCT02068872|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151890|NCT03225807|||COHORT||PROSPECTIVE|||||||
34151891|NCT01804309|||COHORT||RETROSPECTIVE|||||||
34151892|NCT02029794|RANDOMIZED|PARALLEL||SCREENING||NONE||||||
34151893|NCT06095167|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34151894|NCT03350555|RANDOMIZED|PARALLEL||OTHER||DOUBLE||One arm includes participants who will receive additioned endoscopy assisted ERCP, and the other arm includes participants who will not receive additioned endoscopy assisted ERCP.|t|f|f|t
34151895|NCT01252979|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151896|NCT04892108|RANDOMIZED|PARALLEL||TREATMENT||SINGLE||"This randomized controlled trial is designed to compare the outcome of patients with obstructed defecation syndrome (ODS) and rectal prolapse undergoing transanal prolassectomy surgery with mechanical stapler (STARR: stapled transanal rectal resection) versus laparoscopic ventral rectopexy (LVR) surgery, with the aim of evaluating the most appropriate surgical choice. Patients eligible for the study will be randomized on a 1:1 basis to undergo transanal prolassectomy (Group 1: STARR) or laparoscopic ventral rectopexy with mesh placement (Group 2: LVR).~Randomization will be performed by a randomized list. The assignment sequence will be generated from a random numerical series generated through a computerized list. Randomization will be in blocks of 4. Group assignments will be unknown to those responsible for data collection and those who will be responsible for statistical analysis and clinical evaluation of patients."|f|f|f|t
34151897|NCT05178862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34151898|NCT03169257|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||SINGLE|A sonographer will perform cardiovascular imaging. Images will be reviewed by an expert pediatric cardiologist and an expert vascular surgeon blinded to patients' clinical data.|Only one group, the obese children group (OB) will be followed for one year. At baseline they received a behavioral intervention which comprises a Mediterranean balanced diet plus daily aerobic training.|f|f|f|t
34151899|NCT03762798|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34151900|NCT04214678|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34151901|NCT00598325|NON_RANDOMIZED|PARALLEL||PREVENTION||NONE||||||
34151902|NCT04826016|NON_RANDOMIZED|SEQUENTIAL||TREATMENT||NONE||||||
34152337|NCT04194814|NA|SINGLE_GROUP||OTHER||NONE|Allocation of the treatments to the test sites (right/left forearm) will be randomised (to avoid site position-dependent artefacts) Observer-blind - The collection of study data will be conducted in a separate area (dedicated skin barrier research suite) by a separate team (comprising skilled dermatology researchers) who will be blind.|An observer-blind forearm-controlled clinical trial in 37 AD patients, wherein each participant will undergo 4 weeks treatment with crisaborole (2%) ointment on one forearm and betamethasone valerate (0.1%) cream on the other (twice daily application in each case and randomised site allocation). At the start of the study the skin of the test sites (forearms) will be clear of the signs of AD so that the investigation focuses on local adverse effects on the skin as opposed to anti-inflammatory effects (focus on local adverse effects and not clinical efficacy). The condition of the skin will be assessed before, during and after treatment.||||
34152338|NCT00057369|RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152339|NCT01970059|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152340|NCT03125460|||COHORT||PROSPECTIVE|||||||
34152341|NCT01179165|||COHORT||CROSS_SECTIONAL|||||||
34152342|NCT01675362|RANDOMIZED|PARALLEL||PREVENTION||TRIPLE|||t|t|t|f
34152343|NCT01086176|||CASE_CONTROL||PROSPECTIVE|||||||
34152344|NCT02660892|NA|SINGLE_GROUP||BASIC_SCIENCE||NONE||||||
34152345|NCT04794881|RANDOMIZED|PARALLEL||DIAGNOSTIC||SINGLE|||f|f|f|t
34152346|NCT01311440|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152347|NCT05060965|NA|SINGLE_GROUP||HEALTH_SERVICES_RESEARCH||NONE||||||
34152348|NCT03164330|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|Professionals who implement the biometric screenings, health risk assessments, and wellness courses do no know the exact treatment group of study participants.|Our primary analysis compares outcomes between a control group and six (6) treatment groups. Our secondary analysis compares pre-determined characteristics across members of the treatment group who adopt the intervention and those who do not.|f|t|f|f
34152349|NCT05974813|RANDOMIZED|CROSSOVER||PREVENTION||QUADRUPLE|||t|t|t|t
34152350|NCT03010020|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||t|f|f|f
34152351|NCT00486382|NON_RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152352|NCT03925051|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|subjects, investigator, sponsor|Randomized, Double-masked, Parallel-group|t|t|t|t
34152353|NCT00943189|||COHORT||PROSPECTIVE|||||||
34152354|NCT00346710|||COHORT||PROSPECTIVE|||||||
34152355|NCT02746185|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||f|f|f|t
34152356|NCT03035682|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152357|NCT06216249|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152358|NCT00783081|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE|||t|f|t|f
34152359|NCT02161419|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152360|NCT03409250|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152361|NCT05934864|||COHORT||PROSPECTIVE|||||||
34152362|NCT00875862|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152363|NCT00222885|||||PROSPECTIVE|||||||
34152364|NCT02088567|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|||t|f|f|f
34152365|NCT03191253|RANDOMIZED|PARALLEL||SUPPORTIVE_CARE||NONE||We will randomize 200 participants to the intervention (n=100) or control (n=100). The intervention consists of providing comprehensive, medically-appropriate food support, individual nutritional counseling, and group-based nutritional education over 6 months to low-income clients who have been diagnosed with HIV in order to improve their viral load and health-related quality of life (primary outcomes) as well as depression, ART adherence, food security and diet quality (secondary outcomes).||||
34152366|NCT00831870|||CASE_ONLY||PROSPECTIVE|||||||
34152367|NCT04596111|||COHORT||PROSPECTIVE|||||||
34152368|NCT02443818|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152369|NCT05047146|||COHORT||RETROSPECTIVE|||||||
34152370|NCT00559988|RANDOMIZED|PARALLEL||PREVENTION||SINGLE|||f|f|t|f
34152371|NCT02251210|RANDOMIZED|PARALLEL||TREATMENT||DOUBLE||||||
34152372|NCT03106467|RANDOMIZED|PARALLEL||TREATMENT||NONE||||||
34152373|NCT02350738|RANDOMIZED|CROSSOVER||TREATMENT||DOUBLE|||t|f|f|t
34152374|NCT04332575|||CASE_ONLY||CROSS_SECTIONAL|||||||
34152375|NCT05036291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152376|NCT05464264|||OTHER||PROSPECTIVE|||||||
34152377|NCT01798030|||OTHER||RETROSPECTIVE|||||||
34152378|NCT01028170|RANDOMIZED|PARALLEL||TREATMENT||QUADRUPLE|||t|t|t|t
34152379|NCT00934674|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152380|NCT06453317|RANDOMIZED|PARALLEL||TREATMENT||SINGLE|Due to the comparative nature of the study, aiming to compare the effectiveness of dual biological therapy with biologic drugs administered solely, we have not implemented treatment blinding. However, a blinded central endoscopy reader was included. Each endoscopy procedure will be recorded using an external device and sent to the central reader who will be blinded to the patient's treatment arm. It is important to note that the final decision regarding the endoscopic disease activity will remain with the endoscopist performing the procedure.||f|f|f|t
34152381|NCT00551291|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152382|NCT01310478|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152383|NCT05065450|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152384|NCT01691976|RANDOMIZED|PARALLEL||OTHER||NONE||||||
34152385|NCT03006887|NA|SINGLE_GROUP||TREATMENT||NONE||||||
34152386|NCT00119171|NON_RANDOMIZED|SINGLE_GROUP||TREATMENT||NONE||||||
34152387|NCT02215005|RANDOMIZED|CROSSOVER||TREATMENT||NONE||||||
34152388|NCT00932165|||CASE_ONLY||PROSPECTIVE|||||||
34152389|NCT05041348|||CASE_CONTROL||CROSS_SECTIONAL|||||||
34152390|NCT00006056||||TREATMENT||||||||
34152391|NCT00592332|RANDOMIZED|CROSSOVER||||SINGLE|||t|f|f|f
34152392|NCT03100110|NA|SINGLE_GROUP||DEVICE_FEASIBILITY||NONE||||||
34152393|NCT06267664|||COHORT||PROSPECTIVE|||||||
34152394|NCT00762541|NA|SINGLE_GROUP||TREATMENT||NONE||||||
